,pmid,ti,ab,year,punchline_text,population,interventions,outcomes,population_mesh,interventions_mesh,outcomes_mesh,num_randomized,prob_low_rob,punchline_text,authors,journal,dois 0,32342496,Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.,"AIM To assess the efficacy, safety, and tolerability of oromucosal nabiximols cannabinoid medicine as adjunct therapy for children with spasticity due to cerebral palsy/traumatic central nervous system injury with inadequate response to existing treatment. METHOD Overall, 72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y) were randomized at a ratio of 2:1 to receive nabiximols (n=47; 29 males, 18 females) or placebo (n=25; 15 males, 10 females) for 12 weeks (12 sprays/day max. based on clinical response/tolerability). The primary outcome was change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS), assessed by the primary caregiver at 12 weeks. Secondary outcomes included additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety. RESULTS There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks. No statistically significant differences were observed for any secondary endpoint. Adverse events were predominantly mild or moderate in severity; however, three cases of hallucinations were reported. INTERPRETATION Nabiximols was generally well tolerated; however, neuropsychiatric adverse events were observed. No significant reduction in spasticity with nabiximols treatment versus placebo was observed. WHAT THIS PAPER ADDS Oromucosal nabiximols is generally well tolerated by paediatric patients. However, three cases of hallucinations were observed, one of which involved auditory hallucinations and a suicide attempt. Oromucosal nabiximols versus placebo did not reduce cerebral palsy/central nervous system injury-related spasticity.",2020,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"['n=47; 29 males, 18 females) or', '72 patients (mean [SD] age 12y 4mo [3y 1mo], range 8-18y', 'paediatric patients', 'children with spasticity due to cerebral palsy/traumatic central nervous system injury', 'paediatric spasticity in cerebral palsy or traumatic brain injury']","['nabiximols cannabinoid medicine', 'nabiximols', 'oromucosal nabiximols cannabinoid medicine', 'placebo']","['spasticity 0', 'Adverse events', 'change from baseline in level of spasticity on a 0 to 10 Numerical Rating Scale (NRS', 'Efficacy and safety', 'spasticity', 'additional measures for spasticity, sleep quality, pain, health-related quality of life, comfort, depression, and safety', 'neuropsychiatric adverse events', 'cerebral palsy/central nervous system injury-related spasticity', 'efficacy, safety, and tolerability']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C2347556', 'cui_str': 'nabiximols'}, {'cui': 'C0006864', 'cui_str': 'cannabinoids'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1299004', 'cui_str': 'Oromucosal route'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C1264238', 'cui_str': 'Injury of central nervous system'}]",72.0,0.447635,There was no significant difference in the spasticity 0 to 10 NRS between nabiximols versus placebo groups after 12 weeks.,"[{'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Fairhurst', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Kumar', 'Affiliation': ""Department of Paediatric Neurology, Alder Hey Children's Hospital, Liverpool, UK.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Checketts', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Bola', 'Initials': 'B', 'LastName': 'Tayo', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Turner', 'Affiliation': ""Department of Paediatric Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.""}]",Developmental medicine and child neurology,['10.1111/dmcn.14548'] 1,32343107,Implementation of an Evidence-Based Guideline of Enteral Nutrition for Infants With Congenital Heart Disease: A Controlled Before-and-After Study.,"OBJECTIVES To describe the implementation process of a nutrition risk screening and assessment guideline for infants with congenital heart disease and to assess the impact of nurses' behavior and the effect on infants' outcomes. DESIGN A controlled before-and-after implementation study. The three dimensions of the integrated-Promoting Action on Research Implementation in Health Services framework were used to assess barriers and promoting factors. SETTING Cardiac center at Children's Hospital of Fudan University, Shanghai, China. PATIENTS Infants with congenital heart disease (n = 142) and nurses (n = 100). INTERVENTIONS Implementation of an evidenced-based nutrition risk screening and assessment guideline. MEASUREMENTS AND MAIN RESULTS Implementation processes were assessed on nurses' knowledge, attitude, behavior, and compliance of the guideline. Infants' clinical outcomes were evaluated before-and-after the implementation. Knowledge, attitude, and behavior of nurses about nutrition risk screening and assessment increased significantly after implementing the guideline. Nurses' compliance with the recommendations for nutritional risk screening improved significantly on three criteria; assessment of nutritional status stability (p < 0.001), assessment of nutritional status deterioration (p = 0.003), and nutritional assessment among infants with moderate risk and above (p < 0.001). The nurses' compliance with the recommendations for nutrition assessment improved significantly in eight of the 10 criteria (p < 0.001). The proportion of infants receiving comprehensive nutrition assessment when they were first screened with moderate or high nutritional risk were higher in the intervention group (24.3% vs 83.3%; p < 0.001). The accuracy rates of nutrition risk screening were higher in the intervention group (52.9% vs 81.9%; p < 0.001). CONCLUSIONS Using the integrated-Promoting Action on Research Implementation in Health Services framework contributed to a successful implementation of the nutrition guideline. The nurses' knowledge, attitude, and behavior toward the nutrition guideline were positive resulting in a significantly higher nutrition assessments in infants with moderate or high nutritional risk.",2020,"The accuracy rates of nutrition risk screening were higher in the intervention group (52.9% vs 81.9%; p < 0.001). ","['Infants with congenital heart disease (n = 142) and nurses (n = 100', ""Cardiac center at Children's Hospital of Fudan University, Shanghai, China"", 'infants with congenital heart disease', 'infants with moderate or high nutritional risk', 'Infants With Congenital Heart Disease']","['Implementation of an evidenced-based nutrition risk screening and assessment guideline', 'nutrition risk screening and assessment guideline', 'Enteral Nutrition']","['proportion of infants receiving comprehensive nutrition assessment', ""nurses' knowledge, attitude, behavior, and compliance of the guideline"", 'nutritional status stability', 'moderate or high nutritional risk', 'nutritional status deterioration', 'accuracy rates of nutrition risk screening']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0028708', 'cui_str': 'Assessment of nutritional status'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1268620', 'cui_str': 'At risk for nutritional problem'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]",142.0,0.0233883,"The accuracy rates of nutrition risk screening were higher in the intervention group (52.9% vs 81.9%; p < 0.001). ","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Gu', 'Affiliation': ""Nursing Department, Children's Hospital of Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': ""School of Nursing, Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Huiwen', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': ""Shanghai University of Medicine & Health Science, Shanghai, People's Republic of China.""}, {'ForeName': 'Weijia', 'Initials': 'W', 'LastName': 'Fu', 'Affiliation': ""Cardiac Intensive Care Unit, Children's Hospital of Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Yuxia', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': ""Cardiovascular Department, Children's Hospital of Fudan University, Shanghai, People's Republic of China.""}, {'ForeName': 'Jos M', 'Initials': 'JM', 'LastName': 'Latour', 'Affiliation': 'School of Nursing and Midwifery, Faculty of Health and Human Sciences, University of Plymouth, Plymouth, United Kingdom.'}]",Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies,['10.1097/PCC.0000000000002296'] 2,32343288,Examining the characteristics of patients who continue participation in vs those who drop out of a PTSD clinical trial,"BACKGROUND Patients who drop out of clinical trials examining posttraumatic stress disorder (PTSD) may have different characteristics than patients who continue. These characteristics have never been examined in prior PTSD and attrition trials. Our goal was to examine how demographic and clinical characteristics of patients with PTSD impact attrition in a randomized controlled trial. METHODS A total of 18 participants were recruited. Data were collected through questionnaires to assess PTSD, depression, and mood disorders. Fisher’s exact test was used to examine the association of various categorical demographic and clinical variables with dropout. A Wilcoxon rank sum test was used to examine differences in medians. RESULTS The median total PTSD Checklist for DSM-5 score was 38 for patients who dropped out and 53 for those who did not. The depression scale total was also lower for the dropout group (7 vs 15). The insomnia index was lower for those who did not remain in the study (15 vs 21). CONCLUSIONS Posttraumatic stress disorder symptoms, depression, and insomnia were less severe in patients who dropped out compared with those who did not. Larger studies are needed to further examine these findings. This study could help guide future recruitment efforts for clinical trials examining PTSD.",2020,The depression scale total was also lower for the dropout group (7 vs 15).,"['patients with PTSD impact attrition', 'A total of 18 participants were recruited', 'Patients who drop out of clinical trials examining posttraumatic stress disorder (PTSD', 'patients who continue participation in vs those who drop out of a PTSD clinical trial']",[],"['insomnia index', 'PTSD, depression, and mood disorders', 'depression scale total', 'median total PTSD Checklist for DSM-5 score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]",[],"[{'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0525045', 'cui_str': 'Mood disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",18.0,0.0712566,The depression scale total was also lower for the dropout group (7 vs 15).,"[{'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Ponkshe', 'Affiliation': ''}, {'ForeName': 'Angelia', 'Initials': 'A', 'LastName': 'Holland-Winkler', 'Affiliation': ''}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Waller', 'Affiliation': ''}, {'ForeName': 'Nagy A', 'Initials': 'NA', 'LastName': 'Youssef', 'Affiliation': ''}]",Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,[] 3,32339370,Histology of augmented autogenous bone covered by a platelet-rich fibrin membrane or deproteinized bovine bone mineral and a collagen membrane: A pilot randomized controlled trial.,"OBJECTIVES This study aimed to evaluate histologic and histomorphometric bone characteristics with a focus on vitality after lateral alveolar ridge augmentation using an autogenous bone graft as a block covered by either a platelet-rich fibrin (PRF) membrane (test group) or a standard procedure involving coverage of the bone block with a deproteinized bovine bone mineral and a resorbable collagen membrane (control group). MATERIAL AND METHODS A total of 27 (test = 14, control = 13) partially edentulous patients with indication for bone block augmentation before implant installation were included. For analyses, a biopsy of augmented bone was retrieved six months after bone grafting. RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone toward the periosteum and few localized areas of vital bone in the center of the graft in both groups. In contrast, augmented bone toward the native bone demonstrated extensive bone remodeling in both groups. Histomorphometric analyses demonstrated a mean of 14% vital bone, 80% non-vital bone, 5% soft tissue, and 1% blood vessels in the test group. In the control group, the corresponding shares were 14% vital bone, 63% non-vital bone, 22% soft tissue, and 1% blood vessels. We observed no significant differences between the groups (p > .05). CONCLUSION In conclusion, a comparable low bone vitality of augmented bone was observed in the PRF and in the control group. Consequently, the present study could not verify the potential beneficial effect of a PRF membrane on bone vitality of an autogenous bone graft used as a block.",2020,"RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone towards the periosteum and few localized areas of vital bone in the center of the graft in both groups.","['A total of 27 (test = 14, control = 13) partially edentulous patients with indication for bone block augmentation before implant installation were included']","['PRF membrane', 'platelet-rich fibrin (PRF) membrane (test group) or a standard procedure involving coverage of the bone block with a deproteinized bovine bone mineral and a resorbable collagen membrane (control group', 'platelet-rich fibrin membrane or deproteinized bovine bone mineral and a collagen membrane']","['bone vitality', 'low bone vitality of augmented bone']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026644', 'cui_str': 'Edentulous'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C1293164', 'cui_str': 'Bone block procedure'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C4505052', 'cui_str': 'Leukocyte- and Platelet-Rich Fibrin'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C1293164', 'cui_str': 'Bone block procedure'}, {'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",80.0,0.0407757,"RESULTS Histologic evaluation of augmented bone revealed a predominance of non-vital bone towards the periosteum and few localized areas of vital bone in the center of the graft in both groups.","[{'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Hartlev', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Surgery and Oral Pathology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Erik Nørholt', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Surgery and Oral Pathology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Rubens', 'Initials': 'R', 'LastName': 'Spin-Neto', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Oral Radiology, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kraft', 'Affiliation': 'Department of Dentistry and Oral Health, Section of Orthodontics, Aarhus University, Aarhus C, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Schou', 'Affiliation': 'Faculty of Health Sciences, Department of Periodontology, School of Dentistry, University of Copenhagen, Copenhagen N, Denmark.'}, {'ForeName': 'Flemming', 'Initials': 'F', 'LastName': 'Isidor', 'Affiliation': 'Department of Dentistry and Oral Health, Section for Prosthetic Dentistry, Aarhus University, Aarhus C, Denmark.'}]",Clinical oral implants research,['10.1111/clr.13605'] 4,32339648,Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.,"BACKGROUND The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We report updated efficacy data from the second interim analysis. PATIENTS AND METHODS Treatment-naive patients with aRCC were randomized (1 : 1) to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The two independent primary end points were PFS and overall survival (OS) among patients with programmed death ligand 1-positive (PD-L1+) tumors. Key secondary end points were OS and PFS in the overall population. RESULTS Of 886 patients, 442 were randomized to the avelumab plus axitinib arm and 444 to the sunitinib arm; 270 and 290 had PD-L1+ tumors, respectively. After a minimum follow-up of 13 months (data cut-off 28 January 2019), PFS was significantly longer in the avelumab plus axitinib arm than in the sunitinib arm {PD-L1+ population: hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.490-0.777]}; one-sided P < 0.0001; median 13.8 (95% CI 10.1-20.7) versus 7.0 months (95% CI 5.7-9.6); overall population: HR 0.69 (95% CI 0.574-0.825); one-sided P < 0.0001; median 13.3 (95% CI 11.1-15.3) versus 8.0 months (95% CI 6.7-9.8)]. OS data were immature [PD-L1+ population: HR 0.828 (95% CI 0.596-1.151); one-sided P = 0.1301; overall population: HR 0.796 (95% CI 0.616-1.027); one-sided P = 0.0392]. CONCLUSION Among patients with previously untreated aRCC, treatment with avelumab plus axitinib continued to result in a statistically significant improvement in PFS versus sunitinib; OS data were still immature. CLINICAL TRIAL NUMBER NCT02684006.",2020,OS data were immature (PD-L1+ population: HR 0.828,"['886 patients', 'advanced renal cell carcinoma (aRCC', 'patients with advanced renal cell carcinoma', 'Treatment-naïve patients with aRCC']","['axitinib (5 mg) orally twice daily or sunitinib', 'avelumab plus axitinib versus sunitinib', 'avelumab', 'avelumab plus axitinib']","['progression-free survival (PFS', 'PFS', 'OS and PFS in the overall population', 'PFS and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1700874', 'cui_str': 'axitinib'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C4055417', 'cui_str': 'avelumab'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",,0.268726,OS data were immature (PD-L1+ population: HR 0.828,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': ""Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, USA. Electronic address: toni_choueiri@dcfi.harvard.edu.""}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Motzer', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'B I', 'Initials': 'BI', 'LastName': 'Rini', 'Affiliation': 'Cleveland Clinic, Cleveland, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Haanen', 'Affiliation': 'Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Campbell', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Houston, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Venugopal', 'Affiliation': 'University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kollmannsberger', 'Affiliation': 'British Columbia Cancer Agency, Vancouver Centre, Vancouver, Canada.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Gravis-Mescam', 'Affiliation': 'Institut Paoli-Calmettes, Department of Medical Oncology, Aix-Marseille Université, Inserm, CNRS, CRCM, Marseille, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uemura', 'Affiliation': 'Osaka University Hospital, Osaka, Japan.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.'}, {'ForeName': 'M-O', 'Initials': 'MO', 'LastName': 'Grimm', 'Affiliation': 'Jena University Hospital, Department of Urology, Jena, Germany.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gurney', 'Affiliation': 'Macquarie University, Sydney, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Schmidinger', 'Affiliation': 'Clinical Division of Oncology, Department of Medicine I Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'Royal Marsden NHS Foundation Trust, London, UK.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Atkins', 'Affiliation': 'Georgetown University Medical Center, Washington, DC.'}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Pal', 'Affiliation': 'City of Hope National Medical Center, Duarte, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Pfizer, Cambridge, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mariani', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Krishnaswami', 'Affiliation': 'Pfizer, Groton, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Cislo', 'Affiliation': 'Pfizer, New York, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chudnovsky', 'Affiliation': 'Pfizer, Cambridge, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Fowst', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': 'Pfizer, Groton, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'di Pietro', 'Affiliation': 'Pfizer Italia SRL, Milan, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Albiges', 'Affiliation': 'Institut Gustave Roussy, Villejuif, France.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.010'] 5,32341291,Test-Retest Reliability and the Effects of Exercise on the King-Devick Test.,"OBJECTIVE To determine the test-retest reliability and the influence of exercise on King-Devick (K-D) test performance. DESIGN Crossover study design. SETTING Controlled laboratory. PARTICIPANTS Participants consisted of 63 (39 women and 24 men) healthy, recreationally active college students who were 21.0 + 1.5 years of age. INDEPENDENT VARIABLES Participants completed the K-D test using a 2-week, test-retest interval. The K-D test was administered before and after a counterbalanced exercise or rest intervention. Reliability was assessed using testing visits (visit 1 and visit 2) as the independent variables. Exercise or rest and time (baseline, postintervention) were used as independent variables to examine the influence of exercise. MAIN OUTCOME MEASURES Intraclass correlation (ICC) coefficients with 95% confidence intervals were calculated between visits to assess reliability of K-D test completion time. A repeated-measure 2 x 2 analysis of variance (intervention × time) with post hoc paired t tests was used to assess the influence of exercise on K-D test performance. RESULTS The K-D test was observed to have strong test-retest reliability [ICC2,1 = 0.90 (0.71, 0.96)] over time. No significant intervention-by-time interaction (P = 0.55) or intervention main effects (P = 0.68) on K-D time were observed. Mean differences of -1.5 and -1.7 seconds (P < 0.001) were observed between baseline and rest and exercise interventions for K-D test performance, respectively. Up to 32% (20/63) of participants were observed to have a false-positive K-D test performance before and after each intervention. CONCLUSIONS Although strong test-retest reliability coefficients were observed using clinically relevant time points, a high false-positive rate warrants caution when interpreting the K-D test.",2020,"Up to 32% (20/63) of participants were observed to have a false-positive K-D test performance before and after each intervention. ","['Participants consisted of 63 (39 women and 24 men) healthy, recreationally active college students who were 21.0 + 1.5 years of age']",['counterbalanced exercise or rest intervention'],"['Reliability', 'Exercise or rest and time (baseline, postintervention', 'K-D time', 'false-positive K-D test performance', 'King-Devick (K-D) test performance']","[{'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205557', 'cui_str': 'False positive'}, {'cui': 'C4759290', 'cui_str': 'King-Devick test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",,0.088008,"Up to 32% (20/63) of participants were observed to have a false-positive K-D test performance before and after each intervention. ","[{'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Eddy', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Goetschius', 'Affiliation': 'Department of Exercise Science and Athletic Training, Adrian College, Adrian, Michigan.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Hertel', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Resch', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000586'] 6,32340519,Comparative analysis of the outcome of external and endoscopic frontal sinus surgery in children.,"Background: Both open and functional endoscopic sinus surgery (FESS) are performed in the case of pediatric frontal rhinosinusitis. However, data from comparative analysis of these surgery types are insufficient. Objective: Prospective randomized trial for comparison of open and endoscopic surgery outcome in pediatric chronic rhinosinusitis. Material and methods: The cohort included 30 pediatric patients (7-17 years) with open frontal sinus surgery and 34 patients who underwent FESS using DrafIIa. Lund-Kennedy and Lund-Mackay scores, as well as Sino-Nasal Outcome Test-20 (SNOT-20)questionnaire was used for pre- and postoperative assessment. Results: Open surgery and FESS resulted in a significant improvement in total Lund-Kennedy, Lund-Mackay, and SNOT-20 scores, being more profound in FESS group. Using FESS significantly reduced surgery duration by 15% as compared to open surgery. In addition, open surgery was associated with a higher rate of scar formation, reduced local sensitivity, as well as local soreness, lacrimation, and psychological discomfort. In regression models FESS was negatively associated with postoperative total Lund-Kennedy, Lund-Mackay, and SNOT-20 scores. Conclusion and significance: Generally, FESS resulted in better surgery outcome as compared to open surgery, although both approaches resulted in a significant improvement in chronic rhinosinusitis.",2020,"Generally, FESS resulted in better surgery outcome as compared to open surgery, although both approaches resulted in a significant improvement in chronic rhinosinusitis.","['30 pediatric patients (7-17\u2009years) with open frontal sinus surgery and 34 patients who underwent FESS using DrafIIa', 'pediatric chronic rhinosinusitis', 'children']","[': Both open and functional endoscopic sinus surgery (FESS', 'external and endoscopic frontal sinus surgery', 'Open surgery and FESS', 'open and endoscopic surgery', 'FESS']","['local soreness, lacrimation, and psychological discomfort', 'postoperative total Lund-Kennedy, Lund-Mackay, and SNOT-20 scores', 'Lund-Kennedy and Lund-Mackay scores', 'chronic rhinosinusitis', 'rate of scar formation, reduced local sensitivity', 'surgery duration', 'total Lund-Kennedy, Lund-Mackay, and SNOT-20 scores']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0016734', 'cui_str': 'Frontal sinus structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0442968', 'cui_str': 'Functional endoscopic sinus surgery'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0016734', 'cui_str': 'Frontal sinus structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0282493', 'cui_str': 'Endoscopy with surgical procedure'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0423153', 'cui_str': 'Lacrimation'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C5197691', 'cui_str': 'SNOT-20'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",30.0,0.0314268,"Generally, FESS resulted in better surgery outcome as compared to open surgery, although both approaches resulted in a significant improvement in chronic rhinosinusitis.","[{'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Alekseenko', 'Affiliation': 'Department of Otorhinolaryngology, I.I Mechnikov North-Western State Medical University, St. Petersburg, Russia.'}, {'ForeName': 'Sergey', 'Initials': 'S', 'LastName': 'Karpischenko', 'Affiliation': ""K.A. Rauhfus Children's City Multidisciplinary Clinical Center for High Medical Technologies, St. Petersburg, Russia.""}]",Acta oto-laryngologica,['10.1080/00016489.2020.1752932'] 7,32341044,(Cost-)effectiveness of lower extremity nerve decompression surgery in subjects with diabetes: the DeCompression (DECO) trial-study protocol for a randomised controlled trial.,"INTRODUCTION The peripheral nerves of patients with diabetes are often pathologically swollen, which results in entrapment at places of anatomical narrowing. This results in nerve dysfunction. Surgical treatment of compression neuropathies in the lower extremities (lower extremity nerve decompression (LEND)) results in relief of symptoms and gain in peripheral nerve function, which may lead to less sensory loss (short term) and less associated detrimental effects including foot ulceration and amputations, and lower costs (long term). The aim of the DeCompression trial is to evaluate the effectiveness and (cost-)effectiveness of surgical decompression of compressed lower extremity nerves (LEND surgery) compared with patients treated with conventional (non-surgical) care. METHODS AND ANALYSIS A stratified randomised (1 to 1) controlled trial comparing LEND surgery (intervention) with conventional non-surgical care (control strategy) in subjects with diabetes with problems of neuropathy due to compression neuropathies in the lower extremity. Randomisation is stratified for participating hospital (n=11) and gender. Patients and controls have the same follow-up at 1.5, 3, 6, 9, 12, 18, 24 and 48 months. Participants (n=344) will be recruited in 12 months and enrolled in all affiliated hospitals in which they receive both the intervention or conventional non-surgical care and follow-up. Outcome assessors are blinded to group assignment. PRIMARY OUTCOME disease-specific quality of life (Norfolk Quality of Life Questionnaire-Diabetic Neuropathy). SECONDARY OUTCOMES health-related quality of life (EuroQoL 5-dimension 5-level (EQ-5D5L), 36-item Short Form (SF-36)), plantar sensation (Rotterdam Diabetic Foot Test Battery), incidence of ulcerations/amputations, resource use and productivity loss (Medical Cost Questionnaire, Productivity Cost Questionnaire) during follow-up. The incremental cost-effectiveness ratio will be estimated on the basis of the collected empirical data and a cost-utility model. ETHICS AND DISSEMINATION Ethics approval has been granted by the Medical Research Ethics Committee of Utrecht University Medical Center (reference: NL68312.041.19v5, protocol number: 19-335/M). Dissemination of results will be via journal articles and presentations at national and international conferences. TRIAL REGISTRATION NUMBER NetherlandsTrial Registry NL7664.",2020,"Surgical treatment of compression neuropathies in the lower extremities (lower extremity nerve decompression (LEND)) results in relief of symptoms and gain in peripheral nerve function, which may lead to less sensory loss (short term) and less associated detrimental effects including foot ulceration and amputations, and lower costs (long term).","['participating hospital (n=11) and gender', 'Utrecht University Medical Center (reference', 'patients treated with conventional (non-surgical) care', 'subjects with diabetes with problems of neuropathy due to compression neuropathies in the lower extremity', 'subjects with diabetes', 'Participants (n=344) will be recruited in 12 months and enrolled in all affiliated hospitals in which they receive both the intervention or conventional non-surgical care and follow-up']","['surgical decompression of compressed lower extremity nerves (LEND surgery', 'extremity nerve decompression surgery', 'LEND surgery (intervention) with conventional non-surgical care (control strategy']","['incremental cost-effectiveness ratio', 'disease-specific quality of life (Norfolk Quality of Life Questionnaire-Diabetic Neuropathy', 'health-related quality of life (EuroQoL 5-dimension 5-level (EQ-5D5L), 36-item Short Form (SF-36)), plantar sensation (Rotterdam Diabetic Foot Test Battery), incidence of ulcerations/amputations, resource use and productivity loss (Medical Cost Questionnaire, Productivity Cost Questionnaire']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0393814', 'cui_str': 'Hereditary liability to pressure palsies'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0376530', 'cui_str': 'Surgical decompression - action'}, {'cui': 'C0446822', 'cui_str': 'Peripheral nerve of lower limb'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0196571', 'cui_str': 'Decompression of nerve'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0454866', 'cui_str': 'Norfolk'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0011882', 'cui_str': 'Diabetic neuropathy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0206172', 'cui_str': 'Diabetic foot'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",344.0,0.135549,"Surgical treatment of compression neuropathies in the lower extremities (lower extremity nerve decompression (LEND)) results in relief of symptoms and gain in peripheral nerve function, which may lead to less sensory loss (short term) and less associated detrimental effects including foot ulceration and amputations, and lower costs (long term).","[{'ForeName': 'Willem D', 'Initials': 'WD', 'LastName': 'Rinkel', 'Affiliation': 'Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University Medical Center, Utrecht, The Netherlands w.d.rinkel@umcutrecht.nl.'}, {'ForeName': 'Tirzah M', 'Initials': 'TM', 'LastName': 'Fakkel', 'Affiliation': 'Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University Medical Center, Utrecht, The Netherlands.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Castro Cabezas', 'Affiliation': 'Department of Internal Medicine, Franciscus Gasthuis en Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Birnie', 'Affiliation': 'Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University Medical Center, Utrecht, The Netherlands.'}, {'ForeName': 'J Henk', 'Initials': 'JH', 'LastName': 'Coert', 'Affiliation': 'Department of Plastic-, Reconstructive- and Hand Surgery, Utrecht University Medical Center, Utrecht, The Netherlands.'}]",BMJ open,['10.1136/bmjopen-2019-035644'] 8,32341047,Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol.,"INTRODUCTION Mobile health may be an effective means of delivering customised individually directed health promotion interventions for cardiovascular disease (CVD) primary prevention. The aim of this study is to evaluate the effectiveness of a lifestyle-focused text messaging programme for primary CVD prevention. METHODS AND ANALYSIS Single-blind randomised controlled trial with 6 months' follow-up in 246 patients with moderate-high absolute cardiovascular risk and without coronary heart disease recruited from a rapid access cardiology clinic. Participants will be randomised to receive either usual care or TextMe2 (text message-based prevention programme). The TextMe2 programme provides support, motivation and education on five topics: diet, physical activity, smoking, general cardiovascular health and medication adherence, and is delivered in four text messages per week over 6 months. The primary outcome is change in the proportion of patients who have three or more of five key modifiable risk factors that are uncontrolled (low-density lipoprotein >2.0 mmol/L, systolic blood pressure >140 mm Hg, body mass index >24.9 kg/m 2 , physical activity (less than the equivalent of 150 min of moderate intensity each week), current smoker). Secondary outcomes are changes in single biomedical risk factors, behavioural risk factors, quality of life, depression/anxiety scores, medication adherence, cardiovascular health literacy and hospital readmissions/representations. Analysis will be according to the intention-to-treat principle and full statistical analysis plan developed prior to data lock. ETHICS AND DISSEMINATION This study has been approved by the Western Sydney Local Health District Human Research Ethics Committee at Westmead (AU/RED/HREC/17/WMEAD/186). Results will be presented at scientific meetings and published in peer-reviewed publications. TRIAL REGISTRATION NUMBER ACTRN12618001153202.",2020,"INTRODUCTION Mobile health may be an effective means of delivering customised individually directed health promotion interventions for cardiovascular disease (CVD) primary prevention.",['246 patients with moderate-high absolute cardiovascular risk and without coronary heart disease recruited from a rapid access cardiology clinic'],"['lifestyle-focused text messaging programme', 'usual care or TextMe2 (text message-based prevention programme']","['systolic blood pressure ', 'physical activity', 'cardiovascular disease', 'changes in single biomedical risk factors, behavioural risk factors, quality of life, depression/anxiety scores, medication adherence, cardiovascular health literacy and hospital readmissions/representations']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C3810847', 'cui_str': 'Cardiology clinic'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}]",246.0,0.211198,"INTRODUCTION Mobile health may be an effective means of delivering customised individually directed health promotion interventions for cardiovascular disease (CVD) primary prevention.","[{'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Klimis', 'Affiliation': 'Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia harry.klimis@sydney.edu.au.'}, {'ForeName': 'Aravinda', 'Initials': 'A', 'LastName': 'Thiagalingam', 'Affiliation': 'Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Clara K', 'Initials': 'CK', 'LastName': 'Chow', 'Affiliation': 'Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-036767'] 9,31270136,Automatic Measurement of Kidney and Liver Volumes from MR Images of Patients Affected by Autosomal Dominant Polycystic Kidney Disease.,"BACKGROUND The formation and growth of cysts in kidneys, and often liver, in autosomal dominant polycystic kidney disease (ADPKD) cause progressive increases in total kidney volume (TKV) and liver volume (TLV). Laborious and time-consuming manual tracing of kidneys and liver is the current gold standard. We developed a fully automated segmentation method for TKV and TLV measurement that uses a deep learning network optimized to perform semantic segmentation of kidneys and liver. METHODS We used 80% of a set of 440 abdominal magnetic resonance images (T2-weighted HASTE coronal sequences) from patients with ADPKD to train the network and the remaining 20% for validation. Both kidneys and liver were also segmented manually. To evaluate the method's performance, we used an additional test set of images from 100 patients, 45 of whom were also involved in longitudinal analyses. RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV). For longitudinal analysis, bias and precision were <0.1%±3.2% for TKV and 1.4%±2.9% for TLV growth. CONCLUSIONS These findings demonstrate a fully automated segmentation method that measures TKV, TLV, and changes in these parameters as accurately as manual tracing. This technique may facilitate future studies in which automated and reproducible TKV and TLV measurements are needed to assess disease severity, disease progression, and treatment response.",2019,"RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV).","['patients with ADPKD to train the network and the remaining 20% for validation', 'Patients Affected by Autosomal Dominant Polycystic Kidney Disease', '100 patients, 45 of whom were also involved in longitudinal analyses']",[],"['total kidney volume (TKV) and liver volume (TLV', 'Automatic Measurement of Kidney and Liver Volumes', 'TKV and TLV']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085413', 'cui_str': 'Autosomal dominant polycystic kidney disease'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",,0.0219092,"RESULTS TKV and TLV measured by the automated approach correlated highly with manually traced TKV and TLV (intraclass correlation coefficients, 0.998 and 0.996, respectively), with low bias and high precision (<0.1%±2.7% for TKV and -1.6%±3.1% for TLV); this was comparable with inter-reader variability of manual tracing (<0.1%±3.5% for TKV and -1.5%±4.8% for TLV).","[{'ForeName': 'Maatje D A', 'Initials': 'MDA', 'LastName': 'van Gastel', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Marie E', 'Initials': 'ME', 'LastName': 'Edwards', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Vicente E', 'Initials': 'VE', 'LastName': 'Torres', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Erickson', 'Affiliation': 'Department of Radiology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Ron T', 'Initials': 'RT', 'LastName': 'Gansevoort', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands and.'}, {'ForeName': 'Timothy L', 'Initials': 'TL', 'LastName': 'Kline', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine; kline.timothy@mayo.edu.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2018090902'] 10,32343967,Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers.,"BACKGROUND Peak inspiratory flow (PIF) has been proposed as a measure to assess a patient's ability to use dry powder inhalers (DPIs). However, robust quality criteria to determine a repeatability limit for measuring PIF are lacking. RESEARCH QUESTIONS What are the repeatability limits for measuring PIF? What is the relationship between PIF measured using the In-Check DIAL device at Diskus (GlaxoSmithKline; PIF D ) and HandiHaler (Boehringer Ingelheim; PIF HH ) resistances? STUDY DESIGN AND METHODS Data from a randomized, controlled, phase 3 trial (study 0149; see Clinical Trial Registration data) were used to define repeatability limits for PIF. In addition, a model to characterize the relationship between PIF measured with the In-Check DIAL device at PIF D and PIF HH was defined using data from two randomized, controlled, phase 3 trials (studies 0128 and 0149). RESULTS In study 0128, the mean values (SD) for PIF at zero resistance and PIF HH were 84.6 (33.4) and 57.3 (26.1) L/min, respectively. In study 0149, the mean values (SD) for PIF D and PIF HH were 42.4 (11.2) and 29.0 (8.3) L/min, respectively. At the mean level, the mean difference between measurement attempts for PIF D and PIF HH was small, < 5 and < 3 L/min, respectively. The repeatability limit was determined as 10 and 5 L/min for PIF D and PIF HH , respectively. Modeling the relationship between PIF D and PIF HH , after controlling for significant covariates, demonstrated that a PIF D value of 60 L/min was approximately equivalent to PIF HH of 40 L/min. INTERPRETATIONS This analysis demonstrated that the two highest values of PIF using the In-Check DIAL device among three inspiratory efforts, met the repeatability limit. Altogether, these data provide guidance for measuring PIF against the simulated resistance of a specific DPI in clinical practice and research studies. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov; Nos.: NCT02518139 (study 0128) and NCT03095456 (study 0149); URL: www.clinicaltrials.gov.",2020,"At the mean level, the mean difference between measurement attempts for PIF D and PIF HH was small, < 5 L/min and < 3 L/min, respectively.",[],['Peak inspiratory flow (PIF'],"['repeatability limit', 'mean values (standard deviation [SD]) for PIF at zero resistance and PIF HH', 'mean values (SD) for PIF D and PIF HH', 'PIF D and PIF HH']",[],"[{'cui': 'C0429742', 'cui_str': 'Peak inspiratory flow rate'}]","[{'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0429742', 'cui_str': 'Peak inspiratory flow rate'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",,0.0420994,"At the mean level, the mean difference between measurement attempts for PIF D and PIF HH was small, < 5 L/min and < 3 L/min, respectively.","[{'ForeName': 'Chris N', 'Initials': 'CN', 'LastName': 'Barnes', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Mahler', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Hanover, NH.'}, {'ForeName': 'Jill A', 'Initials': 'JA', 'LastName': 'Ohar', 'Affiliation': 'Wake Forest University Medical Center, Winston-Salem, NC.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Lombardi', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA.'}, {'ForeName': 'Glenn D', 'Initials': 'GD', 'LastName': 'Crater', 'Affiliation': 'Theravance Biopharma US, Inc., South San Francisco, CA. Electronic address: gcrater@theravance.com.'}]",Chest,['10.1016/j.chest.2020.03.072'] 11,32346804,Feasibility of using a computer-assisted working memory training program for healthy older women.,"Interventions for age-associated cognitive impairment are of increasing significance as populations age. Using N-back and memory strategy enhancement, the present study aimed to explore the feasibility of using, and outcomes of a working memory (WM) training program on visuospatial and verbal WM in older female adults. Older women from two comparable local health centers who scored 26 and higher on Mini-Mental State Examination were invited to participate. Women at one center (experimental group) received three sessions on memory enhancement techniques and a computerized training program with N-back. Women at the other center (control group) received three sessions on memory and aging and training on using various features of cellphones. All participants completed the Corsi Block Task and Digit Span Task at pre- and post-training. The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group. These findings support the brain's plasticity in the elderly. WM training for improving cognitive performance in older adults has potential and should be further investigated.",2020,The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group.,"['Older women from two comparable local health centers who scored 26 and higher on Mini-Mental State Examination were invited to participate', 'healthy older women', 'older adults', 'older female adults']","['working memory (WM) training program', 'computer-assisted working memory training program', 'three sessions on memory enhancement techniques and a computerized training program with N-back', 'WM training', 'three sessions on memory and aging and training']","['visuospatial and verbal WM', 'cognitive performance', 'Corsi Block Task and Digit Span Task']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}]",,0.0158536,The experimental group showed significant improvements in their visuospatial and verbal WM compared to the control group.,"[{'ForeName': 'Fahimeh', 'Initials': 'F', 'LastName': 'Ghavidel', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran.'}, {'ForeName': 'Javad Salehi', 'Initials': 'JS', 'LastName': 'Fadardi', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran. j.s.fadardi@um.ac.ir.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Gatto', 'Affiliation': 'Claremont Graduate University, Claremont, CA, USA.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Sedaghat', 'Affiliation': 'Sedaghat Cognitive Neuroscience Clinic, Mashhad, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Tabibi', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, Ferdowsi University of Mashhad, 9177948991, Mashhad, Iran.'}]",Cognitive processing,['10.1007/s10339-020-00975-7'] 12,32347208,"Yoga improves balance, mobility, and perceived occupational performance in adults with chronic brain injury: A preliminary investigation.","BACKGROUND AND PURPOSE This was a preliminary investigation to investigate potential benefits of group yoga, as past work has indicated that one-on-one yoga can improve functional deficits in adults with brain injury. MATERIALS AND METHODS Participants served as their own controls. Nine participants with chronic brain injury were recruited, and seven (four female) completed the study. Performance measures of balance and mobility and self-reported measures of balance confidence, pain, and occupational performance and satisfaction were used. Data were collected 3 times: baseline (study onset), pre-yoga (after an 8-week no-contact period), and post-yoga (after 8 weeks of yoga). Group yoga was led by a yoga instructor/occupational therapist, and sessions lasted 1 h and occurred twice a week. RESULTS No participants withdrew due to adverse effects from yoga. There were no significant changes between baseline and pre-yoga. Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). CONCLUSION We observed significant improvements in balance, mobility, and self-reported occupational performance in adults with chronic brain injury.",2020,"Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). ","['Nine participants with chronic brain injury were recruited, and seven (four female) completed the study', 'adults with brain injury', 'Participants served as their own controls', 'adults with chronic brain injury']",[],"['self-reported occupational performance', 'balance confidence, pain, and occupational performance and satisfaction', 'balance, mobility, and perceived occupational performance', 'functional deficits', 'balance, mobility, and self-reported occupational performance', 'mobility']","[{'cui': 'C0751813', 'cui_str': 'Chronic Brain Injury'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",9.0,0.0225685,"Significant improvement was observed post-yoga in balance (p = 0.05), mobility (p = 0.03), and self-reported occupational performance (p = 0.04). ","[{'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Stephens', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: jaclyn.stephens@colostate.edu.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Van Puymbroeck', 'Affiliation': 'Clemson University, Recreational Therapy Program, USA.'}, {'ForeName': 'P L', 'Initials': 'PL', 'LastName': 'Sample', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: pat.sample@colostate.edu.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Schmid', 'Affiliation': 'Colorado State University, Department of Occupational Therapy, USA. Electronic address: arlene.schmid@colostate.edu.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101172'] 13,32347209,"Evaluation of the effectiveness of self-healing training on self-compassion, body image concern, and recovery process in patients with skin cancer.","BACKGROUND AND PURPOSE The present study aimed to investigate the effect of self-healing training on self-compassion, body image concern, and recovery process in patients with skin cancer. MATERIALS AND METHODS The sample consisted of 34 volunteers who were purposefully selected and then randomly divided into experimental (n = 16) and control (n = 18) groups. The research instrument included the Self-Compassion Scale and Body Image Concern Inventory. The self-healing training intervention was then performed on the experimental group for twelve 90-min sessions. Finally, both groups underwent the post-test. Follow-up was performed two and four months after the post-test. RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). CONCLUSION The self-healing is an appropriate intervention method to increase self-compassion and reduce body image concern and thus accelerate the process of skin cancer recovery.",2020,"RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). ","['patients with skin cancer', '34 volunteers who were purposefully selected']",['self-healing training'],"['level of body image concern, isolation, and over-identification', 'self-compassion, including self-kindness, self-judgment, and sense of common humanity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0885003', 'cui_str': 'Xiakucao'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0022423', 'cui_str': 'Judgement'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0020157', 'cui_str': 'Humanities'}]",34.0,0.00947867,"RESULTS Self-healing training significantly increased self-compassion, including self-kindness, self-judgment, and sense of common humanity (p < 0.01), and decreased the level of body image concern, isolation, and over-identification (p < 0.05). ","[{'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Latifi', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran. Electronic address: latifizh@gmail.com.'}, {'ForeName': 'Mozhgan', 'Initials': 'M', 'LastName': 'Soltani', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}, {'ForeName': 'Shokoufeh', 'Initials': 'S', 'LastName': 'Mousavi', 'Affiliation': 'Department of Psychology, Payame Noor University, PO BOX 19395-4697, Tehran, Iran.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101180'] 14,32344891,Patient-Reported Outcome Measures (PROMs) for Two Implant Placement Techniques in Sinus Region (Bone Graft versus Computer-Aided Implant Surgery): A Randomized Prospective Trial.,"PURPOSE To assess patient-reported outcomes measures (PROMs) for two implant placement techniques in cases of sinus bone atrophy (bone graft surgery (BGS) versus computer-aided implant surgery (CAIS)), after surgery and one year later, and to evaluate the clinical success of both treatments. METHODS Sixty patients with bone atrophy in the posterior maxilla and in need of implant placement were randomly assigned to two groups, and in accordance with the case report form (CRF), 30 were treated with BGS and 30 with CAIS. Immediately after treatment and one year later, PROMs were assessed, and the clinical success of both treatments was evaluated. RESULTS No significant differences were found between BGS and CAIS with regard to the following: loss of implants ( p = 492); patient recommendation ( p = 210); duration of surgery ( p = 987); pain on the intervention day ( p = 512); pain in the week after intervention ( p = 299); and complications in the stage of surgery ( p = 1.00). Similarly, at one year, no differences were found with regard to the following: pain around implant ( p = 481); infection of implants ( p = 491); abnormal radiographic imaging ( p = 226); occurrence of undesirable events ( p = 1.00); loss of one of the implants ( p = 1.00); plaque detection ( p = 1.00); bleeding on probing ( p = 236); and presence of keratinized mucosa ( p = 226). However, a significant difference was found among BGS and CAIS with regard to the number of consultations ( p = 0001); number of implants placed ( p = 033); and treatment difficulty ( p = 0369). Significant differences were found for peri-implantitis ( p = 0481) and radiology of craterization ( p = 020) in clinical examination at the first year. CONCLUSION Treatment difficulty and number of consultations were higher for BGS than for CAIS, as well as peri-implantitis and bone craterization at one year, indicating significant differences between the two treatments. However, there were no statistically significant differences between BGS and CAIS regarding the other PROMs, at placement and after one year.",2020,"Significant differences were found for peri-implantitis ( p = 0481) and radiology of craterization ( p = 020) in clinical examination at the first year. ",['Sixty patients with bone atrophy in the posterior maxilla and in need of implant placement'],"['sinus bone atrophy (bone graft surgery (BGS) versus computer-aided implant surgery (CAIS', 'BGS and 30 with CAIS']","['BGS and CAIS', 'plaque detection', 'abnormal radiographic imaging', 'occurrence of undesirable events', 'peri-implantitis and bone craterization', 'pain around implant', 'pain', 'peri-implantitis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1389037', 'cui_str': 'Bone atrophy'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C1389037', 'cui_str': 'Bone atrophy'}, {'cui': 'C0005976', 'cui_str': 'Bone graft'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0064494', 'cui_str': 'carboxyamido-triazole'}, {'cui': 'C0265308', 'cui_str': 'Baller-Gerold syndrome'}]","[{'cui': 'C0265308', 'cui_str': 'Baller-Gerold syndrome'}, {'cui': 'C0064494', 'cui_str': 'carboxyamido-triazole'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0457276', 'cui_str': 'Radiographic imaging - action'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C2936258', 'cui_str': 'Dental peri-implantitis'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]",60.0,0.0360508,"Significant differences were found for peri-implantitis ( p = 0481) and radiology of craterization ( p = 020) in clinical examination at the first year. ","[{'ForeName': 'Ghazwan', 'Initials': 'G', 'LastName': 'Almahrous', 'Affiliation': 'Department of Oral Surgery, Dental School, University Claude Bernard, 69003 Lyon, France.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'David-Tchouda', 'Affiliation': 'ThEMAS TIMC UMR CNRS 5525, Grenoble Joseph Fourier University, 38041 Grenoble, France.'}, {'ForeName': 'Aboubacar', 'Initials': 'A', 'LastName': 'Sissoko', 'Affiliation': 'Cellule Data Stat, University Hospital of Grenoble, 38700 Grenoble, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Rancon', 'Affiliation': 'Department of Oral Surgery, Hospices Civils, 69003 Lyon, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Bosson', 'Affiliation': 'ThEMAS TIMC UMR CNRS 5525, Grenoble Joseph Fourier University, 38041 Grenoble, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Fortin', 'Affiliation': 'Department of Oral Surgery, Dental School, University Claude Bernard, 69003 Lyon, France.'}]",International journal of environmental research and public health,['10.3390/ijerph17092990'] 15,32345699,"Study protocol for optimising glycaemic control in type 1 diabetes treated with multiple daily insulin injections: intermittently scanned continuous glucose monitoring, carbohydrate counting with automated bolus calculation, or both? A randomised controlled trial.","INTRODUCTION There are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes. We aim to compare the effects of isCGM, training in carbohydrate counting with ABC and the combination of the two concepts with standard care. METHODS AND ANALYSIS A multi-centre randomised controlled trial with inclusion criteria: ≥18 years, type 1 diabetes ≥1 year, injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting and/or CGM/isCGM wear are exclusion criteria. Inclusion was initiated in October 2018 and is ongoing. Eligible persons are randomised into four groups: standard care, ABC, isCGM or ABC+isCGM. Devices used are FreeStyle Libre Flash and smart phone diabetes application mySugr. Participants attend group courses according to treatment allocation with different educational contents. Participants are followed for 26 weeks with clinical visits and telephone consultations. At baseline and at study end, participants wear blinded CGM, have blood samples performed and fill in questionnaires on person-related outcomes, and at baseline also on personality traits and hypoglycaemia awareness. The primary outcome is the difference in time spent in normoglycaemia (4-10 mmol/L) at study end versus baseline between the isCGM group and the standard care group. Secondary outcomes will also be analysed. Results are expected in 2020. ETHICS AND DISSEMINATION Regional Scientific Ethics Committee approval (H-17040573). Results will be sought disseminated at conferences and in high impact journals.Trial registration numberClinicalTrial.gov registry (NCT03682237).",2020,There are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes.,"['Eligible persons', 'inclusion criteria: ≥18 years, type 1 diabetes ≥1 year, injection therapy, HbA1c >53 mmol/mol, whereas daily use of carbohydrate counting and/or CGM/isCGM wear are exclusion criteria', 'type 1 diabetes treated with multiple daily insulin injections', 'persons with type 1 diabetes']","['advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM', 'standard care, ABC, isCGM or ABC+isCGM']","['personality traits and hypoglycaemia awareness', 'time spent in normoglycaemia']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1562940', 'cui_str': 'Carbohydrate counting'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0199782', 'cui_str': 'Administration of insulin'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0870240', 'cui_str': 'Calculator'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0233849', 'cui_str': 'Character trait finding'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.208788,There are beneficial effects of advanced carbohydrate counting with an automatic bolus calculator (ABC) and intermittently scanned continuous glucose monitoring (isCGM) in persons with type 1 diabetes.,"[{'ForeName': 'Anna Lilja', 'Initials': 'AL', 'LastName': 'Secher', 'Affiliation': 'Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark anna.elisabet.lilja.secher@regionh.dk.'}, {'ForeName': 'Ulrik', 'Initials': 'U', 'LastName': 'Pedersen-Bjergaard', 'Affiliation': 'Endocrine Section, Department of Endocrinology and Nephrology, Nordsjællands Hospital, Hillerod, Denmark.'}, {'ForeName': 'Ole Lander', 'Initials': 'OL', 'LastName': 'Svendsen', 'Affiliation': 'Department of Endocrinology I, Bispebjerg Hospital, Kobenhavn, Denmark.'}, {'ForeName': 'Birthe', 'Initials': 'B', 'LastName': 'Gade-Rasmussen', 'Affiliation': 'Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Almdal', 'Affiliation': 'Department of Endocrinology, Rigshospitalet, Kobenhavn, Denmark.'}, {'ForeName': 'Liv', 'Initials': 'L', 'LastName': 'Dørflinger', 'Affiliation': 'Administration, Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Dorte', 'Initials': 'D', 'LastName': 'Vistisen', 'Affiliation': 'Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Nørgaard', 'Affiliation': 'Clinical Research, Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}]",BMJ open,['10.1136/bmjopen-2019-036474'] 16,32345700,Investigating the effect of clinical pharmacist intervention in transitions of care on drug-related hospital readmissions among the elderly: study protocol for a randomised controlled trial.,"INTRODUCTION Drug-related problems (DRPs) are a major cause of unplanned hospital admissions among elderly people, and transitions of care have been emphasised as a key area for improving patient safety. We have designed a complex clinical pharmacist intervention that targets people ≥75 years of age undergoing transitions of care from hospital to home and primary care. The main objective is to investigate if the intervention can reduce the risk of unplanned drug-related readmission within the first 180 days after the person is discharged from hospital. METHODS AND ANALYSIS This is a randomised, controlled, superiority trial with two parallel arms. A total of 700 people ≥75 years will be assigned to either intervention or routine care (control). The intervention, which aims to find and manage DRPs, is initiated within a week of the person being discharged from hospital and combines repeated medical chart reviews, phone interviews and in some cases medication reviews. People in both study arms may have been the subject of a medication review during their ward stay. As the primary outcome, we will measure time until unplanned drug-related readmission within 180 days of leaving hospital and use log rank tests and Cox proportional hazard models to analyse differences between the groups. Further investigations of subgroup effects and adjustments of the regression models will be based on heart failure and cognitive impairment as prognostic factors. ETHICS AND DISSEMINATION The study has been approved by the Regional Ethical Review Board in Umeå (registration numbers 2017-69-31M, 2018-83-32M and 2018-254-32M). We intend to publish the results with open access in international peer-reviewed journals and present our findings at international conferences. The trial is expected to result in more than one published article and form part of two PhD theses. TRIAL REGISTRATION NUMBER NCT03671629.",2020,"The intervention, which aims to find and manage DRPs, is initiated within a week of the person being discharged from hospital and combines repeated medical chart reviews, phone interviews and in some cases medication reviews.","['Umeå (registration numbers 2017-69-31M, 2018-83-32M and 2018-254-32M', '700 people ≥75 years', 'transitions of care on drug-related hospital readmissions among the elderly', 'people ≥75 years of age undergoing transitions of care from hospital to home and primary care']","['clinical pharmacist intervention', 'intervention or routine care (control']",['measure time until unplanned drug-related readmission within 180 days of leaving hospital and use log rank tests and Cox proportional hazard models'],"[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3266241', 'cui_str': 'Transition of care'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C1449564', 'cui_str': 'Clinical pharmacist'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0010235', 'cui_str': 'Cox Proportional Hazards Models'}]",,0.128434,"The intervention, which aims to find and manage DRPs, is initiated within a week of the person being discharged from hospital and combines repeated medical chart reviews, phone interviews and in some cases medication reviews.","[{'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Kindstedt', 'Affiliation': 'Department of Integrative Medical Biology, Umeå University, Umeå, Sweden jonas.kindstedt@umu.se.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Svahn', 'Affiliation': 'Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Sjölander', 'Affiliation': 'Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Eva-Lotta', 'Initials': 'EL', 'LastName': 'Glader', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Lövheim', 'Affiliation': 'Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gustafsson', 'Affiliation': 'Department of Integrative Medical Biology, Umeå University, Umeå, Sweden.'}]",BMJ open,['10.1136/bmjopen-2019-036650'] 17,32349223,Effects of Small-Sided Recreational Volleyball on Health Markers and Physical Fitness in Middle-Aged Men.,"The present study aimed to investigate whether recreational volleyball organized as small-sided games could improve fitness and health profiles of middle-aged men after 10 weeks of training. Twenty-four healthy men aged 35-55 were randomized in a small-sided recreational volleyball group (RV = 12; age: 44.7 ± 6.34 years; body mass index: 25.85 ± 1.74) and control group (CON = 12; age: 42.9 ± 8.72 years; body mass index: 25.62 ± 1.48). The RV group carried out a volleyball training program, whereas the CON group continued their daily life activities during this period. The participants in the RV group performed 2/3 training sessions of 90 min per week. Results from a repeated measure ANOVA indicated a significant group × time interaction for low-density lipoprotein (LDL) cholesterol (F = 6.776, p = 0.016, partial ƞ 2 = 0.235) and for resting heart rate (F = 11.647, p = 0.002, partial ƞ 2 = 0.346) in favor of the RV group. No significant changes were observed for body weight, body mass index, and diastolic blood pressure. Results for physical fitness indicated a significant interaction for Yo-Yo intermittent recovery test-level 2 (F = 11.648, p = 0.003, partial ƞ 2 = 0.380), with no significant changes in both groups for handgrip strength. Recreational small-sided volleyball can be an effective training modality to stimulate a decrease in LDL cholesterol and resting HR with small improvements in cardiovascular fitness. Recreational volleyball played only two times per week shows positive cardiovascular fitness and health-related adaptations, which may contribute to the reduction of the risk of developing lifestyle diseases.",2020,"Results for physical fitness indicated a significant interaction for Yo-Yo intermittent recovery test-level 2 (F = 11.648, p = 0.003, partial ƞ 2 = 0.380), with no significant changes in both groups for handgrip strength.","['middle-aged men after 10 weeks of training', 'Twenty-four healthy men aged 35-55 were randomized in a small-sided recreational volleyball group (RV = 12; age: 44.7 ± 6.34 years; body mass index: 25.85 ± 1.74) and control group (CON = 12; age: 42.9 ± 8.72 years; body mass index: 25.62 ± 1.48', 'Middle-Aged Men']","['volleyball training program', 'CON', 'recreational volleyball organized as small-sided games', 'Small-Sided Recreational Volleyball']","['Health Markers and Physical Fitness', 'LDL cholesterol and resting HR', 'resting heart rate', 'time interaction for low-density lipoprotein (LDL) cholesterol ', 'handgrip strength', 'body weight, body mass index, and diastolic blood pressure', 'fitness and health profiles']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C1956059', 'cui_str': 'Volleyball'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517773', 'cui_str': '42.9'}]","[{'cui': 'C1956059', 'cui_str': 'Volleyball'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1300196', 'cui_str': 'Organized'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",24.0,0.0215048,"Results for physical fitness indicated a significant interaction for Yo-Yo intermittent recovery test-level 2 (F = 11.648, p = 0.003, partial ƞ 2 = 0.380), with no significant changes in both groups for handgrip strength.","[{'ForeName': 'Nebojša', 'Initials': 'N', 'LastName': 'Trajković', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, 21101 Novi Sad, Serbia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Sporiš', 'Affiliation': 'Faculty of Kinesiology, University of Zagreb, 10110 Zagreb, Croatia.'}, {'ForeName': 'Tomislav', 'Initials': 'T', 'LastName': 'Krističević', 'Affiliation': 'Faculty of Kinesiology, University of Zagreb, 10110 Zagreb, Croatia.'}, {'ForeName': 'Špela', 'Initials': 'Š', 'LastName': 'Bogataj', 'Affiliation': 'Department of Nephrology, University Medical Centre, 1000 Ljubljana, Slovenia.'}]",International journal of environmental research and public health,['10.3390/ijerph17093021'] 18,32349260,Impact of Combined Theory-Based Intervention on Psychological Effects and Physical Activity among Chinese Adolescents.,"PURPOSE The current study was intended to assess the effect of a facilitated behavioral intervention based on the extended theory of planned behavior (TPB) on psychological constructs and physical activity among adolescents over a period of eight weeks. METHODS Students ( n = 51, 12 ± 0.3 years of age) in the seventh grade at a junior middle school in China were randomly assigned to two groups: the intervention group ( n = 24) and the control group ( n = 27). Both groups were pre- and post-tested with the related psychological constructs of the extended TPB, along with behavioral measures of the Physical Activity Scale and ActiGraph accelerometer (model wGT3X-BT). The intervention group took part in 45 min classes once per week for 8 weeks, including five indoor theoretical courses and three outdoor basketball matches. The control group was not required to make any change to their normal school day. Also, 2 × 2 repeated measures analysis of variance (ANOVA) was conducted to compare the differences between the two groups, and then t -test was employed to compare the independent and paired differences. RESULTS Significant increases in pre-post subjective norms (SN) ( p = 0.041, Cohen's d = 0.62), perceived behavior control (PBC) ( p = 0.023, Cohen's d = 0.72), exercise intention (EI) ( p = 0.043, Cohen's d = 0.61), and self-efficacy (SE) ( p = 0.035, Cohen's d = 1.36) were observed in the intervention group. In addition, participants in the intervention group increased their exercise frequency ( p < 0.001, Cohen's d = 1.25) and intensity ( p = 0.028, Cohen's d = 0.68), especially their time spent on light intensity physical activity (light-PA%; p = 0.031, Cohen's d = 0.68), and their percentage of sedentary time (SB%) was also reduced (from 68% ± 10% to 58% ± 7%, p < 0.001, Cohen's d = 1.17). Furthermore, the intervention group showed significantly better performance in PBC ( p = 0.032, Cohen's d = 0.62), EI ( p < 0.001, Cohen's d = 1.32), SE ( p < 0.001, Cohen's d = 1.15), SB% ( p < 0.001, Cohen's d = 1.22), light-PA% ( p < 0.001, Cohen's d = 1.12), and total physical activity (TPA) ( p = 0.015, Cohen's d = 0.72) compared to the control group at the post-test. No significant pre post differences were observed for any psychological or behavioral variables in the control group, except for exercise frequency, but the values were still lower than those in the intervention group after the 8-week intervention (3.70 ± 0.72 versus 3.92 ± 0.83). CONCLUSION The combined theory-based intervention was effective at improving psychological constructs and physical activity among seventh-grade adolescents in 8 weeks.",2020,"No significant pre post differences were observed for any psychological or behavioral variables in the control group, except for exercise frequency, but the values were still lower than those in the intervention group after the 8-week intervention (3.70 ± 0.72 versus 3.92 ± 0.83). ","['Chinese Adolescents', 'Students ( n = 51, 12 ± 0.3 years of age) in the seventh grade at a junior middle school in China', 'adolescents over a period of eight weeks']","['planned behavior (TPB', 'facilitated behavioral intervention', 'Combined Theory-Based Intervention']","['SB', 'perceived behavior control (PBC', 'exercise frequency', 'time spent on light intensity physical activity', 'psychological constructs and physical activity', 'performance in PBC', 'pre-post subjective norms (SN', 'percentage of sedentary time (SB', 'light-PA', 'total physical activity (TPA', 'exercise intention (EI', 'Physical Activity Scale and ActiGraph accelerometer (model wGT3X-BT', 'self-efficacy (SE', 'psychological or behavioral variables', 'Psychological Effects and Physical Activity']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205441', 'cui_str': 'Seventh'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0376287', 'cui_str': 'Behavioral Manipulation'}, {'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}, {'cui': 'C0556455', 'cui_str': 'Frequency of exercise'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0277631,"No significant pre post differences were observed for any psychological or behavioral variables in the control group, except for exercise frequency, but the values were still lower than those in the intervention group after the 8-week intervention (3.70 ± 0.72 versus 3.92 ± 0.83). ","[{'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Yin', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}, {'ForeName': 'Jianxiu', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}, {'ForeName': 'Zeshi', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}, {'ForeName': 'Xindong', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'Division of Sports Science & Physical Education, Tsinghua University, Qinghuayuan street, Haidian district, Beijing 100084, China.'}]",International journal of environmental research and public health,['10.3390/ijerph17093026'] 19,32347799,The Effect of Shame on Patients With Social Anxiety Disorder in Internet-Based Cognitive Behavioral Therapy: Randomized Controlled Trial.,"BACKGROUND Prior research has demonstrated the efficacy of internet-based cognitive behavioral therapy (ICBT) for social anxiety disorder (SAD). However, it is unclear how shame influences the efficacy of this treatment. OBJECTIVE This study aimed to investigate the role shame played in the ICBT treatment process for participants with SAD. METHODS A total of 104 Chinese participants (73 females; age: mean 24.92, SD 4.59 years) were randomly assigned to self-help ICBT, guided ICBT, or wait list control groups. For the guided ICBT group, half of the participants were assigned to the group at a time due to resource constraints. This led to a time difference among the three groups. Participants were assessed before and immediately after the intervention using the Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). RESULTS Participants' social anxiety symptoms (self-help: differences between pre- and posttreatment SIAS=-12.71; Cohen d=1.01; 95% CI 9.08 to 16.32; P<.001 and differences between pre- and posttreatment SPS=11.13; Cohen d=0.89; 95% CI 6.98 to 15.28; P<.001; guided: SIAS=19.45; Cohen d=1.20; 95% CI 14.67 to 24.24; P<.001 and SPS=13.45; Cohen d=0.96; 95% CI 8.26 to 18.64; P<.001) and shame proneness (self-help: differences between pre- and posttreatment ESS=7.34; Cohen d=0.75; 95% CI 3.99 to 10.69; P<.001 and guided: differences between pre- and posttreatment ESS=9.97; Cohen d=0.88; 95% CI 5.36 to 14.57; P<.001) in both the self-help and guided ICBT groups reduced significantly after treatment, with no significant differences between the two intervention groups. Across all the ICBT sessions, the only significant predictors of reductions in shame proneness were the average number of words participants wrote in the exposure module (β=.222; SE 0.175; t 96 =2.317; P=.02) and gender (β=-.33; SE 0.002; t 77 =-3.13; P=.002). We also found a mediation effect, wherein reductions in shame fully mediated the relationship between the average number of words participants wrote in the exposure module and reductions in social anxiety symptoms (SIAS: β=-.0049; SE 0.0016; 95% CI -0.0085 to -0.0019 and SPS: β=-.0039; SE 0.0015; 95% CI -0.0075 to -0.0012). CONCLUSIONS The findings of this study suggest that participants' engagement in the exposure module in ICBT alleviates social anxiety symptoms by reducing the levels of shame proneness. Our study provides a new perspective for understanding the role of shame in the treatment of social anxiety. The possible mechanisms of the mediation effect and clinical implications are discussed. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR1900021952; http://www.chictr.org.cn/showproj.aspx?proj=36977.",2020,"Participants were assessed before and immediately after the intervention using Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). ","['104 Chinese participants (73 females; age: mean 24.92 years, SD 4.59', 'Patients With Social Anxiety Disorder in Internet-Based', 'participants with SAD.\nMETHODS']","['ICBT', 'internet-based cognitive behavioral therapy (ICBT', 'Cognitive Behavioral Therapy']","['social anxiety symptoms', 'shame proneness', 'Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS', 'ICBT alleviates social anxiety symptoms']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036938', 'cui_str': 'Shame'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031572', 'cui_str': 'Social phobia'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]",104.0,0.0369145,"Participants were assessed before and immediately after the intervention using Social Interaction Anxiety Scale (SIAS), Social Phobia Scale (SPS), and Experience of Shame Scale (ESS). ","[{'ForeName': 'Haoyu', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Qingxue', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Mu', 'Affiliation': 'Center for the Treatment and Study of Anxiety, University of Pennsylvania, Pennsylvania, PA, United States.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Psychology, Pitzer College, California, CA, United States.'}, {'ForeName': 'Mingyi', 'Initials': 'M', 'LastName': 'Qian', 'Affiliation': 'School of Psychological and Cognitive Sciences, Peking University, Beijing, China.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berger', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}]",JMIR mental health,['10.2196/15797'] 20,32348007,"A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.","OBJECTIVE Helicobacter pylori (H. pylori) infection is closely associated with gastric ulcers and gastric adenocarcinomas. We aimed to assess the efficacy and safety of a quadruple regimen with amoxicillin plus berberine vs tetracycline plus furazolidone in rescue therapy for H. pylori eradication. METHODS We conducted a randomized, open-label, multicenter, noninferiority trial. Patients with previous treatment failures recruited from five centers were randomized (1:1) to receive a regimen with esomeprazole and bismuth plus either berberine and amoxicillin (the BA group) or tetracycline and furazolidone (the TF group) for 14 days. Their H. pylori infection status was confirmed 4-8 weeks after treatment. The primary outcome was the eradication rate. The secondary outcomes included the rates of symptom improvement, compliance, and adverse events. This study was registered at ClinicalTrials.gov (NCT03609892). RESULTS Altogether 658 participants were consecutively enrolled. An intention-to-treat analysis demonstrated that the two regimens achieved a similar eradication rate (76.3% vs 77.5%; P = 0.781). The per-protocol analysis reached a similar result (81.5% vs 85.0%; P = 0.278). The eradication rate reached in the BA group was greater than the pre-established margin of noninferiority, at -10% (the lower bounds of the 95% CI were -7.66% and -9.43%, respectively). The rate of adverse events was lower for the BA group than the TF group (18.5% vs 26.1%, P = 0.024). Rates of compliance and symptom improvement were similar for the two therapies. CONCLUSION The efficacy of both regimens in rescue treatment for H. pylori eradication was satisfactory, 14-day BA-based quadruple therapy is noninferior to the TF-based therapy.",2020,"The rate of adverse events was lower for BA than TF therapy (18.5% vs 26.1%, P = 0.024).","['Subjects with previous treatment failures recruited from 5 centers', 'gastric ulcers and gastric adenocarcinoma', '658 subjects were consecutively enrolled in total']","['esomeprazole and bismuth plus either berberine and amoxicillin (BA group) or tetracycline and furazolidone (TF group', 'amoxicillin plus berberine vs tetracycline plus furazolidone', 'Amoxicillin plus Berberine vs Tetracycline plus Furazolidone']","['rate of adverse events', 'rates of symptom improvement, compliance and adverse events', 'rates of compliance and symptom improvement', 'H. pylori infection status', 'eradication rate', 'efficacy and safety']","[{'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038358', 'cui_str': 'Gastric ulcer'}, {'cui': 'C0278701', 'cui_str': 'Adenocarcinoma of stomach'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0937846', 'cui_str': 'Esomeprazole'}, {'cui': 'C0005642', 'cui_str': 'Bismuth'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039644', 'cui_str': 'Tetracycline'}, {'cui': 'C0016855', 'cui_str': 'Furazolidone'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",658.0,0.115176,"The rate of adverse events was lower for BA than TF therapy (18.5% vs 26.1%, P = 0.024).","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi Province, China.""}, {'ForeName': 'Chuan', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': ""State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi Province, China.""}, {'ForeName': 'Wen Quan', 'Initials': 'WQ', 'LastName': 'Lu', 'Affiliation': 'Department of Gastroenterology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': ""State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi Province, China.""}, {'ForeName': 'Si Ran', 'Initials': 'SR', 'LastName': 'Wu', 'Affiliation': ""State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi Province, China.""}, {'ForeName': 'Yong Xi', 'Initials': 'YX', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi Province, China.'}, {'ForeName': 'Jin Ping', 'Initials': 'JP', 'LastName': 'Ma', 'Affiliation': 'Department of Gastroenterology, Xianyang Central Hospital, Xianyang, Shaanxi Province, China.'}, {'ForeName': 'Jie Hong', 'Initials': 'JH', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi Province, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Hao', 'Affiliation': 'Department of Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi Province, China.'}, {'ForeName': 'Dong Hong', 'Initials': 'DH', 'LastName': 'Yuan', 'Affiliation': ""Department of Gastroenterology, Yan'an University Affiliated Hospital, Yan'an, Shaanxi Province, China.""}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Liu', 'Affiliation': ""Department of Gastroenterology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.""}, {'ForeName': 'Yong Quan', 'Initials': 'YQ', 'LastName': 'Shi', 'Affiliation': ""State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Air Force Military Medical University, Xi'an, Shaanxi Province, China.""}]",Journal of digestive diseases,['10.1111/1751-2980.12870'] 21,32350016,Clinical and cost-effectiveness of a diabetes education and behavioural weight management programme versus a diabetes education programme in adults with a recent diagnosis of type 2 diabetes: study protocol for the Glucose Lowering through Weight management (GLoW) randomised controlled trial.,"INTRODUCTION People with type 2 diabetes (T2D) can improve glycaemic control or even achieve remission through weight loss and reduce their use of medication and risk of cardiovascular disease. The Glucose Lowering through Weight management (GLoW) trial will evaluate whether a tailored diabetes education and behavioural weight management programme (DEW) is more effective and cost-effective than a diabetes education (DE) programme in helping people with overweight or obesity and a recent diagnosis of T2D to lower their blood glucose, lose weight and improve other markers of cardiovascular risk. METHODS AND ANALYSIS This study is a pragmatic, randomised, single-blind, parallel group, two-arm, superiority trial. We will recruit 576 adults with body mass index>25 kg/m 2 and diagnosis of T2D in the past 3 years and randomise them to a tailored DEW or a DE programme. Participants will attend measurement appointments at a local general practitioner practice or research centre at baseline, 6 and 12 months. The primary outcome is 12-month change in glycated haemoglobin. The effect of the intervention on the primary outcome will be estimated and tested using a linear regression model (analysis of covariance) including randomisation group and adjusted for baseline value of the outcome and the randomisation stratifiers. Participants will be included in the group to which they were randomised, under the intention-to-treat principle. Secondary outcomes include 6-month and 12-month changes in body weight, body fat percentage, systolic and diastolic blood pressure and lipid profile; probability of achieving good glycaemic control; probability of achieving remission from diabetes; probability of losing 5% and 10% body weight and modelled cardiovascular risk (UKPDS). An intention-to-treat within-trial cost-effectiveness analysis will be conducted from NHS and societal perspectives using participant-level data. Qualitative interviews will be conducted with participants to understand why and how the programme achieved its results and how participants manage their weight after the programme ends. ETHICS AND DISSEMINATION Ethical approval was received from East of Scotland Research Ethics Service on 15 May 2018 (18/ES/0048). This protocol (V.3) was approved on 19 June 2019. Findings will be published in peer-reviewed scientific journals and communicated to other stakeholders as appropriate. TRIAL REGISTRATION NUMBER ISRCTN18399564.",2020,"The Glucose Lowering through Weight management (GLoW) trial will evaluate whether a tailored diabetes education and behavioural weight management programme (DEW) is more effective and cost-effective than a diabetes education (DE) programme in helping people with overweight or obesity and a recent diagnosis of T2D to lower their blood glucose, lose weight and improve other markers of cardiovascular risk. ","['adults with a recent diagnosis of type 2 diabetes', '576 adults with body mass index>25 kg/m 2 and diagnosis of T2D in the past 3 years and randomise them to a tailored DEW or a DE programme', 'People with type 2 diabetes (T2D', 'Participants will attend measurement appointments at a local general practitioner practice or research centre at baseline, 6 and 12 months']","['diabetes education programme', 'behavioural weight management programme (DEW', 'diabetes education (DE) programme', 'diabetes education and behavioural weight management programme']","['12-month change in glycated haemoglobin', '6-month and 12-month changes in body weight, body fat percentage, systolic and diastolic blood pressure and lipid profile; probability of achieving good glycaemic control; probability of achieving remission from diabetes; probability of losing 5% and 10% body weight and modelled cardiovascular risk (UKPDS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",576.0,0.178744,"The Glucose Lowering through Weight management (GLoW) trial will evaluate whether a tailored diabetes education and behavioural weight management programme (DEW) is more effective and cost-effective than a diabetes education (DE) programme in helping people with overweight or obesity and a recent diagnosis of T2D to lower their blood glucose, lose weight and improve other markers of cardiovascular risk. ","[{'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'Ahern', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK ala34@cam.ac.uk.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Woolston', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Wells', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Sharp', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Nazrul', 'Initials': 'N', 'LastName': 'Islam', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Emma Ruth', 'Initials': 'ER', 'LastName': 'Lawlor', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Robbie', 'Initials': 'R', 'LastName': 'Duschinsky', 'Affiliation': 'Primary Care Unit, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Hill', 'Affiliation': 'School of Medicine, University of Leeds, Leeds, West Yorkshire, UK.'}, {'ForeName': 'Brett', 'Initials': 'B', 'LastName': 'Doble', 'Affiliation': 'Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Ed', 'Initials': 'E', 'LastName': 'Wilson', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norwich, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Morris', 'Affiliation': 'Primary Care Unit, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Carly A', 'Initials': 'CA', 'LastName': 'Hughes', 'Affiliation': 'Patient and Public Involvement Representative, Fakenham Medical Practice, Fakenham, Norfolk, UK.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Brennan', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bostock', 'Affiliation': 'Patient and Public Involvement Representative, Kent, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Boothby', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Griffin', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, Cambridgeshire, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035020'] 22,32291107,"Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021.",,2020,,['Metastatic Castration-sensitive Prostate Cancer'],"['Androgen Deprivation Therapy', 'Abiraterone Acetate plus Prednisone or Placebos']",[],"[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C2607886', 'cui_str': 'Abiraterone acetate'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0565058,,"[{'ForeName': 'B Andes', 'Initials': 'BA', 'LastName': 'Hess', 'Affiliation': 'Department of Chemistry, Vanderbilt University, Nashville, TN, 37235 USA. Electronic address: b.andes.hess@vanderbilt.edu.'}]",European urology,['10.1016/j.eururo.2020.03.018'] 23,32353246,Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial.,"Rationale: Excessive daytime sleepiness in patients with obstructive sleep apnea is associated with substantial burden of illness. Objectives: To assess treatment effects of solriamfetol, a dopamine/norepinephrine reuptake inhibitor, on daily functioning, health-related quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness as additional outcomes in a 12-week phase 3 trial (www.clinicaltrials.gov identifier NCT02348606). Methods: Participants ( N  = 476) were randomized to solriamfetol 37.5, 75, 150, or 300 mg or to placebo. Outcome measures included the Functional Outcomes of Sleep Questionnaire short version, Work Productivity and Activity Impairment Questionnaire: Specific Health Problem, and 36-item Short Form Health Survey version 2. A mixed-effects model with repeated measures was used for comparisons with placebo. Results: Demographics, baseline disease characteristics, daily functioning, health-related quality of life, and work productivity were similar across groups. At Week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 mg (mean difference from placebo [95% confidence interval]) on the basis of Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57 to 1.88] and 1.47 [0.80 to 2.13], respectively), overall work impairment (-11.67 [-19.66 to -3.69] and -11.75 [-19.93 to -3.57], respectively), activity impairment (-10.42 [-16.37 to -4.47] and -10.51 [-16.59 to -4.43], respectively), physical component summary (2.07 [0.42 to 3.72] and 1.91 [0.22 to 3.59], respectively), and mental component summary (150 mg only, 2.05 [0.14 to 3.96]). Common adverse events were headache, nausea, decreased appetite, and anxiety. Conclusions: Solriamfetol improved measures of functioning, quality of life, and work productivity in participants with obstructive sleep apnea and excessive daytime sleepiness. Safety was consistent with previous studies.Clinical trial registered with www.clinicaltrials.gov (NCT02348606).",2020,"At week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 milligrams (mean difference from placebo [95% confidence interval]): Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57, 1.88]) and (1.47 [0.80, 2.13], respectively), overall work impairment (-11.67 [-19.66, -3.69] and -11.75","['patients with obstructive sleep apnea', 'Participants (N=476', 'participants with obstructive sleep apnea and excessive daytime sleepiness']","['Solriamfetol', 'placebo']","['Functional Outcomes of Sleep Questionnaire short version, Work Productivity and Activity Impairment questionnaire for Specific Health Problem, and 36-Item Short Form Health Survey version 2', 'respectively) activity impairment ', 'functioning, quality of life, and work productivity', 'increased functioning and decreased impairment', 'Quality of Life Measures', 'headache, nausea, decreased appetite, and anxiety', 'overall work impairment', 'Demographics, baseline disease characteristics, daily functioning, health-related quality of life, and work productivity', 'daily functioning, health-related quality of life, and work productivity', 'Functional Outcomes of Sleep Questionnaire total score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}]","[{'cui': 'C4726765', 'cui_str': 'Solriamfetol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",476.0,0.19542,"At week 12, increased functioning and decreased impairment were observed with solriamfetol 150 and 300 milligrams (mean difference from placebo [95% confidence interval]): Functional Outcomes of Sleep Questionnaire total score (1.22 [0.57, 1.88]) and (1.47 [0.80, 2.13], respectively), overall work impairment (-11.67 [-19.66, -3.69] and -11.75","[{'ForeName': 'Terri E', 'Initials': 'TE', 'LastName': 'Weaver', 'Affiliation': 'University of Illinois at Chicago College of Nursing, Chicago, Illinois.'}, {'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Drake', 'Affiliation': 'Henry Ford Hospital Sleep Disorders and Research Center, Detroit, Michigan.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Benes', 'Affiliation': 'Somni Bene Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Stern', 'Affiliation': 'Advanced Respiratory and Sleep Medicine, PLLC, Huntersville, North Carolina.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Maynard', 'Affiliation': 'CTI Clinical Research Center, Cincinnati, Ohio.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Thein', 'Affiliation': 'Pacific Research Network, Evolution Research Group, LLC, San Diego, California.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Andry', 'Affiliation': 'Sleep Therapy & Research Center, San Antonio, Texas.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Hudson', 'Affiliation': 'FutureSearch Trials of Neurology LP, Austin, Texas.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Lawrence P', 'Initials': 'LP', 'LastName': 'Carter', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Bron', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lee', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Black', 'Affiliation': 'Jazz Pharmaceuticals, Palo Alto, California.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Bogan', 'Affiliation': 'SleepMed, Inc., Columbia, South Carolina; and.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.202002-136OC'] 24,32349359,Effectiveness of the Reasoning and Rehabilitation V2 Programme for Improving Personal and Social Skills in Spanish Adolescent Students.,"Significant progress has been made in developing intervention programmes for adolescents at high risk of delinquency, school failure and emotional problems. The most effective programmes incorporate behavioural and skills training aimed at changing attitudes and promoting psychosocial and emotional skills in adolescents. This study examined the effectiveness of a school-based intervention programme based on the Reasoning and Rehabilitation V2 (R&R2). R&R2 is a cognitive behavioural programme developed using psychological theories about the aetiology of delinquency, as well as the cognitive, behavioural and socioemotional deficits in high-risk youth populations. A sample of 142 students (aged 13-17 years old) who were attending alternative education provision in Spain were randomly assigned to two experimental conditions (68 experimental group, 74 control group). The results showed that the R&R2 improved participants' self-esteem, social skills, empathy and rational problem-solving with a medium-large effect size (η2 = 0.08 to 0.26). The effects of the programme were significant after controlling for age and the pre-test scores in baseline. These findings confirm the effectiveness of the Reasoning and Rehabilitation V2 programme in Spanish adolescent students and offer additional evidence regarding the implementation of the R&R2 programme in both alternative educational and mainstream school settings.",2020,"The results showed that the R&R2 improved participants' self-esteem, social skills, empathy and rational problem-solving with a medium-large effect size (η2 = 0.08 to 0.26).","['142 students (aged 13-17 years old) who were attending alternative education provision in Spain', 'Spanish Adolescent Students', 'Spanish adolescent students', 'adolescents at high risk of delinquency, school failure and emotional problems', 'adolescents']","['Reasoning and Rehabilitation V2 Programme', 'R&R2', 'school-based intervention programme']","['Personal and Social Skills', ""R&R2 improved participants' self-esteem, social skills, empathy and rational problem-solving with a medium-large effect size""]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0022438', 'cui_str': 'Juvenile Delinquency'}, {'cui': 'C0681374', 'cui_str': 'Academic Failure'}, {'cui': 'C0677660', 'cui_str': 'Emotional problems'}]","[{'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",142.0,0.0212119,"The results showed that the R&R2 improved participants' self-esteem, social skills, empathy and rational problem-solving with a medium-large effect size (η2 = 0.08 to 0.26).","[{'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Sánchez-SanSegundo', 'Affiliation': 'Department of Health Psychology, Faculty of Health Science, University of Alicante, 03690 Alicante, Spain.'}, {'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Ferrer-Cascales', 'Affiliation': 'Department of Health Psychology, Faculty of Health Science, University of Alicante, 03690 Alicante, Spain.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Albaladejo-Blazquez', 'Affiliation': 'Department of Health Psychology, Faculty of Health Science, University of Alicante, 03690 Alicante, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Alarcó-Rosales', 'Affiliation': 'Department of Health Psychology, Faculty of Health Science, University of Alicante, 03690 Alicante, Spain.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Bowes', 'Affiliation': 'Cardiff School of Sport and Health Sciences, University of Cardiff, Cardiff CF23 6XD, UK.'}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Ruiz-Robledillo', 'Affiliation': 'Department of Health Psychology, Faculty of Health Science, University of Alicante, 03690 Alicante, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17093040'] 25,32349413,Feasibility and Tolerability of a Culture-Based Virtual Reality (VR) Training Program in Patients with Mild Cognitive Impairment: A Randomized Controlled Pilot Study.,"The present study examined whether a culture-based virtual reality (VR) training program is feasible and tolerable for patients with amnestic mild cognitive impairment (aMCI), and whether it could improve cognitive function in these patients. Twenty-one outpatients with aMCI were randomized to either the VR-based training group or the control group in a 1∶1 ratio. The VR-based training group participated in training for 30 min/day, two days/week, for three months (24 times). The VR-based program was designed based on Korean traditional culture and used attention, processing speed, executive function and memory conditions to stimulate cognitive function. The adherence to the culture-based VR training program was 91.55% ± 6.41% in the VR group. The only adverse events observed in the VR group were dizziness (4.2%) and fatigue (8.3%). Analysis revealed that the VR-based training group exhibited no significant differences following the three-month VR program in Korean Mini-Mental State Examination (K-MMSE) scores, working memory functions such as performance on the digit span test, or in Stroop test performance and word fluency. We conclude that although the 12-week culture-based VR training program did not improve cognitive function, our findings revealed that the culture-based VR training program was feasible and tolerable for participants with aMCI.",2020,The adherence to the culture-based VR training program was 91.55% ± 6.41% in the VR group.,"['patients with amnestic mild cognitive impairment (aMCI', 'Twenty-one outpatients with aMCI', 'participants with aMCI', 'Patients with Mild Cognitive Impairment']","['VR-based training group or the control', 'culture-based virtual reality (VR) training program', 'Culture-Based Virtual Reality (VR) Training Program']","['dizziness', 'fatigue', 'Feasibility and Tolerability', 'cognitive function', 'Korean Mini-Mental State Examination (K-MMSE) scores, working memory functions such as performance on the digit span test, or in Stroop test performance and word fluency', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",21.0,0.0105873,The adherence to the culture-based VR training program was 91.55% ± 6.41% in the VR group.,"[{'ForeName': 'Jong-Hwan', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Health Convergence Medicine Laboratory, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea.'}, {'ForeName': 'Yung', 'Initials': 'Y', 'LastName': 'Liao', 'Affiliation': 'Department of Health Promotion and Health Education, National Taiwan Normal University, Taipei 10610, Taiwan.'}, {'ForeName': 'Du-Ri', 'Initials': 'DR', 'LastName': 'Kim', 'Affiliation': 'Health Convergence Medicine Laboratory, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea.'}, {'ForeName': 'Seunghwan', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Korea.'}, {'ForeName': 'Jun Ho', 'Initials': 'JH', 'LastName': 'Lim', 'Affiliation': 'Department of Neurology, College of Medicine, Dong-A University, Busan 49201, Korea.'}, {'ForeName': 'Hyuntae', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Department of Health Care and Science, Dong-A University, Busan 49315, Korea.'}, {'ForeName': 'Yeanhwa', 'Initials': 'Y', 'LastName': 'Lee', 'Affiliation': 'SY Inotech, Busan 48520, Korea.'}, {'ForeName': 'Kyung Won', 'Initials': 'KW', 'LastName': 'Park', 'Affiliation': 'Department of Neurology, College of Medicine, Dong-A University, Busan 49201, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17093030'] 26,32349779,"CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled clinical trial.","BACKGROUND Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy is widely used in peripheral T cell lymphoma (PTCL). Here we conducted a phase 2, multicenter, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating regimen with CEOP in newly diagnosed PTCL. METHODS PTCL patients, except for anaplastic large cell lymphoma-anaplastic lymphoma kinase positive, were 1:1 randomly assigned to receive CEOP/IVE/GDP (CEOP, cyclophosphamide 750 mg/m 2 , epirubicin 70 mg/m 2 , vincristine 1.4 mg/m 2 [maximum 2 mg] on day 1, and prednisone 60 mg/m 2 [maximum 100 mg] on days 1-5 every 21 days, at the first and fourth cycle; IVE, ifosfamide 2000 mg/m 2 on days 1-3, epirubicin 70 mg/m 2 on day 1, and etoposide 100 mg/m 2 on days 1-3 every 21 days, at the second and fifth cycle; and GDP, gemcitabine 1000 mg/m 2 on days 1 and 8, cisplatin 25 mg/m 2 on days 1-3, and dexamethasone 40 mg on days 1-4 every 21 days, at the third and sixth cycle) and CEOP (every 21 days for 6 cycles). Analysis of efficacy and safety was of the intent-to-treatment population. The primary endpoint was a complete response rate at the end of treatment. Meanwhile, whole exome sequencing and targeted sequencing were performed in 62 patients with available tumor samples to explore prognostic biomarkers in this cohort as an exploratory post hoc analysis. RESULTS Among 106 patients, 53 each were enrolled to CEOP/IVE/GDP and CEOP. With 51 evaluable patients each in two groups, a complete response rate of the CEOP/IVE/GDP group was similar to that of the CEOP group (37.3% vs. 31.4%, p = 0.532). There was no difference in median progression-free survival (PFS; 15.4 months vs. 9.2 months, p = 0.122) or overall survival (OS; 24.3 months vs. 21.9 months, p = 0.178). Grade 3-4 hematological and non-hematological adverse events were comparable. Histone modification genes were most frequently mutated (25/62, 40.3%), namely KMT2D, KMT2A, SETD2, EP300, and CREBBP. Multivariate analysis indicated that CREBBP and IDH2 mutations were independent factors predicting poor PFS and OS (all p < 0.001), while KMT2D predicting poor PFS (p = 0.002). CONCLUSIONS CEOP/IVE/GDP alternating regimen showed no remission or survival advantage to standard chemotherapy. Future clinical trials should aim to develop alternative regimen targeting disease biology as demonstrated by recurrent mutations in epigenetic factors. TRIAL REGISTRATION The study was registered on ClinicalTrial.gov (NCT02533700) on August 27, 2015.",2020,"There was no difference in median progression-free survival (PFS; 15.4 months vs. 9.2 months, p = 0.122) or overall survival (OS; 24.3 months vs. 21.9 months, p = 0.178).","['106 patients, 53 each were enrolled to CEOP/IVE/GDP and CEOP', '62 patients with available tumor samples', 'newly diagnosed patients with peripheral T cell lymphoma', 'PTCL patients, except for anaplastic large cell lymphoma-anaplastic lymphoma kinase positive']","['CEOP/IVE/GDP alternating regimen with CEOP', 'Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)/CHOP-like chemotherapy', 'ifosfamide 2000\u2009mg/m 2 on days 1-3, epirubicin 70\u2009mg/m 2 on day 1, and etoposide', 'CEOP/IVE/GDP (CEOP, cyclophosphamide 750\u2009mg/m 2 , epirubicin 70\u2009mg/m 2 , vincristine 1.4\u2009mg/m 2 [maximum 2\u2009mg] on day 1, and prednisone 60\u2009mg/m 2 [maximum 100\u2009mg', 'IVE/GDP alternating regimen', 'CEOP', 'GDP, gemcitabine 1000\u2009mg/m 2 on days 1 and 8, cisplatin 25\u2009mg/m 2 on days 1-3, and dexamethasone']","['Grade 3-4 hematological and non-hematological adverse events', 'median progression-free survival', 'overall survival', 'remission or survival advantage', 'efficacy and safety', 'complete response rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018340', 'cui_str': 'Guanosine diphosphate'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0079774', 'cui_str': 'Peripheral T-cell lymphoma'}, {'cui': 'C0332300', 'cui_str': 'Except for'}, {'cui': 'C0206180', 'cui_str': 'Large cell anaplastic lymphoma'}, {'cui': 'C0252409', 'cui_str': 'ALK Tyrosine Kinase Receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0018340', 'cui_str': 'Guanosine diphosphate'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0014582', 'cui_str': 'Epirubicin'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4057589', 'cui_str': 'gemcitabine 1000 MG'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]",62.0,0.0697427,"There was no difference in median progression-free survival (PFS; 15.4 months vs. 9.2 months, p = 0.122) or overall survival (OS; 24.3 months vs. 21.9 months, p = 0.178).","[{'ForeName': 'Ming-Ci', 'Initials': 'MC', 'LastName': 'Cai', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Cheng', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Jian-Da', 'Initials': 'JD', 'LastName': 'Hu', 'Affiliation': 'Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Yong-Ping', 'Initials': 'YP', 'LastName': 'Song', 'Affiliation': 'Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Yao-Hui', 'Initials': 'YH', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Zi-Xun', 'Initials': 'ZX', 'LastName': 'Yan', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Yu-Jie', 'Initials': 'YJ', 'LastName': 'Jiang', 'Affiliation': 'Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Xiao-Sheng', 'Initials': 'XS', 'LastName': 'Fang', 'Affiliation': 'Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Zheng', 'Affiliation': 'Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Li-Hua', 'Initials': 'LH', 'LastName': 'Dong', 'Affiliation': 'Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Meng-Meng', 'Initials': 'MM', 'LastName': 'Ji', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Peng-Peng', 'Initials': 'PP', 'LastName': 'Xu', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China.'}, {'ForeName': 'Wei-Li', 'Initials': 'WL', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Er Road, Shanghai, 200025, China. zhao.weili@yahoo.com.'}]",Genome medicine,['10.1186/s13073-020-00739-0'] 27,32354051,Developing and Evaluating an Educational Program for Respiratory Infection Prevention among Rural Elderly Residents in South Korea.,"Based on social cognitive theory (SCT), an educational program was developed to prevent rural elderly residents from respiratory infections in South Korea. The effectiveness of the program was investigated in terms of knowledge, attitudes, and practices about respiratory infection prevention, as well as social capital. A pretest-posttest nonequivalent control group quasi-experimental design was used to test the short-term effect of this program. In addition, 1- and 6-month follow-up surveys were administered to evaluate the long-term effects. A total of 69 subjects (37 in the experimental group and 32 in the control group) participated in the experiment. The results showed that knowledge about respiratory infection prevention, respiratory infection prevention practices, and social capital were enhanced among the elderly residents who participated in the educational program. The educational effects differed significantly across time periods (pretest, posttest, 1- and 6-month follow up) in all the above variables. In particular, the program remained effective 1 month after the intervention, but a reinforcement session extended the program's effects up to 6 months later. This educational program would be used as an effective intervention to help rural elderly residents prevent respiratory infections.",2020,"The results showed that knowledge about respiratory infection prevention, respiratory infection prevention practices, and social capital were enhanced among the elderly residents who participated in the educational program.","['rural elderly residents prevent respiratory infections', 'rural elderly residents from respiratory infections in South Korea', 'Rural Elderly Residents in South Korea', '69 subjects (37 in the experimental group and 32 in the control group) participated in the experiment', 'elderly residents who participated in the educational program']","['Educational Program', 'social cognitive theory (SCT']","['knowledge about respiratory infection prevention, respiratory infection prevention practices, and social capital']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C1510639', 'cui_str': 'Social Capital'}]",69.0,0.0112395,"The results showed that knowledge about respiratory infection prevention, respiratory infection prevention practices, and social capital were enhanced among the elderly residents who participated in the educational program.","[{'ForeName': 'Jin Soon', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Dang-Rim Primary Health Care Post, Chuncheon Public Health Center, Gangwon-do 24463, Chuncheon-si, Korea.'}, {'ForeName': 'Ji Hye', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': 'Health and New Media Research Institute, Hallym University, Gangwon-do 24252, Chuncheon-si, Korea.'}, {'ForeName': 'Myung Soon', 'Initials': 'MS', 'LastName': 'Kwon', 'Affiliation': 'School of Nursing, Research Institute of Nursing Science, Hallym University, Gangwon-do 24252, Chuncheon-si, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17093057'] 28,32358638,Transcutaneous Stimulation of Auricular Branch of the Vagus Nerve Attenuates the Acute Inflammatory Response After Lung Lobectomy.,"OBJECTIVES Systemic inflammation is a potentially debilitating complication of thoracic surgeries with significant physical and economic morbidity. There is compelling evidence for the role of the central nervous system in regulating inflammatory processes through humoral mechanisms. Activation of the afferent vagus nerve by cytokines triggers anti-inflammatory responses. Peripheral electrical stimulation of the vagus nerve in vivo during lethal endotoxemia in rats inhibited tumor necrosis factor synthesis and prevented shock development. However, the vagal regulatory role of systemic inflammation after lung lobectomy is unknown. METHODS One hundred patients who underwent lobectomy via thoracotomy were recruited and equally randomized to treated group or controls. Intermittent stimulation of the auricular branch of vagus nerve in the triangular fossa was applied in the treated group using neurostimulator V (Ducest ® , Germany), starting 24 h preoperatively and continued till the 4th postoperative day (POD). Inflammatory interleukins (IL) were analyzed using ELISA preoperatively, on the 1st and 4th POD. RESULTS On the 1st POD, patients who underwent neurostimulation had reduced serum concentrations of CRP (p = 0.01), IL6 (p = 0.02) but elevated IL10 (p = 0.03) versus controls. On the 4th POD, serum concentrations of CRP, IL6 and IL10 were similar in both groups. Moreover, the treated group was associated with lower incidence of pneumonia (p = 0.04) and shorter hospitalization time (p = 0.04) versus controls. CONCLUSIONS Modulations in the brain stem caused by noninvasive transcutaneous stimulation of the vagus nerve after lung lobectomy attenuate the acute postsurgical inflammatory response by the regulation of IL6 and IL10, resulting in  reduced incidence of postoperative pneumonia and short hospitalization time. CLINICAL TRIAL REGISTRY NUMBER NCT03204968.",2020,"On the 1st POD, patients who underwent neurostimulation had reduced serum concentrations of CRP (p = 0.01), IL6 (p = 0.02) but elevated IL10 (p = 0.03) versus controls.",['One hundred patients who underwent'],['lobectomy via thoracotomy'],"['serum concentrations of CRP, IL6 and IL10', 'lower incidence of pneumonia', 'Inflammatory interleukins (IL', 'serum concentrations of CRP', 'shorter hospitalization time', 'Acute Inflammatory Response']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0023928', 'cui_str': 'Lobectomy'}, {'cui': 'C0039991', 'cui_str': 'Chest wall incision'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]",100.0,0.0448228,"On the 1st POD, patients who underwent neurostimulation had reduced serum concentrations of CRP (p = 0.01), IL6 (p = 0.02) but elevated IL10 (p = 0.03) versus controls.","[{'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Salama', 'Affiliation': 'Department of Thoracic Surgery, North Clinic, Bruennerstrasse 68, 1210, Vienna, Austria.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Akan', 'Affiliation': 'Department of Thoracic Surgery, North Clinic, Bruennerstrasse 68, 1210, Vienna, Austria.'}, {'ForeName': 'Michael Rolf', 'Initials': 'MR', 'LastName': 'Mueller', 'Affiliation': 'Department of Thoracic Surgery, North Clinic, Bruennerstrasse 68, 1210, Vienna, Austria. michael.rolf.mueller@wienkav.at.'}]",World journal of surgery,['10.1007/s00268-020-05543-w'] 29,32354777,"Results of a prospective, mixed methods study to assess feasibility, acceptability and effectiveness of TRIumPH (Treatment and Recovery In PsycHosis): an integrated care pathway for psychosis, compared to usual treatment.","OBJECTIVES To evaluate whether a newly developed care pathway, Treatment and Recovery In PsycHosis (TRIumPH), is feasible, acceptable and effective in meeting National Institute of Health and Care Excellence (NICE) quality standards in a timely manner. METHODS This is a pragmatic, non-randomised, prospective, mixed methods study comparing an implementation (TRIumPH) and comparator site (not implementing TRIumPH) across three cohorts to assess feasibility, acceptability and effectiveness of the integrated pathway. SETTING Early intervention in psychosis (EIP) services at two National Health Service organisations in South of England. PARTICIPANTS All patients accepted into EIP services between 1 June 2014 and 31 May 2017 were each followed up for 1 year within their respective cohorts. METHODOLOGY Quantitative data consisted of routinely collected clinical data retrieved from patient records to assess whether the implementation of TRIumPH achieved better concordance to NICE standards. These included time to access services, physical health assessments, clinical outcomes based timeliness of delivery and acute data. The controlled trial has evaluated the effect of TRIumPH (Intervention) with Care As Usual (Comparator). Qualitative measures consisted of questionnaires, interviews and focus groups to assess acceptability and satisfaction. Outcome measures were compared within the baseline, year 1 and year 2 cohorts and between the two sites. Quantitative data were statistically analysed by comparing means and proportions. RESULTS Time to assessment improved in the implementation site and remained within the target in comparator site. Meeting of quality standards increased substantially in the implementation site but was more variable and reached lower levels in the comparator site especially for physical health standards. Cognitive therapy for psychosis, family intervention and carer and employment support were all offered to a greater extent in the implementation site and uptake increased over the period. CONCLUSIONS Pathway implementation generally led to greater improvements in achievement of access and quality standards compared with comparator site. TRIAL REGISTRATION NUMBER UK Clinical Research Network Portfolio (19187).",2020,Meeting of quality standards increased substantially in the implementation site but was more variable and reached lower levels in the comparator site especially for physical health standards.,"['psychosis', 'PsycHosis', 'All patients accepted into EIP services between 1 June 2014 and 31 May 2017 were each followed up for 1\u2009year within their respective cohorts', 'EIP) services at two National Health Service organisations in South of England']","['Cognitive therapy', 'implementation (TRIumPH) and comparator site (not implementing TRIumPH', 'TRIumPH', 'TRIumPH (Intervention) with Care As Usual (Comparator']","['achievement of access and quality standards', 'feasibility, acceptability and effectiveness', 'time to access services, physical health assessments, clinical outcomes based timeliness of delivery and acute data', 'acceptability and satisfaction']","[{'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C1272289', 'cui_str': 'Early intervention in psychosis'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0014282', 'cui_str': 'England'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C3643615', 'cui_str': 'Triumph'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C3874265', 'cui_str': 'Assessment of physical health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0990838,Meeting of quality standards increased substantially in the implementation site but was more variable and reached lower levels in the comparator site especially for physical health standards.,"[{'ForeName': 'Shanaya', 'Initials': 'S', 'LastName': 'Rathod', 'Affiliation': 'Research and Development, Southern Health NHS Foundation Trust, Southampton, UK shanayarathod@nhs.net.'}, {'ForeName': 'Kerensa', 'Initials': 'K', 'LastName': 'Thorne', 'Affiliation': 'Research and Development, Southern Health NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Graves', 'Affiliation': 'Research and Development, Southern Health NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Phiri', 'Affiliation': 'Research and Development, Southern Health NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Asher', 'Affiliation': 'Research and Development, Southern Health NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Griffiths', 'Affiliation': 'Wessex Academic Health Sciences Network, Southampton, UK.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Read', 'Affiliation': 'Dorset HealthCare NHS Foundation Trust, Poole, Poole, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kingdon', 'Affiliation': 'Medicine, University of Southampton, Southampton, UK.'}]",BMJ open,['10.1136/bmjopen-2019-033711'] 30,32356609,Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.,"BACKGROUND Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea, and a reduction in lung function, quality of life, and life expectancy. Apart from smoking cessation, no other treatments that slow lung function decline are available. Roflumilast and cilomilast are oral phosphodiesterase-4 (PDE₄) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD. This Cochrane Review was first published in 2011, and was updated in 2017 and 2020. OBJECTIVES To evaluate the efficacy and safety of oral PDE₄ inhibitors for management of stable COPD. SEARCH METHODS We identified randomised controlled trials (RCTs) from the Cochrane Airways Trials Register (date of last search 9 March 2020). We found other trials at web-based clinical trials registers. SELECTION CRITERIA We included RCTs if they compared oral PDE₄ inhibitors with placebo in people with COPD. We allowed co-administration of standard COPD therapy. DATA COLLECTION AND ANALYSIS We used standard Cochrane methods. Two independent review authors selected trials for inclusion, extracted data, and assessed risk of bias. We resolved discrepancies by involving a third review author. We assessed our confidence in the evidence by using GRADE recommendations. Primary outcomes were change in lung function (minimally important difference (MID) = 100 mL) and quality of life (scale 0 to 100; higher score indicates more limitations). MAIN RESULTS We found 42 RCTs that met the inclusion criteria and were included in the analyses for roflumilast (28 trials with 18,046 participants) or cilomilast (14 trials with 6457 participants) or tetomilast (1 trial with 84 participants), with a duration between six weeks and one year or longer. These trials included people across international study centres with moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades II to IV), with mean age of 64 years. We judged risks of selection bias, performance bias, and attrition bias as low overall amongst the 39 published and unpublished trials. Lung function Treatment with a PDE₄ inhibitor was associated with a small, clinically insignificant improvement in forced expiratory volume in one second (FEV₁) over a mean of 40 weeks compared with placebo (mean difference (MD) 49.33 mL, 95% confidence interval (CI) 44.17 to 54.49; participants = 20,815; studies = 29; moderate-certainty evidence). Forced vital capacity (FVC) and peak expiratory flow (PEF) were also improved over 40 weeks (FVC: MD 86.98 mL, 95% CI 74.65 to 99.31; participants = 22,108; studies = 17; high-certainty evidence; PEF: MD 6.54 L/min, 95% CI 3.95 to 9.13; participants = 4245; studies = 6; low-certainty evidence). Quality of life Trials reported improvements in quality of life over a mean of 33 weeks (St George's Respiratory Questionnaire (SGRQ) MD -1.06 units, 95% CI -1.68 to -0.43; participants = 7645 ; moderate-certainty evidence). Incidence of exacerbations Treatment with a PDE₄ inhibitor was associated with a reduced likelihood of COPD exacerbation over a mean of 40 weeks (odds ratio (OR) 0.78, 95% CI 0.73 to 0.84; participants = 20,382; studies = 27; high-certainty evidence), that is, for every 100 people treated with PDE₄ inhibitors, five more remained exacerbation-free during the study period compared with those given placebo (number needed to treat for an additional beneficial outcome (NNTB) 20, 95% CI 16 to 27). No change in COPD-related symptoms nor in exercise tolerance was found. Adverse events More participants in the treatment groups experienced an adverse effect compared with control participants over a mean of 39 weeks (OR 1.30, 95% CI 1.22 to 1.38; participants = 21,310; studies = 30; low-certainty evidence). Participants experienced a range of gastrointestinal symptoms such as diarrhoea, nausea, vomiting, or dyspepsia. Diarrhoea was more commonly reported with PDE₄ inhibitor treatment (OR 3.20, 95% CI 2.74 to 3.50; participants = 20,623; studies = 29; high-certainty evidence), that is, for every 100 people treated with PDE₄ inhibitors, seven more suffered from diarrhoea during the study period compared with those given placebo (number needed to treat for an additional harmful outcome (NNTH) 15, 95% CI 13 to 17). The likelihood of psychiatric adverse events was higher with roflumilast 500 µg than with placebo (OR 2.13, 95% CI 1.79 to 2.54; participants = 11,168; studies = 15 (COPD pool data); moderate-certainty evidence). Roflumilast in particular was associated with weight loss during the trial period and with an increase in insomnia and depressive mood symptoms. Participants treated with PDE₄ inhibitors were more likely to withdraw from trial participation; on average, 14% in the treatment groups withdrew compared with 8% in the control groups. Mortality No effect on mortality was found (OR 0.98, 95% CI 0.77 to 1.24; participants = 19,786; studies = 27; moderate-certainty evidence), although mortality was a rare event during these trials. AUTHORS' CONCLUSIONS For this current update, five new studies from the 2020 search contributed to existing findings but made little impact on outcomes described in earlier versions of this review. PDE₄ inhibitors offered a small benefit over placebo in improving lung function and reducing the likelihood of exacerbations in people with COPD; however, they had little impact on quality of life or on symptoms. Gastrointestinal adverse effects and weight loss were common, and the likelihood of psychiatric symptoms was higher, with roflumilast 500 µg. The findings of this review provide cautious support for the use of PDE₄ inhibitors in COPD. In accordance with GOLD 2020 guidelines, they may have a place as add-on therapy for a subgroup of people with persistent symptoms or exacerbations despite optimal COPD management (e.g. people whose condition is not controlled by fixed-dose long-acting beta₂-agonist (LABA) and inhaled corticosteroid (ICS) combinations). More longer-term trials are needed to determine whether or not PDE₄ inhibitors modify FEV₁ decline, hospitalisation, or mortality in COPD.",2020,"Lung function Treatment with a PDE₄ inhibitor was associated with a small, clinically insignificant improvement in forced expiratory volume in one second (FEV₁) over a mean of 40 weeks compared with placebo (mean difference (MD) 49.33 mL, 95% confidence interval (CI) 44.17 to 54.49; participants = 20,815; studies = 29; moderate-certainty evidence).","['Chronic obstructive pulmonary disease (COPD', 'chronic obstructive pulmonary disease', 'people with COPD', '42 RCTs that met the inclusion criteria and were included in the analyses for roflumilast (28 trials with 18,046 participants) or cilomilast (14 trials with 6457 participants) or tetomilast (1 trial with 84 participants), with a duration between six weeks and one year or longer', 'people across international study centres with moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades II to IV), with mean age of 64 years']","['Roflumilast and cilomilast', 'Phosphodiesterase-4 inhibitors', 'phosphodiesterase-4 (PDE₄) inhibitors', 'Roflumilast', 'standard COPD therapy', 'PDE₄ inhibitor', 'PDE₄ inhibitors', 'oral PDE₄ inhibitors', 'placebo']","['quality of life', 'likelihood of psychiatric adverse events', 'Diarrhoea', 'forced expiratory volume', 'Adverse events', 'Forced vital capacity (FVC) and peak expiratory flow (PEF', 'lung function', 'efficacy and safety', 'weight loss', 'change in lung function (minimally important difference (MID) = 100 mL) and quality of life', 'range of gastrointestinal symptoms such as diarrhoea, nausea, vomiting, or dyspepsia', 'Mortality', 'COPD exacerbation', 'mortality', 'Gastrointestinal adverse effects and weight loss', 'insomnia and depressive mood symptoms', 'adverse effect', 'likelihood of psychiatric symptoms']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C0968887', 'cui_str': 'Cilomilast'}, {'cui': 'C1876228', 'cui_str': 'tetomilast'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C3641272', 'cui_str': 'Very severe'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C0968887', 'cui_str': 'Cilomilast'}, {'cui': 'C2936609', 'cui_str': 'Phosphodiesterase 4 inhibitor'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0233401', 'cui_str': 'Psychiatric symptom'}]",84.0,0.731139,"Lung function Treatment with a PDE₄ inhibitor was associated with a small, clinically insignificant improvement in forced expiratory volume in one second (FEV₁) over a mean of 40 weeks compared with placebo (mean difference (MD) 49.33 mL, 95% confidence interval (CI) 44.17 to 54.49; participants = 20,815; studies = 29; moderate-certainty evidence).","[{'ForeName': 'Sadia', 'Initials': 'S', 'LastName': 'Janjua', 'Affiliation': ""Cochrane Airways, Population Health Research Institute, St George's, University of London, London, UK.""}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Fortescue', 'Affiliation': ""Cochrane Airways, Population Health Research Institute, St George's, University of London, London, UK.""}, {'ForeName': 'Phillippa', 'Initials': 'P', 'LastName': 'Poole', 'Affiliation': 'Department of Medicine, University of Auckland, Auckland, New Zealand.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD002309.pub6'] 31,32378654,A Comparison of the Weight Loss Effect between a Low-carbohydrate Diet and a Calorie-restricted Diet in Combination with Intragastric Balloon Therapy.,"Objective Intragastric balloon (IGB) therapy is a low-invasion treatment for obesity. Recently, a low-carbohydrate diet has shown effectiveness for encouraging weight loss, but whether or not a low-carbohydrate diet improves the efficacy of IGB therapy remains unclear. Therefore, we examined the effectiveness of a low-carbohydrate diet compared with a calorie-restricted diet in combination with IGB therapy. Methods A prospective study was conducted on 51 patients who had undergone IGB therapy from October 2012 to December 2017. Overall, 31 of the 51 patients were included in this study (12-month assessment after IGB placement). These 31 cases consisted of 18 IGB plus low-carbohydrate diet and 13 IGB plus calorie-restricted diet. We compared the two groups with respect to body weight loss as outcomes. Results At 12 months after IGB placement, the body weight was significantly lower than that observed at baseline in both the IGB plus low-carbohydrate diet group (baseline 101.9±25.8 kg, 12 months 88.2±21.9 kg) (p<0.0001) and the IGB plus calorie-restricted diet group (baseline 103.5±17.0 kg, 12 months 89.1±6.2 kg) (p<0.005). The percentage of excess weight loss in the IGB plus low-carbohydrate diet group was slightly higher than that in the IGB plus calorie-restricted diet group, but there was no significant difference between the 2 groups at 12 months after IGB placement (IGB plus low-carbohydrate 49.9±60.0%, IGB plus calorie-restricted diet 33.1±27.0%). Conclusion Our study demonstrated that both a low-carbohydrate diet and a calorie-restricted diet were effective interventions for weight reduction in combination with IGB therapy.",2020,"At 12 months after IGB placement, the body weight was significantly lower than that observed at baseline in both the IGB plus low-carbohydrate diet group (baseline 101.9±25.8 kg, 12 months 88.2±21.9 kg) (p<0.0001) and the IGB plus calorie-restricted diet group (baseline 103.5±17.0 kg, 12 months 89.1±6.2 kg) (p<0.005).",['51 patients who had undergone IGB therapy from October 2012 to December 2017'],"['Objective Intragastric balloon (IGB) therapy', 'low-carbohydrate diet', 'IGB plus low-carbohydrate diet and 13 IGB plus calorie-restricted diet', 'Low-carbohydrate Diet and a Calorie-restricted Diet in Combination with Intragastric Balloon Therapy', 'calorie-restricted diet in combination with IGB therapy']","['body weight', 'percentage of excess weight loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0259836', 'cui_str': 'Carbohydrate restricted diet'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",51.0,0.0136192,"At 12 months after IGB placement, the body weight was significantly lower than that observed at baseline in both the IGB plus low-carbohydrate diet group (baseline 101.9±25.8 kg, 12 months 88.2±21.9 kg) (p<0.0001) and the IGB plus calorie-restricted diet group (baseline 103.5±17.0 kg, 12 months 89.1±6.2 kg) (p<0.005).","[{'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Maekawa', 'Affiliation': 'Nagano Matsushiro General Hospital, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Niizawa', 'Affiliation': 'Nagano Matsushiro General Hospital, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Harada', 'Affiliation': 'Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.'}]","Internal medicine (Tokyo, Japan)",['10.2169/internalmedicine.4153-19'] 32,32353115,ACTH Infusion Impairs Baroreflex Sensitivity-Implications for Cardiovascular Hypoglycemia-Associated Autonomic Failure.,"CONTEXT Hypoglycemia attenuates cardiovascular homeostatic autonomic control. This attenuation, known as the cardiovascular component of hypoglycemia-associated autonomic failure (HAAF), is characterized most notably by decreased baroreflex sensitivity (BRS) that begins during hypoglycemia and persists until at least the next day, despite return to euglycemia. Understanding the mechanisms underlying this reduction in BRS is important because BRS attenuation is associated with increased morbidity and mortality. OBJECTIVE The objective of this work is to investigate the role of the adrenocorticotropin (ACTH)-adrenal axis in decreasing BRS. We tested the hypothesis that infusion of ACTH 1-24 (cosyntropin), as compared to placebo, would acutely suppress BRS, and that this decrease in BRS would be present the next day. DESIGN A double-blind, placebo-controlled, random-order, cross-over study was conducted. SETTING This study took place in a clinical research center. PARTICIPANTS Participants included healthy men and women. INTERVENTIONS Interventions included an intravenous infusion of cosyntropin (70 μg/hour for 2.5 hours in the morning and again in the early afternoon) vs normal saline placebo. MAIN OUTCOME MEASURES Outcome measures included BRS during and 16 hours after cosyntropin vs placebo infusions. RESULTS Cosyntropin infusion attenuated BRS (mm Hg/ms) as compared to placebo (baseline 17.8 ± 1.38 vs 17.0 ± 2.07; during 14.4 ± 1.43 vs 17.3 ± 1.65; and next day 14.8 ± 1.42 vs 18.9 ± 2.04; P < .05, time by treatment, analysis of variance). BRS was decreased during the final 30 minutes of the morning cosyntropin infusion as compared to baseline (P < .01) and remained suppressed the next day (16 hours after afternoon infusion) (P < .025). Placebo infusion did not significantly change BRS. Corrected QT interval was not affected. CONCLUSIONS ACTH attenuates BRS, raising the possibility that hypoglycemia-induced increases in ACTH may contribute to the cardiovascular component of HAAF.",2020,"QTc was not affected. ",['Healthy men and women'],"['normal saline placebo', 'Placebo', 'ACTH Infusion', 'cosyntropin', 'adrenocorticotropin hormone (ACTH)-adrenal axis', 'placebo']","['change BRS', 'BRS', 'QTc', 'baroreflex sensitivity (BRS']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}, {'cui': 'C0199780', 'cui_str': 'Administration of hormone'}, {'cui': 'C0010192', 'cui_str': 'Cosyntropin'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0001625', 'cui_str': 'Adrenal structure'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0860814', 'cui_str': 'QTc'}]",,0.120712,"QTc was not affected. ","[{'ForeName': 'Janet H', 'Initials': 'JH', 'LastName': 'Leung', 'Affiliation': 'Division of Endocrinology and Diabetes, Virginia Mason Medical Center, Seattle, Washington.'}, {'ForeName': 'Omar F', 'Initials': 'OF', 'LastName': 'Bayomy', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Istvan', 'Initials': 'I', 'LastName': 'Bonyhay', 'Affiliation': 'Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Celli', 'Affiliation': 'Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'White', 'Affiliation': 'Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Freeman', 'Affiliation': 'Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Gail K', 'Initials': 'GK', 'LastName': 'Adler', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.""}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa221'] 33,32354780,Study protocol for a prospective randomised double-blind placebo-controlled clinical trial investigating a Better Outcome with Melatonin compared to Placebo Administered to normalize sleep-wake cycle and treat hypoactive ICU Delirium: the Basel BOMP-AID study.,"INTRODUCTION Delirium is frequently observed in the intensive care unit (ICU) population, in particular. Until today, there is no evidence for any reliable pharmacological intervention to treat delirium. The Basel BOMP-AID ( B etter O utcome with M elatonin compared to P lacebo A dministered to normalize sleep-wake cycle and treat hypoactive I CU D elirium) randomised trial targets improvement of hypoactive delirium therapy in critically ill patients and will be conducted as a counterpart to the Basel ProDex Study (Study Protocol, BMJ Open, July 2017) on hyperactive and mixed delirium. The aim of the BOMP-AID trial is to assess the superiority of melatonin to placebo for the treatment of hypoactive delirium in the ICU. The study hypothesis is based on the assumption that melatonin administered at night restores a normal circadian rhythm, and that restoration of a normal circadian rhythm will cure delirium. METHODS AND ANALYSIS The Basel BOMP-AID study is an investigator-initiated, single-centre, randomised controlled clinical trial for the treatment of hypoactive delirium with the once daily oral administration of melatonin 4 mg versus placebo in 190 critically ill patients. The primary outcome measure is delirium duration in 8-hour shifts. Secondary outcome measures include delirium-free days and death at 28 days after study inclusion, number of ventilator days, length of ICU and hospital stay, and sleep quality. Patients will be followed after 3 and 12 months for activities of daily living and mortality assessment. Sample size was calculated to demonstrate superiority of melatonin compared with placebo regarding the duration of delirium. Results will be presented using an intention-to-treat approach. ETHICS AND DISSEMINATION This study has been approved by the Ethics Committee of Northwestern and Central Switzerland and will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the International Conference on Harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use; Good Clinical Practice (GCP) or ISO EN 14155 (as far as applicable), as well as all national legal and regulatory requirements. Study results will be presented in international conferences and published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER NCT03438526. PROTOCOL VERSION Clinical Study Protocol Version 3, 10.03.2019.",2020,Sample size was calculated to demonstrate superiority of melatonin compared with placebo regarding the duration of delirium.,"['190 critically ill patients', 'critically ill patients']","['Placebo', 'placebo', 'melatonin 4\u2009mg versus placebo', 'O utcome with M elatonin', 'Melatonin', 'melatonin to placebo', 'melatonin', 'hypoactive delirium therapy']","['Basel BOMP-AID ( B etter', 'activities of daily living and mortality assessment', 'delirium-free days and death at 28 days after study inclusion, number of ventilator days, length of ICU and hospital stay, and sleep quality', 'delirium duration in 8-hour shifts', 'duration of delirium']","[{'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C3203501', 'cui_str': 'Hypoactive delirium'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0053926', 'cui_str': 'BOMP protocol'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0087153', 'cui_str': 'Ventilator'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1292429', 'cui_str': '8 hours'}, {'cui': 'C0333051', 'cui_str': 'Shift'}]",190.0,0.483933,Sample size was calculated to demonstrate superiority of melatonin compared with placebo regarding the duration of delirium.,"[{'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Hollinger', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland alexa.hollinger@usb.ch.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'von Felten', 'Affiliation': 'Department of Clinical Research, Clinical Trial Unit, c/o University Hospital Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Sutter', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Huber', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Tran', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Reinhold', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Abdelhamid', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Atanas', 'Initials': 'A', 'LastName': 'Todorov', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Caroline Eva', 'Initials': 'CE', 'LastName': 'Gebhard', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Cajochen', 'Affiliation': 'Faculty of Medicine, University of Basel, Basel, BS, Switzerland.'}, {'ForeName': 'Luzius A', 'Initials': 'LA', 'LastName': 'Steiner', 'Affiliation': 'Faculty of Medicine, University of Basel, Basel, BS, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siegemund', 'Affiliation': 'Intensive Care Unit, University Hospital Basel, Basel, Switzerland.'}]",BMJ open,['10.1136/bmjopen-2019-034873'] 34,32357445,Dietary Intervention through Flipped Learning as a Techno Pedagogy for the Promotion of Healthy Eating in Secondary Education.,"Technological progress in the educational field has led to the application of active and innovative teaching methods, such as flipped learning, including in the field of dietary education. This is considered a mixed formative approach that combines face-to-face and outside the classroom education. The objective of this research was to analyze the effectiveness of flipped learning methodology on a traditional training practice in dietary training, both in the sixth grade of primary education and in the fourth level of secondary education. A quasi-experimental design was adopted with two experimental groups, two control groups and only posttest. The final sample was composed of 115 students divided into four groups, two of each educational stage mentioned. A didactic unit consisting of six sessions in all groups was applied. Two different training methodologies were followed according to the nature of the group (control-traditional; experimental-flipped learning). The results reveal that flipped learning is effective both in primary education and in secondary education, being more influential in student development in this last stage. It is concluded that the flipped learning approach has meant an improvement of the academic indicators evaluated after a diet education program.",2020,It is concluded that the flipped learning approach has meant an improvement of the academic indicators evaluated after a diet education program.,"['115 students divided into four groups, two of each educational stage mentioned', 'Healthy Eating in Secondary Education']",['Dietary Intervention through Flipped Learning'],[],"[{'cui': 'C4517540', 'cui_str': '115'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0540654', 'cui_str': 'Casper Protein'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",[],115.0,0.0136494,It is concluded that the flipped learning approach has meant an improvement of the academic indicators evaluated after a diet education program.,"[{'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'López Núñez', 'Affiliation': 'Department of Didactics and School Organization, University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'López-Belmonte', 'Affiliation': 'Department of Didactics and School Organization, University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'Antonio-José', 'Initials': 'AJ', 'LastName': 'Moreno-Guerrero', 'Affiliation': 'Department of Didactics and School Organization, University of Granada, 18071 Granada, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'Marín-Marín', 'Affiliation': 'Department of Didactics and School Organization, University of Granada, 18071 Granada, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17093007'] 35,32354590,Reducing Pain During Emergency Arterial Sampling Using Three Anesthetic Methods: A Randomized Controlled Clinical Trial.,"BACKGROUND Taking a sample of arterial blood is widely reported as a cause of significant pain. OBJECTIVES To compare three anesthetic methods with standard practice (no anesthesia) to establish which was the most effective in reducing pain caused by radial artery puncture in patients requiring an arterial blood gas test in the emergency department (ED). METHODS A randomized controlled trial was conducted to compare the effectiveness between anesthetic cream, cryoanalgesia, and subcutaneous mepivacaine in reducing pain caused by radial artery puncture in ED patients. RESULTS After comparing perceived pain during arterial puncture, the lowest median score was obtained in the mepivacaine group (1 interquartile range 0.6-1.3) and the highest median score in the control group (5 interquartile range 4.0-7.0). When comparing the control group with the three intervention groups, the Kruskal-Wallis test showed that mepivacaine (p = 0.023) and cryoanalgesia (p = 0.012) were associated with significantly lower pain scores. The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. CONCLUSIONS The results of this study encourage the use of anesthetic methods like cryoanalgesia or mepivacaine for their proven effectiveness in reducing or eliminating pain during arterial puncture.",2020,"The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. ","['patients requiring an arterial blood gas test in the emergency department (ED', 'ED patients']","['standard practice (no anesthesia', 'anesthetic cream, cryoanalgesia, and subcutaneous mepivacaine', 'mepivacaine']","['pain scores', 'Reducing Pain', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0524318', 'cui_str': 'Cryoanalgesia'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0025384', 'cui_str': 'Mepivacaine'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.296661,"The anesthetic cream (p = 0.861) intervention group did not produce a statistically significant median difference compared with the control group. ","[{'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Pagnucci', 'Affiliation': 'Department of Clinical and Experimental Medicine, Universita degli Studi di Pisa Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Pagliaro', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Maccheroni', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Sichi', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Scateni', 'Affiliation': 'Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Tolotti', 'Affiliation': 'Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2020.03.027'] 36,32365097,"A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.","BACKGROUND Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis. METHODS 132 women with bacterial vaginosis were randomized 1:1:1:1 to Astodrimer 0.5% (N = 34), 1% (N = 33), or 3% (N = 32) Gel or hydroxyethyl cellulose placebo gel (N = 33) at a dose of 5 g vaginally once daily for 7 days at 6 centers in the United States. The primary endpoint was clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH ≥4.5; 2) ≥20% clue cells; or 3) positive whiff test) at study days 21-30. Secondary analyses included clinical cure at study days 9-12, patient-reported symptoms, acceptability and adverse events. RESULTS The Astodrimer 1% Gel dose was superior to placebo for the primary and selected secondary efficacy measures in the modified intent-to-treat population. Clinical cure rates at day 9-12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P = .002], 74.1% [20/27; P < .001], and 55.2% [16/29; P = .001], respectively, vs. 22.2% [6/27]). At day 21-30, clinical cure rates were 46.2% (12/26) for the 1% dose vs. 11.5% for placebo (3/26; P = .006). A greater proportion of patients reported absence of vaginal discharge and vaginal odor at day 9-12 and day 21-30 for Astodrimer Gel groups compared with placebo. Adverse events considered potentially treatment-related occurred in only 25% of Astodrimer Gel-treated patients vs. 22% of placebo patients. CONCLUSION Astodrimer Gel once daily for 7 days was superior to placebo for treatment of bacterial vaginosis and was well-tolerated. The 1% dose consistently showed the strongest efficacy across endpoints. These results support a role for Astodrimer Gel, 1%, as an effective treatment for bacterial vaginosis.",2020,"Clinical cure rates at day 9-12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P = .002], 74.1% [20/27; P < .001], and 55.2% [16/29; P = .001], respectively, vs. 22.2% [6/27]).","['bacterial vaginosis', '132 women with bacterial vaginosis']","['Gel or hydroxyethyl cellulose placebo gel', 'Astodrimer Gel', 'placebo']","['symptoms, acceptability and adverse events', 'efficacy and safety', 'clinical cure', 'Clinical cure rates', 'clinical cure rates', 'vaginal discharge and vaginal odor', 'clinical cure (no bacterial vaginosis vaginal discharge and no more than one of 1) vaginal pH ≥4.5']","[{'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0063131', 'cui_str': 'hydroxyethyl cellulose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0227791', 'cui_str': 'Vaginal discharge'}, {'cui': 'C0235678', 'cui_str': 'Vaginal odor'}, {'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0429263', 'cui_str': 'Vaginal pH'}]",132.0,0.559696,"Clinical cure rates at day 9-12 were superior to placebo for the Astodrimer 3%, 1% and 0.5% Gel groups (62.5% [15/24; P = .002], 74.1% [20/27; P < .001], and 55.2% [16/29; P = .001], respectively, vs. 22.2% [6/27]).","[{'ForeName': 'Arthur S', 'Initials': 'AS', 'LastName': 'Waldbaum', 'Affiliation': ""Downtown Women's Health Care, Denver, CO, United States of America.""}, {'ForeName': 'Jane R', 'Initials': 'JR', 'LastName': 'Schwebke', 'Affiliation': 'Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, United States of America.'}, {'ForeName': 'Jeremy R A', 'Initials': 'JRA', 'LastName': 'Paull', 'Affiliation': 'Starpharma Pty Ltd, Melbourne, VIC, Australia.'}, {'ForeName': 'Clare F', 'Initials': 'CF', 'LastName': 'Price', 'Affiliation': 'Starpharma Pty Ltd, Melbourne, VIC, Australia.'}, {'ForeName': 'Stephanie R', 'Initials': 'SR', 'LastName': 'Edmondson', 'Affiliation': 'Starpharma Pty Ltd, Melbourne, VIC, Australia.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Castellarnau', 'Affiliation': 'Starpharma Pty Ltd, Melbourne, VIC, Australia.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McCloud', 'Affiliation': 'McCloud Consulting Group, Sydney, NSW, Australia.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Kinghorn', 'Affiliation': 'Royal Hallamshire and Sheffield Teaching Hospitals, Sheffield, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0232394'] 37,32361414,Neural correlates of NOS1 ex1f-VNTR allelic variation in panic disorder and agoraphobia during fear conditioning and extinction in fMRI.,"Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior in animals. In humans, the short (S) allele of a functional promotor polymorphism of NOS1 (NOS1 ex1f-VNTR) has been shown to be associated with higher anxiety and altered fear conditioning in healthy subjects in the amygdala and hippocampus (AMY/HIPP). Here, we explore the role of NOS1 ex1f-VNTR as a pathophysiological correlate of panic disorder and agoraphobia (PD/AG). In a sub-sample of a multicenter cognitive behavioral therapy (CBT) randomized controlled trial in patients with PD/AG (n = 48: S/S-genotype n=15, S/L-genotype n=21, L/L-genotype n=12) and healthy control subjects, HS (n = 34: S/S-genotype n=7, S/L-genotype n=17, L/L-genotype=10), a differential fear conditioning and extinction fMRI-paradigm was used to investigate how NOS1 ex1f-VNTR genotypes are associated with differential neural activation in AMY/HIPP. Prior to CBT, L/L-allele carriers showed higher activation than S/S-allele carriers in AMY/HIPP. A genotype × diagnosis interaction revealed that the S-allele in HS was associated with a pronounced deactivation in AMY/HIPP, while patients showed contrary effects. The interaction of genotype × stimulus type (CS+, conditioned stimulus associated with an aversive stimulus vs. CS-, unassociated) showed effects on differential learning in AMY/HIPP. All effects were predominately found during extinction. Genotype associated effects in patients were not altered after CBT. Low statistical power due to small sample size in each subgroup is a major limitation. However, our findings provide first preliminary evidence for dysfunctional neural fear conditioning/extinction associated with NOS1 ex1f-VNTR genotype in the context of PD/AG, shedding new light on the complex interaction between genetic risk, current psychopathology and treatment-related effects.",2020,Genotype associated effects in patients were not altered after CBT.,"['n\xa0=\xa048', 'healthy subjects', 'animals', 'patients with PD/AG', 'panic disorder and agoraphobia during fear conditioning and extinction in fMRI']",['cognitive behavioral therapy (CBT'],['Neuronal nitric oxide synthase (NOS-I) impacts on fear/anxiety-like behavior'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030319', 'cui_str': 'Panic disorder'}, {'cui': 'C0001818', 'cui_str': 'Agoraphobia'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015347', 'cui_str': 'Psychological Extinction'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0669368', 'cui_str': 'Nitric Oxide Synthase, Type I'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0249077,Genotype associated effects in patients were not altered after CBT.,"[{'ForeName': 'Isabelle C', 'Initials': 'IC', 'LastName': 'Ridderbusch', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany. Electronic address: isabelle.ridderbusch@med.uni-marburg.de.'}, {'ForeName': 'Yunbo', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Weber', 'Affiliation': 'Department of Psychiatry, Psychosomatics, and Psychotherapy, University Hospital of Würzburg, Würzburg, Germany; Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Reif', 'Affiliation': 'Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Herterich', 'Affiliation': 'Clinical Chemistry and Laboratory Medicine, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ströhle', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Pfleiderer', 'Affiliation': 'Medical Faculty, University of Münster and Department Clinical Radiology, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Arolt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Wittchen', 'Affiliation': 'Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany; Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-Universität (LMU), München, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lueken', 'Affiliation': 'Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Tilo', 'Initials': 'T', 'LastName': 'Kircher', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Straube', 'Affiliation': 'Department of Psychiatry and Psychotherapy & Center for Mind, Brain and Behavior - CMBB, Philipps-Universität Marburg, Marburg, Germany.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102268'] 38,32299086,Young adults born preterm below 30 weeks of gestation and risk of QT tract prolongation.,,2020,,['Young adults born preterm below 30 weeks of gestation and risk of QT tract prolongation'],[],[],"[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",[],[],,0.0253211,,"[{'ForeName': 'Pier Paolo', 'Initials': 'PP', 'LastName': 'Bassareo', 'Affiliation': ""University College of Dublin, Mater Misericordiae University Hospital and Our Lady's Children's Hospital Crumlin, Dublin, Ireland. piercard@inwind.it.""}, {'ForeName': 'Vassilios', 'Initials': 'V', 'LastName': 'Fanos', 'Affiliation': 'Neonatal Intensive Care Unit, University of Cagliari, Cagliari, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mercuro', 'Affiliation': 'Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.'}]",Pediatric research,['10.1038/s41390-020-0904-8'] 39,32367611,Accommodative dynamics and attention: the influence of manipulating attentional capacity on accommodative lag and variability.,"PURPOSE There is evidence that attention can modulate ocular dynamics, but its effects on accommodative dynamics have yet to be fully determined. We investigated the effects of manipulating the capacity to focus on task-relevant stimuli, using two levels of dual-tasking (arithmetic task) and auditory feedback, on the accommodative dynamics at three different target distances (500, 40 and 20 cm). METHODS The magnitude and variability of the accommodative response were objectively measured in 20 healthy young adults using the Grand Seiko WAM-5500 autorefractor. In randomised order, participants fixated on a Maltese cross while 1) performing an arithmetic task with two levels of complexity (low and high mental load); 2) being provided with two levels of auditory feedback (low and high feedback); and 3) without performing any mental task or receiving feedback (control). Accommodative and pupil dynamics were monitored for 90 seconds during each of the 15 trials (5 experimental conditions x 3 target distances). RESULTS The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009). The imposition of mental load while fixating on a distant target led to a greater accommodative response (corrected p-value = 0.010), but no effects were found for the near targets. There was a main effect of the experimental manipulation on the accommodative variability (p < 0.001), with the use of auditory feedback improving the accuracy of the accommodative system. CONCLUSIONS Our data show that accommodative dynamics is affected by varying the capacity to focus on task-relevant stimuli, observing an improvement in accommodative stability and response with auditory feedback. These results highlight an association between attention and ocular dynamics and provide new insight into the control of accommodation.",2020,"The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009).",['20 healthy young adults using the Grand Seiko WAM-5500 autorefractor'],['participants fixated on a Maltese cross while 1) performing an arithmetic task with two levels of complexity (low and high mental load); 2) being provided with two levels of auditory feedback (low and high feedback); and 3) without performing any mental task or receiving feedback (control'],"['accommodative stability and response with auditory feedback', 'lag of accommodation was sensitive to the attentional state', 'lag of accommodation', 'accommodative response', 'accommodative variability', 'dual-tasking (arithmetic task) and auditory feedback', 'Accommodative and pupil dynamics']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1275634', 'cui_str': 'Automated infrared optometer'}]","[{'cui': 'C0324395', 'cui_str': 'Maltese dog'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0332324', 'cui_str': 'Sensitive'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1827224', 'cui_str': 'Accommodative response'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}]",20.0,0.0395495,"The lag of accommodation was sensitive to the attentional state (p = 0.001), where a lower lag of accommodation was observed for the high feedback condition compared to the control (corrected p-value = 0.009).","[{'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Redondo', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Vera', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Molina', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}, {'ForeName': 'Leon N', 'Initials': 'LN', 'LastName': 'Davies', 'Affiliation': 'School of Optometry, Aston University, Birmingham, UK.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Jiménez', 'Affiliation': 'Department of Optics, University of Granada, Granada, Spain.'}]",Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists),['10.1111/opo.12690'] 40,32365242,"Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial.","BACKGROUND Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment. OBJECTIVES To compare the clinical and non-invasive microscopic features in a psoriatic target lesion treated with clobetasol cream or calcipotriol/betamethasone dipropionate foam (Cal/BD foam). METHODS Prospective, unicentric, open, randomized clinical trial comparing clinical data [total clinical score (TCS)] and microscopic data (dermoscopy, RCM and OCT) in psoriasis patients treated with clobetasol or Cal/BD foam. RESULTS We included 36 adult patients (22 men). At week 4, more patients treated with Cal/BD foam achieved TCS ≤1 than with clobetasol (63.2% vs. 18.8%, P = 0.016). Treatment satisfaction was higher with Cal/BD foam (P < 0.03). Microscopically, Cal/BD foam induced more reduction in epidermal thickness at week 4 (P < 0.049). Dilated horizontal blood vessels were more common with clobetasol than with Cal/BD foam at week 8 (69.2% vs. 31.2%, P = 0.159). If epidermal hyperplasia was noted at baseline, the response was poorer with clobetasol (P = 0.029). LIMITATIONS Small sample size, open study, imaging sampling bias. CONCLUSION Cal/BD foam is more effective than clobetasol, has better patient satisfaction and induces greater reduction in the hyperkeratosis/acanthosis, regardless of baseline epidermal hyperplasia.",2020,"Microscopically, Cal/BD-foam induced more reduction of epidermal thickness at week 4 (p<0.049).","['mild to moderate plaque psoriasis', '36 adult patients (22 men', 'psoriasis patients treated with clobetasol or Cal/BD-foam']","['clobetasol cream versus calcipotriol/betamethasone dipropionate foam', 'clobetasol cream or calcipotriol/betamethasone dipropionate foam']","['Dilated horizontal blood vessels', 'microscopic data (dermoscopy, RCM, OCT', 'Treatment satisfaction', 'Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT', 'reduction of epidermal thickness', 'epidermal hyperplasia']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0008992', 'cui_str': 'Clobetasol'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0991510', 'cui_str': 'Foam'}]","[{'cui': 'C0008992', 'cui_str': 'Clobetasol'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0065767', 'cui_str': 'calcipotriene'}, {'cui': 'C0053523', 'cui_str': 'Betamethasone dipropionate'}, {'cui': 'C0991510', 'cui_str': 'Foam'}]","[{'cui': 'C0700124', 'cui_str': 'Ectatic'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205288', 'cui_str': 'Microscopic'}, {'cui': 'C1449565', 'cui_str': 'Dermatoscopy'}, {'cui': 'C0242842', 'cui_str': 'Confocal Microscopy'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0263641', 'cui_str': 'Epithelial hyperplasia of skin'}]",36.0,0.0802139,"Microscopically, Cal/BD-foam induced more reduction of epidermal thickness at week 4 (p<0.049).","[{'ForeName': 'O', 'Initials': 'O', 'LastName': 'Yélamos', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Alejo', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'S S', 'Initials': 'SS', 'LastName': 'Ertekin', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Villa-Crespo', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Zamora-Barquero', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Martinez', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Domínguez', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Iglesias', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Herrero', 'Affiliation': ""Dermatology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Malvehy', 'Affiliation': 'CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Puig', 'Affiliation': 'CIBER de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16559'] 41,32365607,Effectiveness of a Teacher Training Program for Students with Symptoms of Developmental Disorders: Data from a Correspondence High School in Japan.,"In the present study, a teacher training program based on behavioral therapy was conducted for high school correspondence course teachers of adolescents aged between 15 and 18 years who showed developmental difficulties. Participating teachers were assigned to either an immediate treatment (IT; n = 13) or delayed treatment control (DTC; n = 17) group to evaluate the effectiveness of the program, which comprised five 90-min sessions with small groups of three to six participants and was conducted over three months. The results showed significant improvement in students' behaviors and social responsiveness and in teachers' confidence among those in the IT group; however, those in the DTC group did not show any such improvement. We discuss the program's feasibility in terms of developing support resources for teachers in Japanese high schools.",2020,"The results showed significant improvement in students' behaviors and social responsiveness and in teachers' confidence among those in the IT group; however, those in the DTC group did not show any such improvement.","['Students with Symptoms of Developmental Disorders', 'teachers in Japanese high schools', 'high school correspondence course teachers of adolescents aged between 15 and 18 years who showed developmental difficulties']","['teacher training program based on behavioral therapy', 'Teacher Training Program', 'immediate treatment (IT; n = 13) or delayed treatment control (DTC']","[""students' behaviors and social responsiveness and in teachers' confidence""]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0008073', 'cui_str': 'Developmental disorder'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0010104', 'cui_str': 'Correspondence Courses'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]","[{'cui': 'C4082803', 'cui_str': 'Teacher Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3693346', 'cui_str': 'Treatment Delay'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0012194', 'cui_str': 'Dithiocarb'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",,0.0115432,"The results showed significant improvement in students' behaviors and social responsiveness and in teachers' confidence among those in the IT group; however, those in the DTC group did not show any such improvement.","[{'ForeName': 'Atsuko', 'Initials': 'A', 'LastName': 'Ishii', 'Affiliation': 'United Graduate School of Child Development, Osaka University, Osaka 565-0871, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Okuno', 'Affiliation': 'United Graduate School of Child Development, Osaka University, Osaka 565-0871, Japan.'}, {'ForeName': 'Takayoshi', 'Initials': 'T', 'LastName': 'Nakaoka', 'Affiliation': 'Clark Memorial International High School, Hyogo 669-1512, Japan.'}, {'ForeName': 'Hidemi', 'Initials': 'H', 'LastName': 'Iwasaka', 'Affiliation': 'Developmental Center for Child and Adult, Shigisan Hospital, Nara 636-0815, Japan.'}, {'ForeName': 'Masako', 'Initials': 'M', 'LastName': 'Taniike', 'Affiliation': 'United Graduate School of Child Development, Osaka University, Osaka 565-0871, Japan.'}]",International journal of environmental research and public health,['10.3390/ijerph17093100'] 42,32365613,Multi-System Physical Exercise Intervention for Fall Prevention and Quality of Life in Pre-Frail Older Adults: A Randomized Controlled Trial.,"Effective interventions for indicated fall prevention are necessary for older adults with frailty. We aimed to determine the effectiveness of a Multi-system Physical Exercise (MPE) for fall prevention and Health-Related Quality of Life (HRQOL) in pre-frail older adults. This randomized control trial with allocation concealment included 72 adults aged 65 and above, identified as pre-frailty and with mild and moderate fall risk scores measured by the Physiological Profile Assessment (PPA). Randomly, using block randomization, participants were divided into two groups: an MPE group (n = 36) and a control group (n = 36). The intervention consisted mainly of proprioception, muscle strengthening, reaction time, and balance training and was carried out three days per week for 12 weeks. The primary outcome was fall risk assessed using PPA at 12 weeks post-baseline and at a 24 week follow-up. Significant differences were found in the improvement in fall risk, proprioception, muscle strength, reaction time and postural sway, and fear of fall scores in the MPE group compared with controls at week 12 and 24. In addition, HRQOL had increased significantly in the MPE group in comparison to controls. The MPE program significantly increased muscle strength and improved proprioception, reaction time, and postural sway leading to fall risk reduction in older adults with pre-frailty. Therefore, the MPE program is recommended for used in day-to-day primary care practice in the pre-frail population.",2020,"Significant differences were found in the improvement in fall risk, proprioception, muscle strength, reaction time and postural sway, and fear of fall scores in the MPE group compared with controls at week 12 and 24.","['older adults with frailty', 'older adults with pre-frailty', '72 adults aged 65 and above, identified as pre-frailty and with mild and moderate fall risk scores measured by the Physiological Profile Assessment (PPA', 'Pre-Frail Older Adults', 'pre-frail older adults']","['MPE', 'Multi-system Physical Exercise (MPE', 'intervention consisted mainly of proprioception, muscle strengthening, reaction time, and balance training', 'Multi-System Physical Exercise Intervention']","['fall prevention and Health-Related Quality of Life (HRQOL', 'HRQOL', 'fall risk, proprioception, muscle strength, reaction time and postural sway, and fear of fall scores', 'muscle strength and improved proprioception, reaction time, and postural sway leading to fall risk reduction', 'fall risk assessed using PPA', 'Fall Prevention and Quality of Life']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0079379', 'cui_str': 'Frail Older Adults'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",72.0,0.0349773,"Significant differences were found in the improvement in fall risk, proprioception, muscle strength, reaction time and postural sway, and fear of fall scores in the MPE group compared with controls at week 12 and 24.","[{'ForeName': 'Jiraporn', 'Initials': 'J', 'LastName': 'Chittrakul', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Penprapa', 'Initials': 'P', 'LastName': 'Siviroj', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Somporn', 'Initials': 'S', 'LastName': 'Sungkarat', 'Affiliation': 'Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'ForeName': 'Ratana', 'Initials': 'R', 'LastName': 'Sapbamrer', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}]",International journal of environmental research and public health,['10.3390/ijerph17093102'] 43,32361959,A multicentre randomized controlled follow-up study of the effects of the underwater traction therapy in chronic low back pain.,"Low back pain (LBP) is one of the most costly diseases in the developed world. This study aimed to investigate the effects of underwater traction therapy on chronic low back pain. The primary objective was to prove that underwater traction therapy has favorable effects on LBP. Our secondary objective was to evaluate whether it also leads to improvement in the quality of life. This is a prospective, multicenter, follow-up study. A total of 176 patients with more than 3 months of low back pain enrolled from outpatient clinics were randomized into three groups: underwater weight bath traction therapy and non-steroidal anti-inflammatory drugs (NSAIDs); weight bath; and only NSAIDs. The following parameters were measured before, right after, and 9 weeks after the 3-week therapy: levels of low back pain in rest and during activity were tested using the visual analogue scale (VAS), the Oswestry Low Back Disability Questionnaire, and the EuroQol-5D-5L Questionnaire.The VAS levels improved significantly (p < 0.05) in both underwater weight bath traction therapy groups by the end of the treatment, whereas the improvement in the third group was not statistically significant. Furthermore, the improvements measured in the groups receiving traction therapy were persistent during the follow-up period. There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.Based on our results, for patients suffering from LBP pain who underwent underwater weight bath traction therapy, there were favorable impacts on the pain levels at rest or during activity. Clinical trial registration ID: NCT03488498, April 5, 2018.",2020,There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.,"['patients suffering from LBP pain who underwent', '176 patients with more than 3\xa0months of low back pain enrolled from outpatient clinics', 'chronic low back pain']","['underwater weight bath traction therapy', 'underwater weight bath traction therapy and non-steroidal anti-inflammatory drugs (NSAIDs); weight bath; and only NSAIDs', 'underwater traction therapy']","['quality of life', 'pain levels', 'chronic low back pain', 'visual analogue scale (VAS), the Oswestry Low Back Disability Questionnaire, and the EuroQol-5D-5L Questionnaire', 'low back pain in rest and during activity', 'VAS levels', 'Oswestry Index or the EuroQol-5D-5L without VAS parameters']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",176.0,0.0250049,There were no significant changes in the Oswestry Index or the EuroQol-5D-5L without VAS parameters in any of the groups.,"[{'ForeName': 'Tamás', 'Initials': 'T', 'LastName': 'Gáti', 'Affiliation': 'Rheumatology Department, Polyclinic of The Hospitaller Brothers of St John of God, Árpád fejedelem út 7, Budapest, 1027, Hungary. tomgati@gmail.com.'}, {'ForeName': 'Éva', 'Initials': 'É', 'LastName': 'Czímer', 'Affiliation': 'Aquarius Experience Bath, Sóstó, Fürdőház tér 2, Nyíregyháza, 4431, Hungary.'}, {'ForeName': 'Györgyi', 'Initials': 'G', 'LastName': 'Cserháti', 'Affiliation': 'Medical Department of Bath, Kenézy Gyula University Hospital, Debrecen, Hungary.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Fehér', 'Affiliation': 'Hungarospa Hajdúszoboszló Private Limited Company, Hajdúszoboszló, Hungary.'}, {'ForeName': 'Mihály', 'Initials': 'M', 'LastName': 'Oláh', 'Affiliation': 'Hungarospa Hajdúszoboszló Private Limited Company, Hajdúszoboszló, Hungary.'}, {'ForeName': 'Ágota', 'Initials': 'Á', 'LastName': 'Kulisch', 'Affiliation': 'St. Andrew Hospital for Rheumatic Diseases, Hévíz, Hungary.'}, {'ForeName': 'Zsuzsanna', 'Initials': 'Z', 'LastName': 'Mándó', 'Affiliation': 'St. Andrew Hospital for Rheumatic Diseases, Hévíz, Hungary.'}, {'ForeName': 'Tamás', 'Initials': 'T', 'LastName': 'Bender', 'Affiliation': 'Rheumatology Department, Polyclinic of The Hospitaller Brothers of St John of God, Árpád fejedelem út 7, Budapest, 1027, Hungary.'}]",International journal of biometeorology,['10.1007/s00484-020-01919-8'] 44,32365870,Outcomes and Feasibility of a 12-Week Physical Literacy Intervention for Children in an Afterschool Program.,"Children ( N = 90) from eight afterschool programs ( n = 4 experimental sites with 47 children; n = 4 control sites with 43 children), along with the program leaders ( N = 7) from the experimental sites, participated in a 12-week physical literacy intervention. Children were assessed on their physical literacy (movement competence, affect, confidence, and motivation) pre- and post-intervention using a suite of assessment tools that included the PLAYfun assessment of movement competence and a comprehensive child questionnaire. Experimental participants engaged in a daily physical literacy intervention at their afterschool program; controls engaged in their usual afterschool programming. Experimental group program leaders were assessed on their cognitions pre- and post-training and post-intervention, alongside questions regarding program acceptability and feasibility. Program leaders' perceived knowledge and self-efficacy to implement the physical literacy program increased ( p < 0.05) from pre- to post-training and these effects were maintained at post-intervention. No group differences were observed in the change of children's motor competence, self-efficacy, or motivation from baseline to post-intervention. However, significant increases in affect were observed among participants in the experimental group ( p < 0.05). Program leaders said they would recommend the program to future leaders. However, they reported challenges with implementation due to equipment availability and behavioral challenges. Results suggest a comprehensive physical literacy program during the afterschool period can be feasible to implement and can lead to improvements in the affective domain of children's physical literacy. Further research on childhood physical literacy interventions is warranted.",2020,"No group differences were observed in the change of children's motor competence, self-efficacy, or motivation from baseline to post-intervention.","['Children ( N = 90) from eight afterschool programs ( n = 4 experimental sites with 47 children; n = 4 control sites with 43 children), along with the program leaders ( N = 7) from the experimental sites, participated in a 12-week', 'Children in an Afterschool Program']","['physical literacy intervention', '12-Week Physical Literacy Intervention', 'daily physical literacy intervention at their afterschool program; controls engaged in their usual afterschool programming']","['physical literacy (movement competence, affect, confidence, and motivation) pre', ""change of children's motor competence, self-efficacy, or motivation"", 'knowledge and self-efficacy', 'physical literacy program']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0023865', 'cui_str': 'Literacy Programs'}]",,0.00973743,"No group differences were observed in the change of children's motor competence, self-efficacy, or motivation from baseline to post-intervention.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bremer', 'Affiliation': 'Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, M5S 2W6, Canada.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Graham', 'Affiliation': 'INfant and Child Health (INCH) Lab, Department of Family Medicine, McMaster University, Hamilton, ON L8P 1H6, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Cairney', 'Affiliation': 'School of Human Movement and Nutrition Sciences, University of Queensland, St Lucia 4072, Australia.'}]",International journal of environmental research and public health,['10.3390/ijerph17093129'] 45,32365601,Preschoolers Build Fundamental Motor Skills Critical to an Active Lifestyle: The All 4 Kids © Intervention Study.,"This pragmatic, real world study examined the effects of the All 4 Kids © intervention on preschoolers' mastery of movement skills and determined whether the instruction had greater impact than natural development. Methods included a quasi-experimental intervention-comparison subsample of 379 children (COMPARISON) and a pretest-posttest design with convenience scale-up sampling of 2817 preschoolers (SCALE-UP). Children receiving education and dance instruction 3 times/week for 8 weeks were assessed using the Preschool Movement Assessment to evaluate skills pre and post intervention. Using repeated measures ANOVA, McNemar and Wilcoxon signed ranks tests, preschooler's participation in the intervention resulted in greater improvement in 12 movement skills ( F = 83.451, df = 1, p < 0.001, η p 2 = 0.555), balance ( p = 0.028), hopping ( t = -3.545, df = 112, p = 0.001) and crossing the midline ( p < 0.001) than natural development (COMPARISON). In the SCALE-UP study, children significantly improved in all measures based on post-intervention scores. Significant differences were observed between Hispanic and non-Hispanic children for the 12-skills ( b = -0.758, se = 0.161, p < 0.001) using hierarchical linear models; boys' and girls' scores were not differentially impacted by the intervention. Therefore, implementation of interventions focused on fundamental movement skill development have the potential to remediate secular motor skill decline in young children.",2020,"Significant differences were observed between Hispanic and non-Hispanic children for the 12-skills ( b = -0.758, se = 0.161, p < 0.001) using hierarchical linear models; boys' and girls' scores were not differentially impacted by the intervention.","['Preschoolers Build Fundamental Motor Skills Critical to an Active Lifestyle', 'young children', '379 children (COMPARISON) and a pretest-posttest design with convenience scale-up sampling of 2817 preschoolers (SCALE-UP']",[],['12 movement skills'],"[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C3831015', 'cui_str': 'Convenient'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}]",[],"[{'cui': 'C0026649', 'cui_str': 'Movement'}]",379.0,0.0172845,"Significant differences were observed between Hispanic and non-Hispanic children for the 12-skills ( b = -0.758, se = 0.161, p < 0.001) using hierarchical linear models; boys' and girls' scores were not differentially impacted by the intervention.","[{'ForeName': 'Anne R', 'Initials': 'AR', 'LastName': 'Lindsay', 'Affiliation': 'Extension, College of Agriculture, Biotechnology & Natural Resources (CABNR), University of Nevada, Reno, NV 89123, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Starrett', 'Affiliation': 'Department of Educational Studies, College of Education, University of South Carolina, Columbia, SC 29208, USA.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Brian', 'Affiliation': 'Department of Physical Education, College of Education, University of South Carolina, Columbia, SC 29208, USA.'}, {'ForeName': 'Teresa A', 'Initials': 'TA', 'LastName': 'Byington', 'Affiliation': 'Extension, College of Agriculture, Biotechnology & Natural Resources (CABNR), University of Nevada, Reno, NV 89123, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Lucas', 'Affiliation': 'Department of Family Medicine, Oregon Health & Science University, Portland, OR 97239, USA.'}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Sigman-Grant', 'Affiliation': 'Extension, College of Agriculture, Biotechnology & Natural Resources (CABNR), University of Nevada, Reno, NV 89123, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17093098'] 46,32361963,Development and Pilot Test of a Virtual Reality Respiratory Biofeedback Approach.,"Breathing exercises with biofeedback have benefits over breathing exercises without biofeedback. However, the traditional measurement of respiratory signals that is required as part of feeding back the breath incurs high cost and effort. We propose a novel virtual reality (VR) based approach to respiratory biofeedback that utilizes the positionally tracked hand controllers integrated into modern VR systems to capture and feedback the respiration-induced abdominal movements. In a randomized controlled laboratory study, we investigated the feasibility and efficacy of the developed biofeedback algorithm. In total, 72 participants performed a short breathing exercise in VR with or without respiratory biofeedback. The feedback integration resulted in a satisfactory user experience, a heightened breath awareness, a greater focus on slow diaphragmatic breathing and an increased respiratory sinus arrhythmia. This evidences that the novel biofeedback approach is low-cost, unobtrusive, usable and effective in increasing breath awareness and promoting slow diaphragmatic breathing in the context of VR-based breathing exercises. Future studies need to investigate the broader applicability and long-term effects.",2020,"The feedback integration resulted in a satisfactory user experience, a heightened breath awareness, a greater focus on slow diaphragmatic breathing and an increased respiratory sinus arrhythmia.",['72 participants performed a'],"['short breathing exercise in VR with or without respiratory biofeedback', 'novel virtual reality (VR) based approach to respiratory biofeedback that utilizes the positionally tracked hand controllers integrated into modern VR systems to capture and feedback the respiration-induced abdominal movements', 'Virtual Reality Respiratory Biofeedback Approach']","['feasibility and efficacy', 'slow diaphragmatic breathing and an increased respiratory sinus arrhythmia']","[{'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C1286159', 'cui_str': 'Movement of abdomen'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0231898', 'cui_str': 'Diaphragmatic breathing'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}]",72.0,0.0136611,"The feedback integration resulted in a satisfactory user experience, a heightened breath awareness, a greater focus on slow diaphragmatic breathing and an increased respiratory sinus arrhythmia.","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Blum', 'Affiliation': 'Department of Occupational and Consumer Psychology, Albert-Ludwigs-Universität Freiburg, Engelbergerstr. 41, 79106, Freiburg, Germany. johannes.blum@psychologie.uni-freiburg.de.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Rockstroh', 'Affiliation': 'Department of Occupational and Consumer Psychology, Albert-Ludwigs-Universität Freiburg, Engelbergerstr. 41, 79106, Freiburg, Germany.'}, {'ForeName': 'Anja S', 'Initials': 'AS', 'LastName': 'Göritz', 'Affiliation': 'Department of Occupational and Consumer Psychology, Albert-Ludwigs-Universität Freiburg, Engelbergerstr. 41, 79106, Freiburg, Germany.'}]",Applied psychophysiology and biofeedback,['10.1007/s10484-020-09468-x'] 47,32303383,"Re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.02.009.",,2020,,['Clinically Localized Prostate Cancer'],['Radical Prostatectomy or Observation'],[],"[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",[],,0.0184225,,"[{'ForeName': 'Roderick C N', 'Initials': 'RCN', 'LastName': 'van den Bergh', 'Affiliation': 'Department of Urology, Antonius Hospital, Soestwetering 1, Utrecht 3543 AZ, The Netherlands. Electronic address: roodvdb@hotmail.com.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Valerio', 'Affiliation': 'Department of Urology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Tilki', 'Affiliation': 'Department of Urology, University Hospital-Hamburg Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Gandaglia', 'Affiliation': 'Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology,['10.1016/j.eururo.2020.03.046'] 48,32363556,"The efficacy of vitamin D combined with clomiphene citrate in ovulation induction in overweight women with polycystic ovary syndrome: a double blind, randomized clinical trial.","PURPOSE The aim of this study was to assess the effect of vitamin D supplementation on ovulation rate in overweight subfertile women with PCOS undergoing ovulation induction. METHODS This was a single center, parallel-groups, double-blind, and placebo-controlled randomized trial involving 186 eligible women undergoing induction of ovulation with clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily starting from the third day of menstrual cycle and for 5 days combined with either oral Vitamin D (ossofortin®, EVA PHARMA) 10,000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries) 1250 mg twice daily or to receive a placebo with calcium for three successive induction cycles. The vitamin D or placebo supplementation started 1 month before induction cycles (total four cycles). Cycles were monitored with ultrasound follicle tracking and mid-luteal serum progesterone measurement. The primary outcome was the ovulation rate after three induction cycles. RESULTS The study was performed during the period between January 2018 and September 2018, Eighty six (92.5%) women in the treatment group and 73 (78.5%) in the control group had successful ovulation (p = 0.007). The absolute and relative risk reduction was 14% and 65% respectively. Biochemical and clinical pregnancy occurred in 61.3 and 50.5% in the treatment group, and in 49.5 and 39.8% in the control group (p = 0.105 and 0.141 respectively). CONCLUSION In subfertile women with PCOS undergoing induction of ovulation, vitamin D supplementation significantly improved the ovulation rate; however, there was no effect on clinical or biochemical pregnancy.",2020,"Biochemical and clinical pregnancy occurred in 61.3 and 50.5% in the treatment group, and in 49.5 and 39.8% in the control group (p = 0.105 and 0.141 respectively). ","['overweight women with polycystic ovary syndrome', '186 eligible women undergoing induction of ovulation with', 'subfertile women with PCOS undergoing induction of', 'overweight subfertile women with PCOS undergoing ovulation induction']","['clomiphene citrate (Clomid®, Aventis) 50\u2009mg tablet twice daily starting from the third day of menstrual cycle and for 5 days combined with either oral Vitamin D (ossofortin®, EVA PHARMA', 'calcium (calciprex®, Marcyrl Pharmaceutical Industries) 1250', 'vitamin D or placebo', 'ovulation, vitamin D supplementation', 'vitamin D combined with clomiphene citrate', 'placebo with calcium', 'vitamin D supplementation', 'placebo']","['absolute and relative risk reduction', 'ovulation rate', 'Biochemical and clinical pregnancy', 'successful ovulation']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0029967', 'cui_str': 'Ovulation induction'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0546859', 'cui_str': 'Clomiphene citrate'}, {'cui': 'C0591268', 'cui_str': 'Clomide'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0388017', 'cui_str': 'Ossofortin'}, {'cui': 'C0242686', 'cui_str': 'EVA'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0013185', 'cui_str': 'Industry, Drug'}, {'cui': 'C4517554', 'cui_str': '1250'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",186.0,0.693051,"Biochemical and clinical pregnancy occurred in 61.3 and 50.5% in the treatment group, and in 49.5 and 39.8% in the control group (p = 0.105 and 0.141 respectively). ","[{'ForeName': 'Radwa', 'Initials': 'R', 'LastName': 'Rasheedy', 'Affiliation': 'Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. radwaebed@yahoo.com.'}, {'ForeName': 'Hazem', 'Initials': 'H', 'LastName': 'Sammour', 'Affiliation': 'Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Abdellatif', 'Initials': 'A', 'LastName': 'Elkholy', 'Affiliation': 'Obstetrics and Gynecology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Yasmine', 'Initials': 'Y', 'LastName': 'Salim', 'Affiliation': 'Port Said General Hospital, Port Said, Egypt.'}]",Endocrine,['10.1007/s12020-020-02315-3'] 49,32365109,The influence of an induced negative emotional state on autobiographical memory coherence.,"Individuals who experience difficulty constructing coherent narratives about significant personal experiences generally report less psychological well-being and more depressive symptoms. It remains, however, unclear whether a negative emotional state, one of the core symptoms of depression, causes this impairment in autobiographical memory coherence. The current study aimed to examine the causal relation between mood and memory coherence by means of a mood induction paradigm. A group of 165 students were randomly allocated to one of three mood groups: negative, positive, and neutral. We hypothesized that memory coherence would decrease following a negative mood induction. In addition, working memory capacity was expected to mediate the association between mood and memory coherence. Contrary to predictions, memory coherence increased following a negative mood induction. This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group. This effect of mood on memory coherence was solely observed in female participants and not in the small male subsample. Results provided no support for the hypothesis that working memory capacity functioned as an underlying mechanism. Different theoretical explanations are discussed.",2020,"This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group.","['A group of 165 students', 'female participants and not in the small male subsample']",[],"['memory coherence', 'autobiographical memory coherence']","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}]",165.0,0.0311399,"This increase was likewise observed in the positive mood group, though memory coherence remained consistent in the neutral mood group.","[{'ForeName': 'Elien', 'Initials': 'E', 'LastName': 'Vanderveren', 'Affiliation': 'Center for the Psychology of Learning and Experimental Psychopathology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Loes', 'Initials': 'L', 'LastName': 'Aerts', 'Affiliation': 'Undergraduate students clinical and health psychology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Rousseaux', 'Affiliation': 'Undergraduate students clinical and health psychology, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Bijttebier', 'Affiliation': 'School Psychology and Development in Context, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Hermans', 'Affiliation': 'Center for the Psychology of Learning and Experimental Psychopathology, KU Leuven, Leuven, Belgium.'}]",PloS one,['10.1371/journal.pone.0232495'] 50,32370202,Outcome Expectations for Exercise and Decisional Balance Questionnaires Predict Adherence and Efficacy of Exercise Programs in Dialysis Patients.,"The purpose of this study was to define if Outcomes Expectations for Exercise (OEE) and Decisional Balance (DB) scales predict adherence to guided exercise programs and associate with the improvement in physical performance in the dialysis population. Participants ( n = 40; age 63.6 ± 12.5 years) completed OEE and DB questionnaires before randomization to the experimental group ( n = 20) and control group ( n = 20) of a two-phased exercise program-the experimental group received eight weeks of supervised functional exercise and exercise counseling (1st phase) before commencing eight weeks of home-based exercise on non-dialysis days (2nd phase). Both groups performed intradialytic cycling on dialysis days during both study phases. Patients with above-median OEE and DB scores (>3.15 and >1.3, respectively) expressed significantly better adherence to intradialytic cycling (89% vs. 76%, 89% vs. 77%, respectively, p < 0.05). Experimental group patients with an above-median OEE (but not DB) score had significantly better adherence to supervised and home-based functional exercise (93% vs. 81% and 85% vs. 60%, respectively, p < 0.05). Baseline DB score predicted the final result in the hand-grip test and 6-min walk test. Low OEE and, to a lesser degree, low DB questionnaire scores associate with inferior adherence to dialysis bundled and home-based exercise programs and may help define patient subsets in need of intensified motivational input by exercise caregivers.",2020,"Experimental group patients with an above-median OEE (but not DB) score had significantly better adherence to supervised and home-based functional exercise (93% vs. 81% and 85% vs. 60%, respectively, p < 0.05).","['Participants ( n = 40; age 63.6 ± 12.5 years) completed OEE and DB questionnaires before randomization to the experimental group ( n = 20) and control group ( n = 20) of a', 'dialysis population', 'Dialysis Patients']",['two-phased exercise program-the experimental group received eight weeks of supervised functional exercise and exercise counseling (1st phase) before commencing eight weeks of home-based exercise'],"['Baseline DB score', 'DB scores', 'adherence to supervised and home-based functional exercise', 'low DB questionnaire scores', 'physical performance', 'adherence to intradialytic cycling']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0418878', 'cui_str': 'Recommendation to exercise'}, {'cui': 'C0205435', 'cui_str': 'First'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0311714,"Experimental group patients with an above-median OEE (but not DB) score had significantly better adherence to supervised and home-based functional exercise (93% vs. 81% and 85% vs. 60%, respectively, p < 0.05).","[{'ForeName': 'Špela', 'Initials': 'Š', 'LastName': 'Bogataj', 'Affiliation': 'Department of Nephrology, University Medical Centre, 1000 Ljubljana, Slovenia.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Pajek', 'Affiliation': 'Faculty of Sport, University of Ljubljana, 1000 Ljubljana, Slovenia.'}, {'ForeName': 'Jadranka', 'Initials': 'J', 'LastName': 'Buturović Ponikvar', 'Affiliation': 'Department of Nephrology, University Medical Centre, 1000 Ljubljana, Slovenia.'}, {'ForeName': 'Jernej', 'Initials': 'J', 'LastName': 'Pajek', 'Affiliation': 'Department of Nephrology, University Medical Centre, 1000 Ljubljana, Slovenia.'}]",International journal of environmental research and public health,['10.3390/ijerph17093175'] 51,32359702,"Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.",,2020,,['Upper Tract Urothelial Carcinoma (the POUT Trial'],['Re: Adjuvant Chemotherapy'],[],"[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0007138', 'cui_str': 'Transitional cell carcinoma'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]",[],,0.179276,,"[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Afferi', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Moschini', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Mattei', 'Affiliation': 'Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Montorsi', 'Affiliation': 'Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Briganti', 'Affiliation': 'Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Cathelineau', 'Affiliation': 'Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Sanchez-Salas', 'Affiliation': 'Department of Urology, Institut Mutualiste Montsouris and Université Paris Descartes, Paris, France. Electronic address: rafael.sanchez-salas@imm.fr.'}]",European urology,['10.1016/j.eururo.2020.04.006'] 52,32376477,Effects of progressive resistance training prior to total HIP arthroplasty - a secondary analysis of a randomized controlled trial.,"OBJECTIVE To investigate 1-year postoperative effect of preoperative resistance training (RT) in patients undergoing total hip arthroplasty (THA) on patient-reported outcomes on activity and function and objective outcomes on muscle strength and physical performance. DESIGN A 3-12 months follow-up of a randomized controlled trial. Patients scheduled for THA were randomized into: RT-group, twice a week for 10 weeks prior to THA, or 'care-as-usual' (CG). Primary endpoint of this sequel analysis is HOOS-ADL at 12 months follow-up. Secondary outcome measures are; other HOOS subscales, knee- and hip muscle strength plus function (gait, ascending/descending stairs, and sit-to-stand) at three and/or 12 months. CLINICALTRIALS.GOV: NCT01164111. RESULTS Eighty patients (70% women, 70.4 ± 7.6 years, BMI of 27.8 ± 4.6) were randomized to RT (n = 40) or CG (n = 40); data from 85% were available at 12 months. No superior effects were observed at 12 months for HOOS ADL (between-group change score [95%CI]) (2.6 [-4.2; 9.8], P = 0.44) or remaining subscales. However, ascending (1.3 s [0.3; 2.3], P = 0.01)) and descending stairs (1.6 s [0.3; 2.9], P = 0.01) demonstrated additional effects. At 3 months clinically relevant change-scores in favour of RT was observed on HOOS-Sport/Rec (10.5 points [1.4; 19.6], P = 0.023), together with higher knee strength of the affected side (14.6 Nm [6.3; 22.9], P < 0.001), and selected outcomes of physical function. CONCLUSIONS At 12 months after surgery, there was no additional effect of preoperative RT compared with THA alone, but rehabilitation was accelerated at 3 months.",2020,No superior effects were observed at 12 months for HOOS ADL (between-group change score [95%CI]) (,"['Patients scheduled for THA', 'patients undergoing total hip arthroplasty (THA', 'Eighty patients (70% women, 70.4 ± 7.6 years, BMI of 27.8 ± 4.6']","['THA', ""THA, or 'care-as-usual' (CG"", 'preoperative resistance training (RT', 'progressive resistance training']","['muscle strength and physical performance', 'HOOS subscales, knee- and hip muscle strength plus function (gait, ascending/descending stairs, and sit-to-stand', 'HOOS-ADL', 'knee strength', 'HOOS ADL']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517764', 'cui_str': '4.6'}]","[{'cui': 'C0040508', 'cui_str': 'Total replacement of hip'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0224415', 'cui_str': 'Skeletal muscle structure of hip'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}]",85.0,0.111012,No superior effects were observed at 12 months for HOOS ADL (between-group change score [95%CI]) (,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Holsgaard-Larsen', 'Affiliation': 'Orthopedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark. Electronic address: ahlarsen@health.sdu.dk.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hermann', 'Affiliation': 'Orthopedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark; Department of Orthopedic Surgery, Herlev University Hospital, Denmark. Electronic address: ahermann@dadlnet.dk.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Zerahn', 'Affiliation': 'Department of Clinical Physiology and Nuclear Medicine, Herlev University Hospital, Denmark. Electronic address: Bo.Zerahn@regionh.dk.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mejdahl', 'Affiliation': 'Department of Orthopedic Surgery, Herlev University Hospital, Denmark. Electronic address: Steen.Mejdahl@regionh.dk.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Overgaard', 'Affiliation': 'Orthopedic Research Unit, Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Denmark; Department of Clinical Research, University of Southern Denmark, Denmark. Electronic address: Soeren.Overgaard@rsyd.dk.'}]",Osteoarthritis and cartilage,['10.1016/j.joca.2020.04.010'] 53,32375964,Effectiveness of ongoing face-to-face anti-tobacco intervention in children with asthma.,"Background: Interventions to help parents quit smoking may yield important benefits for children with asthma. Children's exposure to environmental tobacco smoke can be measured by reporting of an adult in the household and testing the child's biomarker, e.g., cotinine. Objective: The aim of the study was to assess the effectiveness of ""face-to-face"" intervention carried out since 2016 in families with children diagnosed with asthma 3 years after beginning the anti-tobacco intervention. Methods: This study was a follow-up to an interventional study that assessed the effectiveness of direct patient education versus educational leaflets alone about parental tobacco smoking. The patients with asthma (ages 4-17 years) enrolled in our original intervention study conducted in 2016 were under the care of the allergy outpatient clinic. The active group was individually educated about the harmful effects of environmental tobacco smoke on their children. The control group included patients and parents, among whom only leaflets were distributed. After 3 years of ongoing intervention, in patients from both groups, exposure to tobacco smoking was evaluated with a questionnaire addressed to parents and/or caregivers and measurement of cotinine in children's urine. The forced expiratory volume in the first second of expiration and fractional exhaled nitric oxide levels were measured. Results: Seventy participants completed the study: 37 in the active group and 33 in the control group. In the active group, 27% of the parents quit smoking entirely compared with 9.4% of parents in the control group. In the group of active intervention, a significant decrease in the cotinine level (p < 0 .001) and the number of cigarettes smoked daily were observed (p < 0.001) 3 years after the active intervention compared with values right after the intervention. In the control group, there were no significant changes in the above-mentioned parameters. Conclusion: ""Face-to-face"" intervention among families with smokers were effective and lowered cotinine levels in children with asthma and the number of cigarettes smoked assessed 3 years after the intervention.",2020,were effective and lowered cotinine levels in children with asthma and the number of cigarettes smoked assessed 3 years after the intervention.,"['families with children diagnosed with asthma 3 years after beginning the anti-tobacco intervention', 'patients with asthma (ages 4-17 years) enrolled in our original intervention study conducted in 2016 were under the care of the allergy outpatient clinic', 'children with asthma', 'families with smokers', 'Seventy participants completed the study: 37 in the active group and 33 in the control group']","['ongoing face-to-face anti-tobacco intervention', 'face-to-face"" intervention', 'direct patient education versus educational leaflets alone about parental tobacco smoking', 'Face-to-face"" intervention']","['forced expiratory volume in the first second of expiration and fractional exhaled nitric oxide levels', 'cotinine levels', 'number of cigarettes smoked daily', 'cotinine level']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0453996', 'cui_str': 'Tobacco smoking behavior - finding'}]","[{'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0010194', 'cui_str': 'Cotinine'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",70.0,0.0262481,were effective and lowered cotinine levels in children with asthma and the number of cigarettes smoked assessed 3 years after the intervention.,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bobrowska-Korzeniowska', 'Affiliation': 'From the Department of Paediatrics and Allergy, N. Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland, and.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Jerzyńska', 'Affiliation': 'From the Department of Paediatrics and Allergy, N. Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland, and.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mitał', 'Affiliation': 'Social Medicine Institute, Department of Social and Preventive Medicine, Medical University of Lodz, Lodz, Poland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Podlecka', 'Affiliation': 'From the Department of Paediatrics and Allergy, N. Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland, and.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Brzozowska', 'Affiliation': 'From the Department of Paediatrics and Allergy, N. Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland, and.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Stelmach', 'Affiliation': 'From the Department of Paediatrics and Allergy, N. Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland, and.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Stelmach', 'Affiliation': 'Social Medicine Institute, Department of Social and Preventive Medicine, Medical University of Lodz, Lodz, Poland.'}]",Allergy and asthma proceedings,['10.2500/aap.2020.41.200010'] 54,32375251,"Personal and Social Responsibility Programme Effects, Prosocial Behaviours, and Physical Activity Levels in Adolescents and Their Families.","The aim of this study was to analyse a personal and social responsibility programme in students and their family's perceptions relative to responsibility, prosocial behaviours, empathy, violence perception and physical activity levels. A sample consisting of 57 physical education students between 11 and 14 years old (mean (M) = 11.93; standard deviation (SD) = 0.73) that included 32 of their parents (M = 49.31; SD = 6.39) was distributed into experimental and control groups. The main results indicate that there were initial significant differences in favour of the control group for personal and social responsibility compared to the experimental group and they disappeared at the end of the treatment. There was an increase in antisocial behaviours for the control group at the end of the treatment. The experimental group also enhanced the values in violence perception for both students and families as compared to the control group. These results seem contradictory, which may be due in part to a short-time intervention programme and a low number of participants in the sample. More studies will clarify the improvements this kind of programme can bring to the variables studied.",2020,The main results indicate that there were initial significant differences in favour of the control group for personal and social responsibility compared to the experimental group and they disappeared at the end of the treatment.,"[""students and their family's"", 'Adolescents and Their Families', '57 physical education students between 11 and 14 years old (mean (M) = 11.93; standard deviation (SD) = 0.73) that included 32 of their parents (M = 49.31; SD = 6.39']",[],"['Personal and Social Responsibility Programme Effects, Prosocial Behaviours, and Physical Activity Levels', 'personal and social responsibility', 'perceptions relative to responsibility, prosocial behaviours, empathy, violence perception and physical activity levels', 'antisocial behaviours', 'values in violence perception']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]",[],"[{'cui': 'C0037433', 'cui_str': 'Responsibility, Social'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0233523', 'cui_str': 'Antisocial behavior'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0167587,The main results indicate that there were initial significant differences in favour of the control group for personal and social responsibility compared to the experimental group and they disappeared at the end of the treatment.,"[{'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'García-García', 'Affiliation': 'Health, Physical Activity and Education (SAFE) Research Group, Sport Sciences Faculty, University of Murcia, 30720 Santiago de la Ribera, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Manzano-Sánchez', 'Affiliation': 'Department of Physical Activity and Sport, CEI Campus Mare Nostrum, University of Murcia, 30720 Santiago de la Ribera, Spain.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Belando-Pedreño', 'Affiliation': 'Faculty of Sports Science, Universidad Europea de Madrid, 28670 Villaviciosa de Odón, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Valero-Valenzuela', 'Affiliation': 'Department of Physical Activity and Sport, Sport Sciences Faculty, CEI Campus Mare Nostrum, University of Murcia, 30720 Santiago de la Ribera, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17093184'] 55,32375328,Influence of Interval Training Frequency on Time-Trial Performance in Elite Endurance Athletes.,"PURPOSE To determine the impact of interval training frequency in elite endurance athletes. It was hypothesized that two longer sessions would elicit greater performance improvements and physiological adaptation than four shorter sessions at the same intensity. METHODS Elite cross-country skiers and biathletes were randomly assigned to either a high-frequency group (HF group) (5 M, 1 F, age 22 (19-26), VO 2max 67.8 (65.5-70.2) mL/kg/min) doing four short interval sessions per week or a low-frequency group (LF group) (8 M, 1 F, age 22 (18-23), VO 2max 70.7 (67.0-73.9) mL/kg/min) doing two longer interval sessions. All interval sessions were performed at ~85% of maximum heart rate, and groups were matched for total weekly training volume. Pre- and post-intervention, athletes completed an 8 km rollerski time-trial, maximal oxygen uptake (VO 2max ) test, and an incremental, submaximal exercise test. RESULTS The LF group had a statistically significant improved time-trial performance following the intervention ( p = 0.04), with no statistically significant changes in the HF group. Similarly, percentage utilization of VO 2max at anaerobic threshold ( p = 0.04) and exercise economy ( p = 0.01) were statistically significantly improved following the intervention in the LF group only. No statistically significant changes in VO 2max were observed in either group. CONCLUSIONS Two longer interval sessions appear superior to four shorter sessions per week in promoting endurance adaptations and performance improvements in elite endurance athletes. Despite matched training volume and exercise intensity, the larger, more concentrated exercise stimulus in the LF group appears to induce more favorable adaptations. The longer time between training sessions in the LF group may also have allowed athletes to recover more effectively and better ""absorb"" the training. These findings are in line with the ""best practice"" observed by many of the world's best endurance athletes.",2020,"Similarly, percentage utilization of VO 2max at anaerobic threshold ( p = 0.04) and exercise economy ( p = 0.01) were statistically significantly improved following the intervention in the LF group only.","['Elite cross-country skiers and biathletes', 'Elite Endurance Athletes', 'elite endurance athletes']",['Pre- and post-intervention'],"['percentage utilization of VO 2max at anaerobic threshold', 'time-trial performance', 'maximal oxygen uptake (VO 2max ) test, and an incremental, submaximal exercise test', 'VO 2max', 'exercise economy', 'performance improvements and physiological adaptation']","[{'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0425040', 'cui_str': 'Skier'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0002749', 'cui_str': 'Anaerobic Threshold'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0001400', 'cui_str': 'Adaptations, Physiological'}]",,0.041482,"Similarly, percentage utilization of VO 2max at anaerobic threshold ( p = 0.04) and exercise economy ( p = 0.01) were statistically significantly improved following the intervention in the LF group only.","[{'ForeName': 'Espen', 'Initials': 'E', 'LastName': 'Tønnessen', 'Affiliation': 'School of Health Sciences, Kristiana University College, 0153 Oslo, Norway.'}, {'ForeName': 'Jonny', 'Initials': 'J', 'LastName': 'Hisdal', 'Affiliation': 'Department of Vascular Investigations, Oslo University Hospital-Aker, 0586 Oslo, Norway.'}, {'ForeName': 'Bent R', 'Initials': 'BR', 'LastName': 'Ronnestad', 'Affiliation': 'Section for Health and Exercise Physiology, Inland Norway University, 2624 Lillehammer, Norway.'}]",International journal of environmental research and public health,['10.3390/ijerph17093190'] 56,32376981,Longitudinal follow-up after telephone disclosure in the randomized COGENT study.,"PURPOSE To better understand the longitudinal risks and benefits of telephone disclosure of genetic test results in the era of multigene panel testing. METHODS Adults who were proceeding with germline cancer genetic testing were randomized to telephone disclosure (TD) with a genetic counselor or in-person disclosure (IPD) (i.e., usual care) of test results. All participants who received TD were recommended to return to meet with a physician to discuss medical management recommendations. RESULTS Four hundred seventy-three participants were randomized to TD and 497 to IPD. There were no differences between arms for any cognitive, affective, or behavioral outcomes at 6 and 12 months. Only 50% of participants in the TD arm returned for the medical follow-up appointment. Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002). Mammography was lower at 12 months among those who had TD and did not return for medical follow-up (70%) compared with those who had TD and returned (86%) and those who had IPD (87%, adjusted p < 0.01). CONCLUSION Telephone disclosure of genetic test results is a reasonable alternative to in-person disclosure, but attention to medical follow-up may remain important for optimizing appropriate use of genetic results.",2020,"Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002).","['Four hundred seventy-three participants were randomized to TD and 497 to IPD', 'Adults who were proceeding with germline cancer genetic testing']","['telephone disclosure (TD) with a genetic counselor or in-person disclosure (IPD)\xa0(i.e., usual care']","['cognitive, affective, or behavioral outcomes', 'Mammography']","[{'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0679560', 'cui_str': 'Genetic test'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0587719', 'cui_str': 'Genetic counselor'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}]",473.0,0.0669023,"Returning was associated with site (p < 0.0001), being female (p = 0.047), and not having a true negative result (p < 0.002).","[{'ForeName': 'Madison K', 'Initials': 'MK', 'LastName': 'Kilbride', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Egleston', 'Affiliation': 'Fox Chase Cancer Center, Temple University Health System, Biostatistics and Bioinformatics Facility, Philadelphia, PA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Patrick-Miller', 'Affiliation': 'Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Daly', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Ganschow', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Generosa', 'Initials': 'G', 'LastName': 'Grana', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Olufunmilayo I', 'Initials': 'OI', 'LastName': 'Olopade', 'Affiliation': 'Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Fetzer', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Brandt', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Chambers', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Dana F', 'Initials': 'DF', 'LastName': 'Clark', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Forman', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Rikki', 'Initials': 'R', 'LastName': 'Gaber', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Cassandra', 'Initials': 'C', 'LastName': 'Gulden', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Horte', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Long', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Terra', 'Initials': 'T', 'LastName': 'Lucas', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Shreshtha', 'Initials': 'S', 'LastName': 'Madaan', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Mattie', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'McKenna', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Montgomery', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Nielsen', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Jacquelyn', 'Initials': 'J', 'LastName': 'Powers', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Rainey', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Rybak', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Savage', 'Affiliation': 'Department of Medical Genetics, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Seelaus', 'Affiliation': 'Department of Internal Medicine, The John H. Stroger Jr. Hospital of Cook County, Chicago, IL, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Stoll', 'Affiliation': 'Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, The University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Jill E', 'Initials': 'JE', 'LastName': 'Stopfer', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Xinxin Shirley', 'Initials': 'XS', 'LastName': 'Yao', 'Affiliation': 'Division of Hematology-Oncology, MD Anderson Cancer Center at Cooper, Camden, NJ, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Domchek', 'Affiliation': 'Department of Medicine, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Angela R', 'Initials': 'AR', 'LastName': 'Bradbury', 'Affiliation': 'Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA. Angela.Bradbury@uphs.upenn.edu.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-020-0808-3'] 57,32379201,Influenza or Meningococcal Immunization During Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials.,"This analysis includes pooled data from 2 placebo-controlled maternal influenza immunization trials, with a separate analysis on a meningococcal conjugate vaccine-controlled maternal influenza immunization trial. Maternal influenza immunization was not associated with infant or maternal all-cause mortality in placebo-controlled trials. In the meningococcal conjugate vaccine-controlled trial, there were fewer deaths during low or any influenza circulation weeks among infants whose mothers received meningococcal conjugate vaccine. ClinicalTrials.gov identifiers: NCT01430689, NCT01034254 and NCT02465190.",2020,"In the meningococcal conjugate vaccine-controlled trial, there were fewer deaths during low or any influenza circulation weeks among infants whose mothers received meningococcal conjugate vaccine.",['Women and Infants'],"['Influenza or Meningococcal Immunization', 'meningococcal conjugate vaccine']",['Maternal influenza immunization'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C3888669', 'cui_str': 'Meningococcal immunisation'}, {'cui': 'C1660580', 'cui_str': 'Meningococcal conjugate vaccine'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0042200', 'cui_str': 'Influenza vaccination'}]",,0.546968,"In the meningococcal conjugate vaccine-controlled trial, there were fewer deaths during low or any influenza circulation weeks among infants whose mothers received meningococcal conjugate vaccine.","[{'ForeName': 'Dayna R', 'Initials': 'DR', 'LastName': 'Clark', 'Affiliation': 'From the Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA.'}, {'ForeName': 'Saad B', 'Initials': 'SB', 'LastName': 'Omer', 'Affiliation': 'Yale Institute for Global Health.'}, {'ForeName': 'Milagritos D', 'Initials': 'MD', 'LastName': 'Tapia', 'Affiliation': 'Centre pour le Développement des Vaccins, Bamako, Mali.'}, {'ForeName': 'Marta C', 'Initials': 'MC', 'LastName': 'Nunes', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Clare L', 'Initials': 'CL', 'LastName': 'Cutland', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Tielsch', 'Affiliation': 'Department of Global Health, Milken Institute School of Public Health, George Washington University, Washington, Columbia.'}, {'ForeName': 'Niteen', 'Initials': 'N', 'LastName': 'Wairagkar', 'Affiliation': 'Bill & Melinda Gates Foundation, Seattle, WA.'}, {'ForeName': 'Shabir A', 'Initials': 'SA', 'LastName': 'Madhi', 'Affiliation': 'Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002629'] 58,32376326,Family History Influences the Effectiveness of Home Exercise in Older People With Chronic Low Back Pain: A Secondary Analysis of a Randomized Controlled Trial.,"OBJECTIVE To investigate whether a family history of low back pain (LBP) influences patient outcomes and treatment effects following home exercises in older people with chronic LBP. DESIGN Secondary analysis of a randomized controlled trial. SETTING Local community. PARTICIPANTS People older than 55 years with chronic LBP (N=60). INTERVENTIONS Participants in the intervention group completed video game exercises for 60 minutes 3 times per week for 8 weeks. Participants in the control group were instructed to maintain their usual levels of activity and care seeking behaviors. MAIN OUTCOMES MEASURES Participants indicated whether any of their immediate family members had a history of ""any"" LBP or ""activity-limiting"" LBP at baseline. We collected self-reported measures of pain, function, pain self-efficacy, care seeking, physical activity, disability, fear of movement and/or reinjury, and falls efficacy at baseline, 8 weeks, 3 months, and 6 months. We performed regression analyses to determine whether a family history of LBP predicted patient outcomes and moderated the effects of home exercise. RESULTS Participants with a family history of any LBP were less likely to be highly active than those without a family history (odds ratio, 0.08; 95% CI, 0.01-0.42; P=.003). Home-based video game exercises led to improvements in function in those without a family history of activity-limiting LBP (β=1.78; 95% CI, 0.56-3.00; P=.006) but not in those with a family history (β=-0.17; 95% CI, -2.56 to 2.21; P=.880) (interaction P=.049). A family history of LBP did not influence the remaining patient outcomes or treatment effects. CONCLUSIONS A family history of LBP appears to negatively influence physical activity levels in older people with chronic LBP. Further, home-based video game exercises appear to be beneficial for older people with chronic LBP that do not have a family history of LBP.",2020,"Home-based video-game exercises led to improvements in function in those without a family history of activity-limiting LBP (β=1.78 95%CI: 0.56-3.00, p=0.006), but not in those with a family history (β=-0.17 95%CI: -2.56 to 2.21, p=0.880) (interaction p=0.049).","['older people with chronic LBP', 'Local community', 'People over 55 years old with chronic LBP', 'OF HOME-EXERCISE IN OLDER PEOPLE WITH CHRONIC LOW BACK PAIN']","['home-exercises', 'video-game exercises']","['pain, function, pain self-efficacy, care seeking, physical activity, disability, fear of movement/re-injury, and falls-efficacy', ""history of 'any' LBP or 'activity-limiting' LBP"", 'physical activity levels']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0788307,"Home-based video-game exercises led to improvements in function in those without a family history of activity-limiting LBP (β=1.78 95%CI: 0.56-3.00, p=0.006), but not in those with a family history (β=-0.17 95%CI: -2.56 to 2.21, p=0.880) (interaction p=0.049).","[{'ForeName': 'Joshua R', 'Initials': 'JR', 'LastName': 'Zadro', 'Affiliation': 'Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia; Institute for Musculoskeletal Health, Sydney Local Health District, Sydney, NSW, Australia. Electronic address: joshua.zadro@sydney.edu.au.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Shirley', 'Affiliation': 'Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney, NSW, Australia.'}, {'ForeName': 'Tom I L', 'Initials': 'TIL', 'LastName': 'Nilsen', 'Affiliation': 'Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; Clinic of Anaesthesia and Intensive Care, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Mork', 'Affiliation': 'Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Paulo H', 'Initials': 'PH', 'LastName': 'Ferreira', 'Affiliation': 'Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney, NSW, Australia.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.03.019'] 59,32374724,The impact of an integrated depression and HIV treatment program on mental health and HIV care outcomes among people newly initiating antiretroviral therapy in Malawi.,"BACKGROUND Depression is highly prevalent among patients newly starting antiretroviral treatment (ART) in Malawi and many other countries. Untreated depression at ART initiation can disrupt the HIV care continuum. Effective approaches for depression screening and treatment exist for low-resource settings, but they are rarely applied. Identifying effective implementation strategies are critical. METHODS A pilot program integrated depression screening and treatment into routine HIV care using existing staff at two public health clinics in Malawi in two phases; a screening-only ""control"" phase and an active ""intervention"" phase. During the intervention phase, providers prescribed antidepressants or referred patients for Friendship Bench problem-solving therapy. We evaluated the program's impact on retention in HIV care, viral suppression, and depression remission at 6 months using tabular comparisons and log-binomial models to estimate adjusted risk ratios and mean differences among the intervention group relative to the control group. RESULTS Nearly all consenting participants were screened for depression appropriately and 25% had mild to severe depressive symptoms. During the intervention phase, 86% of participants with mild depressive symptoms started Friendship Bench therapy and 96% of participants with moderate to severe depressive symptoms started antidepressants. Few participants in the intervention group received consistent depression treatment over their first 6 months in care. In the adjusted main analysis, program exposure did not demonstrably affect most HIV or mental health outcomes, though the probability of currently being on ART at 6 months was significantly lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. CONCLUSIONS While it is feasible to integrate depression screening and treatment initiation into ART initiation, providing ongoing depression treatment over time is challenging. Similar implementation science studies focused on maintaining depression management will be increasingly important as we strive to understand and test the best ways to implement evidence-based depression treatment within HIV care.",2020,"In the adjusted main analysis, program exposure did not demonstrably affect most HIV or mental health outcomes, though the probability of currently being on ART at 6 months was significantly lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. ","['A pilot program integrated depression screening and treatment into routine HIV care using existing staff at two public health clinics in Malawi in two phases; a', 'Nearly all consenting participants were screened for depression appropriately and 25% had mild to severe depressive symptoms', 'patients newly starting antiretroviral treatment (ART) in Malawi and many other countries', 'people newly initiating antiretroviral therapy in Malawi', 'participants with mild depressive symptoms started Friendship Bench therapy and 96% of participants with moderate to severe depressive symptoms started antidepressants']","['Friendship Bench problem-solving therapy', 'consistent depression treatment', 'screening-only ""control"" phase and an active ""intervention"" phase', 'integrated depression and HIV treatment program']","['mental health and HIV care outcomes', 'HIV or mental health outcomes', 'retention in HIV care, viral suppression, and depression remission']","[{'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0740218', 'cui_str': 'Depression screening'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0178647', 'cui_str': 'Friendship'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}]","[{'cui': 'C0178647', 'cui_str': 'Friendship'}, {'cui': 'C1303140', 'cui_str': 'Problem solving therapy'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",,0.0805605,"In the adjusted main analysis, program exposure did not demonstrably affect most HIV or mental health outcomes, though the probability of currently being on ART at 6 months was significantly lower among the intervention group than the control group [RR 0.6(95%CI: 0.4-0.9)]. ","[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Stockton', 'Affiliation': 'Epidemiology Department, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Udedi', 'Affiliation': 'NCDs & Mental Health Unit, Ministry of Health, Lilongwe, Malawi.'}, {'ForeName': 'Kazione', 'Initials': 'K', 'LastName': 'Kulisewa', 'Affiliation': 'Department of Mental Health, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Mina C', 'Initials': 'MC', 'LastName': 'Hosseinipour', 'Affiliation': 'University of North Carolina Project-Malawi, Tidziwe Centre, Lilongwe, Malawi.'}, {'ForeName': 'Bradley N', 'Initials': 'BN', 'LastName': 'Gaynes', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Mphonda', 'Affiliation': 'University of North Carolina Project-Malawi, Tidziwe Centre, Lilongwe, Malawi.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Maselko', 'Affiliation': 'Epidemiology Department, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Audrey E', 'Initials': 'AE', 'LastName': 'Pettifor', 'Affiliation': 'Epidemiology Department, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, United States of America.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Verhey', 'Affiliation': 'Friendship Bench Zimbabwe, Milton Park, Harare, Zimbabwe.'}, {'ForeName': 'Dixon', 'Initials': 'D', 'LastName': 'Chibanda', 'Affiliation': 'Friendship Bench Zimbabwe, Milton Park, Harare, Zimbabwe.'}, {'ForeName': 'Ilana', 'Initials': 'I', 'LastName': 'Lapidos-Salaiz', 'Affiliation': 'United States Agency for International Development (USAID), Arlington, VA, United States of America.'}, {'ForeName': 'Brian W', 'Initials': 'BW', 'LastName': 'Pence', 'Affiliation': 'Epidemiology Department, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, United States of America.'}]",PloS one,['10.1371/journal.pone.0231872'] 60,32371123,Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.,"BACKGROUND The impact of rituximab on health-related quality of life (HRQoL) in primary central nervous system lymphoma patients is not well known. We determined the impact of rituximab added to standard high-dose methotrexate-based treatment on HRQoL in patients in a large randomised trial. PATIENTS AND METHODS Patients from a large phase III trial (HOVON 105/ALLG NHL 24), randomly assigned to receive standard chemotherapy with or without rituximab and followed by 30 Gy whole brain radiotherapy (WBRT) in patients ≤60 years, completed the EORTC QLQ-C30 and QLQ-BN20 questionnaires before and during treatment, and up to 24 months of follow-up or progression. Differences between treatment arms over time in global health status, role functioning, social functioning, fatigue, and motor dysfunction were assessed. Differences ≥10 points were deemed clinically relevant. The effect of WBRT on HRQoL was analysed in irradiated patients. RESULTS A total of 160/175 patients eligible for the HRQoL study completed at least one questionnaire and were included. Over time, scores improved statistically significantly and were clinically relevant in both arms. Between arms, there were no differences on any scale (range: -3.8 to +4.0). Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared with baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively). In irradiated patients (n = 59), scores in all preselected scales, except motor dysfunction, remained stable up to 24 months compared with shortly after WBRT, overall mean difference ranging between 0.02 and 4.570. CONCLUSION Compared with baseline, treatment resulted in improved HRQoL scores. The addition of rituximab to standard chemotherapy did not impact HRQoL over time. WBRT did not result in deterioration of HRQoL in the first 2 years.",2020,"Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared to baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively).","['160/175 patients eligible for the HRQoL study completed at least one questionnaire and were included', 'Patients from a large phase III trial (HOVON 105/ALLG NHL 24', 'irradiated patients', 'primary central nervous system lymphoma patients']","['standard chemotherapy with or without rituximab and followed by 30Gy whole brain radiotherapy (WBRT', 'chemotherapy with or without rituximab', 'rituximab to standard chemotherapy', 'rituximab', 'WBRT', 'rituximab added to standard high-dose methotrexate-based treatment']","['health-related quality of life (HRQoL', 'fatigue and motor dysfunction', 'HRQoL', 'global health status, role functioning, social functioning, fatigue, and motor dysfunction', 'HRQoL scores', 'deterioration of HRQoL', 'Health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0024305', 'cui_str': 'Malignant lymphoma, non-Hodgkin'}, {'cui': 'C1277077', 'cui_str': 'Irradiated blood product'}, {'cui': 'C0280803', 'cui_str': 'Primary central nervous system lymphoma'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",,0.17791,"Scores on all scales were improved to a clinically relevant extent at 12 and 24 months compared to baseline in both arms, except for fatigue and motor dysfunction at 12 months (-7.4 and -8.8, respectively).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'van der Meulen', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands. Electronic address: m.vandermeulen.2@erasmusmc.nl.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bakunina', 'Affiliation': 'HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nijland', 'Affiliation': 'Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Minnema', 'Affiliation': 'Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cull', 'Affiliation': 'Haematology Department, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine, Nedlands, Australia; University of Western Australia, Crawley, Australia.'}, {'ForeName': 'W B C', 'Initials': 'WBC', 'LastName': 'Stevens', 'Affiliation': 'Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Baars', 'Affiliation': 'Department of Hemato-Oncology, Antoni van Leeuwenhoek Hospital/Dutch Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'K D', 'Initials': 'KD', 'LastName': 'Mason', 'Affiliation': 'Department of Hematology, Royal Melbourne Hospital, Melbourne, Australia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Beeker', 'Affiliation': 'Department of Hematology, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Beijert', 'Affiliation': 'Department of Radiotherapy, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'M J B', 'Initials': 'MJB', 'LastName': 'Taphoorn', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'van den Bent', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Issa', 'Affiliation': 'Department of Hematology, Middlemore Hospital, Auckland, New Zealand.'}, {'ForeName': 'J K', 'Initials': 'JK', 'LastName': 'Doorduijn', 'Affiliation': 'Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'J E C', 'Initials': 'JEC', 'LastName': 'Bromberg', 'Affiliation': 'Department of Neuro-Oncology, Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Dirven', 'Affiliation': 'Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands; Department of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.014'] 61,32379763,Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.,"AIM That clinical trial (RAINBOW) showed that a 7.4 months overall survival benefit with the combination therapy with ramucirumab (RAM) and paclitaxel (PAC) as second-line therapy for patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma, compared with placebo (PLA) plus paclitaxel. We performed an analysis to assess the cost-effectiveness of RAM from a Chinese perspective and recognized the range of drug costs. METHODS By building a Markov model to estimate quality-adjusted life-years (QALYs), life-years (LYs) and lifetime costs. Transition probabilities, costs and utilities were estimated for the published literature, Chinese health care system and local price setting. We performed threshold analyses and probabilistic sensitivity analyses to evaluate the uncertainty of the model. RESULTS Compared with PLA strategy, RAM strategy provided an incremental survival benefit of 1.22 LYs and 0.64 QALYs. The probabilistic sensitivity analysis showed that when RAM costs less than $151 or $753 per 4 weeks, the incremental cost-effectiveness ratio (ICER) approximated the willingness-to-pay threshold (WTP), suggesting that there was 50% likelihood that the ICER for RAM + PAC would be less than $44528.4 per QALY or $48121 per QALY, respectively. CONCLUSIONS For patients with advanced gastric or gastro-oesophageal junction adenocarcinoma who fail first-line chemotherapy, our results are conducive to the multilateral drug price guidance negotiations of RAM in China.",2020,"Compared with PLA strategy, RAM strategy provided an incremental survival benefit of 1.22 LYs and 0.64 QALYs.","['advanced gastric or gastro-oesophageal cancer in China', 'patients with advanced gastric or gastro-oesophageal junction adenocarcinoma who fail first-line chemotherapy', 'patients with recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma']","['ramucirumab plus paclitaxel', 'placebo (PLA) plus paclitaxel', 'ramucirumab (RAM) and paclitaxel (PAC']","['Transition probabilities, costs and utilities', 'quality-adjusted life-years (QALYs), life-years (LYs) and lifetime costs', 'incremental survival benefit', 'overall survival benefit', 'incremental cost-effectiveness ratio (ICER']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}]","[{'cui': 'C2742502', 'cui_str': 'ramucirumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0632798,"Compared with PLA strategy, RAM strategy provided an incremental survival benefit of 1.22 LYs and 0.64 QALYs.","[{'ForeName': 'Sini', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'The Xiangya Nursing School, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Liubao', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Chongqing', 'Initials': 'C', 'LastName': 'Tan', 'Affiliation': 'Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'The Second Xiangya Hospital, PET-CT Center, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Wan', 'Affiliation': 'The Xiangya Nursing School, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Luo', 'Affiliation': 'Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Lidan', 'Initials': 'L', 'LastName': 'Yi', 'Affiliation': 'Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Jianhe', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}]",PloS one,['10.1371/journal.pone.0232240'] 62,32382082,High-risk additional chromosomal abnormalities at low blast counts herald death by CML.,"Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV were analyzed for ACA/Ph+ and blast increase. By impact on survival, ACAs were grouped into high risk (+8, +Ph, i(17q), +17, +19, +21, 3q26.2, 11q23, -7/7q abnormalities; complex) and low risk (all other). The presence of high- and low-risk ACAs was linked to six cohorts with different blast levels (1%, 5%, 10%, 15%, 20%, and 30%) in a Cox model. One hundred and twenty-three patients displayed ACA/Ph+ (8.1%), 91 were high risk. At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA. No effect was observed at blast levels of 20-30%. Sixty-three patients with high-risk ACA (69%) died (n = 37) or were alive after progression or progression-related transplantation (n = 26). High-risk ACA at low blast counts identify end-phase CML earlier than current diagnostic systems. Mortality was lower with earlier treatment. Cytogenetic monitoring is indicated when signs of progression surface or response to therapy is unsatisfactory.",2020,"At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA.","['chronic myeloid leukemia (CML', 'Sixty-three patients with high-risk ACA (69%) died (n\u2009=\u200937) or were alive after progression or progression-related transplantation (n\u2009=\u200926', 'One thousand five hundred and ten imatinib-treated patients with Philadelphia-chromosome-positive (Ph+) CML randomized in CML-study IV']",[],"['Mortality', 'survival, ACAs']","[{'cui': 'C0023473', 'cui_str': 'Chronic myeloid leukemia'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0149561', 'cui_str': 'Structure of anterior cerebral artery'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0856536', 'cui_str': 'Philadelphia chromosome positive'}, {'cui': 'C0450407', 'cui_str': 'ph+'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],"[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0008625', 'cui_str': 'Abnormalities, Chromosome'}]",63.0,0.0438058,"At low blast levels (1-15%), high-risk ACA showed an increased hazard to die compared to no ACA (ratios: 3.65 in blood; 6.12 in marrow) in contrast to low-risk ACA.","[{'ForeName': 'Rüdiger', 'Initials': 'R', 'LastName': 'Hehlmann', 'Affiliation': 'ELN Foundation, Weinheim, Germany. hehlmann.eln@gmail.com.'}, {'ForeName': 'Astghik', 'Initials': 'A', 'LastName': 'Voskanyan', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lauseker', 'Affiliation': 'IBE Universität München, München, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Pfirrmann', 'Affiliation': 'IBE Universität München, München, Germany.'}, {'ForeName': 'Lida', 'Initials': 'L', 'LastName': 'Kalmanti', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Sebastien', 'Initials': 'S', 'LastName': 'Rinaldetti', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Kohlbrenner', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Haferlach', 'Affiliation': 'MLL, München, Germany.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Schlegelberger', 'Affiliation': 'Institut für Humangenetik, MHH, Hannover, Germany.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Fabarius', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Seifarth', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Spieß', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Wuchter', 'Affiliation': 'Institut für Transfusionsmedizin und Immunologie, Medizinische Fakultät Mannheim, Universität Heidelberg und DRK-Blutspendedienst, Mannheim, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Krause', 'Affiliation': 'Medizinische Klinik 5, Universitätsklinikum, Erlangen, Germany.'}, {'ForeName': 'Hans-Jochem', 'Initials': 'HJ', 'LastName': 'Kolb', 'Affiliation': 'Medizinische Klinik III, Universitätsklinikum Großhadern, München, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Neubauer', 'Affiliation': 'Klinik für Innere Medizin, Universitätsklinikum, Marburg, Germany.'}, {'ForeName': 'Dieter K', 'Initials': 'DK', 'LastName': 'Hossfeld', 'Affiliation': '2. Medizinische Klinik, Universitätsklinikum Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Nerl', 'Affiliation': 'Klinikum Schwabing, München, Germany.'}, {'ForeName': 'Alois', 'Initials': 'A', 'LastName': 'Gratwohl', 'Affiliation': 'Universitätsspital, Basel, Switzerland.'}, {'ForeName': 'Gabriela M', 'Initials': 'GM', 'LastName': 'Baerlocher', 'Affiliation': 'Inselspital, Bern, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Burchert', 'Affiliation': 'Klinik für Innere Medizin, Universitätsklinikum, Marburg, Germany.'}, {'ForeName': 'Tim H', 'Initials': 'TH', 'LastName': 'Brümmendorf', 'Affiliation': 'Uniklinik RWTH, Aachen, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Hasford', 'Affiliation': 'IBE Universität München, München, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hochhaus', 'Affiliation': 'Klinik für Innere Medizin II, Universitätsklinikum, Jena, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Saußele', 'Affiliation': 'III. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Baccarani', 'Affiliation': 'Department of Hematology-Oncology, Policlinico S.Orsola-Malpighi, University of Bologna, Bologna, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Leukemia,['10.1038/s41375-020-0826-9'] 63,32380460,Pilot Randomized Trial of a Transdisciplinary Geriatric and Palliative Care Intervention for Older Adults With Cancer.,"BACKGROUND Oncologists often struggle with managing the unique care needs of older adults with cancer. This study sought to determine the feasibility of delivering a transdisciplinary intervention targeting the geriatric-specific (physical function and comorbidity) and palliative care (symptoms and prognostic understanding) needs of older adults with advanced cancer. METHODS Patients aged ≥65 years with incurable gastrointestinal or lung cancer were randomly assigned to a transdisciplinary intervention or usual care. Those in the intervention arm received 2 visits with a geriatrician, who addressed patients' palliative care needs and conducted a geriatric assessment. We predefined the intervention as feasible if >70% of eligible patients enrolled in the study and >75% of eligible patients completed study visits and surveys. At baseline and week 12, we assessed patients' quality of life (QoL), symptoms, and communication confidence. We calculated mean change scores in outcomes and estimated intervention effect sizes (ES; Cohen's d) for changes from baseline to week 12, with 0.2 indicating a small effect, 0.5 a medium effect, and 0.8 a large effect. RESULTS From February 2017 through June 2018, we randomized 62 patients (55.9% enrollment rate [most common reason for refusal was feeling too ill]; median age, 72.3 years; cancer types: 56.5% gastrointestinal, 43.5% lung). Among intervention patients, 82.1% attended the first visit and 79.6% attended both. Overall, 89.7% completed all study surveys. Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). CONCLUSIONS In this pilot trial, enrollment exceeded 55%, and >75% of enrollees completed all study visits and surveys. The transdisciplinary intervention targeting older patients' unique care needs showed encouraging ES estimates for enhancing patients' QoL, symptom burden, and communication confidence.",2020,"Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). ","['Older Adults With Cancer', '62 patients (55.9% enrollment rate [most common reason for refusal was feeling too ill]; median age, 72.3 years; cancer types: 56.5% gastrointestinal, 43.5% lung', 'Patients aged ≥65 years with incurable gastrointestinal or lung cancer', 'eligible patients enrolled in the study and >75% of eligible patients completed study visits and surveys', 'older adults with cancer', 'From February 2017 through June 2018', 'older adults with advanced cancer']","['Transdisciplinary Geriatric and Palliative Care Intervention', 'transdisciplinary intervention', 'transdisciplinary intervention or usual care']","['QoL decrement', 'reduced number of moderate/severe symptoms', ""patients' quality of life (QoL), symptoms, and communication confidence"", 'communication confidence']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0040809', 'cui_str': 'Refusal of treatment by patient'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0436345', 'cui_str': 'Symptom severe'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}]",62.0,0.108189,"Compared with usual care, intervention patients had less QoL decrement (-0.77 vs -3.84; ES = 0.21), reduced number of moderate/severe symptoms (-0.69 vs +1.04; ES = 0.58), and improved communication confidence (+1.06 vs -0.80; ES = 0.38). ","[{'ForeName': 'Ryan D', 'Initials': 'RD', 'LastName': 'Nipp', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Temel', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Charn-Xin', 'Initials': 'CX', 'LastName': 'Fuh', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kay', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Landay', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lage', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Franco-Garcia', 'Affiliation': 'Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Scott', 'Affiliation': 'Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Stevens', 'Affiliation': 'Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Terrence', 'Initials': 'T', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Supriya', 'Initials': 'S', 'LastName': 'Mohile', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, New York.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Dale', 'Affiliation': 'Department of Supportive Care Medicine, City of Hope National Medical Center, Duarte, California; and.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Traeger', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Ardeshir Z.', 'Initials': 'AZ', 'LastName': 'Hashmi', 'Affiliation': 'Department of Internal Medicine and Geriatrics, Cleveland Clinic, Cleveland, Ohio'}, {'ForeName': 'Vicki', 'Initials': 'V', 'LastName': 'Jackson', 'Affiliation': 'Department of Medicine, Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Greer', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Areej', 'Initials': 'A', 'LastName': 'El-Jawahri', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Temel', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, and.'}]",Journal of the National Comprehensive Cancer Network : JNCCN,['10.6004/jnccn.2019.7386'] 64,32380679,"Effect of Dynamic Balance Exercises Based on Visual Feedback on Physical Function, Balance Ability, and Depression in Women after Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial.","The aim of this study was to compare the effects of dynamic balance exercises with and without visual feedback on recovery from total knee arthroplasty. The participants were 30 women who underwent total knee arthroplasty more than one week before the study, and were randomly allocated into two groups. The average ages of the experimental and control groups were 70.13 and 69.00 years, respectively. The dynamic balance exercise with visual feedback (VF) group practiced dynamic balance exercises using a laser pointer for five 30-min sessions over a 4-week period. The dynamic balance exercise without visual feedback (control) group practiced dynamic balance exercises for five 30 min sessions over a 4 week period. The following clinical measures were used for assessing physical function, balance ability, and depression. Compared with the control group, the VF group showed significant improvements in the physical performance test, Western Ontario and McMaster Universities Arthritis Index (WOMAC), confidence ellipse area (CEA), path length (PL), average velocity (AV), and Timed Up and Go test (TUG test) ( p < 0.05). Furthermore, the VF group showed significant improvements in all post-surgery outcome measures compared with the pre-surgery values ( p < 0.05). The above results indicated that the dynamic balance exercises based on visual feedback improved physical function and balance ability in patients following total knee arthroplasty, suggesting the need for effective rehabilitation programs for patients with total knee arthroplasty.",2020,"Compared with the control group, the VF group showed significant improvements in the physical performance test, Western Ontario and McMaster Universities Arthritis Index (WOMAC), confidence ellipse area (CEA), path length (PL), average velocity (AV), and Timed Up and Go test (TUG test) ( p < 0.05).","['Women after Bilateral Total Knee Arthroplasty', 'total knee arthroplasty', 'participants were 30 women who underwent total knee arthroplasty more than one week before the study', 'patients with total knee arthroplasty']","['Dynamic Balance Exercises', 'dynamic balance exercise without visual feedback (control) group practiced dynamic balance exercises', 'dynamic balance exercises with and without visual feedback', 'dynamic balance exercises', 'dynamic balance exercise with visual feedback (VF) group practiced dynamic balance exercises']","['visual feedback improved physical function and balance ability', 'Physical Function, Balance Ability, and Depression', 'physical function, balance ability, and depression', 'physical performance test, Western Ontario and McMaster Universities Arthritis Index (WOMAC), confidence ellipse area (CEA), path length (PL), average velocity (AV), and Timed Up and Go test (TUG test']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0018262', 'cui_str': 'Group Practice'}]","[{'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0560184', 'cui_str': 'Ability to balance'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0003864', 'cui_str': 'Arthritis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}]",30.0,0.0218742,"Compared with the control group, the VF group showed significant improvements in the physical performance test, Western Ontario and McMaster Universities Arthritis Index (WOMAC), confidence ellipse area (CEA), path length (PL), average velocity (AV), and Timed Up and Go test (TUG test) ( p < 0.05).","[{'ForeName': 'Ju-Yeon', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': 'Graduate School of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}, {'ForeName': 'Jung-Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Andong Science College, Andong 36616, Korea.'}, {'ForeName': 'Byoung-Hee', 'Initials': 'BH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Sahmyook University, Seoul 01795, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17093203'] 65,32383125,Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial.,"BACKGROUND The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there is a lack of evidence-based therapies to prevent COVID-19 following exposure to the virus, or to prevent worsening of symptoms following confirmed infection. We describe the design of a clinical trial of hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET) for COVID-19. METHODS We will conduct two nested multicentre international double-blind randomized placebo-controlled clinical trials of hydroxychloroquine for: 1) PEP of asymptomatic household contacts or healthcare workers exposed to COVID-19 within the past four days, and 2) PET for symptomatic outpatients with COVID-19 showing symptoms for less than four days. We will recruit 1,500 patients each for the PEP and PET trials. Participants will be randomized 1:1 to receive five days of hydroxychloroquine or placebo. The primary PEP trial outcome will be the incidence of symptomatic COVID-19. The primary PET trial outcome will be an ordinal scale of disease severity (not hospitalized, hospitalized without intensive care, hospitalization with intensive care, or death). Participant screening, informed consent, and follow-up will be exclusively internet-based with appropriate regulatory and research ethics board approvals in Canada and the United States. DISCUSSION These complementary randomized-controlled trials are innovatively designed and adequately powered to rapidly answer urgent questions regarding the effectiveness of hydroxychloroquine to reduce virus transmission and disease severity of COVID-19 during a pandemic. In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel. Innovative trial approaches are needed to urgently assess therapeutic options to mitigate the global impact of this pandemic. TRIALS REGISTRATION clinicaltrials.gov (NCT04308668); registered 16 March, 2020.",2020,In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel.,"['severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2', 'symptomatic outpatients with COVID-19 showing symptoms for less than four days', '1,500 patients each for the PEP and PET trials']","['hydroxychloroquine or placebo', 'Post-exposure prophylaxis or pre-emptive therapy', 'hydroxychloroquine', 'hydroxychloroquine for post-exposure prophylaxis (PEP) and pre-emptive therapy (PET', 'placebo']","['incidence of symptomatic COVID-19', 'ordinal scale of disease severity (not hospitalized, hospitalized without intensive care, hospitalization with intensive care, or death']","[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1443861', 'cui_str': 'Post-exposure prophylaxis'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1443861', 'cui_str': 'Post-exposure prophylaxis'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",1500.0,0.697151,In-person participant follow-up will not be conducted to facilitate social distancing strategies and reduce risks of exposure to study personnel.,"[{'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada. slother@manitoba-physicians.ca.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Agostinis', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'Divisions of Infectious Diseases & Medical Microbiology, McGill University Health Centre, Montreal, QC, Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'Department of Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Engen', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'Critical Care Research, St-Boniface Hospital, Winnipeg, MB, Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Schwartz', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': 'CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec, QC, Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'Department of Internal Medicine, Section of Critical Care, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}]",Canadian journal of anaesthesia = Journal canadien d'anesthesie,['10.1007/s12630-020-01684-7'] 66,32379671,The effect of aromatherapy hand massage on distress and sleep quality in hemodialysis patients: A randomized controlled trial.,,2020,,['hemodialysis patients'],['aromatherapy hand massage'],['distress and sleep quality'],"[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0024875', 'cui_str': 'Massage'}]","[{'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}]",,0.102858,,"[{'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Efe Arslan', 'Affiliation': 'University of Erciyes, Health School, Kayseri, Turkey. Electronic address: dilekea@erciyes.edu.tr.'}, {'ForeName': 'Nazan', 'Initials': 'N', 'LastName': 'Kılıç Akça', 'Affiliation': 'University of Izmir Bakırçay, Faculty of Health Sciences, Turkey. Electronic address: nazan.akca@bakircay.edu.tr.'}]",Complementary therapies in clinical practice,['10.1016/j.ctcp.2020.101136'] 67,32379766,Nocebo hyperalgesia can be induced by classical conditioning without involvement of expectancy.,"Influential theoretical accounts take the position that classical conditioning can induce placebo effects through conscious expectancies. In the current study two different conditioning procedures (hidden and open) were used to separate expectancy from conditioning in order to reveal the role of expectancy in the formation of nocebo hyperalgesia. Eighty-seven healthy females were randomly assigned to three groups (hidden conditioning, open conditioning, and control). Participants were selected according to the Fear of Pain Questionnaire scores and assigned to two subgroups: high and low level of fear of pain (trait). They received electrocutaneous pain stimuli preceded by either an orange or blue color. During the conditioning phase, one color was paired with pain stimuli of moderate intensity (control stimuli) and the other color was paired with pain stimuli of high intensity (nocebo stimuli) in both hidden and open conditioning groups. Only participants in the open conditioning group were informed about this association, however just before the testing phase the expectancy of hyperalgesia induced in this way was withdrawn. In the control group, both colors were followed by control pain stimuli. During the testing phase all participants received a series of stimuli of the same intensity, regardless of the preceding color. Participants rated pain intensity, expectancy of pain intensity and fear (state). We found that nocebo hyperalgesia was induced by hidden rather than open conditioning. The hidden conditioning procedure did not produce conscious expectancies related to pain. Nocebo hyperalgesia was induced in participants with low and high fear of pain and there was no difference in the magnitude of the nocebo effect between both groups. Nocebo hyperalgesia was not predicted by the fear of upcoming painful stimuli.",2020,Nocebo hyperalgesia was induced in participants with low and high fear of pain and there was no difference in the magnitude of the nocebo effect between both groups.,['Eighty-seven healthy females'],['electrocutaneous pain stimuli preceded by either an orange or blue color'],"['Fear of Pain Questionnaire scores', 'pain intensity, expectancy of pain intensity and fear (state', 'nocebo hyperalgesia', 'Nocebo hyperalgesia', 'low level of fear of pain (trait']","[{'cui': 'C4517895', 'cui_str': '87'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0440277', 'cui_str': 'Orange - fruit'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}]","[{'cui': 'C0233702', 'cui_str': 'Algophobia'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C3658218', 'cui_str': 'Nocebo'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesia'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",87.0,0.0171263,Nocebo hyperalgesia was induced in participants with low and high fear of pain and there was no difference in the magnitude of the nocebo effect between both groups.,"[{'ForeName': 'Elżbieta A', 'Initials': 'EA', 'LastName': 'Bajcar', 'Affiliation': 'Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Wacław M', 'Initials': 'WM', 'LastName': 'Adamczyk', 'Affiliation': 'Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Wiercioch-Kuzianik', 'Affiliation': 'Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Przemysław', 'Initials': 'P', 'LastName': 'Bąbel', 'Affiliation': 'Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}]",PloS one,['10.1371/journal.pone.0232108'] 68,32384578,"Investigation of topical intranasal cocaine for sinonasal procedures: a randomized, phase III clinical trial.","BACKGROUND The objective of this trial was to demonstrate the clinical efficacy and safety of topical cocaine as part of the effort to gain regulatory approval from the United States Food and Drug Administration. METHODS This phase III, randomized, prospective, double-blind, multicenter, single-dose, placebo- and dose-controlled, parallel-group study aimed to evaluate the safety and efficacy of topical intranasal cocaine (RX0041-002). A total of 925 subjects were screened and a total of 648 subjects were randomized: 95 to placebo; 275 to 4% RX0041-002; and 278 to 8% RX0041-002. Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test. Adverse events (AEs), vital signs, Holter monitoring, nasal irritation on visual examination, and smell assessment were recorded. The placebo and experimental groups were compared using a two-tailed Fisher's exact test. RESULTS Topical 4% and 8% cocaine achieved significant subject analgesia, the primary efficacy endpoint. Both doses were safe and well-tolerated, with a safety profile similar to placebo. In the 4% and 8% groups, headache (1.5% and 2.5%, respectively), epistaxis (0.7% and 1.1%), and anxiety (0.7% and 0%) were the only AEs reported by >1 subject. No cardiovascular AEs, serious AEs, or deaths occurred. A higher percentage of subjects in the 4% and 8% groups compared with the placebo group had a modest increase in either systolic or diastolic blood pressure. CONCLUSION Topical 4% and 8% cocaine is an effective anesthetic that can be safely administered for nasal procedures.",2020,Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test.,"['925 subjects were screened and a total of 648 subjects were randomized: 95 to', 'sinonasal procedures']","['topical intranasal cocaine (RX0041-002', 'cocaine', 'topical intranasal cocaine', 'topical cocaine', 'placebo']","['headache', 'significant subject analgesia', 'anxiety', 'subjective pain intensity scores', 'systolic or diastolic blood pressure', 'visual numeric rating scale and objectively using the von Frey filament test', 'safety and efficacy', 'Efficacy', 'safe and well-tolerated', 'No cardiovascular AEs, serious AEs, or deaths', 'epistaxis', 'Adverse events (AEs), vital signs, Holter monitoring, nasal irritation on visual examination, and smell assessment']","[{'cui': 'C4517904', 'cui_str': '925'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C3208689', 'cui_str': 'Cocaine-containing product in cutaneous dose form'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0162473', 'cui_str': 'Auriculotemporal syndrome'}, {'cui': 'C0010851', 'cui_str': 'Cytoskeletal Filaments'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013801', 'cui_str': 'Electrocardiography, Holter'}, {'cui': 'C0240557', 'cui_str': 'Irritation of nose'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",925.0,0.302563,Efficacy was assessed with subjective pain intensity scores using the visual numeric rating scale and objectively using the von Frey filament test.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'McGrath', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'McGrath', 'Affiliation': 'Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Burdett', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Shokri', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Penn State Hershey Medical Center, Hershey, PA.'}, {'ForeName': 'Jason E', 'Initials': 'JE', 'LastName': 'Cohn', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.'}]",International forum of allergy & rhinology,['10.1002/alr.22561'] 69,32384053,A Digital Intervention for Adolescent Depression (MoodHwb): Mixed Methods Feasibility Evaluation.,"BACKGROUND Treatment and prevention guidelines highlight the key role of health information and evidence-based psychosocial interventions for adolescent depression. Digital health technologies and psychoeducational interventions have been recommended to help engage young people and to provide accurate health information, enhance self-management skills, and promote social support. However, few digital psychoeducational interventions for adolescent depression have been robustly developed and evaluated in line with research guidance. OBJECTIVE We aimed to evaluate the feasibility, acceptability, and potential impact of a theory-informed, co-designed digital intervention program, MoodHwb. METHODS We used a mixed methods (quantitative and qualitative) approach to evaluate the program and the assessment process. Adolescents with or at elevated risk of depression and their parents and carers were recruited from mental health services, school counselors and nurses, and participants from a previous study. They completed a range of questionnaires before and after the program (related to the feasibility and acceptability of the program and evaluation process, and changes in mood, knowledge, attitudes, and behavior), and their Web usage was monitored. A subsample was also interviewed. A focus group was conducted with professionals from health, education, social, and youth services and charities. Interview and focus group transcripts were analyzed using thematic analysis with NVivo 10 (QSR International Pty Ltd). RESULTS A total of 44 young people and 31 parents or carers were recruited, of which 36 (82%) young people and 21 (68%) parents or carers completed follow-up questionnaires. In all, 19 young people and 12 parents or carers were interviewed. Overall, 13 professionals from a range of disciplines participated in the focus group. The key themes from the interviews and groups related to the design features, sections and content, and integration and context of the program in the young person's life. Overall, the participants found the intervention engaging, clear, user-friendly, and comprehensive, and stated that it could be integrated into existing services. Young people found the ""Self help"" section and ""Mood monitor"" particularly helpful. The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents and carers). CONCLUSIONS Findings from this early stage evaluation suggest that MoodHwb and the assessment process were feasible and acceptable, and that the intervention has the potential to be helpful for young people, families and carers as an early intervention program in health, education, social, and youth services and charities. A randomized controlled trial is needed to further evaluate the digital program.",2020,"The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents or carers). ","['Adolescents with or at elevated risk of depression and their parents and carers were recruited from mental health services, school counselors and nurses, and participants from a previous study', 'Adolescent Depression (MoodHwb', 'adolescent depression', '44 young people and 31 parents or carers were recruited, of which 36 (82%) young people and 21 (68%) parents or carers completed follow-up questionnaires', 'Young people', '19 young people and 12 parents or carers were interviewed']",['Digital Intervention'],[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1571885', 'cui_str': 'Professional counselor'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],44.0,0.0418669,"The findings provided initial support for the intervention program theory, for example, depression literacy improved after using the intervention (difference in mean literacy score: 1.7, 95% CI 0.8 to 2.6; P<.001 for young people; 1.3, 95% CI 0.4 to 2.2; P=.006 for parents or carers). ","[{'ForeName': 'Rhys', 'Initials': 'R', 'LastName': 'Bevan Jones', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Thapar', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Rice', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Becky', 'Initials': 'B', 'LastName': 'Mars', 'Affiliation': 'Population Health Sciences, University of Bristol, Bristol, England, United Kingdom.'}, {'ForeName': 'Sharifah Shameem', 'Initials': 'SS', 'LastName': 'Agha', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Merry', 'Affiliation': 'Faculty of Medical and Health Sciences, School of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Stallard', 'Affiliation': 'Department for Health, University of Bath, Bath, England, United Kingdom.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Thapar', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jones', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, Wales, United Kingdom.'}, {'ForeName': 'Sharon A', 'Initials': 'SA', 'LastName': 'Simpson', 'Affiliation': 'Medical Research Council/Chief Scientist Office Social and Public Health Sciences Unit, Institute of Health and Wellbeing, University of Glasgow, Glasgow, Scotland, United Kingdom.'}]",JMIR mental health,['10.2196/14536'] 70,32384727,Benefits of a Three-Day Bamboo Forest Therapy Session on the Physiological Responses of University Students.,"Studies have indicated that natural environments have the potential to improve the relationship between a stressful life and psychological well-being and physical health. Forest therapy has recently received widespread attention as a novel solution for stress recovery and health promotion. Bamboo is an important forest type in many countries, especially in East and Southeast Asia and in African countries. Bamboo is widespread throughout southwestern China. Empirical field research on the physiological effects of bamboo forest therapy is currently lacking. To explore the benefits of bamboo forest therapy on the physiological responses of university students, 120 university volunteers between the ages of 19 and 24 participated in this study (60 males and 60 females) and were randomly divided into four groups of equal size (15 males and 15 females in each). Four sites were selected for the experiment, including two natural bamboo forests (YA and YB), a bamboo forest park (DJY), and an urban environment (CS). During the testing period, all participants were asked to view the landscape for 15 min in the morning and then walk in the testing area for 15 min in the afternoon. Blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO2) were measured as the physiological indexes, and the semantic differential method (SDM) questionnaire was completed for the environmental satisfaction evaluation. The SDM for the subjective environmental evaluation differed significantly among the university students; they obtained a better environmental experience, in terms of sensory perception, atmosphere, climate, place, and space, in the bamboo forest sites. The three-day bamboo forest therapy session improved the physiological well-being of university students. First, the blood pressure and heart rate of the university students decreased, and the SpO2 increased, after the three-day viewing and walking activities of the three-day bamboo forest therapy session. The viewing activities had a more pronounced effect on decreased heart rate in university students. Additionally, three-day bamboo forest therapy had a positive impact on decreased systolic blood pressure and heart rate in the university students, and it was significantly decreased in females, while peripheral oxygen saturation (SpO2) remained relatively low. Finally, compared with the urban site (CS), the bamboo forest sites effectively improved the university students' physiological state of health, decreased their physical pressure, and stabilized their physiological indicators. These findings provide scientific evidence that a three-day bamboo forest therapy session can increase positive physiological responses. The potential for a longer-term effect on human physiological health requires further investigation.",2020,"The SDM for the subjective environmental evaluation differed significantly among the university students; they obtained a better environmental experience, in terms of sensory perception, atmosphere, climate, place, and space, in the bamboo forest sites.","['university students, 120 university volunteers between the ages of 19 and 24 participated in this study (60 males and 60 females) and were randomly divided into four groups of equal size (15 males and 15 females in each', 'Four sites were selected for the experiment, including two natural bamboo forests (YA and YB), a bamboo forest park (DJY), and an urban environment (CS', 'University Students', 'university students']",['bamboo forest therapy'],"['Blood pressure (BP), heart rate (HR), and peripheral oxygen saturation (SpO2', ""university students' physiological state of health, decreased their physical pressure, and stabilized their physiological indicators"", 'semantic differential method (SDM) questionnaire', 'heart rate', 'blood pressure and heart rate of the university students', 'peripheral oxygen saturation (SpO2', 'systolic blood pressure and heart rate', 'positive physiological responses']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C1337281', 'cui_str': 'Bamboo extract'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}]","[{'cui': 'C1337281', 'cui_str': 'Bamboo extract'}, {'cui': 'C0086312', 'cui_str': 'Forest'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0036611', 'cui_str': 'Differential, Semantic'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",120.0,0.0259646,"The SDM for the subjective environmental evaluation differed significantly among the university students; they obtained a better environmental experience, in terms of sensory perception, atmosphere, climate, place, and space, in the bamboo forest sites.","[{'ForeName': 'Chengcheng', 'Initials': 'C', 'LastName': 'Zeng', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Bingyang', 'Initials': 'B', 'LastName': 'Lyu', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Songyuan', 'Initials': 'S', 'LastName': 'Deng', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Nian', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Lin', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}, {'ForeName': 'Qibing', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'College of Landscape Architecture, Sichuan Agricultural University, Chengdu 611130, China.'}]",International journal of environmental research and public health,['10.3390/ijerph17093238'] 71,32391919,Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever.,"BACKGROUND Fungal infections are a major complication of neutropaenia following chemotherapy. Their early diagnosis is difficult, and empirical antifungal treatment is widely used, and uses of less toxic drugs that reduce breakthrough infection are required. OBJECTIVE We conducted a multicentre, open-label, randomised, non-inferiority trial to compare the safety and efficacy of intravenous itraconazole (ivITCZ) and liposomal amphotericin B (LAmB) as empirical antifungal therapy in patients with haematological malignancies with neutropaenia and persistent fever. METHODS Patients with haematological malignancies who developed fever refractory to broad-spectrum antibacterial agents under neutropaenia conditions were enrolled. Patients were randomised for treatment with LAmB (3.0 mg/kg/d) or ivITCZ (induction: 400 mg/d, maintenance: 200 mg/d). RESULTS Observed overall favourable response rates of 17/52 (32.7%) and 18/50 (36.0%) in the LAmB and ivITCZ groups, with a model-based estimate of a 4% difference (90% CI, -12% to 20%), did not fulfil the statistical non-inferiority criterion. In the LAmB group, there were two cases of breakthrough infection and five cases of probable invasive fungal disease, whereas in the itraconazole group, neither breakthrough infection nor probable invasive fungal disease occurred. Patients in the ivITCZ group had significantly fewer grade 3-4 hypokalaemia-related events than LAmB group patients (P < .01). The overall incidence of adverse events tended to be lower in the ivITCZ group (P = .07). CONCLUSION ivITCZ showed similar efficacy and safety as LAmB as empirical antifungal therapy in haematological malignancy patients with febrile neutropaenia, although the small sample size and various limitations prevented demonstration of its non-inferiority.",2020,"The overall incidence of adverse events tended to be lower in the ivITCZ group (P = 0.07). ","['patients with neutropaenia and persistent fever', 'haematological malignancy patients with febrile neutropaenia', 'Patients with haematological malignancies who developed fever refractory to broad-spectrum antibacterial agents under neutropaenia conditions were enrolled', 'patients with haematological malignancies with neutropaenia and persistent fever']","['itraconazole', 'itraconazole (ivITCZ) and liposomal amphotericin B (LAmB', 'Intravenous itraconazole', 'ivITCZ', 'LAmB', 'liposomal amphotericin B']","['breakthrough infection nor probable invasive fungal disease', 'overall incidence of adverse events', 'grade 3-4 hypokalaemia-related events', 'efficacy and safety', 'safety and efficacy', 'overall favourable response rates', 'breakthrough infection']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0476474', 'cui_str': 'Persistent fever'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0279516', 'cui_str': 'Antibacterial'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0064113', 'cui_str': 'Itraconazole'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C1145701', 'cui_str': 'amphotericin B liposomal'}]","[{'cui': 'C3666010', 'cui_str': 'Breakthrough infection'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1262313', 'cui_str': 'Invasive fungal infection'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.107165,"The overall incidence of adverse events tended to be lower in the ivITCZ group (P = 0.07). ","[{'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Akiko M', 'Initials': 'AM', 'LastName': 'Saito', 'Affiliation': 'Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Ilseung', 'Initials': 'I', 'LastName': 'Choi', 'Affiliation': 'Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Hidaka', 'Affiliation': 'Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.'}, {'ForeName': 'Yasuhiko', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Yamasaki', 'Affiliation': 'Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.'}, {'ForeName': 'Toshiya', 'Initials': 'T', 'LastName': 'Kagoo', 'Affiliation': 'Department of Hematology and Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.'}, {'ForeName': 'Hiroatsu', 'Initials': 'H', 'LastName': 'Iida', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Hiromasa', 'Initials': 'H', 'LastName': 'Niimi', 'Affiliation': 'Department of Internal Medicine, National Hospital Organization Hiroshima-Nishi Medical Center, Otake, Japan.'}, {'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Komeno', 'Affiliation': 'Department of Hematology, National Hospital Organization Mito Medical Center, Higashiibarakigun, Japan.'}, {'ForeName': 'Chikamasa', 'Initials': 'C', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematology, National Hospital Organization Minami-Okayama Medical Center, Okayama, Japan.'}, {'ForeName': 'Fumihito', 'Initials': 'F', 'LastName': 'Tajima', 'Affiliation': 'Stem Cell Transplantation Center, National Hospital Organization Yonago Medical Center, Yonago, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Takase', 'Affiliation': 'Department of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Ueno', 'Affiliation': 'Department of Hematology and Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Shimomura', 'Affiliation': 'Department of Internal Medicine, National Hospital Organization Hiroshima-Nishi Medical Center, Otake, Japan.'}, {'ForeName': 'Tatsunori', 'Initials': 'T', 'LastName': 'Sakai', 'Affiliation': 'Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Nakashima', 'Affiliation': 'Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.'}, {'ForeName': 'Chikashi', 'Initials': 'C', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematology, National Hospital Organization Mito Medical Center, Higashiibarakigun, Japan.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Kubonishi', 'Affiliation': 'Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.'}, {'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Sunami', 'Affiliation': 'Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Yoshida', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.'}, {'ForeName': 'Aki', 'Initials': 'A', 'LastName': 'Sakurai', 'Affiliation': 'Department of Hematologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Yukihiro', 'Initials': 'Y', 'LastName': 'Kaneko', 'Affiliation': 'Department of Bacteriology, Osaka City University Graduate School of Medicine, Osaka, Japan.'}, {'ForeName': 'Yoshitsugu', 'Initials': 'Y', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Chemotherapy and Mycoses, National Institute of Infectious Diseases, Tokyo, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Nagai', 'Affiliation': 'Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.'}]",Mycoses,['10.1111/myc.13100'] 72,32386407,Reflection on modern methods: when is a stepped-wedge cluster randomized trial a good study design choice?,"The stepped-wedge cluster randomized trial (SW-CRT) involves the sequential transition of clusters (such as hospitals, public health units or communities) from control to intervention conditions in a randomized order. The use of the SW-CRT is growing rapidly. Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT). For this reason, the CONSORT extension for SW-CRTs requires that investigators provide a clear justification for the choice of study design. In this paper, we argue that all other things being equal, the SW-CRT is at greater risk of bias due to misspecification of the secular trends at the analysis stage. This is particularly problematic for studies randomizing a small number of heterogeneous clusters. We outline the potential conditions under which an SW-CRT might be an appropriate choice. Potentially appropriate and often overlapping justifications for conducting an SW-CRT include: (i) the SW-CRT provides a means to conduct a randomized evaluation which otherwise would not be possible; (ii) the SW-CRT facilitates cluster recruitment as it enhances the acceptability of a randomized evaluation either to cluster gatekeepers or other stakeholders; (iii) the SW-CRT is the only feasible design due to pragmatic and logistical constraints (for example the roll-out of a scare resource); and (iv) the SW-CRT has increased statistical power over other study designs (which will include situations with a limited number of clusters). As the number of arguments in favour of an SW-CRT increases, the likelihood that the benefits of using the SW-CRT, as opposed to a parallel-CRT, outweigh its risks also increases. We argue that the mere popularity and novelty of the SW-CRT should not be a factor in its adoption. In situations when a conventional parallel-CRT is feasible, it is likely to be the preferred design.",2020,Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT).,[],[],[],[],[],[],,0.0694736,Yet the SW-CRT is at greater risks of bias compared with the conventional parallel cluster randomized trial (parallel-CRT).,"[{'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Taljaard', 'Affiliation': 'Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.'}]",International journal of epidemiology,['10.1093/ije/dyaa077'] 73,32385134,Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVES There are no US Food and Drug Administration-approved therapies for neonatal seizures. Phenobarbital and phenytoin frequently fail to control seizures. There are concerns about the safety of seizure medications in the developing brain. Levetiracetam has proven efficacy and an excellent safety profile in older patients; therefore, there is great interest in its use in neonates. However, randomized studies have not been performed. Our objectives were to study the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment of neonatal seizures. METHODS The study was a multicenter, randomized, blinded, controlled, phase IIb trial investigating the efficacy and safety of levetiracetam compared with phenobarbital as a first-line treatment for neonatal seizures of any cause. The primary outcome measure was complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 neurophysiologists. RESULTS Eighty percent of patients (24 of 30) randomly assigned to phenobarbital remained seizure free for 24 hours, compared with 28% of patients (15 of 53) randomly assigned to levetiracetam ( P < .001; relative risk 0.35 [95% confidence interval: 0.22-0.56]; modified intention-to-treat population). A 7.5% improvement in efficacy was achieved with a dose escalation of levetiracetam from 40 to 60 mg/kg. More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). CONCLUSIONS In this phase IIb study, phenobarbital was more effective than levetiracetam for the treatment of neonatal seizures. Higher rates of adverse effects were seen with phenobarbital treatment. Higher-dose studies of levetiracetam are warranted, and definitive studies with long-term outcome measures are needed.",2020,"More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). ","['Neonatal Seizures', 'neonatal seizures of any cause', 'older patients']","['levetiracetam', 'phenobarbital', 'Phenobarbital and phenytoin', 'Levetiracetam', 'Levetiracetam Versus Phenobarbital']","['complete seizure freedom for 24 hours, assessed by independent review of the EEGs by 2 neurophysiologists', 'phenobarbital remained seizure free', 'efficacy and safety', 'efficacy', 'adverse effects']","[{'cui': 'C0159020', 'cui_str': 'Convulsions in the newborn'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0031412', 'cui_str': 'Phenobarbital'}, {'cui': 'C0031507', 'cui_str': 'Phenytoin'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0699752', 'cui_str': 'Review of'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0031412', 'cui_str': 'Phenobarbital'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.327532,"More adverse effects were seen in subjects randomly assigned to phenobarbital (not statistically significant). ","[{'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Sharpe', 'Affiliation': ""Department of Paediatric Neurology, Starship Children's Health, Auckland, New Zealand.""}, {'ForeName': 'Gail E', 'Initials': 'GE', 'LastName': 'Reiner', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California.""}, {'ForeName': 'Suzanne L', 'Initials': 'SL', 'LastName': 'Davis', 'Affiliation': ""Department of Paediatric Neurology, Starship Children's Health, Auckland, New Zealand.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nespeca', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California.""}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Gold', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California.""}, {'ForeName': 'Maynard', 'Initials': 'M', 'LastName': 'Rasmussen', 'Affiliation': 'San Diego Neonatology Inc and.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kuperman', 'Affiliation': ""Pediatric Neurology, University of California, San Francisco Benioff Children's Hospital Oakland, Oakland, California.""}, {'ForeName': 'Mary Jo', 'Initials': 'MJ', 'LastName': 'Harbert', 'Affiliation': 'Department of Neurosciences, School of Medicine, University of California, San Diego and Sharp Mary Birch Hospital for Women & Newborns, San Diego, California.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Michelson', 'Affiliation': ""Division of Pediatric Neurology, Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, California.""}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Joe', 'Affiliation': 'Division of Neonatology, Departments of Pediatrics and.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California.""}, {'ForeName': 'Neggy', 'Initials': 'N', 'LastName': 'Rismanchi', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California.""}, {'ForeName': 'Ngoc Minh', 'Initials': 'NM', 'LastName': 'Le', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, California.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Mower', 'Affiliation': ""Department of Neurology, Children's Hospital of Orange County, Orange, California.""}, {'ForeName': 'Jae', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Division of NeoNatology, Departments of Pediatrics and.'}, {'ForeName': 'Malcolm R', 'Initials': 'MR', 'LastName': 'Battin', 'Affiliation': 'Department of Neonatology, Auckland District Health Board, Auckland, New Zealand; and.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Lane', 'Affiliation': ""Division of Neonatology, Departments of Pediatrics, University of California, San Diego and Rady Children's Hospital San Diego, San Diego, California.""}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Honold', 'Affiliation': ""Division of Neonatology, Departments of Pediatrics, University of California, San Diego and Rady Children's Hospital San Diego, San Diego, California.""}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Knodel', 'Affiliation': ""Division of Neonatology, Departments of Pediatrics, University of California, San Diego and Rady Children's Hospital San Diego, San Diego, California.""}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Arnell', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, California.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Bridge', 'Affiliation': 'Division of NeoNatology, Departments of Pediatrics and.'}, {'ForeName': 'Lilly', 'Initials': 'L', 'LastName': 'Lee', 'Affiliation': 'Neurosciences, School of Medicine, University of California, San Diego, San Diego, California.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Ernstrom', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.""}, {'ForeName': 'Rema', 'Initials': 'R', 'LastName': 'Raman', 'Affiliation': ""Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, Los Angeles, California.""}, {'ForeName': 'Richard H', 'Initials': 'RH', 'LastName': 'Haas', 'Affiliation': ""Department of Neurosciences, School of Medicine, University of California, San Diego and Rady Children's Hospital-San Diego, San Diego, California; rhaas@health.ucsd.edu.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatrics,['10.1542/peds.2019-3182'] 74,32391667,[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].,"OBJECTIVE To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19). METHODS We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1：1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517). RESULTS One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group ( P >0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, P >0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function ( P >0.05). CONCLUSIONS The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.",2020,"On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group ( P >0.05).","['patients with moderate COVID-19', 'patients with moderate coronavirus disease 2019 (COVID-19', 'enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center']","['HCQ', 'hydroxychloroquine (HCQ', 'hydroxychloroquine']","['Radiological progression', 'transient diarrhea and abnormal liver function', 'efficacy and safety', 'median duration from hospitalization to virus nucleic acid negative conservation', 'negative conversion rate of SARS-CoV-2 nucleic acid', 'median time for body temperature normalization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040704', 'cui_str': 'Transients'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0028606', 'cui_str': 'Nucleic acid'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}]",30.0,0.0309209,"On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group ( P >0.05).","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Danping', 'Initials': 'D', 'LastName': 'Liu', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Qingnian', 'Initials': 'Q', 'LastName': 'Xu', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Xia', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Ling', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Shuli', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Qian', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Yinzhong', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}, {'ForeName': 'Hongzhou', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.'}]",Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,['10.3785/j.issn.1008-9292.2020.03.03'] 75,32390248,An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine.,"WHAT IS KNOWN AND OBJECTIVE Tolperisone is a centrally acting muscle relaxant under development in the United States as a treatment for acute and painful symptoms of muscle spasms. The objective of this three-way, randomized, blinded, three-period crossover study was to assess the safety and cognitive effects of tolperisone compared to placebo and the widely used muscle relaxant cyclobenzaprine in healthy volunteers. METHODS Subjects were randomized to 1 of 3 treatment arms to receive tolperisone (150 mg), cyclobenzaprine (10 mg) or placebo 3 times per day (TID) in 3 separate study periods. Subjects completed a driving test on the Cognitive Research Corporation's Driving Simulator (CRCDS Mini-Sim), a validated driving simulator, on day 1 at time to maximum plasma concentration, on day 2 before the morning dose of study drug and on day 3 at steady state following the morning dose. Subjects were assessed on various driving parameters and on a computer-administered digit-symbol substitution test (CogScreen symbol digit coding test). The driving scenario is a monotonous 100 km highway route on which subjects are instructed to maintain speed and lane position. RESULTS AND DISCUSSION The performance of subjects who had received tolperisone was not significantly different from those who had received placebo in terms of the primary end point: standard deviation of lateral position, a measure of weaving. Subjects who had received tolperisone also performed comparably to those who had received placebo on a range of secondary measures assessing driving ability, cognition and psychomotor performance. In contrast, subjects who had received cyclobenzaprine showed significant impairment compared to placebo (P < .01) on the primary end point of standard deviation of lateral position and on the majority of the secondary end points of driving ability. Despite their markedly poorer driving performance after receiving cyclobenzaprine, few subjects reported feeling unsafe to drive on day 1 (10.3%) and day 2 (3.4%). The incidence of adverse events was similar for tolperisone (36.4%) and placebo (29.0%) and was greater for cyclobenzaprine (45.4%). WHAT IS NEW AND CONCLUSION Subjects who received tolperisone (150 mg TID) experienced no impact on various measures of driving, self-reported sleepiness and cognition measures compared to placebo, in contrast to those who received the widely used muscle relaxant cyclobenzaprine (10 mg TID).",2020,"In contrast, subjects who had received cyclobenzaprine showed significant impairment compared to placebo (P < .01) on the primary end point of standard deviation of lateral position and on the majority of the secondary end points of driving ability.","['Subjects who had received tolperisone also performed comparably to those who had received', 'healthy volunteers', 'Subjects']","['cyclobenzaprine', 'muscle relaxant cyclobenzaprine', 'relaxant cyclobenzaprine', 'tolperisone', 'placebo and cyclobenzaprine', 'placebo']","['safety and cognitive effects', 'driving ability and cognitive effects', 'driving ability, cognition and psychomotor performance', 'incidence of adverse events', 'standard deviation of lateral position, a measure of weaving']","[{'cui': 'C0040382', 'cui_str': 'Tolperisone'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0056732', 'cui_str': 'cyclobenzaprine'}, {'cui': 'C0026827', 'cui_str': 'Decreased muscle tone'}, {'cui': 'C0040382', 'cui_str': 'Tolperisone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0033923', 'cui_str': 'Psychomotor Performance'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0444379', 'cui_str': 'Lateral decubitus position'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0895344,"In contrast, subjects who had received cyclobenzaprine showed significant impairment compared to placebo (P < .01) on the primary end point of standard deviation of lateral position and on the majority of the secondary end points of driving ability.","[{'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Caron', 'Affiliation': 'Neurana Pharmaceuticals, Inc., San Diego, CA, USA.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Kaye', 'Affiliation': 'Neurana Pharmaceuticals, Inc., San Diego, CA, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wessel', 'Affiliation': 'Neurana Pharmaceuticals, Inc., San Diego, CA, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Halseth', 'Affiliation': 'Neurana Pharmaceuticals, Inc., San Diego, CA, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Kay', 'Affiliation': 'Drug Development, Cognitive Research Corporation, St. Petersburg, FL, USA.'}]",Journal of clinical pharmacy and therapeutics,['10.1111/jcpt.13165'] 76,32387453,"Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel.","BACKGROUND Primary tumour location (PTL) is being adopted by clinicians to guide treatment decisions in metastatic colorectal cancer (mCRC). Here we test PTL as a predictive marker for panitumumab efficacy, and examine its relationship with an extended biomarker profile. We also examine rectal tumours as a separate location. PATIENTS AND METHODS mCRC patients from the second-line PICCOLO trial of irinotecan versus irinotecan/panitumumab (IrPan). PTL was classified as right-PTL, left-PTL or rectal-PTL. PTL was assessed as a predictive biomarker for IrPan effect in RAS-wild-type (RAS-wt) patients (compared with irinotecan alone), then tested for independence alongside an extended biomarker profile (BRAF, epiregulin/amphiregulin (EREG/AREG) and HER3 mRNA expression). RESULTS PTL data were available for 1180 patients (98.5%), of whom 558 were RAS-wt. High HER3 expression was independently predictive of panitumumab overall survival improvement, but PTL and EREG/AREG were not. IrPan progression-free survival (PFS) improvement compared with irinotecan was seen in left-PTL [hazard ratio (HR) = 0.61, P = 0.002) but not right-PTL (HR = 0.98, P = 0.90) (interaction P = 0.05; RAS/BRAF-wt interaction P = 0.10), or in rectal-PTL (HR = 0.82, P = 0.20) (interaction P = 0.14 compared with left-PTL; RAS/BRAF-wt interaction P = 0.04). Patients with right-PTL and high EREG/AREG or HER3 expression, had IrPan PFS improvement (high EREG/AREG HR = 0.20, P = 0.04; high HER3 HR = 0.33, P = 0.10) compared with irinotecan. Similar effect was seen for rectal-PTL patients (high EREG/AREG HR = 0.44, P = 0.03; high HER3 HR = 0.34, P = 0.05). CONCLUSIONS RAS-wt patients with left-PTL are more likely to have panitumumab PFS advantage than those with right-PTL or rectal-PTL. However, an extended biomarker panel demonstrated significant heterogeneity in panitumumab PFS effect within a tumour location. AREG/EREG and HER3 mRNA expression identifies patients with right-PTL or rectal-PTL who achieve similar PFS effect with panitumumab as left-colon patients. Testing could provide a more reliable basis for clinical decision making. Further validation and development of these biomarkers is required to optimise routine patient care. CLINICAL TRIAL REGISTRATION ISRCTN identifier: ISRCTN93248876.",2020,"IrPan PFS improvement compared with irinotecan was seen in left-PTL (HR=0.61,p=0.002) but not right-PTL (HR=0.98,p=0.90)(interaction p=0.05; RAS/BRAF-wt interaction p=0.10), or in rectal-PTL (HR=0.82,p=0.20)(interaction p=0.14 compared with left-PTL; RAS/BRAF-wt interaction p=0.04).","['advanced colorectal cancer (aCRC', 'advanced right-colon, left-colon and rectal cancers', '1180 patients in a phase III trial of panitumumab with an extended biomarker panel', 'aCRC patients from the second-line PICCOLO trial of']","['irinotecan /panitumumab', 'irinotecan versus irinotecan/panitumumab', 'panitumumab', 'irinotecan']","['IrPan PFS improvement', 'High HER3 expression', 'EREG/AREG or HER3 expression, had IrPan PFS improvement']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C1305188', 'cui_str': 'Right colon structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}]","[{'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0072460', 'cui_str': 'Proto-Oncogene Protein erbB-3'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C3884279', 'cui_str': 'EREG protein, human'}, {'cui': 'C3884535', 'cui_str': 'AREG protein, human'}]",558.0,0.0774107,"IrPan PFS improvement compared with irinotecan was seen in left-PTL (HR=0.61,p=0.002) but not right-PTL (HR=0.98,p=0.90)(interaction p=0.05; RAS/BRAF-wt interaction p=0.10), or in rectal-PTL (HR=0.82,p=0.20)(interaction p=0.14 compared with left-PTL; RAS/BRAF-wt interaction p=0.04).","[{'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Seligmann', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK. Electronic address: j.seligmann@leeds.ac.uk.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Elliott', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Richman', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Hemmings', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Brown', 'Affiliation': 'Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Jacobs', 'Affiliation': 'Molecular Digestive Oncology Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Williams', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tejpar', 'Affiliation': 'Molecular Digestive Oncology Unit, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'Barrett', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Quirke', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Seymour', 'Affiliation': ""Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.""}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.476'] 77,32387007,Intramuscular Versus Buccal Midazolam for Pediatric Seizures: A Randomized Double-Blinded Trial.,"BACKGROUND We compared the efficacy and safety of intramuscular with buccal midazolam as first-line treatment for active seizures in children brought to the emergency department. METHODS In a double-blind, double-dummy randomized trial, patients with an active seizure lasting more than five minutes received blinded treatments on arrival. We employed deferred consent. The proportion of patients with cessation of seizure within five minutes of drug administration was the primary efficacy outcome; proportions needing additional medication to control seizure, duration of seizure activity, and side effects were secondary outcomes. RESULTS We enrolled 150 children presenting with active seizure, age range 4.5 to 167.5 months. Cessation of seizure occurred in 61% of the intramuscular and 46% of the buccal treatment groups, (P = 0.07, difference 15.5%, 95% confidence interval for the difference -1.0 to 32.0%). Proportions requiring additional anti-seizure treatment were 39% in the intramuscular and 51% in the buccal groups. Mean duration of seizure activity after administration of study medication was 15.9 minutes (S.D. 28.7) in the intramuscular and 17.8 minutes (S.D. 27.5) in the buccal group. One patient in the intramuscular group developed respiratory depression and hypotension; there were no side effects attributed to investigational treatment in the buccal group. CONCLUSIONS Efficacy and safety of intramuscular midazolam as first-line treatment for pediatric seizures compare favorably to that of buccal midazolam.",2020,"One patient in the intramuscular group developed respiratory depression and hypotension; there were no side effects attributed to investigational treatment in the buccal group. ","['150 children presenting with active seizure, age range 4.5 to 167.5\xa0months', 'active seizures in children brought to the emergency department', 'Pediatric Seizures', 'patients with an active seizure lasting more than five\xa0minutes received blinded treatments on arrival']","['buccal midazolam', 'Intramuscular Versus Buccal Midazolam', 'midazolam']","['efficacy outcome; proportions needing additional medication to control seizure, duration of seizure activity, and side effects', 'Proportions requiring additional anti-seizure treatment', 'efficacy and safety', 'respiratory depression and hypotension', 'Mean duration of seizure activity', 'Cessation of seizure']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332302', 'cui_str': 'Brought on by'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0730597', 'cui_str': 'Duration of seizure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0235063', 'cui_str': 'Decreased respiratory function'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",150.0,0.442737,"One patient in the intramuscular group developed respiratory depression and hypotension; there were no side effects attributed to investigational treatment in the buccal group. ","[{'ForeName': 'Khalid', 'Initials': 'K', 'LastName': 'Alansari', 'Affiliation': 'Department of Emergency Medicine, Sidra Medicine, Doha, Qatar; Weill Cornell Medicine - Qatar, Doha, Qatar. Electronic address: dkmaa@hotmail.com.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Barkat', 'Affiliation': 'Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamad Medical Corporation, Doha, Qatar.'}, {'ForeName': 'AbdelNasir H', 'Initials': 'AH', 'LastName': 'Mohamed', 'Affiliation': 'Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamad Medical Corporation, Doha, Qatar.'}, {'ForeName': 'Shahaza Alali', 'Initials': 'SA', 'LastName': 'Al Jawala', 'Affiliation': 'Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamad Medical Corporation, Doha, Qatar.'}, {'ForeName': 'Shadi Ahmad', 'Initials': 'SA', 'LastName': 'Othman', 'Affiliation': 'Department of Pediatrics, Division of Pediatric Emergency Medicine, Hamad Medical Corporation, Doha, Qatar.'}]",Pediatric neurology,['10.1016/j.pediatrneurol.2020.03.011'] 78,32289353,Risk of contamination when planning psychological therapy trials can be assessed using a simple framework.,"OBJECTIVES The objective of this study was to develop and pilot a standard framework that could be used to assess risk of contamination in psychological therapy trials, at the protocol development stage. STUDY DESIGN AND SETTING We developed and piloted a risk of contamination framework on a sample of 100 psychological therapy trial protocols registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry (www.isrctn.com). We assessed all protocols as being low or high risk via three possible sources of contamination: 1) participants in the control arm, 2) participants in the intervention arm, 3) therapists in the intervention arm. RESULTS Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%). We identified 14 studies that had a potentially high risk for contamination. Most of these (N = 10) were identified as risk of contamination arising from a therapist in the intervention arm. CONCLUSION The risk of contamination framework we piloted in this study could be a helpful tool for researchers aiming to identify and manage risk of contamination in their trial protocol development. We found that the risk of contamination was relatively low in the psychological therapy trials we sampled for this study, as measured by our framework, and could usually be mitigated through reasonable adjustments to the study design.",2020,"Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%).","['contamination: 1) participants in the control arm, 2) participants in the intervention arm, 3) therapists in the intervention arm']",[],['risk of contamination'],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}]",10.0,0.109149,"Overall, we found that the risk of contamination across all three sources was low for most studies (86 of 100 trial protocols; 86%).","[{'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Jacobsen', 'Affiliation': ""Department of Psychology, University of Bath, Bath BA2 7AY; King's College London, Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), De Crespigny Park, London SE5 8AF. Electronic address: p.c.jacobsen@bath.ac.uk.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Wood', 'Affiliation': 'Acute and Rehabilitation Directorate Psychology Team, North East London NHS Foundation Trust, Goodmayes Hospital, Barley Lane, Ilford IG3 8XJ; Division of Psychiatry, University College London, Maple House, 149 Tottenham Court Road W1T 7DN.'}]",Journal of clinical epidemiology,['10.1016/j.jclinepi.2020.04.005'] 79,32386891,A Nitrate-Rich Vegetable Intervention Elevates Plasma Nitrate and Nitrite Concentrations and Reduces Blood Pressure in Healthy Young Adults.,"BACKGROUND Emerging evidence suggests that increasing dietary nitrate intake may be an effective approach to reduce blood pressure. Beetroot juice is often used to supplement dietary nitrate, whereas nitrate intake levels from habitual diet are low. An increase in the habitual intake of nitrate-rich vegetables may represent an alternative to nitrate supplementation. However, the effectiveness and acceptability of a nitrate-rich-vegetables diet remain to be established. OBJECTIVE The aim was to investigate the effect and feasibility of two different intervention strategies to increase dietary nitrate intake, on plasma nitrate/nitrite concentrations and blood pressure. DESIGN A randomized, crossover trial was used. PARTICIPANTS Participants were healthy men and women (both n=15; age: 24±6 years) from the Netherlands. INTERVENTION Participants were instructed to consume ∼400 mg nitrate at lunch, provided through nitrate-rich vegetables and dietary counseling, or beetroot juice supplementation. Both interventions lasted 1 week, with 1-week washout (January to April 2017). MAIN OUTCOME Plasma nitrate and nitrite concentrations and resting systolic and diastolic blood pressure were measured in an overnight fasted state (before and after intervention) and ∼2.5 hours after lunch (before and throughout intervention on day 1, 4, and 7). STATISTICAL ANALYSIS Two-factor (time × treatment) repeated-measures analyses of variance were performed. RESULTS Mean plasma nitrate concentrations increased with both interventions, with a larger increase in beetroot juice vs nitrate-rich vegetables, both in a fasted state and ∼2.5 hours after lunch (day 1, beetroot juice: 2.31±0.56 mg/dL [373±90 μmol/L] vs nitrate-rich vegetables: 1.71±0.83 mg/dL [277±134 μmol/L]; P<0.001). Likewise, mean plasma nitrite concentrations increased with both interventions, but were higher after lunch in beetroot juice than in nitrate-rich vegetables (day 1: 2.58±1.52 μg/dL [560±331 nmol/L] vs 2.15±1.21 μg/dL [468±263 nmol/L]; P=0.020). Fasting mean systolic and diastolic blood pressure did not change, but mean systolic and diastolic blood pressure assessed ∼2.5 hours after lunch were significantly reduced throughout both intervention periods (P<0.05), with no differences between beetroot juice and nitrate-rich vegetables (day 1, systolic blood pressure: -5.1±9.5 mm Hg and diastolic blood pressure: -5.3±8.9 mm Hg). CONCLUSION Short-term consumption of dietary nitrate in the form of nitrate-rich vegetables represents an effective means to increase plasma nitrate and nitrite concentrations, and reduces blood pressure to the same extent as beetroot juice supplementation.",2020,"Fasting mean systolic and diastolic blood pressure did not change, but mean systolic and diastolic blood pressure assessed ∼2.5 hours after lunch were significantly reduced throughout both intervention periods (P<0.05), with no differences between beetroot juice and nitrate-rich vegetables (day 1, systolic blood pressure:","['Two-factor (time\xa0× treatment', 'Healthy Young Adults', 'Participants were healthy men and women (both n=15; age: 24±6 years) from the Netherlands']","['consume ∼400 mg nitrate at lunch, provided through nitrate-rich vegetables and dietary counseling, or beetroot juice supplementation', 'Nitrate-Rich Vegetable Intervention', 'dL']","['mean plasma nitrite concentrations', 'blood pressure', 'Mean plasma nitrate concentrations', 'beetroot juice vs nitrate-rich vegetables', 'plasma nitrate/nitrite concentrations and blood pressure', 'plasma nitrate and nitrite concentrations', 'mean systolic and diastolic blood pressure assessed ∼2.5 hours after lunch', 'beetroot juice and nitrate-rich vegetables (day 1, systolic blood pressure', 'Fasting mean systolic and diastolic blood pressure', 'Plasma nitrate and nitrite concentrations and resting systolic and diastolic blood pressure']","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}]","[{'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C2697949', 'cui_str': 'Lunch'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0427757', 'cui_str': 'Dipstick test of nitrite concentration'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C1879668', 'cui_str': 'After lunch'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]",,0.0144949,"Fasting mean systolic and diastolic blood pressure did not change, but mean systolic and diastolic blood pressure assessed ∼2.5 hours after lunch were significantly reduced throughout both intervention periods (P<0.05), with no differences between beetroot juice and nitrate-rich vegetables (day 1, systolic blood pressure:","[{'ForeName': 'Cindy M T', 'Initials': 'CMT', 'LastName': 'van der Avoort', 'Affiliation': ''}, {'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Jonvik', 'Affiliation': ''}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Nyakayiru', 'Affiliation': ''}, {'ForeName': 'Luc J C', 'Initials': 'LJC', 'LastName': 'van Loon', 'Affiliation': ''}, {'ForeName': 'Maria T E', 'Initials': 'MTE', 'LastName': 'Hopman', 'Affiliation': ''}, {'ForeName': 'Lex B', 'Initials': 'LB', 'LastName': 'Verdijk', 'Affiliation': ''}]",Journal of the Academy of Nutrition and Dietetics,['10.1016/j.jand.2020.02.014'] 80,32387716,Hypertension during Diabetic Ketoacidosis in Children.,"OBJECTIVES To characterize hemodynamic alterations occurring during diabetic ketoacidosis (DKA) in a large cohort of children and to identify clinical and biochemical factors associated with hypertension. STUDY DESIGN This was a planned secondary analysis of data from the Pediatric Emergency Care Applied Research Network Fluid Therapies Under Investigation in DKA Study, a randomized clinical trial of fluid resuscitation protocols for children in DKA. Hemodynamic data (heart rate, blood pressure) from children with DKA were assessed in comparison with normal values for age and sex. Multivariable statistical modeling was used to explore clinical and laboratory predictors of hypertension. RESULTS Among 1258 DKA episodes, hypertension was documented at presentation in 154 (12.2%) and developed during DKA treatment in an additional 196 (15.6%), resulting in a total of 350 DKA episodes (27.8%) in which hypertension occurred at some time. Factors associated with hypertension at presentation included more severe acidosis, (lower pH and lower pCO 2 ), and stage 2 or 3 acute kidney injury. More severe acidosis and lower Glasgow Coma Scale scores were associated with hypertension occurring at any time during DKA treatment. CONCLUSIONS Despite dehydration, hypertension occurs in a substantial number of children with DKA. Factors associated with hypertension include greater severity of acidosis, lower pCO 2, and lower Glasgow Coma Scale scores during DKA treatment, suggesting that hypertension might be centrally mediated.",2020,"More severe acidosis and lower Glasgow Coma Scale (GCS) scores were associated with hypertension occurring at any time during DKA treatment. ","['children with DKA', 'children in DKA', 'Hypertension During Diabetic Ketoacidosis in Children']",[],"['severity of acidosis, lower PCO 2 and lower GCS scores', 'Hemodynamic data (heart rate, blood pressure', 'severe acidosis and lower Glasgow Coma Scale (GCS) scores', 'hypertension']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011880', 'cui_str': 'Diabetic ketoacidosis'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001122', 'cui_str': 'Acidosis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",,0.0665684,"More severe acidosis and lower Glasgow Coma Scale (GCS) scores were associated with hypertension occurring at any time during DKA treatment. ","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'DePiero', 'Affiliation': 'Division of Emergency Medicine, Department of Pediatrics, Nemours/A.I. DuPont Hospital for Children, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Kuppermann', 'Affiliation': 'Department of Emergency Medicine, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA; Department of Pediatrics, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Brown', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's National Medical Center, The George Washington School of Medicine and Health Sciences, Washington, DC.""}, {'ForeName': 'Jeff E', 'Initials': 'JE', 'LastName': 'Schunk', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Julie K', 'Initials': 'JK', 'LastName': 'McManemy', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.""}, {'ForeName': 'Arleta', 'Initials': 'A', 'LastName': 'Rewers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, The Colorado Children's Hospital, University of Colorado-Denver School of Medicine, Denver, CO.""}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Stoner', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University School of Medicine, Columbus, OH.""}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Tzimenatos', 'Affiliation': 'Department of Emergency Medicine, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA.'}, {'ForeName': 'Aris', 'Initials': 'A', 'LastName': 'Garro', 'Affiliation': 'Departments of Emergency Medicine and Pediatrics, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'Sage R', 'Initials': 'SR', 'LastName': 'Myers', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.""}, {'ForeName': 'Kimberly S', 'Initials': 'KS', 'LastName': 'Quayle', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, St. Louis Children's Hospital, Washington University School of Medicine in St. Louis, St. Louis, MO.""}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Trainor', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL.""}, {'ForeName': 'Maria Y', 'Initials': 'MY', 'LastName': 'Kwok', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, New York Presbyterian Morgan Stanley Children's Hospital, Columbia University College of Physicians and Surgeons, New York, NY.""}, {'ForeName': 'Lise E', 'Initials': 'LE', 'LastName': 'Nigrovic', 'Affiliation': ""Division of Emergency Medicine, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'Cody S', 'Initials': 'CS', 'LastName': 'Olsen', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'T Charles', 'Initials': 'TC', 'LastName': 'Casper', 'Affiliation': 'Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Ghetti', 'Affiliation': 'Department of Psychology, University of California Davis, Sacramento, CA.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Glaser', 'Affiliation': 'Department of Pediatrics, University of California Davis Health, University of California Davis, School of Medicine, Sacramento, CA. Electronic address: nsglaser@ucdavis.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of pediatrics,['10.1016/j.jpeds.2020.04.066'] 81,32387326,The influence of postoperative environment on patient pain and satisfaction: a randomized trial.,"BACKGROUND Improving the patient experience, controlling pain with nonopiate therapies, and preparing for value-based reimbursement are increasingly important foci for both physicians and hospitals. OBJECTIVE We aimed to determine whether the addition of music and a natural landscape image to postoperative hospital rooms would result in improved pain and satisfaction scores among inpatients undergoing pelvic reconstructive surgery. STUDY DESIGN This randomized controlled trial was approved by an Institutional Review Board. Eligible candidates were 18-85 years old, English speaking, and scheduled to undergo native tissue vaginal vault suspension for symptomatic pelvic organ prolapse. Patients with history of a chronic pain or substance abuse were excluded. Subjects were advised that the purpose of the study was to assess the effect of changes to the hospital environment on patient experience but were blinded to their group and intervention details. Changes included a landscape image mounted to the wall and access to a speaker with preprogrammed music selections. The intervention group was instructed to listen to their preferred music for a minimum of 2 30-minute sessions postoperatively. The control group had a standard hospital room, without music or landscape. All patient rooms were private. The primary outcome was the visual analog scale for pain in the morning of postoperative day 1. Secondary outcomes included narcotic use, likelihood to refer family to the same hospital facility, satisfaction with care and the hospital, and perception of a healing environment. A sample size of 43 subjects per arm was calculated to detect a difference of 10 mm in visual analog scale pain score. RESULTS A total of 133 subjects were enrolled; primary outcome data were available for 92 (46 per arm). The mean age was 63.8 (standard deviation, 9.5) years, median Charlson comorbidity score was 2 (min, 0; max, 7), and 94.6% of subjects were white. On postoperative day 1, median visual analog scale pain scores were low (28.8 mm [0, 86]; 24.5 mm [0, 81]) and did not differ between intervention and control, respectively (P=.57). Total morphine equivalents (P=.817) and nursing pain scores (P=.774) were also similar. However, the intervention group displayed a higher likelihood to refer family members to the hospital (98 mm (47, 100); 96 mm (65, 100); P=.037). At postoperative 2 weeks, the intervention group indicated higher satisfaction with their care (98 mm, (34, 100); 95 mm (42, 100); P=.032), the hospital (98 mm (71, 100); 94 mm (6, 100); P=.004), and the healing environment provided during their stay (98 mm; 92 mm (19, 100); P=.020) than those in the standard hospital rooms. CONCLUSION In this randomized trial, we found music and landscape imagery did not substantially affect postoperative pain scores; however, they had a positive effect on the postoperative experience. Furthermore, this effect appeared to broaden 2 weeks after surgery. Given the importance of value-based care, interventions such as these should be emphasized to enhance patient satisfaction, quality scores, and overall well-being.",2020,Total morphine equivalents (p=0.817) and nursing pain scores (p=0.774) were also similar.,"['One hundred thirty-three subjects were enrolled; primary outcome data was available for 92 (46 per arm', 'The mean age was 63.8 (SD 9.5) years, median Charlson Comorbidity score was 2 (min=0,max=7), and 94.6% were Caucasian', 'inpatients undergoing pelvic reconstructive surgery', 'Exclusions included history of a chronic pain or substance abuse', 'Eligible candidates were 18-85 years old, English speaking, and scheduled to undergo native tissue vaginal vault suspension for symptomatic pelvic organ prolapse']","['standard hospital room, without music or landscape', 'Postoperative Environment']","['VAS pain score', 'Total morphine equivalents', 'healing environment', 'nursing pain scores', 'narcotic use, likelihood to refer family to the same hospital facility, satisfaction with care and the hospital, and perception of a healing environment', 'Patient Pain and Satisfaction', 'higher satisfaction with their care', 'Visual Analogue Scale (VAS) for pain on the morning of post-operative day one', 'pain and satisfaction scores', 'median VAS scores for pain']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0030797', 'cui_str': 'Pelvic'}, {'cui': 'C0524865', 'cui_str': 'Reconstruction - action'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0740858', 'cui_str': 'Substance abuse'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0079891', 'cui_str': 'Indigenous Population'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0227794', 'cui_str': 'Structure of fornix of vagina'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0014406', 'cui_str': 'Environment'}]","[{'cui': 'C2732809', 'cui_str': 'Visual analog scale pain score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0027415', 'cui_str': 'Narcotic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",133.0,0.174362,Total morphine equivalents (p=0.817) and nursing pain scores (p=0.774) were also similar.,"[{'ForeName': 'Austin M', 'Initials': 'AM', 'LastName': 'Hill', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH. Electronic address: austinm.hill1@gmail.com.'}, {'ForeName': 'Catrina C', 'Initials': 'CC', 'LastName': 'Crisp', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Shatkin-Margolis', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Tiffanie', 'Initials': 'T', 'LastName': 'Tam', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Eunsun', 'Initials': 'E', 'LastName': 'Yook', 'Affiliation': 'Hatton Research Institute, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Kleeman', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}, {'ForeName': 'Rachel N', 'Initials': 'RN', 'LastName': 'Pauls', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, TriHealth Good Samaritan Hospital, Cincinnati, OH.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.05.006'] 82,32387408,"A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.","INTRODUCTION Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β 2 -agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. METHODS This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. The study population was enriched for patients who were responsive to ICS therapy. The primary objective of the present study was to show non-inferiority of these doses, i.e. the low (80 μg) and high (320 μg) doses of MF delivered via Breezhaler® once daily, compared with the corresponding low (200 μg) and high (800 μg) doses of MF delivered via Twisthaler® once daily. The primary endpoint was 24 h post-dose trough forced expiratory volume in 1 s (FEV 1 ), after four weeks of treatment in patients with asthma. A secondary objective was to evaluate the efficacy of MF 80 μg and 320 μg delivered via Breezhaler®, and MF 200 μg and 800 μg delivered via Twisthaler® in terms of Asthma Control Questionnaire-5 (ACQ-5) after one, two, three and four weeks of treatment. RESULTS The LS mean difference in trough FEV 1 after four weeks of treatment between MF low dose 80 μg (Breezhaler®) and MF low dose 200 μg (Twisthaler®) was 27 mL (95% CI -34, 89); for MF high dose 320 μg (Breezhaler®) and MF high dose 800 μg (Twisthaler®) the difference was 0 mL (95% CI -60, 61). These differences were neither clinically nor statistically significant. All treatment arms provided similar clinically relevant improvements in ACQ-5 after four weeks of treatment compared with baseline. Both treatments showed a similar safety profile with a low incidence of adverse events. CONCLUSION The similarities in effects on lung function and ACQ after four weeks of treatment demonstrate the comparability of MF at low (80 μg) and high (320 μg) doses delivered with Breezhaler® with MF at low (200 μg) and high (800 μg) doses delivered with Twisthaler®, respectively. The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.",2020,"The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.","['739 adolescents and adults with persistent asthma', 'patients with asthma', 'patients who were responsive to ICS therapy']","['ICS', 'MF 80 μg and 320 μg delivered via Breezhaler®, and MF 200 μg and 800 μg delivered via Twisthaler®', 'Mometasone furoate (MF', 'MF high dose 800 μg (Twisthaler®', 'mometasone furoate delivered via Breezhaler® or Twisthaler®']","['ACQ-5', 'efficacy and safety', '24h post-dose trough forced expiratory volume in one second (FEV 1 ', 'lung function and ACQ']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0149783', 'cui_str': 'Administration of steroid'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0444956', 'cui_str': 'High dose'}]","[{'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439568', 'cui_str': 'Post-dose'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",739.0,0.543909,"The study formally demonstrated that MF, delivered via Breezhaler®, is non-inferior to MF, delivered via Twisthaler® at corresponding ICS doses.","[{'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Buhl', 'Affiliation': 'Pulmonary Department, Johannes Gutenberg University Hospital, Mainz, Germany.'}, {'ForeName': 'Ana-Maria', 'Initials': 'AM', 'LastName': 'Tanase', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Motoi', 'Initials': 'M', 'LastName': 'Hosoe', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Weihua', 'Initials': 'W', 'LastName': 'Cao', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Demin', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Bartels', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Jauernig', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Ziegler', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Patalano', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Hederer', 'Affiliation': 'Novartis Institutes for Biomedical Research, Basel, Switzerland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Kanniess', 'Affiliation': 'Gemeinschaftspraxis Reinfeld, Reinfeld, Germany.'}, {'ForeName': 'Hanns-Christian', 'Initials': 'HC', 'LastName': 'Tillmann', 'Affiliation': 'Novartis Institutes for Biomedical Research, Basel, Switzerland. Electronic address: hanns-christian.tillmann@novartis.com.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2020.101919'] 83,32392700,Evaluation of the Stomatognathic System before and after Osteopathic Manipulative Treatment in 120 Healthy People by Using Surface Electromyography.,"Objective: To investigate the action of osteopathic manipulative treatment on the muscular activity of the stomatognathic apparatus by using surface electromyography (sEMG). Material and Methods: Surface electromyography (sEMG) was performed on the masseter and anterior temporalis muscles of 120 subjects (73 F; 47 M), both at time T0 and T2. The sample was divided into three randomized groups of 40 subjects each: control, placebo, and osteopathic manipulative treatment (OMT). In the T1 interval between the two evaluations, the control group was not treated, the placebo group underwent a placebo treatment, and the OMT group underwent manipulative treatment. The mean value of each measurement and its coefficient of variation, between time T0 and T2, were calculated for both the intragroup (OMT, placebo, control) and the intergroup (OMT-placebo, OMT-control). Outcomes: In 40% of the subjects, statistically significant improvements were highlighted in the OMT. Whereas, the statistically significant results of the placebo and control groups were 7.5% and 17.5%, respectively, of which more than 75% moved away from the physiological range, showing a worsening of the muscular activity. This analysis showed statistically significant variations ( p ≤ 0.05) in the OMT group compared to the placebo and the control groups. Conclusions: OMT determines variations of the activity of masticatory muscles.",2020,This analysis showed statistically significant variations ( p ≤ 0.05) in the OMT group compared to the placebo and the control groups. ,"['120 Healthy People by Using Surface Electromyography', '40 subjects each']","['control, placebo, and osteopathic manipulative treatment (OMT', 'Surface electromyography (sEMG', 'OMT', 'osteopathic manipulative treatment', 'placebo']",['OMT'],"[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0430815', 'cui_str': 'Surface EMG'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0949744', 'cui_str': 'Osteopathic manipulation'}, {'cui': 'C0430815', 'cui_str': 'Surface EMG'}]",[],120.0,0.05336,This analysis showed statistically significant variations ( p ≤ 0.05) in the OMT group compared to the placebo and the control groups. ,"[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Manzotti', 'Affiliation': 'SOMA-osteopathic Institute of Milan, 20126 Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Viganoni', 'Affiliation': 'SOMA-osteopathic Institute of Milan, 20126 Milan, Italy.'}, {'ForeName': 'Dorina', 'Initials': 'D', 'LastName': 'Lauritano', 'Affiliation': 'Department of Medicine and Surgery, Centre of Neuroscience of Milan, University of Milano-Bicocca, 20126 Milan, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Bernasconi', 'Affiliation': 'SOMA-osteopathic Institute of Milan, 20126 Milan, Italy.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Paparo', 'Affiliation': 'SOMA-osteopathic Institute of Milan, 20126 Milan, Italy.'}, {'ForeName': 'Rachele', 'Initials': 'R', 'LastName': 'Risso', 'Affiliation': 'SOMA-osteopathic Institute of Milan, 20126 Milan, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Nanussi', 'Affiliation': 'Department of Medicine and Surgery, Centre of Neuroscience of Milan, University of Milano-Bicocca, 20126 Milan, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph17093250'] 84,32393559,Efficacy of Intra-Articular Hypertonic Dextrose (Prolotherapy) for Knee Osteoarthritis: A Randomized Controlled Trial.,"PURPOSE To test the efficacy of intra-articular hypertonic dextrose prolotherapy (DPT) vs normal saline (NS) injection for knee osteoarthritis (KOA). METHODS A single-center, parallel-group, blinded, randomized controlled trial was conducted at a university primary care clinic in Hong Kong. Patients with KOA (n = 76) were randomly allocated (1:1) to DPT or NS groups for injections at weeks 0, 4, 8, and 16. The primary outcome was the Western Ontario McMaster University Osteoarthritis Index (WOMAC; 0-100 points) pain score. The secondary outcomes were the WOMAC composite, function and stiffness scores; objectively assessed physical function test results; visual analogue scale (VAS) for knee pain; and EuroQol-5D score. All outcomes were evaluated at baseline and at 16, 26, and 52 weeks using linear mixed model. RESULTS Randomization produced similar groups. The WOMAC pain score at 52 weeks showed a difference-in-difference estimate of -10.34 (95% CI, -19.20 to -1.49, P = 0.022) points. A similar favorable effect was shown on the difference-in-difference estimate on WOMAC function score of -9.55 (95% CI, -17.72 to -1.39, P = 0.022), WOMAC composite score of -9.65 (95% CI, -17.77 to -1.53, P = 0.020), VAS pain intensity score of -10.98 (95% CI, -21.36 to -0.61, P = 0.038), and EuroQol-5D VAS score of 8.64 (95% CI, 1.36 to 5.92, P = 0.020). No adverse events were reported. CONCLUSION Intra-articular dextrose prolotherapy injections reduced pain, improved function and quality of life in patients with KOA compared with blinded saline injections. The procedure is straightforward and safe; the adherence and satisfaction were high.",2020,"CONCLUSION Intra-articular dextrose prolotherapy injections reduced pain, improved function and quality of life in patients with KOA compared with blinded saline injections.","['Patients with KOA (n = 76', 'Knee Osteoarthritis', 'university primary care clinic in Hong Kong', 'patients with KOA', 'knee osteoarthritis (KOA']","['DPT or NS', 'Intra-Articular Hypertonic Dextrose (Prolotherapy', 'intra-articular hypertonic dextrose prolotherapy (DPT) vs normal saline (NS) injection']","['EuroQol-5D VAS score', 'WOMAC composite score', 'WOMAC function score', 'pain, improved function and quality of life', 'Western Ontario McMaster University Osteoarthritis Index (WOMAC; 0-100 points) pain score', 'WOMAC composite, function and stiffness scores; objectively assessed physical function test results; visual analogue scale (VAS) for knee pain; and EuroQol-5D score', 'adverse events', 'WOMAC pain score', 'VAS pain intensity score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0500223', 'cui_str': 'Prolotherapy'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0442108', 'cui_str': 'Intra-articular'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",76.0,0.385251,"CONCLUSION Intra-articular dextrose prolotherapy injections reduced pain, improved function and quality of life in patients with KOA compared with blinded saline injections.","[{'ForeName': 'Regina Wing Shan', 'Initials': 'RWS', 'LastName': 'Sit', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong reginasit@cuhk.edu.hk.'}, {'ForeName': 'Ricky Wing Keung', 'Initials': 'RWK', 'LastName': 'Wu', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rabago', 'Affiliation': 'Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.'}, {'ForeName': 'Kenneth Dean', 'Initials': 'KD', 'LastName': 'Reeves', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, The University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Dicken Cheong Chun', 'Initials': 'DCC', 'LastName': 'Chan', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Benjamin Hon Kei', 'Initials': 'BHK', 'LastName': 'Yip', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Vincent Chi Ho', 'Initials': 'VCH', 'LastName': 'Chung', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Samuel Yeung Shan', 'Initials': 'SYS', 'LastName': 'Wong', 'Affiliation': 'Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong.'}]",Annals of family medicine,['10.1370/afm.2520'] 85,32392833,"Effects of Augmented-Reality-Based Exercise on Muscle Parameters, Physical Performance, and Exercise Self-Efficacy for Older Adults.","This study was intended to determine the applicability of an augmented-reality-based muscle reduction prevention exercise program for elderly Korean women by observing changes in exercise self-efficacy and verifying the effectiveness of the program in the elderly after the application of the program. A total of 27 participants, who were elderly women aged 65+ and had not participated in any exercise programs until this study, were recruited for this study. They were divided into an experimental group (13 people) and a control group (14 people), and then the augmented-reality-based muscle reduction prevention exercise program was applied. This was a 30-min program, which included regular, aerobic, and flexibility exercises, and it was applied 5 times a week for 12 weeks. As a result of observing changes, it was found that the appendicular skeletal muscle mass (ASM) (F = 11.222, p < 0.002) and the skeletal muscle index (SMI) (kg/m 2 ) (F = 10.874, p < 0.003) muscle parameters increased more in the experimental group compared to the control group, and there was a significant increase in gait speed (m/s) (F = 7.221, p < 0.005). For physical performance, as a result of conducting the Senior Fitness Test (SFT), a significant change was observed in the chair stand test (F = 5.110, p < 0.033), 2-min step test (2MST) (F = 6.621, p < 0.020), and the timed up-and-go test (TUG) (F = 5.110, p < 0.032) and a significant increase was also observed for exercise self-efficacy (F = 20.464, p < 0.001). Finally, the augmented-reality-based exercise program in this study was found to be effective in inducing physical activity in the elderly. Therefore, the augmented-reality-based muscle reduction prevention exercise program is considered to be effective in increasing the sustainability of exercise, thus preventing muscle reduction in the elderly.",2020,"For physical performance, as a result of conducting the Senior Fitness Test (SFT), a significant change was observed in the chair stand test (F = 5.110, p < 0.033), 2-min step test (2MST) (F = 6.621, p < 0.020), and the timed up-and-go test (TUG) (F = 5.110, p < 0.032) and a significant increase was also observed for exercise self-efficacy (F = 20.464, p < 0.001).","['elderly Korean women', '27 participants, who were elderly women aged 65+ and had not participated in any exercise programs until this study, were recruited for this study', 'Older Adults']","['Augmented-Reality-Based Exercise', 'augmented-reality-based muscle reduction prevention exercise program', 'control group (14 people), and then the augmented-reality-based muscle reduction prevention exercise program']","['exercise self-efficacy', 'appendicular skeletal muscle mass (ASM', 'physical activity', 'gait speed (m/s', 'skeletal muscle index (SMI', 'Muscle Parameters, Physical Performance, and Exercise Self-Efficacy', 'chair stand test']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C5197824', 'cui_str': 'Mixed Reality'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0439493', 'cui_str': 'm/s'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0915075', 'cui_str': 'samarium diiodide'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",27.0,0.0120384,"For physical performance, as a result of conducting the Senior Fitness Test (SFT), a significant change was observed in the chair stand test (F = 5.110, p < 0.033), 2-min step test (2MST) (F = 6.621, p < 0.020), and the timed up-and-go test (TUG) (F = 5.110, p < 0.032) and a significant increase was also observed for exercise self-efficacy (F = 20.464, p < 0.001).","[{'ForeName': 'Sangwan', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': 'Exercise Rehabilitation Convergence Institute, Gachon University191 Hombakmoero, Yeonsu-gu, Incheon 406-799, Korea.'}, {'ForeName': 'Jiyoun', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Exercise Rehabilitation & Welfare, Gachon University 191 Hombakmoero, Yeonsu-gu, Incheon 406799, Korea.'}]",International journal of environmental research and public health,['10.3390/ijerph17093260'] 86,32392863,The Effect of Mind Subtraction Meditation Intervention on Smartphone Addiction and the Psychological Wellbeing among Adolescents.,"As the smartphone has become an indispensable device in modern lives, consequential psychosocial problems such as smartphone addiction have been getting attention worldwide, especially regarding adolescents. Based on its positive effect on young individuals' mental health, mind subtraction meditation has been widely applied to many school-based programs in South Korea. This study aims to identify the effects of a school program based on mind subtraction on the smartphone addiction of adolescents. A total of 49 high school sophomores, 24 from the experimental group (mean age = 16), and 25 from the control group (mean age = 16) are included in this case-control study. The experimental group is given the meditation program sessions in the morning, two times a week for 20 min per session, for a total of 12 weeks. The experimental group shows improvements regarding the 'smartphone addiction' section ( p < 0.001), for instant satisfaction ( p < 0.001) and long-term satisfaction ( p < 0.001). Concerning the 'self-control' section and decreasing stress ( p < 0.001), problem focusing ( p < 0.001), and social support navigation ( p = 0.018), there are improvements in these 'stress coping strategies' sections. This study directly shows the positive effect of mind subtraction meditation on smartphone addiction in adolescents and, thus, provides guidance to the future development of smartphone addiction prevention programs for young individuals.",2020,"The experimental group shows improvements regarding the 'smartphone addiction' section ( p < 0.001), for instant satisfaction (","['Adolescents', ""young individuals' mental health"", 'young individuals', 'A total of 49 high school sophomores, 24 from the experimental group (mean age = 16), and 25 from the control group (mean age = 16) are included in this case-control study', 'adolescents']","['meditation program sessions', 'Mind Subtraction Meditation Intervention', 'mind subtraction meditation', 'school program based on mind subtraction']","['Smartphone Addiction and the Psychological Wellbeing', ""smartphone addiction' section"", 'long-term satisfaction', 'instant satisfaction ', 'social support navigation']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007328', 'cui_str': 'Case Control Studies'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",49.0,0.016192,"The experimental group shows improvements regarding the 'smartphone addiction' section ( p < 0.001), for instant satisfaction (","[{'ForeName': 'Eun-Hi', 'Initials': 'EH', 'LastName': 'Choi', 'Affiliation': 'Department of Nursing, Eulji University, Daejeon 34824, Korea.'}, {'ForeName': 'Min Young', 'Initials': 'MY', 'LastName': 'Chun', 'Affiliation': ""Department of Global Medical Science, Sungshin Women's University, Seoul 02844, Korea.""}, {'ForeName': 'Insoo', 'Initials': 'I', 'LastName': 'Lee', 'Affiliation': 'Department of Paramedic Science, Korea National University of Transportation, Chungcheongbuk-do 27909, Korea.'}, {'ForeName': 'Yang-Gyeong', 'Initials': 'YG', 'LastName': 'Yoo', 'Affiliation': 'Department of Nursing, Kunsan National University, Jeollabuk-do 54150, Korea.'}, {'ForeName': 'Min-Jae', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': ""Research Institute of Basic Science, Sungshin Women's University, Seoul 02844, Korea.""}]",International journal of environmental research and public health,['10.3390/ijerph17093263'] 87,30553700,The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.,"Spinal muscular atrophy (SMA) is a rare genetic and progressively debilitating neuromuscular disease. It is the leading genetic cause of death among infants. In SMA, low levels of survival of motor neuron (SMN) protein lead to motor neuron death and muscle atrophy as the SMN protein is critical to motor neuron survival. SMA is caused by mutations in, or deletion of, the SMN1 gene. A second SMN gene, SMN2, produces only low levels of functional SMN protein due to alternative splicing which excludes exon 7 from most transcripts, generating truncated, rapidly degraded SMN protein. Patients with SMA rely on limited expression of functional SMN full-length protein from the SMN2 gene, but insufficient levels are generated. RG7800 is an oral, selective SMN2 splicing modifier designed to modulate alternative splicing of SMN2 to increase the levels of functional SMN protein. In two trials, oral administration of RG7800 increased in blood full-length SMN2 mRNA expression in healthy adults and SMN protein levels in SMA patients by up to two-fold, which is expected to provide clinical benefit.",2019,"In two trials, oral administration of RG7800 increased in blood full-length SMN2 mRNA expression in healthy adults and SMN protein levels in SMA patients by up to two-fold, which is expected to provide clinical benefit.","['Patients with SMA', 'healthy adults and patients with spinal muscular atrophy', 'healthy adults']",['RG7800'],"['full length survival of motor neuron 2 mRNA and survival of motor neuron protein', 'blood full-length SMN2 mRNA expression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026847', 'cui_str': 'Spinal muscular atrophy'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]",[],"[{'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0026609', 'cui_str': 'Motor neuron'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}]",,0.0192204,"In two trials, oral administration of RG7800 increased in blood full-length SMN2 mRNA expression in healthy adults and SMN protein levels in SMA patients by up to two-fold, which is expected to provide clinical benefit.","[{'ForeName': 'Heidemarie', 'Initials': 'H', 'LastName': 'Kletzl', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland. Electronic address: heidemarie.kletzl@roche.com.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Marquet', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Günther', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Wakana', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Research, Genomics & Oncology, Roche Molecular Systems, Inc., Pleasanton, USA.'}, {'ForeName': 'Jules', 'Initials': 'J', 'LastName': 'Heuberger', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Geert Jan', 'Initials': 'GJ', 'LastName': 'Groeneveld', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'Birkhoff', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Mercuri', 'Affiliation': 'Policlinico Agostino Gemelli, Rome, Italy.'}, {'ForeName': 'Hanns', 'Initials': 'H', 'LastName': 'Lochmüller', 'Affiliation': ""Medical Center-University of Freiburg, Freiburg, Germany; Center for Genomic Regulation, Barcelona Institute of Science and Technology (BIST), Barcelona, Spain; John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada and Division of Neurology, Department of Medicine, The Ottawa Hospital, Ottawa, Canada.""}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Wood', 'Affiliation': 'John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Fischer', 'Affiliation': 'Universitäts-Kinderspital beider Basel, Basel, Switzerland; University Clinic of Internal Medicine, Kantonsspital Baselland, Bruderholz, Switzerland.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Gerlach', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Heinig', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Teodorica', 'Initials': 'T', 'LastName': 'Bugawan', 'Affiliation': 'Research, Genomics & Oncology, Roche Molecular Systems, Inc., Pleasanton, USA.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Dziadek', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Kinch', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Welwyn, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Czech', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}, {'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Khwaja', 'Affiliation': 'Roche Innovation Center, Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.'}]",Neuromuscular disorders : NMD,['10.1016/j.nmd.2018.10.001'] 88,32394686,Evaluation of the cardioprotective effects of crystalloid del Nido cardioplegia solution via a rapid and accurate cardiac marker: Heart-type fatty acid-binding protein.,"BACKGROUND/AIM Our aim in this study was to compare the efficacy and safety of crystalloid del Nido solution and cold blood cardioplegia solution on clinical and laboratory parameters. MATERIALS AND METHODS Sixty patients who underwent elective coronary bypass operation between July 2019 and January 2020 were included in our study. Patients were divided into two groups of 30 patients using del Nido solution (DNS) and cold blood cardioplegia solution (CBCS), which were given for cardiac arrest. Demographic data, preoperative, postoperative 0. hour, 6. hour and 4. day Creatine Kinase Myocardial Band (CK-MB) and troponin I values were compared with a specific cardiac enzyme Heart-type fatty acid-binding protein (H-FABP). RESULTS We found that aortic cross clamp duration and cardiopulmonary bypass (CPB) time were shorter in patients using del Nido solution than cold blood cardioplegia solution (57.30±23.57 minutes, 76.07±27.18 minutes, p=0.006) (95.07±23.06 minutes, 114.13±33.93, p=0.014). Total cardioplegia solution volume was higher in the cold blood cardioplegia solution group (1426.67±416.00 vs 1200±310.73 p=0.02). Preoperative and postoperative levels of cardiac enzymes including CK-MB, troponin I and H-FABP were comparable in del Nido solution and cold blood cardioplegia solution groups. CONCLUSION According to these results, when we compare both demographic data and CK-MB, Troponin-I and H-FABP levels, both cardioplegia solutions were comparable regarding safety and efficacy in terms of myocardial protection.",2020,"Preoperative and postoperative levels of cardiac enzymes including CK-MB, troponin I and H-FABP were comparable in del Nido solution and cold blood cardioplegia solution groups. ",['Sixty patients who underwent elective coronary bypass operation between July 2019 and January 2020 were included in our study'],"['del Nido solution (DNS) and cold blood cardioplegia solution (CBCS', 'crystalloid del Nido cardioplegia solution', 'crystalloid del Nido solution and cold blood cardioplegia solution']","['aortic cross clamp duration and cardiopulmonary bypass (CPB) time', 'demographic data and CK-MB, Troponin-I and H-FABP levels', 'efficacy and safety', 'day Creatine Kinase Myocardial Band (CK-MB) and troponin', 'Preoperative and postoperative levels of cardiac enzymes including CK-MB, troponin I and H-FABP', 'Total cardioplegia solution volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0007200', 'cui_str': 'cardioplegia solutions'}, {'cui': 'C0056562', 'cui_str': 'Crystalloid'}]","[{'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0077401', 'cui_str': 'Troponin I'}, {'cui': 'C1312696', 'cui_str': 'FABP3 protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0201934', 'cui_str': 'Cardiac enzymes/isoenzymes measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007200', 'cui_str': 'cardioplegia solutions'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",60.0,0.0963738,"Preoperative and postoperative levels of cardiac enzymes including CK-MB, troponin I and H-FABP were comparable in del Nido solution and cold blood cardioplegia solution groups. ","[{'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Kirişci', 'Affiliation': ''}, {'ForeName': 'Aydemir', 'Initials': 'A', 'LastName': 'Koçarslan', 'Affiliation': ''}, {'ForeName': 'Duygun', 'Initials': 'D', 'LastName': 'Altintaş Aykan', 'Affiliation': ''}, {'ForeName': 'Filiz', 'Initials': 'F', 'LastName': 'Alkan Baylan', 'Affiliation': ''}, {'ForeName': 'Adem', 'Initials': 'A', 'LastName': 'Doğaner', 'Affiliation': ''}, {'ForeName': 'Yavuz', 'Initials': 'Y', 'LastName': 'Orak', 'Affiliation': ''}]",Turkish journal of medical sciences,['10.3906/sag-2002-53'] 89,32395836,Effectiveness of an avatar educational application for improving heart failure patients' knowledge and self-care behaviors: A pragmatic randomized controlled trial.,"AIM To evaluate the effectiveness of education using avatars for improving patients' heart failure knowledge and self-care. BACKGROUND A lack of knowledge and self-care contributes to poor outcomes and rehospitalization for people with heart failure. DESIGN A multi-centred, non-blinded pragmatic randomized controlled trial. METHODS Heart failure patients were randomly assigned to intervention (avatar education application) or usual care groups. Participants were followed up at baseline, 30 and 90 days. ANCOVA was used to compare the scores of heart failure knowledge and self-care, between the two groups. Fisher's exact test was used to compare the two groups' heart failure-cause readmission. Bivariate exact binary logistic regression was used to identify the predictors associated with baseline levels of knowledge. RESULTS A total of 36 participants were recruited (between October 2018 - March 2019). The mean age of participants was 67.5 (SD 11.3) years. At enrolment, approximately half (47.2%) have been living with Heart Failure for over 5 years. Two groups were comparable at baseline in their demographic and clinical characteristics. At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% versus 3.7% P = .002, partial η 2  = 0.262, 95% CI -2.755 to -0.686). There was no between-group difference observed at 30- or 90-day follow-up, on self-care behaviour (Self-care of heart failure index) or healthcare use. Overall satisfaction with the avatar app was 91.3%. CONCLUSION The addition of a co-designed avatar app to usual care improved knowledge in our group of Heart Failure participants at 30 days and continued to increase up to 90 days. The results suggest that our avatar app was perceived as an enjoyable and engaging means of delivering critical knowledge and self-care information. IMPACT Heart failure is associated with poor clinical outcomes (i.e., readmission rates and mortality rate) and substantial economic burden. The effectiveness of Heart Failure patient education using avatar have not been investigated previously. In this study, the avatar app improved knowledge and self-care behaviours. This innovation could be used at the bedside, at home by nurses, patients and families. TRIAL REGISTRATION Australian New Zealand Trial Registry ACTRN12617001403325.",2020,"At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% vs. 3.7% p = 0.002, partial η 2 =0.262, 95% CI -2.755, -0.686).","['Heart failure patients', 'The\u202fmean\xa0age\u202fof participants was\u202f67.5 (SD 11.3) years', 'A total of 36 participants were recruited (between October 2018 and March 2019', 'people with heart failure']","['avatar educational application', 'intervention (avatar education application) or usual care groups']","['knowledge score on the Dutch Heart Failure Knowledge Scales', '30-day or 90-day follow-up, on self-care behaviour (Self-care of heart failure index) or healthcare use', 'scores of heart failure knowledge and self-care', ""heart failure patients' knowledge and self-care behaviors"", 'Overall\u202fsatisfaction', 'knowledge and self-care behaviors']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",36.0,0.0906889,"At 90 days, the intervention group participants had a higher increase in knowledge score on the Dutch Heart Failure Knowledge Scales compared with the control group (22.2% vs. 3.7% p = 0.002, partial η 2 =0.262, 95% CI -2.755, -0.686).","[{'ForeName': 'Parichat', 'Initials': 'P', 'LastName': 'Wonggom', 'Affiliation': 'Department of Adult Nursing, Faculty of Nursing, Khon Kaen University, Thailand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Nolan', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Robyn A', 'Initials': 'RA', 'LastName': 'Clark', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Barry', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Burdeniuk', 'Affiliation': 'Department of Cardiology, Southern Adelaide Local Health Network, Adelaide, SA, Australia.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Nesbitt', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': ""O'Toole"", 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}, {'ForeName': 'Huiyun', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'College of Nursing and Health Sciences, Flinders University, Adelaide, SA, Australia.'}]",Journal of advanced nursing,['10.1111/jan.14414'] 90,32399286,Weight Change and Its Association with Cardiometabolic Risk Markers in Overweight and Obese Women.,"Objectives To examine the association of weight loss magnitude with changes in cardiometabolic risk markers in overweight and obese women from low socioeconomic areas engaged in a lifestyle intervention. Methods Analyses were performed on 243 women (mean body mass index 31.27 ± 4.14 kg/m 2 ) who completed a 12-month lifestyle intervention in low socioeconomic communities in Klang Valley, Malaysia. Analysis of covariance (ANCOVA) was used to compare changes of cardiometabolic risk factors across weight change categories (2% gain, ±2% maintain, >2 to <5% loss, and 5 to 20% loss) within intervention and control group. Results A graded association for changes in waist circumference, fasting insulin, and total cholesterol ( p =0.002, for all variables) across the weight change categories were observed within the intervention group at six months postintervention. Participants who lost 5 to 20% of weight had the greatest improvements in those risk markers (-5.67 cm CI: -7.98 to -3.36, -4.27  μ U/mL CI: -7.35, -1.19, and -0.59 mmol/L CI: -.99, -0.19, respectively) compared to those who did not. Those who lost >2% to <5% weight reduced more waist circumference (-4.24 cm CI: -5.44 to -3.04) and fasting insulin (-0.36  μ U/mL CI: -1.95 to 1.24) than those who maintained or gained weight. No significant association was detected in changes of risk markers across the weight change categories within the control group except for waist circumference and adiponectin. Conclusion Weight loss of >2 to <5% obtained through lifestyle intervention may represent a reasonable initial weight loss target for women in the low socioeconomic community as it led to improvements in selected risk markers, particularly of diabetes risk.",2020,"No significant association was detected in changes of risk markers across the weight change categories within the control group except for waist circumference and adiponectin. ","['Overweight and Obese Women', 'overweight and obese women from low socioeconomic areas engaged in a lifestyle intervention', '243 women (mean body mass index 31.27\u2009±\u20094.14\u2009kg/m 2 ) who completed a 12-month lifestyle intervention in low socioeconomic communities in Klang Valley, Malaysia']",['μ U/mL CI'],"['fasting insulin', 'waist circumference, fasting insulin, and total cholesterol', 'waist circumference', 'cardiometabolic risk markers']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0037464', 'cui_str': 'Factors, Socioeconomic'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0563004', 'cui_str': 'Valley'}, {'cui': 'C0024552', 'cui_str': 'Malaysia'}]","[{'cui': 'C0439340', 'cui_str': 'kU/L'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",243.0,0.0307575,"No significant association was detected in changes of risk markers across the weight change categories within the control group except for waist circumference and adiponectin. ","[{'ForeName': 'Liyana', 'Initials': 'L', 'LastName': 'Ahmad Zamri', 'Affiliation': 'Endocrine and Metabolic Unit, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Geeta', 'Initials': 'G', 'LastName': 'Appannah', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.'}, {'ForeName': 'Siti Yazmin', 'Initials': 'SY', 'LastName': 'Zahari Sham', 'Affiliation': 'Department of Pathology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia.'}, {'ForeName': 'Fazliana', 'Initials': 'F', 'LastName': 'Mansor', 'Affiliation': 'Endocrine and Metabolic Unit, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Rashidah', 'Initials': 'R', 'LastName': 'Ambak', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.'}, {'ForeName': 'Noor Safiza', 'Initials': 'NS', 'LastName': 'Mohd Nor', 'Affiliation': 'Allied Health Sciences Division, Ministry of Health Malaysia, 62050 Putrajaya, Malaysia.'}, {'ForeName': 'Tahir', 'Initials': 'T', 'LastName': 'Aris', 'Affiliation': 'Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.'}]",Journal of obesity,['10.1155/2020/3198326'] 91,32397695,Pilot study on non-celiac gluten sensitivity: effects of Bifidobacterium longum ES1 co-administered with a gluten-free diet.,"BACKGROUND Bifidobacterium longum ES1 is a strain probiotic, colonizing the human gut and capable of a degradative action on gliadin. In an attempt to find new nutritional solutions aimed at improving the quality of life of patients with non-celiac gluten sensitivity (NCGS) we evaluated the effectiveness of this strain, in association with a gluten-free diet, comparing its efficacy versus diet therapy alone. METHODS The experimental design included a non-randomized, open-label, 1:1 intervention study in parallel groups. Enrolled patients with symptoms attributable to NCGS, and with negative diagnoses of both wheat allergy and celiac disease, were included in this three-month trial divided into four outpatient visits (baseline, T1, T2 and T3). Fifteen patients for each group completed the experimental protocol. RESULTS Our results showed that a combination of diet and probiotic determined a more significant reduction in the frequency and intensity of intestinal and extra-intestinal symptoms, and a clear improvement in stool consistency. CONCLUSIONS Although the study was carried out on a small number of patients, the results of our pilot trial suggest that a combined strategy of naturally gluten-free diet therapy with administration of the probiotic strain ES1 appears to offer a greater advantage than the dietary regime alone in improving the clinical symptomatic picture and in stabilizing the intestinal microbiota.",2020,"Our results showed that a combination of diet and probiotic determined a more significant reduction in the frequency and intensity of intestinal and extra-intestinal symptoms, and a clear improvement in stool consistency. ","['Enrolled patients with symptoms attributable to NCGS, and with negative diagnoses of both wheat allergy and celiac disease', 'patients with non-celiac gluten sensitivity (NCGS', 'non-celiac gluten sensitivity']","['probiotic strain ES1', 'Bifidobacterium longum ES1 co-administered with a gluten-free diet']","['quality of life', 'stool consistency', 'frequency and intensity of intestinal and extra-intestinal symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2711053', 'cui_str': 'Non-celiac gluten sensitivity'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0949570', 'cui_str': 'Allergy to wheat'}, {'cui': 'C0007570', 'cui_str': 'Celiac disease'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0631734', 'cui_str': 'Es1'}, {'cui': 'C0314977', 'cui_str': 'Bifidobacterium longum'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0344351', 'cui_str': 'Gluten free diet'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",15.0,0.0147521,"Our results showed that a combination of diet and probiotic determined a more significant reduction in the frequency and intensity of intestinal and extra-intestinal symptoms, and a clear improvement in stool consistency. ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Di Pierro', 'Affiliation': 'Scientific Department, Velleja Research, Milan, Italy - f.dipierro@vellejaresearch.com.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Bergomas', 'Affiliation': ""Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca' Granda Foundation, Milan, Italy.""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Marraccini', 'Affiliation': ""Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca' Granda Foundation, Milan, Italy.""}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Ingenito', 'Affiliation': ""Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca' Granda Foundation, Milan, Italy.""}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Ferrari', 'Affiliation': ""Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca' Granda Foundation, Milan, Italy.""}, {'ForeName': 'Luisella', 'Initials': 'L', 'LastName': 'Vigna', 'Affiliation': ""Obesity and Work Center, Occupational Medicine Unit, Department of Preventive Medicine, Maggiore Polyclinic Hospital, IRCCS Ca' Granda Foundation, Milan, Italy.""}]",Minerva gastroenterologica e dietologica,['10.23736/S1121-421X.20.02673-2'] 92,32400227,"Correlates of Posttraumatic Stress Symptoms among Formerly Incarcerated, Homeless Women.","Posttraumatic stress symptoms are a pressing issue among women experiencing incarceration and homelessness. Baseline data were collected among formerly incarcerated homeless women (N = 130) who were on average 38.9 (SD = 11.36, range 19-64) years of age and recruited into a pilot randomized control trial (RCT) intervention program. A logistic regression was used to assess correlates of PTSD symptoms. The majority of the sample self-reported witnessing violence (85%) and had moderate PTSD symptoms (M = 1.61, SD = 1.62, range: 0-4). No past month drug use ( p  = 0.006), higher anger scores ( p  = 0.002), greater emotional support ( p  = 0.009), and psychological frailty ( p  = 0.02) were significantly associated with higher odds of PTSD symptoms. Moreover, women who experienced minor family conflicts had lower odds of PTSD symptoms relative to those that had family conflicts most of the time ( p  = 0.02). Similarly, controlling for all other variables, women who had a higher positive social interaction score also had lower odds of PTSD symptoms ( p  = 0.006). These findings are a call to action for academicians, service providers, and health practitioners to develop an intervention which integrates comprehensive PTSD screening, and discussion of ways to build coping skills, relationships with family and social networks, and utilizes a trauma-informed approach during reentry.",2020,"No past month drug use ( p  = 0.006), higher anger scores ( p  = 0.002), greater emotional support ( p  = 0.009), and psychological frailty ( p  = 0.02) were significantly associated with higher odds of PTSD symptoms.","['women experiencing incarceration and homelessness', 'formerly incarcerated homeless women (N\u2009=\u2009130) who were on average 38.9 (SD = 11.36, range 19-64) years of age', 'Homeless Women']",[],"['psychological frailty', 'higher anger scores', 'witnessing violence', 'PTSD symptoms', 'greater emotional support', 'positive social interaction score', 'moderate PTSD symptoms']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205255', 'cui_str': 'Imprisonment'}, {'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0392751', 'cui_str': 'In prison'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",[],"[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0600015', 'cui_str': 'Emotional support'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0037420', 'cui_str': 'Interaction with others'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]",,0.015236,"No past month drug use ( p  = 0.006), higher anger scores ( p  = 0.002), greater emotional support ( p  = 0.009), and psychological frailty ( p  = 0.02) were significantly associated with higher odds of PTSD symptoms.","[{'ForeName': 'Benissa E', 'Initials': 'BE', 'LastName': 'Salem', 'Affiliation': 'School of Nursing, University of California, Los Angeles, California, USA.'}, {'ForeName': 'Angela L', 'Initials': 'AL', 'LastName': 'Hudson', 'Affiliation': 'School of Nursing, Azusa Pacific University, Azusa, California, USA.'}, {'ForeName': 'Kartik', 'Initials': 'K', 'LastName': 'Yadav', 'Affiliation': 'School of Nursing, University of California, Irvine, California, USA.'}, {'ForeName': 'Jaemilyn', 'Initials': 'J', 'LastName': 'Lucas', 'Affiliation': 'School of Nursing, San Bernardino and College of the Desert, California State University, San Bernardino, California, USA.'}, {'ForeName': 'Joy', 'Initials': 'J', 'LastName': 'Toyama', 'Affiliation': 'School of Nursing, University of California, Los Angeles, California, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Los Angeles County Department of Health Services, Los Angeles, California, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Faucette', 'Affiliation': 'Housing for Health/Office of Diversion and Reentry, Los Angeles County Department of Health Services, Los Angeles, California, USA.'}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Ekstrand', 'Affiliation': 'San Francisco School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Adeline M', 'Initials': 'AM', 'LastName': 'Nyamathi', 'Affiliation': 'School of Nursing, University of California, Irvine, California, USA.'}]",Issues in mental health nursing,['10.1080/01612840.2020.1720050'] 93,32400245,Analysis on the correlation between Eustachian tube function and outcomes of type I tympanoplasty for chronic suppurative otitis media.,"Background: The potential influence of Eustachian tube dysfunction (ETD) on the efficacy of tympanoplasty is controversial. Objective: This study aims to investigate the correlation between Eustachian tube function (ETF) and outcomes of type I tympanoplasty for chronic suppurative otitis media (CSOM). Materials and Methods: 53 patients with CSOM and receiving type I tympanoplasty were divided into a dysfunction group (Eustachian tube score; ETS ≤ 5points) and a normal group (ETS > 5 points) according to their preoperative ETS. During the one-year follow-up, the ETS, hearing results, and eardrum condition of the patients were recorded and analyzed. Results: The ETS improved significantly from 2.57 (±1.73SD) to 4.68 (±2.00SD), while the mean air-bone gap (ABG) decreased significantly from 20.94 (±9.04SD) dB to 16.43 (±9.06SD) dB in the dysfunction group ( p  < .05). The postoperative ABG showed no significant difference in the two groups. The healing rate of the tympanic membrane was 96.43% in the dysfunction group, and 100% in the normal group. Conclusions and significance: The ETF was significantly improved after type I tympanoplasty for CSOM combined with ETD, and the postoperative efficacy was not adversely affected. The ETD may not influence the outcomes of type I tympanoplasty for CSOM.",2020,"The healing rate of the tympanic membrane was 96.43% in the dysfunction group, and 100% in the normal group.","['chronic suppurative otitis media', 'chronic suppurative otitis media (CSOM', '53 patients with CSOM and receiving type I tympanoplasty']","['dysfunction group (Eustachian tube score; ETS ≤ 5points) and a normal group (ETS > 5 points) according to their preoperative ETS', 'Eustachian tube dysfunction (ETD', 'Eustachian tube function (ETF']","['mean air-bone gap (ABG', 'healing rate of the tympanic membrane', 'postoperative ABG', 'postoperative efficacy', 'ETF']","[{'cui': 'C0271454', 'cui_str': 'Chronic purulent otitis media'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0041447', 'cui_str': 'Repair of middle ear'}]","[{'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015183', 'cui_str': 'Structure of pharyngotympanic tube'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0271468', 'cui_str': 'Eustachian tube disorder'}, {'cui': 'C0457584', 'cui_str': 'Eustachian tube function'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0041445', 'cui_str': 'Tympanic membrane structure'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",53.0,0.0205689,"The healing rate of the tympanic membrane was 96.43% in the dysfunction group, and 100% in the normal group.","[{'ForeName': 'Ruixiang', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': 'Medical School of Chinese PLA, Beijing, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Wu', 'Affiliation': 'Medical School of Chinese PLA, Beijing, China.'}, {'ForeName': 'Jiabing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Graduate School, Chinese PLA General Hospital, Beijing, China.'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Hou', 'Affiliation': 'Medical School of Chinese PLA, Beijing, China.'}, {'ForeName': 'Shiming', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Medical School of Chinese PLA, Beijing, China.'}]",Acta oto-laryngologica,['10.1080/00016489.2020.1754462'] 94,32396564,The effect of monetary incentive on survey response for vulnerable children and youths: A randomized controlled trial.,"AIM In surveys non-responders may introduce bias and lower the validity of the studies. Ways to increase response rates are therefore important. The purpose of the study was to investigate if an unconditional monetary incentive can increase the response rate for vulnerable children and youths in a postal questionnaire survey. METHODS The study was designed as a randomized controlled trial. The study population consisted of 262 children and youth who participated in an established intervention study aimed at creating networks for different groups of vulnerable children and youths. The mean age of the participants was 16.7 years (range 11-28) and 67.9% were female. The questionnaire was adapted to three different age groups and covered different aspects of the participants' life situation, including the dimensions from the Strengths and Difficulties Questionnaire (SDQ). In the follow-up survey, participants were randomly allocated to two groups that either received a €15 voucher for a supermarket together with the questionnaire or only received the questionnaire. We used Poisson regression to estimate the differences in response rate (Rate Ratio RR) between the intervention group and the control group. RESULTS The response rate was 75.5% in the intervention group and 42.9% in the control group. The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17). We did not find any significant differences in scales scores between the two groups for the five scales of the SDQ. In stratified analyses, we found the effect of the incentive to be higher for males (RR 2.81; 95% CI 1.61-4.91) than for females (1.43; 95% CI 1.12-1.84). CONCLUSIONS Monetary incentives can increase the response rate for vulnerable children and youths in surveys. TRIAL REGISTRATION The trial was retrospectively registered at ClinicalTrials.gov Identifier: NCT01741675.",2020,"The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17).","['The mean age of the participants was 16.7 years (range 11-28) and 67.9% were female', 'vulnerable children and youths', '262 children and youth who participated in an established intervention study aimed at creating networks for different groups of vulnerable children and youths', 'vulnerable children and youths in a postal questionnaire survey', 'vulnerable children and youths in surveys']","['monetary incentive', '€15 voucher for a supermarket together with the questionnaire or only received the questionnaire']","['survey response', 'response rate', 'response rate (Rate Ratio RR', 'scales scores']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0557778', 'cui_str': 'Supermarket'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",262.0,0.0763144,"The response rate in the intervention group was significantly higher than in the control group when adjusting for age and gender (Rate Ratio, RR 1.73; 95% CI 1.38-2.17).","[{'ForeName': 'Jan Hyld', 'Initials': 'JH', 'LastName': 'Pejtersen', 'Affiliation': 'VIVE-The Danish Center for Social Science Research, Copenhagen, Denmark.'}]",PloS one,['10.1371/journal.pone.0233025'] 95,32396578,Special footwear designed for pregnant women and its effect on kinematic gait parameters during pregnancy and postpartum period.,"During pregnancy, an array of changes occurs in women body to enable the growth and development of the future baby and the consequent delivery. These changes are reflected in the range of motion of trunk, pelvis, lower limbs and other body segments, affect the locomotion and some of these changes may persist to the postpartum period. The aim of this study was to describe the changes affecting the gait during pregnancy and to determine the effect of tested footwear on kinematic gait characteristics during pregnancy as previous studies indicate that special orthopaedic insoles and footwear might be useful in prevention of the common musculoskeletal pain and discomfort related to pregnancy. Participants from the control group (n = 18), without any intervention, and the experimental group (n = 23), which was wearing the tested shoes, were measured at their 14, 28 and 37 gestational weeks and 28 weeks postpartum to capture the complete pregnancy-related changes in gait. The gait 3D kinematic data were obtained using Simi Motion System. The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern. The effect of tested footwear on kinematic gait pattern changes may be explained by its preventive effect against the foot arches falling. In the control group, changes associated previously with the foot arches falling and hindfoot hyperpronation were observed during advanced phases of pregnancy and postpartum, e.g. increase in knee flexion or increase in spinal curvature. For the comprehensive evaluation of the tested footwear on pregnancy gait pattern, future studies combining the kinematic and dynamic plantographic methods are needed.",2020,"The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern.",['pregnant women'],[],"['knee flexion or increase in spinal curvature', 'kinematic gait parameters', 'foot arches falling and hindfoot hyperpronation']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]",[],"[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0037932', 'cui_str': 'Curvature of spine'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0230467', 'cui_str': 'Structure of arch of foot'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0230459', 'cui_str': 'Hindfoot'}]",,0.0341883,"The differences between the control and experimental group at the first data collection session in most of the analysed variables, as well as relatively high standard deviations of analysed variables indicate large individual differences in the gait pattern.","[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Gimunová', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Zvonař', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Sebera', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Turčínek', 'Affiliation': 'Department of Informatics, Faculty of Business and Economics, Mendel University, Brno, Czech Republic.'}, {'ForeName': 'Kateřina', 'Initials': 'K', 'LastName': 'Kolářová', 'Affiliation': 'Department of Kinesiology, Faculty of Sports Studies, Masaryk University, Brno, Czech Republic.'}]",PloS one,['10.1371/journal.pone.0232901'] 96,32302930,"Attentional prioritization in dual-task walking: Effects of stroke, environment, and instructed focus.","BACKGROUND The impact of high distraction, real-world environments on dual-task interference and flexibility of attentional prioritization during dual-task walking in people with stroke is unknown. RESEARCH QUESTION How does a real-world environment affect dual-task performance and flexible task prioritization during dual-task walking in adults with and without stroke? METHODS Adults with stroke (n = 29) as well as age-, gender-, and education-matched adults without stroke (n = 23) participated. Single and dual-task walking were examined in two different environments (lab hallway, hospital lobby). Two different dual-task combinations were assessed (Stroop-gait, speech-gait). Each dual-task was performed first without explicit instruction about task prioritization (no-priority) and then with gait-priority instruction and Stroop/speech-priority instruction in randomized order. RESULTS People with stroke had significantly slower dual-task gait speed (Stroop only) in the lobby than the lab, but the effect was not clinically meaningful. Stroop reaction time for all participants was also slower in the lobby than the lab. All participants slowed their walking speed while generating spontaneous speech, but this effect was not influenced by environment. The dual-task attention allocation strategy was generally inflexible to instructed prioritization in adults with and without stroke in both environments, however, the volitional attention allocation strategy differed for the two dual-task conditions such that speech was prioritized in the speech-gait dual-task and gait appeared to be prioritized in the Stroop-gait dual-task. SIGNIFICANCE Although dual-tasking slows walking speed and verbal responses to auditory stimuli in people with stroke, the effects are not considerably impacted by a more complex, distracting environment. Adults with and without stroke may have difficulty overriding the preferred attention allocation strategy during dual-task walking, especially for habitual dual-tasks such as walking while speaking. It may also be that the cognitive control strategy governing task prioritization is influenced by degree of cognitive engagement.",2020,"The dual-task attention allocation strategy was generally inflexible to instructed prioritization in adults with and without stroke in both environments, however, the volitional attention allocation strategy differed for the two dual-task conditions such that speech was prioritized in the speech-gait dual-task and gait appeared to be prioritized in the Stroop-gait dual-task. ","['Adults with and without stroke', 'adults with and without stroke', 'Adults with stroke (n = 29) as well as age-, gender-, and education-matched adults without stroke (n = 23) participated', 'people with stroke']",['explicit instruction about task prioritization (no-priority) and then with gait-priority instruction and Stroop/speech-priority instruction'],"['walking speed while generating spontaneous speech', 'Stroop reaction time', 'dual-task gait speed']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0439607', 'cui_str': 'Priorities'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0037817', 'cui_str': 'Speech'}]","[{'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205173', 'cui_str': 'Double'}]",23.0,0.0469792,"The dual-task attention allocation strategy was generally inflexible to instructed prioritization in adults with and without stroke in both environments, however, the volitional attention allocation strategy differed for the two dual-task conditions such that speech was prioritized in the speech-gait dual-task and gait appeared to be prioritized in the Stroop-gait dual-task. ","[{'ForeName': 'Prudence', 'Initials': 'P', 'LastName': 'Plummer', 'Affiliation': 'Department of Physical Therapy, MGH Institute of Health Professions, 36 1st Avenue, Boston, MA, 02129, United States. Electronic address: pplummer@mghihp.edu.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Altmann', 'Affiliation': 'Department of Speech, Language, and Hearing Sciences, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Jody', 'Initials': 'J', 'LastName': 'Feld', 'Affiliation': 'Department of Orthopaedic Surgery, Duke University, NC, United States.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Zukowski', 'Affiliation': 'Department of Physical Therapy, High Point University, High Point, NC, United States.'}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Najafi', 'Affiliation': 'Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United States.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Giuliani', 'Affiliation': 'Department of Allied Health Sciences, University of North Carolina at Chapel Hill, NC, United States.'}]",Gait & posture,['10.1016/j.gaitpost.2020.03.013'] 97,32337693,Effect of Sheng Xue Ning Tablets on Renal Anemia in Patients Subject to Maintenance Hemodialysis and Safety Evaluation: A Multi-setting Prospective Randomized Study.,"This study compared Sheng Xue Ning (SXN) tablets with ferrous succinate (FS) tablets in terms of their efficacy for the treatment of iron-deficient renal anemia and safety in patients subject to maintenance hemodialysis (MHD). A total of 94 patients undergoing MHD were randomly assigned to an experiment group (receiving oral SXN tablets, SXN group) and a control group (orally given FS tablets, FS group) and followed up for 12 weeks. Erythropoietin (EPO) was used in both groups. The efficacy was assessed by detecting the subsequent changes in hemoglobin (Hb), serum iron (SI), SF and transferrin saturation (TSAT). At the 12th week, Hb and TSAT levels in both groups were significantly increased compared to those in the screening period (P<0.05). However, no significant difference in Hb and TSAT was found between the two groups. The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week. Our study showed that SXN tablets can effectively ameliorate renal anemia and keep iron metabolism stable in MHD patients, and its efficacy is virtually close to that of FS tablets. Meanwhile, SXN tablets can reduce the dosage of EPO and have a good safety profile.",2020,The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week.,"['MHD patients', '94 patients undergoing MHD', 'patients subject to maintenance hemodialysis (MHD', 'Patients Subject to Maintenance Hemodialysis and Safety Evaluation']","['Sheng Xue Ning Tablets', 'experiment group (receiving oral SXN tablets, SXN', 'Sheng Xue Ning (SXN) tablets with ferrous succinate (FS) tablets', 'Erythropoietin (EPO', 'SXN tablets']","['hemoglobin (Hb), serum iron (SI), SF and transferrin saturation (TSAT', 'Hb and TSAT', 'Hb and TSAT levels', 'renal anemia', 'Renal Anemia', 'average weekly EPO dosage']","[{'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0060281', 'cui_str': 'ferrous succinate'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1142276', 'cui_str': 'Renal anemia'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",94.0,0.0117874,The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week.,"[{'ForeName': 'Xiao-Jing', 'Initials': 'XJ', 'LastName': 'Tang', 'Affiliation': 'Department of Nephrology, Changzheng Hospital, the Second Military Medical University, Shanghai, 20003, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Rong', 'Affiliation': 'Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.'}, {'ForeName': 'Chang-Lin', 'Initials': 'CL', 'LastName': 'Mei', 'Affiliation': 'Department of Nephrology, Changzheng Hospital, the Second Military Medical University, Shanghai, 20003, China. chlmei1954@126.com.'}, {'ForeName': 'Zhao-Hui', 'Initials': 'ZH', 'LastName': 'Ni', 'Affiliation': 'Department of Nephrology, Renji Hospital, Jiaotong University, Shanghai, 200003, China.'}, {'ForeName': 'Geng-Ru', 'Initials': 'GR', 'LastName': 'Jiang', 'Affiliation': 'Department of Nephrology, Xinhua Hospital, Jiaotong University, Shanghai, 200092, China.'}, {'ForeName': 'Wei-Jie', 'Initials': 'WJ', 'LastName': 'Yuan', 'Affiliation': 'Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.'}, {'ForeName': 'Nian-Song', 'Initials': 'NS', 'LastName': 'Wang', 'Affiliation': ""Department of Nephrology, the Sixth People's Hospital, Jiaotong University, Shanghai, 200233, China.""}, {'ForeName': 'Zhi-Yong', 'Initials': 'ZY', 'LastName': 'Guo', 'Affiliation': 'Department of Nephrology, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'Department of Nephrology, Tongji Hospital, Tongji University, Shanghai, 200065, China.'}, {'ForeName': 'Hai-Dong', 'Initials': 'HD', 'LastName': 'Yan', 'Affiliation': 'Department of Nephrology, East Hospital, Tongji University, Shanghai, 200120, China.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'ZHang', 'Affiliation': 'Department of Nephrology, Zhabei District Central Hospital, Changzhen Hospital, Shanghai, 200070, China.'}]",Current medical science,['10.1007/s11596-020-2179-z'] 98,32337698,Efficacy of Electro-acupuncture in Treatment of Functional Constipation: A Randomized Controlled Trial.,"Functional constipation (FC) is a chronic disease that significantly affects the life quality of patients. Acupuncture has been used for the treatment of FC for many years, but its effectiveness has not been scientifically assessed. The present study aimed to evaluate the efficacy of electro-acupuncture (EA) in relieving the symptoms, mental states and quality of life (QOL) of FC patients. A total of 96 FC patients were randomly allocated into EA, mosapride & sham EA group (MS) and mosapride control group (MC). In the EA group, patients were treated with 16 sessions of needling at Quchi (LI11) and Shangjuxu (ST37) bilaterally, 5 times a week in the first 2 weeks, and 3 times a week in the last 2 weeks. In the MC group, patients were treated with 5 mg mosapride citrate three times a day for 4 weeks. In the MS group, patients underwent sham EA and the same mosapride citrate treatment as in the MC group. The primary outcome was the number of weekly spontaneous bowel movements (SBMs). The secondary outcomes included stool consistency, intensity of defecating difficulty, 36-Item Short-Form Health Survey (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and the validated Patient Assessment of Constipation-Quality of Life (PAC-QOL). The results showed that as compared with the baseline, EA significantly improved the weekly SBMs, stool consistency and intensity of defecating difficulty (P<0.05). It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05). However, no significant difference was observed between MS and MC groups in bowel function outcomes and QOL scores. It was concluded that EA could effectively improve bowel function, mental states and QOL of FC patients.",2020,"It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05).","['96 FC patients', 'Functional Constipation']","['electro-acupuncture (EA', 'EA, mosapride & sham', 'Acupuncture', 'Electro-acupuncture', 'EA']","['bowel function outcomes and QOL scores', 'bowel function, mental states and QOL', 'stool consistency, intensity of defecating difficulty, 36-Item Short-Form Health Survey (SF-36), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS), and the validated Patient Assessment of Constipation-Quality of Life (PAC-QOL', 'number of weekly spontaneous bowel movements (SBMs', 'weekly SBMs, stool consistency and intensity of defecating difficulty', 'symptoms, mental states and quality of life (QOL', 'Functional constipation (FC', 'PAC-QOL, SF-36, SDS and SAS scores']","[{'cui': 'C0401146', 'cui_str': 'Constipation - functional'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0526501', 'cui_str': 'mosapride'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0278060', 'cui_str': 'Mental state'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0033036', 'cui_str': 'Atrial premature complex'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0401146', 'cui_str': 'Constipation - functional'}]",96.0,0.0313138,"It also partly ameliorated the PAC-QOL, SF-36, SDS and SAS scores when compared with MC or MS group (P<0.05).","[{'ForeName': 'Xiao-Hu', 'Initials': 'XH', 'LastName': 'Xu', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Ming-Min', 'Initials': 'MM', 'LastName': 'Zhang', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Sha-Bei', 'Initials': 'SB', 'LastName': 'Xu', 'Affiliation': 'Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Cui-Hong', 'Initials': 'CH', 'LastName': 'Zheng', 'Affiliation': 'Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. chzheng@tjh.tjmu.edu.cn.'}, {'ForeName': 'Guang-Ying', 'Initials': 'GY', 'LastName': 'Huang', 'Affiliation': 'Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. gyhuang@tjh.tjmu.edu.cn.'}]",Current medical science,['10.1007/s11596-020-2188-y'] 99,32337700,Effect of Nalmefene on Delayed Neurocognitive Recovery in Elderly Patients Undergoing Video-assisted Thoracic Surgery with One Lung Ventilation.,"The intravenous use of nalmefene has been found to exert neuroprotective effect in patients with severe traumatic brain injury and acute cerebral infarction; nonetheless, it is unknown whether nalmefene alleviates delayed neurocognitive recovery. Our purpose of the current research was to clarify the impact of nalmefene on delayed neurocognitive recovery in aged patients experiencing video-assisted thoracic surgery (VATS) with intraoperative use of one lung ventilation (OLV). The present study involved 120 patients undergoing selective VATS, randomized to accept low-dose nalmefene (N1 group, n=40), high-dose nalmefene (N2 group, n=40) or equal volume of physiologic saline (control group, n=40). A battery of neuropsychological tests were used to estimate cognitive function 1 day before surgery (t 0 ) and 10 days after surgery or before discharge (t 1 ). Regional cerebral oxygen saturation (rSO 2 ) was detected 5 min before induction (t 0 ), 5 min after induction (t 1 ), 15 and 60 min after onset of OLV (t 2 and t 3 ), and 15 min after termination of OLV (t 4 ). The plasma values of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and adiponectin (ADP) were also detected prior to induction of anesthesia (T0), 1 h, 2 h and 6 h after surgery (T1, T2, T3). On t 1 , delayed neurocognitive recovery occurred in 5/40 (12.5%) patients of N1 group, in 5/40 (12.5%) patients of N2 group and in 13/40 (32.5%) patients of control group (P0.05). There were no statistical differences in rSO 2 among three groups at different time points. At T1, T2 and T3, IL-1β, IL-6 and TNF-α values significantly increased and ADP value significantly decreased (P0.05) in control group. In contrast, at T1, T2 and T3, IL-1β, IL-6 and TNF-α values decreased and ADP value decreased less in N1 and N2 groups (P0.05). At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05). The result of our present research supports the hypothesis that the perioperative intravenous treatment with nalmefene to VATS with OLV ameliorates postoperative cognitive function and decreases the incidence of delayed neurocognitive recovery, most likely by suppression of inflammatory responses.",2020,"At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05).","['patients with severe traumatic brain injury and acute cerebral infarction', 'aged patients experiencing video-assisted thoracic surgery (VATS) with intraoperative use of one lung ventilation (OLV', 'Elderly Patients Undergoing Video-assisted Thoracic Surgery with One Lung Ventilation', '120 patients undergoing selective VATS, randomized to accept low-dose nalmefene (N1 group, n=40']","['Nalmefene', 'high-dose nalmefene (N2 group, n=40) or equal volume of physiologic saline (control']","['T2 and T3, IL-1β, IL-6 and TNF-α values', 'delayed neurocognitive recovery', 'ADP value', 'plasma values of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α and adiponectin (ADP', 'Regional cerebral oxygen saturation (rSO 2 ', 'T2 and T3, IL-1β, IL-6 and TNF-α concentrations', 'postoperative cognitive function', 'T2 and T3, IL-1β, IL-6 and TNF-α values decreased and ADP value', 'Delayed Neurocognitive Recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0752151', 'cui_str': 'Surgery, Thoracic, Video-Assisted'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0559312', 'cui_str': 'One lung ventilation'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0068377', 'cui_str': 'nalmefene'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0068377', 'cui_str': 'nalmefene'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",120.0,0.0301072,"At T1, T2 and T3, IL-1β, IL-6 and TNF-α concentrations presented a trend of N2 group N1 group control group and ADP presented a trend of N2 groupN1 groupcontrol group (P0.05).","[{'ForeName': 'Meng-Yun', 'Initials': 'MY', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Zheng-Gang', 'Initials': 'ZG', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Jian-Juan', 'Initials': 'JJ', 'LastName': 'Ke', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.'}, {'ForeName': 'Xiao-Bo', 'Initials': 'XB', 'LastName': 'Feng', 'Affiliation': 'Department of Anesthesiology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China. 283647213@qq.com.'}]",Current medical science,['10.1007/s11596-020-2170-8'] 100,32334615,Effectiveness of a multi-level intervention to reduce men's perpetration of intimate partner violence: a cluster randomised controlled trial.,"BACKGROUND Men's perpetration of intimate partner violence (IPV) limits gains in health and wellbeing for populations globally. Largely informal, rapidly expanding peri-urban settlements, with limited basic services such as electricity, have high prevalence rates of IPV. Evidence on how to reduce men's perpetration, change social norms and patriarchal attitudes within these settings is limited. Our cluster randomised controlled trial aimed to determine the effectiveness of the Sonke CHANGE intervention in reducing use of sexual and/or physical IPV and severity of perpetration by men aged 18-40 years over 2 years. METHODOLOGY The theory-based intervention delivered activities to bolster community action, including door-to-door discussions, workshops, drawing on the CHANGE curriculum, and deploying community action teams over 18 months. In 2016 and 2018, we collected data from a cohort of men, recruited from 18 clusters; nine were randomised to receive the intervention, while the nine control clusters received no intervention. A self-administered questionnaire, using audio-computer assisted software, asked about sociodemographics, gender attitudes, mental health, and the use and severity of IPV. We conducted an intention-to-treat analysis at the cluster level comparing the expected risk to observed risk of using IPV while controlling for baseline characteristics. A secondary analysis used latent classes (LCA) of men to see whether there were differential effects of the intervention for subgroups of men. RESULTS Of 2406 men recruited, 1458 (63%) were followed to 2 years. Overall, we saw a reduction in men's reports of physical, sexual and severe IPV from baseline to endpoint (40.2% to 25.4%, 31.8% to 15.8%, and 33.4% to 18.2%, respectively). Intention-to-treat analysis showed no measurable differences between intervention and control clusters for primary IPV outcomes. Difference in the cluster-level proportion of physical IPV perpetration was 0.002 (95% confidence interval [CI] - 0.07 to 0.08). Similarly, differences between arms for sexual IPV was 0.01 (95% CI - 0.04 to 0.06), while severe IPV followed a similar pattern (Diff = 0.01; 95% CI - 0.05 to 0.07). A secondary analysis using LCA suggests that among the men living in intervention communities, there was a greater reduction in IPV among less violent and more law abiding men than among more highly violent men, although the differences did not reach statistical significance. CONCLUSION The intervention, when implemented in a peri-urban settlement, had limited effect in reducing IPV perpetrated by male residents. Further analysis showed it was unable to transform entrenched gender attitudes and use of IPV by those men who use the most violence, but the intervention showed promise for men who use violence less. TRIAL REGISTRATION ClinicalTrials.gov, NCT02823288. Registered on 30 June 2016.",2020,"The intervention, when implemented in a peri-urban settlement, had limited effect in reducing IPV perpetrated by male residents.","['Of 2406 men recruited, 1458 (63%) were followed to 2 years', 'In 2016 and 2018, we collected data from a cohort of men, recruited from 18 clusters; nine', ""Men's perpetration of intimate partner violence (IPV) limits gains in health and wellbeing for populations globally"", 'by men aged 18-40\u2009years over 2 years', ""men's perpetration of intimate partner violence""]","['multi-level intervention', 'Sonke CHANGE intervention']","['severe IPV', 'IPV', 'sexual IPV', 'sexual and/or physical IPV and severity of perpetration', 'physical, sexual and severe IPV']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0205455', 'cui_str': '9'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",2406.0,0.183564,"The intervention, when implemented in a peri-urban settlement, had limited effect in reducing IPV perpetrated by male residents.","[{'ForeName': 'Nicola J', 'Initials': 'NJ', 'LastName': 'Christofides', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa. nicola.christofides@wits.ac.za.'}, {'ForeName': 'Abigail M', 'Initials': 'AM', 'LastName': 'Hatcher', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa.'}, {'ForeName': 'Dumisani', 'Initials': 'D', 'LastName': 'Rebombo', 'Affiliation': 'Sonke Gender Justice, Juta Street, Braamfontein, Johannesburg, South Africa.'}, {'ForeName': 'Ruari-Santiago', 'Initials': 'RS', 'LastName': 'McBride', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa.'}, {'ForeName': 'Shehnaz', 'Initials': 'S', 'LastName': 'Munshi', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa.'}, {'ForeName': 'Angelica', 'Initials': 'A', 'LastName': 'Pino', 'Affiliation': 'Sonke Gender Justice, Juta Street, Braamfontein, Johannesburg, South Africa.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Abdelatif', 'Affiliation': 'South African Medical Research Council, 1 Soutpansberg Road, Pretoria, South Africa.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Peacock', 'Affiliation': 'Sonke Gender Justice, Juta Street, Braamfontein, Johannesburg, South Africa.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Levin', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa.'}, {'ForeName': 'Rachel K', 'Initials': 'RK', 'LastName': 'Jewkes', 'Affiliation': 'Faculty of Health Sciences, School of Public Health, University of the Witwatersrand, 27 St Andrews Rd, Parktown, Johannesburg, 2193, South Africa.'}]",Trials,['10.1186/s13063-020-4185-7'] 101,32336177,Total mouth photodynamic therapy mediated by blue led and curcumin in individuals with AIDS.,"OBJECTIVES To test the effectiveness of an efficient therapeutic protocol for the total mouth antimicrobial photodynamic therapy (aPDT) mediated by 450 nm blue LED associated with curcumin in individuals with AIDS. METHODS Patients were selected by exclusion criteria and randomly distributed in groups to test the effectiveness of antimicrobial aPDT with curcumin 0.75 mg/mL associated with the blue LED (67 mW/cm 2 , 20.1 J/cm 2 ). Before and after the treatments, samples were collected from the saliva being processed in duplicate in selective culture media. The colonies were counted and the results obtained in log10 CFU/mL were statistically tested (T-paired statistical test, 5%). RESULTS The log10 CFU/mL of Streptococcus spp., Staphylococcus spp., and total count of microorganisms showed statistically significant (p = 0.023; p = 0.001 and p = 0.017, respectively) reduction after treatment in patients with aPDT. CONCLUSION aPDT was effective in reducing Streptococcus spp. in addition to reducing Staphylococcus spp., enterobacteria and the total count of microorganisms when considering the numbers of TCD4 and TCD8 lymphocytes. The aPDT in the studied protocol was able to control clinically important intraoral microorganisms for AIDS patients, both those with TCD4 lymphocytes above or below 25% of normal and those with TCD8 lymphocytes above 25% of normal.",2020,"The aPDT in the studied protocol was able to control clinically important intraoral microorganisms for AIDS patients, both those with TCD4 lymphocytes above or below 25% of normal and those with TCD8 lymphocytes above 25% of normal.","['patients with aPDT', 'individuals with AIDS']","['antimicrobial aPDT with curcumin 0.75 mg/mL associated with the blue LED', 'total mouth antimicrobial \ufeffphotodynamic therapy (aPDT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]",[],,0.046435,"The aPDT in the studied protocol was able to control clinically important intraoral microorganisms for AIDS patients, both those with TCD4 lymphocytes above or below 25% of normal and those with TCD8 lymphocytes above 25% of normal.","[{'ForeName': 'Francine', 'Initials': 'F', 'LastName': 'Cristina Da Silva', 'Affiliation': 'Federal University of Bahia, Multidisciplinary Health Institute , Vitória Da Conquista, BA, Brazil.'}, {'ForeName': 'Luciano Pereira', 'Initials': 'LP', 'LastName': 'Rosa', 'Affiliation': 'Federal University of Bahia, Multidisciplinary Health Institute , Vitória Da Conquista, BA, Brazil.'}, {'ForeName': 'Gabriel Pinto De Oliveira', 'Initials': 'GPO', 'LastName': 'Santos', 'Affiliation': 'Federal University of Bahia, Multidisciplinary Health Institute , Vitória Da Conquista, BA, Brazil.'}, {'ForeName': 'Natália Mayumi', 'Initials': 'NM', 'LastName': 'Inada', 'Affiliation': 'São Carlos Institute of Physics, University of São Paulo , São Carlos, Brazil.'}, {'ForeName': 'Kate Cristina', 'Initials': 'KC', 'LastName': 'Blanco', 'Affiliation': 'São Carlos Institute of Physics, University of São Paulo , São Carlos, Brazil.'}, {'ForeName': 'Thalita Santos Dantas', 'Initials': 'TSD', 'LastName': 'Araújo', 'Affiliation': 'Federal University of Bahia, Multidisciplinary Health Institute , Vitória Da Conquista, BA, Brazil.'}, {'ForeName': 'Vanderlei Salvador', 'Initials': 'VS', 'LastName': 'Bagnato', 'Affiliation': 'São Carlos Institute of Physics, University of São Paulo , São Carlos, Brazil.'}]",Expert review of anti-infective therapy,['10.1080/14787210.2020.1756774'] 102,32315965,Baduanjin mind-body exercise improves logical memory in long-term hospitalized patients with schizophrenia: A randomized controlled trial.,"Neurocognitive impairment is one of the core symptoms in schizophrenia and poses a great challenge to effective treatment. Sixty-one long-term hospitalized patients with schizophrenia were recruited and randomly assigned to two groups: Baduanjin exercise and brisk walking. Patients in the Baduanjin group received 24 weeks of Baduanjin training (5 days/week, 40 min/day), while patients in the brisk walking group received 24 weeks of brisk walking (5 days/week, 40 min/day). Scores on the Wechsler Memory Scale, Digit Symbol Substitution Test (DSST), and the positive and negative syndrome scale were used to evaluate the logical memory (LM), processing speed, and clinical symptoms of all participants, while the score of Trail Making Test-A (TMT-A) was applied to assess the visual attention and graphomotor speed, at baseline and the 16th week and 24th week of intervention. The one-way repeated measures analysis of variance (ANOVA) was used to test the differences in neurocognitive changes between the two groups. Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328). A significant effect of time was also detected in the LM immediate (F=10.24, p = 0.000) and LM delayed (F=4.93, p = 0.009) scores and in the completion time of the TMT-A (F=33.10, p = 0.000), but not in the DSST scores (F=2.12, p = 0.122). Baduanjin exercise could improve logical memory in the long-term hospitalized patients with schizophrenia.",2020,"Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328).","['long-term hospitalized patients with schizophrenia', 'hospitalized patients with schizophrenia', 'Sixty-one long-term hospitalized patients with schizophrenia']","['Baduanjin exercise', 'Baduanjin training', 'brisk walking group received 24 weeks of brisk walking', 'Baduanjin exercise and brisk walking', 'Baduanjin mind-body exercise']","['LM immediate', 'logical memory (LM), processing speed, and clinical symptoms', 'neurocognitive changes', 'LM delayed', 'logical memory', 'visual attention and graphomotor speed', 'completion time of the TMT-A', 'Wechsler Memory Scale, Digit Symbol Substitution Test (DSST), and the positive and negative syndrome scale', 'DSST scores']","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C4517832', 'cui_str': '61'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0589102', 'cui_str': 'Visual attention'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451575', 'cui_str': 'Wechsler memory scale'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",61.0,0.0321369,"Repeated measures ANOVA showed significant differences between the two groups in the LM immediate (F = 6.21, p = 0.003) and LM delayed (F=5.60, p = 0.005) scores, but not in the completion times of TMT-A (F=.22, p = 0.806) or DSST scores (F=0.97, p = 0.328).","[{'ForeName': 'Mingli', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': ""Mental Health Center and Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China; The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China. Electronic address: limingli0517@qq.com.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Yusubujiang', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': ""The Mental Rehabilitation Centers, Karamay Municipal People's Hospital, Karamay, Xinjiang 830054, China. Electronic address: 577827619@qq.com.""}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102046'] 103,32194222,Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: A double-blind randomised placebo-controlled clinical trial.,"BACKGROUND Nrf2 is a transcription factor that induces the expression of several proteins with antioxidant properties such as sestrin2 (Sesn2) and is therefore considered as the major regulator of anti-oxidative defence system. OBJECTIVES The aim of this research was to study the effect of supplementation with n-3 PUFAs on the antioxidant status and the gene expression of Nrf2 and Sestrin2 (Sesn2) in patients with type 2 diabetes mellitus (T2DM). PARTICIPANTS Sixty patients with T2DM were enrolled in a placebo-controlled, double-blind, randomised clinical trial. INTERVENTION AND DESIGN The participants were randomly allocated to two intervention groups receiving either n-3 PUFAs (2,700 mg/day) (n = 30) or placebo soft gels containing 900 mg of edible paraffin (n = 30). The main outcome measures were the expression of Sesn2 and Nrf2 genes which were assessed in peripheral blood mononuclear cells (PBMCs) after RNA extraction and cDNA synthesis by real-time PCR. Total antioxidant status in plasma samples was also measured based on the ferric reducing ability of plasma. RESULTS NRF2 gene expression was significantly increased in n-3 PUFA-supplemented subjects, compared with the placebo group. Plasma total antioxidant status was also significantly augmented in n-3 PUFA-supplemented subjects. SESN2 gene expression was not significantly affected by n-3 PUFA supplementation although a slight up-regulation was observed. CONCLUSION Supplementation with n-3 PUFAs enhanced NRF2 gene expression and improved overall antioxidant capacity and thus might be considered beneficial in the amelioration of oxidative stress and prevention of T2DM complications. TRIAL REGISTRATION IRCT20150926024198N4.",2020,"RESULTS Nrf2 gene expression was significantly increased in n-3 PUFA-supplemented subjects, compared with the placebo group.","['patients with type 2 diabetes mellitus after supplementation with', 'Sixty patients with T2DM were enrolled in a', 'patients with type 2 diabetes mellitus (T2DM']","['placebo soft gels containing 900 mg of edible paraffin', 'n-3 PUFAs', 'omega-3 polyunsaturated fatty acids', 'placebo', 'n-3 PUFA supplementation']","['expression of Sesn2 and Nrf2 genes which were assessed in peripheral blood mononuclear cells (PBMCs) after RNA extraction and cDNA synthesis by real-time PCR', 'Plasma total antioxidant status', 'Sesn2 gene expression', 'Total antioxidant status in plasma samples', 'antioxidant status and the gene expression of Nrf2 and Sestrin2 (Sesn2', 'overall antioxidant capacity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205358', 'cui_str': 'Soft (qualifier value)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0030415', 'cui_str': 'Paraffin'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}]","[{'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C3839010', 'cui_str': 'RNA extraction'}, {'cui': 'C0006556', 'cui_str': 'cDNA'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",60.0,0.432506,"RESULTS Nrf2 gene expression was significantly increased in n-3 PUFA-supplemented subjects, compared with the placebo group.","[{'ForeName': 'Pegah', 'Initials': 'P', 'LastName': 'Golpour', 'Affiliation': 'Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.'}, {'ForeName': 'Mitra', 'Initials': 'M', 'LastName': 'Nourbakhsh', 'Affiliation': 'Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran; Finetech in Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: nourbakhsh.m@iums.ac.ir.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Mazaherioun', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Janani', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Nourbakhsh', 'Affiliation': 'Hazrat Aliasghar Hospital, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Parichehreh', 'Initials': 'P', 'LastName': 'Yaghmaei', 'Affiliation': 'Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108120'] 104,32333847,"Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.","BACKGROUND Raxibacumab is a monoclonal antibody against protective antigen, which is the cell-binding part of Bacillus anthracis toxin, and is approved for treatment and postexposure prophylaxis of inhalational anthrax. Anthrax Vaccine Adsorbed (AVA), for anthrax prophylaxis, consists primarily of adsorbed protective antigen. We did a postapproval study to assess the effect of raxibacumab on immunogenicity of AVA. METHODS We did an open-label, parallel-group, randomised non-inferiority study at three centres in the USA. We enrolled healthy volunteers (aged 18-65 years) with no evidence of exposure to protective antigen. Participants were randomly allocated (1:1) according to a pregenerated balanced independent randomisation schedule to either subcutaneous 0·5 mL AVA on days 1, 15, and 29 or raxibacumab intravenous infusion (40 mg/kg) immediately before AVA on day 1, followed by AVA only on days 15 and 29. It was an open-label study to investigators and participants; however, the sponsor remained blinded during the study. The primary outcome was the ratio of geometric mean concentrations (GMCs) of anti-protective antigen antibodies (attributable to the immune response to AVA) between AVA and AVA plus raxibacumab 4 weeks after the first AVA dose in the per-protocol population. The per-protocol population comprised all individuals who received the allocated treatment within the protocol-specified visit window and completed the primary study outcome assessment, without a protocol deviation requiring exclusion. The non-inferiority margin for the ratio of GMCs was predefined (upper limit of 90% CI <1·5). This trial is registered with ClinicalTrials.gov, NCT02339155. FINDINGS Between Feb 24, 2015, and June 6, 2017, 873 participants were screened for eligibility, of whom 300 were excluded. 573 were randomly allocated either AVA (n=287) or AVA plus raxibacumab (n=286). The per-protocol population comprised 276 individuals assigned AVA and 269 allocated AVA plus raxibacumab. At week 4, the GMC of anti-protective antigen antibodies in participants allocated AVA was 26·5 μg/mL (95% CI 23·6-29·8) compared with 22·5 μg/mL (20·1-25·1) among individuals allocated AVA plus raxibacumab. The ratio between groups was 1·18 (90% CI 1·03-1·35; p=0·0019), which met the predefined non-inferiority margin. Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. INTERPRETATION Co-administration of raxibacumab with AVA does not negatively affect AVA immunogenicity. This finding suggests that combining raxibacumab with AVA might provide added benefit in postexposure prophylaxis against inhalational anthrax. FUNDING US Biomedical Advanced Research and Development Authority, and GlaxoSmithKline.",2020,"Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. ","['enrolled healthy volunteers (aged 18-65 years) with no evidence of exposure to protective antigen', '276 individuals assigned AVA and 269 allocated', '873 participants were screened for eligibility, of whom 300 were excluded', 'Between Feb 24, 2015, and June 6, 2017']","['AVA', 'AVA plus raxibacumab', 'raxibacumab intravenous infusion', 'Anthrax Vaccine Adsorbed (AVA', 'raxibacumab with AVA', 'subcutaneous 0·5 mL AVA', 'raxibacumab']","['AVA immunogenicity', 'ratio of geometric mean concentrations (GMCs) of anti-protective antigen antibodies', 'serious adverse events', 'Adverse events']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332125', 'cui_str': 'No evidence of'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C1443846', 'cui_str': 'Anthrax toxin protective antigen'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0358297', 'cui_str': 'Anthrax vaccine'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0358297', 'cui_str': 'Anthrax vaccine'}, {'cui': 'C1329979', 'cui_str': 'Anthrax Vaccine Adsorbed'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2717174', 'cui_str': 'raxibacumab'}, {'cui': 'C0021440', 'cui_str': 'Intravenous infusion'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}]","[{'cui': 'C1329979', 'cui_str': 'Anthrax Vaccine Adsorbed'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1443846', 'cui_str': 'Anthrax toxin protective antigen'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",873.0,0.343685,"Adverse events in the safety population were similar across groups (87 [30%] of 286 in the AVA group vs 80 [29%] of 280 in the AVA plus raxibacumab group) and no treatment-related serious adverse events were reported. ","[{'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Skoura', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang-Jairaj', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Della Pasqua', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Vijayalakshmi', 'Initials': 'V', 'LastName': 'Chandrasekaran', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Billiard', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Yeakey', 'Affiliation': 'GlaxoSmithKline, Rockville, MD, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Smith', 'Affiliation': 'Alliance for Multispecialty Research at University of Tennessee Medical Center, Knoxville, TN, USA; New Orleans Center for Clinical Research, New Orleans, LA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Steel', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK.'}, {'ForeName': 'Lionel K', 'Initials': 'LK', 'LastName': 'Tan', 'Affiliation': 'GlaxoSmithKline, Uxbridge, UK. Electronic address: lionel.x.tan@gsk.com.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30069-4'] 105,32196749,"A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ® ) in healthy male subjects.","OBJECTIVES ABP 959 is a proposed biosimilar to eculizumab, a monoclonal antibody targeting the human C5 complement protein. The objective of this randomized, double-blind, three-arm, study was to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity of ABP 959 relative to the eculizumab reference product (RP) in healthy adult male subjects. METHODS Eligible subjects aged 18-45 years were randomized to receive a 300-mg IV infusion of ABP 959, or FDA-licensed eculizumab (eculizumab US), or EU-authorized eculizumab (eculizumab EU). Primary PK endpoint was area under the total serum concentration-time curve from 0 to infinity (AUC 0-∞ ); primary PD endpoint was area between the effect curve (ABEC) of CH50-time data. RESULTS The geometric mean of PK and PD parameters were similar between ABP 959 versus eculizumab US and eculizumab EU; PK and PD similarity was established based on 90% confidence intervals of the geometric mean ratio being within prespecified equivalence margin of 0.8 and 1.25. The incidence of treatment-emergent adverse events was similar across groups. The incidence of binding anti-drug antibodies was similar across treatments; no subjects developed neutralizing antibodies. CONCLUSIONS This study demonstrated PK and PD similarity of ABP 959 to eculizumab RP; safety and immunogenicity profiles were also similar.",2020,"The incidence of binding anti-drug antibodies was similar across treatments; no subjects developed neutralizing antibodies. ","['healthy adult male subjects', 'Healthy Male Subjects', 'Eligible subjects aged 18-45 years']","['300-mg IV infusion of ABP 959, or FDA-licensed eculizumab (eculizumab US), or EU-authorized eculizumab (eculizumab EU', 'ABP 959 and Eculizumab (Soliris ® ']","['geometric mean of PK and PD parameters', 'incidence of treatment-emergent adverse events', 'area under the total serum concentration-time curve', 'incidence of binding anti-drug antibodies', 'pharmacokinetic (PK) and pharmacodynamic (PD) similarity']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0023636', 'cui_str': 'Permits'}, {'cui': 'C1541483', 'cui_str': 'eculizumab'}, {'cui': 'C1744173', 'cui_str': 'Soliris'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}]",,0.331056,"The incidence of binding anti-drug antibodies was similar across treatments; no subjects developed neutralizing antibodies. ","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Chow', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Pan', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Chien', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Daniel T', 'Initials': 'DT', 'LastName': 'Mytych', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Hanes', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}]",European journal of haematology,['10.1111/ejh.13411'] 106,31347002,Triple Puncture for Primary Trigeminal Neuralgia: A Randomized Clinical Trial.,"To evaluate the effect of triple puncture on primary trigeminal neuralgia (pTN), 64 patients with pTN were randomly assigned to two groups: treatment group and control group. The participants in the treatment group received triple puncture treatment of 6 times per week for 4 weeks, and those in control group were given carbamazepine (300-600 mg per day) for at least 1 month. Before and after treatment, the primary outcomes including the total efficiency rate and the VAS pain scores, and the secondary outcomes including the frequency of pain attack and adverse events were observed. Sixty-two participants finished the study (33 in treatment group and 29 in control group individually). After treatment, the symptoms (mainly pain) of the two groups were alleviated. The total efficiency rate in the treatment group and control group was 90.9% and 75.9% respectively. The VAS pain scores and frequency of pain attack were significantly reduced in the treatment group as compared with the control group (P<0.05). The incidence of adverse events in the treatment group and control group was 9.1% and 24.1% respectively. It can be inferred that triple puncture can effectively improve the quality of life of patients with pTN and has less side effects.",2019,The VAS pain scores and frequency of pain attack were significantly reduced in the treatment group as compared with the control group (P<0.05).,"['primary trigeminal neuralgia (pTN), 64 patients with pTN', 'Primary Trigeminal Neuralgia']","['carbamazepine', 'triple puncture', 'triple puncture treatment', 'Triple Puncture']","['frequency of pain attack and adverse events', 'total efficiency rate', 'incidence of adverse events', 'total efficiency rate and the VAS pain scores', 'symptoms (mainly pain', 'quality of life', 'VAS pain scores and frequency of pain attack']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0040997', 'cui_str': 'Fothergill Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0006949', 'cui_str': 'Carbamazepine'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}]",62.0,0.0330086,The VAS pain scores and frequency of pain attack were significantly reduced in the treatment group as compared with the control group (P<0.05).,"[{'ForeName': 'Yang-Pu', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, 430015, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Sector of P.E., China University of Geosciences, Wuhan, 430074, China.'}, {'ForeName': 'Wen-Guang', 'Initials': 'WG', 'LastName': 'Xia', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, 430015, China.'}, {'ForeName': 'Ai-Qun', 'Initials': 'AQ', 'LastName': 'Song', 'Affiliation': 'Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China. 245855503@qq.com.'}]",Current medical science,['10.1007/s11596-019-2085-4'] 107,32334141,Blood eosinophil count group shifts and kinetics in severe eosinophilic asthma.,"BACKGROUND Blood eosinophil count (BEC) measurements are a noninvasive, relatively reliable surrogate marker for eosinophilic airway inflammation. Single measurements of peripheral BEC greater than or equal to 150 cells/μL predict the response to anti-eosinophil therapies for patients with characteristics of severe eosinophilic asthma. OBJECTIVE To describe how BECs shift over time for patients with severe, uncontrolled asthma receiving placebo in 2 large, randomized, placebo-controlled clinical trials of benralizumab (SIROCCO and CALIMA). METHODS Our analysis included all adult patients who were randomized to placebo in the SIROCCO and CALIMA phase III benralizumab studies. Patients were categorized into baseline BEC groups of less than 150 cells/μL, greater than or equal to 150 cells/μL but less than 300 cells/μL, and greater than or equal to 300 cells/μL. The timing of the initial shift from baseline to a different group was evaluated at weeks 4, 8, 24, and 40 and at the end of treatment. Baseline characteristics, including oral corticosteroid use, were described based on the presence or absence of a BEC group shift. RESULTS Of the 734 evaluable patients, 65% (n = 474) shifted BEC groups during the study, and most patients (86% [n = 410]) shifted by week 24. Patients who started in the less than 150 cells/μL group tended to shift groups earlier, with 59% shifting by week 4 compared with 38% to 55% for other groups in the same time frame. Patients who shifted BEC groups vs those who did not tend to have lower BECs, more oral corticosteroid use, and less incidence of nasal polyps or past polypectomy. CONCLUSION A single BEC measurement, particularly when low, may be inadequate to help establish a phenotype of severe eosinophilic asthma. TRIAL REGISTRATION ClinicalTrials.gov Identifiers NCT01928771 (SIROCCO trial) and NCT01914757 (CALIMA trial).",2020,"Patients who shifted blood eosinophil count groups vs. those who did not tended to have lower blood eosinophil counts, more OCS use, and less incidence of nasal polyps/past polypectomy. ","['patients with severe, uncontrolled asthma receiving', 'patients with characteristics of severe eosinophilic asthma', '734 evaluable patients, 65% (n=474) shifted blood eosinophil count groups during the study, and the majority (86% [n=410]) shifted by Week 24']",['placebo'],"['incidence of nasal polyps/past polypectomy', 'blood eosinophil counts']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0034068', 'cui_str': 'Eosinophilic asthma'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}]",734.0,0.0497634,"Patients who shifted blood eosinophil count groups vs. those who did not tended to have lower blood eosinophil counts, more OCS use, and less incidence of nasal polyps/past polypectomy. ","[{'ForeName': 'Njira L', 'Initials': 'NL', 'LastName': 'Lugogo', 'Affiliation': 'University of Michigan Medical Center, Ann Arbor, Michigan. Electronic address: nlugogo@med.umich.edu.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Kreindler', 'Affiliation': 'AstraZeneca, Wilmington, Delaware.'}, {'ForeName': 'Ubaldo J', 'Initials': 'UJ', 'LastName': 'Martin', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Cook', 'Affiliation': 'AstraZeneca, Wilmington, Delaware.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Hirsch', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Trudo', 'Affiliation': 'AstraZeneca, Wilmington, Delaware.'}]","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",['10.1016/j.anai.2020.04.011'] 108,32187464,A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.,"BACKGROUND No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao 2 ) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao 2 ) to the fraction of inspired oxygen (Fio 2 ) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).",2020,"Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).","['Adults Hospitalized with Severe Covid-19', 'hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao 2 ) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao 2 ) to the fraction of inspired oxygen (Fio 2 ) of less than 300 mm Hg', '199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the', 'patients with severe illness']","['lopinavir-ritonavir', 'Lopinavir-ritonavir', 'Lopinavir-Ritonavir']","['Gastrointestinal adverse events', 'serious adverse events', 'time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first', 'Mortality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'TS-COV19'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0428167', 'cui_str': 'FIO2'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0222045'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",199.0,0.162561,"Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72).","[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yeming', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Danning', 'Initials': 'D', 'LastName': 'Wen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jingli', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Guohui', 'Initials': 'G', 'LastName': 'Fan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lianguo', 'Initials': 'L', 'LastName': 'Ruan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Song', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Wei', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xingwang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jiaan', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Nanshan', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Xiang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Bai', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xuelei', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Caihong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Huadong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hanping', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shengjing', 'Initials': 'S', 'LastName': 'Tu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fengyun', 'Initials': 'F', 'LastName': 'Gong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chongya', 'Initials': 'C', 'LastName': 'Dong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Gu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jiuyang', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Zhibo', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lianhan', 'Initials': 'L', 'LastName': 'Shang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Kunxia', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Zhaohui', 'Initials': 'Z', 'LastName': 'Qu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Sixia', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xujuan', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shunan', 'Initials': 'S', 'LastName': 'Ruan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Peng', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Cheng', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Lihong', 'Initials': 'L', 'LastName': 'Pan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chunmin', 'Initials': 'C', 'LastName': 'Jia', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Shuzhen', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Xudong', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Ge', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Zhan', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Qiu', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chaolin', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Jaki', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Frederick G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Horby', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Dingyu', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'From the Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases (B.C., Yeming Wang, G.F., F.Z., X.G., Z.L., Y.Z., Hui Li, L.S., C.W.), and the Institute of Clinical Medical Sciences (G.F., X.G.), China-Japan Friendship Hospital, the Institute of Respiratory Medicine, Chinese Academy of Medical Sciences (B.C., Yeming Wang, F.Z., Z.L., Y.Z., Hui Li, C.W.), the Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University (Xingwang Li), Peking University Clinical Research Institute, Peking University First Hospital (C.D.), Tsinghua University School of Medicine (Jiuyang Xu), Beijing University of Chinese Medicine (L.S.), NHC Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (L.G.), and Peking Union Medical College (L.G., C.W.), Beijing, and Jin Yin-tan Hospital, Wuhan (D.W., W.L., Jingli Wang, L.R., B.S., Y.C., M.W., Jiaan Xia, N.C., Jie Xiang, T.Y., T.B., X.X., L.Z., C.L., Y.Y., H.C., Huadong Li, H.H., S.T., F.G., Y.L., Yuan Wei, K.W., K.L., X.Z., X.D., Z.Q., Sixia Lu, X.H., S.R., Shanshan Luo, Jing Wu, Lu Peng, F.C., Lihong Pan, J.Z., C.J., Juan Wang, Xia Liu, S.W., X.W., Q.G., J.H., H.Z., F.Q., C.H., D.Z.) - all in China; Lancaster University, Lancaster (T.J.), and the University of Oxford, Oxford (P.W.H.) - both in the United Kingdom; and the University of Virginia School of Medicine, Charlottesville (F.G.H.).'}]",The New England journal of medicine,['10.1056/NEJMoa2001282'] 109,32194219,Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study.,"AIM This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D). METHODS This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment. RESULTS A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group but not in the non-sitagliptin group. Serum TG and total, LDL and HDL cholesterol levels did not change in either group. Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group. The change in urinary albumin was significantly different between the groups with a preferable change in the sitagliptin group. There were no changes in serum sterols levels in the two groups. CONCLUSIONS The treatment of sitagliptin for 6 months improves the metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins in patients with T2D.",2020,"Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group.","['patients with T2D', '164 patients completed the 6-month observation (n=81 for sitagliptin and n=83 for non-sitagliptin', 'Type 2 Diabetes', 'T2D patients with HbA1c 6.9-8.9% (52-74 mmol/mol) who were under treatment with sulfonylurea', 'patients with type 2 diabetes mellitus (T2D']","['dipeptidyl peptidase-4 inhibitors', 'sitagliptin group or the non-sitagliptin group', 'Sitagliptin']","['Apo B-48, apo CII, and apo CIII levels', 'change in urinary albumin', 'HbA1c', 'serum sterols levels', 'metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins', 'lipid metabolism', 'Plasma Apolipoprotein Profile', 'Serum TG and total, LDL and HDL cholesterol levels', 'Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C4517826', 'cui_str': 'Six point nine'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea Compounds'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0103839', 'cui_str': 'Chylomicron Apo B'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0038323', 'cui_str': 'Sterols'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0008731', 'cui_str': 'Chylomicrons'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0523476', 'cui_str': 'Apolipoprotein measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",164.0,0.028987,"Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group.","[{'ForeName': 'Kyoko', 'Initials': 'K', 'LastName': 'Tanimura-Inagaki', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Mototsugu', 'Initials': 'M', 'LastName': 'Nagao', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Harada', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Sugihara', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Shigeki', 'Initials': 'S', 'LastName': 'Moritani', 'Affiliation': 'Moritani Clinic, Tokyo, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Sasaki', 'Affiliation': 'International University of Health and Welfare, Fukuoka, Japan.'}, {'ForeName': 'Suminori', 'Initials': 'S', 'LastName': 'Kono', 'Affiliation': 'MedStatCorporation, Fukuoka, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Oikawa', 'Affiliation': 'Department of Endocrinology, Diabetes and Metabolism, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan; Fukujuji Hospital, Tokyo, Japan. Electronic address: shinichi@nms.ac.jp.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108119'] 110,31982170,Evaluation of the efficacy of postoperative antibiotic treatment in transoral endoscopic thyroidectomy: a prospective randomised controlled trial.,"Transoral endoscopic thyroid surgery (TOET) is a new, minimally-invasive approach that does not result in a scar in the anterior neck. To prevent infection of the surgical site from oral cavity flora into the thyroidectomy area, postoperative antibiotics are generally given orally for 3-7 days. However, there is no clinical evidence to support this approach. This study was an open-label, randomised, controlled trial to evaluate the clinical usefulness of postoperative antibiotics given orally to patients having TOET. Patients were randomly assigned to receive amoxicillin-clavulanate 625mg orally three times a day for a week after operation (treated group) or no antibiotics (untreated group). Fifty patients - 25 treated and 25 untreated - were enrolled. Maximum body temperature, pulse rate, white blood cell count, and C-reactive protein concentrations did not differ between the two groups. Evaluation of the surgical site showed no significant differences between them. Seven patients in the treated group developed nausea, vomiting, and diarrhoea compared with none in the untreated group. The results suggest that postoperative oral antibiotics are not essential after TOET. Large-scale prospective series are required to confirm this finding.",2020,"Maximum body temperature, pulse rate, white blood cell count, and C-reactive protein concentrations did not differ between the two groups.","['Fifty patients - 25 treated and 25 untreated - were enrolled', 'transoral endoscopic thyroidectomy', 'patients having TOET']","['Transoral endoscopic thyroid surgery (TOET', 'postoperative antibiotic treatment', 'amoxicillin-clavulanate 625mg orally three times a day for a week after operation (treated group) or no antibiotics', 'postoperative antibiotics']","['Maximum body temperature, pulse rate, white blood cell count, and C-reactive protein concentrations', 'nausea, vomiting, and diarrhoea']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach (qualifier value)'}, {'cui': 'C0040145', 'cui_str': 'Thyroidectomy'}]","[{'cui': 'C0442366', 'cui_str': 'Transoral approach (qualifier value)'}, {'cui': 'C0040134', 'cui_str': 'thyroid (USP)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0110038', 'cui_str': 'Clavulanate'}, {'cui': 'C4517838', 'cui_str': 'Six hundred and twenty-five'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0232117', 'cui_str': 'Pulse Rate'}, {'cui': 'C0023508', 'cui_str': 'Blood Cell Count, White'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.0480307,"Maximum body temperature, pulse rate, white blood cell count, and C-reactive protein concentrations did not differ between the two groups.","[{'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Yi', 'Affiliation': 'Department of Surgery, Inha University Hospital, Incheon, Republic of Korea; Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address: gnsljw@gmail.com.'}, {'ForeName': 'S-J', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'K E', 'Initials': 'KE', 'LastName': 'Lee', 'Affiliation': 'Department of Surgery, Seoul National University Hospital, Seoul, Republic of Korea.'}]",The British journal of oral & maxillofacial surgery,['10.1016/j.bjoms.2020.01.004'] 111,31654654,Acute consumption of flavanol-rich cocoa beverage improves attenuated cutaneous microvascular function in healthy young African Americans.,"Flavanols have beneficial effects on vascular health and we have recently demonstrated that cerebral vasodilatory capacity in healthy young African Americans (AA) is improved with acute flavanol intake relative to aged-matched Caucasian Americans (CA). However, whether the positive benefits of acute flavanol consumption would also be present in the cutaneous microvascular circulation of AA remains unknown. Thus, we hypothesized that acute consumption of flavanol-rich cocoa (FC) would improve the previously reported reduced cutaneous microvascular responses to local heating in young AA. Seven AA and seven CA participated in this double-blind crossover study. Data were collected on two different days, separated by a minimum of one week. Two intradermal microdialysis membranes were inserted in the forearm and each site was randomly assigned to receive lactated Ringer's solution or NO synthase (NOS) inhibitor. Participants were randomly assigned to consume either a non-flavanol containing (NF) beverage or FC beverage. Cutaneous vascular conductance (CVC) was calculated as cutaneous blood flux/mean arterial pressure and normalized as % maximal CVC (%CVCmax). The difference in %CVCmax between the Ringer's site and NOS inhibited site was calculated to assess NO contribution (Δ %CVCmax). In the Ringer's site, acute consumption of FC beverage improved %CVCmax during 39 °C heating when compared to NF beverage in AA (NF: 36 ± 6 vs. FC: 47 ± 5%CVCmax; P < .01) while there was similar %CVCmax during 39 °C heating between beverages in CA (NF: 55 ± 4 vs. FC: 59 ± 5%CVCmax; P = .40). During 39 °C heating, NO contribution was significantly higher with FC beverage than NF beverage in AA (NF: 27 ± 5 vs. FC: 35 ± 4 Δ %CVCmax; P = .03) while there was similar NO contribution between beverages in CA (NF: 42 ± 4 vs. FC: 45 ± 4 Δ %CVCmax; P = .36). This data suggests that acute consumption of FC could be a therapeutic solution to improve an attenuated microvascular function in young AA.",2020,"During 39 °C heating, NO contribution was significantly higher with FC beverage than NF beverage in AA (NF: 27 ± 5 vs. FC: 35 ± 4 Δ %CVCmax; P = .03) while there was similar NO contribution between beverages in CA (NF: 42 ± 4 vs. FC: 45 ± 4 Δ %CVCmax; P = .36).","['aged-matched Caucasian Americans (CA', 'healthy young African Americans', 'healthy young African Americans (AA']","['flavanol-rich cocoa (FC', 'flavanol-rich cocoa beverage', 'non-flavanol containing (NF) beverage or FC beverage', ""lactated Ringer's solution or NO synthase (NOS) inhibitor""]","['Cutaneous vascular conductance (CVC', 'acute consumption of FC beverage improved %CVCmax', 'cutaneous microvascular function']","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C4521844', 'cui_str': 'Cocoa'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0073385', 'cui_str': ""Hartmann's Solution""}, {'cui': 'C0132555', 'cui_str': 'Nitric Oxide Synthase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.152353,"During 39 °C heating, NO contribution was significantly higher with FC beverage than NF beverage in AA (NF: 27 ± 5 vs. FC: 35 ± 4 Δ %CVCmax; P = .03) while there was similar NO contribution between beverages in CA (NF: 42 ± 4 vs. FC: 45 ± 4 Δ %CVCmax; P = .36).","[{'ForeName': 'Kiyoung', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Department of Pharmacology & Experimental Therapeutics and the Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA, United States of America.'}, {'ForeName': 'R Matthew', 'Initials': 'RM', 'LastName': 'Brothers', 'Affiliation': 'Department of Kinesiology, The University of Texas at Arlington, Arlington, TX, United States of America. Electronic address: matthew.brothers@uta.edu.'}]",Microvascular research,['10.1016/j.mvr.2019.103931'] 112,31981518,Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study.,"BACKGROUND Colonoscopy performance varies among endoscopists, impairing the discovery of colorectal cancers and precursor lesions. We aimed to construct a real-time quality improvement system (ENDOANGEL) to monitor real-time withdrawal speed and colonoscopy withdrawal time and to remind endoscopists of blind spots caused by endoscope slipping. We also aimed to evaluate the effectiveness of this system for improving adenoma yield of everyday colonoscopy. METHODS The ENDOANGEL system was developed using deep neural networks and perceptual hash algorithms. We recruited consecutive patients aged 18-75 years from Renmin Hospital of Wuhan University in China who provided written informed consent. We randomly assigned patients (1:1) using computer-generated random numbers and block randomisation (block size of four) to either colonoscopy with the ENDOANGEL system or unassisted colonoscopy (control). Endoscopists were not masked to the random assignment but analysts and patients were unaware of random assignments. The primary endpoint was the adenoma detection rate (ADR), which is the proportion of patients having one or more adenomas detected at colonoscopy. The primary analysis was done per protocol (ie, in all patients having colonoscopy done in accordance with the assigned intervention) and by intention to treat (ie, in all randomised patients). This trial is registered with http://www.chictr.org.cn, ChiCTR1900021984. FINDINGS Between June 18, 2019, and Sept 6, 2019, 704 patients were randomly allocated colonoscopy with the ENDOANGEL system (n=355) or unassisted (control) colonoscopy (n=349). In the intention-to-treat population, ADR was significantly greater in the ENDOANGEL group than in the control group, with 58 (16%) of 355 patients allocated ENDOANGEL-assisted colonoscopy having one or more adenomas detected, compared with 27 (8%) of 349 allocated control colonoscopy (odds ratio [OR] 2·30, 95% CI 1·40-3·77; p=0·0010). In the per-protocol analysis, findings were similar, with 54 (17%) of 324 patients assigned ENDOANGEL-assisted colonoscopy and 26 (8%) of 318 patients assigned control colonoscopy having one or more adenomas detected (OR 2·18, 95% CI 1·31-3·62; p=0·0026). No adverse events were reported. INTERPRETATION The ENDOANGEL system significantly improved the adenoma yield during colonoscopy and seems to be effective and safe for use during routine colonoscopy. FUNDING Hubei Provincial Clinical Research Center for Digestive Disease Minimally Invasive Incision, Hubei Province Major Science and Technology Innovation Project, and the National Natural Science Foundation of China.",2020,"The ENDOANGEL system significantly improved the adenoma yield during colonoscopy and seems to be effective and safe for use during routine colonoscopy. ","['Between June 18, 2019, and Sept 6, 2019, 704 patients were randomly allocated colonoscopy with the ENDOANGEL system (n=355) or unassisted (control) colonoscopy (n=349', 'consecutive patients aged 18-75 years from Renmin Hospital of Wuhan University in China who provided written informed consent']","['endoscope slipping', 'real-time computer-aided system', 'computer-generated random numbers and block randomisation (block size of four) to either colonoscopy with the ENDOANGEL system or unassisted colonoscopy (control']","['adenoma detection rate (ADR), which is the proportion of patients having one or more adenomas detected at colonoscopy', 'adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}]","[{'cui': 'C0014243', 'cui_str': 'Endoscopes'}, {'cui': 'C0337209', 'cui_str': 'Slipping (event)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",704.0,0.14788,"The ENDOANGEL system significantly improved the adenoma yield during colonoscopy and seems to be effective and safe for use during routine colonoscopy. ","[{'ForeName': 'Dexin', 'Initials': 'D', 'LastName': 'Gong', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Lianlian', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Ganggang', 'Initials': 'G', 'LastName': 'Mu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Hubei Provincial Clinical Research Center for Digestive Disease Minimally Invasive Incision, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Zhengqiang', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'An', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xiaoda', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Yanxia', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xinyue', 'Initials': 'X', 'LastName': 'Wan', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'School of Resource and Environmental Sciences, Wuhan University, Wuhan, China.'}, {'ForeName': 'Yiyun', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'School of Resource and Environmental Sciences, Wuhan University, Wuhan, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'School of Resource and Environmental Sciences, Wuhan University, Wuhan, China.'}, {'ForeName': 'Youming', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xiaoyun', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Suqin', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Liwen', 'Initials': 'L', 'LastName': 'Yao', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xinqi', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': 'Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Xuemei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'ForeName': 'Honggang', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China. Electronic address: yuhonggang1968@163.com.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30413-3'] 113,32145674,"A double-blind, randomized, sham-controlled study of cranial electrotherapy stimulation as an add-on treatment for tic disorders in children and adolescents.","AIM The aim of this study was to determine the efficacy and safety of cranial electrotherapy stimulation (CES) as an add-on treatment for TD. METHODS A randomized, double-blind, sham-controlled trial was conducted at an outpatient, single-center academic setting. A total of 62 patients aged 6-17 years with TD and lack of clinical response to 4 weeks' pharmacotherapy were enrolled. Patients were divided randomly into 2 groups and given 4 weeks' treatment, including 30 min sessions of active CES (500 μA-2 mA) or sham CES (lower than 100 μA) per day for 40 d on weekdays. Change in Yale Global Tic Severity Scale (YGTSS), Clinical Global Impression-severity of illness-severity (CGI-S) and Hamilton Anxiety Scale-14 items (HAMA-14) were performed at baseline, week 2, week 4. Adverse events (AEs) were also evaluated. RESULTS 53 patients (34 males and 9 females) completed the trial, including 29 in the active CES group and 24 in the sham CES group. Both groups showed clinical improvement in tic severities compared to baseline respectively at week 4. Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). CONCLUSION Four-week's treatment of CES for children and adolescents with TD is effective and safe, but the improvement for tic severity may be related to placebo effect.",2020,"Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). ","[""62 patients aged 6-17 years with TD and lack of clinical response to 4 weeks' pharmacotherapy were enrolled"", 'tic disorders in children and adolescents', '53 patients (34 males and 9 females) completed the trial, including 29 in the active CES group and 24 in the sham CES group']","['cranial electrotherapy stimulation', 'active CES', 'cranial electrotherapy stimulation (CES', 'active CES (500\u2009μA-2\u2009mA) or sham CES']","['clinical improvement in tic severities', 'Yale Global Tic Severity Scale (YGTSS), Clinical Global Impression-severity of illness-severity (CGI-S) and Hamilton Anxiety', 'efficacy and safety', 'Adverse events (AEs', 'YGTSS score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332268', 'cui_str': 'Lacking (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0040188', 'cui_str': 'Tic disorder (disorder)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C3163632', 'cui_str': 'Cranial'}, {'cui': 'C0013787', 'cui_str': 'Electrical Stimulation Therapy'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0278076', 'cui_str': 'Habit Chorea'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C4720888', 'cui_str': 'Yale global tic severity scale (assessment scale)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",62.0,0.38816,"Participants receiving active CES showed a reduction of 31.66 % in YGTSS score, compared with 23.96 % in participants in sham CES group, resulting in no significant difference between the two groups (t = 1.54, p = 0.13). ","[{'ForeName': 'Wen-Jun', 'Initials': 'WJ', 'LastName': 'Wu', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: wenjun104@126.com.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: fgx995@163.com.""}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Cai', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: caimin@fmmu.edu.cn.""}, {'ForeName': 'Yi-Huan', 'Initials': 'YH', 'LastName': 'Chen', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: 182368179@qq.com.""}, {'ForeName': 'Cui-Hong', 'Initials': 'CH', 'LastName': 'Zhou', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: zch4610@126.com.""}, {'ForeName': 'Hua-Ning', 'Initials': 'HN', 'LastName': 'Wang', 'Affiliation': ""Department of Psychiatry, Xijing Hospital, Fourth Military Medical University, 127# West Changle Road, Xi'an, 710032, China. Electronic address: xskzhu@fmmu.edu.cn.""}, {'ForeName': 'Long-Biao', 'Initials': 'LB', 'LastName': 'Cui', 'Affiliation': ""Department of Clinical Psychology, School of Medical Psychology, Fourth Military Medical University, 169 # West Changle Road, Xi'an, 710032, China. Electronic address: lbcui@fmmu.edu.cn.""}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.101992'] 114,31025714,Interventions for hand eczema.,"BACKGROUND Hand eczema is an inflammation of the skin of the hands that tends to run a chronic, relapsing course. This common condition is often associated with itch, social stigma, and impairment in employment. Many different interventions of unknown effectiveness are used to treat hand eczema. OBJECTIVES To assess the effects of topical and systemic interventions for hand eczema in adults and children. SEARCH METHODS We searched the following up to April 2018: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, AMED, LILACS, GREAT, and four trials registries. We checked the reference lists of included studies for further references to relevant trials. SELECTION CRITERIA We included randomised controlled trials (RCTs) that compared interventions for hand eczema, regardless of hand eczema type and other affected sites, versus no treatment, placebo, vehicle, or active treatments. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. Primary outcomes were participant- and investigator-rated good/excellent control of symptoms, and adverse events. MAIN RESULTS We included 60 RCTs, conducted in secondary care (5469 participants with mild to severe chronic hand eczema). Most participants were over 18 years old. The duration of treatment was short, generally up to four months. Only 24 studies included a follow-up period. Clinical heterogeneity in treatments and outcome measures was evident. Few studies performed head-to-head comparisons of different interventions. Risk of bias varied considerably, with only five studies at low risk in all domains. Twenty-two studies were industry-funded.Eighteen trials studied topical corticosteroids or calcineurin inhibitors; 10 studies, phototherapy; three studies, systemic immunosuppressives; and five studies, oral retinoids. Most studies compared an active intervention against no treatment, variants of the same medication, or placebo (or vehicle). Below, we present results from the main comparisons.Corticosteroid creams/ointments: when assessed 15 days after the start of treatment, clobetasol propionate 0.05% foam probably improves participant-rated control of symptoms compared to vehicle (risk ratio (RR) 2.32, 95% confidence interval (CI) 1.38 to 3.91; number needed to treat for an additional beneficial outcome (NNTB) 3, 95% CI 2 to 8; 1 study, 125 participants); the effect of clobetasol compared to vehicle for investigator-rated improvement is less clear (RR 1.43, 95% CI 0.86 to 2.40). More participants had at least one adverse event with clobetasol (11/62 versus 5/63; RR 2.24, 95% CI 0.82 to 6.06), including application site burning/pruritus. This evidence was rated as moderate certainty.When assessed 36 weeks after the start of treatment, mometasone furoate cream used thrice weekly may slightly improve investigator-rated symptom control compared to twice weekly (RR 1.23, 95% CI 0.94 to 1.61; 1 study, 72 participants) after remission is reached. Participant-rated symptoms were not measured. Some mild atrophy was reported in both groups (RR 1.76, 95% CI 0.45 to 6.83; 5/35 versus 3/37). This evidence was rated as low certainty.Irradiation with ultraviolet (UV) light: local combination ultraviolet light therapy (PUVA) may lead to improvement in investigator-rated symptom control when compared to local narrow-band UVB after 12 weeks of treatment (RR 0.50, 95% CI 0.22 to 1.16; 1 study, 60 participants). However, the 95% CI indicates that PUVA might make little or no difference. Participant-rated symptoms were not measured. Adverse events (mainly erythema) were reported by 9/30 participants in the narrow-band UVB group versus none in the PUVA group. This evidence was rated as moderate certainty.Topical calcineurin inhibitors: tacrolimus 0.1% over two weeks probably improves investigator-rated symptom control measured after three weeks compared to vehicle (14/14 tacrolimus versus 0/14 vehicle; 1 study). Participant-rated symptoms were not measured. Four of 14 people in the tacrolimus group versus zero in the vehicle group had well-tolerated application site burning/itching.A within-participant study in 16 participants compared 0.1% tacrolimus to 0.1% mometasone furoate but did not measure investigator- or participant-rated symptoms. Both treatments were well tolerated when assessed at two weeks during four weeks of treatment.Evidence from these studies was rated as moderate certainty.Oral interventions: oral cyclosporin 3 mg/kg/d probably slightly improves investigator-rated (RR 1.88, 95% CI 0.88 to 3.99; 1 study, 34 participants) or participant-rated (RR 1.25, 95% CI 0.69 to 2.27) control of symptoms compared to topical betamethasone dipropionate 0.05% after six weeks of treatment. The risk of adverse events such as dizziness was similar between groups (up to 36 weeks; RR 1.22, 95% CI 0.80 to 1.86, n = 55; 15/27 betamethasone versus 19/28 cyclosporin). The evidence was rated as moderate certainty.Alitretinoin 10 mg improves investigator-rated symptom control compared with placebo (RR 1.58, 95% CI 1.20 to 2.07; NNTB 11, 95% CI 6.3 to 26.5; 2 studies, n = 781) and alitretinoin 30 mg also improves this outcome compared with placebo (RR 2.75, 95% CI 2.20 to 3.43; NNTB 4, 95% CI 3 to 5; 2 studies, n = 1210). Similar results were found for participant-rated symptom control: alitretinoin 10 mg RR 1.73 (95% CI 1.25 to 2.40) and 30 mg RR 2.75 (95% CI 2.18 to 3.48). Evidence was rated as high certainty. The number of adverse events (including headache) probably did not differ between alitretinoin 10 mg and placebo (RR 1.01, 95% CI 0.66 to 1.55; 1 study, n = 158; moderate-certainty evidence), but the risk of headache increased with alitretinoin 30 mg (RR 3.43, 95% CI 2.45 to 4.81; 2 studies, n = 1210; high-certainty evidence). Outcomes were assessed between 48 and 72 weeks. AUTHORS' CONCLUSIONS Most findings were from single studies with low precision, so they should be interpreted with caution. Topical corticosteroids and UV phototherapy were two of the major standard treatments, but evidence is insufficient to support one specific treatment over another. The effect of topical calcineurin inhibitors is not certain. Alitretinoin is more effective than placebo in controlling symptoms, but advantages over other treatments need evaluating.Well-designed and well-reported, long-term (more than three months), head-to-head studies comparing different treatments are needed. Consensus is required regarding the definition of hand eczema and its subtypes, and a standard severity scale should be established.The main limitation was heterogeneity between studies. Small sample size impacted our ability to detect differences between treatments.",2019,"Alitretinoin 10 mg improves investigator-rated symptom control compared with placebo (RR 1.58, 95% CI 1.20 to 2.07; NNTB 11, 95% CI 6.3 to 26.5; 2 studies, n = 781) and alitretinoin 30 mg also improves this outcome compared with placebo (RR 2.75, 95% CI 2.20 to 3.43; NNTB 4, 95% CI 3 to 5; 2 studies, n = 1210).","['More participants had at least one adverse event with clobetasol (11/62 versus 5/63', 'hand eczema in adults and children', 'Twenty-two studies were industry-funded', 'Most participants were over 18 years old', '5469 participants with mild to severe chronic hand eczema']","['PUVA', 'betamethasone', 'mometasone furoate cream', 'placebo', 'topical and systemic interventions', 'placebo, vehicle, or active treatments', 'Topical calcineurin inhibitors: tacrolimus', 'cyclosporin', 'Irradiation with ultraviolet (UV) light: local combination ultraviolet light therapy (PUVA', 'Alitretinoin', 'tacrolimus', 'topical betamethasone dipropionate', 'tacrolimus to 0.1% mometasone furoate', 'Corticosteroid creams/ointments', 'topical corticosteroids or calcineurin inhibitors', 'Topical corticosteroids and UV phototherapy', 'topical calcineurin inhibitors']","['Adverse events (mainly erythema', 'tolerated', 'number of adverse events (including headache', 'well-tolerated application site burning/itching', 'investigator-rated symptom control', 'investigator- or participant-rated symptoms', 'investigator-rated', 'risk of adverse events such as dizziness', 'risk of headache', 'mild atrophy', 'application site burning/pruritus', 'participant- and investigator-rated good/excellent control of symptoms, and adverse events']","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0008992', 'cui_str': 'Clobetasol'}, {'cui': 'C0239816', 'cui_str': 'Hand eczema (disorder)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0021267', 'cui_str': 'Industry'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1276092', 'cui_str': 'Chronic hand eczema'}]","[{'cui': 'C0853073', 'cui_str': 'PUVA'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0066700', 'cui_str': 'mometasone furoate'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4521884', 'cui_str': 'Calcineurin inhibitor (disposition)'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0010594', 'cui_str': 'Cyclosporins'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}, {'cui': 'C0041625', 'cui_str': 'Ultraviolet Light'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0041626', 'cui_str': 'Actinotherapy'}, {'cui': 'C0281666', 'cui_str': 'alitretinoin'}, {'cui': 'C0053523', 'cui_str': 'betamethasone dipropionate'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0028912', 'cui_str': 'Salves'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0877661', 'cui_str': 'Application site burn'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C1274136', 'cui_str': 'Symptom control'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C1961136', 'cui_str': 'Excellent (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",5469.0,0.575728,"Alitretinoin 10 mg improves investigator-rated symptom control compared with placebo (RR 1.58, 95% CI 1.20 to 2.07; NNTB 11, 95% CI 6.3 to 26.5; 2 studies, n = 781) and alitretinoin 30 mg also improves this outcome compared with placebo (RR 2.75, 95% CI 2.20 to 3.43; NNTB 4, 95% CI 3 to 5; 2 studies, n = 1210).","[{'ForeName': 'Wietske Andrea', 'Initials': 'WA', 'LastName': 'Christoffers', 'Affiliation': 'Department of Dermatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, Groningen, Netherlands, 9700RB.'}, {'ForeName': 'Pieter-Jan', 'Initials': 'PJ', 'LastName': 'Coenraads', 'Affiliation': ''}, {'ForeName': 'Åke', 'Initials': 'Å', 'LastName': 'Svensson', 'Affiliation': ''}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Diepgen', 'Affiliation': ''}, {'ForeName': 'Janine L', 'Initials': 'JL', 'LastName': 'Dickinson-Blok', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xia', 'Affiliation': ''}, {'ForeName': 'Hywel C', 'Initials': 'HC', 'LastName': 'Williams', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD004055.pub2'] 115,32249950,"Efficacy of electrical stimulation of denervated muscle: A multicenter, double-blind, randomized clinical trial.","BACKGROUND This was a multicenter, double-blind, randomized clinical trial to investigate the efficacy of electrical stimulation of denervated muscle (ESDM) on recovery of patients with peripheral nerve injuries. METHODS We enrolled 38 patients with traumatic peripheral nerve injuries with axonal damage and clinical impairment of two muscles, who were randomly treated with real or sham electrical stimulation (ES). Clinical and neurophysiological examinations were performed before treatment, at the end of treatment, and 3 mo posttreatment, by the same physician who was blinded to the ES allocation. RESULTS All patients improved but there was no significant beneficial effect of ESDM compared with sham treatment. CONCLUSIONS This study failed to demonstrate the efficacy of ESDM for peripheral nerve injuries. However, given the large number of variables related to ES and the heterogeneity in disease etiologies and clinical manifestations, future studies on homogeneous populations using different stimulation protocols may be useful.",2020,"All patients improved but there was no significant beneficial effect of ESDM compared to sham treatment. ","['denervated muscle', 'patients with peripheral nerve injuries', '38 patients with traumatic peripheral nerve injuries with axonal damage and clinical impairment of two muscles, who were randomly treated with']","['ESDM', 'electrical stimulation', 'electrical stimulation of denervated muscle (ESDM', 'real or sham electrical stimulation (ES']",[],"[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0262593', 'cui_str': 'Injury of peripheral nerve'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]",[],38.0,0.408084,"All patients improved but there was no significant beneficial effect of ESDM compared to sham treatment. ","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Piccinini', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cuccagna', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Caliandro', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Coraci', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Germanotta', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.'}, {'ForeName': 'Cristiano', 'Initials': 'C', 'LastName': 'Pecchioli', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Taly.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Padua', 'Affiliation': 'Fondazione Policlinico Universitario A, Gemelli IRCCS, Rome, Italy.'}]",Muscle & nerve,['10.1002/mus.26880'] 116,31586170,Comment on: A trial of a mechanical device for the treatment of blepharospasm.,,2020,,[],['mechanical device'],[],[],"[{'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",[],,0.0269564,,"[{'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Go', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.'}, {'ForeName': 'Ashley N', 'Initials': 'AN', 'LastName': 'Anderson', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.'}, {'ForeName': 'Ashwini', 'Initials': 'A', 'LastName': 'Kini', 'Affiliation': 'Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 6550 Fannin St, Houston, TX, 77030, USA.'}, {'ForeName': 'Bayan', 'Initials': 'B', 'LastName': 'Al Othman', 'Affiliation': 'Department of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, 6550 Fannin St, Houston, TX, 77030, USA.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Lee', 'Affiliation': 'Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. aglee@houstonmethodist.org.'}]","Eye (London, England)",['10.1038/s41433-019-0621-x'] 117,31613390,Fluoxetine for adults who are overweight or obese.,"BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression. It is also thought to affect weight control: this seems to happen through appetite changes resulting in decreased food intake and normalisation of unusual eating behaviours. However, the benefit-risk ratio of this off-label medication is unclear. OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults. SEARCH METHODS We searched the Cochrane Library, MEDLINE, Embase, LILACS, the ICTRP Search Portal and ClinicalTrials.gov and World Health Organization (WHO) ICTRP Search Portal. The last date of the search was December 2018 for all databases, to which we applied no language restrictions . SELECTION CRITERIA We included randomised controlled trials (RCTs) comparing the administration of fluoxetine versus placebo, other anti-obesity agents, non-pharmacological therapy or no treatment in overweight or obese adults without depression, mental illness or abnormal eating patterns. DATA COLLECTION AND ANALYSIS Two review authors independently screened abstracts and titles for relevance. Screening for inclusion, data extraction and risk of bias assessment was performed by one author and checked by the second. We assessed trials for the overall certainty of the evidence using the GRADE instrument. For additional information we contacted trial authors by email. We performed random-effects meta-analyses and calculated the risk ratio (RR) with 95% confidence intervals (95% CI) for dichotomous outcomes and the mean difference (MD) with 95% CI for continuous outcomes. MAIN RESULTS We identified 1036 records, scrutinized 52 full-text articles and included 19 completed RCTs (one trial is awaiting assessment). A total of 2216 participants entered the trials, 1280 participants were randomly assigned to fluoxetine (60 mg/d, 40 mg/d, 20 mg/d and 10 mg/d) and 936 participants were randomly assigned to various comparison groups (placebo; the anti-obesity agents diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine, fluvoxamine, 5-hydroxy-tryptophan; no treatment; and omega-3 gel). Within the 19 RCTs there were 56 trial arms. Fifteen trials were parallel RCTs and four were cross-over RCTs. The participants in the included trials were followed up for periods between three weeks and one year. The certainty of the evidence was low or very low: the majority of trials had a high risk of bias in one or more of the risk of bias domains.For our main comparison group - fluoxetine versus placebo - and across all fluoxetine dosages and durations of treatment, the MD was -2.7 kg (95% CI -4 to -1.4; P < 0.001; 10 trials, 956 participants; low-certainty evidence). The 95% prediction interval ranged between -7.1 kg and 1.7 kg. The MD in body mass index (BMI) reduction across all fluoxetine dosages compared with placebo was -1.1 kg/m² (95% CI -3.7 to 1.4; 3 trials, 97 participants; very low certainty evidence). Only nine placebo-controlled trials reported adverse events. A total of 399 out of 627 participants (63.6%) receiving fluoxetine compared with 352 out of 626 participants (56.2%) receiving placebo experienced an adverse event. Random-effects meta-analysis showed an increase in the risk of having at least one adverse event of any type in the fluoxetine groups compared with placebo (RR 1.18, 95% CI 0.99 to 1.42; P = 0.07; 9 trials, 1253 participants; low-certainty evidence). The 95% prediction interval ranged between 0.74 and 1.88. Following fluoxetine treatment the adverse events of dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often compared to placebo. A total of 15 out of 197 participants (7.6%) receiving fluoxetine compared with 12 out of 196 participants (6.1%) receiving placebo experienced depression. The RR across all fluoxetine doses compared with placebo was 1.20 (95% CI 0.57 to 2.52; P = 0.62; 3 trials, 393 participants; very low certainty evidence). All-cause mortality, health-related quality of life and socioeconomic effects were not reported.The comparisons of fluoxetine with other anti-obesity agents (3 trials, 234 participants), omega-3 gel (1 trial, 48 participants) and no treatment (1 trial, 60 participants) showed inconclusive results (very low certainty evidence). AUTHORS' CONCLUSIONS Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo. However, low-certainty evidence suggests an increase in the risk for dizziness, drowsiness, fatigue, insomnia and nausea following fluoxetine treatment.",2019,"Following fluoxetine treatment the adverse events of dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often compared to placebo.","['adults who are overweight or obese', 'overweight or obese adults without depression, mental illness or abnormal eating patterns', '936 participants', '2216 participants entered the trials, 1280 participants', 'overweight or obese adults', 'A total of 399 out of 627 participants (63.6%) receiving', '1036 records, scrutinized 52 full-text articles and included 19 completed RCTs (one trial is awaiting assessment', 'A total of 15 out of 197 participants (7.6%) receiving']","['fluoxetine with other anti-obesity agents', 'fluoxetine versus placebo, other anti-obesity agents, non-pharmacological therapy', 'omega-3 gel', 'placebo', 'fluoxetine', 'various comparison groups (placebo; the anti-obesity agents diethylpropion, fenproporex, mazindol, sibutramine, metformin, fenfluramine, dexfenfluramine, fluvoxamine, 5-hydroxy-tryptophan; no treatment; and omega-3 gel', 'Fluoxetine']","['adverse events of dizziness, drowsiness, fatigue, insomnia and nausea', 'adverse events', 'All-cause mortality, health-related quality of life and socioeconomic effects', 'adverse event', 'MD in body mass index (BMI) reduction', 'risk of having at least one adverse event', 'risk for dizziness, drowsiness, fatigue, insomnia and nausea']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0376607', 'cui_str': 'Antiobesity Agents'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0012201', 'cui_str': 'amfepramone'}, {'cui': 'C0060194', 'cui_str': 'fenproporex'}, {'cui': 'C0024977', 'cui_str': 'Mazindol'}, {'cui': 'C0074493', 'cui_str': 'sibutramine'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0015827', 'cui_str': 'Fenfluramine'}, {'cui': 'C0011786', 'cui_str': 'Dexfenfluramine'}, {'cui': 'C0085228', 'cui_str': 'Fluvoxamine'}, {'cui': 'C0000578', 'cui_str': '5-Hydroxytryptophan'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",52.0,0.39632,"Following fluoxetine treatment the adverse events of dizziness, drowsiness, fatigue, insomnia and nausea were observed approximately twice as often compared to placebo.","[{'ForeName': 'Aurora E', 'Initials': 'AE', 'LastName': 'Serralde-Zúñiga', 'Affiliation': 'Clinical Nutrition, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Sección XVI, Tlalpan, Mexico City, Distrito Federal, Mexico, 14000.'}, {'ForeName': 'Alejandro G', 'Initials': 'AG', 'LastName': 'Gonzalez Garay', 'Affiliation': ''}, {'ForeName': 'Yanelli', 'Initials': 'Y', 'LastName': 'Rodríguez-Carmona', 'Affiliation': ''}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Melendez', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011688.pub2'] 118,32000167,Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer.,"BACKGROUND Preoperative chemotherapy is important in the management of women with breast cancer, with the ability to downstage the breast primary tumor and axillary lymph nodes. Long-term studies are needed to identify late toxicities, recurrence patterns, and equivalency with postoperative chemotherapy for recurrence-free survival (RFS) and overall survival (OS). PATIENTS AND METHODS We conducted a single-institution prospective randomized control trial comparing preoperative or postoperative fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor chemotherapy for women with untreated clinical stage II (T1N1, T2N0, and T2N1) breast cancer. Long-term follow-up was conducted to define toxicities, recurrence patterns and RFS and OS. RESULTS Fifty-three women with clinical stage II breast cancer were randomized, 26 patients to receive preoperative chemotherapy and 27 to receive postoperative chemotherapy. Long-term follow-up, with a median of 25.3 years, was obtained. Local or systemic recurrence occurred in 8 women in the preoperative group and in 10 women in the postoperative group, and recurrences were predominantly within 10 years of treatment. Late toxicities included local upper extremity paresthesia's, upper extremity edema and congestive heart failure in 1 patient each. Analysis revealed no difference in RFS (20-year RFS probabilities; preoperative: 61.3%, postoperative: 54.7%, P=0.42), or in OS between the 2 treatment groups (20-year probabilities, preoperative: 64.6%, postoperative: 62.2%, P=0.44). Twenty-five of 53 patients (47%) were alive and without disease at this follow-up. CONCLUSION Twenty-five-year follow-up for this prospective randomized trial confirms the equivalency of preoperative versus postoperative chemotherapy with fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor for stage II breast cancer for both RFS and OS.",2020,"Late toxicities included local upper extremity paresthesia's, upper extremity edema and congestive heart failure in 1 patient each.","['Fifty-three women with clinical stage II breast cancer', 'Stage II Breast Cancer', 'women with untreated clinical stage II (T1N1, T2N0, and T2N1) breast cancer', 'women with breast cancer']","['Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy', 'preoperative chemotherapy', 'preoperative or postoperative fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor chemotherapy', 'postoperative chemotherapy with fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor', 'postoperative chemotherapy']","['RFS', ""Late toxicities included local upper extremity paresthesia's, upper extremity edema and congestive heart failure"", 'recurrence-free survival (RFS) and overall survival (OS', 'Local or systemic recurrence', 'toxicities, recurrence patterns and RFS and OS']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205571', 'cui_str': 'Clinical stage II (finding)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C4553330', 'cui_str': 'Flac'}, {'cui': 'C0018183', 'cui_str': 'Granulocytic cell'}, {'cui': 'C0439158', 'cui_str': 'colonies (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0731033', 'cui_str': 'Leucovorin Calcium'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C1273551', 'cui_str': 'Postoperative chemotherapy'}]","[{'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure (disorder)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]",53.0,0.0608369,"Late toxicities included local upper extremity paresthesia's, upper extremity edema and congestive heart failure in 1 patient each.","[{'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Malekzadeh', 'Affiliation': 'Surgery Branch.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Cowan', 'Affiliation': 'Eppley Institute, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.'}, {'ForeName': 'Seth M', 'Initials': 'SM', 'LastName': 'Steinberg', 'Affiliation': 'Biostatistics and Data Management Section.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Camphausen', 'Affiliation': 'Radiation Oncology Branch, Center for Cancer Research.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Shriver', 'Affiliation': 'Department of Surgery, Uniformed Services University of the Health Sciences, Walter Reed National Military Medical Center, Murtha Cancer Center (MCC), Research Program (MCCRP), Bethesda, MD.'}, {'ForeName': 'Maria J', 'Initials': 'MJ', 'LastName': 'Merino', 'Affiliation': 'Laboratory of Pathology, Intramural Research Program, National Cancer Institute, National Institutes of Health.'}, {'ForeName': 'Meghan L', 'Initials': 'ML', 'LastName': 'Good', 'Affiliation': 'Surgery Branch.'}, {'ForeName': 'Arlene', 'Initials': 'A', 'LastName': 'Berman', 'Affiliation': 'National Cancer Institute, National Institutes of Health.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Danforth', 'Affiliation': 'Surgery Branch.'}]",American journal of clinical oncology,['10.1097/COC.0000000000000667'] 119,32166681,"Application of Low Tube Voltage, Low-concentration Contrast Agent Using a 320-row CT in Coronary CT Angiography: Evaluation of Image Quality, Radiation Dose and Iodine Intake.","The effect of low voltage and low concentration contrast agent on image quality of coronary CT angiography, radiation dose and iodine intake was evaluated. A total of 121 patients with body mass index (BMI) <26 kg/m 2 and heart rate (HR) <70 beats/min were randomly divided into four groups: group A (n=31, 80 kVp, 270 mgI/mL); group B (n=33, 100 kVp, 270 mgI/mL); group C (n=30, 100 kVp, 320 mgI/mL); group D (n=27, 100 kVp, 400 mgI/mL). The automatic current modulation system and the iterative algorithm for reconstruction were adopted in each group. The CT values and SD values of the aortic root (AR), subcutaneous fat, left coronary artery opening (LCA), and right coronary artery opening (RCA) were measured in all groups, the signal-to-noise ratio (SNR) and contrast noise ratio (CNR) were calculated, and effective radiation dose and iodine intake were recorded. The subjective assessment for image quality was performed by two physicians using a 4-point scale. The results were compared using the one-way ANOVA and rank sum tests. The image quality of the four groups met the clinical diagnostic requirements. The CT values of AR in groups A, B, C, and D were 537.6±71.4, 447.2±81.9, 445.2±64.9 and 518.5±94.9 Hu, respectively, with no significant difference between group A and group D, or between group B and group C, while CT values in groups B and C were significantly lower than those in groups A and D (P<0.05). In groups A, B, C, and D, the LCA SNR values were 22.7±9.1, 23.3±9.1, 23.3±7.7 and 26.6±8.9, and the RCA CNR values were 26.9±9.8, 28.5±11.4, 27.7±8.8 and 32.1±10.6, respectively. The AR visual scores in groups A, B, C and D were 3.8±0.2, 3.9±0.3, 3.9±0.3 and 4.0±0.3, respectively. There were no significant differences in SNR, CNR and visual score among the four groups (P>0.05). The radiation doses in groups A, B, C and D were 2.6±1.4, 3.6±1.8, 4.9±3.5 and 4.9±2.8 mSv, respectively. The radiation dose in group A was significantly less than that in the rest three groups (P<0.05). The iodine intakes in groups A, B, C and D were 14.9±1.5, 15.0±1.5, 17.7±2.0 and 18.1±2.5 g, respectively. There was no significant difference in the intake of iodine between groups C and D, or between groups A and B, while iodine intake in groups A and B were significantly reduced as compared with that in groups C and D (P<0.05). It was concluded that for patients with low BMI and controlled HR, compared to 100 kVp tube voltage combined with multiple concentration contrast agents, 80 kVp combined with 270 mgI/mL contrast agent is enough to ensure the quality of the images, and can reduce the radiation dose significantly, while reducing the amount of iodine intake notably, thus reducing the incidence of adverse reaction.",2020,The radiation dose in group A was significantly less than that in the rest three groups (P<0.05).,['121 patients with body mass index (BMI) <26 kg/m 2 and heart rate (HR) <70 beats/min'],['low voltage and low concentration contrast agent'],"['signal-to-noise ratio (SNR) and contrast noise ratio (CNR', 'CT values', 'LCA SNR values', 'CT values and SD values of the aortic root (AR), subcutaneous fat, left coronary artery opening (LCA), and right coronary artery opening (RCA', 'CT values of AR', 'RCA CNR values', 'SNR, CNR and visual score', 'effective radiation dose and iodine intake', 'intake of iodine', 'image quality of coronary CT angiography, radiation dose and iodine intake', 'AR visual scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0439385', 'cui_str': 'beats per minute'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}]","[{'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0549113', 'cui_str': 'Supraaortic valve area structure'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}, {'cui': 'C1261082', 'cui_str': 'Left coronary artery structure'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C1261316', 'cui_str': 'Right coronary artery structure'}, {'cui': 'C0610301', 'cui_str': 'RCA II'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}]",121.0,0.0131779,The radiation dose in group A was significantly less than that in the rest three groups (P<0.05).,"[{'ForeName': 'Yue-Ying', 'Initials': 'YY', 'LastName': 'Pan', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. xpyy02@sina.com.'}, {'ForeName': 'Shu-Chang', 'Initials': 'SC', 'LastName': 'Zhou', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Yu-Jin', 'Initials': 'YJ', 'LastName': 'Wang', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Zhu', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Chun-Xia', 'Initials': 'CX', 'LastName': 'Liu', 'Affiliation': 'Department of Health Records, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}, {'ForeName': 'Han-Xiong', 'Initials': 'HX', 'LastName': 'Guan', 'Affiliation': 'Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.'}]",Current medical science,['10.1007/s11596-020-2162-8'] 120,32316911,Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome.,"BACKGROUND The purpose of this study was to conduct a 20-week controlled trial of lovastatin (10 to 40 mg/day) in youth with fragile X syndrome (FXS) ages 10 to 17 years, combined with an open-label treatment of a parent-implemented language intervention (PILI), delivered via distance video teleconferencing to both treatment groups, lovastatin and placebo. METHOD A randomized, double-blind trial was conducted at one site in the Sacramento, California, metropolitan area. Fourteen participants were assigned to the lovastatin group; two participants terminated early from the study. Sixteen participants were assigned to the placebo group. Lovastatin or placebo was administered orally in a capsule form, starting at 10 mg and increasing weekly or as tolerated by 10 mg increments, up to a maximum dose of 40 mg daily. A PILI was delivered to both groups for 12 weeks, with 4 activities per week, through video teleconferencing by an American Speech-Language Association-certified Speech-Language Pathologist, in collaboration with a Board-Certified Behavior Analyst. Parents were taught to use a set of language facilitation strategies while interacting with their children during a shared storytelling activity. The main outcome measures included absolute change from baseline to final visit in the means for youth total number of story-related utterances, youth number of different word roots, and parent total number of story-related utterances. RESULTS Significant increases in all primary outcome measures were observed in both treatment groups. Significant improvements were also observed in parent reports of the severity of spoken language and social impairments in both treatment groups. In all cases, the amount of change observed did not differ across the two treatment groups. Although gains in parental use of the PILI-targeted intervention strategies were observed in both treatment groups, parental use of the PILI strategies was correlated with youth gains in the placebo group and not in the lovastatin group. CONCLUSION Participants in both groups demonstrated significant changes in the primary outcome measures. The magnitude of change observed across the two groups was comparable, providing additional support for the efficacy of the use of PILI in youth with FXS. TRIAL REGISTRATION US National Institutes of Health (ClinicalTrials.gov), NCT02642653. Registered 12/30/2015.",2020,"Although gains in parental use of the PILI-targeted intervention strategies were observed in both treatment groups, parental use of the PILI strategies was correlated with youth gains in the placebo group and not in the lovastatin group. ","['Sixteen participants', 'youth with fragile X syndrome', 'one site in the Sacramento, California, metropolitan area', 'Fourteen participants', 'youth with fragile X syndrome (FXS) ages 10 to 17\u2009years']","['lovastatin combined with an open-label treatment of a parent-implemented language intervention', 'placebo', 'lovastatin', 'Lovastatin or placebo', 'combined with an open-label treatment of a parent-implemented language intervention (PILI), delivered via distance video teleconferencing to both treatment groups, lovastatin and placebo']","['absolute change from baseline to final visit in the means for youth total number of story-related utterances, youth number of different word roots, and parent total number of story-related utterances', 'severity of spoken language and social impairments']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0016667', 'cui_str': 'Fragile X syndrome'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0024027', 'cui_str': 'Lovastatin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0424919', 'cui_str': 'Language spoken'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",16.0,0.181326,"Although gains in parental use of the PILI-targeted intervention strategies were observed in both treatment groups, parental use of the PILI strategies was correlated with youth gains in the placebo group and not in the lovastatin group. ","[{'ForeName': 'Angela John', 'Initials': 'AJ', 'LastName': 'Thurman', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA. ajthurman@ucdavis.edu.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Potter', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Kyoungmi', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Tassone', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Banasik', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Sarah Nelson', 'Initials': 'SN', 'LastName': 'Potter', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Bullard', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Nguyen', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'McDuffie', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Hagerman', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Abbeduto', 'Affiliation': 'MIND Institute, University of California Davis Health, 2825 50th Street, Room 2335, Sacramento, CA, 95817, USA.'}]",Journal of neurodevelopmental disorders,['10.1186/s11689-020-09315-4'] 121,31485039,Posterior capsule opacification and Nd:YAG laser rates with two hydrophobic acrylic single-piece IOLs.,"OBJECTIVES To evaluate the development of posterior capsule opacification (PCO) and Nd:YAG capsulotomy rates following implantation of two hydrophobic acrylic IOLs. METHODS In a randomized, controlled trial, 80 patients with bilateral senile cataract were implanted with the hydrophobic acrylic single-piece intraocular Lenses (IOLs) EyeCee One in one eye and iMics1 in the other. Outcomes of 39 patients (78 eyes) were evaluated after 3 years. Automated Quantification of After-Cataract (AQUA; for PCO occurrence), visual acuity, anterior fibrosis, capsule-optic edge interaction and distance between anterior and posterior capsule IOL surface were analysed. RESULTS After a mean follow-up of 38 ± 1.95 months, Nd:YAG capsulotomy occurred at a rate of 15.4% and 46.2% in the EyeCee One and iMics1 groups, respectively (p < 0.01). Respective mean PCO scores measured by AQUA were 1.57 ± 1.63 and 2.45 ± 1.44 (p = 0.019). A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes. A gap between the posterior capsule and the posterior surface of the lens was observed in 76% of EyeCee One eyes and 35% of iMics1 eyes. CONCLUSIONS Study findings suggest that PCO and Nd:YAG capsulotomy rates are significantly lower in eyes implanted with the EyeCee One IOL compared to the iMics1 IOL. Optic sharpness and lens material seem to be the decisive factors, while the stepped edge beneath the haptic junction appeared to be ineffective.",2020,A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes.,"['80 patients with bilateral senile cataract', '39 patients (78 eyes) were evaluated after 3 years']","['hydrophobic acrylic single-piece intraocular Lenses (IOLs', 'hydrophobic acrylic single-piece IOLs', 'posterior capsule opacification (PCO) and Nd']","['PCO and Nd:YAG capsulotomy rates', 'Respective mean PCO scores', 'visual acuity, anterior fibrosis, capsule-optic edge interaction and distance between anterior and posterior capsule IOL surface', 'IOL optic', 'YAG capsulotomy rates', 'YAG capsulotomy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2025430', 'cui_str': 'Senile cataract of both eyes'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0440181', 'cui_str': 'Acrylic dental material (substance)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0023319', 'cui_str': 'Lenses, Intraocular'}, {'cui': 'C1444680', 'cui_str': 'Posterior capsule opacification'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0205154', 'cui_str': 'Along edge (qualifier value)'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}]",80.0,0.0689483,A distinct gap between the anterior capsule and the IOL optic was present in 89% of eyes implanted with EyeCee One and 13% of iMics1 eyes.,"[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schartmüller', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Schriefl', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Schwarzenbacher', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Leydolt', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kundi', 'Affiliation': 'Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090, Vienna, Austria.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Pieh', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Menapace', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. rupert.menapace@meduniwien.ac.at.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Kriechbaum', 'Affiliation': 'Department of Ophthalmology and Optometry of the Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}]","Eye (London, England)",['10.1038/s41433-019-0569-x'] 122,24956457,Ultrasound and shockwave therapy for acute fractures in adults.,"BACKGROUND The morbidity and socioeconomic costs of fractures are considerable. The length of time to healing is an important factor in determining a person's recovery after a fracture. Ultrasound may have a therapeutic role in reducing the time to union after fracture. This is an update of a review previously published in February 2012. OBJECTIVES To assess the effects of low-intensity ultrasound (LIPUS), high-intensity focused ultrasound (HIFUS) and extracorporeal shockwave therapies (ECSW) as part of the treatment of acute fractures in adults. SEARCH METHODS We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (2 June 2014), the Cochrane Central Register of Controlled Trials (The Cochrane Library 2014, Issue 5), MEDLINE (1946 to May Week 3 2014), EMBASE (1980 to 2014 Week 22), trial registers and reference lists of articles. SELECTION CRITERIA Randomised and quasi-randomised controlled trials evaluating ultrasound treatment in the management of acute fractures in adults. Studies had to include participants over 18 years of age with acute fractures, reporting outcomes such as function; time to union; non-union; secondary procedures such as for fixation or delayed union or non-union; adverse effects; pain; costs; and patient adherence. DATA COLLECTION AND ANALYSIS Two authors independently extracted data from the included studies. Treatment effects were assessed using mean differences, standardised mean differences or risk ratios using a fixed-effect model, except where there was substantial heterogeneity, when data were pooled using a random-effects model. Results from 'worst case' analyses, which gave more conservative estimates of treatment effects for time to fracture union, are reported in preference to those from 'as reported' analyses. MAIN RESULTS We included 12 studies, involving 622 participants with 648 fractures. Eight studies were randomised placebo-controlled trials, two were randomised controlled trials without placebo controls, one was a quasi-randomised placebo-controlled trial and one was a quasi-randomised controlled trial without placebo control. Eleven trials tested LIPUS and one trial tested ECSW. Four trials included participants with conservatively treated upper limb complete fractures and six trials included participants with lower limb complete fractures; these were surgically fixed in four trials. The remaining two trials reported results for conservatively treated tibial stress fractures.'Risk of bias' assessment of the included studies was hampered by the poor reporting of methods, frequently resulting in the risk of bias of individual domains being judged as 'unclear'. Both quasi-randomised studies were at high risk of bias, including selection and attrition bias. Three studies were at low risk of selection bias relating to allocation concealment the majority of studies were at low risk of performance bias as they employed a form of intervention blinding.Only limited data were available from three of only four studies reporting on functional outcome. One study of complete fractures found little evidence of a difference between the two groups in the time to return to work (mean difference (MD) 1.95 days favouring control, 95% confidence interval (CI) -2.18 to 6.08; 101 participants). Pooled data from two studies found LIPUS did not significantly affect the time to return to training or duty in soldiers or midshipmen with stress fractures (MD -8.55 days, 95% CI -22.71 to 5.61; 93 participants).We adopted a conservative strategy for data analysis that was more likely to underestimate than to overestimate a benefit of the intervention. After pooling results from eight studies (446 fractures), the data showed no statistically significant reduction in time to union of complete fractures treated with LIPUS (standardised mean difference (SMD) -0.47, 95% CI -1.14 to 0.20). This result could include a clinically important benefit or harm, and should be seen in the context of the highly significant statistical heterogeneity (I² = 90%). This heterogeneity was not explained by the a priori subgroup analyses (upper limb versus lower limb fracture, smoking status). An additional subgroup analysis comparing conservatively and operatively treated fractures raised the possibility that LIPUS may be effective in reducing healing time in conservatively managed fractures, but the test for subgroup differences did not confirm a significant difference between the subgroups.Pooled results from five of the eight trials (333 fractures) reporting proportion of delayed union or non-union showed no significant difference between LIPUS and control (10/168 versus 13/165; RR 0.75; 95% CI 0.24 to 2.28). Adverse effects directly associated with LIPUS and associated devices were found to be few and minor, and compliance with treatment was generally good. One study reporting on pain scores found no difference between groups at eight weeks (101 participants).One quasi-randomised study found no significant difference in non-union at 12 months between internal fixation supplemented with ECSW and internal fixation alone (3/27 versus 6/30; RR 0.56, 95% CI 0.15 to 2.01). There was a clinically small but statistically significant difference in the visual analogue scores for pain in favour of ECSW at three month follow-up (MD -0.80, 95% CI -1.23 to -0.37). The only reported complication was infection, with no significant difference between the two groups. AUTHORS' CONCLUSIONS While a potential benefit of ultrasound for the treatment of acute fractures in adults cannot be ruled out, the currently available evidence from a set of clinically heterogeneous trials is insufficient to support the routine use of this intervention in clinical practice. Future trials should record functional outcomes and follow-up all trial participants.",2014,Pooled data from two studies found LIPUS did not significantly affect the time to return to training or duty in soldiers or midshipmen with stress fractures (,"['acute fractures in adults', '622 participants with 648 fractures', 'participants with conservatively treated upper limb complete fractures and six trials included participants with lower limb complete fractures']","['placebo', 'ECSW and internal fixation alone', 'ECSW', 'Ultrasound and shockwave therapy', 'placebo control', 'ultrasound treatment', 'low-intensity ultrasound (LIPUS), high-intensity focused ultrasound (HIFUS) and extracorporeal shockwave therapies (ECSW']","['non-union', 'length of time to healing', 'pain scores', 'visual analogue scores for pain', 'function; time to union; non-union; secondary procedures such as for fixation or delayed union or non-union; adverse effects; pain; costs; and patient adherence', 'healing time', 'delayed union or non-union', 'time to union of complete fractures']","[{'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0016642', 'cui_str': 'Osteosynthesis, Fracture'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0441583', 'cui_str': 'High intensity focused ultrasound (qualifier value)'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal Shockwave Therapy'}]","[{'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0445275', 'cui_str': 'Secondary procedure (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1321605', 'cui_str': 'Patient Cooperation'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}]",622.0,0.159969,Pooled data from two studies found LIPUS did not significantly affect the time to return to training or duty in soldiers or midshipmen with stress fractures (,"[{'ForeName': 'Xavier L', 'Initials': 'XL', 'LastName': 'Griffin', 'Affiliation': 'Warwick Orthopaedics, Warwick Medical School, University of Warwick, Clinical Sciences Building, Clifford Bridge Road, Coventry, UK, CV2 2DX.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Parsons', 'Affiliation': ''}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Metcalfe', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD008579.pub3'] 123,32217922,The Design of a Prospective Trial to Evaluate the Role of Preoperative Frailty Assessment in Older Women Undergoing Surgery for the Treatment of Pelvic Organ Prolapse: The FASt Supplemental Trial.,"OBJECTIVE We present the rationale for and the design of a prospective trial to evaluate the role of preoperative frailty and mobility assessments in older women undergoing surgery for the treatment of pelvic organ prolapse (POP) as a planned prospective supplemental trial to the ASPIRe (Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design) trial. The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial. The primary objective of FASt is to determine the impact of preoperative age, multimorbidity, frailty, and decreased mobility on postoperative outcomes in older women (≥65 years old) undergoing surgery for POP. METHODS The selection of the preoperative assessments, primary outcome measures, and participant inclusion is described. Frailty and mobility measurements will be collected at the preoperative visit and include the 6 Robinson frailty measurements and the Timed Up and Go mobility test. The main outcome measure in the FASt supplemental study will be moderate to severe postoperative adverse events according to the Clavien-Dindo Severity Classification. CONCLUSIONS This trial will assess impact of preoperative age, multimorbidity, frailty, and decreased mobility on postoperative outcomes in older women (≥65 years old) undergoing surgical procedures for the correction of apical POP. Information from this trial may help both primary care providers and surgeons better advise/inform women on their individual risks of surgical complications and provide more comprehensive postoperative care to women at highest risk of complications.",2020,The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial.,"['older women (≥65 years old) undergoing surgery for POP', 'older women undergoing surgery for the treatment of pelvic organ prolapse (POP', 'Older Women Undergoing Surgery for the Treatment of Pelvic Organ Prolapse', 'older women (≥65 years) participating in the ASPIRe trial', 'older women (≥65 years old) undergoing surgical procedures for the correction of apical POP']","['FASt', 'Preoperative Frailty Assessment', 'ASPIRe (Apical Suspension Repair for Vault Prolapse']","['Frailty and mobility measurements', 'moderate to severe postoperative adverse events according to the Clavien-Dindo Severity Classification']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439820', 'cui_str': 'Popping sensation quality'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877015', 'cui_str': 'Urogenital Prolapse'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205111', 'cui_str': 'Apical (qualifier value)'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}]","[{'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}]",,0.0665108,The Frailty ASPIRe Study (FASt) examines the impact of preoperative frailty and mobility on surgical outcomes in older women (≥65 years) participating in the ASPIRe trial.,"[{'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Erekson', 'Affiliation': 'From the Department of Obstetrics and Gynecology, The Geisel School of Medicine at Dartmouth, Hanover, NH.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Menefee', 'Affiliation': 'University of California, San Diego, and Kaiser Permanente, San Diego, CA.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Whitworth', 'Affiliation': 'RTI International, Research Triangle Park.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Amundsen', 'Affiliation': 'Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Lily A', 'Initials': 'LA', 'LastName': 'Arya', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Yuko M', 'Initials': 'YM', 'LastName': 'Komesu', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM.'}, {'ForeName': 'Cecile A', 'Initials': 'CA', 'LastName': 'Ferrando', 'Affiliation': ""Department of Obstetrics, Gynecology & Women's Health Institute, Cleveland Clinic, Cleveland, OH.""}, {'ForeName': 'Halina M', 'Initials': 'HM', 'LastName': 'Zyczynski', 'Affiliation': 'The Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Magee-Womens Research Institute, Pittsburgh, PA.'}, {'ForeName': 'Vivian W', 'Initials': 'VW', 'LastName': 'Sung', 'Affiliation': 'Alpert Medical School of Brown University, Providence, RI.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Rahn', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Tan-Kim', 'Affiliation': 'University of California, San Diego, and Kaiser Permanente, San Diego, CA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Mazloomdoost', 'Affiliation': 'The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD.'}, {'ForeName': 'Marie G', 'Initials': 'MG', 'LastName': 'Gantz', 'Affiliation': 'RTI International, Research Triangle Park.'}, {'ForeName': 'Holly E', 'Initials': 'HE', 'LastName': 'Richter', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Female pelvic medicine & reconstructive surgery,['10.1097/SPV.0000000000000833'] 124,31352486,Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers: A Pre-Post Clinical Trial.,"INTRODUCTION The major aim of this study was to test whether abstinence from e-cigarettes causes withdrawal symptoms in former smokers. METHODS We conducted an unblinded, within-participants, pre-post clinical trial in which 109 former smokers who were current daily electronic cigarette (e-cigarette) users used their own e-cigarette for 7 days followed by 6 days of biologically confirmed abstinence engendered via an escalating contingency payment system. Participants monitored symptoms of nicotine withdrawal daily via an Interactive Voice Response system. They also attended three laboratory visits per week for carbon monoxide and cotinine testing to verify abstinence. RESULTS Half of participants completely abstained for a week. All the Diagnostic and Statistical Manual, Fifth Edition (DSM-5) tobacco withdrawal symptoms, craving for e-cigarettes, craving for tobacco cigarettes, and the four possible new withdrawal symptoms (anhedonia, impulsivity, mood swings, and positive affect) increased during abstinence. Weight increased and heart rate decreased with abstinence. Symptoms showed the prototypical inverted U time pattern of a withdrawal state. The magnitude of withdrawal appeared to be somewhat less than that in a prior study of abstinent daily tobacco cigarette smokers. More severe withdrawal on the first 2 days of abstinence did not predict abstinence on the last day of the study. CONCLUSIONS Former smokers who are daily e-cigarette users transfer physical dependence on tobacco cigarettes to dependence on e-cigarettes. The severity of withdrawal from e-cigarettes appears to be only somewhat less than that from daily tobacco cigarette use. Replication tests that include placebo controls, testing for pharmacological specificity, and including never-smokers, non-daily e-cigarette users and dual users are indicated. IMPLICATIONS Our results indicate e-cigarettes can maintain physical dependence. This adverse effect should be included in any risk vs. benefit calculation. Also, potential and current e-cigarette users should be informed that abrupt cessation of e-cigarettes can cause withdrawal symptoms. TRIAL REGISTRATION NCT02825459.",2020,"More severe withdrawal on the first two days of abstinence did not predict abstinence on the last day of the study. ","['Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers', '109 former smokers who were current daily e-cigarette users used their own e-cigarette for 7 days followed by 6 days of biologically confirmed abstinence engendered via an escalating contingency payment system', 'abstinent daily tobacco cigarette smokers']",[],"['symptoms of nicotine withdrawal daily via an Interactive Voice Response system', 'DSM-5 tobacco withdrawal symptoms, craving for e-cigarettes, craving for tobacco cigarettes', 'Weight increased and heart rate']","[{'cui': 'C0087169', 'cui_str': 'Withdrawal Symptoms'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4087159', 'cui_str': 'Electronic cigarette user (finding)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}]",[],"[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0028047', 'cui_str': 'Nicotine withdrawal (disorder)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1167842', 'cui_str': 'Tobacco withdrawal symptoms'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",109.0,0.0552199,"More severe withdrawal on the first two days of abstinence did not predict abstinence on the last day of the study. ","[{'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Hughes', 'Affiliation': 'Department of Psychiatry, Vermont Center for Behavior and Health, University of Vermont, Burlington, VT.'}, {'ForeName': 'Erica N', 'Initials': 'EN', 'LastName': 'Peters', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Baltimore, MD.'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Callas', 'Affiliation': 'Medical Biostatistics, University of Vermont, Burlington, VT.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Peasley-Miklus', 'Affiliation': 'Department of Psychiatry, Vermont Center for Behavior and Health, University of Vermont, Burlington, VT.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Oga', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Baltimore, MD.'}, {'ForeName': 'Jean-Francois', 'Initials': 'JF', 'LastName': 'Etter', 'Affiliation': 'Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Morley', 'Affiliation': 'Department of Psychiatry, Vermont Center for Behavior and Health, University of Vermont, Burlington, VT.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz129'] 125,31178433,Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.,"β-Cell dysfunction is central to the pathogenesis of impaired glucose tolerance (IGT) and type 2 diabetes. Compared with adults, youth have hyperresponsive β-cells and their decline in β-cell function appears to be more rapid. However, there are no direct comparisons of β-cell responses to pharmacological intervention between the two age-groups. The Restoring Insulin Secretion (RISE) Adult Medication Study and the RISE Pediatric Medication Study compared interventions to improve or preserve β-cell function. Obese youth ( n = 91) and adults ( n = 132) with IGT or recently diagnosed type 2 diabetes were randomized to 3 months of insulin glargine followed by 9 months of metformin, or 12 months of metformin. Hyperglycemic clamps conducted at baseline, after 12 months of medication, and 3 months after medication withdrawal assessed β-cell function as steady-state and maximal C-peptide responses adjusted for insulin sensitivity. Temporal changes in β-cell function were distinctly different. In youth, β-cell function deteriorated during treatment and after treatment withdrawal, with no differences between treatment groups. In adults, β-cell function improved during treatment, but this was not sustained after treatment withdrawal. The difference in β-cell function outcomes in response to medications in youth versus adults supports a more adverse trajectory of β-cell deterioration in youth.",2019,"In youth, β-cell function deteriorated during treatment and after treatment withdrawal, with no differences between treatment groups.","['Obese youth ( n = 91) and adults ( n = 132) with IGT or recently diagnosed type 2 diabetes', 'Youth And Adults']","['insulin glargine', 'metformin, or 12 months of metformin', 'Metformin Alone or in Combination With Insulin Glargine']","['β-cell function', 'Restoring Insulin Secretion (RISE', 'β-cell function as steady-state and maximal C-peptide responses adjusted for insulin sensitivity']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0006558', 'cui_str': 'Proinsulin C-Peptide'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}]",132.0,0.028769,"In youth, β-cell function deteriorated during treatment and after treatment withdrawal, with no differences between treatment groups.","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes,['10.2337/db19-0299'] 126,31186299,"Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.","OBJECTIVE Higher serum uric acid (SUA) is associated with diabetic kidney disease (DKD). Preventing Early Renal Loss in Diabetes (PERL) evaluates whether lowering SUA with allopurinol slows glomerular filtration rate (GFR) loss in people with type 1 diabetes (T1D) and mild to moderate DKD. We present the PERL rationale, design, and baseline characteristics. RESEARCH DESIGN AND METHODS This double-blind, placebo-controlled, multicenter trial randomized 530 participants with T1D, estimated GFR (eGFR) of 40-99.9 mL/min/1.73 m 2 , SUA ≥4.5 m/dL, and micro- to macroalbuminuric DKD or normoalbuminuria with declining kidney function (NDKF) (defined as historical eGFR decline ≥3 mL/min/1.73 m 2 /year) to allopurinol or placebo. The primary outcome is baseline-adjusted iohexol GFR (iGFR) after 3 years of treatment plus a 2-month washout period. RESULTS Participants are 66% male and 84% white. At baseline, median age was 52 years and diabetes duration was 35 years, 93% of participants had hypertension, and 90% were treated with renin-angiotensin system inhibitors (median blood pressure 127/71 mmHg). Median HbA 1c was 8%, SUA 5.9 mg/dL, iGFR 68 mL/min/1.73 m 2 , and historical eGFR slope -3.5 mL/min/1.73 m 2 /year. Compared with participants with albuminuria ( n = 419), those with NDKF ( n = 94) were significantly older (56 vs. 52 years), had lower HbA 1c (7.7 vs. 8.1%) and SUA (5.4 vs. 6.0 mg/dL), and had higher eGFR (82 vs. 74 mL/min/1.73 m 2 ) and historical eGFR loss (-4.7 vs. -2.5 mL/min/1.73 m 2 /year). These differences persisted when comparing groups with similar rates of historical eGFR loss. CONCLUSIONS PERL will determine the effect of allopurinol on mild to moderate DKD in T1D, with or without albuminuria. Participants with normoalbuminuria and rapid GFR loss manifested many DKD risk factors of those with albuminuria, but with less severity.",2019,"These differences persisted when comparing groups with similar rates of historical eGFR loss. ","['people with type 1 diabetes (T1D) and mild to moderate DKD', 'Participants are 66% male and 84% white', 'diabetic kidney disease (DKD', 'PERL in Diabetes Study', '530 participants with T1D, estimated GFR (eGFR) of 40-99.9 mL/min/1.73 m 2 , SUA ≥4.5 m/dL, and micro- to macroalbuminuric DKD or normoalbuminuria with declining kidney function (NDKF) (defined as historical eGFR decline ≥3 mL/min/1.73 m 2 /year) to', 'At baseline, median age was 52 years and diabetes duration was 35 years, 93% of participants had hypertension, and 90% were treated with']","['SUA with allopurinol', 'placebo', 'renin-angiotensin system inhibitors', 'Allopurinol', 'allopurinol or placebo', 'allopurinol']","['glomerular filtration rate (GFR) loss', 'historical eGFR loss', 'baseline-adjusted iohexol GFR (iGFR']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4524116', 'cui_str': 'Estimated GFR'}, {'cui': 'C4517914', 'cui_str': '99.9 (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439508', 'cui_str': 'per year'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0165079', 'cui_str': 'IS 35'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0002144', 'cui_str': 'Allopurinol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0035096'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C0022005', 'cui_str': 'Iohexol'}]",530.0,0.554368,"These differences persisted when comparing groups with similar rates of historical eGFR loss. ","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Afkarian', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of California, Davis, Davis, CA.'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Polsky', 'Affiliation': 'Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO.'}, {'ForeName': 'Afshin', 'Initials': 'A', 'LastName': 'Parsa', 'Affiliation': 'Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.'}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Aronson', 'Affiliation': 'LMC Diabetes & Endocrinology, Toronto, Ontario, Canada.'}, {'ForeName': 'Maria Luiza', 'Initials': 'ML', 'LastName': 'Caramori', 'Affiliation': 'Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'David Z', 'Initials': 'DZ', 'LastName': 'Cherney', 'Affiliation': 'Departments of Medicine and Physiology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jill P', 'Initials': 'JP', 'LastName': 'Crandall', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, New York, NY.'}, {'ForeName': 'Ian H', 'Initials': 'IH', 'LastName': 'de Boer', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Elliott', 'Affiliation': 'BCDiabetes, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Andrzej T', 'Initials': 'AT', 'LastName': 'Galecki', 'Affiliation': 'Division of Geriatrics, Institute of Gerontology, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Allison B', 'Initials': 'AB', 'LastName': 'Goldfine', 'Affiliation': 'Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, MA.'}, {'ForeName': 'J Sonya', 'Initials': 'JS', 'LastName': 'Haw', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, GA.'}, {'ForeName': 'Irl B', 'Initials': 'IB', 'LastName': 'Hirsch', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'Amy B', 'Initials': 'AB', 'LastName': 'Karger', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'Department of Internal Medicine and Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Maahs', 'Affiliation': 'Department of Pediatrics, Stanford University, Palo Alto, CA.'}, {'ForeName': 'Janet B', 'Initials': 'JB', 'LastName': 'McGill', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, St. Louis, MO.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Molitch', 'Affiliation': 'Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Perkins', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Rodica', 'Initials': 'R', 'LastName': 'Pop-Busui', 'Affiliation': 'Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Marlon', 'Initials': 'M', 'LastName': 'Pragnell', 'Affiliation': 'JDRF, New York, NY.'}, {'ForeName': 'Sylvia E', 'Initials': 'SE', 'LastName': 'Rosas', 'Affiliation': 'Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, MA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Senior', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Sigal', 'Affiliation': 'Departments of Medicine, Cardiac Sciences, and Community Health Sciences, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Spino', 'Affiliation': 'Statistical Analysis of Biomedical and Educational Research, Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Katherine R', 'Initials': 'KR', 'LastName': 'Tuttle', 'Affiliation': 'Providence Health Care, Spokane, WA.'}, {'ForeName': 'Guillermo E', 'Initials': 'GE', 'LastName': 'Umpierrez', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, GA.'}, {'ForeName': 'Amisha', 'Initials': 'A', 'LastName': 'Wallia', 'Affiliation': 'Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.'}, {'ForeName': 'Ruth S', 'Initials': 'RS', 'LastName': 'Weinstock', 'Affiliation': 'Department of Medicine, State University of New York Upstate Medical University, Syracuse, NY.'}, {'ForeName': 'Chunyi', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mauer', 'Affiliation': 'Departments of Pediatrics and Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Doria', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0342'] 127,31217579,Management of primary pterygium with intra-lesional injection of 5 flurouracil and bevacizumab (Avastin).,"BACKGROUND To assess the efficacy of combined 5FU and Avastin injections in the treatment of primary pterygium METHODS: Sixteen eyes with primary pterygium received intralesional 5 fluorouracil and Avastin (2.5-5 mg) injections every 2 weeks for a maximum of five injections. Fourteen eyes of 14 patients received five injections, one eye received three injections and one eye received two injections. All eyes were followed at monthly intervals for 3 months after last injection. Tissue was obtained by surgical excision of primary pterygium from four eyes who received injections and three eyes with primary pterygium who did not receive injections (control) and subjected to immunohistological examination for beta fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), von-Willebrand factor (vWF), lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and collagen-I. RESULTS Pterygium progression was arrested in all patients. Sixty-two percent of patients had improvement of redness while 89% had reduced thickness of the lesion. VEGF, bFGF, EGF, vWF, LYVE-1 and collagen-I were all reduced in the injected samples. CONCLUSIONS The injection of 5 fluorouracil and Avastin act synergistically to arrest progression and induce atrophy in primary pterygium. This is related to the effect of agents on fibroblasts, collagen, and vascular tissues. Such medical intervention is a safe and viable option in the management of primary pterygium though excision of residual tissue is still required in some cases. Longer follow up is needed to ascertain whether this will reduce the recurrence rate following excision.",2019,"VEGF, bFGF, EGF, vWF, LYVE-1 and collagen-I were all reduced in the injected samples. ","['primary pterygium', 'Fourteen eyes of 14 patients', 'primary pterygium with intra-lesional injection of 5', 'Sixteen eyes with primary pterygium']","['combined 5FU and Avastin injections', 'intralesional 5 fluorouracil and Avastin', 'primary pterygium who did not receive injections (control) and subjected to immunohistological examination for beta fibroblast growth factor (bFGF', 'fluorouracil and Avastin', 'flurouracil and bevacizumab (Avastin']","['Pterygium progression', 'vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), von-Willebrand factor (vWF), lymphatic vessel endothelial hyaluronan receptor (LYVE-1) and collagen-I', 'redness', 'VEGF, bFGF, EGF, vWF, LYVE-1 and collagen-I', 'recurrence rate']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0033999', 'cui_str': 'Pterygium'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C3715157', 'cui_str': '16'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C1135130', 'cui_str': 'Avastin'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0033999', 'cui_str': 'Pterygium'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0016026', 'cui_str': 'DNA Synthesis Factor'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0033999', 'cui_str': 'Pterygium'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0242275', 'cui_str': 'Epidermal Growth Factor'}, {'cui': 'C0042971', 'cui_str': 'von Willebrand factor'}, {'cui': 'C0229889', 'cui_str': 'Structure of lymphatic vessel'}, {'cui': 'C0243982', 'cui_str': 'Hyaluronan Receptors'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",,0.0193891,"VEGF, bFGF, EGF, vWF, LYVE-1 and collagen-I were all reduced in the injected samples. ","[{'ForeName': 'Noha', 'Initials': 'N', 'LastName': 'Ghoz', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Britton', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Ross', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Mohammed', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Hogan', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'Dalia G', 'Initials': 'DG', 'LastName': 'Said', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK.'}, {'ForeName': 'Harminder S', 'Initials': 'HS', 'LastName': 'Dua', 'Affiliation': 'Academic section of ophthalmology, Division of Clinical Neuroscience, University of Nottingham and Department of Ophthalmology, Nottingham University Hospitals, NHS Trust, Nottingham, UK. harminder.dua@nottingham.ac.uk.'}]","Eye (London, England)",['10.1038/s41433-019-0493-0'] 128,31444404,Low-molecular-weight-heparin increases Th1- and Th17-associated chemokine levels during pregnancy in women with unexplained recurrent pregnancy loss: a randomised controlled trial.,"Low-molecular-weight heparin (LMWH) is widely used to treat recurrent pregnancy loss (RPL) because of its anti-coagulant effects. Although in vitro studies have suggested additional immunological effects, these are debated. We therefore investigated whether LMWH could modulate immune responses in vivo during pregnancy of women with unexplained RPL. A Swedish open multi-centre randomised controlled trial included 45 women treated with tinzaparin and 42 untreated women. Longitudinally collected plasma samples were obtained at gestational weeks (gw) 6, 18, 28 and 34 and analysed by multiplex bead technology for levels of 11 cytokines and chemokines, chosen to represent inflammation and T-helper subset-associated immunity. Mixed linear models test on LMWH-treated and untreated women showed differences during pregnancy of the Th1-associated chemokines CXCL10 (p = 0.01), CXCL11 (p < 0.001) and the Th17-associated chemokine CCL20 (p = 0.04), while CCL2, CCL17, CCL22, CXCL1, CXCL8, CXCL12, CXCL13 and IL-6 did not differ. Subsequent Student's t-test showed significantly higher plasma levels of CXCL10 and CXCL11 in treated than untreated women at gw 28 and 34. The consistent increase in the two Th1-associated chemokines suggests a potential proinflammatory and unfavourable effect of LMWH treatment during later stages of pregnancy, when Th1 immunity is known to disrupt immunological tolerance.",2019,Subsequent Student's t-test showed significantly higher plasma levels of CXCL10 and CXCL11 in treated than untreated women at gw 28 and 34.,"['women with unexplained RPL', '45 women treated with', 'women with unexplained recurrent pregnancy loss', 'and 42 untreated women']","['LMWH', 'tinzaparin', 'Low-molecular-weight heparin (LMWH']","['Th17-associated chemokine CCL20', 'CCL2, CCL17, CCL22, CXCL1, CXCL8, CXCL12, CXCL13', 'CXCL11', 'plasma levels of CXCL10 and CXCL11']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C2921106', 'cui_str': 'Recurrent pregnancy loss'}]","[{'cui': 'C0019139', 'cui_str': 'LMWH'}, {'cui': 'C0216278', 'cui_str': 'tinzaparin'}]","[{'cui': 'C1961104', 'cui_str': 'Small Inducible Cytokine A20'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",45.0,0.211614,Subsequent Student's t-test showed significantly higher plasma levels of CXCL10 and CXCL11 in treated than untreated women at gw 28 and 34.,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Rasmark Roepke', 'Affiliation': 'Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö and Lund University, Lund, Sweden. emma_36@hotmail.com.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Bruno', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Nedstrand', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Boij', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'C Petersson', 'Initials': 'CP', 'LastName': 'Strid', 'Affiliation': 'Departmen of Obstetrics and Gynecology, Kalmar Hospital, Kalmar, Sweden.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Piccione', 'Affiliation': 'Section of Gynecology and Obstetrics, Academic Department of Biomedicine and Prevention, and Clinical Department of Surgery, Tor Vergata University Hospital, Rome, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Berg', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Svensson-Arvelund', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Jenmalm', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rubér', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ernerudh', 'Affiliation': 'Department of Clinical Immunology and Transfusion Medicine, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.'}]",Scientific reports,['10.1038/s41598-019-48799-6'] 129,31338998,"Weight Loss Experiences of African American, Hispanic, and Non-Hispanic White Men and Women with Type 2 Diabetes: The Look AHEAD Trial.","OBJECTIVE The aim of this study was to characterize weight loss, treatment engagement, and weight control strategies utilized by African American, Hispanic, and non-Hispanic white participants in the Action for Health in Diabetes (Look AHEAD) Intensive Lifestyle Intervention by racial/ethnic and sex subgroups. METHODS Weight losses at 1, 4, and 8 years among 2,361 adults with obesity and type 2 diabetes randomized to intervention (31% minority; 42% men) are reported by subgroup. Multivariable models within subgroups examine relative contributions of treatment engagement variables and self-reported weight control behaviors. RESULTS All subgroups averaged weight losses ≥ 5% in year 1 but experienced regain; losses ≥ 5% were sustained at year 8 by non-Hispanic white participants and minority women (but not men). Session attendance was high (≥ 86%) in year 1 and exceeded protocol-specified minimum levels into year 8. Individual session attendance had stronger associations with weight loss among Hispanic and African American participants than non-Hispanic white participants at 4 years (P = 0.04) and 8 years (P = 0.001). Daily self-weighing uptake was considerable in all subgroups and was a prominent factor associated with year 1 weight loss among African American men and women. Greater meal replacement use was strongly associated with poorer 1-year weight losses among African American women. CONCLUSIONS Experiences of minority men and women with diabetes in lifestyle interventions fill important gaps in the literature that can inform treatment delivery.",2019,Daily self-weighing uptake was considerable in all subgroups and was a prominent factor associated with year 1 weight loss among African American men and women.,"['Weight losses at 1, 4, and 8 years among 2,361 adults with obesity and type 2 diabetes randomized to intervention (31% minority; 42% men', 'Weight Loss Experiences of African American, Hispanic, and Non-Hispanic White Men and Women with Type 2 Diabetes', 'African American women', 'African American men and women', 'African American, Hispanic, and non-Hispanic white participants in the Action for Health in Diabetes ']",['Intensive Lifestyle Intervention'],"['Daily self-weighing uptake', 'Session attendance', '1-year weight losses', 'weight loss']","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]",2361.0,0.027542,Daily self-weighing uptake was considerable in all subgroups and was a prominent factor associated with year 1 weight loss among African American men and women.,"[{'ForeName': 'Delia Smith', 'Initials': 'DS', 'LastName': 'West', 'Affiliation': 'Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Dutton', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Delahanty', 'Affiliation': 'Diabetes Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Helen P', 'Initials': 'HP', 'LastName': 'Hazuda', 'Affiliation': 'Division of Nephrology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Amy D', 'Initials': 'AD', 'LastName': 'Rickman', 'Affiliation': 'Department of Exercise & Rehabilitative Sciences, Slippery Rock University, Slippery Rock, Pennsylvania, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Knowler', 'Affiliation': 'Diabetes Epidemiology and Clinical Research Section, NIDDK, Phoenix, Arizona, USA.'}, {'ForeName': 'Mara Z', 'Initials': 'MZ', 'LastName': 'Vitolins', 'Affiliation': 'Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Neiberg', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Peters', 'Affiliation': 'Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Gee', 'Affiliation': 'Behavioral Medicine Research Center, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Cassidy Begay', 'Affiliation': 'NIDDK and Indian Health Service, Shiprock, New Mexico, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22522'] 130,31339000,Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans.,"OBJECTIVE Eating earlier in the daytime to align with circadian rhythms in metabolism enhances weight loss. However, it is unknown whether these benefits are mediated through increased energy expenditure or decreased food intake. Therefore, this study performed the first randomized trial to determine how meal timing affects 24-hour energy metabolism when food intake and meal frequency are matched. METHODS Eleven adults with overweight practiced both early time-restricted feeding (eTRF) (eating from 8 am to 2 pm) and a control schedule (eating from 8 am to 8 pm) for 4 days each. On the fourth day, 24-hour energy expenditure and substrate oxidation were measured by whole-room indirect calorimetry, in conjunction with appetite and metabolic hormones. RESULTS eTRF did not affect 24-hour energy expenditure (Δ = 10 ± 16 kcal/d; P = 0.55). Despite the longer daily fast (intermittent fasting), eTRF decreased mean ghrelin levels by 32 ± 10 pg/mL (P = 0.006), made hunger more even-keeled (P = 0.006), and tended to increase fullness (P = 0.06-0.10) and decrease the desire to eat (P = 0.08). eTRF also increased metabolic flexibility (P = 0.0006) and decreased the 24-hour nonprotein respiratory quotient (Δ = -0.021 ± 0.010; P = 0.05). CONCLUSIONS Meal-timing interventions facilitate weight loss primarily by decreasing appetite rather than by increasing energy expenditure. eTRF may also increase fat loss by increasing fat oxidation.",2019,"eTRF also increased metabolic flexibility (P = 0.0006) and decreased the 24-hour nonprotein respiratory quotient (Δ = -0.021 ± 0.010; P = 0.05). ",['Eleven adults with overweight practiced both early time-restricted feeding (eTRF) (eating from 8 am to 2 pm) and a control schedule (eating from 8 am to 8 pm) for 4 days each'],['eTRF'],"['Fat Oxidation', 'increase fullness', '24-hour nonprotein respiratory quotient', '24-hour energy expenditure and substrate oxidation', 'desire to eat', 'longer daily fast (intermittent fasting), eTRF decreased mean ghrelin levels', 'metabolic flexibility', 'fat loss', '24-hour energy expenditure']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",[],"[{'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient (observable entity)'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C4704881', 'cui_str': 'Intermittent Fastings'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",11.0,0.0313331,"eTRF also increased metabolic flexibility (P = 0.0006) and decreased the 24-hour nonprotein respiratory quotient (Δ = -0.021 ± 0.010; P = 0.05). ","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ravussin', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Poggiogalle', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Hsia', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Peterson', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22518'] 131,30996338,"Visual Function Questionnaire as an outcome measure for homonymous hemianopia: subscales and supplementary questions, analysis from the VISION trial.","BACKGROUND We conduct supplementary analyses of the NEI VFQ-25 data to evaluate where changes occurred within subscales of the NEI VFQ-25 leading to change in the composite scores between the three treatment arms, and evaluate the NEI VFQ-25 with and without the Neuro 10 supplement. METHODS A prospective, multicentre, parallel, single-blind, three-arm RCT of fourteen UK acute stroke units was conducted. Stroke survivors with homonymous hemianopia were recruited. Interventions included: Fresnel prisms for minimum 2 h, 5 days/week over 6-weeks (Arm a), Visual search training for minimum 30 min, 5 days/week over 6-weeks (Arm b) and standard care-information only (Arm c). Primary and secondary outcomes (including NEI VFQ-25 data) were measured at baseline, 6, 12 and 26 weeks after randomisation. RESULTS Eighty seven patients were recruited (69% male; mean age (SD) equal to 69 (12) years). At 26 weeks, outcomes for 24, 24 and 22 patients, respectively, were compared to baseline. NEI VFQ-25 (with and without Neuro 10) responses improved from baseline to 26 weeks with visual search training compared to Fresnel prisms and standard care. In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. CONCLUSIONS Composite scores differed systematically for the NEI VFQ-25 (Neuro 10) versus NEI VFQ-25 at all time points. For subscale scores, descriptive statistics suggest clinically relevant improvement in distance activities and vision-specific dependency subscales for NEI VFQ-25 scores in the visual search treatment arm. TRIAL REGISTRATION Current Controlled Trials ISRCTN05956042.",2019,"In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. ","['Stroke survivors with homonymous hemianopia', 'fourteen UK acute stroke units', 'seven patients were recruited (69% male; mean age (SD) equal to 69 (12) years', 'Eighty']","['visual search training', 'Visual search training', 'NEI VFQ-25']","[""colour vision' and 'ocular pain"", 'Visual Function Questionnaire', 'distance activities and vision-specific dependency subscales for NEI VFQ-25 scores', 'NEI VFQ-25 data']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0271202', 'cui_str': 'Hemianopsia, Homonymous'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}]","[{'cui': 'C0086032', 'cui_str': 'Daylight Vision'}, {'cui': 'C0151827', 'cui_str': 'Eye pain'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0011546', 'cui_str': 'Dependency'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",87.0,0.249442,"In subscale analysis, the most impacted across all treatment arms was 'driving' whilst the least impacted were 'colour vision' and 'ocular pain'. ","[{'ForeName': 'Fiona J', 'Initials': 'FJ', 'LastName': 'Rowe', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, L69 3GB, UK. rowef@liverpool.ac.uk.'}, {'ForeName': 'Lauren R', 'Initials': 'LR', 'LastName': 'Hepworth', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, L69 3GB, UK.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Conroy', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Naomi E A', 'Initials': 'NEA', 'LastName': 'Rainford', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Bedson', 'Affiliation': 'Clinical Trials Research Unit, University of Liverpool, Liverpool, L69 3GL, UK.'}, {'ForeName': 'Avril', 'Initials': 'A', 'LastName': 'Drummond', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'García-Fiñana', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, L69 3GA, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Howard', 'Affiliation': 'Department of Orthoptics, Salford Royal NHS Foundation Trust, Manchester, M6 8HD, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Pollock', 'Affiliation': 'Nursing, Midwifery and Allied Health Professions Research Unit, Glasgow Caledonian University, Glasgow, G4 0BA, UK.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Shipman', 'Affiliation': 'Department of Orthoptics, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, S10 2JF, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Dodridge', 'Affiliation': 'Department of Orthoptics, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK.'}, {'ForeName': 'Stevie', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Eye Clinic Support Service, Royal National Institute of Blind People, Birmingham, B29 6NA, UK.'}, {'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Noonan', 'Affiliation': 'Department of Ophthalmology, Aintree University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Sackley', 'Affiliation': ""Division of Health and Social Care, King's College, London, WC2B 5RL, UK.""}]","Eye (London, England)",['10.1038/s41433-019-0441-z'] 132,32321115,Beneficial effect of fluid warming in elderly patients with bladder cancer undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy.,"OBJECTIVES The enhanced recovery after surgery (ERAS) protocol recommends prevention of intraoperative hypothermia. However, the beneficial effect of maintaining normothermia after radical cystectomy has not been evaluated. This study aimed to investigate the efficacy of fluid warming nursing in elderly patients undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy. METHODS A total of 108 patients with bladder cancer scheduled to undergo DaVinci robotic-assisted laparoscopic radical cystectomy were recruited and randomly divided into the control group (n=55), which received a warming blanket (43°C) during the intraoperative period and the warming group (n=53), in which all intraoperative fluids were administered via a fluid warmer (41°C). The surgical data, body temperature, coagulation function indexes, and postoperative complications were compared between the two groups. RESULTS Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05). During the entire intraoperative period (from 1 to 6h), body temperature was significantly higher in the warming group than in the control group. There were significant differences in preoperative fibrinogen level, white blood cell count, total bilirubin level, intraoperative lactose level, postoperative thrombin time (TT), and platelet count between the control and warming groups. Multivariate linear regression analysis demonstrated that TT was the only significant factor, suggesting that the warming group had a lower TT than the control group. CONCLUSION Fluid warming nursing can effectively reduce transfusion requirement and hospitalization days, maintain intraoperative normothermia, and promote postoperative coagulation function in elderly patients undergoing Da Vinci robotic-assisted laparoscopic radical cystectomy.",2020,"Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05).","['elderly patients undergoing', '108 patients with bladder cancer scheduled to undergo', 'elderly patients with bladder cancer undergoing']","['fluid warming', 'DaVinci robotic-assisted laparoscopic radical cystectomy', 'warming blanket', 'Da Vinci robotic-assisted laparoscopic radical cystectomy', 'fluid warming nursing']","['intraoperative transfusion', 'preoperative fibrinogen level, white blood cell count, total bilirubin level, intraoperative lactose level, postoperative thrombin time (TT), and platelet count', 'surgical data, body temperature, coagulation function indexes, and postoperative complications', 'body temperature']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0184351', 'cui_str': 'Warming blanket'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0337428', 'cui_str': 'Fibrinogen assay'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0201913', 'cui_str': 'Bilirubin, total measurement'}, {'cui': 'C0428594', 'cui_str': 'Lactose measurement, urine, quantitative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0677634', 'cui_str': 'Reptilase time'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",108.0,0.0656869,"Compared to the control group, the warming group had significantly less intraoperative transfusion (p=0.028) and shorter hospitalization days (p<0.05).","[{'ForeName': 'Jianwei', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Department of Intensive Care Unit, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Shaoman', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Wenchan', 'Initials': 'W', 'LastName': 'Yan', 'Affiliation': 'Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Emergency, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}, {'ForeName': 'Sihua', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Operating Room, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1639'] 133,32327474,Reducing medicine-induced deterioration and adverse reactions (ReMInDAR) trial: study protocol for a randomised controlled trial in residential aged-care facilities assessing frailty as the primary outcome.,"INTRODUCTION Many medicines have adverse effects which are difficult to detect and frequently go unrecognised. Pharmacist monitoring of changes in signs and symptoms of these adverse effects, which we describe as medicine-induced deterioration, may reduce the risk of developing frailty. The aim of this trial is to determine the effectiveness of a 12-month pharmacist service compared with usual care in reducing medicine-induced deterioration, frailty and adverse reactions in older people living in aged-care facilities in Australia. METHODS AND ANALYSIS The reducing medicine-induced deterioration and adverse reactions trial is a multicentre, open-label randomised controlled trial. Participants will be recruited from 39 facilities in South Australia and Tasmania. Residents will be included if they are using four or more medicines at the time of recruitment, or taking more than one medicine with anticholinergic or sedative properties. The intervention group will receive a pharmacist assessment which occurs every 8 weeks. The pharmacists will liaise with the participants' general practitioners when medicine-induced deterioration is evident or adverse events are considered serious. The primary outcome is a reduction in medicine-induced deterioration from baseline to 6 and 12 months, as measured by change in frailty index. The secondary outcomes are changes in cognition scores, 24-hour movement behaviour, grip strength, weight, percentage robust, pre-frail and frail classification, rate of adverse medicine events, health-related quality of life and health resource use. The statistical analysis will use mixed-models adjusted for baseline to account for repeated outcome measures. A health economic evaluation will be conducted following trial completion using data collected during the trial. ETHICS AND DISSEMINATION Ethics approvals have been obtained from the Human Research Ethics Committee of University of South Australia (ID:0000036440) and University of Tasmania (ID:H0017022). A copy of the final report will be provided to the Australian Government Department of Health. TRIAL REGISTRATION NUMBER Australian and New Zealand Trials Registry ACTRN12618000766213.",2020,"The secondary outcomes are changes in cognition scores, 24-hour movement behaviour, grip strength, weight, percentage robust, pre-frail and frail classification, rate of adverse medicine events, health-related quality of life and health resource use.","['Participants will be recruited from 39 facilities in South Australia and Tasmania', 'Residents will be included if they are using four or more medicines at the time of recruitment, or taking more than one medicine with anticholinergic or sedative properties', 'residential aged-care facilities', 'older people living in aged-care facilities in Australia']",['pharmacist service compared with usual care'],"['frailty index', 'reduction in medicine-induced deterioration', 'changes in cognition scores, 24-hour movement behaviour, grip strength, weight, percentage robust, pre-frail and frail classification, rate of adverse medicine events, health-related quality of life and health resource use']","[{'cui': 'C0037715', 'cui_str': 'South Australia'}, {'cui': 'C0039335', 'cui_str': 'Tasmania'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0419193', 'cui_str': 'Care of aged'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0557854', 'cui_str': 'Services'}]","[{'cui': 'C4075886', 'cui_str': 'Frailty Index'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",,0.319413,"The secondary outcomes are changes in cognition scores, 24-hour movement behaviour, grip strength, weight, percentage robust, pre-frail and frail classification, rate of adverse medicine events, health-related quality of life and health resource use.","[{'ForeName': 'Renly', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia renly.lim@unisa.edu.au.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Bereznicki', 'Affiliation': 'School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Corlis', 'Affiliation': 'Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Kalisch Ellett', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Ai Choo', 'Initials': 'AC', 'LastName': 'Kang', 'Affiliation': 'Southern Cross Care (SA&NT), Adelaide, South Australia, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Merlin', 'Affiliation': 'Discipline of Public Health, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Gaynor', 'Initials': 'G', 'LastName': 'Parfitt', 'Affiliation': 'UniSA Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Pratt', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Rowett', 'Affiliation': 'UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Torode', 'Affiliation': 'Southern Cross Care (SA&NT), Adelaide, South Australia, Australia.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Whitehouse', 'Affiliation': 'Pharmacy Improvement Centre Ltd, Welland, South Australia, Australia.'}, {'ForeName': 'Andre Q', 'Initials': 'AQ', 'LastName': 'Andrade', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bilton', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Cousins', 'Affiliation': 'School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Kelly', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Schubert', 'Affiliation': 'Discipline of Public Health, University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Mackenzie', 'Initials': 'M', 'LastName': 'Williams', 'Affiliation': 'University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Elizabeth Ellen', 'Initials': 'EE', 'LastName': 'Roughead', 'Affiliation': 'Quality Use of Medicines and Pharmacy Research Centre, UniSA Clinical & Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}]",BMJ open,['10.1136/bmjopen-2019-032851'] 134,32221987,"Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.","OBJECTIVE To evaluate long-term safety/tolerability of brivaracetam at individualized doses ≤200 mg/d (primary) and maintenance of efficacy over time (secondary) in adults with focal seizures or primary generalized seizures (PGS) enrolled in phase 3, open-label, long-term follow-up trial N01199 (NCT00150800). METHODS Patients ≥16 years of age who had completed double-blind, placebo-controlled adjunctive brivaracetam trials NCT00175825, NCT00490035, NCT00464269, or NCT00504881 were eligible. Outcomes included safety, efficacy, and quality of life. RESULTS The safety set included 667 patients (focal seizures, 97.8%; PGS, 2.2%); the efficacy set included 648 patients with focal seizures and 15 patients with PGS. Overall, 49.2% of patients had ≥48 months of exposure. Treatment-emergent adverse events (TEAEs) occurred in 91.2% of all patients (91.3% of focal seizures group), brivaracetam discontinuation due to TEAEs in 14.8%, drug-related TEAEs in 56.7%, and serious TEAEs in 22.8%. The most common TEAEs in the focal seizures group (≥15%) were headache (25.3%) and dizziness (21.9%). Mean changes from baseline in Hospital Anxiety and Depression Scale scores at last value during 2-year evaluation were -0.7 (standard deviation [SD] = 4.3) and -0.2 (SD = 4.4) overall. In the focal seizures group, median reduction from baseline in focal seizure frequency/28 days was 57.3%, 50% responder rate was 55.6%, and 6-month and 12-month seizure freedom rates were 30.3% and 20.3%, respectively. Efficacy outcomes improved by exposure duration cohort and then stabilized through the 108-month cohort. Mean improvement from baseline in Patient-Weighted Quality of Life in Epilepsy Inventory total score (efficacy set) was 5.7 (SD = 16.1, Cohen's d = 0.35) at month 12 and 6.5 (SD = 18.0, Cohen's d = 0.36) at month 24. SIGNIFICANCE Adjunctive brivaracetam was well tolerated, with a good safety profile in long-term use in adults with epilepsy at individualized doses. Approximately half of the patients remained in the trial at 4 years. Brivaracetam reduced focal seizure frequency versus baseline. Efficacy improved with increasing exposure duration and remained stable through the 9-year cohort.",2020,"Treatment-emergent adverse events (TEAEs) occurred in 91.2% of all patients (91.3% of focal seizures group), brivaracetam discontinuation due to TEAEs in 14.8%, drug-related TEAEs in 56.7%, and serious TEAEs in 22.8%.","['patients with epilepsy', '667 patients (focal seizures, 97.8%; PGS, 2.2%); the efficacy set included 648 patients with focal seizures and 15 patients with PGS', 'adults with epilepsy at individualized doses', 'adults with focal seizures or primary generalized seizures (PGS', 'Patients ≥16\xa0years of age who had completed double-blind']","['brivaracetam', 'placebo-controlled adjunctive brivaracetam', 'adjunctive brivaracetam']","['focal seizure frequency', 'headache', 'Long-term safety, efficacy, and quality of life', 'Efficacy outcomes', 'Efficacy', 'brivaracetam discontinuation due to TEAEs', 'seizure freedom rates', 'Patient-Weighted Quality of Life in Epilepsy Inventory total score (efficacy set', 'Hospital Anxiety and Depression Scale scores', 'safety, efficacy, and quality of life', 'dizziness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C4517851', 'cui_str': '667 (qualifier value)'}, {'cui': 'C0751495', 'cui_str': 'Seizures, Focal'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0234533', 'cui_str': 'Generalized convulsion'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0751495', 'cui_str': 'Seizures, Focal'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0034380'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",648.0,0.186291,"Treatment-emergent adverse events (TEAEs) occurred in 91.2% of all patients (91.3% of focal seizures group), brivaracetam discontinuation due to TEAEs in 14.8%, drug-related TEAEs in 56.7%, and serious TEAEs in 22.8%.","[{'ForeName': 'Terence J', 'Initials': 'TJ', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Neuroscience, Central Clinical School, Alfred Health, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Borghs', 'Affiliation': 'UCB Pharma, Slough, UK.'}, {'ForeName': 'Qin Jane', 'Initials': 'QJ', 'LastName': 'He', 'Affiliation': 'UCB Pharma, Raleigh, North Carolina.'}, {'ForeName': 'Anne-Liv', 'Initials': 'AL', 'LastName': 'Schulz', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Yates', 'Affiliation': 'UCB Pharma, Raleigh, North Carolina.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Biton', 'Affiliation': 'Clinical Trials Inc, Little Rock, Arkansas.'}]",Epilepsia,['10.1111/epi.16484'] 135,32324651,The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial.,"OBJECTIVES Growth impairment is common in children with Crohn disease (CD). We aimed to assess the effect of adalimumab (ADL) treatment on linear growth in children with CD in a post-hoc analysis of the Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment randomized controlled trial. METHODS Children 6 to 17 years who responded to ADL induction were assessed consecutively for anthropometric parameters. Associations of these parameters with disease characteristics and disease activity were analyzed. RESULTS Overall, 66 patients completed 72 weeks of follow-up (25% girls, mean age of 15.6 ± 2.5 years). Median (interquartile range [IQR]) height z score improved from -0.6 (-1.6-0.15) at baseline to -0.33 (-1.3-0.5) at week 72 (P = 0.005) with lesser improvement in patients with perianal disease. Similar effect was noted in children with growth potential (boys younger than 16 years, girls younger than 14 years). Median (IQR) height velocity standard deviation was -0.32 (-1.5-0.8) at week 26, and +0.11 (-1.1-1.3) at week 72. Median weight z score increased from -0.54 (-1.2-0.15) to -0.1 (-0.9-0.6), P < 0.001 and body mass index from -0.4 (-1.0-0.5) to 0.0 (-0.8-0.9), P = 0.005. Pediatric CD activity index and erythrocyte sedimentation rate at week 4 correlated negatively with height z score changes (P = 0.043 and P = 0.048, respectively), whereas sustained clinical and biologic remission (week 4-72) were positively associated with changes in height z scores. Significant improvement in linear growth was predicted by lower pediatric CD activity index and erythrocyte sedimentation rate at the end of induction and sustained clinical remission (P = 0.05) and sustained normal C-reactive protein (P = 0.001) at all visits. CONCLUSION In children with moderate-to-severe CD, ADL treatment had a significant effect on linear growth, with normalization of weight and body mass index (clinicaltrials.gov no: NCT02256462).",2020,Pediatric CD activity index (PCDAI) and erythrocyte sedimentation rate (ESR) at week 4 correlated negatively with height z-score changes (p = ,"[""children with Crohn's disease (CD"", '66 patients completed 72 weeks of follow-up [25% females, mean age of 15.6\u200a±\u200a2.5 years', 'children with CD', 'children with growth potential (boys\u200a<\u200a16 years, girls<14 years', 'patients with perianal disease', ""Children with Crohn's Disease"", 'Children 6-17 years who responded to ADL induction were assessed consecutively for anthropometric parameters']","['adalimumab (ADL', 'Adalimumab']","['Pediatric CD activity index (PCDAI) and erythrocyte sedimentation rate (ESR', 'Median weight z-score', 'Median (IQR) height velocity standard deviation', 'linear growth, with normalization of weight and BMI', 'Linear Growth', 'Median (IQR) height z-score', 'sustained clinical and biologic remission', 'height z-scores', 'lower PCDAI and ESR at the end of induction and sustained clinical remission', 'linear growth', 'sustained normal C-reactive protein']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}]","[{'cui': 'C2931133', 'cui_str': ""Pediatric Crohn's disease""}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",72.0,0.113056,Pediatric CD activity index (PCDAI) and erythrocyte sedimentation rate (ESR) at week 4 correlated negatively with height z-score changes (p = ,"[{'ForeName': 'Manar', 'Initials': 'M', 'LastName': 'Matar', 'Affiliation': ""The Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital, Petach-Tikva.""}, {'ForeName': 'Raanan', 'Initials': 'R', 'LastName': 'Shamir', 'Affiliation': ""The Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital, Petach-Tikva.""}, {'ForeName': 'Raffi', 'Initials': 'R', 'LastName': 'Lev-Zion', 'Affiliation': 'The Juliet Keidan institute of Pediatric Gastroenterology, Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem.'}, {'ForeName': 'Efrat', 'Initials': 'E', 'LastName': 'Broide', 'Affiliation': 'The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.'}, {'ForeName': 'Batia', 'Initials': 'B', 'LastName': 'Weiss', 'Affiliation': 'The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Ledder', 'Affiliation': 'The Juliet Keidan institute of Pediatric Gastroenterology, Nutrition, Shaare Zedek Medical Center, The Hebrew University, Jerusalem.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Guz-Mark', 'Affiliation': ""The Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital, Petach-Tikva.""}, {'ForeName': 'Firas', 'Initials': 'F', 'LastName': 'Rinawi', 'Affiliation': ""The Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital, Petach-Tikva.""}, {'ForeName': 'Shlomi', 'Initials': 'S', 'LastName': 'Cohen', 'Affiliation': 'The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.'}, {'ForeName': 'Chani', 'Initials': 'C', 'LastName': 'Topf-Olivestone', 'Affiliation': 'Pediatric Gastroenterology Unit, Kaplan Medical Center, Rehovot.'}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Shaoul', 'Affiliation': 'Pediatric Gastroenterology Unit, Rambam Medical Center, Haifa.'}, {'ForeName': 'Baruch', 'Initials': 'B', 'LastName': 'Yerushalmi', 'Affiliation': 'Pediatric Gastroenterology Unit, Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Assa', 'Affiliation': ""The Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Hospital, Petach-Tikva.""}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002728'] 136,32273183,"The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.","BACKGROUND External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT) is an established treatment option to prolong survival for patients with intermediate- and high-risk prostate cancer (PCa). Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, was evaluated in this clinical setting in comparison with degarelix, an injectable GnRH antagonist. OBJECTIVE To evaluate the safety and efficacy of relugolix to achieve and maintain castration. DESIGN, SETTING, AND PARTICIPANTS A phase 2 open-label study was conducted in 103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015. INTERVENTION Patients randomly assigned (3:2) to 24-wk treatment with either daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was the rate of effective castration (testosterone <1.73nmol/l) in relugolix patients between 4 and 24 wk of treatment. Secondary endpoints included rate of profound castration (testosterone <0.7nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL) assessed using the Aging Males' Symptoms scale, and the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (30-item EORTC core questionnaire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25]) questionnaires, and safety. No formal statistical comparisons with degarelix were planned. RESULTS AND LIMITATIONS Castration rates during treatment were 95% and 82% with relugolix and 89% and 68% with degarelix for 1.73 and 0.7nmol/l thresholds, respectively. Median time to castration in the relugolix arm was 4 d. During treatment, PSA levels and prostate volumes were reduced in both groups. Three months after discontinuing treatment, 52% of men on relugolix and 16% on degarelix experienced testosterone recovery (statistical significance of differences not tested). Mean and median QoL scores improved following treatment discontinuation. The most common adverse event was hot flush (relugolix 57%; degarelix 61%). Lack of blinding was a potential limitation. CONCLUSIONS Relugolix achieved testosterone suppression to castrate levels within days and maintained it over 24 wk with a safety profile consistent with its mechanism of action. PATIENT SUMMARY Oral once-daily relugolix may be a novel oral alternative to injectable androgen deprivation therapies.",2020,The most common adverse event was hot flush (relugolix 57%; degarelix 61%).,"['Patients with Localised Intermediate-risk Prostate Cancer', '103 intermediate-risk PCa patients undergoing primary EBRT and neoadjuvant/adjuvant ADT between June 2014 and December 2015', 'patients with intermediate- and high-risk prostate cancer (PCa']","['Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy', 'degarelix', 'oral gonadotropin-releasing hormone (GnRH) receptor antagonist', 'External beam radiotherapy (EBRT) with neoadjuvant/adjuvant androgen deprivation therapy (ADT', 'Open-label', 'daily oral relugolix or 4-wk subcutaneous depot degarelix (reference control']","['Castration rates', 'degarelix experienced testosterone recovery', 'testosterone suppression to castrate levels', 'rate of effective castration (testosterone <1.73nmol/l', 'Quality of Life (30-item EORTC core questionnaire [EORTC QLQ-C30] and 25-item EORTC prostate cancer module [EORTC QLQ-PR25]) questionnaires, and safety', 'PSA levels and prostate volumes', 'Median time to castration', ""rate of profound castration (testosterone <0.7nmol/l), prostate-specific antigen (PSA) levels, prostate volume, quality of life (QoL) assessed using the Aging Males' Symptoms scale, and the European Organization for Research and Treatment of Cancer (EORTC"", 'Mean and median QoL scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1268855', 'cui_str': 'Gonadotropin releasing hormone receptor antagonist-containing product'}, {'cui': 'C3896936', 'cui_str': 'relugolix'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0419095', 'cui_str': 'Teleradiotherapy procedure'}, {'cui': 'C1455035', 'cui_str': 'degarelix'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0007344', 'cui_str': 'Gonadectomy'}, {'cui': 'C1455035', 'cui_str': 'degarelix'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439808', 'cui_str': 'Profound'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0914332,The most common adverse event was hot flush (relugolix 57%; degarelix 61%).,"[{'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Dearnaley', 'Affiliation': 'The Institute of Cancer Research and Royal Marsden Hospital, London, UK. Electronic address: david.dearnaley@icr.ac.uk.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Saltzstein', 'Affiliation': 'Urology San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Sylvester', 'Affiliation': '21st Century Oncology, Bradenton, FL, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Karsh', 'Affiliation': 'The Urology Center of Colorado, Denver, CO, USA.'}, {'ForeName': 'Bryan A', 'Initials': 'BA', 'LastName': 'Mehlhaff', 'Affiliation': 'Oregon Urology, Springfield, OR, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Pieczonka', 'Affiliation': 'Associated Medical Professionals of NY, Syracuse, NY, USA.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Bailen', 'Affiliation': 'First Urology, Jeffersonville, IN, USA.'}, {'ForeName': 'Hongliang', 'Initials': 'H', 'LastName': 'Shi', 'Affiliation': 'Blueprint Medicines Corporation, Cambridge, MA, USA.'}, {'ForeName': 'Zhan', 'Initials': 'Z', 'LastName': 'Ye', 'Affiliation': 'Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(†).'}, {'ForeName': 'Hélène M', 'Initials': 'HM', 'LastName': 'Faessel', 'Affiliation': 'Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(†).'}, {'ForeName': 'Huamao', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(†).'}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(†).'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'University of Montreal Hospital Center, Montreal, QC, Canada.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'MacLean', 'Affiliation': 'Millennium Pharmaceuticals, Inc., Cambridge, MA, USA(†).'}, {'ForeName': 'Neal D', 'Initials': 'ND', 'LastName': 'Shore', 'Affiliation': 'Carolina Urologic Research Center, Myrtle Beach, SC, USA.'}]",European urology,['10.1016/j.eururo.2020.03.001'] 137,32329237,Addressing Challenging Behavior During Hospitalizations for Children with Autism: A Pilot Applied Behavior Analysis Randomized Controlled Trial.,"This study evaluated the feasibility, acceptance, and potential clinical benefit of brief applied behavior analysis (ABA)-based interventions for children and adolescents with autism spectrum disorder (ASD) displaying challenging behaviors during hospitalizations. Participants included 36 children diagnosed with ASD, 6-17 years of age, who were medically or psychiatrically hospitalized. Children in the intervention group received a brief ABA intervention and were compared to children in the evaluation and monitoring-only group. Families and staff recommended the intervention, children receiving the intervention demonstrated significantly more improvement in unblinded ratings of clinical severity, data from physicians indicated a positive effect of the intervention on levels of staffing and restraints and attending medical providers universally reported satisfaction and benefit of the intervention. Improvements in challenging behaviors were not significantly different as reported by parents, and the length of hospitalization did not differ between the groups. Ultimately, the outcomes of this pilot study suggest incorporating specialized ABA-based assessment and intervention during hospitalization may be feasible and well accepted by clinicians and families. However, future research must address potent methodological challenges related to capturing meaningful data during hospitalizations in order to answer questions of ultimate pragmatic, clinical, and system-level benefits. Trial Registration ClinicalTrials.gov Identifier NCT02339935, Registered 16 January 2015, First participant consented 23 February 2015. Autism Res 2020, 13: 1072-1078. © 2020 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: Inpatient hospitalizations for children with autism spectrum disorder (ASD) and severe behavior are common, challenging, and costly in terms of human experience. This study evaluated the benefit of brief applied behavior analysis-based interventions to children and adolescents with ASD displaying challenging behaviors during hospitalizations. Families and staff evaluating the procedures noted perceived potential benefits of the intervention, but this initial pilot study did not document changes in hospitalization length or blinded rating of improvement.",2020,"Families and staff recommended the intervention, children receiving the intervention demonstrated significantly more improvement in unblinded ratings of clinical severity, data from physicians indicated a positive effect of the intervention on levels of staffing and restraints and attending medical providers universally reported satisfaction and benefit of the intervention.","['children and adolescents with autism spectrum disorder (ASD', 'Registered 16 January 2015, First participant consented 23 February 2015', 'Participants included 36 children diagnosed with ASD, 6-17\u2009years of age, who were medically or psychiatrically hospitalized', 'Children with Autism', 'children with autism spectrum disorder (ASD', 'children and adolescents with ASD displaying challenging behaviors during hospitalizations']","['brief ABA intervention', 'brief applied behavior analysis (ABA)-based interventions', 'specialized ABA-based assessment and intervention']","['levels of staffing and restraints', 'length of hospitalization', 'hospitalization length']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0474414', 'cui_str': 'Challenging behavior'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C4277701', 'cui_str': 'Applied Behavior Analysis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",36.0,0.0853917,"Families and staff recommended the intervention, children receiving the intervention demonstrated significantly more improvement in unblinded ratings of clinical severity, data from physicians indicated a positive effect of the intervention on levels of staffing and restraints and attending medical providers universally reported satisfaction and benefit of the intervention.","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Sanders', 'Affiliation': 'Department of Psychiatry and Behavior Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Staubitz', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'A Pablo', 'Initials': 'AP', 'LastName': 'Juárez', 'Affiliation': 'Department of Psychiatry and Behavior Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Marler', 'Affiliation': 'Department of Psychiatry and Behavior Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Whitney', 'Initials': 'W', 'LastName': 'Browning', 'Affiliation': 'Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'McDonnell', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Lily', 'Initials': 'L', 'LastName': 'Altstein', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Macklin', 'Affiliation': 'Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Warren', 'Affiliation': 'Department of Psychiatry and Behavior Sciences, Vanderbilt University Medical Center, Nashville, Tennessee, USA.'}]",Autism research : official journal of the International Society for Autism Research,['10.1002/aur.2308'] 138,32325164,Perineural Dextrose and Corticosteroid Injections for Ulnar Neuropathy at the Elbow: A Randomized Double-blind Trial.,"OBJECTIVE To assess the effects of perineural corticosteroid and 5% dextrose water (D5W) injections in patients with mild to moderate ulnar neuropathy at the elbow (UNE). DESIGN Prospective, randomized, double-blind, controlled trial (6-month follow-up). SETTING Outpatients of local medical center settings. PARTICIPANTS Patients (N=36) with mild to moderate UNE were randomized, and 33 participants were included in the final data analysis. INTERVENTIONS Patients were administered a single perineural injection with 5 mL D5W and 3 mL corticosteroid (triamcinolone acetonide, 10mg/mL) mixed with 2 mL normal saline under ultrasound guidance in the dextrose and steroid groups, respectively. MAIN OUTCOME MEASURES The visual analog scale digital pain or paresthesia/dysesthesia score was the primary outcome. The secondary outcomes were the Disabilities of the Arm, Shoulder, and Hand questionnaire, motor nerve conduction velocity, and cross-sectional area (CSA) of the ulnar nerve. The measurement assessment was conducted before and 1, 3, 4, and 6 months after injection. RESULTS Thirty-three patients completed the study. Both injections were found to be equally effective at most measurement points, although the dextrose group experienced larger reductions in symptom severity and CSA of the ulnar nerve from the third month onward. CONCLUSIONS We suggest D5W as a more suitable injectate for perineural injection in patients with UNE.",2020,"Both injections were found to be equally effective at most measurement points, although the dextrose group experienced larger reductions in symptom severity and CSA of the ulnar nerve from the 3 rd month onward. ","['ulnar neuropathy at the elbow', 'Outpatients of local medical center settings', 'Thirty-six patients with mild-to-moderate UNE were randomized and 33 participants were included in the final data analysis', 'patients with mild-to-moderate ulnar neuropathy at the elbow (UNE', 'Thirty-three patients completed the study']","['perineural corticosteroid and 5% dextrose water', 'Perineural dextrose and corticosteroid injections', 'single perineural injection with 5 mL D5W and 3 mL corticosteroid (10 mg/mL) mixed with 2 mL normal saline under ultrasound guidance in the dextrose and steroid groups, respectively']","['symptom severity and CSA of the ulnar nerve', 'dysesthesia score', 'Disabilities of the Arm, Shoulder, and Hand questionnaire, motor nerve conduction velocity, and cross-sectional area (CSA) of the ulnar nerve', 'visual analog scale digital pain or paresthesia']","[{'cui': 'C0154743', 'cui_str': 'Ulnar neuropathy'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1518982', 'cui_str': 'Perineural route'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0985452', 'cui_str': 'Glucose 50 MG/ML'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0041602', 'cui_str': 'Structure of ulnar nerve'}, {'cui': 'C0241057', 'cui_str': 'Burning sensation of skin'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0457379', 'cui_str': 'Motor nerve conduction velocity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}]",36.0,0.570527,"Both injections were found to be equally effective at most measurement points, although the dextrose group experienced larger reductions in symptom severity and CSA of the ulnar nerve from the 3 rd month onward. ","[{'ForeName': 'Liang-Cheng', 'Initials': 'LC', 'LastName': 'Chen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Tsung-Yen', 'Initials': 'TY', 'LastName': 'Ho', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China; Department of Physical Medicine and Rehabilitation, Taichung Armed Forces General Hospital, Taichung City, Taiwan, Republic of China.'}, {'ForeName': 'Yu-Ping', 'Initials': 'YP', 'LastName': 'Shen', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Yu-Chi', 'Initials': 'YC', 'LastName': 'Su', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Tsung-Ying', 'Initials': 'TY', 'LastName': 'Li', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China; Integrated Pain Management Center, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Chia-Kuang', 'Initials': 'CK', 'LastName': 'Tsai', 'Affiliation': 'Department of Neurology, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China; Graduate Institute of Medical Science, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.'}, {'ForeName': 'Yung-Tsan', 'Initials': 'YT', 'LastName': 'Wu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China; Integrated Pain Management Center, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China. Electronic address: crwu98@gmail.com.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.03.016'] 139,32286643,Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.,"Importance Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP) vaccine in endemic regions. Design, Setting, and Participants This was a randomized, placebo-controlled, double-blind, phase 2 clinical trial to assess the vaccine VRC-CHKVLP059-00-VP (CHIKV VLP). The trial was conducted at 6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico. A total of 400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria. The first study enrollment occurred on November 18, 2015; the final study visit, March 6, 2018. Interventions Participants were randomized 1:1 to receive 2 intramuscular injections 28 days apart (20 µg, n = 201) or placebo (n = 199) and were followed up for 72 weeks. Main Outcomes and Measures The primary outcome was the safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity) of the vaccine, and the secondary outcome was immune response by neutralization assay 4 weeks after second vaccination. Results Of the 400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis. All injections were well tolerated. Of the 16 serious adverse events unrelated to the study drugs, 4 (25%) occurred among 4 patients in the vaccine group and 12 (75%) occurred among 11 patients in the placebo group. Of the 16 mild to moderate unsolicited adverse events that were potentially related to the drug, 12 (75%) occurred among 8 patients in the vaccine group and 4 (25%) occurred among 3 patients in the placebo group. All potentially related adverse events resolved without clinical sequelae. At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57). Eight weeks following the first administration, the EC50 GMT in the vaccine group was 2005 (95% CI, 1680-2392) vs 43 (95% CI, 32-58; P < .001) in the placebo group. Durability of the immune response was demonstrated through 72 weeks after vaccination. Conclusions and Relevance Among healthy adults in a chikungunya endemic population, a virus-like particle vaccine compared with placebo demonstrated safety and tolerability. Phase 3 trials are needed to assess clinical efficacy. Trial Registration ClinicalTrials.gov Identifier: NCT02562482.",2020,"At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57).","['endemic regions', 'healthy adults in a chikungunya endemic population', '400 healthy adults aged 18 through 60 years were enrolled after meeting eligibility criteria', '400 randomized participants (mean age, 35 years; 199 [50%] women), 393 (98%) completed the primary safety analysis', '6 outpatient clinical research sites located in Haiti, Dominican Republic, Martinique, Guadeloupe, and Puerto Rico']","['Chikungunya Virus-Like Particle Vaccine', 'vaccine VRC-CHKVLP059-00-VP (CHIKV VLP', 'placebo', 'investigational CHIKV virus-like particle (VLP) vaccine']","['EC50 GMT', 'tolerated', 'safety and tolerability', 'safety (laboratory parameters, adverse events, and CHIKV infection) and tolerability (local and systemic reactogenicity', 'Safety and Tolerability Outcomes']","[{'cui': 'C0243130', 'cui_str': 'endemics'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0008055', 'cui_str': 'Chikungunya fever'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517754', 'cui_str': '393'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0018510', 'cui_str': 'Haiti'}, {'cui': 'C0013014', 'cui_str': 'Dominican Republic'}, {'cui': 'C0024853', 'cui_str': 'Martinique'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}, {'cui': 'C0034044', 'cui_str': 'Puerto Rico'}]","[{'cui': 'C0008056', 'cui_str': 'Chikungunya virus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0333785', 'cui_str': 'Virus-like particles'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0008055', 'cui_str': 'Chikungunya fever'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",400.0,0.684011,"At baseline, there was no significant difference between the effective concentration (EC50)-which is the dilution of sera that inhibits 50% infection in viral neutralization assay-geometric mean titers (GMTs) of neutralizing antibodies of the vaccine group (46; 95% CI, 34-63) and the placebo group (43; 95% CI, 32-57).","[{'ForeName': 'Grace L', 'Initials': 'GL', 'LastName': 'Chen', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Coates', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Sarah H', 'Initials': 'SH', 'LastName': 'Plummer', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Cristina A', 'Initials': 'CA', 'LastName': 'Carter', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Berkowitz', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Conan-Cibotti', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Josephine H', 'Initials': 'JH', 'LastName': 'Cox', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Beck', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': ""O'Callahan"", 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Charla', 'Initials': 'C', 'LastName': 'Andrews', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Ingelise J', 'Initials': 'IJ', 'LastName': 'Gordon', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Larkin', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Lampley', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Kaltovich', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Gall', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Carlton', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Mendy', 'Affiliation': 'Emergent BioSolutions, San Diego, California.'}, {'ForeName': 'Doug', 'Initials': 'D', 'LastName': 'Haney', 'Affiliation': 'Emergent BioSolutions, San Diego, California.'}, {'ForeName': 'Jeanine', 'Initials': 'J', 'LastName': 'May', 'Affiliation': 'The Emmes Company, Rockville, Maryland.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Bray', 'Affiliation': 'The Emmes Company, Rockville, Maryland.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Bailer', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Dowd', 'Affiliation': 'Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Brittanie', 'Initials': 'B', 'LastName': 'Brockett', 'Affiliation': 'Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gordon', 'Affiliation': 'Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Koup', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schwartz', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Mascola', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Barney S', 'Initials': 'BS', 'LastName': 'Graham', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Theodore C', 'Initials': 'TC', 'LastName': 'Pierson', 'Affiliation': 'Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Yeycy', 'Initials': 'Y', 'LastName': 'Donastorg', 'Affiliation': 'Instituto Dermatologico y Cirugia de Piel (IDCP), Dominican Republic.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rosario', 'Affiliation': 'San Juan Hospital, Puerto Rico.'}, {'ForeName': 'Jean William', 'Initials': 'JW', 'LastName': 'Pape', 'Affiliation': ""The Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (Centres GHESKIO), Haiti.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Hoen', 'Affiliation': ""INSERM Centre d'Investigation Clinique (CIC) 1424, Centre Hospitalier Universitaire (CHU) de la Guadeloupe, France.""}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Cabié', 'Affiliation': ""INSERM Centre d'Investigation Clinique (CIC) 1424, Centre Hospitalier Universitaire (CHU) de Martinique, France.""}, {'ForeName': 'Clemente', 'Initials': 'C', 'LastName': 'Diaz', 'Affiliation': 'PR Clinical and Translational Research Consortium (PRCTRC), Puerto Rico.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Ledgerwood', 'Affiliation': 'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2020.2477'] 140,30653422,"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.","PURPOSE Single-cycle melphalan 200 mg/m 2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression. PATIENTS AND METHODS Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS. RESULTS The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms. CONCLUSION Second AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.",2019,"Toxicity profiles and development of second primary malignancies were similar across treatment arms. ","['Multiple Myeloma', 'transplantation-eligible patients with multiple myeloma (MM', 'Patients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger', 'The study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment']","['melphalan 200 mg/m 2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance', 'AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD', 'AHCT + RVD + len', 'Autologous Transplantation, Consolidation, and Maintenance Therapy', 'AHCT + len', 'AHCT/AHCT + len']","['38-month PFS', 'complete response rates', '38-month PFS rate', 'Toxicity profiles and development of second primary malignancies', 'progression-free survival (PFS) and overall survival (OS', 'PFS or OS', 'OS rates']","[{'cui': 'C0026764', 'cui_str': 'Myelomatosis'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0206153', 'cui_str': 'Cell Transplantation'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0075804', 'cui_str': 'TANDEM'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0040736', 'cui_str': 'Autotransplantation'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0751623', 'cui_str': 'Second Cancer'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",257.0,0.105093,"Toxicity profiles and development of second primary malignancies were similar across treatment arms. ","[{'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': 'Stadtmauer', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Marcelo C', 'Initials': 'MC', 'LastName': 'Pasquini', 'Affiliation': '2 Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Blackwell', 'Affiliation': '3 The Emmes Corporation, Rockville, MD.'}, {'ForeName': 'Parameswaran', 'Initials': 'P', 'LastName': 'Hari', 'Affiliation': '2 Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Asad', 'Initials': 'A', 'LastName': 'Bashey', 'Affiliation': '4 BMT Group of Georgia, Atlanta, GA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Devine', 'Affiliation': '5 The Ohio State University, Columbus, OH.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Efebera', 'Affiliation': '5 The Ohio State University, Columbus, OH.'}, {'ForeName': 'Siddharta', 'Initials': 'S', 'LastName': 'Ganguly', 'Affiliation': '6 University of Kansas Hospital, Kansas City, KS.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Gasparetto', 'Affiliation': '7 Duke University, Durham, NC.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Geller', 'Affiliation': '8 National Heart, Lung, and Blood Institute, Rockville, MD.'}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Horowitz', 'Affiliation': '2 Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Koreth', 'Affiliation': '9 Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Knust', 'Affiliation': '3 The Emmes Corporation, Rockville, MD.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Landau', 'Affiliation': '10 Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Brunstein', 'Affiliation': '11 University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McCarthy', 'Affiliation': '12 Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Nelson', 'Affiliation': '3 The Emmes Corporation, Rockville, MD.'}, {'ForeName': 'Muzaffar H', 'Initials': 'MH', 'LastName': 'Qazilbash', 'Affiliation': '13 The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': '14 University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Vesole', 'Affiliation': '15 Hackensack University, Hackensack, NJ.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Vij', 'Affiliation': '16 Washington University, St Louis, MO.'}, {'ForeName': 'Dan T', 'Initials': 'DT', 'LastName': 'Vogl', 'Affiliation': '1 University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Giralt', 'Affiliation': '10 Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Somlo', 'Affiliation': '17 City of Hope, Los Angeles, CA.'}, {'ForeName': 'Amrita', 'Initials': 'A', 'LastName': 'Krishnan', 'Affiliation': '17 City of Hope, Los Angeles, CA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.18.00685'] 141,31427637,Statin treatment after acute coronary syndrome: Adherence and reasons for non-adherence in a randomized controlled intervention trial.,"Studies of secondary prevention for cardiovascular disease show low fulfilment of guideline-recommended targets. This study explored whether nurse-led follow-up could increase adherence to statins over time and reasons for discontinuation. All patients admitted for acute coronary syndrome at Östersund hospital between 2010-2014 were screened for the randomized controlled NAILED-ACS trial. The trial comprises two groups, one with nurse-led annual follow-up and medical titration by telephone to reach set intervention targets and one with usual care. All discontinuations of statins were recorded prospectively for at least 36 months and categorized as avoidable or unavoidable. Kaplan-Meier estimates were conducted for first and permanent discontinuations. Predictors for discontinuation were analysed using multivariate Cox regression, statin type and mean LDL-C at end of follow-up. Female gender was a predictor for discontinuation. Allocation in the intervention group predicted increased risk for a first but decreased risk for permanent discontinuation. A nurse-led telemedical secondary prevention programme in a relatively unselected ACS cohort leads to increased adherence to statins over time, greater percentage on potent treatment and lower LDL-C compared to usual care. An initially increased tendency toward early discontinuation in the intervention group stresses the importance of a longer duration of structured follow-up.",2019,"A nurse-led telemedical secondary prevention programme in a relatively unselected ACS cohort leads to increased adherence to statins over time, greater percentage on potent treatment and lower LDL-C compared to usual care.","['after acute coronary syndrome', 'All patients admitted for acute coronary syndrome at Östersund hospital between 2010-2014 were screened for the randomized controlled NAILED-ACS trial']","['Statin treatment', 'nurse-led annual follow-up and medical titration by telephone to reach set intervention targets and one with usual care']",[],"[{'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0027342', 'cui_str': 'Nails'}]","[{'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0036849', 'cui_str': 'Set'}]",[],2014.0,0.0324895,"A nurse-led telemedical secondary prevention programme in a relatively unselected ACS cohort leads to increased adherence to statins over time, greater percentage on potent treatment and lower LDL-C compared to usual care.","[{'ForeName': 'Huber', 'Initials': 'H', 'LastName': 'Daniel', 'Affiliation': 'Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Östersund, Sweden. daniel.huber@regionjh.se.'}, {'ForeName': 'Wikén', 'Initials': 'W', 'LastName': 'Christian', 'Affiliation': 'Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Östersund, Sweden.'}, {'ForeName': 'Henriksson', 'Initials': 'H', 'LastName': 'Robin', 'Affiliation': 'Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Östersund, Sweden.'}, {'ForeName': 'Söderström', 'Initials': 'S', 'LastName': 'Lars', 'Affiliation': 'Unit of Research, Development and Education, Region Jämtland Härjedalen, Östersund Hospital, Östersund, Sweden.'}, {'ForeName': 'Mooe', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Östersund, Sweden.'}]",Scientific reports,['10.1038/s41598-019-48540-3'] 142,32329527,"Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES).","OBJECTIVE To evaluate the effectiveness and tolerability of lacosamide added to one or two antiepileptic drugs (AEDs) in the treatment of patients with brain tumor-related epilepsy (BTRE), and to evaluate patients' global impression of change and quality of life (QoL). METHODS This was a prospective, multicenter, single-arm, noninterventional study with a 6-month observation period (EP0045; NCT02276053). Eligible patients (≥16 years old) had active BTRE secondary to low-grade glioma (World Health Organization grade 1 and 2) and were receiving treatment with one or two AEDs at baseline. Lacosamide was initiated by the treating physician in the course of routine clinical practice. Primary outcomes were 50% responders (≥50% reduction in focal seizure frequency from baseline) and Patient's Global Impression of Change (PGIC) at month 6. Secondary outcomes included seizure-free status and Clinical Global Impression of Change (CGIC) at month 6, change in QoL (5-Level EuroQol-5 Dimension Quality of Life Assessment) and symptom outcomes (MD Anderson Symptom Inventory-Brain Tumor) from baseline to month 6, and Kaplan-Meier estimated 6-month retention on lacosamide. Safety variables included adverse drug reactions (ADRs). RESULTS Patients were recruited from 24 sites in Europe. Ninety-three patients received lacosamide (mean [standard deviation] age = 44.5 [14.7] years; 50 [53.8%] male; median baseline focal seizure frequency = five seizures/28 days [range = 1-280]), of whom 79 (84.9%) completed the study. At 6 months, 66 of 86 (76.7%) patients were 50% responders and 30 of 86 (34.9%) were seizure-free. Improvements on PGIC were reported by 49 of 76 (64.5%) patients. Based on CGIC, 52 of 81 (64.2%) patients improved. QoL and symptoms outcome measures remained stable. Kaplan-Meier estimated 6-month retention rate was 86.0% (N = 93). Fifteen (16.1%) patients reported ADRs; four (4.3%) had ADRs leading to discontinuation (N = 93). SIGNIFICANCE Results of this prospective, noninterventional study suggest that add-on lacosamide is effective and generally well tolerated in patients with BTRE.",2020,"Based on CGIC, 52 of 81 (64.2%) patients improved.","['Patients were recruited from 24 sites in Europe', 'patients with brain tumor-related epilepsy (BTRE', 'patients with BTRE', 'patients with brain tumor-related epilepsy', 'Ninety-three patients received lacosamide (mean [standard deviation] age = 44.5 [14.7] years; 50 [53.8%] male; median baseline focal seizure frequency = five seizures/28\xa0days [range = 1-280]), of whom 79 (84.9%) completed the study', 'Eligible patients (≥16\xa0years old) had active BTRE secondary to low-grade glioma (World Health Organization grade 1 and 2) and were receiving treatment with one or two AEDs at baseline']","['antiepileptic drugs (AEDs', 'Lacosamide', 'lacosamide']","['seizure-free status and Clinical Global Impression of Change (CGIC) at month 6, change in QoL (5-Level EuroQol-5 Dimension Quality of Life Assessment) and symptom outcomes (MD Anderson Symptom Inventory-Brain Tumor) from baseline to month 6, and Kaplan-Meier estimated 6-month retention on lacosamide', 'adverse drug reactions (ADRs', 'PGIC', ""focal seizure frequency from baseline) and Patient's Global Impression of Change (PGIC"", 'Kaplan-Meier estimated 6-month retention rate', 'effectiveness and tolerability', 'Effectiveness and tolerability', 'seizure-free']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0006118', 'cui_str': 'Neoplasm of brain'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0893761', 'cui_str': 'lacosamide'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C1997217', 'cui_str': 'Low grade glioma'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}]","[{'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0893761', 'cui_str': 'lacosamide'}]","[{'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0456951', 'cui_str': 'Level 5'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0006118', 'cui_str': 'Neoplasm of brain'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1720943', 'cui_str': 'Kaplan-Meier Analysis'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0893761', 'cui_str': 'lacosamide'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0621912,"Based on CGIC, 52 of 81 (64.2%) patients improved.","[{'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Rudà', 'Affiliation': 'Department of Neuro-Oncology, City of Health and Science and University of Turin, Turin, Italy.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Houillier', 'Affiliation': 'AP-HP, Sorbonne Université, IHU, ICM, Public Hospital Network of Paris, Service de Neurologie 2-Mazarin, Hôpitaux, Universitaires La Pitié Salpêtrière - Charles Foix, Paris, France.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Maschio', 'Affiliation': 'Center for Tumor-Related Epilepsy, UOSD Neuro-Oncology IRCCS, Regina Elena National Cancer Institute, Rome, Italy.'}, {'ForeName': 'Jaap C', 'Initials': 'JC', 'LastName': 'Reijneveld', 'Affiliation': 'Amsterdam UMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Scarlett', 'Initials': 'S', 'LastName': 'Hellot', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'De Backer', 'Affiliation': 'UCB Pharma, Brussels, Belgium.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Chan', 'Affiliation': 'UCB Pharma, Slough, UK.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Joeres', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Iryna', 'Initials': 'I', 'LastName': 'Leunikava', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Glas', 'Affiliation': 'Division of Clinical Neuro-oncology, Department of Neurology, West German Cancer Center and German Cancer Consortium Partner Site, Essen University Hospital, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Grant', 'Affiliation': 'Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK.'}]",Epilepsia,['10.1111/epi.16486'] 143,32325005,Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial.,"Rationale: Idiopathic pulmonary fibrosis (IPF) is a deadly disease with increasingly impaired health-related quality of life (HRQOL). eHealth technologies facilitate collection of physiological outcomes and patient-reported outcomes at home, but randomized controlled trials (RCTs) on the effects of eHealth are scarce. Objectives: To investigate whether a home monitoring program improves HRQOL and medication use for patients with IPF. Methods: We performed a multicenter RCT in newly treated patients with IPF. Patients were randomly assigned to standard care or a home monitoring program on top of standard care for 24 weeks. The home monitoring program included home spirometry, reporting of symptoms and side effects, patient-reported outcomes, information, a medication coach, and eConsultations. The primary endpoint was between-group difference in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks. Measurements and Main Results: A total of 90 patients were randomized (46 assigned to the home monitoring group and 44 to the standard care group). After 24 weeks, no statistically significant difference was found in K-BILD total score, with a 2.70-point increase in the home monitoring group (SD = 9.5) and a 0.03-point increase in the standard care group (SD = 10.4); between-group difference was 2.67 points (95% confidence interval [CI], -1.85 to 7.17; P  = 0.24). Between-group difference in psychological domain score was 5.6 points (95% CI, -1.13 to 12.3; P  = 0.10), with an increase of 5.12 points in the home monitoring group (SD = 15.8) and a decline of 0.48 points in the standard care group (SD = 13.3). In the home monitoring group, medication was more often adjusted (1 vs. 0.3 adjustments per patient; 95% CI, 0.2 to 1.3; P  = 0.027). Patient satisfaction with the home monitoring program was high. Home-based spirometry was highly correlated with hospital-based spirometry over time. Conclusions: The results of this first-ever eHealth RCT in IPF showed that a comprehensive home monitoring program did not improve overall HRQOL measured with K-BILD but tended to improve psychological well-being. Home monitoring was greatly appreciated by patients and allowed for individually tailored medication adjustments.Clinical trial registered with www.clinicaltrials.gov (NCT03420235).",2020,"After 24 weeks, no statistically significant differences were found in K-BILD total score (home monitoring group:+2.7 points, standard care:+0.03, p=0.24) and psychological domain score (home monitoring group:+5.1, standard care:-0.5, p=0.1).","['IPF patients', '90 patients were randomized (46 patients home monitoring, 44 standard care', 'Patients with Idiopathic Pulmonary Fibrosis', 'Idiopathic pulmonary fibrosis (IPF', 'newly treated patients with IPF']",['standard care or a home monitoring program'],"['psychological domain score', 'change in Kings Brief Interstitial Lung disease (K-BILD) questionnaire score', 'psychological wellbeing', 'home spirometry, reporting of symptoms and side-effects, PROMs, information, a medication coach and eConsultations', 'overall HRQOL', 'K-BILD total score']","[{'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",90.0,0.0641793,"After 24 weeks, no statistically significant differences were found in K-BILD total score (home monitoring group:+2.7 points, standard care:+0.03, p=0.24) and psychological domain score (home monitoring group:+5.1, standard care:-0.5, p=0.1).","[{'ForeName': 'Catharina C', 'Initials': 'CC', 'LastName': 'Moor', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Rémy L M', 'Initials': 'RLM', 'LastName': 'Mostard', 'Affiliation': 'Department of Respiratory Medicine, Zuyderland Medical, Heerlen, the Netherlands.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Department of Pulmonology, Interstitial Lung Diseases Centre of Excellence, St. Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bresser', 'Affiliation': 'Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands; and.'}, {'ForeName': 'Joachim G J V', 'Initials': 'JGJV', 'LastName': 'Aerts', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Niels H', 'Initials': 'NH', 'LastName': 'Chavannes', 'Affiliation': 'Department of Public Health and Primary Care, National eHealth Living Lab, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Marlies S', 'Initials': 'MS', 'LastName': 'Wijsenbeek', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.202002-0328OC'] 144,32325162,Effects of an Individualized Comprehensive Rehabilitation Program on Impaired Postural Control in Women With Chronic Pelvic Pain: A Randomized Controlled Trial.,"OBJECTIVE To assess the effectiveness of an individualized comprehensive rehabilitation program (ICPR) on impaired postural control, pain, self-perceived health status, and functionality in women with chronic pelvic pain. DESIGN Randomized controlled trial. SETTING Women with chronic pelvic pain were recruited from the Gynecology Department of the University Hospital San Cecilio in Granada, Spain. PARTICIPANTS Participants (N=38) who were randomly divided into 2 groups. INTERVENTIONS The intervention group received an 8-week ICRP, and the control group received a leaflet with ergonomic information. MAIN OUTCOME MEASURES The main outcomes included were postural control (Mini Balance Evaluation Systems [Mini BESTest] and timed Up and Go [TUG]), pain (Brief Pain Inventory), self-perceived health status (EuroQol 5 dimensions [EQ-5D]), and functionality (Oswestry Disability Index [ODI]). RESULTS Significant differences were found between groups in the Mini BESTest and TUG scores with large effect sizes. The Brief Pain Inventory, EQ-5D, and ODI also presented significant differences in the between-groups analysis, with better scores in the intervention group after treatment. In the follow-up analysis, significant differences were found between groups in the Mini BESTest (P<.001), the cognitive TUG subscale (P=.032), interference of pain (P<.001), anxiety and depression (P=.001), and visual analog scale EQ-5D (P=.026) subscales, as well as the ODI (P<.001). CONCLUSIONS Our results show significant improvements on postural control, pain, self-perceived health status, and functionality in women with chronic pelvic pain who received an 8-week ICRP.",2020,"Our results show significant improvements on postural control, pain, self-perceived health status and functionality in women with CPP that received an eight-week ICRP.","['Women with chronic pelvic pain were recruited from the Gynaecology Department of the ""Hospital San Cecilio"" in Granada', '38 participants were included in the study and randomly divided into two groups', 'women with CPP', 'women with chronic pelvic pain']","['Individualized Comprehensive Rehabilitation Program', 'eight-week ICRP and the control group received a leaflet with ergonomic information', 'Individualized Comprehensive Rehabilitation Program (ICPR']","['Mini BESTest and TUG scores', 'VAS EQ-5D', 'interference of pain (p<0.001), anxiety/depression', 'postural control (Mini Balance Evaluation Systems, Mini BESTest and Timed Up and Go Test, TUG), pain (Brief Pain Inventory, BPI), self-perceived health status (Euroqol-5dimensions, EQ-5D) and functionality (Oswestry Disability Index, ODI', 'postural control', 'BPI, EQ-5D and ODI', 'cognitive TUG subscale', 'postural control, pain, self-perceived health status and functionality']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0404484', 'cui_str': 'Chronic pelvic pain of female'}, {'cui': 'C0587481', 'cui_str': 'Gynecology department'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0047123', 'cui_str': '3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid'}]","[{'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086246', 'cui_str': 'Human Engineering'}]","[{'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4760618', 'cui_str': 'Posture Control'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}]",38.0,0.0673424,"Our results show significant improvements on postural control, pain, self-perceived health status and functionality in women with CPP that received an eight-week ICRP.","[{'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Rodríguez-Torres', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'López-López', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cabrera-Martos', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Prados-Román', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Granados-Santiago', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Marie C', 'Initials': 'MC', 'LastName': 'Valenza', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, University of Granada, Granada, Spain. Electronic address: cvalenza@ugr.es.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.02.019'] 145,32324700,Protecting the Mental Health of Small-to-Medium Enterprise Owners: A Randomized Control Trial Evaluating a Self-Administered Versus Telephone Supported Intervention.,"OBJECTIVE Small-medium enterprises (SMEs) are under-represented in occupational health research. Owner/managers face mental ill-health risks/exacerbating factors including financial stress and long hours. This study assessed the effectiveness of a mental health intervention specifically for SME owner/managers. METHODS 297 owner/managers of SMEs were recruited and invited to complete a baseline survey assessing their mental health and wellbeing and were then randomly allocated to one of three intervention groups: 1) self-administered, 2) self-administered plus telephone, or 3) an active control condition. After a four-month intervention period they were followed up with a second survey. RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. CONCLUSION The provision of telephone support for self-administered interventions in this context appears warranted.",2020,"RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. ",['297\u200aowner/managers of SMEs were recruited and invited to complete a baseline survey assessing their mental health and wellbeing'],"['mental health intervention', 'self-administered, 2) self-administered plus telephone, or 3) an active control condition']",['psychological distress'],"[{'cui': 'C0335141', 'cui_str': 'Manager'}, {'cui': 'C2919920', 'cui_str': 'Northern Sami language'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0815107', 'cui_str': 'Emotional Distress'}]",,0.0686994,"RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. ","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Department of University of Tasmania, Australia (Martin, Kilpatrick, Scott, Cocker, Dawkins), Griffith University, Australia (Brough), University of East Anglia, United Kingdom (Sanderson).'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Kilpatrick', 'Affiliation': ''}, {'ForeName': 'Jenn', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Cocker', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dawkins', 'Affiliation': ''}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Brough', 'Affiliation': ''}, {'ForeName': 'Kristy', 'Initials': 'K', 'LastName': 'Sanderson', 'Affiliation': ''}]",Journal of occupational and environmental medicine,['10.1097/JOM.0000000000001882'] 146,30878623,Design and patient characteristics of the randomized controlled trial TExT-MED + FANS A test of mHealth augmented social support added to a patient-focused text-messaging intervention for emergency department patients with poorly controlled diabetes.,"Although diabetes is a nationwide epidemic, US Latinos are a particularly vulnerable population. Culturally appropriate interventions can combat this disparity, especially those that increase social support. However, these interventions face significant cost and time barriers, which mHealth (mobile health) may overcome. This trial examines the benefit of adding social support to an existing text-message based, patient-focused mHealth intervention for emergency department patients with poorly controlled diabetes. Family members and friends of patients were randomized to mHealth augmented social support training (daily text-messages that synchronize with the patient messages) or a pamphlet based training (the same content mailed to their house.) We hypothesize that patients who received mHealth augmented social support will have a larger improvement in diabetes management (glycosylated hemoglobin or A1C) than those receiving standard support at six-months, and that improvement will be sustained at twelve-months. Secondary patient outcomes are clinical (weight, blood pressure), behavioral (medication adherence, self-care activities) and psychosocial (general and diabetes-specific social support, self-efficacy, diabetes-related distress, depression, fatalism and quality of life). We screened 2004 patients and enrolled 166 patient/supporter dyads. 70% of patients are Spanish-speaking, 51% female, with a mean A1C of 10.8. We employed innovative measures to remotely enroll family members and support a bilingual population, which will assist other investigators in design of similar trials. The findings of our trial will have real-world applicability for clinicians, health system administrators, health educators and mHealth developers who aim to improve the health of this vulnerable population.",2019,Family members and friends of patients were randomized to mHealth augmented social support training (daily text-messages that synchronize with the patient messages) or a pamphlet based training (the same content mailed to their house.),"['emergency department patients with poorly controlled diabetes', '2004 patients and enrolled 166 patient/supporter dyads', 'Family members and friends of patients']","['mHealth augmented social support training (daily text-messages that synchronize with the patient messages) or a pamphlet based training (the same content mailed to their house', 'social support to an existing text-message based, patient-focused mHealth intervention', 'mHealth augmented social support added to a patient-focused text-messaging intervention', '\u202fFANS']","['diabetes management (glycosylated hemoglobin or A1C', 'clinical (weight, blood pressure), behavioral (medication adherence, self-care activities) and psychosocial (general and diabetes-specific social support, self-efficacy, diabetes-related distress, depression, fatalism and quality of life']","[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0079382', 'cui_str': 'Friend (person)'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0037438'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C2003847', 'cui_str': 'House (environment)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0441039', 'cui_str': 'Fan (physical object)'}]","[{'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0037438'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0034380'}]",2004.0,0.0522023,Family members and friends of patients were randomized to mHealth augmented social support training (daily text-messages that synchronize with the patient messages) or a pamphlet based training (the same content mailed to their house.),"[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Burner', 'Affiliation': 'Department of Emergency Medicine, Keck School of Medicine of the University of Southern California, United States. Electronic address: elizabeth.burner@med.usc.edu.'}, {'ForeName': 'Janisse', 'Initials': 'J', 'LastName': 'Mercado', 'Affiliation': 'Department of Emergency Medicine, Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Hernandez-Saenz', 'Affiliation': 'Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Peters', 'Affiliation': 'Division of Endocrinology, Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Mack', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Baezconde-Garbanati', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Arora', 'Affiliation': 'Department of Emergency Medicine, Keck School of Medicine of the University of Southern California, United States.'}, {'ForeName': 'Shinyi', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'School of Social Work, University of Southern California, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.003'] 147,32318288,Risk Factors Associated with Cardiac Autonomic Modulation in Obese Individuals.,"Obesity leads to an imbalance in the autonomic nervous system, especially in increased sympathetic modulation and decreased vagal tone, and some anthropometric, metabolic, and lifestyle variables may increase the risk of developing cardiovascular disease. Objective . To analyze the association between cardiovascular autonomic modulation and biochemical and anthropometric markers, food intake, and physical activity level in severely obese individuals. Methodology . The present study is a cutout of a randomized clinical trial ""Effect of nutritional intervention and olive oil in severe obesity"" (DieTBra Trial), where the baseline data were analyzed. Anthropometric data, biochemical exams, heart rate variability (HRV), accelerometry, and 24 h recall (R24H) of obese patients (body mass index BMI ≥35 kg/m 2 ) were collected. Results . 64 obese patients were analyzed, with a mean age of 39.10 ± 7.74 years (27 to 58 years). By HRV analysis, in the frequency domain, the obese had a higher predominance of sympathetic autonomic modulation (low frequency (LF) 56.44 ± 20.31 nu) and lower parasympathetic modulation (high frequency (HF) 42.52 ± 19.18 nu). A negative association was observed between the variables Homeostasis Evaluation Model (HOMA-IR) and HF ( p = 0.049). In the physical activity analysis, there was a negative association between moderate to vigorous physical activity and the sympathetic component ( p = 0.043), and for sedentary time (ST), there was a negative association with HF ( p = 0.049) and LF/HF ( p = 0.036) and a positive association with LF ( p = 0.014). For multiple linear regression, waist circumference (WC) and HOMA-IR values were negatively associated with HF ( β  = -0.685, p = 0.010; β  = -14.989, p = 0.010; respectively). HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. Conclusion . Among the cardiovascular risk variables studied, insulin resistance and central adiposity showed the greatest influence on cardiac autonomic modulation of obese, increasing the risk for cardiovascular disease.",2020,"HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. ","['severely obese individuals', 'Obese Individuals', '64 obese patients were analyzed, with a mean age of 39.10\u2009±\u20097.74 years (27 to 58 years']",['nutritional intervention and olive oil'],"['vigorous physical activity and the sympathetic component', 'parasympathetic modulation', 'sympathetic autonomic modulation', 'insulin resistance and central adiposity', 'sedentary time (ST', 'HOMA-IR', 'percentage of lipids ingested', 'waist circumference (WC) and HOMA-IR values', 'Anthropometric data, biochemical exams, heart rate variability (HRV), accelerometry, and 24\u2009h recall (R24H', 'variables Homeostasis Evaluation Model (HOMA-IR) and HF', 'cardiovascular autonomic modulation and biochemical and anthropometric markers, food intake, and physical activity level']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C4551560', 'cui_str': 'Central obesity'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",64.0,0.0503632,"HOMA-IR ( β  = 0.141, p = 0.003) and the percentage of lipids ingested ( β  = -0.030, p = 0.043) were negatively associated with LF/HF. ","[{'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Oliveira', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Erika Aparecida', 'Initials': 'EA', 'LastName': 'Silveira', 'Affiliation': 'Medicine Faculty, Coordinator of the Severe Obesity Study Group, Federal University of Goiás, Goiânia, Brazil.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Rosa', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Annelisa', 'Initials': 'A', 'LastName': 'Santos', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Rodrigues', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Mendonça', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Lucas', 'Initials': 'L', 'LastName': 'Silva', 'Affiliation': 'Medicine Faculty, Health Science Post-Graduation Program, Universidade Federal de Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Gentil', 'Affiliation': 'College of Physical Education and Dance, Federal University of Goiás, Goiânia, Brazil.'}, {'ForeName': 'Ana Cristina', 'Initials': 'AC', 'LastName': 'Rebelo', 'Affiliation': 'Department of Morphology, Biological Sciences Institute, Federal University of Goiás, Goiânia, Goiás, Brazil.'}]",Journal of obesity,['10.1155/2020/7185249'] 148,30940887,The effect of single periocular injection of methylprednisolone and drainage of suprachoroidal fluid in the treatment of rhegmatogenous retinal detachment combined with choroidal detachment.,"PURPOSE In this study we compared the anatomic and functional outcomes of two steroid treatments on rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD), namely treatment with oral prednisolone (1 mg/kg daily) for 3-7 days before vitrectomy or a single periocular injection of methylprednisolone (40 mg) 1-3 days before vitrectomy. We also analyzed the outcomes of the eyes with subsided CD and the eyes with persistent CD that underwent drainage of suprachoroidal fluids during the vitrectomy. METHODS This was a prospective randomized study. Seventy five eyes with RRD combined with CD were divided into 2 groups based on the two different treatment regimens as above. The eyes in each group were further divided into 2 subgroups (A: CD subsided eyes; B: CD persistent eyes) according to the response of CD to the treatment of steroids. Retinal reattachment rates were measured at 6 months after the removal of silicone oil. RESULTS At 6 months after silicone oil removal, the retinal reattachment rate was similar (p = 0.666) in the oral prednisolone group (91.7%, 33/36) and the periocular injection group (94.9%, 37/39). Similar retinal reattachment rates (p = 0.364) were also found in the CD subsided eyes (97.1%, 34/35) and the CD persistent eyes (90.0%, 36/40). The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). CONCLUSIONS For RRD combined with CD, eyes treated with a single periocular injection of methylprednisolone (40 mg, 1-3 days before pars plana vitrectomy) combined with the drainage of suprachoroidal fluids during the surgery had similar anatomic and functional outcomes compared to the eyes treated with oral prednisolone for 3-7 days before vitrectomy.",2019,"The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). ","['rhegmatogenous retinal detachment combined with choroidal detachment', 'Seventy five eyes with RRD combined with CD']","['methylprednisolone and drainage of suprachoroidal fluid', 'oral prednisolone', 'methylprednisolone', 'rhegmatogenous retinal detachment (RRD) combined with choroidal detachment (CD', 'steroid treatments', 'silicone oil', 'prednisolone']","['retinal reattachment rate', 'Retinal reattachment rates', 'Similar retinal reattachment rates']","[{'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0162279', 'cui_str': 'Choroidal detachment (disorder)'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0395611', 'cui_str': 'Drainage of suprachoroidal fluid (procedure)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0162279', 'cui_str': 'Choroidal detachment (disorder)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0037111', 'cui_str': 'Silicone Oils'}]","[{'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0185042', 'cui_str': 'Refixation (procedure)'}]",75.0,0.0482548,"The retinal reattachment rate was comparable among the subgroups (p = 0.395; oral prednisolone A group: 95.2%, 20/21; oral prednisolone B group: 86.7%, 13/15; periocular injection A group: 100%, 14/14; periocular injection B group: 92.0%, 23/25). ","[{'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Wei', 'Affiliation': 'The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China. weiyongdoctor@163.com.'}, {'ForeName': 'RongLe', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': ""Shaanxi Ophthalmic Medical Center, Xi'an No.4 Hospital, Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710004, China.""}, {'ForeName': 'Xiaobo', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Xiamen Eye Center Affiliated to Xiamen University, Xiamen, 361000, China.'}, {'ForeName': 'Xiuju', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Xiamen Eye Center Affiliated to Xiamen University, Xiamen, 361000, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325027, China.'}]","Eye (London, England)",['10.1038/s41433-019-0420-4'] 149,31689359,Interventions for prodromal stage of psychosis.,"BACKGROUND Psychosis is a serious mental condition characterised by a loss of contact with reality. There may be a prodromal period or stage of psychosis, where early signs of symptoms indicating onset of first episode psychosis (FEP) occur. A number of services, incorporating multimodal treatment approaches (pharmacotherapy, psychotherapy and psychosocial interventions), developed worldwide, now focus on this prodromal period with the aim of preventing psychosis in people at risk of developing FEP. OBJECTIVES The primary objective is to assess the safety and efficacy of early interventions for people in the prodromal stage of psychosis. The secondary objective is, if possible, to compare the effectiveness of the various different interventions. SEARCH METHODS We searched Cochrane Schizophrenia's study-based Register of studies (including trials registers) on 8 June 2016 and 4 August 2017. SELECTION CRITERIA All randomised controlled trials (RCTs) evaluating interventions for participants older than 12 years, who had developed a prodromal stage of psychosis. DATA COLLECTION AND ANALYSIS Review authors independently inspected citations, selected studies, extracted data, and assessed study quality. MAIN RESULTS We included 20 studies with 2151 participants. The studies analysed 13 different comparisons. Group A comparisons explored the absolute effects of the experimental intervention. Group B were comparisons within which we could not be clear whether differential interactive effects were also ongoing. Group C comparisons explored differential effects between clearly distinct treatments. A key outcome for this review was 'transition to psychosis'. For details of other main outcomes please see 'Summary of findings' tables. In Group A (comparisons of absolute effects) we found no clear difference between amino acids and placebo (risk ratio (RR) 0.48 95% confidence interval (CI) 0.08 to 2.98; 2 RCTs, 52 participants; very low-quality evidence). When omega-3 fatty acids were compared to placebo, fewer participants given the omega-3 (10%) transitioned to psychosis compared to the placebo group (33%) during long-term follow-up of seven years (RR 0.24 95% CI 0.09 to 0.67; 1 RCT, 81 participants; low-quality evidence). In Group B (comparisons where complex interactions are probable) and in the subgroup focusing on antipsychotic drugs added to specific care packages, the amisulpiride + needs-focused intervention (NFI) compared to NFI comparison (no reporting of transition to psychosis; 1 RCT, 102 participants; very low-quality evidence) and the olanzapine + supportive intervention compared to supportive intervention alone comparison (RR 0.58 95% CI 0.28 to 1.18; 1 RCT, 60 participants; very low-quality evidence) showed no clear differences between groups. In the second Group B subgroup (cognitive behavioural therapies (CBT)), when CBT + supportive therapy was compared with supportive therapy alone around 8% of participants allocated to the combination of CBT and supportive therapy group transitioned to psychosis during follow-up by 18 months, compared with double that percentage in the supportive therapy alone group (RR 0.45 95% CI 0.23 to 0.89; 2 RCTs, 252 participants; very low-quality evidence). The CBT + risperidone versus CBT + placebo comparison identified no clear difference between treatments (RR 1.02 95% CI 0.39 to 2.67; 1 RCT, 87 participants; very low-quality evidence) and this also applies to the CBT + needs-based intervention (NBI) + risperidone versus NBI comparison (RR 0.75 95% CI 0.39 to 1.46; 1 RCT, 59 participants; very low-quality evidence). Group C (differential effects) also involved six comparisons. The first compared CBT with supportive therapy. No clear difference was found for the 'transition to psychosis' outcome (RR 0.74 95% CI 0.28 to 1.98; 1 RCT, 72 participants; very low-quality evidence). The second subgroup compared CBT + supportive intervention was compared with a NBI + supportive intervention, again, data were equivocal, few and of very low quality (RR 6.32 95% CI 0.34 to 117.09; 1 RCT, 57 participants). In the CBT + risperidone versus supportive therapy comparison, again there was no clear difference between groups (RR 0.76 95% CI 0.28 to 2.03; 1 RCT, 71 participants; very low-quality evidence). The three other comparisons in Group C demonstrated no clear differences between treatment groups. When cognitive training was compared to active control (tablet games) (no reporting of transition to psychosis; 1 RCT, 62 participants; very low quality data), family treatment compared with enhanced care comparison (RR 0.54 95% CI 0.18 to 1.59; 2 RCTs, 229 participants; very low-quality evidence) and integrated treatment compared to standard treatment comparison (RR 0.57 95% CI 0.28 to 1.15; 1 RCT, 79 participants; very low-quality evidence) no effects of any of these approaches was evident. AUTHORS' CONCLUSIONS There has been considerable research effort in this area and several interventions have been trialled. The evidence available suggests that omega-3 fatty acids may prevent transition to psychosis but this evidence is low quality and more research is needed to confirm this finding. Other comparisons did not show any clear differences in effect for preventing transition to psychosis but again, the quality of this evidence is very low or low and not strong enough to make firm conclusions.",2019,"The CBT + risperidone versus CBT + placebo comparison identified no clear difference between treatments (RR 1.02 95% CI 0.39 to 2.67; 1 RCT, 87 participants; very low-quality evidence) and this also applies to the CBT + needs-based intervention (NBI) + risperidone versus NBI comparison (RR 0.75 95% CI 0.39 to 1.46; 1 RCT, 59 participants; very low-quality evidence).","['20 studies with 2151 participants', 'participants older than 12 years, who had developed a prodromal stage of psychosis', 'people at risk of developing FEP', 'prodromal stage of psychosis', 'people in the prodromal stage of psychosis', ""Cochrane Schizophrenia's study-based Register of studies (including trials registers) on 8 June 2016 and 4 August 2017""]","['CBT + risperidone', 'CBT + placebo', 'cognitive behavioural therapies (CBT', 'CBT + supportive therapy', 'olanzapine + supportive intervention', 'CBT and supportive therapy', 'multimodal treatment approaches (pharmacotherapy, psychotherapy and psychosocial interventions', 'placebo', 'omega-3 fatty acids']","['safety and efficacy', ""transition to psychosis' outcome""]","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3494361', 'cui_str': 'Prodromal Stage'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0009429', 'cui_str': 'Multimodal Treatment'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}]",252.0,0.277609,"The CBT + risperidone versus CBT + placebo comparison identified no clear difference between treatments (RR 1.02 95% CI 0.39 to 2.67; 1 RCT, 87 participants; very low-quality evidence) and this also applies to the CBT + needs-based intervention (NBI) + risperidone versus NBI comparison (RR 0.75 95% CI 0.39 to 1.46; 1 RCT, 59 participants; very low-quality evidence).","[{'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Bosnjak Kuharic', 'Affiliation': 'University Psychiatric Hospital Vrapče, Bolnicka cesta 32, Zagreb, Grad Zagreb, Croatia, 10000.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Kekin', 'Affiliation': 'Clinical Hospital Centre Zagreb, Department of Psychiatry, Kispaticeva 12, 10 000, Zagreb, Croatia.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Hew', 'Affiliation': 'South London and Maudsley NHS Foundation Trust, Department of Acute Care Psychiatry, Ladywell Unit, University Hospital Lewisham, London, UK.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Rojnic Kuzman', 'Affiliation': 'Clinical Hospital Centre Zagreb, Department of Psychiatry, Kispaticeva 12, 10 000, Zagreb, Croatia.'}, {'ForeName': 'Livia', 'Initials': 'L', 'LastName': 'Puljak', 'Affiliation': 'Catholic University of Croatia, Center for Evidence-Based Medicine and Health Care, Ilica 242, Zagreb, Croatia, 10000.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012236.pub2'] 150,32323707,CO2 laser ablation of oral leukoplakia: with or without extension of margins?,"PURPOSE The purpose is to determine the sufficient extension of margins during laser ablation of oral leukoplakia and observe its short-term recurrence rate. MATERIALS AND METHODS The study was designed as a randomized controlled clinical trial was conducted on 33 oral leukoplakia lesions diagnosed in 30 patients (16 Females and 14 Males) with an age range between 39 and 79 years. The lesions were divided into three groups; Group A: 11 lesions in 11 patients, in which the laser ablation was done for the entire lesion without extension of margins; Group B: 11 lesions in 8 patients, in which the laser ablation was done for the lesion adding at least 3mm extension of margins; and finally the Group Control: consists of 11 untreated lesions in 11 patients, in which only ""wait and see"" approach was done. RESULTS Complete healing of 13 lesions occurred in both groups A and B. Complete regression of 3 lesions occurred in Group Control. After 6 months of follow-up, 6 of 9 lesions in both groups A and B that showed the recurrence, had shown an initial recurrence after 3 weeks of the laser ablation. Patients with no history of smoking habits showed complete healing of 87.5%, while in ex-smokers complete healing was 42.8%. The statistical analysis was performed, and the averages of all groups are significantly different (p <0.00001). DISCUSSION The primary treatment focuses on the elimination of associated risk factors (smoking, alcohol, and local irritating factors). In the literature, the recurrence rate varies between 13.6% and 40.7%, while in our study, it was 45.5% in Group A and 36.4% in Group B. CONCLUSION The recommended extension of margins should be at least 3mm in width. Further research can be performed to evaluate the immediate re-ablation of the lesions which showed an initial recurrence after 3 weeks of laser ablation.",2020,"RESULTS Complete healing of 13 lesions occurred in both groups A and B. Complete regression of 3 lesions occurred in Group Control.",['33 oral leukoplakia lesions diagnosed in 30 patients (16 Females and 14 Males) with an age range between 39 and 79 years'],"['laser ablation was done for the lesion adding at least 3mm extension of margins; and finally the Group Control: consists of 11 untreated lesions in 11 patients, in which only ""wait and see"" approach was done', 'CO2 laser ablation of oral leukoplakia', 'laser ablation']","['elimination of associated risk factors (smoking, alcohol, and local irritating factors', 'complete healing', 'Complete healing of 13 lesions', 'recurrence rate varies', 'ex-smokers complete healing', 'initial recurrence']","[{'cui': 'C0023532', 'cui_str': 'Leukoplakia of oral mucosa'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0348007', 'cui_str': 'Laser Ablation'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0439792', 'cui_str': 'Extent'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0023532', 'cui_str': 'Leukoplakia of oral mucosa'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]",,0.0231921,"RESULTS Complete healing of 13 lesions occurred in both groups A and B. Complete regression of 3 lesions occurred in Group Control.","[{'ForeName': 'U', 'Initials': 'U', 'LastName': 'Romeo', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Mohsen', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Palaia', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bellisario', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Del Vecchio', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Tenore', 'Affiliation': 'Department of Oral Sciences and Maxillofacial Surgery, Sapienza University of Rome, Italy.'}]",La Clinica terapeutica,['10.7417/CT.2020.2215'] 151,32309882,"The effect of repetitive transcranial magnetic stimulation on food choice-related self-control in patients with severe, enduring anorexia nervosa.","OBJECTIVE Individuals with anorexia nervosa (AN) pursue low-fat, low-calorie diets even when in a state of emaciation. These maladaptive food choices may involve fronto-limbic circuitry associated with cognitive control, habit, and reward. We assessed whether high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left dorsolateral prefrontal cortex (DLPFC) influenced food-related choice behavior in patients with severe, enduring (SE)-AN. METHOD Thirty-four females with SE-AN completed a Food Choice Task before and after 20 sessions of real or sham rTMS treatment and at a 4-month follow-up. During the task, participants rated high- and low-fat food items for healthiness and tastiness and then made a series of choices between a neutral-rated food and high- and low-fat foods. Outcomes included the proportion of high-fat and self-controlled choices made. A comparison group of 30 healthy women completed the task at baseline only. RESULTS Baseline data were consistent with previous findings: relative to healthy controls, SE-AN participants showed a preference for low-fat foods and exercised self-control on a greater proportion of trials. There was no significant effect of rTMS treatment nor time on food choices related to fat content. However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline. Specifically, there was an increase in the selection of tasty-unhealthy foods. DISCUSSION In SE-AN, rTMS may promote more flexibility in relation to food choice. This may result from neuroplastic changes in the DLPFC and/or in associated brain areas.",2020,"However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline.","['30 healthy women completed the task at baseline only', 'patients with severe, enduring (SE)-AN.\nMETHOD\n\n\nThirty-four females with SE-AN completed a', 'patients with severe, enduring anorexia nervosa', 'Individuals with anorexia nervosa (AN']","['repetitive transcranial magnetic stimulation', 'high-frequency repetitive transcranial magnetic stimulation (rTMS', 'real rTMS', 'Food Choice Task before and after 20 sessions of real or sham rTMS', 'rTMS']","['self-controlled food choices', 'proportion of high-fat and self-controlled choices made']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",34.0,0.0323544,"However, among SE-AN participants who received real rTMS, there was a decrease in self-controlled food choices at post-treatment, relative to baseline.","[{'ForeName': 'Bethan', 'Initials': 'B', 'LastName': 'Dalton', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Foerde', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York City, New York, USA.'}, {'ForeName': 'Savani', 'Initials': 'S', 'LastName': 'Bartholdy', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McClelland', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kekic', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Luiza', 'Initials': 'L', 'LastName': 'Grycuk', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Iain C', 'Initials': 'IC', 'LastName': 'Campbell', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Schmidt', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Joanna E', 'Initials': 'JE', 'LastName': 'Steinglass', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center and New York State Psychiatric Institute, New York City, New York, USA.'}]",The International journal of eating disorders,['10.1002/eat.23267'] 152,32069460,Enhanced Efficacy of Dust Mite Sublingual Immunotherapy in Low-Response Allergic Rhinitis Patients after Dose Increment at 6 Months: A Prospective Study.,"BACKGROUND Several studies have suggested that sublingual immunotherapy (SLIT) involves a dose-response relationship and inadequate dosage might not achieve a favorable clinical effect. OBJECTIVE The aim of this prospective study was to investigate the efficacy and safety of increasing SLIT dosage at 6 months in patients with house dust mite-induced allergic rhinitis (AR) who had low response to treatment. METHODS A total of 157 AR participants aged 4-60 years were enrolled and received SLIT with Dermatophagoides farinae drops. After 6 months of SLIT, patients were interviewed and then classified into a high-response (HR) group and a low-response (LR) group based on the combined symptom and medication score (CSMS) reduction rate. Patients with a CSMS reduction rate over 50% were defined as HR and continued the original dose, while patients with a CSMS reduction rate ranging from 20 to 50% were defined as LR and received an increased dose (percentage of dosage increment, 33.33% for patients aged <14 years and 50% for patients aged ≥14 years). Patients with a CSMS reduction rate below 20% were considered nonresponse (NR) and recommended to withdraw from SLIT. CSMS, visual analog scale (VAS), and adverse events were assessed at 0.5, 1, 2, and 3 years during the 3-year treatment. RESULTS A total of 54 and 56 patients completed the treatment in the HR and LR groups, respectively. The CSMS and VAS of both groups decreased significantly at 6 months (p < 0.05). Significant differences between the two groups were found in CSMS and VAS at 6 months and 1 year (p < 0.05), but not in later follow-ups (p > 0.05). The improvement of adults in the LR group was significantly lower than that of children at 6 months (p < 0.05), but there was no difference in later follow-ups (p > 0.05). There was no difference in CSMS or VAS in patients with monosensitization and polysensitization in the same treatment group at 1 year and in subsequent visits (p> 0.05). Overall, 47 patients withdrew from this study due to NR (n = 22) and other reasons (n = 25). CONCLUSIONS Six months might be a critical time point for efficacy assessment and dosage adjustment for AR patients after SLIT. In patients with low response, dosage enhancement within a certain range may enhance the effectiveness of SLIT.",2020,"Significant differences between the two groups were found in CSMS and VAS at 6 months and 1 year (p < 0.05), but not in later follow-ups (p > 0.05).","['Low-Response Allergic Rhinitis Patients after Dose Increment at 6 Months', '157 AR participants aged 4-60 years', 'patients with house dust mite-induced allergic rhinitis (AR) who had low response to treatment', '47 patients withdrew from this study due to NR']","['SLIT with Dermatophagoides farinae drops', 'sublingual immunotherapy (SLIT', 'Dust Mite Sublingual Immunotherapy']","['CSMS, visual analog scale (VAS), and adverse events', 'efficacy and safety', 'CSMS reduction rate', 'CSMS and VAS', 'CSMS or VAS', 'combined symptom and medication score (CSMS) reduction rate']","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3539110', 'cui_str': 'house dust mites'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0521982', 'cui_str': 'Therapeutic response, function (observable entity)'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]","[{'cui': 'C0184904', 'cui_str': 'Slitting (procedure)'}, {'cui': 'C0323677', 'cui_str': 'House Dust Mite, American'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C0013330', 'cui_str': 'Dust'}, {'cui': 'C0026231', 'cui_str': 'Mites'}]","[{'cui': 'C4521841', 'cui_str': 'MGySgt'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",157.0,0.0167031,"Significant differences between the two groups were found in CSMS and VAS at 6 months and 1 year (p < 0.05), but not in later follow-ups (p > 0.05).","[{'ForeName': 'Yingqin', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': ""Department of Otolaryngology - Head and Neck Surgery, Kunming Children's Hospital, Kunming, China.""}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Lin', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Hainan General Hospital, Haikou, China, linxia3073@126.com.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': ""Department of Otolaryngology - Head and Neck Surgery, Kunming Children's Hospital, Kunming, China.""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Hainan General Hospital, Haikou, China.'}, {'ForeName': 'Qiuju', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Department of Otorhinolaryngology - Head and Neck Surgery, Hainan General Hospital, Haikou, China.'}, {'ForeName': 'Meilan', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Otolaryngology - Head and Neck Surgery, Kunming Children's Hospital, Kunming, China.""}]",International archives of allergy and immunology,['10.1159/000505746'] 153,31187552,Behavioral therapy for urinary symptoms in Parkinson's disease: A randomized clinical trial.,"AIM Determine the efficacy of behavioral therapy for urinary symptoms in Parkinson's disease. METHODS Randomized trial of behavioral therapy compared with control condition among adults (aged 54-85 years, 74% male, 10% Black/ 83% White) with Parkinson's and greater than or equal to 4 incontinence episodes weekly. Behavioral therapy included pelvic floor muscle exercises, bladder training, fluid and constipation management. Both groups completed bladder diary self-monitoring. Outcomes included diary-derived incontinence and ICIQ-overactive bladder (OAB) score (range, 0-16) with bother and quality of life questionnaires (higher scores = worse outcomes). RESULTS Fifty-three participants randomized and 47 reported 8-week outcomes including 26 behavioral therapy and 21 control. Behavioral vs control participants were similar with respect to age (71.0 ± 6.1 vs 69.7 ± 8.2 years), sex (70% vs 78% male), motor score, cognition, mean weekly incontinence episodes (13.9 ± 9.6 vs 15.1 ± 11.1) and OAB symptoms (8.9 ± 2.4 vs 8.3 ± 2.2). Weekly incontinence reduction was similar between behavioral (-6.2 ± 8.7) and control participants (-6.5 ± 13.8) (P = 0.89). After multiple imputation analysis, behavioral therapy participants reported statistically similar reduction in OAB symptoms compared to control (-3.1 ± 2.8 vs -1.9 ± 2.2, P = 0.19); however quality of life (-22.6 ± 19.1 vs -7.0 ± 18.4, P = 0.048) and bother (-12.6 ± 17.2 vs - 6.7 ± 8.8, P = 0.037) improved significantly more with behavioral therapy. CONCLUSION Self-monitoring resulted in fewer urinary symptoms; however, only multicomponent behavioral therapy was associated with reduced bother and improved quality of life. Providers should consider behavioral therapy as initial treatment for urinary symptoms in Parkinson's disease.",2019,Weekly incontinence reduction was similar between behavioral (-6.2 ± 8.7) and control participants (-6.5 ± 13.8) (P = 0.89).,"[""adults (aged 54-85 years, 74% male, 10% Black/ 83% White) with Parkinson's and greater than or equal to 4 incontinence episodes weekly"", ""urinary symptoms in Parkinson's disease"", 'Fifty-three participants randomized and 47 reported 8-week outcomes including 26', ""Parkinson's disease"", 'Behavioral vs control participants were similar with respect to age (71.0\u2009±\u20096.1 vs 69.7\u2009±\u20098.2 years), sex (70% vs 78% male), motor score, cognition, mean weekly incontinence episodes (13.9\u2009±\u20099.6 vs 15.1\u2009±\u200911.1) and OAB symptoms (8.9\u2009±\u20092.4 vs 8.3\u2009±\u20092.2']","['behavioral therapy', 'behavioral therapy and 21 control', 'Behavioral therapy']","['OAB symptoms', 'Weekly incontinence reduction', 'diary-derived incontinence and ICIQ-overactive bladder (OAB) score (range, 0-16) with bother and quality of life questionnaires', 'quality of life', 'pelvic floor muscle exercises, bladder training, fluid and constipation management', 'urinary symptoms']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0426359', 'cui_str': 'Urinary symptoms (finding)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517562', 'cui_str': '13.9 (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4517631', 'cui_str': '2.4 (qualifier value)'}, {'cui': 'C4517629', 'cui_str': '2.2'}]","[{'cui': 'C0004933', 'cui_str': 'Behavior Modification'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0206248', 'cui_str': 'Pelvic Diaphragm'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0150474', 'cui_str': 'Urinary bladder training'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C1300313', 'cui_str': 'Constipation management'}, {'cui': 'C0426359', 'cui_str': 'Urinary symptoms (finding)'}]",53.0,0.0455237,Weekly incontinence reduction was similar between behavioral (-6.2 ± 8.7) and control participants (-6.5 ± 13.8) (P = 0.89).,"[{'ForeName': 'Camille P', 'Initials': 'CP', 'LastName': 'Vaughan', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Atlanta VA Health System, Atlanta, Georgia.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Burgio', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Birmingham VA Health System, Birmingham, Alabama.'}, {'ForeName': 'Patricia S', 'Initials': 'PS', 'LastName': 'Goode', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Birmingham VA Health System, Birmingham, Alabama.'}, {'ForeName': 'Jorge L', 'Initials': 'JL', 'LastName': 'Juncos', 'Affiliation': 'Department of Neurology, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'McGwin', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Birmingham VA Health System, Birmingham, Alabama.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Muirhead', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Atlanta VA Health System, Atlanta, Georgia.'}, {'ForeName': 'Alayne D', 'Initials': 'AD', 'LastName': 'Markland', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Birmingham VA Health System, Birmingham, Alabama.'}, {'ForeName': 'Theodore M', 'Initials': 'TM', 'LastName': 'Johnson', 'Affiliation': 'Birmingham/Atlanta VA Geriatric Research, Education, and Clinical Center, Atlanta VA Health System, Atlanta, Georgia.'}]",Neurourology and urodynamics,['10.1002/nau.24052'] 154,32324082,Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.,"Objective: To assess the efficacy and safety of the sodium-glucose cotransporter 2 inhibitor ertugliflozin across racial groups in patients with type 2 diabetes mellitus (T2DM). Methods: Pooled analysis of data from randomized, double-blind studies in the ertugliflozin phase III development program. Seven placebo- and comparator-controlled studies were used to assess safety ( N  = 4859) and three placebo-controlled studies were used to assess efficacy ( N  = 1544). Least-squares (LS) mean change from baseline was calculated for glycated hemoglobin (HbA1c), body weight and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs). Results: At Week 26, ertugliflozin provided a greater reduction in HbA1c, body weight and SBP versus placebo in all racial subgroups. The placebo-adjusted LS mean change (95% confidence interval) from baseline in HbA1c was -0.8% (-1.0, -0.7) and -1.0% (-1.1, -0.8) with ertugliflozin 5 mg and 15 mg, respectively, in the White subgroup, -0.7% (-1.2, -0.2) and -0.8% (-1.3, -0.3) in the Black subgroup, and -0.8% (-1.1, -0.5) and -1.0% (-1.3, -0.8) in the Asian subgroup. The incidences of overall AEs, serious AEs and AEs leading to discontinuation from study medication were similar between the ertugliflozin 5 mg, 15 mg and non-ertugliflozin groups within each racial subgroup. The incidence of female genital mycotic infection (GMI) was higher with ertugliflozin than non-ertugliflozin across all racial subgroups. The incidence of male GMI was higher with ertugliflozin than non-ertugliflozin in the White sub-group; however, there were few male GMI events in the non-White subgroups. Conclusions: In patients with T2DM, treatment with ertugliflozin improved HbA1c, body weight and SBP across all racial subgroups. Ertugliflozin had a generally similar safety profile across racial subgroups and was generally well tolerated. Clinicaltrials.gov identifiers: NCT01986855, NCT01999218, NCT01958671, NCT02099110, NCT02036515, NCT02033889, and NCT02226003.",2020,"At Week 26, ertugliflozin provided a greater reduction in HbA1c, body weight and SBP versus placebo in all racial subgroups.","['patients with type 2 diabetes mellitus', 'patients with type 2 diabetes mellitus (T2DM']","['Ertugliflozin', 'sodium-glucose cotransporter 2 inhibitor ertugliflozin', 'placebo', 'ertugliflozin']","['incidence of female genital mycotic infection (GMI', 'efficacy and safety', 'tolerated', 'glycated hemoglobin (HbA1c), body weight, and systolic blood pressure (SBP', 'HbA1c, body weight, and SBP', 'HbA1c, body weight and SBP', 'incidence of male GMI', 'Efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0017739', 'cui_str': 'Glucose-Sodium Transport System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0017421', 'cui_str': 'Female genital'}, {'cui': 'C0026946', 'cui_str': 'Mycosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",,0.166963,"At Week 26, ertugliflozin provided a greater reduction in HbA1c, body weight and SBP versus placebo in all racial subgroups.","[{'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Tarasenko', 'Affiliation': 'Pfizer Inc., New York, NY, USA.'}, {'ForeName': 'Annpey', 'Initials': 'A', 'LastName': 'Pong', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Huyck', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Shrita', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Hickman', 'Affiliation': 'Pfizer Inc., Groton, CT, USA.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Mancuso', 'Affiliation': 'Pfizer Inc., Groton, CT, USA.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Gantz', 'Affiliation': 'Merck & Co. Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc., Andover, MA, USA.'}]",Current medical research and opinion,['10.1080/03007995.2020.1760228'] 155,31680625,Examining key sociodemographic characteristics of adolescents and young adults with cancer: A post hoc analysis of the Promoting Resilience in Stress Management randomized clinical trial.,"BACKGROUND The ""Promoting Resilience in Stress Management"" intervention is a skills-based, early palliative care intervention with demonstrated efficacy in adolescents and young adults with cancer. AIM Utilizing data from a randomized clinical trial of Promoting Resilience in Stress Management versus Usual Care, we examined whether response to Promoting Resilience in Stress Management differed across key sociodemographic characteristics. DESIGN Adolescents and young adults with cancer completed patient-reported outcome measures of resilience, hope, benefit-finding, quality of life, and distress at enrollment and 6 months. Participants were stratified by sex, age, race, and neighborhood socioeconomic disadvantage based on home address (Area Deprivation Index scores with 8-10 = most disadvantaged). Differences in the magnitude of effect sizes between stratification subgroups were noted using a conservative cutoff of d  > 0.5. SETTING/PARTICIPANTS Participants were 12 to 25 years old, English-speaking, and receiving cancer care at Seattle Children's Hospital. RESULTS In total, 92 adolescents and young adults (48 Promoting Resilience in Stress Management, 44 Usual Care) completed baseline measures. They were 43% female, 73% 12 to 17 years old, 64% White, and 24% most disadvantaged. Effect sizes stratified by sex, age, and race were in an expected positive direction and of similar magnitude for the majority of outcomes with some exceptions in magnitude of treatment effect. Those who lived in less disadvantaged neighborhoods benefited more from Promoting Resilience in Stress Management, and those living in most disadvantaged neighborhoods benefited less. CONCLUSION The ""Promoting Resilience in Stress Management"" intervention demonstrated a positive effect for the majority of outcomes regardless of sex, age, and race. It may not be as helpful for adolescents and young adults living in disadvantaged neighborhoods. Future studies must confirm its generalizability and integrate opportunities for improvement by targeting individual needs.",2020,"The ""Promoting Resilience in Stress Management"" intervention demonstrated a positive effect for the majority of outcomes regardless of sex, age, and race.","['They were 43% female, 73% 12 to 17\u2009years old, 64% White, and 24% most disadvantaged', 'Participants were stratified by sex, age, race, and neighborhood socioeconomic disadvantage based on home address (Area Deprivation Index scores with 8-10\u2009=\u2009most disadvantaged', '92 adolescents and young adults (48 Promoting Resilience in Stress Management, 44 Usual Care) completed baseline measures', ""Participants were 12 to 25\u2009years old, English-speaking, and receiving cancer care at Seattle Children's Hospital"", 'adolescents and young adults with cancer', 'Adolescents and young adults with cancer completed patient', 'adolescents and young adults living in disadvantaged neighborhoods']",[],"['resilience, hope, benefit-finding, quality of life, and distress']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205393', 'cui_str': 'Most (qualifier value)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0034380'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}]",92.0,0.144515,"The ""Promoting Resilience in Stress Management"" intervention demonstrated a positive effect for the majority of outcomes regardless of sex, age, and race.","[{'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Lau', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Miranda C', 'Initials': 'MC', 'LastName': 'Bradford', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Steineck', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Scott', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Kira', 'Initials': 'K', 'LastName': 'Bona', 'Affiliation': 'Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Joyce P', 'Initials': 'JP', 'LastName': 'Yi-Frazier', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McCauley', 'Affiliation': 'Division of Child Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA.'}, {'ForeName': 'Abby R', 'Initials': 'AR', 'LastName': 'Rosenberg', 'Affiliation': ""Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA.""}]",Palliative medicine,['10.1177/0269216319886215'] 156,30503967,Low Literacy Level Instructions and Reminder Calls Improve Patient Handling of Fecal Immunochemical Test Samples.,"BACKGROUND & AIMS The fecal immunochemical test (FIT) is an alternative to colonoscopy and can increase overall screening for colorectal cancer (CRC). However, little is known about the frequency of and reasons for mishandled FIT samples. METHODS We performed a prospective study, nested within a randomized controlled trial of patients, recruited from December 2015 through August 2017, who were not up to date with colorectal cancer screening (50-75 years old). The patients were randomly assigned to usual care or outreach groups that received a mailed FIT with low literacy level instructions or a reminder call, or both. We examined frequency of and reasons for mishandled FIT samples, including absence of collection date; time from collection to laboratory receipt of more than 14 days; or mishandling of stool, buffer, or cap. The outcomes were the frequency of mishandled FIT samples, effects of outreach on mishandling, and positive results from the FIT among proper and mishandled samples. RESULTS FIT samples were returned from 1871 patients assigned to usual care and 3045 who received the low literacy level instructions and a reminder call. In total, 19.8% of samples were mishandled; most of these (93.7%) had not labeled the date of stool collection but were still processed. Of the received samples, 1.2% of were not processed because the time from patient collection to laboratory receipt was more than 14 days. Outreach was associated with a lower proportion of mishandled samples (16.5% vs 25.0% for usual care; P < .0001). The proportion of mishandled samples was lowest among patients who received the low literacy level instruction and a reminder call (12.8%, P < .0001). There was no significant difference in proportions of positive results between properly processed samples (7.5%) and improperly processed samples (6.2%) (P = .14). CONCLUSION In a prospective study of patients who were not up to date with colorectal cancer screening, we found that almost 20% of FIT samples were mishandled, with most patients missing the stool collection date. Patient outreach was associated with a lower proportion of mishandled samples, but there was no difference in proportions of positive results between properly and improperly handled samples. Our findings indicate that routine processing of undated FIT samples is associated with similar rates of positive results. There are limited data on test characteristics for FIT samples beyond the 14 days of stool acquisition. The inclusion of low literacy level instructions with reminder calls was associated with improved patient handling of the FIT sample. ClincialTrials.gov no: NCT02613260.",2019,"The proportion of mishandled samples was lowest among patients who received the low literacy level instruction and a reminder call (12.8%, P < .0001).","['1871 patients assigned to usual care and 3045 who received the low literacy level instructions and a reminder call', 'patients, recruited from December 2015 through August 2017, who were not up to date with colorectal cancer screening (50-75 years old', 'patients who were not up to date with colorectal cancer screening']","['usual care or outreach groups that received a mailed FIT with low literacy level instructions or a reminder call, or both']","['proportion of mishandled samples', 'fecal immunochemical test (FIT', 'proportions of positive results', 'frequency of mishandled FIT samples, effects of outreach on mishandling, and positive results from the FIT among proper and mishandled samples']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0011008', 'cui_str': 'Dates'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}]","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.0960817,"The proportion of mishandled samples was lowest among patients who received the low literacy level instruction and a reminder call (12.8%, P < .0001).","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wang', 'Affiliation': 'Graduate Division, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Rachocki', 'Affiliation': 'Division of Gastroenterology, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Jean A', 'Initials': 'JA', 'LastName': 'Shapiro', 'Affiliation': 'Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.'}, {'ForeName': 'Rachel B', 'Initials': 'RB', 'LastName': 'Issaka', 'Affiliation': 'Clinical Research and Public Health Science Divisions, Fred Hutchinson, Seattle, Washington; Division of Gastroenterology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Ma', 'Initials': 'M', 'LastName': 'Somsouk', 'Affiliation': 'Division of Gastroenterology, University of California, San Francisco, San Francisco, California; Center for Vulnerable Populations, University of California, San Francisco, San Francisco, California. Electronic address: ma.somsouk@ucsf.edu.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2018.11.050'] 157,32323706,The alteration of stress-related physiological parameters after probiotics administration in oral surgeons with different degrees of surgical experience.,"PURPOSE Stress is a multifactorial and complex pathway, gaining growing attention from the healthcare community. Surgeons are subjected to higher levels of stress, due to surgical procedures that are demanding and repetitive; unfortunately, high-stress levels may also cause side-effects, as surgical mistakes. This study aimed to evaluate the efficacy of specific probiotics strains formula on stress levels in oral and maxillofacial surgeons, to improve their quality of life. METHODS We have investigated the hormonal (salivary Cortisol; sC), immune (salivary Immunoglobulin A; sIgA) and cardiovascular (Heart rate, HR, and systolic blood pressure, SBP) responses induced by stress conditions in 40 oral surgeons, randomly selected and allocated, according to their experience level, in three categories: senior, expert, and junior. RESULTS The results described how the number of heartbeats/ minute and SBP are slightly raised in all surgeons at different timepoints. Such data allow us to assess that work-related stress can induce an increase in cardiovascular parameters, even if they are not significantly modified by the use of probiotics. On the other hand, our data indicate that 10 weeks of probiotic integration may induce the improvement of other stress-related physiological parameters in oral surgeons with different degrees of surgical experience, such as the salivary cortisol levels, even under stress conditions. Moreover, in the test group (probiotics administration), the immunoglobulin levels were higher than the control (placebo administration) group: this happens as a consequence of the regular use of probiotics, which may induce an increased number of IgA producing cells. DISCUSSION Our data indicated that 10 weeks of probiotics-enriched diet modify some stress-related physiological parameters in oral surgeons with different degrees of surgical experience, but it does not impact on the overall cardiovascular risk.",2020,"Moreover, in the test group (probiotics administration), the immunoglobulin levels were higher than the control (placebo administration) group: this happens as a consequence of the regular use of probiotics, which may induce an increased number of IgA producing cells. ","['oral surgeons with different degrees of surgical experience', '40 oral surgeons, randomly selected and allocated, according to their experience level, in three categories: senior, expert, and junior']","['specific probiotics strains formula', 'control (placebo']","['number of heartbeats/ minute and SBP', 'stress levels', 'cardiovascular parameters', 'number of IgA producing cells', 'cardiovascular (Heart rate, HR, and systolic blood pressure, SBP) responses', 'salivary cortisol levels', 'immunoglobulin levels', 'quality of life', 'overall cardiovascular risk']","[{'cui': 'C0260272', 'cui_str': 'Oral surgeon'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0428536', 'cui_str': 'Immunoglobulin level - finding'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",,0.0345446,"Moreover, in the test group (probiotics administration), the immunoglobulin levels were higher than the control (placebo administration) group: this happens as a consequence of the regular use of probiotics, which may induce an increased number of IgA producing cells. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Pacifici', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, Sapienza University of Rome.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Pacifici', 'Affiliation': 'Department of Oral and Maxillofacial Sciences, Sapienza University of Rome.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nuzzolese', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Cascella', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ballini', 'Affiliation': 'Department of Biosciences, Biotechnologies and Biopharmaceutics, Campus Universitario ""Ernesto Quagliariello"", University of Bari ""Aldo Moro"", Bari - Department of Precision Medicine, University of Campania ""Luigi Vanvitelli"", Naples - Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Santacroce', 'Affiliation': 'Ionian Department, University of Bari ""Aldo Moro"", Bari - School of Technical Medical Sciences, ""A. Xhuvani"" University, Elbasan, Albania.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Dipalma', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Aiello', 'Affiliation': 'Tecnologica Research Institute, Marrelli Health, Crotone.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Amantea', 'Affiliation': 'Tecnologica Research Institute, Marrelli Health, Crotone.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Saini', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cantore', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari - Sorriso & Benessere Ricerca e Clinica S.r.l., Bari, Italy.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Inchingolo', 'Affiliation': 'Department of Interdisciplinary Medicine, University of Bari ""Aldo Moro"", Bari.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Scacco', 'Affiliation': 'Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari Aldo Moro, Bari, Italy.'}]",La Clinica terapeutica,['10.7417/CT.2020.2214'] 158,32320144,Weight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study.,"OBJECTIVE This study evaluated weight changes after cessation of the 10-year intensive lifestyle intervention (ILI) in the Look AHEAD (Action for Health in Diabetes) study. It was hypothesized that ILI participants would be more likely to gain weight during the 2-year observational period following termination of weight-loss-maintenance counseling than would participants in the diabetes support and education (DSE) control group. METHODS Look AHEAD was a randomized controlled trial that compared the effects of ILI and DSE on cardiovascular morbidity and mortality in participants with overweight/obesity and type 2 diabetes. Look AHEAD was converted to an observational study in September 2012. RESULTS Two years after the end of the intervention (EOI), ILI and DSE participants lost a mean  (SE) of 1.2  (0.2) kg and 1.8  (0.2) kg, respectively (P = 0.003). In addition, 31% of ILI and 23.9% of DSE participants gained ≥ 2% (P < 0.001) of EOI weight, whereas 36.3% and 45.9% of the respective groups lost ≥ 2% of EOI weight (P = 0.001). Two years after the EOI, ILI participants reported greater use of weight-control behaviors than DSE participants. CONCLUSIONS Both groups lost weight during the 2-year follow-up period, but more ILI than DSE participants gained ≥ 2% of EOI weight. Further understanding is needed of factors that affected long-term weight change in both groups.",2020,"In addition, 31% of ILI and 23.9% of DSE participants gained ≥ 2% (P < 0.001) of EOI weight, whereas 36.3% and 45.9% of the respective groups lost ≥ 2% of EOI weight (P = 0.001).","['participants with overweight/obesity and type 2 diabetes', 'Two years after the end of the intervention (EOI), ILI and DSE participants', 'Weight Change 2 Years']","['ILI and DSE', '10-year intensive lifestyle intervention (ILI', 'Intensive Lifestyle Intervention']","['cardiovascular morbidity and mortality', 'EOI weight', 'gain weight', 'weight-control behaviors']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C1321111', 'cui_str': 'Weight control behavior'}]",,0.0402555,"In addition, 31% of ILI and 23.9% of DSE participants gained ≥ 2% (P < 0.001) of EOI weight, whereas 36.3% and 45.9% of the respective groups lost ≥ 2% of EOI weight (P = 0.001).","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Ariana M', 'Initials': 'AM', 'LastName': 'Chao', 'Affiliation': 'Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Wadden', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Robert I', 'Initials': 'RI', 'LastName': 'Berkowitz', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Blackburn', 'Affiliation': 'Division of Nutrition, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Bolin', 'Affiliation': ""Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.""}, {'ForeName': 'Jeanne M', 'Initials': 'JM', 'LastName': 'Clark', 'Affiliation': 'Division of General Internal Medicine, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Mace', 'Initials': 'M', 'LastName': 'Coday', 'Affiliation': 'Departments of Preventive Medicine and Psychiatry, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Curtis', 'Affiliation': ""Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.""}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Delahanty', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Gareth R', 'Initials': 'GR', 'LastName': 'Dutton', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Ewing', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Foreyt', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Gay', 'Affiliation': 'Department of Psychiatry, The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.'}, {'ForeName': 'Edward W', 'Initials': 'EW', 'LastName': 'Gregg', 'Affiliation': 'Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.'}, {'ForeName': 'Helen P', 'Initials': 'HP', 'LastName': 'Hazuda', 'Affiliation': 'Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'James O', 'Initials': 'JO', 'LastName': 'Hill', 'Affiliation': 'Anschutz Health and Wellness Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Horton', 'Affiliation': 'Department of Integrative Physiology and Metabolism, Joslin Diabetes Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Denise K', 'Initials': 'DK', 'LastName': 'Houston', 'Affiliation': 'Department of Internal Medicine - Geriatrics, Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Jakicic', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Jeffery', 'Affiliation': 'Divisions of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Johnson', 'Affiliation': 'Departments of Preventive Medicine and Psychiatry, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Kahn', 'Affiliation': 'Division of Metabolism, Endocrinology and Nutrition, US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Knowler', 'Affiliation': ""Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Kure', 'Affiliation': 'Division of Metabolism, Endocrinology and Nutrition, US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Michalski', 'Affiliation': 'Division of General Internal Medicine, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Montez', 'Affiliation': 'Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Neiberg', 'Affiliation': 'Department of Internal Medicine - Geriatrics, Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Patricio', 'Affiliation': ""Department of Medicine, St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Peters', 'Affiliation': 'Division of Endocrinology, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pi-Sunyer', 'Affiliation': ""Department of Medicine, St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.""}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Pownall', 'Affiliation': 'Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Reboussin', 'Affiliation': 'Department of Internal Medicine - Geriatrics, Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Redmon', 'Affiliation': 'Divisions of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'W Jack', 'Initials': 'WJ', 'LastName': 'Rejeski', 'Affiliation': 'Department of Internal Medicine - Geriatrics, Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Steinburg', 'Affiliation': 'Departments of Preventive Medicine and Psychiatry, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Walker', 'Affiliation': 'Division of Endocrinology, University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Williamson', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Rena R', 'Initials': 'RR', 'LastName': 'Wing', 'Affiliation': 'Department of Psychiatry, The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Wyatt', 'Affiliation': 'Anschutz Health and Wellness Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Susan Z', 'Initials': 'SZ', 'LastName': 'Yanovski', 'Affiliation': 'Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22769'] 159,32018252,Perinatal Probiotic Mixture and Development of Allergic Sensitization up to 13 Years of Age.,"BACKGROUND Probiotics have shown promising results in primary prevention of allergies in early years, but the long-term effects on allergic sensitization need more evaluation. OBJECTIVES We conducted a randomized double-blind placebo-controlled study to determine whether the use of a mixture of pre- and probiotics perinatally affects the prevalence of immunoglobulin E (IgE) sensitization up to 13 years in high-risk children. METHODS One thousand two hundred twenty-three pregnant women were randomized to receiving probiotics or placebo from 36 gestational weeks until delivery, and their infants received pre- and probiotics or placebo from birth until 6 months. At 2, 5, and 13 years, blood samples were taken to determine specific IgE levels against common foods, pollen, and animal antigens. RESULTS The prevalence of IgE sensitization to any allergen was high and increased with age. No significant difference in the prevalence of IgE sensitization to any particular one of the tested allergens was found between the groups. At 2, 5, and 13 years these prevalence rates of IgE sensitization to any allergen were 31.1 and 34.1%, 50.1 and 45.6%, and 61.4 and 56.8% in the probiotic and placebo groups, respectively. At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). CONCLUSIONS In high-risk children, perinatal use of a mixture of probiotics did not affect the prevalence of sensitization to any one of the tested allergens, but it was associated with more frequent IgE sensitization to cat/dog dander at 13 years.",2020,"At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). ","['13 years in high-risk children', 'Allergic Sensitization up to 13 Years of Age', 'One thousand two hundred twenty-three pregnant women']","['placebo', 'probiotics or placebo', 'pre- and probiotics or placebo']","['prevalence rates of IgE sensitization', 'prevalence of IgE sensitization', 'IgE sensitization to cat/dog dander', 'prevalence of immunoglobulin E (IgE) sensitization']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3662483', 'cui_str': 'Allergic sensitization'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C0450348', 'cui_str': '23 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0202086', 'cui_str': 'Immunoglobulin E measurement (procedure)'}, {'cui': 'C1325847', 'cui_str': 'Sensitization'}, {'cui': 'C0524517', 'cui_str': 'Felis'}, {'cui': 'C0440458', 'cui_str': 'Dog dander (substance)'}]",1223.0,0.136193,"At 13 years, IgE sensitization to cat/dog dander was more frequent in the probiotic group compared to the placebo group (40.2 vs. 31.0%, p = 0.03). ","[{'ForeName': 'Päivi Susanna', 'Initials': 'PS', 'LastName': 'Peldan', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland, paivi.peldan@hus.fi.""}, {'ForeName': 'Anna Kaarina', 'Initials': 'AK', 'LastName': 'Kukkonen', 'Affiliation': 'Skin and Allergy Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Erkki', 'Initials': 'E', 'LastName': 'Savilahti', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland.""}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Kuitunen', 'Affiliation': ""Pediatric Research Center, University of Helsinki and Helsinki University Hospital, New Children's Hospital, Helsinki, Finland.""}]",International archives of allergy and immunology,['10.1159/000504915'] 160,32229466,The Effect of Narrative on Physical Activity via Immersion During Active Video Game Play in Children: Mediation Analysis.,"BACKGROUND Active video games (AVGs) can increase physical activity (PA) and help produce higher physiological expenditure. Animated narrative videos (NVs) possess unique immersive and motivational properties. When added to AVGs, they have been found to increase moderate-to-vigorous physical activity (MVPA) as opposed to the original no video condition. However, there is no evidence of whether that was due to the NV or the addition of an animated video to an AVG. OBJECTIVE This study aimed to investigate the differential effect of adding an NV versus a nonnarrative video (NNV) to an AVG on PA parameters and physiological responses and to explore the mediating role of immersion. METHODS A total of 22 children aged 8 to 12 years were randomly assigned to the NV or NNV condition. They were instructed to play an AVG (on Xbox Kinect) for as long as they wanted. We used accelerometers to estimate the time spent (in minutes) in MVPA. Heart rate (HR) and rate of perceived exertion (RPE) were measured before, during, and after the AVG play session. The participants then reported their experience of narrative immersion via a questionnaire. RESULTS The NV group had significantly higher narrative immersion (mean 3.50, SD 0.55 vs mean 2.91, SD 0.59; P=.03) and MVPA than the NNV group (mean 20.11, SD 13.75 vs mean 7.85, SD 5.83; P=.02). Narrative immersion was positively correlated with MVPA (r=0.52; P=.01) and average HR during AVG (r=0.43; P=.05). Mediation analysis indicated that narrative immersion mediated the effect of NV (NV vs NNV) on MVPA (direct effect: beta=7.51; P=.01). The indirect effect was that NV was positively correlated with the mediator variable narrative immersion (beta=.59; P=.03), which was itself marginally associated with MVPA (beta=6.95; P=.09); when narrative immersion was included in the model, the regression coefficient was attenuated. CONCLUSIONS AVG with added narratives elicits more narrative immersion, resulting in more minutes in MVPA. Narrative immersion served as a mediator between NV and MVPA via its elicitation of an elevated HR without increasing RPE. The inclusion of immersive narratives in AVG could be helpful for inducing MVPA, to enhance AVG engagement without additional exertion.",2020,"The NV group had significantly higher narrative immersion (mean 3.50, SD 0.55 vs mean 2.91, SD 0.59; P=.03) and MVPA than the NNV group (mean 20.11, SD 13.75 vs mean 7.85, SD 5.83; P=.02).","['22 children aged 8 to 12 years', 'Children']","['Narrative on Physical Activity via Immersion', 'Active video games (AVGs', 'NV versus a nonnarrative video (NNV', 'Animated narrative videos (NVs) possess unique immersive and motivational properties']","['MVPA', 'Narrative immersion', 'narrative immersion', 'Heart rate (HR) and rate of perceived exertion (RPE', 'physical activity (PA']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}]","[{'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",22.0,0.0859879,"The NV group had significantly higher narrative immersion (mean 3.50, SD 0.55 vs mean 2.91, SD 0.59; P=.03) and MVPA than the NNV group (mean 20.11, SD 13.75 vs mean 7.85, SD 5.83; P=.02).","[{'ForeName': 'Caio Victor', 'Initials': 'CV', 'LastName': 'Sousa', 'Affiliation': 'College of Arts, Media, and Design, Bouvé College of Health Sciences, Health Technology Lab, Northeastern University, Boston, MA, United States.'}, {'ForeName': 'Austin', 'Initials': 'A', 'LastName': 'Fernandez', 'Affiliation': 'College of Arts, Media, and Design, Bouvé College of Health Sciences, Health Technology Lab, Northeastern University, Boston, MA, United States.'}, {'ForeName': 'Jungyun', 'Initials': 'J', 'LastName': 'Hwang', 'Affiliation': 'Stanford University Medical Center, Department of Medicine, Palo Alto, CA, United States.'}, {'ForeName': 'Amy Shirong', 'Initials': 'AS', 'LastName': 'Lu', 'Affiliation': 'College of Arts, Media, and Design, Bouvé College of Health Sciences, Health Technology Lab, Northeastern University, Boston, MA, United States.'}]",Journal of medical Internet research,['10.2196/17994'] 161,32320457,Sexual network distribution of HIV self-testing kits: Findings from the process evaluation of an intervention for men who have sex with men in China.,"BACKGROUND The World Health Organization has recommended HIV self-testing (HIVST) as an alternative testing strategy given the limitations of facility-based testing. While the benefits of HIV self-testing have been demonstrated at the individual level among men who have sex with men (MSM), limited data exist on if this testing approach can be effectively diffused through individuals' social or sexual networks. The objectives of this study were to examine patterns and correlates of HIVST distribution within Chinese MSM's sexual networks. METHODS Data used for this analysis was a part of the process evaluation of an HIVST intervention trial among MSM in Nanjing, China. Between May and October 2017, we enrolled 400 men into the trial. Participants assigned to the intervention group (N = 200) were given three HIVST kits at baseline and could request more during the follow-up periods. We incorporated measures for process evaluation in the self-administered online follow-up surveys. This analysis reported findings from the three-month follow-up survey in the intervention group. Frequencies and percentages were used to describe characteristics of participants who distributed kits to their sexual partners as well as patterns of distribution. Multivariable logistic regression was conducted to identify independent correlates of participants who distributed the kits. RESULTS Of the 177 participants retained (88.5%) at the three-month follow-up, 72 (40.7%) distributed one or more kits to either primary or casual partners. About half of distributors (51.4%) gave one HIVST kit to their sexual partners while 15.3% distributed 3 or more. Over half gave these kits (58.3%) to primary sexual partners while 27.8% reported giving the kits to both primary and casual partners. About half (54.2%) of distributors used the kits together with their partners. Compared to participants who had an HIV test in the past six months, those who tested over six months ago or never tested had significantly lower odds of distributing the kits (AOR = 0.484, 95% CI: 0.250-0.983, p = 0.032). Compared to those who had not used the kits themselves, participants who did had significantly higher odds of distributing the kits (AOR = 3.345, 95% CI: 1.488-7.517, p = 0.003). Participants who reported higher HIV testing efficacy had 2.051 fold greater odds (95% CI: 1.062-3.961, p = 0.033) of distributing the kits compared to those who had lower efficacy. CONCLUSION Our study demonstrated that a sexual network-based approach to distributing HIVST among Chinese MSM is feasible and can be a promising strategy to improve the effectiveness of HIVST programs including its reach to untested men. Such approach should be complimented by intervention components that enhance HIV testing efficacy and improve experiences of HIVST.",2020,"Participants who reported higher HIV testing efficacy had 2.051 fold greater odds (95% CI: 1.062-3.961, p = 0.033) of distributing the kits compared to those who had lower efficacy. ","['men who have sex with men (MSM', 'men who have sex with men in China', '400 men into the trial', 'Of the 177 participants retained (88.5%) at the three-month follow-up, 72 (40.7%) distributed one or more kits to either primary or casual partners']",['HIV self-testing kits'],['HIV testing efficacy'],"[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}]","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}]","[{'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",400.0,0.0417201,"Participants who reported higher HIV testing efficacy had 2.051 fold greater odds (95% CI: 1.062-3.961, p = 0.033) of distributing the kits compared to those who had lower efficacy. ","[{'ForeName': 'Wenjing', 'Initials': 'W', 'LastName': 'Xiao', 'Affiliation': 'Nanjing Medical University, Nanjing, Jiangsu, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yan', 'Affiliation': 'Xuzhou Central Hospital, Xuzhou, Jiangsu, China.'}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Gengfeng', 'Initials': 'G', 'LastName': 'Fu', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Institute of Parasitic Diseases, Wuxi, Jiangsu, China.'}, {'ForeName': 'Cui', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.'}, {'ForeName': 'Hongjing', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Chongyi', 'Initials': 'C', 'LastName': 'Wei', 'Affiliation': 'Department of Health Behavior, Society, and Policy, Rutgers School of Public Health, New Jersey, United States of America.'}]",PloS one,['10.1371/journal.pone.0232094'] 162,31357206,Pharmacological mechanisms of interhemispheric signal propagation: a TMS-EEG study.,"Interhemispheric connections across the corpus callosum have a predominantly inhibitory effect. Previous electrophysiology studies imply that local inhibitory circuits are responsible for inducing transcallosal inhibition, likely through inhibitory GABA B -mediated neurotransmission. We investigated the neurochemical mechanisms involved in interhemispheric connectivity by measuring transcranial magnetic stimulation (TMS)-induced interhemispheric signal propagation (ISP) in the motor cortex and dorsolateral prefrontal cortex (DLPFC) with electroencephalography (EEG) recordings under the pharmacological effects of baclofen, L-DOPA, dextromethorphan, and rivastigmine. We hypothesized that for both stimulated regions, GABA B receptor agonist baclofen would decrease ISP when compared against baseline while drugs that target other neurotransmitter systems (dopaminergic, acetylcholinergic, and glutamatergic systems) would have no effect on ISP. Twelve right-handed healthy volunteers completed this study and underwent TMS across five sessions in a randomized order. In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions. There were no drug-induced changes in ISP in the DLPFC and baseline ISP did not differ across experimental sessions for both brain regions. Together, our results suggest that the inhibitory effects observed with interhemispheric signal transmission are mediated by a population of interneurons involving GABA B receptor neurotransmission. Inhibitory mechanisms of ISP may be more salient for motor-related functions in the motor cortex than for cognitive control in the DLPFC. These findings are a fundamental step in advancing our understanding of interhemispheric connectivity and may be used to identify treatments for disorders in which transcallosal transmission is dysfunctional.",2020,"In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions.",['Twelve right-handed healthy volunteers'],"['baclofen, L-DOPA, dextromethorphan, and rivastigmine', 'TMS', 'transcranial magnetic stimulation (TMS)-induced interhemispheric signal propagation (ISP']","['ISP under baclofen', 'ISP']","[{'cui': 'C0344333', 'cui_str': 'Right handed (finding)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0004609', 'cui_str': 'Baclofen'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0649350', 'cui_str': 'rivastigmine'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]","[{'cui': 'C0004609', 'cui_str': 'Baclofen'}]",12.0,0.0545946,"In the motor cortex, participants showed a significant decrease in ISP under baclofen, but not in the other drug conditions.","[{'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Hui', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Zomorrodi', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Pantelis', 'Initials': 'P', 'LastName': 'Lioumis', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Bahar', 'Initials': 'B', 'LastName': 'Salavati', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Tarek K', 'Initials': 'TK', 'LastName': 'Rajji', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada. Jeff.Daskalakis@camh.ca.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0468-7'] 163,31506808,Long-term outcomes of a randomized controlled trial comparing trans-obturator vaginal mesh with native tissue repair in the treatment of anterior vaginal wall prolapse.,"INTRODUCTION AND HYPOTHESIS The aim of this study was to report the long-term subjective and objective outcomes after transvaginal mesh (TVM) or native tissue repair. METHODS Prospective, randomized, multicenter study conducted between April 2005 and December 2009 comparing anterior colporrhaphy with trans-obturator vaginal mesh (Pelvitex/Ugytex®, Sofradim, Trevoux, France) for the treatment of anterior vaginal wall prolapse. The primary endpoint was functional recurrence rate 5-8 years after surgery. Secondary endpoints consisted of anatomical results, mesh-related morbidity and patient satisfaction measured through validated questionnaires. RESULTS Of the 147 women originally included, 75 (51%) were successfully re-contacted a median of 7 years after the initial surgery. The primary outcome, subjective recurrence of prolapse, was similar between the TVM and the anterior colporrhaphy groups (31 vs 34% respectively). Anatomical recurrence was less likely in the TVM group (67 vs 24%, p = 0.004). Mesh exposure occurred in 4 of the 39 patients (13%) during follow-up, 2 of which had a surgical reintervention. Reintervention for prolapse took place in 7 patients (9%). CONCLUSION Seven-year follow-up showed similar functional outcomes for mesh and native tissue repair in anterior vaginal wall prolapse. TVM did not reduce repeat surgery in the long term; it did, however, reduce anatomical recurrence. Mesh exposure rates were relatively high, but no difference in outcome of pain or dyspareunia was noted.",2020,"Anatomical recurrence was less likely in the TVM group (67 vs 24%, p = 0.004).","['147 women originally included, 75 (51%) were successfully re-contacted a median of 7\xa0years after the initial surgery', 'multicenter study conducted between April 2005 and December 2009 comparing', 'anterior vaginal wall prolapse']","['anterior colporrhaphy with trans-obturator vaginal mesh (Pelvitex/Ugytex®, Sofradim, Trevoux, France', 'trans-obturator vaginal mesh with native tissue repair', 'TVM', 'transvaginal mesh (TVM) or native tissue repair']","['subjective recurrence of prolapse', 'functional recurrence rate', 'Anatomical recurrence', 'Mesh exposure rates', 'anatomical results, mesh-related morbidity and patient satisfaction measured through validated questionnaires', 'surgical reintervention', 'anatomical recurrence', 'pain or dyspareunia', 'Mesh exposure']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0425852', 'cui_str': 'Anterior vaginal wall prolapse (disorder)'}]","[{'cui': 'C0195224', 'cui_str': 'Anterior colporrhaphy (procedure)'}, {'cui': 'C0182021', 'cui_str': 'Obturator (physical object)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0302891', 'cui_str': 'Native (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0175672', 'cui_str': 'Vaginal approach (qualifier value)'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse (finding)'}]",147.0,0.138094,"Anatomical recurrence was less likely in the TVM group (67 vs 24%, p = 0.004).","[{'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Allègre', 'Affiliation': 'Department of Obstetrics and Gynecology, CHU Nîmes, University of Montpellier, Nîmes, France.'}, {'ForeName': 'Geertje', 'Initials': 'G', 'LastName': 'Callewaert', 'Affiliation': 'Department of Obstetrics and Gynecology, CHU Nîmes, University of Montpellier, Nîmes, France. geertje.callewaert@chu-nimes.fr.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Alonso', 'Affiliation': 'Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology (BESPIM), CHU Nîmes, University of Montpellier, Nîmes, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Cornille', 'Affiliation': 'Department of Obstetrics and Gynecology, Clinique Beau Soleil, Montpellier, France.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Fernandez', 'Affiliation': 'Department of Obstetrics and Gynecology, Kremin Bicêtre Hospital, Kremin Bicêtre, France.'}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Eglin', 'Affiliation': 'Department of Obstetrics and Gynecology, Clinique Champeau, Béziers, France.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'de Tayrac', 'Affiliation': 'Department of Obstetrics and Gynecology, CHU Nîmes, University of Montpellier, Nîmes, France.'}]",International urogynecology journal,['10.1007/s00192-019-04073-x'] 164,31410518,TVT-O vs. TVT-Abbrevo for stress urinary incontinence treatment in women: a randomized trial.,"INTRODUCTION To compare the efficacy, safety and complications of the trans-obturator midurethral sling from inside to outside (TVT-O) and of the shorter trans-obturator midurethral sling (TVT-Abbrevo) for treatment of female SUI. MATERIALS AND METHODS One hundred fifty-eight recruited patients were randomized into either the TVT-O or TVT-Abbrevo group. Preoperative assessment included history and general assessment, urinalysis and urine culture, urogynaecological clinical examination, urodynamic evaluation and urogynaecologic interview by ICIQ-SF-UI, PGI-I and PISQ12. Operative time, perioperative complications, spontaneous voiding, postoperative complications and hospital stay were prospectively recorded in all patients. At 3, 6, 12, 24 and 36 months after surgery, patients were asked to answer urogynaecological interviews by ICIQ-SF-UI, PGI-I and PISQ12. The urodynamic assessment was performed at 12, 24 and 36 months. Success rate was assessed at 12, 24 and 36 months postoperatively. RESULTS Overall, 138 of 158 patients (87%) were cured of SUI 36 months after the operation with no significant differences between groups [69 (87%) and 69 (87%) patients in the TVT-O and TVT Abbrevo groups, respectively]. The two groups did not significantly differ in operative time, intraoperative blood loss and length of hospital stay. Nine patients (11%) had postoperative groin pain in the TVT-O group and one patient in the TVT Abbrevo group (p = 0.02). Three-year control demonstrated an equal objective cure rate in both groups. There was a significant improvement in total PISQ-12 and ICIQ-SF-UI scores in both groups at 36 months FU. CONCLUSION TVT-Abbrevo has similar efficacy and safety compared with TVT-O in women with SUI; the use of a shorter sling reduces postoperative pain.",2020,"There was a significant improvement in total PISQ-12 and ICIQ-SF-UI scores in both groups at 36 months FU. ","['women with SUI', 'female SUI', 'One hundred fifty-eight recruited patients', 'stress urinary incontinence treatment in women']","['TVT-O', 'trans-obturator midurethral sling from inside to outside (TVT-O) and of the shorter trans-obturator midurethral sling (TVT-Abbrevo', 'TVT-O vs. TVT-Abbrevo', 'TVT-O or TVT-Abbrevo group']","['Success rate', 'postoperative pain', 'efficacy, safety and complications', 'history and general assessment, urinalysis and urine culture, urogynaecological clinical examination, urodynamic evaluation and urogynaecologic interview by ICIQ-SF-UI, PGI-I and PISQ12', 'objective cure rate', 'total PISQ-12 and ICIQ-SF-UI scores', 'operative time, intraoperative blood loss and length of hospital stay', 'postoperative groin pain', 'Operative time, perioperative complications, spontaneous voiding, postoperative complications and hospital stay']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042025', 'cui_str': 'Urinary Stress Incontinence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0182021', 'cui_str': 'Obturator (physical object)'}, {'cui': 'C1141000', 'cui_str': 'Sled, device (physical object)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C3179501', 'cui_str': 'Midurethral Slings'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0588388', 'cui_str': 'General observation (regime/therapy)'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0430404', 'cui_str': 'Urine culture (procedure)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain (finding)'}, {'cui': 'C4545429', 'cui_str': 'Perioperative complication'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}]",158.0,0.0478452,"There was a significant improvement in total PISQ-12 and ICIQ-SF-UI scores in both groups at 36 months FU. ","[{'ForeName': 'Marzio Angelo', 'Initials': 'MA', 'LastName': 'Zullo', 'Affiliation': 'Department of Surgery-Week Surgery, Campus Biomedico, University of Rome, Rome, Italy.'}, {'ForeName': 'Michele Carlo', 'Initials': 'MC', 'LastName': 'Schiavi', 'Affiliation': 'Department of Gynecological and Obstetric Sciences, and Urological Sciences, University of Rome ""Sapienza"", Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy. michelecarlo.schiavi@gmail.com.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Luffarelli', 'Affiliation': 'Department of Surgery-Week Surgery, Campus Biomedico, University of Rome, Rome, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Prata', 'Affiliation': 'Department of Gynecological and Obstetric Sciences, and Urological Sciences, University of Rome ""Sapienza"", Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Di Pinto', 'Affiliation': 'Department of Gynecological and Obstetric Sciences, and Urological Sciences, University of Rome ""Sapienza"", Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'ForeName': 'Cosimo', 'Initials': 'C', 'LastName': 'Oliva', 'Affiliation': 'Department of Gynecological and Obstetric, San Filippo Neri Hospital, Rome, Italy.'}]",International urogynecology journal,['10.1007/s00192-019-04077-7'] 165,32175593,Topical benzoyl peroxide for acne.,"BACKGROUND Acne is a common, economically burdensome condition that can cause psychological harm and, potentially, scarring. Topical benzoyl peroxide (BPO) is a widely used acne treatment; however, its efficacy and safety have not been clearly evaluated. OBJECTIVES To assess the effects of BPO for acne. SEARCH METHODS We searched the following databases up to February 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of relevant randomised controlled trials (RCTs) and systematic reviews. SELECTION CRITERIA We included RCTs that compared topical BPO used alone (including different formulations and concentrations of BPO) or as part of combination treatment against placebo, no treatment, or other active topical medications for clinically diagnosed acne (used alone or in combination with other topical drugs not containing BPO) on the face or trunk. DATA COLLECTION AND ANALYSIS We used standard methodological procedures as expected by Cochrane. Primary outcome measures were 'participant global self-assessment of acne improvement' and 'withdrawal due to adverse events in the whole course of a trial'. 'Percentage of participants experiencing any adverse event in the whole course of a trial' was a key secondary outcome. MAIN RESULTS We included 120 trials (29,592 participants randomised in 116 trials; in four trials the number of randomised participants was unclear). Ninety-one studies included males and females. When reported, 72 trials included participants with mild to moderate acne, 26 included participants with severe acne, and the mean age of participants ranged from 18 to 30 years. Our included trials assessed BPO as monotherapy, as add-on treatment, or combined with other active treatments, as well as BPO of different concentrations and BPO delivered through different vehicles. Comparators included different concentrations or formulations of BPO, placebo, no treatment, or other active treatments given alone or combined. Treatment duration in 80 trials was longer than eight weeks and was only up to 12 weeks in 108 trials. Industry funded 50 trials; 63 trials did not report funding. We commonly found high or unclear risk of performance, detection, or attrition bias. Trial setting was under-reported but included hospitals, medical centres/departments, clinics, general practices, and student health centres. We reported on outcomes assessed at the end of treatment, and we classified treatment periods as short-term (two to four weeks), medium-term (five to eight weeks), or long-term (longer than eight weeks). For 'participant-reported acne improvement', BPO may be more effective than placebo or no treatment (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.12 to 1.45; 3 RCTs; 2234 participants; treatment for 10 to 12 weeks; low-certainty evidence). Based on low-certainty evidence, there may be little to no difference between BPO and adapalene (RR 0.99, 95% CI 0.90 to 1.10; 5 RCTs; 1472 participants; treatment for 11 to 12 weeks) or between BPO and clindamycin (RR 0.95, 95% CI 0.68 to 1.34; 1 RCT; 240 participants; treatment for 10 weeks) (outcome not reported for BPO versus erythromycin or salicylic acid). For 'withdrawal due to adverse effects', risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment (RR 2.13, 95% CI 1.55 to 2.93; 24 RCTs; 13,744 participants; treatment for 10 to 12 weeks; low-certainty evidence); the most common causes of withdrawal were erythema, pruritus, and skin burning. Only very low-certainty evidence was available for the following comparisons: BPO versus adapalene (RR 1.85, 95% CI 0.94 to 3.64; 11 RCTs; 3295 participants; treatment for 11 to 24 weeks; causes of withdrawal not clear), BPO versus clindamycin (RR 1.93, 95% CI 0.90 to 4.11; 8 RCTs; 3330 participants; treatment for 10 to 12 weeks; causes of withdrawal included local hypersensitivity, pruritus, erythema, face oedema, rash, and skin burning), erythromycin (RR 1.00, 95% CI 0.07 to 15.26; 1 RCT; 60 participants; treatment for 8 weeks; withdrawal due to dermatitis), and salicylic acid (no participants had adverse event-related withdrawal; 1 RCT; 59 participants; treatment for 12 weeks). There may be little to no difference between these groups in terms of withdrawal; however, we are unsure of the results because the evidence is of very low certainty. For 'proportion of participants experiencing any adverse event', very low-certainty evidence leaves us uncertain about whether BPO increased adverse events when compared with placebo or no treatment (RR 1.40, 95% CI 1.15 to 1.70; 21 RCTs; 11,028 participants; treatment for 10 to 12 weeks), with adapalene (RR 0.71, 95% CI 0.50 to 1.00; 7 RCTs; 2120 participants; treatment for 11 to 24 weeks), with erythromycin (no participants reported any adverse events; 1 RCT; 89 participants; treatment for 10 weeks), or with salicylic acid (RR 4.77, 95% CI 0.24 to 93.67; 1 RCT; 41 participants; treatment for 6 weeks). Moderate-certainty evidence shows that the risk of adverse events may be increased for BPO versus clindamycin (RR 1.24, 95% CI 0.97 to 1.58; 6 RCTs; 3018 participants; treatment for 10 to 12 weeks); however, the 95% CI indicates that BPO might make little to no difference. Most reported adverse events were mild to moderate, and local dryness, irritation, dermatitis, erythema, application site pain, and pruritus were the most common. AUTHORS' CONCLUSIONS Current evidence suggests that BPO as monotherapy or add-on treatment may be more effective than placebo or no treatment for improving acne, and there may be little to no difference between BPO and either adapalene or clindamycin. Our key efficacy evidence is based on participant self-assessment; trials of BPO versus erythromycin or salicylic acid did not report this outcome. For adverse effects, the evidence is very uncertain regarding BPO compared with adapalene, erythromycin, or salicylic acid. However, risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment. Withdrawal may be linked to tolerability rather than to safety. Risk of mild to moderate adverse events may be higher with BPO compared with clindamycin. Further trials should assess the comparative effects of different preparations or concentrations of BPO and combination BPO versus monotherapy. These trials should fully assess and report adverse effects and patient-reported outcomes measured on a standardised scale.",2020,Primary outcome measures were 'participant global self-assessment of acne improvement' and 'withdrawal due to adverse events in the whole course of a trial'. ',"['Ninety-one studies included males and females', '120 trials (29,592 participants randomised in 116 trials; in four trials the number of randomised participants was unclear', 'clinically diagnosed acne (used alone or in combination with other topical drugs not containing BPO) on the face or trunk', '72 trials included participants with mild to moderate acne, 26 included participants with severe acne, and the mean age of participants ranged from 18 to 30 years', 'Trial setting was under-reported but included hospitals, medical centres/departments, clinics, general practices, and student health centres']","['BPO and combination BPO versus monotherapy', 'BPO versus adapalene', 'adapalene, erythromycin, or salicylic acid', 'clindamycin', 'adapalene', 'erythromycin or salicylic acid', 'Topical benzoyl peroxide', 'placebo', 'salicylic acid', 'erythromycin', 'BPO, placebo', 'Topical benzoyl peroxide (BPO']","['adverse events', 'withdrawal included local hypersensitivity, pruritus, erythema, face oedema, rash, and skin burning), erythromycin', 'erythema, pruritus, and skin burning', 'local dryness, irritation, dermatitis, erythema, application site pain, and pruritus', ""participant global self-assessment of acne improvement' and 'withdrawal due to adverse events""]","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C4517541', 'cui_str': '116 (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0702166', 'cui_str': 'Acne'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0086343', 'cui_str': 'General Practice'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}]","[{'cui': 'C0165631', 'cui_str': 'adapalene'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0036080', 'cui_str': 'Salicylic Acids'}, {'cui': 'C0008947', 'cui_str': 'Clindamycin'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0005088', 'cui_str': 'Benzoyl Peroxide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C3544362', 'cui_str': 'Hypersensitivity (SMQ)'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0542571', 'cui_str': 'Edema of face (finding)'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0441723', 'cui_str': 'Irritation (qualifier value)'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0521491', 'cui_str': 'Application site pain (finding)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment (Psychology)'}, {'cui': 'C0702166', 'cui_str': 'Acne'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]",29592.0,0.366858,Primary outcome measures were 'participant global self-assessment of acne improvement' and 'withdrawal due to adverse events in the whole course of a trial'. ',"[{'ForeName': 'Zhirong', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': ""School of Clinical Medicine, University of Cambridge, Primary Care Unit, Department of Public Health and Primary Care, Strangeways Research Laboratory, 2 Worts' Causeway, Cambridge, UK, CB1 8RN.""}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'McMaster University, Department of Health Research Methods, Evidence, and Impact, 1280 Main Street West, Hamilton, ON, Canada, L8S 4K1.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Lazic Mosler', 'Affiliation': 'Catholic University of Croatia, Department of Nursing, Ilica 242, Zagreb, Croatia, 10000.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'School of Public Health, Peking University, Centre for Evidence Based Medicine and Clinical Research, Department of Epidemiology and Biostatistics, Beijing, China, 100191.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Peking University First Hospital, Department of Dermatology and Venereology, 8 Xishiku Main Street, Beijing, Xicheng District, China, 100034.'}, {'ForeName': 'Yanchang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Yale School of Public Health, Department of Chronic Disease Epidemiology, 367 Cedar ST RM 704, New Haven, Connecticut, USA, 06510.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Xuanwu Hospital, Capital Medical University, Department of Neurology, Changchun Street 45, Beijing, China, 100053.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': ""The University of Nottingham, c/o Cochrane Skin Group, A103, King's Meadow Campus, Lenton Lane, Nottingham, UK, NG7 2NR.""}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011154.pub2'] 166,31489559,Discharge Information and Support for Patients Discharged from the Emergency Department: Results from a Randomized Controlled Trial.,"BACKGROUND Little research has been done on primary care-based models to improve health care use after an emergency department (ED) visit. OBJECTIVE To examine the effectiveness of a primary care-based, nurse telephone support intervention for Veterans treated and released from the ED. DESIGN Randomized controlled trial with 1:1 assignment to telephone support intervention or usual care arms (ClinicalTrials.gov: NCT01717976). SETTING Department of Veterans Affairs Health Care System (VAHCS) in Durham, NC. PARTICIPANTS Five hundred thirteen Veterans who were at high risk for repeat ED visits. INTERVENTION The telephone support intervention consisted of two core calls in the week following an ED visit. Call content focused on improving the ED to primary care transition, enhancing chronic disease management, and educating Veterans and family members about VHA and community services. MAIN MEASURES The primary outcome was repeat ED use within 30 days. KEY RESULTS Observed rates of repeat ED use at 30 days in usual care and intervention groups were 23.1% and 24.9%, respectively (OR = 1.1; 95% CI = 0.7, 1.7; P = 0.6). The intervention group had a higher rate of having at least 1 primary care visit at 30 days (OR = 1.6, 95% CI = 1.1-2.3). At 180 days, the intervention group had a higher rate of usage of a weight management program (OR = 3.5, 95% CI = 1.6-7.5), diabetes/nutrition (OR = 1.8, 95% CI = 1.0-3.0), and home telehealth services (OR = 1.7, 95% CI = 1.0-2.9) compared with usual care. CONCLUSIONS A brief primary care-based nurse telephone support program after an ED visit did not reduce repeat ED visits within 30 days, despite intervention participants' increased engagement with primary care and some chronic disease management services. TRIALS REGISTRATION ClinicalTrials.gov NCT01717976.",2020,"A brief primary care-based nurse telephone support program after an ED visit did not reduce repeat ED visits within 30 days, despite intervention participants' increased engagement with primary care and some chronic disease management services. ","['Patients', 'Five hundred thirteen Veterans who were at high risk for repeat ED visits', 'Discharged from the Emergency Department', 'Veterans treated and released from the ED', 'Department of Veterans Affairs Health Care System (VAHCS) in Durham, NC']","['telephone support intervention', 'primary care-based nurse telephone support program', 'primary care-based, nurse telephone support intervention']","['diabetes/nutrition', 'higher rate of usage of a weight management program', 'higher rate of having at least 1 primary care visit', 'home telehealth services', 'repeat ED use within 30\xa0days']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}, {'cui': 'C0454851', 'cui_str': 'Durham (geographic location)'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C4520476', 'cui_str': 'Telehealth service'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",513.0,0.135765,"A brief primary care-based nurse telephone support program after an ED visit did not reduce repeat ED visits within 30 days, despite intervention participants' increased engagement with primary care and some chronic disease management services. ","[{'ForeName': 'Susan N', 'Initials': 'SN', 'LastName': 'Hastings', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA. susan.hastings@va.gov.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Stechuchak', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Coffman', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Elizabeth P', 'Initials': 'EP', 'LastName': 'Mahanna', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Morris', 'Initials': 'M', 'LastName': 'Weinberger', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Courtney H', 'Initials': 'CH', 'LastName': 'Van Houtven', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Kenneth E', 'Initials': 'KE', 'LastName': 'Schmader', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Cristina C', 'Initials': 'CC', 'LastName': 'Hendrix', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, Durham VA Health Care System, Durham, NC, USA.'}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Kessler', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Jaime M', 'Initials': 'JM', 'LastName': 'Hughes', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Ramos', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'G Darryl', 'Initials': 'GD', 'LastName': 'Wieland', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, Durham VA Health Care System, Durham, NC, USA.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Weiner', 'Affiliation': 'Geriatric Research, Education, and Clinical Center, Durham VA Health Care System, Durham, NC, USA.'}, {'ForeName': 'Katina', 'Initials': 'K', 'LastName': 'Robinson', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Oddone', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation, Durham VA Health Care System, HSR&D, Fulton Street, Durham, NC, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05319-6'] 167,31604081,Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.,"BACKGROUND & AIMS There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. METHODS We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. RESULTS At evaluation, HCV antibody prevalence ranged from 7.2-76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34-10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14-44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52-63.8). CONCLUSIONS We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. CLINICALTRIALS. GOV IDENTIFIER NCT01686750. LAY SUMMARY Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.",2020,"At evaluation, PWID in ICC clusters were four times more likely to report being tested for HCV than UC clusters adjusting for baseline testing (adjusted prevalence ratio [aPR]: 3.69; 95% confidence interval [CI]: 1.34, 10.2).","['5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed', 'people who inject drugs', 'people who inject drugs (PWID) across India using a cluster-randomized trial', 'across the 12 sites (n=11,993 recruited at baseline; n=11,721 recruited at evaluation']","['respondent-driven sampling (RDS', 'ICCs with usual care (UC', 'HCV testing/education into integrated care centers (ICCs) delivering HIV services', 'HIV programs']","['hepatitis C outcomes', 'HCV antibody prevalence', 'population-level self-reported HCV testing history']","[{'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C4521936', 'cui_str': 'Inject (administration method)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0019196', 'cui_str': 'Parenterally-Transmitted Non-A, Non-B Hepatitis'}, {'cui': 'C0166049', 'cui_str': 'Hepatitis C Virus Antibodies'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}]",2278.0,0.150156,"At evaluation, PWID in ICC clusters were four times more likely to report being tested for HCV than UC clusters adjusting for baseline testing (adjusted prevalence ratio [aPR]: 3.69; 95% confidence interval [CI]: 1.34, 10.2).","[{'ForeName': 'Sunil Suhas', 'Initials': 'SS', 'LastName': 'Solomon', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sss@jhmi.edu.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Quinn', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Suniti', 'Initials': 'S', 'LastName': 'Solomon', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'McFall', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Aylur K', 'Initials': 'AK', 'LastName': 'Srikrishnan', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Vinita', 'Initials': 'V', 'LastName': 'Verma', 'Affiliation': 'National AIDS Control Organisation, Ministry of Health and Family Welfare, New Delhi, India.'}, {'ForeName': 'Muniratnam S', 'Initials': 'MS', 'LastName': 'Kumar', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Laeyendecker', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Celentano', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Syed H', 'Initials': 'SH', 'LastName': 'Iqbal', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Santhanam', 'Initials': 'S', 'LastName': 'Anand', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Canjeevaram K', 'Initials': 'CK', 'LastName': 'Vasudevan', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'Shanmugam', 'Initials': 'S', 'LastName': 'Saravanan', 'Affiliation': 'YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Thomas', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Kuldeep Singh', 'Initials': 'KS', 'LastName': 'Sachdeva', 'Affiliation': 'National AIDS Control Organisation, Ministry of Health and Family Welfare, New Delhi, India.'}, {'ForeName': 'Gregory M', 'Initials': 'GM', 'LastName': 'Lucas', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Shruti H', 'Initials': 'SH', 'LastName': 'Mehta', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Journal of hepatology,['10.1016/j.jhep.2019.09.022'] 168,31652479,"17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.","BACKGROUND Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or ""17P"") to placebo has been published, and this trial was stopped early due to a large treatment benefit. OBJECTIVE This study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. STUDY DESIGN This was a double-blind, placebo-controlled international trial involving women with a previous singleton SPTB ( clinicaltrials.gov : NCT01004029). Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 16 0/7 to 20 6/7 weeks in a 2:1 ratio, to receive either weekly intramuscular (IM) injections of 250 mg of 17-OHPC or an inert oil placebo; treatment was continued until delivery or 36 weeks. Co-primary outcomes were PTB < 35 weeks and a neonatal morbidity composite index. The composite included any of the following: neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis. A planned sample size of 1,707 patients was estimated to provide 98% power to detect a 30% reduction in PTB < 35 weeks (30% to 21%) and 90% power to detect a 35% reduction in neonatal composite index (17%-11%) using a two-sided type-I error of 5%. Finally, this sample size would also provide 82.8% power to rule out a doubling in the risk of fetal/early infant death assuming a 4% fetal/early infant death rate. Analysis was performed according to the intention-to-treat principle. RESULTS Baseline characteristics between the 1,130 women who received 17-OHPC and 578 women who received placebo were similar. Overall, 87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner. Prior to receiving study drug, 73% women had a transvaginal cervical length measurement performed and <2% had cervical shortening <25 mm. There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71-1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68-1.61]). There were also no differences in frequency of fetal/early infant death (17-OHPC 1.7% vs. placebo 1.9%; relative risk = 0.87 [95% CI: 0.4-1.81]. Maternal outcomes were also similar. In the subgroup of women enrolled in the United States ( n  = 391; 23% of all patients), although the rate of PTB < 35 weeks was higher than the overall study population, there were no statistically significant differences between groups (15.6% vs. 17.6%; relative risk = 0.88 [95% CI: 0.55, 1.40]. CONCLUSION In this study population, 17-OHPC did not decrease recurrent PTB and was not associated with increased fetal/early infant death.",2020,There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71-1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68-1.61]).,"['women with a previous singleton SPTB ( clinicaltrials.gov ', 'women with a prior SPTB in a singleton gestation', 'Singleton Gestations (PROLONG Study', '87% of enrolled women were Caucasian, 12% had >1 prior SPTB, 7% smoked cigarettes, and 89% were married/lived with partner', 'Women were enrolled at 93 clinical centers (41 in the United States and 52 outside the United States) between 16 0/7 to 20 6/7 weeks in a 2:1 ratio', '1,130 women who received 17-OHPC and 578 women who received', 'Women with a history of spontaneous preterm birth (SPTB']","['placebo', 'intramuscular (IM) injections of 250\u2009mg of 17-OHPC or an inert oil placebo', '17-OHPC', '17-OHPC (17-α-hydroxyprogesterone caproate']","['Maternal outcomes', 'frequency of fetal/early infant death', 'neonatal death, grade 3 or 4 intraventricular hemorrhage, respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, or proven sepsis', 'fetal/early infant death', 'neonatal composite index', 'recurrent PTB', 'frequency of PTB', 'transvaginal cervical length measurement', 'neonatal morbidity index', 'neonatal morbidity composite index', 'rate of PTB', 'recurrent PTB and neonatal morbidity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0555047', 'cui_str': 'Married (finding)'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021492', 'cui_str': 'Intramuscular injection (procedure)'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0044971', 'cui_str': 'hydroxyprogesterone caproate (USP)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0549159', 'cui_str': 'Infant Death'}, {'cui': 'C0410916', 'cui_str': 'Neonatal Death'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage (disorder)'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0175672', 'cui_str': 'Vaginal approach (qualifier value)'}, {'cui': 'C1956055', 'cui_str': 'Cervical Length Measurement'}, {'cui': 'C0580966', 'cui_str': 'Morbidity index (observable entity)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",1707.0,0.813189,There were no significant differences in the frequency of PTB < 35 weeks (17-OHPC 11.0% vs. placebo 11.5%; relative risk = 0.95 [95% confidence interval (CI): 0.71-1.26]) or neonatal morbidity index (17-OHPC 5.6% vs. placebo 5.0%; relative risk = 1.12 [95% CI: 0.68-1.61]).,"[{'ForeName': 'Sean C', 'Initials': 'SC', 'LastName': 'Blackwell', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School-UTHealth, Houston, Texas.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Biggio', 'Affiliation': ""Section of Maternal Fetal Medicine, Women's Services, Ochsner Health Systems, New Orleans, Louisiana.""}, {'ForeName': 'Suneet P', 'Initials': 'SP', 'LastName': 'Chauhan', 'Affiliation': 'Department of Obstetrics, Gynecology, and Reproductive Sciences, McGovern Medical School-UTHealth, Houston, Texas.'}, {'ForeName': 'Brenna L', 'Initials': 'BL', 'LastName': 'Hughes', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University, Durham, North Carolina.'}, {'ForeName': 'Judette M', 'Initials': 'JM', 'LastName': 'Louis', 'Affiliation': 'Department of Obstetrics and Gynecology, University of South Florida, Tampa, Florida.'}, {'ForeName': 'Tracy A', 'Initials': 'TA', 'LastName': 'Manuck', 'Affiliation': 'Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina.'}, {'ForeName': 'Hugh S', 'Initials': 'HS', 'LastName': 'Miller', 'Affiliation': 'Valley Perinatal Services, Watching Over Mothers and Babies Foundation, Tucson, Arizona.'}, {'ForeName': 'Anita F', 'Initials': 'AF', 'LastName': 'Das', 'Affiliation': 'Das Consulting, Guerneville, California.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Saade', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Texas Medical Branch, University of Texas, Galveston, Texas.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Nielsen', 'Affiliation': ""Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine and The Children's Hospital of San Antonio, San Antonio, Texas.""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Baker', 'Affiliation': 'Clinical Research Prime, Idaho Falls, Idaho.'}, {'ForeName': 'Oleksandr M', 'Initials': 'OM', 'LastName': 'Yuzko', 'Affiliation': 'Department of Obstetrics and Gynecology, Bukovinian State Medical University, Chernivtsi, Ukraine.'}, {'ForeName': 'Galyna I', 'Initials': 'GI', 'LastName': 'Reznichenko', 'Affiliation': 'Department of Obstetrics and Gynecology, Clinical Maternity Hospital # 4, Zaporizhzhya, Ukraine.'}, {'ForeName': 'Nataliya Y', 'Initials': 'NY', 'LastName': 'Reznichenko', 'Affiliation': 'Department of Obstetrics and Gynecology, Clinical Maternity Hospital # 4, Zaporizhzhya, Ukraine.'}, {'ForeName': 'Oleg', 'Initials': 'O', 'LastName': 'Pekarev', 'Affiliation': 'Department of Obstetrics and Gynecology, State Government-financed Healthcare Institution of Novosibirsk Region, Novosibirsk, Russia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Tatarova', 'Affiliation': 'Department of Obstetrics and Gynecology, Saint-Petersburg Government-financed Healthcare Institution ""Maternity Hospital #17,"" Saint-Petersburg, Russia.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Gudeman', 'Affiliation': 'AMAG Pharmaceuticals, Inc, Medical Development, Waltham, Massachusetts.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Birch', 'Affiliation': 'Formerly at AMAG Pharmaceuticals, Inc, Medical Development, Waltham, Massachusetts.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Jozwiakowski', 'Affiliation': 'Jozwiakowski Pharma Consulting LLC, Santa Fe, New Mexico.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Duncan', 'Affiliation': 'AMAG Pharmaceuticals, Inc, Medical Development, Waltham, Massachusetts.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Williams', 'Affiliation': 'AMAG Pharmaceuticals, Inc, Medical Development, Waltham, Massachusetts.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Krop', 'Affiliation': 'AMAG Pharmaceuticals, Inc, Medical Development, Waltham, Massachusetts.'}]",American journal of perinatology,['10.1055/s-0039-3400227'] 169,31752517,Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.,"BACKGROUND Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater incidence of diabetes mellitus and risk for LEA, prompting this investigation of clinical outcomes in patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering). METHODS EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo on the rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke) among patients with type 2 diabetes mellitus. In this post hoc analysis, we assessed the association of baseline PAD with rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PAD. RESULTS EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00-1.27]; P =0.047). Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P <0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P <0.001). Patients treated with exenatide or placebo had similar rates of MACE and LEA, regardless of PAD status. CONCLUSIONS EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without PAD. There were no differences in MACE or LEA rates with exenatide versus placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.",2019,"Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P <0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P <0.001).","['patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering', 'Patients with peripheral artery disease (PAD', '2800 patients with PAD (19% of the trial population', 'patients with type 2 diabetes mellitus', 'Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease', 'patients with and without PAD']","['exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo', 'placebo', 'exenatide or placebo', 'exenatide', 'exenatide versus placebo']","['rates of MACE and LEA, regardless of PAD status', 'rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke', 'cause mortality', 'frequent LEA', 'MACE or LEA rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C4517680', 'cui_str': 'Two thousand eight hundred'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C4543206', 'cui_str': 'Receptor agonist (disposition)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}]",2800.0,0.527936,"Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P <0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P <0.001).","[{'ForeName': 'Anish', 'Initials': 'A', 'LastName': 'Badjatiya', 'Affiliation': 'Department of Internal Medicine (A.B.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Merrill', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill (J.B.B.).'}, {'ForeName': 'Shaun G', 'Initials': 'SG', 'LastName': 'Goodman', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.).'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Katona', 'Affiliation': 'AstraZeneca Research and Development, Gaithersburg, MD (B.K.).'}, {'ForeName': 'Nayyar', 'Initials': 'N', 'LastName': 'Iqbal', 'Affiliation': ''}, {'ForeName': 'Neha J', 'Initials': 'NJ', 'LastName': 'Pagidipati', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Sattar', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow (N.S.).'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (R.R.H.).'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Manesh R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'W Schuyler', 'Initials': 'WS', 'LastName': 'Jones', 'Affiliation': 'Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC.'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008018'] 170,31975475,Selenium: A sole treatment for erosive oral lichen planus (Randomized controlled clinical trial).,"Oral lichen planus (OLP) is a chronic disease with immune-mediated pathogenesis. Selenium (Se), an antioxidant, plays a role in modulating immunity. The aim of this clinical trial was to evaluate two Se forms (novel topical hydrogel and oral capsules), solely, in treating erosive OLP based on clinical evaluation and salivary oxidative stress markers. Patients were allocated into one of three groups: group I, topical corticosteroids; group II, topical Se; and group III, systemic Se. Treatment lasted for 6 weeks; patients were clinically evaluated at baseline, 6, and 12 weeks. Biochemical analysis for salivary malondialdehyde (MDA) and total antioxidant capacity (TAC) levels at baseline and 6 weeks was performed. There was a significant reduction in signs and symptoms in response to all treatment modalities. However, there was no significant difference among the three groups at 6 weeks. At 12 weeks, group II had significantly lower pain scores compared with group I. Salivary MDA levels showed a significant decrease in patients of group I and group III. TAC levels showed no significant difference in response to treatment. Selenium can be proposed as a treatment for OLP. Salivary MDA levels can be a biomarker for OLP disease severity.",2020,"At 12- weeks, group II had significantly lower pain scores compared to group I. Salivary MDA levels showed a significant decrease in patients of group I and group III.",[],"['topical corticosteroids', 'Selenium (Se', 'Selenium', 'Oral lichen planus (OLP']","['pain scores', 'TAC levels', 'Salivary MDA levels', 'salivary Malondialdehyde (MDA) and Total Antioxidant Capacity (TAC) levels']",[],"[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0023643', 'cui_str': 'Lichen condition'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",,0.0546721,"At 12- weeks, group II had significantly lower pain scores compared to group I. Salivary MDA levels showed a significant decrease in patients of group I and group III.","[{'ForeName': 'Passant O', 'Initials': 'PO', 'LastName': 'Qataya', 'Affiliation': 'Faculty of Dentistry, Oral Medicine, Periodontology, Diagnosis and Radiology Department, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Naguiba Mahmoud', 'Initials': 'NM', 'LastName': 'Elsayed', 'Affiliation': 'Faculty of Dentistry, Oral Medicine, Periodontology, Diagnosis and Radiology Department, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Nihal Mohamed', 'Initials': 'NM', 'LastName': 'Elguindy', 'Affiliation': 'Faculty of Science, Biochemistry Department, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Marwa', 'Initials': 'M', 'LastName': 'Ahmed Hafiz', 'Affiliation': 'Faculty of Pharmacy, Industrial Pharmacy Department, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Wael Mahmoud', 'Initials': 'WM', 'LastName': 'Samy', 'Affiliation': 'Faculty of Pharmacy, Industrial Pharmacy Department, Alexandria University, Alexandria, Egypt.'}]",Oral diseases,['10.1111/odi.13285'] 171,31707972,Interlimb coupling in poststroke rehabilitation: a pilot randomized controlled trial.,"Background : The interlimb coupling, coordination between the limbs, gets hampered in post-stroke hemiparesis. Most of the poststroke motor regimes primarily focus on the more affected limb. Objectives : To develop an interlimb coupling protocol and assess its feasibility and effect on motor recovery, gait and disability among post-stroke subjects. Design : A pilot randomized controlled, doubled blinded trial Setting : A rehabilitation institute Methods : 50 post-stroke (> 6 months) hemiparetic subjects (Brunnstrom recovery stage ≥ 3) were randomly divided into experimental (n=26) and control (n=24) groups. The 8-week experimental intervention (3 sessions of 1 hour each, per week) comprised activities demanding coordinated, alternate, and rhythmic use of the affected as well as the less-affected limbs. The outcome measures were feasibility of activities, Fugl-Meyer assessment (FMA), Rivermead visual gait assessment (RVGA), Functional ambulation category (FAC) and modified Rankin scale (mRS). Results : The experimental protocol was found to be feasible by the participants. Post intervention, the experimental group exhibited highly significant difference for FMA (mean difference = 7.12, 95% CI = 5.71 - 8.53, p < 0.001), RVGA reduction (mean difference = - 6.32, 95% CI = 7.51 - 5.13, p < 0.001), and median FAC enhancement (p < 0.001) in comparison to the controls. However, the median mRS level of experimental group did not change significantly (p = 0.056) when compared with the controls. Conclusions : The interlimb coupling training, a feasible program may enhance recovery of the upper and lower limbs and gait in stroke. Further definitive randomized trials are warranted to validate the present findings.",2020,"However, the median mRS level of experimental group did not change significantly (p = 0.056) when compared with the controls.","['post-stroke subjects', 'poststroke rehabilitation', 'post-stroke (> 6 months) hemiparetic subjects (Brunnstrom recovery stage ≥ 3']",[' '],"['feasibility of activities, Fugl-Meyer assessment (FMA), Rivermead visual gait assessment (RVGA), Functional ambulation category (FAC) and modified Rankin scale (mRS', 'median FAC enhancement', 'FMA', 'motor recovery, gait and disability', 'median mRS level', 'RVGA reduction']","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}]",[],"[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0945826', 'cui_str': 'Ambulation'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",50.0,0.0976603,"However, the median mRS level of experimental group did not change significantly (p = 0.056) when compared with the controls.","[{'ForeName': 'Kamal Narayan', 'Initials': 'KN', 'LastName': 'Arya', 'Affiliation': 'Department of Occupational Therapy, Pandit Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, New Delhi, India.'}, {'ForeName': 'Shanta', 'Initials': 'S', 'LastName': 'Pandian', 'Affiliation': 'Department of Occupational Therapy, Pandit Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, New Delhi, India.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Occupational Therapy, Pandit Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, New Delhi, India.'}, {'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Department of Occupational Therapy, Pandit Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, New Delhi, India.'}, {'ForeName': 'Varun Kumar', 'Initials': 'VK', 'LastName': 'Kashyap', 'Affiliation': 'Department of Community Medicine, Jamia Hamdard, New Delhi, India.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1682368'] 172,31794974,One-year clinical outcomes following theta burst stimulation for post-traumatic stress disorder.,"Theta burst transcranial magnetic stimulation (TBS) is a potential new treatment for post-traumatic stress disorder (PTSD). We previously reported active intermittent TBS (iTBS) was associated with superior clinical outcomes for up to 1-month, in a sample of fifty veterans with PTSD, using a crossover design. In that study, participants randomized to the active group received a total of 4-weeks of active iTBS, or 2-weeks if randomized to sham. Results were superior with greater exposure to active iTBS, which raised the question of whether observed effects persisted over the longer-term. This study reviewed naturalistic outcomes up to 1-year from study endpoint, to test the hypothesis that greater exposure to active iTBS would be associated with superior outcomes. The primary outcome measure was clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospitalization, etc.,) or need for retreatment with repetitive transcranial magnetic stimulation (rTMS). Forty-six (92%) of the initial study's intent-to-treat participants were included. Mean age was 51.0 ± 12.3 years and seven (15.2%) were female. The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79. Mean days to relapse were 296.0 ± 22.1 in the 4-week group, and 182.0 ± 31.9 in the 2-week group. When used, rTMS retreatment was generally effective. Exploratory neuroimaging revealed default mode network connectivity was predictive of 1-year outcomes (corrected p < 0.05). In summary, greater accumulated exposure to active iTBS demonstrated clinically meaningful improvements in the year following stimulation, and default mode connectivity could be used to predict longer-term outcomes.",2020,"The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79.","['post-traumatic stress disorder (PTSD', 'Mean age was 51.0\u2009±\u200912.3 years and seven (15.2%) were female', 'fifty veterans with PTSD', ""Forty-six (92%) of the initial study's intent-to-treat participants were included""]","['total of 4-weeks of active iTBS', 'active iTBS (4-weeks active iTBS', 'theta burst stimulation', 'active intermittent TBS (iTBS', 'Theta burst transcranial magnetic stimulation (TBS', 'TMS']","['clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospitalization, etc.,) or need for retreatment with repetitive transcranial magnetic stimulation (rTMS', 'Mean days to relapse']","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",50.0,0.149203,"The group originally randomized to active iTBS (4-weeks active iTBS) demonstrated superior outcomes at one year compared to those originally randomized to sham (2-weeks active iTBS); log-rank ChiSq = 5.871, df = 1, p = 0.015; OR = 3.50, 95% CI = 1.04-11.79.","[{'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Petrosino', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': ""Mascha van 't"", 'Initials': ""MV'"", 'LastName': 'Wout-Frank', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Aiken', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Swearingen', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Barredo', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Zandvakili', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA.'}, {'ForeName': 'Noah S', 'Initials': 'NS', 'LastName': 'Philip', 'Affiliation': 'From the VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, and The Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02903, USA. noah_philip@brown.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0584-4'] 173,31742488,Four-week training involving self-ankle mobilization with movement versus calf muscle stretching in patients with chronic stroke: a randomized controlled study.,"Background : In self-ankle mobilization with movement (S-MWM) therapy, a strap can be utilized to stabilize the posterior glide of the talus during ankle dorsiflexion movements. Objectives : Our objective was to compare the effects of 4-week self-mobilization with movement (S-MWM) with those of calf muscle stretching (CMS) on ankle dorsiflexion passive range of motion (DF-PROM), gait parameters, and fall risk in patients with chronic stroke with limited ankle dorsiflexion. Methods : Participants were randomized into the S-MWM (n = 19) and CMS groups (n = 19). Both groups received conventional physiotherapy for 30 minutes per session. In addition, S-MWM and CMS techniques were performed 3 times per week for 4 weeks and were performed by the participants themselves. Ankle DF-PROM, gait parameters, and fall risk were measured after 4 weeks of training. Results : After 4 weeks of training, both groups showed significant improvement in all outcome measures ( p < .05). Furthermore, ankle DF-PROM, gait parameters (gait speed, cadence, and stride lengths on both sides), and fall risk showed greater improvement in the S-MWM group than in the CMS group ( p < .05). Conclusions : This study shows that S-MWM training combined with conventional physiotherapy improved ankle DF-PROM, gait parameters, and fall risk in patients with chronic stroke.",2020,"After 4 weeks of training, both groups showed significant improvement in all outcome measures ( p < .05).","['patients with chronic stroke', 'patients with chronic stroke with limited ankle dorsiflexion']","['CMS', 'S-MWM training combined with conventional physiotherapy', 'Four-week training involving self-ankle mobilization with movement versus calf muscle stretching', 'calf muscle stretching (CMS', 'conventional physiotherapy', '4-week self-mobilization with movement (S-MWM', ' ', 'S-MWM']","['ankle DF-PROM, gait parameters, and fall risk', 'Furthermore, ankle DF-PROM, gait parameters (gait speed, cadence, and stride lengths on both sides), and fall risk', 'Ankle DF-PROM, gait parameters, and fall risk', 'ankle dorsiflexion passive range of motion (DF-PROM), gait parameters, and fall risk']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0448482', 'cui_str': 'Posterior crural muscle structure'}]","[{'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0015944', 'cui_str': 'Premature Rupture of Membrane (Pregnancy)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0079991', 'cui_str': 'Passive Range of Motion'}]",,0.0288185,"After 4 weeks of training, both groups showed significant improvement in all outcome measures ( p < .05).","[{'ForeName': 'Donghwan', 'Initials': 'D', 'LastName': 'Park', 'Affiliation': 'Department of Physical Therapy, Graduate School, Yonsei University, Wonju, Kangwon-do, Republic of South Korea.'}, {'ForeName': 'Heon-Seock', 'Initials': 'HS', 'LastName': 'Cynn', 'Affiliation': 'Department of Physical Therapy, Graduate School, Yonsei University, Wonju, Kangwon-do, Republic of South Korea.'}, {'ForeName': 'Chunghwi', 'Initials': 'C', 'LastName': 'Yi', 'Affiliation': 'Department of Physical Therapy, Graduate School, Yonsei University, Wonju, Kangwon-do, Republic of South Korea.'}, {'ForeName': 'Woochol Joseph', 'Initials': 'WJ', 'LastName': 'Choi', 'Affiliation': 'Department of Physical Therapy, Graduate School, Yonsei University, Wonju, Kangwon-do, Republic of South Korea.'}, {'ForeName': 'Jae-Hun', 'Initials': 'JH', 'LastName': 'Shim', 'Affiliation': 'Department of Physical Therapy, Division of Health Science, Baekseok University, Cheonan-si, Chungcheongnam-do, Republic of South Korea.'}, {'ForeName': 'Duck-Won', 'Initials': 'DW', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Cheongju University, Cheongju-si, Chungcheongbuk-do, Republic of South Korea.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1690831'] 174,31995812,Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment.,"Major depressive disorder (MDD) is associated with altered global brain connectivity (GBC), as assessed via resting-state functional magnetic resonance imaging (rsfMRI). Previous studies found that antidepressant treatment with ketamine normalized aberrant GBC changes in the prefrontal and cingulate cortices, warranting further investigations of GBC as a putative imaging marker. These results were obtained via global signal regression (GSR). This study is an independent replication of that analysis using a separate dataset. GBC was analyzed in 28 individuals with MDD and 22 healthy controls (HCs) at baseline, post-placebo, and post-ketamine. To investigate the effects of preprocessing, three distinct pipelines were used: (1) regression of white matter (WM)/cerebrospinal fluid (CSF) signals only (BASE); (2) WM/CSF + GSR (GSR); and (3) WM/CSF + physiological parameter regression (PHYSIO). Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal. Ketamine had no effect compared to baseline or placebo in either group in any pipeline. PHYSIO did not resemble GBC preprocessed with GSR. These results concur with several studies that used GSR to study GBC. Further investigations are warranted into disease-specific components of global fMRI signals that may drive these results and of GBCr as a potential imaging marker in MDD.",2020,"Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal.","['Major depressive disorder (MDD', '28 individuals with MDD and 22 healthy controls (HCs) at baseline, post']","['placebo', 'Ketamine', 'placebo-controlled ketamine', 'ketamine', 'white matter (WM)/cerebrospinal fluid (CSF) signals only (BASE); (2) WM/CSF\u2009+\u2009GSR (GSR); and (3) WM/CSF\u2009+\u2009physiological parameter regression (PHYSIO']","['GBC', 'Reduced GBC']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0682708'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0684321', 'cui_str': 'Regression'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",28.0,0.0521611,"Reduced GBC was observed in individuals with MDD only at baseline in the anterior and medial cingulate cortices, as well as in the prefrontal cortex only after regressing the global signal.","[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Kraus', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. christoph.kraus@nih.gov.'}, {'ForeName': 'Anahit', 'Initials': 'A', 'LastName': 'Mkrtchian', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Bashkim', 'Initials': 'B', 'LastName': 'Kadriu', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Allison C', 'Initials': 'AC', 'LastName': 'Nugent', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Zarate', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Evans', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0624-0'] 175,31995813,"Modafinil enhances cognitive, but not emotional conflict processing via enhanced inferior frontal gyrus activation and its communication with the dorsomedial prefrontal cortex.","Cognitive control regulates cognitive and emotional systems to facilitate goal-directed behavior in the context of task-irrelevant distractors. Cognitive control deficits contribute to residual functional impairments across psychiatric disorders and represent a promising novel treatment target. Translational evidence suggests that modafinil may enhance performance in executive functions; however, differential effects on regulatory control in cognitive and emotional domains have not been examined. The present pre-registered randomized-controlled pharmacological fMRI trial examined differential effects of modafinil (single-dose, 200 mg) on cognitive and emotional conflict processing. To further separate objective cognitive enhancing effects from subjective performance perception, a metacognitive paradigm was employed. Results indicated that modafinil specifically enhanced cognitive conflict performance and concomitantly increased activation in the inferior frontal gyrus and its functional communication with the dorsomedial prefrontal cortex. Exploratory analysis further revealed modafinil-enhanced basolateral amygdala reactivity to cognitive conflict, with stronger reactivity being associated with higher cognitive conflict performance. Whereas modafinil enhanced cognitive performance in the metacognitive paradigm, confidence indices remained unaffected. Overall, the present results suggest that modafinil has the potential to enhance cognitive conflict processing while leaving emotional conflict processing unaffected. On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information. The pattern of cognitive enhancing effects in the absence of effects on affective processing suggests a promising potential to enhance cognitive control in clinical populations.",2020,"On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information.",[],"['Modafinil', 'modafinil']","['cognitive performance', 'cognitive and emotional conflict processing', 'cognitive conflict performance']",[],"[{'cui': 'C0066677', 'cui_str': 'modafinil'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}]",,0.0288783,"On the neural level modafinil enhanced the recruitment of a network engaged in general conflict and regulatory control processes, whereas effects on the amygdala may reflect improved arousal-mediated attention processes for conflicting information.","[{'ForeName': 'Jialin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Congcong', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Zhenyu', 'Initials': 'Z', 'LastName': 'Wei', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xin', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Daumann', 'Affiliation': 'LVR Clinics of Cologne, Cologne, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Daumann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Kendrick', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Becker', 'Affiliation': 'The Clinical Hospital of the Chengdu Brain Science Institute, MOE Key Laboratory for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, China. ben_becker@gmx.de.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0625-z'] 176,31958404,"Effectiveness of post-partum family planning interventions on contraceptive use and method mix at 1 year after childbirth in Kinshasa, DR Congo (Yam Daabo): a single-blind, cluster-randomised controlled trial.","BACKGROUND In rural Burkina Faso, a package of six low-technology, post-partum contraceptive interventions (ie, refresher training for providers, a counselling tool, supportive supervision, daily availability of contraceptive services, client appointment cards, and invitation letters to attend appointments for partners), aimed at strengthening existing primary health-care services and enhancing demand for them, doubled the use of modern contraceptives at 12 months post partum (ie, 55% uptake in intervention recipients vs 29% in routine-care users). This study assessed the effect of a similar package but in urban settings of Kinshasa province, Democratic Republic of the Congo, in an effort to reduce the unmet need for post-partum family planning. METHODS Yam Daabo was a multi-intervention, single-blinded, cluster-randomised controlled trial done in six primary health-care centres (clusters) in Kinshasa. Centres were randomly allocated to receive the six-component intervention or standard antenatal and postnatal care in matched pairs (1:1) on the basis of number of monthly births, the ratio of health workers per population in the health zone, and the urban and suburban settings. Only data analysts could be masked to cluster allocation. Health-care facilities were eligible if they provided a continuum of antenatal, delivery, and postnatal care, were well stocked with contraceptives, and were situated close to the main study centre. All pregnant women presenting to the six centres were eligible if they were in their third pregnancy trimester and had no counterindications to deliver in the facility. The main outcome was prevalence of use of modern contraceptives at 12 months after delivery. Analysis was by modified intention-to-treat using generalised linear mixed models or Fisher's exact test for small groups. Prevalence ratios were adjusted for cluster effects and baseline characteristics. This study was registered with the Pan-African Clinical Trials Registry (PACTR201609001784334). FINDINGS From July 1, 2016, to Feb 2, 2017, eight of 52 clinics assessed for eligibility met the criteria and were randomised. Of 690 women approached, 576 (83%) women were enrolled: 286 in the four intervention clusters and 290 in the four control clusters. Of them, 519 (90%) completed the 12-month study exit interview (252 in the intervention group and 267 in the control group) and were included in the intention-to-treat analysis. At 12 months, 115 (46%) of 252 women in the intervention group and 94 (35%) of 267 in the control group were using modern contraceptives (adjusted prevalence ratio [PR] 1·58, 95% CI 0·74-3·38), with significant differences in the use of contraceptive implants (22% vs 6%; adjusted PR 4·36, 95% CI 1·96-9·70), but without difference in the use of short-acting contraceptives (23% vs 28%; 0·92, 0·29-2·98) and non-modern or inappropriate methods (7% vs 18%; 0·45, 0·13-1·54). There were no serious adverse events or maternal deaths related to the study. INTERPRETATION The Yam Daabo intervention package did not have a significant effect on the overall use of effective modern contraceptives but significantly increased implant use in women post partum who live in urban settings in Kinshasa up to a year after childbirth. However, interferences from external family planning initiatives in the control group might have diminished differences between the services received. Such an intervention could be potentially relevant in similar contexts in DR Congo and other countries. FUNDING Government of France; UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction.",2020,The Yam Daabo intervention package did not have a significant effect on the overall use of effective modern contraceptives but significantly increased implant use in women post partum who live in urban settings in Kinshasa up to a year after childbirth.,"['urban settings of Kinshasa province, Democratic Republic of the Congo', 'From July 1, 2016, to Feb 2, 2017, eight of 52 clinics assessed for eligibility met the criteria and were randomised', '690 women approached, 576 (83%) women were enrolled: 286 in the four intervention clusters and 290 in the four control clusters', 'Of them, 519 (90%) completed the 12-month study exit interview (252 in the intervention group and 267 in the control group) and were included in the intention-to-treat analysis', 'Government of France', 'six primary health-care centres (clusters) in Kinshasa', 'All pregnant women presenting to the six centres were eligible if they were in their third pregnancy trimester and had no counterindications to deliver in the facility']","['six-component intervention or standard antenatal and postnatal care in matched pairs (1:1) on the basis of number of monthly births, the ratio of health workers per population in the health zone, and the urban and suburban settings', 'post-partum family planning interventions']","['serious adverse events or maternal deaths', 'overall use of effective modern contraceptives', 'use of contraceptive implants', 'prevalence of use of modern contraceptives', 'Prevalence ratios']","[{'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0043444', 'cui_str': 'Belgian Congo'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0337094', 'cui_str': 'Exit (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0032981', 'cui_str': 'Last Trimester'}]","[{'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2828394', 'cui_str': 'Antenatal (qualifier value)'}, {'cui': 'C0032782', 'cui_str': 'Postpartum Care'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0009861', 'cui_str': 'Family Planning Services'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3494405', 'cui_str': 'Maternal Death'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0009871', 'cui_str': 'Contraceptives'}, {'cui': 'C1657106', 'cui_str': 'Contraceptive implant'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",690.0,0.242724,The Yam Daabo intervention package did not have a significant effect on the overall use of effective modern contraceptives but significantly increased implant use in women post partum who live in urban settings in Kinshasa up to a year after childbirth.,"[{'ForeName': 'Nguyen Toan', 'Initials': 'NT', 'LastName': 'Tran', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland; Australian Centre for Public and Population Health Research, Faculty of Health, University of Technology, Sydney, NSW, Australia. Electronic address: nguyen-toan.tran@unige.ch.'}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Seuc', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Béatrice', 'Initials': 'B', 'LastName': 'Tshikaya', 'Affiliation': 'Programme National de Santé de la Reproduction, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Maurice', 'Initials': 'M', 'LastName': 'Mutuale', 'Affiliation': 'School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Sihem', 'Initials': 'S', 'LastName': 'Landoulsi', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Kini', 'Affiliation': 'World Health Organization Country Office in the Democratic Republic of the Congo, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Mbu Nkolomonyi', 'Affiliation': 'World Health Organization Country Office in the Democratic Republic of the Congo, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Nyandwe Kyloka', 'Affiliation': 'School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Félicité', 'Initials': 'F', 'LastName': 'Langwana', 'Affiliation': 'School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Asa', 'Initials': 'A', 'LastName': 'Cuzin-Kihl', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Kiarie', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Mary Eluned', 'Initials': 'ME', 'LastName': 'Gaffield', 'Affiliation': 'Department of Reproductive Health and Research, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Yodi', 'Affiliation': 'Programme National de Santé de la Reproduction, Kinshasa, Democratic Republic of the Congo.'}, {'ForeName': 'Désiré', 'Initials': 'D', 'LastName': 'Mashinda Kulimba', 'Affiliation': 'School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.'}]",The Lancet. Global health,['10.1016/S2214-109X(19)30546-7'] 177,29121400,Dexamethasone as an adjuvant to peripheral nerve block.,"BACKGROUND Peripheral nerve block (infiltration of local anaesthetic around a nerve) is used for anaesthesia or analgesia. A limitation to its use for postoperative analgesia is that the analgesic effect lasts only a few hours, after which moderate to severe pain at the surgical site may result in the need for alternative analgesic therapy. Several adjuvants have been used to prolong the analgesic duration of peripheral nerve block, including perineural or intravenous dexamethasone. OBJECTIVES To evaluate the comparative efficacy and safety of perineural dexamethasone versus placebo, intravenous dexamethasone versus placebo, and perineural dexamethasone versus intravenous dexamethasone when added to peripheral nerve block for postoperative pain control in people undergoing surgery. SEARCH METHODS We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, DARE, Web of Science and Scopus from inception to 25 April 2017. We also searched trial registry databases, Google Scholar and meeting abstracts from the American Society of Anesthesiologists, the Canadian Anesthesiologists' Society, the American Society of Regional Anesthesia, and the European Society of Regional Anaesthesia. SELECTION CRITERIA We included all randomized controlled trials (RCTs) comparing perineural dexamethasone with placebo, intravenous dexamethasone with placebo, or perineural dexamethasone with intravenous dexamethasone in participants receiving peripheral nerve block for upper or lower limb surgery. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. MAIN RESULTS We included 35 trials of 2702 participants aged 15 to 78 years; 33 studies enrolled participants undergoing upper limb surgery and two undergoing lower limb surgery. Risk of bias was low in 13 studies and high/unclear in 22. Perineural dexamethasone versus placeboDuration of sensory block was significantly longer in the perineural dexamethasone group compared with placebo (mean difference (MD) 6.70 hours, 95% confidence interval (CI) 5.54 to 7.85; participants1625; studies 27). Postoperative pain intensity at 12 and 24 hours was significantly lower in the perineural dexamethasone group compared with control (MD -2.08, 95% CI -2.63 to -1.53; participants 257; studies 5) and (MD -1.63, 95% CI -2.34 to -0.93; participants 469; studies 9), respectively. There was no significant difference at 48 hours (MD -0.61, 95% CI -1.24 to 0.03; participants 296; studies 4). The quality of evidence is very low for postoperative pain intensity at 12 hours and low for the remaining outcomes. Cumulative 24-hour postoperative opioid consumption was significantly lower in the perineural dexamethasone group compared with placebo (MD 19.25 mg, 95% CI 5.99 to 32.51; participants 380; studies 6). Intravenous dexamethasone versus placeboDuration of sensory block was significantly longer in the intravenous dexamethasone group compared with placebo (MD 6.21, 95% CI 3.53 to 8.88; participants 499; studies 8). Postoperative pain intensity at 12 and 24 hours was significantly lower in the intravenous dexamethasone group compared with placebo (MD -1.24, 95% CI -2.44 to -0.04; participants 162; studies 3) and (MD -1.26, 95% CI -2.23 to -0.29; participants 257; studies 5), respectively. There was no significant difference at 48 hours (MD -0.21, 95% CI -0.83 to 0.41; participants 172; studies 3). The quality of evidence is moderate for duration of sensory block and postoperative pain intensity at 24 hours, and low for the remaining outcomes. Cumulative 24-hour postoperative opioid consumption was significantly lower in the intravenous dexamethasone group compared with placebo (MD -6.58 mg, 95% CI -10.56 to -2.60; participants 287; studies 5). Perinerual versus intravenous dexamethasoneDuration of sensory block was significantly longer in the perineural dexamethasone group compared with intravenous by three hours (MD 3.14 hours, 95% CI 1.68 to 4.59; participants 720; studies 9). We found that postoperative pain intensity at 12 hours and 24 hours was significantly lower in the perineural dexamethasone group compared with intravenous, however, the MD did not surpass our pre-determined minimally important difference of 1.2 on the Visual Analgue Scale/Numerical Rating Scale, therefore the results are not clinically significant (MD -1.01, 95% CI -1.51 to -0.50; participants 217; studies 3) and (MD -0.77, 95% CI -1.47 to -0.08; participants 309; studies 5), respectively. There was no significant difference in severity of postoperative pain at 48 hours (MD 0.13, 95% CI -0.35 to 0.61; participants 227; studies 3). The quality of evidence is moderate for duration of sensory block and postoperative pain intensity at 24 hours, and low for the remaining outcomes. There was no difference in cumulative postoperative 24-hour opioid consumption (MD -3.87 mg, 95% CI -9.93 to 2.19; participants 242; studies 4). Incidence of severe adverse eventsFive serious adverse events were reported. One block-related event (pneumothorax) occurred in one participant in a trial comparing perineural dexamethasone and placebo; however group allocation was not reported. Four non-block-related events occurred in two trials comparing perineural dexamethasone, intravenous dexamethasone and placebo. Two participants in the placebo group required hospitalization within one week of surgery; one for a fall and one for a bowel infection. One participant in the placebo group developed Complex Regional Pain Syndrome Type I and one in the intravenous dexamethasone group developed pneumonia. The quality of evidence is very low due to the sparse number of events. AUTHORS' CONCLUSIONS Low- to moderate-quality evidence suggests that when used as an adjuvant to peripheral nerve block in upper limb surgery, both perineural and intravenous dexamethasone may prolong duration of sensory block and are effective in reducing postoperative pain intensity and opioid consumption. There is not enough evidence to determine the effectiveness of dexamethasone as an adjuvant to peripheral nerve block in lower limb surgeries and there is no evidence in children. The results of our review may not apply to participants at risk of dexamethasone-related adverse events for whom clinical trials would probably be unsafe.There is not enough evidence to determine the effectiveness of dexamethasone as an adjuvant to peripheral nerve block in lower limb surgeries and there is no evidence in children. The results of our review may not be apply to participants who at risk of dexamethasone-related adverse events for whom clinical trials would probably be unsafe. The nine ongoing trials registered at ClinicalTrials.gov may change the results of this review.",2017,"Postoperative pain intensity at 12 and 24 hours was significantly lower in the intravenous dexamethasone group compared with placebo (MD -1.24, 95% CI -2.44 to -0.04; participants 162; studies 3) and (MD -1.26, 95% CI -2.23 to -0.29; participants 257; studies 5), respectively.","['participants 380; studies 6', '2702 participants aged 15 to 78 years; 33 studies enrolled participants undergoing', 'participants receiving peripheral nerve block for upper or lower limb surgery', 'people undergoing surgery']","['Intravenous dexamethasone', 'dexamethasone and placebo', 'placebo', 'upper limb surgery and two undergoing lower limb surgery', 'Dexamethasone', 'perineural dexamethasone', 'perineural dexamethasone versus placebo, intravenous dexamethasone versus placebo, and perineural dexamethasone versus intravenous dexamethasone', 'Perineural dexamethasone', 'perineural dexamethasone with placebo, intravenous dexamethasone with placebo, or perineural dexamethasone with intravenous dexamethasone', 'dexamethasone']","['Complex Regional Pain Syndrome', 'severity of postoperative pain', 'One block-related event (pneumothorax', 'placeboDuration of sensory block', 'Visual Analgue Scale/Numerical Rating Scale', 'cumulative postoperative 24-hour opioid consumption', 'postoperative pain intensity', 'sensory block', 'Postoperative pain intensity', 'hospitalization', 'Cumulative 24-hour postoperative opioid consumption', 'duration of sensory block and postoperative pain intensity', 'pneumonia']","[{'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0198807', 'cui_str': 'Peripheral block anesthesia (procedure)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]","[{'cui': 'C0458219', 'cui_str': 'CRPS (Complex Regional Pain Syndromes)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0032326', 'cui_str': 'Pneumothorax'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}]",2702.0,0.670069,"Postoperative pain intensity at 12 and 24 hours was significantly lower in the intravenous dexamethasone group compared with placebo (MD -1.24, 95% CI -2.44 to -0.04; participants 162; studies 3) and (MD -1.26, 95% CI -2.23 to -0.29; participants 257; studies 5), respectively.","[{'ForeName': 'Carolyne', 'Initials': 'C', 'LastName': 'Pehora', 'Affiliation': 'Department of Anesthesia and Pain Medicine, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, Canada, M5G 1X8.'}, {'ForeName': 'Annabel Me', 'Initials': 'AM', 'LastName': 'Pearson', 'Affiliation': ''}, {'ForeName': 'Alka', 'Initials': 'A', 'LastName': 'Kaushal', 'Affiliation': ''}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Crawford', 'Affiliation': ''}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Johnston', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011770.pub2'] 178,31834660,The effects of non-surgical periodontal therapy on glycemic control in diabetic patients: A randomized controlled trial.,"AIM The present study aimed to monitor the clinical outcomes and the metabolic response of periodontal therapy (non-surgical) in patients with periodontitis (chronic) and uncontrolled diabetes (type 2). METHODS Eighty-eight subjects with periodontitis (chronic) and uncontrolled diabetes (type 2) were enrolled in this controlled trial and allocated randomly to the test group (44 patients were received immediate periodontal therapy) or the control group (44 patients were received delayed periodontal therapy). The metabolic and clinical evaluations were conducted at baseline and 3 months. This included clinical attachment level, glycated hemoglobin (HbA1c), bleeding on probing, visible plaque, and pocket depth. The periodontal therapy in this study consists of one-stage scaling and root planning, a combination of systemic antibiotics (amoxicillin 500 mg and metronidazole 400 mg), and oral hygiene instructions. RESULTS Regarding clinical and metabolic parameters at baseline, no statistically significant differences were displayed between the two groups. However, at 3-month follow-up period the patients within the test group demonstrated significantly better clinical and metabolic outcomes than patients in the control group. CONCLUSION The non-surgical periodontal treatment using a combination of metronidazole and amoxicillin significantly improved the metabolic outcome in addition to periodontal health in diabetic subjects with chronic periodontitis.",2020,"However, at 3-month follow-up period the patients within the test group demonstrated significantly better clinical and metabolic outcomes than patients in the control group. ","['Eighty-eight subjects with periodontitis (chronic) and uncontrolled diabetes (type 2', 'patients with periodontitis (chronic) and uncontrolled diabetes (type 2', 'diabetic patients', 'diabetic subjects with chronic periodontitis']","['systemic antibiotics (amoxicillin 500\xa0mg and metronidazole', 'periodontal therapy (non-surgical', 'delayed periodontal therapy', 'immediate periodontal therapy', 'non-surgical periodontal therapy', 'metronidazole and amoxicillin']","['clinical and metabolic outcomes', 'clinical attachment level, glycated hemoglobin (HbA1c), bleeding on probing, visible plaque, and pocket depth', 'metabolic outcome']","[{'cui': 'C4517898', 'cui_str': '88 (qualifier value)'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0266929', 'cui_str': 'Adult Periodontitis'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0993263', 'cui_str': 'Amoxicillin 500 MG'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205379', 'cui_str': 'Visible (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}]",88.0,0.0247819,"However, at 3-month follow-up period the patients within the test group demonstrated significantly better clinical and metabolic outcomes than patients in the control group. ","[{'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'El-Makaky', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Hany K', 'Initials': 'HK', 'LastName': 'Shalaby', 'Affiliation': 'Department of Periodontology, Faculty of Dentistry, Suez Canal University, Ismailia, Egypt.'}]",Oral diseases,['10.1111/odi.13256'] 179,32320566,Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.,"BACKGROUND Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy. (Funded by Novartis; REACH2 ClinicalTrials.gov number, NCT02913261.).",2020,"The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60).","['patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation', '309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group', 'patients with glucocorticoid-refractory acute GVHD']",['oral ruxolitinib'],"['efficacy outcomes', 'efficacy and safety', 'hazard ratio for relapse or progression of hematologic disease, non-relapse-related death', 'thrombocytopenia', 'Overall response', 'Durable overall response', 'anemia', 'cumulative incidence of loss of response', 'median failure-free survival', 'durable overall response', 'median overall survival', 'overall response (complete response or partial response', 'cytomegalovirus infection']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0856825', 'cui_str': 'Acute graft-versus-host disease'}, {'cui': 'C2242529', 'cui_str': 'Allogenic stem cell transplantation'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C2931926', 'cui_str': 'ruxolitinib'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C2931926', 'cui_str': 'ruxolitinib'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0018939', 'cui_str': 'Disorder of hematopoietic system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}]",309.0,0.161116,"The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60).","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Zeiser', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Nikolas', 'Initials': 'N', 'LastName': 'von Bubnoff', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Mohamad', 'Initials': 'M', 'LastName': 'Mohty', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Dietger', 'Initials': 'D', 'LastName': 'Niederwieser', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Reuven', 'Initials': 'R', 'LastName': 'Or', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Szer', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Wagner', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Tsila', 'Initials': 'T', 'LastName': 'Zuckerman', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Bruyère', 'Initials': 'B', 'LastName': 'Mahuzier', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Celine', 'Initials': 'C', 'LastName': 'Wilke', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Kunal K', 'Initials': 'KK', 'LastName': 'Gandhi', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': 'Gérard', 'Initials': 'G', 'LastName': 'Socié', 'Affiliation': ""From the Department of Medicine I, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg (R.Z.), the Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck (N.B.), the Department of Hematology and Oncology, University of Leipzig, Leipzig (D.N.), and the Department of Hematology, Oncology, and Pneumology, University Medical Center Mainz, Mainz (E.M.W.) - all in Germany; the Department of Bone Marrow Transplantation, Royal Brisbane and Women's Hospital, Brisbane, QLD (J.B.), and the Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC (J.S.) - all in Australia; Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Sorbonne and INSERM Unité Mixte de Recherche (UMR) 938 (M.M.), and AP-HP, Hématologie-Transplantation, Hôpital St. Louis, Université de Paris and INSERM UMR 976 (G.S.), Paris, and Novartis Pharma, Rueil-Malmaison (B.M.) - all in France; the Cancer Immunotherapy and Immunobiology Research Center, Hadassah University Hospital, Jerusalem (R.O.), and the Hematology Institute and Bone Marrow Transplantation, Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa (T.Z.) - both in Israel; Novartis Pharmaceuticals, East Hanover, NJ (J.X., K.K.G.); and Novartis Pharma, Basel, Switzerland (C.W.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1917635'] 180,32092760,Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.,"Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized to pretreatment with oral rapamycin (6 mg) or placebo 2 h prior to the intravenous administration of ketamine 0.5 mg/kg in a double-blind cross-over design with treatment days separated by at least 2 weeks. Depression severity was assessed using Montgomery-Åsberg Depression Rating Scale (MADRS). Rapamycin pretreatment did not alter the antidepressant effects of ketamine at the 24-h timepoint. Over the subsequent 2-weeks, we found a significant treatment by time interaction (F (8,245)  = 2.02, p = 0.04), suggesting a prolongation of the antidepressant effects of ketamine by rapamycin. Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively). In summary, single dose rapamycin pretreatment failed to block the antidepressant effects of ketamine, but it prolonged ketamine's antidepressant effects. This observation raises questions about the role of systemic vs. local blockade of mTORC1 in the antidepressant effects of ketamine, provides preliminary evidence that rapamycin may extend the benefits of ketamine, and thereby potentially sheds light on mechanisms that contribute to depression relapse after ketamine administration.",2020,"Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively).",['Twenty patients suffering a major depressive episode'],"['rapamycin\u2009+\u2009ketamine', 'placebo', 'ketamine', 'Rapamycin', 'rapamycin', 'placebo\u2009+\u2009ketamine', 'rapamycin, an mTORC1 inhibitor, prior to receiving ketamine', 'oral rapamycin']","['remission rates', 'Montgomery-Åsberg Depression Rating Scale (MADRS', 'Depression severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3888046', 'cui_str': 'mTORC1 Complex'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0810233,"Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively).","[{'ForeName': 'Chadi G', 'Initials': 'CG', 'LastName': 'Abdallah', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA. chadi.abdallah@yale.edu.'}, {'ForeName': 'Lynnette A', 'Initials': 'LA', 'LastName': 'Averill', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Biostatistics, Yale University School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Selin', 'Initials': 'S', 'LastName': 'Goktas', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Prerana', 'Initials': 'P', 'LastName': 'Purohit', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Mohini', 'Initials': 'M', 'LastName': 'Ranganathan', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Sherif', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Kyung-Heup', 'Initials': 'KH', 'LastName': 'Ahn', 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Deepak Cyril', 'Initials': 'DC', 'LastName': ""D'Souza"", 'Affiliation': 'Departments of Psychiatry, Neuroscience, and Psychology Yale University, New Haven, CT, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Formica', 'Affiliation': 'Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Southwick', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Ronald S', 'Initials': 'RS', 'LastName': 'Duman', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Sanacora', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'National Center for PTSD - Clinical Neurosciences Division, US Department of Veterans Affairs, West Haven, CT, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0644-9'] 181,32053828,Global connectivity and local excitability changes underlie antidepressant effects of repetitive transcranial magnetic stimulation.,"Repetitive transcranial magnetic stimulation (rTMS) is a commonly- used treatment for major depressive disorder (MDD). However, our understanding of the mechanism by which TMS exerts its antidepressant effect is minimal. Furthermore, we lack brain signals that can be used to predict and track clinical outcome. Such signals would allow for treatment stratification and optimization. Here, we performed a randomized, sham-controlled clinical trial and measured electrophysiological, neuroimaging, and clinical changes before and after rTMS. Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays. To capture the rTMS-driven changes in connectivity and causal excitability, resting fMRI and TMS/EEG were performed before and after the treatment. Baseline causal connectivity differences between depressed patients and healthy controls were also evaluated with concurrent TMS/fMRI. We found that active, but not sham rTMS elicited (1) an increase in dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials. Global connectivity changes predicted clinical outcome, while both global connectivity and TMS/EEG changes tracked clinical outcome. In patients but not healthy participants, we observed a perturbed inhibitory effect of the dlPFC on the amygdala. Taken together, rTMS induced lasting connectivity and excitability changes from the site of stimulation, such that after active treatment, the dlPFC appeared better able to engage in top-down control of the amygdala. These measures of network functioning both predicted and tracked clinical outcome, potentially opening the door to treatment optimization.",2020,Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays.,"['Patients (N\u2009=\u200936', 'depressed patients and healthy controls', 'major depressive disorder (MDD']","['Repetitive transcranial magnetic stimulation (rTMS', 'active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC', 'TMS', 'repetitive transcranial magnetic stimulation', 'rTMS']","['connectivity and causal excitability, resting fMRI and TMS/EEG', 'global connectivity and TMS/EEG changes tracked clinical outcome', 'dlPFC global connectivity, (2) induction of negative dlPFC-amygdala connectivity, and (3) local and distributed changes in TMS/EEG potentials']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0450424', 'cui_str': 'To the left (qualifier value)'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}]","[{'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",36.0,0.0327488,Patients (N = 36) were randomized to receive either active or sham rTMS to the left dorsolateral prefrontal cortex (dlPFC) for 20 consecutive weekdays.,"[{'ForeName': 'Neir', 'Initials': 'N', 'LastName': 'Eshel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Corey J', 'Initials': 'CJ', 'LastName': 'Keller', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Mills-Finnerty', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Huemer', 'Affiliation': 'Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Wright', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Fonzo', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Naho', 'Initials': 'N', 'LastName': 'Ichikawa', 'Affiliation': 'Department of Psychiatry and Neurosciences, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Carreon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Wong', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Yee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Shpigel', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': ""Department of Neurology, Shenzhen People's Hospital, Shenzhen, China.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'McTeague', 'Affiliation': 'Department of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Maron-Katz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Etkin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, 94305, USA. amitetkin@stanford.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0633-z'] 182,31086274,The effect of paired corticospinal-motoneuronal stimulation on maximal voluntary elbow flexion in cervical spinal cord injury: an experimental study.,"STUDY DESIGN Randomised, controlled, crossover study. OBJECTIVES Paired corticospinal-motoneuronal stimulation (PCMS) involves repeatedly pairing stimuli to corticospinal neurones and motoneurones to induce changes in corticospinal transmission. Here, we examined whether PCMS could enhance maximal voluntary elbow flexion in people with cervical spinal cord injury. SETTING Neuroscience Research Australia, Sydney, Australia. METHODS PCMS comprised 100 pairs of transcranial magnetic and electrical peripheral nerve stimulation (0.1 Hz), timed so corticospinal potentials arrived at corticospinal-motoneuronal synapses 1.5 ms before antidromic motoneuronal potentials. On two separate days, sets of five maximal elbow flexions were performed by 11 individuals with weak elbow flexors post C4 or C5 spinal cord injury before and after PCMS or control (100 peripheral nerve stimuli) conditioning. During contractions, supramaximal biceps brachii stimulation elicited superimposed twitches, which were expressed as a proportion of resting twitches to give maximal voluntary activation. Maximal torque and electromyographic activity were also assessed. RESULTS Baseline median (range) maximal torque was 11 Nm (6-41 Nm) and voluntary activation was 92% (62-99%). Linear mixed modelling revealed no significant differences between PCMS and control protocols after conditioning (maximal torque: p = 0.87, superimposed twitch: p = 0.87, resting twitch: p = 0.44, voluntary activation: p = 0.36, biceps EMG: p = 0.25, brachioradialis EMG: 0.67). CONCLUSIONS Possible explanations for the lack of effect include a potential ceiling effect for voluntary activation, or that PCMS may be less effective for elbow flexors than distal muscles. Despite results, previous studies suggest that PCMS is worthy of further investigation.",2019,"Linear mixed modelling revealed no significant differences between PCMS and control protocols after conditioning (maximal torque: p = 0.87, superimposed twitch: p = 0.87, resting twitch: p = 0.44, voluntary activation: p = 0.36, biceps EMG: p = 0.25, brachioradialis EMG: 0.67). ","['cervical spinal cord injury', 'Neuroscience Research Australia, Sydney, Australia', '11 individuals with weak elbow flexors post C4 or C5 spinal cord injury before and after', 'people with cervical spinal cord injury', 'PCMS comprised 100 pairs of']","['PCMS or control (100 peripheral nerve stimuli) conditioning', 'Paired corticospinal-motoneuronal stimulation (PCMS', 'PCMS', 'transcranial magnetic and electrical peripheral nerve stimulation (0.1\u2009Hz), timed so corticospinal potentials arrived at corticospinal-motoneuronal synapses 1.5\u2009ms before antidromic motoneuronal potentials', 'paired corticospinal-motoneuronal stimulation']","['maximal voluntary elbow flexion', 'voluntary activation', 'Maximal torque and electromyographic activity', 'Baseline median (range) maximal torque']","[{'cui': 'C0840414', 'cui_str': 'Cervical spinal cord injury'}, {'cui': 'C0027910', 'cui_str': 'Neurosciences'}, {'cui': 'C0035168'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1762617', 'cui_str': 'Weak (qualifier value)'}, {'cui': 'C0013769', 'cui_str': 'Elbow'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0031119', 'cui_str': 'Peripheral Nerves'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach (qualifier value)'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C0436544', 'cui_str': 'Electrical peripheral nerve stimulation (procedure)'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0039062', 'cui_str': 'Synapses'}, {'cui': 'C3844012', 'cui_str': '1.5'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0013769', 'cui_str': 'Elbow'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",,0.0859074,"Linear mixed modelling revealed no significant differences between PCMS and control protocols after conditioning (maximal torque: p = 0.87, superimposed twitch: p = 0.87, resting twitch: p = 0.44, voluntary activation: p = 0.36, biceps EMG: p = 0.25, brachioradialis EMG: 0.67). ","[{'ForeName': 'Siobhan C', 'Initials': 'SC', 'LastName': 'Dongés', 'Affiliation': 'Neuroscience Research Australia, Sydney, Australia.'}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': 'Boswell-Ruys', 'Affiliation': 'Neuroscience Research Australia, Sydney, Australia.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Butler', 'Affiliation': 'Neuroscience Research Australia, Sydney, Australia.'}, {'ForeName': 'Janet L', 'Initials': 'JL', 'LastName': 'Taylor', 'Affiliation': 'Neuroscience Research Australia, Sydney, Australia. janet.taylor@ecu.edu.au.'}]",Spinal cord,['10.1038/s41393-019-0291-3'] 183,32217498,Improving Self-Care in Patients With Coexisting Type 2 Diabetes and Hypertension by Technological Surrogate Nursing: Randomized Controlled Trial.,"BACKGROUND Technological surrogate nursing (TSN) derives from the idea that nurse-caregiver substitutes can be created by technology to support chronic disease self-care. OBJECTIVE This paper begins by arguing that TSN is a useful and viable approach to chronic disease self-care. The analysis then focuses on the empirical research question of testing and demonstrating the effectiveness and safety of prototype TSN supplied to patients with the typical complex chronic disease of coexisting type 2 diabetes and hypertension. At the policy level, it is shown that the data allow for a calibration of TSN technology augmentation, which can be readily applied to health care management. METHODS A 24-week, parallel-group, randomized controlled trial (RCT) was designed and implemented among diabetic and hypertensive outpatients in two Hong Kong public hospitals. Participants were randomly assigned to an intervention group, supplied with a tablet-based TSN app prototype, or to a conventional self-managing control group. Primary indices-hemoglobin A 1c , systolic blood pressure, and diastolic blood pressure-and secondary indices were measured at baseline and at 8, 12, 16, and 24 weeks after initiation, after which the data were applied to test TSN effectiveness and safety. RESULTS A total of 299 participating patients were randomized to the intervention group (n=151) or the control group (n=148). Statistically significant outcomes that directly indicated TSN effectiveness in terms of hemoglobin 1c were found in both groups but not with regard to systolic and diastolic blood pressure. These findings also offered indirect empirical support for TSN safety. Statistically significant comparative changes in these primary indices were not observed between the groups but were suggestive of an operational calibration of TSN technology augmentation. Statistically significant changes in secondary indices were obtained in one or both groups, but not between the groups. CONCLUSIONS The RCT's strong behavioral basis, as well as the importance of safety and effectiveness when complex chronic illness is proximately self-managed by layperson patients, prompted the formulation of the empirical joint hypothesis that TSN would improve patient self-care while satisfying the condition of patient self-safety. Statistical and decision analysis applied to the experimental outcomes offered support for this hypothesis. Policy relevance of the research is demonstrated by the derivation of a data-grounded operational calibration of TSN technology augmentation with ready application to health care management. TRIAL REGISTRATION ClinicalTrials.gov NCT02799953; https://clinicaltrials.gov/ct2/show/NCT02799953.",2020,Statistically significant comparative changes in these primary indices were not observed between the groups but were suggestive of an operational calibration of TSN technology augmentation.,"['diabetic and hypertensive outpatients in two Hong Kong public hospitals', 'With Coexisting Type 2 Diabetes and Hypertension by Technological Surrogate Nursing', 'patients with the typical complex chronic disease of coexisting type 2 diabetes and hypertension', '299 participating patients', 'Patients']","['TSN', 'intervention group, supplied with a tablet-based TSN app prototype, or to a conventional self-managing control group', 'prototype TSN']","['TSN effectiveness', 'TSN effectiveness and safety', 'Primary indices-hemoglobin A 1c , systolic blood pressure, and diastolic blood pressure-and secondary indices', 'systolic and diastolic blood pressure']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0019907', 'cui_str': 'Hongkong'}, {'cui': 'C0020022', 'cui_str': 'Hospitals, Public'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0008679', 'cui_str': 'Chronic Illness'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1875802', 'cui_str': 'Healthcare supplies'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0019018', 'cui_str': 'Glycated Hemoglobin A'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",299.0,0.0459725,Statistically significant comparative changes in these primary indices were not observed between the groups but were suggestive of an operational calibration of TSN technology augmentation.,"[{'ForeName': 'Calvin Kalun', 'Initials': 'CK', 'LastName': 'Or', 'Affiliation': 'Department of Industrial and Manufacturing Systems Engineering, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Kaifeng', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': 'Department of Industrial and Manufacturing Systems Engineering, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Mike K P', 'Initials': 'MKP', 'LastName': 'So', 'Affiliation': 'Department of Information Systems, Business Statistics, and Operations Management, Hong Kong University of Science and Technology, Hong Kong, Hong Kong.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Cheung', 'Affiliation': 'Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Loretta Y C', 'Initials': 'LYC', 'LastName': 'Yam', 'Affiliation': 'Ambulatory Diabetes Centre, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Tiwari', 'Affiliation': 'School of Nursing, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Yuen Fun Emmy', 'Initials': 'YFE', 'LastName': 'Lau', 'Affiliation': 'Ambulatory Diabetes Centre, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Lau', 'Affiliation': 'Ambulatory Diabetes Centre, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Pui Sze Grace', 'Initials': 'PSG', 'LastName': 'Hui', 'Affiliation': 'Diabetes Mellitus Centre, Tung Wah Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Hop Chun', 'Initials': 'HC', 'LastName': 'Cheng', 'Affiliation': 'Diabetes Mellitus Centre, Tung Wah Eastern Hospital, Hong Kong, Hong Kong.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Tan', 'Affiliation': 'DeGroote School of Business, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Michael Tow', 'Initials': 'MT', 'LastName': 'Cheung', 'Affiliation': 'Department of Industrial and Manufacturing Systems Engineering, University of Hong Kong, Hong Kong, Hong Kong.'}]",Journal of medical Internet research,['10.2196/16769'] 184,32207689,The Association of Therapeutic Alliance With Long-Term Outcome in a Guided Internet Intervention for Depression: Secondary Analysis From a Randomized Control Trial.,"BACKGROUND Therapeutic alliance has been well established as a robust predictor of face-to-face psychotherapy outcomes. Although initial evidence positioned alliance as a relevant predictor of internet intervention success, some conceptual and methodological concerns were raised regarding the methods and instruments used to measure the alliance in internet interventions and its association with outcomes. OBJECTIVE The aim of this study was to explore the alliance-outcome association in a guided internet intervention using a measure of alliance especially developed for and adapted to guided internet interventions, showing evidence of good psychometric properties. METHODS A sample of 223 adult participants with moderate depression received an internet intervention (ie, Deprexis) and email support. They completed the Working Alliance Inventory for Guided Internet Intervention (WAI-I) and a measure of treatment satisfaction at treatment termination and measures of depression severity and well-being at termination and 3- and 9-month follow-ups. For data analysis, we used two-level hierarchical linear modeling that included two subscales of the WAI-I (ie, tasks and goals agreement with the program and bond with the supporting therapist) as predictors of the estimated values of the outcome variables at the end of follow-up and their rate of change during the follow-up period. The same models were also used controlling for the effect of patient satisfaction with treatment. RESULTS We found significant effects of the tasks and goals subscale of the WAI-I on the estimated values of residual depressive symptoms (γ 02 =-1.74, standard error [SE]=0.40, 95% CI -2.52 to -0.96, t 206 =-4.37, P<.001) and patient well-being (γ 02 =3.10, SE=1.14, 95% CI 0.87-5.33, t 198 =2.72, P=.007) at the end of follow-up. A greater score in this subscale was related to lower levels of residual depressive symptoms and a higher level of well-being. However, there were no significant effects of the tasks and goals subscale on the rate of change in these variables during follow-up (depressive symptoms, P=.48; patient well-being, P=.26). The effects of the bond subscale were also nonsignificant when predicting the estimated values of depressive symptoms and well-being at the end of follow-up and the rate of change during that period (depressive symptoms, P=.08; patient well-being, P=.68). CONCLUSIONS The results of this study point out the importance of attuning internet interventions to patients' expectations and preferences in order to enhance their agreement with the tasks and goals of the treatment. Thus, the results support the notion that responsiveness to a patient's individual needs is crucial also in internet interventions. Nevertheless, these findings need to be replicated to establish if they can be generalized to different diagnostic groups, internet interventions, and supporting formats.",2020,A greater score in this subscale was related to lower levels of residual depressive symptoms and a higher level of well-being.,"['Depression', '223 adult participants with moderate depression received an']","['guided internet intervention', 'internet intervention (ie, Deprexis) and email support', 'Guided Internet Intervention']","['tasks and goals subscale of the WAI', 'residual depressive symptoms']","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0588007', 'cui_str': 'Moderate depression (disorder)'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",223.0,0.0785418,A greater score in this subscale was related to lower levels of residual depressive symptoms and a higher level of well-being.,"[{'ForeName': 'Juan Martín', 'Initials': 'JM', 'LastName': 'Gómez Penedo', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Anna Margarete', 'Initials': 'AM', 'LastName': 'Babl', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Grosse Holtforth', 'Affiliation': 'Department of Psychosomatic Medicine, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Fritz', 'Initials': 'F', 'LastName': 'Hohagen', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Lübeck University, Lübeck, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Krieger', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Lutz', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Trier, Trier, Germany.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Meyer', 'Affiliation': 'Department of Psychology, City, University of London, London, United Kingdom.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Klein', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Lübeck University, Lübeck, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berger', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bern, Bern, Switzerland.'}]",Journal of medical Internet research,['10.2196/15824'] 185,32209536,Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.,"BACKGROUND Measuring patient-reported outcomes (PROs) requires an individual's perspective on their symptoms, functional status, and quality of life. Digital health enables remote electronic PRO (ePRO) assessments as a clinical decision support tool to facilitate meaningful provider interactions and personalized treatment. OBJECTIVE This study explored the feasibility and acceptability of collecting ePROs using validated health-related quality of life (HRQoL) questionnaires for prostate cancer. METHODS Using Apple ResearchKit software, the Strength Through Insight app was created with content from validated HRQoL tools 26-item Expanded Prostate Cancer Index Composite (EPIC) or EPIC for Clinical Practice and 8-item Functional Assessment of Cancer Therapy Advanced Prostate Symptom Index. In a single-arm pilot study with patients receiving prostate cancer treatment at Thomas Jefferson University Hospital and affiliates, participants were recruited, and instructed to download Strength Through Insight and complete ePROs once a week over 12 weeks. A mixed methods approach, including qualitative pre- and poststudy interviews, was used to evaluate the feasibility and acceptability of Strength Through Insight for the collection and care management of cancer treatment. RESULTS Thirty patients consented to the study; 1 patient failed to complete any of the questionnaires and was left out of the analysis of the intervention. Moreover, 86% (25/29) reached satisfactory questionnaire completion (defined as completion of 60% of weekly questions over 12 weeks). The lower bound of the exact one-sided 95% CI was 71%, exceeding the 70% feasibility threshold. Most participants self-identified with having a high digital literacy level (defined as the ability to use, understand, evaluate, and analyze information from multiple formats from a variety of digital sources), and only a few participants identified with having a low digital literacy level (defined as only having the ability to gather information on the Web). Interviews were thematically analyzed to reveal the following: (1) value of emotional support and wellness in cancer treatment, (2) rise of social patient advocacy in online patient communities and networks, (3) patient concerns over privacy, and (4) desire for personalized engagement tools. CONCLUSIONS Strength Through Insight was demonstrated as a feasible and acceptable method of data collection for ePROs. A high compliance rate confirmed the app as a reliable tool for patients with localized and advanced prostate cancer. Nearly all participants reported that using the smartphone app is easier than or equivalent to the traditional paper-and-pen approach, providing evidence of acceptability and support for the use of remote PRO monitoring. This study expands on current research involving the value of digital health, as a social and behavioral science, augmented with technology, can begin to contribute to population health management, as it shapes psychographic segmentation by demographic, socioeconomic, health condition, or behavioral factors to group patients by their distinct personalities and motivations, which influence their choices. TRIAL REGISTRATION ClinicalTrials.gov NC03197948; http://clinicaltrials.gov/ct2/show/NC03197948.",2020,"Nearly all participants reported that using the smartphone app is easier than or equivalent to the traditional paper-and-pen approach, providing evidence of acceptability and support for the use of remote PRO monitoring.","['patients receiving prostate cancer treatment at Thomas Jefferson University Hospital and affiliates, participants', 'patients with localized and advanced prostate cancer', 'Prostate Cancer']",[],"['emotional support and wellness in cancer treatment, (2) rise of social patient advocacy in online patient communities and networks, (3) patient concerns over privacy, and (4) desire for personalized engagement tools', 'quality of life (HRQoL) questionnaires', 'satisfactory questionnaire completion']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}]",[],"[{'cui': 'C0600015', 'cui_str': 'Emotional support (regime/therapy)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0030674', 'cui_str': 'Advocating for individual patient'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0522474', 'cui_str': 'Patient concerned (contextual qualifier) (qualifier value)'}, {'cui': 'C0080048', 'cui_str': 'Privacy'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",30.0,0.0484851,"Nearly all participants reported that using the smartphone app is easier than or equivalent to the traditional paper-and-pen approach, providing evidence of acceptability and support for the use of remote PRO monitoring.","[{'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Tran', 'Affiliation': 'Thomas Jefferson University, Sidney Kimmel Medical College and Cancer Center, Jefferson Center for Digital Health & Data Science, Philadelphia, PA, United States.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Dicker', 'Affiliation': 'Thomas Jefferson University, Sidney Kimmel Medical College and Cancer Center, Jefferson Center for Digital Health & Data Science, Philadelphia, PA, United States.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Leiby', 'Affiliation': 'Thomas Jefferson University, Sidney Kimmel Medical College and Cancer Center, Jefferson Center for Digital Health & Data Science, Philadelphia, PA, United States.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Gressen', 'Affiliation': 'Thomas Jefferson University, Sidney Kimmel Medical College and Cancer Center, Jefferson Center for Digital Health & Data Science, Philadelphia, PA, United States.'}, {'ForeName': 'Noelle', 'Initials': 'N', 'LastName': 'Williams', 'Affiliation': 'Levine Cancer Institute at Atrium Health, Southeast Radiation Oncology Group, Charlotte, NC, United States.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Jim', 'Affiliation': 'H Lee Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, FL, United States.'}]",Journal of medical Internet research,['10.2196/12689'] 186,32247251,Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer - A randomized controlled trial.,"OBJECTIVES Neoadjuvant chemotherapy causes distressing symptoms, which have to be managed by patients at home. Assessing and acting upon relevant patient-reported symptoms regularly with the support of mHealth such as apps, has shown to decrease symptom burden and improve health-related quality of life (HRQoL). There is a lack of apps for patients with breast cancer which are tested in rigorous trials and only a few include interactive components for immediate clinical management. The aim of this study was to evaluate whether the use of the interactive app Interaktor improves patients' levels of symptom burden and HRQoL during neoadjuvant chemotherapy for breast cancer. MATERIALS AND METHODS This randomized controlled trial included patients in an intervention group (n = 74) and a control group (n = 75), recruited at two university hospitals in Stockholm, Sweden. The intervention group used Interaktor for symptom reporting, self-care advice and support from health-care professionals during treatment, and the control group received standard care alone. Self-reported symptoms and HRQoL were assessed at two time points to determine differences between the groups. RESULTS The intervention group rated statistically significant less symptom prevalence in nausea, vomiting, feeling sad, appetite loss and constipation. Overall symptom distress and physical symptom distress were rated statistically significant lower in the intervention group. Further, emotional functioning was rated statistically significant higher in the intervention group. CONCLUSIONS By using the Interaktor app in clinical practice, patients get individual support when managing treatment-related symptoms during neoadjuvant chemotherapy for breast cancer, leading to decreased symptom burden and improved emotional functioning.",2020,Overall symptom distress and physical symptom distress were rated statistically significant lower in the intervention group.,"['patients with breast cancer', 'patients in an intervention group (n\xa0=\xa074) and a control group (n\xa0=\xa075), recruited at two university hospitals in Stockholm, Sweden', ""patients' levels of symptom burden and HRQoL during neoadjuvant chemotherapy for breast cancer""]","['intervention group used Interaktor for symptom reporting, self-care advice and support from health-care professionals during treatment, and the control group received standard care alone', 'neoadjuvant chemotherapy', 'interactive app Interaktor']","['Overall symptom distress and physical symptom distress', 'Self-reported symptoms and HRQoL', 'symptom burden and improved emotional functioning', 'emotional functioning', 'symptom prevalence in nausea, vomiting, feeling sad, appetite loss and constipation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C1688635', 'cui_str': 'Feeling unhappy'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",,0.134241,Overall symptom distress and physical symptom distress were rated statistically significant lower in the intervention group.,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fjell', 'Affiliation': 'Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden. Electronic address: maria.fjell@ki.se.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Langius-Eklöf', 'Affiliation': 'Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden; Karolinska University Hospital, Function Area Social Work in Health Care, Stockholm, Sweden; Stockholm County Council, Academic Primary Health Care Center, Stockholm, Sweden.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Wengström', 'Affiliation': 'Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden; Karolinska University Hospital, Cancer Theme, Stockholm, Sweden.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Sundberg', 'Affiliation': 'Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Nursing, Stockholm, Sweden.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.03.004'] 187,32213470,Brief Web-Based Intervention for Depression: Randomized Controlled Trial on Behavioral Activation.,"BACKGROUND Web-based interventions have been shown to be effective for the treatment of depression. However, interventions are often complex and include a variety of elements, making it difficult to identify the most effective component(s). OBJECTIVE The aim of this pilot study was to shed light on mechanisms in the online treatment of depression by comparing a single-module, fully automated intervention for depression (internet-based behavioral activation [iBA]) to a nonoverlapping active control intervention and a nonactive control group. METHODS We assessed 104 people with at least mild depressive symptoms (Patient Health Questionnaire-9, >4) via the internet at baseline (t 0 ) and 2 weeks (t 1 ) and 4 weeks (t 2 ) later. After the t 0 assessment, participants were randomly allocated to one of three groups: (1) iBA (n=37), (2) active control using a brief internet-based mindfulness intervention (iMBI, n=32), or (3) care as usual (CAU, n=35). The primary outcome was improvement in depressive symptoms, as measured using the Patient Health Questionnaire-9. Secondary parameters included changes in activity, dysfunctional attitudes, and quality of life. RESULTS While groups did not differ regarding the change in depression from t 0 to t 1 (η p 2 =.007, P=.746) or t 0 to t 2 (η p 2 =.008, P=.735), iBA was associated with a larger decrease in dysfunctional attitudes from t 0 to t 2 in comparison to CAU (η p 2 =.053, P=.04) and a larger increase in activity from t 0 to t 1 than the pooled control groups (η p 2 =.060, P=.02). A change in depression from t 0 to t 2 was mediated by a change in activity from t 0 to t 1 . At t 1 , 22% (6/27) of the participants in the iBA group and 12% (3/25) of the participants in the iMBI group indicated that they did not use the intervention. CONCLUSIONS Although we did not find support for the short-term efficacy of the single-module iBA regarding depression, long-term effects are still conceivable, potentially initiated by changes in secondary outcomes. Future studies should use a longer intervention and follow-up interval. TRIAL REGISTRATION DKRS (#DRKS00011562).",2020,"While groups did not differ regarding the change in depression from t 0 to t 1 (η p 2 =.007, P=.746) or t 0 to t 2 (η p 2 =.008, P=.735), iBA was associated with a larger decrease in dysfunctional attitudes from t 0 to t 2 in comparison to CAU (η p 2 =.053, P=.04) and a larger increase in activity from t 0 to t 1 than the pooled control groups (η p 2 =.060, P=.02).","['Depression', '104 people with at least mild depressive symptoms (Patient Health Questionnaire-9, >4) via the internet at baseline (t 0 ) and 2 weeks (t 1 ) and 4 weeks (t 2 ) later']","['active control using a brief internet-based mindfulness intervention (iMBI, n=32), or (3) care as usual (CAU', 'Brief Web-Based Intervention']","['changes in activity, dysfunctional attitudes, and quality of life', 'activity', 'depressive symptoms, as measured using the Patient Health Questionnaire-9', 'depression', 'dysfunctional attitudes', 'change in depression']","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0444892', 'cui_str': 'CAU'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0034380'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",104.0,0.154823,"While groups did not differ regarding the change in depression from t 0 to t 1 (η p 2 =.007, P=.746) or t 0 to t 2 (η p 2 =.008, P=.735), iBA was associated with a larger decrease in dysfunctional attitudes from t 0 to t 2 in comparison to CAU (η p 2 =.053, P=.04) and a larger increase in activity from t 0 to t 1 than the pooled control groups (η p 2 =.060, P=.02).","[{'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Jelinek', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Sönke', 'Initials': 'S', 'LastName': 'Arlt', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Schröder', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Westermann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cludius', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",Journal of medical Internet research,['10.2196/15312'] 188,32213473,"Text Messaging as a Screening Tool for Depression and Related Conditions in Underserved, Predominantly Minority Safety Net Primary Care Patients: Validity Study.","BACKGROUND SMS text messaging is an inexpensive, private, and scalable technology-mediated assessment mode that can alleviate many barriers faced by the safety net population to receive depression screening. Some existing studies suggest that technology-mediated assessment encourages self-disclosure of sensitive health information such as depressive symptoms while other studies show the opposite effect. OBJECTIVE This study aimed to evaluate the validity of using SMS text messaging to screen depression and related conditions, including anxiety and functional disability, in a low-income, culturally diverse safety net primary care population. METHODS This study used a randomized design with 4 study groups that permuted the order of SMS text messaging and the gold standard interview (INTW) assessment. The participants for this study were recruited from the participants of the prior Diabetes-Depression Care-management Adoption Trial (DCAT). Depression was screened by using the 2-item and 8-item Patient Health Questionnaire (PHQ-2 and PHQ-8, respectively). Anxiety was screened by using the 2-item Generalized Anxiety Disorder scale (GAD-2), and functional disability was assessed by using the Sheehan Disability Scale (SDS). Participants chose to take up the assessment in English or Spanish. Internal consistency and test-retest reliability were evaluated by using Cronbach alpha and intraclass correlation coefficient (ICC), respectively. Concordance was evaluated by using an ICC, a kappa statistic, an area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity. A regression analysis was conducted to examine the association between the participant characteristics and the differences in the scores between the SMS text messaging and INTW assessment modes. RESULTS Overall, 206 participants (average age 57.1 [SD 9.18] years; females: 119/206, 57.8%) were enrolled. All measurements except the SMS text messaging-assessed PHQ-2 showed Cronbach alpha values ≥.70, indicating acceptable to good internal consistency. All measurements except the INTW-assessed SDS had ICC values ≥0.75, indicating good to excellent test-retest reliability. For concordance, the PHQ-8 had an ICC of 0.73 and AUROC of 0.93, indicating good concordance. The kappa statistic, sensitivity, and specificity for major depression (PHQ-8 ≥8) were 0.43, 0.60, and 0.86, respectively. The concordance of the shorter PHQ-2, GAD-2, and SDS scales was poor to fair. The regression analysis revealed that a higher level of personal depression stigma was associated with reporting higher SMS text messaging-assessed PHQ-8 and GAD-2 scores than the INTW-assessed scores. The analysis also determined that the differences in the scores were associated with marital status and personality traits. CONCLUSIONS Depression screening conducted using the longer PHQ-8 scale via SMS text messaging demonstrated good internal consistency, test-retest reliability, and concordance with the gold standard INTW assessment mode. However, care must be taken when deploying shorter scales via SMS text messaging. Further regression analysis supported that a technology-mediated assessment, such as SMS text messaging, may create a private space with less pressure from the personal depression stigma and therefore encourage self-disclosure of depressive symptoms. TRIAL REGISTRATION ClinicalTrials.gov NCT01781013; https://clinicaltrials.gov/ct2/show/NCT01781013. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/12392.",2020,"The kappa statistic, sensitivity, and specificity for major depression (PHQ-8 ≥8) were 0.43, 0.60, and 0.86, respectively.","['participants for this study were recruited from the participants of the prior Diabetes-Depression Care-management Adoption Trial (DCAT', '206 participants (average age 57.1 [SD 9.18] years; females: 119/206, 57.8%) were enrolled']","['SMS text messaging and the gold standard interview (INTW) assessment', 'SMS text messaging']","['personal depression stigma', 'Sheehan Disability Scale (SDS', 'Anxiety', 'Depression', '2-item Generalized Anxiety Disorder scale (GAD-2), and functional disability', 'kappa statistic, sensitivity, and specificity for major depression (PHQ-8 ≥8', 'PHQ-8 and GAD-2 scores', 'Internal consistency and test-retest reliability', 'shorter PHQ-2, GAD-2, and SDS scales']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4708576', 'cui_str': 'Depression care management'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C4720840', 'cui_str': 'Sheehan disability scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0222045'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0439099', 'cui_str': 'Kappa'}, {'cui': 'C0600673', 'cui_str': 'Statistics'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0543431', 'cui_str': 'ret (qualifier value)'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]",206.0,0.0829912,"The kappa statistic, sensitivity, and specificity for major depression (PHQ-8 ≥8) were 0.43, 0.60, and 0.86, respectively.","[{'ForeName': 'Haomiao', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Suzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA, United States.'}, {'ForeName': 'Shinyi', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Suzanne Dworak-Peck School of Social Work, University of Southern California, Los Angeles, CA, United States.'}]",Journal of medical Internet research,['10.2196/17282'] 189,32297945,Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial.,,2020,,[],[],['Placebo Response and Analgesic Efficacy'],[],[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.420829,,"[{'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Sanders', 'Affiliation': 'Division of Pediatric and Public Health, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Slade', 'Affiliation': 'Division of Pediatric and Public Health, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Department of Community Dentistry and Behavioral Science, University of Florida, Gainesville.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ohrbach', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, University at Buffalo, State University of New York, Buffalo.'}, {'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Arbes', 'Affiliation': 'Rho Inc, Durham, North Carolina.'}, {'ForeName': 'Inna E', 'Initials': 'IE', 'LastName': 'Tchivileva', 'Affiliation': 'Division of Oral and Craniofacial Health Sciences, Adams School of Dentistry, University of North Carolina at Chapel Hill.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.2907'] 190,32224483,Experiences of Internet-Based Stepped Care in Individuals With Cancer and Concurrent Symptoms of Anxiety and Depression: Qualitative Exploration Conducted Alongside the U-CARE AdultCan Randomized Controlled Trial.,"BACKGROUND Individuals with newly diagnosed cancer may experience impaired health in several aspects and often have a large need for information and support. About 30% will experience symptoms of anxiety and depression, with varying needs of knowledge and support. Despite this, many of these patients lack appropriate support. Internet-based support programs may offer a supplement to standard care services, but must be carefully explored from a user perspective. OBJECTIVE The purpose of this study was to explore the participants' perceptions of the relevance and benefits of an internet-based stepped care program (iCAN-DO) targeting individuals with cancer and concurrent symptoms of anxiety and depression. METHODS We performed a qualitative study with an inductive approach, in which we used semistructured questions to interview 15 individuals using iCAN-DO. We analyzed the interviews using content analysis. RESULTS The analysis found 17 subcategories regarding the stepped care intervention, resulting in 4 categories. Participants described the need for information as large and looked upon finding information almost as a survival strategy when receiving the cancer diagnosis. iCAN-DO was seen as a useful, reliable source of information and support. It was used as a complement to standard care and as a means to inform next of kin. Increased knowledge was a foundation for continued processing of participants' own feelings. The optimal time to gain access to iCAN-DO would have been when being informed of the diagnosis. The most common denominator was feeling acknowledged and supported, but with a desire for further adaptation of the system to each individual's own situation and needs. CONCLUSIONS Users saw the internet-based stepped care program as safe and reliable and used it as a complement to standard care. Similar interventions may gain from more personalized contents, being integrated into standard care, or using symptom tracking to adjust the contents. Offering this type of program close to diagnosis may provide benefits to users. TRIAL REGISTRATION ClincalTrials.gov NCT-01630681; https://clinicaltrials.gov/ct2/show/NCT01630681.",2020,"CONCLUSIONS Users saw the internet-based stepped care program as safe and reliable and used it as a complement to standard care.","['Individuals With Cancer and Concurrent Symptoms of Anxiety and Depression', 'Individuals with newly diagnosed cancer', 'individuals with cancer and concurrent symptoms of anxiety and depression']","['U-CARE', 'internet-based stepped care program (iCAN-DO', 'Internet-Based Stepped Care']",[],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],,0.105588,"CONCLUSIONS Users saw the internet-based stepped care program as safe and reliable and used it as a complement to standard care.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hauffman', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Alfonsson', 'Affiliation': ""Department of Women's and Children's Health, Section of Clinical Psychology in Healthcare, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Igelström', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Birgitta', 'Initials': 'B', 'LastName': 'Johansson', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden.'}]",Journal of medical Internet research,['10.2196/16547'] 191,32224489,Affect-Focused Psychodynamic Internet-Based Therapy for Adolescent Depression: Randomized Controlled Trial.,"BACKGROUND Adolescent depression is one of the largest health issues in the world and there is a pressing need for effective and accessible treatments. OBJECTIVE This trial examines whether affect-focused internet-based psychodynamic therapy (IPDT) with therapist support is more effective than an internet-based supportive control condition on reducing depression in adolescents. METHODS The trial included 76 adolescents (61/76, 80% female; mean age 16.6 years), self-referred via an open access website and fulfilling criteria for major depressive disorder. Adolescents were randomized to 8 weeks of IPDT (38/76, 50%) or supportive control (38/76, 50%). The primary outcome was self-reported depressive symptoms, measured with the Quick Inventory of Depressive Symptomatology for Adolescents (QIDS-A17-SR). Secondary outcomes were anxiety severity, emotion regulation, self-compassion, and an additional depression measure. Assessments were made at baseline, postassessment, and at 6 months follow-up, in addition to weekly assessments of the primary outcome measure as well as emotion regulation during treatment. RESULTS IPDT was significantly more effective than the control condition in reducing depression (d=0.82, P=.01), the result of which was corroborated by the second depression measure (d=0.80, P<.001). IPDT was also significantly more effective in reducing anxiety (d=0.78, P<.001) and increasing emotion regulation (d=0.97, P<.001) and self-compassion (d=0.65, P=.003). Significantly more patients in the IPDT group compared to the control group met criteria for response (56% vs 21%, respectively) and remission (35% vs 8%, respectively). Results on depression and anxiety symptoms were stable at 6 months follow-up. On average, participants completed 5.8 (SD 2.4) of the 8 modules. CONCLUSIONS IPDT may be an effective intervention to reduce adolescent depression. Further research is needed, including comparisons with other treatments. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number (ISRCTN) 16206254; http://www.isrctn.com/ISRCTN16206254.",2020,"IPDT was also significantly more effective in reducing anxiety (d=0.78, P<.001) and increasing emotion regulation (d=0.97, P<.001) and self-compassion (d=0.65, P=.003).","['Adolescent Depression', 'Adolescents', '76 adolescents (61/76, 80% female; mean age 16.6 years), self-referred via an open access website and fulfilling criteria for major depressive disorder', 'adolescents']","['internet-based psychodynamic therapy (IPDT', 'Psychodynamic Internet-Based Therapy', 'supportive control', 'IPDT']","['self-compassion', 'depression', 'depression and anxiety symptoms', 'remission', 'anxiety', 'anxiety severity, emotion regulation, self-compassion, and an additional depression measure', 'self-reported depressive symptoms, measured with the Quick Inventory of Depressive Symptomatology for Adolescents (QIDS-A17-SR', 'emotion regulation during treatment', 'emotion regulation']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3266254', 'cui_str': 'Referred by self (finding)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C4720917', 'cui_str': 'Quick inventory of depressive symptomatology (assessment scale)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",76.0,0.208104,"IPDT was also significantly more effective in reducing anxiety (d=0.78, P<.001) and increasing emotion regulation (d=0.97, P<.001) and self-compassion (d=0.65, P=.003).","[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Lindqvist', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Mechler', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Carlbring', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Lilliengren', 'Affiliation': 'Ersta Sköndal Bräcke University College, Stockholm, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Falkenström', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Johansson', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Edbrooke-Childs', 'Affiliation': 'Evidence Based Practice Unit, Anna Freud National Centre for Children and Families, London, United Kingdom.'}, {'ForeName': 'Hanne-Sofie J', 'Initials': 'HJ', 'LastName': 'Dahl', 'Affiliation': 'Vestfold Hospital Trust, Oslo, Norway.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Lindert Bergsten', 'Affiliation': 'Department of Psychology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Midgley', 'Affiliation': 'Department of Clinical, Educational and Health Psychology, University College London, London, United Kingdom.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Sandell', 'Affiliation': 'Department of Psychology, Lund University, Lund, Sweden.'}, {'ForeName': 'Agneta', 'Initials': 'A', 'LastName': 'Thorén', 'Affiliation': 'The Erica Foundation, Stockholm, Sweden.'}, {'ForeName': 'Naira', 'Initials': 'N', 'LastName': 'Topooco', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Ulberg', 'Affiliation': 'Division of Mental Health and Addiction, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Philips', 'Affiliation': 'Department of Psychology, Stockholm University, Stockholm, Sweden.'}]",Journal of medical Internet research,['10.2196/18047'] 192,32120379,Electrocardiographic features at rest and during exercise in young adults born preterm below 30 weeks of gestation.,"BACKGROUND Preterm birth has adverse consequences on the cardiovascular system. Whether premature birth is associated with conduction and repolarisation abnormalities past childhood and into adulthood still needs to be demonstrated. METHODS We analyzed the ECG of young adults (23.9 ± 3.1 years) born term (≥37 weeks, n = 53) and preterm (<30 weeks, n = 49) at rest, peak exercise and 3 min into recovery during an exercise test on a cycle ergometer. We measured PR, QRS and QT intervals, calculated the corrected QT (QTc), and determined blood calcium, magnesium, potassium and fasting glucose. RESULTS Mean gestational age was 39.7 ± 1.1 and 27.3 ± 1.3 weeks for the term and the preterm groups, respectively. Apart from an increased heart rate at rest in individuals born preterm, no significant difference was found between both groups for any other ECG parameters at rest. None of the participants had a severely prolonged QTc (>500 ms) at rest; exercise revealed severely prolonged QTc in two participants including one in the preterm group. The use of QT-prolonging medications did not influence ECG parameters in either groups. CONCLUSIONS We observed no significant difference in electrocardiographic measurements between young adults born preterm and term. Current results do not support avoidance of QT-prolonging medications in individuals born preterm. IMPACT Preterm birth is associated with adverse cardiovascular consequences in early adulthood, but controversial evidence exists regarding differences in electrocardiographic features between young individuals born term and preterm.This study aims to assess the differences in electrocardiographic features between young adults born term and preterm, at rest and during exercise training.In contrast with previously published data, we observed no significant difference in electrocardiographic measurements between young adults born preterm and term.Our study does not support that preterm birth itself exposes young adults to a higher risk of QT prolongation.Current results do not support avoidance of QT-prolonging medications in individuals born preterm.",2020,None of the participants had a severely prolonged QTc (>500 ms) at rest; exercise revealed severely prolonged QTc in two participants including one in the preterm group.,"['young individuals born term and preterm', 'individuals born preterm', 'young adults born preterm and term', 'Mean gestational age was 39.7\u2009±\u20091.1 and 27.3\u2009±\u20091.3 weeks for the term and the preterm groups, respectively', 'young adults born preterm below 30 weeks of gestation', 'young adults born term and preterm, at rest and during exercise training', 'young adults (23.9\u2009±\u20093.1 years) born term (≥37 weeks, n\u2009=\u200953) and preterm (<30 weeks, n\u2009=\u200949) at']","['rest, peak exercise and 3\u2009min into recovery during an exercise test on a cycle ergometer']","['electrocardiographic measurements', 'Electrocardiographic features', 'electrocardiographic features', 'PR, QRS and QT intervals, calculated the corrected QT (QTc), and determined blood calcium, magnesium, potassium and fasting glucose', 'severely prolonged QTc', 'heart rate']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4517683', 'cui_str': '3.1 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1285812', 'cui_str': 'ECG feature'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0729820', 'cui_str': 'Blood calcium measurement'}, {'cui': 'C3540792', 'cui_str': 'Magnesium supplements, alimentary tract and metabolism'}, {'cui': 'C0304475', 'cui_str': 'Potassium supplement'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",2.0,0.180576,None of the participants had a severely prolonged QTc (>500 ms) at rest; exercise revealed severely prolonged QTc in two participants including one in the preterm group.,"[{'ForeName': 'Anne-Sophie', 'Initials': 'AS', 'LastName': 'Gervais', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Flahault', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Tevy', 'Initials': 'T', 'LastName': 'Chan', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Bastien-Tardif', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Al-Simaani', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Anik', 'Initials': 'A', 'LastName': 'Cloutier', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Thuy Mai', 'Initials': 'TM', 'LastName': 'Luu', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Abadir', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Anne-Monique', 'Initials': 'AM', 'LastName': 'Nuyt', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal, Montreal, QC, Canada. anne.monique.nuyt@umontreal.ca.'}]",Pediatric research,['10.1038/s41390-020-0814-9'] 193,32042166,An electroencephalographic signature predicts antidepressant response in major depression.,"Antidepressants are widely prescribed, but their efficacy relative to placebo is modest, in part because the clinical diagnosis of major depression encompasses biologically heterogeneous conditions. Here, we sought to identify a neurobiological signature of response to antidepressant treatment as compared to placebo. We designed a latent-space machine-learning algorithm tailored for resting-state electroencephalography (EEG) and applied it to data from the largest imaging-coupled, placebo-controlled antidepressant study (n = 309). Symptom improvement was robustly predicted in a manner both specific for the antidepressant sertraline (versus placebo) and generalizable across different study sites and EEG equipment. This sertraline-predictive EEG signature generalized to two depression samples, wherein it reflected general antidepressant medication responsivity and related differentially to a repetitive transcranial magnetic stimulation treatment outcome. Furthermore, we found that the sertraline resting-state EEG signature indexed prefrontal neural responsivity, as measured by concurrent transcranial magnetic stimulation and EEG. Our findings advance the neurobiological understanding of antidepressant treatment through an EEG-tailored computational model and provide a clinical avenue for personalized treatment of depression.",2020,Symptom improvement was robustly predicted in a manner both specific for the antidepressant sertraline (versus placebo) and generalizable across different study sites and EEG equipment.,['major depression'],"['placebo', 'latent-space machine-learning algorithm tailored for resting-state electroencephalography (EEG']","['sertraline resting-state EEG signature indexed prefrontal neural responsivity', 'Symptom improvement']","[{'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205275', 'cui_str': 'Latent (qualifier value)'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0002045'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0013819', 'cui_str': 'EEG'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.035978,Symptom improvement was robustly predicted in a manner both specific for the antidepressant sertraline (versus placebo) and generalizable across different study sites and EEG equipment.,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'School of Automation Science and Engineering, South China University of Technology, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Molly V', 'Initials': 'MV', 'LastName': 'Lucas', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Fonzo', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Camarin E', 'Initials': 'CE', 'LastName': 'Rolle', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Cherise', 'Initials': 'C', 'LastName': 'Chin-Fatt', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Noralie', 'Initials': 'N', 'LastName': 'Krepel', 'Affiliation': 'Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands.'}, {'ForeName': 'Carena A', 'Initials': 'CA', 'LastName': 'Cornelssen', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Wright', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Russell T', 'Initials': 'RT', 'LastName': 'Toll', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Hersh M', 'Initials': 'HM', 'LastName': 'Trivedi', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Monuszko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Trevor L', 'Initials': 'TL', 'LastName': 'Caudle', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Kamron', 'Initials': 'K', 'LastName': 'Sarhadi', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Jha', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Trombello', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Deckersbach', 'Affiliation': 'Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Adams', 'Affiliation': 'New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'McGrath', 'Affiliation': 'New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Myrna M', 'Initials': 'MM', 'LastName': 'Weissman', 'Affiliation': 'New York State Psychiatric Institute & Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA.'}, {'ForeName': 'Diego A', 'Initials': 'DA', 'LastName': 'Pizzagalli', 'Affiliation': 'Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA, USA.'}, {'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'Arns', 'Affiliation': 'Research Institute Brainclinics, Brainclinics Foundation, Nijmegen, the Netherlands.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Etkin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. amitetkin@stanford.edu.'}]",Nature biotechnology,['10.1038/s41587-019-0397-3'] 194,31147478,Financial incentives to Medicaid smokers for engaging tobacco quit line treatment: maximising return on investment.,"BACKGROUND Low-income smokers experience greater difficulty in quitting smoking than do other smokers. Providing financial incentives for treatment engagement increases smoking cessation success. This study models the cost-effectiveness of varying levels of financial incentives to maximise return on investment (ROI) for engaging low-income Medicaid recipients who smoke to take calls from a tobacco quit line. METHODS Participants (N=1900) were recruited from May 2013 to June 2015 through quit line-based (n=980), clinic-based (n=444) or community-based referrals (n=476) into the Wisconsin Medicaid Quit Line Incentive project. Incentive (n=948) and control group participants (n=952) received $30 versus $0 per call, respectively, for taking up to five Wisconsin Tobacco Quit Line (WTQL) calls. Cost-effectiveness analyses estimated the incremental cost-effectiveness ratio for alternative financial incentives for engagement with WTQL calls. Probabilistic sensitivity analysis was employed to determine an optimal strategy for financial incentives to minimise the cost per individual who quit smoking. RESULTS Using fixed payments, the incremental cost-effectiveness ratio of $2316 per smoker who quit in the randomised trial decreased to $2150 per smoker who quit when the incentives were modelled at $20 per each of five WTQL calls taken. Using variable payments, the minimal cost per additional smoker who quit was $2125 when incentives for the first four WTQL calls were set at $20, and the financial payment for the fifth WTQL call was set at $70. CONCLUSIONS Modelling suggests that financial incentives in the amount of $20 per call for taking the first four quit line calls and $70 for taking a fifth quit line call maximise ROI to engage low-income smokers with evidence-based smoking cessation treatment.",2020,"RESULTS Using fixed payments, the incremental cost-effectiveness ratio of $2316 per smoker who quit in the randomised trial decreased to $2150 per smoker who quit when the incentives were modelled at $20 per each of five WTQL calls taken.","['Participants (N=1900) were recruited from May 2013 to June 2015 through quit line-based (n=980), clinic-based (n=444) or community-based referrals (n=476) into the Wisconsin Medicaid Quit Line Incentive project', 'engaging low-income Medicaid recipients who smoke to take calls from a tobacco quit line']","['control group participants (n=952) received $30 versus $0 per call, respectively, for taking up to five Wisconsin Tobacco Quit Line (WTQL) calls', 'financial incentives to maximise return on investment (ROI']",['incremental cost-effectiveness ratio'],"[{'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0021953', 'cui_str': 'Investments'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",1900.0,0.0367152,"RESULTS Using fixed payments, the incremental cost-effectiveness ratio of $2316 per smoker who quit in the randomised trial decreased to $2150 per smoker who quit when the incentives were modelled at $20 per each of five WTQL calls taken.","[{'ForeName': 'Marlon P', 'Initials': 'MP', 'LastName': 'Mundt', 'Affiliation': 'Family Medicine and Community Health, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA marlon.mundt@fammed.wisc.edu.'}, {'ForeName': 'Timothy B', 'Initials': 'TB', 'LastName': 'Baker', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Piper', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'Stevens S', 'Initials': 'SS', 'LastName': 'Smith', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Fraser', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Fiore', 'Affiliation': 'Center for Tobacco Research and Intervention, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054811'] 195,31177181,Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study.,"OBJECTIVE We examined the relationship between habitual daily physical activity and measures of glucose tolerance, insulin sensitivity, and β-cell responses in adults with impaired glucose tolerance (IGT) or drug-naive, recently diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS Participants included 230 adults (mean ± SD age 54.5 ± 8.5 years, BMI 35 ± 5.5 kg/m 2 ; 42.6% women) who underwent a 3-h oral glucose tolerance test (OGTT) and hyperglycemic clamp. Wrist accelerometers worn for 7 consecutive days measured total physical activity counts (TAC) (daily mean 233,460 [∼50th percentile for age]). We evaluated whether TAC was associated with fasting plasma glucose, OGTT 2-h plasma glucose or glucose incremental area under the curve (G-iAUC), hyperglycemic clamp measures of insulin sensitivity (steady-state glucose infusion rate/insulin [M/I]) and β-cell responses (acute C-peptide response to glucose, steady-state C-peptide, and maximal β-cell response), and OGTT C-peptide index (ΔC-peptide 0-30 /Δglucose 0-30 ). RESULTS After adjustments for confounders, there was no association of TAC with fasting plasma glucose, 2-h glucose, or G-iAUC. Higher TAC was associated with higher insulin sensitivity (M/I). After adjusting for M/I, higher TAC was not associated with measures of β-cell response. CONCLUSIONS In adults with IGT or drug-naive, recently diagnosed type 2 diabetes, higher levels of habitual physical activity are associated with higher insulin sensitivity. Further studies are needed to understand why higher levels of physical activity are not associated with better β-cell response.",2019,"After adjustments for confounders, there was no association of TAC with fasting plasma glucose, 2-h glucose, or G-iAUC.","['Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study', 'adults with impaired glucose tolerance (IGT) or drug-naive, recently diagnosed type 2 diabetes', 'Participants included 230 adults (mean ± SD age 54.5 ± 8.5 years, BMI 35 ± 5.5 kg/m 2 ; 42.6% women) who underwent a 3-h oral glucose tolerance test (OGTT) and hyperglycemic clamp']","['Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function', 'TAC']","['habitual physical activity', 'β-cell responses (acute C-peptide response to glucose, steady-state C-peptide, and maximal β-cell response', 'total physical activity counts (TAC', 'TAC with fasting plasma glucose, 2-h glucose, or G-iAUC', 'glucose tolerance, insulin sensitivity, and β-cell responses', 'fasting plasma glucose, OGTT 2-h plasma glucose or glucose incremental area under the curve (G-iAUC), hyperglycemic clamp measures of insulin sensitivity (steady-state glucose infusion rate/insulin']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0151671', 'cui_str': 'Glucose tolerance decreased'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0041119', 'cui_str': 'Tritium'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0007613', 'cui_str': 'Physiology, Cell'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439157', 'cui_str': 'counts'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]",230.0,0.0195765,"After adjustments for confounders, there was no association of TAC with fasting plasma glucose, 2-h glucose, or G-iAUC.","[{'ForeName': 'Karla A', 'Initials': 'KA', 'LastName': 'Temple', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Ashley H', 'Initials': 'AH', 'LastName': 'Tjaden', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD.'}, {'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Atkinson', 'Affiliation': 'VA Puget Sound Health Care System and University of Washington, Seattle, WA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Barengolts', 'Affiliation': 'Jesse Brown VA Medical Center, Chicago, IL.'}, {'ForeName': 'Tamara S', 'Initials': 'TS', 'LastName': 'Hannon', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Kieren J', 'Initials': 'KJ', 'LastName': 'Mather', 'Affiliation': 'Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Utzschneider', 'Affiliation': 'VA Puget Sound Health Care System and University of Washington, Seattle, WA.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Edelstein', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Ehrmann', 'Affiliation': 'University of Chicago, Chicago, IL.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Mokhlesi', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0538'] 196,31189564,Cost-effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial.,"OBJECTIVE Young adults with type 1 diabetes (T1D) often struggle to achieve glycemic control and maintain routine clinic visits. We aimed to evaluate the societal cost-effectiveness of the Colorado young adults with T1D (CoYoT1) Clinic, an innovative care model of shared medical appointments through home telehealth. RESEARCH DESIGN AND METHODS Patients self-selected into the CoYoT1 ( N = 42) or usual care ( N = 39) groups. RESULTS Within the trial, we found no significant differences in 9-month quality-adjusted life; however, the control group had a larger decline from baseline in utility than the CoYoT1 group, indicating a quality of life (QoL) benefit of the intervention (difference in difference mean ± SD: 0.04 ± 0.09; P = 0.03). There was no significant difference in total costs. The CoYoT1 group had more study-related visits but fewer nonstudy office visits and hospitalizations. CONCLUSIONS: The CoYoT1 care model may help young adults with T1D maintain a higher QoL with no increase in costs.",2019,"Within the trial, we found no significant differences in 9-month quality-adjusted life; however, the control group had a larger decline from baseline in utility than the CoYoT1 group, indicating a quality of life (QoL) benefit of the intervention (difference in difference mean ± SD: 0.04 ± 0.09; P = 0.03). ","['Young Adults', 'Young adults (YAs) with type 1 diabetes (T1D) often struggle to achieve glycemic control and maintain routine clinic visits', 'Patients self-selected into the CoYoT1 ( N = 42) or usual care ( N = 39) groups']","['Colorado YAs with T1D (CoYoT1) Clinic', 'Shared Telemedicine Appointments']","['quality of life (QoL) benefit', 'total costs', 'societal cost-effectiveness', 'Cost-Effectiveness', '9-month quality-adjusted life']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C0034380'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",,0.0575454,"Within the trial, we found no significant differences in 9-month quality-adjusted life; however, the control group had a larger decline from baseline in utility than the CoYoT1 group, indicating a quality of life (QoL) benefit of the intervention (difference in difference mean ± SD: 0.04 ± 0.09; P = 0.03). ","[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Wan', 'Affiliation': 'Section of General Internal Medicine, The University of Chicago, Chicago, IL wwan1@medicine.bsd.uchicago.edu.'}, {'ForeName': 'Aviva G', 'Initials': 'AG', 'LastName': 'Nathan', 'Affiliation': 'Section of General Internal Medicine, The University of Chicago, Chicago, IL.'}, {'ForeName': 'M Reza', 'Initials': 'MR', 'LastName': 'Skandari', 'Affiliation': 'Section of General Internal Medicine, The University of Chicago, Chicago, IL.'}, {'ForeName': 'Parmida', 'Initials': 'P', 'LastName': 'Zarei', 'Affiliation': 'Section of General Internal Medicine, The University of Chicago, Chicago, IL.'}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Reid', 'Affiliation': ""Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA.""}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Raymond', 'Affiliation': ""Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA.""}, {'ForeName': 'Elbert S', 'Initials': 'ES', 'LastName': 'Huang', 'Affiliation': 'Section of General Internal Medicine, The University of Chicago, Chicago, IL.'}]",Diabetes care,['10.2337/dc19-0363'] 197,31167889,Changes in Visceral and Subcutaneous Fat in Youth With Type 2 Diabetes in the TODAY Study.,"OBJECTIVE In the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study, metformin plus rosiglitazone (M + R) maintained glycemic control better than metformin alone (M) or metformin plus lifestyle (M + L) in youth with type 2 diabetes (T2D). We hypothesized that changes in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) would explain the differential treatment effects on glycemia. RESEARCH DESIGN AND METHODS In 626 youth ages 11-17 years with T2D duration <2 years, VAT and SAT were estimated by DXA at baseline and at 6 and 24 months. Changes from baseline were analyzed in linear mixed models. RESULTS Baseline mean age was 13.9 years, 66.4% were female, 72.2% were Hispanic/non-Hispanic black, and 20.3% were non-Hispanic white (NHW). Mean BMI was 33.7 kg/m 2 . VAT increased more in M + R (13.1%) than M + L (3.9%, P = 0.0006) or M (6.5%, P = 0.0146). SAT also increased more in M + R (13.3%) than in M + L (5.4%, P < 0.0001) or M (6.4%, P = 0.0005), indicating no significant fat redistribution in M + R. In NHWs, VAT increased more in M + R than M ( P = 0.0192) and M + L ( P = 0.0482) but did not explain the race-ethnicity differences in treatment effects on glycemic control among treatment groups. VAT and SAT increases correlated with higher HbA 1c , lower insulin sensitivity, and lower oral disposition index (all P < 0.05), but associations did not differ by treatment group. CONCLUSIONS In contrast to the existing reports in adults with T2D, in TODAY, M + R resulted in the most VAT accumulation compared with M + L or M. Differential effects on depot-specific indirect measures of adiposity are unrelated to treatment effects in sustaining glycemic control. Additional studies are needed to understand the clinical markers of metabolic risk profile in youth with T2D on rosiglitazone.",2019,"In NHWs, VAT increased more in M + R than M ( P = 0.0192) and M + L ( P = 0.0482) but did not explain the race-ethnicity differences in treatment effects on glycemic control among treatment groups.","['626 youth ages 11-17 years with T2D duration <2 years, VAT and SAT were estimated by DXA at baseline and at 6 and 24 months', 'youth with type 2 diabetes (T2D', 'Youth With Type 2 Diabetes', 'Baseline mean age was 13.9 years, 66.4% were female, 72.2% were Hispanic/non-Hispanic black, and 20.3% were non-Hispanic white (NHW']","['rosiglitazone', 'metformin alone (M) or metformin plus lifestyle (M + L', 'metformin plus rosiglitazone (M + R']","['VAT and SAT increases correlated with higher HbA 1c , lower insulin sensitivity, and lower oral disposition index', 'VAT increased more in M + R', 'SAT also increased more in M + R', 'Mean BMI', 'Visceral and Subcutaneous Fat']","[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517562', 'cui_str': '13.9 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0289313', 'cui_str': 'rosiglitazone'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0442045', 'cui_str': 'Visceral (qualifier value)'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}]",,0.0163867,"In NHWs, VAT increased more in M + R than M ( P = 0.0192) and M + L ( P = 0.0482) but did not explain the race-ethnicity differences in treatment effects on glycemic control among treatment groups.","[{'ForeName': 'Ruban', 'Initials': 'R', 'LastName': 'Dhaliwal', 'Affiliation': 'State University of New York Upstate Medical University, Syracuse, NY.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Shepherd', 'Affiliation': 'University of Hawaii, Honolulu, HI.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'El Ghormli', 'Affiliation': 'George Washington University Biostatistics Center, Rockville, MD elghorml@bsc.gwu.edu.'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Copeland', 'Affiliation': 'University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'ForeName': 'Mitchell E', 'Initials': 'ME', 'LastName': 'Geffner', 'Affiliation': ""The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA.""}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Higgins', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Lynne L', 'Initials': 'LL', 'LastName': 'Levitsky', 'Affiliation': 'Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'Kristen J', 'Initials': 'KJ', 'LastName': 'Nadeau', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Ruth S', 'Initials': 'RS', 'LastName': 'Weinstock', 'Affiliation': 'State University of New York Upstate Medical University, Syracuse, NY.'}, {'ForeName': 'Neil H', 'Initials': 'NH', 'LastName': 'White', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc18-1935'] 198,32281159,Intensive control of hypertension and risk of Alzheimer's dementia in older adults with depression.,"OBJECTIVES Intensive control of hypertension has been reported to decrease risk of cognitive decline. However, the effect of this in older adults with hypertension and comorbid depression is not well understood. We aim to identify whether intensive control of systolic blood pressure (BP) is associated with reduced risk of Alzheimer's dementia (AD) in a clinical population. METHODS Using data from the National Alzheimer's Coordinating Center, we conducted survival analyses in older adults with normal cognition at baseline and treated hypertension. We also examined those with comorbid depression, to determine if intensive control of systolic BP (≤120 mmHg) was associated with reduced risk of AD. RESULTS In all older adults with treated hypertension (n = 4505), 298 (6.6%) developed AD during a median follow-up duration of 4.2 years. In the comorbid depression subgroup (n = 1327), 152 (11.5%) developed AD. Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64). However, in the comorbid depression subgroup, intensive control of systolic BP (≤120 mmHg) was associated with increased risk of AD (HR 1.49, 95%, 1.03-2.15) compared to standard control (121-139 mmHg). CONCLUSIONS In a clinical population of older adults with hypertension and comorbid depression, we found that an intensive systolic BP target of ≤120 mmHg was associated with increased risk of AD. While these findings are preliminary, they suggest that a more cautious approach to hypertension treatment may be warranted in this vulnerable subgroup.",2020,"Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64).","[""Using data from the National Alzheimer's Coordinating Center, we conducted survival analyses in older adults with normal cognition at baseline and treated hypertension"", 'older adults with hypertension and comorbid depression', 'older adults with depression', 'older adults with treated hypertension (n = 4505), 298 (6.6%) developed AD during a median follow-up duration of 4.2\u2009years']",['intensive control of systolic blood pressure (BP'],"['risk of AD', 'intensive control of systolic BP']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2712133', 'cui_str': 'Normal cognition'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4517823', 'cui_str': '6.6'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517758', 'cui_str': '4.2'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",4505.0,0.143044,"Intensive control of systolic BP was not significantly associated with reduced risk of AD in the overall sample (HR 1.13, 95%, 0.79-1.64).","[{'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Yeung', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Evaluative Clinical Sciences, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Gallagher', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}]",International journal of geriatric psychiatry,['10.1002/gps.5309'] 199,31674058,"Oral ferroportin inhibitor VIT-2763: First-in-human, phase 1 study in healthy volunteers.","Restriction of iron availability by ferroportin inhibition is a novel approach to treating non-transfusion-dependent thalassemia (β-thalassemia intermedia). This first-in-human, Phase I study (https://www.clinicaltrialsregister.eu; EudraCT no. 2017-003395-31) assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses (SAD and MAD) of the oral ferroportin inhibitor, VIT-2763, in healthy volunteers. Participants received VIT-2763 5/15/60/120/240 mg or placebo in the SAD phase and VIT-2763 60/120 mg once daily, VIT-2763 60/120 mg twice daily, or placebo for 7 days in the MAD phase. Seventy-two participants completed treatment. VIT-2763 was well tolerated and demonstrated a similar safety profile to the placebo. There were no serious or severe adverse events, or discontinuations due to adverse events. VIT-2763 absorption was relatively fast, with detectable levels 15 to 30 minutes post-dose. Following multiple dosing there was no apparent change in absorption and accumulation was minimal. Mean elimination half-life was 1.9 to 5.3 hours following single dosing, and 2.1 to 3.8 hours on Day 1 and 2.6 to 5.3 hours on Day 7, following repeated dosing. There was a temporary decrease in mean serum iron levels with VIT-2763 single doses ≥60 mg and all multiple doses; mean calculated transferrin saturation (only assessed following multiple dosing) also temporarily decreased. A shift in mean serum hepcidin peaks followed administration of all iron-lowering doses of VIT-2763. This effect was less pronounced after 7 days of multiple dosing (aside from with 120 mg once daily). These results support the initiation of clinical studies in patients with non-transfusion-dependent thalassemia and documented iron overload due to ineffective erythropoiesis.",2020,There was a temporary decrease in mean serum iron levels with VIT-2763 single doses ≥ ,"['patients with non-transfusion-dependent thalassemia and documented iron overload due to ineffective erythropoiesis', 'healthy volunteers']","['placebo', 'SAD phase and VIT-2763 60/120 mg once daily, VIT-2763 60/120 mg twice daily, or placebo', 'VIT-2763 5/15/60/120/240 mg or placebo', 'Oral ferroportin inhibitor VIT-2763']","['safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses (SAD and MAD', 'Mean elimination half-life', 'serious or severe adverse events', 'transferrin saturation', 'VIT-2763 absorption', 'mean serum iron levels', 'absorption and accumulation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3805143', 'cui_str': 'Non-transfusion dependent thalassaemia'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0282193', 'cui_str': 'Iron Overload'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0392708', 'cui_str': 'Ineffective erythropoiesis (finding)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0915115', 'cui_str': 'solute carrier family 40 (iron-regulated transporter), member 1'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0671759', 'cui_str': 'MAD'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation index (procedure)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}]",72.0,0.0548298,There was a temporary decrease in mean serum iron levels with VIT-2763 single doses ≥ ,"[{'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Richard', 'Affiliation': 'Research and Development, Vifor Pharma Group, Glattbrugg, Switzerland.'}, {'ForeName': 'Jan Jaap', 'Initials': 'JJ', 'LastName': 'van Lier', 'Affiliation': 'Early Development Services, PRA Health Sciences, Groningen, Netherlands.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Roubert', 'Affiliation': 'Research and Development, Vifor Pharma Group, Glattbrugg, Switzerland.'}, {'ForeName': 'Teba', 'Initials': 'T', 'LastName': 'Haboubi', 'Affiliation': 'Research and Development, Vifor Pharma Group, Glattbrugg, Switzerland.'}, {'ForeName': 'Udo-Michael', 'Initials': 'UM', 'LastName': 'Göhring', 'Affiliation': 'Research and Development, Vifor Pharma Group, Glattbrugg, Switzerland.'}, {'ForeName': 'Franz', 'Initials': 'F', 'LastName': 'Dürrenberger', 'Affiliation': 'Chemical and Preclinical Research and Development, Vifor (International) AG, St. Gallen, Switzerland.'}]",American journal of hematology,['10.1002/ajh.25670'] 200,32314828,HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs - a post-hoc analysis.,"Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV + subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV + SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n = 88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n = 78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression + CNIs for >50% (B1; n = 44) or <50% (B2; n = 34) of the time. While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P = 0.0136) and group B2 (64.7%; P = 0.0326); Interestingly, further subgroup analysis revealed an increase (P = 0.0012) in liver enzyme values in group B2. Taken together, in HCV-infected patients with HCC and LTx, mTORi immunosuppression + CNIs yields excellent outcomes. Unexpectedly, higher levels of liver inflammation and poorer outcomes occur with mTORi monotherapy in the HCV + subgroup.",2020,"While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P=0.0136) and group B2 (64.7%; P=0.0326); Interestingly, further subgroup analysis revealed an increase (P=0.0012) in liver-enzyme values in group B2. ","['Control patients (group A: n=88) received', 'liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection', 'HCV patients after liver transplantation', '166 HCV + SiLVER Study patients regarding HCC outcome after LTx']","['sirolimus-based immunosuppression + CNIs', 'sirolimus', 'mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression']","['liver inflammation', 'HCV-RNA titer', 'liver-enzyme values', 'HCV-RNA titers', 'HCC recurrence', 'HCC recurrence-free survival']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0455647', 'cui_str': 'H/O: liver recipient'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C0037125', 'cui_str': 'silver'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021079', 'cui_str': 'Immunosuppressive therapy'}, {'cui': 'C1307407', 'cui_str': 'FRAP1 protein, human'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1453118', 'cui_str': 'CABIN1 protein, human'}]","[{'cui': 'C0019158', 'cui_str': 'Inflammatory disease of liver'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}]",,0.0596776,"While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P=0.0136) and group B2 (64.7%; P=0.0326); Interestingly, further subgroup analysis revealed an increase (P=0.0012) in liver-enzyme values in group B2. ","[{'ForeName': 'Jens M', 'Initials': 'JM', 'LastName': 'Werner', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Hornung', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Rubertha', 'Initials': 'R', 'LastName': 'Krah', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Götz', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Andreas A', 'Initials': 'AA', 'LastName': 'Schnitzbauer', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Hans J', 'Initials': 'HJ', 'LastName': 'Schlitt', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': 'Edward K', 'Initials': 'EK', 'LastName': 'Geissler', 'Affiliation': 'Department of Surgery, University Hospital Regensburg, Regensburg, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Transplant international : official journal of the European Society for Organ Transplantation,['10.1111/tri.13621'] 201,32312727,Multiple Interventions for Diabetic Foot Ulcer Treatment Trial (MIDFUT): study protocol for a randomised controlled trial.,"INTRODUCTION Diabetes affects more than 425 million people worldwide with a lifetime risk of diabetic foot ulcer (DFU) of up to 25%. Management includes wound debridement, wound dressings, offloading, treatment of infection and ischaemia, optimising glycaemic control; use of advanced adjuvant therapies is limited by high cost and lack of robust evidence. METHODS AND ANALYSIS A multicentre, seamless phase II/III, open, parallel group, multi-arm multi-stage randomised controlled trial in patients with a hard-to-heal DFU, with blinded outcome assessment. A maximum of 447 participants will be randomised (245 participants in phase II and 202 participants in phase III). The phase II primary objective will determine the efficacy of treatment strategies including hydrosurgical debridement ± decellularised dermal allograft, or the combination with negative pressure wound therapy, as an adjunct to treatment as usual (TAU), compared with TAU alone, with patients randomised in a 1:1:1:2 allocation. The outcome is achieving at least 50% reduction in index ulcer area at 4 weeks post randomisation.The phase III primary objective will determine whether one treatment strategy, continued from phase II, reduces time to healing of the index ulcer compared with TAU alone, with participants randomised in a 1:1 allocation. Secondary objectives will compare healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post randomisation. Phase II and phase III primary endpoint analysis will be conducted using a mixed-effects logistic regression model and Cox proportional hazards regression, respectively. A within-trial economic evaluation will be undertaken; the primary economic analysis will be a cost-utility analysis presenting ICERs for each treatment strategy in rank order of effectiveness, with effects expressed as quality-adjusted life years.The trial has predefined progression criteria for the selection of one treatment strategy into phase III based on efficacy, safety and costs at 4 weeks. ETHICS AND DISSEMINATION Ethics approval has been granted by the National Research Ethics Service (NRES) Committee Yorkshire and The Humber - Bradford Leeds Research Ethics Committee; approved 26 April 2017; (REC reference: 17/YH/0055). There is planned publication of a monograph in National Institute for Health Research journals and main trial results and associated papers in high-impact peer-reviewed journals. TRIAL REGISTRATION NUMBER ISRCTN64926597; registered on 6 June 2017.",2020,"Secondary objectives will compare healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post randomisation.","['patients with a hard-to-heal DFU, with blinded outcome assessment', '447 participants will be randomised (245 participants in phase II and 202 participants in phase III']","['TAU alone', 'hydrosurgical debridement ± decellularised dermal allograft, or the combination with negative pressure wound therapy']","['index ulcer area', 'healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}, {'cui': 'C0085565', 'cui_str': 'Outcome Assessment (Health Care)'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",447.0,0.157794,"Secondary objectives will compare healing status of the index ulcer, infection rate, reulceration, quality of life, cost-effectiveness and incidence of adverse events over 52 weeks post randomisation.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Brown', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK medsbro@leeds.ac.uk.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Nixon', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Myka', 'Initials': 'M', 'LastName': 'Ransom', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Gilberts', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Nikki', 'Initials': 'N', 'LastName': 'Dewhirst', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McGinnis', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Longo', 'Affiliation': 'Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Game', 'Affiliation': 'Derby Teaching Hospitals NHS Fundation Trust, Derby, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Bojke', 'Affiliation': 'Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Chadwick', 'Affiliation': 'College of Podiatry, London, UK.'}, {'ForeName': 'Akila', 'Initials': 'A', 'LastName': 'Chandrasekar', 'Affiliation': 'NHS Blood and Transplant, Liverpool, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Chetter', 'Affiliation': 'University of Hull, Hull, UK.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Collier', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Fernandez', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}, {'ForeName': 'Shervanthi', 'Initials': 'S', 'LastName': 'Homer-Vanniasinkam', 'Affiliation': 'Leeds Teaching Hospitals NHS Trust, Leeds, UK.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Jude', 'Affiliation': 'Tameside General Hospital, Manchester, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Leigh', 'Affiliation': 'Royal Free London NHS Foundation Trust, London, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lomas', 'Affiliation': 'NHS Blood and Transplant, Liverpool, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vowden', 'Affiliation': 'Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wason', 'Affiliation': 'MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Sharples', 'Affiliation': 'Department of Medical Statistics, London Schoool of Hygience and Tropical Medicine, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Russell', 'Affiliation': 'Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035947'] 202,32315648,Validity and Responsiveness of Floor Sitting-Rising Test in Post-Total Knee Arthroplasty: A Cohort Study.,"OBJECTIVES To assess the construct validity and responsiveness of the floor sitting-rising test (SRT) in individuals with total knee arthroplasty (TKA). DESIGN Cohort study with 6-month follow-up. Secondary analysis using data from a randomized controlled trial. SETTING An outpatient rehabilitation research center. PARTICIPANTS Participants (N=240) enrolled in the parent study who had unilateral primary TKA. INTERVENTION Participants in the parent study underwent 12 weeks of exercise programs. MAIN OUTCOME MEASURES Validity analysis correlated baseline data of participants who completed the SRT and measures of knee motion, muscle strength, performance-based tests, and patient-reported outcomes of physical and psychosocial function. Responsiveness analysis used the 3- and 6-month follow-up data. Effect sizes were calculated using changes from baseline. Areas under the receiving operating characteristics curve were calculated using a global rating of change as the external anchor. RESULTS Of the 240 participants (148 women; age, 70±7y), 180 (75%) were able to perform the SRT at baseline. Performers scored significantly better in all physical function tests (P<.0001) than nonperformers. SRT scores generally converged with measures of knee impairment and performance-based tests (associations ranged from small [r=0.15; P=.0516] to moderate [r=0.52; P<.0001]). SRT scores associated with self-efficacy for function (r=0.34; P<.0001) and fear of falls (r=-0.25; P=.001). At 3 (n=174) and 6 months (n=160), SRT effect sizes were 0.38 (95% confidence interval, 0.25-0.52) and 0.42 (95% confidence interval, 0.25-0.60), and areas under the curve were 0.59 (95% confidence interval, 0.49-0.69) and 0.62 (95% confidence interval, 0.52-0.73), respectively. CONCLUSIONS The results add evidence to the validity of the SRT in patients after TKA. The strength of the associations suggests that the SRT measures a physical function construct not captured by the other tests. The magnitude of indices of responsiveness for the SRT were similar to other performance-based tests, indicating comparable responsiveness to more widespread tests of functional performance.",2020,SRT scores associated with self-efficacy for function (r=0.34; p=<0.0001) and fear of falls (r=-0.25; p=0.001).,"['All 240 participants enrolled in the parent study who had unilateral primary TKA', '240 participants (148 female, age 70±7SD years), 180 (75', 'Post-Total Knee Arthroplasty', 'Outpatient rehabilitation research center', 'individuals with total knee arthroplasty (TKA']","['exercise programs', 'floor sitting-rising test (SRT']","['fear of falls', 'SRT effect sizes', 'SRT scores', 'Validity and responsiveness of floor Sitting-Rising Test', 'knee motion, muscle strength, performance-based tests, and patient-reported outcomes (PROs) of physical and psychosocial function']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1514830', 'cui_str': 'Rehabilitation Research'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0016249', 'cui_str': 'Walking surface of room'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}, {'cui': 'C0016249', 'cui_str': 'Walking surface of room'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",240.0,0.113594,SRT scores associated with self-efficacy for function (r=0.34; p=<0.0001) and fear of falls (r=-0.25; p=0.001).,"[{'ForeName': 'Jehan A', 'Initials': 'JA', 'LastName': 'Alomar', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Maria Beatriz C', 'Initials': 'MBC', 'LastName': 'Catelani', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Clair N', 'Initials': 'CN', 'LastName': 'Smith', 'Affiliation': 'Department of Orthopedic Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Charity G', 'Initials': 'CG', 'LastName': 'Patterson', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Tamara M', 'Initials': 'TM', 'LastName': 'Artman', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Sara R', 'Initials': 'SR', 'LastName': 'Piva', 'Affiliation': 'Department of Physical Therapy, School of Health and Rehabilitation Science, University of Pittsburgh, Pittsburgh, PA. Electronic address: spiva@pitt.edu.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.03.012'] 203,31927219,Influencing college students' normative perceptions of protective behavioral strategies: A pilot randomized trial.,"INTRODUCTION Personalized feedback interventions (PFIs) are associated with small but reliable decreases in alcohol consumption among college students. While they often include information regarding protective behavioral strategies (PBS), PFIs do not typically include feedback aimed to modify normative perceptions of PBS. This study aimed to enhance the efficacy of existing PFIs among college students by incorporating normative feedback on participants' use of PBS. METHODS Students enrolled in undergraduate courses (N = 268) completed baseline and 1-month follow-up assessments of past-month use of PBS, normative perceptions of PBS use, alcohol consumption, and alcohol-related consequences. Participants were randomized to one of three conditions: typical feedback on PBS (typical strategies PFI), descriptive normative feedback on PBS (strategy norms PFI), or assessment-only control (AOC). Participants in the typical strategies PFI and strategy norms PFI conditions received web-based personalized feedback profiles. RESULTS Compared to AOC, both the strategy norms PFI and typical strategies PFI were effective in correcting participants' perceptions of other students' engagement in PBS (p = .01) but did not differ significantly from one another. No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). DISCUSSION The strategy norms and typical strategies PFIs were both successful in increasing normative perceptions of PBS use, indicating that general (rather than normative) feedback regarding PBS use may be sufficient for changing perceptions of PBS use.",2020,"No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). ","['college students', 'Students enrolled in undergraduate courses (N\xa0=\xa0268']","['Personalized feedback interventions (PFIs', 'typical feedback on PBS (typical strategies PFI), descriptive normative feedback on PBS (strategy norms PFI), or assessment-only control (AOC']","['actual PBS use, alcohol consumption, or alcohol-related consequences']","[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C4517673', 'cui_str': '268'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]",,0.0309089,"No statistically significant differences were observed between conditions in terms of actual PBS use, alcohol consumption, or alcohol-related consequences at 1-month follow-up (p > .05). ","[{'ForeName': 'Eleanor L S', 'Initials': 'ELS', 'LastName': 'Leavens', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry, University of Missouri, Columbia, MO, United States.'}, {'ForeName': 'Emma I', 'Initials': 'EI', 'LastName': 'Brett', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Baraldi', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States.'}, {'ForeName': 'Thad R', 'Initials': 'TR', 'LastName': 'Leffingwell', 'Affiliation': 'Department of Psychology, Oklahoma State University, Stillwater, OK, United States. Electronic address: leavens@okstate.edu.'}]",Addictive behaviors,['10.1016/j.addbeh.2019.106256'] 204,32238507,Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial.,"OBJECTIVE To determine whether, for patients with depression and Parkinson disease (PD), telephone-based cognitive-behavioral treatment (T-CBT) alleviates depressive symptoms significantly more than treatment as usual (TAU), we conducted a randomized controlled trial to evaluate the efficacy of a 10-session T-CBT intervention for depression in PD, compared to TAU. METHODS Seventy-two people with PD (PWP) were randomized to T-CBT + TAU or TAU only. T-CBT tailored to PWPs' unique needs was provided weekly for 3 months, then monthly during 6-month follow-up. CBT targeted negative thoughts (e.g., ""I have no control""; ""I am helpless"") and behaviors (e.g., social withdrawal, excessive worry). It also trained care partners to help PWP practice healthy habits. Blind raters assessed outcomes at baseline, midtreatment, treatment end, and 1 and 6 months post-treatment. Analyses were intent to treat. RESULTS T-CBT outperformed TAU on all depression, anxiety, and quality of life measures. The primary outcome (Hamilton Depression Rating Scale score) improved significantly in T-CBT compared to TAU by treatment end. Mean improvement from baseline was 6.53 points for T-CBT and -0.27 points for TAU ( p < 0.0001); gains persisted over 6-month follow-up ( p < 0.0001). Improvements were moderated by a reduction in negative thoughts in the T-CBT group only, reflecting treatment target engagement. CONCLUSIONS T-CBT may be an effective depression intervention that addresses a significant unmet PD treatment need and bypasses access barriers to multidisciplinary, evidence-based care. CLINICALTRIALSGOV IDENTIFIER NCT02505737. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that for patients with depression and PD, T-CBT significantly alleviated depressive symptoms compared to usual care.",2020,Mean improvement from baseline was 6.53 points for T-CBT and -0.27 points for TAU ( p < 0.0001); gains persisted over 6-month follow-up ( p < 0.0001).,"['patients with depression and Parkinson disease (PD), telephone-based cognitive-behavioral treatment (T-CBT) alleviates depressive symptoms significantly more than treatment as usual (TAU', 'Parkinson disease', 'Seventy-two people with PD (PWP']","['10-session T-CBT intervention', 'T-CBT + TAU or TAU', 'Telephone-based cognitive behavioral therapy']","['depressive symptoms', 'negative thoughts', 'depression, anxiety, and quality of life measures', 'primary outcome (Hamilton Depression Rating Scale score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1142075', 'cui_str': 'Negative thoughts'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",72.0,0.0946385,Mean improvement from baseline was 6.53 points for T-CBT and -0.27 points for TAU ( p < 0.0001); gains persisted over 6-month follow-up ( p < 0.0001).,"[{'ForeName': 'Roseanne D', 'Initials': 'RD', 'LastName': 'Dobkin', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons. dobkinro@rutgers.edu.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Mann', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Gara', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Interian', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons.'}, {'ForeName': 'Kailyn M', 'Initials': 'KM', 'LastName': 'Rodriguez', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Menza', 'Affiliation': 'From the Departments of Psychiatry (R.D.D., M.A.G., K.M.R., M.M.) and Neurology (M.M.), Rutgers-Robert Wood Johnson Medical School, Piscataway; and VA New Jersey Health Care System (R.D.D., S.L.M., A.I.), Lyons.'}]",Neurology,['10.1212/WNL.0000000000009292'] 205,32102112,Biologics for chronic rhinosinusitis.,"BACKGROUND This living systematic review is one of several Cochrane Reviews evaluating the medical management of patients with chronic rhinosinusitis. Chronic rhinosinusitis is common. It is characterised by inflammation of the nasal and sinus linings, nasal blockage, rhinorrhoea, facial pressure/pain and loss of sense of smell. It occurs with or without nasal polyps.   'Biologics' are medicinal products produced by a biological process. Monoclonal antibodies are one type, already evaluated in related inflammatory conditions (e.g. asthma and atopic dermatitis). OBJECTIVES To assess the effects of biologics for the treatment of chronic rhinosinusitis. SEARCH METHODS The Cochrane ENT Information Specialist searched the Cochrane ENT Register; CENTRAL (2019, Issue 9); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 16 September 2019. SELECTION CRITERIA Randomised controlled trials (RCTs) with at least three months follow-up comparing biologics (currently, monoclonal antibodies) against placebo/no treatment in patients with chronic rhinosinusitis. DATA COLLECTION AND ANALYSIS We used standard Cochrane methodological procedures. Our primary outcomes were disease-specific health-related quality of life (HRQL), disease severity and serious adverse events (SAEs). The secondary outcomes were avoidance of surgery, extent of disease (measured by endoscopic or computerised tomography (CT) score), generic HRQL and adverse events (nasopharyngitis, including sore throat). We used GRADE to assess the certainty of the evidence for each outcome. MAIN RESULTS We included eight RCTs. Of 986 adult participants, 984 had severe chronic rhinosinusitis with nasal polyps; 43% to 100% of participants also had asthma. Three biologics, with different targets, were evaluated: dupilumab, mepolizumab and omalizumab. All the studies were sponsored or supported by industry. Anti-IL-4Rα mAb (dupilumab) versusplacebo/no treatment (all receiving intranasal steroids) Three studies (784 participants) evaluated dupilumab. Disease-specific HRQL was measured with the SNOT-22 (score 0 to 110; minimal clinically important difference (MCID) 8.9 points). At 24 weeks, the SNOT-22 score was 19.61 points lower (better) in participants receiving dupilumab (mean difference (MD) -19.61, 95% confidence interval (CI) -22.54 to -16.69; 3 studies; 784 participants; high certainty). Symptom severity measured on a 0- to 10-point visual analogue scale (VAS) was 3.00 lower in those receiving dupilumab (95% CI -3.47 to -2.53; 3 studies; 784 participants; moderate certainty). The risk of serious adverse events may be lower in the dupilumab group (risk ratio (RR) 0.45, 95% CI 0.28 to 0.75; 3 studies; 782 participants; low certainty).  The number of participants requiring nasal polyp surgery (actual or planned) during the treatment period is probably lower in those receiving dupilumab (RR 0.17, 95% CI 0.05 to 0.52; 2 studies; 725 participants; moderate certainty). Change in the extent of disease using the Lund Mackay computerised tomography (CT) score (0 to 24, higher = worse) was -7.00 (95% CI -9.61 to -4.39; 3 studies; 784 participants; high certainty), a large effect favouring the dupilumab group.  The EQ-5D visual analogue scale (0 to 100, higher = better; MCID 8 points) was used to measure change in generic quality of life. The mean difference favouring dupilumab was 8.59 (95% CI 5.31 to 11.86; 2 studies; 706 participants; moderate certainty). There may be little or no difference in the risk of nasopharyngitis (RR 0.95, 95% CI 0.72 to 1.25; 3 studies; 783 participants; low certainty). Anti-IL-5 mAb (mepolizumab) versusplacebo/no treatment (all receiving intranasal steroids) Two studies (137 participants) evaluated mepolizumab. Disease-specific HRQL measured with the SNOT-22 at 25 weeks was 13.26 points lower (better) in participants receiving mepolizumab (95% CI -22.08 to -4.44; 1 study; 105 participants; low certainty; MCID 8.9).  It is very uncertain whether there is a difference in s ymptom severity: on a 0- to 10-point VAS symptom severity was -2.03 lower in those receiving mepolizumab (95% CI -3.65 to -0.41; 1 study; 72 participants; very low certainty). It is very uncertain if there is difference in the risk of serious adverse events (RR 1.57, 95% CI 0.07 to 35.46; 2 studies; 135 participants, very low certainty). It is very uncertain whether or not the overall risk that patients still need surgery at trial end is lower in the mepolizumab group (RR 0.78, 95% CI 0.64 to 0.94; 2 studies; 135 participants; very low certainty). It is very uncertain whether mepolizumab reduces the extent of disease as measured by endoscopic nasal polyps score (scale range 0 to 8). The mean difference was 1.23 points lower in the mepolizumab group (MD -1.23, 95% -1.79 to -0.68; 2 studies; 137 participants; very low certainty). The difference in generic quality of life (EQ-5D) was 5.68 (95% CI -1.18 to 12.54; 1 study; 105 participants; low certainty), favouring the mepolizumab group. This difference is smaller than the MCID of 8 points. There may be little or no difference in the risk of nasopharyngitis (RR 0.73, 95% 0.36 to 1.47; 2 studies; 135 participants; low certainty). Anti-IgE mAb (omalizumab) versus placebo/no treatment (all receiving intranasal steroids) Three very small studies (65 participants) evaluated omalizumab. We are very uncertain about the effect of omalizumab on disease-specific HRQL, severe adverse events, extent of disease (CT scan scores), generic HRQL and adverse effects. AUTHORS' CONCLUSIONS In adults with severe chronic rhinosinusitis and nasal polyps, using regular topical nasal steroids, dupilumab improves disease-specific HRQL compared to placebo, and reduces the extent of the disease as measured on a CT scan. It probably also improves symptoms and generic HRQL and there is no evidence of an increased risk of serious adverse events. It may reduce the need for further surgery. There may be little or no difference in the risk of nasopharyngitis. In similar patients, mepolizumab may improve both disease-specific and generic HRQL. It is uncertain whether it reduces the need for surgery or improves nasal polyp scores. There may be little or no difference in the risk of nasopharyngitis. It is uncertain if there is a difference in symptom severity and the risk of serious adverse events. We are uncertain about the effects of omalizumab.",2020,The difference in generic quality of life (EQ-5D) was 5.68,"['986 adult participants, 984 had severe chronic rhinosinusitis with nasal polyps; 43% to 100% of\xa0participants also had asthma', 'adults with severe chronic rhinosinusitis and nasal polyps', 'chronic rhinosinusitis', 'to -4.39; 3 studies; 784 participants; high certainty),\xa0a large effect favouring the dupilumab group', 'patients with chronic rhinosinusitis', '3.47\xa0to -2.53; 3 studies; 784 participants; moderate\xa0certainty']","['omalizumab', 'Anti-IL-4Rα mAb (dupilumab', 'Anti-IL-5 mAb (mepolizumab', 'placebo', 'versusplacebo/no treatment (all receiving intranasal steroids', 'Anti-IgE mAb (omalizumab)\xa0versus placebo/no treatment (all receiving\xa0intranasal steroids', 'biologics']","['SNOT-22 score', 'Lund Mackay computerised tomography (CT) score', 'avoidance of surgery, extent of disease (measured by endoscopic or computerised tomography (CT) score), generic HRQL and adverse events (nasopharyngitis, including sore throat', 'generic quality of life', 'Disease-specific HRQL', '10-point VAS\xa0symptom severity', 'risk\xa0of nasopharyngitis', 'endoscopic nasal polyps score', 'nasal polyp scores', 'number of participants requiring nasal polyp\xa0surgery (actual or planned', 'EQ-5D visual analogue scale', 'generic quality of life (EQ-5D', 'risk of nasopharyngitis', 'disease-specific HRQL, severe adverse events, extent of disease (CT scan scores), generic HRQL and adverse effects', 'Symptom severity measured on\xa0a 0- to 10-point visual analogue scale (VAS', 'disease-specific HRQL', 'disease-specific and generic HRQL', 'disease-specific health-related quality of life (HRQL), disease severity and serious adverse events (SAEs']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4524092', 'cui_str': 'Chronic rhinosinusitis with nasal polyps'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0149516', 'cui_str': 'Chronic sinusitis (disorder)'}, {'cui': 'C0027430', 'cui_str': 'Nasal Polyps'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439543', 'cui_str': 'Certainties (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]","[{'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0051978', 'cui_str': 'anti-IgE antibodies'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0040405', 'cui_str': 'Tomography, Xray Computed'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0449279', 'cui_str': 'Extent of disease (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C0034380'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0027430', 'cui_str': 'Nasal Polyps'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",986.0,0.240152,The difference in generic quality of life (EQ-5D) was 5.68,"[{'ForeName': 'Lee-Yee', 'Initials': 'LY', 'LastName': 'Chong', 'Affiliation': 'UK Cochrane Centre, Oxford, UK.'}, {'ForeName': 'Patorn', 'Initials': 'P', 'LastName': 'Piromchai', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Department of Otorhinolaryngology, Khon Kaen, Thailand.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Sharp', 'Affiliation': 'National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, UK, M1 4BT.'}, {'ForeName': 'Kornkiat', 'Initials': 'K', 'LastName': 'Snidvongs', 'Affiliation': 'Chulalongkorn University, Department of Otolaryngology, Faculty of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Philpott', 'Affiliation': 'Norwich Medical School, University of East Anglia, Department of Medicine, Norwich, UK, NR4 7TJ.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Hopkins', 'Affiliation': ""Guy's Hospital, ENT Department, Gerat Maze Pond, London, UK, SE1 9RT.""}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Burton', 'Affiliation': 'Cochrane UK, Summertown Pavilion, 18 - 24 Middle Way, Oxford, UK, OX2 7LG.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013513.pub2'] 206,32311072,Pharmacological treatment for familial amyloid polyneuropathy.,"BACKGROUND Disease-modifying pharmacological agents for transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on disease-modifying pharmacological treatment for TTR-related and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors. OBJECTIVES To assess and compare the efficacy, acceptability, and tolerability of disease-modifying pharmacological agents for familial amyloid polyneuropathies (FAPs). SEARCH METHODS On 18 November 2019, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We reviewed reference lists of articles and textbooks on peripheral neuropathies. We also contacted experts in the field. We searched clinical trials registries and manufacturers' websites. SELECTION CRITERIA We included randomised clinical trials (RCTs) or quasi-RCTs investigating any disease-modifying pharmacological agent in adults with FAPs. Disability due to FAP progression was the primary outcome. Secondary outcomes were severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events during the trial. DATA COLLECTION AND ANALYSIS We followed standard Cochrane methodology. MAIN RESULTS The review included four RCTs involving 655 people with TTR-FAP. The manufacturers of the drugs under investigation funded three of the studies. The trials investigated different drugs versus placebo and we did not conduct a meta-analysis. One RCT compared tafamidis with placebo in early-stage TTR-FAP (128 randomised participants). The trial did not explore our predetermined disability outcome measures. After 18 months, tafamidis might reduce progression of peripheral neuropathy slightly more than placebo (Neuropathy Impairment Score (NIS) in the lower limbs; mean difference (MD) -3.21 points, 95% confidential interval (CI) -5.63 to -0.79; P = 0.009; low-certainty evidence). However, tafamidis might lead to little or no difference in the change of quality of life between groups (Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score; MD -4.50 points, 95% CI -11.27 to 2.27; P = 0.19; very low-certainty evidence). No clear between-group difference was found in the numbers of participants who died (risk ratio (RR) 0.65, 95% CI 0.11 to 3.74; P = 0.63; very low-certainty evidence), who dropped out due to adverse events (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very low-certainty evidence), or who experienced at least one severe adverse event during the trial (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very low-certainty evidence). One RCT compared diflunisal with placebo (130 randomised participants). At month 24, diflunisal might reduce progression of disability (Kumamoto Score; MD -4.90 points, 95% CI -7.89 to -1.91; P = 0.002; low-certainty evidence) and peripheral neuropathy (NIS plus 7 nerve tests; MD -18.10 points, 95% CI -26.03 to -10.17; P < 0.001; low-certainty evidence) more than placebo. After 24 months, changes from baseline in the quality of life measured by the 36-Item Short-Form Health Survey score showed no clear difference between groups for the physical component (MD 6.10 points, 95% CI 2.56 to 9.64; P = 0.001; very low-certainty evidence) and the mental component (MD 4.40 points, 95% CI -0.19 to 8.99; P = 0.063; very low-certainty evidence). There was no clear between-group difference in the number of people who died (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very low-certainty evidence), in the number of dropouts due to adverse events (RR 2.06, 95% CI 0.39 to 10.87; P = 0.39; very low-certainty evidence), and in the number of people who experienced at least one severe adverse event (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very low-certainty evidence) during the trial. One RCT compared patisiran with placebo (225 randomised participants). After 18 months, patisiran reduced both progression of disability (Rasch-built Overall Disability Scale; least-squares MD 8.90 points, 95% CI 7.00 to 10.80; P < 0.001; moderate-certainty evidence) and peripheral neuropathy (modified NIS plus 7 nerve tests - Alnylam version; least-squares MD -33.99 points, 95% CI -39.86 to -28.13; P < 0.001; moderate-certainty evidence) more than placebo. At month 18, the change in quality of life between groups favoured patisiran (Norfolk QOL-DN total score; least-squares MD -21.10 points, 95% CI -27.20 to -15.00; P < 0.001; low-certainty evidence). There was little or no between-group difference in the number of participants who died (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; low-certainty evidence), dropped out due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; low-certainty evidence), or experienced at least one severe adverse event (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; low-certainty evidence) during the trial. One RCT compared inotersen with placebo (172 randomised participants). The trial did not explore our predetermined disability outcome measures. From baseline to week 66, inotersen reduced progression of peripheral neuropathy more than placebo (modified NIS plus 7 nerve tests - Ionis version; MD -19.73 points, 95% CI -26.50 to -12.96; P < 0.001; moderate-certainty evidence). At week 65, the change in quality of life between groups favoured inotersen (Norfolk QOL-DN total score; MD -10.85 points, 95% CI -17.25 to -4.45; P < 0.001; low-certainty evidence). Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low-certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low-certainty evidence) compared to placebo. More dropouts due to adverse events were observed in the inotersen than in the placebo group (RR 8.57, 95% CI 1.16 to 63.07; P = 0.035; low-certainty evidence). There were no studies addressing apolipoprotein AI-FAP, gelsolin-FAP, and beta-2-microglobulin-FAP. AUTHORS' CONCLUSIONS Evidence on the pharmacological treatment of FAPs from RCTs is limited to TTR-FAP. No studies directly compare disease-modifying pharmacological treatments for TTR-FAP. Results from placebo-controlled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTR-FAP, but further investigations are needed. Since direct comparative studies for TTR-FAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, long-term non-randomised open-label studies monitoring their efficacy and safety are needed.",2020,"Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low-certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low-certainty evidence) compared to placebo.","['655 people with TTR-FAP', 'familial amyloid polyneuropathy', 'familial amyloid polyneuropathies (FAPs', 'adults with FAPs']","['placebo', 'diflunisal with placebo', 'quasi-RCTs', 'diflunisal']","['adverse events', 'efficacy, acceptability, and tolerability', 'peripheral neuropathy', 'severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events', 'apolipoprotein AI-FAP, gelsolin-FAP, and beta-2-microglobulin-FAP', 'number of participants who died', 'severe adverse event', 'progression of disability', 'number of people who died', 'progression of peripheral neuropathy', 'mortality', 'progression of disability (Rasch-built Overall Disability Scale', 'occurrence of severe adverse events', 'quality of life']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032923', 'cui_str': 'Prealbumin'}, {'cui': 'C0206245', 'cui_str': 'Familial amyloid polyneuropathy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0012228', 'cui_str': 'Diflunisal'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0085201', 'cui_str': 'Apolipoprotein A-I'}, {'cui': 'C0206245', 'cui_str': 'Familial amyloid polyneuropathy'}, {'cui': 'C0061187', 'cui_str': 'Gelsolin'}, {'cui': 'C0005149', 'cui_str': 'Beta 2 microglobulin'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",655.0,0.543706,"Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; low-certainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; low-certainty evidence) compared to placebo.","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Magrinelli', 'Affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Piazzale L.A. Scuro n. 10, Verona, VR, Italy, 37134.'}, {'ForeName': 'Gian Maria', 'Initials': 'GM', 'LastName': 'Fabrizi', 'Affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Piazzale L.A. Scuro n. 10, Verona, VR, Italy, 37134.'}, {'ForeName': 'Lucio', 'Initials': 'L', 'LastName': 'Santoro', 'Affiliation': 'University Federico II of Naples, Department of Neurosciences, Reproductive Sciences and Odontostomatology, Via Sergio Pansini n. 5, Naples, Italy, 80131.'}, {'ForeName': 'Fiore', 'Initials': 'F', 'LastName': 'Manganelli', 'Affiliation': 'University Federico II of Naples, Department of Neurosciences, Reproductive Sciences and Odontostomatology, Via Sergio Pansini n. 5, Naples, Italy, 80131.'}, {'ForeName': 'Giampietro', 'Initials': 'G', 'LastName': 'Zanette', 'Affiliation': 'Pederzoli Hospital, Neurology Section, Via Monte Baldo n° 24, Peschiera del Garda, VR, Italy, 37019.'}, {'ForeName': 'Tiziana', 'Initials': 'T', 'LastName': 'Cavallaro', 'Affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Piazzale L.A. Scuro n. 10, Verona, VR, Italy, 37134.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tamburin', 'Affiliation': 'University of Verona, Department of Neurosciences, Biomedicine and Movement Sciences, Piazzale L.A. Scuro n. 10, Verona, VR, Italy, 37134.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012395.pub2'] 207,32096706,Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.,"Background Radiofrequency ultrasound data from the liver contain rich information about liver microstructure and composition. Deep learning might exploit such information to assess nonalcoholic fatty liver disease (NAFLD). Purpose To develop and evaluate deep learning algorithms that use radiofrequency data for NAFLD assessment, with MRI-derived proton density fat fraction (PDFF) as the reference. Materials and Methods A HIPAA-compliant secondary analysis of a single-center prospective study was performed for adult participants with NAFLD and control participants without liver disease. Participants in the parent study were recruited between February 2012 and March 2014 and underwent same-day US and MRI of the liver. Participants were randomly divided into an equal number of training and test groups. The training group was used to develop two algorithms via cross-validation: a classifier to diagnose NAFLD (MRI PDFF ≥ 5%) and a fat fraction estimator to predict MRI PDFF. Both algorithms used one-dimensional convolutional neural networks. The test group was used to evaluate the classifier for sensitivity, specificity, positive predictive value, negative predictive value, and accuracy and to evaluate the estimator for correlation, bias, limits of agreements, and linearity between predicted fat fraction and MRI PDFF. Results A total of 204 participants were analyzed, 140 had NAFLD (mean age, 52 years ± 14 [standard deviation]; 82 women) and 64 were control participants (mean age, 46 years ± 21; 42 women). In the test group, the classifier provided 96% (95% confidence interval [CI]: 90%, 99%) (98 of 102) accuracy for NAFLD diagnosis (sensitivity, 97% [95% CI: 90%, 100%], 68 of 70; specificity, 94% [95% CI: 79%, 99%], 30 of 32; positive predictive value, 97% [95% CI: 90%, 99%], 68 of 70; negative predictive value, 94% [95% CI: 79%, 98%], 30 of 32). The estimator-predicted fat fraction correlated with MRI PDFF (Pearson r = 0.85). The mean bias was 0.8% ( P = .08), and 95% limits of agreement were -7.6% to 9.1%. The predicted fat fraction was linear with an MRI PDFF of 18% or less ( r = 0.89, slope = 1.1, intercept = 1.3) and nonlinear with an MRI PDFF greater than 18%. Conclusion Deep learning algorithms using radiofrequency ultrasound data are accurate for diagnosis of nonalcoholic fatty liver disease and hepatic fat fraction quantification when other causes of steatosis are excluded. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Lockhart and Smith in this issue.",2020,Conclusion Deep learning algorithms using radiofrequency ultrasound data are accurate for diagnosis of nonalcoholic fatty liver disease and hepatic fat fraction quantification when other causes of steatosis are excluded.,"['adult participants with NAFLD and control participants without liver disease', 'Participants in the parent study were recruited between February 2012 and March 2014 and underwent same-day US and MRI of the liver', 'A total of 204 participants were analyzed, 140 had NAFLD (mean age, 52 years ± 14 [standard deviation]; 82 women) and 64 were control participants (mean age, 46 years ± 21; 42 women']","['Radiofrequency Ultrasound Data', 'MRI-derived proton density fat fraction (PDFF']",['mean bias'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023895', 'cui_str': 'Disorder of liver (disorder)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0033727', 'cui_str': 'Hydrogen Ions'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005346', 'cui_str': 'Bias'}]",204.0,0.0877033,Conclusion Deep learning algorithms using radiofrequency ultrasound data are accurate for diagnosis of nonalcoholic fatty liver disease and hepatic fat fraction quantification when other causes of steatosis are excluded.,"[{'ForeName': 'Aiguo', 'Initials': 'A', 'LastName': 'Han', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Byra', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'Elhamy', 'Initials': 'E', 'LastName': 'Heba', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Andre', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Erdman', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'Claude B', 'Initials': 'CB', 'LastName': 'Sirlin', 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': ""O'Brien"", 'Affiliation': 'From the Bioacoustics Research Laboratory, Department of Electrical and Computer Engineering (A.H., W.D.O.), and Department of Food Science and Human Nutrition (J.W.E.), University of Illinois at Urbana-Champaign, 306 N Wright St, Urbana, IL 61801; Department of Radiology (M.B., M.P.A.), Liver Imaging Group, Department of Radiology (E.H., C.B.S.), and NAFLD Research Center, Division of Gastroenterology, Department of Medicine (R.L.), University of California, San Diego, La Jolla, Calif; and Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Warsaw, Poland (M.B.).'}]",Radiology,['10.1148/radiol.2020191160'] 208,31961967,Six-dimensional quantitative DCE MR Multitasking of the entire abdomen: Method and application to pancreatic ductal adenocarcinoma.,"PURPOSE To develop a quantitative DCE MRI technique enabling entire-abdomen coverage, free-breathing acquisition, 1-second temporal resolution, and T 1 -based quantification of contrast agent concentration and kinetic modeling for the characterization of pancreatic ductal adenocarcinoma (PDAC). METHODS Segmented FLASH readouts following saturation-recovery preparation with randomized 3D Cartesian undersampling was used for incoherent data acquisition. MR Multitasking was used to reconstruct 6-dimensional images with 3 spatial dimensions, 1 T 1 recovery dimension for dynamic T 1 quantification, 1 respiratory dimension to resolve respiratory motion, and 1 DCE time dimension to capture the contrast kinetics. Sixteen healthy subjects and 14 patients with pathologically confirmed PDAC were recruited for the in vivo studies, and kinetic parameters v p , K trans , v e , and K ep were evaluated for each subject. Intersession repeatability of Multitasking DCE was assessed in 8 repeat healthy subjects. One-way unbalanced analysis of variance was performed between control and patient groups. RESULTS In vivo studies demonstrated that v p , K trans , and K ep of PDAC were significantly lower compared with nontumoral regions in the patient group (P = .002, .003, .004, respectively) and normal pancreas in the control group (P = .011, <.001, <.001, respectively), while v e was significantly higher than nontumoral regions (P < .001) and healthy pancreas (P < .001). The kinetic parameters showed good in vivo repeatability (interclass correlation coefficient: v p , 0.95; K trans , 0.98; v e , 0.96; K ep , 0.99). CONCLUSION The proposed Multitasking DCE is promising for the quantification of vascular properties of PDAC. Quantitative DCE parameters were repeatable in vivo and showed significant differences between normal pancreas and both tumor and nontumoral regions in patients with PDAC.",2020,while v e was significantly higher than nontumoral regions (P < .001) and healthy pancreas (P < .001).,"['8 repeat healthy subjects', 'patients with PDAC', 'Sixteen healthy subjects and 14 patients with pathologically confirmed PDAC', 'entire abdomen', 'pancreatic ductal adenocarcinoma']",['Multitasking DCE'],"['healthy pancreas', 'K trans , and K ep of PDAC', 'vivo repeatability']","[{'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}]",[],[],16.0,0.0351948,while v e was significantly higher than nontumoral regions (P < .001) and healthy pancreas (P < .001).,"[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Srinivas', 'Initials': 'S', 'LastName': 'Gaddam', 'Affiliation': 'Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Lixia', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Yibin', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Zhaoyang', 'Initials': 'Z', 'LastName': 'Fan', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Wensha', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': 'Department of Clinical Radiation Oncology, University of Southern California, Los Angeles, California.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tuli', 'Affiliation': 'Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Lo', 'Affiliation': 'Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hendifar', 'Affiliation': 'Department of Gastrointestinal Malignancies, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Pandol', 'Affiliation': 'Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Anthony G', 'Initials': 'AG', 'LastName': 'Christodoulou', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Debiao', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Biomedical Imaging Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}]",Magnetic resonance in medicine,['10.1002/mrm.28167'] 209,31260791,Rationale and design of the regimen education and messaging in diabetes (REMinD) trial.,"BACKGROUND Individuals with type 2 diabetes manage complex multi-drug regimens, but nearly half of all patients do not consistently take the dose prescribed for them, and therefore may not receive the full potential therapeutic benefit. Both patient and health system factors contribute to achieving and maintaining medication adherence. To determine if patients with type 2 diabetes who are concurrently managing other chronic conditions could improve their adherence, we devised and are testing a multifaceted, primary care-based strategy to provide health literacy-appropriate and language concordant regimen information, guidance and reminders. OBJECTIVE We are testing the effectiveness of an electronic health record (EHR) based strategy and short message service (SMS) text reminders to help patients with type 2 diabetes adhere to their medications. METHODS We are conducting a 3-arm, multi-site trial to test and compare the effectiveness of the EHR, and EHR + SMS text reminder strategies compared to usual care on medication adherence. Our goal is to enroll a total of 900 English or Spanish-speaking patients with type 2 diabetes and hemoglobin A1C value ≥7.5%. Enrolled participants will complete interviews at baseline and 3 and 6 months following their baseline interview. CONCLUSIONS Our trial is evaluating practical, clinic-based, scalable, evidence-based solutions for patients with type 2 diabetes managing complex medication regimens. Our findings will evaluate strategies that can be implemented broadly in primary care practices, and programmed as defaults within EHRs to support appropriate medication adherence to allow the widespread implementation of those strategies.",2019,"OBJECTIVE We are testing the effectiveness of an electronic health record (EHR) based strategy and short message service (SMS) text reminders to help patients with type 2 diabetes adhere to their medications. ","['900 English or Spanish-speaking patients with type 2 diabetes and hemoglobin A1C value ≥7.5', 'patients with type 2 diabetes adhere to their medications', 'patients with type 2 diabetes who are concurrently managing other chronic conditions', 'patients with type 2 diabetes managing complex medication regimens']",['electronic health record (EHR) based strategy and short message service (SMS) text reminders'],[],"[{'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}]","[{'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3178909'}, {'cui': 'C3541382', 'cui_str': 'Text'}]",[],900.0,0.0778754,"OBJECTIVE We are testing the effectiveness of an electronic health record (EHR) based strategy and short message service (SMS) text reminders to help patients with type 2 diabetes adhere to their medications. ","[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': ""O'Conor"", 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America. Electronic address: r-oconor@northwestern.edu.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Arvanitis', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Guisselle', 'Initials': 'G', 'LastName': 'Wismer', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Opsasnick', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Sanchez Muñoz', 'Affiliation': 'Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Kannry', 'Affiliation': 'Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.'}, {'ForeName': 'Jenny J', 'Initials': 'JJ', 'LastName': 'Lin', 'Affiliation': 'Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Kaiser', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Mary J', 'Initials': 'MJ', 'LastName': 'Kwasny', 'Affiliation': 'Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Persell', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Parker', 'Affiliation': 'Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States of America.'}, {'ForeName': 'Alastair J J', 'Initials': 'AJJ', 'LastName': 'Wood', 'Affiliation': 'Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, United States of America.'}, {'ForeName': 'Alex D', 'Initials': 'AD', 'LastName': 'Federman', 'Affiliation': 'Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Wolf', 'Affiliation': 'Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.016'] 210,32125256,Drug-coated Balloon Angioplasty of Femoropopliteal Lesions Maintained Superior Efficacy over Conventional Balloon: 2-year Results of the Randomized EffPac Trial.,"Background Paclitaxel drug-coated balloon (DCB) catheter angioplasty is the preferred treatment for revascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a safety concern. Purpose To assess 2-year efficacy and safety of DCB angioplasty compared with conventional balloon angioplasty (also known as plain old balloon angioplasty or POBA). Materials and Methods This prospective, multicenter, randomized controlled trial enrolled consecutive participants with symptomatic superficial femoral and/or popliteal artery disease at 11 German centers between September 2015 and December 2016. Participants underwent DCB angioplasty or conventional balloon angioplasty. Primary outcome of 6-month late lumen loss showed superiority of DCB angioplasty over conventional balloon angioplasty. Evaluation at 2 years included secondary outcomes of primary patency and target lesion revascularization (TLR) estimated with Kaplan-Meier analysis, clinical and hemodynamic improvement, quality of life, target limb amputation, and all-cause mortality. Results A total of 171 participants (mean age, 69 years ± 8; 111 men) were evaluated. At 2 years, primary patency was achieved in 90.2% (95% confidence interval [CI]: 80.4%, 95.2%) of DCB angioplasty and 62.7% (95% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants ( P < .001). Freedom from TLR occurred in 97.2% (95% CI: 89.1%, 99.3%) of DCB angioplasty and 78% (95% CI: 66.5%, 86.0%) of conventional balloon angioplasty participants ( P = .001). The groups did not differ in sustained improvement from baseline to 2 years in Rutherford-Becker category (row mean scores difference, 1.7; P = .19) and showed no difference in mean improvement in the Walking Impairment Questionnaire score (-0.8%; 95% CI: -11.8%, 10.2%; P = .88), EuroQol Group's five-dimension index of quality of life (-0.06; 95% CI: -0.17, 0.03; P = .20), or ankle-brachial index (0.03; 95% CI: -0.08, 0.14; P = .57). No major amputation was necessary. One DCB angioplasty and two conventional balloon angioplasty participants died (risk ratio, 0.48; 95% CI: 0.04, 5.10). Conclusion At 2 years after paclitaxel drug-coated balloon (DCB) angioplasty, primary patency and freedom from target lesion revascularization remained superior compared with conventional balloon angioplasty. DCB angioplasty resulted in sustained clinical and hemodynamic improvement with no increased risk of mortality. © RSNA, 2020 Online supplemental material in available for this article.",2020,"At 2 years, primary patency was achieved in 90.2% (95% confidence interval [CI]: 80.4%, 95.2%) of DCB angioplasty and 62.7% (95% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants ( P < .001).","['A total of 171 participants (mean age, 69 years ± 8; 111 men', 'consecutive participants with symptomatic superficial femoral and/or popliteal artery disease at 11 German centers between September 2015 and December 2016']","['conventional balloon angioplasty', 'paclitaxel drug-coated balloon (DCB) angioplasty', 'DCB angioplasty or conventional balloon angioplasty', 'Drug-coated Balloon Angioplasty of Femoropopliteal Lesions', 'DCB) catheter angioplasty', 'DCB angioplasty', ' Paclitaxel drug-coated balloon', 'Conventional Balloon']","['TLR', '2-year efficacy and safety', 'ankle-brachial index', 'primary patency and target lesion revascularization (TLR) estimated with Kaplan-Meier analysis, clinical and hemodynamic improvement, quality of life, target limb amputation, and all-cause mortality', 'risk of mortality', 'primary patency', 'dimension index of quality of life', '6-month late lumen loss showed superiority of DCB angioplasty over conventional balloon angioplasty', 'Walking Impairment Questionnaire score']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0032649', 'cui_str': 'Popliteal Artery'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1328319', 'cui_str': 'Ankle Brachial Index'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0034380'}, {'cui': 'C0002689', 'cui_str': 'Amputation of limb'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",171.0,0.256992,"At 2 years, primary patency was achieved in 90.2% (95% confidence interval [CI]: 80.4%, 95.2%) of DCB angioplasty and 62.7% (95% CI: 50.0%, 73.0%) of conventional balloon angioplasty participants ( P < .001).","[{'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Teichgräber', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lehmann', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Aschenbach', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Dierk', 'Initials': 'D', 'LastName': 'Scheinert', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zeller', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Brechtel', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Blessing', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lichtenberg', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'von Flotow', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Heilmeier', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Sixt', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Brucks', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Erbel', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Beschorner', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Werk', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Vicenç', 'Initials': 'V', 'LastName': 'Riambau', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wienke', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Christof Tobias', 'Initials': 'CT', 'LastName': 'Klumb', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Thieme', 'Affiliation': 'From the Department of Radiology, Jena University Hospital, Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle Radiologie, Am Klinikum 1, 07747 Jena, Germany (U.T., R.A., C.T.K.); Center for Clinical Studies, Jena University Hospital, Jena, Germany (T.L.); Department of Angiology, University Hospital Leipzig, Leipzig, Germany (D.S.); Heart Center Bad Krozingen, Bad Krozingen, Germany (T.Z., U.B.); Radiology group practice, Ihre Radiologen, Berlin, Germany (K.B.); SRH Clinic Karlsbad-Langensteinbach, Karlsbad, Germany (E.B.); Clinic of Angiology Arnsberg, Arnsberg, Germany (M.L.); Department of Angiology, Westpfalz-Clinic, Kusel, Germany (P.v.F.); Center for Internal Medicine and Analysis III, Ruprechts-Karls-University Heidelberg, Heidelberg, Germany (B.H., C.E.); Angiologikum Hamburg, Hamburg, Germany (S.S.); Martin-Luther-Hospital, Berlin, Germany (S.B., M.W.); Department of Vascular Surgery, Hospital Clínic de Barcelona, Barcelona, Spain (V.R.); Institute for Medical Epidemiology, Biometry and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle, Germany (A.W.); Department of Radiology, Armed Forces Hospital Ulm, Ulm, Germany (C.T.K.); and Department of Angiology, Cardiology, and Diabetology, REGIOMED Clinics, Sonneberg, Germany (M.T.).'}]",Radiology,['10.1148/radiol.2020191619'] 211,30715153,Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.,"BACKGROUND Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who received a second course of pembrolizumab were also analyzed. PATIENTS AND METHODS Patients aged ≥18 years with previously treated or treatment-naive advanced/metastatic melanoma received pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) were calculated. Objective response rate and PFS were based on immune-related response criteria by investigator assessment (data cut-off, September 1, 2017). RESULTS KEYNOTE-001 enrolled 655 patients with melanoma; median follow-up was 55 months. Estimated 5-year OS was 34% in all patients and 41% in treatment-naive patients; median OS was 23.8 months (95% CI, 20.2-30.4) and 38.6 months (95% CI, 27.2-not reached), respectively. Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively. Median response duration was not reached; 73% of all responses and 82% of treatment-naive responses were ongoing at data cut-off; the longest response was ongoing at 66 months. Four patients [all with prior response of complete response (CR)] whose disease progressed during observation subsequently received second-course pembrolizumab. One patient each achieved CR and partial response (after data cut-off). Treatment-related AEs (TRAEs) occurred in 86% of patients and resulted in study discontinuation in 7.8%; 17% experienced grade 3/4 TRAE. CONCLUSIONS This 5-year analysis of KEYNOTE-001 represents the longest follow-up for pembrolizumab to date and confirms the durable antitumor activity and tolerability of pembrolizumab in advanced melanoma. CLINICAL TRIAL REGISTRY ClinicalTrials.gov, NCT01295827.",2019,"Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively.","['patients with advanced melanoma treated with', 'enrolled 655 patients with melanoma; median follow-up was 55\u2009months', 'Patients aged ≥18\u2009years with previously treated or treatment-naive advanced/metastatic melanoma received']","['pembrolizumab 2\u2009mg/kg every 3\u2009weeks, 10\u2009mg/kg every 3\u2009weeks, or 10\u2009mg/kg', 'pembrolizumab']","['Estimated 5-year PFS rates', 'Objective response rate and PFS', 'Median response duration', 'overall survival (OS) and progression-free survival (PFS', 'antitumor activity and safety', 'complete response (CR', 'Estimated 5-year OS', 'CR and partial response', 'median OS', 'median PFS', 'Treatment-related AEs (TRAEs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}]","[{'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0585333', 'cui_str': 'Triweekly'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",655.0,0.454713,"Estimated 5-year PFS rates were 21% in all patients and 29% in treatment-naive patients; median PFS was 8.3 months (95% CI, 5.8-11.1) and 16.9 months (95% CI, 9.3-35.5), respectively.","[{'ForeName': 'O', 'Initials': 'O', 'LastName': 'Hamid', 'Affiliation': 'Medical Oncology, The Angeles Clinic and Research Institute, Los Angeles, USA. Electronic address: ohamid@theangelesclinic.org.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Robert', 'Affiliation': 'Department of Dermatology, Gustave Roussy, Villejuif; Department of Medicine, University of Paris-Sud, Paris, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Daud', 'Affiliation': 'Department of Medicine, University of California, San Francisco, San Francisco.'}, {'ForeName': 'F S', 'Initials': 'FS', 'LastName': 'Hodi', 'Affiliation': 'Medical Oncology, Dana-Farber Cancer Institute, Boston.'}, {'ForeName': 'W J', 'Initials': 'WJ', 'LastName': 'Hwu', 'Affiliation': 'Department of Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Kefford', 'Affiliation': 'Medical Oncology, Westmead Hospital, Westmead; Medical Oncology, Melanoma Institute Australia, Sydney; Medical Oncology, Macquarie University, Macquarie Park; Medical Oncology, University of Sydney, Sydney, Australia.'}, {'ForeName': 'J D', 'Initials': 'JD', 'LastName': 'Wolchok', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Hersey', 'Affiliation': 'Medical Oncology, University of Sydney, Sydney, Australia; Department of Medicine, Centenary Institute, Sydney, Australia.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Joseph', 'Affiliation': 'Medical Oncology, Mayo Clinic Cancer Center-Florida, Jacksonville.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Weber', 'Affiliation': 'Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, New York.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dronca', 'Affiliation': 'Medical Oncology, Mayo Clinic Cancer Center-Florida, Jacksonville.'}, {'ForeName': 'T C', 'Initials': 'TC', 'LastName': 'Mitchell', 'Affiliation': 'Division of Hematology Oncology, Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Patnaik', 'Affiliation': 'Medical Oncology, South Texas Accelerated Research Therapeutics, San Antonio.'}, {'ForeName': 'H M', 'Initials': 'HM', 'LastName': 'Zarour', 'Affiliation': 'Department of Immunology, University of Pittsburgh Cancer Institute, Pittsburgh, USA.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Joshua', 'Affiliation': ""Medical Oncology, Melanoma Institute Australia, Sydney; Medical Oncology, University of Sydney, Sydney, Australia; Kinghorn Cancer Centre, St. Vincent's Hospital, Medical Oncology, Garvan Institute of Medical Research, Sydney; Medical Oncology, University of New South Wales, Sydney, Australia.""}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Merck & Co., Inc., Kenilworth.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Jensen', 'Affiliation': 'Merck & Co., Inc., Kenilworth.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ahsan', 'Affiliation': 'Merck & Co., Inc., Kenilworth.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Ibrahim', 'Affiliation': 'Merck & Co., Inc., Kenilworth.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ribas', 'Affiliation': 'Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz011'] 212,30688523,Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).,"BACKGROUND More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage). For this group, high rates of cure can be achieved with the combination of pelvic radiation and sensitizing 5-fluorouracil (chemoradiation), surgery and chemotherapy, but treatment is long, arduous and toxicities are substantial. The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity. The statistical design balanced the twin co-primary goals of achieving low local and distant recurrence rates. Study design features contended with the need for stringent safeguards given limited phase II data, the need for straightforward criteria to facilitate both accrual and protocol fidelity and the importance of patients' perspectives on symptom burden and treatment toxicity. METHODS PROSPECT is an ongoing multi-site two-group seamless phase II/III randomized trial comparing standard neoadjuvant chemoradiation versus neoadjuvant chemotherapy with selective use of chemoradiation for patients with locally advanced rectal cancer. Challenges addressed in the design and conduct of PROSPECT have included the following: (1) setting safety thresholds given limited single-center phase II data, (2) establishing workable eligibility criteria, (3) balancing competing time to local and distant recurrence as co-primary endpoints and (4) obtaining reliable and complete data for patients' symptom burden. The design and implementation challenges, choices, modifications and their implications for the design of future national cooperative group clinical trials are presented. RESULTS PROSPECT incorporated stringent thresholds for both complete surgical resection (R0) and the time to local recurrence as early stopping rules. When predetermined stopping criteria were not met after evaluation of the first 366 participants in the randomized phase II, the study transitioned seamlessly to phase III with cumulative accrual of over 1000 participants. Eligibility criteria stipulating rectal tumor location based on distance from the anal verge were unworkable, and the protocol was amended to a more pragmatic approach that assigned surgeons with primary responsibility for determining eligibility. Central radiology review was feasible and in some cases prompted discontinuation of protocol treatment. Participation in toxicity reporting using the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events was uniformly high and was well accepted by participants from over 200 sites in the United States, Canada and Switzerland. CONCLUSION The strategies used to overcome these obstacles may inform the design of other studies that involve multi-modality treatment interventions, particularly trials where implementation of consistent criteria for eligibility and outcomes across hundreds of practice settings is necessary.",2019,"The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity.","['patients with locally advanced rectal cancer', '366 participants in the randomized phase II, the study transitioned seamlessly to phase III with cumulative accrual of over 1000 participants', '40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage']","['standard neoadjuvant chemoradiation versus neoadjuvant chemotherapy with selective use of chemoradiation', '5-fluorouracil and oxaliplatin (FOLFOX', 'pelvic radiation and sensitizing 5-fluorouracil (chemoradiation), surgery and chemotherapy']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007113', 'cui_str': 'Cancer of Rectum'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205571', 'cui_str': 'Clinical stage II (finding)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0030797', 'cui_str': 'Pelvic Region'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]",[],40000.0,0.0969033,"The PROSPECT trial (N1048, NCT01515787) was designed to determine whether neoadjuvant chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX) could be used as an alternative to neoadjuvant chemoradiation without compromising treatment outcomes and to spare these patients excess toxicity.","[{'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Schrag', 'Affiliation': '1 Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Weiser', 'Affiliation': '2 Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Saltz', 'Affiliation': '3 Department of Medical Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.'}, {'ForeName': 'Harvey', 'Initials': 'H', 'LastName': 'Mamon', 'Affiliation': ""4 Department of Radiation Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Gollub', 'Affiliation': '5 Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA.'}, {'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Basch', 'Affiliation': '6 Division of Medical Oncology, UNC Lineberger Comprehensive Cancer Center and University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Venook', 'Affiliation': '7 Division of Medical Oncology, University of California San Francisco Cancer Center and University of California San Francisco School of Medicine, San Francisco, CA, USA.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Shi', 'Affiliation': '8 Alliance Statistics and Data Center, Mayo Clinic Cancer Center, Rochester, MN, USA.'}]","Clinical trials (London, England)",['10.1177/1740774518824539'] 213,30797707,Clinical prognostic model for older patients with advanced non-small cell lung cancer.,"BACKGROUND Older patients with non-small cell lung cancer (NSCLC) are often not prescribed standard therapy. It is important to know which older patients would be candidates for aggressive therapy based on their prognosis, and to develop a model that can help determine prognosis. METHODS Data on older patients (≥70 years) enrolled on 38 NCI cooperative group trials of advanced NSCLC from 1991 to 2011 were analyzed. Multivariable Cox PH model was built with a stepwise selection. We derived a prognostic score using the estimated Cox PH regression coefficient. We then calculated the area under receiver operating characteristic (ROC) curve of survival in the testing set. RESULTS The final analysis included 1467 patients, who were randomly divided into a training (n = 963) and a testing set (n = 504). The prognostic risk score was calculated as: 3 (if male) + 3 (if PS = 1) + 8 (if PS = 2) + 11 (if initial stage = IV) + 4 (if weight loss). Patients were classified into two prognostic groups: good (0-8) and poor (≥9). The median survival in the two groups in the testing set were 13.15 (95% CI, 10.82-15.91) and 8.52 months (95% CI, 7.5-9.63), respectively. The model had area under the 1-year and 2-year ROCs (0.6 and 0.65, respectively) that were higher than existing models. CONCLUSIONS Male gender, poor performance status, distant metastases and recent weight loss predict for poor overall survival (OS) in older patients with advanced NSCLC. This study proposes a simple prognostic model for older adults with advanced NSCLC.",2019,"The median survival in the two groups in the testing set were 13.15 (95% CI, 10.82-15.91) and 8.52 months (95% CI, 7.5-9.63), respectively.","['older patients with advanced non-small cell lung cancer', 'older adults with advanced NSCLC', 'older patients (≥70\u202fyears) enrolled on 38 NCI cooperative group trials of advanced NSCLC from 1991 to 2011 were analyzed', 'Older patients with non-small cell lung cancer (NSCLC', '1467 patients', 'older patients', 'older patients with advanced NSCLC']",[],"['prognostic risk score', '1-year and 2-year ROCs', 'median survival']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0838813,"The median survival in the two groups in the testing set were 13.15 (95% CI, 10.82-15.91) and 8.52 months (95% CI, 7.5-9.63), respectively.","[{'ForeName': 'Apar Kishor', 'Initials': 'AK', 'LastName': 'Ganti', 'Affiliation': 'VA-Nebraska Western Iowa Health Care System; University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: aganti@unmc.edu.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Stinchcombe', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Yinpeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Bradley', 'Affiliation': 'Washington University School of Medicine, St. Louis, MO. USA.'}, {'ForeName': 'Harvey J', 'Initials': 'HJ', 'LastName': 'Cohen', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Kelly', 'Affiliation': 'University of California Davis Cancer Center, Sacramento, CA. USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Paulus', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Pittsburgh, PA, USA.'}, {'ForeName': 'Suresh S', 'Initials': 'SS', 'LastName': 'Ramalingam', 'Affiliation': 'Winship Cancer Institute of Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Everett E', 'Initials': 'EE', 'LastName': 'Vokes', 'Affiliation': 'University of Chicago, Chicago, IL. USA.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Pang', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA; Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.'}]",Journal of geriatric oncology,['10.1016/j.jgo.2019.02.007'] 214,30889042,An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).,"OBJECTIVES One of the standard of care regimens for advanced pancreatic cancer is gemcitabine-based chemotherapy. The efficacy of gemcitabine is limited by dose-limiting hematologic toxicities especially neutropenia. Uncovering the variability of these toxicities attributed to germline DNA variation is of great importance. PATIENTS AND METHODS CALGB 80303 was a randomized study in advanced pancreatic cancer patients treated with gemcitabine with or without bevacizumab. The study protocol included genotyping of genes of gemcitabine disposition (CDA, DCTD, SLC29A1, SLC28A1, and SLC29A2), as well as a genome-wide analysis. The clinical phenotype was time to early high-grade neutropenia event accounting for progression or death or other treatment-terminating adverse events as competing for informative events. The inference was carried out on the basis of the association between genotype and cause-specific hazard of a neutropenic event. RESULTS The primary analyses were carried out on the basis of 294 genetically estimated European pancreatic cancer patients. For CDA rs2072671 (A>C), AC and CC patients had a lower risk of neutropenia than AA patients (P=0.01, hazard ratio: 0.61, 95% confidence interval: 0.41-0.89). For SLC28A1 rs3825876 (G>A), AA patients have a higher risk of neutropenia than GA and GG patients (P=0.02, hazard ratio: 1.51, 95% confidence interval: 1.06-2.16). CDA rs2072671 was associated with increased mRNA expression in whole blood in three studies (P=2.7e-14, 6.61e-62, and 9.70e-65). In the genome-wide analysis, variants in TGFB2 were among the top hits (lowest P=1.62e-06) but had no effect in luciferase assays. CONCLUSION This is the first genetic analysis of gemcitabine-induced neutropenia using a competing risk model in a prospective randomized clinical study has proposed a potentially novel mechanism of the protective effect of the CDA rs2072671 variant. Further confirmation is needed.",2019,"For CDA rs2072671 (A>C), AC and CC patients had a lower risk of neutropenia than AA patients (P=0.01, hazard ratio: 0.61, 95% confidence interval: 0.41-0.89).","['advanced pancreatic cancer patients treated with', 'advanced pancreatic cancer', 'pancreatic cancer patients in CALGB 80303 (Alliance', '294 genetically estimated European pancreatic cancer patients']","['gemcitabine disposition (CDA, DCTD, SLC29A1, SLC28A1, and SLC29A2', 'gemcitabine', 'gemcitabine with or without bevacizumab', 'gemcitabine-based chemotherapy']","['risk of neutropenia', 'mRNA expression']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0743223', 'cui_str': 'Disposition (disposition)'}, {'cui': 'C0002876', 'cui_str': 'Congenital dyserythropoietic anemia (disorder)'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",,0.0315318,"For CDA rs2072671 (A>C), AC and CC patients had a lower risk of neutropenia than AA patients (P=0.01, hazard ratio: 0.61, 95% confidence interval: 0.41-0.89).","[{'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Innocenti', 'Affiliation': 'UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jiang', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Alexander B', 'Initials': 'AB', 'LastName': 'Sibley', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Denning', 'Affiliation': 'UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Etheridge', 'Affiliation': 'UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Watson', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Ace J', 'Initials': 'AJ', 'LastName': 'Hatch', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Herbert I', 'Initials': 'HI', 'LastName': 'Hurwitz', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Andrew B', 'Initials': 'AB', 'LastName': 'Nixon', 'Affiliation': 'Duke Cancer Institute.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Furukawa', 'Affiliation': 'Center for Genomic Medicine, RIKEN, Yokohama.'}, {'ForeName': 'Michiaki', 'Initials': 'M', 'LastName': 'Kubo', 'Affiliation': 'RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Crona', 'Affiliation': 'UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill.'}, {'ForeName': 'Hedy L', 'Initials': 'HL', 'LastName': 'Kindler', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, Illinois.'}, {'ForeName': 'Howard L', 'Initials': 'HL', 'LastName': 'McLeod', 'Affiliation': 'Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, USA.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Ratain', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, Illinois.'}, {'ForeName': 'Kouros', 'Initials': 'K', 'LastName': 'Owzar', 'Affiliation': 'Duke Cancer Institute.'}]",Pharmacogenetics and genomics,['10.1097/FPC.0000000000000375'] 215,32305124,Effects of Different Immunosuppressive Drugs on Incretins in Renal Transplant Patients.,"BACKGROUND Immunosuppressive drugs used in transplantation patients, may contribute to the development of post-transplant diabetes mellitus through their possible adverse effects on incretins. We aimed to compare the effects of different immunosuppressive drugs used in renal transplantation patients on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels. PATIENTS AND METHODS Forty five subjects were enrolled in the study (cyclosporine-treated 15 and tacrolimus-treated renal transplant patients 15, and healthy volunteers as a control group 15). Oral glucose tolerance test with 75 gr glucose was performed. GLP-1 and GIP levels were measured at 0 (baseline), 30, 60, 90, 120 min using ELISA method. RESULTS A statistically significant level of difference was detected in GLP-1 levels at the baseline, 30th and 120th minutes among all three groups (p < 0,001, p = 0,026 and p = 0,022, respectively). Baseline GLP-1 levels in cyclosporine-treated renal transplant patients were higher than in both tacrolimus-treated renal transplant patients (p = 0,016) and control groups (p < 0,001). GLP-1 levels at the 30th minute were higher in tacrolimus-treated renal transplant patients when compared to the cyclosporine-treated renal transplant patients (p = 0,024). GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024). The areas under the curve of GLP-1 was higher in tacrolimus-treated renal transplant patients when compared to the control group (p = 0,018). GIP levels at 120th was lower in cyclosporine-treated renal transplant patients when compared to control group (p = 0,003). CONCLUSION These findings showed a temporally affected incretin hormones in renal transplant patients, a preserved GLP-1 response to an oral glucose load in renal transplant patients on cyclosporine and increased GLP -1 response to an oral glucose load in those on tacrolimus.",2020,"GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024).","['treated renal transplant patients', 'Renal Transplant Patients', 'transplantation patients', 'renal transplant patients', 'renal transplantation patients on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels', 'treated renal transplant patients 15, and healthy volunteers as a control group 15', 'Forty five subjects were enrolled in the study ']","['cyclosporine', 'Immunosuppressive Drugs', 'cyclosporine-treated 15 and tacrolimus']","['GLP-1 and GIP levels', 'GLP -1 response', 'GIP levels', 'Oral glucose tolerance test', 'Baseline GLP-1 levels', 'curve of GLP-1', 'GLP-1 levels']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0010592', 'cui_str': 'Cyclosporine'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0017132', 'cui_str': 'Gastric inhibitory polypeptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205134', 'cui_str': 'Curved'}]",45.0,0.0200643,"GLP-1 levels at the 120th minute were higher in tacrolimus-treated renal transplant patients than the control group (p = 0,024).","[{'ForeName': 'Nusret', 'Initials': 'N', 'LastName': 'Yilmaz', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Endocrinology, Antalya, Turkey.'}, {'ForeName': 'Ramazan', 'Initials': 'R', 'LastName': 'Sari', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Endocrinology, Antalya, Turkey. Electronic address: drsari@hotmail.com.'}, {'ForeName': 'Gultekin', 'Initials': 'G', 'LastName': 'Suleymanlar', 'Affiliation': 'Akdeniz University, School of Medicine, Division of Nephrology, Antalya, Turkey.'}, {'ForeName': 'Sebahat', 'Initials': 'S', 'LastName': 'Ozdem', 'Affiliation': 'Akdeniz University, School of Medicine, Department of Biochemistry, Antalya, Turkey.'}]",Journal of the National Medical Association,['10.1016/j.jnma.2020.03.012'] 216,32303515,Seizure First Aid Training For people with Epilepsy (SAFE) frequently attending emergency departments and their significant others: results of a UK multi-centre randomised controlled pilot trial.,"OBJECTIVE To determine the feasibility and optimal design of a randomised controlled trial (RCT) of Seizure First Aid Training For Epilepsy (SAFE). DESIGN Pilot RCT with embedded microcosting. SETTING Three English hospital emergency departments (EDs). PARTICIPANTS Patients aged ≥16 with established epilepsy reporting ≥2 ED visits in the prior 12 months and their significant others (SOs). INTERVENTIONS Patients (and their SOs) were randomly allocated (1:1) to SAFE plus treatment-as-usual (TAU) or TAU alone. SAFE is a 4-hour group course. MAIN OUTCOME MEASURES Two criteria evaluated a definitive RCT's feasibility: (1) ≥20% of eligible patients needed to be consented into the pilot trial; (2) routine data on use of ED over the 12 months postrandomisation needed securing for ≥75%. Other measures included eligibility, ease of obtaining routine data, availability of self-report ED data and comparability, SAFE's effect and intervention cost. RESULTS Of ED attendees with a suspected seizure, 424 (10.6%) patients were eligible; 53 (12.5%) patients and 38 SOs consented. Fifty-one patients (and 37 SOs) were randomised. Routine data on ED use at 12 months were secured for 94.1% patients. Self-report ED data were available for 66.7% patients. Patients reported more visits compared with routine data. Most (76.9%) patients randomised to SAFE received it and no related serious adverse events occurred. ED use at 12 months was lower in the SAFE+TAU arm compared with TAU alone, but not significantly (rate ratio=0.62, 95% CI 0.33 to 1.17). A definitive trial would need ~674 patient participants and ~39 recruitment sites. Obtaining routine data was challenging, taking ~8.5 months. CONCLUSIONS In satisfying only one predetermined 'stop/go' criterion, a definitive RCT is not feasible. The low consent rate in the pilot trial raises concerns about a definitive trial's finding's external validity and means it would be expensive to conduct. Research is required into how to optimise recruitment from the target population. TRIAL REGISTRATION NUMBER ISRCTN13871327.",2020,"ED use at 12 months was lower in the SAFE+TAU arm compared with TAU alone, but not significantly (rate ratio=0.62, 95% CI 0.33 to 1.17).","['674 patient participants and ~39 recruitment sites', ""Two criteria evaluated a definitive RCT's feasibility: (1) ≥20% of eligible patients needed to be consented into the pilot trial; (2) routine data on use of ED over the 12\u2009months postrandomisation needed securing for ≥75"", 'Of ED attendees with a suspected seizure, 424 (10.6', 'patients were eligible; 53 (12.5%) patients and 38 SOs consented', 'Patients aged ≥16 with established epilepsy reporting ≥2 ED visits in the prior 12 months and their significant others (SOs', 'people with Epilepsy (SAFE) frequently attending emergency departments and their significant others', 'Fifty-one patients (and 37 SOs', 'Three English hospital emergency departments (EDs']","['TAU', 'Seizure First Aid Training', 'SAFE plus treatment-as-usual (TAU) or TAU alone']","[""eligibility, ease of obtaining routine data, availability of self-report ED data and comparability, SAFE's effect and intervention cost"", 'serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C4225412', 'cui_str': 'Spondylo-ocular syndrome'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",3.0,0.14735,"ED use at 12 months was lower in the SAFE+TAU arm compared with TAU alone, but not significantly (rate ratio=0.62, 95% CI 0.33 to 1.17).","[{'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Noble', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, UK adam.noble@liverpool.ac.uk.'}, {'ForeName': 'Dee', 'Initials': 'D', 'LastName': 'Snape', 'Affiliation': 'Department of Health Services Research, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Nevitt', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Holmes', 'Affiliation': 'Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor, UK.'}, {'ForeName': 'Myfanwy', 'Initials': 'M', 'LastName': 'Morgan', 'Affiliation': ""Institute of Pharmaceutical Science, King's College London, London, UK.""}, {'ForeName': 'Catrin', 'Initials': 'C', 'LastName': 'Tudur-Smith', 'Affiliation': 'Department of Biostatistics, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Dyfrig A', 'Initials': 'DA', 'LastName': 'Hughes', 'Affiliation': 'Centre for Health Economics & Medicines Evaluation, Bangor University, Bangor, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Buchanan', 'Affiliation': 'Emergency Department, Arrowe Park Hospital, Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'McVicar', 'Affiliation': 'MacKinnon Memorial Hospital / Broadford Hospital, NHS Highland, Broadford, Isle of Skye, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'MacCallum', 'Affiliation': 'Emergency Department, Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Goodacre', 'Affiliation': 'School of Health and Related Research, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Leone', 'Initials': 'L', 'LastName': 'Ridsdale', 'Affiliation': ""Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Anthony G', 'Initials': 'AG', 'LastName': 'Marson', 'Affiliation': 'Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035516'] 217,32212268,"Death audits and reviews for reducing maternal, perinatal and child mortality.","BACKGROUND The United Nations' Sustainable Development Goals (SDGs) include reducing the global maternal mortality rate to less than 70 per 100,000 live births and ending preventable deaths of newborns and children under five years of age, in every country, by 2030. Maternal and perinatal death audit and review is widely recommended as an intervention to reduce maternal and perinatal mortality, and to improve quality of care, and could be key to attaining the SDGs. However, there is uncertainty over the most cost-effective way of auditing and reviewing deaths: community-based audit (verbal and social autopsy), facility-based audits (significant event analysis (SEA)) or a combination of both (confidential enquiry). OBJECTIVES To assess the impact and cost-effectiveness of different types of death audits and reviews in reducing maternal, perinatal and child mortality. SEARCH METHODS We searched the following from inception to 16 January 2019: CENTRAL, Ovid MEDLINE, Embase OvidSP, and five other databases. We identified ongoing studies using ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform, and searched reference lists of included articles. SELECTION CRITERIA Cluster-randomised trials, cluster non-randomised trials, controlled before-and-after studies and interrupted time series studies of any form of death audit or review that involved reviewing individual cases of maternal, perinatal or child deaths, identifying avoidable factors, and making recommendations. To be included in the review, a study needed to report at least one of the following outcomes: perinatal mortality rate; stillbirth rate; neonatal mortality rate; mortality rate in children under five years of age or maternal mortality rate. DATA COLLECTION AND ANALYSIS We used standard Cochrane Effective Practice and Organisation of Care (EPOC) group methodological procedures. Two review authors independently extracted data, assessed risk of bias and assessed the certainty of the evidence using GRADE. We planned to perform a meta-analysis using a random-effects model but included studies were not homogeneous enough to make pooling their results meaningful. MAIN RESULTS We included two cluster-randomised trials. Both introduced death review and audit as part of a multicomponent intervention, and compared this to current care. The QUARITE study (QUAlity of care, RIsk management, and TEchnology) concerned maternal death reviews in hospitals in West Africa, which had very high maternal and perinatal mortality rates. In contrast, the OPERA trial studied perinatal morbidity/mortality conferences (MMCs) in maternity units in France, which already had very low perinatal mortality rates at baseline. The OPERA intervention in France started with an outreach visit to brief obstetricians, midwives and anaesthetists on the national guidelines on morbidity/mortality case management, and was followed by a series of perinatal MMCs. Half of the intervention units were randomised to receive additional support from a clinical psychologist during these meetings. The OPERA intervention may make little or no difference to overall perinatal mortality (low certainty evidence), however we are uncertain about the effect of the intervention on perinatal mortality related to suboptimal care (very low certainty evidence).The intervention probably reduces perinatal morbidity related to suboptimal care (unadjusted odds ratio (OR) 0.62, 95% confidence interval (CI) 0.40 to 0.95; 165,353 births; moderate-certainty evidence). The effect of the intervention on stillbirth rate, neonatal mortality, mortality rate in children under five years of age, maternal mortality or adverse effects was not reported. The QUARITE intervention in West Africa focused on training leaders of hospital obstetric teams using the ALARM (Advances in Labour And Risk Management) course, which included one day of training about conducting maternal death reviews. The leaders returned to their hospitals, established a multidisciplinary committee and started auditing maternal deaths, with the support of external facilitators. The intervention probably reduces inpatient maternal deaths (adjusted OR 0.85, 95% CI 0.73 to 0.98; 191,167 deliveries; moderate certainty evidence) and probably also reduces inpatient neonatal mortality within 24 hours following birth (adjusted OR 0.74, 95% CI 0.61 to 0.90; moderate certainty evidence). However, QUARITE probably makes little or no difference to the inpatient stillbirth rate (moderate certainty evidence) and may make little or no difference to the inpatient neonatal mortality rate after 24 hours, although the 95% confidence interval includes both benefit and harm (low certainty evidence). The QUARITE intervention probably increases the percent of women receiving high quality of care (OR 1.87, 95% CI 1.35 - 2.57, moderate-certainty evidence). The effect of the intervention on perinatal mortality, mortality rate in children under five years of age, or adverse effects was not reported. We did not find any studies that evaluated child death audit and review or community-based death reviews or costs. AUTHORS' CONCLUSIONS A complex intervention including maternal death audit and review, as well as development of local leadership and training, probably reduces inpatient maternal mortality in low-income country district hospitals, and probably slightly improves quality of care. Perinatal death audit and review, as part of a complex intervention with training, probably improves quality of care, as measured by perinatal morbidity related to suboptimal care, in a high-income setting where mortality was already very low. The WHO recommends that maternal and perinatal death reviews should be conducted in all hospitals globally. However, conducting death reviews in isolation may not be sufficient to achieve the reductions in mortality observed in the QUARITE trial. This review suggests that maternal death audit and review may need to be implemented as part of an intervention package which also includes elements such as training of a leading doctor and midwife in each hospital, annual recertification, and quarterly outreach visits by external facilitators to provide supervision and mentorship. The same may also apply to perinatal and child death reviews. More operational research is needed on the most cost-effective ways of implementing maternal, perinatal and paediatric death reviews in low- and middle-income countries.",2020,"The intervention probably reduces inpatient maternal deaths (adjusted OR 0.85, 95% CI 0.73 to 0.98; 191,167 deliveries; moderate certainty evidence) and probably also reduces inpatient neonatal mortality within 24 hours following birth (adjusted OR 0.74, 95% CI 0.61 to 0.90; moderate certainty evidence).","['children under five years of age', 'low-income country district hospitals', 'children under five years of age or maternal mortality rate']",['OPERA intervention'],"['mortality', 'overall perinatal mortality', 'perinatal morbidity/mortality conferences (MMCs', 'inpatient maternal deaths', 'stillbirth rate, neonatal mortality, mortality rate', 'perinatal mortality rate; stillbirth rate; neonatal mortality rate; mortality rate', 'inpatient neonatal mortality', 'percent of women receiving high quality of care', 'inpatient stillbirth rate', 'global maternal mortality rate', 'perinatal mortality rates', 'perinatal mortality, mortality rate', 'maternal mortality or adverse effects', 'inpatient neonatal mortality rate']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0020006', 'cui_str': 'Hospitals, District'}, {'cui': 'C0024923', 'cui_str': 'Maternal Mortality'}]",[],"[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0031062', 'cui_str': 'Perinatal Mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0086047', 'cui_str': 'Conferences'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C3494405', 'cui_str': 'Maternal Death'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0024923', 'cui_str': 'Maternal Mortality'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",,0.149034,"The intervention probably reduces inpatient maternal deaths (adjusted OR 0.85, 95% CI 0.73 to 0.98; 191,167 deliveries; moderate certainty evidence) and probably also reduces inpatient neonatal mortality within 24 hours following birth (adjusted OR 0.74, 95% CI 0.61 to 0.90; moderate certainty evidence).","[{'ForeName': 'Merlin L', 'Initials': 'ML', 'LastName': 'Willcox', 'Affiliation': 'University of Southampton, Aldermoor Health Centre, Department of Primary Care and Population Sciences, Aldermoor Close, Southampton, Hampshire, UK, SO16 5ST.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Price', 'Affiliation': 'University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Scott', 'Affiliation': 'University of Southampton, Aldermoor Health Centre, Department of Primary Care and Population Sciences, Aldermoor Close, Southampton, Hampshire, UK, SO16 5ST.'}, {'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Nicholson', 'Affiliation': 'University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK.'}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Stuart', 'Affiliation': 'University of Southampton, Primary Care and Population Sciences, Faculty of Medicine, Southampton, UK, SO16 5ST.'}, {'ForeName': 'Nia W', 'Initials': 'NW', 'LastName': 'Roberts', 'Affiliation': 'University of Oxford, Bodleian Health Care Libraries, Knowledge Centre, ORC Research Building, Old Road Campus, Oxford, Oxfordshire, UK, OX3 7DQ.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Allott', 'Affiliation': 'Liverpool School of Tropical Medicine, Centre for Maternal and Newborn Health, Pembroke Pl, Liverpool, UK, L3 5QA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Mubangizi', 'Affiliation': 'Mbarara University of Science and Technology (MUST), Family medicine and community practice, MUST, PLOT 10-18, KABALE ROAD, Mbarara, Uganda, 1410, Mbarara.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Dumont', 'Affiliation': 'Institut de recherche pour le développement, Paris Descartes University, UMR 196 CEPED, Faculté de Pharmacie, 4 avenue de l?Observatoire, Paris, France, 75006.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Harnden', 'Affiliation': 'University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012982.pub2'] 218,31375713,Enhanced Depth Navigation Through Augmented Reality Depth Mapping in Patients with Low Vision.,"Patients diagnosed with Retinitis Pigmentosa (RP) show, in the advanced stage of the disease, severely restricted peripheral vision causing poor mobility and decline in quality of life. This vision loss causes difficulty identifying obstacles and their relative distances. Thus, RP patients use mobility aids such as canes to navigate, especially in dark environments. A number of high-tech visual aids using virtual reality (VR) and sensory substitution have been developed to support or supplant traditional visual aids. These have not achieved widespread use because they are difficult to use or block off residual vision. This paper presents a unique depth to high-contrast pseudocolor mapping overlay developed and tested on a Microsoft Hololens 1 as a low vision aid for RP patients. A single-masked and randomized trial of the AR pseudocolor low vision aid to evaluate real world mobility and near obstacle avoidance was conducted consisting of 10 RP subjects. An FDA-validated functional obstacle course and a custom-made grasping setup were used. The use of the AR visual aid reduced collisions by 50% in mobility testing (p = 0.02), and by 70% in grasp testing (p = 0.03). This paper introduces a new technique, the pseudocolor wireframe, and reports the first significant statistics showing improvements for the population of RP patients with mobility and grasp.",2019,"The use of the AR visual aid reduced collisions by 50% in mobility testing (p = 0.02), and by 70% in grasp testing (p = 0.03).","['Patients with Low Vision', '10 RP subjects', 'Patients diagnosed with Retinitis Pigmentosa (RP']","['virtual reality (VR) and sensory substitution', 'AR pseudocolor low vision']",['quality of life'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042798', 'cui_str': 'Vision, Diminished'}, {'cui': 'C0035334', 'cui_str': 'Pigmentary Retinopathy'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0042798', 'cui_str': 'Vision, Diminished'}]",[{'cui': 'C0034380'}],,0.0267623,"The use of the AR visual aid reduced collisions by 50% in mobility testing (p = 0.02), and by 70% in grasp testing (p = 0.03).","[{'ForeName': 'Anastasios Nikolas', 'Initials': 'AN', 'LastName': 'Angelopoulos', 'Affiliation': 'University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA. nikolasa@stanford.edu.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Ameri', 'Affiliation': 'University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Mitra', 'Affiliation': 'University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Humayun', 'Affiliation': 'University of Southern California, USC Ginsburg Institute for Biomedical Therapeutics, Los Angeles, 90033, USA. humayun@med.usc.edu.'}]",Scientific reports,['10.1038/s41598-019-47397-w'] 219,31227493,How do the costs of physical therapy and arthroscopic partial meniscectomy compare? A trial-based economic evaluation of two treatments in patients with meniscal tears alongside the ESCAPE study.,"OBJECTIVES To examine whether physical therapy (PT) is cost-effective compared with arthroscopic partial meniscectomy (APM) in patients with a non-obstructive meniscal tear, we performed a full trial-based economic evaluation from a societal perspective. In a secondary analysis-this paper-we examined whether PT is non-inferior to APM. METHODS We recruited patients aged 45-70 years with a non-obstructive meniscal tear in nine Dutch hospitals. Resource use was measured using web-based questionnaires. Measures of effectiveness included knee function using the International Knee Documentation Committee (IKDC) and quality-adjusted life-years (QALYs). Follow-up was 24 months. Uncertainty was assessed using bootstrapping techniques. The non-inferiority margins for societal costs, the IKDC and QALYs, were €670, 8 points and 0.057 points, respectively. RESULTS We randomly assigned 321 patients to PT (n=162) or APM (n=159). PT was associated with significantly lower costs after 24 months compared with APM (-€1803; 95% CI -€3008 to -€838). The probability of PT being cost-effective compared with APM was 1.00 at a willingness to pay of €0/unit of effect for the IKDC (knee function) and QALYs (quality of life) and decreased with increasing values of willingness to pay. The probability that PT is non-inferior to APM was 0.97 for all non-inferiority margins for the IKDC and 0.89 for QALYs. CONCLUSIONS The probability of PT being cost-effective compared with APM was relatively high at reasonable values of willingness to pay for the IKDC and QALYs. Also, PT had a relatively high probability of being non-inferior to APM for both outcomes. This warrants further deimplementation of APM in patients with non-obstructive meniscal tears. TRIAL REGISTRATION NUMBERS NCT01850719 and NTR3908.",2020,PT was associated with significantly lower costs after 24 months compared with APM (-€1803; 95% CI -€3008 to -€838).,"['patients with a non-obstructive meniscal tear', '321 patients to PT (n=162) or APM (n=159', 'patients with non-obstructive meniscal tears', 'patients with meniscal tears alongside the ESCAPE study', 'patients aged 45-70 years with a non-obstructive meniscal tear in nine Dutch hospitals']","['physical therapy (PT', 'arthroscopic partial meniscectomy (APM']","['probability of PT being cost-effective', 'International Knee Documentation Committee (IKDC) and quality-adjusted life-years (QALYs', 'IKDC (knee function) and QALYs (quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205304', 'cui_str': 'Non-obstructive (qualifier value)'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0187901', 'cui_str': 'Meniscal Resection'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0034380'}]",321.0,0.0651893,PT was associated with significantly lower costs after 24 months compared with APM (-€1803; 95% CI -€3008 to -€838).,"[{'ForeName': 'Victor A', 'Initials': 'VA', 'LastName': 'van de Graaf', 'Affiliation': 'Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands v.a.vandegraaf@olvg.nl.'}, {'ForeName': 'Johanna M', 'Initials': 'JM', 'LastName': 'van Dongen', 'Affiliation': 'Department of Health Sciences, VU University, Amsterdam, The Netherlands.'}, {'ForeName': 'Nienke W', 'Initials': 'NW', 'LastName': 'Willigenburg', 'Affiliation': 'Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands.'}, {'ForeName': 'Julia C A', 'Initials': 'JCA', 'LastName': 'Noorduyn', 'Affiliation': 'Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands.'}, {'ForeName': 'Ise K', 'Initials': 'IK', 'LastName': 'Butter', 'Affiliation': 'Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'de Gast', 'Affiliation': 'Department of Orthopaedic Surgery, Clinical Orthopaedic Research Centre - mN, Diakonessenhuis, Utrecht, The Netherlands.'}, {'ForeName': 'Daniel B F', 'Initials': 'DBF', 'LastName': 'Saris', 'Affiliation': 'Department of Orthopaedic Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Maurits W', 'Initials': 'MW', 'LastName': 'van Tulder', 'Affiliation': 'Department of Health Sciences, VU University, Amsterdam, The Netherlands.'}, {'ForeName': 'Rudolf W', 'Initials': 'RW', 'LastName': 'Poolman', 'Affiliation': 'Department of Orthopaedic Surgery, Joint Research, OLVG, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of sports medicine,['10.1136/bjsports-2018-100065'] 220,31833175,Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel.,"BACKGROUND Platelet P2Y12 antagonist ticagrelor reduces mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets, leukocytes, and endothelial cells release proinflammatory and prothrombotic extracellular vesicles (EVs), we hypothesized that the release of EVs is more efficiently inhibited by ticagrelor compared to clopidogrel. OBJECTIVES We compared EV concentrations and EV procoagulant activity in plasma of patients after AMI treated with ticagrelor or clopidogrel. METHODS After percutaneous coronary intervention, 60 patients with first AMI were randomized to ticagrelor or clopidogrel. Flow cytometry was used to determine concentrations of EVs from activated platelets (CD61 + , CD62p + ), fibrinogen + , phosphatidylserine (PS + ), leukocytes (CD45 + ), endothelial cells (CD31 + , 146 + ), and erythrocytes (CD235a + ) in plasma at randomization, after 72 hours and 6 months of treatment. A fibrin generation test was used to determine EV procoagulant activity. RESULTS Concentrations of platelet, fibrinogen + , PS + , leukocyte, and erythrocyte EVs increased 6 months after AMI compared to the acute phase of AMI (P ≤ .03). Concentrations of platelet EVs were lower on ticagrelor compared to clopidogrel after 6 months (P = .03). Concentrations of fibrinogen + , PS + , and leukocyte EVs were lower on ticagrelor compared to clopidogrel both after 72 hours and 6 months (P ≤ .03). Concentrations of endothelial EVs and EV procoagulant activity did not differ between patient groups and over time (P ≥ .17). CONCLUSIONS Ticagrelor attenuates the increase of EV concentrations in plasma after acute myocardial infarction compared to clopidogrel. The ongoing release of EVs despite antiplatelet therapy might explain recurrent thrombotic events after AMI and worse clinical outcomes on clopidogrel compared to ticagrelor.",2020,Concentrations of platelet EVs were lower on ticagrelor compared to clopidogrel after 6 months (P = .03).,['60 patients with first AMI'],"['clopidogrel', 'ticagrelor or clopidogrel', 'Ticagrelor', 'percutaneous coronary intervention', 'ticagrelor', 'Platelet P2Y12 antagonist ticagrelor']","['Concentrations of platelet EVs', 'Concentrations of endothelial EVs and EV procoagulant activity', 'EV concentrations', 'Concentrations of platelet, fibrinogen + , PS + , leukocyte, and erythrocyte EVs', 'EV concentrations and EV procoagulant activity', 'concentrations of EVs from activated platelets (CD61 + , CD62p + ), fibrinogen + , phosphatidylserine (PS + ), leukocytes (CD45 + ), endothelial cells (CD31 + , 146 + ), and erythrocytes (CD235a + ) in plasma', 'Concentrations of fibrinogen + , PS + , and leukocyte EVs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0031623', 'cui_str': 'Phosphatidyl Serines'}, {'cui': 'C0225336', 'cui_str': 'Endothelial Cells'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",60.0,0.0264082,Concentrations of platelet EVs were lower on ticagrelor compared to clopidogrel after 6 months (P = .03).,"[{'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Gasecka', 'Affiliation': 'First Chair and Department of Cardiology, Medical University of Warsaw, Poland.'}, {'ForeName': 'Rienk', 'Initials': 'R', 'LastName': 'Nieuwland', 'Affiliation': 'Vesicle Observation Centre, and Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, the Netherlands.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Budnik', 'Affiliation': 'First Chair and Department of Cardiology, Medical University of Warsaw, Poland.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Dignat-George', 'Affiliation': 'INSERM, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Ceren', 'Initials': 'C', 'LastName': 'Eyileten', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Harrison', 'Affiliation': 'Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Romaric', 'Initials': 'R', 'LastName': 'Lacroix', 'Affiliation': 'INSERM, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'Leroyer', 'Affiliation': 'INSERM, Faculty of Pharmacy, Aix-Marseille University, Marseille, France.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Opolski', 'Affiliation': 'First Chair and Department of Cardiology, Medical University of Warsaw, Poland.'}, {'ForeName': 'Kinga', 'Initials': 'K', 'LastName': 'Pluta', 'Affiliation': 'First Chair and Department of Cardiology, Medical University of Warsaw, Poland.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'van der Pol', 'Affiliation': 'Vesicle Observation Centre, and Laboratory of Experimental Clinical Chemistry, Amsterdam UMC, University of Amsterdam, the Netherlands.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Postuła', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, Poland.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Siljander', 'Affiliation': 'EV-group, Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Finland.'}, {'ForeName': 'Jolanta M', 'Initials': 'JM', 'LastName': 'Siller-Matula', 'Affiliation': 'Department of Cardiology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Krzysztof J', 'Initials': 'KJ', 'LastName': 'Filipiak', 'Affiliation': 'First Chair and Department of Cardiology, Medical University of Warsaw, Poland.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14689'] 221,31279324,Effects of hydrocortisone on autobiographical memory retrieval in patients with posttraumatic stress disorder and borderline personality disorder: the role of childhood trauma.,"In a previous study, we found that patients with posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD) showed better autobiographical memory (AM) retrieval after hydrocortisone administration than after placebo administration. Here we investigate the neural correlates of AM retrieval after hydrocortisone administration in patients with PTSD or BPD. We recruited 78 female participants for this placebo-controlled crossover study: 40 healthy controls, 20 patients with PTSD, and 18 patients with BPD (all without medication). All participants received an oral placebo or 10 mg hydrocortisone in a randomized order before performing an AM task. Neural activity was monitored during the task by functional magnetic resonance imaging. Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake. Multiple regression analysis revealed that Childhood Trauma Questionnaire scores correlated positively with hydrocortisone effects on activation in the anterior medial prefrontal cortex (amPFC), ventrolateral prefrontal cortex (vlPFC), posterior cingulate cortex (PCC), angular gyrus, and cerebellum. These results suggest that hydrocortisone-induced neural activation pattern during AM retrieval is related to childhood trauma. Previously described effects in the hippocampus, which were absent in the current study, might be related to PTSD caused by trauma in adulthood. The effects of hydrocortisone on brain activation and how these effects are influenced by childhood trauma, trauma in adulthood, and PTSD symptoms should be determined in future studies.",2019,"Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake.","['patients with PTSD or BPD', 'patients with posttraumatic stress disorder (PTSD) and borderline personality disorder (BPD', '78 female participants for this placebo-controlled crossover study: 40 healthy controls, 20 patients with PTSD, and 18 patients with BPD (all without medication', 'patients with posttraumatic stress disorder and borderline personality disorder']","['oral placebo', 'hydrocortisone']","['Neural activation', 'autobiographical memory retrieval', 'Childhood Trauma Questionnaire scores', 'autobiographical memory (AM) retrieval', 'anterior medial prefrontal cortex (amPFC), ventrolateral prefrontal cortex (vlPFC), posterior cingulate cortex (PCC), angular gyrus, and cerebellum', 'brain activation', 'Neural activity', 'neural activation pattern']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0006012', 'cui_str': 'Borderline Personality Disorder'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}]","[{'cui': 'C0561843', 'cui_str': 'Autobiographical Memory'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C3266730', 'cui_str': 'Ventrolateral'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate'}, {'cui': 'C0152305', 'cui_str': 'Prelunate Gyrus'}, {'cui': 'C0007765', 'cui_str': 'Parencephalon'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]",78.0,0.0472001,"Neural activation did not differ between the three groups during AM retrieval, neither in the placebo condition nor after hydrocortisone intake.","[{'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Metz', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany. sophie.metz@charite.de.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Fleischer', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Gärnter', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Golde', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Duesenberg', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Roepke', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Oliver T', 'Initials': 'OT', 'LastName': 'Wolf', 'Affiliation': 'Department of Cognitive Psychology, Institute of Cognitive Neuroscience, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, 12203, Germany.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0459-8'] 222,32309918,Novel cardiovascular biomarkers in patients with cardiovascular diseases undergoing intensive physical exercise.,"BACKGROUND In this trial, we analyzed the plasma levels of novel biomarkers that reflect different pathophysiological pathways (sST2: mechanical strain, IGF-BP2: metabolic pathways, suPAR and GDF-15: inflammatory processes) in patients undergoing physical exercise to investigate the effects of training on their plasma concentrations. METHODS Plasma concentrations of novel biomarkers (sST2, IGF-BP2, suPAR and GDF-15) were analyzed by means of ELISA in patients with stable coronary artery disease (CAD) undergoing four weeks of high- and moderate-intensity training (EXCITE Trial) and in patients with one or more cardiovascular risk factors undergoing eight months of intensive physical exercise (IGF-BP2). Plasma levels of sST2 in patients undergoing eight months of intensive exercise have been published previously by our study group (1.13-fold change, P=0.045). RESULTS Four weeks of high-intensity exercise training resulted in a statistically significant change in the plasma level of sST2 (1.106-fold change, P=0.0054) and IGF-BP2 (1.24-fold-change, P=0.0165). Eight months of intensive exercise resulted in a significant increase of IGF-BP2 (median 61.2 ng/mL to 80.7 ng/mL, 1.319-fold change, P=0.006). CONCLUSIONS The significant increase of sST2 after four weeks might be a short-term effect due to the mechanical strain caused by the high-intensity training program, whereas the increase in IGF-BP2 after four weeks and eight months is likely a result of metabolic changes due to physical exercise.",2020,"Eight months of intensive exercise resulted in a significant increase of IGF- BP2 (median 61.2 ng/mL to 80.7 ng/mL, 1.319-fold change, p= 0.006). ","['patients undergoing', 'patients with cardiovascular diseases undergoing intensive physical exercise', 'patients undergoing eight months of', 'patients with stable coronary artery disease (CAD) undergoing four weeks of high- and moderate-intensity training (EXCITE trial) and in patients with one or more cardiovascular risk factors undergoing eight months of']","['intensive physical exercise (IGF-BP2', 'physical exercise', 'intensive exercise', 'high-intensity exercise training']","['Plasma levels of sST2', 'plasma level of sST2', 'novel biomarkers (sST2, IGF-BP2, suPAR and GDF-15', 'IGF-BP2', 'sST2', 'IGF- BP2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0668195', 'cui_str': 'Macrophage Inhibitory Cytokine 1'}]",,0.0334396,"Eight months of intensive exercise resulted in a significant increase of IGF- BP2 (median 61.2 ng/mL to 80.7 ng/mL, 1.319-fold change, p= 0.006). ","[{'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Mirna', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria - m.mirna@salk.at.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lichtenauer', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Wernly', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Paar', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jung', 'Affiliation': 'Division of Cardiology, Pulmonology, and Vascular Medicine, Faculty of Medicine, Heinrich Heine University, Duesseldorf, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Kretzschmar', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine I, Friedrich Schiller University, Jena, Germany.'}, {'ForeName': 'Madlen', 'Initials': 'M', 'LastName': 'Uhlemann', 'Affiliation': 'Department of Cardiology, Heart Center Leipzig, Leipzig, Germany.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Franz', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine I, Friedrich Schiller University, Jena, Germany.'}, {'ForeName': 'Uta C', 'Initials': 'UC', 'LastName': 'Hoppe', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Paracelsus Medical University of Salzburg, Salzburg, Austria.'}, {'ForeName': 'P Christian', 'Initials': 'PC', 'LastName': 'Schulze', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine I, Friedrich Schiller University, Jena, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Hilberg', 'Affiliation': 'Faculty II/Sports Science, Sports Medicine, University of Wuppertal, Wuppertal, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Adams', 'Affiliation': 'Department of Internal Medicine and Cardiology, Heart Center Dresden, Technical University, Dresden, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sponder', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Möbius-Winkler', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine I, Friedrich Schiller University, Jena, Germany.'}]",Panminerva medica,['10.23736/S0031-0808.20.03838-0'] 223,32314466,Use of an emollient-containing diaper and pH-buffered wipe regimen restores skin pH and reduces residual enzymatic activity.,"BACKGROUND/OBJECTIVES Diaper dermatitis is one of the most frequent skin conditions affecting infants and is associated with elevated skin pH, exposure to urine and feces, and increased fecal protease and lipase activity, resulting in stratum corneum barrier damage and increased risk of infection. The study aim was to determine the impact of two diaper and wipe regimens on newborn infant skin pH and residual enzyme activity after stool cleaning. METHODS Two diaper and wipe regimens were compared in a randomized, single-blinded crossover study. Regimen A paired an emollient-containing diaper with an acidic, pH-buffered wipe. Regimen B was a non-emollient diaper and wipe with limited buffering capacity. A 3-day washout period preceded each 3-day regimen use period. Skin pH at the perianal/buttocks interface (PBI), genital region, and undiapered chest control were measured at baseline and day 3. Skin swabs were collected for residual enzyme activity after a stool cleaning event. RESULTS Diapered skin pH at the PBI was similar to undiapered skin after 3 days of use for Regimen A, while PBI pH for Regimen B was elevated versus control. PBI pH was lower for Regimen A versus Regimen B. After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. CONCLUSIONS These results suggest that the use of an emollient-containing diaper with a pH-buffered wipe creates conditions favorable to optimum diapered skin health.",2020,"After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. ",['Two diaper and wipe regimens'],"['emollient-containing diaper with an acidic, pH-buffered wipe']","['Diapered skin pH', 'PBI pH', 'Skin pH at the perianal/buttocks interface (PBI), genital region, and undiapered chest control', 'residual enzyme activity', 'newborn infant skin pH and residual enzyme activity', 'residual enzymatic activity']","[{'cui': 'C0180416', 'cui_str': 'Diaper'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0013983', 'cui_str': 'Emollient'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0180416', 'cui_str': 'Diaper'}, {'cui': 'C0001128', 'cui_str': 'Acid'}, {'cui': 'C0006353', 'cui_str': 'Buffers'}]","[{'cui': 'C0232445', 'cui_str': 'Acid mantle'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0006497', 'cui_str': 'Buttock structure'}, {'cui': 'C0446509', 'cui_str': 'Genital region'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.033102,"After a stool cleaning, PBI skin pH for Regimen A was lower immediately and had lower residual enzyme activity versus Regimen B (P < .05), and the pH-lowering effect was sustained up to 60 minutes. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Gustin', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bohman', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Ogle', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Tanuja', 'Initials': 'T', 'LastName': 'Chaudhary', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Fadayel', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Mitchell', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Narendran', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Marty O', 'Initials': 'MO', 'LastName': 'Visscher', 'Affiliation': 'James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Andrew N', 'Initials': 'AN', 'LastName': 'Carr', 'Affiliation': 'The Procter and Gamble Company, Cincinnati, OH, USA.'}]",Pediatric dermatology,['10.1111/pde.14169'] 224,31421635,Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.,"Increasing evidence supports a rapid antidepressant and antisuicidal effect of a single subanesthetic dose of ketamine infusion for treatment-resistant depression (TRD). Maintaining the initial clinical response after ketamine infusion in TRD is a crucial next-step challenge. D-cycloserine (DCS), a partial agonist of the glycine co-agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, is potentially effective as a depression augmentation treatment. However, whether DCS maintains the antidepressant and antisuicidal effects of ketamine infusion remains unknown. In all, 32 patients with TRD (17 with major depression and 15 with bipolar depression) who responded to ketamine infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47 ± 4.11 at baseline were randomly divided to 6-week DCS treatment (250 mg for 2 days, 500 mg for 2 days, 750 mg for 3 days, and 1000 mg for 5 weeks) and placebo groups. Depression symptoms were rated at timepoints of dose titration and weekly. During the 6-week treatment, the total scores of HAMD did not differ between the DCS and placebo groups. The results remained consistent when stratified by disorder. A mixed model analysis indicated that the DCS group exhibited lower scores of HAMD item 3 (suicide) compared with the placebo group throughout the follow-up period (p = 0.01). A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group. DCS may be therapeutically beneficial for patients with TRD who responded to ketamine infusion but have a residual suicidal risk.",2019,A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group.,"['32 patients with TRD (17 with major depression and 15 with bipolar depression', 'infusion with an average 17-item Hamilton Depression Rating Scale (HAMD) score of 9.47\u2009±\u20094.11 at baseline', 'patients with treatment-resistant depression who responded to low-dose ketamine infusion', 'patients with TRD']","['DCS treatment', 'placebo', 'DCS', 'ketamine', 'D-cycloserine (DCS', 'D-cycloserine']","['total scores of HAMD', 'Depression symptoms', 'HAMD item 3 (suicide']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0005587', 'cui_str': 'Depression, Bipolar'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}]",,0.143272,A superior maintenance of the antisuicidal effect of ketamine was observed in the DCS group than in the placebo group.,"[{'ForeName': 'Mu-Hong', 'Initials': 'MH', 'LastName': 'Chen', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chih-Ming', 'Initials': 'CM', 'LastName': 'Cheng', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Wei-Chen', 'Initials': 'WC', 'LastName': 'Lin', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Ta', 'Initials': 'CT', 'LastName': 'Li', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Chen-Jee', 'Initials': 'CJ', 'LastName': 'Hong', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Pei-Chi', 'Initials': 'PC', 'LastName': 'Tu', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Ya-Mei', 'Initials': 'YM', 'LastName': 'Bai', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Shih-Jen', 'Initials': 'SJ', 'LastName': 'Tsai', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krystal', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. john.krystal@yale.edu.'}, {'ForeName': 'Tung-Ping', 'Initials': 'TP', 'LastName': 'Su', 'Affiliation': 'Division of Psychiatry, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan. tomsu0402@gmail.com.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0480-y'] 225,31997543,Comprehensive geriatric intervention in community-dwelling older adults: a cluster-randomized controlled trial.,"BACKGROUND In longevity societies, one of the most serious social issues is sarcopenia and/or frailty. Preventing them is important for maintaining independence and quality of life in the older population. This study investigated the effect of a self-monitoring comprehensive geriatric intervention programme (CGIP) on physical function and muscle size in community-dwelling older adults. We compared the effects of a CGIP using weekly class-styled (CS) sessions and a home-based (HB) programme. METHODS The 526 participants were randomized into one of two groups (CS 251, HB 275) based on their residential districts. We conducted a 12 week CGIP, which consisted of low-load resistance exercise, physical activity increments, oral function improvements, and a nutritional guide. All participants were encouraged to attend two 90 min lectures that included instructions on the CGIP. They were provided with exercise materials (triaxial-accelerometers/pedometers, ankle weights, and elastic bands) and diary logs. The CS group attended 90 min weekly sessions and independently executed the programme on other days, whereas the HB group only received instructions on how to execute the programme. Physical functions, such as knee extension strength (KES), normal and maximum walking speed, the timed up-and-go test, and anterior thigh muscle thickness (MT), were measured and analysed using intention-to-treat analysis before and after the 12 week intervention. RESULTS Of the 526 participants identified, 517 (CS 243 age 74.0 ± 5.4 women 57.2%, HB 274 age 74.0 ± 5.6 women 58.8%) were enrolled. Nine (CS 8, HB 1) were excluded from the analysis because they did not participate in the pre-intervention measurements. Both interventions significantly improved KES (CS 18.5%, HB 10.6%), normal walking speed (CS 3.7%, HB 2.8%), and MT (CS 3.2%, HB 3.5%). Greater improvement of KES was observed in the CS group (P = 0.003). Maximum walking speed (CS 4.7%, HB 1.8%; P = 0.001) and timed up-and-go (CS -4.7%, HB -0.2%; P < 0.001) significantly improved in the CS group only. CONCLUSIONS The intervention was effective in preventing sarcopenia and/or frailty. Most physical functions and MT improved after both interventions. The HB intervention is cost-effective and may help prevent sarcopenia and/or frailty in the large older population.",2020,"Maximum walking speed (CS 4.7%, HB 1.8%; P = 0.001) and timed up-and-go (CS -4.7%, HB -0.2%; P < 0.001) significantly improved in the CS group only. ","['community-dwelling older adults', '526 participants were randomized into one of two groups (CS 251, HB 275) based on their residential districts', '526 participants identified', ' 517 (CS 243 age 74.0 ± 5.4 women 57.2%, HB 274 age 74.0 ± 5.6 women 58.8%) were enrolled']","['CGIP using weekly class-styled (CS) sessions and a home-based (HB) programme', 'HB intervention', 'Comprehensive geriatric intervention', 'self-monitoring comprehensive geriatric intervention programme (CGIP']","['normal walking speed', 'KES', 'Maximum walking speed', 'physical function and muscle size', 'Physical functions, such as knee extension strength (KES), normal and maximum walking speed, the timed up-and-go test, and anterior thigh muscle thickness (MT', 'sarcopenia and/or frailty']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C4517676', 'cui_str': '275'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517792', 'cui_str': 'Five point four'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenias'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]",526.0,0.0410446,"Maximum walking speed (CS 4.7%, HB 1.8%; P = 0.001) and timed up-and-go (CS -4.7%, HB -0.2%; P < 0.001) significantly improved in the CS group only. ","[{'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Watanabe', 'Affiliation': 'Faculty of Health and Sports Science, Doshisha University, Kyoto, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Yamada', 'Affiliation': 'Laboratory of Applied Health Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Tsukasa', 'Initials': 'T', 'LastName': 'Yoshida', 'Affiliation': 'Laboratory of Applied Health Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Yokoyama', 'Affiliation': 'Non-profit Organization Genki-up AGE Project, Kameoka, Japan.'}, {'ForeName': 'Motoko', 'Initials': 'M', 'LastName': 'Miyake', 'Affiliation': 'Department of Health and Sports Sciences, Kyoto Gakuen University, Kameoka, Japan.'}, {'ForeName': 'Emi', 'Initials': 'E', 'LastName': 'Yamagata', 'Affiliation': ""Faculty of Nursing, Doshisha Women's College of Liberal Arts, Kyotanabe, Japan.""}, {'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Yamada', 'Affiliation': 'Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tokyo, Japan.'}, {'ForeName': 'Yasuko', 'Initials': 'Y', 'LastName': 'Yoshinaka', 'Affiliation': 'Non-profit Organization Genki-up AGE Project, Kameoka, Japan.'}, {'ForeName': 'Misaka', 'Initials': 'M', 'LastName': 'Kimura', 'Affiliation': 'Laboratory of Applied Health Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12504'] 226,31375749,Effect of flavor on neuronal responses of the hypothalamus and ventral tegmental area.,"Although it is well known that food intake is affected by the palatability of food, the actual effect of flavoring on regulation of energy-homeostasis and reward perception by the brain, remains unclear. We investigated the effect of ethyl-butyrate (EB), a common non-caloric food flavoring, on the blood oxygen level dependent (BOLD) response in the hypothalamus (important in regulating energy homeostasis) and ventral tegmental area (VTA; important in reward processes). The 16 study participants (18-25 years, BMI 20-23 kg/m 2 ) drank four study stimuli on separate visits using a crossover design during an fMRI setup in a randomized order. The stimuli were; plain water, water with EB, glucose solution (50gram/300 ml) and glucose solution with EB. BOLD responses to ingestion of the stimuli were determined in the hypothalamus and VTA as a measure of changes in neuronal activity after ingestion. In the hypothalamus and VTA, glucose had a significant effect on the BOLD response but EB flavoring did not. Glucose with and without EB led to similar decrease in hypothalamic BOLD response and glucose with EB resulted in a decrease in VTA BOLD response. Our results suggest that the changes in neuronal activity in the hypothalamus are mainly driven by energy ingestion and EB does not influence the hypothalamic response. Significant changes in VTA neuronal activity are elicited by energy combined with flavor.",2019,Glucose with and without EB led to similar decrease in hypothalamic BOLD response and glucose with EB resulted in a decrease in VTA BOLD response.,"['16 study participants (18-25 years, BMI 20-23\u2009kg/m 2 ) drank four study stimuli on separate visits using a crossover design during an']","['plain water, water with EB, glucose solution (50gram/300\u2009ml) and glucose solution with EB', 'Glucose with and without EB', 'fMRI setup', 'ethyl-butyrate (EB', 'flavor']","['hypothalamic BOLD response and glucose with EB', 'neuronal activity', 'BOLD response', 'VTA BOLD response', 'neuronal responses of the hypothalamus and ventral tegmental area', 'VTA neuronal activity', 'blood oxygen level dependent (BOLD) response']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0242817', 'cui_str': 'Cross-Over Design'}]","[{'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0059755', 'cui_str': 'ethyl butyrate'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0020663', 'cui_str': 'Preoptico-Hypothalamic Area'}, {'cui': 'C0175405', 'cui_str': 'Area Tegmentalis Ventralis'}, {'cui': 'C0005768'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}]",,0.0325444,Glucose with and without EB led to similar decrease in hypothalamic BOLD response and glucose with EB resulted in a decrease in VTA BOLD response.,"[{'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'van Opstal', 'Affiliation': 'Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands. a.m.van_opstal@lumc.nl.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'van den Berg-Huysmans', 'Affiliation': 'Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hoeksma', 'Affiliation': 'Unilever Research & Development, Vlaardingen, The Netherlands.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Blonk', 'Affiliation': 'Unilever Research & Development, Vlaardingen, The Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Pijl', 'Affiliation': 'Leiden University Medical Center, Department of Internal Medicine, Section Endocrinology, Leiden, The Netherlands.'}, {'ForeName': 'S A R B', 'Initials': 'SARB', 'LastName': 'Rombouts', 'Affiliation': 'Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'van der Grond', 'Affiliation': 'Leiden University Medical Center, Department of Radiology, Leiden, The Netherlands.'}]",Scientific reports,['10.1038/s41598-019-47771-8'] 227,31375753,A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease.,"Currently, there is no effective therapy for non-alcoholic fatty liver disease (NAFLD), although intensive calorie restriction is typically recommended but dietary adherence is an issue. The current study aimed to determine the effectiveness and adherence of eight weeks of modified alternate-day calorie restriction (MACR) in the control of NAFLD activity. This was a randomized controlled trial with MACR as the intervention and normal habitual diet as control. The outcome measures were body mass index (BMI), blood lipids, fasting blood sugar (FBS), liver enzymes (ALT and AST), and ultrasonographic measurements of liver steatosis and shear wave elastography (SWE). Per-protocol (PP) and intention-to-treat (ITT) analysis were performed within and between-groups with P < 0.05 as significant. 43 individuals with NAFLD satisfied study entry criteria, 33 were randomized to MACR and 10 to control group, and, 30 from MACR and 9 from control group completed PP. In between-group analysis of MACR vs. control, BMI were reduced in PP (P = 0.02) and ITT (P = 0.04). Only ALT was reduced in between-group analysis of MACR vs. control, both PP and ITT (P = 0.02 and 0.04 respectively). No reductions in all lipid parameters and FBS were found in between-group analyses (PP and ITT, all P > 0.22). Both liver steatosis grades and fibrosis (SWE) scores were reduced in between-group analyses of MACR vs. controls (PP and ITT, all P < 0.01). Adherence level remained between 75-83% throughout the study. As conclusion, 8 weeks of MACR protocol appears more effective than usual habitual diet in the control of NAFLD activity and with good adherence rate.",2019,"Both liver steatosis grades and fibrosis (SWE) scores were reduced in between-group analyses of MACR vs. controls (PP and ITT, all P < 0.01).","['Non-Alcoholic Fatty Liver Disease', '43 individuals with NAFLD satisfied study entry criteria, 33 were randomized to']","['modified alternate-day calorie restriction (MACR', 'MACR', 'Modified Alternate-day Calorie Restriction']","['liver steatosis grades and fibrosis (SWE) scores', 'body mass index (BMI), blood lipids, fasting blood sugar (FBS), liver enzymes (ALT and AST), and ultrasonographic measurements of liver steatosis and shear wave elastography (SWE', 'Per-protocol (PP) and intention-to-treat (ITT) analysis', 'Adherence level', 'lipid parameters and FBS']","[{'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0558287', 'cui_str': 'Alternate days (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}]","[{'cui': 'C2711227', 'cui_str': 'Liver Steatosis'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005768'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1955928', 'cui_str': 'Elastography'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",43.0,0.0659386,"Both liver steatosis grades and fibrosis (SWE) scores were reduced in between-group analyses of MACR vs. controls (PP and ITT, all P < 0.01).","[{'ForeName': 'Muhammad Izzad', 'Initials': 'MI', 'LastName': 'Johari', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Khairiah', 'Initials': 'K', 'LastName': 'Yusoff', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Juhara', 'Initials': 'J', 'LastName': 'Haron', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Chandran', 'Initials': 'C', 'LastName': 'Nadarajan', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Khairun Nisah', 'Initials': 'KN', 'LastName': 'Ibrahim', 'Affiliation': 'Hospital Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Mung Seong', 'Initials': 'MS', 'LastName': 'Wong', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Muhammad Ilham Abdul', 'Initials': 'MIA', 'LastName': 'Hafidz', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Bee Eng', 'Initials': 'BE', 'LastName': 'Chua', 'Affiliation': 'Hospital Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Nurhazwani', 'Initials': 'N', 'LastName': 'Hamid', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Wan Nor', 'Initials': 'WN', 'LastName': 'Arifin', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Zheng Feei', 'Initials': 'ZF', 'LastName': 'Ma', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia.'}, {'ForeName': 'Yeong Yeh', 'Initials': 'YY', 'LastName': 'Lee', 'Affiliation': 'School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia. yylee@usm.my.'}]",Scientific reports,['10.1038/s41598-019-47763-8'] 228,31769533,Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.,"BACKGROUND In patients with coeliac disease, FODMAPs in gluten-containing foods, and participant anticipation of a harmful ('nocebo') effect, may contribute to acute symptoms after gluten challenge. AIM To establish acute gluten-specific symptoms linked to immune activation in coeliac disease METHODS: We included 36 coeliac disease patients on a gluten-free diet receiving placebo in the RESET CeD trial. Double-blind, bolus vital wheat gluten (~6-g gluten protein) and sham challenges low in FODMAPs were consumed 2 weeks apart. Assessments included daily Coeliac Disease Patient Reported Outcome (CeD PRO) symptom scores (0-10), adverse events and serum interleukin-2 (baseline and 4 hours). RESULTS Median CeD PRO score for nausea increased most (sham: 0 vs gluten: 5.5; P < .001). Apart from tiredness (1 vs 4, P = .005) and headache (0 vs 2, P = .002), changes in other symptoms were small or absent. Only nausea increased significantly in occurrence with gluten (11% vs 69%, P < .001). Without nausea, only tiredness and flatulence were common after gluten. Nausea (6% vs 61%, P < .001; median onset: 1:34 hours) and vomiting (0% vs 44%, P < .001; 1:51 hours) were the only adverse events more common with gluten than sham. Interleukin-2 was always below the level of quantitation (0.5 pg/mL) at baseline, and after sham. Interleukin-2 was elevated after gluten in 97% of patients (median fold-change: 20), and correlated with severity of nausea (r s  = .49, P = .0025) and occurrence of vomiting (P = .0005). CONCLUSIONS Nausea and vomiting are relatively specific indicators of acute gluten ingestion, and correlate with immune activation. IBS-like symptoms without nausea are unlikely to indicate recent gluten exposure.",2020,"Apart from tiredness (1 vs 4, P = .005) and headache (0 vs 2, P = .002), changes in other symptoms were small or absent.",['36 coeliac disease patients on a'],"['gluten-free diet receiving placebo', 'bolus vital wheat gluten (~6-g gluten protein']","['Nausea', 'occurrence of vomiting', 'Median CeD PRO score for nausea', 'Interleukin-2', 'headache', 'vomiting', 'severity of nausea', 'Without nausea, only tiredness and flatulence', 'nausea', 'daily Coeliac Disease Patient Reported Outcome (CeD PRO) symptom scores (0-10), adverse events and serum interleukin-2 (baseline and 4\xa0hours']","[{'cui': 'C0007570', 'cui_str': 'Sprue, Nontropical'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0344351', 'cui_str': 'Gluten-Free Diet'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0442732', 'cui_str': 'Vital (qualifier value)'}, {'cui': 'C3812405', 'cui_str': 'Wheat gluten'}, {'cui': 'C2362561', 'cui_str': 'Gluten'}]","[{'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0007570', 'cui_str': 'Sprue, Nontropical'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1292426', 'cui_str': '4 hours (qualifier value)'}]",,0.455522,"Apart from tiredness (1 vs 4, P = .005) and headache (0 vs 2, P = .002), changes in other symptoms were small or absent.","[{'ForeName': 'A James M', 'Initials': 'AJM', 'LastName': 'Daveson', 'Affiliation': 'Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia.'}, {'ForeName': 'Jason A', 'Initials': 'JA', 'LastName': 'Tye-Din', 'Affiliation': 'Immunology Division, The Walter and Eliza Hall Institute, Parkville, Vic., Australia.'}, {'ForeName': 'Gautam', 'Initials': 'G', 'LastName': 'Goel', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Kaela E', 'Initials': 'KE', 'LastName': 'Goldstein', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Holly L', 'Initials': 'HL', 'LastName': 'Hand', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Kristin M', 'Initials': 'KM', 'LastName': 'Neff', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Leslie J', 'Initials': 'LJ', 'LastName': 'Williams', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Kenneth E', 'Initials': 'KE', 'LastName': 'Truitt', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Anderson', 'Affiliation': 'ImmusanT, Inc., Cambridge, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15551'] 229,31930781,Interventions to slow progression of myopia in children.,"BACKGROUND Nearsightedness (myopia) causes blurry vision when one is looking at distant objects. Interventions to slow the progression of myopia in children include multifocal spectacles, contact lenses, and pharmaceutical agents. OBJECTIVES To assess the effects of interventions, including spectacles, contact lenses, and pharmaceutical agents in slowing myopia progression in children. SEARCH METHODS We searched CENTRAL; Ovid MEDLINE; Embase.com; PubMed; the LILACS Database; and two trial registrations up to February 2018. A top up search was done in February 2019. SELECTION CRITERIA We included randomized controlled trials (RCTs). We excluded studies when most participants were older than 18 years at baseline. We also excluded studies when participants had less than -0.25 diopters (D) spherical equivalent myopia. DATA COLLECTION AND ANALYSIS We followed standard Cochrane methods. MAIN RESULTS We included 41 studies (6772 participants). Twenty-one studies contributed data to at least one meta-analysis. Interventions included spectacles, contact lenses, pharmaceutical agents, and combination treatments. Most studies were conducted in Asia or in the United States. Except one, all studies included children 18 years or younger. Many studies were at high risk of performance and attrition bias. Spectacle lenses: undercorrection of myopia increased myopia progression slightly in two studies; children whose vision was undercorrected progressed on average -0.15 D (95% confidence interval [CI] -0.29 to 0.00; n = 142; low-certainty evidence) more than those wearing fully corrected single vision lenses (SVLs). In one study, axial length increased 0.05 mm (95% CI -0.01 to 0.11) more in the undercorrected group than in the fully corrected group (n = 94; low-certainty evidence). Multifocal lenses (bifocal spectacles or progressive addition lenses) yielded small effect in slowing myopia progression; children wearing multifocal lenses progressed on average 0.14 D (95% CI 0.08 to 0.21; n = 1463; moderate-certainty evidence) less than children wearing SVLs. In four studies, axial elongation was less for multifocal lens wearers than for SVL wearers (-0.06 mm, 95% CI -0.09 to -0.04; n = 896; moderate-certainty evidence). Three studies evaluating different peripheral plus spectacle lenses versus SVLs reported inconsistent results for refractive error and axial length outcomes (n = 597; low-certainty evidence). Contact lenses: there may be little or no difference between vision of children wearing bifocal soft contact lenses (SCLs) and children wearing single vision SCLs (mean difference (MD) 0.20D, 95% CI -0.06 to 0.47; n = 300; low-certainty evidence). Axial elongation was less for bifocal SCL wearers than for single vision SCL wearers (MD -0.11 mm, 95% CI -0.14 to -0.08; n = 300; low-certainty evidence). Two studies investigating rigid gas permeable contact lenses (RGPCLs) showed inconsistent results in myopia progression; these two studies also found no evidence of difference in axial elongation (MD 0.02mm, 95% CI -0.05 to 0.10; n = 415; very low-certainty evidence). Orthokeratology contact lenses were more effective than SVLs in slowing axial elongation (MD -0.28 mm, 95% CI -0.38 to -0.19; n = 106; moderate-certainty evidence). Two studies comparing spherical aberration SCLs with single vision SCLs reported no difference in myopia progression nor in axial length (n = 209; low-certainty evidence). Pharmaceutical agents: at one year, children receiving atropine eye drops (3 studies; n = 629), pirenzepine gel (2 studies; n = 326), or cyclopentolate eye drops (1 study; n = 64) showed significantly less myopic progression compared with children receiving placebo: MD 1.00 D (95% CI 0.93 to 1.07), 0.31 D (95% CI 0.17 to 0.44), and 0.34 (95% CI 0.08 to 0.60), respectively (moderate-certainty evidence). Axial elongation was less for children treated with atropine (MD -0.35 mm, 95% CI -0.38 to -0.31; n = 502) and pirenzepine (MD -0.13 mm, 95% CI -0.14 to -0.12; n = 326) than for those treated with placebo (moderate-certainty evidence) in two studies. Another study showed favorable results for three different doses of atropine eye drops compared with tropicamide eye drops (MD 0.78 D, 95% CI 0.49 to 1.07 for 0.1% atropine; MD 0.81 D, 95% CI 0.57 to 1.05 for 0.25% atropine; and MD 1.01 D, 95% CI 0.74 to 1.28 for 0.5% atropine; n = 196; low-certainty evidence) but did not report axial length. Systemic 7-methylxanthine had little to no effect on myopic progression (MD 0.07 D, 95% CI -0.09 to 0.24) nor on axial elongation (MD -0.03 mm, 95% CI -0.10 to 0.03) compared with placebo in one study (n = 77; moderate-certainty evidence). One study did not find slowed myopia progression when comparing timolol eye drops with no drops (MD -0.05 D, 95% CI -0.21 to 0.11; n = 95; low-certainty evidence). Combinations of interventions: two studies found that children treated with atropine plus multifocal spectacles progressed 0.78 D (95% CI 0.54 to 1.02) less than children treated with placebo plus SVLs (n = 191; moderate-certainty evidence). One study reported -0.37 mm (95% CI -0.47 to -0.27) axial elongation for atropine and multifocal spectacles when compared with placebo plus SVLs (n = 127; moderate-certainty evidence). Compared with children treated with cyclopentolate plus SVLs, those treated with atropine plus multifocal spectacles progressed 0.36 D less (95% CI 0.11 to 0.61; n = 64; moderate-certainty evidence). Bifocal spectacles showed small or negligible effect compared with SVLs plus timolol drops in one study (MD 0.19 D, 95% CI 0.06 to 0.32; n = 97; moderate-certainty evidence). One study comparing tropicamide plus bifocal spectacles versus SVLs reported no statistically significant differences between groups without quantitative results. No serious adverse events were reported across all interventions. Participants receiving antimuscarinic topical medications were more likely to experience accommodation difficulties (Risk Ratio [RR] 9.05, 95% CI 4.09 to 20.01) and papillae and follicles (RR 3.22, 95% CI 2.11 to 4.90) than participants receiving placebo (n=387; moderate-certainty evidence). AUTHORS' CONCLUSIONS Antimuscarinic topical medication is effective in slowing myopia progression in children. Multifocal lenses, either spectacles or contact lenses, may also confer a small benefit. Orthokeratology contact lenses, although not intended to modify refractive error, were more effective than SVLs in slowing axial elongation. We found only low or very low-certainty evidence to support RGPCLs and sperical aberration SCLs.",2020,"Orthokeratology contact lenses were more effective than SVLs in slowing axial elongation (MD -0.28 mm, 95% CI -0.38 to -0.19; n = 106; moderate-certainty evidence).","['children 18 years or younger', 'children', 'Spectacle lenses', 'myopia in children', 'participants had less than -0.25 diopters (D) spherical equivalent myopia', 'participants were older than 18 years at baseline', '41 studies (6772 participants']","['SVLs plus timolol', 'Orthokeratology contact lenses', 'placebo: MD', 'interventions', 'timolol', 'rigid gas permeable contact lenses (RGPCLs', 'placebo', 'placebo plus SVLs', 'atropine', 'cyclopentolate plus SVLs', 'pirenzepine gel', 'tropicamide', 'cyclopentolate eye drops']","['refractive error and axial length outcomes', 'slowing axial elongation', 'serious adverse events', 'Axial elongation', 'slowed myopia progression', 'experience accommodation difficulties', 'myopia progression nor in axial length', 'myopia progression', 'myopic progression', 'axial length', 'spectacles, contact lenses, pharmaceutical agents, and combination treatments', 'axial elongation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0015421', 'cui_str': 'Glasses'}, {'cui': 'C0023318', 'cui_str': 'Lenses'}, {'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0439486', 'cui_str': 'Diopters - (qualifier value)'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0040233', 'cui_str': 'Timolol'}, {'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0231517', 'cui_str': 'Rigid (qualifier value)'}, {'cui': 'C0444946', 'cui_str': 'Gas permeable (qualifier value)'}, {'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0010582', 'cui_str': 'Cyclopentolate'}, {'cui': 'C0031978', 'cui_str': 'Pirenzepine'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0041190', 'cui_str': 'Tropicamide'}, {'cui': 'C0015399', 'cui_str': 'Ophthalmic Drops'}]","[{'cui': 'C0034951', 'cui_str': 'Refractive Disorders'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027092', 'cui_str': 'Nearsightedness'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0152198', 'cui_str': 'Disorder of accommodation (disorder)'}, {'cui': 'C0015421', 'cui_str': 'Glasses'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.514633,"Orthokeratology contact lenses were more effective than SVLs in slowing axial elongation (MD -0.28 mm, 95% CI -0.38 to -0.19; n = 106; moderate-certainty evidence).","[{'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Walline', 'Affiliation': 'The Ohio State University, College of Optometry, 338 West Tenth Avenue, Columbus, Ohio, USA, 43210-1240.'}, {'ForeName': 'Kristina B', 'Initials': 'KB', 'LastName': 'Lindsley', 'Affiliation': 'IBM Watson Health, Life Sciences, Oncology, & Genomics, Baltimore, Maryland, USA.'}, {'ForeName': 'S Swaroop', 'Initials': 'SS', 'LastName': 'Vedula', 'Affiliation': 'Johns Hopkins University, 3400 N. Charles Street, Baltimore, Maryland, USA, 21218.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Cotter', 'Affiliation': 'Southern California College of Optometry, 2575 Yorba Linda Boulevard, Fullerton, California, USA, 92831.'}, {'ForeName': 'Donald O', 'Initials': 'DO', 'LastName': 'Mutti', 'Affiliation': 'The Ohio State University, College of Optometry, 338 West Tenth Avenue, Columbus, Ohio, USA, 43210-1240.'}, {'ForeName': 'Sueko M', 'Initials': 'SM', 'LastName': 'Ng', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, 615 N. Wolfe Street, W5010, c/o Cochrane Eyes and Vision Group, Baltimore, Maryland, USA, 21205.'}, {'ForeName': 'J Daniel', 'Initials': 'JD', 'LastName': 'Twelker', 'Affiliation': 'University of Arizona, Department of Ophthalmology, 655 North Alvernon Way Suite 108, Tucson, Arizona, USA, 85711.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD004916.pub4'] 230,31808596,The intestinal microbiome potentially affects thrombin generation in human subjects.,"BACKGROUND The intestinal microbiome plays a versatile role in the etiology of arterial thrombosis. In venous thrombosis, driven chiefly by plasma coagulation, no such role has yet been established. We hypothesized that the intestinal microbiome composition affects coagulation in humans. METHODS We used healthy donor fecal microbiota transplant (FMT) to experimentally change the microbiome composition in metabolic syndrome patients. Thirty-five subjects were randomized in a blinded fashion to healthy donor FMT or autologous FMT as a control in a 2:1 ratio. We measured thrombin generation at baseline and after 6 weeks using automated calibrated thrombinography, and we determined plasma abundance of 32 coagulation related proteins using a targeted mass spectrometry-based quantitative proteomics assay with heavy labeled internal standards. RESULTS Healthy donor FMT prolonged the thrombinography lag time (median delta 0.0 versus 0.25 minutes, P = .039). The other thrombinography parameters showed no significant difference. Unsupervised cluster analysis suggested overall downregulation of coagulation related plasma proteins in subject clusters containing predominantly subjects that had a metabolic response to healthy donor FMT. FMT treatment status itself showed no clear clustering pattern with up- or downregulation, however, and proteins did not cluster according to an apparent biological grouping. DISCUSSION A single healthy donor FMT tends to modestly suppress the onset thrombin generation in metabolic syndrome patients, representing initial proof-of-principle that the intestinal microbiota composition might affect the coagulation system in humans. The findings merit external validation as a role for intestinal microbiota in coagulation can have clinically important implications.",2020,"Healthy donor FMT prolonged the thrombinography lag time (median delta 0.0 versus 0.25 minutes, P = .039).","['human subjects', 'metabolic syndrome patients', 'Thirty-five subjects']","['healthy donor FMT or autologous FMT', 'FMT', 'healthy donor fecal microbiota transplant (FMT']","['thrombin generation', 'thrombinography lag time']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}]","[{'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}]","[{'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",35.0,0.0465963,"Healthy donor FMT prolonged the thrombinography lag time (median delta 0.0 versus 0.25 minutes, P = .039).","[{'ForeName': 'Yassene', 'Initials': 'Y', 'LastName': 'Mohammed', 'Affiliation': 'Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Ruud S', 'Initials': 'RS', 'LastName': 'Kootte', 'Affiliation': 'Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Wil F', 'Initials': 'WF', 'LastName': 'Kopatz', 'Affiliation': 'Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Christoph H', 'Initials': 'CH', 'LastName': 'Borchers', 'Affiliation': 'University of Victoria-Genome BC Proteomics Centre, University of Victoria, Victoria, BC, Canada.'}, {'ForeName': 'Harry R', 'Initials': 'HR', 'LastName': 'Büller', 'Affiliation': 'Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Henri H', 'Initials': 'HH', 'LastName': 'Versteeg', 'Affiliation': 'Department of Internal Medicine, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Max', 'Initials': 'M', 'LastName': 'Nieuwdorp', 'Affiliation': 'Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Thijs E', 'Initials': 'TE', 'LastName': 'van Mens', 'Affiliation': 'Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14699'] 231,31836635,Cost-effectiveness of strategies preventing late-onset infection in preterm infants.,"OBJECTIVE Developing a model to analyse the cost-effectiveness of interventions preventing late-onset infection (LOI) in preterm infants and applying it to the evaluation of anti-microbial impregnated peripherally inserted central catheters (AM-PICCs) compared with standard PICCs (S-PICCs). DESIGN Model-based cost-effectiveness analysis, using data from the Preventing infection using Antimicrobial Impregnated Long Lines (PREVAIL) randomised controlled trial linked to routine healthcare data, supplemented with published literature. The model assumes that LOI increases the risk of neurodevelopmental impairment (NDI). SETTING Neonatal intensive care units in the UK National Health Service (NHS). PATIENTS Infants born ≤32 weeks gestational age, requiring a 1 French gauge PICC. INTERVENTIONS AM-PICC and S-PICC. MAIN OUTCOME MEASURES Life expectancy, quality-adjusted life years (QALYs) and healthcare costs over the infants' expected lifetime. RESULTS Severe NDI reduces life expectancy by 14.79 (95% CI 4.43 to 26.68; undiscounted) years, 10.63 (95% CI 7.74 to 14.02; discounted) QALYs and costs £19 057 (95% CI £14 197; £24697; discounted) to the NHS. If LOI causes NDI, the maximum acquisition price of an intervention reducing LOI risk by 5% is £120. AM-PICCs increase costs (£54.85 (95% CI £25.95 to £89.12)) but have negligible impact on health outcomes (-0.01 (95% CI -0.09 to 0.04) QALYs), compared with S-PICCs. The NHS can invest up to £2.4 million in research to confirm that AM-PICCs are not cost-effective. CONCLUSIONS The model quantifies health losses and additional healthcare costs caused by NDI and LOI during neonatal care. Given these consequences, interventions preventing LOI, even by a small extent, can be cost-effective. AM-PICCs, being less effective and more costly than S-PICC, are not likely to be cost-effective. TRIAL REGISTRATION NUMBER NCT03260517.",2020,"Severe NDI reduces life expectancy by 14.79 (95% CI 4.43 to 26.68; undiscounted) years, 10.63","['Infants born ≤32 weeks gestational age, requiring a 1 French gauge PICC', 'preterm infants', 'Neonatal intensive care units in the UK National Health Service (NHS']",['standard PICCs (S-PICCs'],"['health outcomes', 'AM-PICCs increase costs', 'LOI risk', 'risk of neurodevelopmental impairment (NDI', ""Life expectancy, quality-adjusted life years (QALYs) and healthcare costs over the infants' expected lifetime"", 'Severe NDI reduces life expectancy']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0580793', 'cui_str': 'French gauge'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C1563705', 'cui_str': 'Diabetes Insipidus, Nephrogenic, Type I'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",,0.142018,"Severe NDI reduces life expectancy by 14.79 (95% CI 4.43 to 26.68; undiscounted) years, 10.63","[{'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Grosso', 'Affiliation': 'Centre for Health Economics, University of York, York, UK alessandro.grosso@york.ac.uk.'}, {'ForeName': 'Rita Isabel', 'Initials': 'RI', 'LastName': 'Neves de Faria', 'Affiliation': 'Centre for Health Economics, University of York, York, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bojke', 'Affiliation': 'Centre for Health Economics, University of York, York, UK.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Donohue', 'Affiliation': 'Clinical Trials Research Centre, University of Liverpool, Liverpool, Merseyside, UK.'}, {'ForeName': 'Caroline Isabel', 'Initials': 'CI', 'LastName': 'Fraser', 'Affiliation': 'UCL Great Ormond Street Institute of Child Health, London, United Kingdom.'}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Harron', 'Affiliation': 'UCL Great Ormond Street Institute of Child Health, London, United Kingdom.'}, {'ForeName': 'Sam J', 'Initials': 'SJ', 'LastName': 'Oddie', 'Affiliation': 'Bradford Neonatology, Bradford Royal Infirmary, West Yorkshire, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Gilbert', 'Affiliation': 'MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health, London, United Kingdom.'}]",Archives of disease in childhood,['10.1136/archdischild-2019-317640'] 232,31864932,Laser ablation versus mechanochemical ablation in the treatment of primary varicose veins: A randomized clinical trial.,"OBJECTIVE to prospectively compare the surgical outcome of using endovenous laser ablation (EVLA) and mechanochemical ablation (MOCA) in management of patients with primary varicose veins (VV). METHODS The present study prospectively recruited 100 patients with primary VV. They were randomly and equally allocated to one of two treatment group: the EVLA group (n = 50) or the MOCA group (n = 50). Before intervention, all patients underwent to clinical and ultrasound assessment of the vascular system. The Venous Clinical Severity Score was used to assess clinical severity. In addition, patients completed the Chronic Venous Insufficiency Questionnaire. The primary study outcome was treatment success. After intervention, patients were followed up at 1 week, 1 months, 6 months, and 12 months. RESULTS Operative success was achieved in all patients. The MOCA group had a significantly shorter operative time when compared with EVLA group. The Venous Clinical Severity Score significantly improved in both groups over the follow-up period and showed significantly lower levels in the MOCA group. Perceived pain was significantly improved in both groups postoperatively with no significant differences. The Chronic Venous Insufficiency Questionnaire was significantly improved after 12 months of operation without significant differences between groups. MOCA patients had significantly lower rate of postoperative phlebitis and significantly shorter time to return to work. CONCLUSIONS MOCA for primary VV is a feasible, effective, and safe procedure with better clinical outcome and lower rate of postoperative phlebitis when compared with EVLA.",2020,The Venous Clinical Severity Score significantly improved in both groups over the follow-up period and showed significantly lower levels in the MOCA group.,"['100 patients with primary VV', 'primary varicose veins', 'patients with primary varicose veins (VV']","['endovenous laser ablation (EVLA) and mechanochemical ablation (MOCA', 'Laser ablation versus mechanochemical ablation', 'MOCA', 'EVLA']","['postoperative phlebitis', 'Perceived pain', 'rate of postoperative phlebitis', 'Chronic Venous Insufficiency Questionnaire', 'Venous Clinical Severity Score', 'Operative success', 'operative time']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0042345', 'cui_str': 'Varices'}]","[{'cui': 'C0348007', 'cui_str': 'Pulsed Laser Tissue Ablation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0031542', 'cui_str': 'Phlebitis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1306557', 'cui_str': 'Chronic venous insufficiency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}]",100.0,0.0577375,The Venous Clinical Severity Score significantly improved in both groups over the follow-up period and showed significantly lower levels in the MOCA group.,"[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Tawfik', 'Affiliation': 'Department of Vascular Surgery, Faculty of Medicine, Zagazig University, Zagazig, Sharqiyah, Egypt. Electronic address: tawfik2carotid@yahoo.com.'}, {'ForeName': 'Waleed A', 'Initials': 'WA', 'LastName': 'Sorour', 'Affiliation': 'Department of Vascular Surgery, Faculty of Medicine, Zagazig University, Zagazig, Sharqiyah, Egypt.'}, {'ForeName': 'Medhat E', 'Initials': 'ME', 'LastName': 'El-Laboudy', 'Affiliation': 'Department of Vascular Surgery, Faculty of Medicine, Zagazig University, Zagazig, Sharqiyah, Egypt.'}]",Journal of vascular surgery. Venous and lymphatic disorders,['10.1016/j.jvsv.2019.10.025'] 233,32306477,The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.,"BACKGROUND Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) ensuring ultrafast absorption and effect. AIM To compare the pharmacokinetics between faster aspart and IAsp, based on free or total IAsp measurement, and investigate the association between anti-IAsp antibodies and faster aspart and IAsp pharmacological properties in children and adolescents with type 1 diabetes (T1D). METHODS In a randomized, two-period crossover trial, 12 children, 16 adolescents, and 15 adults (6-11, 12-17, and 18-64 years) received 0.2 U/kg double-blindsingle-dose subcutaneous faster aspart or IAsp followed by a standardized liquid meal test. RESULTS Across age groups, the pharmacokinetic profile was left-shifted including greater early exposure for faster aspart vs IAsp irrespective of free or total IAsp assay. Onset of appearance occurred 2.4 to 5.0 minutes (free) or 1.8 to 3.0 minutes (total) earlier for faster aspart vs IAsp (P < .05). Treatment ratios (faster aspart/IAsp) for 0 to 30 minutes IAsp exposure were 1.60 to 2.11 and 1.62 to 1.96, respectively (children, free: P = .062; otherwise P < .05). The ratio of free/total IAsp for overall exposure (AUC IAsp,0-t ) was negatively associated with anti-IAsp antibody level across age. Pooling with a previous similar trial showed no clear association between anti-IAsp antibodies and meal test 1- or 2-hour postprandial glucose increment independent of age and insulin treatment (R 2 ≤ .070; P ≥ .17). CONCLUSIONS In children and adolescents with T1D, faster aspart provides ultrafast pharmacokinetics irrespective of free or total IAsp assay. Elevated anti-IAsp antibodies are associated with higher total IAsp concentration, but do not impact faster aspart and IAsp glucose-lowering effect.",2020,"The ratio of free/total IAsp for overall exposure (AUC IAsp,0-t ) was negatively associated with anti-IAsp antibody level across age.","['children and adolescents with type 1 diabetes', 'children and adolescents with type 1 diabetes (T1D', '12 children, 16 adolescents and 15 adults (6-11, 12-17 and 18-64 years) received']","['0.2 U/kg double-blind single-dose subcutaneous faster aspart or IAsp followed by a standardized liquid meal test', 'fast-acting insulin aspart', 'Fast-acting insulin aspart (faster aspart']",['Onset of appearance'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C1300561', 'cui_str': 'U/kg'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0123677', 'cui_str': 'Insulin, Aspart, Human'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}]","[{'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}]",12.0,0.0243365,"The ratio of free/total IAsp for overall exposure (AUC IAsp,0-t ) was negatively associated with anti-IAsp antibody level across age.","[{'ForeName': 'Torben', 'Initials': 'T', 'LastName': 'Biester', 'Affiliation': 'Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.'}, {'ForeName': 'Thekla', 'Initials': 'T', 'LastName': 'von dem Berge', 'Affiliation': 'Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.'}, {'ForeName': 'Line Quist', 'Initials': 'LQ', 'LastName': 'Bendtsen', 'Affiliation': 'Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Mette Dahl', 'Initials': 'MD', 'LastName': 'Bendtsen', 'Affiliation': 'Biostatistics, Novo Nordisk A/S, Aalborg Ø, Denmark.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Rathor', 'Affiliation': 'Global Medical Affairs, Novo Nordisk Service Centre India Private Ltd., Bangalore, India.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Danne', 'Affiliation': 'Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover, Germany.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Haahr', 'Affiliation': 'Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark.'}]",Pediatric diabetes,['10.1111/pedi.13026'] 234,32249446,"Periodontal regeneration versus extraction and dental implant or prosthetic replacement of teeth severely compromised by attachment loss to the apex: A randomized controlled clinical trial reporting 10-year outcomes, survival analysis and mean cumulative cost of recurrence.","BACKGROUND Periodontal regeneration can change tooth prognosis and represents an alternative to extraction in teeth compromised by severe intra-bony defects. The aim of this study was to compare periodontal regeneration (PR) with tooth extraction and replacement (TER) in a population with attachment loss to or beyond the apex of the root in terms of professional, patient-reported and economic outcomes. METHODS This was a 10-year randomized controlled clinical trial. 50 stage III or stage IV periodontitis subjects with a severely compromised tooth with attachment loss to or beyond the apex were randomized to PR or TER with either an implant- or a tooth-supported fixed partial denture. Subjects were kept on a strict periodontal supportive care regimen every 3 months and examined yearly. Survival and recurrence analysis were performed. RESULTS 88% and 100% survival rates were observed in the PR and TER groups. Complication-free survival was not significantly different: 6.7-9.1 years for PR and 7.3-9.1 years for TER (p = .788). In PR, the observed 10-year attachment gain was 7.3 ± 2.3 mm and the residual probing depths were 3.4 ± 0.8 mm. Recurrence analysis showed that the 95% confidence interval of the costs was significantly lower for PR compared with TER throughout the whole 10-year period. Patient-reported outcomes and oral health-related quality-of-life measurements improved in both groups. CONCLUSIONS Periodontal regeneration can change the prognosis of hopeless teeth and is a less costly alternative to tooth extraction and replacement. The complexity of the treatment limits widespread application to the most complex cases but provides powerful proof of principle for the benefits of PR in deep intra-bony defect.",2020,Recurrence analysis showed that the 95% confidence interval of the costs was significantly lower for PR compared to TER throughout the whole 10-year period.,['50 stage III or IV periodontitis subjects with a severely compromised tooth with attachment loss to or beyond the apex'],"['Periodontal regeneration versus extraction and dental implant or prosthetic replacement', 'tooth extraction and replacement (TER', 'PR or TER with either an implant or a tooth supported fixed partial denture']","['survival rates', 'oral health related quality of life measurements', 'Complication free survival', 'periodontal regeneration (PR', '10-year attachment gain', 'survival analysis and mean cumulative cost of recurrence', 'Survival and recurrence analysis']","[{'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0034963', 'cui_str': 'Regeneration'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0040440', 'cui_str': 'Tooth extraction'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0227089', 'cui_str': 'Structure of deciduous maxillary right second molar tooth'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0011461', 'cui_str': 'Fixed Partial Denture'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0034963', 'cui_str': 'Regeneration'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",,0.167162,Recurrence analysis showed that the 95% confidence interval of the costs was significantly lower for PR compared to TER throughout the whole 10-year period.,"[{'ForeName': 'Pierpaolo', 'Initials': 'P', 'LastName': 'Cortellini', 'Affiliation': 'Accademia Toscana di Ricerca Odontostomatologia (ATRO), Florence, Italy.'}, {'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Stalpers', 'Affiliation': 'Private Practice, Florence, Italy.'}, {'ForeName': 'Aniello', 'Initials': 'A', 'LastName': 'Mollo', 'Affiliation': 'Private Practice, Florence, Italy.'}, {'ForeName': 'Maurizio S', 'Initials': 'MS', 'LastName': 'Tonetti', 'Affiliation': 'European Research Group on Periodontology (ERGOPERIO), Genova, Italy.'}]",Journal of clinical periodontology,['10.1111/jcpe.13289'] 235,30886326,Adverse influence of bisoprolol on central blood pressure in the upright position: a double-blind placebo-controlled cross-over study.,"Treatment with beta-blockers is characterized by inferior reduction of central versus peripheral blood pressure. We examined changes in blood pressure, cardiac function, and vascular resistance after 3 weeks of bisoprolol treatment (5 mg/day) during passive head-up tilt in 16 never-treated Caucasian males with grade I-II primary hypertension. A double-blind, randomized, placebo-controlled cross-over design was applied, and hemodynamics were recorded using continuous tonometric pulse wave analysis and whole-body impedance cardiography. Bisoprolol decreased blood pressure in the aorta (~8/10 mmHg, p ≤ 0.032) and radial artery (~10/9 mmHg, p ≤ 0.037), but upright aortic systolic blood pressure was not significantly reduced (p = 0.085). Bisoprolol reduced heart rate and left cardiac work, and increased subendocardial viability index in supine and upright positions (p ≤ 0.044 for all). Bisoprolol increased stroke volume in the supine (~11 ml, p = 0.02) but not in the upright position, while only upright (~1 l/min, p = 0.007) but not supine cardiac output was reduced. Upright elevation in systemic vascular resistance was increased 2.7-fold (p = 0.002), while upright pulse pressure amplification was decreased by ~20% (p = 0.002) after bisoprolol. Aortic augmentation index, augmentation pressure, and pulse pressure were not changed in the supine position but were increased in the upright position (from 9% to 17%, 3-6 mmHg, and 30-34 mmHg, respectively, p ≤ 0.016 for all). In conclusion, although bisoprolol treatment reduced peripheral blood pressure, central systolic blood pressure in the upright position was not decreased. Importantly, the harmful influences of bisoprolol on central pulse pressure and pressure wave reflection were manifested in the upright position.",2020,"Bisoprolol decreased blood pressure in the aorta (~8/10 mmHg, p ≤ 0.032) and radial artery (~10/9 mmHg, p ≤ 0.037), but upright aortic systolic blood pressure was not significantly reduced (p = 0.085).",['16 never-treated Caucasian males with grade I-II primary hypertension'],"['beta-blockers', 'bisoprolol treatment (5\u2009mg/day) during passive head-up tilt', 'bisoprolol', 'placebo']","['blood pressure', 'central pulse pressure and pressure wave reflection', 'central blood pressure', 'supine cardiac output', 'upright aortic systolic blood pressure', 'Bisoprolol increased stroke volume', 'blood pressure, cardiac function, and vascular resistance', 'upright pulse pressure amplification', 'Upright elevation in systemic vascular resistance', 'Aortic augmentation index, augmentation pressure, and pulse pressure', 'radial artery', 'peripheral blood pressure, central systolic blood pressure', 'upright position', 'Bisoprolol reduced heart rate and left cardiac work, and increased subendocardial viability index']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0085580', 'cui_str': 'Essential Hypertension'}]","[{'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0053799', 'cui_str': 'Bisoprolol'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C1293898', 'cui_str': 'Head up'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0949236', 'cui_str': 'Pulse Pressure'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0053799', 'cui_str': 'Bisoprolol'}, {'cui': 'C0520872', 'cui_str': 'Increased cardiac stroke volume (finding)'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function (observable entity)'}, {'cui': 'C0429119', 'cui_str': 'Vascular resistance (observable entity)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C1258192', 'cui_str': 'Total Peripheral Resistance'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0162857', 'cui_str': 'Radial Artery'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",,0.133562,"Bisoprolol decreased blood pressure in the aorta (~8/10 mmHg, p ≤ 0.032) and radial artery (~10/9 mmHg, p ≤ 0.037), but upright aortic systolic blood pressure was not significantly reduced (p = 0.085).","[{'ForeName': 'Lauri', 'Initials': 'L', 'LastName': 'Suojanen', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland. lsuojanen@gmail.com.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Haring', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Tikkakoski', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Heini', 'Initials': 'H', 'LastName': 'Huhtala', 'Affiliation': 'Faculty of Social Sciences, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Kähönen', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Arttu', 'Initials': 'A', 'LastName': 'Eräranta', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Jukka T', 'Initials': 'JT', 'LastName': 'Mustonen', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}, {'ForeName': 'Ilkka H', 'Initials': 'IH', 'LastName': 'Pörsti', 'Affiliation': 'Faculty of Medicine and Health Technology, P.O. Box 100, FIN-33014 University of Tampere, Tampere, Finland.'}]",Journal of human hypertension,['10.1038/s41371-019-0188-9'] 236,32160968,Maternal physiological changes at rest induced by exercise during pregnancy: A randomized controlled trial.,"OBJECTIVE to analyse maternal physiological changes in several areas (cardiovascular, metabolic, renal and hepatic) related to the regular practice of a supervised exercise program. METHODS This is an unplanned secondary analysis from a randomized controlled trial carried out in a single maternity unit in Madrid, Spain (NCT 02,756,143). From November 2014 to June 2015, 92 women were randomly assigned to perform a mild-moderate supervised exercise program during pregnancy (Intervention group, IG) or to continue with their routine pregnancy care (control group, CG). For the purpose of this study we collected clinical and analytical data (heart blood pressure, weight, blood glucose, AST, ALT, blood Creatinine and blood Uric acid) available from all obstetric visits and examined the differences between groups. RESULTS We did not find any differences in: pregnancy weight (IG: 11.4 ± 4.4 Kg vs. CG: 10.1 ± 5.3 Kg; p = 0.173); fasting glucose at 10 +0 -12 +6 weeks (IG: 78.48±8.34 vs. CG: 76±13.26, p = 0.305) or at 34 +0 -36 +4 weeks (IG: 73.25±10.27 vs CG: 73.45± 8.29,p = 0.920), and 50 gs glucose tolerance at 24 +4 -26 +6 weeks (IG: 116.23±35.07 vs CG: 116.36±25.98, p = 0.984); Aspartate-amino-transferase at 10 +0 -12 +6 weeks (IG: 15.38±4.17 vs CG: 17.33±7.05, p = 0.124) and at 34 +0 -36 +4 weeks (IG: 21.65±5.25 vs CG: 19.53±8.32, p = 0.165) or Alanine-amino- transferase at 10 +0 -12 +6 weeks (IG: 27.50±10.63 vs CG: 28.27±11.77, p = 0.746) or at 34 +0 -36 +4 weeks (IG: 22.93±9.23 vs CG: 20.84±13.49, p = 0.407); blood Creatinine concentrations at 34 +0 -36 +4 weeks (IG: 0.595±0.401 vs CG: 0.575±0.100, p = 0.757) and blood uric acid concentrations at 34 +0 -36 +4 weeks (IG: 3.526 ± 0.787 vs CG: 3.262±0.672, p = 0.218). Heart blood pressure was similar between groups except at 27 +0 -28 +6 weeks, where systolic blood pressure was significantly lower in the CG in comparison to the IG (116.31±10.8 mmHg vs. 120.22 ± 10.3 mmHg, p = 0.010). CONCLUSION Regular supervised exercise during pregnancy does not alter normal maternal physiology.",2020,"Heart blood pressure was similar between groups except at 27 +0 -28 +6 weeks, where systolic blood pressure was significantly lower in the CG in comparison to the IG (116.31±10.8 mmHg vs. 120.22±10.3 mmHg, p=0.010). ","['From November 2014 to June 2015, 92 women']","['mild-moderate supervised exercise program during pregnancy (Intervention group, IG) or to continue with their routine pregnancy care (control group, CG', 'CG']","['systolic blood pressure', 'Maternal physiological changes', 'glucose tolerance', 'Aspartate-amino-transferase', 'blood Creatinine concentrations', 'analytical data (heart blood pressure, weight, blood glucose, AST, ALT, blood Creatinine and blood Uric acid', 'fasting glucose', 'Heart blood pressure', 'blood uric acid concentrations', 'normal maternal physiology']","[{'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0085845', 'cui_str': 'Aspartate'}, {'cui': 'C0040676', 'cui_str': 'Transferase'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0373739', 'cui_str': 'Blood uric acid'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",92.0,0.124229,"Heart blood pressure was similar between groups except at 27 +0 -28 +6 weeks, where systolic blood pressure was significantly lower in the CG in comparison to the IG (116.31±10.8 mmHg vs. 120.22±10.3 mmHg, p=0.010). ","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Fernández-Buhigas', 'Affiliation': 'Obstetrics Department, Hospital Universitario de Torrejon, Madrid, Spain; Faculty of Medicine, Pozuelo de Alarcón, Universidad Francisco de Vitoria, Madrid, Spain. Electronic address: ibuhigas80@gmail.com.'}, {'ForeName': 'Maia', 'Initials': 'M', 'LastName': 'Brik', 'Affiliation': ""Obstetrics Department, Hospital Universitario de Torrejon, Madrid, Spain; Faculty of Medicine, Pozuelo de Alarcón, Universidad Francisco de Vitoria, Madrid, Spain; Maternal Fetal Medicine Department. Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona. Barcelona, Spain. Electronic address: mbrik@vhebron.net.""}, {'ForeName': 'Aranzazu', 'Initials': 'A', 'LastName': 'Martin-Arias', 'Affiliation': 'Obstetrics Department, Hospital Universitario de Torrejon, Madrid, Spain; Faculty of Medicine, Pozuelo de Alarcón, Universidad Francisco de Vitoria, Madrid, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Vargas-Terrones', 'Affiliation': 'AFIPE Research Group, Faculty of Sciences for Physical Activity and Sport, INEF, Universidad Politécnica de Madrid (UPM), Madrid, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Varillas', 'Affiliation': 'Faculty of Medicine, Pozuelo de Alarcón, Universidad Francisco de Vitoria, Madrid, Spain. Electronic address: david.varillas@ufv.es.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Barakat', 'Affiliation': 'AFIPE Research Group, Faculty of Sciences for Physical Activity and Sport, INEF, Universidad Politécnica de Madrid (UPM), Madrid, Spain.'}, {'ForeName': 'Belén', 'Initials': 'B', 'LastName': 'Santacruz', 'Affiliation': 'Obstetrics Department, Hospital Universitario de Torrejon, Madrid, Spain; Faculty of Medicine, Pozuelo de Alarcón, Universidad Francisco de Vitoria, Madrid, Spain. Electronic address: bsantacruz@torrejonsalud.com.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.112863'] 237,31366975,"Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.","Defibrotide is approved for the treatment of sinusoidal obstruction syndrome after allogeneic stem cell transplantation. The exact mode of action of defibrotide is unclear and human in vivo data are scarce. In this randomized, double blind, crossover trial we included 20 healthy volunteers. Four were randomized to receive placebo, while 16 received a 2 ng/kg bodyweight bolus of lipopolysaccharide (LPS). Infusion of 6.25 mg/kg defibrotide or placebo was started one hour before the injection of the LPS bolus. Plasma levels of prothrombin fragments F1 + 2, thrombin-antithrombin complexes, von Willebrand factor, E-selectin, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), plasmin-antiplasmin complexes (PAP), tumor necrosis factor-α, interleukin 6, and C-reactive protein were measured. Thromboelastometry was performed. Infusion of defibrotide did not reduce the LPS-induced activation of coagulation, the endothelium or the release of pro-inflammatory cytokines. However, defibrotide increased t-PA antigen levels by 31% (Quartiles: 2-49%, p = 0.026) and PAP concentrations by 13% (-4-41%, p = 0.039), while PAI-1 levels remained unaffected. Moreover, defibrotide reduced C-reactive protein levels by 13% (0-17%, p = 0.002). A transient increase in the clotting time in thromboelastometry and a decrease in F1 + 2 prothrombin fragments suggests modest anticoagulant properties. In conclusion, defibrotide infusion enhanced fibrinolysis and reduced C-reactive protein levels during experimental endotoxemia.",2019,"Infusion of defibrotide did not reduce the LPS-induced activation of coagulation, the endothelium or the release of pro-inflammatory cytokines.","['human endotoxemia ', '20 healthy volunteers', 'sinusoidal obstruction syndrome after allogeneic stem cell transplantation', 'healthy volunteers']","['defibrotide', 'defibrotide or placebo', 'placebo', 'lipopolysaccharide (LPS', 'Defibrotide']","['fibrinolysis and reduced C-reactive protein levels', 'PAI-1 levels', 'PAI-1), plasmin-antiplasmin complexes (PAP', 'Plasma levels of prothrombin fragments F1\u2009+\u20092, thrombin-antithrombin complexes, von Willebrand factor, E-selectin, tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1', 'defibrotide reduced C-reactive protein levels', 'PAP concentrations', 'clotting time', 'LPS-induced activation of coagulation, the endothelium or the release of pro-inflammatory cytokines', 't-PA antigen levels', ' tumor necrosis factor-α, interleukin 6, and C-reactive protein']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0376618', 'cui_str': 'Endotoxemia'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0019156', 'cui_str': 'Sinusoidal Obstruction Syndrome'}, {'cui': 'C2242529', 'cui_str': 'Allogenic stem cell transplantation'}]","[{'cui': 'C0057257', 'cui_str': 'defibrotide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}]","[{'cui': 'C1305868', 'cui_str': 'Fibrinolysis'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0030190', 'cui_str': 'SERPINE1 Protein'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0016016', 'cui_str': 'fibrinolysin'}, {'cui': 'C0003410', 'cui_str': 'alpha 2-Plasmin Inhibitor'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0033706', 'cui_str': 'coagulation factor II'}, {'cui': 'C0863178', 'cui_str': 'Thrombin'}, {'cui': 'C0003440', 'cui_str': 'Direct Thrombin Inhibitors'}, {'cui': 'C0042971', 'cui_str': 'von Willebrand factor'}, {'cui': 'C0115305', 'cui_str': 'LECAM-2'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0057257', 'cui_str': 'defibrotide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0014257', 'cui_str': 'Endothelium'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0430420', 'cui_str': 'Antigen level'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",20.0,0.360124,"Infusion of defibrotide did not reduce the LPS-induced activation of coagulation, the endothelium or the release of pro-inflammatory cytokines.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schoergenhofer', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Buchtele', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Gelbenegger', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Derhaschnig', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Firbas', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Katarina D', 'Initials': 'KD', 'LastName': 'Kovacevic', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schwameis', 'Affiliation': 'Department of Emergency Medicine, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Wohlfarth', 'Affiliation': 'Department of Blood and Bone Marrow Transplantation, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Rabitsch', 'Affiliation': 'Department of Blood and Bone Marrow Transplantation, Medical University of Vienna, Wien, Austria.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Jilma', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Wien, Austria. Bernd.jilma@meduniwien.ac.at.'}]",Scientific reports,['10.1038/s41598-019-47630-6'] 238,31366977,Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients.,"Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies in the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial. Paired blood and tissue samples were assessed by methylation-specific PCR (MSP) and pyrosequencing (PYR). After establishing the minimum PYR cut-off that could yield a significant difference in overall survival, we assessed the sensitivity, specificity, positive predictive value and negative predictive value (NPV) of the analyses. Methylation could be detected in cfDNA by both MSP and PYR but with low concordance with results in tissue. Sensitivity was low for both methods (31% and 38%, respectively), while specificity was higher for MSP in blood than for PYR in plasma (96% vs 76%) and NPV was similar (56 vs 57%). Concordance of results in tissue by MSP and PYR was 84.3% (P < 0.001) and correlated with outcome. We conclude that detection of cfDNA in the blood of glioblastoma patients can be an alternative when tumor tissue is not available but methods for the detection of cfDNA in blood must improve before it can replace analysis in tumor tissue.",2019,Concordance of results in tissue by MSP and PYR was 84.3% (P < 0.001) and correlated with outcome.,"['glioblastoma patients', 'unresected glioblastoma patients who had been included in the randomized GENOM-009 trial']",[],"['methylation-specific PCR (MSP) and pyrosequencing (PYR', 'sensitivity, specificity, positive predictive value and negative predictive value (NPV', 'Sensitivity', 'overall survival']","[{'cui': 'C0017636', 'cui_str': 'Astrocytoma, Grade IV'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0025723', 'cui_str': 'Methylation'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C2732543', 'cui_str': 'Pyrosequencing'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0976339,Concordance of results in tissue by MSP and PYR was 84.3% (P < 0.001) and correlated with outcome.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Estival', 'Affiliation': 'Medical Oncology Service, Catalan Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Applied Research Group in Oncology (B-ARGO Group), Badalona, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Sanz', 'Affiliation': 'Pathology Service, University Hospital Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Jose-Luis', 'Initials': 'JL', 'LastName': 'Ramirez', 'Affiliation': 'Medical Oncology Service, Catalan Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Applied Research Group in Oncology (B-ARGO Group), Badalona, Spain.'}, {'ForeName': 'Jose Maria', 'Initials': 'JM', 'LastName': 'Velarde', 'Affiliation': 'Statistical Unit, Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Domenech', 'Affiliation': 'Medical Oncology Service, Catalan Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Applied Research Group in Oncology (B-ARGO Group), Badalona, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Carrato', 'Affiliation': 'Pathology Service, University Hospital Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'de Las Peñas', 'Affiliation': 'Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Gil-Gil', 'Affiliation': ""Medical Oncology Service, Catalan Institute of Oncology l'Hospitalet de LLobregat, Bellvitge Biomedical Research Institute (IDIBELL) l'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Sepúlveda', 'Affiliation': 'Medical Oncology Service, University Hospital 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Roser', 'Initials': 'R', 'LastName': 'Armengol', 'Affiliation': 'Neurosurgery Service, Hospital Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Cardiel', 'Affiliation': 'Neurosurgery Service, Hospital Germans Trias i Pujol, Badalona, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Berrocal', 'Affiliation': 'Medical Oncology Service, University Hospital General de Valencia, Valencia, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Luque', 'Affiliation': 'Medical Oncology Service, University Hospital Virgen de las Nieves, Granada, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Herrero', 'Affiliation': 'Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Balana', 'Affiliation': 'Medical Oncology Service, Catalan Institute of Oncology Badalona, Hospital Germans Trias i Pujol, Applied Research Group in Oncology (B-ARGO Group), Badalona, Spain. cbalana@iconcologia.net.'}]",Scientific reports,['10.1038/s41598-019-47642-2'] 239,31366980,A randomized feasibility study of the effect of ascorbic acid on post-angioplasty restenosis of hemodialysis vascular access (NCT03524846).,"Restenosis remains a significant problem after angioplasty of hemodialysis vascular access. Both experimental and clinical studies have shown a protective effect of antioxidants against post-angioplasty restenosis. A prospective, randomized, feasibility study was conducted to investigate the effect of ascorbic acid to prevent restenosis. Ninety-three hemodialysis patients were randomized into three groups after angioplasty: placebo (n = 31), 300 mg ascorbic acid (n = 31), and 600 mg ascorbic acid (n = 31), treated intravenously 3 times per week for 3 months. Eighty-nine completed the clinical follow-up, and 81 had angiographic follow-up. In the angiographic follow-up, the mean (stand deviation) late loss of luminal diameter for the placebo, 300 mg, and 600 mg groups were 3.15 (1.68) mm, 2.52 (1.70) mm (P = 0.39 vs. placebo group), and 1.59 (1.67) mm (P = 0.006, vs. placebo group), with corresponding angiographic binary restenosis of 79%, 67% (P = 0.38 vs. placebo group), and 54% (P = 0.08 vs. placebo group). The post-interventional primary patency rates at 3 months were 47%, 55% (P = 0.59 vs. placebo group), and 70% (P = 0.18 vs. placebo group) for placebo, 300 mg, and 600 mg groups. Our results demonstrated that intravenous 600 mg ascorbic acid was a feasible therapy and might attenuate restenosis after angioplasty; however, its effect on post-interventional primary patency was modest.",2019,"The post-interventional primary patency rates at 3 months were 47%, 55% (P = 0.59 vs. placebo group), and 70% (P = 0.18 vs. placebo group) for placebo, 300 mg, and 600 mg groups.","['Ninety-three hemodialysis patients', 'Eighty-nine completed the clinical follow-up, and 81 had angiographic follow-up']","['angioplasty: placebo', 'placebo', 'ascorbic acid']","['angiographic binary restenosis', 'mean (stand deviation) late loss of luminal diameter', 'patency rates']","[{'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}]","[{'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0012727', 'cui_str': 'Displacement (morphologic abnormality)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]",89.0,0.228914,"The post-interventional primary patency rates at 3 months were 47%, 55% (P = 0.59 vs. placebo group), and 70% (P = 0.18 vs. placebo group) for placebo, 300 mg, and 600 mg groups.","[{'ForeName': 'Chung-Wei', 'Initials': 'CW', 'LastName': 'Yang', 'Affiliation': 'Division of Nephrology, Department of Medicine, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan.'}, {'ForeName': 'Chih-Cheng', 'Initials': 'CC', 'LastName': 'Wu', 'Affiliation': 'Cardiovascular Center, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan. chihchengwumd@gmail.com.'}, {'ForeName': 'Chien-Ming', 'Initials': 'CM', 'LastName': 'Luo', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan.'}, {'ForeName': 'Shao-Yuan', 'Initials': 'SY', 'LastName': 'Chuang', 'Affiliation': 'Division of Preventive Medicine and Health Services Research, Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.'}, {'ForeName': 'Chiu-Hui', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'Department of Nursing, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan.'}, {'ForeName': 'Yung-Fang', 'Initials': 'YF', 'LastName': 'Shen', 'Affiliation': 'Department of Nursing, National Taiwan University Hospital, Hsinchu Branch, Hsinchu, Taiwan.'}, {'ForeName': 'Der-Cheng', 'Initials': 'DC', 'LastName': 'Tarng', 'Affiliation': 'Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan. dctarng@gmail.com.'}]",Scientific reports,['10.1038/s41598-019-47583-w'] 240,32307124,"Changes in Firearm and Medication Storage Practices in Homes of Youths at Risk for Suicide: Results of the SAFETY Study, a Clustered, Emergency Department-Based, Multisite, Stepped-Wedge Trial.","STUDY OBJECTIVE We evaluate whether a counseling intervention implemented at the hospital level resulted in safer firearm and medication storage by caregivers of youths aged 10 to 17 years after their child's evaluation in the emergency department (ED) for a behavioral health concern. METHODS We used a stepped-wedge clustered design rolled out at 4 hospital sites to assess primary preregistered outcomes (self-reported storage changes caregivers made to household firearms and medications), assessed by survey 2 weeks after the ED visit. Three logistic models provided estimates of the intervention effect: an unadjusted model, a model with hospital-level fixed effects, and a model that further adjusts for time. RESULTS Of the 575 caregiver participants, 208 were firearm owners (123 in usual care, 85 in the intervention). Baseline (pre-ED visit) characteristics did not differ between usual care and intervention phases. During the 2-year study period, twice as many caregivers whose child visited the ED after (compared with before) a hospital adopted the intervention improved firearm storage and 3 times as many improved medication storage (odds ratio [OR]=2.1 [95% confidence interval {CI} 1.0 to ∞] and OR=3.0 [95% CI 2.2 to ∞], respectively). After adjusting for time, the intervention effect for medications persisted (OR=2.0 [95% CI 1.0 to ∞]); the effect on firearms did not (OR=0.7 [95% CI 0.1 to ∞]). CONCLUSION To our knowledge, this study is the first controlled trial to estimate the effectiveness of an intervention on firearm and medication storage in homes of youths at elevated risk of suicide. We found evidence that caregivers' medication storage improved after their child's ED visit, with evidence suggestive of improvement for firearm storage.",2020,"We evaluate whether a counseling intervention implemented at the hospital level resulted in safer firearm and medication storage by caregivers of youths aged 10 to 17 years after their child's evaluation in the emergency department (ED) for a behavioral health concern. ","[""caregivers of youths aged 10 to 17 years after their child's evaluation in the emergency department (ED) for a behavioral health concern"", 'Homes of Youths at Risk for Suicide', 'homes of youths at elevated risk of suicide', 'Of the 575 caregiver participants, 208 were firearm owners (123 in usual care, 85 in the intervention']",['counseling intervention'],['firearm storage and 3 times as many improved medication storage'],"[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0563664', 'cui_str': 'At risk for suicide'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C3844102', 'cui_str': '575'}, {'cui': 'C0016139', 'cui_str': 'Firearm'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0016139', 'cui_str': 'Firearm'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",575.0,0.122917,"We evaluate whether a counseling intervention implemented at the hospital level resulted in safer firearm and medication storage by caregivers of youths aged 10 to 17 years after their child's evaluation in the emergency department (ED) for a behavioral health concern. ","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Miller', 'Affiliation': 'Northeastern University, Boston, MA; Harvard Injury Control Research Center, Harvard Chan School of Public Health, Boston, MA. Electronic address: ma.miller@northeastern.edu.'}, {'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Salhi', 'Affiliation': 'Northeastern University, Boston, MA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Barber', 'Affiliation': 'Harvard Injury Control Research Center, Harvard Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Azrael', 'Affiliation': 'Harvard Injury Control Research Center, Harvard Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Beatriz', 'Affiliation': 'Northeastern University, Boston, MA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Berrigan', 'Affiliation': 'Harvard Injury Control Research Center, Harvard Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Brandspigel', 'Affiliation': 'Colorado School of Public Health, Aurora, CO.'}, {'ForeName': 'Marian E', 'Initials': 'ME', 'LastName': 'Betz', 'Affiliation': 'University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Runyan', 'Affiliation': 'Colorado School of Public Health, Aurora, CO.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2020.02.007'] 241,30609099,CBT for late-life insomnia and the accuracy of sleep and wake perceptions: Results from a randomized-controlled trial.,"Subjective and objective estimates of sleep are often discordant among individuals with insomnia who typically under-report sleep time and over-report wake time at night. This study examined the impact and durability of cognitive-behavioural therapy for insomnia on improving the accuracy of sleep and wake perceptions in older adults, and tested whether changes in sleep quality were related to changes in the accuracy of sleep/wake perceptions. One-hundred and fifty-nine older veterans (97% male, mean age 72.2 years) who met diagnostic criteria for insomnia disorder were randomized to: (1) cognitive-behavioural therapy for insomnia (n = 106); or (2) attention control (n = 53). Assessments were conducted at baseline, post-treatment, 6-months and 12-months follow-up. Sleep measures included objective (via wrist actigraphy) and subjective (via self-report diary) total sleep time and total wake time, along with Pittsburgh Sleep Quality Index score. Discrepancy was computed as the difference between objective and subjective estimates of wake and sleep. Minutes of discrepancy were compared between groups across time, as were the relationships between Pittsburgh Sleep Quality Index scores and subsequent changes in discrepancy. Compared with controls, participants randomized to cognitive-behavioural therapy for insomnia became more accurate (i.e. minutes discrepancy was reduced) in their perceptions of sleep/wake at post-treatment, 6-months and 12-months follow-up (p < .05). Improved Pittsburgh Sleep Quality Index scores at each study assessment preceded and predicted reduced discrepancy at the next study assessment (p < .05). Cognitive-behavioural therapy for insomnia reduces sleep/wake discrepancy among older adults with insomnia. The reductions may be driven by improvements in sleep quality. Improving sleep quality appears to be a viable path to improving sleep perception and may contribute to the underlying effectiveness of cognitive-behavioural therapy for insomnia.",2019,"Compared with controls, participants randomized to cognitive-behavioural therapy for insomnia became more accurate (i.e. minutes discrepancy was reduced) in their perceptions of sleep/wake at post-treatment, 6-months and 12-months follow-up (p < .05).","['older adults with insomnia', 'One-hundred and fifty-nine older veterans (97% male, mean age 72.2\u2005years) who met diagnostic criteria for insomnia disorder', 'older adults']","['cognitive-behavioural therapy for insomnia (n\u2005=\u2005106); or (2) attention control', 'cognitive-behavioural therapy', 'Cognitive-behavioural therapy', 'CBT']","['objective and subjective estimates of wake and sleep', 'objective (via wrist actigraphy) and subjective (via self-report diary) total sleep time and total wake time, along with Pittsburgh Sleep Quality Index score', 'Improved Pittsburgh Sleep Quality Index scores', 'accuracy of sleep and wake perceptions', 'sleep quality', 'Pittsburgh Sleep Quality Index scores']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0442696', 'cui_str': 'Waking (observable entity)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4545801', 'cui_str': 'PSQI (Pittsburgh Sleep Quality Index) score'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",159.0,0.0378559,"Compared with controls, participants randomized to cognitive-behavioural therapy for insomnia became more accurate (i.e. minutes discrepancy was reduced) in their perceptions of sleep/wake at post-treatment, 6-months and 12-months follow-up (p < .05).","[{'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Dzierzewski', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Martin', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, California, USA.'}, {'ForeName': 'Constance H', 'Initials': 'CH', 'LastName': 'Fung', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, California, USA.'}, {'ForeName': 'Yeonsu', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'VA Greater Los Angeles Healthcare System, Geriatric Research, Education and Clinical Center, Los Angeles, California, USA.'}, {'ForeName': 'Lavinia', 'Initials': 'L', 'LastName': 'Fiorentino', 'Affiliation': 'School of Medicine, Psychiatry Department, University of California, San Diego, California, USA.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Jouldjian', 'Affiliation': 'VA Greater Los Angeles Healthcare System, Geriatric Research, Education and Clinical Center, Los Angeles, California, USA.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Rodriguez', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, California, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mitchell', 'Affiliation': 'VA Greater Los Angeles Healthcare System, Geriatric Research, Education and Clinical Center, Los Angeles, California, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Josephson', 'Affiliation': 'VA Greater Los Angeles Healthcare System, Geriatric Research, Education and Clinical Center, Los Angeles, California, USA.'}, {'ForeName': 'Cathy A', 'Initials': 'CA', 'LastName': 'Alessi', 'Affiliation': 'David Geffen School of Medicine, University of California, Los Angeles, California, USA.'}]",Journal of sleep research,['10.1111/jsr.12809'] 242,31443102,Colonization by B. infantis EVC001 modulates enteric inflammation in exclusively breastfed infants.,"BACKGROUND Infant gut dysbiosis, often associated with low abundance of bifidobacteria, is linked to impaired immune development and inflammation-a risk factor for increased incidence of several childhood diseases. We investigated the impact of B. infantis EVC001 colonization on enteric inflammation in a subset of exclusively breastfed term infants from a larger clinical study. METHODS Stool samples (n = 120) were collected from infants randomly selected to receive either 1.8 × 10 10 CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal. The fecal microbiome was analyzed using 16S ribosomal RNA, proinflammatory cytokines using multiplexed immunoassay, and fecal calprotectin using ELISA at three time points: days 6 (Baseline), 40, and 60 postnatal. RESULTS Fecal calprotectin concentration negatively correlated with Bifidobacterium abundance (P < 0.0001; ρ = -0.72), and proinflammatory cytokines correlated with Clostridiaceae and Enterobacteriaceae, yet negatively correlated with Bifidobacteriaceae abundance. Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. CONCLUSION Our findings indicate that gut dysbiosis (absence of B. infantis) is associated with increased intestinal inflammation. Early addition of EVC001 to diet represents a novel strategy to prevent enteric inflammation during a critical developmental phase.",2019,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","['exclusively breastfed infants', 'Stool samples (n\u2009=\u2009120']","['CFU B. infantis EVC001 daily for 21 days (EVC001) or breast milk alone (controls), starting at day 7 postnatal']","['Proinflammatory cytokines', 'intestinal inflammation', 'fecal microbiome', 'Fecal calprotectin concentration', 'enteric inflammation', 'proinflammatory cytokines']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1550661', 'cui_str': 'Feces specimen'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}]","[{'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C3889047', 'cui_str': 'Intestinal inflammation'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",1010.0,0.0603489,"Proinflammatory cytokines were significantly lower in EVC001-fed infants on days 40 and 60 postnatally compared to baseline and compared to control infants. ","[{'ForeName': 'Bethany M', 'Initials': 'BM', 'LastName': 'Henrick', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA. bhenrick2@unl.edu.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Chew', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Casaburi', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Heather K', 'Initials': 'HK', 'LastName': 'Brown', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Frese', 'Affiliation': 'Evolve Biosystems, Inc, Davis, CA, USA.'}, {'ForeName': 'You', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Morrison Microscopy Core Research Facility, University of Nebraska, Lincoln, NE, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Underwood', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Jennifer T', 'Initials': 'JT', 'LastName': 'Smilowitz', 'Affiliation': 'Foods for Health Institute, University of California Davis, Davis, CA, USA.'}]",Pediatric research,['10.1038/s41390-019-0533-2'] 243,25099640,Methotrexate for induction of remission in refractory Crohn's disease.,"BACKGROUND Although corticosteroids are effective for induction of remission of Crohn's disease, many patients relapse when steroids are withdrawn or become steroid dependent. Furthermore, corticosteroids exhibit significant adverse effects. The success of methotrexate as a treatment for rheumatoid arthritis led to its evaluation in patients with refractory Crohn's disease. Methotrexate has been studied for induction of remission of refractory Crohn's disease and has become the principal alternative to azathioprine or 6-mercaptopurine therapy. This systematic review is an update of previously published Cochrane reviews. OBJECTIVES The primary objective was to assess the efficacy and safety of methotrexate for induction of remission in patients with active Crohn's disease in the presence or absence of concomitant steroid therapy. SEARCH METHODS We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD/FBD group specialized register from inception to June 9, 2014 for relevant studies. Conference proceedings and reference lists were also searched to identify additional studies. SELECTION CRITERIA Randomized controlled trials of methotrexate compared to placebo or an active comparator for treatment of active refractory Crohn's disease in adult patients (> 17 years) were considered for inclusion. DATA COLLECTION AND ANALYSIS The primary outcome was failure to enter remission and withdraw from steroids. Secondary outcomes included adverse events, withdrawal due to adverse events, serious adverse events and quality of life. We calculated the relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. Data were analyzed on an intention-to-treat basis. The Cochrane risk of bias tool was used to assess the methodological quality of included studies. The GRADE approach was used to assess the overall quality of evidence supporting the primary outcome. MAIN RESULTS Seven studies (495 patients) were included. Four studies were rated as low risk of bias. Three studies were rated as high risk of bias due to open label or single-blind designs. The seven studies differed with respect to participants, intervention, and outcomes to the extent that meta-analysis was considered to be inappropriate. GRADE analyses indicated that the quality of evidence was very low to low for most outcomes due to sparse data and inadequate blinding. Three small studies which employed low dose oral methotrexate showed no statistically significant difference in failure to induce remission between methotrexate and placebo or between methotrexate and 6-mercaptopurine. For the study using 15 mg/week of oral methotrexate 33% (5/15) of methotrexate patients failed to enter remission compared to 11% (2/18) of placebo patients (RR 3.00, 95% CI 0.68 to 13.31). For the study using 12.5 mg/week of oral methotrexate 81% (21/26) of methotrexate patients failed to enter remission compared to 77% (20/26) of placebo patients (RR 1.05, 95% CI 0.79 to 1.39). This study also had an active comparator arm, 81% (21/26) of methotrexate patients failed to enter remission compared to 59% (19/32) of 6-mercaptopurine patients (RR 1.36, 95% CI 0.97 to 1.92). For the active comparator study using 15 mg/week oral methotrexate, 20% (3/15) of methotrexate patients failed to enter remission compared to 6% of 6-mercaptopurine patients (RR 3.20, 95% CI 0.37 to 27.49). This study also had a 5-ASA arm and found that methotrexate patients were significantly more likely to enter remission than 5-ASA patients. Twenty per cent (3/15) of methotrexate patients failed to enter remission compared to 86% (6/7) of 5-ASA patients (RR 0.23, 95% CI 0.08 to 0.67). One small study which used a higher dose of intravenous or oral methotrexate (25 mg/week) showed no statistically significant difference between methotrexate and azathioprine. Forty-four per cent (12/27) of methotrexate patients failed to enter remission compared to 37% of azathioprine patients (RR 1.20, 95% CI 0.63 to 2.29). Two studies found no statistically significant difference in failure to enter remission between the combination of infliximab and methotrexate and infliximab monotherapy. One small study utilized intravenous methotrexate (20 mg/week) for 5 weeks and then switched to oral (20 mg/week). Forty-five per cent (5/11) of patients in the combination group failed to enter remission compared to 62% of infliximab patients (RR 0.73, 95% CI 0.31 to 1.69). The other study assessing combination therapy utilized subcutaneous methotrexate (maximum dose 25 mg/week). Twenty-four per cent (15/63) of patients in the combination group failed to enter remission compared to 22% (14/63) of infliximab patients (RR 1.07, 95% CI 0.57 to 2.03). A large placebo-controlled study which employed a high dose of methotrexate intramuscularly showed a statistically significant benefit relative to placebo. Sixty-one per cent of methotrexate patients failed to enter remission compared to 81% of placebo patients (RR 0.75, 95% CI 0.61 to 0.93; number needed to treat, NNT=5). Withdrawals due to adverse events were significantly more common in methotrexate patients than placebo in this study. Seventeen per cent of methotrexate patients withdrew due to adverse events compared to 2% of placebo patients (RR 8.00, 95% CI 1.09 to 58.51). The incidence of adverse events was significantly more common in methotrexate patients (63%, 17/27) than azathioprine patients (26%, 7/27) in one small study (RR 2.42, 95% CI 1.21 to 4.89). No other statistically significant differences in adverse events, withdrawals due to adverse events or serious adverse events were reported in any of the other placebo-controlled or active comparator studies. Common adverse events included nausea and vomiting, abdominal pain, diarrhea, skin rash and headache. AUTHORS' CONCLUSIONS There is evidence from a single large randomized trial which suggests that intramuscular methotrexate (25 mg/week) provides a benefit for induction of remission and complete withdrawal from steroids in patients with refractory Crohn's disease. Lower dose oral methotrexate does not appear to provide any significant benefit relative to placebo or active comparator. However, these trials were small and further studies of oral methotrexate may be justified. Comparative studies of methotrexate to drugs such as azathioprine or 6-mercaptopurine would require the randomization of large numbers of patients. The addition of methotrexate to infliximab therapy does not appear to provide any additional benefit over infliximab monotherapy. However these studies were relatively small and further research is needed to determine the role of methotrexate when used in conjunction with infliximab or other biological therapies.",2014,Three small studies which employed low dose oral methotrexate showed no statistically significant difference in failure to induce remission between methotrexate and placebo or between methotrexate and 6-mercaptopurine.,"[""active refractory Crohn's disease in adult patients (> 17 years"", ""patients with active Crohn's disease in the presence or absence of concomitant steroid therapy"", ""patients with refractory Crohn's disease"", 'Seven studies (495 patients) were included']","['methotrexate and azathioprine', 'Methotrexate', '6-mercaptopurine', 'methotrexate', 'placebo', 'intramuscular methotrexate', 'methotrexate and 6-mercaptopurine', 'azathioprine or 6-mercaptopurine therapy', 'oral methotrexate', 'azathioprine', 'subcutaneous methotrexate', 'infliximab and methotrexate', '5-ASA', 'azathioprine or 6-mercaptopurine', 'methotrexate and placebo']","['nausea and vomiting, abdominal pain, diarrhea, skin rash and headache', 'enter remission', 'failure to induce remission', 'efficacy and safety', 'relative risk (RR', 'remission', 'adverse events, withdrawals due to adverse events or serious adverse events', 'adverse events', 'incidence of adverse events', 'adverse events, withdrawal due to adverse events, serious adverse events and quality of life', 'failure to enter remission and withdraw from steroids', 'failure to enter remission']","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0149783', 'cui_str': 'Steroid therapy (procedure)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0000618', 'cui_str': 'mercaptopurine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0127615', 'cui_str': 'mesalazine'}]","[{'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0034380'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}]",,0.417374,Three small studies which employed low dose oral methotrexate showed no statistically significant difference in failure to induce remission between methotrexate and placebo or between methotrexate and 6-mercaptopurine.,"[{'ForeName': 'John W D', 'Initials': 'JW', 'LastName': 'McDonald', 'Affiliation': 'Robarts Clinical Trials, Robarts Research Institute, P.O. Box 5015, 100 Perth Drive, London, ON, Canada, N6A 5K8.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Tsoulis', 'Affiliation': ''}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'MacDonald', 'Affiliation': ''}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Feagan', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD003459.pub4'] 244,30537561,Long-Term Efficacy and Dose-Finding Trial of Japanese Cedar Pollen Sublingual Immunotherapy Tablet.,"BACKGROUND Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan. The JC pollen sublingual immunotherapy (SLIT) tablet was developed using the highest concentration of JC pollen extract. OBJECTIVE This was a randomized, double-blind, placebo-controlled phase II/III trial to investigate the optimal dose of the JC pollen SLIT tablet and examine long-term efficacy and safety for 3 years with the selected dose, and 2-year follow-up. METHODS A total of 1042 patients with JC pollinosis (aged 5-64 years) were equally randomized into 4 groups and received daily treatment with 2,000, 5,000, or 10,000 Japanese allergy unit (JAU) or placebo. The primary end point was the total nasal symptom and medication score (TNSMS) during the peak symptom period in the first season. Key secondary end points were TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score for the peak symptom period and JC pollen dispersion season. RESULTS For the primary end point, absolute reductions and relative mean reductions in TNSMS compared with placebo were 1.50 and 21.4%, 2.24 and 32.1%, and 2.18 and 31.2% for 2,000, 5,000, and 10,000 JAU, respectively (P < .001 in all groups). For all key secondary end points, efficacy was confirmed for all doses (P < .001 in all groups). The treatment was well tolerated. Long-term efficacy of 5,000 JAU was shown over the 3 years. CONCLUSIONS The optimal dose of the JC pollen SLIT tablet was 5,000 JAU, with good efficacy and safety over a 3-year treatment period. This sustained effect was dependent on treatment duration.",2019,"For all key secondary end points, efficacy was confirmed for all doses (P < .001 in all groups).","['Japanese cedar (JC) pollinosis is a common allergic rhinitis in Japan', '1042 patients with JC pollinosis (aged 5-64 years']","['Japanese allergy unit (JAU) or placebo', 'Japanese Cedar Pollen Sublingual Immunotherapy Tablet', 'placebo']","['TNSMS for the JC pollen dispersion season and total nasal and ocular symptom and medication score for the peak symptom period and JC pollen dispersion season', 'tolerated', 'total nasal symptom and medication score (TNSMS']","[{'cui': 'C0996622', 'cui_str': 'Cedar, Japanese'}, {'cui': 'C0018621', 'cui_str': 'Rhinitis, Allergic, Seasonal'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0002111', 'cui_str': 'Allergy Specialty'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0440380', 'cui_str': 'Japanese cedar pollen (substance)'}, {'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0032385', 'cui_str': 'Pollen Grains'}, {'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0231918', 'cui_str': 'Nasal symptom'}]",1042.0,0.127519,"For all key secondary end points, efficacy was confirmed for all doses (P < .001 in all groups).","[{'ForeName': 'Minoru', 'Initials': 'M', 'LastName': 'Gotoh', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. Electronic address: m.gotoh@nms.ac.jp.'}, {'ForeName': 'Syuji', 'Initials': 'S', 'LastName': 'Yonekura', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Imai', 'Affiliation': 'Association of Pollen Information of Japan, Tokyo, Japan.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Kaneko', 'Affiliation': 'Department of Clinical Development, Torii Pharmaceutical Co., Ltd, Tokyo, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Horikawa', 'Affiliation': 'Department of Clinical Development, Torii Pharmaceutical Co., Ltd, Tokyo, Japan.'}, {'ForeName': 'Akiyoshi', 'Initials': 'A', 'LastName': 'Konno', 'Affiliation': 'Allergy and Head and Neck Tumor Center, Southern Tohoku General Hospital, Fukushima, Japan.'}, {'ForeName': 'Yoshitaka', 'Initials': 'Y', 'LastName': 'Okamoto', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Kimihiro', 'Initials': 'K', 'LastName': 'Okubo', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2018.11.044'] 245,30828771,Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.,"OBJECTIVES The aim of this study was to prove the suitability of simultaneously administered microdoses of the factor Xa inhibitors (FXaIs) rivaroxaban, apixaban and edoxaban (100 µg in total). To evaluate drug-drug interactions, the impact of ketoconazole, a known strong inhibitor of cytochrome P450 3A4 and P-glycoprotein, was studied. METHODS In a crossover clinical trial, 18 healthy volunteers were randomized to the two treatments using microdoses of rivaroxaban, apixaban and edoxaban alone and when coadministered with ketoconazole. Plasma and urine concentrations of microdosed apixaban, edoxaban and rivaroxaban were quantified using a validated ultra-performance liquid chromatography-tandem mass spectrometry assay with a lower limit of quantification of 2.5 pg/ml. RESULTS The microdosed FXaI cocktail showed similar pharmacokinetic parameters compared with published data, using normal therapeutic doses of each FXaI. Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban). CONCLUSION The microdosed FXaI cocktail approach was able to precisely predict the drug interaction with ketoconazole. This is the first study that has been conducted to evaluate drug-drug interactions with a drug class, and the low administered doses also allow evaluation in vulnerable target populations. STUDY PROTOCOL EudraCT 2016-003024-23.",2019,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban). ","['EudraCT 2016-003024-23', '18 healthy volunteers']","['factor Xa inhibitors (FXaIs) rivaroxaban, apixaban and edoxaban', 'Ketoconazole', 'ketoconazole', 'rivaroxaban, apixaban and edoxaban alone and when coadministered with ketoconazole', 'edoxaban and rivaroxaban', 'FXaI']","['Plasma and urine concentrations', 'geometric mean AUC ratios']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4553708', 'cui_str': 'Factor Xa inhibitor'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0022625', 'cui_str': 'Ketoconazole'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0042037'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",18.0,0.084234,"Ketoconazole significantly increased exposure, with geometric mean AUC ratios of 1.90 (apixaban), 2.35 (edoxaban) and 2.27 (rivaroxaban). ","[{'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Mikus', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. gerd.mikus@med.uni-heidelberg.de.'}, {'ForeName': 'Kathrin I', 'Initials': 'KI', 'LastName': 'Foerster', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Schaumaeker', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.'}, {'ForeName': 'Marie-Louise', 'Initials': 'ML', 'LastName': 'Lehmann', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Burhenne', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.'}, {'ForeName': 'Walter E', 'Initials': 'WE', 'LastName': 'Haefeli', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00749-1'] 246,31175806,Colonic mucosal and exfoliome transcriptomic profiling and fecal microbiome response to a flaxseed lignan extract intervention in humans.,"BACKGROUND Microbial metabolism of lignans from high-fiber plant foods produces bioactive enterolignans, such as enterolactone (ENL) and enterodiol (END). Enterolignan exposure influences cellular pathways important to cancer risk and is associated with reduced colon tumorigenesis in animal models and lower colorectal cancer risk in humans. OBJECTIVES The aim of this study was to test the effects of a flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d) compared with placebo on host gene expression in colon biopsies and exfoliated colonocyte RNA in feces and fecal microbial community composition, and to compare responses in relation to ENL excretion. METHODS We conducted a 2-period randomized, crossover intervention in 42 healthy men and women (20-45 y). We used RNA-seq to measure differentially expressed (DE) genes in colonic mucosa and fecal exfoliated cells through the use of edgeR and functional analysis with Ingenuity Pathway Analysis. We used 16S ribosomal RNA gene (V1-V3) analysis to characterize the fecal microbiome, and measured END and ENL in 24-h urine samples by gas chromatography-mass spectrometry. RESULTS We detected 32 DE genes (false discovery rate <0.05) in the exfoliome, but none in the mucosal biopsies, in response to 60 d of lignan supplement compared with placebo. Statistically significant associations were detected between ENL excretion and fecal microbiome measured at baseline and at the end of the intervention periods. Further, we detected DE genes in colonic mucosa and exfoliome between low- and high-ENL excreters. Analysis of biopsy samples indicated that several anti-inflammatory upstream regulators, including transforming growth factor β and interleukin 10 receptor, were suppressed in low-ENL excreters. Complementary analyses in exfoliated cells also suggested that low-ENL excreters may be predisposed to proinflammatory cellular events due to upregulation of nuclear transcription factor κB and NOS2, and an inhibition of the peroxisome proliferator-activated receptor γ network. CONCLUSIONS These results suggest that ENL or other activities of the associated gut microbial consortia may modulate response to a dietary lignan intervention. This has important implications for dietary recommendations and chemoprevention strategies. This study was registered at clinicaltrials.gov as NCT01619020.",2019,"Analysis of biopsy samples indicated that several anti-inflammatory upstream regulators, including transforming growth factor β and interleukin 10 receptor, were suppressed in low-ENL excreters.","['humans', '42 healthy men and women (20-45 y']","['flaxseed lignan extract intervention', 'ENL', 'placebo', 'flaxseed lignan supplement (50 mg secoisolariciresinol diglucoside/d']",['ENL excretion and fecal microbiome'],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0023753', 'cui_str': 'Flaxseed'}, {'cui': 'C0064971', 'cui_str': 'Lignans'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0290196', 'cui_str': 'secoisolariciresinol diglucoside'}]","[{'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}]",42.0,0.0518649,"Analysis of biopsy samples indicated that several anti-inflammatory upstream regulators, including transforming growth factor β and interleukin 10 receptor, were suppressed in low-ENL excreters.","[{'ForeName': 'Johanna W', 'Initials': 'JW', 'LastName': 'Lampe', 'Affiliation': 'Public Health Sciences Division.'}, {'ForeName': 'Eunji', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'Department of Electrical & Computer Engineering.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Levy', 'Affiliation': 'Public Health Sciences Division.'}, {'ForeName': 'Laurie A', 'Initials': 'LA', 'LastName': 'Davidson', 'Affiliation': 'Center for Translational Environmental Health Research.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Goldsby', 'Affiliation': 'Center for Translational Environmental Health Research.'}, {'ForeName': 'Fayth L', 'Initials': 'FL', 'LastName': 'Miles', 'Affiliation': 'Public Health Sciences Division.'}, {'ForeName': 'Sandi L', 'Initials': 'SL', 'LastName': 'Navarro', 'Affiliation': 'Public Health Sciences Division.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Randolph', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Ni', 'Initials': 'N', 'LastName': 'Zhao', 'Affiliation': 'Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Ivanov', 'Affiliation': 'Center for Translational Environmental Health Research.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Kaz', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Damman', 'Affiliation': 'School of Medicine, University of Washington, Seattle, WA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Hockenbery', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Meredith A J', 'Initials': 'MAJ', 'LastName': 'Hullar', 'Affiliation': 'Public Health Sciences Division.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Chapkin', 'Affiliation': 'Center for Translational Environmental Health Research.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqy325'] 247,28263370,Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.,"BACKGROUND Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events. We also sought to determine the effect of fixed-dose combination therapy on blood pressure, lipids, adherence, discontinuation rates, health-related quality of life, and costs. SEARCH METHODS We updated our previous searches in September 2016 of CENTRAL, MEDLINE, Embase, ISI Web of Science, and DARE, HTA, and HEED. We also searched two clinical trials registers in September 2016. We used no language restrictions. SELECTION CRITERIA We included randomised controlled trials of a fixed-dose combination therapy including at least one blood pressure-lowering and one lipid-lowering component versus usual care, placebo, or an active drug comparator for any treatment duration in adults 18 years old or older, with no restrictions on presence or absence of pre-existing ASCVD. DATA COLLECTION AND ANALYSIS Three review authors independently selected studies for inclusion and extracted the data for this update. We evaluated risk of bias using the Cochrane 'Risk of bias' assessment tool. We calculated risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI) using fixed-effect models when heterogeneity was low (I 2 < 50%) and random-effects models when heterogeneity was high (I 2 ≥ 50%). We used the GRADE approach to evaluate the quality of evidence. MAIN RESULTS In the initial review, we identified nine randomised controlled trials with a total of 7047 participants and four additional trials (n = 2012 participants; mean age range 62 to 63 years; 30% to 37% women) were included in this update. Eight of the 13 trials evaluated the effects of fixed-dose combination (FDC) therapy in populations without prevalent ASCVD, and the median follow-up ranged from six weeks to 23 months. More recent trials were generally larger with longer follow-up and lower risk of bias. The main risk of bias was related to lack of blinding of participants and personnel, which was inherent to the intervention. Compared with the comparator groups (placebo, usual care, or active drug comparator), the effects of the fixed-dose combination treatment on mortality (FDC = 1.0% versus control = 1.0%, RR 1.10, 95% CI 0.64 to 1.89,  I 2 = 0%, 5 studies, N = 5300) and fatal and non-fatal ASCVD events (FDC = 4.7% versus control = 3.7%, RR 1.26, 95% CI 0.95 to 1.66, I 2 = 0%, 6 studies, N = 4517) were uncertain (low-quality evidence). The low event rates for these outcomes and indirectness of evidence for comparing fixed-dose combination to usual care versus individual drugs suggest that these results should be viewed with caution. Adverse events were common in both the intervention (32%) and comparator (27%) groups, with participants randomised to fixed-dose combination therapy being 16% (RR 1.16, 95% CI 1.09 to 1.25, 11 studies, 6906 participants, moderate-quality evidence) more likely to report an adverse event . The mean differences in systolic blood pressure between the intervention and control arms was -6.34 mmHg (95% CI -9.03 to -3.64, 13 trials, 7638 participants, moderate-quality evidence). The mean differences (95% CI) in total and LDL cholesterol between the intervention and control arms were -0.61 mmol/L (95% CI -0.88 to -0.35, 11 trials, 6565 participants, low-quality evidence) and -0.70 mmol/L (95% CI -0.98 to -0.41, 12 trials, 7153 participants, moderate-quality evidence), respectively. There was a high degree of statistical heterogeneity in comparisons of blood pressure and lipids (I 2 ≥ 80% for all) that could not be explained, so these results should be viewed with caution. Fixed-dose combination therapy improved adherence to a multidrug strategy by 44% (26% to 65%) compared with usual care (4 trials, 3835 participants, moderate-quality evidence). AUTHORS' CONCLUSIONS The effects of fixed-dose combination therapy on all-cause mortality or ASCVD events are uncertain. A limited number of trials reported these outcomes, and the included trials were primarily designed to observe changes in ASCVD risk factor levels rather than clinical events, which may partially explain the observed differences in risk factors that were not translated into differences in clinical outcomes among the included trials. Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen. Ongoing, longer-term trials of fixed-dose combination therapy will help demonstrate whether short-term changes in risk factors might be maintained and lead to expected differences in clinical events based on these changes.",2017,"Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen.","['adults 18 years old or older, with no restrictions on presence or absence of pre-existing ASCVD', '7047 participants and four additional trials (n = 2012 participants; mean age range 62 to 63 years; 30% to 37% women']","['Fixed-dose combination therapy', 'fixed-dose combination therapy including at least one blood pressure-lowering and one lipid-lowering component versus usual care, placebo, or an active drug comparator', 'fixed-dose combination (FDC) therapy']","['total and LDL cholesterol', 'blood pressure and lipids', 'Adverse events', 'adherence to a multidrug strategy', 'cause mortality, fatal and non-fatal ASCVD events, and adverse events', 'calculated risk ratios (RR', 'adverse events', 'fatal and non-fatal ASCVD events', 'systolic blood pressure', 'blood pressure, lipids, adherence, discontinuation rates, health-related quality of life, and costs', 'mortality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",4517.0,0.564458,"Fixed-dose combination therapy is associated with modest increases in adverse events compared with placebo, active comparator, or usual care but may be associated with improved adherence to a multidrug regimen.","[{'ForeName': 'Ehete', 'Initials': 'E', 'LastName': 'Bahiru', 'Affiliation': 'Internal Medicine; Division of Cardiology, Northwestern University, 201 E. Huron St. Galter 19-100, Chicago, Illinois, USA, 60611.'}, {'ForeName': 'Angharad N', 'Initials': 'AN', 'LastName': 'de Cates', 'Affiliation': 'Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK, CV4 7AL.'}, {'ForeName': 'Matthew Rb', 'Initials': 'MR', 'LastName': 'Farr', 'Affiliation': 'Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK, CV4 7AL.'}, {'ForeName': 'Morag C', 'Initials': 'MC', 'LastName': 'Jarvis', 'Affiliation': 'Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK, CV4 7AL.'}, {'ForeName': 'Mohan', 'Initials': 'M', 'LastName': 'Palla', 'Affiliation': 'Department of Medicine, Wayne State University, 540 E Canfield St, Detroit, Michigan, USA, 48201.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Rees', 'Affiliation': 'Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK, CV4 7AL.'}, {'ForeName': 'Shah', 'Initials': 'S', 'LastName': 'Ebrahim', 'Affiliation': 'Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK, WC1E 7HT.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Huffman', 'Affiliation': 'Departments of Preventive Medicine and Medicine (Cardiology), Northwestern University Feinberg School of Medicine, 680 N. Lake Shore Drive, Suite 1400, Chicago, IL, USA, 60611.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009868.pub3'] 248,31347292,A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.,"PURPOSE Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. PATIENTS AND METHODS Aphase 2, randomized, placebo-controlled, multicenter trial evaluated the activity of tarextumab in combination with nab-paclitaxel and gemcitabine in patients with metastatic PDAC. Patients were stratified based on ECOG performance score and Ca 19-9 level and randomized 1:1 to nab-paclitaxel, gemcitabine with either tarextumab or placebo. Based on preclinical and phase Ib results suggesting a positive correlation between Notch3 gene expression and tarextumab anti-tumor activity, patients were also divided into subgroups of low, intermediate, and high Notch3 gene expression. Primary endpoint was overall survival (OS) in all and in patients with the three Notch3 gene expression subgroups (≥25th, ≥50% and ≥75% percentiles); secondary end points included progression-free survival (PFS), 12-month OS, overall response rate (ORR), and safety and biomarker investigation. RESULTS Median OS was 6.4 months in the tarextumab group vs 7.9 months in the placebo group (HR = 1.34 [95% CI = 0.95, 1.89], P = .0985). No difference observed in OS in the Notch3 gene expression subgroups. PFS in the tarextumab-treated group (3.7 months) was significantly shorter compared with the placebo group (5.5 months) (hazard ratio was 1.43 [95% CI = 1.01, 2.01]; P = .04). Grade 3 diarrhea and thrombocytopenia were more common in the tarextumab group. CONCLUSIONS The addition of tarextumab to nab-paclitaxel and gemcitabine did not improve OS, PFS, or ORR in first-line metastatic PDAC, and PFS was specifically statistically worse in the tarextumab-treated patients. CLINICAL TRIAL REGISTRY NO NCT01647828.",2019,"PFS in the tarextumab-treated group (3.7 months) was significantly shorter compared with the placebo group (5.5 months) (hazard ratio was 1.43 [95% CI = 1.01, 2.01];","['patients with untreated metastatic pancreatic cancer', 'patients with metastatic PDAC', 'Patients were stratified based on ECOG performance score and Ca 19-9 level and randomized 1:1 to', 'pancreatic adenocarcinoma (PDAC']","['nab-paclitaxel and gemcitabine with tarextumab or placebo', 'placebo', 'nab-paclitaxel, gemcitabine with either tarextumab or placebo', 'tarextumab in combination with nab-paclitaxel and gemcitabine', 'tarextumab to nab-paclitaxel and gemcitabine']","['OS, PFS, or ORR in first-line metastatic PDAC, and PFS', 'PFS', 'overall survival (OS', 'Median OS', 'Grade 3 diarrhea and thrombocytopenia', 'OS', 'progression-free survival (PFS), 12-month OS, overall response rate (ORR), and safety and biomarker investigation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0430797', 'cui_str': 'Intracranial EEG'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0201551', 'cui_str': 'CA 199 measurement'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0281361', 'cui_str': 'Adenocarcinoma of pancreas'}]","[{'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C4053948', 'cui_str': 'tarextumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",,0.10106,"PFS in the tarextumab-treated group (3.7 months) was significantly shorter compared with the placebo group (5.5 months) (hazard ratio was 1.43 [95% CI = 1.01, 2.01];","[{'ForeName': 'Zishuo Ian', 'Initials': 'ZI', 'LastName': 'Hu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Johanna C', 'Initials': 'JC', 'LastName': 'Bendell', 'Affiliation': 'Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Bullock', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Noelle K', 'Initials': 'NK', 'LastName': 'LoConte', 'Affiliation': 'University of Wisconsin, Cancer Center, Madison, Wisconsin.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Hatoum', 'Affiliation': 'University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Ritch', 'Affiliation': 'Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Hool', 'Affiliation': 'Torrance Memorial Physician Network, Redondo Beach, California.'}, {'ForeName': 'Joseph W', 'Initials': 'JW', 'LastName': 'Leach', 'Affiliation': 'Virginia Piper Cancer Institute, Minneapolis, Minnesota.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Sanchez', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Henderson, Nevada.'}, {'ForeName': 'Davendra P S', 'Initials': 'DPS', 'LastName': 'Sohal', 'Affiliation': 'Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Strickler', 'Affiliation': 'Duke University, Durham, North Carolina.'}, {'ForeName': 'Ravindranath', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Comprehensive Blood and Cancer Center, Bakersfield, California.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Wang-Gillam', 'Affiliation': 'Washington University School of Medicine, Saint Louis, Missouri.'}, {'ForeName': 'Irfan', 'Initials': 'I', 'LastName': 'Firdaus', 'Affiliation': 'Oncology Hematology Cancer, Inc., Cincinnati, Ohio.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Yu', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Kapoun', 'Affiliation': 'Oncomed Pharmaceuticals Inc, Redwood City, California.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Holmgren', 'Affiliation': 'Oncomed Pharmaceuticals Inc, Redwood City, California.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhou', 'Affiliation': 'Oncomed Pharmaceuticals Inc, Redwood City, California.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Dupont', 'Affiliation': 'Oncomed Pharmaceuticals Inc, Redwood City, California.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Picozzi', 'Affiliation': 'Virginia Mason Medical Center, Seattle, Washington.'}, {'ForeName': 'Vaibhav', 'Initials': 'V', 'LastName': 'Sahai', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}]",Cancer medicine,['10.1002/cam4.2425'] 249,30945118,"Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.","BACKGROUND Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs may be altered due to enhancement by SNAC, potential gastric emptying delay by semaglutide, or other mechanisms. Two one-sequence crossover trials investigated the effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin. METHODS In trial 1, 52 healthy subjects received lisinopril (20 mg single dose) or warfarin (25 mg single dose) with subsequent coadministration with SNAC alone (300 mg single dose), followed by oral semaglutide 20 mg once daily (steady state). In trial 2, 32 healthy subjects received digoxin (500 μg single dose) or metformin (850 mg twice daily for 4 days), with subsequent coadministration with SNAC alone followed by oral semaglutide, as in trial 1. RESULTS There were no apparent effects of oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C max ) for lisinopril, warfarin, and digoxin. The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the C max was unaffected. SNAC alone did not affect exposure of lisinopril, warfarin, digoxin, or metformin. Adverse events were in line with those previously observed for GLP-1 receptor agonists. CONCLUSIONS Oral semaglutide or SNAC alone did not appear to affect the exposure of lisinopril, warfarin, or digoxin, and, based on its wide therapeutic index, the higher metformin exposure with oral semaglutide was not considered clinically relevant.",2019,"The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the C max was unaffected.","['Healthy Subjects', '32 healthy subjects received', '52 healthy subjects received']","['SNAC', 'lisinopril', 'lisinopril, warfarin, digoxin, and metformin', 'metformin', 'GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl', 'lisinopril, warfarin, digoxin, or metformin', 'SNAC alone', 'SNAC alone followed by oral semaglutide', 'digoxin', 'lisinopril, warfarin, or digoxin', 'warfarin', 'Lisinopril, Warfarin, Digoxin, and Metformin', 'Oral Semaglutide']","['Adverse events', 'AUC of metformin', 'oral semaglutide on area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C max ) for lisinopril, warfarin, and digoxin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0065374', 'cui_str': 'Lisinopril'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0065374', 'cui_str': 'Lisinopril'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}]",52.0,0.0270316,"The AUC of metformin was increased by 32% (90% confidence interval 1.23-1.43) by oral semaglutide coadministration versus metformin alone, whereas the C max was unaffected.","[{'ForeName': 'Tine A', 'Initials': 'TA', 'LastName': 'Bækdal', 'Affiliation': 'Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark. tabq@novonordisk.com.'}, {'ForeName': 'Jeanett', 'Initials': 'J', 'LastName': 'Borregaard', 'Affiliation': 'Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark.'}, {'ForeName': 'Cilie W', 'Initials': 'CW', 'LastName': 'Hansen', 'Affiliation': 'Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Thomsen', 'Affiliation': 'Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Anderson', 'Affiliation': 'Novo Nordisk A/S, Vandtårnsvej 108-110, 2860, Søborg, Denmark.'}]",Clinical pharmacokinetics,['10.1007/s40262-019-00756-2'] 250,31303277,Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): A protocol for a sham-controlled clinical trial.,"INTRODUCTION Morbidity and mortality in adults with late-onset Pompe disease (LOPD) results primarily from persistent progressive respiratory muscle weakness despite treatment with enzyme replacement therapy (ERT). To address this need, we have developed a 12-week respiratory muscle training (RMT) program that provides calibrated, individualized, and progressive pressure-threshold resistance against inspiration and expiration. Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength. We now conduct an exploratory double-blind, randomized control trial (RCT) to determine: 1) utility and feasibility of sham-RMT as a control condition, 2) the clinically meaningful outcome measures for inclusion in a future efficacy trial. This manuscript provides comprehensive information regarding the design and methods used in our trial and will aid in the reporting and interpretation of our future findings. METHODS Twenty-eight adults with LOPD will be randomized (1:1) in blocks of 4 to RMT (treatment) or sham-RMT (control). Assessments will be conducted at pretest, posttest, 3-months detraining, and 6-months detraining. The primary outcome is maximum inspiratory pressure (MIP). Secondary outcomes include maximum expiratory pressure (MEP), 6-min walk test (6MWT), Gait, Stairs, Gowers, and Chair test (GSGC), peak cough flow (PCF), and patient-reported life activity/social participation (Rasch-built Pompe-specific Activity scale [R-Pact]). Exploratory outcomes include quantitative measures from polysomnography; patient reported measures of fatigue, daytime sleepiness, and sleep quality; and ultrasound measures of diaphragm thickness. This research will use a novel tool to provide automated data collection and user feedback, and improve control over dose. ETHICS AND DISSEMINATION The results of this clinical trial will be promptly analyzed and submitted for publication. Results will also be made available on clinicaltrials.gov. ClinicalTrials.gov: NCT02801539, R21AR069880.",2019,"Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength.","['adults with late-onset Pompe disease (LOPD', 'late-onset Pompe disease (LOPD', 'Twenty-eight adults with LOPD']","['RMT (treatment) or sham-RMT (control', 'respiratory muscle training (RMT) program', 'Respiratory muscle training (RMT', 'sham-RMT', 'enzyme replacement therapy (ERT']","['respiratory muscle strength', 'fatigue, daytime sleepiness, and sleep quality; and ultrasound measures of diaphragm thickness', 'maximum expiratory pressure (MEP), 6-min walk test (6MWT), Gait, Stairs, Gowers, and Chair test (GSGC), peak cough flow (PCF), and patient-reported life activity/social participation (Rasch-built Pompe-specific Activity scale [R-Pact', 'maximum inspiratory pressure (MIP']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0342753', 'cui_str': 'Glycogen storage disease type II late onset'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0006155', 'cui_str': 'Respiratory Muscle Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0598391', 'cui_str': 'Enzyme Replacement Therapy'}]","[{'cui': 'C0035231', 'cui_str': 'Ventilatory Muscles'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0011980', 'cui_str': 'Respiratory Diaphragm'}, {'cui': 'C0232022', 'cui_str': 'Maximum expiratory pressure (observable entity)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0814554', 'cui_str': 'Social Participation'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0222045'}, {'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}]",28.0,0.201259,"Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength.","[{'ForeName': 'Harrison N', 'Initials': 'HN', 'LastName': 'Jones', 'Affiliation': 'Department of Surgery, Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, NC, USA; Department of Speech Pathology and Audiology, Duke University Medical Center, Durham, NC, USA. Electronic address: harrison.jones@duke.edu.'}, {'ForeName': 'Maragatha', 'Initials': 'M', 'LastName': 'Kuchibhatla', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Crisp', 'Affiliation': 'Department of Surgery, Division of Head and Neck Surgery & Communication Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Hobson Webb', 'Affiliation': 'Department of Neurology, Neuromuscular Division, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Case', 'Affiliation': 'Division of Physical Therapy, Duke University School Of Medicine, Durham, NC, USA.'}, {'ForeName': 'Milisa T', 'Initials': 'MT', 'LastName': 'Batten', 'Affiliation': 'Department of Speech Pathology and Audiology, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Jill A', 'Initials': 'JA', 'LastName': 'Marcus', 'Affiliation': 'Department of Speech Pathology and Audiology, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Kravitz', 'Affiliation': 'Division of Pediatric Pulmonary and Sleep Medicine, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Priya S', 'Initials': 'PS', 'LastName': 'Kishnani', 'Affiliation': 'Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, NC, USA.'}]",Molecular genetics and metabolism,['10.1016/j.ymgme.2019.05.001'] 251,31229609,The flipped-classroom approach to teaching horizontal strabismus in ophthalmology residency: a pilot study.,"PURPOSE To compare the flipped classroom (home pre-taped lectures followed by in-class group exercise) to the traditional classroom (home reading assignment followed by in-class lecture) for horizontal strabismus didactics in ophthalmology residency. METHODS All PGY2-4 residents from four U.S. ophthalmology residencies without prior residency flipped-classroom experience were invited to esotropia and exotropia sessions sequentially, with random order and assignment to flipped and traditional classrooms. Content test scores before and after the two classrooms were compared. Surveys were administered to assess participant experience. RESULTS A total of 40 residents attended each session. Likert scale evaluation of preparatory material and classroom activity did not differ between sessions; however, divided by year of training, 70% of senior residents (PGY3-4) and 39% of first-year (PGY2) residents preferred the flipped classroom over the traditional classroom. Pre- and post-test scores for the flipped classroom exceeded those of the traditional classroom for the exotropia course (P = 0.01 and P = 0.001, resp.) but not for the esotropia course. There was significant improvement between pre- and post-tests for both styles of learning. CONCLUSIONS The flipped classroom had a favorable effect on test scores for only one of the two strabismus subjects but was preferred over the traditional classroom among PGY3-4 residents.",2019,"Pre- and post-test scores for the flipped classroom exceeded those of the traditional classroom for the exotropia course (P = 0.01 and P = 0.001, resp.)","['All PGY2-4 residents from four US ophthalmology residencies without prior residency flipped-classroom experience', '40 residents attended each session']",['flipped classroom (home pre-taped lectures followed by in-class group exercise) to the traditional classroom (home reading assignment followed by in-class lecture) for horizontal strabismus didactics in ophthalmology residency'],['Likert scale evaluation of preparatory material and classroom activity'],"[{'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0035182', 'cui_str': 'Residency'}, {'cui': 'C0540654', 'cui_str': 'FLICE-Inhibitory Protein'}, {'cui': 'C1456498', 'cui_str': 'Attended'}]","[{'cui': 'C0540654', 'cui_str': 'FLICE-Inhibitory Protein'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1704747', 'cui_str': 'Tape (basic dose form)'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1276393', 'cui_str': 'Group exercise (regime/therapy)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0205126', 'cui_str': 'Horizontal (qualifier value)'}, {'cui': 'C0038379', 'cui_str': 'Phorias'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0035182', 'cui_str': 'Residency'}]","[{'cui': 'C0451267', 'cui_str': 'Likert scale (assessment scale)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",,0.0170913,"Pre- and post-test scores for the flipped classroom exceeded those of the traditional classroom for the exotropia course (P = 0.01 and P = 0.001, resp.)","[{'ForeName': 'Michelle T', 'Initials': 'MT', 'LastName': 'Cabrera', 'Affiliation': ""Department of Ophthalmology, University of Washington, Seattle; Department of Ophthalmology, Seattle Children's Hospital, Seattle. Electronic address: cabreram@uw.edu.""}, {'ForeName': 'Tammy L', 'Initials': 'TL', 'LastName': 'Yanovitch', 'Affiliation': 'Department of Ophthalmology, University of Oklahoma, Oklahoma City.'}, {'ForeName': 'Nandini G', 'Initials': 'NG', 'LastName': 'Gandhi', 'Affiliation': 'Department of Ophthalmology, University of California, Davis.'}, {'ForeName': 'Leona', 'Initials': 'L', 'LastName': 'Ding', 'Affiliation': 'Department of Ophthalmology, University of Washington, Seattle.'}, {'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Enyedi', 'Affiliation': 'Department of Ophthalmology, Duke University, Durham, North Carolina; Department of Pediatrics, Duke University, Durham, North Carolina.'}]",Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus,['10.1016/j.jaapos.2019.02.009'] 252,32299999,"Effects of a traditional Chinese mind-body exercise, Baduanjin, on the physical and cognitive functions in the community of older adults with cognitive frailty: study protocol for a randomised controlled trial.","INTRODUCTION Cognitive frailty (CF) is a clinical manifestation characterised by the simultaneous presence of both physical frailty and cognitive impairment among older adults without dementia and has become a new target for healthy ageing. Increasing evidence shows that regular Baduanjin (a traditional Chinese mind-body exercise) training is beneficial in improving physical function and cognitive ability in the older adults. The primary aim of this trial is to observe the effect of Baduanjin on physical and cognitive functions in older adults with CF. METHODS AND ANALYSIS In this prospective, outcome assessor-blind, two-arm randomised controlled trial, a total of 102 participants with CF will be recruited and randomly allocated (1:1) into the Baduanjin training or usual physical activity control group. The control group will receive health education for 30 min at least once a month. Based on health education, participants in the Baduanjin exercise group will receive a 24-week Baduanjin training with 60 min per session and 3 sessions per week, while those in the usual physical activity control group will maintain their original lifestyle. Primary outcomes (frailty index and global cognitive ability), body composition, grip force, balance, fatigue, specific cognitive domain, including memory, execution and visual spatial abilities, and life quality of secondary outcomes will be measured at baseline, and at 13 and 25 weeks after randomisation, while the structural and functional MRI will be measured at baseline and 25 weeks after randomisation. The mixed linear model will be conducted to observe the intervention effects. ETHICS AND DISSEMINATION The study has been approved by the ethics committee of the second people's hospital of Fujian province (Approval no. 2018-KL015). Results will be submitted for publication in peer-reviewed journals and disseminated at scientific conferences. TRIAL REGISTRATION NUMBER ChiCTR1800020341; Pre-results.",2020,"Primary outcomes (frailty index and global cognitive ability), body composition, grip force, balance, fatigue, specific cognitive domain, including memory, execution and visual spatial abilities, and life quality of secondary outcomes will be measured at baseline, and at 13 and 25 weeks after randomisation, while the structural and functional MRI will be measured at baseline and 25 weeks after randomisation.","['older adults without dementia', 'older adults', '102 participants with CF', 'older adults with cognitive frailty', 'older adults with CF']","['Baduanjin training with 60\u2009min per session and 3 sessions per week, while those in the usual physical activity control group will maintain their original lifestyle', 'regular Baduanjin (a traditional Chinese mind-body exercise) training', 'traditional Chinese mind-body exercise, Baduanjin', 'Baduanjin training or usual physical activity control group', 'Baduanjin']","['physical and cognitive functions', 'Primary outcomes (frailty index and global cognitive ability), body composition, grip force, balance, fatigue, specific cognitive domain, including memory, execution and visual spatial abilities, and life quality of secondary outcomes', 'physical function and cognitive ability', 'structural and functional MRI']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4075886', 'cui_str': 'Frailty Index'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0679024', 'cui_str': 'Spatial Ability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]",102.0,0.100742,"Primary outcomes (frailty index and global cognitive ability), body composition, grip force, balance, fatigue, specific cognitive domain, including memory, execution and visual spatial abilities, and life quality of secondary outcomes will be measured at baseline, and at 13 and 25 weeks after randomisation, while the structural and functional MRI will be measured at baseline and 25 weeks after randomisation.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Xia', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Mingyue', 'Initials': 'M', 'LastName': 'Wan', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Huiying', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Pingting', 'Initials': 'P', 'LastName': 'Qiu', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Ye', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Jianquan', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Lianhua', 'Initials': 'L', 'LastName': 'Yin', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Tao', 'Affiliation': 'Rehabilitation Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.'}, {'ForeName': 'Lidian', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'College of Rehabilitation Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, China.'}, {'ForeName': 'Guohua', 'Initials': 'G', 'LastName': 'Zheng', 'Affiliation': 'College of Nursing and Health Management, Shanghai University of Medicine & Health Sciences, Shanghai, China zhenggh@sumhs.edu.cn.'}]",BMJ open,['10.1136/bmjopen-2019-034965'] 253,32304555,Is Carbon Dioxide Insufflation During Endoscopy in Children as Safe and as Effective as We Think?,"OBJECTIVES Distension of the gastrointestinal lumen is crucial for visualization and advancement during endoscopic procedures. An increasing number of pediatric centers now use carbon dioxide (CO2) preferentially over air as many adult studies and a few pediatric studies have concluded that CO2 is better tolerated than air, especially for colonoscopy. AIMS The aim of the study was to determine if CO2 is as safe and as effective as air and if it reduces abdominal discomfort and distension in children undergoing upper endoscopy and colonoscopy. METHODS Double blinded, prospective, randomized clinical study. Patient- and nursing-reported outcomes of pain and distension were recorded. End tidal CO2 (EtCO2) was monitored continuously with a CO2-sampling nasal cannula for patients undergoing procedural sedation and via the endotracheal tube for those who were intubated. RESULTS One hundred seventy-eight patients with 180 procedures were enrolled, 91 procedures were randomized to receive CO2, and 89 to air. Groups did not differ significantly with respect to nursing-assessed abdominal discomfort, change in girth from baseline, or endoscopist-perceived ease of inflation. Use of CO2 was associated with transient spikes in the EtCO2 (≥60 mmHg) in a significant number of patients during sedated upper endoscopy without endotracheal intubation. There was a reduction of bloating and flatulence for all procedures in the CO2 group. CONCLUSIONS The benefits of using CO2 for insufflation were minimal in our patients. The observed transient elevations of EtCO2 during sedated upper endoscopy raise concerns of possible systemic hypercarbia. The wisdom of its routine use for all pediatric endoscopic procedures is questioned.",2020,"Groups did not differ significantly with respect to nursing-assessed abdominal discomfort, change in girth from baseline, or endoscopist-perceived ease of inflation.","['178 patients with 180 procedures were enrolled, 91 procedures', 'children undergoing upper endoscopy and colonoscopy']","['carbon dioxide (CO2', 'CO2-sampling nasal cannula', 'Carbon Dioxide Insufflation', 'CO2']","['pain and distension', 'End tidal CO2 (EtCO2', 'bloating and flatulence', 'nursing-assessed abdominal discomfort, change in girth from baseline, or endoscopist-perceived ease of inflation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0017195', 'cui_str': 'Endoscopy of stomach'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C3267130', 'cui_str': 'End-tidal CO2'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0232487', 'cui_str': 'Abdominal discomfort'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0021398', 'cui_str': 'Economic Inflation'}]",178.0,0.0923888,"Groups did not differ significantly with respect to nursing-assessed abdominal discomfort, change in girth from baseline, or endoscopist-perceived ease of inflation.","[{'ForeName': 'Chinenye R', 'Initials': 'CR', 'LastName': 'Dike', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, Pancreatology and Nutrition, Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Riad', 'Initials': 'R', 'LastName': 'Rahhal', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, Pancreatology and Nutrition, Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Warren P', 'Initials': 'WP', 'LastName': 'Bishop', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology, Pancreatology and Nutrition, Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA.'}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002724'] 254,32298558,"Therapeutic Listening for Preterm Children with Sensory Dysregulation, Attention and Cognitive Problems.","Introduction Is Therapeutic Listening effective for children born preterm presenting with sensory dysregulation, attention and cognitive problems? Methods 22 children (BW<1500g) 3-4 years were enrolled in a single centre, prospective, assessor-blinded RTC. Outcome measures: Winnie-Dunn Sensory Profile; Peabody Developmental Motor Scales; Reynell Attention Scale; Preschool Language Scales - 3; RAPT; WPPSI - IV; Parent Review Questionnaires. Results The intervention group (n=9) showed better improvement in sensory processing, compared to controls (n=9) (6.4 fold improvement in sensation seeking; 5.0 in auditory processing; 4.0 in tactile processing). Six intervention children (67%) improved in vestibular processing. Attention levels improved for 9 (100%) children in the intervention group and for 7 (78%) in the control group. Higher level domains (Peabody motor skills, Auditory Comprehension, Expressive Communication, RAPT scale, and WPPSI scores) showed mixed results. Parents reported positive changes in their child's development. Conclusion Therapeutic Listening (TL) is a feasible intervention for preterm children to improve attention levels and sensory processing skills.",2020,"Results The intervention group (n=9) showed better improvement in sensory processing, compared to controls (n=9) (6.4 fold improvement in sensation seeking; 5.0 in auditory processing; 4.0 in tactile processing).","['preterm children', '22 children (BW<1500g) 3-4 years', 'children born preterm presenting with sensory dysregulation, attention and cognitive problems', 'Preterm Children with Sensory Dysregulation, Attention and Cognitive Problems']","['Conclusion Therapeutic Listening (TL', 'Therapeutic Listening']","['Higher level domains (Peabody motor skills, Auditory Comprehension, Expressive Communication, RAPT scale, and WPPSI scores', 'Outcome measures: Winnie-Dunn Sensory Profile; Peabody Developmental Motor Scales; Reynell Attention Scale; Preschool Language Scales - 3; RAPT; WPPSI - IV; Parent Review Questionnaires', 'sensory processing', 'Attention levels', 'vestibular processing']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2828074', 'cui_str': 'WPPSI'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C2732625', 'cui_str': 'Sensory profile'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0451389', 'cui_str': 'Preschool language scale'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}]",22.0,0.0452075,"Results The intervention group (n=9) showed better improvement in sensory processing, compared to controls (n=9) (6.4 fold improvement in sensation seeking; 5.0 in auditory processing; 4.0 in tactile processing).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Slevin', 'Affiliation': 'National Maternity Hospital, Holles St, Dublin 2, Ireland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': ""Karen O'Connor, Listening Therapy Child Development Centre, Furbo, Co. Galway, Ireland.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Segurado', 'Affiliation': 'UCD CSTAR and School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'J F A', 'Initials': 'JFA', 'LastName': 'Murphy', 'Affiliation': 'National Maternity Hospital, Holles St, Dublin 2, Ireland.'}]",Irish medical journal,[] 255,31984480,Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.,"BACKGROUND Tofacitinib is an oral Janus kinase (JAK) inhibitor which blocks cytokine signaling involved in the pathogenesis of autoimmune diseases including ulcerative colitis (UC). The etiology of UC is poorly understood, however research suggests the development and progression of the disease is due to a dysregulated immune response leading to inflammation of the colonic mucosa in genetically predisposed individuals. Additional medications are currently required since some patients do not respond to the available medications and some medications are associated with serious adverse events (SAEs). JAK inhibitors have been widely studied in diseases including rheumatoid arthritis and Crohn's disease and may represent a promising and novel therapeutic option for the treatment of UC. OBJECTIVES The primary objective was to assess the efficacy and safety of oral JAK inhibitors for the maintenance of remission in participants with quiescent UC. SEARCH METHODS We searched the following databases from inception to 20 September 2019: MEDLINE, Embase, CENTRAL, and the Cochrane IBD Group Specialized Register, WHO trials registry and clinicaltrials.gov. References and conference abstracts were searched to identify additional studies. SELECTION CRITERIA Randomized control trial (RCTs) in which an oral JAK inhibitor was compared with placebo or active comparator in the treatment of quiescent UC were eligible for inclusion. DATA COLLECTION AND ANALYSIS Two review authors independently screened studies for inclusion and extraction. Bias was assessed using the Cochrane 'Risk of bias' tool. The primary outcome was the proportion of participants who failed to maintain remission as defined by any included studies. Secondary outcomes included failure to maintain clinical response, failure to maintain endoscopic remission, failure to maintain endoscopic response, disease-specific quality of life, adverse events (AEs), withdrawal due to AEs and SAEs. We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for each dichotomous outcome. Data were analyzed on an intention-to-treat basis. The overall certainty of the evidence supporting the outcomes was evaluated using the GRADE criteria. MAIN RESULTS One RCT (593 participants) including patients with moderately to severely active UC met the inclusion criteria. Patients were randomly assigned in a 1:1:1 ratio to receive maintenance therapy with tofacitinib at 5 mg twice daily, 10 mg twice daily or placebo for 52 weeks. The primary endpoint was remission at 52 weeks and the secondary endpoints included mucosal healing at 52 weeks, sustained remission at 24 and 52 weeks and glucocorticosteroid-free remission. This study was rated as low risk of bias. The study reported on most of the pre-specified primary and secondary outcomes for this review including clinical remission, clinical response, endoscopic remission, AEs, SAEs and withdrawal due to AEs. However, the included study did not report on endoscopic response or disease-specific quality of life. Sixty-three per cent (247/395) of tofacitinib participants failed to maintain clinical remission at 52 weeks compared to 89% (176/198) of placebo participants (RR 0.70, 95% CI 0.64 to 0.77; high-certainty evidence). Forty-three per cent (171/395) of tofacitinib participants failed to maintain clinical response at 52 weeks compared to 80% (158/198) of placebo participants (RR 0.54, 95% CI 0.48 to 0.62; high-certainty evidence). Eighty-four per cent (333/395) of tofacitinib participants failed to maintain endoscopic remission at 52 weeks compared to 96% (190/198) of placebo participants (RR 0.88, 95% CI 0.83 to 0.92; high-certainty evidence). AEs were reported in 76% (299/394) of tofacitinib participants compared with 75% (149/198) of placebo participants (RR 1.01, 95% CI 0.92 to 1.11; high-certainty evidence). Commonly reported AEs included worsening UC, nasopharyngitis, arthralgia (joint pain)and headache. SAEs were reported in 5% (21/394) of tofacitinib participants compared with 7% (13/198) of placebo participants (RR 0.81, 95% CI 0.42 to 1.59; low-certainty evidence). SAEs included non-melanoma skin cancers, cardiovascular events, cancer other than non-melanoma skin cancer, Bowen's disease, skin papilloma and uterine leiomyoma (a tumour in the uterus). There was a higher proportion of participants who withdrew due to an AE in the placebo group compared to the tofacitinib group. Nine per cent (37/394) of participants taking tofacitinib withdrew due to an AE compared to 19% (37/198) of participants taking placebo (RR 0.50, 95% CI 0.33 to 0.77; moderate-certainty evidence). The most common reason for withdrawal due to an AE was worsening UC. The included study did not report on endoscopic response or on mean disease-specific quality of life scores. AUTHORS' CONCLUSIONS High-certainty evidence suggests that tofacitinib is superior to placebo for maintenance of clinical and endoscopic remission at 52 weeks in participants with moderate-to-severe UC in remission. The optimal dose of tofacitinib for maintenance therapy is unknown. High-certainty evidence suggests that there is no increased risk of AEs with tofacitinib compared to placebo. However, we are uncertain about the effect of tofacitinib on SAEs due to the low number of events. Further studies are required to look at the long-term effectiveness and safety of using tofacitinib and other oral JAK inhibitors as maintenance therapy in participants with moderate-to-severe UC in remission.",2020,"Nine per cent (37/394) of participants taking tofacitinib withdrew due to an AE compared to 19% (37/198) of participants taking placebo (RR 0.50, 95% CI 0.33 to 0.77; moderate-certainty evidence).","['participants with moderate-to-severe UC in remission', 'participants with quiescent UC', 'quiescent UC were eligible for inclusion']","['oral JAK inhibitors', 'tofacitinib', 'maintenance therapy with tofacitinib', 'placebo', 'Oral Janus kinase inhibitors']","['endoscopic response or disease-specific quality of life', 'failure to maintain clinical response, failure to maintain endoscopic remission, failure to maintain endoscopic response, disease-specific quality of life, adverse events (AEs), withdrawal due to AEs and SAEs', 'mucosal healing at 52 weeks, sustained remission', 'efficacy and safety', 'SAEs', 'endoscopic response or on mean disease-specific quality of life scores', 'clinical remission, clinical response, endoscopic remission, AEs, SAEs and withdrawal due to AEs', 'maintain clinical response', 'maintain endoscopic remission', 'maintain clinical remission', 'worsening UC, nasopharyngitis, arthralgia (joint pain)and headache', 'proportion of participants who failed to maintain remission', 'risk ratio (RR', ""non-melanoma skin cancers, cardiovascular events, cancer other than non-melanoma skin cancer, Bowen's disease, skin papilloma and uterine leiomyoma""]","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3854325', 'cui_str': 'JAK Inhibitors'}, {'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521962', 'cui_str': 'Janus kinase inhibitor'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0034380'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0003862', 'cui_str': 'Joint Pain'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0151779', 'cui_str': 'Familial Atypical Mole-Malignant Melanoma Syndrome'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0006079', 'cui_str': ""Bowen's Disease""}, {'cui': 'C0347390', 'cui_str': 'Papilloma of skin (disorder)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}]",,0.687987,"Nine per cent (37/394) of participants taking tofacitinib withdrew due to an AE compared to 19% (37/198) of participants taking placebo (RR 0.50, 95% CI 0.33 to 0.77; moderate-certainty evidence).","[{'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Davies', 'Affiliation': 'University of Western Ontario, Schulich School of Medicine & Dentistry, London, ON, Canada.'}, {'ForeName': 'Isra M', 'Initials': 'IM', 'LastName': 'Hussein', 'Affiliation': ""University of Toronto, Faculty of Medicine, 1 King's College Circle, Toronto, ON, Canada, M5S 1A8.""}, {'ForeName': 'Tran M', 'Initials': 'TM', 'LastName': 'Nguyen', 'Affiliation': 'Robarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada.'}, {'ForeName': 'Claire E', 'Initials': 'CE', 'LastName': 'Parker', 'Affiliation': 'Robarts Clinical Trials, 100 Dundas Street, Suite 200, London, ON, Canada.'}, {'ForeName': 'Reena', 'Initials': 'R', 'LastName': 'Khanna', 'Affiliation': 'University of Western Ontario, Department of Medicine, London, ON, Canada.'}, {'ForeName': 'Vipul', 'Initials': 'V', 'LastName': 'Jairath', 'Affiliation': 'University of Western Ontario, Department of Medicine, London, ON, Canada.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012381.pub2'] 256,32303386,"Reply to Roderick C.N. van den Bergh, Massimo Valerio, Derya Tilki, and Giorgio Gandaglia's Letter to the Editor re: Timothy J. Wilt, Tien N. Vo, Lisa Langsetmo, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2020.02.009.",,2020,,['Clinically Localized Prostate Cancer'],['Radical Prostatectomy or Observation'],[],"[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]",[],,0.0166434,,"[{'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Wilt', 'Affiliation': 'Minneapolis VA Center for Care Delivery and Outcomes Research, Minneapolis, MN, USA; Section of General Medicine, University of Minnesota School of Medicine, Minneapolis, MN, USA. Electronic address: tim.wilt@va.gov.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Dahm', 'Affiliation': 'Minneapolis VA Section of Urology, Minneapolis, MN, USA; Department of Urology, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Brawer', 'Affiliation': 'MDx Health, Irvine, CA, USA; Nanospectra Biosciences, Houston, TX, USA.'}]",European urology,['10.1016/j.eururo.2020.03.047'] 257,32302665,Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial.,"AIMS Hypoglycemia is one of the most important complications associated with Ramadan fasting in people with type 2 diabetes. LixiRam (NCT02941367) was the first randomized trial comparing safety and efficacy of lixisenatide + basal insulin (BI) vs. sulphonylurea + BI in people with type 2 diabetes who fast during Ramadan. This post hoc analysis focuses on the LixiRam study population from India. METHODS Adults with type 2 diabetes insufficiently controlled with sulphonylurea + BI ± another oral anti-hyperglycemic drug were randomized 1:1 to receive lixisenatide + BI or to continue sulphonylurea + BI treatment. RESULTS In total, 150 participants were randomized in India. One participant (1.3%) with lixisenatide + BI vs. 5 participants (6.8%) with sulphonylurea + BI experienced ≥1 documented symptomatic hypoglycemic event during the Ramadan fast (odds ratio [OR]: 0.22; 95% confidence interval [CI]: 0.02-1.93). Incidence of any hypoglycemia was numerically lower with lixisenatide + BI vs. sulphonylurea + BI during Ramadan fasting (1.3% [1/75] vs. 14.7% [11/75], respectively; OR: 0.09; 95% CI: 0.01-0.69). No new safety signals were identified. CONCLUSIONS A combination of lixisenatide prandial GLP1-RA + BI may be a suitable treatment option for people with type 2 diabetes who elect to fast during Ramadan. Clinical Trial Registry: clinicaltrials.gov (NCT02941367).",2020,Incidence of any hypoglycemia was numerically lower with lixisenatide + BI vs. sulphonylurea + BI during Ramadan fasting (1.3% [1/75],"['people with type 2 diabetes who fast during Ramadan', 'Indian people with type 2 diabetes mellitus during Ramadan fast', 'Adults with type 2 diabetes insufficiently controlled with sulphonylurea + BI ± another oral anti-hyperglycemic drug', 'people with type 2 diabetes', '150 participants were randomized in India', 'people with type 2 diabetes who elect to fast during Ramadan']","['lixisenatide + basal insulin (BI) vs. sulphonylurea + BI', 'lixisenatide prandial GLP1-RA + BI', 'lixisenatide + BI vs. sulphonylurea + BI', 'lixisenatide plus basal insulin treatment regimen', 'lixisenatide + BI or to continue sulphonylurea + BI treatment']","['symptomatic hypoglycemic event', 'Incidence of any hypoglycemia']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C2973895', 'cui_str': 'Lixisenatide'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C2350813', 'cui_str': 'EHMT1 protein, human'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",150.0,0.0907296,Incidence of any hypoglycemia was numerically lower with lixisenatide + BI vs. sulphonylurea + BI during Ramadan fasting (1.3% [1/75],"[{'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Sahay', 'Affiliation': 'Department of Endocrinology, Osmania Medical College, Hyderabad, India. Electronic address: sahayrk@gmail.com.'}, {'ForeName': 'Khadijah', 'Initials': 'K', 'LastName': 'Hafidh', 'Affiliation': 'Rashid Hospital, Dubai, United Arab Emirates.'}, {'ForeName': 'Khier', 'Initials': 'K', 'LastName': 'Djaballah', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Coudert', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Azar', 'Affiliation': 'American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Naim', 'Initials': 'N', 'LastName': 'Shehadeh', 'Affiliation': 'Rambam Medical Center, Haifa, Israel.'}, {'ForeName': 'Wasim', 'Initials': 'W', 'LastName': 'Hanif', 'Affiliation': 'University Hospital Birmingham, Birmingham, UK.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Hassanein', 'Affiliation': 'Dubai Hospital, Dubai, United Arab Emirates.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108148'] 258,32302702,Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.,"INTRODUCTION Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated atezolizumab with platinum-based chemotherapy in stage IV squamous NSCLC. METHODS A total of 1021 patients were randomized 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) (n = 343), or carboplatin+nab-paclitaxel (CnP) (n = 340) for four or six 21-day cycles; patients randomized to the A+CP or A+CnP arms received atezolizumab maintenance therapy until progressive disease or loss of clinical benefit. The coprimary end points were investigator-assessed progression-free survival (PFS) and overall survival (OS) in the intention-to-treat (ITT) population. The secondary end points included PFS and OS in PD-L1 subgroups and safety. The primary PFS (January 22, 2018) and final OS (October 3, 2018) for A+CnP versus CnP are reported. RESULTS PFS improvement with A+CnP versus CnP was seen in the ITT population (median, 6.3 versus 5.6 mo; hazard ratio [HR] = 0.71, 95% confidence interval [CI]: 0.60-0.85; p = 0.0001). Median OS in the ITT population was 14.2 and 13.5 months in the A+CnP and CnP arms (HR = 0.88, 95% CI: 0.73-1.05; p = 0.16), not reaching statistical significance. OS improvement with A+CnP versus CnP was observed in the PD-L1-high subgroup (HR = 0.48, 95% CI: 0.29-0.81), despite not being formally tested. Treatment-related grade 3 and 4 adverse events and serious adverse events occurred in 68.0% and 47.9% (A+CnP) and 57.5% and 28.7% (CnP) of patients, respectively. CONCLUSIONS Adding atezolizumab to platinum-based chemotherapy significantly improved PFS in patients with first-line squamous NSCLC; OS was similar between the arms.",2020,"Treatment-related grade 3-4 adverse events (AEs) and serious AEs occurred in 68.0% and 47.9% (A+CnP) and 57.5% and 28.7% (CnP) of patients. ","['patients with first-line squamous NSCLC', 'Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131', 'stage IV squamous non-small cell lung cancer (NSCLC', '1021 patients']","['atezolizumab with platinum-based chemotherapy', 'atezolizumab+carboplatin+paclitaxel (A+CP', 'A+CP or A+CnP', 'atezolizumab+carboplatin+nab-paclitaxel (A+CnP) (n=343), or carboplatin+nab-paclitaxel (CnP', 'Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel', 'atezolizumab to platinum-based chemotherapy', 'atezolizumab maintenance therapy']","['PFS and OS in PD-L1 subgroups and safety', 'Treatment-related grade 3-4 adverse events (AEs) and serious AEs', 'investigator-assessed progression-free survival (PFS) and overall survival (OS) in the intention-to-treat (ITT) population', 'OS improvement with A+CnP vs CnP', 'Median OS', 'PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C4509816', 'cui_str': 'Squamous non-small cell lung cancer'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",1021.0,0.214137,"Treatment-related grade 3-4 adverse events (AEs) and serious AEs occurred in 68.0% and 47.9% (A+CnP) and 57.5% and 28.7% (CnP) of patients. ","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jotte', 'Affiliation': 'Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado; US Oncology, Houston, Texas. Electronic address: robert.jotte@usoncology.com.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Cappuzzo', 'Affiliation': 'Department of Oncology and Hematology, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy.'}, {'ForeName': 'Ihor', 'Initials': 'I', 'LastName': 'Vynnychenko', 'Affiliation': 'Department of Oncology and Radiology, Sumy State University, Sumy, Ukraine.'}, {'ForeName': 'Daniil', 'Initials': 'D', 'LastName': 'Stroyakovskiy', 'Affiliation': 'Chemotherapeutic Department, Moscow City Oncology Hospital, Moscow Healthcare Department, Moscow, Russia.'}, {'ForeName': 'Delvys', 'Initials': 'D', 'LastName': 'Rodríguez-Abreu', 'Affiliation': 'Department of Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.'}, {'ForeName': 'Maen', 'Initials': 'M', 'LastName': 'Hussein', 'Affiliation': 'Department of Cancer Research, Florida Cancer Specialists, Lady Lake, Florida; Sarah Cannon Research Institute, Nashville, Tennessee.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Soo', 'Affiliation': 'Department of Hematology-Oncology, National University Hospital, Singapore.'}, {'ForeName': 'Henry J', 'Initials': 'HJ', 'LastName': 'Conter', 'Affiliation': 'Department of Medicine, William Osler Health System, Brampton, Ontario, Canada.'}, {'ForeName': 'Toshiyuki', 'Initials': 'T', 'LastName': 'Kozuki', 'Affiliation': 'National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Kuan-Chieh', 'Initials': 'KC', 'LastName': 'Huang', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Vilma', 'Initials': 'V', 'LastName': 'Graupner', 'Affiliation': 'Product Development, Oncology F. Hoffmann-La Roche, Ltd., Basel, Switzerland.'}, {'ForeName': 'Shawn W', 'Initials': 'SW', 'LastName': 'Sun', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Tien', 'Initials': 'T', 'LastName': 'Hoang', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Jessop', 'Affiliation': 'Department of Clinical Safety, Roche Products Ltd., Welwyn Garden City, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'McCleland', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Ballinger', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Sandler', 'Affiliation': 'Product Development, Oncology Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Socinski', 'Affiliation': 'Department of Thoracic Oncology, AdventHealth Cancer Institute, Orlando, Florida.'}]",Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,['10.1016/j.jtho.2020.03.028'] 259,32303784,Comparison of types 2 and 3 quadratus lumborum muscle blocks : Open inguinal hernia surgery in patients with spinal anesthesia.,"OBJECTIVE The efficacy of quadratus lumborum muscle block (QLB) in abdominal surgery is known; however, the efficacy of different QLB types is unclear. The objective of this study was to investigate the effects of ultrasound-guided QLB type 2 and type 3 on postoperative opioid consumption and pain scores in patients undergoing inguinal hernia surgery. MATERIAL AND METHODS In this study 60 patients undergoing open inguinal hernia surgery were randomly assigned to 3 groups. Group QLB2 received ultrasound-guided QLB type 2 and group QLB3 received ultrasound-guided QLB type 3 with 0.25% 20 mL bupivacaine. In the control group (group C) no intervention was performed. Postoperative analgesia was performed intravenously with 1000 mg paracetamol every 6 h and patient-controlled analgesia with fentanyl. Postoperative visual analog scale scores (VAS), opioid consumption, and first analgesic requirement time were evaluated. RESULTS Fentanyl consumption was significantly higher in group C compared to the other groups at all time intervals (p < 0.05). Fentanyl consumption was significantly higher in group QLB2 compared to QLB3 at the 4-8 h, 8-24 h, and total 24 h. Passive VAS 4h and 8 h, active VAS 4h, 8h, and 12 h were significantly lower in group QLB3 compared to QLB2 (p < 0.05). The first analgesic time was significantly later in group QLB2 compared to group C (280.52 ± 89.20 min and 183.75 ± 42.79 min, respectively) and even later in group QLB3 compared to the other two groups (463.42 ± 142.43 min, p < 0.05). CONCLUSION The use of QLB2 and QLB3 decreased postoperative opioid consumption and pain scores in patients undergoing inguinal hernia surgery. Furthermore, QLB3 provided more effective and longer lasting postoperative analgesia and lower opioid consumption compared to QLB2.",2020,The use of QLB2 and QLB3 decreased postoperative opioid consumption and pain scores in patients undergoing inguinal hernia surgery.,"['patients undergoing inguinal hernia surgery', 'patients with spinal anesthesia', '60 patients undergoing open inguinal hernia surgery']","['QLB2 and QLB3', 'types 2 and 3 quadratus lumborum muscle blocks : Open inguinal hernia surgery', 'quadratus lumborum muscle block (QLB', 'bupivacaine', 'ultrasound-guided QLB type 2 and type 3', 'paracetamol every 6\u202fh and patient-controlled analgesia with fentanyl', 'QLB3', 'ultrasound-guided QLB type 2 and group']","['analgesic time', 'effective and longer lasting postoperative analgesia and lower opioid consumption', 'Postoperative visual analog scale scores (VAS), opioid consumption, and first analgesic requirement time', 'postoperative opioid consumption and pain scores', 'Fentanyl consumption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0224380', 'cui_str': 'Structure of quadratus lumborum muscle'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0019294', 'cui_str': 'Inguinal hernia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0441731', 'cui_str': 'Type 3'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0078944', 'cui_str': 'Patient controlled analgesia'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]",60.0,0.0368686,The use of QLB2 and QLB3 decreased postoperative opioid consumption and pain scores in patients undergoing inguinal hernia surgery.,"[{'ForeName': 'O', 'Initials': 'O', 'LastName': 'Bagbanci', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kursad', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Yayik', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey. m_yayik@hotmail.com.'}, {'ForeName': 'E O', 'Initials': 'EO', 'LastName': 'Ahiskalioglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Aydin', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ahiskalioglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ataturk University School of Medicine, Erzurum, Turkey.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Karadeniz', 'Affiliation': 'Department of General Surgery, Ataturk University School of Medicine, Erzurum, Turkey.'}]",Der Anaesthesist,['10.1007/s00101-020-00766-x'] 260,32300002,Cognitive-behavioral therapy-based intervention to treat symptoms of anxiety in pregnancy in a prenatal clinic using non-specialist providers in Pakistan: design of a randomised trial.,"INTRODUCTION Prenatal anxiety is a prevalent condition that is harmful for women and a strong predictor of postpartum depression. This trial assesses an intervention initiated in early pregnancy to mid pregnancy among women with clinical or subclinical symptoms of anxiety in Pakistan. METHODS AND ANALYSIS: Happy Mother, Healthy Baby (HMHB) is a phase three, two-arm, single-blind, individual randomised clinical trial conducted in the outpatient department of Holy Family Hospital, a large public tertiary care facility affiliated with Rawalpindi Medical University (RMU). Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms. Two to six booster sessions are given between the fifth consecutive weekly core session and the sixth core session that occurs in the third trimester. Apart from baseline data, data are collected in the third trimester, at birth and at 6-weeks postpartum. Primary outcomes include diagnoses of postpartum common mental disorders. Secondary outcomes include symptoms of anxiety and of depression, and birth outcomes including small-for-gestational age, low birth weight and preterm birth. An economic analysis will determine the cost effectiveness of the intervention. ETHICS Ethics approval was obtained from the Johns Hopkins Bloomberg School of Health Institutional Review Board (Baltimore, USA), the Human Development Research Foundation Ethics Committee (Islamabad, Pakistan), the RMU Institutional Research Forum (Rawalpindi, Pakistan) and the National Institute of Mental Health-appointed Global Mental Health Data Safety and Monitoring Board. DISSEMINATION Results from this trial will build evidence for the efficacy of a CBT-based intervention for pregnant women delivered by non-specialised providers. Identification of an evidence-based intervention for anxiety starting in early pregnancy to mid pregnancy may be transferable for use and scale-up in other low-income and middle-income countries. TRIAL REGISTRATION NUMBER NCT03880032.",2020,Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms.,"['anxiety in pregnancy in a prenatal clinic using non-specialist providers in Pakistan', 'women with clinical or subclinical symptoms of anxiety in Pakistan', 'outpatient department of Holy Family Hospital, a large public tertiary care facility affiliated with Rawalpindi Medical University (RMU', 'pregnant women delivered by non-specialised providers', 'Pregnant women (enrolled at ≤22 weeks of gestation) receive']","['Happy Mother, Healthy Baby (HMHB', 'six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms', 'Cognitive-behavioral therapy-based intervention', 'CBT-based intervention']","['diagnoses of postpartum common mental disorders', 'symptoms of anxiety and of depression, and birth outcomes including small-for-gestational age, low birth weight and preterm birth']","[{'cui': 'C4543692', 'cui_str': 'Anxiety in pregnancy'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0035029', 'cui_str': 'Relaxation technique'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0235991', 'cui_str': 'Small for gestational age'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}]",,0.279811,Pregnant women (enrolled at ≤22 weeks of gestation) receive six individual HMHB sessions based on cognitive-behavioral therapy (CBT) and relaxation techniques that are administered by non-specialist providers and tailored to address anxiety symptoms.,"[{'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Surkan', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA psurkan@jhu.edu.'}, {'ForeName': 'Syed Usman', 'Initials': 'SU', 'LastName': 'Hamdani', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Zill-E', 'Initials': 'ZE', 'LastName': 'Huma', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Huma', 'Initials': 'H', 'LastName': 'Nazir', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Najia', 'Initials': 'N', 'LastName': 'Atif', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Armaan A', 'Initials': 'AA', 'LastName': 'Rowther', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Rizwana', 'Initials': 'R', 'LastName': 'Chaudhri', 'Affiliation': 'Department of Gynaecology and Obstetrics, Holy Family Hospital, Rawalpindi Medical University, Rawalpindi, Pakistan.'}, {'ForeName': 'Shamsa', 'Initials': 'S', 'LastName': 'Zafar', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Luke C', 'Initials': 'LC', 'LastName': 'Mullany', 'Affiliation': 'Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Abid', 'Initials': 'A', 'LastName': 'Malik', 'Affiliation': 'Human Development Research Foundation, Rawalpindi, Pakistan.'}, {'ForeName': 'Atif', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool, UK.'}]",BMJ open,['10.1136/bmjopen-2020-037590'] 261,31407876,Inter-individual variability in response to exercise intervention or usual care in hospitalized older adults.,"BACKGROUND Exercise protocols applied during hospitalization can prevent functional and cognitive decline in older adults. The purpose of this study was to examine the individual response of acutely hospitalized patients to usual care and to physical exercise on functional capacity, muscle strength, and cognitive function and to assess the relationship with mortality at 1 year post-discharge. METHODS In a single-blind randomized clinical trial, 370 hospitalized patients [56.5% women; mean age (standard deviation) 87.3 (4.9) years] were allocated to an exercise intervention group (IG, n = 185) or a control group (CG, n = 185). The participants were older adults aged 75 years or older in an acute care unit in a tertiary public hospital in Navarra, Spain. The usual care group received habitual hospital care, which included physical rehabilitation when needed. The in-hospital intervention included individualized multicomponent exercise training programme performed during 5-7 consecutive days (two sessions/day). Functional capacity was assessed with the Short Physical Performance Battery (SPPB) test and the Gait Velocity Test (GVT). Handgrip strength and cognitive function were also measured at admission and discharge. Patients in both groups were categorized as responders (Rs), non-responders (NRs), and adverse responders (ARs) based on the individual response to each treatment during hospitalization. RESULTS The prevalence of Rs was higher and the prevalence of NRs and ARs was lower in the intervention group than in the control group for functional capacity (SPPB IG: Rs 85.3%, NRs 8.7%, ARs 6.0% vs. CG: Rs 37.9%, NRs 28.8%, ARs 33.3% and GVT IG: Rs 51.2%, NRs 47.3, ARs 1.6% vs. CG: Rs 18.0%, NRs 67.7%, ARs 14.3%), muscle strength (IG: Rs 62.3%, NRs 26.5%, ARs 11.3% vs. CG: Rs 20.0%, NRs 38.0%, ARs 42.0%), and cognition (IG: Rs 41.5%, NRs 57.1%, ARs 1.4% vs. CG: Rs 13.8%, NRs 76.6%, ARs 9.7%) (all P < 0.001). The ARs for the GVT in the control group and the ARs for the SPPB in the intervention group had a significantly higher rate of mortality than the NRs and Rs in the equivalent groups (0.01 and 0.03, respectively) at follow-up. CONCLUSIONS Older patients performing an individualized exercise intervention presented higher prevalence of Rs and a lower prevalence of NRs and ARs for functional capacity, muscle strength, and cognitive function than those who were treated with usual care during acute hospitalization. An adverse response on functional capacity in older patients to physical exercise or usual care during hospitalization was associated with mortality at 1 year post-discharge.",2019,"The prevalence of Rs was higher and the prevalence of NRs and ARs was lower in the intervention group than in the control group for functional capacity (SPPB IG: Rs 85.3%, NRs 8.7%, ARs 6.0% vs. CG: Rs 37.9%, NRs 28.8%, ARs 33.3% and GVT IG: Rs 51.2%, NRs 47.3, ARs 1.6% vs. CG:","['acutely hospitalized patients to usual care and to', '370 hospitalized patients [56.5% women; mean age (standard deviation) 87.3 (4.9) years', 'hospitalized older adults', 'older patients', 'Older patients performing an', 'older adults', 'participants were older adults aged 75 years or older in an acute care unit in a tertiary public hospital in Navarra, Spain']","['individualized exercise intervention', 'habitual hospital care, which included physical rehabilitation', 'physical exercise', 'exercise intervention', 'CG', 'individualized multicomponent exercise training programme']","['Functional capacity', 'Short Physical Performance Battery (SPPB) test and the Gait Velocity Test (GVT', 'functional capacity, muscle strength, and cognitive function', 'rate of mortality', 'prevalence of NRs and ARs', 'Handgrip strength and cognitive function', 'muscle strength']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517743', 'cui_str': 'Three hundred and seventy'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0020022', 'cui_str': 'Hospitals, Public'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205353', 'cui_str': 'Habitual (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",370.0,0.0321945,"The prevalence of Rs was higher and the prevalence of NRs and ARs was lower in the intervention group than in the control group for functional capacity (SPPB IG: Rs 85.3%, NRs 8.7%, ARs 6.0% vs. CG: Rs 37.9%, NRs 28.8%, ARs 33.3% and GVT IG: Rs 51.2%, NRs 47.3, ARs 1.6% vs. CG:","[{'ForeName': 'Mikel L', 'Initials': 'ML', 'LastName': 'Sáez de Asteasu', 'Affiliation': 'Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain.'}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Martínez-Velilla', 'Affiliation': 'Navarrabiomed, IdiSNA, Navarra Institute for Health Research, Pamplona, Navarra, Spain.'}, {'ForeName': 'Fabricio', 'Initials': 'F', 'LastName': 'Zambom-Ferraresi', 'Affiliation': 'Navarrabiomed, IdiSNA, Navarra Institute for Health Research, Pamplona, Navarra, Spain.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'Casas-Herrero', 'Affiliation': 'Navarrabiomed, IdiSNA, Navarra Institute for Health Research, Pamplona, Navarra, Spain.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Cadore', 'Affiliation': 'Federal University of the Rio Grande of Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Robinson', 'Initials': 'R', 'LastName': 'Ramirez-Velez', 'Affiliation': 'Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Department of Health Sciences, Public University of Navarra, Pamplona, Navarra, Spain.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12481'] 262,30536589,"Pharmacokinetics, Safety, and Tolerability Evaluation of Single and Multiple Doses of GSK3342830 in Healthy Volunteers.","This was a first-time-in-human randomized, double-blind, single-center, placebo-controlled dose-escalation study to determine the safety, tolerability, and pharmacokinetic (PK) profiles of GSK3342830 after single and repeat intravenous doses in healthy adult subjects (NCT0271424). Sixty-two subjects were enrolled: 48 subjects in part 1 (single dose) and 14 subjects in part 2 (multiple doses). Following single intravenous infusions, total systemic exposure of GSK3342830 was dose proportional over the 250- to 6000-mg dose range evaluated, whereas peak exposure was approximately dose proportional over the dose range. Following repeat intravenous infusions 3 times a day, GSK3342830 showed time invariance with no drug accumulation. Steady state was reached before day 3, and approximately 90% of GSK3342830 was excreted unchanged in urine. All 48 subjects in part 1 (100.0%) completed the study. In part 2, 9 subjects (64.3%) completed the study, and 5 subjects, all receiving GSK3342830, discontinued early (35.7%), 4 after experiencing fever, headache, and malaise, whereas 1 subject met predefined criteria for drug discontinuation because of transaminitis. GSK3342830 demonstrated PK consistent with other cephalosporin-class antibiotics but poor tolerability following multiple doses in healthy volunteers.",2019,"Following repeat intravenous infusions 3 times a day, GSK3342830 showed time invariance with no drug accumulation.","['Healthy Volunteers', 'healthy volunteers', 'Sixty-two subjects were enrolled: 48 subjects in part 1 (single dose) and 14 subjects in part 2 (multiple doses', 'In part 2, 9 subjects (64.3%) completed the study, and 5 subjects, all receiving GSK3342830, discontinued early (35.7%), 4 after experiencing fever, headache, and malaise, whereas 1 subject met predefined criteria for drug discontinuation because of transaminitis', 'All 48 subjects in part 1 (100.0%) completed the study', 'healthy adult subjects (NCT0271424']","['cephalosporin-class antibiotics', 'placebo']","['Pharmacokinetics, Safety, and Tolerability Evaluation', 'Steady state', 'safety, tolerability, and pharmacokinetic (PK) profiles']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0231218', 'cui_str': 'Undifferentiated illness: Vague ill health'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C2242708', 'cui_str': 'Transaminitis'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C4706514', 'cui_str': 'Cephalosporin product'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]",62.0,0.043389,"Following repeat intravenous infusions 3 times a day, GSK3342830 showed time invariance with no drug accumulation.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Tenero', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Farinola', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Elchonon M', 'Initials': 'EM', 'LastName': 'Berkowitz', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Tiffany', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Yanwen', 'Initials': 'Y', 'LastName': 'Qian', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Zhengyu', 'Initials': 'Z', 'LastName': 'Xue', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'Aparna', 'Initials': 'A', 'LastName': 'Raychaudhuri', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Gardiner', 'Affiliation': 'GlaxoSmithKline, Clinical Pharmacology Modeling & Simulation, Collegeville, PA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.637'] 263,31513552,"Project Shikamana: Community Empowerment-Based Combination HIV Prevention Significantly Impacts HIV Incidence and Care Continuum Outcomes Among Female Sex Workers in Iringa, Tanzania.","OBJECTIVE To determine the impact of a community empowerment model of combination HIV prevention (Project Shikamana) among female sex workers (FSW) in Iringa, Tanzania. METHODS We conducted a 2-community randomized trial. Intervention elements included the following: (1) Community-led drop-in center and mobilization activities; (2) venue-based peer education, condom distribution, and HIV testing; (3) peer service navigation; (4) provider sensitivity trainings; and (5) SMS reminders. We used time-location sampling to enroll 496 FSW and conducted a survey and blood draws to screen for HIV and assess viral load at 0 and 18 months. We conducted an intent-to-treat analysis using logistic and Poisson regression and inverse probability weighting for primary outcomes. RESULTS The analysis included 171 HIV-positive and 216 HIV-negative FSW who completed baseline and 18-month study visits. Participants in the intervention were significantly less likely to become infected with HIV at 18-month follow-up (RR 0.38; P = 0.047), with an HIV incidence of 5.0% in the intervention vs. 10.4% control. Decreases in inconsistent condom use over time were significantly greater in the intervention (72.0%-43.6%) vs. control (68.8%-54.0%; RR 0.81, P = 0.042). At follow-up, we observed significant differences in behavioral HIV care continuum outcomes, and positive, but nonsignificant, increases in viral suppression (40.0%-50.6%) in the intervention vs. control (35.9%-47.4%). There was a strong association of between higher intervention exposure and HIV outcomes including viral suppression. CONCLUSIONS Project Shikamana is the first trial of community empowerment-based combination prevention among FSW in Africa to show a significant reduction in HIV incidence warranting its broader implementation and evaluation.",2019,"Decreases in inconsistent condom use over time were significantly greater in the intervention (72.0%-43.6%) vs. control (68.8%-54.0%; RR 0.81, P = 0.042).","['female sex workers (FSW) in Iringa, Tanzania', '171 HIV-positive and 216 HIV-negative FSW who completed baseline and 18-month study visits', 'Female Sex Workers in Iringa, Tanzania']","['Community-led drop-in center and mobilization activities; (2) venue-based peer education, condom distribution, and HIV testing; (3) peer service navigation; (4) provider sensitivity trainings; and (5) SMS reminders', 'community empowerment model of combination HIV prevention (Project Shikamana']","['viral suppression', 'behavioral HIV care continuum outcomes', 'HIV incidence']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0240816', 'cui_str': 'Prostitutes'}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C4708905', 'cui_str': 'Two hundred and sixteen'}, {'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009653', 'cui_str': 'Condoms'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0700628', 'cui_str': 'Sensitivity training'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0009853', 'cui_str': 'Continuity of Care'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",171.0,0.10898,"Decreases in inconsistent condom use over time were significantly greater in the intervention (72.0%-43.6%) vs. control (68.8%-54.0%; RR 0.81, P = 0.042).","[{'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Kerrigan', 'Affiliation': 'Department of Sociology, Center on Health, Risk and Society, American University, Washington, DC.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Mbwambo', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Likindikoki', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Davis', 'Affiliation': 'Department of Sociology, Center on Health, Risk and Society, American University, Washington, DC.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Mantsios', 'Affiliation': 'Department of Sociology, Center on Health, Risk and Society, American University, Washington, DC.'}, {'ForeName': 'S Wilson', 'Initials': 'SW', 'LastName': 'Beckham', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Leddy', 'Affiliation': 'Department of Medicine, University of California at San Francisco, San Francisco, CA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Shembilu', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Ard', 'Initials': 'A', 'LastName': 'Mwampashi', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Said', 'Initials': 'S', 'LastName': 'Aboud', 'Affiliation': 'Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.'}, {'ForeName': 'Noya', 'Initials': 'N', 'LastName': 'Galai', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002123'] 264,31568675,Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men.,"BACKGROUND The andropause is associated with declines in serum testosterone (T), loss of muscle mass (sarcopenia), and frailty. Two major interventions purported to offset sarcopenia are anabolic steroid therapies and resistance exercise training (RET). Nonetheless, the efficacy and physiological and molecular impacts of T therapy adjuvant to short-term RET remain poorly defined. METHODS Eighteen non-hypogonadal healthy older men, 65-75 years, were assigned in a random double-blinded fashion to receive, biweekly, either placebo (P, saline, n = 9) or T (Sustanon 250 mg, n = 9) injections over 6 week whole-body RET (three sets of 8-10 repetitions at 80% one-repetition maximum). Subjects underwent dual-energy X-ray absorptiometry, ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies were taken to quantify myogenic/anabolic gene expression, anabolic signalling, muscle protein synthesis (D 2 O), and breakdown (extrapolated). RESULTS Testosterone adjuvant to RET augmented total fat-free mass (P=0.007), legs fat-free mass (P=0.02), and appendicular fat-free mass (P=0.001) gains while decreasing total fat mass (P=0.02). Augmentations in VL muscle thickness, fascicle length, and quadriceps cross-section area with RET occured to a greater extent in T (P < 0.05). Sum strength (P=0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased significantly more in the T group. Mechanistically, both muscle protein synthesis rates (T: 2.13 ± 0.21%·day -1 vs. P: 1.34 ± 0.13%·day -1 , P=0.0009) and absolute breakdown rates (T: 140.2 ± 15.8 g·day -1 vs. P: 90.2 ± 11.7 g·day -1 , P=0.02) were elevated with T therapy, which led to higher net turnover and protein accretion in the T group (T: 8.3 ± 1.4 g·day -1 vs. P: 1.9 ± 1.2 g·day -1 , P=0.004). Increases in ribosomal biogenesis (RNA:DNA ratio); mRNA expression relating to T metabolism (androgen receptor: 1.4-fold; Srd5a1: 1.6-fold; AKR1C3: 2.1-fold; and HSD17β3: two-fold); insulin-like growth factor (IGF)-1 signalling [IGF-1Ea (3.5-fold) and IGF-1Ec (three-fold)] and myogenic regulatory factors; and the activity of anabolic signalling (e.g. mTOR, AKT, and RPS6; P < 0.05) were all up-regulated with T therapy. Only T up-regulated mitochondrial citrate synthase activity (P=0.03) and transcription factor A (1.41 ± 0.2-fold, P=0.0002), in addition to peroxisome proliferator-activated receptor-γ co-activator 1-α mRNA (1.19 ± 0.21-fold, P=0.037). CONCLUSIONS Administration of T adjuvant to RET enhanced skeletal muscle mass and performance, while up-regulating myogenic gene programming, myocellular translational efficiency and capacity, collectively resulting in higher protein turnover, and net protein accretion. T coupled with RET is an effective short-term intervention to improve muscle mass/function in older non-hypogonadal men.",2019,Sum strength (P=0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased significantly more in the T group.,"['Eighteen non-hypogonadal healthy older men, 65-75 years', 'older non-hypogonadal men', 'older men']","['placebo (P, saline, n = 9) or T (Sustanon 250 mg, n = 9) injections over 6 week whole-body RET', 'RET', 'sarcopenia are anabolic steroid therapies and resistance exercise training (RET', 'dual-energy X-ray absorptiometry, ultrasound of vastus lateralis (VL) muscle architecture, and knee extensor isometric muscle force tests; VL muscle biopsies', 'Testosterone therapy']","['Sum strength', 'muscle protein synthesis rates', 'total fat-free mass', 'serum testosterone (T), loss of muscle mass (sarcopenia), and frailty', 'absolute breakdown rates', 'legs fat-free mass', 'mitochondrial citrate synthase activity', 'net turnover and protein accretion', 'total fat mass', 'maximal voluntary contract', 'VL muscle thickness, fascicle length, and quadriceps cross-section area with RET']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0075665', 'cui_str': 'Sustanon'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0543431', 'cui_str': 'ret (qualifier value)'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenias'}, {'cui': 'C0002845', 'cui_str': 'Anabolic Steroids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0224444', 'cui_str': 'Vastus Lateralis'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0185283', 'cui_str': 'Biopsy of muscle (procedure)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}]","[{'cui': 'C0026832', 'cui_str': 'Muscle Proteins'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0428413', 'cui_str': 'Serum testosterone measurement'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0312285', 'cui_str': 'Citrate (re)-synthase (substance)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0443331', 'cui_str': 'Turnover technique (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0333038', 'cui_str': 'Accretion'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0543431', 'cui_str': 'ret (qualifier value)'}]",,0.0510255,Sum strength (P=0.0009) and maximal voluntary contract (e.g. knee extension at 70°) (P=0.002) increased significantly more in the T group.,"[{'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Gharahdaghi', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Supreeth', 'Initials': 'S', 'LastName': 'Rudrappa', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Brook', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Iskandar', 'Initials': 'I', 'LastName': 'Idris', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Crossland', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Hamrock', 'Affiliation': 'Institute of Food and Health, University College Dublin, Belfield, Dublin, Ireland.'}, {'ForeName': 'Muhammad Hariz', 'Initials': 'MH', 'LastName': 'Abdul Aziz', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Fawzi', 'Initials': 'F', 'LastName': 'Kadi', 'Affiliation': 'Division of Sports Sciences, School of Health and Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Tarum', 'Affiliation': 'Division of Sports Sciences, School of Health and Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Paul L', 'Initials': 'PL', 'LastName': 'Greenhaff', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Nottingham, Nottingham, UK.'}, {'ForeName': 'Dumitru', 'Initials': 'D', 'LastName': 'Constantin-Teodosiu', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham, Nottingham, Nottingham, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Cegielski', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Bethan E', 'Initials': 'BE', 'LastName': 'Phillips', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Wilkinson', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Nathaniel J', 'Initials': 'NJ', 'LastName': 'Szewczyk', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Smith', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Atherton', 'Affiliation': 'MRC-ARUK Centre for Musculoskeletal Ageing Research and Nottingham NIHR BRC, School of Medicine, University of Nottingham, Derby, UK.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12472'] 265,31468659,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.,"AIMS The AleCardio trial aimed to characterize the efficacy and safety of peroxisome proliferator-activated receptor-αγ agonist aleglitazar in patients with type 2 diabetes mellitus and acute coronary syndrome. The trial terminated early because of futility and safety signals. We evaluated whether the safety signals could be attributed to increased exposure to aleglitazar. MATERIALS AND METHODS The AleCardio trial enrolled 7226 patients to receive aleglitazar 150 μg or matching placebo on top of standard care. A population pharmacokinetic analysis was conducted in a pharmacokinetic substudy to identify covariates that explained interindividual variability in exposure. Subsequently, the effect of these covariates on surrogate and clinical outcomes was assessed in the full patient population. RESULTS Concomitant administration of clopidogrel was identified as a covariate that influenced the apparent clearance of aleglitazar. Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC 0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel. The effect of aleglitazar compared with placebo on HbA1c, haemoglobin, serum creatinine and adiponectin was modified by concomitant clopidogrel use (P for interaction 0.007, 0.002, <0.001 and < 0.001, respectively). CONCLUSIONS Concomitant use of clopidogrel was identified as a covariate that explained interindividual variability in exposure to aleglitazar. Patients using clopidogrel showed an additional lowering of HbA1c, at the expense of an additional decrease in haemoglobin, and an increase in serum creatinine and adiponectin. Clopidogrel is a moderate inhibitor of CYP2C8. Because aleglitazar is metabolized by CYP2C8, a pharmacokinetic interaction could explain differences in exposure and response to aleglitazar.",2020,"The effect of aleglitazar compared to placebo on HbA1c, hemoglobin, serum creatinine and adiponectin was modified by concomitant clopidogrel use (p for interaction 0.007, 0.002, <0.001 and <0.001 respectively). ","['7226 patients to receive', 'on top of standard of care', 'patients with type 2 diabetes mellitus and acute coronary syndrome']","['aleglitazar', 'placebo', 'Clopidogrel', 'clopidogrel', 'aleglitazar 150 μg or matching placebo', 'PPARαγ agonist aleglitazar']","['serum creatinine and adiponectin', 'cardiovascular risk markers and safety outcomes', 'HbA1c, hemoglobin, serum creatinine and adiponectin', 'hemoglobin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}]","[{'cui': 'C2348244', 'cui_str': 'aleglitazar'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0243192', 'cui_str': 'agonists'}]","[{'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",,0.473923,"The effect of aleglitazar compared to placebo on HbA1c, hemoglobin, serum creatinine and adiponectin was modified by concomitant clopidogrel use (p for interaction 0.007, 0.002, <0.001 and <0.001 respectively). ","[{'ForeName': 'Jeroen V', 'Initials': 'JV', 'LastName': 'Koomen', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Hiddo J L', 'Initials': 'HJL', 'LastName': 'Heerspink', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Ilse C', 'Initials': 'IC', 'LastName': 'Schrieks', 'Affiliation': 'Julius Clinical & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'Cardiology Section, Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Colorado, Aurora.'}, {'ForeName': 'A Michael', 'Initials': 'AM', 'LastName': 'Lincoff', 'Affiliation': 'C5Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Nicholls', 'Affiliation': 'Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Svensson', 'Affiliation': 'Clinical Development, Cardio Metabolism, F. Hoffmann-La Roche Ltd., Basel, Switzerland.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Wedel', 'Affiliation': 'Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Arlette', 'Initials': 'A', 'LastName': 'Weichert', 'Affiliation': 'Product Development, Immunology, Infectious Disease and Ophthalmology (I2O), F. Hoffmann-La Roche Ltd., Basel, Switzerland.'}, {'ForeName': 'Diederick E', 'Initials': 'DE', 'LastName': 'Grobbee', 'Affiliation': 'Julius Clinical & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Jasper', 'Initials': 'J', 'LastName': 'Stevens', 'Affiliation': 'Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13862'] 266,30929284,"Effect of acute total sleep deprivation on plasma melatonin, cortisol and metabolite rhythms in females.","Disruption to sleep and circadian rhythms can impact on metabolism. The study aimed to investigate the effect of acute sleep deprivation on plasma melatonin, cortisol and metabolites, to increase understanding of the metabolic pathways involved in sleep/wake regulation processes. Twelve healthy young female participants remained in controlled laboratory conditions for ~92 hr with respect to posture, meals and environmental light (18:00-23:00 hr and 07:00-09:00 hr <8 lux; 23:00-07:00 hr 0 lux (sleep opportunity) or <8 lux (continuous wakefulness); 09:00-18:00 hr ~90 lux). Regular blood samples were collected for 70 hr for plasma melatonin and cortisol, and targeted liquid chromatography-mass spectrometry metabolomics. Timepoints between 00:00 and 06:00 hr for day 1 (baseline sleep), day 2 (sleep deprivation) and day 3 (recovery sleep) were analysed. Cosinor analysis and MetaCycle analysis were performed for detection of rhythmicity. Night-time melatonin levels were significantly increased during sleep deprivation and returned to baseline levels during recovery sleep. No significant differences were observed in cortisol levels. Of 130 plasma metabolites quantified, 41 metabolites were significantly altered across the study nights, with the majority decreasing during sleep deprivation, most notably phosphatidylcholines. In cosinor analysis, 58 metabolites maintained their rhythmicity across the study days, with the majority showing a phase advance during acute sleep deprivation. This observation differs to that previously reported for males. Our study is the first of metabolic profiling in females during sleep deprivation and recovery sleep, and offers a novel view of human sleep/wake regulation and sex differences.",2020,"Of 130 plasma metabolites quantified, 41 metabolites were significantly altered across the study nights, with the majority decreasing during sleep deprivation, most notably phosphatidylcholines.","['Twelve healthy young female participants remained in controlled laboratory conditions for ~92', 'females']","['acute sleep deprivation', 'acute total sleep deprivation', 'posture, meals and environmental light']","['Night-time melatonin levels', 'cortisol levels', 'plasma melatonin, cortisol and metabolite rhythms', 'plasma melatonin, cortisol and metabolites']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0037316', 'cui_str': 'Sleep Deprivation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1262869', 'cui_str': 'Posture'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}]","[{'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",12.0,0.0199892,"Of 130 plasma metabolites quantified, 41 metabolites were significantly altered across the study nights, with the majority decreasing during sleep deprivation, most notably phosphatidylcholines.","[{'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Honma', 'Affiliation': 'Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Victoria L', 'Initials': 'VL', 'LastName': 'Revell', 'Affiliation': 'Surrey Clinical Research Centre, University of Surrey, Guildford, UK.'}, {'ForeName': 'Pippa J', 'Initials': 'PJ', 'LastName': 'Gunn', 'Affiliation': 'Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Davies', 'Affiliation': 'Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Benita', 'Initials': 'B', 'LastName': 'Middleton', 'Affiliation': 'Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Florence I', 'Initials': 'FI', 'LastName': 'Raynaud', 'Affiliation': 'Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Debra J', 'Initials': 'DJ', 'LastName': 'Skene', 'Affiliation': 'Chronobiology, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.'}]",The European journal of neuroscience,['10.1111/ejn.14411'] 267,32300013,"Asking young children to ""do science"" instead of ""be scientists"" increases science engagement in a randomized field experiment.","Subtle features of common language can imply to young children that scientists are a special and distinct kind of person-a way of thinking that can interfere with the development of children's own engagement with science. We conducted a large field experiment (involving 45 prekindergarten schools, 130 teachers, and over 1,100 children) to test if targeting subtle properties of language can increase science engagement in children's daily lives. Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students. These changes in language were powerful enough to predict children's science interest and behavior days later. Thus, subtle features of language shape children's beliefs and behaviors as they unfold in real world environments. Harnessing these mechanisms could promote science engagement in early childhood.",2020,"Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students.","[""children's daily lives"", '45 prekindergarten schools, 130 teachers, and over 1,100 children']",[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}]",[],[],1100.0,0.0458692,"Despite strong tendencies to describe scientists as a special kind of person (in a baseline control condition), brief video-based training changed the language that teachers used to introduce science to their students.","[{'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Rhodes', 'Affiliation': 'Department of Psychology, New York University, New York, NY 10003; marjorie.rhodes@nyu.edu.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Cardarelli', 'Affiliation': 'Department of Psychology, New York University, New York, NY 10003.'}, {'ForeName': 'Sarah-Jane', 'Initials': 'SJ', 'LastName': 'Leslie', 'Affiliation': 'Department of Philosophy, Princeton University, Princeton, NJ 08544.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.1919646117'] 268,30980733,Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.,"AIMS There is a need for predictive and surrogate response biomarkers to support treatment with antiangiogenic vascular endothelial growth factor (VEGF) inhibitors. We aimed to identify a minimally-invasive biomarker predicting benefit from cediranib pretreatment or early during treatment in patients with recurrent or metastatic cervical cancer. METHODS Blood samples were collected before treatment, during treatment and upon disease progression where appropriate from patients enrolled in CIRCCa, a randomised phase II trial of carboplatin and paclitaxel with or without cediranib. Plasma concentrations of VEGF-A, VEGF-receptor 2, Ang1 and Tie2 were measured using multiplex enzyme-linked immunosorbent assay. Pretreatment and temporal changes of the biomarkers were investigated using proportional hazard regression and unsupervised clustering analysis. RESULTS Samples (n = 556) from 52 patients were analysed. VEGF-receptor 2 (P = .0006) and Tie2 (P = .04) were downregulated following cediranib, while VEGF-A (P = .0025) was upregulated. High Eastern Cooperative Oncology Group performance status (P = .02, hazard ratio [HR] = 2.15, 95% confidence interval [CI] 1.13-4.09) and low pretreatment Tie2 concentrations (P = .003, HR = 0.57, 95%CI 0.39-0.83) were independent prognostic factors associated with reduced progression-free survival. Two patterns of changes in VEGF-A following cediranib were identified. Patients with elevated VEGF-A in the first 3 treatment cycles, regardless of magnitude, had reduced progression-free survival in the placebo arm but improved survival with the addition of cediranib (P = .019, HR = 0.13, 95% CI 0.02-0.71). CONCLUSION Patterns of early elevation in plasma VEGF-A should be studied further as a potential biomarker to predict treatment benefit from cediranib.",2019,"VEGF-receptor 2 (P = .0006) and Tie2 (P = .04) were downregulated following cediranib, while VEGF-A (P = .0025) was upregulated.","['patients with recurrent or metastatic cervical cancer', 'metastatic or recurrent cervical cancer patients', 'Samples (n\xa0', '556) from 52 patients were analysed']","['antiangiogenic cediranib', 'cediranib', 'carboplatin and paclitaxel with or without cediranib']","['survival', 'Plasma concentrations of VEGF-A, VEGF-receptor 2', 'progression-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4517811', 'cui_str': 'Five hundred and fifty-six'}]","[{'cui': 'C1698364', 'cui_str': '4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0148199', 'cui_str': 'VEGF Receptors'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",556.0,0.258577,"VEGF-receptor 2 (P = .0006) and Tie2 (P = .04) were downregulated following cediranib, while VEGF-A (P = .0025) was upregulated.","[{'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': 'Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Tugwood', 'Affiliation': 'Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Simpson', 'Affiliation': 'Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.'}, {'ForeName': 'Gordon C', 'Initials': 'GC', 'LastName': 'Jayson', 'Affiliation': 'Division of Cancer Sciences, University of Manchester, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Symonds', 'Affiliation': 'Department of Cancer Studies, University of Leicester, Leicester, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Paul', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Davidson', 'Affiliation': 'Christie Hospital NHS Trust, Manchester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Carty', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'McCartney', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Rai', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Dive', 'Affiliation': 'Clinical & Experimental Pharmacology Group, Cancer Research UK Manchester Institute and Manchester Centre for Cancer Biomarker Sciences, University of Manchester, UK.'}, {'ForeName': 'Catharine', 'Initials': 'C', 'LastName': 'West', 'Affiliation': 'Division of Cancer Sciences, University of Manchester, Christie Hospital NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.'}]",British journal of clinical pharmacology,['10.1111/bcp.13965'] 269,31271875,Design and baseline characteristics of the cocoa supplement and multivitamin outcomes study for the Mind: COSMOS-Mind.,"BACKGROUND Large simple trials are potentially efficient and cost-effective approaches to assess interventions to preserve cognitive function in older adults. High-dose cocoa flavanols supplementation is a promising intervention that warrants additional testing. We describe the design, recruitment success, and baseline characteristics of the Cocoa Supplement and Multivitamin Outcomes Study for the Mind (COSMOS-Mind) trial. METHODS COSMOS-Mind is an ancillary study to the large-scale and predominantly mail-based COSMOS randomized controlled clinical trial. COSMOS is assessing whether cocoa extract (including 600 mg/d cocoa flavanols) and a multivitamin reduce risks for major cardiovascular events and total invasive cancer. COSMOS-Mind uses telephone-based interviews to assess cognitive function and impairment to determine whether cocoa flavanols benefit cognitive function in adults aged 65 years or older, targeting the enrollment of 2000 participants to provide >90% statistical power across 3 years of annual follow-up. RESULTS Of the 3224 COSMOS screenees who expressed interest in COSMOS-Mind, 2350 (76%) successfully completed baseline cognitive assessments and 2262 (96%) geographically diverse, eligible individuals were ultimately enrolled over one year. At baseline, the primary outcome, a composite of cognitive test scores, was inversely associated with age in a manner consistent with assumptions used in projections of statistical power. CONCLUSIONS Older adults are willing to enroll in large simple trials that include telephone-based cognitive assessments. Embedding these trials in large studies of other health outcomes is efficient and expands the scientific knowledge gained from the research. ClinicalTrials.gov Identifiers: NCT03035201 (COSMOS-Mind); NCT102422745 (parent COSMOS).",2019,"At baseline, the primary outcome, a composite of cognitive test scores, was inversely associated with age in a manner consistent with assumptions used in projections of statistical power. ","['Of the 3224 COSMOS screenees who expressed interest in COSMOS-Mind, 2350 (76%) successfully completed baseline cognitive assessments and 2262 (96%) geographically diverse, eligible individuals were ultimately enrolled over one year', 'Older adults', 'adults aged 65\u202fyears or older, targeting the enrollment of 2000 participants to provide >90% statistical power across 3\u202fyears of annual follow-up', 'older adults']","['multivitamin', 'cocoa supplement and multivitamin', 'High-dose cocoa flavanols supplementation', 'cocoa extract']",['composite of cognitive test scores'],"[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439083', 'cui_str': '>90 (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C4521844', 'cui_str': 'Cocoa'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C1138626', 'cui_str': 'Cocoa extract'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.340227,"At baseline, the primary outcome, a composite of cognitive test scores, was inversely associated with age in a manner consistent with assumptions used in projections of statistical power. ","[{'ForeName': 'Laura D', 'Initials': 'LD', 'LastName': 'Baker', 'Affiliation': 'Department of Internal Medicine, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America; Department of Social Sciences and Health Policy, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: ldbaker@wakehealth.edu.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Rapp', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America; Department of Psychiatry and Prevention, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: srapp@wakehealth.edu.'}, {'ForeName': 'Sally A', 'Initials': 'SA', 'LastName': 'Shumaker', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: sshumake@wakehealth.edu.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, 900 Commonwealth Avenue, Boston, MA 02115, United States of America. Electronic address: jmanson@rics.bwh.harvard.edu.""}, {'ForeName': 'Howard D', 'Initials': 'HD', 'LastName': 'Sesso', 'Affiliation': ""Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, 900 Commonwealth Avenue, Boston, MA 02115, United States of America. Electronic address: hsesso@hsph.harvard.edu.""}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Gaussoin', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: sgaussoi@wakehealth.edu.'}, {'ForeName': 'Darrin', 'Initials': 'D', 'LastName': 'Harris', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: dharris@wakehealth.edu.'}, {'ForeName': 'Brad', 'Initials': 'B', 'LastName': 'Caudle', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: bcaudle@wakehealth.edu.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Pleasants', 'Affiliation': 'Department of Social Sciences and Health Policy, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: depleasan@wakehealth.edu.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Espeland', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, One Medical Center Boulevard, Winston-Salem, NC, 27157, United States of America. Electronic address: mespelan@wakehealth.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.019'] 270,31845455,Reference-based multiple imputation for missing data sensitivity analyses in trial-based cost-effectiveness analysis.,"Missing data are a common issue in cost-effectiveness analysis (CEA) alongside randomised trials and are often addressed assuming the data are 'missing at random'. However, this assumption is often questionable, and sensitivity analyses are required to assess the implications of departures from missing at random. Reference-based multiple imputation provides an attractive approach for conducting such sensitivity analyses, because missing data assumptions are framed in an intuitive way by making reference to other trial arms. For example, a plausible not at random mechanism in a placebo-controlled trial would be to assume that participants in the experimental arm who dropped out stop taking their treatment and have similar outcomes to those in the placebo arm. Drawing on the increasing use of this approach in other areas, this paper aims to extend and illustrate the reference-based multiple imputation approach in CEA. It introduces the principles of reference-based imputation and proposes an extension to the CEA context. The method is illustrated in the CEA of the CoBalT trial evaluating cognitive behavioural therapy for treatment-resistant depression. Stata code is provided. We find that reference-based multiple imputation provides a relevant and accessible framework for assessing the robustness of CEA conclusions to different missing data assumptions.",2020,We find that reference-based multiple imputation provides a relevant and accessible framework for assessing the robustness of CEA conclusions to different missing data assumptions.,[],[],[],[],[],[],,0.0962054,We find that reference-based multiple imputation provides a relevant and accessible framework for assessing the robustness of CEA conclusions to different missing data assumptions.,"[{'ForeName': 'Baptiste', 'Initials': 'B', 'LastName': 'Leurent', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Gomes', 'Affiliation': 'Department of Applied Health Research, University College London, London, UK.'}, {'ForeName': 'Suzie', 'Initials': 'S', 'LastName': 'Cro', 'Affiliation': 'Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Wiles', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Carpenter', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.'}]",Health economics,['10.1002/hec.3963'] 271,31109915,Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial.,"BACKGROUND We examined the effectiveness of integrated stepped alcohol treatment (ISAT) on alcohol use and HIV outcomes among patients living with HIV and alcohol use disorder. METHODS In this multisite, randomised controlled trial, conducted in five Veterans Affairs-based HIV clinics in the USA (Atlanta, GA; Brooklyn-Manhattan, NY; Dallas and Houston, TX; and Washington, DC), we recruited people living with HIV and an alcohol use disorder who were not otherwise receiving formal alcohol treatment. Patients were eligible if they were aged 18 years or older, HIV positive, English speaking, and met criteria for alcohol use disorder by the Diagnostic and Statistical Manual for Mental Disorders-IV criteria for alcohol abuse or dependence. Key exclusion criteria included if the patient was acutely suicidal or had a psychiatric condition that affected their ability to participate in counselling interventions, or if they had any medical conditions that would preclude completing the study or cause harm during the course of the study. Using a web-based clinical trial management system, we randomly assigned participants (1:1) to receive ISAT or treatment as usual; patients, investigators, and clinicians were unmasked to allocation. ISAT involved three steps: step 1, addiction physician management, comprising eight sessions; step 2, addiction physician management plus motivational enhancement therapy, comprising four sessions; and step 3, specialty referral. Participants were stepped up at weeks 4 and 12 if they exceeded a priori drinking criteria. Treatment as usual involved referral to substance use treatment services. The primary outcome was number of drinks per week over the past 30 days at week 24 by use of the timeline followback method, assessed in the intention-to-treat population. Adverse events were tracked throughout the study period in all randomly assigned participants. This trial is registered at ClinicalTrials.gov, number NCT01410123. FINDINGS Between Jan 28, 2013, and July 14, 2017, 128 of 351 patients assessed for eligibility were eligible and randomly assigned to receive ISAT (n=63) or treatment as usual (n=65). Mean age was 54 years (range 23-70), 125 (98%) of 128 participants were men, and 101 (79%) were black. 25 (20%) were lost to follow-up. In the ISAT group, of 57 participants who did not die or withdraw, 30 (52%) advanced to step 2, and 17 (57%) of 30 advanced to step 3. 32 (51%) of 63 participants assigned to ISAT versus 17 (26%) of 65 assigned to treatment as usual received at least one alcohol treatment medication (p=0·004). Participants in both groups decreased their alcohol consumption, but at week 24 we did not detect a difference in number of drinks per week between the groups (least squares mean 10·4 drinks per week [SD 16·5] in the ISAT group vs 15·6 drinks per week [SD 17·6] in the treatment as usual group; adjusted mean difference -4·2, 95% CI -9·4 to 0·9; p=0·11). One adverse event occurred that was possibly related to treatment occurred in the ISAT group (headache). INTERPRETATION ISAT increases the receipt of alcohol treatment medications and counselling without changes in drinking at week 24. Strategies to implement and enhance ISAT are needed. Future efforts should focus on promoting ISAT with attention to enhancing patient engagement and retention in alcohol-related care. FUNDING US National Institute on Alcohol Abuse and Alcoholism.",2019,"Participants in both groups decreased their alcohol consumption, but at week 24 we did not detect a difference in number of drinks per week between the groups (least squares mean 10·4 drinks per week [SD 16·5] in the ISAT group vs 15·6 drinks per week [SD 17·6] in the treatment as usual group; adjusted mean difference -4·2, 95% CI -9·4 to 0·9; p=0·11).","['patients living with HIV and alcohol use disorder', 'Between Jan 28, 2013, and July 14, 2017', 'Key exclusion criteria included if the patient was acutely suicidal or had a psychiatric condition that affected their ability to participate in counselling interventions, or if they had any medical conditions that would preclude completing the study or cause harm during the course of the study', 'Mean age was 54 years (range 23-70), 125 (98%) of 128 participants were men, and 101 (79%) were black', '57 participants who did not die or withdraw, 30 (52%) advanced to step 2, and 17 (57%) of 30 advanced to step 3', 'patients with HIV and alcohol use disorder', 'five Veterans Affairs-based HIV clinics in the USA (Atlanta, GA; Brooklyn-Manhattan, NY; Dallas and Houston, TX; and Washington, DC), we recruited people living with HIV and an alcohol use disorder who were not otherwise receiving formal alcohol treatment', '128 of 351 patients assessed for eligibility were eligible', 'Patients were eligible if they were aged 18 years or older, HIV positive, English speaking, and met criteria for alcohol use disorder by the Diagnostic and Statistical Manual for Mental Disorders-IV criteria for alcohol abuse or dependence']","['integrated stepped alcohol treatment (ISAT', 'ISAT', 'addiction physician management plus motivational enhancement therapy', 'Integrated stepped alcohol treatment']","['number of drinks', 'number of drinks per week over the past 30 days', 'alcohol consumption', 'Adverse events', 'alcohol use and HIV outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0001956', 'cui_str': 'Alcohol Use Disorder'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0438696', 'cui_str': 'Suicidal (finding)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0085762', 'cui_str': 'Alcohol abuse (disorder)'}, {'cui': 'C0439857', 'cui_str': 'Patient dependence on (contextual qualifier) (qualifier value)'}]","[{'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0085281', 'cui_str': 'Addictive Behavior'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]",128.0,0.136665,"Participants in both groups decreased their alcohol consumption, but at week 24 we did not detect a difference in number of drinks per week between the groups (least squares mean 10·4 drinks per week [SD 16·5] in the ISAT group vs 15·6 drinks per week [SD 17·6] in the treatment as usual group; adjusted mean difference -4·2, 95% CI -9·4 to 0·9; p=0·11).","[{'ForeName': 'E Jennifer', 'Initials': 'EJ', 'LastName': 'Edelman', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA. Electronic address: ejennifer.edelman@yale.edu.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Maisto', 'Affiliation': 'Syracuse University, Syracuse, NY, USA.'}, {'ForeName': 'Nathan B', 'Initials': 'NB', 'LastName': 'Hansen', 'Affiliation': 'Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA; College of Public Health, University of Georgia, Athens, GA, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Cutter', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Yale Center for Analytic Sciences, Yale University School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Yale Center for Analytic Sciences, Yale University School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Lynn E', 'Initials': 'LE', 'LastName': 'Fiellin', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Patrick G', 'Initials': 'PG', 'LastName': ""O'Connor"", 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Bedimo', 'Affiliation': 'Veterans Affairs North Texas Health Care System and UT Southwestern, Dallas, TX, USA.'}, {'ForeName': 'Cynthia L', 'Initials': 'CL', 'LastName': 'Gibert', 'Affiliation': 'Washington DC Veterans Affairs Medical Center and George Washington University School of Medicine and Health Sciences, Washington, DC, USA.'}, {'ForeName': 'Vincent C', 'Initials': 'VC', 'LastName': 'Marconi', 'Affiliation': 'Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rimland', 'Affiliation': 'Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Rodriguez-Barradas', 'Affiliation': 'Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Simberkoff', 'Affiliation': 'Veterans Affairs NY Harbor Healthcare System and New York University School of Medicine, New York, NY, USA.'}, {'ForeName': 'Janet P', 'Initials': 'JP', 'LastName': 'Tate', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Veterans Affairs Connecticut Healthcare System, Veterans Aging Cohort Study, West Haven, CT, USA.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Justice', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA; Veterans Affairs Connecticut Healthcare System, Veterans Aging Cohort Study, West Haven, CT, USA.'}, {'ForeName': 'Kendall J', 'Initials': 'KJ', 'LastName': 'Bryant', 'Affiliation': 'National Institute on Alcohol Abuse and Alcoholism HIV/AIDS Program, Bethesda, MD, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fiellin', 'Affiliation': 'Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.'}]",The lancet. HIV,['10.1016/S2352-3018(19)30076-1'] 272,32239737,"Meralgia paresthetica: Nerve stimulator-guided injection with methylprednisolone/lidocaine, a double-blind randomized placebo-controlled study.","BACKGROUND Meralgia paresthetica is a mononeuropathy of the lateral femoral cutaneous nerve. A common therapy is injection with corticosteroids. The goal of this study was to analyze the effect of injection with methylprednisolone/lidocaine vs placebo. METHODS After randomization, 10 patients received a nerve stimulator-guided injection with methylprednisolone/lidocaine, and 10 patients received saline. The primary outcome measure was pain (visual analogue scale, VAS). RESULTS In the placebo group, there was a significant pain reduction (baseline VAS, 6.8; VAS week 12, 4.3; P = .014). The VAS score in the methylprednisolone group did not show a significant reduction (baseline VAS, 7.4; VAS week 12, 4.8; P = .053). There was no significant difference in pain reduction between the groups. CONCLUSIONS We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paresthetica, although this study is limited by a small sample size. Future placebo-controlled studies using ultrasound-guided injection are warranted.",2020,"We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paraesthetica, although this study is limited by a small sample size.",[],"['methylprednisolone', 'placebo', 'methylprednisolone/lidocaine', 'saline', 'nerve stimulator-guided injection with methylprednisolone/lidocaine']","['VAS score', 'pain (visual analogue scale, VAS', 'pain reduction']",[],"[{'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0582124', 'cui_str': 'Neurostimulator'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.599475,"We found no objective evidence for benefit from nerve stimulator-guided injection with corticosteroids in meralgia paraesthetica, although this study is limited by a small sample size.","[{'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Kloosterziel', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Dénes L J', 'Initials': 'DLJ', 'LastName': 'Tavy', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Arends', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Joyce M', 'Initials': 'JM', 'LastName': 'Zijdewind', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}, {'ForeName': 'Erik W', 'Initials': 'EW', 'LastName': 'van Zwet', 'Affiliation': 'Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, The Netherlands.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Wirtz', 'Affiliation': 'Department of Neurology, Haga Hospital, The Hague, The Netherlands.'}]",Muscle & nerve,['10.1002/mus.26877'] 273,32105341,"Pretreatment of Root Canal with Photodynamic Therapy Facilitates Adhesion, Viability and Differentiation of Stem Cells of the Apical Papilla.","This study was to test the hypothesis that root canal pretreated with photodynamic therapy (PDT) would promote stem cells from the apical papilla (SCAP) adhesion, proliferation and differentiation without affecting smear layer removal and microhardness of root canal. Standardized root canals were randomized into four groups (n = 30/group): (1) sodium hypochlorite(NaOCl) group, (2) NaOCl + ethylene diaminetetraacetic acid (EDTA) group, (3) NaOCl + PDT group, (4) NaOCl + EDTA + PDT group. After treatments, smear layer removal and microhardness of root canal were evaluated. SCAP with hydroxyapatite-based scaffolds were seeded into root canals for 7 days. SCAP adhesion was observed by scanning electron microscope (SEM), and viable cells were calculated by CellTiter-Glo Luminescent kit. Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression of SCAP were evaluated by Quantitative Reverse Transcriptase-Polymerase Chain Reaction. There was no significant difference in the smear layer removal and microhardness of root dentin between the groups with and without PDT treatment (P > 0.05). SCAP with elongated cytoplasmic processes and cell-cell contact were observed on the dentin surfaces treated with PDT. Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P < 0.05). Under the experimental conditions, PDT could provide positive microenvironment for SCAP growth.",2020,"Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P<0.05).",[],"['root canal with photodynamic therapy', 'SCAP with hydroxyapatite-based scaffolds', 'sodium hypochlorite(NaOCl', 'photodynamic therapy (PDT', 'SCAP', 'NaOCl +EDTA+PDT', 'NaOCl + ethylene diaminetetraacetic acid (EDTA) group, 3) NaOCl +PDT group, 4']","['smear layer removal and microhardness of root canal', 'smear layer removal and microhardness of root dentin', 'Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) expression of SCAP', 'SCAP adhesion', 'Elevated cell viability, PDGF and VEGF expression']",[],"[{'cui': 'C0086881', 'cui_str': 'Root Canal'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}, {'cui': 'C0115137', 'cui_str': 'Durapatite'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0337143', 'cui_str': 'Scaffold, device (physical object)'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0044588', 'cui_str': 'PDT'}, {'cui': 'C0015075', 'cui_str': 'Ethylene'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0085070', 'cui_str': 'Smear Layer'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0086881', 'cui_str': 'Root Canal'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0011429', 'cui_str': 'Dentin'}, {'cui': 'C0032200', 'cui_str': 'Platelet-Derived Growth Factor'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0007620', 'cui_str': 'Cell Viability'}]",,0.0416994,"Elevated cell viability, PDGF and VEGF expression were found in root canal treated with PDT (P<0.05).","[{'ForeName': 'Yijun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Ge', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Lixuan', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Lishan', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Yanhuang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Jiang', 'Affiliation': 'Restorative Dental Sciences, Faculty of Dentistry, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.'}, {'ForeName': 'Zhiyu', 'Initials': 'Z', 'LastName': 'Cai', 'Affiliation': 'Department of Stomatology, Fujian Medical University Union Hospital, Fuzhou, China.'}, {'ForeName': 'Xiaojing', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Fujian Key Laboratory of Oral Diseases & Fujian Provincial Engineering Research Center of Oral Biomaterial & Stomatological Key lab of Fujian College and University, School and Hospital of Stomatology, Fujian Medical University, Fuzhou, China.'}]",Photochemistry and photobiology,['10.1111/php.13240'] 274,31295358,Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.,"AIM In the EMPA-REG OUTCOME trial, empagliflozin therapy reduced cardiovascular death by 38% compared with placebo when added to standard of care. Using the trial results, we created a discrete-event simulation model to assess lifetime health economic outcomes in people with Type 2 diabetes and established cardiovascular disease. METHODS Time-dependent survival regression analysis was performed on data from EMPA-REG OUTCOME for 10 cardiovascular and renal events (e.g. stroke, heart failure hospitalization, macroalbuminuria, cardiovascular mortality) to capture event rates over time, and interaction between events. Model performance was assessed by comparing predicted and observed outcomes at 3 years. Costs in the United Kingdom (UK) and health utilities were obtained from published literature. Outcomes included cumulative event rates, life-years, costs and quality-adjusted life-years (QALYs). RESULTS The model predicted an 18% relative increase (by 2.1 life-years) in survival for empagliflozin (14.0 life-years) vs. standard of care (11.9 life-years), attributable to direct treatment effect on cardiovascular mortality, and to indirect effect via reductions in other events. Participants treated with empagliflozin may experience improved quality of life (1.0 QALY) and higher costs (£3737/participant), yielding an incremental cost-effectiveness ratio (ICER) of £4083/QALY. Sensitivity analyses confirmed the robustness of these results to changes in input parameters. CONCLUSIONS Based on extrapolation of EMPA-REG OUTCOME trial data using a participant-level simulation model, empagliflozin in addition to standard of care is projected to be highly cost-effective using UK healthcare costs. The impact in other countries will vary due to differences in drug pricing and accrual of other costs. (Clinical Trial Registry No: NCT01131676).",2019,"Participants treated with empagliflozin may experience improved quality of life (1.0 QALY) and higher costs (£3737/participant), yielding an incremental cost-effectiveness ratio (ICER) of £4083/QALY.","['people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial', 'people with Type 2 diabetes and established cardiovascular disease']","['empagliflozin', 'placebo']","['cardiovascular mortality', 'survival', 'cumulative event rates, life-years, costs and quality-adjusted life-years (QALYs', '10 cardiovascular and renal events (e.g. stroke, heart failure hospitalization, macroalbuminuria, cardiovascular mortality) to capture event rates over time, and interaction between events', 'quality of life (1.0 QALY) and higher costs (£3737/participant), yielding an incremental cost-effectiveness ratio (ICER) of £4083/QALY', 'Model performance', 'cardiovascular death']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1654921', 'cui_str': 'Macroalbuminuria'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0034380'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",,0.212958,"Participants treated with empagliflozin may experience improved quality of life (1.0 QALY) and higher costs (£3737/participant), yielding an incremental cost-effectiveness ratio (ICER) of £4083/QALY.","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Kansal', 'Affiliation': 'Evidera, Bethesda, MD, USA.'}, {'ForeName': 'O S', 'Initials': 'OS', 'LastName': 'Reifsnider', 'Affiliation': 'Evidera, Bethesda, MD, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Proskorovsky', 'Affiliation': 'Evidera, Bethesda, MD, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Evidera, Bethesda, MD, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Pfarr', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim am Rhein, Germany.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim Ltd, Bracknell, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Kandaswamy', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim am Rhein, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ruffolo', 'Affiliation': 'Boehringer Ingelheim International, Ingelheim am Rhein, Germany.'}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14076'] 275,26728940,Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia.,"BACKGROUND Usual-type vulval intraepithelial neoplasia (uVIN) is a pre-cancerous condition of the vulval skin. Also known as high-grade VIN, VIN 2/3 or high-grade vulval squamous intraepithelial lesion (HSIL), uVIN is associated with high-risk subtype human papilloma virus (HPV) infection. The condition causes distressing vulval symptoms in the majority of affected women and may progress to vulval cancer, therefore is usually actively managed. There is no consensus on the optimal management of uVIN. High morbidity and recurrence rates associated with surgical treatments make less invasive treatments highly desirable. OBJECTIVES To determine which interventions are the most effective, safe and tolerable for treating women with uVIN. SEARCH METHODS We searched the Cochrane Gynaecological Cancer Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), Issue 8 2015, MEDLINE and EMBASE (up to 1 September 2015). We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of included studies and contacted experts in the field. SELECTION CRITERIA Randomised controlled trials (RCTs) that assessed medical and surgical interventions in women with uVIN. If no RCTs were available, we included non-randomised studies (NRSs) with concurrent comparison groups that controlled for baseline case mix in multivariate analysis. DATA COLLECTION AND ANALYSIS We used Cochrane methodology with two review authors independently extracting data and assessing risk of bias. Where possible, we synthesised data in meta-analyses using random-effects methods. Network meta-analysis was not possible due to insufficient data. MAIN RESULTS We included six RCTs involving 327 women and five NRSs involving 648 women. The condition was variously named by investigators as uVIN, VIN2/3 or high-grade VIN. Five RCTs evaluated medical treatments (imiquimod, cidofovir, indole-3 carbinol), and six studies (one RCT and five NRSs) evaluated surgical treatments or photodynamic therapy. We judged two RCTs and four NRSs to be at a high or unclear risk of bias; we considered the others at relatively low risk of bias. Types of outcome measures reported in NRSs varied and we were unable to pool NRS data. Medical interventions: Topical imiquimod was more effective than placebo in achieving a response (complete or partial) to treatment at five to six months post-randomisation (three RCTs, 104 women; risk ratio (RR) 11.95, 95% confidence interval (CI) 3.21 to 44.51; high-quality evidence). At five to six months, a complete response occurred in 36/62 (58%) and 0/42 (0%) women in the imiquimod and placebo groups, respectively (RR 14.40, 95% CI 2.97 to 69.80). Moderate-quality evidence suggested that the complete response was sustained at one year (one RCT, nine complete responses out of 52 women (38%)) and beyond, particularly in women with smaller VIN lesions. Histologically confirmed complete response rates with imiquimod versus cidofovir at six months were 45% (41/91) and 46% (41/89), respectively (one RCT, 180 women; RR 1.00, 95% CI 0.73 to 1.37; moderate-quality evidence). Twelve-month data from this trial are awaited; however, interim findings suggested that complete responses were sustained at 12 months. Only one trial reported vulval cancer at one year (1/24 and 2/23 in imiquimod and placebo groups, respectively). Adverse events were more common with imiquimod than placebo and dose reductions occurred more frequently in the imiquimod group than in the placebo group (two RCTs, 83 women; RR 7.77, 95% CI 1.61 to 37.36; high-quality evidence). Headache, fatigue and discontinuation were slightly more common with imiquimod than cidofovir (moderate-quality evidence). Quality of life scores reported in one trial (52 women) were not significantly different for imiquimod and placebo. The evidence of effectiveness of topical treatments in immunosuppressed women was scant. There was insufficient evidence on other medical interventions. Surgical and other interventions: Low-quality evidence from the best included NRS indicated, when data were adjusted for confounders, that there was little difference in the risk of VIN recurrence between surgical excision and laser vaporisation. Recurrence occurred in 51% (37/70) of women overall, at a median of 14 months, and was more common in multifocal than unifocal lesions (66% versus 34%). Vulval cancer occurred in 11 women (15.1%) overall at a median of 71.5 months (9 to 259 months). The risk of vulval cancer did not differ significantly between excision and laser vaporisation in any of the NRSs; however, events were too few for robust findings. Alternative surgical procedures that might be as effective include Cavitron ultrasonic surgical aspiration (CUSA) and loop electrosurgical excision (LEEP) procedures, based on low- to very low-quality evidence, respectively. Very low-quality evidence also suggested that photodynamic therapy may be a useful treatment option.We found one ongoing RCT of medical treatment (imiquimod) compared with surgical treatment. AUTHORS' CONCLUSIONS Topical treatment (imiquimod or cidofovir) may effectively treat about half of uVIN cases after a 16-week course of treatment, but the evidence on whether this effect is sustained is limited. Factors predicting response to treatment are not clear, but small lesions may be more likely to respond. The relative risk of progression to vulval cancer is uncertain. However, imiquimod and cidofovir appear to be relatively well tolerated and may be favoured by some women over primary surgical treatment.There is currently no evidence on how medical treatment compares with surgical treatment. Women who undergo surgical treatment for uVIN have about a 50% chance of the condition recurring one year later, irrespective of whether treatment is by surgical excision or laser vaporisation. Multifocal uVIN lesions are at a higher risk of recurrence and progression, and pose greater therapeutic dilemmas than unifocal lesions. If occult cancer is suspected despite a biopsy diagnosis of uVIN, surgical excision remains the treatment of choice. If occult cancer is not a concern, treatment needs to be individualised to take into account the site and extent of disease, and a woman's preferences. Combined modalities may hold the key to optimal treatment of this complex disease.",2016,Quality of life scores reported in one trial (52 women) were not significantly different for imiquimod and placebo.,"['women with uVIN', 'usual-type vulval intraepithelial neoplasia', '327 women and five NRSs involving 648 women', 'immunosuppressed women']","['placebo', 'photodynamic therapy', 'imiquimod', 'Cavitron ultrasonic surgical aspiration (CUSA) and loop electrosurgical excision (LEEP', 'imiquimod versus cidofovir', 'imiquimod and placebo', 'medical treatment (imiquimod', 'imiquimod and cidofovir', 'Topical treatment (imiquimod or cidofovir', 'Medical and surgical interventions']","['Quality of life scores', 'High morbidity and recurrence rates', 'complete response rates', 'Adverse events', 'Headache, fatigue and discontinuation', 'vulval cancer', 'Recurrence', 'risk of vulval cancer', 'complete response', 'Vulval cancer']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0346210', 'cui_str': 'Vulval intraepithelial neoplasia (VIN)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}, {'cui': 'C0165032', 'cui_str': 'imiquimod'}, {'cui': 'C1456803', 'cui_str': 'Ultrasonics'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0445022', 'cui_str': 'Loop (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0184930', 'cui_str': 'Loop electrosurgical excision procedure (procedure)'}, {'cui': 'C0286079', 'cui_str': 'Cidofovir'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0549433', 'cui_str': 'Surgical intervention'}]","[{'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0375071', 'cui_str': 'Cancer of Vulva'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",648.0,0.334445,Quality of life scores reported in one trial (52 women) were not significantly different for imiquimod and placebo.,"[{'ForeName': 'Theresa A', 'Initials': 'TA', 'LastName': 'Lawrie', 'Affiliation': 'Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, Royal United Hospital, Education Centre, Bath, UK, BA1 3NG.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Nordin', 'Affiliation': ''}, {'ForeName': 'Manas', 'Initials': 'M', 'LastName': 'Chakrabarti', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bryant', 'Affiliation': ''}, {'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Kaushik', 'Affiliation': ''}, {'ForeName': 'Litha', 'Initials': 'L', 'LastName': 'Pepas', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011837.pub2'] 276,31358922,Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after Conbercept therapy: a post-hoc analysis.,"OBJECTIVES The objective of this study is to evaluate the progression and new onset of macular retinoschisis (MRS) in the patients treated with intravitreal Conbercept injections for myopic choroidal neovascularization (mCNV). METHODS Post-hoc analysis of 160 mCNV patients included in SHINY study was performed to evaluate the impact of Conbercept injection on MRS in patients with mCNV undergoing intravitreal Conbercept injections. The patients were 3:1 randomized to the study group (three loading dose and thereafter pro re nata [PRN]) and the control group (3 months' sham injection, then one Conbercept injection at month 4 and thereafter PRN). MRS was assessed with optical coherence tomography by masked graders. RESULTS At baseline, 28 of 122 eyes in study group and 10 of 38 eyes in control group had MRS. At month 3, two patients showed MRS progression and one patient had new onset MRS in study group. No MRS progression nor new onset MRS was found in the control group. At final visit, the cumulative incidence of MRS was 1.3% (2/160). Both Spearman's correlation and multiple logistic regression demonstrated no association between the progression and new onset of MRS and intravitreal injection frequency (correlation coefficient = 0.017, P = 0.851 and odds ratio = 0.996, P = 0.982). In addition, baseline vitreoretinal adhesion was the most likely potential risk factor resulting in MRS progression (odds ratio = 4.566, P = 0.027). Furthermore, MRS progression was more likely to take place in outer retinal layers. CONCLUSIONS The progression and new onset of MRS was not associated with the frequency of intravitreal Conbercept injections.",2020,No MRS progression nor new onset MRS was found in the control group.,"['myopic choroidal neovascularization eyes after Conbercept therapy', '160 mCNV patients included in SHINY study', 'for myopic choroidal neovascularization (mCNV', 'patients with mCNV undergoing intravitreal Conbercept injections']","['Conbercept injection on MRS', 'intravitreal Conbercept injections']","['MRS', 'cumulative incidence of MRS', 'progression and new onset of MRS and intravitreal injection frequency', 'MRS progression nor new\xa0onset MRS', 'MRS progression', 'new onset MRS']","[{'cui': 'C3665926', 'cui_str': 'Myopic choroidal neovascularization'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C2352201', 'cui_str': 'KH902 fusion protein'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}]",,0.0474506,No MRS progression nor new onset MRS was found in the control group.,"[{'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Shiqi', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Yuanzhi', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Ophthalmology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Minlu', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Fenglei', 'Initials': 'F', 'LastName': 'Kuang', 'Affiliation': 'R&D Center, Chengdu Kanghong Biotech Ltd., Sichuan, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Peking, China.'}, {'ForeName': 'Fenghua', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. shretina@sjtu.edu.cn.""}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': ""Department of Ophthalmology, Shanghai General Hospital (Shanghai First People's Hospital), Shanghai Jiao Tong University School of Medicine, Shanghai, China. xdsun@sjtu.edu.cn.""}]","Eye (London, England)",['10.1038/s41433-019-0516-x'] 277,31206358,Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome.,"OBJECTIVE A high plasma level of inflammasome mediator interleukin-18 was associated with mortality in observational acute respiratory distress syndrome cohorts. Statin exposure increases both inflammasome activation and lung injury in mouse models. We tested whether randomization to statin therapy correlated with increased interleukin-18 in the ARDS Network Statins for Acutely Injured Lungs from Sepsis trial. DESIGN Retrospective analysis of randomized controlled clinical trial. SETTING Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis. PATIENTS Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population. INTERVENTIONS Random assignment of rosuvastatin or placebo for up to 28 days or 3 days after ICU discharge. MEASUREMENTS AND MAIN RESULTS We measured plasma interleukin-18 levels in all Statins for Acutely Injured Lungs from Sepsis patients with sample available at day 0 (baseline, n = 683) and day 3 (after randomization, n = 588). We tested the association among interleukin-18 level at baseline, rising interleukin-18, and the impact of statin therapy on 60-day mortality, adjusting for severity of illness. Baseline plasma interleukin-18 level greater than or equal to 800 pg/mL was highly associated with 60-day mortality, with a hazard of death of 2.3 (95% CI, 1.7-3.1). Rising plasma interleukin-18 was also associated with increased mortality. For each unit increase in log2 (interleukin-18) at day 3 compared with baseline, the hazard of death increased by 2.3 (95% CI, 1.5-3.5). Subjects randomized to statin were significantly more likely to experience a rise in plasma interleukin-18 levels. Subjects with acute kidney injury, shock, low baseline interleukin-18, and those not receiving systemic corticosteroids were more likely to experience rising interleukin-18. Randomization to statin therapy was associated with rising in interleukin-18 in all of those subsets, however. CONCLUSIONS Elevated baseline plasma interleukin-18 was associated with higher mortality in sepsis-induced acute respiratory distress syndrome. A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.",2019,A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.,"['Acute Respiratory Distress Syndrome', 'Acutely Injured Lungs from Sepsis trial', 'Subjects with acute kidney injury', 'Multicenter North American clinical trial, the ARDS Network Statins for Acutely Injured Lungs from Sepsis', 'Six hundred eighty-three subjects with infection-related acute respiratory distress syndrome, representing 92% of the original trial population']","['rosuvastatin or placebo', 'statin therapy']","['hazard of death', '60-day mortality', 'Baseline plasma interleukin-18 level', 'plasma interleukin-18 levels', 'mortality']","[{'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0383327', 'cui_str': 'Interferon-gamma-Inducing Factor'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",683.0,0.63108,A rise in plasma interleukin-18 was also associated with increased mortality and was more common in subjects randomized to statin therapy in this clinical trial.,"[{'ForeName': 'Angela J', 'Initials': 'AJ', 'LastName': 'Rogers', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA.'}, {'ForeName': 'Jiazhen', 'Initials': 'J', 'LastName': 'Guan', 'Affiliation': ""Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Trtchounian', 'Affiliation': ""Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Gary M', 'Initials': 'GM', 'LastName': 'Hunninghake', 'Affiliation': ""Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'Rajani', 'Initials': 'R', 'LastName': 'Kaimal', 'Affiliation': 'Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA.'}, {'ForeName': 'Manisha', 'Initials': 'M', 'LastName': 'Desai', 'Affiliation': 'Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, CA.'}, {'ForeName': 'Lori-Ann', 'Initials': 'LA', 'LastName': 'Kozikowski', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'DeSouza', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Mogan', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, TN.'}, {'ForeName': 'Kathleen D', 'Initials': 'KD', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Matthay', 'Affiliation': 'Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Steingrub', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA.'}, {'ForeName': 'Art', 'Initials': 'A', 'LastName': 'Wheeler', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, TN.'}, {'ForeName': 'Joo Heon', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kiichi', 'Initials': 'K', 'LastName': 'Nakahira', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Augustine M', 'Initials': 'AM', 'LastName': 'Choi', 'Affiliation': 'Department of Medicine, Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Rebecca M', 'Initials': 'RM', 'LastName': 'Baron', 'Affiliation': ""Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA.""}]",Critical care medicine,['10.1097/CCM.0000000000003816'] 278,31320735,Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial.,"PURPOSE To determine the utility of the dexamethasone implant (IVD) as an alternative to systemic steroids as prophylaxis against cystoid macular edema (CMO) in patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery. METHODS This was a randomized, parallel design, and clinical trial. Patients with IU/PU and cataract scheduled for cataract surgery were randomly assigned to receive the IVD concurrently with cataract surgery (Group 1: 20 patients) or systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care. Patients with glaucoma/contraindications to steroids were excluded. All patients were followed up for 6 months. OUTCOME MEASURE Primary-incidence of postoperative CMO. Secondary-the change in BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications. Appropriate statistical analysis was done. RESULTS The median age was 47.3 ± 4.23 years (group 1) and 49.12 ± 5.32 years (Group 2). One patient (Group 1) and two (Group 2) developed CMO. The BCVA improved significantly in both groups (p = 0.013). The CST change was insignificant. Four patients (Group 1) required intraocular pressure (IOP) lowering medications. Three patients (Group 2) required early steroid taper. CONCLUSIONS IVD is a good alternative as prophylaxis in IU/PU and cataract in preventing postoperative CMO.",2020,The BCVA improved significantly in both groups (p = 0.013).,"['uveitic cataract surgery', 'Patients with IU/PU and cataract scheduled for cataract surgery', 'The median age was 47.3\u2009±\u20094.23 years (group 1) and 49.12\u2009±\u20095.32 years (Group 2', 'Patients with glaucoma/contraindications to steroids were excluded', 'patients with chronic, recurrent CMO associated intermediate or posterior uveitis (IU/PU), and cataract undergoing cataract surgery']","['dexamethasone implant (IVD', 'IVD concurrently with cataract surgery', 'systemic steroids (Group 2: 23 patients) tapered over 4-6 weeks along with uneventful cataract surgery and routine postoperative care', 'Intravitreal dexamethasone implant']","['CMO', 'BCVA', 'postoperative CMO', 'BCVA (corrected distance visual acuity) and Central Subfield thickness (CST) and complications', 'intraocular pressure (IOP) lowering medications']","[{'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C2242746', 'cui_str': 'Glaucoma (SMQ)'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to (contextual qualifier) (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0042167', 'cui_str': 'Uveitis, Posterior'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0032786', 'cui_str': 'Postoperative Care'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity (observable entity)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}]",,0.0567074,The BCVA improved significantly in both groups (p = 0.013).,"[{'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Sudhalkar', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India. adityasudhalkar@yahoo.com.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Bhojwani', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Viraj', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Shail', 'Initials': 'S', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Vaishali', 'Initials': 'V', 'LastName': 'Vasavada', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}, {'ForeName': 'Samaresh', 'Initials': 'S', 'LastName': 'Srivastava', 'Affiliation': 'Raghudeep Eye Hospital and Ila Devi Cataract and IOL Research Centre, Ahmedabad, India.'}]","Eye (London, England)",['10.1038/s41433-019-0534-8'] 279,31320738,Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.,"BACKGROUND/OBJECTIVES This post hoc analysis explores the relationship between residual oedema exposure after ranibizumab treatment initiation and long-term visual acuity outcome in eyes with centre-involved diabetic macular oedema (DMO). SUBJECTS/METHODS Eyes randomised to the ranibizumab + prompt or deferred laser treatment arms in the Protocol I trial and with observed central retinal thickness (CRT) readings at baseline and ≥1 follow-up visits (n = 367) were stratified by 1) oedema duration (number of study visits with CRT ≥ 250 µm during the first 52 weeks of ranibizumab treatment); and 2) oedema extent (amount of excess CRT [≥ 250 µm] at each study visit, averaged over the first 52 weeks). Associations between measures of residual oedema and best-corrected visual acuity (BCVA) were assessed in multiple regression analyses. RESULTS Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156. Eyes with the most persistent oedema gained (mean) 4.4 (95% CI 0.1─8.7) fewer Early Treatment Diabetic Retinopathy Study (ETDRS) letters at week 156 than eyes with the least persistent oedema (P = 0.044). Eyes with the greatest amount of oedema gained (mean) 9.3 (95% CI 4.0─14.5) fewer ETDRS letters at week 156 than eyes with the least amount of oedema (P < 0.001). CONCLUSIONS Macular oedema exposure over the first 52 weeks of ranibizumab treatment is a negative prognostic factor for long-term visual acuity improvement in centre-involved DMO.",2020,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","['diabetic macular oedema', 'eyes with centre-involved diabetic macular oedema (DMO']","['ranibizumab + prompt or deferred laser treatment', 'ranibizumab']","['oedema and visual acuity outcome', 'residual oedema and best-corrected visual acuity (BCVA', 'Oedema duration and oedema extent', 'ETDRS letters']","[{'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}]",367.0,0.11728,"Oedema duration and oedema extent during the first 52 weeks of ranibizumab treatment showed significant negative associations with BCVA improvement at weeks 52, 104 and 156.","[{'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Sadda', 'Affiliation': 'Doheny Eye Institute, Los Angeles, CA, USA. SSadda@doheny.org.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Campbell', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix, AZ, USA.'}, {'ForeName': 'Nancy M', 'Initials': 'NM', 'LastName': 'Holekamp', 'Affiliation': 'Pepose Vision Institute and Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Szilárd', 'Initials': 'S', 'LastName': 'Kiss', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Loewenstein', 'Affiliation': 'Department of Ophthalmology, Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Albert J', 'Initials': 'AJ', 'LastName': 'Augustin', 'Affiliation': 'Department of Ophthalmology, Staedtisches Klinikum Karlsruhe, Karlsruhe, Germany.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Shih', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Xiaoshu', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': 'Allergan plc, Irvine, CA, USA.'}, {'ForeName': 'Charles C', 'Initials': 'CC', 'LastName': 'Wykoff', 'Affiliation': 'Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USA.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Whitcup', 'Affiliation': 'Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]","Eye (London, England)",['10.1038/s41433-019-0522-z'] 280,32243609,The benefits of iron supplementation following blood donation vary with baseline iron status.,"Whole blood donation rapidly removes approximately 10% of a donor's blood volume and stimulates substantial changes in iron metabolism and erythropoiesis. We sought to identify donors who benefit from iron supplementation, describe the nature of the benefit, and define the time course for recovery from donation. Blood samples were collected over 24 weeks following whole blood donation from 193 participants, with 96 participants randomized to 37.5 mg daily oral iron. Changes in total body, red blood cell (RBC), and storage iron, hepcidin, erythropoietin, and reticulocyte count were modeled using semiparametric curves in a mixed model. and the changes were compared among six groups defined by baseline ferritin (<12; 12-50; ≥50 ng/mL) and iron supplementation. The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12 ng/mL had a ""ripple"" increase in reticulocytes ~100 days after donation indicating physiological responses occur months following donation. Thus, iron supplements markedly enhance recovery from whole blood donation in donors with ferritin <50 ng/mL. However, full recovery from donation requires over 100 days when taking iron. The findings also highlight the value of the study of blood donors for understanding human hemoglobin and iron metabolism and their usefulness for future studies as additional biomarkers are discovered.",2020,"The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12","['donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12', 'donors with ferritin <50 ng/mL']",['iron supplementation'],"['storage and RBC iron recovery', 'total body, RBC, and storage iron, hepcidin, erythropoietin, and reticulocyte count']","[{'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0337051', 'cui_str': 'Pool'}, {'cui': 'C0014792', 'cui_str': 'erythrocytes'}]","[{'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}]","[{'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0206161', 'cui_str': 'Reticulocyte count'}]",96.0,0.117661,"The effect of oral iron on storage and RBC iron recovery was minimal in donors with baseline ferritin ≥50 ng/mL, but sizeable when ferritin was <50 ng/mL. Iron initially absorbed went to RBC and storage iron pools when ferritin was <12 ng/mL but went mostly to RBCs when ferritin was ≥12 ng/mL. Donors with ferritin ≥12","[{'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Mast', 'Affiliation': 'Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Aniko', 'Initials': 'A', 'LastName': 'Szabo', 'Affiliation': 'Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Mars', 'Initials': 'M', 'LastName': 'Stone', 'Affiliation': 'Vitalant Research Institute, San Francisco, California, USA.'}, {'ForeName': 'Ritchard G', 'Initials': 'RG', 'LastName': 'Cable', 'Affiliation': 'American Red Cross Scientific Affairs, Farmington, Connecticut, USA.'}, {'ForeName': 'Bryan R', 'Initials': 'BR', 'LastName': 'Spencer', 'Affiliation': 'American Red Cross Scientific Affairs, Dedham, Massachusetts, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Kiss', 'Affiliation': 'Vitalant Northeast Division, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of hematology,['10.1002/ajh.25800'] 281,32297703,"Safety and efficacy of intrarenal arterial autologous CD34+ cell transfusion in patients with chronic kidney disease: A randomized, open-label, controlled phase II clinical trial.","BACKGROUND This was a randomized, open-label, controlled phase II clinical trial to investigate the safety, efficacy, and outcomes of intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells for patients with chronic kidney disease (CKD; ie, stage III or IV). MATERIALS AND METHODS Between October 2016 and July 2018, 52 consecutive patients with CKD at stage III or IV were randomly allocated into a treatment group (TG; 2.5 × 10 7 cells for each intrarenal artery; n = 26) and a control group (CG; standardized pharmacotherapy only; n = 26). The primary endpoints included safety and change of creatinine level/creatinine clearance. The secondary endpoints were 12-month combined unfavorable clinical outcomes (defined as dialysis or death), improvement in proteinuria, and CD34+ cell-related adverse events. RESULTS All patients were uneventfully discharged after CD34+ cell therapy. The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5). Flow cytometric analysis showed increases in circulating EPC (ie, CD34+KDR+CD45 dim / CD34+CD133+CD45 dim /CD31+CD133+CD45 dim /CD34+CD133+KDR+/CD133+) and hematopoietic stem cell (CD34+) populations after granulocyte-colony stimulating factor treatment (all P < .001). Besides, Matrigel assay of angiogenesis was also significantly enhanced (all P < .001). Renal-venous blood samplings (ie, at 0, 5, 10, and 30 minutes after CD34+ cell infusion) demonstrated significant progressive increases in EPC level (P for trend <.001) among the TG patients. One-year combined unfavorable clinical outcomes were significantly lower in TG than those in CG (0% [0] vs 13.3% [4], P = .038). By 12 months after CD34+ cell therapy, circulating creatinine level, ratio of urine protein to urine creatinine, and creatinine clearance showed no difference between TG and CG (all P > .1). CONCLUSION CD34+ cell therapy was safe and improved 1-year outcome.",2020,The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5).,"['Between October 2016 and July 2018, 52 consecutive patients with CKD at stage III or IV', 'patients with chronic kidney disease (CKD; ie, stage III or IV', 'patients with chronic kidney disease']","['CD31+CD133+CD45', 'control group (CG; standardized pharmacotherapy', 'intrarenal arterial autologous CD34+ cell transfusion', 'CD34+CD133+KDR+/CD133', 'CD34+ cell therapy', 'intrarenal artery infusion of autologous peripheral-blood-derived CD34+ cells']","['Safety and efficacy', 'safety and change of creatinine level/creatinine clearance', 'circulating EPC', 'Renal-venous blood samplings', '12-month combined unfavorable clinical outcomes (defined as dialysis or death), improvement in proteinuria, and CD34+ cell-related adverse events', 'EPC level', 'baseline endothelial progenitor cell (EPC) populations', 'Matrigel assay of angiogenesis', 'circulating creatinine level, ratio of urine protein to urine creatinine, and creatinine clearance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C3850017', 'cui_str': 'Circulating Endothelial Progenitor Cells'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0190979', 'cui_str': 'Phlebotomy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0882849', 'cui_str': 'Cell positive for CD34 antigen'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0065749', 'cui_str': 'matrigel'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0262923', 'cui_str': 'Urine protein test'}, {'cui': 'C1318439', 'cui_str': 'Creatinine measurement, urine'}]",52.0,0.0442942,The baseline endothelial progenitor cell (EPC) populations did not differ between TG and CG (P > .5).,"[{'ForeName': 'Chih-Chao', 'Initials': 'CC', 'LastName': 'Yang', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Pei-Hsun', 'Initials': 'PH', 'LastName': 'Sung', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Ben-Chung', 'Initials': 'BC', 'LastName': 'Cheng', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Yi-Chen', 'Initials': 'YC', 'LastName': 'Li', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Yi-Ling', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Mel S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopedics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}, {'ForeName': 'Hon-Kan', 'Initials': 'HK', 'LastName': 'Yip', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.'}]",Stem cells translational medicine,['10.1002/sctm.19-0409'] 282,32297782,Influence of menthol and green apple e-liquids containing different nicotine concentrations among youth e-cigarette users.,"E-cigarettes are popular among adolescents. Given that flavors enhance e-cigarette appeal, this study examined the influence of flavors on nicotine in e-cigarettes. Youth e-cigarette users (average 26.2 days [SD = 3.6] in past 28 days) were randomized to use e-cigarettes containing 6 or 12 mg/mL of freebase nicotine and completed 4 test sessions. During the first 3 test sessions, participants completed 3 fixed puffing bouts (1 puffing bout = 10 puffs, 3 s each, 30-s interval), using menthol, green-apple, and unflavored e-liquids (50 propylene glycol [PG]/50 vegetable glycerin [VG]) with their assigned nicotine concentration in a random order using a ∼5.5-W V2 e-cigarette device. After each puffing bout, participants assessed subjective effects of nicotine and flavor. In the 4th test session, participants used any of the e-liquids they had tried in the earlier sessions, ad libitum for 60 min and the amount of e-liquid used for each flavor and the number of puffs was assessed. Participants (n = 49; 6 mg/mL [n = 24]; 12 mg/mL [n = 25]) were 63.3% male, 65.3% non-Hispanic White with an average age of 18.7 (SD = 0.9). Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste. In addition, green apple produced higher ratings of fruitiness, sourness, sweetness, and menthol produced higher ratings of coolness. We did not observe any interactions between nicotine and flavor. Youth liked the taste of e-liquids containing green-apple flavor or low nicotine concentration which highlights the appeal of fruit flavors in e-cigarettes to adolescents. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste.,"['Youth e-cigarette users (average 26.2 days [SD = 3.6] in past 28 days', 'n = 25]) were 63.3% male, 65.3% non-Hispanic White with an average age of 18.7 (SD = 0.9', 'youth e-cigarette users']","['e-cigarettes containing 6 or 12 mg/mL of freebase nicotine', 'nicotine', 'menthol, green-apple, and unflavored e-liquids (50 propylene glycol [PG]/50 vegetable glycerin [VG]) with their assigned nicotine concentration', 'menthol and green apple e-liquids']",['liking of e-cigarette taste'],"[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4505216', 'cui_str': 'Electronic cigarette user'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068881', 'cui_str': '0.9'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C4543628', 'cui_str': 'Electronic cigarette liquid'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]","[{'cui': 'C3849993', 'cui_str': 'Electronic cigarette'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}]",,0.0546791,Mixed models analysis revealed that green apple and 6 mg/mL of nicotine independently increased liking of e-cigarette taste.,"[{'ForeName': 'Asti', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Green', 'Affiliation': 'Department of Surgery.'}, {'ForeName': 'Hanno C', 'Initials': 'HC', 'LastName': 'Erythropel', 'Affiliation': 'Department of Chemical and Environmental Engineering.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Dana A', 'Initials': 'DA', 'LastName': 'Cavallo', 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Tore', 'Initials': 'T', 'LastName': 'Eid', 'Affiliation': 'Department of Laboratory Medicine.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Buta', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': ""O'Malley"", 'Affiliation': 'Department of Psychiatry.'}, {'ForeName': 'Suchitra', 'Initials': 'S', 'LastName': 'Krishnan-Sarin', 'Affiliation': 'Department of Psychiatry.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000368'] 283,30951598,"Effect of Blood Flow Restriction Training on Quadriceps Muscle Strength, Morphology, Physiology, and Knee Biomechanics Before and After Anterior Cruciate Ligament Reconstruction: Protocol for a Randomized Clinical Trial.","BACKGROUND Despite best practice, quadriceps strength deficits often persist for years after anterior cruciate ligament reconstruction. Blood flow restriction training (BFRT) is a possible new intervention that applies a pressurized cuff to the proximal thigh that partially occludes blood flow as the patient exercises, which enables patients to train at reduced loads. This training is believed to result in the same benefits as if the patients were training under high loads. OBJECTIVE The objective is to evaluate the effect of BFRT on quadriceps strength and knee biomechanics and to identify the potential mechanism(s) of action of BFRT at the cellular and morphological levels of the quadriceps. DESIGN This will be a randomized, double-blind, placebo-controlled clinical trial. SETTING The study will take place at the University of Kentucky and University of Texas Medical Branch. PARTICIPANTS Sixty participants between the ages of 15 to 40 years with an ACL tear will be included. INTERVENTION Participants will be randomly assigned to (1) physical therapy plus active BFRT (BFRT group) or (2) physical therapy plus placebo BFRT (standard of care group). Presurgical BFRT will involve sessions 3 times per week for 4 weeks, and postsurgical BFRT will involve sessions 3 times per week for 4 to 5 months. MEASUREMENTS The primary outcome measure was quadriceps strength (peak quadriceps torque, rate of torque development). Secondary outcome measures included knee biomechanics (knee extensor moment, knee flexion excursion, knee flexion angle), quadriceps muscle morphology (physiological cross-sectional area, fibrosis), and quadriceps muscle physiology (muscle fiber type, muscle fiber size, muscle pennation angle, satellite cell proliferation, fibrogenic/adipogenic progenitor cells, extracellular matrix composition). LIMITATIONS Therapists will not be blinded. CONCLUSIONS The results of this study may contribute to an improved targeted treatment for the protracted quadriceps strength loss associated with anterior cruciate ligament injury and reconstruction.",2019,"Secondary outcome measures: knee biomechanics (knee extensor moment, knee flexion excursion, knee flexion angle), quadriceps muscle morphology (physiological cross-sectional area, fibrosis), and quadriceps muscle physiology (muscle fiber type, muscle fiber size, muscle pennation angle, satellite cell proliferation, fibrogenic/adipogenic progenitor cells, extracellular matrix composition). ","['Sixty participants between the ages of 15 to 40 years with an ACL tear will be included', 'The study will take place at the University of Kentucky and University of Texas Medical Branch', 'years after anterior cruciate ligament (ACL) reconstruction', 'Anterior Cruciate Ligament Reconstruction', 'patients were training under high loads']","['Blood flow restriction training (BFRT', 'Blood Flow Restriction Training', 'placebo', 'physical therapy plus active BFRT (BFRT group) or (2) physical therapy plus placebo BFRT (standard of care group', 'BFRT']","['knee biomechanics (knee extensor moment, knee flexion excursion, knee flexion angle), quadriceps muscle morphology (physiological cross-sectional area, fibrosis), and quadriceps muscle physiology (muscle fiber type, muscle fiber size, muscle pennation angle, satellite cell proliferation, fibrogenic/adipogenic progenitor cells, extracellular matrix composition', 'Quadriceps Muscle Strength, Morphology, Physiology, and Knee Biomechanics', 'quadriceps strength and knee biomechanics', 'quadriceps strength (peak quadriceps torque, rate of torque development']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0409312', 'cui_str': 'Anterior Cruciate Ligament Tear'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022557', 'cui_str': 'Kentucky'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0205384', 'cui_str': 'Branching (qualifier value)'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}]","[{'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0332221', 'cui_str': 'Satellite (qualifier value)'}, {'cui': 'C0596290', 'cui_str': 'Cell Proliferation'}, {'cui': 'C0038250', 'cui_str': 'Mother Cells'}, {'cui': 'C0015350', 'cui_str': 'Extracellular Matrix'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0243107', 'cui_str': 'development'}]",60.0,0.0694303,"Secondary outcome measures: knee biomechanics (knee extensor moment, knee flexion excursion, knee flexion angle), quadriceps muscle morphology (physiological cross-sectional area, fibrosis), and quadriceps muscle physiology (muscle fiber type, muscle fiber size, muscle pennation angle, satellite cell proliferation, fibrogenic/adipogenic progenitor cells, extracellular matrix composition). ","[{'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Erickson', 'Affiliation': 'Department of Rehabilitation Sciences, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Kathryn C Hickey', 'Initials': 'KCH', 'LastName': 'Lucas', 'Affiliation': 'Department of Rehabilitation Sciences, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Kylie A', 'Initials': 'KA', 'LastName': 'Davis', 'Affiliation': 'Department of Rehabilitation Sciences, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Cale A', 'Initials': 'CA', 'LastName': 'Jacobs', 'Affiliation': 'Department of Rehabilitation Sciences and Department of Orthopaedic Surgery & Sports Medicine, University of Kentucky.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Thompson', 'Affiliation': 'Department of Statistics, University of Kentucky.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Hardy', 'Affiliation': 'Department of Radiology and Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky.'}, {'ForeName': 'Anders H', 'Initials': 'AH', 'LastName': 'Andersen', 'Affiliation': 'Department of Neuroscience and Magnetic Resonance Imaging and Spectroscopy Center, University of Kentucky.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Fry', 'Affiliation': 'Department of Nutrition & Metabolism, University of Texas Medical Branch, Galveston, Texas.'}, {'ForeName': 'Brian W', 'Initials': 'BW', 'LastName': 'Noehren', 'Affiliation': 'Department of Rehabilitation Sciences, University of Kentucky, 900 S. Limestone, Room 204D, Lexington, KY 40536-0200 (USA); and Department of Orthopaedic Surgery & Sports Medicine, University of Kentucky.'}]",Physical therapy,['10.1093/ptj/pzz062'] 284,31253849,Effects of a coping-oriented supportive programme for people with spinal cord injury during inpatient rehabilitation: a quasi-experimental study.,"STUDY DESIGN Parallel-group, quasi-experimental study. OBJECTIVES To evaluate the effectiveness of a coping-oriented supportive programme (COSP) for people with spinal cord injury (SCI) over a 12-week follow-up. SETTING SCI wards in two rehabilitation hospitals of Shaanxi, China. METHODS Ninety-nine participants (mean age = 41, 88% males and 74% paraplegia) joined the COSP intervention (n = 50) or attention control (n = 49) group. The COSP intervention was focussed on the facilitation of coping skills and consisted of 8 weekly sessions, whereas the attentional control group was provided with 8 weekly didactic education sessions. Effects of the COSP intervention were determined by primary outcomes (coping and self-efficacy) and secondary outcomes (depression, anxiety, social support, life satisfaction and pain). Data were collected at pre- and post-intervention, as well as 4- and 12-week follow-up. RESULTS Intention to treat analysis indicated statistically significant effects (with moderate to large effect sizes, all P-values < 0.01) on participants' maladaptive coping, adaptive coping, self-efficacy, depression, anxiety, satisfaction of social support and life satisfaction immediately post-COSP. Statistically significant effects were found for maladaptive coping, self-efficacy, anxiety, depression, satisfaction of social support and life satisfaction at 4-week follow-up. Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. CONCLUSION The COSP intervention resulted in medium-term psychosocial benefits for people with SCI and has potential for integration into routine inpatient rehabilitation practice.",2020,"Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. ","['people with spinal cord injury during inpatient rehabilitation', 'SCI wards in two rehabilitation hospitals of Shaanxi, China', 'people with spinal cord injury (SCI', 'Ninety-nine participants (mean age\u2009=\u200941, 88% males and 74% paraplegia) joined the', 'n\u2009=\u200950) or attention control (n\u2009=\u200949) group']","['coping-oriented supportive programme', 'coping-oriented supportive programme (COSP', 'COSP intervention']","['Maladaptive coping, anxiety, satisfaction of social support and life satisfaction', ""participants' maladaptive coping, adaptive coping, self-efficacy, depression, anxiety, satisfaction of social support and life satisfaction"", 'maladaptive coping, self-efficacy, anxiety, depression, satisfaction of social support and life satisfaction', 'primary outcomes (coping and self-efficacy) and secondary outcomes (depression, anxiety, social support, life satisfaction and pain']","[{'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0337962', 'cui_str': 'Rehabilitation hospital (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C3828813', 'cui_str': 'Ninety-nine'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037438'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",99.0,0.0323196,"Maladaptive coping, anxiety, satisfaction of social support and life satisfaction were also significantly improved at 12-week follow-up. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""The Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK. yan.li@kcl.ac.uk.""}, {'ForeName': 'Wai Tong', 'Initials': 'WT', 'LastName': 'Chien', 'Affiliation': 'The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bressington', 'Affiliation': 'The School of Nursing, Faculty of Health and Social Science, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.'}]",Spinal cord,['10.1038/s41393-019-0320-2'] 285,31612956,Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults.,"INTRODUCTION The co-use of cannabis and alcohol among tobacco-using youth is common. Alcohol co-use is associated with worse tobacco cessation outcomes, but results are mixed regarding the impact of cannabis on tobacco outcomes and if co-use leads to increased use of non-treated substances. This secondary analysis from a youth smoking cessation trial aimed to (1) evaluate the impact of cannabis or alcohol co-use on smoking cessation, (2) examine changes in co-use during the trial, and (3) explore secondary effects of varenicline on co-use. METHODS The parent study was a 12-week, randomized clinical trial of varenicline for smoking cessation among youth (ages 14-21, N = 157; Mage = 19, 40% female; 76% White). Daily cigarette, cannabis, and alcohol use data were collected via daily diaries during treatment and Timeline Follow-back for 14 weeks post-treatment. RESULTS Baseline cannabis co-users (68%) had double the odds of continued cigarette smoking throughout the trial compared with noncannabis users, which was pronounced in males and frequent cannabis users. Continued smoking during treatment was associated with higher probability of concurrent cannabis use. Baseline alcohol co-users (80%) did not have worse smoking outcomes compared with nonalcohol users, but continued smoking was associated with higher probability of concurrent drinking. Varenicline did not affect co-use. CONCLUSIONS Inconsistent with prior literature, results showed that alcohol co-users did not differ in smoking cessation, whereas cannabis co-users had poorer cessation outcomes. Youth tobacco treatment would benefit from added focus on substance co-use, particularly cannabis, but may need to be tailored appropriately to promote cessation. IMPLICATIONS Among youth cigarette smokers enrolled in a pharmacotherapy evaluation clinical trial, alcohol and/or cannabis co-use was prevalent. The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation. Reductions in smoking were accompanied by concurrent reductions in alcohol or cannabis use. Substance co-use does not appear to affect all youth smokers in the same manner and treatment strategies may need to be tailored appropriately for those with lower odds of smoking cessation.",2020,"The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation.","['youth cigarette smokers', 'Adolescents and Emerging Adults', 'smoking cessation among youth (ages 14-21, N = 157; Mage = 19, 40% female; 76% White']","['varenicline', 'cannabis or alcohol co-use', 'Varenicline']",['cigarette smoking'],"[{'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C1569608', 'cui_str': 'varenicline'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0700219', 'cui_str': 'Cigarette Smoking'}]",,0.0318818,"The co-use of cannabis affected smoking cessation outcomes, but more so for males and frequent cannabis users, whereas alcohol co-use did not affect smoking cessation.","[{'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, University of Kentucky, Lexington, KY.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Lindsay M', 'Initials': 'LM', 'LastName': 'Squeglia', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz170'] 286,31462757,Sprint interval training versus moderate-intensity continuous training during inpatient rehabilitation after spinal cord injury: a randomized trial.,"STUDY DESIGN Randomized trial. OBJECTIVES To evaluate the effectiveness of a 5-week sprint interval training (SIT) protocol on an arm-crank ergometer in individuals with sub-acute spinal cord injury (SCI). SETTING Inpatient rehabilitation. METHODS Individuals with SCI (N = 20; 9 tetraplegia/11 paraplegia; time since injury, 14-182 days; age, 46 ± 16 years; 15 M/5 F) were randomized to SIT or moderate-intensity continuous training (MICT). SIT consisted of 3 × 20 s. 'all-out' cycle sprints (≥100% peak power output) interspersed with 2 min of active recovery (10% peak power output; total time commitment, 10 mins). MICT involved 20 min of cycling (45% peak power output; total time commitment, 25 mins). Both training interventions were delivered 3 times/week for 5 weeks. Heart rate and Borg's Rating of Perceived Exertion (RPE; 6-20) were monitored throughout training sessions. Maximal and sub-maximal power outputs were assessed on an arm-crank ergometer. Exercise enjoyment, exercise self-efficacy, and pain were assessed at the end of the intervention. RESULTS During training sessions, heart rate (135 bpm vs. 119 bpm; p = 0.05), peripheral RPE (16 vs. 12; p = 0.000), and central RPE (15 vs. 11; p = 0.004) responses were higher in the SIT group, yet total work performed was greater in MICT. Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524). Similarly, improvements in sub-maximal power output were not different across groups. There were no between-group differences in exercise enjoyment (p = 0.385), exercise self-efficacy (p = 0.930), or pain (p = 0780). CONCLUSIONS Five weeks of SIT improved physical capacity to the same extent as MICT in individuals with sub-acute SCI, despite a significantly lower time commitment with SIT.",2020,"Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524).","['inpatient rehabilitation after spinal cord injury', 'Individuals with SCI (N\u2009', 'Inpatient rehabilitation', '20; 9 tetraplegia/11 paraplegia; time since injury, 14-182 days; age, 46\u2009±\u200916 years; 15\u2009M/5\u2009F', 'individuals with sub-acute spinal cord injury (SCI']","['MICT', 'SIT or moderate-intensity continuous training (MICT', 'Sprint interval training versus moderate-intensity continuous training', '5-week sprint interval training (SIT) protocol']","['sub-maximal power output', 'Exercise enjoyment, exercise self-efficacy, and pain', ""Heart rate and Borg's Rating of Perceived Exertion"", 'Peak power output', 'heart rate', 'physical capacity', 'exercise enjoyment', 'peripheral RPE', 'exercise self-efficacy', 'central RPE']","[{'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030486', 'cui_str': 'Paralysis, Legs'}, {'cui': 'C0449246', 'cui_str': 'Time since injury (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0445194', 'cui_str': 'Power output (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",780.0,0.0764155,"Peak power output increased significantly with training (36%), with no difference between groups (39% vs. 33%; p = 0.524).","[{'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Mcleod', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Herrington', 'Initials': 'H', 'LastName': 'Diana', 'Affiliation': 'Regional Rehabilitation Centre, Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Audrey L', 'Initials': 'AL', 'LastName': 'Hicks', 'Affiliation': 'Department of Kinesiology, McMaster University, Hamilton, ON, Canada. hicksal@mcmaster.ca.'}]",Spinal cord,['10.1038/s41393-019-0345-6'] 287,31025363,"Randomized immunotherapy trial in dual-allergic patients using ""active allergen placebo"" as control.","BACKGROUND Placebo control in allergen immunotherapy (AIT) trials presents ethical and blinding concerns. We tested a trial design with an ""active allergen placebo,"" as proposed by ARIA-GA 2 LEN, to investigate in a double-blind trial the efficacy and safety of AIT in dual-allergic patients (grass and birch pollen) using active untargeted treatments as controls. METHODS We randomized 95 patients to receive either grass (N = 47) or birch AIT (N = 48). Patients were exposed to both allergens in an allergen challenge chamber (ACC) before and after 9 months of AIT. Targeted (ACC-allergen = AIT-allergen) and untargeted (ACC-allergen ≠ AIT-allergen) treatment effects were assessed. RESULTS Immunotherapy reduced significantly the mean (95% confidence interval) area under the curve of total nasal symptom score (targeted effects) by -13.55 (-17.56, -9.54; P < 0.001) after grass and -9.81 (-14.13, -5.50; P < 0.001) after birch AIT. Differences in targeted vs untargeted effects between AIT groups (utility of control group) were statistically significant for both grass (P = 0.02) and birch (P = 0.02) allergens. Targeted vs untargeted differences within-treatment groups (specificity of ACC measurement) were significant for grass AIT (P < 0.001) but not significant for birch AIT group (P = 0.24). Specific immunoglobulin G 4 to both allergens increased significantly (P < 0.001) after targeted treatment, while remained unchanged for untargeted treatments. Both treatments were well tolerated. CONCLUSIONS Immunotherapies for both grass and birch allergens were efficacious and safe. The study confirms the specificity of AIT. Untargeted treatment groups could serve as controls in future AIT trials.",2019,"Specific immunoglobulin G 4 to both allergens increased significantly (P < 0.001) after targeted treatment, while remained unchanged for untargeted treatments.","['dual-allergic patients using ""active allergen', '95 patients to receive either grass (N\xa0=\xa047) or birch AIT (N\xa0=\xa048', 'dual-allergic patients (grass and birch pollen']","['Immunotherapy', 'active allergen placebo', 'Targeted (ACC-allergen\xa0', 'placebo']","['total nasal symptom score', 'tolerated']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0002092', 'cui_str': 'Allergens'}, {'cui': 'C0018210', 'cui_str': 'Grasses'}, {'cui': 'C0330312', 'cui_str': 'Birch'}, {'cui': 'C4047367', 'cui_str': 'Birch pollen'}]","[{'cui': 'C0021083', 'cui_str': 'Immunotherapy'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0002092', 'cui_str': 'Allergens'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0231918', 'cui_str': 'Nasal symptom'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",95.0,0.334757,"Specific immunoglobulin G 4 to both allergens increased significantly (P < 0.001) after targeted treatment, while remained unchanged for untargeted treatments.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wagenmann', 'Affiliation': 'Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany.'}, {'ForeName': 'Margitta', 'Initials': 'M', 'LastName': 'Worm', 'Affiliation': 'Division of Allergy and Immunology, Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Akboga', 'Affiliation': 'Department of Research and Clinical Development, Allergopharma GmbH & Co. KG, A Business of Merck, Reinbek, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Karjalainen', 'Affiliation': 'Department of Research and Clinical Development, Allergopharma GmbH & Co. KG, A Business of Merck, Reinbek, Germany.'}, {'ForeName': 'Jens M', 'Initials': 'JM', 'LastName': 'Hohlfeld', 'Affiliation': 'Fraunhofer Institute for Toxicology and Experimental Medicine, Department of Respiratory Medicine, Hannover Medical School, German Center for Lung Research, Hannover, Germany.'}]",Allergy,['10.1111/all.13842'] 288,31026086,"Analgesic efficacy and pharmacokinetics of epidural oxycodone in pain management after gynaecological laparoscopy-A randomised, double blind, active control, double-dummy clinical comparison with intravenous administration.","AIMS Early pain after laparoscopy is often severe. Oxycodone is a feasible analgesic option after laparoscopy, but there are sparse data on epidural administration. The aim was to evaluate the analgesic efficacy and pharmacokinetics of a single dose of epidural oxycodone as a part of multimodal analgesia after gynaecological laparoscopy. METHODS Women (n = 60), aged 23-71 years, undergoing elective gynaecological laparoscopy, were administrated either epidural oxycodone 0.1 mg kg -1 and intravenous (i.v.) saline (EPI-group n = 31), or epidural saline and i.v. oxycodone 0.1 mg kg -1 (IV-group = 29) in a randomised, double blind, active control, double dummy clinical trial. A pharmacokinetic model was developed using population modelling of plasma and cerebrospinal fluid (CSF) concentrations obtained in these patients and data of 2 published studies. The primary outcome was the amount of i.v. fentanyl for rescue analgesia during the first 4 hours. RESULTS Twenty of the 31 patients in the EPI-group and 26 of the 29 patients in the IV-group needed i.v. fentanyl for rescue analgesia, P = .021. The median (interquartile range) number of fentanyl doses were 1.0 (1.0-3.0) in the EPI-group and 2.5 (1.0-4.0) doses in the IV-group, P = .008. Plasma concentrations were similar, but CSF concentrations were 100-fold higher in the EPI-group. The population model indicated that 60% of oxycodone injected into the epidural space enters into CSF and 40% is absorbed into the systemic circulation. CONCLUSIONS The data support superiority of epidural administration of oxycodone compared to i.v. administration during the first hours after laparoscopic surgery. This is likely to be based on enhanced permeation into the central nervous system after epidural administration.",2019,"Plasma concentrations were similar, but CSF concentrations were 100-fold higher in the EPI-group.","['Twenty of the 31 patients in the EPI-group and 26 of the 29 patients in the IV-group needed i.v', 'pain management after gynaecological laparoscopy', 'Women (n\xa0=\xa060), aged 23-71\xa0years, undergoing']","['oxycodone', 'epidural saline', 'fentanyl', 'elective gynaecological laparoscopy', 'Oxycodone', 'saline', 'epidural oxycodone']","['median (interquartile range) number of fentanyl doses', 'Analgesic efficacy and pharmacokinetics', 'CSF concentrations', 'amount of i.v', 'Plasma concentrations', 'analgesic efficacy and pharmacokinetics']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0267963', 'cui_str': 'Pancreatic Insufficiency'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0031150', 'cui_str': 'Celioscopy'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0031150', 'cui_str': 'Celioscopy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",,0.551475,"Plasma concentrations were similar, but CSF concentrations were 100-fold higher in the EPI-group.","[{'ForeName': 'Panu', 'Initials': 'P', 'LastName': 'Piirainen', 'Affiliation': 'School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Kokki', 'Affiliation': 'School of Medicine, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Anderson', 'Affiliation': 'Departments of Anaesthesiology, and Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Hannam', 'Affiliation': 'Departments of Anaesthesiology, and Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Hautajärvi', 'Affiliation': 'Admescope Ltd, Oulu, Finland.'}, {'ForeName': 'Veli-Pekka', 'Initials': 'VP', 'LastName': 'Ranta', 'Affiliation': 'School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland.'}, {'ForeName': 'Merja', 'Initials': 'M', 'LastName': 'Kokki', 'Affiliation': 'Department of Anaesthesia and Operative Services, Kuopio University Hospital, Kuopio, Finland.'}]",British journal of clinical pharmacology,['10.1111/bcp.13971'] 289,31312016,Advanced weight-bearing mat exercises combined with functional electrical stimulation to improve the ability of wheelchair-dependent people with spinal cord injury to transfer and attain independence in activities of daily living: a randomized controlled trial.,"STUDY DESIGN Randomized controlled trial. OBJECTIVE To determine the effects of advanced weight-bearing mat exercises (AWMEs) with/without functional electrical stimulation (FES) of the quadriceps and gastrocnemius muscles on the ability of wheelchair-dependent people with spinal cord injury (SCI) to transfer and attain independence in activities of daily living (ADLs). SETTING An outpatient clinic, Iran. METHODS People with traumatic chronic paraplegia (N = 16) were randomly allocated to three groups. The exercise group (EX; N = 5) performed AWMEs of quadruped unilateral reaching and tall-kneeling for 24 weeks (3 days/week). Sessions were increased from 10 min to 54 min over the 24-week period. The exercise-FES group (EX + FES; N = 5) performed AWMEs simultaneously with FES of the quadriceps and gastrocnemius muscles. The control group performed no exercise and no FES (N = 6). The primary outcomes were the total Spinal Cord Independence Measure-III (SCIM-III) to reflect independence with ADL, and the sum of the four SCIM-III transfer items to reflect ability to transfer. There were six other outcomes. RESULTS The mean (95% CI) between-group differences of the four transfer items of the SCIM-III for the EX vs. control group was 1.8 points (0.2-3.4), and for the EX + FES vs. control group was 2 points (0.4-3.6). The equivalent differences for the total SCIM-III scores were 2.7 points (-0.6-6.0) and 4.1 points (0.8-7.4), respectively. There were no significant between-group differences for any other outcomes. CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.",2020,"CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.","['People with traumatic chronic paraplegia (N\u2009=\u200916', 'wheelchair-dependent people with spinal cord injury (SCI', 'An outpatient clinic, Iran']","['no exercise and no FES', 'advanced weight-bearing mat exercises (AWMEs) with/without functional electrical stimulation (FES', 'Advanced weight-bearing mat exercises combined with functional electrical stimulation', 'exercise group (EX; N\u2009=\u20095) performed AWMEs of quadruped unilateral reaching and tall-kneeling']","['total SCIM-III scores', 'total Spinal Cord Independence Measure-III (SCIM-III) to reflect independence with ADL, and the sum of the four SCIM-III transfer items to reflect ability to transfer']","[{'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C3698571', 'cui_str': 'Chronic paraplegia'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0674267', 'cui_str': 'greigite'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}, {'cui': 'C0066317', 'cui_str': 'trisulfide methyl 2-propenyl'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456677', 'cui_str': 'Total spinal blockade (finding)'}, {'cui': 'C3698497', 'cui_str': 'Axillary web syndrome'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0665244,"CONCLUSIONS Advanced weight-bearing mat exercises improve the ability of wheelchair-dependent people with SCI to transfer and attain independence in ADL.","[{'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Rahimi', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Giti', 'Initials': 'G', 'LastName': 'Torkaman', 'Affiliation': 'Department of Physiotherapy, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. torkamg@modares.ac.ir.'}, {'ForeName': 'Mojdeh', 'Initials': 'M', 'LastName': 'Ghabaee', 'Affiliation': 'Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ghasem-Zadeh', 'Affiliation': 'Departments of Medicine and Endocrinology, Austin Health, The University of Melbourne, Melbourne, VIC, Australia.'}]",Spinal cord,['10.1038/s41393-019-0328-7'] 290,31712614,Study protocol of a double-blind randomised placebo-controlled trial on the effect of a multispecies probiotic on the incidence of antibiotic-associated diarrhoea in persons with spinal cord injury.,"STUDY DESIGN Multi-centre, double-blind randomised placebo-controlled study. OBJECTIVE To investigate whether the use of a multispecies probiotic can prevent antibiotic-associated diarrhoea in people with spinal cord injury (SCI). SETTING Three Dutch SCI rehabilitation centres. METHODS Fifty-six people aged 18-75 years with SCI during inpatient rehabilitation, who require antibiotics, will be given probiotics or placebo randomly assigned (T0). After cessation of the antibiotics (T1), the participants will use probiotics/placebo for 3 more weeks (T2). Defaecation, assessed by the Bristol Stool Scale, and bowel management will be monitored daily until 2 weeks after cessation of probiotics/placebo intake (T3). Also, the degree of nausea and information on quality of life will be collected at T0, T1, T2 and T3. MAIN OUTCOME MEASURES The difference between the incidence of antibiotic-associated diarrhoea between people with SCI using probiotics compared to those using a placebo at the moment the antibiotics stops, the probiotics stops and two weeks thereafter. SECONDARY OUTCOME MEASURES The time to reach effective bowel management, degree of nausea and quality of life. REGISTRATION The Dutch Trial Register- NTR 5831.",2020,"The difference between the incidence of antibiotic-associated diarrhoea between people with SCI using probiotics compared to those using a placebo at the moment the antibiotics stops, the probiotics stops and two weeks thereafter. ","['persons with spinal cord injury', 'Fifty-six people aged 18-75 years with SCI during inpatient rehabilitation, who require antibiotics, will be given probiotics or placebo randomly assigned (T0', 'Three Dutch SCI rehabilitation centres', 'people with\xa0spinal cord injury (SCI']","['placebo', 'multispecies probiotic', 'probiotics/placebo']","['degree of nausea and information on quality of life', 'incidence of antibiotic-associated diarrhoea', 'Bristol Stool Scale, and bowel management', 'time to reach effective bowel management, degree of nausea and quality of life']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}]","[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0034380'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0578159', 'cui_str': 'Antibiotic-associated diarrhea (disorder)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0222045'}, {'cui': 'C0150155', 'cui_str': 'Bowel management'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",56.0,0.712196,"The difference between the incidence of antibiotic-associated diarrhoea between people with SCI using probiotics compared to those using a placebo at the moment the antibiotics stops, the probiotics stops and two weeks thereafter. ","[{'ForeName': 'W X M', 'Initials': 'WXM', 'LastName': 'Faber', 'Affiliation': 'Heliomare Rehabilitation Center, Wijk aan Zee, The Netherlands. w.faber@heliomare.nl.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Nachtegaal', 'Affiliation': 'Department of Research & Development, Heliomare Rehabilitation Center, Wijk aan Zee, The Netherlands.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Stolwijk-Swuste', 'Affiliation': 'Center of Excellence for Rehabilitation Medicine, Brain Center Rudolf Magnus, University Medical Center Utrecht and De Hoogstraat Rehabilitation, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'W J', 'Initials': 'WJ', 'LastName': 'Achterberg-Warmer', 'Affiliation': 'Amsterdam Rehabilitation Research Center, Reade, the Netherlands.'}, {'ForeName': 'C J M', 'Initials': 'CJM', 'LastName': 'Koning', 'Affiliation': 'Winclove Probiotics B.V, Amsterdam, The Netherlands.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Besseling-van der Vaart', 'Affiliation': 'Winclove Probiotics B.V, Amsterdam, The Netherlands.'}, {'ForeName': 'C A M', 'Initials': 'CAM', 'LastName': 'van Bennekom', 'Affiliation': 'Heliomare Rehabilitation Center, Wijk aan Zee, The Netherlands.'}]",Spinal cord,['10.1038/s41393-019-0369-y'] 291,30814669,Influence of training protocols on text input speed on a computer in individuals with cervical spinal cord injury: a randomised controlled trial.,"STUDY DESIGN Randomised controlled trial. OBJECTIVES To evaluate the impact of two different word prediction software (WPS) training protocols on text input speed (TIS) in people with tetraplegia and to determine which was the most effective. SETTING Rehabilitation department, Garches, France. METHODS Participants with neurological levels between C6 and C8 were allocated to one of three different groups. The REHAB group underwent training with an occupational therapist. The SELF group carried out a standardised home self-training with a written training guide. The CONTROL group had no training. Participants were assessed at day 15 (D15) and day 30 (D30). The primary outcome was a copying task with and without WPS (WITH and WITHOUT). RESULTS Forty-two participants (mean age ± SD of 39.8 ± 12) were included and 38 completed the study. At D30, the mean (95% confidence interval) difference in TIS between the CONTROL and SELF groups was 3.8 [-1.7 to 9.4] characters per minute (cpm) (p = 0.23), between the REHAB and SELF groups was 12.9 [7.4 to 18.4] cpm (p < 0.001), and between the REHAB and CONTROL groups was 9.1 [3.5 to 14.6] cpm (p < 0.001). CONCLUSIONS The results of this study showed that occupational therapist-supervised training improved TIS but word prediction software did not increase TIS. These results suggest that supervised training should be provided to all individuals who are prescribed with devices and systems to facilitate computer access in order to increase their TIS.",2019,"To evaluate the impact of two different word prediction software (WPS) training protocols on text input speed (TIS) in people with tetraplegia and to determine which was the most effective. ","['Participants with neurological levels between C6 and C8', 'individuals with cervical spinal cord injury', 'people with tetraplegia', 'Forty-two participants (mean age\u2009±\u2009SD of 39.8\u2009±\u200912) were included and 38 completed the study', 'Rehabilitation department, Garches, France']","['training protocols', 'word prediction software (WPS) training protocols', 'standardised home self-training with a written training guide', 'training with an occupational therapist']","['TIS', 'text input speed (TIS', 'copying task with and without WPS (WITH and WITHOUT']","[{'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0840414', 'cui_str': 'Cervical spinal cord injury'}, {'cui': 'C0034372', 'cui_str': 'Tetraplegia'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0587478', 'cui_str': 'Rehabilitation department (environment)'}, {'cui': 'C0016674', 'cui_str': 'France'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist (occupation)'}]","[{'cui': 'C3541382', 'cui_str': 'Text'}]",,0.0702357,"To evaluate the impact of two different word prediction software (WPS) training protocols on text input speed (TIS) in people with tetraplegia and to determine which was the most effective. ","[{'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Pouplin', 'Affiliation': 'New Technologies Plate-Form, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France. samuel.pouplin@aphp.fr.'}, {'ForeName': 'Djamel', 'Initials': 'D', 'LastName': 'Bensmail', 'Affiliation': 'New Technologies Plate-Form, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Vaugier', 'Affiliation': 'Clinical Innovations Centre 1429, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France.'}, {'ForeName': 'Axelle', 'Initials': 'A', 'LastName': 'Gelineau', 'Affiliation': 'New Technologies Plate-Form, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Pottier', 'Affiliation': 'Clinical Innovations Centre 1429, AP-HP, Raymond Poincaré Teaching Hospital, Garches, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Roche', 'Affiliation': 'Inserm Unit 1179, Team 3: Technologies and Innovative Therapies Applied to Neuromuscular Diseases, University of Versailles, St-Quentin-en-Yvelines, France.'}]",Spinal cord,['10.1038/s41393-019-0265-5'] 292,31425620,Advanced sperm selection techniques for assisted reproduction.,"BACKGROUND Assisted reproductive technologies (ART) including in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), combine gametes to enhance the probability of fertilisation and pregnancy. Advanced sperm selection techniques are increasingly employed in ART, most commonly in cycles utilising ICSI. Advanced sperm selection techniques are proposed to improve the chance that structurally intact and mature sperm with high DNA integrity are selected for fertilisation. Strategies include selection according to surface charge; sperm apoptosis; sperm birefringence; ability to bind to hyaluronic acid; and sperm morphology under ultra-high magnification. These techniques are intended to improve ART outcomes. OBJECTIVES To evaluate the effectiveness and safety of advanced sperm selection techniques on ART outcomes. SEARCH METHODS We conducted a systematic search of electronic databases (Cochrane Gynaecology and Fertility Group Specialised Register, CENTRAL via the Cochrane Register of Studies Online, MEDLINE, Embase, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL); trials registers (ClinicalTrials.gov, Current Controlled Trials, and the World Health Organization International Clinical Trials Registry Platform); conference abstracts (Web of Knowledge); and grey literature (OpenGrey) for relevant randomised controlled trials (RCTs). We handsearched the reference lists of included studies and similar reviews. The search was conducted in June 2018. SELECTION CRITERIA We included RCTs comparing advanced sperm selection techniques versus standard IVF, ICSI, or another technique. We excluded studies of intracytoplasmic morphologically selected sperm injection (IMSI), as they are subject to a separate Cochrane Review. Primary outcomes measured were live birth and miscarriage per woman randomly assigned. Secondary outcome measures included clinical pregnancy per woman randomly assigned. Secondary adverse events measured included miscarriage per clinical pregnancy and foetal abnormality. DATA COLLECTION AND ANALYSIS Two review authors independently assessed study eligibility and risk of bias and extracted data. Any disagreements were resolved by consultation with a third review author. We consulted study investigators to resolve queries. Risk ratios (RRs) were calculated with 95% confidence intervals (CIs). We combined studies using a fixed-effect model. We evaluated the quality of the evidence using GRADE methods. MAIN RESULTS We included eight RCTs (4147 women). The quality of evidence ranged from very low to low. The main limitations were imprecision, performance bias, and attrition bias.Hyaluronic acid selected sperm-intracytoplasmic sperm injection (HA-ICSI) compared to ICSITwo RCTs compared the effects of HA-ICSI versus ICSI on live birth. The quality of the evidence was low. There may be little or no difference between groups: 25% chance of live birth with ICSI versus 24.5% to 31% with HA-ICSI (RR 1.09, 95% CI 0.97 to 1.23, 2903 women, I 2 = 0%, low-quality evidence). Three RCTs reported on miscarriage. HA-ICSI may decrease miscarriage per woman randomly assigned: 7% chance of miscarriage with ICSI versus 3% to 6% chance with HA-ICSI (RR 0.61, 95% CI 0.45 to 0.83, 3005 women, I 2 = 0%, low-quality evidence) and per clinical pregnancy: 20% chance of miscarriage with ICSI compared to 9% to 16% chance with HA-ICSI (RR 0.62, 95% CI 0.46 to 0.82, 1065 women, I 2 = 0%, low-quality evidence). Four RCTs reported on clinical pregnancy. There may be little or no difference between groups: 37% chance of pregnancy with ICSI versus 34% to 40% chance with HA-ICSI (RR 1.00, 95% CI 0.92 to 1.09, 3492 women, I 2 = 0%, low-quality evidence).HA-ICSI compared to SpermSlowOne RCT compared HA-ICSI to SpermSlow. The quality of the evidence was very low. We are uncertain whether HA-ICSI improves live birth compared to SpermSlow (RR 1.13, 95% CI 0.64 to 2.01, 100 women) or clinical pregnancy (RR 1.05, 95% CI 0.66 to 1.68, 100 women). We are uncertain whether HA-ICSI reduces miscarriage per woman (RR 0.80, 95% CI 0.23 to 2.81, 100 women) or per clinical pregnancy (RR 0.76, 95% CI 0.24 to 2.44, 41 women).Magnetic-activated cell sorting (MACS) compared to ICSIOne RCT compared MACS to ICSI for live birth; three reported clinical pregnancy; and two reported miscarriage. The quality of the evidence was very low. We are uncertain whether MACS improves live birth (RR 1.95, 95% CI 0.89 to 4.29, 62 women) or clinical pregnancy (RR 1.05, 95% CI 0.84 to 1.31, 413 women, I 2 = 81%). We are also uncertain if MACS reduces miscarriage per woman (RR 0.95, 95% CI 0.16 to 5.63, 150 women, I 2 = 0%) or per clinical pregnancy (RR 0.51, 95%CI 0.09 to 2.82, 53 women, I 2 =0)Zeta sperm selection compared to ICSIOne RCT evaluated Zeta sperm selection. The quality of the evidence was very low. We are uncertain of the effect of Zeta sperm selection on live birth (RR 2.48, 95% CI 1.34 to 4.56, 203 women) or clinical pregnancy (RR 1.82, 95% CI 1.20 to 2.75, 203 women). We are also uncertain if Zeta sperm selection reduces miscarriage per woman (RR 0.73, 95% CI 0.16 to 3.37, 203 women) or per clinical pregnancy (RR 0.41, 95% CI 0.10 to 1.68, 1 RCT, 62 women).MACS compared to HA-ICSIOne RCT compared MACS to HA-ICSI. This study did not report on live birth. The quality of the evidence was very low. We are uncertain of the effect on miscarriage per woman (RR 1.52, 95% CI 0.10 to 23.35, 78 women) or per clinical pregnancy (RR 1.06, 95% CI 0.07 to 15.64, 37 women). We are also uncertain of the effect on clinical pregnancy (RR 1.44, 95% CI 0.91 to 2.27, 78 women). AUTHORS' CONCLUSIONS The evidence suggests that sperm selected by hyaluronic acid binding may have little or no effect on live birth or clinical pregnancy but may reduce miscarriage. We are uncertain of the effect of Zeta sperm selection on live birth, clinical pregnancy, and miscarriage due principally to the very low quality of the evidence for this intervention. We are uncertain of the effect of the other selection techniques on live birth, miscarriage, or pregnancy.Further high-quality studies, including the awaited data from the identified ongoing studies, are required to evaluate whether any of these advanced sperm selection techniques can be recommended for use in routine practice.",2019,"We are uncertain whether MACS improves live birth (RR 1.95, 95% CI 0.89 to 4.29, 62 women) or clinical pregnancy (RR 1.05, 95% CI 0.84 to 1.31, 413 women,",['eight RCTs (4147 women'],"['ICSITwo RCTs', 'advanced sperm selection techniques', 'Hyaluronic acid selected sperm-intracytoplasmic sperm injection (HA-ICSI', 'intracytoplasmic morphologically selected sperm injection (IMSI', 'HA-ICSI', 'SpermSlowOne RCT', 'ICSIOne RCT', 'Zeta sperm selection', 'MACS']","['clinical pregnancy', 'live birth and miscarriage', 'live birth, miscarriage, or pregnancy', 'live birth or clinical pregnancy', 'clinical pregnancy per woman randomly assigned', 'imprecision, performance bias, and attrition bias', 'miscarriage per clinical pregnancy and foetal abnormality', 'live birth', 'Risk ratios (RRs']","[{'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1141990', 'cui_str': 'Hyaluronic acid'}, {'cui': 'C0455164', 'cui_str': 'ICSI'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1719914', 'cui_str': 'Zeta'}, {'cui': 'C0009545', 'cui_str': 'C5b-9'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0000786', 'cui_str': 'Vaginal expulsion of product of conception'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",1065.0,0.623261,"We are uncertain whether MACS improves live birth (RR 1.95, 95% CI 0.89 to 4.29, 62 women) or clinical pregnancy (RR 1.05, 95% CI 0.84 to 1.31, 413 women,","[{'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Lepine', 'Affiliation': 'Department of Obstetrics and Gynaecology, Capital and Coast District Health Board, Wellington, New Zealand.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'McDowell', 'Affiliation': ''}, {'ForeName': 'Leigh M', 'Initials': 'LM', 'LastName': 'Searle', 'Affiliation': ''}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Kroon', 'Affiliation': ''}, {'ForeName': 'Demián', 'Initials': 'D', 'LastName': 'Glujovsky', 'Affiliation': ''}, {'ForeName': 'Anusch', 'Initials': 'A', 'LastName': 'Yazdani', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD010461.pub3'] 293,31320177,The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.,"OBJECTIVE To investigate serum IL-6 (sIL-6) levels during active disease, complete remission (CR), and relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and to explore the association of changes in sIL-6 with clinical outcomes. METHODS sIL-6 levels were measured at baseline and longitudinally over 18 months, in 78 patients with AAV enrolled in a randomized controlled trial comparing treatment with either rituximab (RTX) or cyclophosphamide (CYC)/azathioprine (AZA). Outcome variables included baseline clinical features, ANCA specificity, disease activity (active disease versus CR), time to relapse events, B cell repopulation, and ANCA titer increases. RESULTS At baseline, sIL6 levels were detectable in 81% of patients; 73% (n = 57) of subjects were proteinase 3 (PR3)-ANCA positive, sIL-6 levels were higher in subjects with PR3-ANCAs and positively correlated with their levels (r s  = 0.36,p < 0.01), but not with levels of myeloperoxidase (MPO)-ANCA (r s  = -0.17,p = 0.47). Higher baseline sIL-6 levels were associated with PR3-ANCA positivity, fever, pulmonary nodules/cavities, conductive deafness, and absence of urinary red blood cell casts (p < 0.05). Baseline sIL6 levels did not predict CR at month 6 (p = 0.71), and the median sIL-6 level declined from baseline with induction therapy, regardless of CR achievement. An increase in sIL-6 during CR was a predictor for subsequent severe relapse in RTX-treated patients (hazard ratio (HR):7.24,p = 0.01), but not in CYC/AZA-treated patients (HR:0.62,p = 0.50). In contrast, a sIL-6 increase did not predict B cell repopulation or ANCA titer increase in either treatment arm (p > 0.05). CONCLUSION At baseline, sIL-6 concentrations correlate with PR3-ANCA titers and are associated with specific clinical manifestations of AAV. Baseline sIL6 concentrations do not predict CR at 6 months, but the increase in sIL-6 concentrations during CR is associated with subsequent severe relapse among RTX-treated patients. Further investigation into the mechanistic role of IL6 in AAV might lead to identifying this pathway as a potential therapeutic target in this disease.",2019,"(PR3)-ANCA positive, sIL-6 levels were higher in subjects with PR3-ANCAs and positively correlated with their levels (r s  = 0.36,p < 0.01), but not with levels of myeloperoxidase (MPO)-ANCA (r s  = -0.17,p = 0.47).",['78 patients with AAV enrolled'],['rituximab (RTX) or cyclophosphamide (CYC)/azathioprine (AZA'],"['PR3-ANCA positivity, fever, pulmonary nodules/cavities, conductive deafness, and absence of urinary red blood cell casts', 'baseline clinical features, ANCA specificity, disease activity (active disease versus CR), time to relapse events, B cell repopulation, and ANCA titer increases', 'sIL-6 increase did not predict B cell repopulation or ANCA titer increase', 'sIL6 levels', 'Baseline sIL6 concentrations', 'sIL-6', 'serum IL-6', 'Higher baseline sIL-6 levels', 'sIL-6 concentrations', 'Baseline sIL6 levels', 'sIL-6) levels during active disease, complete remission (CR), and relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV', 'median sIL-6 level', 'PR3)-ANCA positive, sIL-6 levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0201530', 'cui_str': 'Antineutrophil cytoplasmic antibody measurement (procedure)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0028259', 'cui_str': 'Nodule (morphologic abnormality)'}, {'cui': 'C1510420', 'cui_str': 'Cavity (morphologic abnormality)'}, {'cui': 'C0018777', 'cui_str': 'Conductive hearing loss (disorder)'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0475208', 'cui_str': 'TITR'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0333873', 'cui_str': 'Squamous intraepithelial lesion'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C2609436', 'cui_str': 'Vasculitis (SMQ)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0238874', 'cui_str': 'Antineutrophil cytoplasmic antibody positive (finding)'}]",78.0,0.149311,"(PR3)-ANCA positive, sIL-6 levels were higher in subjects with PR3-ANCAs and positively correlated with their levels (r s  = 0.36,p < 0.01), but not with levels of myeloperoxidase (MPO)-ANCA (r s  = -0.17,p = 0.47).","[{'ForeName': 'Alvise', 'Initials': 'A', 'LastName': 'Berti', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Roscoe', 'Initials': 'R', 'LastName': 'Warner', 'Affiliation': 'University of Michigan Medical School, Ann Arbor, MI, USA.'}, {'ForeName': 'Kent', 'Initials': 'K', 'LastName': 'Johnson', 'Affiliation': 'University of Michigan Medical School, Ann Arbor, MI, USA.'}, {'ForeName': 'Divi', 'Initials': 'D', 'LastName': 'Cornec', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Darrell R', 'Initials': 'DR', 'LastName': 'Schroeder', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Brian F', 'Initials': 'BF', 'LastName': 'Kabat', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Carol A', 'Initials': 'CA', 'LastName': 'Langford', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Cees G M', 'Initials': 'CGM', 'LastName': 'Kallenberg', 'Affiliation': 'University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Seo', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Spiera', 'Affiliation': 'Hospital for Special Surgery, New York, NY, USA.'}, {'ForeName': 'E William', 'Initials': 'EW', 'LastName': 'St Clair', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Fernando C', 'Initials': 'FC', 'LastName': 'Fervenza', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Stone', 'Affiliation': 'Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Monach', 'Affiliation': 'Boston University and VA Boston Healthcare System, Boston, MA, USA.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Specks', 'Affiliation': 'Mayo Clinic, Rochester, MN, USA. Electronic address: specks.ulrich@mayo.edu.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Merkel', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of autoimmunity,['10.1016/j.jaut.2019.07.001'] 294,32295683,#CRCFREE: Using Social Media to Reduce Colorectal Cancer Risk in Rural Adults.,"Objectives: In this study, we pilot-tested #CRCFree, a Facebook-based intervention aimed at reducing colorectal cancer (CRC) risk in rural Appalachian adults at risk for CRC. Methods: Participants were 56 rural Appalachian adults aged > 50 years. Daily #CRCFree Facebook posts addressed diet, physical activity, and CRC screening. Participants' sociodemographics, diet, body mass index, physical activity, and CRC screening status were measured pre- and post-intervention. The Healthy Eating Index (HEI) and the Dietary Inflammatory Index (DII) assessed dietary patterns. Facebook engagement was measured throughout the intervention. A post-intervention focus group evaluated intervention acceptability. Results: Participants were Caucasian, aged 58 ± 6 years, and predominantly female (66%). Post-intervention, HEI scores increased (49.9 ± 9.9 vs 58.6 ± 12.1, p = <.001), and DII scores decreased from baseline (2.8 ± 1.1 vs 1.6 ± 1.7, p = .002). There was no change in physical activity, BMI, or CRC screening status. Focus group participants found the intervention to be educational and motivating. Conclusions: These results provide preliminary evidence to support using Facebook to address CRC risk in this population. Participants were responsive to this intervention, and Facebook is a novel and accessible modality for health promotion.",2020,"Post-intervention, HEI scores increased (49.9 ± 9.9 vs 58.6 ± 12.1, p = <.001), and DII scores decreased from baseline (2.8 ± 1.1 vs 1.6 ± 1.7, p = .002).","['Rural Adults', 'rural Appalachian adults at risk for CRC', 'Participants were 56 rural Appalachian adults aged > 50 years', 'Participants were Caucasian, aged 58 ± 6 years, and predominantly female (66']",['Social Media'],"['Facebook engagement', 'Healthy Eating Index (HEI) and the Dietary Inflammatory Index (DII) assessed dietary patterns', 'physical activity, BMI, or CRC screening status', ""Participants' sociodemographics, diet, body mass index, physical activity, and CRC screening status"", 'DII scores', 'HEI scores', 'colorectal cancer (CRC) risk']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C3179065', 'cui_str': 'Social Medium'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0421330', 'cui_str': 'Screening status'}, {'cui': 'C0385506', 'cui_str': 'didodecylindocarbocyanine'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",56.0,0.0201364,"Post-intervention, HEI scores increased (49.9 ± 9.9 vs 58.6 ± 12.1, p = <.001), and DII scores decreased from baseline (2.8 ± 1.1 vs 1.6 ± 1.7, p = .002).","[{'ForeName': 'Kaitlin Voigts', 'Initials': 'KV', 'LastName': 'Key', 'Affiliation': 'Kaitlin Voigts Key, Doctoral Candidate, University of Kentucky College of Nursing, Lexington, KY;, Email: kaitlin.key@uky.edu.'}, {'ForeName': 'Adebola', 'Initials': 'A', 'LastName': 'Adegboyega', 'Affiliation': 'Adebola Adegboyega, Assistant Professor, University of Kentucky College of Nursing, Lexington, KY.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Bush', 'Affiliation': 'Heather Bush, Kate Spade & Co. Foundation Endowed Professor, Department of Biostatistics, University of Kentucky College of Public Health.'}, {'ForeName': 'Mollie E', 'Initials': 'ME', 'LastName': 'Aleshire', 'Affiliation': 'Mollie E. Aleshire, DNP Program Director/Associate Professor, University of North Carolina at Greensboro School of Nursing, Greensboro, NC.'}, {'ForeName': 'Omar A', 'Initials': 'OA', 'LastName': 'Contreras', 'Affiliation': 'Omar A. Contreras, Program Director of Policy and Translational Research, Office of Community Outreach and Engagement, The University of Arizona Cancer Center.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hatcher', 'Affiliation': 'Jennifer Hatcher, Professor, Mel & Enid Zuckerman College of Public Health, Associate Director for Community Outreach & Engagement, The University of Arizona Cancer Center.'}]",American journal of health behavior,['10.5993/AJHB.44.3.8'] 295,32295773,Family-based habit intervention to promote parent support for child physical activity in Canada: protocol for a randomised trial.,"INTRODUCTION Regular physical activity (PA) participation has many important physical and psychological health benefits, managing and preventing over 25 chronic conditions. Being more physically active as a child is associated with being more active as an adult, but less than 10% of Canadian children are achieving the recommended PA guidelines of 60 minutes per day of moderate to vigorous PA. Parental support is a predictor of child PA, but parent intention to support child PA does not always predict enacted support. Targeting factors that assist in the sustainability of parent support behaviour of child PA may have an impact on child PA. The purpose of this study is to evaluate an intervention designed to promote habit formation of parental support (HABIT, independent variable) on child PA (dependant variable) compared with a planning and education group (PLANNING) and an education only group (EDUCATION). METHODS AND ANALYSIS The three conditions will be compared using a 6-month longitudinal randomised trial. Eligible families have at least one child aged 6-12 years who is not meeting the 2011 Canadian PA Guidelines. Intervention materials are delivered at baseline, with check-in sessions at 6 weeks and 3 months. Child's moderate-to-vigorous PA, measured by accelerometry, is assessed at baseline, 6 weeks, 3 months and 6 months as the primary outcome. At baseline and 6 months, children perform fitness testing. Parents and children complete questionnaires at all timepoints. So far, 123 families have been recruited from the Greater Victoria and surrounding area. Recruitment will be continuing through 2020 with a target of 240 families. ETHICS AND DISSEMINATION This protocol has been approved by the University of Victoria Human Research Ethics Board (Victoria, Canada). Results will be shared at conferences as presentations and as published manuscripts. Study findings will be made available to interested participants. TRIAL REGISTRATION NUMBER NCT03145688; Pre-results.",2020,"Parental support is a predictor of child PA, but parent intention to support child PA does not always predict enacted support.","['123 families have been recruited from the Greater Victoria and surrounding area', 'Eligible families have at least one child aged 6-12 years who is not meeting the 2011 Canadian PA Guidelines']",[],[],"[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C1282914', 'cui_str': 'Circumscribed'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]",[],[],,0.174607,"Parental support is a predictor of child PA, but parent intention to support child PA does not always predict enacted support.","[{'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Medd', 'Affiliation': 'Behavioural Medicine Laboratory, School of Exercise Science, Physical and Health Education, Faculty of Education, University of Victoria, Victoria, British Columbia, Canada ermedd@uvic.ca.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Beauchamp', 'Affiliation': 'School of Kinesiology, Faculty of Education, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Chris M', 'Initials': 'CM', 'LastName': 'Blanchard', 'Affiliation': 'School of Health and Human Performance, Faculty of Health, Dalhousie University, Halifax, Nova Scotia, Canada.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Carson', 'Affiliation': 'Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Gardner', 'Affiliation': ""Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.""}, {'ForeName': 'Darren Er', 'Initials': 'DE', 'LastName': 'Warburton', 'Affiliation': 'School of Kinesiology, Faculty of Education, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Rhodes', 'Affiliation': 'Behavioural Medicine Laboratory, School of Exercise Science, Physical and Health Education, Faculty of Education, University of Victoria, Victoria, British Columbia, Canada.'}]",BMJ open,['10.1136/bmjopen-2019-033732'] 296,32295776,Mobile technology intervention for weight loss in rural men: protocol for a pilot pragmatic randomised controlled trial.,"INTRODUCTION Men who are overweight or obese in the rural Midwestern USA are an unrepresented, at-risk group exhibiting rising rates of cardiovascular disease, poor access to preventive care and poor lifestyle behaviours that contribute to sedentary lifestyle and unhealthy diet. Self-monitoring of eating and activity has demonstrated efficacy for weight loss. Use of mobile technologies for self-monitoring eating and activity may address rural men's access disparities to preventive health resources and support weight loss. Our pilot trial will assess the feasibility and acceptability of two mobile applications for weight loss in rural men to inform a future, full-scale trial. METHODS AND ANALYSIS A 6-month randomised controlled trial with contextual evaluation will randomise 80 men using a 1:1 ratio to either a Mobile Technology Plus (MT+) intervention or a basic Mobile Technology (MT) intervention in rural, midlife men (aged 40-69 years). The MT+ intervention consists of a smartphone self-monitoring application enhanced with discussion group (Lose-It premium), short message service text-based support and Wi-Fi scale. The MT group will receive only a self-monitoring application (Lose-It basic). Feasibility and acceptability will be evaluated using number of men recruited and retained, and evaluative focus group feedback. We seek to determine point estimates and variability of outcome measures of weight loss (kg and % body weight) and improved dietary and physical activity behaviours (Behavioral Risk Factor Surveillance System (BRFSS) physical activity and fruit and vegetable consumption surveys, data from Lose-It! application (kcal/day, steps/day)). Community capacity will be assessed using standard best practice methods. Descriptive content analysis will evaluate intervention acceptability and contextual sensitivity. ETHICS AND DISSEMINATION This protocol was approved by the University of Nebraska Medical Center Institutional Review Board (IRB# 594-17-EP). Dissemination of findings will occur through ClinicalTrials.gov and publish pilot data to inform the design of a larger clinical trial. TRIAL REGISTRATION NUMBER NCT03329079; preresults. Protocol V.10, study completion date 31 August 2020. Roles and responsibilities funder: NIH/NINR Health Disparities Section 1R15NR017522-01.",2020,Use of mobile technologies for self-monitoring eating and activity may address rural men's access disparities to preventive health resources and support weight loss.,"['rural men', 'Men who are overweight or obese in the rural Midwestern USA', 'in rural, midlife men (aged 40-69 years', 'Roles and responsibilities funder', '80 men using a 1:1 ratio to either a']","['Mobile Technology Plus (MT+) intervention or a basic Mobile Technology (MT) intervention', 'Mobile technology intervention', 'mobile technologies']","['Feasibility and acceptability', 'weight loss (kg and % body weight) and improved dietary and physical activity behaviours (Behavioral Risk Factor Surveillance System (BRFSS) physical activity and fruit and vegetable consumption surveys, data from Lose-It', 'weight loss']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0026062', 'cui_str': 'Middle-age'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1136355', 'cui_str': 'Behavior Risk Factor Surveillance System'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]",,0.112289,Use of mobile technologies for self-monitoring eating and activity may address rural men's access disparities to preventive health resources and support weight loss.,"[{'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Eisenhauer', 'Affiliation': 'College of Nursing- Northern Division, University of Nebraska Medical Center, Norfolk, Nebraska, USA ceisenhauer@unmc.edu.'}, {'ForeName': 'Fabiana Almeida', 'Initials': 'FA', 'LastName': 'Brito', 'Affiliation': 'College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Yoder', 'Affiliation': 'College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Kupzyk', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}, {'ForeName': 'Carol H', 'Initials': 'CH', 'LastName': 'Pullen', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Salinas', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'College of Nursing- Northern Division, University of Nebraska Medical Center, Norfolk, Nebraska, USA.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Hageman', 'Affiliation': 'College of Allied Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.'}]",BMJ open,['10.1136/bmjopen-2019-035089'] 297,32295778,Live birth after in vitro maturation versus standard in vitro fertilisation for women with polycystic ovary syndrome: protocol for a non-inferiority randomised clinical trial.,"INTRODUCTION Polycystic ovary syndrome (PCOS) is the first common cause of anovulatory infertility. Currently, in vitro fertilisation (IVF) is recommended when conventional attempts have failed. In vitro maturation (IVM) of human oocytes is an emerging treatment option in infertile women with PCOS. It is a patient-friendly intervention, avoiding the risk of ovarian hyperstimulation syndrome, which is a serious complication of controlled ovarian stimulation in the standard IVF procedure. We plan a randomised controlled trial (RCT) to evaluate whether IVM is non-inferior to the standard IVF for live birth in women with PCOS. METHODS AND ANALYSIS This is a single-centre, open-label, non-inferiority RCT performed in a large reproductive medicine centre in China. Infertile women with PCOS will be randomised to receive either IVM or standard IVF in a 1:1 treatment ratio after informed consent. IVF procedures used in our study are all standard treatments and other standard-assisted reproductive technologies will be similar between the two groups. The primary outcome is ongoing pregnancy leading to live birth within 6 months of the first oocyte retrieval cycle after randomisation. Pregnancy outcome, maternal safety and obstetric and perinatal complications will be secondary outcomes. The planned sample size is 350 (175 per group). ETHICS AND DISSEMINATION Ethical permission was acquired from the Ethics Committee of Peking University Third Hospital. The results will be issued to publications through scientific journals and conference reports. TRIAL REGISTRATION NUMBER NCT03463772.",2020,IVF procedures used in our study are all standard treatments and other standard-assisted reproductive technologies will be similar between the two groups.,"['women with polycystic ovary syndrome', 'women with PCOS', 'infertile women with PCOS', 'Infertile women with PCOS']","['Live birth after in vitro maturation versus standard in vitro fertilisation', 'IVM', 'IVM or standard IVF']","['ongoing pregnancy leading to live birth within 6 months of the first oocyte retrieval cycle', 'Pregnancy outcome, maternal safety and obstetric and perinatal complications']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}]","[{'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0021135', 'cui_str': 'In Vitro'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0404268', 'cui_str': 'Oocyte recovery'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.283637,IVF procedures used in our study are all standard treatments and other standard-assisted reproductive technologies will be similar between the two groups.,"[{'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Guo', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zeng', 'Affiliation': 'Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Danni', 'Initials': 'D', 'LastName': 'Zheng', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'OB/GYN, School of Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Ben W', 'Initials': 'BW', 'LastName': 'Mol', 'Affiliation': 'OB/GYN, School of Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Qiao', 'Affiliation': 'Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China Jie.qiao@263.net.'}]",BMJ open,['10.1136/bmjopen-2019-035334'] 298,32295779,STEP.De study-a multicentre cluster-randomised effectiveness trial of exercise therapy for patients with depressive symptoms in healthcare services: study protocol.,"INTRODUCTION Although exercise therapy has widely been shown to be an efficacious treatment modality for depression, evidence for its effectiveness and cost efficiency is lacking. The Sport/Exercise Therapy for Depression study is a multicentre cluster-randomised effectiveness trial that aims to compare the effectiveness and cost efficiency of exercise therapy and psychotherapy as antidepressant treatment. METHODS AND ANALYSIS 480 patients (aged 18-65) with an International Classification of Diseases diagnosis associated with depressive symptoms are recruited. Up to 30 clusters (psychotherapists) are randomly assigned to allocate patients to either an exercise or a psychotherapy treatment as usual in a 2:1 ratio. The primary outcome (depressive symptoms) and the secondary outcomes (work and social adjustment, quality of life) will be assessed at six measurement time points (t0: baseline, t1: 8 weeks after treatment initiation, t2: 16 weeks after treatment initiation, t3/4/5: 2, 6, 12 months after treatment). Linear regression analyses will be used for the primary endpoint data analysis. For the secondary endpoints, mixed linear and logistic regression models with fixed and random factors will be added. For the cost efficiency analysis, expenditures in the 12 months before and after the intervention and the outcome difference will be compared between groups in a multilevel model. Recruitment start date was 1 July 2018 and the planned recruitment end date is 31 December 2020. ETHICS AND DISSEMINATION The study protocol was approved by the ethics committee of the University of Potsdam (No. 17/2018) and the Freie Universität Berlin (No. 206/2018) and registered in the ISRCTN registry. Informed written consent will be obtained from all participants. The study will be reported in accordance with the Consolidated Standards of Reporting Trials and the Recommendations for Interventional Trials statements. The results will be published in peer-reviewed academic journals and disseminated to the public. TRIAL REGISTRATION NUMBER ISRCTN28972230.",2020,"The primary outcome (depressive symptoms) and the secondary outcomes (work and social adjustment, quality of life) will be assessed at six measurement time points (t0: baseline, t1: 8 weeks after treatment initiation, t2: 16 weeks after treatment initiation, t3/4/5: 2, 6, 12 months after treatment).","['patients with depressive symptoms in healthcare services', '480 patients (aged 18-65) with an International Classification of Diseases diagnosis associated with depressive symptoms are recruited']","['exercise or a psychotherapy treatment', 'exercise therapy and psychotherapy', 'exercise therapy']","['primary outcome (depressive symptoms) and the secondary outcomes (work and social adjustment, quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0870733', 'cui_str': 'International Statistical Classification of Diseases and Related Health Problems'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.306613,"The primary outcome (depressive symptoms) and the secondary outcomes (work and social adjustment, quality of life) will be assessed at six measurement time points (t0: baseline, t1: 8 weeks after treatment initiation, t2: 16 weeks after treatment initiation, t3/4/5: 2, 6, 12 months after treatment).","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Heissel', 'Affiliation': 'Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany andreas.heissel@uni-potsdam.de.'}, {'ForeName': 'Anou', 'Initials': 'A', 'LastName': 'Pietrek', 'Affiliation': 'Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Schwefel', 'Affiliation': 'Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.'}, {'ForeName': 'Kahar', 'Initials': 'K', 'LastName': 'Abula', 'Affiliation': 'Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Wilbertz', 'Affiliation': 'Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Heinzel', 'Affiliation': 'Department of Education and Psychology, Freie Universität Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Rapp', 'Affiliation': 'Social and Preventive Medicine, Department Sport and Health Sciences, Faculty of Human Sciences, University of Potsdam, Potsdam, Brandenburg, Germany.'}]",BMJ open,['10.1136/bmjopen-2019-036287'] 299,32295780,Randomised controlled trial of a person-centred transition programme for adolescents with type 1 diabetes (STEPSTONES-DIAB): a study protocol.,"INTRODUCTION Adolescence is a critical period for youths with chronic conditions, when they are supposed to take over the responsibility for their health. Type 1 diabetes (T1D) is one of the most common chronic conditions in childhood and inadequate self-management increases the risk of short-term and long-term complications. There is a lack of evidence regarding the effectiveness of transition programmes. As a part of the Swedish Transition Effects Project Supporting Teenagers with chrONic mEdical conditionS research programme, the objective of this study is to evaluate the effectiveness and experiences of different transitional care models, including a person-centred transition programme aiming to empower adolescents with T1D to become active partners in their health and care. METHODS AND ANALYSIS In this randomised controlled trial, patients are recruited from two paediatric diabetes clinics at the age of 16 years. Patients are randomly assigned to either the intervention group (n=70) where they will receive usual care plus the structured transition programme, or to the control group (n=70) where they will only receive usual care. Data will be collected at 16, 17 and 18.5 years of age. In a later stage, the intervention group will be compared with adolescents in a dedicated youth clinic in a third setting. The primary outcome is patient empowerment. Secondary outcomes include generic, diabetes-specific and transfer-specific variables. ETHICS AND DISSEMINATION The study has been approved by the Ethical Review Board in Stockholm (Dnr 2018/1725-31). Findings will be reported following the Consolidated Standards of Reporting Trials statement and disseminated in peer-reviewed journals and at international conferences. TRIAL REGISTRATION NUMBER NCT03994536.",2020,"Patients are randomly assigned to either the intervention group (n=70) where they will receive usual care plus the structured transition programme, or to the control group (n=70) where they will only receive usual care.","['Teenagers with chrONic mEdical conditionS research programme', 'youths with chronic conditions', 'adolescents with type 1 diabetes (STEPSTONES-DIAB', 'adolescents with T1D to become active partners in their health and care', 'patients are recruited from two paediatric diabetes clinics at the age of 16 years']","['person-centred transition programme', 'usual care plus the structured transition programme, or to the control group (n=70) where they will only receive usual care']","['generic, diabetes-specific and transfer-specific variables', 'patient empowerment']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C3839636', 'cui_str': 'Diabetes clinic'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C3853035', 'cui_str': 'Patient Empowerment'}]",,0.136449,"Patients are randomly assigned to either the intervention group (n=70) where they will receive usual care plus the structured transition programme, or to the control group (n=70) where they will only receive usual care.","[{'ForeName': 'Anna Lena', 'Initials': 'AL', 'LastName': 'Brorsson', 'Affiliation': 'Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden anna-lena.brorsson@ki.se.'}, {'ForeName': 'Ewa-Lena', 'Initials': 'EL', 'LastName': 'Bratt', 'Affiliation': 'Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Moons', 'Affiliation': 'Institute of Health and Care Sciences, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ek', 'Affiliation': 'Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Jelleryd', 'Affiliation': ""Department of Paediatric Diabetes, Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Torun', 'Initials': 'T', 'LastName': 'Torbjörnsdotter', 'Affiliation': ""Department of Paediatric Diabetes, Astrid Lindgren's Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Carina', 'Initials': 'C', 'LastName': 'Sparud-Lundin', 'Affiliation': 'Gothenburg Centre for Person-Centred Care (GPCC), University of Gothenburg, Gothenburg, Sweden.'}]",BMJ open,['10.1136/bmjopen-2019-036496'] 300,30175628,Early administration of Fab antivenom resulted in faster limb recovery in copperhead snake envenomation patients.,"BACKGROUND No previous research has studied whether early snake antivenom administration leads to better clinical outcomes than late antivenom administration in North American pit viper envenomation. METHODS A secondary analysis of data from a clinical trial of Fab antivenom (FabAV) versus placebo for copperhead snake envenomation was conducted. Patients treated before the median time to FabAV administration were classified as receiving early treatment and those treated after the median time were defined as the late treatment group. A Cox proportional hazards model was used to compare time to full recovery on the Patient-Specific Functional Scale (PSFS) instrument between groups. Secondary analyses compared estimated mean PSFS scores using a generalized linear model and the estimated proportion of patients with full recovery at each time point using logistic regression. To evaluate for confounding, the main analysis was repeated using data from placebo-treated subjects. RESULTS Forty-five subjects were treated with FabAV at a median of 5.47 h after envenomation. Patients in the early treatment group had a significantly shorter time to full recovery than those treated late (median time: 17 versus 28 days, p = .025). Model-estimated PSFS scores were numerically higher at each time point in the early group. No difference was found between patients treated early versus late with placebo. CONCLUSIONS In this secondary analysis of trial data, recovery of limb function was faster when Fab antivenom was administered soon after envenomation, as opposed to late administration.",2019,"Patients in the early treatment group had a significantly shorter time to full recovery than those treated late (median time: 17 versus 28 days, p = .025).","['North American pit viper envenomation', 'Forty-five subjects', 'copperhead snake envenomation patients']","['Fab antivenom (FabAV) versus placebo', 'Fab antivenom']","['shorter time to full recovery', 'faster limb recovery', 'recovery of limb function', 'median time to FabAV administration', 'Model-estimated PSFS scores', 'Patient-Specific Functional Scale (PSFS', 'mean PSFS scores']","[{'cui': 'C0327512', 'cui_str': 'Pit Viper'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0206310', 'cui_str': 'Copperhead'}, {'cui': 'C0037379', 'cui_str': 'Snake Envenomation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0003450', 'cui_str': 'Antivenoms'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale (assessment scale)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",45.0,0.184114,"Patients in the early treatment group had a significantly shorter time to full recovery than those treated late (median time: 17 versus 28 days, p = .025).","[{'ForeName': 'Victoria E', 'Initials': 'VE', 'LastName': 'Anderson', 'Affiliation': 'a Rocky Mountain Poison and Drug Center , Denver Health and Hospital Authority , Denver , CO , USA.'}, {'ForeName': 'Charles J', 'Initials': 'CJ', 'LastName': 'Gerardo', 'Affiliation': 'b Division of Emergency Medicine , Duke University School of Medicine , Durham , NC , USA.'}, {'ForeName': 'Malin', 'Initials': 'M', 'LastName': 'Rapp-Olsson', 'Affiliation': 'a Rocky Mountain Poison and Drug Center , Denver Health and Hospital Authority , Denver , CO , USA.'}, {'ForeName': 'Sean P', 'Initials': 'SP', 'LastName': 'Bush', 'Affiliation': 'c Department of Emergency Medicine , Brody School of Medicine , Greenville , NC , USA.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Mullins', 'Affiliation': 'd Division of Emergency Medicine , Washington University School of Medicine , St. Louis , MO , USA.'}, {'ForeName': 'Spencer', 'Initials': 'S', 'LastName': 'Greene', 'Affiliation': 'e Department of Emergency Medicine , Baylor College of Medicine , Houston , TX , USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Toschlog', 'Affiliation': 'f Department of Surgery , Brody School of Medicine , Greenville , NC , USA.'}, {'ForeName': 'Eugenia', 'Initials': 'E', 'LastName': 'Quackenbush', 'Affiliation': 'g Department of Emergency Medicine , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'S Rutherfoord', 'Initials': 'SR', 'LastName': 'Rose', 'Affiliation': 'h Department of Emergency Medicine , Virginia Commonwealth University , Richmond , VA , USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Schwartz', 'Affiliation': 'i Department of Emergency Medicine and Hospital Services , Medical College of Georgia , Augusta , GA , USA.'}, {'ForeName': 'Nathan P', 'Initials': 'NP', 'LastName': 'Charlton', 'Affiliation': 'j Department of Emergency Medicine , University of Virginia , Charlottesville , VA , USA.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Lewis', 'Affiliation': 'k Texas A&M Health Science Center , College Station , TX , USA.'}, {'ForeName': 'Kurt C', 'Initials': 'KC', 'LastName': 'Kleinschmidt', 'Affiliation': 'l Department of Emergency Medicine , University of Texas Southwestern Medical Center , Dallas , TX , USA.'}, {'ForeName': 'Kapil', 'Initials': 'K', 'LastName': 'Sharma', 'Affiliation': 'l Department of Emergency Medicine , University of Texas Southwestern Medical Center , Dallas , TX , USA.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Lavonas', 'Affiliation': 'm Department of Emergency Medicine and Rocky Mountain Poison and Drug Center , Denver Health and Hospital Authority , Denver , CO , USA.'}]","Clinical toxicology (Philadelphia, Pa.)",['10.1080/15563650.2018.1491982'] 301,32284387,Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS).,"INTRODUCTION Chronic headaches are poorly diagnosed and managed and can be exacerbated by medication overuse. There is insufficient evidence on the non-pharmacological approaches to helping people living with chronic headaches. METHODS AND ANALYSIS Chronic Headache Education and Self-management Study is a pragmatic randomised controlled trial to test the effectiveness and cost-effectiveness of a self-management education support programme on top of usual care for patients with chronic headaches against a control of usual care and relaxation. The intervention is a 2-day group course based on education, personal reflection and a cognitive behavioural approach, plus a nurse-led one-to-one consultation and follow-up over 8 weeks. We aim to recruit 689 participants (356 to the intervention arm and 333 to the control) from primary care and self-referral in London and the Midlands. The trial is powered to show a difference of 2.0 points on the Headache Impact Test, a patient-reported outcome measure at 12 months post randomisation. Secondary outcomes include health related quality of life, self-efficacy, social activation and engagement, anxiety and depression and healthcare utilisation. Outcomes are being measured at 4, 8 and 12 months. Cost-effectiveness will be expressed in terms of incremental cost per quality-adjusted life year gained. ETHICS AND DISSEMINATION This trial will provide data on effectiveness and cost-effectiveness of a self-management support programme for chronic headaches. The results will inform commissioning of services and clinical practice. North West - Greater Manchester East Research Ethics Committee have approved the trial. The current protocol version is 3.6 date 7 March 2019. TRIAL REGISTRATION NUMBER ISRCTN79708100.",2020,"Secondary outcomes include health related quality of life, self-efficacy, social activation and engagement, anxiety and depression and healthcare utilisation.","['689 participants (356 to the intervention arm and 333 to the control) from primary care and self-referral in London and the Midlands', 'people living with chronic headache disorders', 'patients with chronic headaches against a control of usual care and relaxation', 'chronic headaches']","['self-management education support programme', '2-day group course based on education, personal reflection and a cognitive behavioural approach, plus a nurse-led one-to-one consultation and follow-up over 8 weeks', 'self-management support programme', 'Usual care and a self-management support programme versus usual care and a relaxation programme']","['health related quality of life, self-efficacy, social activation and engagement, anxiety and depression and healthcare utilisation', 'Cost-effectiveness']","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4517724', 'cui_str': '333'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0237824', 'cui_str': 'Self-referral'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C2316225', 'cui_str': 'Chronic headache disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151293', 'cui_str': 'Chronic Headache'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0282333', 'cui_str': 'Relaxation training therapy'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.120678,"Secondary outcomes include health related quality of life, self-efficacy, social activation and engagement, anxiety and depression and healthcare utilisation.","[{'ForeName': 'Shilpa', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK shilpa.patel@warwick.ac.uk.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Achana', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Dawn', 'Initials': 'D', 'LastName': 'Carnes', 'Affiliation': 'Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Eldridge', 'Affiliation': 'Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Ellard', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Griffiths', 'Affiliation': 'Warwick Medical School, Division of Health Sciences, University of Warwick, Coventry, UK.'}, {'ForeName': 'Kirstie', 'Initials': 'K', 'LastName': 'Haywood', 'Affiliation': 'Warwick Medical School, Division of Health Sciences, University of Warwick, Coventry, UK.'}, {'ForeName': 'Siew Wan', 'Initials': 'SW', 'LastName': 'Hee', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Dipesh', 'Initials': 'D', 'LastName': 'Mistry', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Hema', 'Initials': 'H', 'LastName': 'Mistry', 'Affiliation': 'Warwick Medical School, Warwick Evidence, University of Warwick, Coventry, UK.'}, {'ForeName': 'Vivien P', 'Initials': 'VP', 'LastName': 'Nichols', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Petrou', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Tamar', 'Initials': 'T', 'LastName': 'Pincus', 'Affiliation': 'Department of Psychology, Royal Holloway University of London, Egham, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Potter', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Harbinder Kaur', 'Initials': 'HK', 'LastName': 'Sandhu', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Stewart', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Taylor', 'Affiliation': 'Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Underwood', 'Affiliation': 'Warwick Medical School, Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Manjit', 'Initials': 'M', 'LastName': 'Matharu', 'Affiliation': 'University College London Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-033520'] 302,29670279,"Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.","F-652 is a recombinant fusion protein consisting of two human interleukin-22 (IL-22) molecules linked to an immunoglobulin constant region (IgG 2 -Fc). IL-22 plays critical roles in promoting tissue repair and suppressing bacterial infection. The safety, pharmacokinetics (PK), tolerability, and biomarkers of F-652 were evaluated following a single dose in healthy male volunteers in a randomized, double-blind, placebo-controlled study. Following single-dose subcutaneous (SC) injection of F-652 at 2.0 µg/kg into healthy subjects, six out of six subjects experienced delayed injection site reactions, which presented as erythematous and/or discoid eczematous lesions 10 to 17 days post-dosing. F-652 was then administered to the healthy subjects via an intravenous (IV) infusion at 2.0, 10, 30, and 45 µg/kg. No severe adverse event (SAE) was observed during the study. Among the IV-dosed cohorts, eye and skin treatment emergent adverse events (TEAEs) were observed in the 30 and 45 µg/kg cohorts. F-652 IV dosing resulted in linear increases in C max and AUC (0-t) , and the T 1/2 ranged from 39.4 to 206 h in the cohorts. An IV injection of F-652 induced dose-dependent increases in serum marker serum amyloid A, C-reactive protein, and FIB, and decreased serum triglycerides. The serum levels of 36 common pro-inflammatory cytokines/chemokines were not altered by the treatment of F-652 at 45 μg/kg. In conclusion, IV administration of F-652 to healthy male volunteers is safe and well-tolerated and demonstrates favorable PK and pharmacodynamic properties. These results warrant further clinical development of F-652 to treat inflammatory diseases.",2019,The serum levels of 36 common pro-inflammatory cytokines/chemokines were not altered by the treatment of F-652 at 45 μg/kg.,"['healthy subjects', 'healthy male volunteers']","['single-dose subcutaneous (SC) injection of F-652', 'placebo', 'F-652']","['Safety, pharmacokinetics, and biomarkers of F-652', 'serum marker serum amyloid A, C-reactive protein, and FIB, and decreased serum triglycerides', 'safety, pharmacokinetics (PK), tolerability, and biomarkers of F-652', 'C max and AUC (0-t', 'serum levels of 36 common pro-inflammatory cytokines/chemokines', 'safe and well-tolerated', 'severe adverse event (SAE']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0162491', 'cui_str': 'Serum Markers'}, {'cui': 'C0002723', 'cui_str': 'Amyloid Protein SAA'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.063582,The serum levels of 36 common pro-inflammatory cytokines/chemokines were not altered by the treatment of F-652 at 45 μg/kg.,"[{'ForeName': 'Kai-Yang', 'Initials': 'KY', 'LastName': 'Tang', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Lickliter', 'Affiliation': 'Nucleus Network, Melbourne, VIC, Australia.'}, {'ForeName': 'Zhi-Hua', 'Initials': 'ZH', 'LastName': 'Huang', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Zong-Shu', 'Initials': 'ZS', 'LastName': 'Xian', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Han-Yang', 'Initials': 'HY', 'LastName': 'Chen', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Chong', 'Initials': 'C', 'LastName': 'Xiao', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Yu-Peng', 'Initials': 'YP', 'LastName': 'Wang', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Lin-Feng', 'Initials': 'LF', 'LastName': 'Xu', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Yu-Liang', 'Initials': 'YL', 'LastName': 'Huang', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China.'}, {'ForeName': 'Xiao-Qiang', 'Initials': 'XQ', 'LastName': 'Yan', 'Affiliation': 'Generon (Shanghai) Corporation Ltd., Zhangjiang Hi-Tech Park, Shanghai, China. yanxq@generonbiomed.com.'}]",Cellular & molecular immunology,['10.1038/s41423-018-0029-8'] 303,32289159,Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.,"AIMS The COMPASS trial demonstrated that the combination of rivaroxaban 2.5mg twice-daily and aspirin 100mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) by 24% during a mean follow-up of 23 months. We explored whether this effect varies by sex. METHODS AND RESULTS The effects were examined in women and men using log-rank tests and Kaplan-Meier curve. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were obtained from stratified Cox proportional hazards models to explore subgroup effects including subgroup of women and men according to baseline modified REACH risk score. Of 27,395 patients randomized, 18,278 were allocated to receive rivaroxaban plus aspirin (n = 9,152) or aspirin alone (n = 9,126), and of these 22.1% were women. Women compared with men had similar incidence rates for MACE and major bleeding but borderline lower rates for MI (1.7% vs. 2.2%, p = 0.05). The effect of combination therapy compared with aspirin in women and men were consistent for MACE (women: 3.8% vs. 5.2%, HR 0.72, 95% CI 0.54-0.97; men: 4.2% vs. 5.5%, HR 0.76, 95% CI 0.66-0.89; p interaction 0.75) and major bleeding (women: 3.1% vs. 1.4%, HR 2.22, 95% CI 1.42-3.46; men: 3.2% vs. 2.0%, HR 1.60, 95% CI 1.29-1.97; p interaction 0.19). There was no significant interaction between randomized treatment and baseline modified REACH score above or below the median for MACE or major bleeding. CONCLUSIONS In patients with stable CAD or PAD, the combination of rivaroxaban (2x2.5mg twice-daily) and aspirin compared with aspirin alone appears to produce consistent benefits in women and men, independent of baseline cardiovascular risk.",2020,"There was no significant interaction between randomized treatment and baseline modified REACH score above or below the median for MACE or major bleeding. ","['patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD', 'women and men with chronic coronary or peripheral artery disease', '27,395 patients randomized, 18,278 were allocated to receive', 'women and men']","['aspirin alone', 'rivaroxaban plus aspirin', 'rivaroxaban', 'aspirin']","['Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs', 'major adverse cardiovascular events (MACE', 'major bleeding', 'Efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0009667', 'cui_str': 'Confidence Intervals'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",27395.0,0.281454,"There was no significant interaction between randomized treatment and baseline modified REACH score above or below the median for MACE or major bleeding. ","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, #167 Beilishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, #167 Beilishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Lisheng', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, #167 Beilishi Road, Xicheng District, Beijing, China.'}, {'ForeName': 'Sonia S', 'Initials': 'SS', 'LastName': 'Anand', 'Affiliation': 'Departments of Medicine and Epidemiology, Population Health Research Institute, McMaster University, Hamilton Health Sciences.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Connolly', 'Affiliation': 'Department of Medicine; Director, Division of Cardiology, Department of Medicine, Population Health Research Institute, McMaster University, Hamilton, Ontario.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Bosch', 'Affiliation': 'Population Health Research Institute, Ontario, Canada.'}, {'ForeName': 'Tomasz J', 'Initials': 'TJ', 'LastName': 'Guzik', 'Affiliation': 'Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK\nCollegium Medicum, Jagiellonian University, Krakow, Poland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': ""O'Donnell"", 'Affiliation': 'Translational Medicine, NUI Galway and Saolta Hospital Group, HRB-Clinical Research Facility, Newcastle Rd, Galway, Ireland.'}, {'ForeName': 'Gilles R', 'Initials': 'GR', 'LastName': 'Dagenais', 'Affiliation': 'Professor of Medicine, Laval University and Quebec Heart and Lung Institute, Quebec City, Canada.'}, {'ForeName': 'Keith A A', 'Initials': 'KAA', 'LastName': 'Fox', 'Affiliation': 'Professor Keith Fox is Duke of Edinburgh Professor of Cardiology of the University of Edinburgh, Head of Medical and Radiological Sciences and Consultant Cardiologist in the Royal Infirmary of Edinburgh.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Shestakovska', 'Affiliation': 'Statistician, Population Health Research Institute, Ontario, Canada.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Berkowitz', 'Affiliation': 'Vice President Clinical Development, Group Head Thrombosis. Bayer U.S. LLC, Research & Development, Pharmaceuticals. Thrombosis & Hematology Therapeutic Area.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Muehlhofer', 'Affiliation': 'Global Clinical Leader Thrombosis, Bayer AG. Research & Development, Pharmaceuticals, TA Thrombosis & Hematology.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Keller', 'Affiliation': 'Sr. Study Medical Expert CV, Bayer AG, Research & Development, Pharmaceuticals, Medical Experts Cardio & Coagulant.'}, {'ForeName': 'Salim', 'Initials': 'S', 'LastName': 'Yusuf', 'Affiliation': 'Distinguished University Professor of Medicine, McMaster University. Executive Director, Population Health Research Institute, McMaster University, Hamilton Health Sciences. Chief Scientist, Hamilton Health Sciences. Heart and Stroke Foundation/Marion W. Burke Chair in Cardiovascular Disease.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Eikelboom', 'Affiliation': 'Professor of Department of Medicine, McMaster University, Senior Investigator, Population Health Research Institute and Haematologist at the Hamilton General Hospital, Ontario, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, #167 Beilishi Road, Xicheng District, Beijing, China.'}]",Cardiovascular research,['10.1093/cvr/cvaa100'] 304,32289190,Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.,"BACKGROUND Patients treated with tumour necrosis factor (TNF) inhibitors are at risk of new-onset tuberculosis (TB) or reactivation of latent tuberculosis infection (LTBI). Association between TB/LTBI and interleukin (IL)-23 inhibitors for psoriasis is unclear. Patients with LTBI typically initiate LTBI therapy before receiving biologics. OBJECTIVES Safety in moderate-to-severe psoriasis patients with LTBI treated with guselkumab (IL-23 inhibitor) and LTBI treatment was evaluated. METHODS In the VOYAGE 1 & VOYAGE 2 studies, patients screened for LTBI were randomized to guselkumab, placebo, or adalimumab (TNF inhibitor) at baseline. Placebo → guselkumab crossover occurred at week 16 and adalimumab → guselkumab at week 52 (VOYAGE 1), or at week 28 or later (VOYAGE 2). Incidence of active TB, adverse events (AEs), serious AEs (SAEs), and markedly abnormal liver function tests [alanine aminotransferase test (ALT); aspartate aminotransferase test (AST)] were evaluated using pooled data through week 100 in guselkumab-treated patients receiving and not receiving LTBI treatment. RESULTS At baseline, 130 randomized patients (guselkumab: n = 69; adalimumab: n = 36; placebo: n = 25) tested positive for LTBI and received concomitant LTBI treatments (LTBI+). No active TB was reported among guselkumab-treated patients without LTBI (LTBI-) through week 100. Two cases of active TB occurred in LTBI- patients treated with adalimumab. Through week 16, across all treatment groups, greater proportions of LTBI+ patients reported ALT and AST elevations compared with LTBI- patients. Through week 100, proportions of patients experiencing AEs and SAEs were comparable between LTBI+ and LTBI- patients. CONCLUSIONS No cases of active TB, including reactivation of LTBI, were reported in patients with or without LTBI treated with guselkumab through up to 2 years. LTBI treatment was effective across all treatment groups in preventing reactivation of LTBI. Long-term treatment with guselkumab was generally well-tolerated through up to 2 years in patients receiving LTBI medications.",2020,"Through wk100, proportions of patients experiencing AEs and SAEs were comparable between LTBI+ and LTBI- patients. ","['130 randomized patients (guselkumab: n=69', 'Patients with LTBI typically initiate LTBI therapy before receiving biologics', 'moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with', 'moderate-to-severe psoriasis patients with LTBI treated with']","['LTBI', 'guselkumab (IL-23 inhibitor', 'tumor necrosis factor (TNF) inhibitors', 'placebo', 'guselkumab and anti-tuberculosis', 'guselkumab, placebo, or adalimumab (TNF inhibitor', 'adalimumab', 'LTBI and received concomitant LTBI treatments (LTBI', 'Placebo→guselkumab', 'guselkumab']","['active TB', 'ALT and AST elevations', 'active TB, including reactivation of LTBI', 'Incidence of active TB, adverse events (AEs), serious AEs (SAEs) and markedly abnormal liver function tests (alanine aminotransferase test [ALT]; aspartate aminotransferase test [AST']","[{'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C1609538', 'cui_str': 'Inactive tuberculosis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C1609538', 'cui_str': 'Inactive tuberculosis'}, {'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C3537192', 'cui_str': 'TNF Antagonists'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1609538', 'cui_str': 'Inactive tuberculosis'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0522501', 'cui_str': 'Massive'}, {'cui': 'C0151766', 'cui_str': 'Liver function tests abnormal'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",130.0,0.0864569,"Through wk100, proportions of patients experiencing AEs and SAEs were comparable between LTBI+ and LTBI- patients. ","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Puig', 'Affiliation': 'Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'T-F', 'Initials': 'TF', 'LastName': 'Tsai', 'Affiliation': 'National Taiwan University Hospital, Taipei, Taiwan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Bhutani', 'Affiliation': 'University of California San Francisco Medical Center, San Francisco, CA, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Uy', 'Affiliation': 'Janssen Scientific Affairs, LLC, Horsham, PA, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ramachandran', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'You', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gooderham', 'Affiliation': 'SKiN Centre for Dermatology, Peterborough, ON, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16460'] 305,31650067,Biobehavioral effects of Tai Chi Qigong in men with prostate cancer: Study design of a three-arm randomized clinical trial.,"Fatigue is often one of the most commonly reported symptoms in prostate cancer survivors, but it is also one of the least understood cancer-related symptoms. Fatigue is associated with psychological distress, disruptions in sleep quality, and impairments in health-related quality of life. Moreover, inflammatory processes and changes related to the hypothalamic-pituitary-adrenal (HPA) axis and/or autonomic nervous system may also play a role in cancer-related fatigue. Thus, effective treatments for fatigue in prostate cancer survivors represent a current unmet need. Prior research has shown that Tai Chi Qigong, a mind-body exercise intervention, can improve physical and emotional health. Herein, we describe the protocol of the ongoing 3-arm randomized controlled Health Empowerment & Recovery Outcomes (HERO) clincal trial. One hundred sixty-six prostate cancer survivors with fatigue are randomized to a modified Tai Chi Qigong intervention (TCQ), intensity-matched body training intervention (BT), or usual care (UC) condition. Guided by biopsychosocial and psychoneuroimmunology models, we propose that TCQ, as compared to BT or UC will: i) reduce fatigue (primary outcome) in prostate cancer survivors; ii) reduce inflammation; and iii) regulate the expression of genes from two major functional clusters: a) inflammation, vasodilation and metabolite sensing and b) energy and adrenergic activation. Assessments are conducted at baseline, the 6-week midpoint of the intervention, and 1 week, 3 months, and 12 months post-intervention. If our findings show that TCQ promotes recovery from prostate cancer and its treatment, this type of intervention can be integrated into survivorship care plans as the standard of care. The study's findings will also provide novel information about underlying biobehavioral mechanisms of cancer-related fatigue. Trial registration number NCT03326713; clinicaltrials.gov.",2019,"Prior research has shown that Tai Chi Qigong, a mind-body exercise intervention, can improve physical and emotional health.","['men with prostate cancer', 'One hundred sixty-six prostate cancer survivors with fatigue', 'prostate cancer survivors']","['TCQ', 'Tai Chi Qigong', 'modified Tai Chi Qigong intervention (TCQ), intensity-matched body training intervention (BT), or usual care (UC) condition']","['Biobehavioral effects', 'sleep quality, and impairments in health-related quality of life']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4517841', 'cui_str': 'Sixty-six'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]","[{'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C0282077', 'cui_str': ""Ch'i Kung""}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}]",,0.0830083,"Prior research has shown that Tai Chi Qigong, a mind-body exercise intervention, can improve physical and emotional health.","[{'ForeName': 'Anita Y', 'Initials': 'AY', 'LastName': 'Kinney', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, Piscataway, NJ, USA.'}, {'ForeName': 'Cindy K', 'Initials': 'CK', 'LastName': 'Blair', 'Affiliation': 'Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.'}, {'ForeName': 'Dolores D', 'Initials': 'DD', 'LastName': 'Guest', 'Affiliation': 'University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'Julianne K', 'Initials': 'JK', 'LastName': 'Ani', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Harding', 'Affiliation': 'University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'Fabiano', 'Initials': 'F', 'LastName': 'Amorim', 'Affiliation': 'Department of Health, Exercise and Sports Sciences, University of New Mexico, Albuquerque, NM, USA.'}, {'ForeName': 'Tawny', 'Initials': 'T', 'LastName': 'Boyce', 'Affiliation': 'University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Rodman', 'Affiliation': 'University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'C Graham', 'Initials': 'CG', 'LastName': 'Ford', 'Affiliation': 'University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Schwartz', 'Affiliation': 'Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Rosenberg', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Foran', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}, {'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Gardner', 'Affiliation': 'Department of Theatre, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health, Rutgers University, Piscataway, NJ, USA.'}, {'ForeName': 'Wadih', 'Initials': 'W', 'LastName': 'Arap', 'Affiliation': 'Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Irwin', 'Affiliation': 'Cousins Center for Psychoneuroimmunology, Semel Institute for Neurosciences, University of California Los Angeles, California, USA.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2019.100431'] 306,32169459,Aquatic Cycling Improves Knee Pain and Physical Functioning in Patients With Knee Osteoarthritis: A Randomized Controlled Trial.,"OBJECTIVE To assess the efficacy of a 12-week aquatic cycling training program for improving knee pain and physical functioning in patients with knee osteoarthritis (OA). DESIGN Two-arm, single-blind, parallel-group randomized controlled trial. SETTINGS OA outpatient clinic of the Maastricht University Medical Center+. PARTICIPANTS Patients (N=111, 50-70y) with unilateral mild-to-moderate knee OA. INTERVENTIONS Participants (aquatic cycling [AC] group, n=55) received AC sessions of 45 min each 2 times per week. Each session combined upright seated cycling with out-of-saddle positions and exercises for the upper and lower body. The usual care (UC) group (n=47) continued with UC and was offered 12 AC sessions in a local swimming pool after their trial participation. MAIN OUTCOME MEASURES The Knee Injury and Osteoarthritis Outcome Score (KOOS) on knee pain and physical function was assessed at baseline, postintervention, and at 24-wk follow-up. Multilevel (mixed regression) analysis examined the effects. RESULTS Average attendance rate for the AC sessions was 80%. Statistically significant differences at postintervention and follow-up were found for knee pain in mean ± SD (UC pretest, 57.89±15.26; posttest, 55.90±18.04; follow-up, 57.24±19.16; and AC pretest, 56.96±12.96; posttest, 63.55±15.33; follow-up, 64.35±17.26; estimate, 8.16; SE, 3.27; 95% confidence interval [CI], 1.67-14.64; effect size [ES], 0.50) and physical functioning (UC pretest, 66.32±16.28; posttest, 66.80±19.04; follow-up, 65.42±17.98; and AC pretest, 61.89±17.151; posttest, 70.14±17.52; follow-up, 69.00±16.84; estimate, 7.16; SE, 3.19; 95% CI, 0.83-13.49; ES, 0.43) in favor of the aquatic group. CONCLUSIONS The results suggest that a 12-week AC training program improves self-reported knee pain and physical functioning in patients with mild-to-moderate knee OA compared to UC.",2020,The results suggest that a 12-week aquatic cycling training programme improves self-reported knee pain and physical functioning in patients with mild to moderate knee OA compared to usual care.,"['patients with mild to moderate knee OA', 'Patients (N=111, 50-70 years old) with unilateral mild to moderate knee OA', 'OA outpatient clinic of the Maastricht University Medical Center', 'patients with knee osteoarthritis']","['aquatic cycling training programme', 'Aquatic cycling', 'aquatic cycling training program', 'aquatic cycling sessions of 45 min twice-weekly', 'usual care group (UC, n=47) continued with usual care and was offered twelve aquatic cycling sessions']","['physical functioning', 'Average attendance rate', 'knee pain', 'knee pain and physical functioning', 'self-reported knee pain and physical functioning', 'Knee Injury and Osteoarthritis Outcome Score (KOOS) on knee pain and physical function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0556985', 'cui_str': 'Two times a week'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0231749', 'cui_str': 'Knee pain (finding)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0022744', 'cui_str': 'Knee Injuries'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0525992,The results suggest that a 12-week aquatic cycling training programme improves self-reported knee pain and physical functioning in patients with mild to moderate knee OA compared to usual care.,"[{'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Rewald', 'Affiliation': 'Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'A F Ton', 'Initials': 'AFT', 'LastName': 'Lenssen', 'Affiliation': 'Department of Physiotherapy, Maastricht University Medical Center+, Maastricht, The Netherlands.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Emans', 'Affiliation': 'Department of Orthopedic Surgery, Maastricht University Medical Center+, Maastricht, The Netherlands.'}, {'ForeName': 'Rob A', 'Initials': 'RA', 'LastName': 'de Bie', 'Affiliation': 'Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'van Breukelen', 'Affiliation': 'Department of Methodology & Statistics, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Mesters', 'Affiliation': 'Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands. Electronic address: ilse.mesters@maastrichtuniversity.nl.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2019.12.023'] 307,31909809,Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils Lowers Atherogenic Lipoprotein Classes Without Increasing Lipoprotein(a).,"BACKGROUND Walnuts have established lipid-/lipoprotein-lowering properties; however, their effect on lipoprotein subclasses has not been investigated. Furthermore, the mechanisms by which walnuts improve lipid/lipoprotein concentrations are incompletely understood. OBJECTIVES We aimed to examine, as exploratory outcomes of this trial, the effect of replacing SFAs with unsaturated fats from walnuts or vegetable oils on lipoprotein subclasses, cholesterol efflux, and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS A randomized, crossover, controlled-feeding study was conducted in individuals at risk of cardiovascular disease (CVD) (n = 34; 62% men; mean ± SD age 44 ± 10 y; BMI: 30.1 ± 4.9 kg/m2). After a 2-wk run-in diet (12% SFAs, 7% PUFAs, 12% MUFAs), subjects consumed the following diets, in randomized order, for 6 wk: 1) walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs [2.7% α-linolenic acid (ALA)], 9% MUFAs]; 2) walnut fatty acid-matched diet [7% SFAs, 16% PUFAs (2.6% ALA), 9% MUFAs]; and 3) oleic acid replaces ALA diet (ORAD) [7% SFAs, 14% PUFAs (0.4% ALA); 12% MUFAs] (all percentages listed are of total kilocalories ). Serum collected after the run-in (baseline) and each diet period was analyzed for lipoprotein classes and subclasses (vertical auto profile), cholesterol efflux, and PCSK9. Linear mixed models were used for data analysis. RESULTS Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed. There were no between-diet differences for HDL-cholesterol or LDL-cholesterol subclasses. Lipoprotein(a) [Lp(a)], cholesterol efflux, and PCSK9 were unchanged after the diets. CONCLUSIONS In individuals at risk of CVD, replacement of SFAs with unsaturated fats from walnuts or vegetable oils improved lipid/lipoprotein classes, including LDL-cholesterol, non-HDL cholesterol, and total cholesterol, without an increase in Lp(a). These improvements were not explained by changes in cholesterol efflux capacity or PCSK9. This trial was registered at clinicaltrials.gov as NCT01235832.",2020,"Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed.","['10', 'individuals at risk of cardiovascular disease (CVD) (n =\xa034; 62% men; mean ± SD age 44\xa0±', 'Lipoprotein(a']","['Replacing Saturated Fats with Unsaturated Fats from Walnuts or Vegetable Oils', 'replacing SFAs with unsaturated fats from walnuts or vegetable oils', 'walnut fatty acid-matched diet [7% SFAs, 16% PUFAs (2.6% ALA), 9% MUFAs]; and 3) oleic acid replaces ALA diet (ORAD) [7% SFAs, 14% PUFAs (0.4% ALA); 12% MUFAs']","['lipid/lipoprotein concentrations', 'lipoprotein subclasses, cholesterol efflux, and proprotein convertase subtilisin/kexin type 9 (PCSK9', 'Lp(a)], cholesterol efflux, and PCSK9', 'cholesterol efflux capacity or PCSK9', 'LDL cholesterol', 'HDL-cholesterol or LDL-cholesterol subclasses', 'ORAD, total cholesterol', 'lipid/lipoprotein classes, including LDL-cholesterol, non-HDL cholesterol, and total cholesterol, without an increase in Lp(a', 'non-HDL cholesterol']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0597423', 'cui_str': 'Fatty Acids, Saturated'}, {'cui': 'C0015678', 'cui_str': 'Fats, Unsaturated'}, {'cui': 'C0993635', 'cui_str': 'English walnut'}, {'cui': 'C0042438', 'cui_str': 'Vegetable Oils'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C4517633', 'cui_str': 'Two point six'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0445604', 'cui_str': 'Subclass (attribute)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C1100660', 'cui_str': 'Proprotein Convertases'}, {'cui': 'C0038601', 'cui_str': 'Subtilisins'}, {'cui': 'C0165249', 'cui_str': 'kexin protein, S cerevisiae'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",,0.158711,"Compared with the ORAD, total cholesterol (mean ± SEM -8.9± 2.3 mg/dL; -5.1%; P < 0.001), non-HDL cholesterol (-7.4 ± 2.0 mg/dL; -5.4%; P = 0.001), and LDL cholesterol (-6.9 ± 1.9 mg/dL; -6.5%; P = 0.001) were lower after the WD; no other pairwise differences existed.","[{'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kristina S', 'Initials': 'KS', 'LastName': 'Petersen', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz313'] 308,31909811,Provision of Lipid-Based Nutrient Supplements to Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting: Secondary Outcomes of a Randomized Trial.,"BACKGROUND Diet may alter the configuration of gut microbiota, but the impact of prenatal and postnatal nutritional interventions on infant gut microbiota has not been investigated. OBJECTIVE We evaluated whether providing lipid-based nutrient supplements (LNSs) to mother-infant dyads promotes a more diverse and mature infant gut microbiota, compared to maternal supplementation with multiple micronutrients (MMN) or iron and folic acid (IFA). METHODS We enrolled 869 pregnant women in a randomized trial in Malawi. There were 3 study groups, with women receiving 1 MMN capsule daily during pregnancy and 6 mo postpartum, or 1 LNS sachet (20 g) daily during pregnancy and 6 mo postpartum, or 1 IFA capsule daily (during pregnancy) then a placebo daily (postpartum). Infants in the LNS group received LNS from 6 to 18 mo; infants in the other groups did not receive supplements. The infants' fecal microbiota were characterized by PCR amplification and sequencing of the bacterial 16S rRNA gene (variable region 4). The primary outcomes were microbiota α diversity and maturation [as microbiota-for-age z score (MAZ)]. Specific associations of taxa with intervention were established with indicator species analysis (ISA). RESULTS Primary outcomes did not differ between IFA and MMN groups, so these groups were combined (IFA + MMN). Mean ± SD α diversity was higher in the LNS group at 18 mo for Shannon index [3.01 ± 0.57 (LNS) compared with 2.91 ± 0.60 (IFA + MMN), P = 0.032] and Pielou's evenness index [0.61 ± 0.08 (LNS) compared with 0.60 ± 0.09 (IFA + MMN), P = 0.043]; no significant differences were observed at 1, 6, 12, or 30 mo. MAZ and β diversity did not differ at any age. We found 10 and 3 operational taxonomic units (OTUs) positively associated with LNS and IFA + MMN, respectively; however, these associations became nonsignificant following false discovery rate correction at 10%. CONCLUSIONS Prenatal and postnatal LNS intake promoted infant gut microbiota diversity at 18 mo, after 12 mo of child supplementation, but did not alter microbiota maturation. This trial was registered at clinicaltrials.gov as NCT01239693.",2020,"We found 10 and 3 operational taxonomic units (OTUs) positively associated with LNS and IFA + MMN, respectively; however, these associations became nonsignificant following false discovery rate correction at 10%. ","['women receiving 1 MMN capsule daily during pregnancy and 6\xa0mo postpartum, or 1 LNS sachet (20 g) daily during pregnancy and 6', '869 pregnant women in a randomized trial in Malawi', 'Mothers During Pregnancy and 6 Months Postpartum and to Their Infants from 6 to 18 Months Promotes Infant Gut Microbiota Diversity at 18 Months of Age but Not Microbiota Maturation in a Rural Malawian Setting']","['Lipid-Based Nutrient Supplements', 'lipid-based nutrient supplements (LNSs', 'maternal supplementation with multiple micronutrients (MMN) or iron and folic acid (IFA', 'Prenatal and postnatal LNS intake', 'LNS']","['microbiota α diversity and maturation [as microbiota-for-age z score (MAZ', 'SD α diversity', 'Mean\xa0±', 'infant gut microbiota diversity', 'microbiota maturation']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C4319662', 'cui_str': 'Sachet'}, {'cui': 'C0450403', 'cui_str': '20G (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0024548', 'cui_str': 'Republic of Malawi'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}]","[{'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}]",869.0,0.248488,"We found 10 and 3 operational taxonomic units (OTUs) positively associated with LNS and IFA + MMN, respectively; however, these associations became nonsignificant following false discovery rate correction at 10%. ","[{'ForeName': 'Arox W', 'Initials': 'AW', 'LastName': ""Kamng'ona"", 'Affiliation': 'Department of Biomedical Sciences, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Young', 'Affiliation': 'Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA 95616, USA.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Arnold', 'Affiliation': 'Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA 95616, USA.'}, {'ForeName': 'Noel', 'Initials': 'N', 'LastName': 'Patson', 'Affiliation': 'School of Public Health and Family Medicine, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Josh M', 'Initials': 'JM', 'LastName': 'Jorgensen', 'Affiliation': 'Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA 95616, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Kortekangas', 'Affiliation': 'Center for Child Health Research, University of Tampere Faculty of Medicine and Life Sciences, 33100 Tampere, Finland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Chaima', 'Affiliation': 'School of Public Health and Family Medicine, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Chikondi', 'Initials': 'C', 'LastName': 'Malamba', 'Affiliation': 'School of Public Health and Family Medicine, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Ashorn', 'Affiliation': 'Center for Child Health Research, University of Tampere Faculty of Medicine and Life Sciences, 33100 Tampere, Finland.'}, {'ForeName': 'Yin B', 'Initials': 'YB', 'LastName': 'Cheung', 'Affiliation': 'Program in Health Services & Systems Research and Center for Quantitative Medicine, Duke-NUS Medical School, Singapore 169857.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ashorn', 'Affiliation': 'Center for Child Health Research, University of Tampere Faculty of Medicine and Life Sciences, 33100 Tampere, Finland.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Maleta', 'Affiliation': 'School of Public Health and Family Medicine, University of Malawi, College of Medicine, Blantyre, Malawi.'}, {'ForeName': 'Kathryn G', 'Initials': 'KG', 'LastName': 'Dewey', 'Affiliation': 'Institute for Global Nutrition and Department of Nutrition, University of California, Davis, Davis, CA 95616, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz298'] 309,31677583,Ethnicity and health outcomes among people with epilepsy participating in an epilepsy self-management RCT.,"People with epilepsy (PWE) may experience negative health events (NHEs) such as seizures, emergency room visits, and hospitalizations, with ethnic and racial minorities disproportionately affected. Epilepsy self-management may reduce NHEs; however, few reports examine self-management outcomes in racial minorities. Using data from a longitudinal 6-month randomized controlled trial (RCT) of 120 PWE, this analysis compared African-American and Whites at baseline, 10 weeks and 24 weeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program. The primary RCT outcome was number of NHEs. At baseline, compared to Whites, African-Americans had less education (p = 0.02) and greater depressive severity (p = 0.04). Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses. Given known racial disparities in epilepsy care, it may be particularly important to reach out to minority PWE with self-management programs.",2019,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","['African-American and Whites at baseline, 10\u202fweeks and 24\u202fweeks after receiving the ""Self-management for people with epilepsy (SMART) and a history of NHEs"" self-management program', 'People with epilepsy (PWE', 'people with epilepsy participating in an epilepsy self-management RCT']",[],"['number of NHEs', 'Ethnicity and health outcomes', 'depressive severity']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",[],"[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.0414492,"Both African-American and Whites generally improved with SMART, and there were no racial differences in NHE counts or other outcomes' responses.","[{'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Aebi', 'Affiliation': 'Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Lu', 'Affiliation': 'Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Burant', 'Affiliation': 'Case Western Reserve University, Frances Payne Bolton School of Nursing, Cleveland, Ohio, USA.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Sajatovic', 'Affiliation': 'Department of Psychiatry and of Neurology, Neurological & Behavioral Outcomes Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Electronic address: Martha.Sajatovic@uhhospitals.org.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106469'] 310,31848609,"Walnuts and Vegetable Oils Containing Oleic Acid Differentially Affect the Gut Microbiota and Associations with Cardiovascular Risk Factors: Follow-up of a Randomized, Controlled, Feeding Trial in Adults at Risk for Cardiovascular Disease.","BACKGROUND It is unclear whether the favorable effects of walnuts on the gut microbiota are attributable to the fatty acids, including α-linolenic acid (ALA), and/or the bioactive compounds and fiber. OBJECTIVE This study examined between-diet gut bacterial differences in individuals at increased cardiovascular risk following diets that replace SFAs with walnuts or vegetable oils. METHODS Forty-two adults at cardiovascular risk were included in a randomized, crossover, controlled-feeding trial that provided a 2-wk standard Western diet (SWD) run-in and three 6-wk isocaloric study diets: a diet containing whole walnuts (WD; 57-99 g/d walnuts; 2.7% ALA), a fatty acid-matched diet devoid of walnuts (walnut fatty acid-matched diet; WFMD; 2.6% ALA), and a diet replacing ALA with oleic acid without walnuts (oleic acid replaces ALA diet; ORAD; 0.4% ALA). Fecal samples were collected following the run-in and study diets to assess gut microbiota with 16S rRNA sequencing and Qiime2 for amplicon sequence variant picking. RESULTS Subjects had elevated BMI (30 ± 1 kg/m2), blood pressure (121 ± 2/77 ± 1 mmHg), and LDL cholesterol (120 ± 5 mg/dL). Following the WD, Roseburia [relative abundance (RA) = 4.2%, linear discriminant analysis (LDA) = 4], Eubacterium eligensgroup (RA = 1.4%, LDA = 4), LachnospiraceaeUCG001 (RA = 1.2%, LDA = 3.2), Lachnospiraceae UCG004 (RA = 1.0%, LDA = 3), and Leuconostocaceae (RA = 0.03%, LDA = 2.8) were most abundant relative to taxa in the SWD (P ≤ 0.05 for all). The WD was also enriched in Gordonibacter relative to the WFMD. Roseburia (3.6%, LDA = 4) and Eubacterium eligensgroup (RA = 1.5%, LDA = 3.4) were abundant following the WFMD, and Clostridialesvadin BB60group (RA = 0.3%, LDA = 2) and gutmetagenome (RA = 0.2%, LDA = 2) were most abundant following the ORAD relative to the SWD (P ≤ 0.05 for all). Lachnospiraceae were inversely correlated with blood pressure and lipid/lipoprotein measurements following the WD. CONCLUSIONS The results indicate similar enrichment of Roseburia following the WD and WFMD, which could be explained by the fatty acid composition. Gordonibacter enrichment and the inverse association between Lachnospiraceae and cardiovascular risk factors following the WD suggest that the gut microbiota may contribute to the health benefits of walnut consumption in adults at cardiovascular risk. This trial was registered at clinicaltrials.gov as NCT02210767.",2020,"RESULTS Subjects had elevated BMI (30 ± 1 kg/m2), blood pressure (121 ± 2/77 ± ","['Forty-two adults at cardiovascular risk', 'Subjects had elevated BMI (30\xa0±\xa01\xa0kg/m2), blood pressure (121\xa0±\xa02/77\xa0±', 'individuals at increased cardiovascular risk following diets that replace', 'adults at cardiovascular risk', 'Adults at Risk for Cardiovascular Disease']","['2-wk standard Western diet (SWD) run-in and three 6-wk isocaloric study diets: a diet containing whole walnuts (WD; 57-99\xa0g/d walnuts; 2.7% ALA), a fatty acid-matched diet devoid of walnuts (walnut fatty acid-matched diet; WFMD; 2.6% ALA), and a diet replacing ALA with oleic acid without walnuts (oleic acid replaces ALA diet; ORAD', 'SFAs with walnuts or vegetable oils', 'Walnuts and Vegetable Oils Containing Oleic Acid']","['LDL cholesterol', 'Eubacterium eligensgroup', 'blood pressure and lipid/lipoprotein measurements', 'Lachnospiraceae UCG004']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3849996', 'cui_str': 'Western Dietary Pattern'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0993635', 'cui_str': 'English walnut'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4517633', 'cui_str': 'Two point six'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C0042438', 'cui_str': 'Vegetable Oils'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0015146', 'cui_str': 'Eubacterium'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0523753', 'cui_str': 'Lipoproteins measurement (procedure)'}, {'cui': 'C1210564', 'cui_str': 'Lachnospiraceae'}]",42.0,0.0586296,"RESULTS Subjects had elevated BMI (30 ± 1 kg/m2), blood pressure (121 ± 2/77 ± ","[{'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'McLimans', 'Affiliation': 'Department of Biology, Juniata College, Huntingdon, PA, USA.'}, {'ForeName': 'Kristina S', 'Initials': 'KS', 'LastName': 'Petersen', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Lamendella', 'Affiliation': 'Department of Biology, Juniata College, Huntingdon, PA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz289'] 311,32006028,Lipid-Based Nutrient Supplementation Reduces Child Anemia and Increases Micronutrient Status in Madagascar: A Multiarm Cluster-Randomized Controlled Trial.,"BACKGROUND Iron deficiency anemia affects hundreds of millions of women and children worldwide and is associated with impaired infant outcomes. Small-quantity lipid-based nutrient supplement (LNS) have been found to reduce the prevalence of anemia and iron deficiency in some trials. OBJECTIVES We evaluated the effectiveness of daily LNS supplementation on child anemia and micronutrient status in Madagascar within the context of an existing, scaled-up nutrition program. METHODS We cluster-randomized 125 communities to (T0) a routine program with monthly growth monitoring and nutrition education; (T1) T0 + home visits for intensive nutrition counselling; (T2) T1 + LNS for children aged 6-18 mo; (T3) T2 + LNS for pregnant/lactating women; or (T4) T1 + parenting messages. Pregnant women and infants aged <12 mo were enrolled in 2014 and followed for 2 y. Child outcome measures included hemoglobin and anemia assessed using the HemoCue 301 system (n = 3561), and serum ferritin and soluble transferrin receptor as markers of iron status, retinol-binding protein as a marker of vitamin A status, and C-reactive protein and α-1 acid glycoprotein from a finger stick blood draw among a subsample (n = 387). We estimated mean difference using linear regression and prevalence ratios using modified Poisson regression accounting for the clustered design. All analyses were intention-to-treat. RESULTS Children in the LNS groups (T2 and T3) had ∼40% lower prevalence of anemia and iron deficiency anemia and 25% lower prevalence of iron deficiency than children in the control group (T0) (P < 0.05 for all). There were no differences in any of the biomarkers when comparing children in the T4 group with those in T0; nor were there differences between T3 and T2. CONCLUSIONS Our findings suggest the provision of LNS in the context of a large-scale program offers significant benefits on anemia and iron status in young children.This trial was registered at www.isrctn.com as ISRCTN14393738.",2020,"There were no differences in any of the biomarkers when comparing children in the T4 group with those in T0; nor were there differences between T3 and T2. ","['Madagascar', 'young children', 'Pregnant women and infants aged <12\xa0mo were enrolled in 2014 and followed for 2 y. Child outcome measures included hemoglobin and anemia assessed using the HemoCue 301 system (n\xa0=\xa03561), and serum ferritin and soluble transferrin receptor as markers of iron status, retinol-binding protein as a marker of vitamin A status, and C-reactive protein and α-1 acid glycoprotein from a finger stick blood draw among a subsample (n\xa0=\xa0387']","['Lipid-Based Nutrient Supplementation', 'routine program with monthly growth monitoring and nutrition education; (T1) T0\xa0+\xa0home visits for intensive nutrition counselling; (T2) T1\xa0+\xa0LNS for children aged 6-18\xa0mo; (T3) T2\xa0+\xa0LNS for pregnant/lactating women; or (T4) T1', 'daily LNS supplementation', 'Small-quantity lipid-based nutrient supplement (LNS']","['prevalence of anemia and iron deficiency anemia', 'anemia and iron status', 'prevalence of iron deficiency']","[{'cui': 'C0024443', 'cui_str': 'Malagasy Republic'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble (substance)'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1446172', 'cui_str': 'Retinol binding protein measurement (procedure)'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0017968', 'cui_str': 'Glycoproteins'}, {'cui': 'C0457575', 'cui_str': 'Finger-prick sampling (procedure)'}, {'cui': 'C0190979', 'cui_str': 'Venesection'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1265611', 'cui_str': 'Quantity finding'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0240066', 'cui_str': 'Iron deficiency (disorder)'}]",125.0,0.234137,"There were no differences in any of the biomarkers when comparing children in the T4 group with those in T0; nor were there differences between T3 and T2. ","[{'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Lia C H', 'Initials': 'LCH', 'LastName': 'Fernald', 'Affiliation': 'Division of Community Health Sciences, School of Public Health, University of California Berkeley, Berkeley, CA, USA.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Weber', 'Affiliation': 'School of Community Health Sciences, University of Nevada Reno, Reno, NV, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Arnold', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Galasso', 'Affiliation': 'Development Research Group, The World Bank, Washington, DC, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz320'] 312,32279690,Resistant starch supplementation increases crypt cell proliferative state in the rectal mucosa of older healthy participants.,"There is strong evidence that foods containing dietary fibre protect against colorectal cancer, resulting at least in part from its anti-proliferative properties. This study aimed to investigate the effects of supplementation with two non-digestible carbohydrates, resistant starch (RS) and polydextrose (PD), on crypt cell proliferative state (CCPS) in the macroscopically normal rectal mucosa of healthy individuals. We also investigated relationships between expression of regulators of apoptosis and of the cell cycle on markers of CCPS. Seventy-five healthy participants were supplemented with RS and/or PD or placebo for 50 d in a 2 × 2 factorial design in a randomised, double-blind, placebo-controlled trial (the Dietary Intervention, Stem cells and Colorectal Cancer (DISC) Study). CCPS was assessed, and the expression of regulators of the cell cycle and of apoptosis was measured by quantitative PCR in rectal mucosal biopsies. SCFA concentrations were quantified in faecal samples collected pre- and post-intervention. Supplementation with RS increased the total number of mitotic cells within the crypt by 60 % (P = 0·001) compared with placebo. This effect was limited to older participants (aged ≥50 years). No other differences were observed for the treatments with PD or RS as compared with their respective controls. PD did not influence any of the measured variables. RS, however, increased cell proliferation in the crypts of the macroscopically-normal rectum of older adults. Our findings suggest that the effects of RS on CCPS are not only dose, type of RS and health status-specific but are also influenced by age.",2020,Supplementation with RS increased the total number of mitotic cells within the crypt by 60% (p=0.001) compared with placebo.,"['75 healthy participants', 'older participants (aged ≥50', 'older healthy participants', 'macroscopically-normal rectal mucosa of healthy individuals']","['RS and/or PD or placebo', 'supplementation with two non-digestible carbohydrates, resistant starch (RS) and polydextrose (PD', 'Resistant starch supplementation', 'placebo']","['expression of regulators of the cell cycle and of apoptosis', 'SCFA concentrations', 'total number of mitotic cells', 'crypt cell proliferative state (CCPS', 'cell proliferation', 'crypt cell proliferative state']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0227395', 'cui_str': 'Rectal mucous membrane structure'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0071545', 'cui_str': 'polydextrose'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0015691', 'cui_str': 'Short chain fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0230518', 'cui_str': 'Mitotic cell'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0596290', 'cui_str': 'Cellular Proliferation'}]",75.0,0.290488,Supplementation with RS increased the total number of mitotic cells within the crypt by 60% (p=0.001) compared with placebo.,"[{'ForeName': 'Fiona C', 'Initials': 'FC', 'LastName': 'Malcomson', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle upon TyneNE2 4HH, UK.'}, {'ForeName': 'Naomi D', 'Initials': 'ND', 'LastName': 'Willis', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle upon TyneNE2 4HH, UK.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'McCallum', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, North ShieldsNE29 8NH, UK.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle upon TyneNE2 4HH, UK.'}, {'ForeName': 'Arthur C', 'Initials': 'AC', 'LastName': 'Ouwehand', 'Affiliation': 'DuPont Nutrition & Biosciences, 02460Kantvik, Finland.'}, {'ForeName': 'Julian D', 'Initials': 'JD', 'LastName': 'Stowell', 'Affiliation': 'DuPont Nutrition & Biosciences, ReigateRH2 9PQ, UK.'}, {'ForeName': 'Seamus', 'Initials': 'S', 'LastName': 'Kelly', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, North ShieldsNE29 8NH, UK.'}, {'ForeName': 'D Michael', 'Initials': 'DM', 'LastName': 'Bradburn', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, AshingtonNE63 9JJ, UK.'}, {'ForeName': 'Nigel J', 'Initials': 'NJ', 'LastName': 'Belshaw', 'Affiliation': 'University of East Anglia, Norwich Research Park, NorwichNR4 7TJ, UK.'}, {'ForeName': 'Ian T', 'Initials': 'IT', 'LastName': 'Johnson', 'Affiliation': 'Quadram Institute, Norwich Research Park, NorwichNR4 7UQ, UK.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Mathers', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle upon TyneNE2 4HH, UK.'}]",The British journal of nutrition,['10.1017/S0007114520001312'] 313,32128957,"Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.","AIMS To determine the optimal dose(s) of once-monthly administration of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. MATERIALS AND METHODS In this phase 2, randomized, placebo-controlled, double-blind trial (NCT02081118), patients were randomized 1:1:1:1 to subcutaneous efpeglenatide (8, 12 or 16 mg once monthly; n = 158) or placebo (n = 51). The 16-week treatment period included a 4-week titration phase with once-weekly efpeglenatide 4 mg, followed by one dose of efpeglenatide 8 mg once monthly and two doses of the assigned once-monthly dose. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to week 17. RESULTS All efpeglenatide doses significantly reduced HbA1c versus placebo (P < 0.0001 for all). Overall, the least squares mean difference in HbA1c reductions between efpeglenatide and placebo was -7.7 mmol/mol (-0.71%; baseline to week 17). At week 17, a significantly greater proportion of efpeglenatide patients had an HbA1c level <53 mmol/mol (<7%) versus placebo (48.7% vs. 30.6%; P = 0.0320). Significant body weight loss occurred across all efpeglenatide doses (placebo-corrected reduction -2.0 kg [efpeglenatide overall]; P = 0.0003). The safety profile was consistent with GLP-1RAs, with gastrointestinal (GI) disorders being the most common treatment-emergent adverse events. Fluctuations in effects on glucose levels and rates of GI events occurred between peak and trough efpeglenatide concentrations. CONCLUSIONS Efpeglenatide once monthly (following once-weekly titration) has significant benefits with regard to HbA1c and weight reduction versus placebo in patients with T2D. Further studies are needed to evaluate the long-term efficacy and safety of efpeglenatide once monthly.",2020,All efpeglenatide doses significantly reduced HbA1c versus placebo (P < 0.0001 for all).,"['patients with type 2 diabetes', 'patients with type 2 diabetes inadequately controlled on']","['metformin', 'subcutaneous efpeglenatide', 'placebo', 'Efpeglenatide QM', 'efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA', '4-week titration phase with once-weekly (QW) efpeglenatide 4\u2009mg, followed by one dose of efpeglenatide 8\u2009mg QM']","['change in HbA1c', 'Efficacy and safety', 'HbA1c and weight reduction', 'HbA1c reductions', 'Significant body weight loss', 'glucose levels and rates of gastrointestinal events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0378073', 'cui_str': 'GLP-1 Receptor'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0558293', 'cui_str': 'Once a week (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",,0.613438,All efpeglenatide doses significantly reduced HbA1c versus placebo (P < 0.0001 for all).,"[{'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Del Prato', 'Affiliation': 'Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Jahoon', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Hanmi Pharmaceutical Co., Ltd, Seoul, South Korea.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Trautmann', 'Affiliation': 'ProSciento, Chula Vista, California.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Sanofi Canada, Laval, Quebec, Canada.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Sorli', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Derwahl', 'Affiliation': 'IKFE Berlin GmbH Institute for Clinical Research and Development, Berlin, Germany.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Soto', 'Affiliation': 'Servicio de Endocrinología y Nutrición, Hospital de A Coruña, La Coruña, Spain.'}, {'ForeName': 'Kun-Ho', 'Initials': 'KH', 'LastName': 'Yoon', 'Affiliation': 'The Catholic University of Korea, Seoul, South Korea.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14020'] 314,32290880,Using fundraising incentives and point-of-purchase nutrition promotion to improve food choices among school families in restaurants: a pilot and feasibility study.,"OBJECTIVE To assess the feasibility and efficacy of in-restaurant interventions aiming to promote healthy choices via fundraising incentives benefiting school wellness programmes and point-of-purchase nutrition promotion. DESIGN Twelve schools were randomly assigned to one of the two intervention periods: Fundraising Incentive (FI) donated funds for visiting the study restaurant and Fundraising-Healthy Eating Incentive (F-HEI) included FI with additional funds given when selecting a healthier item. Both conditions included point-of-purchase nutrition promotions. Families were recruited to attend their designated intervention and complete a survey. Feasibility was assessed based on recruitment and participation, implementation fidelity and intervention acceptability. Efficacy was assessed by comparing participant receipts between intervention periods and by comparing overall restaurant sales during intervention v. two no-intervention time frames. SETTING Fast-casual restaurant in Southern California. PARTICIPANTS Parents with children attending participating schools. RESULTS Eighty-one families visited the restaurant during the intervention, with sixty-six completing surveys. All study activities were implemented successfully, but school family participation in the intervention was low (0·95 %). Among participants completing surveys, all indicated satisfaction with the programme. The percentage of healthier items ordered was significantly greater during both FI (χ2 = 5·97, P = 0·01) and F-HEI (χ2 = 8·84, P = 0·003) v. Comparison 2. Results were similar but did not reach statistical significance when comparing the interventions to Comparison 1. CONCLUSIONS Results support potential efficacy of this programme, but more research is needed to inform feasibility. Fidelity and acceptability data supported feasibility, but participation rates were low in this initial study. Methods evaluating this intervention with a greater proportion of parents should be considered.",2020,"The percentage of healthier items ordered was significantly greater during both FI (χ2 = 5·97, P = 0·01) and F-HEI (χ2 = 8·84, P = 0·003) v. Comparison 2.","['Eighty-one families visited the restaurant during the intervention, with sixty-six completing surveys', 'Fast-casual restaurant in Southern California', 'Parents with children attending participating schools', 'school families in restaurants', 'Twelve schools']","['restaurant interventions', 'fundraising incentives and point-of-purchase nutrition promotion', 'Fundraising Incentive (FI) donated funds for visiting the study restaurant and Fundraising-Healthy Eating Incentive (F-HEI) included FI with additional funds given when selecting a healthier item']","['percentage of healthier items ordered', 'Efficacy', 'recruitment and participation, implementation fidelity and intervention acceptability']","[{'cui': 'C4517884', 'cui_str': '81'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035255', 'cui_str': 'Restaurant'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0035255', 'cui_str': 'Restaurant'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0016816', 'cui_str': 'Fund Raising'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1947971', 'cui_str': 'Give'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C4284072', 'cui_str': 'Order document'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",81.0,0.0238933,"The percentage of healthier items ordered was significantly greater during both FI (χ2 = 5·97, P = 0·01) and F-HEI (χ2 = 8·84, P = 0·003) v. Comparison 2.","[{'ForeName': 'Shawna L', 'Initials': 'SL', 'LastName': 'McNally', 'Affiliation': 'Department of Research, Accents on Health, Inc. (dba Healthy Dining), San Diego, CA92123, USA.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Anzman-Frasca', 'Affiliation': 'Department of Pediatrics, University at Buffalo, Buffalo, NY14214, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Bowman', 'Affiliation': 'Virginia Department of Education, James Monroe Building, Richmond, VA23219, USA.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Beleche', 'Affiliation': 'Department of Research, Accents on Health, Inc. (dba Healthy Dining), San Diego, CA92123, USA.'}, {'ForeName': 'Sara C', 'Initials': 'SC', 'LastName': 'Folta', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA02111, USA.'}, {'ForeName': 'Anjali A', 'Initials': 'AA', 'LastName': 'Patel', 'Affiliation': 'Department of Research, Accents on Health, Inc. (dba Healthy Dining), San Diego, CA92123, USA.'}]",Public health nutrition,['10.1017/S1368980019004609'] 315,31868632,"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.","BACKGROUND Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin lymphoma. In the FLYER trial, we assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis. METHODS This two-arm, open-label, international, multicentre, prospective, randomised phase 3 non-inferiority trial was done at 138 clinical sites in Denmark, Israel, Italy, Norway, and Germany. We enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7·5 cm). Randomisation was computer-based and done centrally in a 1:1 ratio using the Pocock minimisation algorithm after stratification for centres, stage (I vs II), and extralymphatic sites (no vs yes). Patients were assigned to receive either six cycles of R-CHOP or four cycles of R-CHOP plus two doses of rituximab. CHOP comprised cyclophosphamide (750 mg/m 2 ), doxorubicin (50 mg/m 2 ), and vincristine (1·4 mg/m 2 , with a maximum total dose of 2 mg), all administered intravenously on day 1, plus oral prednisone or prednisolone at the discretion of the investigator (100 mg) administered on days 1-5. Rituximab was given at a dose of 375 mg/m 2 of body surface area. Cycles were repeated every 21 days. No radiotherapy was planned except for testicular lymphoma treatment. The primary endpoint was progression-free survival after 3 years. The primary analysis was done in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned treatment. A non-inferiority margin of -5·5% was chosen. The trial, which is completed, was prospectively registered at ClinicalTrials.gov, NCT00278421. FINDINGS Between Dec 2, 2005, and Oct 7, 2016, 592 patients were enrolled, of whom 295 patients were randomly assigned to receive six cycles of R-CHOP and 297 were assigned to receive four cycles of R-CHOP plus two doses of rituximab. Four patients in the four-cycles group withdrew informed consent before the start of treatment, so 588 patients were included in the intention-to-treat analysis. After a median follow-up of 66 months (IQR 42-100), 3-year progression-free survival of patients who had four cycles of R-CHOP plus two doses of rituximab was 96% (95% CI 94-99), which was 3% better (lower limit of the one-sided 95% CI for the difference was 0%) than six cycles of R-CHOP, demonstrating the non-inferiority of the four-cycles regimen. 294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group. Two patients, both in the six-cycles group, died during study therapy. INTERPRETATION In young patients with aggressive B-cell non-Hodgkin lymphoma and favourable prognosis, four cycles of R-CHOP is non-inferior to six cycles of R-CHOP, with relevant reduction of toxic effects. Thus, chemotherapy can be reduced without compromising outcomes in this population. FUNDING Deutsche Krebshilfe.",2019,294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group.,"['young patients with aggressive B-cell non-Hodgkin lymphoma', '138 clinical sites in Denmark, Israel, Italy, Norway, and Germany', 'patients with aggressive B-cell lymphoma with favourable prognosis (FLYER', '588 patients were included in the intention-to-treat analysis', 'aggressive B-cell non-Hodgkin lymphoma', '592 patients were enrolled, of whom 295 patients', 'enrolled patients aged 18-60 years, with stage I-II disease, normal serum lactate dehydrogenase concentration, ECOG performance status 0-1, and without bulky disease (maximal tumour diameter <7·5 cm']","['prednisone or prednisolone', 'CHOP comprised cyclophosphamide', 'doxorubicin', 'Rituximab', 'R-CHOP or four cycles of R-CHOP plus two doses of rituximab', 'R-CHOP plus two doses of rituximab', 'vincristine', 'radiotherapy', 'R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone', 'rituximab', 'CHOP chemotherapy']","['progression-free survival', 'Safety', '294 haematological and 1036 non-haematological adverse events', '3-year progression-free survival']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0024305', 'cui_str': ""Lymphoma, Nonhodgkin's""}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0028423', 'cui_str': 'Kingdom of Norway'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0079731', 'cui_str': 'B-Cell Lymphomas'}, {'cui': 'C0033325', 'cui_str': 'Prognosis'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C1278052', 'cui_str': 'Serum lactate dehydrogenase measurement'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",588.0,0.372173,294 haematological and 1036 non-haematological adverse events were documented in the four-cycles group compared with 426 haematological and 1280 non-haematological adverse events in the six-cycles group.,"[{'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Poeschel', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany. Electronic address: viola.poeschel@uks.eu.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Held', 'Affiliation': 'Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany. Electronic address: gheld@westpfalz-klinikum.de.'}, {'ForeName': 'Marita', 'Initials': 'M', 'LastName': 'Ziepert', 'Affiliation': 'Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Witzens-Harig', 'Affiliation': 'Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Holte', 'Affiliation': 'Department of Oncology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'Thurner', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Borchmann', 'Affiliation': 'Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Viardot', 'Affiliation': 'Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Soekler', 'Affiliation': 'Department of Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Keller', 'Affiliation': 'Department of Internal Medicine III, Klinikum Rechts der Isar der TU München, Munich, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schmidt', 'Affiliation': 'Department of Medicine III, University Hospital, Munich, Germany.'}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'Truemper', 'Affiliation': 'Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Mahlberg', 'Affiliation': 'Department of Internal Medicine I, Klinikum Mutterhaus der Borromaerinnen, Trier, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Marks', 'Affiliation': 'Department of Hematology and Oncology, University Medical Center, Freiburg, Germany.'}, {'ForeName': 'Heinz-Gert', 'Initials': 'HG', 'LastName': 'Hoeffkes', 'Affiliation': 'Klinikum Fulda Tumorklinik, Fulda, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Metzner', 'Affiliation': 'Department of Hematology and Oncology, Klinikum Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Dierlamm', 'Affiliation': 'Department of Internal Medicine II, University Hospital Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Frickhofen', 'Affiliation': 'Department of Internal Medicine III, Dr Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Haenel', 'Affiliation': 'Department of Internal Medicine III, Küchwald Hospital Chemnitz, Chemnitz, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Neubauer', 'Affiliation': 'Department of Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kneba', 'Affiliation': 'Department of Internal Medicine II, City Hospital Kiel, Kiel, Germany.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Merli', 'Affiliation': 'Hematology Azienda Unità Sanitarie Locali-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Tucci', 'Affiliation': 'Hematology Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'de Nully Brown', 'Affiliation': 'Department of Hematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Federico', 'Affiliation': 'Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, University of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Lengfelder', 'Affiliation': 'Department of Internal Medicine III, University Hospital Mannheim, Mannheim, Germany.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'di Rocco', 'Affiliation': 'Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Trappe', 'Affiliation': 'Department of Internal Medicine II, Evangelisches Diakonie-Krankenhaus, Bremen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Rosenwald', 'Affiliation': 'Institute of Pathology, University of Wuerzburg, and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Berdel', 'Affiliation': 'Department of Radiooncology, Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Maisenhoelder', 'Affiliation': 'Department of Oncology, University Hospital of North Norway, Tromsø, Norway.'}, {'ForeName': 'Ofer', 'Initials': 'O', 'LastName': 'Shpilberg', 'Affiliation': 'Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tiqwa, Israel.'}, {'ForeName': 'Josif', 'Initials': 'J', 'LastName': 'Amam', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Christofyllakis', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hartmann', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Murawski', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': 'Maike', 'Initials': 'M', 'LastName': 'Nickelsen', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Wulf', 'Affiliation': 'Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany.'}, {'ForeName': 'Bertram', 'Initials': 'B', 'LastName': 'Glass', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Schmitz', 'Affiliation': 'Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Altmann', 'Affiliation': 'Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Loeffler', 'Affiliation': 'Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pfreundschuh', 'Affiliation': 'Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)33008-9'] 316,31182491,Effects of a Mediterranean Eating Plan on the Need for Glucose-Lowering Medications in Participants With Type 2 Diabetes: A Subgroup Analysis of the PREDIMED Trial.,"OBJECTIVE To examine the effects of two Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan on the need for glucose-lowering medications. RESEARCH DESIGN AND METHODS From the Prevención con Dieta Mediterránea (PREDIMED) trial, we selected 3,230 participants with type 2 diabetes at baseline. These participants were randomly assigned to one of three eating plans: Med-EatPlan supplemented with extra-virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control). In a subgroup (15%), the allocation was done in small clusters instead of using individual randomization, and the clustering effect was taken into account in the statistical analysis. In multivariable time-to-event survival models, we assessed two outcomes: 1 ) introduction of the first glucose-lowering medication (oral or injectable) among participants on lifestyle management at enrollment and 2 ) insulin initiation. RESULTS After a median follow-up of 3.2 years, in multivariable analyses adjusting for baseline characteristics and propensity scores, the hazard ratios (HRs) of starting a first glucose-lowering medication were 0.78 (95% CI 0.62-0.98) for Med-EatPlan + EVOO and 0.89 (0.71-1.12) for Med-EatPlan + nuts, compared with the control eating plan. After a median follow-up of 5.1 years, the adjusted HRs of starting insulin treatment were 0.87 (0.68-1.11) for Med-EatPlan + EVOO and 0.89 (0.69-1.14) for Med-EatPlan + nuts compared with the control eating plan. CONCLUSIONS Among participants with type 2 diabetes, a Med-EatPlan + EVOO may delay the introduction of new-onset glucose-lowering medications. The Med-EatPlan did not result in a significantly lower need for insulin.",2019,The Med-EatPlan did not result in a significantly lower need for insulin.,"['Participants With Type 2 Diabetes', '3,230 participants with type 2 diabetes at baseline', 'participants with type 2 diabetes']","['eating plans: Med-EatPlan supplemented with extra virgin olive oil (EVOO), Med-EatPlan supplemented with mixed nuts, or a low-fat eating plan (control', 'Mediterranean eating plans (Med-EatPlans) versus a low-fat eating plan', 'Mediterranean Eating Plan']","['hazard ratios (HRs) of starting a first glucose-lowering medication', 'outcomes: 1 ) introduction of the first glucose-lowering medication (oral or injectable', 'adjusted HRs of starting insulin treatment']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0555061', 'cui_str': 'Virgin (finding)'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0453347', 'cui_str': 'Mixed nuts (substance)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",3230.0,0.106183,The Med-EatPlan did not result in a significantly lower need for insulin.,"[{'ForeName': 'F Javier', 'Initials': 'FJ', 'LastName': 'Basterra-Gortari', 'Affiliation': 'Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Ruiz-Canela', 'Affiliation': 'Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Martínez-González', 'Affiliation': 'Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Babio', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'José V', 'Initials': 'JV', 'LastName': 'Sorlí', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Fito', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Ros', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Gómez-Gracia', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Fiol', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lapetra', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Estruch', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Serra-Majem', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pinto', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'José I', 'Initials': 'JI', 'LastName': 'González', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Bulló', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Castañer', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Alonso-Gómez', 'Affiliation': 'Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Forga', 'Affiliation': 'Department of Endocrinology and Nutrition, Complejo Hospitalario de Navarra, Instituto de investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Arós', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc18-2475'] 317,31858128,"Tubaramure, a Food-Assisted Maternal and Child Health and Nutrition Program in Burundi, Increased Household Food Security and Energy and Micronutrient Consumption, and Maternal and Child Dietary Diversity: A Cluster-Randomized Controlled Trial.","BACKGROUND Food-assisted maternal and child health and nutrition programs are a widely used approach to address undernutrition. Little is known about the effects of these programs' combined household and individual food rations on household and individual food consumption. Tubaramure in Burundi targeted women and children during the first 1000 d of life, and included: 1) food rations (corn-soy blend and micronutrient-fortified vegetable oil); 2) health services strengthening and promotion of their use; and 3) behavior change communication on nutrition, hygiene, and health practices. OBJECTIVES The objectives were: 1) to assess Tubaramure's impact on household food consumption and food security, maternal dietary diversity, and infant and young child feeding practices; 2) to explore the role of the food rations; and 3) assess 6-8 mo impacts around 8 mo after the end of the program. METHODS We used a 4-arm cluster-randomized controlled repeated cross-sectional design (11,906 observations). The treatment arms received the same food ration but differed in the ration timing and duration: 1) the first 1000 d; 2) from pregnancy through 17.9 mo of age; or 3) from birth through 23.9 mo of age. RESULTS Tubaramure significantly (P < 0.05) improved the percentage of food secure households [from 4.5 to 7.3 percentage points (pp)], and increased household energy consumption (from 17% to 20%) and micronutrient consumption. The program had a positive effect on maternal dietary diversity (+0.4 food groups, P < 0.05) and increased the proportion of children aged 6-23.9 mo consuming ≥4 food groups (from 8.0 to 9.6 pp, P < 0.05). The effects on many outcomes were attributable to the food rations. Postprogram effects (P < 0.05) were found on household food security, maternal dietary diversity, and younger sibling's complementary feeding practices. CONCLUSIONS Programs such as Tubaramure have the potential to improve food security and household and individual energy and micronutrient consumption in severely resource-constrained populations, as seen in rural Burundi. This trial was registered at clinicaltrials.gov as NCT01072279.",2020,"The program had a positive effect on maternal dietary diversity (+0.4 food groups, P < 0.05) and increased the proportion of children aged 6-23.9 mo consuming ≥4 food groups (from 8.0 to 9.6 pp, P ",[],['food rations (corn-soy blend and micronutrient-fortified vegetable oil); 2) health services strengthening and promotion of their use; and 3) behavior change communication'],"['Household Food Security and Energy and Micronutrient Consumption, and Maternal and Child Dietary Diversity', 'maternal dietary diversity', 'percentage of food secure households', 'household food consumption and food security, maternal dietary diversity, and infant and young child feeding practices; 2) to explore the role of the food rations; and 3)\xa0assess 6-8', 'household energy consumption']",[],"[{'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0087179', 'cui_str': 'Zea'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0042438', 'cui_str': 'Vegetable Oils'}, {'cui': 'C0018747', 'cui_str': 'Health Services'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]","[{'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C3178753', 'cui_str': 'Food Security'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0035820', 'cui_str': 'Role'}]",,0.0796038,"The program had a positive effect on maternal dietary diversity (+0.4 food groups, P < 0.05) and increased the proportion of children aged 6-23.9 mo consuming ≥4 food groups (from 8.0 to 9.6 pp, P ","[{'ForeName': 'Jef L', 'Initials': 'JL', 'LastName': 'Leroy', 'Affiliation': 'International Food Policy Research Institute, 2033\xa0K Street NW, Washington DC 20006, USA.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'K Olney', 'Affiliation': 'International Food Policy Research Institute, 2033\xa0K Street NW, Washington DC 20006, USA.'}, {'ForeName': 'Lilia', 'Initials': 'L', 'LastName': 'Bliznashka', 'Affiliation': 'International Food Policy Research Institute, 2033\xa0K Street NW, Washington DC 20006, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Ruel', 'Affiliation': 'International Food Policy Research Institute, 2033\xa0K Street NW, Washington DC 20006, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz295'] 318,32279927,Effects of a single session of SMR neurofeedback training on anxiety and cortisol levels.,"OBJECTIVES According to some studies, a putatively calming effect of EEG neurofeedback training could be useful as a therapeutic tool in psychiatric practice. With the aim of elucidating this possibility, we tested the efficacy of a single session of ↑sensorimotor (SMR)/↓theta neurofeedback training for mood improvement in 32 healthy men, taking into account trainability, independence and interpretability of the results. METHODS A pre-post design, with the following dependent variables, was applied: (i) psychometric measures of mood with regards to anxiety, depression, and anger (Profile of Mood State, POMS, and State Trait Anxiety Inventory, STAI); (ii) biological measures (salivary levels of cortisol); (iii) neurophysiological measures (EEG frequency band power analysis). In accordance with general recommendations for research in neurofeedback, a control group receiving sham neurofeedback was included. RESULTS Anxiety levels decreased after the real neurofeedback and increased after the sham neurofeedback (P<0.01, size effect 0.9 for comparison between groups). Cortisol decreased after the experiment in both groups, though with significantly more pronounced effects in the desired direction after the real neurofeedback (P<0.04; size effect 0.7). The group receiving real neurofeedback significantly enhanced their SMR band (P<0.004; size effect 0.88), without changes in the theta band. The group receiving sham neurofeedback did not show any EEG changes. CONCLUSIONS The improvement observed in anxiety was greater in the experimental group than in the sham group, confirmed by both subjective (psychometric) measures and objective (biological) measures. This was demonstrated to be associated with the real neurofeedback, though a nonspecific (placebo) effect likely also contributed.",2020,"The group receiving real neurofeedback significantly enhanced their SMR band (P<0.004; size effect 0.88), without changes in the theta band.",['32 healthy men'],"['↑sensorimotor', 'SMR)/↓theta neurofeedback training', 'SMR neurofeedback training']","['anxiety and cortisol levels', 'subjective (psychometric) measures and objective (biological) measures', 'Cortisol', 'psychometric measures of mood with regards to anxiety, depression, and anger (Profile of Mood State, POMS, and State Trait Anxiety Inventory, STAI); (ii) biological measures (salivary levels of cortisol); (iii) neurophysiological measures (EEG frequency band power analysis', 'anxiety', 'Anxiety levels']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}]",32.0,0.0524174,"The group receiving real neurofeedback significantly enhanced their SMR band (P<0.004; size effect 0.88), without changes in the theta band.","[{'ForeName': 'Marien', 'Initials': 'M', 'LastName': 'Gadea', 'Affiliation': 'Department of Psychobiology, University of Valencia, Valencia, Spain. Electronic address: Marien.Gadea@uv.es.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Aliño', 'Affiliation': 'Department of Psychology, Universidad Internacional de Valencia, Valencia, Spain.'}, {'ForeName': 'Vanesa', 'Initials': 'V', 'LastName': 'Hidalgo', 'Affiliation': 'Area of Psychobiology, Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Espert', 'Affiliation': 'Department of Psychobiology, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Salvador', 'Affiliation': 'Laboratory of Cognitive Social Neuroscience, Department of Psychobiology and IDOCAL, University of Valencia, Valencia, Spain.'}]",Neurophysiologie clinique = Clinical neurophysiology,['10.1016/j.neucli.2020.03.001'] 319,32275359,[Fire needling on dysphagia due to pseudobulbar palsy after stroke: a randomized controlled trial].,"OBJECTIVE To observe the clinical effect of fire needling on dysphagia due to pseudobulbar paralysis after stroke and to compare the difference in clinical effect between fire needling and swallowing function rehabilitation training. METHODS A total of 76 patients with dysphagia due to pseudobulbar paralysis after stroke were randomly divided into an observation group and a control group, 38 cases in each group (1 case dropped out in the control group). The both groups were based on conventional western medication treatment. Fire needle pricking was exerted at Lianquan (CV 23), Fengchi (GB 20), Wangu (GB 12), Shuigou (GV 26), Neiguan (PC 6) and Zusanli (ST 36) without needle retaining every other day in the observation group. The control group was treated with the swallowing function rehabilitation training. In both groups, treatment for 2 weeks was as one course and 2 courses of treatment with 2-day interval were required. After treatment, swallowing scores of Fujishima Ichiro and swallow quality of life questionnaire (SWAL-QOL) scores were observed in both groups, and the clinical effect was compared. Follow-up of swallowing scores of Fujishima Ichiro in 4 weeks after treatment was completed to evaluate the clinical effect. RESULTS The clinical effective rates after treatment and follow-up were 92.1% (35/38) and 94.7% (36/38) in the observation group, higher than 75.7% (28/37) and 83.8% (31/37) in the control group ( P <0.05). After treatment, the swallowing scores of Fujishima Ichiro and SWAL-QOL scores were increased in the two groups ( P <0.05), and those in the observation group were higher than the control group ( P <0.05). The swallowing scores of Fujishima Ichiro were increased during follow-up in the two groups ( P <0.05). CONCLUSION Fire needling has a better effect than conventional rehabilitation training in the treatment of dysphagia due to pseudobulbar paralysis after stroke, which can obviously improve the swallowing function and quality of life in patients with dysphagia.",2020,"The swallowing scores of Fujishima Ichiro were increased during follow-up in the two groups ( P <0.05). ","['patients with dysphagia', '76 patients with dysphagia due to pseudobulbar paralysis after stroke', 'pseudobulbar palsy after stroke']","['Fire needle pricking', 'Fire needling', 'swallowing function rehabilitation training', 'fire needling and swallowing function rehabilitation training', 'conventional rehabilitation training', 'fire needling']","['swallowing scores of Fujishima Ichiro and SWAL-QOL scores', 'swallowing scores of Fujishima Ichiro', 'clinical effective rates', 'swallowing scores of Fujishima Ichiro and swallow quality of life questionnaire (SWAL-QOL) scores', 'swallowing function and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0033790', 'cui_str': 'Pseudobulbar palsy'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0014007', 'cui_str': 'Dismissed from job'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",76.0,0.0216551,"The swallowing scores of Fujishima Ichiro were increased during follow-up in the two groups ( P <0.05). ","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': 'Department of Acupuncture-Moxibustion and Tuina, Changhai Hospital of Naval Military Medical University, Shanghai 200433, China.'}, {'ForeName': 'Xiao-Lu', 'Initials': 'XL', 'LastName': 'Qian', 'Affiliation': 'Department of Acupuncture-Moxibustion and Tuina, Changhai Hospital of Naval Military Medical University, Shanghai 200433, China.'}, {'ForeName': 'Wen-Min', 'Initials': 'WM', 'LastName': 'Yan', 'Affiliation': 'Department of Acupuncture-Moxibustion and Tuina, Changhai Hospital of Naval Military Medical University, Shanghai 200433, China; School of Acupuncture-Moxibustion and Tuina, Shanghai University of TCM, Shanghai 201203.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Zhou', 'Affiliation': 'School of Acupuncture-Moxibustion and Tuina, Shanghai University of TCM, Shanghai 201203.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190502-0003'] 320,32275360,[Effect of electronic moxibustion on memory function in patients with amnestic mild cognitive impairment].,"OBJECTIVE To observe the effect of electronic moxibustion on memory function in the patients with amnestic mild cognitive impairment (aMCI). METHODS A total of 59 aMCI patients were randomized into an electronic moxibustion group (30 cases) and a placebo moxibustion group (29 cases). In the electronic moxibustion group, the electronic moxibustion was applied to Baihui (GV 20), Dazhui (GV 14), Mingmen (GV 4) and Taixi (KI 3), 45 ℃ in temperature, 20 min each time. The treatment was given once a day, 5 times a week. The treatment for 4 weeks was as one course and 2 courses were required totally. In the placebo moxibustion group, the moxa-free patch was used, 38 ℃ in temperature. The acupoint selection and the treatment frequency were same as the electronic moxibustion group. Before and after treatment, Rivermead behavior memory test (RBMT) was adopted to evaluate the global memory function of the patients in the two groups and the N-back task test was adopted to evaluate working memory function separately. Additionally, the mini-mental state examination (MMSE) and its immediate memory, Montreal cognitive assessment (MoCA) and its delay recall were adopted to evaluate the global cognitive function and memory function . RESULTS In the electronic moxibustion group, after treatment, RBMT score, N-back accuracy rates, MMSE and MoCA scores and the scores of immediate memory and delay recall were improved significantly as compared with those before treatment ( P <0.01). In the placebo moxibustion group, the accuracy rates of 1-back and 2-back task and the scores of immediate memory and delay recall were improved obviously as compared with those before treatment ( P <0.05, P <0.01). After treatment, the improvements of RBMT score, the accuracy rates of N-back task and MMSE and MoCA scores in the electronic moxibustion group were higher than those in the placebo moxibustion group ( P <0.05). CONCLUSION Electronic moxibustion improves memory function in the patients with amnestic mild cognitive impairment.",2020,"After treatment, the improvements of RBMT score, the accuracy rates of N-back task and MMSE and MoCA scores in the electronic moxibustion group were higher than those in the placebo moxibustion group ( P <0.05). ","['patients with amnestic mild cognitive impairment (aMCI', '59 aMCI patients', 'patients with amnestic mild cognitive impairment']","['electronic moxibustion', 'mini-mental state examination (MMSE) and its immediate memory, Montreal cognitive assessment (MoCA', 'placebo moxibustion', 'Electronic moxibustion']","['RBMT score, N-back accuracy rates, MMSE and MoCA scores and the scores of immediate memory and delay recall', 'accuracy rates of 1-back and 2-back task and the scores of immediate memory and delay recall', 'RBMT score, the accuracy rates of N-back task and MMSE and MoCA scores', 'memory function', 'global cognitive function and memory function ', 'Rivermead behavior memory test (RBMT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",59.0,0.058445,"After treatment, the improvements of RBMT score, the accuracy rates of N-back task and MMSE and MoCA scores in the electronic moxibustion group were higher than those in the placebo moxibustion group ( P <0.05). ","[{'ForeName': 'Qi-Qi', 'Initials': 'QQ', 'LastName': 'Liu', 'Affiliation': 'Graduate School, Anhui University of CM, Hefei 230038, China; Department of Rehabilitation Medicine, Shenzhen Baoan Hospital Affiliated to Southern Medical University, Shenzhen 518101, Guangdong Province.'}, {'ForeName': 'Shang-Jie', 'Initials': 'SJ', 'LastName': 'Chen', 'Affiliation': 'Graduate School, Anhui University of CM, Hefei 230038, China; Department of Rehabilitation Medicine, Shenzhen Baoan Hospital Affiliated to Southern Medical University, Shenzhen 518101, Guangdong Province.'}, {'ForeName': 'Guo-Ming', 'Initials': 'GM', 'LastName': 'Shen', 'Affiliation': 'Graduate School, Anhui University of CM, Hefei 230038, China.'}, {'ForeName': 'Xin-Yan', 'Initials': 'XY', 'LastName': 'Jia', 'Affiliation': 'Department of Rehabilitation Medicine, Shenzhen Baoan Hospital Affiliated to Southern Medical University, Shenzhen 518101, Guangdong Province.'}, {'ForeName': 'Xiao-di', 'Initials': 'XD', 'LastName': 'Qiao', 'Affiliation': 'Graduate School, Anhui University of CM, Hefei 230038, China.'}, {'ForeName': 'Guo-Long', 'Initials': 'GL', 'LastName': 'Wu', 'Affiliation': 'Department of Rehabilitation Medicine, Shenzhen Baoan Hospital Affiliated to Southern Medical University, Shenzhen 518101, Guangdong Province.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190608-k0002'] 321,31154891,Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states.,"BACKGROUND Cannabis, and specifically one of its active compounds delta-9-tetrahydrocannabinol in recreational doses, has a variety of effects on cognitive processes. Most studies employ resting state functional magnetic resonance imaging techniques to assess the stationary effects of cannabis and to-date one report addressed the impact of delta-9-tetrahydrocannabinol on the dynamics of whole-brain functional connectivity. METHODS Using a repeated-measures, within-subjects design, 19 healthy occasional cannabis users (smoking cannabis ⩽2 per week) underwent resting state functional magnetic resonance imaging scans. Each subject underwent two scans: in the intoxicated condition, shortly after smoking a cannabis cigarette, and in the non-intoxicated condition, with the subject being free from cannabinoids for at least one week before. All sessions were randomized and performed in a four-week interval. Data were analysed employing a standard independent component analysis approach with subsequent tracking of the functional connectivity dynamics, which allowed six connectivity clusters (states) to be individuated. RESULTS Using standard independent component analysis in resting state functional connectivity, a group effect was found in the precuneus connectivity. With a dynamic independent component analysis approach, we identified one transient connectivity state, characterized by high connectivity within and between auditory and somato-motor cortices and anti-correlation with subcortical structures and the cerebellum that was only found during the intoxicated condition. Behavioural measures of the subjective experiences of changed perceptions and tetrahydrocannabinol plasma levels during intoxication were associated with this state. CONCLUSIONS With the help of the dynamic connectivity approach we could elucidate neural correlates of the transitory perceptual changes induced by delta-9-tetrahydrocannabinol in cannabis users, and possibly identify a biomarker of cannabis intoxication.",2019,"RESULTS Using standard independent component analysis in resting state functional connectivity, a group effect was found in the precuneus connectivity.",['19 healthy occasional cannabis users (smoking cannabis ⩽2 per week) underwent'],['resting state functional magnetic resonance imaging scans'],['resting state functional connectivity'],"[{'cui': 'C0521114', 'cui_str': 'Infrequent (qualifier value)'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0441633'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",19.0,0.0355757,"RESULTS Using standard independent component analysis in resting state functional connectivity, a group effect was found in the precuneus connectivity.","[{'ForeName': 'Yuliya', 'Initials': 'Y', 'LastName': 'Zaytseva', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Jiří', 'Initials': 'J', 'LastName': 'Horáček', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Jaroslav', 'Initials': 'J', 'LastName': 'Hlinka', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Iveta', 'Initials': 'I', 'LastName': 'Fajnerová', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Androvičová', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Jaroslav', 'Initials': 'J', 'LastName': 'Tintěra', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Virginio', 'Initials': 'V', 'LastName': 'Salvi', 'Affiliation': '5 Department of Neuroscience, ASST Fatebenefratelli Sacco, Milan, Italy.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Balíková', 'Affiliation': '6 Institute of Forensic Medicine and Toxicology, Charles University in Prague, Czech Republic.'}, {'ForeName': 'Tomáš', 'Initials': 'T', 'LastName': 'Hložek', 'Affiliation': '6 Institute of Forensic Medicine and Toxicology, Charles University in Prague, Czech Republic.'}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Španiel', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}, {'ForeName': 'Tomáš', 'Initials': 'T', 'LastName': 'Páleníček', 'Affiliation': '1 National Institute of Mental Health, Klecany, Czech Republic.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119849814'] 322,31279090,Improving family caregiver and patient outcomes in lung cancer surgery: Study protocol for a randomized trial of the multimedia self-management (MSM) intervention.,"OBJECTIVE To describe the study protocol of the Multimedia Self-Management (MSM) intervention to prepare patients and family caregivers (FCGs) for lung cancer surgery. DESIGN The study is a five-year, single site, randomized controlled trial of 160 lung cancer surgery FCG and patient dyads (320 total participants), comparing intervention and attention control arms. SETTING One National Cancer-Institute (NCI) designated comprehensive cancer center in Southern California. PARTICIPANTS Patients who are scheduled to undergo lung cancer surgery and their FCGs are enrolled as dyads only. INTERVENTION Based on the Chronic Care Self-Management Model (CCM), the intervention is a nurse-led, caregiver-based, multimedia care program for lung cancer surgery. Its primary focus is to help FCGs develop self-management skills related to their caregiving role through goal setting, proactive planning, building problem-solving skills, and accessing family support services. The intervention also supports dyads to prepare for surgery and post-operative recovery at home. It includes videos, print, web-based, and post-discharge telephone support. MAIN OUTCOME MEASURES FCG and patient psychological distress and QOL; FCG burden and preparedness for caregiving; FCG and patient healthcare resource use (in-home nursing care, urgent care/ER visits, readmissions). ANALYSIS Repeated measures ANCOVA statistical design will be used, removing variances prior to examining mean squares for the group by occasion interactions, and co-varying the baseline scores. In addition, structured equation modeling (SEM) will assess whether mediating and moderating factors are associated with outcomes. ClinicalTrials.gov Identifier: NCT03686007.",2019,"Based on the Chronic Care Self-Management Model (CCM), the intervention is a nurse-led, caregiver-based, multimedia care program for lung cancer surgery.","['One National Cancer-Institute (NCI', 'Patients who are scheduled to undergo lung cancer surgery and their FCGs are enrolled as dyads only', '160 lung cancer surgery FCG and patient dyads (320 total participants', 'patients and family caregivers (FCGs) for lung cancer surgery', 'designated comprehensive cancer center in Southern California', 'lung cancer surgery']","['Multimedia Self-Management (MSM) intervention', 'multimedia self-management (MSM) intervention', 'structured equation modeling (SEM', 'Chronic Care Self-Management Model (CCM']","['FCG and patient psychological distress and QOL; FCG burden and preparedness for caregiving; FCG and patient healthcare resource use (in-home nursing care, urgent care/ER visits, readmissions']","[{'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1720467', 'cui_str': 'Only'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0019860', 'cui_str': 'Home Care, Nonprofessional'}, {'cui': 'C2362545', 'cui_str': 'Urgent Care'}]",160.0,0.0652866,"Based on the Chronic Care Self-Management Model (CCM), the intervention is a nurse-led, caregiver-based, multimedia care program for lung cancer surgery.","[{'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Sun', 'Affiliation': 'Division of Nursing Research and Education, Department of Population Sciences, United States of America. Electronic address: vsun@coh.org.'}, {'ForeName': 'Dan J', 'Initials': 'DJ', 'LastName': 'Raz', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, United States of America.'}, {'ForeName': 'Loretta', 'Initials': 'L', 'LastName': 'Erhunmwunsee', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, United States of America.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Ruel', 'Affiliation': 'Biostatistics and Mathematical Modeling Core City of Hope, Duarte, CA, United States of America.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Carranza', 'Affiliation': 'Division of Nursing Research and Education, Department of Population Sciences, United States of America.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Prieto', 'Affiliation': 'Division of Nursing Research and Education, Department of Population Sciences, United States of America.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Ferrell', 'Affiliation': 'Division of Nursing Research and Education, Department of Population Sciences, United States of America.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Krouse', 'Affiliation': 'Surgical Services, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, United States of America; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'McCorkle', 'Affiliation': 'School of Nursing, Yale University, New Haven, CT, United States of America.'}, {'ForeName': 'Jae Y', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.07.002'] 323,32291982,[Application of intravenous injection of tranexamic acid combined with local use of tranexamic acid cocktail in intertrochanteric fracture fixation].,"Objective To explore the efficacy and safety of intravenous injection of tranexamic acid (TXA) combined with local use of TXA cocktail in intertrochanteric fracture fixation with proximal femoral nail antirotation (PFNA). Methods Patients with intertrochanteric fractures who underwent close reduction and internal fixation with PFNA between February 2018 and March 2019 were enrolled in the study. Among them, 45 patients who met the selection criteria were included in the study and randomly allocated into 3 groups ( n =15). The patients in group A were not received TXA during perioperative period. The patients were intravenously injected of 1.0 g TXA before operation in group B and combined with local use of TXA cocktail during operation in group C. There was no significant difference in the age, gender, body mass index, fracture classification, disease duration, and complications between groups ( P >0.05). The perioperative blood loss and blood transfusion rate, the visual analogue scale (VAS) score before operation and at 12, 24, and 48 hours after operation, the levels of prostaglandin E2 (PGE2) and bradykinin (BK) before operation and at 1 and 3 days after operation, postoperative complications, and the maximum amplitude (MA) of thromboelastogram were recorded and compared between groups. Results The total blood loss, hidden blood loss, and visible blood loss were significantly lower in groups B and C than those in group A ( P <0.05), and the total blood loss and hidden blood loss were significantly lower in group C than those in group B ( P <0.05). There was no significant difference in the blood transfusion rate, preoperative VAS scores and the levels of PGE2 and BK between groups ( P >0.05). The postoperative VAS scores and the levels of PGE2 and BK were significantly lower in group C than in groups A and B ( P <0.05). There was no significant difference in pre- and post-operative MA of thromboelastogram between groups ( P >0.05). The incidences of postoperative complications were 33.33% (5/15), 20.00% (3/15), and 13.33% (2/15) in groups A, B, and C, respectively, with no significant difference between groups ( χ 2 =1.721, P =0.550). Conclusion For intertrochanteric fractures, application of intravenous injection of TXA combined with local use of TXA cocktail in PFNA fixation can reduce perioperative blood loss, relieve pain after operation, and do not increase the risk of complications.",2020,"There was no significant difference in the blood transfusion rate, preoperative VAS scores and the levels of PGE2 and BK between groups ( P >0.05).","['intertrochanteric fracture fixation', '45 patients who met the selection criteria', 'intertrochanteric fracture fixation with proximal femoral nail antirotation (PFNA', 'Patients with intertrochanteric fractures who underwent close reduction and internal fixation with PFNA between February 2018 and March 2019 were enrolled in the study']","['TXA cocktail in PFNA fixation', 'TXA', 'tranexamic acid (TXA', 'tranexamic acid cocktail', 'tranexamic acid', 'TXA cocktail']","['pre- and post-operative MA of thromboelastogram', 'incidences of postoperative complications', 'body mass index, fracture classification, disease duration, and complications', 'postoperative complications, and the maximum amplitude (MA) of thromboelastogram', 'efficacy and safety', 'perioperative blood loss and blood transfusion rate, the visual analogue scale (VAS) score', 'blood transfusion rate, preoperative VAS scores and the levels of PGE2 and BK', 'perioperative blood loss, relieve pain', 'total blood loss and hidden blood loss', 'postoperative VAS scores and the levels of PGE2 and BK', 'total blood loss, hidden blood loss, and visible blood loss', 'levels of prostaglandin E2 (PGE2) and bradykinin (BK']","[{'cui': 'C0162385', 'cui_str': 'Intertrochanteric fracture'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0678420', 'cui_str': 'Cocktail'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0040017', 'cui_str': 'Thromboelastography'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0006100', 'cui_str': 'Kallidin I'}]",,0.0154984,"There was no significant difference in the blood transfusion rate, preoperative VAS scores and the levels of PGE2 and BK between groups ( P >0.05).","[{'ForeName': 'Qingyan', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xiang', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Xiaoting', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Jiang', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Wei', 'Affiliation': 'Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong Sichuan, 637000, P.R.China.'}]",Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery,['10.7507/1002-1892.201908138'] 324,32291983,[A comparative study on effectiveness of closed reduction and internal fixation of intertrochanteric fracture assisted with skeletal tractor and traction table].,"Objective To investigate the effectiveness and advantages of skeletal tractor in closed reduction and proximal femoral nail antirotation (PFNA) internal fixation of intertrochanteric fracture compared with traction table. Methods The clinical data of 86 patients with intertrochanteric fractures, who were treated with closed reduction and PFNA internal fixation between October 2016 and March 2018 and met the selection criteria, was retrospectively analysed. Among them, 44 cases were treated with skeletal tractor (trial group) and 42 cases were treated with traction table (control group). There was no significant difference between the two groups in gender, age, cause of injury, fracture side, AO classification, and degree of osteoporosis ( P >0.05). The preoperative position time, operation time, intraoperative fluoroscopy times, intraoperative blood loss, fracture healing time, intraoperative and postoperative complications, and postoperative Harris score were compared between the two groups. Results The operation was successfully completed in both groups. Compared with the control group, the patients in the trial group had shorter preoperative position time and operation time, fewer intraoperative fluoroscopy times, and less intraoperative blood loss ( P <0.05). The patients were followed up 12-21 months in trial group (mean, 14.2 months) and 12-22 months in control group (mean, 14.3 months). Venous thrombosis of lower extremity occurred in 8 patients (3 cases of trial group and 5 cases of control group) after operation. Internal fixation failure occurred in 5 patients (2 cases of trial group and 3 cases of control group) during 1 year after operation. All fractures healed except for those with internal fixation failure, the fracture healing time was (11.6±2.9) weeks in trial group and (12.4±3.6) weeks in control group; and there was no significant difference between the two groups ( t =1.250, P =0.214). At 1 year after operation, Harris score of the trial group was 86.2±5.9 and that of the control group was 84.1±6.1. There was no significant difference between the two groups ( t =1.768, P =0.080). Conclusion Compared with traction table, skeletal tractor in closed reduction and PFNA internal fixation of intertrochanteric fracture can significantly shorten the preoperative position time and operation time, reduce the intraoperative fluoroscopy times, improve the operation efficiency, and have similar effectiveness.",2020,"There was no significant difference between the two groups in gender, age, cause of injury, fracture side, AO classification, and degree of osteoporosis ( P >0.05).","['86 patients with intertrochanteric fractures, who were treated with closed reduction and PFNA internal fixation between October 2016 and March 2018 and met the selection criteria, was retrospectively analysed', '44 cases were treated with skeletal tractor (trial group) and 42 cases were treated with']","['traction table', 'skeletal tractor', 'closed reduction and internal fixation of intertrochanteric fracture assisted with skeletal tractor and traction table', 'traction table (control group']","['fracture healing time', 'operation efficiency', 'preoperative position time and operation time, reduce the intraoperative fluoroscopy times', 'shorter preoperative position time and operation time, fewer intraoperative fluoroscopy times', 'Venous thrombosis of lower extremity', 'Internal fixation failure', 'intraoperative blood loss', 'injury, fracture side, AO classification, and degree of osteoporosis', 'preoperative position time, operation time, intraoperative fluoroscopy times, intraoperative blood loss, fracture healing time, intraoperative and postoperative complications, and postoperative Harris score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162385', 'cui_str': 'Intertrochanteric fracture'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0336781', 'cui_str': 'Farm tractor'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0183817', 'cui_str': 'Traction table'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0336781', 'cui_str': 'Farm tractor'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0162385', 'cui_str': 'Intertrochanteric fracture'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",86.0,0.0135344,"There was no significant difference between the two groups in gender, age, cause of injury, fracture side, AO classification, and degree of osteoporosis ( P >0.05).","[{'ForeName': 'Gangqiang', 'Initials': 'G', 'LastName': 'Du', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Shuye', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Jia', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}, {'ForeName': 'Jianhao', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Orthopedics Trauma, Binzhou Medical University Hospital, Binzhou Shandong, 256603, P.R.China.'}]",Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery,['10.7507/1002-1892.201908120'] 325,31907924,"A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea.","BACKGROUND Papulopustular rosacea is characterized by chronic facial erythema and inflammatory facial lesions. Minocycline has anti-inflammatory properties which may be effective in the treatment of rosacea inflammatory lesions. OBJECTIVES To assess the safety and efficacy of once-daily topical minocycline gel 1% and 3% in patients with papulopustular rosacea. METHODS This was a prospective, 12-week, double-blinded study conducted at 26 sites in the United States; 270 patients with papulopustular rosacea and 12-40 inflammatory lesions were randomized to minocycline 1%, minocycline 3% or vehicle. The primary endpoint was the mean change in inflammatory lesions at week 12. Key secondary endpoints included success on an Investigator's Global Assessment (IGA). RESULTS Baseline mean lesion counts were 24·6, 25·1 and 24·3 in the minocycline 1%, minocycline 3% and vehicle groups, respectively; at week 12, the counts had decreased by 12·6, 13·1 and 7·9, respectively. Minocycline significantly decreased lesions, compared with the vehicle [P = 0·01, 95% confidence interval (CI) 7·9 to 0·9, for minocycline 1%; P = 0·007, 95% CI 8·3 to 1·3, for minocycline 3%]. The proportion of patients achieving IGA success was 39% in the minocycline 1% arm [P = 0·34, odds ratio (OR) 1·396 and OR 95% CI 0·71 to 2·75 vs. vehicle], 46% in the minocycline 3% arm (P = 0·04, OR 2·03 and OR 95% CI 1·04 to 3·95 vs. vehicle) and 31% in the vehicle arm. CONCLUSIONS Minocycline topical gel appears to be safe and tolerable at concentrations of 1% and 3%, and both concentrations significantly decreased inflammatory lesion counts, with a significantly larger proportion of patients achieving IGA success at week 12 in the minocycline 3% arm. These findings support further evaluation of minocycline gel for treating inflammatory lesions associated with papulopustular rosacea.",2020,1% and 3% topical minocycline gel significantly decreased inflammatory lesion counts and a significantly larger proportion of subjects achieved IGA success at week 12 in the 3% topical minocycline group.,"['subjects with papulopustular rosacea', '26 sites in the United States', '270 subjects were randomized', 'Subjects with papulopustular rosacea and between 12 and 40 inflammatory lesions', 'patients with Papulopustular Rosacea']","['minocycline gel', 'topical minocycline gel', 'minocycline, 3% minocycline, or vehicle', 'Minocycline Gel', 'minocycline', 'Minocycline', 'topical Minocycline Gel']","['mean inflammatory lesion count', 'success on the investigator global assessments (IGA', 'proportion of subjects achieving IGA success', 'mean change in inflammatory lesions', 'inflammatory lesion counts', 'safety and efficacy', 'IGA success', 'safe and tolerable', 'baseline mean lesion count', 'inflammatory lesions']","[{'cui': 'C1449853', 'cui_str': 'Papulopustular Rosacea'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C4319603', 'cui_str': '270 (qualifier value)'}, {'cui': 'C3872830', 'cui_str': 'Inflammatory lesion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3872830', 'cui_str': 'Inflammatory lesion'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]",270.0,0.3645,1% and 3% topical minocycline gel significantly decreased inflammatory lesion counts and a significantly larger proportion of subjects achieved IGA success at week 12 in the 3% topical minocycline group.,"[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Webster', 'Affiliation': 'Department of Dermatology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA.'}, {'ForeName': 'Z D', 'Initials': 'ZD', 'LastName': 'Draelos', 'Affiliation': 'Dermatology Consulting Services, High Point, NC, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Graber', 'Affiliation': 'Northeastern University and The Dermatology Institute of Boston, Boston, MA, USA.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Lee', 'Affiliation': 'Lee Medical Associates, San Antonio, TX, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dhawan', 'Affiliation': 'Center for Dermatology, Cosmetic, and Laser Surgery, Freemont, CA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Salman', 'Affiliation': 'Hovione Scientia Ltd., Loughbeg, Ringaskiddy, Cork, Ireland.'}, {'ForeName': 'G N', 'Initials': 'GN', 'LastName': 'Magrath', 'Affiliation': 'Hovione Scientia Ltd., Loughbeg, Ringaskiddy, Cork, Ireland.'}]",The British journal of dermatology,['10.1111/bjd.18857'] 326,32284339,Neurofeedback-Linked Suppression of Cortical β Bursts Speeds Up Movement Initiation in Healthy Motor Control: A Double-Blind Sham-Controlled Study.,"Abnormally increased β bursts in cortical-basal ganglia-thalamic circuits are associated with rigidity and bradykinesia in patients with Parkinson's disease. Increased β bursts detected in the motor cortex have also been associated with longer reaction times (RTs) in healthy participants. Here we further hypothesize that suppressing β bursts through neurofeedback training can improve motor performance in healthy subjects. We conducted a double-blind sham-controlled study on 20 human volunteers (10 females) using a sequential neurofeedback-behavior task with the neurofeedback reflecting the occurrence of β bursts over sensorimotor cortex quantified in real time. The results show that neurofeedback training helps healthy participants learn to volitionally suppress β bursts in the sensorimotor cortex, with training being accompanied by reduced RT in subsequent cued movements. These changes were only significant in the real feedback group but not in the sham group, confirming the effect of neurofeedback training over simple motor imagery. In addition, RTs correlated with the rate and accumulated duration of β bursts in the contralateral motor cortex before the go-cue, but not with averaged β power. The reduced RTs induced by neurofeedback training positively correlated with reduced β bursts across all tested hemispheres. These results strengthen the link between the occurrence of β bursts in the sensorimotor cortex before the go-cue and slowed movement initiation in healthy motor control. The results also highlight the potential benefit of neurofeedback training in facilitating voluntary suppression of β bursts to speed up movement initiation. SIGNIFICANCE STATEMENT This double-blind sham-controlled study suggested that neurofeedback training can facilitate volitional suppression of β bursts in sensorimotor cortex in healthy motor control better than sham feedback. The training was accompanied by reduced reaction time (RT) in subsequent cued movements, and the reduced RT positively correlated with the level of reduction in cortical β bursts before the go-cue, but not with average β power. These results provide further evidence of a causal link between sensorimotor β bursts and movement initiation and suggest that neurofeedback training could potentially be used to train participants to speed up movement initiation.",2020,"These changes were only significant in the real feedback group but not in the sham group, confirming the effect of neurofeedback training over simple motor imagery.","['healthy subjects', '20 human volunteers (10 females', 'healthy participants', ""patients with Parkinson's disease"", 'healthy motor control']","['neurofeedback training', 'sequential neurofeedback-behaviour task']","['reaction time', 'rigidity and bradykinesia', 'reduced reaction time in subsequent cued movements', 'reduced reaction times', 'motor performance']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0026837', 'cui_str': 'Muscle rigidity'}, {'cui': 'C0233565', 'cui_str': 'Bradykinesia'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]",20.0,0.0558813,"These changes were only significant in the real feedback group but not in the sham group, confirming the effect of neurofeedback training over simple motor imagery.","[{'ForeName': 'Shenghong', 'Initials': 'S', 'LastName': 'He', 'Affiliation': 'MRC Brain Network Dynamics Unit at the University of Oxford, United Kingdom Oxford OX1 3TH.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Everest-Phillips', 'Affiliation': 'MRC Brain Network Dynamics Unit at the University of Oxford, United Kingdom Oxford OX1 3TH.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Clouter', 'Affiliation': 'MRC Brain Network Dynamics Unit at the University of Oxford, United Kingdom Oxford OX1 3TH.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brown', 'Affiliation': 'MRC Brain Network Dynamics Unit at the University of Oxford, United Kingdom Oxford OX1 3TH.'}, {'ForeName': 'Huiling', 'Initials': 'H', 'LastName': 'Tan', 'Affiliation': 'MRC Brain Network Dynamics Unit at the University of Oxford, United Kingdom Oxford OX1 3TH huiling.tan@ndcn.ox.ac.uk.'}]",The Journal of neuroscience : the official journal of the Society for Neuroscience,['10.1523/JNEUROSCI.0208-20.2020'] 327,31587271,Interventions for idiopathic toe walking.,"BACKGROUND Idiopathic toe walking (ITW) is an exclusionary diagnosis given to healthy children who persist in walking on their toes after they should typically have achieved a heel-toe gait. The literature discusses conservative and surgical interventions using a variety of treatment modalities. Young children and children without a limitation in ankle dorsiflexion (the upwards movement of the foot towards the shin of the leg) are commonly treated with conservative interventions. Older children who continue toe walking and present with limitations in ankle dorsiflexion are sometimes treated with surgical procedures. This systematic review is needed to evaluate the evidence for any intervention for the treatment of ITW. The conclusions of this review may support decision making by clinicians caring for children with ITW. It may also assist families when deciding on treatment options for their children with ITW. Many of the treatments employed have financial implications for parents or healthcare services. This review also aims to highlight any deficits in the current research base. OBJECTIVES To assess the effects of conservative and surgical interventions in children with ITW, specifically effects on gait normalisation, ankle range of motion, pain, frequency of recurrence, and any adverse effects. SEARCH METHODS On 29 April 2019, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, CINAHL Plus, and PEDro. We searched the following registers of clinical trials for ongoing and recently completed trials: the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP, apps.who.int/trialsearch), and ClinicalTrials.gov (clinicaltrials.gov). We searched conference proceedings and other grey literature in the BIOSIS databases and System for Information on Grey Literature in Europe (OpenGrey, opengrey.eu). We searched guidelines via the Turning Research Into Practice database (TRIP, tripdatabase.com) and National Guideline Clearinghouse (guideline.gov). We did not apply language restrictions. SELECTION CRITERIA We considered randomised or quasi-randomised trials for inclusion in the review if they involved participants diagnosed with ITW gait in the absence of a medical condition known to cause toe walking, or associated with toe walking. As there is no universally accepted age group for ITW, this review includes ITW at any age, who have been toe walking for more than six months, who can or cannot walk with a heel-toe gait, and who may or may not have limited dorsiflexion of the ankle joint. DATA COLLECTION AND ANALYSIS We used standard Cochrane methodological procedures. The primary outcome was improvement in toe walking (defined as greater than 50% of time spent heel-toe walking). Secondary outcomes were active and passive range of motion of the ankle joint, pain, recurrence of ITW after treatment, and adverse events. We assessed the certainty of the evidence using the GRADE framework. MAIN RESULTS Four studies, comprising 104 participants, met the inclusion criteria. One study did not report data within the appropriate follow-up timeframe and data from two studies were insufficient for analysis. The single study from which we extracted data had 47 participants and was a randomised, controlled, parallel-group trial conducted in Sweden. It tested the hypothesis that combined treatment with serial casting and botulinum toxin type A (BTX) was more effective than serial casting alone in reducing ITW gait.This study found that more participants treated with BTX improved (defined as toe walking less than 50% of the time, as reported by parents) (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.57 to 2.55; 1 trial, 46 participants; very low-certainty evidence). However, there was little or no difference between groups in passive ankle joint dorsiflexion range of movement on the right with the knee extended (mean difference (MD) -1.48º, 95% CI -4.13 to 1.16; 1 trial, 47 participants), on the right with the knee flexed (MD -0.04º, 95% CI -1.80 to 1.73; 1 trial, 46 participants), on the left with the knee flexed (MD 1.07, 95% CI -1.22 to 3.37), or on the left with the knee extended (MD 0.05, 95% CI -0.91 to 1.91). Nor was there a clear difference between the groups in recurrence of toe-walking gait (assessed via severity of toe walking (graded 1 (mild), 2 (moderate), or 3 (severe)) on gait analysis, analysed as continuous data: MD 0.34 points, 95% CI -0.09 to 0.78; 46 participants). In principle, MDs greater than zero (i.e.) positive values) would favour BTX and casting and negative values would favour casting alone. We have not reported effects as better or worse because all results were from evidence of very low certainty. We downgraded the certainty of evidence because of study limitations (outcome assessment was not blinded) and imprecision. Outcomes of pain and active range of motion were not reported in the included study.In terms of adverse events, calf pain was reported twice in the casting-only group and three times in the BTX group. There were three minor skin problems in each group and one reported case of pain directly after BTX injection. The report did not state if calf pain and skin irritation were from the same or different participants. The study authors reported that adverse events did not alter treatment adherence. AUTHORS' CONCLUSIONS The certainty of evidence from one study, which compared serial casting with serial casting with BTX for ITW in children, was too low for conclusions to be drawn. A further three studies reported outcomes relating to BTX, footwear, exercises, and different types of orthoses as interventions, however the outcome data were too limited to assess their effects.",2019,"Nor was there a clear difference between the groups in recurrence of toe-walking gait (assessed via severity of toe walking (graded 1 (mild), 2 (moderate), or 3 (severe)) on gait analysis, analysed as continuous data: MD 0.34 points, 95% CI -0.09 to 0.78; 46 participants).","['idiopathic toe walking', 'participants diagnosed with ITW gait in the absence of a medical condition known to cause toe walking, or associated with toe walking', 'Young children and children', '47 participants', 'children with ITW', 'Older children', 'parents or healthcare services', 'healthy children who persist in walking on their toes after they should typically have achieved a heel-toe gait']","['conservative and surgical interventions', 'serial casting and botulinum toxin type A (BTX', 'BTX']","['gait normalisation, ankle range of motion, pain, frequency of recurrence, and any adverse effects', 'pain and active range of motion', 'calf pain and skin irritation', 'recurrence of toe-walking gait (assessed via severity of toe walking (graded 1 (mild), 2 (moderate), or 3 (severe)) on gait analysis', 'passive ankle joint dorsiflexion range of movement', 'parents) (risk ratio (RR', 'adverse events, calf pain', 'active and passive range of motion of the ankle joint, pain, recurrence of ITW after treatment, and adverse events', 'time spent heel-toe walking', 'ITW gait', 'skin problems', 'toe walking']","[{'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C0427144', 'cui_str': 'Toe-walking gait (finding)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services (qualifier value)'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0231779', 'cui_str': 'Heel toe gait (finding)'}]","[{'cui': 'C0549433', 'cui_str': 'Surgical intervention'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0576183', 'cui_str': 'Joint movement: ankle'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0236040', 'cui_str': 'Pain in calf (finding)'}, {'cui': 'C0152030', 'cui_str': 'Skin irritation (disorder)'}, {'cui': 'C0427144', 'cui_str': 'Toe-walking gait (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0558820', 'cui_str': 'Gait Analysis'}, {'cui': 'C0003087', 'cui_str': 'Ankle Syndesmosis'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0079991', 'cui_str': 'Passive Range of Motion'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0018870', 'cui_str': 'Heel'}, {'cui': 'C0281822', 'cui_str': 'Skin problem (finding)'}]",47.0,0.264237,"Nor was there a clear difference between the groups in recurrence of toe-walking gait (assessed via severity of toe walking (graded 1 (mild), 2 (moderate), or 3 (severe)) on gait analysis, analysed as continuous data: MD 0.34 points, 95% CI -0.09 to 0.78; 46 participants).","[{'ForeName': 'Antoni J', 'Initials': 'AJ', 'LastName': 'Caserta', 'Affiliation': 'Child and Family Team, Monash Health, 140-154 Sladen St, Cranbourne, Victoria, Australia, 3977.'}, {'ForeName': 'Verity', 'Initials': 'V', 'LastName': 'Pacey', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Fahey', 'Affiliation': ''}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Gray', 'Affiliation': ''}, {'ForeName': 'Raoul Hh', 'Initials': 'RH', 'LastName': 'Engelbert', 'Affiliation': ''}, {'ForeName': 'Cylie M', 'Initials': 'CM', 'LastName': 'Williams', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012363.pub2'] 328,31039580,Quitting starts in the brain: a randomized controlled trial of app-based mindfulness shows decreases in neural responses to smoking cues that predict reductions in smoking.,"Current treatments for smoking yield suboptimal outcomes, partly because of an inability to reduce cue-induced smoking. Mindfulness training (MT) has shown preliminary efficacy for smoking cessation, yet its neurobiological target remains unknown. Our prior work with nonsmokers indicates that MT reduces posterior cingulate cortex (PCC) activity. In individuals who smoke, the PCC, consistently a main hub of the ""default mode network,"" activates in response to smoking cues. In this randomized controlled trial, we tested the effects of app-delivered MT on PCC reactivity to smoking cues and whether individual differences in MT-mediated PCC changes predicted smoking outcomes. Smoking cue-induced PCC reactivity was measured using functional magnetic resonance imaging at baseline and 1 month after receiving smartphone app-based MT (n = 33) vs. an active control (National Cancer Institute's QuitGuide, n = 34). Whether individual differences in treatment-related changes in PCC activity predicted smoking behavior was assessed. The MT group demonstrated a significant correlation between a reduction in PCC reactivity to smoking cues and a decline in cigarette consumption (r = 0.39, p = 0.02). No association was found in the control group (r = 0.08, p = 0.65). No effects of group alone were found in PCC or cigarette reduction. Post hoc analysis revealed this association is sex specific (women, r = 0.49, p = 0.03; men: r = -0.08, p = 0.79). This initial report indicates that MT specifically reduces smoking cue-induced PCC activity in a subject-specific manner, and the reduction in PCC activity predicts a concurrent decline in smoking. These findings link the hypothesized behavioral effects of MT for smoking to neural mechanisms particularly in women. This lays the groundwork for identifying individuals who may benefit from targeted digital therapeutic treatments such as smartphone-based MT, yielding improved clinical outcomes.",2019,No effects of group alone were found in PCC or cigarette reduction.,[],"['app-delivered MT', 'MT', 'smartphone app-based MT', 'Mindfulness training (MT']","['smoking cue-induced PCC activity', 'posterior cingulate cortex (PCC) activity', 'PCC reactivity to smoking cues and a decline in cigarette consumption', 'Smoking cue-induced PCC reactivity']",[],"[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption (observable entity)'}]",,0.0279824,No effects of group alone were found in PCC or cigarette reduction.,"[{'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Janes', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, 02478, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Datko', 'Affiliation': 'Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 Thirteenth St. #2301, Charlestown, MA, 02129, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': 'Mindfulness Center, Brown University School of Public Health and Warren Alpert School of Medicine, 121S Main St, Providence, RI, 02903, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Barton', 'Affiliation': 'Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Druker', 'Affiliation': 'Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655, USA.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Neal', 'Affiliation': 'University of Oklahoma-Tulsa School of Community Medicine, Tulsa, OK, 74135, USA.'}, {'ForeName': 'Kyoko', 'Initials': 'K', 'LastName': 'Ohashi', 'Affiliation': 'McLean Imaging Center, McLean Hospital, Belmont, MA, 02478, USA.'}, {'ForeName': 'Hanif', 'Initials': 'H', 'LastName': 'Benoit', 'Affiliation': 'Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655, USA.'}, {'ForeName': 'Remko', 'Initials': 'R', 'LastName': 'van Lutterveld', 'Affiliation': 'Mindfulness Center, Brown University School of Public Health and Warren Alpert School of Medicine, 121S Main St, Providence, RI, 02903, USA.'}, {'ForeName': 'Judson A', 'Initials': 'JA', 'LastName': 'Brewer', 'Affiliation': 'Mindfulness Center, Brown University School of Public Health and Warren Alpert School of Medicine, 121S Main St, Providence, RI, 02903, USA. judson_brewer@brown.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0403-y'] 329,31060042,Emotion-based brain mechanisms and predictors for SSRI and CBT treatment of anxiety and depression: a randomized trial.,"Mechanisms and predictors for the successful treatment of anxiety and depression have been elusive, limiting the effectiveness of existing treatments and curtailing the development of new interventions. In this study, we evaluated the utility of three widely used neural probes of emotion (experience, regulation, and perception) in their ability to predict symptom improvement and correlate with symptom change following two first-line treatments-selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT). Fifty-five treatment-seeking adults with anxiety and/or depression were randomized to 12 weeks of SSRI or CBT treatment (ClinicalTrials.gov identifier: NCT01903447). Functional magnetic resonance imaging (fMRI) was used to examine frontolimbic brain function during emotion experience, regulation, and perception, as probed by the Emotion Regulation Task (ERT; emotion experience and regulation) and emotional face assessment task (EFAT; emotion perception). Brain function was then related to anxiety and depression symptom change. Results showed that both SSRI and CBT treatments similarly attenuated insula and amygdala activity during emotion perception, and greater treatment-related decrease in insula and amygdala activity was correlated with greater reduction in anxiety symptoms. Both treatments also reduced amygdala activity during emotion experience but brain change did not correlate with symptom change. Lastly, greater pre-treatment insula and amygdala activity during emotion perception predicted greater anxiety and depression symptom improvement. Thus, limbic activity during emotion perception is reduced by both SSRI and CBT treatments, and predicts anxiety and depression symptom improvement. Critically, neural reactivity during emotion perception may be a non-treatment-specific mechanism for symptom improvement.",2019,"Results showed that both SSRI and CBT treatments similarly attenuated insula and amygdala activity during emotion perception, and greater treatment-related decrease in insula and amygdala activity was correlated with greater reduction in anxiety symptoms.",['Fifty-five treatment-seeking adults with anxiety and/or depression'],"['SSRI or CBT', 'serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy (CBT', 'Functional magnetic resonance imaging (fMRI', 'SSRI and CBT']","['Brain function', 'limbic activity during emotion perception', 'anxiety and depression symptom improvement', 'Emotion Regulation Task (ERT; emotion experience and regulation) and emotional face assessment task (EFAT; emotion perception', 'anxiety and depression symptom change', 'anxiety symptoms', 'insula and amygdala activity', 'insula and amygdala activity during emotion perception', 'amygdala activity']","[{'cui': 'C0450382', 'cui_str': '55 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0162758', 'cui_str': '5-HT Uptake Inhibitors'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0021640', 'cui_str': 'Insula of Reil'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}]",55.0,0.0131036,"Results showed that both SSRI and CBT treatments similarly attenuated insula and amygdala activity during emotion perception, and greater treatment-related decrease in insula and amygdala activity was correlated with greater reduction in anxiety symptoms.","[{'ForeName': 'Stephanie M', 'Initials': 'SM', 'LastName': 'Gorka', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA. sgorka2@uic.edu.'}, {'ForeName': 'Christina B', 'Initials': 'CB', 'LastName': 'Young', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Heide', 'Initials': 'H', 'LastName': 'Klumpp', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'Kennedy', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Francis', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Olusola', 'Initials': 'O', 'LastName': 'Ajilore', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Langenecker', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Stewart A', 'Initials': 'SA', 'LastName': 'Shankman', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Michelle G', 'Initials': 'MG', 'LastName': 'Craske', 'Affiliation': 'Department of Psychology, University of California-Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Murray B', 'Initials': 'MB', 'LastName': 'Stein', 'Affiliation': 'Departments of Psychiatry and Family Medicine and Public Health, University of California-San Diego, La Jolla, CA, USA.'}, {'ForeName': 'K Luan', 'Initials': 'KL', 'LastName': 'Phan', 'Affiliation': 'Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0407-7'] 330,31113277,"Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.","OBJECTIVE Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). METHODS In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. RESULTS Two treatments showed similar safety and primary and secondary outcomes. CONCLUSIONS Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.",2019,"RESULTS Two treatments showed similar safety and primary and secondary outcomes. ","['97 patients with BPSD', 'behavioral and psychological symptoms of dementia (BPSD']","['Sodium benzoate', 'Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor', 'placebo', 'placebo or benzoate']",['ADAS-cog and BEHAVE-AD'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1868717', 'cui_str': 'BPSD'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}]","[{'cui': 'C0142805', 'cui_str': 'Sodium Benzoate'}, {'cui': 'C0010895', 'cui_str': 'dextro-Amino Acid Oxidase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0005058', 'cui_str': 'Benzoates'}]",[],97.0,0.570097,"RESULTS Two treatments showed similar safety and primary and secondary outcomes. ","[{'ForeName': 'C-H', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': '1 Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.'}, {'ForeName': 'P-K', 'Initials': 'PK', 'LastName': 'Chen', 'Affiliation': '4 School of Medicine, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'S-H', 'Initials': 'SH', 'LastName': 'Wang', 'Affiliation': '6 Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan.'}, {'ForeName': 'H-Y', 'Initials': 'HY', 'LastName': 'Lane', 'Affiliation': '2 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119849815'] 331,31264943,"Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.","BACKGROUND Fragile X syndrome, the most common inherited cause for intellectual disability, is associated with alterations in cholinergic among other neurotransmitter systems. This study investigated the effects of donepezil hydrochloride, a cholinesterase inhibitor that has potential to correct aberrant cholinergic signaling. METHOD Forty-two individuals with fragile X syndrome (mean age=19.61 years) were randomized to receive 2.5-10.0 mg of donepezil ( n =20, seven females) or placebo ( n =22, eight females) per day. One individual in the active group withdrew at week 7. Outcomes included the contingency naming test, the aberrant behavior checklist, and behavior and brain activation patterns during a functional magnetic resonance imaging gaze discrimination task. RESULTS There were no significant differences between active and placebo groups on cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes. At baseline, the active and placebo groups did not differ in functional magnetic resonance imaging activation patterns during the gaze task. After 12 weeks of treatment the active group displayed reduced activation in response to the averted vs direct gaze contrast, relative to the placebo group, in the left superior frontal gyrus. CONCLUSIONS Reduced functional brain activation for the active group may represent less arousal in response to direct eye gaze, relative to the placebo group. Change in functional magnetic resonance imaging activation patterns may serve as a more sensitive metric and predictor of response to treatment when compared to cognitive and behavioral assessments. Our results suggest that donepezil may have an impact on brain functioning, but longer term follow-up and concomitant behavioral intervention may be required to demonstrate improvement in cognition and behavior.",2019,There were no significant differences between active and placebo groups on cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes.,"['Forty-two individuals with fragile X syndrome (mean age=19.61 years', 'fragile X syndrome']","['donepezil', 'placebo', 'donepezil hydrochloride']","['brain functioning', 'cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes', 'contingency naming test, the aberrant behavior checklist, and behavior and brain activation patterns during a functional magnetic resonance imaging gaze discrimination task', 'Brain circuitry, behavior, and cognition', 'functional magnetic resonance imaging activation patterns', 'functional brain activation']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0016667', 'cui_str': 'X-Linked Mental Retardation and Macroorchidism'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0771848', 'cui_str': 'Donepezil hydrochloride'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0443127', 'cui_str': 'Aberrant (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0553544', 'cui_str': 'Gaze (finding)'}, {'cui': 'C0012632', 'cui_str': 'Discrimination'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",42.0,0.268645,There were no significant differences between active and placebo groups on cognitive (contingency naming task) or behavioral (total score or subscales of the aberrant behavior checklist) outcomes.,"[{'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Bruno', 'Affiliation': '1 Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sm Hadi', 'Initials': 'SH', 'LastName': 'Hosseini', 'Affiliation': '1 Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Amy A', 'Initials': 'AA', 'LastName': 'Lightbody', 'Affiliation': '1 Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Mai K', 'Initials': 'MK', 'LastName': 'Manchanda', 'Affiliation': '1 Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Allan L', 'Initials': 'AL', 'LastName': 'Reiss', 'Affiliation': '1 Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119858304'] 332,31707107,Neurofeedback impacts cognition and quality of life in pediatric focal epilepsy: An exploratory randomized double-blinded sham-controlled trial.,"OBJECTIVE Children with epilepsy experience cognitive deficits and well-being issues that have detrimental effects on their development. Pharmacotherapy is the standard of care in epilepsy; however, few interventions exist to promote cognitive development and to mitigate disease burden. We aimed to examine the impact of two different modalities of neurofeedback (NFB) on cognitive functioning and quality-of-life (QOL) measurements in children and adolescents with controlled focal epilepsy. The study also explored the effects of NFB on clinical outcomes and electroencephalography (EEG) quantitative analysis. METHODS Participants (n = 44) with controlled focal epilepsy were randomized to one of three arms: sensorimotor rhythm (SMR) NFB (n = 15), slow cortical potentials (SCP) NFB (n = 16), or sham NFB (n = 13). All participants received 25 sessions of intervention. The attention switching task (AST), Liverpool Seizure Severity Scale (LSSS), seizure frequency (SF), EEG power spectrum, and coherence were measured at baseline, postintervention, and at 3-month follow-up. RESULTS In children and adolescents with controlled focal epilepsy, SMR training significantly reduced reaction time in the AST (p = 0.006), and this was correlated with the difference of change for theta power on EEG (p = 0.03); only the SMR group showed a significant decrease in beta coherence (p = 0.03). All groups exhibited improvement in QOL (p = <0.05). CONCLUSIONS This study provides the first data on two NFB modalities (SMR and SCP) including cognitive, neurophysiological, and clinical outcomes in pediatric epilepsy. Sensorimotor rhythm NFB improved cognitive functioning, while all the interventions showed improvements in QOL, demonstrating a powerful placebo effect in the sham group.",2019,"All groups exhibited improvement in QOL (p = <0.05). ","['pediatric focal epilepsy', 'Participants (n\u202f=\u202f44) with controlled focal epilepsy', 'Children with epilepsy experience cognitive deficits', 'pediatric epilepsy', 'children and adolescents with controlled focal epilepsy']","['neurofeedback (NFB', 'Pharmacotherapy', 'NFB modalities (SMR and SCP', 'NFB', 'sensorimotor rhythm (SMR) NFB (n\u202f=\u202f15), slow cortical potentials (SCP) NFB (n\u202f=\u202f16), or sham NFB']","['reaction time', 'clinical outcomes and electroencephalography (EEG) quantitative analysis', 'Neurofeedback impacts cognition and quality of life', 'cognitive functioning', 'beta coherence', 'QOL', 'cognitive functioning and quality-of-life (QOL) measurements', 'attention switching task (AST), Liverpool Seizure Severity Scale (LSSS), seizure frequency (SF), EEG power spectrum, and coherence']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0014547', 'cui_str': 'Focal Seizure Disorder'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0034380'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",,0.331688,"All groups exhibited improvement in QOL (p = <0.05). ","[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Morales-Quezada', 'Affiliation': 'Neuromodulation Center, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA. Electronic address: jmorales-quezada@partners.org.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Martinez', 'Affiliation': 'Boston Neurodynamics, Brookline, MA, USA; Neocemod, Centro de Neuromodulacion, Aguascalientes, Mexico.'}, {'ForeName': 'Mirret M', 'Initials': 'MM', 'LastName': 'El-Hagrassy', 'Affiliation': 'Neuromodulation Center, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA.'}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Program in Placebo Studies and Therapeutic Encounter, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'M Barry', 'Initials': 'MB', 'LastName': 'Sterman', 'Affiliation': 'Department of Neurobiology, UCLA School of Medicine, USA; Department of Biobehavioral Psychiatry, UCLA School of Medicine, USA.'}, {'ForeName': 'Gloria Y', 'Initials': 'GY', 'LastName': 'Yeh', 'Affiliation': ""Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Osher Center for Integrative Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106570'] 333,31056202,The Autism Managing Eating Aversions and Limited Variety Plan vs Parent Education: A Randomized Clinical Trial.,"OBJECTIVE To assess the feasibility and initial efficacy of a structured parent training program for children with autism spectrum disorder and moderate food selectivity. STUDY DESIGN This 16-week randomized trial compared the Managing Eating Aversions and Limited variety (MEAL) Plan with parent education. MEAL Plan (10 core and 3 booster sessions) provided parents with nutrition education and strategies to structure meals and expand the child's diet. Parent education (10 sessions) provided information about autism without guidance on nutrition, meal structure, or diet. In addition to feasibility outcomes, primary efficacy outcomes included the Clinical Global Impression - Improvement scale and the Brief Autism Mealtime Behaviors Inventory. Grams consumed during a meal observation served as a secondary outcome. RESULTS There were 38 eligible children (19 per group, 32 males). For MEAL Plan, attrition was <10% and attendance >80%. Therapists achieved >90% fidelity. At week 16, positive response rates on the Clinical Global Impression - Improvement scale were 47.4% for the MEAL Plan and 5.3% for parent education (P < .05). The adjusted mean difference (SE) on Brief Autism Mealtime Behaviors Inventory at week 16 was 7.04 (2.71) points (P = .01) in favor of MEAL Plan. For grams consumed, the adjusted standard mean difference (SE) was 30.76 (6.75), also in favor of MEAL Plan (P = .001). CONCLUSIONS The MEAL Plan seems to be feasible, and preliminary efficacy results are encouraging. If further study replicates these results, the MEAL Plan could expand treatment options for children with autism spectrum disorder and moderate food selectivity. TRIAL REGISTRATION Clinicaltrials.gov: NCT02712281.",2019,"At week 16, positive response rates on the Clinical Global Impression - Improvement scale were 47.4% for the MEAL Plan and 5.3% for parent education (P < .05).","['children with autism spectrum disorder and moderate food selectivity', '38 eligible children (19 per group, 32 males']","[""parents with nutrition education and strategies to structure meals and expand the child's diet"", 'structured parent training program', 'Parent education (10 sessions) provided information about autism without guidance on nutrition, meal structure, or diet', 'Limited Variety Plan vs Parent\xa0Education', 'Managing Eating Aversions and Limited variety (MEAL) Plan with parent education']","['Brief Autism Mealtime Behaviors Inventory', 'feasibility and initial efficacy', 'Clinical Global Impression - Improvement scale', 'Clinical Global Impression - Improvement scale and the Brief Autism Mealtime Behaviors Inventory']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0205229', 'cui_str': 'Expanding (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0242261', 'cui_str': 'Parenting Education'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0233496', 'cui_str': 'Aversion (finding)'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0587119', 'cui_str': 'Meal Times'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0222045'}]",38.0,0.0714205,"At week 16, positive response rates on the Clinical Global Impression - Improvement scale were 47.4% for the MEAL Plan and 5.3% for parent education (P < .05).","[{'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Sharp', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Marcus Autism Center, Atlanta, GA. Electronic address: wgsharp@emory.edu.'}, {'ForeName': 'T Lindsey', 'Initials': 'TL', 'LastName': 'Burrell', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Marcus Autism Center, Atlanta, GA.'}, {'ForeName': 'Rashelle C', 'Initials': 'RC', 'LastName': 'Berry', 'Affiliation': 'Marcus Autism Center, Atlanta, GA.'}, {'ForeName': 'Kathryn H', 'Initials': 'KH', 'LastName': 'Stubbs', 'Affiliation': 'Marcus Autism Center, Atlanta, GA.'}, {'ForeName': 'Courtney E', 'Initials': 'CE', 'LastName': 'McCracken', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Gillespie', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Scahill', 'Affiliation': 'Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; Marcus Autism Center, Atlanta, GA.'}]",The Journal of pediatrics,['10.1016/j.jpeds.2019.03.046'] 334,31332027,Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial.,"OBJECTIVE Type 2 diabetes is related to obesity and altered bone health, and both are affected by gut microbiota. We examined associations of weight loss diet-induced changes in a gut microbiota-related metabolite trimethylamine N-oxide (TMAO), and its precursors (choline and l-carnitine), with changes in bone mineral density (BMD) considering diabetes-related factors. RESEARCH DESIGN AND METHODS In the 2-year Preventing Overweight Using Novel Dietary Strategies trial (POUNDS Lost), 264 overweight and obese participants with measurement of BMD by DXA scan were included in the present analysis. The participants were randomly assigned to one of four diets varying in macronutrient intake. Association analysis was performed in pooled participants and different diet groups. Changes in blood levels of TMAO, choline, and l-carnitine from baseline to 6 months after the dietary intervention were calculated. RESULTS We found that a greater reduction in plasma levels of TMAO from baseline to 6 months was associated with a greater loss in whole-body BMD at 6 months and 2 years ( P = 0.03 and P = 0.02). The greater reduction in TMAO was also associated with a greater loss in spine BMD ( P = 0.005) at 2 years, independent of body weight changes. The associations were not modified by baseline diabetes status and glycemic levels. Changes in l-carnitine, a precursor of TMAO, showed interactions with dietary fat intake in regard to changes of spine BMD and hip BMD at 6 months (all P < 0.05). Participants with the smallest decrease in l-carnitine showed less bone loss in the low-fat diet group than the high-fat diet group ( P spine = 0.03 and P hip = 0.02). CONCLUSIONS TMAO might protect against BMD reduction during weight loss, independent of diet interventions varying in macronutrient content and baseline diabetes risk factors. Dietary fat may modify the relation between change in plasma l-carnitine level and changes in BMD. Our findings highlight the importance of investigating the relation between TMAO and bone health in patients with diabetes.",2019,"The greater reduction in TMAO was also associated with a greater loss in spine BMD ( P = 0.005) at 2 years, independent of body weight changes.","['264 overweight and obese participants with measurement of BMD by DXA scan', 'patients with diabetes']","['TMAO', 'four diets varying in macronutrient intake']","['spine BMD', 'Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO', 'TMAO', 'blood levels of TMAO, choline, and l-carnitine', 'plasma levels of TMAO', 'plasma l-carnitine level and changes in BMD', 'l-carnitine', 'bone loss', 'spine BMD and hip BMD']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1959592', 'cui_str': 'DEXA Scan'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C0077194', 'cui_str': 'trimethylammonium oxide'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}]","[{'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbial Community'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0077194', 'cui_str': 'trimethylammonium oxide'}, {'cui': 'C0005768'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008405', 'cui_str': 'Choline'}, {'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}]",264.0,0.0222115,"The greater reduction in TMAO was also associated with a greater loss in spine BMD ( P = 0.005) at 2 years, independent of body weight changes.","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhou', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.'}, {'ForeName': 'Yoriko', 'Initials': 'Y', 'LastName': 'Heianza', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.'}, {'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.'}, {'ForeName': 'Dianjianyi', 'Initials': 'D', 'LastName': 'Sun', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'DiDonato', 'Affiliation': 'Department of Cardiovascular & Metabolic Sciences, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Xiaofang', 'Initials': 'X', 'LastName': 'Pei', 'Affiliation': 'Department of Public Health Laboratory Sciences, West China School of Public Health, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Meryl S', 'Initials': 'MS', 'LastName': 'LeBoff', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Boston, MA.""}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Bray', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.'}, {'ForeName': 'Frank M', 'Initials': 'FM', 'LastName': 'Sacks', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA lqi1@tulane.edu.'}]",Diabetes care,['10.2337/dc19-0134'] 335,31580490,Antioxidant supplementation for lung disease in cystic fibrosis.,"BACKGROUND Airway infection leads to progressive damage of the lungs in cystic fibrosis (CF) and oxidative stress has been implicated in the etiology. Supplementation of antioxidant micronutrients (vitamin E, vitamin C, beta-carotene and selenium) or N-acetylcysteine (NAC) as a source of glutathione, may therefore potentially help maintain an oxidant-antioxidant balance. Glutathione or NAC can also be inhaled and if administered in this way can also have a mucolytic effect besides the antioxidant effect. Current literature suggests a relationship between oxidative status and lung function. This is an update of a previously published review. OBJECTIVES To synthesise existing knowledge on the effect of antioxidants such as vitamin C, vitamin E, beta-carotene, selenium and glutathione (or NAC as precursor of glutathione) on lung function through inflammatory and oxidative stress markers in people with CF. SEARCH METHODS The Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register and PubMed were searched using detailed search strategies. We contacted authors of included studies and checked reference lists of these studies for additional, potentially relevant studies. We also searched online trials registries.Last search of Cystic Fibrosis Trials Register: 08 January 2019. SELECTION CRITERIA Randomised and quasi-randomised controlled studies comparing antioxidants as listed above (individually or in combination) in more than a single administration to placebo or standard care in people with CF. DATA COLLECTION AND ANALYSIS Two authors independently selected studies, extracted data and assessed the risk of bias in the included studies. We contacted study investigators to obtain missing information. If meta-analysed, studies were subgrouped according to supplement, method of administration and the duration of supplementation. We assessed the quality of the evidence using GRADE. MAIN RESULTS One quasi-randomised and 19 randomised controlled studies (924 children and adults) were included; 16 studies (n = 639) analysed oral antioxidant supplementation and four analysed inhaled supplements (n = 285). Only one of the 20 included studies was judged to be free of bias.Oral supplements versus controlThe change from baseline in forced expiratory volume in one second (FEV 1 ) % predicted at three months and six months was only reported for the comparison of NAC to control. Four studies (125 participants) reported at three months; we are uncertain whether NAC improved FEV 1 % predicted as the quality of the evidence was very low, mean difference (MD) 2.83% (95% confidence interval (CI) -2.16 to 7.83). However, at six months two studies (109 participants) showed that NAC probably increased FEV 1 % predicted from baseline (moderate-quality evidence), MD 4.38% (95% CI 0.89 to 7.87). A study of a combined vitamin and selenium supplement (46 participants) reported a greater change from baseline in FEV 1 % predicted in the control group at two months, MD -4.30% (95% CI -5.64 to -2.96). One study (61 participants) found that NAC probably makes little or no difference in the change from baseline in quality of life (QoL) at six months (moderate-quality evidence), standardised mean difference (SMD) -0.03 (95% CI -0.53 to 0.47), but the two-month combined vitamin and selenium study reported a small difference in QoL in favour of the control group, SMD -0.66 (95% CI -1.26 to -0.07). The NAC study reported on the change from baseline in body mass index (BMI) (62 participants) and similarly found that NAC probably made no difference between groups (moderate-quality evidence). One study (69 participants) found that a mixed vitamin and mineral supplement may lead to a slightly lower risk of pulmonary exacerbation at six months than a multivitamin supplement (low-quality evidence). Nine studies (366 participants) provided information on adverse events, but did not find any clear and consistent evidence of differences between treatment or control groups with the quality of the evidence ranging from low to moderate. Studies of β-carotene and vitamin E consistently reported greater plasma levels of the respective antioxidants.Inhaled supplements versus controlTwo studies (258 participants) showed inhaled glutathione probably improves FEV 1 % predicted at three months, MD 3.50% (95% CI 1.38 to 5.62), but not at six months compared to placebo, MD 2.30% (95% CI -0.12 to 4.71) (moderate-quality evidence). The same studies additionally reported an improvement in FEV 1 L in the treated group compared to placebo at both three and six months. One study (153 participants) reported inhaled glutathione probably made little or no difference to the change in QoL from baseline, MD 0.80 (95% CI -1.63 to 3.23) (moderate-quality evidence). No study reported on the change from baseline in BMI at six months, but one study (16 participants) reported at two months and a further study (105 participants) at 12 months; neither study found any difference at either time point. One study (153 participants) reported no difference in the time to the first pulmonary exacerbation at six months. Two studies (223 participants) reported treatment may make little or no difference in adverse events (low-quality evidence), a further study (153 participants) reported that the number of serious adverse events were similar across groups. AUTHORS' CONCLUSIONS With regards to micronutrients, there does not appear to be a positive treatment effect of antioxidant micronutrients on clinical end-points; however, oral supplementation with glutathione showed some benefit to lung function and nutritional status. Based on the available evidence, inhaled and oral glutathione appear to improve lung function, while oral administration decreases oxidative stress; however, due to the very intensive antibiotic treatment and other concurrent treatments that people with CF take, the beneficial effect of antioxidants remains difficult to assess in those with chronic infection without a very large population sample and a long-term study period. Further studies, especially in very young children, using outcome measures such as lung clearance index and the bronchiectasis scores derived from chest scans, with improved focus on study design variables (such as dose levels and timing), and elucidating clear biological pathways by which oxidative stress is involved in CF, are necessary before a firm conclusion regarding effects of antioxidants supplementation can be drawn. The benefit of antioxidants in people with CF who receive CFTR modulators therapies should also be assessed in the future.",2019,Oral supplements versus controlThe change from baseline in forced expiratory volume in one second (FEV 1 ) % predicted at three months and six months was only reported for the comparison of NAC to control.,"['people with CF', 'lung disease in cystic fibrosis', '08 January 2019', '924 children and adults) were included; 16 studies (n = 639) analysed']","['β-carotene and vitamin E', 'Antioxidant supplementation', 'NAC', 'placebo', 'antioxidants', 'Glutathione or NAC', 'mixed vitamin and mineral supplement', 'glutathione', 'combined vitamin and selenium supplement', 'oral antioxidant supplementation and four analysed inhaled supplements', 'antioxidant micronutrients (vitamin E, vitamin C, beta-carotene and selenium) or N-acetylcysteine (NAC', 'antioxidants such as vitamin C, vitamin E, beta-carotene, selenium and glutathione (or NAC as precursor of glutathione']","['risk of pulmonary exacerbation', 'adverse events', 'quality of life (QoL', 'forced expiratory volume', 'FEV', 'oxidative stress', 'number of serious adverse events', 'body mass index (BMI', 'lung function', 'FEV 1 L', 'lung clearance index and the bronchiectasis scores', 'plasma levels', 'QoL', 'standardised mean difference (SMD', 'BMI', 'time to the first pulmonary exacerbation', 'inhaled glutathione probably improves FEV']","[{'cui': 'C0024115', 'cui_str': 'Pulmonary Diseases'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0373568', 'cui_str': 'Carotene measurement (procedure)'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0556112', 'cui_str': 'Mineral supplementation (product)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0521939', 'cui_str': 'Selenium supplement'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0053396', 'cui_str': 'betacarotene'}, {'cui': 'C0036581', 'cui_str': 'Selenium'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034380'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0231990', 'cui_str': 'Lung clearance index (observable entity)'}, {'cui': 'C0006267', 'cui_str': 'Bronchiectasis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",924.0,0.439618,Oral supplements versus controlThe change from baseline in forced expiratory volume in one second (FEV 1 ) % predicted at three months and six months was only reported for the comparison of NAC to control.,"[{'ForeName': 'Oana', 'Initials': 'O', 'LastName': 'Ciofu', 'Affiliation': 'Department of International Health, Immunology and Microbiology, University of Copenhagen, Blegdamsvej 3, Copenhagen, Denmark, 2200.'}, {'ForeName': 'Sherie', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lykkesfeldt', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD007020.pub4'] 336,31827412,The role of maternal social networks on the outcomes of a home-based childhood obesity prevention pilot intervention.,"Background Despite evidence that obesity and related behaviors are influenced by social networks and social systems, few childhood obesity initiatives have focused on social network factors as moderators of intervention outcomes, or targets for intervention strategies. Objectives This pilot study examines associations between maternal social network characteristics hypothesized to influence health behaviors, and the target outcomes of a family-centered childhood obesity prevention initiative. The pilot intervention entailed the provision of healthy eating and activity components as part of an existing home visiting program (HVP) delivered to mothers and infants, to test the feasibility of this approach for improving mother diet, physical activity, and weight status; and infant diet and weight trajectory. Methods Mothers and their infants (N=50 dyads) receiving services from our HVP partner were recruited and randomized to receive the HVP core curriculum with or without a nutrition and physical activity enhancement module for six months. Assessments of mothers' social network characteristics, mother/infant food intake and mother physical activity, and mothers' postpartum weight retention and children's growth velocity were conducted at baseline and post-intervention. Results Several features of mothers' social networks, including the receipt of health-related social support, were significantly associated with the focal intervention outcomes ( p < .05) at follow-up, controlling for study condition. Conclusions Integrating childhood obesity prevention into HVPs appears promising. Future family-based interventions to prevent childhood obesity may be enhanced by including social network intervention strategies. For example, by addressing family network characteristics that impede healthy behavior change, or enhancing networks by fostering social support for healthy behavior and weight change.",2019,"Assessments of mothers' social network characteristics, mother/infant food intake and mother physical activity, and mothers' postpartum weight retention and children's growth velocity were conducted at baseline and post-intervention. ",['Methods\n\n\nMothers and their infants (N=50 dyads) receiving services from our HVP partner'],"['healthy eating and activity components as part of an existing home visiting program (HVP', 'HVP core curriculum with or without a nutrition and physical activity enhancement module for six months']","[""mothers' social network characteristics, mother/infant food intake and mother physical activity, and mothers' postpartum weight retention and children's growth velocity""]","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0682323', 'cui_str': 'Companion'}]","[{'cui': 'C0452415', 'cui_str': 'Healthy Diet'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0220815', 'cui_str': 'curriculum'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C4082120', 'cui_str': 'Six months'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0021274', 'cui_str': 'Infant Food'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4704811', 'cui_str': 'Postpartum Weight Retention'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",50.0,0.0172439,"Assessments of mothers' social network characteristics, mother/infant food intake and mother physical activity, and mothers' postpartum weight retention and children's growth velocity were conducted at baseline and post-intervention. ","[{'ForeName': 'Kayla', 'Initials': 'K', 'LastName': 'de la Haye', 'Affiliation': 'University of Southern California.'}, {'ForeName': 'Brooke M', 'Initials': 'BM', 'LastName': 'Bell', 'Affiliation': 'University of Southern California.'}, {'ForeName': 'Sarah-Jeanne', 'Initials': 'SJ', 'LastName': 'Salvy', 'Affiliation': 'Cedars-Sinai Medical Center.'}]",Journal of social structure : JOSS,['10.21307/joss-2019-004'] 337,31039579,Neural predictors of treatment response to brain stimulation and psychological therapy in depression: a double-blind randomized controlled trial.,"Standard depression treatments, including antidepressant medication and cognitive behavioural therapy (CBT), are ineffective for many patients. Prefrontal transcranial direct current stimulation (tDCS) has been proposed as an alternative treatment, but has shown inconsistent efficacy for depression, and its mechanisms are poorly understood. We recruited unmedicated patients with major depressive disorder (N = 71 approached; N = 39 randomised) for a mechanistic, double-blind, randomized controlled trial consisting of eight weekly sessions of prefrontal tDCS administered to the left prefrontal cortex prior to CBT. We probed (1) whether tDCS improved the efficacy of CBT relative to sham stimulation; and (2) whether neural measures predicted clinical response. We found a modest and non-significant effect of tDCS on clinical outcome over and above CBT (active: 50%; sham: 31.6%; odds ratio: 2.16, 95% CI = 0.59-7.99), but a strong relationship, predicted a priori, between baseline activation during a working memory task in the stimulated prefrontal region and symptom improvement. Repeating our analyses of symptom outcome splitting the sample according to this biomarker revealed that tDCS was significantly superior to sham in individuals with high left prefrontal cortex activation at baseline; we also show 86% accuracy in predicting clinical response using this measure. Exploratory analyses revealed several other regions where activation at baseline was associated with subsequent response to CBT, irrespective of tDCS. This mechanistic trial revealed variable, but predictable, clinical effects of prefrontal tDCS combined with CBT for depression. We have discovered a potential explanation for this variability: individual differences in baseline activation of the region stimulated. Such a biomarker could potentially be used to pre-select patients for trials and, eventually, in the clinic.",2019,"We found a modest and non-significant effect of tDCS on clinical outcome over and above CBT (active: 50%; sham: 31.6%; odds ratio: 2.16, 95% CI = 0.59-7.99), but a strong relationship, predicted a priori, between baseline activation during a working memory task in the stimulated prefrontal region and symptom improvement.","['unmedicated patients with major depressive disorder (N\u2009=\u200971 approached; N\u2009=\u200939 randomised', 'depression']","['antidepressant medication and cognitive behavioural therapy (CBT', 'Prefrontal transcranial direct current stimulation (tDCS', 'prefrontal tDCS', 'brain stimulation and psychological therapy', 'tDCS']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0870227', 'cui_str': 'Brain stimulation'}, {'cui': 'C0841584', 'cui_str': 'Psychological therapies (procedure)'}]",[],,0.175638,"We found a modest and non-significant effect of tDCS on clinical outcome over and above CBT (active: 50%; sham: 31.6%; odds ratio: 2.16, 95% CI = 0.59-7.99), but a strong relationship, predicted a priori, between baseline activation during a working memory task in the stimulated prefrontal region and symptom improvement.","[{'ForeName': 'Camilla L', 'Initials': 'CL', 'LastName': 'Nord', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK. Camilla.Nord@mrc-cbu.cam.ac.uk.'}, {'ForeName': 'D Chamith', 'Initials': 'DC', 'LastName': 'Halahakoon', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}, {'ForeName': 'Tarun', 'Initials': 'T', 'LastName': 'Limbachya', 'Affiliation': 'Camden and Islington NHS Foundation Trust, London, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Charpentier', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}, {'ForeName': 'Níall', 'Initials': 'N', 'LastName': 'Lally', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Walsh', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Leibowitz', 'Affiliation': 'Camden and Islington NHS Foundation Trust, London, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Pilling', 'Affiliation': 'Camden and Islington NHS Foundation Trust, London, UK.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Roiser', 'Affiliation': 'Institute of Cognitive Neuroscience, University College London, London, UK.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0401-0'] 338,31212100,Adaptation of a sustained care cessation intervention for smokers hospitalized for psychiatric disorders: Study protocol for a randomized controlled trial.,"BACKGROUND Individuals with serious mental illness (SMI) smoke at disproportionately higher rates than those without SMI, have lifespans 25-32 years shorter, and thus bear an especially large burden of tobacco-related morbidity and mortality. Several recent studies demonstrate that smokers with SMI can successfully quit smoking with adequate support. Further evidence shows that using technology to deliver sustained care interventions to hospitalized smokers can lead to smoking cessation up to 6 months after discharge. The current comparative effectiveness trial adapts a technology-assisted sustained care intervention designed for smokers admitted to a general hospital and tests whether this approach can produce higher cessation rates compared to usual care for smokers admitted to a psychiatric inpatient unit. METHODS A total of 353 eligible patients hospitalized for psychiatric illness are randomized by cohort into one of two conditions, Sustained Care (SusC) or Usual Care (UC), and are followed for six months after discharge. Participants assigned to UC receive brief tobacco education delivered by a hospital nurse during or soon after admission. Those assigned to SusC receive a 40-min, in-hospital motivational counseling intervention. Upon discharge, they also receive up to 8 weeks of free nicotine patches, automated interactive voice response (IVR) telephone and text messaging, and access to cessation counseling resources lasting 3 months post discharge. Smoking cessation outcomes are measured at 1-, 3- and 6-months post hospital discharge. CONCLUSION Results from this comparative effectiveness trial will add to our understanding of acceptable and effective smoking cessation approaches for patients hospitalized with SMI.",2019,Further evidence shows that using technology to deliver sustained care interventions to hospitalized smokers can lead to smoking cessation up to 6 months after discharge.,"['smokers admitted to a general hospital', 'smokers admitted to a psychiatric inpatient unit', 'hospitalized smokers', 'Individuals with serious mental illness (SMI) smoke', 'smokers hospitalized for psychiatric disorders', 'patients hospitalized with SMI', '353 eligible patients hospitalized for psychiatric illness']","['UC receive brief tobacco education', 'technology-assisted sustained care intervention', 'sustained care cessation intervention', 'hospital motivational counseling intervention', 'nicotine patches, automated interactive voice response (IVR) telephone and text messaging, and access to cessation counseling resources lasting 3\u202fmonths post discharge', 'Sustained Care (SusC) or Usual Care (UC']",['Smoking cessation outcomes'],"[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric inpatient'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0915075', 'cui_str': 'samarium diiodide'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]","[{'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]",353.0,0.0619445,Further evidence shows that using technology to deliver sustained care interventions to hospitalized smokers can lead to smoking cessation up to 6 months after discharge.,"[{'ForeName': 'Jacki', 'Initials': 'J', 'LastName': 'Hecht', 'Affiliation': 'School of Nursing, The University of Texas at Austin, Austin, TX, United States of America.'}, {'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Rigotti', 'Affiliation': 'Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School Boston, MA, United States of America.'}, {'ForeName': 'Haruka', 'Initials': 'H', 'LastName': 'Minami', 'Affiliation': 'Department of Psychology, Fordham University, Bronx, NY, United States of America.'}, {'ForeName': 'Kimberly L', 'Initials': 'KL', 'LastName': 'Kjome', 'Affiliation': 'Ascension Seton Shoal Creek Hospital and Department of Psychiatry, Dell Medical School at the University of Texas at Austin, Austin, TX, United States of America.'}, {'ForeName': 'Erika L', 'Initials': 'EL', 'LastName': 'Bloom', 'Affiliation': 'Rhode Island Hospital and the Departments of Psychiatry and Human Behavior and Medicine, Alpert Medical School of Brown University, United States of America.'}, {'ForeName': 'Christopher W', 'Initials': 'CW', 'LastName': 'Kahler', 'Affiliation': 'Center for Alcohol and Addiction Studies and the Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America.'}, {'ForeName': 'Lawrence H', 'Initials': 'LH', 'LastName': 'Price', 'Affiliation': 'Butler Hospital and the Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, United States of America.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Levy', 'Affiliation': 'Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital and Harvard Medical School Boston, MA, United States of America.'}, {'ForeName': 'Kelly M', 'Initials': 'KM', 'LastName': 'Carpenter', 'Affiliation': 'Center for Wellbeing Research, Optum, Seattle, WA, United States of America.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Brown', 'Affiliation': 'School of Nursing, The University of Texas at Austin, Austin, TX, United States of America. Electronic address: brown2@utexas.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.001'] 339,31219367,Impulsivity moderates the effects of dopamine D2 and mixed D1-D2 antagonists in individuals with gambling disorder.,"BACKGROUND The functional role of dopamine D1 and D2 receptors in gambling disorder (GD) remains unclear. AIMS This study aimed to investigate the role of D1 activation and the moderating effects of impulsivity, a trait linked with weaker D2-mediated inhibition of dopamine release, in GD subjects. METHODS Thirty (nine female) non-comorbid GD subjects with low (LI), moderate (MI), or high impulsivity (HI) received the preferential D2 antagonist haloperidol (HAL; 3 mg) or the mixed D1-D2 antagonist fluphenazine (FLU; 3 mg), on separate sessions before a 15-minute slot machine game or amphetamine (AMPH; 20 mg), in a placebo-controlled, double-blind, counterbalanced design. RESULTS On their own, HAL and FLU led to linear increases and decreases, respectively, in desire to gamble across increasing levels of impulsivity. The slot machine and AMPH each evoked an inverted-U pattern of desire to gamble across increasing impulsivity. HAL reversed this effect of the game, whereas FLU did not alter post-game desire. HAL and FLU decreased and increased psychostimulant-like effects of the game, respectively, in LI and MI subjects, but consistently reduced these effects in HI subjects. HAL also altered the salience of negative affective words on a reading task, such that greater salience of negative words coincided with lower post-game desire to gamble. CONCLUSIONS D1 receptors appear to gauge the incentive value of gambling in GD subjects. D1 activation has negative reinforcing effects in HI gamblers and positive reinforcing effects in LI gamblers. Medications that activate D1 could curtail chasing in HI gamblers. D1 blockade could benefit HI gamblers whose main concern is craving.",2019,"HAL and FLU decreased and increased psychostimulant-like effects of the game, respectively, in LI and MI subjects, but consistently reduced these effects in HI subjects.","['gambling disorder (GD', 'LI gamblers', 'nine female) non-comorbid GD subjects with low (LI), moderate (MI), or high impulsivity (HI) received the', 'Thirty', 'individuals with gambling disorder', 'GD subjects', 'HI gamblers']","['HAL', 'amphetamine (AMPH', 'D1 blockade', 'preferential D2 antagonist haloperidol (HAL; 3\u2009mg) or the mixed D1-D2 antagonist fluphenazine (FLU', 'dopamine D2 and mixed D1-D2 antagonists', 'dopamine D1 and D2 receptors', 'placebo-controlled, double-blind, counterbalanced design']",['HAL and FLU'],"[{'cui': 'C0030662', 'cui_str': 'Gambling, Pathologic'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}]","[{'cui': 'C0002658', 'cui_str': 'Amphetamine'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}, {'cui': 'C0016368', 'cui_str': 'Fluphenazine'}, {'cui': 'C0021400', 'cui_str': 'Influenza, Human'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C0021400', 'cui_str': 'Influenza, Human'}]",39.0,0.0602228,"HAL and FLU decreased and increased psychostimulant-like effects of the game, respectively, in LI and MI subjects, but consistently reduced these effects in HI subjects.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Zack', 'Affiliation': '1 Molecular Brain Sciences Research Department, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Lobo', 'Affiliation': '1 Molecular Brain Sciences Research Department, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.'}, {'ForeName': 'Candice', 'Initials': 'C', 'LastName': 'Biback', 'Affiliation': '2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Fang', 'Affiliation': '2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Smart', 'Affiliation': '2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Tatone', 'Affiliation': '2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Aditi', 'Initials': 'A', 'LastName': 'Kalia', 'Affiliation': '2 Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Digiacomo', 'Affiliation': '3 Department of Psychiatry, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Kennedy', 'Affiliation': '1 Molecular Brain Sciences Research Department, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119855972'] 340,31788880,"Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial.","Depression in patients with diabetes is associated with poor glycemic control and linked to an increased risk for diabetes complications such as neuropathy. Curcumin has shown potential antidepressant-like activities in some studies. The present study is the first randomized controlled trial to test the efficacy of nano-curcumin supplementation on depression, anxiety, and stress in patients with diabetic polyneuropathy. Eighty patients with diabetes were enrolled in this parallel, double-blind, randomized, placebo-controlled clinical trial. The participants were allocated randomly to the intervention (n = 40) and control (n = 40) groups. They received 80 mg of nano-curcumin or placebo capsules daily for 8 weeks. At baseline and end of study, anthropometric measurements, dietary intake, physical activity, glycemic indices, and severity of neuropathy were assessed. The depression, anxiety, and stress level were measured by Depression, Anxiety, Stress Scale (DASS-21-items) questionnaire before and after the intervention. After intervention, there was a significant reduction in the mean score of depression in the nano-curcumin group (from 16.7 [3.1] to 15.3 [2.6]) compared with placebo group (17.5 [3.2] to 17.3 [3.1]; p = .02). In addition, a significant fall was found in the mean score of anxiety in the nano-curcumin group (from 22.4 [4.03] to 20.6 [3.4]) compared with the placebo group (21.9 [3.5] to 21.2 [3.5]; p = .009). Changes in stress score were not statistically significant between the two groups. These findings suggested that nano-curcumin supplementation for 8 weeks was effective in reducing depression and anxiety scores in patients with diabetic polyneuropathy.",2020,Changes in stress score were not statistically significant between the two groups.,"['patients with diabetic polyneuropathy', 'Eighty patients with diabetes', 'diabetic patients with peripheral neuropathy', 'patients with diabetes']","['placebo', 'nano-curcumin supplementation', 'nano-curcumin or placebo', 'nano-curcumin supplement']","['depression and anxiety', 'Depression, Anxiety, Stress Scale (DASS-21-items) questionnaire', 'Changes in stress score', 'depression and anxiety scores', 'mean score of anxiety', 'depression, anxiety, and stress level', 'depression, anxiety, and stress', 'anthropometric measurements, dietary intake, physical activity, glycemic indices, and severity of neuropathy', 'mean score of depression']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0271680', 'cui_str': 'Diabetic Polyneuropathies'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0031117', 'cui_str': 'PNS (Peripheral Nervous System) Diseases'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0222045'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}]",80.0,0.251825,Changes in stress score were not statistically significant between the two groups.,"[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Asadi', 'Affiliation': ""Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Mohammad Saeed', 'Initials': 'MS', 'LastName': 'Gholami', 'Affiliation': 'Department of Community Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Fereydoun', 'Initials': 'F', 'LastName': 'Siassi', 'Affiliation': 'Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Qorbani', 'Affiliation': 'Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.'}, {'ForeName': 'Gity', 'Initials': 'G', 'LastName': 'Sotoudeh', 'Affiliation': 'Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6571'] 341,31828863,"The effects of wheat germ supplementation on metabolic profile in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.","The aim of the present trial was to examine the effects of wheat germ (WG) consumption on metabolic control and oxidative stress status of type 2 diabetes mellitus (T2DM) patients. Eighty participants with T2DM were randomly allocated to receive 20-g WG (n = 40) or placebo (n = 40) in a randomized double-blind clinical trial for 12 weeks. Serum lipid profiles, glycaemic indices, total antioxidant capacity, and malondialdhyde (MDA) were assessed. A total of 75 subjects completed the trial. Compared with the placebo, WG consumption led to significant reduction in total cholesterol (TC) concentrations (p = .04). There was a trend regarding TC to high density lipoprotein ratio (p = .08) following 12 weeks WG consumption, although they were not statistically significant after correcting for multiple testing. In addition, within-group comparison revealed a significant rise in total antioxidant capacity concentration (p = .001) in WG group. We observed no significant effects of WG intake on glycaemic status, blood pressure, MDA, triglyceride, and low density lipoprotein levels. WG consumption for 12 weeks could decrease serum TC levels and had no significant effects on other metabolic variables and MDA in patients with T2DM. Though observed health benefit effects were small, it might lead to a major impact on wider public health.",2020,"Compared with the placebo, WG consumption led to significant reduction in total cholesterol (TC) concentrations (p = .04).","['type 2 diabetes mellitus (T2DM) patients', 'patients with type 2 diabetes mellitus', 'patients with T2DM', 'Eighty participants with T2DM', '75 subjects completed the trial']","['placebo', '20-g WG', 'wheat germ supplementation', 'wheat germ (WG) consumption']","['TC to high density lipoprotein ratio', 'metabolic control and oxidative stress status', 'total antioxidant capacity concentration', 'metabolic variables and MDA', 'total cholesterol (TC) concentrations', 'glycaemic status, blood pressure, MDA, triglyceride, and low density lipoprotein levels', 'serum TC levels', 'metabolic profile', 'Serum lipid profiles, glycaemic indices, total antioxidant capacity, and malondialdhyde (MDA']","[{'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0450403', 'cui_str': '20G (qualifier value)'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",80.0,0.580839,"Compared with the placebo, WG consumption led to significant reduction in total cholesterol (TC) concentrations (p = .04).","[{'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Mohammadi', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mozhgan', 'Initials': 'M', 'LastName': 'Karimifar', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Heidari', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Zare', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Amani', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6570'] 342,30867551,Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.,"Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. They may have additional therapeutic utility also in the absence of opioid agonist drugs, but the onset and duration of action at brain MORs have been inadequately characterized to allow such projections. This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the absence of a competing opioid agonist. Fourteen participants were scanned twice using positron emission tomography (PET) and [ 11 C]carfentanil, a selective MOR agonist radioligand. Concentrations of naloxone in plasma and MOR availability (relative to placebo) were monitored from 0 to 60 min and at 300-360 min post naloxone. Naloxone plasma concentrations peaked at ~20 min post naloxone, associated with slightly delayed development of brain MOR occupancy (half of peak occupancy reached at ~10 min). Estimated peak occupancies were 67 and 85% following 2 and 4 mg IN doses, respectively. The estimated half-life of occupancy disappearance was ~100 min. The rapid onset of brain MOR occupancy by IN naloxone, evidenced by the rapid onset of its action in opioid overdose victims, was directly documented in humans for the first time. The employed high temporal-resolution PET method establishes a model that can be used to predict brain MOR occupancy from plasma naloxone concentrations. IN naloxone may have therapeutic utility in various addictions where brain opioid receptors are implicated, such as gambling disorder and alcohol use disorder.",2019,Naloxone plasma concentrations peaked at ~20 ,"['healthy volunteers', 'human subjects', 'Fourteen participants were']","['naloxone', 'scanned twice using positron emission tomography (PET) and [ 11 C]carfentanil, a selective MOR agonist radioligand', 'intranasal (IN) naloxone', 'naloxone, a mu-opioid receptor (MOR) antagonist', 'Intranasal naloxone']","['Naloxone plasma concentrations', 'brain MOR occupancy', 'Estimated peak occupancies', 'plasma and MOR availability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C3715152', 'cui_str': '14'}]","[{'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0441633'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0066908', 'cui_str': 'Receptors, mu'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0027358', 'cui_str': 'Naloxone'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",14.0,0.0381696,Naloxone plasma concentrations peaked at ~20 ,"[{'ForeName': 'Jarkko', 'Initials': 'J', 'LastName': 'Johansson', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, Finland. Jarkko.johansson@umu.se.'}, {'ForeName': 'Jussi', 'Initials': 'J', 'LastName': 'Hirvonen', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, Finland.'}, {'ForeName': 'Zsófia', 'Initials': 'Z', 'LastName': 'Lovró', 'Affiliation': 'Clinical Research Services Turku - CRST Ltd, Turku, Finland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ekblad', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, Finland.'}, {'ForeName': 'Valtteri', 'Initials': 'V', 'LastName': 'Kaasinen', 'Affiliation': 'Division of Clinical Neurosciences, University of Turku and Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Rajasilta', 'Affiliation': 'Institute of Biomedicine, University of Turku and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Semi', 'Initials': 'S', 'LastName': 'Helin', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, Finland.'}, {'ForeName': 'Jouni', 'Initials': 'J', 'LastName': 'Tuisku', 'Affiliation': 'Turku PET Centre, University of Turku, Turku, Finland.'}, {'ForeName': 'Saija', 'Initials': 'S', 'LastName': 'Sirén', 'Affiliation': 'Institute of Biomedicine, University of Turku and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Mirka', 'Initials': 'M', 'LastName': 'Pennanen', 'Affiliation': 'Clinical Research Services Turku - CRST Ltd, Turku, Finland.'}, {'ForeName': 'Arvind', 'Initials': 'A', 'LastName': 'Agrawal', 'Affiliation': 'Opiant Pharmaceuticals Inc., Santa Monica, CA, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Crystal', 'Affiliation': 'Opiant Pharmaceuticals Inc., Santa Monica, CA, USA.'}, {'ForeName': 'Petri J', 'Initials': 'PJ', 'LastName': 'Vainio', 'Affiliation': 'Institute of Biomedicine, University of Turku and Unit of Clinical Pharmacology, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Alho', 'Affiliation': 'National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Scheinin', 'Affiliation': 'Clinical Research Services Turku - CRST Ltd, Turku, Finland.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0368-x'] 343,30912701,Evaluation of simulated driving in comparison to laboratory-based tests to assess the pharmacodynamics of alprazolam and alcohol.,"RATIONALE Assessment of the effects of medicines on the risks of car driving must be derived from laboratory tests, simulated driving or real on-road driving tests. Relevance of tests is determined by their sensitivity and predictive ability for the probability of accidents or damage. This cannot be determined directly, but methods should be able to at least detect the effects of a positive control in dosage known to be clearly associated with increased risk. OBJECTIVES A driving simulator was evaluated in comparison with a battery of validated tests of CNS performance, the NeuroCart®. Alcohol in a concentration exactly at the legal limit (0.5 g L -1 ) and well above (1.0 g L -1 ) as well as alprazolam (1 mg) was used as positive control. METHODS This was a randomised, cross-over study using a double dummy blinded design in 24 healthy study subjects (12 M, 12 F) aged 20-43 years. Alcohol was infused intravenously using a validated clamping protocol to obtain concentrations of 0.5 g L -1 and on another occasion 1.0 g L -1 . Alprazolam was given orally. Driving tests and lab tests were done at regular time intervals during a study day. RESULTS Alprazolam and alcohol significantly affected the main parameters of driving in the simulator and affected scores of safe driving and alprazolam increased the odds ratio of a virtual crash. Several laboratory measurements of psychomotor performance were affected by the reference substances as expected and correlated significantly with the driving performance. CONCLUSIONS The driving simulator can detect effects of reference substances at levels that are known to negatively affect driving.",2019,"RESULTS Alprazolam and alcohol significantly affected the main parameters of driving in the simulator and affected scores of safe driving and alprazolam increased the odds ratio of a virtual crash.","['24 healthy study subjects (12 M, 12 F) aged 20-43 years']","['alprazolam', 'Alprazolam', 'alprazolam and alcohol', 'Alcohol']","['psychomotor performance', 'odds ratio of a virtual crash']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0002333', 'cui_str': 'Alprazolam'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0033923', 'cui_str': 'Psychomotor Performance'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",24.0,0.085144,"RESULTS Alprazolam and alcohol significantly affected the main parameters of driving in the simulator and affected scores of safe driving and alprazolam increased the odds ratio of a virtual crash.","[{'ForeName': 'Coen Rh', 'Initials': 'CR', 'LastName': 'Huizinga', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Rob G', 'Initials': 'RG', 'LastName': 'Zuiker', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Marieke L', 'Initials': 'ML', 'LastName': 'de Kam', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Ziagkos', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Jorrit', 'Initials': 'J', 'LastName': 'Kuipers', 'Affiliation': '2 Green Dino BV, Wageningen, The Netherlands.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Mejia', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Joop Ma', 'Initials': 'JM', 'LastName': 'van Gerven', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Adam F', 'Initials': 'AF', 'LastName': 'Cohen', 'Affiliation': '1 Centre for Human Drug Research, Leiden, The Netherlands.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119836198'] 344,31229621,Health coaching to encourage obese adults to enroll in commercially-available weight management programs: The path to health study.,"Physicians are recommended to screen and refer obese patients to weight management programs (WMPs). There are often limited referral options for physicians, though commercially-available WMPs could be a potential solution. The purpose of this study (Path to Health) was to evaluate the efficacy of health coaching to promote enrollment in commercially-available WMPs through a two-arm, RCT with obese patients (n = 168) randomly assigned to intervention (n = 84) or control groups (n = 84). Intervention participants received phone health coaching to help them select and enroll in WMPs. We collected data on program enrollment, weight, self-reported physical activity (PA), and fruit and vegetable (FV) intake at baseline, 3- and 6-months. We used logistic regression to assess the intervention effect on enrollment in WMPs and longitudinal regression models to evaluate the effect on weight change, PA and FV intake. The average age was 54.7 years, 59% were female and 43% were Black and 49% were White. At 6 months, 39% of the intervention group (vs. 29% of control) had enrolled in WMPs. We found no longitudinal intervention effect on weight, PA and FV intake. We found that there was more weight loss for those who completed ≥4 calls as compared to those who completed <4 calls. We also found significant dose response relationships for PA and FV intake at 3 months. In this study, we found that phone health coaching was successful in increasing obese adults' enrollment in commercially-available WMPs and that there was a dose response relationship for weight and behavioral outcomes.",2019,We found that there was more weight loss for those who completed ≥4 calls as compared to those who completed <4 calls.,"['obese patients (n\u202f=\u202f168) randomly assigned to intervention (n\u202f=\u202f84) or control groups (n\u202f=\u202f84', 'The average age was 54.7\u202fyears, 59% were female and 43% were Black and 49% were White']","['Health coaching', 'health coaching', 'phone health coaching to help them select and enroll in WMPs', 'phone health coaching']","['weight loss', 'weight, PA and FV intake', 'WMPs', 'weight, self-reported physical activity (PA), and fruit and vegetable (FV) intake', 'weight change, PA and FV intake']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1271941', 'cui_str': 'Fruit and vegetable intake'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}]",168.0,0.0245321,We found that there was more weight loss for those who completed ≥4 calls as compared to those who completed <4 calls.,"[{'ForeName': 'Natalia I', 'Initials': 'NI', 'LastName': 'Heredia', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Health Disparities Research, 1400 Pressler St, Houston, TX 77030, United States. Electronic address: niheredia@mdanderson.org.'}, {'ForeName': 'MinJae', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'McGovern Medical School at The University of Texas Health Science Center at Houston, United States.'}, {'ForeName': 'Kevin O', 'Initials': 'KO', 'LastName': 'Hwang', 'Affiliation': 'McGovern Medical School at The University of Texas Health Science Center at Houston, United States.'}, {'ForeName': 'Belinda M', 'Initials': 'BM', 'LastName': 'Reininger', 'Affiliation': 'The University of Texas Health Science Center Houston, School of Public Health in Brownsville, United States.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Fernandez', 'Affiliation': 'The University of Texas Health Science Center at Houston, School of Public Health, United States.'}, {'ForeName': 'Lorna H', 'Initials': 'LH', 'LastName': 'McNeill', 'Affiliation': 'The University of Texas MD Anderson Cancer Center, Health Disparities Research, 1400 Pressler St, Houston, TX 77030, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.006'] 345,31229622,Protocol for a cluster-randomized controlled trial of a technology-assisted health coaching intervention for weight management in primary care: The GEM (goals for eating and moving) study.,"INTRODUCTION Over one-third of American adults have obesity with increased risk of chronic disease. Primary care providers often do not counsel patients about weight management due to barriers such as lack of time and training. To address this problem, we developed a technology-assisted health coaching intervention called Goals for Eating and Moving (GEM) to facilitate obesity counseling within the patient-centered medical home (PCMH) model of primary care. The objective of this paper is to describe the rationale and design of a cluster-randomized controlled trial to test the GEM intervention when compared to Enhanced Usual Care (EUC). METHOD We have randomized 19 PCMH teams from two NYC healthcare systems (VA New York Harbor Healthcare System and Montefiore Medical Group practices) to either the GEM intervention or EUC. Eligible participants are English and Spanish-speaking primary care patients (ages 18-69 years) with obesity or who are overweight with comorbidity (e.g., arthritis, sleep apnea, hypertension). The GEM intervention consists of a tablet-delivered goal setting tool, a health coaching visit and twelve telephone calls for patients, and provider counseling training. Patients in the EUC arm receive health education materials. The primary outcome is mean weight loss at 1 year. Secondary outcomes include changes in waist circumference, diet, and physical activity. We will also examine the impact of GEM on obesity-related provider counseling competency and attitudes. CONCLUSION If GEM is found to be efficacious, it could provide a structured approach for improving weight management for diverse primary care patient populations with elevated cardiovascular disease risk.",2019,"If GEM is found to be efficacious, it could provide a structured approach for improving weight management for diverse primary care patient populations with elevated cardiovascular disease risk.","['primary care', 'Eligible participants are English and Spanish-speaking primary care patients (ages 18-69\u202fyears) with obesity or who are overweight with comorbidity (e.g., arthritis, sleep apnea, hypertension']","['technology-assisted health coaching intervention called Goals for Eating and Moving (GEM', 'GEM intervention or EUC', 'GEM', 'provider counseling training', 'technology-assisted health coaching intervention', 'health education materials', 'GEM intervention']","['changes in waist circumference, diet, and physical activity', 'mean weight loss']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C3666006', 'cui_str': 'Arthritis (SMQ)'}, {'cui': 'C0037315', 'cui_str': 'Sleep Hypopnea'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0578671', 'cui_str': 'Does move (finding)'}, {'cui': 'C0445501', 'cui_str': 'Gem (qualifier value)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0018701'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]",,0.0379654,"If GEM is found to be efficacious, it could provide a structured approach for improving weight management for diverse primary care patient populations with elevated cardiovascular disease risk.","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Wittleder', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: sandra.wittleder@nyulangone.org.'}, {'ForeName': 'Adefunke', 'Initials': 'A', 'LastName': 'Ajenikoko', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: adefunke.ajenikoko@nyulangone.org.'}, {'ForeName': 'Dylaney', 'Initials': 'D', 'LastName': 'Bouwman', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: dylaney.bouwman@nyulangone.org.'}, {'ForeName': 'Yixin', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: yixin.fang@nyulangone.org.'}, {'ForeName': 'M Diane', 'Initials': 'MD', 'LastName': 'McKee', 'Affiliation': 'Department of Family and Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Electronic address: diane.mckee@einstein.yu.edu.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Meissner', 'Affiliation': 'Department of Family and Social Medicine, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Electronic address: pmeissne@montefiore.org.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Orstad', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: stephanie.orstad@nyulangone.org.'}, {'ForeName': 'Colin D', 'Initials': 'CD', 'LastName': 'Rehm', 'Affiliation': 'Office of Community & Population Health, Montefiore Medical Center, 3514 Dekalb Ave, Bronx, NY 10467, USA. Electronic address: crehm@montefiore.org.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Sherman', 'Affiliation': 'Department of Population Health, New York University School of Medicine, 550 1(st) Avenue, New York, NY 10016, USA; Veterans Affairs New York Harbor Healthcare System, 423 East 23rd Street, New York, NY 10010, USA. Electronic address: scott.sherman@nyulangone.org.'}, {'ForeName': 'Shea', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: shea.smith@nyulangone.org.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Sweat', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine and Clinical Innovation, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: victoria.sweat@nyulangone.org.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Velastegui', 'Affiliation': 'Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Electronic address: lorena.velastegui@einstein.yu.edu.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Wylie-Rosett', 'Affiliation': 'Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA. Electronic address: judith.wylie-rosett@einstein.yu.edu.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Jay', 'Affiliation': 'Veterans Affairs New York Harbor Healthcare System, 423 East 23rd Street, New York, NY 10010, USA; Department of Medicine and Population Health, New York University School of Medicine, 550 1st Avenue, New York, NY 10016, USA. Electronic address: melanie.jay@nyulangone.org.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.005'] 346,31233859,"Kids SIPsmartER, a cluster randomized controlled trial and multi-level intervention to improve sugar-sweetened beverages behaviors among Appalachian middle-school students: Rationale, design & methods.","The intake of sugar-sweetened beverages (SSB) is disproportionately high in Appalachia, including among adolescents whose intake is more than double the national average and more than four times the recommended daily amount. Unfortunately, there is insufficient evidence for effective strategies targeting SSB behaviors among Appalachian youth in real-world settings, including rural schools. Kids SIPsmartER is a 6-month, school-based, behavior and health literacy program aimed at improving SSB behaviors among middle school students. The program also integrates a two-way short message service (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes. Kids SIPsmartER is grounded by the Theory of Planned Behavior and health literacy, media literacy, numeracy, and public health literacy concepts. Guided by the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance), this type 1 hybrid design and cluster randomized controlled trial targets 12 Appalachian middle schools in southwest Virginia. The primary aim evaluates changes in SSB behaviors at 7-months among 7th grade students at schools receiving Kids SIPsmartER, as compared to control schools. Secondary outcomes include other changes in students (e.g., BMI, quality of life, theory-related variables) and caregivers (e.g., SSB behaviors, home SSB environment), and 19-month maintenance of these outcomes. Reach is assessed, along with mixed-methods strategies (e.g., interviews, surveys, observation) to determine how teachers implement Kids SIPsmartER and the potential for institutionalization within schools. This paper discusses the rationale for implementing and evaluating a type 1 hybrid design and multi-level intervention addressing pervasive SSB behaviors in Appalachia. Clincialtrials.gov: NCT03740113.",2019,"Kids SIPsmartER is grounded by the Theory of Planned Behavior and health literacy, media literacy, numeracy, and public health literacy concepts.","['12 Appalachian middle schools in southwest Virginia', 'Appalachian middle-school students', 'middle school students']","['multi-level intervention', 'sugar-sweetened beverages (SSB']","['changes in students (e.g., BMI, quality of life, theory-related variables) and caregivers (e.g., SSB behaviors, home SSB environment), and 19-month maintenance of these outcomes', 'SSB behaviors']","[{'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}, {'cui': 'C0042753', 'cui_str': 'Virginia'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0034380'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]",12.0,0.0638532,"Kids SIPsmartER is grounded by the Theory of Planned Behavior and health literacy, media literacy, numeracy, and public health literacy concepts.","[{'ForeName': 'Jamie M', 'Initials': 'JM', 'LastName': 'Zoellner', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA. Electronic address: Jz9q@virginia.edu.'}, {'ForeName': 'Kathleen J', 'Initials': 'KJ', 'LastName': 'Porter', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'You', 'Affiliation': 'Virginia Tech, Department of Agricultural and Applied Economics, 321A Hutcheson Hall, 24060, USA.'}, {'ForeName': 'Phillip I', 'Initials': 'PI', 'LastName': 'Chow', 'Affiliation': 'University of Virginia, Department of Psychiatry and Neurobehavioral Sciences, 560 Ray C Hunt Drive, Charlottesville, Virginia 22908, USA.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Ritterband', 'Affiliation': 'University of Virginia, Department of Psychiatry and Neurobehavioral Sciences, 560 Ray C Hunt Drive, Charlottesville, Virginia 22908, USA.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Yuhas', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Loyd', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA.'}, {'ForeName': 'Brittany A', 'Initials': 'BA', 'LastName': 'McCormick', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA.'}, {'ForeName': 'Donna-Jean P', 'Initials': 'DP', 'LastName': 'Brock', 'Affiliation': 'University of Virginia, Department of Public Health Sciences, UVA Cancer Center Research and Outreach Office, 16 East Main Street, Christiansburg, VA 24073, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.011'] 347,32027620,Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.,"BACKGROUNDThe anti-programmed cell death 1 (anti-PD-1) antibody pembrolizumab is clinically active against non-small cell lung cancer (NSCLC). In addition to T cells, human natural killer (NK) cells, reported to have the potential to prolong the survival of patients with advanced NSCLC, also express PD-1. This study aimed to investigate the safety and efficacy of pembrolizumab plus allogeneic NK cells in patients with previously treated advanced NSCLC.METHODSIn total, 109 enrolled patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or higher were randomly allocated to group A (n = 55 patients given pembrolizumab plus NK cells) or group B (n = 54 patients given pembrolizumab alone). The patients received i.v. pembrolizumab (10 mg/kg) once every 3 weeks and continued treatment until the occurrence of tumor progression or unacceptable toxicity. The patients in group A continuously received 2 cycles of NK cell therapy as 1 course of treatment.RESULTSIn our study, patients in group A had longer survival than did patients in group B (median overall survival [OS]: 15.5 months vs. 13.3 months; median progression-free survival [PFS]: 6.5 months vs. 4.3 months; P < 0.05). In group A patients with a TPS of 50% or higher, the median OS and PFS was significantly longer. Moreover, the patients in group A treated with multiple courses of NK cell infusion had better OS (18.5 months) than did those who received a single course of NK cell infusion (13.5 months).CONCLUSIONPembrolizumab plus NK cell therapy yielded improved survival benefits in patients with previously treated PD-L1+ advanced NSCLC.TRIAL REGISTRATIONClinicalTrials.gov NCT02843204.FUNDINGThis work was supported by grants from the National Natural Science Foundation of China (NSFC) - Guangdong Joint Foundation of China (no. U1601225); the NSFC (no. 81671965); the Guangdong Provincial Key Laboratory Construction Project of China (no. 2017B030314034); and the Key Scientific and Technological Program of Guangzhou City (no. 201607020016).",2020,"CONCLUSIONS Pembrolizumab plus NK cell therapy yielded improved survival benefits in patients with previously treated PD-L1-positive advanced NSCLC.","['patients with previously treated PD-L1-positive advanced NSCLC', 'patients with previously treated advanced NSCLC.\nMETHODS', '109 enrolled patients with a programmed death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1', 'advanced non-small cell lung cancer patients']","['NK cell therapy', 'intravenous pembrolizumab', 'Pembrolizumab plus allogeneic NK cells', 'pembrolizumab plus NK cells', 'Pembrolizumab plus NK cell therapy', 'pembrolizumab plus allogeneic NK cells']","['safety and efficacy', 'median OS and PFS', 'survival benefits', 'better survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0023688', 'cui_str': 'Ligands'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}]","[{'cui': 'C0022688', 'cui_str': 'NK Cells'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}]",109.0,0.0803667,"CONCLUSIONS Pembrolizumab plus NK cell therapy yielded improved survival benefits in patients with previously treated PD-L1-positive advanced NSCLC.","[{'ForeName': 'Mao', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failure Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Haihua', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failure Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Shuzhen', 'Initials': 'S', 'LastName': 'Liang', 'Affiliation': 'Medical Research Centre, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jibing', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Guangzhou, China.'}, {'ForeName': 'Aihua', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Lizhi', 'Initials': 'L', 'LastName': 'Niu', 'Affiliation': 'Biological Treatment Center, Fuda Cancer Hospital, Jinan University, Guangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Guangdong Provincial Key Laboratory of Proteomics, State Key Laboratory of Organ Failure Research, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.'}]",The Journal of clinical investigation,['10.1172/JCI132712'] 348,32275361,[Clinical observation of tiaoshen acupuncture on restless leg syndrome].,"OBJECTIVE To observe the clinical therapeutic effect of tiaoshen acupuncture (acupuncture for regulating the spirit) on restless leg syndrome and its concomitance symptoms of sleep disorder and anxiety, and to provide theoretical basis for the clinical application of tiaoshen acupuncture. METHODS A total of 60 patients were randomized into an observation group and a control group, 30 cases in each one. Conventional acupuncture at lower limbs' acupoints such as Zusanli (ST 36), Yanglingquan (GB 34) and Xuanzhong (GB 39) was applied in the control group. On the basis of the control group, acupuncture at Baihui (GV 20), Shenting (GV 24) and Benshen (GB 13) was added in the observation group. In both groups, the treatment was given once a day, 6 times a week, one week as a course and totally 3 courses were required. Scores of international restless leg syndrome rating scale (IRLS), Pittsburgh sleep quality index (PSQI) and Hamilton anxiety scale (HAMA) were observed before and after treatment in the two groups. RESULTS Compared before treatment, scores of IRLS, PSQI and HAMA after treatment were decreased in both groups ( P <0.05), and the improvement in the observation group was superior to the control group ( P <0.05). CONCLUSION On the basis of conventional acupuncture, tiaoshen acupuncture can effectively relieve the discomforts of the lower limbs in patients with restless leg syndrome, improve the sleep disorder and anxiety, which is better than conventional acupuncture.",2020,"Compared before treatment, scores of IRLS, PSQI and HAMA after treatment were decreased in both groups ( P <0.05), and the improvement in the observation group was superior to the control group ( P <0.05). ","['restless leg syndrome', '60 patients', 'patients with restless leg syndrome']","['conventional acupuncture, tiaoshen acupuncture', 'Conventional acupuncture', 'tiaoshen acupuncture (acupuncture', 'acupuncture', 'tiaoshen acupuncture']","['Scores of international restless leg syndrome rating scale (IRLS), Pittsburgh sleep quality index (PSQI) and Hamilton anxiety scale (HAMA', 'scores of IRLS, PSQI and HAMA']","[{'cui': 'C0035258', 'cui_str': 'Restless legs'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0035258', 'cui_str': 'Restless legs'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",60.0,0.0301482,"Compared before treatment, scores of IRLS, PSQI and HAMA after treatment were decreased in both groups ( P <0.05), and the improvement in the observation group was superior to the control group ( P <0.05). ","[{'ForeName': 'Yuan-Zheng', 'Initials': 'YZ', 'LastName': 'Sun', 'Affiliation': 'Second Clinical Medical College, Heilongjiang University of CM, Harbin 150040, China; Sencond Department of Acupuncture and Moxibustion, Second Affiliated Hospital of Heilongjiang University of CM, Harbin 150000.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Second Clinical Medical College, Heilongjiang University of CM, Harbin 150040, China.'}, {'ForeName': 'Ying-Zhe', 'Initials': 'YZ', 'LastName': 'Sun', 'Affiliation': 'Second Clinical Medical College, Heilongjiang University of CM, Harbin 150040, China; Sencond Department of Acupuncture and Moxibustion, Second Affiliated Hospital of Heilongjiang University of CM, Harbin 150000.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190323-k0001'] 349,32275362,[Effect of herb-partitioned moxibustion at fanwei point on plasma motilin and serum gastrin in patients of diabetic gastroparesis].,"OBJECTIVE To explore the clinical therapeutic effect of herb-partitioned moxibustion at fanwei point in patients of diabetic gastroparesis differentiated as spleen and stomach deficiency and retention of turbid dampness as well as its effect mechanism. METHODS A total of 134 patients with diabetic gastroparesis were randomized into an observation group and a control group, 67 cases in each one. In the observation group, herb-partitioned moxibustion at fanwei point was adopted, 40 min each time, once a day for 5 times a week. In the control group, itopride hydrochloride tablets were prescribed for oral administration, 50 mg each time, three times a day. A total of 6 weeks of treatment was required in the two groups. Before and after treatment, the gastroparesis cardinal symptom index (GCSI) scores, 4-hour gastric emptying rate, TCM symptom score, as well as the levels of plasma motilin and serum gastrin were observed in the patients of the two groups. Additionally, the clinical therapeutic effect was evaluated in the two groups. RESULTS After treatment, the score of every item of GCSI, TCM symptom scores and the levels of plasma motilin and serum gastrin were all reduced as compared with those before treatment in the patients of the two groups ( P <0.05), and those in the observation group were lower than the control group ( P <0.05). Regarding 4-hour gastric emptying rates, which were increased as compared with those before treatment in the two group ( P <0.05), and the rate in the observation group was higher remarkably than that in the control group ( P <0.05). The total effective rate was 92.5% (62/67) in the observation group, higher than 74.6% (50/67) in the control group ( P <0.05). CONCLUSION Herb-partitioned moxibustion at fanwei point relieves the clinical symptoms in the patients with diabetic gastroparesis and increases the gastric emptying rate, which is probably related to the regulation of the levels of plasma motilin and serum gastrin.",2020,"After treatment, the score of every item of GCSI, TCM symptom scores and the levels of plasma motilin and serum gastrin were all reduced as compared with those before treatment in the patients of the two groups ( P <0.05), and those in the observation group were lower than the control group ( P <0.05).","['134 patients with diabetic gastroparesis', 'patients with diabetic gastroparesis', 'patients of diabetic gastroparesis', 'patients of diabetic gastroparesis differentiated as spleen and stomach deficiency and retention of turbid dampness']","['Herb-partitioned moxibustion', 'itopride hydrochloride tablets', 'herb-partitioned moxibustion']","['score of every item of GCSI, TCM symptom scores and the levels of plasma motilin and serum gastrin', '4-hour gastric emptying rates', 'gastroparesis cardinal symptom index (GCSI) scores, 4-hour gastric emptying rate, TCM symptom score, as well as the levels of plasma motilin and serum gastrin', 'plasma motilin and serum gastrin', 'gastric emptying rate', 'total effective rate', 'clinical therapeutic effect']","[{'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0267176', 'cui_str': 'Gastroparesis with diabetes mellitus'}, {'cui': 'C0205615', 'cui_str': 'Well differentiated'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0311420', 'cui_str': 'Turbid'}]","[{'cui': 'C0019240', 'cui_str': 'Herb'}, {'cui': 'C0026652', 'cui_str': 'Moxibustion'}, {'cui': 'C0531483', 'cui_str': 'itopride'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0967114', 'cui_str': 'goblet cell silencer inhibitor'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0026594', 'cui_str': 'Motilin'}, {'cui': 'C0428386', 'cui_str': 'Serum gastrin measurement'}, {'cui': 'C1292426', 'cui_str': '4 hours'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0152020', 'cui_str': 'Gastroparesis syndrome'}, {'cui': 'C0326926', 'cui_str': 'Cardinalis cardinalis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017127', 'cui_str': 'Gastric emptying'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",134.0,0.0216456,"After treatment, the score of every item of GCSI, TCM symptom scores and the levels of plasma motilin and serum gastrin were all reduced as compared with those before treatment in the patients of the two groups ( P <0.05), and those in the observation group were lower than the control group ( P <0.05).","[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Meng', 'Affiliation': 'Second Department of Endocrinology, Tangshan Gongren Hospital, Tangshan 063000, Hebei Province, China.'}, {'ForeName': 'Zhi-Min', 'Initials': 'ZM', 'LastName': 'Shi', 'Affiliation': 'Department of Spleen and Stomach Disorders, Tangshan TCM Hospital, Tangshan 063000, Hebei Province.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190415-0001'] 350,32275363,[Efficacy of medicinal penetration on acupoint as adjunctive therapy on histiocytic necrotizing lymphadenitis of heat-toxin syndrome: a randomized controlled trial].,"OBJECTIVE To evaluate the clinical efficacy of medicinal penetration on acupoint combined with medication for histiocytic necrotizing lymphadenitis (HNL) of heat-toxin syndrome, and to explore the methods of improving the clinical effect. METHODS A total of 72 cases with HNL with heat-toxin syndrome were randomly divided into an observation group and a control group, 36 cases in each group. The patients in the control group were treated with oral administration of prednisone tablets for 40 days (first 5 days: 10 mg, three times a day; since then, reduced by 5 mg every 7 days). In the observation group, on the basis of the medication in the control group, the patients were treated with acupoint application and ultrasonic drug penetration therapy, once a day for 14 days. The acupoints of Waiguan (TE 5), Fengchi (GB 20) of affected side and ashi points were selected. The changes of target lymph node swelling, visual analogue score (VAS), axillary temperature and total score of symptoms and signs were evaluated before treatment and 7, 14, 28 and 40 d into treatment; the changes of white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and lactic dehydrogenase (LDH) were evaluated on 14 d and 40 d into treatment; the patients were followed-up for half a year. RESULTS ① Fourteen days into treatment, the clinical cured rate in the observation group was 38.9% (14/36), which was superior to 16.7% (6/36) in the control group ( P <0.01); the clinical cured rates were both 100% in the two groups on 40 d into treatment. ② The VAS score, axillary temperature and the total score 7 d into treatment, as well as node swelling, VAS score, axillary temperature and the total score 14, 28 and 40 d into treatment in the two groups were significantly improved ( P <0.01); the total score and VAS score of 7 d into treatment, target lymph node swelling, VAS score and total score of 14 d into treatment in the observation group were significantly improved than those in the control group ( P <0.01). ③ Compared before treatment, WBC, CRP, ESR in the two groups were significantly improved 14 d and 40 d into treatment ( P <0.01), and LDH in the two groups were decreased 40 d into treatment ( P <0.01), but there was no significant difference between the two groups ( P >0.05). ④ The recurrence rate in the observation group was 5.6% (2/36), which was similar to 16.7% (6/36) in the control group ( P >0.05). CONCLUSION The medicinal penetration on acupoint as adjunctive treatment could effectively relieve the discomfort symptoms of HNL patients with syndrome of heat and toxin, improve the clinical cured rate, and provide the research direction for shortening the course of medication.",2020,"Compared before treatment, WBC, CRP, ESR in the two groups were significantly improved 14 d and 40 d into treatment ( P <0.01), and LDH in the two groups were decreased 40 d into treatment ( P <0.01), but there was no significant difference between the two groups ( P >0.05).","['72 cases with HNL with heat-toxin syndrome', 'histiocytic necrotizing lymphadenitis of heat-toxin syndrome']","['prednisone tablets', 'acupoint application and ultrasonic drug penetration therapy', 'acupoint combined with medication', 'medicinal penetration']","['clinical cured rate', 'changes of target lymph node swelling, visual analogue score (VAS), axillary temperature and total score of symptoms and signs', 'node swelling, VAS score, axillary temperature and the total score', 'total score and VAS score', 'clinical cured rates', 'LDH', 'VAS score, axillary temperature and the total score', 'recurrence rate', 'WBC, CRP, ESR', 'target lymph node swelling, VAS score and total score', 'changes of white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and lactic dehydrogenase (LDH']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0024205', 'cui_str': 'Lymphadenitis'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0040549', 'cui_str': 'Toxin'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0398367', 'cui_str': 'Histiocytic necrotizing lymphadenitis'}]","[{'cui': 'C1247653', 'cui_str': 'Prednisone Oral Tablet'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C4282165', 'cui_str': 'Enlarged lymph nodes, unspecified'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0030016', 'cui_str': 'Oxidoreductase'}]",72.0,0.0202627,"Compared before treatment, WBC, CRP, ESR in the two groups were significantly improved 14 d and 40 d into treatment ( P <0.01), and LDH in the two groups were decreased 40 d into treatment ( P <0.01), but there was no significant difference between the two groups ( P >0.05).","[{'ForeName': 'Ru-Hui', 'Initials': 'RH', 'LastName': 'Jin', 'Affiliation': 'Department of LuoLi, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing 210014, Jiangsu Province, China.'}, {'ForeName': 'Zi-Hui', 'Initials': 'ZH', 'LastName': 'Huang', 'Affiliation': 'Department of LuoLi, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing 210014, Jiangsu Province, China.'}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Niu', 'Affiliation': 'Department of LuoLi, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing 210014, Jiangsu Province, China.'}, {'ForeName': 'Qian-Yi', 'Initials': 'QY', 'LastName': 'Xue', 'Affiliation': 'Department of LuoLi, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing 210014, Jiangsu Province, China.'}, {'ForeName': 'Yong-Kang', 'Initials': 'YK', 'LastName': 'Zhu', 'Affiliation': 'Department of General Surgery, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190421-k0001'] 351,32275364,[Clinical efficacy of different waves of electroacupuncture on knee osteoarthritis and its effect on TGF-β1 in joint fluid].,"OBJECTIVE To observe the therapeutic effects of different waves of electroacupuncture (EA) on knee osteoarthritis (KOA), and to explore the mechanism of different waves of EA on promoting cartilage repair. METHODS Ninety- seven patients with KOA were randomly divided into a dilatational wave group (32 cases, 2 cases dropped off), a continuous wave group (32 cases, 2 cases dropped off) and a discontinuous wave group (33 cases, 3 cases dropped off). The same acupoints of Xuehai (SP 10), Liangqiu (ST 34), Dubi (ST 35) and Neixiyan (EX-LE 4) were selected in the three groups. The dilatational wave (frequency of 2 Hz/10 Hz) was used in the dilatational wave group, the continuous wave (frequency of 10 Hz) was used in the continuous wave group, and the discontinuous wave (frequency of 10 Hz) was used in the discontinuous wave group. All the needles were retained for 30 min. All the treatment was given 3 times a week (on Monday, Wednesday and Friday) for 4 weeks. Lysholm knees scoring scale (LKSS) was used to evaluate the knee joint function before and after treatment, and the content of transforming growth factor-β1 (TGF-β1) in the joint effusion before and after treatment was determined by enzyme-linked immunosorbent assay (ELISA). RESULTS Compared before treatment, the total score and each score of LKSS were increased after treatment in the three groups (all P <0.05). The improvements of total score, pain score, instability score, swelling score of LKSS in the continuous wave group and the dilatational wave group were superior to those in the discontinuous wave group (all P <0.05). The content of TGF-β1 in the joint effusion in each group was increased after treatment ( P <0.05), and the improvement in dilatational wave group was superior to thoes in the continuous wave group and the discontinuous wave group (all P <0.05). CONCLUSION The three different waves of EA could all improve the clinical symptoms of KOA, which may promote cartilage repair by increasing TGF-β1 content. The dilatational wave had the best overall effect, which can be used as a clinical optimal treatment.",2020,"The content of TGF-β1 in the joint effusion in each group was increased after treatment ( P <0.05), and the improvement in dilatational wave group was superior to thoes in the continuous wave group and the discontinuous wave group (all P <0.05). ","['Ninety- seven patients with KOA', 'knee osteoarthritis (KOA']","['electroacupuncture', 'electroacupuncture (EA']","['total score, pain score, instability score, swelling score of LKSS', 'total score and each score of LKSS', 'Lysholm knees scoring scale (LKSS', 'knee joint function', 'content of TGF-β1 in the joint effusion']","[{'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0040691', 'cui_str': 'Transforming Growth Factor'}, {'cui': 'C1253936', 'cui_str': 'Effusion of joint'}]",97.0,0.013966,"The content of TGF-β1 in the joint effusion in each group was increased after treatment ( P <0.05), and the improvement in dilatational wave group was superior to thoes in the continuous wave group and the discontinuous wave group (all P <0.05). ","[{'ForeName': 'Dong-E', 'Initials': 'DE', 'LastName': 'Huang', 'Affiliation': 'Department of Physical Therapy of TCM, the 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou 350025, Fujian Province, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Department of Physical Therapy of TCM, the 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou 350025, Fujian Province, China.'}, {'ForeName': 'Mu-Nan', 'Initials': 'MN', 'LastName': 'Lin', 'Affiliation': 'Department of Physical Therapy of TCM, the 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou 350025, Fujian Province, China.'}, {'ForeName': 'Xiao-Ling', 'Initials': 'XL', 'LastName': 'Lai', 'Affiliation': 'Department of Physical Therapy of TCM, the 900th Hospital of Joint Service Corps of Chinese PLA, Fuzhou 350025, Fujian Province, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190422-0005'] 352,31237183,The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the sleep-promoting effects of tryptophan: A randomized placebo-controlled crossover study.,"BACKGROUND The low-expressive short (S) allele of a functional polymorphism (5-HTTLPR) within the serotonin (5-hydroxytriptamine; 5-HT) transporter gene (SLC6A4) has been associated with a reduced functioning of the brain 5-HT system relative to the long (L) allele. As a consequence, the S-allele is found to predispose individuals to a higher risk of sleep quality reduction and clinical insomnia. AIMS The present study investigated whether subchronic pre-sleep tryptophan administration could compensate for this predisposition by improving sleep in 5-HTTLPR S-allele carriers. METHODS In a double-blind placebo-controlled crossover design a sample of homozygous 5-HTTLPR S-allele ( n = 47) and L-allele ( n = 51) carriers were assessed for subjective (sleep diary) and objective (actigraphy) sleep during a treatment protocol consisting of 1 week of placebo (1000 mg/day) and 1 week of tryptophan administration (1000 mg/day). RESULTS The results support the sleep-promoting effects of tryptophan. Tryptophan improved objective sleep efficiency and objective wake after sleep onset irrespective of allelic variation. There was a marginally significant improvement of subjective sleep quality in the 5-HTTLPR S-allele group but not in the L-allele group following tryptophan relative to placebo intake. In contrast, a significantly poorer sleep quality in the S-allele as opposed to the L-allele group in the placebo condition was not observed in the tryptophan condition. CONCLUSIONS Tryptophan augmentation promises to be a valuable treatment strategy for sleep impairments related to genetic deficiencies in 5-HT functioning.",2019,There was a marginally significant improvement of subjective sleep quality in the 5-HTTLPR S-allele group but not in the L-allele group following tryptophan relative to placebo intake.,['sample of homozygous 5-HTTLPR S-allele ( n = 47) and L-allele ( n = 51) carriers'],"['Tryptophan', 'placebo', 'tryptophan', 'subchronic pre-sleep tryptophan', 'tryptophan administration']","['objective sleep efficiency', 'subjective sleep quality', 'sleep quality', 'subjective (sleep diary) and objective (actigraphy) sleep']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0002085', 'cui_str': 'Allelomorphs'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}]","[{'cui': 'C0041249', 'cui_str': 'L-tryptophan'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}]",,0.275924,There was a marginally significant improvement of subjective sleep quality in the 5-HTTLPR S-allele group but not in the L-allele group following tryptophan relative to placebo intake.,"[{'ForeName': 'Jens H', 'Initials': 'JH', 'LastName': 'van Dalfsen', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'C Rob', 'Initials': 'CR', 'LastName': 'Markus', 'Affiliation': 'Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, the Netherlands.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119855978'] 353,31238172,Embedding caregiver support in community-based services for older adults: A multi-site randomized trial to test the Adult Day Service Plus Program (ADS Plus).,"There are over five million people in the United States living with dementia. Most live at home and are cared for by family. These family caregivers often assume care responsibilities without education about the disease, skills training, or support, and in turn become at risk for depression, burden, and adverse health outcomes when compared to non-dementia caregivers. Despite over 200 caregiver interventions with proven benefits, many caregivers lack access to these programs. One approach to enhance access is to embed evidence-based caregiver support programs in existing community-based services for people with dementia such as adult day services (ADS). Here we describe the protocol for an embedded pragmatic trial designed to augment standard ADS known as ADS Plus. ADS Plus provides family caregivers with support via education, referrals, and problem-solving techniques over 12 months, and is delivered on-site by existing ADS staff. Embedding a program in ADS requires an understanding of outcomes and implementation processes in that specific context. Thus, we deploy a hybrid design involving a cluster randomized two-group trial to evaluate treatment effects on caregiver wellbeing, ADS utilization, as well as nursing home placement. We describe implementation practices in 30 to 50 geographically and racially/ethnically diverse participating sites. Clinical trial registration #: NCT02927821.",2019,Here we describe the protocol for an embedded pragmatic trial designed to augment standard ADS known as ADS,"['30 geographically and racially/ethnically diverse participating sites', 'people with dementia such as adult day services (ADS', 'older adults']","['standard ADS known as ADS', 'ADS']","['caregiver wellbeing, ADS utilization']","[{'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0042153', 'cui_str': 'use'}]",,0.147567,Here we describe the protocol for an embedded pragmatic trial designed to augment standard ADS known as ADS,"[{'ForeName': 'Laura N', 'Initials': 'LN', 'LastName': 'Gitlin', 'Affiliation': 'Drexel University, 1601 Cherry Street, 10th Floor, Room 1092, Philadelphia, PA 19102, United States of America. Electronic address: Lng45@drexel.edu.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Marx', 'Affiliation': 'Johns Hopkins School of Nursing, Center for Innovative Care in Aging, 901 N. Broadway, Room 214, Baltimore, MD 21205, United States of America. Electronic address: kmarx1@jhu.edu.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Scerpella', 'Affiliation': 'Johns Hopkins School of Nursing, Center for Innovative Care in Aging, 901 North Broadway, 2nd Floor, Baltimore, MD 21205, United States of America. Electronic address: dscerpe1@jhu.edu.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Dabelko-Schoeny', 'Affiliation': 'College of Social Work, 207 Stillman Hall, 1947 College Rd N., Columbus, OH 43210, United States of America. Electronic address: dabelko-schoeny.1@csw.osu.edu.'}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Anderson', 'Affiliation': 'University of Montana, School of Social Work, 014 Jeannette Rankin Hall, 32 Campus Drive, Missoula, MT 59812-4392, United States of America. Electronic address: keith.anderson@mso.umt.edu.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Johns Hopkins School of Medicine, Center on Aging and Health, 2024 East Monument Street, Baltimore, MD 21205, United States of America. Electronic address: j.huang@jhu.edu.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pizzi', 'Affiliation': 'University Ernest Mario School of Pharmacy, Center for Health Outcomes, Policy, and Economics, 160 Frelinghuysen Road - Suite 417, Piscataway, NJ 08854, United States of America. Electronic address: laura.pizzi@rutgers.edu.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Jutkowitz', 'Affiliation': 'Brown University School of Public Health, Department of Health Services, Policy & Practice, BoxG-S121 (6), 121 S Main Street, Providence, RI 02912, United States of America. Electronic address: jutkowitz@brown.edu.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Roth', 'Affiliation': 'Johns Hopkins School of Medicine, Center on Aging and Health, 2024 East Monument Street, Baltimore, MD 21205, United States of America. Electronic address: droth@jhu.edu.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Gaugler', 'Affiliation': 'University of Minnesota, School of Nursing, 308 SE Harvard St, Minneapolis, MN 55455, United States of America. Electronic address: gaug0015@umn.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.010'] 354,31870756,Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease.,"BACKGROUND Randomized trials of people with peripheral artery disease (PAD) and intermittent claudication have traditionally used maximal treadmill walking distance as the primary outcome, but the 6-minute walk test is increasingly used as a primary outcome in randomized trials of PAD. This study compared relative changes in maximal treadmill walking distance versus 6-minute walk distance in response to a therapeutic intervention or control in randomized trials of participants with PAD. METHODS Data from four randomized trials of therapeutic interventions in participants with PAD that measured both 6-minute walk and treadmill walking performance at baseline and the 6-month follow-up were combined. Two trials studied supervised treadmill exercise, one studied home-based walking exercise, and one studied resveratrol. RESULTS Of 467 participants (mean age, 69.8; standard deviation, 9.7), the mean ankle-brachial index was 0.66 (standard deviation, 0.17). At the 6-month follow-up, participants with PAD randomized to control or placebo significantly declined in 6-minute walk distance (-10.2 m; 95% confidence interval, -18.2 to -2.2; P = .013), but improved maximal treadmill walking distance (+25.7 m; 95% CI, +6.0 to +45.3 m; P = .010; difference between change in 6-minute walk versus maximal treadmill walking distance: -37.3 m; 95% CI, -56.4 to -18.2; P < .001). Home-based exercise improved the 6-minute walk distance by 43.2 m (95% CI, +28.4 to +57.9), and supervised treadmill exercise improved the 6-minute walk distance by 25.0 m (95% CI, +14.7 to +35.2; mean difference, +18.2 m favoring home-based exercise [95% CI, +0.2 to +36.2 m; P = .048]). Among all participants, the presence (vs absence) of treadmill exercise training was associated with a 141.3-m greater improvement in maximal treadmill walking distance compared to 6-minute walk distance (95% CI, 88.2-194.4; P < .001), suggesting a benefit from treadmill training on the treadmill outcome. CONCLUSIONS Maximal treadmill walking distance and the 6-minute walk distance are not interchangeable outcomes in participants with PAD. Participants with PAD randomized to control groups improved treadmill walking distance but simultaneously meaningfully declined in 6-minute walk distance. Supervised treadmill exercise training amplified improvement in treadmill walking distance because of a training to the outcome measure phenomenon.",2020,"Home-based exercise improved the 6-minute walk distance by 43.2 m (95% CI, +28.4 to +57.9), and supervised treadmill exercise improved the 6-minute walk distance by 25.0 m (95% CI, +14.7 to +35.2; mean difference, +18.2 m favoring home-based exercise [95% CI, +0.2 to +36.2 m; P = .048]).","['Of 467 participants (mean age, 69.8; standard deviation, 9.7', 'participants with PAD', 'participants with PAD that measured both', 'people with peripheral artery disease (PAD) and intermittent claudication']","['supervised treadmill exercise', 'placebo', 'treadmill exercise training', 'supervised treadmill exercise, one studied home-based walking exercise, and one studied resveratrol', '6-minute walk versus treadmill walking distance', 'Supervised treadmill exercise training', 'maximal treadmill walking distance versus 6-minute walk distance']","['6-minute walk and treadmill walking performance', 'maximal treadmill walking distance', 'treadmill walking distance', 'mean ankle-brachial index', '6-minute walk distance']","[{'cui': 'C4517784', 'cui_str': '467 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C0021775', 'cui_str': 'Intermittent Claudication'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2930481', 'cui_str': 'cis-Resveratrol'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1328319', 'cui_str': 'Ankle Brachial Index'}]",467.0,0.325181,"Home-based exercise improved the 6-minute walk distance by 43.2 m (95% CI, +28.4 to +57.9), and supervised treadmill exercise improved the 6-minute walk distance by 25.0 m (95% CI, +14.7 to +35.2; mean difference, +18.2 m favoring home-based exercise [95% CI, +0.2 to +36.2 m; P = .048]).","[{'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'McDermott', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: mdm608@northwestern.edu.'}, {'ForeName': 'Jack M', 'Initials': 'JM', 'LastName': 'Guralnik', 'Affiliation': 'Department of Epidemiology, University of Maryland, Baltimore, Md.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Tian', 'Affiliation': 'Department of Biomedical Data Science, Stanford University, Palo Alto, Calif.'}, {'ForeName': 'Lihui', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.'}, {'ForeName': 'Tamar S', 'Initials': 'TS', 'LastName': 'Polonsky', 'Affiliation': 'Department of Medicine, University of Chicago, Chicago, Ill.'}, {'ForeName': 'Melina R', 'Initials': 'MR', 'LastName': 'Kibbe', 'Affiliation': 'Department of Surgery, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Criqui', 'Affiliation': 'Department of Family Medicine and Public Health, University of California at San Diego, San Diego, Calif.'}, {'ForeName': 'Dongxue', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Conte', 'Affiliation': 'Division of Endovascular and Vascular Surgery, University of California San Francisco, San Francisco, Calif.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Domanchuk', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.'}, {'ForeName': 'Lingyu', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Sufit', 'Affiliation': 'Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Ill.'}, {'ForeName': 'Christiaan', 'Initials': 'C', 'LastName': 'Leeuwenburgh', 'Affiliation': 'Department of Aging and Geriatric Research, University of Florida, Gainesville, Fla.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Ferrucci', 'Affiliation': 'Intramural Research Program, National Institute on Aging, Baltimore, Md.'}]",Journal of vascular surgery,['10.1016/j.jvs.2019.05.058'] 355,32275365,"[Effect of electroacupuncture at governor vessel on learning-memory ability and serum level of APP, Aβ 1-42 in patients with Alzheimer's disease].","OBJECTIVE To compare the therapeutic effect of electroacupuncture (EA) combined with donepezil hydrochloride and donepezil hydrochloride alone on improving learning-memory ability in patients with Alzheimer's disease (AD), and to explore its action mechanism. METHODS Sixty patients of AD were randomly divided into an observation group and a control group, 30 cases in each group. The patients in the observation group were treated with EA at governor vessel (GV) combined with donepezil hydrochloride. EA was applied at Baihui (GV 20) and Fengfu (GV 16) with dilatational wave (10 Hz/50 Hz of frequency, 0.5 to 5.0 mA of intensity), and the needles were kept for 40 min, EA was given once a day; the donepezil hydrochloride tablet was taken orally, 5 mg, once a day, and after 4 weeks the dosage might be increased to 10 mg per day according to the specific situation. All the treatment was given for 8 weeks. The patients in the control group were only treated with donepezil hydrochloride with the identical procedure as the observation group. The Montreal cognitive assessment (MoCA) and Alzheimer's disease assessment scale cognitive part (ADAS-Cog) were evaluated before and after treatment; P300 (latency and amplitude of N2 and P3) was detected by EEG/ERP system brain event related potential instrument, and amyloid precursor protein (APP) and β-amyloid protein 1-42 (Aβ 1-42 ) were detected by ELISA. RESULTS Compared before treatment, the MoCA scores were increased after treatment in the two groups ( P <0.05), and the MoCA score in the observation group was higher than that in the control group ( P <0.05). Compared before treatment, the ADAS-Cog scores were decreased after treatment in the two groups ( P <0.05), and the ADAS-Cog score in the observation group was lower than that in the control group ( P <0.05). Compared before treatment, the latency of N2 and P3 was shortened and the amplitude was increased after treatment in the two groups ( P <0.05); after treatment, the latency of N2 and P3 in the observation group was shorter than that in the control group and the amplitude was higher than that in the control group ( P <0.05). Compared before treatment, the serum levels of APP and Aβ 1-42 were lower after treatment in the two groups ( P <0.05), and the serum levels of APP and Aβ 1-42 in the observation group were lower than those in the control group ( P <0.05). CONCLUSION EA at Baihui (GV 20) and Fengfu (GV 6) combined with donepezil hydrochloride can effectively reduce the serum levels of APP and Aβ 1-42 and improve the scores of MoCA and ADAS-Cog and the levels of N2 and P3 of P300 in AD patients, which has superior effect to donepezil hydrochloride alone in improving the learning-memory of AD patients.",2020,"Compared before treatment, the serum levels of APP and Aβ 1-42 were lower after treatment in the two groups ( P <0.05), and the serum levels of APP and Aβ 1-42 in the observation group were lower than those in the control group ( P <0.05). ","[""patients with Alzheimer's disease (AD"", 'Sixty patients of AD', ""patients with Alzheimer's disease""]","['electroacupuncture (EA) combined with donepezil hydrochloride and donepezil hydrochloride alone', 'donepezil hydrochloride tablet', 'EA at Baihui (GV 20) and Fengfu (GV 6) combined with donepezil hydrochloride', 'EA at governor vessel (GV) combined with donepezil hydrochloride', 'electroacupuncture', 'donepezil hydrochloride']","['latency of N2 and P3', 'MoCA scores', 'ADAS-Cog scores', 'learning-memory ability and serum level of APP', 'serum levels of APP', 'learning-memory ability', ""Montreal cognitive assessment (MoCA) and Alzheimer's disease assessment scale cognitive part (ADAS-Cog"", 'P300 (latency and amplitude of N2 and P3', 'ADAS-Cog score', 'MoCA score', 'serum levels of APP and Aβ 1-42']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0771848', 'cui_str': 'Donepezil hydrochloride'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}]","[{'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0085151', 'cui_str': 'Amyloid beta Precursor Protein'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0444781', 'cui_str': 'P300 (P3)'}]",60.0,0.0261204,"Compared before treatment, the serum levels of APP and Aβ 1-42 were lower after treatment in the two groups ( P <0.05), and the serum levels of APP and Aβ 1-42 in the observation group were lower than those in the control group ( P <0.05). ","[{'ForeName': 'Kun-Peng', 'Initials': 'KP', 'LastName': 'Xia', 'Affiliation': 'Graduate School of Heilongjiang University of CM, Harbin 150040, China; Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Pang', 'Affiliation': 'Graduate School of Heilongjiang University of CM, Harbin 150040, China; Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}, {'ForeName': 'Shu-Lin', 'Initials': 'SL', 'LastName': 'Li', 'Affiliation': 'Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}, {'ForeName': 'Miao', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}, {'ForeName': 'Hong-Lin', 'Initials': 'HL', 'LastName': 'Li', 'Affiliation': 'Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}, {'ForeName': 'Yu-Jue', 'Initials': 'YJ', 'LastName': 'Wang', 'Affiliation': 'Third Ward of Rehabilitation Department, Second Clinical Medical College of Heilongjiang University of CM, Harbin 150001.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190728-0003'] 356,32275366,[Efficacy and mechanism of electroacupuncture on insulin resistant polycystic ovary syndrome].,"OBJECTIVE To explore the therapeutic effect and partial mechanism of electroacupuncture (EA) for patients with insulin resistance (IR) polycystic ovary syndrome (PCOS). METHODS Seventy patients with IR-PCOS were randomly divided into an EA group (36 cases, 5 cases dropped off) and a medication group (34 cases, 4 cases dropped off). The patients in the medication group were treated with oral administration of metformin hydrochloride, 500 mg each time, twice a day. The patients in the EA group were treated with EA (continuous wave, 2 Hz of frequency) at Zusanli (ST 36), Zhongwan (CV 12), Qihai (CV 6), Yishu (EX-B 3), Shenshu (BL 23), Pishu (BL 20), Ciliao (BL 32) for 30 min, three times a week. One menstrual cycle or 4 weeks were taken as a course of treatment, and 3 continuous courses were given. The follow-up was 3 months. The lipid metabolism indexes of triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL), homeostasis model assessment-insulin resistance index (HOMA-IR) and testosterone (T) in serum were compared before and after treatment, and the clinical effects of the two groups were evaluated during the follow-up. RESULTS The total effective rate was 67.7% (21/31) in the EA group and 60.0% (18/30) in the medication group, with no significant difference between the two groups ( P >0.05). After treatment, the levels of serum T, HOMA-IR, LDL, TG and TC were decreased significantly in the two groups ( P <0.01, P <0.05), and HDL was increased significantly ( P <0.01); the levels of TC in the EA group after treatment was lower than that in the medication group ( P <0.05). CONCLUSION EA may adjust some dyslipidemia in patients to correct IR and improve endocrine disorder of PCOS, which had superior/similar effects to metformin.",2020,"After treatment, the levels of serum T, HOMA-IR, LDL, TG and TC were decreased significantly in the two groups ( P <0.01, P <0.05), and HDL was increased significantly ( P <0.01); the levels of TC in the EA group after treatment was lower than that in the medication group ( P <0.05). ","['patients with insulin resistance (IR) polycystic ovary syndrome (PCOS', 'Seventy patients with IR-PCOS']","['electroacupuncture (EA', 'metformin hydrochloride', 'EA', 'electroacupuncture', 'metformin']","['lipid metabolism indexes of triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL), homeostasis model assessment-insulin resistance index (HOMA-IR) and testosterone (T) in serum', 'levels of TC', 'total effective rate', 'HDL', 'levels of serum T, HOMA-IR, LDL, TG and TC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0770893', 'cui_str': 'Metformin hydrochloride'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",70.0,0.0163585,"After treatment, the levels of serum T, HOMA-IR, LDL, TG and TC were decreased significantly in the two groups ( P <0.01, P <0.05), and HDL was increased significantly ( P <0.01); the levels of TC in the EA group after treatment was lower than that in the medication group ( P <0.05). ","[{'ForeName': 'Li-Qing', 'Initials': 'LQ', 'LastName': 'Yu', 'Affiliation': 'Acupuncture- Moxibustion Department, Shanghai Tianshan Hospital of TCM, Shanghai 200051, China.'}, {'ForeName': 'Lian-Ying', 'Initials': 'LY', 'LastName': 'Cao', 'Affiliation': 'Acupuncture- Moxibustion Department, Shanghai Tianshan Hospital of TCM, Shanghai 200051, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'Gynecology Department, Shanghai Tianshan Hospital of TCM, Shanghai 200051, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Outpatient Department of Shanghai Institute of Acupuncture-Moxibustion and Meridians.'}, {'ForeName': 'Li-Yan', 'Initials': 'LY', 'LastName': 'Zhou', 'Affiliation': 'Department of Acupuncture and Moxibustion, Shanghai Jiading Hospital of TCM.'}, {'ForeName': 'Tian-Feng', 'Initials': 'TF', 'LastName': 'He', 'Affiliation': 'Department of Acupuncture and Moxibustion, Shanghai Jiading Hospital of TCM.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Chu', 'Affiliation': 'Department of Acupuncture and Moxibustion, Shanghai Jiading Hospital of TCM.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190903-k0003'] 357,32275367,[Acupuncture ameliorates negative emotion in PCOS patients: a randomized controlled trial].,"OBJECTIVE To evaluate the effectiveness and possible mechanism of acupuncture treatment for negative emotion in patients with polycystic ovary syndrome (PCOS). METHODS A total of 40 PCOS patients were randomly divided into an observation group and a control group, 20 cases in each one. Both groups received lifestyle interventions (exercise and diet guidance) on the 5th day of menstruation. On the basis of above treatment, the patients in the observation group received acupuncture at Guanyuan (CV 4), Zhongwan (CV 12), Guilai (ST 29), Futu (ST 32), Liangqiu (ST 34), Sanyinjiao (SP 6), Zusanli (ST 36), Hegu (LI 4), Shenmen (HT 7), Baihui (GV 20) as the main acupoints, and connected the electroacupuncture (continuous wave, 2 Hz, 30 min), once every other day, 3 times a week. The treatment for 1 month was as one course and 4 courses were required totally in both groups. Before and after treatment, the body mass index (BMI), ferriman-gallway (F-G) score, self-rating anxiety scale (SAS) score, self-rating depression scale (SDS) score, PCOS health-related quality of life questionnaire (PCOSQ) score were observed, meanwhile, serum sex hormone, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E 2 ), progestin (P), prolactin (PRL), testosterone (T), sex hormone-binding globulin (SHBG) and free androgen index (FAI) levels, and serumβ-endorphin levels were detected. RESULTS Compared with before treatment, the BMI, F-G score, SAS score, SDS score and serum FAI level were decreased and the PCOSQ score and the levels of serum SHBG andβ-endorphin were increased in the observation group after treatment (all P <0.05). Compared with before treatment, the SDS score was decreased in the control group after treatment ( P <0.05). Compared with the control group, the F-G score, SDS score, SAS score, and serum FAI level were lower, and the PCOSQ score and serumβ-endorphin level were higher in the observation group after treatment (all P <0.05). CONCLUSION Applying acupuncture to the treatment of patients with PCOS can effectively relieve anxiety and depression, and the mechanism may be related to the regulation on the levels of serumβ-endorphin and androgen.",2020,"Compared with before treatment, the SDS score was decreased in the control group after treatment ( P <0.05).","['patients with PCOS', '40 PCOS patients', 'patients with polycystic ovary syndrome (PCOS', 'PCOS patients']","['acupuncture at Guanyuan (CV 4), Zhongwan (CV 12), Guilai (ST 29), Futu (ST 32), Liangqiu (ST 34), Sanyinjiao (SP 6), Zusanli (ST 36), Hegu (LI 4), Shenmen (HT 7), Baihui (GV 20) as the main acupoints, and connected the electroacupuncture', 'acupuncture', 'Acupuncture', 'lifestyle interventions (exercise and diet guidance']","['BMI, F-G score, SAS score, SDS score and serum FAI level', 'SDS score', 'PCOSQ score and the levels of serum SHBG andβ-endorphin', 'PCOSQ score and serumβ-endorphin level', 'body mass index (BMI), ferriman-gallway (F-G) score, self-rating anxiety scale (SAS) score, self-rating depression scale (SDS) score, PCOS health-related quality of life questionnaire (PCOSQ) score were observed, meanwhile, serum sex hormone, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen (E 2 ), progestin (P), prolactin (PRL), testosterone (T), sex hormone-binding globulin (SHBG) and free androgen index (FAI) levels, and serumβ-endorphin levels', 'negative emotion', 'F-G score, SDS score, SAS score, and serum FAI level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0626533', 'cui_str': 'SP 6'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0428629', 'cui_str': 'Free androgen index measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0455307', 'cui_str': 'Serum sex hormone binding globulin measurement'}, {'cui': 'C0014242', 'cui_str': 'Endorphin'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0036884', 'cui_str': 'Sex hormone'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0033371', 'cui_str': 'Prolactin'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0036883', 'cui_str': 'Sex steroid binding globulin'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]",40.0,0.0325089,"Compared with before treatment, the SDS score was decreased in the control group after treatment ( P <0.05).","[{'ForeName': 'Hao-Lin', 'Initials': 'HL', 'LastName': 'Zhang', 'Affiliation': 'Department of TCM, Institute of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Ze-Jun', 'Initials': 'ZJ', 'LastName': 'Huo', 'Affiliation': 'Department of TCM, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Hai-Ning', 'Initials': 'HN', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Cui-Qing', 'Initials': 'CQ', 'LastName': 'Chang', 'Affiliation': 'Institute of Sports Medicine, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of TCM, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Li', 'Affiliation': 'Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Qiao', 'Affiliation': 'Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China.'}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20191231-k0005'] 358,32275368,[Therapeutic effect of acupuncture on dysphagia in children with severe hand foot and mouth disease].,"OBJECTIVE To observe the effect of acupuncture combined with conventional symptomatic and supportive treatments on swallowing function and nutritional status in children with severe hand foot and mouth disease complicated with dysphagia. METHODS A total of 68 children with severe hand foot and mouth disease complicated with dysphagia were randomized into an observation group and a control group, 34 cases in each one. Symptomatic and supportive treatments such as lowering temperature, tranquilizing and mechanical ventilation were adopted in the control group. On the basis of the treatments in the control group, acupuncture was applied at Lianquan (CV 23), Jialianquan (Extra), cervical Jiaji (EX-B 2), Fengfu (GV 16), Fengchi (GB 20), Yamen (GV 15), scalp motor and sensory areas in the observation group, once a day, 6 times a week, one month as a course and totally 3 courses were required. Time spent on restoring swallowing function was observed in both groups. Besides, score of dysphagia disorder survey (DDS) and nutritional status were evaluated before and after treatment, and the clinical effects were compared. RESULTS The total effective rate was 91.2% (31/34) in the observation group, which was superior to 73.5% (25/34) in the control group ( P <0.05). The time of restoring swallowing function in the observation group was advanced than the control group ( P <0.05). Compared before treatment, the DDS scores after treatment were decreased in both groups, and the reduction in the observation group was larger than the control group (all P <0.05). After the treatment, the normal rate of nutritional status was 61.8% (21/34) in the observation group, which was superior to 32.4% (11/34) in the control group ( P <0.05). CONCLUSION On the basis of conventional treatment, acupuncture can effectively treat the severe hand foot and mouth disease complicated with dysphagia, improve the swallowing function and nutritional status.",2020,The time of restoring swallowing function in the observation group was advanced than the control group ( P <0.05).,"['68 children with severe hand foot and mouth disease complicated with dysphagia', 'children with severe hand foot and mouth disease complicated with dysphagia', 'children with severe hand foot and mouth disease']","['acupuncture', 'acupuncture combined with conventional symptomatic and supportive treatments']","['swallowing function and nutritional status', 'DDS scores', 'Time spent on restoring swallowing function', 'total effective rate', 'lowering temperature, tranquilizing and mechanical ventilation', 'time of restoring swallowing function', 'score of dysphagia disorder survey (DDS) and nutritional status', 'normal rate of nutritional status']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018572', 'cui_str': 'Enteroviral vesicular stomatitis with exanthem'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]",68.0,0.0215949,The time of restoring swallowing function in the observation group was advanced than the control group ( P <0.05).,"[{'ForeName': 'Yu-Jing', 'Initials': 'YJ', 'LastName': 'Jin', 'Affiliation': ""Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou 450046, China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': ""Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou 450046, China.""}, {'ForeName': 'Guo-Lan', 'Initials': 'GL', 'LastName': 'Ge', 'Affiliation': ""Henan Children's Hospital/Zhengzhou Children's Hospital, Zhengzhou 450046, China.""}]",Zhongguo zhen jiu = Chinese acupuncture & moxibustion,['10.13703/j.0255-2930.20190820-k0001'] 359,31246145,Resting-state dynamics as a neuromarker of dopamine administration in healthy female adults.,"BACKGROUND Different neuromarkers of people's emotions, personality traits and behavioural performance have recently been identified. However, not much attention has been devoted to neuromarkers of neural responsiveness to drug administration. AIMS We investigated the predictive neuromarkers of acute dopamine (DA) administration. METHODS In a double-blind, within-subject study, we administrated a DA agonist (pramipexole) or placebo to 27 healthy female subjects. Using multivariate classification and prediction analyses, we examined whether dopaminergic modulations of task-free resting-state brain dynamics predict individual differences in pramipexole's modulation of facial attractiveness evaluations. RESULTS Our results demonstrate that pramipexole's effects on brain dynamics could be successfully discriminated from resting-state functional connectivity (accuracy: 78.9%; p < 0.0001). On the behavioural level, pramipexole increased facial attractiveness evaluations ( t (39) = 4.44; p < 0.0001). In particular, pramipexole administration enhanced connectivity strength of the cinguloopercular network ( t (23) = 3.29; p = 0.003) and increased brain signal variability in subcortical and prefrontal brain areas ( t (13) = 3.05, p = 0.009). Importantly, multivariate predictive models reveal that pramipexole-dependent modulation of resting-state dynamics predicted the increase of facial attractiveness evaluations after pramipexole (connectivity strength: standardized mean squared error, smse = 0.65; p = 0.0007; brain signal variability: smse = 0.94, p = 0.015). CONCLUSION These results demonstrate that modulations of resting-state brain dynamics induced by a DA agonist predict drug-related effects on evaluation processes, providing a neuromarker of the neural responsiveness of specific brain networks to DA administration.",2019,"On the behavioural level, pramipexole increased facial attractiveness evaluations ( t (39) = 4.44; p < 0.0001).","['27 healthy female subjects', 'healthy female adults']","['pramipexole', 'DA agonist (pramipexole) or placebo']","['brain signal variability in subcortical and prefrontal brain areas', 'connectivity strength of the cinguloopercular network', 'facial attractiveness evaluations']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0686752', 'cui_str': 'Well female adult (finding)'}]","[{'cui': 'C0074710', 'cui_str': 'Pramipexole'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",27.0,0.177741,"On the behavioural level, pramipexole increased facial attractiveness evaluations ( t (39) = 4.44; p < 0.0001).","[{'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Bellucci', 'Affiliation': '1 Department of Psychology I, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Münte', 'Affiliation': '3 Department of Neurology, Universitätsklinikum Schleswig-Holstein, Lübeck, Germany.'}, {'ForeName': 'Soyoung Q', 'Initials': 'SQ', 'LastName': 'Park', 'Affiliation': '1 Department of Psychology I, University of Lübeck, Lübeck, Germany.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119855983'] 360,31255801,Randomized controlled trial of the mySmartSkin web-based intervention to promote skin self-examination and sun protection behaviors among individuals diagnosed with melanoma: study design and baseline characteristics.,">1.2 million people in the United States have a personal history of melanoma skin cancer and are at increased risk for disease recurrence and second primary melanomas. Many of these individuals do not follow recommendations to conduct regular, thorough skin self-examinations that facilitate early disease detection and do not sufficiently engage in sun protection behaviors. In this project, we are conducting a randomized controlled trial of an innovative, tailored, theory-driven Internet intervention-called mySmartSkin-to promote these behaviors among melanoma patients. This paper outlines the study design and characteristics of the study sample. A total of 441 patients were recruited (40.9% response rate) and randomized to the mySmartSkin or a Usual Care condition. Participants complete surveys at baseline and 8 weeks, 24 weeks, and 48 weeks later. The primary aim of the project is to examine the impact of mySmartSkin versus Usual Care on skin self-examination and sun protection behaviors. The secondary aim focuses on identifying mediators of the intervention's effects. In an exploratory aim, we will examine potential moderators of the impact of the intervention. At baseline, the recruited participants had a mean age of 61 years, 49% were female, 7.5% met criteria for having conducted a recent, thorough skin self-examination, and the mean score on the index of sun protection behaviors was 3.3 (on a scale from 1 to 5). The results of the project will determine whether the mySmartSkin intervention is efficacious in promoting skin self-examination and sun protection behaviors among individuals diagnosed with melanoma. Trial registration: ClinicalTrials.govNCT03028948.",2019,>1.2 million people in the United States have a personal history of melanoma skin cancer and are at increased risk for disease recurrence and second primary melanomas.,"['melanoma patients', 'A total of 441 patients were recruited (40.9% response rate) and randomized to the mySmartSkin or a Usual Care condition', 'recruited participants had a mean age of 61\u202fyears, 49% were female, 7.5% met criteria for having conducted a recent, thorough skin self-examination, and the mean score on the index of sun protection behaviors was 3.3 (on a scale from 1 to 5', 'individuals diagnosed with melanoma']","['mySmartSkin intervention', 'mySmartSkin web-based intervention', 'mySmartSkin versus Usual Care']",['skin self-examination and sun protection behaviors'],"[{'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C4517688', 'cui_str': '3.3 (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",441.0,0.214329,>1.2 million people in the United States have a personal history of melanoma skin cancer and are at increased risk for disease recurrence and second primary melanomas.,"[{'ForeName': 'Elliot J', 'Initials': 'EJ', 'LastName': 'Coups', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Medicine, Rutgers Robert Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Health Behavior, Systems & Policy, Rutgers School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ, United States. Electronic address: elliot.coups@rutgers.edu.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Manne', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Medicine, Rutgers Robert Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Health Behavior, Systems & Policy, Rutgers School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Ohman Strickland', 'Affiliation': 'Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hilgart', 'Affiliation': 'Center for Behavioral Health and Technology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States.'}, {'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'Goydos', 'Affiliation': 'East Brunswick, NJ, United States.'}, {'ForeName': 'Carolyn J', 'Initials': 'CJ', 'LastName': 'Heckman', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Medicine, Rutgers Robert Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States; Department of Health Behavior, Systems & Policy, Rutgers School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ, United States.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Chamorro', 'Affiliation': 'Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.'}, {'ForeName': 'Babar K', 'Initials': 'BK', 'LastName': 'Rao', 'Affiliation': 'Department of Dermatology, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, United States.'}, {'ForeName': 'Moira', 'Initials': 'M', 'LastName': 'Davis', 'Affiliation': 'Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, United States.'}, {'ForeName': 'Franz O', 'Initials': 'FO', 'LastName': 'Smith', 'Affiliation': 'Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, United States.'}, {'ForeName': 'Frances P', 'Initials': 'FP', 'LastName': 'Thorndike', 'Affiliation': 'Pear Therapeutics, Boston, MA, United States.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Ritterband', 'Affiliation': 'Center for Behavioral Health and Technology, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.06.014'] 361,32242355,Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding.,"BACKGROUND It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation. The role of endoscopy performed within time frames shorter than 24 hours has not been adequately defined. METHODS To evaluate whether urgent endoscopy improves outcomes in patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow-Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation. The primary end point was death from any cause within 30 days after randomization. RESULTS A total of 516 patients were enrolled. The 30-day mortality was 8.9% (23 of 258 patients) in the urgent-endoscopy group and 6.6% (17 of 258) in the early-endoscopy group (difference, 2.3 percentage points; 95% confidence interval [CI], -2.3 to 6.9). Further bleeding within 30 days occurred in 28 patients (10.9%) in the urgent-endoscopy group and in 20 (7.8%) in the early-endoscopy group (difference, 3.1 percentage points; 95% CI, -1.9 to 8.1). Ulcers with active bleeding or visible vessels were found on initial endoscopy in 105 of the 158 patients (66.4%) with peptic ulcers in the urgent-endoscopy group and in 76 of 159 (47.8%) in the early-endoscopy group. Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. CONCLUSIONS In patients with acute upper gastrointestinal bleeding who were at high risk for further bleeding or death, endoscopy performed within 6 hours after gastroenterologic consultation was not associated with lower 30-day mortality than endoscopy performed between 6 and 24 hours after consultation. (Funded by the Health and Medical Fund of the Food and Health Bureau, Government of Hong Kong Special Administrative Region; ClinicalTrials.gov number, NCT01675856.).",2020,"Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. ","['patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation', 'patients predicted to be at high risk for further bleeding or death, we randomly assigned patients with overt signs of acute upper gastrointestinal bleeding and a Glasgow-Blatchford score of 12 or higher (scores range from 0 to 23, with higher scores indicating a higher risk of further bleeding or death) to undergo endoscopy within 6 hours (urgent-endoscopy group) or between 6 and 24 hours (early-endoscopy group) after gastroenterologic consultation', '516 patients were enrolled']",['Endoscopic hemostatic treatment'],"['death', 'peptic ulcers', 'Ulcers with active bleeding or visible vessels', '30-day mortality', 'Further bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0266809', 'cui_str': 'Acute upper gastrointestinal hemorrhage'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C1292428', 'cui_str': '6 hours'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0030920', 'cui_str': 'Peptic ulcer'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205379', 'cui_str': 'Visible'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",516.0,0.0981341,"Endoscopic hemostatic treatment was administered at initial endoscopy for 155 patients (60.1%) in the urgent-endoscopy group and for 125 (48.4%) in the early-endoscopy group. ","[{'ForeName': 'James Y W', 'Initials': 'JYW', 'LastName': 'Lau', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Raymond S Y', 'Initials': 'RSY', 'LastName': 'Tang', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Heyson C H', 'Initials': 'HCH', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Hon-Chi', 'Initials': 'HC', 'LastName': 'Yip', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Sally W Y', 'Initials': 'SWY', 'LastName': 'Luk', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Sunny H', 'Initials': 'SH', 'LastName': 'Wong', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Louis H S', 'Initials': 'LHS', 'LastName': 'Lau', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Rashid N', 'Initials': 'RN', 'LastName': 'Lui', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Ting T', 'Initials': 'TT', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Joyce W Y', 'Initials': 'JWY', 'LastName': 'Mak', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Francis K L', 'Initials': 'FKL', 'LastName': 'Chan', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}, {'ForeName': 'Joseph J Y', 'Initials': 'JJY', 'LastName': 'Sung', 'Affiliation': 'From the Institute of Digestive Disease, the Chinese University of Hong Kong, Shatin, Hong Kong.'}]",The New England journal of medicine,['10.1056/NEJMoa1912484'] 362,31849123,"The effect of l-carnitine supplementation on serum levels of omentin-1, visfatin and SFRP5 and glycemic indices in patients with pemphigus vulgaris: A randomized, double-blind, placebo-controlled clinical trial.","Pemphigus vulgaris (PV) is a chronic autoimmune disorder with potentially fatal outcomes. The aim of this study was to investigate the effect of l-carnitine (LC) on secreted frizzled-related protein-5 (SFRP5), omentin, visfatin, and glycemic indices in PV patients under corticosteroid treatment. In this randomized, double-blind, placebo-controlled clinical trial, 52 patients with PV were divided randomly into two groups to receive 2 g of LC or a placebo for 8 weeks. Serum levels of SFRP5, omentin, visfatin, and also glycemic indices were evaluated at the baseline and end of the study. LC supplementation significantly decreased the serum level of visfatin (95% CI [-14.718, -0.877], p = .05) and increased the serum levels of SFRP5 (95%CI [1.637, 11.380], p < .006) and omentin (95% CI [9.014, 65.286], p < .01). However, LC supplementation had no significant effects on the serum levels of glycemic factors such as insulin (95% CI [-1.125, 3.056], p = .426), fasting blood sugar (95% CI [-4.743, 3.642], p = .894), homeostatic model assessment of insulin resistance (95% CI [-0.305, 0.528], p = .729), and quantitative insulin-sensitivity check index (95% CI [-0.016, -0.010], p = .81). LC supplementation decreased visfatin serum level and increased omentin-1 and SFRP5 serum levels in patients with PV. However, it has no significant effect on the serum levels of insulin and glycemic indices.",2020,LC supplementation decreased visfatin serum level and increased omentin-1 and SFRP5 serum levels in patients with PV.,"['52 patients with PV', 'PV patients under corticosteroid treatment', 'patients with pemphigus vulgaris', 'patients with PV']","['l-carnitine supplementation', 'LC', 'placebo', 'l-carnitine (LC', 'LC supplementation']","['quantitative insulin-sensitivity check index', 'serum levels of SFRP5', 'homeostatic model assessment of insulin resistance', 'serum levels of insulin and glycemic indices', 'visfatin serum level', 'fasting blood sugar', 'serum level of visfatin', 'serum levels of omentin-1, visfatin and SFRP5 and glycemic indices', 'secreted frizzled-related protein-5 (SFRP5), omentin, visfatin, and glycemic indices', 'serum levels of glycemic factors such as insulin', 'omentin-1 and SFRP5 serum levels', 'Serum levels of SFRP5, omentin, visfatin, and also glycemic indices']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030809', 'cui_str': 'Pemphigus Vulgaris'}]","[{'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1136206', 'cui_str': 'Glycemic Index Number'}, {'cui': 'C0068707', 'cui_str': 'Visfatin'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0530702', 'cui_str': 'frezzled protein'}]",52.0,0.504235,LC supplementation decreased visfatin serum level and increased omentin-1 and SFRP5 serum levels in patients with PV.,"[{'ForeName': 'Farnaz', 'Initials': 'F', 'LastName': 'Sepandar', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Daneshpazhooh', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Djalali', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Mohammadi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Science, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Yaghubi', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Fakhri', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hajar', 'Initials': 'H', 'LastName': 'Tavakoli', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Ghaedi', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Keshavarz', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Zarei', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Amin', 'Initials': 'MA', 'LastName': 'Shahrbaf', 'Affiliation': 'Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Narges', 'Initials': 'N', 'LastName': 'Ghandi', 'Affiliation': 'Autoimmune Bullous Diseases Research Center, Department of Dermatology, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Darand', 'Affiliation': 'Student Research Committee, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohamad Hassan', 'Initials': 'MH', 'LastName': 'Javanbakht', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6568'] 363,32276953,Effects of brief family psychoeducation for caregivers of people with schizophrenia in Japan provided by visiting nurses: protocol for a cluster randomised controlled trial.,"INTRODUCTION Development of a support system for families caring for people with schizophrenia in routine psychiatric care settings is an important issue worldwide. Regional mental health systems are inadequate for delivering effective services to such family members. Despite evidence that family psychoeducation (FPE) alleviates the burden of schizophrenia on families, its dissemination in routine clinical practice remains insufficient, suggesting the need for developing an effective and implementable intervention for family caregivers in the existing mental health system setting. In Japan, the visiting nurse service system would be a practical way of providing family services. Visiting nurses in local communities are involved in the everyday lives of people with schizophrenia and their families. Accordingly, visiting nurses understand their needs and are able to provide family support as a service covered by national health insurance. The purpose of this study is to discover whether a brief FPE programme provided by visiting nurses caring for people with schizophrenia will alleviate family burden through a cluster randomised controlled trial (cRCT). METHODS AND ANALYSIS The study will be a two-arm, parallel-group (visiting nurse agency) cRCT. Forty-seven visiting nurse agencies will be randomly allocated to the brief FPE group (intervention group) or treatment as usual group (control group). Caregivers of people with schizophrenia will be recruited by visiting nurses using a randomly ordered list. The primary outcome will be caregiver burden, measured using the Japanese version of Zarit Burden Interview. Outcome assessments will be conducted at baseline, 1-month follow-up and 6-month follow-up. Multiple levels of three-way interactions in mixed models will be used to examine whether the brief FPE programme will alleviate the burden on caregivers relative to treatment as usual. ETHICS AND DISSEMINATION The Research Ethics Committee of the Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Japan (No 2019065NI) approved this study. The results will be published in a scientific peer-reviewed journal. TRIAL REGISTRATION NUMBER UMIN000038044.",2020,Forty-seven visiting nurse agencies will be randomly allocated to the brief FPE group (intervention group) or treatment as usual group (control group).,"['caregivers of people with schizophrenia in Japan provided by visiting nurses', 'families caring for people with schizophrenia in routine psychiatric care settings', 'Caregivers of people with schizophrenia', 'people with schizophrenia and their families', 'visiting nurses caring for people with schizophrenia', 'Forty-seven visiting nurse agencies']","['FPE group (intervention group) or treatment as usual group (control group', 'brief family psychoeducation', 'family psychoeducation (FPE', 'FPE programme']","['caregiver burden, measured using the Japanese version of Zarit Burden Interview']","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0042799', 'cui_str': 'Home Nurses'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0204523', 'cui_str': 'Psychiatric therapeutic procedure'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]",,0.156218,Forty-seven visiting nurse agencies will be randomly allocated to the brief FPE group (intervention group) or treatment as usual group (control group).,"[{'ForeName': 'Naonori', 'Initials': 'N', 'LastName': 'Yasuma', 'Affiliation': 'Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan nnyy712@gmail.com.'}, {'ForeName': 'Sayaka', 'Initials': 'S', 'LastName': 'Sato', 'Affiliation': 'Department of Community Mental Health and Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Sosei', 'Initials': 'S', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Community Mental Health and Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Asami', 'Initials': 'A', 'LastName': 'Matsunaga', 'Affiliation': 'Department of Community Mental Health and Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Takuma', 'Initials': 'T', 'LastName': 'Shiozawa', 'Affiliation': 'Department of Community Mental Health and Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Hisateru', 'Initials': 'H', 'LastName': 'Tachimori', 'Affiliation': 'Department of Clinical Epidemiology, Translational Medical Center, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Kotaro', 'Initials': 'K', 'LastName': 'Imamura', 'Affiliation': 'Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Nishi', 'Affiliation': 'Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Chiyo', 'Initials': 'C', 'LastName': 'Fujii', 'Affiliation': 'Department of Community Mental Health and Law, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.'}, {'ForeName': 'Norito', 'Initials': 'N', 'LastName': 'Kawakami', 'Affiliation': 'Department of Mental Health, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.'}]",BMJ open,['10.1136/bmjopen-2019-034425'] 364,30914491,Effect of Health Coaching Delivered by a Respiratory Therapist or Nurse on Self-Management Abilities in Severe COPD: Analysis of a Large Randomized Study.,"BACKGROUND Self-management of patients with COPD has received increasing attention in recent years given its association with improved outcomes. There is a scarcity of feasible interventions that can improve self-management abilities. We recently reported the positive effect of health coaching, started at the time of hospital discharge, on re-hospitalizations and emergency department visits for patients with COPD admitted for an exacerbation. In this substudy, we aimed to investigate the effects of health coaching delivered by a respiratory therapist or a nurse compared with guideline-based usual care on self-management abilities in COPD. METHODS Self-management was measured by using the Chronic Respiratory Disease Questionnaire mastery domain and was assessed at baseline, at 6 months, and at 12 months after hospitalization. RESULTS Two hundred and fifteen subjects hospitalized for a COPD exacerbation were randomized to the intervention or the control. The mean change in the Chronic Respiratory Disease Questionnaire mastery score from baseline to month 6 was Δ0.58 32 ± 1.29 on the intervention arm and Δ0.17 32 ± 1.14 on the control arm ( P = .02). Of the intervention subjects, 55% had at least a 0.5-point increase in Chronic Respiratory Disease Questionnaire mastery (minimum clinically important difference) compared with 38% in the control group. Health coaching was an independent predictor of the minimum clinically important difference or greater change in the Chronic Respiratory Disease Questionnaire mastery score at 6 months after initiation of the intervention (odds ratio 1.95, 95% CI 1.01-3.79). The changes in the Chronic Respiratory Disease Questionnaire mastery score at 12 months showed a trend but did not attain statistical significance. CONCLUSIONS Health coaching delivered by a respiratory therapist or a nurse improved self-management abilities when applied to subjects with COPD after hospital discharge for an exacerbation. (ClinicalTrials.gov Identifier: NCT01058486, Mayo IRB 09-004341).",2019,"The changes in the Chronic Respiratory Disease Questionnaire mastery score at 12 months showed a trend but did not attain statistical significance. ","['patients with COPD', 'Severe COPD', 'patients with COPD admitted for an exacerbation', 'Two hundred and fifteen subjects hospitalized for a COPD exacerbation']","['health coaching delivered by a respiratory therapist or a nurse compared with guideline-based usual care', 'Health Coaching Delivered by a Respiratory Therapist or Nurse']","['Chronic Respiratory Disease Questionnaire mastery score', 'Chronic Respiratory Disease Questionnaire mastery', 'Chronic Respiratory Disease Questionnaire mastery domain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4709308', 'cui_str': '215 (qualifier value)'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1709924', 'cui_str': 'Respiratory therapist'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C3164900', 'cui_str': 'Chronic respiratory disease questionnaire (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}]",215.0,0.0590598,"The changes in the Chronic Respiratory Disease Questionnaire mastery score at 12 months showed a trend but did not attain statistical significance. ","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Benzo', 'Affiliation': 'Mindful Breathing Laboratory, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota. benzo.roberto@mayo.edu.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'McEvoy', 'Affiliation': 'HealthPartners Institute for Education and Research, Bloomington, Minnesota.'}]",Respiratory care,['10.4187/respcare.05927'] 365,32276809,Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial.,"BACKGROUND In a randomized controlled trial (MOMENTUM 3), the HeartMate 3 (HM3) fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) demonstrated superiority over the HeartMate II (HMII) axial-flow LVAD. These findings were driven by hemocompatibility-related outcomes, but infection-related outcomes were not altered by device choice. In this trial-level analysis, we analyzed the clinical patterns of infection-related outcomes over 2 years of support. METHODS In MOMENTUM 3, 1,020 patients were implanted with either the HM3 (n = 515) or HMII (n = 505) pump. Clinical characteristics and morbidity- and mortality-related outcomes were evaluated to identify predictors associated with major infectious complications, using univariable and multivariable models. RESULTS The cumulative number of infections at 2 years was 1,213 (634 HM3 and 579 HMII), and major infection occurred in 58% of patients with the HM3 and 56% of patients with the HMII (p = 0.57). Infections of a local nature unrelated to pump components were most common (n = 681/1,213; 56%), followed by driveline-associated infection (n = 329/1,213; 27%), sepsis (n = 194/1,213; 16%), and other events (n = 9/1,213; 0.7%). Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001). Most deaths in those with infection occurred owing to non-infectious causes. CONCLUSION Infection is the most common adverse effect in patients implanted with contemporary continuous-flow LVADs, with most such events unrelated to the pump or its peripheral components. Whether chronic mechanical circulatory devices confer an immunomodulatory effect pre-disposing to infection warrants closer scrutiny to understand and ameliorate this morbidity.",2020,"Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001).","['1,020 patients were implanted with either the HM3 (n\u202f=\u202f515) or']",['HMII'],"['major infection', 'Bacterial pathogens', 'sepsis', 'cumulative number of infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",1020.0,0.142918,"Bacterial pathogens were implicated in 806 of 1,213 events (66%); significant predictors of infection included sex (women vs men; hazard ratio [HR]: 1.38, p = 0.003), pre-implant use of intra-aortic balloon pump (HR: 1.33, p = 0.02), pre-implant history of cardiac surgery (HR: 1.28, p = 0.01), and body mass index ≥ 30 (HR: 1.40, p < 0.0001).","[{'ForeName': 'Chetan B', 'Initials': 'CB', 'LastName': 'Patel', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Blue', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cagliostro', 'Affiliation': 'New York-Presbyterian/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Stephen H', 'Initials': 'SH', 'LastName': 'Bailey', 'Affiliation': 'Allegheny General Hospital, Pittsburgh, Pennsylvania.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Entwistle', 'Affiliation': 'Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Ranjit', 'Initials': 'R', 'LastName': 'John', 'Affiliation': 'University of Minnesota Medical Center, Minneapolis, Minnesota.'}, {'ForeName': 'Vinay', 'Initials': 'V', 'LastName': 'Thohan', 'Affiliation': 'Mission Health System, Asheville, North Carolina.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Cleveland', 'Affiliation': 'University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Goldstein', 'Affiliation': 'Montefiore Einstein Center for Heart and Vascular Care, New York, New York.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Uriel', 'Affiliation': 'New York-Presbyterian/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Xiaolu', 'Initials': 'X', 'LastName': 'Su', 'Affiliation': 'Abbott, Abbott Park, Illinois.'}, {'ForeName': 'Sami I', 'Initials': 'SI', 'LastName': 'Somo', 'Affiliation': 'Abbott, Abbott Park, Illinois.'}, {'ForeName': 'Poornima', 'Initials': 'P', 'LastName': 'Sood', 'Affiliation': 'Abbott, Abbott Park, Illinois.'}, {'ForeName': 'Mandeep R', 'Initials': 'MR', 'LastName': 'Mehra', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.""}]",The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,['10.1016/j.healun.2020.03.002'] 366,31062834,"Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.","BACKGROUND/OBJECTIVES depressive symptoms are common in Alzheimer's disease(AD). Aim of the study was to investigate the efficacy of vortioxetine compared with other conventional antidepressants on cognitive functions in AD patients with depressive symptoms. DESIGN Prospective, randomized, 12 month, parallel-group study. SETTING All participants were evaluated on-site at Neurodegenerative Disorders Unit, ASP2 Caltanissetta(Italy). PARTICIPANTS 108(71 female, 37 male) AD patients with depression(mean age 76.7 ± 4.3). INTERVENTION Randomized subjects received vortioxetine, 15 mg/day(n=36) or other common antidepressants(n=72). MEASURES Primary outcome was change from baseline in the MMSE; secondary outcomes were change in Attentive Matrices, Raven Coloured Progressive Matrices, Digit Span, HAM-D and Cornell scale. RESULTS Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores.The most commonly reported adverse events were nausea and headache for votioxetine; nausea in the control group. CONCLUSIONS Vortioxetine had a beneficial effect on cognition and mood in elderly AD patients and was safe and well tolerated.",2019,Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores.,"['108(71 female, 37 male) AD patients with depression(mean age 76.7 ± 4.3', 'All participants were evaluated on-site at Neurodegenerative Disorders Unit, ASP2 Caltanissetta(Italy', 'AD patients with depressive symptoms', ""Mild Alzheimer's Disease Patients with Depressive Symptoms"", 'elderly AD patients']","['vortioxetine', 'Vortioxetine', 'conventional antidepressants', 'vortioxetine, 15 mg/day(n=36) or other common antidepressants(n=72']","['cognitive functions', 'safe and well tolerated', 'nausea and headache for votioxetine; nausea', 'Cognitive Functions', 'change in Attentive Matrices, Raven Coloured Progressive Matrices, Digit Span, HAM-D and Cornell scale', 'cognition and mood', 'HAM-D and Cornell total scores']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517759', 'cui_str': 'Four point three'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0524851', 'cui_str': 'Degenerative Neurologic Disorders'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}]","[{'cui': 'C3661282', 'cui_str': 'vortioxetine'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C4319583', 'cui_str': 'Matrix'}, {'cui': 'C0475506', 'cui_str': 'Ravens colored progressive matrices (assessment scale)'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C3853311', 'cui_str': 'Ham'}, {'cui': 'C0222045'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.153132,Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores.,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Cumbo', 'Affiliation': 'Eduardo Cumbo, Neurodegenerative Disorders Unit, ASP 2 Caltanissetta, via L.Monaco 109 Caltanissetta (Italy);email: eduardo.cumbo@tiscali.it; tel. +39 0934506309/0934 506321.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cumbo', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Torregrossa', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Migliore', 'Affiliation': ''}]",The journal of prevention of Alzheimer's disease,['10.14283/jpad.2019.24'] 367,31484629,"Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.","BACKGROUND Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. METHODS The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). FINDINGS Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8-3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74-0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction =0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78-1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75-1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48-2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36-3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74-1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75-0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction =0·012. Benefit was present irrespective of time from most recent PCI. INTERPRETATION In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk. FUNDING AstraZeneca.",2019,"The same effect was not observed in patients without PCI (p=0·76, p interaction =0·16).","['diabEtes Mellitus patients Intervention Study (THEMIS', 'Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery', 'patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk', '5536 patients with', 'controlled trial, done in 1315 sites in 42 countries', 'patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI', 'patients with diabetes, stable coronary artery disease', 'Patients with stable coronary artery disease and diabetes with previous', '5536 patients receiving', 'Between Feb 17, 2014, and May 24, 2016, 11\u2008154 patients (58% of the overall THEMIS trial) with a history of previous PCI', 'Eligible patients']","['percutaneous coronary intervention (PCI', 'Ticagrelor', 'aspirin plus ticagrelor', 'ticagrelor or placebo, by use of an interactive voice-response or web-response system', 'placebo', 'aspirin', 'ticagrelor']","['cardiovascular death, myocardial infarction, and stroke', 'fatal bleeding', 'Intracranial haemorrhage', 'proportion of patients with cardiovascular death', 'TIMI major bleeding', 'Health Outcomes', 'composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population']","[{'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",5536.0,0.373806,"The same effect was not observed in patients without PCI (p=0·76, p interaction =0·16).","[{'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School Boston, MA, USA. Electronic address: dlbhattmd@post.harvard.edu.""}, {'ForeName': 'Philippe Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale U-1148, Paris, France; National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.'}, {'ForeName': 'Shamir R', 'Initials': 'SR', 'LastName': 'Mehta', 'Affiliation': 'Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada; McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Lawrence A', 'Initials': 'LA', 'LastName': 'Leiter', 'Affiliation': ""Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Tabassome', 'Initials': 'T', 'LastName': 'Simon', 'Affiliation': 'Department of Clinical Pharmacology-Clinical Research Platform (URCEST-CRB-CRCEST), AP-HP, Hôpital Saint Antoine, Sorbonne-Université, Paris, France.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Fox', 'Affiliation': 'National Heart and Lung Institute, Royal Brompton Hospital, Imperial College London, London, UK.'}, {'ForeName': 'Claes', 'Initials': 'C', 'LastName': 'Held', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Marielle', 'Initials': 'M', 'LastName': 'Andersson', 'Affiliation': 'AstraZeneca BioPharmaceuticals Research & Development, Late-stage Development, Cardiovascular, Renal and Metabolic, Mölndal, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Himmelmann', 'Affiliation': 'AstraZeneca BioPharmaceuticals Research & Development, Late-stage Development, Cardiovascular, Renal and Metabolic, Mölndal, Sweden.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Ridderstråle', 'Affiliation': 'AstraZeneca BioPharmaceuticals Research & Development, Late-stage Development, Cardiovascular, Renal and Metabolic, Mölndal, Sweden.'}, {'ForeName': 'Jersey', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'AstraZeneca BioPharmaceuticals Research & Development, Late-stage Development, Cardiovascular, Renal and Metabolic, Gaithersburg, MD, USA.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Baim Institute for Clinical Research, Boston, MA, USA.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'Department of Medicine, Estudios Clínicos Latino América, Rosario, Argentina.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Goto', 'Affiliation': 'Department of Medicine (Cardiology), Tokai University School of Medicine, Isehara, Japan.'}, {'ForeName': 'Stefan K', 'Initials': 'SK', 'LastName': 'James', 'Affiliation': 'Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK.'}, {'ForeName': 'Alexander N', 'Initials': 'AN', 'LastName': 'Parkhomenko', 'Affiliation': 'Institute of Cardiology, Emergency Cardiology Department, Kiev, Ukraine.'}, {'ForeName': 'Mikhail N', 'Initials': 'MN', 'LastName': 'Kosiborod', 'Affiliation': ""Saint Luke's Mid-America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Harrington', 'Affiliation': 'Department of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)31887-2'] 368,32271261,Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes: rationale and design of the semaglutide treatment on coronary progression trial.,"BACKGROUND Cardiovascular morbidity and mortality are a major burden in patients with type 2 diabetic mellitus. In a landmark study, semaglutide (an injectable glucagon like peptide-1 receptor agonist) has been shown to significantly reduce cardiovascular events, however, the mechanism of benefit is still unknown. The primary hypothesis of our current study is to assess the effect of semaglutide to reduce progression of noncalcified coronary atherosclerotic plaque volume as measured by serial coronary CTA as compared to placebo in persons with diabetes over 1 year. METHODS One hundred forty patients will be enrolled after signing informed consent and followed up for 12 months and with a phone call 30 days after medical discontinuation. All the participants will undergo coronary artery calcium scoring and coronary computed tomography angiography at our center at baseline and 12 months. Eligible participants will be randomly assigned to semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous (SC) injection or placebo 1.5 ml, pen-injector for SC injection in a 1:1 fashion as add-on to their standard of care. RESULTS As of July 2019, the study was approximately 30% enrolled with an estimated enrollment completion by first quarter of 2020 and end of study by first quarter 2021. Thirty patients were enrolled as of 23 July 2019. Preliminary data of demographics and clinical characteristics were summarized. CONCLUSION Our current study will provide important imaging-derived data that may add relevance to the clinically derived outcomes from liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results and semaglutide and cardiovascular outcomes in patients with type 2 diabetic mellitus 6 trials.",2020,"As of July 2019, the study was approximately 30% enrolled with an estimated enrollment completion by first quarter of 2020 and end of study by first quarter 2021.","['One hundred forty patients will be enrolled after signing informed consent and followed up for 12 months and with a phone call 30 days after medical discontinuation', 'persons with diabetes over 1 year', 'patients with type II diabetes', 'Eligible participants', 'patients with type 2 diabetic mellitus', 'Thirty patients were enrolled as of 23 July 2019', 'patients with type 2 diabetic mellitus 6 trials', 'As of July 2019, the study was approximately 30% enrolled with an estimated enrollment completion by first quarter of 2020 and end of study by first quarter 2021']","['semaglutide', 'coronary artery calcium scoring and coronary computed tomography angiography', 'placebo', 'semaglutide 2 mg/1.5 ml (1.34 mg/ml) prefilled pen for subcutaneous (SC) injection or placebo 1.5 ml, pen-injector for SC injection']","['cardiovascular events', 'coronary atherosclerosis progression']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0036369', 'cui_str': 'School Enrollment'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C2825178', 'cui_str': 'Coronary artery calcium score'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1536105', 'cui_str': 'CT angiography'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4517501', 'cui_str': '1.34'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0070220', 'cui_str': 'penclomedine'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous injection'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4025916', 'cui_str': 'Pen Injector'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",30.0,0.200433,"As of July 2019, the study was approximately 30% enrolled with an estimated enrollment completion by first quarter of 2020 and end of study by first quarter 2021.","[{'ForeName': 'Sajad', 'Initials': 'S', 'LastName': 'Hamal', 'Affiliation': ''}, {'ForeName': 'Lavanya', 'Initials': 'L', 'LastName': 'Cherukuri', 'Affiliation': ''}, {'ForeName': 'Kashif', 'Initials': 'K', 'LastName': 'Shaikh', 'Affiliation': ''}, {'ForeName': 'April', 'Initials': 'A', 'LastName': 'Kinninger', 'Affiliation': ''}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Doshi', 'Affiliation': ''}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Birudaraju', 'Affiliation': ''}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Budoff', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000830'] 369,32273244,Sleep Improvement Effect on Sexual Life Quality Among Rotating Female Shift Workers: A Randomized Controlled Trial.,"BACKGROUND Poor sleep quality consequences among shift working nurses are well recognized. AIM To investigate the impact of sleep improvement on sexual quality of life. METHODS The study was a parallel randomized controlled trial, conducted among 120 female nurses in 2 educational hospitals in the Northeast of Iran, Shahroud. Using random blocks of four, 120 eligible participants were randomly assigned to study groups. Data collecting tools included a demographic data questionnaire, Pittsburgh Sleep Quality Index to assess sleep quality, and the survey of sexual quality of life-female and Sexual Self-Efficacy Questionnaire to evaluate level of sexual quality of life and sexual self-efficacy, respectively. The intervention consisted of 3 weekly sleep intervention sessions that lasted from 90 to 120 minutes. OUTCOMES The study's primary and secondary outcomes were sleep quality, and the level of sexual self-efficacy and sexual quality of life, respectively. RESULTS By 3-month follow-up, the loss to follow-up rate was 5.9%. The mean sleep quality score was 7.61 ± 2.26 in the recruited participants. Following the intervention, the sleep quality score showed statistically significant differences compared to the control group [mean difference (CI 99.98%), -1.89 (-2.40, -1.38)]. Participants in the intervention group showed modest increases in both measures; sexual self-efficacy [mean difference (CI 99.98%), 8.82 (6.83, 10.81)] and sexual quality of life [mean difference (CI 99.98%), 19.64 (18.08, 21.20)]. CLINICAL IMPLICATIONS These findings suggest that sleep improvement could promote the sexual quality of life among shift working nurses. STRENGTHS & LIMITATIONS Strengths of this study include the use of a validated outcome measure. Focusing the study on female nurses and the small size of the study population are the limitations. CONCLUSION Improved sleep showed an impact on sexual quality of life among rotating female shift workers. Khastar H, Mirrezaie SM, Chashmi NA, et al. Sleep Improvement Effect on Sexual Life Quality Among Rotating Female Shift Workers: A Randomized Controlled Trial. J Sex Med 2020;17:1467-1475.",2020,"Following the intervention, the sleep quality score showed statistically significant differences compared to the control group [mean difference (CI 99.98%), -1.89","['Rotating Female Shift Workers', '120 eligible participants', '120 female nurses in 2 educational hospitals in the Northeast of Iran, Shahroud']",[],"['sleep quality, and the level of sexual self-efficacy and sexual quality of life, respectively', 'measures; sexual self-efficacy', 'demographic data questionnaire, Pittsburgh Sleep Quality Index to assess sleep quality, and the survey of sexual quality of life-female and Sexual Self-Efficacy Questionnaire to evaluate level of sexual quality of life and sexual self-efficacy', 'sexual quality of life', 'sleep quality score', 'Sexual Life Quality', 'mean sleep quality score']","[{'cui': 'C0231458', 'cui_str': 'Rotated'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0425104', 'cui_str': 'Shift worker'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]",[],"[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",120.0,0.107333,"Following the intervention, the sleep quality score showed statistically significant differences compared to the control group [mean difference (CI 99.98%), -1.89","[{'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Khastar', 'Affiliation': 'School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.'}, {'ForeName': 'Seyed Mohammad', 'Initials': 'SM', 'LastName': 'Mirrezaie', 'Affiliation': 'Center for Health Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Shahroud, Iran. Electronic address: mirrezaie@shmu.ac.ir.'}, {'ForeName': 'Nooshin Ahmadian', 'Initials': 'NA', 'LastName': 'Chashmi', 'Affiliation': 'Student Research Committee, School of Nursing and Midwifery, Shahroud University of Medical Sciences, Shahroud, Iran; Department of Psychology, Shahroud Branch, Islamic Azad University, Shahroud, Iran.'}, {'ForeName': 'Shayesteh', 'Initials': 'S', 'LastName': 'Jahanfar', 'Affiliation': 'Assistant Professor, MPH Program, Health Science Program, Central Michigan University, Mount Pleasant, MI, USA.'}]",The journal of sexual medicine,['10.1016/j.jsxm.2020.03.003'] 370,32272030,Dry Needling Combined With Guideline-Based Physical Therapy Provides No Added Benefit in the Management of Chronic Neck Pain: A Randomized Controlled Trial.,"OBJECTIVE To determine the added benefit of combining dry needling with a guideline-based physical therapy treatment program consisting of exercise and manual therapy on pain and disability in people with chronic neck pain. DESIGN Randomized controlled trial. METHODS Participants were randomized to receive either guideline-based physical therapy or guideline-based physical therapy plus dry needling. The primary outcomes, measured at 1 month post randomization, were average pain intensity in the previous 24 hours and previous week, measured with a numeric pain-rating scale (0-10), and disability, measured with the Neck Disability Index (0-100). The secondary outcomes were pain and disability measured at 3 and 6 months post randomization and global perceived effect, quality of sleep, pain catastrophizing, and self-efficacy measured at 1, 3, and 6 months post randomization. RESULTS One hundred sixteen participants were recruited. At 1 month post randomization, people who received guideline-based physical therapy plus dry needling had a small reduction in average pain intensity in the previous 24 hours (mean difference, 1.56 points; 95% confidence interval [CI]: 1.11, 2.36) and in the previous week (mean difference, 1.20 points; 95% CI: 1.02, 2.21). There was no effect of adding dry needling to guideline-based physical therapy on disability at 1 month post randomization (mean difference, -2.08 points; 95% CI: -3.01, 5.07). There was no effect for any of the secondary outcomes. CONCLUSION When combined with guideline-based physical therapy for neck pain, dry needling resulted in small improvements in pain only at 1 month post randomization. There was no effect on disability. J Orthop Sports Phys Ther 2020;50(8):447-454. Epub 9 Apr 2020. doi:10.2519/jospt.2020.9389 .",2020,There was no effect of adding dry needling to guideline-based physical therapy on disability at 1-month post-randomization (mean difference: -2.08 points; 95% CI -1.16 to 5.07).,"['Participants', 'people with chronic neck pain', '116 participants were recruited', 'Chronic Neck Pain']","['Guideline-Based Physical Therapy', 'guideline-based physical therapy', 'guideline-based physical therapy or guideline-based physical therapy plus dry needling', 'exercise and manual therapy', 'Combining Dry Needling', 'dry needling plus guideline-based physical therapy']","['numerical pain rating scale (0-10), and disability measured with the Neck Disability Index', 'pain and disability measured at 3 and 6 months, and global perceived effect, quality of sleep, pain catastrophizing, and self-efficacy', 'average pain intensity', 'disability', 'pain', 'pain and disability']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C4517541', 'cui_str': '116'}]","[{'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",116.0,0.188397,There was no effect of adding dry needling to guideline-based physical therapy on disability at 1-month post-randomization (mean difference: -2.08 points; 95% CI -1.16 to 5.07).,"[{'ForeName': 'Fábio Franciscatto', 'Initials': 'FF', 'LastName': 'Stieven', 'Affiliation': ''}, {'ForeName': 'Giovanni Esteves', 'Initials': 'GE', 'LastName': 'Ferreira', 'Affiliation': ''}, {'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Wiebusch', 'Affiliation': ''}, {'ForeName': 'Francisco Xavier', 'Initials': 'FX', 'LastName': 'de Araújo', 'Affiliation': ''}, {'ForeName': 'Luis Henrique Telles', 'Initials': 'LHT', 'LastName': 'da Rosa', 'Affiliation': ''}, {'ForeName': 'Marcelo Faria', 'Initials': 'MF', 'LastName': 'Silva', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2020.9389'] 371,32112114,Comparison of intubating conditions after induction with propofol and remifentanil or sufentanil : Randomized controlled REMIDENT trial for surgical tooth extraction.,"PURPOSE The aim of this study was to compare tracheal intubation conditions after induction of anesthesia with a bolus of propofol-sufentanil or propofol-remifentanil and a rapid induction technique. MATERIAL AND METHODS A total of 70 patients (American Society of Anesthesiologists (ASA) classification I‑II) undergoing outpatient surgery under general anesthesia with intubation for tooth extraction were randomly assigned to two groups in this double-blind study. Patients received either a bolus of remifentanil (3 μg/kg) or sufentanil (0.3 μg/kg) together with 2.5 mg/kg propofol for intubation. The primary outcome was the percentage of excellent intubation conditions and the secondary outcomes were the percentage of patients with a decrease of over 20% in mean arterial pressure (MAP) or heart rate (HR), time to achieve spontaneous respiration, time between the end of surgery and extubation and time to achieve an Aldrete score of 10. VAS pain score was >3 or having laryngeal pain 15 min after arriving in the postanesthesia care unit (PACU) were also analyzed. RESULTS Intubating conditions (perfect + good conditions) were significantly better with remifentanil than with sufentanil (88.5% vs. 68.6%; p = 0.01). When using remifentanil, the hemodynamic conditions were good. Using remifentanil did not significantly increase the pain score or the laryngeal pain in the recovery room. This was confirmed by no significant differences between the groups for morphine consumption. Remifentanil significantly decreased the time to achieve an Aldrete score of 10. CONCLUSION When intubation without muscle relaxants is required, intubating conditions are much better when a remifentanil bolus is used compared to a sufentanil bolus. The remifentanil/propofol rapid induction technique is a valuable technique to quickly intubate and achieve good conditions.",2020,"RESULTS Intubating conditions (perfect + good conditions) were significantly better with remifentanil than with sufentanil (88.5% vs. 68.6%; p = 0.01).",['70\xa0patients (American Society of Anesthesiologists (ASA) classification I‑II) undergoing outpatient surgery under general anesthesia with intubation for tooth extraction'],"['Remifentanil', 'propofol and remifentanil', 'propofol', 'sufentanil ', 'remifentanil/propofol', 'remifentanil', 'sufentanil', 'propofol-sufentanil or propofol-remifentanil']","['mean arterial pressure (MAP) or heart rate (HR), time to achieve\xa0spontaneous respiration, time between the end of surgery and extubation and time to achieve an Aldrete score of\xa010', 'pain score or the laryngeal pain', 'VAS pain score', 'percentage of excellent intubation conditions', 'time to achieve an Aldrete score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0002428', 'cui_str': 'Ambulatory Surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0040440', 'cui_str': 'Tooth Extraction'}]","[{'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}]","[{'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0412771', 'cui_str': 'Spontaneous respiration (finding)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0549373', 'cui_str': 'Laryngeal pain'}, {'cui': 'C1961136', 'cui_str': 'Excellent (qualifier value)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",,0.236305,"RESULTS Intubating conditions (perfect + good conditions) were significantly better with remifentanil than with sufentanil (88.5% vs. 68.6%; p = 0.01).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Dolsan', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Bruneteau', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Roche', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ferré', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Labaste', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sommet', 'Affiliation': 'Laboratory of Medical and Clinical Pharmacology, Pharmacoepidemiology, Inserm U1027, Toulouse University, Faculty of Medicine, Toulouse, France.'}, {'ForeName': 'J-M', 'Initials': 'JM', 'LastName': 'Conil', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Minville', 'Affiliation': 'Department of Anaesthesiology and Intensive Care, Toulouse University Hospital, Avenue Jean Poulhès, 31432, Toulouse, France. minville.v@chu-toulouse.fr.'}]",Der Anaesthesist,['10.1007/s00101-020-00739-0'] 372,31705466,Hypertension Self-management in Socially Disadvantaged African Americans: the Achieving Blood Pressure Control Together (ACT) Randomized Comparative Effectiveness Trial.,"BACKGROUND Effective hypertension self-management interventions are needed for socially disadvantaged African Americans, who have poorer blood pressure (BP) control compared to others. OBJECTIVE We studied the incremental effectiveness of contextually adapted hypertension self-management interventions among socially disadvantaged African Americans. DESIGN Randomized comparative effectiveness trial. PARTICIPANTS One hundred fifty-nine African Americans at an urban primary care clinic. INTERVENTIONS Participants were randomly assigned to receive (1) a community health worker (""CHW"") intervention, including the provision of a home BP monitor; (2) the CHW plus additional training in shared decision-making skills (""DoMyPART""); or (3) the CHW plus additional training in self-management problem-solving (""Problem Solving""). MAIN MEASURES We assessed group differences in BP control (systolic BP (SBP) < 140 mm Hg and diastolic BP (DBP) < 90 mmHg), over 12 months using generalized linear mixed models. We also assessed changes in SBP and DBP and participants' BP self-monitoring frequency, clinic visit patient-centeredness (i.e., extent of patient-physician discussions focused on patient emotional and psychosocial concerns), hypertension self-management behaviors, and self-efficacy. KEY RESULTS BP control improved in all groups from baseline (36%) to 12 months (52%) with significant declines in SBP (estimated mean [95% CI] - 9.1 [- 15.1, - 3.1], - 7.4 [- 13.4, - 1.4], and - 11.3 [- 17.2, - 5.3] mmHg) and DBP (- 4.8 [- 8.3, - 1.3], - 4.0 [- 7.5, - 0.5], and - 5.4 [- 8.8, - 1.9] mmHg) for CHW, DoMyPART, and Problem Solving, respectively). There were no group differences in BP outcomes, BP self-monitor use, or clinic visit patient-centeredness. The Problem Solving group had higher odds of high hypertension self-care behaviors (OR [95% CI] 18.7 [4.0, 87.3]) and self-efficacy scores (OR [95% CI] 4.7 [1.5, 14.9]) at 12 months compared to baseline, while other groups did not. Compared to DoMyPART, the Problem Solving group had higher odds of high hypertension self-care behaviors (OR [95% CI] 5.7 [1.3, 25.5]) at 12 months. CONCLUSION A context-adapted CHW intervention was correlated with improvements in BP control among socially disadvantaged African Americans. However, it is not clear whether improvements were the result of this intervention. Neither the addition of shared decision-making nor problem-solving self-management training to the CHW intervention further improved BP control. TRIAL REGISTRY ClinicalTrials.gov Identifier: NCT01902719.",2020,"Neither the addition of shared decision-making nor problem-solving self-management training to the CHW intervention further improved BP control. ","['Socially Disadvantaged African Americans', 'socially disadvantaged African Americans', 'One hundred fifty-nine African Americans at an urban primary care clinic']","['DoMyPART', 'community health worker (""CHW"") intervention, including the provision of a home BP monitor; (2) the CHW plus additional training in shared decision-making skills (""DoMyPART""); or (3) the CHW plus additional training in self-management problem-solving (""Problem Solving', 'contextually adapted hypertension self-management interventions']","['DBP', 'BP control (systolic BP (SBP', 'self-efficacy scores', ""SBP and DBP and participants' BP self-monitoring frequency, clinic visit patient-centeredness"", 'blood pressure (BP) control', 'high hypertension self-care behaviors', 'patient emotional and psychosocial concerns), hypertension self-management behaviors, and self-efficacy', 'SBP', 'BP outcomes, BP self-monitor use, or clinic visit patient-centeredness', 'diastolic BP (DBP', 'BP control']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3830128', 'cui_str': '59 (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}]","[{'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C3179495', 'cui_str': 'Decision Making, Shared'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior (finding)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",159.0,0.0618435,"Neither the addition of shared decision-making nor problem-solving self-management training to the CHW intervention further improved BP control. ","[{'ForeName': 'L Ebony', 'Initials': 'LE', 'LastName': 'Boulware', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, \xa0Duke University School of Medicine, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA. ebony.boulware@duke.edu.'}, {'ForeName': 'Patti L', 'Initials': 'PL', 'LastName': 'Ephraim', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Hill-Briggs', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Debra L', 'Initials': 'DL', 'LastName': 'Roter', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Lee R', 'Initials': 'LR', 'LastName': 'Bone', 'Affiliation': 'Johns Hopkins Center for Health Equity, Johns Hopkins University, MD, USA.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Wolff', 'Affiliation': 'Department of Health Policy and Management, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'LaPricia', 'Initials': 'L', 'LastName': 'Lewis-Boyer', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Levine', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Raquel C', 'Initials': 'RC', 'LastName': 'Greer', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Deidra C', 'Initials': 'DC', 'LastName': 'Crews', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Gudzune', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Albert', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Hema C', 'Initials': 'HC', 'LastName': 'Ramamurthi', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Ameling', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Clemontina A', 'Initials': 'CA', 'LastName': 'Davenport', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Hui-Jie', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Jane F', 'Initials': 'JF', 'LastName': 'Pendergast', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Nae-Yuh', 'Initials': 'NY', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Carson', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Sneed', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Debra J', 'Initials': 'DJ', 'LastName': 'Gayles', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Flynn', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Dwyan', 'Initials': 'D', 'LastName': 'Monroe', 'Affiliation': 'Community Advisory Board, Johns Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Hickman', 'Affiliation': 'Community Advisory Board, Johns Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD, USA.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Purnell', 'Affiliation': 'Community Advisory Board, Johns Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Simmons', 'Affiliation': 'Community Advisory Board, Johns Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD, USA.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Fisher', 'Affiliation': 'Community Advisory Board, Johns Hopkins Center to Eliminate Cardiovascular Health Disparities, Baltimore, MD, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'DePasquale', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, \xa0Duke University School of Medicine, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Charleston', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Hanan J', 'Initials': 'HJ', 'LastName': 'Aboutamar', 'Affiliation': 'Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Ashley N', 'Initials': 'AN', 'LastName': 'Cabacungan', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, \xa0Duke University School of Medicine, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Cooper', 'Affiliation': 'Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05396-7'] 373,32186521,Postoperative Remote Automated Monitoring and Virtual Hospital-to-Home Care System Following Cardiac and Major Vascular Surgery: User Testing Study.,"BACKGROUND Cardiac and major vascular surgeries are common surgical procedures associated with high rates of postsurgical complications and related hospital readmission. In-hospital remote automated monitoring (RAM) and virtual hospital-to-home patient care systems have major potential to improve patient outcomes following cardiac and major vascular surgery. However, the science of deploying and evaluating these systems is complex and subject to risk of implementation failure. OBJECTIVE As a precursor to a randomized controlled trial (RCT), this user testing study aimed to examine user performance and acceptance of a RAM and virtual hospital-to-home care intervention, using Philip's Guardian and Electronic Transition to Ambulatory Care (eTrAC) technologies, respectively. METHODS Nurses and patients participated in systems training and individual case-based user testing at two participating sites in Canada and the United Kingdom. Participants were video recorded and asked to think aloud while completing required user tasks and while being rated on user performance. Feedback was also solicited about the user experience, including user satisfaction and acceptance, through use of the Net Promoter Scale (NPS) survey and debrief interviews. RESULTS A total of 37 participants (26 nurses and 11 patients) completed user testing. The majority of nurse and patient participants were able to complete most required tasks independently, demonstrating comprehension and retention of required Guardian and eTrAC system workflows. Tasks which required additional prompting by the facilitator, for some, were related to the use of system features that enable continuous transmission of patient vital signs (eg, pairing wireless sensors to the patient) and assigning remote patient monitoring protocols. NPS scores by user group (nurses using Guardian: mean 8.8, SD 0.89; nurses using eTrAC: mean 7.7, SD 1.4; patients using eTrAC: mean 9.2, SD 0.75), overall NPS scores, and participant debrief interviews indicated nurse and patient satisfaction and acceptance of the Guardian and eTrAC systems. Both user groups stressed the need for additional opportunities to practice in order to become comfortable and proficient in the use of these systems. CONCLUSIONS User testing indicated a high degree of user acceptance of Philips' Guardian and eTrAC systems among nurses and patients. Key insights were provided that informed refinement of clinical workflow training and systems implementation. These results were used to optimize workflows before the launch of an international RCT of in-hospital RAM and virtual hospital-to-home care for patients undergoing cardiac and major vascular surgery.",2020,These results were used to optimize workflows before the launch of an international RCT of in-hospital RAM and virtual hospital-to-home care for patients undergoing cardiac and major vascular surgery.,"['Nurses and patients participated in systems training and individual case-based user testing at two participating sites in Canada and the United Kingdom', 'patients undergoing cardiac and major vascular surgery', '37 participants (26 nurses and 11 patients) completed user testing']","['Cardiac and Major Vascular Surgery', ""RAM and virtual hospital-to-home care intervention, using Philip's Guardian and Electronic Transition to Ambulatory Care (eTrAC) technologies"", 'Postoperative Remote Automated Monitoring and Virtual Hospital-to-Home Care System']","['overall NPS scores', 'NPS scores', 'comprehension and retention of required Guardian and eTrAC system workflows', 'nurse and patient satisfaction and acceptance of the Guardian and eTrAC systems']","[{'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3714645', 'cui_str': 'Vascular surgery'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3714645', 'cui_str': 'Vascular surgery'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1710679', 'cui_str': 'Work Flow'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",37.0,0.0384262,These results were used to optimize workflows before the launch of an international RCT of in-hospital RAM and virtual hospital-to-home care for patients undergoing cardiac and major vascular surgery.,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'McGillion', 'Affiliation': 'School of Nursing, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Carley', 'Initials': 'C', 'LastName': 'Ouellette', 'Affiliation': 'McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Good', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Marissa', 'Initials': 'M', 'LastName': 'Bird', 'Affiliation': 'School of Nursing, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Shaunattonie', 'Initials': 'S', 'LastName': 'Henry', 'Affiliation': 'School of Nursing, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Clyne', 'Affiliation': 'Hope for the Community CIC, Coventry, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Turner', 'Affiliation': 'Coventry University, Coventry, United Kingdom.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Ritvo', 'Affiliation': 'York University, Toronto, ON, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Ritvo', 'Affiliation': 'York University, Toronto, ON, Canada.'}, {'ForeName': 'Nazari', 'Initials': 'N', 'LastName': 'Dvirnik', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Lamy', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Whitlock', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lawton', 'Affiliation': 'Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Walsh', 'Affiliation': 'Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Paterson', 'Affiliation': 'Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Duquette', 'Affiliation': 'Cardiac and Vascular Program, Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Sanchez Medeiros', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Fadi', 'Initials': 'F', 'LastName': 'Elias', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}, {'ForeName': 'Ted', 'Initials': 'T', 'LastName': 'Scott', 'Affiliation': 'Hamilton Health Sciences, Hamilton, ON, Canada.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Mills', 'Affiliation': 'Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Harrington', 'Affiliation': 'Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Field', 'Affiliation': 'Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.'}, {'ForeName': 'Prathiba', 'Initials': 'P', 'LastName': 'Harsha', 'Affiliation': 'McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'McGill University, Montreal, ON, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Peter', 'Affiliation': 'Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Bhavnani', 'Affiliation': 'Scripps Clinic & Research Foundation, San Diego, CA, United States.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Devereaux', 'Affiliation': 'Population Health Research Institute, Hamilton, ON, Canada.'}]",Journal of medical Internet research,['10.2196/15548'] 374,31658134,Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention.,"OBJECTIVES The purpose of this study was to explore the effect of nicorandil on the incidence of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention. METHODS This study randomized 300 patients undergoing percutaneous coronary intervention to receive conventional treatment in the control group (hydration only; n = 150) vs. nicorandil therapy (nicorandil 10 mg three times daily plus hydration; n = 150). The primary endpoint was the incidence of contrast-induced nephropathy, defined as rise in serum creatinine ≥44.2 μmol/L or >25% above baseline within 72 hours after exposure to contrast administered during percutaneous coronary intervention. Secondary endpoints included differences in post-percutaneous coronary intervention serum creatinine, blood urea nitrogen, creatinine clearance rate, cystatin-C, and occurrence of major adverse events. RESULTS Contrast-induced nephropathy incidence was 3.3% (5/150) in the nicorandil group vs. 10.7% (16/150) in the control group (P < 0.05). At 48 and 72 hours after contrast administration, cystatin-C levels were significantly lower and creatinine clearance rate were significantly higher with nicroandil therapy compared to conventional treatment (all P values <0.05). No statistical difference was observed in the incidence of major post-procedure side effect events in hospital and fourteen days of follow-up period between the nicorandil group and control group (3.3% vs. 4.0%, P > 0.05). CONCLUSION Compared to conventional treatment, oral nicorandil therapy was associated with less contrast-induced nephropathy and improved renal function following contrast administration during percutaneous coronary intervention.",2020,"No statistical difference was observed in the incidence of major post-procedure side effect events in hospital and fourteen days of follow-up period between the nicorandil group and control group (3.3% vs. 4.0%, P > 0.05). ","['patients with coronary heart disease undergoing percutaneous coronary intervention', '300 patients undergoing percutaneous coronary intervention to receive conventional treatment in the control group (hydration only; n = 150) vs']","['nicorandil therapy (nicorandil 10 mg three times daily plus hydration', 'nicorandil', 'nicroandil therapy', 'nicorandil therapy']","['post-percutaneous coronary intervention serum creatinine, blood urea nitrogen, creatinine clearance rate, cystatin-C, and occurrence of major adverse events', 'creatinine clearance rate', 'cystatin-C levels', 'renal function', 'incidence of contrast-induced nephropathy, defined as rise in serum creatinine ≥44.2 μmol/L', 'nephropathy incidence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1321013', 'cui_str': 'Hydration'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}]","[{'cui': 'C0068700', 'cui_str': 'Nicorandil'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1128446', 'cui_str': 'Nicorandil 10 MG'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1321013', 'cui_str': 'Hydration'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0071744', 'cui_str': 'Cystatin 3'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}]",300.0,0.0257263,"No statistical difference was observed in the incidence of major post-procedure side effect events in hospital and fourteen days of follow-up period between the nicorandil group and control group (3.3% vs. 4.0%, P > 0.05). ","[{'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Graduate School, Tianjin Medical University.'}, {'ForeName': 'Shicheng', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.'}, {'ForeName': 'Naikuan', 'Initials': 'N', 'LastName': 'Fu', 'Affiliation': 'Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.'}]",Coronary artery disease,['10.1097/MCA.0000000000000826'] 375,31658145,"Effect of intracoronary tirofiban following aspiration thrombectomy on infarct size, in patients with large anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.","BACKGROUND Myocardial recovery following primary percutaneous coronary intervention is often suboptimal despite of restoration of thrombolysis in myocardial infarction (TIMI) 3 flow, in part due to thrombus embolization which results in impairing microvascular reperfusion besides increasing infarct size. The purpose of the present study was to estimate the effect of aspiration thrombectomy followed by intracoronary delivery of tirofiban on decreasing the infarct size utilizing cardiac MRI (cMR) in large anterior ST-segment elevation myocardial infarction (STEMI) patients. PATIENTS A prospective randomized controlled study of 100 patients with large anterior STEMI were randomized to (Study group) using intracoronary tirofiban (intracoronary) and (control group) without intocoronary tirofiban. A 6 F thrombus aspiration catheter was used in all patients. Tirofiban was injected locally at the place of the highly thrombus burden through the aspiration device after flushing the aspiration device well. RESULTS Patients of intracoronary tirofiban group compared with control group had a significant difference in decreasing the infarct size at 30 days [median, 15.451 g - interquartile range (IQR), 17.404 gm - n = 50] vs (median, 43.828 g - IQR, 49.599 g - n = 50) P value = 0.002. CONCLUSION In patients early presented with large anterior STEMI, infarct size at 30 days was significantly decreased by intracoronary tirofiban delivered to the infarct lesion site followed aspiration thrombectomy.",2020,"RESULTS Patients of intracoronary tirofiban group compared with control group had a significant difference in decreasing the infarct size at 30 days [median, 15.451 g - interquartile range (IQR), 17.404 gm - n = 50] vs (median, 43.828 g - IQR, 49.599 g - n = 50) P value =","['patients with large anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention', '100 patients with large anterior STEMI', 'large anterior ST-segment elevation myocardial infarction (STEMI) patients']","['tirofiban', 'intracoronary tirofiban', 'intracoronary tirofiban (intracoronary) and (control group) without intocoronary tirofiban', 'Tirofiban']","['infarct size', 'infarct size utilizing cardiac MRI (cMR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C3874460', 'cui_str': 'Anterior ST segment elevation'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}]","[{'cui': 'C0247025', 'cui_str': 'tirofiban'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0021308', 'cui_str': 'Infarction'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0412692', 'cui_str': 'Magnetic resonance imaging of heart'}]",100.0,0.058423,"RESULTS Patients of intracoronary tirofiban group compared with control group had a significant difference in decreasing the infarct size at 30 days [median, 15.451 g - interquartile range (IQR), 17.404 gm - n = 50] vs (median, 43.828 g - IQR, 49.599 g - n = 50) P value =","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Basuoni', 'Affiliation': 'Cardiology Department, Dar Al-Fouad Hospital.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'El-Naggar', 'Affiliation': 'Cardiology Department, Dar Al-Fouad Hospital.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Mahdy', 'Affiliation': 'Cardiology Department, Cairo University, Giza, Egypt.'}, {'ForeName': 'Sameh', 'Initials': 'S', 'LastName': 'Al-Kaffas', 'Affiliation': 'Cardiology Department, Cairo University, Giza, Egypt.'}]",Coronary artery disease,['10.1097/MCA.0000000000000825'] 376,32202505,The Effectiveness of a Guided Internet-Based Tool for the Treatment of Depression and Anxiety in Pregnancy (MamaKits Online): Randomized Controlled Trial.,"BACKGROUND Pregnant women with symptoms of depression or anxiety often do not receive adequate treatment. In view of the high incidence of these symptoms in pregnancy and their impact on pregnancy outcomes, getting treatment is of the utmost importance. A guided internet self-help intervention may help to provide more women with appropriate treatment. OBJECTIVE This study aimed to examine the effectiveness of a guided internet intervention (MamaKits online) for pregnant women with moderate to severe symptoms of anxiety or depression. Assessments took place before randomization (T0), post intervention (T1), at 36 weeks of pregnancy (T2), and 6 weeks postpartum (T3). We also explored effects on perinatal child outcomes 6 weeks postpartum. METHODS This randomized controlled trial included pregnant women (<30 weeks) with depressive symptoms above threshold (ie, Center for Epidemiological Studies Depression scale [CES-D] >16) or anxiety above threshold (ie, Hospital Anxiety and Depression Scale-Anxiety subscale [HADS-A] >8) or both of them. Participants were recruited via general media and flyers in prenatal care waiting rooms or via obstetricians and midwives. After initial assessment, women were randomized to (1) MamaKits online in addition to treatment as usual or (2) treatment as usual (control condition). MamaKits online is a 5-week guided internet intervention based on problem solving treatment. Guidance was was provided by trained students pursuing a Master's in Psychology. Outcomes were based on a Web-based self-report. Women in the control condition were allowed to receive the intervention after the last assessment (6 weeks postpartum). RESULTS Of the 159 included women, 79 were randomized to MamaKits online, 47% (79/37) of whom completed the intervention. Both groups showed a substantial decrease in affective symptoms on the CES-D, HADS-A, and Edinburgh Postnatal Depression Scale over time. In the intervention group, affective symptoms decreased more than that in the control group, but between-group effect sizes were small to medium (Cohen d at T3=0.45, 0.21, and 0.23 for the 3 questionnaires, respectively) and statistically not significant. Negative perinatal child outcomes did not differ between the 2 groups (χ 2 1 =0.1; P=.78). Completer analysis revealed no differences in outcome between the treatment completers and the control group. The trial was terminated early for reasons of futility based on the results of an interim analysis, which we performed because of inclusion problems. CONCLUSIONS Our study did show a significant reduction in affective symptoms in both groups, but the differences in reduction of affective symptoms between the intervention and control groups were not significant. There were also no differences in perinatal child outcomes. Future research should examine for which women these interventions might be effective or if changes in the internet intervention might make the intervention more effective. TRIAL REGISTRATION Netherlands Trial Register NL4162; https://tinyurl.com/sdckjek.",2020,"In the intervention group, affective symptoms decreased more than that in the control group, but between-group effect sizes were small to medium (Cohen d at T3=0.45, 0.21, and 0.23 for the 3 questionnaires, respectively) and statistically not significant.","['Pregnant women with symptoms of depression or anxiety', ""trained students pursuing a Master's in Psychology"", 'Of the 159 included women', 'pregnant women (<30 weeks) with depressive symptoms above threshold (ie, Center for Epidemiological Studies Depression scale [CES-D] >16) or', 'pregnant women with moderate to severe symptoms of anxiety or depression', 'Depression and Anxiety in Pregnancy (MamaKits Online', 'Participants were recruited via general media and flyers in prenatal care waiting rooms or via obstetricians and midwives']","['guided internet intervention (MamaKits online', 'MamaKits online in addition to treatment as usual or (2) treatment as usual (control condition', 'Guided Internet-Based Tool']","['Negative perinatal child outcomes', 'reduction of affective symptoms', 'affective symptoms', 'affective symptoms on the CES-D, HADS-A, and Edinburgh Postnatal Depression Scale', 'perinatal child outcomes', 'anxiety above threshold (ie, Hospital Anxiety and Depression Scale-Anxiety subscale [HADS-A']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0444649', 'cui_str': 'Master (qualifier value)'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0443129', 'cui_str': 'Above threshold (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0002783', 'cui_str': 'Epidemiological Studies'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4543692', 'cui_str': 'Anxiety in pregnancy'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}, {'cui': 'C0334897', 'cui_str': 'Obstetrician (occupation)'}, {'cui': 'C0026083', 'cui_str': 'Midwife'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0001726', 'cui_str': 'Affective Symptoms'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh Postnatal Depression Scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0443129', 'cui_str': 'Above threshold (qualifier value)'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}]",159.0,0.130197,"In the intervention group, affective symptoms decreased more than that in the control group, but between-group effect sizes were small to medium (Cohen d at T3=0.45, 0.21, and 0.23 for the 3 questionnaires, respectively) and statistically not significant.","[{'ForeName': 'Hanna M', 'Initials': 'HM', 'LastName': 'Heller', 'Affiliation': 'Department of Psychiatry, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Adriaan W', 'Initials': 'AW', 'LastName': 'Hoogendoorn', 'Affiliation': 'Department of Psychiatry, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Adriaan', 'Initials': 'A', 'LastName': 'Honig', 'Affiliation': 'Department of Psychiatry, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Birit F P', 'Initials': 'BFP', 'LastName': 'Broekman', 'Affiliation': 'Department of Psychiatry, Amsterdam Universitair Medische Centra, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Annemieke', 'Initials': 'A', 'LastName': 'van Straten', 'Affiliation': 'Amsterdam Public Health Research Institute, Amsterdam, Netherlands.'}]",Journal of medical Internet research,['10.2196/15172'] 377,32273317,Community-based weight loss programme targeting overweight Chinese adults with pre-diabetes: study protocol of a randomised controlled trial.,"INTRODUCTION Type 2 diabetes mellitus (T2DM) is one of the world's fastest growing health problems. Asians have a strong ethnic predisposition for T2DM, developing T2DM at a lower degree of obesity and at younger ages than other ethnic groups. T2DM has a gradual onset, with most individuals progressing through a pre-diabetic state, providing an opportunity to prevent T2DM and its complications. This study aims to evaluate the effectiveness of a community-based lifestyle intervention programme on weight loss and improvements in insulin sensitivity and cardiometabolic profiles in Chinese adults with pre-diabetes. METHODS AND ANALYSIS This study is a 12-month, assessor-blinded randomised controlled trial. Adults with pre-diabetes (aged 40-64 years, n=180) with pre-diabetes are randomised into either an intervention group (receiving group-based lifestyle interventions) or a control group (receiving text messages containing health information). The intervention programme targets a weight loss of 5% during the first 6 months by restricting caloric intake and increasing physical activity. Participants in the intervention group will attend six group sessions and two individual face-to-face diet counselling sessions during the first 6 months, followed by monthly telephone support during the 6-month maintenance phase. Participants in the control group will receive monthly text messages containing general health information only. The primary outcome is weight loss (%). Secondary outcomes include insulin sensitivity (assessed using fasting insulin level and homeostatic model assessment of insulin resistance), glycaemic control (assessed using glycated haemoglobin level), lipid profile, blood pressure, carotid artery thickness, dietary intake and level of physical activity. Intention-to-treat analysis will be conducted using a generalised linear mixed effects model with a logit link and linear mixed models. ETHICS AND DISSEMINATION This study has been approved by the relevant research ethics committee. The results will be disseminated through peer-reviewed journals and scientific presentations. TRIAL REGISTRATION NUMBER NCT03609697.",2020,"This study aims to evaluate the effectiveness of a community-based lifestyle intervention programme on weight loss and improvements in insulin sensitivity and cardiometabolic profiles in Chinese adults with pre-diabetes. METHODS AND ANALYSIS ","['Chinese adults with pre-diabetes', 'Adults with pre-diabetes (aged 40-64 years, n=180) with pre-diabetes', 'overweight Chinese adults with pre-diabetes']","['T2DM', 'community-based lifestyle intervention programme', 'intervention group (receiving group-based lifestyle interventions) or a control group (receiving text messages containing health information', 'monthly text messages containing general health information only', 'Community-based weight loss programme']","['insulin sensitivity (assessed using fasting insulin level and homeostatic model assessment of insulin resistance), glycaemic control (assessed using glycated haemoglobin level), lipid profile, blood pressure, carotid artery thickness, dietary intake and level of physical activity', 'insulin sensitivity and cardiometabolic profiles', 'weight loss']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}]","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",,0.110396,"This study aims to evaluate the effectiveness of a community-based lifestyle intervention programme on weight loss and improvements in insulin sensitivity and cardiometabolic profiles in Chinese adults with pre-diabetes. METHODS AND ANALYSIS ","[{'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Ho', 'Affiliation': 'School of Nursing, University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong mandyho1@hku.hk.'}, {'ForeName': 'Pui Hing', 'Initials': 'PH', 'LastName': 'Chau', 'Affiliation': 'School of Nursing, University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong.'}, {'ForeName': 'Esther Yee Tak', 'Initials': 'EYT', 'LastName': 'Yu', 'Affiliation': 'Department of Family Medicine and Primary Care, University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong.'}, {'ForeName': 'Michael Tin-Cheung', 'Initials': 'MT', 'LastName': 'Ying', 'Affiliation': 'Department of Health Technology and Informatics, Hong Kong Polytechnic University, Kowloon, Hong Kong.'}, {'ForeName': 'Cindy Lo Kuen', 'Initials': 'CLK', 'LastName': 'Lam', 'Affiliation': 'Department of Family Medicine and Primary Care, University of Hong Kong Li Ka Shing Faculty of Medicine, Pokfulam, Hong Kong.'}]",BMJ open,['10.1136/bmjopen-2019-035196'] 378,31764003,The effect of pre-procedural sublingual nifedipine on radial artery diameter.,"OBJECTIVE This study aimed to investigate the effect of nifedipine on radial artery (RA) relaxation before puncture for coronary intervention. METHODS In all, 120 patients were randomly assigned to nifedipine or control group. The diameter, resistance index (RI), and peak systolic velocity (PSV) of the RA were observed at 5, 15, and 30 min after nifedipine administration by a Doppler ultrasound examination. RESULTS The greatest effect on RA diameter, PSV and resistance index (RI) was observed 5 minutes after sublingual nifedipine administration. The RA parameter were associated with the baseline diameter. CONCLUSIONS Sublingual nifedipine administration before RA puncture has an obvious dilatation effect on small diameter RAs.",2020,"The diameter, resistance index (RI), and peak systolic velocity (PSV) of the RA were observed at 5, 15, and 30 min after nifedipine administration by a Doppler ultrasound examination. ",['120 patients'],"['nifedipine', 'Sublingual nifedipine', 'pre-procedural sublingual nifedipine']","['radial artery (RA) relaxation', 'diameter, resistance index (RI), and peak systolic velocity (PSV) of the RA', 'RA diameter, PSV and resistance index (RI', 'radial artery diameter']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0028066', 'cui_str': 'Nifedipine'}, {'cui': 'C4521982', 'cui_str': 'Sublingual'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]","[{'cui': 'C0162857', 'cui_str': 'Radial Artery'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",120.0,0.138072,"The diameter, resistance index (RI), and peak systolic velocity (PSV) of the RA were observed at 5, 15, and 30 min after nifedipine administration by a Doppler ultrasound examination. ","[{'ForeName': 'Xile', 'Initials': 'X', 'LastName': 'Bi', 'Affiliation': ''}, {'ForeName': 'Hongdan', 'Initials': 'H', 'LastName': 'Jia', 'Affiliation': ''}, {'ForeName': 'Qingsheng', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000816'] 379,32166395,Unilateral transversus abdominis plane block and port-site infiltration : Comparison of postoperative analgesic efficacy in laparoscopic cholecystectomy.,"PURPOSE To compare the analgesic efficacy of unilateral subcostal transversus abdominis plane (TAP) block with local anesthetic infiltration, applied to the port site in patients undergoing laparoscopic cholecystectomy (LC). METHODS Group T received a unilateral subcostal TAP block, group I received a local anesthetic infiltration at port sites, and group C was the control group. Groups T and I received 20 mL 0.25% bupivacaine. Intravenous patient-controlled analgesia with tramadol was similarly applied to all groups. Postoperative pain levels during rest and cough were evaluated using a numeric rating scale (NRS). Nausea and vomiting were evaluated using postoperative nausea vomiting scores (PONV) at 1, 3, 6, 12 and 24 h and tramadol consumption was also determined. Patient satisfaction was evaluated using a Likert-type scale. RESULTS Postoperative resting NRS scores were lower in group T than the other groups at 1 h and 12 h (p = 0.007 and p = 0.016), while NRS values during cough were statistically significant at 1 h (p = 0.004). The 24‑h tramadol consumption was different: group T 229 ± 33 mg, group I 335 ± 95 mg, and group C 358 ± 66 mg (p < 0.001). The percentages of patients reporting that they would prefer the applied postoperative pain control method again were 83.3%, 62.5% and 70.8% in groups T, I and C, respectively (p = 0.118). CONCLUSION Unilateral subcostal TAP block was superior to local anesthetic infiltration at port sites after LC, in terms of low opioid consumption. Unilateral subcostal TAP block is recommended as part of a multimodal analgesic protocol.",2020,"Postoperative resting NRS scores were lower in group T than the other groups at 1 h and 12 h (p = 0.007 and p = 0.016), while NRS values during cough were statistically significant at 1 h (p = 0.004).",['patients undergoing laparoscopic cholecystectomy (LC'],"['Unilateral transversus abdominis plane block and port-site infiltration ', '20\u202fmL 0.25% bupivacaine', 'laparoscopic cholecystectomy', 'tramadol', 'Unilateral subcostal TAP block', 'unilateral subcostal transversus abdominis plane (TAP) block with local anesthetic infiltration', 'unilateral subcostal TAP block, group\xa0I received a local anesthetic infiltration']","['analgesic efficacy', 'postoperative nausea vomiting scores (PONV', 'Postoperative resting NRS scores', 'NRS values during cough', 'numeric rating scale (NRS', 'Patient satisfaction', 'Nausea and vomiting', 'Postoperative pain levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}, {'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0442184', 'cui_str': 'Subcostal (qualifier value)'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration (procedure)'}, {'cui': 'C0441843', 'cui_str': 'Group I (qualifier value)'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0520904', 'cui_str': 'Postoperative Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0251994,"Postoperative resting NRS scores were lower in group T than the other groups at 1 h and 12 h (p = 0.007 and p = 0.016), while NRS values during cough were statistically significant at 1 h (p = 0.004).","[{'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Arık', 'Affiliation': 'Department of Anesthesiology and Reanimation, University of Health Science, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Altındağ, Ankara, Turkey. emineincearik@yahoo.com.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Akkaya', 'Affiliation': 'Department of Anesthesiology, Pain Clinic, University of Health Science, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ozciftci', 'Affiliation': 'Department of Anesthesiology and Reanimation, TC Ministry of Health Hitit University Erol Olçok Training and Research Hospital, Çorum, Turkey.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Alptekin', 'Affiliation': 'Department of Anesthesiology, Pain Clinic, University of Health Science, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.'}, {'ForeName': 'Ş', 'Initials': 'Ş', 'LastName': 'Balas', 'Affiliation': 'Department of Surgery, University of Health Science, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.'}]",Der Anaesthesist,['10.1007/s00101-020-00746-1'] 380,32202507,Development and Assessment of a Gastroscopy Electronic Learning System for Primary Learners: Randomized Controlled Trial.,"BACKGROUND Endoscopic examination is a popular and routine procedure for the diagnosis and treatment of gastrointestinal (GI) diseases. Skilled endoscopists are in great demand in clinical practice, but the training process for beginners to become endoscopy specialists is fairly long. Convenience and a self-paced, learner-centered approach make electronic learning (e-learning) an excellent instructional prospect. OBJECTIVE This study aimed to develop and apply an e-learning system in gastroscopy teaching and learning and to evaluate its effectiveness and user satisfaction. METHODS The e-learning software Gastroscope Roaming System was developed for primary learners. The system simulates the real structure of the upper gastrointestinal (UGI) tract to teach the main characteristics of gastroscopy under both normal conditions and conditions of common UGI tract diseases. A randomized controlled trial was conducted. Participants were randomly allocated to an e-learning group (EG)or a non-e-learning control group after a pretest. On completing the training, participants undertook a posttest and gastroscopy examination. In addition, the EG completed a satisfaction questionnaire. RESULTS Of the 44 volunteers, 41 (93%) completed the gastroscopy learning and testing components. No significant pretest differences were found between the intervention and control groups (mean 50.86, SD 6.12 vs mean 50.76, SD 6.88; P=.96). After 1 month of learning, the EG's posttest scores were higher (mean 83.70, SD 5.99 vs mean 78.76, SD 7.58; P=.03) and improved more (P=.01) than those of the control group, with better performance in the gastroscopy examination (mean 91.05, SD 4.58 vs mean 84.38, SD 5.19; P<.001). Overall, 85% (17/20) of the participants were satisfied with the e-learning system, and 95% (19/20) of the participants considered it successful. CONCLUSIONS E-learning is an effective educational strategy for primary learners to acquire skills in gastroscopy examination and endoscopic imaging of the GI tract. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR-IOR-17013091; http://www.chictr.org.cn/showproj.aspx?proj=22142.",2020,"CONCLUSIONS E-learning is an effective educational strategy for primary learners to acquire skills in gastroscopy examination and endoscopic imaging of the GI tract. ","['44 volunteers, 41 (93%) completed the gastroscopy learning and testing components', 'Primary Learners']","['Gastroscopy Electronic Learning System', 'Convenience and a self-paced, learner-centered approach make electronic learning (e-learning', 'e-learning group (EG)or a non-e-learning control']",[],"[{'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0017195', 'cui_str': 'Gastroscopy'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0017195', 'cui_str': 'Gastroscopy'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],44.0,0.153367,"CONCLUSIONS E-learning is an effective educational strategy for primary learners to acquire skills in gastroscopy examination and endoscopic imaging of the GI tract. ","[{'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Guoqing', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Wanying', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Ningning', 'Initials': 'N', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Haoyuan', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Kunpeng', 'Initials': 'K', 'LastName': 'Luo', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Shizhu', 'Initials': 'S', 'LastName': 'Jin', 'Affiliation': 'Department of Gastroenterology and Hepatology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.'}]",Journal of medical Internet research,['10.2196/16233'] 381,31594892,"Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial.","INTRODUCTION Genomic sequencing has rapidly transitioned into clinical practice, improving diagnosis and treatment options for patients with hereditary disorders. However, large-scale implementation of genomic sequencing faces challenges, especially with regard to the return of incidental results, which refer to genetic variants uncovered during testing that are unrelated to the primary disease under investigation, but of potential clinical significance. High-quality evidence evaluating health outcomes and costs of receiving incidental results is critical for the adoption of genomic sequencing into clinical care and to understand the unintended consequences of adoption of genomic sequencing. We aim to evaluate the health outcomes and costs of receiving incidental results for patients undergoing genomic sequencing. METHODS AND ANALYSIS We will compare health outcomes and costs of receiving, versus not receiving, incidental results for adult patients with cancer undergoing genomic sequencing in a mixed-methods randomised controlled trial. Two hundred and sixty patients who have previously undergone first or second-tier genetic testing for cancer and received uninformative results will be recruited from familial cancer clinics in Toronto, Ontario. Participants in both arms will receive cancer-related results. Participants in the intervention arm have the option to receive incidental results. Our primary outcome is psychological distress at 2 weeks following return of results. Secondary outcomes include behavioural consequences, clinical and personal utility assessed over the 12 months after results are returned and health service use and costs at 12 months and 5 years. A subset of participants and providers will complete qualitative interviews about utility of incidental results. ETHICS AND DISSEMINATION This study has been approved by Clinical Trials Ontario Streamlined Research Ethics Review System that provides ethical review and oversight for multiple sites participating in the same clinical trial in Ontario.Results from the trial will be shared through stakeholder workshops, national and international conferences, and peer-reviewed journals. TRIAL REGISTRATION NUMBER NCT03597165.",2019,"Secondary outcomes include behavioural consequences, clinical and personal utility assessed over the 12 months after results are returned and health service use and costs at 12 months and 5 years.","['patients with hereditary disorders', 'multiple sites participating in the same clinical trial in Ontario', 'Two hundred and sixty patients who have previously undergone first or second-tier genetic testing for cancer and received uninformative results will be recruited from familial cancer clinics in Toronto, Ontario', 'patients undergoing genomic sequencing', 'adult patients with cancer undergoing genomic sequencing in a mixed-methods randomised controlled trial']",[],"['behavioural consequences, clinical and personal utility assessed over the 12 months after results are returned and health service use and costs', 'psychological distress', 'Health outcomes, utility and costs of returning incidental results']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019247', 'cui_str': 'Hereditary Diseases'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C4517669', 'cui_str': 'Two hundred and sixty'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0679560', 'cui_str': 'Genetic Testing'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1611743', 'cui_str': 'Familial (FPAH)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],"[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0018747', 'cui_str': 'Health Services'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0444507', 'cui_str': 'Incidental (qualifier value)'}]",260.0,0.234148,"Secondary outcomes include behavioural consequences, clinical and personal utility assessed over the 12 months after results are returned and health service use and costs at 12 months and 5 years.","[{'ForeName': 'Salma', 'Initials': 'S', 'LastName': 'Shickh', 'Affiliation': 'Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Clausen', 'Affiliation': ""Genomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Mighton', 'Affiliation': 'Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Gutierrez Salazar', 'Affiliation': ""Genomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Kathleen-Rose', 'Initials': 'KR', 'LastName': 'Zakoor', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Kodida', 'Affiliation': ""Genomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Reble', 'Affiliation': ""Genomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Elser', 'Affiliation': 'Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Eisen', 'Affiliation': 'Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Panchal', 'Affiliation': 'Marvelle Koffler Breast Centre, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Melyssa', 'Initials': 'M', 'LastName': 'Aronson', 'Affiliation': 'Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Graham', 'Affiliation': 'Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Susan Randall', 'Initials': 'SR', 'LastName': 'Armel', 'Affiliation': 'Familial Breast Ovarian Cancer Clinic, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'Chantal F', 'Initials': 'CF', 'LastName': 'Morel', 'Affiliation': 'Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Ramzi', 'Initials': 'R', 'LastName': 'Fattouh', 'Affiliation': ""Department of Laboratory Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Glogowski', 'Affiliation': 'GeneDx, Elmwood Park, New Jersey, USA.'}, {'ForeName': 'Kasmintan A', 'Initials': 'KA', 'LastName': 'Schrader', 'Affiliation': 'Department of Molecular Oncology and Hereditary Cancer Program, BC Cancer Agency, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Jada G', 'Initials': 'JG', 'LastName': 'Hamilton', 'Affiliation': 'Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Offit', 'Affiliation': 'Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Robson', 'Affiliation': 'Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.'}, {'ForeName': 'June C', 'Initials': 'JC', 'LastName': 'Carroll', 'Affiliation': 'Ray D Wolfe Department of Family Medicine, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Wanrudee', 'Initials': 'W', 'LastName': 'Isaranuwatchai', 'Affiliation': 'Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Raymond H', 'Initials': 'RH', 'LastName': 'Kim', 'Affiliation': 'Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Lerner-Ellis', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Thorpe', 'Affiliation': ""Applied Health Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Laupacis', 'Affiliation': 'Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Bombard', 'Affiliation': 'Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada yvonne.bombard@utoronto.ca.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-031092'] 382,31454263,Balanced Crystalloids versus Saline in Sepsis. A Secondary Analysis of the SMART Clinical Trial.,"Rationale: Administration of intravenous crystalloid solutions is a fundamental therapy for sepsis, but the effect of crystalloid composition on patient outcomes remains unknown. Objectives: To compare the effect of balanced crystalloids versus saline on 30-day in-hospital mortality among critically ill adults with sepsis. Methods: Secondary analysis of patients from SMART (Isotonic Solutions and Major Adverse Renal Events Trial) admitted to the medical ICU with an International Classification of Diseases, 10th Edition, Clinical Modification System code for sepsis, using multivariable regression to control for potential confounders. Measurements and Main Results: Of 15,802 patients enrolled in SMART, 1,641 patients were admitted to the medical ICU with a diagnosis of sepsis. A total of 217 patients (26.3%) in the balanced crystalloids group experienced 30-day in-hospital morality compared with 255 patients (31.2%) in the saline group (adjusted odds ratio [aOR], 0.74; 95% confidence interval [CI], 0.59-0.93; P  = 0.01). Patients in the balanced group experienced a lower incidence of major adverse kidney events within 30 days (35.4% vs. 40.1%; aOR, 0.78; 95% CI, 0.63-0.97) and a greater number of vasopressor-free days (20 ± 12 vs. 19 ± 13; aOR, 1.25; 95% CI, 1.02-1.54) and renal replacement therapy-free days (20 ± 12 vs. 19 ± 13; aOR, 1.35; 95% CI, 1.08-1.69) compared with the saline group. Conclusions: Among patients with sepsis in a large randomized trial, use of balanced crystalloids was associated with a lower 30-day in-hospital mortality compared with use of saline.Clinical trial registered with www.clinicaltrials.gov (NCT02444988).",2019,"Patients in the balanced group experienced a lower incidence of major adverse kidney events within 30 days (35.4% vs 40.1%; aOR 0.78; 95% CI 0.63 - 0.97) and a greater number of vasopressor-free days (20 ± 12 vs 19 ± 13; aOR 1.25; 95% CI 1.02 - 1.54) and renal replacement therapy-free days (20 ± 12 vs 19 ± 13; aOR 1.35 [1.08 - 1.69]), compared to the saline group. ","['patients with sepsis', 'Secondary analysis of patients from the Isotonic Solutions and Major Adverse Renal Events Trial', 'critically ill adults with sepsis', '15,802 patients enrolled in SMART, 1,641 patients were admitted to the medical intensive care unit with a diagnosis of sepsis', 'Sepsis']","['balanced crystalloids', 'intravenous crystalloid solutions', 'balanced crystalloids versus saline', 'saline', 'Balanced Crystalloids Versus Saline']","['hospital mortality', '30-day in-hospital morality', 'lower incidence of major adverse kidney events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0022260', 'cui_str': 'Isotonic Solutions'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2711734', 'cui_str': 'Medical intensive care unit'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0056562', 'cui_str': 'Crystalloid'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0026531', 'cui_str': 'Morality'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",1641.0,0.389231,"Patients in the balanced group experienced a lower incidence of major adverse kidney events within 30 days (35.4% vs 40.1%; aOR 0.78; 95% CI 0.63 - 0.97) and a greater number of vasopressor-free days (20 ± 12 vs 19 ± 13; aOR 1.25; 95% CI 1.02 - 1.54) and renal replacement therapy-free days (20 ± 12 vs 19 ± 13; aOR 1.35 [1.08 - 1.69]), compared to the saline group. ","[{'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Brown', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Taylor D', 'Initials': 'TD', 'LastName': 'Coston', 'Affiliation': 'Department of Medicine.'}, {'ForeName': 'Nathan I', 'Initials': 'NI', 'LastName': 'Krishnan', 'Affiliation': 'Department of Medicine.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Casey', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Wanderer', 'Affiliation': 'Department of Anesthesiology.'}, {'ForeName': 'Jesse M', 'Initials': 'JM', 'LastName': 'Ehrenfeld', 'Affiliation': 'Department of Anesthesiology.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Byrne', 'Affiliation': 'Department of Biostatistics.'}, {'ForeName': 'Joanna L', 'Initials': 'JL', 'LastName': 'Stollings', 'Affiliation': 'Department of Pharmaceutical Services.'}, {'ForeName': 'Edward D', 'Initials': 'ED', 'LastName': 'Siew', 'Affiliation': 'Vanderbilt Center for Kidney Disease and Integrated Program for Acute Kidney Injury Research, Division of Nephrology and Hypertension, and.'}, {'ForeName': 'Gordon R', 'Initials': 'GR', 'LastName': 'Bernard', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine.'}, {'ForeName': 'Wesley H', 'Initials': 'WH', 'LastName': 'Self', 'Affiliation': 'Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.'}, {'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Rice', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Semler', 'Affiliation': 'Division of Allergy, Pulmonary, and Critical Care Medicine.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201903-0557OC'] 383,32269026,"Effect of a web drama video series on HIV and other sexually transmitted infection testing among gay, bisexual and queer men: study protocol for a community-based, pragmatic randomised controlled trial in Singapore: the People Like Us (PLU) Evaluation Study.","INTRODUCTION Gay, bisexual and queer (GBQ) men are at disproportionately higher risk of acquiring HIV and other sexually transmitted infections (STI). While HIV/STI testing rates among GBQ men are increasing worldwide, they remain suboptimal in a variety of settings. METHODS AND ANALYSIS The study is a pragmatic randomised controlled trial designed to evaluate an online video series developed by a community-based organisation in Singapore for GBQ men. A total of 300 HIV-negative GBQ men in Singapore aged 18-29 years old will be recruited for this study. Participants will subsequently be randomised into the intervention arm (n=150) and the control arm (n=150). The intervention arm (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet. Participants should also not have watched the video prior to their participation in this study, which will be ascertained through a questionnaire. Primary outcomes for this evaluation are changes in self-reported intention to test for, actual testing for and regularity of testing for HIV, syphilis, chlamydia and gonorrhoea at the 3 and 6 months after intervention. Secondary outcomes include changes in self-reported risk perception for HIV and other STIs, knowledge of HIV, knowledge of risks associated with acquiring STIs, knowledge of HIV pre-exposure prophylaxis, consistent condom use for anal sex with casual partners, incidence of STIs, connectedness to the lesbian, gay, bisexual and transgender community, self-concealment of sexual orientation, perceived homophobia, internalised homophobia, HIV testing self-efficacy and HIV testing social norms. ETHICS AND DISSEMINATION The study has been approved by the National University of Singapore Institutional Review Board (S-19-059) and registered at ClinicalTrials.gov. The results will be published in peer-reviewed academic journals and disseminated to community-based organisations and policymakers. TRIAL REGISTRATION NUMBER NCT04021953.",2020,"The intervention arm (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet.","['300 HIV-negative GBQ men in Singapore aged 18-29 years old', 'Singapore for GBQ men', 'HIV and other sexually transmitted infection testing among gay, bisexual and queer men']","['sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet']","['changes in self-reported intention to test for, actual testing for and regularity of testing for HIV, syphilis, chlamydia and gonorrhoea', 'changes in self-reported risk perception for HIV and other STIs, knowledge of HIV, knowledge of risks associated with acquiring STIs, knowledge of HIV pre-exposure prophylaxis, consistent condom use for anal sex with casual partners, incidence of STIs, connectedness to the lesbian, gay, bisexual and transgender community, self-concealment of sexual orientation, perceived homophobia, internalised homophobia, HIV testing self-efficacy and HIV testing social norms']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0481430', 'cui_str': 'HIV negative'}, {'cui': 'C1688582', 'cui_str': 'GBq'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0019898', 'cui_str': 'Queers'}, {'cui': 'C0005639', 'cui_str': 'Bisexuality'}]","[{'cui': 'C2362326', 'cui_str': 'Sexual Health'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0039128', 'cui_str': 'Syphilis'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C1096319', 'cui_str': 'Prophylaxis against HIV infection'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0282347', 'cui_str': 'Anal sex'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0242659', 'cui_str': 'Female homosexual'}, {'cui': 'C0019898', 'cui_str': 'Queers'}, {'cui': 'C0005639', 'cui_str': 'Bisexuality'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205949', 'cui_str': 'Sexual orientation'}, {'cui': 'C0680423', 'cui_str': 'Anti-Homosexual Bias'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",300.0,0.180459,"The intervention arm (n=150) will be assigned the intervention along with sexual health information via a pamphlet, while the control group (n=150) will be assigned only the sexual health information via a pamphlet.","[{'ForeName': 'Rayner Kay Jin', 'Initials': 'RKJ', 'LastName': 'Tan', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore rayner.tan@u.nus.edu.'}, {'ForeName': 'Wee Ling', 'Initials': 'WL', 'LastName': 'Koh', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Le', 'Affiliation': 'Action for AIDS Singapore, Singapore.'}, {'ForeName': 'Avin', 'Initials': 'A', 'LastName': 'Tan', 'Affiliation': 'Action for AIDS Singapore, Singapore.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Tyler', 'Affiliation': 'Action for AIDS Singapore, Singapore.'}, {'ForeName': 'Calvin', 'Initials': 'C', 'LastName': 'Tan', 'Affiliation': 'Action for AIDS Singapore, Singapore.'}, {'ForeName': 'Sumita', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Action for AIDS Singapore, Singapore.'}, {'ForeName': 'Chen Seong', 'Initials': 'CS', 'LastName': 'Wong', 'Affiliation': 'National Centre for Infectious Diseases, Singapore.'}, {'ForeName': 'Mee-Lian', 'Initials': 'ML', 'LastName': 'Wong', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}, {'ForeName': 'Martin Tze-Wei', 'Initials': 'MT', 'LastName': 'Chio', 'Affiliation': 'Department of STI Control (DSC) Clinic, National Skin Centre, Singapore.'}, {'ForeName': 'Mark I-Cheng', 'Initials': 'MI', 'LastName': 'Chen', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore.'}]",BMJ open,['10.1136/bmjopen-2019-033855'] 384,32269028,Effectiveness of nicotine replacement therapy sample at outdoor smoking hotspots for initiating quit attempts and use of smoking cessation services: a protocol for a cluster randomised controlled trial.,"INTRODUCTION More than half of the smoking population in Hong Kong are unmotivated to quit. Only about 2% of tobacco users in the territory have ever used cessation aids such as nicotine replacement therapy (NRT). The present study aims to assess the effectiveness of delivering 1-week free NRT sample plus brief intervention to smokers at outdoor smoking hotspots on quit attempts and use of smoking cessation services. METHODS AND ANALYSIS This is a two-arm, pragmatic, multisite, cluster randomised controlled trial (RCT) on the effectiveness of increasing quit attempts, use of cessation service and recruitment outcomes. Trained smoking cessation ambassadors will approach smokers at outdoor smoking hotspots, and deliver brief smoking cessation advice. Recruitment sessions are randomised to intervention or control group (allocation ratio 1:1). Participants in the intervention group (n=550) will receive 1-week free NRT sample (either patch or gum), brief medication advice from an onsite nurse and cessation service referral, whereas participants in control group (n=275) will only receive the brief advice and service referral. The primary outcomes are the proportion of participants who enrol in any cessation service in Hong Kong within 1 month of the recruitment, and the proportion of participants who report quit attempts at 1-month follow-up. Secondary outcomes include self-reported use of NRT, self-reported 7-day tobacco abstinence, 30-day abstinence at 3 months and 6 months, biochemically validated abstinence at 6 months, perceived importance, difficulty and confidence to quit (scale 0-10), and Incremental Behavior Change towards Smoking Cessation. Process outcomes include number of smokers who will be approached, will accept the brief smoking cessation advice or be recruited to participate in the RCT. ETHICS AND DISSEMINATION The Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster approved the trial (UW 18-118). Findings will be disseminated through funding website, publication and conference presentations. TRIAL REGISTRATION NUMBER NCT03717051.",2020,Only about 2% of tobacco users in the territory have ever used cessation aids such as nicotine replacement therapy (NRT).,"['sample at outdoor smoking hotspots for initiating quit attempts and use of smoking cessation services', 'Participants in the intervention group (n=550']","['NRT sample plus brief intervention', 'will receive 1-week free NRT sample (either patch or gum), brief medication advice from an onsite nurse and cessation service referral, whereas participants in control group (n=275) will only receive the brief advice and service referral', 'nicotine replacement therapy']","['number of smokers who will be approached, will accept the brief smoking cessation advice', 'proportion of participants who enrol in any cessation service in Hong Kong within 1\u2009month of the recruitment, and the proportion of participants who report quit attempts', 'self-reported use of NRT, self-reported 7-day tobacco abstinence, 30-day abstinence at 3 months and 6\u2009months, biochemically validated abstinence at 6\u2009months, perceived importance, difficulty and confidence to quit (scale 0-10), and Incremental Behavior Change towards Smoking Cessation']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C1621885', 'cui_str': 'Smoking cessation education'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]",550.0,0.0917086,Only about 2% of tobacco users in the territory have ever used cessation aids such as nicotine replacement therapy (NRT).,"[{'ForeName': 'Yee Tak Derek', 'Initials': 'YTD', 'LastName': 'Cheung', 'Affiliation': 'School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong derekcheung@hku.hk.'}, {'ForeName': 'Ching Han Helen', 'Initials': 'CHH', 'LastName': 'Chan', 'Affiliation': 'Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong, Hong Kong.'}, {'ForeName': 'Kin Sang', 'Initials': 'KS', 'LastName': 'Ho', 'Affiliation': 'Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong, Hong Kong.'}, {'ForeName': 'Celeste', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Integrated Centre on Smoking Cessation, Tung Wah Group of Hospitals, Hong Kong, Hong Kong.'}, {'ForeName': 'Chloe Wing Hei', 'Initials': 'CWH', 'LastName': 'Lau', 'Affiliation': 'School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'William Ho Cheung', 'Initials': 'WHC', 'LastName': 'Li', 'Affiliation': 'School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Man Ping', 'Initials': 'MP', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, The University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Tai Hing', 'Initials': 'TH', 'LastName': 'Lam', 'Affiliation': 'School of Public Health, The University of Hong Kong, Hong Kong, Hong Kong.'}]",BMJ open,['10.1136/bmjopen-2019-036339'] 385,30484283,Interventions for preventing intensive care unit delirium in adults.,"BACKGROUND Delirium is defined as a disturbance in attention, awareness and cognition with reduced ability to direct, focus, sustain and shift attention, and reduced orientation to the environment. Critically ill patients in the intensive care unit (ICU) frequently develop ICU delirium. It can profoundly affect both them and their families because it is associated with increased mortality, longer duration of mechanical ventilation, longer hospital and ICU stay and long-term cognitive impairment. It also results in increased costs for society. OBJECTIVES To assess existing evidence for the effect of preventive interventions on ICU delirium, in-hospital mortality, the number of delirium- and coma-free days, ventilator-free days, length of stay in the ICU and cognitive impairment. SEARCH METHODS We searched CENTRAL, MEDLINE, Embase, BIOSIS, International Web of Science, Latin American Caribbean Health Sciences Literature, CINAHL from 1980 to 11 April 2018 without any language limits. We adapted the MEDLINE search for searching the other databases. Furthermore, we checked references, searched citations and contacted study authors to identify additional studies. We also checked the following trial registries: Current Controlled Trials; ClinicalTrials.gov; and CenterWatch.com (all on 24 April 2018). SELECTION CRITERIA We included randomized controlled trials (RCTs) of adult medical or surgical ICU patients receiving any intervention for preventing ICU delirium. The control could be standard ICU care, placebo or both. We assessed the quality of evidence with GRADE. DATA COLLECTION AND ANALYSIS We checked titles and abstracts to exclude obviously irrelevant studies and obtained full reports on potentially relevant ones. Two review authors independently extracted data. If possible we conducted meta-analyses, otherwise we synthesized data narratively. MAIN RESULTS The electronic search yielded 8746 records. We included 12 RCTs (3885 participants) comparing usual care with the following interventions: commonly used drugs (four studies); sedation regimens (four studies); physical therapy or cognitive therapy, or both (one study); environmental interventions (two studies); and preventive nursing care (one study). We found 15 ongoing studies and five studies awaiting classification. The participants were 48 to 70 years old; 48% to 74% were male; the mean acute physiology and chronic health evaluation (APACHE II) score was 14 to 28 (range 0 to 71; higher scores correspond to more severe disease and a higher risk of death). With the exception of one study, all participants were mechanically ventilated in medical or surgical ICUs or mixed. The studies were overall at low risk of bias. Six studies were at high risk of detection bias due to lack of blinding of outcome assessors. We report results for the two most commonly explored approaches to delirium prevention: pharmacologic and a non-pharmacologic intervention.Haloperidol versus placebo (two RCTs, 1580 participants)The event rate of ICU delirium was measured in one study including 1439 participants. No difference was identified between groups, (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.87 to 1.17) (moderate-quality evidence). Haloperidol versus placebo neither reduced or increased in-hospital mortality, (RR 0.98, 95% CI 0.80 to 1.22; 2 studies; 1580 participants (moderate-quality evidence)); the number of delirium- and coma-free days, (mean difference (MD) -0.60, 95% CI -1.37 to 0.17; 2 studies, 1580 participants (moderate-quality of evidence)); number of ventilator-free days (mean 23.8 (MD -0.30, 95% CI -0.93 to 0.33) 1 study; 1439 participants, (high-quality evidence)); length of ICU stay, (MD 0.18, 95% CI -0.60 to 0.97); 2 studies, 1580 participants; high-quality evidence). None of the studies measured cognitive impairment. In one study there were three serious adverse events in the intervention group and five in the placebo group; in the other there were five serious adverse events and three patients died, one in each group. None of the serious adverse events were judged to be related to interventions received (moderate-quality evidence).Physical and cognitive therapy interventions (one study, 65 participants)The study did not measure the event rate of ICU delirium. A physical and cognitive therapy intervention versus standard care neither reduced nor increased in-hospital mortality, (RR 0.94, 95% CI 0.40 to 2.20, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of delirium- and coma-free days, (MD -2.8, 95% CI -10.1 to 4.6, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of ventilator-free days (within the first 28/30 days) was median 27.4 (IQR 0 to 29.2) and 25 (IQR 0 to 28.9); 1 study, 65 participants; very low-quality evidence, length of ICU stay, (MD 1.23, 95% CI -0.68 to 3.14, I² = 0; 1 study, 65 participants; very low-quality evidence); cognitive impairment measured by the MMSE: Mini-Mental State Examination with higher scores indicating better function, (MD 0.97, 95% CI -0.19 to 2.13, I² = 0; 1 study, 30 participants; very low-quality evidence); or measured by the Dysexecutive questionnaire (DEX) with lower scores indicating better function (MD -8.76, 95% CI -19.06 to 1.54, I² = 0; 1 study, 30 participants; very low-quality evidence). One patient experienced acute back pain accompanied by hypotensive urgency during physical therapy. AUTHORS' CONCLUSIONS There is probably little or no difference between haloperidol and placebo for preventing ICU delirium but further studies are needed to increase our confidence in the findings. There is insufficient evidence to determine the effects of physical and cognitive intervention on delirium. The effects of other pharmacological interventions, sedation, environmental, and preventive nursing interventions are unclear and warrant further investigation in large multicentre studies. Five studies are awaiting classification and we identified 15 ongoing studies, evaluating pharmacological interventions, sedation regimens, physical and occupational therapy combined or separately, and environmental interventions, that may alter the conclusions of the review in future.",2018,"A physical and cognitive therapy intervention versus standard care neither reduced nor increased in-hospital mortality, (RR 0.94, 95% CI 0.40 to 2.20, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of delirium- and coma-free days, (MD -2.8, 95% CI -10.1 to 4.6, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of ventilator-free days (within the first 28/30 days) was median 27.4 (IQR 0 to 29.2) and 25 (IQR 0 to 28.9); 1 study, 65 participants; very low-quality evidence, length of ICU stay, (MD 1.23, 95% CI -0.68 to 3.14, I² = 0; 1 study, 65 participants; very low-quality evidence); cognitive impairment measured by the MMSE: Mini-Mental State Examination with higher scores indicating better function, (MD 0.97, 95% CI -0.19 to 2.13, I² = 0; 1 study, 30 participants; very low-quality evidence); or measured by the Dysexecutive questionnaire (DEX) with lower scores indicating better function (MD -8.76, 95% CI -19.06 to 1.54, I² = 0; 1 study, 30 participants; very low-quality evidence).","['adult medical or surgical ICU patients receiving any intervention for preventing ICU delirium', 'Critically ill patients in the intensive care unit (ICU) frequently develop ICU delirium', 'intensive care unit delirium in adults', 'participants were mechanically ventilated in medical or surgical ICUs or mixed', '1439 participants', 'participants were 48 to 70 years old; 48% to 74% were male; the mean acute physiology and chronic health evaluation (APACHE II) score was 14 to 28', '1 study; 1439 participants, (high-quality evidence)); length of ICU stay, (MD 0.18, 95% CI -0.60 to 0.97); 2 studies, 1580 participants; high-quality evidence']","['usual care with the following interventions: commonly used drugs (four studies); sedation regimens (four studies); physical therapy or cognitive therapy, or both (one study); environmental interventions (two studies); and preventive nursing care', 'placebo', 'Haloperidol', 'haloperidol', 'Haloperidol versus placebo']","['low-quality evidence); cognitive impairment', 'acute back pain', 'event rate of ICU delirium', 'serious adverse events', 'cognitive impairment', 'ICU delirium', 'ICU delirium, in-hospital mortality, the number of delirium- and coma-free days, ventilator-free days, length of stay in the ICU and cognitive impairment', 'Dysexecutive questionnaire (DEX', 'low-quality evidence, length of ICU stay', 'mortality, longer duration of mechanical ventilation, longer hospital and ICU stay and long-term cognitive impairment', 'risk of death', 'hospital mortality', 'quality of evidence with GRADE', 'risk ratio (RR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C4524095', 'cui_str': 'Intensive care unit delirium'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0243030', 'cui_str': 'Acute Physiology and Chronic Health Evaluation'}, {'cui': 'C0243028', 'cui_str': 'APACHE II'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C4517433', 'cui_str': '0.18'}]","[{'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0026118', 'cui_str': 'Situational Therapy'}, {'cui': 'C1456501', 'cui_str': 'Preventive'}, {'cui': 'C0028682', 'cui_str': 'Nursing Care'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0018546', 'cui_str': 'Haloperidol'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0699896', 'cui_str': 'Acute back pain'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0009421', 'cui_str': 'Comatose'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439591', 'cui_str': 'Long duration (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",65.0,0.23622,"A physical and cognitive therapy intervention versus standard care neither reduced nor increased in-hospital mortality, (RR 0.94, 95% CI 0.40 to 2.20, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of delirium- and coma-free days, (MD -2.8, 95% CI -10.1 to 4.6, I² = 0; 1 study, 65 participants; very low-quality evidence); the number of ventilator-free days (within the first 28/30 days) was median 27.4 (IQR 0 to 29.2) and 25 (IQR 0 to 28.9); 1 study, 65 participants; very low-quality evidence, length of ICU stay, (MD 1.23, 95% CI -0.68 to 3.14, I² = 0; 1 study, 65 participants; very low-quality evidence); cognitive impairment measured by the MMSE: Mini-Mental State Examination with higher scores indicating better function, (MD 0.97, 95% CI -0.19 to 2.13, I² = 0; 1 study, 30 participants; very low-quality evidence); or measured by the Dysexecutive questionnaire (DEX) with lower scores indicating better function (MD -8.76, 95% CI -19.06 to 1.54, I² = 0; 1 study, 30 participants; very low-quality evidence).","[{'ForeName': 'Suzanne Forsyth', 'Initials': 'SF', 'LastName': 'Herling', 'Affiliation': 'The Neuroscience Centre, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, Denmark, 2100.'}, {'ForeName': 'Ingrid E', 'Initials': 'IE', 'LastName': 'Greve', 'Affiliation': ''}, {'ForeName': 'Eduard E', 'Initials': 'EE', 'LastName': 'Vasilevskis', 'Affiliation': ''}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Egerod', 'Affiliation': ''}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Bekker Mortensen', 'Affiliation': ''}, {'ForeName': 'Ann Merete', 'Initials': 'AM', 'LastName': 'Møller', 'Affiliation': ''}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Svenningsen', 'Affiliation': ''}, {'ForeName': 'Thordis', 'Initials': 'T', 'LastName': 'Thomsen', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009783.pub2'] 386,31386042,"Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers.","Background While the use of behavioral medicine in managing glioma patients' symptoms is not well studied, the high symptom burden in patients and their family caregivers is well established. We conducted a pilot randomized, controlled trial to examine the feasibility and preliminary efficacy of a dyadic yoga (DY) intervention as a supportive care strategy. Methods Glioma patients undergoing radiotherapy and their caregivers were randomized to a 12-session DY or waitlist control (WLC) group. Prior to radiotherapy and randomization, both groups completed measures of cancer-related symptoms (MD Anderson Symptom Inventory-Brain Tumor module), depressive symptoms (Center for Epidemiological Studies-Depression measure), fatigue (Brief Fatigue Inventory), and overall quality of life (QOL; Medical Outcomes Study 36-item short-form survey). Dyads were reassessed at the last day of radiotherapy. Results Twenty patients (mean age: 46 years, 50% female, 80% WHO grade IV and caregivers (mean age: 50 years, 70% female, 50% spouses) participated in the trial. A priori feasibility criteria were met regarding consent (70%), adherence (88%), and retention (95%) rates. Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity ( d = 0.96) and symptom interference ( d = 0.74), depressive symptoms ( d = 0.71), and mental QOL ( d = 0.69). Caregivers in the DY group reported clinically significant improvements in depressive symptoms ( d = 1.12), fatigue ( d = 0.89), and mental QOL ( d = 0.49) relative to those in the WLC group. Conclusion A DY intervention appears to be a feasible and beneficial symptom and QOL management strategy for glioma patients undergoing radiotherapy and their caregivers. An efficacy trial with a more stringent control group is warranted. Clinical Trial Number NCT02481349.",2019,"Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity ( d = 0.96) and symptom interference ( d = 0.74), depressive symptoms ( d = 0.71), and mental QOL ( d = 0.69).","['Glioma patients undergoing radiotherapy and their caregivers', 'glioma patients undergoing radiotherapy and their family caregivers', 'glioma patients undergoing radiotherapy and their caregivers', 'WHO grade IV and caregivers (mean age', 'Twenty patients (mean age: 46 years, 50% female, 80', '50 years, 70% female, 50% spouses) participated in the trial']","['dyadic yoga (DY) intervention', 'dyadic yoga program', '12-session DY or waitlist control (WLC', 'behavioral medicine', 'WLC']","['fatigue', 'depressive symptoms', 'symptom interference', 'overall cancer symptom severity', 'mental QOL', 'cancer-related symptoms (MD Anderson Symptom Inventory-Brain Tumor module), depressive symptoms (Center for Epidemiological Studies-Depression measure), fatigue (Brief Fatigue Inventory), and overall quality of life (QOL; Medical Outcomes Study 36-item short-form survey']","[{'cui': 'C0017638', 'cui_str': 'Glial Cell Tumors'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0162409', 'cui_str': 'Married Persons'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0004937', 'cui_str': 'Behavioral Medicine'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0006118', 'cui_str': 'Brain Tumors'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0002783', 'cui_str': 'Epidemiological Studies'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]",,0.147501,"Controlling for relevant covariates, change score analyses revealed clinically significant improvements for patients in the DY compared with the WLC group for overall cancer symptom severity ( d = 0.96) and symptom interference ( d = 0.74), depressive symptoms ( d = 0.71), and mental QOL ( d = 0.69).","[{'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Milbury', 'Affiliation': 'Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Shiao-Pei', 'Initials': 'SP', 'LastName': 'Weathers', 'Affiliation': 'Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Smitha', 'Initials': 'S', 'LastName': 'Mallaiah', 'Affiliation': 'Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Armstrong', 'Affiliation': 'Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Yisheng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bruera', 'Affiliation': 'Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Cohen', 'Affiliation': 'Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.'}]",Neuro-oncology practice,['10.1093/nop/npy052'] 387,30582156,Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.,"OBJECTIVE Add-on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double-blind, placebo-controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo-controlled trial, GWPCARE2 (NCT02224703), were invited to enroll in a long-term open-label extension trial, GWPCARE5 (NCT02224573). We present an interim analysis of the safety, efficacy, and patient-reported outcomes from GWPCARE5. METHODS Patients received a pharmaceutical formulation of highly purified CBD in oral solution (100 mg/mL), titrated from 2.5 to 20 mg/kg/d over a 2-week period, with their existing medications. Based on response and tolerance, CBD could be reduced or increased up to 30 mg/kg/d. RESULTS By November 2016, a total of 278 patients had completed the original randomized trials, and 264 (95%) enrolled in this open-label extension. Median treatment duration was 274 days (range 1-512) with a mean modal dose of 21 mg/kg/d, and patients received a median of 3 concomitant antiepileptic medications. Adverse events (AEs) occurred in 93.2% of patients and were mostly mild (36.7%) or moderate (39.0%). Commonly reported AEs were diarrhea (34.5%), pyrexia (27.3%), decreased appetite (25.4%), and somnolence (24.6%). Seventeen patients (6.4%) discontinued due to AEs. Twenty-two of the 128 patients from GWPCARE1 (17.2%), all taking valproic acid, had liver transaminase elevations ≥3 times the upper limit of normal. In patients from GWPCARE1 Part B, the median reduction from baseline in monthly seizure frequency assessed in 12-week periods up to week 48 ranged from 38% to 44% for convulsive seizures and 39% to 51% for total seizures. After 48 weeks of treatment, 85% of patients/caregivers reported improvement in the patient's overall condition on the Subject/Caregiver Global Impression of Change scale. SIGNIFICANCE This trial shows that long-term CBD treatment had an acceptable safety profile and led to sustained, clinically meaningful reductions in seizure frequency in patients with treatment-resistant DS.",2019,Adverse events (AEs) occurred in 93.2% of patients and were mostly mild (36.7%) or moderate (39.0%).,"['patients with treatment-resistant DS', 'Patients received a', 'By November 2016, a total of 278 patients had completed the original randomized trials, and 264 (95%) enrolled in this open-label extension', 'Seventeen patients (6.4%) discontinued due to AEs', 'patients with Dravet syndrome']","['pharmaceutical formulation of highly purified CBD in oral solution', 'placebo']","['decreased appetite', 'pyrexia', 'response and tolerance, CBD', ""patient's overall condition on the Subject/Caregiver Global Impression of Change scale"", 'liver transaminase elevations ≥3 times the upper limit of normal', 'diarrhea', 'Adverse events (AEs', 'somnolence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C4517822', 'cui_str': '6.4 (qualifier value)'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0751122', 'cui_str': 'Myoclonic Epilepsy, Severe, Of Infancy'}]","[{'cui': 'C0524527', 'cui_str': 'Drug Formulation'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0232462', 'cui_str': 'Decrease in appetite (finding)'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferases'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}]",278.0,0.49901,Adverse events (AEs) occurred in 93.2% of patients and were mostly mild (36.7%) or moderate (39.0%).,"[{'ForeName': 'Orrin', 'Initials': 'O', 'LastName': 'Devinsky', 'Affiliation': 'NYU Comprehensive Epilepsy Center, New York, New York.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Nabbout', 'Affiliation': 'Necker Hospital for Sick Children, Imagine Institute, Paris, France.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Miller', 'Affiliation': ""Nicklaus Children's Hospital, Miami, Florida.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Laux', 'Affiliation': ""Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Zolnowska', 'Affiliation': 'Medical Center Pleiades, Krakow, Poland.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Wright', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Roberts', 'Affiliation': 'GW Research Ltd, Cambridge, UK.'}]",Epilepsia,['10.1111/epi.14628'] 388,28853979,"The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized, Placebo-Controlled Pilot Clinical Trial.","Purpose: Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS). Methods: Twenty-seven young adult (age 26.8 ± 6.2 years) survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma were randomly assigned (1:1) 40 mg/day of atorvastatin or placebo for 6 months. Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness were assessed. Results: Fifteen participants completed the trial. No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]: -5.3, -0.7]) and a trending significant decrease in RHI (-0.3 [95% CI: -0.62, 0.01]) was observed in the placebo group, resulting in a trend toward a treatment effects ( p  < 0.10). No effect on arterial stiffness, carotid arterial elasticity, or thickness was observed. Conclusion: Six months of atorvastatin treatment did not improve endothelial function or arterial stiffness in young adult CCS. While a trend toward an improvement in endothelial function was present, findings should be interpreted with caution owing to the small number of evaluable participants and subsequent lack of sufficient power. Further research in a larger sample size is needed to fully elucidate the effects of atorvastatin on vascular function. Trial registered at clinicaltrials.gov as NCT01733953.",2019,"No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]:","['Fifteen participants completed the trial', 'Twenty-seven young adult (age 26.8\u2009±\u20096.2 years', 'young adult CCS', ""survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma"", 'childhood cancer survivors (CCS', 'Young Adult Survivors of Childhood Cancer']","['Placebo', 'Atorvastatin', 'atorvastatin', 'atorvastatin or placebo']","['Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness', 'endothelial function', 'arterial stiffness, carotid arterial elasticity, or thickness', 'Vascular Function and Structure', 'endothelial function or arterial stiffness', 'vascular outcomes', 'RHI', 'peak FMD']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0024305', 'cui_str': ""Lymphoma, Nonhodgkin's""}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}]","[{'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0226001', 'cui_str': 'Structure of small artery'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0013764'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",27.0,0.289083,"No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (-3.0 [95% confidence interval [CI]:","[{'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Marlatt', 'Affiliation': '1Pennington Biomedical Research Center, Baton Rouge, Louisiana.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Steinberger', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Kyle D', 'Initials': 'KD', 'LastName': 'Rudser', 'Affiliation': '3Division of Biostatistics, School of Public Health, and Clinical and Translational Science Institute, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Donald R', 'Initials': 'DR', 'LastName': 'Dengel', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Karim T', 'Initials': 'KT', 'LastName': 'Sadak', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Jill L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Anne H', 'Initials': 'AH', 'LastName': 'Blaes', 'Affiliation': ""5Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.""}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Duprez', 'Affiliation': '6Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Joanna L', 'Initials': 'JL', 'LastName': 'Perkins', 'Affiliation': ""5Cancer and Blood Disorders Program, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota.""}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Ross', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}, {'ForeName': 'Aaron S', 'Initials': 'AS', 'LastName': 'Kelly', 'Affiliation': '2Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota.'}]",Journal of adolescent and young adult oncology,['10.1089/jayao.2017.0075'] 389,31324734,Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT.,"BACKGROUND The Systolic BP Intervention Trial (SPRINT) found that intensive versus standard systolic BP control (targeting <120 or <140 mm Hg, respectively) reduced the risks of death and major cardiovascular events in persons with elevated cardiovascular disease risk. However, the intensive intervention was associated with an early decline in eGFR, and the clinical implications of this early decline are unclear. METHODS In a post hoc analysis of SPRINT, we defined change in eGFR as the percentage change in eGFR at 6 months compared with baseline. We performed causal mediation analyses to separate the overall effects of the randomized systolic BP intervention on the SPRINT primary cardiovascular composite and all-cause mortality into indirect effects (mediated by percentage change in eGFR) and direct effects (mediated through pathways other than percentage change in eGFR). RESULTS About 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm ( P <0.001). After the 6-month visit, there were 591 cardiovascular composite events during 27,849 person-years of follow-up. The hazard ratios for total effect, direct effect, and indirect effect of the intervention on the cardiovascular composite were 0.67 (95% confidence interval [95% CI], 0.56 to 0.78), 0.68 (95% CI, 0.57 to 0.79), and 0.99 (95% CI, 0.95 to 1.03), respectively. All-cause mortality results were similar. CONCLUSIONS Although intensive systolic BP lowering resulted in greater early decline in eGFR, there was no evidence that the reduction in eGFR owing to intensive systolic BP lowering attenuated the beneficial effects of this intervention on cardiovascular events or all-cause mortality.",2019,About 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm ( P <0.001).,['persons with elevated cardiovascular disease risk'],['randomized systolic BP intervention'],"['risks of death and major cardiovascular events', 'cardiovascular events', '591 cardiovascular composite events', 'cardiovascular composite', 'eGFR decline']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0039155', 'cui_str': 'Systole'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",591.0,0.152778,About 10.3% of the 4270 participants in the intensive group had a ≥20% eGFR decline versus 4.4% of the 4256 participants in the standard arm ( P <0.001).,"[{'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Beddhu', 'Affiliation': 'Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah; Srinivasan.beddhu@hsc.utah.edu.'}, {'ForeName': 'Jincheng', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Division of Biostatistics, Departments of Population Health Sciences and Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.'}, {'ForeName': 'Alfred K', 'Initials': 'AK', 'LastName': 'Cheung', 'Affiliation': 'Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.'}, {'ForeName': 'Paul L', 'Initials': 'PL', 'LastName': 'Kimmel', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Division of Nephrology, Stanford University School of Medicine, Palo Alto, California.'}, {'ForeName': 'Guo', 'Initials': 'G', 'LastName': 'Wei', 'Affiliation': 'Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Boucher', 'Affiliation': 'Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Chonchol', 'Affiliation': 'Division of Renal Diseases and Hypertension, University of Colorado, Aurora, Colorado.'}, {'ForeName': 'Farid', 'Initials': 'F', 'LastName': 'Arman', 'Affiliation': 'Division of Nephrology, University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'Ruth C', 'Initials': 'RC', 'LastName': 'Campbell', 'Affiliation': 'Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Contreras', 'Affiliation': 'Division of Nephrology, University of Miami, Miami, Florida.'}, {'ForeName': 'Jamie P', 'Initials': 'JP', 'LastName': 'Dwyer', 'Affiliation': 'Division of Nephrology and Hypertension, Vanderbilt University, Nashville, Tennessee.'}, {'ForeName': 'Barry I', 'Initials': 'BI', 'LastName': 'Freedman', 'Affiliation': 'Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Joachim H', 'Initials': 'JH', 'LastName': 'Ix', 'Affiliation': 'Division of Nephrology-Hypertension, Department of Medicine, University of California, San Diego, San Diego, California.'}, {'ForeName': 'Kent', 'Initials': 'K', 'LastName': 'Kirchner', 'Affiliation': 'Division of Nephrology, G.V. (Sonny) Montgomery Veteran Affairs Medical Center, Jackson, Mississippi.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Papademetriou', 'Affiliation': 'Division of Cardiology, Veterans Administration Medical Center, Washington, DC.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Pisoni', 'Affiliation': 'Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Rocco', 'Affiliation': 'Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Whelton', 'Affiliation': 'Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Greene', 'Affiliation': 'Division of Biostatistics, Departments of Population Health Sciences and Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2018121261'] 390,31805787,Randomized Trial of an Intervention to Improve Blood Pressure Control in Stroke Survivors.,"BACKGROUND We conducted the first-of-its kind randomized stroke trial in Africa to test whether a THRIVES (Tailored Hospital-based Risk reduction to Impede Vascular Events after Stroke) intervention improved blood pressure (BP) control among patients with stroke. METHODS AND RESULTS Intervention comprised a patient global risk factor control report card, personalized phone text-messaging, and educational video. Four hundred patients recruited from 4 distinct medical facilities in Nigeria, aged ≥18 years with stroke-onset within one-year, were randomized to THRIVES intervention and control group. The control group also received text messages, and both groups received modest financial incentives. The primary outcome was mean change in systolic BP (SBP) at 12 months. There were 36.5% females, 72.3% with ischemic stroke; mean age was 57.2±11.7 years; 93.5% had hypertension and mean SBP was 138.33 (23.64) mm Hg. At 12 months, there was no significant difference in SBP reduction from baseline in the THRIVES versus control group (2.32 versus 2.01 mm Hg, P =0.82). In an exploratory analysis of subjects with baseline BP >140/90 mm Hg (n=168), THRIVES showed a significant mean SBP (diastolic BP) decrease of 11.7 (7.0) mm Hg while control group showed a significant mean SBP (diastolic BP) decrease of 11.2 (7.9) mm Hg at 12 months. CONCLUSIONS THRIVES intervention did not significantly reduce SBP compared with controls. However, there was similar significant decrease in mean BP in both treatment arms in the subgroup with baseline hypertension. As text-messaging and a modest financial incentive were the common elements between both treatment arms, further research is required to establish whether these measures alone can improve BP control among stroke survivors. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01900756.",2019,"At 12 months, there was no significant difference in SBP reduction from baseline in the THRIVES versus control group (2.32 versus 2.01 mm Hg, P =0.82).","['patients with stroke', 'Stroke Survivors', 'Four hundred patients recruited from 4 distinct medical facilities in Nigeria, aged ≥18 years with stroke-onset within one-year']","['text messages, and both groups received modest financial incentives', 'patient global risk factor control report card, personalized phone text-messaging, and educational video']","['SBP', 'mean SBP (diastolic BP', 'Blood Pressure Control', 'mean change in systolic BP (SBP', 'SBP reduction', 'blood pressure (BP) control', 'mean BP', 'hypertension and mean SBP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C4082117', 'cui_str': 'One year'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",400.0,0.14993,"At 12 months, there was no significant difference in SBP reduction from baseline in the THRIVES versus control group (2.32 versus 2.01 mm Hg, P =0.82).","[{'ForeName': 'Mayowa O', 'Initials': 'MO', 'LastName': 'Owolabi', 'Affiliation': 'Department of Medicine, University College Hospital and University of Ibadan, Nigeria and Center for Genomic and Precision Medicine, College of Medicine (M.O.O., R.O.A.), University of Ibadan, Nigeria.'}, {'ForeName': 'Mulugeta', 'Initials': 'M', 'LastName': 'Gebregziabher', 'Affiliation': 'Division of Biostatistics and Bioinformatics, Department of Public Health Sciences (M.G.), Medical University of South Carolina.'}, {'ForeName': 'Rufus O', 'Initials': 'RO', 'LastName': 'Akinyemi', 'Affiliation': 'Department of Medicine, University College Hospital and University of Ibadan, Nigeria and Center for Genomic and Precision Medicine, College of Medicine (M.O.O., R.O.A.), University of Ibadan, Nigeria.'}, {'ForeName': 'Joshua O', 'Initials': 'JO', 'LastName': 'Akinyemi', 'Affiliation': 'Department of Epidemiology and Medical Statistics (J.O.A., O. Akpa), University of Ibadan, Nigeria.'}, {'ForeName': 'Onoja', 'Initials': 'O', 'LastName': 'Akpa', 'Affiliation': 'Department of Epidemiology and Medical Statistics (J.O.A., O. Akpa), University of Ibadan, Nigeria.'}, {'ForeName': 'Olanrewaju', 'Initials': 'O', 'LastName': 'Olaniyan', 'Affiliation': 'Department of Economics (O.O.), University of Ibadan, Nigeria.'}, {'ForeName': 'Babatunde L', 'Initials': 'BL', 'LastName': 'Salako', 'Affiliation': 'Department of Medicine (B.L.S., E.U., A.F.), University of Ibadan, Nigeria.'}, {'ForeName': 'Oyedunni', 'Initials': 'O', 'LastName': 'Arulogun', 'Affiliation': 'Department of Health Promotion and Education (O. Arulogun), University of Ibadan, Nigeria.'}, {'ForeName': 'Raelle', 'Initials': 'R', 'LastName': 'Tagge', 'Affiliation': 'Department of Neurosciences (R.T.), Medical University of South Carolina.'}, {'ForeName': 'Ezinne', 'Initials': 'E', 'LastName': 'Uvere', 'Affiliation': 'Department of Medicine (B.L.S., E.U., A.F.), University of Ibadan, Nigeria.'}, {'ForeName': 'Adekunle', 'Initials': 'A', 'LastName': 'Fakunle', 'Affiliation': 'Department of Medicine (B.L.S., E.U., A.F.), University of Ibadan, Nigeria.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Ovbiagele', 'Affiliation': 'Department of Neurology, University of California, San Francisco (B.O.).'}]",Circulation. Cardiovascular quality and outcomes,['10.1161/CIRCOUTCOMES.119.005904'] 391,31067356,Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group.,"BACKGROUND The purpose of this study was to evaluate risk and response-based multi-agent therapy for patients with rhabdomyosarcoma (RMS) at first relapse. METHODS Patients with RMS and measurable disease at first relapse with unfavorable-risk (UR) features were randomized to a 6-week phase 2 window with 1 of 2 treatment schedules of irinotecan with vincristine (VI) (previously reported). Those with at least a partial response to VI continued to receive 44 weeks of multi-agent chemotherapy including the assigned VI regimen. UR patients who did not have measurable disease at study entry, did not have a radiographic response after the VI window, or declined VI window therapy received 31 weeks of multi-agent chemotherapy including tirapazamine (TPZ) at weeks 1, 4, 10, 19, and 28. Favorable-risk (FR) patients received 31 weeks of the same multi-agent chemotherapy without VI and TPZ. RESULTS One hundred thirty-six eligible patients were enrolled. For 61 patients not responding to VI, the 3-year failure-free survival (FFS) and overall survival (OS) rates were 17% (95% confidence interval [CI], 8%-29%) and 24% (13%-37%), respectively. For 30 UR patients not treated with VI, the 3-year FFS and OS rates were 21% (8%-37%) and 39% (20%-57%), respectively. FR patients had 3-year FFS and OS rates of 79% (47%-93%) and 84% (50%-96%), respectively. There were no unexpected toxicities. CONCLUSIONS Patients with UR RMS at first relapse or disease progression have a poor prognosis when they are treated with this multi-agent therapy, whereas FR patients have a higher chance of being cured with second-line therapy.",2019,"For 61 patients not responding to VI, the 3-year failure-free survival (FFS) and overall survival (OS) rates were 17% (95% confidence interval [CI], 8%-29%) and 24% (13%-37%), respectively.","['Patients with RMS and measurable disease at first relapse with unfavorable-risk (UR) features', 'patients with first relapse or progression of rhabdomyosarcoma', 'patients with rhabdomyosarcoma (RMS) at first relapse', 'One hundred thirty-six eligible patients were enrolled']","['multi-agent chemotherapy including tirapazamine (TPZ', 'irinotecan with vincristine (VI']","['3-year FFS and OS rates', '3-year failure-free survival (FFS) and overall survival (OS) rates', 'toxicities', 'radiographic response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0035412', 'cui_str': 'Rhabdomyosarcoma'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}]","[{'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0208407', 'cui_str': '3-Amino-1,2,4-benzotriazine-1,4-dioxide'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}]",136.0,0.16764,"For 61 patients not responding to VI, the 3-year failure-free survival (FFS) and overall survival (OS) rates were 17% (95% confidence interval [CI], 8%-29%) and 24% (13%-37%), respectively.","[{'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Mascarenhas', 'Affiliation': ""Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California.""}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Lyden', 'Affiliation': 'Department of Preventive and Societal Medicine, University of Nebraska, Omaha, Nebraska.'}, {'ForeName': 'Philip P', 'Initials': 'PP', 'LastName': 'Breitfeld', 'Affiliation': 'Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Walterhouse', 'Affiliation': ""Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'ForeName': 'Sarah S', 'Initials': 'SS', 'LastName': 'Donaldson', 'Affiliation': 'Department of Radiation Oncology, Stanford University, Stanford, California.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Rodeberg', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, East Carolina University, Greenville, North Carolina.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Parham', 'Affiliation': ""Department of Pathology, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.""}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Anderson', 'Affiliation': 'Department of Preventive and Societal Medicine, University of Nebraska, Omaha, Nebraska.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Meyer', 'Affiliation': 'Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.'}, {'ForeName': 'Douglas S', 'Initials': 'DS', 'LastName': 'Hawkins', 'Affiliation': ""Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.""}]",Cancer,['10.1002/cncr.32122'] 392,31897483,Multinutrient Supplementation Increases Collagen Synthesis during Early Wound Repair in a Randomized Controlled Trial in Patients with Inguinal Hernia.,"BACKGROUND Inguinal hernia disease is associated with an imbalanced collagen metabolism. Surgical stress has a negative impact on nutrients important for collagen synthesis. OBJECTIVE We hypothesized that supplementation with a combination of nutrients would enhance collagen biosynthesis in inguinal hernia disease patients when undergoing hernia repair. METHODS In this exploratory randomized controlled trial, 21 men (age: 55.2 ± 2.8 y; BMI: 25.0 ± 0.7 kg/m2) scheduled for Lichtenstein inguinal hernia repair were assigned to multinutrient supplementation (n = 10; multinutrient group) or no multinutrient supplementation (n = 11; control group). The multinutrient group received 14 g l-arginine, 14 g l-glutamine, 1250 mg vitamin C, and 55 mg zinc daily starting 14 d before surgery and ending 14 d after surgery. The multinutrient and control groups received high-quality protein to ensure a daily intake of 1.5 g protein/kg. Collagen biosynthesis was measured by the biomarkers type I procollagen propeptide (CICP), type III procollagen propeptide (PRO-C3), and type V procollagen propeptide (PRO-C5) in the sera on days -14, 0, and 1, and in the wound fluids on postoperative days 1 and 2. Compliance was recorded after the 28-d intervention period. RESULTS Serum PRO-C5 concentrations decreased (P < 0.05) postoperatively in the control but not the multinutrient group. Neither CICP nor PRO-C3 serum concentrations differed significantly between the 2 groups. In wound fluid, the CICP concentrations increased (P < 0.05) from days 1 to 2 in the multinutrient group and were 49% higher (P = 0.10) than those in the control group on day 2. Wound fluid concentrations PRO-C3 and PRO-C5 showed no significant time or group differences. The 28-d compliance was similar (P = 0.27) in the 2 groups. CONCLUSION Oral supplementation with arginine, glutamine, vitamin C, and zinc augment collagen synthesis during the first 2 d after inguinal hernia repair. This trial was registered at clinicaltrials.gov as NCT03221686.",2020,"RESULTS Serum PRO-C5 concentrations decreased (P < 0.05) postoperatively in the control but not the multinutrient group.","['21 men (age: 55.2\xa0±\xa02.8 y; BMI: 25.0\xa0±\xa00.7\xa0kg/m2) scheduled for Lichtenstein inguinal hernia repair', 'Patients with Inguinal Hernia', 'inguinal hernia disease patients when undergoing hernia repair']","['high-quality protein', '14\xa0g l-arginine, 14\xa0g l-glutamine, 1250\xa0mg vitamin C', 'Multinutrient Supplementation', 'multinutrient supplementation (n\xa0=\xa010; multinutrient group) or no multinutrient supplementation', 'arginine, glutamine, vitamin C, and zinc']","['CICP concentrations', 'Collagen Synthesis', 'biomarkers type I procollagen propeptide (CICP), type III procollagen propeptide (PRO-C3), and type V procollagen propeptide (PRO-C5', 'CICP nor PRO-C3 serum concentrations', 'Compliance', 'Serum PRO-C5 concentrations', 'Collagen biosynthesis']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517474', 'cui_str': '0.7 (qualifier value)'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019294', 'cui_str': 'Hernia, Inguinal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0019328', 'cui_str': 'Hernia Repair'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1318184', 'cui_str': '14G'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C4517554', 'cui_str': 'One thousand two hundred and fifty'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0968133', 'cui_str': 'alpha-(trifluoromethyl)arginine'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0041457', 'cui_str': 'Procollagen Type I'}, {'cui': 'C0033240', 'cui_str': 'Type III Procollagen'}, {'cui': 'C0071997', 'cui_str': 'C3 Precursor'}, {'cui': 'C0033243', 'cui_str': 'Procollagen Type V'}, {'cui': 'C0645500', 'cui_str': 'Precursor C5'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",,0.164561,"RESULTS Serum PRO-C5 concentrations decreased (P < 0.05) postoperatively in the control but not the multinutrient group.","[{'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Kjaer', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Amalie Kruse Sigersted', 'Initials': 'AKS', 'LastName': 'Frederiksen', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Neel Ingemann', 'Initials': 'NI', 'LastName': 'Nissen', 'Affiliation': 'Nordic Bioscience A/S, Herlev, Denmark.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Willumsen', 'Affiliation': 'Nordic Bioscience A/S, Herlev, Denmark.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'van Hall', 'Affiliation': 'Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, and Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars Nannestad', 'Initials': 'LN', 'LastName': 'Jorgensen', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens Rikardt', 'Initials': 'JR', 'LastName': 'Andersen', 'Affiliation': 'Department of Nutrition, Exercise, and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Magnus S', 'Initials': 'MS', 'LastName': 'Ågren', 'Affiliation': 'Digestive Disease Center, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.'}]",The Journal of nutrition,['10.1093/jn/nxz324'] 393,28476075,Drugs for discoid lupus erythematosus.,"BACKGROUND Discoid lupus erythematosus (DLE) is a chronic form of cutaneous lupus, which can cause scarring. Many drugs have been used to treat this disease and some (such as thalidomide, cyclophosphamide and azathioprine) are potentially toxic. This is an update of a Cochrane Review first published in 2000, and previously updated in 2009. We wanted to update the review to assess whether any new information was available to treat DLE, as we were still unsure of the effectiveness of available drugs and how to select the most appropriate treatment for an individual with DLE. OBJECTIVES To assess the effects of drugs for discoid lupus erythematosus. SEARCH METHODS We updated our searches of the following databases to 22 September 2016: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and LILACS. We also searched five trials databases, and checked the reference lists of included studies for further references to relevant trials. Index Medicus (1956 to 1966) was handsearched and we approached authors for information about unpublished trials. SELECTION CRITERIA We included all randomised controlled trials (RCTs) of drugs to treat people with DLE in any population group and of either gender. Comparisons included any drug used for DLE against either another drug or against placebo cream. We excluded laser treatment, surgery, phototherapy, other forms of physical therapy, and photoprotection as we did not consider them drug treatments. DATA COLLECTION AND ANALYSIS At least two reviewers independently extracted data onto a data extraction sheet, resolving disagreements by discussion. We used standard methods to assess risk of bias, as expected by Cochrane. MAIN RESULTS Five trials involving 197 participants were included. Three new trials were included in this update. None of the five trials were of high quality.'Risk of bias' assessments identified potential sources of bias in each study. One study used an inappropriate randomisation method, and incomplete outcome data were a concern in another as 15 people did not complete the trial. We found most of the trials to be at low risk in terms of blinding, but three of the five did not describe allocation concealment.The included trials inadequately addressed the primary outcome measures of this review (percentage with complete resolution of skin lesions, percentage with clearing of erythema in at least 50% of lesions, and improvement in patient satisfaction/quality of life measures).One study of fluocinonide cream 0.05% (potent steroid) compared with hydrocortisone cream 1% (low-potency steroid) in 78 people reported complete resolution of skin lesions in 27% (10/37) of participants in the fluocinonide cream group and in 10% (4/41) in the hydrocortisone group, giving a 17% absolute benefit in favour of fluocinonide (risk ratio (RR) 2.77, 95% CI 0.95 to 8.08, 1 study, n = 78, low-quality evidence). The other primary outcome measures were not reported. Adverse events did not require discontinuation of the drug. Skin irritation occurred in three people using hydrocortisone, and one person developed acne. Burning occurred in two people using fluocinonide (moderate-quality evidence).A comparative trial of two oral agents, acitretin (50 mg daily) and hydroxychloroquine (400 mg daily), reported two of the outcomes of interest: complete resolution was seen in 13 of 28 participants (46%) on acitretin and 15 of 30 participants (50%) on hydoxychloroquine (RR 0.93, 95% CI 0.54 to 1.59, 1 study, n = 58, low-quality evidence). Clearing of erythema in at least 50% of lesions was reported in 10 of 24 participants (42%) on acitretin and 17 of 25 (68%) on hydroxychloroquine (RR 0.61, 95% CI 0.36 to 1.06, 1 study, n = 49, low-quality evidence). This comparison did not assess improvement in patient satisfaction/quality of life measures. Participants taking acitretin showed a small increase in serum triglyceride, not sufficient to require withdrawal of the drug. The main adverse effects were dry lips (93% of the acitretin group and 20% of the hydroxychloroquine group) and gastrointestinal disturbance (11% of the acitretin group and 17% of the hydroxychloroquine group). Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate-quality evidence).One trial randomised 10 people with DLE to apply a calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17-valerate 0.1% cream, for eight weeks. The study reported none of the primary outcome measures, nor did it present data on adverse events.A trial of calcineurin inhibitors compared tacrolimus cream 0.1% with placebo (vehicle) over 12 weeks in 14 people, but reported none of our primary outcome measures. In the tacrolimus group, five participants complained of slight burning and itching, and for one participant, a herpes simplex infection was reactivated (moderate-quality evidence).Topical R-salbutamol 0.5% cream was compared with placebo (vehicle) over eight weeks in one trial of 37 people with DLE. There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life. None of the primary outcome measures were reported. Changes in erythema did not show benefit of salbutamol over placebo, but we could not obtain from the trial report the number of participants with clearing of erythema in at least 50% of lesions. There were 15 events in the placebo group (experienced by 12 participants) and 24 in the salbutamol group (experienced by nine participants). None of the adverse events were considered serious (moderate-quality evidence). AUTHORS' CONCLUSIONS Fluocinonide cream may be more effective than hydrocortisone in clearing DLE skin lesions. Hydroxychloroquine and acitretin appear to be of equal efficacy in terms of complete resolution, although adverse effects might be more frequent with acitretin, and clearing of erythema in at least 50% of lesions occurred less often in participants applying acitretin. Moderate-quality evidence found adverse events were minor on the whole. There is not enough reliable evidence about other drugs used to treat DLE. Overall, the quality of the trials and levels of uncertainty were such that there is a need for further trials of sufficient duration comparing, in particular, topical steroids with other agents.",2017,"There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life.","['Four participants on acitretin withdrew due to gastrointestinal events or dry lips (moderate-quality evidence).One trial randomised 10 people with DLE to apply a', 'people with DLE in any population group and of either gender', 'Five trials involving 197 participants were included', 'discoid lupus erythematosus']","['placebo', 'hydoxychloroquine', 'hydrocortisone cream', 'calcineurin inhibitors compared tacrolimus cream', 'Hydroxychloroquine', 'hydroxychloroquine', 'placebo (vehicle', 'tacrolimus', 'calcineurin inhibitor, pimecrolimus 1% cream, or a potent steroid, betamethasone 17-valerate 0.1% cream', 'acitretin', 'salbutamol', 'hydrocortisone', 'fluocinonide cream', 'Fluocinonide cream', 'fluocinonide', 'placebo cream', 'thalidomide, cyclophosphamide and azathioprine']","['serum triglyceride', 'Adverse events', 'patient satisfaction/quality of life measures', 'patient satisfaction/quality of life measures).One', 'herpes simplex infection', 'adverse events', 'Clearing of erythema', 'slight burning and itching', 'pain and itch', 'Skin irritation', 'quality of life', 'complete resolution of skin lesions', 'gastrointestinal disturbance', 'complete resolution of skin lesions, percentage with clearing of erythema']","[{'cui': 'C0050559', 'cui_str': 'Acitretin'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0555724', 'cui_str': 'On examination - dry lips (disorder)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C1257890', 'cui_str': 'Population Group'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0024138', 'cui_str': 'Lupus Erythematosus, Cutaneous, Chronic'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C4521884', 'cui_str': 'Calcineurin inhibitor (disposition)'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C1099414', 'cui_str': 'Pimecrolimus'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0750848', 'cui_str': 'Betamethasone valerate'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C0050559', 'cui_str': 'Acitretin'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0016299', 'cui_str': 'Fluocinonide'}, {'cui': 'C0039736', 'cui_str': 'Thalidomide'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}]","[{'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C2937276', 'cui_str': 'Slight (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0152030', 'cui_str': 'Skin irritation (disorder)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion (disorder)'}, {'cui': 'C0232459', 'cui_str': 'Impaired digestion'}]",10.0,0.434029,"There was a significant improvement in pain and itch in the salbutamol group at two, four, six, and eight weeks compared to placebo, but the trial did not record a formal measure of quality of life.","[{'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Jessop', 'Affiliation': 'Department of Medicine, University of Cape Town Groote Schuur Hospital, Main Road, 7925 Observatory Cape Town, Cape Town, Western Cape, South Africa.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Whitelaw', 'Affiliation': 'Department of Medicine, Division of Rheumatology, University of Stellenbosch, Cape Town, Tygerberg, South Africa, 7500.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Grainge', 'Affiliation': 'Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK, NG7 2UH.'}, {'ForeName': 'Prativa', 'Initials': 'P', 'LastName': 'Jayasekera', 'Affiliation': 'Department of Dermatology, Broadgreen Hospital, Liverpool, UK, L14 3LB.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD002954.pub3'] 394,30256919,Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1.,"BACKGROUND The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1-infected individuals are likely to progress to active disease is unknown. METHODS Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1-infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. RESULTS Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. CONCLUSIONS Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.",2019,"Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups.","['Thirteen analytes were measured from', 'individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB', '421 HIV-1-infected persons recruited within the screening and enrollment phases']","['isoniazid preventive therapy', 'QuantiFERON Gold in-tube (QFT) plasma samples']","['C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α', 'Unstimulated IL-2 and IFN-γ', 'analyte concentrations']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0443354', 'cui_str': 'Analyte (substance)'}, {'cui': 'C0449770', 'cui_str': 'Measured from (attribute)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}]","[{'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0021756', 'cui_str': 'TCGF'}, {'cui': 'C0040691', 'cui_str': 'Animal growth regulators, transforming growth factors'}, {'cui': 'C0439819', 'cui_str': 'Unstimulated (qualifier value)'}, {'cui': 'C0443354', 'cui_str': 'Analyte (substance)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",13.0,0.0950443,"Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups.","[{'ForeName': 'Maia', 'Initials': 'M', 'LastName': 'Lesosky', 'Affiliation': 'Division of Epidemiology & Biostatistics, School of Public Health and Family Medicine.'}, {'ForeName': 'Molebogeng X', 'Initials': 'MX', 'LastName': 'Rangaka', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Pienaar', 'Affiliation': 'Division of Epidemiology & Biostatistics, School of Public Health and Family Medicine.'}, {'ForeName': 'Anna K', 'Initials': 'AK', 'LastName': 'Coussens', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Goliath', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}, {'ForeName': 'Shaheed', 'Initials': 'S', 'LastName': 'Mathee', 'Affiliation': 'Site B Khayelitsha Community Health Centre, Western Cape Department of Health, South Africa.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Mwansa-Kambafwile', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Maartens', 'Affiliation': 'Department of Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, South Africa.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Wilkinson', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}, {'ForeName': 'Katalin Andrea', 'Initials': 'KA', 'LastName': 'Wilkinson', 'Affiliation': 'Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, Observatory, South Africa.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy823'] 395,32238163,Development and validation of a survival model for lung adenocarcinoma based on autophagy-associated genes.,"BACKGROUND Given that abnormal autophagy is involved in the pathogenesis of cancers, we sought to explore the potential value of autophagy-associated genes in lung adenocarcinoma (LUAD). METHODS RNA sequencing and clinical data on tumour and normal samples were acquired from The Cancer Genome Atlas (TCGA) database and randomly assigned to training and testing groups. Differentially expressed autophagy-associated genes (AAGs) were screened. Within the training group, Cox regression and Lasso regression analyses were conducted to screen five prognostic AAGs, which were used to develop a model. Kaplan-Meier (KM) and receiver operating characteristic (ROC) curves were plotted to determine the performance of the model in both groups. Immunohistochemistry was used to demonstrate the differential expression of AAGs in tumour and normal tissues at the protein level. Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were utilized to further elucidate the roles of AAGs in LUAD. RESULTS The data from the TCGA database included 497 tumour and 54 normal samples, within which 30 differentially expressed AAGs were screened. Using Cox regression and Lasso regression analyses for the training group, 5 prognostic AAGs were identified and the prognostic model was constructed. Patients with low risk had better overall survival (OS) in the training group (3-year OS, 73.0% vs 48.0%; 5-year OS, 45.0% vs 33.8%; P = 1.305E-04) and in the testing group (3-year OS, 66.8% vs 41.2%; 5-year OS, 31.7% vs 25.8%; P = 1.027E-03). The areas under the ROC curves (AUC) were significant for both the training and testing groups (3-year AUC, 0.810 vs 0.894; 5-year AUC, 0.792 vs 0.749). CONCLUSIONS We developed a survival model for LUAD and validated the performance of the model, which may provide superior outcomes for the patients.",2020,"Patients with low risk had better overall survival (OS) in the training group (3-year OS, 73.0% vs 48.0%; 5-year OS, 45.0% vs 33.8%; P = 1.305E-04) and in the testing group (3-year OS, 66.8% vs 41.2%; 5-year OS, 31.7% vs 25.8%; P = 1.027E-03).",[],[],"['overall survival (OS', 'ROC curves (AUC', 'Kaplan-Meier (KM) and receiver operating characteristic (ROC) curves', '5-year OS']",[],[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0035787', 'cui_str': 'ROC Analysis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0439234', 'cui_str': 'year'}]",,0.0357827,"Patients with low risk had better overall survival (OS) in the training group (3-year OS, 73.0% vs 48.0%; 5-year OS, 45.0% vs 33.8%; P = 1.305E-04) and in the testing group (3-year OS, 66.8% vs 41.2%; 5-year OS, 31.7% vs 25.8%; P = 1.027E-03).","[{'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Yao', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Zengtuan', 'Initials': 'Z', 'LastName': 'Xiao', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Jialin', 'Initials': 'J', 'LastName': 'Gong', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Zuo', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Baoai', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China.'}, {'ForeName': 'Zhenfa', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Lung Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Rd, Tianjin, China. zhangzhenfa@tmu.edu.cn.'}]",Journal of translational medicine,['10.1186/s12967-020-02321-z'] 396,31645004,"The effect of simulation-based education on childhood epileptic seizure management knowledge, skills, and attitudes of nursing students.","BACKGROUND Lack of knowledge about epileptic seizure management and negative attitudes toward children with epilepsy among nursing students may negatively affect the quality of healthcare services they deliver. AIM This study aimed to examine the effect of training given to nursing students using simulation and standard child mannequins on their childhood epileptic seizure management knowledge, skills, and attitudes. METHODS Participants (n = 72) were recruited from a Nursing Faculty in Izmir, Turkey. Students were randomly assigned to the intervention and control groups (n = 36 in each). The intervention group received simulation-based training on epilepsy while the control group received standard child mannequin training on epilepsy. One week after the training, the students were asked to demonstrate their epileptic seizure management knowledge and skills on a simulation model or a standard child mannequin. During this process, they were observed and assessed by two independent observers on the basis of a list of epileptic seizure management skills. All participants completed the personal information form, the Epilepsy and Epileptic Seizure Management Knowledge Test, and the Epilepsy Knowledge and Attitude Scale before, and after the training, McNemar's test, repeated measure ANOVA (intravenous), dependent t-test, chi-square test, Fisher's exact test, independent t-test, Pearson's correlation analysis, and Pearson's chi-square test were used to compare the groups. Intraclass correlation coefficient (ICC) was used to evaluate the consistency between observers. RESULTS The epilepsy knowledge scale mean scores of both groups significantly increased after their respective trainings (p < 0.001), but the difference between the groups was not statistically significant (p = 0.829). There was no statistically significant difference between the pre- and posttraining epilepsy attitude scale mean scores of the control group (p = 0.630), however, a statistically significant increase was observed in the epilepsy attitude scale mean score of the intervention group (p = 0.008). In addition, both groups' self-confidence in epileptic seizure management significantly increased after the training (p = 0.000). CONCLUSIONS Simulation-based training was beneficial for students insofar as it helped them to develop positive attitudes toward epilepsy.",2019,"The epilepsy knowledge scale mean scores of both groups significantly increased after their respective trainings (p < 0.001), but the difference between the groups was not statistically significant (p = 0.829).","['Participants (n\u202f=\u202f72) were recruited from a Nursing Faculty in Izmir, Turkey', 'nursing students', 'children with epilepsy among nursing students']","['simulation-based training on epilepsy while the control group received standard child mannequin training on epilepsy', 'simulation-based education', 'training given to nursing students using simulation and standard child mannequins']","['epilepsy knowledge scale mean scores', 'epilepsy attitude scale mean score', 'self-confidence in epileptic seizure management', 'Intraclass correlation coefficient (ICC', 'pre- and posttraining epilepsy attitude scale mean scores']","[{'cui': 'C0015538', 'cui_str': 'Faculty, Nursing'}, {'cui': 'C0041400', 'cui_str': 'Turkey'}, {'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}]","[{'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C4317109', 'cui_str': 'Epileptic Seizures'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]",,0.0274323,"The epilepsy knowledge scale mean scores of both groups significantly increased after their respective trainings (p < 0.001), but the difference between the groups was not statistically significant (p = 0.829).","[{'ForeName': 'Ayşe', 'Initials': 'A', 'LastName': 'Kahraman', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey. Electronic address: ayse.kahraman@ege.edu.tr.'}, {'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Gümüş', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}, {'ForeName': 'Şeyda', 'Initials': 'Ş', 'LastName': 'Binay', 'Affiliation': 'Izmir Bakırçay University, Faculty of Health Sciences, Nursing Department, Menemen, İzmir 35665, Turkey.'}, {'ForeName': 'Dilek', 'Initials': 'D', 'LastName': 'Zengin', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}, {'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'Uzşen', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}, {'ForeName': 'Seda', 'Initials': 'S', 'LastName': 'Ardahan Sevgili', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}, {'ForeName': 'Hamide Nur', 'Initials': 'HN', 'LastName': 'Çevik Özdemir', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}, {'ForeName': 'Zümrüt', 'Initials': 'Z', 'LastName': 'Başbakkal', 'Affiliation': 'Ege University Faculty of Nursing, Pediatric Nursing Department, Bornova, İzmir 35100, Turkey.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106497'] 397,31278194,A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.,"BACKGROUND Researchers have yet to determine the optimal care of patients with advanced CKD. Evidence suggests that anemia and CKD-related disordered mineral metabolism (including abnormalities in phosphate and fibroblast growth factor 23 [FGF23]) contribute to adverse outcomes in this population. METHODS To investigate whether fixed-dose ferric citrate coordination complex favorably affects multiple biochemical parameters in patients with advanced CKD, we randomly assigned 203 patients with eGFR≤20 ml/min per 1.73 m 2 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care for 9 months or until 3 months after starting dialysis. No single biochemical end point was designated as primary; sample size was determined empirically. RESULTS The two groups had generally similar baseline characteristics, although diabetes and peripheral vascular disease were more common in the usual-care group. Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 ( P <0.001 for all). Of the 133 patients randomized to ferric citrate coordination complex, 31 (23%) initiated dialysis during the study period, as did 32 of 66 (48%) patients randomized to usual care ( P =0.001). Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation ( P =0.002). CONCLUSIONS The beneficial effects of fixed-dose ferric citrate coordination complex on biochemical parameters, as well as the exploratory results regarding the composite end point and hospitalization, suggest that fixed-dose ferric citrate coordination complex has an excellent safety profile in an unselected population with advanced CKD and merits further study.",2019,"Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation ( P =0.002). ","['patients with advanced CKD', 'Advanced CKD', '133 patients randomized to', 'patients with advanced CKD, we randomly assigned 203 patients with']","['fixed-dose ferric citrate coordination complex', 'eGFR≤20 ml/min per 1.73 m 2 2:1 to receive a fixed dose of ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet) or usual care', 'ferric citrate coordination complex', 'Ferric Citrate Coordination Complex']","['hemoglobin, transferrin saturation, and serum ferritin', 'annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation', 'serum phosphate and intact FGF23', 'diabetes and peripheral vascular disease']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0060231', 'cui_str': 'ferric citrate'}, {'cui': 'C0596913', 'cui_str': 'Metal Complexes'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation index (procedure)'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0036820', 'cui_str': 'Serum phosphate'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0085096', 'cui_str': 'Peripheral Angiopathies'}]",203.0,0.0528871,"Compared with usual care, ferric citrate coordination complex treatment resulted in significantly fewer annualized hospital admissions, fewer days in hospital, and a lower incidence of the composite end point of death, provision of dialysis, or transplantation ( P =0.002). ","[{'ForeName': 'Geoffrey A', 'Initials': 'GA', 'LastName': 'Block', 'Affiliation': 'Reata Pharmaceuticals, Dallas, Texas; geoff@goldenblocks.org.'}, {'ForeName': 'Martha S', 'Initials': 'MS', 'LastName': 'Block', 'Affiliation': 'Denver Nephrology Research Division, Denver, Colorado.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Smits', 'Affiliation': 'CSC, Inc., Santa Barbara, California.'}, {'ForeName': 'Rupal', 'Initials': 'R', 'LastName': 'Mehta', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Feinberg School of Medicine, Jesse Brown Veterans Administration Medical Center.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Isakova', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Myles', 'Initials': 'M', 'LastName': 'Wolf', 'Affiliation': 'Division of Nephrology, Department of Medicine, and Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina; and.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Chertow', 'Affiliation': 'Stanford University, Palo Alto, California.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2018101016'] 398,31037789,Exploratory analysis of treatment response trajectories in the PRISM trial: Models of psychosocial care.,"OBJECTIVE Adolescents and young adults (AYAs) with cancer are at high risk of negative psychosocial outcomes. Promoting Resilience in Stress Management (PRISM), a novel, brief, skill-based intervention, has demonstrated efficacy in improving psychosocial well-being for AYAs. We utilized data from a recent randomized trial of PRISM versus usual care (UC) to categorize and explore group differences in change trajectories of patient reported outcomes (PROs) over time. METHODS One hundred English-speaking AYAs (aged 12-25 years old) with cancer were randomized to PRISM versus UC. At enrollment and 6 months later, AYAs completed validated PROs measuring resilience (Connor-Davidson Resilience Scale [CDRISC-10]), hope (Hope Scale), benefit finding (Benefit and Burden Scale for Children), cancer-specific quality of life (Pediatric Quality of Life [PedsQL] Cancer Module), and distress (Kessler-6). Patient response trajectories were categorized as ""improved,"" ""consistently well,"" ""consistently at risk,"" or ""deteriorated"" using minimal clinically important differences (MCIDs) or established measure cutoffs for all PROs. Positive response trajectories consisted of the first two categories (""improved"" and ""consistently well""), and negative response trajectories consisted of the latter two categories (""consistently at risk"" and ""deteriorated""). RESULTS Across all PROs, more patients in the PRISM arm ""improved"" in psychosocial well-being over time, and fewer PRISM recipients ""deteriorated"" over time. Across all PROs, a greater proportion of PRISM participants (vs UC) experienced positive response trajectories. Across all PROs, a greater proportion of UC participants experienced negative response trajectories. CONCLUSIONS PRISM shows evidence of both a prevention effect and an intervention effect. Thus, PRISM may serve as a viable prevention and early intervention model for psychosocial care.",2019,"Across all PROs, more patients in the PRISM arm ""improved"" in psychosocial well-being over time, and fewer PRISM recipients ""deteriorated"" over time.","['Adolescents and young adults (AYAs) with cancer', 'One hundred English-speaking AYAs (aged 12-25 years old) with cancer']","['PRISM versus UC', 'PRISM versus usual care (UC']","['PROs measuring resilience (Connor-Davidson Resilience Scale [CDRISC-10]), hope (Hope Scale), benefit finding (Benefit and Burden Scale for Children), cancer-specific quality of life (Pediatric Quality of Life [PedsQL] Cancer Module), and distress (Kessler-6']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]",[],"[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0392347', 'cui_str': 'Hope'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0034380'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}]",100.0,0.0429357,"Across all PROs, more patients in the PRISM arm ""improved"" in psychosocial well-being over time, and fewer PRISM recipients ""deteriorated"" over time.","[{'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Lau', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Miranda C', 'Initials': 'MC', 'LastName': 'Bradford', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Steineck', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Courtney C', 'Initials': 'CC', 'LastName': 'Junkins', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Joyce P', 'Initials': 'JP', 'LastName': 'Yi-Frazier', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McCauley', 'Affiliation': 'Division of Child Psychiatry, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington.'}, {'ForeName': 'Abby R', 'Initials': 'AR', 'LastName': 'Rosenberg', 'Affiliation': ""Palliative Care and Resilience Research Program, Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}]",Psycho-oncology,['10.1002/pon.5098'] 399,32265500,Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.,"Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patients with suboptimal response to first-line imatinib. Adult patients with CML-CP were randomized (2:1) to receive 100 mg dasatinib (n = 174) or continue imatinib at ≥400 mg (n = 86). The primary endpoint was the rate of major molecular response (MMR) at 12 months, which was 29% (dasatinib) and 13% (imatinib; P = 0.005). After ≥2 years of follow-up, 45 patients (52%) randomized to continue imatinib had crossed over to dasatinib. Considering treatment crossover, the 2-year cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, respectively by intent-to-treat). Adverse events were consistent with the established safety profiles of both drugs. The results of this first prospective study support early monitoring of patients treated with first-line imatinib, and suggest that switching to dasatinib in cases of suboptimal response may offer clinical benefit. Further follow-up is needed to assess the long-term clinical benefit of early switching.",2020,"Considering treatment crossover, the 2-year cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, respectively by intent-to-treat).","['patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy', 'patients with CML-CP', 'Adult patients with CML-CP', 'patients with suboptimal response to first-line imatinib']","['Dasatinib vs. imatinib', '100\u2009mg dasatinib (n\u2009=\u2009174) or continue imatinib']","['probability of deep molecular response and superior survival', '2-year cumulative MMR rate', 'Adverse events', 'rate of major molecular response (MMR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023473', 'cui_str': 'Chronic myeloid leukemia'}, {'cui': 'C0457343', 'cui_str': 'Chronic phase'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205132', 'cui_str': 'Linear'}]","[{'cui': 'C1455147', 'cui_str': 'dasatinib'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0006416', 'cui_str': 'Burma'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",,0.0336482,"Considering treatment crossover, the 2-year cumulative MMR rate was 64% with dasatinib and 41% with imatinib (66% and 67%, respectively by intent-to-treat).","[{'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Cortes', 'Affiliation': 'Georgia Cancer Center, Augusta University, Augusta, GA, USA. jorge.cortes@augusta.edu.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Jiang', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Jianxiang', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.'}, {'ForeName': 'Jianyu', 'Initials': 'J', 'LastName': 'Weng', 'Affiliation': ""Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.""}, {'ForeName': 'Huanling', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'West China Hospital of Sichuan University, Chengdu, Sichuan, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hochhaus', 'Affiliation': 'Universitätsklinikum Jena, Jena, Germany.'}, {'ForeName': 'Dong-Wook', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'The Catholic University of Korea, Seoul, Republic of Korea.'}, {'ForeName': 'Jerald', 'Initials': 'J', 'LastName': 'Radich', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Savona', 'Affiliation': 'Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Martin-Regueira', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Oumar', 'Initials': 'O', 'LastName': 'Sy', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Renuka', 'Initials': 'R', 'LastName': 'Gurnani', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Saglio', 'Affiliation': 'University of Turin, Turin, Italy.'}]",Leukemia,['10.1038/s41375-020-0805-1'] 400,31577988,Positive outcome of visuospatial deficit rehabilitation in children with epilepsy using computer-based FORAMENRehab program.,"Children with epilepsy often show deficits in attention and visuospatial functions. Still, very few systematically controlled evidence-based pediatric neurorehabilitation methods exist. The aim was to assess the effectiveness of a computer-based rehabilitation program for visuospatial deficit remediation in children with epilepsy. Fifty-eight children aged 8-12 years participated: 17 children with epilepsy diagnosis in intervention group, 22 patients in waiting-list control group, and 19 healthy age equivalent controls. The intervention group received guided visuospatial functions rehabilitation with FORAMENRehab software twice a week for a 5-week period. Baseline assessments were carried out before and immediately after the intervention period, and as follow-up 1.31 years later. Intervention group showed positive immediate rehabilitation effect in 3 out of 4 visuospatial components: visual organization, visual attention, and visuospatial perception. A long-term rehabilitation effect in the study group was observed in all 4 of the trained components. Also, a positive generalized effect was confirmed by the parents' and children's qualitative feedback with some of the improved skills transferring to children's everyday life. One hundred percent compliance further confirmed the children's motivation to participate and the effectiveness of FORAMENRehab for pediatric neurorehabilitation.",2019,"Intervention group showed positive immediate rehabilitation effect in 3 out of 4 visuospatial components: visual organization, visual attention, and visuospatial perception.","['children with epilepsy', 'Children with epilepsy', 'children with epilepsy using computer-based FORAMENRehab program', 'Fifty-eight children aged 8-12\u202fyears participated: 17 children with epilepsy diagnosis in intervention group, 22 patients in waiting-list control group, and 19 healthy age equivalent controls']","['visuospatial deficit rehabilitation', 'guided visuospatial functions rehabilitation with FORAMENRehab software', 'computer-based rehabilitation program']","['positive immediate rehabilitation effect', '4 visuospatial components: visual organization, visual attention, and visuospatial perception']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C2921138', 'cui_str': 'Visuospatial deficit'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C0589102', 'cui_str': 'Visual attention, function (observable entity)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",58.0,0.023474,"Intervention group showed positive immediate rehabilitation effect in 3 out of 4 visuospatial components: visual organization, visual attention, and visuospatial perception.","[{'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Saard', 'Affiliation': 'University of Tartu, Faculty of Medicine, Tartu, Estonia. Electronic address: mariannesaard@gmail.com.'}, {'ForeName': 'Madis', 'Initials': 'M', 'LastName': 'Bachmann', 'Affiliation': 'Cognitive Psychology Laboratory, Tallinn, Estonia.'}, {'ForeName': 'Kirsi', 'Initials': 'K', 'LastName': 'Sepp', 'Affiliation': 'University of Tartu, Faculty of Social Sciences, Institute of Education, Tartu, Estonia.'}, {'ForeName': 'Lisanna', 'Initials': 'L', 'LastName': 'Pertens', 'Affiliation': ""Tartu University Hospital Children's Clinic, Department of Pediatrics and Neurology, Tartu, Estonia.""}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Kornet', 'Affiliation': 'University of Tartu, Faculty of Medicine, Tartu, Estonia.'}, {'ForeName': 'Liina', 'Initials': 'L', 'LastName': 'Reinart', 'Affiliation': ""Tartu University Hospital Children's Clinic, Department of Pediatrics and Neurology, Tartu, Estonia; University of Tartu, Faculty of Social Sciences, Institute of Psychology, Tartu, Estonia.""}, {'ForeName': 'Christen', 'Initials': 'C', 'LastName': 'Kööp', 'Affiliation': 'University of Tartu, Faculty of Medicine, Tartu, Estonia.'}, {'ForeName': 'Anneli', 'Initials': 'A', 'LastName': 'Kolk', 'Affiliation': ""University of Tartu, Faculty of Medicine, Tartu, Estonia; Tartu University Hospital Children's Clinic, Department of Pediatrics and Neurology, Tartu, Estonia.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.106521'] 401,31904760,The Combination of Whey Protein and Dietary Fiber Does Not Alter Low-Grade Inflammation or Adipose Tissue Gene Expression in Adults with Abdominal Obesity.,"BACKGROUND Abdominal obesity is characterized by low-grade inflammation and plays a central role in the development of type 2 diabetes and cardiovascular diseases. Dietary factors can influence low-grade inflammation and affect adipose tissue function. AIM To investigate the separate and combined effects of whey protein and cereal fiber on inflammatory markers and adipose tissue gene expression in abdominal obesity. METHODS We performed a 12-week, double-blind, randomized controlled dietary intervention in 65 adults with abdominal obesity. The participants were randomized to 4 groups using a 2 × 2 factorial design; they received either 60 g/day of whey protein or maltodextrin in combination with high-fiber wheat bran products (30 g fiber/day) or low-fiber refined wheat products (10 g fiber/day). Plasma concentrations of tumor necrosis factor α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), interleukin 1 receptor antagonist (IL-1Ra), and adiponectin were measured before and after intervention. Changes in gene expression related to inflammation, insulin signaling, and lipid metabolism were measured in abdominal subcutaneous adipose tissue. RESULTS After intervention, TNF-α was reduced for both high-fiber groups compared with baseline, but did not significantly differ from the low-fiber groups. There were no differences in fasting or postprandial inflammatory markers between the groups. The relative gene expression of ribosomal protein S6 kinase B1 (S6K1) was increased after whey protein compared with maltodextrin consumption. CONCLUSION Intake of whey protein in combination with high cereal fiber content did not differentially affect low-grade inflammation or adipose tissue gene expression compared with maltodextrin and low fiber content in individuals with abdominal obesity.",2019,"The relative gene expression of ribosomal protein S6 kinase B1 (S6K1) was increased after whey protein compared with maltodextrin consumption. ","['individuals with abdominal obesity', 'Adults with Abdominal Obesity', '65 adults with abdominal obesity']","['whey protein and cereal fiber', 'Whey Protein and Dietary Fiber', 'maltodextrin', 'whey protein or maltodextrin in combination with high-fiber wheat bran products']","['low-grade inflammation or adipose tissue gene expression', 'relative gene expression of ribosomal protein S6 kinase B1 (S6K1', 'TNF-α', 'fasting or postprandial inflammatory markers', 'inflammation, insulin signaling, and lipid metabolism', 'Plasma concentrations of tumor necrosis factor α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein-1 (MCP-1), interleukin 1 receptor antagonist (IL-1Ra), and adiponectin']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0311277', 'cui_str': 'Central Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0007757', 'cui_str': 'Cereal Grain'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0012173', 'cui_str': 'Dietary Fiber'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0043138', 'cui_str': 'Wheat Bran'}]","[{'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0001527', 'cui_str': 'Fatty Tissue'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0073337', 'cui_str': 'S6-H4 Kinase'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0128897', 'cui_str': 'Chemokine (C-C Motif) Ligand 2'}, {'cui': 'C2317059', 'cui_str': 'Interleukin 1 receptor antagonist product'}, {'cui': 'C1704264', 'cui_str': 'IL-1 Inhibitor, Urine'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}]",65.0,0.044585,"The relative gene expression of ribosomal protein S6 kinase B1 (S6K1) was increased after whey protein compared with maltodextrin consumption. ","[{'ForeName': 'Elin', 'Initials': 'E', 'LastName': 'Rakvaag', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Rasmus', 'Initials': 'R', 'LastName': 'Fuglsang-Nielsen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Knud Erik', 'Initials': 'KE', 'LastName': 'Bach Knudsen', 'Affiliation': 'Department of Animal Science, Aarhus University, 8830 Tjele, Denmark.'}, {'ForeName': 'Kjeld', 'Initials': 'K', 'LastName': 'Hermansen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.'}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Gregersen', 'Affiliation': 'Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark.'}]",The review of diabetic studies : RDS,['10.1900/RDS.2019.15.83'] 402,31634729,"Multidisciplinary management improves anxiety, depression, medication adherence, and quality of life among patients with epilepsy in eastern China: A prospective study.","OBJECTIVE The objective of this study was to investigate the effect of a multidisciplinary program on anxiety, depression, medication adherence, and quality of life in patients with epilepsy in eastern China. METHODS A cohort of 184 patients with epilepsy from the epilepsy clinic of a tertiary hospital in eastern China completed this program, out of which 92 were randomized into the intervention group and 92 the control group. Patients in both groups received standard antiepileptic drugs (AEDs), while those of the intervention group received an additional 12-month multidisciplinary program developed by a group of the epileptologist, pharmacist, psychiatrist, and epilepsy specialist nurse. Patients were assessed both before and after the 12-month period. The Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), and the eight-item Morisky Medication Adherence Scale (MMAS-8) were used to assess the severity of depression, anxiety, and medication adherence, respectively, along with Quality of life in Epilepsy-31 (QOLIE-31) and self-reported seizure frequency for life quality and seizure severity. RESULTS The 12-month multidisciplinary program significantly reduced the number of patients with severe depression (p = 0.013) and anxiety (p = 0.002), increased the number of patients with moderate-to-high AED adherence (p = 0.006) and the overall QOLIE-31 score (p < 0.001) in the intervention group. Both groups demonstrated a significant increase in the number of patients with a low seizure frequency after the 12-month period (p < 0.001). CONCLUSION The 12-month multidisciplinary program offers an effective management strategy in improving psychiatric comorbidities, medication adherence, and quality of life in patients with epilepsy in eastern China.",2019,"The 12-month multidisciplinary program significantly reduced the number of patients with severe depression (p = 0.013) and anxiety (p = 0.002), increased the number of patients with moderate-to-high AED adherence (p = 0.006) and the overall QOLIE-31 score (p < 0.001) in the intervention group.","['184 patients with epilepsy from the epilepsy clinic of a tertiary hospital in eastern China completed this program, out of which 92', 'patients with epilepsy in eastern China']","['standard antiepileptic drugs (AEDs', 'multidisciplinary program', 'additional 12-month multidisciplinary program developed by a group of the epileptologist, pharmacist, psychiatrist, and epilepsy specialist nurse']","['number of patients with a low seizure frequency', 'overall QOLIE-31 score', 'Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI), and the eight-item Morisky Medication Adherence Scale (MMAS-8', 'severity of depression, anxiety, and medication adherence, respectively, along with Quality of life in Epilepsy-31 (QOLIE-31) and self-reported seizure frequency for life quality and seizure severity', 'psychiatric comorbidities, medication adherence, and quality of life', 'anxiety', 'anxiety, depression, medication adherence, and quality of life', 'number of patients with moderate-to-high AED adherence', 'number of patients with severe depression']","[{'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003299', 'cui_str': 'Antiepileptic Agents'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0033872', 'cui_str': 'Psychiatrist'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0222045'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0588008', 'cui_str': 'Severe depression (disorder)'}]",92.0,0.0453534,"The 12-month multidisciplinary program significantly reduced the number of patients with severe depression (p = 0.013) and anxiety (p = 0.002), increased the number of patients with moderate-to-high AED adherence (p = 0.006) and the overall QOLIE-31 score (p < 0.001) in the intervention group.","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Ding', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China. Electronic address: yiguo@zju.edu.cn.'}, {'ForeName': 'Qiaozhen', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Weijun', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}, {'ForeName': 'Meiping', 'Initials': 'M', 'LastName': 'Ding', 'Affiliation': 'Department of Neurology, Epilepsy Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, China.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.07.001'] 403,31140202,The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.,"OBJECTIVE Breast cancer survivors experience problems with cognition that interfere with daily life and can last for years. In the general population, obesity and diabetes are risk factors for cognitive decline, and weight loss can improve cognition; however, the impact of intentional weight loss on cancer survivors' cognition has not been tested. We investigated the impact of weight loss and metformin on changes in cognitive function in a sample of breast cancer survivors. METHODS Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design. Outcomes were changes in five cognitive domains from baseline to 6 months measured by objective neurocognitive tests. RESULTS There were no statistically significant intervention effects for the metformin or weight loss interventions in five neurocognitive domains. Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125). These effect modifications were independent of percent weight loss achieved during the 6-month study period. CONCLUSIONS This randomized controlled trial of weight loss and metformin interventions that examined changes to cognition among breast cancer survivors suggests that these interventions may not improve cognitive functioning among breast cancer survivors in general. However, weight loss may improve verbal functioning among individuals with a higher BMI.",2019,Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125).,"['breast cancer survivors in general', 'individuals with a higher BMI', 'Overweight/obese postmenopausal breast cancer survivors (n\xa0', '333', 'breast cancer survivors']","['weight loss and metformin', 'metformin interventions', 'weight loss intervention versus control and metformin versus placebo', 'metformin']","['weight loss', 'verbal functioning', 'objective neurocognitive tests', 'Baseline body mass index (BMI', 'verbal functioning for the weight loss', 'cognitive functioning']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C4517724', 'cui_str': 'Three hundred and thirty-three'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0872227', 'cui_str': 'Neurocognitive Tests'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031843', 'cui_str': 'function'}]",333.0,0.0365786,Baseline body mass index (BMI) was a significant effect modifier of the changes in verbal functioning for the weight loss (P = 0.009) and metformin interventions (P = 0.0125).,"[{'ForeName': 'Sheri J', 'Initials': 'SJ', 'LastName': 'Hartman', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, California.'}, {'ForeName': 'Sandahl H', 'Initials': 'SH', 'LastName': 'Nelson', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, California.'}, {'ForeName': 'Catherine R', 'Initials': 'CR', 'LastName': 'Marinac', 'Affiliation': 'Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'Loki', 'Initials': 'L', 'LastName': 'Natarajan', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, California.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Parker', 'Affiliation': 'UC San Diego Moores Cancer Center, UC San Diego, La Jolla, California.'}, {'ForeName': 'Ruth E', 'Initials': 'RE', 'LastName': 'Patterson', 'Affiliation': 'Department of Family Medicine and Public Health, UC San Diego, La Jolla, California.'}]",Psycho-oncology,['10.1002/pon.5129'] 404,32265240,"Biomarker-guided implementation of the KDIGO guidelines to reduce the occurrence of acute kidney injury in patients after cardiac surgery (PrevAKI-multicentre): protocol for a multicentre, observational study followed by randomised controlled feasibility trial.","INTRODUCTION Acute kidney injury (AKI) is a frequent complication after cardiac surgery with adverse short-term and long-term outcomes. Although prevention of AKI (PrevAKI) is strongly recommended, the optimal strategy is uncertain. The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommended a bundle of supportive measures in high-risk patients. In a single-centre trial, we recently demonstrated that the strict implementation of the KDIGO bundle significantly reduced the occurrence of AKI after cardiac surgery. In this feasibility study, we aim to evaluate whether the study protocol can be implemented in a multicentre setting in preparation for a large multicentre trial. METHODS AND ANALYSIS We plan to conduct a prospective, observational survey followed by a randomised controlled, multicentre, multinational clinical trial including 280 patients undergoing cardiac surgery with cardiopulmonary bypass. The purpose of the observational survey is to explore the adherence to the KDIGO recommendations in routine clinical practice. The second phase is a randomised controlled trial. The objective is to investigate whether the trial protocol is implementable in a large multicentre, multinational setting. The primary endpoint of the interventional part is the compliance rate with the protocol. Secondary endpoints include the occurrence of any AKI and moderate/severe AKI as defined by the KDIGO criteria within 72 hours after surgery, renal recovery at day 90, use of renal replacement therapy (RRT) and mortality at days 30, 60 and 90, the combined endpoint major adverse kidney events consisting of persistent renal dysfunction, RRT and mortality at day 90 and safety outcomes. ETHICS AND DISSEMINATION The PrevAKI multicentre study has been approved by the leading Research Ethics Committee of the University of Münster and the respective Research Ethics Committee at each participating site. The results will be used to design a large, definitive trial. TRIAL REGISTRATION NUMBER NCT03244514.",2020,"Secondary endpoints include the occurrence of any AKI and moderate/severe AKI as defined by the KDIGO criteria within 72 hours after surgery, renal recovery at day 90, use of renal replacement therapy (RRT) and mortality at days 30, 60 and 90, the combined endpoint major adverse kidney events consisting of persistent renal dysfunction, RRT and mortality at day 90 and safety outcomes. ETHICS AND DISSEMINATION ","['patients after cardiac surgery (PrevAKI-multicentre', 'high-risk patients', 'Kidney Disease', '280 patients undergoing cardiac surgery with cardiopulmonary bypass']",[],"['occurrence of any AKI and moderate/severe AKI as defined by the KDIGO criteria within 72 hours after surgery, renal recovery at day 90, use of renal replacement therapy (RRT) and mortality', 'combined endpoint major adverse kidney events consisting of persistent renal dysfunction, RRT and mortality at day 90 and safety outcomes.\nETHICS AND DISSEMINATION', 'occurrence of AKI', 'compliance rate with the protocol']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]",[],"[{'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0015000', 'cui_str': 'Ethics'}, {'cui': 'C0205221', 'cui_str': 'Disseminated'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]",280.0,0.211025,"Secondary endpoints include the occurrence of any AKI and moderate/severe AKI as defined by the KDIGO criteria within 72 hours after surgery, renal recovery at day 90, use of renal replacement therapy (RRT) and mortality at days 30, 60 and 90, the combined endpoint major adverse kidney events consisting of persistent renal dysfunction, RRT and mortality at day 90 and safety outcomes. ETHICS AND DISSEMINATION ","[{'ForeName': 'Mira', 'Initials': 'M', 'LastName': 'Küllmar', 'Affiliation': 'Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, Munster, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Massoth', 'Affiliation': 'Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, Munster, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Ostermann', 'Affiliation': ""Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.""}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Campos', 'Affiliation': ""Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.""}, {'ForeName': 'Neus', 'Initials': 'N', 'LastName': 'Grau Novellas', 'Affiliation': ""Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.""}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Thomson', 'Affiliation': ""Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Haffner', 'Affiliation': ""Department of Critical Care, King's College London, Guy's & St Thomas' Hospital, London, UK.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Arndt', 'Affiliation': 'Department of Anesthesiology and Operative Intensive Care, University Hospital Marburg, Marburg, UK.'}, {'ForeName': 'Hinnerk', 'Initials': 'H', 'LastName': 'Wulf', 'Affiliation': 'Anesthesiology & Intensive Care Medicine, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Irqsusi', 'Affiliation': 'Department of Cardiothoracic Surgery, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Germany.'}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Monaco', 'Affiliation': 'Intensive Care and Anesthesia Unit, Scientific Institute San Raffaele, Milano, Italy.'}, {'ForeName': 'Ambra', 'Initials': 'A', 'LastName': 'Di Prima', 'Affiliation': 'Intensive Care and Anesthesia Unit, Scientific Institute San Raffaele, Milano, Italy.'}, {'ForeName': 'Mercedes', 'Initials': 'M', 'LastName': 'Garcia Alvarez', 'Affiliation': 'Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Italiano', 'Affiliation': 'Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Cegarra SanMartin', 'Affiliation': 'Department of Anesthesiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Kunst', 'Affiliation': ""Department of Anesthesia, Critical Care and Pain, King's College London, London, UK.""}, {'ForeName': 'Shrijit', 'Initials': 'S', 'LastName': 'Nair', 'Affiliation': ""Department of Anesthesia, Critical Care and Pain, King's College London, London, UK.""}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': ""L'Acqua"", 'Affiliation': 'Department of Anesthesia and Critical Care, Centro Cardiologico Monzino IRCCS, Milano, Lombardia, Italy.'}, {'ForeName': 'Eric A J', 'Initials': 'EAJ', 'LastName': 'Hoste', 'Affiliation': 'ICU, Universiteit Gent, Gent, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Vandenberghe', 'Affiliation': 'ICU, Universiteit Gent, Gent, Belgium.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Honore', 'Affiliation': 'Department of Intensive Care, CHU Brugmann, Brussels, Belgium.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kellum', 'Affiliation': 'Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Lui', 'Initials': 'L', 'LastName': 'Forni', 'Affiliation': 'Department of Intensive Care Medicine, Royal Surrey County Hospital NHS Trust, Guildford, Surrey, UK.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Grieshaber', 'Affiliation': 'Department of Cardiac Surgery, Justus Liebig Universität Giessen Fachbereich Medizin, Giessen, Hessen, Germany.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Weiss', 'Affiliation': 'Department of Anaesthesiology, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Gerss', 'Affiliation': 'Institute of Biostatistics and Clinical Research, Westfälische Wilhelms-Universität Münster, Münster, Germany.'}, {'ForeName': 'Carola', 'Initials': 'C', 'LastName': 'Wempe', 'Affiliation': 'Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, Munster, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Meersch', 'Affiliation': 'Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, Munster, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zarbock', 'Affiliation': 'Anesthesiology, Intensive Care and Pain Medicine, Universitatsklinikum Munster, Munster, Nordrhein-Westfalen, Germany zarbock@uni-muenster.de.'}]",BMJ open,['10.1136/bmjopen-2019-034201'] 405,32266730,Gamification improves melanoma visual identification among high school students: Results from a randomized study.,"Identification of melanoma or worrisome moles is often taught as an important part of routine skin checks. We sought to evaluate the efficacy of gamified education vs. traditional ABCDEs education on melanoma identification and self-confidence in identifying worrisome moles. We report that in our cohort (n = 271), participants randomized to the gamified intervention were more likely to correctly identify melanoma and non-melanoma skin lesions than those randomized to the ABCDE control cohort (74.2% vs 63.5% correct, P < .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant. These novel findings have significant implications on improved ways to educate young patients on the visual identification of melanoma and worrisome moles.",2020,"< .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.",['high school students'],['gamified education vs. traditional ABCDEs education'],"['melanoma identification and self-confidence', 'correctly identify melanoma and non-melanoma skin lesions', 'melanoma visual identification', 'perceived confidence in self-identifying worrisome lesions']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0151779', 'cui_str': 'Malignant melanoma of skin'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",271.0,0.0582645,"< .0001) and perceived confidence in self-identifying worrisome lesions was slightly higher in the gamified group than the traditional group, though the trend was not significant.","[{'ForeName': 'Justin L', 'Initials': 'JL', 'LastName': 'Jia', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Shen', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Mika M', 'Initials': 'MM', 'LastName': 'Tabata', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kavita Y', 'Initials': 'KY', 'LastName': 'Sarin', 'Affiliation': 'Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA.'}]",Pediatric dermatology,['10.1111/pde.14158'] 406,30656404,"Low-dose dexmedetomidine provides hemodynamics stabilization during emergence and recovery from general anesthesia in patients undergoing carotid endarterectomy: a randomized double-blind, placebo-controlled trial.","PURPOSE Carotid artery stenosis is a major risk factor for ischemic stroke. Carotid endarterectomy protects patients with severe atherosclerotic carotid artery stenosis against stroke. In such patients, arterial blood pressure is often difficult to control and perioperative hemodynamic instability is associated with high morbidity and mortality after carotid endarterectomy. We performed a randomized double-blind placebo-control trial to evaluate the effects of low-dose dexmedetomidine on hemodynamic stability during the emergence and the recovery phases of general anesthesia in patients undergoing carotid endarterectomy. METHODS Forty-seven patients (68-84 years) were randomly assigned to receive either dexmedetomidine (DEX group) or 0.9% saline (control group). Infusion of dexmedetomidine 1.0 µg/kg/hr for 1 h, followed by 0.2 µg/kg/hr or the same dose of saline was started after carotid artery declamping in the DEX and in the control group, respectively. At the end of surgery, nicardipine was used to maintain systolic arterial pressure within 20% of preoperative values. We compared the maximum dose of nicardipine, time to extubation, plasma catecholamine levels, arterial blood gases, the Richmond Agitation Sedation Scales, visual analogue scale (VAS) in the postanesthesia care unit, and adverse events within 30-days between the control and Dex groups. RESULTS The baseline clinical characteristics were similar in the two groups. The maximum dose of nicardipine (p = 0.021), plasma norepinephrine level (p = 0.033), sedation score and VAS were significantly lower in the Dex group than the control group. There were no differences between the two groups regarding time to extubation, arterial blood gases, and adverse events. CONCLUSIONS Low-dose dexmedetomidine improves hemodynamic stability during emergence and recovery from general anesthesia in patients receiving carotid endarterectomy. TRIAL REGISTRY NUMBER UMIN000010607.",2019,"The maximum dose of nicardipine (p = 0.021), plasma norepinephrine level (p = 0.033), sedation score and VAS were significantly lower in the Dex group than the control group.","['protects patients with severe atherosclerotic carotid artery stenosis against stroke', 'patients undergoing carotid endarterectomy', 'Forty-seven patients (68-84\xa0years', 'patients receiving carotid endarterectomy']","['Carotid endarterectomy', 'placebo', 'nicardipine', 'dexmedetomidine (DEX group) or 0.9% saline', 'Dex', 'dexmedetomidine', 'low-dose dexmedetomidine']","['arterial blood pressure', 'systolic arterial pressure', 'time to extubation, plasma catecholamine levels, arterial blood gases, the Richmond Agitation Sedation Scales, visual analogue scale (VAS) in the postanesthesia care unit, and adverse events within 30-days', 'plasma norepinephrine level', 'sedation score and VAS', 'hemodynamic stability', 'time to extubation, arterial blood gases, and adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0007282', 'cui_str': 'Carotid Artery Narrowing'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0014099', 'cui_str': 'Carotid Endarterectomy'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0014099', 'cui_str': 'Carotid Endarterectomy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0028005', 'cui_str': 'Nicardipine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}]","[{'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0553891', 'cui_str': 'Tracheal Extubation'}, {'cui': 'C1446052', 'cui_str': 'Plasma catecholamine measurement'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C4720839', 'cui_str': 'Richmond agitation-sedation scale'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0262723', 'cui_str': 'Postanesthesia care (regime/therapy)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1275472', 'cui_str': 'Plasma norepinephrine measurement'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}]",,0.55899,"The maximum dose of nicardipine (p = 0.021), plasma norepinephrine level (p = 0.033), sedation score and VAS were significantly lower in the Dex group than the control group.","[{'ForeName': 'Shogo', 'Initials': 'S', 'LastName': 'Tsujikawa', 'Affiliation': 'Department of Anesthesiology, Yao Tokushukai General Hospital, 1-17, Wakakusamachi, Yao City, Osaka, 581-0011, Japan. seashogo@shirt.ocn.ne.jp.'}, {'ForeName': 'Kazutoshi', 'Initials': 'K', 'LastName': 'Ikeshita', 'Affiliation': 'Department of Anesthesiology, Yao Tokushukai General Hospital, 1-17, Wakakusamachi, Yao City, Osaka, 581-0011, Japan.'}]",Journal of anesthesia,['10.1007/s00540-019-02612-w'] 407,30844878,"Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.","OBJECTIVE Opioid use disorder (OUD) is associated with physical, social, psychological, and economic burden. This analysis assessed the effects of RBP-6000, referred to as BUP-XR (extended-release buprenorphine), a subcutaneously injected, monthly buprenorphine treatment for OUD compared with placebo on patient-centered outcomes measuring meaningful life changes. METHODS Patient-centered outcomes were collected in a 24-week, phase 3, placebo-controlled study assessing the efficacy, safety, and tolerability of BUP-XR 300/300 mg (6 × 300 mg) and 300/100 mg (2 × 300 mg followed by 4 × 100 mg) injections in treatment-seeking participants with moderate-to-severe OUD. Measures included the EQ-5D-5L, SF-36v2, Medication Satisfaction Questionnaire, employment/insurance status, and healthcare resource utilization (HCRU). Changes from baseline to end of study were compared across treatment arms, using mixed models for repeated measures. RESULTS Participants receiving BUP-XR (n = 389) versus placebo (n = 98) had significantly greater changes from baseline on the EQ-5D-5L index (300/300 mg: difference = 0.0636, P = 0.003), EQ-5D-5L visual analog scale (300/300 mg: difference = 5.9, P = 0.017; 300/100 mg: difference = 7.7, P = 0.002), and SF-36v2 physical component summary score (300/300 mg: difference = 3.8, P < 0.001; 300/100 mg: difference = 3.2, P = 0.002). Satisfaction was significantly higher for participants receiving BUP-XR 300/300 mg (88%, P < 0.001) and 300/100 mg (88%, P < 0.001) than placebo (46%). Employment and percentage of insured participants increased by 10.8% and 4.1% with BUP-XR 300/300 mg and 10.0% and 4.7% with 300/100 mg but decreased by 12.6% and 8.4% with placebo. Participants receiving BUP-XR compared with placebo had significantly fewer hospital days per person-year observed. CONCLUSIONS These results show the feasibility of measuring patient-centered life changes in substance use disorder clinical studies. Participants receiving up to 6 monthly injections of BUP-XR, compared with placebo, reported better health, increased medication satisfaction, increased employment, and decreased healthcare utilization.",2019,"Participants receiving up to 6 monthly injections of BUP-XR, compared with placebo, reported better health, increased medication satisfaction, increased employment, and decreased healthcare utilization.","['participants with moderate-to-severe OUD', 'Patient-centered outcomes', 'Participants receiving BUP-XR']","['BUP-XR 300/300\u200amg (6\u200a×\u200a300\u200amg) and 300/100\u200amg (2\u200a×\u200a300\u200amg followed by 4\u200a×\u200a100\u200amg) injections in treatment-seeking', 'placebo', 'buprenorphine', 'BUP-XR', 'Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo']","['efficacy, safety, and tolerability', 'EQ-5D-5L, SF-36v2, Medication Satisfaction Questionnaire, employment/insurance status, and healthcare resource utilization (HCRU', 'Satisfaction', 'hospital days per person-year observed', 'EQ-5D-5L index', 'EQ-5D-5L visual analog scale', 'better health, increased medication satisfaction, increased employment, and decreased healthcare utilization', 'SF-36v2 physical component summary score']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0376629', 'cui_str': 'Insurance Status'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.179379,"Participants receiving up to 6 monthly injections of BUP-XR, compared with placebo, reported better health, increased medication satisfaction, increased employment, and decreased healthcare utilization.","[{'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Ling', 'Affiliation': 'UCLA David Geffen School of Medicine, Department of Family Medicine, Center for Behavioral & Addiction Medicine, Los Angeles, CA (WL); Indivior Inc., Richmond, VA (VRN, SML, CH); Pharmerit International, Bethesda, MD (CTS); RTI Health Solutions, Research Triangle Park, NC (NAR); Pharmerit International, Newton, MA (YCY); Artemis Institute for Clinical Research, San Diego, CA (VM).'}, {'ForeName': 'Vijay R', 'Initials': 'VR', 'LastName': 'Nadipelli', 'Affiliation': ''}, {'ForeName': 'Caitlyn T', 'Initials': 'CT', 'LastName': 'Solem', 'Affiliation': ''}, {'ForeName': 'Naoko A', 'Initials': 'NA', 'LastName': 'Ronquest', 'Affiliation': ''}, {'ForeName': 'Yu-Chen', 'Initials': 'YC', 'LastName': 'Yeh', 'Affiliation': ''}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Learned', 'Affiliation': ''}, {'ForeName': 'Vishaal', 'Initials': 'V', 'LastName': 'Mehra', 'Affiliation': ''}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Heidbreder', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000517'] 408,32013722,Teaching Undergraduate Clinicians Empirically Supported Practices for Preschool Vocabulary Instruction.,"Purpose To incorporate evidence-based practice into clinical settings, there is a need for efficient, effective ways to share information from research to speech-language pathologists (SLPs) and to students preparing to become SLPs. The purpose of this study was to implement and evaluate a method for teaching undergraduate student clinicians to use empirically supported practices in vocabulary instruction during shared storybook reading with preschoolers. Method Undergraduate students enrolled in a semester-long preschool practicum participated in the study. In Study 1, 11 students participated in a multiple-baseline, single-case design. In Study 2, an additional 10 students were included in a quasi-experimental group design. All students completed prerecorded, online teaching modules that taught empirically supported practices for teaching vocabulary during shared storybook reading. Half of the students received weekly e-mails with performance feedback. Targeted practices included selection of appropriate vocabulary targets, explicit teaching, and use of interactive teaching strategies. Results In Study 1, treatment effects were observed for targeted practices for many of the student clinicians. In Study 2, group comparisons indicated an effect of e-mail performance feedback for 1 of 3 outcomes with a large effect size. Conclusion Prerecorded teaching modules may be an efficient, effective way to teach specific empirically supported practices to undergraduate student clinicians. E-mail feedback might improve use of taught practices for some students or for some practices. Future studies can examine the potential of these types of teaching modules for other outcomes or with groups of practicing SLPs.",2020,"Conclusion Prerecorded teaching modules may be an efficient, effective way to teach specific empirically supported practices to undergraduate student clinicians.","['Method Undergraduate students enrolled in a semester-long preschool practicum participated in the study', 'additional 10 students were included in a quasi-experimental group design', 'teaching undergraduate student clinicians to use empirically supported practices in vocabulary instruction during shared storybook reading with preschoolers', '11 students participated in a multiple-baseline, single-case design']",[],[],"[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}]",[],[],11.0,0.0292127,"Conclusion Prerecorded teaching modules may be an efficient, effective way to teach specific empirically supported practices to undergraduate student clinicians.","[{'ForeName': 'Elizabeth Spencer', 'Initials': 'ES', 'LastName': 'Kelley', 'Affiliation': 'Department of Speech, Language and Hearing Sciences, University of Missouri, Columbia.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Hull', 'Affiliation': 'Department of Speech, Language and Hearing Sciences, University of Missouri, Columbia.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Eubank', 'Affiliation': 'Department of Speech, Language and Hearing Sciences, University of Missouri, Columbia.'}, {'ForeName': 'Greta', 'Initials': 'G', 'LastName': 'Roettgen', 'Affiliation': 'Department of Speech, Language and Hearing Sciences, University of Missouri, Columbia.'}]","Language, speech, and hearing services in schools",['10.1044/2019_LSHSS-19-00061'] 409,30603828,Influence of intraoperative sevoflurane or desflurane on postoperative sore throat: a prospective randomized study.,"PURPOSE Tracheal intubation for general anesthesia causes postoperative sore throat. The purpose of this study was to evaluate the effect of sevoflurane and desflurane on prevalence of postoperative sore throat in patients after general anesthesia. METHODS Ninety-six patients scheduled for orthopedic lower extremity surgery under general anesthesia were assigned to sevoflurane group or desflurane group. In the sevoflurane group (n = 48), sevoflurane was used as a maintenance anesthetic agent. In the desflurane group (n = 48), desflurane was used. Prevalence of sore throat, number of patients with rescue analgesics, and analgesics requirements were evaluated. RESULTS The overall prevalence of postoperative sore throat in the sevoflurane group was lower than that in the desflurane group [21 (44%) vs. 32 (67%), p = 0.024]. The prevalence of sore throat at postoperative 4 h in the sevoflurane group was lower than that in the desflurane group [6 (13%) vs. 18 (38%), p = 0.005]. The number of patients requiring rescue analgesics was lower in the sevoflurane group [25 (52%) vs. 36 (75%), p = 0.020]. The requirement of diclofenac was also lower in the sevoflurane group (30 ± 37 mg vs. 47 ± 40 mg, p = 0.031). CONCLUSIONS We have shown that sevoflurane was associated with less frequent sore throat than desflurane in patients undergoing orthopedic lower extremity surgery.",2019,"The prevalence of sore throat at postoperative 4 h in the sevoflurane group was lower than that in the desflurane group [6 (13%) vs. 18 (38%), p = 0.005].","['general anesthesia causes postoperative sore throat', 'patients after general anesthesia', 'patients undergoing orthopedic lower extremity surgery', 'Ninety-six patients scheduled for orthopedic lower extremity surgery under general anesthesia']","['sevoflurane and desflurane', 'sevoflurane group or desflurane', 'sevoflurane', 'intraoperative sevoflurane or desflurane', 'desflurane', 'diclofenac']","['Prevalence of sore throat, number of patients with rescue analgesics, and analgesics requirements', 'number of patients requiring rescue analgesics', 'postoperative sore throat', 'prevalence of sore throat at postoperative 4\xa0h', 'overall prevalence of postoperative sore throat']","[{'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0242429', 'cui_str': 'Sore Throat'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",96.0,0.0921079,"The prevalence of sore throat at postoperative 4 h in the sevoflurane group was lower than that in the desflurane group [6 (13%) vs. 18 (38%), p = 0.005].","[{'ForeName': 'Ji-Hoon', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, 56 Dalseung-ro, Joong-gu, Daegu, 41931, Republic of Korea.'}, {'ForeName': 'Yong-Cheol', 'Initials': 'YC', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, 56 Dalseung-ro, Joong-gu, Daegu, 41931, Republic of Korea.'}, {'ForeName': 'Jiwon', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, 56 Dalseung-ro, Joong-gu, Daegu, 41931, Republic of Korea.'}, {'ForeName': 'Sangbaek', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, 56 Dalseung-ro, Joong-gu, Daegu, 41931, Republic of Korea.'}, {'ForeName': 'Hyun-Chang', 'Initials': 'HC', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, 56 Dalseung-ro, Joong-gu, Daegu, 41931, Republic of Korea. onidori1979@gmail.com.'}]",Journal of anesthesia,['10.1007/s00540-018-2600-y'] 410,32255549,"First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.","MW01-6-189WH (MW189) is a novel central nervous system-penetrant small-molecule drug candidate that selectively attenuates stressor-induced proinflammatory cytokine overproduction and is efficacious in intracerebral hemorrhage and traumatic brain injury animal models. We report first-in-human, randomized, double-blind, placebo-controlled phase 1 studies to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending intravenous doses of MW189 in healthy adult volunteers. MW189 was safe and well tolerated in single and multiple doses up to 0.25 mg/kg, with no clinically significant concerns. The most common drug-related treatment-emergent adverse event was infusion-site reactions, likely related to drug solution acidity. No clinically concerning changes were seen in vital signs, electrocardiograms, physical or neurological examinations, or safety laboratory results. PK analysis showed dose-proportional increases in plasma concentrations of MW189 after single or multiple doses, with approximately linear kinetics and no significant drug accumulation. Steady state was achieved by dose 3 for all dosing cohorts. A pilot pharmacodynamic study administering low-dose endotoxin to induce a systemic inflammatory response was done to evaluate the effects of a single intravenous dose of MW189 on plasma cytokine levels. MW189 treatment resulted in lower levels of the proinflammatory cytokine TNF-α and higher levels of the anti-inflammatory cytokine IL-10 compared with placebo treatment. The outcomes are consistent with the pharmacological mechanism of MW189. Overall, the safety profile, PK properties, and pharmacodynamic effect support further development of MW189 for patients with acute brain injury.",2020,MW189 treatment resulted in lower levels of the proinflammatory cytokine TNF-α and higher levels of the anti-inflammatory cytokine IL-10 compared with placebo treatment.,"['healthy adult volunteers', 'Healthy Adult Volunteers', 'patients with acute brain injury']","['MW189', 'endotoxin', 'placebo', 'MW01-6-189WH (MW189']","['plasma concentrations of MW189', 'vital signs, electrocardiograms, physical or neurological examinations, or safety laboratory results', 'safety, tolerability, and pharmacokinetics (PK', 'safety profile, PK properties, and pharmacodynamic effect', 'safe and well tolerated', 'plasma cytokine levels', 'proinflammatory cytokine TNF-α and higher levels of the anti-inflammatory cytokine IL-10']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085742', 'cui_str': 'Acute Brain Injuries'}]","[{'cui': 'C0014264', 'cui_str': 'Bacterial endotoxin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0027853', 'cui_str': 'Neurological examination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}]",,0.286496,MW189 treatment resulted in lower levels of the proinflammatory cytokine TNF-α and higher levels of the anti-inflammatory cytokine IL-10 compared with placebo treatment.,"[{'ForeName': 'Linda J', 'Initials': 'LJ', 'LastName': 'Van Eldik', 'Affiliation': 'Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Lumy', 'Initials': 'L', 'LastName': 'Sawaki', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Kentucky, Lexington, Kentucky, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Bowen', 'Affiliation': 'Bluegrass Research Consultants, Inc., Versailles, Kentucky, USA.'}, {'ForeName': 'Daniel T', 'Initials': 'DT', 'LastName': 'Laskowitz', 'Affiliation': 'Department of Neurology, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Noveck', 'Affiliation': 'Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.'}, {'ForeName': 'Byron', 'Initials': 'B', 'LastName': 'Hauser', 'Affiliation': 'Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Jordan', 'Affiliation': 'Duke Early Phase Clinical Research Unit, Durham, North Carolina, USA.'}, {'ForeName': 'Tracy G', 'Initials': 'TG', 'LastName': 'Spears', 'Affiliation': 'Duke Clinical Research Institute, Durham, North Carolina, USA.'}, {'ForeName': 'Huali', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Duke Clinical Research Institute, Durham, North Carolina, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Watt', 'Affiliation': 'Duke Clinical Research Institute, Durham, North Carolina, USA.'}, {'ForeName': 'Shruti', 'Initials': 'S', 'LastName': 'Raja', 'Affiliation': 'Department of Neurology, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'Saktimayee M', 'Initials': 'SM', 'LastName': 'Roy', 'Affiliation': 'Department of Pharmacology, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'D Martin', 'Initials': 'DM', 'LastName': 'Watterson', 'Affiliation': 'Department of Pharmacology, Northwestern University, Chicago, Illinois, USA.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Guptill', 'Affiliation': 'Department of Neurology, Duke University, Durham, North Carolina, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.795'] 411,30838446,"The analgesic efficacy and duration of lidocaine on vascular pain induced by hypertonic saline infusion: a double-blinded, randomized control trial.","PURPOSE To determine the analgesic efficacy and analgesic duration of lidocaine 20 mg and 40 mg on eliminating the vascular pain associated with hypertonic saline infusion. METHOD Patients who complained pain during infusion of hypertonic saline were randomized into three groups. They received normal saline (Group C), or lidocaine 20 mg (Group L20), or lidocaine 40 mg (Group L40). An electronic stopwatch was used to record the time to onset (T1) and the time to termination (T2) of the analgesic effect, and the analgesic duration (AD) was calculated as T2 - T1. RESULTS The incidence of pain elimination was significantly higher in both of the lidocaine groups (83.3 and 56.1% in Groups L40 and L20, respectively) than in the saline group (16.3%). Furthermore, lidocaine 40 mg was significantly more effective than 20 mg in eliminating the pain. The analgesic duration was significantly longer in Group L40 than in Group L20 (211.4 ± 50.2 vs. 130.3 ± 39.5 s, P < 0.001) and Group C (211.4 ± 50.2 vs. 45.1 ± 14.5 s, P < 0.001), and the analgesic duration in Group L20 was significantly longer than in Group C (P < 0.001). The incidence of transient tinnitus/dizziness was significantly higher in Group L40 than in Group L20 (19.0 vs. 2.4%, P < 0.05). CONCLUSION A single bolus of Lidocaine was effective in eliminating the pain induced by hypertonic saline infusion, but just for a short period of time. Lidocaine (without venous occlusion) only provides a short analgesic duration for local vein.",2019,"The analgesic duration was significantly longer in Group L40 than in Group L20 (211.4 ± 50.2 vs. 130.3 ± 39.5 s, P < 0.001) and Group C (211.4 ± 50.2 vs. 45.1 ± 14.5 s, P < 0.001), and the analgesic duration in Group L20 was significantly longer than in Group C (P < 0.001).",['Patients who complained pain during infusion of'],"['Lidocaine', 'lidocaine 20\xa0mg (Group L20), or lidocaine', 'lidocaine', 'normal saline', 'hypertonic saline infusion', 'hypertonic saline']","['analgesic efficacy', 'incidence of pain elimination', 'incidence of transient tinnitus/dizziness', 'analgesic duration (AD', 'vascular pain', 'analgesic duration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0040264', 'cui_str': 'Ringing-Buzzing-Tinnitus'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0858765', 'cui_str': 'Vascular pain'}]",,0.19033,"The analgesic duration was significantly longer in Group L40 than in Group L20 (211.4 ± 50.2 vs. 130.3 ± 39.5 s, P < 0.001) and Group C (211.4 ± 50.2 vs. 45.1 ± 14.5 s, P < 0.001), and the analgesic duration in Group L20 was significantly longer than in Group C (P < 0.001).","[{'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Song', 'Affiliation': 'Department of Anesthesia, First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Nanchang, Jiangxi, China. pig.12345@163.com.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesia, First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Nanchang, Jiangxi, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesia, First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Nanchang, Jiangxi, China.'}]",Journal of anesthesia,['10.1007/s00540-019-02628-2'] 412,31953540,Very Low and Higher Carbohydrate Diets Promote Differential Appetite Responses in Adults with Type 2 Diabetes: A Randomized Trial.,"BACKGROUND Effects of very low carbohydrate (VLC) diets on appetite response in individuals with type 2 diabetes remain unclear. OBJECTIVE A secondary analysis was conducted to determine appetite responses to an energy-restricted [30% of energy (%E) deficit] very low carbohydrate (VLC) diet compared with a higher carbohydrate (HC) diet in adults who were overweight or obese with type 2 diabetes. METHODS Forty-four men and 40 women (mean ± SD, age: 58.7 ± 6.6 y; weight: 100.4 ± 15.5 kg; BMI: 34.5 ± 4.1 kg/m2; glycated hemoglobin: 7.3 ± 1.0%; duration of diabetes: 6.7 ± 5.6 y) were randomly assigned to diets categorized as VLC [14%E carbohydrate (<50 g/d), 28%E protein, 58%E fat (<10%E saturated fat)], or energy-matched HC [53%E carbohydrate, 17%E protein, 30%E fat (<10%E saturated fat)] combined with progressive multicomponent exercise (60 min; 3 d/wk). Body weight, average weekly ""daily fasting"" and ""daily overall"" appetite perceptions (hunger, fullness, prospective consumption, and desire to eat-visual analog scales) were assessed at baseline and after 4 and 16 wk. Changes between diets over time were assessed using repeated measures ANOVA. RESULTS Significant decreases in body weight did not differ between groups (VLC: -11.0 ± 5.4 kg/16 wk compared with HC: -10.1 ± 4.3 kg/16 wk, P = 0.40). Compared with HC, VLC had greater decreases in ""daily overall"" ratings of fullness (P time × diet < 0.01), such that scores were higher in HC at Week 4 (VLC:48 ± 3 vs HC:56 ± 3 mm, P = 0.001) and 16 (VLC:51 ± 2 vs HC:57 ± 3 mm, P = 0.019). Compared with HC, VLC had greater increases in prospective consumption ratings (P time × diet = 0.03), such that scores were lower in HC at Week 4 (VLC:33 ± 2 vs HC:28 ± 2 mm, P = 0.008), but not at Week 16 (VLC:33 ± 2 vs HC 31 ± 2 mm, P = 0.289). CONCLUSIONS In the context of energy restriction, both HC and VLC energy-matched diets promoted comparable effects on fasting perceptions of appetite, but the HC diet resulted in greater ""daily overall"" fullness and reduced prospective consumption. Further research is required to evaluate the effects of ad libitum diets differing in amounts of carbohydrate on appetite response in populations with type 2 diabetes. This trial was registered at www.anzctr.org.au as ACTRN12612000369820.",2020,"There was no difference between diet groups in ""daily fasting"" appetite ratings (P ≥ 0.30) or ""daily overall"" hunger and desire to eat (P ","['Forty-four men and 40 women (mean\xa0±\xa0SD, age: 58.7\xa0±', 'individuals with type 2 diabetes remain unclear', 'Adults with Type 2 Diabetes', 'populations with type 2 diabetes', '6.6 y; weight: 100.4\xa0±\xa015.5\xa0kg; BMI: 34.5\xa0±\xa04.1\xa0kg/m2; glycated hemoglobin: 7.3\xa0±\xa01.0%; duration of diabetes: 6.7\xa0±\xa05.6 y', 'adults who were overweight or obese with type 2 diabetes']","['low carbohydrate (VLC) diets', 'low carbohydrate (VLC) diet compared with a higher carbohydrate (HC) diet', 'HC', 'HC, VLC', 'Carbohydrate Diets', 'diets categorized as VLC [14%E carbohydrate (<50\xa0g/d), 28%E protein, 58%E fat (<10%E saturated fat)], or energy-matched HC [53%E carbohydrate, 17%E protein, 30%E fat (<10%E saturated fat)] combined with progressive multicomponent exercise']","['daily overall"" ratings of fullness', 'Body weight, average weekly ""daily fasting"" and ""daily overall"" appetite perceptions (hunger, fullness, prospective consumption, and desire to eat-visual analog scales', 'body weight', 'daily overall"" hunger and desire to eat (P', 'appetite response', 'daily fasting"" appetite ratings', 'daily overall"" fullness', 'prospective consumption ratings', 'appetite responses']","[{'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4517823', 'cui_str': '6.6 (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517794', 'cui_str': '5.6 (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0259836', 'cui_str': 'Diet, Carbohydrate-Restricted'}, {'cui': 'C0259835', 'cui_str': 'High carbohydrate diet (finding)'}, {'cui': 'C0301577', 'cui_str': 'Carbohydrate diet (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0597423', 'cui_str': 'Fatty Acids, Saturated'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}]",44.0,0.0441091,"There was no difference between diet groups in ""daily fasting"" appetite ratings (P ≥ 0.30) or ""daily overall"" hunger and desire to eat (P ","[{'ForeName': 'Noor A', 'Initials': 'NA', 'LastName': 'Struik', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation - Health and Biosecurity, North Ryde, Australia.'}, {'ForeName': 'Grant D', 'Initials': 'GD', 'LastName': 'Brinkworth', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation - Health and Biosecurity, North Ryde, Australia.'}, {'ForeName': 'Campbell H', 'Initials': 'CH', 'LastName': 'Thompson', 'Affiliation': 'Discipline of Medicine, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Buckley', 'Affiliation': 'Alliance for Research in Exercise, Nutrition and Activity (ARENA), Sansom Institute for Health Research, University of South Australia, Adelaide, Australia.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Wittert', 'Affiliation': 'Discipline of Medicine, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Natalie D', 'Initials': 'ND', 'LastName': 'Luscombe-Marsh', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation - Health and Biosecurity, Adelaide, Australia.'}]",The Journal of nutrition,['10.1093/jn/nxz344'] 413,32267058,"Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.","Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are recommended for glycaemic management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP-1RA, has recently been approved for clinical use, based on the results of the randomized, Phase 3a Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) clinical trials. The PIONEER programme tested oral semaglutide in patients with T2D of duration ranging from 3.5 to 15 years, from monotherapy through to insulin add-on, in global populations and two trials dedicated to Japanese patients. Outcomes (glycated haemoglobin [HbA1c] and body weight reduction, plus other relevant efficacy and safety endpoints) were tested against both placebo and active standard-of-care medications. A separate trial evaluated the cardiovascular safety of oral semaglutide in patients with T2D at high cardiovascular risk. Over periods of treatment up to 78 weeks, oral semaglutide 7 and 14 mg once daily reduced HbA1c and body weight across the spectrum of T2D, and improved other diabetes-related endpoints, such as fasting plasma glucose. Oral semaglutide provided significantly better efficacy than placebo and commonly used glucose-lowering medications from the dipeptidyl peptidase-4 inhibitor (sitagliptin) and sodium-glucose co-transporter-2 inhibitor (empagliflozin) classes, as well as the subcutaneous GLP-1RAs liraglutide and dulaglutide. Oral semaglutide was well tolerated in line with the known safety profile of GLP-1RAs, with transient gastrointestinal events being the most common side effects reported. Cardiovascular safety was demonstrated for oral semaglutide in patients with cardiovascular disease or high cardiovascular risk. The results of the PIONEER programme suggest that oral semaglutide is efficacious and well tolerated for glycaemic control of T2D. The availability of oral semaglutide may help to broaden treatment choice and facilitate adoption of earlier GLP-1RA treatment in the paradigm of T2D management.",2020,"Over periods of treatment up to 78 weeks, oral semaglutide 7 and 14 mg once daily reduced HbA 1c and body weight across the spectrum of T2D, and improved other diabetes-related endpoints, such as fasting plasma glucose.","['patients with type 2 diabetes (T2D', 'patients with type 2 diabetes', 'patients with cardiovascular disease or high cardiovascular risk', 'patients with T2D at high cardiovascular risk', 'patients with T2D of duration ranging from 3.5 to 15\u2009years, from monotherapy through to insulin add-on, in global populations and two trials dedicated to Japanese patients']","['Glucagon-like peptide-1 receptor agonists (GLP-1RAs', 'once-daily oral semaglutide', 'placebo', 'oral semaglutide']","['Efficacy, safety and cardiovascular outcomes', 'Outcomes (glycated haemoglobin', 'Cardiovascular safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}]","[{'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0018301', 'cui_str': 'Guadeloupe island'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0017853', 'cui_str': 'Glycosylated hemoglobin'}]",,0.0294568,"Over periods of treatment up to 78 weeks, oral semaglutide 7 and 14 mg once daily reduced HbA 1c and body weight across the spectrum of T2D, and improved other diabetes-related endpoints, such as fasting plasma glucose.","[{'ForeName': 'Tina K', 'Initials': 'TK', 'LastName': 'Thethi', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pratley', 'Affiliation': 'AdventHealth Translational Research Institute, Orlando, Florida, USA.'}, {'ForeName': 'Juris J', 'Initials': 'JJ', 'LastName': 'Meier', 'Affiliation': 'Diabetes Centre Bochum-Hattingen, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14054'] 414,32267071,A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic medications: A lesson from real-world experience.,"BACKGROUND Chinese guidelines for the treatment of type 2 diabetes (T2D) recommend basal or premixed insulins as insulin starters after failed oral antihyperglycaemic medication (OAM). This pragmatic study compared effectiveness and safety of add-on basal insulin analog (BI) and mid-mixture insulin analog (MMI; 50:50 premixed insulin) as starter insulin regimens in Chinese patients with T2D in a real-world setting. MATERIALS AND METHODS This was a multicentre, open-label, randomized, parallel, pragmatic trial. Patients receiving OAMs were randomized 1:1 to BI (n = 410) or MMI (n = 404) for 24 weeks. Insulin titration and OAM adjustment were determined by investigators following usual standard-of-care. The primary outcome was change in glycated haemoglobin (HbA1c) from baseline. RESULTS Least-squares mean changes in HbA1c from baseline to week 24 were -2.00% and -2.15% for BI and MMI groups, respectively (P = .13). The MMI group demonstrated a greater reduction in concomitant OAM therapies used than BI group (53.8% vs. 35.3%, respectively; P < .001). Very limited daily insulin dose increments were observed from baseline to week 24 in both BI and MMI groups (2.5 U/day and 1.8 U/day, respectively). Although both insulin analogs were well-tolerated without severe hypoglycaemia, small weight gains were seen with both treatments. Higher total hypoglycaemia rates were noticed with the MMI group, while nocturnal hypoglycaemia events were comparable. CONCLUSIONS In real-world settings, BI and MMI provided similar improvement in glucose control without conceding hypoglycaemia. The BI group received a greater number of OAMs in real-world settings. Limited insulin dose titration was observed, while more adjustments occurred with OAM usage.",2020,"The MMI group demonstrated greater reduction in concomitant OAM therapies used than BI group (53.8% vs 35.3%, respectively; P < 0.001).","['Patients receiving OAMs', 'Chinese patients with T2D in a real-world setting', 'patients with type 2 diabetes uncontrolled with oral antihyperglycemic medications']","['basal insulin analog (BI) and mid-mixture insulin analog (MMI; 50/50 premixed insulin', 'mid-mixture insulin and basal insulin treatment', 'MMI']","['tolerated without severe hypoglycemia, small weight gains', 'Insulin titration and OAM adjustment', 'glycated hemoglobin (HbA1c', 'concomitant OAM therapies', 'nocturnal hypoglycemia events', 'total hypoglycemia rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0342315', 'cui_str': 'Nocturnal hypoglycemia'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",,0.0741634,"The MMI group demonstrated greater reduction in concomitant OAM therapies used than BI group (53.8% vs 35.3%, respectively; P < 0.001).","[{'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology, Peking University International Hospital, Beijing, China.'}, {'ForeName': 'Yujin', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Endocrinology, First Hospital, affiliate with Henan University of Science and Technology, Luoyang, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Lou', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.'}, {'ForeName': 'Linong', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': ""Department of Endocrinology, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Lulu', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Endocrinology, Hubei Provincial, Clinical Research Center for Diabetes and Metabolic Disorders, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14052'] 415,30882553,Randomized Trial of an Innovative Electronic Screening and Brief Intervention for Reducing Drinking Among Women of Childbearing Age.,"OBJECTIVES To evaluate the efficacy of an innovative, self-administered, electronic Screening and Brief Intervention (e-SBI) in English and Spanish, ""DrinkWise,"" for reducing drinking among nonpregnant women of childbearing age. METHODS A parallel design, phase 1 trial included 185 nonpregnant women reporting risky drinking (8 or more drinks in a week or 3 or more drinks in a day) who were recruited from 2 publicly funded Nutritional Assistance for Women, Infants and Children (WIC) program sites in the United States from 2016 to 2017. Participants were 18 to 44 years in age, 75% of Hispanic ethnicity, 44% Spanish speakers, 30% had not completed high school, and 15% were currently breastfeeding. Participants were randomized to receive (intervention condition, n = 99) or not receive (control condition, no intervention, n = 86) DrinkWise and followed at 3 and 6 months. RESULTS Women receiving DrinkWise had greater reductions in the odds of self-reported weekly alcohol use (odds ratio [OR] = 0.22, SE = 0.12, P < 0.01) and heavy alcohol use (OR = 0.23, SE = 0.14, P < 0.05) at 6-month follow-up than controls, with no group differences at 3-month follow-up. Compared with heavy drinking controls, heavy drinkers receiving DrinkWise showed a trend (P = 0.06) for greater reductions in drink (pour) size from 3- to 6-month follow-up. CONCLUSIONS DrinkWise may be efficacious in reducing drinking among low-income women of childbearing age and provides a low-cost tool for increasing access to recommended SBI among childbearing-age women. Studies should continue to build DrinkWise's evidence base. TRIAL REGISTRATION ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02337361.",2019,"Compared with heavy drinking controls, heavy drinkers receiving DrinkWise showed a trend (P = 0.06) for greater reductions in drink (pour) size from 3- to 6-month follow-up. ","['Women of Childbearing Age', 'Participants were 18 to 44 years in age, 75% of Hispanic ethnicity, 44% Spanish speakers, 30% had not completed high school, and 15% were currently breastfeeding', 'childbearing-age women', '185 nonpregnant women reporting risky drinking (8 or more drinks in a week or 3 or more drinks in a day) who were recruited from 2 publicly funded Nutritional Assistance for Women, Infants and Children (WIC) program sites in the United States from 2016 to 2017', 'nonpregnant women of childbearing age']","['innovative, self-administered, electronic Screening and Brief Intervention (e-SBI', 'Innovative Electronic Screening and Brief Intervention', 'receive (intervention condition, n\u200a=\u200a99) or not receive (control condition, no intervention, n\u200a=\u200a86) DrinkWise and followed at 3 and 6 months']","['heavy alcohol use', 'drink (pour) size']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C1444661', 'cui_str': 'Not completed'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1623040', 'cui_str': 'Breastfeeding (mother)'}, {'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}]",185.0,0.047543,"Compared with heavy drinking controls, heavy drinkers receiving DrinkWise showed a trend (P = 0.06) for greater reductions in drink (pour) size from 3- to 6-month follow-up. ","[{'ForeName': 'Madhabika B', 'Initials': 'MB', 'LastName': 'Nayak', 'Affiliation': 'Alcohol Research Group, Public Health Institute, Emeryville, CA.'}, {'ForeName': 'Lee A', 'Initials': 'LA', 'LastName': 'Kaskutas', 'Affiliation': ''}, {'ForeName': 'Amy A', 'Initials': 'AA', 'LastName': 'Mericle', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000518'] 416,31504118,Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.,"BACKGROUND Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6 inhibitor in development to proactively preserve HSPC and immune system function during chemotherapy (myelopreservation). Preclinically, trilaciclib transiently maintains HSPC in G1 arrest and protects them from chemotherapy damage, leading to faster hematopoietic recovery and enhanced antitumor immunity. PATIENTS AND METHODS This was a phase Ib (open-label, dose-finding) and phase II (randomized, double-blind placebo-controlled) study of the safety, efficacy and PK of trilaciclib in combination with etoposide/carboplatin (E/P) therapy for treatment-naive extensive-stage small-cell lung cancer patients. Patients received trilaciclib or placebo before E/P on days 1-3 of each cycle. Select end points were prespecified to assess the effect of trilaciclib on myelosuppression and antitumor efficacy. RESULTS A total of 122 patients were enrolled, with 19 patients in part 1 and 75 patients in part 2 receiving study drug. Improvements were seen with trilaciclib in neutrophil, RBC (red blood cell) and lymphocyte measures. Safety on trilaciclib+E/P was improved with fewer ≥G3 adverse events (AEs) in trilaciclib (50%) versus placebo (83.8%), primarily due to less hematological toxicity. No trilaciclib-related ≥G3 AEs occurred. Antitumor efficacy assessment for trilaciclib versus placebo, respectively, showed: ORR (66.7% versus 56.8%, P = 0.3831); median PFS [6.2 versus 5.0 m; hazard ratio (HR) 0.71; P = 0.1695]; and OS (10.9 versus 10.6 m; HR 0.87; P = 0.6107). CONCLUSION Trilaciclib demonstrated an improvement in the patient's tolerability of chemotherapy as shown by myelopreservation across multiple hematopoietic lineages resulting in fewer supportive care interventions and dose reductions, improved safety profile, and no detriment to antitumor efficacy. These data demonstrate strong proof-of-concept for trilaciclib's myelopreservation benefits. CLINICAL TRAIL NUMBER NCT02499770.",2019,No trilaciclib-related ≥ G3 AEs occurred.,"['treatment-naive extensive-stage small cell lung cancer (SCLC) patients', '122 patients were enrolled, with 19 patients in Part 1 and 75 patients in Part 2 receiving study drug', 'patients with small cell lung cancer receiving 1st-line chemotherapy']","['etoposide/carboplatin (E/P) therapy', 'trilaciclib or placebo', 'placebo', 'trilaciclib vs. placebo', 'Myelopreservation with the CDK4/6 inhibitor trilaciclib']","['ORR', 'median PFS', 'neutrophil, RBC and lymphocyte measures', 'hematological toxicity', 'myelosuppression and anti-tumor efficacy']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0149925', 'cui_str': 'Oat Cell Lung Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205435', 'cui_str': 'First (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0854467', 'cui_str': 'Myelosuppression (finding)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}]",122.0,0.302546,No trilaciclib-related ≥ G3 AEs occurred.,"[{'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Weiss', 'Affiliation': 'Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Csoszi', 'Affiliation': 'Oncology, Hetenyi Geza Korhaz, Onkologiai Kozpont, Szolnok, Hungary.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Maglakelidze', 'Affiliation': 'Department of Oncology, Research Institute of Clinical Medicine, Tbilisi, Georgia, USA.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Hoyer', 'Affiliation': 'Department of Oncology, Memorial Hospital, University of Colorado Health, Colorado Springs, USA.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Beck', 'Affiliation': 'Department of Medical Oncology and Hematology, Highlands Oncology Group, Fayetteville, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Domine Gomez', 'Affiliation': 'Department of Oncology, University Hospital Fundacion Jimenez Diaz, IIS-FJD, Madrid, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lowczak', 'Affiliation': 'Department of Pulmonology, Faculty of Health and Science, University of Warmia and Mazury in Olsztyn, Poland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Aljumaily', 'Affiliation': 'Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA.'}, {'ForeName': 'C M', 'Initials': 'CM', 'LastName': 'Rocha Lima', 'Affiliation': 'Gibbs Cancer Center and Research Institute, Spartanburg, USA.'}, {'ForeName': 'R V', 'Initials': 'RV', 'LastName': 'Boccia', 'Affiliation': 'Center for Cancer and Blood Disorders, Bethesda, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Hanna', 'Affiliation': 'Hematology/Oncology, University of Tennessee Medical Center, Knoxville, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Nikolinakos', 'Affiliation': 'University Cancer & Blood Center, LLC, Athens, Greece.'}, {'ForeName': 'V K', 'Initials': 'VK', 'LastName': 'Chiu', 'Affiliation': 'Department of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center, Albuquerque, USA.'}, {'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Owonikoko', 'Affiliation': 'Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Schuster', 'Affiliation': 'University of Colorado, Fort Collins, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Hussein', 'Affiliation': 'Department of Oncology, Florida Cancer Specialists, Leesburg, USA.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Richards', 'Affiliation': 'Department of Oncology, US Oncology Research, Tyler, USA.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Sawrycki', 'Affiliation': 'Department of Cancer Chemotherapy, Provincial Hospital, Toruń, Poland.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Bulat', 'Affiliation': 'ARENSIA Oncology Unit, Institute of Oncology, Chisinau, Moldova.'}, {'ForeName': 'J T', 'Initials': 'JT', 'LastName': 'Hamm', 'Affiliation': 'Department of Medical Oncology, Norton Health Care, Louisville, USA.'}, {'ForeName': 'L L', 'Initials': 'LL', 'LastName': 'Hart', 'Affiliation': 'Drug Development Program, Floridia Cancer Specialists, Fort Myers, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Adler', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Antal', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'A Y', 'Initials': 'AY', 'LastName': 'Lai', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Sorrentino', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'R K', 'Initials': 'RK', 'LastName': 'Malik', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Morris', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Roberts', 'Affiliation': 'Clinical Research, G1 Therapeutics, Inc., Research Triangle Park, USA.'}, {'ForeName': 'K H', 'Initials': 'KH', 'LastName': 'Dragnev', 'Affiliation': 'Department of Hematology/Oncology, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon, USA. Electronic address: konstantin.h.dragnev@hitchcock.org.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz278'] 417,32251570,Comparison of the i-gel™ with the AuraGain™ laryngeal mask airways in patients with a simulated cervical immobilization: a randomized controlled trial.,"BACKGROUND The use of second generation supraglottic airway devices is recommended for airway rescue in failed tracheal intubation. This study was performed to compare the clinical performance of the i-gel™ with that of the AuraGain™ in patients with simulated cervical immobilization. METHODS We conducted a prospective, randomized controlled trial in 104 patients undergoing general anesthesia from June to September 2018 at the Seoul National University Hospital. Patients were randomly allocated to receive either the i-gel™ or the AuraGain™ device. A difficult airway was simulated using a cervical collar limiting the mouth opening and neck movement. The primary outcome was the initial oropharyngeal leak pressure. RESULTS The rate of successful insertion at the first attempt was 92.3% for the i-gel™ and 86% for the AuraGain™. There were no significant differences in the initial and 5-min oropharyngeal leak pressures between the i-gel™ and the AuraGain™ (21±4 vs. 22±5 cmH2O, P=0.229; and 22±5 vs. 23±5 cmH2O, P=0.308, respectively). The time to successful device insertion was shorter (20 [16-23] vs. 25 [20-41] s, P<0.001) and device insertion was easier (P<0.001) in the i-gel™ group than in the AuraGain™ group. The blood staining of the device was more frequently observed in the AuraGain™ (3 [5.8%] vs. 12 [23.5%] patients, P=0.003). CONCLUSIONS The i-gel™ and the AuraGain™ showed comparable oropharyngeal leak pressures and success rates in the first attempt in patients with simulated cervical immobilization. However, the i-gel™ was easier to insert and required less time for insertion than the AuraGain™.",2020,The i-gel and the AuraGain showed comparable oropharyngeal leak pressures and success rates in the first attempt in patients with simulated cervical immobilization.,"['patients with simulated cervical immobilization', 'patients with a simulated cervical immobilization', '104 patients undergoing general anaesthesia from June to September 2018 at the Seoul National University Hospital']","['AuraGainTM laryngeal mask airways', 'AuraGain', 'i-gel or the AuraGain device']","['time to successful device insertion', 'initial and 5-min oropharyngeal leak pressures', 'oropharyngeal leak pressures and success rates', 'rate of successful insertion', 'initial oropharyngeal leak pressure', 'blood staining of the device']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C3850150', 'cui_str': 'Seoul'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0332234', 'cui_str': 'Leaking'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0005835', 'cui_str': 'Blood Stains'}]",104.0,0.075314,The i-gel and the AuraGain showed comparable oropharyngeal leak pressures and success rates in the first attempt in patients with simulated cervical immobilization.,"[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Hur', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, South Korea.'}, {'ForeName': 'Seungeun', 'Initials': 'S', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Hyung S', 'Initials': 'HS', 'LastName': 'Row', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'Tae K', 'Initials': 'TK', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, South Korea - ktkktk@gmail.com.'}]",Minerva anestesiologica,['10.23736/S0375-9393.20.14237-8'] 418,31352467,Neural responses during extinction learning predict exposure therapy outcome in phobia: results from a randomized-controlled trial.,"Extinction learning is assumed to represent a core mechanism underlying exposure therapy. Empirical evaluations of this assumption, however, are largely lacking. The current study investigated whether neural activations and self-report outcomes during extinction learning and extinction recall could specifically predict exposure therapy response in specific phobia. In this double-blind randomized controlled trial, individuals with spider phobia (N = 45; female/male = 41/4) were on group basis randomly allocated to exposure therapy (n = 25; female/male = 24/1) or progressive muscle relaxation (PMR; n = 20; female/male = 17/3). Intervention effects were measured with the Fears of Spiders questionnaire. Participants also underwent a three-day fear conditioning, extinction learning, and extinction recall paradigm during functional magnetic resonance imaging at baseline. Extinction outcomes were self-reported fear and threat expectancy, and neural responses during conditioned stimulus processing and during extinction-related prediction errors (US omissions) in regions of interest (ventromedial prefrontal cortex (vmPFC) and nucleus accumbens). Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90). Exposure therapy response was specifically predicted by prediction-error related vmPFC activation during early extinction. There were also indications vmPFC activations during conditioned safety stimulus processing at early extinction predicted therapy outcome. Neural activations during extinction recall and self-report data did however not predict therapy outcome. These findings indicate that exposure therapy may rely on neural extinction learning processes. Prediction errors are thought to drive the extinction learning process, and prediction error-related vmPFC activation specifically predicted therapy outcome. The extent to which vmPFC processes safety signals may additionally be predictive of exposure therapy response, but the specificity is less clear.",2020,Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90).,"['specific phobia', 'n\u2009=\u200920; female/male\u2009=\u200917/3', 'individuals with spider phobia (N\u2009=\u200945; female/male\u2009=\u200941/4', 'phobia']","['exposure therapy (n\u2009=\u200925; female/male\u2009=\u200924/1) or progressive muscle relaxation (PMR', 'extinction learning and extinction recall', 'extinction learning']","['stronger symptom reductions', 'Fears of Spiders questionnaire', 'self-reported fear and threat expectancy, and neural responses during conditioned stimulus processing and during extinction-related prediction errors (US omissions) in regions of interest', 'Neural responses']","[{'cui': 'C0236801', 'cui_str': 'Phobia, Specific'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0037913', 'cui_str': 'Spiders'}, {'cui': 'C0349231', 'cui_str': 'Phobias'}]","[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0004361', 'cui_str': 'Progressive Relaxation'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}]","[{'cui': 'C0442821', 'cui_str': 'Strong (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392331', 'cui_str': 'Arachnophobia (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0234404', 'cui_str': 'Conditioned stimulus, function (observable entity)'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}]",,0.103046,Results showed that exposure therapy resulted in stronger symptom reductions than PMR (Cohen's d = 0.90).,"[{'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Lange', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands. i.lange@maastrichtuniversity.nl.'}, {'ForeName': 'Liesbet', 'Initials': 'L', 'LastName': 'Goossens', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Michielse', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Jindra', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Vervliet', 'Affiliation': 'Faculty of Psychology and Educational Sciences, Laboratory of Biological Psychology, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Machteld', 'Initials': 'M', 'LastName': 'Marcelis', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'Wichers', 'Affiliation': 'Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'van Os', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'van Amelsvoort', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Schruers', 'Affiliation': 'Department of Psychiatry and Psychology, School for Mental Health and Neuroscience, EURON, Maastricht University Medical Centre, Maastricht, the Netherlands.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0467-8'] 419,30816331,"Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group.","Children's Cancer Group CCG-1882 improved outcome for 1-21-year old with high risk acute lymphoblastic leukemia and Induction Day 8 marrow blasts ≥25% (slow early responders, SER) with longer and stronger post induction intensification (PII). This CCG-1961 explored alternative PII strategies. We report 10-year follow-up for patients with rapid early response (RER) and for the first time details our experience for SER patients. A total of 2057 patients were enrolled, and 1299 RER patients were randomized to 1 of 4 PII regimens: standard vs. augmented intensity and standard vs. increased length. At the end of interim maintenance, 447 SER patients were randomized to idarubicin/cyclophosphamide or weekly doxorubicin in the delayed intensification phases. The 10-year EFS for RER were 79.4 ± 2.4% and 70.9 ± 2.6% (hazard ratio = 0.65, 95% CI 0.52-0.82, p < 0.001) for augmented and standard strength PII; the 10-year OS rates were 87.2 ± 2.0% and 81.0 ± 2.2% (hazard ratio = 0.64, 95% CI 0.48-0.86, p = 0.003). Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin. The EFS and OS advantage of augmented PII is sustained at 10 years for RER patients. Longer PII for RER patients and sequential idarubicin/cyclophosphamide for SER patients offered no advantage. CCG-1961 is the platform for subsequent COG studies.",2019,"Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin.","['patients with rapid early response (RER) and for the first time\xa0details our experience for SER patients', '447 SER patients', '2057 patients were enrolled, and 1299 RER patients']","['idarubicin/cyclophosphamide and weekly doxorubicin', 'idarubicin/cyclophosphamide or weekly doxorubicin', 'idarubicin/cyclophosphamide', 'CCG-1961']","['10-year OS rates', '10-year EFS for RER']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}]","[{'cui': 'C0020789', 'cui_str': 'Idarubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",2057.0,0.0559644,"Outcomes remain similar for standard and longer PII, and for SER patients assigned to idarubicin/cyclophosphamide and weekly doxorubicin.","[{'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Steinherz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA. steinhep@mskcc.org.'}, {'ForeName': 'Nita L', 'Initials': 'NL', 'LastName': 'Seibel', 'Affiliation': ""Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.""}, {'ForeName': 'Harland', 'Initials': 'H', 'LastName': 'Sather', 'Affiliation': ""Children's Oncology Group, Los Angeles, CA, USA.""}, {'ForeName': 'Lingyun', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': ""Children's Oncology Group, Los Angeles, CA, USA.""}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Devidas', 'Affiliation': 'Department of Biostatistics, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Paul S', 'Initials': 'PS', 'LastName': 'Gaynon', 'Affiliation': ""Children's Hospital of Los Angeles, Los Angeles, CA, USA.""}]",Leukemia,['10.1038/s41375-019-0422-z'] 420,31050707,"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.","BACKGROUND Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy. Here we report the long-term safety and efficacy outcomes of KEYNOTE-045. PATIENTS AND METHODS Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line, platinum-containing chemotherapy were enrolled. Patients were randomly assigned 1 : 1 to receive pembrolizumab [200 mg every 3 weeks (Q3W)] or investigator's choice of paclitaxel (175 mg/m2 Q3W), docetaxel (75 mg/m2 Q3W), or vinflunine (320 mg/m2 Q3W). Primary end points were OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central radiology review (BICR). A key secondary end point was objective response rate per RECIST v1.1 by BICR. RESULTS A total of 542 patients were enrolled (pembrolizumab, n = 270; chemotherapy, n = 272). Median follow-up as of 26 October 2017 was 27.7 months. Median 1- and 2-year OS rates were higher with pembrolizumab (44.2% and 26.9%, respectively) than chemotherapy (29.8% and 14.3%, respectively). PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab. The objective response rate was also higher with pembrolizumab (21.1% versus 11.0%). Median duration of response to pembrolizumab was not reached (range 1.6+ to 30.0+ months) versus chemotherapy (4.4 months; range 1.4+ to 29.9+ months). Pembrolizumab had lower rates of any grade (62.0% versus 90.6%) and grade ≥3 (16.5% versus 50.2%) treatment-related adverse events than chemotherapy. CONCLUSIONS Long-term results (>2 years' follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC. TRIAL REGISTRATION ClinicalTrials.gov: NCT02256436.",2019,"PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab.","['Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line, platinum-containing chemotherapy were enrolled', 'patients with advanced urothelial cancer (UC', 'patients with advanced UC that progressed on platinum-based chemotherapy', 'recurrent advanced urothelial cancer', '542 patients were enrolled (pembrolizumab, n = 270; chemotherapy, n =272']","['docetaxel (75\u2009mg/m2 Q3W), or vinflunine', ""pembrolizumab (200\u2009mg every 3 weeks [Q3W]) or investigator's choice of paclitaxel"", 'Pembrolizumab', 'pembrolizumab', 'pembrolizumab versus paclitaxel, docetaxel, or vinflunine']","['1- and 2-year PFS rates', 'OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central radiology review (BICR', 'rates of any-grade', 'objective response rate per RECIST v1.1 by BICR', 'objective response rate', 'PFS rates', 'Median duration of response to pembrolizumab', 'Median 1- and 2-year OS rates']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C4319603', 'cui_str': '270 (qualifier value)'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}, {'cui': 'C0672663', 'cui_str': 'vinflunine'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0034599', 'cui_str': 'Radiology'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}]",542.0,0.296657,"PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab.","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Fradet', 'Affiliation': 'Department of Surgery/Urology, CHU de Québec-Université Laval, Québec City, Canada. Electronic address: yves.fradet@crchudequebec.ulaval.ca.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bellmunt', 'Affiliation': 'Department of Medical Oncology, PSMAR-IMIM Research Institute, Barcelona, Spain and Harvard Medical School University, Boston, USA.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Vaughn', 'Affiliation': 'Department of Medical Oncology, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia, USA.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Fong', 'Affiliation': 'Department of Medicine and Urology, University of California San Francisco, San Francisco.'}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'Vogelzang', 'Affiliation': 'Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, USA.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Climent', 'Affiliation': 'Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Petrylak', 'Affiliation': 'Division of Medical Oncology, Smilow Cancer Hospital at Yale University, New Haven.'}, {'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Necchi', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Gerritsen', 'Affiliation': 'Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Gurney', 'Affiliation': 'Department of Medical Oncology, Westmead Hospital and Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'D I', 'Initials': 'DI', 'LastName': 'Quinn', 'Affiliation': 'Department of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Culine', 'Affiliation': 'Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.'}, {'ForeName': 'C N', 'Initials': 'CN', 'LastName': 'Sternberg', 'Affiliation': 'Department of Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nam', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Frenkl', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Perini', 'Affiliation': 'Department of Medical Oncology, Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'de Wit', 'Affiliation': 'Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.'}, {'ForeName': 'D F', 'Initials': 'DF', 'LastName': 'Bajorin', 'Affiliation': 'Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz127'] 421,31560068,Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.,"BACKGROUND STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. RESULTS Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). CONCLUSIONS The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.",2019,"There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). ","['We randomly allocated patients in 2\u2009', 'Between 05 October 2005 and 31 March 2013, 1086 M1 patients', 'M1 patients', 'low- and high-burden metastatic hormone sensitive prostate cancer', 'metastatic hormone naïve prostate cancer patients regardless of metastatic burden', 'metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy']","['docetaxel', 'SOC', 'SOC\u2009+\u2009docetaxel', '1 ratio to standard-of-care (SOC; control group) or SOC\u2009+\u2009docetaxel', 'upfront docetaxel']","['Metastatic burden', 'survival', 'failure-free survival', 'progression-free survival', 'late toxicity', 'overall survival (OS', 'G3-5 toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer (disorder)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy (procedure)'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",724.0,0.397865,"There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). ","[{'ForeName': 'N W', 'Initials': 'NW', 'LastName': 'Clarke', 'Affiliation': 'Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester. Electronic address: noel.clarke@christie.nhs.uk.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ali', 'Affiliation': 'Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester.'}, {'ForeName': 'F C', 'Initials': 'FC', 'LastName': 'Ingleby', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London; London School of Hygiene and Tropical Medicine, London.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hoyle', 'Affiliation': 'Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Amos', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Attard', 'Affiliation': 'UCL Cancer Institute, London.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Brawley', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Calvert', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chowdhury', 'Affiliation': ""Guy's and Saint Thomas' NHS Foundation Trust, London.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Cook', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Cross', 'Affiliation': 'St James University Hospital, Leeds.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Dearnaley', 'Affiliation': 'Institute of Cancer Research, Sutton-London.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Douis', 'Affiliation': 'Department of Radiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Gilbert', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gillessen', 'Affiliation': 'Division of Cancer Sciences, The University of Manchester, Manchester.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Jones', 'Affiliation': 'Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Langley', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'MacNair', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Malik', 'Affiliation': 'The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Mason', 'Affiliation': 'Cardiff University, Cardiff.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Matheson', 'Affiliation': 'Faculty of Education Health and Wellbeing, University of Wolverhampton, Wolverhampton.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Millman', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Parker', 'Affiliation': 'Institute of Cancer Research, Sutton-London; Royal Marsden NHS Foundation Trust, London.'}, {'ForeName': 'A W S', 'Initials': 'AWS', 'LastName': 'Ritchie', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Rush', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Russell', 'Affiliation': 'Institute of Cancer Sciences, Beatson West of Scotland Cancer Centre, Glasgow.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'University of Sheffield, Sheffield.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Beesley', 'Affiliation': 'Kent Oncology Centre, Maidstone.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Birtle', 'Affiliation': 'Lancashire Teaching Hospitals NHS Foundation Trust, Preston.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Capaldi', 'Affiliation': 'Worcestershire Acute Hospitals NHS Trust, Worcester.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Gale', 'Affiliation': 'Portsmouth Oncology Centre, Queen Alexandra Hospital, Portsmouth.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gibbs', 'Affiliation': ""Queen's Hospital, Romford.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lydon', 'Affiliation': 'Torbay and South Devon NHS Foundation Trust, Torbay.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nikapota', 'Affiliation': 'Sussex Cancer Centre, Brighton.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Omlin', 'Affiliation': 'Department of Oncology and Haematology, Kantonsspital, St Gallen, Switzerland.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': ""Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast.""}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Parikh', 'Affiliation': 'East Lancashire Hospitals NHS Trust, Blackburn.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Protheroe', 'Affiliation': 'Oxford University Hospitals NHS Foundation Trust, Oxford.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rudman', 'Affiliation': ""Guy's and Saint Thomas' NHS Foundation Trust, London.""}, {'ForeName': 'N N', 'Initials': 'NN', 'LastName': 'Srihari', 'Affiliation': 'Shrewsbury and Telford Hospital NHS Trust, Shrewsbury.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Simms', 'Affiliation': 'Hull and East Yorkshire Hospitals NHS Trust, Hull.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Tanguay', 'Affiliation': 'Velindre Cancer Centre, Cardiff.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Tolan', 'Affiliation': 'The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wagstaff', 'Affiliation': 'Swansea University College of Medicine, Swansea.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wallace', 'Affiliation': 'Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wylie', 'Affiliation': 'The Christie NHS Foundation Trust, Manchester.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Zarkar', 'Affiliation': 'Heartlands Hospital, Birmingham.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Sydes', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'M K B', 'Initials': 'MKB', 'LastName': 'Parmar', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London.'}, {'ForeName': 'N D', 'Initials': 'ND', 'LastName': 'James', 'Affiliation': 'Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz396'] 422,31562758,Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.,"BACKGROUND Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. PATIENTS AND METHODS Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. RESULTS Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was <10 points in both arms and there was no significant between-group difference [-2.47; 95% confidence interval (CI) -7.27, 2.33; P = 0.31]. Analysis of physical functioning scores showed a significant between-group difference (-4.45 points; 95% CI -8.75, -0.16; P = 0.04). There was no difference in TSCMD for olaparib versus placebo for GHS [P = 0.25; hazard ratio (HR) 0.72; 95% CI 0.41, 1.27] or physical functioning (P = 0.32; HR 1.38; 95% CI 0.73, 2.63). CONCLUSIONS HRQoL was preserved with maintenance olaparib treatment with no clinically meaningful difference compared with placebo. These results support the observed efficacy benefit of maintenance olaparib in patients with a gBRCAm and metastatic pancreatic cancer. CLINCALTRIALS.GOV NUMBER NCT02184195.",2019,"The adjusted mean change in Global Health Status (GHS) score from baseline was less than 10 points in both arms and there was no significant between-group difference (-2.47; 95% CI - 7.27, 2.33; P=0.31).","['Patients', 'patients with a gBRCAm and mPC', 'patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and mPC whose disease had not progressed during first-line platinum-based chemotherapy', 'patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib', 'Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses', 'Patients with metastatic pancreatic cancer (mPC']","['placebo', 'maintenance olaparib']","['HRQoL', 'physical functioning scores', 'physical functioning', 'Cancer Quality of Life Questionnaire Core 30-item module', 'Global Health Status (GHS) score', 'Health-related quality of life', 'TSCMD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0346647', 'cui_str': 'Cancer of Pancreas'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C2316164', 'cui_str': 'olaparib'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C2316164', 'cui_str': 'olaparib'}]","[{'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",154.0,0.644628,"The adjusted mean change in Global Health Status (GHS) score from baseline was less than 10 points in both arms and there was no significant between-group difference (-2.47; 95% CI - 7.27, 2.33; P=0.31).","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Hammel', 'Affiliation': 'Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. Electronic address: pascal.hammel@aphp.fr.'}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'Kindler', 'Affiliation': 'Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Reni', 'Affiliation': 'Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Macarulla', 'Affiliation': ""Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.""}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Hall', 'Affiliation': 'Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA.'}, {'ForeName': 'J O', 'Initials': 'JO', 'LastName': 'Park', 'Affiliation': 'Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Hochhauser', 'Affiliation': 'Department of Oncology, University College London Cancer Institute, London, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Arnold', 'Affiliation': 'Department of Oncology, Asklepios Tumorzentrum Hamburg Asklepios Klinik Altona, Hamburg, Germany.'}, {'ForeName': 'D-Y', 'Initials': 'DY', 'LastName': 'Oh', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Reinacher-Schick', 'Affiliation': 'Department of Hematology, Oncology and Palliative Care, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Tortora', 'Affiliation': 'Department of Medicine, Section of Medical Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Verona and Fondazione Policlinico Universitario Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Algül', 'Affiliation': 'Second Department of Internal Medicine, Klinikum rechts der Isar, Comprehensive Cancer Center Munich-TUM and Department of Internal Medicine II, Technische Universität München, Munich, Germany.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': ""O'Reilly"", 'Affiliation': 'Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'McGuinness', 'Affiliation': 'AstraZeneca, Cambridge, UK.'}, {'ForeName': 'K Y', 'Initials': 'KY', 'LastName': 'Cui', 'Affiliation': 'AstraZeneca, Gaithersburg, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Joo', 'Affiliation': 'Merck & Co., Inc., Kenilworth, USA.'}, {'ForeName': 'H K', 'Initials': 'HK', 'LastName': 'Yoo', 'Affiliation': 'AstraZeneca, Cambridge, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Patel', 'Affiliation': 'AstraZeneca, Gaithersburg, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Golan', 'Affiliation': 'The Oncology Institute, Sheba Medical Center, Tel Aviv, Israel.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz406'] 423,31374471,Do distance-delivery group interventions improve depression in people with epilepsy?,"About one-third of people with epilepsy experience comorbid depression. The present study examined outcomes of a distance-delivery group intervention program designed to improve emotional well-being. Participants were 55 adults with epilepsy and self-reported depressive symptoms who were randomly assigned to take part in either a mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n = 20), an epilepsy information and self-management program (EpINFO, n = 24) that served as an active control group, or a wait-list control (WLC) group (n = 11). The Quick Inventory of Depressive Symptomatology (QIDS), Neurological Disorders Depression Inventory for Epilepsy (NDDIE), and the psychological health subscale of the World Health Organization Quality of Life (WHOQOL-BREF) scale were used to assess depression and psychological quality of life before and after treatment, and at short-term (six months) and long-term follow-up (one year) upon program completion. From pre- to posttreatment, a main effect of time was found, with participants in both the UPLIFT and EpINFO groups having reported to a similar degree a significant decrease in depressive symptoms and improved psychological health, improvements that were not seen in the WLC group. The time by group interaction effect was not significant. The effects seen at posttreatment in the UPLIFT and EpINFO groups remained at six months and one year after treatment. These data suggest that distance-delivery group intervention programs are effective at improving depression and psychological quality of life, with the EpINFO program offering benefits similar to the UPLIFT program.",2019,The effects seen at posttreatment in the UPLIFT and EpINFO groups remained at six months and one year after treatment.,"['people with epilepsy experience comorbid depression', 'people with epilepsy', 'Participants were 55 adults with epilepsy and self-reported depressive symptoms']","['mindfulness-based cognitive behavioral therapy (CBT) program (UPLIFT, n\u202f=\u202f20), an epilepsy information and self-management program (EpINFO, n\u202f=\u202f24) that served as an active control group, or a wait-list control (WLC']","['depressive symptoms and improved psychological health', 'Quick Inventory of Depressive Symptomatology (QIDS), Neurological Disorders Depression Inventory for Epilepsy (NDDIE), and the psychological health subscale of the World Health Organization Quality of Life (WHOQOL-BREF) scale', 'depression and psychological quality of life']","[{'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4720917', 'cui_str': 'Quick inventory of depressive symptomatology (assessment scale)'}, {'cui': 'C0027765', 'cui_str': 'Neurologic Disorders'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0014544', 'cui_str': 'Seizure Disorder'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0034380'}, {'cui': 'C0222045'}]",55.0,0.0250364,The effects seen at posttreatment in the UPLIFT and EpINFO groups remained at six months and one year after treatment.,"[{'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Hum', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada. Electronic address: Kathryn.hum@utoronto.ca.'}, {'ForeName': 'Cindy J', 'Initials': 'CJ', 'LastName': 'Chan', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Gane', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Lauryn', 'Initials': 'L', 'LastName': 'Conway', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada; Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Mary Pat', 'Initials': 'MP', 'LastName': 'McAndrews', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada; University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'Mary Lou', 'Initials': 'ML', 'LastName': 'Smith', 'Affiliation': 'University of Toronto, Toronto, Ontario, Canada; Hospital for Sick Children, Toronto, Ontario, Canada.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.06.037'] 424,31634532,Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.,"BACKGROUND & AIMS Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. In the present study, we aimed to evaluate the impact of OCA therapy on lipoprotein sub-particles. METHOD This study included 196 patients (99 OCA group and 97 placebo group) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks. Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles were evaluated at baseline, 12 and 72 weeks after randomization, and 24 weeks following EOT. RESULTS Baseline lipoprotein profiles were similar among OCA and placebo groups. OCA did not affect total VLDL particle concentrations, but OCA vs. placebo treatment was associated with decreased large VLDL particle concentration at 12 weeks (baseline-adjusted mean: 6.8 vs. 8.9 nmol/L; p = 0.002), mirrored by an increase in less atherogenic, small VLDL particle concentration (33.9 vs. 28.0 nmol/L; p = 0.02). After 12 weeks, total LDL particle concentration was higher in the OCA group than the placebo group (1,667 vs. 1,329 nmol/L; p <0.0001), characterized by corresponding increases in both less atherogenic, large-buoyant LDL (475 vs. 308 nmol/L; p ≤0.001) and more atherogenic small-dense LDL particles (1,015 vs. 872 nmol/L; p = 0.002). The changes in LDL particle concentrations were similar between treatment groups (OCA and placebo) 24 weeks following EOT due to improvement in the OCA cohort. Compared to placebo, a reduction in total HDL particle concentration, particularly large and medium HDL particles, was noted in the OCA-treated patients, but this resolved after drug discontinuation. CONCLUSION OCA therapy is associated with increases in small VLDL particles, large and small LDL particles, and a reduction in HDL particles at 12 weeks. These lipoprotein concentrations reverted to baseline values 24 weeks after drug discontinuation. LAY SUMMARY Non-alcoholic steatohepatitis is a chronic liver disease that is associated with an increased risk of developing cirrhosis and cardiovascular disease. Recently, obeticholic acid (OCA), a farnesoid X receptor agonist, improved liver disease but led to an increase in cholesterol. However, the impact of OCA on cholesterol is not well understood. In the present study, we show that OCA therapy is associated with a detrimental increase in lipoprotein levels, which improves after drug discontinuation. ClinicalTrials.gov numbers: NCT01265498.",2020,"Compared to placebo, a reduction in total HDL-particle concentration, particularly large and medium HDL-particles, was noted in the OCA treated patients but this resolved after drug discontinuation. ","['Patients with Nonalcoholic Steatohepatitis', 'patients with nonalcoholic steatohepatitis (NASH', '196 patients (99 OCA group and 97 placebo) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks']","['Farnesoid X receptor (FXR) agonist, obeticholic acid (OCA', 'OCA vs. placebo', 'OCA', 'placebo', 'OCA therapy', 'Obeticholic Acid']","['total HDL-particle concentration, particularly large and medium HDL-particles', 'atherogenic small-dense LDL particles', 'Very low-density lipoprotein (VLDL), low density lipoprotein (LDL), and high-density lipoprotein (HDL) particles', 'total and low-density lipoprotein cholesterol (LDL-C', 'impact total VLDL particle concentrations', 'large VLDL particle concentration', 'less-atherogenic small VLDL particle concentration', 'lipoprotein levels', 'LDL particle concentrations', 'Lipoprotein Profile', 'total LDL particle concentration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic Steatohepatitis'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0303753', 'cui_str': 'Flintstone'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver (procedure)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C4707406', 'cui_str': 'Product containing farnesoid X receptor agonist'}, {'cui': 'C1143018', 'cui_str': 'obeticholic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",872.0,0.518232,"Compared to placebo, a reduction in total HDL-particle concentration, particularly large and medium HDL-particles, was noted in the OCA treated patients but this resolved after drug discontinuation. ","[{'ForeName': 'Mohammad Shadab', 'Initials': 'MS', 'LastName': 'Siddiqui', 'Affiliation': 'Virginia Commonwealth University, Richmond, VA, United States. Electronic address: Mohammad.siddiqui@vcuhealth.org.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Van Natta', 'Affiliation': 'John Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Margery A', 'Initials': 'MA', 'LastName': 'Connelly', 'Affiliation': 'Laboratory Corporation of America Holdings (LabCorp), Inc, Morrisville, NC, United States.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Vuppalanchi', 'Affiliation': 'Indiana University, Indianapolis, IN, United States.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Neuschwander-Tetri', 'Affiliation': 'Saint Louis University, St. Louis, MO, United States.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tonascia', 'Affiliation': 'John Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Guy', 'Affiliation': 'Duke University, Durham, NC, United States.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'University of California at San Diego, San Diego, CA, United States.'}, {'ForeName': 'Srinivasan', 'Initials': 'S', 'LastName': 'Dasarathy', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, United States.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Wattacheril', 'Affiliation': 'Columbia University, New York, NY, United States.'}, {'ForeName': 'Naga', 'Initials': 'N', 'LastName': 'Chalasani', 'Affiliation': 'Indiana University, Indianapolis, IN, United States.'}, {'ForeName': 'Arun J', 'Initials': 'AJ', 'LastName': 'Sanyal', 'Affiliation': 'Virginia Commonwealth University, Richmond, VA, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of hepatology,['10.1016/j.jhep.2019.10.006'] 425,31634897,"Augmenting extinction learning with D-cycloserine reduces return of fear: a randomized, placebo-controlled fMRI study.","D-cycloserine (DCS), a partial NMDA-receptor agonist, seems to be a promising enhancer for exposure therapy in anxiety disorders. It has been tested successfully in animal models of fear extinction, where DCS enhanced extinction learning. Applied in clinical studies, results of DCS-augmented exposure therapy remain ambiguous, calling for a deeper understanding of the underlying mechanisms of DCS and its exact effect on extinction learning and return of fear (ROF) in humans. In the present study, we investigated the effect of DCS-augmented extinction learning on behavioral, psychophysiological, and neural indices of ROF during a 24-h delayed recall test. Thirty-seven participants entered a randomized, placebo-controlled, double-blind, 3-day fear conditioning and delayed extinction fMRI design. One hour before extinction training, participants received an oral dose of 50 mg of DCS or a placebo. Behavioral arousal ratings revealed a generalized ROF during extinction recall in the placebo but not DCS group. Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects. Our finding that DCS reduces ROF in arousal ratings and neural structures subserving defensive reactions support a role for NMDA receptors in extinction memory consolidation and encourage further translational research.",2020,"Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects.",['Thirty-seven participants'],"['placebo-controlled, double-blind, 3-day fear conditioning and delayed extinction fMRI design', 'DCS-augmented extinction learning', 'DCS', 'placebo', 'D-cycloserine (DCS']","['hippocampal recruitment', 'return of fear', 'behavioral, psychophysiological, and neural indices of ROF', 'extinction learning and return of fear (ROF', 'Behavioral arousal ratings', 'differential BOLD responses']","[{'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}]",37.0,0.340641,"Furthermore, participants receiving DCS compared to placebo showed attenuated differential BOLD responses in left posterior hippocampus and amygdala from extinction learning to extinction recall, due to increased hippocampal recruitment in placebo and trendwise decreased amygdala responding in DCS subjects.","[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Ebrahimi', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany. claudia.ebrahimi@charite.de.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Gechter', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Lueken', 'Affiliation': 'Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Schlagenhauf', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}, {'ForeName': 'Hans-Ulrich', 'Initials': 'HU', 'LastName': 'Wittchen', 'Affiliation': 'Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Alfons O', 'Initials': 'AO', 'LastName': 'Hamm', 'Affiliation': 'Department of Biological and Clinical Psychology/Psychotherapy, University of Greifswald, Greifswald, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Ströhle', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0552-z'] 426,31655485,Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms.,"The angiotensin-II antagonist losartan is a promising candidate that has enhanced extinction in a post-traumatic stress disorder (PTSD) animal model and was related to reducing PTSD symptom development in humans. Here, we investigate the neurocognitive mechanisms underlying these results, testing the effect of losartan on data-driven and contextual processing of traumatic material, mechanisms proposed to be relevant for PTSD development. In a double-blind between-subject design, 40 healthy participants were randomised to a single oral dose of losartan (50 mg) or placebo, 1 h before being exposed to distressing films as a trauma analogue while heart rate (HR) was measured. Peritraumatic processing was investigated using blurry picture stimuli from the films, which transformed into clear images. Data-driven processing was measured by the level of blurriness at which contents were recognised. Contextual processing was measured as the amount of context information retrieved when describing the pictures' contents. Negative-matched control images were used to test perceptual processing of peripheral trauma-cues. Post-traumatic stress symptoms were assessed via self-report questionnaires after analogue trauma and an intrusion diary completed over 4 days following the experiment. Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures. During the films, the losartan group recorded lower HR and higher HR variability, reflecting lower autonomic stress responses. We discuss potential mechanisms of losartan in preventing PTSD symptomatology, including the role of reduced arousal and increased contextual processing during trauma exposure, as well as increased threat-safety differentiation when encountering peripheral trauma-cues in the aftermaths of traumatic events.",2020,"Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures.",['40 healthy participants'],"['placebo', 'losartan', 'placebo, losartan', 'angiotensin-II antagonist losartan']","['contextual processing and enhanced detail perception', 'Contextual processing', 'lower HR and higher HR variability, reflecting lower autonomic stress responses']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0126174', 'cui_str': 'Losartan'}, {'cui': 'C0373546', 'cui_str': 'Angiotensin II measurement (procedure)'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",40.0,0.0689031,"Compared to placebo, losartan facilitated contextual processing and enhanced detail perception in the negative-match pictures.","[{'ForeName': 'Lorika', 'Initials': 'L', 'LastName': 'Shkreli', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Marcella Lydia', 'Initials': 'ML', 'LastName': 'Woud', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Ramsbottom', 'Affiliation': 'Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.'}, {'ForeName': 'Aleksandra Ewa', 'Initials': 'AE', 'LastName': 'Rupietta', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Gerd Thomas', 'Initials': 'GT', 'LastName': 'Waldhauser', 'Affiliation': 'Department of Neuropsychology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kumsta', 'Affiliation': 'Genetic Psychology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Reinecke', 'Affiliation': 'Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, OX37JX, UK. andrea.reinecke@psych.ox.ac.uk.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0553-y'] 427,31721081,"Promoting healthy beverage consumption habits among elementary school children: results of the Healthy Kids Community Challenge 'Water Does Wonders' interventions in London, Ontario.","INTERVENTION This study examines the impact of London's Healthy Kids Community Challenge (HKCC) 'Water Does Wonders' interventions, which combined water infrastructure and education programs. RESEARCH QUESTION How effective were the HKCC interventions at increasing water and decreasing sugar-sweetened beverage (SSB) consumption among grade 4-8 children in London, Ontario? METHODS Non-randomized controlled trial. Children's knowledge and beverage intake were measured before and after the interventions were implemented during the 2016-2017 school year. Children at intervention schools (n = 521) received education programs (Growing Chefs or UTRCA [Upper Thames River Conservation Authority]) and water bottle filling stations. Children at control schools (n = 410) received filling stations only. Multivariable linear mixed-model ANCOVAs were used to compare water and SSB consumption and knowledge across intervention groups, accounting for school-level clustering. RESULTS Children who received an education intervention and filling station compared with only a filling station consumed more water (β = 2.18 (95% CI - 1.87, 6.22) for Growing Chefs and β = 2.90 (95% CI - 0.23, 6.03) for UTRCA) and fewer SSBs (β = - 1.17 (95% CI - 3.83, 1.49) for Growing Chefs and β = - 2.56 (95% CI - 5.12, 0.001) for UTRCA) post-intervention, and had higher nutrition knowledge (β = 1.57 (95% CI - 1.68, 4.83) for Growing Chefs and β = 2.02 (95% CI - 0.35, 4.39) for UTRCA). These findings were not statistically significant. CONCLUSIONS An intervention intended to promote healthy beverage consumption yielded effects in the expected direction; however, they were small and not statistically significant. This is likely because the educational interventions were not fully aligned with the goals of the 'Water Does Wonders' program, preventing them from evoking meaningful changes in dietary behaviours.",2020,"How effective were the HKCC interventions at increasing water and decreasing sugar-sweetened beverage (SSB) consumption among grade 4-8 children in London, Ontario? ","['Children at control schools (n\u2009=\u2009410) received filling stations only', ""London's Healthy Kids Community Challenge (HKCC) "", 'Children at intervention schools (n\u2009=\u2009521) received', 'elementary school children', ""Healthy Kids Community Challenge 'Water Does Wonders' interventions in London, Ontario""]",['education programs (Growing Chefs or UTRCA\xa0[Upper Thames River Conservation Authority]) and water bottle filling stations'],"['higher nutrition knowledge', ""Children's knowledge and beverage intake""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}]","[{'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0554202', 'cui_str': 'Chef (occupation)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0337050', 'cui_str': 'Rivers'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C4319838', 'cui_str': 'Bottle'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}]",,0.0702693,"How effective were the HKCC interventions at increasing water and decreasing sugar-sweetened beverage (SSB) consumption among grade 4-8 children in London, Ontario? ","[{'ForeName': 'Bridget R', 'Initials': 'BR', 'LastName': 'Irwin', 'Affiliation': 'Human Environments Analysis Laboratory, Western University, 1151 Richmond St, London, Ontario, N6A 3K7, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Speechley', 'Affiliation': 'Department of Epidemiology and Biostatistics, Western University, 1151 Richmond St, London, Ontario, N6A 3K7, Canada.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Wilk', 'Affiliation': 'Human Environments Analysis Laboratory, Western University, 1151 Richmond St, London, Ontario, N6A 3K7, Canada.'}, {'ForeName': 'Andrew F', 'Initials': 'AF', 'LastName': 'Clark', 'Affiliation': 'Human Environments Analysis Laboratory, Western University, 1151 Richmond St, London, Ontario, N6A 3K7, Canada.'}, {'ForeName': 'Jason A', 'Initials': 'JA', 'LastName': 'Gilliland', 'Affiliation': 'Human Environments Analysis Laboratory, Western University, 1151 Richmond St, London, Ontario, N6A 3K7, Canada. jgillila@uwo.ca.'}]",Canadian journal of public health = Revue canadienne de sante publique,['10.17269/s41997-019-00262-9'] 428,29415593,"Maternal obesity, fish intake, and recurrent spontaneous preterm birth.","OBJECTIVE Moderate fish intake in early pregnancy is associated with decreased risk of preterm birth (PTB). Obesity during pregnancy is characterized by inflammation and insufficiency of essential fatty acids. The objective of this study was to measure the association between fish intake during pregnancy and risk of recurrent spontaneous (s) PTB among lean, overweight, and obese women. DESIGN This is secondary analysis of a randomized controlled trial of omega-3 fatty acid supplementation for recurrent PTB prevention, 2005-2006. The primary exposure was fish intake at time of enrollment (16-22.9-week gestation). The primary outcomes were sPTB <37 weeks and sPTB <35 weeks. Maternal prepregnancy body mass index was treated as an effect modifier. SUBJECTS Eight hundred and fifty-two women were included, 47% were lean, 25% overweight, and 28% obese. RESULTS In this cohort, among lean, but not overweight or obese women, ≥1 serving of fish per week was associated with decreased frequency of sPTB <37 weeks compared with <1 serving of fish per week (45.1% versus 27.5%, p = .001) and spontaneous PTB <35 (21.4% versus 11.6%, p = .01). In adjusted models, as fish intake increased, the predicted probability of sPTB decreased in lean women but increased in overweight and obese women (p for interaction < .10). CONCLUSION Fish intake was associated with lower probability of sPTB in lean women and higher probability in obese women. These findings warrant further investigation to understand the dietary or metabolic factors associated with obesity that may modulate benefit of fish intake during pregnancy.",2019,"In adjusted models, as fish intake increased, the predicted probability of sPTB decreased in lean women but increased in overweight and obese women (p for interaction < .10). ","['lean, overweight, and obese women', 'recurrent PTB prevention, 2005-2006', 'Eight hundred and fifty-two women were included, 47% were lean, 25% overweight, and 28% obese', 'obese women']",['omega-3 fatty acid supplementation'],"['Maternal obesity, fish intake, and recurrent spontaneous preterm birth', 'risk of preterm birth (PTB', 'probability of sPTB', 'Maternal prepregnancy body mass index']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C3840657', 'cui_str': '850 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0561929', 'cui_str': 'N-3 fatty acid supplementation (product)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0556216', 'cui_str': 'Fish intake (observable entity)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",852.0,0.309842,"In adjusted models, as fish intake increased, the predicted probability of sPTB decreased in lean women but increased in overweight and obese women (p for interaction < .10). ","[{'ForeName': 'Marcela C', 'Initials': 'MC', 'LastName': 'Smid', 'Affiliation': 'a Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology , University of Utah School of Medicine , Salt Lake City , UT , USA.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Stuebe', 'Affiliation': 'b Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology , University of North Carolina School of Medicine , Chapel Hill , NC , USA.'}, {'ForeName': 'Tracy A', 'Initials': 'TA', 'LastName': 'Manuck', 'Affiliation': 'b Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology , University of North Carolina School of Medicine , Chapel Hill , NC , USA.'}, {'ForeName': 'Sarbattama', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': ""d Department of Pediatric Newborn Medicine , Brigham and Women's Hospital , Boston , MA , USA.""}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2018.1439008'] 429,31820339,"A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera ® ) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL).","BACKGROUND Biosimilars are highly similar to the licensed biologic (""reference product""), with no clinically meaningful differences in safety, purity, or potency between the two products. OBJECTIVE This comparative 52-week clinical study evaluated the efficacy, safety, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-05280586 (Ruxience™ [a rituximab biosimilar]) versus rituximab reference product sourced from the EU (MabThera ® ; rituximab-EU). PATIENTS AND METHODS Subjects with CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL) and an Eastern Cooperative Oncology Group performance status 0-1 were randomized (1:1) to PF-05280586 or rituximab-EU (375 mg/m 2 intravenously [once weekly for 4 weeks at days 1, 8, 15, and 22]), stratified using the Follicular Lymphoma International Prognostic Index 2 classification. The primary endpoint was overall response rate (ORR) at week 26 (percentage of subjects achieving complete response [CR] or partial response [PR]). Therapeutic equivalence was concluded if the two-sided 95% confidence interval (CI) for the difference in ORR between groups was within the prespecified margin (± 16%). Secondary endpoints included progression-free survival (PFS), CR rate, safety, immunogenicity, PK, and PD. RESULTS A total of 394 subjects were randomized: PF-05280586 (n = 196) or rituximab-EU (n = 198). ORR at week 26 was 75.5% (PF-05280586) versus 70.7% (rituximab-EU), for a difference of 4.66%; 95% CI (- 4.16 to 13.47), which was entirely within the prespecified equivalence margin. Rates of CR were 29.3% (PF-05280586) versus 31.0% (rituximab-EU). Estimated 1-year PFS rates were 78.2% (95% CI 70.2-84.2) and 83.0% (95% CI 75.0-88.6) for PF-05280586 and rituximab-EU, respectively. Safety, immunogenicity, and mean serum concentrations were similar between groups. CONCLUSIONS The efficacy, safety, immunogenicity, PK, and PD of PF-05280586 and rituximab-EU were similar up to week 52 in subjects with previously untreated CD20-positive LTB-FL. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02213263 and EudraCT (2014-000132-41).",2020,"Estimated 1-year PFS rates were 78.2% (95% CI 70.2-84.2) and 83.0% (95% CI 75.0-88.6) for PF-05280586 and rituximab-EU, respectively.","['Subjects with CD20-positive, low-tumor-burden follicular lymphoma (LTB-FL) and an Eastern Cooperative Oncology Group performance status 0-1', 'subjects with previously untreated CD20-positive LTB-FL', 'A total of 394 subjects', 'Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL']","['rituximab-EU', 'PF-05280586 or rituximab-EU', 'Rituximab Reference Product (MabThera ® ', 'rituximab reference product sourced from the EU (MabThera ® ; rituximab-EU', 'PF-05280586 (a Rituximab Biosimilar', 'PF-05280586']","['Therapeutic equivalence', 'Rates of CR', 'progression-free survival (PFS), CR rate, safety, immunogenicity, PK, and PD', 'efficacy, safety, immunogenicity, pharmacokinetics (PK), and pharmacodynamics (PD', 'overall response rate (ORR', 'Estimated 1-year PFS rates', 'complete response [CR] or partial response [PR', 'Safety, immunogenicity, and mean serum concentrations', 'ORR', 'efficacy, safety, immunogenicity, PK, and PD of PF-05280586 and rituximab-EU']","[{'cui': 'C3888518', 'cui_str': 'CD20 antigen positive'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1449699', 'cui_str': 'Tumor Load'}, {'cui': 'C0024301', 'cui_str': 'Follicular lymphoma'}, {'cui': 'C1664181', 'cui_str': 'LTB protein, human'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C1314901', 'cui_str': 'Mabthera'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]",394.0,0.51071,"Estimated 1-year PFS rates were 78.2% (95% CI 70.2-84.2) and 83.0% (95% CI 75.0-88.6) for PF-05280586 and rituximab-EU, respectively.","[{'ForeName': 'Jeff P', 'Initials': 'JP', 'LastName': 'Sharman', 'Affiliation': 'Willamette Valley Cancer Institute and Research Center, US Oncology, 520 Country Club Rd, Eugene, OR, 97401, USA.'}, {'ForeName': 'Anna Marina', 'Initials': 'AM', 'LastName': 'Liberati', 'Affiliation': 'Università degli Studi di Perugia, S.C. Oncoematologia-A.O. Santa Maria, 05100, Terni, Italy.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Ishizawa', 'Affiliation': 'Department of Third Internal Medicine, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.'}, {'ForeName': 'Tahira', 'Initials': 'T', 'LastName': 'Khan', 'Affiliation': 'Pfizer Inc, 445 Eastern Point Rd, Groton, 06340, CT, USA. Tahira.Khan@pfizer.com.'}, {'ForeName': 'Jeffery', 'Initials': 'J', 'LastName': 'Robbins', 'Affiliation': 'Pfizer Inc, 445 Eastern Point Rd, Groton, 06340, CT, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Alcasid', 'Affiliation': 'Pfizer Inc, 500 Arcola Rd, Collegeville, 19426, PA, USA.'}, {'ForeName': 'Julie Ann', 'Initials': 'JA', 'LastName': 'Rosenberg', 'Affiliation': 'Pfizer Inc, 445 Eastern Point Rd, Groton, 06340, CT, USA.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Aurer', 'Affiliation': 'University Hospital Centre Zagreb, Kišpatićeva ul. 12, 10000, Zagreb, Croatia.'}]","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",['10.1007/s40259-019-00398-7'] 430,32052313,"Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.","OBJECTIVES The aims were to demonstrate pharmacokinetic (PK) similarity between DRL_RI, a proposed rituximab biosimilar, and two reference innovator products (Rituxan ® [RTX-US] and MabThera ® [RTX-EU]) and compare their pharmacodynamics (PD), efficacy, safety, and immunogenicity in rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX)-based therapy and no prior biologic administration. METHODS In this randomized, double-blind, parallel-group study, 276 patients with moderate-to-severe active RA were randomized to receive DRL_RI, RTX-US, or RTX-EU on days 1 and 15. The primary PK end points included area under the concentration-time curve from time 0 to 336 h after first infusion (AUC 0-14 days, first infusion ), AUC from day 1 through week 16 (AUC 0-∞, entire course ), and AUC from time 0 to time of last quantifiable concentration after the second dose (AUC 0-t, second infusion ). Secondary end points included other PK parameters, such as maximum concentration (C max ), time to C max after each infusion, terminal half-life, systemic clearance, and volume of distribution after the second infusion; PD parameters and efficacy until week 24; safety and immunogenicity at week 24 and 52; and B cell recovery until week 52. AUC from time 0 to time of last quantifiable concentration after the first dose and over the entire course from day 1 through week 16 (AUC 0-t, entire course ) was analyzed as an exploratory end point. RESULTS The 91% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the primary end point of AUC 0-∞, entire course were within the bioequivalence limits of 80-125% for all comparisons: DRL_RI versus RTX-US 100.37% (92.30-109.14), DRL_RI versus RTX-EU 93.58% (85.98-101.85), and RTX-US versus RTX-EU 93.24% (85.62-101.54). PD outcomes (peripheral blood B-cell depletion and mean change in Disease Activity Score [28 joints]-C-reactive protein), efficacy, safety, and immunogenicity were also comparable between DRL_RI and the reference products. CONCLUSION DRL_RI, a proposed biosimilar, demonstrated three-way PK similarity with RTX-EU and RTX-US, the reference innovator products, with comparable efficacy, PD, safety, and immunogenicity. CLINICAL TRIALS REGISTRATION NUMBER ClinicalTrials.gov identifier: NCT02296775.",2020,"The 91% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the primary end point of AUC 0-∞, entire course were within the bioequivalence limits of 80-125% for all comparisons: DRL_RI versus RTX-US 100.37% (92.30-109.14), DRL_RI versus RTX-EU 93.58% (85.98-101.85), and RTX-US versus RTX-EU 93.24% (85.62-101.54).","['276 patients with moderate-to-severe active RA', 'rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX)-based therapy and no prior biologic administration', 'Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis']","['DRL_RI Versus Reference Rituximab', 'DRL_RI, RTX-US, or RTX-EU']","['mean change in Disease Activity Score [28\xa0joints]-C-reactive protein), efficacy, safety, and immunogenicity', 'Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity', 'PK parameters, such as maximum concentration (C max ), time to C max after each infusion, terminal half-life, systemic clearance, and volume of distribution after the second infusion; PD parameters and efficacy until week 24; safety and immunogenicity', 'efficacy, PD, safety, and immunogenicity', 'PD outcomes (peripheral blood B-cell depletion and', 'geometric mean ratios (GMRs', 'pharmacodynamics (PD), efficacy, safety, and immunogenicity', 'area under the concentration-time curve']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0333668', 'cui_str': 'Depletion (morphologic abnormality)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",276.0,0.255532,"The 91% confidence intervals (CIs) of the geometric mean ratios (GMRs) for the primary end point of AUC 0-∞, entire course were within the bioequivalence limits of 80-125% for all comparisons: DRL_RI versus RTX-US 100.37% (92.30-109.14), DRL_RI versus RTX-EU 93.58% (85.98-101.85), and RTX-US versus RTX-EU 93.24% (85.62-101.54).","[{'ForeName': 'Vikram Muralidhar', 'Initials': 'VM', 'LastName': 'Haridas', 'Affiliation': 'Sushruta Multispeciality Hospital, Hubballi, India.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Katta', 'Affiliation': 'Katta Hospital, S.R. Kalla Memorial General Hospital, Jaipur, India.'}, {'ForeName': 'Ajit', 'Initials': 'A', 'LastName': 'Nalawade', 'Affiliation': 'Inamdar Multispecialty Hospital, Pune, India.'}, {'ForeName': 'Sandeep', 'Initials': 'S', 'LastName': 'Kharkar', 'Affiliation': 'Govt Medical College and Hospital, Medical Square, Nagpur, India.'}, {'ForeName': 'Vyacheslav', 'Initials': 'V', 'LastName': 'Zhdan', 'Affiliation': 'M.V.Sklifosovskyi Poltava Regional Hospital, Poltava, Ukraine.'}, {'ForeName': 'Olena', 'Initials': 'O', 'LastName': 'Garmish', 'Affiliation': 'SI NSC M.D. Strazhesko Institute of Cardiology, NAMS of Ukraine, Kiev, Ukraine.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Lopez-Lazaro', 'Affiliation': ""Clinical Sciences, Dr. Reddy's Laboratories Ltd., Elisabethenanlage 11, 4051, Basel, Switzerland. llopezlazaro@drreddys.com.""}, {'ForeName': 'Sonica Sachdeva', 'Initials': 'SS', 'LastName': 'Batra', 'Affiliation': ""Medical Sciences, Dr. Reddy's Laboratories Ltd., Bachupally, Hyderabad, 500090, India.""}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Kankanwadi', 'Affiliation': ""Development, Biologics, Dr. Reddy's Laboratories Ltd., Elisabethenanlage 11, 4051, Basel, Switzerland.""}]","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",['10.1007/s40259-020-00406-1'] 431,31825542,Drug treatment for spinal muscular atrophy type I.,"BACKGROUND Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the survival motor neuron 1 (SMN1) gene on chromosome 5, or a heterozygous deletion in combination with a point mutation in the second SMN1 allele. This results in degeneration of anterior horn cells, which leads to progressive muscle weakness. By definition, children with SMA type I are never able to sit without support and usually die or become ventilator dependent before the age of two years. There have until very recently been no drug treatments to influence the course of SMA. We undertook this updated review to evaluate new evidence on emerging treatments for SMA type I. The review was first published in 2009 and previously updated in 2011. OBJECTIVES To assess the efficacy and safety of any drug therapy designed to slow or arrest progression of spinal muscular atrophy (SMA) type I. SEARCH METHODS We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and ISI Web of Science conference proceedings in October 2018. We also searched two trials registries to identify unpublished trials (October 2018). SELECTION CRITERIA We sought all randomised controlled trials (RCTs) or quasi-RCTs that examined the efficacy of drug treatment for SMA type I. Included participants had to fulfil clinical criteria and have a genetically confirmed deletion or mutation of the SMN1 gene (5q11.2-13.2). The primary outcome measure was age at death or full-time ventilation. Secondary outcome measures were acquisition of motor milestones, i.e. head control, rolling, sitting or standing, motor milestone response on disability scores within one year after the onset of treatment, and adverse events and serious adverse events attributable to treatment during the trial period. Treatment strategies involving SMN1 gene replacement with viral vectors are out of the scope of this review. DATA COLLECTION AND ANALYSIS We followed standard Cochrane methodology. MAIN RESULTS We identified two RCTs: one trial of intrathecal nusinersen in comparison to a sham (control) procedure in 121 randomised infants with SMA type I, which was newly included at this update, and one small trial comparing riluzole treatment to placebo in 10 children with SMA type I. The RCT of intrathecally-injected nusinersen was stopped early for efficacy (based on a predefined Hammersmith Infant Neurological Examination-Section 2 (HINE-2) response). At the interim analyses after 183 days of treatment, 41% (21/51) of nusinersen-treated infants showed a predefined improvement on HINE-2, compared to 0% (0/27) of participants in the control group. This trial was largely at low risk of bias. Final analyses (ranging from 6 months to 13 months of treatment), showed that fewer participants died or required full-time ventilation (defined as more than 16 hours daily for 21 days or more) in the nusinersen-treated group than the control group (hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.32 to 0.89; N = 121; a 47% lower risk; moderate-certainty evidence). A proportion of infants in the nusinersen group and none of 37 infants in the control group achieved motor milestones: 37/73 nusinersen-treated infants (51%) achieved a motor milestone response on HINE-2 (risk ratio (RR) 38.51, 95% CI 2.43 to 610.14; N = 110; moderate-certainty evidence); 16/73 achieved head control (RR 16.95, 95% CI 1.04 to 274.84; moderate-certainty evidence); 6/73 achieved independent sitting (RR 6.68, 95% CI 0.39 to 115.38; moderate-certainty evidence); 7/73 achieved rolling over (RR 7.70, 95% CI 0.45 to 131.29); and 1/73 achieved standing (RR 1.54, 95% CI 0.06 to 36.92; moderate-certainty evidence). Seventy-one per cent of nusinersen-treated infants versus 3% of infants in the control group were responders on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) measure of motor disability (RR 26.36, 95% CI 3.79 to 183.18; N = 110; moderate-certainty evidence). Adverse events and serious adverse events occurred in the majority of infants but were no more frequent in the nusinersen-treated group than the control group (RR 0.99, 95% CI 0.92 to 1.05 and RR 0.70, 95% CI 0.55 to 0.89, respectively; N = 121; moderate-certainty evidence). In the riluzole trial, three of seven children treated with riluzole were still alive at the ages of 30, 48, and 64 months, whereas all three children in the placebo group died. None of the children in the riluzole or placebo group developed the ability to sit, which was the only milestone reported. There were no adverse effects. The certainty of the evidence for all measured outcomes from this study was very low, because the study was too small to detect or rule out an effect, and had serious limitations, including baseline differences. This trial was stopped prematurely because the pharmaceutical company withdrew funding. Various trials and studies investigating treatment strategies other than nusinersen, such as SMN2 augmentation by small molecules, are ongoing. AUTHORS' CONCLUSIONS Based on the very limited evidence currently available regarding drug treatments for SMA type 1, intrathecal nusinersen probably prolongs ventilation-free and overall survival in infants with SMA type I. It is also probable that a greater proportion of infants treated with nusinersen than with a sham procedure achieve motor milestones and can be classed as responders to treatment on clinical assessments (HINE-2 and CHOP INTEND). The proportion of children experiencing adverse events and serious adverse events on nusinersen is no higher with nusinersen treatment than with a sham procedure, based on evidence of moderate certainty. It is uncertain whether riluzole has any effect in patients with SMA type I, based on the limited available evidence. Future trials could provide more high-certainty, longer-term evidence to confirm this result, or focus on comparing new treatments to nusinersen or evaluate them as an add-on therapy to nusinersen.",2019,"The proportion of children experiencing adverse events and serious adverse events on nusinersen is no higher with nusinersen treatment than with a sham procedure, based on evidence of moderate certainty.","['children with SMA type I', 'I. Included participants had to fulfil clinical criteria and have a genetically confirmed deletion or mutation of the SMN1 gene (5q11.2-13.2', 'patients with SMA type', '121 randomised infants with SMA type I, which was newly included at this update, and one small trial comparing', 'infants with SMA type I', 'SMA type', 'spinal muscular atrophy type I', '10 children with SMA type I']","['riluzole or placebo', 'placebo', 'intrathecal nusinersen', 'SMN1 gene replacement with viral vectors', 'riluzole', 'riluzole treatment to placebo']","['Adverse events and serious adverse events', 'efficacy and safety', 'motor milestones', 'participants died or required full-time ventilation', ""Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders"", 'motor milestone response on HINE-2 (risk ratio', 'ventilation-free and overall survival', 'motor disability', 'adverse effects', 'age at death or full-time ventilation', 'acquisition of motor milestones, i.e. head control, rolling, sitting or standing, motor milestone response on disability scores within one year after the onset of treatment, and adverse events and serious adverse events']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C1442161', 'cui_str': 'Deletion (morphologic abnormality)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0043116', 'cui_str': 'Werdnig Hoffman Disease'}]","[{'cui': 'C0073379', 'cui_str': 'Riluzole'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4301236', 'cui_str': 'nusinersen'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0442335', 'cui_str': 'Vectors (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}, {'cui': 'C0031525', 'cui_str': 'Philadelphia'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0027868', 'cui_str': 'Neuromuscular Diseases'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.408622,"The proportion of children experiencing adverse events and serious adverse events on nusinersen is no higher with nusinersen treatment than with a sham procedure, based on evidence of moderate certainty.","[{'ForeName': 'Renske I', 'Initials': 'RI', 'LastName': 'Wadman', 'Affiliation': 'University Medical Center Utrecht, Brain Center Rudolf Magnus, Department of Neurology, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.'}, {'ForeName': 'W Ludo', 'Initials': 'WL', 'LastName': 'van der Pol', 'Affiliation': 'University Medical Center Utrecht, Brain Center Rudolf Magnus, Department of Neurology, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.'}, {'ForeName': 'Wendy Mj', 'Initials': 'WM', 'LastName': 'Bosboom', 'Affiliation': 'Onze Lieve Vrouwe Gasthuis locatie West, Department of Neurology, Amsterdam, Netherlands.'}, {'ForeName': 'Fay-Lynn', 'Initials': 'FL', 'LastName': 'Asselman', 'Affiliation': 'University Medical Center Utrecht, Brain Center Rudolf Magnus, Department of Neurology, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'van den Berg', 'Affiliation': 'University Medical Center Utrecht, Brain Center Rudolf Magnus, Department of Neurology, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.'}, {'ForeName': 'Susan T', 'Initials': 'ST', 'LastName': 'Iannaccone', 'Affiliation': 'University of Texas Southwestern Medical Center, Department of Pediatrics, 5323 Harry Hines Boulevard, Dallas, Texas, USA, 75390.'}, {'ForeName': 'Alexander Fje', 'Initials': 'AF', 'LastName': 'Vrancken', 'Affiliation': 'University Medical Center Utrecht, Brain Center Rudolf Magnus, Department of Neurology, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD006281.pub5'] 432,32175655,Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.,"AIM To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Two randomized, double-blind, placebo-controlled phase 2 trials were conducted. The single-dose study (n = 48) was a first-in-patient, sequential dose-escalation study. Patients received a single subcutaneous injection of efpeglenatide (2-100 μg/kg) or placebo. The repeated-dose study (n = 71) was a multiple-ascending-dose trial. Patients received weekly (1, 2 or 4 mg once weekly; 8-week period) or monthly (8, 12 or 16 mg once monthly; 9-week period) subcutaneous injections of efpeglenatide or placebo (without titration). RESULTS Both studies demonstrated dose-proportional increases in efpeglenatide serum concentrations. The median time to attain maximum serum concentration (t max ) for efpeglenatide ranged from 72 to 144 hours in the single-dose study and from 48 to 120 hours in the repeated-dose study (following final dose). Geometric mean t 1/2 ranged from 135 to 180 hours across studies. Peak-to-trough ratios in the repeated-dose study ranged from 1.3 to 1.4 with once-weekly dosing and from 5.9 to 12.9 with once-monthly dosing. Following a single dose of efpeglenatide 14-100 μg/kg, fasting plasma glucose and postprandial plasma glucose levels were decreased at week 1 and remained below baseline levels for ≥3 weeks post-dosing. Repeated doses of efpeglenatide led to significant reductions in glycated haemoglobin vs placebo. In both studies, efpeglenatide was generally well tolerated. Gastrointestinal disorders were the most frequently reported treatment-emergent adverse events in efpeglenatide-treated patients. CONCLUSIONS The delayed t max, long half-life, and low peak-to-trough ratios observed demonstrate potential for improved efficacy and dosing flexibility, with good tolerability of efpeglenatide in patients with T2D.",2020,Repeated doses of efpeglenatide led to significant reductions in HbA 1c versus placebo.,"['patients with type 2 diabetes (T2D', 'patients with type 2 diabetes', 'patients with T2D']","['efpeglenatide or placebo (without titration', 'placebo', 'single subcutaneous injection of efpeglenatide']","['Gastrointestinal disorders', 'tolerated', 'Peak-to-trough ratios', 'delayed t max, long half-life, and low peak-to-trough ratios', 'efpeglenatide serum concentrations', 'efficacy, safety, and pharmacokinetic/pharmacodynamic properties of efpeglenatide', 'FPG and PPG levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}]","[{'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0444506', 'cui_str': 'Trough (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0049716', 'cui_str': 'thioGDP'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.226372,Repeated doses of efpeglenatide led to significant reductions in HbA 1c versus placebo.,"[{'ForeName': 'Kun-Ho', 'Initials': 'KH', 'LastName': 'Yoon', 'Affiliation': 'The Catholic University of Korea, Seoul, Republic of Korea.'}, {'ForeName': 'Jahoon', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.'}, {'ForeName': 'Se Chang', 'Initials': 'SC', 'LastName': 'Kwon', 'Affiliation': 'Hanmi Pharmaceutical Co., Ltd, Seoul, Republic of Korea.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Trautmann', 'Affiliation': 'ProSciento, Chula Vista, California, USA.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Hompesch', 'Affiliation': 'ProSciento, Chula Vista, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Sanofi Canada, Laval, Quebec, Canada.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Sorli', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14032'] 433,32246728,Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.,"BACKGROUND AND OBJECTIVE When patients seek to discontinue buprenorphine (BUP) treatment, monthly injectable extended-release naltrexone (XR-NTX) may help them avoid relapse. The efficacy of low ascending doses of oral NTX vs placebo for patients transitioning from BUP to XR-NTX is evaluated in this study. METHODS In a phase 3, hybrid residential/outpatient study, clinically stable participants with opioid use disorder (N = 101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment, were randomized (1:1) to 7 residential days of descending doses of BUP and low ascending doses of oral NTX (NTX/BUP, n = 50) or placebo (PBO-N/BUP, n = 51). Both groups received standing ancillary medications and psychoeducational counseling. Following negative naloxone challenge, participants received XR-NTX (day 8). The primary endpoint was the proportion of participants who received and tolerated XR-NTX. RESULTS There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407). The mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score less than or equal to 12 during the treatment period (days 1-7) was similar for NTX/BUP and PBO-N/BUP groups (5.8 vs 6.3; P = .511). Opioid withdrawal symptoms during XR-NTX induction and post-XR-NTX observation period (days 8-11) were mild and similar between groups (mean peak COWS score: NTX/BUP, 5.1 vs PBO-N/BUP, 5.4; P = .464). Adverse events were mostly mild/moderate. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE Low ascending doses of oral NTX did not increase induction rates onto XR-NTX compared with placebo. The overall rate of successful induction across treatment groups supports a brief BUP taper with standing ancillary medications as a well-tolerated approach for patients seeking transition from BUP to XR-NTX. (Am J Addict 2020;00:00-00).",2020,There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407).,"['Patients with Opioid Use Disorder from', 'clinically stable participants with opioid use disorder (N\u2009=\u2009101), receiving BUP for more than or equal to 3 months and seeking antagonist treatment', 'patients transitioning from BUP to XR-NTX']","['naltrexone (XR-NTX', 'oral NTX', 'XR-NTX', 'Buprenorphine', 'discontinue buprenorphine (BUP', 'placebo', 'BUP and low ascending doses of oral NTX (NTX/BUP, n\u2009=\u200950) or placebo (PBO-N/BUP, n\u2009=\u200951', 'standing ancillary medications and psychoeducational counseling', 'Naltrexone', 'oral NTX vs placebo']","['overall rate of successful induction', 'proportion of participants who received and tolerated XR-NTX', 'Adverse events', 'mean number of days with peak Clinical Opiate Withdrawal Scale (COWS) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4019079', 'cui_str': 'Care Transition'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C4706547', 'cui_str': 'Clinical Opiate Withdrawal Scale score'}]",,0.0223737,There was no statistical difference between groups for participants receiving a first dose of XR-NTX: 68.6% (NTX/BUP) vs 76.0% (PBO-N/BUP; P = .407).,"[{'ForeName': 'Sandra D', 'Initials': 'SD', 'LastName': 'Comer', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Mannelli', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Danesh', 'Initials': 'D', 'LastName': 'Alam', 'Affiliation': 'Northwestern Medicine Central DuPage Hospital, Winfield, Illinois.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Douaihy', 'Affiliation': 'Departments of Psychiatry and Medicine, Western Psychiatric Hospital, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Narinder', 'Initials': 'N', 'LastName': 'Nangia', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Akerman', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Zavod', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Bernard L', 'Initials': 'BL', 'LastName': 'Silverman', 'Affiliation': 'Alkermes, Inc., Waltham, Massachusetts.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Sullivan', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York.'}]",The American journal on addictions,['10.1111/ajad.13024'] 434,30896608,Mediators in Preterm Infants With Late-onset Sepsis: A Randomized Controlled Trial.,"OBJECTIVE To evaluate biochemical and clinical effects of 2 different doses of vitamin D supplementation in preterm infants with late-onset sepsis (LOS). STUDY DESIGN A double blinded randomized controlled stratified trial included preterm infants with gestational age (GA) ≥28 weeks with LOS. Subjects were randomly assigned to receive 400 or 800 IU/day of vitamin D3. Serum concentrations of 25(OH)D, TNF-α, and IL-6 were measured at enrollment, 7 days after vitamin D supplementation, and at 40 weeks of postmenstrual age (PMA). Short-term outcomes and growth parameters were assessed. RESULTS A total of 50 infants were enrolled, 25 in each group. Seventy-six percentage of enrolled infants were vitamin D-deficient at enrollment in both groups whereas only one infant in the 400 IU and none in the 800 IU group remained deficient at 40 week's PMA; vitamin D concentrations at 40 weeks PMA were 54.8 ± 35.1 and 67.4 ± 37.1 ng/mL, respectively, P = 0.01). None of the infants enrolled in the study had signs of vitamin D toxicity. Serum pro-inflammatory cytokines IL-6 and TNF- α concentrations decreased at 1 week and at discharge in both groups without differences between groups. The 2 groups did not differ in anthropometric measurements, duration of oxygen and respiratory support, duration of antimicrobial use, length of hospital stay, and mortality. CONCLUSIONS A dose of 400 IU of vitamin D was adequate to treat vitamin D deficiency in the majority of premature infants with LOS. The 2 dosing regimens did not differ in clinical or biochemical changes.",2019,Serum pro-inflammatory cytokines IL-6 and TNF- α concentrations decreased at 1 week and at discharge in both groups without differences between groups.,"['Preterm Infants With Late-onset Sepsis', 'premature infants with LOS', 'A total of 50 infants were enrolled, 25 in each group', 'preterm infants with gestational age (GA) ≥28 weeks with LOS', 'preterm infants with late-onset sepsis (LOS']","['vitamin D', 'vitamin D supplementation', 'vitamin D3']","['vitamin D-deficient', 'Serum pro-inflammatory cytokines IL-6 and TNF- α concentrations', 'anthropometric measurements, duration of oxygen and respiratory support, duration of antimicrobial use, length of hospital stay, and mortality', 'vitamin D toxicity', 'Serum concentrations of 25(OH)D, TNF-α, and IL-6']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C3265062', 'cui_str': 'vitamin D3'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0242154', 'cui_str': 'Vitamin D toxicity'}]",50.0,0.588652,Serum pro-inflammatory cytokines IL-6 and TNF- α concentrations decreased at 1 week and at discharge in both groups without differences between groups.,"[{'ForeName': 'Hesham', 'Initials': 'H', 'LastName': 'Abdel-Hady', 'Affiliation': 'Department of Pediatrics.'}, {'ForeName': 'Sohier', 'Initials': 'S', 'LastName': 'Yahia', 'Affiliation': 'Department of Pediatrics.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Megahed', 'Affiliation': 'Department of Pediatrics.'}, {'ForeName': 'Abeer', 'Initials': 'A', 'LastName': 'Mosbah', 'Affiliation': 'Department of Clinical Pathology, Faculty of Medicine-Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Basma', 'Initials': 'B', 'LastName': 'Seif', 'Affiliation': 'Department of Pediatrics.'}, {'ForeName': 'Eman', 'Initials': 'E', 'LastName': 'Nageh', 'Affiliation': 'Department of Pediatrics.'}, {'ForeName': 'Indrani', 'Initials': 'I', 'LastName': 'Bhattacharjee', 'Affiliation': ""Department of Neonatology, Cleveland Clinic Children's Hospital, Cleveland, OH.""}, {'ForeName': 'Hany', 'Initials': 'H', 'LastName': 'Aly', 'Affiliation': ""Department of Neonatology, Cleveland Clinic Children's Hospital, Cleveland, OH.""}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002238'] 435,31733631,"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects.","Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and D-amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and D-amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three substances induce distinct acute subjective effects. However, differences in acute responses to these prototypical psychoactive substances have not been characterized in a controlled study. We investigated the acute autonomic, subjective, and endocrine effects of single doses of LSD (0.1 mg), MDMA (125 mg), D-amphetamine (40 mg), and placebo in a randomized, double-blind, cross-over study in 28 healthy subjects. All of the substances produced comparable increases in hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses at the doses used. LSD and MDMA increased heart rate more than D-amphetamine, and D-amphetamine increased blood pressure more than LSD and MDMA. LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine. LSD also produced greater subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine. LSD also induced greater impairments in subjective ratings of concentration, sense of time, and speed of thinking compared with MDMA and D-amphetamine. MDMA produced greater ratings of good drug effects, liking, high, and ego dissolution compared with D-amphetamine. D-Amphetamine increased ratings of activity and concentration compared with LSD. MDMA but not LSD or D-amphetamine increased plasma concentrations of oxytocin. None of the substances altered plasma concentrations of brain-derived neurotrophic factor. These results indicate clearly distinct acute effects of LSD, MDMA, and D-amphetamine and may assist the dose-finding in substance-assisted psychotherapy research.",2020,LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine.,"['healthy subjects', '28 healthy subjects']","['3,4-methylenedioxymethamphetamine', 'LSD, MDMA, and D-amphetamine', 'LSD', 'MDMA', 'placebo', 'Lysergic acid diethylamide (LSD', 'D-amphetamine, and D-amphetamine', 'D-amphetamine']","['hemodynamic effects, body temperature, and pupil size, indicating equivalent autonomic responses', 'blood pressure', 'subjective ratings of concentration, sense of time, and speed of thinking', 'ratings of activity and concentration', 'plasma concentrations of oxytocin', 'subjective drug effects, ego dissolution, introversion, emotional excitation, anxiety, and inactivity than MDMA and D-amphetamine', 'LSD and MDMA increased heart rate', 'Consciousness scale and Mystical Experience Questionnaire', 'ratings of good drug effects, liking, high, and ego dissolution']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0115471', 'cui_str': 'MDMA'}, {'cui': 'C0024334', 'cui_str': 'LSD'}, {'cui': 'C0011812', 'cui_str': 'dexamfetamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0728867', 'cui_str': 'Drug action (finding)'}, {'cui': 'C0013712', 'cui_str': 'Ego'}, {'cui': 'C0021924', 'cui_str': 'Introversion'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0115471', 'cui_str': 'MDMA'}, {'cui': 'C0011812', 'cui_str': 'dexamfetamine'}, {'cui': 'C0024334', 'cui_str': 'LSD'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0222045'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",28.0,0.0410698,LSD induced significantly higher ratings on the 5 Dimensions of Altered States of Consciousness scale and Mystical Experience Questionnaire than MDMA and D-amphetamine.,"[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Holze', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Vizeli', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Müller', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ley', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Duerig', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland.'}, {'ForeName': 'Nimmy', 'Initials': 'N', 'LastName': 'Varghese', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Eckert', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Borgwardt', 'Affiliation': 'Psychiatric University Hospital (UPK), University of Basel, Basel, 4012, Switzerland.'}, {'ForeName': 'Matthias E', 'Initials': 'ME', 'LastName': 'Liechti', 'Affiliation': 'Department of Biomedicine and Department of Clinical Research, Division of Clinical Pharmacology and Toxicology, University Hospital Basel, University of Basel, Basel, 4056, Switzerland. matthias.liechti@usb.ch.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-019-0569-3'] 436,31939063,"Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.","OBJECTIVE Our objective was to evaluate the long-term efficacy, safety, and immunogenicity of the infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX), in patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78 weeks or who switched from reference infliximab (Remicade ® ) sourced from the EU (IFX-EU) at week 30 or week 54 in the REFLECTIONS B537-02 study. METHODS In this phase III, double-blind, active-controlled study, patients with moderate-to-severe active RA were initially randomized to PF-SZ-IFX or IFX-EU, each with methotrexate (treatment period [TP] 1; N = 650). At week 30, patients receiving PF-SZ-IFX continued PF-SZ-IFX; patients receiving IFX-EU were re-randomized to continue IFX-EU or switch to PF-SZ-IFX (TP2; n = 566). From weeks 54 to 78, all patients received open-label treatment with PF-SZ-IFX (TP3; n = 505). Efficacy, safety, and immunogenicity data were analyzed during TP3. RESULTS Efficacy was sustained and comparable across groups at week 78, with American College of Rheumatology criteria for ≥ 20% clinical improvement response rates of 75.9% (biosimilar group), 77.8% (week 30 switch group), and 68.3% (week 54 switch group). The incidence of treatment-emergent adverse events was 28.9%, 29.4%, and 30.2%, respectively. The proportion of patients who were antidrug antibody (ADA) positive and neutralizing antibody positive (as a percentage of ADA-positive patients) was stable and comparable between groups. CONCLUSIONS Results to week 78 continue to support the efficacy, safety, and immunogenicity of PF-SZ-IFX in patients with moderate-to-severe active RA. There were no clinically meaningful differences between groups, independent of a single treatment transition from IFX-EU to PF-SZ-IFX at week 30 or week 54. TRIAL REGISTRATION NUMBER NCT02222493.",2020,"Efficacy was sustained and comparable across groups at week 78, with American College of Rheumatology criteria for ≥ 20% clinical improvement response rates of 75.9% (biosimilar group), 77.8% (week 30 switch group), and 68.3% (week 54 switch group).","['patients with moderate-to-severe active RA', 'patients with rheumatoid arthritis (RA) who continued biosimilar treatment throughout 78\xa0weeks or who switched from reference infliximab (Remicade ® ) sourced from the EU (IFX-EU) at week 30 or week 54 in the REFLECTIONS B537-02 study', 'Patients with Rheumatoid Arthritis']","['PF-SZ-IFX or IFX-EU, each with methotrexate', 'infliximab biosimilar, PF-06438179/GP1111 (PF-SZ-IFX', 'Infliximab (IFX', 'open-label treatment with PF-SZ-IFX (TP3']","['efficacy, safety, and immunogenicity', 'incidence of treatment-emergent adverse events', 'Efficacy', 'Efficacy, safety, and immunogenicity data', 'long-term efficacy, safety, and immunogenicity', 'antidrug antibody (ADA) positive and neutralizing antibody positive']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0723012', 'cui_str': 'Remicade'}, {'cui': 'C4521696', 'cui_str': 'Source (property)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0075032', 'cui_str': 'TP3'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}, {'cui': 'C1609515', 'cui_str': 'Neutralising antibodies positive'}]",650.0,0.0748742,"Efficacy was sustained and comparable across groups at week 78, with American College of Rheumatology criteria for ≥ 20% clinical improvement response rates of 75.9% (biosimilar group), 77.8% (week 30 switch group), and 68.3% (week 54 switch group).","[{'ForeName': 'Stanley B', 'Initials': 'SB', 'LastName': 'Cohen', 'Affiliation': 'Metroplex Clinical Research Center, Dallas, TX, USA. arthdoc@aol.com.'}, {'ForeName': 'Sebastiao C', 'Initials': 'SC', 'LastName': 'Radominski', 'Affiliation': 'Universidade Federal do Paraná, Rua General Carneiro, 181-Alto Da Glória, Curitiba, PR, 80060-900, Brazil.'}, {'ForeName': 'Hideto', 'Initials': 'H', 'LastName': 'Kameda', 'Affiliation': 'Toho University, 2-22-36, Ohashi Meguro-ku, Tokyo, 153-8515, Japan.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Kivitz', 'Affiliation': 'Altoona Center for Clinical Research, Duncansville, PA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tee', 'Affiliation': 'Department of Medicine, Medical Center Manila, University of the Philippines, Manila, Philippines.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Cronenberger', 'Affiliation': 'Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Pfizer Inc, La Jolla, CA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Hackley', 'Affiliation': 'Pfizer R&D UK, Ltd, Sandwich, Kent, UK.'}, {'ForeName': 'Muhammad I', 'Initials': 'MI', 'LastName': 'Rehman', 'Affiliation': 'Pfizer Inc, Andover, MA, USA.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'von Richter', 'Affiliation': 'Biopharmaceuticals, Hexal AG (a Sandoz company), Holzkirchen, Germany.'}, {'ForeName': 'Rieke', 'Initials': 'R', 'LastName': 'Alten', 'Affiliation': 'Schlosspark-Klinik University Medicine, Heubnerweg 2, 14059, Berlin, Germany.'}]","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",['10.1007/s40259-019-00403-z'] 437,31241541,ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial.,"BACKGROUND The benefit of immediate antiretroviral therapy (ART) at CD4 >500 cells/μL was established in the Strategic Timing of Antiretroviral Treatment (START) study. The benefits and risks of immediate ART in participants with low pretreatment viremia, including virologic suppressors, were further assessed. SETTING Randomized prospective international study. METHODS START participants with enrollment viremia <3000 c/mL were included. We compared clinical outcomes (grade 4 adverse events, hospitalizations, or death), plasma viremia, CD4 counts, and changes in biomarkers in immediate versus deferred ART groups. RESULTS Participants (N = 1134 including 93 with viremia ≤50 c/mL) had a median age of 37 years, 40% were women, and median CD4 was 713 cells/µL. Ninety-seven percent in the immediate and 29% in the deferred arm initiated ART at a median of 6 and 699 days, respectively. Clinical outcomes were experienced in 64 versus 61 patients in immediate and deferred arms (hazard ratio 1.10, 95% confidence interval: 0.77 to 1.56). The CD4 count difference was 125 cells/µL at 12 and 235 cells/µL at 36 months higher in the immediate versus deferred groups. D-dimer and VCAM levels decreased, and C-reactive protein increased, in the immediate arm at month 8. No significant changes in CD4 counts or biomarkers were observed in persons who maintained spontaneous virologic suppression. CONCLUSIONS START participants with low enrollment viremia experienced higher CD4 counts, greater proportion with suppressed viremia, and decreases in D-dimer levels on immediate ART despite the lack of difference in serious clinical outcomes. These data support immediate ART in people with low viremia, although equipoise remains for suppressors.",2019,"D-dimer and VCAM levels decreased, and C-reactive protein increased, in the immediate arm at month 8.","['START participants with enrollment viremia <3000 c/mL were included', 'HIV-Positive Persons With Low Pretreatment Viremia', 'participants with low pretreatment viremia, including virologic suppressors', 'Participants (N = 1134 including 93 with viremia ≤50 c/mL) had a median age of 37 years, 40% were women, and median CD4 was 713 cells/µL. Ninety-seven percent in the immediate and 29% in the deferred arm']",['immediate antiretroviral therapy (ART) at CD4'],"['D-dimer and VCAM levels', 'C-reactive protein', 'CD4 counts or biomarkers', 'CD4 counts', 'clinical outcomes (grade 4 adverse events, hospitalizations, or death), plasma viremia, CD4 counts, and changes in biomarkers in immediate versus deferred ART groups', 'CD4 count difference']","[{'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C0470279', 'cui_str': 'Three thousand'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439073', 'cui_str': '97 (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}]","[{'cui': 'C0060323', 'cui_str': 'D-dimer fragments'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",,0.406299,"D-dimer and VCAM levels decreased, and C-reactive protein increased, in the immediate arm at month 8.","[{'ForeName': 'Irini', 'Initials': 'I', 'LastName': 'Sereti', 'Affiliation': 'HIV Pathogenesis Section, NIAID/NIH, Bethesda, MD.'}, {'ForeName': 'Roy M', 'Initials': 'RM', 'LastName': 'Gulick', 'Affiliation': 'Infectious Diseases, Weill Cornell Medicine, Weill Cornell Medical College, Cornell University, New York, NY.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Krishnan', 'Affiliation': 'HIV Pathogenesis Section, NIAID/NIH, Bethesda, MD.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Migueles', 'Affiliation': 'HIV-Specific Immunity Section, NIAID/NIH, Bethesda, MD.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Palfreeman', 'Affiliation': 'Department of Genitourinary Medicine, Leicester Royal Infirmary, Leicester, United Kingdom.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Touzeau-Römer', 'Affiliation': 'Department of Immunodermatology and Infectious Skin Diseases, University Vienna General Hospital, Vienna, Austria.'}, {'ForeName': 'Waldo H', 'Initials': 'WH', 'LastName': 'Belloso', 'Affiliation': 'CICAL and Infectious Diseases Section, Internal Medicine Service, Hospital Italiano de Buenos Aires Argentina, Buenos Aires, Argentina.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Emery', 'Affiliation': 'Faculty of Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Matthew G', 'Initials': 'MG', 'LastName': 'Law', 'Affiliation': 'Faculty of Medicine, Kirby Institute, University of New South Wales, Sydney, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002052'] 438,32048107,A time-to-event analysis of the exposure-response relationship for bezlotoxumab concentrations and CDI recurrence.,"Bezlotoxumab is a monoclonal antibody approved for the prevention of recurrent Clostridium difficile infection (rCDI). In a previous exposure-response (E-R) analysis of bezlotoxumab exposure and rCDI, based on data from two phase 3 trials in participants who received placebo or bezlotoxumab 10 mg/kg, rCDI was treated as a binary endpoint and discontinued subjects were imputed as not having rCDI, resulting in an apparent positive E-R trend between rCDI rates and bezlotoxumab exposure. Therefore, a time-to-event (TTE) analysis was applied to investigate the E-R relationship, accounting for the time to rCDI occurrence and participant discontinuation. A TTE model, applying a time-dependent hazard function and right-censoring of data based on rCDI, discontinuation, or study end was developed. Exposure effects and covariates effects were evaluated as predictors affecting the hazard. The TTE model consisted of a Gompertz function with age, endogenous immunoglobulin G to C. difficile toxin B (IgG-B), history of CDI, hospitalization, sex, Charlson Comorbidity Index, and concomitant use of systemic antibiotics affecting the hazard. Exposure effects were characterized with a maximum effect (E max ) E-R relationship on the baseline parameter, and bezlotoxumab exposures achieved at the 10 mg/kg dose were found to be on the plateau of the E-R curve. Endogenous IgG-B significantly impacted the E max , indicating that low-titer participants derive a greater benefit from bezlotoxumab treatment compared with high-titer participants. The results support the conclusions of the previous E-R analysis, where exposures achieved at the 10 mg/kg dose are on the plateau of the E-R curve.",2020,"Endogenous IgG-B significantly impacted the E max , indicating that low-titer participants derive a greater benefit from bezlotoxumab treatment compared with high-titer participants.",[],"['Bezlotoxumab', 'placebo or bezlotoxumab', 'bezlotoxumab']","['maximum effect (E max ', 'bezlotoxumab concentrations and CDI recurrence']",[],"[{'cui': 'C4291320', 'cui_str': 'bezlotoxumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C4291320', 'cui_str': 'bezlotoxumab'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",,0.0679032,"Endogenous IgG-B significantly impacted the E max , indicating that low-titer participants derive a greater benefit from bezlotoxumab treatment compared with high-titer participants.","[{'ForeName': 'Ka Lai', 'Initials': 'KL', 'LastName': 'Yee', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA. Ka_yee@merck.com.'}, {'ForeName': 'Huub Jan', 'Initials': 'HJ', 'LastName': 'Kleijn', 'Affiliation': 'Certara Strategic Consulting, Oss, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zajic', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Dorr', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Rebecca E', 'Initials': 'RE', 'LastName': 'Wrishko', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Journal of pharmacokinetics and pharmacodynamics,['10.1007/s10928-019-09660-5'] 439,30664564,A Phase I/IIa Trial of Intravenous Immunoglobulin Following Portoenterostomy in Biliary Atresia.,"OBJECTIVES Biliary atresia (BA) is a progressive neonatal fibroinflammatory cholangiopathy. We hypothesized that intravenous immunoglobulin (IVIg) would be safe, feasible, acceptable, and efficacious for the treatment of BA. The primary objective of this study was to establish the feasibility, acceptability, and safety profile of IVIg administration after hepatoportoenterostomy (HPE) in BA. The secondary objective was to determine the treatment efficacy of IVIg based on good bile drainage and survival with the native liver. METHODS A multicenter, prospective, open-labeled, phase I/IIA trial of IVIg was conducted, with 1 g/kg/dose of IVIg infused at 3-5, 30, and 60 days post-HPE, and subjects followed for 360 days post-HPE. Twenty-nine participants completed the study. RESULTS Administration of IVIg infusions was feasible and acceptable in 79%. None of the serious adverse events (SAEs) were directly related to IVIg infusions; however, 90% of participants had an SAE. Compared with a historical placebo-arm group, there was no significant increase in the proportion of IVIg participants with a serum total bilirubin <1.5 mg/dL at 90, 180, or 360 days post-HPE. Survival with the native liver in the IVIg participants showed no significant benefit over the historical placebo arm, with a difference at 360 days of -11.9% (IVIg: 58.6%, placebo: 70.5%; 90% UCB: 2.1%; P > 0.05). CONCLUSIONS Although IVIg infusions in infants with BA post-HPE were feasible, acceptable and safe, there was no trend to lower bilirubin levels or improved 360-day survival with the native liver. CLINICAL TRIAL Safety Study of Intravenous Immunoglobulin Post-Portoenterostomy in Biliary Atresia; #NCT01854827.",2019,"Survival with the native liver in the IVIg participants showed no significant benefit over the historical placebo arm, with a difference at 360 days of -11.9% (IVIg: 58.6%, placebo: 70.5%; 90% UCB: 2.1%; P > 0.05). ","['Biliary Atresia', 'Twenty-nine participants completed the study']","['intravenous immunoglobulin (IVIg', 'placebo', 'IVIg infusions', 'historical placebo', 'IVIg administration after hepatoportoenterostomy (HPE', 'Intravenous Immunoglobulin']","['Survival', 'bilirubin levels', 'serious adverse events (SAEs', 'feasibility, acceptability, and safety profile', 'proportion of IVIg participants with a serum total bilirubin']","[{'cui': 'C0005411', 'cui_str': 'Biliary Atresia'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0085297', 'cui_str': 'Immunoglobulins, Intravenous'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0032722', 'cui_str': 'Hepatoportoenterostomy'}, {'cui': 'C0640277', 'cui_str': 'HPED'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0085297', 'cui_str': 'Immunoglobulins, Intravenous'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201913', 'cui_str': 'Bilirubin, total measurement (procedure)'}]",29.0,0.271851,"Survival with the native liver in the IVIg participants showed no significant benefit over the historical placebo arm, with a difference at 360 days of -11.9% (IVIg: 58.6%, placebo: 70.5%; 90% UCB: 2.1%; P > 0.05). ","[{'ForeName': 'Cara L', 'Initials': 'CL', 'LastName': 'Mack', 'Affiliation': ""Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO.""}, {'ForeName': 'Cathie', 'Initials': 'C', 'LastName': 'Spino', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Estella M', 'Initials': 'EM', 'LastName': 'Alonso', 'Affiliation': ""Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.""}, {'ForeName': 'Jorge A', 'Initials': 'JA', 'LastName': 'Bezerra', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, OH.""}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Moore', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Goodhue', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA.""}, {'ForeName': 'Vicky L', 'Initials': 'VL', 'LastName': 'Ng', 'Affiliation': 'The Hospital for Sick Children, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Saul J', 'Initials': 'SJ', 'LastName': 'Karpen', 'Affiliation': 'Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Veena', 'Initials': 'V', 'LastName': 'Venkat', 'Affiliation': ""Children's Hospital of Pittsburgh, Pittsburgh.""}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Loomes', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, PA.""}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': ""Children's Hospital Los Angeles, Los Angeles, CA.""}, {'ForeName': 'Averell H', 'Initials': 'AH', 'LastName': 'Sherker', 'Affiliation': 'National Institute of Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, MA.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Magee', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Sokol', 'Affiliation': ""Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002256'] 440,31147268,Essential Oils to Reduce Postoperative Nausea and Vomiting.,"PURPOSE The purpose of this study was to determine if using essential oil products for adult patients reduced the need for antiemetics for postoperative nausea and vomiting (PONV). DESIGN A prospective and retrospective cross-sectional design using a convenience sample. METHODS Double blinded to the type of essential oil, subjects randomly selected a nasal inhaler containing peppermint, ginger, or a combination of both. A prophylactic dose was given preoperatively, and during the postoperative period nausea was assessed using verbal descriptive scale. FINDINGS Overall 322 same day surgical patients were analyzed (control group [n = 179] and intervention group [n = 143]). The intervention group had a greater history of PONV but received fewer doses of antiemetics postoperatively compared with the control group. There was no significant difference in the effectiveness of the three types of inhalers. CONCLUSIONS Aromatherapy demonstrated a statistically significant (P < .05) reduction in the need for antiemetics to treat PONV.",2019,Aromatherapy demonstrated a statistically significant (P < .05) reduction in the need for antiemetics to treat PONV.,['adult patients reduced the need for antiemetics for postoperative nausea and vomiting (PONV'],['Aromatherapy'],['Postoperative Nausea and Vomiting'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic Drugs'}, {'cui': 'C0520909', 'cui_str': 'PONV'}]","[{'cui': 'C0376547', 'cui_str': 'Therapy, Aroma'}]","[{'cui': 'C0520909', 'cui_str': 'PONV'}]",,0.156389,Aromatherapy demonstrated a statistically significant (P < .05) reduction in the need for antiemetics to treat PONV.,"[{'ForeName': 'Maxine A', 'Initials': 'MA', 'LastName': 'Fearrington', 'Affiliation': ''}, {'ForeName': 'Brandon W', 'Initials': 'BW', 'LastName': 'Qualls', 'Affiliation': ''}, {'ForeName': 'Mary G', 'Initials': 'MG', 'LastName': 'Carey', 'Affiliation': ''}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.01.010'] 441,30879908,Evaluation of Warming Effectiveness on Physiological Indices of Patients Undergoing Laparoscopic Cholecystectomy Surgery: A Randomized Controlled Clinical Trial.,"PURPOSE The present study aimed to evaluate the impact of warming on physiological indices of patients undergoing laparoscopic cholecystectomy. DESIGN The study was a three-group randomized controlled clinical trial. METHODS In the present study, 96 patients were assigned to three groups: forced-air warming system group; warmed intravenous fluid group; and control group. The intervention was performed immediately after the anesthesia induction. Physiological indices (core body temperature, blood pressure, and heart rate) were evaluated at 15-minute intervals, and postoperative shivering was also recorded. FINDINGS The mean systolic blood pressure and the mean heart rate were significantly different in each warming group before, during, and after surgery, but the three groups had no significant differences in terms of physiological indices at any time (P > .05). Postoperative shivering was not seen in any group. CONCLUSIONS Both interventions had similar effects on physiological indices. Therefore, the recommendation is to use the warming method according to patient's other conditions.",2019,"The mean systolic blood pressure and the mean heart rate were significantly different in each warming group before, during, and after surgery, but the three groups had no significant differences in terms of physiological indices at any time (P > .05).","['Patients Undergoing Laparoscopic Cholecystectomy Surgery', 'patients undergoing laparoscopic cholecystectomy', '96 patients were assigned to three groups']",['forced-air warming system group; warmed intravenous fluid group; and control group'],"['physiological indices', 'Postoperative shivering', 'Physiological indices (core body temperature, blood pressure, and heart rate', 'postoperative shivering', 'mean systolic blood pressure and the mean heart rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0184348', 'cui_str': 'Warmer'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1736186', 'cui_str': 'Postoperative shivering'}, {'cui': 'C0456240', 'cui_str': 'Core body temperature (observable entity)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",96.0,0.0706648,"The mean systolic blood pressure and the mean heart rate were significantly different in each warming group before, during, and after surgery, but the three groups had no significant differences in terms of physiological indices at any time (P > .05).","[{'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Baradaranfard', 'Affiliation': ''}, {'ForeName': 'Mitra', 'Initials': 'M', 'LastName': 'Jabalameli', 'Affiliation': ''}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Ghadami', 'Affiliation': ''}, {'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Aarabi', 'Affiliation': ''}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2018.11.013'] 442,31431654,Lack of social support as measured by the Family Resource Scale screening tool is associated with early adverse cognitive outcome in extremely low birth weight children.,"OBJECTIVE Extremely low birth weight children are at high risk for cognitive impairment. STUDY DESIGN Cognitive outcome of extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed. Family resources and social support were assessed using a Family Resource Scale parent questionnaire. Regression analysis was used to determine independent demographic, medical, and family resource factors influencing longitudinal cognitive outcome. RESULT Higher Family Resource Scale scores at 18 months were associated with greater improvement in cognitive scores between 18 and 30 months. Cognitive outcome was most adversely affected in children whose families had the least resources and social support. The adverse effect of poor social support was independent of family income. CONCLUSION Poor interpersonal social support has an independent, adverse impact on cognitive outcomes of extremely low birth weight infants.",2019,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"['extremely low birth weight infants', 'extremely low birth weight children participating in a Neonatal Research Network, randomized trial was evaluated at 18 and 30 months corrected age using the Bayley Scales of Infant Development, 2nd ed', 'extremely low birth weight children']",[],"['Cognitive outcome', 'Higher Family Resource Scale scores', 'cognitive scores']","[{'cui': 'C0456065', 'cui_str': 'Infant, Extremely Low Birth Weight'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0451021', 'cui_str': 'Bayley scale of infant development (assessment scale)'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0599714,Cognitive outcome was most adversely affected in children whose families had the least resources and social support.,"[{'ForeName': 'Martha G', 'Initials': 'MG', 'LastName': 'Fuller', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA. mfuller@sandiego.edu.'}, {'ForeName': 'Yvonne E', 'Initials': 'YE', 'LastName': 'Vaucher', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, University of California San Diego, San Diego, CA, USA.'}, {'ForeName': 'Carla M', 'Initials': 'CM', 'LastName': 'Bann', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Abhik', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'RTI International, Research Triangle Park, North Carolina, NC, USA.'}, {'ForeName': 'Betty R', 'Initials': 'BR', 'LastName': 'Vohr', 'Affiliation': 'Department of Pediatrics, Women, and Infants Hospital, Brown University, Providence, RI, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0462-2'] 443,32238338,Optimizing Text Messages to Promote Engagement With Internet Smoking Cessation Treatment: Results From a Factorial Screening Experiment.,"BACKGROUND Smoking remains a leading cause of preventable death and illness. Internet interventions for smoking cessation have the potential to significantly impact public health, given their broad reach and proven effectiveness. Given the dose-response association between engagement and behavior change, identifying strategies to promote engagement is a priority across digital health interventions. Text messaging is a proven smoking cessation treatment modality and a powerful strategy to increase intervention engagement in other areas of health, but it has not been tested as an engagement strategy for a digital cessation intervention. OBJECTIVE This study examined the impact of 4 experimental text message design factors on adult smokers' engagement with an internet smoking cessation program. METHODS We conducted a 2×2×2×2 full factorial screening experiment wherein 864 participants were randomized to 1 of 16 experimental conditions after registering with a free internet smoking cessation program and enrolling in its automated text message program. Experimental factors were personalization (on/off), integration between the web and text message platforms (on/off), dynamic tailoring of intervention content based on user engagement (on/off), and message intensity (tapered vs abrupt drop-off). Primary outcomes were 3-month measures of engagement (ie, page views, time on site, and return visits to the website) as well as use of 6 interactive features of the internet program. All metrics were automatically tracked; there were no missing data. RESULTS Main effects were detected for integration and dynamic tailoring. Integration significantly increased interactive feature use by participants, whereas dynamic tailoring increased the number of features used and page views. No main effects were found for message intensity or personalization alone, although several synergistic interactions with other experimental features were observed. Synergistic effects, when all experimental factors were active, resulted in the highest rates of interactive feature use and the greatest proportion of participants at high levels of engagement. Measured in terms of standardized mean differences (SMDs), effects on interactive feature use were highest for Build Support System (SMD 0.56; 95% CI 0.27 to 0.81), Choose Quit Smoking Aid (SMD 0.38; 95% CI 0.10 to 0.66), and Track Smoking Triggers (SMD 0.33; 95% CI 0.05 to 0.61). Among the engagement metrics, the largest effects were on overall feature utilization (SMD 0.33; 95% CI 0.06 to 0.59) and time on site (SMD 0.29; 95% CI 0.01 to 0.57). As no SMD >0.30 was observed for main effects on any outcome, results suggest that for some outcomes, the combined intervention was stronger than individual factors alone. CONCLUSIONS This factorial experiment demonstrates the effectiveness of text messaging as a strategy to increase engagement with an internet smoking cessation intervention, resulting in greater overall intervention dose and greater exposure to the core components of tobacco dependence treatment that can promote abstinence. TRIAL REGISTRATION ClinicalTrials.gov NCT02585206; https://clinicaltrials.gov/ct2/show/NCT02585206. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1136/bmjopen-2015-010687.",2020,"No main effects were found for message intensity or personalization alone, although several synergistic interactions with other experimental features were observed.","[""adult smokers' engagement with an internet smoking cessation program"", '864 participants were randomized to 1 of 16 experimental conditions after registering with a']",['free internet smoking cessation program and enrolling in its automated text message program'],"['3-month measures of engagement (ie, page views, time on site, and return visits to the website) as well as use of 6 interactive features of the internet program', 'Synergistic effects', 'Choose Quit Smoking Aid', 'overall feature utilization', 'Track Smoking Triggers']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}]",864.0,0.0987372,"No main effects were found for message intensity or personalization alone, although several synergistic interactions with other experimental features were observed.","[{'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Graham', 'Affiliation': 'Innovations Center, Truth Initiative, Washington, DC, United States.'}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Papandonatos', 'Affiliation': 'Center for Statistical Sciences, Brown University, Providence, RI, United States.'}, {'ForeName': 'Megan A', 'Initials': 'MA', 'LastName': 'Jacobs', 'Affiliation': 'Innovations Center, Truth Initiative, Washington, DC, United States.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Amato', 'Affiliation': 'Innovations Center, Truth Initiative, Washington, DC, United States.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Cha', 'Affiliation': 'Innovations Center, Truth Initiative, Washington, DC, United States.'}, {'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'Cohn', 'Affiliation': 'Oklahoma Tobacco Research Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Lorien C', 'Initials': 'LC', 'LastName': 'Abroms', 'Affiliation': 'Department of Prevention and Community Health, Milken Institute School of Public Health, The George Washington University, Washington, DC, United States.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Whittaker', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}]",Journal of medical Internet research,['10.2196/17734'] 444,31160222,Effect of Listening to Music on Postoperative Cognitive Function in Older Adults After Hip or Knee Surgery: A Randomized Controlled Trial.,"PURPOSE This study aimed to assess the effect of listening to music on postoperative cognitive function in older adults after hip or knee surgery. DESIGN This work was a randomized controlled study that involved an intervention group and control group. METHODS Study data were recollected by using a patient information form, Mini-Mental State Examination (MMSE), and NEECHAM Confusion Scale. Music was played three times a day to the participants in the intervention group for 3 days postoperatively. FINDINGS The mean MMSE and NEECHAM scores of the intervention and control groups were compared. No statistically significant difference was found in the mean MMSE (P > .05) between the two groups. A statistically significant difference in the mean NEECHAM Confusion Scale score was observed between the groups (P < .001). CONCLUSIONS This study demonstrated that listening to music was important in preventing postoperative cognitive dysfunction in patients who underwent hip or knee arthroplasty.",2019,"A statistically significant difference in the mean NEECHAM Confusion Scale score was observed between the groups (P < .001). ","['older adults after hip or knee surgery', 'After Hip or Knee Surgery', 'patients who underwent hip or knee arthroplasty', 'Older Adults']","['Listening to Music', 'listening to music']","['postoperative cognitive function', 'Mini-Mental State Examination (MMSE), and NEECHAM Confusion Scale', 'mean MMSE', 'Postoperative Cognitive Function', 'postoperative cognitive dysfunction', 'mean MMSE and NEECHAM scores', 'mean NEECHAM Confusion Scale score']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0187769', 'cui_str': 'Operative procedure on knee'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0026867', 'cui_str': 'Music'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0009676', 'cui_str': 'Confusional State'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1319200', 'cui_str': 'Postoperative confusion'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.076654,"A statistically significant difference in the mean NEECHAM Confusion Scale score was observed between the groups (P < .001). ","[{'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Çetinkaya', 'Affiliation': ''}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.03.001'] 445,32240143,[Cerebral protection from ischaemia during carotid endarterectomy].,"The purpose of this study was to assess efficacy of cerebral protection during carotid endarterectomy by means of controlled systemic hypertension in patients presenting with various levels of retrograde pressure in the internal carotid artery. The study enrolled a total of 150 patients subjected to carotid endarterectomy. The operation was carried out under general anaesthesia with artificial pulmonary ventilation and was accompanied by haemodynamic monitoring with invasive control of arterial pressure, as well as primary and additional correction of central haemodynamics. Cerebral perfusion was assessed by measuring retrograde pressure in the internal carotid artery. The retrograde pressure index was calculated, according to which the patients were subdivided into three groups: those with values less than 30, with values from 30 to 39, and with values of 40 and more. Controlled systemic arterial hypertension was used as cerebral protection during the period of cross-clamping of the internal carotid artery, with phenylephrine and norepinephrine administered for this purpose. The parameters of central haemodynamics, time intervals of the operation, and the duration of internal carotid artery cross-clamping in the groups did not statistically differ (p>0.05). A statistically significant difference was revealed in the level of systolic arterial pressure necessary for cerebral protection (p<0.05). There were no cerebral circulation impairments, myocardial infarctions, nor lethal outcomes. A conclusion was drawn that individualized correction of central haemodynamics ensured a sufficient level of collateral compensation of the cerebral blood flow, thus making it possible to refuse from using intraluminal shunts.",2020,A statistically significant difference was revealed in the level of systolic arterial pressure necessary for cerebral protection (p<0.05).,"['patients presenting with various levels of retrograde pressure in the internal carotid artery', '150 patients subjected to carotid endarterectomy']","['phenylephrine and norepinephrine', 'carotid endarterectomy']","['central haemodynamics, time intervals of the operation, and the duration of internal carotid artery cross-clamping', 'level of systolic arterial pressure necessary for cerebral protection', 'Cerebral perfusion', 'retrograde pressure index', 'cerebral circulation impairments, myocardial infarctions, nor lethal outcomes', 'retrograde pressure']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0007276', 'cui_str': 'Internal carotid artery structure'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0014099', 'cui_str': 'Carotid endarterectomy'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}, {'cui': 'C0014099', 'cui_str': 'Carotid endarterectomy'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007276', 'cui_str': 'Internal carotid artery structure'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",150.0,0.0286165,A statistically significant difference was revealed in the level of systolic arterial pressure necessary for cerebral protection (p<0.05).,"[{'ForeName': 'A N', 'Initials': 'AN', 'LastName': 'Vachev', 'Affiliation': 'Department of Faculty Surgery, Samara State Medical University of the RF Ministry of Public Health, Samara, Russia.'}, {'ForeName': 'M G', 'Initials': 'MG', 'LastName': 'Prozhoga', 'Affiliation': 'Department of Faculty Surgery, Samara State Medical University of the RF Ministry of Public Health, Samara, Russia.'}, {'ForeName': 'O V', 'Initials': 'OV', 'LastName': 'Dmitriev', 'Affiliation': 'Department of Faculty Surgery, Samara State Medical University of the RF Ministry of Public Health, Samara, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGIO2020109'] 446,31204273,Thermal Suit or Forced Air Warming in Prevention of Perioperative Hypothermia: A Randomized Controlled Trial.,"PURPOSE To prevent perioperative hypothermia, forced air warming blanket was compared with a passive insulation suit. DESIGN Prospective, open, randomized controlled trial. METHODS Thirty patients were scheduled for orthopedic spinal surgery. The intervention group (group TS) received the thermal suit T-Balance before premedication and throughout the perioperative period, whereas the control group (group C) received forced air warming (FAW) during surgery. FINDINGS No statistically significant difference (ns) was found between the groups for core temperature 30 minutes after induction of general anesthesia. Perioperative hypothermia occurred in 10 (66.7%) patients in group TS and 6 (40%) in group C (ns). For hypothermic patients, re-establishment of normothermia took significantly longer in group TS, mean 108 ± 111 minutes, than in group C, 33 ± 59.5 minutes (P = .03). CONCLUSIONS The thermal suit did not prevent hypothermia in this study. FAW was significantly more efficient in re-establishing normothermia.",2019,"For hypothermic patients, re-establishment of normothermia took significantly longer in group TS, mean 108 ± 111 minutes, than in group C, 33 ± 59.5 minutes (P = .03). ","['Perioperative Hypothermia', 'Thirty patients were scheduled for orthopedic spinal surgery']","['thermal suit T-Balance before premedication', 'forced air warming (FAW', 'Thermal Suit or Forced Air Warming']","['Perioperative hypothermia', 'FAW']","[{'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0033045', 'cui_str': 'Premedication'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}]","[{'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}]",30.0,0.061088,"For hypothermic patients, re-establishment of normothermia took significantly longer in group TS, mean 108 ± 111 minutes, than in group C, 33 ± 59.5 minutes (P = .03). ","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Brodshaug', 'Affiliation': ''}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Tettum', 'Affiliation': ''}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Raeder', 'Affiliation': ''}]",Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses,['10.1016/j.jopan.2019.03.002'] 447,32240141,[Autoarterial remodeling of the common carotid artery bifurcation in treatment of stenotic lesions].,"Carotid endarterectomy is the main operation carried out for prevention of ischaemic stroke in haemodynamically significant stenoses of the bifurcation of the common carotid artery. Despite the literature data demonstrating some advantages of eversion carotid endarterectomy over the classical technique there arises a series of complicated, as yet unsolved problems. This concerns the control of the distal portion of an atherosclerotic plaque in prolonged lesions of the internal carotid artery, the absence of a temporary bypass graft, necessity of prosthetic repair of the internal carotid artery in detachment of the distal border of the plaque. We suggested a new technique of carotid endarterectomy making it possible to widen visual removal of atheromatous masses from the internal carotid artery, to improve the control of the distal portion of the plaque in a prolonged lesion of the internal carotid artery. We carried out a comparative assessment of efficacy and safety of the new method of carotid endarterectomy versus the classical variant in a randomized study. The proposed technique of carotid endarterectomy turned out to be compatible by safety and demonstrated similar results with the classical carotid endarterectomy by the number of ischaemic strokes, transitory ischaemic attacks, and myocardial infarctions in the early and remote postoperative periods. When comparing the groups by efficiency, the primary efficacy endpoint, including cases of restenosis >50% according to the findings of ultrasonographic examination of the brachiocephalic arteries, all cases of ischaemic events (acute impairments of cerebral circulation, transitory ischaemic attacks), as well as the presence of the clinical picture of cranial nerve paresis demonstrated a significant advantage of the new technique versus the comparison group at the expense of a lower incidence of restenoses in the area of the operation during the whole period of follow up. In the group of autoarterial remodelling, the composite endpoint of outcomes occurred in 6 patients (6.1%) and in the group with the classic carotid endarterectomy - in 19 (19.6%) patients, p=0.005.",2020,"The proposed technique of carotid endarterectomy turned out to be compatible by safety and demonstrated similar results with the classical carotid endarterectomy by the number of ischaemic strokes, transitory ischaemic attacks, and myocardial infarctions in the early and remote postoperative periods.",['stenotic lesions'],"['Carotid endarterectomy', 'carotid endarterectomy']","['efficacy and safety', 'ischaemic events (acute impairments of cerebral circulation, transitory ischaemic attacks), as well as the presence of the clinical picture of cranial nerve paresis', 'ischaemic strokes, transitory ischaemic attacks, and myocardial infarctions']","[{'cui': 'C0333181', 'cui_str': 'Stenosed'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0014099', 'cui_str': 'Carotid endarterectomy'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0151311', 'cui_str': 'Cranial nerve paralysis'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]",,0.035114,"The proposed technique of carotid endarterectomy turned out to be compatible by safety and demonstrated similar results with the classical carotid endarterectomy by the number of ischaemic strokes, transitory ischaemic attacks, and myocardial infarctions in the early and remote postoperative periods.","[{'ForeName': 'P V', 'Initials': 'PV', 'LastName': 'Ignatenko', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Gostev', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'Sh B', 'Initials': 'SB', 'LastName': 'Saaia', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Rabtsun', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Cheban', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'V B', 'Initials': 'VB', 'LastName': 'Starodubtsev', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Karpenko', 'Affiliation': 'National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGIO2020117'] 448,31869853,Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial.,"OBJECTIVES Evaluating the effectiveness of melatonin in prevention of radiation-induced oral mucositis. MATERIAL AND METHODS A randomized controlled clinical study was conducted on forty head and neck cancer (HNC) patients undergoing radiotherapy at the Department of Clinical Oncology, Alexandria University, Egypt. Patients were assigned equally to either control group who received conventional treatment or test group who received 20 mg of melatonin along with the conventional treatment. All patients were clinically evaluated for oral mucositis severity and pain at three and six weeks after the start of radiotherapy. Additionally, the total antioxidant capacity (TAC) in patients' saliva samples was assessed at the start of radiotherapy and six weeks later. RESULTS 92.5% of all patients have experienced oral mucositis with more severity reported in the control group (30%) compared with the test group (5%). Mean pain scores decreased significantly, in the second assessment, in test group rather than the controls. TAC values showed a significant difference between the test and controls with a significant decrease in TAC in the control group. CONCLUSION The administration of melatonin with conventional treatment has reduced severe oral mucositis development. It aided in decreasing pain and hindering the reduction of TAC resulting from radiotherapy among the test group compared with controls.",2020,"Mean pain scores decreased significantly, in the second assessment, in test group rather than the controls.","['forty head and neck cancer (HNC) patients undergoing radiotherapy at the Department of Clinical Oncology, Alexandria University, Egypt']","['Control group who received conventional treatment or test group who received 20\xa0mg of melatonin', 'Melatonin', 'melatonin with conventional treatment', 'radiotherapy', 'melatonin']","['Mean pain scores', 'severe oral mucositis development', 'TAC', 'oral mucositis severity and pain', 'TAC values', 'total antioxidant capacity (TAC', 'oral mucositis']","[{'cui': 'C0278996', 'cui_str': 'Cancer of Head and Neck'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C1274034', 'cui_str': 'Clinical Oncology'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1568868', 'cui_str': 'Oral Mucositis'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",,0.0398661,"Mean pain scores decreased significantly, in the second assessment, in test group rather than the controls.","[{'ForeName': 'Hossam H', 'Initials': 'HH', 'LastName': 'Elsabagh', 'Affiliation': 'Oral Medicine, Periodontology, Oral Diagnosis and Oral Radiology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Eglal', 'Initials': 'E', 'LastName': 'Moussa', 'Affiliation': 'Oral Medicine, Periodontology, Oral Diagnosis and Oral Radiology Department, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Sabah A', 'Initials': 'SA', 'LastName': 'Mahmoud', 'Affiliation': 'Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Rasha O', 'Initials': 'RO', 'LastName': 'Elsaka', 'Affiliation': 'Clinical Oncology and Nuclear Medicine department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Hams', 'Initials': 'H', 'LastName': 'Abdelrahman', 'Affiliation': 'Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Alexandria University, Alexandria, Egypt.'}]",Oral diseases,['10.1111/odi.13265'] 449,32228627,The effects of rapid weight loss on skeletal muscle in judo athletes.,"OBJECTIVE To observe the effect of rapid weight loss (RWL) methods over 3 days on muscle damage in judokas. METHODS Eighteen judokas participated in this crossover study, meaning that judo athletes were subjected to exercise-only phase (4 days) and RWL phase (3 days). Subjects were tested for myoglobin, creatine kinase, aldolase, hemoglobin, and hematocrit values on seven consecutive days. These biomarkers served as indicators of acute muscle damage. RESULTS During the exercise-only phase, no significant changes were observed. Myoglobin (Mb) (p < 0.001), creatine kinase (CK) (p < 0.001) and aldolase (ALD) (p < 0.001) significantly increased only during the RWL phase, as well as hemoglobin (Hb) (p < 0.001) and hematocrit (Hct) (p < 0.005) values. It was detected that peak values for muscle damage biomarkers were reached on the sixth day, while Hct and Hb values were the highest on the seventh day of the study. CONCLUSION Our study showed significant muscle damage induced by RWL. The prevalence of RWL use by judokas is high but firm scientific evidence is lacking in the evaluation of the current practice of it. Therefore, further knowledge must be gained to evaluate the effectiveness of RWL on performance and its impact on judokas' wellbeing.",2020,"Myoglobin (Mb) (p < 0.001), creatine kinase (CK) (","['Eighteen judokas participated in this crossover study, meaning that judo athletes', 'judo athletes']",['rapid weight loss (RWL'],"['aldolase (ALD', 'hematocrit (Hct', 'creatine kinase (CK) ', 'hemoglobin', 'peak values for muscle damage biomarkers', 'Myoglobin (Mb', 'myoglobin, creatine kinase, aldolase, hemoglobin, and hematocrit values']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0079650', 'cui_str': 'Judo'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C0016762', 'cui_str': 'Fructose Biphosphate Aldolase'}, {'cui': 'C0330318', 'cui_str': 'Alder'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0027078', 'cui_str': 'Myoglobin'}]",18.0,0.0393787,"Myoglobin (Mb) (p < 0.001), creatine kinase (CK) (","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Roklicer', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Nemanja', 'Initials': 'N', 'LastName': 'Lakicevic', 'Affiliation': 'PhD Program in Health Promotion and Cognitive Sciences, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Valdemar', 'Initials': 'V', 'LastName': 'Stajer', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Trivic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Antonino', 'Initials': 'A', 'LastName': 'Bianco', 'Affiliation': 'Sport and Exercise Sciences Research Unit, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Diba', 'Initials': 'D', 'LastName': 'Mani', 'Affiliation': 'Department of Applied Physiology and Kinesiology, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Zoran', 'Initials': 'Z', 'LastName': 'Milosevic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Nebojsa', 'Initials': 'N', 'LastName': 'Maksimovic', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Paoli', 'Affiliation': 'Department of Biomedical Sciences, University of Padova, Padua, Italy.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Drid', 'Affiliation': 'Faculty of Sport and Physical Education, University of Novi Sad, Novi Sad, Serbia. patrikdrid@gmail.com.'}]",Journal of translational medicine,['10.1186/s12967-020-02315-x'] 450,32284389,Impact of nutrition education on nutritional knowledge and intentions towards nutritional counselling in Dutch medical students: an intervention study.,"OBJECTIVE Management of diet-related chronic diseases may benefit from improved nutrition education of medical students. This study aims to investigate the effects of a nutrition education course on nutritional knowledge and intentions towards nutritional counselling in Dutch medical students. DESIGN This is a pre-post intervention study with a comparison group. Participants completed self-reported questionnaires on nutritional knowledge and intentions towards nutritional counselling. PARTICIPANTS In total, 118 medical students (64.4% undergraduate, 73.2% women) were recruited from two medical schools in the Netherlands (n=66 intervention group, n=52 comparison group). INTERVENTION The intervention group completed a 25-hour course in nutritional counselling (the Students Experienced in Lifestyle and Food (SELF) course) in addition to the standard medical curriculum. The comparison group followed the standard medical curriculum. OUTCOME MEASURES Self-reported nutritional knowledge and intentions towards nutritional counselling, including attitude, self-efficacy and social support. RESULTS Nutritional knowledge (B: 2.42, 95% CI 1.81 to 3.02), attitude in men (B: 0.50, 95% CI 0.13 to 0.87) and self-efficacy (B: 0.78, 95% CI 0.62 to 0.95) significantly increased in the intervention group compared with the comparison group. No significant differences were found for social support (B: 0.20, 95% CI -0.02 to 0.43) and attitude in women (B: 0.08, 95% CI -0.24 to 0.31) between the two groups. CONCLUSIONS The SELF course increased medical students' nutritional knowledge and stimulated their intentions towards nutritional counselling. Future research is needed to evaluate the long-term impact of nutrition education interventions on physician practice patterns and patient outcomes.",2020,"No significant differences were found for social support (B: 0.20, 95% CI -0.02 to 0.43) and attitude in women (B: 0.08, 95% CI -0.24 to 0.31) between the two groups. ","['118 medical students (64.4% undergraduate, 73.2% women) were recruited from two medical schools in the Netherlands (n=66 intervention group, n=52 comparison group', 'medical students', 'Dutch medical students']","['nutrition education interventions', 'nutrition education', 'nutrition education course', 'standard medical curriculum', '25-hour course in nutritional counselling (the Students Experienced in Lifestyle and Food (SELF) course) in addition to the standard medical curriculum']","['social support', 'nutritional knowledge and intentions towards nutritional counselling', ""medical students' nutritional knowledge and stimulated their intentions towards nutritional counselling"", 'Nutritional knowledge', 'Self-reported nutritional knowledge and intentions towards nutritional counselling, including attitude, self-efficacy and social support', 'self-efficacy']","[{'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}]","[{'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C3875150', 'cui_str': 'Towards'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",118.0,0.0268801,"No significant differences were found for social support (B: 0.20, 95% CI -0.02 to 0.43) and attitude in women (B: 0.08, 95% CI -0.24 to 0.31) between the two groups. ","[{'ForeName': 'Hester L', 'Initials': 'HL', 'LastName': 'Coppoolse', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Jaap C', 'Initials': 'JC', 'LastName': 'Seidell', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'S Coosje', 'Initials': 'SC', 'LastName': 'Dijkstra', 'Affiliation': 'Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands coosje.dijkstra@vu.nl.'}]",BMJ open,['10.1136/bmjopen-2019-034377'] 451,31789541,Iwankapiya American Indian pilot clinical trial: Historical trauma and group interpersonal psychotherapy.,"American Indians face pervasive trauma exposure, collective histories of communal suffering, and elevated risk for depression and posttraumatic stress disorder. In addition to socioeconomic barriers, access to culturally responsive treatment is limited, which may compromise treatment engagement. The Iwankapiya study piloted the Historical Trauma and Unresolved Grief Intervention (HTUG), combined with Group Interpersonal Psychotherapy (IPT), to reduce symptoms of depression and related trauma and grief. The study hypothesized that HTUG + IPT would lead to greater group engagement and decreased depression and related symptoms compared with IPT-Only. American Indian adults ( n = 52) were randomized into one of two 12-session interventions, HTUG + IPT or IPT-Only, at two tribal sites: one Northern Plains reservation ( n = 26) and one Southwest urban clinic ( n = 26). Standardized measures assessed depression, posttraumatic stress disorder, grief, trauma, and substance use. Data were collected at screening, baseline, end of intervention, and 8 weeks postintervention; depression and group engagement measures were also collected at Weeks 4 and 8 of the intervention. Depression scores significantly decreased for both treatments, but there were no significant differences in depression between the two groups: IPT-Only (30.2 ± 6.4 at baseline to 16.7 ± 12.1 at follow-up) and HTUG + IPT (30.2 ± 8.1 at baseline to 19.9 ± 8.8 at follow-up). However, HTUG + IPT participants demonstrated significantly greater group engagement. Postintervention, clinicians expressed preference for HTUG + IPT based upon qualitative observations of greater perceived gains among participants. Given the degree of trauma exposure in tribal communities, these findings in a relatively small sample suggest HTUG should be further examined in context of treatment engagement. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Depression scores significantly decreased for both treatments, but there were no significant differences in depression between the two groups: IPT-Only (30.2 ± 6.4 at baseline to 16.7 ± 12.1 at follow-up) and HTUG + IPT (30.2 ± 8.1 at baseline to 19.9 ± 8.8 at follow-up).",['American Indian adults ( n = 52'],"['HTUG + IPT or IPT', 'HTUG + IPT', 'Historical Trauma and Unresolved Grief Intervention (HTUG), combined with Group Interpersonal Psychotherapy (IPT']","['depression, posttraumatic stress disorder, grief, trauma, and substance use', 'depression', 'Depression scores']","[{'cui': 'C0002460', 'cui_str': 'American Indians'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0380193', 'cui_str': 'iodine-123-IPT'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0443342', 'cui_str': 'Unresolved (qualifier value)'}, {'cui': 'C0018235', 'cui_str': 'Grief'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy (regime/therapy)'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0018235', 'cui_str': 'Grief'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",2019.0,0.0347707,"Depression scores significantly decreased for both treatments, but there were no significant differences in depression between the two groups: IPT-Only (30.2 ± 6.4 at baseline to 16.7 ± 12.1 at follow-up) and HTUG + IPT (30.2 ± 8.1 at baseline to 19.9 ± 8.8 at follow-up).","[{'ForeName': 'Maria Yellow Horse', 'Initials': 'MYH', 'LastName': 'Brave Heart', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of New Mexico.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Chase', 'Affiliation': 'Department of Social Work, Oglala Lakota College.'}, {'ForeName': 'Orrin', 'Initials': 'O', 'LastName': 'Myers', 'Affiliation': 'Department of Family and Community Medicine, University of New Mexico.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Elkins', 'Affiliation': 'School of Social Work, University of Georgia.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Skipper', 'Affiliation': 'Department of Family and Community Medicine, University of New Mexico.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Schmitt', 'Affiliation': 'Department of Family and Community Medicine, University of New Mexico.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Mootz', 'Affiliation': 'New York State Psychiatric Institute, Columbia University.'}, {'ForeName': 'V Ann', 'Initials': 'VA', 'LastName': 'Waldorf', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of New Mexico.'}]","Psychotherapy (Chicago, Ill.)",['10.1037/pst0000267'] 452,32132641,Impact of change in bedtime variability on body composition and inflammation: secondary findings from the Go Red for Women Strategically Focused Research Network.,"Variability in daily sleep patterns is an emerging factor linked to metabolic syndrome. However, whether reducing bedtime variability improves markers of disease risk has not been tested. Here, we assessed whether body composition and inflammation were impacted by changes in bedtime variability over a 6-week period, during which, women were instructed to maintain healthy, habitual sleep (HS) patterns (one arm of a randomized trial). Data were available for 37 women (age 34.9 ± 12.4 years, BMI 24.7 ± 2.9 kg/m 2 , sleep duration 7.58 ± 0.49 h/night). Body composition and leukocyte platelet aggregates (LPA) were measured at baseline and endpoint using magnetic resonance imaging and flow cytometry, respectively. Sleep data were collected daily using wrist actigraphy. Change in bedtime variability was calculated as the difference in the standard deviation (SD) of bedtimes measured during the 2-week screening period and the 6-week intervention period. Results showed that women who reduced their bedtime variability (n = 29) during the intervention had reductions in total (P < 0.001) and subcutaneous adipose tissue (P < 0.001) relative to women who increased/maintained (n = 8) bedtime variability. Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011). Thus, reducing bedtime variability, without changing sleep duration, could improve cardiometabolic health by reducing adiposity and inflammation.",2020,Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011).,"['37 women (age 34.9\u2009±\u200912.4\u2009years, BMI 24.7\u2009±\u20092.9\u2009kg/m 2 , sleep duration 7.58\u2009±\u20090.49\u2009h/night']",[],"['Change in bedtime variability', 'LPA levels', 'maintained bedtime variability', 'cardiometabolic health', 'Body composition and leukocyte platelet aggregates (LPA', 'Sleep data', 'body composition and inflammation', 'bedtime variability', 'subcutaneous adipose tissue']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517543', 'cui_str': '12.4 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517641', 'cui_str': '2.9 (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",[],"[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0521112', 'cui_str': 'Bedtime (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0205418', 'cui_str': 'Aggregate (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}]",37.0,0.140356,Similar effects were observed for LPA levels between women who reduced vs increased/maintained bedtime variability (P = 0.011).,"[{'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'St-Onge', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA. ms2554@cumc.columbia.edu.'}, {'ForeName': 'Ayanna', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'Zuraikat', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Cheng', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Riddhi', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Berger', 'Affiliation': 'Center for the Prevention of Cardiovascular Disease; Department of Medicine, New York University Langone Health, New York, NY, 10010, USA.'}, {'ForeName': 'Rosemary V', 'Initials': 'RV', 'LastName': 'Sampogna', 'Affiliation': 'Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Jelic', 'Affiliation': 'Sleep center of excellence, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 10032, USA.'}]",International journal of obesity (2005),['10.1038/s41366-020-0555-1'] 453,32162949,"Subjective interpretation of ""objective"" video evidence: Perceptions of male versus female police officers' use-of-force.","OBJECTIVE The police face great scrutiny after highly publicized instances of lethal force. Dash-camera footage ostensibly provides ""objective"" evidence of whether the force was excessive. We tested whether participants interpreted the same ""objective"" video of an officer exerting force differently based on the officer's gender and race. HYPOTHESIS We predicted that when (a) a male (vs. female) officer used force and (b) a Black (vs. White) officer used force, participants would endorse more internal and less external explanations for their use-of-force, which would be associated with less trust in and perceived effectiveness of the officer. METHOD We randomly assigned Amazon's Mechanical Turk workers (N = 452; 53% female, 80% White) to (a) see a segment of a police-civilian interaction video that either included or did not include exertion of force, and to believe that the officer was (b) male versus female, and (c) Black versus White. They reported their trust in the officer and perceptions of the officer's effectiveness, and their degree of agreement with external and internal attributions for the officer's behavior. RESULTS When officers used force, people trusted officers less (d = 1.13) and perceived them to be less effective (d = .78) relative to when they did not. Despite all participants viewing the same interaction, people who thought they saw a male (vs. female) officer perceived his use-of-force to be driven more by internal traits, such as being aggressive and emotionally reactive, and less by the external situation, which was associated with decreased trust and perceived effectiveness. In contrast, people perceived female (vs. male) officers' force to be driven more by external aspects of the dangerous situation, which was associated with increased trust and perceived effectiveness. This pattern did not depend on the officers' race or participants' gender. CONCLUSION This constitutes a rare instance of women benefiting from violating gender stereotypes in the workplace because people assumed her counterstereotypical behavior was more justified by the situation and less about her being an aggressive and emotionally reactive person. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"When officers used force, people trusted officers less (d = 1.13) and perceived them to be less effective (d = .78) relative to when they did not.",['male versus female police officers'],"['police-civilian interaction video that either included or did not include exertion of force, and to believe that the officer was (b) male versus female, and (c) Black versus White']",[],"[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086825', 'cui_str': 'Policeman (occupation)'}]","[{'cui': 'C0085098', 'cui_str': 'Police'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]",[],,0.102339,"When officers used force, people trusted officers less (d = 1.13) and perceived them to be less effective (d = .78) relative to when they did not.","[{'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Salerno', 'Affiliation': 'School of Social and Behavioral Sciences, Arizona State University.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Sanchez', 'Affiliation': 'School of Criminology and Criminal Justice, Arizona State University.'}]",Law and human behavior,['10.1037/lhb0000366'] 454,32241201,Sealing effects of different Chinese herbal medicines on dentinal tubules: a scanning electron microscopic observation.,"BACKGROUND AND OBJECTIVES To evaluate the sealing effects of different Chinese herbal medicines on dentinal tubules, and to provide a reference for the clinical treatment of dentin hypersensitivity. METHODS Forty dentin slices prepared by freshly extracted bovine mandibular central incisors were randomly assigned to procyanidins, tannic acid, gallic acid, naringin, epigallocatechin gallate (EGCG), glycyrrhizic acid, paeonol, and blank groups. Dentin slices in each Chinese herbal medicine group were treated three times a day, each for 5 min, and then immersed in a remineralization solution for the rest of the time. Dentin slices in the blank group were directly immersed in the remineralization solution for 7 days. The dentinal tubule sealing effect was observed under the scanning electron microscope (SEM). RESULTS SEM results showed that the dentinal tubules were almost completely open in the blank group, which was mostly open in the gallic acid, EGCG, glycyrrhizic acid, and paeonol groups, and were sealed in procyanidins, tannic acid, and naringin groups. Significant differences were detected in mean area, mean diameter of dentinal tubules, and mean plugging rate of dentinal tubules between the remaining Chinese herbal medicine groups and blank group ( P < .05). Among them, the dentinal tubule sealing effect of procyanidins, tannic acid, and naringin was obvious. CONCLUSION The findings suggested that procyanidins, tannic acid, and naringin can effectively seal dentinal tubules, which provided a basis for clinical treatment of dentin hypersensitivity.",2020,"Significant differences were detected in mean area, mean diameter of dentinal tubules, and mean plugging rate of dentinal tubules between the remaining Chinese herbal medicine groups and blank group ( P < .05).",['Forty dentin slices prepared by freshly extracted bovine mandibular central incisors'],"['procyanidins, tannic acid, gallic acid, naringin, epigallocatechin gallate (EGCG), glycyrrhizic acid, paeonol, and blank groups', 'Chinese herbal medicines']","['Dentin slices', 'dentinal tubules', 'dentinal tubule sealing effect', 'mean area, mean diameter of dentinal tubules, and mean plugging rate of dentinal tubules']","[{'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}]","[{'cui': 'C0072061', 'cui_str': 'procyanidin'}, {'cui': 'C0039294', 'cui_str': 'Tannic Acid'}, {'cui': 'C0016979', 'cui_str': 'Gallic acid'}, {'cui': 'C0068451', 'cui_str': 'naringin'}, {'cui': 'C0059438', 'cui_str': 'epigallocatechin gallate'}, {'cui': 'C0061751', 'cui_str': 'Glycyrrhizic Acid'}, {'cui': 'C0069939', 'cui_str': 'paeonol'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1273412', 'cui_str': 'Chinese herbal medicine'}]","[{'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0227017', 'cui_str': 'Dentinal tubules'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}]",40.0,0.0379372,"Significant differences were detected in mean area, mean diameter of dentinal tubules, and mean plugging rate of dentinal tubules between the remaining Chinese herbal medicine groups and blank group ( P < .05).","[{'ForeName': 'Yueheng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of preventive dentistry, Stomatological Hospital of Chongqing Medical University , Chongqing, China.'}, {'ForeName': 'Jiao', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of dentistry, Chongqing Qijiang People's Hospital , Chongqing, China.""}, {'ForeName': 'Yanxia', 'Initials': 'Y', 'LastName': 'Duan', 'Affiliation': 'College of Stomatology, Chongqing Medical University , Chongqing, China.'}, {'ForeName': 'Zhi', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of preventive dentistry, Stomatological Hospital of Chongqing Medical University , Chongqing, China.'}]",Ultrastructural pathology,['10.1080/01913123.2020.1749198'] 455,32157697,Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery.,"BACKGROUND Postoperative pancreatic fistula is one of the most frequent and potentially life-threatening complications following pancreatic resections. Fibrin sealants have been used in some centers to reduce postoperative pancreatic fistula. However, the use of fibrin sealants during pancreatic surgery is controversial. This is an update of a Cochrane Review last published in 2018. OBJECTIVES To assess the safety, effectiveness, and potential adverse effects of fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery. SEARCH METHODS We searched trial registers and the following biomedical databases: the Cochrane Library (2019, Issue 2), MEDLINE (1946 to 13 March2019), Embase (1980 to 11 March 2019), Science Citation Index Expanded (1900 to 13 March 2019), and Chinese Biomedical Literature Database (CBM) (1978 to 13 March 2019). SELECTION CRITERIA We included all randomised controlled trials that compared fibrin sealant (fibrin glue or fibrin sealant patch) versus control (no fibrin sealant or placebo) in people undergoing pancreatic surgery. DATA COLLECTION AND ANALYSIS Two review authors independently identified the trials for inclusion, collected the data, and assessed the risk of bias. We performed the meta-analyses using Review Manager 5. We calculated the risk ratio (RR) for dichotomous outcomes (or a Peto odds ratio (OR) for very rare outcomes), and the mean difference (MD) for continuous outcomes, with 95% confidence intervals (CIs). MAIN RESULTS We included 12 studies involving 1604 participants in the review. Application of fibrin sealants to pancreatic stump closure reinforcement after distal pancreatectomy We included seven studies involving 860 participants: 428 were randomised to the fibrin sealant group and 432 to the control group after distal pancreatectomy. Fibrin sealants may lead to little or no difference in postoperative pancreatic fistula (fibrin sealant 19.3%; control 20.1%; RR 0.96, 95% CI 0.68 to 1.35; 755 participants; four studies; low-quality evidence). Fibrin sealants may also lead to little or no difference in postoperative mortality (0.3% versus 0.5%; Peto OR 0.52, 95% CI 0.05 to 5.03; 804 participants; six studies; low-quality evidence), or overall postoperative morbidity (28.5% versus 23.2%; RR 1.23, 95% CI 0.97 to 1.58; 646 participants; three studies; low-quality evidence). We are uncertain whether fibrin sealants reduce reoperation rate (2.0% versus 3.8%; RR 0.51, 95% CI 0.15 to 1.71; 376 participants; two studies; very low-quality evidence) or length of hospital stay (MD 0.99 days, 95% CI -1.83 to 3.82; 371 participants; two studies; very low-quality evidence). The studies did not report serious adverse events, quality of life, or cost effectiveness. Application of fibrin sealants to pancreatic anastomosis reinforcement after pancreaticoduodenectomy We included four studies involving 393 participants: 186 were randomised to the fibrin sealant group and 207 to the control group after pancreaticoduodenectomy. We are uncertain whether fibrin sealants reduce postoperative pancreatic fistula (16.7% versus 11.7%; RR 1.14, 95% CI 0.28 to 4.69; 199 participants; two studies; very low-quality evidence). We are uncertain whether fibrin sealants reduce postoperative mortality (0.5% versus 2.4%; Peto OR 0.26, 95% CI 0.05 to 1.32; 393 participants; four studies; low-quality evidence) or length of hospital stay (MD 0.01 days, 95% CI -3.91 to 3.94; 323 participants; three studies; very low-quality evidence). There is probably little or no difference in overall postoperative morbidity (52.6% versus 50.3%; RR 1.04, 95% CI 0.87 to 1.24; 323 participants; three studies; moderate-quality evidence) between the groups. We are uncertain whether fibrin sealants reduce reoperation rate (5.2% versus 7.7%; RR 0.74, 95% CI 0.33 to 1.66; 323 participants; three studies, very low-quality evidence). The studies did not report serious adverse events, quality of life, or cost effectiveness. Application of fibrin sealants to pancreatic duct occlusion after pancreaticoduodenectomy We included two studies involving 351 participants: 188 were randomised to the fibrin sealant group and 163 to the control group after pancreaticoduodenectomy. Fibrin sealants may lead to little or no difference in postoperative mortality (8.4% versus 6.1%; Peto OR 1.41, 95% CI 0.63 to 3.13; 351 participants; two studies; low-quality evidence) or length of hospital stay (median 16 to 17 days versus 17 days; 351 participants; two studies; low-quality evidence). We are uncertain whether fibrin sealants reduce overall postoperative morbidity (32.0% versus 27.6%; RR 1.16, 95% CI 0.67 to 2.02; 351 participants; two studies; very low-quality evidence), or reoperation rate (13.6% versus 16.0%; RR 0.85, 95% CI 0.52 to 1.41; 351 participants; two studies; very low-quality evidence). Serious adverse events were reported in one study (169 participants; low-quality evidence): more participants developed diabetes mellitus when fibrin sealants were applied to pancreatic duct occlusion, both at three months' follow-up (33.7% fibrin sealant group versus 10.8% control group; 29 participants versus 9 participants) and 12 months' follow-up (33.7% fibrin sealant group versus 14.5% control group; 29 participants versus 12 participants). The studies did not report postoperative pancreatic fistula, quality of life, or cost effectiveness. AUTHORS' CONCLUSIONS Based on the current available evidence, fibrin sealants may have little or no effect on postoperative pancreatic fistula in people undergoing distal pancreatectomy. The effects of fibrin sealants on the prevention of postoperative pancreatic fistula are uncertain in people undergoing pancreaticoduodenectomy.",2020,The effects of fibrin sealants on the prevention of postoperative pancreatic fistula are uncertain in people undergoing pancreaticoduodenectomy.,"['postoperative pancreatic fistula following pancreatic surgery', '351 participants: 188', 'people undergoing pancreatic surgery', 'people undergoing pancreaticoduodenectomy', 'pancreatic stump closure reinforcement after distal pancreatectomy', 'people undergoing distal pancreatectomy', '1604 participants in the review', '1946 to 13 March2019), Embase (1980 to 11 March 2019), Science Citation Index Expanded (1900 to 13 March 2019), and Chinese Biomedical Literature Database (CBM) (1978 to 13 March 2019', '860 participants: 428', '393 participants: 186']","['fibrin sealant', 'fibrin sealants', 'Fibrin sealants', 'pancreaticoduodenectomy', 'control group after pancreaticoduodenectomy', 'fibrin sealant (fibrin glue or fibrin sealant patch) versus control (no fibrin sealant or placebo']","['risk ratio (RR) for dichotomous outcomes (or a Peto odds ratio (OR', 'diabetes mellitus', 'postoperative pancreatic fistula, quality of life, or cost effectiveness', 'safety, effectiveness', 'Serious adverse events', 'postoperative mortality', 'length of hospital stay', 'overall postoperative morbidity', 'postoperative pancreatic fistula', 'serious adverse events, quality of life, or cost effectiveness', 'reoperation rate']","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0030290', 'cui_str': 'Pancreatic Fistula'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0085162', 'cui_str': 'Pancreatoduodenectomy'}, {'cui': 'C0002690', 'cui_str': 'Amputation Stumps'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0035007', 'cui_str': 'Reinforcement'}, {'cui': 'C0176940', 'cui_str': 'Distal subtotal pancreatectomy (procedure)'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205229', 'cui_str': 'Expanding (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0023866', 'cui_str': 'Literature'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0456589', 'cui_str': '1978 (qualifier value)'}, {'cui': 'C4517775', 'cui_str': 'Four hundred and twenty-eight'}, {'cui': 'C4517754', 'cui_str': 'Three hundred and ninety-three'}]","[{'cui': 'C0016004', 'cui_str': 'Fibrin Glue'}, {'cui': 'C0085162', 'cui_str': 'Pancreatoduodenectomy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0030290', 'cui_str': 'Pancreatic Fistula'}, {'cui': 'C0034380'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0035110', 'cui_str': 'Revision Surgery'}]",860.0,0.219335,The effects of fibrin sealants on the prevention of postoperative pancreatic fistula are uncertain in people undergoing pancreaticoduodenectomy.,"[{'ForeName': 'Yilei', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'The First Affiliated Hospital of Zhengzhou University, Department of Hepatopancreatobiliary Surgery, No. 1, Jianshe East Road, Zhengzhou, Henan Province, China, 450000.'}, {'ForeName': 'Sirong', 'Initials': 'S', 'LastName': 'He', 'Affiliation': 'Chongqing Medical University, Department of Immunology, College of Basic Medicine, No. 1 Yixue Road, Chongqing, China, 450000.'}, {'ForeName': 'Yao', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': 'The Second Affiliated Hospital, Chongqing Medical University, Department of Hepatobiliary Surgery, No. 74, Lin Jiang Road, Chongqing, Chongqing, China, 400010.'}, {'ForeName': 'Nansheng', 'Initials': 'N', 'LastName': 'Cheng', 'Affiliation': 'West China Hospital, Sichuan University, Department of Bile Duct Surgery, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Gong', 'Affiliation': 'The Second Affiliated Hospital, Chongqing Medical University, Department of Hepatobiliary Surgery, No. 74, Lin Jiang Road, Chongqing, Chongqing, China, 400010.'}, {'ForeName': 'Junhua', 'Initials': 'J', 'LastName': 'Gong', 'Affiliation': 'First Affiliated Hospital of Kunming Medical University, Organ Transplant Center, No. 295, Xi Chang Road, Kunming, Yunnan, China, 650032.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Zeng', 'Affiliation': 'First Affiliated Hospital of Kunming Medical University, Organ Transplant Center, No. 295, Xi Chang Road, Kunming, Yunnan, China, 650032.'}, {'ForeName': 'Longshuan', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'The First Affiliated Hospital of Zhengzhou University, Department of Hepatopancreatobiliary Surgery, No. 1, Jianshe East Road, Zhengzhou, Henan Province, China, 450000.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009621.pub4'] 456,32237056,Effects of postoperative active warming and early exercise on postoperative body temperature distribution: Non-blinded and randomized controlled trial.,"AIM We tested a hypothesis that postoperative active warming and/or arm leg stretches reduce the difference between core and skin temperatures (primary variable) improving the peripheral circulation immediately after major abdominal surgery. METHODS Fifty-one patients undergoing major abdominal surgeries were randomly assigned to receive one of three interventions immediately after surgery; routine care (control group), mild intermittent exercise on the bed (exercise group), and forced-air warming (warming group). Core and skin temperatures and perfusion index were continuously measured from anesthesia induction to 12 h after arrival at the ward. RESULTS Core body temperature was maintained over 37°C with a relatively greater gap between core and skin temperatures over 1°C and reduced perfusion index in the early postoperative period in the control group. In the warming group, the reduced skin temperature at arrival at the ward approximated to the core temperature leading to significant reduction of the temperature gap and increasing the perfusion index to the preoperative level. Although less evident, both the temperature gap and peripheral perfusion significantly improved in the exercise group after 6 and 8 h after arrival at the ward, respectively. CONCLUSIONS Vasoconstriction in response to cessation after anesthesia and surgery serves to maintain core temperature, but impairs peripheral circulation. Active warming and intermittent mild exercise immediately after arrival at the ward reduces the temperature gap and improves peripheral circulation during the early postoperative period. While cost-effectiveness needs to be considered before clinical application of the intervention, the cost-free mild exercise may be a feasible option for improving postoperative patient care.",2020,"Although less evident, both the temperature gap and peripheral perfusion significantly improved in the exercise group after 6 and 8 h after arrival at the ward, respectively. ",['Fifty-one patients undergoing major abdominal surgeries'],"['postoperative active warming and early exercise', 'three interventions immediately after surgery; routine care (control group), mild intermittent exercise on the bed (exercise group), and forced-air warming (warming group']","['temperature gap and peripheral perfusion', 'postoperative body temperature distribution', 'perfusion index', 'peripheral circulation', 'Core and skin temperatures and perfusion index', 'reduced skin temperature']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0425710', 'cui_str': 'Peripheral blood flow'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C2964282', 'cui_str': 'Perfusion Index'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",51.0,0.0387257,"Although less evident, both the temperature gap and peripheral perfusion significantly improved in the exercise group after 6 and 8 h after arrival at the ward, respectively. ","[{'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Kameda', 'Affiliation': 'Frontier Practice Nursing, Graduate School of Nursing, Chiba University, Chiba, Japan.'}, {'ForeName': 'Shiroh', 'Initials': 'S', 'LastName': 'Isono', 'Affiliation': 'Department of Anesthesiology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Shinobu', 'Initials': 'S', 'LastName': 'Okada', 'Affiliation': 'Frontier Practice Nursing, Graduate School of Nursing, Chiba University, Chiba, Japan.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12335'] 457,32241789,Acupuncture for poststroke hemiplegia focusing on cerebral bilateral connections: study protocol for a randomised controlled neuroimaging trial.,"INTRODUCTION Acupuncture is safe and effective for improving the motor function of poststroke hemiplegic patients, but there still exists a certain gap between clinical practice and understanding its neural mechanisms. The cerebral functional reconstruction after unilateral motor pathway injury exhibits a bilateral tendency, however current studies seldom pay attention to it. Hence, based on cerebral bilateral connections, the underlying mechanism of acupuncture in stroke rehabilitation remains an area for further research. The results of this study will increase our understanding of acupuncture-induced motor recovery in patients who had suffered a stroke and demonstrate the differences in brain response and clinical assessments. METHODS AND ANALYSIS This is a single-centre, randomised controlled, paralleled neuroimaging trial, with patients and outcome assessors blinded. Thirty patients who had a stroke with motor dysfunction meeting the inclusion criteria will be randomly assigned (2:1) to receive either 10 sessions true or sham acupoints treatments (five sessions per week for 2 weeks). All the participants will receive conventional standard medical care and rehabilitation. Motor function assessments and neuroimaging scanning will be conducted before and after the entire acupuncture treatment. The clinical and neuroimaging data will be analysed, respectively. The voxel-mirrored homotopic connectivity will be the primary outcome and the primary effect indicator. The secondary outcomes comprise clinical evaluations and neuroimaging assessments, which include Fugl-Meyer Assessment, the National Institutes of Health Stroke Scale, fractional anisotropy and gray matter volume. The Needle Sensation Assessment Scale is an additional outcome. The correlation analysis will be explored between the neuroimaging indicators, clinical motor assessments and needle sensation. ETHICS AND DISSEMINATION The protocol has been approved by the ethics committee of Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine (DZMEC-KY-2018-04). The results of the neuroimaging trial will be disseminated through peer-reviewed publications and conferences. TRIAL REGISTRATION NUMBER Chinese Clinical Trials Registry (ChiCTR 1800016263).",2020,"INTRODUCTION Acupuncture is safe and effective for improving the motor function of poststroke hemiplegic patients, but there still exists a certain gap between clinical practice and understanding its neural mechanisms.","['Thirty patients who had a stroke with motor dysfunction meeting the inclusion criteria', 'poststroke hemiplegic patients']","['10 sessions true or sham acupoints treatments', 'Acupuncture', 'conventional standard medical care and rehabilitation']","['clinical evaluations and neuroimaging assessments, which include Fugl-Meyer Assessment, the National Institutes of Health Stroke Scale, fractional anisotropy and gray matter volume', 'Needle Sensation Assessment Scale']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0521654', 'cui_str': 'Motor dysfunction'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0205238', 'cui_str': 'True'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0001302', 'cui_str': 'Acupuncture point'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}]","[{'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C3472496', 'cui_str': 'National Institutes of Health stroke scale'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}]",30.0,0.184828,"INTRODUCTION Acupuncture is safe and effective for improving the motor function of poststroke hemiplegic patients, but there still exists a certain gap between clinical practice and understanding its neural mechanisms.","[{'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Hualei', 'Initials': 'H', 'LastName': 'Geng', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Mengxin', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Zhongming', 'Initials': 'Z', 'LastName': 'Du', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing An Ding Hospital, Beijing, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Department of Acupuncture, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Zhongjian', 'Initials': 'Z', 'LastName': 'Tan', 'Affiliation': 'Department of Radiology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yihuai', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': 'Department of Neurology, Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China zouyihuai2004@163.com.'}]",BMJ open,['10.1136/bmjopen-2019-034548'] 458,32241790,Sick leave and return to work after surgery for type II SLAP lesions of the shoulder: a secondary analysis of a randomised sham-controlled study.,"OBJECTIVES To compare days on sick leave and assess predictors of return to work following shoulder surgery. DESIGN A secondary analysis of a randomised controlled trial. SETTING Orthopaedic department. PARTICIPANTS 114 patients with type II superior labral tear from anterior to posterior of the shoulder. INTERVENTIONS Labral repair, biceps tenodesis or sham surgery. OUTCOME MEASURES Sick leave was obtained from national registers for the last year before and 2 years following surgery. Total and shoulder related number of days on sick leave were obtained, using international diagnostic codes. We applied the difference-in-difference approach to compare the differences in the change in mean work days on sick leave between groups over time, backwards logistic regression and lasso regression to evaluate predictors. RESULTS Mean total number of work days on sick leave during the 2 years after surgery was 148 (range 0-460) days. More than 80% of the sick leave days were taken by 22% of the patients. Days on sick leave classified as shoulder-related constituted 80% of the total. In all three treatment groups, the mean total number of days on sick leave doubled the year after surgery. Sham surgery and labral repair had fewer postoperative sickness absence days compared with biceps tenodesis but differences were not significant when adjusted for days of sick leave the year before surgery. Predictors of return to work at 2 years analysed by logistic regression were no sick leave (OR 8.0, 95% CI 2.4 to 26.0) and moderate symptoms of anxiety or depression (OR 0.16, 95% CI 0.05 to 0.5) at inclusion. Similar results were obtained by lasso regression but manual work was an additional predictor. CONCLUSIONS Change in mean work days on sick leave comparing sham surgery, labral repair and biceps tenodesis, was not significantly different. Sick leave, symptoms of anxiety and depression, and manual work at inclusion predicted work status 2 years after surgery. TRIAL REGISTRATION NUMBER NCT00586742.",2020,Sham surgery and labral repair had fewer postoperative sickness absence days compared with biceps tenodesis but differences were not significant when adjusted for days of sick leave the year before surgery.,"['Orthopaedic department', '114 patients with type II superior labral tear from anterior to posterior of the shoulder']","['Labral repair, biceps tenodesis or sham surgery', 'Sham surgery and labral repair']","['Sick leave, symptoms of anxiety and depression, and manual work', 'moderate symptoms of anxiety or depression', 'labral repair and biceps tenodesis', 'Total and shoulder related number of days on sick leave', 'mean total number of days on sick leave', 'sick leave', 'postoperative sickness absence days', 'Mean total number of work days on sick leave']","[{'cui': 'C0587525', 'cui_str': 'Orthopedic department'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0185441', 'cui_str': 'Fixation of tendon'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0185441', 'cui_str': 'Fixation of tendon'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332197', 'cui_str': 'Absent'}]",114.0,0.342906,Sham surgery and labral repair had fewer postoperative sickness absence days compared with biceps tenodesis but differences were not significant when adjusted for days of sick leave the year before surgery.,"[{'ForeName': 'Jens Ivar', 'Initials': 'JI', 'LastName': 'Brox', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway j.i.brox@medisin.uio.no.'}, {'ForeName': 'Øystein', 'Initials': 'Ø', 'LastName': 'Skare', 'Affiliation': 'Surgical Department, Lovisenberg Deakonal Hospital, Oslo, Norway.'}, {'ForeName': 'Petter', 'Initials': 'P', 'LastName': 'Mowinckel', 'Affiliation': 'Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Jostein Skranes', 'Initials': 'JS', 'LastName': 'Brox', 'Affiliation': 'Copenhagen Business School, Frederiksberg, Denmark.'}, {'ForeName': 'Olav', 'Initials': 'O', 'LastName': 'Reikerås', 'Affiliation': 'Orthopedic Department, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Cecilie Piene', 'Initials': 'CP', 'LastName': 'Schrøder', 'Affiliation': 'Surgical Department, Lovisenberg Deakonal Hospital, Oslo, Norway.'}]",BMJ open,['10.1136/bmjopen-2019-035259'] 459,32243043,Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.,"AIMS Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) are affected by renal function in a prespecified subgroup analysis from the BRIGHT trial. MATERIALS AND METHODS BRIGHT (NCT02738151) was a multicentre, open-label, randomized, active-controlled, two-arm, parallel-group, 24-week study in insulin-naïve uncontrolled type 2 diabetes (T2D). Participants were randomized 1:1 to evening Gla-300 (n = 466) or IDeg-100 (n = 463) and stratified based on baseline estimated glomerular filtration rate (eGFR) for this analysis. RESULTS Heterogeneity of treatment effect across renal function subgroups was observed (P = .02), reflecting a greater mean glycated haemoglobin (HbA1c) reduction from baseline to week 24 with Gla-300 versus IDeg-100 in the eGFR <60 mL/min/1.73 m 2 subgroup (least squares mean difference: -0.43% [95% confidence interval: -0.74% to -0.12%]), while there were no differences in hypoglycaemia incidence or rates over 24 weeks in that subgroup. HbA1c reductions were similar between treatments in the other eGFR subgroups. However, heterogeneity was observed for annualized rates of anytime (24 hours) or nocturnal (00:00-05:59 hours) confirmed hypoglycaemia (≤70 mg/dL [≤3.9 mmol/L]) over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90 mL/min/1.73 m 2 . CONCLUSIONS Kidney function seems to affect the glucose-lowering effects of Gla-300 versus IDeg-100 in insulin-naïve T2D. Greater HbA1c reductions with Gla-300 without increase in hypoglycaemia risk, were observed in patients with eGFR <60 mL/min/1.73 m 2 .",2020,over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90,[],"['basal insulin glargine 300 U/mL versus degludec 100 U/mL', 'L', 'evening Gla-300 (n=466) or IDeg-100', 'insulin-naïve uncontrolled type 2 diabetes (T2D', 'insulin glargine 300 U/mL']","['annualised rates of anytime (24 h) or nocturnal', 'hypoglycaemia risk', 'hypoglycaemia', 'renal function subgroups', 'hypoglycaemia incidence or rates', 'cardiovascular morbidity and mortality']",[],"[{'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439340', 'cui_str': 'kU/L'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0061078', 'cui_str': 'gamolenic acid'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0970807,over 24 weeks showing less hypoglycaemia with Gla-300 versus IDeg-100 in the ≥90,"[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Haluzík', 'Affiliation': 'Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Cheng', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Müller-Wieland', 'Affiliation': 'Department of Cardiology, University Hospital RWTH Aachen, Aachen, Germany.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Westerbacka', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Bosnyak', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Lauand', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Lydie', 'Initials': 'L', 'LastName': 'Melas-Melt', 'Affiliation': 'Ividata, Levallois-Perret, France.'}, {'ForeName': 'Janaka', 'Initials': 'J', 'LastName': 'Karalliedde', 'Affiliation': ""Department of Diabetes and Endocrinology, Guy's and St Thomas' NHS Trust, London, UK.""}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosenstock', 'Affiliation': 'Dallas Diabetes Research Center at Medical City, Dallas, Texas.'}, {'ForeName': 'Geremia B', 'Initials': 'GB', 'LastName': 'Bolli', 'Affiliation': 'Section of Endocrinology and Metabolism, Department of Medicine, Perugia University Medical School, Perugia, Italy.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14043'] 460,30542055,Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study.,"Evidence indicating Prostatic Urethral Lift (PUL) delivers significant improvement in symptomatic BPH with low morbidity is based on subjects with lateral lobe (LL) enlargement only. MedLift was an FDA IDE extension of the L.I.F.T. randomized study designed to examine safety and efficacy of PUL for treatment of obstructive middle lobes (OML). Inclusion criteria for this non-randomized cohort were identical to the L.I.F.T. randomized study, except for requiring an OML: ≥ 50 years of age, IPSS ≥ 13, and Qmax ≤ 12 ml/s. Primary endpoint analysis quantified improvement in IPSS over baseline and rate of post-procedure serious complications. Quantification of symptom relief, quality of life, flow rate, and sexual function occurred through 12 months. Outcomes were compared to historical L.I.F.T LL results and were combined to demonstrate the full effectiveness of PUL. Of the 71 screened subjects, 45 were enrolled. At 1, 3, 6, and 12 months, mean IPSS improved from baseline at least 13.5 points (p < 0.0001). Quality of life and BPHII were similarly improved (>60% and >70%, respectively at 3, 6, and 12 months, p < 0.0001). Mean Qmax improvement ranged from 90 to 129% (p < 0.0001). At 1 month, 86% (CI 73-94%) reported ≥70 on the Quality of Recovery scale, 80% (CI 66-89%) reported being ""much"" or ""very much better,"" and 89% (CI 76-95%) would recommend the procedure. Compared to LL subjects, OML subjects' symptoms improved at least as much at every time point (OML range 13.5-15.9, LL range 9.9-11.1, p ≤ 0.01). On combining OML with LL data, >70% (range CI 63-81%) of subjects demonstrated ≥ 8 point improvement in IPSS through 12 months. Analysis of the combined dataset indicates ≥ 40% (CI 30-51%) of sexually active men improved the minimal clinically important difference in erectile function through 12 months. Prostates, including those with middle lobe obstruction, can be treated with the PUL procedure safely and effectively.",2019,"At 1, 3, 6, and 12 months, mean IPSS improved from baseline at least 13.5 points (p < 0.0001).","['subjects with lateral lobe (LL) enlargement only', '71 screened subjects, 45 were enrolled']","['PUL', 'Prostatic Urethral Lift (PUL']","['Quality of life and BPHII', 'IPSS over baseline and rate of post-procedure serious complications', 'erectile function', ""OML subjects' symptoms"", 'Mean Qmax improvement', 'Quantification of symptom relief, quality of life, flow rate, and sexual function', 'mean IPSS', 'Quality of Recovery scale']","[{'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C1293134', 'cui_str': 'Enlargement procedure'}]","[{'cui': 'C0449197', 'cui_str': 'PUL (body structure)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0041967', 'cui_str': 'Urethra'}, {'cui': 'C0181620', 'cui_str': 'Lift'}]","[{'cui': 'C0034380'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0278092', 'cui_str': 'Sexual function (observable entity)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0222045'}]",45.0,0.0797457,"At 1, 3, 6, and 12 months, mean IPSS improved from baseline at least 13.5 points (p < 0.0001).","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Rukstalis', 'Affiliation': 'Wake Forest University Health Sciences Medical Center Blvd, Winston-Salem, NC, 27157, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Grier', 'Affiliation': 'Sound Urological Associates, 21822 76th Avenue West Edmonds, Edmonds, WA, 98026, USA.'}, {'ForeName': 'Sean P', 'Initials': 'SP', 'LastName': 'Stroup', 'Affiliation': 'Department of Urology, Naval Medical Center San Diego, 34800 Bob Wilson Drive San Diego, San Diego, CA, 92134, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Tutrone', 'Affiliation': 'Chesapeake Urology Research Associates, 6535 N, Charles St., Suite 625, Towson, MD, 21204, USA.'}, {'ForeName': 'Euclid', 'Initials': 'E', 'LastName': 'deSouza', 'Affiliation': 'Adult & Pediatric Urology, PC 10707 Pacific Street Suite 101, Omaha, NE, 68114, USA.'}, {'ForeName': 'Sheldon', 'Initials': 'S', 'LastName': 'Freedman', 'Affiliation': 'Sheldon J. Freedman, M.D., LTD 653 N Town Center Drive, Suite 308, Las Vegas, NV, 89144, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'David', 'Affiliation': 'Skyline Urology, 5522 Sepulveda Blvd Sherman Oaks, Oaks, CA, 91411, USA.'}, {'ForeName': 'Jed', 'Initials': 'J', 'LastName': 'Kamientsky', 'Affiliation': 'Manhattan Medical Research Practice, PLLC 215 Lexington Avenue 21th Floor, New York, 10016, USA.'}, {'ForeName': 'Gregg', 'Initials': 'G', 'LastName': 'Eure', 'Affiliation': 'Urology of Virginia, PLLC 225 Clearfield Ave, Virginia Beach, VA, 23462, USA. greure@me.com.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-018-0118-x'] 461,32236521,A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression.,"BACKGROUND Ketamine has rapid-acting antidepressant effects but is associated with psychotomimetic and other adverse effects. A 7-chlorokynurenic acid is a potent and specific glycine site N-methyl-d-aspartate receptor antagonist but crosses the blood-brain barrier inefficiently. Its prodrug, L-4-chlorokynurenine (4-Cl-KYN), exerts acute and sustained antidepressant-like effects in rodents and has no reported psychotomimetic effects in either rodents or healthy volunteers. This study examined whether 4-Cl-KYN has rapid antidepressant effects in individuals with treatment-resistant depression. METHODS After a 2-week drug-free period, 19 participants with treatment-resistant depression were randomized to receive daily oral doses of 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days) or placebo for 14 days in a randomized, placebo-controlled, double-blind, crossover manner. The primary outcome measure was the Hamilton Depression Rating Scale score, assessed at several time points over a 2-week period; secondary outcome measures included additional rating scale scores. Pharmacokinetic measures of 7-chlorokynurenic acid and 4-Cl-KYN and pharmacodynamic assessments were obtained longitudinally and included 1H-magnetic resonance spectroscopy brain glutamate levels, resting-state functional magnetic resonance imaging, and plasma and cerebrospinal fluid measures of kynurenine metabolites and neurotrophic factors. RESULTS Linear mixed models detected no treatment effects, as assessed by primary and secondary outcome measures. No difference was observed for any of the peripheral or central biological indices or for adverse effects at any time between groups. A 4-Cl-KYN was safe and well-tolerated, with generally minimal associated adverse events. CONCLUSIONS In this small crossover trial, 4-Cl-KYN monotherapy exerted no antidepressant effects at the doses and treatment duration studied.ClinicalTrials.gov identifier: NCT02484456.",2020,"In this small crossover trial, 4-Cl-KYN monotherapy exerted no antidepressant effects at the doses and treatment duration studied.","['individuals with treatment-resistant depression (TRD', '19 participants with TRD', 'rodents or healthy volunteers']","['placebo', '7-chlorokynurenic acid (7-Cl-KYNA', 'Ketamine', '4-Cl-KYN monotherapy', 'N-methyl-d-aspartate Receptor Glycine Site Antagonist Prodrug 4-chlorokynurenine', '4-Cl-KYN', 'L-4-chlorokynurenine (4-Cl-KYN']","['Hamilton Depression Rating Scale (HAM-D) score, assessed at several time points', 'peripheral or central biological indices or for adverse effects', 'safe and well-tolerated', 'additional rating scale scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0087050', 'cui_str': 'T-Cell Receptor delta-Chain'}, {'cui': 'C0035804', 'cui_str': 'Order Rodentia'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0049860', 'cui_str': '7-chlorokynurenic acid'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0022818', 'cui_str': 'Kynurenine'}, {'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}, {'cui': 'C0017890', 'cui_str': 'Glycine'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0033262', 'cui_str': 'Drug Precursors'}, {'cui': 'C0244033', 'cui_str': '4-chlorokynurenine'}]","[{'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",19.0,0.485397,"In this small crossover trial, 4-Cl-KYN monotherapy exerted no antidepressant effects at the doses and treatment duration studied.","[{'ForeName': 'Lawrence T', 'Initials': 'LT', 'LastName': 'Park', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Bashkim', 'Initials': 'B', 'LastName': 'Kadriu', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Todd D', 'Initials': 'TD', 'LastName': 'Gould', 'Affiliation': 'Veterans Affairs Maryland Health Care System, Baltimore, MD.'}, {'ForeName': 'Panos', 'Initials': 'P', 'LastName': 'Zanos', 'Affiliation': 'Departments of Psychiatry, Pharmacology, Anatomy & Neurobiology and Physiology, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Greenstein', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Jennifer W', 'Initials': 'JW', 'LastName': 'Evans', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Peixiong', 'Initials': 'P', 'LastName': 'Yuan', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Cristan A', 'Initials': 'CA', 'LastName': 'Farmer', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Oppenheimer', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Jomy M', 'Initials': 'JM', 'LastName': 'George', 'Affiliation': 'Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Lilian W', 'Initials': 'LW', 'LastName': 'Adeojo', 'Affiliation': 'Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'H Ralph', 'Initials': 'HR', 'LastName': 'Snodgrass', 'Affiliation': 'VistaGen Therapeutics, Inc., San Francisco, CA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Smith', 'Affiliation': 'VistaGen Therapeutics, Inc., San Francisco, CA.'}, {'ForeName': 'Ioline D', 'Initials': 'ID', 'LastName': 'Henter', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Machado-Vieira', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Science Center, Houston, TX.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Mannes', 'Affiliation': 'Clinical Center, Department of Perioperative Medicine, National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Zarate', 'Affiliation': 'Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.'}]",The international journal of neuropsychopharmacology,['10.1093/ijnp/pyaa025'] 462,32238795,Longitudinal effects of a nurse-managed comprehensive cardiovascular disease prevention program for hospitalized coronary heart disease patients and primary care high-risk patients.,"BACKGROUND The EUROACTION study (nurse‑coordinated multidisciplinary, family‑based cardiovascular disease prevention program) documented the efficacy of a nurse‑managed, comprehensive prevention program in reducing risk factors for cardiovascular disease (CVD). No information was available on survival. AIMS The aim of the study was to assess the effects of EUROACTION intervention on CVD risk factors and 12‑year survival in the Polish component of the study. METHODS Two district hospitals and 2 primary care practices were allocated randomly to intervention (INT) or usual care (UC). The primary endpoints were lifestyle and risk factors changes at 1‑year follow‑up. Differences in survival were analyzed using the multivariable Cox proportional hazards regression models. RESULTS The study involved 628 patients with coronary heart disease (CHD) and 711 high‑risk patients. Compared to UC, INT patients achieved healthier lifestyles and a larger reduction of risk factors at 1 year but these differences were not maintained 12 years after the intervention. Less deaths occurred in patients from the INT hospital and from INT primary practice (hazard ratio [HR], 0.58; 95% CI, 0.42-0.82 and HR, 0.53; 95% CI, 0.3-0.95, respectively). Adjustment for the covariates slightly attenuated the estimates and removed significance (HR, 0.74; 95% CI, 0.52-1.04 and HR, 0.66; 95% CI, 0.36-1.24, respectively). For combined CHD and high‑risk patient groups, compared with UC, INT patients had a 36% lower risk of death after adjustment for age, sex, and history of CHD (HR, 0.64; 95% CI, 0.48-0.86). CONCLUSIONS The impact of the EUROACTION intervention on lifestyle and CVD risk factors could have contributed to lower mortality in INT coronary and high‑risk patients. These results emphasize the need for sustaining the interventions to help patients maintain a healthy lifestyle.",2020,"Compared to UC, INT patients achieved healthier life styles and a larger reduction of risk factors at 1 year but these differences were not maintained 12 years after intervention.","['Two district hospitals and two primary practices', '628 CHD patients and 601 high-risk patients', 'hospitalized coronary heart disease patients and primary care high-risk patients']","['nurse managed, comprehensive prevention programme', 'nurse-managed comprehensive cardiovascular disease prevention programme', 'intervention (INT) or usual care (UC']","['survival', 'healthier life styles', 'Less deaths', 'CVD risk factors', 'risk factors', 'lifestyle and risk factors changes at 1 year observation', 'risk of death']","[{'cui': 'C0020006', 'cui_str': 'District hospital'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",628.0,0.0552067,"Compared to UC, INT patients achieved healthier life styles and a larger reduction of risk factors at 1 year but these differences were not maintained 12 years after intervention.","[{'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Pająk', 'Affiliation': 'Department of Epidemiology and Population Studies, Jagiellonian University Medical College, Kraków, Poland. andrzej.pajak@uj.edu.pl'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Wolfshaut-Wolak', 'Affiliation': 'Department of Epidemiology and Population Studies, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Doryńska', 'Affiliation': 'Department of Epidemiology and Population Studies, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Jankowski', 'Affiliation': '1st Department of Cardiology and Intervention Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fornal', 'Affiliation': 'Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Grodzicki', 'Affiliation': 'Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Catriona', 'Initials': 'C', 'LastName': 'Jennings', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, United Kingdom; National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Republic of Ireland'}, {'ForeName': 'Kalina', 'Initials': 'K', 'LastName': 'Kawecka-Jaszcz', 'Affiliation': '1st Department of Cardiology and Intervention Electrocardiology and Hypertension, Jagiellonian University Medical College, Kraków, Poland'}, {'ForeName': 'Kornelia', 'Initials': 'K', 'LastName': 'Kotseva', 'Affiliation': 'Imperial College Healthcare NHS Trust, London, United Kingdom; National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Republic of Ireland'}, {'ForeName': 'Krystyna', 'Initials': 'K', 'LastName': 'Pająk', 'Affiliation': 'Centre of Preventive Medicine, Kraków, Poland'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Wood', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, London, United Kingdom; National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Republic of Ireland'}]",Kardiologia polska,['10.33963/KP.15273'] 463,31574209,Satiety testing in diabetic gastroparesis: Effects of insulin pump therapy with continuous glucose monitoring on upper gastrointestinal symptoms and gastric myoelectrical activity.,"BACKGROUND Symptoms induced by caloric or non-caloric satiety test meals and gastric myoelectrical activity (GMA) have not been studied in patients with diabetic gastroparesis (DGP) before and after intense glucose management. AIMS We determined the effects of continuous subcutaneous insulin infusion (CSII) with continuous glucose monitoring (CGM) on GI symptoms, volume consumed, and GMA induced by the caloric meal satiety test (CMST) and water load satiety test (WLST) in DGP. METHODS Forty-five patients with DGP underwent CMST and WLST at baseline and 24 weeks after CSII with CGM. Subjects ingested the test meals until they were completely full. Visual analog scales were used to quantify pre- and postmeal symptoms, and GMA was recorded with cutaneous electrodes and analyzed visually and by computer. KEY RESULTS: At baseline and 24-week visits, nausea, bloating, abdominal discomfort, and fullness were immediately increased after CMST and WLST (Ps < 0.01). The meal volumes ingested were significantly less than normal controls at both visits in almost one-third of the subjects. After the CMST, the percentage 3 cycle per minute GMA increased and bradygastria decreased compared with WLST (Ps < 0.05). After treatment for 24 weeks meal volumes ingested, postmeal symptoms and GMA were no different than baseline. CONCLUSIONS AND INFERENCES: (a) Satiety test meals elicited symptoms of nausea, bloating, and abdominal discomfort; (b) CMST stimulated more symptoms and changes in GMA than WLST; and (c) CSII with CGM for 24 weeks did not improve symptoms, volumes ingested, or GMA elicited by the two satiety test meals in these patients with diabetic GP. Satiety tests in diabetic gastropresis are useful to study acute postprandial symptoms and GMA, but these measures were not improved by intensive insulin therapy.",2020,"At baseline and 24-week visits, nausea, bloating, abdominal discomfort, and fullness were immediately increased after CMST and WLST","['patients with diabetic gastroparesis (DGP) before and after intense glucose management', 'diabetic gastroparesis', 'Forty-five patients with DGP underwent CMST and WLST at baseline and 24\xa0weeks after CSII with CGM']","['WLST ', 'caloric or non-caloric satiety test meals and gastric myoelectrical activity (GMA', 'CMST and WLST', 'insulin pump therapy with continuous glucose monitoring', 'Satiety testing', 'continuous subcutaneous insulin infusion (CSII) with continuous glucose monitoring (CGM']","['upper gastrointestinal symptoms and gastric myoelectrical activity', 'postmeal symptoms and GMA', 'nausea, bloating, and abdominal discomfort', 'nausea, bloating, abdominal discomfort, and fullness', 'percentage 3 cycle per minute GMA increased and bradygastria', 'Visual analog scales', 'GI symptoms, volume consumed, and GMA induced by the caloric meal satiety test (CMST) and water load satiety test (WLST']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0267176', 'cui_str': 'Gastroparesis co-occurrent and due to diabetes mellitus (disorder)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0857493', 'cui_str': 'Upper gastrointestinal symptoms'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0232487', 'cui_str': 'Abdominal discomfort (finding)'}, {'cui': 'C0439650', 'cui_str': 'Fullness (qualifier value)'}, {'cui': 'C0702093', 'cui_str': '/min'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}]",45.0,0.0301565,"At baseline and 24-week visits, nausea, bloating, abdominal discomfort, and fullness were immediately increased after CMST and WLST","[{'ForeName': 'Kenneth L', 'Initials': 'KL', 'LastName': 'Koch', 'Affiliation': 'Section on Gastroenterology, Wake Forest University, Winston-Salem, North Carolina.'}, {'ForeName': 'William L', 'Initials': 'WL', 'LastName': 'Hasler', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Van Natta', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Calles-Escandon', 'Affiliation': 'Endocrinology Section, MetroHealth Medical Center, Cleveland, Ohio.'}, {'ForeName': 'Madhusudan', 'Initials': 'M', 'LastName': 'Grover', 'Affiliation': 'May Clinic, Rochester, Minnesota.'}, {'ForeName': 'Pankaj J', 'Initials': 'PJ', 'LastName': 'Pasricha', 'Affiliation': 'Center for Neurogastroenterology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Snape', 'Affiliation': 'California Pacific Medical Center, San Francisco, California.'}, {'ForeName': 'Henry P', 'Initials': 'HP', 'LastName': 'Parkman', 'Affiliation': 'Section of Gastroenterology, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Abell', 'Affiliation': 'Digestive and Liver Health, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Richard W', 'Initials': 'RW', 'LastName': 'McCallum', 'Affiliation': 'Division of Gastroenterology, Texas Tech University, El Paso, Texas.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Nguyen', 'Affiliation': 'Division of Gastroenterology, Stanford University, Palo Alto, California.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Sarosiek', 'Affiliation': 'Division of Gastroenterology, Texas Tech University, El Paso, Texas.'}, {'ForeName': 'Gianrico', 'Initials': 'G', 'LastName': 'Farrugia', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tonascia', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Lee', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Miriel', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hamilton', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,['10.1111/nmo.13720'] 464,32149716,A Mobile Just-in-Time Adaptive Intervention for Smoking Cessation: Pilot Randomized Controlled Trial.,"BACKGROUND Smartphone apps for smoking cessation could offer easily accessible, highly tailored, intensive interventions at a fraction of the cost of traditional counseling. Although there are hundreds of publicly available smoking cessation apps, few have been empirically evaluated using a randomized controlled trial (RCT) design. The Smart-Treatment (Smart-T2) app is a just-in-time adaptive intervention that uses ecological momentary assessments (EMAs) to assess the risk for imminent smoking lapse and tailors treatment messages based on the risk of lapse and reported symptoms. OBJECTIVE This 3-armed pilot RCT aimed to determine the feasibility and preliminary efficacy of an automated smartphone-based smoking cessation intervention (Smart-T2) relative to standard in-person smoking cessation clinic care and the National Cancer Institute's free smoking cessation app, QuitGuide. METHODS Adult smokers who attended a clinic-based tobacco cessation program were randomized into groups and followed for 13 weeks (1 week prequitting through 12 weeks postquitting). All study participants received nicotine patches and gum and were asked to complete EMAs five times a day on study-provided smartphones for 5 weeks. Participants in the Smart-T2 group received tailored treatment messages after the completion of each EMA. Both Smart-T2 and QuitGuide apps offer on-demand smoking cessation treatment. RESULTS Of 81 participants, 41 (50%) were women and 55 (68%) were white. On average, participants were aged 49.6 years and smoked 22.4 cigarettes per day at baseline. A total of 17% (14/81) of participants were biochemically confirmed 7-day point prevalence abstinent at 12 weeks postquitting (Smart-T2: 6/27, 22%, QuitGuide: 4/27, 15%, and usual care: 4/27, 15%), with no significant differences across groups (P>.05). Participants in the Smart-T2 group rated the app positively, with most participants agreeing that they can rely on the app to help them quit smoking, and endorsed the belief that the app would help them stay quit, and these responses were not significantly different from the ratings given by participants in the usual care group. CONCLUSIONS Dynamic smartphone apps that tailor intervention content in real time may increase user engagement and exposure to treatment-related materials. The results of this pilot RCT suggest that smartphone-based smoking cessation treatments may be capable of providing similar outcomes to traditional, in-person counseling. TRIAL REGISTRATION ClinicalTrials.gov NCT02930200; https://clinicaltrials.gov/show/NCT02930200.",2020,"CONCLUSIONS Dynamic smartphone apps that tailor intervention content in real time may increase user engagement and exposure to treatment-related materials.","['A total of 17% (14/81) of participants were biochemically confirmed 7-day point prevalence abstinent at 12 weeks postquitting (Smart-T2', 'Of 81 participants, 41 (50%) were women and 55 (68%) were white', 'Adult smokers who attended a clinic-based tobacco cessation program', 'participants were aged 49.6 years and smoked 22.4 cigarettes per day at baseline']","['nicotine patches and gum', 'QuitGuide', 'automated smartphone-based smoking cessation intervention (Smart-T2']",['stay quit'],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': 'per day'}]","[{'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C1378701', 'cui_str': 'Gum (basic dose form)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]",[],81.0,0.0934406,"CONCLUSIONS Dynamic smartphone apps that tailor intervention content in real time may increase user engagement and exposure to treatment-related materials.","[{'ForeName': 'Emily T', 'Initials': 'ET', 'LastName': 'Hébert', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Chaelin K', 'Initials': 'CK', 'LastName': 'Ra', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Adam C', 'Initials': 'AC', 'LastName': 'Alexander', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Helt', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Moisiuc', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Darla E', 'Initials': 'DE', 'LastName': 'Kendzor', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Damon J', 'Initials': 'DJ', 'LastName': 'Vidrine', 'Affiliation': 'Moffitt Cancer Center, Tampa, FL, United States.'}, {'ForeName': 'Rachel K', 'Initials': 'RK', 'LastName': 'Funk-Lawler', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Businelle', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}]",Journal of medical Internet research,['10.2196/16907'] 465,31907625,Triclosan toothpaste as an adjunct therapy to plaque control in children from periodontitis families: a crossover clinical trial.,"OBJECTIVES Studies have demonstrated that children from aggressive periodontitis (AgP) parents presented precocious alterations in their periodontal condition, and the use of chemical agents in association to plaque control could be useful to control these alterations. This study aimed to evaluate the effect of Triclosan toothpaste to modulate the clinical and subgingival condition in children from AgP parents. METHODS Fifteen children from AgP parents and 15 from periodontally healthy parents were included in this crossover placebo study. Children were randomly allocated into triclosan or placebo therapy, using selected toothpaste for 45 days. After 15 days of wash-out, groups were crossed, changing the used toothpaste. Clinical examination and saliva, crevicular gingival fluid (GCF), and subgingival biofilm collection were performed at baseline and 45 days of each phase. GCF cytokines' levels were analyzed by Luminex/MAGpix platform and subgingival and salivary periodontal pathogens' levels by qPCR. RESULTS At baseline, AgP group presented higher plaque index (PI), gingival index (GI), and bleeding on probing (BoP), higher Aggregatibacter actinomycetemcomitans (Aa) abundance in saliva and subgingival biofilm, and lower levels of INF-ɣ, IL-4, and IL-17 in GCF. Placebo therapy only reduced PI in both groups. Triclosan toothpaste reduced PI and GI in both groups. Triclosan promoted reduction of BoP and probing depth (PD), Aa salivary, and IL-1β levels in AgP group. In health group, triclosan reduced INF-ɣ and IL-4 concentration. CONCLUSION Triclosan toothpaste demonstrated to be more effective than placebo toothpaste to control the periodontal condition in children from AgP parents, by reducing the BoP, PD, salivary Aa, and IL-1β. CLINICAL RELEVANCE Triclosan toothpaste can improve oral conditions in higher-risk population for AgP. TRIAL REGISTRATION This study was registered at ClinicalTrials.gov with the identifier NCT03642353.",2020,"Triclosan promoted reduction of BoP and probing depth (PD), Aa salivary, and IL-1β levels in AgP group.","['children from periodontitis families', 'children from AgP parents', 'Fifteen children from AgP parents and 15 from periodontally healthy parents']","['triclosan or placebo therapy', 'Placebo', 'placebo toothpaste', 'Triclosan toothpaste']","[""GCF cytokines' levels"", 'Clinical examination and saliva, crevicular gingival fluid (GCF), and subgingival biofilm collection', 'reduction of BoP and probing depth (PD), Aa salivary, and IL-1β levels', 'plaque index (PI), gingival index (GI), and bleeding on probing (BoP), higher Aggregatibacter actinomycetemcomitans (Aa) abundance in saliva and subgingival biofilm, and lower levels of INF-ɣ, IL-4, and IL-17 in GCF', 'PI and GI']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0029297', 'cui_str': 'alpha 1-Acid Glycoprotein'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0040958', 'cui_str': 'Triclosan'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0036087', 'cui_str': 'Saliva (substance)'}, {'cui': 'C4521854', 'cui_str': 'Gingival (intended site)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0081786', 'cui_str': 'Biofilms'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1896186', 'cui_str': 'Aggregatibacter'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0021758', 'cui_str': 'Interleukin-4'}, {'cui': 'C0384648', 'cui_str': 'IL-17'}]",15.0,0.217831,"Triclosan promoted reduction of BoP and probing depth (PD), Aa salivary, and IL-1β levels in AgP group.","[{'ForeName': 'Mabelle Freitas', 'Initials': 'MF', 'LastName': 'Monteiro', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Henrique', 'Initials': 'H', 'LastName': 'Tonelli', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Aurélio Amorim', 'Initials': 'AA', 'LastName': 'Reis', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Marcio Zaffalon', 'Initials': 'MZ', 'LastName': 'Casati', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Karina Gonzales', 'Initials': 'KG', 'LastName': 'Silvério', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Francisco Humberto', 'Initials': 'FH', 'LastName': 'Nociti Junior', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Enilson Antônio', 'Initials': 'EA', 'LastName': 'Sallum', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil.'}, {'ForeName': 'Renato Corrêa Viana', 'Initials': 'RCV', 'LastName': 'Casarin', 'Affiliation': 'Division of Periodontics, Piracicaba Dental School, University of Campinas, Av. Limeira, 901 - Areião, Piracicaba, SP, 13414-903, Brazil. casarinrcv@yahoo.com.br.'}]",Clinical oral investigations,['10.1007/s00784-019-03121-6'] 466,32144515,Alvogyl and absorbable gelatin sponge as palatal wound dressings following epithelialized free gingival graft harvest: a randomized clinical trial.,"OBJECTIVES This randomized controlled trial compares for the first time effects of Alvogyl versus absorbable gelatin sponge as palatal wound dressings on postoperative pain, amount of analgesic consumption, post-surgical bleeding, and wound re-epithelization. MATERIALS AND METHODS Following sample size calculation, 36 systemically healthy patients requiring palatal mucosal graft harvesting were randomized to receive Alvogyl (intervention group, 18 patients) or absorbable gelatin sponge (control group, 18 patients) palatal dressings. Patient-reported VAS pain scores over 2 weeks were defined as primary outcome. Post-surgical bleeding, number of analgesics consumed, and complete re-epithelialization of the palatal wound for up to 5 weeks were defined as secondary outcomes. RESULTS Although significantly higher VAS pain scores were reported in the control as compared with the intervention group up to 12 days post-surgically (from (median [range]) 8.5 [2-10] to 1 [0-2] and from 6 [0-10] to 0 [0-2] respectively), with higher analgesics consumption (from 2 [1-3] to 1 [0-3] and from 1 [0-3] to 0 [0-2] tablets respectively), a multivariate regression analysis considering age, gender, graft width/length, tissue thickness, analgesics intake, and dressing type demonstrated no statistically significant effect of any factor, including dressing type on VAS pain scores. At 4 weeks, 22.2% of patients in the intervention group versus 11.1% in the control group demonstrated complete re-epithelization of their palatal engraftment site, before complete re-epithelization in both groups at 5 weeks. No post-surgical bleeding was reported with both dressings. CONCLUSIONS Within the study's limitations, results suggest Alvogyl as a practical palatal surgical dressing, comparable with absorbable gelatin sponge in cost, pain reduction, hemostasis, and re-epithelization properties. TRIAL REGISTRATION www.ClinicalTrials.gov Identifier: NCT03402321 CLINICAL RELEVANCE: Alvogyl could present a novel palatal wound dressing material, comparable with gelatin sponge.",2020,Although significantly higher VAS pain scores were reported in the control as compared with the intervention group up to 12 days,"['36 systemically healthy patients requiring palatal mucosal graft harvesting', 'epithelialized free gingival graft harvest']","['absorbable gelatin sponge', 'Alvogyl (intervention', 'Alvogyl and absorbable gelatin sponge', 'Alvogyl versus absorbable gelatin sponge', 'absorbable gelatin sponge (control group, 18 patients) palatal dressings', 'gelatin sponge']","['postoperative pain, amount of analgesic consumption, post-surgical bleeding, and wound re-epithelization', 'Post-surgical bleeding, number of analgesics consumed, and complete re-epithelialization of the palatal wound', 'cost, pain reduction, hemostasis, and re-epithelization properties', 'analgesics consumption', 'VAS pain scores', 'complete re-epithelization of their palatal engraftment site']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0450135', 'cui_str': 'Mucosal graft (substance)'}, {'cui': 'C0398967', 'cui_str': 'Free soft dentoalveolar tissue graft procedure, including donor site (procedure)'}]","[{'cui': 'C0017238', 'cui_str': 'Gelatin Sponge, Absorbable'}, {'cui': 'C0051530', 'cui_str': 'alvogyl'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C1705741', 'cui_str': 'Sponge (basic dose form)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0334221', 'cui_str': 'Re-Epithelialization'}, {'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0301944', 'cui_str': 'Graft acceptance (finding)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]",36.0,0.13495,Although significantly higher VAS pain scores were reported in the control as compared with the intervention group up to 12 days,"[{'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Ehab', 'Affiliation': 'Private dental clinic, Fayyoum, Egypt.'}, {'ForeName': 'Omneya', 'Initials': 'O', 'LastName': 'Abouldahab', 'Affiliation': 'Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine, Cairo University, Giza, Egypt.'}, {'ForeName': 'Abdallah', 'Initials': 'A', 'LastName': 'Hassan', 'Affiliation': 'Periodontology Department, School of Dentistry, New Giza University, Giza, Egypt.'}, {'ForeName': 'Karim M', 'Initials': 'KM', 'LastName': 'Fawzy El-Sayed', 'Affiliation': 'Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine, Cairo University, Giza, Egypt. karim.fawzy@gmail.com.'}]",Clinical oral investigations,['10.1007/s00784-020-03254-z'] 467,32239794,Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.,"AIMS While the associations of health-related quality of life scores in heart failure (HF) [e.g. the Kansas City Cardiomyopathy Questionnaire (KCCQ)] with clinical outcomes are well established, their interpretation in the context of what magnitudes of change are clinically important to patients is less clear. The main objective of this study was to correlate the changes in the KCCQ and Patient Global Assessment (PGA) in patients with HF with reduced ejection fraction (HFrEF) to determine minimal clinically important difference (MCID). METHODS AND RESULTS We analysed data from 459 patients of the FAIR-HF trial. Both KCCQ and PGA were assessed at 4 and 24 weeks after enrolment. An anchor-based approach was used to calculate MCID at week 4 and 24. PGA was chosen as the clinical anchor against which changes in the KCCQ scores were calibrated. For each category of change in PGA, the corresponding differences were calculated by the mean scores of various domains of KCCQ along with 95% confidence intervals (CIs). There was fair correlation between PGA and changes in overall summary scores (OSS) (r = 0.31; P < 0.001), clinical summary scores (CSS) (r = 0.36; P < 0.001) and physical limitation scores (PLS) (r = 0.31; P < 0.001) from baseline to week 4. KCCQ OSS, CSS and PLS MCID for 'little improvement' at week 4 were 3.6 (1.0-6.2), 4.5 (1.8-7.2) and 4.7 (1.4-8.0) points, respectively. OSS, CSS and PLS MCID for 'little improvement' at week 24 were 4.3 (0.2-8.4), 4.5 (0.5-8.5) and 4.0 (-0.9-9.0) points, respectively. CONCLUSION The MCID threshold for KCCQ score was generally consistent and numerically lower than the threshold of 5-point change considered for clinical outcome prognosis and were stable between 4 and 24 weeks. This suggests that even changes smaller than the traditional 5-point improvements in KCCQ may be clinically meaningful. Also, these results can aid in the clinical interpretation of patient-reported outcomes, and better endpoint selection in future studies.",2020,"There was fair correlation between PGA and changes in overall summary scores (OSS) (r = 0.31; P < 0.001), clinical summary scores (CSS) (r = 0.36; P < 0.001) and physical limitation scores (PLS) (r = 0.31; P < 0.001) from baseline to week 4.","['patients with HF with reduced ejection fraction (HFrEF', '459 patients of the FAIR-HF trial', 'heart failure (HF) [e.g. the Kansas City Cardiomyopathy Questionnaire (KCCQ', 'patients with heart failure and reduced ejection fraction']",['PGA'],"['physical limitation scores (PLS', ""OSS, CSS and PLS MCID for 'little improvement"", 'KCCQ OSS, CSS and PLS MCID', 'overall summary scores (OSS', 'KCCQ and Patient Global Assessment (PGA', 'quality of life scores', 'MCID threshold for KCCQ score', 'clinical summary scores (CSS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C2911689', 'cui_str': 'Fair'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0022497', 'cui_str': 'Kansas'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030360', 'cui_str': 'Papillon-Lefèvre syndrome'}, {'cui': 'C0449206', 'cui_str': 'OSS'}, {'cui': 'C0265338', 'cui_str': 'Coffin-Siris syndrome'}, {'cui': 'C0023882', 'cui_str': 'Spastic diplegia'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",,0.0651068,"There was fair correlation between PGA and changes in overall summary scores (OSS) (r = 0.31; P < 0.001), clinical summary scores (CSS) (r = 0.36; P < 0.001) and physical limitation scores (PLS) (r = 0.31; P < 0.001) from baseline to week 4.","[{'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi, Jackson, MO, USA.'}, {'ForeName': 'Muhammad Shahzeb', 'Initials': 'MS', 'LastName': 'Khan', 'Affiliation': 'Department of Medicine, Cook County Hospital, Chicago, IL, USA.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Mori', 'Affiliation': 'Vifor Pharma Ltd., Glattbrugg, Switzerland.'}, {'ForeName': 'Gerasimos S', 'Initials': 'GS', 'LastName': 'Filippatos', 'Affiliation': 'Medical School, University of Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Ponikowski', 'Affiliation': 'Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Comin-Colet', 'Affiliation': 'Department of Cardiology, Bellvitge University Hospital and IDIBELL, University of Barcelona, Hospitalet de Llobregat, Barcelona, Spain.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Roubert', 'Affiliation': 'Vifor Pharma Ltd., Glattbrugg, Switzerland.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Spertus', 'Affiliation': ""Department of Cardiology, University of Missouri-Kansas City, Saint Luke's Mid America Heart Institute, Kansas City, MO, USA.""}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Center for Cardiovascular Research (DZHK) partner site Berlin; Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",European journal of heart failure,['10.1002/ejhf.1810'] 468,31342245,"Comparison of four different suture materials in respect to oral wound healing, microbial colonization, tissue reaction and clinical features-randomized clinical study.","OBJECTIVES Sutures are the most frequently used medical device for wound closure. They support tissue during the early phase of healing until it regains enough tensile strength. The aim of this study was to compare four different suture materials in terms of the influence on wound healing, microbial adherence, tissue reaction, and relevant clinical parameters which determine their clinical value. MATERIALS AND METHODS Total number of 32 patients undergoing surgical extraction of four impacted third molars were involved in the study. Clinical parameters were estimated intraoperatively and during the control check-ups. Soft tissue healing around sutures were evaluated on the 3rd and 7th day postoperatively. Microbial colonization was assessed by means of qPCR. Also, histological analysis was done to assess inflammatory reaction. RESULTS Significantly better soft tissue healing was found around monofilament and synthetic sutures compared to multifilament and natural ones respectively. Soft tissue healing was significantly better around all sutures on the 7th day than on the 3rd day postoperatively. CONCLUSIONS Non-resorbable polypropylene suture showed superior clinical characteristics among all sutures. Moreover, the best healing of soft tissue and the least inflammatory reaction was found around this thread. The poorest soft tissue healing was found around non-resorbable silk suture. This suture elicited strongest inflammatory reaction and showed the greatest microbial adherence affinity compared to alternative sutures. CLINICAL RELEVANCE Monofilament synthetic suture should be used in order to obtain the best soft tissue healing, reduce the risk of postoperative infection, and alleviate the suturing after oral surgery procedures.",2020,Significantly better soft tissue healing was found around monofilament and synthetic sutures compared to multifilament and natural ones respectively.,['Total number of 32 patients undergoing surgical extraction of four impacted third molars were involved in the study'],[],"['Soft tissue healing around sutures', 'poorest soft tissue healing', 'Microbial colonization', 'wound healing, microbial adherence, tissue reaction', 'soft tissue healing', 'Soft tissue healing', 'healing of soft tissue and the least inflammatory reaction']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1293139', 'cui_str': 'Surgical extraction'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0026369', 'cui_str': 'Tooth, Wisdom'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],"[{'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0205249', 'cui_str': 'Healed (qualifier value)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",,0.016994,Significantly better soft tissue healing was found around monofilament and synthetic sutures compared to multifilament and natural ones respectively.,"[{'ForeName': 'Miroslav', 'Initials': 'M', 'LastName': 'Dragovic', 'Affiliation': 'Department of Oral Surgery, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Pejovic', 'Affiliation': 'Department of Oral Surgery, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Stepic', 'Affiliation': 'Department of Oral Surgery, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Snjezana', 'Initials': 'S', 'LastName': 'Colic', 'Affiliation': 'Department of Oral Surgery, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Branko', 'Initials': 'B', 'LastName': 'Dozic', 'Affiliation': 'Department of Pathology, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Dragovic', 'Affiliation': 'Department of Prosthodontics, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Milos', 'Initials': 'M', 'LastName': 'Lazarevic', 'Affiliation': 'Department of Human Genetics, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Nikolic', 'Affiliation': 'Department of Human Genetics, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Milasin', 'Affiliation': 'Department of Human Genetics, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia.'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Milicic', 'Affiliation': 'Department of Medical Statistics and Informatics, School of Dental Medicine, University of Belgrade, Dr Subotica 8, Belgrade, 11000, Serbia. biljana.milicic@stomf.bg.ac.rs.'}]",Clinical oral investigations,['10.1007/s00784-019-03034-4'] 469,31651206,Improving self-efficacy for hearing aid self-management: the early delivery of a multimedia-based education programme in first-time hearing aid users.,"Objectives: This study examined the effect of a multimedia educational programme for first-time hearing aid users (C2Hear reusable learning objects, RLOs), delivered at the hearing assessment on (1) self-efficacy for hearing aids (primary outcome), and (2) readiness for hearing rehabilitation and hearing aid knowledge (secondary outcomes). Design: A single-centre, prospective, pre-post, randomised controlled trial with two arms. The intervention group ( n  = 24) received RLOs, and the waitlist control group ( n  = 23) received a printed booklet on hearing aids. Outcomes were measured at the hearing assessment and hearing aid fitting appointments. Study sample: Fifty-six adult first-time hearing aid users attending a publicly funded audiology service. Results: The RLO group showed significantly greater improvement in self-efficacy and knowledge of hearing aids than the control group. A borderline effect of readiness for hearing rehabilitation was also found. Potential links between hearing aid self-efficacy and knowledge were identified. Conclusions: Early delivery of the RLOs results in greater hearing aid self-efficacy and knowledge at the hearing aid fitting appointment, with indications that RLOs increase readiness for hearing rehabilitation. As knowledge, self-efficacy and readiness are cornerstones of self-management, the C2Hear RLOs can prime first-time hearing aid users to better self-manage their hearing aids before they receive them.",2020,The RLO group showed significantly greater improvement in self-efficacy and knowledge of hearing aids than the control group.,"['Study sample: Fifty-six adult first-time hearing aid users attending a publicly funded audiology service', 'first-time hearing aid users']","['RLOs, and the waitlist control group ( n \u2009=\u200923) received a printed booklet on hearing aids', 'multimedia-based education programme', 'multimedia educational programme']","['self-efficacy and knowledge of hearing aids', 'hearing assessment and hearing aid fitting appointments']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0919808', 'cui_str': 'Hearing aid wearer'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0016820', 'cui_str': 'Funds'}, {'cui': 'C0004285', 'cui_str': 'Audiology'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C1960376', 'cui_str': 'Hearing assessment (procedure)'}, {'cui': 'C0018768', 'cui_str': 'Hearing Aids'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]",56.0,0.0219064,The RLO group showed significantly greater improvement in self-efficacy and knowledge of hearing aids than the control group.,"[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Gomez', 'Affiliation': 'Nottingham Audiology Services, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Ferguson', 'Affiliation': 'Nottingham Audiology Services, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}]",International journal of audiology,['10.1080/14992027.2019.1677953'] 470,32163181,Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.,"BACKGROUND The liver is affected by two of the most common groups of malignant tumours: primary liver tumours and liver metastases from colorectal carcinoma or other extrahepatic primary cancers. Liver metastases are significantly more common than primary liver cancer, and long-term survival rate after radical surgical treatment is approximately 50%. However, R0 resection (resection for cure) is not feasible in the majority of people; therefore, other treatments have to be considered. One possible option is based on the concept that the blood supply to hepatic tumours originates predominantly from the hepatic artery. Transarterial chemoembolisation (TACE) of the hepatic artery can be achieved by administering a chemotherapeutic drug followed by vascular occlusive agents, and can lead to selective necrosis of the liver tumour while it may leave normal parenchyma virtually unaffected. This can also be performed without chemotherapy, which is called bland transarterial embolisation (TAE). OBJECTIVES To assess the beneficial and harmful effects of TAE or TACE compared with no intervention or placebo in people with liver metastases. SEARCH METHODS We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, and four more databases (December 2019). We also searched two trials registers and the US Food and Drug Administration database (September 2019). SELECTION CRITERIA Randomised clinical trials assessing beneficial and harmful effects of TAE or TACE compared with no intervention or placebo for liver metastases. DATA COLLECTION AND ANALYSIS We followed standard Cochrane methodological procedures. We extracted information on participant characteristics, interventions, study outcomes, study design, and trial methods. Two review authors independently extracted data and assessed risk of bias. We assessed the certainty of evidence with GRADE. We resolved disagreements by discussion. MAIN RESULTS We included one randomised clinical trial with 61 participants (43 male and 18 female) with colorectal cancer with liver metastases: 22 received transarterial embolisation (TAE; hepatic artery embolisation), 19 received transarterial chemoembolisation (TACE; 5-fluorouracil hepatic artery infusion chemotherapy with degradable microspheres), and 20 received 'no active therapeutic intervention' as a control. Most tumours were synchronous, unresectable metastases involving up to 75% of the liver. Participants were followed for a minimum of seven months. The trial was at high risk of bias. Very-low-certainty evidence found inconclusive results for mortality at 44 months between the TAE and TACE versus no intervention groups (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.74 to 1.06; 61 participants). Local recurrence was reported in 10 participants without any details about the group allocation. Very-low-certainty evidence found little or no difference in mortality between the TAE and no intervention groups (RR 0.91, 95% CI 0.75 to 1.10; 42 participants). Median survival was 7 months from trial entry (range 2 to 44 months) in the TAE group and 7.9 months (range 1 to 26 months) in the control group, and 8.7 months after diagnosis (range 2 to 49 months) in the TAE group and 9.6 months (range 1 to 27 months) in the control group. The trial authors reported the differences were not statistically significant. There were no reported side effects in the control group. In the TAE group, 18 participants experienced short-term symptoms of 'post-embolisation syndrome', which were relieved with symptomatic treatment; one participant also had a local puncture site haematoma. Very-low-certainty evidence found little or no difference in mortality between the TACE and no intervention groups (RR 0.83, 95% CI 0.65 to 1.07; 39 participants). Median survival in the TACE group was 10.7 months (range 3 to 38 months) from trial entry, and 13.0 months (range 3 to 38 months) after diagnosis. The trial authors reported that differences between groups were not statistically significant. All participants experienced short-term nausea, with or without vomiting, immediately after treatment; one participant developed a wound infection, and one developed deep vein thrombosis. The trial did not measure failure to clear liver metastases, time to progression of liver metastases, tumour response measures, or health-related quality of life. Cancer Research Campaign, a non-profit organisation, provided a grant for the trial; Pharmacia Ltd. delivered the Port-a-Cath arterial delivery systems and degradable starch microspheres. We identified one ongoing trial comparing TACE plus chemotherapy versus chemotherapy alone in people with unresectable colorectal liver metastases who failed with first-line chemotherapy (NCT03783559). AUTHORS' CONCLUSIONS Based on one, small randomised trial at high risk of bias, the evidence is very uncertain about the effect of TAE or TACE versus no active therapeutic intervention on mortality for people with liver metastases as the true effect may be substantially different. The trial did not measure failure to clear liver metastases, time to progression of liver metastases, tumour response measures, or health-related quality of life. Short-term, minor adverse events were recorded in the intervention groups only. Large trials, following current standards of conduct and reporting, are required to explore the benefits and harms of TAE or TACE compared with no intervention or placebo in people with resectable and unresectable liver metastasis.",2020,"All participants experienced short-term nausea, with or without vomiting, immediately after treatment; one participant developed a wound infection, and one developed deep vein thrombosis.","['people with liver metastases', '61 participants (43 male and 18 female) with colorectal cancer with liver metastases', 'people with unresectable colorectal liver metastases who failed with first-line chemotherapy (NCT03783559', 'people with resectable and unresectable liver metastasis']","['Transarterial (chemo)embolisation versus no intervention or placebo', ""transarterial chemoembolisation (TACE; 5-fluorouracil hepatic artery infusion chemotherapy with degradable microspheres), and 20 received 'no active therapeutic intervention"", 'chemotherapy alone', 'placebo', 'TAE', 'TACE', 'Transarterial chemoembolisation (TACE', 'transarterial embolisation (TAE; hepatic artery embolisation', 'TACE plus chemotherapy', 'TAE or TACE', 'R0 resection (resection']","['mortality', 'Local recurrence', 'local puncture site haematoma', 'adverse events', 'short-term nausea, with or without vomiting', 'failure to clear liver metastases, time to progression of liver metastases, tumour response measures, or health-related quality of life', 'side effects', 'deep vein thrombosis', ""short-term symptoms of 'post-embolisation syndrome"", 'survival rate', 'wound infection', 'Median survival']","[{'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C3163695', 'cui_str': 'Transarterial embolization'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0522522', 'cui_str': 'Transarterial approach (qualifier value)'}, {'cui': 'C0796679', 'cui_str': 'Chemoembolization'}, {'cui': 'C0529196', 'cui_str': 'ADAM-17 Protein'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0019145', 'cui_str': 'Hepatic artery (body structure)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013931', 'cui_str': 'Embolotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042965', 'cui_str': 'Vomitus (substance)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2609042', 'cui_str': 'Post embolisation syndrome'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",10.0,0.262466,"All participants experienced short-term nausea, with or without vomiting, immediately after treatment; one participant developed a wound infection, and one developed deep vein thrombosis.","[{'ForeName': 'Mateusz J', 'Initials': 'MJ', 'LastName': 'Swierz', 'Affiliation': 'Jagiellonian University Medical College, Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Systematic Reviews Unit, Krakow, Poland.'}, {'ForeName': 'Dawid', 'Initials': 'D', 'LastName': 'Storman', 'Affiliation': 'Jagiellonian University Medical College, Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Systematic Reviews Unit, Krakow, Poland.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Riemsma', 'Affiliation': 'Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Riccall Road, Escrick, York, UK, YO19 6FD.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wolff', 'Affiliation': 'Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Riccall Road, Escrick, York, UK, YO19 6FD.'}, {'ForeName': 'Jerzy W', 'Initials': 'JW', 'LastName': 'Mitus', 'Affiliation': 'The Maria Sklodowska-Curie Institute, Oncology Center, Krakow Branch; Department of Anatomy, Jagiellonian University Medical College, Department of Surgical Oncology, ul. Garncarska 11, Krakow, Poland, 31-115.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Pedziwiatr', 'Affiliation': 'Jagiellonian University Medical College, 2nd Department of General Surgery, Jakubowskiego Street 2, Krakow, Malopolska, Poland, 30-688.'}, {'ForeName': 'Jos', 'Initials': 'J', 'LastName': 'Kleijnen', 'Affiliation': 'School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, 6200 MD.'}, {'ForeName': 'Malgorzata M', 'Initials': 'MM', 'LastName': 'Bala', 'Affiliation': 'Jagiellonian University Medical College, Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics; Systematic Reviews Unit, Krakow, Poland.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009498.pub4'] 471,30987497,Combined microwave ablation and antiangiogenic therapy to increase local efficacy.,"Purpose: We aim to evaluate the efficacy, safety and survival time of microwave ablation (MWA) with adjuvant antiangiogenic therapy-endostatin in animal models. Material and methods: A total of 40 rabbits successfully implanted with VX2 tumors were randomly assigned to four experimental groups: Group A underwent only microwave ablation of the tumors; Group B received only antiangiogenic drugs endostatin; Group C received endostatin immediately after MWA; Group D followed up without treatment. Results: Two months post-treatment, tumor sizes of Group A and Group C were reduced to 1.936 ± 0.373 cm 3 and 1.592 ± 0.382 cm 3 , respectively. However, tumors grew to 15.091 ± 1.735 cm 3 and 47.825 ± 7.664 cm 3 in Group B and the control group. Three months post-treatment, tumor sizes in Group A and Group C maintained as 1.395 ± 0.394 cm 3 and 1.482 ± 0.305 cm 3 , significantly smaller than Group B (35.277 ± 6.019 cm 3 ). All animals in the control group died, while four (40%) survived in Group B (Endo Group). The numbers of survivals in Groups A and C were seven (70%) and eight (80%), respectively. The lowest metastasis rate (2/10, 20%) was observed in Group C (combination therapy). Conclusion: The combination of MWA and antiangiogenic therapy triggered a significant reduction in the growth rate and metastases of tumors and may potentially improve survivals.",2020,"Three months post-treatment, tumor sizes in Group A and Group C maintained as 1.395 ± 0.394 cm 3 and 1.482 ± 0.305 cm 3 , significantly smaller than Group B (35.277 ± ",['40 rabbits successfully implanted with VX2 tumors'],"['Combined microwave ablation and antiangiogenic therapy', 'Group A underwent only microwave ablation of the tumors; Group B received only antiangiogenic drugs endostatin; Group C received endostatin immediately after MWA; Group D followed up without treatment', 'microwave ablation (MWA) with adjuvant antiangiogenic therapy-endostatin', 'MWA and antiangiogenic therapy']","['local efficacy', 'growth rate and metastases of tumors', 'efficacy, safety and survival time', 'numbers of survivals', 'survivals', 'lowest metastasis rate']","[{'cui': 'C3887509', 'cui_str': 'Rabbits'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C3854551', 'cui_str': 'Microwave ablation'}, {'cui': 'C2363719', 'cui_str': 'Antiangiogenic therapy'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0534628', 'cui_str': 'Endostatins'}, {'cui': 'C0441837', 'cui_str': 'Group C (qualifier value)'}, {'cui': 'C0441838', 'cui_str': 'Group D (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0449249', 'cui_str': 'Growth rate (attribute)'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]",,0.0243568,"Three months post-treatment, tumor sizes in Group A and Group C maintained as 1.395 ± 0.394 cm 3 and 1.482 ± 0.305 cm 3 , significantly smaller than Group B (35.277 ± ","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Ni', 'Affiliation': 'Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': 'Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Zhichao', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': 'Department of Oncology, Taishan Hospital Affiliated to Taishan Medical University, Taian, China.'}, {'ForeName': 'Jiaju', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Oncology, Taishan Hospital Affiliated to Taishan Medical University, Taian, China.'}, {'ForeName': 'Guanglian', 'Initials': 'G', 'LastName': 'Shan', 'Affiliation': 'Department of Oncology, Taishan Hospital Affiliated to Taishan Medical University, Taian, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.'}]",Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy,['10.1080/13645706.2019.1601632'] 472,32232608,Retinal Image Slip Must Pass the Threshold for Human Vestibulo-Ocular Reflex Adaptation.,"We sought to determine whether repeated vestibulo-ocular reflex (VOR) adaptation training to increase the VOR gain (eye/head velocity) had a lasting effect in normal subjects and whether there was a retinal image slip tolerance threshold for VOR adaptation. We used the unilateral incremental VOR adaptation technique and horizontal active (self-generated, predictable) head impulses as the vestibular stimulus. Both active and passive (imposed, unpredictable) head impulse VOR gains were measured before and after unilateral incremental VOR adaptation training. The adapting side was pseudo-randomized for left or right. We tested ten normal subjects over one block (10 sessions over 12 days) of VOR adaptation training and testing, immediately followed by a second block (5 sessions over 19 days) of testing only without training. Our findings show robust short-term VOR adaptation of ~ 10 % immediately after each 15-min training session, but that the daily pre-adaptation gain was most different on days 1 and 2, and for subsequent training days before saturating to ~ 5 % greater than the pre-adaptation gain on day 1. This increase was partially retained for 19 days after regular training stopped. The data suggest that stable vision in normal subjects is maintained when there is < 5 % deviation in VOR gain from the original baseline, which corresponds to < 9°/s retinal image slip. Below this threshold, there is poor adaptive drive to return the gain to its original baseline value.",2020,"Both active and passive (imposed, unpredictable) head impulse VOR gains were measured before and after unilateral incremental VOR adaptation training.",['normal subjects'],"['VOR adaptation training and testing, immediately followed by a second block (5 sessions over 19\xa0days) of testing only without training', 'unilateral incremental VOR adaptation technique and horizontal active (self-generated, predictable) head impulses as the vestibular stimulus', 'repeated vestibulo-ocular reflex (VOR) adaptation training']","['VOR gain (eye/head velocity', 'VOR gain']","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]","[{'cui': 'C0034944', 'cui_str': 'Reflexes, Vestibo-Ocular'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0205126', 'cui_str': 'Horizontal (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0443235', 'cui_str': 'Impulse (qualifier value)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}]","[{'cui': 'C0034944', 'cui_str': 'Reflexes, Vestibo-Ocular'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",10.0,0.022205,"Both active and passive (imposed, unpredictable) head impulse VOR gains were measured before and after unilateral incremental VOR adaptation training.","[{'ForeName': 'M Muntaseer', 'Initials': 'MM', 'LastName': 'Mahfuz', 'Affiliation': 'Balance and Vision Laboratory, Neuroscience Research Australia, Cnr Barker Street & Easy Street Randwick, Sydney, NSW, 2031, Australia.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Schubert', 'Affiliation': 'Department of Otolaryngology - Head and Neck Surgery, Laboratory of Vestibular NeuroAdaptation, Johns Hopkins University, Baltimore, MD, 21205, USA.'}, {'ForeName': 'William V C', 'Initials': 'WVC', 'LastName': 'Figtree', 'Affiliation': 'Balance and Vision Laboratory, Neuroscience Research Australia, Cnr Barker Street & Easy Street Randwick, Sydney, NSW, 2031, Australia.'}, {'ForeName': 'Americo A', 'Initials': 'AA', 'LastName': 'Migliaccio', 'Affiliation': 'Balance and Vision Laboratory, Neuroscience Research Australia, Cnr Barker Street & Easy Street Randwick, Sydney, NSW, 2031, Australia. a.migliaccio@neura.edu.au.'}]",Journal of the Association for Research in Otolaryngology : JARO,['10.1007/s10162-020-00751-6'] 473,32128995,"Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial.","BACKGROUND Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common form of liver disease among adolescents in industrialized countries. While lifestyle intervention remains the hallmark treatment for NAFLD, the most effective dietary strategy to reverse NAFLD in children is unknown. OBJECTIVE The objective of this study was to determine the effects of a moderately CHO-restricted diet (CRD) vs fat-restricted diet (FRD) in adolescents with NAFLD on reduction in liver fat and insulin resistance. METHODS Thirty-two children/adolescents (age 9-17) with obesity and NAFLD were randomized to a CRD (<25:25:>50% energy from CHO:protein:fat) or FRD (55:25:20) for 8 weeks. Caloric intakes were calculated to be weight maintaining. Change in hepatic lipid content was measured via magnetic resonance imaging, body composition via dual energy X ray absorptiometry and insulin resistance via a fasting blood sample. RESULTS Change in hepatic lipid did not differ with diet, but declined significantly (-6.0 ± 4.7%, P < .001 only within the CRD group. We found significantly greater decreases in insulin resistance (HOMA-IR, <.05), abdominal fat mass (P < .01) and body fat mass (P < .01) in response to the CRD vs FRD. CONCLUSION These findings suggest that consumption of a moderately CHO-restricted diet may result in decreased hepatic lipid as well as improvements in body composition and insulin resistance in adolescents with NAFLD even in the absence of intentional caloric restriction. Larger studies are needed to determine whether a CHO-restricted diet induces change in hepatic lipid independent of change in body fat.",2020,"We found significantly greater decreases in insulin resistance (HOMA-IR, <.05), abdominal fat mass (P < .01) and body fat mass (P < .01) in response to the CRD vs FRD. ","['adolescents with NAFLD', 'Thirty-two children/adolescents (age 9-17) with obesity and NAFLD', 'adolescents with NAFLD on reduction in liver fat and insulin resistance', 'adolescents with non-alcoholic fatty liver disease']","['CRD (<25:25:>50% energy from CHO:protein:fat) or FRD', 'carbohydrate-restricted diet', 'moderately CHO-restricted diet (CRD) vs fat-restricted diet (FRD']","['insulin resistance (HOMA-IR, <.05), abdominal fat mass', 'body composition and insulin resistance', 'hepatic lipid content', 'hepatic lipid', 'Caloric intakes', 'body fat mass']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C0242970', 'cui_str': 'Fat-Restricted Diet'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C1563742', 'cui_str': 'Abdominal Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}]",32.0,0.0735436,"We found significantly greater decreases in insulin resistance (HOMA-IR, <.05), abdominal fat mass (P < .01) and body fat mass (P < .01) in response to the CRD vs FRD. ","[{'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'Goss', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Dowla', 'Affiliation': 'School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'May', 'Initials': 'M', 'LastName': 'Pendergrass', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Ambika', 'Initials': 'A', 'LastName': 'Ashraf', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Bolding', 'Affiliation': 'Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Morrison', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Alesha', 'Initials': 'A', 'LastName': 'Amerson', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Taraneh', 'Initials': 'T', 'LastName': 'Soleymani', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Gower', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.'}]",Pediatric obesity,['10.1111/ijpo.12630'] 474,31233935,"Effects of Integrated Brain, Body, and Social (IBBS) intervention on ERP measures of attentional control in children with ADHD.","A primary goal of this study was to examine the impact of an Integrated Brain, Body, and Social (IBBS) intervention (multi-faceted treatment consisting of computerized cognitive training, physical exercise, and behavior management) on ERPs of attentional control (P3 & N2) in children with ADHD. The secondary goal was to test the differences between children with and without ADHD on ERP and Go/No-Go behavioral measures. A total of twenty-nine participants (M age = 7.14 years; 52% male; 41.4% white) recruited from the IBBS efficacy study comparing IBBS to Treatment-As-Usual (TAU) completed a Go/No-Go task before and after treatment as brain activity was recorded using EEG. Thirty-four matched healthy controls (HC) completed the same EEG procedures at a single time point. Following treatment, the Go P3 latency was significantly earlier for the IBBS group relative to the TAU group. No treatment effects were found on any behavioral measures. Prior to treatment, there was a significant difference between the ADHD group and HC group for the N2 difference wave. Children with ADHD also showed slower reaction times on behavioral measures. Although this pilot study did not reveal robust treatment effects, it suggests that IBBS may prevent the worsening of attentional systems in the brain and larger studies are needed for replication purposes.",2019,"Following treatment, the Go P3 latency was significantly earlier for the IBBS group relative to the TAU group.","['Children with ADHD', 'Thirty-four matched healthy controls (HC) completed the same EEG procedures at a single time point', 'A total of twenty-nine participants (M age\u202f=\u202f7.14 years; 52% male; 41.4% white', 'children with ADHD']","['Integrated Brain, Body, and Social (IBBS) intervention (multi-faceted treatment consisting of computerized cognitive training, physical exercise, and behavior management', 'Integrated Brain, Body, and Social (IBBS) intervention']","['ERP measures of attentional control', 'slower reaction times on behavioral measures', 'ERPs of attentional control (P3 & N2', 'Go P3 latency']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0150143', 'cui_str': 'Behavior modification case management'}]","[{'cui': 'C0337380', 'cui_str': 'Endoscopic retrograde pancreatography (procedure)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",34.0,0.0142298,"Following treatment, the Go P3 latency was significantly earlier for the IBBS group relative to the TAU group.","[{'ForeName': 'Stephanie D', 'Initials': 'SD', 'LastName': 'Smith', 'Affiliation': 'Department of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA; Child Study Center, Yale School of Medicine, New Haven, CT, USA. Electronic address: SD.Smith@usm.edu.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Crowley', 'Affiliation': 'Child Study Center, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Ferrey', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, England.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Ramsey', 'Affiliation': 'Department of Psychology, University of Southern Mississippi, Hattiesburg, MS, USA.'}, {'ForeName': 'Bruce E', 'Initials': 'BE', 'LastName': 'Wexler', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Leckman', 'Affiliation': 'Child Study Center, Yale School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Denis G', 'Initials': 'DG', 'LastName': 'Sukhodolsky', 'Affiliation': 'Child Study Center, Yale School of Medicine, New Haven, CT, USA.'}]",Psychiatry research,['10.1016/j.psychres.2019.06.021'] 475,31773372,Effect of photobiomodulation therapies on the root resorption associated with orthodontic forces: a pilot study using micro computed tomography.,"OBJECTIVES The aim of this study is to investigate the effect of photobiomodulation therapies on root resorption compared with the placebo group. MATERIALS AND METHODS Thirty patients who were admitted to the Gaziantep University Faculty of Dentistry Orthodontics Department for treatment, with an indication of upper right first premolar tooth extraction were included. Before the individuals' orthodontic treatment, 0.022 slot MBT brackets and tubes were placed on the maxillary first premolar and molar. A 150-g buccal tipping force was applied to the first premolar. Cantilever spring with 0.017 × 0.025 Beta Titanium wire was used for force application. Individuals were then randomly divided into three groups. For the first group, laser application was performed with an 810-nm GaAlAs laser device at 0, 3, 7, 14, 21, and 28 days to 8 J/cm 2 . For the second group, an LED application according to the manufacturer's instructions with an 850-nm wavelength and 20 mW/cm 2 output power for 10 min per day during the experiment. For the third group, a placebo therapy was completed whereby a laser device that did not make active pulses was used. At the end of 4 weeks, the amount of root surface resorption was compared using micro-CT imaging after the extraction of the teeth. RESULTS No significant difference was found between the groups in terms of regional and total crater volumes. It was observed that photobiomodulation therapies were not different from the control group in terms of forming root resorption. CONCLUSIONS It is seen that laser and LED photobiomodulation therapies used for accelerate orthodontic tooth movement do not differ from the control group in terms of forming root resorption. CLINICAL RELEVANCE According to the results of this pilot study on this subject, which needs to be clarified with new findings in the future, LED and laser applications may not increase the risk for root resorption.",2020,No significant difference was found between the groups in terms of regional and total crater volumes.,"['Thirty patients who were admitted to the Gaziantep\xa0University Faculty of Dentistry Orthodontics Department for treatment, with an indication of upper right first premolar tooth extraction were included']","['photobiomodulation therapies', 'placebo', 'micro computed tomography']","['amount of root surface resorption', 'orthodontic tooth movement', 'root resorption', 'regional and total crater volumes']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0011438', 'cui_str': 'Dentistry'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C1704302', 'cui_str': 'Premolar'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}]","[{'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C4543707', 'cui_str': 'Resorption of surface of tooth'}, {'cui': 'C0040446', 'cui_str': 'Tooth Movement Techniques'}, {'cui': 'C0035851', 'cui_str': 'Root Resorption'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]",30.0,0.02736,No significant difference was found between the groups in terms of regional and total crater volumes.,"[{'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Goymen', 'Affiliation': 'Dentistry Faculty, Department of Orthodontics, Gaziantep University, 27300 Şehitkamil, Gaziantep, Turkey. mervegoymen@gmail.com.'}, {'ForeName': 'Aysegul', 'Initials': 'A', 'LastName': 'Gulec', 'Affiliation': 'Dentistry Faculty, Department of Orthodontics, Gaziantep University, 27300 Şehitkamil, Gaziantep, Turkey.'}]",Clinical oral investigations,['10.1007/s00784-019-03155-w'] 476,32229194,"Intraoperative tranexamic acid to decrease blood loss during myomectomy: a randomized, double-blind, placebo-controlled trial.","BACKGROUND Myomectomy is associated with a significant risk of hemorrhage. Tranexamic acid is a synthetic lysine derivative with antifibrinolytic activity used in other surgical disciplines to reduce blood loss during surgery. However, its utility in gynecologic surgery is not well understood. OBJECTIVE This study aimed to determine the effect of early administration of intravenous tranexamic acid on perioperative bleeding and blood transfusion requirements in women undergoing myomectomy. STUDY DESIGN This study was a double-blinded, randomized, placebo-controlled trial conducted in an academic teaching hospital. Women with symptomatic fibroids thought to be at risk for large intraoperative blood loss who met the following criteria were included in the study: (1) at least 1 fibroid ≥10 cm, (2) any intramural or broad ligament fibroid ≥6 cm, and/or (3) at least 5 total fibroids based on preoperative imaging. Patients were randomized to receive a single intravenous bolus injection of tranexamic acid 15 mg/kg (intervention group) versus an intravenous bolus injection of saline of equivalent volume (placebo group) 20 minutes before the initial surgical incision. Perioperative bleeding was defined by measuring intraoperative estimated blood loss, change between pre- and postoperative hemoglobin, and frequency of blood transfusions. Estimated blood loss was calculated by combining the blood volume collected within the suction canister and the weight of used sponges. The 2 groups were compared for age; body mass index; perioperative hemoglobin and hematocrit; perioperative blood loss; duration of surgery; blood transfusion requirements; and the number, total weight, and volume of myomas removed. RESULTS A total of 60 patients (30 per arm) were enrolled into the study between March 1, 2015, and January 29, 2018. Age, body mass index, baseline hemoglobin and/or hematocrit, number and total weight of myomas removed, and size of myomas did not differ between arms. Of 60 patients, 32 (53%) had laparoscopic myomectomy, 24 (40%) had robotic myomectomy, and 4 (7%) had laparotomy. Median estimated blood loss was 200 mL for the tranexamic acid group and 240 mL for the placebo group (P=.88). There was no difference in median duration of surgery (165 vs 164 minutes; P=.64) or change in perioperative hemoglobin (1.00 vs 1.1 g/dL; P=.64). Patients in the tranexamic acid group did not require blood transfusions; however, 4 patients (13.3%) in the placebo group (P=.11) required blood transfusions. CONCLUSION Intravenous administration of tranexamic acid in patients undergoing laparoscopic or robotic myomectomies was not associated with decreased blood loss.",2020,There was no difference in median duration of surgery (165 versus 164 minutes; p=0.64) or change in perioperative hemoglobin (1.00 versus 1.1 g/dL; p=0.64).,"['Women with symptomatic fibroids thought to be at risk for large intraoperative blood loss based on the following criteria were included in the study', 'academic teaching hospital', 'patients undergoing mostly laparoscopic or robotic myomectomies', 'Sixty patients (30 per arm) were enrolled into the study between March 1, 2015 and January 29, 2018', 'women undergoing a myomectomy']","['placebo', 'Intraoperative Tranexamic Acid', 'Tranexamic acid', 'Placebo', 'tranexamic acid', 'tranexamic 15 mg/kg (intervention group) versus an intravenous bolus injection of saline of equivalent volume (placebo group) 20 minutes prior to initial surgical incision']","['intraoperative estimated blood loss, change between pre- and post-operative hemoglobin, and frequency of blood transfusions', 'body mass index, perioperative hemoglobin and hematocrit, perioperative blood loss, duration of surgery, blood transfusion requirements, and the number, total weight and volume of myomas removed', 'perioperative hemoglobin', 'blood loss', 'perioperative bleeding and blood transfusion requirements', 'Perioperative bleeding', 'blood transfusions', 'Estimated blood loss', 'median duration of surgery', 'Median estimated blood loss', 'Age, body mass index, baseline hemoglobin/hematocrit, number and total weight of myomas', 'Blood Loss']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C4319827', 'cui_str': 'Thought'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C4255212', 'cui_str': 'Myomectomy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0195309', 'cui_str': 'Uterine Myomectomy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0184898', 'cui_str': 'Incision - attribute'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]",,0.669796,There was no difference in median duration of surgery (165 versus 164 minutes; p=0.64) or change in perioperative hemoglobin (1.00 versus 1.1 g/dL; p=0.64).,"[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Opoku-Anane', 'Affiliation': 'Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA. Electronic address: jopokua1@gmail.com.'}, {'ForeName': 'Maria V', 'Initials': 'MV', 'LastName': 'Vargas', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University, Washington, DC.'}, {'ForeName': 'Cherie Q', 'Initials': 'CQ', 'LastName': 'Marfori', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University, Washington, DC.'}, {'ForeName': 'Gaby', 'Initials': 'G', 'LastName': 'Moawad', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University, Washington, DC.'}, {'ForeName': 'Marloes S', 'Initials': 'MS', 'LastName': 'Maasen', 'Affiliation': 'Department of Obstetrics and Gynecology, George Washington University, Washington, DC.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Robinson', 'Affiliation': 'MedStar Washington Hospital Center, Georgetown University, Washington, DC.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.02.019'] 477,32054791,Bladder training for urinary tract symptoms in Parkinson disease: A randomized controlled trial.,"OBJECTIVE To assess the feasibility and efficacy of bladder training for troublesome lower urinary tract symptoms (LUTS) in Parkinson disease (PD). METHODS In this single-center, single-blinded, randomized controlled trial, participants with a history of PD and LUTS were randomized to a 12-week bladder training program (BT) or conservative advice (CA). Outcome measures included a 3-day volume frequency diary, International Consultation on Incontinence Questionnaire (ICIQ)-Overactive Bladder Module, and ICIQ-Quality of Life Module. Co-primary endpoints were (1) patient perception of change and (2) change in number of urgency episodes at 12 weeks. Secondary endpoints included change in ICIQ scores, number of micturitions, and volume voided. RESULTS Thirty-eight participants were randomized (18 to CA, 20 to BT). Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05). At 12 weeks, compared to CA, BT was associated with significant superiority on patient perception of improvement ( p = 0.001), significantly greater reductions in number of voids in 24 hours (mean decrease 2.3 ± 0.8 voids vs 0.3 ± 0.5 [ p < 0.05]), and greater reductions in interference with daily life (2.1 ± 0.8 point improvement vs 0.3 ± 0.7 point deterioration [ p < 0.05]). BT was not associated with change in urgency episodes (mean change 2.4 ± 1.5 urgency episodes vs 3.5 ± 1.5 [ p NS]). At 20 weeks, BT remained associated with greater improvement in interference in daily life. Loss of significance in other measures may reflect loss of power from loss to follow-up. CONCLUSION This controlled trial demonstrated the potential benefits of BT for LUTS in PD. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that for patients with PD and LUTS, BT significantly increased patient perception of improvement but did not significantly reduce urgency episodes.",2020,"Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05).","['Parkinson disease (PD', 'participants with a history of PD and LUTS', 'urinary tract symptoms in PD']","['bladder training program (BT) or conservative advice (CA', 'Bladder training', 'bladder training']","['number of voids', 'patient perception of improvement', 'change in ICIQ scores, number of micturitions, and volume voided', 'interference with daily life', 'patient perception of change and (2) change in number of urgency episodes', 'volume voided, number of micturitions, symptom severity scores, and measures of quality of life', 'interference in daily life', 'urgency episodes', '3-day volume frequency diary, International Consultation on Incontinence Questionnaire (ICIQ)-Overactive Bladder Module, and ICIQ-Quality of Life Module']","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0042027'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0150474', 'cui_str': 'Urinary bladder training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire (assessment scale)'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}]",38.0,0.229963,"Both CA and BT were associated with significant improvements in volume voided, number of micturitions, symptom severity scores, and measures of quality of life (all p < 0.05).","[{'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'McDonald', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark. claire.mcdonald@ncl.ac.uk.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Rees', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Winge', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Newton', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Burn', 'Affiliation': 'From Gateshead Health (C.M.) and Newcastle Upon Tyne Hospitals (J.R., J.L.N.), NHS Foundation Trust; Faculty of Medical Sciences (C.M., J.L.N., D.J.B.), Newcastle University, UK; and Zealand University Hospital (K.W.), Roskilde, Denmark.'}]",Neurology,['10.1212/WNL.0000000000008931'] 478,30826660,Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.,"BACKGROUND Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E 2 (PGE 2 ) pathway promotes tumour progression. Considering evidence suggesting increased PGE 2 synthesis by BRAF mutation in tumour cells, we hypothesised that the association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality might be stronger in BRAF-mutated tumours than in BRAF-wild-type tumours. METHODS Using 1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803), we evaluated tumour PTGS2 (COX-2) expression status using immunohistochemistry. We examined the prognostic association of PTGS2 (COX-2) expression in strata of BRAF mutation status by multivariable Cox proportional hazards regression models to adjust for potential confounders, including disease stage, tumour differentiation, microsatellite instability status and KRAS and PIK3CA mutations. RESULTS In NHS and HPFS, the association of PTGS2 (COX-2) expression with colorectal cancer-specific survival differed by BRAF mutation status (P interaction  = 0.0005); compared with PTGS2 (COX-2)-negative/low carcinomas, the multivariable-adjusted hazard ratios for PTGS2 (COX-2)-high carcinomas were 2.44 (95% confidence interval, 1.39-4.28) in BRAF-mutated cases and 0.82 (95% confidence interval, 0.65-1.04) in BRAF-wild-type cases. Differential prognostic associations of PTGS2 (COX-2) expression in strata of BRAF mutation status were similarly observed in CALGB/Alliance 89803 trial (P interaction  = 0.03). CONCLUSIONS The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.",2019,"The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.","['patients with colorectal cancer', 'colorectal cancer', ""1708 patients, including 1200 stage I-IV colorectal carcinoma cases in the Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) and 508 stage III colon cancer cases in a National Cancer Institute-sponsored randomised controlled trial of adjuvant therapy (CALGB/Alliance 89803""]","['Prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase-2, COX-2)-prostaglandin E 2 (PGE 2 ', 'PTGS2 (COX-2']","['BRAF mutation status', 'PTGS2 (COX-2) expression with colorectal cancer-specific survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0009402', 'cui_str': 'Colorectal Carcinoma'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0016441', 'cui_str': 'Followup Studies'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0033551', 'cui_str': 'Prostaglandin H2 Synthetase'}, {'cui': 'C0387583', 'cui_str': 'COX-2 Prostaglandin Synthase'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C0033559', 'cui_str': 'PGE'}, {'cui': 'C0763149', 'cui_str': 'PG(6)E'}]","[{'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0387583', 'cui_str': 'COX-2 Prostaglandin Synthase'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.0942052,"The association of tumour PTGS2 (COX-2) expression with colorectal cancer mortality is stronger in BRAF-mutated tumours than in BRAF-wild-type tumours, supporting interactive roles of PTGS2 (COX-2) expression and BRAF mutation statuses in prognostication of patients with colorectal cancer; ClinicalTrials.gov Identifier, NCT00003835.","[{'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Kosumi', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Hamada', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Huazhong University of Science and Technology, Wuhan, PR China.'}, {'ForeName': 'Annacarolina', 'Initials': 'A', 'LastName': 'da Silva', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Koh', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan.'}, {'ForeName': 'Tyler S', 'Initials': 'TS', 'LastName': 'Twombly', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Mima', 'Affiliation': 'Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Teppei', 'Initials': 'T', 'LastName': 'Morikawa', 'Affiliation': 'Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Mingyang', 'Initials': 'M', 'LastName': 'Song', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Nowak', 'Affiliation': ""Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Nishihara', 'Affiliation': ""Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.""}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Saltz', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Alliance Statistics and Data Center and Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.'}, {'ForeName': 'Fang-Shu', 'Initials': 'FS', 'LastName': 'Ou', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Zemla', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Kimmie', 'Initials': 'K', 'LastName': 'Ng', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Marios', 'Initials': 'M', 'LastName': 'Giannakis', 'Affiliation': ""Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Xuehong', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Kana', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': ""Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Giovannucci', 'Affiliation': ""Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Chan', 'Affiliation': ""Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.""}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': 'Yale Cancer Center, New Haven, CT, USA; Department of Medicine, Yale School of Medicine, New Haven, CT, USA; Smilow Cancer Hospital, New Haven, CT, USA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Ogino', 'Affiliation': ""Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: shuji_ogino@dfci.harvard.edu.""}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.01.022'] 479,30981087,Stress and the medial temporal lobe at rest: Functional connectivity is associated with both memory and cortisol.,"When acute stress is experienced immediately after memory encoding (i.e., post-encoding stress) it can significantly impact subsequent memory for that event. For example, recent work has suggested that post-encoding stress occurring in a different context from encoding impairs memory. However, the neural processes underlying these effects are poorly understood. We aimed to expand this understanding by conducting an analysis of resting functional connectivity in the period following post-encoding stress that occurred in a different context than encoding, using seed regions in the medial temporal lobes known for their roles in memory. In the current study of 44 males randomized to stress (n = 23) or control (n = 21) groups, we found that stress increased cortisol, impaired recollection of neutral materials, and altered functional connectivity with medial temporal lobe regions. Although stress did not significantly alter hippocampus-amygdala functional connectivity, relative to participants in the control group, participants in the post-encoding stress group showed lower functional connectivity between the hippocampus and a region with a peak in the superior temporal gyrus. Across participants in both groups, functional connectivity between these regions was related to greater increases in cortisol, and it was also inversely related to recollection of neutral materials. In contrast, the stress group showed greater parahippocampal cortex functional connectivity with a region in the left middle temporal gyrus than the control group. Moreover, greater functional connectivity between the parahippocampal cortex and the observed cluster in the middle temporal gyrus was associated with greater cortisol changes from pre- to post-manipulation, but was not related to differences in memory. The results show that post-encoding stress can alter the resting-state functional connectivity between the medial temporal lobe and neocortex, which may help explain how stress impacts memory.",2019,"Although stress did not significantly alter hippocampus-amygdala functional connectivity, relative to participants in the control group, participants in the post-encoding stress group showed lower functional connectivity between the hippocampus and a region with a peak in the superior temporal gyrus.",['44 males randomized to stress (n\u2009=\u200923) or control (n\u2009=\u200921) groups'],[],"['parahippocampal cortex functional connectivity', 'cortisol changes', 'functional connectivity', 'resting-state functional connectivity', 'hippocampus-amygdala functional connectivity']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],"[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0949582', 'cui_str': 'Seahorses'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid Body'}]",44.0,0.0295909,"Although stress did not significantly alter hippocampus-amygdala functional connectivity, relative to participants in the control group, participants in the post-encoding stress group showed lower functional connectivity between the hippocampus and a region with a peak in the superior temporal gyrus.","[{'ForeName': 'Grant S', 'Initials': 'GS', 'LastName': 'Shields', 'Affiliation': 'Department of Psychology and Center for Neuroscience, University of California, Davis, USA. Electronic address: gsshields@ucdavis.edu.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'McCullough', 'Affiliation': 'Department of Psychology and Center for Neuroscience, University of California, Davis, USA.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Ritchey', 'Affiliation': 'Department of Psychology, Boston College, USA.'}, {'ForeName': 'Charan', 'Initials': 'C', 'LastName': 'Ranganath', 'Affiliation': 'Department of Psychology and Center for Neuroscience, University of California, Davis, USA.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Yonelinas', 'Affiliation': 'Department of Psychology and Center for Neuroscience, University of California, Davis, USA.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2019.04.001'] 480,28108189,The Longitudinal Impact of an Internet Safety Decision Aid for Abused Women.,"INTRODUCTION Women experiencing intimate partner violence (IPV) navigate complex, dangerous decisions. Tailored safety information and safety planning, typically provided by domestic violence service providers, can prevent repeat IPV exposure and associated adverse health outcomes; however, few abused women access these services. The Internet represents a potentially innovative way to connect abused women with tailored safety planning resources and information. The purpose of this study was to compare safety and mental health outcomes at baseline, 6 months, and 12 months among abused women randomized to: (1) a tailored, Internet-based safety decision aid; or (2) control website (typical safety information available online). DESIGN Multistate, community-based longitudinal RCT with one-to-one allocation ratio and blocked randomization. Data were collected March 2011-May 2013 and analyzed June-July 2015. SETTING/PARTICIPANTS Currently abused Spanish- or English-speaking women (N=720). INTERVENTION A tailored Internet-based safety decision aid included priority-setting activities, risk assessment, and tailored feedback and safety plans. A control website offered typical safety information available online. MAIN OUTCOME MEASURES Primary outcomes were decisional conflict, safety behaviors, and repeat IPV; secondary outcomes included depression and post-traumatic stress disorder. RESULTS At 12 months, there were no significant group differences in IPV, depression, or post-traumatic stress disorder. Intervention women experienced significantly less decisional conflict after one use (β= -2.68, p=0.042) and greater increase in safety behaviors they rated as helpful from baseline to 12 months (12% vs 9%, p=0.033) and were more likely to have left the abuser (63% vs 53%, p=0.008). Women who left had higher baseline risk (14.9 vs 13.1, p=0.003) found more of the safety behaviors they tried helpful (61.1% vs 47.5%, p<0.001), and had greater reductions in psychological IPV ((11.69 vs 7.5, p=0.001) and sexual IPV (2.41 vs 1.25, p=0.001) than women who stayed. CONCLUSIONS Internet-based safety planning represents a promising tool to reduce the public health impact of IPV.",2017,"Women who left had higher baseline risk (14.9 vs 13.1, p=0.003) found more of the safety behaviors","['Abused Women', 'Women experiencing intimate partner violence (IPV', 'domestic violence service providers']",['Internet-based safety decision aid; or (2) control website (typical safety information available online'],"['decisional conflict', 'safety behaviors', 'psychological IPV', 'IPV, depression, or post-traumatic stress disorder', 'sexual IPV', 'safety and mental health outcomes', 'decisional conflict, safety behaviors, and repeat IPV; secondary outcomes included depression and post-traumatic stress disorder']","[{'cui': 'C0242810', 'cui_str': 'Women, Abused'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}, {'cui': 'C0206073', 'cui_str': 'Domestic Violence'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C1321226', 'cui_str': 'Safety behavior'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",,0.165823,"Women who left had higher baseline risk (14.9 vs 13.1, p=0.003) found more of the safety behaviors","[{'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Glass', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Center for Global Health, Baltimore, Maryland. Electronic address: nglass1@jhu.edu.'}, {'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Perrin', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Center for Global Health, Baltimore, Maryland.'}, {'ForeName': 'Ginger C', 'Initials': 'GC', 'LastName': 'Hanson', 'Affiliation': 'Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.'}, {'ForeName': 'Tina L', 'Initials': 'TL', 'LastName': 'Bloom', 'Affiliation': 'Sinclair School of Nursing at the University of Missouri-Columbia, Columbia, Missouri.'}, {'ForeName': 'Jill T', 'Initials': 'JT', 'LastName': 'Messing', 'Affiliation': 'School of Social Work, Arizona State University, Phoenix, Arizona.'}, {'ForeName': 'Amber S', 'Initials': 'AS', 'LastName': 'Clough', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Center for Global Health, Baltimore, Maryland.'}, {'ForeName': 'Jacquelyn C', 'Initials': 'JC', 'LastName': 'Campbell', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Center for Global Health, Baltimore, Maryland.'}, {'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Gielen', 'Affiliation': 'Johns Hopkins Center for Injury Research and Policy, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Case', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Center for Global Health, Baltimore, Maryland.'}, {'ForeName': 'Karen B', 'Initials': 'KB', 'LastName': 'Eden', 'Affiliation': 'Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon.'}]",American journal of preventive medicine,['10.1016/j.amepre.2016.12.014'] 481,30427594,Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults.,"The pharmacokinetics (PK) and safety of single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. In this open-label study (NCT02837380), subjects received once-daily FF/UMEC/VI 100/62.5/25 µg on day 1 and repeat doses on days 2-7. PK parameters (days 1 and 7) included maximum observed concentration (C max ) and area under the plasma concentration-time curve (AUC) from time zero (predose) to last time of quantifiable concentration (AUC 0-t ). Terminal phase half-life (t ½ ) on day 1 was estimated. The primary objective was to assess systemic exposure of FF 100 µg, UMEC 62.5 µg, and VI 25 µg following single-inhaler triple therapy on days 1 and 7. On day 1, geometric mean t ½ of UMEC and VI was 0.36 and 0.52 hours, respectively; t ½ of FF was not representative because of nonquantifiable concentration data. On days 1 and 7, geometric mean C max of FF was 10.46 and 27.32 pg/mL, respectively; C max of UMEC was 144.14 and 241.35 pg/mL, respectively; and C max of VI was 120.42 and 196.78 pg/mL, respectively. AUC 0-t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC 0-t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC 0-t of VI, 42.46 and 101.12 pg·h/mL, respectively. The PK of FF/UMEC/VI was as expected for the individual-component PK previously reported in healthy Chinese adults. No new safety signals were observed.",2019,"On days 1 and 7, geometric mean C max of FF was 10.46 and 27.32 pg/mL, respectively; C max of UMEC was 144.14 and 241.35 pg/mL, respectively; and C max of VI was 120.42 and 196.78 pg/mL, respectively.","['Healthy Chinese Adults', 'healthy Chinese adults']","['single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI', 'Fluticasone Furoate/Umeclidinium/Vilanterol']","['AUC 0-t of FF', 'maximum observed concentration (C max ) and area under the plasma concentration-time curve (AUC) from time zero (predose) to last time of quantifiable concentration (AUC 0-t ', 'pharmacokinetics (PK) and safety', 'geometric mean C max of FF']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C3709478', 'cui_str': 'umeclidinium / vilanterol'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0919414', 'cui_str': '0 (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.467723,"On days 1 and 7, geometric mean C max of FF was 10.46 and 27.32 pg/mL, respectively; C max of UMEC was 144.14 and 241.35 pg/mL, respectively; and C max of VI was 120.42 and 196.78 pg/mL, respectively.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Shanghai Mental Health Center,\xa0Shanghai Key Laboratory of Psychotic Disorders, Shanghai Jiao Tong University School of Medicine, Xuhui Qu, Shanghai, China.'}, {'ForeName': 'Huafang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shanghai Mental Health Center,\xa0Shanghai Key Laboratory of Psychotic Disorders, Shanghai Jiao Tong University School of Medicine, Xuhui Qu, Shanghai, China.'}, {'ForeName': 'Yucheng', 'Initials': 'Y', 'LastName': 'Sheng', 'Affiliation': 'Research and Development, GSK, Pudong Xinqu, Shanghai, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Du', 'Affiliation': 'Research and Development, GSK, Chaoyang District, Beijing, China.'}, {'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Yao', 'Affiliation': 'Research and Development, GSK, Pudong Xinqu, Shanghai, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Luo', 'Affiliation': 'Research and Development, GSK, Pudong Xinqu, Shanghai, China.'}, {'ForeName': 'Peiming', 'Initials': 'P', 'LastName': 'Ma', 'Affiliation': 'Research and Development, GSK, Pudong Xinqu, Shanghai, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.626'] 482,32209650,Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.,"OBJECTIVE To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). METHODS The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12. RESULTS Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). CONCLUSION In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 weeks of treatment. CLINICALTRIALSGOV IDENTIFIER NCT02974153.",2020,"Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).","['patients with CM', 'chronic migraine (CM', 'Adults with CM', 'patients with chronic migraine']","['IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo', 'eptinezumab', 'placebo (placebo', 'placebo']","['Efficacy and safety', 'mean monthly migraine days (MMDs', 'baseline mean number of MMDs', 'acceptable safety profile', 'MMDs', 'Nasopharyngitis']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1960870', 'cui_str': 'Chronic migraine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}]",1072.0,0.62084,"Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo).","[{'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ. richard.lipton@einsteinmed.org.""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Schaeffler', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Biondi', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Hirman', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Pederson', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Allan', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Cady', 'Affiliation': ""From the Montefiore Headache Center (R.B.L.); Department of Neurology (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; NIHR-Wellcome Trust King's Clinical Research Facility (P.J.G.), SLaM Biomedical Research Centre, King's College London, UK; Alder BioPharmaceuticals, Ltd (J.S.), Dublin, Ireland; Lundbeck Seattle BioPharmaceuticals, Inc (B.A.S., D.M.B., S.P., B.A., R.C.), Bothell, WA; and Pacific Northwest Statistical Consulting, Inc (J.H.), Woodinville, WA. Dr. Biondi is now at Cohen Veterans Bioscience, Cambridge, MA. Dr. Allan is now at Global Safety Docs, Paradise Valley, AZ.""}]",Neurology,['10.1212/WNL.0000000000009169'] 483,32154784,The Ecofisio Mobile App for Assessment and Diagnosis Using Ultrasound Imaging for Undergraduate Health Science Students: Multicenter Randomized Controlled Trial.,"BACKGROUND Generation Z is starting to reach college age. They have adopted technology from an early age and have a deep dependence on it; therefore, they have become more drawn to the virtual world. M-learning has experienced huge growth in recent years, both in the medical context and in medical and health sciences education. Ultrasound imaging is an important diagnosis technique in physiotherapy, especially in sports pathology. M-learning systems could be useful tools for improving the comprehension of ultrasound concepts and the acquisition of professional competencies. OBJECTIVE The purpose of this study was to evaluate the efficacy and use of an interactive platform accessible through mobile devices-Ecofisio-using ultrasound imaging for the development of professional competencies in the evaluation and diagnosis of sports pathologies. METHODS Participants included 110 undergraduate students who were placed into one of two groups of a randomized controlled multicenter study: control group (ie, traditional learning) and experimental group (ie, Ecofisio mobile app). Participants' theoretical knowledge was assessed using a multiple-choice questionnaire (MCQ); students were also assessed by means of the Objective Structured Clinical Examination (OSCE). Moreover, a satisfaction survey was completed by the students. RESULTS The statistical analyses revealed that Ecofisio was effective in most of the processes evaluated when compared with the traditional learning method: all OSCE stations, P<.001; MCQ, 43 versus 15 students passed in the Ecofisio and control groups, respectively, P<.001. Moreover, the results revealed that the students found the app to be attractive and useful. CONCLUSIONS The Ecofisio mobile app may be an effective way for physiotherapy students to obtain adequate professional competencies regarding evaluation and diagnosis of sports pathologies. TRIAL REGISTRATION ClinicalTrials.gov NCT04138511; https://clinicaltrials.gov/ct2/show/NCT04138511.",2020,"The statistical analyses revealed that Ecofisio was effective in most of the processes evaluated when compared with the traditional learning method: all OSCE stations, P<.001; MCQ, 43 versus 15 students passed in the Ecofisio and control groups, respectively, P<.001.","['Participants included 110 undergraduate students who were placed into one of two groups of a randomized controlled multicenter study', 'Undergraduate Health Science Students']","['interactive platform accessible through mobile devices-Ecofisio-using ultrasound imaging', 'control group (ie, traditional learning) and experimental group (ie, Ecofisio mobile app', 'Ultrasound imaging']",['Objective Structured Clinical Examination (OSCE'],"[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0332286', 'cui_str': 'Into (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036397', 'cui_str': 'Science'}]","[{'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}]",110.0,0.0708381,"The statistical analyses revealed that Ecofisio was effective in most of the processes evaluated when compared with the traditional learning method: all OSCE stations, P<.001; MCQ, 43 versus 15 students passed in the Ecofisio and control groups, respectively, P<.001.","[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Lozano-Lozano', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Noelia', 'Initials': 'N', 'LastName': 'Galiano-Castillo', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fernández-Lao', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Postigo-Martin', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Álvarez-Salvago', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Arroyo-Morales', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cantarero-Villanueva', 'Affiliation': 'Department of Physical Therapy, University of Granada, Granada, Spain.'}]",Journal of medical Internet research,['10.2196/16258'] 484,32159519,Efficacy of a Web App for Cognitive Training (MeMo) Regarding Cognitive and Behavioral Performance in People With Neurocognitive Disorders: Randomized Controlled Trial.,"BACKGROUND Cognitive and behavioral symptoms are the clinical hallmarks of neurocognitive disorders. Cognitive training may be offered to reduce the risks of cognitive decline and dementia and to reduce behavioral symptoms, such as apathy. Information and communication technology approaches, including serious games, can be useful in improving the playful aspect of computerized cognitive training and providing motivating solutions in elderly patients. OBJECTIVE The objective of this study was to assess the effectiveness of employing the MeMo (Memory Motivation) Web app with regard to cognitive and behavioral symptoms in patients with neurocognitive disorders. METHODS MeMo is a Web app that can be used on any Web browser (computer or tablet). The training activities proposed in MeMo are divided into the following two parts: memory and mental flexibility/attention. The study included 46 individuals (mean age 79.4 years) with a diagnosis of neurocognitive disorders at the Institut Claude Pompidou Memory Center in Nice. This randomized controlled study compared the evolution of cognition and behavior between patients not using MeMo (control group) and patients using MeMo (MeMo group) for 12 weeks (four sessions per week). Patients underwent memory and attention tests, as well as an apathy assessment at baseline, week 12 (end of the training period), and week 24 (12 weeks after the end of the training sessions). In addition, to assess the impact of high and low game uses, the MeMo group was divided into patients who used MeMo according to the instructions (about once every 2 days; active MeMo group) and those who used it less (nonactive MeMo group). RESULTS When comparing cognitive and behavioral scores among baseline, week 12, and week 24, mixed model analysis for each cognitive and behavioral score indicated no significant interaction between testing time and group. On comparing the active MeMo group (n=9) and nonactive MeMo group (n=13), there were significant differences in two attention tests (Trial Making Test A [P=.045] and correct Digit Symbol Substitution Test items [P=.045]) and in the Apathy Inventory (AI) (P=.02). Mixed analysis (time: baseline, week 12, and week 24 × number of active days) indicated only one significant interaction for the AI score (P=.01), with a significant increase in apathy in the nonactive MeMo group. CONCLUSIONS This study indicates that the cognitive and behavioral efficacies of MeMo, a Web-based training app, can be observed only with regular use of the app. Improvements were observed in attention and motivation. TRIAL REGISTRATION ClinicalTrials.gov NCT04142801; https://clinicaltrials.gov/ct2/show/NCT04142801.",2020,"Information and communication technology approaches, including serious games, can be useful in improving the playful aspect of computerized cognitive training and providing motivating solutions in elderly patients. ","['patients with neurocognitive disorders', 'People With Neurocognitive Disorders', '46 individuals (mean age 79.4 years) with a diagnosis of neurocognitive disorders at the Institut Claude Pompidou Memory Center in Nice', 'patients not using MeMo (control group) and patients using', 'elderly patients']","['Cognitive training', 'MeMo (MeMo group', 'Web App for Cognitive Training (MeMo', 'nonactive MeMo']","['attention and motivation', 'AI score', 'correct Digit Symbol Substitution Test items [P=.045]) and in the Apathy Inventory (AI', 'Cognitive and Behavioral Performance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4041080', 'cui_str': 'Neurocognitive Disorders'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0721912', 'cui_str': ""N'ICE""}, {'cui': 'C0445107', 'cui_str': 'Not used (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0085632', 'cui_str': 'Apathy'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",46.0,0.0667222,"Information and communication technology approaches, including serious games, can be useful in improving the playful aspect of computerized cognitive training and providing motivating solutions in elderly patients. ","[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Robert', 'Affiliation': ""Cognition Behaviour Technology Lab, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Manera', 'Affiliation': ""Cognition Behaviour Technology Lab, Université Côte d'Azur, Nice, France.""}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Derreumaux', 'Affiliation': 'Association Innovation Alzheimer, Nice, France.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Ferrandez Y Montesino', 'Affiliation': 'Association Innovation Alzheimer, Nice, France.'}, {'ForeName': 'Elsa', 'Initials': 'E', 'LastName': 'Leone', 'Affiliation': 'Centre Memoire, Centre Hospitalier Universitaire de Nice, Nice, France.'}, {'ForeName': 'Roxane', 'Initials': 'R', 'LastName': 'Fabre', 'Affiliation': 'Departement de Santé Publique, Centre Hospitalier Universitaire de Nice, Nice, France.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Bourgeois', 'Affiliation': 'Centre Memoire, Centre Hospitalier Universitaire de Nice, Nice, France.'}]",Journal of medical Internet research,['10.2196/17167'] 485,32163038,Utilization of a Voice-Based Virtual Reality Advanced Cardiac Life Support Team Leader Refresher: Prospective Observational Study.,"BACKGROUND The incidence of cardiac arrests per year in the United States continues to increase, yet in-hospital cardiac arrest survival rates significantly vary between hospitals. Current methods of training are expensive, time consuming, and difficult to scale, which necessitates improvements in advanced cardiac life support (ACLS) training. Virtual reality (VR) has been proposed as an alternative or adjunct to high-fidelity simulation (HFS) in several environments. No evaluations to date have explored the ability of a VR program to examine both technical and behavioral skills and demonstrate a cost comparison. OBJECTIVE This study aimed to explore the utility of a voice-based VR ACLS team leader refresher as compared with HFS. METHODS This prospective observational study performed at an academic institution consisted of 25 postgraduate year 2 residents. Participants were randomized to HFS or VR training and then crossed groups after a 2-week washout. Participants were graded on technical and nontechnical skills. Participants also completed self-assessments about the modules. Proctors were assessed for fatigue and task saturation, and cost analysis based on local economic data was performed. RESULTS A total of 23 of 25 participants were included in the scoring analysis. Fewer participants were familiar with VR compared with HFS (9/25, 36% vs 25/25, 100%; P<.001). Self-reported satisfaction and utilization scores were similar; however, significantly more participants felt HFS provided better feedback: 99 (IQR 89-100) vs 79 (IQR 71-88); P<.001. Technical scores were higher in the HFS group; however, nontechnical scores for decision making and communication were not significantly different between modalities. VR sessions were 21 (IQR 19-24) min shorter than HFS sessions, the National Aeronautics and Space Administration task load index scores for proctors were lower in each category, and VR sessions were estimated to be US $103.68 less expensive in a single-learner, single-session model. CONCLUSIONS Utilization of a VR-based team leader refresher for ACLS skills is comparable with HFS in several areas, including learner satisfaction. The VR module was more cost-effective and was easier to proctor; however, HFS was better at delivering feedback to participants. Optimal education strategies likely contain elements of both modalities. Further studies are needed to examine the utility of VR-based environments at scale.",2020,"Technical scores were higher in the HFS group; however, nontechnical scores for decision making and communication were not significantly different between modalities.","['A total of 23 of 25 participants were included in the scoring analysis', 'academic institution consisted of 25 postgraduate year 2 residents']","['Virtual reality (VR', 'HFS', 'HFS or VR training']","['fatigue and task saturation, and cost analysis based on local economic data', 'National Aeronautics and Space Administration task load index scores', 'nontechnical scores for decision making and communication', 'Technical scores', 'Self-reported satisfaction and utilization scores']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0010171', 'cui_str': 'Cost Analysis'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042153', 'cui_str': 'use'}]",25.0,0.0242053,"Technical scores were higher in the HFS group; however, nontechnical scores for decision making and communication were not significantly different between modalities.","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Katz', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Ronak', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'City University of New York City Medical School, New York, NY, United States.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Anjan', 'Initials': 'A', 'LastName': 'Shah', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Levine', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Garrett', 'Initials': 'G', 'LastName': 'Burnett', 'Affiliation': 'Department of Anesthesiology, Pain, & Perioperative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}]",Journal of medical Internet research,['10.2196/17425'] 486,32227613,Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).,"AIM To assess what drives change in health-related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores. MATERIALS AND METHODS The Short Form (SF)-36v2® questionnaire [comprising physical component summary (PCS) and mental component summary (MCS)] was used to assess changes in HRQoL from baseline to week 104, by treatment, in a prespecified analysis. This post-hoc analysis assessed change in PCS and MCS using the following factors as parameter/covariate, using descriptive statistics and linear regressions: major adverse cardiac events, hypoglycaemia, gastrointestinal adverse events, at least one episode of nausea, vomiting or diarrhoea, and change in glycated haemoglobin (HbA1c), body weight, blood pressure, heart rate and estimated glomerular filtration rate. RESULTS Mean change in overall PCS score was +1.0 with semaglutide versus +0.4 with placebo, and +0.5 versus -0.2 for MCS. The treatment effect of semaglutide versus placebo (unadjusted estimate) was 0.7 [(95% confidence interval 0.1, 1.2); P = 0.018] on PCS and this was reduced when adjusted for change in HbA1c [0.4 (-0.2, 1.0), P = .167] and body weight [0.3 (-0.3, 0.9), P = .314]. The unadjusted treatment effect on MCS [0.7 (-0.0, 1.5), P = .054] was only reduced when adjusted for change in HbA1c [0.3 (-0.4, 1.1), P = .397]. When adjusting for all other parameters separately, the estimated effect of semaglutide on PCS and MCS qualitatively did not change. CONCLUSIONS Semaglutide improved HRQoL versus placebo; greater improvements with semaglutide versus placebo were possibly mediated, in part, by change in HbA1c and body weight. Clinicaltrials.gov: NCT01720446 (SUSTAIN 6).",2020,"Mean change in overall PCS score was +1.0 with semaglutide vs +0.4 with placebo, and +0.5 vs -0.2 for MCS.",['patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6'],"['SF-36v2® questionnaire (comprising physical component summary [PCS] and mental component summary [MCS', 'placebo', 'semaglutide vs placebo']","['overall PCS score', 'MCS', 'health-related quality of life (HRQoL', 'body weight', 'health-related quality of life', 'adverse cardiac events, hypoglycaemia, gastrointestinal adverse events, at least one episode of nausea, vomiting or diarrhoea, and change in HbA 1c , body weight, blood pressure, heart rate and estimated glomerular filtration rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C3811844'}]",,0.165028,"Mean change in overall PCS score was +1.0 with semaglutide vs +0.4 with placebo, and +0.5 vs -0.2 for MCS.","[{'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Jódar', 'Affiliation': 'Faculty of Medicine, Universidad Europea de Madrid, Madrid, Spain.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Michelsen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Polonsky', 'Affiliation': 'Behavioral Diabetes Institute, San Diego, California.'}, {'ForeName': 'Rosangela', 'Initials': 'R', 'LastName': 'Réa', 'Affiliation': 'Department of Clinical Medicine, SEMPR, Universidade Federal do Paraná, Curitiba, Brazil.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Sandberg', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Steno Diabetes Center Copenhagen, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Warren', 'Affiliation': 'Department of Endocrinology, Physicians East, Greenville, North Carolina.'}, {'ForeName': 'Signe', 'Initials': 'S', 'LastName': 'Harring', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Ziegler', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Bain', 'Affiliation': 'Diabetes Research Unit Cymru, Swansea University Medical School, Swansea, UK.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14039'] 487,31995662,Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).,"BACKGROUND The Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism (SELECT-D) trial demonstrated reduction in recurrent venous thromboembolism (VTE) but increased bleeding with rivaroxaban compared with dalteparin for treatment of acute VTE in cancer patients, at 6 months. Uncertainty remains around optimal duration of anticoagulation. OBJECTIVES To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months. PATIENTS/METHODS In SELECT-D, after 6 months of trial treatment for VTE, patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE) were eligible for randomization to a further 6 months of rivaroxaban or placebo. Patients with no RDVT stopped anticoagulation. Primary outcome was VTE recurrence at 12 months. The second randomization closed prematurely because of low recruitment when 92 of the planned 300 patients were recruited. RESULTS Ninety-two of 136 eligible patients were randomized to rivaroxaban or placebo. The cumulative VTE recurrence after 6 months from the second randomization was 14% with placebo and 4% with rivaroxaban (hazard ratio, 0.32; 95% confidence interval [CI], 0.06-1.58). The major and clinically relevant non-major bleeding rates were 0% and 0% with placebo; and 5% (95% CI, 1-18) and 4% (95% CI, 1-17) with rivaroxaban. In an exploratory analysis, 7 (15%) of 46 placebo patients with RDVT or an index PE experienced recurrent VTE compared to none in the 35 patients in the RDVT-negative cohort (P = .03). CONCLUSION The SELECT-D trial was underpowered to detect a statistically significant reduction in recurrent VTE with extended anticoagulation. The absence of RDVT and/or index PE, defined a population at low risk of recurrence.",2020,"The cumulative VTE recurrence after 6 months from the second randomisation, was 14% with placebo and 4% with rivaroxaban (Hazard Ratio 0.32; 95% CI 0.06-1.58).","['Cancer-Associated Venous Thromboembolism', 'Patients with no RDVT stopped anticoagulation', 'patients with active cancer and residual deep vein thrombosis (RDVT) or index pulmonary embolism (PE', '92 of 136 eligible patients', '92 of the planned 300 patients were recruited']","['placebo', 'dalteparin', 'rivaroxaban', 'rivaroxaban or placebo']","['VTE recurrence and bleeding', 'VTE recurrence', 'major and clinically-relevant non-major bleeding rates', 'cumulative VTE recurrence', 'index PE experienced recurrent VTE']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450446', 'cui_str': 'Stops (attribute)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary Embolism'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0206461', 'cui_str': 'Dalteparin'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}]","[{'cui': 'C0630906', 'cui_str': 'triethoxyvinylsilane'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}]",300.0,0.603433,"The cumulative VTE recurrence after 6 months from the second randomisation, was 14% with placebo and 4% with rivaroxaban (Hazard Ratio 0.32; 95% CI 0.06-1.58).","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Marshall', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Levine', 'Affiliation': 'McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Hill', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Hale', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Thirlwall', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Wilkie', 'Affiliation': 'University of Worcester, Worcester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'French', 'Affiliation': 'Haematology and Oncology, University Hospitals Coventry and Warwickshire, Coventry, UK.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Kakkar', 'Affiliation': 'Thrombosis Research Institute, London, UK.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Lokare', 'Affiliation': 'Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Maraveyas', 'Affiliation': 'Hull York Medical School, University of Hull, Hull, UK.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Chapman', 'Affiliation': 'Haematology and Oncology, University Hospitals Coventry and Warwickshire, Coventry, UK.'}, {'ForeName': 'Azra', 'Initials': 'A', 'LastName': 'Arif', 'Affiliation': 'Haematology and Oncology, University Hospitals Coventry and Warwickshire, Coventry, UK.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Petrou', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Mandy', 'Initials': 'M', 'LastName': 'Maredza', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hobbs', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Dunn', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Annie M', 'Initials': 'AM', 'LastName': 'Young', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14752'] 488,31455897,"Body weight, body composition and survival after 1 year: follow-up of a nutritional intervention trial in allo-HSCT recipients.","The role of body weight change in survival among recipients of hematopoietic stem-cell transplantation is controversial. We assessed the effect of optimizing energy and protein intake on 1-year survival, body weight and body composition, and the effect of body weight and body composition on 1-year survival in 117 patients (57 intervention, 60 control) in a randomized controlled trial. Cox regression was used to study effects of the intervention, weight and body composition on death, relapse, and nonrelapse mortality (NRM). We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90). Body weight, fat-free mass index, body fat mass index and total body water changed over time (p < 0.001), similarly in both groups (0.17 ≤ p ≤ 0.98). In multivariable analyses adjusted for group, gender and age, HRs and 95% CIs per one kilo increase in weight were 1.03 (1.01-1.06) and 1.04 (1.01-1.08) for death and NRM after 1 year (p ≤ 0.02), respectively, and 1.08 (1.01-1.15) for relapse after 3 months (p = 0.02). In conclusion, weight gain is possibly due to fluid retention and is an indicator of a complication in HSCT, rather than a marker of improved nutritional status.",2019,"We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90).","['allo-HSCT recipients', '117 patients (57 intervention, 60 control', 'recipients of hematopoietic stem-cell transplantation']",['optimizing energy and protein intake'],"['Body weight, body composition and survival', 'relapse', 'weight and body composition on death, relapse, and nonrelapse mortality (NRM', 'weight', 'Body weight, fat-free mass index, body fat mass index and total body water changed over time', 'weight gain', 'death and NRM', 'death hazard ratio', '1-year survival, body weight and body composition']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0429632', 'cui_str': 'Total body water (observable entity)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",117.0,0.156154,"We found no significant effect of intervention versus control on death hazard ratio (HR) 1.05, 95% confidence interval (CI) 0.54-2.04, p = 0.88), relapse (HR 1.15, 95% CI 0.48-2.27, p = 0.75), and NRM (HR 0.95, 95% CI 0.39-2.28, p = 0.90).","[{'ForeName': 'K J', 'Initials': 'KJ', 'LastName': 'Skaarud', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway. kskaarud@ous-hf.no.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Veierød', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lergenmuller', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bye', 'Affiliation': 'European Palliative Care Research Centre, Department of Oncology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.'}, {'ForeName': 'P O', 'Initials': 'PO', 'LastName': 'Iversen', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'G E', 'Initials': 'GE', 'LastName': 'Tjønnfjord', 'Affiliation': 'Department of Haematology, Oslo University Hospital, Oslo, Norway.'}]",Bone marrow transplantation,['10.1038/s41409-019-0638-6'] 489,30605260,No Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects.,"Plazomicin is an aminoglycoside that was engineered to overcome aminoglycoside-modifying enzymes, which are the most common aminoglycoside resistance mechanism in Enterobacteriaceae. Because plazomicin is predominantly eliminated via renal pathways, an in vitro study was conducted to determine whether plazomicin inhibits the organic cation transporter 2 (OCT2) and the multidrug and toxin extrusion (MATE1 and MATE2-K) transporters, using metformin as a probe substrate. Plazomicin inhibited OCT2, MATE1, and MATE2-K transporters with half-maximal inhibition of the transporter values of 5120, 1300, and 338 µg/mL, respectively. To determine whether this in vitro inhibition translates in vivo, an open-label, randomized, 2-period, 2-treatment crossover study (NCT03270553) was carried out in healthy subjects (N = 16), who received a single oral dose of metformin 850 mg alone and in combination with a single intravenous infusion of plazomicin 15 mg/kg. Geometric least-squares mean ratios of the test treatment (combination) vs the reference treatment (metformin alone) and 90% confidence intervals were within the equivalence interval of 80% to 125% (peak plasma concentration, 104.5 [95.1-114.9]; area under the plasma concentration-time curve from time zero to time of last quantifiable concentration, 103.7 [93.5-115.0]; area under the plasma concentration-time curve from time zero to infinity, 104.0 [94.2-114.8]). The results demonstrate that there is no clinically significant drug-drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects. Coadministration of plazomicin and metformin was well tolerated in healthy subjects.",2019,The results demonstrate that there is no clinically significant drug-drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects.,"['Healthy Subjects', 'healthy subjects (N = 16', 'healthy subjects']","['Plazomicin', 'plazomicin and metformin', 'oral metformin', 'plazomicin', 'Metformin', 'metformin 850 mg alone and in combination with a single intravenous infusion of plazomicin 15\xa0mg/kg']",[],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3502652', 'cui_str': 'plazomicin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3840657', 'cui_str': '850 (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0021440', 'cui_str': 'Infusions, Intravenous'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}]",[],,0.0698877,The results demonstrate that there is no clinically significant drug-drug interaction resulting from coadministration of single doses of intravenous plazomicin 15 mg/kg and oral metformin 850 mg in healthy subjects.,"[{'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Choi', 'Affiliation': 'Achaogen, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Allison S', 'Initials': 'AS', 'LastName': 'Komirenko', 'Affiliation': 'Achaogen, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Riddle', 'Affiliation': 'BioPharmAdvisors LLC, Parrish, FL, USA.'}, {'ForeName': 'Aryun', 'Initials': 'A', 'LastName': 'Kim', 'Affiliation': 'Achaogen, Inc., South San Francisco, CA, USA.'}, {'ForeName': 'Shyeilla V', 'Initials': 'SV', 'LastName': 'Dhuria', 'Affiliation': 'Achaogen, Inc., South San Francisco, CA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.648'] 490,32228133,Evaluation of Human Papillomavirus Vaccination After Pharmacist-Led Intervention: A Pilot Project in an Ambulatory Clinic at a Large Academic Urban Medical Center.,"OBJECTIVES Despite the safety and efficacy of the human papillomavirus (HPV) vaccine, many persons are still not receiving it. The purpose of this pilot project was to evaluate the number of first doses of the 9-valent HPV (9vHPV) vaccination administered after a pharmacist-led intervention in the Adult Family Planning Clinic at Grady Health System (GHS), a large academic urban medical center in Atlanta, Georgia. METHODS The pilot project had 3 phases: pre-intervention (November 15, 2016, through March 31, 2017), active intervention (November 15, 2017, through December 29, 2017), and post-intervention (December 30, 2017, through March 31, 2018). The pre-intervention phase was used as a historical control. The active intervention phase consisted of pharmacist interventions in the clinic and patient and health care provider education. The post-intervention phase evaluated the durability of pharmacist-led interventions performed and education provided during the active phase. RESULTS Eighty-nine first-dose 9vHPV vaccines (of the 3-dose series) were administered to young adults aged 18-26 during the project period (November 15, 2017, through March 31, 2018); none were administered during the pre-intervention phase. Of 89 patients who received a first 9vHPV vaccine dose, 20 patients also received a second 9vHPV vaccine dose. During the project period, 166 doses of 9vHPV vaccine (first, second, or third doses) were administered. CONCLUSION This pharmacist-led intervention led to an increase in the number of young adult patients receiving their first dose of the 9vHPV vaccination series. With the support of other health care providers, pharmacist-led initiatives can expand vaccine-related health literacy and facilitate access to immunization services.",2020,This pharmacist-led intervention led to an increase in the number of young adult patients receiving their first dose of the 9vHPV vaccination series.,"['Adult Family Planning Clinic at Grady Health System (GHS), a large academic urban medical center in Atlanta, Georgia', 'Eighty-nine first-dose 9vHPV vaccines (of the 3-dose series) were administered to young adults aged 18-26 during the project period (November 15, 2017, through March 31, 2018); none were administered during the pre-intervention phase', '89 patients who received a first', 'Human Papillomavirus', 'Ambulatory Clinic at a Large Academic Urban Medical Center']","['9-valent HPV (9vHPV) vaccination', '9vHPV vaccine dose', 'pharmacist interventions', 'human papillomavirus (HPV) vaccine', 'Pharmacist-Led Intervention', '9vHPV vaccine']",['Vaccination'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3840184', 'cui_str': 'Family planning clinic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0017454', 'cui_str': 'Georgian S.S.R.'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0205549', 'cui_str': 'Series (qualifier value)'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}]",,0.0352415,This pharmacist-led intervention led to an increase in the number of young adult patients receiving their first dose of the 9vHPV vaccination series.,"[{'ForeName': 'Julianna', 'Initials': 'J', 'LastName': 'Cebollero', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}, {'ForeName': 'Suzanne M', 'Initials': 'SM', 'LastName': 'Walton', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Cavendish', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}, {'ForeName': 'Kristi', 'Initials': 'K', 'LastName': 'Quairoli', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Cwiak', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Kottke', 'Affiliation': '1365 Grady Health System, Atlanta, GA, USA.'}]","Public health reports (Washington, D.C. : 1974)",['10.1177/0033354920914340'] 491,31941795,Randomized controlled trial of N -acetylcysteine therapy for RYR1 -related myopathies.,"OBJECTIVE To investigate the efficacy of N -acetylcysteine (NAC) for decreasing elevated oxidative stress and increasing physical endurance in individuals with ryanodine receptor 1-related myopathies ( RYR1 -RM). METHODS In this 6-month natural history assessment (n = 37) followed by a randomized, double-blinded, placebo-controlled trial, 33 eligible participants were block-randomized (1:1) to receive NAC (n = 16) or placebo (n = 17), orally for 6 months (adult dose 2,700 mg/d; pediatric dose 30 mg/kg/d). The primary endpoint was urine 15-F2t isoprostane concentration and the clinically meaningful co-primary endpoint was 6-minute walk test (6MWT) distance. RESULTS When compared to the general population, participants had elevated baseline 15-F2t isoprostane concentrations and most had a decreased 6MWT distance (mean ± SD 3.2 ± 1.5 vs 1.1 ± 1.7 ng/mg creatinine and 468 ± 134 vs 600 ± 58 m, respectively, both p < 0.001). 15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively). NAC treatment did not improve 15-F2t isoprostane concentration (least squares means difference 0.1 [95% confidence interval [CI] -1.4 to 1.6] ng/mg creatinine, p = 0.88) or 6MWT distance (least squares means difference 24 [95% CI -5.5 to 53.4] m, p = 0.11). NAC was safe and well-tolerated at the doses administered in this study. CONCLUSION In ambulatory RYR1 -RM-affected individuals, we observed stable disease course, and corroborated preclinical reports of elevated oxidative stress and decreased physical endurance. NAC treatment did not decrease elevated oxidative stress, as measured by 15-F2t isoprostane. CLASSIFICATION OF EVIDENCE This study provides Class I evidence that, for people with RYR1 -RM, treatment with oral NAC does not decrease oxidative stress as measured by 15-F2t isoprostane. CLINICALTRIALSGOV IDENTIFIER NCT02362425.",2020,"15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively).","['RYR1 -related myopathies', 'individuals with ryanodine receptor 1-related myopathies ( RYR1 -RM', '33 eligible participants were block-randomized (1:1) to receive']","['N -acetylcysteine therapy', 'placebo', 'NAC', 'N -acetylcysteine (NAC', 'oral NAC']","['15-F2t isoprostane concentration', '6MWT distance', 'safe and well-tolerated', '15-F2t isoprostane concentration and 6MWT distance', 'oxidative stress', 'elevated oxidative stress', 'urine 15-F2t isoprostane concentration and the clinically meaningful co-primary endpoint was 6-minute walk test (6MWT) distance']","[{'cui': 'C0524965', 'cui_str': 'RyR1'}, {'cui': 'C0026848', 'cui_str': 'Muscle Disorders'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0295541', 'cui_str': '8-isoprostaglandin F2alpha'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0042037'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0444858', 'cui_str': 'AM 6 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",33.0,0.628661,"15-F2t isoprostane concentration and 6MWT distance did not change over the 6-month natural history assessment ( p = 0.98 and p = 0.61, respectively).","[{'ForeName': 'Joshua J', 'Initials': 'JJ', 'LastName': 'Todd', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Tokunbor A', 'Initials': 'TA', 'LastName': 'Lawal', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Jessica W', 'Initials': 'JW', 'LastName': 'Witherspoon', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Irene C', 'Initials': 'IC', 'LastName': 'Chrismer', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Muslima S', 'Initials': 'MS', 'LastName': 'Razaqyar', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Monal', 'Initials': 'M', 'LastName': 'Punjabi', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Elliott', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Fatoumata', 'Initials': 'F', 'LastName': 'Tounkara', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Kuo', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Monique O', 'Initials': 'MO', 'LastName': 'Shelton', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Allen', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Cosgrove', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Melody', 'Initials': 'M', 'LastName': 'Linton', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Michael', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Minal S', 'Initials': 'MS', 'LastName': 'Jain', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Waite', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Drinkard', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Wakim', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Dowling', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Carsten G', 'Initials': 'CG', 'LastName': 'Bönnemann', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Magalie', 'Initials': 'M', 'LastName': 'Emile-Backer', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada.'}, {'ForeName': 'Katherine G', 'Initials': 'KG', 'LastName': 'Meilleur', 'Affiliation': 'From the Neuromuscular Symptoms Unit, National Institute of Nursing Research (J.J.T., T.A.L., J.W.W., I.C.C., M.S.R., M.P., J.S.E., F.T., A.K., M.O.S., C.A., M.M.C., M.L., M.E.-B., K.G.M.), Mark O. Hatfield Clinical Research Center, Rehabilitation Medicine Department (M.S.J., M.W., B.D.), and Neurogenetics Branch, National Institute of Neurological Disorders and Stroke (C.G.B.), NIH, Bethesda, MD; Hyperion Biotechnology Inc. (D.M.), San Antonio, TX; Biostatistics and Clinical Epidemiology Service (P.G.W.), NIH Clinical Center, Bethesda, MD; Division of Neurology and Program for Genetics and Genome Biology (J.J.D.) and Departments of Paediatrics and Molecular Genetics (J.J.D.), Hospital for Sick Children, Toronto, Canada. meilleurk@mail.nih.gov.'}]",Neurology,['10.1212/WNL.0000000000008872'] 492,30861337,"A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects.","GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins. This first-in-human, randomized, double-blind, phase 1 study assessed the safety and pharmacokinetics of GSK3389404 administered subcutaneously (SC) in healthy subjects. Four single ascending-dose cohorts (10 mg, 30 mg, 60 mg, and 120 mg) and 3 multiple ascending-dose cohorts (30 mg, 60 mg, and 120 mg once weekly for 4 weeks) each comprised 6 subjects randomized to GSK3389404 and 2 subjects randomized to placebo. There were no serious adverse events (AEs) or withdrawals due to AEs. The safety profile did not worsen with repeated dosing. The most frequent treatment-related AEs were injection site reactions (19.0% [n = 8/42], frequency unrelated to dose levels); all were mild (Grade 1) and resolved without dose modification or discontinuation. GSK3389404 administered subcutaneously was readily absorbed with a time to maximum plasma concentration (T max ) of 1-4 hours and an elimination half-life of 3-6 hours in plasma. Plasma area under the concentration-time curve (AUC) and maximum observed concentration (C max ) were dose-proportional. Dose-normalized plasma AUC from time 0 to infinity averaged 69.9 ng·h/(mL·mg dose) across cohorts, and C max 9.5 ng/(mL·mg dose). Pharmacokinetic profiles and parameters were comparable between single and multiple dosing. No accumulation was observed with once-weekly dosing. The metabolite was undetectable in urine and plasma. In the pooled urine, GSK3389404 was estimated to account for <0.1% of the total dose. In summary, GSK3389404 dosing has been tested up to 120 mg for 4 weeks with an acceptable safety and pharmacokinetic profile, supporting further clinical investigation in patients with chronic hepatitis B.",2019,GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins.,"['Healthy Subjects', 'patients with chronic hepatitis B', 'healthy subjects']","['GSK3389404 administered subcutaneously (SC', 'Placebo', 'placebo']","['injection site reactions', 'Plasma area under the concentration-time curve (AUC) and maximum observed concentration (C max ', 'serious adverse events (AEs) or withdrawals due to AEs', 'Safety, Tolerability, and Pharmacokinetics']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524909', 'cui_str': 'Chronic Hepatitis B Virus Infection'}]","[{'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",,0.194148,GSK3389404 is a liver-targeted antisense oligonucleotide that inhibits synthesis of hepatitis B surface antigen and all other hepatitis B virus proteins.,"[{'ForeName': 'Kelong', 'Initials': 'K', 'LastName': 'Han', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cremer', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Elston', 'Affiliation': 'GlaxoSmithKline, Stevenage, Hertfordshire, UK.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Oliver', 'Affiliation': 'IQVIA, London, UK.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Baptiste-Brown', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Shuguang', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gardiner', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Davies', 'Affiliation': 'GlaxoSmithKline, Stockley Park, Uxbridge, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Saunders', 'Affiliation': 'GlaxoSmithKline, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hamatake', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Losos', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Leivers', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Hood', 'Affiliation': 'GlaxoSmithKline, Stevenage, Hertfordshire, UK.'}, {'ForeName': 'Frans', 'Initials': 'F', 'LastName': 'van der Berg', 'Affiliation': 'Hammersmith Medicines Research, London, UK.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Paff', 'Affiliation': 'GlaxoSmithKline, Beijing, China.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Ritter', 'Affiliation': 'GlaxoSmithKline, Cambridge, UK.'}, {'ForeName': 'Dickens', 'Initials': 'D', 'LastName': 'Theodore', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, North Carolina, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.670'] 493,31003136,Examining reactivity patterns in burnout and other indicators of chronic stress.,"INTRODUCTION Burnout symptomatology is associated with various negative health consequences; however, the mechanisms underlying these associations remain unclear. One potential pathway involves alterations in the acute stress response. The aims of the present study were to examine burnout-associated alterations in stress-reactivity patterns, during a standardized social stressor compared to a control condition, as well as to examine whether effects associated with greater burnout symptomatology were distinct from other, conceptually overlapping indicators of chronic stress (i.e. depressive symptomatology and elevated hair cortisol concentration [HCC]). MATERIALS AND METHODS In a randomized two-factor design a total of 70 employed males with varying burnout symptoms but without evidence of physical or psychiatric disease were exposed to the Trier Social Stress Test for Groups (TSST-G) or a non-stressful control condition. Acute stress reactivity was assessed using self-report stress measures and non-invasive biomarkers. Associations among acute stress reactivity, burnout and depressive symptoms (assessed with self-report measures), as well as HCC were analysed using repeated measure ANCOVAs and moderation analysis. RESULTS Burnout symptomatology was associated with elevated stress perception independent of the experimental condition. In addition, depressive symptomatology was associated with enhanced anticipatory appraisal, whereas HCC was not related to any subjective stress measure. On a physiological level, burnout and depressive symptomatology, as well as HCC were associated with a pattern of blunted cardiovascular reactivity, however the timing of this effect varied. CONCLUSION Our results indicate burnout-associated modulations in stress reactivity, which diverge, at least partly, from other indicators of chronic stress.",2019,"In addition, depressive symptomatology was associated with enhanced anticipatory appraisal, whereas HCC was not related to any subjective stress measure.",['70 employed males with varying burnout symptoms but without evidence of physical or psychiatric disease'],['Trier Social Stress Test for Groups (TSST-G) or a non-stressful control condition'],"['depressive symptomatology', 'Acute stress reactivity', 'acute stress reactivity, burnout and depressive symptoms', 'elevated stress perception']","[{'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0065404', 'cui_str': 'Tri (L)'}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state (disorder)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",70.0,0.0279806,"In addition, depressive symptomatology was associated with enhanced anticipatory appraisal, whereas HCC was not related to any subjective stress measure.","[{'ForeName': 'Magdalena K', 'Initials': 'MK', 'LastName': 'Wekenborg', 'Affiliation': 'Department of Psychology, TU Dresden, Germany. Electronic address: magdalena.wekenborg@tu-dresden.de.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'von Dawans', 'Affiliation': 'Department of Biological and Clinical Psychology, University of Trier, Trier, Germany.'}, {'ForeName': 'LaBarron K', 'Initials': 'LK', 'LastName': 'Hill', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Julian F', 'Initials': 'JF', 'LastName': 'Thayer', 'Affiliation': 'Department of Psychology, The Ohio State University, Columbus, USA.'}, {'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Penz', 'Affiliation': 'Department of Psychology, TU Dresden, Germany.'}, {'ForeName': 'Clemens', 'Initials': 'C', 'LastName': 'Kirschbaum', 'Affiliation': 'Department of Psychology, TU Dresden, Germany.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2019.04.002'] 494,32149711,Precourse Preparation Using a Serious Smartphone Game on Advanced Life Support Knowledge and Skills: Randomized Controlled Trial.,"BACKGROUND In the past several years, gamified learning has been growing in popularity in various medical educational contexts including cardiopulmonary resuscitation (CPR) training. Furthermore, prior work in Basic Life Support (BLS) training has demonstrated the benefits of serious games as a method for pretraining among medical students. However, there is little evidence to support these benefits with regard to Advanced Life Support (ALS) training. OBJECTIVE We compare the effects of a brief precourse ALS preparation using a serious smartphone game on student knowledge, skills, and perceptions in this area with those of conventional ALS training alone. METHODS A serious game (Resus Days) was developed by a Thai physician based on global ALS clinical practice guidelines. Fifth-year medical students were enrolled and randomized to either the game group or the control group. Participants in both groups attended a traditional ALS lecture, but the game group was assigned to play Resus Days for 1 hour before attending the lecture and were allowed to play as much as they wished during the training course. All students underwent conventional ALS training, and their abilities were evaluated using multiple-choice questions and with hands-on practice on a mannequin. Subject attitudes and perceptions about the game were evaluated using a questionnaire. RESULTS A total of 105 students participated in the study and were randomly assigned to either the game group (n=52) or the control group (n=53). Students in the game group performed better on the ALS algorithm knowledge posttest than those in the control group (17.22 [SD 1.93] vs 16.60 [SD 1.97], P=.01; adjusted mean difference [AMD] 0.93; 95% CI 0.21-1.66). The game group's pass rate on the skill test was also higher but not to a statistically significant extent (79% vs 66%, P=.09; adjusted odds ratio [AOR] 2.22; 95% CI 0.89-5.51). Students indicated high satisfaction with the game (9.02 [SD 1.11] out of 10). CONCLUSIONS Engaging in game-based preparation prior to an ALS training course resulted in better algorithm knowledge scores for medical students than attending the course alone. TRIAL REGISTRATION Thai Clinical Trials Registry HE611533; https://tinyurl.com/wmbp3q7.",2020,"Students in the game group performed better on the ALS algorithm knowledge posttest than those in the control group (17.22 [SD 1.93] vs 16.60 [SD 1.97], P=.01; adjusted mean difference [AMD] 0.93; 95% CI 0.21-1.66).","['A total of 105 students participated in the study and were randomly assigned to either the game group (n=52) or the control group (n=53', 'Fifth-year medical students']","['conventional ALS training', 'brief precourse ALS preparation', 'conventional ALS training alone', 'Serious Smartphone Game']","['algorithm knowledge scores', 'ALS algorithm knowledge posttest', 'student knowledge, skills, and perceptions', 'pass rate on the skill test']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}]","[{'cui': 'C0002045'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",105.0,0.0466122,"Students in the game group performed better on the ALS algorithm knowledge posttest than those in the control group (17.22 [SD 1.93] vs 16.60 [SD 1.97], P=.01; adjusted mean difference [AMD] 0.93; 95% CI 0.21-1.66).","[{'ForeName': 'Pariwat', 'Initials': 'P', 'LastName': 'Phungoen', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Songwoot', 'Initials': 'S', 'LastName': 'Promto', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Sivit', 'Initials': 'S', 'LastName': 'Chanthawatthanarak', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Sawitree', 'Initials': 'S', 'LastName': 'Maneepong', 'Affiliation': 'CPR Training Unit, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Korakot', 'Initials': 'K', 'LastName': 'Apiratwarakul', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Praew', 'Initials': 'P', 'LastName': 'Kotruchin', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Thapanawong', 'Initials': 'T', 'LastName': 'Mitsungnern', 'Affiliation': 'Department of Emergency Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}]",Journal of medical Internet research,['10.2196/16987'] 495,32149713,The Interactive Web-Based Program MSmonitor for Self-Management and Multidisciplinary Care in Persons With Multiple Sclerosis: Quasi-Experimental Study of Short-Term Effects on Patient Empowerment.,"BACKGROUND Empowerment helps persons with a chronic disease to self-manage their condition and increase their autonomy and participation. MSmonitor (Curavista bv) is an interactive Web-based program for self-management and multidisciplinary care in multiple sclerosis (MS). It includes, among others, short questionnaires on fatigue (Modified Fatigue Impact Scale-5 [MFIS-5]) and health-related quality of life (HRQoL, Leeds Multiple Sclerosis Quality of Life [LMSQoL]); long questionnaires on disabilities, perception of disabilities (Multiple Sclerosis Impact Profile), and HRQoL (Multiple Sclerosis Quality of Life-54); a Medication and Adherence Inventory and an Activity Diary. The combination MFIS-5, LMSQoL, and Medication and Adherence Inventory constitutes the Quick Scan. OBJECTIVE This study aimed to investigate the short-term effects of MSmonitor on empowerment in patients with MS. METHODS We conducted a quasi-experimental study in a general hospital. Of the 180 patients with MS, 125 were eligible, 30 used MSmonitor, and 21 participated in the study (mean age 45.4 years, SD 10.2 years). A total of 24 eligible patients who did not use MSmonitor constituted the control group (mean age 49.3 years, SD 11.4 years). At baseline and at 4 months, we assessed self-efficacy (Multiple Sclerosis Self-Efficacy Scale [MSSES]), participation and autonomy (Impact on Participation and Autonomy [IPA] questionnaire), and self-management (Partners In Health [PIH] questionnaire). Differences between time points and groups were tested with paired t tests and χ² tests. RESULTS In the MSmonitor group, follow-up values remained unchanged for MSSES control (P=.19), MSSES function (P=.62), IPA limitations (P=.26), IPA problems (P=.40), PIH recognition and management of symptoms (P=.52), PIH adherence to treatment (P=.80), and PIH coping (P=.73), whereas the PIH knowledge score had improved (mean 27.8, SD 1.7 vs mean 28.7, SD 2.0; P=.02). The overall utilization rate of the program components was 83% and that of the Quick Scan was 95%. In the control group, all outcomes had remained unchanged. CONCLUSIONS The results suggest that for first-time users of the MSmonitor program and their health care providers, it may not be justified to expect a short-term improvement in empowerment in terms of self-efficacy, self-management, autonomy, or participation. Furthermore, a lack of effect on empowerment is not because of nonusage of the program components.",2020,"In the MSmonitor group, follow-up values remained unchanged for MSSES control (P=.19), MSSES function (P=.62), IPA limitations (P=.26), IPA problems (P=.40), PIH recognition and management of symptoms (P=.52), PIH adherence to treatment (P=.80), and PIH coping (P=.73), whereas the PIH knowledge score had improved (mean 27.8, SD 1.7 vs mean 28.7, SD 2.0; P=.02).","['Persons With Multiple Sclerosis', 'patients with MS.\nMETHODS\n\n\nWe conducted a quasi-experimental study in a general hospital', 'mean age 49.3 years, SD 11.4 years', '24 eligible patients who did not use MSmonitor constituted the control group ', '180 patients with MS, 125 were eligible, 30 used MSmonitor, and 21 participated in the study (mean age 45.4 years, SD 10.2 years']","['MSmonitor', 'Interactive Web-Based Program MSmonitor for Self-Management and Multidisciplinary Care']","['PIH knowledge score', 'self-efficacy (Multiple Sclerosis Self-Efficacy Scale [MSSES]), participation and autonomy (Impact on Participation and Autonomy [IPA] questionnaire), and self-management (Partners In Health [PIH] questionnaire', 'IPA limitations', 'PIH adherence to treatment (P=.80), and PIH coping', 'IPA problems', 'MSSES function', 'overall utilization rate', 'fatigue (Modified Fatigue Impact Scale-5 [MFIS-5]) and health-related quality of life (HRQoL, Leeds Multiple Sclerosis Quality of Life [LMSQoL]); long questionnaires on disabilities, perception of disabilities (Multiple Sclerosis Impact Profile), and HRQoL (Multiple Sclerosis Quality of Life-54); a Medication and Adherence Inventory and an Activity Diary', 'PIH recognition and management of symptoms']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C2985410', 'cui_str': 'Clinical Trials, Nonrandomized'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0222045'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0614109', 'cui_str': 'I(S)pA(S)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale (assessment scale)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",180.0,0.0263371,"In the MSmonitor group, follow-up values remained unchanged for MSSES control (P=.19), MSSES function (P=.62), IPA limitations (P=.26), IPA problems (P=.40), PIH recognition and management of symptoms (P=.52), PIH adherence to treatment (P=.80), and PIH coping (P=.73), whereas the PIH knowledge score had improved (mean 27.8, SD 1.7 vs mean 28.7, SD 2.0; P=.02).","[{'ForeName': 'Peter Joseph', 'Initials': 'PJ', 'LastName': 'Jongen', 'Affiliation': 'Department of Community and Occupational Medicine, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.'}, {'ForeName': 'Gezien', 'Initials': 'G', 'LastName': 'Ter Veen', 'Affiliation': 'Zorggroep Noorderboog, Meppel, Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Lemmens', 'Affiliation': 'Radboud University Medical Center, Department for Health Evidence, Nijmegen, Netherlands.'}, {'ForeName': 'Rogier', 'Initials': 'R', 'LastName': 'Donders', 'Affiliation': 'Radboud University Medical Center, Department for Health Evidence, Nijmegen, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'van Noort', 'Affiliation': 'Curavista bv, Geertruidenberg, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Zeinstra', 'Affiliation': 'Isala Hospital, Meppel, Netherlands.'}]",Journal of medical Internet research,['10.2196/14297'] 496,30720931,"Randomized Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Topical Daprodustat in Healthy Volunteers and in Patients With Diabetic Foot Ulcers.","Daprodustat, a small-molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia-inducible factor (HIF), leading to increased transcription of HIF-responsive genes. This randomized, placebo-controlled study evaluated the safety, tolerability, and pharmacokinetics of a topical formulation of daprodustat in healthy volunteers (intact skin) and in patients with diabetic foot ulcers (DFUs) following single and/or 14-day repeat-dose administration. In the diabetic patients, exploratory assessments of wound area, volume, and depth were made to qualitatively assess effectiveness. Systemic absorption via topical application was limited across doses up to 1.0% at 100 mg/cm 2 for 14 days. Systemic pharmacokinetics were quantifiable in a few samples from a few patients. Because only sporadic concentrations were observed versus pharmacokinetic profiles, pharmacokinetic parameters were not determined. Wound area, depth, and volume showed consistent but weak improvements in the treatment arm; however, the variability in response and small sample size of the standard-of-care and placebo arms limited the ability to assess trends in wound healing compared with the daprodustat arm. Overall, topically applied daprodustat was well tolerated, raised no safety concerns, and provided limited to nonquantifiable systemic exposures. The healing of DFUs will need to be evaluated in studies designed to test this hypothesis over a longer treatment duration.",2019,"Daprodustat, a small-molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia-inducible factor (HIF), leading to increased transcription of HIF-responsive genes.","['Healthy Volunteers and in Patients With Diabetic Foot Ulcers', 'healthy volunteers (intact skin) and in patients with diabetic foot ulcers (DFUs']",['placebo'],"['Systemic pharmacokinetics', 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics', 'safety, tolerability, and pharmacokinetics', 'wound healing']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer (disorder)'}, {'cui': 'C2712179', 'cui_str': 'Intact skin'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]",,0.0774477,"Daprodustat, a small-molecule inhibitor of prolyl hydroxylases, prevents breakdown of hypoxia-inducible factor (HIF), leading to increased transcription of HIF-responsive genes.","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Olson', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Kelly M', 'Initials': 'KM', 'LastName': 'Mahar', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Morgan', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Fillmore', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Holland', 'Affiliation': 'GlaxoSmithKline, Collegeville, PA, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Lavery', 'Affiliation': 'University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.654'] 497,31610073,Intervention to reduce hypoglycemia fear in parents of young kids using video-based telehealth (REDCHiP).,"OBJECTIVE To evaluate the efficacy of a new video-based telehealth intervention to reduce hypoglycemia fear in parents of young children with type 1 diabetes. METHODS We randomized 42 parents to either immediate treatment (reducing emotional distress for childhood hypoglycemia in parents, REDCHiP; n = 22) or a waitlist control (WAITLIST; n = 21) condition. REDCHiP parents completed a 10-session video-based telehealth intervention, while WAITLIST parents continued in usual care. After 14-weeks, WAITLIST parents completed the telehealth treatment. We examined for between group changes in parental hypoglycemia fear and parenting stress (n = 18 per condition), 3-month maintenance of treatment effects for parents randomized to REDCHiP (n = 15), and pre-post changes for the entire sample (n = 36). RESULTS Mostly mothers participated (97.6%). They reported a mean age of 35.2 ± 5.0 years at pre-treatment. Children were 4.4 ± 1.4 years old and 59.5% boys. Between group comparisons showed a significant reduction in hypoglycemia fear (P = .04) and a trend toward reduction in parenting stress-frequency (P = .092) for REDCHiP parents compared to WAITLIST parents. After the three-month maintenance period, REDCHiP parents reported significant reductions in hypoglycemia fear, parenting stress-frequency, and parenting stress-difficulty (P's < .01) compared to pre-treatment. When all parents received the telehealth treatment, we also observed significant reductions in hypoglycemia fear, parenting stress-frequency, and parenting stress-difficulty (P's < .001), and sensitivity analyses revealed a significant reduction in child glycated hemoglobin for children who entered the treatment above target (P < .05). CONCLUSION Our new video-based telehealth intervention appears to reduce hypoglycemia fear and parenting stress and may help parents of very young children with T1D to better achieve optimal child glycemic control when children are above target.",2020,Our new video-based telehealth intervention appears to reduce hypoglycemia fear and parenting stress and may help parents of very young children with T1D to better achieve optimal child glycemic control when children are above target.,"['n=15), and pre-post changes for the entire sample (n=36', 'parents of young children with type 1 diabetes', 'Children were 4.4+1.4\u2009years old and 59.5% boys']","['Video-Based Telehealth (REDCHiP', 'REDCHiP', 'video-based telehealth intervention', 'immediate treatment (REDCHiP; n=22) or a waitlist control', 'new video-based telehealth intervention']","['Hypoglycemia Fear', 'hypoglycemia fear and parenting stress', 'parental hypoglycemia fear and parenting stress', 'parenting stress-frequency', 'child glycated hemoglobin', 'hypoglycemia fear', 'hypoglycemia fear, parenting stress-frequency, and parenting stress-difficulty']","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C4517503', 'cui_str': '1.4 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]","[{'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",42.0,0.0200217,Our new video-based telehealth intervention appears to reduce hypoglycemia fear and parenting stress and may help parents of very young children with T1D to better achieve optimal child glycemic control when children are above target.,"[{'ForeName': 'Susana R', 'Initials': 'SR', 'LastName': 'Patton', 'Affiliation': 'Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Clements', 'Affiliation': ""Center for Children's Healthy Lifestyles and Nutrition, Kansas City, Missouri.""}, {'ForeName': 'Arwen M', 'Initials': 'AM', 'LastName': 'Marker', 'Affiliation': 'University of Kansas, Clinical Child Psychology Program, Lawrence, Kansas.'}, {'ForeName': 'Eve-Lynn', 'Initials': 'EL', 'LastName': 'Nelson', 'Affiliation': 'Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas.'}]",Pediatric diabetes,['10.1111/pedi.12934'] 498,30842109,Effects of home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring in patients with chronic heart failure: a study protocol for a randomised controlled trial.,"INTRODUCTION Patients with chronic heart failure (CHF) can benefit from exercise rehabilitation (ER) with significant improvements in exercise capacity, quality of life and reduction in hospitalisations. Despite its reported benefits, only a small number of patients with CHF attend ER due to poor adherence, and improper exercise may even lead to adverse events. Remote ECG monitoring system (REMS) has the potential to overcome these obstacles. We hypothesise that home-based cardiac ER using REMS in CHF patients is effective compared with conventional ER without monitoring. METHODS AND ANALYSIS This study is a prospective, randomised, parallel controlled clinical trial designed to evaluate the effectiveness of home-based phase-II ER with REMS in the treatment of CHF with a target enrolment of 120 patients (left ventricular ejection fraction <50%, New York Heart Association (NYHA) classes I to III). Patients are randomised to either REMS rehabilitation group or conventional rehabilitation group in a 1:1 ratio. All patients start an exercise training in a supervised setting and then transition to a home-based regimen. The supervised training phase consists of 12 supervised training sessions, three sessions per week for 4 weeks. During the home exercise phase, patients exercise five times per week for 8 weeks. In the REMS group, patients wear monitors during exercise to ensure that exercise intensity is within the set ranges. REMS will also detect risky arrhythmia and alert the patients and their doctors on time. The training intensity is not monitored in the conventional rehabilitation group. The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO 2 peak) (baseline vs 3 m). Secondary outcomes include 6-min walk test, NYHA classes, echocardiographic parameters, cardiac biomarkers, major adverse cardiovascular events, quality of life, psychological well-being and patients' adherence to the rehabilitation programme. ETHICS AND DISSEMINATION This study was approved by Ethics Committee of China-Japan Friendship Hospital for Clinical Research (No. 2018-55 K39). The results of this study will be disseminated via peer-reviewed publications and presentations at conferences. TRIAL REGISTRATION NUMBER ChiCTR-RNR-17012446; Pre-results.",2019,The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO 2 peak) (baseline vs 3 m).,"['Patients with chronic heart failure (CHF', '120 patients (left ventricular ejection fraction <50%, New York Heart Association (NYHA) classes I to III', 'patients with chronic heart failure']","['REMS rehabilitation group or conventional rehabilitation', 'home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring', 'exercise rehabilitation (ER', 'exercise training', 'Remote ECG monitoring system (REMS', 'home-based phase-II ER with REMS', 'REMS']","[""6-min walk test, NYHA classes, echocardiographic parameters, cardiac biomarkers, major adverse cardiovascular events, quality of life, psychological well-being and patients' adherence to the rehabilitation programme"", 'exercise capacity, quality of life and reduction in hospitalisations', 'exercise capacity improvement measured by peak oxygen uptake (VO 2 peak']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441885', 'cui_str': 'Class 1 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0560134', 'cui_str': 'rem'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0034380'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}]",,0.0538706,The primary outcome is exercise capacity improvement measured by peak oxygen uptake (VO 2 peak) (baseline vs 3 m).,"[{'ForeName': 'Jiahui', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Dongliang', 'Initials': 'D', 'LastName': 'Fu', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Xiaojun', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Department of Rehabilitation, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Yiyun', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Phase I Clinical Ward of Clinical Trial Research Center, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Mingjing', 'Initials': 'M', 'LastName': 'Shao', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Department of Integrative Cardiology, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Xianlun', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.'}]",BMJ open,['10.1136/bmjopen-2018-023923'] 499,31047960,Deleterious Effects of Higher Body Mass Index on Subjective and Objective Measures of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors.,"CONTEXT Recent, albeit, limited evidence suggests that body mass index (BMI) may be a modifiable risk factor to reduce the deleterious effects of chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. OBJECTIVES To evaluate for differences in demographic, clinical, pain, sensation, and balance characteristics among three BMI groups. We hypothesized that as BMI increased, survivors would report higher pain intensity scores and have significant decrements in measures of sensation and balance. METHODS A total of 416 survivors with CIPN were evaluated using subjective and objective measures of CIPN. Survivors were divided into three BMI groups (i.e., normal weight, overweight, and obese). Differences among the BMI groups were evaluated using parametric and nonparametric statistics. RESULTS Of the 416 survivors, 45.4% were normal weight, 32.5% were overweight, and 22.1% were obese. Compared with the normal-weight group, survivors in the other two groups had lower functional status scores, a higher comorbidity burden, higher pain intensity scores, and higher interference scores. In addition, compared with the normal-weight group, survivors in the other two BMI groups had significantly worse balance scores. CONCLUSION Our findings support the hypothesis that as BMI increased, pain sensation and balance characteristics worsened. Our findings suggest that nutritional counseling as well as exercise and weight management programs in survivors with CIPN may improve these clinically important problems.",2019,"Compared with the normal-weight group, survivors in the other two groups had lower functional status scores, a higher comorbidity burden, higher pain intensity scores, and higher interference scores.","['Of the 416 survivors, 45.4% were normal weight, 32.5% were overweight, and 22.1% were obese', '416 survivors with CIPN', 'survivors with CIPN', 'Cancer Survivors']",[],"['sensation and balance', 'balance scores', 'pain intensity scores', 'pain sensation', 'demographic, clinical, pain, sensation, and balance characteristics', 'lower functional status scores']","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C4517710', 'cui_str': '32.5 (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}]",[],"[{'cui': 'C0036658', 'cui_str': 'Sensory Function'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",416.0,0.047797,"Compared with the normal-weight group, survivors in the other two groups had lower functional status scores, a higher comorbidity burden, higher pain intensity scores, and higher interference scores.","[{'ForeName': 'Iva', 'Initials': 'I', 'LastName': 'Petrovchich', 'Affiliation': 'School of Nursing, University of California, San Francisco, California, USA.'}, {'ForeName': 'Kord M', 'Initials': 'KM', 'LastName': 'Kober', 'Affiliation': 'School of Nursing, University of California, San Francisco, California, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Wagner', 'Affiliation': 'School of Nursing, University of California, San Francisco, California, USA.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Paul', 'Affiliation': 'School of Nursing, University of California, San Francisco, California, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Abrams', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Chesney', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Topp', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Smoot', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Schumacher', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Yvette P', 'Initials': 'YP', 'LastName': 'Conley', 'Affiliation': 'School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Hammer', 'Affiliation': 'Mount Sinai Medical Center, New York, New York, USA.'}, {'ForeName': 'Jon D', 'Initials': 'JD', 'LastName': 'Levine', 'Affiliation': 'School of Medicine, University of California, San Francisco, California, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Miaskowski', 'Affiliation': 'School of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2019.04.029'] 500,30325583,Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4-Way Replicate Crossover Investigation by a Reference-Scaled Average Bioequivalence Approach.,"Sarpogrelate is widely used to treat peripheral vascular disorders. However, it has been demonstrated to have a poor pharmacokinetic (PK) profile and marked within-subject variability. Here, the bioequivalence of 2 formulations of sarpogrelate (100-mg tablets) was assessed by using the reference-scaled average bioequivalence (RSABE) method, and the PK parameters were quantified in healthy Chinese subjects under fasting (n = 38) and fed (n = 35) conditions. In this open and randomized 4-way replicate study, a single dose of sarpogrelate was administered followed by a 3-day washout period. The sarpogrelate concentration in blood samples was measured by liquid chromatography-tandem mass spectrometry within 6 hours (fasting) or 10 hours (fed) of drug administration, and the PK parameters were determined by a noncompartmental model. The bioequivalence of the 2 formulations under both conditions was assessed using the ratios of ln(peak concentration [C max ]) and ln(area under the concentration-time curve [AUC]) within the limits based on the RSABE method. The 90% CIs for the ratios of lnC max , lnAUC 0-t , and lnAUC 0-∞ were 0.8531-1.1100, 0.9616-1.0737, and 0.9550-1.0684, respectively, under fasting conditions and 0.8918-1.1076, 0.9818-1.0694, and 0.9818-1.0686, respectively, under fed conditions, which were within the RSABE acceptance limits. Food intake decreased the systemic exposure and the C max of sarpogrelate by 0.9-fold and 0.5-fold, respectively.",2019,"Food intake decreased the systemic exposure and the C max of sarpogrelate by 0.9-fold and 0.5-fold, respectively.","['healthy Chinese subjects under fasting (n = 38) and fed (n = 35) conditions', 'Healthy Chinese Subjects Under Fasting and Fed Conditions']","['sarpogrelate', 'Sarpogrelate']","['ratios of lnC max , lnAUC 0-t , and lnAUC 0-∞', 'ratios of ln(peak concentration [C max ]) and ln(area under the concentration-time curve [AUC']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0286592', 'cui_str': 'mono-(2-(dimethylamino)-1-((2-(2-(3-methoxyphenyl)ethyl)phenoxy)methyl)ethyl)succinate hydrochloride'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.0207672,"Food intake decreased the systemic exposure and the C max of sarpogrelate by 0.9-fold and 0.5-fold, respectively.","[{'ForeName': 'Y H', 'Initials': 'YH', 'LastName': 'Ding', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Liu', 'Affiliation': 'Department of Hand Surgery, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Lou', 'Affiliation': 'Department of Geriatrics, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'J X', 'Initials': 'JX', 'LastName': 'Sun', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'X X', 'Initials': 'XX', 'LastName': 'Zhu', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'G L', 'Initials': 'GL', 'LastName': 'Chen', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'X J', 'Initials': 'XJ', 'LastName': 'Li', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Liu', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'Z W', 'Initials': 'ZW', 'LastName': 'Shen', 'Affiliation': 'First Hospital, and Institute of Immunology, Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'C Y', 'Initials': 'CY', 'LastName': 'Li', 'Affiliation': 'Phase 1 Clinical Unit, China-Frontage USA, First Hospital, Jilin University, Changchun, Jilin, China.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.624'] 501,30570839,"The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.","Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK + non-small-cell lung cancer who have progressed on or are intolerant to crizotinib. A clinical study was conducted to assess the effect of food on brigatinib pharmacokinetics (PK). Healthy subjects received a single oral dose of brigatinib 180 mg (2 × 90-mg tablets) after a 10-hour fast or after a high-fat meal in a 2-period, 2-sequence crossover study. Plasma samples for PK characterization were collected over 168 hours postdose. Twenty-four subjects were enrolled (mean age 44 years; 58% male), with 21 included in the PK-evaluable population. Brigatinib peak concentration was reduced by 13% under fed (high-fat meal) versus fasted conditions, with no effect on area under the concentration-time curve. The median time to peak concentration of brigatinib was longer under fed conditions (5 hours) than in fasted conditions (2 hours). Treatment-emergent adverse events were similar under fasted (48%) and fed (46%) conditions and were of mild intensity. Consumption of a high-fat meal decreased the rate of brigatinib oral absorption but had no impact on the extent of absorption, thereby supporting brigatinib administration without regard to meals. These recommendations are reflected in the US prescribing information for brigatinib.",2019,Treatment-emergent adverse events were similar under fasted (48%) and fed (46%) conditions and were of mild intensity.,"['Twenty-four subjects were enrolled (mean age 44 years; 58% male), with 21 included in the PK-evaluable population', 'Healthy Volunteers', 'Healthy subjects', 'patients with metastatic ALK + non-small-cell lung cancer who have progressed on or are intolerant to crizotinib']",['High-Fat Meal'],"['brigatinib pharmacokinetics (PK', 'median time to peak concentration of brigatinib', 'Brigatinib peak concentration', 'rate of brigatinib oral absorption']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C2974289', 'cui_str': 'crizotinib'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C4287815', 'cui_str': 'brigatinib'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}]",24.0,0.0635866,Treatment-emergent adverse events were similar under fasted (48%) and fed (46%) conditions and were of mild intensity.,"[{'ForeName': 'Meera', 'Initials': 'M', 'LastName': 'Tugnait', 'Affiliation': 'ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Neeraj', 'Initials': 'N', 'LastName': 'Gupta', 'Affiliation': 'Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Hanley', 'Affiliation': 'Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Karthik', 'Initials': 'K', 'LastName': 'Venkatakrishnan', 'Affiliation': 'Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Daryl', 'Initials': 'D', 'LastName': 'Sonnichsen', 'Affiliation': 'Sonnichsen Pharmaceutical Associates, LLC, Collegeville, PA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kerstein', 'Affiliation': 'Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Dorer', 'Affiliation': 'ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}, {'ForeName': 'Narayana', 'Initials': 'N', 'LastName': 'Narasimhan', 'Affiliation': 'ARIAD Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.641'] 502,32227247,Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial.,"Background Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD). Objective To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD. Design Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842). Setting 57 Parkinson Study Group sites in North America. Participants Patients with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment. Intervention 5 mg of immediate-release isradipine twice daily or placebo for 36 months. Measurements The primary outcome was change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III score measured in the antiparkinson medication ""ON"" state between baseline and 36 months. Secondary outcomes included time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor disability, and quality-of-life measures. Results 336 patients were randomly assigned (mean age, 62 years [SD, 9]; 68% men; disease duration, 0.9 year [SD, 0.7]; mean UPDRS part I to III score, 23.1 [SD, 8.6]); 95% of patients completed the study. Adjusted least-squares mean changes in total UPDRS score in the antiparkinson medication ON state over 36 months for isradipine and placebo recipients were 2.99 (95% CI, 0.95 to 5.03) points versus 3.26 (CI, 1.25 to 5.26) points, respectively, with a treatment effect of -0.27 (CI, -3.02 to 2.48) point (P = 0.85). Statistical adjustment for antiparkinson medication use did not change the findings. Secondary outcomes showed no effect of isradipine treatment. The most common adverse effects of isradipine were edema and dizziness. Limitation The isradipine dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects. Conclusion Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD. Primary Funding Source National Institute of Neurological Disorders and Stroke.",2020,"Conclusion Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD. ","['336 patients were randomly assigned (mean age, 62 years [SD, 9]; 68% men; disease duration, 0.9 year [SD, 0.7]; mean UPDRS part I to III score, 23.1 [SD, 8.6]); 95% of patients completed the study', 'Participants\n\n\nPatients with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment', 'Setting\n\n\n57 Parkinson Study Group sites in North America', 'Early Parkinson Disease']","['dihydropyridine calcium-channel blocker', 'placebo', 'dihydropyridine calcium-channel blockers', 'isradipine', 'Intervention\n\n\n5 mg of immediate-release isradipine twice daily or placebo', 'Isradipine Versus Placebo']","[""Unified Parkinson's Disease Rating Scale (UPDRS) parts"", 'time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor disability, and quality-of-life measures', 'total UPDRS score', 'edema and dizziness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C4517474', 'cui_str': '0.7 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4517879', 'cui_str': '8.6 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}]","[{'cui': 'C0220821', 'cui_str': 'dihydropyridine'}, {'cui': 'C0006684', 'cui_str': 'Calcium Channel Blocking Drugs'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1153433', 'cui_str': 'Calcium channel'}, {'cui': 'C0071304', 'cui_str': 'Isradipine'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0222045'}, {'cui': 'C0449719', 'cui_str': 'Part (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",336.0,0.515182,"Conclusion Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of internal medicine,['10.7326/M19-2534'] 503,32224129,Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.,"BACKGROUND & AIMS We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.",2020,Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P=.01).,"['Fifty percent of patients (n=61', ""patients with early Crohn's disease (CD"", 'below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median 3.02 y; range, 0.05-6.26 y', '122 patients (mean age, 31.2±11.3 y) with early, moderate to severe CD (median duration 0.2 y; interquartile range, 0.1-0.5 y) who participated in the effect of tight control management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population']",['tight control strategy (increased therapy'],"['composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD', 'Deep Remission', 'deep remission', 'major adverse outcomes', 'composite rates', 'deep remission (CD endoscopic index of severity scores']","[{'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C3887532', 'cui_str': 'Ulceration (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0453911', 'cui_str': 'Tights (physical object)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0453911', 'cui_str': 'Tights (physical object)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0333330', 'cui_str': 'Internal fistula (morphologic abnormality)'}, {'cui': 'C0000833', 'cui_str': 'Abscess'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0267561', 'cui_str': 'Fistula of perianal skin'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}]",122.0,0.0825621,Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P=.01).,"[{'ForeName': 'Ryan C', 'Initials': 'RC', 'LastName': 'Ungaro', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Yzet', 'Affiliation': 'Amiens University Hospital, Department of Gastroenterology, Amiens, France.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bossuyt', 'Affiliation': 'Imelda Gastroenterology Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium.'}, {'ForeName': 'Filip J', 'Initials': 'FJ', 'LastName': 'Baert', 'Affiliation': 'AZ Delta Roeselare, Roeselare, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Vanasek', 'Affiliation': 'Second Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic.'}, {'ForeName': 'Geert R', 'Initials': 'GR', 'LastName': ""D'Haens"", 'Affiliation': 'Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Vincent Wilhelmus', 'Initials': 'VW', 'LastName': 'Joustra', 'Affiliation': 'Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Remo', 'Initials': 'R', 'LastName': 'Panaccione', 'Affiliation': 'Inflammatory Bowel Disease Unit, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Gottfried', 'Initials': 'G', 'LastName': 'Novacek', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Reinisch', 'Affiliation': 'Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Armuzzi', 'Affiliation': 'Inflammatory Bowel Disease Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS-Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Oleksandr', 'Initials': 'O', 'LastName': 'Golovchenko', 'Affiliation': 'Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Prymak', 'Affiliation': 'Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Goldis', 'Affiliation': 'Universitatea de Medicina si Farmacie, Timisoara, Romania.'}, {'ForeName': 'Simon P', 'Initials': 'SP', 'LastName': 'Travis', 'Affiliation': 'Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Hébuterne', 'Affiliation': 'Gastroenterology and Clinical Nutrition Department, Centre Hospitalier Universitaire of Nice, University of Nice Sophia-Antipolis, Nice, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ferrante', 'Affiliation': 'University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Rogler', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Mathurin', 'Initials': 'M', 'LastName': 'Fumery', 'Affiliation': 'Amiens University Hospital, Department of Gastroenterology, Amiens, France.'}, {'ForeName': 'Silvio', 'Initials': 'S', 'LastName': 'Danese', 'Affiliation': 'Humanitas University, Istituto Clinico Humanitas, Milan, Italy.'}, {'ForeName': 'Grazyna', 'Initials': 'G', 'LastName': 'Rydzewska', 'Affiliation': 'Central Clinical Hospital of Ministry of Interior and Administration in Warsaw, Warsaw, Poland.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Pariente', 'Affiliation': 'Claude Huriez Hospital, Lille University, Lille, France.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Hertervig', 'Affiliation': 'Skane University Hospital, Lund, Sweden.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Stanciu', 'Affiliation': 'Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Serrero', 'Affiliation': 'Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France.'}, {'ForeName': 'Mircea', 'Initials': 'M', 'LastName': 'Diculescu', 'Affiliation': 'University of Medicine and Pharmacy ""Carol Davila,"" Bucharest, Romania.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Peyrin-Biroulet', 'Affiliation': 'Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Laharie', 'Affiliation': ""Service d'Hépato-gastroentérologie et Oncologie Digestive, Hôpital Haut-Lévêque, Bordeaux, France.""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Wright', 'Affiliation': 'Kingsbury Hospital, Cape Town, South Africa.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Gomollón', 'Affiliation': 'Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Gubonina', 'Affiliation': 'Military Medical Academy named after S.M. Kirov, Saint Petersburg, Russian Federation.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schreiber', 'Affiliation': 'Department of Internal Medicine I, Kiel University, Kiel, Germany.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Motoya', 'Affiliation': 'Inflammatory Bowel Disease Center, Sapporo Kosei General Hospital, Sapporo, Japan.'}, {'ForeName': 'Per M', 'Initials': 'PM', 'LastName': 'Hellström', 'Affiliation': 'Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Halfvarson', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Butler', 'Affiliation': 'AbbVie, Inc, North Chicago, Illinois.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Petersson', 'Affiliation': 'AbbVie, Inc, North Chicago, Illinois.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Petralia', 'Affiliation': 'Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jean-Frederic', 'Initials': 'JF', 'LastName': 'Colombel', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York. Electronic address: jean-frederic.colombel@mssm.edu.'}]",Gastroenterology,['10.1053/j.gastro.2020.03.039'] 504,30421018,Validation of overestimation ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI.,"OBJECTIVE We aimed to determine in the ""THRACE"" trial, the clinical and MRI technical parameters associated with the two-layered susceptibility vessel sign (TL-SVS) and the overestimation ratio (overR). MATERIALS AND METHODS Patients with pre-treatment brain gradient echo (GRE) sequence and an etiological work-up were identified. Two readers reviewed TL-SVS, i.e., a SVS with a linear low-intense signal core surrounded by a higher intensity and measured the overR as the width of SVS divided by the width of the artery. Binomial and ordinal logistic regression respectively tested the association between TL-SVS and quartiles of overR with patient characteristics, cardioembolic stroke (CES), time from onset to imaging, and GRE sequence parameters (inter slice gap, slice thickness, echo time, flip angle, voxel size, and field strength). RESULTS Among 258 included patients, 102 patients were examined by 3 Tesla MRI and 156 by 1.5 Tesla MRI. Intra- and inter-reader agreements for quartiles of overR and TL-SVS were good to excellent. The median overR was 1.59 (IQR, 1.30 to 1.86). TL-SVS was present in 101 patients (39.2%, 95%CI, 33.1 to 45.1%). In multivariate analysis, only CES was associated with overR quartiles (OR, 1.83; 95%CI, 1.11 to 2.99), and every 60 min increase from onset to MRI time was associated with TL-SVS (OR, 1.72; 95%CI, 1.10 to 2.67). MRI technical parameters were statistically associated with neither overR nor TL-SVS. CONCLUSION Independent of GRE sequence parameters, an increased overR was associated to CES, while the TL-SVS is independently related to a longer time from onset to MRI. KEY POINTS • An imaging biomarker would be useful to predict the etiology of stroke in order to adapt secondary prevention of stroke. • The two-layered susceptibility vessel sign and the overestimation ratio are paramagnetic effect derived markers that vary according to the MRI machines and sequence parameters. • Independent of sequence parameters, an increased overestimation ratio was associated to cardioembolic stroke, while the two-layered susceptibility vessel sign is independently related to a longer time from onset to MRI.",2019,"TL-SVS was present in 101 patients (39.2%, 95%CI, 33.1 to 45.1%).","['258 included patients, 102 patients were examined by 3 Tesla MRI and 156 by 1.5 Tesla MRI', 'Patients with pre-treatment brain gradient echo']",[],"['TL-SVS and quartiles of overR with patient characteristics, cardioembolic stroke (CES), time from onset to imaging, and GRE sequence parameters (inter slice gap, slice thickness, echo time, flip angle, voxel size, and field strength', 'TL-SVS', 'median overR', 'MRI technical parameters', 'overestimation ratio (overR', 'MRI time']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1531624', 'cui_str': 'Cardioembolic stroke'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0540654', 'cui_str': 'FLICE-Inhibitory Protein'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",258.0,0.0254678,"TL-SVS was present in 101 patients (39.2%, 95%CI, 33.1 to 45.1%).","[{'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Bourcier', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France. romain.bourcier2@gmail.com.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Legrand', 'Affiliation': 'Department of Neuroradiology, Université Paris-Descartes. INSERM U894, Sainte-Anne Hospital, Paris, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Soize', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, University Hospital of Reims, Reims, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Labreuche', 'Affiliation': 'Centre Hospitalier Regional Universitaire de Lille, Biostatistics, Lille, Hauts-de-France, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Beaumont', 'Affiliation': 'CIC1433, INSERM, IADI, U1254, Université de Lorraine, INSERM, CHRU de Nancy CIC-IT Nancy, Nancy, France.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Desal', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France.'}, {'ForeName': 'Imad', 'Initials': 'I', 'LastName': 'Derraz', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, Hopital Gui de Chauillac, Montpellier, France.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Bracard', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology, University Hospital of Nancy, Nancy, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Oppenheim', 'Affiliation': 'Department of Neuroradiology, Université Paris-Descartes. INSERM U894, Sainte-Anne Hospital, Paris, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Naggara', 'Affiliation': 'Department of Neuroradiology, Université Paris-Descartes. INSERM U894, Sainte-Anne Hospital, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European radiology,['10.1007/s00330-018-5835-y'] 505,30617472,Evaluation of pressure-controlled mammography compression paddles with respect to force-controlled compression paddles in clinical practice.,"OBJECTIVES To reduce pain and discomfort associated with breast compression in mammography, a pressure-controlled compression paddle was recently introduced. The objective was to evaluate the pressure-controlled paddle by comparing it to the standard force-controlled paddle. METHODS Differences of compressed breast thickness (CBT), compression force, compression pressure, and average glandular dose (AGD) between annual follow-up full-field digital mammography exams of 3188 patients were retrospectively examined. Two groups were compared: (1) force-force group (FF-group), both examinations were performed with the force-controlled paddle, and (2) force-pressure group (FP-group), only the follow-up examination was performed with the pressure-controlled paddle. In an additional group of patients, pain scores on a scale of 0 (no pain at all) to 10 (worst pain imaginable) were evaluated prospectively (n = 343) who were randomly assigned to either paddle. RESULTS Median differences between follow-up exams in CBT, compression force, compression pressure, and AGD were for the FF- and FP-group respectively - 1.0 vs 0.0 mm (p < 0.001); 0.0 vs - 1.0 daN (p = 0.002); - 1.0 vs - 0.5 kPa (p = 0.005); and 0.05 vs - 0.02 mGy (p < 0.001). These differences were, although statistically significant, clinically non-relevant (defined as ΔCBT > ± 2 mm; Δforce > ± 2 daN; Δpressure > ± 1 kPa and ΔAGD > ± 0.1 mGy). The subanalysis dividing CBT into five categories revealed similar results. The median [interquartile range] pain scores were 6 [3, 7] and 5 [3, 7] for the force-controlled and pressure-controlled paddle, respectively, which was not significantly different (p = 0.113). CONCLUSIONS We observed no clinically relevant differences in CBT, compression force, compression pressure, AGD, or pain score between the force- and pressure-controlled paddle. As such, we found no basis for preferring one paddle over the other. KEY POINTS • The pressure-controlled paddle did not show any clinically relevant changes in breast compression parameters compared to the force-controlled paddle. • The pressure-controlled paddle did not lead to significant reduction in pain scores indicated by the patients compared to the force-controlled paddle. • A large variation in compression force and compression pressure was observed in mammography exams for the both the force- and pressure-controlled compression paddle.",2019,The pressure-controlled paddle did not lead to significant reduction in pain scores indicated by the patients compared to the force-controlled paddle.,['3188 patients'],"['pressure-controlled mammography compression paddles', 'force-force group (FF-group), both examinations were performed with the force-controlled paddle, and (2) force-pressure group (FP-group), only the follow-up examination was performed with the pressure-controlled paddle']","['CBT, compression force, compression pressure, and AGD', 'CBT, compression force, compression pressure, AGD, or pain score', 'compressed breast thickness (CBT), compression force, compression pressure, and average glandular dose (AGD', 'pain scores', 'compression force and compression pressure', 'median [interquartile range] pain scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C1268544', 'cui_str': 'Compression paddle'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0332260', 'cui_str': 'Compressing (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0225353', 'cui_str': 'Glandular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]",3188.0,0.0371652,The pressure-controlled paddle did not lead to significant reduction in pain scores indicated by the patients compared to the force-controlled paddle.,"[{'ForeName': 'C R L P N', 'Initials': 'CRLPN', 'LastName': 'Jeukens', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, PO Box 5800, 6202AZ, Maastricht, The Netherlands. Cecile.Jeukens@mumc.nl.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'van Dijk', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, PO Box 5800, 6202AZ, Maastricht, The Netherlands.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Berben', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, PO Box 5800, 6202AZ, Maastricht, The Netherlands.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Wildberger', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, PO Box 5800, 6202AZ, Maastricht, The Netherlands.'}, {'ForeName': 'M B I', 'Initials': 'MBI', 'LastName': 'Lobbes', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, P. Debyelaan 25, PO Box 5800, 6202AZ, Maastricht, The Netherlands.'}]",European radiology,['10.1007/s00330-018-5953-6'] 506,32160019,"Effects of intraduodenal coadministration of lauric acid and leucine on gut motility, plasma cholecystokinin, and energy intake in healthy men.","The fatty acid, lauric acid (C12), and the amino acid, leucine (Leu) stimulate gut hormones, including CCK, associated with suppression of energy intake. In our recent study, intraduodenal infusion of a combination of C12 and l-tryptophan, at loads that individually did not affect energy intake, reduced energy intake substantially, associated with much greater stimulation of CCK. We have now investigated whether combined administration of C12 and Leu would enhance the intake-suppressant effects of each nutrient, when given at loads that each suppress energy intake individually. Sixteen healthy, lean males (age: 23 ± 2 yr) received, in randomized, double-blind fashion, 90-min intraduodenal infusions of control (saline), C12 (0.4 kcal/min), Leu (0.45 kcal/min), or C12+Leu (0.85 kcal/min). Antropyloroduodenal pressures were measured continuously and plasma CCK at 15-min intervals, and energy intake from a standardized buffet-meal, consumed immediately postinfusion, was quantified. All nutrient infusions stimulated plasma CCK compared with control ( P < 0.05). Moreover, C12 and C12+Leu stimulated CCK compared with Leu ( P < 0.05) (mean concentration, pmol/L; control: 2.3 ± 0.3, C12: 3.8 ± 0.3, Leu: 2.7 ± 0.3, and C12+Leu: 4.0 ± 0.4). C12+Leu, but not C12 or Leu, stimulated pyloric pressures ( P < 0.05). C12+Leu and C12 reduced energy intake ( P < 0.05), and there was a trend for Leu to reduce ( P = 0.06) energy intake compared with control, with no differences between the three nutrient treatments (kcal; control: 1398 ± 84, C12: 1226 ± 80, Leu: 1260 ± 92, and C12+Leu: 1208 ± 83). In conclusion, combination of C12 and Leu, at the loads given, did not reduce energy intake beyond their individual effects, possibly because maximal effects had been evoked.",2020,"C12+Leu, but not C12 or Leu, stimulated pyloric pressures (P<0.05).","['16 healthy, lean males (age: 23±2 years', 'healthy men']","['intraduodenal co-administration of lauric acid and leucine', '90-min intraduodenal infusions of control (saline), C12 (0.4 kcal/min), Leu (0.45 kcal/min) or C12+Leu', 'C12 and Leu', 'C12 and L-tryptophan']","['energy intake', 'gut motility, plasma cholecystokinin and energy intake', 'Antropyloroduodenal pressures']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0023139', 'cui_str': 'lauric acid'}, {'cui': 'C0023401', 'cui_str': 'L-leucine'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C4068884', 'cui_str': '0.45'}, {'cui': 'C0041249', 'cui_str': 'L-tryptophan'}]","[{'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0008328', 'cui_str': 'pancreozymin (cholecystokinin)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}]",16.0,0.136199,"C12+Leu, but not C12 or Leu, stimulated pyloric pressures (P<0.05).","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'McVeay', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Steinert', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Penelope C E', 'Initials': 'PCE', 'LastName': 'Fitzgerald', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Sina S', 'Initials': 'SS', 'LastName': 'Ullrich', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Feinle-Bisset', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00352.2019'] 507,31498127,Safety Profile of Opicapone in the Management of Parkinson's Disease.,"BACKGROUND Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson's disease (PD) and motor fluctuations. OBJECTIVE To characterize the safety and tolerability of adjunct opicapone (25 and 50 mg) in a pooled population of levodopa-treated PD patients who participated in the opicapone Phase-3 clinical program. METHODS Patient-level data (placebo, opicapone 25 mg and 50 mg) from the BIPARK-1 and BIPARK-2 double-blind and open-label studies were combined. RESULTS Pooled analyses included 766 patients from the double-blind studies and 848 patients from the open-label studies. In the double-blind studies, 63.3% of opicapone-treated patients reported treatment-emergent adverse events (TEAEs) versus 57.2% in the placebo group. The most common TEAEs reported in the opicapone group compared to placebo were dyskinesia, constipation and insomnia. The incidence of serious TEAEs was similar across opicapone and placebo groups (3.5% versus 4.3%, respectively). Overall, 71.3% patients treated with open-label opicapone reported at least one TEAE; most occurred within the first 2 months of the open-label studies, and then decreased thereafter. Throughout the Phase-3 clinical program, there were no serious AEs suggestive of hepatic toxicity, and the incidence of gastrointestinal disorders such as nausea and diarrhea remained low (<2%). There were no relevant changes in laboratory parameters including liver enzymes, vital signs, physical or neurological examinations, or ECG readings. CONCLUSIONS Long-term use of opicapone once-daily over 1-year at doses of 25 mg or 50 mg was generally safe and well tolerated, supporting its clinical usefulness in the management of PD motor fluctuations.",2019,"There were no relevant changes in laboratory parameters including liver enzymes, vital signs, physical or neurological examinations, or ECG readings. ","['treated PD patients who participated in the opicapone Phase-3 clinical program', '766 patients from the double-blind studies and 848 patients from the open-label studies', ""patients with Parkinson's disease (PD) and motor fluctuations"", 'Patient-level data ', ""Parkinson's Disease""]","['levodopa therapy', 'opicapone', 'levodopa', 'Opicapone', 'placebo', 'placebo, opicapone 25\u200amg and 50\u200amg) from the BIPARK-1 and BIPARK-2 double-blind and open-label studies were combined', 'adjunct opicapone']","['nausea and diarrhea', 'hepatic toxicity', 'laboratory parameters including liver enzymes, vital signs, physical or neurological examinations, or ECG readings', 'treatment-emergent adverse events (TEAEs', 'incidence of serious TEAEs', 'safe and well tolerated', 'dyskinesia, constipation and insomnia', 'safety and tolerability']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2933912', 'cui_str': '2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0013072', 'cui_str': 'Double-Masked Method'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C1868976', 'cui_str': 'Motor fluctuations'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2933912', 'cui_str': '2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0518766'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0027853', 'cui_str': 'Neurological Examination'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1869094', 'cui_str': 'Dyskinesia (SMQ)'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",766.0,0.194163,"There were no relevant changes in laboratory parameters including liver enzymes, vital signs, physical or neurological examinations, or ECG readings. ","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lees', 'Affiliation': 'University College London, Reta Lila Weston Institute, London, UK.'}, {'ForeName': 'Joaquim J', 'Initials': 'JJ', 'LastName': 'Ferreira', 'Affiliation': 'Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.'}, {'ForeName': 'José-Francisco', 'Initials': 'JF', 'LastName': 'Rocha', 'Affiliation': 'Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Rascol', 'Affiliation': 'Department of Clinical Pharmacology and Neurosciences, INSERM and University Hospital of Toulouse, Toulouse, France.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Gama', 'Affiliation': 'Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.'}, {'ForeName': 'Patrício', 'Initials': 'P', 'LastName': 'Soares-da-Silva', 'Affiliation': 'Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.'}]",Journal of Parkinson's disease,['10.3233/JPD-191593'] 508,30897305,"Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers.","Rapid onset of analgesic action is linked with rapid absorption of analgesics (high maximum concentration [C max ] and short time to maximum concentration [t max ]). After overnight fasting, ibuprofen lysinate reaches higher peak plasma levels (C max ) earlier than ibuprofen acid (t max ) with comparable exposure (area under the plasma concentration-time curve [AUC]); however, subjects usually take ibuprofen with or within a short time of a meal. Therefore, pharmacokinetic (PK) studies under fed conditions may better characterize properties under real-life conditions. We investigated a new fixed-dose combination (FDC) of ibuprofen acid 400 mg and caffeine 100 mg in 2 single-dose, randomized, crossover PK studies in healthy subjects (both N = 36). The FDC was compared with ibuprofen 400 mg as acid and as lysinate after an overnight fast in Study 1, and with ibuprofen lysinate after a meal in Study 2. After fasting, results for ibuprofen in the FDC were comparable with those from ibuprofen acid alone. Caffeine did not affect the C max , t max , and AUC. As expected, a higher C max and shorter t max were observed with ibuprofen lysinates vs the FDC. Compared with administration after fasting, C max and t max for ibuprofen lysinate administered postprandially were markedly different, while with FDC, these parameters were less sensitive to food intake. Taken after a meal, ibuprofen in the FDC reached t max earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and C max was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate. Thus, under real-life conditions, ibuprofen lysinate had no PK advantage over the FDC. All preparations were well tolerated.",2019,"Compared with administration after fasting, C max and t max for ibuprofen lysinate administered postprandially were markedly different, while with FDC, these parameters were less sensitive to food intake.","['Healthy Volunteers', 'healthy subjects (both N\xa0=\xa036']","['mg; FDC', 'ibuprofen', 'ibuprofen acid 400\xa0mg and caffeine', 'Caffeine', 'ibuprofen acid', 'Ibuprofen (IBU']","['tolerated', 'C max , t max , and AUC']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0721022', 'cui_str': 'Ibu'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}]",,0.102054,"Compared with administration after fasting, C max and t max for ibuprofen lysinate administered postprandially were markedly different, while with FDC, these parameters were less sensitive to food intake.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Weiser', 'Affiliation': 'Consumer Health Care, Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Schepers', 'Affiliation': 'Biostatistics and Data Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Frankfurt am Main, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Mück', 'Affiliation': 'Consumer Health Care, Medical Affairs, Germany, Switzerland, Austria, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lange', 'Affiliation': 'Consumer Health Care, Global Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.672'] 509,30230257,Relative and Absolute Bioavailability Study of Emicizumab to Bridge Drug Products and Subcutaneous Injection Sites in Healthy Volunteers.,"Emicizumab (ACE910) is a bispecific antibody that is a novel, subcutaneously injectable treatment for patients with hemophilia A. This study assessed the relative bioavailability of emicizumab between old and new drug products (DPs) and among 3 commonly used subcutaneous injection sites (abdomen, upper arm, and thigh), together with its absolute bioavailability in healthy volunteers. Forty-eight healthy volunteers were randomized into 4 groups to receive a single subcutaneous injection of 1 mg/kg with the old or new DP, and another 12 volunteers each received a single, 90-minute, intravenous infusion of 0.25 mg/kg with the new DP. Similar pharmacokinetic profiles were observed between the DPs, with geometric mean ratios of 1.199 (90% confidence interval [CI] 1.060-1.355) for the maximum plasma concentration and 1.083 (90% CI 0.920-1.275) for area under the plasma concentration-time curve extrapolated to infinity. The geometric mean ratios of maximum plasma concentration and area under the plasma concentration-time curve extrapolated to infinity for upper arm versus abdomen were 0.823 (90% CI 0.718-0.943) and 0.926 (90% CI 0.814-1.053), respectively, and those for thigh versus abdomen were 1.168 (90% CI 1.030-1.324) and 1.073 (90% CI 0.969-1.189), respectively. Absolute bioavailability ranged from 80.4% to 93.1%. These results suggested that no emicizumab dose adjustment would be needed when switching the DPs or injecting to different sites interchangeably and that emicizumab injected subcutaneously is highly bioavailable.",2019,"Similar pharmacokinetic profiles were observed between the DPs, with geometric mean ratios of 1.199 (90% confidence interval [CI] 1.060-1.355) for the maximum plasma concentration and 1.083 (90% CI 0.920-1.275) for area under the plasma concentration-time curve extrapolated to infinity.","['patients with hemophilia A', 'Healthy Volunteers', 'healthy volunteers', 'Forty-eight healthy volunteers']","['single subcutaneous injection of 1 mg/kg with the old or new DP', 'Emicizumab (ACE910', 'emicizumab', 'Emicizumab']","['Absolute bioavailability', 'geometric mean ratios of maximum plasma concentration and area under the plasma concentration-time curve extrapolated to infinity for upper arm versus abdomen', 'maximum plasma concentration']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019069', 'cui_str': 'Classic Hemophilia'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0021499', 'cui_str': 'Subcutaneous Injections'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C4278463', 'cui_str': 'emicizumab'}, {'cui': 'C4279750', 'cui_str': 'ACE910'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0446516', 'cui_str': 'Brachiums'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}]",48.0,0.0266611,"Similar pharmacokinetic profiles were observed between the DPs, with geometric mean ratios of 1.199 (90% confidence interval [CI] 1.060-1.355) for the maximum plasma concentration and 1.083 (90% CI 0.920-1.275) for area under the plasma concentration-time curve extrapolated to infinity.","[{'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Kotani', 'Affiliation': 'Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Yoneyama', 'Affiliation': 'Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Kawakami', 'Affiliation': 'Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.'}, {'ForeName': 'Tohru', 'Initials': 'T', 'LastName': 'Shimuta', 'Affiliation': 'Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Fukase', 'Affiliation': 'CPC Clinic, Medipolis Medical Research Institute, Kagoshima, Japan.'}, {'ForeName': 'Takehiko', 'Initials': 'T', 'LastName': 'Kawanishi', 'Affiliation': 'Chugai Pharmaceutical Co, Ltd, Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.617'] 510,32223849,Older adults' evaluations of the standard and modified pedometer-based Green Prescription.,"INTRODUCTION The Green Prescription is a primary care programme designed to increase physical activity in individuals with low activity levels. Older adults tend to engage in insufficient physical activity to obtain health-related gain. AIM To examine participants' ratings of the Healthy Steps intervention and to assess how participants rated the use of a pedometer-based Green Prescription in aiding their physical activity. METHODS In total, 330 community-dwelling older adults who have low levels of activity were randomised to receive either a standard time-based Green Prescription or a modified pedometer-based Green Prescription. Post-intervention, 259 participants completed the participant evaluation questionnaire via postal survey. Data were analysed using descriptive statistics and Chi-squared analyses. RESULTS The standard components of the Green Prescription (general practitioner consultations and telephone counselling) received similar and higher ratings across both allocation groups than the use of print materials. A pedometer-based Green Prescription was rated as being helpful in aiding physical activity. DISCUSSION This study supports the importance of general practitioners' initial role in prescribing physical activity for older adults and of ongoing telephone support for longer-term adherence. Incorporating a pedometer can be effective in helping low-active older adults initiate and maintain regular physical activity.",2020,The standard components of the Green Prescription (general practitioner consultations and telephone counselling) received similar and higher ratings across both allocation groups than the use of print materials.,"['Older adults', 'individuals with low activity levels', 'older adults', '259 participants completed the participant evaluation questionnaire via postal survey', '330 community-dwelling older adults who have low levels of activity']","['standard and modified pedometer-based Green Prescription', 'pedometer-based Green Prescription', 'standard time-based Green Prescription or a modified pedometer-based Green Prescription']",[],"[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C4517719', 'cui_str': '330 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332583', 'cui_str': 'Green color (qualifier value)'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",[],330.0,0.0510419,The standard components of the Green Prescription (general practitioner consultations and telephone counselling) received similar and higher ratings across both allocation groups than the use of print materials.,"[{'ForeName': 'Asmita', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'School of Clinical Sciences, Faculty Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand; and South Pacific College of Natural Medicine, Auckland, New Zealand; and Corresponding author. Email: asmita.patel@aut.ac.nz.'}, {'ForeName': 'Grant M', 'Initials': 'GM', 'LastName': 'Schofield', 'Affiliation': 'Human Potential Centre, Faculty Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Gregory S', 'Initials': 'GS', 'LastName': 'Kolt', 'Affiliation': 'School of Science and Health, Western Sydney University, Sydney, New South Wales, Australia.'}, {'ForeName': 'Justin W L', 'Initials': 'JWL', 'LastName': 'Keogh', 'Affiliation': 'Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia; and Human Potential Centre, Faculty Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand; and Cluster for Health Improvement, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, Sunshine Coast, Queensland, Australia.'}]",Journal of primary health care,['10.1071/HC19007'] 511,30730474,Parent-Child Interaction Therapy for Children with Developmental Delay: The Role of Sleep Problems.,"OBJECTIVE Sleep problems are common and associated with externalizing behavior problems in young children, particularly among young children with developmental delay (DD). The aims of the current study, which was a secondary data analysis of 2 previously conducted randomized controlled trials, were to assess whether parent-child interaction therapy (PCIT) led to decreases in child sleep problems and whether initial sleep problems moderated the effect of PCIT on child behavior. METHODS The study participants were 44 children (M = 49.19 months, SD = 13.1) with DD or borderline DD and with co-occurring clinically significant levels of externalizing behavior problems and their mothers (M = 35.9 years, SD = 7.3). These participants were randomly assigned to either an immediate treatment group or a waitlist control group. RESULTS Findings revealed a significant direct effect of PCIT on decreases in sleep problems. Additionally, moderation analyses revealed that lower levels of child sleep problems at pretreatment were associated with greater improvements in observed child compliance compared with higher levels of child sleep problems at pretreatment. CONCLUSION This study extends previous findings by providing support for the preliminary efficacy of PCIT in reducing sleep problems in children with DD and borderline DD and highlighting the role of sleep problems as a factor associated with differential treatment effects in behavioral parenting intervention research.",2019,This study extends previous findings by providing support for the preliminary efficacy of PCIT in reducing sleep problems in children with DD and borderline DD and highlighting the role of sleep problems as a factor associated with differential treatment effects in behavioral parenting intervention research.,"['young children', 'The study participants were 44 children (M = 49.19 months, SD = 13.1) with DD or borderline DD and with co-occurring clinically significant levels of externalizing behavior problems and their mothers (M = 35.9 years, SD = 7.3', 'young children with developmental delay (DD', 'children with DD and borderline DD', 'Children with Developmental Delay']","['immediate treatment group or a waitlist control group', 'Parent-Child Interaction Therapy', 'PCIT', 'parent-child interaction therapy (PCIT']","['lower levels of child sleep problems', 'sleep problems', 'child sleep problems']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0911524', 'cui_str': 'AM 44'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0424605', 'cui_str': 'Developmental delay (disorder)'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}]",44.0,0.0732721,This study extends previous findings by providing support for the preliminary efficacy of PCIT in reducing sleep problems in children with DD and borderline DD and highlighting the role of sleep problems as a factor associated with differential treatment effects in behavioral parenting intervention research.,"[{'ForeName': 'Juliana', 'Initials': 'J', 'LastName': 'Acosta', 'Affiliation': 'Department of Psychology and Center for Children and Families, Florida International University, Miami, FL.'}, {'ForeName': 'Dainelys', 'Initials': 'D', 'LastName': 'Garcia', 'Affiliation': 'Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, FL.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Bagner', 'Affiliation': 'Department of Psychology and Center for Children and Families, Florida International University, Miami, FL.'}]",Journal of developmental and behavioral pediatrics : JDBP,['10.1097/DBP.0000000000000647'] 512,30402705,Patients' experience of screening CT colonography with reduced and full bowel preparation in a randomised trial.,"OBJECTIVES To assess patients' experience of bowel preparation and procedure for screening CT colonography with reduced (r-CTC) and full cathartic preparation (f-CTC) that showed similar detection rate for advanced neoplasia in a randomised trial. METHODS Six hundred seventy-four subjects undergoing r-CTC and 612 undergoing f-CTC in the SAVE trial were asked to complete two pre-examination questionnaires-(1) Life Orientation Test - Revised (LOT-R) assessing optimism and (2) bowel preparation questionnaire-and a post-examination questionnaire evaluating overall experience of CTC screening test. Items were analysed with chi-square and t test separately and pooled. RESULTS LOT-R was completed by 529 (78%) of r-CTC and by 462 (75%) of f-CTC participants and bowel preparation questionnaire by 531 (79%) subjects in the r-CTC group and by 465 (76%) in the f-CTC group. Post-examination questionnaire was completed by 525 (78%) subjects in the r-CTC group and by 453 (74%) in the f-CTC group. LOT-R average score was not different between r-CTC (14.27 ± 3.66) and f-CTC (14.54 ± 3.35) (p = 0.22). In bowel preparation questionnaire, 88% of r-CTC subjects reported no preparation-related symptoms as compared to 70% of f-CTC subjects (p < 0.001). No interference of bowel preparation with daily activities was reported in 80% of subjects in the r-CTC group as compared to 53% of subjects in the f-CTC group (p < 0.001). In post-examination questionnaire, average scores for discomfort of the procedure were not significantly different between r-CTC (3.53 ± 0.04) and f-CTC (3.59 ± 0.04) groups (p = 0.84). CONCLUSIONS Reduced bowel preparation is better tolerated than full preparation for screening CT colonography. KEY POINTS • Reduced bowel preparation is better tolerated than full preparation for screening CT colonography. • Procedure-related discomfort of screening CT colonography is not influenced by bowel preparation. • Males tolerate bowel preparation and CT colonography screening procedure better than females.",2019,No interference of bowel preparation with daily activities was reported in 80% of subjects in the r-CTC group as compared to 53% of subjects in the f-CTC group (p < 0.001).,"['Six hundred seventy-four subjects undergoing r-CTC and 612 undergoing f-CTC in the SAVE trial were asked to complete two pre-examination questionnaires-(1', 'Males tolerate bowel preparation and CT colonography screening procedure better than females']","['screening CT colonography with reduced (r-CTC) and full cathartic preparation (f-CTC', 'screening CT colonography with reduced and full bowel preparation']","['bowel preparation questionnaire', 'interference of bowel preparation with daily activities', 'LOT-R average score', 'Life Orientation Test - Revised (LOT-R) assessing optimism and (2) bowel preparation questionnaire']","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C4517834', 'cui_str': '612 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure (procedure)'}, {'cui': 'C0935912', 'cui_str': 'CT Colonography'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0935912', 'cui_str': 'CT Colonography'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0007422', 'cui_str': 'Purgatives'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure (procedure)'}]","[{'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure (procedure)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582640', 'cui_str': 'Life orientation test (assessment scale)'}, {'cui': 'C0237428', 'cui_str': 'Optimism'}]",674.0,0.112721,No interference of bowel preparation with daily activities was reported in 80% of subjects in the r-CTC group as compared to 53% of subjects in the f-CTC group (p < 0.001).,"[{'ForeName': 'Lapo', 'Initials': 'L', 'LastName': 'Sali', 'Affiliation': 'Department of Biomedical, Experimental and Clinical Sciences ""Mario Serio"", University of Florence, Viale Morgagni 50, 50134, Florence, Italy. lapo.sali@unifi.it.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Ventura', 'Affiliation': 'Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.'}, {'ForeName': 'Grazia', 'Initials': 'G', 'LastName': 'Grazzini', 'Affiliation': 'Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Borgheresi', 'Affiliation': 'School of Radiology, Università Politecnica delle Marche, Piazza Roma 22, 60121, Ancona, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Delsanto', 'Affiliation': 'im3D S.p.A, Via Livorno 60, 10153, Turin, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Falchini', 'Affiliation': 'Department of Biomedical, Experimental and Clinical Sciences ""Mario Serio"", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Mallardi', 'Affiliation': 'Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Mantellini', 'Affiliation': 'Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Milani', 'Affiliation': 'Department of Biomedical, Experimental and Clinical Sciences ""Mario Serio"", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Pallanti', 'Affiliation': 'Department of Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Zappa', 'Affiliation': 'Institute for Cancer Research, Prevention and Oncological Network (ISPRO), Via Cosimo il Vecchio 2, 50139, Florence, Italy.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Mascalchi', 'Affiliation': 'Department of Biomedical, Experimental and Clinical Sciences ""Mario Serio"", University of Florence, Viale Morgagni 50, 50134, Florence, Italy.'}]",European radiology,['10.1007/s00330-018-5808-1'] 513,32087146,Evaluation of an external fetal electrocardiogram monitoring system: a randomized controlled trial.,"OBJECTIVE The objective of the study was to compare interpretability of 2 intrapartum abdominal fetal heart rate-monitoring strategies. We hypothesized that an external fetal electrocardiography monitoring system, a newer technology using wireless abdominal pads, would generate more interpretable fetal heart rate data compared with standard external Doppler fetal heart rate monitoring (standard external monitoring). STUDY DESIGN We conducted a randomized controlled trial at 4 Utah hospitals. Patients were enrolled at labor admission and randomized in blocks based on body mass index to fetal electrocardiography or standard external monitoring. Two reviewers, blinded to study allocation, reviewed each fetal heart rate tracing. The primary outcome was the percentage of interpretable minutes of fetal heart rate tracing. An interpretable minute was defined as >25% fetal heart rate data present and no more than 25% continuous missing fetal heart rate data or artifact present. Secondary outcomes included the percentage of interpretable minutes of fetal heart rate tracing obtained while on study device only, the number of device adjustments required intrapartum, clinical outcomes, and patient/provider device satisfaction. We determined that 100 patients per arm (200 total) would be needed to detect a 5% difference in interpretability with 95% power. RESULTS A total of 218 women were randomized, 108 to fetal electrocardiography and 110 to standard external monitoring. Device setup failure occurred more often in the fetal electrocardiography group (7.5% [8 of 107] vs 0% [0 of 109] for standard external monitoring). There were no differences in the percentage of interpretable tracing between the 2 groups. However, fetal electrocardiography produced more interpretable fetal heart rate tracing in subjects with a body mass index ≥30 kg/m 2 . When considering the percentage of interpretable minutes of fetal heart rate tracing while on study device only, fetal electrocardiography outperformed standard external monitoring for all subjects, regardless of maternal body mass index. Maternal demographics and clinical outcomes were similar between arms. In the fetal electrocardiography group, more device changes occurred compared with standard external monitoring (51% vs 39%), but there were fewer nursing device adjustments (2.9 vs 6.2 mean adjustments intrapartum, P < .01). There were no differences in physician device satisfaction scores between groups, but fetal electrocardiography generated higher patient satisfaction scores. CONCLUSION Fetal electrocardiography performed similarly to standard external monitoring when considering percentage of interpretable tracing generated in labor. Furthermore, patients reported overall greater satisfaction with fetal electrocardiography in labor. Fetal electrocardiography may be particularly useful in patients with a body mass index ≥30 kg/m 2 .",2020,Device set up failure occurred more often in the fetal electrocardiography group (7.5% (8/107) versus 0% (0/109) for standard external monitoring).,"['subjects with body mass index ≥30', '100 patients per arm (200 total', 'patients with body mass index ≥30', 'Patients were enrolled at labor admission and randomized in', '218 women were randomized, 108 to fetal electrocardiography and 110 to standard external monitoring', 'four Utah hospitals']","['fetal electrocardiography', 'blocks based on body mass index to fetal electrocardiography or standard external monitoring', 'external fetal electrocardiogram monitoring system', 'Fetal electrocardiography']","['percentage of interpretable minutes of fetal heart rate tracing', 'device changes', 'percentage of interpretable minutes of fetal heart rate tracing obtained while on study device only, the number of device adjustments required intrapartum, clinical outcomes, and patient/provider device satisfaction', 'Maternal demographics and clinical outcomes', 'fetal heart rate tracing', 'physician device satisfaction scores']","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}, {'cui': 'C4517647', 'cui_str': 'Two hundred and eighteen'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0042124', 'cui_str': 'Utah'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0278336', 'cui_str': 'Fetal electrocardiogram (procedure)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0018811', 'cui_str': 'Heart Rate, Fetal'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0442822', 'cui_str': 'Trace (qualifier value)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",218.0,0.107003,Device set up failure occurred more often in the fetal electrocardiography group (7.5% (8/107) versus 0% (0/109) for standard external monitoring).,"[{'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Monson', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT; University of Utah Health, Salt Lake City, UT. Electronic address: martha.monson@hsc.utah.edu.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Heuser', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT; University of Utah Health, Salt Lake City, UT.'}, {'ForeName': 'Brett D', 'Initials': 'BD', 'LastName': 'Einerson', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT; University of Utah Health, Salt Lake City, UT.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Esplin', 'Affiliation': 'Brigham Young University, Salt Lake City, UT.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Snow', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Varner', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT; University of Utah Health, Salt Lake City, UT.'}, {'ForeName': 'M Sean', 'Initials': 'MS', 'LastName': 'Esplin', 'Affiliation': 'Intermountain Healthcare, Salt Lake City, UT; University of Utah Health, Salt Lake City, UT.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.02.012'] 514,32094154,Prospective community programme versus parent-driven care to prevent respiratory morbidity in children following hospitalisation with severe bronchiolitis or pneumonia.,"BACKGROUND Hospitalisation with severe lower respiratory tract infection (LRTI) in early childhood is associated with ongoing respiratory symptoms and possible later development of bronchiectasis. We aimed to reduce this intermediate respiratory morbidity with a community intervention programme at time of discharge. METHODS This randomised, controlled, single-blind trial enrolled children aged <2 years hospitalised for severe LRTI to 'intervention' or 'control'. Intervention was three monthly community clinics treating wet cough with prolonged antibiotics referring non-responders. All other health issues were addressed, and health resilience behaviours were encouraged, with referrals for housing or smoking concerns. Controls followed the usual pathway of parent-initiated healthcare access. After 24 months, all children were assessed by a paediatrician blinded to randomisation for primary outcomes of wet cough, abnormal examination (crackles or clubbing) or chest X-ray Brasfield score ≤22. FINDINGS 400 children (203 intervention, 197 control) were enrolled in 2011-2012; mean age 6.9 months, 230 boys, 87% Maori/Pasifika ethnicity and 83% from the most deprived quintile. Final assessment of 321/400 (80.3%) showed no differences in presence of wet cough (33.9% intervention, 36.5% controls, relative risk (RR) 0.93, 95% CI 0.69 to 1.25), abnormal examination (21.7% intervention, 23.9% controls, RR 0.92, 95% CI 0.61 to 1.38) or Brasfield score ≤22 (32.4% intervention, 37.9% control, RR 0.85, 95% CI 0.63 to 1.17). Twelve (all intervention) were diagnosed with bronchiectasis within this timeframe. INTERPRETATION We have identified children at high risk of ongoing respiratory disease following hospital admission with severe LRTI in whom this intervention programme did not change outcomes over 2 years. TRIAL REGISTRATION NUMBER ACTRN12610001095055.",2020,"Final assessment of 321/400 (80.3%) showed no differences in presence of wet cough (33.9% intervention, 36.5% controls, relative risk (RR) 0.93, 95% CI 0.69 to 1.25), abnormal examination (21.7% intervention, 23.9% controls, RR 0.92, 95% CI 0.61 to 1.38) or Brasfield score ≤22 (32.4% intervention, 37.9% control, RR 0.85, 95% CI 0.63 to 1.17).","['children following hospitalisation with severe bronchiolitis or pneumonia', '400 children (203 intervention, 197 control) were enrolled in 2011-2012; mean age 6.9 months, 230 boys, 87% Maori/Pasifika ethnicity and 83% from the most deprived quintile', ""enrolled children aged <2 years hospitalised for severe LRTI to 'intervention' or 'control""]",['Prospective community programme versus parent-drive care'],"['wet cough, abnormal examination (crackles or clubbing) or chest X-ray Brasfield score ≤22', 'respiratory morbidity', 'presence of wet cough', 'abnormal examination']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0006271', 'cui_str': 'Bronchiolitis'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517826', 'cui_str': 'Six point nine'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0024770', 'cui_str': 'Maori (ethnic group)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection (disorder)'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}]","[{'cui': 'C0205381', 'cui_str': 'Wet (qualifier value)'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0034642', 'cui_str': 'Rales'}, {'cui': 'C0039985', 'cui_str': 'Radiologic examination of chest'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1301752', 'cui_str': 'Respiratory morbidity'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]",400.0,0.203638,"Final assessment of 321/400 (80.3%) showed no differences in presence of wet cough (33.9% intervention, 36.5% controls, relative risk (RR) 0.93, 95% CI 0.69 to 1.25), abnormal examination (21.7% intervention, 23.9% controls, RR 0.92, 95% CI 0.61 to 1.38) or Brasfield score ≤22 (32.4% intervention, 37.9% control, RR 0.85, 95% CI 0.63 to 1.17).","[{'ForeName': 'Catherine Ann', 'Initials': 'CA', 'LastName': 'Byrnes', 'Affiliation': 'Department of Paediatrics, Child and Youth Health, The University of Auckland, Auckland, New Zealand c.byrnes@auckland.ac.nz.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Trenholme', 'Affiliation': 'Department of Paediatrics, Child and Youth Health, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Lawrence', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Harley', 'Initials': 'H', 'LastName': 'Aish', 'Affiliation': 'Otara Family and Christian Health Centre, Otara, Auckland, New Zealand.'}, {'ForeName': 'Julie Anne', 'Initials': 'JA', 'LastName': 'Higham', 'Affiliation': 'Hunter Corner Medical Centre, Papatoetoe, Auckland, New Zealand.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hoare', 'Affiliation': 'Greenstone Family Clinic, Manurewa, Auckland, New Zealand.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Elborough', 'Affiliation': 'Pukekohe Family Health Centre, Pukekohe, Auckland, New Zealand.'}, {'ForeName': 'Charissa', 'Initials': 'C', 'LastName': 'McBride', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Lyndsay', 'Initials': 'L', 'LastName': 'Le Comte', 'Affiliation': 'Counties Manukau District Health Board, Middlemore Clinical Trials Unit, Auckland, New Zealand.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'McIntosh', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Florina', 'Initials': 'F', 'LastName': 'Chan Mow', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Mirjana', 'Initials': 'M', 'LastName': 'Jaksic', 'Affiliation': 'Department of Paediatrics, Child and Youth Health, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Metcalfe', 'Affiliation': ""Department of Radiology, Starship Children's Health, Auckland, New Zealand.""}, {'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Coomarasamy', 'Affiliation': 'Research and Evaluation Office, Koawatea, Auckland, New Zealand.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Leung', 'Affiliation': 'Department of Health Economy, Wellington School of Medicine, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Vogel', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Teuila', 'Initials': 'T', 'LastName': 'Percival', 'Affiliation': 'Department of Paediatrics, KidzFirst Hospital Middlemore, Auckland, New Zealand.'}, {'ForeName': 'Henare', 'Initials': 'H', 'LastName': 'Mason', 'Affiliation': 'Koawatea, Middlemore Hospital, Auckland, New Zealand.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Stewart', 'Affiliation': 'Department of Population Health, The University of Auckland, Auckland, New Zealand.'}]",Thorax,['10.1136/thoraxjnl-2019-213142'] 515,31899848,Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study.,"BACKGROUND After a proximal lower limb deep vein thrombosis (DVT; involving popliteal veins or above), up to 40% of patients develop postthrombotic syndrome (PTS) as assessed by the Villalta scale (VS). Poor initial anticoagulant treatment is a known risk factor for PTS. The risk of developing PTS after isolated distal DVT (infra-popliteal DVT without pulmonary embolism), and the impact of anticoagulant treatment on this risk, are uncertain. METHODS Long-term follow-up of CACTUS double-blind trial comparing 6 weeks of s.c. nadroparin (171 IU/kg/d) versus s.c. placebo for a first symptomatic isolated distal DVT. At least 1 year after randomization, patients had a PTS assessment in clinic or by phone using the VS. RESULTS After a median follow-up of 6 years, PTS was present in 30% (n = 54) of the 178 patients who had a PTS assessment. PTS was moderate or severe in 24% (n = 13) of cases. There was no statistically significant difference in prevalence of PTS in the nadroparin versus placebo groups (29% versus 32%, P = .6), except in patients without evidence of primary chronic venous insufficiency (9% versus 24%, P = .04). Rates of venous thromboembolism recurrence during follow-up in the nadroparin and placebo groups were, respectively, 8% (n = 7) and 14% (n = 13; P = .2). CONCLUSION After a first isolated distal DVT, the risk of PTS is substantial but much lower than that reported after proximal DVT. Anticoagulation with nadroparin doesn't provide any clear benefit to prevent PTS, except in patients without preexisting chronic venous insufficiency. Anticoagulation might be associated with a lower risk of venous thromboembolism recurrence.",2020,"Rates of venous thromboembolism recurrence during follow-up in the nadroparin and placebo groups were respectively 8% (n=7) and 14% (n=13) (p=0.2). ","['patients without pre-existing chronic venous insufficiency', 'Symptomatic Distal Deep-Vein Thrombosis', '178 patients who had a PTS assessment']","['placebo', 'nadroparin']","['prevalence of PTS', 'venous thromboembolism recurrence', 'primary chronic venous insufficiency', 'Rates of venous thromboembolism recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1306557', 'cui_str': 'Chronic venous insufficiency'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}]","[{'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1306557', 'cui_str': 'Chronic venous insufficiency'}]",178.0,0.245907,"Rates of venous thromboembolism recurrence during follow-up in the nadroparin and placebo groups were respectively 8% (n=7) and 14% (n=13) (p=0.2). ","[{'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Galanaud', 'Affiliation': 'Department of Vascular Medicine, Montpellier University Hospital and University of Montpellier, Montpellier, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Righini', 'Affiliation': 'Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland.'}, {'ForeName': 'Lorris', 'Initials': 'L', 'LastName': 'Le Collen', 'Affiliation': 'Department of Vascular Medicine, Montpellier University Hospital and University of Montpellier, Montpellier, France.'}, {'ForeName': 'Aymeric', 'Initials': 'A', 'LastName': 'Douillard', 'Affiliation': 'Clinical Research and Epidemiology Unit, University Hospital, Montpellier, France.'}, {'ForeName': 'Helia', 'Initials': 'H', 'LastName': 'Robert-Ebadi', 'Affiliation': 'Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospital, Geneva, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pontal', 'Affiliation': 'Department of Vascular Medicine, Montpellier University Hospital and University of Montpellier, Montpellier, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Morrison', 'Affiliation': 'Department of Medicine and Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.'}, {'ForeName': 'Marie-Thérèse', 'Initials': 'MT', 'LastName': 'Barrellier', 'Affiliation': 'Vascular Medicine Unit, Caen University Hospital, Caen, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Diard', 'Affiliation': 'Vascular Medicine Office, Langoiran, France.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Guénnéguez', 'Affiliation': 'Clinique Mégival, St Aubin sur Scié, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Brisot', 'Affiliation': 'Vascular Medicine Unit, Clinique du Parc, Castelnau Le Lez, France.'}, {'ForeName': 'Pascale', 'Initials': 'P', 'LastName': 'Faïsse', 'Affiliation': 'Vascular Medicine Physician, Alès, France.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Accassat', 'Affiliation': 'Clinical Investigation Centre, Saint Etienne University Hospital, Saint Etienne, France.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Martin', 'Affiliation': 'Vascular Medicine Physician, Annecy, France.'}, {'ForeName': 'Aurélien', 'Initials': 'A', 'LastName': 'Delluc', 'Affiliation': 'Department of Medicine, Brest University Hospital, Brest, France.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Solymoss', 'Affiliation': ""Division of Hematology, St Mary's Hospital, Montreal, QC, Canada.""}, {'ForeName': 'Jeannine', 'Initials': 'J', 'LastName': 'Kassis', 'Affiliation': 'Division of Hematology, Hôpital Rosemont-Maisonneuve, Montréal, QC, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': 'Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Quéré', 'Affiliation': 'Department of Vascular Medicine, Montpellier University Hospital and University of Montpellier, Montpellier, France.'}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Kahn', 'Affiliation': 'Vascular Medicine Physician, Alès, France.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14728'] 516,32124520,Effects of tocolysis with nifedipine or atosiban on child outcome: follow-up of the APOSTEL III trial.,"OBJECTIVE To compare the long-term effects of tocolysis with nifedipine or atosiban on child outcome at age 2.5-5.5 years. DESIGN The APOSTEL III trial was a multicentre randomised controlled trial that compared tocolysis with nifedipine or atosiban in 503 women with threatened preterm birth. Neonatal outcomes did not differ between both treatment arms, except for a higher incidence of intubation in the atosiban group. METHODS Parents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems, and general health. MAIN OUTCOME MEASURES The main long-term outcome measure was a composite of abnormal development at the age of 2.5-5.5 years. RESULTS Of the 426 women eligible for follow-up, 196 (46%) parents returned the questionnaires for 115 children in the nifedipine group and 110 children in the atosiban group. Abnormal development occurred in 32 children (30%) in the nifedipine group and in 38 children (38%) in the atosiban group (OR 0.74, 95% CI 0.41-1.34). The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups. Sensitivity analysis for all children of the APOSTEL III trial, including a comparison of deceased children, resulted in a higher rate of healthy survival in the nifedipine group (64 versus 54%), but there was no significant difference in the overall mortality rate (5.4 versus 2.7%). There were no significant subgroup effects. CONCLUSION Outcomes on broad child neurodevelopment, executive function, behaviour, and general health were comparable in both groups. Neither nifedipine nor atosiban can be considered as the preferred treatment for women with threatened preterm birth. TWEETABLE ABSTRACT Nifedipine- and atosiban-exposed children had comparable long-term outcomes, including neurodevelopment, executive function, and behaviour.",2020,"The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups.","['503 women with threatened preterm birth', 'child outcome at age 2.5-5.5 years', 'Parents were asked to complete four questionnaires regarding neurodevelopment, executive function, behaviour problems, and general health', '426 women eligible for follow up', 'women with threatened preterm birth']","['nifedipine', 'nifedipine or atosiban']","['rate of healthy survival', 'neurodevelopment, executive function, behaviour, and general health', 'Abnormal development', 'composite of abnormal development', 'broad child neurodevelopment, executive function, behaviour and general health', 'child outcome', 'overall mortality']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0028066', 'cui_str': 'Nifedipine'}, {'cui': 'C0164398', 'cui_str': 'Atosiban'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0000768', 'cui_str': 'Birth Defects'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",503.0,0.145086,"The separate outcomes for neurodevelopment, executive function, behaviour, and general health showed no significant differences between the groups.","[{'ForeName': 'Tms', 'Initials': 'T', 'LastName': 'van Winden', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Klumper', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'C E', 'Initials': 'CE', 'LastName': 'Kleinrouweler', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Tichelaar', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'C A', 'Initials': 'CA', 'LastName': 'Naaktgeboren', 'Affiliation': 'Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'T A', 'Initials': 'TA', 'LastName': 'Nijman', 'Affiliation': 'Department of Obstetrics and Gynaecology, Leiden University Medical Centre, Leiden, the Netherlands.'}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'van Baar', 'Affiliation': 'Child and Adolescent Studies, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'A G', 'Initials': 'AG', 'LastName': 'van Wassenaer-Leemhuis', 'Affiliation': 'Paediatrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'T J', 'Initials': 'TJ', 'LastName': 'Roseboom', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': ""Van't Hooft"", 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Roos', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'B W', 'Initials': 'BW', 'LastName': 'Mol', 'Affiliation': 'Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Pajkrt', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Oudijk', 'Affiliation': 'Obstetrics, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",BJOG : an international journal of obstetrics and gynaecology,['10.1111/1471-0528.16186'] 517,29728704,The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study.,"Rodent studies indicate that ghrelin receptor blockade reduces alcohol consumption. However, no ghrelin receptor blockers have been administered to heavy alcohol drinking individuals. Therefore, we evaluated the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a novel ghrelin receptor inverse agonist, PF-5190457, when co-administered with alcohol. We tested the effects of PF-5190457 combined with alcohol on locomotor activity, loss-of-righting reflex (a measure of alcohol sedative actions), and on blood PF-5190457 concentrations in rats. Then, we performed a single-blind, placebo-controlled, within-subject human study with PF-5190457 (placebo/0 mg b.i.d., 50 mg b.i.d., 100 mg b.i.d.). Twelve heavy drinkers during three identical visits completed an alcohol administration session, subjective assessments, and an alcohol cue-reactivity procedure, and gave blood samples for PK/PD testing. In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex. Alcohol did not affect blood PF-5190457 concentrations. In humans, all adverse events were mild or moderate and did not require discontinuation or dose reductions. Drug dose did not alter alcohol concentration or elimination, alcohol-induced stimulation or sedation, or mood during alcohol administration. Potential PD markers of PF-5190457 were acyl-to-total ghrelin ratio and insulin-like growth factor-1. PF-5190457 (100 mg b.i.d.) reduced alcohol craving during the cue-reactivity procedure. This study provides the first translational evidence of safety and tolerability of the ghrelin receptor inverse agonist PF-5190457 when co-administered with alcohol. PK/PD/behavioral findings support continued research of PF-5190457 as a potential pharmacological agent to treat alcohol use disorder.",2020,"In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex.","['rats', 'Twelve heavy drinkers']","['PF-5190457', 'placebo', 'PF-5190457 (placebo/0', 'ghrelin receptor inverse agonist', 'PF-5190457 combined with alcohol']","['reduced alcohol craving', 'alcohol consumption', 'locomotor activity, loss-of-righting reflex', 'safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects', 'alcohol concentration or elimination, alcohol-induced stimulation or sedation, or mood', 'blood PF-5190457 concentrations', 'locomotor activity or loss-of-righting reflex']","[{'cui': 'C0034721', 'cui_str': 'Rats'}, {'cui': 'C0337678', 'cui_str': 'Heavy drinker (finding)'}]","[{'cui': 'C4279098', 'cui_str': 'PF-5190457'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0391690', 'cui_str': 'GHSR Protein'}, {'cui': 'C0439850', 'cui_str': 'Inverse (qualifier value)'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0234156', 'cui_str': 'Righting Response'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0005768'}, {'cui': 'C4279098', 'cui_str': 'PF-5190457'}]",,0.0182118,"In rats, PF-5190457 did not interact with the effects of alcohol on locomotor activity or loss-of-righting reflex.","[{'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': 'Lee', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jenica D', 'Initials': 'JD', 'LastName': 'Tapocik', 'Affiliation': 'Section on Molecular Pathophysiology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mwlod', 'Initials': 'M', 'LastName': 'Ghareeb', 'Affiliation': 'Clinical Pharmacokinetics Research Laboratory, Department of Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.'}, {'ForeName': 'Melanie L', 'Initials': 'ML', 'LastName': 'Schwandt', 'Affiliation': 'Office of the Clinical Director, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Alexandra A', 'Initials': 'AA', 'LastName': 'Dias', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'April N', 'Initials': 'AN', 'LastName': 'Le', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Enoch', 'Initials': 'E', 'LastName': 'Cobbina', 'Affiliation': 'Clinical Pharmacokinetics Research Laboratory, Department of Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Farinelli', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Bouhlal', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Farokhnia', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Heilig', 'Affiliation': 'Section on Molecular Pathophysiology, Laboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Akhlaghi', 'Affiliation': 'Clinical Pharmacokinetics Research Laboratory, Department of Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Leggio', 'Affiliation': 'Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Alcohol Abuse and Alcoholism and National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA. lorenzo.leggio@nih.gov.'}]",Molecular psychiatry,['10.1038/s41380-018-0064-y'] 518,31990759,Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial.,"BACKGROUND Metformin reduces glucose uptake in physiologic tissues and has been shown to affect non-small cell lung cancer (NSCLC) metabolism. We hypothesized that positron emission tomography (PET) scans could detect the impact of metformin on glucose uptake in NSCLC and we sought to test this hypothesis in a prospective clinical trial. MATERIALS AND METHODS A single-blinded phase II clinical trial was performed with subjects randomized 6:1 to 3 to 4 weeks of metformin versus placebo for inoperable early-stage NSCLC. PET scans were performed at baseline, mid-treatment (after 2 wk study medication), and 6 months postradiation. The primary endpoint of the trial was tumor metabolic response to metformin by PERCIST before definitive radiation. Stereotactic body radiotherapy to 50 Gy in 4 fractions was used for peripheral tumors and 70 Gy in 10 fractions for central tumors. RESULTS There were 14 subjects randomized to the metformin and 1 to placebo. Histologies were 60% adenocarcinoma, 33.3% squamous cell carcinoma, and 6.7% poorly differentiated carcinoma. At mid-treatment PET scan, 57% of subjects randomized to metformin met PERCIST criteria for metabolic response, of which 75% had progressive metabolic disease and 25% had partial metabolic response, whereas the placebo subject had stable metabolic disease. At 6 months, the metformin arm had 69% complete metabolic response, 23% partial metabolic response and 1 progressive metabolic disease, and the subject treated with placebo had a complete metabolic response. There were no CTCAE grade ≥3 toxicities. CONCLUSIONS Despite low accrual, majority of subjects treated with metformin had metabolic responses by PERCIST criteria on PET imaging. Contrary to the effect of metformin on most physiologic tissues, most tumors had increased metabolic activity in response to metformin.",2020,"There were no CTCAE grade ≥3 toxicities. ","['Inoperable Early-stage Non-Small Cell Lung Cancer', 'inoperable early-stage NSCLC']","['metformin', 'metformin versus placebo', 'Stereotactic Radiotherapy', 'Stereotactic body radiotherapy', 'placebo', 'Metformin', 'positron emission tomography (PET) scans']","['partial metabolic response', 'metabolic activity', 'Metabolic Responses', 'CTCAE grade ≥3 toxicities', 'tumor metabolic response', 'complete metabolic response', 'metabolic response, 23% partial metabolic response and 1 progressive metabolic disease', 'stable metabolic disease', 'progressive metabolic disease']","[{'cui': 'C0205187', 'cui_str': 'Inoperable (qualifier value)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4552093', 'cui_str': 'Stereotactic Radiation Therapy'}, {'cui': 'C1720823', 'cui_str': 'Stereotactic Body Radiotherapy'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0441633'}]","[{'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0025517', 'cui_str': 'Thesaurismosis'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}]",14.0,0.0959454,"There were no CTCAE grade ≥3 toxicities. ","[{'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Chun', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Zhongxing', 'Initials': 'Z', 'LastName': 'Liao', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Melenda D', 'Initials': 'MD', 'LastName': 'Jeter', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Joe Y', 'Initials': 'JY', 'LastName': 'Chang', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Lin', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Ritsuko U', 'Initials': 'RU', 'LastName': 'Komaki', 'Affiliation': 'Department of Radiation Oncology, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Guerrero', 'Affiliation': 'Department of Radiation Oncology, William Beaumont School of Medicine, Royal Oak, MI.'}, {'ForeName': 'Ray C', 'Initials': 'RC', 'LastName': 'Mayo', 'Affiliation': 'Departments of Diagnostic Radiology.'}, {'ForeName': 'Bobby M', 'Initials': 'BM', 'LastName': 'Korah', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Suja M', 'Initials': 'SM', 'LastName': 'Koshy', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Heymach', 'Affiliation': 'Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, University of Texas, M.D. Anderson Cancer Center.'}, {'ForeName': 'Albert C', 'Initials': 'AC', 'LastName': 'Koong', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}, {'ForeName': 'Heath D', 'Initials': 'HD', 'LastName': 'Skinner', 'Affiliation': 'Department of Radiation Oncology, Division of Radiation Oncology.'}]",American journal of clinical oncology,['10.1097/COC.0000000000000632'] 519,30548139,Spatial analysis of factors influencing choice of paediatric practice for mothers from low-income and minority populations.,"AIM Publicly reported quality data theoretically enable parents to choose higher-performing paediatric practices. However, little is known about how parents decide where to seek paediatric care. We explored the relationship between geographic factors, care quality and choice of practice to see if the decision-making process could be described in terms of a 'gravity model' of spatial data. METHODS In the context of a randomised controlled trial, we used a geographic information system to calculate flow volume between practice locations and participants' homes, to locate subjects within a census tract, to determine distances between points and to perform exploratory mapping. Generalised linear modelling was then used to determine whether the data fit a gravity model, which is a spatial model that evaluates factors impacting travel from one set of locations to another. RESULTS A total of 662 women and 52 paediatric practices were included in the analysis. Proximity of a practice to home was the most important factor in choosing a practice (Z = -15.01, P < 0.001). Practice size was important to a lesser extent, with larger practices more likely to be chosen (Z = 8.96, P < 0.001). A practice's performance on quality measures was associated with choice only for women who had received an intervention to increase use of quality data (Z = 2.51, P < 0.05). CONCLUSIONS The gravity model and the concept of flow can help explain the choice of paediatric practice in a predominantly low-income, racially ethnic minority (non-White) urban population. This has important ramifications for the potential impact of publicly reported quality data.",2019,"A practice's performance on quality measures was associated with choice only for women who had received an intervention to increase use of quality data (Z = 2.51, P < 0.05). ","['racially ethnic minority (non-White) urban population', 'mothers from low-income and minority populations', '662 women and 52 paediatric practices']",[],"['quality data', 'quality measures']","[{'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0041935', 'cui_str': 'Urban Population'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]",[],"[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",662.0,0.0676395,"A practice's performance on quality measures was associated with choice only for women who had received an intervention to increase use of quality data (Z = 2.51, P < 0.05). ","[{'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Goff', 'Affiliation': 'Department of Medicine, General Internal Medicine, Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}, {'ForeName': 'Jane L', 'Initials': 'JL', 'LastName': 'Garb', 'Affiliation': 'Office of Research, Epidemiology and Biostatistics Core, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}, {'ForeName': 'Haley', 'Initials': 'H', 'LastName': 'Guhn-Knight', 'Affiliation': 'Department of Medicine, General Internal Medicine, Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}, {'ForeName': 'Aruna', 'Initials': 'A', 'LastName': 'Priya', 'Affiliation': 'Department of Medicine, General Internal Medicine, Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}, {'ForeName': 'Penelope S', 'Initials': 'PS', 'LastName': 'Pekow', 'Affiliation': 'Department of Medicine, General Internal Medicine, Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Lindenauer', 'Affiliation': 'Department of Medicine, General Internal Medicine, Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School, Springfield, Massachusetts, United States.'}]",Journal of paediatrics and child health,['10.1111/jpc.14322'] 520,31896735,Comparing treatment effects of a convenient vibratory positional device to CPAP in positional OSA: a crossover randomised controlled trial.,"OBJECTIVES Up to 77% of patients with obstructive sleep apnoea (OSA) have positional OSA (POSA) but traditional positional therapy (PT) methods have failed as they were poorly tolerated. New convenient vibratory PT devices have been invented but while recent studies suggest high treatment efficacy and adherence, there are no published data comparing these devices directly with continuous positive airway pressure (CPAP). Our objective is to evaluate if a convenient vibratory PT device is non-inferior to CPAP in POSA treatment. METHODS In this crossover randomised controlled trial, we enrolled patients with POSA with significant daytime sleepiness (Epworth Sleepiness Scale (ESS)≥10). POSA diagnosis was based on: (1) total Apnoea/Hypopnoea Index (AHI)>10/hour and non-supine AHI<10/hour (2) supine AHI≥2 × non-supine AHI. Patients used their initial allocated devices (PT or CPAP) for 8 weeks before crossing to the alternative intervention after a 1 week washout. The primary aim is to measure changes in ESS between the two treatments. Secondary outcomes include sleep study parameters and patient treatment preference (ClinicalTrials.gov: NCT03125512). RESULTS 40 patients completed the trial between April 2017 and December 2018. Difference in ESS after 8 weeks of device use (PT minus CPAP) was 2.0 (95% CI 0.68 to 3.32), exceeding our predetermined non-inferiority margin of 1.5. AHI on CPAP was lower than with PT (4.0±3.2 vs 13.0±13.8 events/hour, respectively, p=0.001), although both were lower than at baseline. Time spent supine was significantly lower with PT than CPAP (p<0.001). 60% of patients preferred CPAP, 20% preferred PT, while 20% preferred neither device. CONCLUSIONS The non-inferiority ESS endpoint for PT compared with CPAP was not met and the results were inconclusive. Future trials with larger sample sizes or in less symptomatic patients are warranted to provide further insight into the role of these new vibratory PT devices.",2020,Time spent supine was significantly lower with PT than CPAP (p<0.001).,"['40 patients completed the trial between April 2017 and December 2018', 'patients with obstructive sleep apnoea (OSA) have positional OSA (POSA) but', 'positional OSA', 'enrolled patients with POSA with significant daytime sleepiness (Epworth Sleepiness Scale (ESS)≥10']","['initial allocated devices (PT or CPAP', 'convenient vibratory positional device to CPAP', 'traditional positional therapy (PT', 'CPAP']","['Time spent supine', 'AHI on CPAP', 'ESS', 'total Apnoea/Hypopnoea Index (AHI)>10/hour', 'sleep study parameters and patient treatment preference (ClinicalTrials.gov: NCT03125512']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}]","[{'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C3831015', 'cui_str': 'Convenient (qualifier value)'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0235546', 'cui_str': 'Slow shallow breathing (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0162701', 'cui_str': 'Monitoring, Sleep'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}]",40.0,0.0527833,Time spent supine was significantly lower with PT than CPAP (p<0.001).,"[{'ForeName': 'Yingjuan', 'Initials': 'Y', 'LastName': 'Mok', 'Affiliation': 'Department of Sleep Medicine, Surgery and Science, Changi General Hospital, Singapore, Singapore mok.yingjuan@singhealth.com.sg.'}, {'ForeName': 'Alvin', 'Initials': 'A', 'LastName': 'Tan', 'Affiliation': 'Department of Sleep Medicine, Surgery and Science, Changi General Hospital, Singapore, Singapore.'}, {'ForeName': 'Pon Poh', 'Initials': 'PP', 'LastName': 'Hsu', 'Affiliation': 'Department of Sleep Medicine, Surgery and Science, Changi General Hospital, Singapore, Singapore.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Seow', 'Affiliation': 'Allied Health Division, Changi General Hospital, Singapore, Singapore.'}, {'ForeName': 'Yiong Huak', 'Initials': 'YH', 'LastName': 'Chan', 'Affiliation': 'Biostatistics Unit, Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore.'}, {'ForeName': 'Hang Siang', 'Initials': 'HS', 'LastName': 'Wong', 'Affiliation': 'Department of Sleep Medicine, Surgery and Science, Changi General Hospital, Singapore, Singapore.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Poh', 'Affiliation': 'Allied Health Division, Changi General Hospital, Singapore, Singapore.'}, {'ForeName': 'Keith K H', 'Initials': 'KKH', 'LastName': 'Wong', 'Affiliation': 'Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.'}]",Thorax,['10.1136/thoraxjnl-2019-213547'] 521,31399500,Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.,"Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158). In the trial, 157 patients were randomized 1:1 to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Here, PFS and ORR, both determined by independent radiology committee (IRC), were analyzed by subgroups of baseline characteristics. Cabozantinib treatment was generally associated with improved PFS and ORR versus sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden. Clinical trial identification number NCT01835158.",2019,Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158).,"['157 patients', 'Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk', 'patients with advanced renal cell carcinoma (RCC']","['sunitinib', 'Cabozantinib Versus Sunitinib', 'cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases']","['objective response rate (ORR', 'PFS and ORR', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007134', 'cui_str': 'Nephroid Carcinoma'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C1176020', 'cui_str': 'sunitinib'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",157.0,0.0900642,Cabozantinib treatment prolonged progression-free survival (PFS) and improved objective response rate (ORR) compared with sunitinib in patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria in the phase II CABOSUN trial (NCT01835158).,"[{'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'George', 'Affiliation': 'Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA daniel.george@duke.edu.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Hessel', 'Affiliation': 'Exelixis, Inc., Alameda, California, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Halabi', 'Affiliation': 'Alliance Statistics and Data Center, and Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina, USA.'}, {'ForeName': 'M Dror', 'Initials': 'MD', 'LastName': 'Michaelson', 'Affiliation': 'Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Olwen', 'Initials': 'O', 'LastName': 'Hahn', 'Affiliation': 'Alliance Protocol Operations Office, Chicago, Illinois, USA.'}, {'ForeName': 'Meghara', 'Initials': 'M', 'LastName': 'Walsh', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Picus', 'Affiliation': 'Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Small', 'Affiliation': 'UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.'}, {'ForeName': 'Shaker', 'Initials': 'S', 'LastName': 'Dakhil', 'Affiliation': 'University of Kansas - Wichita, Wichita, Kansas, USA.'}, {'ForeName': 'Darren R', 'Initials': 'DR', 'LastName': 'Feldman', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Mangeshkar', 'Affiliation': 'Exelixis, Inc., Alameda, California, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Scheffold', 'Affiliation': 'Exelixis, Inc., Alameda, California, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Morris', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'Toni K', 'Initials': 'TK', 'LastName': 'Choueiri', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.'}]",The oncologist,['10.1634/theoncologist.2019-0316'] 522,32121288,A Linked Community and Health Facility Intervention to Improve Newborn Health in Cambodia: the NICCI Stepped-Wedge Cluster-Randomized Controlled Trial.,"BACKGROUND Newborn mortality in Cambodia remains high, with sepsis and complications of delayed care-seeking important contributing factors. Intervention study objectives were to improve infection control behavior by staff in health centers; improve referral of sick newborns; increase recognition of danger signs, and prompt care-seeking at an appropriate health facility; and appropriate referral for sick newborns by mothers and families of newborn infants. METHODS The stepped-wedge cluster-randomized controlled trial took place in rural Cambodia from February 2015 to November 2016. Sixteen clusters consisted of public health center catchment areas serving the community. The intervention included health center staff training and home visits to mothers by community health volunteers within 24 hours of birth and on days 3 and 7 after delivery, including assessment of newborns for danger signs and counselling mothers. The trial participants included women who had recently delivered a newborn who were visited in their homes in the first week, as well as health center staff and community volunteers who were trained in newborn care. Women in their last trimester of pregnancy greater than 18 years of age were recruited and were blinded to their group assignment. Mothers and caregivers (2494) received counseling on handwashing practices, breastfeeding, newborn danger signs, and prompt, appropriate referral to facilities. RESULTS Health center staff in the intervention group had increased likelihood of hand washing at recommended key moments when compared with the control group, increased knowledge of danger signs, and higher recall of at least three hygiene messages. Of mother/caregiver participants at 14 days after delivery, women in the intervention group were much more likely to know at least three danger signs and to have received messages on care-seeking compared with controls. CONCLUSIONS The intervention improved factors understood to be associated with newborn survival and health. Well-designed training, followed by regular supervision, enhanced the knowledge and self-reported behavior of health staff and health volunteers, as well as mothers' own knowledge of newborn danger signs. However, further improvement in newborn care, including care-seeking for illness and handwashing among mothers and families, will require additional involvement from broader stakeholders in the community.",2020,"RESULTS Health center staff in the intervention group had increased likelihood of hand washing at recommended key moments when compared with the control group, increased knowledge of danger signs, and higher recall of at least three hygiene messages.","['Sixteen clusters consisted of public health center catchment areas serving the community', 'sick newborns by mothers and families of newborn infants', 'rural Cambodia from February 2015 to November 2016', 'Women in their last trimester of pregnancy greater than 18 years of age', 'trial participants included women who had recently delivered a newborn who were visited in their homes in the first week, as well as health center staff and community volunteers who were trained in newborn care', 'to mothers by community health volunteers within 24 hours of birth and on days 3 and 7 after delivery, including assessment of newborns for danger signs and counselling mothers', 'Mothers and caregivers (2494) received', 'Newborn Health in Cambodia']","['Health Facility Intervention', 'health center staff training and home visits', 'counseling on handwashing practices, breastfeeding, newborn danger signs, and prompt, appropriate referral to facilities']","['knowledge of danger signs', 'newborn survival and health', 'likelihood of hand washing']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0007403', 'cui_str': 'Health Service Area'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0006797', 'cui_str': 'Khmer Republic'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032981', 'cui_str': 'Last Trimester'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0204792', 'cui_str': 'Newborn health care'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0341618', 'cui_str': 'Counsel (occupation)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4042838', 'cui_str': 'Health of Newborn Infants'}]","[{'cui': 'C0018704', 'cui_str': 'Health Facilities'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0341618', 'cui_str': 'Counsel (occupation)'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}]",,0.0390873,"RESULTS Health center staff in the intervention group had increased likelihood of hand washing at recommended key moments when compared with the control group, increased knowledge of danger signs, and higher recall of at least three hygiene messages.","[{'ForeName': 'Chivorn', 'Initials': 'C', 'LastName': 'Var', 'Affiliation': 'National Institute of Public Health, #2 Kim Y Sung Blvd, Tuol Kork, P.O. Box 1300, Phnom Penh 12150, Cambodia.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Oberhelman', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St., New Orleans, LA 70112, USA.'}, {'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Shu', 'Affiliation': 'Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St., New Orleans, LA 70112, USA.'}, {'ForeName': 'Supheap', 'Initials': 'S', 'LastName': 'Leang', 'Affiliation': 'National Institute of Public Health, #2 Kim Y Sung Blvd, Tuol Kork, P.O. Box 1300, Phnom Penh 12150, Cambodia.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Duggal', 'Affiliation': 'Tulane University School of Medicine, Tulane Ave, New Orleans, LA 70112, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Le', 'Affiliation': 'Louisiana Department of Health, Bureau of Family Health, New Orleans, LA 70112, USA.'}, {'ForeName': 'Alessandra N', 'Initials': 'AN', 'LastName': 'Bazzano', 'Affiliation': 'Department of Global Community Health and Behavioral Sciences, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St., New Orleans, LA 70112, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17051559'] 523,32217612,FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.,"On May 3, 2019, the FDA granted regular approval to ado-trastuzumab emtansine (KADCYLA), for the adjuvant treatment of patients with HER2-positive early-breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane-based chemotherapy and trastuzumab-based treatment. Approval was based on data from the KATHERINE trial, which randomized patients to receive ado-trastuzumab emtansine or trastuzumab. At 3 years, the event-free rate for invasive disease-free survival in the ado-trastuzumab emtansine arm was 88.3% [95% confidence interval (CI), 85.8-90.7] compared with 77.0% (95% CI, 73.8-80.7) in the trastuzumab arm, (HR, 0.50; 95% CI, 0.39-0.64; P < 0.0001). Results from secondary endpoints, subgroup analyses, and sensitivity analyses generally supported the primary efficacy endpoint results. Common adverse reactions (>25% and higher incidence in ado-trastuzumab emtansine arm) with ado-trastuzumab emtansine were fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia. Ado-trastuzumab emtansine is the first drug approved for the treatment of patients with residual disease after neoadjuvant treatment and surgery. This article summarizes the FDA review and the data supporting the approval of ado-trastuzumab emtansine as a component of treatment for patients with HER2-positive EBC with residual disease.",2020,"At three years, the event free rate for invasive disease free survival in the ado-trastuzumab emtansine arm was 88.3% (95% confidence interval [CI]: 85.8, 90.7) compared to 77.0% (95% CI: 73.8, 80.7) in the trastuzumab arm, (HR=0.50; 95% CI: 0.39, 0.64; p<.0001).","['patients with HER2-positive EBC with residual disease', 'patients with residual disease after neoadjuvant treatment and surgery', 'patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane based chemotherapy and trastuzumab-based treatment', 'HER2-positive early breast cancer']","['trastuzumab emtansine', 'ado-trastuzumab emtansine or trastuzumab']","['fatigue, nausea, increased transaminases, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, peripheral neuropathy, and arthralgia', 'invasive disease free survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant Treatment'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C3496586', 'cui_str': 'epidermal growth factor receptor 2, human'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2935436', 'cui_str': 'ado-trastuzumab emtansine'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferases'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal Pain'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0031117', 'cui_str': 'PNS (Peripheral Nervous System) Diseases'}, {'cui': 'C0003862', 'cui_str': 'Joint Pain'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}]",,0.0410225,"At three years, the event free rate for invasive disease free survival in the ado-trastuzumab emtansine arm was 88.3% (95% confidence interval [CI]: 85.8, 90.7) compared to 77.0% (95% CI: 73.8, 80.7) in the trastuzumab arm, (HR=0.50; 95% CI: 0.39, 0.64; p<.0001).","[{'ForeName': 'Suparna', 'Initials': 'S', 'LastName': 'Wedam', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. Suparna.Wedam@fda.hhs.gov.'}, {'ForeName': 'Lola', 'Initials': 'L', 'LastName': 'Fashoyin-Aje', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Bloomquist', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Shenghui', 'Initials': 'S', 'LastName': 'Tang', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Rajeshwari', 'Initials': 'R', 'LastName': 'Sridhara', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Kirsten B', 'Initials': 'KB', 'LastName': 'Goldberg', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Bellinda L', 'Initials': 'BL', 'LastName': 'King-Kallimanis', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Theoret', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Amna', 'Initials': 'A', 'LastName': 'Ibrahim', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Laleh', 'Initials': 'L', 'LastName': 'Amiri-Kordestani', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pazdur', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Julia A', 'Initials': 'JA', 'LastName': 'Beaver', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-3980'] 524,32134394,A Values-Tailored Web-Based Intervention for New Mothers to Increase Infant Vaccine Uptake: Development and Qualitative Study.,"BACKGROUND Vaccine hesitancy among parents leads to childhood undervaccination and outbreaks of vaccine-preventable disease. As the reasons for vaccine hesitancy are diverse, there is often not enough time during regular clinical visits for medical providers to adequately address all the concerns that parents have. Providing individually tailored vaccine information via the internet before a clinical visit may be a good mechanism for effectively allaying parents' vaccination concerns while also being time efficient. Including tailoring based on values is a promising, but untested, approach to message creation. OBJECTIVE This study aimed to describe the process by which we developed a Web-based intervention that is being used in an ongoing randomized controlled trial aimed at improving the timeliness of infant vaccination by reducing parental vaccine hesitancy. METHODS Development of the intervention incorporated evidence-based health behavior theories. A series of interviews, surveys, and feedback sessions were used to iteratively develop the intervention in collaboration with vaccination experts and potential end users. RESULTS In all, 41 specific content areas were identified to be included in the intervention. User feedback elucidated preferences for specific design elements to be incorporated throughout the website. The tile-based architecture chosen for the website was perceived as easy to use. Creating messages that were two-sided was generally preferred over other message formats. Quantitative surveys identified associations between specific vaccine values and vaccination beliefs, suggesting that values tailoring should vary, depending on the specific belief being endorsed. CONCLUSIONS Using health behavior theories, qualitative and quantitative data, and significant expert and end user input, we created a novel, Web-based intervention to improve infant vaccination timeliness. The intervention is based on tailoring messages according to each individual's values and beliefs. This intervention is currently being tested in a controlled randomized clinical trial.",2020,Providing individually tailored vaccine information via the internet before a clinical visit may be a good mechanism for effectively allaying parents' vaccination concerns while also being time efficient.,[],[],[],[],[],[],41.0,0.0498151,Providing individually tailored vaccine information via the internet before a clinical visit may be a good mechanism for effectively allaying parents' vaccination concerns while also being time efficient.,"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Dempsey', 'Affiliation': 'University of Colorado, Denver, Aurora, CO, United States.'}, {'ForeName': 'Bethany M', 'Initials': 'BM', 'LastName': 'Kwan', 'Affiliation': 'University of Colorado, Denver, Aurora, CO, United States.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Wagner', 'Affiliation': 'Kaiser Permanente Colorado Institute for Health Research, Denver, CO, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Pyrzanowski', 'Affiliation': 'University of Colorado, Denver, Aurora, CO, United States.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Brewer', 'Affiliation': 'University of Colorado, Denver, Aurora, CO, United States.'}, {'ForeName': 'Carter', 'Initials': 'C', 'LastName': 'Sevick', 'Affiliation': 'University of Colorado, Denver, Aurora, CO, United States.'}, {'ForeName': 'Komal', 'Initials': 'K', 'LastName': 'Narwaney', 'Affiliation': 'Kaiser Permanente Colorado Institute for Health Research, Denver, CO, United States.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Resnicow', 'Affiliation': 'University of Michigan, Department of Health Behavior & Health Education, School of Public Health, Ann Arbor, MI, United States.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Glanz', 'Affiliation': 'Kaiser Permanente Colorado Institute for Health Research, Denver, CO, United States.'}]",Journal of medical Internet research,['10.2196/15800'] 525,32218417,Application of mineral waters in the complex treatment of patients with gastroesophageal reflux disease.,"BACKGROUND Gastroesophageal reflux disease (GERD) is one of the most common gastric pathologies. Recently, there has been a growing interest in the healing effects of mineral waters (MW). METHODS Ninety patients with GERD were under observation. The study used the following methods: anamnestic, clinical, studies of biochemical blood parameters, ultrasonographic studies of the digestive system, fibroesophagogastroduodenoscopy with intragastric pH-metric. After preliminary research, all patients were randomly divided into three groups of 30 people. The control group (group 1) who were prescribed a basic treatment complex-dietary and proton pump inhibitor group drugs. Patients of group 2 in addition to the standard course of treatment received boric highly mineralized bicarbonate sodium water. Patients of group 3 in addition to the basic therapy were prescribed an internal course treatment of highly mineralized sulfate-bicarbonate sodium-magnesium water. RESULTS The use of the basic complex of treatment for a month in control group did not lead to a significant leveling of signs of dyspeptic and asthenic syndromes. The use of boron highly mineralized sodium bicarbonate water led to a significant leveling of signs of abdominal pain and dyspeptic syndromes, improvement of acid-forming function of the stomach, but no reliable dynamics were observed in eliminating signs of cytolytic, mesenchymal inflammatory and cholestatic syndromes. Application of highly mineralized sulfate-hydrocarbonate sodium magnesium water improves the elimination of dyspepsia and pain syndromes, normalization of the functional state of the liver. CONCLUSIONS The obtained data confirm the prospects of using highly mineralized mineral waters in the complex treatment of GERD patients.",2020,The use of the basic complex of treatment for a month in control group did not lead to a significant leveling of signs of dyspeptic and asthenic syndromes.,"['90 patients with GERD were under observation', 'GERD patients', 'patients with gastroesophageal reflux disease']","['highly mineralized sulfate-hydrocarbonate sodium magnesium', 'fibroesophagogastroduodenoscopy with intragastric pH-metric', 'basic treatment complex - dietary and proton pump inhibitor group drugs', 'boron highly mineralized sodium bicarbonate', 'boric highly mineralized bicarbonate sodium water', 'bicarbonate sodium-magnesium water']","['signs of dyspeptic and asthenic syndromes', 'elimination of dyspepsia and pain syndromes, normalization of the functional state of the liver']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017168', 'cui_str': 'Gastric Acid Reflux Disease'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]","[{'cui': 'C0038720', 'cui_str': 'Sulfates, Inorganic'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C3540792', 'cui_str': 'Magnesium supplements, alimentary tract and metabolism'}, {'cui': 'C0442113', 'cui_str': 'Intragastric (qualifier value)'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C4521480', 'cui_str': 'Hydrogen/potassium adenosine triphosphatase enzyme system inhibitor (disposition)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0006030', 'cui_str': 'Boron'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C0043047', 'cui_str': 'Water'}]","[{'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0023884', 'cui_str': 'Liver'}]",90.0,0.0162874,The use of the basic complex of treatment for a month in control group did not lead to a significant leveling of signs of dyspeptic and asthenic syndromes.,"[{'ForeName': 'Nataliya V', 'Initials': 'NV', 'LastName': 'Dragomiretska', 'Affiliation': 'Department of Medical Rehabilitation, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Konstantin D', 'Initials': 'KD', 'LastName': 'Babov', 'Affiliation': 'Department of Medical Rehabilitation, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Sergey G', 'Initials': 'SG', 'LastName': 'Gushcha', 'Affiliation': 'Department of Basic Research, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Irina B', 'Initials': 'IB', 'LastName': 'Zabolotna', 'Affiliation': 'Department of Medical Rehabilitation, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Alexander L', 'Initials': 'AL', 'LastName': 'Plakida', 'Affiliation': 'Department of Physical Rehabilitation, Sports Medicine, Physical Education and Valeology, Odessa National Medical University, Odessa, Ukraine - aplakida@mail.ru.'}, {'ForeName': 'Anna N', 'Initials': 'AN', 'LastName': 'Izha', 'Affiliation': 'Department of Medical Rehabilitation, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Irina K', 'Initials': 'IK', 'LastName': 'Babova', 'Affiliation': 'Odessa Regional Institute of Public Administration of the National Academy of Public Administration under the President of Ukraine, Odessa, Ukraine.'}, {'ForeName': 'Boris A', 'Initials': 'BA', 'LastName': 'Nasibullin', 'Affiliation': 'Department of Basic Research, State Institution "Ukrainian Research Institute of Medical Rehabilitation and Resorts of the Ministry of Health of Ukraine, " Odessa, Ukraine.'}, {'ForeName': 'Irina A', 'Initials': 'IA', 'LastName': 'Trubka', 'Affiliation': ""Shupik' National Medical Academy of Postgraduate Education, Kyiv, Ukraine.""}]",Minerva gastroenterologica e dietologica,['10.23736/S1121-421X.20.02601-X'] 526,32218424,"Effects of Hoodia Parviflora on satiety, abdominal obesity and weight in a group of overweight subjects: a randomized, blinded, placebo-controlled trial.","BACKGROUND This study aimed to assess the effects of supplementation with Hoodia Parviflora (H. Parviflora) at 9 mg+200 mg of fructo-oligosaccharides on weight loss, body composition, hydration and satiety parameters. METHODS A randomized blinded controlled trial was conducted in a sample of 30 overweight and obese patients (5 males and 25 females). Patients were randomly assigned in 2 groups: the intervention group, which received H. Parviflora twice a day for 4 weeks and the control group, which received a placebo. RESULTS After a 4-week follow-up period, the study results showed an improvement of Δ=-1.632 kg (Confidence Interval [CI]95% -2.545; -0.719) and a statistically significant decrease in waist circumference (WC) compared with the placebo group -2.080 cm ([CI]95% -4.082; -0.078). The visual analogue scale reported an improvement of satiety sensation after day 5 (P=0.001). CONCLUSIONS This study shows for the first time the simultaneous effect of H. Parviflora on weight loss, decreasing satiety, and improving fat mass, in particular Visceral Adipose Tissue (VAT).",2020,"The visual analogue scale reported an improvement of satiety sensation after day 5 (p=0.001). ","['30 overweight and obese patients (5M;25F', 'a group of overweight subjects']","['Hoodia Parviflora', 'supplementation with H. Parviflora at 9 mg + 200 mg of fructo-oligosaccharides', 'placebo']","['weight loss, body composition, hydration and satiety parameters', 'waist circumference (WC', 'visual analogue scale', 'satiety sensation', 'satiety, abdominal obesity and weight', 'weight loss, decreasing satiety, and improving fat mass']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1218365', 'cui_str': 'Hoodia'}, {'cui': 'C0651569', 'cui_str': ""9-(1'-hydroxy-2'-(hydroxymethyl)ethoxy)methylguanine""}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0028959', 'cui_str': 'Oligosaccharides'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1321013', 'cui_str': 'Hydration'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0036658', 'cui_str': 'Sensory Function'}, {'cui': 'C0311277', 'cui_str': 'Central Obesity'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}]",30.0,0.426571,"The visual analogue scale reported an improvement of satiety sensation after day 5 (p=0.001). ","[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Perna', 'Affiliation': 'Department of Biology, College of Science, University of Bahrain, Sakhir, Bahrain.'}, {'ForeName': 'Vittoria', 'Initials': 'V', 'LastName': 'Infantino', 'Affiliation': 'Unit of Human and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Peroni', 'Affiliation': 'Unit of Endocrinology and Nutrition, Azienda di Servizi alla Persona Istituto Santa Margherita, University of Pavia, Pavia, Italy - gabriella.peroni01@universitadipavia.it.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Gasparri', 'Affiliation': 'Unit of Endocrinology and Nutrition, Azienda di Servizi alla Persona Istituto Santa Margherita, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Milena A', 'Initials': 'MA', 'LastName': 'Faliva', 'Affiliation': 'Unit of Endocrinology and Nutrition, Azienda di Servizi alla Persona Istituto Santa Margherita, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Naso', 'Affiliation': 'Unit of Endocrinology and Nutrition, Azienda di Servizi alla Persona Istituto Santa Margherita, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Tariq A', 'Initials': 'TA', 'LastName': 'Alalwan', 'Affiliation': 'Department of Biology, College of Science, University of Bahrain, Sakhir, Bahrain.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Borsani', 'Affiliation': 'PromoPharma S.p.A. Acquaviva, San Marino, Italy.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Berardi', 'Affiliation': 'PromoPharma S.p.A. Acquaviva, San Marino, Italy.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Ilyas', 'Affiliation': 'Department of Biology, College of Science, University of Bahrain, Sakhir, Bahrain.'}, {'ForeName': 'Zahraa', 'Initials': 'Z', 'LastName': 'Alaali', 'Affiliation': 'Department of Biology, College of Science, University of Bahrain, Sakhir, Bahrain.'}, {'ForeName': 'Layla', 'Initials': 'L', 'LastName': 'Alsowaid', 'Affiliation': 'Department of Biology, College of Science, University of Bahrain, Sakhir, Bahrain.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Spadaccini', 'Affiliation': 'Unit of Endocrinology and Nutrition, Azienda di Servizi alla Persona Istituto Santa Margherita, University of Pavia, Pavia, Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Rondanelli', 'Affiliation': 'Unit of Human and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.'}]",Minerva gastroenterologica e dietologica,['10.23736/S1121-421X.20.02669-0'] 527,31189618,TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.,"BACKGROUND When carcinoid syndrome (CS) diarrhea (CSD) is inadequately controlled with long-acting somatostatin analogs (SSAs), clinical practice guidelines recommend addition of the tryptophan hydroxylase inhibitor telotristat ethyl (TE). In a 12-week multinational, randomized controlled trial, TE added to SSA reduced peripheral serotonin and the frequency of CSD. We evaluated real-world effectiveness of TE using patient-reported data from a nurse support program over 3 months. MATERIALS AND METHODS This study used a deidentified data set of patients initiating TE who opted into a nurse support program between March and November 2017 and reported CS symptom burden at baseline and at least one follow-up time point at months 1, 2, and 3. Patients reported demographic and medical history information as well as frequency of bowel movements (BMs) and flushing episodes, severity of nausea, urgency and abdominal pain (0 ""no/not at all"" to 100 ""worst imaginable/very urgent""), and stool form (1 ""very hard"" to 10 ""watery""). Mean changes from baseline in CS symptom burden were reported using paired-sample t tests and Wilcoxon signed-rank tests. RESULTS Most patients initiating TE enrolled in the nurse program (791/898, 88%), of whom 369 (47%) were included in the analysis. Patients treated with TE reported significant reductions in CSD and other CS symptoms (all p < .001). At least half of patients treated with TE experienced ≥30% improvement from baseline in BM frequency and an average reduction of at least two BMs per day within 3 months. CONCLUSION Patients taking SSA therapy showed substantial burden of disease before initiating TE and significant improvements with the addition of TE treatment in this real-world effectiveness study. IMPLICATIONS FOR PRACTICE Patients with carcinoid syndrome diarrhea uncontrolled by high doses of long-acting somatostatin analogs may be candidates for additional therapy with the tryptophan hydroxylase inhibitor telotristat ethyl. Understanding the real-world prevalence of uncontrolled symptoms and the effectiveness of telotristat ethyl in clinical practice may further support clinical and policy decisions for these patients. This study investigated self-reported carcinoid syndrome symptom burden and improvements among patients initiating telotristat ethyl and participating in a voluntary nurse support program. Disease burden and off-label somatostatin analog treatment before initiating telotristat ethyl were high, and symptoms improved markedly over 1, 2, and 3 months of treatment.",2019,Patients treated with TE reported significant reductions in CSD and other CS symptoms (all p < .001).,"['patients initiating telotristat ethyl and participating in a voluntary nurse support program', 'patients initiating TE who opted into a nurse support program between March and November 2017 and reported CS symptom burden at baseline and at least one follow-up time point at months 1, 2, and 3', 'Patients with carcinoid syndrome diarrhea', 'Most patients initiating TE enrolled in the nurse program (791/898, 88%), of whom 369 (47%) were included in the analysis', 'carcinoid syndrome (CS) diarrhea (CSD']","['TE', 'TELEPRO']","['BM frequency', 'peripheral serotonin and the frequency of CSD', 'frequency of bowel movements (BMs) and flushing episodes, severity of nausea, urgency and abdominal pain', 'CSD and other CS symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4317559', 'cui_str': 'telotristat ethyl'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C4543399', 'cui_str': 'Carcinoid syndrome diarrhea'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]",[],"[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0426642', 'cui_str': 'Frequency of bowel action (observable entity)'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0627981,Patients treated with TE reported significant reductions in CSD and other CS symptoms (all p < .001).,"[{'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Strosberg', 'Affiliation': 'Moffitt Cancer Center, Tampa, Florida, USA jonathan.strosberg@moffitt.org.'}, {'ForeName': 'Vijay N', 'Initials': 'VN', 'LastName': 'Joish', 'Affiliation': 'Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Giacalone', 'Affiliation': 'Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Perez-Olle', 'Affiliation': 'Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Fish-Steagall', 'Affiliation': 'Biologics McKesson, Inc., Raleigh, North Carolina, USA.'}, {'ForeName': 'Kanika', 'Initials': 'K', 'LastName': 'Kapoor', 'Affiliation': 'Diplomat, Flint, Michigan, USA.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Dharba', 'Affiliation': 'Datawave Solutions, Cranbury, New Jersey, USA.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Lapuerta', 'Affiliation': 'Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Al B', 'Initials': 'AB', 'LastName': 'Benson', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.'}]",The oncologist,['10.1634/theoncologist.2018-0921'] 528,32020731,Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.,"AIMS/INTRODUCTION This secondary analysis of the 24-week SMART study examined the efficacy of add-on saxagliptin or acarbose to metformin across different patient subgroups with type 2 diabetes mellitus, based on baseline characteristics. MATERIALS AND METHODS Randomized patients (n = 481) were classified into subgroups based on their baseline age (<65, ≥65 years), body mass index (BMI; <24, 24-<28, ≥28 kg/m 2 ), glycated hemoglobin (HbA1c; <8%, 8-<9%, 9-<10%, ≥10%) and renal function (creatinine clearance 50-<80, ≥80 mL/min). Treatment effects on primary outcome (HbA1c) and key secondary outcomes of fasting plasma glucose (FPG), 2-h postprandial glucose and homeostatic model assessment of β-cell function were assessed across patient subgroups. RESULTS For saxagliptin, reductions in HbA1c from baseline to week 24 were consistent across different subgroups regardless of baseline age, body mass index, HbA1c and renal function (range -0.66 to -1.16%). Saxagliptin was associated with consistent reductions in FPG (-0.60 to -1.33 mmol/L) and 2-h postprandial glucose (-0.48 to -1.95 mmol/L) across the majority of subgroups studied. The efficacy of acarbose on FPG attenuated progressively with increasing baseline HbA1c (+0.86 to -1.43 mmol/L); an increase from baseline FPG was observed in patients with HbA1c >9%. The effect of acarbose on postprandial glucose was also variable (+0.23 to -3.38 mmol/L). CONCLUSIONS As add-on to metformin, both saxagliptin and acarbose reduced HbA1c regardless of baseline HbA1c, age, body mass index and renal function; however, only saxagliptin was effective at a stable glycemic control (FPG and PPG). The efficacy of acarbose on FPG and PPG was significantly attenuated in patients with higher baseline HbA1c (≥8%).",2020,The efficacy of acarbose on FPG and PPG was significantly attenuated in patients with higher baseline HbA1c (≥8%).,"['patient subgroups with type 2 diabetes mellitus (T2DM', 'Randomized patients (N=481) were classified into subgroups based on their baseline age (<65, ≥65 years), body mass index (BMI; <24, 24-<28, ≥28Kg/m 2 ), glycated hemoglobin (HbA1c; <8%, 8-<9%, 9-<10%, ≥10%), and renal function (creatinine clearance 50-<80, ≥80mL/min', 'Chinese patients with type 2 diabetes mellitus', 'patients with higher baseline HbA1c (≥8']","['saxagliptin or acarbose to metformin', 'Saxagliptin', 'acarbose', 'metformin therapy', 'saxagliptin or acarbose', 'saxagliptin', 'saxagliptin and acarbose']","['FPG', 'glycemic effects', 'baseline FPG', 'FPG and PPG', 'FPG attenuated progressively with increasing baseline HbA1c', 'primary outcome (HbA1c) and key secondary outcomes of fasting plasma glucose (FPG), 2-hour postprandial glucose (2h-PPG), and homeostatic model assessment of β-cell function', 'PPG', 'BMI, HbA1c, and renal function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C0050393', 'cui_str': 'Acarbose'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0049716', 'cui_str': 'thioGDP'}, {'cui': 'C0332161', 'cui_str': 'Attenuated by (contextual qualifier) (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C1292425', 'cui_str': '2 hours (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}]",481.0,0.0638924,The efficacy of acarbose on FPG and PPG was significantly attenuated in patients with higher baseline HbA1c (≥8%).,"[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Fang', 'Affiliation': 'Department of Endocrinology, Tangshan Gongren Hospital, Tangshan, China.'}, {'ForeName': 'Fengmei', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Department of Endocrinology, Hebi Coal (Group) Co. Ltd, General Hospital, Hebi, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': ""Department of Endocrinology, Chinese People's Liberation Army General Hospital, Beijing, China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liang', 'Affiliation': ""Department of Endocrinology, People's Hospital of Liaoning Province, Shenyang, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.'}, {'ForeName': 'Liya', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of Geriatrics, Wuhan 6th Hospital, Wuhan, China.'}, {'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Jinzhou Central Hospital, Jinzhou, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': ""Department of Endocrinology, Chinese People's Armed Police Force General Hospital, Beijing, China.""}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Bian', 'Affiliation': ""Department of Endocrinology, Cangzhou People's Hospital, Cangzhou, China.""}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Mu', 'Affiliation': ""Department of Endocrinology, Chinese People's Liberation Army General Hospital, Beijing, China.""}]",Journal of diabetes investigation,['10.1111/jdi.13224'] 529,30877049,A Randomized Controlled Trial of Attention Bias Modification Treatment in Youth With Treatment-Resistant Anxiety Disorders.,"OBJECTIVE Randomized clinical trials of augmentation strategies for youth with treatment-resistant anxiety disorders do not exist. This report presents findings from an efficacy trial of attention bias modification treatment (ABMT) as an augment for this population compared with attention control training (ACT). METHOD Sixty-four youths (34 boys; mean age 11.7 years) who continued to meet for anxiety diagnoses after completing cognitive-behavioral therapy were randomized to ABMT or ACT. ABMT and ACT consisted of dot-probe attention training trials presenting angry and neutral faces; probes appeared in the location of neutral faces on 100% of trials in ABMT and 50% of trials in ACT. Independent evaluators, youths, and parents completed ratings of youth anxiety severity, and youths completed measures of attention bias to threat and attention control at pretreatment, post-treatment, and 2-month follow-up. RESULTS The 2 arms showed significant decreases in anxiety severity, with no differences between arms. Specifically, across informants, anxiety severity was significantly decreased at post-treatment and decreases were maintained at follow-up. Primary anxiety disorder diagnostic recovery combined across arms was 50% at post-treatment and 58% at follow-up. Attention control, but not attention bias to threat, was significantly improved at post-treatment in the 2 arms. CONCLUSION This is the first study to show anxiety can be decreased in youth who did not respond to cognitive-behaviorial therapy, and that the anxiety-decreasing effect is found using these 2 attention training contingency schedules. These findings and increases in attention control in the 2 arms raise intriguing questions about mechanisms of decreasing anxiety in treatment-resistant youth with attention training that require further research. CLINICAL TRIAL REGISTRATION INFORMATION Attention Bias Modification Training for Child Anxiety CBT Nonresponders; https://clinicaltrials.gov/; NCT01819311.",2020,"Attention control, but not attention bias to threat, was significantly improved at post-treatment in the 2 arms. ","['Sixty-four youths (34 boys; mean age 11.7 years) who continued to meet for anxiety diagnoses after completing cognitive-behavioral therapy', 'youth with treatment-resistant anxiety disorders', 'Youth With Treatment-Resistant Anxiety Disorders']","['attention bias modification treatment (ABMT', 'ABMT or ACT']","['attention bias to threat and attention control', 'Primary anxiety disorder diagnostic recovery', 'anxiety severity']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517535', 'cui_str': '11.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005346', 'cui_str': 'Bias'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",,0.059929,"Attention control, but not attention bias to threat, was significantly improved at post-treatment in the 2 arms. ","[{'ForeName': 'Jeremy W', 'Initials': 'JW', 'LastName': 'Pettit', 'Affiliation': 'Florida International University, Miami. Electronic address: jpettit@fiu.edu.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Bechor', 'Affiliation': 'Florida International University, Miami.'}, {'ForeName': 'Yasmin', 'Initials': 'Y', 'LastName': 'Rey', 'Affiliation': 'Florida International University, Miami.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Vasey', 'Affiliation': 'Ohio State University, Columbus.'}, {'ForeName': 'Rany', 'Initials': 'R', 'LastName': 'Abend', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Pine', 'Affiliation': 'National Institute of Mental Health, Bethesda, MD.'}, {'ForeName': 'Yair', 'Initials': 'Y', 'LastName': 'Bar-Haim', 'Affiliation': 'Tel Aviv University, Israel.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Jaccard', 'Affiliation': 'New York University, New York, NY.'}, {'ForeName': 'Wendy K', 'Initials': 'WK', 'LastName': 'Silverman', 'Affiliation': 'Yale University, New Haven CT.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2019.02.018'] 530,31145919,"Food craving, cortisol and ghrelin responses in modeling highly palatable snack intake in the laboratory.","Overeating of highly palatable (HP) foods in the ubiquitous HP food cue environment and under stress is associated with weight gain and contributes to the global obesity epidemic. However, subjective and biobehavioral processes that may increase HP overeating are not clear. Using a novel experimental approach, we examined HP food motivation and intake and neuroendocrine responses in the context of food cues, stress and a control neutral relaxing cue exposure in healthy individuals. METHODS Twenty individuals (12 M; 8F; ages 18-45) with body mass index (BMI) in the lean (LN: N = 8; 3/8 female BMI: 18-24.9) or overweight/obese (OW: N = 12; 5/12 female; BMI: 25-37) range were enrolled in a controlled, hospital-based, 3-day laboratory experiment. On each day, subjects were exposed to a brief 5-min individualized guided imagery of stress, food cue or an active neutral-relaxing control cue script, followed by a food snack test (FST), with one imagery condition per day and order of imagery exposure randomized and counterbalanced across subjects. Subjective HP food craving and caloric intake, anxiety, cortisol and total ghrelin was assessed repeatedly during each test day. RESULTS Significant condition and condition × group effects for food craving, anxiety and HP calorie intake were observed, with food cue relative to neutral condition increasing HP food craving and intake across all subjects (p < .001), but stress relative to neutral condition increased HP food craving and intake in the OW but not LN group (p < .01). Pre-snack increases in food craving after exposure to food cues and to stress predicted greater subsequent HP food intake (p's < 0.01). Furthermore, ghrelin increased in the food cue and stress conditions (p < .01), but stress-induced increases in ghrelin was associated with HP food intake only in the OW/OB condition (p < .01). Finally, cortisol increased during food cue exposure and increased cortisol responses were associated with greater HP food caving and with intake (p's < 0.05). CONCLUSIONS These findings, while preliminary, validate a laboratory model of HP food motivation and intake and identify specific subjective and neuroendocrine responses that may play a role in HP snacking with implications for weight gain and obesity risk. (342 words).",2019,"Furthermore, ghrelin increased in the food cue and stress conditions (p < .01), but stress-induced increases in ghrelin was associated with HP food intake only in the OW/OB condition (p < .01).","['Twenty individuals (12\u202fM; 8F; ages 18-45) with body mass index (BMI) in the lean (LN: N\u202f=\u202f8; 3/8 female BMI: 18-24.9) or overweight/obese (OW: N\u202f=\u202f12; 5/12 female; BMI: 25-37) range were enrolled in a controlled, hospital-based, 3-day laboratory experiment', 'healthy individuals']","['brief 5-min individualized guided imagery of stress, food cue or an active neutral-relaxing control cue script, followed by a food snack test (FST), with one imagery condition per day and order of imagery exposure randomized and counterbalanced across subjects']","['food craving', 'HP overeating', 'food cue and stress conditions', 'HP food craving and intake', 'Food craving, cortisol and ghrelin responses', 'cortisol increased during food cue exposure and increased cortisol responses', 'subsequent HP food intake', 'food craving, anxiety and HP calorie intake', 'Subjective HP food craving and caloric intake, anxiety, cortisol and total ghrelin']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0150627', 'cui_str': 'Imagery'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0542193', 'cui_str': 'Relaxed (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C3494314', 'cui_str': 'Snacking'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}]","[{'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0541847', 'cui_str': 'Cortisol increased'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.027216,"Furthermore, ghrelin increased in the food cue and stress conditions (p < .01), but stress-induced increases in ghrelin was associated with HP food intake only in the OW/OB condition (p < .01).","[{'ForeName': 'Rajita', 'Initials': 'R', 'LastName': 'Sinha', 'Affiliation': 'Yale University School of Medicine, Department of Psychiatry, New Haven, CT 06159, United States of America. Electronic address: Rajita.Sinha@yale.edu.'}, {'ForeName': 'Peihua', 'Initials': 'P', 'LastName': 'Gu', 'Affiliation': 'Yale University, Yale Center for Analytic Sciences, New Haven, CT 06159, United States of America.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hart', 'Affiliation': 'Yale University School of Medicine, Department of Psychiatry, New Haven, CT 06159, United States of America.'}, {'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Guarnaccia', 'Affiliation': 'Yale University School of Medicine, Department of Neurology, New Haven, CT 06519, United States of America.'}]",Physiology & behavior,['10.1016/j.physbeh.2019.112563'] 531,31272326,Intensive Blood Pressure Reduction and Perihematomal Edema Expansion in Deep Intracerebral Hemorrhage.,"Background and Purpose- It is unknown whether blood pressure (BP) reduction influences secondary brain injury in spontaneous intracerebral hemorrhage (ICH). We tested the hypothesis that intensive BP reduction is associated with decreased perihematomal edema expansion rate (PHER) in deep ICH. Methods- We performed an exploratory analysis of the ATACH-2 randomized trial (Antihypertensive Treatment of Acute Cerebral Hemorrhage-2). Patients with deep, supratentorial ICH were included. PHER was calculated as the difference in perihematomal edema volume between baseline and 24-hour computed tomography scans divided by hours between scans. We used regression analyses to determine whether intensive BP reduction was associated with PHER and if PHER was associated with poor outcome (3-month modified Rankin Scale score 4-6). We then used interaction analyses to test whether specific deep location (basal ganglia versus thalamus) modified these associations. Results- Among 1000 patients enrolled in ATACH-2, 870 (87%) had supratentorial, deep ICH. Of these, 780 (90%) had neuroimaging data (336 thalamic and 444 basal ganglia hemorrhages). Baseline characteristics of the treatment groups remained balanced (P>0.2). Intensive BP reduction was associated with a decrease in PHER in univariable (β= -0.15; 95% CI, -0.26 to -0.05; P=0.007) and multivariable (β=-0.12; 95% CI, -0.21 to -0.02; P=0.03) analyses. PHER was not independently associated with outcome in all deep ICH (odds ratio, 1.14; 95% CI, 0.93-1.41; P=0.20), but this association was modified by the specific deep location involved (multivariable interaction P=0.02); in adjusted analyses, PHER was associated with poor outcome in basal ganglia (odds ratio, 1.42; 1.05-1.97; P=0.03) but not thalamic (odds ratio, 1.02; 95% CI, 0.74-1.40; P=0.89) ICH. Conclusions- Intensive BP reduction was associated with decreased 24-hour PHER in deep ICH. PHER was not independently associated with outcome in all deep ICH but was associated with poor outcome in basal ganglia ICH. PHER may be a clinically relevant end point for clinical trials in basal ganglia ICH.",2019,"PHER was not independently associated with outcome in all deep ICH (odds ratio, 1.14; 95% CI, 0.93-1.41; P=0.20), but this association was modified by the specific deep location involved (multivariable interaction P=0.02); in adjusted analyses, PHER was associated with poor outcome in basal ganglia (odds ratio, 1.42; 1.05-1.97; P=0.03) but not thalamic (odds ratio, 1.02; 95% CI, 0.74-1.40; P=0.89) ICH.","['Deep Intracerebral Hemorrhage', 'spontaneous intracerebral hemorrhage (ICH', '780 (90%) had neuroimaging data (336 thalamic and 444 basal ganglia hemorrhages', 'Acute Cerebral Hemorrhage-2', '1000 patients enrolled in ATACH-2, 870 (87%) had supratentorial, deep ICH', 'Patients with deep, supratentorial ICH were included']","[' and Purpose', 'Methods', 'blood pressure (BP) reduction']","['intensive BP reduction', 'Conclusions- Intensive BP reduction', 'Intensive BP reduction', 'perihematomal edema expansion rate (PHER', 'PHER', 'basal ganglia ICH', 'perihematomal edema volume', '24-hour PHER']","[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0679575', 'cui_str': 'Neuroimaging'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441938', 'cui_str': 'Supratentorial (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1285529', 'cui_str': 'Purpose (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}]",1000.0,0.12252,"PHER was not independently associated with outcome in all deep ICH (odds ratio, 1.14; 95% CI, 0.93-1.41; P=0.20), but this association was modified by the specific deep location involved (multivariable interaction P=0.02); in adjusted analyses, PHER was associated with poor outcome in basal ganglia (odds ratio, 1.42; 1.05-1.97; P=0.03) but not thalamic (odds ratio, 1.02; 95% CI, 0.74-1.40; P=0.89) ICH.","[{'ForeName': 'Audrey C', 'Initials': 'AC', 'LastName': 'Leasure', 'Affiliation': 'From the Department of Neurology (A.C.L., L.H.S., G.J.F., K.N.S.), Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St. Cloud, MN (A.I.Q.).'}, {'ForeName': 'Santosh B', 'Initials': 'SB', 'LastName': 'Murthy', 'Affiliation': 'Department of Neurology, Weill Cornell Medical College, New York, NY (S.B.M. H.K.).'}, {'ForeName': 'Hooman', 'Initials': 'H', 'LastName': 'Kamel', 'Affiliation': 'Department of Neurology, Weill Cornell Medical College, New York, NY (S.B.M. H.K.).'}, {'ForeName': 'Joshua N', 'Initials': 'JN', 'LastName': 'Goldstein', 'Affiliation': 'Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (J.N.G.).'}, {'ForeName': 'Kyle B', 'Initials': 'KB', 'LastName': 'Walsh', 'Affiliation': 'Department of Emergency Medicine (K.B.W.), University of Cincinnati, OH.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Woo', 'Affiliation': 'Department of Neurology and Rehabilitation Medicine (D.W.), University of Cincinnati, OH.'}, {'ForeName': 'Fu-Dong', 'Initials': 'FD', 'LastName': 'Shi', 'Affiliation': 'Department of Neurology, Barrow Neurological Institute, Phoenix, AZ (F.-D.S.).'}, {'ForeName': 'Hagen B', 'Initials': 'HB', 'LastName': 'Huttner', 'Affiliation': 'Department of Neurology, University of Erlangen-Nuremberg, Germany (H.B.S.).'}, {'ForeName': 'Wendy C', 'Initials': 'WC', 'LastName': 'Ziai', 'Affiliation': 'Department of Neurology, Johns Hopkins University, Baltimore, MD (W.C.Z., D.F.H.).'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Hanley', 'Affiliation': 'Department of Neurology, Johns Hopkins University, Baltimore, MD (W.C.Z., D.F.H.).'}, {'ForeName': 'Charles C', 'Initials': 'CC', 'LastName': 'Matouk', 'Affiliation': 'Department of Neurosurgery (C.C.M.), Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Lauren H', 'Initials': 'LH', 'LastName': 'Sansing', 'Affiliation': 'From the Department of Neurology (A.C.L., L.H.S., G.J.F., K.N.S.), Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Guido J', 'Initials': 'GJ', 'LastName': 'Falcone', 'Affiliation': 'From the Department of Neurology (A.C.L., L.H.S., G.J.F., K.N.S.), Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Kevin N', 'Initials': 'KN', 'LastName': 'Sheth', 'Affiliation': 'From the Department of Neurology (A.C.L., L.H.S., G.J.F., K.N.S.), Yale School of Medicine, New Haven, CT.'}]",Stroke,['10.1161/STROKEAHA.119.024838'] 532,31279073,"Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.","Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. At week 52 participants in the boosted PI arm were offered switch to D/C/F/TAF (late-switch, 44 weeks D/C/F/TAF exposure). All participants were followed on D/C/F/TAF until week 96. Efficacy endpoints were percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL < 50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis). Of 1141 randomized patients, 1080 continued in the extension phase. Few patients had PDVR (D/C/F/TAF: 3.1%, 24/763 cumulative through week 96; late-switch: 2.3%, 8/352 week 52-96). Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch). VF was 1.2% and 1.7%, respectively. No darunavir, primary PI, tenofovir or emtricitabine resistance-associated mutations were observed post-baseline. No patients discontinued for efficacy-related reasons. Few discontinued due to adverse events (2% D/C/F/TAF arm). Improved renal and bone parameters were maintained in the D/C/F/TAF arm and observed in the late-switch arm, with small increases in total cholesterol/high-density-lipoprotein-cholesterol ratio. A study limitation was the lack of a control arm in the week 96 analysis. Through 96 weeks, D/C/F/TAF resulted in low PDVR rates, high virologic suppression rates, very few VFs, and no resistance development. Late-switch results were consistent with D/C/F/TAF week 48 results. EMERALD week 96 results confirm the efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF.",2019,Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch).,"['adults living with HIV-1', '1141 randomized patients, 1080 continued in the extension phase']","['tenofovir or emtricitabine', 'Darunavir/cobicistat/emtricitabine/tenofovir alafenamide', 'darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF', 'switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate', 'TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF']","['percentage cumulative protocol-defined virologic rebound (PDVR; confirmed viral load [VL] ≥50 copies/mL) and VL\u202f<\u202f50 copies/mL (virologic suppression) and ≥50 copies/mL (VF) (FDA-snapshot analysis', 'virologic suppression', 'low PDVR rates, high virologic suppression rates', 'total cholesterol/high-density-lipoprotein-cholesterol ratio', 'Improved renal and bone parameters', 'efficacy, high genetic barrier to resistance and safety benefits of D/C/F/TAF']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]","[{'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}, {'cui': 'C4059167', 'cui_str': 'emtricitabine / tenofovir alafenamide'}, {'cui': 'C1268897', 'cui_str': 'Product containing protease inhibitor'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2929052', 'cui_str': 'emtricitabine / tenofovir disoproxil'}, {'cui': 'C0220833', 'cui_str': 'fumarate'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",1141.0,0.0712341,Week 96 virologic suppression was 90.7% (692/763) (D/C/F/TAF) and 93.8% (330/352) (late-switch).,"[{'ForeName': 'Joseph J', 'Initials': 'JJ', 'LastName': 'Eron', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: jeron@med.unc.edu.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Orkin', 'Affiliation': 'Queen Mary University, London, UK.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Pueblo Family Physicians, Phoenix, AZ, USA.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Pulido', 'Affiliation': 'HIV Unit, Hospital 12 de Octubre, imas12, UCM, Madrid, Spain.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Post', 'Affiliation': ""King's College Hospital NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'De Wit', 'Affiliation': 'Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.'}, {'ForeName': 'Erkki', 'Initials': 'E', 'LastName': 'Lathouwers', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Veerle', 'Initials': 'V', 'LastName': 'Hufkens', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jezorwski', 'Affiliation': 'Janssen Research & Development, Pennington, NJ, USA.'}, {'ForeName': 'Romana', 'Initials': 'R', 'LastName': 'Petrovic', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Van Landuyt', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Opsomer', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Antiviral research,['10.1016/j.antiviral.2019.104543'] 533,31332099,Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer.,"LESSONS LEARNED This clinical trial, evaluating the efficacy and safety of a carboplatin plus paclitaxel regimen in a biweekly or weekly schedule instead of the more toxic 3-weekly administration, showed that the weekly regimen was better in efficacy than the biweekly regimen, with mild toxicities, for patients with non-small cell lung cancer (NSCLC).The weekly carboplatin plus paclitaxel regimen could be considered as an alternative to the 3-weekly regimen in Japanese patients with NSCLC. BACKGROUND Combination therapy comprising carboplatin (C) and paclitaxel (P) is the most commonly used regimen for the treatment of advanced non-small cell lung cancer (NSCLC). Common toxicities associated with the regimen, such as neuropathy and myelosuppression, cause its discontinuation. In the present study, we conducted a clinical trial evaluating the efficacy of biweekly (B) and weekly (W) PC therapy to identify the appropriate chemotherapy schedule for Asian patients. METHODS Chemonaive patients with IIIB/IV NSCLC and a performance status of 0-1 were randomly assigned to a biweekly regimen (paclitaxel 135 mg/m 2 with carboplatin area under the curve [AUC] 3 on days 1 and 15 of every 4 weeks) or to a weekly regimen (paclitaxel 90 mg/m 2 on days 1, 8, and 15 with carboplatin AUC 6 on day 1 of every 4 weeks). RESULTS A total of 140 patients were enrolled in the study. The objective response rates (ORRs) were 28.1% (B) and 38.0% (W). The most common toxicity was neutropenia, with incidence rates of 62.0% (B) and 57.8% (W). Progression-free survivals (PFSs) were 4.3 months (B) and 5.1 months (W), and overall survival durations were 14.2 months (B) and 13.3 months (W). CONCLUSION The ORR and PFS in the weekly regimen were better than those in the biweekly schedule, although a statistical difference was not observed. The toxicity profile was generally mild for both regimens. The weekly CP regimen was suitable to be considered as an alternative to the current 3-weekly regimen in NSCLC treatment.",2019,"The most common toxicity was neutropenia, with incidence rates of 62.0% (B) and 57.8% (W).","['Asian patients', 'patients with non-small cell lung cancer ', 'A total of 140 patients were enrolled in the study', 'Japanese patients with NSCLC', 'Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer', 'Chemonaive patients with IIIB/IV NSCLC and a performance status of 0-1', 'advanced non-small cell lung cancer (NSCLC']","['biweekly (B) and weekly (W) PC therapy', 'Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin', 'carboplatin (C) and paclitaxel (P', 'biweekly regimen (paclitaxel 135 mg/m 2 with carboplatin area under the curve [AUC] 3 on days 1 and 15 of every 4 weeks) or to a weekly regimen (paclitaxel 90 mg/m 2 on days 1, 8, and 15 with carboplatin AUC', 'carboplatin plus paclitaxel', 'NSCLC).The weekly carboplatin plus paclitaxel regimen']","['Progression-free survivals (PFSs', 'ORR and PFS', 'efficacy and safety', 'overall survival durations', 'objective response rates (ORRs', 'toxicity profile']","[{'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]","[{'cui': 'C0585332', 'cui_str': 'Biweekly (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1275555', 'cui_str': 'q4wk'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",140.0,0.0307371,"The most common toxicity was neutropenia, with incidence rates of 62.0% (B) and 57.8% (W).","[{'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Takayama', 'Affiliation': 'Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Ichiki', 'Affiliation': 'Kyushu Medical Center, Fukuoka, Japan.'}, {'ForeName': 'Shoji', 'Initials': 'S', 'LastName': 'Tokunaga', 'Affiliation': 'Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': 'Kitakyushu Municipal Medical Center, Kitakyushu, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Kawasaki', 'Affiliation': 'Fukuoka-Higashi Medical Center, Koga, Japan.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Uchino', 'Affiliation': 'Kyoto Prefectural University of Medicine, Kyoto, Japan uchino@koto.kpu-m.ac.jp.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Nakanishi', 'Affiliation': 'Kyushu University, Fukuoka, Japan.'}]",The oncologist,['10.1634/theoncologist.2019-0513'] 534,31339827,Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.,"PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years. Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine. We now update results at a median follow-up of 11.4 years. PATIENTS AND METHODS Patients age 65 years or older with early breast cancer were randomly assigned to either standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine. An adaptive Bayesian design was used to determine sample size and test noninferiority of capecitabine. The primary end point was RFS. RESULTS The design stopped accrual with 633 patients at its first sample size assessment. RFS remains significantly longer for patients treated with standard chemotherapy. At 10 years, in patients treated with standard chemotherapy versus capecitabine, the RFS rates were 56% and 50%, respectively (hazard ratio [HR], 0.80; P = .03); breast cancer-specific survival rates were 88% and 82%, respectively (HR, 0.62; P = .03); and overall survival rates were 62% and 56%, respectively (HR, 0.84; P = .16). With longer follow-up, standard chemotherapy remains superior to capecitabine among hormone receptor-negative patients (HR, 0.66; P = .02), but not among hormone receptor-positive patients (HR, 0.89; P = .43). Overall, 43.9% of patients have died (13.1% from breast cancer, 16.4% from causes other than breast cancer, and 14.1% from unknown causes). Second nonbreast cancers occurred in 14.1% of patients. CONCLUSION With longer follow-up, RFS remains superior for standard adjuvant chemotherapy versus capecitabine, especially in patients with hormone receptor-negative disease. Competing risks in this older population dilute overall survival benefits.",2019,Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine.,"['Older women with breast cancer remain under-represented in clinical trials', 'Older Women With Early Breast Cancer', 'patients with hormone receptor-negative disease', 'women age 65 years and older', '633 patients at its first sample size assessment', 'Patients age 65 years or older with early breast cancer']","['capecitabine', 'standard chemotherapy', 'Standard Adjuvant Chemotherapy Regimens Versus Capecitabine', ""standard adjuvant chemotherapy (physician's choice of either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide and doxorubicin) or capecitabine"", 'standard chemotherapy versus capecitabine']","['overall survival rates', 'RFS', 'recurrence-free survival (RFS) and overall survival', 'died', 'RFS rates', 'breast cancer-specific survival rates']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0205369', 'cui_str': 'Specified'}]",633.0,0.250812,Standard adjuvant chemotherapy showed significant improvements in recurrence-free survival (RFS) and overall survival compared with capecitabine.,"[{'ForeName': 'Hyman B', 'Initials': 'HB', 'LastName': 'Muss', 'Affiliation': 'University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.'}, {'ForeName': 'Mei-Yin C', 'Initials': 'MC', 'LastName': 'Polley', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Berry', 'Affiliation': 'Alliance Statistics and Data Center, The University of Texas MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Heshan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Constance T', 'Initials': 'CT', 'LastName': 'Cirrincione', 'Affiliation': 'Robert H Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Theodoulou', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Mauer', 'Affiliation': 'Advocate Illinois Masonic Medical Center, Chicago, IL.'}, {'ForeName': 'Alice B', 'Initials': 'AB', 'LastName': 'Kornblith', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Ann H', 'Initials': 'AH', 'LastName': 'Partridge', 'Affiliation': 'Advocate Illinois Masonic Medical Center, Chicago, IL.'}, {'ForeName': 'Lynn G', 'Initials': 'LG', 'LastName': 'Dressler', 'Affiliation': 'University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.'}, {'ForeName': 'Harvey J', 'Initials': 'HJ', 'LastName': 'Cohen', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, NC.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Kartcheske', 'Affiliation': 'Robert H Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL.'}, {'ForeName': 'Edith A', 'Initials': 'EA', 'LastName': 'Perez', 'Affiliation': 'Mayo Clinic, Jacksonville, FL.'}, {'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Wolff', 'Affiliation': 'Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Julie R', 'Initials': 'JR', 'LastName': 'Gralow', 'Affiliation': 'University of Washington Seattle Cancer Alliance, Seattle, WA.'}, {'ForeName': 'Harold J', 'Initials': 'HJ', 'LastName': 'Burstein', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Ahmad A', 'Initials': 'AA', 'LastName': 'Mahmood', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, NC.'}, {'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Sutton', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, NC.'}, {'ForeName': 'Gustav', 'Initials': 'G', 'LastName': 'Magrinat', 'Affiliation': 'Cone Health Cancer Center, Greensboro, NC.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Parker', 'Affiliation': 'Moores Cancer Center, University of California San Diego, La Jolla, CA.'}, {'ForeName': 'Ronald D', 'Initials': 'RD', 'LastName': 'Hart', 'Affiliation': 'Harold Alfond Center for Cancer Care, Augusta, ME.'}, {'ForeName': 'Debjani', 'Initials': 'D', 'LastName': 'Grenier', 'Affiliation': 'St Boniface General Hospital, Winnipeg, Manitoba, Canada.'}, {'ForeName': 'Arti', 'Initials': 'A', 'LastName': 'Hurria', 'Affiliation': 'City of Hope Comprehensive Cancer Center, Duarte, CA.'}, {'ForeName': 'Aminah', 'Initials': 'A', 'LastName': 'Jatoi', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Larry', 'Initials': 'L', 'LastName': 'Norton', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Clifford A', 'Initials': 'CA', 'LastName': 'Hudis', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Eric P', 'Initials': 'EP', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Carey', 'Affiliation': 'University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.00647'] 535,30460454,The Biomechanics of Competitive Male Runners in Three Marathon Racing Shoes: A Randomized Crossover Study.,"BACKGROUND We have shown that a prototype marathon racing shoe reduced the metabolic cost of running for all 18 participants in our sample by an average of 4%, compared to two well-established racing shoes. Gross measures of biomechanics showed minor differences and could not explain the metabolic savings. OBJECTIVE To explain the metabolic savings by comparing the mechanics of the shoes, leg, and foot joints during the stance phase of running. METHODS Ten male competitive runners, who habitually rearfoot strike ran three 5-min trials in prototype shoes (NP) and two established marathon shoes, the Nike Zoom Streak 6 (NS) and the adidas adizero Adios BOOST 2 (AB), at 16 km/h. We measured ground reaction forces and 3D kinematics of the lower limbs. RESULTS Hip and knee joint mechanics were similar between the shoes, but peak ankle extensor moment was smaller in NP versus AB shoes. Negative and positive work rates at the ankle were lower in NP shoes versus the other shoes. Dorsiflexion and negative work at the metatarsophalangeal (MTP) joint were reduced in the NP shoes versus the other shoes. Substantial mechanical energy was stored/returned in compressing the NP midsole foam, but not in bending the carbon-fiber plate. CONCLUSION The metabolic savings of the NP shoes appear to be due to: (1) superior energy storage in the midsole foam, (2) the clever lever effects of the carbon-fiber plate on the ankle joint mechanics, and (3) the stiffening effects of the plate on the MTP joint.",2019,Dorsiflexion and negative work at the metatarsophalangeal (MTP) joint were reduced in the NP shoes versus the other shoes.,"['Ten male competitive runners, who habitually rearfoot strike ran three 5-min trials in prototype shoes (NP) and two established marathon shoes, the Nike Zoom Streak 6 (NS) and the adidas adizero Adios BOOST 2', 'Competitive Male Runners in Three Marathon Racing Shoes']",[],"['metabolic cost', 'peak ankle extensor moment', 'Negative and positive work rates', 'Dorsiflexion and negative work at the metatarsophalangeal (MTP) joint', 'Substantial mechanical energy', 'metabolic savings', 'Hip and knee joint mechanics', 'ground reaction forces and 3D kinematics of the lower limbs']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0038452', 'cui_str': 'Strikes'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0185506', 'cui_str': 'Shoeing'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}]",[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0025589', 'cui_str': 'Metatarsophalangeal Joint'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0022745', 'cui_str': 'Superior Tibiofibular Joint'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]",10.0,0.0313365,Dorsiflexion and negative work at the metatarsophalangeal (MTP) joint were reduced in the NP shoes versus the other shoes.,"[{'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Hoogkamer', 'Affiliation': 'Locomotion Lab, Department of Integrative Physiology, University of Colorado, Boulder, 354 UCB, Boulder, CO, 80309-0354, USA. wouter.hoogkamer@colorado.edu.'}, {'ForeName': 'Shalaya', 'Initials': 'S', 'LastName': 'Kipp', 'Affiliation': 'Locomotion Lab, Department of Integrative Physiology, University of Colorado, Boulder, 354 UCB, Boulder, CO, 80309-0354, USA.'}, {'ForeName': 'Rodger', 'Initials': 'R', 'LastName': 'Kram', 'Affiliation': 'Locomotion Lab, Department of Integrative Physiology, University of Colorado, Boulder, 354 UCB, Boulder, CO, 80309-0354, USA.'}]","Sports medicine (Auckland, N.Z.)",['10.1007/s40279-018-1024-z'] 536,32212297,The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF.,"AIMS Non-cardiac comorbidities are highly prevalent in patients with heart failure (HF). Our objective was to define the association between non-cardiac comorbidity burden and clinical outcomes, costs of care, and length of stay within a large randomized trial of acute HF patients. METHODS AND RESULTS Patients with complete medical history for the following comorbidities were included: diabetes mellitus, chronic obstructive pulmonary disease, chronic liver disease, history of cancer within the last 5 years, chronic renal disease (baseline serum creatinine >3.0 mg/mL), current smoking, alcohol abuse, depression, anaemia, peripheral arterial disease, and cerebrovascular disease. Patients were classified by overall burden of non-cardiac comorbidities (0, 1, 2, 3, and 4+). Hierarchical generalized linear models were used to assess associations between comorbidity burden and 30-day all-cause death or HF hospitalization and 180-day all-cause death in addition to costs of care and length of stay. A total of 6945 patients were included in the final analysis. Mean comorbidity number was 2.2 (± 1.34). Patients with 4+ comorbidities had higher rates of 30-day all-cause death/HF hospitalization as compared with patients with no comorbidities [odds ratio (OR) 3.32, 95% confidence interval (CI) 1.61-6.84; P < 0.01]. Similar results were seen with respect to 180-day death (OR 2.13, 95% CI 1.33-3.43; P < 0.01). Higher comorbidity burden was associated with higher 180-day costs of care and length of stay. CONCLUSIONS Higher comorbidity burden is associated with poor clinical outcomes, higher costs of care, and extended length of stay. Further studies are needed to define the impact of comorbidity management programmes on outcomes for HF patients.",2020,"Similar results were seen with respect to 180-day death (OR 2.13, 95% CI 1.33-3.43; P < 0.01).","['HF patients', 'A total of 6945 patients were included in the final analysis', 'Patients with complete medical history for the following comorbidities were included: diabetes mellitus, chronic obstructive pulmonary disease, chronic liver disease, history of cancer within the last 5\u2009years, chronic renal disease (baseline serum creatinine', 'patients with heart failure (HF', 'acute HF patients']",[],"['180-day death', 'comorbidity burden and 30-day all-cause death or HF hospitalization and 180-day all-cause death in addition to costs of care and length of stay', 'overall burden of non-cardiac comorbidities', '180-day costs of care and length of stay', 'burden of non-cardiac comorbidities', 'current smoking, alcohol abuse, depression, anaemia, peripheral arterial disease, and cerebrovascular disease', 'Mean comorbidity number', 'rates of 30-day all-cause death/HF hospitalization', 'costs of care, and length of stay', 'costs of care, and extended length of stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0341439', 'cui_str': 'Chronic liver disease (disorder)'}, {'cui': 'C0455471', 'cui_str': 'H/O: malignant neoplasm'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}]",[],"[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0085762', 'cui_str': 'Alcohol abuse (disorder)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C0007820', 'cui_str': 'Intracranial Vascular Disorders'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",6945.0,0.141703,"Similar results were seen with respect to 180-day death (OR 2.13, 95% CI 1.33-3.43; P < 0.01).","[{'ForeName': 'Ankeet S', 'Initials': 'AS', 'LastName': 'Bhatt', 'Affiliation': ""Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Ambrosy', 'Affiliation': 'Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Dunning', 'Affiliation': 'Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Adam D', 'Initials': 'AD', 'LastName': 'DeVore', 'Affiliation': 'Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Javed', 'Initials': 'J', 'LastName': 'Butler', 'Affiliation': 'Department of Medicine, University of Mississippi, Jackson, MS, USA.'}, {'ForeName': 'Shelby', 'Initials': 'S', 'LastName': 'Reed', 'Affiliation': 'Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Adriaan', 'Initials': 'A', 'LastName': 'Voors', 'Affiliation': 'University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Starling', 'Affiliation': 'Heart and Vascular Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Armstrong', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Ezekowitz', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Metra', 'Affiliation': 'Division of Cardiology, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Adrian F', 'Initials': 'AF', 'LastName': 'Hernandez', 'Affiliation': 'Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': ""O'Connor"", 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, VA, USA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}]",European journal of heart failure,['10.1002/ejhf.1795'] 537,30923036,Immunotherapy of Melanoma: Facts and Hopes.,"Melanoma is among the most sensitive of malignancies to immune modulation. Although multiple trials conducted over decades with vaccines, cytokines, and cell therapies demonstrated meaningful responses in a small subset of patients with metastatic disease, a true increase in overall survival (OS) within a randomized phase III trial was not observed until the development of anti-CTLA-4 (ipilimumab). Further improvements in OS for metastatic disease were observed with the anti-PD-1-based therapies (nivolumab, pembrolizumab) as single agents or combined with ipilimumab. A lower bound for expected 5-year survival for metastatic melanoma is currently approximately 35% and could be as high as 50% for the nivolumab/ipilimumab combination among patients who would meet criteria for clinical trials. Moreover, a substantial fraction of long-term survivors will likely remain progression-free without continued treatment. The hope and major challenge for the future is to understand the immunobiology of tumors with primary or acquired resistance to anti-PD-1 or anti-PD-1/anti-CTLA-4 and to develop effective immune therapies tailored to individual patient subsets not achieving long-term clinical benefit. Additional goals include optimal integration of immune therapy with nonimmune therapies, the development and validation of predictive biomarkers in the metastatic setting, improved prognostic and predictive biomarkers for the adjuvant setting, understanding mechanisms of and decreasing toxicity, and optimizing the duration of therapy.",2019,"Further improvements in OS for metastatic disease were observed with the anti-PD-1-based therapies (nivolumab, pembrolizumab) as single agents or combined with ipilimumab.",[],['ipilimumab'],"['5-year survival', 'overall survival (OS']",[],"[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0690909,"Further improvements in OS for metastatic disease were observed with the anti-PD-1-based therapies (nivolumab, pembrolizumab) as single agents or combined with ipilimumab.","[{'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Weiss', 'Affiliation': 'Yale University School of Medicine, New Haven, Connecticut. sarah.a.weiss@yale.edu.'}, {'ForeName': 'Jedd D', 'Initials': 'JD', 'LastName': 'Wolchok', 'Affiliation': 'Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Sznol', 'Affiliation': 'Yale University School of Medicine, New Haven, Connecticut.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-18-1550'] 538,30506427,Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial.,"BACKGROUND Physical activity has been shown to mitigate the unwanted psychological and physiological side effects of prostate cancer treatments, but sustainable exercise possibilities are limited. OBJECTIVE Our objective was to examine whether football in a real-world setting (i.e., local football clubs) was safe and feasible in practice and could improve quality of life, mitigate decline in muscle mass and bone density, and increase fat mass in patients with prostate cancer. METHODS In this pragmatic, multicentre, parallel randomized controlled trial, men diagnosed with prostate cancer were recruited from five Danish urological departments. Men (N = 214) diagnosed with prostate cancer were randomly allocated, using random generated lists (block size 4-8) stratified for center and androgen-deprivation therapy status, to either 1 h of football twice weekly in a local football club or to usual care, which was a 15- to 30-min telephone session covering their options for physical activity or free-of-charge rehabilitation delivered as standard in Denmark. Allocation was concealed from the trial investigator performing the randomization, but-given the nature of the intervention-this was not possible for personnel and participants. Assessments were performed at baseline, 12 weeks, and 6 months. The primary outcome was mean change difference in prostate cancer-specific quality of life at 12 weeks. Secondary outcomes were body composition, 12-Item Short Form Health Survey (SF-12) physical and mental health, and safety-reported as fractures, falls, and serious adverse events. RESULTS Attrition was 1 and 3% at 12 weeks, and 5% and 5% at 6 months for the usual care and football groups, respectively. Prostate cancer-specific quality of life was equal between groups at 12 weeks (mean difference + 1.9 points, 95% confidence interval [CI] -1.0-4.8; P = 0.20) and at 6 months (+ 0.5 points, 95% CI -2.8-3.8; P = 0.76). Fractures were equally distributed, with two fractures in the usual care group and one in the football group. Likewise, body composition outcomes were equal. Mental health improved after 6 months of football (mean difference + 2.7 points, 95% CI 0.8-4.6; P = 0.006). CONCLUSIONS In this trial, community-based football was a feasible exercise strategy for men with prostate cancer. Football did not improve prostate cancer-specific quality of life but did improve mental health; the clinical significance of this is unclear. TRIAL REGISTRATION ClinicalTrials.gov: NCT02430792.",2019,"Prostate cancer-specific quality of life was equal between groups at 12 weeks (mean difference + 1.9 points, 95% confidence interval [CI] -1.0-4.8; P = 0.20) and at 6 months (+ 0.5 points, 95% CI -2.8-3.8; P = 0.76).","['men diagnosed with prostate cancer were recruited from five Danish urological departments', 'men with prostate cancer', 'Men with Prostate Cancer (FC Prostate Community Trial', 'patients with prostate cancer', 'Men (N\u2009=\u2009214) diagnosed with prostate cancer']","['random generated lists (block size 4-8) stratified for center and androgen-deprivation therapy status, to either 1\xa0h of football twice weekly in a local football club or to usual care, which was a 15- to 30-min telephone session covering their options for physical activity or free-of-charge rehabilitation delivered as standard in Denmark', 'Usual Care']","['Mental health', 'Prostate cancer-specific quality of life', 'mental health', 'mean change difference in prostate cancer-specific quality of life', 'body composition, 12-Item Short Form Health Survey (SF-12) physical and mental health, and safety-reported as fractures, falls, and serious adverse events', 'prostate cancer-specific quality of life']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C3653764', 'cui_str': 'UROLOGICALS'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C0336986', 'cui_str': 'Football'}, {'cui': 'C0556985', 'cui_str': 'Two times a week'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0439844', 'cui_str': 'Covered (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332296', 'cui_str': 'Free of (attribute)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0034380'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.223399,"Prostate cancer-specific quality of life was equal between groups at 12 weeks (mean difference + 1.9 points, 95% confidence interval [CI] -1.0-4.8; P = 0.20) and at 6 months (+ 0.5 points, 95% CI -2.8-3.8; P = 0.76).","[{'ForeName': 'Eik Dybboe', 'Initials': 'ED', 'LastName': 'Bjerre', 'Affiliation': ""The University Hospitals' Centre for Health Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark. eb@ucsf.dk.""}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Brasso', 'Affiliation': 'Department of Urology, Rigshospitalet, Copenhagen Prostate Cancer Center, University of Copenhagen, 2100, Copenhagen Ø, Denmark.'}, {'ForeName': 'Anders Bojer', 'Initials': 'AB', 'LastName': 'Jørgensen', 'Affiliation': ""The University Hospitals' Centre for Health Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark.""}, {'ForeName': 'Thomas Hindborg', 'Initials': 'TH', 'LastName': 'Petersen', 'Affiliation': ""The University Hospitals' Centre for Health Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark.""}, {'ForeName': 'Alexandra Röthlin', 'Initials': 'AR', 'LastName': 'Eriksen', 'Affiliation': ""The University Hospitals' Centre for Health Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark.""}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Tolver', 'Affiliation': 'Data Science Laboratory, Department of Mathematical Sciences, University of Copenhagen, 2100, Copenhagen Ø, Denmark.'}, {'ForeName': 'Jesper Frank', 'Initials': 'JF', 'LastName': 'Christensen', 'Affiliation': 'Centre of Inflammation and Metabolism/Centre for Physical Activity Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark.'}, {'ForeName': 'Mads Hvid', 'Initials': 'MH', 'LastName': 'Poulsen', 'Affiliation': 'Department of Urology, Odense University Hospital, 5000, Odense C, Denmark.'}, {'ForeName': 'Søren Sørensen', 'Initials': 'SS', 'LastName': 'Madsen', 'Affiliation': 'Department of Urology, Hospital of Southwest Denmark Esbjerg, 6700, Esbjerg, Denmark.'}, {'ForeName': 'Peter Busch', 'Initials': 'PB', 'LastName': 'Østergren', 'Affiliation': 'Department of Urology, Herlev and Gentofte University Hospital, 2730, Herlev, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Borre', 'Affiliation': 'Department of Urology, Aarhus University Hospital, 8200, Aarhus N, Denmark.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Krustrup', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, 5230, Odense M, Denmark.'}, {'ForeName': 'Christoffer', 'Initials': 'C', 'LastName': 'Johansen', 'Affiliation': 'Unit of Survivorship, Danish Cancer Society Research Center, 2100, Copenhagen Ø, Denmark.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Rørth', 'Affiliation': 'Department of Oncology, Rigshospitalet, University of Copenhagen, 2100, Copenhagen Ø, Denmark.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Midtgaard', 'Affiliation': ""The University Hospitals' Centre for Health Research, Rigshospitalet, 2100, Copenhagen Ø, Denmark.""}]","Sports medicine (Auckland, N.Z.)",['10.1007/s40279-018-1031-0'] 539,32207048,"Effect of the ""Recruitment"" Maneuver on Respiratory Mechanics in Laparoscopic Sleeve Gastrectomy Surgery.","PURPOSE LSG surgery is used for surgical treatment of morbid obesity. Obesity, anesthesia, and pneumoperitoneum cause reduced pulmoner functions and a tendency for atelectasis. The alveolar ""recruitment"" maneuver (RM) keeps airway pressure high, opening alveoli, and increasing arterial oxygenation. The aim of our study is to research the effect on respiratory mechanics and arterial blood gases of performing the RM in LSG surgery. MATERIALS AND METHODS Sixty patients undergoing LSG surgery were divided into two groups (n = 30) Patients in group R had the RM performed 5 min after desufflation with 100% oxygen, 40 cmH 2 O pressure for 40 s. Group C had standard mechanical ventilation. Assessments of respiratory mechanics and arterial blood gases were made in the 10th min after induction (T1), 10th min after insufflation (T2), 5th min after desufflation (T3), and 15th min after desufflation (T4). Arterial blood gases were assessed in the 30th min (T5) in the postoperative recovery unit. RESULTS In group R, values at T5, PaO 2 were significantly high, while PaCO 2 were significantly low compared with group C. Compliance in both groups reduced with pneumoperitoneum. At T4, the compliance in the recruitment group was higher. In both groups, there was an increase in PIP with pneumoperitoneum and after desufflation this was identified to reduce to levels before pneumoperitoneum. CONCLUSION Adding the RM to PEEP administration for morbidly obese patients undergoing LSG surgery is considered to be effective in improving respiratory mechanics and arterial blood gas values and can be used safely.",2020,"In group R, values at T5, PaO 2 were significantly high, while PaCO 2 were significantly low compared with group C. Compliance in both groups reduced with pneumoperitoneum.","['morbidly obese patients undergoing LSG surgery', 'Laparoscopic Sleeve Gastrectomy Surgery', 'Sixty patients undergoing LSG surgery']","['RM performed 5\xa0min after desufflation with 100% oxygen, 40\xa0cmH 2 O pressure for 40\xa0s. Group C had standard mechanical ventilation', 'Recruitment"" Maneuver']","['Arterial blood gases', 'respiratory mechanics and arterial blood gases', 'PIP with pneumoperitoneum', 'Respiratory Mechanics', 'respiratory mechanics and arterial blood gas values']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}]","[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0441837', 'cui_str': 'Group C (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}]","[{'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",60.0,0.0255194,"In group R, values at T5, PaO 2 were significantly high, while PaCO 2 were significantly low compared with group C. Compliance in both groups reduced with pneumoperitoneum.","[{'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Sümer', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey. isumer@bezmialem.edu.tr.'}, {'ForeName': 'Ufuk', 'Initials': 'U', 'LastName': 'Topuz', 'Affiliation': 'Health Cares Vocational School, İstanbul Esenyurt University, Istanbul, Turkey.'}, {'ForeName': 'Selçuk', 'Initials': 'S', 'LastName': 'Alver', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, İstanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Tarik', 'Initials': 'T', 'LastName': 'Umutoglu', 'Affiliation': 'İstanbul Acıbadem Taksim Hospital, Istanbul, Turkey.'}, {'ForeName': 'Mefkur', 'Initials': 'M', 'LastName': 'Bakan', 'Affiliation': 'Health Cares Vocational School, İstanbul Esenyurt University, Istanbul, Turkey.'}, {'ForeName': 'Seniyye Ülgen', 'Initials': 'SÜ', 'LastName': 'Zengin', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Marmara University, Istanbul, Turkey.'}, {'ForeName': 'Halil', 'Initials': 'H', 'LastName': 'Coşkun', 'Affiliation': 'Department of General Surgery, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.'}, {'ForeName': 'Ziya', 'Initials': 'Z', 'LastName': 'Salihoglu', 'Affiliation': 'Department of Anesthesiology and Reanimation, Cerrahpasa Faculty of Medicine, İstanbul University Cerrahpasa, Istanbul, Turkey.'}]",Obesity surgery,['10.1007/s11695-020-04551-y'] 540,30841946,Effects of intrauterine growth restriction and postnatal nutrition on pediatric asthma in Bangladesh.,"Numerous studies have investigated the risk of developing asthma due to early-life experiences and environmental exposures. However, the influence of intrauterine growth restriction and postnatal undernutrition on childhood wheezing/asthma remains unclear. Thus, we examined the effects of both small for gestational age (SGA) and postnatal stunted growth on ever asthma among children in the rural areas in Bangladesh.Multiple follow-up studies were conducted in a cohort of randomized clinical trial of nutrition interventions during pregnancy (the MINIMat trial). Overall, 1208 and 1697 children were followed-up for asthma at 4.5 and 10 years, respectively. Anthropometric measurements were obtained at various intervals from birth to 10 years of age. Ever asthma was identified using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire.Results showed that SGA was significantly associated with increased risk of ever asthma at 4.5 and 10 years after adjusting for sex, body mass index, socioeconomic status, family history of asthma, gestational age at birth, mother's parity, mother's age at birth and intervention trial arm [odds ratio (OR)=1.97 (95% confidence interval (CI): 1.34-2.90) and 1.86 (95% CI: 1.18-2.72)]. For the postnatal effect of undernutrition, stunting at 1 and 2 years was significantly associated with ever asthma at 4.5 and 10 years [1 year: OR=1.77 (95% CI: 1.22-2.57) and OR=1.72 (95% CI: 1.16-2.56), 2 years: OR=1.49 (95% CI: 1.06-2.10) and OR=1.41 (95% CI: 1.02-1.96)].In conclusion, SGA and undernutrition during infancy has an influence on childhood asthma among children in Bangladesh, indicating the need for nutritional interventions early in life.",2019,"Results showed that SGA was significantly associated with increased risk of ever asthma at 4.5 and 10 years after adjusting for sex, body mass index, socioeconomic status, family history of asthma, gestational age at birth, mother's parity, mother's age at birth and intervention trial arm [odds ratio (OR)=1.97 (95% confidence interval (CI): 1.34-2.90) and 1.86 (95% CI: 1.18-2.72)].","['1208 and 1697 children were followed-up for asthma at 4.5 and 10 years, respectively', 'children in the rural areas in Bangladesh', 'pediatric asthma in Bangladesh']","['intrauterine growth restriction and postnatal nutrition', 'nutrition interventions', 'SGA']","['risk of ever asthma', 'Anthropometric measurements']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]","[{'cui': 'C0015934', 'cui_str': 'Intrauterine Growth Restriction'}, {'cui': 'C0443281', 'cui_str': 'Postnatal (qualifier value)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}]",1697.0,0.0532341,"Results showed that SGA was significantly associated with increased risk of ever asthma at 4.5 and 10 years after adjusting for sex, body mass index, socioeconomic status, family history of asthma, gestational age at birth, mother's parity, mother's age at birth and intervention trial arm [odds ratio (OR)=1.97 (95% confidence interval (CI): 1.34-2.90) and 1.86 (95% CI: 1.18-2.72)].","[{'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Nozawa', 'Affiliation': 'Department of Clinical Trial and Clinical Epidemiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.'}, {'ForeName': 'M D H', 'Initials': 'MDH', 'LastName': 'Hawlader', 'Affiliation': 'Department of Public Health, School of Health and Life Sciences, North South University, Dhaka, Bangladesh.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ferdous', 'Affiliation': 'Department of Clinical Trial and Clinical Epidemiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Raqib', 'Affiliation': 'International Centre for Diarrhoeal Disease Research (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Tofail', 'Affiliation': 'International Centre for Diarrhoeal Disease Research (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'E-C', 'Initials': 'EC', 'LastName': 'Ekström', 'Affiliation': ""Department of Women's and Children's Health, International Maternal and Child Health Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Wagatsuma', 'Affiliation': 'Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.'}]",Journal of developmental origins of health and disease,['10.1017/S2040174419000096'] 541,32206812,Collaborative Home-Visit Program for Young Children With Motor Delays in Rural Taiwan: A Pilot Randomized Controlled Trial.,"BACKGROUND Caregiver engagement and collaborative team early childhood intervention (ECI) services are international trends; however, relevant evidence of collaborative home-visiting ECI in rural areas is as yet undetermined. OBJECTIVE The study aimed to investigate the effectiveness of a collaborative ECI program in a rural area of Taiwan. DESIGN The study was a pilot randomized control led trial. METHODS Children aged 6 to 33 months experiencing motor delays and their caregivers were enrolled in Taitung, Taiwan. Using stratified randomization, 24 participants were allocated to either experimental or control groups, and both received 5 home visits within 3 months. The experimental group received ECI services based on the International Classification of Functioning, Disability and Health framework and family-centered approaches. The control group received regular home visits by local social workers. Child outcomes included Pediatric Evaluation of Disability Inventory Chinese Version and Peabody Developmental Motor Scale, 2nd edition. Family outcomes included the Disability-Adapted Infant-Toddler version of Home Observation for Measurement, and Chinese versions of the Knowledge of Infant Development Inventory and Parental Stress Index-Short Form. A tester blinded to the study conducted assessments at baseline, postintervention, and 3-month follow-up. Two-way mixed analysis of variance was used with α = .05 (2-tailed). RESULTS The experimental group improved scores on the Disability-Adapted Infant-Toddler version of Home Observation for Measurement significantly more than the control group with an effect size of 0.64 at follow-up. In other outcomes, both groups showed no significant differences. The follow-up rate was 69%, and adherence to the ECI program was acceptable. LIMITATIONS A limitation of the study was the heterogeneity of the sample. CONCLUSIONS This pilot study revealed possible effectiveness in implementing collaborative ECI programs based on family-centered approaches and the International Classification of Functioning, Disability and Health in rural areas. Larger field studies are needed to confirm our findings.",2020,The experimental group improved scores on the DA-IT-HOME significantly more than the control group with ESf of 0.64 at follow-up.,"['Children aged 6 to 33 months experiencing motor delays and their caregivers were enrolled in Taitung, Taiwan', 'rural area of Taiwan', 'rural areas', 'Young Children With Motor Delays in Rural Taiwan']","['regular home visits by local social workers', 'collaborative ECI program', 'Collaborative Home-Visit Program', 'ECI services based on the International Classification of Functioning, Disability and Health (ICF) framework and family-centered approaches', 'Caregiver engagement and collaborative team early childhood intervention']","['Pediatric Evaluation of Disability Inventory Chinese Version and Peabody Developmental Motor Scale, 2nd Edition', 'Disability-Adapted Infant-Toddler version of Home Observation for Measurement', 'scores on the DA-IT-HOME']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0520947', 'cui_str': 'Clumsy child (finding)'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}]","[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0020043', 'cui_str': 'Home Visits'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0037444', 'cui_str': 'Social worker (occupation)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2370861', 'cui_str': 'International Classification of Functioning, Disability and Health'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0458003', 'cui_str': 'Developmental (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",24.0,0.0651495,The experimental group improved scores on the DA-IT-HOME significantly more than the control group with ESf of 0.64 at follow-up.,"[{'ForeName': 'Yu-Hsin', 'Initials': 'YH', 'LastName': 'Hsieh', 'Affiliation': 'Department of Special Education, Stockholm University, Stockholm, Sweden.'}, {'ForeName': 'Hua-Fang', 'Initials': 'HF', 'LastName': 'Liao', 'Affiliation': 'Academic Committee, Taiwan Society of ICF, 5th Floor, No. 166, Dayei Road, Baitou District, New Taipei City, Taiwan; and School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Suh-Fang', 'Initials': 'SF', 'LastName': 'Jeng', 'Affiliation': 'School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University.'}, {'ForeName': 'Mei-Hui', 'Initials': 'MH', 'LastName': 'Tseng', 'Affiliation': 'School and Graduate Institute of Occupational Therapy, College of Medicine, National Taiwan University.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Schiariti', 'Affiliation': 'Division of Medical Sciences, University of Victoria, Victoria, British Columbia, Canada.'}, {'ForeName': 'Mei-Yan', 'Initials': 'MY', 'LastName': 'Tsai', 'Affiliation': 'Taiwan Social Welfare Action Alliance, Taitung, Taiwan.'}, {'ForeName': 'Sheh-Chia', 'Initials': 'SC', 'LastName': 'Sun', 'Affiliation': 'Department of Early Childhood Education, Teachers College, National Taitung University, Taitung County, Taiwan.'}]",Physical therapy,['10.1093/ptj/pzaa033'] 542,32400903,Severe and enduring anorexia nervosa: No easy solutions.,"There is currently no evidence-based definition of severe and enduring anorexia nervosa (SE-AN) with which to reliably inform clinical practice and research. Indeed, data on the effect of AN severity and duration on treatment outcome are inconsistent. A large group of patients with SE-AN are repeatedly unsuccessfully managed with the available eating disorders treatments and have no access to adequate treatment for their illness. Cognitive behavioral therapy (CBT) adapted for SE-AN has been designed to enhance quality of life and reduce harm rather than promoting weight gain in such patients, and has had some success. However, a percentage of patients with SE-AN achieves remission, or at least returns to a normal weight range, with available evidence-based treatments for eating disorders, such as enhanced CBT (CBT-E). It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.",2020,"It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.",['Severe and enduring anorexia nervosa'],"['Cognitive behavioral therapy (CBT', 'CBT']",['quality of life and medical stability; cost-effectiveness'],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0280831,"It would therefore be worth conducting a large-scale randomized controlled trial comparing CBT adapted for SE-AN with CBT-E to assess their relative acceptability; efficacy, including their effect on quality of life and medical stability; cost-effectiveness; and the treatment response moderators that might allow better matching of patients with SE-AN to a treatment oriented either to harm reduction or to change.","[{'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Dalle Grave', 'Affiliation': 'Department of Eating and Weight Disorders, Villa Garda Hospital, Garda, Italy.'}]",The International journal of eating disorders,['10.1002/eat.23295'] 543,32202520,A Training Program Using an Agility Ladder for Community-Dwelling Older Adults.,"Aging impairs physical and cognitive functions and limits daily activities. Agility training can improve or maintain physical functioning in older people. The purpose of this study is to report the physical fitness benefits of a training program for independent community-dwelling older adults using an agility ladder. Each training session lasted approximately 30 minutes, and the benefits were achieved with two sessions per week for 14 weeks. Training was timed and involved four different drills and varying levels of difficulty through time. The exercises were performed at the School of Physical Education of the University of Campinas, São Paulo state, Brazil. The study participants (n = 16; mean age of 66.9 ± 5.0 years) were instructed to perform the exercises as quickly as possible without making mistakes and were assisted by a physical trainer when they made mistakes. Assessments were performed both before and after training using five functional tests (i.e., Illinois agility, five times sit-to-stand, timed up-and-go, walking usual speed, and one-leg stand). Although the study sample was not compared with a control group, the results indicate that training protocols using an agility ladder are easy and practical and improve physical function performance in older adults.",2020,"Although the study sample was not compared with a control group, the results indicate that training protocols using an agility ladder are easy and practical and improve physical function performance in older adults.","['community-dwelling older adults using an agility ladder', 'older adults', 'Community-Dwelling Older Adults', 'study participants (n = 16; mean age of 66.9 ± 5.0 years', 'older people']","['Agility training', 'Training Program Using an Agility Ladder', 'training program']",['physical function performance'],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0336762', 'cui_str': 'Ladder, device (physical object)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0336762', 'cui_str': 'Ladder, device (physical object)'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.00989359,"Although the study sample was not compared with a control group, the results indicate that training protocols using an agility ladder are easy and practical and improve physical function performance in older adults.","[{'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Castillo de Lima', 'Affiliation': 'Applied Kinesiology Laboratory, School of Physical Education, University of Campinas, UNICAMP.'}, {'ForeName': 'Luz Albany Arcila', 'Initials': 'LAA', 'LastName': 'Castaño', 'Affiliation': 'Applied Kinesiology Laboratory, School of Physical Education, University of Campinas, UNICAMP.'}, {'ForeName': 'Vanessa Vilas', 'Initials': 'VV', 'LastName': 'Boas', 'Affiliation': 'Applied Kinesiology Laboratory, School of Physical Education, University of Campinas, UNICAMP; Centro Universitário das Faculdades Associadas de Ensino - FAE.'}, {'ForeName': 'Marco Carlos', 'Initials': 'MC', 'LastName': 'Uchida', 'Affiliation': 'Applied Kinesiology Laboratory, School of Physical Education, University of Campinas, UNICAMP; uchida@unicamp.br.'}]",Journal of visualized experiments : JoVE,['10.3791/60468'] 544,32207051,Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?,"Immunoglobulin light chain amyloidosis (AL) is a plasma cell disorder characterized by accumulation of misfolded proteins, which can induce organ damage. Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation. t(11;14) translocation is the most common cytogenetic abnormality in AL patients; venetoclax may thus be a useful additional treatment option for this disease. However, a recent trial in multiple myeloma patients (BELLINI) reported increased mortality associated with venetoclax versus placebo in combination with bortezomib and dexamethasone. In this report, we describe an AL patient who had suffered from recurrent infection during previous treatment, but who responded to and tolerated well single-agent venetoclax for more than 1 year. The present report indicates that venetoclax monotherapy may be active and safe for refractory AL amyloidosis.",2020,"Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation.","['frail patient with refractory AL amyloidosis', 'AL patient who had suffered from recurrent infection during previous treatment, but who responded to and tolerated well single-agent venetoclax for more than 1 year']","['venetoclax monotherapy', 'Venetoclax', 'Immunoglobulin light chain amyloidosis (AL', 'placebo', 'Venetoclax monotherapy', 'bortezomib and dexamethasone']",['mortality'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0268381', 'cui_str': 'AL Amyloidosis'}, {'cui': 'C0239998', 'cui_str': 'Recurrent infectious disease'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C4079830', 'cui_str': 'venetoclax'}, {'cui': 'C0268381', 'cui_str': 'AL Amyloidosis'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.0532864,"Venetoclax is active in multiple myeloma patients, in particular those with t(11;14) translocation.","[{'ForeName': 'Pui-Lun', 'Initials': 'PL', 'LastName': 'Yip', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR. ypl741@ha.org.hk.'}, {'ForeName': 'June S M', 'Initials': 'JSM', 'LastName': 'Lau', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR.'}, {'ForeName': 'Ching-Pong', 'Initials': 'CP', 'LastName': 'Lam', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, SAR.'}]",International journal of hematology,['10.1007/s12185-020-02857-2'] 545,32404742,Bovine Lactoferrin Supplementation Does Not Disrupt Microbiota Development in Preterm Infants Receiving Probiotics.,"OBJECTIVE The aim of the study was to assess whether bovine lactoferrin (bLf) supplementation disrupts intestinal microbiota development in preterm infants less than 31 weeks gestational age receiving prophylactic probiotic administration. METHODS Subjects were recruited from the LACUNA trial (ISRCTN66482337), designed to assess bLf safety. These subjects were randomized to daily receive either probiotic supplements or probiotics supplemented with 100 mg bLf mixed with their feeds (human milk or formula). Stools were collected weekly from enrolled infants for 1 month and the microbiota characterized using V6-16S rRNA gene amplicon profiling. RESULTS Infants' microbiomes did not increase in alpha diversity over time in both feeding interventions. Infants receiving bLf supplementation had overall higher species richness as compared with those not receiving these supplements and lactoferrin supplementation had differing effects on infant microbiota species richness depending on the infant's gestational age. Principal co-ordinate analysis revealed that the infant microbiotas did not separate by intervention group, gestational age bracket at birth or sampling time and the main factor dictating sample clustering was infant identity. There were very few detectable differences in taxa relative abundance or functional gene content between the microbiotas in the 2 study groups. CONCLUSIONS Bovine lactoferrin supplementation has minimal impact on microbiota composition/function in preterm infants receiving probiotics, and therefore, is unlikely to disrupt microbiota development.",2020,"There were very few detectable differences in taxa relative abundance or functional gene content between the microbiotas in the two study groups. ","['preterm infants receiving probiotics', 'Preterm Infants Receiving Probiotics', 'preterm infants less than 31 weeks gestational age receiving prophylactic probiotic administration', 'Subjects']","['bovine lactoferrin supplementation', 'Bovine lactoferrin supplementation', 'lactoferrin supplementation', 'Bovine Lactoferrin Supplementation', 'probiotic supplements or probiotics supplemented with 100\u200amg bovine lactoferrin mixed with their feeds (human milk or formula']","['intestinal microbiota development', 'infant microbiota species richness', 'bovine lactoferrin safety', 'alpha diversity']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C1440867', 'cui_str': 'Bovine lactoferrin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}]","[{'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C1440867', 'cui_str': 'Bovine lactoferrin'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}]",,0.0920702,"There were very few detectable differences in taxa relative abundance or functional gene content between the microbiotas in the two study groups. ","[{'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Grzywacz', 'Affiliation': 'Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Butcher', 'Affiliation': 'Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Barrington', 'Affiliation': 'Department of Neonatology, CHU Sainte Justine, Montreal, Quebec, Canada.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Mohamed', 'Affiliation': 'Department of Neonatology, CHU Sainte Justine, Montreal, Quebec, Canada.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Stintzi', 'Affiliation': 'Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario.'}]",Journal of pediatric gastroenterology and nutrition,['10.1097/MPG.0000000000002734'] 546,32401967,Posterior Capsule Opacification after Cataract Surgery in Children Over Five Years of Age with Square-edge Hydrophobic versus Hydrophilic Acrylic Intraocular Lenses: A Prospective Randomized Study.,"OBJECTIVE To compare the effects of hydrophobic and hydrophilic materials in square-edged acrylic intraocular lenses (IOLs) on the development of posterior capsule opacification (PCO) after pediatric cataract surgery. METHODS Patients were randomly assigned to group 1 (hydrophobic acrylic square-edged IOLs; 13 eyes) or group 2 (hydrophilic acrylic square-edged IOLs; 13 eyes). The study evaluated PCO rates using Evaluation of Posterior Capsule Opacification (EPCO) 2000 software at one, three, six and 12 months postoperatively. Postoperative measurements also included corrected distance visual acuity (CDVA), neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy and postoperative complications other than PCO. RESULTS Both groups had significant increases in PCO rates after one year. Comparison of the groups showed no significant differences in the EPCO scores at three (group 1, 0.007±0.016 vs group 2, 0.008±0.014; p=0.830), six (group 1, 0.062±0.103 vs group 2, 0.021±0.023; p=0.184), or twelve months postoperatively (group 1, 0.200±0.193 vs group 2, 0.192±0.138; p=0.902). We also found no significant group differences regarding the change (delta, Δ) in EPCO scores between three and six months (group 1, 0.055±0.09 vs group 2, 0.013±0.02; p=0.113) or between six and twelve months postoperatively (group 1, 0.139±0.14 vs group 2, 0.171±0.14; p=0.567). Twenty-three percent of patients required Nd:YAG capsulotomy at the twelve-month visit. CONCLUSIONS No differences in PCO rates were found between hydrophobic and hydrophilic acrylic square-edged IOLs in children between five and twelve years of age at one year of follow-up.",2020,No differences in PCO rates were found between hydrophobic and hydrophilic acrylic square-edged IOLs in children between five and twelve years of age at one year of follow-up.,"['posterior capsule opacification (PCO) after pediatric cataract surgery', 'Children', 'Patients']","['acrylic intraocular lenses (IOLs', 'hydrophobic and hydrophilic materials', 'hydrophobic acrylic square-edged IOLs; 13 eyes) or group 2 (hydrophilic acrylic square-edged IOLs', 'Hydrophilic Acrylic Intraocular Lenses']","['corrected distance visual acuity (CDVA), neodymium:yttrium-aluminum-garnet', 'PCO rates', 'EPCO scores']","[{'cui': 'C1444680', 'cui_str': 'Posterior capsule opacification'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0440181', 'cui_str': 'Acrylic dental material'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C0598629', 'cui_str': 'Hydrophobicity'}, {'cui': 'C0475370', 'cui_str': 'Hydrophilic'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}]","[{'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0027599', 'cui_str': 'Neodymium'}, {'cui': 'C1609285', 'cui_str': 'yttrium-aluminum-garnet'}, {'cui': 'C1444680', 'cui_str': 'Posterior capsule opacification'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0547806,No differences in PCO rates were found between hydrophobic and hydrophilic acrylic square-edged IOLs in children between five and twelve years of age at one year of follow-up.,"[{'ForeName': 'Camila Ribeiro', 'Initials': 'CR', 'LastName': 'Koch', 'Affiliation': 'Departamento de Oftalmologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Marcony R', 'Initials': 'MR', 'LastName': 'Santhiago', 'Affiliation': 'Departamento de Oftalmologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Priscilla A', 'Initials': 'PA', 'LastName': 'Jorge', 'Affiliation': 'Departamento de Oftalmologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Sena', 'Affiliation': 'Hospital Humberto Castro Lima, Salvador, BA, BR.'}, {'ForeName': 'Newton', 'Initials': 'N', 'LastName': 'Kara-Júnior', 'Affiliation': 'Departamento de Oftalmologia, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1604'] 547,32406112,Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.,"BACKGROUND Linaclotide, a guanylate cyclase C agonist relieves irritable bowel syndrome with predominant constipation (IBS-C) symptoms, but how it improves pain in humans is unknown. AIMS To investigate the effects of linaclotide and placebo on the afferent and efferent gut-brain-gut signalling in IBS-C patients, in a randomised clinical trial. METHODS Patients with IBS-C (Rome III) and rectal hypersensitivity were randomised (2:1) to receive linaclotide (290 µg) or placebo for 10 weeks and undergo bi-directional gut and brain axis assessment using anorectal electrical stimulations and transcranial/transspinal-anorectal magnetic stimulations. Rectal sensations were examined by balloon distention. Assessments included abdominal pain, bowel symptoms and quality of life (QOL) scores. Primary outcomes were latencies of recto-cortical and cortico-rectal evoked potentials. RESULTS Thirty-nine patients participated; 26 received linaclotide and 13 received placebo. Rectal cortical evoked potentials latencies (milliseconds) were significantly prolonged with linaclotide compared to baseline (P1:Δ 19 ± 6, P < 0.005; N1:Δ 20 ± 7, P < 0.02) but not with placebo (P1:Δ 3 ± 5; N1:Δ 4.7 ± 5,P = 0.3) or between groups. The efferent cortico-anorectal and spino-anorectal latencies were unchanged. The maximum tolerable rectal volume (cc) increased significantly with linaclotide compared to baseline (P < 0.001) and placebo (Δ 29 ± 10 vs 4 ± 20, (P < 0.03). Abdominal pain decreased (P < 0.001) with linaclotide but not between groups. Complete spontaneous bowel movement frequency increased (P < 0.001), and IBS-QOL scores improved (P = 0.01) with linaclotide compared to baseline and placebo. There was no difference in overall responders between linaclotide and placebo (54% vs 23%, P = 0.13). CONCLUSIONS Linaclotide prolongs afferent gut-brain signalling from baseline but both afferent and efferent signalling were unaffected compared to placebo. Linaclotide significantly improves rectal hypersensitivity, IBS-C symptoms and QOL compared to placebo. These mechanisms may explain the effects of linaclotide on pain relief in IBS-C patients. ClinicalTrials.Gov: Registered at Clinical trials.gov no NCT02078323.",2020,"Complete spontaneous bowel movement frequency increased (P < 0.001), and IBS-QOL scores improved (P = 0.01) with linaclotide compared to baseline and placebo.","['Thirty-nine patients participated; 26 received', 'IBS-C patients', 'Patients with IBS-C (Rome III) and rectal hypersensitivity']","['linaclotide', 'linaclotide (290\xa0µg) or placebo for 10\xa0weeks and undergo bi-directional gut and brain axis assessment using anorectal electrical stimulations and transcranial/transspinal-anorectal magnetic stimulations', 'Linaclotide', 'linaclotide vs placebo', 'linaclotide and placebo', 'placebo']","['abdominal pain, bowel symptoms and quality of life (QOL) scores', 'pain relief', 'overall responders', 'rectal hypersensitivity, IBS-C symptoms and QOL', 'Rectal sensations', 'latencies of recto-cortical and cortico-rectal evoked potentials', 'IBS-QOL scores', 'efferent cortico-anorectal and spino-anorectal latencies', 'Abdominal pain', 'Rectal cortical evoked potentials latencies (milliseconds', 'Complete spontaneous bowel movement frequency', 'maximum tolerable rectal volume (cc']","[{'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]","[{'cui': 'C2000261', 'cui_str': 'linaclotide'}, {'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0024488', 'cui_str': 'Magnetics'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205052', 'cui_str': 'Rectal'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0232717', 'cui_str': 'Rectal sensation'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0205116', 'cui_str': 'Efferent'}, {'cui': 'C0439223', 'cui_str': 'ms'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0426642', 'cui_str': 'Frequency of bowel action'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0449468', 'cui_str': 'Volume'}]",39.0,0.636366,"Complete spontaneous bowel movement frequency increased (P < 0.001), and IBS-QOL scores improved (P = 0.01) with linaclotide compared to baseline and placebo.","[{'ForeName': 'Satish S C', 'Initials': 'SSC', 'LastName': 'Rao', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Xuelian', 'Initials': 'X', 'LastName': 'Xiang', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Kulthep', 'Initials': 'K', 'LastName': 'Rattanakovit', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Tanisa', 'Initials': 'T', 'LastName': 'Patcharatrakul', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Parr', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Ayyala', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Amol', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Division of Neurogastroenterology/Motility, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15772'] 548,32401715,"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.","BACKGROUND Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19. METHODS This was a multicentre, prospective, open-label, randomised, phase 2 trial in adults with COVID-19 who were admitted to six hospitals in Hong Kong. Patients were randomly assigned (2:1) to a 14-day combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group). The primary endpoint was the time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT04276688. FINDINGS Between Feb 10 and March 20, 2020, 127 patients were recruited; 86 were randomly assigned to the combination group and 41 were assigned to the control group. The median number of days from symptom onset to start of study treatment was 5 days (IQR 3-7). The combination group had a significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days [IQR 5-11]) than the control group (12 days [8-15]; hazard ratio 4·37 [95% CI 1·86-10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir-ritonavir because of biochemical hepatitis. No patients died during the study. INTERPRETATION Early triple antiviral therapy was safe and superior to lopinavir-ritonavir alone in alleviating symptoms and shortening the duration of viral shedding and hospital stay in patients with mild to moderate COVID-19. Future clinical study of a double antiviral therapy with interferon beta-1b as a backbone is warranted. FUNDING The Shaw-Foundation, Richard and Carol Yu, May Tam Mak Mei Yin, and Sanming Project of Medicine.",2020,Adverse events included self-limited nausea and diarrhoea with no difference between the two groups.,"['patients with COVID-19', '127 patients were recruited; 86', 'adults with COVID-19 who were admitted to six hospitals in Hong Kong', 'Between Feb 10 and March 20, 2020', 'patients admitted to hospital with COVID-19', 'patients with mild to moderate COVID-19']","['lopinavir-ritonavir alone', 'lopinavir 400 mg and ritonavir', 'interferon beta-1b, lopinavir-ritonavir, and ribavirin', 'combined interferon beta-1b, lopinavir-ritonavir, and ribavirin', 'lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin', 'lopinavir-ritonavir']","['self-limited nausea and diarrhoea', 'shorter median time', 'efficacy and safety', 'time to providing a nasopharyngeal swab negative for severe acute respiratory syndrome coronavirus 2 RT-PCR, and was done in the intention-to-treat population', 'duration of viral shedding and hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0939237', 'cui_str': 'lopinavir and ritonavir'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0244713', 'cui_str': 'interferon beta-1b'}, {'cui': 'C0035525', 'cui_str': 'Ribavirin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0992889', 'cui_str': 'Ritonavir 100 MG'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444192', 'cui_str': 'Nasopharyngeal swab'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0162633', 'cui_str': 'Viral Shedding'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",127.0,0.118203,Adverse events included self-limited nausea and diarrhoea with no difference between the two groups.,"[{'ForeName': 'Ivan Fan-Ngai', 'Initials': 'IF', 'LastName': 'Hung', 'Affiliation': 'Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China; State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Kwok-Cheung', 'Initials': 'KC', 'LastName': 'Lung', 'Affiliation': 'Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Eugene Yuk-Keung', 'Initials': 'EY', 'LastName': 'Tso', 'Affiliation': 'Department of Medicine, United Christian Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Tom Wai-Hin', 'Initials': 'TW', 'LastName': 'Chung', 'Affiliation': 'Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Man-Yee', 'Initials': 'MY', 'LastName': 'Chu', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Yuk-Yung', 'Initials': 'YY', 'LastName': 'Ng', 'Affiliation': 'Department of Medicine, Tuen Mun Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Lo', 'Affiliation': 'Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Jacky', 'Initials': 'J', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, Princess Margaret Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Anthony Raymond', 'Initials': 'AR', 'LastName': 'Tam', 'Affiliation': 'Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Hoi-Ping', 'Initials': 'HP', 'LastName': 'Shum', 'Affiliation': 'Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, United Christian Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Alan Ka-Lun', 'Initials': 'AK', 'LastName': 'Wu', 'Affiliation': 'Department of Microbiology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Kit-Man', 'Initials': 'KM', 'LastName': 'Sin', 'Affiliation': 'Department of Medicine, Tuen Mun Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Wai-Shing', 'Initials': 'WS', 'LastName': 'Leung', 'Affiliation': 'Department of Medicine, Princess Margaret Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Wai-Lam', 'Initials': 'WL', 'LastName': 'Law', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China.'}, {'ForeName': 'David Christopher', 'Initials': 'DC', 'LastName': 'Lung', 'Affiliation': 'Department of Microbiology, Queen Elizabeth Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Sin', 'Affiliation': 'Department of Intensive Care, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Yeung', 'Affiliation': 'Department of Intensive Care, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Cyril Chik-Yan', 'Initials': 'CC', 'LastName': 'Yip', 'Affiliation': 'Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Ricky Ruiqi', 'Initials': 'RR', 'LastName': 'Zhang', 'Affiliation': 'Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China; State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Agnes Yim-Fong', 'Initials': 'AY', 'LastName': 'Fung', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Erica Yuen-Wing', 'Initials': 'EY', 'LastName': 'Yan', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Kit-Hang', 'Initials': 'KH', 'LastName': 'Leung', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Jonathan Daniel', 'Initials': 'JD', 'LastName': 'Ip', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Allen Wing-Ho', 'Initials': 'AW', 'LastName': 'Chu', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Wan-Mui', 'Initials': 'WM', 'LastName': 'Chan', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Anthony Chin-Ki', 'Initials': 'AC', 'LastName': 'Ng', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Lee', 'Affiliation': 'Department of Microbiology, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Kitty', 'Initials': 'K', 'LastName': 'Fung', 'Affiliation': 'Department of Microbiology, United Christian Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Alwin', 'Initials': 'A', 'LastName': 'Yeung', 'Affiliation': 'Department of Medicine and Geriatrics, Ruttonjee Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Tak-Chiu', 'Initials': 'TC', 'LastName': 'Wu', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Johnny Wai-Man', 'Initials': 'JW', 'LastName': 'Chan', 'Affiliation': 'Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Wing-Wah', 'Initials': 'WW', 'LastName': 'Yan', 'Affiliation': 'Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Wai-Ming', 'Initials': 'WM', 'LastName': 'Chan', 'Affiliation': 'Department of Intensive Care, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Jasper Fuk-Woo', 'Initials': 'JF', 'LastName': 'Chan', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Albert Kwok-Wai', 'Initials': 'AK', 'LastName': 'Lie', 'Affiliation': 'Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Owen Tak-Yin', 'Initials': 'OT', 'LastName': 'Tsang', 'Affiliation': 'Department of Medicine, Princess Margaret Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Vincent Chi-Chung', 'Initials': 'VC', 'LastName': 'Cheng', 'Affiliation': 'Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Tak-Lun', 'Initials': 'TL', 'LastName': 'Que', 'Affiliation': 'Department of Microbiology, Tuen Mun Hospital, Hong Kong SAR, China.'}, {'ForeName': 'Chak-Sing', 'Initials': 'CS', 'LastName': 'Lau', 'Affiliation': 'Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Kwok-Hung', 'Initials': 'KH', 'LastName': 'Chan', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Kelvin Kai-Wang', 'Initials': 'KK', 'LastName': 'To', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China.'}, {'ForeName': 'Kwok-Yung', 'Initials': 'KY', 'LastName': 'Yuen', 'Affiliation': 'State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, The University of Hong Kong, Hong Kong Special Administrative Region (SAR), China. Electronic address: kyyuen@hku.hk.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)31042-4'] 549,32402060,Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial.,"AIMS The association of body weight and weight change with mortality and cardiovascular (CV) outcome in patients with diabetes mellitus (DM) is not clearly established. We assessed the relationship between weight, weight change, and outcomes in patients with established CV risk factors and type 2 DM or pre-diabetes. METHODS AND RESULTS A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI) < 22 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40 kg/m2, respectively). Outcome variables included total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization. Follow-up was 6.2 years (interquartile range 5.8-6.7 years). After multivariable adjustment, lowest risks were seen in patients with overweight and mild obesity for total mortality [overweight: hazard ratio (HR) 0.80 (95% confidence interval (CI) 0.69-0.91); obesity Grade 1: HR 0.82 (0.71-0.95), both P < 0.01)] and CV mortality [overweight: HR 0.79 (0.66-0.94); obesity Grade 1: 0.79 (0.65-0.95), all compared to patients with normal BMI, P < 0.05]. Obesity of any severity was not associated with higher mortality. Low body weight was related to higher mortality [HR 1.28 (1.02-1.61); CV mortality: HR 1.34 (1.01-1.79), P < 0.05]. A continued 2-year weight loss was associated with higher risk of mortality [HR 1.32 (1.18-1.46), P < 0.0001] and CV mortality [HR 1.18 (1.02-1.35), compared to patients without weight loss, P < 0.05]. In turn, weight gain was not related to any adverse outcome. CONCLUSION Obesity in patients with DM or pre-diabetes and CV risk profile was not associated with higher mortality or adverse CV outcome. The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2). Weight loss was an independent risk factor for higher mortality compared to no weight loss.",2020,The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2).,"['patients with diabetes mellitus (DM', 'A total of 12 521 participants from the ORIGIN trial were grouped in BMI categories of low body weight [body mass index (BMI)\u2009<\u200922 kg/m2] normal (22-24.9), overweight (25-29.9), obesity Grades 1-3 (30-34.9, 35-39.9, ≥40\u2009kg/m2, respectively', 'patients with established CV risk factors and type 2 DM or pre-diabetes']",[],"['body weight and weight change with mortality and cardiovascular (CV) outcome', 'Weight loss', '2-year weight loss', 'weight gain', 'Obesity and weight loss', 'CV mortality', 'total and CV mortality and composite outcomes of CV death, non-fatal stroke, or myocardial infarction plus revascularization or heart failure hospitalization', 'mortality or adverse CV outcome', 'Low body weight', 'lowest mortality risk']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]",[],"[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",12521.0,0.0708303,The lowest mortality risk was seen in patients with overweight and moderate obesity (BMI 25-35 kg/m2).,"[{'ForeName': 'Wolfram', 'Initials': 'W', 'LastName': 'Doehner', 'Affiliation': 'Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.'}, {'ForeName': 'Hertzel C', 'Initials': 'HC', 'LastName': 'Gerstein', 'Affiliation': 'Population Health Research Institute, McMaster University, Hamilton Health Sciences, L8S 4K1 Hamilton, ON, Canada.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Ried', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Hyejung', 'Initials': 'H', 'LastName': 'Jung', 'Affiliation': 'Population Health Research Institute, McMaster University, Hamilton Health Sciences, L8S 4K1 Hamilton, ON, Canada.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Asbrand', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Hess', 'Affiliation': 'Sanofi-Aventis Deutschland GmbH, Research & Development, 65926 Frankfurt, Germany.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Berlin Institute of Health Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.'}]",European heart journal,['10.1093/eurheartj/ehaa293'] 550,32197732,Psychometric Analysis of the Abdominal Score From the Diary for Irritable Bowel Syndrome Symptoms-Constipation Using Phase IIb Clinical Trial Data.,"OBJECTIVES The Diary for Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C) has been developed to assess the core signs and symptoms of irritable bowel syndrome with constipation (IBS-C). This article presents the psychometric evaluation of the DIBSS-C abdominal score. METHODS Data for these analyses are from a multicenter phase IIb study in IBS-C patients (NCT02559206). Subjects completed a number of assessments via handheld electronic diary throughout the study. The analyses used the intent-to-treat population and were blinded to randomized treatment group. The analyses evaluated the reliability, validity, and responsiveness of the DIBSS-C abdominal score; identified an appropriate scoring algorithm; and determined thresholds for interpreting clinically meaningful changes at the individual level. RESULTS The correlations between the DIBSS-C abdominal symptom items (ie, abdominal pain, discomfort, and bloating) were strong (>0.75). Cronbach's alpha for the abdominal symptom severity items was very strong (.94), indicating that the 3 abdominal symptom items produce a reliable score. The intraclass correlation coefficient for the abdominal score was 0.82, exceeding the threshold of 0.70 and indicating good test-retest reliability. Guyatt's responsiveness statistic values all exceeded the threshold for a large effect of 0.80, so the DIBSS-C abdominal score can be considered highly responsive to change. Triangulation across 3 sets of anchor-based analyses indicated that a threshold of -2.0 points on the abdominal score is an appropriate threshold for identifying meaningful change. CONCLUSIONS Overall, this study provides evidence that the DIBSS-C abdominal score is valid, reliable, responsive to change, and interpretable for assessing treatment benefit in patients with IBS-C.",2020,"Cronbach's alpha for the abdominal symptom severity items was very strong (.94), indicating that the 3 abdominal symptom items produce a reliable score.","['patients with IBS-C', 'Irritable Bowel Syndrome Symptoms-Constipation (DIBSS-C']",[],"['DIBSS-C abdominal symptom items (ie, abdominal pain, discomfort, and bloating', 'abdominal score', 'Irritable Bowel Syndrome Symptoms-Constipation', 'reliability, validity, and responsiveness of the DIBSS-C abdominal score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",[],"[{'cui': 'C0740651', 'cui_str': 'Abdominal symptom'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0042283', 'cui_str': 'Validity (Epidemiology)'}]",,0.0463545,"Cronbach's alpha for the abdominal symptom severity items was very strong (.94), indicating that the 3 abdominal symptom items produce a reliable score.","[{'ForeName': 'Cheryl D', 'Initials': 'CD', 'LastName': 'Coon', 'Affiliation': 'Outcometrix, St Petersburg, FL, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hanlon', 'Affiliation': 'Ironwood Pharmaceuticals, Inc, Boston, MA, USA.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Abel', 'Affiliation': 'Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'J Jason', 'Initials': 'JJ', 'LastName': 'Lundy', 'Affiliation': 'Outcometrix, St Petersburg, FL, USA. Electronic address: jlundy@outcometrix.com.'}, {'ForeName': 'Robyn T', 'Initials': 'RT', 'LastName': 'Carson', 'Affiliation': 'Allergan plc, Madison, NJ, USA.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Reasner', 'Affiliation': 'Imbria Pharmaceuticals, Boston, MA, USA.'}]",Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,['10.1016/j.jval.2020.01.002'] 551,31074164,Learning knee arthrocentesis using YouTube videos.,"BACKGROUND This study aims to compare medical students' educational outcomes in performing knee arthrocentesis through searching and using YouTube videos versus traditional supervisor-led sessions. METHOD Seventy-one medical students were randomly assigned to three groups. Group A had a traditional supervisor-led clinical session, where the supervisor demonstrated the procedure. Students in group B were provided with links to YouTube videos of knee arthrocentesis that were deemed to be of high educational quality, whereas group C searched and learned from any YouTube video that they found themselves based on the learning objectives provided. Student performance was first examined following the learning sessions, and then again after receiving feedback on the performance. RESULTS Prior to feedback, statistically significant higher mean scores were noted for group A in the identification of an appropriate puncture site (p = 0.015), puncture site sterilization (p = 0.046), wearing sterile gloves (p < 0.001) and direction of needle insertion (p < 0.001). The overall mean scores (maximum possible score is 21) before feedback for groups A, B and C were 17.9 ± 1.9, 14.9 ± 2.0 and 15.4 ± 1.8, respectively (p < 0.001). The overall mean scores after feedback for groups A, B and C were 21.0 ± 0.0, 20.9 ± 0.3 and 21.0 ± 0.0, respectively (p = 0.037). CONCLUSION Students performed equally whether they were provided with videos or found their own; however, without appropriate learner feedback from an instructor, YouTube videos cannot replace traditional supervisor-led sessions for learning knee arthrocentesis.",2020,", statistically significant higher mean scores were noted for group A in the identification of an appropriate puncture site (p = 0.015), puncture site sterilization (p = 0.046), wearing sterile gloves (p < 0.001) and direction of needle insertion (p < 0.001).",['Seventy-one medical students'],"['YouTube videos versus traditional supervisor-led sessions', 'YouTube videos']","['overall mean scores', 'direction of needle insertion', 'wearing sterile gloves', 'mean scores', 'puncture site sterilization']","[{'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0403172', 'cui_str': 'Supervisor (occupation)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439755', 'cui_str': 'Directions (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0232920', 'cui_str': 'Sterile (qualifier value)'}, {'cui': 'C0206069', 'cui_str': 'Glove'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0362065', 'cui_str': 'Sterilization'}]",71.0,0.0524661,", statistically significant higher mean scores were noted for group A in the identification of an appropriate puncture site (p = 0.015), puncture site sterilization (p = 0.046), wearing sterile gloves (p < 0.001) and direction of needle insertion (p < 0.001).","[{'ForeName': 'Jumanah', 'Initials': 'J', 'LastName': 'Karim', 'Affiliation': 'Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada.'}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Marwan', 'Affiliation': 'Division of Orthopaedic Surgery, McGill University Health Centre, Montreal, Quebec, Canada.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Dawas', 'Affiliation': 'Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Esmaeel', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Health Sciences Centre, Kuwait University, Kuwait City, Kuwait.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Snell', 'Affiliation': 'Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.'}]",The clinical teacher,['10.1111/tct.13031'] 552,32199708,"Efficacy of Furosemide, Oral Sodium Chloride, and Fluid Restriction for Treatment of Syndrome of Inappropriate Antidiuresis (SIAD): An Open-label Randomized Controlled Study (The EFFUSE-FLUID Trial).","RATIONALE & OBJECTIVE First-line therapy for syndrome of inappropriate antidiuresis (SIAD) is fluid restriction. Additional treatment for patients who do not respond to fluid restriction are water restriction with furosemide or water restriction with furosemide and salt supplementation. However, the efficacy of these treatments has never been tested in a randomized controlled study. The objective of this study was to investigate whether, combined with fluid restriction, furosemide with or without sodium chloride (NaCl) supplementation was more effective than fluid restriction alone in the treatment of hyponatremia in SIAD. STUDY DESIGN Open-label randomized controlled study. SETTING & PARTICIPANTS Patients with serum sodium concentrations ([Na + ]) ≤ 130mmol/L due to SIAD. INTERVENTION(S) Random assignment to 1 of 3 groups: fluid restriction alone (FR), fluid restriction and furosemide (FR+FM), or fluid restriction, furosemide, and NaCl (FR+FM+NaCl). Strictness of fluid restriction (<1,000 or<500mL/d) was guided by the urine to serum electrolyte ratio. Furosemide dosage was 20 to 40mg/d. NaCl supplements were 3g/d. All treatments were continued for 28 days. OUTCOMES The primary outcome was change in [Na + ] at days 4, 7, 14, and 28 after randomization. RESULTS 92 patients were recruited (FR, n=31; FR+FM, n=30; FR+FM+NaCl, n=31). Baseline [Na + ] was 125±4mmol/L, and there were no significant differences between groups. Mean [Na + ] on day 4 in all treatment groups was significantly increased from baseline by 5mmol/L (P<0.001); however, the change in [Na + ] was not significantly different across groups (P=0.7). There was no significant difference in percentage of patients or time to reach [Na + ] ≥ 130 or≥135mmol/L across the 3 groups. Acute kidney injury and hypokalemia (potassium≤3.0mmol/L) were more common in patients receiving furosemide. LIMITATIONS Open-label treatment. CONCLUSIONS In patients with SIAD, furosemide with NaCl supplement in combination with fluid restriction did not show benefits in correction of [Na + ] compared with treatment with fluid restriction alone. Incidences of acute kidney injury and hypokalemia were increased in patients receiving furosemide. FUNDING None. TRIAL REGISTRATION Registered at the Thai Clinical Trial Registry with study number TCTR20170629004.",2020,There was no significant difference in percentage of patients or time to reach [Na + ] ≥ 130 or≥135mmol/L across the 3 groups.,"['patients receiving furosemide', 'Syndrome of Inappropriate Antidiuresis (SIAD', 'Patients with serum sodium concentrations ([Na + ])\xa0≤ 130mmol/L due to SIAD', 'patients who do not respond to fluid restriction are water restriction with', '92 patients were recruited (FR, n=31']","['fluid restriction alone (FR), fluid restriction and furosemide (FR+FM), or fluid restriction, furosemide, and NaCl (FR+FM+NaCl', 'Furosemide, Oral Sodium Chloride, and Fluid Restriction', 'furosemide with NaCl supplement', 'Furosemide', 'combined with fluid restriction, furosemide with or without sodium chloride (NaCl) supplementation', 'furosemide or water restriction with furosemide and salt supplementation']","['Acute kidney injury and hypokalemia\xa0(potassium≤3.0mmol/L', 'acute kidney injury and hypokalemia', 'Mean', 'change in [Na + ', 'percentage of patients or\xa0time to reach [Na + ']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0021141', 'cui_str': 'Syndrome of Inappropriate ADH (SIADH) Secretion'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0204700', 'cui_str': 'Fluid restriction (procedure)'}, {'cui': 'C0043047', 'cui_str': 'Water'}]","[{'cui': 'C0204700', 'cui_str': 'Fluid restriction (procedure)'}, {'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0036140', 'cui_str': 'Salts'}]","[{'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0020621', 'cui_str': 'Hypopotassemia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}]",92.0,0.18245,There was no significant difference in percentage of patients or time to reach [Na + ] ≥ 130 or≥135mmol/L across the 3 groups.,"[{'ForeName': 'Pajaree', 'Initials': 'P', 'LastName': 'Krisanapan', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Surachet', 'Initials': 'S', 'LastName': 'Vongsanim', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Pathomporn', 'Initials': 'P', 'LastName': 'Pin-On', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Chidchanok', 'Initials': 'C', 'LastName': 'Ruengorn', 'Affiliation': 'Department of Pharmaceutical Care, Chiang Mai University, Chiang Mai, Thailand; Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Kajohnsak', 'Initials': 'K', 'LastName': 'Noppakun', 'Affiliation': 'Division of Nephrology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand; Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Electronic address: kajohnsak.noppakun@cmu.ac.th.'}]",American journal of kidney diseases : the official journal of the National Kidney Foundation,['10.1053/j.ajkd.2019.11.012'] 553,32192275,Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting.,"PURPOSE The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)-induced nausea and vomiting. Materials and Methods Patients were randomly assigned (1:1) to receive RAD or PAD:RAM (0.3 mg intravenously) or PAL (0.25 mg intravenously) D1, combined with APR (125 mg orally, D1 and 80 mg orally, D2-3) and DEX (12 mg orally or intravenously, D1 and 8 mg orally, D2-4). Patients were stratified by sex, cisplatin-based chemotherapy, and administration schedule. The primary endpoint was overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC. Secondary endpoints were overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score < 5 mm). Quality of life was assessed by Functional Living Index Emesis (FLIE) questionnaire on D0 and D6. RESULTS A total of 279 patients receiving RAD (n=137) or PAD (n=142) were evaluated. Overall CR rates in RAD and PAD recipients were 81.8% and 79.6% (risk difference [RD], 2.2%; 95% confidence interval [CI], -7.1 to 11.4), respectively. Overall CP and TC rates for RAD and PAD were 56.2% and 58.5% (RD, -2.3%; 95% CI, -13.9 to 9.4) and 47.5% vs. 43.7% (RD, 3.8%; 95% CI, -7.9 to 15.5), respectively. FLIE total score ≥ 108 (no impact on daily life) was comparable between RAD and PAD (73.9% vs. 73.4%, respectively). Adverse events were similar between the two groups. CONCLUSION In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.",2020,"In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.","['cancer patients receiving HEC', '279 patients receiving RAD (n=137) or PAD (n=142) were evaluated']","['DEX', 'PAL (0.25 mg intravenously) D1, combined with APR', 'RAD or PAD:RAM', 'ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD', 'Ramosetron', 'cisplatin-based chemotherapy', 'Dexamethasone']","['Nausea and Vomiting', 'Overall CR rates', 'Adverse events', 'Functional Living Index Emesis (FLIE) questionnaire on D0 and D6', 'overall complete response (CR), defined as no emesis and no rescue regimen during 5 days of HEC', 'Overall CP and TC rates for RAD and PAD', 'efficacy, safety and QOL, RAD', 'overall complete protection (CP; CR+nausea score < 25 mm) and total control (TC; CR+nausea score', 'Quality of life', 'FLIE total score ≥ 108 (no impact on daily life']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0318598', 'cui_str': 'Human enteric calicivirus (organism)'}, {'cui': 'C0556643', 'cui_str': 'rad (qualifier value)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}]","[{'cui': 'C4517443', 'cui_str': '0.25 (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0556643', 'cui_str': 'rad (qualifier value)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C0526950', 'cui_str': 'ramosetron'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0220578', 'cui_str': 'palonosetron'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0318598', 'cui_str': 'Human enteric calicivirus (organism)'}, {'cui': 'C0556643', 'cui_str': 'rad (qualifier value)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",279.0,0.262672,"In all aspects of efficacy, safety and QOL, RAD is non-inferior to PAD for the control of CINV in cancer patients receiving HEC.","[{'ForeName': 'Jin Hyoung', 'Initials': 'JH', 'LastName': 'Kang', 'Affiliation': ""Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.""}, {'ForeName': 'Jung Hye', 'Initials': 'JH', 'LastName': 'Kwon', 'Affiliation': 'Division of Hemato-Oncology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Yun-Gyoo', 'Initials': 'YG', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Keon Uk', 'Initials': 'KU', 'LastName': 'Park', 'Affiliation': 'Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Ho Jung', 'Initials': 'HJ', 'LastName': 'An', 'Affiliation': ""Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Joohyuk', 'Initials': 'J', 'LastName': 'Sohn', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Young Mi', 'Initials': 'YM', 'LastName': 'Seol', 'Affiliation': 'Division of Hemato-Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.'}, {'ForeName': 'Hyunwoo', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Department of Hematology-Oncology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Hwan-Jung', 'Initials': 'HJ', 'LastName': 'Yun', 'Affiliation': 'Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.'}, {'ForeName': 'Jin Seok', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Division of Hematology & Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Ji Hyun', 'Initials': 'JH', 'LastName': 'Yang', 'Affiliation': ""Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.""}, {'ForeName': 'Hunho', 'Initials': 'H', 'LastName': 'Song', 'Affiliation': 'Division of Hemato-Oncology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Dong-Hoe', 'Initials': 'DH', 'LastName': 'Koo', 'Affiliation': 'Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.'}, {'ForeName': 'Jin Young', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Gun Min', 'Initials': 'GM', 'LastName': 'Kim', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hwa Jung', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}]",Cancer research and treatment : official journal of Korean Cancer Association,['10.4143/crt.2019.713'] 554,31524046,Responsiveness of different dynamic contrast-enhanced magnetic resonance imaging approaches: a post-hoc analysis of a randomized controlled trial of certolizumab pegol in rheumatoid arthritis.,"Objective : The aim was to explore dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as an early marker of therapeutic response in patients with rheumatoid arthritis (RA) starting treatment with certolizumab pegol (CZP). Method : In 40 RA patients initiating CZP (27 patients) or 2 weeks of placebo (PCB) followed by CZP (13 patients), DCE-MRI of the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints was performed at weeks 0, 1, 2, 4, 8, and 16. Using semi-automated software, three methods for drawing volume regions of interest (ROIs) in MCP2-5 and PIP2-5 were applied: 'Standard' (slices: all; joints: MCP2-5 together and PIP2-5 together), 'Detailed' (slices: slices with high-quality visualization; joints: as Standard), and 'Single-joint' (slices: as Detailed; joints: each joint separately). The number of enhancing voxels (Nvoxel), initial rate of enhancement (IRE), and maximum enhancement (ME) were extracted and analysed for each method. Results : Nvoxel in MCP2-5, and IRE and ME in PIP2-5 decreased statistically significantly (Wilcoxon rank-sum test, p < 0.02-0.03) after 16 weeks of treatment for the Standard method. Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points. There were no significant changes for DCE-MRI parameters for the Detailed and Single-joint methods. Conclusions : Certain DCE-MRI parameters detected decreased inflammation during CZP treatment in RA patients. Using specific criteria for ROIs, as in the Detailed and Single-joint methods, decreased the statistical power and could not show any changes over time.",2020,"Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points.","['RA patients', 'rheumatoid arthritis', '40 RA patients initiating', 'patients with rheumatoid arthritis (RA) starting treatment with certolizumab pegol (CZP']","['dynamic contrast-enhanced magnetic resonance imaging approaches', 'certolizumab pegol', 'placebo (PCB) followed by CZP', 'PCB', 'dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI', 'CZP']","['DCE-MRI parameters', 'Nvoxel and ME', 'number of enhancing voxels (Nvoxel), initial rate of enhancement (IRE), and maximum enhancement (ME']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1872109', 'cui_str': 'certolizumab pegol'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1872109', 'cui_str': 'certolizumab pegol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0032447', 'cui_str': 'PCBs'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}]","[{'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C1627358', 'cui_str': 'Refractive surgery enhancement'}]",,0.0889267,"Nvoxel and ME decreased significantly more in the CZP group than in the PCB group after 1 week of treatment, but not at later time-points.","[{'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Axelsen', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Boesen', 'Affiliation': 'Department of Radiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Bliddal', 'Affiliation': 'The Parker Institute, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Lth', 'Initials': 'L', 'LastName': 'Jacobsson', 'Affiliation': 'Department of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Hansen', 'Affiliation': 'Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.'}]",Scandinavian journal of rheumatology,['10.1080/03009742.2019.1639820'] 555,32130116,Dose-Response Effect of a Digital Health Intervention During Cardiac Rehabilitation: Subanalysis of Randomized Controlled Trial.,"BACKGROUND Previous data have validated the benefit of digital health interventions (DHIs) on weight loss in patients following acute coronary syndrome entering cardiac rehabilitation (CR). OBJECTIVE The primary purpose of this study was to test the hypothesis that increased DHI use, as measured by individual log-ins, is associated with improved weight loss. Secondary analyses evaluated the association between log-ins and activity within the platform and exercise, dietary, and medication adherence. METHODS We obtained DHI data including active days, total log-ins, tasks completed, educational modules reviewed, medication adherence, and nonmonetary incentive points earned in patients undergoing standard CR following acute coronary syndrome. Linear regression followed by multivariable models were used to evaluate associations between DHI log-ins and weight loss or dietary adherence. RESULTS Participants (n=61) were 79% male (48/61) with mean age of 61.0 (SD 9.7) years. We found a significant positive association of total log-ins during CR with weight loss (r 2 =.10, P=.03). Educational modules viewed (r 2 =.11, P=.009) and tasks completed (r 2 =.10, P=.01) were positively significantly associated with weight loss, yet total log-ins were not significantly associated with differences in dietary adherence (r 2 =.05, P=.12) or improvements in minutes of exercise per week (r 2 =.03, P=.36). CONCLUSIONS These data extend our previous findings and demonstrate increased DHI log-ins portend improved weight loss in patients undergoing CR after acute coronary syndrome. DHI adherence can potentially be monitored and used as a tool to selectively encourage patients to adhere to secondary prevention lifestyle modifications. TRIAL REGISTRATION ClinicalTrials.gov (NCT01883050); https://clinicaltrials.gov/ct2/show/NCT01883050.",2020,"Educational modules viewed (r 2 =.11, P=.009) and tasks completed (r 2 =.10, P=.01) were positively significantly associated with weight loss, yet total log-ins were not significantly associated with differences in dietary adherence (r 2 =.05, P=.12) or improvements in minutes of exercise per week (r 2 =.03, P=.36). ","['patients following acute coronary syndrome entering cardiac rehabilitation (CR', 'patients undergoing CR after acute coronary syndrome', 'Participants (n=61) were 79% male (48/61) with mean age of 61.0 (SD 9.7) years']","['digital health interventions (DHIs', 'Digital Health Intervention']","['weight loss', 'dietary adherence', 'association between log-ins and activity within the platform and exercise, dietary, and medication adherence', 'DHI log-ins and weight loss or dietary adherence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}]",79.0,0.149347,"Educational modules viewed (r 2 =.11, P=.009) and tasks completed (r 2 =.10, P=.01) were positively significantly associated with weight loss, yet total log-ins were not significantly associated with differences in dietary adherence (r 2 =.05, P=.12) or improvements in minutes of exercise per week (r 2 =.03, P=.36). ","[{'ForeName': 'R Jay', 'Initials': 'RJ', 'LastName': 'Widmer', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Senecal', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Allison', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Lopez-Jimenez', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Lilach O', 'Initials': 'LO', 'LastName': 'Lerman', 'Affiliation': 'Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Lerman', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.'}]",Journal of medical Internet research,['10.2196/13055'] 556,31882376,"ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand.","BACKGROUND The proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab significantly reduces low-density lipoprotein cholesterol (LDL-C). OBJECTIVE This study (ODYSSEY EAST) assessed the efficacy and safety of alirocumab vs ezetimibe in high cardiovascular risk patients from Asia. METHODS Patients (n = 615) from China, India, and Thailand with hypercholesterolemia at high cardiovascular risk on maximally tolerated statin were randomized (2:1) to alirocumab (75 mg every 2 weeks [Q2W]; with dose increase to 150 mg Q2W at week 12 if week 8 LDL-C was >1.81 mmol/L [>70 mg/dL]) or ezetimibe (10 mg daily) for 24 weeks. The primary efficacy endpoint was percentage change in calculated LDL-C from baseline to week 24. Safety was assessed throughout. RESULTS Baseline data were similar in both groups. LDL-C levels were reduced from baseline to week 24 by 56.0% and 20.3% in the alirocumab and ezetimibe groups, respectively (P < .0001 vs ezetimibe). Overall, 18.8% of alirocumab-treated patients received a dose increase to 150 mg Q2W. At week 24, 85.1% of alirocumab-treated and 40.5% of ezetimibe-treated patients reached LDL-C <1.81 mmol/L (<70 mg/dL, P < .0001 vs ezetimibe). Treatment-emergent adverse events occurred in 68.5% of alirocumab-treated and 63.1% of ezetimibe-treated patients, with upper respiratory tract infection the most common (alirocumab: 13.3%; ezetimibe: 14.1%). Injection-site reactions occurred more frequently in alirocumab-treated patients (2.7%) than in ezetimibe-treated patients (1.0%). CONCLUSIONS Alirocumab significantly reduced LDL-C vs ezetimibe in high cardiovascular risk patients from Asia and was generally well tolerated. These findings are consistent with previous ODYSSEY studies.",2020,"LDL-C levels were reduced from baseline to week 24 by 56.0% and 20.3% in the alirocumab and ezetimibe groups, respectively (P < .0001 vs ezetimibe).","['high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand', 'high cardiovascular risk patients from Asia', 'Patients (n\xa0', '615) from China, India, and Thailand with hypercholesterolemia at high cardiovascular risk on maximally tolerated statin']","['ezetimibe', 'alirocumab', 'alirocumab vs ezetimibe', 'EAST']","['low-density lipoprotein cholesterol (LDL-C', 'LDL-C', 'Treatment-emergent adverse events', 'efficacy and safety', 'LDL-C levels', 'Injection-site reactions', 'Safety', 'percentage change in calculated LDL-C', 'tolerated']","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0039725', 'cui_str': 'Kingdom of Thailand'}, {'cui': 'C0003980', 'cui_str': 'Asia'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}]",615.0,0.122665,"LDL-C levels were reduced from baseline to week 24 by 56.0% and 20.3% in the alirocumab and ezetimibe groups, respectively (P < .0001 vs ezetimibe).","[{'ForeName': 'Yaling', 'Initials': 'Y', 'LastName': 'Han', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. Electronic address: hanyaling@263.net.'}, {'ForeName': 'Jiyan', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Guangdong General Hospital, Guangdong, China.'}, {'ForeName': 'Vijay Kumar', 'Initials': 'VK', 'LastName': 'Chopra', 'Affiliation': 'Department of Cardiology, Medanta - The Medicity, Delhi, India.'}, {'ForeName': 'Shuyang', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Guohai', 'Initials': 'G', 'LastName': 'Su', 'Affiliation': 'Institute of Translational Medicine, Jinan Central Hospital, Jinan, China.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhouqing', 'Initials': 'Z', 'LastName': 'Huang', 'Affiliation': 'Division of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'ForeName': 'Yingyan', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.'}, {'ForeName': 'Zhuhua', 'Initials': 'Z', 'LastName': 'Yao', 'Affiliation': 'Department of Cardiology, Tianjin Union Medical Center, Tianjin, China.'}, {'ForeName': 'Zuyi', 'Initials': 'Z', 'LastName': 'Yuan', 'Affiliation': ""Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Department of Cardiac Surgery, Ruijin Hospital of Shanghai, Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Srun', 'Initials': 'S', 'LastName': 'Kuanprasert', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Chiang Mai Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Baccara-Dinet', 'Affiliation': 'Clinical Development, R&D, Sanofi, Montpellier, France.'}, {'ForeName': 'Garen', 'Initials': 'G', 'LastName': 'Manvelian', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA.'}, {'ForeName': 'Jianyong', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'R&D, Sanofi, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Chen', 'Affiliation': 'R&D, Sanofi, China.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.015'] 557,32020853,Potential benefits of oral administration of AMORPHOPHALLUS KONJAC glycosylceramides on skin health - a randomized clinical study.,"BACKGROUND Ceramides play a fundamental role in maintaining the skin health as a function of improved barrier permeability. Reduced ceramide content results in skin dryness and wrinkledness. Intake of dietary ceramides potentially compensates the skin ceramide content. In the present study we have assessed the skin health benefits of oral supplementation of a hydroalcoholic extract from Amorphophallus konjac tubers standardized to 5% glycosylceramides, in a placebo-controlled clinical trial. METHODS Fifty-one healthy human volunteers (aged 18-60 years) were supplemented with 100 mg/day of either a placebo or A. konjac extract capsules (5 mg glycosylceramides) for 6-weeks. The skin parameters were evaluated through dermatological diagnosis. Subject perceived efficacy of the product was further evaluated by a self-assessment questionnaire. RESULTS Oral intake of A. konjac extract significantly decreased the skin dryness, hyperpigmentation, redness, itching and oilyness (p < 0.05). The improvement in skin health following intake of A. konjac extract was observed to be time-dependent from the start. Further, A. konjac extract was well-tolerated throughout the study, as no adverse events or toxic changes were recorded. CONCLUSION The study demonstrates the skincare properties of orally ingested glycosyl ceramides from konjac tubers. TRIAL REGISTRATION CTRI/2018/12/016661 dated 13/12/2018 retrospectively registered, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19851&EncHid=&userName=SkinCera.",2020,"RESULTS Oral intake of A. konjac extract significantly decreased the skin dryness, hyperpigmentation, redness, itching and oilyness (p < 0.05).",['Fifty-one healthy human volunteers (aged 18-60\u2009years'],"['AMORPHOPHALLUS KONJAC glycosylceramides', 'hydroalcoholic extract', 'placebo or A. konjac extract capsules (5\u2009mg glycosylceramides']","['skin health', 'skin dryness, hyperpigmentation, redness, itching and oilyness']","[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1135791', 'cui_str': 'Konjac'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0162834', 'cui_str': 'Hypermelanosis'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}]",51.0,0.0482544,"RESULTS Oral intake of A. konjac extract significantly decreased the skin dryness, hyperpigmentation, redness, itching and oilyness (p < 0.05).","[{'ForeName': 'Sudeep', 'Initials': 'S', 'LastName': 'Heggar Venkataramana', 'Affiliation': 'Research Scientist, No. 14A, KIADB, R & D Center for Excellence, Vidya Herbs (P) Ltd., Jigani Industrial Area, Bangalore, Anekal Taluk, 560 105, India. sudeepkashyap.82@vidyaherbs.com.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Puttaswamy', 'Affiliation': 'Research Scientist, No. 14A, KIADB, R & D Center for Excellence, Vidya Herbs (P) Ltd., Jigani Industrial Area, Bangalore, Anekal Taluk, 560 105, India.'}, {'ForeName': 'Shyamprasad', 'Initials': 'S', 'LastName': 'Kodimule', 'Affiliation': 'Research Scientist, No. 14A, KIADB, R & D Center for Excellence, Vidya Herbs (P) Ltd., Jigani Industrial Area, Bangalore, Anekal Taluk, 560 105, India.'}]",BMC complementary medicine and therapies,['10.1186/s12906-019-2721-3'] 558,32020889,Electroacupuncture versus solifenacin for women with urgency-predominant mixed urinary incontinence: a protocol for a three-armed non-inferiority randomized controlled trial.,"BACKGROUND Among women suffering from urinary incontinence (UI), about one-third are diagnosed with mixed urinary incontinence (MUI), among which urgency-predominant MUI causes more shame and inconvenience to patients. The treatments for urgency-predominant MUI have limited guidelines and previous studies have indicated that electroacupuncture (EA) might be a safe and effective option. The present study aims to evaluate the effect of EA on women with urgency-predominant MUI. METHODS The study is a multicentered, three-armed, non-inferiority randomized clinical trial. A total of 282 female patients with urgency-predominant MUI will be randomly divided into three groups, namely the EA group, sham electroacupuncture (SA) group, and solifenacin treatment group at a ratio of 1:1:1. Thirty-six sessions of acupuncture treatment over 12 weeks and solifenacin treatment over 36 weeks will be provided. The primary outcome will be the decrease of urgency urinary incontinence (UUI) episodes after 12-week treatment. Secondary outcomes will include changes in incontinence episodes, urinary frequency, urgency, severity of symptoms, and influence on quality of life, assessed using the International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and Overactive Bladder Questionnaire Short Form (OAB-q SF). All patients will be continuously followed up until week 36 and their allocations will be statistically analyzed. DISCUSSION Though placebo of solifenacin is rather difficult to access and all patients in the trial cannot be fully blinded, the present study will serve as an introduction of three-armed, randomized, non-inferiority, and sham acupuncture-controlled clinical trials to the acupuncture field, in an attempt to compare the effects of EA and solifenacin for treating women with urgency-predominant MUI. TRIAL REGISTRATION ClinicalTrials.gov: NCT03787654. Registered on 25 December, 2018.",2020,"Secondary outcomes will include changes in incontinence episodes, urinary frequency, urgency, severity of symptoms, and influence on quality of life, assessed using the International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and Overactive Bladder Questionnaire Short Form (OAB-q SF).","['women with urgency-predominant MUI', '282 female patients with urgency-predominant MUI', 'women suffering from urinary incontinence (UI', 'women with urgency-predominant mixed urinary incontinence']","['EA', 'acupuncture', 'solifenacin treatment', 'sham electroacupuncture (SA', 'Electroacupuncture versus solifenacin', 'placebo of solifenacin', 'electroacupuncture (EA', 'EA and solifenacin', 'solifenacin']","['urgency urinary incontinence (UUI) episodes', 'changes in incontinence episodes, urinary frequency, urgency, severity of symptoms, and influence on quality of life, assessed using the International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and Overactive Bladder Questionnaire Short Form (OAB-q SF']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C1720722', 'cui_str': 'Mix'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C1099677', 'cui_str': 'Solifenacin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0042023', 'cui_str': 'Increased frequency of urination (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire (assessment scale)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",282.0,0.245198,"Secondary outcomes will include changes in incontinence episodes, urinary frequency, urgency, severity of symptoms, and influence on quality of life, assessed using the International Consultation on Incontinence Questionnaire Short Form (ICIQ SF) and Overactive Bladder Questionnaire Short Form (OAB-q SF).","[{'ForeName': 'Yuanjie', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Tongsheng', 'Initials': 'T', 'LastName': 'Su', 'Affiliation': ""Shanxi Province Hospital of Traditional Chinese Medicine, Xi'an, China.""}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'School of Public Health, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Zhishun', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. zhishunjournal@163.com.""}]",BMC complementary medicine and therapies,['10.1186/s12906-019-2784-1'] 559,31859127,Postprandial remodeling of high-density lipoprotein following high saturated fat and high carbohydrate meals.,"BACKGROUND Humans spend most of the time in the postprandial state, yet most knowledge about high-density lipoproteins (HDL) derives from the fasted state. HDL protein and lipid cargo mediate HDL's antiatherogenic effects, but whether these HDL constituents change in the postprandial state and are affected by dietary macronutrients remains unknown. OBJECTIVES This study aimed to assess changes in HDL protein and lipid composition after the consumption of a high-carbohydrate or high saturated fat (HSF) meal. METHODS We isolated HDL from plasma collected during a randomized, cross-over study of metabolically healthy subjects. Subjects consumed isocaloric meals consisting predominantly of either carbohydrate or fat. At baseline and at 3 and 6 hours postprandial, we quantified HDL protein and lipid composition by liquid chromatography-mass spectrometry. RESULTS A total of 15 subjects were included (60% female, aged 34 ± 15 years, body mass index: 24.1 ± 2.7 kg/m 2 ). Consumption of the HSF meal led to HDL enrichment in total lipid (P = .006), triglyceride (P = .02), and phospholipid (P = .008) content and a corresponding depletion in protein content. After the HSF meal, 16 of the 25 measured phosphatidylcholine species significantly increased in abundance (P values range from .027 to <.001), along with several sphingolipids including ceramides (P < .004), lactosylceramide (P = .023), and sphingomyelin-14 (P = .013). Enrichment in apolipoprotein A-I (P = .001) was the only significant change in HDL protein composition after the HSF meal. The high-carbohydrate meal conferred only minimal changes in HDL composition. CONCLUSION Meal macronutrient content acutely affects HDL composition in the postprandial state, with the HSF meal resulting in enrichment of HDL phospholipid content with possible consequences for HDL function.",2020,"Consumption of the HSF meal led to HDL enrichment in total lipid (P = .006), triglyceride (P = .02), and phospholipid (P = .008)","['We isolated HDL from plasma collected during a randomized, cross-over study of metabolically healthy subjects', 'A total of 15 subjects were included (60% female, aged 34\xa0±\xa015\xa0years, body mass index: 24.1\xa0±\xa02.7\xa0kg/m 2 ']",[],"['HDL protein composition', 'lactosylceramide', 'triglyceride', 'HDL protein and lipid composition', 'HDL enrichment in total lipid']","[{'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517635', 'cui_str': '2.7'}]",[],"[{'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0022954', 'cui_str': 'Lactosyl Ceramides'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.0406746,"Consumption of the HSF meal led to HDL enrichment in total lipid (P = .006), triglyceride (P = .02), and phospholipid (P = .008)","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Averill', 'Affiliation': 'Nutritional Sciences Department, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Katya B', 'Initials': 'KB', 'LastName': 'Rubinow', 'Affiliation': 'Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Cain', 'Affiliation': 'Department of Biostatistics, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Wimberger', 'Affiliation': 'Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Ilona', 'Initials': 'I', 'LastName': 'Babenko', 'Affiliation': 'Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jessica O', 'Initials': 'JO', 'LastName': 'Becker', 'Affiliation': 'Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Karen E', 'Initials': 'KE', 'LastName': 'Foster-Schubert', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Cummings', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Andrew N', 'Initials': 'AN', 'LastName': 'Hoofnagle', 'Affiliation': 'Department of Laboratory Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Vaisar', 'Affiliation': 'Division of Metabolism, Endocrinology, and Nutrition, UW Medicine Diabetes Institute, University of Washington, Seattle, WA, USA. Electronic address: tvaisar@uw.edu.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.11.002'] 560,32189663,Comparing intravenous dexmedetomidine and clonidine in hemodynamic changes and block following spinal anesthesia with ropivacaine in lower limb orthopedic surgery: a randomized clinical trial.,"Dexmedetomidine (DEX) can prolong duration of anesthesia and shorten onset of sensory and motor block relative to clonidine. This study attempted to compare the efficacy of intravenous DEX and clonidine for hemodynamic changes and block after spinal anesthesia with ropivacaine in lower limb orthopedic surgery. In a double-blind randomized clinical trial, 120 patients undergoing spinal anesthesia in lower limb orthopedic surgery were recruited and divided into three groups using balanced block randomization: DEX group (n = 40; intravenous DEX 0.2 µg/kg), clonidine group (n = 40; intravenous clonidine 0.4 µg/kg), and placebo group (n = 40; intravenous normal saline 10 mL) in which pain scores were assessed using visual analogue scales (at recovery, and 2, 4, 6, and 12 hours after surgery) and time to achieve and onset of sensory and motor block. Statistically significant differences were found in mean arterial pressure among the groups at all times except baseline (P = 0.001), with a less mean arterial pressure and a prolonged duration of sensory and motor block (P = 0.001) in the DEX group where pain relieved in patients immediately after surgery and at above mentioned time points (P = 0.001). Simultaneous administration of intravenous DEX with ropivacaine for spinal anesthesia prolongs the duration of sensory and motor block and relieves postoperative pain, and however, can decrease blood pressure. Although intravenous DEX as an adjuvant can be helpful during spinal anesthesia with ropivacaine, it should be taken with caution owing to a lowering of mean arterial pressure in patients especially in the older adults. This study was approved by Ethical Committee of Arak University of Medical Sciences (No. IR.Arakmu.Rec.1395.450) in March, 2017, and the trial was registered and approved by the Iranian Registry of Clinical Trials (IRCT No. IRCT2017092020258N60) in 2017.",2020,"Statistically significant differences were found in mean arterial pressure among the groups at all times except baseline (P = 0.001), with a less mean arterial pressure and a prolonged duration of sensory and motor block (P = 0.001) in the DEX group where pain relieved in patients immediately after surgery and at above mentioned time points (P = 0.001).","['120 patients undergoing spinal anesthesia in lower limb orthopedic surgery', 'lower limb orthopedic surgery', 'Arak University of Medical Sciences']","['Dexmedetomidine (DEX', 'DEX', 'balanced block randomization: DEX', 'dexmedetomidine', 'clonidine 0.4 µg/kg), and placebo', 'ropivacaine', 'clonidine']","['duration of sensory and motor block and relieves postoperative pain', 'pain', 'blood pressure', 'mean arterial pressure and a prolonged duration of sensory and motor block', 'mean arterial pressure']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0162439', 'cui_str': 'Orthopedic Surgery'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0009014', 'cui_str': 'Clonidine'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0445254', 'cui_str': 'Sensory (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C1301771', 'cui_str': 'Relieved'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}]",120.0,0.202553,"Statistically significant differences were found in mean arterial pressure among the groups at all times except baseline (P = 0.001), with a less mean arterial pressure and a prolonged duration of sensory and motor block (P = 0.001) in the DEX group where pain relieved in patients immediately after surgery and at above mentioned time points (P = 0.001).","[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Javahertalab', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Susanabadi', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Hesameddin', 'Initials': 'H', 'LastName': 'Modir', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Kamali', 'Affiliation': 'Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Amani', 'Affiliation': 'Department of Orthopedic Surgery, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Almasi-Hashiani', 'Affiliation': 'Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran.'}]",Medical gas research,['10.4103/2045-9912.279977'] 561,32189664,Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trial.,"Persistent postconcussion syndrome (PPCS) after mild traumatic brain injury (mTBI) is a significant public health and military problem for which there is limited treatment evidence. The aim of this study was to determine whether forty 150 kPa hyperbaric oxygen therapies (HBOTs) can improve symptoms and cognitive function in subjects with the PPCS of mTBI, using a randomized controlled crossover design with 2-month follow-up. Sixty-three civilian and military subjects with mTBI/PPCS were randomized to either 40 HBOTs at 150 kPa/60 minutes, once daily, 5 days per week in 8 weeks or an equivalent no-treatment control period. The Control Group was then crossed over to HBOT. Subjects underwent symptom, neuropsychological, and psychological testing, before and after treatment or control with retesting 2 months after the 40 th HBOT. Fifty subjects completed the protocol with primary outcome testing. HBOT subjects experienced significant improvements in Neurobehavioral Symptom Inventory, Memory Index, Automated Neuropsychological Assessment Metrics, Hamilton Depression Scale, Hamilton Anxiety Scale, Post-Traumatic Stress Disorder Checklist, Pittsburgh Sleep Quality Index, and Quality Of Life after Brain Injury compared to the Control Group. After crossing over to HBOT the Control Group experienced near-identical significant improvements. Further improvements were experienced by both groups during the 2-month follow-up period. These data indicate that 40 HBOTs at 150 kPa/60 minutes demonstrated statistically significant improvements in postconcussion and Post-Traumatic Stress Disorder symptoms, memory, cognitive functions, depression, anxiety, sleep, and quality of life in civilian and military subjects with mTBI/PPCS compared to controls. Improvements persisted at least 2 months after the 40 th HBOT. The study was registered on ClinicalTrials.gov (NCT02089594) on March 18, 2014 and with the U.S. Food and Drug Administration under Investigational New Drug #113823. The Institutional Review Boards of the United States Army Medical Research and Materiel Command Office of Research Protections Human Research Protection Office and the Louisiana State University School of Medicine (approval No. 7381) approved the study on May 13, 2014 and December 20, 2013, respectively.",2020,"HBOT subjects experienced significant improvements in Neurobehavioral Symptom Inventory, Memory Index, Automated Neuropsychological Assessment Metrics, Hamilton Depression Scale, Hamilton Anxiety Scale, Post-Traumatic Stress Disorder Checklist, Pittsburgh Sleep Quality Index, and Quality Of Life after Brain Injury compared to the Control Group.","['Fifty subjects completed the protocol with primary outcome testing', 'Persistent postconcussion syndrome (PPCS) after mild traumatic brain injury (mTBI', 'mild traumatic brain injury persistent postconcussion syndrome', 'Sixty-three civilian and military subjects with mTBI/PPCS', 'subjects with the PPCS of mTBI', 'March 18, 2014 and with the U.S. Food and Drug Administration under Investigational New Drug #113823', 'forty 150 kPa']","['Hyperbaric oxygen therapy', 'hyperbaric oxygen therapies (HBOTs']","['postconcussion and Post-Traumatic Stress Disorder symptoms, memory, cognitive functions, depression, anxiety, sleep, and quality of life', 'Neurobehavioral Symptom Inventory, Memory Index, Automated Neuropsychological Assessment Metrics, Hamilton Depression Scale, Hamilton Anxiety Scale, Post-Traumatic Stress Disorder Checklist, Pittsburgh Sleep Quality Index, and Quality Of Life after Brain Injury']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0546983', 'cui_str': 'Post-Concussion Symptoms'}, {'cui': 'C3508472', 'cui_str': 'Mild Traumatic Brain Injury'}, {'cui': 'C4319614', 'cui_str': '63 (qualifier value)'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0041714', 'cui_str': 'Food and Drug Administration'}, {'cui': 'C0013230', 'cui_str': 'Investigational New Drugs'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0439474', 'cui_str': 'kPa'}]","[{'cui': 'C0020431', 'cui_str': 'Hyperbaric Oxygen Therapy'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]","[{'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0222045'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0270611', 'cui_str': 'Brain Injuries'}]",,0.0770851,"HBOT subjects experienced significant improvements in Neurobehavioral Symptom Inventory, Memory Index, Automated Neuropsychological Assessment Metrics, Hamilton Depression Scale, Hamilton Anxiety Scale, Post-Traumatic Stress Disorder Checklist, Pittsburgh Sleep Quality Index, and Quality Of Life after Brain Injury compared to the Control Group.","[{'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Harch', 'Affiliation': 'Department of Medicine, Section of Emergency and Hyperbaric Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Andrews', 'Affiliation': 'Department of Medicine and Psychiatry, School of Medicine, Louisiana State University Health Sciences Center, Metairie, LA, USA.'}, {'ForeName': 'Cara J', 'Initials': 'CJ', 'LastName': 'Rowe', 'Affiliation': 'CaTS Clinical Translational Unit, Tulane University School of Medicine, LA, New Orleans, LA, USA.'}, {'ForeName': 'Johannes R', 'Initials': 'JR', 'LastName': 'Lischka', 'Affiliation': 'Family Physicians Center, Marrero, LA, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Townsend', 'Affiliation': 'Louisiana State University-Ochsner Psychiatry Residency Training Program, Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Qingzhao', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': 'School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.'}, {'ForeName': 'Donald E', 'Initials': 'DE', 'LastName': 'Mercante', 'Affiliation': 'School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA.'}]",Medical gas research,['10.4103/2045-9912.279978'] 562,32195857,The Wrist and Radius Injury Surgical Trial: 12-Month Outcomes from a Multicenter International Randomized Clinical Trial.,"BACKGROUND Optimal treatment for distal radius fractures in older adults remains uncertain. No randomized trials comparing the most frequently used treatments in this population have been conducted. Surgical treatment rates vary widely, and the sustained benefits of surgery are uncertain. METHODS The Wrist and Radius Injury Surgical Trial, a randomized, multicenter trial, enrolled 304 adults aged 60 years and older with isolated, unstable distal radius fractures at 24 institutions. Patients who wanted surgery (n = 187) were randomized to internal fixation, external fixation, or percutaneous pinning; patients who preferred conservative management (n = 117) received casting. The primary outcome was the 12-month Michigan Hand Outcomes Questionnaire (MHQ) summary score. RESULTS At 12 months, there were no differences by treatment in primary outcome. Twelve-month MHQ summary scores differed between internal fixation and external fixation by 3 points (97.5 percent CI, 6.0 to 11.5) and between internal fixation and pinning by -0.14 (97.5 percent CI, -9.2 to 8.9). However, at 6 weeks, the mean MHQ summary score for internal fixation was greater than for external fixation by 19 (p < 0.001), pinning by 11 (p < 0.001), and casting by 7 (p = 0.03). Internal fixation participants demonstrated significantly better radiologic alignment throughout the follow-up period. Malunion was experienced by 48 percent of casting participants. CONCLUSIONS Recovery was fastest for internal fixation and slowest for external fixation according to most measures, but by 12 months there were no meaningful differences in outcomes. Casting participants experienced satisfactory results despite loss of radiologic alignment. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,"Twelve-month MHQ Summary scores differed between VLPS and EFP by 3 points (97.5% CL: -6.0, 11.5) and between VLPS and pinning by -0.14(-9.2,8.9).","['distal radius fractures (DRFs) in older adults', 'Patients who wanted surgery (n=187', 'enrolled 304 adults age 60 years and older with isolated, unstable DRFs at 24 institutions']","['VLPS', 'internal fixation with volar plate (VLPS), external fixation (EFP), or percutaneous pinning; patients who preferred conservative management (n=117) received casting']","['12-month Michigan Hand Outcomes Questionnaire (MHQ) Summary score', 'radiologic alignment', 'mean MHQ Summary score for VLPS', 'MHQ domain scores and radiographic parameters']","[{'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1444647', 'cui_str': 'Wanted'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}]","[{'cui': 'C0016642', 'cui_str': 'Osteosynthesis, Fracture'}, {'cui': 'C0443349', 'cui_str': 'Volar (qualifier value)'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate (procedure)'}, {'cui': 'C0407333', 'cui_str': 'Fixation of fracture using external fixator (procedure)'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}, {'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205483', 'cui_str': 'Radiologic (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",304.0,0.137787,"Twelve-month MHQ Summary scores differed between VLPS and EFP by 3 points (97.5% CL: -6.0, 11.5) and between VLPS and pinning by -0.14(-9.2,8.9).","[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Ann Arbor, Mich. From the Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School; and the Center for Statistical Consulting and Research, University of Michigan.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Sunitha', 'Initials': 'S', 'LastName': 'Malay', 'Affiliation': ''}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006829'] 563,32195858,"The Effect of Surgical Video on Resident Performance of Carpal Tunnel Release: A Cadaveric Simulation-Based, Prospective, Randomized, Blinded Pilot Study.","BACKGROUND Surgical videos are increasingly common, although their role in residency curricula remains unclear. The aim of this study was to evaluate the impact of an educational surgical video on resident performance of an open carpal tunnel release through an Objective Structured Assessment of Technical Skills and serial questionnaires. METHODS Twenty-two residents representing six postgraduate years were randomized to receive text-based materials with or without a surgical video before performing a carpal tunnel release on human cadavers. Procedures were video recorded, anonymized, and independently evaluated by three hand surgeons using the Objective Structured Assessment of Technical Skills global rating scale, a procedure-specific technical rating scale, a record of operative errors, and pass/fail designation. Residents completed questionnaires before and after the procedure to track confidence in their technical skills. RESULTS Residents in their first and second postgraduate years (n = 10) who watched the surgical video committed fewer operative errors (median, 4 versus 1.3; p = 0.043) and were more confident in their abilities following the procedure (median, 75 versus 32; p = 0.043) than those receiving text resources alone. There were no significant differences in Objective Structured Assessment of Technical Skills performance or questionnaire responses among more senior residents (n = 12). The technical rating scale was internally consistent (Cronbach α = 0.95; 95 percent CI, 0.91 to 0.98), reliable (intraclass correlation coefficient, 0.73; 95 percent CI, 0.40 to 0.88), and correlated with surgical experience (Spearman ρ = 0.57; p = 0.006). CONCLUSION Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.",2020,Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.,"['Twenty-two residents representing six postgraduate years', 'Carpal Tunnel Release']","['educational surgical video', 'text-based materials with or without a surgical video before performing a carpal tunnel release on human cadavers', 'Surgical Video']","['OSATS global rating scale, a procedure-specific technical rating scale, a record of operative errors, and pass/fail designation', 'technical rating scale', 'operative errors', 'OSATS performance or questionnaire responses']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0196576', 'cui_str': 'Carpal tunnel decompression'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0196576', 'cui_str': 'Carpal tunnel decompression'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0006629', 'cui_str': 'Corpse'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C2355580', 'cui_str': 'Record of (contextual qualifier) (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0372309,Watching an educational surgical video to prepare for a cadaveric procedure significantly reduced operative errors and improved confidence among junior trainees performing a carpal tunnel release.,"[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Yee', 'Affiliation': 'St. Louis, Mo.; and Utrecht, The Netherlands From the Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine; and the Department of Plastic, Reconstructive and Hand Surgery, Utrecht University Medical Center.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Padovano', 'Affiliation': ''}, {'ForeName': 'Amanda G', 'Initials': 'AG', 'LastName': 'Rowe', 'Affiliation': ''}, {'ForeName': 'Elspeth J R', 'Initials': 'EJR', 'LastName': 'Hill', 'Affiliation': ''}, {'ForeName': 'Ida K', 'Initials': 'IK', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'Amy M', 'Initials': 'AM', 'LastName': 'Moore', 'Affiliation': ''}, {'ForeName': 'J Henk', 'Initials': 'JH', 'LastName': 'Coert', 'Affiliation': ''}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Mackinnon', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006817'] 564,32195861,Postoperative Antibiotic Prophylaxis in Reduction Mammaplasty: A Randomized Controlled Trial.,"BACKGROUND Reduction mammaplasty is a well-established procedure. Studies have shown benefits of using antibiotics in this procedure. Nevertheless, there is no solid evidence to support postoperative antibiotic prophylaxis. The authors evaluated the influence of postoperative antibiotic delivery on infection rates after reduction mammaplasty. METHODS The authors conducted a randomized trial of noninferiority, with two parallel groups, with triple blinding. The participants were 124 women with breast hypertrophy, with reduction mammaplasty already scheduled, selected consecutively. All patients underwent reduction mammaplasty, performed by the same surgical team, using the superomedial pedicle technique for ascending the nipple-areola complex. All patients received cephalothin (1 g) intravenously at the anesthetic induction and every 6 hours for 24 hours. At hospital discharge, they were assigned randomly to either the placebo (n = 62) or antibiotic group (n = 62) and were instructed to take identical capsules containing 500 mg of cephalexin or placebo, respectively, every 6 hours, for 7 days. Patients were assessed weekly, for 4 weeks, regarding the occurrence of surgical-site infection, by a surgeon who was unaware of the allocation. The criteria and definitions of the Centers for Disease Control and Prevention were adopted. RESULTS There was no statistical difference between groups regarding age, body mass index, or resected breast tissue weight. The overall surgical-site infection rate was 0.81 percent. Only one patient, allocated to the antibiotic, presented infection, classified as superficial incisional (p = 1.00). In the placebo group, surgery time was higher (p = 0.003). CONCLUSION The maintenance of antibiotics in the postoperative period of reduction mammaplasty did not influence the rates of surgical-site infection. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, I.",2020,"Only one patient, allocated to AG, presented infection, classified as superficial incisional (p=1.00).","['124 women with breast hypertrophy, with reduction mammaplasty already scheduled, selected consecutively', 'reduction mammaplasty']","['Postoperative antibiotic prophylaxis', 'placebo', 'antibiotic', 'cephalothin', 'cephalexin or placebo']","['infection rates', 'surgery time', 'overall surgical site infection rate', 'rates of surgical site infection']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0191922', 'cui_str': 'Breast reduction'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0007735', 'cui_str': 'cefalotin'}, {'cui': 'C0007716', 'cui_str': 'Cephalexin'}]","[{'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}]",124.0,0.159188,"Only one patient, allocated to AG, presented infection, classified as superficial incisional (p=1.00).","[{'ForeName': 'Edgard S', 'Initials': 'ES', 'LastName': 'Garcia', 'Affiliation': 'São Paulo and Pouso Alegre, Brazil From the Graduate Program in Translational Surgery, Universidade Federal de São Paulo; the Division of Plastic Surgery and the Department of Bioestatistics, Universidade do Vale do Sapucaí; and Universidade de Santo.'}, {'ForeName': 'Daniela F', 'Initials': 'DF', 'LastName': 'Veiga', 'Affiliation': ''}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Veiga-Filho', 'Affiliation': ''}, {'ForeName': 'Isaías V', 'Initials': 'IV', 'LastName': 'Cabral', 'Affiliation': ''}, {'ForeName': 'Natália L L', 'Initials': 'NLL', 'LastName': 'Pinto', 'Affiliation': ''}, {'ForeName': 'Neil F', 'Initials': 'NF', 'LastName': 'Novo', 'Affiliation': ''}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Sabino-Neto', 'Affiliation': ''}, {'ForeName': 'Lydia M', 'Initials': 'LM', 'LastName': 'Ferreira', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006809'] 565,32024496,Study protocol for a randomized controlled trial: Qiliqiangxin in heart failUre: assESsment of reduction in morTality (QUEST).,"BACKGROUND Qiliqiangxin (QLQX) capsule is a Traditional Chinese Medicine (TCM) that has been approved in China for the treatment of chronic heart failure (CHF). Our previous study showed with a background of standard HF treatment, QLQX capsules further reduced the levels of NT-proBNP and the incidence of composite cardiac events (CCEs) in CHF patients. This study aims to further assess the reduction in mortality when using QLQX compared with placebo for heart failure with reduced ejection fraction (HFrEF) patients. METHODS This study is a randomized, double-blind, placebo-controlled, parallel-group, multi-center, event-driven clinical study of approximately 3080 patients for a targeted 620 events. Patients must have a diagnosis of heart failure for at least 3 months prior to screening. Patients will be randomized 1:1 to receive the placebo or QLQX in addition to their standard medications of CHF. The primary efficacy outcome event is a composite cardiovascular death and re-hospitalization due to the worsening of heart failure. DISCUSSION The QUEST study is a randomized control study of TCM in chronic heart failure. It will determine the place of QLQX as an new treatment approach and provide additional and innovative information regarding TCM - and the specific used of QLQX in HFrEF. TRIAL REGISTRATION The trial was registered at http://www.chictr.org.cn. ( Registration No.: ChiCTR1900021929); Date: 2019-03-16.",2020,"Our previous study showed with a background of standard HF treatment, QLQX capsules further reduced the levels of NT-proBNP and the incidence of composite cardiac events (CCEs) in CHF patients.","['chronic heart failure', 'heart failure with reduced ejection fraction (HFrEF) patients', 'approximately 3080 patients for a targeted 620 events', 'CHF patients', 'heart failUre']","['Qiliqiangxin (QLQX) capsule', 'TCM', 'placebo', 'QLQX', 'Qiliqiangxin', 'placebo or QLQX']","['levels of NT-proBNP and the incidence of composite cardiac events (CCEs', 'diagnosis of heart failure', 'composite cardiovascular death and re-hospitalization due to the worsening of heart failure']","[{'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]","[{'cui': 'C3492419', 'cui_str': 'qiliqiangxin'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]",3080.0,0.341045,"Our previous study showed with a background of standard HF treatment, QLQX capsules further reduced the levels of NT-proBNP and the incidence of composite cardiac events (CCEs) in CHF patients.","[{'ForeName': 'Wenming', 'Initials': 'W', 'LastName': 'Yao', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Iokfai', 'Initials': 'I', 'LastName': 'Cheang', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Shengen', 'Initials': 'S', 'LastName': 'Liao', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Yanli', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Zhou', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Dongjie', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Zhenhua', 'Initials': 'Z', 'LastName': 'Jia', 'Affiliation': 'National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, China.'}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Chang', 'Affiliation': 'National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, China.'}, {'ForeName': 'Haifeng', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China.'}, {'ForeName': 'Xinli', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road 300, Nanjing, 210029, China. xinli3267@yeah.net.'}]",BMC complementary medicine and therapies,['10.1186/s12906-020-2821-0'] 566,32192644,Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial.,"BACKGROUND The 24-week randomized, double-blind ODYSSEY ALTERNATIVE trial (NCT01709513) demonstrated significant low-density lipoprotein cholesterol (LDL-C) reductions with the PCSK9 inhibitor alirocumab vs ezetimibe in statin-intolerant patients, with significantly fewer skeletal muscle events (SMEs; 32.5%) vs atorvastatin (46.0%; hazard ratio: 0.61, 95% confidence interval: 0.38 to 0.99, P = .042). OBJECTIVE ALTERNATIVE participants could enter an open-label treatment period (OLTP) for assessment of long-term safety. METHODS Two hundred and eighty one patients entered the OLTP; 93.7%, 84.0%, and 92.9% of patients who received atorvastatin, ezetimibe, and alirocumab, respectively, during double-blind treatment, including 216 patients (76.9%) who completed double-blind treatment, as well as patients who either prematurely discontinued treatment due to SME (n = 51 [18.1%]) or other reasons (n = 14 [5.0%]) but completed week 24 assessments. All patients in the OLTP received alirocumab (75 or 150 mg every 2 weeks based on investigator decision) for ∼3 years or until commercial availability, whichever came first. RESULTS SMEs were reported by 38.4% of patients in the OLTP. Safety results from the OLTP were similar to those of the alirocumab group in the double-blind period, except for a lower rate of discontinuations due to SMEs observed with alirocumab in the OLTP (3.2% vs 15.9% in the double-blind period). At OLTP week 8, mean LDL-C reduction from baseline (=week 0 of double-blind period) was 52.0%, with reductions sustained through to the end-of-treatment visits (55.4% and 53.7% reduction at weeks 100 and 148, respectively). CONCLUSIONS In this population of statin-intolerant patients, alirocumab was well tolerated and produced durable LDL-C reductions over 3 years.",2020,"In this population of statin-intolerant patients, alirocumab was well tolerated and produced durable LDL-C reductions over 3 years.","['Two hundred and eighty one patients entered the', '216 patients (76.9%) who completed double-blind treatment, as well as patients who either prematurely discontinued treatment due to SME (n\xa0=\xa051 [18.1%]) or other reasons (n\xa0=\xa014 [5.0%]) but completed week 24 assessments', 'statin-intolerant patients over 3\xa0years']","['atorvastatin, ezetimibe, and alirocumab', 'PCSK9 inhibitor alirocumab vs ezetimibe', 'atorvastatin', 'OLTP', 'alirocumab', 'alirocumab ']","['tolerated and produced durable LDL-C reductions', 'mean LDL-C reduction', 'Efficacy and safety', 'low-density lipoprotein cholesterol (LDL-C) reductions', 'skeletal muscle events']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4517884', 'cui_str': '81'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4708905', 'cui_str': 'Two hundred and sixteen'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C4522007', 'cui_str': 'Proprotein convertase subtilisin/kexin type 9 inhibitor'}]","[{'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",281.0,0.448887,"In this population of statin-intolerant patients, alirocumab was well tolerated and produced durable LDL-C reductions over 3 years.","[{'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Moriarty', 'Affiliation': 'Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: pmoriart@kumc.edu.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Thompson', 'Affiliation': 'Hartford Hospital, Hartford, CT, USA.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': 'Baim Institute for Clinical Research, Boston, MA, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Guyton', 'Affiliation': 'Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bergeron', 'Affiliation': 'Lipid Clinic, Centre Hospitalier Universitaire de Quebec, Laval University, Quebec, Canada.'}, {'ForeName': 'Franklin J', 'Initials': 'FJ', 'LastName': 'Zieve', 'Affiliation': 'McGuire VA Medical Center, Richmond, VA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bruckert', 'Affiliation': 'Groupe Hospitalier Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris), Paris, France.'}, {'ForeName': 'Terry A', 'Initials': 'TA', 'LastName': 'Jacobson', 'Affiliation': 'Department of Medicine, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Baccara-Dinet', 'Affiliation': 'Sanofi, Montpellier, France.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Donahue', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Shazia', 'Initials': 'S', 'LastName': 'Ali', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Garen', 'Initials': 'G', 'LastName': 'Manvelian', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2020.01.001'] 567,32189094,"Delegating Clozapine Monitoring to Advanced Nurse Practitioners: An Exploratory, Randomized Study to Assess the Effect on Prescription and Its Safety.","To test whether: (1) psychiatrists will prescribe clozapine more often if they can delegate the monitoring tasks to an advanced nurse practitioner (ANP), (2) clozapine monitoring by an ANP is at least as safe as monitoring by a psychiatrist. Patients from 23 Dutch outpatient teams were assessed for an indication for clozapine. ANPs affiliated to these teams were randomized to Condition A: clozapine monitoring by an ANP, or Condition B: monitoring by the psychiatrist. The safety of monitoring was evaluated by determining whether the weekly neutrophil measurements were performed. Staff and patients were blinded regarding the first hypothesis. Of the 173 patients with an indication for clozapine at baseline, only seven in Condition A and four in Condition B were prescribed clozapine (Odds Ratio = 2.24, 95% CI 0.61-8.21; p = 0.225). These low figures affected the power of this study. When we considered all patients who started with clozapine over the 15-month period (N = 49), the Odds Ratio was 1.90 (95% CI 0.93-3.87; p = 0.078). With regard to the safety of the monitoring of the latter group of patients, 71.2% of the required neutrophil measurements were performed in condition A and 67.3% in condition B (OR = 0.98; CI = 0.16-3.04; p = 0.98). Identifying patients with an indication for clozapine does not automatically lead to improved prescription rates, even when an ANP is available for the monitoring. Clozapine-monitoring performed by an ANP seemed as safe as that by a psychiatrist.",2020,"Identifying patients with an indication for clozapine does not automatically lead to improved prescription rates, even when an ANP is available for the monitoring.","['Advanced Nurse Practitioners', '173 patients with an indication for', 'Patients from 23 Dutch outpatient teams']","['Clozapine', 'clozapine']",['prescription rates'],"[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner (occupation)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C0009079', 'cui_str': 'Clozapine'}]","[{'cui': 'C0033080', 'cui_str': 'Prescriptions'}]",173.0,0.0393801,"Identifying patients with an indication for clozapine does not automatically lead to improved prescription rates, even when an ANP is available for the monitoring.","[{'ForeName': 'Y C', 'Initials': 'YC', 'LastName': 'van der Zalm', 'Affiliation': 'Rivierduinen Institute for Mental Health, Leiden, The Netherlands. y.vanderzalm@rivierduinen.nl.'}, {'ForeName': 'P F', 'Initials': 'PF', 'LastName': 'Schulte', 'Affiliation': 'Dutch Clozapine Collaboration Group, Castricum, The Netherlands.'}, {'ForeName': 'J P A M', 'Initials': 'JPAM', 'LastName': 'Bogers', 'Affiliation': 'Rivierduinen Institute for Mental Health, Leiden, The Netherlands.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Termorshuizen', 'Affiliation': 'Rivierduinen Institute for Mental Health, Leiden, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Marcelis', 'Affiliation': 'Department of Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'M A G B', 'Initials': 'MAGB', 'LastName': 'van Piere', 'Affiliation': 'Rivierduinen Institute for Mental Health, Leiden, The Netherlands.'}, {'ForeName': 'I E', 'Initials': 'IE', 'LastName': 'Sommer', 'Affiliation': 'Department of Neuroscience and Department of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Selten', 'Affiliation': 'Rivierduinen Institute for Mental Health, Leiden, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Administration and policy in mental health,['10.1007/s10488-020-01031-4'] 568,32014842,"Feasibility, Acceptability, and Clinical Effectiveness of a Technology-Enabled Cardiac Rehabilitation Platform (Physical Activity Toward Health-I): Randomized Controlled Trial.","BACKGROUND Cardiac rehabilitation (CR) is highly effective as secondary prevention for cardiovascular diseases (CVDs). Uptake of CR remains suboptimal (30% of eligible patients), and long-term adherence to a physically active lifestyle is even lower. Innovative strategies are needed to counteract this phenomenon. OBJECTIVE The Physical Activity Toward Health (PATHway) system was developed to provide a comprehensive, remotely monitored, home-based CR program for CVD patients. The PATHway-I study aimed to investigate its feasibility and clinical efficacy during phase III CR. METHODS Participants were randomized on a 1:1 basis to the PATHway (PW) intervention group or usual care (UC) control group in a single-blind, multicenter, randomized controlled pilot trial. Outcomes were assessed at completion of phase II CR and 6-month follow-up. The primary outcome was physical activity (PA; Actigraph GT9X link). Secondary outcomes included measures of physical fitness, modifiable cardiovascular risk factors, endothelial function, intima-media thickness of the common carotid artery, and quality of life. System usability and patients' experiences were evaluated only in PW. A mixed-model analysis of variance with Bonferroni adjustment was used to analyze between-group effects over time. Missing values were handled by means of an intention-to-treat analysis. Statistical significance was set at a 2-sided alpha level of .05. Data are reported as mean (SD). RESULTS A convenience sample of 120 CVD patients (mean 61.4 years, SD 13.5 years; 22 women) was included. The PATHway system was deployed in the homes of 60 participants. System use decreased over time and system usability was average with a score of 65.7 (SD 19.7; range 5-100). Moderate-to-vigorous intensity PA increased in PW (PW: 127 [SD 58] min to 141 [SD 69] min, UC: 146 [SD 66] min to 143 [SD 71] min; P interaction =.04; effect size of 0.42), while diastolic blood pressure (PW: 79 [SD 11] mmHg to 79 [SD 10] mmHg, UC: 78 [SD 9] mmHg to 83 [SD 10] mmHg; P interaction =.004; effect size of -0.49) and cardiovascular risk score (PW: 15.9% [SD 10.4%] to 15.5% [SD 10.5%], UC: 14.5 [SD 9.7%] to 15.7% [SD 10.9%]; P interaction =.004; effect size of -0.36) remained constant, but deteriorated in UC. CONCLUSIONS This pilot study demonstrated the feasibility and acceptability of a technology-enabled, remotely monitored, home-based CR program. Although clinical effectiveness was demonstrated, several challenges were identified that could influence the adoption of PATHway. TRIAL REGISTRATION ClinicalTrials.gov NCT02717806; https://clinicaltrials.gov/ct2/show/NCT02717806. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1136/bmjopen-2017-016781.",2020,System use decreased over time and system usability was average with a score of 65.7 (SD 19.7; range 5-100).,"['Participants', 'homes of 60 participants', '120 CVD patients (mean 61.4 years, SD 13.5 years; 22 women) was included', 'CVD patients']","['Cardiac rehabilitation (CR', 'technology-enabled, remotely monitored, home-based CR program', 'PATHway (PW) intervention group or usual care (UC) control group', 'mmHg, UC', 'Technology-Enabled Cardiac Rehabilitation Platform (Physical Activity Toward Health']","['time and system usability', 'physical fitness, modifiable cardiovascular risk factors, endothelial function, intima-media thickness of the common carotid artery, and quality of life', 'Feasibility, Acceptability, and Clinical Effectiveness', 'Moderate-to-vigorous intensity PA', 'cardiovascular risk score', 'diastolic blood pressure', 'physical activity (PA; Actigraph GT9X link']","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0162859', 'cui_str': 'Common carotid artery structure'}, {'cui': 'C0034380'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",120.0,0.15419,System use decreased over time and system usability was average with a score of 65.7 (SD 19.7; range 5-100).,"[{'ForeName': 'Jomme', 'Initials': 'J', 'LastName': 'Claes', 'Affiliation': 'Physiotherapy Department, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Cornelissen', 'Affiliation': 'Department of Rehabilitation Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'McDermott', 'Affiliation': 'Department of Health & Human Performance, Dublin City University, Dublin, Ireland.'}, {'ForeName': 'Niall', 'Initials': 'N', 'LastName': 'Moyna', 'Affiliation': 'Department of Health & Human Performance, Dublin City University, Dublin, Ireland.'}, {'ForeName': 'Nele', 'Initials': 'N', 'LastName': 'Pattyn', 'Affiliation': 'Department of Rehabilitation Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Cornelis', 'Affiliation': 'Department of Rehabilitation Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Gallagher', 'Affiliation': 'Mater Misericordiae University Hospital, Dublin, Ireland.'}, {'ForeName': 'Ciara', 'Initials': 'C', 'LastName': 'McCormack', 'Affiliation': 'Department of Health & Human Performance, Dublin City University, Dublin, Ireland.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Newton', 'Affiliation': 'Beaumont Hospital, Dublin, Ireland.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Gillain', 'Affiliation': 'Physiotherapy Department, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Budts', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Kaatje', 'Initials': 'K', 'LastName': 'Goetschalckx', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Woods', 'Affiliation': 'Physical Activity for Health, Health Research Institute, Department of Physical Education and Sport Sciences, University of Limerick, Limerick, Ireland.'}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Moran', 'Affiliation': 'Department of Health & Human Performance, Dublin City University, Dublin, Ireland.'}, {'ForeName': 'Roselien', 'Initials': 'R', 'LastName': 'Buys', 'Affiliation': 'Department of Rehabilitation Sciences, University of Leuven, Leuven, Belgium.'}]",Journal of medical Internet research,['10.2196/14221'] 569,32184056,"Patient Navigation to Reduce Emergency Department (ED) Utilization Among Medicaid Insured, Frequent ED Users: A Randomized Controlled Trial.","BACKGROUND Some Medicaid enrollees frequently utilize the emergency department (ED) due to barriers accessing health care services in other settings. OBJECTIVES To determine whether an ED-initiated Patient Navigation program (ED-PN) designed to improve health care access for Medicaid-insured frequent ED users could decrease ED visits, hospitalizations, and costs. METHODS We conducted a prospective, randomized controlled trial comparing ED-PN with usual care (UC) among 100 Medicaid-enrolled frequent ED users (defined as 4-18 ED visits in the prior year), assessing ED utilization during the 12 months pre- and post-enrollment. Secondary outcomes included hospitalizations, outpatient utilization, hospital costs, and Medicaid costs. We also compared characteristics between ED-PN patients with and without reduced ED utilization. RESULTS Of 214 eligible patients approached, 100 (47%) consented to participate. Forty-nine were randomized to ED-PN and 51 to UC. Sociodemographic characteristics and prior utilization were similar between groups. ED-PN participants had a significant reduction in ED visits and hospitalizations during the 12-month evaluation period compared with UC, averaging 1.4 fewer ED visits per patient (p = 0.01) and 1.0 fewer hospitalizations per patient (p = 0.001). Both groups increased outpatient utilization. ED-PN patients showed a trend toward reduced per-patient hospital costs (-$10,201, p = 0.10); Medicaid costs were unchanged (-$5,765, p = 0.26). Patients who demonstrated a reduction in ED usage were older (mean age 42 vs. 33 years, p = 0.03) and had lower health literacy (78% low health literacy vs. 40%, p = 0.02). CONCLUSION An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.",2020,An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.,"['Forty-nine', '214 eligible patients approached, 100 (47%) consented to participate', '100 Medicaid-enrolled frequent ED users (defined as 4-18 ED visits in the prior year), assessing ED utilization during the 12\xa0months pre- and post-enrollment', 'Medicaid Insured, Frequent ED Users']","['ED-initiated Patient Navigation program (ED-PN', 'usual care (UC']","['Emergency Department (ED) Utilization', 'Medicaid costs', 'outpatient utilization', 'ED visits, hospitalizations, and costs', 'health literacy', 'hospitalizations, outpatient utilization, hospital costs, and Medicaid costs', 'reduced per-patient hospital costs', 'ED visits and hospitalizations', 'Sociodemographic characteristics and prior utilization']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C3494323', 'cui_str': 'Navigations, Patient'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0206174', 'cui_str': 'Hospital Costs'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",214.0,0.102574,An ED-PN program targeting Medicaid-insured high ED utilizers demonstrated significant reductions in ED visits and hospitalizations in the 12 months after enrollment.,"[{'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Kelley', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Capp', 'Affiliation': 'Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Carmona', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': ""D'Onofrio"", 'Affiliation': 'Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Mei', 'Affiliation': 'Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Darcey', 'Initials': 'D', 'LastName': 'Cobbs-Lomax', 'Affiliation': 'Project Access-New Haven, New Haven, Connecticut.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ellis', 'Affiliation': 'Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2019.12.001'] 570,32186050,Influence of the quickness and duration of De Qi on the analgesic effect of acupuncture in primary dysmenorrhea patients with a cold and dampness stagnation pattern.,"OBJECTIVE To investigate the influence of the quickness and duration of De Qi (or Qi arrival) on the analgesic effect of acupuncture in primary dysmenorrhea patients with a cold and dampness stagnation pattern. METHODS Sixty-eight patients were randomly assigned to the De Qi group (deep needling with thick needles and manipulation, n = 17) or the non-De Qi group (shallow needling with thin needles and no manipulation, n = 51). Both groups underwent needling at Sanyinjiao (SP 6) for 30 min. The visual analogue scale was used to measure the degree of menstrual pain, and the Acupuncture De Qi Clinical Assessment Scale was used to assess De Qi. Only data from patients who experienced actual De Qi were included in the analysis. RESULTS Thirty-nine patients experienced actual De Qi. Patients who experienced actual De Qi in the De Qi group (n = 14) felt De Qi more rapidly (P = 0.028) and for a longer duration (P = 0.04) than patients who experienced actual De Qi in the non-De Qi group (n = 25). Both groups showed a reduction in the visual analogue scale score for pain after treatment. The analgesic effect did not significantly differ between the two groups. The occurrence time of De Qi showed a significant negative correlation with pain reduction at 20 and 30 min after needle removal (P < 0.05). There was no correlation between the duration of De Qi and the therapeutic effect. CONCLUSION In primary dysmenorrhea patients with a cold and dampness stagnation pattern, quicker onset of De Qi when needling Sanyinjiao (SP 6) achieves a better analgesic outcome. However, a longer duration of De Qi does not affect the degree of analgesia. Compared with minimal acupuncture, active acupuncture stimulation achieves a more rapid onset and longer duration of De Qi.",2019,The analgesic effect did not significantly differ between the two groups.,"['Sixty-eight patients', 'primary dysmenorrhea patients with a cold and dampness stagnation pattern']","['acupuncture', 'De Qi (or Qi arrival', 'minimal acupuncture, active acupuncture stimulation', 'De Qi group (deep needling with thick needles and manipulation, n = 17) or the non-De Qi group (shallow needling with thin needles and no manipulation']","['analgesic effect', 'quicker onset of De Qi', 'visual analogue scale', 'duration of De Qi and the therapeutic effect', 'rapid onset and longer duration of De Qi', 'visual analogue scale score for pain', 'actual De Qi', 'pain reduction', 'occurrence time of De Qi', 'degree of menstrual pain, and the Acupuncture De Qi Clinical Assessment Scale']","[{'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea (disorder)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1280412', 'cui_str': 'Thick (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0332528', 'cui_str': 'Decreased thickness (finding)'}]","[{'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1527144'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0439591', 'cui_str': 'Long duration (qualifier value)'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales (assessment scale)'}]",68.0,0.0325102,The analgesic effect did not significantly differ between the two groups.,"[{'ForeName': 'Nijuan', 'Initials': 'N', 'LastName': 'Hu', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Liangxiao', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Pei', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Guiwen', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Minyi', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Shangqing', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Junjun', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Yafeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Zhuang', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': 'School of Acupuncture Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing 100029, China.'}, {'ForeName': 'Liangxiao', 'Initials': 'L', 'LastName': 'Ma', 'Affiliation': 'the Key Unit of State Administration of Traditional Chines Medicine, Evaluation of Characteristic Acupuncture Therapy, Beijing 100029, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 571,32186047,Effect of herb-partitioned moxibustion for primary dysmenorrhea: a randomized clinical trial.,"OBJECTIVE To observe the effect of herb-partitioned moxibustion (HPM) for primary dysmenorrhea. METHODS Six hundred and forty patients were randomized assigned (1∶1) to HPM group and control group. Duration of treatment was 3 months with 3 month follow-up. The primary outcome was pain relief measured by visual analogue scale (VAS). The second outcomes were Cox Menstrual Symptom Scale (CMSS), menstrual pain duration and frequency of analgesics usage. The exploratory outcome included quality of life, RESULTS: After the 3-month treatment and follow-ups, the pain intensity measured by VAS was significantly reduced in both groups compared with baseline (P < 0.05), and it was significantly decreased in HPM group than that of control group (P < 0.001). The higher proportion of participants in the HPM group had a decrease of at least 50% in VAS at the end of treatment, as compared with the control group (P < 0.001). At the 3rd and 6th month, the menstrual pain duration, CMSS score and frequency of analgesics usage in HPM group were significantly lower than those of control group (P < 0.05). After 3 month treatment and follow-ups,the scores of physical, psychological, social and environmental domains were significantly increased than baseline in both groups (P < 0.05), and the sores of physical, psychological and environmental domains were significantly higher in HPM group than those of control group (P < 0.05) . CONCLUSION Herb-partitioned moxibustion reduced menstrual pain and improved quality of life, these were sustained for up to 3 months after treatment. Further research is needed to understand long term effect and the mechanism of the intervention.",2019,"After 3 month treatment and follow-ups,the scores of physical, psychological, social and environmental domains were significantly increased than baseline in both groups (P < 0.05), and the sores of physical, psychological and environmental domains were significantly higher in HPM group than those of control group (P < 0.05) . ","['Six hundred and forty patients', 'primary dysmenorrhea']","['Herb-partitioned moxibustion', 'herb-partitioned moxibustion (HPM', 'HPM group and control group', 'herb-partitioned moxibustion', 'HPM']","['sores of physical, psychological and environmental domains', 'scores of physical, psychological, social and environmental domains', 'quality of life', 'menstrual pain duration, CMSS score and frequency of analgesics usage', 'menstrual pain and improved quality of life', 'pain intensity measured by VAS', 'pain relief measured by visual analogue scale (VAS', 'Cox Menstrual Symptom Scale (CMSS), menstrual pain duration and frequency of analgesics usage', 'VAS']","[{'cui': 'C4708790', 'cui_str': '640'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea (disorder)'}]","[{'cui': 'C0019240', 'cui_str': 'Herb (substance)'}, {'cui': 'C0026652', 'cui_str': 'Moxabustion'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1455785', 'cui_str': 'Sore sensation quality'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0013390', 'cui_str': 'Pain, Menstrual'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0222045'}]",640.0,0.04434,"After 3 month treatment and follow-ups,the scores of physical, psychological, social and environmental domains were significantly increased than baseline in both groups (P < 0.05), and the sores of physical, psychological and environmental domains were significantly higher in HPM group than those of control group (P < 0.05) . ","[{'ForeName': 'Yinghua', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Obstetrics and Gynecology, Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Obstetrics and Gynecology, Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics and Gynecology, Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110032, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Shi', 'Affiliation': 'Department of Gynecology, Second Affiliated Hospital, Liaoning University of Traditional Chinese Medicine, Shenyang 110034, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Department of Gynecology, First Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 572,31958161,Interventions for chronic palmoplantar pustulosis.,"BACKGROUND Palmoplantar pustulosis is a chronic inflammatory disease in which sterile, relapsing pustules appear on the palms and soles, possibly in conjunction with other symptoms. The previous Cochrane Review on this topic was published in 2006, before biological treatments were extensively used. OBJECTIVES To assess the effects of interventions for chronic palmoplantar pustulosis to induce and maintain complete remission. SEARCH METHODS We searched the following databases up to March 2019: Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of the included studies for further references to relevant randomised controlled trials (RCTs). SELECTION CRITERIA We considered RCTs including people with palmoplantar pustulosis or chronic palmoplantar pustular psoriasis assessing topical therapy, systemic therapy, combinations of topical or systemic therapies, or non-pharmacological therapies compared with placebo, no intervention, or each other. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. Our outcomes included 'Proportion of participants cleared or almost cleared', 'Proportion of participants with adverse effects serious or severe enough to cause withdrawal', 'Proportion of participants with at least 50% improvement in disease severity', and 'Proportion of participants with adverse effects'. MAIN RESULTS We included 37 studies (1663 participants; mean age 50 years (range 34 to 63); 24% males). These studies reported condition severity differently. Around half of the included trials stated the setting (hospitals, community clinics, or both). More than half of the studies were at high risk of bias in at least one domain. Our included studies assessed mainly systemic treatments (retinoids, ciclosporin, biologics, etretinate + PUVA (combination of psoralens and long-wave ultraviolet radiation) therapy combined, and antibiotics), but also topical treatments (dermocorticoids, vitamin D) and phototherapy (PUVA, ultraviolet A1 (UVA1)). Other interventions were assessed by single studies. The most common comparator was placebo. All results presented in this abstract were assessed in the short term (mean treatment duration was 11 weeks (range 8 to 24 weeks)) and are based on participants with chronic palmoplantar pustulosis. All outcome time point measurements were taken from baseline and assessed at the end of treatment. Short-term and long-term outcomes were defined as measurement up to 24 weeks after randomisation and between 24 and 104 weeks after randomisation, respectively. One trial (188 participants) assessed the topical vitamin D derivative maxacalcitol versus placebo and found that maxacalcitol may be more effective than placebo in achieving clearance (risk ratio (RR) 7.83, 95% confidence interval (CI) 1.85 to 33.12; low-quality evidence), and the risk of adverse effects (such as mild local irritation, pruritus, and haematological or urinary test abnormalities) is probably similar in both groups (RR 0.87, 95% CI 0.64 to 1.19; moderate-quality evidence). Severity was not reported. Two trials (49 participants) assessed PUVA therapy versus placebo or no treatment, providing very low-quality evidence. Adverse effects were reported with oral PUVA (including nausea, ankle swelling, and non-purulent conjunctivitis) and with local PUVA (including blistering, erythema, and pruritus). With regard to the systemic retinoid alitretinoin, one trial (33 participants; moderate-quality evidence) showed that alitretinoin probably makes little or no difference in reducing severity when compared to placebo (RR 0.69, 95% CI 0.36 to 1.30). A similar number of adverse events were reported in both treatment groups, including headache, cheilitis, nausea, arthralgia, and nasopharyngitis (RR 0.84, 95% CI 0.61 to 1.17). Clearance was not reported. There may be little or no difference between etanercept and placebo in achieving clearance (RR 1.64, 95% CI 0.08 to 34.28; 1 study; 15 participants; low-quality evidence); however, the 95% CI was very wide, showing there may be a difference between groups. Severity was not measured. More patients treated with placebo may achieve reduced severity than those treated with ustekinumab, but the wide 95% CI indicates there might be little or no difference between groups and there might be greater effect with ustekinumab (RR 0.48, 95% CI 0.11 to 2.13; 1 study; 33 participants; low-quality evidence). Clearance was not reported. It is uncertain whether guselkumab increases clearance when compared to placebo (2 studies; 154 participants) because the quality of evidence is very low, but guselkumab probably better reduces disease severity (RR 2.88, 95% CI 1.24 to 6.69; 1 study; 49 participants; moderate-quality evidence). Secukinumab is probably superior to placebo in reducing severity (RR 1.55, 95% CI 1.02 to 2.35; 1 study; 157 participants; moderate-quality evidence), but our clearance outcome was not reported. None of these trials reported on occurrence of adverse effects. Only two of the studies discussed above reported adverse effects serious or severe enough to cause withdrawal. Guselkumab may cause more serious adverse events when compared to placebo, but there is uncertainty due to the very wide 95% CI showing there may be little or no difference and showing more events with placebo (RR 2.88, 95% CI 0.32 to 25.80; 1 study; 49 participants; low-quality evidence). Secukinumab probably causes more serious adverse events than placebo (RR 3.29, 95% CI 1.40 to 7.75; 1 study; 157 participants; moderate-quality evidence). AUTHORS' CONCLUSIONS Evidence is lacking for major chronic palmoplantar pustulosis treatments such as superpotent corticosteroids, phototherapy, acitretin, methotrexate, and ciclosporin. Risk of bias and imprecision limit our confidence. Maxacalcitol may be more effective than placebo in achieving clearance in the short term (low-quality evidence), and the risk of adverse effects is probably similar (moderate-quality evidence). Oral alitretinoin is probably no more effective than placebo in reducing severity, with a similar risk of adverse effects (moderate-quality evidence). Regarding biological treatments, we are uncertain of the effect of etanercept on clearance and the effect of ustekinumab on severity (low-quality evidence). Secukinumab and guselkumab are probably superior to placebo in reducing severity (moderate-quality evidence). Adverse events not requiring withdrawal were not reported for these treatments. Reporting of serious adverse effects was incomplete: compared to placebo, secukinumab probably caused more participant withdrawals (moderate-quality evidence), but we are uncertain of the effect of guselkumab (low-quality evidence). Future trials should assess commonly used treatments using validated severity and quality of life scales.",2020,"Secukinumab is probably superior to placebo in reducing severity (RR 1.55, 95% CI 1.02 to 2.35; 1 study; 157 participants; moderate-quality evidence), but our clearance outcome was not reported.","['37 studies (1663 participants; mean age 50 years (range 34 to 63); 24% males', 'people with palmoplantar pustulosis or chronic palmoplantar pustular psoriasis', 'chronic palmoplantar pustulosis']","['placebo', 'PUVA therapy versus placebo', 'Secukinumab and guselkumab', 'etretinate + PUVA (combination of psoralens and long-wave ultraviolet radiation) therapy combined, and antibiotics', 'topical vitamin D derivative maxacalcitol versus placebo', 'RCTs', 'topical treatments (dermocorticoids, vitamin D) and phototherapy (PUVA, ultraviolet A1 (UVA1', 'etanercept', 'oral PUVA']","['achieving clearance (risk ratio (RR', 'adverse effects', 'adverse events', 'Adverse effects', 'nausea, ankle swelling, and non-purulent conjunctivitis) and with local PUVA (including blistering, erythema, and pruritus', 'mild local irritation, pruritus, and haematological or urinary test abnormalities', ""disease severity', and 'Proportion of participants with adverse effects"", 'disease severity', 'headache, cheilitis, nausea, arthralgia, and nasopharyngitis', 'risk of adverse effects', 'serious adverse events', ""Proportion of participants cleared or almost cleared', 'Proportion of participants with adverse effects serious or severe enough to cause withdrawal', 'Proportion"", 'Clearance', 'achieving clearance']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030246', 'cui_str': 'Pustulosis of Palms and Soles'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0034172', 'cui_str': 'Psoralen Ultraviolet A Therapy'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C3852217', 'cui_str': 'guselkumab'}, {'cui': 'C0015137', 'cui_str': 'Etretinate'}, {'cui': 'C0853073', 'cui_str': 'PUVA'}, {'cui': 'C0016072', 'cui_str': 'Psoralen'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C4319812', 'cui_str': 'Ultraviolet Radiation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0043872', 'cui_str': 'maxacalcitriol'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C1532472', 'cui_str': 'Ultraviolet'}, {'cui': 'C0717758', 'cui_str': 'Etanercept'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0009768', 'cui_str': 'Conjunctivitis, Mucopurulent'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0853073', 'cui_str': 'PUVA'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0441723', 'cui_str': 'Irritation (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0007971', 'cui_str': 'Cheilitis'}, {'cui': 'C0003862', 'cui_str': 'Joint Pain'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}]",1663.0,0.750782,"Secukinumab is probably superior to placebo in reducing severity (RR 1.55, 95% CI 1.02 to 2.35; 1 study; 157 participants; moderate-quality evidence), but our clearance outcome was not reported.","[{'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Obeid', 'Affiliation': 'Hôpital du Sacré Cœur, Department of Dermatology, Beirut, Lebanon.'}, {'ForeName': 'Giao', 'Initials': 'G', 'LastName': 'Do', 'Affiliation': 'Hôpital Henri Mondor, Department of Dermatology, 51 avenue du Général de Lattre de Tassigny, Créteil, France, 94010.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Kirby', 'Affiliation': 'Queen Elizabeth University Hospital (The Southern General Hospital), Department of Dermatology, 1345 Govan Road, Glasgow, UK, G51 4TF.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Hughes', 'Affiliation': ""The University of Nottingham, c/o Cochrane Skin Group, A103, King's Meadow Campus, Lenton Lane, Nottingham, UK, NG7 2NR.""}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Sbidian', 'Affiliation': 'Hôpital Henri Mondor, Department of Dermatology, 51 avenue du Général de Lattre de Tassigny, Créteil, France, 94010.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Le Cleach', 'Affiliation': 'Hôpital Henri Mondor, Department of Dermatology, 51 avenue du Général de Lattre de Tassigny, Créteil, France, 94010.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011628.pub2'] 573,31493397,Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.,"BACKGROUND & AIMS Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of interleukin 23, in a phase 2 study of patients with UC. METHODS We performed a trial of the efficacy and safety of mirikizumab in patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017. Patients were randomly assigned to groups given intravenous placebo (N = 63), mirikizumab 50 mg (N = 63) or 200 mg (N = 62) with exposure-based dosing, or mirikizumab 600 mg with fixed dosing (N = 61) at weeks 0, 4, and 8. Of assigned patients, 63% had prior exposure to a biologic agent. Clinical responders (decrease in 9-point Mayo score, including ≥2 points and ≥35% from baseline with either a decrease of rectal bleeding subscore of ≥1 or a rectal bleeding subscore of 0 or 1) at week 12 who had received mirikizumab were randomly assigned to groups that received maintenance treatment with mirikizumab 200 mg subcutaneously every 4 weeks (N = 47) or every 12 weeks (N = 46). The primary endpoint was clinical remission (Mayo subscores of 0 for rectal bleeding, with 1-point decrease from baseline for stool frequency, and 0 or 1 for endoscopy) at week 12. A multiple testing procedure was used that began with the 600-mg dose group, and any nonsignificant comparison result ended the formal statistical testing procedure. RESULTS At week 12, 15.9% (P = .066), 22.6% (P = .004), and 11.5% (P = .142) of patients in the 50-mg, 200-mg, and 600-mg groups achieved clinical remission, respectively, compared with 4.8% of patients given placebo. The primary endpoint was not significant (comparison to 600 mg, P > .05). Clinical responses occurred in 41.3% (P = .014), 59.7% (P < .001), and 49.2% (P = .001) of patients in the 50-mg, 200-mg, and 600-mg groups, respectively, compared with 20.6% of patients given placebo. At week 52, 46.8% of patients given subcutaneous mirikizumab 200 mg every 4 weeks and 37.0% given subcutaneous mirikizumab 200 mg every 12 weeks were in clinical remission. CONCLUSIONS In a randomized trial of patients with UC, mirikizumab was effective in inducing a clinical response after 12 weeks. Additional studies are required to determine the optimal dose for induction of remission. Mirikizumab showed durable efficacy throughout the maintenance period. Clinicaltrials.gov, Number NCT02589665.",2020,"Clinical responses occurred in 41.3% (P=.014), 59.7% (P<.001), and 49.2% (P=.001) of patients in the 50-mg, 200-mg, and 600-mg groups, respectively, compared to 20.6% of patients given placebo.","['Patients With Ulcerative Colitis', 'patients with UC', 'patients with moderate to severely active UC, enrolling patients from 14 countries from January 2016 through September 2017']","['mirikizumab 50 mg (n=63) or 200 mg (n=62) with exposure-based dosing, or mirikizumab 60 mg with fixed dosing', 'intravenous placebo', 'Mirikizumab', 'mirikizumab', 'placebo', 'subcutaneous mirikizumab']","['rectal bleeding subscore of ≥1 or a rectal bleeding subscore', 'Clinical responses', 'efficacy and safety', 'clinical remission', 'Efficacy and Safety', 'durable efficacy', 'clinical remission (Mayo subscores of 0 for rectal bleeding, with 1-point decrease from baseline for stool frequency, and 0 or 1 for endoscopy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}]","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0267596', 'cui_str': 'Rectal hemorrhage (disorder)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0454788', 'cui_str': 'Mayo (geographic location)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}]",,0.20817,"Clinical responses occurred in 41.3% (P=.014), 59.7% (P<.001), and 49.2% (P=.001) of patients in the 50-mg, 200-mg, and 600-mg groups, respectively, compared to 20.6% of patients given placebo.","[{'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Sandborn', 'Affiliation': 'University of California San Diego, La Jolla, California. Electronic address: wsandborn@ucsd.edu.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ferrante', 'Affiliation': 'Department of Gastroenterology and Hepatology, Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.'}, {'ForeName': 'Bal R', 'Initials': 'BR', 'LastName': 'Bhandari', 'Affiliation': 'Delta Research Partners, Bastrop, Louisiana.'}, {'ForeName': 'Elina', 'Initials': 'E', 'LastName': 'Berliba', 'Affiliation': 'Nicolae Testemitanu State University of Medicine, Arsenia Exploratory Medicine, Chisinau, Moldova.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Feagan', 'Affiliation': 'Western University, Robarts Clinical Trials Inc, London, Ontario, Canada.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Kitasato Institute Hospital Center for Advanced Inflammatory Bowel Disease Research and Treatment, Minato-ku, Tokyo, Japan.'}, {'ForeName': 'Jay L', 'Initials': 'JL', 'LastName': 'Tuttle', 'Affiliation': 'Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Klekotka', 'Affiliation': 'Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Friedrich', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Durante', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'MaryAnn', 'Initials': 'M', 'LastName': 'Morgan-Cox', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Janelle', 'Initials': 'J', 'LastName': 'Laskowski', 'Affiliation': 'Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Schmitz', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Geert R', 'Initials': 'GR', 'LastName': ""D'Haens"", 'Affiliation': 'Amsterdam University Medical Centers, Amsterdam, The Netherlands.'}]",Gastroenterology,['10.1053/j.gastro.2019.08.043'] 574,32129892,Myasthenia gravis patient and physician opinions about immunosuppressant reduction.,"INTRODUCTION To reduce myasthenia gravis (MG) patient risk of immunosuppressant (IS) exposure adverse events (AEs), such as infections and malignancies, and to reduce treatment burden, international guidelines recommend decreasing IS dose in stable MG patients. METHODS Online surveys were conducted of self-identified MG patients and MG physician experts about the importance of IS dose reduction for MG patients who achieve prolonged periods of disease stability. RESULTS Eighty-four percent of MG patients (n = 283) and 100% of physicians (n = 45) were concerned about long-term IS-associated AEs. Although both groups favored attempting IS reduction, they raised concerns including MG relapse, hospitalization, and uncertainty about the future. Presented with an estimated 12% significant relapse rate with IS dose reduction, 76% of patients would be willing to enroll in a randomized IS dose reduction trial. DISCUSSION Patients and physicians favor considering IS dose reduction but are also concerned about potential negative sequelae.",2020,"Although both groups favored attempting IS reduction, they raised concerns including: MG relapse, hospitalization, and uncertainty about the future.","['Myasthenia Gravis Patient and Physician Opinions', 'Online surveys were conducted of self-identified MG patients and MG physician experts about the importance of IS dose reduction for MG patients who achieve prolonged periods of disease stability']",[],['relapse rate'],"[{'cui': 'C0947912'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0871010', 'cui_str': 'Opinions'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0425945', 'cui_str': 'Prolonged periods (finding)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",[],"[{'cui': 'C0035020', 'cui_str': 'Relapse'}]",45.0,0.025263,"Although both groups favored attempting IS reduction, they raised concerns including: MG relapse, hospitalization, and uncertainty about the future.","[{'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Hehir', 'Affiliation': 'The Robert Larner M.D. College of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Anna Rostedt', 'Initials': 'AR', 'LastName': 'Punga', 'Affiliation': 'Department of Neuroscience Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ciafaloni', 'Affiliation': 'University of Rochester School of Medicine, Rochester, New York, USA.'}]",Muscle & nerve,['10.1002/mus.26850'] 575,32186048,Effect of acupuncture on blood pressure control in hypertensive patients.,"OBJECTIVE To study the effect of acupuncture on blood pressure (BP) control in hypertensive patients. METHODS A total of 80 out-patients with primary hypertension at the family medicine unit and the social security unit were randomly and equally divided into an acupuncture plus medication group and a control group that received only medication. Patients of the acupuncture group were treated with acupuncture stimulation of Yinlinquan (SP 9), Zusanli (ST 36), Taichong (LR 3), Hegu (LI 4), Quchi (LI 11), Neiguan (PC 6) for 30 min, once per week, continuously for eight weeks. In addition, both groups received amlodipine (5 mg) once daily, continuously for eight weeks. Systolic BP (SBP), diastolic BP (DBP) and mean arterial BP (mABP) were recorded. Data were analyzed by Mann-Whitney U test. RESULTS SBP of the 40 cases in the acupuncture group significantly improved compared to the medication only group [Z =－ 4.265, P (2-tailed) = 0.001] and DBP of acupuncture group was lower than that of the control group (Z =－ 2.813, P = 0.005). mABP of acupuncture group was the marked improvement in the reduction of blood pressure to that of medication group in controlling blood pressure. (Z = －2.416, P = 0.016). CONCLUSION These results indicate that the effectiveness of acupuncture with the acupuncture group is superior to the only medication group in the control of hypertension.",2019,"RESULTS SBP of the 40 cases in the acupuncture group significantly improved compared to the medication only group [Z =－ 4.265, P (2-tailed) = 0.001] and DBP of acupuncture group was lower than that of the control group (Z =－ 2.813, P = 0.005).","['80 out-patients with primary hypertension at the family medicine unit and the social security unit', 'hypertensive patients']","['acupuncture', 'amlodipine', 'acupuncture stimulation of Yinlinquan (SP 9), Zusanli (ST 36), Taichong (LR 3), Hegu (LI 4), Quchi (LI 11), Neiguan (PC 6', 'acupuncture plus medication group and a control group that received only medication']","['Systolic BP (SBP), diastolic BP (DBP) and mean arterial BP (mABP', 'blood pressure control', 'DBP', 'blood pressure (BP) control', 'blood pressure']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0085580', 'cui_str': 'Essential Hypertension'}, {'cui': 'C0015607', 'cui_str': 'Family Practice'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0037435', 'cui_str': 'Social Insurance'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",80.0,0.018063,"RESULTS SBP of the 40 cases in the acupuncture group significantly improved compared to the medication only group [Z =－ 4.265, P (2-tailed) = 0.001] and DBP of acupuncture group was lower than that of the control group (Z =－ 2.813, P = 0.005).","[{'ForeName': 'Termklinchan', 'Initials': 'T', 'LastName': 'Vilaval', 'Affiliation': 'Thai Traditional and Alternative Medicine Unit, Department of Family Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand.'}, {'ForeName': 'Wasin', 'Initials': 'W', 'LastName': 'Sasinan', 'Affiliation': 'Thai Traditional and Alternative Medicine Unit, Department of Family Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand.'}, {'ForeName': 'Choesomboon', 'Initials': 'C', 'LastName': 'Mayuree', 'Affiliation': 'Thai Traditional and Alternative Medicine Unit, Department of Family Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand.'}, {'ForeName': 'Praditbatuka', 'Initials': 'P', 'LastName': 'Chananun', 'Affiliation': 'Thai Traditional and Alternative Medicine Unit, Department of Family Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand.'}, {'ForeName': 'Sukareechai', 'Initials': 'S', 'LastName': 'Somchai', 'Affiliation': 'Thai Traditional and Alternative Medicine Unit, Department of Family Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi 11120, Thailand.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 576,32186049,Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage Ⅲ colon cancer.,"OBJECTIVE To investigate the effect of a modified Banxia Xiexin decoction (MBXD) plus chemotherapy on postoperative adverse reaction in patients with stage Ⅲ colon cancer in patients whose symptoms were identified as cold-heat complicated pattern in terms of the theory of Traditional Chinese Medicine (TCM). METHODS A prospective non-randomized control study of patients with stage Ⅲ colon cancer in Beijing Shijitan Hospital and Guang'anmen Hospital between January 2012 and December 2013. A total of 80 patients were divided into experimental group (MBXD + chemotherapy) and control group (chemotherapy). The adverse reactions, life quality and disease-free survival (DFS) were compared between the two groups. RESULTS The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group (P < 0.05). Life quality was improved in 24 vs 14 cases, stabilized in 9 vs 14 cases whereas decreased in 2 vs 15 cases in experimental group and control group, respectively (P < 0.05). The average DFS was 22.371 months in experimental group, while 13.932 months in control group (P < 0.05). CONCLUSION MBXD combined with chemotherapy may significantly relieve clinical symptoms, reduce chemotherapy associated adverse effects, improve life quality, and prolong DFS of patients with stage Ⅲ colon cancer (cold-heat complicated pattern).",2019,The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group (P < 0.05).,"['patients with stage Ⅲ colon cancer in patients whose symptoms were identified as cold-heat complicated pattern in terms of the theory of Traditional Chinese Medicine (TCM', ""patients with stage Ⅲ colon cancer in Beijing Shijitan Hospital and Guang'anmen Hospital between January 2012 and December 2013"", '80 patients', 'stage Ⅲ colon cancer']","['modified Banxia Xiexin decoction plus chemotherapy', 'experimental group (MBXD + chemotherapy) and control group (chemotherapy', 'MBXD combined with chemotherapy', 'modified Banxia Xiexin decoction (MBXD) plus chemotherapy']","['postoperative adverse reaction', 'Life quality', 'cold-heat complex pattern', 'adverse reactions, life quality and disease-free survival (DFS', 'life quality', 'average DFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0231242', 'cui_str': 'Complicated (qualifier value)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0025124', 'cui_str': 'Zhong Yi Xue'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C1869339', 'cui_str': 'Xiexin decoction'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0034380'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}]",80.0,0.0178541,The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group (P < 0.05).,"[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Li', 'Affiliation': 'Department of oncological surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}, {'ForeName': 'Guangzhong', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': 'Department of oncological surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Department of oncological surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhu', 'Affiliation': 'Department of oncological surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': ""Department of oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.""}, {'ForeName': 'Baojin', 'Initials': 'B', 'LastName': 'Hua', 'Affiliation': ""Department of oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.""}, {'ForeName': 'Weihua', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}, {'ForeName': 'Xingzhong', 'Initials': 'X', 'LastName': 'Feng', 'Affiliation': 'Traditional Chinese Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 577,32052503,Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B.,"Hepatitis B virus (HBV) RNA in serum is a novel biomarker that reflects cccDNA activity. We investigated whether HBV RNA can predict serological response to peginterferon (PEG-IFN) treatment. Serum HBV RNA levels were retrospectively measured at weeks 0, 12, 24 and 52 of therapy and after treatment discontinuation (week 78) in 266 HBeAg-positive chronic HBV patients who had participated in a global randomized controlled trial (HBV99-01 study). Patients received 52 weeks PEG-IFN monotherapy (n = 136) or PEG-IFN and lamivudine (n = 130). The primary end point was HBeAg loss 24 weeks after PEG-IFN discontinuation. At baseline, the mean serum level of HBV RNA was 6.8 (SD 1.2) log c/mL. HBV RNA levels declined to 4.7 (1.7) log c/mL after one year of PEG-IFN therapy alone and to 3.3 (1.2)log c/mL after combination therapy. From week 12 onward, HBV RNA level was significantly lower in patients who achieved HBeAg loss at the end of follow-up as compared to those who did not, regardless of treatment allocation (week 12:4.4 vs 5.1 log c/mL, P = .01; week 24:3.7 vs 4.9 log c/mL, P < .001). The performance of a multivariable model based on HBV RNA level was comparable at week 12 (AUC 0.68) and 24 (AUC 0.72) of therapy. HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes A/B/C/D for the prediction of HBeAg loss. In conclusion, HBV RNA in serum declines profoundly during PEG-IFN treatment. Early on-treatment HBV RNA level may be used to predict nonresponse.",2020,HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes,"['266 HBeAg-positive chronic HBV patients who had participated', 'HBeAg-positive chronic hepatitis B']","['orPEG-IFN and lamivudine', 'peginterferon', 'Hepatitis B virus (HBV) RNA', 'HBV RNA', 'PEG-IFN monotherapy']","['Serum HBV RNA levels', 'mean serum level of HBV RNA', 'HBV RNA levelwas', 'HBeAg loss 24 weeks after PEG-IFN discontinuation', 'HBV RNA level', 'mL.HBV RNA levels']","[{'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0524909', 'cui_str': 'Chronic Hepatitis B Virus Infection'}]","[{'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]",,0.0431353,HBV RNA level above 5.5 log c/mL at week 12 showed negative predictive values of 93/67/90/64% for HBV genotypes,"[{'ForeName': 'Margo J H', 'Initials': 'MJH', 'LastName': 'van Campenhout', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'van Bömmel', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pfefferkorn', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Janett', 'Initials': 'J', 'LastName': 'Fischer', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'Deichsel', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Boonstra', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Anneke J', 'Initials': 'AJ', 'LastName': 'van Vuuren', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Berg', 'Affiliation': 'Department of Gastroenterology and Rheumatology, Section of Hepatology, University Hospital Leipzig, Leipzig, Germany.'}, {'ForeName': 'Bettina E', 'Initials': 'BE', 'LastName': 'Hansen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Harry L A', 'Initials': 'HLA', 'LastName': 'Janssen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.'}]",Journal of viral hepatitis,['10.1111/jvh.13272'] 578,32164522,Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder.,"BACKGROUND Despite the high prevalence of fetal alcohol spectrum disorder (FASD), there are few interventions targeting its core neurocognitive and behavioral deficits. FASD is often conceptualized as static and permanent, but interventions that capitalize on brain plasticity and critical developmental windows are emerging. We present a long-term follow-up study evaluating the neurodevelopmental effects of choline supplementation in children with FASD 4 years after an initial efficacy trial. METHODS The initial study was a randomized, double-blind, placebo-controlled trial of choline vs. placebo in 2-5-year-olds with FASD. Participants include 31 children (16 placebo; 15 choline) seen 4 years after trial completion. The mean age at follow-up was 8.6 years. Diagnoses were 12.9% fetal alcohol syndrome (FAS), 41.9% partial FAS, and 45.1% alcohol-related neurodevelopmental disorder. The follow-up included measures of intelligence, memory, executive functioning, and behavior. RESULTS Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group. No differences were seen for verbal intelligence, visual memory, or other executive functions. CONCLUSIONS These data support choline as a potential neurodevelopmental intervention for FASD and highlight the need for long-term follow-up to capture treatment effects on neurodevelopmental trajectories. TRIAL REGISTRATION ClinicalTrials.Gov #NCT01149538; Registered: June 23, 2010; first enrollment July 2, 2010.",2020,"RESULTS Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group.","['Participants include 31 children (16 placebo; 15 choline) seen 4\xa0years after trial completion', 'children with FASD 4\xa0years after an initial efficacy trial', '2-5-year-olds with FASD', 'fetal alcohol spectrum disorder']","['placebo', 'FASD', 'choline supplementation', 'choline vs. placebo', 'choline']","['verbal intelligence, visual memory, or other executive functions', 'intelligence, memory, executive functioning, and behavior', 'non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0008405', 'cui_str': 'Choline'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2985290', 'cui_str': 'FASD'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2985290', 'cui_str': 'FASD'}, {'cui': 'C0556089', 'cui_str': 'Choline supplementation (product)'}, {'cui': 'C0008405', 'cui_str': 'Choline'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0021704', 'cui_str': 'Intelligence'}, {'cui': 'C0542316', 'cui_str': 'Visual memory (observable entity)'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}]",31.0,0.594646,"RESULTS Children who received choline had higher non-verbal intelligence, higher visual-spatial skill, higher working memory ability, better verbal memory, and fewer behavioral symptoms of attention deficit hyperactivity disorder than the placebo group.","[{'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Wozniak', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA. jwozniak@umn.edu.'}, {'ForeName': 'Birgit A', 'Initials': 'BA', 'LastName': 'Fink', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Anita J', 'Initials': 'AJ', 'LastName': 'Fuglestad', 'Affiliation': 'University of North Florida, Jacksonville, FL, USA.'}, {'ForeName': 'Judith K', 'Initials': 'JK', 'LastName': 'Eckerle', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Boys', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Kristin E', 'Initials': 'KE', 'LastName': 'Sandness', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Joshua P', 'Initials': 'JP', 'LastName': 'Radke', 'Affiliation': 'Fagron Inc., St. Paul, MN, USA.'}, {'ForeName': 'Neely C', 'Initials': 'NC', 'LastName': 'Miller', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lindgren', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Ann M', 'Initials': 'AM', 'LastName': 'Brearley', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}, {'ForeName': 'Steven H', 'Initials': 'SH', 'LastName': 'Zeisel', 'Affiliation': 'University of North Carolina, Nutrition Research Institute, Kannapolis, NC, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Georgieff', 'Affiliation': 'University of Minnesota Twin Cities, Minneapolis, MN, USA.'}]",Journal of neurodevelopmental disorders,['10.1186/s11689-020-09312-7'] 579,32044750,Impact of a Knowledge Translation Intervention on Physical Activity and Mobility in Older Adults (the Move4Age Study): Randomized Controlled Trial.,"BACKGROUND The McMaster Optimal Aging Portal (the Portal) was launched in 2014 as a knowledge translation (KT) tool to increase access to evidence-based health information. OBJECTIVE The purpose of this study was to understand if and how dissemination of mobility information through the Portal impacts physical activity (PA) in older adults. METHODS In this randomized controlled trial, participants (n=510) were assigned to a 12-week mobility-focused KT intervention or self-serve control group. The intervention included weekly email alerts and a study-specific social media hashtag linking to mobility-focused Portal materials. The control group was able to access the Portal on their own but did not receive targeted KT strategies. Participants completed questionnaires (including the Rapid Assessment of Physical Activity to quantify PA) at baseline, end of the study, and 3-month follow-up. RESULTS Participants were predominantly female (430/510, 84.3%), mean age 64.7 years, with no baseline differences between groups. Over half (277/510, 54.3%) of the participants were classified as ""active"" at baseline. There was no significant between-group difference in the PA category. Overall, both groups increased their PA with improvements maintained at 3-month follow-up (P<.001). In planned subgroup analyses, the KT intervention had a significant effect for those with poor or fair baseline self-rated health (P=.03). CONCLUSIONS No differences were found between those who received the targeted intervention and a control group with self-serve access to the Portal, except in subgroups with low self-rated health. Both groups did report increases in PA that were sustained beyond participation in a research study. Findings suggest that different KT strategies may be needed for different types of users, with more intense interventions being most impactful for certain groups (ie, those with lower self-rated health). TRIAL REGISTRATION ClinicalTrials.gov NCT02947230; https://clinicaltrials.gov/ct2/show/NCT02947230.",2020,"No differences were found between those who received the targeted intervention and a control group with self-serve access to the Portal, except in subgroups with low self-rated health.","['Participants were predominantly female (430/510, 84.3%), mean age 64.7 years', 'older adults', 'Older Adults (the Move4Age Study', 'participants (n=510']","['weekly email alerts and a study-specific social media hashtag linking to mobility-focused Portal materials', 'Knowledge Translation Intervention', 'KT intervention', 'mobility-focused KT intervention or self-serve control group']","['Physical Activity and Mobility', 'poor or fair baseline self-rated health']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C3179065', 'cui_str': 'Social Media'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0205054', 'cui_str': 'Portal (qualifier value)'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C3494164', 'cui_str': 'Knowledge Translation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C2911689', 'cui_str': 'Fair'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",510.0,0.0915012,"No differences were found between those who received the targeted intervention and a control group with self-serve access to the Portal, except in subgroups with low self-rated health.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Neil-Sztramko', 'Affiliation': 'School of Nursing, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Smith-Turchyn', 'Affiliation': 'Faculty of Kinesiology & Physical Education, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Richardson', 'Affiliation': 'School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Dobbins', 'Affiliation': 'School of Nursing, McMaster University, Hamilton, ON, Canada.'}]",Journal of medical Internet research,['10.2196/15125'] 580,32043426,Human adipose-derived mesenchymal progenitor cells plus microfracture and hyaluronic acid for cartilage repair: a Phase IIa trial.,"Aim: This study aimed to preliminarily evaluate the safety and efficacy of human adipose-derived mesenchymal progenitor cells (haMPCs) in combination with microfracture and hyaluronic acid (HA) for treating cartilage defects. Materials & methods:  A total of 30 patients with medial femoro-tibial condylar cartilage defects were randomized into three groups: arthroscopic microfracture group and normal saline injection, arthroscopic microfracture and intra-articular injection of HA, or arthroscopic microfracture in combination with intra-articular injection of HA and haMPCs. Results & conclusions: The data demonstrated that intra-articular injection of haMPCs plus microfracture and HA is a safe procedure to improve joint function in patients with knee cartilage defects. These findings provide an impetus for future research on this treatment. ClinicalTrials.gov Identifier: NCT02855073.",2020,The data demonstrated that intra-articular injection of haMPCs plus microfracture and HA is a safe procedure to improve joint function in patients with knee cartilage defects.,"['patients with knee cartilage defects', '30 patients with medial femoro-tibial condylar cartilage defects']","['arthroscopic microfracture group and normal saline injection, arthroscopic microfracture and intra-articular injection of HA, or arthroscopic microfracture in combination with intra-articular injection of HA and haMPCs', 'microfracture and hyaluronic acid (HA', 'human adipose-derived mesenchymal progenitor cells (haMPCs', 'Human adipose-derived mesenchymal progenitor cells plus microfracture and hyaluronic acid']","['safety and efficacy', 'joint function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0007301', 'cui_str': 'Cartilage'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}]","[{'cui': 'C1265651', 'cui_str': 'Micro Fractures'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0021488', 'cui_str': 'Intra-Articular Injections'}, {'cui': 'C1141990', 'cui_str': 'Hyaluronic acid'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4552764', 'cui_str': 'Mesenchymal Progenitor Cell'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0031843', 'cui_str': 'function'}]",30.0,0.0648589,The data demonstrated that intra-articular injection of haMPCs plus microfracture and HA is a safe procedure to improve joint function in patients with knee cartilage defects.,"[{'ForeName': 'Zhiguang', 'Initials': 'Z', 'LastName': 'Qiao', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}, {'ForeName': 'Jiaxin', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Yue', 'Affiliation': 'Department of Bone & Joint Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200020, China.'}, {'ForeName': 'Jinwu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Xuan', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}, {'ForeName': 'Chengxiang', 'Initials': 'C', 'LastName': 'Dai', 'Affiliation': 'Cellular Biomedicine Group, Shanghai 201210, China.'}, {'ForeName': 'Suke', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, Shanghai 201210, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, Shanghai 201210, China.'}, {'ForeName': 'Cuili', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Cellular Biomedicine Group, Shanghai 201210, China.'}, {'ForeName': 'Kerong', 'Initials': 'K', 'LastName': 'Dai', 'Affiliation': 'Department of Bone & Joint Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200020, China.'}, {'ForeName': 'You', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Shanghai Key Laboratory of Orthopaedic Implants, Department of Orthopaedic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China.""}]",Regenerative medicine,['10.2217/rme-2019-0068'] 581,32189665,Hydrogen-rich water suppresses the reduction in blood total antioxidant capacity induced by 3 consecutive days of severe exercise in physically active males.,"Repeated sprint exercise can interfere with intramuscular redox balance and cause systemic oxidative stress and muscle damage. There is growing evidence that molecular hydrogen counteracts oxidative and/or inflammatory responses. Therefore, we investigated the effects of molecular hydrogen-rich water (HW) on muscle performance and oxidative stress markers induced by strenuous exercise. A single-blind, crossover, randomized controlled trial has been designed. Eight male volunteers completed two 3-day consecutive exercise tests under two conditions: HW and placebo water (PW). The exercise test included a countermovement jump, maximal voluntary isometric contraction of knee extensors, and sprint cycling. The sprint cycling exercise was comprised three repetitions of 10-second maximal pedaling against a resistance of 7.5% body mass and 110-second active rest (no-load pedaling). Before and after the exercise test, participants drank the 500 mL of HW (5.14 ± 0.03 ppm in H 2 concentration) or PW (0.00 ± 0.00 ppm). At 7 hours before the first exercise test (Day 1), as baseline, and 16 hours after the exercise test on each day, blood samples were obtained. Exercise performances in both conditions were not significantly different over 3 consecutive days. In PW trial, relative changes in biological antioxidant potential/diacron-reactive oxygen metabolites, as an index of systemic antioxidant potential, from baseline gradually decreased as the day passed. However, HW suppressed the reduction in biological antioxidant potential/diacron-reactive oxygen metabolites observed in PW. Drinking HW contributed to the maintenance of the redox status during consecutive days of strenuous exercise and might help prevent accumulative muscular fatigue. The study was approved by the Human Research Ethics Committee of the University of Yamanashi, Japan (approval No. H26-008) on December 17, 2014.",2020,Exercise performances in both conditions were not significantly different over 3 consecutive days.,"['University of Yamanashi, Japan (approval', 'physically active males', 'Eight male volunteers completed two 3-day consecutive exercise tests under two conditions', 'H26-008) on December 17, 2014']","['HW and placebo water (PW', 'sprint cycling exercise', 'molecular hydrogen-rich water (HW', 'Repeated sprint exercise']","['biological antioxidant potential/diacron-reactive oxygen metabolites', 'blood total antioxidant capacity', 'countermovement jump, maximal voluntary isometric contraction of knee extensors, and sprint cycling', 'Exercise performances', 'muscle performance and oxidative stress markers']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0556453', 'cui_str': 'Physically active (finding)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}]","[{'cui': 'C4049351', 'cui_str': 'Biological antioxidant potential'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0005768'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0022205', 'cui_str': 'Isometric Contraction'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}]",8.0,0.099417,Exercise performances in both conditions were not significantly different over 3 consecutive days.,"[{'ForeName': 'Shohei', 'Initials': 'S', 'LastName': 'Dobashi', 'Affiliation': 'Management Office of Education for Graduate Student, University of Yamanashi, Yamanashi, Japan.'}, {'ForeName': 'Kaito', 'Initials': 'K', 'LastName': 'Takeuchi', 'Affiliation': 'Faculty of Education and Human Sciences, University of Yamanashi, Yamanashi, Japan.'}, {'ForeName': 'Katsuhiro', 'Initials': 'K', 'LastName': 'Koyama', 'Affiliation': 'Graduate School Department of Interdisciplinary Research, University of Yamanashi, Yamanashi, Japan.'}]",Medical gas research,['10.4103/2045-9912.279979'] 582,32186121,Whole body vibration and auriculotherapy improve handgrip strength in individuals with knee osteoarthritis.,"OBJECTIVE To verify the action of non-pharmacological interventions, whole body vibration exercise (WBVE) and auriculotherapy (AT) on the management of knee osteoarthritis (KOA) analyzing the handgrip strength (HS). METHODS One hundred twelve participants with KOA were allocated in (a) WBVE group with peak-to-peak displacement of 2.5 to 7.5 mm, frequency from 5 up to 14 Hz, acceleration peak from 0.12 up to 2.95 g (2 d/weekly for 5 weeks), (b) AT group, points of both ears (Kidney, Knee-correspondent point and Shenmen) were stimulated with seeds, (c) WBVE + AT group and (d) respective control groups. HS was assessed in all the participants, in acute and cumulative responses. RESULTS The intervention with WBVE alone and combined with AT improved (P < 0.05), in a cumulative response, the HS. CONCLUSION WBVE alone or combined with AT might promote biological effects that interfere with the HS in individuals with KOA.",2019,"The intervention with WBVE alone and combined with AT improved (P < 0.05), in a cumulative response, the HS. CONCLUSION WBVE alone or combined with AT might promote biological effects that interfere with the HS in individuals with KOA.","['individuals with knee osteoarthritis', 'individuals with KOA', 'One hundred twelve participants with KOA']","['Whole body vibration and auriculotherapy', 'whole body vibration exercise (WBVE) and auriculotherapy (AT', 'WBVE alone and combined with AT']","['HS', 'handgrip strength']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C2350276', 'cui_str': 'Auriculotherapies'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]",[],112.0,0.0374085,"The intervention with WBVE alone and combined with AT improved (P < 0.05), in a cumulative response, the HS. CONCLUSION WBVE alone or combined with AT might promote biological effects that interfere with the HS in individuals with KOA.","[{'ForeName': 'Moreira-Marconi', 'Initials': 'MM', 'LastName': 'Eloá', 'Affiliation': 'Postgraduate Program in Clinical and Experimental Physiopathology, University of the State of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Dionello', 'Initials': 'D', 'LastName': 'Carla F', 'Affiliation': 'Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Morel', 'Initials': 'M', 'LastName': 'Danielle S', 'Affiliation': 'Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Sá-Caputo', 'Initials': 'SC', 'LastName': 'Danubia C', 'Affiliation': 'Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Sousa-Goncalves', 'Initials': 'SG', 'LastName': 'Cintia R', 'Affiliation': ''}, {'ForeName': 'Paineiras-Domingos', 'Initials': 'PD', 'LastName': 'Laisa L', 'Affiliation': 'Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Teixeira-Silva', 'Initials': 'TS', 'LastName': 'Ygor', 'Affiliation': 'Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': '', 'Initials': '', 'LastName': 'Mario José Dos Santos', 'Affiliation': 'Pereira, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil- Department of Biophysics and Biometrics, Institute of Biology Roberto Alcantara Gomes- Department of Physiological Sciences Mario, Bernardo-Filho, Department of Biophysics and Biometrics, Laboratory of Mechanical Vibrations and Integrative Practices-LAVIMPI, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University, Rio de Janeiro, RJ, Brazil.'}]",Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan,[] 583,31980512,Blood pressure monitoring in high-risk pregnancy to improve the detection and monitoring of hypertension (the BUMP 1 and 2 trials): protocol for two linked randomised controlled trials.,"INTRODUCTION Self-monitoring of blood pressure (BP) in pregnancy could improve the detection and management of pregnancy hypertension, while also empowering and engaging women in their own care. Two linked trials aim to evaluate whether BP self-monitoring in pregnancy improves the detection of raised BP during higher risk pregnancies (BUMP 1) and whether self-monitoring reduces systolic BP during hypertensive pregnancy (BUMP 2). METHODS AND ANALYSES Both are multicentre, non-masked, parallel group, randomised controlled trials. Participants will be randomised to self-monitoring with telemonitoring or usual care. BUMP 1 will recruit a minimum of 2262 pregnant women at higher risk of pregnancy hypertension and BUMP 2 will recruit a minimum of 512 pregnant women with either gestational or chronic hypertension. The BUMP 1 primary outcome is the time to the first recording of raised BP by a healthcare professional. The BUMP 2 primary outcome is mean systolic BP between baseline and delivery recorded by healthcare professionals. Other outcomes will include maternal and perinatal outcomes, quality of life and adverse events. An economic evaluation of BP self-monitoring in addition to usual care compared with usual care alone will be assessed across both study populations within trial and with modelling to estimate long-term cost-effectiveness. A linked process evaluation will combine quantitative and qualitative data to examine how BP self-monitoring in pregnancy is implemented and accepted in both daily life and routine clinical practice. ETHICS AND DISSEMINATION The trials have been approved by a Research Ethics Committee (17/WM/0241) and relevant research authorities. They will be published in peer-reviewed journals and presented at national and international conferences. If shown to be effective, BP self-monitoring would be applicable to a large population of pregnant women. TRIAL REGISTRATION NUMBER NCT03334149.",2020,"Two linked trials aim to evaluate whether BP self-monitoring in pregnancy improves the detection of raised BP during higher risk pregnancies (BUMP 1) and whether self-monitoring reduces systolic BP during hypertensive pregnancy (BUMP 2). ","['2262 pregnant women', '512 pregnant women with either gestational or chronic hypertension']","['BP self-monitoring', 'Self-monitoring of blood pressure (BP', 'telemonitoring or usual care', 'BUMP', 'Blood pressure monitoring']","['time to the first recording of raised BP by a healthcare professional', 'systolic BP', 'mean systolic BP', 'maternal and perinatal outcomes, quality of life and adverse events']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C1704312', 'cui_str': 'Healthcare professional (occupation)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0034380'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",2262.0,0.18161,"Two linked trials aim to evaluate whether BP self-monitoring in pregnancy improves the detection of raised BP during higher risk pregnancies (BUMP 1) and whether self-monitoring reduces systolic BP during hypertensive pregnancy (BUMP 2). ","[{'ForeName': 'Greig', 'Initials': 'G', 'LastName': 'Dougall', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marloes', 'Initials': 'M', 'LastName': 'Franssen', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Katherine Louise', 'Initials': 'KL', 'LastName': 'Tucker', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ly-Mee', 'Initials': 'LM', 'LastName': 'Yu', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hinton', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Rivero-Arias', 'Affiliation': 'National Perinatal Epidemiology Unit (NPEU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Abel', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Allen', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Rebecca Jane', 'Initials': 'RJ', 'LastName': 'Band', 'Affiliation': 'Academic Unit of Psychology, University of Southampton, Southampton, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Chisholm', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Crawford', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'Action on Pre-eclampsia, Evesham, UK.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Greenfield', 'Affiliation': 'Primary Care Clinical Sciences, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Hodgkinson', 'Affiliation': 'Primary Care Clinical Sciences, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Leeson', 'Affiliation': 'Cardiovascular Clinical Research Facility, Division of Cardiovascular Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'McCourt', 'Affiliation': 'Centre for Maternal & Child Health Research, School of Health Sciences, City University, London, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'MacKillop', 'Affiliation': ""Nuffield Department of Women's & Reproductive Health, Oxford University Hospitals NHS Trust, Oxford, UK.""}, {'ForeName': 'Alecia', 'Initials': 'A', 'LastName': 'Nickless', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Sandall', 'Affiliation': ""Department of Women and Children's Health, Kings College, London, London, UK.""}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': 'Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Tarassenko', 'Affiliation': 'Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.'}, {'ForeName': 'Carmelo', 'Initials': 'C', 'LastName': 'Velardo', 'Affiliation': 'Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Wilson', 'Affiliation': ""Department of Women and Children's Health, Kings College, London, London, UK.""}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Yardley', 'Affiliation': 'Academic Unit of Psychology, University of Southampton, Southampton, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Chappell', 'Affiliation': ""Department of Women and Children's Health, Kings College, London, London, UK lucy.chappell@kcl.ac.uk.""}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McManus', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}]",BMJ open,['10.1136/bmjopen-2019-034593'] 584,30991441,Sex-Specific Differences in Late Preterm Neonatal Outcomes.,"OBJECTIVE To estimate sex-specific differences in late preterm outcomes and evaluate whether betamethasone modifies this association. STUDY DESIGN We conducted a secondary analysis of a multicenter trial of women at risk for late preterm birth randomized to receive betamethasone or placebo. We included women who delivered at 34 to 37 weeks and excluded major fetal anomalies. The primary outcome was severe neonatal morbidity (mechanical ventilation, respiratory distress syndrome, bronchopulmonary dysplasia, sepsis, necrotizing enterocolitis, and intraventricular hemorrhage). Maternal characteristics were compared using chi-square test, t -test, or Mann-Whitney U -test. Multivariable logistic regression estimated the association between sex and morbidity, and likelihood ratio testing assessed for effect modification by betamethasone. RESULTS Of 2,831 women in the primary trial, 2,331 met the inclusion criteria: 1,236 delivered males and 1,095 delivered females. Betamethasone modified the association between sex and severe morbidity ( p  = 0.047). Among those who received betamethasone, male sex was associated with higher odds of severe morbidity (adjusted odds ratio: 1.95, 95% confidence interval: 1.25-3.05), compared with female sex. Among those who did not receive betamethasone, there was no significant association between sex and morbidity. CONCLUSION Male sex is a risk factor for adverse late preterm outcomes, including severe neonatal morbidity after betamethasone receipt.",2019,Betamethasone modified the association between sex and severe morbidity ( p  = 0.047).,"['2,331 met the inclusion criteria: 1,236 delivered males and 1,095 delivered females', 'women who delivered at 34 to 37 weeks and excluded major fetal anomalies', 'women at risk for late preterm birth', '2,831 women in the primary trial']","['Betamethasone', 'betamethasone', 'betamethasone or placebo']","['sex and severe morbidity', 'severe morbidity', 'severe neonatal morbidity', 'severe neonatal morbidity (mechanical ventilation, respiratory distress syndrome, bronchopulmonary dysplasia, sepsis, necrotizing enterocolitis, and intraventricular hemorrhage', 'sex and morbidity']","[{'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0266647', 'cui_str': 'Fetal anomaly'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0035220', 'cui_str': 'Respiratory Distress Syndrome, Newborn'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary Dysplasia'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage (disorder)'}]",2831.0,0.287313,Betamethasone modified the association between sex and severe morbidity ( p  = 0.047).,"[{'ForeName': 'Ashley N', 'Initials': 'AN', 'LastName': 'Battarbee', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Angelica V', 'Initials': 'AV', 'LastName': 'Glover', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Vladutiu', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Gyamfi-Bannerman', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Aliaga', 'Affiliation': 'Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Tracy A', 'Initials': 'TA', 'LastName': 'Manuck', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Boggess', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}]",American journal of perinatology,['10.1055/s-0039-1683886'] 585,31548678,Brain regulation of emotional conflict predicts antidepressant treatment response for depression.,"The efficacy of antidepressant treatment for depression is controversial due to the only modest superiority demonstrated over placebo. However, neurobiological heterogeneity within depression may limit overall antidepressant efficacy. We sought to identify a neurobiological phenotype responsive to antidepressant treatment by testing pretreatment brain activation during response to, and regulation of, emotional conflict as a moderator of the clinical benefit of the antidepressant sertraline versus placebo. Using neuroimaging data from a large randomized controlled trial, we found widespread moderation of clinical benefits by brain activity during regulation of emotional conflict, in which greater downregulation of conflict-responsive regions predicted better sertraline outcomes. Treatment-predictive machine learning using brain metrics outperformed a model trained on clinical and demographic variables. Our findings demonstrate that antidepressant response is predicted by brain activity underlying a key self-regulatory emotional capacity. Leveraging brain-based measures in psychiatry will forge a path toward better treatment personalization, refined mechanistic insights and improved outcomes.",2019,"Using neuroimaging data from a large randomized controlled trial, we found widespread moderation of clinical benefits by brain activity during regulation of emotional conflict, in which greater downregulation of conflict-responsive regions predicted better sertraline outcomes.",[],['placebo'],[],[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.0530251,"Using neuroimaging data from a large randomized controlled trial, we found widespread moderation of clinical benefits by brain activity during regulation of emotional conflict, in which greater downregulation of conflict-responsive regions predicted better sertraline outcomes.","[{'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Fonzo', 'Affiliation': 'Department of Psychiatry, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Etkin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. amitetkin@stanford.edu.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Cherise', 'Initials': 'C', 'LastName': 'Chin-Fatt', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Jha', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Trombello', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Deckersbach', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Adams', 'Affiliation': 'New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Melvin', 'Initials': 'M', 'LastName': 'McInnis', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'McGrath', 'Affiliation': 'New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Myrna M', 'Initials': 'MM', 'LastName': 'Weissman', 'Affiliation': 'New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}]",Nature human behaviour,['10.1038/s41562-019-0732-1'] 586,31079282,Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.,"PURPOSE Aromatase inhibitors (AIs) are associated with musculoskeletal symptoms and risk of developing carpal tunnel syndrome (CTS), which can impair quality of life and prompt treatment discontinuation. The incidence of CTS and clinical utility of diagnostic tests such as 2-point discrimination (2-PD) have not been prospectively examined among women receiving AIs. METHODS Postmenopausal women with stage 0-III hormone receptor-positive breast cancer who were enrolled in a randomized clinical trial investigating adjuvant AIs (Exemestane and Letrozole Pharmacogenetics, ELPh) underwent prospective evaluation of 2-PD with the Disc-criminator™ (sliding aesthesiometer) and completed a CTS questionnaire at baseline, 3, 6, and 12 months, following initiation of AI. Changes in mean 2-PD were analyzed with multivariable mixed effects modelling. A p value < 0.05 was considered statistically significant. RESULTS Of 100 women who underwent baseline 2-PD testing, CTS was identified by questionnaire in 11% at baseline prior to AI initiation. Prevalence of CTS at any time in the first year was 26%. A significant increase in worst 2-PD score was observed from baseline to 3 months (3.7 mm to 3.9 mm, respectively, p = 0.03) when adjusted for age, prior chemotherapy, randomized treatment assignment, and diabetes. There were no significant differences in treatment discontinuation due to CTS between the arms. CONCLUSION For women receiving adjuvant AI, 2-PD scores were significantly worse at 3 months compared to baseline. Studies are required to assess whether change in 2-PD is an adequate objective assessment for CTS with AI therapy. Early diagnosis of CTS may expedite management, improve AI adherence, and enhance breast cancer outcomes.",2019,"There were no significant differences in treatment discontinuation due to CTS between the arms. ","['Postmenopausal women with stage 0-III hormone receptor-positive breast cancer', 'women receiving AIs', '100 women who underwent baseline 2-PD testing', 'women with breast cancer receiving adjuvant aromatase inhibitor therapy']","['CTS', 'adjuvant AI', 'adjuvant AIs (Exemestane and Letrozole Pharmacogenetics, ELPh']","['mean 2-PD', 'worst 2-PD score', 'AI adherence', '2-PD scores', 'carpal tunnel syndrome', 'Prevalence of CTS']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0441763', 'cui_str': 'Stage 0 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0593802', 'cui_str': 'Aromatase Inhibitors'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0031325', 'cui_str': 'Pharmacogenetics'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0007286', 'cui_str': 'Amyotrophy, Thenar, Of Carpal Origin'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",100.0,0.0358894,"There were no significant differences in treatment discontinuation due to CTS between the arms. ","[{'ForeName': 'Jennifer Y', 'Initials': 'JY', 'LastName': 'Sheng', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Blackford', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Bardia', 'Affiliation': 'Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.'}, {'ForeName': 'Raghunandan', 'Initials': 'R', 'LastName': 'Venkat', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Gedge', 'Initials': 'G', 'LastName': 'Rosson', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Giles', 'Affiliation': 'Vagelos College of Physicians and Surgeons, Columbia University, New York, USA.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Hayes', 'Affiliation': 'University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.'}, {'ForeName': 'Stacie C', 'Initials': 'SC', 'LastName': 'Jeter', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Hayden', 'Affiliation': 'University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Nguyen', 'Affiliation': 'Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.'}, {'ForeName': 'Anna Maria', 'Initials': 'AM', 'LastName': 'Storniolo', 'Affiliation': 'Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.'}, {'ForeName': 'Karineh', 'Initials': 'K', 'LastName': 'Tarpinian', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.'}, {'ForeName': 'Norah Lynn', 'Initials': 'NL', 'LastName': 'Henry', 'Affiliation': 'University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.'}, {'ForeName': 'Vered', 'Initials': 'V', 'LastName': 'Stearns', 'Affiliation': 'Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. vstearn1@jhmi.edu.'}]",Breast cancer research and treatment,['10.1007/s10549-019-05270-4'] 587,32130136,Effectiveness and Parental Acceptability of Social Networking Interventions for Promoting Seasonal Influenza Vaccination Among Young Children: Randomized Controlled Trial.,"BACKGROUND Seasonal influenza vaccination (SIV) coverage among young children remains low worldwide. Mobile social networking apps such as WhatsApp Messenger are promising tools for health interventions. OBJECTIVE This was a preliminary study to test the effectiveness and parental acceptability of a social networking intervention that sends weekly vaccination reminders and encourages exchange of SIV-related views and experiences among mothers via WhatsApp discussion groups for promoting childhood SIV. The second objective was to examine the effect of introducing time pressure on mothers' decision making for childhood SIV for vaccination decision making. This was done using countdowns of the recommended vaccination timing. METHODS Mothers of child(ren) aged 6 to 72 months were randomly allocated to control or to one of two social networking intervention groups receiving vaccination reminders with (SNI+TP) or without (SNI-TP) a time pressure component via WhatsApp discussion groups at a ratio of 5:2:2. All participants first completed a baseline assessment. Both the SNI-TP and SNI+TP groups subsequently received weekly vaccination reminders from October to December 2017 and participated in WhatsApp discussions about SIV moderated by a health professional. All participants completed a follow-up assessment from April to May 2018. RESULTS A total of 84.9% (174/205), 71% (57/80), and 75% (60/80) who were allocated to the control, SNI-TP, and SNI+TP groups, respectively, completed the outcome assessment. The social networking intervention significantly promoted mothers' self-efficacy for taking children for SIV (SNI-TP: odds ratio [OR] 2.69 [1.07-6.79]; SNI+TP: OR 2.50 [1.13-5.55]), but did not result in significantly improved children's SIV uptake. Moreover, after adjusting for mothers' working status, introducing additional time pressure reduced the overall SIV uptake in children of working mothers (OR 0.27 [0.10-0.77]) but significantly increased the SIV uptake among children of mothers without a full-time job (OR 6.53 [1.87-22.82]). Most participants' WhatsApp posts were about sharing experience or views (226/434, 52.1%) of which 44.7% (101/226) were categorized as negative, such as their concerns over vaccine safety, side effects and effectiveness. Although participants shared predominantly negative experience or views about SIV at the beginning of the discussion, the moderator was able to encourage the discussion of more positive experience or views and more knowledge and information. Most intervention group participants indicated willingness to receive the same interventions (110/117, 94.0%) and recommend the interventions to other mothers (102/117, 87.2%) in future. CONCLUSIONS Online information support can effectively promote mothers' self-efficacy for taking children for SIV but alone it may not sufficient to address maternal concerns over SIV to achieve a positive vaccination decision. However, the active involvement of health professionals in online discussions can shape positive discussions about vaccination. Time pressure on decision making interacts with maternal work status, facilitating vaccination uptake among mothers who may have more free time, but having the opposite effect among busier working mothers. TRIAL REGISTRATION Hong Kong University Clinical Trials Registry HKUCTR-2250; https://tinyurl.com/vejv276.",2020,This was a preliminary study to test the effectiveness and parental acceptability of a social networking intervention that sends weekly vaccination reminders and encourages exchange of SIV-related views and experiences among mothers via WhatsApp discussion groups for promoting childhood SIV.,"['Mothers of child(ren) aged 6 to 72 months', 'young children', 'Young Children', 'mothers via WhatsApp discussion groups for promoting childhood SIV']","['social networking intervention groups receiving vaccination reminders with (SNI+TP) or without (SNI-TP) a time pressure component via WhatsApp discussion', 'social networking intervention', 'Social Networking Interventions', 'HKUCTR-2250']","['SIV uptake', 'effectiveness and parental acceptability', ""mothers' self-efficacy"", ""children's SIV uptake"", 'overall SIV uptake', 'Seasonal Influenza Vaccination']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}]","[{'cui': 'C3179002', 'cui_str': 'Social Networking'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course (qualifier value)'}, {'cui': 'C0042200', 'cui_str': 'Influenza vaccination (procedure)'}]",,0.0702659,This was a preliminary study to test the effectiveness and parental acceptability of a social networking intervention that sends weekly vaccination reminders and encourages exchange of SIV-related views and experiences among mothers via WhatsApp discussion groups for promoting childhood SIV.,"[{'ForeName': 'Qiuyan', 'Initials': 'Q', 'LastName': 'Liao', 'Affiliation': 'University of Hong Kong, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Fielding', 'Affiliation': 'University of Hong Kong, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Yee Tak Derek', 'Initials': 'YTD', 'LastName': 'Cheung', 'Affiliation': 'University of Hong Kong, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Jinxiao', 'Initials': 'J', 'LastName': 'Lian', 'Affiliation': 'The Hong Kong Polytechnic University, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Jiehu', 'Initials': 'J', 'LastName': 'Yuan', 'Affiliation': 'University of Hong Kong, Hong Kong, China (Hong Kong).'}, {'ForeName': 'Wendy Wing Tak', 'Initials': 'WWT', 'LastName': 'Lam', 'Affiliation': 'University of Hong Kong, Hong Kong, China (Hong Kong).'}]",Journal of medical Internet research,['10.2196/16427'] 588,32130142,Online Self-Management Support for Family Caregivers Dealing With Behavior Changes in Relatives With Dementia (Part 2): Randomized Controlled Trial.,"BACKGROUND Online contacts with a health professional have the potential to support family caregivers of people with dementia. OBJECTIVE The goal of the research was to study the effects of an online self-management support intervention in helping family caregivers deal with behavior changes of a relative with dementia. The intervention-involving among others personal email contacts with a dementia nurse-was compared with online interventions without these email contacts. METHODS A randomized controlled trial was conducted with 81 family caregivers of people with dementia who live at home. Participants were randomly assigned to a (1) major self-management support intervention consisting of personal email contacts with a specialist dementia nurse, online videos, and e-bulletins; (2) medium intervention consisting only of online videos and e-bulletins; or (3) minor intervention consisting of only the e-bulletins. The primary outcome was family caregivers' self-efficacy in dealing with behavior changes of the relative with dementia. Secondary outcomes were family caregivers' reports of behavior problems in the people with dementia and the quality of the relationship between the family caregiver and the person with dementia. Measurements were performed at the baseline and at 6 (T1) and 12 weeks (T2) after the baseline. A mixed-model analysis was conducted to compare the outcomes of the 3 intervention arms. RESULTS Family caregivers participating in the major intervention involving email contacts showed no statistically significant differences in self-efficacy after the intervention compared with the minor intervention involving only e-bulletins (difference -0.02, P=.99). In the adjusted analysis, the medium intervention (involving videos and e-bulletins) showed a negative trend over time (difference -4.21, P=.09) and at T1 (difference -4.71, P=.07) compared with the minor intervention involving only e-bulletins. No statistical differences were found between the intervention arms in terms of the reported behavior problems and the quality of the relationship between the family caregiver and the person with dementia. CONCLUSIONS The expectation that an online self-management support intervention involving email contacts would lead to positive effects and be more effective than online interventions without personal email contacts was not borne out. One explanation might be related to the fact that not all family caregivers who were assigned to that intervention actually made use of the opportunity for personal email contact. The online videos were also not always viewed. To obtain more definite conclusions, future research involving extra efforts to reach higher use rates is required. TRIAL REGISTRATION Netherlands Trial Registry NTR6237; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6237 (Archived by WebCite at http://www.webcitation.org/6v0S4fxTC). INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/resprot.8365.",2020,"RESULTS Family caregivers participating in the major intervention involving email contacts showed no statistically significant differences in self-efficacy after the intervention compared with the minor intervention involving only e-bulletins (difference -0.02, P=.99).","['Family Caregivers', '81 family caregivers of people with dementia who live at home', 'Relatives With Dementia (Part 2']","['online self-management support intervention', 'major self-management support intervention consisting of personal email contacts with a specialist dementia nurse, online videos, and e-bulletins; (2) medium intervention consisting only of online videos and e-bulletins; or (3) minor intervention consisting of only the e-bulletins']","[""family caregivers' self-efficacy in dealing with behavior changes of the relative with dementia"", 'self-efficacy', ""family caregivers' reports of behavior problems in the people with dementia and the quality of the relationship between the family caregiver and the person with dementia""]","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}]","[{'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0332158', 'cui_str': 'Contact with (contextual qualifier) (qualifier value)'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0026193', 'cui_str': 'Minors'}]","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]",81.0,0.115156,"RESULTS Family caregivers participating in the major intervention involving email contacts showed no statistically significant differences in self-efficacy after the intervention compared with the minor intervention involving only e-bulletins (difference -0.02, P=.99).","[{'ForeName': 'Judith G', 'Initials': 'JG', 'LastName': 'Huis In Het Veld', 'Affiliation': 'Department of Public and Occupational Health, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Bernadette M', 'Initials': 'BM', 'LastName': 'Willemse', 'Affiliation': 'Netherlands Institute of Mental Health and Addiction, Trimbos Institute, Utrecht, Netherlands.'}, {'ForeName': 'Iris Fm', 'Initials': 'IF', 'LastName': 'van Asch', 'Affiliation': 'Netherlands Institute of Mental Health and Addiction, Trimbos Institute, Utrecht, Netherlands.'}, {'ForeName': 'Rob Bm', 'Initials': 'RB', 'LastName': 'Groot Zwaaftink', 'Affiliation': ""Dutch Alzheimer's Society, Amersfoort, Netherlands.""}, {'ForeName': 'Paul-Jeroen', 'Initials': 'PJ', 'LastName': 'Verkade', 'Affiliation': 'The Geriant Foundation, Region North of Amsterdam, Netherlands.'}, {'ForeName': 'Jos Wr', 'Initials': 'JW', 'LastName': 'Twisk', 'Affiliation': 'Department of Clinical Epidemiology and Biostatistics, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Verkaik', 'Affiliation': 'Netherlands Institute for Health Services Research, Utrecht, Netherlands.'}, {'ForeName': 'Marco M', 'Initials': 'MM', 'LastName': 'Blom', 'Affiliation': ""Dutch Alzheimer's Society, Amersfoort, Netherlands.""}, {'ForeName': 'Berno', 'Initials': 'B', 'LastName': 'van Meijel', 'Affiliation': 'Department of Psychiatry, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Anneke L', 'Initials': 'AL', 'LastName': 'Francke', 'Affiliation': 'Department of Public and Occupational Health, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.'}]",Journal of medical Internet research,['10.2196/13001'] 589,32187150,"The Effect of 12 Weeks of Different Exercise Training Modalities or Nutritional Guidance on Cardiometabolic Risk Factors, Vascular Parameters, and Physical Fitness in Overweight Adults: Cardiometabolic High-Intensity Interval Training-Resistance Training Randomized Controlled Study.","Ramírez-Vélez, R, Castro-Astudillo, K, Correa-Bautista, JE, González-Ruíz, K, Izquierdo, M, García-Hermoso, A, Álvarez, C, Ramírez-Campillo, R, and Correa-Rodríguez, M. The effect of 12 weeks of different exercise training modalities or nutritional guidance on cardiometabolic risk factors, vascular parameters and physical fitness in overweight adults: cardiometabolic high-intensity interval training-resistance training randomized controlled study. J Strength Cond Res 34(8): 2178-2188, 2020-Evidence suggests that exercise training improves cardiometabolic risk factors. The aim of this study was to investigate whether 12 weeks of high-intensity interval training (HIIT), resistance training (RT), concurrent training (CT = HIIT + RT), or nutritional guidance (NG) induced improvements in cardiometabolic risk factors, vascular parameters, and physical fitness in overweight adults, and to compare the responses between the 4 intervention groups. This is a twelve-weeks factorial randomized design examining the effects of different exercise regimes and/or NG on anthropometric and body composition (fat and lean mass at whole body, trunk fat, fat mass index, appendicular muscle mass, and waist circumference); cardiometabolic risk factors and vascular parameters (blood lipids, fasting glucose, blood pressure, flow-mediated dilation [FMD%], aortic pulse wave velocity (PWV), and augmentation index); and physical fitness (cardiorespiratory fitness and handgrip strength). Adjusted mixed linear models revealed a significant improvement in cardiorespiratory fitness (mL·kg·min): HIIT +8.3, RT +4.1, and CT +6.3 (all p < 0.001). The improvement difference between the groups was statistically significant between the HIIT and NG group (p = 0.014), (time × group interaction F(23.564); p < 0.001; η partial = 0.365). In addition, the RT and CT groups have a significant positive impact on PWV (m·s) (d = 0.391 and 0.229 respectively; p < 0.001, (time × group interaction F(5.457); p = 0.003; η partial = 0.280). Hereafter, the RT group has a significant positive impact on the FMD (%) in comparison to HIIT, CT, or NG group (time × group interaction F(2.942); p = 0.044; η partial = 0.174). The main findings of this study are that 12 weeks of HIIT leads to significant improvements in cardiorespiratory fitness, whereas RT resulted in improvements in the vascular profile, supporting the positive effect of both training programs for cardiometabolic risk factors in sedentary and overweight adults.",2020,"The improvement difference between the groups was statistically significant between the HIIT and NG group (p = 0.014), (time × group interaction F(23.564); p < 0.001; η partial = 0.365).","['sedentary and overweight adults', 'overweight adults', 'Overweight Adults']","['high-intensity interval training (HIIT), resistance training (RT), concurrent training (CT = HIIT + RT), or nutritional guidance (NG', 'exercise training modalities or nutritional guidance', 'exercise training', 'Exercise Training Modalities or Nutritional Guidance', 'J Strength Cond Res XX(X', 'exercise regimes']","['FMD', 'cardiometabolic risk factors, vascular parameters, and physical fitness', 'cardiometabolic risk factors, vascular parameters and physical fitness', 'cardiorespiratory fitness (mL·kg·min', 'cardiorespiratory fitness', 'Cardiometabolic Risk Factors, Vascular Parameters, and Physical Fitness', 'anthropometric and body composition (fat and lean mass at whole body, trunk fat, fat mass index, appendicular muscle mass, and waist circumference); cardiometabolic risk factors and vascular parameters (blood lipids, fasting glucose, blood pressure, flow-mediated dilation [FMD%], aortic pulse wave velocity (PWV), and augmentation index); and physical fitness (cardiorespiratory fitness and handgrip strength', 'PWV (m·s', 'cardiometabolic risk factors']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0454291', 'cui_str': 'Exercise regime (regime/therapy)'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0005768'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}]",,0.0213597,"The improvement difference between the groups was statistically significant between the HIIT and NG group (p = 0.014), (time × group interaction F(23.564); p < 0.001; η partial = 0.365).","[{'ForeName': 'Robinson', 'Initials': 'R', 'LastName': 'Ramírez-Vélez', 'Affiliation': 'Navarrabiomed-Public University of Navarra (UPNA)-Navarra Hospital Complex (CHN), Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.'}, {'ForeName': 'Karem', 'Initials': 'K', 'LastName': 'Castro-Astudillo', 'Affiliation': 'Physical Fitness and Nutrition Center, KCFIT. Santiago de Cali, Colombia.'}, {'ForeName': 'Jorge Enrique', 'Initials': 'JE', 'LastName': 'Correa-Bautista', 'Affiliation': 'Department of Health Sciences, Public University of Navarra, Pamplona, Spain.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'González-Ruíz', 'Affiliation': 'Physical Exercise and Sports Group, School of Health, Program Physiotherapy, Manuela Beltrán University, Bogota, Colombia.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Navarrabiomed-Public University of Navarra (UPNA)-Navarra Hospital Complex (CHN), Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Hermoso', 'Affiliation': 'Navarrabiomed-Public University of Navarra (UPNA)-Navarra Hospital Complex (CHN), Health Research Institute of Navarra (IdiSNA), Pamplona, Spain.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Álvarez', 'Affiliation': 'Laboratory of Human Performance, Quality of Life and Wellness Research Group, Department of Physical Activity Sciences, University of Los Lagos, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Ramírez-Campillo', 'Affiliation': 'Research Nucleus in Health, Physical Activity and Sports, University of Los Lagos, Osorno, Chile.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Correa-Rodríguez', 'Affiliation': 'Department of Nursing, Faculty of Health Sciences, University of Granada, Granada, Spain.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003533'] 590,31865282,"""Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia"".","BACKGROUND Randomized controlled trials (RCT) of scalp cooling (SC) to prevent chemotherapy induced alopecia (CIA) did not evaluate its effect on hair regrowth (HR) and was conducted in a predominantly taxane (T) treated population. We conducted an RCT of SC in a setting of anthracycline (A) and taxane chemotherapy (CT) and assessed its effect on CIA and HR. METHODS Non-metastatic breast cancer women undergoing (neo) adjuvant CT were randomized to receive SC using the Paxman scalp cooling system during every cycle of CT, or no SC. The primary end point (PEP) was successful hair preservation (HP) assessed clinically and by review of photographs after CT. HR was assessed at 6 and 12 weeks. RESULTS 51 patients were randomized to SC (34) or control arm (17) in a 2:1 ratio. Twenty-five (49%) patients received A followed by T and the two arms were balanced with respect to this factor. HP rate was significantly higher in SC arm compared to control arm (56.3% vs 0%, P = 0.000004). HR was higher in SC arm compared to control at 6 weeks (89% vs 12%; P < 0.001) and 12 weeks (100% vs 59%, P = 0.0003). Loss of hair at PEP evaluation, which was a quality of life measure, was significantly lower in SC versus control arm (45% vs 82%, P = 0.016). There were no grade 3-4 cold related adverse effects. CONCLUSIONS Women with breast cancer receiving A or T chemotherapy receiving SC were significantly more likely to have less than 50% hair loss after CT, superior hair regrowth and improvement in patient reported outcomes, with acceptable tolerance. It merits wider usage.",2020,"Loss of hair at PEP evaluation, which was a quality of life measure, was significantly lower in SC versus control arm (45% vs 82%, P = 0.016).","['51 patients', 'Non-metastatic breast cancer women undergoing (neo) adjuvant CT', 'Women with breast cancer receiving A or']","['scalp cooling', 'SC using the Paxman scalp cooling system during every cycle of CT, or no SC', 'T chemotherapy receiving SC', 'scalp cooling (SC', 'anthracycline (A) and taxane chemotherapy (CT']","['quality of life measure', 'HP rate', 'hair regrowth (HR', 'alopecia', 'HR', 'Loss of hair at PEP evaluation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C4304352', 'cui_str': 'Scalp cooling system'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0455074', 'cui_str': 'Scalp cooling (procedure)'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}]","[{'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C0002170', 'cui_str': 'Hair Loss'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",51.0,0.229968,"Loss of hair at PEP evaluation, which was a quality of life measure, was significantly lower in SC versus control arm (45% vs 82%, P = 0.016).","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bajpai', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India. Electronic address: dr_jyotibajpai@yahoo.co.in.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kagwade', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Chandrasekharan', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Dandekar', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kanan', 'Affiliation': 'Statistician Department, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kembhavi', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ghosh', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Banavali', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2019.12.004'] 591,32178787,Comparison of the effect of manual compression and closure pad on postangiography complications: A randomized controlled trial.,"BACKGROUND Different methods are available for the closure of the femoral artery after catheterization. The present study aimed at comparing the effect of manual compression (MC) and closure pad (CP) on vascular complications (hematoma and bleeding) of coronary angiography. METHODS In the current clinical trial, a total of 238 patients who were candidates for angiography were randomly assigned to the MC and CP groups. In the MC group, after removal of the arterial sheath, the arterial puncture site was manually compressed for 5-10 minutes and hemostasis was achieved. In the CP group, after removal of the arterial sheath, the arterial puncture site was first manually compressed for 5-10 minutes and initial coagulation was achieved. Then, to continue the coagulation process, a CP was attached to the artery puncture site. Postangiography complications including bleeding and hematoma were monitored in both groups immediately and up to 24 hours after hemostasis. Data were analyzed by SPSS-18 software. RESULTS After angiography, 7 (9.5%) and 5 (2.4%) patients had hematoma in the MC and CP groups, respectively; however, no significant difference was found between the groups. Rebleeding after hemostasis was observed in 2 (7.1%) patients in the MC group, but none of the subjects in the CP group had rebleeding. There was no significant difference in bleeding volume between the groups. CONCLUSION The results indicated the same efficacy of MC and CP methods in the prevention of postangiography vascular complications. Given the advantages of CP such as the possibility of changing the position in bed and increased physical comfort in the patient, this method is recommended for angiography and catheterization.",2020,"There was no significant difference in bleeding volume between the groups. ",['238 patients who were candidates for angiography'],"['manual compression (MC) and closure pad (CP', 'MC and CP', 'manual compression and closure pad']","['bleeding volume', 'rebleeding', 'postangiography complications', 'bleeding and hematoma', 'Rebleeding after hemostasis', 'hematoma', 'vascular complications (hematoma and bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}]","[{'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}]","[{'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}]",238.0,0.0604766,"There was no significant difference in bleeding volume between the groups. ","[{'ForeName': 'Shahriar', 'Initials': 'S', 'LastName': 'Moeinian', 'Affiliation': 'Critical Care Nursing, Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Nesa', 'Initials': 'N', 'LastName': 'Cheraghbeigi', 'Affiliation': 'Medical Surgical Nursing, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Aghaei', 'Affiliation': 'Social Determinants of Health Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Bahremand', 'Affiliation': 'Clinical Research Development Center, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Khatony', 'Affiliation': 'Health Institute, Social Development and Health Promotion Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: Akhatony@gmail.com.'}]",Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing,['10.1016/j.jvn.2020.01.001'] 592,31608930,Ghrelin Does Not Directly Stimulate Secretion of Glucagon-like Peptide-1.,"CONTEXT The gastrointestinal hormone ghrelin stimulates growth hormone secretion and appetite, but recent studies indicate that ghrelin also stimulates the secretion of the appetite-inhibiting and insulinotropic hormone glucagon-like peptide-1 (GLP-1). OBJECTIVE To investigate the putative effect of ghrelin on GLP-1 secretion in vivo and in vitro. SUBJECTS AND METHODS A randomized placebo-controlled crossover study was performed in eight hypopituitary subjects. Ghrelin or saline was infused intravenously (1 pmol/min × kg) after collection of baseline sample (0 min), and blood was subsequently collected at time 30, 60, 90, and 120 minutes. Mouse small intestine was perfused (n = 6) and GLP-1 output from perfused mouse small intestine was investigated in response to vascular ghrelin administration in the presence and absence of a simultaneous luminal glucose stimulus. Ghrelin receptor expression was quantified in human (n = 11) and mouse L-cells (n = 3) by RNA sequencing and RT-qPCR, respectively. RESULTS Ghrelin did not affect GLP-1 secretion in humans (area under the curve [AUC; 0-120 min]: ghrelin infusion = 1.37 ± 0.05 min × nmol vs. saline infusion = 1.40 ± 0.06 min × nmol [P = 0.63]), but induced peripheral insulin resistance. Likewise, ghrelin did not stimulate GLP-1 secretion from the perfused mouse small intestine model (mean outputs during baseline/ghrelin infusion = 19.3 ± 1.6/25.5 ± 2.0 fmol/min, n = 6, P = 0.16), whereas glucose-dependent insulinotropic polypeptide administration, used as a positive control, doubled GLP-1 secretion (P < 0.001). Intraluminal glucose increased GLP-1 secretion by 4-fold (P < 0.001), which was not potentiated by ghrelin. Finally, gene expression of the ghrelin receptor was undetectable in mouse L-cells and marginal in human L-cells. CONCLUSIONS Ghrelin does not interact directly with the L-cell and does not directly affect GLP-1 secretion.",2020,Intra-luminal glucose increased GLP-1 secretion by 4-fold (P<0.001) which was not potentiated by ghrelin.,['eight hypopituitary subjects'],"['placebo', 'Ghrelin or saline']","['Ghrelin receptor expression', 'GLP-1 secretion', 'peripheral insulin resistance']",[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0391690', 'cui_str': 'GHSR Protein'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]",,0.090868,Intra-luminal glucose increased GLP-1 secretion by 4-fold (P<0.001) which was not potentiated by ghrelin.,"[{'ForeName': 'Sara Lind', 'Initials': 'SL', 'LastName': 'Jepsen', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Esben Thyssen', 'Initials': 'ET', 'LastName': 'Vestergaard', 'Affiliation': 'Medical Research Laboratories Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Larraufie', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Fiona Mary', 'Initials': 'FM', 'LastName': 'Gribble', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Reimann', 'Affiliation': ""Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, UK.""}, {'ForeName': 'Jens Otto Lunde', 'Initials': 'JOL', 'LastName': 'Jørgensen', 'Affiliation': 'Medical Research Laboratories Aarhus University, Aarhus N, Denmark.'}, {'ForeName': 'Jens Juul', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Rune Ehrenreich', 'Initials': 'RE', 'LastName': 'Kuhre', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz046'] 593,29450678,"Predicting the Effectiveness of Work-Focused CBT for Common Mental Disorders: The Influence of Baseline Self-Efficacy, Depression and Anxiety.","Purpose This study examined who benefits most from a cognitive behavioural therapy (CBT)-based intervention that aims to enhance return to work (RTW) among employees who are absent due to common mental disorders (CMDs) (e.g., depression, anxiety, or adjustment disorder). We researched the influence of baseline work-related self-efficacy and mental health (depressive complaints and anxiety) on treatment outcomes of two psychotherapeutic interventions. Methods Using a quasi-experimental design, 12-month follow-up data of 168 employees were collected. Participants either received work-focused cognitive behavioural therapy (W-CBT) that integrated work aspects early into the treatment (n = 89) or regular cognitive behavioural therapy (R-CBT) without a focus on work (n = 79). Results Compared with R-CBT, W-CBT resulted in a faster partial RTW, irrespective of baseline self-efficacy. Among individuals with high self-efficacy, W-CBT also resulted in faster full RTW. The effectiveness of W-CBT on RTW did not depend on baseline depressive complaints or anxiety. The decline of mental health complaints did not differ between the two interventions, nor depended on baseline self-efficacy or mental health. Conclusions Considering the benefits of W-CBT for partial RTW, we recommend this intervention as a preferred method for employees with CMDs, irrespective of baseline self-efficacy, depression and anxiety. For individuals with high baseline self-efficacy, this intervention also results in higher full RTW. For those with low self-efficacy, extra exercises or components may be needed to promote full RTW.",2019,"The decline of mental health complaints did not differ between the two interventions, nor depended on baseline self-efficacy or mental health.","['Common Mental Disorders', 'employees who are absent due to common mental disorders (CMDs) (e.g., depression, anxiety, or adjustment disorder', '168 employees were collected']","['cognitive behavioural therapy (CBT)-based intervention', 'Work-Focused CBT', 'work-focused cognitive behavioural therapy (W-CBT) that integrated work aspects early into the treatment (n\u2009=\u200989) or regular cognitive behavioural therapy (R-CBT']","['baseline self-efficacy or mental health', 'decline of mental health complaints']","[{'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0599987', 'cui_str': 'Employee (person)'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0001546', 'cui_str': 'Reactive Disorders'}, {'cui': 'C4319556', 'cui_str': 'One hundred and sixty-eight'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}]",168.0,0.035906,"The decline of mental health complaints did not differ between the two interventions, nor depended on baseline self-efficacy or mental health.","[{'ForeName': 'Veerle', 'Initials': 'V', 'LastName': 'Brenninkmeijer', 'Affiliation': 'Department of Social, Health and Organizational Psychology, Utrecht University, PO Box 80.140, 3508 TC, Utrecht, The Netherlands. v.brenninkmeijer@uu.nl.'}, {'ForeName': 'Suzanne E', 'Initials': 'SE', 'LastName': 'Lagerveld', 'Affiliation': 'Department of Social, Health and Organizational Psychology, Utrecht University, PO Box 80.140, 3508 TC, Utrecht, The Netherlands.'}, {'ForeName': 'Roland W B', 'Initials': 'RWB', 'LastName': 'Blonk', 'Affiliation': 'TNO, Leiden, The Netherlands.'}, {'ForeName': 'Wilmar B', 'Initials': 'WB', 'LastName': 'Schaufeli', 'Affiliation': 'Department of Social, Health and Organizational Psychology, Utrecht University, PO Box 80.140, 3508 TC, Utrecht, The Netherlands.'}, {'ForeName': 'Leoniek D N V', 'Initials': 'LDNV', 'LastName': 'Wijngaards-de Meij', 'Affiliation': 'Department of Social, Health and Organizational Psychology, Utrecht University, PO Box 80.140, 3508 TC, Utrecht, The Netherlands.'}]",Journal of occupational rehabilitation,['10.1007/s10926-018-9760-3'] 594,31784345,"Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects.","BACKGROUND Fish oil enriched in omega-11 long-chain monounsaturated fatty acids (LCMUFAs; C20:1 and C22:1 isomers combined) have shown lipid-lowering and atheroprotective effects in animal models. OBJECTIVE To perform a first-in-human trial of LCMUFA-rich saury fish oil supplementation to test its safety and possible effect on plasma lipids. METHODS A double-blind, randomized, crossover clinical trial was carried out in 30 healthy normolipidemic adults (BMI <25 kg/m 2 ; mean TG, 84 mg/dL). Treatment periods of 8 weeks were separated by an 8-week washout period. Subjects were randomized to receive either 12 g of saury oil (3.5 g of LCMUFA and 3.4 g of omega-3 FAs) or identical capsules with control oil (a mixture of sardine and olive oil; 4.9 g of shorter-chain MUFA oleate and 3 g of omega-3 FAs). RESULTS Saury oil supplementation was safe and resulted in LDL particle counts 12% lower than control oil (P < .001). Saury oil also had a minor effect on increasing HDL particle size (9.8 nm vs 9.7 nm; P < .05) based on a linear mixed effect model. In contrast, control oil, but not saury oil, increased LDL-C by 7.5% compared with baseline (P < .05). Saury oil had similar effects compared with control oil on lowering plasma TG levels, VLDL, and TG-rich lipoprotein particle counts (by ∼16%, 25%, and 35%, respectively; P < .05), and increasing HDL-C and cholesterol efflux capacity (by ∼6% and 8%, respectively; P < .05) compared with baseline. CONCLUSION Saury oil supplementation is well tolerated and has beneficial effects on several cardiovascular parameters, such as LDL particle counts, HDL particle size, and plasma TG levels.",2020,"RESULTS Saury oil supplementation was safe and resulted in LDL particle counts 12% lower than control oil (P < .001).","['healthy subjects', '30 healthy normolipidemic adults (BMI <25\xa0kg/m 2 ; mean TG, 84\xa0mg/dL']","['Saury oil supplementation', 'control oil', 'Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids', 'saury oil (3.5\xa0g of LCMUFA and 3.4\xa0g of omega-3 FAs) or identical capsules with control oil (a mixture of sardine and olive oil; 4.9\xa0g of shorter-chain MUFA oleate and 3\xa0g of omega-3 FAs', 'LCMUFA-rich saury fish oil supplementation']","['LDL particle counts, HDL particle size, and plasma TG levels', 'lowering plasma TG levels, VLDL, and TG-rich lipoprotein particle counts', 'plasma lipids', 'HDL-C and cholesterol efflux capacity', 'HDL particle size', 'LDL-C', 'LDL particle counts']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}]","[{'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0015687', 'cui_str': 'Fatty Acids, Monounsaturated'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C4517692', 'cui_str': '3.4 (qualifier value)'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0453041', 'cui_str': 'Sardine (substance)'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C0220884', 'cui_str': 'Oleate'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}]","[{'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0030608', 'cui_str': 'Particle Size'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipids'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}]",30.0,0.135229,"RESULTS Saury oil supplementation was safe and resulted in LDL particle counts 12% lower than control oil (P < .001).","[{'ForeName': 'Zhi-Hong', 'Initials': 'ZH', 'LastName': 'Yang', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA. Electronic address: zhihong.yang@nih.gov.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Amar', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Alexander V', 'Initials': 'AV', 'LastName': 'Sorokin', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Troendle', 'Affiliation': 'Office of Biostatistics Research, Division of Cardiovascular Sciences, NHLBI, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Amber B', 'Initials': 'AB', 'LastName': 'Courville', 'Affiliation': 'Clinical Center, Nutrition Department, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Sampson', 'Affiliation': 'Clinical Center, Department of Laboratory Medicine, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Martin P', 'Initials': 'MP', 'LastName': 'Playford', 'Affiliation': 'Section of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Shanna', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Clinical Center, Nutrition Department, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Stagliano', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Clarence', 'Initials': 'C', 'LastName': 'Ling', 'Affiliation': 'Clinical Center, Department of Laboratory Medicine, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Kwame', 'Initials': 'K', 'LastName': 'Donkor', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Shamburek', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}, {'ForeName': 'Nehal N', 'Initials': 'NN', 'LastName': 'Mehta', 'Affiliation': 'Section of Inflammation and Cardiometabolic Diseases, Cardiovascular Branch, NHLBI, NIH, Bethesda, MD, USA.'}, {'ForeName': 'Alan T', 'Initials': 'AT', 'LastName': 'Remaley', 'Affiliation': 'Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.'}]",Journal of clinical lipidology,['10.1016/j.jacl.2019.10.013'] 595,32182336,Health Warnings and Beverage Purchase Behavior: Mediators of Impact.,"BACKGROUND To reduce diet-related chronic disease, policymakers have proposed requiring health warnings on sugar-sweetened beverages (SSBs). Health warnings reduced purchases of these products by 22% in our recent randomized controlled trial, but the mechanisms remain unclear. PURPOSE We sought to identify the psychological mechanisms that explain why SSB health warnings affect purchase behavior. METHODS In 2018, we recruited 400 adult SSB consumers to complete a shopping task in a naturalistic convenience store laboratory in North Carolina, USA. We randomly assigned participants to either a health warning arm (all SSBs in the store displayed a text health warning) or to a control arm (SSBs displayed a control label). Participants selected items to purchase with cash. RESULTS Compared to control labels, health warnings elicited more attention, negative affect, anticipated social interactions, and thinking about harms (range of ds = 0.63-1.34; all p < .001). Health warnings also led to higher injunctive norms about limiting SSB consumption (d = 0.27, p = .008). Except for attention, all of these constructs mediated the effect of health warnings on SSB purchases (all p < .05). In contrast, health warnings did not influence other attitudes or beliefs about SSBs or SSB consumption (e.g., healthfulness, outcome expectations, and response efficacy). CONCLUSIONS Health warnings on sugar-sweetened beverages affected purchase behavior by eliciting negative emotions, increasing anticipated social interactions, keeping SSBs' harms at top of mind, and shifting norms about beverage consumption. Results are consistent with recent studies of why tobacco warnings influence quitting behavior, pointing toward a general framework for understanding how health warnings affect behavior. CLINICAL TRIALS REGISTRATION NCT #03511937.",2020,"Compared to control labels, health warnings elicited more attention, negative affect, anticipated social interactions, and thinking about harms (range of ds = 0.63-1.34; all p < .001).","['Participants selected items to purchase with cash', '400 adult SSB consumers to complete a shopping task in a naturalistic convenience store laboratory in North Carolina, USA']",['health warning arm (all SSBs in the store displayed a text health warning) or to a control arm (SSBs displayed a control label'],"['attitudes or beliefs about SSBs or SSB consumption (e.g., healthfulness, outcome expectations, and response efficacy']","[{'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0150768', 'cui_str': 'Shopping (observable entity)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0028407', 'cui_str': 'North Carolina'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}]",400.0,0.0604292,"Compared to control labels, health warnings elicited more attention, negative affect, anticipated social interactions, and thinking about harms (range of ds = 0.63-1.34; all p < .001).","[{'ForeName': 'Anna H', 'Initials': 'AH', 'LastName': 'Grummon', 'Affiliation': 'Harvard Center for Population and Development Studies, Harvard T. H. Chan School of Public Health, Cambridge, MA, USA.'}, {'ForeName': 'Noel T', 'Initials': 'NT', 'LastName': 'Brewer', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,['10.1093/abm/kaaa011'] 596,32179001,Reducing the Burden of Complex Medication Regimens: SImplification of Medications Prescribed to Long-tErm care Residents (SIMPLER) Cluster Randomized Controlled Trial.,"OBJECTIVE To assess the application of a structured process to consolidate the number of medication administration times for residents of aged care facilities. DESIGN A nonblinded, matched-pair, cluster randomized controlled trial. SETTING AND PARTICIPANTS Permanent residents who were English-speaking and taking at least 1 regular medication, recruited from 8 South Australian residential aged care facilities (RACFs). METHODS The intervention involved a clinical pharmacist applying a validated 5-step tool to identify opportunities to reduce medication complexity (eg, by administering medications at the same time or through use of longer-acting or combination formulations). Residents in the comparison group received routine care. The primary outcome at 4-month follow-up was the number of administration times per day for medications charted regularly. Resident satisfaction and quality of life were secondary outcomes. Harms included falls, medication incidents, hospitalizations, and mortality. The association between the intervention and primary outcome was estimated using linear mixed models. RESULTS Overall, 99 residents participated in the intervention arm and 143 in the comparison arm. At baseline, the mean resident age was 86 years, 74% were female, and medications were taken an average of 4 times daily. Medication simplification was possible for 62 (65%) residents in the intervention arm, with 57 (62%) of 92 simplification recommendations implemented at follow-up. The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01). No significant changes in secondary outcomes or harms were observed. CONCLUSIONS AND IMPLICATIONS One-off application of a structured tool to reduce regimen complexity is a low-risk intervention to reduce the burden of medication administration in RACFs and may enable staff to shift time to other resident care activities.",2020,"The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01).","['Permanent residents who were English-speaking and taking at least 1 regular medication', 'residents of aged care facilities', 'recruited from 8 South Australian residential aged care facilities (RACFs', '99 residents participated in the intervention arm and 143 in the comparison arm']",['routine care'],"['Resident satisfaction and quality of life', 'number of administration times per day for medications charted regularly', 'falls, medication incidents, hospitalizations, and mortality', 'mean number of administration times']","[{'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0978887,"The mean number of administration times at follow-up was reduced in the intervention arm in comparison to usual care (-0.36, 95% confidence interval -0.63 to -0.09, P = .01).","[{'ForeName': 'Janet K', 'Initials': 'JK', 'LastName': 'Sluggett', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia. Electronic address: janet.sluggett@monash.edu.'}, {'ForeName': 'Esa Y H', 'Initials': 'EYH', 'LastName': 'Chen', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Jenni', 'Initials': 'J', 'LastName': 'Ilomäki', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Corlis', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Emden', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Hogan', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Caporale', 'Affiliation': 'Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Keen', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Ria', 'Initials': 'R', 'LastName': 'Hopkins', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Choon Ean', 'Initials': 'CE', 'LastName': 'Ooi', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia.'}, {'ForeName': 'Sarah N', 'Initials': 'SN', 'LastName': 'Hilmer', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Kolling Institute of Medical Research, Royal North Shore Hospital, Northern Clinical School, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia.'}, {'ForeName': 'Georgina A', 'Initials': 'GA', 'LastName': 'Hughes', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Luu', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.'}, {'ForeName': 'Kim-Huong', 'Initials': 'KH', 'LastName': 'Nguyen', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Centre for Health Services Research, The University of Queensland, Woolloogabba, Queensland, Australia.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Comans', 'Affiliation': 'NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Centre for Health Services Research, The University of Queensland, Woolloogabba, Queensland, Australia.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Edwards', 'Affiliation': 'Drug & Therapeutics Information Service, GP Plus Marion, South Australia, Australia.'}, {'ForeName': 'Lyntara', 'Initials': 'L', 'LastName': 'Quirke', 'Affiliation': 'Consumer Representative, Dementia Australia, Scullin, Australian Capital Territory, Australia.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Patching', 'Affiliation': 'Helping Hand Consumer and Carer Reference Group, Helping Hand Aged Care, North Adelaide, South Australia, Australia.'}, {'ForeName': 'J Simon', 'Initials': 'JS', 'LastName': 'Bell', 'Affiliation': 'Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.02.003'] 597,31701566,Monetary reinforcement for self-monitoring of blood glucose among young people with type 1 diabetes: evaluating effects on psychosocial functioning.,"AIMS To explore the auxiliary psychosocial effects of a monetary reinforcement intervention targeting self-monitoring of blood glucose among young people with Type 1 diabetes. METHODS Sixty young people with Type 1 diabetes, HbA 1c concentrations between 58 and 119 mmol/mol (7.5-13.0%), and average self-monitoring of blood glucose <4 times per day were randomized to either enhanced usual care or a 24-week intervention of monetary rewards for self-monitoring of blood glucose and associated behaviours (e.g. uploading glucose meters). Data were collected from the young people and their parents at baseline, during the intervention (6, 12 and 24 weeks) and after the intervention (36 weeks). RESULTS Linear mixed models were used to evaluate the intervention effects on psychosocial outcomes, adjusting for corresponding baseline levels and potential moderation by baseline level. The intervention reduced diabetes distress at week 6 among young people who had average and high baseline distress. It also reduced diabetes distress at weeks 12 and 24 among those with low baseline distress. The intervention also reduced young person-reported diabetes-related family conflict and diabetes-related interference among those with high baseline scores in these areas; however, the intervention worsened young person-reported diabetes interference among those with low baseline interference. Effects were medium-sized and time-limited. CONCLUSIONS Findings indicate predominantly positive impacts of monetary reinforcement interventions on psychosocial outcomes, although effects varied by outcome and time point. Whereas early improvements in diabetes distress were observed for all who received the intervention, improvements in other areas varied according to the level of psychosocial challenge at baseline. Incorporating psychosocial interventions may bolster and maintain effects over time.",2020,"The intervention also reduced young person-reported diabetes-related family conflict and diabetes-related interference among those with high baseline scores in these areas; however, the intervention worsened young person-reported diabetes interference among those with low baseline interference.","['young people with type 1 diabetes', 'young people with Type 1 diabetes', 'Sixty young people with Type 1 diabetes, HbA 1c concentrations between 58 and 119 mmol/mol (7.5-13.0%), and average self-monitoring of blood glucose <4 times per day']","['monetary reinforcement intervention targeting self-monitoring', 'enhanced usual care or a 24-week intervention of monetary rewards for self-monitoring of blood glucose and associated behaviours (e.g. uploading glucose meters']","['diabetes distress', 'psychosocial outcomes', 'blood glucose']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0005803', 'cui_str': 'Monitoring, Home Blood Glucose'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439505', 'cui_str': 'per day'}]","[{'cui': 'C0035007', 'cui_str': 'Reinforcement'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0005803', 'cui_str': 'Monitoring, Home Blood Glucose'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0475209', 'cui_str': 'm'}]","[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}]",60.0,0.0182264,"The intervention also reduced young person-reported diabetes-related family conflict and diabetes-related interference among those with high baseline scores in these areas; however, the intervention worsened young person-reported diabetes interference among those with low baseline interference.","[{'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Wong', 'Affiliation': 'Department of Pediatrics, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Addala', 'Affiliation': 'Department of Pediatrics, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Naranjo', 'Affiliation': 'Department of Pediatrics, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'K K', 'Initials': 'KK', 'LastName': 'Hood', 'Affiliation': 'Department of Pediatrics, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Cengiz', 'Affiliation': 'Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Ginley', 'Affiliation': 'East Tennessee State University, Johnson City, TN, USA.'}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Feinn', 'Affiliation': 'Quinnipiac University, Hamden, CT, USA.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Wagner', 'Affiliation': 'School of Dental Medicine and School of Medicine, University of Connecticut, Storrs, CT, USA.'}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14174'] 598,31915189,Effects of acute sleep loss on diurnal plasma dynamics of CNS health biomarkers in young men.,"OBJECTIVE Disrupted sleep increases CSF levels of tau and β-amyloid (Aβ) and is associated with an increased risk of Alzheimer disease (AD). Our aim was to determine whether acute sleep loss alters diurnal profiles of plasma-based AD-associated biomarkers. METHODS In a 2-condition crossover study, 15 healthy young men participated in 2 standardized sedentary in-laboratory conditions in randomized order: normal sleep vs overnight sleep loss. Plasma levels of total tau (t-tau), Aβ40, Aβ42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP) were assessed using ultrasensitive single molecule array assays or ELISAs, in the fasted state in the evening prior to, and in the morning after, each intervention. RESULTS In response to sleep loss (+17.2%), compared with normal sleep (+1.8%), the evening to morning ratio was increased for t-tau ( p = 0.035). No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10). The AD risk genotype rs4420638 did not significantly interact with sleep loss-related diurnal changes in plasma levels of Aβ40 or Aβ42 ( p > 0.10). Plasma levels of Aβ42 (-17.1%) and GFAP (-12.1%) exhibited an evening to morning decrease across conditions ( p < 0.05). CONCLUSIONS Our exploratory study suggests that acute sleep loss results in increased blood levels of t-tau. These changes provide further evidence that sleep loss may have detrimental effects on brain health even in younger individuals. Larger cohorts are warranted to delineate sleep vs circadian mechanisms, implications for long-term recurrent conditions (e.g., in shift workers), as well as interactions with other lifestyle and genetic factors.",2020,"No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10).","['15 healthy young men participated in 2 standardized sedentary in-laboratory conditions in randomized order', 'young men']",['normal sleep vs overnight sleep loss'],"['levels of Aβ40, Aβ42, NfL, or GFAP', 'evening to morning ratio', 'blood levels', 'normal sleep', 'sleep loss', 'Plasma levels of Aβ42', 'CSF levels of tau and β-amyloid ', 'risk of Alzheimer disease (AD', 'diurnal plasma dynamics of CNS health biomarkers', 'Plasma levels of total tau (t-tau), Aβ40, Aβ42, neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP', 'GFAP']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0235161', 'cui_str': 'Sleep loss'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0017626', 'cui_str': 'Glial Intermediate Filament Protein'}, {'cui': 'C0587117', 'cui_str': 'Evening (qualifier value)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0235161', 'cui_str': 'Sleep loss'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}]",15.0,0.110715,"No changes between the sleep conditions were seen for levels of Aβ40, Aβ42, NfL, or GFAP (all p > 0.10).","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Benedict', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Kaj', 'Initials': 'K', 'LastName': 'Blennow', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Cedernaes', 'Affiliation': 'From the Departments of Neuroscience (C.B., J.C.) and Medical Sciences (J.C.), Uppsala University; Clinical Neurochemistry Laboratory (K.B., H.Z.), Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (K.B., H.Z.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK. jonathan.cedernaes@medsci.uu.se.'}]",Neurology,['10.1212/WNL.0000000000008866'] 599,32078362,Automated Noncontact Ultrasound Imaging and Ablation System for the Treatment of Atrial Fibrillation: Outcomes of the First-in-Human VALUE Trial.,"BACKGROUND Catheter ablation for atrial fibrillation (AF) using point-by-point radiofrequency energy or single-application one-shot balloons is either technically challenging or have limited ability to accommodate variable patient anatomy to achieve acute and durable pulmonary vein (PV) isolation. A novel ablation system employs low intensity collimated ultrasound (LICU)-guided anatomic mapping and robotic ablation to isolate PVs. In this first-in-human, single-center, multioperator trial, VALUE trial (VytronUS Ablation System for Treatment of Paroxysmal Atrial Fibrillation; NCT03639597) in patients with paroxysmal atrial fibrillation, this LICU system was evaluated to determine its safety, effectiveness in PV isolation, and freedom from recurrent atrial arrhythmias. METHODS In the enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies were successfully created, and ablation was performed under robotic control along an operator-defined lesion path. The LICU system software advanced over the course of the study: the last 13 patients were ablated with enhanced software. RESULTS Acute PV isolation was achieved in 98% of PVs-using LICU-only in 77.3% (153/198) of PVs and requiring touch-up with a standard radiofrequency ablation catheter in 22.7% (45/198) PVs. The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software. Freedom from atrial arrhythmia recurrence was 79.6% (39/49 patients) at 12 months or 92.3% (12/13 patients) with the enhanced software. Major adverse events occurred in 3 patients (5.8%): one had transient diaphragmatic paralysis, one vascular access complication, and one had transient ST-segment elevation from air-embolism, without sequelae. CONCLUSIONS In this first-in-human study, low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation allows PV isolation with good chronic safety; PV isolation success is improving with device enhancements. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03639597.",2020,The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software.,"['patients with paroxysmal atrial fibrillation', 'enrolled 52 patients with paroxysmal atrial fibrillation, ultrasound M-mode-based left atrial anatomies', 'Atrial Fibrillation']","['standard radiofrequency ablation catheter', 'low- intensity collimated ultrasound-guided anatomic mapping and robotic ablation', 'Catheter ablation', 'Automated Noncontact Ultrasound Imaging and Ablation System']","['Major adverse events', 'touch-up rate', 'atrial arrhythmia recurrence', 'transient diaphragmatic paralysis, one vascular access complication', 'PV isolation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0235480', 'cui_str': 'Paroxysmal atrial fibrillation (disorder)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0002808', 'cui_str': 'Anatomy'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0162563', 'cui_str': 'Catheter Ablation'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia (disorder)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0035232', 'cui_str': 'Diaphragmatic Paralysis'}, {'cui': 'C0920165'}, {'cui': 'C0220862', 'cui_str': 'isolation'}]",52.0,0.0248762,The touch-up rate decreased to 5.8% (3/52) in patients undergoing LICU-ablation with enhanced software.,"[{'ForeName': 'Mohit K', 'Initials': 'MK', 'LastName': 'Turagam', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, NY (M.K.T., W.W., S.R.D., V.Y.R.).'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Petru', 'Affiliation': 'Department of Cardiology, Homolka Hospital, Prague, Czech Republic (J.P., P.N., K.K., S.K., V.Y.R.).'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Neuzil', 'Affiliation': 'Department of Cardiology, Homolka Hospital, Prague, Czech Republic (J.P., P.N., K.K., S.K., V.Y.R.).'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Kakita', 'Affiliation': 'Department of Cardiology, Homolka Hospital, Prague, Czech Republic (J.P., P.N., K.K., S.K., V.Y.R.).'}, {'ForeName': 'Stepan', 'Initials': 'S', 'LastName': 'Kralovec', 'Affiliation': 'Department of Cardiology, Homolka Hospital, Prague, Czech Republic (J.P., P.N., K.K., S.K., V.Y.R.).'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Harari', 'Affiliation': 'VytronUS, Inc, Sunnyvale, CA (D.H., P.P., D.P.).'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Phillips', 'Affiliation': 'VytronUS, Inc, Sunnyvale, CA (D.H., P.P., D.P.).'}, {'ForeName': 'Danielo', 'Initials': 'D', 'LastName': 'Piazza', 'Affiliation': 'VytronUS, Inc, Sunnyvale, CA (D.H., P.P., D.P.).'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Whang', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, NY (M.K.T., W.W., S.R.D., V.Y.R.).'}, {'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Dukkipati', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, NY (M.K.T., W.W., S.R.D., V.Y.R.).'}, {'ForeName': 'Vivek Y', 'Initials': 'VY', 'LastName': 'Reddy', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, NY (M.K.T., W.W., S.R.D., V.Y.R.).'}]",Circulation. Arrhythmia and electrophysiology,['10.1161/CIRCEP.119.007917'] 600,32180059,"Counting fast or slow, aloud or silently? A comparison of adult stutterers and non-stutterers.","This study assesses factors influencing the capacity to maintain a steady rhythm during explicit counting activities. There are three counting paces (count every 800, 1200, or 1600 ms) and three experimental conditions (count silently, aloud and aloud in the presence of someone). The study also assesses the effect of a speech disorder, namely stuttering, on this counting ability by comparing the performance of a group of adult stutterers (n = 21) to that of a group of adult non-stutterers (n = 24). For temporal variability, in addition to replicating the fact that counting more slowly leads to lower performance, the results show that there are benefits to expect when participants count aloud instead of silently. There is no main effect of group, but the interaction between the experimental condition, the counting pace, and the group is significant. Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms). The significantly higher variability at 1600 ms indicates a loss of efficiency in the capacity to keep time constant when counting is slow, and it is in this condition that stutterers will gain the most benefits from counting aloud instead of silently.",2020,Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms).,['group of adult stutterers (n\u2009=\u200921) to that of a group of adult non-stutterers (n\u2009=\u200924'],[],[],"[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],[],,0.0368474,Adult non-stutterers are better than adult stutterers in the silent and long time-interval conditions (1600 ms).,"[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Plamondon', 'Affiliation': 'École de Psychologie, Université Laval, 2325 Rue des Bibliothèques, Quebec, QC, G1V 0A6, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Grondin', 'Affiliation': 'École de Psychologie, Université Laval, 2325 Rue des Bibliothèques, Quebec, QC, G1V 0A6, Canada. simon.grondin@psy.ulaval.ca.'}]",Cognitive processing,['10.1007/s10339-020-00955-x'] 601,31373701,Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.,"BACKGROUND Alcohol consumption is associated with poor health outcomes in women living with HIV (WLWH), but whether medication can help to reduce drinking in non-treatment-seeking women or whether reduction in drinking improves HIV outcomes is unclear. We conducted a randomized clinical trial (RCT) of daily oral naltrexone (50 mg) versus placebo in WLWH who met criteria for current unhealthy alcohol use. METHODS WLWH with current unhealthy alcohol use (>7 drinks/wk or >3 drinks/occasion) were randomly assigned to daily oral naltrexone 50 mg (n = 96) or placebo (n = 98) for 4 months. Drinking outcomes, including the proportion of women who reduced (7\xa0drinks/wk or >3\xa0drinks/occasion']","['naltrexone', 'daily oral naltrexone', 'Naltrexone Versus Placebo', 'placebo', 'oral naltrexone 50\xa0mg (n\xa0=\xa096) or placebo']","['proportion of women who reduced ( 30kg.mg -2 ), excluding Grade II and III obese. We measured pulmonary ventilation mechanics data before pneumoperitoneum (baseline), and five, fifteen and thirty minutes after peritoneal insufflation, and fifteen minutes after disinflation (final). RESULTS Mean BMI of non-obese was 22.72 ± 1.43kg.m -2 and of the obese 31.78 ± 1.09kg.m -2 , p < 0.01. Duration of anesthesia and of peritoneal insufflation was similar between groups. Baseline pulmonary compliance (Crs) of the obese (38.3 ± 8.3mL.cm H 2 O -1 ) was lower than of the non-obese (47.4 ± 5.7mL.cm H 2 O -1 ), p = 0.01. After insufflation, Crs decreased in both groups and remained even lower in the obese at all moments assessed (GLM p < 0.01). Respiratory system peak pressure and plateau pressure were higher in the obese, albeit variations were similar at moments analyzed (GLM p > 0.05). The same occurred with elastic pressure, higher in the obese at all times (GLM p = 0.04), and resistive pressure showed differences in variations between groups during pneumoperitoneum (GLM p = 0,05). CONCLUSIONS Grade I obese presented more changes in pulmonary mechanics than the non-obese during video laparoscopies and the fact requires mechanical ventilation-related care.",2020,"The same occurred with elastic pressure, higher in the obese at all times (GLM p = 0.04), and resistive pressure showed differences in variations between groups during pneumoperitoneum (GLM p = 0,05). ","['Grade I obese', '20 patients submitted to video laparoscopic cholecystectomy, normal spirometry, divided into non-obese (BMI ≤ 25kg.m -2 ) and obese']","['video laparoscopic surgery', 'pneumoperitoneum']","['Mean BMI of non-obese', 'respiratory mechanics', 'Duration of anesthesia and of peritoneal insufflation', 'Respiratory system peak pressure and plateau pressure', 'pulmonary ventilation mechanics data', 'Baseline pulmonary compliance (Crs', 'elastic pressure', 'pulmonary mechanics', 'resistive pressure']","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0332849', 'cui_str': 'Divide'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0032320', 'cui_str': 'Pneumoperitoneum'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0035230', 'cui_str': 'Breathing Mechanics'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0442034', 'cui_str': 'Peritoneal (qualifier value)'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C3541375', 'cui_str': 'RESPIRATORY SYSTEM'}, {'cui': 'C0445174', 'cui_str': 'Peak pressure (qualifier value)'}, {'cui': 'C0445176', 'cui_str': 'Plateau pressure (qualifier value)'}, {'cui': 'C0035213', 'cui_str': 'Respiratory Airflow'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}]",20.0,0.0295339,"The same occurred with elastic pressure, higher in the obese at all times (GLM p = 0.04), and resistive pressure showed differences in variations between groups during pneumoperitoneum (GLM p = 0,05). ","[{'ForeName': 'Orlandira Costa', 'Initials': 'OC', 'LastName': 'Araujo', 'Affiliation': 'Universidade de São Paulo (USP), Hospital Universitário (HU), São Paulo, SP, Brasil; Instituto de Assistência Médica do Servidor Público Estadual do Estado de São Paulo (IAMSPE), São Paulo, SP, Brasil. Electronic address: ocaraujo@usp.br.'}, {'ForeName': 'Eloisa Bonetti', 'Initials': 'EB', 'LastName': 'Espada', 'Affiliation': 'Universidade de São Paulo (USP), Hospital Universitário (HU), São Paulo, SP, Brasil; Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}, {'ForeName': 'Fernanda Magalhães Arantes', 'Initials': 'FMA', 'LastName': 'Costa', 'Affiliation': 'Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}, {'ForeName': 'Julia Araujo', 'Initials': 'JA', 'LastName': 'Vigiato', 'Affiliation': 'Faculdade de Medicina do ABC, São Paulo, SP, Brasil.'}, {'ForeName': 'Maria José Carvalho', 'Initials': 'MJC', 'LastName': 'Carmona', 'Affiliation': 'Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}, {'ForeName': 'José Pinhata', 'Initials': 'JP', 'LastName': 'Otoch', 'Affiliation': 'Universidade de São Paulo (USP), Hospital Universitário (HU), São Paulo, SP, Brasil; Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}, {'ForeName': 'João Manoel', 'Initials': 'JM', 'LastName': 'Silva', 'Affiliation': 'Instituto de Assistência Médica do Servidor Público Estadual do Estado de São Paulo (IAMSPE), São Paulo, SP, Brasil; Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}, {'ForeName': 'Milton de Arruda', 'Initials': 'MA', 'LastName': 'Martins', 'Affiliation': 'Universidade de São Paulo (USP), Faculdade de Medicina (FM), Hospital das Clínicas (HC), São Paulo, SP, Brasil.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.12.001'] 608,30561577,Mass Oral Azithromycin for Childhood Mortality: Timing of Death After Distribution in the MORDOR Trial.,"In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites. Here, we present a prespecified secondary analysis showing that much of the protective effect was in the first 3 months postdistribution. Distributing more frequently than biannually could be considered if logistically feasible. Clinical Trials Registration. NCT02047981.",2019,"In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites.","['Childhood Mortality', 'sub-Saharan African sites']","['biannual azithromycin', 'Azithromycin']","['Timing of Death', 'postneonatal childhood mortality']","[{'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}]","[{'cui': 'C0449243', 'cui_str': 'Timing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",,0.134499,"In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites.","[{'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Hart', 'Affiliation': 'London School of Hygiene and Tropical Medicine, United Kingdom.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Arzika', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Jerusha', 'Initials': 'J', 'LastName': 'Weaver', 'Affiliation': 'The Dana Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Khumbo', 'Initials': 'K', 'LastName': 'Kalua', 'Affiliation': 'Blantyre Institute for Community Outreach, Blantyre.'}, {'ForeName': 'Zakayo', 'Initials': 'Z', 'LastName': 'Mrango', 'Affiliation': 'National Institute for Medical Research, Dar es Salaam, Tanzania.'}, {'ForeName': 'Sun Y', 'Initials': 'SY', 'LastName': 'Cotter', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Nicole E', 'Initials': 'NE', 'LastName': 'Stoller', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Kieran S', 'Initials': 'KS', 'LastName': ""O'Brien"", 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Dionna M', 'Initials': 'DM', 'LastName': 'Fry', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Vanderschelden', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Oldenburg', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Sheila K', 'Initials': 'SK', 'LastName': 'West', 'Affiliation': 'The Dana Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Robin L', 'Initials': 'RL', 'LastName': 'Bailey', 'Affiliation': 'London School of Hygiene and Tropical Medicine, United Kingdom.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy973'] 609,31999308,Development of a Sleep Apnea-Specific Health State Utility Algorithm.,"Importance With the increasing emphasis on economic evaluations, there is a need for additional methods of measuring patient utility in the obstructive sleep apnea population. Objective To develop and validate a utility scoring algorithm for a sleep apnea-specific quality-of-life instrument. Design, Setting, and Participants Development and validation were conducted at 2 tertiary referral sleep centers and associated sleep clinics and included patients with newly diagnosed obstructive sleep apnea from a randomized clinical trial and an associated observational cohort study. Baseline participants were randomly divided into a model development group (60%) and a cross-validation group (40%). Main Outcomes and Measures Utility scoring of the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25) was mapped from the SF-6D utility index through multiple linear regression in the development sample using the Akaike information criterion to determine the best model. Results A total of 500 participants (development, n = 300; validation, n = 200) were enrolled; the analyzed sample of 500 participants included 295 men (59%), and the mean (SD) age was 48.6 (12.8) years, with a range of 18 to 90 years. The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups. The best-fit model (the SNORE Utility Index) was the natural log conversion of the instrument subscales (r2 = 0.32 in the development sample). The SNORE Utility Index retained this association within the validation sample (r2 = 0.33). Conclusions and Relevance The SNORE Utility Index provides a validated, disease-specific, preference-weighted utility instrument that can be used in future studies of patients with obstructive sleep apnea.",2020,"The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups.","['patients with obstructive sleep apnea', 'Participants\n\n\nDevelopment and validation were conducted at 2 tertiary referral sleep centers and associated sleep clinics and included patients with newly diagnosed obstructive sleep apnea from a randomized clinical trial and an associated observational cohort study', 'obstructive sleep apnea population', '500 participants (development, n\u2009=\u2009300; validation, n\u2009=\u2009200) were enrolled; the analyzed sample of 500 participants included 295 men (59%), and the mean (SD) age was 48.6 (12.8) years, with a range of 18 to 90 years']",[],"['Measures\n\n\nUtility scoring of the Symptoms of Nocturnal Obstruction and Related Events (SNORE-25', 'mean (SD) SF-6D utility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517547', 'cui_str': '12.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]",[],"[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0037384', 'cui_str': 'Snorings'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",500.0,0.0226285,"The mean (SD) SF-6D utility among participants with untreated sleep apnea was 0.61 (0.08; range, 0.40-0.85) with similar utility across sleep apnea severity groups.","[{'ForeName': 'Jonathan R', 'Initials': 'JR', 'LastName': 'Skirko', 'Affiliation': 'Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, University of Utah, Salt Lake City.'}, {'ForeName': 'Kathryn T', 'Initials': 'KT', 'LastName': 'James', 'Affiliation': 'Comparative Effectiveness, Cost and Outcomes Research Center, University of Washington, Seattle.'}, {'ForeName': 'Louis P', 'Initials': 'LP', 'LastName': 'Garrison', 'Affiliation': 'Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Weaver', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle.'}]",JAMA otolaryngology-- head & neck surgery,['10.1001/jamaoto.2019.4469'] 610,30289478,Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.,"BACKGROUND Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis. METHODS Adult patients were randomized 1:1 to isavuconazole (200 mg intravenous [IV] three-times-daily [TID] for 2 days, followed by 200 mg IV once-daily [OD]) or caspofungin (70 mg IV OD on day 1, followed by 50 mg IV OD [70 mg in patients > 80 kg]) for a maximum of 56 days. After day 10, patients could switch to oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm). Primary efficacy endpoint was successful overall response at the end of IV therapy (EOIVT) in patients with proven infections who received ≥1 dose of study drug (modified-intent-to-treat [mITT] population). The pre-specified noninferiority margin was 15%. Secondary outcomes in the mITT population were successful overall response at 2 weeks after the end of treatment, all-cause mortality at days 14 and 56, and safety. RESULTS Of 450 patients randomized, 400 comprised the mITT population. Baseline characteristics were balanced between groups. Successful overall response at EOIVT was observed in 60.3% of patients in the isavuconazole arm and 71.1% in the caspofungin arm (adjusted difference -10.8, 95% confidence interval -19.9--1.8). The secondary endpoints, all-cause mortality, and safety were similar between arms. Median time to clearance of the bloodstream was comparable between groups. CONCLUSIONS This study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of invasive candidiasis. Secondary endpoints were similar between both groups. CLINICAL TRIALS REGISTRATION NCT00413218.",2019,This study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of invasive candidiasis.,"['patients with proven infections who received ≥1 dose of study drug (modified-intent-to-treat [mITT] population', 'Candidemia and Other Invasive Candida Infections', 'patients with candidemia or invasive candidiasis', 'Adult patients', 'primary treatment of invasive candidiasis', '450 patients randomized, 400 comprised the mITT population']","['isavuconazole', 'caspofungin', 'oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm', 'isavuconazole to caspofungin', 'Isavuconazole Versus Caspofungin', 'caspofungin followed by oral voriconazole', 'isavuconazole (200 mg intravenous [IV] three-times-daily [TID']","['successful overall response at the end of IV therapy (EOIVT', 'successful overall response', 'cause mortality, and safety', 'Median time to clearance of the bloodstream', 'Successful overall response at EOIVT']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0877445', 'cui_str': 'Candidemia'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0006840', 'cui_str': 'Moniliasis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3844104', 'cui_str': 'Four hundred and fifty'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}]","[{'cui': 'C1832021', 'cui_str': 'isavuconazole'}, {'cui': 'C0537894', 'cui_str': 'Caspofungin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0393080', 'cui_str': 'voriconazole'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0556984', 'cui_str': 'Three times daily (qualifier value)'}, {'cui': 'C0908863', 'cui_str': 'TIDS'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}]",450.0,0.620311,This study did not demonstrate non-inferiority of isavuconazole to caspofungin for primary treatment of invasive candidiasis.,"[{'ForeName': 'Bart Jan', 'Initials': 'BJ', 'LastName': 'Kullberg', 'Affiliation': 'Radboud Center for Infectious Diseases, and Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Viscoli', 'Affiliation': 'Dipartimento di Scienze della Salute, University of Genova.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Pappas', 'Affiliation': 'University of Alabama at Birmingham.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Vazquez', 'Affiliation': 'Medical College of Georgia/Augusta University.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Ostrosky-Zeichner', 'Affiliation': 'University of Texas, Houston.'}, {'ForeName': 'Coleman', 'Initials': 'C', 'LastName': 'Rotstein', 'Affiliation': 'University Health Network, University of Toronto, Ontario, Canada.'}, {'ForeName': 'Jack D', 'Initials': 'JD', 'LastName': 'Sobel', 'Affiliation': 'Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Herbrecht', 'Affiliation': 'Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, Inserm, UMR-S1113/IRFAC, France.'}, {'ForeName': 'Galia', 'Initials': 'G', 'LastName': 'Rahav', 'Affiliation': 'Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Israel.'}, {'ForeName': 'Sutep', 'Initials': 'S', 'LastName': 'Jaruratanasirikul', 'Affiliation': 'Songklanagarind Hospital, Hat Yai.'}, {'ForeName': 'Ploenchan', 'Initials': 'P', 'LastName': 'Chetchotisakd', 'Affiliation': 'Srinagarind Hospital, Khon Kaen University, Thailand.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Van Wijngaerden', 'Affiliation': 'Ku Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'De Waele', 'Affiliation': 'Ghent University Hospital, Belgium.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lademacher', 'Affiliation': 'Astellas Pharma Global Development, Inc, Northbrook, Illinois.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Engelhardt', 'Affiliation': 'Basilea Pharmaceutica International Ltd., Basel, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Kovanda', 'Affiliation': 'Astellas Pharma Global Development, Inc, Northbrook, Illinois.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Croos-Dabrera', 'Affiliation': 'Astellas Pharma Global Development, Inc, Northbrook, Illinois.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Fredericks', 'Affiliation': 'Astellas Pharma Global Development, Inc, Northbrook, Illinois.'}, {'ForeName': 'George R', 'Initials': 'GR', 'LastName': 'Thompson', 'Affiliation': 'Department of Medicine, University of California Davis.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy827'] 611,32164877,"Adjuvant 131 I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial.","BACKGROUND Effective adjuvant treatment after hepatectomy for hepatocellular carcinoma (HCC) is an important area of research. Radioactive iodine ( 131 I)-labelled metuximab is a radiolabelled monoclonal antibody against the CD147 (also known as basigin or HAb18G) antigen that is expressed in HCC. We aimed to examine the role of 131 I-metuximab as an adjuvant therapy after HCC resection. METHODS This randomised, controlled, multicentre, open-label, phase 2 trial was done at five medical centres in China. Patients aged 18-75 years who underwent curative-intent resection of histologically confirmed HCC expressing CD147 were randomly assigned (1:1) by a computer-generated random sequence, stratified by centre, to receive either adjuvant transarterial injection of one dose of 27·75 MBq/kg 131 I-metuximab 4-6 weeks after the hepatectomy (treatment group) or no adjuvant treatment (control group). Patients and physicians were not masked to the study groups. The primary outcome was 5-year recurrence-free survival (RFS) in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00819650. FINDINGS Between April 1, 2009, and Nov 30, 2012, 485 patients were screened for eligibility. 329 (68%) of these patients were excluded and 156 (32%) were randomly assigned to receive either 131 I-metuximab (n=78) or no adjuvant treatment (n=78). The median follow-up was 55·9 months (IQR 18·6-79·4). In the intention-to-treat population, the 5-year RFS was 43·4% (95% CI 33·6-55·9) in the 131 I-metuximab group and 21·7% (14·2-33·1) in the control group (hazard ratio 0·49 [95% CI 0·34-0·72]; Z=2·96, p=0·0031). 131 I-metuximab-associated adverse events occurred within the first 4 weeks in 34 (45%) of 76 patients, seven (21%) of whom had grade 3 or 4 adverse events. These adverse events were all resolved with appropriate treatment within 2 weeks of being identified. INTERPRETATION Adjuvant 131 I-metuximab treatment significantly improved the 5-year RFS of patients after hepatectomy for HCC tumours expressing CD147. This treatment was well tolerated by patients. FUNDING State Key Project on Infectious Diseases of China.",2020,"INTERPRETATION Adjuvant 131 I-metuximab treatment significantly improved the 5-year RFS of patients after hepatectomy for HCC tumours expressing CD147.","['five medical centres in China', 'Patients aged 18-75 years who underwent curative-intent resection of histologically confirmed HCC expressing CD147', 'hepatocellular carcinoma (HCC', 'hepatocellular carcinoma after liver resection', 'Between April 1, 2009, and Nov 30, 2012, 485 patients were screened for eligibility', '329 (68%) of these patients were excluded and 156 (32%) were randomly assigned to receive either 131']","['adjuvant transarterial injection of one dose of 27·75 MBq/kg 131', 'I-metuximab (n=78) or no adjuvant treatment', 'hepatectomy (treatment group) or no adjuvant treatment (control group', 'Radioactive iodine']","['5-year recurrence-free survival (RFS', 'adverse events', '5-year RFS']","[{'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C2239176', 'cui_str': 'Liver Cell Carcinoma, Adult'}, {'cui': 'C0019144', 'cui_str': 'Hepatectomy'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0522522', 'cui_str': 'Transarterial approach (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0556640', 'cui_str': 'MBq'}, {'cui': 'C1722700', 'cui_str': 'metuximab'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0019144', 'cui_str': 'Hepatectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",485.0,0.168194,"INTERPRETATION Adjuvant 131 I-metuximab treatment significantly improved the 5-year RFS of patients after hepatectomy for HCC tumours expressing CD147.","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Jingliang', 'Initials': 'J', 'LastName': 'Xing', 'Affiliation': ""Cell Engineering Research Center, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Yefa', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Jingfeng', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Department of Hepatobiliary Surgery, First Affiliated and Mengchao Hepatobiliary Surgery Hospital, Fujian Medical University, Fuzhou, China.'}, {'ForeName': 'Wentao', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Hepatopancreatobiliary Surgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Xia', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Zhenlin', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Kui', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Xuying', 'Initials': 'X', 'LastName': 'Wan', 'Affiliation': 'Department of Clinical Database, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Tian', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Chunfang', 'Initials': 'C', 'LastName': 'Gao', 'Affiliation': 'Clinical Laboratory, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Anfeng', 'Initials': 'A', 'LastName': 'Si', 'Affiliation': 'Department of Clinical Database, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Hongyang', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'National Centre for Liver Cancer, Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer of the Ministry of Education of China, Shanghai Key Laboratory of Hepatobiliary Tumor Biology, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Mengchao', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.'}, {'ForeName': 'Wan Yee', 'Initials': 'WY', 'LastName': 'Lau', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Faculty of Medicine, Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Area, China.'}, {'ForeName': 'Zhinan', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': ""Cell Engineering Research Center, Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Shen', 'Affiliation': 'Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Electronic address: shenfengehbh@sina.com.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30422-4'] 612,30239620,Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.,"BACKGROUND Young men who have sex with men are among the most vulnerable to human immunodeficiency virus (HIV) infection. Although preexposure prophylaxis (PrEP) has demonstrated effectiveness, adherence and retention have been low among youth. METHODS We conducted a randomized controlled trial to evaluate the impact of a youth-tailored, bidirectional text-messaging intervention (PrEPmate) on study retention and PrEP adherence. Young individuals at risk for HIV initiating PrEP within Chicago's safety-net system were randomized 2:1 to receive PrEPmate or standard of care (SoC) for 36 weeks. The primary retention outcome was study-visit completion, and the primary adherence outcome was tenofovir diphosphate (TFV-DP) concentrations ≥700 fmol/punch (consistent with ≥4 doses/week) assessed at 4, 12, 24, and 36 weeks. The impact of PrEPmate on retention and adherence was evaluated using generalized estimating equation logistic models with robust standard errors. RESULTS From April 2015 to March 2016, 121 participants enrolled (mean age 24; 27% black, 36% Latino). Participants who received PrEPmate were more likely to attend study visits (86% PrEPmate vs. 71% SoC, odds ratio [OR] = 2.62, 95% confidence interval [CI] 1.24-5.54) and have TFV-DP levels consistent with ≥4 doses/week (72% PrEPmate vs. 57% SoC, OR = 2.05, 95% CI 1.06-3.94). PrEPmate efficacy did not differ significantly by age, race/ethnicity, education, or insurance. Overall, 88% reported PrEPmate to be very/somewhat helpful, and 92% would recommend PrEPmate to others. CONCLUSIONS An interactive text-messaging intervention had high acceptability and significantly increased study-visit retention and PrEP adherence among young individuals at risk for HIV acquisition. CLINICAL TRIALS REGISTRATION NCT02371525.",2019,"An interactive text-messaging intervention had high acceptability and significantly increased study-visit retention and PrEP adherence among young individuals at risk for HIV acquisition. ","[""Young individuals at risk for HIV initiating PrEP within Chicago's safety-net system"", 'Young People at Risk for Human Immunodeficiency Virus', 'young individuals at risk for HIV acquisition', 'Young men who have sex with men', 'From April 2015 to March 2016, 121 participants enrolled (mean age 24; 27% black, 36% Latino']","['Mobile Health Intervention', 'PrEPmate or standard of care (SoC', 'PrEPmate', 'Preexposure Prophylaxis', 'youth-tailored, bidirectional text-messaging intervention (PrEPmate', 'interactive text-messaging intervention', 'preexposure prophylaxis (PrEP']","['TFV-DP levels', 'study-visit retention and PrEP adherence', 'retention and adherence', 'study-visit completion, and the primary adherence outcome was tenofovir diphosphate (TFV-DP) concentrations ≥700 fmol/punch']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0008044', 'cui_str': 'Chicago'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C3178908', 'cui_str': 'Texting'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C3712637', 'cui_str': 'tenofovir diphosphate'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439195', 'cui_str': 'fmol'}, {'cui': 'C0182555', 'cui_str': 'Punch, device (physical object)'}]",121.0,0.210699,"An interactive text-messaging intervention had high acceptability and significantly increased study-visit retention and PrEP adherence among young individuals at risk for HIV acquisition. ","[{'ForeName': 'Albert Y', 'Initials': 'AY', 'LastName': 'Liu', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, University of California, San Francisco.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vittinghoff', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'von Felten', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, University of California, San Francisco.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Rivet Amico', 'Affiliation': 'Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Anderson', 'Affiliation': 'Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Lester', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Andrew', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, University of California, San Francisco.'}, {'ForeName': 'Ixchell', 'Initials': 'I', 'LastName': 'Estes', 'Affiliation': 'Ruth M. Rothstein CORE Center.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Serrano', 'Affiliation': 'Ruth M. Rothstein CORE Center.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Brothers', 'Affiliation': 'Ruth M. Rothstein CORE Center.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Buchbinder', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, University of California, San Francisco.'}, {'ForeName': 'Sybil', 'Initials': 'S', 'LastName': 'Hosek', 'Affiliation': 'Ruth M. Rothstein CORE Center.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Fuchs', 'Affiliation': 'Department of Medicine, University of California, San Francisco.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy810'] 613,31981369,Interventions for chronic pruritus of unknown origin.,"BACKGROUND Pruritus is a sensation that leads to the desire to scratch; its origin is unknown in 8% to 15% of affected patients. The prevalence of chronic pruritus of unknown origin (CPUO) in individuals with generalised pruritus ranges from 3.6% to 44.5%, with highest prevalence among the elderly. When the origin of pruritus is known, its management may be straightforward if an effective treatment for the causal disease is available. Treatment of CPUO is particularly difficult due to its unknown pathophysiology. OBJECTIVES To assess the effects of interventions for CPUO in adults and children. SEARCH METHODS We searched the following up to July 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and trials registries. We checked the reference lists of included studies for additional references to relevant trials. SELECTION CRITERIA We sought to include randomised controlled trials and quasi-randomised controlled trials that assessed interventions for CPUO, as defined in category VI ('Other pruritus of undetermined origin, or chronic pruritus of unknown origin') of the International Forum for the Study of Itch (IFSI) classification, in children and adults. Eligible interventions were non-pharmacological or topical or systemic pharmacological interventions, and eligible comparators were another active treatment, placebo, sham procedures, or no treatment or equivalent (e.g. waiting list). DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. Our primary outcomes were 'Patient- or parent-reported pruritus intensity' and 'Adverse events'. Our secondary outcomes were 'Health-related quality of life', 'Sleep disturbances', 'Depression', and 'Patient satisfaction'. We used GRADE to assess the certainty of evidence. MAIN RESULTS We found there was an absence of evidence for the main interventions of interest: emollient creams, cooling lotions, topical corticosteroids, topical antidepressants, systemic antihistamines, systemic antidepressants, systemic anticonvulsants, and phototherapy. We included one study with 257 randomised (253 analysed) participants, aged 18 to 65 years; 60.6% were female. This study investigated the safety and efficacy of three different doses of oral serlopitant (5 mg, 1 mg, and 0.25 mg, once daily for six weeks) compared to placebo for severe chronic pruritus; 25 US centres participated (clinical research centres and universities). All outcomes were measured at the end of treatment (six weeks from baseline), except adverse events, which were monitored throughout. A pharmaceutical company funded this study. Fifty-five per cent of participants suffered from CPUO, and approximately 45% presented a dermatological diagnosis (atopic dermatitis/eczema 37.3%, psoriasis 6.7%, acne 3.6%, among other diagnoses). We unsuccessfully attempted to retrieve outcome data from study authors for the subgroup of participants with CPUO. Participants had pruritus for six weeks or longer. Total study duration was 10 weeks. Participants who received serlopitant 5 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by the visual analogue scale (VAS; a reduction in VAS score indicates improvement) compared to placebo (126 participants, risk ratio (RR) 2.06, 95% confidence interval (CI) 1.27 to 3.35; low-certainty evidence). We are uncertain of the effects of serlopitant 5 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (127 participants; RR 1.48, 95% CI 0.87 to 2.50); health-related quality of life (as measured by the Dermatology Life Quality Index (DLQI); a higher score indicates greater impairment; 127 participants; mean difference (MD) -4.20, 95% CI -11.68 to 3.28); and sleep disturbances (people with insomnia measured by the Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-I), a dichotomous measure; 128 participants; RR 0.49, 95% CI 0.24 to 1.01). Participants who received serlopitant 1 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (126 participants; RR 1.50, 95% CI 0.89 to 2.54; low-certainty evidence). We are uncertain of the effects of serlopitant 1 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (128 participants; RR 1.45, 95% CI 0.86 to 2.47); health-related quality of life (DLQI; 128 participants; MD -6.90, 95% CI -14.38 to 0.58); and sleep disturbances (PSSQ-I; 128 participants; RR 0.38, 95% CI 0.17 to 0.84). Participants who received serlopitant 0.25 mg may have a greater rate of relief of patient-reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (127 participants; RR 1.66, 95% CI 1.00 to 2.77; low-certainty evidence). We are uncertain of the effects of serlopitant 0.25 mg compared to placebo on the following outcomes due to very low-certainty evidence: adverse events (127 participants; RR 1.29, 95% CI 0.75 to 2.24); health-related quality of life (DLQI; 127 participants; MD -5.70, 95% CI -13.18 to 1.78); and sleep disturbances (PSSQ-I; 127 participants; RR 0.60, 95% CI 0.31 to 1.17). The most commonly reported adverse events were somnolence, diarrhoea, headache, and nasopharyngitis, among others. Our included study did not measure depression or patient satisfaction. We downgraded the certainty of evidence for all outcomes due to indirectness (only 55% of study participants had CPUO) and imprecision. We downgraded outcomes other than patient-reported pruritus intensity a further level due to concerns regarding risk of bias in selection of the reported result and some concerns with risk of bias due to missing outcome data (sleep disturbances only). We deemed risk of bias to be generally low. AUTHORS' CONCLUSIONS We found lack of evidence to address our review question: for most of our interventions of interest, we found no eligible studies. The neurokinin 1 receptor (NK1R) antagonist serlopitant was the only intervention that we could assess. One study provided low-certainty evidence suggesting that serlopitant may reduce pruritus intensity when compared with placebo. We are uncertain of the effects of serlopitant on other outcomes, as certainty of the evidence is very low. More studies with larger sample sizes, focused on patients with CPUO, are needed. Healthcare professionals, patients, and other stakeholders may have to rely on indirect evidence related to other forms of chronic pruritus when deciding between the main interventions currently used for this condition.",2020,"The most commonly reported adverse events were somnolence, diarrhoea, headache, and nasopharyngitis, among others.","['children and adults', '257 randomised (253 analysed) participants, aged 18 to 65 years; 60.6% were female', 'adults and children', 'participants with CPUO', 'severe chronic pruritus; 25 US centres participated (clinical research centres and universities']","['CPUO', 'pharmacological or topical or systemic pharmacological interventions', 'oral serlopitant', 'placebo', 'placebo, sham procedures, or no treatment or equivalent (e.g. waiting list']","['visual analogue scale (VAS; a reduction in VAS score', 'somnolence, diarrhoea, headache, and nasopharyngitis', 'safety and efficacy', ""Patient- or parent-reported pruritus intensity' and 'Adverse events"", 'rate of relief of patient-reported pruritus intensity', 'Dermatology Life Quality Index (DLQI', 'sleep disturbances (people with insomnia measured by the Pittsburgh Sleep Symptom Questionnaire-Insomnia', ""Health-related quality of life', 'Sleep disturbances', 'Depression', and 'Patient satisfaction"", 'sleep disturbances', 'dermatological diagnosis (atopic dermatitis/eczema', 'health-related quality of life', 'pruritus intensity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C2825662', 'cui_str': 'serlopitant'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}]","[{'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1301676', 'cui_str': 'Relieves (qualifier value)'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index (assessment scale)'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0011625', 'cui_str': 'Agent, Dermatological'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C0013595', 'cui_str': 'Dermatitis, Eczematous'}]",1.0,0.529225,"The most commonly reported adverse events were somnolence, diarrhoea, headache, and nasopharyngitis, among others.","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Andrade', 'Affiliation': 'Hospital Italiano de Buenos Aires, Department of Dermatology, Tte. Peron 4230, Buenos Aires, Argentina, 1199.'}, {'ForeName': 'Chii Yang', 'Initials': 'CY', 'LastName': 'Kuah', 'Affiliation': ""King's College Hospital NHS Foundation Trust, Denmark Hill, London, UK, SE5 9RS.""}, {'ForeName': 'Juliana Esther', 'Initials': 'JE', 'LastName': 'Martin-Lopez', 'Affiliation': 'Andalusian Public Foundation for Progress and Health, Department of Research for Health Technology Assessment Service, Seville, Spain.'}, {'ForeName': 'Shunjie', 'Initials': 'S', 'LastName': 'Chua', 'Affiliation': 'urong East St21 Blk288A #03-358, Singapore, Singapore, 601288.'}, {'ForeName': 'Volha', 'Initials': 'V', 'LastName': 'Shpadaruk', 'Affiliation': 'University Hospitals of Leicester, Department of Dermatology, Leicester Royal Infirmary, OPD3 Balmoral Building, Leicester, UK, LE1 5WW.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Sanclemente', 'Affiliation': 'Universidad de Antioquia, Grupo de Investigación Dermatológica (GRID), Carrera 25 A #1 A Sur 45, Of 2026, Torre Medica El Tesoro, Medellín, Colombia.'}, {'ForeName': 'Juan Va', 'Initials': 'JV', 'LastName': 'Franco', 'Affiliation': 'Instituto Universitario Hospital Italiano, Argentine Cochrane Centre, Potosi 4234, Buenos Aires, Buenos Aires, Argentina, C1199ACL.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013128.pub2'] 614,31710096,School Interventions-based Prevention of Early-Childhood Caries among 3-5-year-old children from very low socioeconomic status: Two-year randomized trial.,"OBJECTIVES To assess the effectiveness of school-based interventions to prevent early childhood caries (ECC) among preschool children from very low socioeconomic background over a period of 2 years. MATERIALS AND METHODS Four hundred and twenty preschool children between the ages of 3-5 years participated in this double blind, three parallel arm clinical trial. School only interventions such as prohibition of sugary snack consumption in school, teacher supervised daily brushing using fluoridated toothpaste, and oral health education were implemented with regular follow-up at 6 months, 1, and 2 years. The study group had all three interventions, in active control-tooth brushing and oral health education, and in negative control, only oral health education. Decay at d1/d2 using World Health Organization criteria, visible plaque and gingival inflammation were assessed at all follow-ups. The value of P < 0.05 was considered significant. RESULTS Absolute caries risk reduction in the study group was 20 percent and 12 percent when compared to active, negative controls after 2 years. Mean caries increment in the study group was 0.4 for d1/d2, for the active control group was 0.9 and negative control 0.8. The effect of interventions to prevent ECC in each group was calculated using the Çohen's d, and the study group had a score of 0.6 when compared with active controls and 0.9 in comparison to the negative control group. CONCLUSIONS Prohibition of sugary snacking in school and daily supervised tooth brushing, with or without oral health education is effective in preventing ECC among preschool children with health neglect in very low-resource settings.",2020,"Mean caries increment in the study group was 0.4 for d1/d2, for the active control group was 0.9 and negative control 0.8.","['of Early-Childhood Caries among 3-5-year-old children from very low socioeconomic status', 'preschool children from very low socioeconomic background over a period of 2\u2009years', 'active control-tooth brushing and oral health education, and in negative control, only oral health education', 'Four hundred and twenty preschool children between the ages of 3-5\u2009years', 'preschool children with health neglect in very low-resource settings']","['school-based interventions', 'School Interventions-based Prevention']","['Absolute caries risk reduction', 'visible plaque and gingival inflammation', 'Mean caries increment']","[{'cui': 'C3714731', 'cui_str': 'Early childhood caries'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442811', 'cui_str': 'Very low (qualifier value)'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0018703', 'cui_str': 'Health Education, Dental'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C4517774', 'cui_str': 'Four hundred and twenty'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0521874', 'cui_str': 'Victim of neglect'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0205379', 'cui_str': 'Visible (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",420.0,0.0469511,"Mean caries increment in the study group was 0.4 for d1/d2, for the active control group was 0.9 and negative control 0.8.","[{'ForeName': 'Srinivasan Raj', 'Initials': 'SR', 'LastName': 'Samuel', 'Affiliation': 'Department of Public Health Dentistry, Saveetha Dental College, SIMATS, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Shashidhar', 'Initials': 'S', 'LastName': 'Acharya', 'Affiliation': 'Department of Public Health Dentistry, Manipal College of Dental Sciences, Manipal University, Manipal, Karnataka, India.'}, {'ForeName': 'Jeevika Chandrasekar', 'Initials': 'JC', 'LastName': 'Rao', 'Affiliation': 'Department of Public Health Dentistry, Thai Moogambigai Dental College and Hospital, Dr. M.G.R Educational and Research Institute University, Chennai, Tamil Nadu, India.'}]",Journal of public health dentistry,['10.1111/jphd.12348'] 615,32003822,Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial.,"Importance Lung cancer screening with low-dose computed tomography lowers lung cancer mortality but has potential harms. Current guidelines support patients receiving information about the benefits and harms of lung cancer screening during decision-making. Objective To examine the effect of a patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU) on decision-making outcomes among smokers. Design, Setting, and Participants This randomized clinical trial was conducted using 13 state tobacco quitlines. Current and recent tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017. Data analysis was conducted between May 5, 2017, and September 30, 2018. Interventions Participants were randomized to the PDA video Lung Cancer Screening: Is It Right for Me? (n = 259) or to EDU (n = 257). Main Outcomes and Measures The primary outcomes were preparation for decision-making and decisional conflict measured at 1 week. Secondary outcomes included knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report. Results Of 516 quit line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level. Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001). Feeling informed about their screening choice was reported by 117 of 234 participants (50.0%) using a PDA compared with 66 of 233 participants (28.3%) using EDU (OR, 2.56; 95% CI, 1.72-3.79; P < .001); 159 of 234 participants (68.0%) using a PDA compared with 110 of 232 (47.4%) participants using EDU reported being clear about their values related to the harms and benefits of screening (OR, 2.37; 95% CI, 1.60-3.51; P < .001). Participants using a PDA were more knowledgeable about lung cancer screening than participants using EDU at each follow-up assessment. Intentions to be screened and screening behaviors did not differ between groups. Conclusions and Relevance In this study, a PDA delivered to clients of tobacco quit lines improved informed decision-making about lung cancer screening. Many smokers eligible for lung cancer screening can be reached through tobacco quit lines. Trial Registration ClinicalTrials.gov identifier: NCT02286713.",2020,"Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001).","['smokers', 'Who Smoke', 'tobacco quitline clients who met age and smoking history eligibility for lung cancer screening were enrolled from March 30, 2015, to September 12, 2016, and followed up for 6 months until May 5, 2017', 'Persons', '13 state tobacco quitlines', '516 quit', 'line clients enrolled, 370 (71.7%) were younger than 65 years, 320 (62.0%) were female, 138 (26.7%) identified as black, 47 (9.1%) did not have health insurance, and 226 (43.8%) had a high school or lower educational level']","['PDA video Lung Cancer Screening', 'patient decision aid (PDA) about lung cancer screening compared with a standard educational material (EDU', 'low-dose computed tomography', 'PDA', 'Patient Decision Aid']","['preparation for decision-making and decisional conflict', 'knowledgeable about lung cancer screening', 'knowledge, intentions, and completion of screening within 6 months of receiving the intervention measured by patient report']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0281477', 'cui_str': 'Lung cancer screening (procedure)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C4517743', 'cui_str': 'Three hundred and seventy'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0281477', 'cui_str': 'Lung cancer screening (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}]","[{'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C1998726', 'cui_str': 'Is informed (finding)'}, {'cui': 'C0281477', 'cui_str': 'Lung cancer screening (procedure)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",,0.247978,"Of participants using the PDA, 153 of 227 (67.4%) were well prepared to make a screening decision compared with 108 of 224 participants (48.2%) using EDU (odds ratio [OR], 2.31; 95% CI, 1.56-3.44; P < .001).","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Volk', 'Affiliation': 'Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Lowenstein', 'Affiliation': 'Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Viola B', 'Initials': 'VB', 'LastName': 'Leal', 'Affiliation': 'Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Kamisha H', 'Initials': 'KH', 'LastName': 'Escoto', 'Affiliation': 'Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Scott B', 'Initials': 'SB', 'LastName': 'Cantor', 'Affiliation': 'Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Reginald F', 'Initials': 'RF', 'LastName': 'Munden', 'Affiliation': 'Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Vance A', 'Initials': 'VA', 'LastName': 'Rabius', 'Affiliation': 'Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Bailey', 'Affiliation': 'North American Quitline Consortium, Phoenix, Arizona.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Cinciripini', 'Affiliation': 'Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Ashley J', 'Initials': 'AJ', 'LastName': 'Housten', 'Affiliation': 'Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Pamela Graef', 'Initials': 'PG', 'LastName': 'Luckett', 'Affiliation': 'Information & Quality Healthcare Inc, Ridgeland, Mississippi.'}, {'ForeName': 'Angelina', 'Initials': 'A', 'LastName': 'Esparza', 'Affiliation': 'Houston Department for Health and Human Services, Houston, Texas.'}, {'ForeName': 'Myrna C', 'Initials': 'MC', 'LastName': 'Godoy', 'Affiliation': 'Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Therese B', 'Initials': 'TB', 'LastName': 'Bevers', 'Affiliation': 'Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston.'}]",JAMA network open,['10.1001/jamanetworkopen.2019.20362'] 616,30926189,Prehospital Analgesia With Intranasal Ketamine (PAIN-K): A Randomized Double-Blind Trial in Adults.,"STUDY OBJECTIVE We compare intranasal ketamine with intranasal placebo in providing pain reduction at 30 minutes when added to usual paramedic care with nitrous oxide. METHODS This was a randomized double-blind study of out-of-hospital patients with acute pain who reported a verbal numeric rating scale (VNRS) pain score greater than or equal to 5. Exclusion criteria were younger than 18 years, known ketamine intolerance, nontraumatic chest pain, altered mental status, pregnancy, and nasal occlusion. Patients received usual paramedic care and were randomized to receive either intranasal ketamine or intranasal saline solution at 0.75 mg/kg. The primary outcome was the proportion of patients with VNRS score reduction greater than or equal to 2 at 30 minutes. Secondary outcomes were pain reduction at 15 minutes, patient-reported comfort, satisfaction scores, nitrous oxide consumption, and incidence of adverse events. RESULTS One hundred twenty subjects were enrolled. Seventy-six percent of intranasal ketamine patients versus 41% of placebo patients reported a greater than or equal to 2-point VNRS reduction at 30 minutes (difference 35%; 95% confidence interval 17% to 51%). Median VNRS reduction at 15 minutes was 2.0 and 1.0 and at 30 minutes was 3.0 and 1.0 for ketamine and placebo, respectively. Improved comfort at 15 and 30 minutes was reported for 75% versus 57% and 61% versus 46% of ketamine and placebo patients, respectively. Sixty-two percent of patients (95% confidence interval 49% to 73%) versus 20% (95% confidence interval 12% to 32%) reported adverse events with ketamine and placebo, respectively. Adverse events were minor, with no patients requiring physical or medical intervention. CONCLUSION Added to nitrous oxide, intranasal ketamine provides clinically significant pain reduction and improved comfort compared with intranasal placebo, with more minor adverse events.",2019,"Improved comfort at 15 and 30 minutes was reported for 75% versus 57% and 61% versus 46% of ketamine and placebo patients, respectively.","['Adults', 'out-of-hospital patients with acute pain who reported a verbal numeric rating scale (VNRS) pain score greater than or equal to 5', 'Exclusion criteria were younger than 18 years, known ketamine intolerance, nontraumatic chest pain, altered mental status, pregnancy, and nasal occlusion', 'One hundred twenty subjects were enrolled']","['ketamine', 'Intranasal Ketamine (PAIN-K', 'placebo', 'intranasal ketamine or intranasal saline solution', 'nitrous oxide, intranasal ketamine', 'intranasal placebo', 'intranasal ketamine', 'ketamine with intranasal placebo', 'usual paramedic care', 'ketamine and placebo']","['Median VNRS reduction', 'Adverse events', 'pain reduction and improved comfort', '2-point VNRS reduction', 'pain reduction', 'pain reduction at 15 minutes, patient-reported comfort, satisfaction scores, nitrous oxide consumption, and incidence of adverse events', 'adverse events', 'Improved comfort', 'proportion of patients with VNRS score reduction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0239966', 'cui_str': 'Hospital patient (finding)'}, {'cui': 'C0184567', 'cui_str': 'Acute Pain'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0231199', 'cui_str': 'Intolerance, function (observable entity)'}, {'cui': 'C0008031', 'cui_str': 'Chest Pain'}, {'cui': 'C0278061', 'cui_str': 'Altered mental status (finding)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C0030450', 'cui_str': 'Paramedics'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",120.0,0.569861,"Improved comfort at 15 and 30 minutes was reported for 75% versus 57% and 61% versus 46% of ketamine and placebo patients, respectively.","[{'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Andolfatto', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Emergency Department, Lions Gate Hospital, North Vancouver, British Columbia, Canada. Electronic address: gandolfatto@gmail.com.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Innes', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Dick', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Jenneson', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Willman', 'Affiliation': 'Department of Pathology, Surrey Memorial Hospital, Surrey, British Columbia, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Stenstrom', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Zed', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Benoit', 'Affiliation': 'British Columbia Emergency Health Services, Vancouver, British Columbia, Canada.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2019.01.048'] 617,31613432,Conservative Oxygen Therapy during Mechanical Ventilation in the ICU.,"BACKGROUND Patients who are undergoing mechanical ventilation in the intensive care unit (ICU) often receive a high fraction of inspired oxygen (Fio 2 ) and have a high arterial oxygen tension. The conservative use of oxygen may reduce oxygen exposure, diminish lung and systemic oxidative injury, and thereby increase the number of ventilator-free days (days alive and free from mechanical ventilation). METHODS We randomly assigned 1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive conservative or usual oxygen therapy. In the two groups, the default lower limit for oxygen saturation as measured by pulse oximetry (Spo 2 ) was 90%. In the conservative-oxygen group, the upper limit of the Spo 2 alarm was set to sound when the level reached 97%, and the Fio 2 was decreased to 0.21 if the Spo 2 was above the acceptable lower limit. In the usual-oxygen group, there were no specific measures limiting the Fio 2 or the Spo 2 . The primary outcome was the number of ventilator-free days from randomization until day 28. RESULTS The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P = 0.80). The conservative-oxygen group spent more time in the ICU with an Fio 2 of 0.21 than the usual-oxygen group, with a median duration of 29 hours (interquartile range, 5 to 78) and 1 hour (interquartile range, 0 to 17), respectively (absolute difference, 28 hours; 95% CI, 22 to 34); the conservative-oxygen group spent less time with an Spo 2 exceeding 96%, with a duration of 27 hours (interquartile range, 11 to 63.5) and 49 hours (interquartile range, 22 to 112), respectively (absolute difference, 22 hours; 95% CI, 14 to 30). At 180 days, mortality was 35.7% in the conservative-oxygen group and 34.5% in the usual-oxygen group, for an unadjusted odds ratio of 1.05 (95% CI, 0.81 to 1.37). CONCLUSIONS In adults undergoing mechanical ventilation in the ICU, the use of conservative oxygen therapy, as compared with usual oxygen therapy, did not significantly affect the number of ventilator-free days. (Funded by the Health Research Council of New Zealand; ICU-ROX Australian and New Zealand Clinical Trials Registry number, ACTRN12615000957594.).",2020,"The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P = 0.80).","['1000 adult patients who were anticipated to require mechanical ventilation beyond the day after recruitment in the ICU to receive', 'adults undergoing', 'Patients who are undergoing mechanical ventilation in the intensive care unit (ICU']","['conservative or usual oxygen therapy', 'Conservative Oxygen Therapy', 'mechanical ventilation']","['number of ventilator-free days from randomization until day 28', 'oxygen saturation', 'number of ventilator-free days', 'mortality']","[{'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}]","[{'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",1000.0,0.224172,"The number of ventilator-free days did not differ significantly between the conservative-oxygen group and the usual-oxygen group, with a median duration of 21.3 days (interquartile range, 0 to 26.3) and 22.1 days (interquartile range, 0 to 26.2), respectively, for an absolute difference of -0.3 days (95% confidence interval [CI], -2.1 to 1.6; P = 0.80).","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Mackle', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bailey', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Deane', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Eastwood', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Finfer', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Freebairn', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'King', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Linke', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Litton', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McArthur', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Shay', 'Initials': 'S', 'LastName': 'McGuinness', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Rakshit', 'Initials': 'R', 'LastName': 'Panwar', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Young', 'Affiliation': 'From the Medical Research Institute of New Zealand (D.M., R. Beasley, R.F., C.M., S.M., P.Y.) and the Intensive Care Unit, Wellington Hospital (P.Y.), Wellington, the Intensive Care Unit, Hawkes Bay Hospital, Hastings (R.F.), and the Department of Critical Care Medicine (C.M.) and the Cardiothoracic and Vascular Intensive Care Unit (S.M.), Auckland City Hospital, Auckland - all in New Zealand; the Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC (R. Bellomo, M.B., V.K., N.L.), the Intensive Care Unit, Austin Hospital, Heidelberg, VIC (R. Bellomo, G.E.), the University of Melbourne (R. Bellomo, M.B., A.D.) and the Intensive Care Unit, Royal Melbourne Hospital (A.D.), Parkville, VIC, the Division of Critical Care and Trauma, George Institute for Global Health, Sydney (S.F.), the Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, St. Leonards, NSW (S.F.), the Intensive Care Unit, Fiona Stanley Hospital, Murdoch, WA (E.L.), the Intensive Care Unit, John Hunter Hospital, New Lambton Heights, NSW (R.P.), and the School of Medicine and Public Health, University of Newcastle, Newcastle, NSW (R.P.) - all in Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1903297'] 618,31754687,High Compared with Moderate Protein Intake Reduces Adaptive Thermogenesis and Induces a Negative Energy Balance during Long-term Weight-Loss Maintenance in Participants with Prediabetes in the Postobese State: A PREVIEW Study.,"BACKGROUND Weight loss has been associated with adaptations in energy expenditure. Identifying factors that counteract these adaptations are important for long-term weight loss and weight maintenance. OBJECTIVE The aim of this study was to investigate whether increased protein/carbohydrate ratio would reduce adaptive thermogenesis (AT) and the expected positive energy balance (EB) during weight maintenance after weight loss in participants with prediabetes in the postobese state. METHODS In 38 participants, the effects of 2 diets differing in protein/carbohydrate ratio on energy expenditure and respiratory quotient (RQ) were assessed during 48-h respiration chamber measurements ∼34 mo after weight loss. Participants consumed a high-protein (HP) diet (n = 20; 13 women/7 men; age: 64.0 ± 6.2 y; BMI: 28.9 ± 4.0 kg/m 2) with 25:45:30% or a moderate-protein (MP) diet (n = 18; 9 women/9 men; age: 65.1 ± 5.8 y; BMI: 29.0 ± 3.8 kg/m 2) with 15:55:30% of energy from protein:carbohydrate:fat. Predicted resting energy expenditure (REEp) was calculated based on fat-free mass and fat mass. AT was assessed by subtracting measured resting energy expenditure (REE) from REEp. The main outcomes included differences in components of energy expenditure, substrate oxidation, and AT between groups. RESULTS EB (MP = 0.2 ± 0.9 MJ/d; HP = -0.5 ± 0.9 MJ/d) and RQ (MP = 0.84 ± 0.02; HP = 0.82 ± 0.02) were reduced and REE (MP: 7.3 ± 0.2 MJ/d compared with HP: 7.8 ± 0.2 MJ/d) was increased in the HP group compared with the MP group (P < 0.05). REE was not different from REEp in the HP group, whereas REE was lower than REEp in the MP group (P < 0.05). Furthermore, EB was positively related to AT (rs = 0.74; P < 0.001) and RQ (rs = 0.47; P < 0.01) in the whole group of participants. CONCLUSIONS In conclusion, an HP diet compared with an MP diet led to a negative EB and counteracted AT ∼34 mo after weight loss, in participants with prediabetes in the postobese state. These results indicate the relevance of compliance to an increased protein/carbohydrate ratio for long-term weight maintenance after weight loss. The trial was registered at clinicaltrials.gov as NCT01777893.",2020,"REE was not different from REEp in the HP group, whereas REE was lower than REEp in the MP group (P < 0.05).","['38 participants', 'n\xa0=\xa018; 9 women/9 men; age: 65.1\xa0±\xa05.8 y', 'Participants with Prediabetes in the Postobese State', 'Participants consumed a high-protein (HP) diet (n\xa0=\xa020; 13 women/7 men; age: 64.0\xa0±\xa06.2 y; BMI: 28.9\xa0±\xa04.0\xa0kg/m 2) with 25:45:30% or a', 'participants with prediabetes in the postobese state']","['Moderate Protein Intake', 'moderate-protein (MP) diet', 'HP diet', 'BMI: 29.0\xa0±\xa03.8\xa0kg/m 2) with 15:55:30% of energy from protein:carbohydrate:fat', 'HP']","['Adaptive Thermogenesis', 'Predicted resting energy expenditure (REEp', 'REE', 'RQ', 'components of energy expenditure, substrate oxidation, and AT between groups', 'protein/carbohydrate ratio', 'protein/carbohydrate ratio on energy expenditure and respiratory quotient (RQ']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0425403', 'cui_str': 'Diet, High-Protein'}, {'cui': 'C4517820', 'cui_str': '6.2'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0452269', 'cui_str': 'Protein diet (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0015677', 'cui_str': 'Fats'}]","[{'cui': 'C4235304', 'cui_str': 'Adaptive Thermogenesis'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient (observable entity)'}]",38.0,0.0575814,"REE was not different from REEp in the HP group, whereas REE was lower than REEp in the MP group (P < 0.05).","[{'ForeName': 'Mathijs', 'Initials': 'M', 'LastName': 'Drummen', 'Affiliation': 'Faculty of Health, Medicine and Life Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht UMC+, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Lea', 'Initials': 'L', 'LastName': 'Tischmann', 'Affiliation': 'Faculty of Health, Medicine and Life Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht UMC+, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Blandine', 'Initials': 'B', 'LastName': 'Gatta-Cherifi', 'Affiliation': 'Department of Endocrinology, Diabetology and Nutrition, Universite de Bordeaux, Bordeaux, France.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Fogelholm', 'Affiliation': 'Department of Food and Nutrition Sciences, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Raben', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Tanja C', 'Initials': 'TC', 'LastName': 'Adam', 'Affiliation': 'Faculty of Health, Medicine and Life Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht UMC+, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Margriet S', 'Initials': 'MS', 'LastName': 'Westerterp-Plantenga', 'Affiliation': 'Faculty of Health, Medicine and Life Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht UMC+, Maastricht University, Maastricht, Netherlands.'}]",The Journal of nutrition,['10.1093/jn/nxz281'] 619,31309333,"Probiotics for chronic low back pain with type 1 Modic changes: a randomized double-blind, placebo-controlled trial with 1-year follow-up using Lactobacillus Rhamnosis GG.","PURPOSE To investigate whether treatment by lactic acid bacteria for 100 days is associated with change of disability and pain in chronic low back pain (CLBP) patients with type 1 or mixed Modic changes (MC) during 1-year follow-up. METHODS Eighty-nine patients with CLBP and type 1 MC or mixed MC were randomized to receive either one capsule Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily or placebo capsules for 100 days. RESULTS Missing values at 1 year were 4% and 3% in the disability and pain variables, respectively. The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups. At 1 year, back pain had on average decreased by 1.1 more on a 0-10 scale (95% confidence interval 0.20-1.97) in the group treated by lactic acid bacteria than in the control group. There were no differences regarding other predefined outcomes, i.e. global effect or percentage with minimal disability at 1 year. Nine per cent of the patients reported gastrointestinal side effects without difference between groups. CONCLUSIONS No differences were found regarding the predefined outcomes. Overall, there was little improvement during the 1-year observation period. A small, though hardly clinically relevant, effect on back pain was seen after treatment by Lactobacillus Rhamnosis GG, and the treatment was without side effects in comparison with the control group.",2019,The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups.,"['Eighty-nine patients with CLBP and type 1 MC or mixed MC', 'chronic low back pain with type 1 Modic changes', 'chronic low back pain (CLBP) patients with type 1 or mixed Modic changes (MC) during 1-year follow-up']","['lactic acid bacteria', 'capsule Lactobacillus Rhamnosis GG (6 billion colony-forming unit per capsule) twice daily or placebo capsules for 100\xa0days', 'placebo', 'Probiotics']","['outcomes disability and back\u2009+\u2009leg pain', 'global effect or percentage with minimal disability', 'gastrointestinal side effects', 'back pain']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C1720722', 'cui_str': 'Mix'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C1210581', 'cui_str': 'Lactic Acid Bacteria'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0022938', 'cui_str': 'Lactobacillus'}, {'cui': 'C0553561', 'cui_str': 'colony-forming unit (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0023222', 'cui_str': 'Pain in lower limb (finding)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0004604', 'cui_str': 'Backache'}]",89.0,0.459244,The predefined outcomes disability and back + leg pain only changed little during follow-up with no statistically significant differences between groups.,"[{'ForeName': 'Ole K', 'Initials': 'OK', 'LastName': 'Jensen', 'Affiliation': 'Spine Center, Research Unit, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'Morten H', 'Initials': 'MH', 'LastName': 'Andersen', 'Affiliation': 'University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'René D', 'Initials': 'RD', 'LastName': 'Østgård', 'Affiliation': 'University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark.'}, {'ForeName': 'Niels T', 'Initials': 'NT', 'LastName': 'Andersen', 'Affiliation': 'Department of Biostatistics, University of Aarhus, Aarhus, Denmark.'}, {'ForeName': 'Nanna', 'Initials': 'N', 'LastName': 'Rolving', 'Affiliation': 'DEFACTUM, Central Denmark Region, Aarhus, Denmark.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-019-06046-6'] 620,31877631,Effects of Sucralose Ingestion versus Sucralose Taste on Metabolic Responses to an Oral Glucose Tolerance Test in Participants with Normal Weight and Obesity: A Randomized Crossover Trial.,"Here, we tested the hypothesis that sucralose differentially affects metabolic responses to labeled oral glucose tolerance tests (OGTTs) in participants with normal weight and obesity. Participants (10 with normal weight and 11 with obesity) without diabetes underwent three dual-tracer OGTTs preceded, in a randomized order, by consuming sucralose or water, or by tasting and expectorating sucralose (e.g., sham-fed; sweetness control). Indices of β-cell function and insulin sensitivity (S I ) were estimated using oral minimal models of glucose, insulin, and C-peptide kinetics. Compared with water, sucralose ingested (but not sham-fed) resulted in a 30 ± 10% increased glucose area under the curve in both weight groups. In contrast, the insulin response to sucralose ingestion differed depending on the presence of obesity: decreased within 20-40 min of the OGTT in normal-weight participants but increased within 90-120 min in participants with obesity. Sham-fed sucralose similarly decreased insulin concentrations within 60 min of the OGTT in both weight groups. Sucralose ingested (but not sham-fed) increased S I in normal-weight participants by 52 ± 20% but did not affect S I in participants with obesity. Sucralose did not affect glucose rates of appearance or β-cell function in either weight group. Our data underscore a physiological role for taste perception in postprandial glucose responses, suggesting sweeteners should be consumed in moderation.",2019,Sucralose did not affect glucose rates of appearance or β-cell function in either weight group.,"['Participants with Normal Weight and Obesity', 'participants with normal weight and obesity', 'Participants (10 with normal weight and 11 with obesity) without diabetes', 'participants with obesity']","['Sham-fed sucralose', 'consuming sucralose or water, or by tasting and expectorating sucralose', 'Sucralose Ingestion versus Sucralose Taste']","['Metabolic Responses', 'S', 'presence of obesity', 'glucose rates of appearance or β-cell function', 'glucose area', 'Indices of β-cell function and insulin sensitivity (S I ', 'insulin concentrations']","[{'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0077046', 'cui_str': 'sucralose'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C0566528', 'cui_str': 'Does spit (finding)'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",120.0,0.0887849,Sucralose did not affect glucose rates of appearance or β-cell function in either weight group.,"[{'ForeName': 'Alexander D', 'Initials': 'AD', 'LastName': 'Nichol', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL 61822, USA.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Salame', 'Affiliation': 'Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, IL 61822, USA.'}, {'ForeName': 'Kristina I', 'Initials': 'KI', 'LastName': 'Rother', 'Affiliation': 'National Institutes of Health, Bethesda, MD 20892, USA.'}, {'ForeName': 'M Yanina', 'Initials': 'MY', 'LastName': 'Pepino', 'Affiliation': 'Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL 61822, USA.'}]",Nutrients,['10.3390/nu12010029'] 621,31769299,Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS).,"OBJECTIVE To assess the clinical and cost-effectiveness of cognitive rehabilitation for attention and memory problems in people with multiple sclerosis. DESIGN Multicentre, pragmatic, randomized controlled trial. SETTING Community. PARTICIPANTS People with multiple sclerosis aged 18-69 years, who reported cognitive problems in daily life and had cognitive problems on standardized assessment. INTERVENTIONS A group cognitive rehabilitation programme delivered in 10 weekly sessions in comparison with usual care. MAIN MEASURES The primary outcome was the Multiple Sclerosis Impact Scale Psychological subscale at 12 months after randomization. Secondary outcomes included measures of everyday memory problems, mood, fatigue, cognitive abilities and employment at 6 and 12 months after randomization. RESULTS In all, 245 participants were allocated to cognitive rehabilitation and 204 to usual care. Mean Multiple Sclerosis Impact Scale Psychological at 12 months was 22.2 (SD = 6.1) for cognitive rehabilitation and 23.4 (SD = 6.0) for usual care group; adjusted difference -0.6, 95% confidence interval (CI) = -1.5 to 0.3, P  = 0.20. No differences were observed in cognitive abilities, fatigue or employment. There were small differences in favour of cognitive rehabilitation for the Multiple Sclerosis Impact Scale Psychological at 6 months and everyday memory and mood at 6 and 12 months. There was no evidence of an effect on costs (-£808; 95% CI = -£2248 to £632) or on quality-adjusted life year gain (0.00; 95% CI = -0.01 to 0.02). CONCLUSION This rehabilitation programme had no long-term benefits on the impact of multiple sclerosis on quality of life, but there was some evidence of an effect on everyday memory problems and mood.",2020,There were small differences in favour of cognitive rehabilitation for the Multiple Sclerosis Impact Scale Psychological at 6 months and everyday memory and mood at 6 and 12 months.,"['People with multiple sclerosis aged 18-69\u2009years, who reported cognitive problems in daily life and had cognitive problems on standardized assessment', 'people with multiple sclerosis', '245 participants were allocated to cognitive rehabilitation and 204 to usual care', 'Community']","['cognitive rehabilitation', 'Cognitive rehabilitation', 'cognitive rehabilitation programme']","['Mean Multiple Sclerosis Impact Scale Psychological', 'Multiple Sclerosis Impact Scale Psychological subscale', 'measures of everyday memory problems, mood, fatigue, cognitive abilities and employment at 6 and 12\u2009months after randomization', 'quality of life', 'cognitive abilities, fatigue or employment', 'quality-adjusted life year gain']","[{'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0233794', 'cui_str': 'Memory Deficits'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0034380'}, {'cui': 'C0080071', 'cui_str': 'QALY'}]",245.0,0.169394,There were small differences in favour of cognitive rehabilitation for the Multiple Sclerosis Impact Scale Psychological at 6 months and everyday memory and mood at 6 and 12 months.,"[{'ForeName': 'Nadina B', 'Initials': 'NB', 'LastName': 'Lincoln', 'Affiliation': ""Division of Rehabilitation and Ageing, Queen's Medical Centre, University of Nottingham, Nottingham, UK.""}, {'ForeName': 'Lucy E', 'Initials': 'LE', 'LastName': 'Bradshaw', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Cris S', 'Initials': 'CS', 'LastName': 'Constantinescu', 'Affiliation': 'Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Day', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Avril Er', 'Initials': 'AE', 'LastName': 'Drummond', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Fitzsimmons', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'Swansea Centre for Health Economics, Swansea University, Swansea, UK.'}, {'ForeName': 'Alan A', 'Initials': 'AA', 'LastName': 'Montgomery', 'Affiliation': 'Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'das Nair', 'Affiliation': 'Division of Psychiatry & Applied Psychology, University of Nottingham, Nottingham, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical rehabilitation,['10.1177/0269215519890378'] 622,31786651,Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia.,"RATIONALE There is interest in employing N-acetylcysteine (NAC) in the treatment of schizophrenia, but investigations of the functional signatures of its pharmacological action are scarce. OBJECTIVES The aim of this study was to identify the changes in resting-state functional connectivity (rs-FC) that occur following administration of a single dose of NAC in patients with schizophrenia. A secondary aim was to examine whether differences in rs-FC between conditions were mediated by glutamate metabolites in the anterior cingulate cortex (ACC). METHODS In a double-blind, placebo-controlled crossover design, 20 patients with schizophrenia had two MRI scans administered 7 days apart, following oral administration of either 2400 mg NAC or placebo. Resting state functional fMRI (rsfMRI) assessed the effect of NAC on rs-FC within the default mode network (DMN) and the salience network (SN). Proton magnetic resonance spectroscopy was used to measure Glx/Cr (glutamate plus glutamine, in ratio to creatine) levels in the ACC during the same scanning sessions. RESULTS Compared to the placebo condition, the NAC condition was associated with reduced within the DMN and SN, specifically between the medial pre-frontal cortex to mid frontal gyrus, and ACC to frontal pole (all p < 0.04). There were no significant correlations between ACC Glx/Cr and rs-FC in either condition (p > 0.6). CONCLUSIONS These findings provide preliminary evidence that NAC can reduce medial frontal rs-FC in schizophrenia. Future studies assessing the effects of NAC on rs-FC in early psychosis and on repeated administration in relation to efficacy would be of interest.",2020,"A secondary aim was to examine whether differences in rs-FC between conditions were mediated by glutamate metabolites in the anterior cingulate cortex (ACC). ","['20 patients with schizophrenia had two', 'patients with schizophrenia', 'schizophrenia']","['Proton magnetic resonance spectroscopy', 'NAC or placebo', 'NAC', 'placebo', 'MRI scans', 'single dose N-acetylcysteine administration']","['Glx/Cr (glutamate plus glutamine, in ratio to creatine) levels', 'ACC Glx/Cr and rs-FC']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]","[{'cui': 'C3850002', 'cui_str': '1H-MRS'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0220839', 'cui_str': 'Glutamate'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.145196,"A secondary aim was to examine whether differences in rs-FC between conditions were mediated by glutamate metabolites in the anterior cingulate cortex (ACC). ","[{'ForeName': 'Grant', 'Initials': 'G', 'LastName': 'McQueen', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'Aderlee', 'Initials': 'A', 'LastName': 'Lay', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lally', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'Anthony S', 'Initials': 'AS', 'LastName': 'Gabay', 'Affiliation': 'Department of Experimental Psychology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Tracy', 'Initials': 'T', 'LastName': 'Collier', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lythgoe', 'Affiliation': ""Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroimaging, King's College London, De Crespigny Park, London, UK.""}, {'ForeName': 'Gareth J', 'Initials': 'GJ', 'LastName': 'Barker', 'Affiliation': ""Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroimaging, King's College London, De Crespigny Park, London, UK.""}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Stone', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'McGuire', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'MacCabe', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.""}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Egerton', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK. alice.egerton@kcl.ac.uk.""}]",Psychopharmacology,['10.1007/s00213-019-05382-1'] 623,31622173,Feasibility and trend of pulmonary function in a pilot trial of aerobic walking exercise in non-ambulatory stroke survivors.,"Background : Lung function is compromised in stroke survivors, which may cause fatigue and exercise intolerance. Furthermore, past studies of aerobic exercise have involved only stroke survivors who could walk independently. Stroke survivors who were unable to walk were not included in the previous research-investigating changes in lung function from walking exercise interventions. In this pilot study, the feasibility and the effect of aerobic walking exercise on lung function was examined in non-ambulatory stroke survivors using a treadmill, bodyweight support system, and a gait training device. Methods : This study was a single group trial. Eight non-ambulatory stroke survivors (five males, mean age 63.3 ± 13.7 years, seven with ischemic stroke) completed a low intensity walking exercise program (30 min/session; three sessions/week for 8 weeks) and lung function test. Before and after the intervention, vital capacity (VC) and forced vital capacity (FVC) using a spirometer were measured according to the guideline from American Thoracic Society/European Respiratory Society. Results : The rates of compliance and attrition were 100% and 10%; respectively, and no adverse events were reported. There were significant differences between pre- and post-intervention assessments in FVC ( p = .09), percentage of predicted VC ( p = .08), and percentage of predicted FVC ( p = .08). Conclusions : In non-ambulatory stroke survivors, aerobic walking exercise is feasible and safe. Also, the results are promising and suggest that aerobic walking exercise may improve lung function; more data are needed.",2020,"There were significant differences between pre- and post-intervention assessments in FVC ( p = .09), percentage of predicted VC ( p = .08), and percentage of predicted FVC ( p = .08). ","['non-ambulatory stroke survivors', 'Stroke survivors', 'Eight non-ambulatory stroke survivors (five males, mean age 63.3 ± 13.7 years, seven with ischemic stroke']","['aerobic exercise', 'low intensity walking exercise program', ' ', 'aerobic walking exercise']","['vital capacity (VC) and forced vital capacity (FVC', 'rates of compliance and attrition', 'percentage of predicted VC', 'lung function', 'percentage of predicted FVC', 'FVC']","[{'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0430511', 'cui_str': 'Vital capacity test (procedure)'}, {'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}]",,0.0245141,"There were significant differences between pre- and post-intervention assessments in FVC ( p = .09), percentage of predicted VC ( p = .08), and percentage of predicted FVC ( p = .08). ","[{'ForeName': 'Abdulfattah S', 'Initials': 'AS', 'LastName': 'Alqahtani', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, MO, USA.'}, {'ForeName': 'Ramzi', 'Initials': 'R', 'LastName': 'Alajam', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, MO, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Eickmeyer', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, MO, USA.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Vardey', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, MO, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Liu', 'Affiliation': 'Department of Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, MO, USA.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1673590'] 624,30853124,Is Buddy Taping as Effective as Plaster Immobilization for Adults With an Uncomplicated Neck of Fifth Metacarpal Fracture? A Randomized Controlled Trial.,"STUDY OBJECTIVE We compare buddy taping with plaster casting for uncomplicated fifth metacarpal (boxer's) fractures. We hypothesize buddy taping will give superior functional outcomes at 12 weeks, defined as a 10-point difference on the Shortened Disabilities of the Arm, Shoulder and Hand (quickDASH) score. METHODS This randomized controlled trial included patients aged 18 to 70 years, with uncomplicated boxer's fractures in 2 hospitals in Queensland, Australia. The intervention consisted of buddy taping of the ring and little fingers on the affected side, in which the control group received plaster casting. Primary outcome was hand function as measured by quickDASH score (0 to 100, with 0 indicating no disability) at 12 weeks. Secondary outcomes measured at 3, 6, and 12 weeks included time off work and activities, pain, satisfaction, and the EuroQol 5-Dimension 3-Level score (measure of overall health). RESULTS Ninety-seven patients with primary endpoint data were available for analysis, 48 in the buddy taping group and 49 in the plaster group. At 12 weeks, median quickDASH scores were the same for both groups (buddy 0, interquartile range [IQR] 0 to 2.3; plaster 0, IQR 0 to 4; difference 0; 95% confidence interval of the difference 0 to 0). Patients in the buddy taping group missed a median 0 days (IQR 0 to 7) of work compared with the plaster group's 2 days (IQR 0 to 14). Other secondary outcome measures were the same in both groups. CONCLUSION We found that patients with boxer's fractures who were randomized to buddy taping had functional outcomes similar to those of patients randomized to plaster cast at 12 weeks. We advocate a minimal intervention such as buddy taping for uncomplicated boxer's fractures.",2019,"At 12 weeks, median quickDASH scores were the same for both groups (buddy 0, interquartile range [IQR] 0 to 2.3; plaster 0, IQR 0 to 4; difference 0; 95% confidence interval of the difference 0 to 0).","[""uncomplicated fifth metacarpal (boxer's) fractures"", ""patients with boxer's fractures"", 'Adults With an Uncomplicated Neck of Fifth Metacarpal Fracture', ""patients aged 18 to 70 years, with uncomplicated boxer's fractures in 2 hospitals in Queensland, Australia"", ""uncomplicated boxer's fractures""]","['plaster cast', 'buddy taping', 'buddy taping with plaster casting', 'buddy taping of the ring and little fingers on the affected side, in which the control group received plaster casting', 'Buddy Taping']","['median quickDASH scores', 'time off work and activities, pain, satisfaction, and the EuroQol 5-Dimension 3-Level score (measure of overall health', 'hand function as measured by quickDASH score', 'Shortened Disabilities of the Arm, Shoulder and Hand (quickDASH) score']","[{'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0025526', 'cui_str': 'Metacarpals'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0272682', 'cui_str': 'Fracture of neck of metacarpal bone (disorder)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0448073', 'cui_str': 'Neck of fifth metacarpal'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0032159', 'cui_str': 'Plaster Casts'}, {'cui': 'C1704747', 'cui_str': 'Tape (basic dose form)'}, {'cui': 'C0460977', 'cui_str': 'Plasters (physical object)'}, {'cui': 'C1260969', 'cui_str': 'Ring, device (physical object)'}, {'cui': 'C0230403', 'cui_str': 'Little finger structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0585074', 'cui_str': 'Amount of time off work'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0562230', 'cui_str': 'Hand functions (observable entity)'}, {'cui': 'C1282927', 'cui_str': 'Shortened (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]",97.0,0.200247,"At 12 weeks, median quickDASH scores were the same for both groups (buddy 0, interquartile range [IQR] 0 to 2.3; plaster 0, IQR 0 to 4; difference 0; 95% confidence interval of the difference 0 to 0).","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pellatt', 'Affiliation': 'Gold Coast University Hospital, Southport, Australia. Electronic address: drpellatt@googlemail.com.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Fomin', 'Affiliation': 'Griffith University, Southport, Australia.'}, {'ForeName': 'Carli', 'Initials': 'C', 'LastName': 'Pienaar', 'Affiliation': 'Griffith University, Southport, Australia.'}, {'ForeName': 'Randipsingh', 'Initials': 'R', 'LastName': 'Bindra', 'Affiliation': 'Gold Coast University Hospital, Southport, Australia; Griffith University, Southport, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Gold Coast University Hospital, Southport, Australia.'}, {'ForeName': 'Ezekiel', 'Initials': 'E', 'LastName': 'Tan', 'Affiliation': 'Gold Coast University Hospital, Southport, Australia.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Mervin', 'Affiliation': 'Griffith University, Southport, Australia.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Griffith University, Southport, Australia.'}, {'ForeName': 'Gerben', 'Initials': 'G', 'LastName': 'Keijzers', 'Affiliation': 'Gold Coast University Hospital, Southport, Australia; Griffith University, Southport, Australia; Bond University, Robina, Australia.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2019.01.032'] 625,32159243,Peer mentorship as an adjunct intervention for the treatment of eating disorders: A pilot randomized trial.,"OBJECTIVE Peer mentorship has been shown to be helpful for other mental health conditions, but it has been understudied for patients with eating disorders. The goal of the present study was to evaluate the feasibility and efficacy of peer mentorship for individuals with eating disorders by conducting a randomized controlled trial (RCT). TRIAL DESIGN Parallel three-arm pilot RCT with 1:1:1 allocation to peer mentorship, social support mentorship (active comparison intervention), and waiting list. METHOD Sixty outpatients with anorexia nervosa (AN), bulimia nervosa (BN), or binge-eating disorder (BED) were randomly assigned to a condition. Outcome measures, including eating disorder symptoms and general psychopathology, were completed at baseline, mid-, and postintervention. RESULTS Session attendance and acceptability ratings were higher in peer mentorship than social support mentorship. More participants in social support mentorship (39%) dropped out compared to peer mentorship (5%). In intent-to-treat analysis, peer mentorship showed greater reductions in body dissatisfaction and anxiety compared with both control groups. Compared with social support mentorship, peer mentorship had greater reductions in depression. Compared with waiting list, peer mentorship had greater reduction in binge eating days/week in patients with BN/BED and restriction days/week in patients with AN. Peer mentorship did not impact body mass index or reentry into higher level of care. DISCUSSION This pilot RCT provides preliminary evidence that peer mentorship is effective for some cognitive and behavioral symptoms of eating disorders as an adjunct to outpatient treatment. Additional studies are needed to evaluate the efficacy of peer mentorship in absence of treatment.",2020,"Compared with waiting list, peer mentorship had greater reduction in binge eating days/week in patients with BN/BED and restriction days/week in patients with AN.","['eating disorders', 'patients with eating disorders', 'Sixty outpatients with anorexia nervosa (AN), bulimia nervosa (BN), or binge-eating disorder (BED', 'individuals with eating disorders']","['social support mentorship', 'peer mentorship, social support mentorship (active comparison intervention), and waiting list', 'peer mentorship', 'Peer mentorship', 'social support mentorship, peer mentorship']","['acceptability ratings', 'eating disorder symptoms and general psychopathology', 'body dissatisfaction and anxiety', 'binge eating days', 'feasibility and efficacy', 'depression']","[{'cui': 'C0013473', 'cui_str': 'Eating Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0003125', 'cui_str': 'Anorexia Nervosas'}, {'cui': 'C2267227', 'cui_str': 'Bulimia Nervosa'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0037438'}, {'cui': 'C0025370', 'cui_str': 'Mentorships'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0855228', 'cui_str': 'Eating disorder symptom'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",60.0,0.0469861,"Compared with waiting list, peer mentorship had greater reduction in binge eating days/week in patients with BN/BED and restriction days/week in patients with AN.","[{'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Ranzenhofer', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Mylene', 'Initials': 'M', 'LastName': 'Wilhelmy', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Annabella', 'Initials': 'A', 'LastName': 'Hochschild', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Kaitlin', 'Initials': 'K', 'LastName': 'Sanzone', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'B Timothy', 'Initials': 'BT', 'LastName': 'Walsh', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Attia', 'Affiliation': 'Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.'}]",The International journal of eating disorders,['10.1002/eat.23258'] 626,30972889,Identification of clinically relevant dysglycemia phenotypes based on continuous glucose monitoring data from youth with type 1 diabetes and elevated hemoglobin A1c.,"BACKGROUND/OBJECTIVE To identify and characterize subgroups of adolescents with type 1 diabetes (T1D) and elevated hemoglobin A1c (HbA1c) who share patterns in their continuous glucose monitoring (CGM) data as ""dysglycemia phenotypes."" METHODS Data were analyzed from the Flexible Lifestyles Empowering Change randomized trial. Adolescents with T1D (13-16 years, duration >1 year) and HbA1c 8% to 13% (64-119 mmol/mol) wore blinded CGM at baseline for 7 days. Participants were clustered based on eight CGM metrics measuring hypoglycemia, hyperglycemia, and glycemic variability. Clusters were characterized by their baseline features and 18 months changes in HbA1c using adjusted mixed effects models. For comparison, participants were stratified by baseline HbA1c (≤/>9.0% [75 mmol/mol]). RESULTS The study sample included 234 adolescents (49.8% female, baseline age 14.8 ± 1.1 years, baseline T1D duration 6.4 ± 3.7 years, baseline HbA1c 9.6% ± 1.2%, [81 ± 13 mmol/mol]). Three Dysglycemia Clusters were identified with significant differences across all CGM metrics (P < .001). Dysglycemia Cluster 3 (n = 40, 17.1%) showed severe hypoglycemia and glycemic variability with moderate hyperglycemia and had a lower baseline HbA1c than Clusters 1 and 2 (P < .001). This cluster showed increases in HbA1c over 18 months (p-for-interaction = 0.006). No other baseline characteristics were associated with Dysglycemia Clusters. High HbA1c was associated with lower pump use, greater insulin doses, more frequent blood glucose monitoring, lower motivation, and lower adherence to diabetes self-management (all P < .05). CONCLUSIONS There are subgroups of adolescents with T1D for which glycemic control is challenged by different aspects of dysglycemia. Enhanced understanding of demographic, behavioral, and clinical characteristics that contribute to CGM-derived dysglycemia phenotypes may reveal strategies to improve treatment.",2019,"High HbA1c was associated with lower pump use, greater insulin doses, more frequent blood glucose monitoring, lower motivation, and lower adherence to diabetes self-management (all P < .05). ","['adolescents with type 1 diabetes (T1D) and elevated hemoglobin A1c (HbA1c) who share patterns in their continuous glucose monitoring (CGM) data as ""dysglycemia phenotypes', '234 adolescents (49.8% female, baseline age 14.8\u2009±\u20091.1 years, baseline T1D duration 6.4\u2009±\u20093.7\u2009years, baseline HbA1c 9.6%\u2009±\u20091.2%, [81\u2009±\u200913\u2009mmol/mol', 'Adolescents with T1D (13-16 years, duration >1\u2009year) and HbA1c 8% to 13% (64-119\u2009mmol/mol', 'youth with type 1 diabetes and elevated hemoglobin A1c']",[],"['hypoglycemia, hyperglycemia, and glycemic variability', 'frequent blood glucose monitoring, lower motivation, and lower adherence to diabetes self-management', 'severe hypoglycemia and glycemic variability with moderate hyperglycemia']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C1960636', 'cui_str': 'Dysglycemia'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4517822', 'cui_str': '6.4 (qualifier value)'}, {'cui': 'C4517696', 'cui_str': '3.7 (qualifier value)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C4068880', 'cui_str': 'One point two'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0087178', 'cui_str': 'Youth'}]",[],"[{'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0558078', 'cui_str': 'Low motivation (finding)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]",234.0,0.0750474,"High HbA1c was associated with lower pump use, greater insulin doses, more frequent blood glucose monitoring, lower motivation, and lower adherence to diabetes self-management (all P < .05). ","[{'ForeName': 'Anna R', 'Initials': 'AR', 'LastName': 'Kahkoska', 'Affiliation': 'Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Adair', 'Affiliation': 'Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Allison E', 'Initials': 'AE', 'LastName': 'Aiello', 'Affiliation': 'Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Kyle S', 'Initials': 'KS', 'LastName': 'Burger', 'Affiliation': 'Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Crandell', 'Affiliation': 'School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Maahs', 'Affiliation': 'Department of Pediatrics, School of Medicine, Stanford University, Stanford, California.'}, {'ForeName': 'Crystal T', 'Initials': 'CT', 'LastName': 'Nguyen', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Kosorok', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Mayer-Davis', 'Affiliation': 'Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}]",Pediatric diabetes,['10.1111/pedi.12856'] 627,30726946,Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance).,"BACKGROUND Evidence suggests that diets inducing postprandial hyperinsulinemia may be associated with increased cancer-related mortality. The goal of this study was to assess the influence of postdiagnosis dietary insulin load and dietary insulin index on outcomes of stage III colon cancer patients. METHODS We conducted a prospective observational study of 1023 patients with resected stage III colon cancer enrolled in an adjuvant chemotherapy trial who reported dietary intake halfway through and six months after chemotherapy. We evaluated the association of dietary insulin load and dietary insulin index with cancer recurrence and survival using Cox proportional hazards regression adjusted for potential confounders; statistical tests were two-sided. RESULTS High dietary insulin load had a statistically significant association with worse disease-free survival (DFS), comparing the highest vs lowest quintile (adjusted hazard ratio [HR] = 2.77, 95% confidence interval [CI] = 1.90 to 4.02, Ptrend < .001). High dietary insulin index was also associated with worse DFS (highest vs lowest quintile, HR = 1.75, 95% CI = 1.22 to 2.51, Ptrend= .01). The association between higher dietary insulin load and worse DFS differed by body mass index and was strongest among patients with obesity (HR = 3.66, 95% CI = 1.88 to 7.12, Pinteraction = .04). The influence of dietary insulin load on cancer outcomes did not differ by mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability. CONCLUSIONS Patients with resected stage III colon cancer who consumed a high-insulinogenic diet were at increased risk of recurrence and mortality. These findings support the importance of dietary management following resection of colon cancer, and future research into underlying mechanisms of action is warranted.",2019,"The influence of dietary insulin load on cancer outcomes did not differ by mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability. ","['1023 patients with resected stage III colon cancer enrolled in an adjuvant chemotherapy trial who reported dietary intake halfway through and six months after chemotherapy', 'stage III colon cancer patients', 'Patients With Stage III Colon Cancer', 'Patients with resected stage III colon cancer']",['postdiagnosis dietary insulin load and dietary insulin index'],"['High dietary insulin index', 'dietary insulin load and dietary insulin index with cancer recurrence and survival', 'mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability', 'risk of recurrence and mortality', 'worse disease-free survival (DFS', 'Dietary Insulin Load and Cancer Recurrence and Survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0920269', 'cui_str': 'Microsatellite Instability'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0242793', 'cui_str': 'Disease-Free Survival'}]",1023.0,0.10988,"The influence of dietary insulin load on cancer outcomes did not differ by mutation status of KRAS, BRAF, PIK3CA, TP53, or microsatellite instability. ","[{'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Morales-Oyarvide', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yuan', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Babic', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Niedzwiecki', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Jennie C', 'Initials': 'JC', 'LastName': 'Brand-Miller', 'Affiliation': 'Institute of Obesity, Nutrition, and Exercise, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Sampson-Kent', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Saltz', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mayer', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Rex B', 'Initials': 'RB', 'LastName': 'Mowat', 'Affiliation': 'Toledo Community Hospital Oncology Program, Toledo, OH.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Whittom', 'Affiliation': 'Hôpital du Sacré-Coeur de Montréal, Montreal, Canada.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hantel', 'Affiliation': 'Loyola University Stritch School of Medicine, Naperville, IL.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Atienza', 'Affiliation': 'Virginia Oncology Associates, Norfolk, VA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Messino', 'Affiliation': 'Southeast Clinical Oncology Research Consortium, Mission Hospitals, Asheville, NC.'}, {'ForeName': 'Hedy', 'Initials': 'H', 'LastName': 'Kindler', 'Affiliation': 'University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Venook', 'Affiliation': 'University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA.'}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Ogino', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Kana', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Walter C', 'Initials': 'WC', 'LastName': 'Willett', 'Affiliation': 'Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Giovannucci', 'Affiliation': 'Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Wolpin', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Meyerhardt', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Fuchs', 'Affiliation': 'Yale Cancer Center, Smilow Cancer Hospital and Yale School of Medicine, New Haven, CT.'}, {'ForeName': 'Kimmie', 'Initials': 'K', 'LastName': 'Ng', 'Affiliation': 'Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.'}]",Journal of the National Cancer Institute,['10.1093/jnci/djy098'] 628,31289058,Endoscopic sphincterotoMy for delayIng choLecystectomy in mild acute biliarY pancreatitis (EMILY study): protocol of a multicentre randomised clinical trial.,"INTRODUCTION According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP). A randomised, controlled multicentre trial (the PONCHO trial) revealed that in the case of gallstone-induced pancreatitis, early cholecystectomy was safe in patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy. We hypothesise that carrying out a sphincterotomy (ES) allows us to delay cholecystectomy, thus making it logistically easier to perform and potentially increasing the efficacy and safety of the procedure. METHODS/DESIGN EMILY is a prospective, randomised, controlled multicentre trial. All patients with mild ABP, who underwent ES during the index admission or in the medical history will be informed to take part in EMILY study. The patients will be randomised into two groups: (1) early cholecystectomy (within 6 days after discharge) and (2) patients with delayed (interval) cholecystectomy (between 45 and 60 days after discharge). During a 12-month period, 93 patients will be enrolled from participating clinics. The primary endpoint is a composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic and cholangitis). The secondary endpoints are organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications. ETHICS AND DISSEMINATION The trial has been registered internationally ISRCTN 10667869, and approved by the relevant organisation, the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (EKU/2018/12176-5). TRIAL REGISTRATION NUMBER ISCRTN 10667869; Pre-results.",2019,"According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP).","['mild acute biliarY pancreatitis (EMILY study', 'All patients with mild ABP, who underwent ES during the index admission or in the medical history will be informed to take part in EMILY study', 'patients with mild gallstone pancreatitis and reduced the risk of recurrent gallstone-related complications, as compared with interval cholecystectomy', '93 patients will be enrolled from participating clinics']","['Endoscopic sphincterotoMy', 'early cholecystectomy', 'delayed (interval) cholecystectomy', 'sphincterotomy (ES']","['composite endpoint of mortality and recurrent acute biliary events (that is, recurrent ABP, acute cholecystitis, uncomplicated biliary colic and cholangitis', 'organ failure, biliary leakage, technical difficulty of the cholecystectomy, surgical and other complications']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C1998726', 'cui_str': 'Is informed (finding)'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis (disorder)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0947622', 'cui_str': 'Cholecystolithiasis'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0085263', 'cui_str': 'Endoscopic Biliary Sphincterotomy'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439589', 'cui_str': 'Recurrent acute (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0149520', 'cui_str': 'Acute Cholecystitis'}, {'cui': 'C0151824', 'cui_str': 'Biliary colic (finding)'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction (disorder)'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",93.0,0.160119,"According to the literature, early cholecystectomy is necessary to avoid complications related to gallstones after an initial episode of acute biliary pancreatitis (ABP).","[{'ForeName': 'Levente Pál', 'Initials': 'LP', 'LastName': 'Kucserik', 'Affiliation': 'Division of Surgery, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, Romania.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Márta', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'Áron', 'Initials': 'Á', 'LastName': 'Vincze', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'György', 'Initials': 'G', 'LastName': 'Lázár', 'Affiliation': 'Department of Surgery, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'László', 'Initials': 'L', 'LastName': 'Czakó', 'Affiliation': 'First Department of Medicine, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Szentkereszty', 'Affiliation': 'Department for Surgery, University of Debrecen, Debrecen, Hungary.'}, {'ForeName': 'Mária', 'Initials': 'M', 'LastName': 'Papp', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Debreceni Egyetem, Debrecen, Hungary.'}, {'ForeName': 'Károly', 'Initials': 'K', 'LastName': 'Palatka', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Debreceni Egyetem, Debrecen, Hungary.'}, {'ForeName': 'Ferenc', 'Initials': 'F', 'LastName': 'Izbéki', 'Affiliation': 'Divison of Gastroenterology, Fejer County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, Hungary.'}, {'ForeName': 'Áron', 'Initials': 'Á', 'LastName': 'Altorjay', 'Affiliation': 'Division of Surgery, Fejer County Saint George Teaching Hospital of University of Pécs, Székesfehérvár, Hungary.'}, {'ForeName': 'Imola', 'Initials': 'I', 'LastName': 'Török', 'Affiliation': 'Division of Gastroenterology, Universitatea de Medicina si Farmacie din Targu Mures, Targu Mures, Romania.'}, {'ForeName': 'Sorin', 'Initials': 'S', 'LastName': 'Barbu', 'Affiliation': '4thSurgery Department, ""Iuliu Hatieganu"" University of Medicine & Pharmacy, Cluj-Napoca, Romania.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Tantau', 'Affiliation': '4thSurgery Department, ""Iuliu Hatieganu"" University of Medicine & Pharmacy, Cluj-Napoca, Romania.'}, {'ForeName': 'András', 'Initials': 'A', 'LastName': 'Vereczkei', 'Affiliation': 'Department for Surgery, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Bogár', 'Affiliation': 'Department of Anaesthesiology and Intensive Therapy, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'Márton', 'Initials': 'M', 'LastName': 'Dénes', 'Affiliation': 'Second Department of Surgery, County Hospital Targu Mures, Targu Mures, Romania.'}, {'ForeName': 'Imola', 'Initials': 'I', 'LastName': 'Németh', 'Affiliation': 'Data-Management, Pre-Clinical and Clinical Biostatistics, Adware Research Developing and Consulting Ltd, Balatonfüred, Hungary.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Szentesi', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem, Pecs, Hungary.'}, {'ForeName': 'Noémi', 'Initials': 'N', 'LastName': 'Zádori', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Antal', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}, {'ForeName': 'Markus M', 'Initials': 'MM', 'LastName': 'Lerch', 'Affiliation': 'Department of Medicine A, Universitatsmedizin Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Neoptolemos', 'Affiliation': 'Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, Liverpool, UK.'}, {'ForeName': 'Miklós', 'Initials': 'M', 'LastName': 'Sahin-Tóth', 'Affiliation': 'Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, Boston University, Boston, MA 02118, USA.'}, {'ForeName': 'Ole H', 'Initials': 'OH', 'LastName': 'Petersen', 'Affiliation': 'School of Biosciences, Cardiff University, Cardiff, South Glamorgan, UK.'}, {'ForeName': 'Dezső', 'Initials': 'D', 'LastName': 'Kelemen', 'Affiliation': 'Surgery Clinic, Pecsi Tudomanyegyetem, Pecs, Hungary.'}, {'ForeName': 'Péter', 'Initials': 'P', 'LastName': 'Hegyi', 'Affiliation': 'Institute for Translational Medicine, Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Pecs, Hungary.'}]",BMJ open,['10.1136/bmjopen-2018-025551'] 629,31289059,Acupuncture for cancer pain: protocol for a pilot pragmatic randomised controlled trial.,"INTRODUCTION Although acupuncture has been recommended for alleviating cancer pain by clinical guidelines, the level of the supporting evidence needs to be improved. A pragmatic randomised controlled trial (pRCT) in a hospital setting would provide real-world assessments of the overall clinical effects of acupuncture. This pilot trial aims to explore the feasibility and provide data for sample size calculations for a pRCT evaluating the effectiveness of acupuncture as an adjunctive therapy to routine medical care for cancer pain. METHODS AND ANALYSIS Thirty patients with cancer admitted to the oncology department with moderate or severe pain will be recruited. Participants will be randomised at a ratio of 1:1 to the adjunctive acupuncture group or a control group which receives routine pain management without acupuncture. The standardised section of the acupuncture protocol will be developed based on the results of reviews of the literature, recommendations in clinical guidelines and interviews with clinical experts. The acupuncturist will be allowed to tailor the protocol according to the individual situation of each participant. Primary outcomes relevant to the feasibility of conducting a fully powered trial include: numbers and proportions of participants recruited, screened, consented and randomised; numbers and reasons for withdrawals and dropouts; numbers and types of adverse events; feasibility of implementing the trial procedures; evaluation of the comprehensiveness and ease-of-use of the case report form. Secondary outcomes are clinical measurements of the effectiveness of the treatment that are intended for use in the full-scale trial. Analysis of feasibility will be descriptive and pain intensity measures will be analysed using mixed-effects regression. ETHICS AND DISSEMINATION Ethics approval was obtained from the Institutional Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (approval no: Z2017-184-01) and RMIT University Human Research Ethics Committee (reference no: 21361). Results will be disseminated in a peer-reviewed journal, and trial participants will be informed via email and/or phone calls. TRIAL REGISTRATION NUMBER ChiCTR1800017023.",2019,Participants will be randomised at a ratio of 1:1 to the adjunctive acupuncture group or a control group which receives routine pain management without acupuncture.,"['Thirty patients with cancer admitted to the oncology department with moderate or severe pain will be recruited', 'cancer pain']","['Acupuncture', 'acupuncture', 'adjunctive acupuncture group or a control group which receives routine pain management without acupuncture']","['clinical measurements of the effectiveness of the treatment that are intended for use in the full-scale trial', 'feasibility of conducting a fully powered trial include: numbers and proportions of participants recruited, screened, consented and randomised; numbers and reasons for withdrawals and dropouts; numbers and types of adverse events; feasibility of implementing the trial procedures; evaluation of the comprehensiveness and ease-of-use of the case report form']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0278140', 'cui_str': 'Severe pain (finding)'}, {'cui': 'C0596240', 'cui_str': 'Tumor-Related Pain'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0222045'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0007320', 'cui_str': 'Case Reports'}, {'cui': 'C0376315', 'cui_str': 'Form'}]",30.0,0.287085,Participants will be randomised at a ratio of 1:1 to the adjunctive acupuncture group or a control group which receives routine pain management without acupuncture.,"[{'ForeName': 'Yihan', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'May', 'Affiliation': 'China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anthony Lin', 'Initials': 'AL', 'LastName': 'Zhang', 'Affiliation': 'China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Xinfeng', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yihong', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yanchun', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xuesong', 'Initials': 'X', 'LastName': 'Chang', 'Affiliation': 'The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Chuan-Jian', 'Initials': 'CJ', 'LastName': 'Lu', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Charlie Changli', 'Initials': 'CC', 'LastName': 'Xue', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Science, Guangzhou, Guangdong, China.'}]",BMJ open,['10.1136/bmjopen-2018-025564'] 630,31289060,A tailored approach towards informing relatives at risk of inherited cardiac conditions: study protocol for a randomised controlled trial.,"INTRODUCTION In current practice, probands are asked to inform relatives about the possibility of predictive DNA testing when a pathogenic variant causing an inherited cardiac condition (ICC) is identified. Previous research on the uptake of genetic counselling and predictive DNA testing in relatives suggests that not all relatives are sufficiently informed. We developed a randomised controlled trial to evaluate the effectiveness of a tailored approach in which probands decide together with the genetic counsellor which relatives they inform themselves and which relatives they prefer to have informed by the genetic counsellor. Here, we present the study protocol of this randomised controlled trial. METHODS A multicentre randomised controlled trial with parallel-group design will be conducted in which an intervention group receiving the tailored approach will be compared with a control group receiving usual care. Adult probands diagnosed with an ICC in whom a likely pathogenic or pathogenic variant is identified will be randomly assigned to the intervention or control group (total sample: n=85 probands). Primary outcomes are uptake of genetic counselling and predictive DNA testing by relatives (total sample: n=340 relatives). Secondary outcomes are appreciation of the approach used and impact on familial and psychological functioning, which will be assessed using questionnaires. Relatives who attend genetic counselling will be asked to fill out a questionnaire as well. ETHICS AND DISSEMINATION Ethical approval was obtained from the Medical Ethical Committee of the Amsterdam University Medical Centres (MEC 2017-145), the Netherlands. All participants will provide informed consent prior to participation in the study. Results of the study on primary and secondary outcome measures will be published in peer-reviewed journals. TRIAL REGISTRATION NUMBER NTR6657; Pre-results.",2019,We developed a randomised controlled trial to evaluate the effectiveness of a tailored approach in which probands decide together with the genetic counsellor which relatives they inform themselves and which relatives they prefer to have informed by the genetic counsellor.,['Adult probands diagnosed with an ICC in whom a likely pathogenic or pathogenic variant'],['control group receiving usual care'],"['uptake of genetic counselling and predictive DNA testing by relatives (total sample: n=340 relatives', 'appreciation of the approach used and impact on familial and psychological functioning, which will be assessed using questionnaires', 'peer-reviewed journals']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0702111', 'cui_str': 'Proband (finding)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0599986'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C1611743', 'cui_str': 'Familial (FPAH)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030768', 'cui_str': 'Peer Review'}]",,0.263991,We developed a randomised controlled trial to evaluate the effectiveness of a tailored approach in which probands decide together with the genetic counsellor which relatives they inform themselves and which relatives they prefer to have informed by the genetic counsellor.,"[{'ForeName': 'Lieke M', 'Initials': 'LM', 'LastName': 'van den Heuvel', 'Affiliation': 'Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}, {'ForeName': 'Yvonne M', 'Initials': 'YM', 'LastName': 'Hoedemaekers', 'Affiliation': 'Department of Clinical Genetics, University Medical Centre Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Annette F', 'Initials': 'AF', 'LastName': 'Baas', 'Affiliation': 'Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'J Peter', 'Initials': 'JP', 'LastName': 'van Tintelen', 'Affiliation': 'Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}, {'ForeName': 'Ellen M A', 'Initials': 'EMA', 'LastName': 'Smets', 'Affiliation': 'Department of Medical Psychology, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}, {'ForeName': 'Imke', 'Initials': 'I', 'LastName': 'Christiaans', 'Affiliation': 'Department of Clinical Genetics, Amsterdam University Medical Centres, Amsterdam, The Netherlands.'}]",BMJ open,['10.1136/bmjopen-2018-025660'] 631,31289062,The 'Pleasure&Pregnancy' web-based interactive educational programme versus expectant management in the treatment of unexplained subfertility: protocol for a randomised controlled trial.,"INTRODUCTION Many subfertile couples are diagnosed with (relatively) unexplained subfertility and a good prognosis. National professional guidelines (eg, the Netherlands and UK) advise 'expectant management (EM)' for 6-12 months, in which no interaction with healthcare staff is offered. Underpowered studies indicate that face-to-face sex-counselling increases the ongoing pregnancy rates of these couples. In patients with other conditions, web-based interactive educational programmes have the same effect on sexual functioning as face-to-face sex counselling. The 'Pleasure&Pregnancy randomised controlled trial (RCT)' will examine in couples with unexplained subfertility and a good prognosis whether a new web-based interactive educational programme results in a higher chance of naturally conceiving an ongoing pregnancy within 6 months as compared with EM. METHODS AND ANALYSIS A multicentre RCT with cost-effectiveness analysis will include heterosexual couples diagnosed with (relatively) unexplained subfertility and a good prognosis in Dutch and Belgian secondary or tertiary fertility clinics. Couples will be randomised between 6 months of EM and 6 months of the Pleasure&Pregnancy-programme. This new web-based interactive educational programme includes eight progressive modules of information (on the biology of conception and pleasurable sex) and sensate focus, couple communication and mindfulness exercises. Couples are offered interaction with their coaches via email and can take part in three moderated chat sessions with peers. The primary outcome of this RCT is the probability of naturally conceiving an ongoing pregnancy within 6 months after randomisation. Secondary outcomes include time-to-pregnancy, live birth rate, costs, sexual functioning and personal and relational well-being. Analysis will be according to intention to treat. ETHICS AND DISSEMINATION This study has been approved by the Medical Ethical Committees of the Academic Medical Centre (the Netherlands) and the Leuven University Hospital (Belgium). The findings of this RCT will be disseminated through presentations at international scientific meetings and peer-reviewed publications. TRAIL REGISTRATION NUMBER NTR5709; Pre-results.",2019,"In patients with other conditions, web-based interactive educational programmes have the same effect on sexual functioning as face-to-face sex counselling.","['unexplained subfertility', 'Medical Ethical Committees of the Academic Medical Centre (the Netherlands) and the Leuven University Hospital (Belgium', 'heterosexual couples diagnosed with (relatively) unexplained subfertility and a good prognosis in Dutch and Belgian secondary or tertiary fertility clinics', 'couples with unexplained subfertility']","[""Pleasure&Pregnancy' web-based interactive educational programme versus expectant management"", 'RCT']","['time-to-pregnancy, live birth rate, costs, sexual functioning and personal and relational well-being', 'probability of naturally conceiving an ongoing pregnancy']","[{'cui': 'C0729353', 'cui_str': 'Sub-Fertility'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0278250', 'cui_str': 'Prognosis good (finding)'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0337797', 'cui_str': 'Belgians (ethnic group)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2585455', 'cui_str': 'Expectant management (procedure)'}]","[{'cui': 'C3494204', 'cui_str': 'Time-to-Pregnancy'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]",,0.138813,"In patients with other conditions, web-based interactive educational programmes have the same effect on sexual functioning as face-to-face sex counselling.","[{'ForeName': 'Eline A F', 'Initials': 'EAF', 'LastName': 'Dancet', 'Affiliation': 'Department of Development and Regeneration, KU Leuven - University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': ""D'Hooghe"", 'Affiliation': 'Department of Development and Regeneration, KU Leuven - University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Felicia', 'Initials': 'F', 'LastName': 'Dreischor', 'Affiliation': 'Department of Obstetrics and Gynecology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Madelon', 'Initials': 'M', 'LastName': 'van Wely', 'Affiliation': 'Department of Obstetrics and Gynecology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Ellen T M', 'Initials': 'ETM', 'LastName': 'Laan', 'Affiliation': 'Department of Sexology and Psychosomatic Obstetrics/Gynecology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Cornelius B', 'Initials': 'CB', 'LastName': 'Lambalk', 'Affiliation': 'Department of Obstetrics and Gynaecology, Reproduction and Development, Amsterdam University Medical Centre, Free University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Sjoerd', 'Initials': 'S', 'LastName': 'Repping', 'Affiliation': 'Department of Obstetrics and Gynecology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Inge M', 'Initials': 'IM', 'LastName': 'Custers', 'Affiliation': 'Department of Obstetrics and Gynecology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.'}]",BMJ open,['10.1136/bmjopen-2018-025845'] 632,31335650,"OPRM1 rs1799971, COMT rs4680, and FAAH rs324420 genes interact with placebo procedures to induce hypoalgesia.","Genetics studies on the placebo hypoalgesic effect highlight a promising link between single nucleotide polymorphisms (SNPs) in the dopamine, opioid, and endocannabinoid genes and placebo hypoalgesia. However, epistasis and replication studies are missing. In this study, we expanded on previous findings related to the 3 SNPs in the opioid receptor mu subunit (OPRM1 rs1799971), catechol-O-methyltransferase (COMT rs4680), and fatty acid amide hydrolase (FAAH rs324420) genes associated with placebo hypoalgesia and tested the effect of a 3-way interaction on placebo hypoalgesia. Using 2 well-established placebo procedures (verbal suggestion and learning paradigm), we induced significant placebo hypoalgesic effects in 160 healthy participants. We found that individuals with OPRM1 AA combined with FAAH Pro/Pro and those carrying COMT met/met together with FAAH Pro/Pro showed significant placebo effects. Participants with COMT met/val alleles showed significant placebo effects independently of OPRM1 and FAAH allele combinations. Finally, the model that included the placebo procedure and genotypes predicted placebo responsiveness with a higher accuracy (area under the curve, AUC = 0.773) as compared to the SNPs alone indicating that genetic variants can only partially explain the placebo responder status. Our results suggest that the endogenous mu-opioid system with a larger activation in response to pain in the met/val allele carriers as well as the synergism between endogenous mu-opioid system and cannabinoids might play the most relevant role in driving hypoalgesic responses. Future epistasis studies with larger sample sizes will help us to fully understand the complexity of placebo effects and explain the mechanisms that underlie placebo responsiveness.",2019,Participants with COMT met/val alleles showed significant placebo effects independently of OPRM1 and FAAH allele combinations.,['160 healthy participants'],['placebo procedures (verbal suggestion and learning paradigm'],[],"[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0038659', 'cui_str': 'Suggestion'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",[],160.0,0.212109,Participants with COMT met/val alleles showed significant placebo effects independently of OPRM1 and FAAH allele combinations.,"[{'ForeName': 'Luana', 'Initials': 'L', 'LastName': 'Colloca', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Pedro E', 'Initials': 'PE', 'LastName': 'Martinez', 'Affiliation': 'National Institute of Mental Health (NIMH), Bethesda, MD, United States.'}, {'ForeName': 'Yen-Pei C', 'Initials': 'YC', 'LastName': 'Chang', 'Affiliation': 'Departments of Medicine, University of Maryland, Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Ryan', 'Affiliation': 'Departments of Medicine, University of Maryland, Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Hodgkinson', 'Affiliation': 'Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Goldman', 'Affiliation': 'Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, United States.'}, {'ForeName': 'Susan G', 'Initials': 'SG', 'LastName': 'Dorsey', 'Affiliation': 'Department of Pain and Translational Symptom Science, School of Nursing, University of Maryland, Baltimore, Baltimore, MD, United States.'}]",Pain,['10.1097/j.pain.0000000000001578'] 633,32091672,The clinical utility of remote ischemic preconditioning in protecting against cardiac surgery-associated acute kidney injury: A pilot randomized clinical trial.,"BACKGROUND Cardiac surgery-associated acute kidney injury (CSA-AKI) is a well-known, serious complication and a well-recognized independent risk factor for higher morbidity and mortality among patients undergoing cardiac surgery. OBJECTIVES The aim of the study was to assess the efficacy of remote ischemic preconditioning (RIPC) in reducing the incidence of CSA-AKI, measured with the standard creatinine technique and using neutrophil gelatinase-associated lipocalin (NGAL) serum concentrations as a potential new biomarker of kidney damage. The ethics committee of the Medical University of Lodz prospectively approved the protocol (approval No. RNN/286/13/KE). The study was retrospectively registered with the U.S. National Institutes of Health - NIH (29 June 2017; ClinicalTrials.gov identifier: NCT03205410). MATERIAL AND METHODS We conducted a prospective single-center double-blind randomized and controlled tudy. Data was collected from patients admitted to the Cardiosurgery Clinic at the Medical University of Lodz (Poland) between January and December 2014, scheduled for elective cardiac surgery (an off-pump coronary artery bypass). A total of 28 patients were randomized to receive either RIPC (n = 14) or sham RIPC (n = 14). After the induction of anesthesia, the patients assigned to the RIPC group underwent 3 cycles of five-minute inflation to 200 mm Hg and five-minute deflation of the upper-arm cuff. The control group had a deflated cuff placed on the upper arm for 30 min. The authors measured the patients' serum creatinine concentration to check for the occurrence of a CSA-AKI within 48 h after cardiac surgery, and NGAL serum concentration to check its level within 3 h after the operation. RESULTS Fewer patients in RIPC group developed CSA-AKI within 48 h after cardiac surgery than in the control group (29% vs 93%; p = 0.003). Fewer patients in the RIPC group presented an increase in NGAL 3 h after surgery (medians: 124 vs 176.7; p = 0.0003). CONCLUSIONS In patients undergoing an off-pump coronary artery bypass, RIPC significantly reduces the occurrence of CSA-AKI and protects against increased postoperative NGAL levels.",2020,"In patients undergoing an off-pump coronary artery bypass, RIPC significantly reduces the occurrence of CSA-AKI and protects against increased postoperative NGAL levels.","['protecting against cardiac surgery-associated acute kidney injury', 'patients admitted to the Cardiosurgery Clinic at the Medical University of Lodz (Poland) between January and December 2014, scheduled for elective cardiac surgery (an off-pump coronary artery bypass', 'The study was retrospectively registered with the U.S. National Institutes of Health - NIH (29 June 2017', '28 patients', 'patients undergoing cardiac surgery']","['remote ischemic preconditioning (RIPC', 'remote ischemic preconditioning', 'sham RIPC', 'RIPC']","['CSA-AKI', 'occurrence of CSA-AKI and protects against increased postoperative NGAL levels']","[{'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C1449706', 'cui_str': 'Coronary Artery Bypass, Off-Pump'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C1709632', 'cui_str': 'Precondition (attribute)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0258591', 'cui_str': 'cyclosporin A, 4-(2-butenyl)-4,4,N-trimethylthreonine(1)-'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",28.0,0.276007,"In patients undergoing an off-pump coronary artery bypass, RIPC significantly reduces the occurrence of CSA-AKI and protects against increased postoperative NGAL levels.","[{'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Stokfisz', 'Affiliation': 'Intensive Cardiac Therapy Clinic, Department of Invasive Cardiology and Electrocardiology, Medical University of Lodz, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ledakowicz-Polak', 'Affiliation': 'Intensive Cardiac Therapy Clinic, Department of Invasive Cardiology and Electrocardiology, Medical University of Lodz, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Zagórski', 'Affiliation': 'Cardiosurgery Clinic, Department of Cardiology and Cardiosurgery, Medical University of Lodz, Poland.'}, {'ForeName': 'Sławomir', 'Initials': 'S', 'LastName': 'Jander', 'Affiliation': 'Cardiosurgery Clinic, Department of Cardiology and Cardiosurgery, Medical University of Lodz, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Przybylak', 'Affiliation': 'Intensive Cardiac Therapy Clinic, Department of Invasive Cardiology and Electrocardiology, Medical University of Lodz, Poland.'}, {'ForeName': 'Marzenna', 'Initials': 'M', 'LastName': 'Zielińska', 'Affiliation': 'Intensive Cardiac Therapy Clinic, Department of Invasive Cardiology and Electrocardiology, Medical University of Lodz, Poland.'}]",Advances in clinical and experimental medicine : official organ Wroclaw Medical University,['10.17219/acem/112610'] 634,31496423,"Essential elements of a community empowerment approach to HIV prevention among female sex workers engaged in project Shikamana in Iringa, Tanzania.","Globally, female sex workers bear a disproportionate burden of HIV, with those in sub-Saharan Africa being among the most affected. Community empowerment approaches have proven successful at preventing HIV among this population. These approaches facilitate a process whereby sex workers take collective ownership over programmes to address the barriers they face in accessing their health and human rights. Limited applications of such approaches have been documented in Africa. We describe the community empowerment process among female sex workers in Iringa, Tanzania, in the context of a randomised controlled trial of a community empowerment-based model of combination HIV prevention. We conducted 24 in-depth interviews with participants from the intervention community and 12 key informant interviews with HIV care providers, police, venue managers, community advisory board members and research staff. Content analysis was employed, and salient themes were extracted. Findings reveal that the community empowerment process was facilitated by the meaningful engagement of sex workers in programme development, encouraging sex worker ownership over the programme, providing opportunities for solidarity and capacity building, and forming partnerships with key stakeholders. Through this process, sex workers mobilised their collective agency to access their health and human rights including HIV prevention, care and treatment.",2020,"Findings reveal that the community empowerment process was facilitated by the meaningful engagement of sex workers in programme development, encouraging sex worker ownership over the programme, providing opportunities for solidarity and capacity building, and forming partnerships with key stakeholders.","['24 in-depth interviews with participants from the intervention community and 12 key informant interviews with HIV care providers, police, venue managers, community advisory board members and research staff', 'female sex workers', 'female sex workers engaged in project Shikamana in Iringa, Tanzania']",[],[],"[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0085098', 'cui_str': 'Police'}, {'cui': 'C0335141', 'cui_str': 'Manager (occupation)'}, {'cui': 'C0035168'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0240816', 'cui_str': 'Prostitutes'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}]",[],[],,0.0818917,"Findings reveal that the community empowerment process was facilitated by the meaningful engagement of sex workers in programme development, encouraging sex worker ownership over the programme, providing opportunities for solidarity and capacity building, and forming partnerships with key stakeholders.","[{'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Leddy', 'Affiliation': 'Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Mantsios', 'Affiliation': 'Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Davis', 'Affiliation': 'Department of Sociology, American University, Washington, DC, USA.'}, {'ForeName': 'Ohvia', 'Initials': 'O', 'LastName': 'Muraleetharan', 'Affiliation': 'Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Shembilu', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.'}, {'ForeName': 'Ard', 'Initials': 'A', 'LastName': 'Mwampashi', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.'}, {'ForeName': 'S Wilson', 'Initials': 'SW', 'LastName': 'Beckham', 'Affiliation': 'Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Noya', 'Initials': 'N', 'LastName': 'Galai', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Likindikoki', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Mbwambo', 'Affiliation': 'Department of Psychiatry, Muhimbili University of Health and Allied Sciences, Dar Es Salaam, Tanzania.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Kerrigan', 'Affiliation': 'Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]","Culture, health & sexuality",['10.1080/13691058.2019.1659999'] 635,31289064,Effect of a proficiency-based progression simulation programme on clinical communication for the deteriorating patient: a randomised controlled trial.,"OBJECTIVE This study aimed to determine the effectiveness of a proficiency-based progression (PBP) training approach to clinical communication in the context of a clinically deteriorating patient. DESIGN This is a randomised controlled trial with three parallel arms. SETTING This study was conducted in a university in Ireland. PARTICIPANTS This study included 45 third year nursing and 45 final year medical undergraduates scheduled to undertake interdisciplinary National Early Warning Score (NEWS) training over a 3-day period in September 2016. INTERVENTIONS Participants were prospectively randomised to one of three groups before undertaking a performance assessment of the ISBAR (Identification, Situation, Background, Assessment, Recommendation) communication tool relevant to a deteriorating patient in a high-fidelity simulation facility. The groups were as follows: (i) E, the Irish Health Service national NEWS e-learning programme only; (ii) E+S, the national e-learning programme plus standard simulation; and (iii) E+PBP, the national e-learning programme plus PBP simulation. MAIN OUTCOME MEASURES The primary outcome was the proportion in each group reaching a predefined proficiency benchmark comprising a series of predefined steps, errors and critical errors during the performance of a standardised, high-fidelity simulation assessment case which was recorded and scored by two independent blinded assessors. RESULTS 6.9% (2/29) of the E group and 13% (3/23) of the E+S group demonstrated proficiency in comparison to 60% (15/25) of the E+PBP group. The difference between the E and the E+S groups was not statistically significant (χ 2 =0.55, 99% CI 0.63 to 0.66, p=0.63) but was significant for the difference between the E and the E+PBP groups (χ 2 =22.25, CI 0.00 to 0.00, p<0.000) and between the E+S and the E+PBP groups (χ 2 =11.04, CI 0.00 to 0.00, p=0.001). CONCLUSIONS PBP is a more effective way to teach clinical communication in the context of the deteriorating patient than e-learning either alone or in combination with standard simulation. TRIAL REGISTRATION NUMBER NCT02886754; Results.",2019,"The difference between the E and the E+S groups was not statistically significant (χ 2 =0.55, 99% CI 0.63 to 0.66, p=0.63) but was significant for the difference between the E and the E+PBP groups (χ 2 =22.25, CI 0.00 to 0.00, p<0.000) and between the E+S and the E+PBP groups (χ 2 =11.04, CI 0.00 to 0.00, p=0.001). ","['45 third year nursing and 45 final year medical undergraduates scheduled to', 'deteriorating patient', 'This study was conducted in a university in Ireland']","['proficiency-based progression simulation programme', 'ISBAR (Identification, Situation, , Assessment, Recommendation) communication tool relevant to a deteriorating patient in a high-fidelity simulation facility', 'undertake interdisciplinary National Early Warning Score (NEWS) training', 'proficiency-based progression (PBP) training approach']","['proportion in each group reaching a predefined proficiency benchmark comprising a series of predefined steps, errors and critical errors during the performance of a standardised, high-fidelity simulation assessment case which']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022067', 'cui_str': 'Ireland, Republic of'}]","[{'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0020792', 'cui_str': 'Identification'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0525063', 'cui_str': 'Best Practice Analysis'}, {'cui': 'C0205549', 'cui_str': 'Series (qualifier value)'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}]",,0.101218,"The difference between the E and the E+S groups was not statistically significant (χ 2 =0.55, 99% CI 0.63 to 0.66, p=0.63) but was significant for the difference between the E and the E+PBP groups (χ 2 =22.25, CI 0.00 to 0.00, p<0.000) and between the E+S and the E+PBP groups (χ 2 =11.04, CI 0.00 to 0.00, p=0.001). ","[{'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Breen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Cork University Hospital Group, Cork, Ireland.'}, {'ForeName': 'Sinead', 'Initials': 'S', 'LastName': ""O'Brien"", 'Affiliation': 'School of Nursing and Midwifery, University College Cork National University of Ireland, Cork, Ireland.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'McCarthy', 'Affiliation': 'Medical Education Unit, School of Medicine, University College Cork National University of Ireland, Cork, Ireland.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gallagher', 'Affiliation': 'Faculty of Life and Health Sciences, Ulster University, Londonderry, UK.'}, {'ForeName': 'Nuala', 'Initials': 'N', 'LastName': 'Walshe', 'Affiliation': 'School of Nursing and Midwifery, University College Cork National University of Ireland, Cork, Ireland.'}]",BMJ open,['10.1136/bmjopen-2018-025992'] 636,31542245,"Genetic susceptibility, lifestyle intervention and glycemic changes among women with prior gestational diabetes.","AIMS Women with prior gestational diabetes mellitus (GDM) or high genetic susceptibility are prone to development of type 2 diabetes. We examined whether a lifestyle intervention modified the genetic effect on changes in glycemic markers among women with prior GDM. RESEARCH DESIGN AND METHODS This study included 560 women with prior GDM from a randomized controlled trial, the Tianjin Gestational Diabetes Mellitus Prevention Program, who were assigned into an intervention arm (improved physical activity and healthy dietary intakes) or a control arm. We assessed associations of GDM related genetic variants in/near the CDKAL1 (rs7754840) and MTNR1B (rs10830962) genes with changes in fasting levels of glucose and insulin, β-cell function (HOMA-B) and insulin resistance (HOMA-IR) at 1 year and 2 years after the baseline. RESULTS We found significant interactions between CDKAL1 variant rs7754840 and lifestyle intervention on changes in fasting insulin and HOMA-IR at 1 year (P for interactions = 0.008 and 0.006, respectively). The GDM-increasing C allele was associated with a 0.07-unit greater increase in fasting insulin (P = 0.048) and HOMA-IR (P = 0.045) in the control group, while opposite-directional associations were observed in the intervention group; women with the C allele seemed to decrease more in these glycemic markers than the non-C-carriers (both P ≤ 0.06). The interactions between the CDKAL1 genetic variant and lifestyle intervention on changes in fasting insulin (P = 0.035) and HOMA-IR (P = 0.024) remained significant over the 2-year period, even though the effects of lifestyle intervention were attenuated at 2-year. The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. CONCLUSIONS Healthy lifestyle intervention may be beneficial for women with the GDM predisposing CDKAL1 genetic variant in improvement of insulin resistance. TRIAL REGISTRATION NUMBER ClinicalTrials.gov NCT01554358. URL OF REGISTRATION: https://clinicaltrials.gov/ct2/show/NCT01554358.",2020,"The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. ","['560 women with prior GDM from a randomized controlled trial, the Tianjin Gestational Diabetes Mellitus Prevention Program', 'women with prior gestational diabetes', 'women with prior GDM', 'Women with prior gestational diabetes mellitus (GDM']","['intervention arm (improved physical activity and healthy dietary intakes) or a control arm', 'lifestyle intervention']","['fasting levels of glucose and insulin, β-cell function (HOMA-B) and insulin resistance (HOMA-IR', 'glycemic markers', 'fasting insulin', 'fasting insulin and HOMA-IR', 'HOMA-IR']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}]",560.0,0.0338199,"The MTNR1B variant rs10830962 did not show interaction with lifestyle intervention on changes in the glycemic markers. ","[{'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Liang', 'Affiliation': ""Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Obstetrical, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.""}, {'ForeName': 'Leishen', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Huikun', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Public Health Laboratory Sciences, West China School of Public Health, Sichuan University, Chengdu, Sichuan Province, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhou', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Yoriko', 'Initials': 'Y', 'LastName': 'Heianza', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.'}, {'ForeName': 'Junhong', 'Initials': 'J', 'LastName': 'Leng', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Weiqin', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ""Tianjin Women's and Children's Health Center, Tianjin, China.""}, {'ForeName': 'Xilin', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Epidemiology, School of Public Health, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': ""Pennington Biomedical Research Center, Baton Rouge, LA, USA; Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus, Shanghai, China.""}, {'ForeName': 'Ru', 'Initials': 'R', 'LastName': 'Gao', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Hu', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA, USA.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': ""Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: lqi1@tulane.edu.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.08.032'] 637,31264183,Building a physical activity intervention into clinical care for breast and colorectal cancer survivors in Wisconsin: a randomized controlled pilot trial.,"BACKGROUND Cancer survivorship care plans (""care plans"") often recommend an active lifestyle yet are rarely accompanied by programs to help patients enact the prescribed behavior change. As a step towards bridging this gap, this trial tested the feasibility of augmenting care planning with a multi-level physical activity intervention. METHODS Breast and colorectal cancer survivors were enrolled alongside a self-selected support partner (e.g., spouse, friend). Survivors received a care plan alone (comparison group) versus one augmented with a 12-week physical activity module (intervention group). For the intervention group dyads, both members received a multi-component program including Fitbit trackers, with the survivor's Fitbit linked to his/her electronic health record (EHR). Treating clinicians received periodic updates regarding the survivors' physical activity. The primary outcome was ActiGraph-measured physical activity, analyzed using mixed models. Feedback questionnaires were administered to participants and clinicians at 12 weeks. RESULTS Survivors (n = 50) were 54.4 ± 11.2 years of age and 2.0 ± 1.5 years post-diagnosis. Survivors in the intervention group increased moderate-to-vigorous-intensity physical activity (MVPA) by 69 ± 84 min/week vs. a 20 ± 71 min/week decrease in the comparison group (p = .001). Likewise, daily steps increased by 1470 ± 1881 vs. a 398 ± 1751 decrease (P = .002). Among responding clinicians, 100% looked at survivors' activity data within the EHR at least once and 80% said it provided insight into their patients' lifestyles. CONCLUSIONS Augmenting a standard care plan with a multi-level, technology-based intervention increased physical activity among cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS Technology-based approaches, including activity trackers, can be used by individuals to work towards an active lifestyle after cancer.",2019,Survivors in the intervention group increased moderate-to-vigorous-intensity physical activity (MVPA) by 69 ± 84 min/week vs. a 20 ± 71 min/week decrease in the comparison group (p = .001).,"['Survivors (n\u2009=\u200950) were 54.4\u2009±\u200911.2\xa0years of age and 2.0\u2009±\u20091.5\xa0years post-diagnosis', 'breast and colorectal cancer survivors in Wisconsin', 'Breast and colorectal cancer survivors were enrolled alongside a self-selected support partner (e.g., spouse, friend']","['standard care plan with a multi-level, technology-based intervention', 'physical activity intervention', ""multi-component program including Fitbit trackers, with the survivor's Fitbit linked to his/her electronic health record (EHR"", 'care plan alone (comparison group) versus one augmented with a 12-week physical activity module (intervention group']","['ActiGraph-measured physical activity', 'physical activity', 'moderate-to-vigorous-intensity physical activity (MVPA']","[{'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C4517531', 'cui_str': '11.2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0162409', 'cui_str': 'Married Persons'}, {'cui': 'C0079382', 'cui_str': 'Friend (person)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178916', 'cui_str': 'Care plan (record artifact)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0651691,Survivors in the intervention group increased moderate-to-vigorous-intensity physical activity (MVPA) by 69 ± 84 min/week vs. a 20 ± 71 min/week decrease in the comparison group (p = .001).,"[{'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cadmus-Bertram', 'Affiliation': 'Department of Kinesiology, University of Wisconsin - Madison, 2000 Observatory Drive, Madison, WI, 53706, USA. lisa.bertram@wisc.edu.'}, {'ForeName': 'Amye J', 'Initials': 'AJ', 'LastName': 'Tevaarwerk', 'Affiliation': 'Carbone Comprehensive Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Sesto', 'Affiliation': 'Carbone Comprehensive Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Gangnon', 'Affiliation': 'Carbone Comprehensive Cancer Center, University of Wisconsin - Madison, Madison, WI, USA.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Van Remortel', 'Affiliation': 'Department of Population Health Sciences, University of Wisconsin - Madison, Madison, WI, USA.'}, {'ForeName': 'Preshita', 'Initials': 'P', 'LastName': 'Date', 'Affiliation': 'Department of Population Health Sciences, University of Wisconsin - Madison, Madison, WI, USA.'}]",Journal of cancer survivorship : research and practice,['10.1007/s11764-019-00778-6'] 638,31313626,"Forced, Not Voluntary, Aerobic Exercise Enhances Motor Recovery in Persons With Chronic Stroke.","Background . The recovery of motor function following stroke is largely dependent on motor learning-related neuroplasticity. It has been hypothesized that intensive aerobic exercise (AE) training as an antecedent to motor task practice may prime the central nervous system to optimize motor recovery poststroke. Objective . The objective of this study was to determine the differential effects of forced or voluntary AE combined with upper-extremity repetitive task practice (RTP) on the recovery of motor function in adults with stroke. Methods . A combined analysis of 2 preliminary randomized clinical trials was conducted in which participants (n = 40) were randomized into 1 of 3 groups: (1) forced exercise and RTP (FE+RTP), (2) voluntary exercise and RTP (VE+RTP), or (3) time-matched stroke-related education and RTP (Edu+RTP). Participants completed 24 training sessions over 8 weeks. Results . A significant interaction effect was found indicating that improvements in the Fugl-Meyer Assessment (FMA) were greatest for the FE+RTP group ( P = .001). All 3 groups improved significantly on the FMA by a mean of 11, 6, and 9 points for the FE+RTP, VE+RTP, and Edu+RTP groups, respectively. No evidence of a treatment-by-time interaction was observed for Wolf Motor Function Test outcomes; however, those in the FE+RTP group did exhibit significant improvement on the total, gross motor, and fine-motor performance times ( P ≤ .01 for all observations). Conclusions . Results indicate that FE administered prior to RTP enhanced motor skill acquisition greater than VE or stroke-related education. AE, FE in particular, should be considered as an effective antecedent to enhance motor recovery poststroke.",2019,A significant interaction effect was found indicating that improvements in the Fugl-Meyer Assessment (FMA) were greatest for the FE+RTP group ( P = .001).,"['Persons With Chronic Stroke', 'participants (n = 40', 'adults with stroke']","['FE+RTP', 'Forced, Not Voluntary, Aerobic Exercise', 'FE', 'voluntary AE combined with upper-extremity repetitive task practice (RTP', 'intensive aerobic exercise (AE) training', 'forced exercise and RTP (FE+RTP), (2) voluntary exercise and RTP (VE+RTP), or (3) time-matched stroke-related education and RTP (Edu+RTP']","['motor skill acquisition', 'total, gross motor, and fine-motor performance times', 'Fugl-Meyer Assessment (FMA', 'FMA']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]","[{'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0205232', 'cui_str': 'Fine (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",,0.0679917,A significant interaction effect was found indicating that improvements in the Fugl-Meyer Assessment (FMA) were greatest for the FE+RTP group ( P = .001).,"[{'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Linder', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Anson B', 'Initials': 'AB', 'LastName': 'Rosenfeldt', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Davidson', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Zimmerman', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Penko', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Clark', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Jay L', 'Initials': 'JL', 'LastName': 'Alberts', 'Affiliation': '1 Cleveland Clinic, Cleveland, OH, USA.'}]",Neurorehabilitation and neural repair,['10.1177/1545968319862557'] 639,31038996,Emulating a Novel Clinical Trial Using Existing Observational Data. Predicting Results of the PreVent Study.,"Rationale: ""Target trial emulation"" has been proposed as an observational method to answer comparative effectiveness questions, but it has rarely been attempted concurrently with a randomized clinical trial (RCT). Objectives: We tested the hypothesis that blinded analysts applying target trial emulation to existing observational data could predict the results of an RCT. Methods: PreVent (Preventing Hypoxemia with Manual Ventilation during Endotracheal Intubation) was a multicenter RCT examining the effects of positive-pressure ventilation during tracheal intubation on oxygen saturation and severe hypoxemia. Analysts unaware of PreVent's results used patient-level data from three previous trials evaluating airway management interventions to emulate PreVent's eligibility criteria, randomization procedure, and statistical analysis. After PreVent's release, results of this blinded observational analysis were compared with those of the RCT. Difference-in-differences estimates for comparison of treatment effects between the observational analysis and the PreVent trial are reported on the absolute scale. Results: Using observational data, we were able to emulate PreVent's randomization procedure to produce balanced groups for comparison. The lowest oxygen saturation during intubation was higher in the positive-pressure ventilation group than the no positive-pressure ventilation group in the observational analysis ( n  = 360; mean difference = 1.8%; 95% confidence interval [CI] = -1.0 to 4.6) and in the PreVent trial ( n  = 401; mean difference = 3.9%; 95% CI = 1.4 to 6.4), though the observational analysis could not exclude no difference. Difference-in-differences estimates comparing treatment effects showed reasonable agreement for lowest oxygen saturation between the observational analysis and the PreVent trial (mean difference = -2.1%; 95% CI = -5.9 to 1.7). Positive-pressure ventilation resulted in lower rates of severe hypoxemia in both the observational analysis (risk ratio = 0.60; 95% CI = 0.38 to 0.93) and in the PreVent trial (risk ratio = 0.48; 95% CI = 0.30 to 0.77). The absolute reduction in the incidence of severe hypoxemia with positive-pressure ventilation was similar in the observational analysis (9.4%) and the PreVent trial (12.0%), though the difference between these estimates had wide CIs (mean difference = 2.5%; 95% CI = -8.0 to 13.6%). Conclusions: Applying target trial emulation methods to existing observational data for the evaluation of a novel intervention produced results similar to those of a randomized trial. These findings support the use of target trial emulation for comparative effectiveness research.",2019,"Positive pressure ventilation resulted in lower rates of severe hypoxemia in both the observational analysis (RR 0.60, 95% CI 0.38-0.93) and in the PreVent trial (RR 0.48, 95% CI 0.30-0.77).",[],['positive pressure ventilation'],"['severe hypoxemia', 'severe hypoxemia with positive pressure ventilation', 'oxygen saturation and severe hypoxemia', 'lowest oxygen saturation', 'Positive pressure ventilation', 'lowest oxygen saturation during intubation']",[],"[{'cui': 'C3266857', 'cui_str': 'Positive-Pressure Ventilation'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C3266857', 'cui_str': 'Positive-Pressure Ventilation'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range (finding)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}]",401.0,0.5047,"Positive pressure ventilation resulted in lower rates of severe hypoxemia in both the observational analysis (RR 0.60, 95% CI 0.38-0.93) and in the PreVent trial (RR 0.48, 95% CI 0.30-0.77).","[{'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Admon', 'Affiliation': '1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Donnelly', 'Affiliation': '2Institute for Healthcare Policy and Innovation.'}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Casey', 'Affiliation': '5Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Janz', 'Affiliation': '6Section of Pulmonary/Critical Care & Allergy/Immunology, Louisiana State University School of Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Derek W', 'Initials': 'DW', 'LastName': 'Russell', 'Affiliation': '7Division of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Joffe', 'Affiliation': '8Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.'}, {'ForeName': 'Derek J', 'Initials': 'DJ', 'LastName': 'Vonderhaar', 'Affiliation': '9Department of Pulmonary and Critical Care Medicine, Ochsner Health System New Orleans, New Orleans, Louisiana.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Dischert', 'Affiliation': '9Department of Pulmonary and Critical Care Medicine, Ochsner Health System New Orleans, New Orleans, Louisiana.'}, {'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Stempek', 'Affiliation': '11Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Dargin', 'Affiliation': '11Department of Medicine, Division of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts.'}, {'ForeName': 'Todd W', 'Initials': 'TW', 'LastName': 'Rice', 'Affiliation': '5Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.'}, {'ForeName': 'Theodore J', 'Initials': 'TJ', 'LastName': 'Iwashyna', 'Affiliation': '1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Semler', 'Affiliation': '5Division of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.201903-241OC'] 640,31281343,"The Effect of Combined Patching and Citalopram on Visual Acuity in Adults with Amblyopia: A Randomized, Crossover, Placebo-Controlled Trial.","Nonhuman animal models have demonstrated that selective serotonin reuptake inhibitors (SSRIs) can enhance plasticity within the mature visual cortex and enable recovery from amblyopia. The aim of this study was to test the hypothesis that the SSRI citalopram combined with part-time patching of the fellow fixing eye would improve amblyopic eye visual acuity in adult humans. Following a crossover, randomized, double-blind, placebo-controlled design, participants completed two 2-week blocks of fellow fixing eye patching. One block combined patching with citalopram (20 mg/day) and the other with a placebo tablet. The blocks were separated by a 2-week washout period. The primary outcome was change in amblyopic eye visual acuity. Secondary outcomes included stereoacuity and electrophysiological measures of retinal and cortical function. Seven participants were randomized, fewer than our prespecified sample size of 20. There were no statistically significant differences in amblyopic eye visual acuity change between the active (mean ± SD change = 0.08 ± 0.16 logMAR) and the placebo (mean change = -0.01 ± 0.03 logMAR) blocks. No treatment effects were observed for any secondary outcomes. However, 3 of 7 participants experienced a 0.1 logMAR or greater improvement in amblyopic eye visual acuity in the active but not the placebo blocks. These results from a small sample suggest that larger-scale trials of SSRI treatment for adult amblyopia may be warranted. Considerations for future trials include drug dose, treatment duration, and recruitment challenges. This study was preregistered as a clinical trial (ACTRN12611000669998).",2019,There were no statistically significant differences in amblyopic eye visual acuity change between the active (mean ± SD change = 0.08 ± 0.16 logMAR) and the placebo (mean change = -0.01 ± 0.03 logMAR) blocks.,"['Adults with Amblyopia', 'participants completed two 2-week blocks of fellow fixing eye patching', 'adult humans']","['Combined Patching and Citalopram', 'citalopram', 'placebo', 'Placebo', 'placebo tablet', 'SSRI citalopram combined with part-time patching of the fellow fixing eye', 'SSRI']","['amblyopic eye visual acuity change', 'stereoacuity and electrophysiological measures of retinal and cortical function', 'Visual Acuity', 'amblyopic eye visual acuity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002418', 'cui_str': 'Amblyopia'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0449717', 'cui_str': 'Fixing eye (attribute)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0008845', 'cui_str': 'Citalopram'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449717', 'cui_str': 'Fixing eye (attribute)'}]","[{'cui': 'C0002418', 'cui_str': 'Amblyopia'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1275505', 'cui_str': 'Stereoscopic acuity (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0031843', 'cui_str': 'function'}]",7.0,0.781543,There were no statistically significant differences in amblyopic eye visual acuity change between the active (mean ± SD change = 0.08 ± 0.16 logMAR) and the placebo (mean change = -0.01 ± 0.03 logMAR) blocks.,"[{'ForeName': 'Alice K', 'Initials': 'AK', 'LastName': 'Lagas', 'Affiliation': 'School of Optometry and Vision Science, University of Auckland, New Zealand.'}, {'ForeName': 'Joanna M', 'Initials': 'JM', 'LastName': 'Black', 'Affiliation': 'School of Optometry and Vision Science, University of Auckland, New Zealand.'}, {'ForeName': 'Bruce R', 'Initials': 'BR', 'LastName': 'Russell', 'Affiliation': 'School of Pharmacy, University of Otago, New Zealand.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Kydd', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, New Zealand.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Thompson', 'Affiliation': 'School of Optometry and Vision Science, University of Auckland, New Zealand.'}]",Neural plasticity,['10.1155/2019/5857243'] 641,31359633,Effects of all-out sprint interval training under hyperoxia on exercise performance.,"All-out sprint interval training (SIT) is speculated to be an effective and time-efficient training regimen to improve the performance of aerobic and anaerobic exercises. SIT under hypoxia causes greater improvements in anaerobic exercise performance compared with that under normoxia. The change in oxygen concentration may affect SIT-induced performance adaptations. In this study, we aimed to investigate the effects of all-out SIT under hyperoxia on the performance of aerobic and anaerobic exercises. Eighteen college male athletes were randomly assigned to either the normoxic sprint interval training (NST, n = 9) or hyperoxic (60% oxygen) sprint interval training (HST, n = 9) group and performed 3-week SIT (six sessions) consisting of four to six 30-sec all-out cycling sessions with 4-min passive rest. They performed maximal graded exercise, submaximal exercise, 90-sec maximal exercise, and acute SIT tests on a cycle ergometer before and after the 3-week intervention to evaluate the performance of aerobic and anaerobic exercises. Maximal oxygen uptake significantly improved in both groups. However, blood lactate curve during submaximal exercise test significantly improved only in the HST group. The accumulated oxygen deficit (AOD) during 90-sec maximal exercise test significantly increased only in the NST group. The average values of mean power outputs over four bouts during the acute SIT test significantly improved only in the NST group. These findings suggest that all-out SIT might induce greater improvement in aerobic exercise performance (blood lactate curve) but impair SIT-induced enhancements in anaerobic exercise performance (AOD and mean power output).",2019,The average values of mean power outputs over four bouts during the acute SIT test significantly improved only in the NST group.,['Eighteen college male athletes'],"['maximal graded exercise, submaximal exercise, 90-sec maximal exercise, and acute SIT tests on a cycle ergometer', 'NST', 'sprint interval training under hyperoxia', 'sprint interval training (SIT', 'normoxic sprint interval training (NST, n\xa0=\xa09) or hyperoxic (60% oxygen) sprint interval training (HST, n\xa0=\xa09) group and performed 3-week SIT (six sessions) consisting of four to six 30-sec all-out cycling sessions with 4-min passive rest', 'HST']","['blood lactate curve', 'average values of mean power outputs', 'Maximal oxygen uptake', 'aerobic exercise performance (blood lactate curve', 'anaerobic exercise performance', 'exercise performance', 'accumulated oxygen deficit (AOD', 'anaerobic exercise performance (AOD and mean power output']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0474641', 'cui_str': 'Serum inhibitory titer test (procedure)'}, {'cui': 'C4279979', 'cui_str': 'Sprint Interval Training'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}]","[{'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0445194', 'cui_str': 'Power output (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]",,0.0235937,The average values of mean power outputs over four bouts during the acute SIT test significantly improved only in the NST group.,"[{'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Kon', 'Affiliation': 'School of International Liberal Studies, Chukyo University, Nagoya, Japan.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Nakagaki', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, Tokyo, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Ebi', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, Tokyo, Japan.'}]",Physiological reports,['10.14814/phy2.14194'] 642,31117815,Caregiver outcomes of the REACH-HF multicentre randomized controlled trial of home-based rehabilitation for heart failure with reduced ejection fraction.,"BACKGROUND Caregivers frequently provide support to people living with long-term conditions. However, there is paucity of evidence of interventions that support caregivers in their role. Rehabilitation EnAblement in Chronic Heart Failure (REACH-HF) is a novel home-based, health-professional-facilitated, self-management programme for patients with heart failure (HF) and their caregivers. METHODS Based on the random allocation of individual adult patients with reduced ejection fraction (HFrEF) and left ventricular ejection fraction <45% within the past five years, the caregiver of patients was allocated to receive the REACH-HF intervention over 12 weeks (REACH-HF group) or not (control group). Caregiver outcomes were generic health-related quality of life (EQ-5D-5L), Family Caregiver Quality of Life Scale questionnaire (FamQol), Caregiver Burden Questionnaire HF (CBQ-HF), Caregiver Contribution to Self-care of HF Index questionnaire (CC-SCHFI) and Hospital Anxiety and Depression Scale (HADS). Outcomes were compared between groups at 4, 6 and 12 months follow-up. Twenty caregivers receiving REACH-HF were purposively selected for qualitative interviews at 4 and 12 months. RESULTS Compared with controls (44 caregivers), the REACH-HF group (53 caregivers) had a higher mean CC-SCHFI confidence score at 12 months (57.5 vs 62.8, adjusted mean difference: 9.3, 95% confidence interval: 1.8-16.8, p = 0.016). No significant between group differences were seen in other caregiver outcomes. Qualitative interviews showed that most caregivers who received the REACH-HF intervention made positive changes to how they supported the HF patient they were caring for, and perceived that they had increased their confidence in the caregiver role over time. CONCLUSION Provision of the REACH-HF intervention for caregivers of HF patients improved their confidence of self-management and was perceived for some to be helpful in supporting their caregiver role.",2019,"Compared with controls (44 caregivers), the REACH-HF group (53 caregivers) had a higher mean CC-SCHFI confidence score at 12 months (57.5 vs 62.8, adjusted mean difference:","['patients with heart failure (HF) and their caregivers', 'Twenty caregivers receiving REACH-HF', 'heart failure with reduced ejection fraction', 'caregivers of HF patients', 'individual adult patients with reduced ejection fraction (HFrEF) and left ventricular ejection fraction <45% within the past five years, the caregiver of patients']","['REACH-HF intervention over 12 weeks (REACH-HF group) or not (control group', 'home-based rehabilitation', 'REACH-HF intervention']","['generic health-related quality of life (EQ-5D-5L), Family Caregiver Quality of Life Scale questionnaire (FamQol), Caregiver Burden Questionnaire HF (CBQ-HF), Caregiver Contribution to Self-care of HF Index questionnaire (CC-SCHFI) and Hospital Anxiety and Depression Scale (HADS', 'mean CC-SCHFI confidence score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0451401', 'cui_str': 'Quality of life scale (assessment scale)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.109059,"Compared with controls (44 caregivers), the REACH-HF group (53 caregivers) had a higher mean CC-SCHFI confidence score at 12 months (57.5 vs 62.8, adjusted mean difference:","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wingham', 'Affiliation': 'Primary Care Research Group, University of Exeter Medical School, UK.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Frost', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Nicky', 'Initials': 'N', 'LastName': 'Britten', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Greaves', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, UK.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Abraham', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Fiona C', 'Initials': 'FC', 'LastName': 'Warren', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Jolly', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, UK.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Miles', 'Affiliation': 'Anuerin Bevan University Health Board, Research and Development, Abergavenny, UK.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Paul', 'Affiliation': 'REACH-HF Patient and Public Involvement Group, c/o Royal Cornwall Hospitals NHS Trust, UK.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Doherty', 'Affiliation': 'National Audit of Cardiac Rehabilitation, University of York, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'University Hospitals of Leicester NHS Trust, UK.'}, {'ForeName': 'Russell', 'Initials': 'R', 'LastName': 'Davies', 'Affiliation': 'Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Noonan', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Hasnain', 'Initials': 'H', 'LastName': 'Dalal', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}, {'ForeName': 'Rod S', 'Initials': 'RS', 'LastName': 'Taylor', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, UK.'}]",European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology,['10.1177/1474515119850011'] 643,31050156,"Response of 1,5-anhydroglucitol level to intensive glucose- and blood-pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial.","AIMS To evaluate 1,5-anhydroglucitol (1,5-AG) according to clinical outcomes and assess the effects of glucose- and blood pressure-lowering interventions on change in 1,5-AG levels in people with type 2 diabetes. METHODS We measured 1,5-AG in 6826 stored samples at baseline and in a random subsample of 684 participants at the 1-year follow-up visit in the ADVANCE trial. We examined baseline 1,5-AG [< 39.7, 39.7-66.2, ≥ 66.2 μmol/L (<6, 6-10, ≥10 μg/mL)] and microvascular and macrovascular events and mortality using Cox regression models during 5 years of follow-up. Using an intention-to-treat approach, we examined 1-year change in 1,5-AG (mean and percent) in response to the glucose- and blood pressure-lowering interventions in the subsample. RESULTS Low 1,5-AG level [<39.7 μmol/L vs ≥ 66.2 μmol/L (<6 μg/mL vs ≥10 μg/mL)] was associated with microvascular events (hazard ratio 1.28, 95% confidence interval 1.03-1.60) after adjustment for risk factors and baseline glycated haemoglobin (HbA1c); however, the associations for macrovascular events and mortality were not independent of HbA1c. The glucose-lowering intervention was associated with a significant 1-year increase in 1,5-AG (vs standard control) of 6.69 μmol/L (SE 2.52) [1.01 μg/mL (SE 0.38)], corresponding to an 8.26% (SE 0.10%) increase from baseline. We also observed an increase in 1,5-AG of similar magnitude in response to the blood pressure intervention independent of the glucose-lowering effect. CONCLUSIONS Our results suggest that 1,5-AG is a marker of risk in adults with type 2 diabetes, but only for microvascular events independently of HbA1c. We found that 1,5-AG was improved (increased) in response to an intensive glucose-lowering intervention, although the independent effect of the blood pressure-lowering intervention on 1,5-AG suggests potential non-glycaemic influences.",2019,"/mL)] was associated with microvascular events (hazard ratio 1.28, 95% confidence interval 1.03-1.60) after adjustment for risk factors and baseline glycated haemoglobin (HbA1c); however, the associations for macrovascular events and mortality were not independent of HbA1c.","['adults with type 2 diabetes', 'people with type 2 diabetes', '6826 stored samples at baseline and in a random subsample of 684 participants at the 1-year follow-up visit in the ADVANCE trial']","['glucose- and blood pressure-lowering interventions', 'intensive glucose- and blood-pressure lowering interventions']","['microvascular and macrovascular events and mortality using Cox regression models', 'macrovascular events and mortality', '1,5-AG', 'microvascular events', '1,5-AG levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589121', 'cui_str': 'Follow-up visit (procedure)'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]","[{'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C0684321', 'cui_str': 'Regression'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.102038,"/mL)] was associated with microvascular events (hazard ratio 1.28, 95% confidence interval 1.03-1.60) after adjustment for risk factors and baseline glycated haemoglobin (HbA1c); however, the associations for macrovascular events and mortality were not independent of HbA1c.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Selvin', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'John William', 'Initials': 'JW', 'LastName': 'McEvoy', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Division of General Medicine, Beth Israel Deaconess Medical Centre/Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Lazo', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Hamet', 'Affiliation': ""Department of Medicine, Centre Hospitalier de I'Universite de Montreal (CHUM) | CHUM, Montreal, Quebec, Canada.""}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Cooper', 'Affiliation': 'Diabetes Department, Central Clinical School, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Marre', 'Affiliation': 'Department of Diabetology, Endocrinology, and Nutrition, Assistance Publique-Hôpitaux deParis, Bichat Hospital, France.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Institute of Cardiovascular Sciences, University College London and National Institute of Health Research University College London Hospitals Biomedical Research Centre, United Kingdom.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Harrap', 'Affiliation': 'The University of Melbourne and Royal Melbourne Hospital, Victoria, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chalmers', 'Affiliation': 'The George Institute for Global Health, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Woodward', 'Affiliation': 'Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13755'] 644,30845365,Effect of Alendronic Acid on Fracture Healing: A Multicenter Randomized Placebo-Controlled Trial.,"There is a concern that bisphosphonates may impair fracture healing because of their inhibitory effects on bone turnover. Here we evaluated the effects of early bisphosphonate therapy on fracture healing and functional outcome following a fracture of the distal radius. The fracture and bisphosphonates (FAB) trial was a double-blind, randomized, placebo-controlled trial involving 15 trauma centers in the United Kingdom. We enrolled 421 bisphosphonate-naive patients aged ≥50 years with a radiographically confirmed fracture of the distal radius and randomized them in a 1:1 ratio to receive alendronic acid 70 mg once weekly (n = 215) or placebo (n = 206) within 14 days of the fracture. The primary outcome measure was the proportion of fractures that had radiologically united at 4 weeks as assessed by an observer, blinded to treatment allocation. Secondary outcomes included the Disabilities of the Arm Shoulder and Hand (DASH) questionnaire, range of wrist movement and grip strength, pain and analgesia requirements, and the rate of malunion. The mean ± SD age of participants was 63 ± 8.5 years and 362 (86%) were female. At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36). The absolute proportion difference between groups based on imputed data was 4.5% (95% CI, -4.7% to 13.8%; p = 0.30). There was no significant difference in the proportion of fractures that had united at any other time point and no differences in the DASH score, pain at the fracture site, grip strength, or any other clinical outcome. We conclude that among patients aged 50 years and above with a distal radius fracture, early administration of alendronic acid does not adversely affect fracture union or clinical outcome. These findings suggest bisphosphonate therapy can be safely commenced early after fracture if clinically indicated. © 2019 American Society for Bone and Mineral Research.",2019,"At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36).","['421 bisphosphonate-naive patients aged ≥50 years with a radiographically confirmed fracture of the distal radius and randomized them in a 1:1 ratio to receive', 'patients aged 50 years and above with a distal radius fracture, early administration of', '15 trauma centers in the United Kingdom', '© 2019 American Society for Bone and Mineral Research', 'The mean\u2009±\u2009SD age of participants was 63\u2009±\u20098.5 years and 362 (86%) were female']","['placebo', 'Placebo', 'alendronic acid 70', 'alendronic acid', 'bisphosphonates', 'Alendronic Acid', 'bisphosphonate therapy']","['DASH score, pain at the fracture site, grip strength, or any other clinical outcome', 'fracture healing and functional outcome', 'proportion of fractures that had radiologically united', 'Fracture Healing', 'proportion of fractures', 'Disabilities of the Arm Shoulder and Hand (DASH) questionnaire, range of wrist movement and grip strength, pain and analgesia requirements, and the rate of malunion']","[{'cui': 'C0012544', 'cui_str': 'Bisphosphonates'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0040786', 'cui_str': 'Trauma Centers'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0035168'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0771311', 'cui_str': 'Alendronic acid'}, {'cui': 'C4510264', 'cui_str': 'Disphosphonate therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0162542', 'cui_str': 'Fracture Healing'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C2919270', 'cui_str': 'Disabilities of the arm, shoulder and hand outcome measurement'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]",421.0,0.680244,"At 4 weeks, 48 of 202 (23.8%) fractures had united in the alendronic acid group compared with 52 of 187 (27.8%) in the placebo group (observed absolute proportion difference 4.0%; 95% CI, -4.7% to 12.8%; p = 0.36).","[{'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Duckworth', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'McQueen', 'Affiliation': 'Edinburgh Orthopaedic Trauma, Royal Infirmary of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Tuck', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Jonathan H', 'Initials': 'JH', 'LastName': 'Tobias', 'Affiliation': 'Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Jeremy Mark', 'Initials': 'JM', 'LastName': 'Wilkinson', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Leela C', 'Initials': 'LC', 'LastName': 'Biant', 'Affiliation': 'Trauma & Orthopaedic Surgery, University of Manchester, Manchester, UK.'}, {'ForeName': 'Elizabeth Claire', 'Initials': 'EC', 'LastName': 'Pulford', 'Affiliation': 'Oxford University Hospitals National Health Service (NHS) Foundation Trust, Headington, Oxford, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Aldridge', 'Affiliation': 'The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Edwards', 'Affiliation': 'Norfolk and Norwich University Hospital Foundation Trust, Norwich, UK.'}, {'ForeName': 'Chris P', 'Initials': 'CP', 'LastName': 'Roberts', 'Affiliation': 'Ipswich Hospital NHS Trust, Ipswich, UK.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Ramachandran', 'Affiliation': 'Royal London Hospital, Barts Health NHS Trust, London, UK.'}, {'ForeName': 'Andrew Richard', 'Initials': 'AR', 'LastName': 'McAndrew', 'Affiliation': 'Royal Berkshire Hospital Foundation Trust, Reading, UK.'}, {'ForeName': 'Kenneth Ck', 'Initials': 'KC', 'LastName': 'Cheng', 'Affiliation': 'NHS Ayrshire & Arran, Ayr, UK.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Johnston', 'Affiliation': 'Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Nasir H', 'Initials': 'NH', 'LastName': 'Shah', 'Affiliation': 'Warrington & Halton Hospitals NHS Foundation Trust, Warrington, UK.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Mathew', 'Affiliation': ""Queen's Hospital, Romford, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harvie', 'Affiliation': 'Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Birgit C', 'Initials': 'BC', 'LastName': 'Hanusch', 'Affiliation': 'South Tees, Hospitals NHS Foundation Trust, Middlesbrough, UK.'}, {'ForeName': 'Ronnie', 'Initials': 'R', 'LastName': 'Harkess', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Aryelly', 'Initials': 'A', 'LastName': 'Rodriguez', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Gordon D', 'Initials': 'GD', 'LastName': 'Murray', 'Affiliation': 'Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Stuart H', 'Initials': 'SH', 'LastName': 'Ralston', 'Affiliation': 'Edinburgh Clinical Trials Unit, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3679'] 645,32150492,A Dose-Ranging Study of Epinephrine Hydrofluroalkane Metered-Dose Inhaler (Primatene ® MIST) in Subjects with Intermittent or Mild-to-Moderate Persistent Asthma.,"Background: Two sequential single-dose crossover dose-ranging studies were performed to evaluate the clinical efficacy and safety profile of epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation at various doses in subjects with asthma. Methods: In these multicenter, multiarm, double-blinded, or evaluator-blinded studies, subjects were randomized to receive the epinephrine HFA (Primatene ® MIST HFA) MDI medication at doses ranging from 90 to 440 μg/dose, as well as to a placebo (PLA) control and an active control of epinephrine CFC (chlorofluorocarbon) MDI (Primatene ® MIST CFC) at 220 μg/inhalation. Results: Spirometry testing for FEV1 (Forced Expiratory Volume in one second) demonstrated statistically significant improvements over PLA for epinephrine HFA MDI at all doses above 125 μg, as the amount out of the actuator (i.e., mouthpiece). The efficacy results for epinephrine HFA MDI in the dose range of 125-250 μg were also comparable to epinephrine CFC MDI (220 μg/inh). Safety assessments demonstrated minimal safety concerns for all treatment groups. No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. Conclusion: The findings indicate that epinephrine HFA MDI provided clinically significant bronchodilator efficacy with minimal safety concerns in a dose range of 125-250 μg. These findings confirmed the optimal treatment doses of 125-250 μg that were appropriate for use in longer term 12 and 26 week chronic dosing studies of epinephrine HFA MDI for patients with intermittent or mild to moderate persistent asthma. Clinical trials registration number: NCT01025648.",2020,No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. ,"['subjects with asthma', 'Subjects with Intermittent or Mild-to-Moderate Persistent Asthma', 'patients with intermittent or mild to moderate persistent asthma']","['epinephrine CFC MDI', 'epinephrine HFA (Primatene ® MIST HFA', 'epinephrine CFC (chlorofluorocarbon) MDI (Primatene MIST CFC', 'Epinephrine Hydrofluroalkane Metered-Dose Inhaler (Primatene ® MIST', 'epinephrine HFA MDI', 'epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation']","['bronchodilator efficacy', 'minimal safety concerns', 'FEV1 (Forced Expiratory Volume']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0993596', 'cui_str': 'Metered Dose Inhaler'}, {'cui': 'C0722799', 'cui_str': 'Primatene'}, {'cui': 'C0475209', 'cui_str': 'm'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}]","[{'cui': 'C0006280', 'cui_str': 'Bronchodilators'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}]",,0.109318,No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control formulation of epinephrine CFC MDI. ,"[{'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Kerwin', 'Affiliation': 'Clinical Research Institute of Southern Oregon, Medford, Oregon.'}, {'ForeName': 'Donald P', 'Initials': 'DP', 'LastName': 'Tashkin', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Murphy', 'Affiliation': 'Charleston ENT and Allergy, Charleston, South Carolina.'}, {'ForeName': 'George W', 'Initials': 'GW', 'LastName': 'Bensch', 'Affiliation': 'Allergy, Immunology, and Asthma Medical Group, Inc., Stockton, California.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Marrs', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}, {'ForeName': 'Mary Z', 'Initials': 'MZ', 'LastName': 'Luo', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}, {'ForeName': 'Jack Y', 'Initials': 'JY', 'LastName': 'Zhang', 'Affiliation': 'Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California.'}]",Journal of aerosol medicine and pulmonary drug delivery,['10.1089/jamp.2019.1558'] 646,31404020,"SpHincterotomy for Acute Recurrent Pancreatitis Randomized Trial: Rationale, Methodology, and Potential Implications.","OBJECTIVES In patients with acute recurrent pancreatitis (ARP), pancreas divisum, and no other etiologic factors, endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES) is often performed to enlarge the minor papillary orifice, based on limited data. The aims of this study are to describe the rationale and methodology of a sham-controlled clinical trial designed to test the hypothesis that miES reduces the risk of acute pancreatitis. METHODS The SpHincterotomy for Acute Recurrent Pancreatitis (SHARP) trial is a multicenter, international, sham-controlled, randomized trial comparing endoscopic ultrasound + ERCP with miES versus endoscopic ultrasound + sham for the management of ARP. A total of 234 consented patients having 2 or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis will be randomized. Both cohorts will be followed for a minimum of 6 months and a maximum of 48 months. RESULTS The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency. CONCLUSIONS The SHARP trial will determine whether ERCP with miES benefits patients with idiopathic ARP and pancreas divisum. Trial planning has informed the importance of blinded outcome assessors and long-term follow-up.",2019,"The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency. ","['patients with idiopathic ARP and pancreas divisum', 'patients with acute recurrent pancreatitis (ARP', '234 consented patients having 2 or more discrete episodes of acute pancreatitis, pancreas divisum confirmed by magnetic resonance cholangiopancreatography, and no other clear etiology for acute pancreatitis']","['endoscopic retrograde cholangiopancreatography (ERCP) with minor papilla endoscopic sphincterotomy (miES', 'ERCP', 'SpHincterotomy', 'endoscopic ultrasound + ERCP with miES versus endoscopic ultrasound + sham']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C0266270', 'cui_str': 'Pancreas divisum (disorder)'}, {'cui': 'C0267937', 'cui_str': 'Acute recurrent pancreatitis (disorder)'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0001339', 'cui_str': 'Acute pancreatitis (disorder)'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C0994163', 'cui_str': 'Cholangiopancreatography, Magnetic Resonance'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C0015127', 'cui_str': 'causes'}]","[{'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0026193', 'cui_str': 'Minors'}, {'cui': 'C0085263', 'cui_str': 'Endoscopic Biliary Sphincterotomy'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}, {'cui': 'C0376443', 'cui_str': 'Ultrasonography, Endoscopic'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]",[],,0.297322,"The trial is powered to detect a 33% risk reduction of acute pancreatitis frequency. ","[{'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Coté', 'Affiliation': 'From the Department of Medicine.'}, {'ForeName': 'Valerie L', 'Initials': 'VL', 'LastName': 'Durkalski-Mauldin', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Serrano', 'Affiliation': 'Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Klintworth', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'April W', 'Initials': 'AW', 'LastName': 'Williams', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Zobeida', 'Initials': 'Z', 'LastName': 'Cruz-Monserrate', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Arain', 'Affiliation': 'Department of Medicine, University of California, San Francisco, San Francisco.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Buxbaum', 'Affiliation': 'Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA.'}, {'ForeName': 'Darwin L', 'Initials': 'DL', 'LastName': 'Conwell', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Evan L', 'Initials': 'EL', 'LastName': 'Fogel', 'Affiliation': 'Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.'}, {'ForeName': 'Martin L', 'Initials': 'ML', 'LastName': 'Freeman', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Timothy B', 'Initials': 'TB', 'LastName': 'Gardner', 'Affiliation': 'Department of Medicine, Dartmouth Geisel School of Medicine, Lebanon, NH.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'van Geenen', 'Affiliation': 'Division of Gastroenterology and Hepatology, University Medical Center St Radboud, Nijmegen, Netherlands.'}, {'ForeName': 'J Royce', 'Initials': 'JR', 'LastName': 'Groce', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition.'}, {'ForeName': 'Sreenivasa S', 'Initials': 'SS', 'LastName': 'Jonnalagadda', 'Affiliation': ""Saint Luke's GI Specialists, Saint Luke's Hospital, Kansas City, MO.""}, {'ForeName': 'Rajesh N', 'Initials': 'RN', 'LastName': 'Keswani', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.'}, {'ForeName': 'Shyam', 'Initials': 'S', 'LastName': 'Menon', 'Affiliation': 'Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.'}, {'ForeName': 'Dana C', 'Initials': 'DC', 'LastName': 'Moffatt', 'Affiliation': 'Department of Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.'}, {'ForeName': 'Georgios I', 'Initials': 'GI', 'LastName': 'Papachristou', 'Affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Ross', 'Affiliation': 'Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA.'}, {'ForeName': 'Paul R', 'Initials': 'PR', 'LastName': 'Tarnasky', 'Affiliation': 'Methodist Health System, Dallas, TX.'}, {'ForeName': 'Andrew Y', 'Initials': 'AY', 'LastName': 'Wang', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'C Mel', 'Initials': 'CM', 'LastName': 'Wilcox', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hamilton', 'Affiliation': 'Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.'}, {'ForeName': 'Dhiraj', 'Initials': 'D', 'LastName': 'Yadav', 'Affiliation': 'Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pancreas,['10.1097/MPA.0000000000001370'] 647,31423757,Effect of different walking break strategies on superficial femoral artery endothelial function.,"Breaking up prolonged sitting with physical activity (PA) breaks prevents conduit artery dysfunction. However, the optimal break strategy to achieve this, in terms of the frequency or duration of PA, is not known. This study assessed the effect of breaking up sitting with different PA break strategies on lower limb peripheral artery endothelial function. Fifteen participants (10 male, 35.8 ± 10.2 years, BMI: 25.5 ± 3.2 kg m -2 ) completed, on separate days, three 4-h conditions in a randomized order: (1) uninterrupted sitting (SIT), (2) sitting with 2-min light-intensity walking breaks every 30 min (2WALK), or (3) sitting with 8-min light-intensity walking breaks every 2 h (8WALK). At baseline and 4 h, superficial femoral artery function (flow-mediated dilation; FMD), blood flow, and shear rate (SR) were assessed using Doppler ultrasound. For each condition, the change in outcome variables was calculated and data were statistically analyzed using a linear mixed model. There was no significant main effect for the change in FMD (P = 0.564). A significant main effect was observed for the change in blood flow (P = 0.022), with post hoc analysis revealing a greater reduction during SIT (-42.7 ± 14.2 mL·min) compared to 8WALK (0.45 ± 17.7 mL·min; P = 0.012). There were no significant main effects for mean, antegrade, or retrograde SR (P > 0.05). Superficial femoral artery blood flow, but not FMD, was reduced following uninterrupted sitting. This decline in blood flow was prevented with longer duration, less frequent walking breaks rather than shorter, more frequent breaks suggesting the dose (duration and frequency) of PA may influence the prevention of sitting-induced decreases in blood flow.",2019,"A significant main effect was observed for the change in blood flow (P = 0.022), with post hoc analysis revealing a greater reduction during SIT (-42.7 ± 14.2 mL·min) compared to 8WALK (0.45 ± 17.7 ","['Fifteen participants (10 male, 35.8\xa0±\xa010.2\xa0years, BMI: 25.5\xa0±\xa03.2\xa0kg']","['breaking up sitting with different PA break strategies', 'walking break strategies', 'Breaking up prolonged sitting with physical activity (PA) breaks', '1) uninterrupted sitting (SIT), (2) sitting with 2-min light-intensity walking breaks']","['superficial femoral artery endothelial function', 'superficial femoral artery function (flow-mediated dilation; FMD), blood flow, and shear rate (SR', 'lower limb peripheral artery endothelial function', 'conduit artery dysfunction', 'blood flow', 'FMD', 'Superficial femoral artery blood flow', 'mean, antegrade, or retrograde SR']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517663', 'cui_str': 'Twenty-five point five'}, {'cui': 'C4517687', 'cui_str': '3.2'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}]","[{'cui': 'C0447106', 'cui_str': 'Superficial femoral artery (body structure)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}, {'cui': 'C0441247', 'cui_str': 'Conduit (physical object)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0677513', 'cui_str': 'Antegrade (qualifier value)'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction (qualifier value)'}]",15.0,0.0277428,"A significant main effect was observed for the change in blood flow (P = 0.022), with post hoc analysis revealing a greater reduction during SIT (-42.7 ± 14.2 mL·min) compared to 8WALK (0.45 ± 17.7 ","[{'ForeName': 'Sophie E', 'Initials': 'SE', 'LastName': 'Carter', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Draijer', 'Affiliation': 'Unilever Research and Development, Vlaardingen, The Netherlands.'}, {'ForeName': 'Sophie M', 'Initials': 'SM', 'LastName': 'Holder', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Brown', 'Affiliation': 'Unilever Research and Development, Bedfordshire, United Kingdom.'}, {'ForeName': 'Dick H J', 'Initials': 'DHJ', 'LastName': 'Thijssen', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Nicola D', 'Initials': 'ND', 'LastName': 'Hopkins', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}]",Physiological reports,['10.14814/phy2.14190'] 648,31434161,Integration of a Commercial Barcode-Assisted Medication Dispensing System in a Teaching Hospital.,"OBJECTIVES A commercial barcode-assisted medication administration (BCMA) system was integrated to secure the medication process and particularly the dispensing stage by technicians and the administration stage with nurses. We aimed to assess the impact of this system on medication dispensing errors and barriers encountered during integration process. METHODS We conducted a controlled randomized study in a teaching hospital, during dispensing process at the pharmacy department. Four wards were randomized in the experimental group and control group, with two wards using the system during 3 days with dedicated pharmacy technicians. The system was a closed loop system without information return to the computerized physician order entry system. The two dedicated technicians had a 1-week training session. Observations were performed by one observer among the four potential observers previously trained. The main outcomes assessed were dispensing error rates and the identification of barriers encountered to expose lessons learned from this study. RESULTS There was no difference between the dispensing error rate of the control and experimental groups (7.9% for both, p  = 0.927). We identified 10 barriers to pharmacy barcode-assisted system technology deployment. They concerned technical (problems with semantic interoperability interfaces, bad user interface, false errors generated, lack of barcodes), structural (poor integration with local information technology), work force (short staff training period, insufficient workforce), and strategic issues (system performance problems, insufficient budget). CONCLUSION This study highlights the difficulties encountered in integrating a commercial system in current hospital information systems. Several issues need to be taken into consideration before the integration of a commercial barcode-assisted system in a teaching hospital. In our experience, interoperability of this system with the electronic health record is the key for the success of this process with an entire closed loop system from prescription to administration. BCMA system at the dispensing process remains essential to purchase securing medication administration process.",2019,"There was no difference between the dispensing error rate of the control and experimental groups (7.9% for both, p  = 0.927).",[],"['pharmacy barcode-assisted system technology deployment', 'Commercial Barcode-Assisted Medication Dispensing System', 'commercial barcode-assisted medication administration (BCMA) system']","['dispensing error rate', 'dispensing error rates and the identification of barriers encountered to expose lessons learned from this study']",[],"[{'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C3469597', 'cui_str': 'Medication treatment'}]","[{'cui': 'C0020792', 'cui_str': 'Identification'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",,0.0504472,"There was no difference between the dispensing error rate of the control and experimental groups (7.9% for both, p  = 0.927).","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Berdot', 'Affiliation': 'Department of Pharmacy, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Abdelali', 'Initials': 'A', 'LastName': 'Boussadi', 'Affiliation': 'Equipe 22, Centre de Recherche des Cordeliers, UMR 1138 INSERM, Paris, France.'}, {'ForeName': 'Aurélie', 'Initials': 'A', 'LastName': 'Vilfaillot', 'Affiliation': 'Unité de Recherche Clinique, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Depoisson', 'Affiliation': 'Department of Pharmacy, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Claudine', 'Initials': 'C', 'LastName': 'Guihaire', 'Affiliation': 'Hospital Nursing staff (DSAP), Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Durieux', 'Affiliation': 'Equipe 22, Centre de Recherche des Cordeliers, UMR 1138 INSERM, Paris, France.'}, {'ForeName': 'Laetitia Minh Maï', 'Initials': 'LMM', 'LastName': 'Le', 'Affiliation': 'Department of Pharmacy, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Sabatier', 'Affiliation': 'Department of Pharmacy, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.'}]",Applied clinical informatics,['10.1055/s-0039-1694749'] 649,31814853,Effects of Alternating Standing and Sitting Compared to Prolonged Sitting on Cerebrovascular Hemodynamics.,"Purpose Previous research suggests that prolonged sitting may acutely reduce cerebral blood flow velocity (CBFv). The purpose of this study was to evaluate the effects of alternating standing and sitting vs prolonged sitting on CBFv. Methods This randomized crossover study enrolled working adults (N=25) with pre-to-stage 1 hypertension not using antihypertensive medications, and a body mass index from 25 to < 40 kg/m 2 . Subjects participated in two simulated workday conditions: 1) sitting continuously (SIT), and 2) alternating standing and sitting every 30 min (SS). Beat-to-beat systolic, mean and diastolic CBFv were recorded bilaterally for 1 min via insonation of the middle cerebral artery using transcranial Doppler ultrasonography before (morning), between (midday) and following (afternoon) two 3-hr 40 min work periods. Results Mean±SD age was 42±12 years, blood pressure (BP) was 132±9/83±8 mmHg, and BMI was 32±5 kg/m 2 . Cerebrovascular hemodynamics did not differ across condition (P>0.05). There were, however, significant nonlinear effects of time (decrease from morning to midday; increase from midday to afternoon) on systolic CBFv (P=0.014), mean CBFv (P=0.001), diastolic CBFv (P=0.002), and pulsatility index (P=0.038). When overall time effects were evaluated during each time interval, mean and diastolic CBFv significantly decreased morning to midday and all CBFv increased from midday to afternoon. When separated by condition, significant time effects were observed for all CBFv during SIT (P<0.02) but not SS (P>0.05). Conclusions In individuals with elevated BP and BMI, CBFv significantly decreased by midday and increased by afternoon, especially during a workday of prolonged sitting. Future studies should evaluate the combination of frequent walks and a sit-stand desk to break up prolonged sitting.",2019,"When separated by condition, significant time effects were observed for all CBFv during SIT (P<0.02) but not SS (P>0.05). ","['enrolled working adults (N=25) with pre-to-stage 1 hypertension not using antihypertensive medications, and a body mass index from 25 to < 40 kg/m 2 ']","['sitting continuously (SIT), and 2) alternating standing and sitting every 30 min (SS', 'alternating standing and sitting vs prolonged sitting', 'Alternating Standing and Sitting Compared to Prolonged Sitting']","['blood pressure (BP', 'elevated BP and BMI, CBFv', 'Beat-to-beat systolic, mean and diastolic CBFv', 'Cerebrovascular hemodynamics', 'pulsatility index', 'diastolic CBFv', 'time interval, mean and diastolic CBFv', 'overall time effects', 'systolic CBFv', 'mean CBFv', 'Cerebrovascular Hemodynamics', 'cerebral blood flow velocity (CBFv']","[{'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0445107', 'cui_str': 'Not used (qualifier value)'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C0332270', 'cui_str': 'Alternating (qualifier value)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0429863', 'cui_str': 'Pulsatility index, arterial velocity waveform'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0428714', 'cui_str': 'Cerebral Blood Flow'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",40.0,0.0373242,"When separated by condition, significant time effects were observed for all CBFv during SIT (P<0.02) but not SS (P>0.05). ","[{'ForeName': 'Sophy J', 'Initials': 'SJ', 'LastName': 'Perdomo', 'Affiliation': 'Department of Health and Physical Activity, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Bethany Barone', 'Initials': 'BB', 'LastName': 'Gibbs', 'Affiliation': 'Department of Health and Physical Activity, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Kowalsky', 'Affiliation': 'Department of Health and Physical Activity, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Taormina', 'Affiliation': 'Department of Health and Physical Activity, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Balzer', 'Affiliation': 'Neurological Surgery, University of Pittsburgh, Pittsburgh, PA.'}]",Sport sciences for health,['10.1007/s11332-019-00526-4'] 650,32153038,Conservative therapies to treat pain and anxiety associated with temporomandibular disorders: a randomized clinical trial.,"INTRODUCTION Temporomandibular dysfunction (TMD) is a condition that affects the stomatognathic system. OBJECTIVE To determine the effect of treatment with an occlusal splint (OS), manual therapy (MT), counselling (CS) and the combination of an occlusal splint and counselling (OSCS) on pain and anxiety in patients with TMD. MATERIALS AND METHODS A randomised clinical trial was conducted with 89 patients diagnosed with TMD through RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders) and divided into four groups of treatment: OSCS (n = 25); OS (n = 24); MT (n = 21); and CS (n = 19). Participants were assessed before and after 1 month of therapy for pain, anxiety and TMD diagnosis. Pain was measured by a visual analogue scale. To assess anxiety, Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory (BAI) and the State-Trait Anxiety Inventory (STAI-S and T) were used. The data were analysed using SPSS (Statistical Package for Social Science) 22.0. RESULTS The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment. Treatment in all groups promoted a significant reduction in anxiety symptoms 1 month after completion, HADS (P < 0.001), BAI (P < 0.001), STAI-T (P = 0.006). Thus, no group was superior to the other in reducing the studied variables. CONCLUSION The therapies used were effective in reducing pain and anxiety in patients diagnosed with TMD. However, no treatment was superior to the other in reducing the studied variables.",2020,The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment.,"['patients diagnosed with TMD', 'pain and anxiety associated with temporomandibular disorders', '89 patients diagnosed with TMD through RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders', 'patients with TMD']","['occlusal splint (OS), manual therapy (MT), counselling (CS) and the combination of an occlusal splint and counselling (OSCS', 'OSCS', 'Conservative therapies']","['pain and anxiety', 'anxiety symptoms', 'Pain', 'BAI', 'pain', 'pain, anxiety and TMD diagnosis', 'anxiety, Hospital Anxiety and Depression Scale (HADS), Beck Anxiety Inventory (BAI) and the State-Trait Anxiety Inventory (STAI-S and T']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0039494', 'cui_str': 'TMJ Diseases'}, {'cui': 'C0035168'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0162528', 'cui_str': 'Occlusal Splints'}, {'cui': 'C0454525', 'cui_str': 'Manual Therapies'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0459914', 'cui_str': 'Conservative Management'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",89.0,0.0715685,The four groups obtained a significant reduction (P < 0.001) in the pain after 1 month of treatment.,"[{'ForeName': 'Rafaela Albuquerque', 'Initials': 'RA', 'LastName': 'Melo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Camila Maria Bastos Machado', 'Initials': 'CMBM', 'LastName': 'de Resende', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Cássia Renata de Figueirêdo', 'Initials': 'CRF', 'LastName': 'Rêgo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Andressa de Sousa Leite', 'Initials': 'ASL', 'LastName': 'Bispo', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Gustavo Augusto Seabra', 'Initials': 'GAS', 'LastName': 'Barbosa', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}, {'ForeName': 'Erika Oliveira', 'Initials': 'EO', 'LastName': 'de Almeida', 'Affiliation': 'Department of Dentistry, Universidade Federal, do Rio Grande do Norte (UFRN), Natal, Brazil.'}]",International dental journal,['10.1111/idj.12546'] 651,32153154,Cardiac biomarkers and left ventricular systolic function in acute myocardial infarction with ST- segment elevation in diabetes mellitus type 2 patients.,"Aim To determine a status of systolic function in patients with diabetes mellitus (DM) type 2 with ST-segment elevation acute myocardial infarction (STEMI), to determine values of cardiac biomarkers in patients with DM type 2 with STEMI and correlate the parameters with ejection fraction of left ventricle (EFLV). Methods A total of 80 patients were divided into two groups, the study group (group I) consisting of 40 patients admitted with the diagnosis of DM type 2 and STEMI, and a control group (group II) with 40 patients with STEMI without diagnosed DM type 2. Cardiac biomarkers - creatine kinase MB fraction (CKMB), and troponin I were monitored. The EFLV was evaluated echocardiographically (using Simpson method) five days after primary percutaneous coronary intervention (pPCI). Results In the group I the EFLV five days after pPCI was significantly correlated with troponin values (with a minimum r = -0.47; p=0.002, a maximum r = -0.339; p = 0.032, as well as with an average value of r = -0.389; p=0.013), and with an average CK value (r = -0.319; p=0.045). In the group II there was a significant negative correlation of EFLV with the maximum value of troponin (r = -0.309; p=0.05). Conclusion Troponin values have an effect on the EFLV after STEMI, and thus on the left ventricular status, as well as on the pharmacological modality itself.",2020,"In the group I the EFLV five days after pPCI was significantly correlated with troponin values (with a minimum r = -0.47; p=0.002, a maximum r =","['patients with DM type 2 with STEMI and correlate the parameters with ejection fraction of left ventricle (EFLV', 'patients with diabetes mellitus (DM) type 2 with ST-segment elevation acute myocardial infarction (STEMI', 'diabetes mellitus type 2 patients', 'acute myocardial infarction', '80 patients were divided into two groups, the study group (group I) consisting of 40 patients admitted with the diagnosis of DM type 2 and STEMI, and a control group (group II) with 40 patients with STEMI without diagnosed DM type 2']",['ST- segment elevation'],"['troponin values', 'Cardiac biomarkers - creatine kinase MB fraction (CKMB), and troponin', 'average CK value', 'systolic function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0018827', 'cui_str': 'Heart Ventricle'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation (finding)'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0441843', 'cui_str': 'Group I (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0520886', 'cui_str': 'ST segment elevation (finding)'}]","[{'cui': 'C0523952', 'cui_str': 'Troponin measurement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0523584', 'cui_str': 'Creatine kinase MB measurement'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0031843', 'cui_str': 'function'}]",80.0,0.0264964,"In the group I the EFLV five days after pPCI was significantly correlated with troponin values (with a minimum r = -0.47; p=0.002, a maximum r =","[{'ForeName': 'Mirela', 'Initials': 'M', 'LastName': 'Halilčević', 'Affiliation': 'Department of Cardiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Center University of Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Edin', 'Initials': 'E', 'LastName': 'Begić', 'Affiliation': 'Department of Cardiology, General Hospital ""Prim.dr. Abdulah Nakaš"", Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Alen', 'Initials': 'A', 'LastName': 'Džubur', 'Affiliation': 'Department of Cardiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Center University of Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Nirvana', 'Initials': 'N', 'LastName': 'Šabanović-Bajramović', 'Affiliation': 'Department of Cardiology, Clinic for Heart, Blood Vessel and Rheumatic Diseases, Clinical Center University of Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Mevludin', 'Initials': 'M', 'LastName': 'Mekić', 'Affiliation': 'Department of Rheumatology, Clinic for Heart, Blood Vessels and Rheumatic Diseases, Clinical Center University of Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Malik', 'Initials': 'M', 'LastName': 'Ejubović', 'Affiliation': 'Department of Internal Medicine, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina.'}, {'ForeName': 'Amela', 'Initials': 'A', 'LastName': 'Džubur', 'Affiliation': 'Department for Social Medicine, School of Medicine, Univesity of Sarajevo, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Ena', 'Initials': 'E', 'LastName': 'Štimjanin', 'Affiliation': 'Department of Internal Medicine, Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1094-20'] 652,31124023,Effectiveness of Facebook Groups to Boost Participation in a Parenting Intervention.,"Although family-based prevention programs have been shown to be effective at reducing adolescent substance use, it is often difficult and costly to recruit and retain parents in programs administered in person. The current study tested whether program engagement and parenting practices could be improved by offering parents in a self-directed family program access to a private Facebook group. Parents of middle school children (N = 103) were recruited through paid Facebook ads to a 5-week self-directed teen substance use prevention program to be completed at home together by parents and their children. Two thirds of parents (N = 72) were randomly assigned to a moderated private Facebook group that provided a forum for parents in the study to interact with each other, and one third (N = 31) were randomized to use the intervention materials without additional support. Relatively few parents participated in the Facebook group and most did not find the experience useful. However, satisfaction with the program assessed 3 months after program completion was high among all parents and most parents engaged with the materials, irrespective of Facebook group assignment. Overall, parents reported significantly lower conflict and more household rules 6 months post-intervention compared to baseline. Parenting practices did not change more among those assigned to the Facebook group than among parents who used the materials on their own. The current findings suggest that providing opportunities for parents to interact online while participating in a self-directed family intervention may not help to increase engagement or improvements in parenting practices, particularly when few parents engage with each other.",2019,Parenting practices did not change more among those assigned to the Facebook group than among parents who used the materials on their own.,"['Two\xa0thirds of parents (N\u2009=\u200972', 'Parents of middle school children (N\u2009=\u2009103) were recruited through paid Facebook ads to a 5-week self-directed teen substance use prevention program to be completed at home together by parents and their children']","['intervention materials without additional support', 'moderated private Facebook', 'Facebook']",[],"[{'cui': 'C0205437', 'cui_str': 'Third (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0557797', 'cui_str': 'Middle school (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517526', 'cui_str': 'One hundred and three'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0150358', 'cui_str': 'Substance use prevention (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}]",[],103.0,0.0303321,Parenting practices did not change more among those assigned to the Facebook group than among parents who used the materials on their own.,"[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Epstein', 'Affiliation': 'Social Development Research Group, School of Social Work, University of Washington, 9725 3rd Ave NE, Suite 401, Seattle, WA, 98115, USA. marinaep@uw.edu.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Oesterle', 'Affiliation': 'Social Development Research Group, School of Social Work, University of Washington, 9725 3rd Ave NE, Suite 401, Seattle, WA, 98115, USA.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Haggerty', 'Affiliation': 'Social Development Research Group, School of Social Work, University of Washington, 9725 3rd Ave NE, Suite 401, Seattle, WA, 98115, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-019-01018-0'] 653,31138568,"Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers.","ASN100 is a novel antibody combination of two fully human IgG1(κ) monoclonal antibodies (MAbs), ASN-1 and ASN-2, which neutralize six Staphylococcus aureus cytotoxins, alpha-hemolysin (Hla) and five bicomponent leukocidins. We assessed the safety, tolerability, and serum and lung pharmacokinetics of ASN100 in a randomized, double-blind, placebo-controlled single-dose-escalation first-in-human study. Fifty-two healthy volunteers were enrolled and randomized to receive either ASN-1, ASN-2, a combination of both MAbs (ASN100), or a corresponding placebo. Thirty-two subjects in the double-blind dose escalation portion of the study received ASN-1 or ASN-2 at a 200-, 600-, 1,800-, or 4,000-mg dose, or placebo. Eight subjects received both MAbs simultaneously in a 1:1 ratio (ASN100) at 3,600 or 8,000 mg, or they received placebos. Twelve additional subjects received open-label ASN100 at 3,600 or 8,000 mg to assess the pharmacokinetics of ASN-1 and ASN-2 in epithelial lining fluid (ELF) by bronchoalveolar lavage fluid sampling. Subjects were monitored for 98 days (double-blind cohorts) or 30 days (open-label cohorts) for safety assessment. No dose-limiting toxicities were observed, and all adverse events were mild and transient, with only two adverse events considered possibly related to the investigational product. ASN100 exhibited linear serum pharmacokinetics with a half-life of approximately 3 weeks and showed detectable penetration into the ELF. No treatment-emergent anti-drug antibody responses were detected. The toxin neutralizing potency of ASN100 in human serum was confirmed up to 58 days postdosing. The favorable safety profile, ELF penetration, and maintained functional activity in serum supported the further clinical development of ASN100.",2019,ASN100 exhibited linear serum PK with a half-life of approximately three weeks and showed detectable penetration into the ELF.,"['Lung Epithelial Lining Fluid', 'Healthy Volunteers', 'Twelve additional subjects received', 'Fifty-two healthy volunteers']","['placebo', 'Monoclonal Antibody Combination (ASN100', 'Placebo', 'ASN100', 'ASN-1, ASN-2, or a combination of both mAbs (ASN100), or corresponding placebo', 'ASN-1 or ASN-2', 'placebos', 'open-label ASN100']","['No dose-limiting toxicities', 'safety, tolerability, and serum and lung pharmacokinetics of ASN100']","[{'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319570', 'cui_str': 'Fifty-two'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]",,0.259477,ASN100 exhibited linear serum PK with a half-life of approximately three weeks and showed detectable penetration into the ELF.,"[{'ForeName': 'Zoltan', 'Initials': 'Z', 'LastName': 'Magyarics', 'Affiliation': 'Arsanis Biosciences GmbH, Vienna, Austria Zoltan.Magyarics@x4pharma.com bernd.jilma@meduniwien.ac.at.'}, {'ForeName': 'Fraser', 'Initials': 'F', 'LastName': 'Leslie', 'Affiliation': 'Arsanis, Inc., Waltham, Massachusetts USA.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Bartko', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Rouha', 'Affiliation': 'Arsanis Biosciences GmbH, Vienna, Austria.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Luperchio', 'Affiliation': 'Arsanis, Inc., Waltham, Massachusetts USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schörgenhofer', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schwameis', 'Affiliation': 'Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Ulla', 'Initials': 'U', 'LastName': 'Derhaschnig', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Heimo', 'Initials': 'H', 'LastName': 'Lagler', 'Affiliation': 'Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Leopold', 'Initials': 'L', 'LastName': 'Stiebellehner', 'Affiliation': 'Department of Internal Medicine II, Division of Pulmonology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Firbas', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Weber', 'Affiliation': 'Arsanis Biosciences GmbH, Vienna, Austria.'}, {'ForeName': 'Ed', 'Initials': 'E', 'LastName': 'Campanaro', 'Affiliation': 'Arsanis, Inc., Waltham, Massachusetts USA.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Jilma', 'Affiliation': 'Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria Zoltan.Magyarics@x4pharma.com bernd.jilma@meduniwien.ac.at.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Nagy', 'Affiliation': 'EveliQure Biotechnologies GmbH, Vienna, Austria.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Stevens', 'Affiliation': 'Arsanis, Inc., Waltham, Massachusetts USA.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00350-19'] 654,31135357,Debiasing-Based Noise Suppression for Ultrafast Ultrasound Microvessel Imaging.,"Ultrasound microvessel imaging (UMI) based on the combination of singular value decomposition (SVD) clutter filtering and ultrafast plane wave imaging has recently demonstrated significantly improved Doppler sensitivity, especially to small vessels that are invisible to conventional Doppler imaging. Practical implementation of UMI is hindered by the high computational cost associated with SVD and low blood signal-to-noise ratio (SNR) in deep regions of the tissue due to the lack of transmit focusing of plane waves. Concerning the high computational cost, an accelerated SVD clutter filtering method based on randomized SVD (rSVD) and randomized spatial downsampling (rSD) was recently proposed by our group, which showed the feasibility of real-time implementation of UMI. Concerning the low blood flow SNR in deep imaging regions, here we propose a noise suppression method based on noise debiasing that can be easily applied to the accelerated SVD method to bridge the gap between real-time implementation and high imaging quality. The proposed method experimentally measures the noise-induced bias by collecting the noise signal using the identical imaging sequence as regular UMI, but with the ultrasound transmission turned off. The estimated bias can then be subtracted from the original power Doppler (PD) image to obtain effective noise suppression. The feasibility of the proposed method was validated under different ultrasound imaging parameters [including transmitting voltages and time-gain compensation (TGC) settings] with a phantom experiment. The noise-debiased images showed an increase of up to 15.3 and 13.4 dB in SNR as compared to original PD images on the blood flow phantom and an in vivo human kidney data set, respectively. The proposed noise suppression method has negligible computational cost and can be conveniently combined with the previously proposed accelerated SVD clutter filtering technique to achieve high quality, real-time UMI imaging.",2019,"The proposed noise suppression method has negligible computational cost and can be conveniently combined with the previously proposed accelerated SVD clutter filtering technique to achieve high quality, real-time UMI imaging.",[],['Ultrasound microvessel imaging (UMI'],[],[],"[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C2350570', 'cui_str': 'Microvessels'}]",[],,0.0137576,"The proposed noise suppression method has negligible computational cost and can be conveniently combined with the previously proposed accelerated SVD clutter filtering technique to achieve high quality, real-time UMI imaging.","[{'ForeName': 'Chengwu', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Song', 'Affiliation': ''}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Gong', 'Affiliation': ''}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Trzasko', 'Affiliation': ''}, {'ForeName': 'Armando', 'Initials': 'A', 'LastName': 'Manduca', 'Affiliation': ''}, {'ForeName': 'Shigao', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': ''}]","IEEE transactions on ultrasonics, ferroelectrics, and frequency control",['10.1109/TUFFC.2019.2918180'] 655,31977698,The Efficacy and Safety of Submandibular Transcatheter Perfusion Anesthesia in Submandibular Gland Surgery.,"The present study aims to evaluate the feasibility, safety, and effects of the combined use of submandibular transcatheter perfusion with lingual nerve block and subcutaneous infiltration for anesthetic purposes during submandibular gland surgery. A total of 38 patients with benign tumors, who had undergone resection by submandibular gland surgery were randomly divided into 2 groups. Patients in group A were administered with submandibular anesthesia through catheter perfusion, lingual nerve block, and subcutaneous infiltration anesthesia. Patients in the group B were only treated with lingual nerve block and subcutaneous infiltration anesthesia. The submandibular gland surgery was performed within 5 minutes following anesthesia administration, after which the numerical rating scale (NRS) was evaluated before surgery, during skin incision (T1), during the pulling process of the submandibular gland (T2), during the removal of the submandibular gland (T3), and at 2, 6, 12, and 24 hours post-surgery. The dosage of analgesic drugs was also measured after surgery. The findings revealed no significant difference in NRS before surgery, at T1, 6, 12, and 24 hours after surgery (P > 0.01) while NRS was much lower in group A patients as observed at T2, T3, and 2 hours after surgery when compared with group B (P < 0.01). The combined application of submandibular transcatheter perfusion with lingual nerve block and subcutaneous infiltration can be used as an effective anesthetic method during submandibular gland surgery.",2020,"The findings revealed no significant difference in NRS before surgery, at T1, 6, 12, and 24 hours after surgery (P > 0.01) while NRS was much lower in group","['submandibular gland surgery', '38 patients with benign tumors, who had undergone resection by submandibular gland surgery', 'Submandibular Gland Surgery']","['lingual nerve block and subcutaneous infiltration anesthesia', 'Submandibular Transcatheter Perfusion Anesthesia', 'submandibular anesthesia through catheter perfusion, lingual nerve block, and subcutaneous infiltration anesthesia', 'submandibular transcatheter perfusion with lingual nerve block and subcutaneous infiltration']",['NRS'],"[{'cui': 'C0038556', 'cui_str': 'Submaxillary Gland'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086692', 'cui_str': 'Benign Neoplasm'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C0394805', 'cui_str': 'Local anesthetic lingual nerve block (procedure)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0234945', 'cui_str': 'Anesthesia, Infiltration'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach (qualifier value)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C3669041', 'cui_str': 'Spread by direct extension (qualifier value)'}]",[],38.0,0.0464014,"The findings revealed no significant difference in NRS before surgery, at T1, 6, 12, and 24 hours after surgery (P > 0.01) while NRS was much lower in group","[{'ForeName': 'Ruohuang', 'Initials': 'R', 'LastName': 'Lu', 'Affiliation': 'Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University.'}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Xiao', 'Affiliation': 'Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University.'}, {'ForeName': 'Xincheng', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Stomatology, the Third Xiangya Hospital, Central South University.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Gan', 'Affiliation': 'Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.'}]",The Journal of craniofacial surgery,['10.1097/SCS.0000000000006140'] 656,31978815,A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.,"OBJECTIVES Chemotherapy-induced nausea and vomiting (CINV) are distressing symptoms. This randomized study evaluated the antiemetic efficacies of standard antiemetic regimen with/without olanzapine. PATIENTS AND METHODS Eligible patients were chemotherapy-naive Chinese breast cancer patients who were planned for (neo)adjuvant doxorubicin/cyclophosphamide. Antiemetic regimen for all studied population included aprepitant, ondansetron and dexamethasone; patients were randomized to Olanzapine (with olanzapine) or Standard arms (without olanzapine). Patients filled in self-reported diaries and completed visual analogue scales for nausea, as well as Functional Living Index-Emesis questionnaires. Blood profiles including fasting glucose and lipids were monitored. RESULTS 120 patients were randomized. In Cycle 1 doxorubicin/cyclophosphamide, the Olanzapine arm had significantly higher rates of ""Complete Response"" than the Standard arm: 65.0% vs 38.3% in the overall period (p = 0.0035), 70.0% vs 51.7% in the acute period (p = 0.0397) and 92.9% vs 74.2% in the delayed period (p = 0.0254). Olanzapine arm also had significantly higher rates of ""No significant nausea"" and ""No nausea"" during all 3 time-frames and better QOL. Similar findings were also revealed throughout multiple cycles. Pre-study abnormalities in glucose and lipids occurred in 39.7% and 34.2% of the studied population respectively; there were no differences in these parameters between the two arms at end-of-study assessment. CONCLUSION The addition of olanzapine to standard aprepitant-based antiemetic regimen provides clinically meaningful improvement in controlling CINV. This was associated with a positive impact on QOL and tolerable toxicity profiles among Chinese breast cancer patients receiving doxorubicin/cyclophosphamide chemotherapy. Further studies on metabolic profiles of breast cancer patients are warranted.",2020,"Olanzapine arm also had significantly higher rates of ""No significant nausea"" and ""No nausea"" during all 3 time-frames and better QOL.","['120 patients were randomized', 'Chinese breast cancer patients', 'Chinese breast cancer patients receiving', 'Eligible patients were chemotherapy-naive Chinese breast cancer patients who were planned for (neo)adjuvant', 'breast cancer patients']","['olanzapine', 'olanzapine-containing versus standard antiemetic regimens', 'ondansetron and dexamethasone', 'doxorubicin/cyclophosphamide chemotherapy', 'doxorubicin/cyclophosphamide', 'Olanzapine (with olanzapine) or Standard arms (without olanzapine', 'Olanzapine']","['glucose and lipids', 'rates of ""No significant nausea"" and ""No nausea', 'nausea and vomiting', 'QOL and tolerable toxicity profiles', 'nausea and vomiting (CINV', 'visual analogue scales for nausea', 'antiemetic efficacies', 'rates of ""Complete Response', 'Blood profiles including fasting glucose and lipids', 'Functional Living Index-Emesis questionnaires']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1301732', 'cui_str': 'Planned'}]","[{'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic Drugs'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0423584', 'cui_str': 'No nausea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic Drugs'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",120.0,0.0631505,"Olanzapine arm also had significantly higher rates of ""No significant nausea"" and ""No nausea"" during all 3 time-frames and better QOL.","[{'ForeName': 'Winnie', 'Initials': 'W', 'LastName': 'Yeo', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region; Hong Kong Cancer Institute, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: winnieyeo@cuhk.edu.hk.'}, {'ForeName': 'Thomas Kh', 'Initials': 'TK', 'LastName': 'Lau', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Leung', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Kwai Tung', 'Initials': 'KT', 'LastName': 'Lai', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Pang', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Cheung', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Vicky Tc', 'Initials': 'VT', 'LastName': 'Chan', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Winnie Mt', 'Initials': 'WM', 'LastName': 'Soo', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Vanessa Ty', 'Initials': 'VT', 'LastName': 'Yeung', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Tse', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Daisy Cm', 'Initials': 'DC', 'LastName': 'Lam', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Eva Wm', 'Initials': 'EW', 'LastName': 'Yeung', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Kim Pk', 'Initials': 'KP', 'LastName': 'Ng', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Nelson Ls', 'Initials': 'NL', 'LastName': 'Tang', 'Affiliation': 'Department of Chemical Pathology, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Macy', 'Initials': 'M', 'LastName': 'Tong', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Joyce Js', 'Initials': 'JJ', 'LastName': 'Suen', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}, {'ForeName': 'Frankie Kf', 'Initials': 'FK', 'LastName': 'Mo', 'Affiliation': 'Department of Clinical Oncology, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.01.005'] 657,32152817,Effect of lymphedema self-management group-based education compared with social network-based education on quality of life and fear of cancer recurrence in women with breast cancer: a randomized controlled clinical trial.,"BACKGROUND Breast cancer-related lymphedema (BCRL) and its associated symptoms harm the quality of life (QoL) of cancer survivors and can stimulate fear of cancer recurrence (FCR). Self-management education for lymphedema has been introduced as an effective method in controlling FCR. This study investigates the effect of lymphedema group-based education compared to the social network-based and control group on QoL and FCR in breast cancer patients. METHODS This three-arm clinical trial studied 105 patients with breast cancer-related lymphedema referred to Seyed_Khandan rehabilitation center. Sampling was done by random allocation method in blocks of 3 with 35 subjects in each group. All subjects received routine lymphedema treatments. The group-based education (GE) and social network-based education (SNE) groups received self-management education in the clinic and Telegram™ messenger channel, respectively. Impairment in QoL and mean score of FCR were assessed before, immediately after, and three months after the intervention by using the Persian version of Lymphedema Life Impact Scale (LLIS) and Fear of Progression Questionnaire-Short Form (FoPQ-SF), respectively. Mixed-model ANOVA was applied for statistical analysis. RESULTS There was a significant time effect on total LLIS (P = 0.007), psychosocial (P = 0.038) and functional (P = 0.024) subscale changes in three groups of study. Interaction between the main effect of group and time on psychosocial subscale changes was statistically significant (P = 0.017). The multicomparison results illustrated that the main effect of time, the main effect of group, and interaction of them on the mean score of FCR were P = 0.084, P = 0.380, and P = 0.568, respectively. CONCLUSION Despite no significant reduction in the FCR score, results showed the improvement of most QoL aspects after three months of intervention. Although the social network-based education method was effective, the group-based education method was more beneficial. Applying these educational methods in lymphedema treatment protocols needs cost-effectiveness studies. TRIAL REGISTRATION This study was registered at the Iranian Registry of Clinical Trials (IRCT2017052834176N1).",2020,Interaction between the main effect of group and time on psychosocial subscale changes was statistically significant (P = 0.017).,"['105 patients with breast cancer-related lymphedema referred to Seyed_Khandan rehabilitation center', 'women with breast cancer', 'breast cancer patients']","['lymphedema group-based education', 'lymphedema self-management group-based education compared with social network-based education', 'education (GE) and social network-based education (SNE) groups received self-management education', 'social network-based and control group', 'routine lymphedema treatments']","['quality of life (QoL) of cancer survivors', 'fear of cancer recurrence (FCR', 'FCR score', 'Persian version of Lymphedema Life Impact Scale (LLIS) and Fear of Progression Questionnaire-Short Form (FoPQ-SF', 'total LLIS', 'Impairment in QoL and mean score of FCR', 'quality of life and fear of cancer recurrence', 'psychosocial subscale changes', 'mean score of FCR']","[{'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4277512', 'cui_str': 'Breast Cancer-Related Arm Lymphedema'}, {'cui': 'C0034993', 'cui_str': 'Rehabilitation Centers'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0034380'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0233705', 'cui_str': 'Fear of getting cancer (finding)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",105.0,0.0463289,Interaction between the main effect of group and time on psychosocial subscale changes was statistically significant (P = 0.017).,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Omidi', 'Affiliation': 'Department of Reproductive Health and Midwifery, School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Masoomeh', 'Initials': 'M', 'LastName': 'Kheirkhah', 'Affiliation': 'Nursing Care Research Center (NCRC), School of Nursing and Midwifery, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Jamileh', 'Initials': 'J', 'LastName': 'Abolghasemi', 'Affiliation': 'Department of Biostatistics, School of Public Health, Iran University of Medical Science, Tehran, Iran.'}, {'ForeName': 'Shahpar', 'Initials': 'S', 'LastName': 'Haghighat', 'Affiliation': 'Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. sha_haghighat@yahoo.com.'}]","Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation",['10.1007/s11136-020-02455-z'] 658,30262813,Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial.,"BACKGROUND The effects of probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) and those of its heat-killed form (h-k Ba8145) on human anthropometric adiposity biomarkers are unknown. OBJECTIVE To assess the effect of Ba8145 and h-k Ba8145 ingestion on anthropometric adiposity biomarkers. DESIGN Randomized, parallel, double-blind, placebo-controlled trial with abdominally obese individuals. Participants (n = 135) consumed 1 capsule/day containing 10 10 colony forming unit (CFU) of Ba8145, 10 10 CFU of h-k Ba8145, or placebo (maltodextrin) for 3 months. RESULTS Ba8145 ingestion decreased waist circumference, waist circumference/height ratio, and Conicity index (P < 0.05) versus its baseline. Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment. Ba8145 decreased the body mass index compared with baseline and placebo group (P < 0.05). The decrease in visceral fat area after Ba8145 treatments reached significance (P < 0.05) only after h-k Ba8145. When analyses by gender were performed, significance remained only for women. Diastolic blood pressure and HOMA index decreased (P < 0.05) after h-k Ba8145. Gut microbiome analyses showed an increase in Akkermansia spp. after Ba8145 treatment, particularly in the live form, which was inversely related to weight (P = 0.003). CONCLUSIONS In abdominally obese individuals, consumption of Ba8145, both as viable and mainly as heat-killed cells, improves anthropometric adiposity biomarkers, particularly in women. An increase in the gut Akkermansia genus appears as a possible mechanism involved. Our results support Ba8145 probiotic as a complementary strategy in obesity management.",2019,Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment.,"['abdominally obese subjects', 'abdominally obese individuals']","['probiotic Bifidobacterium animalis subsp', 'lactis CECT', 'placebo (maltodextrin', 'placebo', 'Ba8145 and h-k Ba8145 ingestion']","['Diastolic blood pressure and HOMA index', 'visceral fat area', 'anthropometric adiposity biomarkers', 'waist circumference, waist circumference/height ratio, and Conicity index', 'body mass index', 'Akkermansia spp']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0005380', 'cui_str': 'Bifidobacterium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1563740', 'cui_str': 'Visceral Fat'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1490589', 'cui_str': 'Genus Akkermansia (organism)'}, {'cui': 'C0075148', 'cui_str': 'stable plasma protein solution'}]",,0.269698,Changes versus the placebo group reached significance (P < 0.05) after the h-k Ba8145 treatment.,"[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedret', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Valls', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain. rosamaria.valls@urv.cat.'}, {'ForeName': 'Lorena', 'Initials': 'L', 'LastName': 'Calderón-Pérez', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Llauradó', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Companys', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pla-Pagà', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Moragas', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Martín-Luján', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Ortega', 'Affiliation': 'Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Giralt', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Caimari', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Empar', 'Initials': 'E', 'LastName': 'Chenoll', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Salvador', 'Initials': 'S', 'LastName': 'Genovés', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Martorell', 'Affiliation': 'Biopolis SL/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Francisco M', 'Initials': 'FM', 'LastName': 'Codoñer', 'Affiliation': 'Lifesequencing/Archer Daniels Midland. R&D Department (ADM Nutrition). C/Catedrático Agustín Escardino Benlloch 9, 46980-Paterna, Valencia, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ramón', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Arola', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Solà', 'Affiliation': 'Eurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.'}]",International journal of obesity (2005),['10.1038/s41366-018-0220-0'] 659,31155604,Long-Term Comparison of Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent　- 3-Year Outcomes From the HOST-ASSURE Randomized Clinical Trial.,"BACKGROUND There are limited data on the long-term outcome of platinum chromium-based everolimus-eluting stents (PtCr-EES) vs. cobalt chromium-based zotarolimus-eluting stents (CoCr-ZES).Methods and Results:A total of 3,755 patients undergoing percutaneous coronary intervention (PCI) were randomized 2:1 to PtCr-EES or CoCr-ZES, and 96.0% of patients completed the 3-year clinical follow-up. The primary outcome was target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR). At 3 years, TLF occurred in 5.3% and in 5.4% of the PtCr-EES and CoCr-ZES groups, respectively (hazard ratio 0.978; 95% confidence interval 0.730-1.310, P=0.919). There were no significant differences in the individual components of TLF. Routine angiographic follow-up was performed in 38.9% of the total patients. In a landmark analysis of the subgroup that had follow-up angiography, the clinically-driven TLR rate of CoCr-ZES was significantly higher than PtCr-EES group during the angiography follow-up period (P=0.009). Overall definite and probable stent thrombosis rates were very low in both groups (0.5% vs. 0.6%, P=0.677). CONCLUSIONS PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population.",2019,"CONCLUSIONS PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population.","['3,755 patients undergoing percutaneous coronary intervention (PCI']","['PtCr-EES or CoCr-ZES', 'platinum chromium-based everolimus-eluting stents (PtCr-EES) vs. cobalt chromium-based zotarolimus-eluting stents (CoCr-ZES).Methods\u2004and\u2004Results', 'Platinum Chromium Everolimus-Eluting Stent vs. Cobalt Chromium Zotarolimus-Eluting Stent']","['clinically-driven TLR rate of CoCr-ZES', 'individual components of TLF', 'TLF', 'Overall definite and probable stent thrombosis rates', 'target lesion failure (TLF), defined as a composite of cardiac death, target vessel-related myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}]","[{'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0168430', 'cui_str': 'chromium hexavalent ion'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0009148', 'cui_str': 'Cobalt'}, {'cui': 'C1700035', 'cui_str': 'zotarilumus'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0439544', 'cui_str': 'Definite (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}]",3755.0,0.162366,"CONCLUSIONS PtCr-EES and CoCr-ZES had similar and excellent long-term outcomes in both efficacy and safety after PCI in an all-comer population.","[{'ForeName': 'Chee Hae', 'Initials': 'CH', 'LastName': 'Kim', 'Affiliation': 'VHS Medical Center.'}, {'ForeName': 'Kyung Woo', 'Initials': 'KW', 'LastName': 'Park', 'Affiliation': 'Seoul National University Hospital.'}, {'ForeName': 'Jeehoon', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Seoul National University Hospital.'}, {'ForeName': 'Byoung-Eun', 'Initials': 'BE', 'LastName': 'Park', 'Affiliation': 'Dankook University Hospital.'}, {'ForeName': 'Kwang Soo', 'Initials': 'KS', 'LastName': 'Cha', 'Affiliation': 'Busan National University Hospital.'}, {'ForeName': 'Jay Young', 'Initials': 'JY', 'LastName': 'Rhew', 'Affiliation': 'Presbyterian Medical Center.'}, {'ForeName': 'Hui-Kyung', 'Initials': 'HK', 'LastName': 'Jeon', 'Affiliation': ""Uijeongbu St. Mary's Hospital.""}, {'ForeName': 'Eun-Seok', 'Initials': 'ES', 'LastName': 'Shin', 'Affiliation': 'Ulsan Hospital.'}, {'ForeName': 'Ju Hyeon', 'Initials': 'JH', 'LastName': 'Oh', 'Affiliation': 'Samsung Changwon Hospital.'}, {'ForeName': 'Myung-Ho', 'Initials': 'MH', 'LastName': 'Jeong', 'Affiliation': 'Chonnam National University Hospital.'}, {'ForeName': 'Sanghyun', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Boramae Medical Center.'}, {'ForeName': 'Kyung-Kuk', 'Initials': 'KK', 'LastName': 'Hwang', 'Affiliation': 'Chungbuk National University Hospital.'}, {'ForeName': 'Jung-Han', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Wonju Christian Hospital.'}, {'ForeName': 'Sung Yun', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Inje University Ilsan Paik Hospital.'}, {'ForeName': 'Tae-Ho', 'Initials': 'TH', 'LastName': 'Park', 'Affiliation': 'Dong-A Medical Center.'}, {'ForeName': 'Keon Woong', 'Initials': 'KW', 'LastName': 'Moon', 'Affiliation': ""St. Vincent's Hospital.""}, {'ForeName': 'Hyuck-Moon', 'Initials': 'HM', 'LastName': 'Kwon', 'Affiliation': 'Gangnam Severance Hospital.'}, {'ForeName': 'Seung-Ho', 'Initials': 'SH', 'LastName': 'Hur', 'Affiliation': 'Keimyung University Dongsan Medical Center.'}, {'ForeName': 'Jae-Kean', 'Initials': 'JK', 'LastName': 'Ryu', 'Affiliation': 'Daegu Catholic University Medical Center.'}, {'ForeName': 'Bong-Ryul', 'Initials': 'BR', 'LastName': 'Lee', 'Affiliation': 'Daegu Fatima Hospital.'}, {'ForeName': 'Yong Whi', 'Initials': 'YW', 'LastName': 'Park', 'Affiliation': 'Gyeongsang National University Hospital.'}, {'ForeName': 'In-Ho', 'Initials': 'IH', 'LastName': 'Chae', 'Affiliation': 'Seoul National University Bundang Hospital.'}, {'ForeName': 'Hyo-Soo', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Seoul National University Hospital.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-18-1303'] 660,30150004,Whole body protein anabolism in COPD patients and healthy older adults is not enhanced by adding either carbohydrates or leucine to a serving of protein.,"BACKGROUND & AIMS Carbohydrates (CHO) and leucine (LEU) both have insulinotropic properties, and could therefore enhance the protein anabolic capacity of dietary proteins, which are important nutrients in preventing muscle loss in patients with Chronic Obstructive Pulmonary Disease (COPD). LEU is also known to activate protein anabolic signaling pathways independent of insulin. Based on our previous findings in COPD, we hypothesized that whole body protein anabolism is enhanced to a comparable extent by the separate and combined co-ingestion of CHO and LEU with protein. METHODS To disentangle the protein anabolic effects of CHO and/or free LEU when co-ingested with a high-quality protein, we studied 10 patients with moderate to very severe COPD and dyspnea (GOLD: II-IV, mMRC dyspnea scale ≥ 2), at risk for muscle loss, and 10 healthy age- and gender-matched controls. On four occasions, in a single-blind randomized crossover design, each subject ingested a drink containing 0.6 g/kg fat-free mass (ffm) hydrolyzed casein protein with, a) no add-ons (protein), b) 0.3 g/kg ffm CHO (protein + CHO), c) 0.095 g/kg ffm leucine (protein + LEU), d) both add-ons (protein + CHO + LEU). Whole body protein breakdown (PB), protein synthesis (PS), and net protein balance (= PS - PB) were measured by IV primed and continuous infusion of L-[ring- 2 H 5 ]-phenylalanine and L-[ 13 C 9 , 15 N]-tyrosine. L-[ 15 N]-phenylalanine was added to the protein drinks to measure splanchnic extraction. RESULTS In both groups, whole body PS, PB and net protein balance responses were comparable between the four protein drinks, despite higher postprandial plasma LEU concentrations for the LEU supplemented drinks (P < 0.05), and higher insulin concentrations for the CHO supplemented drinks as compared to the protein only drink (P < 0.05). CONCLUSIONS Adding CHO and/or LEU to a serving of high-quality protein does not further augment whole body protein anabolism in dyspneic COPD patients at risk for muscle loss or healthy older adults. TRIAL REGISTRY ClinicalTrials.gov; No. NCT01734473; URL: www.clinicaltrials.gov.",2019,"In both groups, whole body PS, PB and net protein balance responses were comparable between the four protein drinks, despite higher postprandial plasma LEU concentrations for the LEU supplemented drinks (P < 0.05), and higher insulin concentrations for the CHO supplemented drinks as compared to the protein only drink (P < 0.05). ","['COPD patients and healthy older adults', 'patients with Chronic Obstructive Pulmonary Disease (COPD', 'dyspneic COPD patients at risk for muscle loss or healthy older adults', '10 patients with moderate to very severe COPD and dyspnea (GOLD: II-IV, mMRC dyspnea scale\xa0≥\xa02), at risk for muscle loss, and 10 healthy age- and gender-matched controls']","['L', 'drink containing 0.6\xa0g/kg fat-free mass (ffm) hydrolyzed casein protein with, a) no add-ons (protein), b) 0.3\xa0g/kg ffm CHO (protein\xa0+\xa0CHO), c) 0.095\xa0g/kg ffm leucine (protein\xa0+\xa0LEU', 'CHO and/or LEU', 'Carbohydrates (CHO) and leucine (LEU', 'LEU', 'CHO and/or free LEU']","['Whole body protein breakdown (PB), protein synthesis (PS), and net protein balance (= PS - PB', 'whole body PS, PB and net protein balance responses', 'postprandial plasma LEU concentrations', 'higher insulin concentrations']","[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3641272', 'cui_str': 'Extreme'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0222045'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4068883', 'cui_str': 'Zero point six'}, {'cui': 'C1300563', 'cui_str': 'ug/mg'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0023401', 'cui_str': 'L-leucine'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}]","[{'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]",10.0,0.0141654,"In both groups, whole body PS, PB and net protein balance responses were comparable between the four protein drinks, despite higher postprandial plasma LEU concentrations for the LEU supplemented drinks (P < 0.05), and higher insulin concentrations for the CHO supplemented drinks as compared to the protein only drink (P < 0.05). ","[{'ForeName': 'Renate', 'Initials': 'R', 'LastName': 'Jonker', 'Affiliation': 'Center for Translational Research in Aging & Longevity, Dept. of Health and Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Nicolaas E P', 'Initials': 'NEP', 'LastName': 'Deutz', 'Affiliation': 'Center for Translational Research in Aging & Longevity, Dept. of Health and Kinesiology, Texas A&M University, College Station, TX, USA.'}, {'ForeName': 'Annemie M W J', 'Initials': 'AMWJ', 'LastName': 'Schols', 'Affiliation': 'NUTRIM School for Nutrition, Toxicology and Metabolism, Dept. of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'Eugene A', 'Initials': 'EA', 'LastName': 'Veley', 'Affiliation': 'Dept. of Medicine, Div. of Pulmonary & Critical Care Medicine, Baylor Scott & White Medical Center, College Station, TX, USA.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Harrykissoon', 'Affiliation': 'Center for Pulmonary and Sleep Disorders, College Station Medical Center, College Station, TX, USA.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Zachria', 'Affiliation': 'Center for Pulmonary and Sleep Disorders, College Station Medical Center, College Station, TX, USA.'}, {'ForeName': 'Mariëlle P K J', 'Initials': 'MPKJ', 'LastName': 'Engelen', 'Affiliation': 'Center for Translational Research in Aging & Longevity, Dept. of Health and Kinesiology, Texas A&M University, College Station, TX, USA. Electronic address: mpkj.engelen@ctral.org.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2018.08.006'] 661,30819011,The Relationship Between School Dropout and Pregnancy Among Adolescent Girls and Young Women in South Africa: A HPTN 068 Analysis.,"Background . Prevention of both school dropout and teen pregnancy represent clear public health priorities for South Africa, yet their complex and potentially cyclical relationship has not been fully explored. Objective . To further understand how this relationship operates, we analyzed data from a randomized trial of young women aged 13 to 20 years enrolled in school in rural South Africa to estimate the association between pregnancy and subsequent dropout and between dropout and subsequent pregnancy. Method . We examined inverse probability (IP) of exposure-weighted survival curves for school dropout by pregnancy and for pregnancy by school dropout. We used weighted curves to calculate 1-, 2-, and 3-year risk differences and risk ratios. Additionally, we used an IP-weighted marginal structural cox model to estimate a hazard ratio (HR) for each relationship. Results . Dropout from school was associated with subsequent pregnancy (HR 3.58; 95% confidence interval [CI] [2.04, 6.28]) and pregnancy was associated with subsequent school dropout (HR 2.36; 95% CI [1.29, 4.31]). Young women who attended school but attended fewer days had a higher hazard of pregnancy than those who attended more school (HR 3.64; 95% CI [2.27, 5.84]). Conclusion . Pregnancy is both a cause and a consequence of school dropout. Consideration of school attendance and academic performance could ultimately enhance pregnancy prevention efforts in this population. Programs should be tailored differently for (1) girls who have dropped out of school, (2) those who are in school and at risk for pregnancy, and (3) those who are in school and become pregnant.",2019,"Dropout from school was associated with subsequent pregnancy (HR 3.58; 95% confidence interval [CI] [2.04, 6.28]) and pregnancy was associated with subsequent school dropout (HR 2.36; 95% CI [1.29, 4.31]).","['young women aged 13 to 20 years enrolled in school in rural South Africa to estimate the association between pregnancy and subsequent dropout and between dropout and subsequent pregnancy', '1) girls who have dropped out of school, (2) those who are in school and at risk for pregnancy, and (3) those who are in school and become pregnant', 'Adolescent Girls and Young Women in South Africa', 'Young women who attended school']",[],"['hazard of pregnancy', 'School Dropout and Pregnancy', '1-, 2-, and 3-year risk differences and risk ratios']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0557295', 'cui_str': 'Attending school (finding)'}]",[],"[{'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0038488', 'cui_str': 'School Dropouts'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}]",,0.0387198,"Dropout from school was associated with subsequent pregnancy (HR 3.58; 95% confidence interval [CI] [2.04, 6.28]) and pregnancy was associated with subsequent school dropout (HR 2.36; 95% CI [1.29, 4.31]).","[{'ForeName': 'Marie C D', 'Initials': 'MCD', 'LastName': 'Stoner', 'Affiliation': '1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Katherine B', 'Initials': 'KB', 'LastName': 'Rucinski', 'Affiliation': '2 Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Jessie K', 'Initials': 'JK', 'LastName': 'Edwards', 'Affiliation': '1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Selin', 'Affiliation': '1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Hughes', 'Affiliation': '3 University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': '4 Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Yaw', 'Initials': 'Y', 'LastName': 'Agyei', 'Affiliation': '2 Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'F Xavier', 'Initials': 'FX', 'LastName': 'Gomez-Olive', 'Affiliation': '5 University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'MacPhail', 'Affiliation': '5 University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Kahn', 'Affiliation': '5 University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Pettifor', 'Affiliation': '1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Health education & behavior : the official publication of the Society for Public Health Education,['10.1177/1090198119831755'] 662,31153659,Dose-dependent effects of lifestyle interventions on blood lipid levels: Results from the PREMIER trial.,"OBJECTIVE To assess the effects of comprehensive lifestyle modification on low-density lipoprotein cholesterol (LDL-C) levels and whether greater participation in counseling sessions was associated with greater LDL-C reductions. METHODS Multicenter trial of Pre- or Stage 1 hypertensive adults randomized to: (1)Advice alone, (2)'Established' lifestyle intervention implementing physical activity, sodium reduction, and weight loss, if overweight, or (3)'Established + DASH' lifestyle intervention with DASH diet counseling. Both intervention groups received behavioral counseling. We used generalized estimating equations to model the intervention's effects on lipid outcomes. Analyses of number of sessions and lipids were adjusted for demographics and medical history. RESULTS Among 756 participants (mean age 49.7, 63.2% women, 34.7% black), both lifestyle interventions reduced LDL-C, triglycerides, and total cholesterol (TC) at six months. Compared to the 'Advice' arm, net mean lipid changes in the Established group were: LDL-C of -5.6 mg/dL (p=0.001) and TC of -7.3 mg/dL (p<0.001). Similarly, changes in the 'Established + DASH' group were: LDL-C of -4.0 mg/dL (p=0.03) and TC of -5.7 mg/dL (p=0.006). In dose-response analyses, for every 10-session increase, LDL-C changed by -6.2 mg/dL (p=0.003). CONCLUSIONS Comprehensive lifestyle modification lowers LDL-C with greater benefit among persons who attend more counseling sessions. PRACTICE IMPLICATIONS Patient engagement is a critical aspect of effective lifestyle interventions.",2019,"In dose-response analyses, for every 10-session increase, LDL-C changed by -6.2 ","['Multicenter trial of Pre- or Stage 1 hypertensive adults randomized to', '756 participants (mean age 49.7, 63.2% women, 34.7% black']","['lifestyle interventions', 'comprehensive lifestyle modification', 'behavioral counseling', ""1)Advice alone, (2)'Established' lifestyle intervention implementing physical activity, sodium reduction, and weight loss, if overweight, or (3)'Established\u2009+\u2009DASH' lifestyle intervention with DASH diet counseling""]","['blood lipid levels', 'low-density lipoprotein cholesterol (LDL-C) levels', 'net mean lipid changes', 'LDL-C, triglycerides, and total cholesterol (TC', 'LDL-C']","[{'cui': 'C0206012', 'cui_str': 'Multicenter Trials'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C4546207', 'cui_str': 'Behavioral counseling (procedure)'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches To Stop Hypertension Diet'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0005768'}, {'cui': 'C0428460', 'cui_str': 'Finding of lipid level (finding)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}]",756.0,0.0164917,"In dose-response analyses, for every 10-session increase, LDL-C changed by -6.2 ","[{'ForeName': 'Ramzi', 'Initials': 'R', 'LastName': 'Dudum', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Baltimore, MD, USA; Department of Internal Medicine, The Johns Hopkins Hospital, Baltimore, MD, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, USA; Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Appel', 'Affiliation': 'Welch Center for Prevention, Epidemiology and Clinical Research, The Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: lappel1@jhmi.edu.'}]",Patient education and counseling,['10.1016/j.pec.2019.05.005'] 663,30054777,"The Efficacy of an Event-Specific, Text Message, Personalized Drinking Feedback Intervention.","Tailgating drinking prior to a football game is a type of event-specific drinking associated with increased alcohol use and related problems. Personalized drinking feedback interventions (PFI) are efficacious in reducing alcohol use and problems. The current study aimed to advance understanding of event-specific interventions by examining: (1) the efficacy of an event-specific, text message PFI on tailgating alcohol outcomes, and (2) the extent to which intervention effects generalize to ""typical"" alcohol outcomes at 1-month follow-up. College students (N = 130; 71% female; 92% white) who reported tailgating within the past 30 days and binge drinking when tailgating in the past year completed assessments on tailgating and typical alcohol use. They were randomly assigned to one of two text message conditions delivered on the morning of a home football game: event-specific PFI (TXT PFI) or a control condition. Multilevel modeling examined the association of treatment condition on tailgating and 1-month alcohol outcomes. When tailgating, participants in TXT PFI reported lower estimated peak blood alcohol concentration (eBAC) and consumed less drinks than the control condition. At the 1-month ""typical"" drinking follow-up, participants in TXT PFI reported lower peak eBAC and fewer alcohol-related problems than the control condition. Perceived tailgating drinking norms were found to statistically mediate the relationship between condition and alcohol outcome at tailgating and 1-month follow-ups. Findings provide preliminary support for the efficacy of an event-specific, text message PFI in reducing both tailgating and typical drinking alcohol outcomes. Event-specific TXT PFI can be used for prevention/intervention of alcohol misuse.",2019,"At the 1-month ""typical"" drinking follow-up, participants in TXT PFI reported lower peak eBAC and fewer alcohol-related problems than the control condition.",['College students (N\u2009=\u2009130; 71% female; 92% white) who reported tailgating within the past 30\xa0days and binge drinking when tailgating in the past year completed assessments on tailgating and typical alcohol use'],"['Personalized drinking feedback interventions (PFI', 'text message conditions delivered on the morning of a home football game: event-specific PFI (TXT PFI) or a control condition', 'Event-Specific, Text Message, Personalized Drinking Feedback Intervention']",['peak blood alcohol concentration (eBAC'],"[{'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}]","[{'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0336986', 'cui_str': 'Football'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0684262', 'cui_str': 'Blood Alcohol Level'}]",,0.0144472,"At the 1-month ""typical"" drinking follow-up, participants in TXT PFI reported lower peak eBAC and fewer alcohol-related problems than the control condition.","[{'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Cadigan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA. CadiganJ@uw.edu.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Martens', 'Affiliation': 'Department of Educational, School, and Counseling Psychology, University of Missouri, Columbia, MO, USA.'}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Dworkin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Kenneth J', 'Initials': 'KJ', 'LastName': 'Sher', 'Affiliation': 'Department of Psychological Sciences, University of Missouri, Columbia, MO, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-018-0939-9'] 664,31916007,Age and gender differences in financial distress among hematopoietic cell transplant survivors.,"PURPOSE Cancer has long-term financial consequences. Adolescent and young adult (AYA) and middle-aged cancer survivors may experience more financial toxicity than older adults. This study examined age differences in financial distress in hematopoietic cell transplant survivors and whether these differences result from measurement bias, more financial barriers to care, or an overall higher level of distress. METHODS Hematologic malignancy survivors (n = 1135, 2-10 years post-transplant) completed the Cancer and Treatment Distress Scale (CTXD) and demographics as part of the baseline assessment for a randomized clinical trial. The CTXD has seven subscales, but for this study, we examined the financial distress subscale and the overall score. Item response theory analyses tested for bias by age and gender. Multivariate linear regression tested the association of age and gender with the CTXD scores while controlling for financial barriers to care. RESULTS No bias was found on the CTXD. AYA (p < 0.01) and middle-aged adults (p < 0.001) reported more financial and overall distress than older (age 65+) adults. The same association of age and financial distress was observed in women (p < 0.01). However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18). Financial barriers to care were not associated with financial or overall distress. CONCLUSIONS Part of the increase in financial distress with younger age may be due to a higher risk of general distress. Policy initiatives to control cancer costs should consider life stage and the unique financial challenges at different ages for men and women.",2020,"However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18).","['Hematologic malignancy survivors (n\u2009=\u20091135, 2-10\xa0years post-transplant) completed the Cancer and Treatment Distress Scale (CTXD) and demographics as part of the baseline assessment for a randomized clinical trial', 'Adolescent and young adult (AYA) and middle-aged cancer survivors', 'older adults', 'hematopoietic cell transplant survivors']",[],"['financial distress', 'age and financial distress', 'financial and overall distress', 'financial distress subscale']","[{'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332835', 'cui_str': 'Grafts'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0222045'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0206152', 'cui_str': 'Cell Transplants'}]",[],"[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.0320963,"However, only middle-aged men (p < 0.01) reported more financial and overall distress than older men; AYA men did not (p > 0.18).","[{'ForeName': 'Salene M W', 'Initials': 'SMW', 'LastName': 'Jones', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Yi', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Heather S L', 'Initials': 'HSL', 'LastName': 'Jim', 'Affiliation': 'Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Alison W', 'Initials': 'AW', 'LastName': 'Loren', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Navneet S', 'Initials': 'NS', 'LastName': 'Majhail', 'Affiliation': 'Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Uberti', 'Affiliation': 'Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Whalen', 'Affiliation': 'University of Nebraska, Omaha, NB, USA.'}, {'ForeName': 'Wendy M', 'Initials': 'WM', 'LastName': 'Leisenring', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Mary E D', 'Initials': 'MED', 'LastName': 'Flowers', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Syrjala', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ksyrjala@fredhutch.org.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05291-1'] 665,32151115,The effect of vitamin d status on different neuromuscular blocker agents reverse time.,"BACKGROUND This study is aimed to investigate the effects of vitamin D levels on sugammadex and neostigmine reversal times. METHODS Eighty patients between the ages of 18 and 65 years, with ASA I-III status who were undergoing surgery under general anaesthesia were included in the study. A double blind fashion was used to randomly divide all the patients into two groups. At the end of the operation, sugammadex 2 mg / kg was administered to one group (Group sugammadex) and atropine and neostigmine was administered to the other group Group neostigmine) intravenously. In the data analysis stage, the group was divided into two subgroups according to sugammadex and group neostigmine in itself, with vitamin D levels above and below 30 ng / ml. Statistical analysis was performed on these 4 groups. (Group neostigmine and vitamin D < 30 ng / ml), (Group neostigmine and vitamin D ? 30 ng / ml), ( Group sugammadex and vitamin D < 30 ng / ml), (Group sugammadex and vitamin D ? 30 ng / ml). When two responses to train of four (TOF) stimulation were taken, the following times were recorded until extubation phase. The time until TOF value 50%, 70%, 90% and extubation were recorded. RESULTS There were statistically difference between Group sugammadex and vitamin D < 30 ng / ml and Group sugammadex and vitamin D ? 30 ng / ml (p=0.007) for extubation times and 50% TOF reach times (p=0,015). But there was no differences observed between Group neostigmine and vitamin D < 30 ng / ml and Group neostigmine and vitamin D ? 30 ng / ml. (p=0.999) Conclusion: Vitamin D deficiency is important for anaesthesiologists in terms of muscle strength and extubation time. Vitamin D deficiency seems may effect on sugammadex reverse times but not effect on neostigmine reverse times. This conclusion needs further studies.",2020,"TOF reach times (p=0,015).","['Eighty patients between the ages of 18 and 65 years, with ASA I-III status who were undergoing surgery under general anaesthesia were included in the study']","['atropine and neostigmine', 'sugammadex and vitamin D', 'neostigmine and vitamin D', 'sugammadex and group neostigmine']",['time until TOF value'],"[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0027679', 'cui_str': 'Neostigmine'}, {'cui': 'C1700695', 'cui_str': 'Sugammadex'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",80.0,0.166963,"TOF reach times (p=0,015).","[{'ForeName': 'Ilknur Suidiye', 'Initials': 'IS', 'LastName': 'Yorulmaz', 'Affiliation': ''}, {'ForeName': 'Yavuz', 'Initials': 'Y', 'LastName': 'Demiraran', 'Affiliation': ''}, {'ForeName': 'Onur', 'Initials': 'O', 'LastName': 'Özlü', 'Affiliation': ''}, {'ForeName': 'Burhan', 'Initials': 'B', 'LastName': 'Dost', 'Affiliation': ''}]",Turkish journal of medical sciences,['10.3906/sag-1901-115'] 666,32151119,"Effects of oral/enteral nutrition alone versus plus pantoprazole on gastrointestinal bleeding in critically ill patients with low risk factor: A multicenter, randomized controlled trial.","BACKGROUND/AIM Critically ill patients are at risk of developing gastrointestinal (GI) bleeding due to stress causing mucosal damage. Aim of the study was to determine the effect of oral/ enteral nutrition with or without concomitant pantoprazole on upper GI bleeding in low risk critically ill patients. MATERIALS AND METHODS This was a prospective, randomized, open-label, multicenter study conducted with intensive care unit (ICU) patients receiving oral/enteral nutritional support. Patients were randomly assigned into two groups including intervention group (received oral/EN plus pantoprazole) and control group (received only oral/EN). RESULTS A total of 300 patients (intervention group: 152, control group: 148) participated in the study. Overall, 226 (75 %) patients were fed by oral and 74 (25%) patients fed by enteral tube. Median duration of nutritional support 4 (range: 2-33) days. Overt upper GI bleeding was noted only in one patient (0.65%) who was in the intervention group. The overall length of ICU stay of 4 (2-105) days, while ICU stay was significantly longer in the intervention group than in the control group (p=0.006). CONCLUSIONS Our findings seems to indicate that in patients who are at low risk for GI bleeding and under oral/enteral nutritional support, the use of PPIs may not reduce the risk of bleeding, however these results are imprecise because of low event (GI bleeding) rate and limited power.",2020,"The overall length of ICU stay of 4 (2-105) days, while ICU stay was significantly longer in the intervention group than in the control group (p=0.006). ","['300 patients (intervention group: 152, control group: 148) participated in the study', 'critically ill patients with low risk factor', 'low risk critically ill patients']","['oral/enteral nutrition alone versus plus pantoprazole', 'intervention group (received oral/EN plus pantoprazole) and control group (received only oral/EN', 'intensive care unit (ICU) patients receiving oral/enteral nutritional support', 'oral/ enteral nutrition with or without concomitant pantoprazole']","['upper GI bleeding', 'Overt upper GI bleeding', 'overall length of ICU stay', 'gastrointestinal bleeding', 'ICU stay']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0086225', 'cui_str': 'Enteral Feeding'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0081876', 'cui_str': 'pantoprazole'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1304890', 'cui_str': 'Enteral (qualifier value)'}, {'cui': 'C0242739', 'cui_str': 'Nutritional Support'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}]","[{'cui': 'C0041909', 'cui_str': 'Upper gastrointestinal hemorrhage (disorder)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal Hemorrhage'}]",300.0,0.0612705,"The overall length of ICU stay of 4 (2-105) days, while ICU stay was significantly longer in the intervention group than in the control group (p=0.006). ","[{'ForeName': 'Kürşat', 'Initials': 'K', 'LastName': 'Gündoğan', 'Affiliation': ''}, {'ForeName': 'Emre', 'Initials': 'E', 'LastName': 'Karakoc', 'Affiliation': ''}, {'ForeName': 'Turgut', 'Initials': 'T', 'LastName': 'Teke', 'Affiliation': ''}, {'ForeName': 'Avşar', 'Initials': 'A', 'LastName': 'Zerman', 'Affiliation': ''}, {'ForeName': 'Aliye', 'Initials': 'A', 'LastName': 'Esmaoglu', 'Affiliation': ''}, {'ForeName': 'Şahin', 'Initials': 'Ş', 'LastName': 'Temel', 'Affiliation': ''}, {'ForeName': 'Muhammet', 'Initials': 'M', 'LastName': 'Güven', 'Affiliation': ''}, {'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Sungur', 'Affiliation': ''}]",Turkish journal of medical sciences,['10.3906/sag-1911-42'] 667,32147881,Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.,"BACKGROUND/OBJECTIVES Glycopyrronium tosylate (GT) cloth, 2.4% is a topical anticholinergic approved in the United States for primary axillary hyperhidrosis in patients ≥9 years. This post hoc analysis evaluated long-term response (efficacy and safety) in pediatric patients (≥9 to ≤16 years) to GT in the 44-week, open-label extension (NCT02553798) of two, phase 3, double-blind, vehicle-controlled, 4-week trials (NCT02530281, NCT02530294). METHODS In the double-blind trials, patients ≥9 years with primary axillary hyperhidrosis were randomized 2:1 to once-daily GT:vehicle. Those who completed the study could receive open-label GT for up to an additional 44 weeks. Safety assessments included treatment-emergent adverse events (TEAEs) and local skin reactions (LSRs). Descriptive efficacy assessments included gravimetrically measured sweat production, Hyperhidrosis Disease Severity Scale response (≥2-grade improvement), and Children's Dermatology Life Quality Index. RESULTS Of 43 pediatric patients completing either double-blind trial, 38 (88.4%) entered the open-label extension (age, years: 9 [n = 1], 12 [n = 2], 13 [n = 7], 14 and 15 [n = 9 each], 16 [n = 10]). The safety profile observed was similar to the double-blind trials. Most TEAEs (>95%) were mild/moderate, related to anticholinergic activity, and infrequently led to discontinuation (n = 1/38 [2.6%]). No pediatric patients experienced a serious TEAE. Most anticholinergic TEAEs did not require a dose modification and resolved within 7 days. Approximately, one-third of patients (n = 13/38 [34.2%]) had LSRs; most were mild/moderate in severity. Improvements in efficacy measures were maintained from the double-blind trials. CONCLUSIONS Long-term, once-daily GT for up to 48 weeks (4-week double-blind plus 44 week open label) provides a noninvasive, well-tolerated treatment option for pediatric patients with primary axillary hyperhidrosis.",2020,"Approximately, one-third of patients (n = 13/38 [34.2%]) had LSRs; most were mild/moderate in severity.","['pediatric patients (≥9 to ≤16\xa0years', 'pediatric patients with primary axillary hyperhidrosis', '43 pediatric patients completing either double-blind trial, 38 (88.4%) entered the open-label extension (age, years', 'patients ≥9\xa0years', 'primary axillary hyperhidrosis', 'patients ≥9\xa0years with primary axillary hyperhidrosis']","['4-week double-blind plus 44\xa0week open label', 'open-label GT', 'topical glycopyrronium tosylate']","['serious TEAE', ""sweat production, Hyperhidrosis Disease Severity Scale response (≥2-grade improvement), and Children's Dermatology Life Quality Index"", 'Safety assessments included treatment-emergent adverse events (TEAEs) and local skin reactions (LSRs', 'safety profile', 'LSRs', 'long-term response (efficacy and safety', 'efficacy measures', 'anticholinergic activity']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0004454', 'cui_str': 'Axilla'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C4719440', 'cui_str': 'glycopyrronium tosylate'}]","[{'cui': 'C0038990', 'cui_str': 'Sweating'}, {'cui': 'C0033268'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index (assessment scale)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0242896', 'cui_str': 'Anticholinergic Agents'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",43.0,0.401597,"Approximately, one-third of patients (n = 13/38 [34.2%]) had LSRs; most were mild/moderate in severity.","[{'ForeName': 'Adelaide A', 'Initials': 'AA', 'LastName': 'Hebert', 'Affiliation': 'UTHealth McGovern Medical School, Houston, Texas, United States.'}, {'ForeName': 'Dee Anna', 'Initials': 'DA', 'LastName': 'Glaser', 'Affiliation': 'Saint Louis University, St. Louis, Missouri, United States.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Green', 'Affiliation': 'George Washington University School of Medicine, Washington, District of Columbia, United States.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Hull', 'Affiliation': 'Northwest Arkansas Clinical Trials Center, PLLC, Rogers, Arkansas.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cather', 'Affiliation': 'Modern Research Associates, PLLC, Dallas, Texas, United States.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Drew', 'Affiliation': 'Dermira, Inc., Menlo Park, California, United States.'}, {'ForeName': 'Ramanan', 'Initials': 'R', 'LastName': 'Gopalan', 'Affiliation': 'Dermira, Inc., Menlo Park, California, United States.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Pariser', 'Affiliation': 'Eastern Virginia Medical School, Virginia Clinical Research, Inc., Norfolk, Virginia, United States.'}]",Pediatric dermatology,['10.1111/pde.14135'] 668,32047952,Effect of favorite music on postoperative anxiety and pain.,"BACKGROUND Music is one of the most commonly used non-pharmacological interventions to reduce anxiety. It helps patients overcome emotional and physical alienation, provides comfort and familiarity in an improved environment and offers a pleasant distraction from pain and anxiety. This study aimed to evaluate the effects of listening to preoperative favorite music on postoperative anxiety and pain. MATERIAL AND METHODS This prospective, randomized, single-blinded, controlled trial included the American Society of Anesthesiologists (ASA) I-III patients, aged 18-70 years, undergoing elective inguinal hernia surgery. Demographic data and anxiety status were recorded. Anxiety status was measured using the Spielberger state-trait anxiety inventory form 1 (STAI-1) and state-trait anxiety inventory form 2 (STAI-2). After recording baseline heart rate, blood pressure and STAI levels, patients were randomly allocated to the music group (Group M) or control group (Group C). Patients in Group M listened to their favorite music using headphones and patients in the control group received standard care. The STAI‑1 was repeated after surgery and the numeric rating scale (NRS) and patient satisfaction were measured. RESULTS A total of 117 patients were included. Demographic data, educational status, and previous surgical history were similar between the groups. Mean preoperative STAI‑1 and STAI‑2 scores were similar between the groups (p > 0.05). Mean postoperative STAI‑1 score was significantly lower in Group M than in Group C (39 [range 35-43] vs. 41 [range 37-43], p < 0.05). Moreover, the change in the STAI score was significantly higher in Group M compared with Group C (p < 0.05). The difference of hemodynamic measurements pre-music to post-music was significant between Group M and Group C (p = 0.001). The NRS scores remained similar between the groups. Patient satisfaction score was significantly higher in Group M (p = 0.017). CONCLUSION Listening to patient-preferred favorite music preoperatively reduced anxiety, regulated hemodynamic parameters, and improved postoperative patient satisfaction. Reduced anxiety was not associated with reduced pain.",2020,Mean preoperative STAI‑1 and STAI‑2 scores were similar between the groups (p > 0.05).,"['American Society of Anesthesiologists (ASA)\xa0I-III patients, aged 18-70\xa0years, undergoing', 'A\xa0total of 117 patients were included']","['elective inguinal hernia surgery', 'listening to preoperative favorite music', 'standard care', 'favorite music']","['numeric rating scale (NRS) and patient satisfaction', 'Mean postoperative STAI‑1 score', 'hemodynamic measurements pre-music to post-music', 'Spielberger state-trait anxiety inventory form\xa01 (STAI-1) and state-trait anxiety inventory form\xa02 (STAI-2', 'reduced pain', 'Reduced anxiety', 'STAI score', 'Patient satisfaction score', 'postoperative patient satisfaction', 'blood pressure and STAI levels', 'Demographic data and anxiety status', 'Anxiety status', 'NRS scores', 'postoperative anxiety and pain', 'Mean preoperative STAI‑1 and STAI‑2 scores']","[{'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0019294', 'cui_str': 'Hernia, Inguinal'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0222045'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0204901', 'cui_str': 'Hemodynamic measurements (procedure)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0451497', 'cui_str': 'Spielberger state-trait anxiety inventory'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0451370', 'cui_str': 'Patient satisfaction score (assessment scale)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}]",117.0,0.0916176,Mean preoperative STAI‑1 and STAI‑2 scores were similar between the groups (p > 0.05).,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Kavak Akelma', 'Affiliation': 'Anesthesiology and Reanimation Clinique, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Str. NO:\xa020, Altindağ/Ankara, Turkey. fatmakavak@yahoo.com.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Altınsoy', 'Affiliation': 'Anesthesiology and Reanimation Clinique, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Str. NO:\xa020, Altindağ/Ankara, Turkey.'}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Arslan', 'Affiliation': 'Anesthesiology and Reanimation Clinique, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Str. NO:\xa020, Altindağ/Ankara, Turkey.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ergil', 'Affiliation': 'Anesthesiology and Reanimation Clinique, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Str. NO:\xa020, Altindağ/Ankara, Turkey.'}]",Der Anaesthesist,['10.1007/s00101-020-00731-8'] 669,31931236,Prognostic Significance of the Difference Between Mixed and Jugular Venous Oxygen Saturation After Severe Traumatic Brain Injury: A Post Hoc Analysis of the Brain Hypothermia Study.,"BACKGROUND In patients postcardiac arrest, it has been reported that the small value of the difference between mixed venous oxygen saturation (Svo 2 ) and jugular venous oxygen saturation (Sjvo 2 ) is associated with poor neurologic outcome. However, the importance of the difference between mixed venous oxygen saturation and jugular venous oxygen saturation (ΔSo 2 [v - jv]) remains unknown in severe traumatic brain injury (TBI). The aim of this study was to examine whether ΔSo 2 (v - jv) is associated with neurologic outcome and mortality in patients with severe TBI. METHODS We conducted post hoc analyses of the Brain Hypothermia Study, a multicenter randomized controlled trial of mild therapeutic hypothermia for the treatment of severe TBI. The value of ΔSo 2 (v - jv) on day 1 and day 3 was compared between survivors (n = 65) and nonsurvivors (n = 25) or between patients with favorable (n = 47) and unfavorable (n = 43) neurologic outcomes. RESULTS The reduction in ΔSo 2 (v - jv) on day 3 was -2.0% (range, -6.9% to 6.5%) in the nonsurvivor group and 6.3% (range, -2.5% to 16.7%) in the survivor group. The difference was statistically significant (P = 0.03). The same tendencies were observed in the nonsurvivor group on day 1 and in the unfavorable neurologic outcome group on day 1 and day 3, but the difference was not significant. CONCLUSIONS The reduction in ΔSo 2 (v - jv) on day 3 was associated with high mortality in patients with severe TBI.",2020,The reduction in ΔSO 2 (v-jv) on day 3 was associated with high mortality in severe TBI patients.,"['severe TBI', 'severe TBI patients', 'severe traumatic brain injury', 'survivors (n=65) and non-survivors (n=25) or between patients with favorable (n=47) and unfavorable (n=43) neurological outcomes']","['mild therapeutic hypothermia', 'mixed and jugular venous oxygen saturation']",['mixed venous oxygen saturation (SvO 2 ) and jugular venous oxygen saturation'],"[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}]","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0020674', 'cui_str': 'Targeted Temperature Management'}, {'cui': 'C2711941', 'cui_str': 'SvO2 - Venous oxygen saturation'}]","[{'cui': 'C0428177', 'cui_str': 'Mixed venous oxygen saturation measurement'}, {'cui': 'C2711941', 'cui_str': 'SvO2 - Venous oxygen saturation'}]",,0.047735,The reduction in ΔSO 2 (v-jv) on day 3 was associated with high mortality in severe TBI patients.,"[{'ForeName': 'Naofumi', 'Initials': 'N', 'LastName': 'Bunya', 'Affiliation': 'Departments of Emergency Medicine, Sapporo Medical University, Hokkaido, Japan. Electronic address: naobun1221@gmail.com.'}, {'ForeName': 'Wakiko', 'Initials': 'W', 'LastName': 'Aisaka', 'Affiliation': 'Departments of Emergency Medicine, Sapporo Medical University, Hokkaido, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Miyata', 'Affiliation': 'Departments of Neurosurgery, Sapporo Medical University, Hokkaido, Japan.'}, {'ForeName': 'Eichi', 'Initials': 'E', 'LastName': 'Narimatsu', 'Affiliation': 'Departments of Emergency Medicine, Sapporo Medical University, Hokkaido, Japan.'}, {'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Yamashita', 'Affiliation': 'Emergency and Critical Care Center, Tokuyama Central Hospital, Yamaguchi, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Kuroda', 'Affiliation': 'Department of Emergency Medicine, Kagawa University School of Medicine, Kagawa, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Kobata', 'Affiliation': 'Osaka Mishima Emergency Critical Care Center, Osaka, Japan.'}, {'ForeName': 'Tadashi', 'Initials': 'T', 'LastName': 'Kaneko', 'Affiliation': 'Emergency and General Medicine, Kumamoto University Hospital, Kumamoto, Japan.'}, {'ForeName': 'Motoki', 'Initials': 'M', 'LastName': 'Fujita', 'Affiliation': 'Advanced Medical Emergency and Critical Care Center, Yamaguchi University Hospital, Yamaguchi, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Dohi', 'Affiliation': 'Department of Emergency Medicine, The Jikei University, Tokyo, Japan.'}, {'ForeName': 'Yasutaka', 'Initials': 'Y', 'LastName': 'Oda', 'Affiliation': 'Advanced Medical Emergency and Critical Care Center, Yamaguchi University Hospital, Yamaguchi, Japan.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Maekawa', 'Affiliation': 'Yamaguchi Prefectural Grand Medical Center, Yamaguchi, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",World neurosurgery,['10.1016/j.wneu.2020.01.004'] 670,30531312,Safety of Lactobacillus Reuteri DSM 17938 in Healthy Children 2-5 Years of Age.,"Probiotics are increasingly used for diarrhea, but studies under the Food and Drug Administration and Investigational New Drug program are few. We conducted a phase-one placebo-controlled study of Lactobacillus reuteri DSM 17938 under Investigational New Drug program in 60 children 2-5 years of age (41 L. reuteri, 19 placebos) in a resource-constrained community in Peru. No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.",2019,"No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.","['Healthy Children 2 to 5 Years of Age', '60 children 2-5 years of age (41 L. reuteri, 19 placebo) in a resource constrained community in Peru']","['Lactobacillus reuteri DSM 17938 under IND', 'placebo', 'Lactobacillus reuteri DSM']","['subjective parental reports for fever and diarrhea', 'adverse events']","[{'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0031238', 'cui_str': 'Peru'}]","[{'cui': 'C0317625', 'cui_str': 'Lactobacillus reuteri'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0187831,"No differences in objective data on adverse events were noted, although some differences based on subjective parental reports for fever and diarrhea were seen.","[{'ForeName': 'Margaret N', 'Initials': 'MN', 'LastName': 'Kosek', 'Affiliation': 'From the Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Peñataro-Yori', 'Affiliation': 'Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru.'}, {'ForeName': 'Maribel', 'Initials': 'M', 'LastName': 'Paredes-Olortegui', 'Affiliation': 'Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lefante', 'Affiliation': 'Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}, {'ForeName': 'Cesar', 'Initials': 'C', 'LastName': 'Ramal-Asayag', 'Affiliation': 'Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Zamora-Babilonia', 'Affiliation': 'Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru.'}, {'ForeName': 'Graciela', 'Initials': 'G', 'LastName': 'Meza-Sanchez', 'Affiliation': 'Asociación Benéfica Prisma, Unidad de Investigaciones Biomédicas, Iquitos, Peru.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Oberhelman', 'Affiliation': 'Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002267'] 671,31463686,Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial.,"OBJECTIVES Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for chronic musculoskeletal pain, despite limited evidence of effectiveness and well-documented adverse effects. We assessed the effects of participating in a structured, personalized self-experiment (""N-of-1 trial"") on analgesic prescribing in patients with chronic musculoskeletal pain. METHODS We randomized 215 patients with chronic pain to participate in an N-of-1 trial facilitated by a mobile health app or to receive usual care. Medical records of participating patients were reviewed at enrollment and 6 months later to assess analgesic prescribing. We established thresholds of ≥ 50, ≥ 20, and > 0 morphine milligram equivalents (MMEs) per day to capture patients taking relatively high doses only, patients taking low-moderate as well as relatively high doses, and patients taking any dose of opioids, respectively. RESULTS There was no significant difference between the N-of-1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p = 0.87). There was a clinically substantial but statistically not significant reduction of the percentage of patients receiving ≥ 20 MME (ROR = 0.58; 95% CI = 0.33 to 1.04, p = 0.07) and also in the percentage receiving ≥ 50 MME (ROR = 0.50; 95% CI = 0.19 to 1.34, p = 0.17). There was a significant reduction in the proportion of patients in the N-of-1 group prescribed NSAIDs compared with control (relative odds ratio = 0.53; 95% CI = 0.29 to 0.96, p = 0.04), with no concomitant increase in average pain intensity. There was no significant change in use of adjunctive medications (acetaminophen, gabapentenoids, or topicals). DISCUSSION These exploratory results suggest that participation in N-of-1 trials may reduce long-term use of NSAIDs; there is also a weak signal for an effect on use of opioids. Additional research is needed to confirm these results and elucidate possible mechanisms. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02116621.",2020,"There was no significant difference between the N-of-1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p = 0.87).","['Medical records of participating patients were reviewed at enrollment and 6\xa0months later to assess analgesic prescribing', 'patients with chronic musculoskeletal pain', '215 patients with chronic pain to participate in an N-of-1 trial facilitated by a', 'Chronic Pain']","['mobile health app or to receive usual care', 'personalized self-experiment (""N-of-1 trial', 'Opioids and non-steroidal anti-inflammatory drugs (NSAIDs', 'Mobile Device-Assisted N-of-1 Trial Participation']","['adjunctive medications (acetaminophen, gabapentenoids, or topicals', 'average pain intensity']","[{'cui': 'C0025102', 'cui_str': 'Medical Records'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0746683', 'cui_str': 'Chronic musculoskeletal pain'}, {'cui': 'C4709308', 'cui_str': '215 (qualifier value)'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0003211', 'cui_str': 'Anti Inflammatory Agents, Nonsteroidal'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",215.0,0.286687,"There was no significant difference between the N-of-1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p = 0.87).","[{'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Odineal', 'Affiliation': 'Department of Medicine, Madigan Army Medical Center, Joint Base Lewis McChord, Tacoma, WA, USA.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Marois', 'Affiliation': 'Center for Health Care Policy and Research, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Ward', 'Affiliation': 'Betty Irene Moore School of Nursing, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Schmid', 'Affiliation': 'Department of Biostatistics, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Rima', 'Initials': 'R', 'LastName': 'Cabrera', 'Affiliation': 'Center for Health Care Policy and Research, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Sim', 'Affiliation': 'Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Youdan', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Biostatistics, Brown University School of Public Health, Providence, RI, USA.'}, {'ForeName': 'Barth', 'Initials': 'B', 'LastName': 'Wilsey', 'Affiliation': 'Veterans Affairs Northern California Health Care System, Sacramento Medical Center, Mather, CA, USA.'}, {'ForeName': 'Naihua', 'Initials': 'N', 'LastName': 'Duan', 'Affiliation': 'Department of Psychiatry, Columbia College of Physicians and Surgeons, New York, NY, USA.'}, {'ForeName': 'Stephen G', 'Initials': 'SG', 'LastName': 'Henry', 'Affiliation': 'Department of Internal Medicine, Division of General Medicine, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Kravitz', 'Affiliation': 'Department of Internal Medicine, Division of General Medicine, University of California Davis, Sacramento, CA, USA. rlkravitz@ucdavis.edu.'}]",Journal of general internal medicine,['10.1007/s11606-019-05303-0'] 672,31512187,Telemonitoring and Team-Based Management of Glycemic Control on People with Type 2 Diabetes: a Cluster-Randomized Controlled Trial.,"BACKGROUND Connected devices that allow people with diabetes to monitor their blood glucose levels remotely with data visualization have been shown to improve self-care behavior in diabetes management. However, their effectiveness and usability for a low-middle-income, racially diverse population are unknown. OBJECTIVE This study aims to evaluate the effects of remote telemonitoring with team-based management on people with uncontrolled type 2 diabetes. DESIGN This was a pragmatic 52-week cluster-randomized controlled study among 11 primary care government practices in Malaysia. PARTICIPANTS People with type 2 diabetes aged 18 and above, who had hemoglobin A1c ≥ 7.5% but less than 11.0% within the past 3 months and resided in the state of Selangor. INTERVENTION The intervention group received home gluco-telemonitors and transmitted glucose data to a care team who could adjust therapy accordingly. The team also facilitated self-management by supporting participants to improve medication adherence, and encourage healthier lifestyle and use of resources to reduce risk factors. Usual care group received routine healthcare service. MAIN MEASURE The primary outcome was the change in HbA1c at 24 weeks and 52 weeks. Secondary outcomes included change in fasting plasma glucose, blood pressure, lipid levels, health-related quality of life, and diabetes self-efficacy. RESULTS A total of 240 participants were recruited in this study. The telemonitoring group reported larger improvements in glycemic control compared with control at the end of study (week 24, - 0.05%; 95% CI - 0.10 to 0.00%) and at follow-up (week 52, - 0.03%; - 0.07 to 0.02%, p = 0.226). Similarly, no differences in other secondary outcomes were observed, including the number of adverse events and health-related quality of life. CONCLUSION This study indicates that there is limited benefit of replacing telemedicine with the current practice of self-monitoring of blood glucose. Further innovative methods to improve patient engagement in diabetes care are needed. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02466880.",2020,"The telemonitoring group reported larger improvements in glycemic control compared with control at the end of study (week 24, - 0.05%; 95% CI - 0.10 to 0.00%) and at follow-up (week 52, - 0.03%; - 0.07 to 0.02%, p = 0.226).","['people with uncontrolled type 2 diabetes', 'A total of 240 participants were recruited in this study', '11 primary care government practices in Malaysia', 'People with Type 2 Diabetes', 'People with type 2 diabetes aged 18 and above, who had hemoglobin A1c ≥\u20097.5% but less than 11.0% within the past 3\xa0months and resided in the state of Selangor']","['remote telemonitoring with team-based management', 'Telemonitoring and Team-Based Management of Glycemic Control', 'Usual care group received routine healthcare service', 'home gluco-telemonitors and transmitted glucose data to a care team who could adjust therapy accordingly']","['glycemic control', 'number of adverse events and health-related quality of life', 'change in HbA1c', 'change in fasting plasma glucose, blood pressure, lipid levels, health-related quality of life, and diabetes self-efficacy']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0024552', 'cui_str': 'Federation of Malaya'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0428460', 'cui_str': 'Finding of lipid level (finding)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",240.0,0.147249,"The telemonitoring group reported larger improvements in glycemic control compared with control at the end of study (week 24, - 0.05%; 95% CI - 0.10 to 0.00%) and at follow-up (week 52, - 0.03%; - 0.07 to 0.02%, p = 0.226).","[{'ForeName': 'Jun Yang', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': 'School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.'}, {'ForeName': 'Carina Ka Yee', 'Initials': 'CKY', 'LastName': 'Chan', 'Affiliation': 'School of Psychology and Public Health, La Trobe University, Edwards Road, Flora Hill, VIC, 3551, Australia.'}, {'ForeName': 'Siew Siang', 'Initials': 'SS', 'LastName': 'Chua', 'Affiliation': ""School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University Lakeside Campus, No. 1 Jalan Taylor's, 47500, Subang Jaya, Selangor, Malaysia.""}, {'ForeName': 'Chirk Jenn', 'Initials': 'CJ', 'LastName': 'Ng', 'Affiliation': 'Department of Primary Care Medicine, Faculty of Medicine, University Malaya, 50603, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Paraidathathu', 'Affiliation': ""School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University Lakeside Campus, No. 1 Jalan Taylor's, 47500, Subang Jaya, Selangor, Malaysia.""}, {'ForeName': 'Kenneth Kwing Chin', 'Initials': 'KKC', 'LastName': 'Lee', 'Affiliation': 'School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia.'}, {'ForeName': 'Shaun Wen Huey', 'Initials': 'SWH', 'LastName': 'Lee', 'Affiliation': 'School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, 47500, Bandar Sunway, Selangor, Malaysia. shaun.lee@monash.edu.'}]",Journal of general internal medicine,['10.1007/s11606-019-05316-9'] 673,31349348,Earlier time to hemostasis is associated with decreased mortality and rate of complications: Results from the Pragmatic Randomized Optimal Platelet and Plasma Ratio trial.,"BACKDROP Clinicians intuitively recognize that faster time to hemostasis is important in bleeding trauma patients, but these times are rarely reported. METHODS Prospectively collected data from the Pragmatic Randomized Optimal Platelet and Plasma Ratios trial were analyzed. Hemostasis was predefined as no intraoperative bleeding requiring intervention in the surgical field or resolution of contrast blush on interventional radiology (IR). Patients who underwent an emergent (within 90 minutes) operating room (OR) or IR procedure were included. Mixed-effects Poisson regression with robust error variance (controlling for age, Injury Severity Score, treatment arm, injury mechanism, base excess on admission [missing values estimated by multiple imputation], and time to OR/IR as fixed effects and study site as a random effect) with modified Bonferroni corrections tested the hypothesis that decreased time to hemostasis was associated with decreased mortality and decreased incidence of acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), multiple-organ failure (MOF), sepsis, and venous thromboembolism. RESULTS Of 680 enrolled patients, 468 (69%) underwent an emergent procedure. Patients with decreased time to hemostasis were less severely injured, had less deranged base excess on admission, and lower incidence of blunt trauma (all p < 0.05). In 408 (87%) patients in whom hemostasis was achieved, every 15-minute decrease in time to hemostasis was associated with decreased 30-day mortality (RR, 0.97; 95% confidence interval [CI], 0.94-0.99), AKI (RR, 0.97; 95% CI, 0.96-0.98), ARDS (RR, 0.98; 95% CI, 0.97-0.99), MOF (RR, 0.94; 95% CI, 0.91-0.97), and sepsis (RR, 0.98; 95% CI, 0.96-0.99), but not venous thromboembolism (RR, 0.99; 95% CI, 0.96-1.03). CONCLUSION Earlier time to hemostasis was independently associated with decreased incidence of 30-day mortality, AKI, ARDS, MOF, and sepsis in bleeding trauma patients. Time to hemostasis should be considered as an endpoint in trauma studies and as a potential quality indicator. LEVEL OF EVIDENCE Therapeutic/care management, level III.",2019,"Earlier time to hemostasis was independently associated with decreased incidence of 30-day mortality, AKI, ARDS, MOF, and sepsis in bleeding trauma patients.","['Patients who underwent an emergent (within 90 minutes) operating room (OR) or IR procedure were included', '680 enrolled patients, 468 (69%) underwent an emergent procedure']",[],"['MOF', '30-day mortality, AKI, ARDS, MOF, and sepsis', 'time to hemostasis', 'mortality and rate of complications', 'blunt trauma', 'sepsis', 'acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), multiple-organ failure (MOF), sepsis, and venous thromboembolism', '30-day mortality', 'venous thromboembolism', 'ARDS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0029064', 'cui_str': 'Operating Room'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0043253', 'cui_str': 'Injuries, Nonpenetrating'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0026766', 'cui_str': 'Organ Dysfunction Syndrome, Multiple'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}]",680.0,0.4177,"Earlier time to hemostasis was independently associated with decreased incidence of 30-day mortality, AKI, ARDS, MOF, and sepsis in bleeding trauma patients.","[{'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Chang', 'Affiliation': 'From the Center for Translational Injury Research (R.C., K.J.K., E.E.F., B.A.C., J.M.P., C.E.W., J.B.H.), University of Texas Health Science Center; Department of Surgery (R.C., K.J.K., E.E.F., B.A.C., C.E.W., J.B.H.), McGovern Medical School, Houston, Texas; Department of Surgery (J.D.K.), University of Alabama at Birmingham School of Medicine, Birmingham, Alabama; Department of Biostatistics and Environmental and Occupational Health Sciences (G.V.B.), University of Washington School of Medicine, Seattle, Washington; Department of Surgery (M.J.C.), University of Colorado School of Medicine, Denver, Colorado; Department of Surgery (M.A.S., K.B.), Oregon Health & Science University, Portland, Oregon; Department of Surgery (E.M.B), University of Washington School of Medicine, Seattle, Washington; Department of Surgery (K.I.), University of Southern California School of Medicine, Los Angeles, California; and Department of Surgery (S.R.), University of Toronto, Toronto, Canada.'}, {'ForeName': 'Jeffrey D', 'Initials': 'JD', 'LastName': 'Kerby', 'Affiliation': ''}, {'ForeName': 'Kyle J', 'Initials': 'KJ', 'LastName': 'Kalkwarf', 'Affiliation': ''}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Van Belle', 'Affiliation': ''}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Fox', 'Affiliation': ''}, {'ForeName': 'Bryan A', 'Initials': 'BA', 'LastName': 'Cotton', 'Affiliation': ''}, {'ForeName': 'Mitchell J', 'Initials': 'MJ', 'LastName': 'Cohen', 'Affiliation': ''}, {'ForeName': 'Martin A', 'Initials': 'MA', 'LastName': 'Schreiber', 'Affiliation': ''}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Brasel', 'Affiliation': ''}, {'ForeName': 'Eileen M', 'Initials': 'EM', 'LastName': 'Bulger', 'Affiliation': ''}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Inaba', 'Affiliation': ''}, {'ForeName': 'Sandro', 'Initials': 'S', 'LastName': 'Rizoli', 'Affiliation': ''}, {'ForeName': 'Jeanette M', 'Initials': 'JM', 'LastName': 'Podbielski', 'Affiliation': ''}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'Wade', 'Affiliation': ''}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Holcomb', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The journal of trauma and acute care surgery,['10.1097/TA.0000000000002263'] 674,31432381,Informing Precision Home Visiting: Identifying Meaningful Subgroups of Families Who Benefit Most from Family Spirit.,"The Maternal, Infant, and Early Childhood Home Visiting Program was reauthorized February 8, 2018, and invests $2 billion over 5 years to improve mothers' and children's outcomes across the life course. Along with this investment, the home-visiting field is striving for implementation innovations to deliver the greatest impact to the most families at the most efficient cost through a focus on precision home visiting. Consistent with the precision home-visiting approach to identify meaningful subgroups to guide content tailoring, the purpose of this paper is to answer (1) how and to what degree an evidence-based home-visiting model benefits mothers and children with substance use or depression and (2) what baseline characteristics indicate who can benefit most. We completed a secondary data analysis of the most recently completed randomized controlled trial (RCT) of Family Spirit (N = 322), a federally endorsed home-visiting intervention designed for young Native American mothers and their children. We examined how baseline differences in mothers' substance use, depression, and demographic characteristics (household mobility, education, parity, and premature birth) moderated mothers' and children's intervention-related outcomes. Children born to mothers with past substance use histories benefited more from the intervention than children born to abstinent mothers (p < 0.01). Unstable housing, parity, and low educational attainment emerged as moderators of intervention effectiveness. Results from this investigation will serve as a basis for designing and evaluating a precision approach to Family Spirit and may provide lessons for other models to explore tailoring variables for optimal impact and efficiency. Trial Registry: NCT00373750.",2019,Children born to mothers with past substance use histories benefited more from the intervention than children born to abstinent mothers (p < 0.01).,"['Children born to mothers with past substance', 'young Native American mothers and their children']",['Family Spirit'],"[""mothers' substance use, depression, and demographic characteristics (household mobility, education, parity, and premature birth) moderated mothers' and children's intervention-related outcomes""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439861', 'cui_str': 'Substance (substance)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0282204', 'cui_str': 'Native Americans'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1705899', 'cui_str': 'Spirit (basic dose form)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",,0.0347634,Children born to mothers with past substance use histories benefited more from the intervention than children born to abstinent mothers (p < 0.01).,"[{'ForeName': 'E E', 'Initials': 'EE', 'LastName': 'Haroz', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. eharoz1@jhu.edu.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ingalls', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kee', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Goklish', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Neault', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Begay', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Barlow', 'Affiliation': 'Center for American Indian Health, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-019-01039-9'] 675,31375659,Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies.,"The identification of biomarkers of response might speed drug development and set the premises to assist clinical practice in psychiatry. In this work, we evaluated a panel of peripheral biomarkers (including IL-6, IL-10, TNF-α, TNFRII, BDNF, CRP, MMP9 and PAI1) in depressed patients receiving paroxetine, venlafaxine, or placebo. Samples were obtained from two randomised placebo-controlled studies evaluating the efficacy and tolerability of a novel drug candidate, using either paroxetine or venlafaxine as active comparators. In both studies, the biomarker candidates were analysed in plasma collected at randomization and after 10 weeks of treatment with either placebo or active comparator (for a total of 106 and 108 subjects in the paroxetine and venlafaxine study, respectively). Data were obtained by multiplexing sandwich-ELISA system. Data were subjected to statistical analysis to assess their correlation with baseline severity and with response outcome. Increases in biomarker levels were correlated with reduction in depression severity for TNF-α, IL-6 IL-10 and CRP. Response to paroxetine treatment correlated with baseline IL-10, IL-6 and TNF-α levels, with the strongest signal being observed in males. In the venlafaxine study, a correlation was observed only between CRP level at randomisation and response, suggesting differences between the two active treatments and the two studies. Our investigations suggest that a combination of pro- and anti-inflammatory cytokines may predict response outcome in patients treated with paroxetine. The potential for IL-10, IL-6 and TNF-α as response biomarkers for a wider range of antidepressants warrants further investigations in clinical trials with other monoamine reuptake inhibitors.",2019,"Increases in biomarker levels were correlated with reduction in depression severity for TNF-α, IL-6 IL-10 and CRP.","['patients treated with', 'major depression', 'depressed patients receiving']","['venlafaxine', 'paroxetine', 'placebo', 'paroxetine, venlafaxine, or placebo', 'paroxetine and venlafaxine', 'paroxetine or venlafaxine']","['peripheral biomarkers (including IL-6, IL-10, TNF-α, TNFRII, BDNF, CRP, MMP9 and PAI1', 'biomarker levels', 'CRP level', 'depression severity for TNF-α, IL-6 IL-10 and CRP', 'baseline IL-10, IL-6 and TNF-α levels', 'efficacy and tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}]","[{'cui': 'C0078569', 'cui_str': 'venlafaxine'}, {'cui': 'C0070122', 'cui_str': 'Paroxetine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",108.0,0.0803742,"Increases in biomarker levels were correlated with reduction in depression severity for TNF-α, IL-6 IL-10 and CRP.","[{'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Carboni', 'Affiliation': 'Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy.'}, {'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'McCarthy', 'Affiliation': 'Indipendent Consultant, Clinical Pharmacology and Translational Science, Newark, DE, USA.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Delafont', 'Affiliation': 'Delafont Statistics, Alençon, France.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Filosi', 'Affiliation': 'Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Ivanchenko', 'Affiliation': 'Leadiant GmbH, München, Germany.'}, {'ForeName': 'Emiliangelo', 'Initials': 'E', 'LastName': 'Ratti', 'Affiliation': 'Neuroscience Therapeutic Area Unit, Takeda, Boston, MA, USA.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Learned', 'Affiliation': 'Global Medicines Development, Indivior, Inc., Richmond, VA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Alexander', 'Affiliation': 'Neuroscience Therapeutic Area Unit, Takeda, Boston, MA, USA.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Domenici', 'Affiliation': 'Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy. enrico.domenici@unitn.it.'}]",Translational psychiatry,['10.1038/s41398-019-0521-7'] 676,31375842,Health Behaviors in Rural Appalachia.,"OBJECTIVES To better understand the disproportionate burdens from cancer, cardiovascular disease, diabetes mellitus, stroke, and other chronic conditions related to energy balance, we studied diet and physical activity patterns in younger and older adults in rural Appalachia by using a nonclinical, cross-sectional, community-based sampling approach. METHODS A total of 651 younger (ages 18-59) and 254 older (ages ≥60) Appalachians were recruited from 43 churches or community organizations. Participants answered questions about fruit and vegetable intake and physical activity. Analyses were adjusted for clustering within churches. RESULTS Compared with older Appalachians, younger Appalachians consumed significantly fewer fruits and vegetables ( P = 0.01) and reported significantly more moderate-to-vigorous physical activity ( P = 0.01). Regardless of age, engagement in healthy behaviors was suboptimal and well below national averages. CONCLUSIONS This community-based sample demonstrated elevated behavioral risk factors that likely contribute to some of the nation's highest rates of premature mortality. Despite suboptimal dietary intake and physical activity, results indicate some potential leverage points between the generations that may be used to improve health. For example, the older generation could benefit from engaging with their younger relatives in physical activities while advocating for a better-rounded diet. Given traditions of intergenerational connectedness, mutual aid, and self-reliance, transmission of healthier behaviors across the generations may be beneficial in the rural Appalachian context.",2019,"Compared with older Appalachians, younger Appalachians consumed significantly fewer fruits and vegetables ( P = 0.01) and reported significantly more moderate-to-vigorous physical activity ( P = 0.01).","['younger and older adults in rural Appalachia by using a nonclinical, cross-sectional, community-based sampling approach', 'Appalachians were recruited from 43 churches or community organizations', '651 younger (ages 18-59) and 254 older (ages ≥60', 'Health Behaviors in Rural Appalachia']",[],"['fruits and vegetables', 'moderate-to-vigorous physical activity']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0003609', 'cui_str': 'Appalachia'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0562324', 'cui_str': 'Church (environment)'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0018687'}]",[],"[{'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",651.0,0.0312489,"Compared with older Appalachians, younger Appalachians consumed significantly fewer fruits and vegetables ( P = 0.01) and reported significantly more moderate-to-vigorous physical activity ( P = 0.01).","[{'ForeName': 'Aasha I', 'Initials': 'AI', 'LastName': 'Hoogland', 'Affiliation': 'From the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, the Department of Psychology, University of South Florida, Tampa, the Sanders Brown Center on Aging, Graduate Center for Gerontology, University of Kentucky, Lexington, the Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, and the Department of Behavioral Science, University of Kentucky, Lexington.'}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'Hoogland', 'Affiliation': 'From the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, the Department of Psychology, University of South Florida, Tampa, the Sanders Brown Center on Aging, Graduate Center for Gerontology, University of Kentucky, Lexington, the Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, and the Department of Behavioral Science, University of Kentucky, Lexington.'}, {'ForeName': 'Shoshana H', 'Initials': 'SH', 'LastName': 'Bardach', 'Affiliation': 'From the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, the Department of Psychology, University of South Florida, Tampa, the Sanders Brown Center on Aging, Graduate Center for Gerontology, University of Kentucky, Lexington, the Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, and the Department of Behavioral Science, University of Kentucky, Lexington.'}, {'ForeName': 'Yelena N', 'Initials': 'YN', 'LastName': 'Tarasenko', 'Affiliation': 'From the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, the Department of Psychology, University of South Florida, Tampa, the Sanders Brown Center on Aging, Graduate Center for Gerontology, University of Kentucky, Lexington, the Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, and the Department of Behavioral Science, University of Kentucky, Lexington.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Schoenberg', 'Affiliation': 'From the Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida, the Department of Psychology, University of South Florida, Tampa, the Sanders Brown Center on Aging, Graduate Center for Gerontology, University of Kentucky, Lexington, the Department of Health Policy and Management, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, and the Department of Behavioral Science, University of Kentucky, Lexington.'}]",Southern medical journal,['10.14423/SMJ.0000000000001008'] 677,31780589,Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).,"INTRODUCTION Antipsychotic medication is effective in reducing acute symptoms of psychosis, but it has a range of potentially serious and debilitating adverse effects and is often disliked by patients. It is therefore essential it is only used when benefits outweigh harms. Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. METHODS AND ANALYSIS This is a multicentre, randomised controlled trial involving people with schizophrenia and related disorders who have had more than one episode. Participants are randomised to have a clinically-supervised, gradual reduction of antipsychotic medication, leading to discontinuation when possible, or to continue with maintenance treatment. Blinded follow-up assessments are conducted at 6, 12 and 24 months and the primary outcome is social functioning, measured by the Social Functioning Scale at 24 months. A minimum of 134 evaluable participants provides 90% power to detect a five-point difference, and 206 to detect a four-point difference. Secondary outcomes include severe relapse (admission to hospital) and the study is also intended to detect a minimum 10% difference in severe relapse, which requires 402 participants, assuming a 15% loss to follow-up. Other secondary outcomes include all relapses, as identified by an independent and blinded endpoint committee, symptoms measured by the Positive and Negative Syndrome Scale, quality of life, adverse effects, self-rated recovery and neuropsychological measures. Enrolment started in 2016. The trial is scheduled to finish in June 2022. ETHICS AND DISSEMINATION Ethical approval was initially obtained on 27 October 2016 (UK Research Ethics Committee reference 16/LO/1507). Results will be published in peer-reviewed journals and disseminated to the public. TRIAL REGISTRATION NUMBER ISRCTN90298520. EudraCT: 2016-000709-36. Pre-results.",2019,"Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. ","['people with schizophrenia and related disorders', 'people with schizophrenia and related disorders who have had more than one episode', '134 evaluable participants']","['EudraCT', 'Antipsychotic medication', 'gradual antipsychotic reduction and discontinuation']","['social functioning, measured by the Social Functioning Scale', 'severe relapse', 'all relapses, as identified by an independent and blinded endpoint committee, symptoms measured by the Positive and Negative Syndrome Scale, quality of life, adverse effects, self-rated recovery and neuropsychological measures', 'severe relapse (admission to hospital', 'risk of relapse']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}]","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0439833', 'cui_str': 'Gradual (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2585826', 'cui_str': 'Social functioning scale (assessment scale)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0034380'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",402.0,0.166369,"Although multiple trials conducted with people with schizophrenia indicate an increased risk of relapse in the short-term following abrupt antipsychotic discontinuation, there is little evidence about the long-term outcome of a gradual process of reduction and discontinuation on social functioning, relapse and other outcomes. ","[{'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Moncrieff', 'Affiliation': 'Division of Psychiatry, University College London and North East London NHS Foundation Trust, London, UK j.moncrieff@ucl.ac.uk.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Freemantle', 'Affiliation': 'Institute for Clinical Trials and Methodology, University College London, London, UK.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Thomas R E', 'Initials': 'TRE', 'LastName': 'Barnes', 'Affiliation': 'Division of Psychiatry, Imperial College London, London, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Morant', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Pinfold', 'Affiliation': 'McPin Foundation, London, UK.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Hunter', 'Affiliation': 'Research Department of Primary Care and Population Health, University College London, London, UK.'}, {'ForeName': 'Lyn J', 'Initials': 'LJ', 'LastName': 'Kent', 'Affiliation': 'Independent consultant, Brentwood, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Smith', 'Affiliation': 'Independent consultant, Brighton, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Darton', 'Affiliation': 'Independent consultant, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horne', 'Affiliation': 'School of Pharmacy, University College London, London, UK.'}, {'ForeName': 'Nadia E', 'Initials': 'NE', 'LastName': 'Crellin', 'Affiliation': 'Division of Psychiatry, University College London, London, UK.'}, {'ForeName': 'Ruth E', 'Initials': 'RE', 'LastName': 'Cooper', 'Affiliation': 'Unit for Social and Community Psychiatry, Queen Mary University of London, London, UK.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Priebe', 'Affiliation': 'Unit for Social and Community Psychiatry, Queen Mary University of London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-030912'] 678,31327670,Randomized controlled study of aerosolized hypertonic xylitol versus hypertonic saline in hospitalized patients with pulmonary exacerbation of cystic fibrosis.,"BACKGROUND Cystic fibrosis (CF) lung disease is characterized by chronic bacterial infection and recurrent pulmonary exacerbations. Xylitol is a 5-carbon sugar that can lower the airway surface salt concentration and augment innate immunity. We examined the safety and efficacy of aerosolized xylitol use for 2 weeks in subjects hospitalized with a pulmonary exacerbation of CF. METHODS In a 2-week study, 60 subjects with cystic fibrosis and FEV 1  > 30% predicted were enrolled to receive aerosolized 7% hypertonic saline (4 ml) or 15% xylitol (5 ml) twice a day for 14 days. Outcomes assessed included change from baseline in FEV 1 % predicted, change in sputum microbial density, revised CF quality of life questionnaire including the respiratory symptom score, time to next hospitalization for a pulmonary exacerbation, and frequency of adverse events. RESULTS 59 subjects completed the study (one subject in the saline group withdrew before any study product administration). No significant differences were noted between the 2 arms in mean changes in lung function, sputum microbial density for Pseudomonas aeruginosa and Staphylococcus aureus, body weight, quality of life, and frequency of adverse events. CONCLUSIONS Aerosolized hypertonic xylitol was well-tolerated among subjects hospitalized for CF pulmonary exacerbation. Future studies examining efficacy for long term use in patients with CF lung disease would be worthwhile. The clinical trial registration number for this study is NCT00928135.",2020,"No significant differences were noted between the 2 arms in mean changes in lung function, sputum microbial density for Pseudomonas aeruginosa and Staphylococcus aureus, body weight, quality of life, and frequency of adverse events. ","['subjects hospitalized for CF pulmonary exacerbation', 'patients with CF lung disease', '60 subjects with cystic fibrosis and FEV 1 \u202f>\u202f30% predicted were enrolled to receive', '59 subjects', 'hospitalized patients with pulmonary exacerbation of cystic fibrosis', 'subjects hospitalized with a pulmonary exacerbation of CF']","['hypertonic saline', 'aerosolized hypertonic xylitol', 'Xylitol', 'aerosolized 7% hypertonic saline (4\u202fml) or 15% xylitol', 'Aerosolized hypertonic xylitol', 'aerosolized xylitol']","['mean changes in lung function, sputum microbial density for Pseudomonas aeruginosa and Staphylococcus aureus, body weight, quality of life, and frequency of adverse events', 'safety and efficacy', 'sputum microbial density, revised CF quality of life questionnaire including the respiratory symptom score, time to next hospitalization for a pulmonary exacerbation, and frequency of adverse events']","[{'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024115', 'cui_str': 'Pulmonary Diseases'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}]","[{'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0043369', 'cui_str': 'Xylitol'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0034380'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0037090', 'cui_str': 'Signs and Symptoms, Respiratory'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}]",60.0,0.0562895,"No significant differences were noted between the 2 arms in mean changes in lung function, sputum microbial density for Pseudomonas aeruginosa and Staphylococcus aureus, body weight, quality of life, and frequency of adverse events. ","[{'ForeName': 'Sachinkumar', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Hornick', 'Affiliation': 'Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Janel', 'Initials': 'J', 'LastName': 'Fedler', 'Affiliation': 'Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Janice L', 'Initials': 'JL', 'LastName': 'Launspach', 'Affiliation': 'Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Teresi', 'Affiliation': 'Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Santacroce', 'Affiliation': 'Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Cavanaugh', 'Affiliation': 'Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Horan', 'Affiliation': 'Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nelson', 'Affiliation': 'Doris Duke Clinical Research Scholar, University of Iowa, USA.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Starner', 'Affiliation': 'Department of Pediatrics, University of Wisconsin-Madison,\xa0600 Highland Ave, Madison, WI 53792, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Zabner', 'Affiliation': 'Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.'}, {'ForeName': 'Lakshmi', 'Initials': 'L', 'LastName': 'Durairaj', 'Affiliation': 'Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA. Electronic address: lakshmi-durairaj@uiowa.edu.'}]",Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,['10.1016/j.jcf.2019.06.016'] 679,31552710,Endothelial function following interval exercise plus low-calorie diet treatment in obese females.,"We determined if interval exercise plus a low-calorie diet (LCD + INT) increases endothelial function more than an energy-matched LCD. Obese women (47.2 ± 2.6y, 37.5 ± 1.3kg/m 2 ) were randomized to 13 days of a LCD (n = 12; mixed meals of ~ 1200kcal/d) or LCD + INT (n = 13; 12 supervised 60-min INT bouts of 3 min at 90% and 50% HR peak ). LCD + INT subjects received 350kcal postexercise to equate energy availability with LCD. Fitness (VO 2 peak) and body composition (BodPod) were determined and a 120 min, 75 g oral glucose tolerance test was performed to examine fasting and postprandial flow-mediated dilation (FMD, endothelial function), respiratory exchange ratio (RER) via indirect calorimetry as well as glucose and insulin incremental area under the curve (iAUC 120min ). LCD + INT increased VO 2 peak (P = 0.02) compared with LCD, and both treatments decreased fat mass (P < 0.001) and insulin iAUC 120min (P = 0.03). There was no overall treatment effect on fasting or iAUC 120min FMD. However, in participants who increased fasting endothelial function after each treatment (Δ > 50%; LCD n = 5, LCD + INT n = 7), LCD + INT increased fasted (P = 0.005) and decreased iAUC 120min (P = 0.003) FMD compared with LCD. Enhanced fitness correlated with increased fasting FMD (r = 0.43, P = 0.03) and diminished FMD iAUC 120min (r = -0.44, P = 0.03). Decreased FMD iAUC 120min correlated with reduced glucose iAUC 120min (r = 0.64, P = 0.001) as well as increased 60-min RER (r = -0.42, P = 0.04). Low baseline fasting and iAUC 120min FMD was also linked to enhanced fasting and iAUC 120min FMD post-treatment (r = -0.71, P < 0.001; r = -0.89, P < 0.001, respectively). In conclusion, increasing fitness via INT may increase the effect of LCD on lowering cardiovascular disease risk in obese women.",2019,"LCD + INT increased VO 2 peak (P = 0.02) compared with LCD, and both treatments decreased fat mass (P < 0.001) and insulin iAUC 120min (P = 0.03).","['Obese women (47.2\xa0±\xa02.6y, 37.5\xa0±\xa01.3kg/m 2 ', 'obese females', 'obese women']","['interval exercise plus low-calorie diet treatment', 'LCD', 'interval exercise plus a low-calorie diet (LCD\xa0+\xa0INT', 'LCD (n\xa0=\xa012; mixed meals of\xa0~\xa01200kcal/d) or LCD\xa0+\xa0INT']","['fasting FMD', 'fat mass', 'fasting and postprandial flow-mediated dilation (FMD, endothelial function), respiratory exchange ratio (RER) via indirect calorimetry as well as glucose and insulin incremental area under the curve (iAUC 120min ', 'Decreased FMD iAUC 120min correlated with reduced glucose', 'fasting or iAUC 120min FMD', 'fasting endothelial function', 'iAUC 120min', 'Endothelial function', 'Fitness (VO 2 peak) and body composition (BodPod', '60-min RER', 'FMD iAUC 120min', 'LCD\xa0+\xa0INT increased VO 2 peak', 'endothelial function']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517742', 'cui_str': '37.5 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2930544', 'cui_str': 'Low-Calorie Diet'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient (observable entity)'}, {'cui': 'C0006781', 'cui_str': 'Calorimetry, Respiration'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",,0.0529531,"LCD + INT increased VO 2 peak (P = 0.02) compared with LCD, and both treatments decreased fat mass (P < 0.001) and insulin iAUC 120min (P = 0.03).","[{'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Gilbertson', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Miller', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Natalie Z M', 'Initials': 'NZM', 'LastName': 'Eichner', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Steven K', 'Initials': 'SK', 'LastName': 'Malin', 'Affiliation': 'Department of Kinesiology, University of Virginia, Charlottesville, Virginia.'}]",Physiological reports,['10.14814/phy2.14239'] 680,31232898,Evaluating Immunopathogenic Biomarkers During Severe Malaria Illness as Modifiers of the Neuropsychologic Benefits of Computer Cognitive Games Rehabilitation in Ugandan Children.,"BACKGROUND We explored 3 immunopathogenic biomarkers collected during acute malaria illness as potential moderators of gains from a computerized cognitive rehabilitation training (CCRT) intervention. METHOD Von Willebrand Factor (vWF), tumor necrosis factor (TNF) and Regulated on Activation, Normal T Expressed and Secreted (RANTES) were assayed from plasma and cerebral spinal fluid (CSF) of children during acute severe malaria anemia or cerebral malaria. Two years after acute malaria illness, 150 surviving children and 150 nonmalaria community controls (CCs) from their households 6-12 years old entered a 3-arm randomized controlled trial of titrating and nontitrating CCRT against no CCRT. Tests of cognition [Kaufman Assessment Battery for Children (KABC)], Tests of Variables of Attention and Achenbach Child Behavior Checklist (CBCL) were administered before and after 24 CCRT sessions over a 3-month period, and at 1-year follow-up. Differences in outcomes by trial arms and biomarker levels were evaluated using linear mixed effects models. RESULTS Severe malaria survivors with lower levels of vWF, lower CSF levels of TNF and higher levels of plasma and CSF RANTES had better KABC cognitive performance after both titrating and nontitrating CCRT compared with no CCRT. For the CBCL, high plasma RANTES was associated with no benefit from either the titrating and nontitrating CCRT, whereas high TNF plasma was predictive of the benefit for both interventions. These biomarker moderating effects were not evident for CC children. CONCLUSIONS Severe malaria immunopathogenic biomarkers may be related to poorer long-term brain/behavior function as evidenced by diminished benefit from a computerized cognitive rehabilitation intervention.",2019,"Severe malaria survivors with lower levels of vWF, lower CSF levels of TNF and higher levels of plasma and CSF RANTES had better KABC cognitive performance after both titrating and nontitrating CCRT compared to no CCRT.","['Ugandan Children', 'Children (KABC', '150 surviving children and 150 nonmalaria community controls (CCs) from their households 6-12 years old', 'children during acute severe malaria anemia or cerebral malaria']","['titrating and nontitrating CCRT against no CCRT', 'computerized cognitive rehabilitation training (CCRT) intervention', 'Computer Cognitive Games Rehabilitation']","['Severe malaria survivors', 'Von Willebrand Factor (vWF), tumor necrosis factor (TNF) and Regulated on Activation, Normal T Expressed and Secreted (RANTES', 'Attention and Achenbach Child Behavior Checklist (CBCL', 'KABC cognitive performance']","[{'cui': 'C0241520', 'cui_str': 'Ugandans (ethnic group)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0024534', 'cui_str': 'Malaria, Cerebral'}]","[{'cui': 'C0870303', 'cui_str': 'Cognitive rehabilitation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0042971', 'cui_str': 'von Willebrand factor'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0072978', 'cui_str': 'RANTES Protein, T-Cell'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0008065', 'cui_str': 'Child Behavior'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]",150.0,0.0512784,"Severe malaria survivors with lower levels of vWF, lower CSF levels of TNF and higher levels of plasma and CSF RANTES had better KABC cognitive performance after both titrating and nontitrating CCRT compared to no CCRT.","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Boivin', 'Affiliation': 'From the Departments of Psychiatry.'}, {'ForeName': 'Alla', 'Initials': 'A', 'LastName': 'Sikorskii', 'Affiliation': 'From the Departments of Psychiatry.'}, {'ForeName': 'Noeline', 'Initials': 'N', 'LastName': 'Nakasujja', 'Affiliation': 'Department of Psychiatry, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Horacio', 'Initials': 'H', 'LastName': 'Ruiseñor-Escudero', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Familiar-Lopez', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Robert O', 'Initials': 'RO', 'LastName': 'Opoka', 'Affiliation': 'Department of Paediatrics and Child Health, Makerere University, Kampala, Uganda, Departments of.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Giordani', 'Affiliation': 'Psychiatry.'}]",The Pediatric infectious disease journal,['10.1097/INF.0000000000002367'] 681,31786963,Short-term integrated rehabilitation for people with newly diagnosed thoracic cancer: a multi-centre randomized controlled feasibility trial.,"OBJECTIVES The main objective of this study is to determine the feasibility of recruiting and retaining patients recently diagnosed with thoracic cancer to a trial of short-term integrated rehabilitation; evaluate uptake of theoretically informed components targeting physical function, symptom self-management and participation; estimate sample size requirements for an efficacy trial. DESIGN Parallel group randomized controlled feasibility trial. SETTING Three U.K. hospitals. PARTICIPANTS Patients ⩽eight weeks of thoracic cancer diagnosis, Eastern Cooperative Oncology Group Performance Status 0-3, any cancer stage and treatment plan. INTERVENTIONS Participants randomly allocated (1:1) to short-term integrated rehabilitation and standard care or standard care alone over 30 days. MAIN MEASURES Primary: participant recruitment and retention, targeting ⩾30% of eligible patients enrolling and ⩾50% of participants reporting outcomes at 30 days. Secondary: intervention fidelity; missing data and performance of outcome measures for self-efficacy, symptoms, physical activity and health-related quality of life. RESULTS Of 159 eligible patients approached, 54 (34%) were recruited. A total of 44 (82%) and 39 (72%) participants reported outcomes at 30 and 60 days, respectively. Intervention fidelity was high. Rehabilitation was delivered across 3 (1-3) sessions over 32 (22-45) days (median (range)). Changes in clinical outcomes were modest but most apparent at 60 days for health-related quality of life: Functional Assessment of Cancer Therapy Lung Cancer score median (interquartile range) change 9.7 (-12.0 to 16.0) rehabilitation versus 2.3 (-15.0 to 14.5) standard care. CONCLUSION A trial to examine efficacy of short-term integrated rehabilitation for people newly diagnosed with thoracic cancer is feasible. A sample of 336 participants could detect a meaningful effect on health-related quality of life as the primary outcome.",2020,"Changes in clinical outcomes were modest but most apparent at 60 days for health-related quality of life: Functional Assessment of Cancer Therapy Lung Cancer score median (interquartile range) change 9.7 (-12.0 to 16.0) rehabilitation versus 2.3 (-15.0 to 14.5) standard care. ","['Patients ⩽eight weeks of thoracic cancer diagnosis, Eastern Cooperative Oncology Group Performance Status 0-3, any cancer stage and treatment plan', 'Three U.K. hospitals', '159 eligible patients approached, 54 (34%) were recruited', 'people with newly diagnosed thoracic cancer', 'people newly diagnosed with thoracic cancer', '336 participants']","['short-term integrated rehabilitation', 'short-term integrated rehabilitation and standard care or standard care alone over 30\u2009days', 'Short-term integrated rehabilitation']","['self-efficacy, symptoms, physical activity and health-related quality of life', 'health-related quality of life', 'health-related quality of life: Functional Assessment of Cancer Therapy Lung Cancer score median']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",336.0,0.21961,"Changes in clinical outcomes were modest but most apparent at 60 days for health-related quality of life: Functional Assessment of Cancer Therapy Lung Cancer score median (interquartile range) change 9.7 (-12.0 to 16.0) rehabilitation versus 2.3 (-15.0 to 14.5) standard care. ","[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Bayly', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Fettes', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Douglas', 'Affiliation': 'University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Maria J', 'Initials': 'MJ', 'LastName': 'Teixiera', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Peat', 'Affiliation': ""Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'India', 'Initials': 'I', 'LastName': 'Tunnard', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Vishit', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gao', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wilcock', 'Affiliation': 'University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Irene J', 'Initials': 'IJ', 'LastName': 'Higginson', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Maddocks', 'Affiliation': ""King's College London, London, UK.""}]",Clinical rehabilitation,['10.1177/0269215519888794'] 682,31659655,Primary Care Providers' Acceptance of Pharmacists' Recommendations to Support Optimal Medication Management for Patients with Diabetic Kidney Disease.,"BACKGROUND Patients with diabetic kidney disease (DKD) often struggle with blood pressure control. In team-based models of care, pharmacists and primary care providers (PCPs) play important roles in supporting patients' blood pressure management. OBJECTIVE To describe whether PCPs' acceptance of pharmacists' recommendations impacts systolic blood pressure (SBP) at 36 months. DESIGN An observational analysis of a subset of participants randomized to the intervention arm of the Simultaneous risk factor control using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD) study. PARTICIPANTS STOP-DKD participants for whom (1) the pharmacist made at least one recommendation to the PCP; (2) there were available data regarding the PCP's corresponding action; and (3) there were SBP measurements at baseline and 36 months. INTERVENTION Participants received monthly telephone calls with a pharmacist addressing health behaviors and medication management. Pharmacists made medication-related recommendations to PCPs. MAIN MEASURES We fit an unadjusted generalized linear mixed model to assess the association between the number of pharmacists' recommendations for DKD and blood pressure management and PCPs' acceptance of such recommendations. We used a linear regression model to evaluate the association between PCP acceptance and SBP at 36 months, adjusted for baseline SBP. KEY RESULTS Pharmacists made 176 treatment recommendations (among 59 participants), of which 107 (61%) were accepted by PCPs. SBP significantly declined by an average of 10.5 mmHg (p < 0.01) among 47 of 59 participants who had valid measurements at baseline and 36 months. There was a significant association between the number of pharmacist recommendations and the odds of PCP acceptance (OR 1.19; 95%CI 1.00, 1.42; p < 0.05), but no association between the number of accepted recommendations and SBP. CONCLUSIONS Pharmacists provided actionable medication-related recommendations. We identified a significant decline in SBP at 36 months, but this reduction was not associated with recommendation acceptance. TRIAL REGISTRATION NCT01829256.",2020,SBP significantly declined by an average of 10.5 mmHg (p < 0.01) among 47 of 59 participants who had valid measurements at baseline and 36 months.,"[""STOP-DKD participants for whom (1) the pharmacist made at least one recommendation to the PCP; (2) there were available data regarding the PCP's corresponding action; and (3) there were SBP measurements at baseline and 36 months"", 'Patients with Diabetic Kidney Disease', 'Patients with diabetic kidney disease (DKD']","['Simultaneous risk factor control using Telehealth', 'monthly telephone calls with a pharmacist addressing health behaviors and medication management']","['systolic blood pressure (SBP', 'SBP', 'number of pharmacist recommendations and the odds of PCP acceptance']","[{'cui': 'C0450446', 'cui_str': 'Stops (attribute)'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to (procedure)'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}]","[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0376649', 'cui_str': 'Address'}, {'cui': 'C0018687'}, {'cui': 'C0150270', 'cui_str': 'Medication administration case management'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}]",176.0,0.0367517,SBP significantly declined by an average of 10.5 mmHg (p < 0.01) among 47 of 59 participants who had valid measurements at baseline and 36 months.,"[{'ForeName': 'Leah L', 'Initials': 'LL', 'LastName': 'Zullig', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, NC, USA.'}, {'ForeName': 'Shelley A', 'Initials': 'SA', 'LastName': 'Jazowski', 'Affiliation': 'Department of Population Health Sciences, Duke University, Durham, NC, USA.'}, {'ForeName': 'Clemontina A', 'Initials': 'CA', 'LastName': 'Davenport', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.'}, {'ForeName': 'Clarissa J', 'Initials': 'CJ', 'LastName': 'Diamantidis', 'Affiliation': 'Department of Population Health Sciences, Duke University, Durham, NC, USA.'}, {'ForeName': 'Megan M', 'Initials': 'MM', 'LastName': 'Oakes', 'Affiliation': 'Department of Population Health Sciences, Duke University, Durham, NC, USA.'}, {'ForeName': 'Sejal', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'Division of General Internal Medicine, Duke University, Durham, NC, USA.'}, {'ForeName': 'Jivan', 'Initials': 'J', 'LastName': 'Moaddeb', 'Affiliation': 'Division of General Internal Medicine, Duke University, Durham, NC, USA.'}, {'ForeName': 'Hayden B', 'Initials': 'HB', 'LastName': 'Bosworth', 'Affiliation': 'Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT), Durham Veterans Affairs Health Care System, Durham, NC, USA. boswo001@duke.edu.'}]",Journal of general internal medicine,['10.1007/s11606-019-05403-x'] 683,31659665,"Capsule Commentary on Odineal et al., Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial.",,2020,,['Chronic Pain'],[],[],"[{'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]",[],[],,0.488005,,"[{'ForeName': 'Michelle S', 'Initials': 'MS', 'LastName': 'Keller', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Michelle.keller@cshs.org.'}]",Journal of general internal medicine,['10.1007/s11606-019-05495-5'] 684,31667738,"Capsule Commentary on Shapiro et al., Impact of a Patient-Centered Behavioral Economics Intervention on Hypertension Control in a Highly Disadvantaged Population: a Randomized Trial.",,2020,,['Highly Disadvantaged Population'],['Behavioral Economics Intervention'],[],"[{'cui': 'C0032659', 'cui_str': 'Population'}]",[],[],,0.0291036,,"[{'ForeName': 'Justin S', 'Initials': 'JS', 'LastName': 'White', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, USA. Justin.White@ucsf.edu.'}]",Journal of general internal medicine,['10.1007/s11606-019-05492-8'] 685,30864534,Longitudinal Changes in Disability Rating Scale Scores: A Secondary Analysis Among Patients With Severe TBI Enrolled in the Epo Clinical Trial.,"OBJECTIVES Long-term neurological response to treatment after a severe traumatic brain injury (sTBI) is a dynamic process. Failure to capture individual heterogeneity in recovery may impact findings from single endpoint sTBI randomized controlled trials (RCT). The present study re-examined the efficacy of erythropoietin (Epo) and transfusion thresholds through longitudinal modeling of sTBI recovery as measured by the Disability Rating Scale (DRS). This study complements the report of primary outcomes in the Epo sTBI RCT, which failed to detect significant effects of acute treatment at 6 months post-injury. METHODS We implemented mixed effects models to characterize the recovery time-course and to examine treatment efficacy as a function of time post-injury and injury severity. RESULTS The inter-quartile range (25th-75th percentile) of DRS scores was 20-28 at week1; 8-24 at week 4; and 3-17 at 6 months. TBI severity group was found to significantly interact with Epo randomization group on mean DRS recovery curves. No significant differences in DRS recovery were found in transfusion threshold groups. CONCLUSIONS This study demonstrated the value of taking a comprehensive view of recovery from sTBI in the Epo RCT as a temporally dynamic process that is shaped by both treatment and injury severity, and highlights the importance of the timing of primary outcome measurement. Effects of Epo treatment varied as a function of injury severity and time. Future studies are warranted to understand the possible moderating influence of injury severity on treatment effects pertaining to sTBI recovery. (JINS, 2019, 25, 293-301).",2019,"No significant differences in DRS recovery were found in transfusion threshold groups. ",['severe traumatic brain injury (sTBI'],"['erythropoietin (Epo', 'Epo']","['Disability Rating Scale (DRS', 'mean DRS recovery curves', 'function of injury severity and time', 'Disability Rating Scale Scores', 'DRS recovery', 'DRS scores']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}]","[{'cui': 'C0014822', 'cui_str': 'Erythropoietin'}]","[{'cui': 'C0451125', 'cui_str': 'Disability rating scale (assessment scale)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4305168', 'cui_str': 'DRS (Disability Rating Scale) score'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0514107,"No significant differences in DRS recovery were found in transfusion threshold groups. ","[{'ForeName': 'Julia S', 'Initials': 'JS', 'LastName': 'Benoit', 'Affiliation': '1Texas Institute for Measurement Evaluation and Statistics (TIMES) and the Department of Basic Vision Sciences,University of Houston,Houston,Texas.'}, {'ForeName': 'H Julia', 'Initials': 'HJ', 'LastName': 'Hannay', 'Affiliation': '2Department of Psychology,TIMES, University of Houston,Houston,Texas.'}, {'ForeName': 'Jose-Miguel', 'Initials': 'JM', 'LastName': 'Yamal', 'Affiliation': '3Department of Biostatistics and Data Science,University of Texas School of Public Health,Houston,Texas.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Francis', 'Affiliation': '2Department of Psychology,TIMES, University of Houston,Houston,Texas.'}, {'ForeName': 'Imoigele', 'Initials': 'I', 'LastName': 'Aisiku', 'Affiliation': ""4Department of Emergency Medicine,Brigham and Women's Hospital,Boston,Massachusetts.""}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Robertson', 'Affiliation': '5Department of Neurosurgery,Baylor College of Medicine,Houston,Texas.'}]",Journal of the International Neuropsychological Society : JINS,['10.1017/S1355617718001078'] 686,31308848,Efficiency of Repetitive Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex in Disorders of Consciousness: A Randomized Sham-Controlled Study.,"Conventional transcranial direct current stimulation (tDCS) targeting the left dorsolateral prefrontal cortex (DLPFC) could improve arousal in disorders of consciousness (DOC). However, the comparative effectiveness of anodal stimulation of the left DLPFC and the electrophysiological effect of tDCS are yet to be determined. In this randomized sham-controlled design, patients were separated into three groups (left/right anodal tDCS, sham). Data on the clinical assessments and EEG were collected at baseline and after 2 weeks of tDCS. The outcome at 3-month follow-up was evaluated using the Glasgow Outcome Scale-Extended. Results showed that sessions of the left tDCS facilitated the excitability of the prefrontal cortex, whereas only one patient had a positive outcome. Targeting the right DLPFC was less effective, merely leading to activation of the stimulation site, with no effect on the state of arousal. Moreover, sham stimulation had minimal or no effect on any of the outcomes. These results provide evidence for a hemispheric asymmetry of tDCS effects in patients with DOC. Left anodal tDCS might be more effective for modulating cortical excitability compared to tDCS on the right DLPFC. However, future studies with large sample sizes are needed to confirm these findings. This trial is registered with NCT03809936.",2019,"Targeting the right DLPFC was less effective, merely leading to activation of the stimulation site, with no effect on the state of arousal.","['Disorders of Consciousness', 'patients with DOC']","['Conventional transcranial direct current stimulation (tDCS', 'Repetitive Transcranial Direct Current Stimulation']","['Glasgow Outcome Scale-Extended', 'excitability of the prefrontal cortex']","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011710', 'cui_str': 'desoxycortone'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0701887', 'cui_str': 'Glasgow Outcome Scale'}, {'cui': 'C0231449', 'cui_str': 'Extended (qualifier value)'}, {'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}]",,0.024924,"Targeting the right DLPFC was less effective, merely leading to activation of the stimulation site, with no effect on the state of arousal.","[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology & Brain Medical Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Yamei', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Department of Neurology & Brain Medical Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Lunjie', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': 'Department of Neurology & Brain Medical Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Yuehao', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology & Brain Medical Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Rehabilitation, Hangzhou Hospital of Zhejiang Armed Police Corps, Hangzhou 310051, China.'}, {'ForeName': 'Xiangming', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': ""Department of Rehabilitation Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, 310014, China.""}, {'ForeName': 'Benyan', 'Initials': 'B', 'LastName': 'Luo', 'Affiliation': 'Department of Neurology & Brain Medical Centre, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.'}]",Neural plasticity,['10.1155/2019/7089543'] 687,31365044,Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.,"Importance Several lines of evidence suggest that estradiol influences the course of schizophrenia, and a previous randomized controlled trial demonstrated that transdermal estradiol improved symptoms in female patients of childbearing age. However, many initial positive findings in schizophrenia research are not later replicated. Objective To independently replicate the results of the effect of estradiol on schizophrenia in women of childbearing age. Design, Setting, and Participants An 8-week randomized, placebo-controlled trial performed in the Republic of Moldova between December 4, 2015, and July 29, 2016, among 200 premenopausal women aged 19 to 46 years with schizophrenia or schizoaffective disorder as defined by the DSM-5. Intervention Patients were randomized to receive a 200-μg estradiol patch or placebo patch changed twice a week added to their antipsychotic treatment. Main Outcomes and Measures The primary outcome was the positive subscale of the Positive and Negative Syndrome Scale (PANSS; lower scores indicated fewer symptoms and higher scores indicated more symptoms), analyzed with mixed models for repeated measures on an intention-to-treat basis. Results A total of 100 women (median age, 38 years; interquartile range, 34-42 years) were randomized to receive an estradiol patch and 100 women (median age, 38 years; interquartile range, 31-41 years) were randomized to receive a placebo patch; the median age at baseline for the entire group of 200 women was 38.0 years (range, 19.5-46.0 years). At baseline, the mean positive PANSS score was 19.6 for both groups combined; at week 8, the mean positive PANSS score was 14.4 in the placebo group and 13.4 in the estradiol group. Compared with placebo, participants receiving add-on estradiol patches had statistically significant improvements in the primary outcome measure, PANSS positive subscale points (-0.94; 95% CI, -1.64 to -0.24; P = .008; effect size = 0.38). Post hoc heterogeneity analyses found that this effect occurred almost entirely in 100 participants older than 38.0 years (46 in placebo group vs 54 in estradiol group; difference, -1.98 points on the PANSS positive subscale; 95% CI, -2.94 to -1.02; P < .001). Younger participants did not benefit from estradiol (difference, 0.08 points on the PANSS positive subscale; 95% CI, -0.91 to 1.07; P = .87). Breast tenderness was more common in the estradiol group (n = 15) than in the placebo group (n = 1) as was weight gain (14 in estradiol group vs 1 in placebo group). Conclusions and Relevance The results independently replicate the finding that transdermal estradiol is an effective add-on treatment for women of childbearing age with schizophrenia and extend it, finding improvements in negative symptoms and finding that the effect could be specific to those older than 38 years. The results should be viewed in the context of the differences in the natural course of schizophrenia between females and males. Trial Registration ClinicalTrials.gov identifier: NCT03848234.",2019,"Compared with placebo, participants receiving add-on estradiol patches had statistically significant improvements in the primary outcome measure, PANSS positive subscale points (-0.94; 95% CI, -1.64 to -0.24; P = .008; effect size = 0.38).","['women of childbearing age', 'female patients of childbearing age', '100 participants older than 38.0 years (46 in', 'controlled trial performed in the Republic of Moldova between December 4, 2015, and July 29, 2016, among 200 premenopausal women aged 19 to 46 years with schizophrenia or schizoaffective disorder as defined by the DSM-5', '100 women (median age, 38 years; interquartile range, 34-42 years', 'Schizophrenia Among Women of Childbearing Age', 'and 100 women (median age, 38 years; interquartile range, 31-41 years', 'women of childbearing age with schizophrenia', 'the median age at baseline for the entire group of 200 women was 38.0 years (range, 19.5-46.0 years']","['transdermal estradiol', '200-μg estradiol patch or placebo patch changed twice a week added to their antipsychotic treatment', 'estradiol', 'placebo', 'placebo patch', 'estradiol patch', 'Adjunctive Estradiol']","['Breast tenderness', 'mean positive PANSS score', 'weight gain', 'positive subscale of the Positive and Negative Syndrome Scale', 'PANSS positive subscale points']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0026374', 'cui_str': 'Moldavian S.S.R.'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0036337', 'cui_str': 'Schizoaffective Disorder'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439751', 'cui_str': 'Entire (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C4521342', 'cui_str': 'Transdermal (intended site)'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0556985', 'cui_str': 'Two times a week'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0262397', 'cui_str': 'Breast tenderness (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}]",100.0,0.6327,"Compared with placebo, participants receiving add-on estradiol patches had statistically significant improvements in the primary outcome measure, PANSS positive subscale points (-0.94; 95% CI, -1.64 to -0.24; P = .008; effect size = 0.38).","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weiser', 'Affiliation': 'Stanley Medical Research Institute, Kensington, Maryland.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Levi', 'Affiliation': 'Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.'}, {'ForeName': 'Daisy', 'Initials': 'D', 'LastName': 'Zamora', 'Affiliation': 'Department of Psychiatry, University of North Carolina, Chapel Hill.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Biegon', 'Affiliation': 'Department of Radiology, Stony Brook University Medical School, Stony Brook, New York.'}, {'ForeName': 'John Paul', 'Initials': 'JP', 'LastName': 'SanGiovanni', 'Affiliation': 'Section on Nutritional Neuroscience, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Davidson', 'Affiliation': 'Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.'}, {'ForeName': 'Shimon', 'Initials': 'S', 'LastName': 'Burshtein', 'Affiliation': 'Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Gonen', 'Affiliation': 'Tangent Alzheimer Care, Breaza, Romania.'}, {'ForeName': 'Paull', 'Initials': 'P', 'LastName': 'Radu', 'Affiliation': 'Tangent Alzheimer Care, Breaza, Romania.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Slobozean Pavalache', 'Affiliation': 'Republican Psychiatric Hospital, Chișinău, Moldova.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Nastas', 'Affiliation': 'Psychiatry, Narcology, and Medical Psychology, State University of Medicine and Pharmaceuticals, ""Nicolae Testemianu,"" Chisinau, Moldova.'}, {'ForeName': 'Rina', 'Initials': 'R', 'LastName': 'Hemi', 'Affiliation': 'Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Ryan', 'Affiliation': 'Department of Psychiatry, University of Illinois, Chicago.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Davis', 'Affiliation': 'Department of Psychiatry, University of Illinois, Chicago.'}]",JAMA psychiatry,['10.1001/jamapsychiatry.2019.1842'] 688,31654351,"Capsule Commentary on Lee et al., Telemonitoring and Team-Based Management of Glycemic Control on People with Type 2 Diabetes: a Cluster Randomized Controlled Trial.",,2020,,['People with Type 2 Diabetes'],['Telemonitoring and Team-Based Management of Glycemic Control'],[],"[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],,0.134007,,"[{'ForeName': 'Shira H', 'Initials': 'SH', 'LastName': 'Fischer', 'Affiliation': 'RAND Corporation, Boston, USA. sfischer@rand.org.'}]",Journal of general internal medicine,['10.1007/s11606-019-05493-7'] 689,30904540,Mycotic Antimicrobial Localized Injection: A Randomized Clinical Trial Evaluating Intrastromal Injection of Voriconazole.,"PURPOSE To determine if there is a benefit to adjuvant intrastromal voriconazole (ISV) injections for primary treatment of filamentous fungal keratitis. DESIGN Outcome-masked, randomized controlled clinical trial. PARTICIPANTS Patients with moderate vision loss resulting from a smear-positive fungal ulcer. METHODS Study eyes were randomized to topical natamycin plus ISV injection versus topical natamycin alone. MAIN OUTCOME MEASURES The primary outcome of the trial was microbiological cure on 3-day repeat culture analysis. Secondary outcomes included microbiological cure on 7-day repeat culture analysis; 3-week and 3-month best spectacle-corrected visual acuity; infiltrate or scar size or both; rate of perforation; therapeutic penetrating keratoplasty (TPK); and other adverse events. RESULTS A total of 151 patients with smear-positive ulcers were screened and 70 were enrolled at Aravind Eye Hospital, Pondicherry, India. Baseline cultures grew Fusarium in 19 samples (27%), Aspergillus in 17 samples (24%), and other filamentous fungi in 19 samples (27%) and showed negative results in 13 samples (19%). Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression). Those randomized to ISV injection showed 0.5 logMAR lines (approximately 0.5 Snellen lines) of decreased visual acuity (95% CI, -2.6 to 3.6 lines; P = 0.75) and 0.55 mm worse infiltrate or scar size or both at 3 months after controlling for baseline values (95% CI, -0.13 to 1.25; P = 0.11). Intrastromal voriconazole injections showed a 2.85-fold increased hazard of perforation after controlling for baseline infiltrate depth (95% CI, 0.76-10.75; P = 0.12) but no difference in the rate of TPK (hazard ratio, 0.95; 95% CI, 0.44-2.04; P = 0.90). CONCLUSIONS There seems to be no benefit to adding ISV injections to topical natamycin in the primary treatment of moderate to severe filamentous fungal ulcers. Studies consistently suggest that voriconazole has a limited role in the treatment of filamentous fungal ulcers.",2019,"Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression).","['Patients with moderate vision loss resulting from a smear-positive fungal ulcer', '151 patients with smear-positive ulcers were screened and 70 were enrolled at Aravind Eye Hospital, Pondicherry, India', 'Study eyes']","['Mycotic Antimicrobial Localized Injection', 'voriconazole', 'Voriconazole', 'adjuvant intrastromal voriconazole (ISV) injections', 'topical natamycin plus ISV injection versus topical natamycin alone', 'Intrastromal voriconazole injections']","['rate of TPK', 'visual acuity', 'microbiological cure on 3-day repeat culture analysis', 'hazard of perforation', 'microbiological cure on 7-day repeat culture analysis; 3-week and 3-month best spectacle-corrected visual acuity; infiltrate or scar size or both; rate of perforation; therapeutic penetrating keratoplasty (TPK); and other adverse events', '3-day culture positivity', 'infiltrate or scar size']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3665346', 'cui_str': 'Unspecified visual loss'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0392752', 'cui_str': 'Localized (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0393080', 'cui_str': 'voriconazole'}, {'cui': 'C4060179', 'cui_str': 'voriconazole Injection [Vfend]'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0027444', 'cui_str': 'Natamycin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0015421', 'cui_str': 'Glasses'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity (observable entity)'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0010042', 'cui_str': 'Grafting, Corneal'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",151.0,0.538906,"Those randomized to ISV injection had 1.82 times the odds of 3-day culture positivity after controlling for baseline culture status (95% confidence interval [CI], 0.65-5.23; P = 0.26, bias-corrected logistic regression) and 1.98 times the odds of positive 7-day culture results, after controlling for baseline culture status (95% CI, 0.69-5.91; P = 0.20, bias-corrected logistic regression).","[{'ForeName': 'Shivananda', 'Initials': 'S', 'LastName': 'Narayana', 'Affiliation': 'Aravind Eye Hospital, Pondicherry, India.'}, {'ForeName': 'Tiruvengada', 'Initials': 'T', 'LastName': 'Krishnan', 'Affiliation': 'Aravind Eye Hospital, Pondicherry, India.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Ramakrishnan', 'Affiliation': 'Aravind Eye Hospital, Pondicherry, India.'}, {'ForeName': 'Puja Prativa', 'Initials': 'PP', 'LastName': 'Samantaray', 'Affiliation': 'Aravind Eye Hospital, Pondicherry, India.'}, {'ForeName': 'Ariana', 'Initials': 'A', 'LastName': 'Austin', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Pickel', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Porco', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Lietman', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Rose-Nussbaumer', 'Affiliation': 'Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California; Department of Ophthalmology, University of California, San Francisco, San Francisco, California. Electronic address: jennifer.rose-nussbaumer@ucsf.edu.'}]",Ophthalmology,['10.1016/j.ophtha.2019.03.020'] 690,30790587,Postoperative Endothelial Cell Density Is Associated with Late Endothelial Graft Failure after Descemet Stripping Automated Endothelial Keratoplasty.,"PURPOSE To determine whether preoperative endothelial cell density (ECD) and postoperative ECD after Descemet stripping automated endothelial keratoplasty (DSAEK) are associated with late endothelial graft failure (LEGF) in the Cornea Preservation Time Study (CPTS). DESIGN Cohort study within a multicenter, randomized clinical trial. PARTICIPANTS A total of 1007 individuals (1223 study eyes), mean age 70 years, undergoing DSAEK for Fuchs' dystrophy (94% of eyes) or pseudophakic or aphakic corneal edema (PACE) (6% of eyes) and followed for up to 5 years. METHODS Central ECD was determined by a central image analysis reading center. Preoperative ECD was determined for 1209 eyes that did not fail and 14 eyes that experienced LEGF. The ECD at 6 and 12 months after DSAEK, the change in ECD from preoperative to 6 and 12 months, surgeon-reported operative complications, and postoperative graft dislocation were investigated for an association with LEGFs unrelated to other postoperative events. Univariable and multivariable Cox proportional hazards regression models were used to assess associations. MAIN OUTCOME MEASURES Late endothelial graft failure and its associations with pre- and postoperative ECD and operative complications. RESULTS The cumulative probability of LEGF was 1.3% (95% confidence interval [CI], 0.8%-2.4%). Median (interquartile range [IQR]) preoperative ECDs were similar for eyes with LEGF (2523; 2367-3161) cells/mm 2 ) and eyes without failure (2727; 2508-2973) cells/mm 2 ) (P = 0.34). The ECD at 6 months was associated with LEGF (P < 0.001) in time-to-event analyses, whereas preoperative ECD was not (P = 0.55). The cumulative incidence (95% CI) of LEGF was 6.5% (3.0%, 14.0%) for 97 grafts with a 6-month ECD less than 1200 cells/mm 2 , 0.3% (0.0%, 2.4%) for 310 grafts with a 6-month ECD between 1200 and 2000 cells/mm 2 , and 0.6% (0.1%, 2.7%) for 589 grafts with a 6-month ECD greater than 2000 cells/mm 2 . In multivariable analyses, ECD at 6 months and operative complications were both associated with LEGF (P = 0.002 and P = 0.01, respectively), whereas graft dislocation was not (P = 0.61). CONCLUSIONS In eyes undergoing DSAEK, preoperative ECD is unrelated to LEGF, whereas lower ECD at 6 months is associated with LEGF. Early endothelial cell loss after DSAEK and intraoperative complications should be minimized to improve graft survival.",2019,"The ECD at 6 months was associated with LEGF (P < 0.001) in time-to-event analyses, whereas preoperative ECD was not (P = 0.55).","[""A total of 1007 individuals (1223 study eyes), mean age 70 years, undergoing DSAEK for Fuchs' dystrophy (94% of eyes) or pseudophakic or aphakic corneal edema (PACE) (6% of eyes) and followed for up to 5 years""]","['LEGF', 'preoperative endothelial cell density (ECD) and postoperative ECD after Descemet stripping automated endothelial keratoplasty (DSAEK']","['graft dislocation', 'Postoperative Endothelial Cell Density', 'graft survival', 'operative complications', 'Late endothelial graft failure', 'Median (interquartile range [IQR]) preoperative ECDs', 'operative complications, and postoperative graft dislocation', 'cumulative probability of LEGF', 'preoperative ECD', 'Preoperative ECD', 'cumulative incidence']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0333606', 'cui_str': 'Dystrophy (morphologic abnormality)'}, {'cui': 'C0339264', 'cui_str': 'Aphakic corneal edema (disorder)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell count'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C2366835', 'cui_str': 'Endothelial keratoplasty'}]","[{'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0429518', 'cui_str': 'Endothelial cell count'}, {'cui': 'C0018131', 'cui_str': 'Graft Survival'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.205406,"The ECD at 6 months was associated with LEGF (P < 0.001) in time-to-event analyses, whereas preoperative ECD was not (P = 0.55).","[{'ForeName': 'Sanjay V', 'Initials': 'SV', 'LastName': 'Patel', 'Affiliation': 'Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Jonathan H', 'Initials': 'JH', 'LastName': 'Lass', 'Affiliation': 'Case Western Reserve University Department of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Cleveland, Ohio. Electronic address: jonathan.lass@uhhospitals.org.'}, {'ForeName': 'Beth Ann', 'Initials': 'BA', 'LastName': 'Benetz', 'Affiliation': 'Case Western Reserve University Department of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Cleveland, Ohio.'}, {'ForeName': 'Loretta B', 'Initials': 'LB', 'LastName': 'Szczotka-Flynn', 'Affiliation': 'Case Western Reserve University Department of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Cleveland, Ohio.'}, {'ForeName': 'Nathan J', 'Initials': 'NJ', 'LastName': 'Cohen', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Allison R', 'Initials': 'AR', 'LastName': 'Ayala', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Maureen G', 'Initials': 'MG', 'LastName': 'Maguire', 'Affiliation': 'Center for Preventive Ophthalmology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Donna C', 'Initials': 'DC', 'LastName': 'Drury', 'Affiliation': 'University of Texas Southwestern, Dallas, Texas.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Dunn', 'Affiliation': 'Michigan Cornea Consultants, P.C., Southfield, Michigan.'}, {'ForeName': 'Bennie H', 'Initials': 'BH', 'LastName': 'Jeng', 'Affiliation': 'University of California-San Francisco, San Francisco, California (now the University of Maryland, Baltimore, Maryland).'}, {'ForeName': 'Marc F', 'Initials': 'MF', 'LastName': 'Jones', 'Affiliation': 'Northeast Ohio Eye Surgeons, Kent, Ohio.'}, {'ForeName': 'Harry J', 'Initials': 'HJ', 'LastName': 'Menegay', 'Affiliation': 'Case Western Reserve University Department of Ophthalmology and Visual Sciences and University Hospitals Eye Institute, Cleveland, Ohio.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Oliva', 'Affiliation': 'Medical Eye Center, Medford, Oregon.'}, {'ForeName': 'George O D', 'Initials': 'GOD', 'LastName': 'Rosenwasser', 'Affiliation': 'Central Pennsylvania Eye Center, Hershey, Pennsylvania.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Seedor', 'Affiliation': 'New York Eye and Ear Infirmary, New York, New York.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Terry', 'Affiliation': 'Devers Eye Institute, Portland, Oregon.'}, {'ForeName': 'David D', 'Initials': 'DD', 'LastName': 'Verdier', 'Affiliation': 'Verdier Eye Center, Grand Rapids, Michigan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2019.02.011'] 691,31042301,Gait Mechanics in Women of the ACL-SPORTS Randomized Control Trial: Interlimb Symmetry Improves Over Time Regardless of Treatment Group.,"Women after anterior cruciate ligament (ACL) injury and ACL reconstruction (ACLR) are more likely than men to exhibit asymmetric movement patterns, which are associated with post-traumatic osteoarthritis. We developed the ACL specialized post-operative return-to-sports (ACL-SPORTS) randomized control trial to test the effect of strength, agility, plyometric, and secondary prevention (SAPP) training with and without perturbation training (SAPP + PERT) on gait mechanics in women after ACLR. We hypothesized that movement symmetry would improve over time across both groups but more so among the SAPP + PERT group. Thirty-nine female athletes 3-9 months after primary ACLR were randomized to SAPP or SAPP + PERT training. Biomechanical testing during overground walking occurred before (Pre-training) and after (Post-training) training and one and 2 years post-operatively. Hip and knee kinematic and kinetic variables were compared using repeated measures analysis of variance with Bonferroni corrections for post hoc comparisons (α = 0.05). There was a time by limb interaction effect (p = 0.028) for peak knee flexion angle (PKFA), the primary outcome which powered the study, characterized by smaller PKFA in the involved compared to uninvolved limbs across treatment groups at Pre-training, Post-training, and 1 year, but not 2 years. Similar findings occurred across sagittal plane knee excursions and kinetics and hip extension excursion at midstance. There were no meaningful interactions involving group. Neither SAPP nor SAPP + PERT training improved walking mechanics, which persisted 1 but not 2 years after ACLR. Statement of clinical significance: Asymmetrical movement patterns persisted long after participants achieved symmetrical strength and functional performance, suggesting more time is needed to recover fully after ACLR. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1743-1753, 2019.",2019,"Neither SAPP nor SAPP + PERT training improved walking mechanics, which persisted 1 but not 2 years after ACLR.","['women after ACLR', 'Women of the ACL-SPORTS Randomized Control Trial', 'Thirty-nine female athletes 3-9 months after primary ACLR']","['strength, agility, plyometric, and secondary prevention (SAPP) training with and without perturbation training (SAPP\u2009+\u2009PERT', 'SAPP or SAPP\u2009+\u2009PERT training', 'anterior cruciate ligament (ACL) injury and ACL reconstruction (ACLR']","['Hip and knee kinematic and kinetic variables', 'walking mechanics', 'gait mechanics', 'Interlimb Symmetry Improves Over Time', 'Gait Mechanics', 'time by limb interaction effect', 'peak knee flexion angle (PKFA', 'sagittal plane knee excursions and kinetics and hip extension excursion']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3816447', 'cui_str': '39 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0679699', 'cui_str': 'Disease Prevention, Secondary'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1456574', 'cui_str': 'Anterior Cruciate Ligament Injuries'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}]","[{'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0376706', 'cui_str': 'Mechanics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332516', 'cui_str': 'Symmetry'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0935598', 'cui_str': 'Sagittal plane'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}]",39.0,0.0583823,"Neither SAPP nor SAPP + PERT training improved walking mechanics, which persisted 1 but not 2 years after ACLR.","[{'ForeName': 'Jacob J', 'Initials': 'JJ', 'LastName': 'Capin', 'Affiliation': 'Biomechanics and Movement Science Program, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarzycki', 'Affiliation': 'Department of Physical Therapy, Arcadia University, Glenside, Pennsylvania.'}, {'ForeName': 'Naoaki', 'Initials': 'N', 'LastName': 'Ito', 'Affiliation': 'Department of Physical Therapy, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Ashutosh', 'Initials': 'A', 'LastName': 'Khandha', 'Affiliation': 'Department of Biomedical Engineering, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Celeste', 'Initials': 'C', 'LastName': 'Dix', 'Affiliation': 'Biomechanics and Movement Science Program, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Manal', 'Affiliation': 'Biomechanics and Movement Science Program, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Thomas S', 'Initials': 'TS', 'LastName': 'Buchanan', 'Affiliation': 'Department of Biomedical Engineering, University of Delaware, Newark, Delaware.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Snyder-Mackler', 'Affiliation': 'Biomechanics and Movement Science Program, University of Delaware, Newark, Delaware.'}]",Journal of orthopaedic research : official publication of the Orthopaedic Research Society,['10.1002/jor.24314'] 692,30796686,Use of a Transparent Cap Increases the Diagnostic Yield in Antegrade Single-Balloon Enteroscopy for Obscure GI Bleed.,"BACKGROUND AND AIMS Single-balloon enteroscopy (SBE) is utilized in the evaluation of obscure gastrointestinal bleeding, but 40-50% of these patients experience continued GI blood loss, in part due to missed lesions. The utilization of a transparent cap attached to the end of the endoscope can improve mucosal visualization in other endoscopic applications, but has not yet been evaluated in SBE. The aim of this study was to evaluate the impact of a cap on the diagnostic yield of SBE. METHODS Consecutive adult patients scheduled for anterograde SBE for the evaluation of obscure GI bleeding were screened for inclusion from 2014 to 2017. Patients were randomized to SBE with or without a transparent cap. The primary outcome was the proportion of enteroscopies in which a P2 lesion (high potential for bleeding) was identified. RESULTS A total of 90 patients (65.7 ± 12.7 years old, 47.7% female) were analyzed. There were significantly more P2 arteriovenous malformations identified in the cap group (14.8% vs. 0%, p = 0.02). Additionally, the use of a cap was associated with a significantly greater depth of small bowel insertion (191.9 cm vs. 156.2 cm, p = 0.01). There was one perforation in the group without a cap, successfully treated with clip placement, and no adverse events in the cap group. CONCLUSIONS The use of a transparent cap during SBE performed for the evaluation of obscure gastrointestinal bleeding may be an important, safe augmentation to standard SBE techniques.",2019,"There was one perforation in the group without a cap, successfully treated with clip placement, and no adverse events in the cap group. ","['90 patients (65.7\u2009±\u200912.7\xa0years old, 47.7% female', 'Consecutive adult patients scheduled for anterograde SBE for the evaluation of obscure GI bleeding were screened for inclusion from 2014 to 2017']","['Transparent Cap', 'balloon enteroscopy (SBE', 'SBE with or without a transparent cap']","['depth of small bowel insertion', 'P2 arteriovenous malformations', 'adverse events', 'proportion of enteroscopies in which a P2 lesion (high potential for bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517546', 'cui_str': '12.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0589502', 'cui_str': 'Antegrade direction (qualifier value)'}, {'cui': 'C0014122', 'cui_str': 'Endocarditis Lenta'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal Hemorrhage'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]","[{'cui': 'C0522503', 'cui_str': 'Translucent (qualifier value)'}, {'cui': 'C0179586', 'cui_str': 'Cap (physical object)'}, {'cui': 'C4277732', 'cui_str': 'Balloon Enteroscopy'}, {'cui': 'C0014122', 'cui_str': 'Endocarditis Lenta'}]","[{'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0021852', 'cui_str': 'Intestines, Small'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0003857', 'cui_str': 'Arteriovenous Malformations'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",90.0,0.0716444,"There was one perforation in the group without a cap, successfully treated with clip placement, and no adverse events in the cap group. ","[{'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Hasak', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA. hasak.s@wustl.edu.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Lang', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Early', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Mullady', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Koushik', 'Initials': 'K', 'LastName': 'Das', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'ChienHuan', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Sayuk', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Kushnir', 'Affiliation': 'Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8124, Saint Louis, MO, 63110, USA.'}]",Digestive diseases and sciences,['10.1007/s10620-019-05532-7'] 693,30790145,Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.,"Postpartum depression is one of the most common complications of childbirth. Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences. There are a number of therapeutic interventions for postpartum depression including pharmacotherapy, psychotherapy, neuromodulation, and hormonal therapy among others, most of which have been adapted from the treatment of major depressive disorder outside of the peripartum period. Current evidence of antidepressant treatment for postpartum depression is limited by the small number of randomized clinical trials, underpowered samples, and the lack of long-term follow-up. The peripartum period is characterized by rapid and significant physiological change in plasma levels of endocrine hormones, peptides, and neuroactive steroids. Evidence supporting the role of neuroactive steroids and γ-aminobutyric acid (GABA) in the pathophysiology of postpartum depression led to the investigation of synthetic neuroactive steroids and their analogs as potential treatment for postpartum depression. Brexanolone, a soluble proprietary intravenous preparation of synthetic allopregnanolone, has been developed. A recent series of open-label and placebo-controlled randomized clinical trials of brexanolone in postpartum depression demonstrated a rapid reduction in depressive symptoms, and has led to the submission for regulatory approval to the US Food and Drug Administration (decision due in March 2019). SAGE-217, an allopregnanolone analog, with oral bioavailability, was recently tested in a randomized, double-blind, placebo-controlled phase III study in severe postpartum depression, with reportedly positive results. Finally, a 3β-methylated synthetic analog of allopregnanolone, ganaxolone, is being tested in both intravenous and oral forms, in randomized, double-blind, placebo-controlled phase II studies in severe postpartum depression.",2019,"Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences.",[],"['neuroactive steroids and γ-aminobutyric acid (GABA', 'placebo', 'allopregnanolone, ganaxolone', 'brexanolone', 'Brexanolone']",[],[],"[{'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0220780', 'cui_str': 'Aminobutyric Acid'}, {'cui': 'C0016904', 'cui_str': 'gamma-Aminobutyric Acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0376202', 'cui_str': 'Allopregnanolone'}, {'cui': 'C0537150', 'cui_str': 'ganaxolone'}, {'cui': 'C4548848', 'cui_str': 'brexanolone'}]",[],,0.279329,"Untreated postpartum depression can have substantial adverse effects on the well-being of the mother and child, negatively impacting child cognitive, behavioral, and emotional development with lasting consequences.","[{'ForeName': 'Ariela', 'Initials': 'A', 'LastName': 'Frieder', 'Affiliation': ""Department of Psychiatry, Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, New York, NY, 11004, USA.""}, {'ForeName': 'Madeleine', 'Initials': 'M', 'LastName': 'Fersh', 'Affiliation': ""Department of Psychiatry, Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, New York, NY, 11004, USA.""}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Hainline', 'Affiliation': 'Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.'}, {'ForeName': 'Kristina M', 'Initials': 'KM', 'LastName': 'Deligiannidis', 'Affiliation': ""Department of Psychiatry, Women's Behavioral Health, Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, New York, NY, 11004, USA. kdeligian1@northwell.edu.""}]",CNS drugs,['10.1007/s40263-019-00605-7'] 694,30994576,"Sexual frequency and pain in a randomized clinical trial of vaginal estradiol tablets, moisturizer, and placebo in postmenopausal women.","OBJECTIVE To evaluate the efficacy of two common interventions for bothersome postmenopausal vaginal symptoms on improving sexual frequency and pain. METHODS This is a post-hoc analysis of data from a 12-week double-blind placebo-controlled trial that randomized postmenopausal women (ages 45-70 years) with moderate-severe genitourinary discomfort to vaginal 10 μg estradiol tablet plus placebo gel (n = 102), placebo tablet plus vaginal moisturizer (n = 100), or dual placebo (n = 100). Outcomes were proportion of sexually active women at 12 weeks, frequency of sexual activity, and pain severity with sexual activity (0-3 scale). Consistent with the original study design, comparisons were made between each active arm and the dual placebo arm. RESULTS Most women enrolled in the trial, 294/302 (97%), had sufficient data to be included in this analysis. Mean age of participants was 61 years, most were white (88%), college educated (66%), and most reported sexual activity in the month before enrollment (81%). After 12 weeks of treatment, a similar proportion of women in the vaginal estrogen and dual placebo groups reported sexual activity in the past week (50% and 40%; P = 0.10) and the past month (78% and 84%, P = 0.52). Mean (standard deviation) pain with sexual activity scores at 12 weeks were similar between vaginal estrogen (1.0 [1.0]) and placebo (0.9 [0.9], P = 0.52] groups. The proportion sexually active at 12 weeks (35%) and mean (standard deviation) pain severity in the vaginal moisturizer group (1.1 [0.9]) did not differ from placebo (P = 0.36). CONCLUSIONS Compared to placebo, neither low-dose vaginal estradiol nor vaginal moisturizer treatment over 12 weeks resulted in significantly greater increases in the proportions of women reporting sexual activity or improvement in pain scores with sexual activity. TRIAL REGISTRATION Clinical trials.gov: NCT02516202.",2019,"Compared to placebo, neither low-dose vaginal estradiol nor vaginal moisturizer treatment over 12 weeks resulted in significantly greater increases in the proportions of women reporting sexual activity or improvement in pain scores with sexual activity. ","['postmenopausal women', 'n = 102', 'Mean age of participants was 61 years, most were white (88%), college educated (66', 'randomized postmenopausal women (ages 45-70 years) with moderate-severe genitourinary discomfort to vaginal 10\u200aμg']","['vaginal estradiol tablets, moisturizer, and placebo', 'estradiol tablet plus placebo gel', 'placebo', 'placebo tablet plus vaginal moisturizer (n\u200a=\u200a100), or dual placebo']","['proportion sexually active', 'mean (standard deviation) pain severity', 'Sexual frequency and pain', 'Mean (standard deviation) pain with sexual activity scores', 'sexual activity', 'pain scores with sexual activity', 'sexual frequency and pain', 'frequency of sexual activity, and pain severity with sexual activity', 'proportions of women reporting sexual activity', 'bothersome postmenopausal vaginal symptoms']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}]","[{'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0241028', 'cui_str': 'Sexually active (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0036864', 'cui_str': 'Sexual Behavior'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",102.0,0.707351,"Compared to placebo, neither low-dose vaginal estradiol nor vaginal moisturizer treatment over 12 weeks resulted in significantly greater increases in the proportions of women reporting sexual activity or improvement in pain scores with sexual activity. ","[{'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Mitchell', 'Affiliation': 'Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Larson', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Diem', 'Affiliation': 'Departments of Medicine and Epidemiology and Community Health, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Andrea Z', 'Initials': 'AZ', 'LastName': 'LaCroix', 'Affiliation': 'Department of Family Medicine and Public Health, University of California at San Diego, La Jolla, CA.'}, {'ForeName': 'Bette', 'Initials': 'B', 'LastName': 'Caan', 'Affiliation': 'Division of Research, Kaiser Permanente, Oakland of Northern California, CA.'}, {'ForeName': 'Jan L', 'Initials': 'JL', 'LastName': 'Shifren', 'Affiliation': 'Vincent Obstetrics and Gynecology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Nancy F', 'Initials': 'NF', 'LastName': 'Woods', 'Affiliation': 'University of Washington School of Nursing, Seattle, WA.'}, {'ForeName': 'Julia R', 'Initials': 'JR', 'LastName': 'Heiman', 'Affiliation': 'Kinsey Institute for Research in Sex, Gender and Reproduction, Psychological and Brain Sciences, Indiana University, Bloomington, IN.'}, {'ForeName': 'Stacy T', 'Initials': 'ST', 'LastName': 'Lindau', 'Affiliation': 'Departments of Obstetrics and Gynecology and Medicine-Geriatrics and Palliative Medicine, University of Chicago, Chicago, IL.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001341'] 695,30421240,"Peak airway pressure is lower during pressure-controlled than during manual facemask ventilation for induction of anesthesia in pediatric patients-a randomized, clinical crossover trial.","PURPOSE Facemask ventilation during the induction of general anesthesia in paediatric patients remains a challenge as it may result in hypoxic conditions and gastric insufflation with subsequent regurgitation and aspiration. So far, it is unclear if pressure-controlled or manual facemask ventilation is preferable in children. We hypothesized that pressure-controlled ventilation in apnoeic children results in lower peak airway pressure and flow rates compared to manual ventilation at comparable respiratory rates and tidal volumes. METHODS Sixty-two lung-healthy children undergoing scheduled ear-nose-throat surgery were included in the study. After the induction of anesthesia, the patient's lungs were consecutively ventilated via a facemask in either manual or pressure-controlled mode, in randomized order. The primary outcome measure was peak airway pressure. Secondary outcome measures included positive end-expiratory pressure, airway compliance, tidal volume and airway flow. RESULTS Data of 52 patients could be analyzed. Pressure-controlled ventilation resulted in a lower mean and peak inspiratory pressure (both p < 0.001), airway pressure amplitude (p = 0.01) and inspiratory peak flow rate (p = 0.005) compared to manual ventilation. The ratio of inspiration to expiration time was lower in pressure-controlled ventilation compared to manual ventilation (p < 0.001). CONCLUSION Pressure-controlled facemask ventilation during induction of anesthesia in pediatric patients results in lower airway pressure, and lower flow rates compared to manual ventilation, at comparable tidal and minute volumes.",2019,"Pressure-controlled ventilation resulted in a lower mean and peak inspiratory pressure (both p < 0.001), airway pressure amplitude (p = 0.01) and inspiratory peak flow rate (p = 0.005) compared to manual ventilation.","['children', 'paediatric patients', 'Sixty-two lung-healthy children undergoing scheduled ear-nose-throat surgery were included in the study', 'pediatric patients']","['Pressure-controlled facemask ventilation', 'manual facemask ventilation']","['peak airway pressure', 'lower airway pressure, and lower flow rates', 'peak airway pressure and flow rates', 'Peak airway pressure', 'positive end-expiratory pressure, airway compliance, tidal volume and airway flow', 'ratio of inspiration to expiration time', 'peak inspiratory pressure', 'airway pressure amplitude', 'inspiratory peak flow rate']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0028429', 'cui_str': 'Nose'}, {'cui': 'C0230069', 'cui_str': 'Structure of anterior portion of neck'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3494516', 'cui_str': 'Positive end expiratory pressure (observable entity)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0232021', 'cui_str': 'Maximum inspiratory pressure (observable entity)'}, {'cui': 'C0729283', 'cui_str': 'Peak flow rate (respiratory)'}]",,0.0508722,"Pressure-controlled ventilation resulted in a lower mean and peak inspiratory pressure (both p < 0.001), airway pressure amplitude (p = 0.01) and inspiratory peak flow rate (p = 0.005) compared to manual ventilation.","[{'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Goebel', 'Affiliation': 'Department of Anesthesiology and Critical Care, Medical Center, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schumann', 'Affiliation': 'Department of Anesthesiology and Critical Care, Medical Center, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Wirth', 'Affiliation': 'Department of Anesthesiology and Critical Care, Medical Center, University of Freiburg, Freiburg, Germany. steffen.wirth@uniklinik-freiburg.de.'}]",Journal of anesthesia,['10.1007/s00540-018-2580-y'] 696,30679770,Can electric fields explain inter-individual variability in transcranial direct current stimulation of the motor cortex?,"The effects of transcranial direct current stimulation (tDCS) on motor cortical excitability are highly variable between individuals. Inter-individual differences in the electric fields generated in the brain by tDCS might play a role in the variability. Here, we explored whether these fields are related to excitability changes following anodal tDCS of the primary motor cortex (M1). Motor evoked potentials (MEPs) were measured in 28 healthy subjects before and after 20 min sham or 1 mA anodal tDCS of right M1 in a double-blind crossover design. The electric fields were individually modelled based on magnetic resonance images. Statistical analysis indicated that the variability in the MEPs could be partly explained by the electric fields, subjects with the weakest and strongest fields tending to produce opposite changes in excitability. To explain the findings, we hypothesized that the likely locus of action was in the hand area of M1, and the effective electric field component was that in the direction normal to the cortical surface. Our results demonstrate that a large part of inter-individual variability in tDCS may be due to differences in the electric fields. If this is the case, electric field dosimetry could be useful for controlling the neuroplastic effects of tDCS.",2019,"Statistical analysis indicated that the variability in the MEPs could be partly explained by the electric fields, subjects with the weakest and strongest fields tending to produce opposite changes in excitability.","['individuals', '28 healthy subjects before and after 20']","['min sham or 1\u2009mA anodal tDCS of right M1', 'transcranial direct current stimulation (tDCS']","['motor cortical excitability', 'Motor evoked potentials (MEPs']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1172076', 'cui_str': '1-(PE)-MA'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}]","[{'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0282617', 'cui_str': 'Evoked Potentials, Motor'}]",28.0,0.0436586,"Statistical analysis indicated that the variability in the MEPs could be partly explained by the electric fields, subjects with the weakest and strongest fields tending to produce opposite changes in excitability.","[{'ForeName': 'Ilkka', 'Initials': 'I', 'LastName': 'Laakso', 'Affiliation': 'Department of Electrical Engineering and Automation, Aalto University, Espoo, 02150, Finland. ilkka.laakso@aalto.fi.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Mikkonen', 'Affiliation': 'Department of Electrical Engineering and Automation, Aalto University, Espoo, 02150, Finland.'}, {'ForeName': 'Soichiro', 'Initials': 'S', 'LastName': 'Koyama', 'Affiliation': 'Faculty of Rehabilitation, School of Health Sciences, Fujita Health University, Toyoake, 470-1192, Japan.'}, {'ForeName': 'Akimasa', 'Initials': 'A', 'LastName': 'Hirata', 'Affiliation': 'Department of Computer Science and Engineering, Nagoya Institute of Technology, Nagoya, 466-8555, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Laboratory of Psychology, Hamamatsu University School of Medicine, Hamamatsu, 431-3192, Japan.'}]",Scientific reports,['10.1038/s41598-018-37226-x'] 697,31150976,Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study.,"Exposure to per- and polyfluoroalkyl substances (PFASs) may interfere with lipid regulation. However, most previous studies were cross-sectional with the risk of reverse causation, suggesting a need for long-term prospective studies. We examined the relationship of baseline plasma PFAS concentrations with repeated measures of blood lipids. We included 888 prediabetic adults from the Diabetes Prevention Program (DPP) and DPP Outcomes Study, who had measurements of 6 plasma PFAS concentrations at baseline (1996-1999) and repeated measures of blood lipids over 15 years of follow-up, and were initially randomized to placebo or a lifestyle intervention. We used linear regression to examine cross-sectional associations of PFAS concentrations and lipid levels at baseline, and evaluated prospective risks of hypercholesterolemia and hypertriglyceridemia using Cox proportional hazard models, and tested for effect modification by study arm. Participants (65.9% female, 57.0% White, 65.9% aged 40-59 years) had comparable PFAS concentrations [e.g., median (IQR) perfluorooctanoic acid (PFOA) 4.9 ng/mL (3.2)] with the general U.S. population in 1999-2000. We observed higher total cholesterol at baseline per doubling of PFOA (β: 6.1 mg/dL, 95% CI: 3.1, 9.04), perfluorohexane sulfonic acid (PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0). Prospectively, baseline concentrations of several PFASs, including PFOA, PFOS, PFHxS and PFNA, predicted higher risks of incident hypercholesterolemia and hypertriglyceridemia, but only in the placebo group and not the lifestyle intervention group. For example, participants in the placebo group with PFOA concentration > median (4.9 ng/mL) were almost twice as likely (HR: 1.90, 95% CI: 1.25, 2.88) to develop hypertriglyceridemia compared to those ≤median. Findings suggest adverse effects of some PFASs on lipid profiles in prediabetic adults. However, the detrimental effect was attenuated with a lifestyle intervention.",2019,"(PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0).","['Participants (65.9% female, 57.0% White, 65.9% aged 40-59\u202fyears) had comparable PFAS concentrations [e.g., median (IQR) perfluorooctanoic acid (PFOA) 4.9\u202fng/mL (3.2)] with the general U.S. population in 1999-2000', 'pre-diabetic adults', '888 prediabetic adults from the Diabetes Prevention Program (DPP) and DPP Outcomes Study, who had measurements of 6 plasma PFAS concentrations at baseline (1996-1999) and repeated measures of blood lipids over 15\u202fyears of follow-up', 'prediabetic adults']","['Per- and polyfluoroalkyl substances', 'placebo', 'perfluorohexane sulfonic acid', 'placebo or a lifestyle intervention', 'per- and polyfluoroalkyl substances (PFASs']","['baseline concentrations of several PFASs, including PFOA, PFOS, PFHxS and PFNA, predicted higher risks of incident hypercholesterolemia and hypertriglyceridemia', 'blood lipid levels', 'total cholesterol', 'PFOA concentration\u202f>\u202fmedian', 'lipid profiles', 'hypertriglyceridemia']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0070403', 'cui_str': 'perfluorooctanoic acid'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0058353', 'cui_str': 'DPPS'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0005768'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0439861', 'cui_str': 'Substance (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1176320', 'cui_str': 'perflexane'}, {'cui': 'C0038762', 'cui_str': 'Sulfonic Acids'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0005768'}, {'cui': 'C0428460', 'cui_str': 'Finding of lipid level (finding)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}]",888.0,0.17023,"(PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0).","[{'ForeName': 'Pi-I D', 'Initials': 'PD', 'LastName': 'Lin', 'Affiliation': 'Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Cardenas', 'Affiliation': 'Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA.'}, {'ForeName': 'Russ', 'Initials': 'R', 'LastName': 'Hauser', 'Affiliation': 'Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Diane R', 'Initials': 'DR', 'LastName': 'Gold', 'Affiliation': ""Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Ken P', 'Initials': 'KP', 'LastName': 'Kleinman', 'Affiliation': 'Department of Biostatistics, School of Public Health and Human Sciences, University of Massachusetts Amherst, Amherst, MA, USA.'}, {'ForeName': 'Marie-France', 'Initials': 'MF', 'LastName': 'Hivert', 'Affiliation': 'Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA; Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Abby F', 'Initials': 'AF', 'LastName': 'Fleisch', 'Affiliation': 'Pediatric Endocrinology and Diabetes, Maine Medical Center, Portland, ME, USA; Center for Outcomes Research and Evaluation, Maine Medical Center Research Institute, Portland, ME, USA.'}, {'ForeName': 'Antonia M', 'Initials': 'AM', 'LastName': 'Calafat', 'Affiliation': 'Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, USA.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Webster', 'Affiliation': 'Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Horton', 'Affiliation': 'Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Oken', 'Affiliation': 'Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA. Electronic address: emily_oken@harvardpilgrim.org.'}]",Environment international,['10.1016/j.envint.2019.05.027'] 698,31148473,"The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies.","BACKGROUND Low adherence to statin (HMG-CoA reductase inhibitors) medication is common. Here, we report on the design and implementation of the Habit Formation trial. This clinical trial assessed whether the interventions, based on principles from behavioral economics, might improve statin adherence and lipid control in at-risk populations. We describe the rationale and methods for the trial, recruitment, conduct and follow-up. We also report on several barriers we encountered with recruitment and conduct of the trial, solutions we devised and efforts we will make to assess their impact on our study. METHODS Habit Formation is a four-arm randomized controlled trial. Recruitment of 805 participants at elevated risk of atherosclerotic cardiovascular disease with evidence of sub-optimal statin adherence and low-density lipoprotein (LDL) control is complete. Initially, we recruited from large employers (Employers) and a national health insurance company (Insurers) using mailed letters; individuals with a statin Medication Possession Ratio less than 80% were invited to participate. Respondents were enrolled if a laboratory measurement of low-density lipoprotein was >130 mg/dL. Subsequently, we recruited participants from the Penn Medicine Health System; individuals with usual-care low-density lipoprotein of >100 mg/dL in the electronic medical record were recruited using phone, text, email, and regular mail. Eligible participants self-reported incomplete medication adherence. During a 6-month intervention period, all participants received a wireless-enabled pill bottle for their statins and daily reminder messages to take their medication. Principles of behavioral economics were used to design three financial incentives, specifically a Simple Daily Sweepstakes rewarding daily medication adherence, a Deadline Sweepstakes where participants received either a full or reduced incentive depending on whether they took their medication before or after a daily reminder or Sweepstakes Plus Deposit Contract with incentives divided between daily sweepstakes and a monthly deposit. Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms. RESULTS AND LESSONS LEARNED Health system recruitment yielded substantially better enrollment and was cost-efficient. Despite unexpected systematic failure and/or poor availability of two wireless pill bottles, we achieved enrollment targets and implemented the interventions. For new trials, we will routinely monitor device function and have contingency plans in the event of systemic failure. CONCLUSION Interventions used in the Habit Formation trial could be translated into clinical practice. Within a large health system, successful recruitment depended on identification of eligible individuals through their electronic medical record, along with flexible ways of contacting these individuals. Challenges with device failure were manageable. The study will add to our understanding of optimally structuring and implementing incentives to motivate durable behavior change.",2019,"Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms. ","['Eligible participants self-reported incomplete medication adherence', 'Initially, we recruited from large employers (Employers) and a national health insurance company (Insurers) using mailed letters; individuals with a statin Medication Possession Ratio less than 80% were invited to participate', '805 participants at elevated risk of atherosclerotic cardiovascular disease with evidence of sub-optimal statin adherence and low-density lipoprotein (LDL) control is complete', 'Respondents were enrolled if a laboratory measurement of low-density lipoprotein was >130\u2009mg/dL. Subsequently, we recruited participants from the Penn Medicine Health System; individuals with usual-care low-density lipoprotein of >100\u2009mg/dL in the electronic medical record were recruited using phone, text, email, and regular mail']","['wireless-enabled pill bottle for their statins and daily reminder messages to take their medication', 'statin (HMG-CoA reductase inhibitors) medication', 'behavioral economic interventions']",[],"[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C1274022', 'cui_str': 'Employer'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0027452', 'cui_str': 'National Health Insurance'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0024492', 'cui_str': 'Mail'}]","[{'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C4319838', 'cui_str': 'Bottle'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1290952', 'cui_str': 'Taking medication (observable entity)'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0020374', 'cui_str': 'HMG CoA Reductases'}, {'cui': 'C1510587', 'cui_str': 'Economics, Behavioral'}]",[],3.0,0.299067,"Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms. ","[{'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Putt', 'Affiliation': '1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Peter P', 'Initials': 'PP', 'LastName': 'Reese', 'Affiliation': '1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Volpp', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Louise B', 'Initials': 'LB', 'LastName': 'Russell', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Loewenstein', 'Affiliation': '5 Department of Social and Decision Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.'}, {'ForeName': 'Jiali', 'Initials': 'J', 'LastName': 'Yan', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pagnotti', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'McGilloway', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Troyen', 'Initials': 'T', 'LastName': 'Brennen', 'Affiliation': '6 Department of Health Policy & Management, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.'}, {'ForeName': 'Darra', 'Initials': 'D', 'LastName': 'Finnerty', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hoffer', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Sakshum', 'Initials': 'S', 'LastName': 'Chadha', 'Affiliation': '3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Iwan', 'Initials': 'I', 'LastName': 'Barankay', 'Affiliation': '7 Department of Management and Department of Business Economics and Public Policy, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.'}]","Clinical trials (London, England)",['10.1177/1740774519846852'] 699,30059196,"Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.","The objective of this study was to evaluate the relative bioavailability of olanzapine in 3 olanzapine-containing tablet formulations. ALKS 3831 is a fixed-dose combination of olanzapine (OLZ, an atypical antipsychotic) and samidorphan (SAM, a μ-opioid receptor antagonist with low intrinsic activity at δ- and κ-opioid receptors), intended to provide the efficacy of OLZ while mitigating its known weight and metabolic effects. Relative bioavailability of OLZ in ALKS 3831, a bilayer tablet containing OLZ and SAM, a matching bilayer tablet containing OLZ only (OLZ), and Zyprexa (brand olanzapine [B-OLZ]) was assessed in an open-label study. Forty-eight healthy volunteers were randomly assigned to receive single oral doses of ALKS 3831 (10 mg OLZ/10 mg SAM), OLZ (10 mg OLZ), and B-OLZ (10 mg B-OLZ) on day 1 of each treatment period. Blood samples for pharmacokinetic evaluation were collected before and after each dose. Ratios of OLZ AUC 0-∞ , AUC 0-t , and C max were compared between treatments and tested for bioequivalence, determined by 90%CIs of the geometric mean ratios (GMRs). GMRs of OLZ AUC 0-∞ , AUC 0-t , and C max were close to 1, and the 90%CIs of the GMRs were contained within the bioequivalence limit of 80%-125% for comparison of ALKS 3831 with B-OLZ, ALKS 3831 with OLZ, and OLZ with B-OLZ, demonstrating bioequivalence of OLZ in ALKS 3831, OLZ, and B-OLZ.",2019,"GMRs of OLZ AUC 0-∞ , AUC 0-t , and C max were close to 1, and the 90%CIs of the GMRs were contained within the bioequivalence limit of 80%-125% for comparison of ALKS 3831 with B-OLZ, ALKS 3831 with OLZ, and OLZ with B-OLZ, demonstrating bioequivalence of OLZ in ALKS 3831, OLZ, and B-OLZ.",['Forty-eight healthy volunteers'],"['Samidorphan', 'Zyprexa (brand olanzapine [B-OLZ', 'olanzapine-containing tablet formulations', 'olanzapine', 'ALKS 3831', 'OLZ (10\xa0mg OLZ), and B-OLZ', 'Olanzapine', 'Olanzapine-Alone Tablets', 'olanzapine (OLZ, an atypical antipsychotic) and samidorphan (SAM', 'OLZ']","['geometric mean ratios (GMRs', 'Ratios of OLZ AUC 0-∞ , AUC 0-t , and C max', 'GMRs of OLZ AUC 0-∞ , AUC 0-t , and C max', 'relative bioavailability']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}, {'cui': 'C0527258', 'cui_str': 'Zyprexa'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1276996', 'cui_str': 'Atypical antipsychotic'}, {'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}]",48.0,0.0456598,"GMRs of OLZ AUC 0-∞ , AUC 0-t , and C max were close to 1, and the 90%CIs of the GMRs were contained within the bioequivalence limit of 80%-125% for comparison of ALKS 3831 with B-OLZ, ALKS 3831 with OLZ, and OLZ with B-OLZ, demonstrating bioequivalence of OLZ in ALKS 3831, OLZ, and B-OLZ.","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'von Moltke', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.601'] 700,30446826,Three versus five lumbar paravertebral injections for inguinal hernia repair in the elderly: a randomized double-blind clinical trial.,"PURPOSE The objective of the study was to compare three nerve stimulator-guided paravertebral injections versus five injections for elderly patients undergoing inguinal hernia repair in terms of the amount of intraoperative fentanyl and propofol consumption and conversion to general anesthesia. The secondary objective was postoperative pain. METHODS A prospective, randomized, double-blind clinical trial was performed. 200 elderly patients undergoing unilateral herniorrhaphy were randomized into two groups. Group III received three PVB injections from T 12 to L 2 and placebo at T 11 and L 3 . Group V received five PVB injections from T 11 to L 3 . RESULTS The mean intraoperative fentanyl and propofol consumption were significantly lower in group V (4.9 ± 7.2 µg versus 20.0 ± 12.9 µg and 5.7 ± 11.6 mg versus 34.6 ± 22.9 mg, respectively, p value < 0.0001). Five patients (5.0%) in group III had failed block and were converted to general anesthesia (p value = 0.024). Group V had significantly lower pain scores compared to group III during the first three postoperative days (p value < 0.0001). CONCLUSION The five PVB injection technique is more suitable as a sole anesthetic technique for elderly patients undergoing herniorrhaphy, since it required less intraoperative supplemental analgesia and provided lower postoperative pain scores compared to the three PVB injection technique. TRIAL REGISTRATION Clinicaltrials.gov identifier: NCT02537860.",2019,"Group V had significantly lower pain scores compared to group III during the first three postoperative days (p value < 0.0001). ","['elderly patients undergoing inguinal hernia repair in terms of the amount of intraoperative fentanyl and propofol consumption and conversion to general anesthesia', 'elderly patients undergoing herniorrhaphy', '200 elderly patients undergoing unilateral herniorrhaphy', 'inguinal hernia repair in the elderly']","['nerve stimulator-guided paravertebral injections', 'PVB injections', 'PVB injections from T 12 to L 2 and placebo', 'lumbar paravertebral injections']","['postoperative pain', 'postoperative pain scores', 'mean intraoperative fentanyl and propofol consumption', 'pain scores']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia (procedure)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0019328', 'cui_str': 'Hernia Repair'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0582124', 'cui_str': 'Neurostimulator, device (physical object)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",200.0,0.286607,"Group V had significantly lower pain scores compared to group III during the first three postoperative days (p value < 0.0001). ","[{'ForeName': 'Zoher', 'Initials': 'Z', 'LastName': 'Naja', 'Affiliation': 'Anesthesia and Pain Management Department, Makassed General Hospital, P.O. Box: 11-6301, Riad EI-Solh, Beirut, 11072210, Lebanon. zouhnaja@yahoo.com.'}, {'ForeName': 'Saleh', 'Initials': 'S', 'LastName': 'Kanawati', 'Affiliation': 'Anesthesia and Pain Management Department, Makassed General Hospital, P.O. Box: 11-6301, Riad EI-Solh, Beirut, 11072210, Lebanon.'}, {'ForeName': 'Ziad El', 'Initials': 'ZE', 'LastName': 'Khatib', 'Affiliation': 'Surgery Department, Makassed General Hospital, Beirut, Lebanon.'}, {'ForeName': 'Fouad', 'Initials': 'F', 'LastName': 'Ziade', 'Affiliation': 'Faculty of Public Health, Lebanese University, Beirut, Lebanon.'}, {'ForeName': 'Rakan', 'Initials': 'R', 'LastName': 'Nasreddine', 'Affiliation': 'American University of Beirut Medical Center, Beirut, Lebanon.'}, {'ForeName': 'Ahmad Salah', 'Initials': 'AS', 'LastName': 'Naja', 'Affiliation': 'American University of Beirut Medical Center, Beirut, Lebanon.'}]",Journal of anesthesia,['10.1007/s00540-018-2582-9'] 701,30659257,The influence of 15-week exercise training on dietary patterns among young adults.,"BACKGROUND/OBJECTIVES Little is currently known about how exercise may influence dietary patterns and/or food preferences. The present study aimed to examine the effect of a 15-week exercise training program on overall dietary patterns among young adults. SUBJECTS/METHODS This study consisted of 2680 young adults drawn from the Training Intervention and Genetics of Exercise Response (TIGER) study. Subjects underwent 15 weeks of aerobic exercise training, and exercise duration, intensity, and dose were recorded for each session using computerized heart rate monitors. In total, 4355 dietary observations with 102 food items were collected using a self-administered food frequency questionnaire before and after exercise training (n = 2476 at baseline; n = 1859 at 15 weeks). Dietary patterns were identified using a Bayesian sparse latent factor model. Changes in dietary pattern preferences were evaluated based on the pre/post-training differences in dietary pattern scores, accounting for the effects of gender, race/ethnicity, and BMI. RESULTS Within each of the seven dietary patterns identified, most dietary pattern scores were decreased following exercise training, consistent with increased voluntary regulation of food intake. A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β: -0.1280; 95% credible interval: -0.1877, -0.0637) patterns, while a higher intensity of exercise was linked to an increased preference for the prudent pattern (β: 0.0623; 95% credible interval: 0.0159, 0.1111). Consequently, a higher dose of exercise was related to a decreased preference for the snacking pattern (β: -0.0023; 95% credible interval: -0.0042, -0.0004) and an increased preference for the prudent pattern (β: 0.0029; 95% credible interval: 0.0009, 0.0048). CONCLUSIONS The 15-week exercise training appeared to motivate young adults to pursue healthier dietary preferences and to regulate their food intake.",2019,"A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β:","['2680 young adults drawn from the Training Intervention and Genetics of Exercise Response (TIGER) study', 'young adults']","['15-week exercise training program', 'aerobic exercise training, and exercise duration, intensity, and dose were recorded for each session using computerized heart rate monitors', '15-week exercise training']","['voluntary regulation of food intake', 'dietary pattern preferences', 'overall dietary patterns', 'dietary pattern scores']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0013113', 'cui_str': 'Drawing'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]","[{'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",4355.0,0.0292461,"A longer duration of exercise was associated with decreased preferences for the western (β: -0.0793; 95% credible interval: -0.1568, -0.0017) and snacking (β:","[{'ForeName': 'Jaehyun', 'Initials': 'J', 'LastName': 'Joo', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Sinead A', 'Initials': 'SA', 'LastName': 'Williamson', 'Affiliation': 'Departments of Information, Risk, & Operations Management and Statistics & Data Science, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Ana I', 'Initials': 'AI', 'LastName': 'Vazquez', 'Affiliation': 'Department of Epidemiology & Biostatistics and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Jose R', 'Initials': 'JR', 'LastName': 'Fernandez', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Molly S', 'Initials': 'MS', 'LastName': 'Bray', 'Affiliation': 'Department of Nutritional Sciences, The University of Texas at Austin, Austin, TX, USA. mbray@austin.utexas.edu.'}]",International journal of obesity (2005),['10.1038/s41366-018-0299-3'] 702,30209271,Parental interest in genomic sequencing of newborns: enrollment experience from the BabySeq Project.,"PURPOSE Newborn genomic sequencing (nGS) has great potential to improve pediatric care. Parental interest and concerns about genomics are relatively unexplored. Understanding why parents decline research consent for nGS may reveal implementation barriers. METHODS We evaluated parental interest in a randomized trial of nGS in well-baby and intensive care unit nursery settings. Interested families attended an informational enrollment session (ES) with a genetic counselor prior to consenting. Reason(s) for declining participation and sociodemographic associations were analyzed. RESULTS Of 3860 eligible approached families, 10% attended ES, 67% of whom enrolled. Of 1760 families queried for decline reasons, 58% were uninterested in research. Among 499 families considering research, principal reasons for decline prior to ES included burdensome study logistics (48%), feeling overwhelmed postpartum (17%), and lack of interest/discomfort with genetic testing (17%). Decliners after ES more often cited concerns about privacy/insurability (41%) and uncertain/unfavorable results (23%). CONCLUSION Low interest in research and study logistics were major initial barriers to postpartum enrollment and are likely generic to many postpartum research efforts. Concerns over privacy and result implications were most commonly cited in decliners after ES. Understanding parental concerns around research nGS may inform future integration of nGS into newborn screening, predictive testing, and pediatric diagnostics.",2019,"Decliners after ES more often cited concerns about privacy/insurability (41%) and uncertain/unfavorable results (23%). ","['well-baby and intensive care unit nursery settings', 'Of 3860 eligible approached families, 10% attended ES, 67% of whom enrolled', '1760 families queried for decline reasons, 58% were uninterested in research', '499 families considering research, principal reasons for decline prior to ES included burdensome study logistics (48%), feeling overwhelmed postpartum (17%), and lack of interest/discomfort with genetic testing (17']","['nGS', 'Newborn genomic sequencing (nGS']",[],"[{'cui': 'C0458075', 'cui_str': 'Well baby (finding)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0028659', 'cui_str': 'Nurseries'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0035168'}, {'cui': 'C0401925', 'cui_str': 'Teaching principal (occupation)'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0242415', 'cui_str': 'Logistics'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0424091', 'cui_str': 'Loss of interest (finding)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0679560', 'cui_str': 'Genetic Testing'}]","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0887950', 'cui_str': 'Genomics'}]",[],3860.0,0.0448702,"Decliners after ES more often cited concerns about privacy/insurability (41%) and uncertain/unfavorable results (23%). ","[{'ForeName': 'Casie A', 'Initials': 'CA', 'LastName': 'Genetti', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Talia S', 'Initials': 'TS', 'LastName': 'Schwartz', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Jill O', 'Initials': 'JO', 'LastName': 'Robinson', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'VanNoy', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Devan', 'Initials': 'D', 'LastName': 'Petersen', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Pereira', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Fayer', 'Affiliation': ""Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Hayley A', 'Initials': 'HA', 'LastName': 'Peoples', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Pankaj B', 'Initials': 'PB', 'LastName': 'Agrawal', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Wendi N', 'Initials': 'WN', 'LastName': 'Betting', 'Affiliation': ""Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Ingrid A', 'Initials': 'IA', 'LastName': 'Holm', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Amy L', 'Initials': 'AL', 'LastName': 'McGuire', 'Affiliation': 'Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Waisbren', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Yu', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Green', 'Affiliation': ""Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Alan H', 'Initials': 'AH', 'LastName': 'Beggs', 'Affiliation': ""Division of Genetics and Genomics and The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.""}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Parad', 'Affiliation': ""Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, USA. rparad@bwh.harvard.edu.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-018-0105-6'] 703,30230694,Effect of a High-Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir.,"Cabotegravir is an integrase inhibitor in clinical development for the treatment and prevention of HIV infection using oral tablets for short-term, lead-in use before subsequent administration of a long-acting injectable formulation. This phase 1, single-center, randomized, 2 × 2 crossover study evaluated the effect of a high-fat meal on the pharmacokinetics (PK) of oral cabotegravir. Healthy adults received oral cabotegravir 30 mg as a single dose on 2 separate occasions, either after fasting or following a high-fat meal (∼53% fat, ∼870 kcal). Safety evaluations and serial PK samples were collected, and a mixed-effects model was used to determine within-participant treatment comparison of noncompartmental PK parameters. Twenty-four patients were enrolled and had a mean body mass index of 25.6 kg/m 2 ; 67% were male. Compared with the fasting state, coadministration of cabotegravir with a high-fat meal increased plasma cabotegravir area under the concentration-time curve and maximal drug concentration, each by 14%. The slight 14% to 17% increase in exposure associated with a high-fat, high-calorie meal was not considered clinically significant. No grade 3/4 adverse events (AEs), drug-related AEs, or AEs leading to discontinuation were reported.",2019,"No grade 3/4 adverse events (AEs), drug-related AEs, or AEs leading to discontinuation were reported.","['Healthy adults', 'Twenty-four patients were enrolled and had a mean body mass index of 25.6 kg/m 2 ; 67% were male']","['high-fat meal', 'oral cabotegravir', 'High-Fat Meal']","['grade 3/4 adverse events (AEs), drug-related AEs, or AEs leading to discontinuation', 'plasma cabotegravir area under the concentration-time curve and maximal drug concentration']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4310385'}]","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C4310385'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}]",24.0,0.0269061,"No grade 3/4 adverse events (AEs), drug-related AEs, or AEs leading to discontinuation were reported.","[{'ForeName': 'Parul', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Ford', 'Affiliation': 'GlaxoSmithKline, Research Triangle Park, NC, USA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Lou', 'Affiliation': 'PAREXEL International, Durham, NC, USA.'}, {'ForeName': 'Kalpana', 'Initials': 'K', 'LastName': 'Bakshi', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'Allan R', 'Initials': 'AR', 'LastName': 'Tenorio', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}, {'ForeName': 'Zhiping', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'PAREXEL International, Durham, NC, USA.'}, {'ForeName': 'Rennan', 'Initials': 'R', 'LastName': 'Pan', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Spreen', 'Affiliation': 'ViiV Healthcare, Research Triangle Park, NC, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.620'] 704,30285186,Brief report of a tablet-delivered psychosocial intervention for men with advanced prostate cancer: Acceptability and efficacy by race.,"Relative to non-Hispanic whites (NHW), black men are disproportionately affected by prostate cancer (PC) incidence, have poorer PC outcomes, and report greater compromises in health-related quality of life. Despite these challenges, black men are underrepresented in psychosocial cancer research, possibly due to limited access to supportive oncology programs. The purpose of this article is to examine the acceptability and efficacy for reducing disease-specific distress of a tablet-delivered psychosocial intervention for older men with advanced PC (APC) and explore differences by race. Men with APC (N = 192, 37.5% black, age M = 68.84 years) were randomized to 10-week Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets. Assessments occurred at baseline in person, weekly during the 10-week program via tablets, and at 6 and 12 months in person. Weekly session evaluations and postprogram exit surveys assessed acceptability. Efficacy was assessed with a measure of PC-anxiety validated with racially diverse PC patients using linear mixed effects modeling. Study retention and group attendance did not differ by race. CBSM and HP were both acceptable among older APC patients. Black men rated both conditions more favorably than NHW men. Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months). Black men in CBSM reported greater decreases in PC-anxiety over time compared with all other groups. Tablet-delivered CBSM and HP were acceptable for black and NHW APC patients, although black men rated both conditions more favorably. Black men reported a unique intervention benefit related to reduced disease-specific distress.",2019,Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months).,"['Black men in CBSM', 'older APC patients', 'N = 192, 37.5% black, age M = 68.84 years', 'Men with APC', 'Black men', 'men with advanced prostate cancer', 'older men with advanced PC (APC']","['Cognitive Behavioral Stress Management (CBSM) or attention-control Health Promotion (HP), both delivered via tablets', 'tablet-delivered psychosocial intervention']","['Efficacy', 'disease-specific distress', 'acceptability and efficacy', 'CBSM and HP', 'PC-anxiety']","[{'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C4517742', 'cui_str': '37.5 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}]","[{'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.0369064,Men in CBSM (vs. HP) reported greater reductions in PC-anxiety at 6 months (not sustained at 12 months).,"[{'ForeName': 'Laura C', 'Initials': 'LC', 'LastName': 'Bouchard', 'Affiliation': 'Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Betina', 'Initials': 'B', 'LastName': 'Yanez', 'Affiliation': 'Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Jason R', 'Initials': 'JR', 'LastName': 'Dahn', 'Affiliation': 'Mental Health and Behavioral Sciences Service, Miami Veterans Affairs Healthcare System, Miami, FL, USA.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Flury', 'Affiliation': 'Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Kent T', 'Initials': 'KT', 'LastName': 'Perry', 'Affiliation': 'Department of Urology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Mohr', 'Affiliation': 'Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Penedo', 'Affiliation': 'Departments of Psychology and Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.'}]",Translational behavioral medicine,['10.1093/tbm/iby089'] 705,30088217,Remote Limb Ischemic Conditioning and Motor Learning: Evaluation of Factors Influencing Response in Older Adults.,"Remote limb ischemic conditioning (RLIC) is a clinically feasible method of promoting tissue protection against subsequent ischemic insult. Recent findings from our lab demonstrated that RLIC robustly enhances motor learning in young, healthy humans. The next step is to determine which individuals would receive maximum benefit from RLIC before applying these findings to clinical rehabilitation populations such as stroke. Numerous factors, such as age, sex, body mass index (BMI), and cardiovascular comorbidities may influence the response. Sixty-nine participants aged 40-80 were randomized to receive either RLIC (n = 33) or sham (n = 36) conditioning. Participants underwent seven consecutive sessions consisting of RLIC or sham conditioning with a blood pressure cuff on the upper extremity and motor training on a stability platform balance task, with two follow-up sessions. Balance change (post-test-pre-test) was compared across participants, groups, and the factors of age, sex, BMI, and comorbidities. Participants in both groups improved their performance on the balance task from pre- to post-test. Overall balance change was independently associated with age and BMI. There was no difference in balance change between RLIC and Sham groups. However, RLIC significantly enhanced balance performance in participants with no comorbidities. Compared with our previous study in young adults, middle-aged and older adults demonstrated smaller improvements on the balance task. RLIC enhanced learning in middle-aged and older adults only in the absence of pre-defined comorbidities. RLIC may be a promising tool for enhancing motor recovery, but the accumulation of comorbidity with age may decrease its effectiveness.",2019,Participants in both groups improved their performance on the balance task from pre- to post-test.,"['young adults, middle-aged and older adults', 'young, healthy humans', 'middle-aged and older adults', 'participants with no comorbidities', 'Sixty-nine participants aged 40-80', 'Older Adults']","['Remote Limb Ischemic Conditioning and Motor Learning', 'RLIC', 'RLIC or sham conditioning with a blood pressure cuff on the upper extremity and motor training', 'Remote limb ischemic conditioning (RLIC']","['balance performance', 'Overall balance change', 'balance change', 'balance task', 'RLIC enhanced learning']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0205847', 'cui_str': 'Middle Aged'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0450388', 'cui_str': '69 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0180208', 'cui_str': 'Blood pressure cuff, device (physical object)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",69.0,0.0265939,Participants in both groups improved their performance on the balance task from pre- to post-test.,"[{'ForeName': 'Ellen N', 'Initials': 'EN', 'LastName': 'Sutter', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Mattlage', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Marghuretta D', 'Initials': 'MD', 'LastName': 'Bland', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Kendra M', 'Initials': 'KM', 'LastName': 'Cherry-Allen', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Elinor', 'Initials': 'E', 'LastName': 'Harrison', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Swati M', 'Initials': 'SM', 'LastName': 'Surkar', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Gidday', 'Affiliation': 'Louisiana State University School of Medicine, New Orleans, LA, USA.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Division of Biostatistics, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Hershey', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Jin-Moo', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Lang', 'Affiliation': 'Program in Physical Therapy, Washington University School of Medicine, Campus Box 8502, 4444 Forest Park, Saint Louis, MO, 63108, USA. langc@wustl.edu.'}]",Translational stroke research,['10.1007/s12975-018-0653-8'] 706,32144015,Snodgrass vs Snodgraft operation to repair the distal hypospadias in the narrow urethral plate.,"BACKGROUND Using the Snodgraft technique in patients with urethral plate less than 8 mm to repair distal hypospadias is still debatable. Some authors assume that augmentation may be beneficial. We aimed to compare the outcomes of the Snodgrass vs Snodgraft procedure in patients with a narrow urethral plate less than 8 mm. METHODOLOGY This prospective randomized study included 60 children who had been treated by the Snodgrass or Snodgraft procedure for repair of distal penile hypospadias with narrow urethral plate from March 2017 to September 2018. They were randomized into two subgroups. Group 1 (30 patients) underwent tubularized incised plate urethroplasty, whereas the second group (30 patients) underwent the Snodgraft procedure by using the inner prepuce. Operative details, postoperative period, and complications were reported and statistically analyzed using IBM SPSS software package version 20.0. RESULTS The operative time was longer for patients who underwent the Snodgraft procedure: 78 (55-95) and 110 (80-140) minutes in groups 1 and 2, respectively. In group 1, there was one case of meatal stenosis which was resolved by urethral dilation using the local anesthetic cream in the outpatient clinic. In addition, there was another case of distal penile fistula. In group 2, there was a case of complete wound disruption and another of distal penile fistula. There was no significant difference in the complication rate in any group. CONCLUSION The operative time was longer in group 2 than in group 1 but with comparable outcomes. The Snodgraft procedure is not superior to the Snodgrass operation in the narrow healthy urethral plate.",2020,The operative time was longer in group 2 than in group 1 but with comparable outcomes.,"['patients with urethral plate less than 8\xa0mm to repair distal hypospadias', '60 children who had been treated by the Snodgrass or Snodgraft procedure for repair of distal penile hypospadias with narrow urethral plate from March 2017 to September 2018', 'patients with a narrow urethral plate less than 8\xa0mm']",['Snodgrass vs Snodgraft procedure'],"['complete wound disruption and another of distal penile fistula', 'operative time', 'Operative details, postoperative period, and complications', 'distal penile fistula', 'complication rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0440785', 'cui_str': 'Urethral plate (substance)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0848558', 'cui_str': 'Hypospadias'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C3839553', 'cui_str': 'Distal penile hypospadias (disorder)'}, {'cui': 'C3854333', 'cui_str': 'Narrowing'}]","[{'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0332453', 'cui_str': 'Disruption (morphologic abnormality)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",60.0,0.0213677,The operative time was longer in group 2 than in group 1 but with comparable outcomes.,"[{'ForeName': 'Mosaab', 'Initials': 'M', 'LastName': 'Eldeeb', 'Affiliation': 'Urology Department, Tanta University, Egypt.'}, {'ForeName': 'Salah', 'Initials': 'S', 'LastName': 'Nagla', 'Affiliation': 'Urology Department, Tanta University, Egypt. Electronic address: salahnaglah@yahoo.com.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Abou-Farha', 'Affiliation': 'Urology Department, Tanta University, Egypt.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Hassan', 'Affiliation': 'Urology Department, Tanta University, Egypt.'}]",Journal of pediatric urology,['10.1016/j.jpurol.2020.01.006'] 707,29952696,Injury Risk Factors Integrated Into Self-Guided Real-Time Biofeedback Improves High-Risk Biomechanics.,"CONTEXT Existing anterior cruciate ligament (ACL) injury prevention programs have failed to reverse the high rate of ACL injuries in adolescent female athletes. OBJECTIVE This investigation attempts to overcome factors that limit efficacy with existing injury prevention programs through the use of a novel, objective, and real-time interactive visual feedback system designed to reduce the biomechanical risk factors associated with ACL injuries. DESIGN Cross-over study. SETTING Medical center laboratory. PARTICIPANTS A total of 20 females (age = 19.7 [1.34] y; height = 1.74 [0.09] m; weight = 72.16 [12.45] kg) participated in this study. METHODS Participants performed sets of 10 bodyweight squats in each of 8 training blocks (ie, 4 real-time and 4 control blocks) and 3 testing blocks for a total of 110 squats. Feedback conditions were blocked and counterbalanced with half of participants randomly assigned to receive the real-time feedback block first and half receiving the control (sham) feedback first. RESULTS Heat map analysis revealed that during interaction with the real-time feedback, squat performance measured in terms of key biomechanical parameters was improved compared with performance when participants squatted with the sham stimulus. CONCLUSIONS This study demonstrates that the interactive feedback system guided participants to significantly improve movement biomechanics during performance of a body weight squat, which is a fundamental exercise for a longer term ACL injury risk reduction intervention. A longer training and testing period is necessary to investigate the efficacy of this feedback approach to effect long-term adaptations in the biomechanical risk profile of athletes.",2019,"This study demonstrates that the interactive feedback system guided participants to significantly improve movement biomechanics during performance of a body weight squat, which is a fundamental exercise for a longer term ACL injury risk reduction intervention.","['Medical center laboratory', 'm; weight\u2009=\u200972.16 [12.45]\xa0kg) participated in this study', 'Participants performed sets of 10 bodyweight squats in each of 8 training blocks (ie,\xa04 real-time and 4 control blocks) and 3 testing blocks for a total of 110 squats', 'A total of 20 females (age\u2009=\u200919.7 [1.34', 'adolescent female athletes']","['interactive feedback system guided participants', 'real-time feedback block first and half receiving the control (sham) feedback first', 'Self-Guided Real-Time Biofeedback']","['real-time feedback, squat performance']","[{'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517501', 'cui_str': '1.34'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}]",110.0,0.0455351,"This study demonstrates that the interactive feedback system guided participants to significantly improve movement biomechanics during performance of a body weight squat, which is a fundamental exercise for a longer term ACL injury risk reduction intervention.","[{'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Bonnette', 'Affiliation': ''}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'DiCesare', 'Affiliation': ''}, {'ForeName': 'Adam W', 'Initials': 'AW', 'LastName': 'Kiefer', 'Affiliation': ''}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Riley', 'Affiliation': ''}, {'ForeName': 'Kim D', 'Initials': 'KD', 'LastName': 'Barber Foss', 'Affiliation': ''}, {'ForeName': 'Staci', 'Initials': 'S', 'LastName': 'Thomas', 'Affiliation': ''}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Kitchen', 'Affiliation': ''}, {'ForeName': 'Jed A', 'Initials': 'JA', 'LastName': 'Diekfuss', 'Affiliation': ''}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Myer', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2017-0391'] 708,30153382,Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule.,"A new formulation of levothyroxine sodium has been developed in the form of an oral solution contained in unit-dose ampules. A study has been conducted to compare the bioavailability of levothyroxine sodium oral solution and levothyroxine sodium soft capsule in healthy volunteers under fasting conditions. The rate and extent of absorption of the new levothyroxine solution were also evaluated when administered on dilution in water or directly into the mouth without water. In each period, according to the randomization scheme, subjects were administered single oral doses of either test, as 4 × 150-μg unit-dose ampules, with or without water, or reference, as 4 × 150-μg capsules in a crossover design. Thirty-six subjects were randomized and dosed in this study; of these, 31 completed all study periods. When comparing the solution with the capsule (both products administered with water), the 90% confidence intervals for the ratio of log-transformed values of AUC 0-48 and C max were within 90.00% and 111.11%, respectively, for baseline-corrected levothyroxine. Moreover, the administration of levothyroxine oral solution without water did not affect the rate and extent of its absorption. In conclusion, levothyroxine oral solution unit-dose ampules were bioequivalent to the levothyroxine capsule when administered with or without water. All formulations were well tolerated, with no major side effects.",2019,"Moreover, the administration of levothyroxine oral solution without water did not affect the rate and extent of its absorption.","['healthy volunteers under fasting conditions', 'Thirty-six subjects']","['levothyroxine sodium oral solution and levothyroxine sodium soft capsule', 'Levothyroxine Sodium Oral Solution and Soft Capsule', 'levothyroxine sodium', 'levothyroxine']","['rate and extent of its absorption', 'Pharmacokinetics and Comparative Bioavailability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}]","[{'cui': 'C0079691', 'cui_str': 'Levothyroxine Sodium'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}, {'cui': 'C1273639', 'cui_str': 'Soft capsule'}, {'cui': 'C1881373', 'cui_str': ""L-3,5,3',5'-Tetraiodothyronine""}]","[{'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}]",36.0,0.0766236,"Moreover, the administration of levothyroxine oral solution without water did not affect the rate and extent of its absorption.","[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Tanguay', 'Affiliation': 'Syneos Health, Quebec City, Quebec, Canada.'}, {'ForeName': 'Johanne', 'Initials': 'J', 'LastName': 'Girard', 'Affiliation': 'Syneos Health, Quebec City, Quebec, Canada.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Scarsi', 'Affiliation': 'IBSA Institut Biochimique SA, Lugano, Switzerland.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Mautone', 'Affiliation': 'IBSA Institut Biochimique SA, Lugano, Switzerland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Larouche', 'Affiliation': 'Syneos Health, Quebec City, Quebec, Canada.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.608'] 709,30585335,"The Effect of Octanoic Acid on Essential Voice Tremor: A Double-Blind, Placebo-Controlled Study.","OBJECTIVES/HYPOTHESIS The purpose of this study was to determine the effects of octanoic acid on acoustic, perceptual, and functional aspects of essential voice tremor (EVT). STUDY DESIGN Prospective, double-blind, placebo-controlled, crossover study. METHODS Sixteen participants with a diagnosis of EVT were randomized to a 3-week dosing condition of octanoic acid or placebo, followed by a 2-week washout period and crossover to the other condition for an additional 3 weeks. Baseline and post-testing sessions were completed before and at the completion of each condition. Primary outcome measures were the magnitude of amplitude and frequency tremor, measured from the acoustic signal. Secondary outcomes were auditory-perceptual ratings of tremor severity and self-ratings of voice handicap. RESULTS Magnitude of amplitude and frequency tremor were significantly lower after 3 weeks of octanoic acid dosing as compared to the placebo condition. Auditory-perceptual ratings of tremor severity did not show significant differences between conditions. A trend toward better voice was seen for the sustained vowel ratings, but not the sentence-level ratings. No significant differences between conditions were seen on self-reported voice disability as assessed on the Voice Handicap Index-10. CONCLUSIONS The results of this controlled investigation support the potential utility of octanoic acid for reducing the magnitude of tremor in people with EVT. Further research is needed to determine whether different dosing or treatment combinations can improve functional communication in EVT. LEVEL OF EVIDENCE 1 Laryngoscope, 129:1882-1890, 2019.",2019,"No significant differences between conditions were seen on self-reported voice disability as assessed on the Voice Handicap Index-10. ","['Sixteen participants with a diagnosis of EVT', 'people with EVT']","['octanoic acid or placebo', 'placebo', 'Placebo', 'octanoic acid', 'Octanoic Acid']","['Auditory-perceptual ratings of tremor severity', 'self-reported voice disability', 'Essential Voice Tremor', 'magnitude of amplitude and frequency tremor, measured from the acoustic signal', 'auditory-perceptual ratings of tremor severity and self-ratings of voice handicap', 'amplitude and frequency tremor', 'Voice Handicap Index-10', 'acoustic, perceptual, and functional aspects of essential voice tremor (EVT']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0054616', 'cui_str': 'caprylic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0234809', 'cui_str': 'Organic voice tremor (finding)'}, {'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0449770', 'cui_str': 'Measured from (attribute)'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018576', 'cui_str': 'Handicapped'}, {'cui': 'C2985106', 'cui_str': 'Voice handicap index (assessment scale)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",16.0,0.180107,"No significant differences between conditions were seen on self-reported voice disability as assessed on the Voice Handicap Index-10. ","[{'ForeName': 'Soren Y', 'Initials': 'SY', 'LastName': 'Lowell', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, Syracuse, New York.'}, {'ForeName': 'Richard T', 'Initials': 'RT', 'LastName': 'Kelley', 'Affiliation': 'Department of Otolaryngology and Communication Sciences, State University of New York Upstate Medical University, Syracuse, New York, U.S.A.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Monahan', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, Syracuse, New York.'}, {'ForeName': 'Carly Jo', 'Initials': 'CJ', 'LastName': 'Hosbach-Cannon', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, Syracuse, New York.'}, {'ForeName': 'Raymond H', 'Initials': 'RH', 'LastName': 'Colton', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, Syracuse, New York.'}, {'ForeName': 'Dragos', 'Initials': 'D', 'LastName': 'Mihaila', 'Affiliation': 'Department of Neurology, State University of New York Upstate Medical University, Syracuse, New York, U.S.A.'}]",The Laryngoscope,['10.1002/lary.27695'] 710,31965548,"Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study.","BACKGROUND AND OBJECTIVES Carotegrast methyl, a novel prodrug, oral antagonist of α4-integrin, is in development for the treatment of active ulcerative colitis. This randomised, placebo-controlled, double-blind, crossover study evaluated the effect of food on the pharmacokinetics and pharmacodynamics as well as the safety profile after a single dose of carotegrast methyl in healthy male subjects. METHODS Subjects were randomised to receive a single dose of carotegrast methyl (240, 480 or 960 mg) or placebo in a 6:2 ratio and received the study drug under both fed and fasted conditions separated by an 8-day washout. The pharmacokinetic profiles of carotegrast methyl and its active metabolite, carotegrast, were assessed. The pharmacodynamic profile was evaluated according to a change in the peripheral lymphocyte count. Safety was monitored throughout. RESULTS Based on the area under the time curve from zero to the time of the last quantifiable concentration (AUC last ), food reduced systemic exposure to both carotegrast methyl and carotegrast by 21-57% and 5-29%, respectively. The fed-to-fasted ratio of least square means for the increase in the lymphocyte count was almost at unity in each dose, indicating no food effect on pharmacodynamics. The time  ≥ 90% of maximum effect was prolonged dose dependently, suggesting that a 960 mg-dose can provide a long-lasting effect. Reported adverse events were all mild. CONCLUSIONS Despite the reduced systemic exposure to both carotegrast methyl and carotegrast, food had no effect on the increase in lymphocyte count. A single administration of carotegrast methyl up to 960 mg was found to be safe.",2020,"The fed-to-fasted ratio of least square means for the increase in the lymphocyte count was almost at unity in each dose, indicating no food effect on pharmacodynamics.","['healthy male subjects', 'Healthy Male Subjects', 'Subjects', 'active ulcerative colitis']","['Placebo', 'placebo', 'carotegrast methyl', 'Carotegrast Methyl, an Oral Antagonist of α4-Integrin']","['adverse events', 'lymphocyte count', 'Safety', 'peripheral lymphocyte count']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0021701', 'cui_str': 'Integrins'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0200635', 'cui_str': 'Lymphocyte Number'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}]",,0.287147,"The fed-to-fasted ratio of least square means for the increase in the lymphocyte count was almost at unity in each dose, indicating no food effect on pharmacodynamics.","[{'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Fukase', 'Affiliation': 'CPC Clinic, Medipolis Medical Research Institute, Kagoshima, Japan. hiroyuki.fukase@crht.jp.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Kajioka', 'Affiliation': 'Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Oikawa', 'Affiliation': 'Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Ikeda', 'Affiliation': 'Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Hidetoshi', 'Initials': 'H', 'LastName': 'Furuie', 'Affiliation': 'Emilio Moriguchi Clinic, Tokyo, Japan.'}]",Clinical drug investigation,['10.1007/s40261-019-00879-1'] 711,30107586,"Using a social marketing approach to develop Healthy Me, Healthy We: a nutrition and physical activity intervention in early care and education.","Although social marketing principles have been successfully employed in school-based interventions to prevent obesity, use in early care and education (ECE) settings has been limited. This paper describes the use of the social marketing approach to develop an ECE-based intervention that encourages an ECE provider-parent partnership to improve the quality of preschool children's diets and their level of physical activity. A six-step social marketing approach for public health interventions guided the development of this ECE-based intervention. These steps were as follows: (i) initial planning, (ii) formative research, (iii) strategy development, (iv) program development, (v) implementation, and (vi) monitoring and evaluation. During this process, we reviewed current literature, conducted focus groups with ECE providers and parents, developed a detailed conceptual model and content map, created and tested the campaign concept, and developed final campaign materials along with strategies for its implementation. The final intervention resulting from this process was an 8-month campaign known as Healthy Me, Healthy We. The campaign is delivered by the child care center and includes branded materials for use in the classroom and at home. The final campaign is being evaluated in a cluster-randomized trial. Healthy Me, Healthy We offers an innovative approach to promoting healthy eating and physical activity during early childhood, a key developmental period, that leverages partnership between ECE providers and parents to affect behavior change.",2019,This paper describes the use of the social marketing approach to develop an ECE-based intervention that encourages an ECE provider-parent partnership to improve the quality of preschool children's diets and their level of physical activity.,[],['nutrition and physical activity intervention'],[],[],"[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",[],,0.0165415,This paper describes the use of the social marketing approach to develop an ECE-based intervention that encourages an ECE provider-parent partnership to improve the quality of preschool children's diets and their level of physical activity.,"[{'ForeName': 'Amber E', 'Initials': 'AE', 'LastName': 'Vaughn', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Bartlett', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Courtney T', 'Initials': 'CT', 'LastName': 'Luecking', 'Affiliation': 'Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Hennink-Kaminski', 'Affiliation': 'School of Media and Journalism, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Dianne S', 'Initials': 'DS', 'LastName': 'Ward', 'Affiliation': 'Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Translational behavioral medicine,['10.1093/tbm/iby082'] 712,29903889,Increasing HIV testing engagement through provision of home HIV self-testing kits for patients who decline testing in the emergency department: a pilot randomisation study.,"OBJECTIVE Up to 60% of patients decline routine HIV testing offer in US emergency departments (EDs). The objective of this study is to determine whether the provision of HIV self-testing (HIVST) kit would increase engagement of HIV testing among these HIV test 'Decliners'. METHODS Patients who declined a test offered in an ED-based triage nurse-driven HIV screening programme were enrolled and randomised to either the HIVST or the control group. The patients in the HIVST group received HIVST kits to take home, were encouraged to report test results to an established internet-based STI/HIV testing recruitment website 'I Want the Kit' (IWTK) and received five referral cards for their peers to request HIVST kits from IWTK. The control group received pamphlets about publicly available HIV testing sites. HIV testing from both groups after enrolment was determined via telephone follow-up at 1 month. Testing rate ratio (RR) was determined using χ 2 tests. RESULTS Fifty-two patients were randomised to the HIVST group and 48 to the control group. Among all 64 patients completing any follow-up, 14/29 (48%) patients in the HIVST group tested themselves at home with the provided kit. Four of these had never had an HIV test. Only 2/35 (6%) in the control group reported having an HIV test after enrolment (RR: 8.45 (95% CI: 2.09 to 34.17)). 57% (8/14) in the HIVST group reported test results to IWTK. CONCLUSION Provision of HIVST kits supplements ED-based screening programme and significantly improved engagement of HIV testing among those test 'Decliners' in the ED. TRIAL REGISTRATION NUMBER NCT03021005, results.",2019,"Among all 64 patients completing any follow-up, 14/29 (48%) patients in the HIVST group tested themselves at home with the provided kit.","['patients who decline testing in the emergency department', '64 patients completing any follow-up, 14/29 (48%) patients in the HIVST group tested themselves at home with the provided kit', 'Patients who declined a test offered in an ED-based triage nurse-driven HIV screening programme', 'Fifty-two patients']","['HIVST kits', 'HIV self-testing (HIVST) kit', 'pamphlets about publicly available HIV testing sites', 'HIVST', 'established internet-based STI/HIV testing recruitment website ']","['having an HIV test', 'Testing rate ratio (RR', 'engagement of HIV testing']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557520', 'cui_str': 'Triage nurse (occupation)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C4319570', 'cui_str': 'Fifty-two'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1690540', 'cui_str': 'Kit'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1321876', 'cui_str': 'Human immunodeficiency virus test (procedure)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0036916', 'cui_str': 'STDs'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}]","[{'cui': 'C1321876', 'cui_str': 'Human immunodeficiency virus test (procedure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]",52.0,0.0853078,"Among all 64 patients completing any follow-up, 14/29 (48%) patients in the HIVST group tested themselves at home with the provided kit.","[{'ForeName': 'Anuj V', 'Initials': 'AV', 'LastName': 'Patel', 'Affiliation': 'Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Samuel M', 'Initials': 'SM', 'LastName': 'Abrams', 'Affiliation': 'Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Charlotte A', 'Initials': 'CA', 'LastName': 'Gaydos', 'Affiliation': 'Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Jett-Goheen', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Carl A', 'Initials': 'CA', 'LastName': 'Latkin', 'Affiliation': 'Department of Health, Behavior and Society, Bloomberg School of Public Health, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Rothman', 'Affiliation': 'Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Yu-Hsiang', 'Initials': 'YH', 'LastName': 'Hsieh', 'Affiliation': 'Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}]",Sexually transmitted infections,['10.1136/sextrans-2018-053592'] 713,31127302,Effectiveness of a school food aid programme in improving household food insecurity; a cluster randomized trial.,"BACKGROUND Aim of this cluster randomized trial was to examine the impact of a school feeding programme combining healthy meals provision and educational activities to reduce food insecurity. METHODS Schools participating in the DIATROFI Program in Greece during the 2014-2015 school year were randomly allocated between a multicomponent intervention (MI: each student received a daily healthy meal along with educational actions; 28 schools) and an educational intervention (EI; 23 schools). A linear-mixed model was used to examine intervention effect on change from baseline in the food insecurity score, as measured via the Food Security Survey Module (FSSM). The analysis was based on 1442 pre-post intervention questionnaire pairs in the MI group and 986 in the EI group. RESULTS The reduction in food insecurity score in the MI group was statistically significantly greater compared to the EI group, by 9.8% or -0.31 [95% confidence interval (CI) -0.61 to -0.01] FSSM units after adjusting for potential confounders. MI intervention was significantly more effective compared to EI, among students in food insecure households (mean -0.44, 95% CI -0.84 to -0.04), students in households facing hunger (mean -1.04, 95% CI -1.91 to -0.17) and overweight/obese students (mean -0.36, 95% CI -0.72 to -0.01). CONCLUSION For interventions aiming to address childhood food insecurity, public health focus should be oriented towards school-based programmes combining food assistance with activities that promote healthy nutrition.",2020,"MI intervention was significantly more effective compared to EI, among students in food insecure households (mean -0.44, 95% CI -0.84 to -0.04), students in households facing hunger (mean",['Schools participating in the DIATROFI Program in Greece during the 2014-2015 school year'],"['school feeding programme combining healthy meals provision and educational activities', 'MI intervention', 'multicomponent intervention (MI: each student received a daily healthy meal along with educational actions; 28 schools) and an educational intervention', 'school food aid programme']",['reduction in food insecurity score'],"[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0013652', 'cui_str': 'Educational Activities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C3494174', 'cui_str': 'Food Insecurity'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0864184,"MI intervention was significantly more effective compared to EI, among students in food insecure households (mean -0.44, 95% CI -0.84 to -0.04), students in households facing hunger (mean","[{'ForeName': 'Archontoula', 'Initials': 'A', 'LastName': 'Dalma', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Athanassios', 'Initials': 'A', 'LastName': 'Petralias', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Tsiampalis', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Nikolakopoulos', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Afroditi', 'Initials': 'A', 'LastName': 'Veloudaki', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Christina-Maria', 'Initials': 'CM', 'LastName': 'Kastorini', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Papadimitriou', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Zota', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}, {'ForeName': 'Athena', 'Initials': 'A', 'LastName': 'Linos', 'Affiliation': 'Institute of Preventive Medicine, Environmental & Occupational Health, Prolepsis, Maroussi, Greece.'}]",European journal of public health,['10.1093/eurpub/ckz091'] 714,31529220,Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study.,"BACKGROUND We recently reported the efficacy of indigo naturalis (IN) in patients with active ulcerative colitis (UC) in a randomized controlled trial (INDIGO study). However, few studies have been conducted to investigate whether IN is effective even in treatment-refractory cases, such as in those with steroid dependency and anti-TNF refractoriness. METHODS In the INDIGO study, 86 patients with active UC were randomly assigned to an IN group (0.5-2.0 g daily) or placebo group. The rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels was compared between refractory [patients with steroid-dependent disease, previous use of anti-TNF-α, and concomitant use of immunomodulators (IM)] and non-refractory patients. We also analyzed factors predicting CR and MH at week 8. RESULTS The rates of CR of IN group were significantly higher than placebo group, even in patients with steroid-dependent disease (p < 0.001), previous use of anti-TNF-α (p = 0.002), and concomitant use of IM (p = 0.013). The rates of MH in IN group were significantly higher than in placebo group in patients with steroid-dependent disease (p = 0.009). In the IN group, median FCP levels, at week 8, were significantly lower than baseline in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α (p < 0.001, respectively). Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. CONCLUSIONS In a sub-analysis of data from a randomized placebo-controlled trial, we found that IN may be useful even in patients with steroid-dependent disease and patients with the previous use of anti-TNF-α.",2020,"Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. ","['refractory patients with ulcerative colitis', '86 patients with active UC', 'patients with active ulcerative colitis (UC', 'patients with steroid-dependent disease and patients with the previous use of anti-TNF-α']","['placebo', 'indigo naturalis (IN']","['rate of clinical response (CR), mucosal healing (MH), and change in fecal calprotectin (FCP) levels', 'rates of CR', 'rates of MH', 'median FCP levels']","[{'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009324', 'cui_str': 'Inflammatory Bowel Disease, Ulcerative Colitis Type'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021218', 'cui_str': 'Indigo'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal Tissue'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",86.0,0.0600478,"Multivariate analysis indicated that the previous use of anti-TNF-α was not a predictive factor for CR and MH at week 8. ","[{'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Naganuma', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. nagamakoto@keio.jp.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Sugimoto', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Fukuda', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Mitsuyama', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.'}, {'ForeName': 'Taku', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Center\xa0for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Yoshimura', 'Affiliation': 'Department of Internal Medicine, Division of IBD, Tokyo Yamate Medical Center, Tokyo, Japan.'}, {'ForeName': 'Hidehisa', 'Initials': 'H', 'LastName': 'Ohi', 'Affiliation': 'Department of Gastroenterology, Imamura Hospital, Kagoshima, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Endoscopy and Medicine, Hiroshima University Hospital, Hiroshima, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Andoh', 'Affiliation': 'Department of Medicine, Shiga University of Medical Science, Otsu, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Ohmiya', 'Affiliation': 'Department of Gastroenterology, Fujita Health University School of Medicine, Toyoake, Japan.'}, {'ForeName': 'Keiichiro', 'Initials': 'K', 'LastName': 'Saigusa', 'Affiliation': 'Department of Medicine, Tokyo Saiseikai Central Hospital, Tokyo, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yamamoto', 'Affiliation': 'IBD Center, Yokkaichi Hazu Medical Center, Yokkaichi, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Morohoshi', 'Affiliation': ""Department of Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.""}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Ichikawa', 'Affiliation': 'Department of Gastroenterology, Tokai University Hachioji Hospital, Hachioji, Japan.'}, {'ForeName': 'Katsuyoshi', 'Initials': 'K', 'LastName': 'Matsuoka', 'Affiliation': 'Department of Gastroenterology, Toho University Sakura Medical Center, Sakura, Japan.'}, {'ForeName': 'Tadakazu', 'Initials': 'T', 'LastName': 'Hisamatsu', 'Affiliation': 'The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan.'}, {'ForeName': 'Shinta', 'Initials': 'S', 'LastName': 'Mizuno', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical and Translational Research Center, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Inflammatory Bowel Disease Center, Toho University Sakura Medical Center, Sakura, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Kanai', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of gastroenterology,['10.1007/s00535-019-01625-2'] 715,31169888,Health-related quality of life in home care recipients after a falls prevention intervention: a 6-month follow-up.,"BACKGROUND Falls in older adults are an increasingly important public health concern due to the expanding older population and contribute considerably to the global burden of disease. Home care recipients have a high incidence of falls and a low level of health-related quality of life (HRQOL). In this understudied group of older adults, exercise interventions could prevent falls, promote HRQOL and enable healthy ageing in the longer term. METHODS The study is a single-blinded parallel-group randomized controlled trial, lasting 3 months with a follow-up at 6 months, conducted in primary care. The objective was to explore the effects of a falls prevention exercise programme post-intervention at a 6-month follow-up in home care recipients 67+ years with a history of falls. The Otago Exercise Programme lasting 3 months was performed. The primary outcome was HRQOL measured by the Short Form 36 Health Survey (SF-36). Linear mixed regression models and structural equation models were employed. RESULTS At 6-month follow-up, the intervention group scored significantly higher on SF-36's physical component summary compared with the controls; 3.0 points, 95% confidence interval (CI) = 0.4, 5.6. This effect was mediated by an increased probability of maintaining exercise in the post-intervention period; odds ratio = 2.3 (CI = 1.1, 5.1). Exercising was associated with a 7.1-point increase in physical component summary (CI = 3.2, 10.9). CONCLUSION A falls prevention exercise programme can improve physical HRQOL in home care recipients post-intervention. The exercise programme also led to longer-term changes in exercise behaviour mediating this effect.",2020,"At 6-month follow-up, the intervention group scored significantly higher on SF-36's physical component summary compared with the controls; 3.0 points, 95% confidence interval (CI) = 0.4, 5.6.","['home care recipients post-intervention', 'home care recipients 67+ years with a history of falls', 'home care recipients after a falls prevention intervention', 'older adults']","['exercise interventions', 'falls prevention exercise programme post-intervention', 'falls prevention exercise programme']","['physical component summary', 'physical HRQOL', 'HRQOL measured by the Short Form 36 Health Survey (SF-36', 'probability of maintaining exercise', 'Health-related quality of life', ""SF-36's physical component summary"", 'incidence of falls and a low level of health-related quality of life (HRQOL']","[{'cui': 'C0204977', 'cui_str': 'Home Care'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1561668', 'cui_str': 'History of fall'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}]",,0.0737435,"At 6-month follow-up, the intervention group scored significantly higher on SF-36's physical component summary compared with the controls; 3.0 points, 95% confidence interval (CI) = 0.4, 5.6.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Bjerk', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'Brovold', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Davis', 'Affiliation': 'Faculty of Management, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Dawn A', 'Initials': 'DA', 'LastName': 'Skelton', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Bergland', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, Oslo, Norway.'}]",European journal of public health,['10.1093/eurpub/ckz106'] 716,31981517,Effect of a deep-learning computer-aided detection system on adenoma detection during colonoscopy (CADe-DB trial): a double-blind randomised study.,"BACKGROUND Colonoscopy with computer-aided detection (CADe) has been shown in non-blinded trials to improve detection of colon polyps and adenomas by providing visual alarms during the procedure. We aimed to assess the effectiveness of a CADe system that avoids potential operational bias. METHODS We did a double-blind randomised trial at the endoscopy centre in Caotang branch hospital of Sichuan Provincial People's Hospital in China. We enrolled consecutive patients (aged 18-75 years) presenting for diagnostic and screening colonoscopy. We excluded patients with a history of inflammatory bowel disease, colorectal cancer, or colorectal surgery or who had a contraindication for biopsy; we also excluded patients who had previously had an unsuccessful colonoscopy and who had a high suspicion for polyposis syndromes, inflammatory bowel disease, and colorectal cancer. We allocated patients (1:1) to colonoscopy with either the CADe system or a sham system. Randomisation was by computer-generated random number allocation. Patients and the endoscopist were unaware of the random assignment. To achieve masking, the output of the system was shown on a second monitor that was only visible to an observer who was responsible for reporting the alerts. The primary outcome was the adenoma detection rate (ADR), which is the proportion of individuals having a complete colonoscopy, from caecum to rectum, who had one or more adenomas detected. The primary analysis was per protocol. We also analysed characteristics of polyps and adenomas missed initially by endoscopists but detected by the CADe system. This trial is complete and is registered with http://www.chictr.org.cn, ChiCTR1800017675. FINDINGS Between Sept 3, 2018, and Jan 11, 2019, 1046 patients were enrolled to the study, of whom 36 were excluded before randomisation, 508 were allocated colonoscopy with polyp detection using the CADe system, and 502 were allocated colonoscopy with the sham system. After further excluding patients who met exclusion criteria, 484 patients in the CADe group and 478 in the sham group were included in analyses. The ADR was significantly greater in the CADe group than in the sham group, with 165 (34%) of 484 patients allocated to the CADe system having one or more adenomas detected versus 132 (28%) of 478 allocated to the sham system (odds ratio 1·36, 95% CI 1·03-1·79; p=0·030). No complications were reported among all colonoscopy procedures. Polyps initially missed by the endoscopist but identified by the CADe system were generally small in size, isochromatic, flat in shape, had an unclear boundary, were partly behind colon folds, and were on the edge of the visual field. INTERPRETATION Polyps initially missed by the endoscopist had characteristics that are sometimes difficult for skilled endoscopists to recognise. Such polyps could be detected using a high-performance CADe system during colonoscopy. The effect of CADe during colonoscopy on the incidence of interval colorectal cancer should be investigated. FUNDING None.",2020,"Polyps initially missed by the endoscopist but identified by the CADe system were generally small in size, isochromatic, flat in shape, had an unclear boundary, were partly behind colon folds, and were on the edge of the visual field. ","[""Caotang branch hospital of Sichuan Provincial People's Hospital in China"", 'adenoma detection during colonoscopy (CADe-DB trial', 'enrolled consecutive patients (aged 18-75 years) presenting for diagnostic and screening colonoscopy', 'Between Sept 3, 2018, and Jan 11, 2019, 1046 patients were enrolled to the study, of whom 36 were excluded before randomisation, 508 were allocated colonoscopy with polyp detection using the CADe system, and 502 were allocated colonoscopy with the sham system', 'patients with a history of inflammatory bowel disease, colorectal cancer, or colorectal surgery or who had a contraindication for biopsy; we also excluded patients who had previously had an unsuccessful colonoscopy and who had a high suspicion for polyposis syndromes, inflammatory bowel disease, and colorectal cancer']","['CADe', 'endoscopy centre', 'Colonoscopy with computer-aided detection (CADe', 'colonoscopy with either the CADe system or a sham system', 'deep-learning computer-aided detection system']","['incidence of interval colorectal cancer', 'adenoma detection rate (ADR), which is the proportion of individuals having a complete colonoscopy, from caecum to rectum', 'ADR']","[{'cui': 'C0020024', 'cui_str': 'Hospitals, Branch'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0330157', 'cui_str': 'Juniperus oxycedrus'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0032584', 'cui_str': 'Polyp (morphologic abnormality)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C3662621', 'cui_str': 'History of inflammatory bowel disease'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0009369', 'cui_str': 'Colon and Rectal Surgery Specialty'}, {'cui': 'C1301624', 'cui_str': 'Contraindications'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory Bowel Diseases'}]","[{'cui': 'C0330157', 'cui_str': 'Juniperus oxycedrus'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C4704761', 'cui_str': 'Deep Learning'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0007531', 'cui_str': 'Cecum'}, {'cui': 'C0034896', 'cui_str': 'Rectum'}, {'cui': 'C0449207', 'cui_str': 'ADR (body structure)'}]",1046.0,0.323385,"Polyps initially missed by the endoscopist but identified by the CADe system were generally small in size, isochromatic, flat in shape, had an unclear boundary, were partly behind colon folds, and were on the edge of the visual field. ","[{'ForeName': 'Pu', 'Initials': 'P', 'LastName': 'Wang', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Xiaogang', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Tyler M', 'Initials': 'TM', 'LastName': 'Berzin', 'Affiliation': 'Center for Advanced Endoscopy, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jeremy R', 'Initials': 'JR', 'LastName': 'Glissen Brown', 'Affiliation': 'Center for Advanced Endoscopy, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Peixi', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Liangping', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Zhenzhen', 'Initials': 'Z', 'LastName': 'Guo', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Lei', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xiong', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Han', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Pan', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.""}, {'ForeName': 'Guanyu', 'Initials': 'G', 'LastName': 'Zhou', 'Affiliation': ""Department of Gastroenterology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China. Electronic address: zhou.guanyu@outlook.com.""}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30411-X'] 717,31388683,Beneficial effects of early administration of recombinant human B-type natriuretic peptide in ST-elevation myocardial infarction patients receiving percutaneous coronary intervention treatment.,"INTRODUCTION We aimed to evaluate the clinical performance of early administration of recombinant human B-type natriuretic peptide (rhBNP) to ST-elevation myocardial infarction (STEMI) patients receiving percutaneous coronary intervention (PCI) treatment. METHODS In total, 185 patients diagnosed with STEMI were enrolled and randomised into either the placebo-treated (n = 88) or rhBNP-treated (n = 97) group. Patients were given either saline or rhBNP ten minutes before PCI and monitored with various cardiac parameters, including accelerated idioventricular rhythm, frequent ventricular premature beat (FVPB), ventricular tachycardia, systolic blood pressure, thrombolysis in myocardial infarction (TIMI) 3 gradation, corrected TIMI frame count (cTFC) and myocardial blush grade (MBG) 3 classification. RESULTS Our results revealed no difference in accelerated idioventricular rhythm between the two groups. However, FVPB and ventricular tachycardia were significantly decreased in rhBNP-treated patients compared to placebo-treated patients (p < 0.05). Moreover, the occurrence ratio of reperfusion-associated low blood pressure in rhBNP-treated patients was lower than in placebo-treated patients (p = 0.03), while no difference was observed in infarction-related arteries TIMI 3 blood flow between the two groups (p = 0.23). Importantly, measurement of post-reperfusion blood flow velocity via cTFC suggested that rhBNP treatment could significantly increase blood circulation (p = 0.003). After stent implantation, the acquisition rate of MBG 3 was higher in rhBNP-treated patients compared to placebo-treated patients (p = 0.071), although the difference was not significant. CONCLUSION We concluded that early administration of rhBNP can ameliorate the severity of reperfusion injury for STEMI patients receiving PCI treatment.",2019,"After stent implantation, the acquisition rate of MBG 3 was higher in rhBNP-treated patients compared to placebo-treated patients (p = 0.071), although the difference was not significant. ","['ST-elevation myocardial infarction patients receiving percutaneous coronary intervention treatment', '185 patients diagnosed with STEMI']","['saline or rhBNP', 'placebo', 'rhBNP', 'recombinant human B-type natriuretic peptide (rhBNP', 'percutaneous coronary intervention (PCI', 'recombinant human B-type natriuretic peptide', 'rhBNP-treated']","['acquisition rate of MBG 3', 'blood circulation', 'FVPB and ventricular tachycardia', 'accelerated idioventricular rhythm, frequent ventricular premature beat (FVPB), ventricular tachycardia, systolic blood pressure, thrombolysis in myocardial infarction (TIMI) 3 gradation, corrected TIMI frame count (cTFC) and myocardial blush grade (MBG) 3 classification', 'occurrence ratio of reperfusion-associated low blood pressure', 'accelerated idioventricular rhythm', 'infarction-related arteries TIMI 3 blood flow']","[{'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0054015', 'cui_str': 'Nesiritide'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C1292734', 'cui_str': 'Treats'}]","[{'cui': 'C0005775', 'cui_str': 'Blood Circulation'}, {'cui': 'C0042514', 'cui_str': 'Tachycardia, Ventricular'}, {'cui': 'C0700363', 'cui_str': 'Idioventricular rhythm (disorder)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C0151636', 'cui_str': 'Ventricular Ectopic Beats'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0180979', 'cui_str': 'Frame (physical object)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0005874', 'cui_str': 'Blushings'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0021308', 'cui_str': 'Infarction'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}]",185.0,0.0543788,"After stent implantation, the acquisition rate of MBG 3 was higher in rhBNP-treated patients compared to placebo-treated patients (p = 0.071), although the difference was not significant. ","[{'ForeName': 'Lijun', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Affiliated Zhongshan Hospital, Dalian University, Dalian, Liaoning, China.'}, {'ForeName': 'Lianna', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Department of Cardiology, Affiliated Zhongshan Hospital, Dalian University, Dalian, Liaoning, China.'}, {'ForeName': 'Xianjing', 'Initials': 'X', 'LastName': 'Wei', 'Affiliation': 'Department of Cardiology, Affiliated Zhongshan Hospital, Dalian University, Dalian, Liaoning, China.'}, {'ForeName': 'Zezhou', 'Initials': 'Z', 'LastName': 'Xie', 'Affiliation': 'Department of Cardiology, Affiliated Zhongshan Hospital, Dalian University, Dalian, Liaoning, China.'}]",Singapore medical journal,['10.11622/smedj.2019093'] 718,31552541,"Effect of Positive Psychotherapy on Psychological Well-Being, Happiness, Life Expectancy and Depression Among Retired Teachers with Depression: A Randomized Controlled Trial.","Despite conducting numerous positive psychotherapy (PPT) tests, the effects of such activities in participants aged 50 and above have been dealt with by few studies. Therefore, the effects of PPT on psychological well-being (PWB), happiness, expectancy life (LX) and depression of retired teachers with depression, was investigated using a randomized controlled trial. In this study, 60 female teachers aged 55-80 years, who obtained the lowest scores in the Beck Depression Inventory-II (BDI-II), were randomly divided into the two PPT (n = 30) and untreated groups (n = 30) at the time of entering the study and 2 months later following their assessments through the Psychological Well-Being Scales-Short (PWBS-S), Oxford Happiness Inventory (OHI), Adult Hope Scale (AHS) and BDI-II. The PPT and untreated groups took part in 10 group sessions and underwent no interventions, respectively. The study was completed with a total number of 52 female teachers (n = 26 per group). The PPT group showed some effectiveness on the variables of PWBS-S, OHI, AHS and BDI-II in a way that the involved retired teachers with depression increased their PWB, happiness and LE after PPT training and teachers reduced their BDI-II after intervention (p < 0.05). PPT can be used in order to increase the level of PWB, happiness, and LX, along with depression symptoms decreasing amongst retired teachers with the age of 55, and also more than that.",2020,"The PPT group showed some effectiveness on the variables of PWBS-S, OHI, AHS and BDI-II in a way that the involved retired teachers with depression increased their PWB, happiness and LE after PPT training and teachers reduced their BDI-II after intervention (p < 0.05).","['60 female teachers aged 55-80\xa0years, who obtained the lowest scores in the Beck Depression Inventory-II (BDI-II', 'Retired Teachers with Depression', 'participants aged 50', 'total number of 52 female teachers (n\u2009=\u200926 per group']","['Positive Psychotherapy', 'PPT']","['level of PWB, happiness, and LX', 'Psychological Well-Being, Happiness, Life Expectancy and Depression', 'psychological well-being (PWB), happiness, expectancy life (LX) and depression of retired teachers with depression', 'PWB, happiness and LE', 'Psychological Well-Being Scales-Short (PWBS-S), Oxford Happiness Inventory (OHI), Adult Hope Scale (AHS) and BDI-II', 'PWBS-S, OHI, AHS and BDI-II']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0018592', 'cui_str': 'Happinesses'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0035345', 'cui_str': 'Retirement'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0222045'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0392347', 'cui_str': 'Hope'}]",60.0,0.0408602,"The PPT group showed some effectiveness on the variables of PWBS-S, OHI, AHS and BDI-II in a way that the involved retired teachers with depression increased their PWB, happiness and LE after PPT training and teachers reduced their BDI-II after intervention (p < 0.05).","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Taghvaienia', 'Affiliation': 'Department of Psychology and Education, Faculty of Humanities, Yasouj University, Yasouj, Iran. Taghvaienia.1355@gmail.com.'}, {'ForeName': 'Nahid', 'Initials': 'N', 'LastName': 'Alamdari', 'Affiliation': 'Department of Psychology and Education, Faculty of Humanities, Yasouj University, Yasouj, Iran.'}]",Community mental health journal,['10.1007/s10597-019-00471-z'] 719,31983056,"Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).","BACKGROUND AND OBJECTIVE Secukinumab, an anti-interleukin (IL)-17A monoclonal antibody, has demonstrated low radiographic progression over 4 years in patients with ankylosing spondylitis (AS). An adalimumab (tumor necrosis factor [TNF] inhibitor) biosimilar, GP2017 (SDZ-ADL; Sandoz), has been approved by the European Medicines Agency (July 2018) for use in all same indications as adalimumab, including AS. Adalimumab has also shown low long-term radiographic progression in patients with AS. Direct comparison of radiographic progression in AS between IL-17A and TNF inhibitors has not been studied. SURPASS is the first head-to-head, Phase IIIb, randomized, biologic-controlled study in AS to compare effects of secukinumab versus SDZ-ADL on spinal radiographic progression. METHODS Overall, 858 biologic-naïve patients with AS with elevated high-sensitivity C-reactive protein (≥ 5 mg/L) and/or at least one syndesmophyte in the cervical/lumbar spine at baseline (without total ankylosis) were randomized (1:1:1) to subcutaneous (sc) secukinumab (300 or 150 mg) or SDZ-ADL (40 mg). Secukinumab will be administered at baseline, weeks 1, 2, 3, and 4, and then every 4 weeks until week 100. SDZ-ADL will be administered every 2 weeks from baseline until week 102. Patients and investigators will be unblinded to drug but blinded to secukinumab doses. Spinal X-rays will be obtained at baseline, and weeks 52 and 104, sacroiliac joint (SIJ) X-rays at baseline and week 104, and magnetic resonance imaging (MRI) of SIJs and spine at baseline, weeks 16, 52, and 104. The primary endpoint is to demonstrate superiority of secukinumab (300 or 150 mg) treatment versus SDZ-ADL regarding proportion of patients with no radiographic progression (change from baseline in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤ 0.5) at week 104. Secondary endpoints include change from baseline in mSASSS, proportion of patients with syndesmophyte at baseline who develop no new syndesmophytes, reduction of osteitis on MRI of SIJs and spine (Berlin method). Assessment of SpondyloArthritis International Society (ASAS) 20/40 responses, ASAS partial remission, and AS Disease Activity Score (ASDAS) inactive disease (ASDAS < 1.3) in secukinumab- versus SDZ-ADL-treated patients at week 104. CONCLUSION This is the first study designed to evaluate superiority of an IL-17A inhibitor, secukinumab, over a TNF inhibitor, SDZ-ADL, in reducing spinal radiographic progression in AS. STUDY REGISTRATION ClinicalTrials.gov, NCT03259074.",2020,The primary endpoint is to demonstrate superiority of secukinumab (300 or 150 mg) treatment versus SDZ-ADL regarding proportion of patients with no radiographic progression (change from baseline in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤ 0.5) at week 104.,"['patients with ankylosing spondylitis (AS', '858 biologic-naïve patients with AS with elevated high-sensitivity C-reactive protein (≥\u20095\xa0mg/L) and/or at least one syndesmophyte in the cervical/lumbar spine at baseline (without total ankylosis', 'Patients with Ankylosing Spondylitis', 'patients with AS']","['IL-17A inhibitor, secukinumab, over a TNF inhibitor, SDZ-ADL', 'SDZ-ADL', 'SpondyloArthritis International Society (ASAS', 'adalimumab', 'Secukinumab and Adalimumab Biosimilar', 'secukinumab versus SDZ-ADL', 'secukinumab', 'Adalimumab', 'IL-17A and TNF inhibitors', 'subcutaneous (sc) secukinumab']","['Radiographic Progression', 'radiographic progression', '20/40 responses, ASAS partial remission, and AS Disease Activity Score (ASDAS) inactive disease', 'spinal radiographic progression', 'change from baseline in mSASSS, proportion of patients with syndesmophyte at baseline who develop no new syndesmophytes, reduction of osteitis on MRI of SIJs and spine (Berlin method']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038013', 'cui_str': 'Spondylarthritis Ankylopoietica'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0439268', 'cui_str': 'microgram/mL'}, {'cui': 'C0221690', 'cui_str': 'Syndesmophyte'}, {'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003090', 'cui_str': 'Ankylosis'}]","[{'cui': 'C1705947', 'cui_str': 'CTLA8'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3179547', 'cui_str': 'secukinumab'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0949690', 'cui_str': 'Spinal Arthritis'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C4045974', 'cui_str': 'Biosimilars'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0221690', 'cui_str': 'Syndesmophyte'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0029400', 'cui_str': 'Bone Inflammation'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0005125', 'cui_str': 'Berlin'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]",,0.202715,The primary endpoint is to demonstrate superiority of secukinumab (300 or 150 mg) treatment versus SDZ-ADL regarding proportion of patients with no radiographic progression (change from baseline in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤ 0.5) at week 104.,"[{'ForeName': 'Xenofon', 'Initials': 'X', 'LastName': 'Baraliakos', 'Affiliation': 'Rheumazentrum Ruhrgebiet, Herne, Germany. baraliakos@me.com.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Center of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark.'}, {'ForeName': 'Lianne S', 'Initials': 'LS', 'LastName': 'Gensler', 'Affiliation': 'University of California, San Francisco, CA, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Poddubnyy', 'Affiliation': 'Charité Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany.'}, {'ForeName': 'Eun Young', 'Initials': 'EY', 'LastName': 'Lee', 'Affiliation': 'College of Medicine, Seoul National University, Seoul, South Korea.'}, {'ForeName': 'Uta', 'Initials': 'U', 'LastName': 'Kiltz', 'Affiliation': 'Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Ruvie', 'Initials': 'R', 'LastName': 'Martin', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Sawata', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Aimee', 'Initials': 'A', 'LastName': 'Readie', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Porter', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical drug investigation,['10.1007/s40261-020-00886-7'] 720,31944826,RADAR: A Multicenter Food and Drug Administration Investigational Device Exemption Clinical Trial of Persistent Atrial Fibrillation.,"BACKGROUND Pulmonary vein isolation is insufficient to treat all patients with persistent atrial fibrillation (AF), and effective adjunctive ablation strategies are needed. Ablation of AF drivers holds promise, but current technologies to identify drivers are limited by spatial resolution. In a single-arm, first-in-human, investigator-initiated Food and Drug Administration Investigational Device Exemption study, we used a novel system for real-time, high-resolution identification of AF drivers in persistent AF. METHODS Patients with persistent or long-standing persistent AF underwent ablation using the RADAR (Real-Time Electrogram Analysis for Drivers of Atrial Fibrillation) system in conjunction with a standard electroanatomical mapping system. After pulmonary vein isolation, electrogram and spatial information was streamed to the RADAR system and analyzed to identify driver domains to target for ablation. RESULTS Across 4 centers, 64 subjects were enrolled: 73% male, age, 64.7±9.5 years; body mass index, 31.7±6.0 kg/m 2 ; left atrium size, 54±10 mm, with persistent/long-standing persistent AF in 53 (83%)/11 (17%), prior AF ablation (re-do group) in 26 (41%). After 12.6±0.8 months follow-up, 68% remained AF-free off all antiarrhythmics; 74% remained AF-free and 66% remained AF/atrial tachycardia/atrial flutter-free on or off AADs (antiarrhythmic drugs). AF terminated with ablation in 35 patients (55%) overall and in 23/38 (61%) of de novo ablation patients. For patients with AF termination during ablation, 82% remained AF-free and 74% AF/atrial tachycardia/atrial flutter-free during follow-up on or off AADs. Patients undergoing first-time ablation generally had higher rates of freedom from AF than the re-do group. CONCLUSIONS This novel technology for panoramic mapping of AF drivers showed promising results in a persistent/long-standing persistent AF population. These data provide the scientific basis for a randomized trial. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT03263702; IDE#G170049.",2020,AF terminated with ablation in 35 patients (55%) overall and in 23/38 (61%) of de novo ablation patients.,"['64 subjects were enrolled: 73% male, age 64.7±9.5 years, BMI 31.7±6.0 kg/m 2 , LA size 54±10 mm, with persistent/longstanding persistent AF in 53 (83%) ', 'Drivers of AtRial Fibrillation (RADAR', 'patients with persistent atrial fibrillation (AF']",[' - Pulmonary vein isolation (PVI'],['rates of freedom from AF'],"[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0034513', 'cui_str': 'Radar'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}]","[{'cui': 'C0016694', 'cui_str': 'Liberty'}]",64.0,0.079909,AF terminated with ablation in 35 patients (55%) overall and in 23/38 (61%) of de novo ablation patients.,"[{'ForeName': 'Subbarao', 'Initials': 'S', 'LastName': 'Choudry', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (S.C., S.R.D., W.W., V.Y.R.).'}, {'ForeName': 'Moussa', 'Initials': 'M', 'LastName': 'Mansour', 'Affiliation': 'Massachusetts General Hospital, Boston (M.M.).'}, {'ForeName': 'Sri', 'Initials': 'S', 'LastName': 'Sundaram', 'Affiliation': 'Section of Cardiac Electrophysiology, South Denver Cardiology Associates, Littleton, CO (S.S.).'}, {'ForeName': 'Duy T', 'Initials': 'DT', 'LastName': 'Nguyen', 'Affiliation': 'Section of Cardiac Electrophysiology, Division of Cardiology, University of Colorado, Aurora (D.T.N.).'}, {'ForeName': 'Srinivas R', 'Initials': 'SR', 'LastName': 'Dukkipati', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (S.C., S.R.D., W.W., V.Y.R.).'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Whang', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (S.C., S.R.D., W.W., V.Y.R.).'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kessman', 'Affiliation': 'AFTx, Inc, Westminster, CO (P.K.).'}, {'ForeName': 'Vivek Y', 'Initials': 'VY', 'LastName': 'Reddy', 'Affiliation': 'Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, NY (S.C., S.R.D., W.W., V.Y.R.).'}]",Circulation. Arrhythmia and electrophysiology,['10.1161/CIRCEP.119.007825'] 721,31977324,Increased Muscle Strength Limits Postural Sway During Daily Living Activities in Total Hip Arthroplasty Patients.,"OBJECTIVE The aim of the study was to investigate the effect of maximal strength training on postural sway after total hip arthroplasty, performed before and after a battery of physical performance tests that resemble daily living activities. DESIGN This study is an exploratory study based on data from a 3-mo randomized controlled trial involving 54 total hip arthroplasty patients performing maximal strength training or conventional rehabilitation. At 3, 6, and 12 mos postoperatively, postural sway was evaluated in two gait tests; ie, one test before and one test after conducting a battery of physical performance tests. RESULTS At 3 mos postoperatively, postural sway in the test after was significantly higher for the conventional rehabilitation group than the maximal strength training group (P = 0.045); however, there was no between-group difference at the test before (P = 0.670). Postural sway was also significantly higher in the test after compared with the test before in the conventional rehabilitation group (P < 0.001). No difference was found between the test before and test after in the maximal strength training group (P = 0.713). At 6 and 12 mos postoperatively, there were no statistically significant within- or between-group differences in postural sway. CONCLUSIONS Increased muscular strength limits postural sway 3 mos postoperatively in total hip arthroplasty patients after a demanding battery of physical performance tests simulating daily living activities.",2020,"At 6 and 12 months postoperatively, there were no statistically significant within- or between-group differences in postural sway. ","['total hip arthroplasty patients', 'postural sway after total hip arthroplasty (THA', '54 THA patients performing']","['MST or conventional rehabilitation (CR', 'MST', 'maximal strength training (MST']","['postural sway in the TA', 'postural sway', 'Postural sway', 'TB and TA']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C0642413', 'cui_str': 'THAS'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}]",54.0,0.0278132,"At 6 and 12 months postoperatively, there were no statistically significant within- or between-group differences in postural sway. ","[{'ForeName': 'Siri B', 'Initials': 'SB', 'LastName': 'Winther', 'Affiliation': 'From the Orthopedic Research Centre, Department of Orthopedic Surgery, Clinic of Orthopedics, Rheumatology and Dermatology, St. Olavs Hospital HF, Trondheim, Norway (SBW, OAF, JK); Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (SBW, OAF); Department of Orthopedic Surgery, Clinic of Orthopedics, Rheumatology and Dermatology, St. Olavs Hospital HF, Trondheim, Norway (SBW, OAF, JK, VSH); Department of Circulation and Medical Imaging, Faculty of Medicine and Health Science, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (VSH); and OsloMet - Oslo Metropolitan University, Faculty of Health Sciences, Institute of Nursing, Oslo, Norway (VSH).'}, {'ForeName': 'Olav A', 'Initials': 'OA', 'LastName': 'Foss', 'Affiliation': ''}, {'ForeName': 'Jomar', 'Initials': 'J', 'LastName': 'Klaksvik', 'Affiliation': ''}, {'ForeName': 'Vigdis S', 'Initials': 'VS', 'LastName': 'Husby', 'Affiliation': ''}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001382'] 722,31967283,Anesthesia upstream of the alcoholic lesion point alleviates the pain of alcohol neurolysis for intercostal neuralgia: a prospective randomized clinical trial.,"OBJECTIVES Alcohol for intercostal neuralgia may induce severe injection pain. Although nerve block provided partial pain relief, alcohol might be diluted, and the curative effect decreased when the local anesthetic and alcohol were given at the same point. Therefore, we observed the modified method for intercostal neuralgia, a Two-point method, in which the local anesthetic and alcohol were given at different sites. METHOD Thirty patients diagnosed with intercostal neuralgia were divided into 2 groups: Single-point group and Two-point group. In the Single-point group, alcohol and local anesthetic were injected at the same point, named the ""lesion point"", which was the lower edge of ribs and 5 cm away from the midline of the spinous process. In the Two-point group, alcohol was injected at the lesion point, whereas the local anesthetic was administered at the ""anesthesia point"", which was 3 cm away from the midline of spinous process. RESULTS After alcohol injection, visual analog scale (VAS) in the Two-point group was lower than the Single-point group, and the satisfaction ratio of patients in the Two-point group was higher (p<0.05). The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05). However, the long-term effects did not differ. CONCLUSIONS Local anesthetic was given upstream of the point where alcohol was administered, was a feasible and safe method to relieve pain during the operation, and improved the satisfaction of the patients and curative effect.",2020,The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05).,"['intercostal neuralgia', 'Thirty patients diagnosed with intercostal neuralgia']",[],"['degree of numbness', 'satisfaction ratio', 'visual analog scale (VAS', 'severe injection pain', 'pain of alcohol neurolysis']","[{'cui': 'C0344306', 'cui_str': 'Intercostal neuralgia (disorder)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",[],"[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0020580', 'cui_str': 'Reduced Sensation'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0196878', 'cui_str': 'Neurolysis (procedure)'}]",30.0,0.016268,The degree of numbness in the Two-point group was greater than the Single-point group at 1 month and 3 months after operation (p<0.05).,"[{'ForeName': 'Jiyu', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Niu', 'Affiliation': 'Department of Anesthesiology, the 211 Hospital of Chinese PLA, Harbin, China.'}, {'ForeName': 'Mengli', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Meng', 'Affiliation': 'Department of Pain Management, the Affiliated Hospital of Qingdao University, Qingdao, China.'}, {'ForeName': 'Huacheng', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1296'] 723,31952938,A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial.,"BACKGROUND In the absence of a well-established therapeutic approach, patients with irritable bowel syndrome seek alternative strategies such as probiotics. AIMS The current trial named LAPIBSS aimed to demonstrate the efficacy of a 2-strain mixture of Lactobacillus acidophilus to improve irritable bowel syndrome symptoms. METHODS Eighty patients diagnosed for irritable bowel syndrome were recruited to a multicentre, double-blinded, in parallel groups, placebo-controlled, randomized clinical trial. Patients were provided with a daily dose of two capsules containing either probiotics (5 × 10 9  cfu/capsule) or placebo for 8 weeks. The primary outcome was abdominal pain score assessed with a 100-mm visual analogue scale. Secondary outcomes included scores of bloating, flatus and rumbling assessed with a 100-mm visual analogue scale, a composite score and bowel habits. RESULTS Abdominal pain score was significantly improved in both groups at weeks 4 and 8 (P < 0.0001), but no significant differences were found between groups at week 8 (19.0 ± 2.5 vs 25.1 ± 2.6, respectively; LS Means differences = 6.0 ± 3.2; P = 0.06). Significant differences between groups were observed for flatus score at week 4 (P = 0.04) and week 8 (P = 0.03) and composite score (P = 0.04) at week 8. CONCLUSIONS The consumption of the 2-strain mixture of L. acidophilus over 8 weeks is safe and decreases significantly flatus and composite scores. TRIAL REGISTRATION NUMBER EudraCT No 2008 A00844-51.",2020,"RESULTS Abdominal pain score was significantly improved in both groups at weeks 4 and 8 (P < 0.0001), but no significant differences were found between groups at week 8 (19.0 ± 2.5 vs 25.1 ± 2.6, respectively; LS Means differences = 6.0 ± 3.2; P = 0.06).","['patients with irritable bowel syndrome', 'irritable bowel syndrome', 'Eighty patients diagnosed for irritable bowel syndrome']","['placebo', 'probiotics', '2-strain mixture of Lactobacillus acidophilus', 'EudraCT']","['abdominal pain score assessed with a 100-mm visual analogue scale', 'scores of bloating, flatus and rumbling assessed with a 100-mm visual analogue scale, a composite score and bowel habits', 'flatus score', 'composite score', 'Abdominal pain score', 'irritable bowel syndrome symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0022939', 'cui_str': 'Lactobacillus acidophilus'}]","[{'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0022104', 'cui_str': 'Irritable Bowel Syndrome'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",80.0,0.640441,"RESULTS Abdominal pain score was significantly improved in both groups at weeks 4 and 8 (P < 0.0001), but no significant differences were found between groups at week 8 (19.0 ± 2.5 vs 25.1 ± 2.6, respectively; LS Means differences = 6.0 ± 3.2; P = 0.06).","[{'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Sadrin', 'Affiliation': 'IAPS Laboratory, University of Toulon, Toulon, France; Laboratoire Denel-Codifra, Le Chesnay, France. Electronic address: stephane.sadrin@gmail.com.'}, {'ForeName': 'Souad', 'Initials': 'S', 'LastName': 'Sennoune', 'Affiliation': 'Department of Cellular Physiology and Molecular Biophysics, Texas Tech University Health Sciences Center, Lubbock, USA.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Gout', 'Affiliation': 'Biomedical and Global Clinical Solutions, Ramonville-Saint-Agne, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Marque', 'Affiliation': 'Capionis, Bordeaux, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Moreau', 'Affiliation': 'Department of Gastroenterology and Hepatology, Rangueil University Hospital of Toulouse, Toulouse, France.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Zinoune', 'Affiliation': 'Qualilab, Olivet, France.'}, {'ForeName': 'Joël-Paul', 'Initials': 'JP', 'LastName': 'Grillasca', 'Affiliation': 'IAPS Laboratory, University of Toulon, Toulon, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Pons', 'Affiliation': 'IAPS Laboratory, University of Toulon, Toulon, France; General Practice, Montady, France.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Maixent', 'Affiliation': 'IAPS Laboratory, University of Toulon, Toulon, France; Department of Physiology, Faculty of Fundamental and Applied Sciences, University of Poitiers, Poitiers, France.'}]",Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,['10.1016/j.dld.2019.12.009'] 724,32030780,Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial.,"BACKGROUND Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua-sublingual immunotherapy (SLIT). METHODS This was a randomized, double-blind, placebo-controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua-SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow-up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported. RESULTS Artemisia annua-SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua-SLIT. CONCLUSION Artemisia annua-SLIT is an efficacious and safe treatment in patients with A annua SAR.",2020,"seasonal Artemisia annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased Cystatin 1(CST1) in nasal secretion after 16 and 32 weeks compared to pre-treatment.","['71 SAR patients', 'seasonal allergic rhinitis', 'patients with Artemisia annua SAR', 'seasonal allergic rhinitis (SAR) in northern China']","['Artemisia annua sublingual immunotherapy', 'placebo', 'Artemisia annua-sublingual immunotherapy (SLIT', 'SLIT with Artemisia annua extract']","['Total nasal symptom score', 'nTreg and Tr1 cells in blood; and increased Cystatin 1(CST1', 'baseline (peak pollen phase (PPP) in the previous year), initiation of Artemisia annua-SLIT', 'seasonal Artemisia annua-SLIT', 'Blood samples and nasal secretions', 'nasal secretion', 'TNSS']","[{'cui': 'C1175743', 'cui_str': 'Severe acute respiratory syndrome-related coronavirus'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018621', 'cui_str': 'Rhinitis, Allergic, Seasonal'}, {'cui': 'C0686899', 'cui_str': 'Sweet Annie'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0686899', 'cui_str': 'Sweet Annie'}, {'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0184904', 'cui_str': 'Slitting (procedure)'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0231918', 'cui_str': 'Nasal symptom'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1563925', 'cui_str': 'Tr1 Cells'}, {'cui': 'C0005768'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010646', 'cui_str': 'Cystatin Superfamily'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0032385', 'cui_str': 'Pollen Grains'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C0686899', 'cui_str': 'Sweet Annie'}, {'cui': 'C0184904', 'cui_str': 'Slitting (procedure)'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}]",71.0,0.310244,"seasonal Artemisia annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased Cystatin 1(CST1) in nasal secretion after 16 and 32 weeks compared to pre-treatment.","[{'ForeName': 'Hongfei', 'Initials': 'H', 'LastName': 'Lou', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yanran', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Ouyang', 'Affiliation': 'Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Xi', 'Affiliation': 'Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.'}, {'ForeName': 'Xiaohan', 'Initials': 'X', 'LastName': 'Chu', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Beijing Key Laboratory of Nasal Disease, Beijing Institute of Otolaryngology, Beijing, China.'}, {'ForeName': 'Chengshuo', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Luo', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China.'}]",Allergy,['10.1111/all.14218'] 725,31960705,Accelerated Resolution Therapy: Randomized Controlled Trial of a Complicated Grief Intervention.,"BACKGROUND AND OBJECTIVES Complicated grief (CG) is severe, prolonged (>12 months) grieving. Complicated grief disproportionately affects older adults and is associated with negative physical/psychological effects. Although treatment options exist, those which do are time-intensive. We report on a randomized clinical trial (RCT) which examined whether accelerated resolution therapy (ART), a novel mind-body therapy, is effective in treating CG, post-traumatic stress disorder (PTSD), and depression among hospice informal caregivers. RESEARCH DESIGN AND METHODS Prospective 2 group, wait-listed RCT. All participants were scheduled to receive 4 ART sessions. INCLUSION ≥60 years, inventory of CG >25, and PTSD checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition >33 or Psychiatric Diagnostic Screen Questionnaire PTSD subscale >5. EXCLUSION Major psychiatric disorder, other current psychotherapy treatment. Depression was measured by the Center for Epidemiologic Studies Depression. RESULTS Mean (standard deviation [SD]) age of 54 participants was 68.7 (7.2) years, 85% female, and 93% white. Participants assigned to ART reported significantly greater mean (SD) CG reduction (-22.8 [10.3]) versus Wait-list participants (-4.3 [6.0]). Within-participant effect sizes (ESs) for change from baseline to 8-week post-treatment were CG (ES = 1.96 (95% confidence interval [CI]: 1.45-2.47; P < .0001), PTSD (ES = 2.40 [95% CI: 1.79-3.00]; P < .0001), depression (ES = 1.63 [95% CI: 1.18-2.08; P < .0001). Treatment effects did not substantially differ by baseline symptom levels. DISCUSSION AND IMPLICATIONS Results suggests that ART presents an effective and less time-intensive intervention for CG in older adults. However, it should undergo further effectiveness testing in a larger, more diverse clinical trial with a focus on determining physiological or behavioral mechanisms of action.",2020,Participants assigned to ART reported significantly greater mean (SD) CG reduction (-22.8 [10.3]) versus Wait-list participants (-4.3 [6.0]).,"['Prospective 2 group, wait-listed RCT', 'older adults', 'age of 54 participants was 68.7 (7.2) years, 85% female, and 93% white']",['accelerated resolution therapy (ART'],"['Depression', 'PTSD checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition >33 or Psychiatric Diagnostic Screen Questionnaire PTSD subscale', 'Mean (standard deviation [SD', 'mean (SD) CG reduction']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517857', 'cui_str': '7.2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1136324', 'cui_str': 'Diagnostic and Statistical Manual of Mental Disorders'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.15627,Participants assigned to ART reported significantly greater mean (SD) CG reduction (-22.8 [10.3]) versus Wait-list participants (-4.3 [6.0]).,"[{'ForeName': 'Harleah G', 'Initials': 'HG', 'LastName': 'Buck', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cairns', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Nnadozie', 'Initials': 'N', 'LastName': 'Emechebe', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Diego F', 'Initials': 'DF', 'LastName': 'Hernandez', 'Affiliation': 'Balanced Living Psychology, Tampa, FL, USA.'}, {'ForeName': 'Tina M', 'Initials': 'TM', 'LastName': 'Mason', 'Affiliation': 'H. Lee Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Bell', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Kip', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Barrison', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Tofthagen', 'Affiliation': 'Mayo Clinic Florida, Jacksonville, FL, USA.'}]",The American journal of hospice & palliative care,['10.1177/1049909119900641'] 726,31726194,"Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF.","BACKGROUND The period shortly after hospitalization for heart failure (HF) represents a high-risk window for recurrent clinical events, including rehospitalization or death. OBJECTIVES This study sought to determine whether the efficacy and safety of sacubitril/valsartan varies in relation to the proximity to hospitalization for HF among patients with HF with preserved ejection fraction (HFpEF). METHODS In this post hoc analysis of PARAGON-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blocker] Global Outcomes in HFpEF), we assessed the risk of clinical events and response to sacubitril/valsartan in relation to time from last HF hospitalization among patients with HFpEF (≥45%). The primary outcome was composite total HF hospitalizations and cardiovascular death, analyzed by using a semiparametric proportional rates method, stratified by geographic region. RESULTS Of 4,796 validly randomized patients in PARAGON-HF, 622 (13%) were screened during hospitalization or within 30 days of prior hospitalization, 555 (12%) within 31 to 90 days, 435 (9%) within 91 to 180 days, and 694 (14%) after 180 days; 2,490 (52%) were never previously hospitalized. Over a median follow-up of 35 months, risk of total HF hospitalizations and cardiovascular death was inversely and nonlinearly associated with timing from prior HF hospitalization (p < 0.001). There was a gradient in relative risk reduction in primary events with sacubitril/valsartan from patients hospitalized within 30 days (rate ratio: 0.73; 95% confidence interval: 0.53 to 0.99) to patients never hospitalized (rate ratio: 1.00; 95% confidence interval: 0.80 to 1.24; trend in relative risk reduction: p interaction  = 0.15). With valsartan alone, the rate of total primary events was 26.7 (≤30 days), 24.2 (31 to 90 days), 20.7 (91 to 180 days), 15.7 (>180 days), and 7.9 (not previously hospitalized) per 100 patient-years. Compared with valsartan, absolute risk reductions with sacubitril/valsartan were more prominent in patients enrolled early after hospitalization: 6.4% (≤30 days), 4.6% (31 to 90 days), and 3.4% (91 to 180 days), whereas no risk reduction was observed in patients screened >180 days or who were never hospitalized (trend in absolute risk reduction: p interaction  = 0.050). CONCLUSIONS Recent hospitalization for HFpEF identifies patients at high risk for near-term clinical progression. In the PARAGON-HF trial, the relative and absolute benefits of sacubitril/valsartan compared with valsartan in HFpEF appear to be amplified when initiated in the high-risk window after hospitalization and warrant prospective validation. (PARAGON-HF; NCT01920711).",2020,"Over median 35 months follow-up, risk of total HF hospitalizations and cardiovascular death was inversely and non-linearly associated with timing from prior HF hospitalization (P<0.001).",['patients with HF and preserved ejection fraction (HFpEF'],"['valsartan', 'sacubitril/valsartan', 'Valsartan']","['absolute risk reductions', 'relative risk reduction', 'composite total HF hospitalizations and cardiovascular death, analyzed using a semiparametric proportional rates method, stratified by geographic region', 'risk reduction', 'rate of total primary events', 'risk of total HF hospitalizations and cardiovascular death']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0728887', 'cui_str': 'Preserving (attribute)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C4033631', 'cui_str': 'sacubitril / valsartan'}]","[{'cui': 'C3179139', 'cui_str': 'Absolute Risk Reduction'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205351', 'cui_str': 'Proportional (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",,0.106937,"Over median 35 months follow-up, risk of total HF hospitalizations and cardiovascular death was inversely and non-linearly associated with timing from prior HF hospitalization (P<0.001).","[{'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/mvaduganathan.""}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Akshay S', 'Initials': 'AS', 'LastName': 'Desai', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/akshaydesaimd.""}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Division of Cardiology and Metabolism, Department of Cardiology and Berlin-Brandenburg Center for Regenerative Therapies; German Centre for Cardiovascular Research (Deutsches Zentrum für Herz-Kreislauf-Forschung), Berlin, Germany; Charité Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Sergio V', 'Initials': 'SV', 'LastName': 'Perrone', 'Affiliation': 'Instituto Fleni, Buenos Aires, Argentina. Electronic address: https://twitter.com/svperrone.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Janssens', 'Affiliation': 'Department of Cardiology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Davor', 'Initials': 'D', 'LastName': 'Milicic', 'Affiliation': 'Department of Cardiovascular Diseases, University Hospital Center Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Juan L', 'Initials': 'JL', 'LastName': 'Arango', 'Affiliation': 'Guatemalan Heart Institute, Guatemala City, Guatemala.'}, {'ForeName': 'Milton', 'Initials': 'M', 'LastName': 'Packer', 'Affiliation': 'Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas; Imperial College, London, United Kingdom.'}, {'ForeName': 'Victor C', 'Initials': 'VC', 'LastName': 'Shi', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, New Jersey.'}, {'ForeName': 'Martin P', 'Initials': 'MP', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis Pharmaceuticals, East Hanover, New Jersey.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: ssolomon@bwh.harvard.edu.""}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.11.003'] 727,31855207,[Efficacy of compression hosiery and elastic bandaging after surgical treatment of varicose veins].,"AIM The purpose of the study was to compare the results of using compression knitwear and elastic bandaging in the postoperative period after endovasal laser coagulation in patients with varicose veins. PATIENTS AND METHODS A total of forty 20-to-55-year-old women with a body mass index of ≤ 35 kg/m2 and CEAP class C2-C3 lower limb varicose veins were randomized into two numerically equal groups. The Study Group included those receiving postoperative compression on the operated leg with the help an elastic stocking, whereas in the Comparison Group compression was achieved by laying an elastic bandage. Both group women underwent laser coagulation of the great saphenous vein and removal of separate veins with the help of Mueller hooks. Efficacy of compression therapy was comparatively assessed based on the results of interviewing the patients prior to intervention and 1 month thereafter, as well as by the level of pain syndrome according to the visual analogue scale at 24 and 48 postoperative hours, by the time spent by the personnel for bandaging of the limb or putting on the compression stocking intraoperatively and at the first dressing, by the degree of lower limb oedema and dynamics of regression thereof, by the area of postoperative haematoma and its dynamics after 2, 7 days and at 1 month. Besides, we evaluated the findings of ultrasonographic angioscanning of lower limb veins at one month postoperatively. RESULTS The obtained findings demonstrated that efficacy of using a medical compression stocking after the procedure of endovasal laser coagulation in women with varicose veins was comparable to that of elastic bandaging. By the incidence rate and area of extension of postoperative haematomas, degree of pain syndrome, patient-oriented assessment using the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), condition of veins according to the findings of ultrasonographic angioscanning no significant differences were revealed between the two methods of elastic compression of the leg. However, using a medical stocking appeared to promote a statistically significant 1.4-1.6-fold reduction in the time spent for formation of elastic compression of the lower limb, as well as a decrease in the incidence rate and degree of local oedema of the lower limb in the postoperative period.",2019,"However, using a medical stocking appeared to promote a statistically significant 1.4-1.6-fold reduction in the time spent for formation of elastic compression of the lower limb, as well as a decrease in the incidence rate and degree of local oedema of the lower limb in the postoperative period.","['varicose veins', 'patients with varicose veins', 'forty 20-to-55-year-old women with a body mass index of ≤ 35 kg/m2 and CEAP class', 'women with varicose veins', 'C2-C3 lower limb varicose veins']","['compression hosiery and elastic bandaging', 'compression knitwear and elastic bandaging', 'laser coagulation of the great saphenous vein and removal of separate veins', 'medical compression stocking', 'compression therapy']","['incidence rate and degree of local oedema', 'incidence rate and area of extension of postoperative haematomas, degree of pain syndrome, patient-oriented assessment using the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), condition of veins']","[{'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]","[{'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0453907', 'cui_str': 'Hosiery (physical object)'}, {'cui': 'C0086524', 'cui_str': 'Thermocoagulation, Laser'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0038348', 'cui_str': 'Compression Stockings'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0013609', 'cui_str': 'Localized edema (morphologic abnormality)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1306557', 'cui_str': 'Chronic venous insufficiency'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0042449', 'cui_str': 'Veins'}]",,0.0176675,"However, using a medical stocking appeared to promote a statistically significant 1.4-1.6-fold reduction in the time spent for formation of elastic compression of the lower limb, as well as a decrease in the incidence rate and degree of local oedema of the lower limb in the postoperative period.","[{'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Turgunov', 'Affiliation': 'Department of Surgical Diseases #2, Karaganda Medical University, Karaganda, Kazakhstan.'}, {'ForeName': 'I Iu', 'Initials': 'II', 'LastName': 'Kiktev', 'Affiliation': 'Department of Vascular and Microsurgery, Regional Clinical Hospital, Karaganda, Kazakhstan.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Balykbaeva', 'Affiliation': 'Department of Surgical Diseases #2, Karaganda Medical University, Karaganda, Kazakhstan.'}, {'ForeName': 'D V', 'Initials': 'DV', 'LastName': 'Korobeĭnikova', 'Affiliation': 'Clinical Diagnostic Rehabilitation Centre SANAD, Karaganda, Kazakhstan.'}, {'ForeName': 'F I', 'Initials': 'FI', 'LastName': 'Galitskiĭ', 'Affiliation': 'Department of Vascular and Microsurgery, Regional Clinical Hospital, Karaganda, Kazakhstan.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGIO2019420'] 728,31951273,Assessment of Anatomic Restoration of Distal Radius Fractures Among Older Adults: A Secondary Analysis of a Randomized Clinical Trial.,"Importance The value of precise anatomic restoration for distal radius fractures (DRFs) in older adults has been debated for many decades, with conflicting results in the literature. In light of the growing population of adults aged 60 years and older, both fracture incidence and associated treatment costs are expected to increase. Objective To determine the association between radiographic measures of reduction and patient outcomes after DRF in older patients. Design, Setting, and Participants Data were collected from the Wrist and Radius Injury Surgical Trial (WRIST), a multicenter randomized clinical trial of DRF treatments for adults aged 60 years and older (enrollment from April 10, 2012, to December 31, 2016, with a 2-year follow-up). Data analysis was performed from January 3, 2019, to August 19, 2019. WRIST participants who completed 12-month assessments were included in the study. According to the biomechanical principle of alignment, 2-phase multivariable regression models were adopted to assess the association between radiographic measures of reduction and functional and patient-reported outcomes 12 months following treatment. Interventions Participants were randomized to receive volar locking plate, percutaneous pinning, or external fixation. Those who opted for nonoperative treatment received casts. Main Outcomes and Measures Hand grip strength, wrist arc of motion, radial deviation, ulnar deviation, the Michigan Hand Outcomes Questionnaire (MHQ) total score, MHQ function score, and MHQ activities of daily living score were measured at 12 months following treatment. Results Data from 166 WRIST participants (144 [86.7%] women; mean [SD] age, 70.9 [8.9] years) found that only 2 of the 84 correlation coefficients calculated were statistically significant. For patients aged 70 years or older, every degree increase in radial inclination away from normal (22°) grip strength in the injured hand was 1.1 kg weaker than the uninjured hand (95% CI, 0.38-1.76; P = .004) and each millimeter increase toward normal (0 mm) in ulnar variance was associated with a 10.4-point improvement in MHQ ADL score (95% CI, -16.84 to -3.86; P = .003). However, neither of these radiographic parameters appeared to be associated with MHQ total or function scores. Conclusions and Relevance The study results suggest that precise restoration of wrist anatomy is not associated with better patient outcomes for older adults with DRF 12 months following treatment. Surgeons can consider this evidence to improve quality of care by prioritizing patient preferences and efficient use of resources over achieving exact realignment. Trial Registration ClinicalTrials.gov identifier: NCT01589692.",2020,The study results suggest that precise restoration of wrist anatomy is not associated with better patient outcomes for older adults with DRF 12 months following treatment.,"['Older Adults', 'adults aged 60 years and older (enrollment from April 10, 2012, to December 31, 2016, with a 2-year follow-up', 'older patients', 'older adults', 'Distal Radius Fractures', 'WRIST participants who completed 12-month assessments were included in the study']","['DRF', 'volar locking plate, percutaneous pinning, or external fixation']","['radial inclination away from normal (22°) grip strength', 'MHQ ADL score', 'MHQ total or function scores', 'Measures\n\n\nHand grip strength, wrist arc of motion, radial deviation, ulnar deviation, the Michigan Hand Outcomes Questionnaire (MHQ) total score, MHQ function score, and MHQ activities of daily living score']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0443349', 'cui_str': 'Volar (qualifier value)'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate (procedure)'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0407333', 'cui_str': 'Fixation of fracture using external fixator (procedure)'}]","[{'cui': 'C0442038', 'cui_str': 'Radial (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1293900', 'cui_str': 'Hand grip'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0001857', 'cui_str': 'Lymphadenopathy Syndrome'}, {'cui': 'C0687704', 'cui_str': 'Motions (qualifier value)'}, {'cui': 'C0449751', 'cui_str': 'Radial deviation (qualifier value)'}, {'cui': 'C0449752', 'cui_str': 'Ulnar deviation (qualifier value)'}, {'cui': 'C0025939', 'cui_str': 'Michigan'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.158434,The study results suggest that precise restoration of wrist anatomy is not associated with better patient outcomes for older adults with DRF 12 months following treatment.,"[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Section of Plastic Surgery, Department of Surgery, Michigan Medicine, Ann Arbor.'}, {'ForeName': 'Hoyune E', 'Initials': 'HE', 'LastName': 'Cho', 'Affiliation': 'Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor.'}, {'ForeName': 'Yeonil', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Early Development Statistics, Merck & Co Inc, Rahway, New Jersey.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'Department of Biostatistics, University of Michigan, Ann Arbor.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': 'Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School, Ann Arbor.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2019.19433'] 729,31842388,"Effects of Stevia Extract on Postprandial Glucose Response, Satiety and Energy Intake: A Three-Arm Crossover Trial.","Non-nutritive sweeteners (NNS) are suggested to lower energy intake in the diet, but they have been paradoxically involved in the epidemic of obesity and Type 2 diabetes. Stevia is the least studied sweetener. This study aims to investigate the effect of stevia on postprandial glucose levels, appetite and food intake. METHODS 30 participants (20 females/10 males; 26.1 (10.56) years; body mass index (BMI) 23.44 (3.42) Kg/m 2 ) took part in a three-arm crossover trial where they received preloads of water, sugar (60 g) and stevia (1 g) on three different days, followed by an ad libitum pizza lunch. Breakfast was standardised. A one-day diet diary was collected on each test day. Visual analogue scales (VAS) were used to assess subjective feelings of appetite. Blood glucose samples were collected at 30-min intervals until 120 min post lunch. RESULTS Energy intake did not significantly differ between preloads for ad libitum meals ( p = 0.78) and overall day ( p = 0.33). VAS scores for hunger and desire to eat (DTE) were lower following stevia preload compared to water ( p < 0.05). After adjusting for the sugar preload and calorie content, postprandial glucose levels did not significantly differ between interventions. CONCLUSION Stevia lowers appetite sensation and does not further increase food intake and postprandial glucose levels. It could be a useful strategy in obesity and diabetes prevention and management.",2019,VAS scores for hunger and desire to eat (DTE) were lower following stevia preload compared to water ( p < 0.05).,['30 participants (20 females/10 males; 26.1 (10.56) years; body mass index (BMI) 23.44'],"['Stevia Extract', 'nutritive sweeteners (NNS']","['Visual analogue scales (VAS', 'sugar preload and calorie content, postprandial glucose levels', 'VAS scores for hunger and desire to eat (DTE', 'postprandial glucose levels, appetite and food intake', 'Energy intake', 'food intake and postprandial glucose levels', 'Blood glucose samples', 'subjective feelings of appetite', 'appetite sensation', 'Postprandial Glucose Response, Satiety and Energy Intake']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C1018893', 'cui_str': 'Stevia'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C3658237', 'cui_str': 'Artificial Sweeteners, Nutritive'}]","[{'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0242209', 'cui_str': 'Sugars'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0036658', 'cui_str': 'Sensory Function'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0036239', 'cui_str': 'Satiations'}]",30.0,0.0592917,VAS scores for hunger and desire to eat (DTE) were lower following stevia preload compared to water ( p < 0.05).,"[{'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Farhat', 'Affiliation': 'School of Health sciences, Liverpool Hope University, Taggart Avenue, Liverpool L16 9JD, UK.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Berset', 'Affiliation': 'School of Agricultural, Forest and Food Sciences, Bern University of Applied Sciences, 3052 Bern, Switzerland.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Moore', 'Affiliation': 'School of Health sciences, Liverpool Hope University, Taggart Avenue, Liverpool L16 9JD, UK.'}]",Nutrients,['10.3390/nu11123036'] 730,31939316,Association of oral estradiol dose/levels with coagulation measures in early/late postmenopausal women.,"Objective: This study evaluated associations of estradiol (E2) dose and serum E2 levels with coagulation/anti-coagulation measures in early (<6 years) compared with late (≥10 years) postmenopausal women. Methods: Postmenopausal women from the REPLENISH trial tested four formulations of oral combined E2 and progesterone compared with placebo. Mixed-effects linear models tested the association of E2 dose and serum E2 levels with the prothrombin time (PT), the activated partial thromboplastin time (APTT), antithrombin (ATHRM), fibrinogen (FIBRINO), protein C (PROTC), and protein S (PROTS), assessed five times over 12 months. Results: Among 1215 early and 297 late postmenopausal women, the E2 dose was statistically significantly inversely associated with the APTT in early postmenopause, PROTC in late postmenopause, and with the PT, ATHRM, and PROTS in both groups. Serum E2 levels were statistically significantly inversely associated with the APTT, PROTS, and FIBRINO in early postmenopause, the PT in late postmenopause, and ATHRM and PROTC in both groups. With longer time since menopause, the inverse E2 dose effect and serum E2 effects became stronger. Conclusion: Increasing E2 dose and serum E2 levels were associated with changes in coagulation/anti-coagulation measures. The associations were stronger among women ≥10 years since menopause when initiating E2. The timing of E2 therapy, E2 dose, and serum E2 levels relative to time since menopause may modify the venous thromboembolism risk.",2020,"Serum E2 levels were statistically significantly inversely associated with the APTT, PROTS, and FIBRINO in early postmenopause, the PT in late postmenopause, and ATHRM and PROTC in both groups.","['Methods: Postmenopausal women', '1215 early and 297 late postmenopausal women', 'early (<6\u2009years) compared with late (≥10\u2009years) postmenopausal women', 'early/late postmenopausal women']","['placebo', 'oral combined E2 and progesterone', 'oral estradiol', 'estradiol (E2) dose and serum E2 levels with coagulation/anti-coagulation measures']","['Serum E2 levels', 'Increasing E2 dose and serum E2 levels', 'association of E2 dose and serum E2 levels with the prothrombin time (PT), the activated partial thromboplastin time (APTT), antithrombin (ATHRM), fibrinogen (FIBRINO), protein C (PROTC), and protein S (PROTS']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0373705', 'cui_str': 'Progesterone measurement (procedure)'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0033707', 'cui_str': 'Prothrombin Time'}, {'cui': 'C0030605', 'cui_str': 'Activated Partial Thromboplastin Time'}, {'cui': 'C0003440', 'cui_str': 'Direct Thrombin Inhibitors'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0611128', 'cui_str': 'protein C (synaptosomal)'}, {'cui': 'C0072393', 'cui_str': 'Protein S'}]",1215.0,0.0190154,"Serum E2 levels were statistically significantly inversely associated with the APTT, PROTS, and FIBRINO in early postmenopause, the PT in late postmenopause, and ATHRM and PROTC in both groups.","[{'ForeName': 'I', 'Initials': 'I', 'LastName': 'Sriprasert', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'H N', 'Initials': 'HN', 'LastName': 'Hodis', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Bernick', 'Affiliation': 'TherapeuticsMD, Boca Raton, FL, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Mirkin', 'Affiliation': 'TherapeuticsMD, Boca Raton, FL, USA.'}, {'ForeName': 'W J', 'Initials': 'WJ', 'LastName': 'Mack', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1703939'] 731,31901783,Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.,"BACKGROUND Recently, the efficacy of cryotherapy and compression therapy to prevent taxane-induced peripheral neuropathy has been reported. We prospectively compared the efficacy of cryotherapy using a frozen glove (FG) and compression therapy using a surgical glove (SG) to prevent nanoparticle albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy. PATIENTS AND METHODS Breast cancer patients who received 260 mg/m 2 of nab-PTX were eligible to participate in this trial. Patients wore a FG on one hand (60 min) without changing and two SGs of the same size (i.e., one size smaller than the size that best fit their hand) on the other hand (90 min) during chemotherapy. Peripheral neuropathy was evaluated at each treatment cycle using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, the Patient Neurotoxicity Questionnaire (PNQ), and the Functional Assessment of Cancer Therapy-Taxane subscale. Temperatures at each fingertip in both groups were measured thermographically. RESULTS Between August 2017 and March 2019, 43 patients were enrolled and 38 were evaluated. No cases showed discordance of peripheral neuropathy between each gloved group in cases of CTCAE ≥ grade 2. In cases of PNQ ≥ grade D, using the Nam equivalence test, the upper test (P = 0.0329) and lower test (P = 0.0052) both showed negative results in comparisons between each gloved group. Fingertip temperature was significantly lower in the FG group than in the SG group after treatment (P < 0.0001). CONCLUSIONS It seems to be no difference in incidence of nab-PTX-induced peripheral neuropathy using either cryotherapy or compression therapy.",2020,It seems to be no difference in incidence of nab-PTX-induced peripheral neuropathy using either cryotherapy or compression therapy.,"['Between August 2017 and March 2019', '43 patients were enrolled and 38 were evaluated', 'Breast cancer patients who received 260\xa0mg/m 2 of nab-PTX were eligible to participate in this trial']","['frozen glove (FG) and compression therapy using a surgical glove (SG) to prevent nanoparticle albumin-bound paclitaxel', 'cryotherapy and compression therapy', 'cryotherapy']","['Patient Neurotoxicity Questionnaire (PNQ), and the Functional Assessment of Cancer Therapy-Taxane subscale', 'Fingertip temperature', 'discordance of peripheral neuropathy', 'Peripheral neuropathy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C4517669', 'cui_str': 'Two hundred and sixty'}]","[{'cui': 'C0206069', 'cui_str': 'Glove'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0017682', 'cui_str': 'Gloves, Surgical'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C1961039', 'cui_str': 'paclitaxel protein-bound'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C0031117', 'cui_str': 'PNS (Peripheral Nervous System) Diseases'}]",43.0,0.0176621,It seems to be no difference in incidence of nab-PTX-induced peripheral neuropathy using either cryotherapy or compression therapy.,"[{'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Kanbayashi', 'Affiliation': 'Departments of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan; Departments of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; Department of Education and Research Center for Clinical Pharmacy, Osaka University of Pharmaceutical Sciences, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan. Electronic address: kanbayashi@gly.oups.ac.jp.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Sakaguchi', 'Affiliation': 'Departments of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Ishikawa', 'Affiliation': 'Departments of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan; Departments of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Yoshimi', 'Initials': 'Y', 'LastName': 'Ouchi', 'Affiliation': 'Departments of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Katsuhiko', 'Initials': 'K', 'LastName': 'Nakatsukasa', 'Affiliation': 'Departments of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Tabuchi', 'Affiliation': 'Departments of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan; Departments of Pharmacy, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Fuminao', 'Initials': 'F', 'LastName': 'Kanehisa', 'Affiliation': 'Departments of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Minako', 'Initials': 'M', 'LastName': 'Hiramatsu', 'Affiliation': 'Departments of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan; Departments of Nursing, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Takagi', 'Affiliation': 'Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Hokkaido, Japan.'}, {'ForeName': 'Isao', 'Initials': 'I', 'LastName': 'Yokota', 'Affiliation': 'Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.'}, {'ForeName': 'Norito', 'Initials': 'N', 'LastName': 'Katoh', 'Affiliation': 'Departments of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Taguchi', 'Affiliation': 'Departments of Outpatient Oncology Unit, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan; Departments of Endocrine and Breast Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2019.12.011'] 732,31276981,Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.,"BACKGROUND Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. PATIENTS AND METHODS We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. RESULTS The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33). CONCLUSION The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity. TRIALS REGISTRATION ClinicalTrial.Gov NCT00545077 and NCT00601900.",2019,PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004).,"['We pooled data from two similar phase III randomised trials of ET\xa0±', '1st line hormone receptor-positive\xa0patients with metastatic breast cancer', '749 patients randomised to ET or ET\xa0+\xa0Bev', 'patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance\xa0and reported grades III-IV hypertension and proteinuria', 'hormone receptor-positive metastatic breast cancer']","['standard endocrine therapy (ET) versus experimental ET\xa0+\xa0bevacizumab (Bev', 'bevacizumab']","['Grade III-IV hypertension', 'progression-free survival (PFS', 'Hypertension and proteinuria', 'OS', 'proteinuria', 'Bev ', 'ORR and CBR with ET and ET', 'overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety', 'cardiovascular', 'liver events', 'Median PFS']","[{'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205435', 'cui_str': 'First (qualifier value)'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0277556', 'cui_str': 'Recurrent disease (disorder)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",,0.14133,PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004).,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Martín', 'Affiliation': 'Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense Madrid, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain. Electronic address: mmartín@geicam.org.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'GBG (German Breast Group), Neu-Isenburg, Germany.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hyslop', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'De la Haba-Rodríguez', 'Affiliation': 'Oncology Department and Research Unit, Instituto Maimónides de Investigación Biomédica de Córdoba, Hospital Reina Sofía, Universidad de Córdoba Spain. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Aktas', 'Affiliation': ""University Women's Hospital Leipzig, Leipzig, Germany.""}, {'ForeName': 'C T', 'Initials': 'CT', 'LastName': 'Cirrincione', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Mehta', 'Affiliation': 'GBG (German Breast Group), Neu-Isenburg, Germany.'}, {'ForeName': 'W T', 'Initials': 'WT', 'LastName': 'Barry', 'Affiliation': 'Alliance Statistics and Data Center, Dana-Farber/Partners Cancer Care, Boston, MA, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Morales', 'Affiliation': 'Medical Oncology, Hospital Arnau de Vilanova de Lérida, GEICAM Spanish Breast Cancer Group, Spain.'}, {'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'Carey', 'Affiliation': 'University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Garcia-Saenz', 'Affiliation': 'Medical Oncology, Instituto de Investigación Sanitaria del Hospital Clinico San Carlos (IdISSC) Madrid, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, GEICAM Spanish Breast Cancer Group, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Partridge', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Martinez-Jañez', 'Affiliation': 'Medical Oncology. Universitary Hospital Ramon y Cajal. GEICAM, Spanish Breast Cancer Group; Madrid, Spain.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Hahn', 'Affiliation': 'Alliance Protocol Operations Office, University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Winer', 'Affiliation': 'Dana-Farber/Partners CancerCare, Boston, MA, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Guerrero-Zotano', 'Affiliation': 'Medical Oncology. Valencian Institute of Oncology. GEICAM Spanish Breast Cancer Group, Valencia, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Hudis', 'Affiliation': 'American Society of Clinical Oncology (ASCO), Alexandria, VA, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Casas', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Rodriguez-Martin', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Furlanetto', 'Affiliation': 'GBG (German Breast Group), Neu-Isenburg, Germany.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Carrasco', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'M N', 'Initials': 'MN', 'LastName': 'Dickler', 'Affiliation': 'Eli Lilly and Co. Indianapolis, IN, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.06.002'] 733,28072667,Does the Use of a Vein Visualization Device for Peripheral Venous Catheter Placement Increase Success Rate in Pediatric Patients?,"BACKGROUND Peripheral intravenous catheterization is one of the most frequently encountered medical procedures for hospitalized children and is one that can often be painful. Pediatric nurses should therefore use techniques that increase the success rate or shorten the duration of peripheral intravenous catheterization. OBJECTIVES This study was performed with the objective of determining the effect of using a vein visualization device on the success of the procedure. Success was determined based on the number of attempts per patient, the duration of the procedure, and the first stick success rate. METHODS This was a randomized, controlled experimental study on 129 children aged 3 to 18 years. RESULTS The duration of peripheral intravenous catheterization was shorter in the study group (S) than in the control (C) patients (37.24 ± 20.07 vs 172.65 ± 153.21 seconds; P = 0.001), with fewer attempts (S, 1.08 ± 0.28; C, 2.23 ± 1.57; P < 0.01). The first stick success rate was higher than [corrected] the control group (S, 91.7%; C, 47.4%; P = 0.001). CONCLUSIONS Peripheral intravenous catheterization using vein visualization device support reduces the number of attempts per patient and the operation duration but increases the rate of first stick success. We may therefore state that vein visualization device support improves the success of peripheral intravenous catheterization.",2019,"The duration of peripheral intravenous catheterization was shorter in the study group (S) than in the control (C) patients (37.24 ± 20.07 vs 172.65 ± 153.21 seconds; P = 0.001), with fewer attempts (S, 1.08 ± 0.28; C, 2.23 ± 1.57; P < 0.01).","['129 children aged 3 to 18 years', 'Pediatric Patients', 'hospitalized children']",['vein visualization device'],"['duration of peripheral intravenous catheterization', 'stick success rate', 'success of peripheral intravenous catheterization', 'number of attempts per patient and the operation duration', 'rate of first stick success']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008098', 'cui_str': 'Child, Hospitalized'}]","[{'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C4318418', 'cui_str': 'Stick'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}]",129.0,0.0721286,"The duration of peripheral intravenous catheterization was shorter in the study group (S) than in the control (C) patients (37.24 ± 20.07 vs 172.65 ± 153.21 seconds; P = 0.001), with fewer attempts (S, 1.08 ± 0.28; C, 2.23 ± 1.57; P < 0.01).","[{'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Demir', 'Affiliation': ''}, {'ForeName': 'Sevil', 'Initials': 'S', 'LastName': 'Inal', 'Affiliation': 'Health Science Faculty, Midwifery Department, Istanbul University, Istanbul, Turkey.'}]",Pediatric emergency care,['10.1097/PEC.0000000000001007'] 734,31935136,Ankle-Joint Self-Mobilization and CrossFit Training in Patients With Chronic Ankle Instability: A Randomized Controlled Trial.,"CONTEXT Ankle-joint mobilization and neuromuscular and strength training have been deemed beneficial in the management of patients with chronic ankle instability (CAI). CrossFit training is a sport modality that involves these techniques. OBJECTIVE To determine and compare the influence of adding self-mobilization of the ankle joint to CrossFit training versus CrossFit alone or no intervention in patients with CAI. DESIGN Randomized controlled clinical trial. SETTING Research laboratory. PATIENTS OR OTHER PARTICIPANTS Seventy recreational athletes with CAI were randomly allocated to either self-mobilization plus CrossFit training, CrossFit training alone, or a control group. INTERVENTION(S) Participants in the self-mobilization plus CrossFit group and the CrossFit training-alone group pursued a CrossFit training program twice a week for 12 weeks. The self-mobilization plus CrossFit group performed an ankle self-mobilization protocol before their CrossFit training, and the control group received no intervention. MAIN OUTCOME MEASURE(S) Ankle-dorsiflexion range of motion (DFROM), subjective feeling of instability, and dynamic postural control were assessed via the weight-bearing lunge test, Cumberland Ankle Instability Tool, and Star Excursion Balance Test (SEBT), respectively. RESULTS After 12 weeks of the intervention, both the self-mobilization plus CrossFit and CrossFit training-alone groups improved compared with the control group ( P < .001). The self-mobilization plus CrossFit intervention was superior to the CrossFit training-alone intervention regarding ankle DFROM as well as the posterolateral- and posteromedial-reach distances of the SEBT but not for the anterior-reach distance of the SEBT or the Cumberland Ankle Instability Tool. CONCLUSIONS Ankle-joint self-mobilization and CrossFit training were effective in improving ankle DFROM, dynamic postural control and self-reported instability in patients with CAI.",2020,"The self-mobilization plus CrossFit intervention was superior to the CrossFit training-alone intervention regarding ankle DFROM as well as the posterolateral- and posteromedial-reach distances of SEBT but not for the anterior-reach distance of SEBT or the Cumberland Ankle Instability Tool. ","['Patients With Chronic Ankle Instability', 'patients with CAI', 'patients with chronic ankle instability (CAI', 'Seventy recreational athletes with CAI']","['self-mobilization plus CrossFit training, CrossFit training alone, or a control group', 'Ankle-Joint Self-Mobilization and CrossFit Training', 'CrossFit training', 'neuromuscular and strength training', 'control group received no intervention', 'CrossFit training-alone group pursued a CrossFit training program', 'CrossFit training versus CrossFit alone or no intervention']","['ankle DFROM, dynamic postural control, and self-reported instability', 'Ankle-dorsiflexion range of motion (DFROM), subjective feeling of instability, and dynamic postural control were assessed via the weight-bearing lunge test, Cumberland Ankle Instability Tool, and Star Excursion Balance Test (SEBT), respectively']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3840097', 'cui_str': 'Chronic ankle instability'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003087', 'cui_str': 'Ankle Syndesmosis'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1444783', 'cui_str': 'Instability'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0277851', 'cui_str': 'Ankle instability (finding)'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}]",70.0,0.0280346,"The self-mobilization plus CrossFit intervention was superior to the CrossFit training-alone intervention regarding ankle DFROM as well as the posterolateral- and posteromedial-reach distances of SEBT but not for the anterior-reach distance of SEBT or the Cumberland Ankle Instability Tool. ","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cruz-Díaz', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Spain.'}, {'ForeName': 'Fidel', 'Initials': 'F', 'LastName': 'Hita-Contreras', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Martínez-Amat', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Spain.'}, {'ForeName': 'Agustin', 'Initials': 'A', 'LastName': 'Aibar-Almazán', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Spain.'}, {'ForeName': 'Kyung-Min', 'Initials': 'KM', 'LastName': 'Kim', 'Affiliation': 'Department of Kinesiology and Sport Sciences, University of Miami, FL.'}]",Journal of athletic training,['10.4085/1062-6050-181-18'] 735,31645131,The effect of an interval fatigue protocol on Vestibular/Ocular Motor Screening (VOMS) performance.,"Objective : The purpose of this study was to examine the effect of a fatigue protocol on Vestibular/Ocular Motor Screening (VOMS) performance. Design : Within subjects, repeated measures, crossover. Methods : Fifteen healthy, physically-active participants (22.20 ± 1.424 years) completed 2 sessions under 2 conditions. A pretest VOMS, condition protocol, and a posttest VOMSwere performed. The control condition consisted of rest, while the experimental consisted of a fatigue protocol. Results : The primary outcome measures were VOMS performance scores and Near Point of Convergence (NPC) measurements. Statistically significant interaction effects for NPC, F(1,14) = 9.38, p = .008, and total VOMS score, F(1,14) = 10.96, p = .005 were observed. For NPC, posttest (9.12 ± 4.99 cm) was significantly different, t(14) = -2.60, p = .021, than pretest scores (7.12 ± 3.19 cm). For total VOMS score, posttest experimental scores (4.93 ± 5.12) were significantly different, t(14) = -3.06, p = .009, than pretest severity scores (1.73 ± 3.67). Conclusions : Significant increases were found in total VOMS and NPC scores following exertional fatigue. Exertional fatigue affects symptoms associated with vestibular, and/or ocular motor system assessments. Clinicians should use the VOMS with caution immediately following activity and allow time for recovery from acute fatigue.",2020,"Statistically significant interaction effects for NPC, F(1,14) = 9.38, p = .008, and total VOMS score, F(1,14) = 10.96, p = .005 were observed.","['Fifteen healthy, physically-active participants (22.20 ± 1.424 years) completed 2 sessions under 2 conditions']",['interval fatigue protocol'],"['total VOMS and NPC scores following exertional fatigue', 'VOMS performance scores and Near Point of Convergence (NPC) measurements', 'Vestibular/Ocular Motor Screening (VOMS) performance', 'total VOMS score']","[{'cui': 'C0556453', 'cui_str': 'Physically active (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0429572', 'cui_str': 'Near point'}, {'cui': 'C0443193', 'cui_str': 'Convergence (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]",15.0,0.0924855,"Statistically significant interaction effects for NPC, F(1,14) = 9.38, p = .008, and total VOMS score, F(1,14) = 10.96, p = .005 were observed.","[{'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Ratka', 'Affiliation': 'Department of Kinesiology, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Cheever', 'Affiliation': 'Department of Kinesiology, Health, and Nutrition, University of Texas at San Antonio, TX, USA.'}, {'ForeName': 'Jamie L', 'Initials': 'JL', 'LastName': 'Mansell', 'Affiliation': 'Department of Kinesiology, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Ryan T', 'Initials': 'RT', 'LastName': 'Tierney', 'Affiliation': 'Department of Kinesiology, Temple University, Philadelphia, PA, USA.'}]",Brain injury,['10.1080/02699052.2019.1682194'] 736,31955461,Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra-individual study.,"BACKGROUND We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. OBJECTIVES The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs. METHODS This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. RESULTS More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month follow-up was 19.6 (±6.0) for DL-PDT and 20.0 (±6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). CONCLUSIONS Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.",2020,"DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs 5.1 respectively (p<0.0001). ","['enrolled 26 subjects', 'actinic keratosis (AK', 'actinic keratosis']","['DL-PDT vs PDT', 'Daylight photodynamic therapy with methyl aminolevulinate cream', 'daylight phototherapy dynamic (DL-PDT']","['raw number of disappeared AK lesions', 'efficacy with clearance of AKs and safety with assessment of pain']","[{'cui': 'C0022602', 'cui_str': 'Senile keratoma (disorder)'}]","[{'cui': 'C0044588', 'cui_str': 'PDT'}, {'cui': 'C0031740', 'cui_str': 'Photodynamic Therapy'}, {'cui': 'C1134467', 'cui_str': 'methyl aminolevulinate'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",26.0,0.0309582,"DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs 5.1 respectively (p<0.0001). ","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Assikar', 'Affiliation': 'Department of Dermatology, CHU Dupuytren, Limoges, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Labrunie', 'Affiliation': ""Centre d'Epidémiologie, de BIostatistique et de MEthodologie de la Recherche (CEBIMER), CHU Dupuytren, Limoges, France.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Kerob', 'Affiliation': 'Galderma International, Paris, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Couraud', 'Affiliation': 'Department of Dermatology, CHU Dupuytren, Limoges, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bédane', 'Affiliation': 'Department of Dermatology, CHU Dupuytren, Limoges, France.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16208'] 737,31847328,Modifications of Own Mothers' Milk Fortification Protocol Affect Early Plasma IGF-I and Ghrelin Levels in Preterm Infants. A Randomized Clinical Trial.,"The aim was to investigate the effect of two own mother's milk (OMM) fortification protocols on (a) IGF-I and ghrelin plasma levels at 35 post-conceptional weeks (PCW, T2) and whether this effect is maintained after elimination of the differences in OMM fortification, and (b) growth until 12 months corrected age. Forty-eight OMM-fed preterm infants (GA 24-32 weeks) were randomly allocated to the fixed-fortification (FF) group ( n = 23) and the protein-targeting fortification (PTF) group ( n = 25) targeting the recommended daily protein intake (PI). Plasma IGF-I and ghrelin were assessed at 35 (T2) and 40 (T3) PCW while growth was longitudinally assessed until 12 months corrected age. PTF group had lower IGF-I and higher ghrelin than FF group at T2, while receiving lower daily protein and energy amounts. PI correlated positively to T2-IGF-I and inversely to T3-ghrelin while energy intake (EI) correlated inversely to T2- and T3-ghrelin. Group and PI were independent predictors of adjusted T2-IGF-I, while group and EI were predictors of adjusted and T2-ghrelin. Growth parameter z -scores were comparable between groups up to 12 months corrected age. Modifications of OMM fortification have a transient effect on early plasma IGF-I and ghrelin levels in preterm infants in a way consistent with the previously recognized protein-energy/endocrine balance, indicating a potential programming effect.",2019,"Modifications of OMM fortification have a transient effect on early plasma IGF-I and ghrelin levels in preterm infants in a way consistent with the previously recognized protein-energy/endocrine balance, indicating a potential programming effect.","['Forty-eight OMM-fed preterm infants (GA 24-32 weeks', 'Preterm Infants', 'preterm infants']","['PTF', 'OMM fortification', 'protein-targeting fortification (PTF) group ( n = 25) targeting the recommended daily protein intake (PI', ""mother's milk (OMM) fortification protocols"", 'fixed-fortification (FF']","['T2-IGF-I and inversely to T3-ghrelin while energy intake (EI', 'IGF-I and ghrelin plasma levels', 'Plasma IGF-I and ghrelin', 'z -scores', 'Plasma IGF-I and Ghrelin Levels', 'early plasma IGF-I and ghrelin levels']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}]","[{'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]",35.0,0.108097,"Modifications of OMM fortification have a transient effect on early plasma IGF-I and ghrelin levels in preterm infants in a way consistent with the previously recognized protein-energy/endocrine balance, indicating a potential programming effect.","[{'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Agakidou', 'Affiliation': '1st Department of Neonatology & NICU, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}, {'ForeName': 'Thomais', 'Initials': 'T', 'LastName': 'Karagiozoglou-Lampoudi', 'Affiliation': 'Department of Nutrition and Dietetics, Alexander Technological Educational Institute of Thessaloniki, 57400 Thessaloniki, Greece.'}, {'ForeName': 'Elisavet', 'Initials': 'E', 'LastName': 'Parlapani', 'Affiliation': '1st Department of Neonatology & NICU, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}, {'ForeName': 'Dimitrios J', 'Initials': 'DJ', 'LastName': 'Fletouris', 'Affiliation': 'Laboratory of Milk Hygiene and Technology, School of Veterinary Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.'}, {'ForeName': 'Kosmas', 'Initials': 'K', 'LastName': 'Sarafidis', 'Affiliation': '1st Department of Neonatology & NICU, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Tzimouli', 'Affiliation': '1st Pediatric Department, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}, {'ForeName': 'Elisavet', 'Initials': 'E', 'LastName': 'Diamanti', 'Affiliation': '1st Department of Neonatology & NICU, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}, {'ForeName': 'Charalampos', 'Initials': 'C', 'LastName': 'Agakidis', 'Affiliation': '1st Pediatric Department, Aristotle University of Thessaloniki, Ippokration General Hospital, Konstantinoupoleos 49, 54246 Thessaloniki, Greece.'}]",Nutrients,['10.3390/nu11123056'] 738,31847976,Comparison of foam sclerotherapy versus radiofrequency ablation in the treatment of primary varicose veins due to incompetent great saphenous vein: Randomized clinical trial.,"BACKGROUND AND OBJECTIVE Minimally invasive procedures such as foam sclerotherapy and radiofrequency ablation (RFA) have gained attention for treatment of incompetent great saphenous vein (GSV). The objective of this study was to compare recurrence rate and quality of life between foam sclerotherapy and RFA in patients with incompetent GSV varicose veins. METHODS In this parallel single-blinded randomized clinical trial, 60 adult patients with primary varicose veins due to incompetent GSV (CEAP classes C2-4EPAsPr) were included and randomly divided to receive RFA or foam sclerotherapy. Health-related quality of life (HRQOL) was assessed by the Short Form 36, and the Aberdeen Varicose Vein Questionnaire (AVVQ) was applied to assess the impact of varicose veins on quality of life of the patients. In addition, pain severity after the procedures was investigated by a visual analog scale (VAS) (range, 0 to 10). The patients were followed at 1 week, 1 month, 3 months, and 6 months postoperation. GSV reflux and recurrence was assessed by color Doppler ultrasound examination after 6 months. RESULTS Twenty-eight patients in RFA and 27 patients in foam sclerotherapy remained for the final analyses. The time interval from the procedure and recovery to daily normal activities was 1 day in both groups. Mean (±SD) pain VAS score in RFA group decreased from preintervention score of 7.35 (±3.28) to 1.21 (±0.68); P < .0001. Likewise, this score decreased from 6.64 (±2.04) to 1.29 (±0.91) in foam sclerotherapy group. HRQOL scores increased gradually at 1, 3, and 6 months after the intervention. AVVQ scores decreased significantly 1 week postintervention in both groups. After 6 months, 17.9% (5 patients) in RFA group and 14.8% (4 patients) in foam sclerotherapy group had recurrence of GSV reflux (P = .52). CONCLUSION Both foam sclerotherapy and RFA were effective in treatment of GSV reflux. Comparable findings were observed between the 2 groups regarding postoperative pain, recovery time, HRQOL, and AVVQ scores.",2019,"Comparable findings were observed between the 2 groups regarding postoperative pain, recovery time, HRQOL, and AVVQ scores.","['60 adult patients with primary varicose veins due to incompetent GSV (CEAP classes C2-4EPAsPr', 'patients with incompetent GSV varicose veins', 'primary varicose veins due to incompetent great saphenous vein']","['sclerotherapy and RFA', 'sclerotherapy and radiofrequency ablation (RFA', 'RFA or foam sclerotherapy', 'foam sclerotherapy', 'radiofrequency ablation']","['AVVQ scores', 'time interval from the procedure and recovery to daily normal activities', 'postoperative pain, recovery time, HRQOL, and AVVQ scores', 'recurrence of GSV reflux', 'pain severity', 'Health-related quality of life (HRQOL', 'GSV reflux and recurrence', 'Mean (±SD) pain VAS score', 'recurrence rate and quality of life', 'HRQOL scores', 'visual analog scale (VAS']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}]","[{'cui': 'C0036435', 'cui_str': 'Sclerotherapy'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",60.0,0.110538,"Comparable findings were observed between the 2 groups regarding postoperative pain, recovery time, HRQOL, and AVVQ scores.","[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Rai', 'Affiliation': 'Department of Cardiology, Imam Ali Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Mahtab', 'Initials': 'M', 'LastName': 'Porsalman', 'Affiliation': 'Department of Surgery, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Khatony', 'Affiliation': 'Department of Community Health, Medical Surgical Nursing, School of Nursing and Midwifery, Infectious Diseases Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Sobhiyeh', 'Affiliation': 'Department of Vascular and Endovascular Surgery, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: mreza.sobhiyeh@yahoo.com.'}]",Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing,['10.1016/j.jvn.2019.10.002'] 739,31926918,"Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.","BACKGROUND Chemoprevention of colorectal adenoma and colorectal cancer remains an important public health goal. The present study aimed to investigate the clinical potential and safety of berberine for prevention of colorectal adenoma recurrence. METHODS This double-blind, randomised, placebo-controlled trial was done in seven hospital centres across six provinces in China. Individuals aged 18-75 years who had at least one but no more than six histologically confirmed colorectal adenomas that had undergone complete polypectomy within the 6 months before recruitment were recruited and randomly assigned (1:1) to receive berberine (0·3 g twice daily) or placebo tablets via block randomisation (block size of six). Participants were to undergo a first follow-up colonoscopy 1 year after enrolment, and if no colorectal adenomas were detected, a second follow-up colonoscopy at 2 years was planned. The study continued until the last enrolled participant reached the 2-year follow-up point. All participants, investigators, endoscopists, and pathologists were blinded to treatment assignment. The primary efficacy endpoint was the recurrence of adenomas at any follow-up colonoscopy. Analysis was based on modified intention-to-treat, with the full analysis set including all randomised participants who received at least one dose of study medication and who had available efficacy data. The study is registered with ClinicalTrials.gov, number NCT02226185; the trial has ended and this report represents the final analysis. FINDINGS Between Nov 14, 2014, and Dec 30, 2016, 553 participants were randomly assigned to the berberine group and 555 to the placebo group. The full analysis set consisted of 429 participants in the berberine group and 462 in the placebo group. 155 (36%) participants in the berberine group and 216 (47%) in the placebo group were found to have recurrent adenoma during follow-up (unadjusted relative risk ratio for recurrence 0·77, 95% CI 0·66-0·91; p=0·001). No colorectal cancers were detected during follow-up. The most common adverse event was constipation (six [1%] of 446 patients in the berberine group vs one [<0·5%] of 478 in the placebo group). No serious adverse events were reported. INTERPRETATION Berberine 0·3 g twice daily was safe and effective in reducing the risk of recurrence of colorectal adenoma and could be an option for chemoprevention after polypectomy. FUNDING National Natural Science Foundation of China.",2020,The most common adverse event was constipation (six [1%] of 446 patients in the berberine group vs one [<0·5%] of 478 in the placebo group).,"['Individuals aged 18-75 years who had at least one but no more than six histologically confirmed colorectal adenomas that had undergone complete polypectomy within the 6 months before recruitment', 'seven hospital centres across six provinces in China', '429 participants in the berberine group and 462 in the', 'Between Nov 14, 2014, and Dec 30, 2016, 553 participants']","['placebo', 'berberine', 'berberine (0·3 g twice daily) or placebo tablets', 'Berberine versus placebo']","['serious adverse events', 'recurrence of adenomas at any follow-up colonoscopy', 'recurrence of colorectal adenoma', 'recurrent adenoma', 'colorectal cancers', 'risk of recurrence of colorectal adenoma']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0005117', 'cui_str': 'Berberine'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",553.0,0.722249,The most common adverse event was constipation (six [1%] of 446 patients in the berberine group vs one [<0·5%] of 478 in the placebo group).,"[{'ForeName': 'Ying-Xuan', 'Initials': 'YX', 'LastName': 'Chen', 'Affiliation': 'Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Qin-Yan', 'Initials': 'QY', 'LastName': 'Gao', 'Affiliation': 'Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Tian-Hui', 'Initials': 'TH', 'LastName': 'Zou', 'Affiliation': 'Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Bang-Mao', 'Initials': 'BM', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Si-De', 'Initials': 'SD', 'LastName': 'Liu', 'Affiliation': 'Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Jian-Qiu', 'Initials': 'JQ', 'LastName': 'Sheng', 'Affiliation': 'Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital, Beijing, China.'}, {'ForeName': 'Jian-Lin', 'Initials': 'JL', 'LastName': 'Ren', 'Affiliation': 'Department of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, China.'}, {'ForeName': 'Xiao-Ping', 'Initials': 'XP', 'LastName': 'Zou', 'Affiliation': 'Division of Gastroenterology and Hepatology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Zhan-Ju', 'Initials': 'ZJ', 'LastName': 'Liu', 'Affiliation': ""Department of Gastroenterology, the Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Yan-Yan', 'Initials': 'YY', 'LastName': 'Song', 'Affiliation': 'Department of Biostatistics, Clinical Research Institute, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Xiao', 'Affiliation': 'Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Xiao-Min', 'Initials': 'XM', 'LastName': 'Sun', 'Affiliation': ""Department of Gastroenterology, the Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.""}, {'ForeName': 'Xiao-Tan', 'Initials': 'XT', 'LastName': 'Dou', 'Affiliation': 'Division of Gastroenterology and Hepatology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Hai-Long', 'Initials': 'HL', 'LastName': 'Cao', 'Affiliation': 'Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Xiao-Ning', 'Initials': 'XN', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital, Beijing, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Kang', 'Affiliation': 'Department of Gastroenterology, the Seventh Medical Center of PLA General Hospital, Beijing, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Hong-Zhi', 'Initials': 'HZ', 'LastName': 'Xu', 'Affiliation': 'Department of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, China.'}, {'ForeName': 'Hui-Min', 'Initials': 'HM', 'LastName': 'Chen', 'Affiliation': 'Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiao-Chuang', 'Initials': 'XC', 'LastName': 'Cao', 'Affiliation': 'Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin, China.'}, {'ForeName': 'Jing-Yuan', 'Initials': 'JY', 'LastName': 'Fang', 'Affiliation': 'Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology & Hepatology, Ministry of Health, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China. Electronic address: jingyuanfang@sjtu.edu.cn.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30409-1'] 740,31672458,"Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials.","AIMS Sevelamer has been reported to have anti-oxidative and anti-inflammatory effects as well as effects on glycaemic control and plasma lipids. The aim of this study was to determine the effects of one-week treatment with sevelamer on oxidative nucleic acid modifications and inflammation markers. METHODS Two double-blinded studies including 30 patients with type 2 diabetes (T2D) and 20 healthy individuals were conducted. Participants were randomised to one week of treatment with sevelamer (1600 mg three times daily) or placebo. RNA and DNA oxidation, measured by urinary excretion of 8-oxo-7,8-dihydroguanosine(8-oxoGuo) and (8-oxo-7,8-dihydro-2'-deoxyguanosine(8-oxodG), and markers of inflammation were determined before and after the intervention. RESULTS In patients with T2D there was no significant placebo-corrected reduction in 8-oxoGuo or 8-oxodG. However, a reduction in 8-oxoGuo was observed within the group treated with sevelamer (∆8-oxoGuo/creatinine (median[IQR]): -0.04 [-0.24; 0.01] nmol/mmol, p = 0.02). A sevelamer-mediated reduction in interleukin-2 (p = 0.04) and a trend towards reduction in interleukin-6 (p = 0.053) were found in patients with T2D. CONCLUSIONS This study reveals a potential effect of sevelamer treatment on inflammation and possible oxidative RNA modifications. The potential protective effects of sevelamer in terms of cardiovascular disease in patients with T2D need further investigation.",2020,"A sevelamer-mediated reduction in interleukin-2 (p = 0.04) and a trend towards reduction in interleukin-6 (p = 0.053) were found in patients with T2D. ","['patients with T2D', 'patients with T2D need further investigation', '30 patients with type 2 diabetes (T2D) and 20 healthy individuals were conducted']","['placebo', 'sevelamer (∆8-oxoGuo/creatinine (median[IQR', 'Sevelamer', 'sevelamer']","[""RNA and DNA oxidation, measured by urinary excretion of 8-oxo-7,8-dihydroguanosine(8-oxoGuo) and (8-oxo-7,8-dihydro-2'-deoxyguanosine(8-oxodG), and markers of inflammation"", 'reduction in 8-oxoGuo', '8-oxoGuo or 8-oxodG', 'oxidative nucleic acid modifications and inflammation markers']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]","[{'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0050092', 'cui_str': '8-oxoG nucleoside'}, {'cui': 'C0050078', 'cui_str': ""2'-deoxy-8-oxo-7,8-dihydroguanosine""}, {'cui': 'C0028606', 'cui_str': 'Nucleic Acids'}]",,0.243645,"A sevelamer-mediated reduction in interleukin-2 (p = 0.04) and a trend towards reduction in interleukin-6 (p = 0.053) were found in patients with T2D. ","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Brønden', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Emil List', 'Initials': 'EL', 'LastName': 'Larsen', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: emil.list.larsen.01@regionh.dk.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Karstoft', 'Affiliation': 'Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Trine', 'Initials': 'T', 'LastName': 'Henriksen', 'Affiliation': 'Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Henrik Enghusen', 'Initials': 'HE', 'LastName': 'Poulsen', 'Affiliation': 'Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Filip Krag', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2019.107446'] 741,31957252,Effects of smelling amniotic fluid on preterm infant's pain and stress during peripheral cannulation: A randomized controlled trial.,"AIM To investigate the effect of smelling amniotic fluid on preterm infants' pain and stress caused by peripheral cannulation. METHODS This was a randomized controlled trial. The study sample consisted of 80 preterm infants meeting the case selection criteria and infants were randomly assigned to each group. However, in addition to the infants excluded from the study, total number of the infants in all the groups was 61. Infants in the amniotic fluid group smelled amniotic fluid for 15 min before, during, and after the application of peripheral cannulation while those in the control group received routine care during the procedure. The Premature Infant Pain Profile was used to assess their pain levels, and salivary cortisol analysis was performed to evaluate stress levels. RESULTS Preterm infants in the amniotic fluid and control groups had similar baseline characteristics. However, the pain levels of infants in the amniotic fluid group were significantly lower than of those in the control group during and after the procedure. After the procedure, cortisol levels of the infants in the amniotic fluid group were lower than of those in the control group, although this difference was not significant. CONCLUSION The intervention of smelling amniotic fluid is a practice that can be used for reducing pain and stress of preterm infants during peripheral cannulation.",2020,"After the procedure, cortisol levels of the infants in the amniotic fluid group were lower than of those in the control group, although this difference was not significant. ","[""preterm infants' pain and stress caused by peripheral cannulation"", 'preterm infants during peripheral cannulation', '80 preterm infants meeting the case selection criteria and infants', ""preterm infant's pain and stress during peripheral cannulation""]",['smelling amniotic fluid'],"['cortisol levels', 'pain levels, and salivary cortisol analysis', 'pain levels']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0242801', 'cui_str': 'Selection Criteria'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0998863', 'cui_str': 'Osmeridae'}, {'cui': 'C0002638', 'cui_str': 'Amniotic Fluid'}]","[{'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]",,0.248122,"After the procedure, cortisol levels of the infants in the amniotic fluid group were lower than of those in the control group, although this difference was not significant. ","[{'ForeName': 'Dilek Küçük', 'Initials': 'DK', 'LastName': 'Alemdar', 'Affiliation': 'Nursing Department, Faculty of Health Sciences, Ordu University, Ordu, Turkey.'}, {'ForeName': 'Fatma Güdücü', 'Initials': 'FG', 'LastName': 'Tüfekci', 'Affiliation': 'Pediatric Nursing Department, Nursing Faculty, Ataturk University, Erzurum, Turkey.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12317'] 742,31910803,Study protocol of a randomized controlled trial of home-based computerized executive function training for children with cerebral palsy.,"BACKGROUND Cerebral palsy (CP) is frequently associated with specific cognitive impairments, such as executive dysfunction which are related to participation and quality of life (QOL). The proposed study will examine whether a computerized executive function (EF) training programme could provide superior benefits for executive functioning, participation, QOL and brain plasticity, as compared to usual care. METHODS A single-blind randomized controlled trial (RCT) design will be performed. Thirty children with CP aged 8 to 12 years will participate in a home-based computerized multi-modal executive training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h). Thirty children with CP matched by age, sex, motor and intelligence quotient (IQ) will compose the waitlist group. Cognitive, behavioural, emotional, participation and QOL measures will be obtained at three time points: before, immediately after and 9 months after completing the training. Additionally, structural and functional (resting state) magnetic resonance images (MRI) will be obtained in a subsample of 15 children from each group. Outcomes between groups will be compared following standard principles for RCTs. DISCUSSION The study will test whether the cognitive training programme exerts a positive effect not only on neuropsychological and daily functioning of children with CP but also on other measures such as participation and QOL. We will also use brain MRI to test brain functional and structural changes after the intervention. If this on-line and home-based training programme proves effective, it could be a cost-effective intervention with short- and long-term effects on EF, participation or QOL in CP. TRIAL REGISTRATION ClinicalTrials.gov: NCT04025749. Registered 19 July 2019. Retrospectively registered.",2020,"Thirty children with CP aged 8 to 12 years will participate in a home-based computerized multi-modal executive training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h).","['Thirty children with CP aged 8 to 12\u2009years', 'children with CP', 'children with cerebral palsy', 'Thirty children with CP matched by age, sex, motor and intelligence quotient (IQ) will compose the waitlist group', '15 children from each group']","['cognitive training programme', 'computerized executive function (EF) training programme', 'home-based computerized executive function training', 'structural and functional (resting state) magnetic resonance images (MRI', 'home-based computerized multi-modal executive training programme']","['executive functioning, participation, QOL and brain plasticity', 'Cognitive, behavioural, emotional, participation and QOL measures']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0007789', 'cui_str': 'CP (Cerebral Palsy)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0456149', 'cui_str': 'Intelligence quotient (observable entity)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0589092', 'cui_str': 'Executive functions training (regime/therapy)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",30.0,0.0729958,"Thirty children with CP aged 8 to 12 years will participate in a home-based computerized multi-modal executive training programme (12 weeks, 5 days a week, 30 min a day training, total dose = 30 h).","[{'ForeName': 'María', 'Initials': 'M', 'LastName': 'García-Galant', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Blasco', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Reid', 'Affiliation': 'Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Brockway 65, Brisbane, 6014, Queensland, Australia.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Pannek', 'Affiliation': 'Australian e-Health Research Centre, Commonwealth Scientific and Industrial Research Organisation, Brockway 65, Brisbane, 6014, Queensland, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Leiva', 'Affiliation': 'Departament de Psicologia Social i Psicologia Quantitativa, Universitat de Barcelona, Barcelona, 08035, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Laporta-Hoyos', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Júlia', 'Initials': 'J', 'LastName': 'Ballester-Plané', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Júlia', 'Initials': 'J', 'LastName': 'Miralbell', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Xavi', 'Initials': 'X', 'LastName': 'Caldú', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Xènia', 'Initials': 'X', 'LastName': 'Alonso', 'Affiliation': 'Servei de Neurologia, Hospital Universitari Sant Joan de Déu, Passeig Sant Joan de Déu 2, Barcelona, 08950, Spain.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Toro-Tamargo', 'Affiliation': ""Servei de Rehabilitació i Medicina Física, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain.""}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Meléndez-Plumed', 'Affiliation': ""Servei de Rehabilitació i Medicina Física, Hospital Universitari Vall d'Hebron, Passeig Vall d'Hebron 119-129, Barcelona, 08035, Spain.""}, {'ForeName': 'Francisca', 'Initials': 'F', 'LastName': 'Gimeno', 'Affiliation': 'Serveis de Rehabilitació, Associació de la Paràlisi Cerebral (ASPACE), Camí Tres Pins 31-35, Barcelona, 08038, Spain.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Coronas', 'Affiliation': ""Departament de Cognició, Desenvolupament i Psicologia de l'Educació, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Emili', 'Initials': 'E', 'LastName': 'Soro-Camats', 'Affiliation': ""Departament de Cognició, Desenvolupament i Psicologia de l'Educació, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain.""}, {'ForeName': 'Roslyn', 'Initials': 'R', 'LastName': 'Boyd', 'Affiliation': 'Queensland Cerebral Palsy and Rehabilitation Research Centre, The University of Queensland, Graham 62, Brisbane, 4101, Queensland, Australia.'}, {'ForeName': 'Roser', 'Initials': 'R', 'LastName': 'Pueyo', 'Affiliation': ""Departament de Psicologia Clínica i Psicobiologia, Universitat de Barcelona, Passeig Vall d'Hebron 171, Barcelona, 08035, Spain. rpueyo@ub.edu.""}]",BMC pediatrics,['10.1186/s12887-019-1904-x'] 743,31955940,Ultralong Versus Standard Long Peripheral Intravenous Catheters: A Randomized Controlled Trial of Ultrasonographically Guided Catheter Survival.,"STUDY OBJECTIVE Ultrasonographically guided intravenous peripheral catheters have dismal dwell time, with most intravenous lines failing before completion of therapy. Catheter length in the vein is directly related to catheter longevity. We investigate the survival of an ultralong ultrasonographically guided intravenous peripheral catheter compared with a standard long one. METHODS We conducted a single-site, nonblinded, randomized trial of catheter survival. Adult patients presenting to the emergency department with difficult vascular access were recruited and randomized to receive either standard long, 4.78-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters or ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters. The primary outcome was duration of catheter survival. The secondary outcome was the optimal length of the catheter in the vein to maximize survival. Additional intravenous-related endpoints included first-stick success, time to insertion, number of attempts, thrombosis, and infection. RESULTS Between October 2018 and March 2019, 257 patients were randomized, with 126 in the standard long ultrasonographically guided intravenous peripheral catheter group and 131 in the ultralong group. Kaplan-Meier estimate of catheter median survival time in the ultralong group was 136 hours (95% confidence interval [CI] 116 to 311 hours) compared with 92 hours (95% CI 71 to 120 hours) in the standard long group, for a difference of 44 hours (95% CI 2 to 218 hours). The optimal catheter length in the vein was 2.75 cm, and intravenous lines with greater than 2.75 cm inserted had a median survival of 129 hours (95% CI 102 to 202 hours) compared with 75 hours (95% CI 52 to 116 hours) for intravenous lines with less than or equal to 2.75 cm, for a difference of 54 hours (95% CI 10 to 134 hours). Insertion characteristics were similar between the groups: 74.1% versus 79.4% first-stick success (95% CI for the difference -2% to 5%), 1.4 versus 1.3 for number of attempts (95% CI for the difference -0.1 to 0.3), and 6.9 versus 5.9 minutes to completion (95% CI for the difference -1.3 to 3.4) with ultralong versus standard long, respectively. There were no cases of infection or thrombosis. CONCLUSION This study demonstrated increased catheter survival when the ultralong compared with the standard long ultrasonographically guided intravenous peripheral catheter was used, whereas insertion characteristics and safety appeared similar.",2020,"This study demonstrated increased catheter survival when the ultralong compared with the standard long ultrasonographically guided intravenous peripheral catheter was used, whereas insertion characteristics and safety appeared similar.","['Adult patients presenting to the emergency department with difficult vascular access', '257 patients were randomized, with 126 in the', 'Between October 2018 and March 2019']","['Ultrasonographically Guided Catheter Survival', '20-gauge ultrasonographically guided intravenous peripheral catheters or ultralong, 6.35-cm, 20-gauge ultrasonographically guided intravenous peripheral catheters', 'Ultralong Versus Standard Long Peripheral Intravenous Catheters', 'standard long ultrasonographically guided intravenous peripheral catheter']","['optimal catheter length', 'Catheter length', 'stick success, time to insertion, number of attempts, thrombosis, and infection', 'optimal length of the catheter in the vein to maximize survival', 'median survival', 'infection or thrombosis', 'catheter median survival time', 'duration of catheter survival', 'Insertion characteristics', 'catheter survival']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0332218', 'cui_str': 'With difficulty'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}]","[{'cui': 'C0221799', 'cui_str': 'Guiding catheter, device (physical object)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0456564', 'cui_str': 'Gauges (qualifier value)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C1827740', 'cui_str': 'Peripheral catheter (physical object)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0179768', 'cui_str': 'Peripheral intravenous catheter, device (physical object)'}]","[{'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C4318418', 'cui_str': 'Stick'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",257.0,0.261121,"This study demonstrated increased catheter survival when the ultralong compared with the standard long ultrasonographically guided intravenous peripheral catheter was used, whereas insertion characteristics and safety appeared similar.","[{'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Bahl', 'Affiliation': 'Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI. Electronic address: amit.bahl@beaumont.edu.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Hijazi', 'Affiliation': 'Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI.'}, {'ForeName': 'Nai-Wei', 'Initials': 'NW', 'LastName': 'Chen', 'Affiliation': 'Department of Biostatistics, William Beaumont Hospital, Royal Oak, MI.'}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Lachapelle-Clavette', 'Affiliation': 'Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Price', 'Affiliation': 'Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2019.11.013'] 744,31948926,Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials.,"BACKGROUND Using latent class analysis (LCA) in five randomised controlled trial (RCT) cohorts, two distinct phenotypes of acute respiratory distress syndrome (ARDS) have been identified: hypoinflammatory and hyperinflammatory. The phenotypes are associated with differential outcomes and treatment response. The objective of this study was to develop parsimonious models for phenotype identification that could be accurate and feasible to use in the clinical setting. METHODS In this retrospective study, three RCT cohorts from the National Lung, Heart, and Blood Institute ARDS Network (ARMA, ALVEOLI, and FACTT) were used as the derivation dataset (n=2022), from which the machine learning and logistic regression classifer models were derived, and a fourth (SAILS; n=715) from the same network was used as the validation test set. LCA-derived phenotypes in all of these cohorts served as the reference standard. Machine-learning algorithms (random forest, bootstrapped aggregating, and least absolute shrinkage and selection operator) were used to select a maximum of six important classifier variables, which were then used to develop nested logistic regression models. Only cases with complete biomarker data in the derivation dataset were used for variable selection. The best logistic regression models based on parsimony and predictive accuracy were then evaluated in the validation test set. Finally, the models' prognostic validity was tested in two external ARDS clinical trial datasets (START and HARP-2) by assessing mortality at days 28, 60, and 90 and ventilator-free days to day 28. FINDINGS The six most important classifier variables were interleukin (IL)-8, IL-6, protein C, soluble tumour necrosis factor receptor 1, bicarbonate, and vasopressor use. From the nested models, three-variable (IL-8, bicarbonate, and protein C) and four-variable (3-variable plus vasopressor use) models were adjudicated to be the best performing. In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95 [95% CI 0·93-0·96] for the four-variable model) against LCA classifications. As with LCA-derived phenotypes, the hyperinflammatory phenotype as identified by the classifier model was associated with higher mortality at day 90 (87 [39%] of 223 patients vs 112 [23%] of 492 patients; p<0·0001) and fewer ventilator-free days (median 14 days [IQR 0-22] vs 22 days [0-25]; p<0·0001). In the external validation datasets, three-variable models developed in the derivation dataset identified two phenotypes with distinct clinical features and outcomes consistent with previous findings, including differential survival with simvastatin versus placebo in HARP-2 (p=0·023 for survival at 28 days). INTERPRETATION ARDS phenotypes can be accurately identified with parsimonious classifier models using three or four variables. Pending the development of real-time testing for key biomarkers and prospective validation, these models could facilitate identification of ARDS phenotypes to enable their application in clinical trials and practice. FUNDING National Institutes of Health.",2020,"In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95","['acute respiratory distress syndrome (ARDS', 'classify acute respiratory distress syndrome phenotypes']",['simvastatin versus placebo'],"['higher mortality', 'interleukin (IL)-8, IL-6, protein C, soluble tumour necrosis factor receptor 1, bicarbonate, and vasopressor use']","[{'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C1314763', 'cui_str': 'Phenotyping (qualifier value)'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0611128', 'cui_str': 'protein C (synaptosomal)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C0005367', 'cui_str': 'Hydrogen Carbonates'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",492.0,0.0742616,"In the validation test set, both models showed good accuracy (AUC 0·94 [95% CI 0·92-0·95] for the three-variable model and 0·95","[{'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Sinha', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA. Electronic address: pratik.sinha@ucsf.edu.'}, {'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Delucchi', 'Affiliation': 'Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK; Regional Intensive Care Unit, The Royal Hospitals, Belfast, UK.""}, {'ForeName': 'Cecilia M', 'Initials': 'CM', 'LastName': ""O'Kane"", 'Affiliation': ""The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK.""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Matthay', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Carolyn S', 'Initials': 'CS', 'LastName': 'Calfee', 'Affiliation': 'Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Anesthesia, University of California, San Francisco, San Francisco, CA, USA.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30369-8'] 745,31948853,Effectiveness of a Diet and Resistance Exercise Intervention on Muscle Health in Older Adults: ProMuscle in Practice.,"OBJECTIVES Clinical studies show that resistance exercise and a protein-rich diet can counteract the age-related decline of muscle mass, strength, and physical performance. The aim of the ProMuscle in Practice study was to test effectiveness of a resistance exercise and dietary protein intervention for older adults implemented in a real-life setting. DESIGN A randomized controlled multicenter intervention study. SETTING AND PARTICIPANTS One hundred sixty-eight community-dwelling older adults were included (age 75 ± 6 years). A 12-week intensive support intervention including progressive resistance exercise supervised by a physiotherapist and dietitian guidance on increasing protein intake was followed by a voluntary 12-week moderate support intervention to continue the adapted lifestyle pattern. The control group received no intervention. METHODS Compliance was measured through attendance lists and 3-day food records. Physical functioning, leg strength (3-repetition maximum, knee extension strength), lean body mass [(LBM) dual-energy X-ray absorptiometry], and quality of life (5-level EQ-5D) were measured at baseline, and after 12 and 24 weeks. Differences in change between groups were assessed with linear mixed model analysis. RESULTS The intervention group increased protein intake and attended 83.6% of the training sessions. Short Physical Performance Battery score slightly increased in intervention participants [from 10.1 (95% confidence interval 9.7-10.5) to 10.4 (10.0-10.8) at week 12 and 10.6 (10.2-10.9) at week 24], where control participants decreased (time × treatment interactions, P < .05). Improvements in intervention group compared with controls were also observed for Timed Up-and-Go, strength and LBM at both time points (time × treatment interactions, P < .05). No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. CONCLUSIONS AND IMPLICATIONS ProMuscle in Practice was effective on improving muscle strength and LBM, with small changes in the composite function score in community-dwelling older adults in a real-life setting. Further research should explore feasibility of real-life implementation, as well as improving long-term compliance.",2020,"No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. ","['Older Adults', 'One hundred sixty-eight community-dwelling older adults were included (age 75\xa0±\xa06\xa0years', 'older adults implemented in a real-life setting', 'community-dwelling older adults']","['progressive resistance exercise supervised by a physiotherapist and dietitian guidance', 'Diet and Resistance Exercise Intervention', 'resistance exercise and a protein-rich diet', 'resistance exercise and dietary protein intervention', 'no intervention']","['Short Physical Performance Battery score', 'Physical functioning, leg strength (3-repetition maximum, knee extension strength), lean body mass [(LBM) dual-energy X-ray absorptiometry], and quality of life (5-level EQ-5D', 'protein intake', 'Muscle Health', '6-Minute Walking Test, activities of daily living, and quality of life']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general) (occupation)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0012177', 'cui_str': 'Dietary Proteins'}]","[{'cui': 'C4075289', 'cui_str': 'Short Physical Performance Battery score (observable entity)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0034380'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}]",168.0,0.0339392,"No difference between groups was found for the 6-Minute Walking Test, activities of daily living, and quality of life. ","[{'ForeName': 'Ellen J I', 'Initials': 'EJI', 'LastName': 'van Dongen', 'Affiliation': 'Food, Health and Consumer Research, Wageningen Food and Biobased Research, Wageningen, the Netherlands.'}, {'ForeName': 'Annemien', 'Initials': 'A', 'LastName': 'Haveman-Nies', 'Affiliation': 'Division of Strategic Communication, Wageningen University and Research, Wageningen, the Netherlands; Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands; GGD Noord-en Oost-Gelderland, Academic Collaborative Center AGORA, Zutphen, the Netherlands.'}, {'ForeName': 'Esmée L', 'Initials': 'EL', 'LastName': 'Doets', 'Affiliation': 'Food, Health and Consumer Research, Wageningen Food and Biobased Research, Wageningen, the Netherlands.'}, {'ForeName': 'Berber G', 'Initials': 'BG', 'LastName': 'Dorhout', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands.'}, {'ForeName': 'Lisette C P G M', 'Initials': 'LCPGM', 'LastName': 'de Groot', 'Affiliation': 'Division of Human Nutrition and Health, Wageningen University and Research, the Netherlands. Electronic address: Lisette.degroot@wur.nl.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2019.11.026'] 746,31588504,The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE.,"CONTEXT Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes. Unintentional weight loss is associated with increased risk of all-cause mortality, but few studies have examined its association with cardiovascular outcomes in patients with diabetes. OBJECTIVE To evaluate 2-year weight change and subsequent risk of cardiovascular events and mortality in established type 2 diabetes. DESIGN AND SETTING The Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation was an international, multisite 2×2 factorial trial of intensive glucose control and blood pressure control. We examined 5 categories of 2-year weight change: >10% loss, 4% to 10% loss, stable (±<4%), 4% to 10% gain, and >10% gain. We used Cox regression with follow-up time starting at 2 years, adjusting for intervention arm, demographics, cardiovascular risk factors, and diabetes medication use from the 2-year visit. RESULTS Among 10 081 participants with valid weight measurements, average age was 66 years. By the 2-year examination, 4.3% had >10% weight loss, 18.4% had 4% to 10% weight loss, and 5.3% had >10% weight gain. Over the following 3 years of the trial, >10% weight loss was strongly associated with major macrovascular events (hazard ratio [HR], 1.75; 95% confidence interval [CI], 1.26-2.44), cardiovascular mortality (HR, 2.76; 95% CI, 1.87-4.09), all-cause mortality (HR, 2.79; 95% CI, 2.10-3.71), but not major microvascular events (HR, 0.91; 95% CI, 0.61-1.36), compared with stable weight. There was no evidence of effect modification by baseline body mass index, age, or type of diabetes medication. CONCLUSIONS In the absence of substantial lifestyle changes, weight loss may be a warning sign of poor health meriting further workup in patients with type 2 diabetes.",2020,"There was no evidence of effect modification by baseline BMI, age, or type of diabetes medication. ","['10,081 participants with valid weight measurements, average age was 66 years', 'patients with diabetes', 'Adults with Diabetes', 'patients with type 2 diabetes', 'overweight and obese adults with type 2 diabetes']",['intensive glucose control and blood pressure control'],"['Unintentional weight loss', 'cardiovascular mortality', 'cause mortality', 'major macrovascular events', 'weight loss', 'major microvascular events', '2-year weight change and subsequent risk of cardiovascular events and mortality']","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]","[{'cui': 'C2363736', 'cui_str': 'Involuntary weight loss'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.0634737,"There was no evidence of effect modification by baseline BMI, age, or type of diabetes medication. ","[{'ForeName': 'Alexandra K', 'Initials': 'AK', 'LastName': 'Lee', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Woodward', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Ohkuma', 'Affiliation': 'The G eorge Institute for Global Health, Sydney 2042, Australia.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Warren', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'A Richey', 'Initials': 'AR', 'LastName': 'Sharrett', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Institute of Cardiovascular Sciences, University College London, London, WC1E 6BT, UK.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Marre', 'Affiliation': 'Fondation Opthalmologique Adolphe de Rothschild, Université Denis Diderot, 75019 Paris, France.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Hamet', 'Affiliation': ""Center de Rechercher, Center Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec H2X 0A9, Canada.""}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Harrap', 'Affiliation': 'Department of Physiology, Royal Melbourne Hospital, University of Melbourne, Victoria 3010, Australia.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Mcevoy', 'Affiliation': 'School of Medicine, National University of Ireland, Galway Campus, and National Institute for Preventive Cardiology, Galway, H91 TK33, Ireland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Chalmers', 'Affiliation': 'The G eorge Institute for Global Health, Sydney 2042, Australia.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Selvin', 'Affiliation': 'Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz045'] 747,31939556,Physical and functional aspects of persons with multiple sclerosis practicing Tai-Geiko: randomized trial.,"OBJECTIVES This study aimed to verify the influence of Tai-Geiko on the physical and functional aspects of people with multiple sclerosis (MS). METHODS This was a parallel-group, randomized trial with two arms. People with MS were allocated to an experimental group (EG) (n=10) and control group (CG) (n=09). The participants received multidisciplinary care supervised by a physiotherapist in the Tai-Geiko exercise. Participants underwent the assessments after the intervention. The Expanded Disability Status Scale (EDSS-maximum score of 6.0), strength test (kgf) using a dynamometer, Timed Up and Go mobility test (TUG), and stabilometric balance test (Platform EMG system®) were evaluated. Demographic data were recorded, including age, sex, comorbidities, lifestyle and classification of MS. Clinical Trials (ReBeC): RBR-4sty47. RESULTS The EG group improved in 12 variables, and the CG improved in 3 variables. The following values were obtained for pre/postintervention, respectively: EG: lumbar force (38/52 kgf), TUG (11/9 s), locomotion velocity (519/393 ms); double task two (53/39 s); platform stabilometric trajectory: traversed get up (39/26 s) and sit (45/29 s); anteroposterior (AP) amplitude rise (11/8 cm) and sit (12.40/9.94 cm) and anteroposterior frequency rise (1.00/1.56 Hz) and sit (0.8/1.25 Hz) (p<0.05); CG: right-hand grip force (26/29 kgf); TUG (9.8 /8.7 s) and AP (11.84 /9.53 cm) stabilometric amplitude at the sitting moment (p<0.05), (3.2/5.99 Hz, p=0.01) and sit (3.47/5.01 Hz, p=0.04). CONCLUSION Tai-Geiko practice can be suggested as complementary exercise in the rehabilitation of persons with MS.",2020,"The Expanded Disability Status Scale (EDSS-maximum score of 6.0), strength test (kgf) using a dynamometer, Timed Up and Go mobility test (TUG), and stabilometric balance test (Platform EMG system®) were evaluated.","['persons with multiple sclerosis practicing Tai-Geiko', 'persons with MS', 'People with MS', 'people with multiple sclerosis (MS']","['Tai-Geiko', 'multidisciplinary care supervised by a physiotherapist in the Tai-Geiko exercise']","['anteroposterior frequency rise', 'Expanded Disability Status Scale (EDSS-maximum score of 6.0), strength test (kgf) using a dynamometer, Timed Up and Go mobility test (TUG), and stabilometric balance test (Platform EMG system®', 'locomotion velocity (519/393 ms); double task two (53/39 s); platform stabilometric trajectory: traversed get up (39/26 s) and sit (45/29 s); anteroposterior (AP) amplitude rise']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer (physical object)'}, {'cui': 'C2919666', 'cui_str': 'Timed up and go mobility test (assessment scale)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}]",,0.0373107,"The Expanded Disability Status Scale (EDSS-maximum score of 6.0), strength test (kgf) using a dynamometer, Timed Up and Go mobility test (TUG), and stabilometric balance test (Platform EMG system®) were evaluated.","[{'ForeName': 'Viviane Regina Leite Moreno', 'Initials': 'VRLM', 'LastName': 'Ultramari', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Adriano Percival Calderaro', 'Initials': 'APC', 'LastName': 'Calvo', 'Affiliation': 'Programa de Pos Graduacao em Desempenho Humano Operacional (PPGDHO), Universidade da Forca Aerea (UNIFA), Rio de Janeiro, RJ, BR.'}, {'ForeName': 'Rosilene Andrade Silva', 'Initials': 'RAS', 'LastName': 'Rodrigues', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Waléria Christiane Rezende', 'Initials': 'WCR', 'LastName': 'Fett', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Jose Urias de', 'Initials': 'JU', 'LastName': 'Moraes Neto', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Almir de França', 'Initials': 'AF', 'LastName': 'Ferraz', 'Affiliation': 'Grupo de Estudos em Actividade Fisica e Promocao da Saude, Departamento de Graduacao em Educacao Fisica, Universidade Sao Judas Tadeu (USJT), Sao Paulo, SP, BR.'}, {'ForeName': 'Michelle Jalousie', 'Initials': 'MJ', 'LastName': 'Kommers', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Heloise Helena Siqueira', 'Initials': 'HHS', 'LastName': 'Borges', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}, {'ForeName': 'Michell Vetoraci', 'Initials': 'MV', 'LastName': 'Viana', 'Affiliation': 'Grupo de Estudos em Actividade Fisica e Promocao da Saude, Departamento de Graduacao em Educacao Fisica, Universidade Sao Judas Tadeu (USJT), Sao Paulo, SP, BR.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Cattafesta', 'Affiliation': 'Programa de Pos Graduacao em Saude Coletiva (PPGSC), Centro de Ciencias da Saude, Universidade Federal do Espirito Santo (UFES), Vitoria, ES, BR.'}, {'ForeName': 'Luciane Bresciani', 'Initials': 'LB', 'LastName': 'Salaroli', 'Affiliation': 'Programa de Pos Graduacao em Saude Coletiva (PPGSC), Centro de Ciencias da Saude, Universidade Federal do Espirito Santo (UFES), Vitoria, ES, BR.'}, {'ForeName': 'Carlos Alexandre', 'Initials': 'CA', 'LastName': 'Fett', 'Affiliation': 'Nucleo de Estudo em Aptidao Fisica, Informatica, Metabolismo, Esporte e Saude (NAFIMES), Universidade Federal do Mato Grosso, MT, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1272'] 748,31930509,The effects of paired kinesthetic movements on literacy skills acquisition with preschoolers.,"Students who fail to acquire foundational literacy skills during preschool are more likely to read below grade level average in elementary school and are at a heightened risk for future school failure, poverty, early mortality, and crime. The purpose of this study was to compare the effects and maintenance of and preference for paired kinesthetic movements (KM) to a traditional drill (TD) procedure on letter-sound correspondence and word recognition with 6 preschool children. In 6 of 11 evaluations, participants mastered the KM set in substantially fewer intervention sessions than the TD set. In 5 of 11 evaluations, participants mastered the KM and TD sets with little differentiation between the number of intervention sessions. No participant mastered the control set. Maintenance data demonstrate a higher number of correct responses for the KM condition across all weeks. Preference varied across participants and was not always consistent with the more effective intervention.",2020,"In 5 of 11 evaluations, participants mastered the KM and TD sets with little differentiation between the number of intervention sessions.","['Students who fail to acquire foundational literacy skills during preschool', '6 preschool children', 'literacy skills acquisition with preschoolers']","['paired kinesthetic movements (KM) to a traditional drill (TD) procedure', 'paired kinesthetic movements']",[],"[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0439661', 'cui_str': 'Acquired (qualifier value)'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0324815', 'cui_str': 'Drill'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]",[],,0.0190778,"In 5 of 11 evaluations, participants mastered the KM and TD sets with little differentiation between the number of intervention sessions.","[{'ForeName': 'Erica D', 'Initials': 'ED', 'LastName': 'Lozy', 'Affiliation': 'Louisiana State University.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Holmes', 'Affiliation': 'Louisiana State University.'}, {'ForeName': 'Jeanne M', 'Initials': 'JM', 'LastName': 'Donaldson', 'Affiliation': 'Louisiana State University.'}]",Journal of applied behavior analysis,['10.1002/jaba.677'] 749,31930828,Isometric Versus Aerobic Training Effects on Vascular Adaptation in Patients with Type 2 Diabetes.,"BACKGROUND AND OBJECTIVE Diabetes is known to be associated with arterial remodeling and dysfunction which predispose to different microvascular complications. This study was aimed to find out the effect of isometric versus aerobic training on vascular adaptation in patients with type 2 diabetes. MATERIALS AND METHODS The study was carried out on 40 type 2 diabetic patients (20 men and 20 women). Patients were selected from the outpatient clinic of El-Agouza Police Authority Hospital. They were assigned into 2 matched and equal groups in number. Group A with mean age of 49.55 years, received unilateral isometric handgrip exercise 22 min per session, 3 sessions per week for 8 weeks and group B with mean age 50.15 years, received aerobic exercise in form of arm ergometry for 30 min, 3 sessions per week for 8 weeks. They were assessed by a Doppler ultrasound for brachial artery adaptation (the brachial artery diameter, blood velocity and shear rate) before and after 8 weeks of training. RESULTS Group A showed significant improvement in brachial artery adaptation as increased brachial artery diameter from 4.28±0.19 to 4.43±0.18, baseline vessel velocity from 7.09±0.41 to 8.62±0.46 and its shear rate from 66.24±4.19 to 77.65±5.27, while in group B who received the aerobic exercise the results showed a minimal change between pre training and post-training results 4.24±0.23 to 4.26±0.21 for brachial artery diameter, 7.26±0.54 to 7.46±0.67 for blood velocity and 67.8±3.16 to 68.81±4.29 for shear rate respectively. CONCLUSION Isometric handgrip exercise improved brachial artery diameter, blood velocity and shear rate in patients with type 2 diabetes.",2019,"RESULTS Group A showed significant improvement in brachial artery adaptation as increased brachial artery diameter from 4.28±0.19 to 4.43±0.18, baseline vessel velocity from 7.09±0.41 to 8.62±0.46 and its shear rate from 66.24±4.19 to 77.65±5.27, while in group B who received the aerobic exercise the results showed a minimal change between pre training and post-training results 4.24±0.23 to 4.26±0.21 for brachial artery diameter, 7.26±0.54 to 7.46±0.67 for blood velocity and 67.8±3.16 to 68.81±4.29 for shear rate respectively. ","['patients with type 2 diabetes', 'Patients with Type 2 Diabetes', 'Patients were selected from the outpatient clinic of El-Agouza Police Authority Hospital', 'Group A with mean age of 49.55 years', '40 type 2 diabetic patients (20 men and 20 women']","['Isometric handgrip exercise', 'aerobic exercise', 'isometric versus aerobic training', 'Isometric Versus Aerobic Training', 'unilateral isometric handgrip exercise']","['Vascular Adaptation', 'vascular adaptation', 'baseline vessel velocity', 'shear rate', 'Doppler ultrasound for brachial artery adaptation (the brachial artery diameter, blood velocity and shear rate', 'brachial artery diameter', 'brachial artery diameter, blood velocity and shear rate', 'brachial artery adaptation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0085098', 'cui_str': 'Police'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]","[{'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}, {'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}]",,0.0205961,"RESULTS Group A showed significant improvement in brachial artery adaptation as increased brachial artery diameter from 4.28±0.19 to 4.43±0.18, baseline vessel velocity from 7.09±0.41 to 8.62±0.46 and its shear rate from 66.24±4.19 to 77.65±5.27, while in group B who received the aerobic exercise the results showed a minimal change between pre training and post-training results 4.24±0.23 to 4.26±0.21 for brachial artery diameter, 7.26±0.54 to 7.46±0.67 for blood velocity and 67.8±3.16 to 68.81±4.29 for shear rate respectively. ","[{'ForeName': 'Nesreen G', 'Initials': 'NG', 'LastName': 'El-Nahas', 'Affiliation': ''}, {'ForeName': 'Manar Mohamed', 'Initials': 'MM', 'LastName': 'Badawy', 'Affiliation': ''}]",Pakistan journal of biological sciences : PJBS,['10.3923/pjbs.2019.400.405'] 750,31925317,A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.,"In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1+ leukaemia stem cells are responsible for disease persistence despite TKI. Based on in vitro data, CHOICES (CHlorOquine and Imatinib Combination to Eliminate Stem cells) was an international, randomised phase II trial designed to study the safety and efficacy of imatinib (IM) and hydroxychloroquine (HCQ) compared with IM alone in CP-CML patients in major cytogenetic remission with residual disease detectable by qPCR. Sixty-two patients were randomly assigned to either arm. Treatment 'successes' was the primary end point, defined as ≥0.5 log reduction in 12-month qPCR level from trial entry. Selected secondary study end points were 24-month treatment 'successes', molecular response and progression at 12 and 24 months, comparison of IM levels, and achievement of blood HCQ levels >2000 ng/ml. At 12 months, there was no difference in 'success' rate (p = 0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (p = 0.21). At 24 months, the 'success' rate was 20.8% higher with IM/HCQ (p = 0.059). No patients progressed. Seventeen serious adverse events, including four serious adverse reactions, were reported; diarrhoea occurred more frequently with combination. IM/HCQ is tolerable in CP-CML, with modest improvement in qPCR levels at 12 and 24 months, suggesting autophagy inhibition maybe of clinical value in CP-CML.",2020,"At 12 months, there was no difference in 'success' rate (p = 0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (p = 0.21).","['2000', 'CP-CML patients in major cytogenetic remission with residual disease detectable by qPCR', 'patients with chronic myeloid leukaemia in major cytogenetic response with residual disease', 'Sixty-two patients']","['hydroxychloroquine and imatinib versus imatinib alone', 'IM/HCQ', 'imatinib (IM) and hydroxychloroquine (HCQ']","['MMR', 'diarrhoea', ""24-month treatment 'successes', molecular response and progression at 12 and 24 months, comparison of IM levels, and achievement of blood HCQ levels"", 'qPCR levels', ""success' rate""]","[{'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0023473', 'cui_str': 'Leukemia, Granulocytic, Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0010802', 'cui_str': 'Cytogenetic'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C4055168', 'cui_str': 'Cytogenetic response'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0935989', 'cui_str': 'imatinib'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}]",62.0,0.0257648,"At 12 months, there was no difference in 'success' rate (p = 0.58); MMR was achieved in 80% (IM) vs 92% (IM/HCQ) (p = 0.21).","[{'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Horne', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Stobo', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Kelly', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Mukhopadhyay', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.""}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Latif', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Dixon-Hughes', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'McMahon', 'Affiliation': 'Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Cony-Makhoul', 'Affiliation': 'Haematology department, CH Annecy-Genevois, Pringy, France.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Byrne', 'Affiliation': 'Department of Haematology, Nottingham City Hospital, Nottingham, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': ""Department of Haematology, St James's University Hospital, Leeds, UK.""}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Koschmieder', 'Affiliation': 'Department of Medicine (Hematology Oncology, Hemostaseology, and Stem Cell Transplantation), Faculty of Medicine, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'T H', 'Initials': 'TH', 'LastName': 'BrÜmmendorf', 'Affiliation': 'Department of Medicine (Hematology Oncology, Hemostaseology, and Stem Cell Transplantation), Faculty of Medicine, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schafhausen', 'Affiliation': 'Department of Internal Medicine, University Medical Center Hamburg, Hamburg, Germany.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Gallipoli', 'Affiliation': 'Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Thomson', 'Affiliation': 'Experimental therapeutics, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Cong', 'Affiliation': 'Experimental therapeutics, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Clark', 'Affiliation': 'Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Milojkovic', 'Affiliation': 'Department of Haematology, Hammersmith Hospital, London, UK.'}, {'ForeName': 'G V', 'Initials': 'GV', 'LastName': 'Helgason', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Foroni', 'Affiliation': 'Department of Haematology, Imperial College London, London, UK.'}, {'ForeName': 'F E', 'Initials': 'FE', 'LastName': 'Nicolini', 'Affiliation': 'Hématologie Clinique and INSERM U1052, CRCL, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Holyoake', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Copland', 'Affiliation': ""Paul O'Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK. Mhairi.Copland@glasgow.ac.uk.""}]",Leukemia,['10.1038/s41375-019-0700-9'] 751,31563641,Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).,,2020,,['Patients With Psoriasis'],[],['Tildrakizumab Efficacy and Safety'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]",[],"[{'cui': 'C4043954', 'cui_str': 'tildrakizumab'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0383807,,"[{'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Department of Dermatology, Mount Sinai Hospital, New York, New York. Electronic address: lebwohl@aol.com.'}, {'ForeName': 'Craig L', 'Initials': 'CL', 'LastName': 'Leonardi', 'Affiliation': 'Central Dermatology and Saint Louis University School of Medicine, St Louis, Missouri.'}, {'ForeName': 'Nehal N', 'Initials': 'NN', 'LastName': 'Mehta', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Alice B', 'Initials': 'AB', 'LastName': 'Gottlieb', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Mendelsohn', 'Affiliation': 'Sun Pharmaceutical Industries, Inc, Princeton, New Jersey.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Parno', 'Affiliation': 'Sun Pharmaceutical Industries, Inc, Princeton, New Jersey.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Rozzo', 'Affiliation': 'Sun Pharmaceutical Industries, Inc, Princeton, New Jersey.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Menter', 'Affiliation': 'Division of Dermatology, Baylor Scott & White, and Texas A&M College of Medicine, Dallas, Texas.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.09.042'] 752,31283023,Vestibular modulation of multisensory integration during actual and vicarious tactile stimulation.,"The vestibular system has been shown to contribute to multisensory integration by balancing conflictual sensory information. It remains unclear whether such modulation of exteroceptive (e.g., vision), proprioceptive, and interoceptive (e.g., affective touch) sensory sources is influenced by epistemically different aspects of tactile stimulation (i.e., felt from within vs. seen, vicarious touch). In the current study, we aimed to (a) replicate previous findings regarding the effects of galvanic stimulation of the right vestibular network in multisensory integration, and (b) examine vestibular contributions to multisensory integration when touch is felt but not seen (and vice versa). During artificial vestibular stimulation (LGVS, i.e., right vestibular stimulation), RGVS (i.e., bilateral stimulation), and sham (i.e., placebo stimulation), healthy participants (N = 36, Experiment 1; N = 37, Experiment 2) looked at a rubber hand while either their own unseen hand or the rubber hand were touched by affective or neutral touch. We found that (a) LGVS led to enhancement of vision over proprioception during visual only conditions (replicating our previous findings), and (b) LGVS (versus sham) favored proprioception over vision when touch was felt (Experiment 1), with the opposite results when touch was vicariously perceived via vision (Experiment 2) and with no difference between affective and neutral touch. We showed how vestibular signals modulate the weight of each sensory modality according to the context in which they are perceived and that such modulation extends to different aspects of tactile stimulation: felt and seen touch are differentially balanced in multisensory integration according to their epistemic relevance.",2019,"We found that (a) LGVS led to enhancement of vision over proprioception during visual only conditions (replicating our previous findings), and (b) LGVS (versus sham) favored proprioception over vision when touch was felt (Experiment 1), with the opposite results when touch was vicariously perceived via vision (Experiment 2) and with no difference between affective and neutral touch.",[],"['LGVS', 'artificial vestibular stimulation (LGVS, i.e., right vestibular stimulation), RGVS (i.e., bilateral stimulation), and sham (i.e., placebo stimulation), healthy participants (N\xa0=\xa036, Experiment 1; N\xa0=\xa037, Experiment 2) looked at a rubber hand while either their own unseen hand or the rubber hand were touched by affective or neutral touch']",[],[],"[{'cui': 'C2004457', 'cui_str': 'Artificial (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0035918', 'cui_str': 'Natural Rubber'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}]",[],,0.0245636,"We found that (a) LGVS led to enhancement of vision over proprioception during visual only conditions (replicating our previous findings), and (b) LGVS (versus sham) favored proprioception over vision when touch was felt (Experiment 1), with the opposite results when touch was vicariously perceived via vision (Experiment 2) and with no difference between affective and neutral touch.","[{'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Ponzo', 'Affiliation': 'School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, UK.'}, {'ForeName': 'Louise P', 'Initials': 'LP', 'LastName': 'Kirsch', 'Affiliation': 'Clinical, Educational & Health Psychology Research Department, Division of Psychology & Language Sciences, University College London, London, UK.'}, {'ForeName': 'Aikaterini', 'Initials': 'A', 'LastName': 'Fotopoulou', 'Affiliation': 'Clinical, Educational & Health Psychology Research Department, Division of Psychology & Language Sciences, University College London, London, UK.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Jenkinson', 'Affiliation': 'School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, UK.'}]",Psychophysiology,['10.1111/psyp.13430'] 753,31927549,Single-Injection Ultrasound-Guided Thoracic Paravertebral Block versus Local Anesthetic Infiltration in Peritoneal Dialysis Catheter Surgeries: A Randomized Controlled Trial.,"INTRODUCTION Ultrasound-guided thoracic paravertebral block (US-TPVB) is generally used for postoperative analgesia. We hypothesized that single-injection US-TPVB could be used as the principal anesthetic technique for a peritoneal dialysis catheter (PDC) procedure (implantation or removal). The anesthetic effect and venous ropivacaine level after a TPVB would be compared with that after local anesthetic infiltration (LAI). METHODS Patients undergoing PDC procedures were randomized into Group LAI or TPVB. In Group LAI, 40 mL of 0.25% ropivacaine were used. In Group TPVB, single-injection of US-TPVB at T10-T11 level was performed with 20 mL of 0.25% ropivacaine. The quality of anesthesia, visual analogue scale of pain, and venous total plasma ropivacaine level were compared between the 2 groups. RESULTS Seventy-four eligible patients were enrolled and 38 in Group TPVB. Thirty patients in Group TPVB and 26 patients in Group LAI underwent PDC procedures successfully. Higher satisfaction rates by nephrologists and patients (76.3 and 78.9%) were reported in Group TPVB (44.4 and 44.4% in Group LAI, respectively). The peak venous total plasma ropivacaine concentrations were below the reported toxic threshold in the 2 groups. CONCLUSIONS A single-injection US-TPVB with 20 mL of 0.25% ropivacaine at T10-T11 could be the principal anesthetic technique for PDC procedures, which provided a comparable anesthetic effect to that of LAI with 40 mL ropivacaine. Higher satisfaction rates by nephrologists and patients were observed in Group TPVB. The 20 mL dose of 0.25% ropivacaine used for an US-TPVB was safe in end-stage renal diseases patients.",2020,"Higher satisfaction rates by nephrologists and patients (76.3 and 78.9%) were reported in Group TPVB (44.4 and 44.4% in Group LAI, respectively).","['Seventy-four eligible patients were enrolled and 38 in Group TPVB', 'Peritoneal Dialysis Catheter Surgeries', 'Patients undergoing PDC procedures']","['Single-Injection Ultrasound-Guided Thoracic Paravertebral Block versus Local Anesthetic Infiltration', 'Ultrasound-guided thoracic paravertebral block (US-TPVB', 'ropivacaine', 'TPVB']","['peak venous total plasma ropivacaine concentrations', 'anesthetic effect and venous ropivacaine level', 'quality of anesthesia, visual analogue scale of pain, and venous total plasma ropivacaine level', 'Higher satisfaction rates']","[{'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0179783', 'cui_str': 'Peritoneal dialysis catheter'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration (procedure)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C3179301', 'cui_str': 'Anesthetic Effect'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",74.0,0.0371587,"Higher satisfaction rates by nephrologists and patients (76.3 and 78.9%) were reported in Group TPVB (44.4 and 44.4% in Group LAI, respectively).","[{'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University and The Research Units of West China, Chinese Academy of Medical Sciences, Chengdu, China.'}, {'ForeName': 'Xiao-Juan', 'Initials': 'XJ', 'LastName': 'Jiang', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University and The Research Units of West China, Chinese Academy of Medical Sciences, Chengdu, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University and The Research Units of West China, Chinese Academy of Medical Sciences, Chengdu, China, liqimd@qq.com.'}, {'ForeName': 'Xiao-Hong', 'Initials': 'XH', 'LastName': 'Tang', 'Affiliation': 'Department of Nephrology, West China Hospital of Sichuan University and The Research Units of West China, Chinese Academy of Medical Sciences, Chengdu, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, West China Hospital of Sichuan University and The Research Units of West China, Chinese Academy of Medical Sciences, Chengdu, China.'}]",Blood purification,['10.1159/000505259'] 754,31927665,Randomized trial comparing the effectiveness of internal (through implantable cardioverter defibrillator) versus external cardioversion of atrial fibrillation.,"PURPOSE When patients with implantable cardioverter defibrillators (ICD) develop symptomatic atrial fibrillation (AF), external direct current cardioversion (EDCCV), as well as internal cardioversion using their ICD, are the options available. It is currently unknown which of these two methods are more effective. We compared the effectiveness of EDCCV versus internal cardioversion to terminate AF in patients with a single-coil ICD. METHODS This randomized controlled trial (clinicaltrial.gov NCT03164395) enrolled consecutive patients with a single-coil ICD that presented with symptomatic AF of less than 1-year duration. They received either the maximum energy internal shock through the ICD or an EDCCV using transcutaneous pads of 200 J. The primary endpoint was a successful conversion to sinus rhythm after one shock. Crossover was permitted if the first shock was unsuccessful. RESULTS Thirty-one patients were enrolled in the study, including 16 in the internal ICD cardioversion group. The study included patients with a mean age of 59.5 ± 16.0 years, 41.9% females, median AF duration 1 month (interquartile range 1-3), 45.2% non-ischemic cardiomyopathies, mean EF 28.6 ± 16.0%, and 45.2% biventricular ICD. There were no significant differences in baseline clinical characteristics between the two groups. In the internal cardioversion group, 5/16 patients (31.3%) met the primary endpoint versus 14/15 (93.3%) in the EDCCV group, p < 0.001. All patients that failed the first shock were subsequently cardioverted externally. CONCLUSION Among patients with a single-coil ICD and symptomatic AF of less than 1 year, external direct current cardioversion is much more effective than internal shock through the ICD.",2020,There were no significant differences in baseline clinical characteristics between the two groups.,"['Thirty-one patients were enrolled in the study, including 16 in the internal ICD cardioversion group', 'patients with a single-coil ICD and symptomatic AF of less than 1\xa0year', 'patients with a single-coil ICD', 'patients with a mean age of 59.5\u2009±\u200916.0\xa0years, 41.9% females, median AF duration 1\xa0month (interquartile range 1-3), 45.2% non-ischemic cardiomyopathies, mean EF 28.6\u2009±\u200916.0%, and 45.2% biventricular ICD', 'enrolled consecutive patients with a single-coil ICD that presented with symptomatic AF of less than 1-year duration', 'patients with implantable cardioverter defibrillators (ICD) develop symptomatic atrial fibrillation (AF']","['internal (through implantable cardioverter defibrillator', 'external direct current cardioversion (EDCCV', 'EDCCV']",['successful conversion to sinus rhythm after one shock'],"[{'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil (physical object)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0877438', 'cui_str': 'Non-ischemic cardiomyopathy'}, {'cui': 'C4517679', 'cui_str': '28.6'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0162589', 'cui_str': 'Implantable Cardioverter-Defibrillators'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0162589', 'cui_str': 'Implantable Cardioverter-Defibrillators'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0542380', 'cui_str': 'Direct current cardioversion (procedure)'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C0232201', 'cui_str': 'Coronary sinus rhythm'}, {'cui': 'C1869063', 'cui_str': 'Shock (SMQ)'}]",31.0,0.0245097,There were no significant differences in baseline clinical characteristics between the two groups.,"[{'ForeName': 'Claude S', 'Initials': 'CS', 'LastName': 'Elayi', 'Affiliation': 'University of Florida, 653 8th St W, Jacksonville, FL, 32209, USA. elayic@yahoo.fr.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Parrott', 'Affiliation': 'Baptist Health, 4000 Kresge Way, Louisville, KY, 40207, USA.'}, {'ForeName': 'Farshid', 'Initials': 'F', 'LastName': 'Etaee', 'Affiliation': 'University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, 75390, USA.'}, {'ForeName': 'Jignesh', 'Initials': 'J', 'LastName': 'Shah', 'Affiliation': 'Cardiology, Gill Heart Institute and Lexington VA Medical Center, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Leung', 'Affiliation': 'Cardiology, Gill Heart Institute and Lexington VA Medical Center, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Guglin', 'Affiliation': 'Indiana University Health, 3777 Frontage Rd, Michigan City, IN, 46360, USA.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Elayi', 'Affiliation': 'Cardiology, Gill Heart Institute and Lexington VA Medical Center, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jessinger', 'Affiliation': 'Cardiology, Gill Heart Institute and Lexington VA Medical Center, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'Gbolahan', 'Initials': 'G', 'LastName': 'Ogunbayo', 'Affiliation': 'Cardiology, Gill Heart Institute and Lexington VA Medical Center, University of Kentucky, Lexington, KY, 40506, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Catanzaro', 'Affiliation': 'University of Florida, 653 8th St W, Jacksonville, FL, 32209, USA.'}, {'ForeName': 'Gustavo', 'Initials': 'G', 'LastName': 'Morales', 'Affiliation': 'Alabama Cardiovascular Group, Al, Birmingham, USA.'}, {'ForeName': 'Yousef', 'Initials': 'Y', 'LastName': 'Darrat', 'Affiliation': 'Veterans Affairs Medical Center, Lexington, KY, USA.'}]",Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing,['10.1007/s10840-019-00689-7'] 755,31037288,HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.,"BACKGROUND Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. METHODS A research-based PAM50 assay was applied in 422 HER2-positive tumors from five II-III clinical trials (SOLTI-PAMELA, TBCRC023, TBCRC006, PER-ELISA, EGF104090). In SOLTI-PAMELA, TBCRC023, TBCRC006, and PER-ELISA, all patients had early disease and were treated with neoadjuvant lapatinib or pertuzumab plus trastuzumab for 12-24 weeks. Primary outcome was pathological complete response (pCR). In EGF104900, 296 women with advanced disease were randomized to receive either lapatinib alone or lapatinib plus trastuzumab. Progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) were evaluated. RESULTS A total of 305 patients with early and 117 patients with advanced HER2-positive disease were analyzed. In early disease, HER2-E represented 83.8% and 44.7% of ERBB2-high and ERBB2-low tumors, respectively. Following lapatinib and trastuzumab, the HER2-E and ERBB2 (HER2-E/ERBB2)-high group showed a higher pCR rate compared to the rest (44.5%, 95% confidence interval [CI] = 35.4% to 53.9% vs 11.6%, 95% CI = 6.9% to 18.0%; adjusted odds ratio [OR] = 6.05, 95% CI = 3.10 to 11.80, P < .001). Similar findings were observed with neoadjuvant trastuzumab and pertuzumab (pCR rate of 66.7% in HER2-E/ERBB2-high, 95% CI = 22.3% to 95.7% vs 14.7% in others, 95% CI = 4.9% to 31.1%; adjusted OR = 11.60, 95% CI = 1.66 to 81.10, P = .01). In the advanced setting, the HER2-E/ERBB2-high group was independently associated with longer PFS (hazard ratio [HR] = 0.52, 95% CI = 0.35 to 0.79, P < .001); higher ORR (16.3%, 95% CI = 8.9% to 26.2% vs 3.7%, 95% CI = 0.8% to 10.3%, P = .02); and longer OS (HR = 0.66, 95% CI = 0.44 to 0.97, P = .01). CONCLUSIONS Combining HER2-E subtype and ERBB2 mRNA into a single assay identifies tumors with high responsiveness to HER2-targeted therapy. This biomarker could help de-escalate chemotherapy in approximately 40% of patients with HER2-positive breast cancer.",2020,"Following lapatinib and trastuzumab, the HER2-E/ERBB2-high group showed a higher pCR rate compared to the rest (44.5% [95% CI = 35.4-53.9%] vs. 11.6% [95% CI = 6.9-18.0%]; adjusted odds ratio [","['296 women with advanced disease', 'patients with HER2-positive breast cancer', '305 patients with early and 117 patients with advanced HER2-positive disease']","['dual HER2 blockade', 'lapatinib alone or lapatinib plus trastuzumab', 'neoadjuvant lapatinib or pertuzumab plus trastuzumab', 'lapatinib and trastuzumab, the HER2-E/ERBB2-high']","['higher ORR', 'Progression-free survival (PFS), overall response rate (ORR) and overall survival (OS', 'longer PFS', 'HER2-enriched subtype and ERBB2 expression', 'pCR rate', 'longer OS (hazard', 'pathological complete response (pCR']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C4517703', 'cui_str': 'Three hundred and five'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]","[{'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C1506770', 'cui_str': 'lapatinib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C1328025', 'cui_str': 'pertuzumab'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C1521733', 'cui_str': 'Pathologic (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",296.0,0.289702,"Following lapatinib and trastuzumab, the HER2-E/ERBB2-high group showed a higher pCR rate compared to the rest (44.5% [95% CI = 35.4-53.9%] vs. 11.6% [95% CI = 6.9-18.0%]; adjusted odds ratio [","[{'ForeName': 'Aleix', 'Initials': 'A', 'LastName': 'Prat', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Pascual', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'De Angelis', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Gutierrez', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Llombart-Cussac', 'Affiliation': 'Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Cortés', 'Affiliation': 'IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain.'}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Rexer', 'Affiliation': 'Department of Medicine, Vanderbilt University, Nashville, TN.'}, {'ForeName': 'Laia', 'Initials': 'L', 'LastName': 'Paré', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Forero', 'Affiliation': 'Department of Medicine, University of Alabama-Birmingham, Birmingham, AL.'}, {'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Wolff', 'Affiliation': 'Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Serafín', 'Initials': 'S', 'LastName': 'Morales', 'Affiliation': 'Department of Medical Oncology, Hospital Universitari Arnau Vilanova, Lleida, Spain.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Adamo', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Fara', 'Initials': 'F', 'LastName': 'Brasó-Maristany', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Vidal', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Jamunarani', 'Initials': 'J', 'LastName': 'Veeraraghavan', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Krop', 'Affiliation': 'Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Galván', 'Affiliation': 'Department of Medical Oncology, Hospital Clínic de Barcelona, Spain.'}, {'ForeName': 'Anne C', 'Initials': 'AC', 'LastName': 'Pavlick', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Begoña', 'Initials': 'B', 'LastName': 'Bermejo', 'Affiliation': 'Department of Medical Oncology, Hospital Clínico de Valencia, Valencia, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Novartis Oncology, Basel, Switzerland.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Rodrik-Outmezguine', 'Affiliation': 'Novartis Oncology, Basel, Switzerland.'}, {'ForeName': 'Jorge S', 'Initials': 'JS', 'LastName': 'Reis-Filho', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Susan G', 'Initials': 'SG', 'LastName': 'Hilsenbeck', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Mafalda', 'Initials': 'M', 'LastName': 'Oliveira', 'Affiliation': ""Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Maria Vittoria', 'Initials': 'MV', 'LastName': 'Dieci', 'Affiliation': 'Department of Genetics, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Gaia', 'Initials': 'G', 'LastName': 'Griguolo', 'Affiliation': 'Department of Genetics, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Fasani', 'Affiliation': ""Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Nuciforo', 'Affiliation': ""Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.""}, {'ForeName': 'Joel S', 'Initials': 'JS', 'LastName': 'Parker', 'Affiliation': 'Department of Genetics, University of North Carolina, Chapel Hill, NC.'}, {'ForeName': 'PierFranco', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Schiff', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Guarneri', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.'}, {'ForeName': 'C Kent', 'Initials': 'CK', 'LastName': 'Osborne', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}, {'ForeName': 'Mothaffar F', 'Initials': 'MF', 'LastName': 'Rimawi', 'Affiliation': 'Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX.'}]",Journal of the National Cancer Institute,['10.1093/jnci/djz042'] 756,31395391,An economic evaluation of a computer-tailored e-learning program to promote smoking cessation counseling guideline adherence among practice nurses.,"OBJECTIVE To conduct an economic evaluation of a tailored e-learning program, which successfully improved practice nurses' smoking cessation guideline adherence. METHODS The economic evaluation was embedded in a randomized controlled trial, in which 269 practice nurses recruited 388 smoking patients. Cost-effectiveness was assessed using guideline adherence as effect measure on practice nurse level, and continued smoking abstinence on patient level. Cost-utility was assessed on patient level, using patients' Quality Adjusted Life Years (QALYs) as effect measure. RESULTS The e-learning program was likely to be cost-effective on practice nurse level, as adherence to an additional guideline step cost €1,586. On patient level, cost-effectiveness was slightly likely after six months (cost per additional quitter: €7,126), but not after twelve months. The cost-utility analysis revealed slight cost-effectiveness (cost per QALY gained: €18,431) on patient level. CONCLUSION Providing practice nurses with a tailored e-learning program is cost-effective to improve their smoking cessation counseling. Though, cost-effectiveness on patient level was not found after twelve months, potentially resulting from smoking relapse. PRACTICE IMPLICATIONS Widespread implementation of the e-learning program can improve the quality of smoking cessation care in general practice. Strategies to prevent patients' smoking relapse should be further explored to improve patients' long-term abstinence.",2019,"The cost-utility analysis revealed slight cost-effectiveness (cost per QALY gained: €18,431) on patient level. ","['practice nurses', '269 practice nurses recruited 388 smoking patients']",['computer-tailored e-learning program'],"['Cost-effectiveness', 'Cost-utility', 'quality of smoking cessation care', 'patient level, cost-effectiveness', 'practice nurse level, and continued smoking abstinence on patient level', 'cost-effectiveness on patient level']","[{'cui': 'C0401999', 'cui_str': 'Practice nurse (occupation)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0401999', 'cui_str': 'Practice nurse (occupation)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]",388.0,0.0115866,"The cost-utility analysis revealed slight cost-effectiveness (cost per QALY gained: €18,431) on patient level. ","[{'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'de Ruijter', 'Affiliation': 'Department of Health Promotion, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands. Electronic address: d.deruijter@maastrichtuniversity.nl.'}, {'ForeName': 'Ciska', 'Initials': 'C', 'LastName': 'Hoving', 'Affiliation': 'Department of Health Promotion, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Evers', 'Affiliation': 'Department of Health Services Research, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands; Centre of Economic Evaluation, Trimbos Institute, National Institute of Mental Health and Addiction, P.O. Box 725, 3500 AS, Utrecht, the Netherlands.'}, {'ForeName': 'Raesita', 'Initials': 'R', 'LastName': 'Hudales', 'Affiliation': 'Department of Health Promotion, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'de Vries', 'Affiliation': 'Department of Health Promotion, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, the Netherlands.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Smit', 'Affiliation': 'Department of Communication Science, University of Amsterdam, P.O. Box 15791, 1001 NG Amsterdam, the Netherlands.'}]",Patient education and counseling,['10.1016/j.pec.2019.07.015'] 757,31566744,Cryosurgical ablation for treatment of rhinitis: A prospective multicenter study.,"OBJECTIVE To assess the efficacy and safety of cryoablation of the posterior nasal nerve (PNN) for treatment of chronic rhinitis. METHODS This was a prospective single-arm trial of 98 adult patients at six U.S. centers with chronic allergic and nonallergic rhinitis. PNN cryoablation was performed in-office under local anesthesia using a handheld device. Patients discontinued use of intranasal ipratropium 3 days prior to treatment and throughout the study period. Reflective Total Nasal Symptom Score (rTNSS) was measured at pretreatment baseline and posttreatment at 1 month, 3 months, 6 months, and 9 months. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was completed at pretreatment and 3 months posttreatment. Adverse effects and postprocedure medication usage were recorded. RESULTS Ninety-eight procedures (100%) were successfully completed. rTNSS significantly improved over pretreatment baseline (6.1 ± 1.9) at 1 month (2.9 ± 1.9, P < 0.001), 3 months (3.0 ± 2.3, P < 0.001), 6 months (3.0 ± 2.1, P < 0.001), and 9 months (3.0 ± 2.4, P < 0.001) postprocedure. Nasal congestion and rhinorrhea subscores improved significantly at all time points (P < 0.001). Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups. RQLQ significantly improved over pretreatment baseline (3.0 ± 1.0) at 3 months (1.5 ± 1.0, P < 0.001), and all RQLQ subdomains demonstrated improvement. Of 54 patients using intranasal medication at baseline, 19 (35.2%) were able to discontinue use. Twenty-nine adverse effects were reported, including headache, epistaxis, and sinusitis. CONCLUSION Cryoablation of the PNN for chronic rhinitis is safe and can result in relief of nasal symptoms and improvements in quality of life. LEVEL OF EVIDENCE 4 Laryngoscope, 130: 1877-1884, 2020.",2020,"Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups.","['98 adult patients at six U.S. centers with chronic allergic and nonallergic rhinitis', 'rhinitis', '54 patients using intranasal medication at baseline, 19 (35.2%) were able to discontinue use', 'Ninety-eight procedures (100%) were successfully completed']","['posterior nasal nerve (PNN', 'intranasal ipratropium', 'PNN cryoablation', 'Cryosurgical ablation']","['Reflective Total Nasal Symptom Score (rTNSS', 'quality of life', 'efficacy and safety', 'headache, epistaxis, and sinusitis', 'rTNSS', 'RQLQ', 'Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ', 'Nasal congestion and rhinorrhea subscores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C4319627', 'cui_str': 'Ninety-eight'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0027740', 'cui_str': 'Nerve structure'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0027235', 'cui_str': 'Ipratropium'}, {'cui': 'C0010408', 'cui_str': 'Cryoablation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0231918', 'cui_str': 'Nasal symptom'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0014591', 'cui_str': 'Nosebleed'}, {'cui': 'C0037199', 'cui_str': 'Sinus Infections'}, {'cui': 'C0861155', 'cui_str': 'Rhinoconjunctivitis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion (finding)'}, {'cui': 'C1260880', 'cui_str': 'Nasal catarrh'}]",98.0,0.0455949,"Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups.","[{'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Chang', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.'}, {'ForeName': 'Sunhee', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.'}, {'ForeName': 'Peter H', 'Initials': 'PH', 'LastName': 'Hwang', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford, California, U.S.A.'}]",The Laryngoscope,['10.1002/lary.28301'] 758,31138731,Bioavailability of Beclometasone From Two HFA-BDP Formulations With a Spacer.,"BACKGROUND The drug delivery characteristics of each inhaler/spacer combination are unique. The spacer size as well as the presence of electrostatic charge greatly influence the inhaler dose emission and in vivo delivery. Using a previously developed urinary pharmacokinetic method, we have measured the relative lung and systemic bioavailability of beclometasone dipropionate (BDP) after inhalation from 2 hydrofluroalkane-beclometasone dipropionate (HFA-BDP) formulations when used with a spacer. METHODS 12 healthy volunteers received 8 randomized doses, separated by 7 d, of inhaled of BDP with either the Clenil pressurized metered-dose inhaler (pMDI; 250 μg) or the breath-actuated Qvar Easi-Breathe inhaler (100 μg), used alone or with a spacer. The urinary amounts of BDP excreted and retained in the spacer were assayed using a liquid chromatographic mass spectrometer. The spacer was assessed after washing with a detergent solution that was either rinsed or not rinsed with water. In addition, the aerodynamic characterization of each inhaler/spacer combination was assessed using the Andersen Cascade Impactor operated at 28 L/min using a 4-L inhalation volume. The amount of BDP deposited in the induction port, spacer, and various Anderson Cascade Impactor stages were determined. RESULTS The in vivo 30-min urinary excretion and the in vitro fine particle dose results were only slightly affected by adding the spacer to the Clenil pMDI or the Qvar Easi-Breathe inhaler. However, the spacer significantly reduced drug particle impaction in the oropharynx and minimized deposition in the gastrointestinal tract. Therefore, using spacers with BDP inhalers is associated with a more favorable therapeutic ratio because it has little effect on lung dose, but it significantly reduced throat deposition. An improved lung deposition was achieved with non-rinsed spacers compared to spacers rinsed with water. CONCLUSION The difference in the BDP particle size between formulations as well as spacer size greatly affected drug deposition in different regions of the respiratory tract.",2019,"However, the spacer significantly reduced drug particle impaction in the oropharynx and minimized deposition in the gastrointestinal tract.",['12 healthy volunteers'],"['Beclometasone From Two HFA-BDP Formulations', 'beclometasone dipropionate (BDP', 'hydrofluroalkane-beclometasone dipropionate (HFA-BDP) formulations', 'BDP with either the Clenil pressurized metered-dose inhaler (pMDI; 250 μ g) or the breath-actuated Qvar Easi-Breathe inhaler (100 μ g), used alone or with a spacer']","['BDP particle size', 'lung deposition', 'throat deposition', 'drug particle impaction']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0004905', 'cui_str': 'Beclomethasone'}, {'cui': 'C0004906', 'cui_str': 'Beclomethasone Dipropionate'}, {'cui': 'C0475209', 'cui_str': 'm'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0731268', 'cui_str': 'Qvar'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0221874', 'cui_str': 'Spacer (physical object)'}]","[{'cui': 'C0030608', 'cui_str': 'Particle Size'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0333562', 'cui_str': 'Deposition (morphologic abnormality)'}, {'cui': 'C0230069', 'cui_str': 'Structure of anterior portion of neck'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0333124', 'cui_str': 'Impaction (morphologic abnormality)'}]",12.0,0.0341185,"However, the spacer significantly reduced drug particle impaction in the oropharynx and minimized deposition in the gastrointestinal tract.","[{'ForeName': 'Amira Sa', 'Initials': 'AS', 'LastName': 'Said', 'Affiliation': 'Clinical Pharmacy Department, College of Pharmacy, Al Ain University of Science and Technology, Al Ain, United Arab Emirates. amira.ahmed@aau.ac.ae.'}, {'ForeName': 'Salahdein', 'Initials': 'S', 'LastName': 'AbuRuz', 'Affiliation': 'Clinical Pharmacy Department, College of Pharmacy, Al Ain University of Science and Technology, Al Ain, United Arab Emirates.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Chrystyn', 'Affiliation': 'Inhalation Consultancy Limited, Leeds, United Kingdom.'}]",Respiratory care,['10.4187/respcare.06689'] 759,30580454,Effects of saxagliptin on adipose tissue inflammation and vascular function in overweight and obese people: a placebo-controlled study.,"AIMS To test the effect of the dipeptidyl peptidase-4 inhibitor saxagliptin on adipose tissue inflammation and microvascular function, and whole-body postprandial endothelial function. METHODS A randomized, double-blind, placebo-controlled, parallel study was conducted between June 2013 and November 2016 in 44 overweight or obese people without diabetes (saxagliptin, n=28; placebo, n=16). Subcutaneous abdominal adipose tissue biopsies, a 4-h fat-enriched meal test and peripheral arterial tonometry for measurement of endothelial function were performed at baseline and after 6 weeks of treatment with saxagliptin (5 mg/day) or matching placebo. RESULTS Forty participants were analysed (saxagliptin, n=26; placebo, n=14). Secretion of interleukin-8 from adipose tissue explants was reduced after saxagliptin (median fold-change from baseline: 0.8 saxagliptin vs 3.3 placebo; P=0.02). Adipose tissue expression of thioredoxin-inhibitory protein (TxNIP) was lower after saxagliptin (0.75 vs 1.0; P=0.02), while there were no significant differences in adipose tissue secretion of interleukin-1b, interleukin-6 or macrophage chemoattractant protein 1 (MCP-1), adipose tissue macrophage content, adipose tissue mRNA levels of mcp1, cd36, cd68, il6, il8, txnip and adpq, and activation of adipose tissue inflammatory pathways [extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF- κB)] or insulin-induced vasodilation of adipose tissue arterioles. Postprandial plasma glucose was slightly lower (by an estimated 0.3 mmol/l; P=0.01), while postprandial insulin, triglyceride levels and endothelial function were unchanged after saxagliptin. CONCLUSIONS The effect of saxagliptin on adipose tissue inflammation was relatively modest, with many inflammatory markers unchanged. We also found no evidence that saxagliptin therapy improved adipose tissue arteriole vasodilation or postprandial endothelial function.",2019,"Postprandial plasma glucose was slightly lower (by an estimated 0.3 mmol/l; P=0.01), while postprandial insulin, triglyceride levels and endothelial function were unchanged after saxagliptin. ","['June 2013 and November 2016 in 44 overweight or obese people without diabetes (saxagliptin, n=28; placebo, n=16', 'overweight and obese people', 'Forty participants were analysed (saxagliptin, n=26; placebo, n=14']","['Subcutaneous abdominal adipose tissue biopsies, a 4-h fat-enriched meal test and peripheral arterial tonometry', 'dipeptidyl peptidase-4 inhibitor saxagliptin', 'placebo', 'saxagliptin']","['Secretion of interleukin-8 from adipose tissue explants', 'Postprandial plasma glucose', 'adipose tissue inflammation', 'adipose tissue arteriole vasodilation or postprandial endothelial function', 'adipose tissue inflammation and microvascular function, and whole-body postprandial endothelial function', 'adipose tissue inflammation and vascular function', 'adipose tissue secretion of interleukin-1b, interleukin-6 or macrophage chemoattractant protein 1 (MCP-1), adipose tissue macrophage content, adipose tissue mRNA levels of mcp1, cd36, cd68, il6, il8, txnip and adpq, and activation of adipose tissue inflammatory pathways [extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF- κB)] or insulin-induced vasodilation of adipose tissue arterioles', 'postprandial insulin, triglyceride levels and endothelial function', 'Adipose tissue expression of thioredoxin-inhibitory protein (TxNIP']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C1563742', 'cui_str': 'Abdominal Fat'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0040420', 'cui_str': 'Tonometry'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}, {'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0001527', 'cui_str': 'Fatty Tissue'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0003847', 'cui_str': 'Arterioles'}, {'cui': 'C0042401', 'cui_str': 'Vasorelaxation'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0024432', 'cui_str': 'Monocyte-Derived Macrophages'}, {'cui': 'C0008013', 'cui_str': 'Chemotaxins'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0521119', 'cui_str': 'Extracellular (qualifier value)'}, {'cui': 'C4521566', 'cui_str': 'Kinase'}, {'cui': 'C0248813', 'cui_str': 'JNK Mitogen-Activated Protein Kinases'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C3496084', 'cui_str': 'Thioredoxin'}]",40.0,0.26497,"Postprandial plasma glucose was slightly lower (by an estimated 0.3 mmol/l; P=0.01), while postprandial insulin, triglyceride levels and endothelial function were unchanged after saxagliptin. ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Koska', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Osredkar', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': ""D'Souza"", 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Sands', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sinha', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Meyer', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}, {'ForeName': 'P D', 'Initials': 'PD', 'LastName': 'Reaven', 'Affiliation': 'Phoenix VA Health Care System, Phoenix, AZ, USA.'}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.13889'] 760,31279028,"Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: A double-blind, randomized, vehicle-controlled trial.","BACKGROUND Psoriasis of the intertriginous, anogenital, and facial regions remains a therapeutic challenge, with current algorithms lacking a topical agent that exhibits both high efficacy and minimal side effects. OBJECTIVE To assess the safety and efficacy of crisaborole 2% ointment-a nonsteroidal phosphodiesterase 4 inhibitor-in the treatment of intertriginous, anogenital, and facial psoriasis. METHODS A double-blind, randomized, vehicle-controlled trial was conducted in 21 participants. Participants were randomized 2:1 to receive 4 weeks of twice-daily treatment with either crisaborole 2% ointment (n = 14) or vehicle ointment (n = 7), followed by 4 weeks of open-label treatment with crisaborole 2% ointment. Disease severity was measured by using the Target Lesion Severity Scale (TLSS). RESULTS After 4 weeks, participants in the crisaborole group demonstrated 66% improvement compared with 9% in the vehicle group (P = .0011). Participants in the crisaborole group continued to experience improvement through the open-label phase, demonstrating 81% lesional improvement by week 8, with 71% of these participants achieving clinical clearance. There were no adverse events. LIMITATIONS The study was limited to a single tertiary care center and small sample size. CONCLUSION Treatment with crisaborole 2% ointment was well-tolerated and led to clinical improvement in participants with intertriginous, anogenital, or facial psoriasis.",2020,"After 4 weeks, subjects in the crisaborole group demonstrated 66% improvement compared to 9% in the vehicle group (p=0.0011).","['21 subjects', 'subjects with intertriginous, anogenital, or facial psoriasis']","['crisaborole 2% ointment', 'crisaborole 2% ointment (n=14) or vehicle ointment', 'Crisaborole 2% ointment', 'crisaborole 2% ointment-a nonsteroidal, phosphodiesterase-4 inhibitor']","['Disease severity', 'safety and efficacy', 'tolerated', 'clinical clearance', 'Target Lesion Severity Scale (TLSS', 'intertriginous, anogenital, and facial psoriasis']","[{'cui': 'C0205268', 'cui_str': 'Intertriginous (qualifier value)'}, {'cui': 'C1276112', 'cui_str': 'Psoriasis of face'}]","[{'cui': 'C4301781', 'cui_str': 'crisaborole'}, {'cui': 'C0028912', 'cui_str': 'Salves'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C2936609', 'cui_str': 'Phosphodiesterase Type 4 Inhibitors'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0222045'}, {'cui': 'C0205268', 'cui_str': 'Intertriginous (qualifier value)'}, {'cui': 'C1276112', 'cui_str': 'Psoriasis of face'}]",,0.220782,"After 4 weeks, subjects in the crisaborole group demonstrated 66% improvement compared to 9% in the vehicle group (p=0.0011).","[{'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Hashim', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Margot', 'Initials': 'M', 'LastName': 'Chima', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Hee J', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bares', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Yao', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Giselle', 'Initials': 'G', 'LastName': 'Singer', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Tinley', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Genece', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Baum', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Grace W', 'Initials': 'GW', 'LastName': 'Kimmel', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Nia', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Gagliotti', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': 'Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: mark.lebwohl@mountsinai.org.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.06.1288'] 761,31621901,GAPcare: The Geriatric Acute and Post-Acute Fall Prevention Intervention in the Emergency Department: Preliminary Data.,"OBJECTIVES We aimed to describe a new multidisciplinary team fall prevention intervention for older adults who seek care in the emergency department (ED) after having a fall, assess its feasibility and acceptability, and review lessons learned during its initiation. DESIGN Single-blind randomized controlled pilot study. SETTING Two urban academic EDs PARTICIPANTS: Adults 65 years old or older (n = 110) who presented to the ED within 7 days of a fall. INTERVENTION Participants were randomized to a usual care (UC) and an intervention (INT) arm. Participants in the INT arm received a brief medication therapy management session delivered by a pharmacist and a fall risk assessment and plan by a physical therapist (PT). INT participants received referrals to outpatient services (eg, home safety evaluation, outpatient PT). MEASUREMENTS We used participant, caregiver, and clinician surveys, as well as electronic health record review, to assess the feasibility and acceptability of the intervention. RESULTS Of the 110 participants, the median participant age was 81 years old, 67% were female, 94% were white, and 16.3% had cognitive impairment. Of the 55 in the INT arm, all but one participant received the pharmacy consult (98.2%); the PT consult was delivered to 83.6%. Median consult time was 20 minutes for pharmacy and 20 minutes for PT. ED length of stay was not increased in the INT arm: UC 5.25 hours vs INT 5.0 hours (P < .94). After receiving the Geriatric Acute and Post-acute Fall Prevention Intervention (GAPcare), 100% of participants and 97.6% of clinicians recommended the pharmacy consult, and 95% of participants and 95.8% of clinicians recommended the PT consult. CONCLUSION These findings support the feasibility and acceptability of the GAPcare model in the ED. A future larger randomized controlled trial is planned to determine whether GAPcare can reduce recurrent falls and healthcare visits in older adults. J Am Geriatr Soc 68:198-206, 2019.",2020,ED length of stay was not increased in the INT arm: UC 5.25 hours vs INT 5.0 hours (P < .94).,"['median participant age was 81\u2009years old, 67% were female, 94% were white, and 16.3% had cognitive impairment', '110 participants', 'older adults', 'older adults who seek care in the emergency department (ED) after having a fall', 'Adults 65\u2009years old or older (n = 110) who presented to the ED within 7\u2009days of a fall', 'Two urban academic EDs PARTICIPANTS']","['brief medication therapy management session delivered by a pharmacist and a fall risk assessment and plan by a physical therapist (PT', 'usual care (UC) and an intervention (INT', 'GAPcare', 'Geriatric Acute and Post-acute Fall Prevention Intervention (GAPcare', 'new multidisciplinary team fall prevention intervention']","['feasibility and acceptability of the intervention', 'ED length of stay', 'recurrent falls and healthcare visits', 'Median consult time']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C1611232', 'cui_str': 'Drug Therapy Management'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C1532976', 'cui_str': 'Fall risk assessment'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention (procedure)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",110.0,0.0377093,ED length of stay was not increased in the INT arm: UC 5.25 hours vs INT 5.0 hours (P < .94).,"[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Goldberg', 'Affiliation': 'Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.'}, {'ForeName': 'Sarah J', 'Initials': 'SJ', 'LastName': 'Marks', 'Affiliation': ""Department of Emergency Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts.""}, {'ForeName': 'Aderonke', 'Initials': 'A', 'LastName': 'Ilegbusi', 'Affiliation': 'Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Resnik', 'Affiliation': 'Department of Health Services, Practice and Policy, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Strauss', 'Affiliation': 'Department of Emergency Medicine, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.'}, {'ForeName': 'Roland C', 'Initials': 'RC', 'LastName': 'Merchant', 'Affiliation': ""Department of Emergency Medicine, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts.""}]",Journal of the American Geriatrics Society,['10.1111/jgs.16210'] 762,31631501,Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.,"The observational CERTITUDE study follows liver transplant patients who completed the SIMCER trial. SIMCER randomized patients at month 1 after transplant to everolimus (EVR) with stepwise tacrolimus (TAC) withdrawal or to standard TAC, both with basiliximab induction and mycophenolic acid ± steroids. After completing SIMCER at 6 months after transplant, 65 EVR-treated patients and 78 TAC-treated patients entered CERTITUDE. At month 24 after transplant, 34/65 (52.3%) EVR-treated patients remained calcineurin inhibitor (CNI) free. Mean estimated glomerular filtration rate (eGFR) was significantly higher with EVR versus TAC during months 3-12. At month 24, eGFR values were 83.6 versus 75.3 mL/minute/1.73 m 2 , respectively (P = 0.90) and adjusted mean change in eGFR from randomization was -8.0 versus -13.5 mL/minute/1.73 m 2 (P = 0.15). At month 24, 45.9%, 31.1%, and 23.0% of EVR-treated patients had chronic kidney disease stages 1, 2, and 3, respectively, versus 25.7%, 45.7%, and 28.6% of TAC-treated patients (P = 0.05). Treated biopsy-proven acute rejection affected 4 EVR-treated patients and 2 TAC patients during months 6-24. Adverse events led to study discontinuation in 15.4% and 7.7% of EVR-treated and TAC-treated patients, respectively. Grade 3 or 4 hematological events were rare in both groups. A CNI-free EVR-based maintenance regimen appears feasible in approximately half of liver transplant patients. It preserves renal function effectively with good efficacy without compromising safety or hematological tolerance.",2019,"Mean estimated GFR was significantly higher with everolimus versus tacrolimus during months 3-12; at month 24, values were 83.6 versus 75.3mL/min/1.73m 2 , respectively (p=0.089) and adjusted mean change in estimated GFR from randomization was -8.0 versus -13.5 mL/min/1.73m 2 (p=0.15).","['after liver transplantation', 'liver transplant patients who completed the SIMCER trial', 'liver transplant patients']","['CNI-free everolimus-based maintenance regimen', 'tacrolimus', 'tacrolimus to everolimus', 'everolimus versus tacrolimus', 'everolimus with stepwise tacrolimus withdrawal or to standard tacrolimus, both with basiliximab induction, mycophenolic acid ± steroids']","['safety or hematological tolerance', 'Mean estimated GFR', 'Grade 3 or 4 hematological events']","[{'cui': 'C0023911', 'cui_str': 'Transplantation, Hepatic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0676831', 'cui_str': 'basiliximab'}, {'cui': 'C0026933', 'cui_str': 'Mycophenolic Acid'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4524116', 'cui_str': 'Estimated GFR'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",65.0,0.0229432,"Mean estimated GFR was significantly higher with everolimus versus tacrolimus during months 3-12; at month 24, values were 83.6 versus 75.3mL/min/1.73m 2 , respectively (p=0.089) and adjusted mean change in estimated GFR from randomization was -8.0 versus -13.5 mL/min/1.73m 2 (p=0.15).","[{'ForeName': 'Faouzi', 'Initials': 'F', 'LastName': 'Saliba', 'Affiliation': 'Centre Hépato-Biliaire, Hôpital Paul Brousse, AP-HP, Villejuif, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Duvoux', 'Affiliation': 'Hôpital Henri Mondor, AP-HP, Créteil, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Dharancy', 'Affiliation': 'CHRU de Lille, Lille, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Dumortier', 'Affiliation': 'Hôpital Edouard Herriot, Lyon, France.'}, {'ForeName': 'Yvon', 'Initials': 'Y', 'LastName': 'Calmus', 'Affiliation': 'Hôpital Pitié Salpêtrière, AP-HP, Paris, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Gugenheim', 'Affiliation': ""Hôpital l'Archet 2, Nice, France.""}, {'ForeName': 'Nassim', 'Initials': 'N', 'LastName': 'Kamar', 'Affiliation': 'Hôpital Rangueil, Toulouse, France.'}, {'ForeName': 'Ephrem', 'Initials': 'E', 'LastName': 'Salamé', 'Affiliation': 'Hôpital Trousseau, Chambray les Tours, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Neau-Cransac', 'Affiliation': 'Hôpital Haut Levèque, Bordeaux, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Vanlemmens', 'Affiliation': 'Hôpital Jean Minjoz, Besançon, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Durand', 'Affiliation': 'Hôpital Beaujon, Clichy, France.'}, {'ForeName': 'Georges', 'Initials': 'G', 'LastName': 'Pageaux', 'Affiliation': 'Hôpital Saint Eloi, Montpellier, France.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Leroy', 'Affiliation': 'Hôpital Albert Michallon, Grenoble, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Hardwigsen', 'Affiliation': 'Hôpital la Timone, Marseille, France.'}, {'ForeName': 'Hakam', 'Initials': 'H', 'LastName': 'Gharbi', 'Affiliation': 'Novartis Pharma SAS, Rueil-Malmaison, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Masson', 'Affiliation': 'Novartis Pharma SAS, Rueil-Malmaison, France.'}, {'ForeName': 'Malka', 'Initials': 'M', 'LastName': 'Tindel', 'Affiliation': 'Novartis Pharma SAS, Rueil-Malmaison, France.'}, {'ForeName': 'Filomena', 'Initials': 'F', 'LastName': 'Conti', 'Affiliation': 'Hôpital Pitié Salpêtrière, AP-HP, Paris, France.'}]",Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,['10.1002/lt.25664'] 763,31943293,Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.,"BACKGROUND AND AIMS Cenicriviroc (CVC) is a C-C chemokine receptors type 2 and 5 dual antagonist under evaluation for treating liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). Year 1 primary analysis of the 2-year CENTAUR study showed that CVC had an antifibrotic effect without impacting steatohepatitis. Herein, we report the final data from year 2 exploratory analyses. APPROACH AND RESULTS This was a randomized, controlled study of adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH Clinical Research Network stage 1-3 fibrosis. Participants in arms A and C received CVC 150 mg or placebo, respectively, for 2 years; arm B received placebo in year 1 and switched to CVC in year 2. Liver biopsy was performed at baseline, year 1, and year 2. Of 289 randomized participants, 242 entered year 2. At year 2, 24% of patients who switched to CVC and 17% who remained on placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (P = 0.37). Twice the proportion on CVC who achieved fibrosis response at year 1 maintained benefit at year 2 (60% arm A versus 30% arm C), including 86% on CVC who had stage 3 fibrosis at baseline. Over 2 years, a similar proportion on CVC or placebo achieved ≥1-stage fibrosis improvement and no worsening of NASH (15% arm A versus 17% arm C). In patients with fibrosis responses, we observed consistent reductions in levels of N-terminal type 3 collagen propeptide and enhanced liver fibrosis scores, while increases in aspartate aminotransferase-to-platelet ratio index and Fibrosis-4 scores were consistently observed in nonresponders. Safety profile was comparable across groups. CONCLUSIONS CVC was well tolerated, and year 2 data corroborate antifibrotic findings from year 1. The majority on CVC who achieved fibrosis response at year 1 maintained it at year 2, with greater effect in advanced fibrosis. ClinicalTrials.gov number, NCT02217475 (CENTAUR).",2020,Safety profile was comparable across groups.,"['Adults with Nonalcoholic Steatohepatitis and Fibrosis', 'adults with nonalcoholic steatohepatitis (NASH', 'Of 289 randomized, 242 participants entered Year 2', 'adults with NASH, nonalcoholic fatty liver disease activity score ≥4, and NASH CRN stage 1-3 fibrosis']","['placebo', 'Cenicriviroc (CVC', 'Cenicriviroc Treatment', 'CVC', 'CVC 150 mg or placebo']","['antifibrotic effect without impacting steatohepatitis', 'Safety profile', 'APRI and FIB-4 scores', '≥1-stage fibrosis improvement AND no worsening of NASH', 'PRO-C3 levels and ELF scores', 'fibrosis response']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic Steatohepatitis'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0400966', 'cui_str': 'NAFLD'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4279622'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C2711227', 'cui_str': 'Liver Steatosis'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0071997', 'cui_str': 'C3 Precursor'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",289.0,0.211356,Safety profile was comparable across groups.,"[{'ForeName': 'Vlad', 'Initials': 'V', 'LastName': 'Ratziu', 'Affiliation': 'Hôpital Pitié Salpêtrière and Sorbonne Université, Paris, France.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Sanyal', 'Affiliation': 'Department of Gastroenterology, Virginia Commonwealth University, Richmond, VA.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Harrison', 'Affiliation': 'Pinnacle Clinical Research, San Antonio, TX.'}, {'ForeName': 'Vincent Wai-Sun', 'Initials': 'VW', 'LastName': 'Wong', 'Affiliation': ""Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, People's Republic of China.""}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Francque', 'Affiliation': 'Gastroenterology and Hepatology, Antwerp University Hospital, University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Goodman', 'Affiliation': 'Center for Liver Diseases, Inova Fairfax Medical Campus, Falls Church, VA.'}, {'ForeName': 'Guruprasad P', 'Initials': 'GP', 'LastName': 'Aithal', 'Affiliation': 'NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Kris V', 'Initials': 'KV', 'LastName': 'Kowdley', 'Affiliation': 'Liver Care Network, Swedish Medical Center, Seattle, WA.'}, {'ForeName': 'Star', 'Initials': 'S', 'LastName': 'Seyedkazemi', 'Affiliation': 'Allergan plc, South San Francisco, CA.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Fischer', 'Affiliation': 'Allergan plc, South San Francisco, CA.'}, {'ForeName': 'Rohit', 'Initials': 'R', 'LastName': 'Loomba', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA.'}, {'ForeName': 'Manal F', 'Initials': 'MF', 'LastName': 'Abdelmalek', 'Affiliation': 'Division of Gastroenterology & Hepatology, Department of Medicine, Duke University, Durham, NC.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Tacke', 'Affiliation': 'Department of Medicine III, University Hospital Aachen, Aachen, Germany.'}]","Hepatology (Baltimore, Md.)",['10.1002/hep.31108'] 764,31805675,The Impact of Herbs and Spices on Increasing the Appreciation and Intake of Low-Salt Legume-Based Meals.,"Flavoring using blends of herbs and spices (H&S) instead of salt may be a promising approach to increase legume consumption and reduce salt content in foods. This study examines the effects of H&S on the appreciation and intake of low-salt legume-based dishes in a real ecological eating environment. Four mezzes with standard (0.8% w / w ) (S) or lower (0.4% w / w ) (LS) salt level and with or without H&S (LSHS, SHS) were developed. In a randomized cross-over trial, 94 participants attended four sessions, one week apart and received the four variants as a starter during lunch. Overall liking, food intake, and appetite ratings (visual analogue scale, VAS) were assessed during lunch. A follow-up study ( n = 130) was performed where the four variants were evaluated, and overall liking was measured at the same session. Overall liking and taste scores of SHS were significantly higher compared with LS ( p = 0.04 and p = 0.03, respectively), but there were no significant differences between LSHS and S. However, there were no differences in energy intake or in appetite ratings among the products. Overall appreciation was similar between the low-salt with H&S and the standard-salt mezze, suggesting that the addition of H&S is a feasible strategy for achieving a 50% reduction in salt content without compromising hedonic appreciation.",2019,"Overall liking and taste scores of SHS were significantly higher compared with LS ( p = 0.04 and p = 0.03, respectively), but there were no significant differences between LSHS and S.","['94 participants attended four sessions, one week apart and received the four variants as a starter during lunch']","['Flavoring using blends of herbs and spices (H&S', 'H&S']","['Overall liking and taste scores of SHS', 'Overall liking, food intake, and appetite ratings (visual analogue scale, VAS', 'energy intake or in appetite ratings', 'overall liking', 'Overall appreciation']","[{'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C4552032', 'cui_str': 'With lunch'}]","[{'cui': 'C0453242', 'cui_str': 'Herbs and spices (substance)'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}]",94.0,0.0572634,"Overall liking and taste scores of SHS were significantly higher compared with LS ( p = 0.04 and p = 0.03, respectively), but there were no significant differences between LSHS and S.","[{'ForeName': 'Anestis', 'Initials': 'A', 'LastName': 'Dougkas', 'Affiliation': 'Institut Paul Bocuse Research Centre, BP 25-69130 Ecully CEDEX, France.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Vannereux', 'Affiliation': 'Institut Paul Bocuse Research Centre, BP 25-69130 Ecully CEDEX, France.'}, {'ForeName': 'Agnès', 'Initials': 'A', 'LastName': 'Giboreau', 'Affiliation': 'Institut Paul Bocuse Research Centre, BP 25-69130 Ecully CEDEX, France.'}]",Nutrients,['10.3390/nu11122901'] 765,31539053,Energy Availability Is Associated With Luteinizing Hormone Pulse Frequency and Induction of Luteal Phase Defects.,"OBJECTIVE Determine the interrelations between reductions in energy availability (EA), luteinizing hormone (LH) pulse frequency, and the induction of menstrual disturbances in previously sedentary, ovulatory women. METHODS Secondary analysis of a randomized controlled trial consisting of a 3-month controlled diet and supervised exercise program. EA was calculated daily by measured energy intake (kcal) and exercise energy expenditure (kcal) normalized to fat-free mass (kg) and averaged during baseline and each of 3 intervention menstrual cycles. Blood samples were obtained every 10 minutes for 24 hours in the early follicular phase before the intervention and after 3 months of diet and exercise (n = 14). LH pulse dynamics were assessed by Cluster. Linear mixed models determined whether EA predicts LH pulse frequency and LH pulse frequency predicts luteal phase defects (LPDs). RESULTS Subjects were 20 ± 1 years old, 165.1 ± 1.4 cm tall, and weighed 58.9 ± 1.5 kg. LH pulse frequency decreased from 0.82 ± 0.06 pulses/h to 0.63 ± 0.09 pulses/h (P = 0.048) as a result of the intervention which produced modest (-3.2 ± 0.6 kg) weight loss. EA, averaged across a menstrual cycle, predicted LH pulse frequency (P = 0.003) such that a single-unit decrease in EA was associated with a 0.017 pulses/h decrease in LH pulse frequency. LH pulse frequency in cycles with LPDs was 49% of that observed in cycles with no menstrual disturbances and for every 0.1-unit decrease in LH pulse frequency, the odds of having an LPD were 22× greater than having an optimal ovulatory cycle (P = 0.01). CONCLUSIONS Modest reductions in EA over a prolonged period are associated with decreased LH pulse frequency and the induction of menstrual disturbances.",2020,LH pulse frequency decreased from 0.82±0.06pulses,"['Subjects were 20±1yrs old 165.1±1.4cm tall and weighed 58.9±1.5kg', 'previously sedentary, ovulatory women']",['controlled diet and supervised exercise program'],"['energy intake (kcal) and exercise energy expenditure (kcal) normalized to fat-free mass (kg', 'EA predicts LH pulse frequency and LH pulse frequency predicts luteal phase defects (LPDs', 'energy availability (EA), LH pulse frequency, and the induction of menstrual disturbances', 'LH pulse dynamics', 'LH pulse frequency']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0429470', 'cui_str': 'Ovulatory (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0014272', 'cui_str': 'Energy Expenditure'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass (observable entity)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0404576', 'cui_str': 'Luteal phase defect (disorder)'}, {'cui': 'C0025345', 'cui_str': 'Menstruation Disorders'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}]",,0.0510295,LH pulse frequency decreased from 0.82±0.06pulses,"[{'ForeName': 'Kristen J', 'Initials': 'KJ', 'LastName': 'Koltun', 'Affiliation': ""Women's Health and Exercise Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania.""}, {'ForeName': 'Mary Jane', 'Initials': 'MJ', 'LastName': 'De Souza', 'Affiliation': ""Women's Health and Exercise Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania.""}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Scheid', 'Affiliation': ""Women's Health and Exercise Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania.""}, {'ForeName': 'Nancy I', 'Initials': 'NI', 'LastName': 'Williams', 'Affiliation': ""Women's Health and Exercise Laboratory, Department of Kinesiology, The Pennsylvania State University, University Park, Pennsylvania.""}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz030'] 766,31024091,Factors associated with plasma n-3 and n-6 polyunsaturated fatty acid levels in Tanzanian infants.,"BACKGROUND/OBJECTIVES To identify factors associated with plasma polyunsaturated fatty acid (PUFA) levels among 3-month-old Tanzanian infants. SUBJECTS/METHODS Infants (n = 238) and mothers (n = 193) randomly selected from participants in the neonatal vitamin A supplementation randomized controlled trial. A cross-sectional study of maternal-infant pairs at 3 months postpartum. RESULTS All infant total, n-3, n-6, and individual PUFA levels were correlated with maternal levels. Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01). Infant plasma docosahexaenoic acid (DHA) levels were positively associated with maternal DHA levels (0.77 ± 0.09; P < 0.01) but were lower for twin births (-0.55 ± 0.27; P = 0.03). Greater birth weight in kilograms (1.00 ± 0.43; P = 0.02) and higher maternal n-6 PUFA levels (0.20 ± 0.07; P < 0.01) were positively associated with higher infant n-6 PUFA levels, whereas maternal mono-unsaturated fatty acid (MUFA) levels (-0.26 ± 0.08; P < 0.01), maternal mid upper arm circumference (MUAC) (-0.22 ± 0.11; P = 0.04), and male sex (-0.99 ± 0.45; P = 0.03) were associated with lower infant plasma n-6 PUFA levels. Infant plasma arachidonic acid (AA) levels were positively associated with maternal plasma AA levels (0.38 ± 0.09; P < 0.01), but inversely associated with twin births (-1.37 ± 0.67; P = 0.04). CONCLUSIONS Greater birth weight and higher maternal plasma PUFA levels at 3 months postpartum were significantly associated with higher infant plasma PUFA levels at 3 months age. Twin births, male sex, and higher maternal MUFA levels were associated with lower infant plasma PUFA levels. Nutrition counseling for optimal intake of PUFA-rich foods, to lactating mothers in resource-limited settings may be beneficial for improved infant health.",2020,Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01).,"['maternal-infant pairs at 3 months postpartum', 'Tanzanian infants', 'Infants (n\u2009=\u2009238) and mothers (n\u2009=\u2009193) randomly selected from participants in the', '3-month-old Tanzanian infants']","['neonatal vitamin', 'Nutrition counseling']","['All infant total, n-3, n-6, and individual PUFA levels', 'lower infant plasma n-6 PUFA levels', 'maternal DHA levels', 'Infant plasma arachidonic acid (AA) levels', 'maternal plasma AA levels', 'infant plasma PUFA levels', 'maternal MUFA levels', 'Infant plasma n-3 PUFA levels', 'higher infant n-6 PUFA levels', 'plasma polyunsaturated fatty acid (PUFA) levels', 'plasma n-3 and n-6 polyunsaturated fatty acid levels', 'birth weight and higher maternal plasma PUFA levels', 'maternal n-6 PUFA levels', 'maternal n-3 PUFA levels', 'maternal mid upper arm circumference (MUAC', 'maternal mono-unsaturated fatty acid (MUFA) levels', 'Greater birth weight in kilograms', 'Infant plasma docosahexaenoic acid (DHA) levels']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C1278199', 'cui_str': 'Plasma arachidonic acid measurement'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference (observable entity)'}, {'cui': 'C0540173', 'cui_str': 'MonoS'}, {'cui': 'C1281901', 'cui_str': 'Fatty acid measurement'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}]",,0.0880946,Infant plasma n-3 PUFA levels were higher when maternal n-3 PUFA levels were higher (mean difference in infant % fatty acid per unit increase in maternal levels ± standard error: 0.79 ± 0.08; P < 0.01).,"[{'ForeName': 'Pili', 'Initials': 'P', 'LastName': 'Kamenju', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA. pillie6@yahoo.co.uk.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Hertzmark', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Edmond K', 'Initials': 'EK', 'LastName': 'Kabagambe', 'Affiliation': 'Division of Epidemiology, Departments of Medicine and Otolaryngology, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Smith', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Alfa', 'Initials': 'A', 'LastName': 'Muhihi', 'Affiliation': 'Africa Academy for Public Health, Dar es Salaam, Tanzania.'}, {'ForeName': 'Ramadhani A', 'Initials': 'RA', 'LastName': 'Noor', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Salum', 'Initials': 'S', 'LastName': 'Mshamu', 'Affiliation': 'Africa Academy for Public Health, Dar es Salaam, Tanzania.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Briegleb', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Sudfeld', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Honorati', 'Initials': 'H', 'LastName': 'Masanja', 'Affiliation': 'Ifakara Health Institute, Dar es Salaam, Tanzania.'}, {'ForeName': 'Wafaie W', 'Initials': 'WW', 'LastName': 'Fawzi', 'Affiliation': 'Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0428-7'] 767,31917607,Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial.,"Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment. Methods: In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mg/d over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient's global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire. Measurements and Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (-2.8; 95% confidence interval, -4.0 to -1.5; P  < 0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians' and patients' questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. Conclusions: Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure.Clinical trial registered with www.clinicaltrials.gov (NCT01072968) and EU Clinical Trials Register (EudraCT 2009-017251-94).",2020,"Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. ","['268 obstructive sleep apnea patients (75% male; mean age: 52 years, Apnea-hypopnea index: 49/hour, baseline sleepiness score: 15.7) were randomized (200 pitolisant; 68', 'obstructive sleep apnea syndrome', 'Obstructive Sleep Apnea Patients Refusing CPAP', 'sleepy patients with obstructive sleep apnea refusing or non-adherent to continuous positive airway pressure', 'patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment']",['placebo'],"['Epworth Sleepiness score', 'Adverse event incidence, mainly headache, insomnia, nausea, and vertigo', 'Daytime Sleepiness', 'self-reported daytime sleepiness, fatigue', 'daytime sleepiness', ""maintenance of wakefulness assessed by the Oxford Sleep Resistance Test, safety, clinical global impressions of severity, patient's global opinion, EQ-5D quality-of-life, and Pichot Fatigue questionnaire scores"", 'Pichot fatigue score', 'change in the Epworth Sleepiness score']","[{'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0520679', 'cui_str': 'Syndrome, Sleep Apnea, Obstructive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2111846', 'cui_str': 'Apnea-hypopnea index'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3529928', 'cui_str': 'Pitolisant (substance)'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0013144', 'cui_str': 'Drowsy (finding)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042571', 'cui_str': 'Spinning Sensation'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0043012', 'cui_str': 'Wakefulnesses'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0871010', 'cui_str': 'Opinions'}, {'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0443172', 'cui_str': 'State changes'}]",268.0,0.277263,"Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. ","[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Dauvilliers', 'Affiliation': 'National Reference Center for Narcolepsy, Sleep and Wake Unit, Department of Neurology, Gui-de-Chauliac Hospital, Montpellier University Hospital, Montpellier, France.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Verbraecken', 'Affiliation': 'Multidisciplinary Sleep Disorders Center, Antwerp University Hospital and University of Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Markku', 'Initials': 'M', 'LastName': 'Partinen', 'Affiliation': 'Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Hedner', 'Affiliation': 'Sleep and Vigilance Laboratory, Department of Internal Medicine, University of Göteborg, Sahlgrenska University Hospital, University of Göteborg, Göteborg, Sweden.'}, {'ForeName': 'Tarja', 'Initials': 'T', 'LastName': 'Saaresranta', 'Affiliation': 'Sleep Research Center, Department of Pulmonary Diseases and Clinical Allergology, University of Turku, Turku, Finland.'}, {'ForeName': 'Ognian', 'Initials': 'O', 'LastName': 'Georgiev', 'Affiliation': 'Pulmonology Unit, Department of Internal Medicine, Alexandrovska Hospital Medical University, Sofia, Bulgaria.'}, {'ForeName': 'Rumen', 'Initials': 'R', 'LastName': 'Tiholov', 'Affiliation': 'Department of Internal Diseases, Sveti Ivan Rilski Multiprofile Hospital for Active Treatment, Kozloduy, Bulgaria.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Lecomte', 'Affiliation': 'Bioprojet, 30 rue Francs Bourgois, Paris, France.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Tamisier', 'Affiliation': 'Hypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Lévy', 'Affiliation': 'Hypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Scart-Gres', 'Affiliation': 'Bioprojet, 30 rue Francs Bourgois, Paris, France.'}, {'ForeName': 'Jeanne-Marie', 'Initials': 'JM', 'LastName': 'Lecomte', 'Affiliation': 'Bioprojet, 30 rue Francs Bourgois, Paris, France.'}, {'ForeName': 'Jean-Charles', 'Initials': 'JC', 'LastName': 'Schwartz', 'Affiliation': 'Bioprojet, 30 rue Francs Bourgois, Paris, France.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Pépin', 'Affiliation': 'Hypoxia-Physiopathology (HP2) Laboratory, INSERM U1042, University Grenoble Alpes, Grenoble, France; and.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201907-1284OC'] 768,31842394,"The Effect of Antioxidant Supplementation in Patients with Tinnitus and Normal Hearing or Hearing Loss: A Randomized, Double-Blind, Placebo Controlled Trial.","Tinnitus is the perception of sound in the absence of any external stimulus. Oxidative stress is possibly involved in its pathogenesis and a variety of antioxidant compounds have been studied as potential treatment approaches. The objective of the present study was to assess the effects of antioxidant supplementation in tinnitus patients. This is a randomized, double-blind, placebo-controlled clinical trial. Patients ( N = 70) were randomly allocated to antioxidant supplementation ( N = 35) or to placebo ( N = 35) for a total of 3 months. Demographic, anthropometric, clinical, and nutritional data were collected. Serum total antioxidant capacity (TAC), oxidized LDL (oxLDL), and superoxide dismutase (SOD), tinnitus loudness, frequency, and minimum masking level (MML), and scores in Tinnitus Handicap Inventory questionnaire (THI), Tinnitus Functional Index (TFI), and Visual Analogue Scale (VAS) were evaluated at baseline and follow-up. Tinnitus loudness and MML significantly decreased from baseline to post measure ( p < 0.001) only in the antioxidant group, the overall change being significantly different between the two groups post-intervention ( p < 0.001). THI and VAS decreased only in the antioxidant group. Differences in changes in serum TAC, SOD, and oxLDL post-intervention were insignificant. In conclusion, antioxidant therapy seems to reduce the subjective discomfort and tinnitus intensity in tinnitus patients.",2019,"Tinnitus loudness and MML significantly decreased from baseline to post measure ( p < 0.001) only in the antioxidant group, the overall change being significantly different between the two groups post-intervention ( p < 0.001).","['Patients with Tinnitus and Normal Hearing or Hearing Loss', 'tinnitus patients', 'Patients ( N = 70']","['antioxidant supplementation', 'Placebo', 'placebo', 'Antioxidant Supplementation', 'antioxidant therapy']","['Tinnitus loudness and MML', 'THI and VAS', 'subjective discomfort and tinnitus intensity', 'Serum total antioxidant capacity (TAC), oxidized LDL (oxLDL), and superoxide dismutase (SOD), tinnitus loudness, frequency, and minimum masking level (MML), and scores in Tinnitus Handicap Inventory questionnaire (THI), Tinnitus Functional Index (TFI), and Visual Analogue Scale (VAS', 'serum TAC, SOD, and oxLDL post-intervention']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0040264', 'cui_str': 'Ringing-Buzzing-Tinnitus'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1879713', 'cui_str': 'Antioxidant therapy'}]","[{'cui': 'C0040264', 'cui_str': 'Ringing-Buzzing-Tinnitus'}, {'cui': 'C0178733', 'cui_str': 'Loudness (finding)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0069638', 'cui_str': 'orgotein'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018576', 'cui_str': 'Handicapped'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C3489891', 'cui_str': 'TAC(a)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",,0.619019,"Tinnitus loudness and MML significantly decreased from baseline to post measure ( p < 0.001) only in the antioxidant group, the overall change being significantly different between the two groups post-intervention ( p < 0.001).","[{'ForeName': 'Anna I', 'Initials': 'AI', 'LastName': 'Petridou', 'Affiliation': '1st ENT Department, School of Medicine, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.'}, {'ForeName': 'Eleftheria T', 'Initials': 'ET', 'LastName': 'Zagora', 'Affiliation': 'ENT Department, General Hospital of Nikaia ""Agios Panteleimon"", Nikaia, 18454 Athens, Greece.'}, {'ForeName': 'Petros', 'Initials': 'P', 'LastName': 'Petridis', 'Affiliation': 'ENT Department, St. Johannes Hospital, 44137 Dortmund, Germany.'}, {'ForeName': 'George S', 'Initials': 'GS', 'LastName': 'Korres', 'Affiliation': '2nd ENT Department, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, 12462 Chaidari, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gazouli', 'Affiliation': 'Department of Biology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Xenelis', 'Affiliation': '1st ENT Department, School of Medicine, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.'}, {'ForeName': 'Efthymios', 'Initials': 'E', 'LastName': 'Kyrodimos', 'Affiliation': '1st ENT Department, School of Medicine, National and Kapodistrian University of Athens, Hippokration Hospital, 11527 Athens, Greece.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Kontothanasi', 'Affiliation': 'ENT Department, General Hospital of Nikaia ""Agios Panteleimon"", Nikaia, 18454 Athens, Greece.'}, {'ForeName': 'Andriana C', 'Initials': 'AC', 'LastName': 'Kaliora', 'Affiliation': 'Department of Dietetics and Nutritional Science, School of Health Science and Education, Harokopio University, 17671 Athens, Greece.'}]",Nutrients,['10.3390/nu11123037'] 769,31150711,"A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.","BACKGROUND Randomized controlled studies of combination therapies in rosacea are limited. OBJECTIVE Evaluate the efficacy and safety of combining ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (ie, 30-mg immediate-release and 10-mg delayed-release beads) (DMR) versus IVM and placebo for treatment of severe rosacea. METHODS This 12-week, multicenter, randomized, investigator-blinded, parallel-group comparative study randomized adult subjects with severe rosacea (Investigator's Global Assessment [IGA] score, 4) to receive either IVM and DMR (combination arm) or IVM and placebo (monotherapy). RESULTS A total of 273 subjects participated. IVM and DMR displayed superior efficacy in reduction of inflammatory lesions (-80.3% vs -73.6% for monotherapy [P = .032]) and IGA score (P = .032). Combination therapy had a faster onset of action as of week 4; it significantly increased the number of subjects achieving an IGA score of 0 (11.9% vs 5.1% [P = .043]) and 100% lesion reduction (17.8% vs 7.2% [P = .006]) at week 12. Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index score, and ocular signs/symptoms and were well tolerated. LIMITATIONS The duration of the study prevented evaluation of potential recurrences or further improvements. CONCLUSION Combining IVM and DMR can produce faster responses, improve response rates, and increase patient satisfaction in cases of severe rosacea.",2020,"Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index and ocular signs/symptoms, and were well-tolerated. ","['273 subjects participated', 'severe rosacea', ""adult subjects with severe rosacea (Investigator's Global Assessment [IGA]=4) to either""]","['IVM and DMR (combination arm) or IVM and PBO (monotherapy', 'topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo', 'ivermectin 1% cream (IVM) and doxycycline 40 mg modified-release capsules ∗ (DMR) versus IVM and placebo (PBO']","[""Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index and ocular signs/symptoms, and were well-tolerated"", 'number of subjects achieving IGA 0', 'response rates', 'IGA score', 'inflammatory lesions']","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0035854', 'cui_str': 'Rosacea'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C4544813', 'cui_str': 'Modified-release'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038340', 'cui_str': 'Stings'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index (assessment scale)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C3872830', 'cui_str': 'Inflammatory lesion'}]",273.0,0.112432,"Both treatments reduced the Clinician's Erythema Assessment score, stinging/burning, flushing episodes, Dermatology Life Quality Index and ocular signs/symptoms, and were well-tolerated. ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schaller', 'Affiliation': 'Department of Dermatology, Tübingen University Hospital, Tübingen, Germany. Electronic address: martin.schaller@med.uni-tuebingen.de.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Kemény', 'Affiliation': 'Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.'}, {'ForeName': 'Blanka', 'Initials': 'B', 'LastName': 'Havlickova', 'Affiliation': 'Dermatology Center, Prague, Czech Republic.'}, {'ForeName': 'J Mark', 'Initials': 'JM', 'LastName': 'Jackson', 'Affiliation': 'Division of Dermatology, University of Louisville, Louisville, Kentucky; Forefront Dermatology, Louisville, Kentucky.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Ambroziak', 'Affiliation': 'Ambroziak Clinic, Warsaw, Poland.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lynde', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Gooderham', 'Affiliation': 'SKiN Centre for Dermatology, Peterborough, Ontario, Canada.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Remenyik', 'Affiliation': 'Department of Dermatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Del Rosso', 'Affiliation': 'JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada.'}, {'ForeName': 'Jolanta', 'Initials': 'J', 'LastName': 'Weglowska', 'Affiliation': 'Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Chavda', 'Affiliation': 'Medical Evidence, Galderma S.A., Vevey, Switzerland.'}, {'ForeName': 'Nabil', 'Initials': 'N', 'LastName': 'Kerrouche', 'Affiliation': 'Galderma R&D, Sophia Antipolis, France.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Dirschka', 'Affiliation': 'CentroDerm-Clinic, Wuppertal, Germany; Faculty of Health, University of Witten-Herdecke, Witten, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Johnson Dermatology, Fort Smith, Arkansas.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.05.063'] 770,31175909,"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.","BACKGROUND Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. OBJECTIVE To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial. METHODS Patients received ustekinumab through week 52 followed by brodalumab 210 mg every 2 weeks, continuous brodalumab 210 mg every 2 weeks, or any dose of brodalumab. Efficacy data were reported through 120 weeks by using observed data, last observation carried forward, and nonresponder imputation analyses. RESULTS Of patients who received brodalumab 210 mg every 2 weeks, 84.4%, 75.6%, and 61.1% achieved 75%, 90%, and 100% improvement from baseline in Psoriasis Area and Severity Index at 120 weeks (observed data analysis), respectively. Patients who received brodalumab 210 mg every 2 weeks after receiving ustekinumab through 52 weeks achieved a similar skin clearance response as patients who received continuous brodalumab 210 mg every 2 weeks. Safety through 120 weeks was comparable to that of the blinded study periods. LIMITATIONS A large number of discontinuations toward the end of the study (31% in the final 6 months) were due to early termination and led to differences between observed data and nonresponder imputation results. CONCLUSIONS Brodalumab is well tolerated and showed robust efficacy for more than 2 years.",2020,"Patients who received brodalumab 210 mg Q2W after receiving ustekinumab through 52 weeks achieved similar skin clearance responses as patients who received continuous brodalumab 210 mg Q2W. Safety through 120 weeks was comparable to that of the blinded study periods. ","['patients with moderate-to-severe plaque psoriasis', 'psoriasis']","['placebo', 'continuous brodalumab 210 mg Q2W. Safety', 'brodalumab 210 mg every 2 weeks (Q2W), continuous brodalumab 210 mg Q2W, or any dose of brodalumab', 'brodalumab', 'brodalumab 210 mg Q2W']","['skin clearance responses', 'psoriasis area and severity index', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C3491331', 'cui_str': 'brodalumab'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.380561,"Patients who received brodalumab 210 mg Q2W after receiving ustekinumab through 52 weeks achieved similar skin clearance responses as patients who received continuous brodalumab 210 mg Q2W. Safety through 120 weeks was comparable to that of the blinded study periods. ","[{'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Puig', 'Affiliation': 'Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: lpuig@santpau.cat.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Bachelez', 'Affiliation': 'Sorbonne Paris Cité Université Paris Diderot, Paris, France; AP-HP Hôpital Saint-Louis, Paris, France.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Sobell', 'Affiliation': 'SkinCare Physicians, Chestnut Hill, MA.'}, {'ForeName': 'Abby A', 'Initials': 'AA', 'LastName': 'Jacobson', 'Affiliation': 'Ortho Dermatologics, Bridgewater, NJ.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.05.095'] 771,31175910,Immunogenicity and skin clearance recapture in clinical studies of brodalumab.,"BACKGROUND Antidrug antibodies (ADAs) may change pharmacokinetic or pharmacodynamic profiles of biologic therapies, potentially decreasing efficacy. OBJECTIVE To evaluate the potential effects of brodalumab immunogenicity on safety, efficacy, and retreatment. METHODS Data from 1 phase 2 and 3 phase 3 studies of brodalumab in psoriasis were analyzed. RESULTS Overall, 2.7% of patients had positive test results for binding ADAs after receiving brodalumab; ADAs were transient in 1.4% of patients, and there were no neutralizing ADAs. Among ADA-positive patients, 60.0% (3/5) achieved a static physician's global assessment score of 0 or 1 at week 12 in the group receiving the brodalumab 210 mg every 2 weeks, compared with 79.1% (1131/1429) of ADA-negative patients. All patients (100%) who experienced return of disease and were retreated with brodalumab 210 mg every 2 weeks (none were ADA positive) achieved at least a 75% improvement in Psoriasis Area And Severity Index, ≥90% of whom regained response by week 8 of retreatment. Hypersensitivity reactions were less frequent with brodalumab than with placebo. Injection site reactions occurred in 1.8% of patients treated with brodalumab versus 2% of patients treated with ustekinumab. LIMITATIONS Retreatment could be assessed in only 1 phase 3 brodalumab study. CONCLUSION Brodalumab compares favorably with other biologics in terms of immunogenicity and high rates of efficacy recapture upon retreatment.",2020,"Among ADA-positive patients, 60.0% (3/5) achieved static physician's global assessment score of 0 or 1 at week 12 in the brodalumab 210 mg every 2 weeks (Q2W) group, compared with 79.1% (1131/1429) of ADA-negative patients.",['Data from one phase 2 and three phase 3 studies of brodalumab in psoriasis were analyzed'],"['placebo', 'brodalumab 210 mg Q2W']","['safety, efficacy, and retreatment', 'Hypersensitivity reactions', 'neutralizing ADA', 'binding ADA', ""static physician's global assessment score"", 'psoriasis area and severity index', 'Immunogenicity and Skin Clearance Recapture', 'Injection-site reactions']","[{'cui': 'C0439560', 'cui_str': 'Phase 2 (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3491331', 'cui_str': 'brodalumab'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3491331', 'cui_str': 'brodalumab'}, {'cui': 'C4319559', 'cui_str': '210'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C3544362', 'cui_str': 'Hypersensitivity (SMQ)'}, {'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0151735', 'cui_str': 'Injection Site Adverse Event'}]",,0.0762853,"Among ADA-positive patients, 60.0% (3/5) achieved static physician's global assessment score of 0 or 1 at week 12 in the brodalumab 210 mg every 2 weeks (Q2W) group, compared with 79.1% (1131/1429) of ADA-negative patients.","[{'ForeName': 'Jerry', 'Initials': 'J', 'LastName': 'Bagel', 'Affiliation': 'Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey. Electronic address: dreamacres1@aol.com.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Israel', 'Affiliation': 'Bausch Health, Bridgewater, New Jersey.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Jacobson', 'Affiliation': 'Ortho Dermatologics, Bridgewater, New Jersey.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.05.094'] 772,31449914,Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.,"BACKGROUND Nemolizumab targets the IL-31 receptor α subunit involved in atopic dermatitis (AD) pathogenesis. OBJECTIVE We sought to evaluate a new dosing strategy of nemolizumab in patients with AD. METHODS We performed a 24-week, randomized, double-blind, multicenter study of nemolizumab (10, 30, and 90 mg) subcutaneous injections every 4 weeks versus placebo, with topical corticosteroids in adults with moderate-to-severe AD, severe pruritus, and inadequate control with topical treatment (n = 226). The Eczema Area and Severity Index (EASI), the peak pruritus (PP) numeric rating scale (NRS), and the Investigator's Global Assessment (IGA) were assessed. Standard safety assessments were performed. RESULTS Nemolizumab improved EASI, IGA, and/or NRS-itch scores, with the 30-mg dose being most effective. Nemolizumab (30 mg) reduced EASI scores versus placebo at week 24 (-68.8% vs -52.1%, P = .016); significant differences were observed by week 8 (P ≤ .01). With significant improvement (P = .028) as early as week 4, IGA 0/1 rates were higher for 30 mg of nemolizumab versus placebo at week 16 (33.3% vs 12.3%, P = .008) but not week 24 because of an increased placebo/topical corticosteroid effect (36.8% vs 21.1%, P = .06). PP-NRS scores were improved for 30 mg of nemolizumab versus placebo at week 16 (-68.6% vs -34.3%, P < .0001) and week 24 (-67.3% vs -35.8%, P < .0001), with a difference by week 1 (P < .001). NRS response rates (≥4-point decrease) were greater for 30 mg of nemolizumab versus placebo at week 16 (P ≤ .001) and week 24 (P ≤ .01). Nemolizumab was safe and well tolerated. The most common adverse events were nasopharyngitis and upper respiratory tract infection. CONCLUSIONS Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. Nemolizumab had an acceptable safety profile.",2020,NRS response rates (≥4-point decrease) were higher for nemolizumab 30 mg vs placebo at wk-16 (p≤0.001) and wk-24 (p≤0.01).,"['adults with moderate-to-severe AD, severe pruritus and inadequate control with topical treatment (n=226', '10, 30, 90 mg', 'Adults with Moderate-Severe Atopic Dermatitis and Severe Pruritus']","['nemolizumab 30 mg vs placebo', 'Nemolizumab', 'topical corticosteroid', 'placebo', 'Nemolizumab 30 mg reduced EASI vs placebo', 'nemolizumab', 'SC injections q 4 weeks vs placebo']","['safe and well-tolerated', 'NRS response rates', 'EASI, IGA and/or NRS-itch', 'cutaneous signs of inflammation and pruritus', ""Eczema Area and Severity Index (EASI), peak-pruritus numeric rating score (PP-NRS), and Investigator's Global Assessment (IGA"", 'PP NRS', 'placebo/TCS effect']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}]","[{'cui': 'C4505530', 'cui_str': 'nemolizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0240291', 'cui_str': 'Mg reduced'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0013595', 'cui_str': 'Dermatitis, Eczematous'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.357643,NRS response rates (≥4-point decrease) were higher for nemolizumab 30 mg vs placebo at wk-16 (p≤0.001) and wk-24 (p≤0.01).,"[{'ForeName': 'Jonathan I', 'Initials': 'JI', 'LastName': 'Silverberg', 'Affiliation': 'Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address: jonathanisilverberg@gmail.com.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Pinter', 'Affiliation': 'Department of Dermatology, Venereology, and Allergology, Goethe-Universität Frankfurt am Main, Frankfurt am Main, Germany.'}, {'ForeName': 'Grazyna', 'Initials': 'G', 'LastName': 'Pulka', 'Affiliation': 'School of Medicine, Jagiellonian University Medical College, Krakow, Poland.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Poulin', 'Affiliation': 'Department of Medicine, Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Jean-David', 'Initials': 'JD', 'LastName': 'Bouaziz', 'Affiliation': 'Department of Dermatology, Paris VII Sorbonne Paris Cité University Assistance Publique-Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wollenberg', 'Affiliation': 'Department of Dermatology and Allergology, Ludwig-Maximilians-Universität, Munich, Germany.'}, {'ForeName': 'Dédée F', 'Initials': 'DF', 'LastName': 'Murrell', 'Affiliation': 'Department of Dermatology, St George Clinical School, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Alexis', 'Affiliation': 'Department of Dermatology, Icahn School of Medicine, Mount Sinai, New York, NY.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Lindsey', 'Affiliation': 'Galderma Laboratories, Fort Worth, Tex.'}, {'ForeName': 'Faiz', 'Initials': 'F', 'LastName': 'Ahmad', 'Affiliation': 'Galderma Laboratories, Fort Worth, Tex.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Piketty', 'Affiliation': 'Galderma R&D, Lausanne, Switzerland.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Clucas', 'Affiliation': 'Retired, Sophia Antipolis, France.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2019.08.013'] 773,31478335,"Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).","The objective of this study was to evaluate the efficacy and safety of gemigliptin added to a stable dose of insulin alone or of insulin in combination with metformin in patients with type 2 diabetes mellitus. After a two-week run-in period, patients were randomized 2:1 to receive gemigliptin 50 mg or placebo once daily as add-on to background therapy with insulin or insulin plus metformin for 24 weeks. The primary endpoint was change in haemoglobin A1c (HbA1c) from baseline at Week 24. Baseline characteristics were similar between the gemigliptin (n = 188) and placebo (n = 95) groups in terms of HbA1c (8.1%). At Week 24, the gemigliptin group showed a statistically significant reduction in mean HbA1c from baseline as compared with placebo (between-group mean difference, -0.7% [95% CI, -0.9% to -0.4%]; P-value < 0.0001). The incidence of overall adverse events and the number of hypoglycaemic adverse events were similar between the study groups. Gemigliptin added to insulin alone or to insulin in combination with metformin resulted in superior glycaemic control compared to that in the placebo group and was well tolerated for 24 weeks in patients with type 2 diabetes mellitus, without causing weight gain or increasing the incidence of hypoglycaemia.",2020,"At week 24, gemigliptin showed a statistically significant reduction in mean HbA1c change from baseline when compared with placebo (between-group mean difference, -0.7% [95% CI: -0.9% to -0.4%]: p-value <0.0001).","['patients with type 2 diabetes mellitus (ZEUS II study', 'patients with type 2 diabetes mellitus']","['insulin alone or insulin in combination with metformin', 'placebo', 'gemigliptin 50 mg or placebo once daily as add-on to background therapy with insulin or insulin plus metformin', 'insulin with or without metformin', 'Gemigliptin', 'gemigliptin']","['tolerated', 'incidence of hypoglycaemia', 'Efficacy and safety', 'efficacy and safety', 'overall adverse events and the number of hypoglycaemic adverse events', 'change in haemoglobin A1c (HbA1c', 'mean HbA1c change']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3501981'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",,0.209193,"At week 24, gemigliptin showed a statistically significant reduction in mean HbA1c change from baseline when compared with placebo (between-group mean difference, -0.7% [95% CI: -0.9% to -0.4%]: p-value <0.0001).","[{'ForeName': 'Young Min', 'Initials': 'YM', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chaicharn', 'Initials': 'C', 'LastName': 'Deerochanawong', 'Affiliation': 'Diabetes and Endocrinology Unit, Rajavithi Hospital, Rangsit University College of Medicine, Bangkok, Thailand.'}, {'ForeName': 'Samroeng', 'Initials': 'S', 'LastName': 'Seekaew', 'Affiliation': 'Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.'}, {'ForeName': 'Swangjit', 'Initials': 'S', 'LastName': 'Suraamornkul', 'Affiliation': 'Vajira Hospital, Faculty of Medicine, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Sunun', 'Initials': 'S', 'LastName': 'Benjachareonwong', 'Affiliation': 'Police General Hospital, Bangkok, Thailand.'}, {'ForeName': 'Sarinya', 'Initials': 'S', 'LastName': 'Sattanon', 'Affiliation': 'Naresuan University Hospital, Phitsanulok, Thailand.'}, {'ForeName': 'Parinya', 'Initials': 'P', 'LastName': 'Chamnan', 'Affiliation': 'Cardiometabolic Research Group, Department of Social Medicine, Sanpasitthiprasong Hospital, Ubon Ratchathani, Thailand.'}, {'ForeName': 'Thanitha', 'Initials': 'T', 'LastName': 'Sirirak', 'Affiliation': 'Department of Family Medicine and Preventive Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.'}, {'ForeName': 'Natapong', 'Initials': 'N', 'LastName': 'Kosachunhanun', 'Affiliation': 'Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Thongchai', 'Initials': 'T', 'LastName': 'Pratipanawatr', 'Affiliation': 'Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Sompongse', 'Initials': 'S', 'LastName': 'Suwanwalaikorn', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Woo Je', 'Initials': 'WJ', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sungrae', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology and Metabolism, Catholic University of Korea, Seoul, South Korea.'}, {'ForeName': 'Seonghui', 'Initials': 'S', 'LastName': 'Choi', 'Affiliation': 'Department of Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Eun Seok', 'Initials': 'ES', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Taekeun', 'Initials': 'T', 'LastName': 'Oh', 'Affiliation': 'Chungbuk National University Hospital, Chungbuk National University College of Medicine, Chungbuk, Cheongju, South Korea.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Kwon', 'Affiliation': 'Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.'}, {'ForeName': 'Moon-Kyu', 'Initials': 'MK', 'LastName': 'Lee', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13873'] 774,31711752,"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.","BACKGROUND Therapies with novel mechanisms of action against hepatitis B virus (HBV) infection are being explored with the goal of achieving a functional cure (sustained off-treatment response) without requiring lifelong therapy. We aimed to evaluate the pharmacokinetics, safety, and antiviral activity of ABI-H0731, an investigational inhibitor of the HBV core protein. METHODS This phase 1, randomised, placebo-controlled study was done in two parts. In part 1, healthy adults without hepatitis B aged 18-65 years at one clinical research centre in New Zealand (eight participants per dose cohort) were randomly assigned (3:1) to receive single oral doses of ABI-H0731 (100, 300, 600, or 1000 mg) or matching placebo, or once-daily or twice-daily doses of ABI-H0731 800 mg or matching placebo for 7 days. In part 2, adults aged 18-65 years at clinical research centres in New Zealand, Australia, the UK, Hong Kong, Taiwan, and South Korea with chronic HBV (12 participants per dose cohort) were randomly assigned (5:1) to receive ABI-H0731 (100, 200, 300, or 400 mg) or matching placebo once daily for 28 days. In part 2, participants were required to have HBeAg-positive or HBeAg-negative chronic HBV infection, with serum HBV DNA concentrations of at least 2 × 10 4 IU/mL (HBeAg-positive) or 2 × 10 3 IU/mL (HBeAg-negative) and serum alanine aminotransferase concentrations less than seven times the upper limit of normal. Both parts used simple randomisation, with study participants, site personnel, and study monitors masked to treatment assignments. The primary study objective was dose-related safety and tolerability of ABI-H0731 in healthy volunteers and in participants with chronic HBV infection, assessed in all treated participants. Key secondary assessments included pharmacokinetic analyses and virological responses. This study is registered with ClinicalTrials.gov, identifier NCT02908191 and is completed. FINDINGS 48 [61%] of 79 healthy volunteers were enrolled in the single-ascending or multiple-ascending dose phase of part 1 between Nov 16, 2016, and Jan, 27, 2017. 38 [55%] of 69 HBV-infected participants were enrolled in part 2 between June 15, 2017, and March 15, 2018. All adverse events were non-specific and of mild or moderate intensity apart from a single HBV-infected participant given the 400 mg dose who developed a severe (grade 3) maculopapular rash and terminated treatment. Overall, the most frequent adverse events of any grade among the 74 participants who received ABI-H0731 were headache (11 [15%]), influenza-like illness (seven [9%]), and dizziness (six [8%]); the most frequent adverse events considered treatment-related were rash (four [5%]) and dizziness (three [4%]). In part 1, ABI-H0731 reached maximum plasma concentrations (T max ) in 2·50-4·17 h; the mean plasma half-life (t 1/2 ) was 23·5-28·4 h. In part 2, mean maximum HBV DNA declines from baseline were 1·7 log 10 IU/mL in the 100 mg dose cohort, 2·1 log 10 IU/mL in the 200 mg dose cohort, and 2·8 log 10 IU/mL in the 300 mg dose cohort. Across dose cohorts, serum HBV RNA declines correlated with HBV DNA declines. INTERPRETATION No pattern of treatment-emergent adverse events was observed at ABI-H0731 doses up to 300 mg in individuals with chronic hepatitis B. ABI-H0731 was rapidly absorbed and exhibited a plasma half-life supportive of once-daily dosing. Dose-dependent decreases in serum HBV DNA and RNA concentrations are consistent with the proposed mechanism of action. FUNDING Assembly Biosciences.",2020,No pattern of treatment-emergent adverse events was observed at ABI-H0731 doses up to 300 mg in individuals with chronic hepatitis B. ABI-H0731 was rapidly absorbed and exhibited a plasma half-life supportive of once-daily dosing.,"['healthy volunteers and in participants with chronic HBV infection, assessed in all treated participants', 'healthy adults without hepatitis B aged 18-65 years at one clinical research centre in New Zealand (eight participants per dose cohort', '79 healthy volunteers were enrolled in the single-ascending or multiple-ascending dose phase of part 1 between Nov 16, 2016, and Jan, 27, 2017', '48', 'adults aged 18-65 years at clinical research centres in New Zealand, Australia, the UK, Hong Kong, Taiwan, and South Korea with chronic HBV (12 participants per dose cohort', '38 [55%] of 69 HBV-infected participants were enrolled in part 2 between June 15, 2017, and March 15, 2018']","['placebo', 'matching placebo', 'matching placebo, or once-daily or twice-daily doses of ABI-H0731 800 mg or matching placebo']","['Safety, pharmacokinetics, and antiviral effects', 'maximum plasma concentrations (T max ', 'influenza-like illness', 'headache', 'pharmacokinetics, safety, and antiviral activity', 'pharmacokinetic analyses and virological responses', 'mean maximum HBV DNA declines', 'serum HBV DNA and RNA concentrations', 'HBeAg-positive or HBeAg-negative chronic HBV infection, with serum HBV DNA concentrations', 'dizziness']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0019163', 'cui_str': 'Hepatitis B Virus Infection'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035168'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205385', 'cui_str': 'Ascending (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0019907', 'cui_str': 'Hongkong'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C1874329', 'cui_str': 'Antivirals, topical'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0521839', 'cui_str': 'Influenza-like illness (finding)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",79.0,0.415045,No pattern of treatment-emergent adverse events was observed at ABI-H0731 doses up to 300 mg in individuals with chronic hepatitis B. ABI-H0731 was rapidly absorbed and exhibited a plasma half-life supportive of once-daily dosing.,"[{'ForeName': 'Man-Fung', 'Initials': 'MF', 'LastName': 'Yuen', 'Affiliation': 'Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: mfyuen@hkucc.hku.hk.'}, {'ForeName': 'Kosh', 'Initials': 'K', 'LastName': 'Agarwal', 'Affiliation': ""Institute of Liver Studies, King's College Hospital, London, UK.""}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Gane', 'Affiliation': 'Auckland Clinical Studies, Auckland, New Zealand.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Schwabe', 'Affiliation': 'Auckland Clinical Studies, Auckland, New Zealand.'}, {'ForeName': 'Sang Hoon', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Severance Hospital, Seoul, South Korea.'}, {'ForeName': 'Dong Joon', 'Initials': 'DJ', 'LastName': 'Kim', 'Affiliation': 'Hallym University, Chuncheon Sacred Heart Hospital, Gangwon-do, South Korea.'}, {'ForeName': 'Young-Suk', 'Initials': 'YS', 'LastName': 'Lim', 'Affiliation': 'Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Cheng', 'Affiliation': 'Linear Clinical Research, Perth, WA, Australia.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Sievert', 'Affiliation': 'Monash Health, Monash University, VIC, Australia.'}, {'ForeName': 'Kumar', 'Initials': 'K', 'LastName': 'Visvanathan', 'Affiliation': ""St Vincent's Hospital, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ruby', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Liaw', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Yan', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Huang', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Colonno', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}, {'ForeName': 'Uri', 'Initials': 'U', 'LastName': 'Lopatin', 'Affiliation': 'Assembly Biosciences, San Francisco, CA, USA.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30346-2'] 775,31498922,High-Impact Exercise Increased Femoral Neck Bone Density With No Adverse Effects on Imaging Markers of Knee Osteoarthritis in Postmenopausal Women.,"High-impact exercise can improve femoral neck bone mass but findings in postmenopausal women have been inconsistent and there may be concern at the effects of high-impact exercise on joint health. We investigated the effects of a high-impact exercise intervention on bone mineral density (BMD), bone mineral content (BMC), and section modulus (Z) as well as imaging biomarkers of osteoarthritis (OA) in healthy postmenopausal women. Forty-two women aged 55 to 70 years who were at least 12 months postmenopausal were recruited. The 6-month intervention consisted of progressive, unilateral, high-impact exercise incorporating multidirectional hops on one randomly assigned exercise leg (EL) for comparison with the contralateral control leg (CL). Dual-energy X-ray absorptiometry (DXA) was used to measure BMD, BMC, and Z of the femoral neck. Magnetic resonance imaging (MRI) of the knee joint was used to analyze the biochemical composition of articular cartilage using T2 relaxometry and to analyze joint pathology associated with OA using semiquantitative analysis. Thirty-five participants (61.7 ± 4.3 years) completed the intervention with a mean adherence of 76.8% ± 22.5%. Femoral neck BMD, BMC, and Z all increased in the EL (+0.81%, +0.69%, and +3.18%, respectively) compared to decreases in the CL (-0.57%, -0.71%, and -0.75%: all interaction effects p < 0.05). There was a significant increase in mean T2 relaxation times (main effect of time p = 0.011) but this did not differ between the EL and CL, indicating no global effect. Semiquantitative analysis showed high prevalence of bone marrow lesions (BML) and cartilage defects, especially in the patellofemoral joint (PFJ), with no indication that the intervention caused pathology progression. In conclusion, a high-impact exercise intervention that requires little time, cost, or specialist equipment improved femoral neck BMD with no negative effects on knee OA imaging biomarkers. Unilateral high-impact exercise is a feasible intervention to reduce hip fracture risk in healthy postmenopausal women. © 2019 American Society for Bone and Mineral Research.",2020,There was a significant increase in mean T 2 relaxation times (main effect of time P = 0.011) but this did not differ between the EL and CL indicating no global effect.,"['Forty-two women aged 55-70 who were at least 12\u2009months postmenopausal were recruited', 'postmenopausal women', 'healthy postmenopausal women', 'Thirty-five participants (61.7\u2009±\u20094.3\u2009yrs) completed the intervention with a mean adherence of 76.8\u2009±\u200922.5']","['Magnetic resonance imaging (MRI', 'Unilateral high impact exercise', 'high impact exercise intervention', 'Dual X-ray absorptiometry (DXA', 'High impact exercise', 'progressive, unilateral, high impact exercise incorporating multidirectional hops on one randomly assigned exercise leg (EL) for comparison with the contralateral control leg (CL']","['hip fracture risk', 'mean T 2 relaxation times', 'femoral neck bone mass', 'bone mineral density (BMD), bone mineral content (BMC) and section modulus (Z', 'femoral neck BMD', 'CL', 'Femoral neck BMD, BMC and Z all increased in the EL', 'femoral neck bone density', 'BMD, BMC and Z of the femoral neck']","[{'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C4517759', 'cui_str': 'Four point three'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517649', 'cui_str': 'Twenty-two point five'}]","[{'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C4018995', 'cui_str': 'Hop'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0441988', 'cui_str': 'Contralateral (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015815', 'cui_str': 'Femoral Neck'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005963', 'cui_str': 'Bone Mineral Content'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",35.0,0.0336735,There was a significant increase in mean T 2 relaxation times (main effect of time P = 0.011) but this did not differ between the EL and CL indicating no global effect.,"[{'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Hartley', 'Affiliation': 'National Centre of Sports and Exercise Medicine, School of Sports and Exercise Science, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Folland', 'Affiliation': 'National Centre of Sports and Exercise Medicine, School of Sports and Exercise Science, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kerslake', 'Affiliation': 'The Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Brooke-Wavell', 'Affiliation': 'National Centre of Sports and Exercise Medicine, School of Sports and Exercise Science, Loughborough University, Loughborough, UK.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3867'] 776,30097652,Predictors for misreporting sodium and potassium intakes by overweight and obese participants in a food-based clinical trial: implications for practice.,"This study compared self-reported sodium and potassium intakes with urinary biomarkers and identified predictive factors. Secondary analysis of the 3-month intensive phase of the HealthTrack study with control (C), interdisciplinary intervention (I), intervention plus 30 g walnuts/day (IW) arms (n = 149). Dietary data was derived from diet history (DH) interviews and biomarker measures from urine. Urine-derived sodium (all, p = 0.000) and potassium (C: p = 0.011; I: p = 0.000; IW: p = 0.004) measures were significantly greater than self-reported intakes over the three months. Multiple linear regression showed body weight at baseline, body mass index (BMI) at baseline, and combined BMI at baseline and DH interviewer significantly negatively predicted the differences in sodium intake and excretion for C (β = -21.226, p = 0.016), I (β = -106.140, p = 0.002) and IW (F (9.530, 2df), p = 0.000), respectively. Where intakes of sodium and potassium are of interest in a trial, both reported intake and urinary biomarker measures are recommended.",2020,"Urine-derived sodium (all, p = 0.000) and potassium (C:",[],['potassium (C'],"['body weight at baseline, body mass index (BMI', 'sodium intake and excretion for C (β']",[],"[{'cui': 'C0304475', 'cui_str': 'Potassium supplement'}]","[{'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}]",,0.0238138,"Urine-derived sodium (all, p = 0.000) and potassium (C:","[{'ForeName': 'Vivienne X', 'Initials': 'VX', 'LastName': 'Guan', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia. xg885@uowmail.edu.au.'}, {'ForeName': 'Yasmine C', 'Initials': 'YC', 'LastName': 'Probst', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}, {'ForeName': 'Elizabeth P', 'Initials': 'EP', 'LastName': 'Neale', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}, {'ForeName': 'Linda C', 'Initials': 'LC', 'LastName': 'Tapsell', 'Affiliation': 'School of Medicine, Faculty of Science, Medicine and Health, University of Wollongong, Wollongong, NSW, 2522, Australia.'}]",European journal of clinical nutrition,['10.1038/s41430-018-0283-y'] 777,30207587,"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.","BACKGROUND The relevance of granulocyte-macrophage colony-stimulating factor (GM-CSF) in the management of psoriasis has not been studied previously. GM-CSF is important in the initiation and maintenance of chronic inflammatory processes. OBJECTIVES To investigate the clinical use of GM-CSF neutralization by evaluating the efficacy and safety of namilumab (AMG203), a monoclonal antibody GM-CSF inhibitor, in patients with moderate-to-severe plaque psoriasis. METHODS A phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-finding, proof-of-concept study (NEPTUNE) was conducted. Four doses of namilumab (20, 50, 80 and 150 mg, via subcutaneous injection) were compared with placebo. Assessment of the primary end point - the proportion of patients achieving ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75 treatment response) - was performed at week 12. Exploratory investigation at the tissue level was conducted in a subset of the overall study population. The trial was registered with the number NCT02129777. RESULTS In total, 122 patients were enrolled and 106 (86·9%) completed the double-blind treatment; 16 (13·1%) prematurely discontinued study medication. Serum concentration-time profiles were as expected for subcutaneous delivery of an IgG1 monoclonal antibody, and exposure increased proportionally with dose elevation. The number of patients showing PASI 75 treatment response at week 12 was low in all groups; no significant difference was recorded in this end point between placebo and any namilumab group. Similar outcomes were recorded for other clinical study end points. Moreover, no significant treatment-related changes from baseline were observed in laboratory investigations of cell types or subpopulations, or cytokines relevant to inflammatory pathways in psoriasis. CONCLUSIONS GM-CSF blockade is not critical for suppression of key inflammatory pathways underlying psoriasis.",2019,The number of patients showing PASI 75 treatment response at week 12 was low in all groups; no significant difference was recorded in this end point between placebo and any namilumab group.,"['122 patients were enrolled and 106 (86·9%) completed the double-blind treatment', 'patients with moderate-to-severe plaque psoriasis', 'psoriasis']","['placebo', 'Granulocyte-macrophage colony-stimulating factor (GM-CSF', 'monoclonal antibody GM-CSF inhibitor', 'granulocyte-macrophage colony-stimulating factor (GM-CSF', 'namilumab (AMG203', 'namilumab']","['number of patients showing PASI 75 treatment response', 'Serum concentration-time profiles', 'Psoriasis Area and Severity Index']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0079460', 'cui_str': 'Tumor-Cell Human GM Colony-Stimulating Factor'}, {'cui': 'C3542957', 'cui_str': 'Antineoplastic MAbs'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3273714', 'cui_str': 'namilumab'}, {'cui': 'C4548249', 'cui_str': 'AMG203'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",122.0,0.203441,The number of patients showing PASI 75 treatment response at week 12 was low in all groups; no significant difference was recorded in this end point between placebo and any namilumab group.,"[{'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Papp', 'Affiliation': 'K Papp Clinical Research and Probity Medical Research, 135 Union St E, Waterloo, ON, N2J1C4, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gooderham', 'Affiliation': ""SKiN Centre for Dermatology, Queen's University and Probity Medical Research, Peterborough, ON, Canada.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Jenkins', 'Affiliation': 'Clinical Science, Takeda International - U.K. Branch, London, U.K.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Vender', 'Affiliation': 'Dermatrials Research Inc, Hamilton, ON, Canada.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Szepietowski', 'Affiliation': 'Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Wagner', 'Affiliation': 'Modelling and Simulation, Takeda Pharmaceuticals International, Zurich, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Hunt', 'Affiliation': 'Statistics, Takeda International, Deerfield, IL, U.S.A.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Souberbielle', 'Affiliation': 'Clinical Science, Takeda International - U.K. Branch, London, U.K.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The British journal of dermatology,['10.1111/bjd.17195'] 778,31595489,The Healthy Heart-Mind Trial: Randomized Controlled Trial of Melatonin for Prevention of Delirium.,"OBJECTIVES Delirium is a serious medical condition with increased incidence in at-risk surgical populations. We sought to determine if melatonin use reduces the incidence of delirium in individuals undergoing major cardiac surgery. DESIGN Randomized double-blind placebo-controlled clinical trial (two arms, 1:1 allocation, parallel design). SETTING The trial took place in two metropolitan hospitals (public tertiary and private) in Perth, Western Australia. PARTICIPANTS We recruited 210 adults aged 50 years or older who were due to undergo coronary artery bypass grafting or valve replacement surgery. INTERVENTION Participants were randomly assigned (1:1) to 7 days of treatment with melatonin 3 mg at night or matching placebo, starting 2 days before the surgery. MEASUREMENTS The primary outcome of interest was incident delirium within 7 days of surgery as assessed via daily clinical assessment that included the Confusion Assessment Method. Secondary outcomes of interest included duration and severity of delirium, length of hospital stay, cognitive function, and mood and anxiety symptoms at discharge and 3 months after the surgery. RESULTS The groups were well balanced for demographic and clinical parameters. Forty-two participants developed delirium, but it was evenly distributed between the groups (melatonin 21/98, 21.4%; placebo 21/104, 20.2%; adjusted odds ratio [OR] = .78; 95% confidence interval [CI] = .35-1.75). The median duration of delirium was 3 (interquartile range [IQR] = 2-4) and 2 (IQR = 1-3) days for people treated with melatonin and placebo, respectively (z = -1.03; P = .304). A similar proportion of participants experienced severe episodes of delirium in each group (melatonin 9/21, 42.9% vs placebo 6/21, 28.6%; χ 2 = .93; P = .334; adjusted OR = 1.98; 95% CI = .40-9.78). The groups did not differ in terms of length of stay, mood, anxiety, and cognitive performance. CONCLUSION The findings of this randomized double-blind placebo-controlled trial do not support the prophylactic use of melatonin to prevent delirium after major cardiac surgery. J Am Geriatr Soc 68:112-119, 2019.",2020,"The groups did not differ in terms of length of stay, mood, anxiety, and cognitive performance. ","['two metropolitan hospitals (public tertiary and private) in Perth, Western Australia', 'We recruited 210 adults aged 50\u2009years or older who were due to undergo coronary artery bypass grafting or valve replacement surgery', 'individuals undergoing major cardiac surgery', 'Healthy Heart-Mind Trial', 'delirium after major cardiac surgery']","['melatonin 3 mg at night or matching placebo', 'placebo', 'melatonin', 'Melatonin', 'melatonin and placebo']","['median duration of delirium', 'delirium', 'incident delirium within 7\u2009days of surgery as assessed via daily clinical assessment that included the Confusion Assessment Method', 'length of stay, mood, anxiety, and cognitive performance', 'duration and severity of delirium, length of hospital stay, cognitive function, and mood and anxiety symptoms at discharge and 3 months after the surgery', 'severe episodes of delirium']","[{'cui': 'C0020029', 'cui_str': 'Hospitals, Metropolitan'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0043128', 'cui_str': 'Western Australia'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}]","[{'cui': 'C1124060', 'cui_str': 'Melatonin 3 MG'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0009676', 'cui_str': 'Confusional State'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]",210.0,0.809496,"The groups did not differ in terms of length of stay, mood, anxiety, and cognitive performance. ","[{'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Ford', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Flicker', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Kelly', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Hema', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Jurgen', 'Initials': 'J', 'LastName': 'Passage', 'Affiliation': 'School of Medicine, University of Notre Dame and Department of Cardiothoracic Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Wibrow', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Anstey', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Edwards', 'Affiliation': 'Department of Cardiothoracic Surgery, Fiona Stanley Hospital, Perth, Western Australia, Australia.'}, {'ForeName': 'Osvaldo P', 'Initials': 'OP', 'LastName': 'Almeida', 'Affiliation': 'Medical School, University of Western Australia, Perth, Western Australia, Australia.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16162'] 779,30414785,Effect of Aerobic and Resistance Exercise on Glycemic Control in Adults With Type 1 Diabetes.,"OBJECTIVES Physical exercise is recommended for individuals with type 1 diabetes, yet the effects of exercise on glycemic control are not well established. We evaluated the impact of different modes of exercise on glycemic control in people with type 1 diabetes. METHODS In a 3-week randomized crossover trial, 10 adults with type 1 diabetes (4 men and 6 women, aged 33±6 years; duration of diabetes, 18±10 years; glycated hemoglobin level, 7.4%±1%) were assigned to 3 weeks of intervention: aerobic exercise (treadmill at 60% of maximum volume of oxygen utilization), resistance training (8 to 12 repetitions of 5 upper and lower body exercises at 60% to 80% of 1 repetition maximum) or no exercise (control). During each exercise week, participants completed 2 monitored 45 min exercise sessions. For each week of the study, we analyzed participants' insulin pump data, sensor glucose data and meal intake using a custom smart-phone application. The primary outcome was the percentage of time in range (glucose >3.9 mmol/L and ≤10 mmol/L) for the 24 h after each bout of exercise or rest during the control week. The study was registered on ClinicalTrials.gov (NCT:02687893). RESULTS Aerobic exercise caused a mean glucose reduction during exercise of 3.94±2.67 mmol/L, whereas the reduction during resistance training was 1.33±1.78 mmol/L (p=0.007). The mean percentage time in range for the 24 h after resistance training was significantly greater than that during the control period (70% vs. 56%, p=0.013) but not after aerobic exercise (60%). CONCLUSIONS The results indicate that when various confounders are considered, resistance training could improve glycemic control in this population.",2019,"RESULTS Aerobic exercise caused a mean glucose reduction during exercise of 3.94±2.67 mmol/L, whereas the reduction during resistance training was 1.33±1.78 mmol/L (p=0.007).","['individuals with type 1 diabetes', 'people with type 1 diabetes', 'Adults With Type 1 Diabetes', '10 adults with type 1 diabetes (4 men and 6 women, aged 33±6 years; duration of diabetes, 18±10 years; glycated hemoglobin level, 7.4%±1']","['Aerobic and Resistance Exercise', 'Physical exercise', 'intervention: aerobic exercise (treadmill at 60% of maximum volume of oxygen utilization), resistance training (8 to 12 repetitions of 5 upper and lower body exercises at 60% to 80% of 1 repetition maximum) or no exercise (control']","['mean glucose reduction', 'glycemic control', 'percentage of time in range (glucose >3.9\u2009mmol/L and ≤10\u2009mmol/L', 'mean percentage time in range']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0017853', 'cui_str': 'Hemoglobin, Glycosylated'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0042153', 'cui_str': 'use'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1268088', 'cui_str': 'Lower body'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C1532563', 'cui_str': 'umol/mL'}]",10.0,0.0376968,"RESULTS Aerobic exercise caused a mean glucose reduction during exercise of 3.94±2.67 mmol/L, whereas the reduction during resistance training was 1.33±1.78 mmol/L (p=0.007).","[{'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Reddy', 'Affiliation': 'Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Wittenberg', 'Affiliation': 'Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Castle', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'El Youssef', 'Affiliation': 'Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA; Department of Medicine, Division of Endocrinology, Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Kerri', 'Initials': 'K', 'LastName': 'Winters-Stone', 'Affiliation': 'School of Nursing, Human Performance Laboratory, Oregon Health and Science University, Portland, Oregon, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Gillingham', 'Affiliation': 'Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, Oregon, USA.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Jacobs', 'Affiliation': 'Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA. Electronic address: jacobsp@ohsu.edu.'}]",Canadian journal of diabetes,['10.1016/j.jcjd.2018.08.193'] 780,31483746,Acute changes in cortical activation during active ankle movement after whole-body vibration for spasticity in hemiplegic legs of stroke patients: a functional near-infrared spectroscopy study.,"Background : A recent study revealed that whole-body vibration (WBV) tends to decrease spasticity in stroke-related hemiplegic legs. However, acute changes in cortical activation after WBV are unclear. Objective : To examine whether WBV induces acute changes in sensorimotor cortical activation in patients with stroke-related hemiplegic legs. Methods : Eleven stroke patients (mean age 52.6 [SD 15.4] years; median time after stroke 3 [25 th and 75 th percentiles; 3 and 10.5, respectively] months) participated in a comparative before-and-after intervention trial. Six healthy adults were also studied. WBV at 30 Hz was applied for 5 min to the hamstrings, gastrocnemius, and soleus muscles. Spasticity was assessed according to the modified Ashworth scale (MAS). Active and passive range of motion (A-ROM and P -ROM, respectively) were also measured. Change in Oxy-Hb concentration in bilateral sensorimotor cortex associated with voluntary ankle dorsiflexion of the affected limb was assessed via functional near-infrared spectroscopy (fNIRS) before and immediately after WBV. Results : MAS score, A-ROM, and P -ROM improved immediately after WBV. In the patients, while there was no significant interaction between effects of region (ipsilesional and contralesional sensorimotor cortex) and the WBV intervention (before and immediately after WBV) ( F 1,10  = 0.702, p = .422), there was a significant main effect of the WBV intervention ( F 1,10  = 6.971, p = .025). In the healthy participants, there was no association with the WBV intervention or region. Conclusions : In patients with stroke-related spastic-hemiplegic legs, WBV might result not only in clinical improvement but also in acute increase in sensorimotor cortical activation.",2020,"In the patients, while there was no significant interaction between effects of region (ipsilesional and contralesional sensorimotor cortex) and the WBV intervention (before and immediately after WBV) ( F 1,10  = 0.702, ","['Six healthy adults', 'Eleven stroke patients (mean age 52.6 [SD 15.4] years; median time after stroke 3 [25 th and 75 th percentiles; 3 and 10.5, respectively] months) participated in a comparative before-and-after intervention trial', 'hemiplegic legs of stroke patients', 'healthy participants', 'patients with stroke-related hemiplegic legs']","['whole-body vibration (WBV', 'active ankle movement after whole-body vibration', ' ', 'WBV']","['region (ipsilesional and contralesional sensorimotor cortex) and the WBV intervention', 'MAS score, A-ROM, and P -ROM', 'sensorimotor cortical activation', 'WBV intervention', 'Spasticity']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517579', 'cui_str': '15.4 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]","[{'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0454474', 'cui_str': 'Active ankle movements (regime/therapy)'}]","[{'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C3499125', 'cui_str': 'Sensory Motor Cortex'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}]",25.0,0.0395245,"In the patients, while there was no significant interaction between effects of region (ipsilesional and contralesional sensorimotor cortex) and the WBV intervention (before and immediately after WBV) ( F 1,10  = 0.702, ","[{'ForeName': 'Kodai', 'Initials': 'K', 'LastName': 'Miyara', 'Affiliation': 'Department of Rehabilitation, Kagoshima University Hospital, Kagoshima, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Kawamura', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.'}, {'ForeName': 'Shuji', 'Initials': 'S', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.'}, {'ForeName': 'Akihiko', 'Initials': 'A', 'LastName': 'Ohwatashi', 'Affiliation': 'Course of Physical Therapy, School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Itashiki', 'Affiliation': 'Department of Rehabilitation, Kagoshima University Hospital, Kagoshima, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Uema', 'Affiliation': 'Department of Rehabilitation, Kagoshima University Hospital, Kagoshima, Japan.'}, {'ForeName': 'Tomokazu', 'Initials': 'T', 'LastName': 'Noma', 'Affiliation': 'Department of Rehabilitation, Faculty of Health Science, Nihon Fukushi University, Aichi, Japan.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Ikeda', 'Affiliation': 'Department of Rehabilitation, Kagoshima University Hospital, Kagoshima, Japan.'}, {'ForeName': 'Megumi', 'Initials': 'M', 'LastName': 'Shimodozono', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1659639'] 781,31031579,Single Sessions of High-Definition Transcranial Direct Current Stimulation Do Not Alter Lower Extremity Biomechanical or Corticomotor Response Variables Post-stroke.,"Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique used to modulate cortical activity. However, measured effects on clinically relevant assessments have been inconsistent, possibly due to the non-focal dispersion of current from traditional two electrode configurations. High-definition (HD)-tDCS uses a small array of electrodes ( N = 5) to improve targeted current delivery. The purpose of this study was to determine the effects of a single session of anodal and cathodal HD-tDCS on gait kinematics and kinetics and the corticomotor response to transcranial magnetic stimulation (TMS) in individuals post-stroke. We hypothesized that ipsilesional anodal stimulation would increase the corticomotor response to TMS leading to beneficial changes in gait. Eighteen participants post-stroke (average age: 64.8 years, SD : 12.5; average months post-stroke: 54, SD : 42; average lower extremity Fugl-Meyer score: 26, SD : 6) underwent biomechanical and corticomotor response testing on three separate occasions prior to and after HD-tDCS stimulation. In a randomized order, anodal, cathodal, and sham HD-tDCS were applied to the ipsilesional motor cortex for 20 min while participants pedaled on a recumbent cycle ergometer. Gait kinetic and kinematic data were collected while walking on an instrumented split-belt treadmill with motion capture. The corticomotor response of the paretic and non-paretic tibialis anterior (TA) muscles were measured using neuronavigated TMS. Repeated measures ANOVAs using within-subject factors of time point (pre, post) and stimulation type (sham, anodal, cathodal) were used to compare effects of HD-tDCS stimulation on measured variables. HD-tDCS had no effect on over ground walking speed ( P > 0.41), or kinematic variables ( P > 0.54). The corticomotor responses of the TA muscles were also unaffected by HD-tDCS (resting motor threshold, P = 0.15; motor evoked potential (MEP) amplitude, P = 0.25; MEP normalized latency, P = 0.66). A single session of anodal or cathodal HD-tDCS delivered to a standardized ipsilesional area of the motor cortex does not appear to alter gait kinematics or corticomotor response post-stroke. Repeated sessions and individualized delivery of HD-tDCS may be required to induce beneficial plastic effects. Contralesional stimulation should also be investigated due to the altered interactions between the cerebral hemispheres post-stroke.",2019,"HD-tDCS had no effect on over ground walking speed ( P > 0.41), or kinematic variables ( P > 0.54).","['individuals post-stroke', 'Eighteen participants post-stroke (average age: 64.8 years, SD : 12.5; average months post-stroke: 54, SD : 42; average lower extremity Fugl-Meyer score: 26, SD : 6) underwent biomechanical and corticomotor response testing on three separate occasions prior to and after HD-tDCS stimulation']","['anodal, cathodal, and sham HD-tDCS', 'transcranial magnetic stimulation (TMS', 'anodal and cathodal HD-tDCS', 'anodal or cathodal HD-tDCS', 'High-Definition Transcranial Direct Current Stimulation', 'ipsilesional anodal stimulation', 'Transcranial direct current stimulation (tDCS']","['motor evoked potential (MEP) amplitude', 'gait kinematics or corticomotor response post-stroke', 'ground walking speed', 'corticomotor response of the paretic and non-paretic tibialis anterior (TA) muscles', 'Gait kinetic and kinematic data', 'gait kinematics and kinetics and the corticomotor response']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517544', 'cui_str': '12.5 (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0443299', 'cui_str': 'Separate (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C0282617', 'cui_str': 'Evoked Potentials, Motor'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0242690', 'cui_str': 'Anterior Tibial Muscle'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}]",,0.035812,"HD-tDCS had no effect on over ground walking speed ( P > 0.41), or kinematic variables ( P > 0.54).","[{'ForeName': 'John Harvey', 'Initials': 'JH', 'LastName': 'Kindred', 'Affiliation': ""Ralph H. Johnson, Veteran's Administration Medical Center, Charleston, SC, United States.""}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kautz', 'Affiliation': ""Ralph H. Johnson, Veteran's Administration Medical Center, Charleston, SC, United States.""}, {'ForeName': 'Elizabeth Carr', 'Initials': 'EC', 'LastName': 'Wonsetler', 'Affiliation': ""Ralph H. Johnson, Veteran's Administration Medical Center, Charleston, SC, United States.""}, {'ForeName': 'Mark Goodman', 'Initials': 'MG', 'LastName': 'Bowden', 'Affiliation': ""Ralph H. Johnson, Veteran's Administration Medical Center, Charleston, SC, United States.""}]",Frontiers in neuroscience,['10.3389/fnins.2019.00286'] 782,30846347,Does Arthroscopic Simulation Training Improve Triangulation and Probing Skills? A Randomized Controlled Trial ✰ .,"OBJECTIVE To determine the effectiveness of simulator training on basic arthroscopic skills utilizing a novel, low-cost arthroscopic triangulation training system. DESIGN A randomized controlled trial of subjects without prior arthroscopy training was conducted, with participants randomized to receive either a fixed protocol of simulation training on a triangulation simulation model (30 minutes of training for 4 consecutive days), or no training. On Days 1 and 5, all participants were evaluated on 3 simulated arthroscopic tasks by an independent observer. Variables analyzed included how many times portals were changed, the time it took to complete the tasks, and the task completion rate. SETTING Arthrex Inc., Naples, FL. PARTICIPANTS Thirty-six participants (92% male, average 28 ± 5 years) with no prior arthroscopy training were randomized into 2 groups, with 17 in the training group (T) and 19 in the no-training group (NT). RESULTS On Day 1, there was no difference in rate of task completion between the T group and NT groups (41% versus 53%, p = 0.52). On Day 5, significantly more participants in the T group completed all tasks compared to the NT group (100% versus 63%, p = 0.008). Participants in the T group had significantly improved task completion times on Day 5 versus Day 1 (p < 0.05). Participants in the NT group had a significantly improved task completion time for Task 1 on Day 5 versus Day 1 (p = 0.037); no differences were found for Tasks 2 or 3. On Day 5, participants in the T group required significantly fewer portal changes compared to the NT group (2.35 ± 2.29 versus 6.95 ± 8.55, p = 0.039). CONCLUSIONS Simulation training on a simple, low-cost arthroscopic triangulation training system resulted in an overall improvement in arthroscopic probing and triangulation skills within 1 week of training, with significantly decreased task completion times and increased efficiency of movement.",2019,Participants in the T group had significantly improved task completion times on Day 5 versus Day 1 (p < 0.05).,"['Thirty-six participants (92% male, average 28 ± 5 years) with no prior arthroscopy training', 'subjects without prior']","['Arthroscopic Simulation Training', 'fixed protocol of simulation training', 'Simulation training', 'training group (T) and 19 in the no-training group (NT', 'arthroscopy training', 'simulator training']","['task completion time', 'time it took to complete the tasks, and the task completion rate', 'task completion times', 'arthroscopic probing and triangulation skills', 'task completion times and increased efficiency of movement', 'rate of task completion', 'portal changes']","[{'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0003904', 'cui_str': 'Arthroscopy'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C4042947', 'cui_str': 'Simulation Training'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0003904', 'cui_str': 'Arthroscopy'}, {'cui': 'C0183309', 'cui_str': 'Simulator (physical object)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205054', 'cui_str': 'Portal (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",3.0,0.0405881,Participants in the T group had significantly improved task completion times on Day 5 versus Day 1 (p < 0.05).,"[{'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Frank', 'Affiliation': 'Department of Orthopaedic Surgery, University of Colorado, School of Medicine, Aurora, Colorado. Electronic address: Rmfrank3@gmail.com.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Rego', 'Affiliation': 'Arthrex Inc., Naples, Florida.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Grimaldi', 'Affiliation': 'Arthrex Inc., Naples, Florida.'}, {'ForeName': 'Hytham S', 'Initials': 'HS', 'LastName': 'Salem', 'Affiliation': 'Department of Orthopaedic Surgery, University of Colorado, School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Anthony A', 'Initials': 'AA', 'LastName': 'Romeo', 'Affiliation': 'Rothman Institute New York, New York, New York; Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Cole', 'Affiliation': 'Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Adams', 'Affiliation': 'Arthrex Inc., Naples, Florida; Arthrex Inc., Naples, Florida.'}]",Journal of surgical education,['10.1016/j.jsurg.2019.01.008'] 783,30443778,Customized virtual surgical planning in bimaxillary orthognathic surgery: a prospective randomized trial.,"OBJECTIVES The aim of the present study was to compare conventional (CSP) versus customized virtual surgical planning (VSP) in bimaxillary orthognathic surgery. The primary goal was to compare the accuracy of defined angles. The secondary purpose was to analyze the accuracy of the splints, the time required for surgery, and the costs of both methods. MATERIALS AND METHODS A total of 21 patients (n CSP  = 12; n VSP  = 9) treated by two-jaw orthognathic surgery were analyzed prospectively between the years 2014 and 2016. Customized VSP consisted of virtual planning as well as CAD/CAM printing of splints and pre-bent osteosynthesis plates. The evaluated parameters were the difference between planned and postoperative situation (SNA/SNB/ANB), accuracy of splints, time required for surgery (min), and total costs of planning (€). RESULTS When compared to CSP, VSP appears to be a more accurate method for orthognathic treatment planning with significant differences in the angle outcome (SNA p < 0.001; SNB p = 0.002; ANB p < 0.001). There were significant differences in splint accuracy in favor of CAD/CAM splints (p = 0.007). VSP significantly reduced the duration of operation (p = 0.041). Nevertheless, VSP increased the total costs (481.80 € vs. 884.00 €). CONCLUSIONS When using virtual 3D technology in combination with printed acrylic splints, 3D models of the jaws and pre-bent osteosynthesis, there is a noticeable reduction in the duration of the operation in conjunction with an improvement in accuracy. CLINICAL RELEVANCE Virtual model surgery and the prefabrication of splints and plates may replace traditional orthognathic surgery as it becomes cost-effective.",2019,"When compared to CSP, VSP appears to be a more accurate method for orthognathic treatment planning with significant differences in the angle outcome (SNA p < 0.001; SNB p = 0.002; ANB p < 0.001).","['21 patients (n CSP \u2009=\u200912; n VSP \u2009=\u20099) treated by two-jaw orthognathic surgery were analyzed prospectively between the years 2014 and 2016', 'bimaxillary orthognathic surgery']","['Customized virtual surgical planning', 'conventional (CSP) versus customized virtual surgical planning (VSP']","['planned and postoperative situation (SNA/SNB/ANB), accuracy of splints, time required for surgery (min), and total costs of planning (€', 'total costs', 'accuracy of defined angles', 'splint accuracy', 'duration of operation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0185624', 'cui_str': 'Orthognathic Surgery'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0068053', 'cui_str': 'N-hydroxysuccinimidyl-5-azido-2-nitrobenzoate'}, {'cui': 'C0204861', 'cui_str': 'Application of splint (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}]",21.0,0.0457473,"When compared to CSP, VSP appears to be a more accurate method for orthognathic treatment planning with significant differences in the angle outcome (SNA p < 0.001; SNB p = 0.002; ANB p < 0.001).","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Schneider', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Helios Kliniken Schwerin, Wismarsche Straße 393-397, 19049, Schwerin, Germany. daniel.schneider2@helios-kliniken.de.'}, {'ForeName': 'Peer W', 'Initials': 'PW', 'LastName': 'Kämmerer', 'Affiliation': 'Department of Oral, Maxillofacial and Plastic Surgery, University Medical Center of Johannes Gutenberg, Mainz, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Hennig', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Helios Kliniken Schwerin, Wismarsche Straße 393-397, 19049, Schwerin, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Schön', 'Affiliation': 'Department of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Daniel G E', 'Initials': 'DGE', 'LastName': 'Thiem', 'Affiliation': 'Department of Oral, Maxillofacial and Plastic Surgery, University Medical Center of Johannes Gutenberg, Mainz, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Bschorer', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Helios Kliniken Schwerin, Wismarsche Straße 393-397, 19049, Schwerin, Germany.'}]",Clinical oral investigations,['10.1007/s00784-018-2732-3'] 784,30053788,The effect of systematic functional assessment and immediate rehabilitation on physical performance in acutely admitted older adults with reduced functional performance: a randomised clinical trial.,"Aims: We hypothesised that a systematic functional assessment in a short stay unit at an emergency department (ED) and/or immediate rehabilitation after discharge will result in sustained or improved physical performance in comparison to a regimen in which neither of these interventions is offered. Methods: A two-way factorial randomised clinical trial was completed in an ED and the primary sector. We enrolled 336 nonsurgical patients of 65 years or older, scoring eight or less in the 30-s chair stand test. The interventions were: 1) Usual assessment; 2) Usual rehabilitation; 3) A systematic functional assessment performed within 48 h of admission, in order to identify those with loss of functional mobility, or at risk thereof; and 4) Immediate rehabilitation initiated within five days after discharge. The primary outcome was the 30-s chair stand test three weeks after admission. Secondary outcome measures were Barthel, EQ-5D-3L, and length of stay (LOS). Results: An intention-to-treat analysis showed no significant difference in the 30-s chair stand test score nor when analysed by groups or by intervention. The changes were approximately 1% when compared to the reference. No significant differences were found in the secondary outcomes. A per-protocol analysis showed that 99% had received assessment as assigned; however, the extent of mobilisation during hospitalisation was not disclosed. Of the patients, 48% were received the post-discharge rehabilitation they were assigned to. Conclusions: Systematic functional assessment and immediate rehabilitation led to no significant differences in physical performance. The study was weakened by the incomplete implementation of mobilisation during hospitalisation and low adherence to protocol on immediate rehabilitation.Implications for rehabilitationA systematic functional assessment within the first 48 h of hospital admission is suitable for the identification of older adults in need of post-discharge rehabilitation when compared to usual assessment.To sustain physical performance in older adults during acute hospitalisation , further research focusing on mobilisation or physical activation is needed in older adults with a loss of functional mobility, or at risk thereof.Further research focusing on physical activation during transition is needed to ameliorate tiredness and inactivity in older adults after acute hospitalisation.",2020,An intention-to-treat analysis showed no significant difference in the 30-s chair stand test score nor when analysed by groups or by intervention.,"['336 nonsurgical patients of 65\xa0years or older, scoring eight or less in the 30-s chair stand test', 'acutely admitted older adults with reduced functional performance', 'older adults after acute hospitalisation', 'older adults during acute hospitalisation']",['systematic functional assessment and immediate rehabilitation'],"['30-s chair stand test three weeks after admission', 'Barthel, EQ-5D-3L, and length of stay (LOS', '30-s chair stand test score', 'physical performance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C3853978'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}]","[{'cui': 'C0220922', 'cui_str': 'systematics'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4082109', 'cui_str': 'Three weeks'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2607857'}]",336.0,0.107935,An intention-to-treat analysis showed no significant difference in the 30-s chair stand test score nor when analysed by groups or by intervention.,"[{'ForeName': 'Inge H', 'Initials': 'IH', 'LastName': 'Bruun', 'Affiliation': 'Department of Physiotherapy and Occupational Therapy, Lillebaelt Hospital, Kolding, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Maribo', 'Affiliation': 'Department of Public Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Birgitte', 'Initials': 'B', 'LastName': 'Norgaard', 'Affiliation': 'Department of Public Health, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Berit', 'Initials': 'B', 'LastName': 'Schiottz-Christensen', 'Affiliation': 'Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Morten G B', 'Initials': 'MGB', 'LastName': 'Jessen', 'Affiliation': 'Department of Physiotherapy and Occupational Therapy, Lillebaelt Hospital, Kolding, Denmark.'}, {'ForeName': 'Christian B', 'Initials': 'CB', 'LastName': 'Mogensen', 'Affiliation': 'Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1492034'] 785,31232179,The Patients Save Lives Program to Facilitate Organ Donor Designation in Primary Care Offices.,"BACKGROUND There are about 120 000 people on the US waiting list for a solid organ transplant; nearly 22 people die every day who could be helped through organ donation. Joining a donor registry and informing one's family of one's preferences increases recovery rates and can avoid misunderstandings during an emotionally difficult time. Although the vast majority of people support organ donation, only about half of adults have joined a state donor registry. Methods. A 3-group design was used. Primary care physician offices were randomly assigned to either web-based training, in-person training, or a control condition. The control condition consisted of a poster and traditional brochure and donor form placed in the waiting room. In the 2 intervention groups, the Patients Save Lives form was distributed during the check-in process in addition to the poster. RESULTS A total of 1521 physicians and office staff at 81 clinic sites (48 in-person and 33 web-based) received the training; there were 33 control locations. A total of 21 189 patients were exposed to the intervention over a 6-month period; 761 (8.1%) of 9428 people who were not already registered completed the designation form to be organ donors. There were no donor designations in the control group locations. CONCLUSION Organ donor designation can be incorporated into the office check-in procedure without disrupting the workflow or burdening clinicians. The program is available online and can be sustained inexpensively with cooperation between primary care offices and regional Organ Procurement Organizations.",2019,"Primary care physician offices were randomly assigned to either web-based training, in-person training, or a control condition.","['A total of 1521 physicians and office staff at 81 clinic sites (48 in-person and 33 web-based) received the training; there were 33 control locations', 'Primary care physician offices', '120 000 people on the US waiting list for a solid organ transplant; nearly 22 people die every day who could be helped through organ donation', 'A total of 21 189 patients were exposed to the intervention over a 6-month period; 761 (8.1%) of 9428 people who were not already registered completed the designation form to be organ donors']","['web-based training, in-person training, or a control condition', 'poster and traditional brochure and donor form placed in the waiting room']",[],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0619283', 'cui_str': 'IS 33'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0033131', 'cui_str': 'Primary Care Physicians'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0730400', 'cui_str': 'Solid organ transplant (procedure)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0282366', 'cui_str': 'Organ Donation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C4517875', 'cui_str': '8.1 (qualifier value)'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0029206', 'cui_str': 'Organ donor (person)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0376675', 'cui_str': 'Poster'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}]",[],21189.0,0.0301091,"Primary care physician offices were randomly assigned to either web-based training, in-person training, or a control condition.","[{'ForeName': 'Howard B', 'Initials': 'HB', 'LastName': 'Degenholtz', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Creppage', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Damian', 'Initials': 'D', 'LastName': 'DaCosta', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Drozd', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Misty', 'Initials': 'M', 'LastName': 'Enos', 'Affiliation': '4 Center for Organ Recovery and Education, Pittsburgh, PA, USA.'}, {'ForeName': 'Meleah', 'Initials': 'M', 'LastName': 'Himber', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Lazzara', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Manik', 'Initials': 'M', 'LastName': 'Razdan', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Resnick', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Yomei', 'Initials': 'Y', 'LastName': 'Shaw', 'Affiliation': '1 University of Pittsburgh, Pittsburgh, PA, USA.'}]","Progress in transplantation (Aliso Viejo, Calif.)",['10.1177/1526924819853836'] 786,31899746,Deceptive and Nondeceptive Placebos to Reduce Pain: An Experimental Study in Healthy Individuals.,"OBJECTIVES Recent research has shown that placebos can be effective even if they are openly prescribed to participants. Yet, it is unclear how such ""open-label placebos"" (OLPs) compare to deceptive placebo (DP) and what the mechanisms of actions are. In this study, we therefore compared 2 versions of OLP to DP and no treatment (NT). MATERIALS AND METHODS Using a standard heat pain paradigm, 117 healthy volunteers underwent a baseline and a posttreatment pain assessment. With the exception of NT, all groups received an inert placebo cream after the first assessment. OLP was administered by either evoking positive expectancies or by raising hope for placebo analgesia, thus distinguishing for the first time conceptually between expectancy and hope in experimental pain research. The primary outcome was pre-post change in pain tolerance. RESULTS Increase in pain tolerance was larger in the 3 treatment groups compared with NT, whereas the treatment groups did not differ from each other. Further results showed that participants receiving DP reported a large reduction of subjective pain intensity and unpleasantness, whereas no such reduction was found for the 2 OLP groups. The 2 OLP versions did not differ in terms of their analgesic effects. DISCUSSION The study provided evidence for traditional placebo analgesia on the basis of deception. For OLP, we found that OLP indeed increased pain tolerance; however, participants receiving OLP were reluctant to report any subjective analgesic effects. Combined with previous studies, the present findings suggest that the effects of OLP are weaker in healthy volunteers than in clinical samples.",2020,"RESULTS Increase in pain tolerance was larger in the 3 treatment groups compared with NT, whereas the treatment groups did not differ from each other.","['117 healthy volunteers underwent a baseline and a posttreatment pain assessment', 'Healthy Individuals', 'healthy volunteers']","['OLP to DP and no treatment (NT', 'placebo (DP', 'Deceptive and Nondeceptive Placebos', 'placebo cream', 'OLP', 'placebos']","['subjective pain intensity and unpleasantness', 'Pain', 'pre-post change in pain tolerance', 'pain tolerance']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C1291733', 'cui_str': 'Posttreatment pain'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1378128', 'cui_str': 'Cream'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}]",117.0,0.0862594,"RESULTS Increase in pain tolerance was larger in the 3 treatment groups compared with NT, whereas the treatment groups did not differ from each other.","[{'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Kube', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'Rief', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'Maj-Britt', 'Initials': 'MB', 'LastName': 'Vivell', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'N Leonora', 'Initials': 'NL', 'LastName': 'Schäfer', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Vermillion', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'Karoline', 'Initials': 'K', 'LastName': 'Körfer', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}, {'ForeName': 'Julia A', 'Initials': 'JA', 'LastName': 'Glombiewski', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Philipps-University of Marburg, Marburg.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000781'] 787,31866419,Effectiveness of Powerful Tools for Caregivers on Caregiver Burden and on Care Recipient Behavioral and Psychological Symptoms of Dementia: A Randomized Controlled Trial.,"OBJECTIVE The aim of this study was to evaluate the effectiveness of a psychoeducational intervention, Powerful Tools for Caregivers (PTC), for family caregivers of individuals with dementia. DESIGN A pragmatic, 2-arm randomized controlled trial compared the PTC intervention, as delivered in practice, to usual care. Participants randomized to usual care functioned as a control group and then received the PTC intervention. INTERVENTION PTC is a 6-week manualized program that includes weekly 2-hour classes in a group setting facilitated by 2 trained and certified leaders. The educational program helps caregivers to enhance self-care practices and manage emotional distress. SETTING AND PARTICIPANTS Two stakeholder organizations delivered the intervention in community settings. Participants were family caregivers of individuals with dementia recruited from the community in Florida. METHODS Primary outcomes were caregiver burden and behavioral and psychological symptoms of dementia of the care recipient. Secondary outcomes included caregiver depressive symptoms, self-efficacy, self-rated health, and life satisfaction. Measures were collected at baseline (n = 60 participants), postintervention (n = 55), and at 6-week follow-up (n = 44). RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients. PTC was rated highly by participants and program attrition was low, with 94% of caregivers completing at least 4 of the 6 classes. CONCLUSIONS AND IMPLICATIONS Although no significant effects were found for behavioral and psychological symptoms of dementia, this trial supports the effectiveness of PTC to improve caregiver outcomes as delivered in the community.",2020,"RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients.","['Participants were family caregivers of individuals with dementia recruited from the community in Florida', 'Caregivers (PTC), for family caregivers of individuals with dementia', 'Caregivers on Caregiver Burden and on Care Recipient Behavioral and Psychological Symptoms of Dementia']","['PTC intervention', 'PTC', 'psychoeducational intervention']","['caregiver burden and behavioral and psychological symptoms of dementia of the care recipient', 'self-confidence', 'caregiver depressive symptoms, self-efficacy, self-rated health, and life satisfaction', 'behavioral and psychological symptoms of dementia', 'depressive symptoms', 'PTC reduced caregiver burden']","[{'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}]","[{'cui': 'C0015491', 'cui_str': 'factor IX'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4285807', 'cui_str': 'Neuropsychiatric symptoms'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0015491', 'cui_str': 'factor IX'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",60.0,0.178322,"RESULTS Intent-to-treat analyses found PTC reduced caregiver burden (d = -0.48) and depressive symptoms (d = -0.53), and increased self-confidence (d = 0.68), but found no significant benefit for behavioral and psychological symptoms of dementia in care recipients.","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Terracciano', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL. Electronic address: antonio.terracciano@med.fsu.edu.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Artese', 'Affiliation': 'Health and Human Performance, Roanoke College, Salem, VA.'}, {'ForeName': 'Jenie', 'Initials': 'J', 'LastName': 'Yeh', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'LaVon', 'Initials': 'L', 'LastName': 'Edgerton', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Granville', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Damaris', 'Initials': 'D', 'LastName': 'Aschwanden', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Luchetti', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Glueckauf', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Yannick', 'Initials': 'Y', 'LastName': 'Stephan', 'Affiliation': 'Euromov, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Angelina R', 'Initials': 'AR', 'LastName': 'Sutin', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Katz', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2019.11.011'] 788,30635256,Enhancement of cognitive insight and higher-order neurocognitive function by fronto-temporal transcranial direct current stimulation (tDCS) in patients with schizophrenia.,"No studies have examined the effects of fronto-temporal transcranial direct current stimulation (tDCS) on cognitive insight and neurocognitive function in schizophrenia patients and the dynamic interplay between tDCS-induced changes in these two outcomes. In this double-blind, randomized, sham-controlled study, we investigated the effects of fronto-temporal tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions for 5 days] on illness severity, psychosocial functioning, cognitive insight and neurocognitive function in schizophrenia patients (N = 60). The authors observed significant trends that tDCS ameliorated the severity of total and general psychopathology as measured by the Positive and Negative Syndrome Scale. No significant effects were observed for other psychopathological symptoms and psychosocial functioning. Cognitive insight as measured by the Beck Cognitive Insight Scale (BCIS) was rapidly enhanced by 10-session tDCS (F = 10.80, Cohen's d = 0.44, p = 0.002) but the beneficial effect became borderline significant 1 month after stimulation. A trend-level improvement with tDCS of planning ability (F = 6.40, Cohen's d = 0.339, p = 0.014) as measured by the accuracy in Tower of London task was also observed. In the active tDCS group, the change in cognitive insight from baseline to immediately after tDCS assessment was positively correlated with that in planning ability (r = 0.46, p = 0.015), which was independent of the corresponding change in illness severity. The promising results regarding the fast-acting beneficial effects of tDCS on cognitive insight and planning ability in schizophrenia require confirmation in future replication studies.",2019,"Cognitive insight as measured by the Beck Cognitive Insight Scale (BCIS) was rapidly enhanced by 10-session tDCS (F = 10.80, Cohen's d = 0.44, p = 0.002) but the beneficial effect became borderline significant 1 month after stimulation.","['schizophrenia patients (N\u202f=\u202f60', 'patients with schizophrenia', 'schizophrenia patients']","['fronto-temporal transcranial direct current stimulation (tDCS', 'fronto-temporal tDCS [anode corresponding to left dorsolateral prefrontal cortex and cathode to left temporo-parietal junction; 2-mA, twice-daily sessions', 'tDCS']","['psychopathological symptoms and psychosocial functioning', 'change in cognitive insight', 'cognitive insight and neurocognitive function', 'severity of total and general psychopathology', 'accuracy in Tower of London task', 'illness severity, psychosocial functioning, cognitive insight and neurocognitive function', 'Beck Cognitive Insight Scale (BCIS']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0442043', 'cui_str': 'Temporal (qualifier value)'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0003103', 'cui_str': 'Anode'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0007441', 'cui_str': 'Cathode'}, {'cui': 'C0442030', 'cui_str': 'Parietal (qualifier value)'}, {'cui': 'C0205144', 'cui_str': 'Junctional (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0233820', 'cui_str': 'Self-understanding'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0222045'}]",,0.0598486,"Cognitive insight as measured by the Beck Cognitive Insight Scale (BCIS) was rapidly enhanced by 10-session tDCS (F = 10.80, Cohen's d = 0.44, p = 0.002) but the beneficial effect became borderline significant 1 month after stimulation.","[{'ForeName': 'Chuan-Chia', 'Initials': 'CC', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.'}, {'ForeName': 'Yu-Chen', 'Initials': 'YC', 'LastName': 'Kao', 'Affiliation': 'Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Department of Psychiatry, Tri-Service General Hospital Songshan Branch, National Defense Medical Center, Taipei, Taiwan.'}, {'ForeName': 'Che-Yi', 'Initials': 'CY', 'LastName': 'Chao', 'Affiliation': 'Department of Psychiatry, Cardinal Tien Hospital, New Taipei, Taiwan.'}, {'ForeName': 'Hsin-An', 'Initials': 'HA', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: chang.ha@mail.ndmctsgh.edu.tw.'}]",Schizophrenia research,['10.1016/j.schres.2018.12.052'] 789,31296936,Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes in Southern India.,"BACKGROUND/OBJECTIVES We examined the prevalence of anaemia, iron deficiency, and inflammation during pregnancy and their associations with adverse pregnancy and infant outcomes in India. SUBJECTS/METHODS Three hundred and sixty-six women participating in a randomised trial of vitamin B 12 supplementation were monitored to assess haemoglobin (Hb), serum ferritin (SF), hepcidin, C-reactive protein (CRP), and alpha-1-acid glycoprotein (AGP) during pregnancy. Women received vitamin B 12 supplementation (50 µg per day) or placebo daily; all women received daily prenatal iron-folic acid supplementation. Binomial and linear regression models were used to examine the associations of maternal iron biomarkers with pregnancy and infant outcomes. RESULTS Thirty percent of women were anaemic (Hb < 11.0 g/dl), 48% were iron deficient (SF < 15.0 µg/l), and 23% had iron deficiency anaemia at their first prenatal visit. The prevalence of inflammation (CRP > 5.0 mg/l: 17%; AGP > 1.0 g/l: 11%) and anaemia of inflammation (Hb < 11.0 g/dl, SF > 15.0 µg/l, plus CRP > 5.0 mg/l or AGP > 1.0 g/l: 2%) were low. Infants born to anaemic women had a twofold higher risk of low birth weight (<2500 g; risk ratio [RR]: 2.15, 95%CI: 1.20-3.84, p = 0.01), preterm delivery (RR: 2.67 (1.43-5.00); p = 0.002), underweight (WAZ < -2; RR: 2.20, 95%CI: 1.16-4.15, p = 0.02), and lower MUAC (β(SE): -0.94 (0.45)cm, p = 0.03). Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006). Maternal SF concentrations were associated with greater birth length (β(SE): 0.44 (0.20) cm, p < 0.03). Findings were similar after adjusting SF concentrations for inflammation. IDA was associated with higher risk of low birth weight (RR: 1.99 (1.08-3.68); p = 0.03) and preterm birth (RR: 3.46 (1.81-6.61); p = 0.0002); and lower birth weight (p = 0.02), gestational age at birth (p = 0.0002), and infant WAZ scores (p = 0.02). CONCLUSIONS The prevalence of anaemia and iron deficiency was high early in pregnancy and associated with increased risk of adverse pregnancy and infant outcomes. A comprehensive approach to prevent anaemia is needed in women of reproductive age, to enhance haematological status and improve maternal and child health outcomes.",2020,"Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006).","['Southern India', 'Infants born to anaemic women', 'Three hundred and sixty-six women participating']","['l', 'vitamin B 12 supplementation', 'IDA', 'placebo daily; all women received daily prenatal iron-folic acid supplementation']","['haemoglobin (Hb), serum ferritin (SF), hepcidin, C-reactive protein (CRP), and alpha-1-acid glycoprotein (AGP', 'lower risk of preterm delivery', 'iron deficiency anaemia', 'Maternal SF concentrations', 'infant birth weight', 'prevalence of anaemia and iron deficiency', 'Anaemia and iron deficiency in pregnancy and adverse perinatal outcomes', 'higher risk of low birth weight', 'infant WAZ scores', 'risk of low birth weight', 'lower birth weight', 'anaemia of inflammation', 'preterm birth', 'preterm delivery']","[{'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}]","[{'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplementation (product)'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0696113', 'cui_str': 'Serum ferritin measurement'}, {'cui': 'C0966897', 'cui_str': 'Liver-Expressed Antimicrobial Peptide'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0029297', 'cui_str': 'alpha 1-Acid Glycoprotein'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0240066', 'cui_str': 'Iron deficiency (disorder)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",366.0,0.459335,"Similarly, maternal Hb concentrations predicted higher infant birth weight (p = 0.02) and greater gestational age at delivery (β(SE): 0.28 (0.08) weeks, p = 0.001), lower risk of preterm delivery (<37 weeks; RR: 0.76, 95%CI: 0.66-86, p < 0.0001); and higher infant MUAC (β(SE): 0.36 (0.13) cm, p = 0.006).","[{'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Finkelstein', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY, USA. jfinkelstein@cornell.edu.'}, {'ForeName': 'Anura V', 'Initials': 'AV', 'LastName': 'Kurpad', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Beena', 'Initials': 'B', 'LastName': 'Bose', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Tinku', 'Initials': 'T', 'LastName': 'Thomas', 'Affiliation': ""St. John's Research Institute, Bangalore, India.""}, {'ForeName': 'Krishnamachari', 'Initials': 'K', 'LastName': 'Srinivasan', 'Affiliation': ""St. John's Medical College, Bangalore, India.""}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Duggan', 'Affiliation': ""St. John's Research Institute, Bangalore, India. Christopher.duggan@childrens.harvard.edu.""}]",European journal of clinical nutrition,['10.1038/s41430-019-0464-3'] 790,31179831,A Pilot Randomized Controlled Trial Comparing Levothyroxine to Placebo in Neurologically Deceased Donors.,"BACKGROUND Although commonly prescribed, the efficacy of levothyroxine to improve heart function in neurologically deceased donors is unclear. We evaluated the feasibility of a randomized controlled trial to compare levothyroxine to placebo on the variation of left ventricular ejection fraction, in hemodynamically unstable donors. METHODS We conducted a pilot, double-blinded, randomized controlled trial. Deceased donors with reduced left ventricular ejection fraction or needing vasopressors were included. We randomized participants to a 20 μg bolus followed by a 20 μg/h infusion of levothyroxine or an identically appearing placebo. We report the proportion of recruited participants, the time to the administration of the study drug, and protocol violations. RESULTS Twenty-four participants (N = 24/104; 23.1%) were eligible. Five of them (N = 5/24; 20.8%) were excluded by the attending physician. Four others were not included, due to family refusal for research (n = 2/24;8.3%) and unavailability of research staff (n = 2/24; 8.3%). Fifteen participants were randomized (N = 15/104; 14.4%). Mean time between the echocardiography and the initiation of the drug was 1.73 hours, and14 (93.3%) of 15 of the participants received the drug within 2 hours after the echocardiography. We report no study violation. The study was stopped prematurely because of low recruitment. CONCLUSION This pilot trial suggests that the success of a definitive randomized control trial to assess the efficacy of levothyroxine in deceased donors could benefit from a multicenter recruitment and education on the evidence surrounding the pharmacological management of organ donors. The need for consent to research interventions in deceased donors should also be clarified.",2019,"We evaluated the feasibility of a randomized controlled trial to compare levothyroxine to placebo on the variation of left ventricular ejection fraction, in hemodynamically unstable donors. ","['Twenty-four participants (N = 24/104; 23.1%) were eligible', 'hemodynamically unstable donors', 'Deceased donors with reduced left ventricular ejection fraction or needing vasopressors were included', 'Neurologically Deceased Donors']","['placebo', 'Placebo', 'Levothyroxine', 'levothyroxine', 'levothyroxine or an identically appearing placebo']","['Mean time', 'variation of left ventricular ejection fraction', 'heart function']","[{'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1881373', 'cui_str': ""L-3,5,3',5'-Tetraiodothyronine""}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C4521692', 'cui_str': 'Cardiac physiological function (observable entity)'}]",15.0,0.456379,"We evaluated the feasibility of a randomized controlled trial to compare levothyroxine to placebo on the variation of left ventricular ejection fraction, in hemodynamically unstable donors. ","[{'ForeName': 'Anne Julie', 'Initials': 'AJ', 'LastName': 'Frenette', 'Affiliation': '1 Pharmacy Department, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Williamson', 'Affiliation': '1 Pharmacy Department, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Williams', 'Affiliation': '2 Research Center, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Anne-Marie', 'Initials': 'AM', 'LastName': 'Lagacé', 'Affiliation': '2 Research Center, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Charbonney', 'Affiliation': '2 Research Center, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Serri', 'Affiliation': '2 Research Center, Hôpital du Sacré-Cœur-de-Montréal, Montreal, Quebec, Canada.'}]","Progress in transplantation (Aliso Viejo, Calif.)",['10.1177/1526924819855083'] 791,31816425,"Chair-based exercise programs in institutionalized older women: Salivary steroid hormones, disabilities and frailty changes.","PURPOSE Many people experience aging-related losses in different physical domains, which leads to a condition often called physical frailty (PF). The aim of this study was to analyse the effects of two different, 28-weeks, class chair-exercise protocols on salivary steroid hormones (SH), PF, and functional disabilities (FD) in frail older women. METHODS A sample of older frail individuals (n = 60, 817.84 years) participated in the study and were divided into three groups: chair elastic-band muscle strength exercises (CSE), n = 20), chair-multimodal exercise (CME, n = 21) and a control non-exercise group (CG ne , n = 19). Both exercise programs consisted of 45 min of supervised chair-based exercise group classes, carried out 3 times/week. CME participants performed a progressive training using walking, mobility and body weight resistance exercises. The CSE participants exercised using an elastic-band system of progressive exercises. Both CSE and CME followed a circuit training protocol. The controls did not change their usual lifestyle. The indicators of PF, FD and SH concentrations were analyzed before and after the intervention. RESULTS Both exercise programs diminished the PF status showing significant time and time versus treatment interactions (p < .01). An increase in the CME group, between baseline and 14-weeks, and in the CSE group, after 28 weeks, for Testosterone concentrations was observed (p < .01). Dehydroepiandrosterone (DHEA) increased after 28-weeks in the CME group and decreased in the CG ne after the same period (p < .05). Both exercise programs decreased the negative scores of several FD domains, specially fear of falling that showed significant effects with time (p < .01), and time vs intervention (p < .05). CONCLUSION Both chair-exercise based programs were effective in stimulating positive changes in physical health and in steroid hormone responses, especially in DHEA. The control group did show a negative trend towards an increased PF status and decreased levels of SH. It is crucial for public health to identify the main factors associated with Functional Disability and Physical Frailty that underlie the development of new methods for complementary therapies, such as the use of low doses of hormonal supplementation combined with long-term exercise interventions.",2020,Both exercise programs diminished the PF status showing significant time and time versus treatment interactions (p < .01).,"['institutionalized older women', 'older frail individuals (n\xa0=\xa060, 817.84\xa0years) participated in the study and were divided into three groups', 'frail older women']","['Chair-based exercise programs', 'CME', 'class chair-exercise protocols', 'chair elastic-band muscle strength exercises (CSE), n\xa0=\xa020), chair-multimodal exercise (CME, n\xa0=\xa021) and a control non-exercise group (CG ne , n\xa0=\xa019', 'CSE and CME']","['Dehydroepiandrosterone (DHEA', 'salivary steroid hormones (SH), PF, and functional disabilities (FD', 'PF status and decreased levels of SH', 'Testosterone concentrations', 'negative scores of several FD domains, specially fear of falling', 'PF status', 'PF, FD and SH concentrations']","[{'cui': 'C0562359', 'cui_str': 'Institutionalized (finding)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0179847', 'cui_str': 'Chair (physical object)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0419118', 'cui_str': 'Muscle strength exercise (regime/therapy)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0011185', 'cui_str': 'prasterone'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling (finding)'}]",,0.0155435,Both exercise programs diminished the PF status showing significant time and time versus treatment interactions (p < .01).,"[{'ForeName': 'Guilherme Eustáquio', 'Initials': 'GE', 'LastName': 'Furtado', 'Affiliation': 'Research Center for Sport and Physical Activity, CIDAF (UID/PTD/04213/2019), Faculty of Sport Sciences and Physical Education, University of Coimbra, Portugal.'}, {'ForeName': 'Humberto Moreira', 'Initials': 'HM', 'LastName': 'Carvalho', 'Affiliation': 'Faculty of Physical Education, Federal University of Santa Catarina, Brazil.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Loureiro', 'Affiliation': 'Laboratory of Biostatistics and Medical Informatics and IBILI, Faculty of Medicine, University of Coimbra, Portugal.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Patrício', 'Affiliation': 'Laboratory of Biostatistics and Medical Informatics and IBILI, Faculty of Medicine, University of Coimbra, Portugal.'}, {'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Uba-Chupel', 'Affiliation': 'Research Center for Sport and Physical Activity, CIDAF (UID/PTD/04213/2019), Faculty of Sport Sciences and Physical Education, University of Coimbra, Portugal.'}, {'ForeName': 'Juan C', 'Initials': 'JC', 'LastName': 'Colado', 'Affiliation': 'Research Group in Prevention and Health in Exercise and Sport, University of Valencia, Spain.'}, {'ForeName': 'Eef', 'Initials': 'E', 'LastName': 'Hogervorst', 'Affiliation': 'School of Sport and Exercise Sciences, Loughborough University, United Kingdom.'}, {'ForeName': 'José Pedro', 'Initials': 'JP', 'LastName': 'Ferreira', 'Affiliation': 'Research Center for Sport and Physical Activity, CIDAF (UID/PTD/04213/2019), Faculty of Sport Sciences and Physical Education, University of Coimbra, Portugal.'}, {'ForeName': 'Ana Maria', 'Initials': 'AM', 'LastName': 'Teixeira', 'Affiliation': 'Research Center for Sport and Physical Activity, CIDAF (UID/PTD/04213/2019), Faculty of Sport Sciences and Physical Education, University of Coimbra, Portugal. Electronic address: cidaf@fcdef.uc.pt.'}]",Experimental gerontology,['10.1016/j.exger.2019.110790'] 792,31622643,"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study.","BACKGROUND There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic adverse effects. OBJECTIVE To assess the efficacy and safety of 1.5% ruxolitinib cream in patients with AA who had at least 25% hair loss by Severity of Alopecia Tool score. METHODS This was a 2-part study. Part A was an open-label, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 99% hair loss followed by a 24-week extension period. Part B was a double-blind, vehicle-controlled, 24-week study of 1.5% ruxolitinib cream in patients with 25% to 100% hair loss, followed by a crossover to ruxolitinib cream in the vehicle group for 24 weeks and additional treatment time for the ruxolitinib cream group. RESULTS Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth based on 50% improvement in Severity of Alopecia Tool scores between patients receiving 1.5% ruxolitinib cream and vehicle in part B. There were no significant safety issues with 1.5% ruxolitinib cream. LIMITATIONS Single strength of ruxolitinib cream. CONCLUSIONS The 1.5% ruxolitinib cream did not have a significant effect in patients with AA.",2020,"Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth by SALT 50 scores between patients on 1.5% ruxolitinib cream and vehicle in Part B.","['patients with AA who had ≥25% hair loss by Severity of Alopecia Tool (SALT) score', 'patients with AA', 'Patients With Alopecia Areata', 'patients with 25%-99% hair loss followed by a 24-week extension period', 'patients with 25%-100% hair loss']","['ruxolitinib cream', 'Ruxolitinib Cream', 'ruxolitinib cream group', 'Ruxolitinib cream']","['efficacy and safety', 'hair regrowth']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002170', 'cui_str': 'Hair Loss'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0002171', 'cui_str': 'Alopecia Circumscripta'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C2931926', 'cui_str': 'ruxolitinib'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018494', 'cui_str': 'Hair'}]",,0.0529731,"Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth by SALT 50 scores between patients on 1.5% ruxolitinib cream and vehicle in Part B.","[{'ForeName': 'Elise A', 'Initials': 'EA', 'LastName': 'Olsen', 'Affiliation': 'Department of Dermatology and Medicine, Duke University Medical Center, Durham, North Carolina.'}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'Kornacki', 'Affiliation': 'Incyte Corporation, Wilmington, Delaware. Electronic address: dkornacki@incyte.com.'}, {'ForeName': 'Kang', 'Initials': 'K', 'LastName': 'Sun', 'Affiliation': 'Incyte Corporation, Wilmington, Delaware.'}, {'ForeName': 'Maria K', 'Initials': 'MK', 'LastName': 'Hordinsky', 'Affiliation': 'Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.10.016'] 793,31553438,"Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer.","BACKGROUND Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. PATIENTS AND METHODS Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. RESULTS OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. CONCLUSION G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease.This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.",2019,"Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in G group and 45.5 and 32.8 months in CD group, respectively. ","['Patients', 'patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung cancer', 'registered with UMIN (University Hospital Medical Information Network in Japan']","['gefitinib (G)in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD', 'cisplatin (80mg/m2 intravenously) plus docetaxel', 'gefitinib versus cisplatin with docetaxel']","['Median survival time for G and CD', 'hazard ratios (HRs) for death', 'postoperative recurrence and stage IIIB/IV disease', 'postoperative recurrence', 'Median survival time (postoperative recurrence versus stage IIIB/IV disease']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0021419', 'cui_str': 'Information Networks'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C1122962', 'cui_str': 'gefitinib'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0034802', 'cui_str': 'c-erbB-1 Protein'}, {'cui': 'C0033681', 'cui_str': 'Tyrosylprotein Kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",172.0,0.15013,"Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in G group and 45.5 and 32.8 months in CD group, respectively. ","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Yoshioka', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Shimokawa', 'Affiliation': 'Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Seto', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Yatabe', 'Affiliation': 'Department of Pathology and Molecular Genetics, Aichi Cancer Center Hospital, Nagoya.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Okamoto', 'Affiliation': 'Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyusyu University, Fukuoka.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Tsurutani', 'Affiliation': 'Advanced Cancer Translational Research Institute, Showa University, Tokyo.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Satouchi', 'Affiliation': 'Department of Thoracic Oncology, Hyogo Cancer Center, Akashi.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hirashima', 'Affiliation': 'Department of Thoracic Oncology, Osaka Habikino Medical Center, Habikino.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Atagi', 'Affiliation': 'Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Shibata', 'Affiliation': 'Department of Medical Oncology, Kouseiren Takaoka Hospital, Takaoka.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Saito', 'Affiliation': 'Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Toyooka', 'Affiliation': 'Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Yamamoto', 'Affiliation': 'Internal Medicine III, Wakayama Medical University Hospital, Wakayama.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Medical Oncology, Kindai University Hospital, Osaka-Sayama.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Mitsudomi', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, Kindai University Hospital, Osaka-Sayama, Japan. Electronic address: mitsudom@med.kindai.ac.jp.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz399'] 794,31915996,Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial.,"BACKGROUND In ENSURE-AF study, edoxaban had similar efficacy and safety profile versus enoxaparin-warfarin (enox-warf) in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. OBJECTIVES To evaluate the efficacy and safety of edoxaban versus enox-warf in patients who were vitamin K antagonists (VKA) naïve or experienced at time of randomisation into ENSURE-AF trial. METHODS The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death during the overall study period, 28 days on study drug after cardioversion and 30 days follow-up. The primary safety endpoint was the composite of major and clinically relevant nonmajor bleeding during the on-medication period from time of first dose to last dose of study drug taken + 3 days. RESULTS Of 2199 patients enrolled in ENSURE-AF, 1095 were randomised to edoxaban and 1104 to enox-warf. There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively). There were no significant differences in the primary safety endpoint [odds ratio (OR) 2.09, 95% confidence interval (CI) 0.72-6.81 in anticoagulant experienced patients, OR 0.77, 95% CI 0.15-3.60 in anticoagulant naïve patients] and in major bleeding rates regardless of treatment or VKA experience (OR 0.69, 95%CI 0.06-6.04, OR 0.48, 95% CI 0.01-9.25, respectively). CONCLUSIONS Edoxaban had comparable efficacy and safety to optimized anticoagulation with enox-warf. The primary efficacy and safety endpoint outcomes were broadly similar between VKA experienced or naïve patients.",2020,"There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively).","['patients undergoing electrical cardioversion of non-valvular atrial fibrillation', '2199 patients enrolled in ENSURE-AF, 1095 were randomised to', 'patients who were vitamin K antagonists (VKA) naïve or experienced at time of randomisation into ENSURE-AF trial', 'subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF']","['Edoxaban versus warfarin', 'edoxaban', 'edoxaban versus warfarin', 'Edoxaban', 'enoxaparin-warfarin (enox-warf']","['composite of major and clinically relevant nonmajor bleeding during the on-medication period from time of first dose to last dose of study drug taken\u2009+\u20093\xa0days', 'composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013778', 'cui_str': 'Electrical Cardioversion'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C3653316', 'cui_str': 'Vitamin K antagonists'}, {'cui': 'C1632851', 'cui_str': 'Times'}]","[{'cui': 'C2975435', 'cui_str': 'edoxaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2199.0,0.152552,"There were numerically fewer primary efficacy endpoint events with edoxaban than enox-warf irrespective of whether VKA experienced or naïve (0.5% vs. 0.9%, 0.3% vs. 1.4%, respectively).","[{'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Kozieł', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool, L78TX, UK.'}, {'ForeName': 'Naab', 'Initials': 'N', 'LastName': 'Al-Saady', 'Affiliation': 'Covance Inc, Cardiovascular/Metabolic, Maidenshead, UK.'}, {'ForeName': 'Søren P', 'Initials': 'SP', 'LastName': 'Hjortshøj', 'Affiliation': 'Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.'}, {'ForeName': 'Assen', 'Initials': 'A', 'LastName': 'Goudev', 'Affiliation': 'Queen Giovanna University Hospital, Sofia, Bulgaria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': '3rd Medical Department, Cardiology and Intensive Care Medicine, Medcial School, Wilhelminenhospital, and Sigmund Freud University, Vienna, Austria.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': 'Hôpital Saint Antoine, Hôpital Tenon; Université Pierre Et Marie Curie (Paris VI), Paris, France.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Jin', 'Affiliation': 'Daiichi Sankyo Pharma Development, Basking Ridge, New York, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Melino', 'Affiliation': 'Daiichi Sankyo, Basking Ridge, New York, USA.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Winters', 'Affiliation': 'Daiichi Sankyo, Basking Ridge, New York, USA.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Goette', 'Affiliation': 'St. Vincenz-Hospital, Paderborn, Germany.'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart and Chest Hospital, William Henry Duncan Building, 6 West Derby Street, Liverpool, L78TX, UK. gregory.lip@liverpool.ac.uk.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-019-01594-9'] 795,30374832,"Treatment of intrabony defects with modified perforated membranes in aggressive periodontitis: subtraction radiography outcomes, prognostic variables, and patient morbidity.","OBJECTIVES The main objectives of this study were (1) to evaluate bone/graft density alterations by digital subtraction radiography; (2) to determine factors associated with favorable clinical and radiographic outcomes, and (3) to report on patient morbidity after guided tissue regeneration (GTR) in aggressive periodontitis (AgP) patients. MATERIALS AND METHODS Adapting a split-mouth design, 30 comparative intrabony defects in 15 patients were randomly treated with xenogenic graft plus modified perforated membranes (MPM, tests) or xenogenic graft plus standard collagen membranes (CM, controls). The time period of observation was 12 months. RESULTS There were significant improvements in clinical and radiographic parameters within each group, without intergroup differences. However, higher PPD reduction for three-wall defects was noted in MPM sites (5.22 versus 3.62 mm; p = 0.033). Moreover, a significant gain in bone/graft density of 4.9% from 6 to 12 months post-operatively was observed in test sites. Multivariate analysis demonstrated that morphology of intrabony defects was a predictor of CAL gain (p = 0.06), while independent prognostic variables effecting changes in bone/graft density were radiographic defect depth (p = 0.025) and radiographic angle (p = 0.033). The majority of patients reported some discomfort, pain, and edema with mild intensity without any significant differences between treatment modalities. CONCLUSIONS This study demonstrated enhanced bone/graft density gain after GTR with MPM, which may indicate greater area of new bone formation. Independent variables effecting treatment outcomes were intrabony defect morphology, radiographic defect depth, and radiographic angle. CLINICAL RELEVANCE This study supports the regenerative treatment of intrabony defects in AgP patients and identifies some variables with prognostic value.",2019,"Multivariate analysis demonstrated that morphology of intrabony defects was a predictor of CAL gain (p = 0.06), while independent prognostic variables effecting changes in bone/graft density were radiographic defect depth (p = 0.025) and radiographic angle (p = 0.033).","['aggressive periodontitis (AgP) patients', 'aggressive periodontitis', 'Adapting a split-mouth design, 30 comparative intrabony defects in 15 patients']","['digital subtraction radiography', 'xenogenic graft plus modified perforated membranes (MPM, tests) or xenogenic graft plus standard collagen membranes (CM, controls', 'guided tissue regeneration (GTR']","['bone/graft density were radiographic defect depth', 'discomfort, pain, and edema with mild intensity', 'CAL gain', 'radiographic angle', 'higher PPD reduction', 'intrabony defect morphology, radiographic defect depth, and radiographic angle', 'bone/graft density', 'MPM sites', 'clinical and radiographic parameters']","[{'cui': 'C0031106', 'cui_str': 'Periodontitis, Prepubertal'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0243067', 'cui_str': 'defects'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C1742123', 'cui_str': '(11C)MPM'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0085147', 'cui_str': 'Guided Tissue Regeneration'}]","[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C1742123', 'cui_str': '(11C)MPM'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",15.0,0.16003,"Multivariate analysis demonstrated that morphology of intrabony defects was a predictor of CAL gain (p = 0.06), while independent prognostic variables effecting changes in bone/graft density were radiographic defect depth (p = 0.025) and radiographic angle (p = 0.033).","[{'ForeName': 'Bartłomiej', 'Initials': 'B', 'LastName': 'Górski', 'Affiliation': 'Department of Periodontology and Oral Mucosa Diseases, Medical Unversity of Warsaw, Miodowa St 18, 00-246, Warsaw, Poland. bartek_g3@tlen.pl.'}, {'ForeName': 'Stanisław', 'Initials': 'S', 'LastName': 'Jalowski', 'Affiliation': 'Department of Dental and Maxillofacial Radiology, Medical University of Warsaw, Nowogrodzka St 59, 02-006, Warsaw, Poland.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Górska', 'Affiliation': 'Department of Periodontology and Oral Mucosa Diseases, Medical Unversity of Warsaw, Miodowa St 18, 00-246, Warsaw, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Zaremba', 'Affiliation': 'Department of Periodontology and Oral Mucosa Diseases, Medical Unversity of Warsaw, Miodowa St 18, 00-246, Warsaw, Poland.'}]",Clinical oral investigations,['10.1007/s00784-018-2712-7'] 796,31896121,Plasma ammonia concentrations in extremely low birthweight infants in the first week after birth: secondary analysis from the ProVIDe randomized clinical trial.,"BACKGROUND Little is known about normative ammonia concentrations in extremely low birthweight (ELBW) babies and whether these vary with birth characteristics. We aimed to determine ammonia concentrations in ELBW babies in the first week after birth and relationships with neonatal characteristics and protein intake. METHODS Arterial blood samples for the measurement of plasma ammonia concentration were collected within 7 days of birth from ProVIDe trial participants in six New Zealand neonatal intensive care units. RESULTS Three hundred and twenty-two babies were included. Median (range) gestational age was 25.7 (22.7-31.6) weeks. Median (interquartile range (IQR)) ammonia concentration was 102 (80-131) µg/dL. There were no statistically significant associations between ammonia concentrations and birthweight or sex. Ammonia concentrations were weakly correlated with mean total (Spearman's r s  = 0.11, P = 0.047) and intravenous (r s  = 0.13, P = 0.02) protein intake from birth, gestational age at birth (r s  = -0.13, P = 0.02) and postnatal age (r s  = -0.13, P = 0.02). CONCLUSIONS Plasma ammonia concentrations in ELBW babies are similar to those of larger and more mature babies and only weakly correlated with protein intake. Currently, recommended thresholds for investigation of hyperammonaemia are appropriate for ELBW babies. Protein intake should not be limited by concerns about potential hyperammonaemia.",2020,ammonia concentration was 102 (80-131) µg/dL. There were no statistically significant associations between ammonia concentrations and birthweight or sex.,"['extremely low birthweight infants', 'Three hundred and twenty-two babies were included', 'trial participants in\xa0six New Zealand neonatal intensive care units']",[],"['ammonia concentration', 'Plasma ammonia concentrations', 'Median (interquartile range (IQR', 'plasma ammonia concentration', 'Ammonia concentrations', 'ammonia concentrations and birthweight or sex']","[{'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4517712', 'cui_str': 'Three hundred and twenty-two'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}]",[],"[{'cui': 'C0002607', 'cui_str': 'Ammonia'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}]",,0.184577,ammonia concentration was 102 (80-131) µg/dL. There were no statistically significant associations between ammonia concentrations and birthweight or sex.,"[{'ForeName': 'Barbara E', 'Initials': 'BE', 'LastName': 'Cormack', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Yannan', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Jane E', 'Initials': 'JE', 'LastName': 'Harding', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Crowther', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Lynn', 'Affiliation': ""Neonatal Intensive Care Unit, Christchurch Women's Hospital, Christchurch, New Zealand.""}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Nair', 'Affiliation': 'Newborn Intensive Care Unit, Waikato Hospital, Hamilton, New Zealand.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hewson', 'Affiliation': 'Neonatal Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Meyer', 'Affiliation': 'Neonatal Unit, Middlemore Hospital, Auckland, New Zealand.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Broadbent', 'Affiliation': 'Neonatal Intensive Care Unit, Dunedin Hospital, Dunedin, New Zealand.'}, {'ForeName': 'Dianne', 'Initials': 'D', 'LastName': 'Webster', 'Affiliation': 'LabPlus, Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Glamuzina', 'Affiliation': 'National Adult and Paediatric Metabolic Service, Auckland, New Zealand.'}, {'ForeName': 'Bryony', 'Initials': 'B', 'LastName': 'Ryder', 'Affiliation': 'National Adult and Paediatric Metabolic Service, Auckland, New Zealand.'}, {'ForeName': 'Frank H', 'Initials': 'FH', 'LastName': 'Bloomfield', 'Affiliation': 'Liggins Institute, University of Auckland, Auckland, New Zealand. f.bloomfield@auckland.ac.nz.'}]",Pediatric research,['10.1038/s41390-019-0730-z'] 797,31879076,"An outpatient nursing nutritional intervention to prehabilitate undernourished patients planned for surgery: A multicentre, cluster-randomised pilot study.","BACKGROUND & AIMS To improve the nutritional status of surgical patients before hospital admission, an Outpatient Nursing Nutritional Intervention (ONNI) was developed. The ONNI comprehends five components: determining causes of undernutrition, performing a nutritional care plan including tailored and general advice, self-monitoring of nutritional intake and eating patterns, counselling and encouragement, and conducting a follow-up telephone call to discuss improvements in nutritional behaviour. Here, we evaluate the feasibility and effectiveness of the ONNI. METHODS In a multi-centred, cluster-randomised pilot study, nurses from outpatient clinics were randomly allocated to usual care (UC) or the ONNI. Patients planned for elective surgery were included if they were at increased risk for undernutrition based on the Malnutrition Universal Screening Tool (MUST) and hospital admission was not planned within seven days. Feasibility outcomes included participation rate, extent of intervention delivery, and patient satisfaction. Nutritional intake was monitored for two days before admission. Body weight, BMI and MUST scores at hospital admission were compared to measurements from the outpatient clinic visit. Data were analysed on an intention-to-treat basis by researchers who were blinded for patients and caregivers. RESULTS Forty-eight patients enrolled the feasibility phase. Participation rate was 72%. Nurses delivered all intervention components adequately in the end of the implementation period. Finally, 152 patients (IG: n = 66, 43%) participated in the study. A significant difference in mean energy intake (870 kcal/d, 95%CI:630-1109 p < 0.000) and mean protein intake (34.1 g/d, 95%CI: 25.0-43.2; p < 0.000) was observed in favour of the IG. Nutritional energy requirements were achieved in 74% (n = 46) of the IG and in 17% (n = 13) of the UC group (p < 0.000), and protein requirements were achieved in 52% (n = 32) of the IG, compared to 8% (n = 6) of the UC group (p < 0.000). Body weight, BMI and MUST scores did not change in either group. CONCLUSIONS The ONNI is a feasible and effective intervention tool for nurses at outpatient clinics. Patients in the IG had more nutritional intake and fulfilled nutritional requirements significantly more often than patients receiving UC. Further research is required to determine the optimal pre-operative timing of nutritional support and to measure its effect on other patients groups. CLINICAL TRIAL REGISTRATION The study protocol was registered at the ClinicalTrial.gov website with the following identifier: NCT02440165.",2020,"A significant difference in mean energy intake (870 kcal/d, 95%CI:630-1109","['prehabilitate undernourished patients planned for surgery', 'nurses from outpatient clinics', 'Forty-eight patients enrolled the feasibility phase', 'nurses at outpatient clinics', 'Patients planned for elective surgery were included if they were at increased risk for undernutrition based on the Malnutrition Universal Screening Tool (MUST) and hospital admission was not planned within seven days', 'n\xa0=\xa013) of the UC group ', '152 patients (IG: n\xa0=\xa066, 43%) participated in the study']","['Outpatient Nursing Nutritional Intervention (ONNI', 'outpatient nursing nutritional intervention', 'usual care (UC) or the ONNI']","['protein requirements', 'mean energy intake', 'Body weight, BMI and MUST scores at hospital admission', 'Nutritional intake', 'Body weight, BMI and MUST scores', 'nutritional intake and fulfilled nutritional requirements', 'Nutritional energy requirements', 'Participation rate', 'mean protein intake', 'participation rate, extent of intervention delivery, and patient satisfaction']","[{'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1532006', 'cui_str': 'Malnutrition universal screening tool (assessment scale)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}]","[{'cui': 'C0556043', 'cui_str': 'Protein requirement (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0028719', 'cui_str': 'Nutrition Requirements'}, {'cui': 'C0489460', 'cui_str': 'Energy requirement (observable entity)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439792', 'cui_str': 'Extents (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",152.0,0.0608191,"A significant difference in mean energy intake (870 kcal/d, 95%CI:630-1109","[{'ForeName': 'Harm H J', 'Initials': 'HHJ', 'LastName': 'van Noort', 'Affiliation': 'Department of Nutrition, Physical Activity and Sports, Department of Surgery, Gelderse Vallei Hospital, Ede, the Netherlands; Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands. Electronic address: Harm.vanNoort@radboudumc.nl.'}, {'ForeName': 'Ben J M', 'Initials': 'BJM', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, the Netherlands; Division of Human Nutrition, Wageningen University, Wageningen, the Netherlands. Electronic address: ben.witteman@wur.nl.'}, {'ForeName': 'Hester', 'Initials': 'H', 'LastName': 'Vermeulen', 'Affiliation': 'Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands; Faculty of Health and Social Studies, HAN University of Applied Sciences, Nijmegen, the Netherlands. Electronic address: Hester.Vermeulen@radboudumc.nl.'}, {'ForeName': 'Getty', 'Initials': 'G', 'LastName': 'Huisman-de Waal', 'Affiliation': 'Radboud University Medical Centre, Radboud Institute for Health Sciences, IQ Healthcare, Nijmegen, the Netherlands. Electronic address: Getty.Huisman-deWaal@radboudumc.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.11.038'] 798,31836196,"Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial.","BACKGROUND Irbesartan, a long acting selective angiotensin-1 receptor inhibitor, in Marfan syndrome might reduce aortic dilatation, which is associated with dissection and rupture. We aimed to determine the effects of irbesartan on the rate of aortic dilatation in children and adults with Marfan syndrome. METHODS We did a placebo-controlled, double-blind randomised trial at 22 centres in the UK. Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion. Study participants were all given 75 mg open label irbesartan once daily, then randomly assigned to 150 mg of irbesartan (increased to 300 mg as tolerated) or matching placebo. Aortic diameter was measured by echocardiography at baseline and then annually. All images were analysed by a core laboratory blinded to treatment allocation. The primary endpoint was the rate of aortic root dilatation. This trial is registered with ISRCTN, number ISRCTN90011794. FINDINGS Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or placebo (n=88), and all were followed for up to 5 years. Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers. Mean baseline aortic root diameter was 34·4 mm in the irbesartan group (SD 5·8) and placebo group (5·5). The mean rate of aortic root dilatation was 0·53 mm per year (95% CI 0·39 to 0·67) in the irbesartan group compared with 0·74 mm per year (0·60 to 0·89) in the placebo group, with a difference in means of -0·22 mm per year (-0·41 to -0·02, p=0·030). The rate of change in aortic Z score was also reduced by irbesartan (difference in means -0·10 per year, 95% CI -0·19 to -0·01, p=0·035). Irbesartan was well tolerated with no observed differences in rates of serious adverse events. INTERPRETATION Irbesartan is associated with a reduction in the rate of aortic dilatation in children and young adults with Marfan syndrome and could reduce the incidence of aortic complications. FUNDING British Heart Foundation, the UK Marfan Trust, the UK Marfan Association.",2019,"Irbesartan was well tolerated with no observed differences in rates of serious adverse events. ","['Median age at recruitment was 18 years (IQR 12-28), 99 (52%) were female, mean blood pressure was 110/65 mm Hg (SDs 16 and 12), and 108 (56%) were taking β blockers', 'Between March 14, 2012, and May 1, 2015, 192 participants were recruited and randomly assigned to irbesartan (n=104) or', 'Individuals aged 6-40 years with clinically confirmed Marfan syndrome were eligible for inclusion', 'children and young adults with Marfan syndrome', 'children and adults with Marfan syndrome', '22 centres in the UK']","['placebo', 'irbesartan']","['rate of change in aortic Z score', 'mean rate of aortic root dilatation', 'Aortic diameter', 'rate of aortic root dilatation', 'rate of aortic dilatation', 'Mean baseline aortic root diameter']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0288171', 'cui_str': 'irbesartan'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0024796', 'cui_str': 'Marfan Syndrome, Type I'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0288171', 'cui_str': 'irbesartan'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0238669', 'cui_str': 'Aortic root dilatation (disorder)'}, {'cui': 'C0579133', 'cui_str': 'Aortic diameter (observable entity)'}, {'cui': 'C0265004', 'cui_str': 'Dilatation of aorta (disorder)'}, {'cui': 'C0549113', 'cui_str': 'Supraaortic valve area structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}]",192.0,0.763642,"Irbesartan was well tolerated with no observed differences in rates of serious adverse events. ","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mullen', 'Affiliation': 'Barts Heart Centre, Barts Health NHS Trust, London, UK; Department of Cardiovascular Medicine and Devices, Queen Mary University, London, UK.'}, {'ForeName': 'Xu Yu', 'Initials': 'XY', 'LastName': 'Jin', 'Affiliation': 'Core Echo Lab, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Child', 'Affiliation': ""Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'A Graham', 'Initials': 'AG', 'LastName': 'Stuart', 'Affiliation': 'Heart Institute, University of Bristol, Bristol, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Dodd', 'Affiliation': 'Clinical Trials Unit, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'Aragon-Martin', 'Affiliation': ""Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gaze', 'Affiliation': 'Department of Life Sciences, University of Westminster, London UK.'}, {'ForeName': 'Anatoli', 'Initials': 'A', 'LastName': 'Kiotsekoglou', 'Affiliation': 'Core Echo Lab, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; School of Medical Sciences, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Yuan', 'Affiliation': ""Core Echo Lab, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Ultrasound Department, Wuhan Children's Hospital, Tongji Medical School, Huazhong University of Science and Technology, Hubei, China.""}, {'ForeName': 'Jiangting', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Core Echo Lab, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Heart Centre, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Foley', 'Affiliation': 'NHS Blood and Transplant, Cambridge, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Van Dyck', 'Affiliation': 'Clinical Trials Unit, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Rosemary', 'Initials': 'R', 'LastName': 'Knight', 'Affiliation': 'Clinical Trials Unit, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Clayton', 'Affiliation': 'Clinical Trials Unit, Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Swan', 'Affiliation': 'Department of Adult Congenital Heart Disease, Royal Brompton and Harefield NHS Foundation Trust, London, UK; Toronto Congenital Cardiac Centre for Adults, Toronto, Canada.'}, {'ForeName': 'John D R', 'Initials': 'JDR', 'LastName': 'Thomson', 'Affiliation': 'Department of Cardiology, Leeds General Infirmary, Leeds, UK.'}, {'ForeName': 'Guliz', 'Initials': 'G', 'LastName': 'Erdem', 'Affiliation': 'Department of Cardiology, Acibadem International Hospital Istanbul, Turkey; School of Medicine, Acibadem University, Istanbul, Turkey.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Crossman', 'Affiliation': 'School of Medicine, University of St Andrews, St Andrews, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Flather', 'Affiliation': 'Norwich Medical School, University of East Anglia, Norfolk, Norwich, UK; Cardiology Department, Norfolk and Norwich University Hospital, Norwich, UK. Electronic address: m.flather@uea.ac.uk.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)32518-8'] 799,31829100,Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study.,"RATIONALE Specialized pro-resolving mediators (SPM-lipoxins, resolvins, protectins, and maresins) are produced via the enzymatic conversion of essential fatty acids, including the omega-3 fatty acids docosahexaenoic acid and n-3 docosapentaenoic acid. These mediators exert potent leukocyte directed actions and control vascular inflammation. Supplementation of animals and humans with essential fatty acids, in particular omega-3 fatty acids, exerts protective actions reducing vascular and systemic inflammation. Of note, the mechanism(s) activated by these supplements in exerting their protective actions remain poorly understood. OBJECTIVE Given that essential fatty acids are precursors in the biosynthesises of SPM, the aim of the present study was to establish the relationship between supplementation and peripheral SPM concentrations. We also investigated the relationship between changes in plasma SPM concentrations and peripheral blood platelet and leukocyte responses. METHODS AND RESULTS Healthy volunteers were enrolled in a double-blinded, placebo-controlled, crossover study, and peripheral blood was collected at baseline, 2, 4, 6, and 24 hours post administration of placebo or one of 3 doses of an enriched marine oil supplement. Assessment of plasma SPM concentrations using lipid mediator profiling demonstrated a time- and dose-dependent increase in peripheral blood SPM concentration. Supplementation also led to a regulation of peripheral blood cell responses. Here we found a dose-dependent increase in neutrophil and monocyte phagocytosis of bacteria and a decrease in the diurnal activation of leukocytes and platelets, as measured by a reduction in adhesion molecule expression. In addition, transcriptomic analysis of peripheral blood cells demonstrated a marked change in transcript levels of immune and metabolic genes 24 hours post supplementation when compared with placebo. CONCLUSIONS Together, these findings demonstrate that supplementation with an enriched marine oil leads to an increase in peripheral blood SPM concentrations and reprograms peripheral blood cells, indicating a role for SPM in mediating the immune-directed actions of this supplement. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT03347006.",2020,Assessment of plasma SPM concentrations using lipid mediator profiling demonstrated a time- and dose-dependent increase in peripheral blood SPM concentration.,['Healthy volunteers'],"['Enriched Marine Oil Supplements', 'placebo or one of 3 doses of an enriched marine oil supplement', 'Placebo', 'placebo']","['neutrophil and monocyte phagocytosis of bacteria', 'peripheral blood cell responses', 'Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses', 'transcript levels of immune and metabolic genes', 'peripheral blood SPM concentrations', 'peripheral blood SPM concentration', 'plasma SPM concentrations and peripheral blood platelet and leukocyte responses', 'diurnal activation of leukocytes and platelets']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0524645', 'cui_str': 'Marines'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C1510439', 'cui_str': 'bacteria'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1704211', 'cui_str': 'Specialized'}, {'cui': 'C3714811', 'cui_str': 'Resolved (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0301872', 'cui_str': 'Immune response, function (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0023516', 'cui_str': 'Blood Corpuscles, White'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}]",,0.237696,Assessment of plasma SPM concentrations using lipid mediator profiling demonstrated a time- and dose-dependent increase in peripheral blood SPM concentration.,"[{'ForeName': 'Patricia R', 'Initials': 'PR', 'LastName': 'Souza', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Raquel M', 'Initials': 'RM', 'LastName': 'Marques', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Esteban A', 'Initials': 'EA', 'LastName': 'Gomez', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Romain A', 'Initials': 'RA', 'LastName': 'Colas', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'De Matteis', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zak', 'Affiliation': 'Clinical Research Centre & the NIHR Biomedical Research Centre at Barts (A.Z., M.P., D.J.C.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Mital', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'Clinical Research Centre & the NIHR Biomedical Research Centre at Barts (A.Z., M.P., D.J.C.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Collier', 'Affiliation': 'Clinical Research Centre & the NIHR Biomedical Research Centre at Barts (A.Z., M.P., D.J.C.), Charterhouse Square, Queen Mary University of London, UK.'}, {'ForeName': 'Jesmond', 'Initials': 'J', 'LastName': 'Dalli', 'Affiliation': 'From the Barts and The London School of Medicine and Dentistry (P.R.S., R.M.M., E.A.G., R.A.C., R.D.M., J.D.), Charterhouse Square, Queen Mary University of London, UK.'}]",Circulation research,['10.1161/CIRCRESAHA.119.315506'] 800,31909725,Efficacy of a Self-Help Web-Based Recovery Training in Improving Sleep in Workers: Randomized Controlled Trial in the General Working Population.,"BACKGROUND Sleep complaints are among the most prevalent health concerns, especially among workers, which may lead to adverse effects on health and work. Internet-delivered cognitive behavioral therapy for insomnia (iCBT-I) offers the opportunity to deliver effective solutions on a large scale. The efficacy of iCBT-I for clinical samples has been demonstrated in recent meta-analyses, and there is evidence that iCBT-I is effective in the working population with severe sleep complaints. However, to date, there is limited evidence from randomized controlled trials that iCBT-I could also be an effective tool for universal prevention among the general working population regardless of symptom severity. Although increasing evidence suggests that negatively toned cognitive activity may be a key factor for the development and maintenance of insomnia, little is known about how iCBT-I improves sleep by reducing presleep cognitive activity. OBJECTIVE This study aimed to examine the efficacy of a self-help internet-delivered recovery training, based on principles of iCBT-I tailored to the work-life domain, among the general working population. General and work-related cognitive activities were investigated as potential mediators of the intervention's effect. METHODS A sample of 177 workers were randomized to receive either the iCBT-I (n=88) or controls (n=89). The intervention is a Web-based training consisting of six 1-week modules. As the training was self-help, participants received nothing but technical support via email. Web-based self-report assessments were scheduled at baseline, at 8 weeks, and at 6 months following randomization. The primary outcome was insomnia severity. Secondary outcomes included measures of mental health and work-related health and cognitive activity. In an exploratory analysis, general and work-related cognitive activities, measured as worry and work-related rumination, were investigated as mediators. RESULTS Analysis of the linear mixed effects model showed that, relative to controls, participants who received iCBT-I reported significantly lower insomnia severity scores at postintervention (between-group mean difference -4.36; 95% CI -5.59 to - 3.03; Cohen d=0.97) and at 6-month follow-up (between-group difference: -3.64; 95% CI -4.89 to -2.39; Cohen d=0.86). The overall test of group-by-time interaction was significant (P<.001). Significant differences, with small-to-large effect sizes, were also detected for cognitive activity and for mental and work-related health, but not for absenteeism. Mediation analysis demonstrated that work-related rumination (indirect effect: a 1 b 1 =-0.80; SE=0.34; 95% boot CI -1.59 to -0.25) and worry (indirect effect: a 2 b 2 =-0.37; SE=0.19; 95% boot CI -0.85 to -0.09) mediate the intervention's effect on sleep. CONCLUSIONS A self-help Web-based recovery training, grounded in the principles of iCBT-I, can be effective in the general working population, both short and long term. Work-related rumination may be a particularly crucial mediator of the intervention's effect, suggesting that tailoring interventions to the workplace, including components to reduce the work-related cognitive activity, might be important when designing recovery interventions for workers. TRIAL REGISTRATION German Clinical Trials Register DRKS00007142; https://www.drks.de/DRKS00007142.",2020,"Significant differences, with small-to-large effect sizes, were also detected for cognitive activity and for mental and work-related health, but not for absenteeism.","['Workers', 'working population with severe sleep complaints', 'A sample of 177 workers']","['iCBT', 'self-help internet-delivered recovery training', 'Self-Help Web-Based Recovery Training', 'Internet-delivered cognitive behavioral therapy']","['cognitive activity and for mental and work-related health', 'insomnia severity', 'measures of mental health and work-related health and cognitive activity', 'insomnia severity scores']","[{'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}]",177.0,0.144009,"Significant differences, with small-to-large effect sizes, were also detected for cognitive activity and for mental and work-related health, but not for absenteeism.","[{'ForeName': 'Doerte', 'Initials': 'D', 'LastName': 'Behrendt', 'Affiliation': 'Department of Health Psychology and Applied Biological Psychology, Institute of Psychology, Leuphana University of Lueneburg, Lueneburg, Germany.'}, {'ForeName': 'David Daniel', 'Initials': 'DD', 'LastName': 'Ebert', 'Affiliation': 'Faculty of Behavioural and Movement Sciences, Clinical, Neuro- & Developmental Psychology, Free University Amsterdam, Amsterdam, Germany.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Spiegelhalder', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Lehr', 'Affiliation': 'Department of Health Psychology and Applied Biological Psychology, Institute of Psychology, Leuphana University of Lueneburg, Lueneburg, Germany.'}]",Journal of medical Internet research,['10.2196/13346'] 801,31672681,Prevention of Fascial Dehiscence with Onlay Prophylactic Mesh in Emergency Laparotomy: A Randomized Clinical Trial.,"BACKGROUND Fascial dehiscence (FD) occurs in up to 14.9% of high-risk patients undergoing emergency laparotomy. Although prophylactic mesh can prevent FD, its use in emergency operations remains controversial. STUDY DESIGN A prospective randomized clinical trial was conducted at the Hospital das Clínicas from Faculdade de Medicina da Universidade de São Paulo in Brazil. It was performed among high-risk patients, defined according to Rotterdam risk model, undergoing midline emergency laparotomy. The patients were randomized into the suture group (SG), with slowly absorbable running sutures placed with a 36-mm-long needle at a suture-to-wound length ratio of 4:1, and the prophylactic mesh group (PMG), with fascial closure as in the SG but reinforced with onlay polypropylene mesh. The primary end point was incidence of FD at 30 days post operation. RESULTS We analyzed 115 patients; 52 and 63 were allocated to the SG and PMG, respectively. In all, 77.4% of the cases were for colorectal resection. FD occurred in 7 (13.5%) patients in the SG and none in the PMG (p = 0.003). There was no difference between the groups in number of patients with surgical site occurrence (SSO) or SSO requiring procedural intervention. However, some specific SSOs had higher incidences in the mesh group: surgical site infection (20.6% versus 7.7%; p = 0.05), seroma (19.0% versus 5.8%; p = 0.03), and nonhealing incisional wound (23.8% versus 5.8%; p = 0.008). Of SSOs in the PMG and SG, 92.3% and 73.3%, respectively, resolved spontaneously or with bedside interventions. CONCLUSIONS Prophylactic onlay mesh reinforcement in emergency laparotomy is safe and prevents FD. Surgical site infection, seroma, and nonhealing incisional wound were more common in the mesh group, but associated with low morbidity within 30 days post operation.",2020,There was no difference between the groups regarding the number of patients with surgical site occurrence (SSO) or SSO requiring procedural intervention.,"['Emergency Laparotomy', 'Hospital das Clínicas from Faculdade de Medicina da Universidade de São Paulo in Brazil', '115 patients; 52 and 63']","['suture group (SG), with slowly absorbable running sutures placed with a 36-mm-long needle at a suture-to-wound length ratio of 4:1, and the prophylactic mesh group (PMG), with fascial closure as in the SG but reinforced with onlay polypropylene mesh', 'Fascial Dehiscence with Onlay Prophylactic Mesh']","['incidence of FD', 'nonhealing incisional wound', 'seroma', 'FD', 'surgical site infection', 'Surgical site infection, seroma and nonhealing incisional wound', 'low morbidity', 'number of patients with surgical site occurrence (SSO']","[{'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}, {'cui': 'C0023038', 'cui_str': 'Laparotomy'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C4517540', 'cui_str': '115 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0181805', 'cui_str': 'Mesh (physical object)'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0677511', 'cui_str': 'Onlay (qualifier value)'}, {'cui': 'C1321585', 'cui_str': 'Polypropylene mesh (physical object)'}, {'cui': 'C0149663', 'cui_str': 'Dehiscence (morphologic abnormality)'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0038941', 'cui_str': 'Postoperative Wound Infection'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}]",115.0,0.0552562,There was no difference between the groups regarding the number of patients with surgical site occurrence (SSO) or SSO requiring procedural intervention.,"[{'ForeName': 'Helber V G', 'Initials': 'HVG', 'LastName': 'Lima', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil. Electronic address: helber.vidal@hc.fm.usp.br.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Rasslan', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Fernando C F', 'Initials': 'FCF', 'LastName': 'Novo', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Tibério M A', 'Initials': 'TMA', 'LastName': 'Lima', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Sérgio H B', 'Initials': 'SHB', 'LastName': 'Damous', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Celso O', 'Initials': 'CO', 'LastName': 'Bernini', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edna F S', 'Initials': 'EFS', 'LastName': 'Montero', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edivaldo M', 'Initials': 'EM', 'LastName': 'Utiyama', 'Affiliation': 'Department of Surgery, Discipline of General Surgery and Trauma, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil.'}]",Journal of the American College of Surgeons,['10.1016/j.jamcollsurg.2019.09.010'] 802,31759229,Devaluation of threat memory using a dual-task intervention does not reduce context renewal of fear.,"Many patients who benefit from exposure-based therapy for anxiety disorders fail to maintain their gains. Learned fear may return when they encounter phobic stimuli in a different context than the one in which extinction occurred. In the current pre-registered experiment, we tested whether threat memory devaluation reduces context renewal of fear. A dual-task intervention was used to devalue threat memory. During this intervention, individuals recall the threat memory while simultaneously performing a demanding secondary task (e.g., making eye movements). On day 1, participants (N = 75) underwent fear acquisition with an aversive film clip in context A. On day 2, 25 participants were assigned to each group, namely a dual-task group, or one of two control groups: recall only task (without the dual-task) or no intervention. Afterwards, all participants underwent extinction training in context B and were then exposed to context A again in a test phase. The dual-task intervention effectively degraded threat memory compared to no intervention, but the recall only intervention was also partly effective. However, all three groups showed comparable fear renewal on subjective and physiological measures. This indicates that threat memory devaluation was not effective to prevent context renewal.",2020,"The dual-task intervention effectively degraded threat memory compared to no intervention, but the recall only intervention was also partly effective.",[],"['extinction training', 'fear acquisition with an aversive film clip in context A', 'dual-task group, or one of two control groups: recall only task (without the dual-task) or no intervention', 'dual-task intervention']",[],[],"[{'cui': 'C0015347', 'cui_str': 'Extinction (Psychology)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C4319646', 'cui_str': 'Film'}, {'cui': 'C0175722', 'cui_str': 'Clip'}, {'cui': 'C0449255', 'cui_str': 'Context (attribute)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],25.0,0.0142567,"The dual-task intervention effectively degraded threat memory compared to no intervention, but the recall only intervention was also partly effective.","[{'ForeName': 'Elze', 'Initials': 'E', 'LastName': 'Landkroon', 'Affiliation': 'Department of Clinical Psychology, Utrecht University, Utrecht, the Netherlands. Electronic address: e.landkroon@uu.nl.'}, {'ForeName': 'Gaëtan', 'Initials': 'G', 'LastName': 'Mertens', 'Affiliation': 'Department of Clinical Psychology, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Iris M', 'Initials': 'IM', 'LastName': 'Engelhard', 'Affiliation': 'Department of Clinical Psychology, Utrecht University, Utrecht, the Netherlands.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103480'] 803,31264494,Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.,"Objectives: The aim of this prospective study was to evaluate the home monitoring with a rapid fecal calprotectin test combined with a symptom questionnaire in patients with colonic IBD in real-life setting. Methods: We randomized 180 patients with colonic IBD in a study or a control group. The home monitoring patients performed the fecal calprotectin test and filled in a symptom questionnaire every second month and in cases with increasing symptoms. The control patients filled in the symptom questionnaire at baseline and at 6 and 12 months as well as for the appointment at the outpatient clinic. The study duration was 12 months. Results: The patient adherence to the self-monitoring program was low. Patients with a higher disease burden were more adherent than patients with better health-related quality of life, but otherwise, there were no significant factors predicting the adherence. The home monitoring patients had fewer contacts with the outpatient clinic, but otherwise, the disease course between the home monitoring and the control group were similar. Conclusions: The self-monitoring of IBD activity with a combination of a rapid fecal calprotectin home test and a symptom questionnaire provides an option for individualized care for IBD patients. However, adherence to the self-monitoring program remains a challenge.",2019,"Patients with a higher disease burden were more adherent than patients with better health-related quality of life, but otherwise, there were no significant factors predicting the adherence.","['patients with colonic IBD in real-life setting', '180 patients with colonic IBD in a study or a control group', 'IBD patients']",['rapid fecal calprotectin test combined with a symptom questionnaire'],"['fecal calprotectin test', 'quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory Bowel Diseases'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0034380'}]",180.0,0.0177075,"Patients with a higher disease burden were more adherent than patients with better health-related quality of life, but otherwise, there were no significant factors predicting the adherence.","[{'ForeName': 'Anna-Maija', 'Initials': 'AM', 'LastName': 'Puolanne', 'Affiliation': 'Clinic of Gastroenterology, Helsinki University Hospital, Jorvi Hospital , Espoo , Finland.'}, {'ForeName': 'Kaija-Leena', 'Initials': 'KL', 'LastName': 'Kolho', 'Affiliation': 'University of Helsinki and Helsinki University Hospital , Helsinki , Finland.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Alfthan', 'Affiliation': 'Department of Clinical Chemistry, University of Helsinki , Helsinki , Finland.'}, {'ForeName': 'Martti', 'Initials': 'M', 'LastName': 'Färkkilä', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Helsinki University Hospital , Helsinki , Finland.'}]",Scandinavian journal of gastroenterology,['10.1080/00365521.2019.1618910'] 804,31815641,COMMENCE trial (Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry): a randomized controlled trial of mild vs moderate hypothermia on patient outcomes in aortic hemiarch surgery with anterograde cerebral perfusion.,"BACKGROUND Aortic arch surgery remains the only viable life-saving treatment for aortic arch disease. However, the necessity for cessation of systemic blood flow with hypothermic cardiac arrest carries substantial risk of morbidity and mortality, including poor neurological outcomes and kidney failure. While uncontrolled studies have suggested the safety of operating at warmer temperatures, significant variables remain un-investigated, supporting the need for a randomized clinical trial (RCT) to produce evidence-based guidelines for perfusion strategies in aortic surgery. This study proposes a multi-center RCT in order to compare outcomes of warmer hypothermic strategies during aortic hemiarch surgery on a composite endpoint of neurologic and acute kidney injury (AKI). METHODS/DESIGN This is a prospective multi-center, single-blind two-arm RCT comparing mild (32 °C) versus moderate (26 °C) hypothermic cardiac arrest in patients (n = 282) undergoing hemiarch surgery with antegrade cerebral perfusion (ACP). The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI. Secondary outcomes include death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures. Patients will undergo 1:1 block randomization to each treatment arm on day of surgery. Sequence of operation will be at the surgeon's discretion with mandatory guidelines for temperature and ACP administration. Perioperative management will occur as per enrolling center standard of care. Neurocognitive function will be assessed for neurological injury using validated neurological screening tests: NIHSS, MOCA, BI, and MRS throughout patient follow-up. Diagnosis and classification of AKI will be based on rising creatinine values as per the KDIGO criteria. Study duration for each patient will be 60 ± 14 days. DISCUSSION It is hoped that performing hemiarch surgery using mild hypothermia (32 °C) and selective ACP will result in a 15% absolute risk reduction in the composite outcomes. The potential of this risk reduction will translate into improved patient outcomes, survival, and long-term financial savings to the health care system. In addition, the results of this trial will be used to create the first-ever guidelines for temperature management strategy during aortic surgery. TRIAL REGISTRATION This trial is registered on ClinicalTrials.gov with the registration number NCT02860364. Registration date August 9th, 2016.",2019,The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI.,"['comparing mild (32\u2009°C) versus moderate (26\u2009°C) hypothermic cardiac arrest in patients (n\u2009=\u2009282) undergoing', 'aortic hemiarch surgery with anterograde cerebral perfusion', 'hemiarCh surgEry']","['hemiarch surgery with antegrade cerebral perfusion (ACP', 'mild vs moderate hypothermia', 'RCT']","['composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI', 'death, cardiopulmonary bypass time, bleeding, transfusion rates, prolonged mechanical ventilation, myocardial infarction, length of stay, and quality of life measures', 'Neurocognitive function']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0018790', 'cui_str': 'Cardiac Arrest'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517681', 'cui_str': '282'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0589502', 'cui_str': 'Antegrade direction (qualifier value)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0677513', 'cui_str': 'Antegrade (qualifier value)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0445045', 'cui_str': 'Moderate hypothermia (qualifier value)'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0751792', 'cui_str': 'Injuries, Nervous System'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0429123', 'cui_str': 'Cardiopulmonary bypass time (observable entity)'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.153665,The primary endpoint is a composite of neurological injury (incidence of transient ischemic attack and/or stroke) and Kidney Disease Improving Global Outcomes (KDIGO) stage 1 or higher AKI.,"[{'ForeName': 'Habib', 'Initials': 'H', 'LastName': 'Jabagi', 'Affiliation': 'Divisions of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Room H-34058A, Ottawa, ON, K1Y 4W7, Canada. hjabagi@ottawaheart.ca.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Wells', 'Affiliation': 'Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, K1Y 4W7, Canada.'}, {'ForeName': 'Munir', 'Initials': 'M', 'LastName': 'Boodhwani', 'Affiliation': 'Divisions of Cardiac Surgery, University of Ottawa Heart Institute, 40 Ruskin Street, Room H-34058A, Ottawa, ON, K1Y 4W7, Canada.'}]",Trials,['10.1186/s13063-019-3713-9'] 805,31815643,"The effect of antibiotics on post-adenotonsillectomy morbidity in Tanzanian children: study protocol for a randomized, double-blind, placebo-controlled trial.","BACKGROUND Adenotonsillectomy is the most frequently performed operation in children worldwide. For decades, prophylactic antibiotics have been prescribed to limit postoperative complications. The effect of this antibiotic use has been refuted in a Cochrane Review. However, all reviewed studies were carried out in developed countries. In Tanzania, like many other developing countries with limited resources and a high burden of infectious diseases, postoperative antibiotic prescription is still very common to decrease the supposed higher postoperative morbidity. However, as a consequence of this widespread use of postoperative antibiotics, cross-resistance and risk of allergic side effects rise. Well-designed randomized controlled trials are needed to limit unnecessary antibiotic prescription and secondary antibiotic resistance. AIM The aim of this study is to analyse the prophylactic role of postoperative antibiotics on morbidity following adenotonsillectomy in children in Tanzania. DESIGN The double-blinded, randomized, placebo-controlled trial was set in northern Tanzania. Participating centres are the Department of Otolaryngology at Kilimanjaro Christian Medical Centre in Moshi and the Department of Paediatric Surgery at the Arusha Lutheran Medical Centre in Arusha. METHODS Around 270 children aged 2-14 years, all scheduled for elective (adeno)tonsillectomy, will be included and assigned to receive either a standard regimen of 5 days of antibiotic prophylaxis or placebo after surgery. The primary outcomes are postoperative haemorrhage, fever and pain. Secondary outcomes are the time until normal diet is resumed, the time until normal activities are resumed and the occurrence of adverse events and microbial recolonization of the tonsillar beds. DISCUSSION This study will enhance an increase of proper antimicrobial prescription in Tanzanian institutions as well as other resource-limited countries where prescription of antibiotics is still very common. In addition, it might augment current knowledge about surface and core tonsillar micro-organisms and sensitivity patterns. TRIAL REGISTRATION Pan African Clinical Trials Registry, PACTR201905466349317. Retrospectively registered on 15 May 2019. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8119.",2019,"In Tanzania, like many other developing countries with limited resources and a high burden of infectious diseases, postoperative antibiotic prescription is still very common to decrease the supposed higher postoperative morbidity.","['northern Tanzania', '270 children aged 2-14\u2009years, all scheduled for elective (adeno)tonsillectomy', 'Participating centres are the Department of Otolaryngology at Kilimanjaro Christian Medical Centre in Moshi and the Department of Paediatric Surgery at the Arusha Lutheran Medical Centre in Arusha', 'Tanzanian children', 'children in Tanzania']","['antibiotic prophylaxis or placebo', 'antibiotics', 'placebo']","['postoperative haemorrhage, fever and pain', 'morbidity', 'time until normal diet is resumed, the time until normal activities are resumed and the occurrence of adverse events and microbial recolonization of the tonsillar beds']","[{'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C4319603', 'cui_str': '270 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0040423', 'cui_str': 'Tonsillectomy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0029892', 'cui_str': 'Otorhinolaryngology'}, {'cui': 'C0344346', 'cui_str': 'Christian, follower of religion (person)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0279077', 'cui_str': 'Pediatric surgery'}, {'cui': 'C0337738', 'cui_str': 'Lutheran Church'}]","[{'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}]","[{'cui': 'C0032788', 'cui_str': 'Blood Loss, Postoperative'}, {'cui': 'C0015967', 'cui_str': 'Hyperthermia'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0184625', 'cui_str': 'Regular diet'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0004916', 'cui_str': 'Beds'}]",270.0,0.74906,"In Tanzania, like many other developing countries with limited resources and a high burden of infectious diseases, postoperative antibiotic prescription is still very common to decrease the supposed higher postoperative morbidity.","[{'ForeName': 'Denis R', 'Initials': 'DR', 'LastName': 'Katundu', 'Affiliation': 'Department of Otolaryngology, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania. katundu101@gmail.com.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Shija', 'Affiliation': 'Department of Otolaryngology, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania.'}, {'ForeName': 'Baltazari', 'Initials': 'B', 'LastName': 'Nyombi', 'Affiliation': 'Department of Microbiology, Kilimanjaro Christian Medical University College, Moshi, Tanzania.'}, {'ForeName': 'Hadija', 'Initials': 'H', 'LastName': 'Semvua', 'Affiliation': 'Department of Pharmacy, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.'}, {'ForeName': 'Fieke K', 'Initials': 'FK', 'LastName': 'Oussoren', 'Affiliation': 'Department of Otolaryngology, Head and Neck Surgery, Radboudumc, Nijmegen, The Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'van Heerbeek', 'Affiliation': 'Department of Otolaryngology, Kilimanjaro Christian Medical Centre, Kilimanjaro, Tanzania.'}]",Trials,['10.1186/s13063-019-3830-5'] 806,31785463,Randomised phase II trial of trofosfamide vs. doxorubicin in elderly patients with untreated metastatic soft-tissue sarcoma.,"Doxorubicin represents the standard first-line treatment for metastatic soft-tissue sarcoma. We assessed the efficacy and safety of trofosfamide in elderly patients. In this controlled phase II trial, we randomly (1:2) assigned 120 previously untreated patients with soft-tissue sarcoma, older than 60 years, with an Eastern Cooperative Oncology Group score of 0-2, to receive either doxorubicin for 6 cycles (arm A) or oral trofosfamide (arm B). The primary end-point was a 6-month progression-free rate (PFR) in the experimental arm (clinical trial information: NCT00204568). Between August 2004 and October 2012, forty and 80 patients were randomly assigned to arm A and arm B, respectively, in 16 centres. The median age was 70 years (range, 60-89). The primary study end-point (6-month PFR) was exceeded, with 27.6% in arm B (95% confidence interval [CI], 18.0-39.1) and 35.9% in arm A: (95% CI, 21.2-52.8). Survival data in terms of progression-free survival were 4.3 months (95% CI, 2.2-6.3) and 2.8 months (95% CI, 1.7-3.6) and in terms of overall survival were 9.8 months (95% CI, 6.7-11.6) and 12.3 months (95% CI, 9.6-16.2), respectively. The number of serious adverse event (SAE) was 59% in arm A and 30.3% in arm B (p = 0.005). Trofosfamide caused more often dyspnoea and low-grade fatigue, whereas with doxorubicin, more often leukocytopenia, neutropenia and mucositis were seen. Discontinuation rates for reasons other than disease progression were 15.4% (arm A) vs. 7.9% (arm B). In an elderly population of patients, oral trofosfamide achieved the estimated primary end-point 6-month PFR and was associated with a favourable toxicity profile compared with doxorubicin.",2020,The number of serious adverse event (SAE) was 59% in arm A and 30.3% in arm B (p = 0.005).,"['The median age was 70 years (range, 60-89', 'elderly patients with untreated metastatic soft-tissue sarcoma', '120 previously untreated patients with soft-tissue sarcoma, older than 60 years, with an Eastern Cooperative Oncology Group score of 0-2, to receive either', 'metastatic soft-tissue sarcoma', 'elderly patients', 'Between August 2004 and October 2012, forty and 80 patients']","['doxorubicin for 6 cycles (arm A) or oral trofosfamide', 'trofosfamide vs. doxorubicin', 'trofosfamide', 'Doxorubicin', 'Trofosfamide', 'doxorubicin']","['progression-free survival', 'dyspnoea and low-grade fatigue', 'efficacy and safety', 'favourable toxicity profile', 'overall survival', 'leukocytopenia, neutropenia and mucositis', '6-month\xa0progression-free rate (PFR', 'number of serious adverse event (SAE', 'Discontinuation rates', 'Survival data']","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4551687', 'cui_str': 'Sarcoma of soft tissue (disorder)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0077375', 'cui_str': 'trofosfamide'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0023530', 'cui_str': 'Leukocytopenia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0333355', 'cui_str': 'Mucositis'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0030735', 'cui_str': 'PEFR'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",120.0,0.0990203,The number of serious adverse event (SAE) was 59% in arm A and 30.3% in arm B (p = 0.005).,"[{'ForeName': 'Joerg T', 'Initials': 'JT', 'LastName': 'Hartmann', 'Affiliation': 'Franziskus Hospital Bielefeld, Catholic Hospital Consortium Eastern Westphalia, Bielefeld, Germany. Electronic address: joerg.hartmann@franziskus.de.'}, {'ForeName': 'Hans-G', 'Initials': 'HG', 'LastName': 'Kopp', 'Affiliation': 'Robert-Bosch Centrum für Tumorerkrankungen (RBCT), Stuttgart, Germany.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Gruenwald', 'Affiliation': 'University Hospital Essen, Internal Medicine (Tumor Research) and Clinic for Urology, Essen, Germany.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Piperno-Neumann', 'Affiliation': 'Medical Oncology Department, Institut Curie, Paris, France.'}, {'ForeName': 'Annegret', 'Initials': 'A', 'LastName': 'Kunitz', 'Affiliation': 'Vivantes Klinikum Spandau, Klinik für Innere Medizin, Hämatologie und Onkologie, Berlin, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Hofheinz', 'Affiliation': 'University Medical Center Mannheim, Mannheim, Germany.'}, {'ForeName': 'Lothar', 'Initials': 'L', 'LastName': 'Mueller', 'Affiliation': 'Onkologie UnterEms, Leer, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Geissler', 'Affiliation': 'Klinikum Esslingen, Department of Hematology/Oncology, Esslingen, Germany.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Horger', 'Affiliation': 'Diagnostic Radiology, Eberhard-Karls-University, Tuebingen, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fix', 'Affiliation': 'Klinikum Weimar, Onkologie, Hämatologie, Palliativmedizin, Weimar, Germany.'}, {'ForeName': 'Jens M', 'Initials': 'JM', 'LastName': 'Chemnitz', 'Affiliation': 'Gemeinschaftsklinikum Mittelrhein GGmbH, Koblenz, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Neise', 'Affiliation': 'Onkologische Schwerpunktpraxis, Krefeld, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wehler', 'Affiliation': 'Evangelisches Krankenhaus, Hamm, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Zander', 'Affiliation': 'Praxis Hämatolgie und Onkologie, Hannover, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Eckert', 'Affiliation': 'Onkologische Schwerpunktpraxis, Esslingen, Germany.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Hann von Weyhern', 'Affiliation': 'Department Pathologie, Städtisches Klinikum, München, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Bauer', 'Affiliation': 'West German Cancer Center, University Hospital, Essen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Mayer', 'Affiliation': 'University Hospital, Medical Center II, Tuebingen, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.016'] 807,30931723,Constructing Matched Groups in Dental Observational Health Disparity Studies for Causal Effects.,"INTRODUCTION Electronic health record (EHR) systems provide investigators with rich data from which to examine actual impacts of care delivery in real-world settings. However, confounding is a major concern when comparison groups are not randomized. OBJECTIVES This article introduced a step-by-step strategy to construct comparable matched groups in a dental study based on the EHR of the Willamette Dental Group. This strategy was employed in preparation for a longitudinal study evaluating the impact of a standardized risk-based caries prevention and management program across patients with public versus private dental insurance in Oregon. METHODS This study constructed comparable dental patient groups through a process of 1) evaluating the need for and feasibility of matching, 2) considering different matching methods, and 3) evaluating matching quality. The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. RESULTS This systematic process resulted in comparably matched groups in baseline covariates but with a clear baseline disparity in caries experience between them. The weighted average ratio in our study showed that, at baseline, publicly insured patients had 1.21-times (95% CI: 1.08 to 1.32) and 1.21-times (95% CI: 1.08 to 1.37) greater number of DMFS + dmfs and number of decayed tooth surfaces (DS + ds) than privately insured patients, respectively. CONCLUSION Matching is a useful tool to create comparable groups with EHR data to resemble randomized studies, as demonstrated by our study where even with similar demographics, neighborhood and clinic characteristics, publicly insured pediatric patients had greater numbers of DMFS + dmfs and DS + ds than privately insured pediatric patients. KNOWLEDGE TRANSFER STATEMENT This article provides a systematic, step-by-step strategy for investigators to follow when matching groups in a study-in this case, a study based on electronic health record data. The results from this study will provide patients, clinicians, and policy makers with information to better understand the disparities in oral health between comparable publicly and privately insured pediatric patients who have similar values in individual, clinic, and community covariates. Such understanding will help clinicians and policy makers modify oral health care and relevant policies to improve oral health and reduce disparities between publicly and privately insured patients.",2020,"The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. ","['pediatric patients had greater numbers of DMFS + dmfs and DS + ds than privately insured pediatric patients', 'patients with public versus private dental insurance in Oregon']",['standardized risk-based caries prevention and management program'],['number of DMFS + dmfs and number of decayed tooth surfaces'],"[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0021681', 'cui_str': 'Insurance, Dental'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1265875', 'cui_str': 'Disintegration'}, {'cui': 'C0447301', 'cui_str': 'Tooth surface (body structure)'}]",,0.0781924,"The matched groups were then compared for their average ratio in the number of decayed, missing, and filled tooth surfaces (DMFS + dmfs) at baseline. ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Gregorich', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Gansky', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Fisher-Owens', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.""}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Kottek', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.""}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'White', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Mertz', 'Affiliation': 'Department of Preventive and Restorative Dental Sciences, School of Dentistry, University of California-San Francisco, San Francisco, CA, USA.'}]",JDR clinical and translational research,['10.1177/2380084419830655'] 808,31899529,Effectiveness of Virtual vs In-Person Inhaler Education for Hospitalized Patients With Obstructive Lung Disease: A Randomized Clinical Trial.,"Importance Many patients who are hospitalized cannot use inhalers correctly, yet education for their use is often not provided. To address the need for an effective intervention feasible for wide-scale implementation, a virtual teach-to-goal intervention was developed to provide tailored patient-directed education using adaptive learning technology. Objective To assess whether the virtual teach-to-goal intervention is noninferior to an in-person teach-to-goal intervention for improving inhaler technique. Design, Setting, and Participants An equivalence and noninferiority randomized clinical trial took place from January 13, 2016, through September 20, 2017, with analyses conducted between October 25, 2017, and September 23, 2019. Adult inpatients with asthma or chronic obstructive pulmonary disease (COPD) admitted to general inpatient wards were eligible. Enrolled participants were randomized to virtual (n = 61) or in-person (n = 60) educational interventions. Investigators and research assistants were masked to interventions. Initial enrollment, study assessments, and delivery of the educational intervention occurred in the hospital; participants returned at 30 days for a follow-up research visit. Interventions Virtual education was a module delivered via handheld tablet with self-assessment questions before demonstration, narrated video demonstration of the correct technique, and self-assessment questions after demonstration; up to 3 rounds were repeated as needed. In-person education participants received iterative rounds of inhaler technique assessment and education by trained staff. Main Outcomes and Measures Noninferiority testing of whether virtual vs in-person education achieved an equal percentage with correct inhaler technique after education (>9 of 12 steps correct) against an a priori noninferiority limit of -10%; logistic regression models were used to adjust for differences in baseline technique and health literacy. Results Among 118 participants (59 in each group), most were black (114 [97%]) and female (76 [64%]), with a mean (SD) age of 54.5 (13.0) years. Correct technique increased similarly before vs after education in virtual (67%; range, 2%-69%) and in-person (66%; range, 17% to 83%) groups, although the difference after intervention exceeded the noninferiority limit (-14%; 95% CI lower bound, -26%). When adjusting for baseline inhaler technique, the difference was equivalent to the noninferiority limit (-10%; 95% CI lower bound, -22%). Conclusions and Relevance The findings suggest that patient-directed virtual education similarly improved the percentage of participants with correct technique compared with in-person education. Future work should confirm whether virtual teach-to-goal education is noninferior to in-person education and whether it is associated with long-term skills retention, medication adherence, and improved health outcomes. Trial Registration ClinicalTrials.gov identifier: NCT02611531.",2020,"Correct technique increased similarly before vs after education in virtual (67%; range, 2%-69%) and in-person (66%; range, 17% to 83%) groups, although the difference after intervention exceeded the noninferiority limit (-14%; 95% CI lower bound, -26%).","['Hospitalized Patients With Obstructive Lung Disease', '118 participants (59 in each group', 'Adult inpatients with asthma or chronic obstructive pulmonary disease (COPD) admitted to general inpatient wards were eligible', 'January 13, 2016, through September 20, 2017, with analyses conducted between October 25, 2017, and September 23, 2019']","['person (n\u2009=\u200960) educational interventions', 'Virtual vs In-Person Inhaler Education']","['Correct technique', 'noninferiority limit']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0600260', 'cui_str': 'Obstructive Pulmonary Diseases'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}]",118.0,0.201069,"Correct technique increased similarly before vs after education in virtual (67%; range, 2%-69%) and in-person (66%; range, 17% to 83%) groups, although the difference after intervention exceeded the noninferiority limit (-14%; 95% CI lower bound, -26%).","[{'ForeName': 'Valerie G', 'Initials': 'VG', 'LastName': 'Press', 'Affiliation': 'Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Vineet M', 'Initials': 'VM', 'LastName': 'Arora', 'Affiliation': 'Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Colleen A', 'Initials': 'CA', 'LastName': 'Kelly', 'Affiliation': 'Pritzker School of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Kyle A', 'Initials': 'KA', 'LastName': 'Carey', 'Affiliation': 'Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Steve R', 'Initials': 'SR', 'LastName': 'White', 'Affiliation': 'Section of Pulmonary and Critical Care Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Wan', 'Affiliation': 'Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Illinois.'}]",JAMA network open,['10.1001/jamanetworkopen.2019.18205'] 809,30857427,Treadmill exercise prevents reduction of bone mineral density after myocardial infarction in apolipoprotein E-deficient mice.,"AIMS Recent clinical studies demonstrated the association between myocardial infarction (MI) and osteoporotic fractures. We examined whether MI causes bone loss and the effects of exercise training on bone in mice after MI. METHODS We created a MI model in 16-week-old male apolipoprotein E-deficient mice ( n  = 42), which were randomly assigned to exercise group (MI-Ex) and sedentary group (MI-Sed). We also performed sham operations in other mice ( n  = 10). Treadmill exercise training was performed from one week after operation to eight weeks. At eight weeks, the bone parameters of the femur were measured by quantitative computed tomography, followed by histological analysis ( n  = 10-17). RESULTS Bone mineral density (BMD) of the femur was significantly decreased in the MI-Sed group as compared with the sham group ( P  < 0.001), whereas the BMD was significantly increased in the MI-Ex group as compared with the MI-Sed group ( P  < 0.05). In histological analysis, Rho-associated coiled-coil kinase 2 and tartrate-resistant acid phosphate positive (bone resorptive) area in distal femur were significantly increased in the MI-Sed group as compared with the sham group ( P  < 0.05), whereas those parameters were significantly decreased in the MI-Ex group as compared with the MI-Sed group ( P  < 0.05). In contrast, alkaline phosphatase (ALP)-positive (bone-forming) area was significantly decreased in the MI-Sed group as compared with the sham group ( P  < 0.05), whereas ALP-positive area was significantly increased in the MI-Ex group as compared with the MI-Sed group ( P  < 0.05). CONCLUSIONS The present study demonstrates that MI reduces BMD and treadmill exercise training prevents the reduction of BMD in apolipoprotein E-deficient mice.",2020,"RESULTS Bone mineral density (BMD) of the femur was significantly decreased in the MI-Sed group as compared with the sham group ( P < 0.001), whereas the BMD was significantly increased in the MI-Ex group as compared with the MI-Sed group ( P < 0.05).","['mice after MI', 'apolipoprotein E-deficient mice', '16-week-old male apolipoprotein E-deficient mice ( n\u2009=\u200942']","['exercise training', 'Treadmill exercise training', 'exercise group (MI-Ex) and sedentary group (MI-Sed', 'treadmill exercise training', 'Treadmill exercise']","['bone mineral density', 'Bone mineral density (BMD) of the femur', 'BMD', 'coiled-coil kinase 2 and tartrate-resistant acid phosphate positive (bone resorptive) area in distal femur', 'ALP-positive area', 'BMD in apolipoprotein E-deficient mice', 'alkaline phosphatase (ALP)-positive (bone-forming) area']","[{'cui': 'C0523511', 'cui_str': 'Apolipoproteins E measurement (procedure)'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil (physical object)'}, {'cui': 'C4521566', 'cui_str': 'Kinase'}, {'cui': 'C0144544', 'cui_str': 'tartrate'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C1601799', 'cui_str': 'phosphate ion'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0523511', 'cui_str': 'Apolipoproteins E measurement (procedure)'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0002059', 'cui_str': 'Orthophosphoric-monoester phosphohydrolase (alkaline optimum)'}]",,0.019592,"RESULTS Bone mineral density (BMD) of the femur was significantly decreased in the MI-Sed group as compared with the sham group ( P < 0.001), whereas the BMD was significantly increased in the MI-Ex group as compared with the MI-Sed group ( P < 0.05).","[{'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Kanazawa', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Yasuharu', 'Initials': 'Y', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Kikuyo', 'Initials': 'K', 'LastName': 'Takahashi', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hironori', 'Initials': 'H', 'LastName': 'Uzuka', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Kensuke', 'Initials': 'K', 'LastName': 'Nishimiya', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Shimokawa', 'Affiliation': 'Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}]",European journal of preventive cardiology,['10.1177/2047487319834399'] 810,31812934,The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: A randomised controlled trial.,"PURPOSE This study evaluated the effect of early integrated palliative care (PC) in oncology on quality of life (QOL) near the end of life and use of health care resources near the end of life. METHOD Patients with advanced cancer and a life expectancy of approximately 1 year were randomly assigned to either early and systematic integration of PC into oncological care (intervention) or standard oncological care alone (control). QOL was assessed with the EORTC QLQ-C30 global health status/QOL scale and McGill Quality of Life (MQOL) Single Item Scale and Summary Scale at baseline, 12 weeks and 6 weekly thereafter until death. Use of health care resources was collected from chart review in patient's electronic medical file for patients who died while participating in the study. RESULTS Of the 186 randomised patients, 185 participants had a baseline measurement and were analysed. By November 2017, 128 patients had died while participating in the study. When applying the terminal decline model, patients in the intervention group scored significantly higher on global health status/QOL of the EORTC QLQ C30, at 6 months (difference: 5.9 [0.06; 11.1], p = 0.03), 3 (difference: 6.8 [1.0; 12.6], p = 0.02), and 1 month (difference: 7.6 [0.7; 14.5], p = 0.03) prior to the patient's death compared to the control group. Similar results were found for the Single Item Scale and Summary Score of the MQOL. We did not observe differences in use of health care resources between groups. DISCUSSION Early integrated palliative care in oncology is a valuable approach since it also increases QOL near the end of life and not only soon after initiation of PC.",2020,"When applying the terminal decline model, patients in the intervention group scored significantly higher on global health status/QOL of the EORTC QLQ C30, at 6 months (difference: 5.9 [0.06; 11.1], p = 0.03), 3 (difference: 6.8 [1.0; 12.6], p = 0.02), and 1 month (difference: 7.6 [0.7; 14.5], p = 0.03) prior to the patient's death compared to the control group.","['186 randomised patients', '185 participants had a baseline measurement and were analysed', '128 patients had died while participating in the study', ""patient's electronic medical file for patients who died while participating in the study"", 'Patients with advanced cancer and a life expectancy of approximately 1 year']","['PC into oncological care (intervention) or standard oncological care alone (control', 'early integrated palliative care (PC']","['QOL', 'global health status/QOL of the EORTC QLQ C30', 'EORTC QLQ-C30 global health status/QOL scale and McGill Quality of Life (MQOL', 'Single Item Scale and Summary Score of the MQOL', 'quality of life and health care', 'quality of life (QOL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0180853', 'cui_str': 'File, device (physical object)'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0023671', 'cui_str': 'Life Expectancy'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0700049', 'cui_str': 'Palliative care'}]","[{'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0034380'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}]",185.0,0.0883458,"When applying the terminal decline model, patients in the intervention group scored significantly higher on global health status/QOL of the EORTC QLQ C30, at 6 months (difference: 5.9 [0.06; 11.1], p = 0.03), 3 (difference: 6.8 [1.0; 12.6], p = 0.02), and 1 month (difference: 7.6 [0.7; 14.5], p = 0.03) prior to the patient's death compared to the control group.","[{'ForeName': 'Gaëlle', 'Initials': 'G', 'LastName': 'Vanbutsele', 'Affiliation': 'End-of-Life Care Research Group, Vrije Universiteit Brussel & Ghent University, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Hematology, Ghent University Hospital, Ghent, Belgium. Electronic address: gaelle.vanbutsele@uzgent.be.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Van Belle', 'Affiliation': 'Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Veerle', 'Initials': 'V', 'LastName': 'Surmont', 'Affiliation': 'Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Respiratory Medicine/Thoracic Oncology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'De Laat', 'Affiliation': 'Palliative Care Team, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Roos', 'Initials': 'R', 'LastName': 'Colman', 'Affiliation': 'Biostatistics Unit, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Eecloo', 'Affiliation': 'End-of-Life Care Research Group, Vrije Universiteit Brussel & Ghent University, Belgium; Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Eline', 'Initials': 'E', 'LastName': 'Naert', 'Affiliation': 'Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'De Man', 'Affiliation': 'Department of Gastroenterology, Division of Digestive Oncology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Geboes', 'Affiliation': 'Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Department of Gastroenterology, Division of Digestive Oncology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Deliens', 'Affiliation': 'End-of-Life Care Research Group, Vrije Universiteit Brussel & Ghent University, Belgium.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Pardon', 'Affiliation': 'End-of-Life Care Research Group, Vrije Universiteit Brussel & Ghent University, Belgium.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.009'] 811,31847574,Benefits of adding stretching to a moderate-intensity aerobic exercise programme in women with fibromyalgia: a randomized controlled trial.,"OBJECTIVE To investigate the effects of adding stretching to a moderate-intensity aerobic exercise programme in women with fibromyalgia. DESIGN Randomized controlled trial. SUBJECTS Sixty-four female patients who were diagnosed with fibromyalgia syndrome based on the American College of Rheumatology criteria were recruited (mean age: 54.27 ± 6.94 years). INTERVENTIONS The control group ( n  = 32) underwent supervised moderate-intensity cycling (50%-70% of the age-predicted maximum heart rate) three times per week for 12 weeks. The experimental group ( n  = 32) underwent the same exercise programme plus a stretching programme once per week for 12 weeks. MAIN MEASURES The main measures of this study were sleep quality assessed by the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale, the impact of fibromyalgia on quality of life assessed by the Fibromyalgia Impact Questionnaire, and pain perception assessed by the visual analogue scale at baseline, after 4 weeks, and after 12 weeks. RESULTS The experimental group experienced significant improvements at 4-week measure compared with control group: Pittsburgh Sleep Quality Index ( P  < 0.001); Epworth Sleepiness Scale ( P  = 0.002); Fibromyalgia Impact Questionnaire (0.93 ± 7.39, P  < 0.001); and visual analogue scale (0.52 ± 0.05, P  < 0.001). Also at 12-week measure, experimental group experienced significant improvements compared with control group: Pittsburgh Sleep Quality Index ( P  < 0.001), Epworth Sleepiness Scale ( P  < 0.001); Fibromyalgia Impact Questionnaire (1.15 ± 9.11, P  < 0.001); and visual analogue scale (0.81 ± 0.62, P  < 0.001). CONCLUSION Adding stretching to a moderate-intensity aerobic exercise programme increased sleep quality, decreased the impact of fibromyalgia on the quality of life, and reduced pain compared with just a moderate-intensity aerobic exercise programme in our sample of women with fibromyalgia.",2020,"The experimental group experienced significant improvements at 4-week measure compared with control group: Pittsburgh Sleep Quality Index ( P  < 0.001); Epworth Sleepiness Scale ( P  = 0.002); Fibromyalgia Impact Questionnaire (0.93 ± 7.39, P  < 0.001); and visual analogue scale (0.52 ± 0.05, P  < 0.001).","['Sixty-four female patients who were diagnosed with fibromyalgia syndrome based on the American College of Rheumatology criteria were recruited (mean age: 54.27\u2009±\u20096.94\u2009years', 'women with fibromyalgia']","['stretching to a moderate-intensity aerobic exercise programme', 'same exercise programme plus a stretching programme', 'supervised moderate-intensity cycling ', 'Adding stretching to a moderate-intensity aerobic exercise programme', 'intensity aerobic exercise programme']","['quality of life, and reduced pain', 'Epworth Sleepiness Scale', 'Pittsburgh Sleep Quality Index', 'Fibromyalgia Impact Questionnaire', 'sleep quality assessed by the Pittsburgh Sleep Quality Index and the Epworth Sleepiness Scale, the impact of fibromyalgia on quality of life assessed by the Fibromyalgia Impact Questionnaire, and pain perception assessed by the visual analogue scale', 'visual analogue scale', 'sleep quality']","[{'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0016053', 'cui_str': 'Fibrositis'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]","[{'cui': 'C0034380'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3541276', 'cui_str': 'ESS - Epworth Sleepiness Scale'}, {'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0016053', 'cui_str': 'Fibrositis'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",64.0,0.114565,"The experimental group experienced significant improvements at 4-week measure compared with control group: Pittsburgh Sleep Quality Index ( P  < 0.001); Epworth Sleepiness Scale ( P  = 0.002); Fibromyalgia Impact Questionnaire (0.93 ± 7.39, P  < 0.001); and visual analogue scale (0.52 ± 0.05, P  < 0.001).","[{'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Gómez-Hernández', 'Affiliation': 'Department of Nursing and Physiotherapy, Universidad de Alcalá, Alcalá de Henares, Spain.'}, {'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Gallego-Izquierdo', 'Affiliation': 'Department of Nursing and Physiotherapy, Universidad de Alcalá, Alcalá de Henares, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Martínez-Merinero', 'Affiliation': 'Physiotherapy Department, Faculty of Health, Exercise and Sport, European University of Madrid, Madrid, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pecos-Martín', 'Affiliation': 'Department of Nursing and Physiotherapy, Universidad de Alcalá, Alcalá de Henares, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Ferragut-Garcías', 'Affiliation': 'Department of Nursing and Physiotherapy, Universidad de las Islas Baleares, Palma de Mallorca, Spain.'}, {'ForeName': 'Fidel', 'Initials': 'F', 'LastName': 'Hita-Contreras', 'Affiliation': 'Department of Health Sciences, Universidad de Jaén, Jaén, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Martínez-Amat', 'Affiliation': 'Department of Health Sciences, Universidad de Jaén, Jaén, Spain.'}, {'ForeName': 'Francisco Javier', 'Initials': 'FJ', 'LastName': 'Montañez-Aguilera', 'Affiliation': 'Department of Physiotherapy, Universidad Cardenal Herrera-CEU, Valencia, Spain.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Achalandabaso Ochoa', 'Affiliation': 'Department of Health Sciences, Universidad de Jaén, Jaén, Spain.'}]",Clinical rehabilitation,['10.1177/0269215519893107'] 812,31296256,Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients.,"BACKGROUND We previously reported the results of a multicentric prospective randomized trial of chemo-refractory metastatic breast cancer patients testing the efficacy of two doses of TGFβ blockade during radiotherapy. Despite a lack of objective responses to the combination, patients who received a higher dose of TGFβ blocking antibody fresolimumab had a better overall survival when compared to those assigned to lower dose (hazard ratio of 2.73, p = 0.039). They also demonstrated an improved peripheral blood mononuclear cell (PBMC) counts and increase in the CD8 central memory pool. We performed additional analysis on residual PBMC using single cell network profiling (SCNP). METHODS The original trial randomized metastatic breast cancer patients to either 1 or 10 mg/kg of fresolimumab, every 3 weeks for 5 cycles, combined with radiotherapy to a metastatic site at week 1 and 7 (22.5 Gy given in 3 doses of 7.5 Gy). Trial immune monitoring results were previously reported. In 15 patients with available residual blood samples, additional functional studies were performed, and compared with data obtained in parallel from seven healthy female donors (HD): SCNP was applied to analyze T cell receptor (TCR) modulated signaling via CD3 and CD28 crosslinking and measurement of evoked phosphorylation of AKT and ERK in CD4 and CD8 T cell subsets defined by PD-1 expression. RESULTS At baseline, a significantly higher level of expression (p < 0.05) of PD-L1 was identified in patient monocytes compared to HD. TCR modulation revealed dysfunction of circulating T-cells in patient baseline samples as compared to HD, and this was more pronounced in PD-1 + cells. Treatment with radiotherapy and fresolimumab did not resolve this dyfunctional signaling. However, in vitro PD-1 blockade enhanced TCR signaling in patient PD-1 + T cells and not in PD-1 - T cells or in PD-1 + T cells from HD. CONCLUSIONS Functional T cell analysis suggests that baseline T cell functionality is hampered in metastatic breast cancer patients, at least in part mediated by the PD-1 signaling pathway. These preliminary data support the rationale for investigating the possible beneficial effects of adding PD-1 blockade to improve responses to TGFβ blockade and radiotherapy. TRIAL REGISTRATION NCT01401062 .",2019,"At baseline, a significantly higher level of expression (p < 0.05) of PD-L1 was identified in patient monocytes compared to HD.","['refractory metastatic breast cancer patients', 'metastatic breast cancer patients', '15 patients with available residual blood samples, additional functional studies']","['radiotherapy', 'radiotherapy and fresolimumab', 'TGFβ blockade during radiotherapy', '1 or 10\u2009mg/kg of fresolimumab']","['peripheral blood mononuclear cell (PBMC) counts', 'level of expression', 'overall survival', 'CD8 central memory pool', 'dysfunction of circulating T-cells']","[{'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C2987643', 'cui_str': 'fresolimumab'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0337051', 'cui_str': 'Pool (environment)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}]",,0.176271,"At baseline, a significantly higher level of expression (p < 0.05) of PD-L1 was identified in patient monocytes compared to HD.","[{'ForeName': 'Silvia C', 'Initials': 'SC', 'LastName': 'Formenti', 'Affiliation': 'Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA. formenti@med.cornell.edu.'}, {'ForeName': 'Rachael E', 'Initials': 'RE', 'LastName': 'Hawtin', 'Affiliation': 'Nodality, 170 Harbor Way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Neha', 'Initials': 'N', 'LastName': 'Dixit', 'Affiliation': 'Nodality, 170 Harbor Way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Evensen', 'Affiliation': 'Nodality, 170 Harbor Way, South San Francisco, CA, 94080, USA.'}, {'ForeName': 'Percy', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': 'Department of Radiation oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Judith D', 'Initials': 'JD', 'LastName': 'Goldberg', 'Affiliation': 'Department of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, 10016, USA.'}, {'ForeName': 'Xiaochun', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Population Health and Environmental Medicine, New York University School of Medicine, New York, NY, 10016, USA.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Vanpouille-Box', 'Affiliation': 'Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA.'}, {'ForeName': 'Dörthe', 'Initials': 'D', 'LastName': 'Schaue', 'Affiliation': 'Department of Radiation oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'McBride', 'Affiliation': 'Department of Radiation oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Demaria', 'Affiliation': 'Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, 10065, USA. szd3005@med.cornell.edu.'}]",Journal for immunotherapy of cancer,['10.1186/s40425-019-0633-x'] 813,30910420,Exercise and Cognitive Training as a Strategy to Improve Neurocognitive Outcomes in Heart Failure: A Pilot Study.,"OBJECTIVE Mild cognitive impairment, especially memory loss, is prevalent in patients with heart failure (HF) and contributes to poor clinical outcomes and higher mortality. METHODS This study evaluated a combined aerobic exercise and cognitive training (EX/CT) program on memory, executive function, attention, processing speed and reaction time compared to exercise only or a usual care attention control (UCAC) stretching and flexibility program. Participants completed a standardized neurocognitive battery at baseline, 3 months, and 6 months along with demographic, clinical, and functional capacity (6-minute walk test). A linear mixed model analysis was used with comorbidity as a covariate. RESULTS Sixty-nine participants were enrolled, the mean age was 61 ± 10 years, 54% were women, 55% were African American, and the mean left ventricular ejection fraction percentage was 35 ± 15. A significant group by time interaction for verbal memory was found at 3 months (F [2, 53] = 4.3, p = 0.018) but was not sustained at 6 months in the EX/CT group. Processing speed/attention differed across treatment groups between baseline and 6 months, but improvement occurred among UCAC participants. There were also significant group differences in the 6MWT distance occurring at 3 months (F [2, 52] = 3.5, p = 0.036); however, significant improvement was observed within the EX/CT group only. There were no significant differences in 6MWT in the other groups at 3 or 6 months. CONCLUSION An EX/CT intervention was associated with improved memory in persons with HF and warrants further investigation in a larger trial. The relationship between functional capacity and cognitive function also needs further study.",2019,"There were also significant group differences in the 6MWT distance occurring at 3 months (F [2, 52] = 3.5, p = 0.036); however, significant improvement was observed within the EX/CT group only.","['Heart Failure', 'patients with heart failure (HF', 'Sixty-nine participants were enrolled, the mean age was 61 ± 10years, 54% were women, 55% were African American, and the mean left ventricular ejection fraction percentage was 35 ± 15']","['EX/CT intervention', 'exercise only or a usual care attention control (UCAC) stretching and flexibility program', 'Exercise and Cognitive Training', 'combined aerobic exercise and cognitive training (EX/CT) program']","['Neurocognitive Outcomes', 'Processing speed/attention', 'memory, executive function, attention, processing speed and reaction time', '6MWT distance', 'time interaction for verbal memory', '6MWT']","[{'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450388', 'cui_str': '69 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0165079', 'cui_str': 'IS 35'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}]","[{'cui': 'C0582591', 'cui_str': 'Processing speed (observable entity)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}]",69.0,0.0488471,"There were also significant group differences in the 6MWT distance occurring at 3 months (F [2, 52] = 3.5, p = 0.036); however, significant improvement was observed within the EX/CT group only.","[{'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Gary', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta. Electronic address: ragary@emory.edu.'}, {'ForeName': 'Sudeshna', 'Initials': 'S', 'LastName': 'Paul', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Corwin', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Butts', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Miller', 'Affiliation': 'Emory University School of Medicine (AHM), Winship Cancer Institute, Atlanta.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Hepburn', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}, {'ForeName': 'Drenna', 'Initials': 'D', 'LastName': 'Waldrop-Valverde', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing (RAG, SP, EC, BB, KH, BW, DWV), Atlanta.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.01.211'] 814,31337877,Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.,"BACKGROUND Retrospective studies suggest that low molecular weight heparin may delay the development of metastasis in patients with resected NSCLC. METHODS Multicentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive chemotherapy with or without nadroparin. The main exclusion criteria were R1/2 and wedge/segmental resection. FDG-PET was required. The primary endpoint was recurrence-free survival (RFS). RESULTS Among 235 registered patients, 202 were randomised (nadroparin: n = 100; control n = 102). Slow accrual enabled a decrease in the number of patients needed from 600 to 202, providing 80% power to compare RFS with 94 events (α = 0.05; 2-sided). There were no differences in bleeding events between the two groups. The median RFS was 65.2 months (95% CI, 36-NA) in the nadroparin arm and 37.7 months (95% CI, 22.7-NA) in the control arm (HR 0.77 (95% CI, 0.53-1.13, P = 0.19). FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). CONCLUSIONS Adjuvant nadroparin did not improve RFS in patients with resected NSCLC. In this study, a high SUVmax predicted a greater likelihood of recurrence in the first year. CLINICAL TRIAL REGISTRATION Netherlands Trial registry: NTR1250/1217.",2019,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","['patients with completely resected non-small-cell lung cancer', '235 registered patients, 202 were randomised (nadroparin: n\u2009=\u2009100; control n\u2009=\u2009102', 'patients with resected NSCLC', 'patients with resected NSCLC.\nMETHODS\n\n\nMulticentre phase 3 study with patients with completely resected NSCLC who were randomised after surgery to receive']","['adjuvant chemotherapy with or without nadroparin', 'chemotherapy with or without nadroparin']","['median RFS', 'RFS', 'recurrence-free survival (RFS', 'bleeding events', 'likelihood of recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4554154', 'cui_str': 'Completely - dosing instruction fragment (qualifier value)'}, {'cui': 'C0007131', 'cui_str': 'Nonsmall Cell Lung Cancer'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0206232', 'cui_str': 'Nadroparin'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",202.0,0.512985,"FDG-PET SUVmax ≥10 predicted a greater likelihood of recurrence in the first year (HR 0.48, 95% CI 0.22-0.9, P = 0.05). ","[{'ForeName': 'Harry J M', 'Initials': 'HJM', 'LastName': 'Groen', 'Affiliation': 'Department of Pulmonary Disease, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands. h.j.m.groen@umcg.nl.'}, {'ForeName': 'Erik H F M', 'Initials': 'EHFM', 'LastName': 'van der Heijden', 'Affiliation': 'Department of Pulmonary Diseases, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Theo J', 'Initials': 'TJ', 'LastName': 'Klinkenberg', 'Affiliation': 'Department of Cardiothoracic Surgery, University of Groningen and University Medical Center Groningen, Hanzeplein 1, Box 30.001, 9700 RB, Groningen, Netherlands.'}, {'ForeName': 'Bonne', 'Initials': 'B', 'LastName': 'Biesma', 'Affiliation': ""Department of Pulmonary Diseases, Jeroen Bosch Hospital, Henri Dunantstraat 1, 5223 GZ, 's-Hertogenbosch, Netherlands.""}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Aerts', 'Affiliation': 'Department of Pulmonary Diseases, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD, Rotterdam, Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'Verhagen', 'Affiliation': 'Department of Cardiothoracic Surgery, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, Netherlands.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Kloosterziel', 'Affiliation': 'Department of Pulmonary Diseases, Isala Hospital, Dokter van Heesweg 2, 8025 AB, Zwolle, Netherlands.'}, {'ForeName': 'Remge', 'Initials': 'R', 'LastName': 'Pieterman', 'Affiliation': 'Department of Pulmonary Diseases, Ommelander Hospital Group, Pastorieweg 1, 9679 BJ, Scheemda, Netherlands.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'van den Borne', 'Affiliation': 'Department of Pulmonary Diseases, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, Netherlands.'}, {'ForeName': 'Hans J M', 'Initials': 'HJM', 'LastName': 'Smit', 'Affiliation': 'Department of Pulmonary Diseases, Rijnstate Hospital, Wagnerlaan 55, 6815 AD, Arnhem, Netherlands.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Hoekstra', 'Affiliation': 'Department of Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081, HVAmsterdam, Netherlands.'}, {'ForeName': 'Frans M N H', 'Initials': 'FMNH', 'LastName': 'Schramel', 'Affiliation': 'Department of Pulmonary Diseases, St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, Netherlands.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'van der Noort', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'van Tinteren', 'Affiliation': 'Department of Biometrics, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Egbert F', 'Initials': 'EF', 'LastName': 'Smit', 'Affiliation': 'Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.'}, {'ForeName': 'Anne-Marie C', 'Initials': 'AC', 'LastName': 'Dingemans', 'Affiliation': 'Department of Pulmonary Diseases, Maastricht University Medical Center, P. Debijelaan 25, 6229 HX, Maastricht, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0533-3'] 815,31316586,External rotation bracing for first-time anterior dislocation of the shoulder: A discontinued randomised controlled trial comparing external rotation bracing with conventional sling.,"Introduction Itoi et al. introduced the concept of bracing in abduction and external rotation to treat traumatic anterior shoulder dislocations. However, controversy remains as studies have reported variable results. Our study investigates whether there is a difference in outcomes between treatment with a conventional sling or external rotation brace. Methods A prospective, multi-centre randomised control trial was conducted between 2006 and 2010. The study was discontinued early with 72 (36 cases in each group) first-time anterior shoulder dislocations recruited. Results The re-dislocation rate over 24 months was comparable 30% (95% CI: 17-47) sling vs. 24% (95% CI: 13-41) external rotation bracing. Sixteen percent (95% CI: 7-32) of sling patients and 12% (95% CI: 5-27) of external rotation-bracing patients had shoulder stabilisation surgery within 24 months of the initial dislocation (p > 0.05). There was no difference in OSI scores at 24 months between the two treatment groups and intolerability of the external rotation brace was high. Conclusion Recruitment to this study was difficult, and lost-to-follow-up rates were high leading to early discontinuation of the study. The results suggest that ER bracing is unlikely to provide clinical benefit in traumatic first-time anterior shoulder dislocation.",2019,"There was no difference in OSI scores at 24 months between the two treatment groups and intolerability of the external rotation brace was high. ","['72 (36 cases in each group) first-time anterior shoulder dislocations recruited', 'for first-time anterior dislocation of the shoulder']","['External rotation bracing', 'conventional sling or external rotation brace', 'external rotation bracing with conventional sling']","['shoulder stabilisation surgery', 're-dislocation rate', 'OSI scores']","[{'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0037005', 'cui_str': 'Glenohumeral Dislocation'}, {'cui': 'C1265658', 'cui_str': 'Anterior dislocation'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}]","[{'cui': 'C0231462', 'cui_str': 'Lateral rotation - action (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0441637', 'cui_str': 'Slinging'}, {'cui': 'C0006086', 'cui_str': 'Braces'}]","[{'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0012691', 'cui_str': 'Joint Dislocations'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.099704,"There was no difference in OSI scores at 24 months between the two treatment groups and intolerability of the external rotation brace was high. ","[{'ForeName': 'Samuel Kl', 'Initials': 'SK', 'LastName': 'Chan', 'Affiliation': 'The Hand and Upper Limb Unit, The Robert Jones and Agnes Hunt Hospital, Oswestry, UK.'}, {'ForeName': 'Kieran R', 'Initials': 'KR', 'LastName': 'Bentick', 'Affiliation': 'Royal Shrewsbury Hospital, Mytton Oak Road, Shrewsbury, Shropshire, UK.'}, {'ForeName': 'Jan H', 'Initials': 'JH', 'LastName': 'Kuiper', 'Affiliation': 'Institute for Science & Technology in Medicine, Keele University, Keele, Staffordshire, UK.'}, {'ForeName': 'Cormac P', 'Initials': 'CP', 'LastName': 'Kelly', 'Affiliation': 'The Hand and Upper Limb Unit, The Robert Jones and Agnes Hunt Hospital, Oswestry, UK.'}]",Shoulder & elbow,['10.1177/1758573218768521'] 816,31316889,Comparison between Rescue Flap and Double Flap Technique.,"Objectives  Endoscopic techniques in pituitary surgery lead to inevitable mucosal loss of the sphenoethmoidal recess and posterior nasal septum in the nasal cavity. There is no other comparative study between primary reconstruction of septal perforation and secondary healing in the literature. The aim of this study is to evaluate postoperative patient morbidity with or without posterior septal perforation in endonasal pituitary surgery by comparing two commonly used techniques: rescue and double nasoseptal flaps. Design  Prospectively randomized study. Setting  Tertiary academic center. Participants  Sixty patients underwent endoscopic endonasal pituitary surgery. Main Outcomes and Measures  Functional results (breathing) using visual analog scale (VAS), sphenoid sinusitis, presence of synechia, perforation in the posterior septum, and crusting in the sphenoethmoidal recess were assessed. Results  Pre- and postoperative mean VAS scores were 71.67 ± 11.47 and 67.67 ± 9.71 mm in the intact septum group and 77.67 ± 14.06 and 62.67 ± 10.48 mm in the posterior septal perforation group. There was a significant difference between pre- and postoperative VAS values in all groups. There was significant worsening in both groups; worsening in VAS values was much higher in the posterior septal perforation group. In the posterior septal perforation group, much more crusting was seen. Conclusions  This is the first study to compare the postoperative patient morbidity in endoscopic endonasal pituitary surgery with and without a posterior septal perforation. Reconstruction of the posterior septum along with less mucosal loss yields better postoperative nasal symptom score.",2019,There was significant worsening in both groups; worsening in VAS values was much higher in the posterior septal perforation group.,"['Setting \u2003Tertiary academic center', 'Participants \u2003Sixty patients underwent']","['Rescue Flap and Double Flap Technique', 'endoscopic endonasal pituitary surgery with and without a posterior septal perforation', 'endoscopic endonasal pituitary surgery', 'endonasal pituitary surgery']","['Pre- and postoperative mean VAS scores', 'crusting', 'postoperative patient morbidity', 'pre- and postoperative VAS values', 'VAS values', 'Measures \u2003Functional results (breathing) using visual analog scale (VAS), sphenoid sinusitis, presence of synechia, perforation in the posterior septum, and crusting in the sphenoethmoidal recess']","[{'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0442004', 'cui_str': 'Septal (qualifier value)'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392749', 'cui_str': 'Crusted (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0037886', 'cui_str': 'Sphenoidal Sinusitis'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0334157', 'cui_str': 'Synechia (morphologic abnormality)'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0225441', 'cui_str': 'Structure of sphenoethmoidal recess'}]",60.0,0.0438542,There was significant worsening in both groups; worsening in VAS values was much higher in the posterior septal perforation group.,"[{'ForeName': 'Murat', 'Initials': 'M', 'LastName': 'Benzer', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Huseyin', 'Initials': 'H', 'LastName': 'Biceroglu', 'Affiliation': 'Department of Neurosurgery, Ege University, Izmir, Turkey.'}, {'ForeName': 'Murat Samet', 'Initials': 'MS', 'LastName': 'Ates', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Isa', 'Initials': 'I', 'LastName': 'Kaya', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Erkin', 'Initials': 'E', 'LastName': 'Ozgiray', 'Affiliation': 'Department of Neurosurgery, Ege University, Izmir, Turkey.'}, {'ForeName': 'Rasit', 'Initials': 'R', 'LastName': 'Midilli', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Bulent', 'Initials': 'B', 'LastName': 'Karcı', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Sercan', 'Initials': 'S', 'LastName': 'Gode', 'Affiliation': 'Department of Otorhinolaryngology, Ege University School of Medicine, Izmir, Turkey.'}]","Journal of neurological surgery. Part B, Skull base",['10.1055/s-0038-1673695'] 817,31328671,Robot-Assisted Arm Training in Chronic Stroke: Addition of Transition-to-Task Practice.,"Background . Robot-assisted therapy provides high-intensity arm rehabilitation that can significantly reduce stroke-related upper extremity (UE) deficits. Motor improvement has been shown at the joints trained, but generalization to real-world function has not been profound. Objective . To investigate the efficacy of robot-assisted therapy combined with therapist-assisted task training versus robot-assisted therapy alone on motor outcomes and use in participants with moderate to severe chronic stroke-related arm disability. Methods . This was a single-blind randomized controlled trial of two 12-week robot-assisted interventions; 45 participants were stratified by Fugl-Meyer (FMA) impairment (mean 21 ± 1.36) to 60 minutes of robot therapy (RT; n = 22) or 45 minutes of RT combined with 15 minutes therapist-assisted transition-to-task training (TTT; n = 23). The primary outcome was the mean FMA change at week 12 using a linear mixed-model analysis. A subanalysis included the Wolf Motor Function Test (WMFT) and Stroke Impact Scale (SIS), with significance P <.05. Results . There was no significant 12-week difference in FMA change between groups, and mean FMA gains were 2.87 ± 0.70 and 4.81 ± 0.68 for RT and TTT, respectively. TTT had greater 12-week secondary outcome improvements in the log WMFT (-0.52 ± 0.06 vs -0.18 ± 0.06; P = .01) and SIS hand (20.52 ± 2.94 vs 8.27 ± 3.03; P = .03). Conclusion . Chronic UE motor deficits are responsive to intensive robot-assisted therapy of 45 or 60 minutes per session duration. The replacement of part of the robotic training with nonrobotic tasks did not reduce treatment effect and may benefit stroke-affected hand use and motor task performance.",2019,Robot-assisted therapy provides high-intensity arm rehabilitation that can significantly reduce stroke-related upper extremity (UE) deficits.,"['45 participants were stratified by Fugl-Meyer (FMA) impairment (mean 21 ± 1.36) to 60 minutes of', 'participants with moderate to severe chronic stroke-related arm disability']","['Robot-assisted therapy', 'robot-assisted therapy combined with therapist-assisted task training versus robot-assisted therapy alone', 'robot therapy (RT; n = 22) or 45 minutes of RT combined with 15 minutes therapist-assisted transition-to-task training (TTT', 'robot-assisted interventions', 'Robot-Assisted Arm Training']","['mean FMA change', 'mean FMA gains', 'FMA change', 'stroke-related upper extremity (UE) deficits', 'Wolf Motor Function Test (WMFT) and Stroke Impact Scale (SIS']","[{'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4708912', 'cui_str': '1.36 (qualifier value)'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}]","[{'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1442463', 'cui_str': 'Forty-five minutes (qualifier value)'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0325001', 'cui_str': 'Wolves'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0222045'}]",45.0,0.209847,Robot-assisted therapy provides high-intensity arm rehabilitation that can significantly reduce stroke-related upper extremity (UE) deficits.,"[{'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Conroy', 'Affiliation': '1 Baltimore VA Medical Center, Baltimore, MD, USA.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Wittenberg', 'Affiliation': '2 University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Hermano I', 'Initials': 'HI', 'LastName': 'Krebs', 'Affiliation': '5 Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhan', 'Affiliation': '2 University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Bever', 'Affiliation': '1 Baltimore VA Medical Center, Baltimore, MD, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Whitall', 'Affiliation': '2 University of Maryland School of Medicine, Baltimore, MD, USA.'}]",Neurorehabilitation and neural repair,['10.1177/1545968319862558'] 818,23229691,Baseline characteristics and response to treatment of participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study: SCORE study report 14.,"OBJECTIVE To compare baseline characteristics and treatment response of participants with hemiretinal vein occlusion (HRVO) with those of participants with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study. METHODS Eyes were randomized to standard care, 1 mg intravitreal triamcinolone acetonide, or 4 mg intravitreal triamcinolone acetonide. Standard care was observation in the SCORE-CRVO trial and grid photocoagulation in the SCORE-BRVO trial. The HRVO eyes were enrolled in the SCORE-BRVO trial. Baseline characteristics, changes in visual acuity and center point thickness, safety outcomes, and number of treatments were compared among HRVO, BRVO, and CRVO participants. RESULTS At baseline, HRVO eyes were intermediate between BRVO and CRVO eyes in area of retinal thickening, area of fluorescein leakage, visual acuity, and center point thickness. No differences in visual acuity change from baseline to 1 year were noted between standard care groups for HRVO and BRVO. Within triamcinolone-treated eyes, HRVO eyes did not differ from BRVO eyes in visual acuity change, but HRVO eyes fared better than CRVO eyes. There were no differences in center point thickness change between standard care groups for HRVO and BRVO, nor were there differences across the 3 disease entities for triamcinolone-treated eyes. There were no differences in frequency of protocol treatments and adverse events. CONCLUSIONS The HRVO participants were similar to BRVO and CRVO participants regarding most demographic characteristics, with fundus findings intermediate between BRVO and CRVO. In the SCORE Study, HRVO was treated as BRVO; HRVO eyes responded to treatment similarly to BRVO eyes, and there was no difference among the 3 disease entities in frequency of protocol treatments and adverse events. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00105027.",2012,No differences in visual acuity change from baseline to 1 year were noted between standard care groups for HRVO and BRVO.,"['participants with hemiretinal vein occlusion (HRVO) with those of participants with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study', 'participants with hemiretinal compared with branch retinal or central retinal vein occlusion in the standard care vs corticosteroid for retinal vein occlusion (SCORE) study', 'Eyes']","['intravitreal triamcinolone acetonide, or 4 mg intravitreal triamcinolone acetonide', 'triamcinolone']","['frequency of protocol treatments and adverse events', 'visual acuity and center point thickness, safety outcomes, and number of treatments', 'visual acuity change', 'BRVO and CRVO eyes in area of retinal thickening, area of fluorescein leakage, visual acuity, and center point thickness', 'HRVO and BRVO', 'center point thickness change']","[{'cui': 'C1735356', 'cui_str': 'Hemiretinal vein occlusion'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205384', 'cui_str': 'Branching (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone Acetonide'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1302690', 'cui_str': 'Retinal thickening'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}]",,0.163329,No differences in visual acuity change from baseline to 1 year were noted between standard care groups for HRVO and BRVO.,"[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Vanveldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Amitha', 'Initials': 'A', 'LastName': 'Domalpally', 'Affiliation': ''}, {'ForeName': 'Bernard H', 'Initials': 'BH', 'LastName': 'Doft', 'Affiliation': ''}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Elman', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Archives of ophthalmology (Chicago, Ill. : 1960)",['10.1001/archophthalmol.2012.2728'] 819,26086920,"Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15.","IMPORTANCE The Standard of Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study showed that intravitreal triamcinolone acetonide (IVTA) is effective at reducing macular edema and improving visual acuity in participants with retinal vein occlusion. Secondary analysis of the incidence, risk factors, and timing of intraocular pressure (IOP) elevation occurring after IVTA provides guidance for clinical decision making and management of patients treated with IVTA. OBJECTIVE To investigate the incidence, risk factors, and time course of IOP elevation in participants in the SCORE Study. DESIGN, SETTING, AND PARTICIPANTS Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites. Six hundred eighty-two patients with macular edema secondary to retinal vein occlusion were enrolled in the study. The SCORE Study enrollment period ran from November 4, 2004, to February 29, 2008, with participant follow-up ending February 28, 2009. INTERVENTIONS Study participants were randomized to standard of care, 1 mg of IVTA, or 4 mg of IVTA therapy and followed up for a mean (SD) of 24.7 (10.3) months. MAIN OUTCOMES AND MEASURES Intraocular pressure elevation greater than 10 mm Hg from baseline. RESULTS Kaplan-Meier incidences of IOP elevation greater than 10 mm Hg from baseline at 36 months were 0.02 (95% CI, 0.01-0.06), 0.09 (95% CI, 0.05-0.14), and 0.45 (95% CI, 0.38-0.53) in the standard of care, 1-mg IVTA, and 4-mg IVTA groups, respectively. The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P ≤ .001 for main outcome measure). Younger age, 4-mg IVTA vs 1-mg IVTA treatment, and higher baseline IOP were found to confer greater risk for IOP-related events (P < .05 for all). The median number of days from time of first injection to IOP elevation greater than 10 mm Hg from baseline was 34.0 and 52.5 days in participants treated with 1-mg and 4-mg IVTA, respectively. CONCLUSIONS AND RELEVANCE Intravitreal triamcinolone acetonide injection therapy, in particular the 4-mg dose, is associated with an increased risk for IOP elevation. The risk factors for an IOP-related event include higher treatment dose, younger age, and higher baseline IOP. Intraocular pressure-related events may take several months from the time of first IVTA injection to occur. Clinicians should be mindful of these risk factors when assessing the risks and benefits of IVTA therapy and also of the need for long-term follow-up of participants at risk for this complication. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00105027.",2015,The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P ≤ .001 for main outcome measure).,"['participants with retinal vein occlusion', 'Retinal Vein Occlusion', 'Macular Edema Secondary to Retinal Vein Occlusion', 'participants in the SCORE Study', 'Six hundred eighty-two patients with macular edema secondary to retinal vein occlusion', 'Secondary analysis conducted from August through December 2014 of a prospective, randomized clinical trial featuring an evaluable population conducted at 75 clinical sites']","['triamcinolone acetonide injection therapy', 'triamcinolone acetonide (IVTA', 'Triamcinolone Acetonide Injection', 'Care vs Corticosteroid', 'IVTA, or 4 mg of IVTA therapy']","['incidence, risk factors, and time course of IOP elevation', 'macular edema and improving visual acuity', 'Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure', 'IOP elevation', 'rates of IOP-related events', 'incidence, risk factors, and timing of intraocular pressure (IOP) elevation', 'Intraocular pressure elevation', 'median number of days from time of first injection to IOP elevation']","[{'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone Acetonide'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0449247', 'cui_str': 'Time course (attribute)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0449243', 'cui_str': 'Timing (attribute)'}, {'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure (finding)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]",682.0,0.301974,The rates of IOP-related events were higher for the 4-mg IVTA group compared with the other groups (P ≤ .001 for main outcome measure).,"[{'ForeName': 'Ahmad A', 'Initials': 'AA', 'LastName': 'Aref', 'Affiliation': 'Illinois Eye and Ear Infirmary, University of Illinois at Chicago School of Medicine.'}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania3Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.'}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': 'The EMMES Corporation, Rockville, Maryland.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': 'University of Wisconsin, Madison.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': 'University of Wisconsin, Madison.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': 'The EMMES Corporation, Rockville, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2015.1823'] 820,31326956,"Effect of flavour manipulation on low and high-frequency waterpipe users' puff topography, toxicant exposures and subjective experiences.","BACKGROUND Flavoured tobacco is one of the major factors behind the popularity of waterpipe (WP) smoking in the USA and internationally. The current study examined the impact of flavour manipulation on satisfaction, puff topography and toxicant exposure among high-frequency and low-frequency WP users. METHOD This cross-over study was conducted among 144 current (past month) WP smokers reporting WP smoking less than once a week (low-frequency users; n=69) or at least once a week (high-frequency users; n=75) in the past 6 months. Participants attended two counterbalanced 45 min ad libitum smoking sessions that differed by flavour (preferred flavoured vs unflavoured tobacco), preceded by ≥12 hours of tobacco use abstinence. Outcome measures included puff topography, expired carbon monoxide (eCO), plasma nicotine and subjective measures. RESULTS Both high-frequency and low-frequency WP users reported an enhanced smoking experience and greater interest in future use after smoking the flavoured compared with unflavoured tobacco (p<0.05 for all). High-frequency users, however, were more keen on smoking the flavoured tobacco in the future, had higher puffing parameters in general compared with low-frequency users (p<0.05 for all) and had no differences in eCO and plasma nicotine concentrations between the flavoured and unflavoured tobacco conditions (p>0.05 for all). On the other hand, low-frequency users had significantly greater eCO and plasma nicotine concentrations following smoking the unflavoured compared with flavoured tobacco condition (p<0.05 for all). CONCLUSIONS Our results indicate that removing flavours will likely negatively affect WP satisfaction and future use and that such an effect will be more pronounced among high-frequency compared with low-frequency WP smokers.",2020,Both high-frequency and low-frequency WP users reported an enhanced smoking experience and greater interest in future use after smoking the flavoured compared with unflavoured tobacco (p<0.05 for all).,['144 current (past month'],"['flavour manipulation', 'counterbalanced 45\u2009min ad libitum smoking sessions that differed by flavour (preferred flavoured vs unflavoured tobacco']","['eCO and plasma nicotine concentrations', 'satisfaction, puff topography and toxicant exposure', 'puff topography, expired carbon monoxide (eCO), plasma nicotine and subjective measures']","[{'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C3543840', 'cui_str': 'Preferred'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1533107', 'cui_str': 'Puffs'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",144.0,0.0211054,Both high-frequency and low-frequency WP users reported an enhanced smoking experience and greater interest in future use after smoking the flavoured compared with unflavoured tobacco (p<0.05 for all).,"[{'ForeName': 'Wasim', 'Initials': 'W', 'LastName': 'Maziak', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA wmaziak@fiu.edu.'}, {'ForeName': 'Ziyad', 'Initials': 'Z', 'LastName': 'Ben Taleb', 'Affiliation': 'Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, Texas, USA.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ebrahimi Kalan', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Ward-Peterson', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Zoran', 'Initials': 'Z', 'LastName': 'Bursac', 'Affiliation': 'Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Olatokunbo', 'Initials': 'O', 'LastName': 'Osibogun', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Eissenberg', 'Affiliation': 'Department of Psychology, Center for the Study of Tobacco Products, Virginia Commonwealth University, Richmond, Virginia, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2019-055040'] 821,31197730,Proactive Population Health Strategy to Offer Tobacco Dependence Treatment to Smokers in a Primary Care Practice Network.,"BACKGROUND Population-based strategies can expand the reach of tobacco cessation treatment beyond clinical encounters. OBJECTIVE To determine the effect of two population-based tobacco cessation strategies, compared with usual care, on providing tobacco treatment outside of clinical encounters. DESIGN 3-arm pragmatic randomized controlled trial. PARTICIPANTS Current smokers ≥ 18 years old with a primary care provider at one of five community health centers in Massachusetts were identified via the electronic health record (n = 5225) and recruited using automated phone calls. INTERVENTIONS One intervention group involved engagement with a health system-based tobacco coach (internal care coordination), and the other connected patients to a national quitline (external community referral). MEASUREMENTS Proportion of smokers with documentation of any evidence-based cessation treatment in the 6 months after enrollment. KEY RESULTS Of 639 individuals who responded to the proactive treatment offer, 233 consented and were randomized 1:1:1 to study arm. At 6-month follow-up, the pooled intervention group, compared with usual care, had higher documentation of any smoking cessation treatment (63% vs. 34%, p < 0.001), cessation medication prescription (52% vs. 30%, p = 0.002), and counseling (47% vs. 9%, p < 0.001). Internal care coordination was more effective than external community referral at connecting smokers to any cessation treatment (76% vs. 50%, p = 0.001) and at providing cessation medication (66% vs. 39%, p < 0.001), but comparable at linking smokers to cessation counseling resources. CONCLUSIONS Smokers responding to a population-based, proactive outreach strategy had better provision of tobacco cessation treatment when referred to either a health system-based or community-based program compared with usual care. The health system-based strategy outperformed the quitline-based one in several measures. Future work should aim to improve population reach and test the effect on smoking cessation rates. TRIAL REGISTRATION ClinicalTrials.gov NCT03612895.",2019,"Internal care coordination was more effective than external community referral at connecting smokers to any cessation treatment (76% vs. 50%, p = 0.001) and at providing cessation medication (66% vs. 39%, p < 0.001), but comparable at linking smokers to cessation counseling resources. ","['18\xa0years old with a primary care provider at one of five community health centers in Massachusetts were identified via the electronic health record (n\u2009=\u20095225) and recruited using automated phone calls', '639 individuals who responded to the proactive treatment offer, 233 consented', 'Current smokers ≥']","['One intervention group involved engagement with a health system-based tobacco coach (internal care coordination), and the other connected patients to a national quitline (external community referral']","['cessation medication prescription', 'higher documentation of any smoking cessation treatment']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider (occupation)'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C3241966'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0242414', 'cui_str': 'Coordination (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0034927', 'cui_str': 'Referral'}]","[{'cui': 'C2239117', 'cui_str': 'Drug Prescribing'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0920316', 'cui_str': 'Documentation'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.0765875,"Internal care coordination was more effective than external community referral at connecting smokers to any cessation treatment (76% vs. 50%, p = 0.001) and at providing cessation medication (66% vs. 39%, p < 0.001), but comparable at linking smokers to cessation counseling resources. ","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kalkhoran', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA. skalkhoran@mgh.harvard.edu.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Inman', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Jennifer H K', 'Initials': 'JHK', 'LastName': 'Kelley', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Ashburner', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Rigotti', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, MA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05079-3'] 822,31250285,Treatment of patients with geriatric depression with repetitive transcranial magnetic stimulation.,"Repetitive transcranial magnetic stimulation (rTMS) has become a useful tool to treat different neuropsychiatric conditions such as depression, dementia and extrapyramidal syndromes insufficiently responding to conventional treatment. In this SHAM-controlled exploratory study safety, symptom improvement as well as changes in inflammation markers and neurotransmitter precursor amino acids availability were studied after a prefrontal cortex (PFC) stimulation using rTMS as add-on treatment in 29 patients with geriatric depression. Out of these, ten patients received SHAM treatment. Treatment was well tolerated, no serious adverse effects were observed. A clear improvement in symptoms of depression with a significant decrease in the HAMD-7 (U = 3.306, p = 0.001) was found by rTMS treatment. In parallel, serum phenylalanine dropped significantly (U = 2.340, p < 0.02), and there was a decline of tryptophan and of Phe/Tyr concentrations, both the effects, however, failed to reach the levels of statistical significance. In the patients who underwent SHAM treatment, no significant changes of HAMD-7 or the concentrations of any biomarker in the study could be found. In addition to the significant effect of rTMS on depression scores, these results point to a possible influence of rTMS on the enzyme phenylalanine hydroxylase (PAH), which plays a crucial role in the biosynthesis of neurotransmitter precursors related to geriatric depression.",2019,"A clear improvement in symptoms of depression with a significant decrease in the HAMD-7 (U = 3.306, p = 0.001) was found by rTMS treatment.","['patients with geriatric depression with repetitive transcranial magnetic stimulation', '29 patients with geriatric depression']","['SHAM', 'rTMS', 'Repetitive transcranial magnetic stimulation (rTMS']","['tolerated, no serious adverse effects', 'HAMD-7', 'symptoms of depression', 'depression scores', 'serum phenylalanine']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0017469', 'cui_str': 'Geriatrics'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0031453', 'cui_str': 'L-phenylalanine'}]",29.0,0.0218417,"A clear improvement in symptoms of depression with a significant decrease in the HAMD-7 (U = 3.306, p = 0.001) was found by rTMS treatment.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Leblhuber', 'Affiliation': 'Department of Gerontology, Kepler University Clinic, Linz, Austria.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Steiner', 'Affiliation': 'Department of Gerontology, Kepler University Clinic, Linz, Austria.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Fuchs', 'Affiliation': 'Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innrain 80, 4th Floor, Room M04-313, 6020, Innsbruck, Austria. dietmar.fuchs@i-med.ac.at.'}]","Journal of neural transmission (Vienna, Austria : 1996)",['10.1007/s00702-019-02037-5'] 823,32204919,[Effects of caudal block in pediatric surgical patients: a randomized clinical trial].,"BACKGROUND Surgery generates a neuroendocrine stress response, resulting in undesirable hemodynamic instability, alterations in metabolic response and malfunctioning of the immune system. OBJECTIVES The aim of this research was to determine the effectiveness of caudal blocks in intra- and postoperative pain management and in reducing the stress response in children during the same periods. METHODS This prospective, randomized clinical trial included 60 patients scheduled for elective herniorrhaphy. One group (n = 30) received general anesthesia and the other (n = 30) received general anesthesia with a caudal block. Hemodynamic parameters, drug consumption and pain intensity were measured. Blood samples for serum glucose and cortisol level were taken before anesthesia induction and after awakening the patient. RESULTS Children who received a caudal block had significantly lower serum glucose (p < 0.01), cortisol concentrations (p < 0.01) and pain scores 3 hours (p = 0.002) and 6 hours (p = 0.003) after the operation, greater hemodynamic stability and lower drug consumption. Also, there were no side effects or complications identified in that group. CONCLUSIONS The combination of caudal block with general anesthesia is a safe method that leads to less stress, greater hemodynamic stability, lower pain scores and lower consumption of medication.",2020,"RESULTS Children who received a caudal block had significantly lower serum glucose (p < 0.01), cortisol concentrations (p < 0.01) and pain scores 3 hours (p = 0.002) and 6 hours (p = 0.003) after the operation, greater hemodynamic stability and lower drug consumption.","['children during the same periods', '60 patients scheduled for elective herniorrhaphy', 'pediatric surgical patients']","['general anesthesia', 'general anesthesia with a caudal block', 'caudal block']","['Hemodynamic parameters, drug consumption and pain intensity', 'pain scores', 'serum glucose', 'hemodynamic stability, lower pain scores', 'stress response', 'hemodynamic stability and lower drug consumption', 'Blood samples for serum glucose and cortisol level', 'cortisol concentrations']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0019328', 'cui_str': 'Hernia Repair'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0205097', 'cui_str': 'Caudal (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum (procedure)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}]",60.0,0.0804957,"RESULTS Children who received a caudal block had significantly lower serum glucose (p < 0.01), cortisol concentrations (p < 0.01) and pain scores 3 hours (p = 0.002) and 6 hours (p = 0.003) after the operation, greater hemodynamic stability and lower drug consumption.","[{'ForeName': 'Anna Uram', 'Initials': 'AU', 'LastName': 'Benka', 'Affiliation': 'University of Novi Sad, Medical Faculty, Department of Anesthesia and Perioperative Medicine, Novi Sad, República da Sérvia; Institute for the Healthcare of Children and Youth of Vojvodina, Clinic of Pediatric surgery, Department for Pediatric Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Pandurov', 'Affiliation': 'University of Novi Sad, Medical Faculty, Department of Anesthesia and Perioperative Medicine, Novi Sad, República da Sérvia; Institute for the Healthcare of Children and Youth of Vojvodina, Clinic of Pediatric surgery, Department for Pediatric Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia. Electronic address: marina.pandurov@mf.uns.ac.rs.'}, {'ForeName': 'Izabella Fabri', 'Initials': 'IF', 'LastName': 'Galambos', 'Affiliation': 'University of Novi Sad, Medical Faculty, Department of Anesthesia and Perioperative Medicine, Novi Sad, República da Sérvia; Institute for the Healthcare of Children and Youth of Vojvodina, Clinic of Pediatric surgery, Department for Pediatric Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Rakić', 'Affiliation': 'Institute for the Healthcare of Children and Youth of Vojvodina, Clinic of Pediatric surgery, Department for Pediatric Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia; University of Novi Sad, Medical Faculty, Department of Emergency Medicine, Novi Sad, República da Sérvia.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Vrsajkov', 'Affiliation': 'University of Novi Sad, Medical Faculty, Department of Anesthesia and Perioperative Medicine, Novi Sad, República da Sérvia; Clinical Centre of Vojvodina, Clinic of Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia.'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Drašković', 'Affiliation': 'University of Novi Sad, Medical Faculty, Department of Anesthesia and Perioperative Medicine, Novi Sad, República da Sérvia; Institute for the Healthcare of Children and Youth of Vojvodina, Clinic of Pediatric surgery, Department for Pediatric Anesthesia, Intensive Care and Pain Therapy, Novi Sad, República da Sérvia.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.12.003'] 824,32109176,A Randomized Controlled Trial Investigating Online Training for Prelinguistic Communication.,"Purpose This study explored the utility of online training as a platform for teaching early intervention speech-language pathologists to recognize potentially communicative, prelinguistic behaviors in young children with physical disabilities and complex communication needs. Method Using a randomized controlled trial, 45 early intervention speech-language pathologists were randomly assigned to one of three conditions within an online training: practice with implicit problem-solving (identification condition), practice with explicit problem-solving (reflection condition), or no practice (control condition). Knowledge about early communication, skill at recognizing prelinguistic behaviors, time taken to complete the training, and perceptions of the training experience were examined. Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions. Conclusions Results suggest the importance of considering efficiency and appeal when designing successful trainings for moving evidence into practice.",2020,"Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions.","['young children with physical disabilities and complex communication needs', '45 early intervention speech-language pathologists']","['online training: practice with implicit problem-solving (identification condition), practice with explicit problem-solving (reflection condition), or no practice (control condition', 'Online Training', 'online training']",[],"[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0520817', 'cui_str': 'Physical handicap (finding)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0242687', 'cui_str': 'Early Intervention'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0023008', 'cui_str': 'Languages'}, {'cui': 'C0334866', 'cui_str': 'Pathologists'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C0020792', 'cui_str': 'Identification'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],45.0,0.033264,"Results Participants in the no-practice control condition took significantly less time to complete the training, achieved the same positive outcomes on the knowledge and skill assessments, and rated the training as appealing as compared with participants assigned to the more time-intensive identification and reflection practice conditions.","[{'ForeName': 'Julie L', 'Initials': 'JL', 'LastName': 'Feuerstein', 'Affiliation': 'School of Communication Sciences and Disorders, College of Health Professions and Sciences, University of Central Florida, Orlando.'}, {'ForeName': 'Lesley B', 'Initials': 'LB', 'LastName': 'Olswang', 'Affiliation': 'Department of Speech and Hearing Sciences, University of Washington, Seattle.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2019_JSLHR-19-00336'] 825,31084656,"A nutrition education programme improves quality of life but not anthropometric status of adults living with HIV in Abeokuta, Nigeria.","OBJECTIVE The focus of interventions for adults living with HIV (ALH) in Nigeria has been mostly on prevention and provision of antiretroviral therapy (ART) with little consideration to nutrition-related matters. Therefore, the present study aimed to improve the quality of life (QoL) and anthropometric status of ALH in Abeokuta, Nigeria. DESIGN A quasi-experimental design where 200 conveniently selected participants were stratified by gender and duration on ART. The intervention group (n 100) received the nutrition education programme (NEP) for 12 weeks. The control group received a brochure on nutrition guidelines for ALH. Socio-biographical information, QoL and anthropometric status were assessed using previously validated questionnaires and standard techniques at baseline, week 12 and week 24. Generalised least squares (GLS) regression analysis was used for group comparisons. Anthropometric status was summarised by gender. SETTING Two tertiary hospitals in Abeokuta, Nigeria. PARTICIPANTS ALH. RESULTS The NEP led to significant improvement in the physical functioning (week 12 and 24: P < 0·01), role limitation due to physical health (week 12: P = 0·01; week 24: P = 0·002) and pain (week 12: P = 0·01) constructs of the QoL of the intervention group compared with the control group. There was no significant difference (P = 0·07) between the mean weights of the two groups at baseline. CONCLUSIONS There was a significant improvement at week 12 and week 24 in the QoL of the intervention participants. The results indicated that a tailored NEP could make a positive contribution to the management of ALH.",2019,"The NEP led to significant improvement in the physical functioning (week 12 and 24: P < 0·01), role limitation due to physical health (week 12: P = 0·01; week 24: P = 0·002) and pain (week 12: P = 0·01) constructs of the QoL of the intervention group compared with the control group.","['Two tertiary hospitals in Abeokuta, Nigeria', 'adults living with HIV in Abeokuta, Nigeria', '200 conveniently selected participants were stratified by gender and duration on ART', 'adults living with HIV (ALH']","['nutrition education programme', 'nutrition education programme (NEP', 'brochure on nutrition guidelines for ALH']","['Socio-biographical information, QoL and anthropometric status', 'pain', 'physical functioning', 'quality of life', 'quality of life (QoL) and anthropometric status of ALH in Abeokuta, Nigeria']","[{'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0028075', 'cui_str': 'Federal Republic of Nigeria'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C3658297', 'cui_str': 'Nutrition Guidelines'}]","[{'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0028075', 'cui_str': 'Federal Republic of Nigeria'}]",200.0,0.034952,"The NEP led to significant improvement in the physical functioning (week 12 and 24: P < 0·01), role limitation due to physical health (week 12: P = 0·01; week 24: P = 0·002) and pain (week 12: P = 0·01) constructs of the QoL of the intervention group compared with the control group.","[{'ForeName': 'Temitope K', 'Initials': 'TK', 'LastName': 'Bello', 'Affiliation': 'Department of Human Nutrition, University of Pretoria,Private Bag X323, Pretoria 0001,South Africa.'}, {'ForeName': 'Gerda J', 'Initials': 'GJ', 'LastName': 'Gericke', 'Affiliation': 'Department of Human Nutrition, University of Pretoria,Private Bag X323, Pretoria 0001,South Africa.'}, {'ForeName': 'Una E', 'Initials': 'UE', 'LastName': 'Maclntyre', 'Affiliation': 'Department of Human Nutrition, University of Pretoria,Private Bag X323, Pretoria 0001,South Africa.'}, {'ForeName': 'Piet', 'Initials': 'P', 'LastName': 'Becker', 'Affiliation': 'Research Office, Faculty of Health Sciences, University of Pretoria,Pretoria,South Africa.'}]",Public health nutrition,['10.1017/S1368980019000636'] 826,31320290,"Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.","BACKGROUND An intravaginal ring that releases the tenofovir prodrug, tenofovir disoproxil fumarate, provided 100% protection in macaques against simian HIV and was safe in a 14-day clinical trial in sexually abstinent women. We aimed to assess the safety and pharmacokinetics of this intravaginal ring over 90 days in sexually active women. METHODS We did a phase 1, single-blind, randomised, placebo-controlled trial to assess safety, pharmacokinetics, and acceptability of a tenofovir disoproxil fumarate intravaginal ring used continuously with monthly ring changes for 3 months. Sexually active women who were HIV negative were randomly assigned (3:1) to a tenofovir disoproxil fumarate ring or placebo ring. Primary safety endpoint was the proportion of women who had grade 2 or higher genitourinary adverse events judged related to study product and any grade 2 or higher adverse event as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. We quantified tenofovir disoproxil fumarate and tenofovir concentrations in cervicovaginal fluid, tenofovir in plasma, and tenofovir diphosphate, the active metabolite, in cervical tissue and dried blood spots 1 month after each ring insertion. We compared changes over time in cervicovaginal fluid cytokine and chemokine concentrations and vaginal microbiota. The study was electively stopped early and is registered with ClinicalTrials.gov, number NCT02762617. FINDINGS Between Feb 24 and July 20, 2017, 17 women were enrolled before study termination. 12 were assigned to receive the tenofovir disoproxil fumarate ring and five were assigned to receive the placebo ring. Two participants in the tenofovir disoproxil fumarate ring group completed 3 months of continuous ring use; eight were asked to discontinue ring use early because of ulcerations (grade 1) near the ring; in the remaining two women, rings were electively removed by study staff on day 20 and day 23. Ulcers were detected a mean of 32 days after ring use (range 23-56). Four of eight participants with ulcers were symptomatic with vaginal discharge; four had ulcers identified when examined; three had two ulcers; all ulcers resolved after ring removal. No participants in the placebo group developed ulcers. No grade 2 product-related adverse events were reported in either group and four non-product-related grade 2 adverse events were reported in the tenofovir disoproxil fumarate ring group. Cervicovaginal fluid tenofovir concentrations did not differ at day 14 (p=0·14) comparing the eight patients who did (median 1·0 × 10 5 ng/mL [IQR 9·1 × 10 4 -1·1 × 10 5 ]) with the four who did not (6·0 × 10 4 ng/mL [5·6 × 10 4 -1·1 × 10 5 ]) develop ulcers. No significant changes in vaginal microbiota were detected in either group. Concentrations of multiple inflammatory cytokines and chemokines were significantly higher at days 14 and 28 compared with baseline in the tenofovir disoproxil fumarate ring group but not the placebo group. INTERPRETATION Future studies are needed to establish whether the unanticipated finding of ulcerations is specific to this tenofovir disoproxil fumarate ring or generalisable to other sustained topical release formulations of tenofovir or its prodrugs. FUNDING National Institutes of Health.",2019,Cervicovaginal fluid tenofovir concentrations did not differ at day 14 (p=0·14) comparing the eight patients who did (median 1·0 × 10,"['10 5 ]) with the four who did not (6·0', 'sexually abstinent women', 'Sexually active women who were HIV negative', 'Between Feb 24 and July 20, 2017', '17 women were enrolled before study termination', 'sexually active women']","['tenofovir disoproxil fumarate', 'tenofovir', 'tenofovir disoproxil fumarate ring or placebo ring', 'placebo', 'Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis', 'tenofovir disoproxil fumarate and tenofovir', 'tenofovir prodrug, tenofovir disoproxil fumarate', 'placebo ring', 'tenofovir disoproxil fumarate intravaginal']","['grade 2 product-related adverse events', 'Cervicovaginal fluid tenofovir concentrations', 'ulcers', 'Concentrations of multiple inflammatory cytokines and chemokines', 'Ulcers', 'safety, pharmacokinetics, and acceptability', 'proportion of women who had grade 2 or higher genitourinary adverse events judged related to study product and any grade 2 or higher adverse event as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events', 'safety and pharmacokinetics', 'vaginal microbiota']","[{'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C4520512', 'cui_str': 'Sexually abstinent (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0241028', 'cui_str': 'Sexually active (finding)'}, {'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C1260969', 'cui_str': 'Ring, device (physical object)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0442122', 'cui_str': 'Intravaginal (qualifier value)'}, {'cui': 'C1096319', 'cui_str': 'HIV pre-exposure prophylaxis'}, {'cui': 'C0033262', 'cui_str': 'Drug Precursors'}]","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0221191', 'cui_str': 'Judge (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}, {'cui': 'C1706074', 'cui_str': 'Table'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}]",17.0,0.405657,Cervicovaginal fluid tenofovir concentrations did not differ at day 14 (p=0·14) comparing the eight patients who did (median 1·0 × 10,"[{'ForeName': 'Marla J', 'Initials': 'MJ', 'LastName': 'Keller', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Lianna', 'Initials': 'L', 'LastName': 'Wood', 'Affiliation': 'Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Billingsley', 'Affiliation': 'Yerkes National Primate Research Center, Atlanta, GA, USA.'}, {'ForeName': 'Laurie L', 'Initials': 'LL', 'LastName': 'Ray', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Goymer', 'Affiliation': 'Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Shada', 'Initials': 'S', 'LastName': 'Sinclair', 'Affiliation': 'Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Aileen P', 'Initials': 'AP', 'LastName': 'McGinn', 'Affiliation': 'Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Marzinke', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Frank', 'Affiliation': 'Particle Sciences, Bethlehem, PA, USA.'}, {'ForeName': 'Sujatha', 'Initials': 'S', 'LastName': 'Srinivasan', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Congzhou', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Atrio', 'Affiliation': ""Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY, USA.""}, {'ForeName': 'Lilia', 'Initials': 'L', 'LastName': 'Espinoza', 'Affiliation': 'Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Nelly', 'Initials': 'N', 'LastName': 'Mugo', 'Affiliation': 'Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Hans M L', 'Initials': 'HML', 'LastName': 'Spiegel', 'Affiliation': 'Division of AIDS, Kelly Government Solutions, Contractor to National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Anderson', 'Affiliation': 'Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Fredricks', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Craig W', 'Initials': 'CW', 'LastName': 'Hendrix', 'Affiliation': 'Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Marrazzo', 'Affiliation': 'Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Bosinger', 'Affiliation': 'Yerkes National Primate Research Center, Atlanta, GA, USA.'}, {'ForeName': 'Betsy C', 'Initials': 'BC', 'LastName': 'Herold', 'Affiliation': 'Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: betsy.herold@einstein.yu.edu.'}]",The lancet. HIV,['10.1016/S2352-3018(19)30145-6'] 827,31302000,Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial.,"BACKGROUND The AspireAssist is the first Food and Drug Administration-approved endoluminal device indicated for treatment of class II and III obesity. OBJECTIVES We earlier reported 1-year results of the PATHWAY study. Here, we report 4-year outcomes. SETTING United States-based, 10-center, randomized controlled trial involving 171 participants with the treatment arm receiving Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization). METHODS AT participants were permitted to continue in the study for an additional year up to a maximum of 5 years providing they maintained at least 10% total weight loss (TWL) from baseline at each year end. For AT participants who continued the study, 5 medical monitoring visits were provided at weeks 60, 68, 76, 90, and 104 and thereafter once every 13 weeks up to week 260. Exclusion criteria were a history of eating disorder or evidence of eating disorder on a validated questionnaire. Follow-up weight, quality of life, and co-morbidities were compared with the baseline levels. In addition, rates of serious adverse event, persistent fistula, withdrawal, and A-tube replacement were reported. All analyses were performed using a per-protocol analysis. RESULTS Of the 82 AT participants who completed 1 year, 58 continued to this phase of the trial. Mean baseline body mass index of these 58 patients was 41.6 ± 4.5 kg/m 2 . At the end of first year (at the beginning of the follow-up study), these 58 patients had a body mass index of 34.1 ± 5.4 kg/m 2 and had achieved an 18.3 ± 8.0% TWL. On a per protocol basis, patients experienced 14.2%, 15.3%, 16.6%, and 18.7% TWL at 1, 2, 3, and 4 years, respectively (P < .01 for all). Forty of 58 patients (69%) achieved at least 10% TWL at 4 years or at time of study withdrawal. Improvements in quality of life scores and select cardiometabolic parameters were also maintained through 4 years. There were 2 serious adverse events reported in the second through fourth years, both of which resolved with removal or replacement of the A tube. Two persistent fistulas required surgical repair, representing approximately 2% of all tube removals. There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders. CONCLUSIONS The results of this midterm study have shown that AT is a safe, effective, and durable weight loss alternative for people with class II and III obesity and who are willing to commit to using the therapy and adhere to adjustments in eating behavior.",2019,"There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders. ","['171 participants with the treatment arm receiving', 'obesity', '58 patients had a body mass index of 34.1 ± 5.4 kg/m 2 and had achieved an 18.3 ± 8.0% TWL', 'AT participants']","['Aspiration Therapy (AT) plus Lifestyle Therapy and the control arm receiving Lifestyle Therapy (2:1 randomization', 'Aspiration therapy']","['serious adverse events', 'rates of serious adverse event, persistent fistula, withdrawal, and A-tube replacement', 'quality of life scores and select cardiometabolic parameters', 'Mean baseline body mass index', 'Follow-up weight, quality of life, and co-morbidities']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517792', 'cui_str': 'Five point four'}]","[{'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}]",171.0,0.0684109,"There were no clinically significant metabolic or electrolytes disorders observed, nor any evidence for development of any eating disorders. ","[{'ForeName': 'Christopher C', 'Initials': 'CC', 'LastName': 'Thompson', 'Affiliation': ""Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: ccthompson@hms.harvard.edu.""}, {'ForeName': 'Barham K', 'Initials': 'BK', 'LastName': 'Abu Dayyeh', 'Affiliation': 'Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Kushnir', 'Affiliation': 'Interventional Research, Washington University St. Louis, St. Louis, Missouri.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Kushner', 'Affiliation': 'Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Pichamol', 'Initials': 'P', 'LastName': 'Jirapinyo', 'Affiliation': ""Division of Gastroenterology, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'Schorr', 'Affiliation': 'Division of Endocrinology, St. Mary Medical Center, Langhorne, Pennsylvania.'}, {'ForeName': 'Louis J', 'Initials': 'LJ', 'LastName': 'Aronne', 'Affiliation': 'Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Anastassia', 'Initials': 'A', 'LastName': 'Amaro', 'Affiliation': 'Division of Endocrinology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Jaffe', 'Affiliation': 'Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Allison R', 'Initials': 'AR', 'LastName': 'Schulman', 'Affiliation': 'University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Dayna', 'Initials': 'D', 'LastName': 'Early', 'Affiliation': 'Washington University, St. Louis, Missouri.'}, {'ForeName': 'Adam C', 'Initials': 'AC', 'LastName': 'Stein', 'Affiliation': 'Division of Gastroenterology and Hepatology, Northwestern University School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Reem', 'Initials': 'R', 'LastName': 'Sharaiha', 'Affiliation': 'Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Edmundowicz', 'Affiliation': 'University of Colorado Denver, Denver, Colorado.'}, {'ForeName': 'J Matthew', 'Initials': 'JM', 'LastName': 'Bohning', 'Affiliation': 'Division of Gastroenterology, St. Mary Medical Center, Langhorne, Pennsylvania.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Jensen', 'Affiliation': 'Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Alpana P', 'Initials': 'AP', 'LastName': 'Shukla', 'Affiliation': 'Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Apovian', 'Affiliation': 'Nutrition and Weight Management Center, Boston Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Dong Wook', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Nutrition and Weight Management Center, Boston Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Tran', 'Affiliation': 'Center for Wellness and Weight Loss Surgery, Howard University, Washington, D.C.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Zarrinpar', 'Affiliation': 'Division of Gastroenterology, University of California, San Diego, California.'}, {'ForeName': 'Michele B', 'Initials': 'MB', 'LastName': 'Ryan', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Young', 'Affiliation': 'Washington University, St. Louis, Missouri.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Lowe', 'Affiliation': 'University of Colorado Denver, Denver, Colorado.'}, {'ForeName': 'Miki', 'Initials': 'M', 'LastName': 'Haas', 'Affiliation': 'Drexel University College of Medicine, Philadelphia, Pennsylvania.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Goldsmith', 'Affiliation': 'Aspire Bariatrics, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McCrea', 'Affiliation': 'Aspire Bariatrics, Inc., King of Prussia, Pennsylvania.'}, {'ForeName': 'Shelby', 'Initials': 'S', 'LastName': 'Sullivan', 'Affiliation': 'University of Colorado Denver, Denver, Colorado.'}]",Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,['10.1016/j.soard.2019.04.026'] 828,31311361,The impact of a question prompt list and video intervention on teen asthma control and quality-of-life one year later: results of a randomized trial.,"Objective : This study examined whether youth who received an asthma question prompt list/video intervention were more likely to have their asthma controlled and better quality-of-life at 12 months than youth who received usual care. Methods : English or Spanish-speaking youth ages 11-17 were enrolled and randomized to intervention or usual care. The 185 youth and parents in the intervention group watched the video on an iPad and then received a one-page asthma question prompt list to complete before their visits. One hundred seventy-four received usual care. Baseline and 6-month visits were audio-tape recorded. Generalized Estimating Equations were used to predict a youth's quality-of-life and whether asthma was controlled at 12 months. Results : Asthma control and quality-of-life improved significantly from baseline to 12-month follow-up in both intervention and usual care groups. Baseline asthma control and quality-of-life were significantly associated with 12-month asthma control and quality-of-life, respectively. Adolescents on a control medication at baseline were significantly more likely to have their asthma controlled at 12 months. Conclusions : Asthma control and quality-of-life did not improve significantly more in the intervention group than in the usual care group.",2020,Asthma control and quality-of-life did not improve significantly more in the intervention group than in the usual care group.,"['Methods : English or Spanish-speaking youth ages 11-17', 'One hundred seventy-four received usual care', '185 youth and parents in the']","['asthma question prompt list/video intervention', 'intervention group watched the video on an iPad and then received a one-page asthma question prompt list to complete before their visits', 'intervention or usual care', 'question prompt list and video intervention']","['Asthma control and quality-of-life', 'Baseline asthma control and quality-of-life']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0034380'}]",185.0,0.0366236,Asthma control and quality-of-life did not improve significantly more in the intervention group than in the usual care group.,"[{'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Sleath', 'Affiliation': 'Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Delesha', 'Initials': 'D', 'LastName': 'Carpenter', 'Affiliation': 'Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Davis', 'Affiliation': 'Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'Alexor, Inc., Morrisville, NC, USA.'}, {'ForeName': 'Nacire', 'Initials': 'N', 'LastName': 'Garcia', 'Affiliation': 'Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Reuland', 'Affiliation': 'Division of General Internal Medicine and Clinical Epidemiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Tudor', 'Affiliation': 'Southern New Hampshire University, Manchester, NH, USA.'}, {'ForeName': 'Ceila E', 'Initials': 'CE', 'LastName': 'Loughlin', 'Affiliation': 'Department of Pediatric Pulmonology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",The Journal of asthma : official journal of the Association for the Care of Asthma,['10.1080/02770903.2019.1633542'] 829,31054032,Efficacy of a web-based women's health survivorship care plan for young breast cancer survivors: a randomized controlled trial.,"PURPOSE Breast cancer survivorship care plans (SCP) have limited content addressing women's health issues. This trial tested if young breast cancer survivors who receive a web-based, women's health SCP were more likely to improve on at least one of the four targeted issues (hot flashes, fertility-related concerns, contraception, and vaginal symptoms) compared to attention controls. METHODS A randomized controlled trial recruited female survivors ages 18-45 at diagnosis, 18-50 at enrollment, completed primary cancer treatment, and had a significant women's health issue: moderate or higher fertility-related concerns; ≥ 4 hot flashes/day with ≥ 1 of moderate severity; ≥ 1 moderate vaginal atrophy symptoms; or not contracepting/using less effective methods. Survivors underwent stratified, block randomization with equal allocation to intervention and control groups. The intervention group accessed the online SCP; controls accessed curated resource lists. In intention-to-treat analysis, the primary outcome of improvement in at least one issue by 24 weeks was compared by group. RESULTS 182 participants (86 intervention, 96 control), mean age 40.0 ± 5.9 and 4.4 ± 3.2 years since diagnosis, were randomized. 61 intervention group participants (70.9%) improved, compared to 55 controls (57.3%) (OR 1.82, 95% CI 0.99-3.4, p = 0.057). The following issue-specific improvements were observed in the intervention versus control arms: fertility-related concerns (27.9% vs. 14.6%, OR 2.3, 95% CI 1.1-4.8); hot flashes (58.5% vs. 55.8%, OR 1.1, 95% CI 0.57-2.2); vaginal symptoms (42.5% vs. 40.7%, OR 1.1, 95% CI 0.6-2.0); contraception (50% vs. 42.6%, OR 1.4, 95% CI 0.74-2.5). CONCLUSIONS In young breast cancer survivors, a novel, web-based SCP did not result in more change in the primary outcome of improvement in at least one of the four targeted women's health issues, than the attention control condition. The intervention was associated with improved infertility concerns, supporting efficacy of disseminating accessible, evidence-based women's health information to this population.",2019,"The intervention was associated with improved infertility concerns, supporting efficacy of disseminating accessible, evidence-based women's health information to this population.","[""young breast cancer survivors who receive a web-based, women's health SCP"", ""female survivors ages 18-45 at diagnosis, 18-50 at enrollment, completed primary cancer treatment, and had a significant women's health issue: moderate or higher\xa0fertility-related concerns;\u2009≥\u20094 hot flashes/day with ≥\u20091 of moderate severity; ≥\u20091 moderate vaginal atrophy symptoms; or not contracepting/using less effective methods"", 'young breast cancer survivors', '182 participants (86 intervention, 96 control), mean age 40.0\u2009±\u20095.9 and 4.4\u2009±\u20093.2\xa0years since diagnosis']","[""web-based women's health survivorship care plan""]","['vaginal symptoms', 'infertility concerns', 'hot flashes', 'fertility-related concerns']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080339', 'cui_str': 'Womens Health'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0600142', 'cui_str': 'Hot Flashes'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080339', 'cui_str': 'Womens Health'}, {'cui': 'C0038955'}, {'cui': 'C0178916', 'cui_str': 'Care plan (record artifact)'}]","[{'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0600142', 'cui_str': 'Hot Flashes'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",182.0,0.206658,"The intervention was associated with improved infertility concerns, supporting efficacy of disseminating accessible, evidence-based women's health information to this population.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Irene Su', 'Affiliation': 'Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Diego, San Diego, USA. hisu@ucsd.edu.'}, {'ForeName': 'Shaylyn', 'Initials': 'S', 'LastName': 'Stark', 'Affiliation': 'Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, Dept. 0901, La Jolla, San Diego, CA, 92093-0901, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Kwan', 'Affiliation': 'Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, Dept. 0901, La Jolla, San Diego, CA, 92093-0901, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Boles', 'Affiliation': 'Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, Dept. 0901, La Jolla, San Diego, CA, 92093-0901, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Chingos', 'Affiliation': 'Young Survival Coalition, New York, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Ehren', 'Affiliation': 'Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, USA.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Gorman', 'Affiliation': 'School of Social and Behavioral Health Sciences, Oregon State University College of Public Health and Human Sciences, Corvalis, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Krychman', 'Affiliation': 'Southern California Center for Sexual Health and Survivorship Medicine, Newport Beach, USA.'}, {'ForeName': 'Sally A D', 'Initials': 'SAD', 'LastName': 'Romero', 'Affiliation': 'Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': 'Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Pierce', 'Affiliation': 'Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, Dept. 0901, La Jolla, San Diego, CA, 92093-0901, USA.'}, {'ForeName': 'Loki', 'Initials': 'L', 'LastName': 'Natarajan', 'Affiliation': 'Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, Dept. 0901, La Jolla, San Diego, CA, 92093-0901, USA.'}]",Breast cancer research and treatment,['10.1007/s10549-019-05260-6'] 830,31302340,Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: a randomized placebo-controlled trial.,"BACKGROUND Many preschool children develop recurrent respiratory tract infections (RRI). Strategies to prevent RRI include the use of immunomodulators as pidotimod or probiotics, but there is limited evidence of their efficacy on clinical features or on urine metabolic profile. OBJECTIVE To evaluate whether pidotimod and/or bifidobacteria can reduce RRI morbidity and influence the urine metabolic profile in preschool children. MATERIALS AND METHODS Children aged 3-6 years with RRI were enrolled in a four-arm, exploratory, prospective, randomized, double-blinded, placebo-controlled trial. Patients were randomly assigned to receive pidotimod plus bifidobacteria, pidotimod plus placebo, bifidobacteria plus placebo or double placebo for the first 10 days of each month over 4 consecutive months. Respiratory symptoms and infections were recorded with a daily diary by parents during the study. Metabolomic analyses on urine samples collected before and after treatment were performed. RESULTS Compared to placebo, children receiving pidotimod, alone or with bifidobacteria, had more symptom-free days (69 versus 44, p = 0.003; and 65 versus 44, p = 0.02, respectively) and a lower percentage of days with common cold (17% versus 37%, p = 0.005; and 15% versus 37%, p = 0.004, respectively). The metabolomic analysis showed that children treated with Pidotimod (alone or in combination with bifidobacteria) present, respect to children treated with placebo, a biochemical profile characterized by compounds related to the pathway of steroids hormones, hippuric acid and tryptophan. No significant difference in the metabolic profile was found between children receiving bifidobacteria alone and controls. CONCLUSIONS Preschool children with RRI treated with pidotimod have better clinical outcomes and a different urine metabolomic profile than subjects receiving placebo. Further investigations are needed to clarify the connection between pidotimod and gut microbiome.",2019,"Compared to placebo, children receiving pidotimod, alone or with bifidobacteria, had more symptom-free days (69 versus 44, p = 0.003; and 65 versus 44, p = 0.02, respectively) and a lower percentage of days with common cold (17% versus 37%, p = 0.005; and 15% versus 37%, p = 0.004, respectively).","['preschool children', 'children with recurrent respiratory infections', 'Preschool children with RRI', 'preschool children develop recurrent respiratory tract infections (RRI', 'Children aged 3-6 years with RRI']","['pidotimod and bifidobacteria mixture', 'placebo', 'pidotimod and/or bifidobacteria', 'pidotimod plus bifidobacteria, pidotimod plus placebo, bifidobacteria plus placebo or double placebo', 'Pidotimod (alone or in combination with bifidobacteria']","['RRI morbidity', 'Respiratory symptoms and infections', 'clinical symptoms and urinary metabolomic profile', 'metabolic profile']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0035243', 'cui_str': 'Infections, Respiratory'}, {'cui': 'C0863094', 'cui_str': 'Recurrent respiratory tract infections'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0081002', 'cui_str': 'pidotimod'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0037090', 'cui_str': 'Signs and Symptoms, Respiratory'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1328813', 'cui_str': 'Metabolomic'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}]",,0.539413,"Compared to placebo, children receiving pidotimod, alone or with bifidobacteria, had more symptom-free days (69 versus 44, p = 0.003; and 65 versus 44, p = 0.02, respectively) and a lower percentage of days with common cold (17% versus 37%, p = 0.005; and 15% versus 37%, p = 0.004, respectively).","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Santamaria', 'Affiliation': 'Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131, Naples, Italy. Electronic address: santamar@unina.it.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Montella', 'Affiliation': 'Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131, Naples, Italy. Electronic address: amina2004@virgilio.it.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Stocchero', 'Affiliation': ""Women's and Children's Health Department, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy. Electronic address: matteo.stocchero@unipd.it.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Pirillo', 'Affiliation': ""Women's and Children's Health Department, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy; Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Corso Stati Uniti 4, 35129, Padova, Italy. Electronic address: paola.pirillo@gmail.com.""}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Bozzetto', 'Affiliation': ""Women's and Children's Health Department, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy. Electronic address: sara.bozzetto@gmail.com.""}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Giordano', 'Affiliation': ""Women's and Children's Health Department, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy; Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Corso Stati Uniti 4, 35129, Padova, Italy. Electronic address: giuseppe.giordano@unipd.it.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Poeta', 'Affiliation': 'Department of Translational Medical Sciences, Federico II University, Via Sergio Pansini 5, 80131, Naples, Italy. Electronic address: po3ta.89@gmail.com.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Baraldi', 'Affiliation': ""Women's and Children's Health Department, University of Padova, Via Nicolò Giustiniani 2, 35128, Padova, Italy; Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Corso Stati Uniti 4, 35129, Padova, Italy. Electronic address: eugenio.baraldi@unipd.it.""}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2019.101818'] 831,31305506,REDUCTION OF POSTINTRAVITREAL INJECTION PAIN USING ICE: An Open-Label Interventional Randomized Controlled Trial.,"PURPOSE Intravitreal injections of intraocular therapeutic agents are a common and effective treatment for various retinal pathologies. Patient discomfort related to injection is a potential barrier to treatment. Our aim in this study was to evaluate whether cooling the eye using topical ice compresses before intravitreal injection will reduce pain or bleeding. METHODS This randomized controlled open-label study included 42 patients. All patients received a standard topical anesthesia protocol and then were randomly assigned to either receive a placement of ice packs (intervention group) or a room-temperature pack (control group) on the eyelid, 2 minutes before the intravitreal injection. Patients' discomfort, itching, burning and pain (using visual analog scale), and bleeding size (using photographs) were measured 1 and 10 minutes after the injection. Tolerability was calculated by averaging patients' discomfort, itching, burning, and pain scores. RESULTS At 1 minute, pain (1.95 vs. 4.27, P = 0.01) and overall tolerability (1.66 vs. 2.98, P = 0.03) were significantly lower in patients receiving ice packs. At 10 minutes, pain (1.6 vs. 3.73, P = 0.02), burning (0.9 vs. 3.09, P = 0.007), discomfort (2.1 vs. 4.27, P = 0.008), and overall tolerability (1.23 vs. 2.87, P = 0.004) were all significantly lower in the ice group compared with the controls. Bleeding size (area or circumference) was not statistical different between groups. CONCLUSION Topical ice patch administered before intravitreal injection significantly decreased pain and overall tolerability. This simple and inexpensive method may be used to ameliorated pain and improve tolerability.",2020,"At 10 minutes, pain (1.6 vs. 3.73, P = 0.02), burning (0.9 vs. 3.09, P = 0.007), discomfort (2.1 vs. 4.27, P = 0.008), and overall tolerability (1.23 vs. 2.87, P = 0.004) were all significantly lower in the ice group compared with the controls.",['42 patients'],"['ICE', 'standard topical anesthesia protocol', 'placement of ice packs (intervention group) or a room-temperature pack (control group']","['discomfort, itching, burning and pain (using visual analog scale), and bleeding size (using photographs', 'Bleeding size (area or circumference', 'pain and improve tolerability', 'pain', 'discomfort', 'pain and overall tolerability', 'discomfort, itching, burning, and pain scores', 'Tolerability', 'overall tolerability', 'pain or bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0349714', 'cui_str': 'Icing (substance)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0181264', 'cui_str': 'Ice bag, device (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C1968515', 'cui_str': 'Pack (physical object)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0441468', 'cui_str': 'Photograph (physical object)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",42.0,0.0725399,"At 10 minutes, pain (1.6 vs. 3.73, P = 0.02), burning (0.9 vs. 3.09, P = 0.007), discomfort (2.1 vs. 4.27, P = 0.008), and overall tolerability (1.23 vs. 2.87, P = 0.004) were all significantly lower in the ice group compared with the controls.","[{'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Yahalomi', 'Affiliation': 'Department of Ophthalmology, Assuta Universitary Medical Center, Ashdod, Israel.'}, {'ForeName': 'Idan', 'Initials': 'I', 'LastName': 'Hecht', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Oded', 'Initials': 'O', 'LastName': 'Lagstein', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Achia', 'Initials': 'A', 'LastName': 'Nemet', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Liron', 'Initials': 'L', 'LastName': 'Peʼer', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Fady', 'Initials': 'F', 'LastName': 'Hadad', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Ari', 'Initials': 'A', 'LastName': 'Keren-Yaar', 'Affiliation': 'Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Rabea', 'Initials': 'R', 'LastName': 'Kassem', 'Affiliation': 'Department of Ophthalmology, Kaplan Medical Center, Rehovot and the Hebrew University of Jerusalem-Hadassah Medical School, Jerusalem, Israel.'}, {'ForeName': 'Zvia', 'Initials': 'Z', 'LastName': 'Burgansky-Eliash', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Asaf', 'Initials': 'A', 'LastName': 'Bar', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}, {'ForeName': 'Asaf', 'Initials': 'A', 'LastName': 'Achiron', 'Affiliation': 'Department of Ophthalmology, Edith Wolfson Medical Center, Holon, Israel.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002608'] 832,31317534,A 2-Year Pragmatic Trial of Antibiotic Stewardship in 27 Community Nursing Homes.,"OBJECTIVES To determine if antibiotic prescribing in community nursing homes (NHs) can be reduced by a multicomponent antibiotic stewardship intervention implemented by medical providers and nursing staff and whether implementation is more effective if performed by a NH chain or a medical provider group. DESIGN Two-year quality improvement pragmatic implementation trial with two arms (NH chain and medical provider group). SETTING A total of 27 community NHs in North Carolina that are typical of NHs statewide, conducted before announcement of the US Centers for Medicare and Medicaid Services antibiotic stewardship mandate. PARTICIPANTS Nursing staff and medical care providers in the participating NHs. INTERVENTION Standardized antibiotic stewardship quality improvement program, including training modules for nurses and medical providers, posters, algorithms, communication guidelines, quarterly information briefs, an annual quality improvement report, an informational brochure for residents and families, and free continuing education credit. MEASUREMENTS Antibiotic prescribing rates per 1000 resident days overall and by infection type; rate of urine test ordering; and incidence of Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA) infections. RESULTS Systemic antibiotic prescription rates decreased from baseline by 18% at 12 months (incident rate ratio [IRR] = 0.82; 95% confidence interval [CI] = 0.69-0.98) and 23% at 24 months (IRR = 0.77; 95% CI = 0.65-0.90). A 10% increase in the proportion of residents with the medical director as primary physician was associated with a 4% reduction in prescribing (IRR = 0.96; 95% CI = 0.92-0.99). Incidence of C. difficile and MRSA infections, hospitalizations, and hospital readmissions did not change significantly. No adverse events from antibiotic nonprescription were reported. Estimated 2-year implementation costs per NH, exclusive of medical provider time, ranged from $354 to $3653. CONCLUSIONS Antibiotic stewardship programs can be successfully disseminated in community NHs through either NH administration or medical provider groups and can achieve significant reductions in antibiotic use for at least 2 years. Medical director involvement is an important element of program success. J Am Geriatr Soc 68:46-54, 2019.",2020,"Incidence of C. difficile and MRSA infections, hospitalizations, and hospital readmissions did not change significantly.","['community nursing homes (NHs', 'Nursing staff and medical care providers in the participating NHs', 'A total of 27 community NHs in North Carolina that are typical of NHs statewide, conducted before announcement of the US Centers for Medicare and Medicaid Services antibiotic stewardship mandate', '27 Community Nursing Homes']","['Antibiotic Stewardship', 'Standardized antibiotic stewardship quality improvement program, including training modules for nurses and medical providers, posters, algorithms, communication guidelines, quarterly information briefs, an annual quality improvement report, an informational brochure for residents and families, and free continuing education credit', 'NH chain and medical provider group']","['Systemic antibiotic prescription rates', 'Antibiotic prescribing rates per 1000 resident days overall and by infection type; rate of urine test ordering; and incidence of Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA) infections', 'Estimated 2-year implementation costs per NH, exclusive of medical provider time', 'Incidence of C. difficile and MRSA infections, hospitalizations, and hospital readmissions', 'proportion of residents with the medical director']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0028698', 'cui_str': 'Nursing Staff'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0028407', 'cui_str': 'North Carolina'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0018717', 'cui_str': 'Health Insurance for Aged and Disabled, Title 18'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]","[{'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0376675', 'cui_str': 'Poster'}, {'cui': 'C0002045'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0013626', 'cui_str': 'Education, Continuing'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C3540005', 'cui_str': 'URINE TESTS'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0079134', 'cui_str': 'Clostridium difficile (bacteria)'}, {'cui': 'C0343401', 'cui_str': 'Methicillin resistant Staphylococcus aureus infection'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1265292', 'cui_str': 'MRSA'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0600290', 'cui_str': 'Hospital Readmissions'}, {'cui': 'C0025081', 'cui_str': 'Medical Directors'}]",,0.0852541,"Incidence of C. difficile and MRSA infections, hospitalizations, and hospital readmissions did not change significantly.","[{'ForeName': 'Philip D', 'Initials': 'PD', 'LastName': 'Sloane', 'Affiliation': 'Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Sheryl', 'Initials': 'S', 'LastName': 'Zimmerman', 'Affiliation': 'Cecil G. Sheps Center for Health Service Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Ward', 'Affiliation': 'Cecil G. Sheps Center for Health Service Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Kistler', 'Affiliation': 'Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Paone', 'Affiliation': 'Paone and Associates LLC, Minneapolis, Minnesota.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Weber', 'Affiliation': 'Division of Infectious Disease, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Wretman', 'Affiliation': 'Cecil G. Sheps Center for Health Service Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Preisser', 'Affiliation': 'Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16059'] 833,31294589,Intensive group behavioral treatment (IGBT) for children with selective mutism: A preliminary randomized clinical trial.,"OBJECTIVE Very few controlled trials have evaluated targeted treatment methods for childhood selective mutism (SM); the availability of evidence-based services remains limited. This study is the first controlled trial to evaluate an intensive group behavioral treatment (IGBT) for children with SM. METHOD Twenty-nine children with SM (5-9 years; 76% female; 35% ethnic minority) were randomized to immediate SM 5-day IGBT or to a 4-week waitlist with psychoeducational resources (WLP), and were assessed at Week 4 and again 8 weeks into the following school year. RESULTS IGBT was associated with high satisfaction and low perceived barriers to treatment participation. At Week 4, 50% of the immediate IGBT condition and 0% of the WLP condition were classified as ""clinical responders."" Further, Time × Condition interactions were significant for social anxiety severity, verbal behavior in social situations, and global functioning (but not for SM severity, verbal behavior in home settings, or overall anxiety). School-year follow-up assessments revealed significant improvements across all outcomes. Eight weeks into the following school year, 46% of IGBT-treated children were free of an SM diagnosis. In addition, teachers in the post-IGBT school year rated less school impairment and more classroom verbal behavior relative to teachers in the pre-IGBT school year. CONCLUSIONS Findings provide the first empirical support for the efficacy and acceptability of IGBT for SM. Further study is needed to examine mechanisms of IGBT response, and other effective SM treatment methods, in order to clarify which treatment formats work best for which affected children. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,School-year follow-up assessments revealed significant improvements across all outcomes.,"['children with SM', 'children with selective mutism', 'Twenty-nine children with SM (5-9 years; 76% female; 35% ethnic minority']","['Intensive group behavioral treatment (IGBT', 'immediate SM 5-day IGBT or to a 4-week waitlist with psychoeducational resources (WLP', 'intensive group behavioral treatment (IGBT']","['classroom verbal behavior', 'social anxiety severity, verbal behavior in social situations, and global functioning', 'SM severity, verbal behavior in home settings, or overall anxiety']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0236818', 'cui_str': 'Selective Mutism'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]","[{'cui': 'C0042530', 'cui_str': 'Verbal Behavior'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",29.0,0.0495299,School-year follow-up assessments revealed significant improvements across all outcomes.,"[{'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Cornacchio', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Jami M', 'Initials': 'JM', 'LastName': 'Furr', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Sanchez', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Hong', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Leah K', 'Initials': 'LK', 'LastName': 'Feinberg', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Tenenbaum', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Del Busto', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Bry', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Poznanski', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Miguel', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Ollendick', 'Affiliation': 'Department of Psychology, Virginia Tech.'}, {'ForeName': 'Steven M S', 'Initials': 'SMS', 'LastName': 'Kurtz', 'Affiliation': 'Private Practice.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Comer', 'Affiliation': 'Center for Children and Families, Mental Health Interventions and Technology (MINT) Program, Department of Psychology, Florida International University.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000422'] 834,31309547,Interventions for morphea.,"BACKGROUND Morphea (morphoea) is an immune-mediated disease in which excess synthesis and deposition of collagen in the skin and underlying connective tissues results in hardened cutaneous areas. Morphea has different clinical features according to the subtype and stage of evolution of the disease. There is currently no consensus on optimal interventions for morphea. OBJECTIVES To assess the effects of treatments for people with any form of morphea. SEARCH METHODS We searched the following databases up to July 2018: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, and five trial registers. We checked the reference lists of included studies for further references to relevant randomised controlled trials. SELECTION CRITERIA Randomised controlled trials of topical, intralesional, or systemic treatments (isolated or combined) in anyone who has been clinically diagnosed by a medical practitioner with any form of morphea. Eligible controls were placebo, no intervention, any other treatment, or different doses or duration of a treatment. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. The primary outcomes were global improvement of disease activity or damage assessed by a medical practitioner or by participants, and adverse effects. Secondary outcomes were improvement of disease activity and improvement of disease damage. We used GRADE to assess the quality of the evidence for each outcome. MAIN RESULTS We included 14 trials, with a total of 429 randomised participants, aged between 3 and 76 years. There were juvenile and adult participants; over half were female, and the majority had circumscribed morphea, followed by linear scleroderma. The settings of the studies (where described) included a dermatologic centre, a national laboratory centre, paediatric rheumatology and dermatology centres, and a university hospital or medical centre.The studies evaluated heterogenous therapies for different types of morphea, covering a wide range of comparisons. We were unable to conduct any meta-analyses. Seven studies investigated topical medications, two evaluated intralesional medications, and five investigated systemic medications. The study duration ranged from seven weeks to 15 months from baseline.We present here results for our primary outcomes for our four key comparisons. All of these results are based on low-quality evidence.The included studies were at high risk of performance, detection, attrition, and reporting bias.Global improvement of disease activity or damage after treatment may be higher with oral methotrexate (15 mg/m², maximum 20 mg, once a week, for 12 months or until disease flare) plus oral prednisone (1 mg/kg a day, maximum of 50 mg, in a single morning dose, for three months, and one month with gradually decreased dose until discontinuation) than with placebo plus oral prednisone in children and adolescents with active morphea (linear scleroderma, generalised morphea or mixed morphea: linear and circumscribed) (risk ratio (RR) 2.31, 95% confidence interval (CI) 1.20 to 4.45; number needed to treat for an additional beneficial outcome (NNTB) 3; 1 randomised controlled trial (RCT); 70 participants, all juvenile). This outcome was measured 12 months from the start of treatment or until flare of the disease. Data were not available separately for each morphea type. There may be little or no difference in the number of participants experiencing at least one adverse event with oral methotrexate (26/46) or placebo (11/24) (RR 1.23, 95% CI 0.75 to 2.04; 1 RCT; 70 participants assessed during the 12-month follow-up). Adverse events related to methotrexate included alopecia, nausea, headache, fatigue and hepatotoxicity, whilst adverse events related to prednisone (given in both groups) included weight gain (more than 5% of body weight) and striae rubrae.One three-armed RCT compared the following treatments: medium-dose (50 J/cm²) UVA-1; low-dose (20 J/cm²) UVA-1; and narrowband UVB phototherapy. There may be little or no difference between treatments in global improvement of disease activity or damage, as assessed through the modified skin score (where high values represent a worse outcome): medium-dose UVA-1 phototherapy versus low-dose UVA-1 group: MD 1.60, 95% CI -1.70 to 4.90 (44 participants); narrowband UVB phototherapy versus medium-dose UVA-1 group: MD -1.70, 95% CI -5.27 to 1.87 (35 participants); and narrowband UVB versus low-dose UVA-1 group: MD -0.10, 95% CI -2.49 to 2.29 (45 participants). This RCT included children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised morphea, or mixed morphea), who received phototherapy five times a week, for eight weeks. Outcomes were measured at eight weeks from the start of treatment.Safety data, measured throughout treatment, from the same RCT (62 participants) showed that treatment with UVA-1 phototherapy may cause mild tanning compared to narrowband UVB: narrowband UVB versus medium-dose UVA-1: RR 0.03, 95% CI 0.00 to 0.42; 35 participants; narrowband UVB versus low-dose UVA-1: RR 0.03, 95% CI 0.00 to 0.41; 45 participants. However, there may be no difference in the number of participants reporting mild tanning when comparing medium and low dose UVA-1 phototherapy (RR 1.00, 95% CI 0.91 to 1.10; 44 participants). Transient erythema was reported in three participants with narrowband UVB and no participants in the low- or medium-dose UVA-1 groups. AUTHORS' CONCLUSIONS Compared to placebo plus oral prednisone, oral methotrexate plus oral prednisone may improve disease activity or damage in juvenile active morphea (linear scleroderma, generalised morphea or mixed morphea: linear and circumscribed), but there may be a slightly increased chance of experiencing at least one adverse event.When medium-dose UVA-1 (50 J/cm²), low-dose UVA-1 (20 J/cm²), and narrowband UVB were compared against each other in treating children and adults with active morphea (circumscribed morphea, linear scleroderma, generalised morphea and mixed morphea), there may be little or no difference between these treatments on global improvement of disease activity or damage. UVA-1 phototherapy may cause more mild tanning than narrowband UVB, but there may be no difference between medium- and low-dose UVA-1 phototherapy. These results are based on low-quality evidence.Limitations of data and analyses include risk of bias and imprecision (small number of participants or events and wide confidence intervals). We encourage multicentre RCTs to increase sample size and evaluate, with validated tools, different treatment responses according to the subtypes of morphea and age groups.",2019,"Compared to placebo plus oral prednisone, oral methotrexate plus oral prednisone may improve disease activity or damage in juvenile active morphea (linear scleroderma, generalised morphea or mixed morphea: linear and circumscribed), but there may be a slightly increased chance of experiencing at least one adverse event.","['14 trials, with a total of 429 randomised participants, aged between 3 and 76 years', 'people with any form of morphea', 'studies (where described) included a dermatologic centre, a national laboratory centre, paediatric rheumatology and dermatology centres, and a university hospital or medical centre', 'anyone who has been clinically diagnosed by a medical practitioner with any form of morphea', 'children and adults with active morphea (circumscribed morphea, linear scleroderma, generalised morphea and mixed morphea', 'children and adults with active morphea (circumscribed morphea, linear scleroderma (with trunk/limb variant and head variant), generalised morphea, or mixed morphea']","['phototherapy', 'oral methotrexate', 'UVA-1', 'UVA-1 phototherapy ', 'placebo', 'narrowband UVB: narrowband UVB versus medium-dose UVA-1', 'oral prednisone', 'methotrexate', 'placebo plus oral prednisone', 'UVA-1 phototherapy', 'placebo plus oral prednisone, oral methotrexate plus oral prednisone', 'narrowband UVB phototherapy']","['modified skin score', 'Transient erythema', 'global improvement of disease activity or damage assessed by a medical practitioner or by participants, and adverse effects', 'alopecia, nausea, headache, fatigue and hepatotoxicity, whilst adverse events', 'disease activity and improvement of disease damage', 'weight gain', 'global improvement of disease activity or damage', 'disease activity or damage']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C1527383', 'cui_str': 'Morphea'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205489', 'cui_str': 'Dermatologic (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1621271', 'cui_str': 'Pediatric rheumatology'}, {'cui': 'C0011627', 'cui_str': 'Dermatology'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C1306754', 'cui_str': 'Medical practitioner (occupation)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1282914', 'cui_str': 'Surrounding (qualifier value)'}, {'cui': 'C0263409', 'cui_str': 'Linear Scleroderma'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0018670', 'cui_str': 'Head'}]","[{'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C3472306', 'cui_str': 'Narrowband ultraviolet B phototherapy (procedure)'}]","[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C1306754', 'cui_str': 'Medical practitioner (occupation)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0002170', 'cui_str': 'Hair Loss'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0235378', 'cui_str': 'Hepatotoxicity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}]",70.0,0.405154,"Compared to placebo plus oral prednisone, oral methotrexate plus oral prednisone may improve disease activity or damage in juvenile active morphea (linear scleroderma, generalised morphea or mixed morphea: linear and circumscribed), but there may be a slightly increased chance of experiencing at least one adverse event.","[{'ForeName': 'Julia V de', 'Initials': 'JV', 'LastName': 'Albuquerque', 'Affiliation': 'Cochrane Brazil, Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde, Rua Borges Lagoa, 564 cj 63, São Paulo, São Paulo, Brazil, 04038-000.'}, {'ForeName': 'Brenda Ng', 'Initials': 'BN', 'LastName': 'Andriolo', 'Affiliation': ''}, {'ForeName': 'Monica Ra', 'Initials': 'MR', 'LastName': 'Vasconcellos', 'Affiliation': ''}, {'ForeName': 'Vinicius T', 'Initials': 'VT', 'LastName': 'Civile', 'Affiliation': ''}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Lyddiatt', 'Affiliation': ''}, {'ForeName': 'Virginia Fm', 'Initials': 'VF', 'LastName': 'Trevisani', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD005027.pub5'] 835,30456780,"Effects of a topical lotion containing aminophylline, caffeine, yohimbe, l-carnitine, and gotu kola on thigh circumference, skinfold thickness, and fat mass in sedentary females.","BACKGROUND AND OBJECTIVE Topical aminophylline, caffeine, yohimbe, l-carnitine, and gotu kola (Centella asiatica) may aid in reducing body fat. Lipoxyderm™ contains these ingredients and was used to test if fat loss of the thigh, in conjunction with a low intensity exercise program and restricted calorie intake, was enhanced via the topical application of this lotion. METHODS This was a double-blind, placebo-controlled, within-group study that investigated the effects of Lipoxyderm™ on thigh fat mass, circumference, and skinfold thickness. Seven participants underwent pre/post-exercise testing for weight, bilateral thigh circumference/skinfold thickness, and body composition/thigh fat mass assessment via dual-energy X-ray absorptiometry. Participants followed a hypocaloric diet, walked 150 minutes/wk, and were randomly assigned to apply a placebo to one leg and Lipoxyderm™ to their other leg for 28 days. Separate two-way mixed factorial repeated measures ANOVAs were used to compare the effects of Lipoxyderm™ to the placebo on thigh circumference, skinfold thickness, and fat mass. RESULTS A significant time x group interaction was found for thigh circumference (F 1,6  = 18.2, P = 0.005), skinfold thickness (F 1,6  = 14.6, P = 0.009), and fat mass (F 1,6  = 37.1, P = 0.001). CONCLUSIONS A twice-daily topical application of Lipoxyderm™ for 28 days compared to a placebo combined with a walking program and a restricted caloric intake is more effective at reducing thigh circumference (1.2 vs 0.8 cm), thigh skinfold thickness (3.7 vs 2.0 mm), and thigh fat mass (100.0 g vs 57.3 g).",2019,"A significant time x group interaction was found for thigh circumference (F 1,6  = 18.2, P = 0.005), skinfold thickness (F 1,6  = 14.6, P = 0.009), and fat mass (F 1,6  = 37.1, P = 0.001). ",['sedentary females'],"['hypocaloric diet', 'placebo', 'aminophylline, caffeine, yohimbe, l-carnitine, and gotu kola (Centella asiatica', 'Lipoxyderm', 'topical lotion containing aminophylline, caffeine, yohimbe, l-carnitine, and gotu kola']","['thigh skinfold thickness', 'thigh circumference', 'thigh fat mass, circumference, and skinfold thickness', 'fat mass', 'thigh circumference, skinfold thickness, and fat mass', 'skinfold thickness', 'thigh fat mass']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0002575', 'cui_str': 'Aminophylline'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C1123032', 'cui_str': 'Pausinystalia johimbe'}, {'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C0772382', 'cui_str': 'Gotu kola'}, {'cui': 'C0991552', 'cui_str': 'Topical Lotion'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0037302', 'cui_str': 'Skinfold Thickness'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}]",7.0,0.147766,"A significant time x group interaction was found for thigh circumference (F 1,6  = 18.2, P = 0.005), skinfold thickness (F 1,6  = 14.6, P = 0.009), and fat mass (F 1,6  = 37.1, P = 0.001). ","[{'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Escalante', 'Affiliation': 'California State University, San Bernardino, San Bernardino, California.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Bryan', 'Affiliation': 'California State University, San Bernardino, San Bernardino, California.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Rodriguez', 'Affiliation': 'California State University, San Bernardino, San Bernardino, California.'}]",Journal of cosmetic dermatology,['10.1111/jocd.12801'] 836,31299352,How Maternal BMI Modifies the Impact of Personalized Asthma Management in Pregnancy.,"BACKGROUND Maternal asthma is associated with perinatal complications and respiratory illness in offspring. Obesity increases asthma exacerbation risk in pregnancy and risk of wheeze in offspring. OBJECTIVES In this secondary analysis of a randomized controlled trial, we investigated the influence of maternal body mass index, gestational weight gain (GWG), and fractional exhaled nitric oxide (F E NO)-based management on asthma exacerbations in pregnancy and offspring wheeze. METHODS A total of 220 women were randomized to asthma treatment adjustment according to symptoms (control group), or F E NO and symptoms (F E NO group). Exacerbations were recorded prospectively. Height and weight were measured at baseline, and in late pregnancy. GWG was categorized according to Institute of Medicine guidelines. A validated parent-completed questionnaire assessed infant wheeze-related outcomes. RESULTS F E NO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104). Recurrent bronchiolitis occurred in 5.3% (n = 1) of infants born to non-overweight mothers, 16.7% (n = 3) of infants of overweight mothers, and 21.7% (n = 5) of infants of obese mothers in the control group. In the F E NO group, 2 infants of obese mothers had recurrent bronchiolitis (7.1%, P = .031). CONCLUSIONS The benefits of F E NO-based management are attenuated among obese mothers and those with excess GWG, indicating the importance of weight management in contributing to improved asthma management in pregnancy.",2020,"RESULTS F E NO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104).","['asthma exacerbations in pregnancy and offspring wheeze', 'obese mothers', 'Pregnancy', '220 women']",[],"['maternal body mass index, gestational weight gain (GWG), and fractional exhaled nitric oxide', 'Height and weight', 'incidence rate ratio for maternal exacerbations', 'recurrent bronchiolitis', 'Recurrent bronchiolitis']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]",[],"[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1398625', 'cui_str': 'Pregnancy Weight Gain'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0424638', 'cui_str': 'Height and weight'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0006271', 'cui_str': 'Bronchiolitis'}]",220.0,0.189097,"RESULTS F E NO-based management was associated with a significantly lower incidence rate ratio for maternal exacerbations in nonobese mothers (0.52, 95% confidence interval [CI], 0.31-0.88, P = .015, n = 129), and women with GWG within recommendations (0.35, 95% CI, 0.12-0.96, P = .042, n = 43), but not for obese mothers (0.59, 95% CI, 0.32-1.08, P = .089, n = 88), or women with excess GWG (0.58, 95% CI, 0.32-1.04, P = .07, n = 104).","[{'ForeName': 'Vanessa E', 'Initials': 'VE', 'LastName': 'Murphy', 'Affiliation': 'Priority Research Centre GrowUpWell(TM) and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia. Electronic address: vanessa.murphy@newcastle.edu.au.'}, {'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Jensen', 'Affiliation': 'Priority Research Centre GrowUpWell(TM) and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Annelies L', 'Initials': 'AL', 'LastName': 'Robijn', 'Affiliation': 'Priority Research Centre GrowUpWell(TM) and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Wright', 'Affiliation': 'Priority Research Centre for Healthy Lungs and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Joerg', 'Initials': 'J', 'LastName': 'Mattes', 'Affiliation': ""Priority Research Centre GrowUpWell(TM) and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia; Department of Paediatric Respiratory and Sleep Medicine, John Hunter Children's Hospital, Newcastle, NSW, Australia.""}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Collison', 'Affiliation': 'Priority Research Centre GrowUpWell(TM) and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Gibson', 'Affiliation': 'Priority Research Centre for Healthy Lungs and Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2019.06.033'] 837,31251094,Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.,"Objective: To assess the effect of asthma exacerbations and mepolizumab treatment on health status of patients with severe asthma using the St George's Respiratory Questionnaire (SGRQ). Methods: Post hoc analyses were conducted using data from two randomized controlled trials in patients ≥12 years old with severe eosinophilic asthma randomized to receive placebo or mepolizumab 75 mg intravenously (32-week MENSA study) or 100 mg subcutaneously (MENSA/24-week MUSCA studies), and an observational single-visit study in patients with severe asthma (IDEAL). Linear regression models assessed the impact of historical exacerbations on baseline SGRQ total and domain scores (using data from each of the three studies), and within-study severe exacerbations and mepolizumab treatment on end-of-study SGRQ scores (using data from MENSA/MUSCA). Results: Overall, 1755 patients were included (MENSA, N  = 540; MUSCA, N = 551; IDEAL, N  = 664). In all studies, higher numbers of historical exacerbations were associated with worse baseline SGRQ total scores. Each additional historical exacerbation (beyond the second [MENSA/MUSCA]) or first [IDEAL] was associated with worsening mean total SGRQ scores of +1.5, +1.1 at baseline and +2.3 within the year prior to study enrollment. During MENSA and MUSCA, each within-study severe exacerbation was associated with a worsening in total SGRQ score of +2.4 and +3.4 points at study end. Independent of exacerbation reduction, mepolizumab accounted for an improvement in total SGRQ score of -5.3 points (MENSA) and -6.2 points (MUSCA). Conclusions: These findings support an association between a higher number of exacerbations and worse health status in patients with severe (eosinophilic) asthma.",2020,"During MENSA and MUSCA, each within-study severe exacerbation was associated with a worsening in total SGRQ score of +2.4 and +3.4 points at study end.","['1755 patients were included (MENSA, N \u2009=\u2009540; MUSCA, N\u2009=\u2009551; IDEAL, N \u2009=\u2009664', 'patients with severe asthma', 'patients ≥12\u2009years old with severe eosinophilic asthma', ""patients with severe asthma using the St George's Respiratory Questionnaire (SGRQ"", 'patients with severe asthma (IDEAL', 'patients with severe (eosinophilic) asthma']","['placebo or mepolizumab 75\u2009mg intravenously (32-week MENSA study) or 100\u2009mg subcutaneously (MENSA/24-week MUSCA studies', 'mepolizumab treatment']","['baseline SGRQ total and domain scores', 'health status', 'worsening mean total SGRQ scores', 'historical exacerbations', 'total SGRQ score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0323065', 'cui_str': 'Musca (organism)'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0034068', 'cui_str': 'Pulmonary Eosinophilia'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0969324', 'cui_str': 'mepolizumab'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0323065', 'cui_str': 'Musca (organism)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",1755.0,0.199655,"During MENSA and MUSCA, each within-study severe exacerbation was associated with a worsening in total SGRQ score of +2.4 and +3.4 points at study end.","[{'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Nelsen', 'Affiliation': 'Patient Centered Outcomes, Value Evidence and Outcomes, GSK, Collegeville, PA, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Cockle', 'Affiliation': 'Value Evidence and Outcomes, GSK House, Brentford, UK.'}, {'ForeName': 'Necdet B', 'Initials': 'NB', 'LastName': 'Gunsoy', 'Affiliation': 'Clinical Statistics, GSK, Stockley Park, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Jones', 'Affiliation': 'Respiratory Medical, GSK House, Brentford, UK.'}, {'ForeName': 'Frank C', 'Initials': 'FC', 'LastName': 'Albers', 'Affiliation': 'Respiratory Medical Franchise, GSK SK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Eric S', 'Initials': 'ES', 'LastName': 'Bradford', 'Affiliation': 'Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Mullerova', 'Affiliation': 'Real World Evidence and Epidemiology, GSK, Stockley Park, Uxbridge, UK.'}]",The Journal of asthma : official journal of the Association for the Care of Asthma,['10.1080/02770903.2019.1630640'] 838,31292734,High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease.,"Various studies report discordant results regarding the efficacy, parameters, and underlying mechanisms of repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training (CT) on Alzheimer's disease (AD). The objective of the study was to assess the effect of rTMS-CT on cognition, the activities of daily life, neuropsychiatric behavioral symptoms, and metabolite levels beneath the stimulated areas of the brain in patients with AD and to investigate the correlation of metabolic changes (measured with proton magnetic resonance spectroscopy [ 1 H-MRS]) with clinical outcomes after treatment. Thirty consecutive patients with mild or moderate AD were enrolled and randomly divided into one of the two intervention groups: (1) real rTMS with CT (i.e., real group) and (2) sham rTMS with CT (i.e., sham group). 10 Hz rTMS was used to stimulate the left dorsolateral prefrontal cortex (DLPFC) and then to stimulate the left lateral temporal lobe (LTL) for 20 min each day for 4 weeks. Each patient underwent neuropsychological assessment at baseline (T0), immediately after treatment (T1), and 4 weeks after treatment (T2). The ratios of N-acetylaspartate/creatine (NAA/Cr), myoinositol/creatine (mI/Cr), and choline/creatine (Cho/Cr) in the stimulated cortex were measured using 1 H-MRS at T0 and T1. Twenty-eight patients were treated with rTMS-CT for 4 weeks. Two patients in the sham group withdrew after being treated several times. Compared with the sham group, the cognitive function and behavior in the real rTMS group improved significantly at T1 and T2. In the real group, compared with the sham group, the NAA/Cr ratio in the left DLPFC was significantly elevated (p = 0.045); however, in the left LTL, it only showed a tendency toward increase (p = 0.162). The change in the NAA/Cr ratio in the left DLPFC was negatively correlated with the change in the cognitive scales of the Alzheimer's Disease Assessment Scale (ADAS-cog). This study indicated a possible modest effect of rTMS-CT on preventing clinical and neuronal functional deterioration in the left DLPFC of patients with AD. The left DLPFC is a better candidate area than the left LTL.",2019,"Compared with the sham group, the cognitive function and behavior in the real rTMS group improved significantly at T1 and T2.","[""Alzheimer's disease (AD"", 'patients with AD', ""Alzheimer's disease"", 'Thirty consecutive patients with mild or moderate AD', '10']","['rTMS-CT', 'real rTMS with CT (i.e., real group) and (2) sham rTMS with CT', 'repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training (CT', 'High-frequency repetitive transcranial magnetic stimulation combined with cognitive training', 'Hz rTMS']","['cognitive function and behavior', 'cognitive function and cortical metabolic ratios', 'cognition, the activities of daily life, neuropsychiatric behavioral symptoms, and metabolite levels', ""cognitive scales of the Alzheimer's Disease Assessment Scale (ADAS-cog"", 'ratios of N-acetylaspartate/creatine (NAA/Cr), myoinositol/creatine (mI/Cr), and choline/creatine (Cho/Cr', 'clinical and neuronal functional deterioration', 'NAA/Cr ratio']","[{'cui': 'C0002395', 'cui_str': 'Alzheimer Dementia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's disease assessment scale (assessment scale)""}, {'cui': 'C0067684', 'cui_str': 'N-acetyl aspartate'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0021547', 'cui_str': 'Inositol'}, {'cui': 'C0008405', 'cui_str': 'Choline'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",30.0,0.0284225,"Compared with the sham group, the cognitive function and behavior in the real rTMS group improved significantly at T1 and T2.","[{'ForeName': 'Fengxia', 'Initials': 'F', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Department of Radiology, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.'}, {'ForeName': 'Lingfeng', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Department of Rehabilitation, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.'}, {'ForeName': 'Caixia', 'Initials': 'C', 'LastName': 'Zheng', 'Affiliation': 'Department of Rehabilitation, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.'}, {'ForeName': 'Xiaolin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Rehabilitation, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. xiaolinh2006@126.com.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. zhang_min_3464@126.com.'}]","Journal of neural transmission (Vienna, Austria : 1996)",['10.1007/s00702-019-02022-y'] 839,31298169,Clinical effectiveness of the START (STrAtegies for RelaTives) psychological intervention for family carers and the effects on the cost of care for people with dementia: 6-year follow-up of a randomised controlled trial.,"BACKGROUND The START (STrAtegies for RelaTives) intervention reduced depressive and anxiety symptoms of family carers of relatives with dementia at home over 2 years and was cost-effective. AIMS To assess the clinical effectiveness over 6 years and the impact on costs and care home admission. METHOD We conducted a randomised, parallel group, superiority trial recruiting from 4 November 2009 to 8 June 2011 with 6-year follow-up (trial registration: ISCTRN 70017938). A total of 260 self-identified family carers of people with dementia were randomised 2:1 to START, an eight-session manual-based coping intervention delivered by supervised psychology graduates, or to treatment as usual (TAU). The primary outcome was affective symptoms (Hospital Anxiety and Depression Scale, total score (HADS-T)). Secondary outcomes included patient and carer service costs and care home admission. RESULTS In total, 222 (85.4%) of 173 carers randomised to START and 87 to TAU were included in the 6-year clinical efficacy analysis. Over 72 months, compared with TAU, the intervention group had improved scores on HADS-T (adjusted mean difference -2.00 points, 95% CI -3.38 to -0.63). Patient-related costs (START versus TAU, respectively: median £5759 v. £16 964 in the final year; P = 0.07) and carer-related costs (median £377 v. £274 in the final year) were not significantly different between groups nor were group differences in time until care home (intensity ratio START:TAU was 0.88, 95% CI 0.58-1.35). CONCLUSIONS START is clinically effective and this effect lasts for 6 years without increasing costs. This is the first intervention with such a long-term clinical and possible economic benefit and has potential to make a difference to individual carers. DECLARATIONS OF INTEREST G.L., Z.W. and C.C. are supported by the UCLH National Institute for Health Research (NIHR) Biomedical Research Centre. G.L. and P.R. were in part supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North Thames at Bart's Health NHS Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Z.W. reports during the conduct of the study; personal fees from GE Healthcare, grants from GE Healthcare, grants from Lundbeck, other from GE Healthcare, outside the submitted work.",2020,"Over 72 months, compared with TAU, the intervention group had improved scores on HADS-T (adjusted mean difference -2.00 points, 95% CI -3.38 to -0.63).","['people with dementia', '260 self-identified family carers of people with dementia', 'In total, 222 (85.4%) of 173 carers randomised to START and 87 to TAU', '4 November 2009 to 8 June 2011 with 6-year follow-up (trial registration: ISCTRN 70017938']","['eight-session manual-based coping intervention delivered by supervised psychology graduates, or to treatment as usual (TAU', 'START (STrAtegies for RelaTives) psychological intervention']","['NIHR', 'carer-related costs', 'time until care home (intensity ratio START', 'scores on HADS-T', 'patient and carer service costs and care home admission', 'affective symptoms (Hospital Anxiety and Depression Scale, total score (HADS-T']","[{'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C4517669', 'cui_str': 'Two hundred and sixty'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0588053', 'cui_str': 'Graduate (person)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}]","[{'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0001726', 'cui_str': 'Affective Symptoms'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",173.0,0.180669,"Over 72 months, compared with TAU, the intervention group had improved scores on HADS-T (adjusted mean difference -2.00 points, 95% CI -3.38 to -0.63).","[{'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Livingston', 'Affiliation': ""Professor of Older People's Psychiatry, Division of Psychiatry, UCL; and Camden and Islington NHS Foundation Trust, St Pancras Hospital, UK.""}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Manela', 'Affiliation': 'Research Doctor, Division of Psychiatry, UCL, UK.'}, {'ForeName': 'Aidan', 'Initials': 'A', 'LastName': ""O'Keeffe"", 'Affiliation': 'Lecturer in Statistics, UCL Statistical Science and PRIMENT Clinical Trials Unit, UCL, UK.'}, {'ForeName': 'Penny', 'Initials': 'P', 'LastName': 'Rapaport', 'Affiliation': 'Principal Clinical Psychologist, Division of Psychiatry, UCL, UK.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Professor, Division of Psychiatry, UCL; and Camden and Islington NHS Foundation Trust, St Pancras Hospital, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Knapp', 'Affiliation': 'Professor of Social Policy, Personal Social Services Research Unit, London School of Economics & Political Science, UK.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'King', 'Affiliation': 'Assistant Professorial Research Fellow, Personal Social Services Research Unit, London School of Economics & Political Science, UK.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Romeo', 'Affiliation': ""Senior Lecturer in Health Economics, Institute of Psychiatry Psychology and Neuroscience, King's College London, UK.""}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Walker', 'Affiliation': 'Professor, Division of Psychiatry, UCL; and Essex Partnership University NHS Foundation Trust, UK.'}, {'ForeName': 'Juanita', 'Initials': 'J', 'LastName': 'Hoe', 'Affiliation': 'Senior Clinical Research Associate, Division of Psychiatry, UCL, UK.'}, {'ForeName': 'Cath', 'Initials': 'C', 'LastName': 'Mummery', 'Affiliation': 'Consultant Neurologist, Honorary Senior Lecturer, Institute of Neurology, UCL, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Barber', 'Affiliation': 'Associate Professor in Medical Statistics, UCL Statistical Science and PRIMENT Clinical Trials Unit, UCL, UK.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2019.160'] 840,31152441,Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.,"TRIAL DESIGN SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo within 4 hours of onset of a migraine attack. The aim of this analysis was to characterize dizziness reported with lasmiditan treatment. METHODS Data from SAMURAI and SPARTAN were pooled for the current post hoc analyses. Onset time and duration of dizziness were analyzed using descriptive statistics. Subgroup analyses based on presence/absence of dizziness were performed for the endpoints of interference with daily activity, patient global impression of change (PGIC), pain at 2 hours, and most bothersome symptom (MBS) at 2 hours based on adverse events occurring within 2 hours of taking study drug. RESULTS Dizziness incidence was as follows: Placebo (N = 1262), 2.9% (0.1% severe); lasmiditan 50 mg (N = 654), 8.6% (0.3% severe); lasmiditan 100 mg (N = 1265), 14.9% (0.7% severe); and lasmiditan 200 mg (N = 1258), 16.8% (1.4% severe). Among participants who received lasmiditan as their first dose, risk factors for dizziness were higher lasmiditan dosage, being non-Hispanic/Latino, mild or moderate severity of migraine attack, and lower body mass index. The median time to onset of dizziness was generally 30-40 minutes, and the median duration was 1.5-2 hours. The presence of dizziness did not appear to have a negative influence on lasmiditan's effect on daily activity, PGIC, freedom from pain, or MBS. Overall, 21 participants experienced vertigo: Lasmiditan 50 mg, n = 2 (0.3%); 100 mg, n = 11 (0.9%); 200 mg, n = 7 (0.6%); and placebo, n = 1 (<0.1%). CONCLUSION The incidence of dizziness with lasmiditan increased with dose. Dizziness was generally mild or moderate in severity and of quick onset and short duration. The presence of dizziness did not influence drug efficacy.",2019,"The presence of dizziness did not appear to have a negative influence on lasmiditan's effect on daily activity, PGIC, freedom from pain, or MBS.","['Individuals with migraine', '21 participants experienced vertigo', 'controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only']","['oral lasmiditan 50\xa0mg (SPARTAN only), 100\xa0mg, 200\xa0mg, or placebo', 'Placebo', 'placebo']","['dizziness with lasmiditan', 'interference with daily activity, patient global impression of change (PGIC), pain at 2\xa0hours, and most bothersome symptom (MBS', 'median duration', 'Dizziness', 'median time to onset of dizziness', 'Onset time and duration of dizziness', 'daily activity, PGIC, freedom from pain, or MBS', 'dizziness']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0042571', 'cui_str': 'Spinning Sensation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0017480', 'cui_str': 'Germany'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1292425', 'cui_str': '2 hours (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}]",,0.254957,"The presence of dizziness did not appear to have a negative influence on lasmiditan's effect on daily activity, PGIC, freedom from pain, or MBS.","[{'ForeName': 'Stewart J', 'Initials': 'SJ', 'LastName': 'Tepper', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Hanover, NH, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Krege', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Lombard', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Josephine K', 'Initials': 'JK', 'LastName': 'Asafu-Adjei', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Sherie A', 'Initials': 'SA', 'LastName': 'Dowsett', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Raskin', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Buchanan', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Deborah I', 'Initials': 'DI', 'LastName': 'Friedman', 'Affiliation': 'University of Texas, Southwestern Medical Center, Dallas, TX, USA.'}]",Headache,['10.1111/head.13544'] 841,31286426,"Effect of hand hygiene intervention on the absenteeism of pre-school children in Klang Valley, Malaysia: a quasi-experimental study.","BACKGROUND Absenteeism amongst pre-school children is often due to illnesses such as hand, foot, and mouth disease, acute gastroenteritis, cold and flu, which are easily spread amongst them. This is because of weak immunity and lack of knowledge on proper hand hygiene. This quasi-experimental study assessed the efficacy of an intervention consisting of a hand hygiene education programme, along with digital tools in bringing about a change in behaviour and health conditions amongst pre-school children in Klang Valley, Malaysia. METHODS A total of 377 school children, male and female, aged 5-6 years old, participated and were assigned to either the intervention or a control group. During the 2 months intervention period, children in the test group were trained on proper hand hygiene practices and techniques with the aid of the interactive android-based tablets. The numbers of absent days of all the children were recorded for 2 months before the intervention and during the intervention. RESULTS In the test group, there was a 25% increase in the total number of absent days from the pre-intervention period to the intervention period, a much lesser increment observed as compared to that of control group in which the increase was much higher at 89%. Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. CONCLUSION These results suggest that proper education and intervention increase hand hygiene compliance, which may help decrease school absenteeism due to illness; however, a longer study duration may be necessary to evaluate the benefit further.",2020,"Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. ","['pre-school children in Klang Valley, Malaysia', 'Absenteeism amongst pre-school children', 'absenteeism of pre-school children in Klang Valley, Malaysia', '377 school children, male and female, aged 5-6\xa0years old']","['trained on proper hand hygiene practices and techniques with the aid of the interactive android-based tablets', 'hand hygiene intervention']","['absenteeism rates', 'total number of absent days']","[{'cui': 'C0424930', 'cui_str': 'Pre-school (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0563004', 'cui_str': 'Valley (environment)'}, {'cui': 'C0024552', 'cui_str': 'Federation of Malaya'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0449435', 'cui_str': 'Aid (attribute)'}, {'cui': 'C0718532', 'cui_str': 'Android'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",377.0,0.0238952,"Results showed a significant difference (P < 0·05) between the absenteeism rates for the test and control group during the intervention period. ","[{'ForeName': 'Nurul Azmawati', 'Initials': 'NA', 'LastName': 'Mohamed', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia. drnurul@usim.edu.my.'}, {'ForeName': 'Mohd Dzulkhairi', 'Initials': 'MD', 'LastName': 'Mohd Rani', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Tengku Zetty Maztura', 'Initials': 'TZM', 'LastName': 'Tengku Jamaluddin', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400, Serdang, Selangor, Malaysia.'}, {'ForeName': 'Zarini', 'Initials': 'Z', 'LastName': 'Ismail', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Shalinawati', 'Initials': 'S', 'LastName': 'Ramli', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Habibah', 'Initials': 'H', 'LastName': 'Faroque', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Farisha Nur', 'Initials': 'FN', 'LastName': 'Abd Samad', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Abdul Rashid', 'Initials': 'AR', 'LastName': 'Ariffien', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Aisyah Ar Redha', 'Initials': 'AAR', 'LastName': 'Che Amir Farid', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Ilina', 'Initials': 'I', 'LastName': 'Isahak', 'Affiliation': 'Faculty of Medicine and Health Sciences, Universiti Sains Islam Malaysia, Pandan Indah, 55100, Kuala Lumpur, Malaysia.'}]",World journal of pediatrics : WJP,['10.1007/s12519-019-00283-x'] 842,31276454,"Acute alcohol effects on conditioned pain modulation, but not temporal summation of pain.","Although pain reduction after alcohol administration has repeatedly been demonstrated, alcohol effects on advanced and clinically relevant dynamic pain paradigms are still unknown. As such, temporal summation of pain (TSP) and conditioned pain modulation (CPM) indicate mechanisms of endogenous pain modulation and involve certain neurotransmitter systems crucially influenced by alcohol. Our study is the first to investigate acute alcohol effects on TSP and CPM. We investigated 39 healthy subjects in a placebo-controlled within-subject design and targeted alcohol levels of 0.06% (dose 1) and 0.08% (dose 2). Pain threshold, TSP, and CPM were evaluated before and after an alcoholic or placebo drink. Temporal summation of pain was assessed as enhanced pain response to 5 repetitive contact heat stimuli (threshold +3°C). Conditioned pain modulation was tested as pain inhibition when a conditioning stimulus (46°C hot water) was applied concurrently to a test stimulus (contact heat; threshold + 3°C). Both alcohol doses boosted CPM, with a greater effect size for the higher dose. Conditioning stimulus ratings increased after alcohol intake but were not correlated with CPM, suggesting independence of these effects. Temporal summation of pain was not affected by alcohol, and alcohol effects on pain threshold were small and limited to the higher dose. Our findings suggest that analgesic alcohol effects might be mainly driven by an enhancement of endogenous pain inhibition. The frequent use of alcohol as self-medication in chronic pain might be motivated by alcohol temporarily restoring deficient CPM, thus leading to pain relief in the short run and alcohol-related problems in the long run.",2019,"Temporal summation of pain was not affected by alcohol, and alcohol effects on pain threshold were small and limited to the higher dose.",['39 healthy subjects in a'],['placebo'],"['Temporal summation of pain', 'pain inhibition', 'Pain threshold, TSP, and CPM', 'conditioned pain modulation', 'enhanced pain response', 'Conditioning stimulus ratings', 'Conditioned pain modulation']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0234110', 'cui_str': 'Temporal summation, function (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C1533179', 'cui_str': 'Tsp'}, {'cui': 'C0392412', 'cui_str': 'cpm'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0234404', 'cui_str': 'Conditioned stimulus, function (observable entity)'}]",39.0,0.0339645,"Temporal summation of pain was not affected by alcohol, and alcohol effects on pain threshold were small and limited to the higher dose.","[{'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Horn-Hofmann', 'Affiliation': 'Physiological Psychology, Otto-Friedrich University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Eva Susanne', 'Initials': 'ES', 'LastName': 'Capito', 'Affiliation': 'Physiological Psychology, Otto-Friedrich University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Wolstein', 'Affiliation': 'Pathopsychology, Otto-Friedrich University of Bamberg, Bamberg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Lautenbacher', 'Affiliation': 'Physiological Psychology, Otto-Friedrich University of Bamberg, Bamberg, Germany.'}]",Pain,['10.1097/j.pain.0000000000001597'] 843,31283892,Randomized Controlled Study to Evaluate Microbial Ecological Effects of CPP-ACP and Cranberry on Dental Plaque.,"INTRODUCTION Ecological approaches to dental caries prevention play a key role in attaining long-term control over the disease and maintaining a symbiotic oral microbiome. OBJECTIVES This study aimed to investigate the microbial ecological effects of 2 interventional dentifrices: a casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) dentifrice and the same dentifrice supplemented with a polyphenol-rich cranberry extract. METHODS The interventional toothpastes were compared with each other and with an active control fluoride dentifrice in a double-blinded randomized controlled trial. Real-time quantitative polymerase chain reaction (qPCR) analysis was used to determine changes in the bacterial loads of 14 key bacterial species (8 caries associated and 6 health associated) in the dental plaque of trial participants after they used the dentifrices for 5 to 6 wk. RESULTS From the baseline to the recall visit, significant differences were observed between the treatment groups in the bacterial loads of 2 caries-associated bacterial species ( Streptococcus mutans [ P < 0.001] and Veillonella parvula [ P < 0.001]) and 3 health-associated bacterial species ( Corynebacterium durum [P = 0.008], Neisseria flavescens [ P = 0.005], and Streptococcus sanguinis [ P < 0.001]). Compared to the fluoride control dentifrice, the CPP-ACP dentifrice demonstrated significant differences for S. mutans ( P = 0.032), C. durum ( P = 0.007), and S. sanguinis ( P < 0.001), while combination CPP-ACP-cranberry dentifrice showed significant differences for S. mutans ( P < 0.001), V. parvula ( P < 0.001), N. flavescens ( P = 0.003), and S. sanguinis ( P < 0.001). However, no significant differences were observed in the bacterial load comparisons between the CPP-ACP and combination dentifrices for any of the targeted bacterial species ( P > 0.05). CONCLUSIONS Overall, the results indicate that dentifrices containing CPP-ACP and polyphenol-rich cranberry extracts can influence a species-level shift in the ecology of the oral microbiome, resulting in a microbial community less associated with dental caries (Australian New Zealand Clinical Trial Registry ANZCTR 12618000095268). KNOWLEDGE TRANSFER STATEMENT The results of this randomized controlled trial indicate that dentifrices containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) and polyphenol-rich cranberry extracts were able to beneficially modulate the microbial ecology of dental plaque in a group of high caries-risk patients. This could contribute toward lowering the risk of developing new caries lesions, an important goal sought by patients, clinicians, and policy makers.",2020,"However, no significant differences were observed in the bacterial load comparisons between the CPP-ACP and combination dentifrices for any of the targeted bacterial species ( P > 0.05). ",['high caries-risk patients'],"['polyphenol-rich cranberry extracts', 'casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) dentifrice', 'dentifrices containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) and polyphenol-rich cranberry extracts', 'polyphenol-rich cranberry extract', 'active control fluoride dentifrice', 'fluoride control dentifrice', 'CPP-ACP and Cranberry', 'CPP-ACP dentifrice', 'Real-time quantitative polymerase chain reaction (qPCR']","['microbial ecological effects', 'bacterial loads of 2 caries-associated bacterial species', 'Dental Plaque']","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0071649', 'cui_str': 'Polyphenol (substance)'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0936050', 'cui_str': 'Cranberry'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0031684', 'cui_str': 'Phosphopeptides'}, {'cui': 'C1956739', 'cui_str': 'Ca9(PO4)6'}, {'cui': 'C1120338', 'cui_str': 'casein phosphopeptide-amorphous calcium phosphate nanocomplex'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0032520', 'cui_str': 'PCR'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C2936404', 'cui_str': 'Bacterial Load'}, {'cui': 'C0333519', 'cui_str': 'Caries (morphologic abnormality)'}, {'cui': 'C0011389', 'cui_str': 'Dental Plaque'}]",,0.134686,"However, no significant differences were observed in the bacterial load comparisons between the CPP-ACP and combination dentifrices for any of the targeted bacterial species ( P > 0.05). ","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Philip', 'Affiliation': 'The University of Queensland School of Dentistry, Brisbane, Australia.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Leishman', 'Affiliation': 'The University of Queensland School of Dentistry, Brisbane, Australia.'}, {'ForeName': 'H M H N', 'Initials': 'HMHN', 'LastName': 'Bandara', 'Affiliation': 'Bristol Dental School, University of Bristol, Bristol, UK.'}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Healey', 'Affiliation': 'The University of Queensland School of Dentistry, Brisbane, Australia.'}, {'ForeName': 'L J', 'Initials': 'LJ', 'LastName': 'Walsh', 'Affiliation': 'The University of Queensland School of Dentistry, Brisbane, Australia.'}]",JDR clinical and translational research,['10.1177/2380084419859871'] 844,31285554,Pretreatment Prevotella-to-Bacteroides ratio and markers of glucose metabolism as prognostic markers for dietary weight loss maintenance.,"BACKGROUND/OBJECTIVES Pre-treatment gut microbial Prevotella-to-Bacteroides (P/B) ratio and markers of glucose metabolism (i.e., fasting glucose and insulin) have been suggested as biomarkers for optimal weight management. However, both biomarkers need further validation, and the interactions between them for optimal weight management are largely unknown. To investigate differences in weight loss maintenance between subjects with low and high P/B ratio and the potential interactions with markers of glucose metabolism and dietary fiber intake. SUBJECTS/METHODS Following an 8-week weight loss period using meal replacement products, subjects losing ≥ 8% of their initial body weight were randomized to one of three protein supplements or maltodextrin for a 24-week weight maintenance period. Habitual diet was consumed along with the supplements expected to constitute 10-15% of total energy. For this analysis we stratified the participants into low and high strata based on median values of pre-intervention P/B ratio, pre-weight loss Homeostatic model assessment of insulin resistance (HOMA-IR) (<2.33 or > 2.33), and dietary fiber intake during the intervention (< 28.5 or > 28.5 g/10 MJ). RESULTS Regardless of weight maintenance regimen, subjects with high P/B ratio (n = 63) regained 1.5 (95% CI 0.4, 2.7) kg body weight (P = 0.007) more than subjects with low P/B ratio (n = 63). The regain among subjects with high P/B ratio was particular evident if HOMA-IR was high and dietary fiber intake was low. Consequently, in the high P/B strata, subjects with high HOMA-IR and low fiber intake (n = 17) regained 5.3 (95% CI 3.3, 7.3) kg (P < 0.001) more body weight compared with participants with low HOMA-IR and high fiber intake (n = 16). CONCLUSIONS Subjects with high P/B ratio were more susceptible to regain body weight compared with subjects with low P/B ratio, especially when dietary fiber intake was low and glucose metabolism was impaired. These observations underline that both the P/B ratio and markers of glucose metabolism should be considered as important biomarkers within personalized nutrition for optimal weight management.",2020,"< 0.001) more body weight compared with participants with low HOMA-IR and high fiber intake (n = 16). ","['subjects with low and high P/B ratio', 'subjects losing\u2009≥\u20098% of their initial body weight']",['protein supplements or maltodextrin'],"['dietary fiber intake', 'weight loss maintenance', 'insulin resistance (HOMA-IR) ', 'body weight']","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}]","[{'cui': 'C0474451', 'cui_str': 'Dietary fiber intake (observable entity)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",,0.014041,"< 0.001) more body weight compared with participants with low HOMA-IR and high fiber intake (n = 16). ","[{'ForeName': 'Mads F', 'Initials': 'MF', 'LastName': 'Hjorth', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. madsfiil@nexs.ku.dk.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Christensen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Kjølbæk', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lesli H', 'Initials': 'LH', 'LastName': 'Larsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Henrik M', 'Initials': 'HM', 'LastName': 'Roager', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Pia', 'Initials': 'P', 'LastName': 'Kiilerich', 'Affiliation': 'Laboratory of Genomics and Molecular Biomedicine, Department of Biology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Kristiansen', 'Affiliation': 'Laboratory of Genomics and Molecular Biomedicine, Department of Biology, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Astrup', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0466-1'] 845,30566847,Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.,"Rationale: Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and N -Acetylcysteine in Patients with IPF) clinical trial. The reason why some patients with IPF experience harm is unknown. Objectives: To determine whether age-adjusted leukocyte telomere length (LTL) was associated with the harmful effect of immunosuppression in patients with IPF. Methods: LTL was measured from available DNA samples from PANTHER-IPF (interim analysis, n  = 79; final analysis, n  = 118). Replication cohorts included ACE-IPF (Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis) ( n  = 101) and an independent observational cohort (University of Texas Southwestern Medical Center-IPF, n  = 170). LTL-stratified and medication-stratified survival analyses were performed using multivariable Cox regression models for composite endpoint-free survival. Measurements and Main Results: Of the subjects enrolled in the PANTHER-IPF and ACE-IPF, 62% (49/79) and 56% (28/50) had an LTL less than the 10th percentile of normal, respectively. In PANTHER-IPF, exposure to prednisone/azathioprine/ N -acetylcysteine was associated with a higher composite endpoint of death, lung transplantation, hospitalization, or FVC decline for those with an LTL less than the 10th percentile (hazard ratio, 2.84; 95% confidence interval, 1.02-7.87; P  = 0.045). This finding was replicated in the placebo arm of ACE-IPF for those exposed to immunosuppression (hazard ratio, 7.18; 95% confidence interval, 1.52-33.84; P  = 0.013). A propensity-matched University of Texas Southwestern Medical Center IPF cohort showed a similar association between immunosuppression and composite endpoints (death, lung transplantation, or FVC decline) for those with an LTL less than the 10th percentile (hazard ratio, 3.79; 95% confidence interval, 1.73-8.30; P  = 0.00085). An interaction was found between immunosuppression and LTL for the combined PANTHER-IPF and ACE-IPF clinical trials ( P interaction  = 0.048), and the University of Texas Southwestern Medical Center IPF cohort ( P interaction  = 0.00049). Conclusions: LTL is a biomarker that may identify patients with IPF at risk for poor outcomes when exposed to immunosuppression.",2019,"An interaction was found between immunosuppression and LTL for the combined PANTHER-IPF and ACE-IPF clinical trials (pinteraction=0.048), as well as the UTSW IPF cohort (pinteraction=0.00049).","['IPF patients', 'Idiopathic Pulmonary Fibrosis', 'idiopathic pulmonary fibrosis (IPF) patients']","['Immunosuppressive Medications', 'prednisone/azathioprine/N-acetylcysteine']","['death, lung transplantation, hospitalization, or forced vital capacity (FVC) decline', 'immunosuppression and composite endpoints (death, lung transplantation or FVC decline']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0085786', 'cui_str': 'Alveolitis, Fibrosing'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0024128', 'cui_str': 'Grafting, Lung'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}]",,0.0544775,"An interaction was found between immunosuppression and LTL for the combined PANTHER-IPF and ACE-IPF clinical trials (pinteraction=0.048), as well as the UTSW IPF cohort (pinteraction=0.00049).","[{'ForeName': 'Chad A', 'Initials': 'CA', 'LastName': 'Newton', 'Affiliation': '1Department of Medicine and.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': '1Department of Medicine and.'}, {'ForeName': 'Justin M', 'Initials': 'JM', 'LastName': 'Oldham', 'Affiliation': '3Department of Medicine, University of California at Davis, Davis, California.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Kozlitina', 'Affiliation': '2Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'ForeName': 'Shwu-Fan', 'Initials': 'SF', 'LastName': 'Ma', 'Affiliation': '4Department of Medicine, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Fernando J', 'Initials': 'FJ', 'LastName': 'Martinez', 'Affiliation': '5Department of Medicine, Weill Cornell Medical Center, New York, New York; and.'}, {'ForeName': 'Ganesh', 'Initials': 'G', 'LastName': 'Raghu', 'Affiliation': '6Department of Medicine, University of Washington Medical Center, Seattle, Washington.'}, {'ForeName': 'Imre', 'Initials': 'I', 'LastName': 'Noth', 'Affiliation': '4Department of Medicine, University of Virginia, Charlottesville, Virginia.'}, {'ForeName': 'Christine Kim', 'Initials': 'CK', 'LastName': 'Garcia', 'Affiliation': '1Department of Medicine and.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201809-1646OC'] 846,31838113,Effect of Oxygen Therapy on Cardiovascular Outcomes in Relation to Baseline Oxygen Saturation.,"OBJECTIVES The aim of this study was to determine the effect of supplemental oxygen in patients with myocardial infarction (MI) on the composite of all-cause death, rehospitalization with MI, or heart failure related to baseline oxygen saturation. A secondary objective was to investigate outcomes in patients developing hypoxemia. BACKGROUND In the DETO2X-AMI (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction) trial, 6,629 normoxemic patients with suspected MI were randomized to oxygen at 6 l/min for 6 to 12 h or ambient air. METHODS The study population of 5,010 patients with confirmed MI was divided by baseline oxygen saturation into a low-normal (90% to 94%) and a high-normal (95% to 100%) cohort. Outcomes are reported within 1 year. To increase power, all follow-up time (between 1 and 4 years) was included post hoc, and interaction analyses were performed with oxygen saturation as a continuous covariate. RESULTS The composite endpoint of all-cause death, rehospitalization with MI, or heart failure occurred significantly more often in patients in the low-normal cohort (17.3%) compared with those in the high-normal cohort (9.5%) (p < 0.001), and most often in patients developing hypoxemia (23.6%). Oxygen therapy compared with ambient air was not associated with improved outcomes regardless of baseline oxygen saturation (interaction p values: composite endpoint, p = 0.79; all-cause death, p = 0.33; rehospitalization with MI, p = 0.86; hospitalization for heart failure, p = 0.35). CONCLUSIONS Irrespective of oxygen saturation at baseline, we found no clinically relevant beneficial effect of routine oxygen therapy in normoxemic patients with MI regarding cardiovascular outcomes. Low-normal baseline oxygen saturation or development of hypoxemia was identified as an independent marker of poor prognosis. (An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction; NCT01787110).",2020,"Oxygen therapy compared with ambient air was not associated with improved outcomes regardless of baseline oxygen saturation (interaction p values: composite endpoint, p = 0.79; all-cause death, p = 0.33; rehospitalization with MI, p = 0.86; hospitalization for heart failure, p = 0.35). ","['patients with myocardial infarction (MI', '6,629 normoxemic patients with suspected MI', '5,010 patients with confirmed MI was divided by baseline oxygen saturation into a low-normal (90% to 94%) and a high-normal (95% to 100%) cohort', 'Patients With Suspected Myocardial Infarction', 'normoxemic patients with MI regarding cardiovascular outcomes', 'patients developing hypoxemia']","['Oxygen therapy', 'routine oxygen therapy', 'supplemental oxygen', 'Oxygen Therapy', 'Supplemental Oxygen Treatment']","['composite endpoint of all-cause death, rehospitalization with MI, or heart failure', 'Low-normal baseline oxygen saturation or development of hypoxemia', 'Cardiovascular Outcomes', 'baseline oxygen saturation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}]","[{'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}]",5010.0,0.112062,"Oxygen therapy compared with ambient air was not associated with improved outcomes regardless of baseline oxygen saturation (interaction p values: composite endpoint, p = 0.79; all-cause death, p = 0.33; rehospitalization with MI, p = 0.86; hospitalization for heart failure, p = 0.35). ","[{'ForeName': 'Stefan K', 'Initials': 'SK', 'LastName': 'James', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Erlinge', 'Affiliation': 'Department of Clinical Sciences, Cardiology, Lund University, Lund, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Herlitz', 'Affiliation': 'Department of Health Sciences, University of Borås, Borås, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Alfredsson', 'Affiliation': 'Department of Medical and Health Sciences and Department of Cardiology, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Sasha', 'Initials': 'S', 'LastName': 'Koul', 'Affiliation': 'Department of Clinical Sciences, Cardiology, Lund University, Lund, Sweden.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Fröbert', 'Affiliation': 'Department of Cardiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Kellerth', 'Affiliation': 'Department of Cardiology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.'}, {'ForeName': 'Annica', 'Initials': 'A', 'LastName': 'Ravn-Fischer', 'Affiliation': 'Department of Molecular and Clinical Medicine and Sahlgrenska University Hospital, Department of Cardiology, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Alström', 'Affiliation': 'Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.'}, {'ForeName': 'Ollie', 'Initials': 'O', 'LastName': 'Östlund', 'Affiliation': 'Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Tomas', 'Initials': 'T', 'LastName': 'Jernberg', 'Affiliation': 'Department of Clinical Sciences, Cardiology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.'}, {'ForeName': 'Bertil', 'Initials': 'B', 'LastName': 'Lindahl', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Hofmann', 'Affiliation': 'Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. Electronic address: robin.hofmann@sll.se.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.09.016'] 847,32409917,Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).,"BACKGROUND Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate. REACT study aimed to investigate the efficacy of reintroducing modified FOLFOX6 (mFOLFOX6) or CAPOX with or without bevacizumab in recurrent colorectal cancer patients after oxaliplatin adjuvant chemotherapy. METHODS Patients that participated in this trial had a medical history of adjuvant chemotherapy, including oxaliplatin with a cumulative dose greater than 400 mg/m 2 , and recurrence that was diagnosed more six months post adjuvant chemotherapy. Primary endpoints were response rate (RR) and disease control rate (DCR), while key secondary endpoints were time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), and safety. RESULTS A total of 31 patients were enrolled between October 2012 and October 2016. Of the 29 eligible patients, 7 received mFOLFOX6 and 22 received CAPOX. The RR was 62.1% (95% confidence interval 42.3-79.3) and the DCR was 82.8% (95% confidence interval 64.2-94.2). The RR for oxaliplatin-free interval was 100.0% in months 6-12 and 56.0% after 12 months. Median TTF, PFS, and OS were 6.3, 10.8, and 28.7 months, respectively. Grade 3 or worse peripheral sensory neuropathy developed in 6.5%. Allergic reactions occurred in 12.9% of the patients, with one (3.2%) grade 3 episode. There were no other severe treatment-related adverse events. CONCLUSION Reintroduction of oxaliplatin was feasible and achieved high RR or DCR in patients after more than 6 months post oxaliplatin adjuvant chemotherapy.",2020,Reintroduction of oxaliplatin was feasible and achieved high RR or DCR in patients after more than 6 months post oxaliplatin adjuvant chemotherapy.,"['31 patients were enrolled between October 2012 and October 2016', 'relapsed colorectal cancer patients treated with', '29 eligible patients, 7 received mFOLFOX6 and 22 received', 'recurrent colorectal cancer patients after oxaliplatin adjuvant chemotherapy', 'Patients that participated in this trial had a medical history of adjuvant chemotherapy, including oxaliplatin with a cumulative dose greater than 400\xa0mg/m 2 , and recurrence that was diagnosed more six months post adjuvant chemotherapy']","['oxaliplatin', 'reintroducing modified FOLFOX6 (mFOLFOX6) or CAPOX with or without bevacizumab', 'oxaliplatin adjuvant chemotherapy', 'FOLFOX or CAPOX reintroduction with or without bevacizumab', 'CAPOX']","['RR for oxaliplatin-free interval', 'time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), and safety', 'Median TTF, PFS, and OS', 'Allergic reactions', 'Grade 3 or worse peripheral sensory neuropathy', 'response rate (RR) and disease control rate (DCR', 'severe treatment-related adverse events', 'DCR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0854750', 'cui_str': 'Colorectal cancer recurrent'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C3494202', 'cui_str': 'Time to Treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",31.0,0.339237,Reintroduction of oxaliplatin was feasible and achieved high RR or DCR in patients after more than 6 months post oxaliplatin adjuvant chemotherapy.,"[{'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Kotaka', 'Affiliation': 'Gastrointestinal Cancer Center, Sano Hospital, 2-5-1, Shimizugaoka, Tarumi-ku, Kobe, 655-0031, Japan. tomomakotaka6410@yahoo.co.jp.'}, {'ForeName': 'Shigeyoshi', 'Initials': 'S', 'LastName': 'Iwamoto', 'Affiliation': 'Cancer Center, Aichi Medical University, Aichi, Japan.'}, {'ForeName': 'Hironaga', 'Initials': 'H', 'LastName': 'Satake', 'Affiliation': 'Cancer Treatment Center, Kansai Medical University Hospital, Osaka, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Sakai', 'Affiliation': 'Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan.'}, {'ForeName': 'Toshihiro', 'Initials': 'T', 'LastName': 'Kudo', 'Affiliation': 'Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Mutsumi', 'Initials': 'M', 'LastName': 'Fukunaga', 'Affiliation': 'Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Konishi', 'Affiliation': 'Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan.'}, {'ForeName': 'Yoshihito', 'Initials': 'Y', 'LastName': 'Ide', 'Affiliation': 'Department of Surgery, Yao Municipal Hospital, Osaka, Japan.'}, {'ForeName': 'Taro', 'Initials': 'T', 'LastName': 'Ikumoto', 'Affiliation': 'Gastrointestinal Cancer Center, Sano Hospital, 2-5-1, Shimizugaoka, Tarumi-ku, Kobe, 655-0031, Japan.'}, {'ForeName': 'Akihito', 'Initials': 'A', 'LastName': 'Tsuji', 'Affiliation': 'Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Sano', 'Affiliation': 'Gastrointestinal Center, Sano Hospital, Hyogo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kato', 'Affiliation': 'Department of Surgery, National Hospital Organization, Osaka National Hospital, Osaka, Japan.'}, {'ForeName': 'Naotoshi', 'Initials': 'N', 'LastName': 'Sugimoto', 'Affiliation': 'Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan.'}, {'ForeName': 'Taroh', 'Initials': 'T', 'LastName': 'Satoh', 'Affiliation': 'Department of Frontier Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Osaka, Japan.'}, {'ForeName': 'Akiyoshi', 'Initials': 'A', 'LastName': 'Kanazawa', 'Affiliation': 'Department of Surgery, Shimane Prefectural Central Hospital, Shimane, Japan.'}, {'ForeName': 'Takayasu', 'Initials': 'T', 'LastName': 'Kurata', 'Affiliation': 'Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.'}, {'ForeName': 'Takeharu', 'Initials': 'T', 'LastName': 'Yamanaka', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan.'}, {'ForeName': 'Naohiro', 'Initials': 'N', 'LastName': 'Tomita', 'Affiliation': 'Division of Lower GI Surgery, Department of Surgery, Hyogo College of Medicine, Hyogo, Japan.'}]",International journal of clinical oncology,['10.1007/s10147-020-01701-1'] 848,30900242,Comparison of Pentax Airway Scope and Macintosh laryngoscope for orotracheal intubation in children: A randomised non-inferiority trial.,"BACKGROUND Pentax Airway Scope (AWS) is a recently developed videolaryngoscope for use in both normal and difficult airways, yet its use in paediatric patients has not been established. The purpose of this study was to evaluate the efficacy of the Pentax AWS regarding intubation time, laryngeal view and ease of intubation in paediatric patients with normal airway, compared to Macintosh laryngoscope. METHOD A total of 136 paediatric patients aged 1-10 with American Society of Anaesthesiologists physical status I or II undergoing general anaesthesia were randomly allocated into two groups: Macintosh laryngoscope (n = 68) and Pentax Airway Scope (n = 68). Primary outcome was intubation time. Cormack-Lehane laryngeal view grade, application of optimal laryngeal external manipulation, intubation difficulty scale, intubation failure rate and adverse events were also measured. RESULT No significant difference was observed between the two groups regarding intubation time (P = 0.713). As for the laryngeal view grade, the Pentax group resulted in lower graded cases compared to the Macintosh group (P = 0.000). No optimal laryngeal external manipulation application was required in the Pentax group. Intubation difficulty scale resulted in lower values for Pentax group (P = 0.001). Failure rate was not different between the two groups (P = 0.619). There were significantly more teeth injury cases in the Pentax group than Macintosh group (P = 0.042). CONCLUSION Pentax Airway Scope provided similar intubation time and success rate, while improving laryngeal view, compared to Macintosh laryngoscopy in children with normal airway. When using Pentax AWS in children, however, the risk of teeth injury may increase.",2019,"There were significantly more teeth injury cases in the Pentax group than Macintosh group (P = 0.042). ","['children', 'paediatric patients with normal airway, compared to Macintosh laryngoscope', '136 paediatric patients aged 1-10 with American Society of Anaesthesiologists physical status I or II undergoing general anaesthesia', 'children with normal airway', 'paediatric patients']","['Pentax AWS', 'Pentax Airway Scope and Macintosh laryngoscope', 'Macintosh laryngoscope (n\xa0=\xa068) and Pentax Airway Scope']","['Intubation difficulty scale', 'intubation time', 'Failure rate', 'teeth injury cases', 'intubation time and success rate', 'intubation time, laryngeal view and ease of intubation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0180453', 'cui_str': 'Laryngoscopes'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}]","[{'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0180453', 'cui_str': 'Laryngoscopes'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0222045'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0242891', 'cui_str': 'Tooth Injuries'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0023078', 'cui_str': 'Larynx'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}]",136.0,0.0793995,"There were significantly more teeth injury cases in the Pentax group than Macintosh group (P = 0.042). ","[{'ForeName': 'In Kyong', 'Initials': 'IK', 'LastName': 'Yi', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Hyun Jeong', 'Initials': 'HJ', 'LastName': 'Kwak', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Gachon University Gil Medical Center, Incheon, Korea.'}, {'ForeName': 'Kyung Mi', 'Initials': 'KM', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Gachon University Gil Medical Center, Incheon, Korea.'}, {'ForeName': 'Soo Hwan', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Sook Young', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Jong Yeop', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, Korea.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13368'] 849,31274710,FOVEA-SPARING VERSUS COMPLETE INTERNAL LIMITING MEMBRANE PEELING IN VITRECTOMY FOR THE TREATMENT OF MACULAR HOLES.,"PURPOSE To compare the anatomical and functional outcomes of vitrectomy involving complete internal limiting membrane peeling (CP) with those of vitrectomy involving fovea-sparing internal limiting membrane peeling (FSP) for the treatment of macular holes measuring >250 µm. METHODS This prospective, randomized, comparative study included 46 eyes with a medium or large macular hole that was randomized to undergo complete (CP group) or fovea-sparing (FSP group) internal limiting membrane peeling during vitrectomy. The main outcome measures included the foveal retinal sensitivity, visual acuity, and central retinal thickness. RESULTS Both groups showed significantly improved foveal retinal sensitivity after surgery; the mean foveal retinal sensitivity change at 12 months after surgery was +2.8 ± 2.1 dB in the CP group and +7.2 ± 2.3 dB in the FSP group. The visual acuity also showed a significant improvement in both groups, with no significant differences in values at any time point. Regarding central retinal thickness, there was a significant decrease in the CP group and no change in the FSP group. Nicks or dimples in the inner retinal layers were visible in the fovea and perifovea of nine eyes in the CP group. CONCLUSION Our findings suggest that both CP and FSP are safe and effective treatments leading to functional and anatomical improvements in patients with all size macular holes. However, the fovea-sparing technique may provide better functional outcomes because of a greater improvement in foveal retinal sensitivity.",2020,"Nicks or dimples in the inner retinal layers were visible in the fovea and perifovea of nine eyes in the CP group. ","['patients with all size macular holes', '46 eyes with a medium or large macular hole that was randomized to']","['vitrectomy involving complete internal limiting membrane peeling (CP', 'undergo complete (CP group) or fovea-sparing (FSP group) internal limiting membrane peeling during vitrectomy', 'vitrectomy involving fovea-sparing internal limiting membrane peeling (FSP', 'CP and FSP']","['foveal retinal sensitivity', 'visual acuity', 'mean foveal retinal sensitivity change', 'central retinal thickness', 'foveal retinal sensitivity, visual acuity, and central retinal thickness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0024441', 'cui_str': 'Macular Holes'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}]","[{'cui': 'C0042903', 'cui_str': 'Vitrectomy'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]",46.0,0.0427441,"Nicks or dimples in the inner retinal layers were visible in the fovea and perifovea of nine eyes in the CP group. ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Morescalchi', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Russo', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Bahja', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Gambicorti', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cancarini', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Ciro', 'Initials': 'C', 'LastName': 'Costagliola', 'Affiliation': 'Department of Health Sciences, Eye Clinic, University of Molise, Campobasso, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Semeraro', 'Affiliation': 'Department of Neurological and Vision Sciences, Eye Clinic, University of Brescia, Brescia, Italy.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002612'] 850,31270176,Short-Term Effects of an Active Heat-and-Moisture Exchanger During Invasive Ventilation.,"BACKGROUND Humidification is a standard of care during invasive mechanical ventilation. Two types of devices are used for this purpose: heated humidifiers and heat-and-moisture exchangers (HME). AIM To compare the short-term physiologic effects of an active HME, with those of heated humidifiers and HMEs in terms of respiratory effort, ventilatory pattern, and arterial blood gases during invasive mechanical ventilation. METHODS We conducted a randomized crossover study with 3 different devices in 15 stable subjects who had a tracheostomy and were ventilator-dependent. Transdiaphragmatic pressure, ventilatory pattern, arterial blood gases, and dyspnea scale were recorded at baseline and at the end of a 20-min period with each device. RESULTS Compared with heated humidifiers, the active HME was associated with higher diaphragmatic pressure-time product per minute (117.10 [interquartile range {IQR} 34.58-298.60]) versus 80.86 (IQR, 25.46-110.55) cm H 2 O×s/min, P = .01), higher P aCO 2 (48.50 [IQR, 40.65-53.70] vs 39.60 [IQR, 37.50-49.95]) mm Hg, P = .02) and lower pH (7.41 [IQR, 7.36-7.49] vs 7.45 [IQR, 7.40-7.51], P = .030) without any significant difference in ventilatory pattern. A significantly worse dyspnea scale score (active HME, 3 (2-4) vs heated humidifiers: 4 (3-5); P = .009) was also observed. No significant differences were seen between active HME and HME. CONCLUSIONS This study indicated that, compared with the heated humidifiers, the use of the active HME or the HME increased inspiratory effort, P aCO 2 , pH, and dyspnea in stable subjects who were tracheostomized and ventilator-dependent. (ClinicalTrials.gov registration NCT02499796.).",2019,"A significantly worse dyspnea scale score (active HME, 3 (2-4) vs heated humidifiers: 4 (3-5); P = .009) was also observed.",['15 stable subjects who had a tracheostomy and were ventilator-dependent'],"['heated humidifiers and heat-and-moisture exchangers (HME', 'active HME, with those of heated humidifiers and HMEs', 'Active Heat-and-Moisture Exchanger During Invasive Ventilation']","['dyspnea scale score', 'HME increased inspiratory effort, P aCO 2 , pH, and dyspnea', 'ventilatory pattern', 'diaphragmatic pressure-time product per minute', 'respiratory effort, ventilatory pattern, and arterial blood gases', 'Transdiaphragmatic pressure, ventilatory pattern, arterial blood gases, and dyspnea scale']","[{'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}]","[{'cui': 'C0181233', 'cui_str': 'Heat and moisture exchanger (physical object)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0181232', 'cui_str': 'Humidifiers'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}]","[{'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0011980', 'cui_str': 'Respiratory Diaphragm'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0702093', 'cui_str': '/min'}, {'cui': 'C0425466', 'cui_str': 'Respiratory effort (observable entity)'}, {'cui': 'C0150411', 'cui_str': 'Blood gases, arterial measurement (procedure)'}, {'cui': 'C0205504', 'cui_str': 'Transdiaphragmatic approach (qualifier value)'}]",15.0,0.162128,"A significantly worse dyspnea scale score (active HME, 3 (2-4) vs heated humidifiers: 4 (3-5); P = .009) was also observed.","[{'ForeName': 'Annia F', 'Initials': 'AF', 'LastName': 'Schreiber', 'Affiliation': 'Respiratory Intensive Care Unit, and Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico di Pavia, Pavia, Italy. annia.schreiber@icloud.com.'}, {'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Ceriana', 'Affiliation': 'Respiratory Intensive Care Unit, and Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico di Pavia, Pavia, Italy.'}, {'ForeName': 'Nicolino', 'Initials': 'N', 'LastName': 'Ambrosino', 'Affiliation': 'Istituti Clinici Scientifici Maugeri IRCCS, Istituto Scientifico di Montescano, Montescano Pavia, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Piran', 'Affiliation': 'Respiratory Intensive Care Unit, and Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico di Pavia, Pavia, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Malovini', 'Affiliation': 'Laboratory of Informatics and Systems Engineering for Clinical Research, Istituti Clinici Scientifici Maugeri IRCCS, Istituto Scientifico di Pavia, Pavia, Italy.'}, {'ForeName': 'Annalisa', 'Initials': 'A', 'LastName': 'Carlucci', 'Affiliation': 'Respiratory Intensive Care Unit, and Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Scientifico di Pavia, Pavia, Italy.'}]",Respiratory care,['10.4187/respcare.06799'] 851,31149842,Sympathetic neural responsiveness to sleep deprivation in older adults: sex differences.,"Our laboratory has previously reported that total sleep deprivation (TSD) modifies muscle sympathetic neural activity (MSNA) differently in young men and women. Because postmenopausal women are among the highest risk for hypertension, this study compares MSNA responses with TSD in older men and women. We hypothesized that TSD would alter MSNA in older adults, with greater sympathoexcitation in postmenopausal women. Twenty-seven participants (14 men and 13 women) between the ages of 55 and 75 yr were tested twice, once after 24-h TSD and once after normal sleep (randomized, crossover design). Our primary outcome measure of MSNA (microneurography) was successful across both conditions in 20 participants (10 men and 10 women). Secondary outcome measures included seated blood pressure, heart rate, and fasting plasma testosterone, estradiol, and progesterone. Age (60 ± 1 vs. 61 ± 2 yr) and BMI (27 ± 1 vs. 26 ± 1 kg/m 2 ) were not different between groups. TSD increased systolic blood pressure in both men (124 ± 5 to 130 ± 4 mmHg) and women (107 ± 5 to 116 ± 4 mmHg), but the increases were not different between groups (condition, P = 0.014; condition × sex, P > 0.05). In contrast, TSD elicited divergent MSNA responses in older men and women. Specifically, MSNA burst frequency increased in postmenopausal women (28 ± 3 to 34 ± 3 burst/min), but not older men (38 ± 3 to 35 ± 3 bursts/min; condition × sex, P = 0.032). In conclusion, TSD elicited sympathoexcitation in postmenopausal women but not age-matched men. These findings provide new mechanistic insight into reported links between sleep deprivation and hypertension. NEW & NOTEWORTHY Epidemiological studies report that sleep deprivation is more strongly associated with hypertension in women than in men. In the present study, 24-h total sleep deprivation (TSD) increased blood pressure in postmenopausal women and age-matched men. In contrast, only women demonstrated increases in muscle sympathetic nerve activity after TSD. The sympathoexcitation observed in postmenopausal women suggests a potential contributing mechanism for epidemiological observations and advances our understanding of the complex relations between sleep, sex, and hypertension.",2019,"Specifically, MSNA burst frequency increased in postmenopausal women (28±3 to 34±3 burst/min), but not older men (38±3 to 35±3 burst/min; condition × sex, p=0.032).","['postmenopausal women, but not age-matched men', 'postmenopausal women', 'Older Adults', 'older men and women', '20 participants (10 men and 10 women', 'older adults', 'young men and women', 'Twenty-seven participants (14 men, 13 women) between the ages of 55 and 75 years were tested twice, once after 24-hour TSD and once after normal sleep (randomized, crossover design']","['TSD', 'MSNA (microneurography', 'Sympathetic Neural Responsiveness']","['TSD elicited sympathoexcitation', 'systolic blood pressure', 'seated blood pressure, heart rate, and fasting plasma testosterone, estradiol, and progesterone', 'MSNA burst frequency']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0039373', 'cui_str': 'Hexosaminidase A Deficiency Disease'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0242817', 'cui_str': 'Cross-Over Design'}]","[{'cui': 'C0039373', 'cui_str': 'Hexosaminidase A Deficiency Disease'}]","[{'cui': 'C0039373', 'cui_str': 'Hexosaminidase A Deficiency Disease'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0857717', 'cui_str': 'Plasma testosterone'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C0373705', 'cui_str': 'Progesterone measurement (procedure)'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",20.0,0.0414749,"Specifically, MSNA burst frequency increased in postmenopausal women (28±3 to 34±3 burst/min), but not older men (38±3 to 35±3 burst/min; condition × sex, p=0.032).","[{'ForeName': 'Jason R', 'Initials': 'JR', 'LastName': 'Carter', 'Affiliation': 'Department of Kinesiology and Integrative Physiology, Michigan Technological University, Houghton, Michigan.'}, {'ForeName': 'Ida T', 'Initials': 'IT', 'LastName': 'Fonkoue', 'Affiliation': 'Department of Kinesiology and Integrative Physiology, Michigan Technological University, Houghton, Michigan.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Greenlund', 'Affiliation': 'Department of Kinesiology and Integrative Physiology, Michigan Technological University, Houghton, Michigan.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Schwartz', 'Affiliation': 'Department of Kinesiology, Saint Ambrose University, Davenport, Iowa.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Mokhlesi', 'Affiliation': 'Sleep Research Center, Department of Medicine, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Carl A', 'Initials': 'CA', 'LastName': 'Smoot', 'Affiliation': 'Department of Kinesiology and Integrative Physiology, Michigan Technological University, Houghton, Michigan.'}]",American journal of physiology. Heart and circulatory physiology,['10.1152/ajpheart.00232.2019'] 852,31262551,The effects of brief chat-based and face-to-face psychotherapy for insomnia: a randomized waiting list controlled trial.,"BACKGROUND Recent studies have directly compared the effects of Internet-based self-help interventions with face-to-face (FtF) treatment, but groups may also differ regarding other aspects, aside from the fact that the former is online and the latter offline. Thus, we examined the effects of a brief three-session psychotherapy for insomnia that was delivered FtF or through synchronous text-based chats. METHODS Seventy-three patients diagnosed with insomnia were randomized to either FtF treatment, a chat-based treatment, or to a waiting list control group (WL). Treatment included topics that covered imagination, sleep restriction, sleep hygiene, repetition, and consolidation. RESULTS Compared to WL, patients in both groups improved regarding sleep quality (d FtF  = 1.02, d chat  = 1.69) and improvements remained at the two-month follow-up (FU; d FtF  = 1.18, d chat  = 2.40). Improvements in actigraphic sleep onset latency that had been gained at the post-test time point, disappeared at FU, while subjective improvements remained. At FU, patients in the chat group outperformed FtF patients regarding subjective total sleep time, anxiety, depression, and cognitive pre-sleep arousal. CONCLUSION Three sessions were efficacious in treating insomnia, and the chat-based treatment slightly outperformed FtF treatment. This may be caused by the highly individualized treatment approach, by the fact that chatting forces both patients and therapists to adhere to the essence of the treatment goal, by increased feelings of privacy, autonomy, and a sense of felt responsibility for treatment. These hypotheses should be validated in future studies. So far, we can summarize that chat-based communication facilitates the treatment of patients who cannot or who do not want to attend FtF treatment.",2019,"At FU, patients in the chat group outperformed FtF patients regarding subjective total sleep time, anxiety, depression, and cognitive pre-sleep arousal. ","['insomnia', 'patients who cannot or who do not want to attend FtF treatment', 'Seventy-three patients diagnosed with insomnia']","['brief chat-based and face-to-face psychotherapy', 'FtF treatment, a chat-based treatment, or to a waiting list control group (WL']","['covered imagination, sleep restriction, sleep hygiene, repetition, and consolidation', 'sleep quality', 'subjective total sleep time, anxiety, depression, and cognitive pre-sleep arousal', 'actigraphic sleep onset latency']","[{'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C1444647', 'cui_str': 'Wanted'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0946707', 'cui_str': 'Chat'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0020913', 'cui_str': 'Imagination'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C4277672', 'cui_str': 'Sleep Hygiene'}, {'cui': 'C0702116', 'cui_str': 'Consolidation (morphologic abnormality)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}]",73.0,0.0258791,"At FU, patients in the chat group outperformed FtF patients regarding subjective total sleep time, anxiety, depression, and cognitive pre-sleep arousal. ","[{'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Gieselmann', 'Affiliation': 'Department of Clinical Psychology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. Electronic address: Annika.Gieselmann@uni-duesseldorf.de.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Pietrowsky', 'Affiliation': 'Department of Clinical Psychology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.'}]",Sleep medicine,['10.1016/j.sleep.2019.03.024'] 853,31262641,Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial With Observational Controls.,"OBJECTIVE To examine and compare nebulizing heparin versus streptokinase for reversing alveolar collapse nonresponsive to recruitment. DESIGN A clinical trial at a tertiary intensive care unit (ICU). Sixty patients with severe acute respiratory distress syndrome (ARDS) (PaO 2 /F I O 2 <100) nonresponsive to recruitment maneuver (RM), prone position, and neuromuscular block (NMB) were randomized into intervention arms or the standard-of-care arm. SETTING The ICU at Beni-Suef University Hospital. PARTICIPANTS Sixty patients with severe ARDS (PaO 2 /F I O 2 <100) nonresponsive to RM, PP, and NMB. INTERVENTIONS Nebulized heparin (10,000 IU/4 h), nebulized streptokinase (250,000 IU/4 h), and conservative management. MEASUREMENTS AND MAIN RESULTS The primary outcome was the change in PaO 2 /F I O 2 ; the secondary outcomes included the change in compliance, plateau pressure, coagulation, and ICU mortality. The PaO 2 /F I O 2 was significantly higher in the streptokinase group from day 1 to day 8 compared to the heparin and standard-of-care groups. Streptokinase produced PaO 2 /F I O 2 >100 at day 1, >200 at day 5, and >300 at day 7. The heparin group achieved a PaO 2 /F I O 2 >100 at day 5 but remained <200 until day 8. The standard-of-care group did not achieve a PaO 2 /F I O 2 >100 after 8 days. Streptokinase significantly reduced plateau pressure and improved compliance at day 8. Only streptokinase decreased PaCO 2 (p < 0.0001). Moreover, ICU mortality was significantly lower in streptokinase patients compared to other groups. Additionally, no heparin-induced thrombocytopenia was observed in all groups. CONCLUSION Inhaled streptokinase serves as rescue therapy in patients with severe ARDS with improving oxygenation and lung mechanics more quickly than heparin or conventional management.",2020,I O 2 was significantly higher in the streptokinase group from day 1 to day 8 compared to the heparin and standard-of-care groups.,"['patients with severe ARDS', 'Sixty patients with severe ARDS (PaO 2', 'The ICU at Beni-Suef University Hospital', 'Sixty patients with severe acute respiratory distress syndrome (ARDS) (PaO 2', 'Patients With Severe Acute Respiratory Distress Syndrome (ARDS']","['Inhaled streptokinase', 'Streptokinase', 'heparin', 'nebulized streptokinase', 'Nebulized heparin', 'streptokinase', 'F', 'Streptokinase Versus Unfractionated Heparin Nebulization', 'nebulizing heparin versus streptokinase']","['change in compliance, plateau pressure, coagulation, and ICU mortality', 'plateau pressure and improved compliance', 'change in PaO 2', 'thrombocytopenia', 'ICU mortality', '100) nonresponsive to RM, PP, and NMB', '100) nonresponsive to recruitment maneuver (RM), prone position, and neuromuscular block (NMB']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0038418', 'cui_str': 'Streptokinase'}, {'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0445176', 'cui_str': 'Plateau pressure (qualifier value)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0232555', 'cui_str': 'Peak gastric acid output (observable entity)'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0033422', 'cui_str': 'Prone Position'}, {'cui': 'C0235062', 'cui_str': 'Neuromuscular Block'}]",60.0,0.14778,I O 2 was significantly higher in the streptokinase group from day 1 to day 8 compared to the heparin and standard-of-care groups.,"[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abdelaal Ahmed Mahmoud', 'Affiliation': 'Department of Anaesthesia, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt; Department of Anaesthesia, Pain Medicine and Critical Care, Tallaght University Hospital, Dublin, Ireland. Electronic address: carnitin7@yahoo.com.'}, {'ForeName': 'Hatem Elmoutaz', 'Initials': 'HE', 'LastName': 'Mahmoud', 'Affiliation': 'Department of Anaesthesia, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Mohamed Ali', 'Initials': 'MA', 'LastName': 'Mahran', 'Affiliation': 'Department of Anaesthesia, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}, {'ForeName': 'Marwa', 'Initials': 'M', 'LastName': 'Khaled', 'Affiliation': 'Department of Anaesthesia, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2019.05.035'] 854,31257574,Fortification of wheat and maize flour with folic acid for population health outcomes.,"BACKGROUND Folate is a B-vitamin required for DNA synthesis, methylation, and cellular division. Wheat and maize (corn) flour are staple crops consumed widely throughout the world and have been fortified with folic acid in over 80 countries to prevent neural tube defects. Folic acid fortification may be an effective strategy to improve folate status and other health outcomes in the overall population. OBJECTIVES To evaluate the health benefits and safety of folic acid fortification of wheat and maize flour (i.e. alone or in combination with other micronutrients) on folate status and health outcomes in the overall population, compared to wheat or maize flour without folic acid (or no intervention). SEARCH METHODS We searched the following databases in March and May 2018: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE In Process, Embase, CINAHL, Web of Science (SSCI, SCI), BIOSIS, Popline, Bibliomap, TRoPHI, ASSIA, IBECS, SCIELO, Global Index Medicus-AFRO and EMRO, LILACS, PAHO, WHOLIS, WPRO, IMSEAR, IndMED, and Native Health Research Database. We searched the International Clinical Trials Registry Platform and ClinicalTrials.gov for ongoing or planned studies in June 2018, and contacted authors for further information. SELECTION CRITERIA We included randomised controlled trials (RCTs), with randomisation at the individual or cluster level. We also included non-RCTs and prospective observational studies with a control group; these studies were not included in meta-analyses, although their characteristics and findings were described. Interventions included wheat or maize flour fortified with folic acid (i.e. alone or in combination with other micronutrients), compared to unfortified flour (or no intervention). Participants were individuals over two years of age (including pregnant and lactating women), from any country. DATA COLLECTION AND ANALYSIS Two review authors independently assessed study eligibility, extracted data, and assessed risk of bias. MAIN RESULTS We included 10 studies: four provided data for quantitative analyses (437 participants); five studies were randomised trials (1182 participants); three studies were non-RCTs (1181 participants, 8037 live births); two studies were interrupted time series (ITS) studies (1 study population of 2,242,438, 1 study unreported). Six studies were conducted in upper-middle-income countries (China, Mexico, South Africa), one study was conducted in a lower-middle-income country (Bangladesh), and three studies were conducted in a high-income country (Canada). Seven studies examined wheat flour fortified with folic acid alone or with other micronutrients. Three studies included maize flour fortified with folic acid alone or with other micronutrients. The duration of interventions ranged from two weeks to 36 months, and the ITS studies included postfortification periods of up to seven years. Most studies had unclear risk of bias for randomisation, blinding, and reporting, and low/unclear risk of bias for attrition and contamination.Neural tube defects: none of the included RCTs reported neural tube defects as an outcome. In one non-RCT, wheat flour fortified with folic acid and other micronutrients was associated with significantly lower occurrence of total neural tube defects, spina bifida, and encephalocoele, but not anencephaly, compared to unfortified flour (total neural tube defects risk ratio (RR) 0.32, 95% confidence interval (CI) 0.21 to 0.48; 1 study, 8037 births; low-certainty evidence).Folate status: pregnant women who received folic acid-fortified maize porridge had significantly higher erythrocyte folate concentrations (mean difference (MD) 238.90 nmol/L, 95% CI 149.40 to 328.40); 1 study, 38 participants; very low-certainty evidence) and higher plasma folate (MD 14.98 nmol/L, 95% CI 9.63 to 20.33; 1 study, 38 participants; very low-certainty evidence), compared to no intervention. Women of reproductive age consuming maize flour fortified with folic acid and other micronutrients did not have higher erythrocyte folate (MD -61.80 nmol/L, 95% CI -152.98 to 29.38; 1 study, 35 participants; very low-certainty evidence) or plasma folate (MD 0.00 nmol/L, 95% CI -0.00 to 0.00; 1 study, 35 participants; very low-certainty evidence) concentrations, compared to women consuming unfortified maize flour. Adults consuming folic acid-fortified wheat flour bread rolls had higher erythrocyte folate (MD 0.66 nmol/L, 95% CI 0.13 to 1.19; 1 study, 30 participants; very low-certainty evidence) and plasma folate (MD 27.00 nmol/L, 95% CI 15.63 to 38.37; 1 study, 30 participants; very low-certainty evidence), versus unfortified flour. In two non-RCTs, serum folate concentrations were significantly higher among women who consumed flour fortified with folic acid and other micronutrients compared to women who consumed unfortified flour (MD 2.92 nmol/L, 95% CI 1.99 to 3.85; 2 studies, 657 participants; very low-certainty evidence).Haemoglobin or anaemia: in a cluster-randomised trial among children, there were no significant effects of fortified wheat flour flatbread on haemoglobin concentrations (MD 0.00 nmol/L, 95% CI -2.08 to 2.08; 1 study, 334 participants; low-certainty evidence) or anaemia (RR 1.07, 95% CI 0.74 to 1.55; 1 study, 334 participants; low-certainty evidence), compared to unfortified wheat flour flatbread. AUTHORS' CONCLUSIONS Fortification of wheat flour with folic acid may reduce the risk of neural tube defects; however, this outcome was only reported in one non-RCT. Fortification of wheat or maize flour with folic acid (i.e. alone or with other micronutrients) may increase erythrocyte and serum/plasma folate concentrations. Evidence is limited for the effects of folic acid-fortified wheat or maize flour on haemoglobin levels or anaemia. The effects of folic acid fortification of wheat or maize flour on other primary outcomes assessed in this review is not known. No studies reported on the occurrence of adverse effects. Limitations of this review were the small number of studies and participants, limitations in study design, and low-certainty of evidence due to how included studies were designed and reported.",2019,"Adults consuming folic acid-fortified wheat flour bread rolls had higher erythrocyte folate (MD 0.66 nmol/L, 95% CI 0.13 to 1.19; 1 study, 30 participants; very low-certainty evidence) and plasma folate (MD 27.00 nmol/L, 95% CI 15.63 to 38.37; 1 study, 30 participants; very low-certainty evidence), versus unfortified flour.","['Six studies were conducted in upper-middle-income countries (China, Mexico, South Africa), one study was conducted in a lower-middle-income country (Bangladesh), and three studies were conducted in a high-income country (Canada', 'Participants were individuals over two years of age (including pregnant and lactating women), from any country', '10 studies: four provided data for quantitative analyses (437 participants); five studies were randomised trials (1182 participants); three studies were non-RCTs (1181 participants, 8037 live births); two studies were interrupted time series (ITS) studies (1 study population of 2,242,438, 1 study unreported']","['folic acid fortification of wheat and maize flour (i.e. alone or in combination with other micronutrients', 'Fortification of wheat flour with folic acid', 'folic acid fortification of wheat or maize flour', 'folic acid-fortified wheat or maize flour', 'wheat flour fortified with folic acid alone', 'wheat or maize flour fortified with folic acid (i.e. alone or in combination with other micronutrients), compared to unfortified flour (or no intervention', 'Fortification of wheat or maize flour with folic acid', 'Wheat and maize (corn) flour', 'Fortification of wheat and maize flour with folic acid', 'wheat or maize flour without folic acid (or no intervention', 'folic acid alone or with other micronutrients', 'folic acid', 'Folic acid fortification']","['low-certainty evidence).Haemoglobin or anaemia', 'erythrocyte folate', 'serum folate concentrations', 'occurrence of total neural tube defects, spina bifida, and encephalocoele', 'anaemia', 'plasma folate', 'folate status and health outcomes', 'erythrocyte and serum/plasma folate concentrations', 'erythrocyte folate concentrations', 'haemoglobin concentrations', 'risk of neural tube defects', 'haemoglobin levels or anaemia', 'Embase, CINAHL, Web of Science (SSCI, SCI), BIOSIS, Popline, Bibliomap, TRoPHI, ASSIA, IBECS, SCIELO, Global Index Medicus-AFRO and EMRO, LILACS, PAHO, WHOLIS, WPRO, IMSEAR, IndMED', 'occurrence of adverse effects']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0948433', 'cui_str': 'High income'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C3850092', 'cui_str': 'Interrupted Time Series'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C0458980', 'cui_str': 'Wheat flour (substance)'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0439543', 'cui_str': 'Certainties (qualifier value)'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0027794', 'cui_str': 'Developmental Defects, Neural Tube'}, {'cui': 'C0080178', 'cui_str': 'Schistorrhachis'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0021194', 'cui_str': 'Index Medicus'}, {'cui': 'C0030260', 'cui_str': 'PAHO'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",38.0,0.246925,"Adults consuming folic acid-fortified wheat flour bread rolls had higher erythrocyte folate (MD 0.66 nmol/L, 95% CI 0.13 to 1.19; 1 study, 30 participants; very low-certainty evidence) and plasma folate (MD 27.00 nmol/L, 95% CI 15.63 to 38.37; 1 study, 30 participants; very low-certainty evidence), versus unfortified flour.","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Centeno Tablante', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, New York, USA.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Pachón', 'Affiliation': ''}, {'ForeName': 'Heather M', 'Initials': 'HM', 'LastName': 'Guetterman', 'Affiliation': ''}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Finkelstein', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012150.pub2'] 855,31261260,Perineal Pressure During Hip Arthroscopy Is Reduced by Use of Trendelenburg: A Prospective Study With Randomized Order of Positioning.,"BACKGROUND The use of traction during hip arthroscopy is commonly used to provide safe joint access and to improve visualization. However, traction during hip arthroscopy has been associated with complications ranging from transient neuropraxias to devastating soft-tissue necrosis. Trendelenburg positioning may be helpful, but the degree to which this is true is not well understood. QUESTIONS/PURPOSES To determine whether there would be a reduction in perineal pressure at 5°, 10°, and 15° of Trendelenburg compared with baseline (0° of Trendelenburg) while in the modified supine position during hip arthroscopy. METHODS A consecutive cohort of 50 patients treated with hip arthroscopy by a single, high-volume orthopaedic surgeon was analyzed. There were 30 females and 20 males in this study, with a mean age of 36 ± 16 years (range, 14 to 66 years); mean BMI was 26 kg/m. In the operating room, patients were placed in the modified supine position on a traction extension table with a well-padded perineal post. A standard blood pressure cuff was secured to the post to measure pressure exerted on the perineum as traction was applied to distract the hip. For each patient, pressure against the perineum was measured at four different positions using a digital level: 0°, 5°, 10°, and 15° of Trendelenburg. These positions were tested in a random order for each patient. Mean pressure was compared within patients under the four-period crossover design using a repeated-measure (mixed) ANOVA model. Examination of the residual error quantile plot showed that the pressure data followed a normal distribution, making the use of a parametric model appropriate. Tests were made for period and order effects. RESULTS Compared with baseline (0° or no Trendelenburg) there was a reduction in pressure of 4.4 (15.5%) at 5° of Trendelenburg (p = 0.203), 8 (28%) at 10° of Trendelenburg (p = 0.022) and 13.1 (46%) at 15° (p = 0.006). These results were maintained regardless of the sequence of positions used in each patient (0°, 5°, 10°, 15°). CONCLUSIONS Trendelenburg positioning of 10° and 15° during hip arthroscopy resulted in decreased perineal pressure compared with the neutral (0°) position. This technique is intended to harness gravity to exert the majority of countertraction while retaining the perineal post as a backup patient stabilizer. Routine introduction of Trendelenburg during hip arthroscopy reduces perineal pressure against the post, which may decrease complications related to traction and perineal pressure. Future studies should assess whether the observed differences in perineal pressure will reduce the frequency of post-related complications after hip arthroscopy. LEVEL OF EVIDENCE Level II, therapeutic study.",2019,"Routine introduction of Trendelenburg during hip arthroscopy reduces perineal pressure against the post, which may decrease complications related to traction and perineal pressure.","['A consecutive cohort of 50 patients treated with hip arthroscopy by a single, high-volume orthopaedic surgeon was analyzed', '30 females and 20 males in this study, with a mean age of 36 ± 16 years (range, 14 to 66 years); mean BMI was 26 kg/m']","['Hip Arthroscopy', 'Trendelenburg']","['Mean pressure', 'Perineal Pressure', 'perineal pressure', 'reduction in pressure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0186190', 'cui_str': 'Arthroscopy of hip (procedure)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0334891', 'cui_str': 'Orthopedists'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}]","[{'cui': 'C0186190', 'cui_str': 'Arthroscopy of hip (procedure)'}]","[{'cui': 'C0445074', 'cui_str': 'Mean pressure (qualifier value)'}, {'cui': 'C0031066', 'cui_str': 'Perineum'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.0289102,"Routine introduction of Trendelenburg during hip arthroscopy reduces perineal pressure against the post, which may decrease complications related to traction and perineal pressure.","[{'ForeName': 'Ajay C', 'Initials': 'AC', 'LastName': 'Lall', 'Affiliation': 'A. C. Lall, M. R. Battaglia, D. R. Maldonado, B. G. Domb, American Hip Institute, Des Plaines, IL, USA A. A. Saadat, Department of Orthopedics, University of Illinois at Chicago, Chicago, IL, USA M. R. Battaglia, University of Chicago Pritzker School of Medicine, Chicago, IL, USA I. Perets, Department of Orthopedics, Hadassah Hebrew University Hospital, Jerusalem, Israel.'}, {'ForeName': 'Ardavan A', 'Initials': 'AA', 'LastName': 'Saadat', 'Affiliation': ''}, {'ForeName': 'Muriel R', 'Initials': 'MR', 'LastName': 'Battaglia', 'Affiliation': ''}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Maldonado', 'Affiliation': ''}, {'ForeName': 'Itay', 'Initials': 'I', 'LastName': 'Perets', 'Affiliation': ''}, {'ForeName': 'Benjamin G', 'Initials': 'BG', 'LastName': 'Domb', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000000804'] 856,31801155,"Meningitis, urinary tract, and bloodstream infections in very low birth weight infants enrolled in a heart rate characteristics monitoring trial.","BACKGROUND Displaying heart rate characteristic (HRC) scores was associated with lower sepsis-associated mortality in very low birth weight (VLBW) infants in a multicenter randomized controlled trial (HeRO trial). The aim of this study was to test whether HRC indices rise before diagnosis of urinary tract infection (UTI) or meningitis, with and without concomitant BSI. METHODS Blood, urine, and cerebrospinal fluid (CSF) culture data after 3 days of age and within 120 days of study enrollment were analyzed from 2989 VLBW infants. The HRC index was analyzed 12 h prior to positive cultures compared to 36 h prior, using paired signed-rank tests. RESULTS UTI, meningitis, and BSI were diagnosed in 10%, 2%, and 24% of infants, respectively. The mean hourly HRC index was significantly higher 12 h prior to diagnosis of UTI and BSI compared to 36 h prior (UTI 2.07 versus 1.81; BSI 2.62 versus 2.25, both p < 0.0001). The baseline HRC index was higher for meningitis, compared to UTI or BSI, but without a statistically significant rise in the day prior to meningitis diagnosis. CONCLUSIONS In a large cohort of VLBW infants enrolled in the HeRO trial, the HRC index increased in the 24-h period prior to diagnosis of UTI and BSI but not meningitis.",2020,"The baseline HRC index was higher for meningitis, compared to UTI or BSI, but without a statistically significant rise in the day prior to meningitis diagnosis. ","['Blood, urine, and cerebrospinal fluid (CSF) culture data after 3 days of age and within 120 days of study enrollment were analyzed from 2989 VLBW infants', 'very low birth weight infants enrolled in a heart rate characteristic monitoring trial']",[],"['HRC index', 'baseline HRC index', 'Meningitis, urinary tract, and bloodstream infections', 'mean hourly HRC index', 'UTI, meningitis, and BSI']","[{'cui': 'C0005768'}, {'cui': 'C0042037'}, {'cui': 'C0430403', 'cui_str': 'Cerebrospinal fluid culture (procedure)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0025289', 'cui_str': 'Meningitis'}, {'cui': 'C0042027'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0558292', 'cui_str': 'Hourly (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",,0.151055,"The baseline HRC index was higher for meningitis, compared to UTI or BSI, but without a statistically significant rise in the day prior to meningitis diagnosis. ","[{'ForeName': 'Joern-Hendrik', 'Initials': 'JH', 'LastName': 'Weitkamp', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, USA. hendrik.weitkamp@vumc.org.'}, {'ForeName': 'Judy L', 'Initials': 'JL', 'LastName': 'Aschner', 'Affiliation': 'Pediatrics, Hackensack Meridian Health School of Medicine, Nutley, NJ, USA.'}, {'ForeName': 'Wallly A', 'Initials': 'WA', 'LastName': 'Carlo', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Bancalari', 'Affiliation': 'University of Miami, Miami, FL, USA.'}, {'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Perez', 'Affiliation': 'Pediatrix Medical Group, Orlando, FL, USA.'}, {'ForeName': 'Cristina T', 'Initials': 'CT', 'LastName': 'Navarrete', 'Affiliation': 'University of Miami, Miami, FL, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Schelonka', 'Affiliation': 'Oregon Health Science University, Portland, OR, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Whit Walker', 'Affiliation': 'USC School of Medicine, Greenville Memorial Hospital, Greenville, SC, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Porcelli', 'Affiliation': 'Pediatrics, Wake Forest University, Winston-Salem, NC, USA.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': ""O'Shea"", 'Affiliation': 'Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Palmer', 'Affiliation': 'Pediatrics, Pennsylvania State University, Hershey, PA, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Grossarth', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Lake', 'Affiliation': 'University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Karen D', 'Initials': 'KD', 'LastName': 'Fairchild', 'Affiliation': 'University of Virginia, Charlottesville, VA, USA.'}]",Pediatric research,['10.1038/s41390-019-0701-4'] 857,31201734,Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.,"BACKGROUND Diabetic peripheral neuropathy (DPN) is a common and severe complication that affects 50% of people with diabetes. Painful DPN is reported to occur in 16% to 24% of people with diabetes. A complete and comprehensive management strategy for the prevention and treatment of DPN, whether painful or not, has not yet been defined.Research into treatment for DPN has been characterised by a series of failed clinical trials, with few noteworthy advances. Strategies that support peripheral nerve regeneration and restore neurological function in people with painful or painless DPN are needed. The amino acid acetyl-L-carnitine (ALC) plays a role in the transfer of long-chain fatty acids into mitochondria for β-oxidation. ALC supplementation also induces neuroprotective and neurotrophic effects in the peripheral nervous system. Therefore, ALC supplementation targets several mechanisms relevant to potential nerve repair and regeneration, and could have clinical therapeutic potential. There is a need for a systematic review of the evidence from clinical trials. OBJECTIVES To assess the effects of ALC for the treatment of DPN. SEARCH METHODS On 2 July 2018, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, LILACS, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. We checked references, searched citations, and contacted study authors to identify additional studies. SELECTION CRITERIA We included randomised controlled trials (RCTs) and quasi-RCTs of ALC compared with placebo, other therapy, or no intervention in the treatment of DPN. Participants could be of any sex and age, and have type 1 or type 2 diabetes mellitus, of any severity, with painful or painless DPN. We accepted any definition of minimum criteria for DPN, in accordance with the Toronto Consensus. We imposed no language restriction.Pain was the primary outcome, measured as the proportion of participants with at least 30% (moderate) or 50% (substantial) decrease in pain over baseline, or as the score on a visual analogue scale (VAS) or Likert scale for pain. DATA COLLECTION AND ANALYSIS We followed standard Cochrane methods. MAIN RESULTS We included four studies with 907 participants, which were reported in three publications. Three trials studied ALC versus placebo (675 participants); in one trial the dose of ALC was 2000 mg/day, and in the other two trials, it was 1500 mg/day or 3000 mg/day. The fourth trial studied ALC 1500 mg/day versus methylcobalamin 1.5 mg/day (232 participants). The risk of bias was high in both trials of different ALC doses and low in the other two trials.No included trial measured the proportion of participants with at least moderate (30%) or substantial (50%) pain relief. ALC reduced pain more than placebo, measured on a 0- to 100-mm VAS (MD -9.16, 95% CI -16.76 to -1.57; three studies; 540 participants; P = 0.02; I² = 56%; random-effects; very low-certainty evidence; a higher score indicating more pain). At doses of 1500 mg/day or less, the VAS score after ALC treatment was little different from placebo (MD -0.05, 95% CI -10.00 to 9.89; two studies; 159 participants; P = 0.99; I² = 0%), but at doses greater than 1500 mg/day, ALC reduced pain more than placebo (MD -14.93, 95% CI -19.16 to -10.70; three studies; 381 participants; P < 0.00001; I² = 0%). This subgroup analysis should be viewed with caution as the evidence was even less certain than the overall analysis, which was already of very low certainty.Two placebo-controlled studies reported that vibration perception improved after 12 months. We graded this evidence as very low certainty, due to inconsistency and a high risk of bias, as the trial authors did not provide any numerical data. The placebo-controlled studies did not measure functional impairment and disability scores. No study used validated symptom scales. One study performed sensory testing, but the evidence was very uncertain.The fourth included study compared ALC with methylcobalamin, but did not report effects on pain. There was a reduction from baseline to 24 weeks in functional impairment and disability, based on the change in mean Neuropathy Disability Score (NDS; scale from zero to 10), but there was no important difference between the ALC group (mean score 1.66 ± 1.90) and the methylcobalamin group (mean score 1.35 ± 1.65) groups (P = 0.23; low-certainty evidence).One placebo-controlled study reported that six of 147 participants in the ALC > 1500 mg/day group (4.1%) and two of 147 participants in the placebo group (1.4%) discontinued treatment because of adverse events (headache, facial paraesthesia, and gastrointestinal disorders) (P = 0.17). The other two placebo-controlled studies reported no dropouts due to adverse events, and more pain, paraesthesia, and hyperaesthesias in the placebo group than the 3000 mg/day ALC group, but provided no numerical data. The overall certainty of adverse event evidence for the comparison of ALC versus placebo was low.The study comparing ALC with methylcobalamin reported that 34/117 participants (29.1%) experienced adverse events in the ALC group versus 33/115 (28.7%) in the methylcobalamin group (P = 0.95). Nine participants discontinued treatment due to adverse events (ALC: 4 participants, methylcobalamin: 5 participants), which were most commonly gastrointestinal symptoms. The certainty of the adverse event evidence for ALC versus methylcobalamin was low.Two studies were funded by the manufacturer of ALC and the other two studies had at least one co-author who was a consultant for an ALC manufacturer. AUTHORS' CONCLUSIONS We are very uncertain whether ALC causes a reduction in pain after 6 to 12 months' treatment in people with DPN, when compared with placebo, as the evidence is sparse and of low certainty. Data on functional and sensory impairment and symptoms are lacking, or of very low certainty. The evidence on adverse events is too uncertain to make any judgements on safety.",2019,"ALC reduced pain more than placebo, measured on a 0- to 100-mm VAS (MD -9.16, 95% CI -16.76 to -1.57; three studies; 540 participants; P = 0.02; I² = 56%; random-effects; very low-certainty evidence; a higher score indicating more pain).","['people with painful or painless DPN', 'people with diabetes', 'diabetic peripheral neuropathy', 'Participants could be of any sex and age, and have type 1 or type 2 diabetes mellitus, of any severity, with painful or painless DPN', '907 participants, which were reported in three publications']","['placebo', 'ALC', 'ALC supplementation', 'Acetyl-L-carnitine', 'methylcobalamin']","['neuroprotective and neurotrophic effects', 'visual analogue scale (VAS) or Likert scale for pain', 'pain', 'Pain', 'vibration perception', 'pain, paraesthesia, and hyperaesthesias', 'VAS score', 'adverse events', 'mean Neuropathy Disability Score (NDS; scale', 'ALC reduced pain', 'functional impairment and disability scores', 'adverse events (headache, facial paraesthesia, and gastrointestinal disorders', 'pain relief']","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234226', 'cui_str': 'Painless (qualifier value)'}, {'cui': 'C0027270', 'cui_str': 'Nicotinamide adenine dinucleotide (NAD)'}, {'cui': 'C0740447', 'cui_str': 'Peripheral neuropathy co-occurrent and due to diabetes mellitus'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0034036', 'cui_str': 'Publications'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001040', 'cui_str': 'Acetylcarnitine'}, {'cui': 'C0065844', 'cui_str': 'methylcobalamin'}]","[{'cui': 'C4704801', 'cui_str': 'Neurotrophic'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0451267', 'cui_str': 'Likert scale (assessment scale)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0057753', 'cui_str': 'NDS'}, {'cui': 'C0222045'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0239517', 'cui_str': 'Facial paresthesia (finding)'}, {'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}]",,0.621303,"ALC reduced pain more than placebo, measured on a 0- to 100-mm VAS (MD -9.16, 95% CI -16.76 to -1.57; three studies; 540 participants; P = 0.02; I² = 56%; random-effects; very low-certainty evidence; a higher score indicating more pain).","[{'ForeName': 'Luiz Csp', 'Initials': 'LC', 'LastName': 'Rolim', 'Affiliation': 'Department of Internal Medicine, Universidade Federal de São Paulo, Rua Borges Lagoa, 1065/110, São Paulo, São Paulo, Brazil, 04038-032.'}, {'ForeName': 'Edina Mk', 'Initials': 'EM', 'LastName': 'da Silva', 'Affiliation': ''}, {'ForeName': 'Ronald Lg', 'Initials': 'RL', 'LastName': 'Flumignan', 'Affiliation': ''}, {'ForeName': 'Marcio M', 'Initials': 'MM', 'LastName': 'Abreu', 'Affiliation': ''}, {'ForeName': 'Sérgio A', 'Initials': 'SA', 'LastName': 'Dib', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011265.pub2'] 858,31248843,"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.","BACKGROUND Acute graft-versus-host-disease (GVHD) after non-myeloablative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with considerable morbidity and mortality. This trial aimed to evaluate the efficacy of adding sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing acute GVHD in this setting. METHODS This multicentre, randomised, phase 3 trial took place at nine HSCT centres based in the USA, Denmark, and Germany. Eligible patients were diagnosed with advanced haematological malignancies treatable by allogeneic HSCT, had a Karnofsky score greater than or equal to 60, were aged older than 50 years, or if they were aged 50 years or younger, were considered at high risk of regimen-related toxicity associated with a high-dose pre-transplantation conditioning regimen. Patients were randomly allocated by an adaptive randomisation scheme stratified by transplantation centre to receive either the standard GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus). Patients and physicians were not masked to treatment. All patients were prepared for HSCT with fludarabine (30 mg/m 2 per day) 4, 3, and 2 days before receiving 2 or 3 Gy total body irradiation on the day of HSCT (day 0). In both study groups, 5·0 mg/kg of cyclosporine was administered orally twice daily starting 3 days before HSCT, and (in the absence of GVHD) tapered from day 96 through to day 150. In the standard GVHD prophylaxis group, 15 mg/kg of mycophenolate mofetil was given orally three times daily from day 0 until day 30, then twice daily until day 150, and (in the absence of GVHD) tapered off by day 180. In the triple-drug group, mycophenolate mofetil doses were the same as in the standard group, but the drug was discontinued on day 40. Sirolimus was started 3 days before HSCT, taken orally at 2 mg once daily and adjusted to maintain trough concentrations between 3-12 ng/mL through to day 150, and (in the absence of GVHD) tapered off by day 180. The primary endpoint was the cumulative incidence of grade 2-4 acute GVHD at day 100 post-transplantation. Secondary endpoints were non-relapse mortality, overall survival, progression-free survival, cumulative incidence of grade 3-4 acute GVHD, and cumulative incidence of chronic GVHD. Efficacy and safety analyses were per protocol, including all patients who received conditioning treatment and underwent transplantation. Toxic effects were measured according to the Common Terminology Criteria for Adverse Events (CTCAE). The current study was closed prematurely by recommendation of the Data and Safety Monitoring Board on July 27, 2016, after 168 patients received the allocated intervention, based on the results of a prespecified interim analysis for futility. This study is registered with ClinicalTrials.gov, number NCT01231412. FINDINGS Participants were recruited between Nov 1, 2010, and July 27, 2016. Of 180 patients enrolled in the study, 167 received the complete study intervention and were included in safety and efficacy analyses: 77 patients in the standard GVHD prophylaxis group and 90 in the triple-drug group. At the time of analysis, median follow-up was 48 months (IQR 31-60). The cumulative incidence of grade 2-4 acute GVHD at day 100 was lower in the triple-drug group compared with the standard GVHD prophylaxis group (26% [95% CI 17-35] in the triple-drug group vs 52% [41-63] in the standard group; HR 0·45 [95% CI 0·28-0·73]; p=0·0013). After 1 and 4 years, non-relapse mortality increased to 4% (95% CI 0-9) and 16% (8-24) in the triple-drug group and 16% (8-24) and 32% (21-43) in the standard group (HR 0·48 [0·26-0·90]; p=0·021). Overall survival at 1 year was 86% (95% CI 78-93) in the triple-drug group and 70% in the standard group (60-80) and at 4 years it was 64% in the triple-drug group (54-75) and 46% in the standard group (34-57%; HR 0·62 [0·40-0·97]; p=0·035). Progression-free survival at 1 year was 77% (95% CI 68-85) in the triple-drug group and 64% (53-74) in the standard drug group, and at 4 years it was 59% in the triple-drug group (49-70) and 41% in the standard group (30-53%; HR 0·64 [0·42-0·99]; p=0·045). We observed no difference in the cumulative incidence of grade 3-4 acute GVHD (2% [0-5] in the triple-drug group vs 8% [2-14] in the standard group; HR 0·55 [0·16-1·96]; p=0·36) and chronic GVHD (49% [39-59] in triple-drug group vs 50% [39-61] in the standard group; HR 0·94 [0·62-1·40]; p=0·74). In both groups the most common CTCAE grade 4 or higher toxic effects were pulmonary. INTERPRETATION Adding sirolimus to cyclosporine and mycophenolate mofetil resulted in a significantly lower proportion of patients developing acute GVHD compared with patients treated with cyclosporine and mycophenolate mofetil alone. Based on these results, the combination of cyclosporine, mycophenolate mofetil, and sirolimus has become the new standard GVHD prophylaxis regimen for patients treated with non-myeloablative conditioning and HLA-matched unrelated HSCT at the Fred Hutchinson Cancer Research Center. FUNDING National Institutes of Health.",2019,"Progression-free survival at 1 year was 77% (95% CI 68-85) in the triple-drug group and 64% (53-74) in the standard drug group, and at 4 years it was 59% in the triple-drug group (49-70) and 41% in the standard group (30-53%; HR 0·64 [0·42-0·99]","['Participants were recruited between Nov 1, 2010, and July 27, 2016', 'patients treated with non-myeloablative conditioning and HLA-matched unrelated HSCT at the Fred Hutchinson Cancer Research Center', 'patients after unrelated non-myeloablative haemopoietic stem cell transplantation', '180 patients enrolled in the study, 167 received the complete study intervention and were included in safety and efficacy analyses: 77 patients in the standard GVHD prophylaxis group and 90 in the triple-drug group', 'Eligible patients were diagnosed with advanced haematological malignancies treatable by allogeneic HSCT, had a Karnofsky score greater than or equal to 60, were aged older than 50 years, or if they were aged 50 years or younger, were considered at high risk of regimen-related toxicity associated with a high-dose pre-transplantation conditioning regimen']","['cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis', 'sirolimus', 'cyclosporine', 'standard GVHD prophylaxis', 'cyclosporine and mycophenolate mofetil alone', 'Sirolimus', 'cyclosporine, mycophenolate mofetil, and sirolimus', 'cyclosporine and mycophenolate mofetil prophylaxis therapy', 'mycophenolate mofetil', 'standard GVHD prophylaxis regimen (cyclosporine and mycophenolate mofetil) or the triple-drug combination regimen (cyclosporine, mycophenolate mofetil, and sirolimus', 'cyclosporine and mycophenolate mofetil', 'allogeneic haemopoietic stem cell transplantation (HSCT', 'HSCT with fludarabine']","['non-relapse mortality, overall survival, progression-free survival, cumulative incidence of grade 3-4 acute GVHD, and cumulative incidence of chronic GVHD', 'Efficacy and safety analyses', 'Progression-free survival', 'chronic GVHD', 'toxic effects', 'non-relapse mortality', 'Overall survival', 'cumulative incidence of grade 2-4 acute GVHD', 'cumulative incidence of grade 3-4 acute GVHD', 'Toxic effects']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0445356', 'cui_str': 'Unrelated (finding)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0035168'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4517595', 'cui_str': '167 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0376450', 'cui_str': 'Transplantation Conditioning'}]","[{'cui': 'C0010594', 'cui_str': 'Cyclosporins'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0013162', 'cui_str': 'Drug Combinations'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0059985', 'cui_str': 'fludarabine'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",180.0,0.127429,"Progression-free survival at 1 year was 77% (95% CI 68-85) in the triple-drug group and 64% (53-74) in the standard drug group, and at 4 years it was 59% in the triple-drug group (49-70) and 41% in the standard group (30-53%; HR 0·64 [0·42-0·99]","[{'ForeName': 'Brenda M', 'Initials': 'BM', 'LastName': 'Sandmaier', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: bsandmai@fredhutch.org.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Kornblit', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Haematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Barry E', 'Initials': 'BE', 'LastName': 'Storer', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Gitte', 'Initials': 'G', 'LastName': 'Olesen', 'Affiliation': 'Department of Hematology and Department of Clinical Medicine, Aarhus Hospital, Aarhus, Denmark.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Maris', 'Affiliation': 'Colorado Blood Cancer Institute, Denver, CO, USA.'}, {'ForeName': 'Amelia A', 'Initials': 'AA', 'LastName': 'Langston', 'Affiliation': 'Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Jonathan A', 'Initials': 'JA', 'LastName': 'Gutman', 'Affiliation': 'Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA.'}, {'ForeName': 'Soeren L', 'Initials': 'SL', 'LastName': 'Petersen', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Chauncey', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA; Marrow Transplant Unit, VA Puget Sound Health Care System, Seattle, WA, USA.'}, {'ForeName': 'Wolfgang A', 'Initials': 'WA', 'LastName': 'Bethge', 'Affiliation': 'Department of Internal Medicine II - Hematology and Oncology, University Hospital of Eberhard Karls University, Tuebingen, Germany.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Pulsipher', 'Affiliation': ""Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA, USA.""}, {'ForeName': 'Ann E', 'Initials': 'AE', 'LastName': 'Woolfrey', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Mielcarek', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Martin', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Fred R', 'Initials': 'FR', 'LastName': 'Appelbaum', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Mary E D', 'Initials': 'MED', 'LastName': 'Flowers', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Maloney', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Storb', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA.'}]",The Lancet. Haematology,['10.1016/S2352-3026(19)30088-2'] 859,31259807,"PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.","PURPOSE To evaluate patient-reported visual function after ocriplasmin through the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) in patients with symptomatic vitreomacular adhesion/vitreomacular traction including macular hole. METHODS This was a prespecified analysis of a secondary endpoint from the OASIS trial. Patients received a single intravitreal injection of ocriplasmin (0.125 mg) or sham and completed the VFQ-25 questionnaire at baseline and at Months 6, 12, and 24. Clinically meaningful (≥5-point) changes from baseline were assessed. RESULTS Of the 220 patients enrolled, 146 received ocriplasmin and 74 received sham. At Month 24, the percentage of patients with a ≥5-point improvement from baseline in VFQ-25 composite scores was higher with ocriplasmin versus sham (51.4% vs. 30.1%, 95% confidence interval, 8.1-34.5, P = 0.003). The percentage of patients with ≥5-point worsening at Month 24 was lower with ocriplasmin versus sham (9.5% vs. 15.6%, 95% confidence interval: -15.6 to 3.5, P = 0.191). A larger percentage of patients treated with ocriplasmin versus sham experienced a ≥5-point improvement in VFQ-25 composite and subscale scores at Month 24 regardless of baseline full-thickness macular hole status. CONCLUSION A larger percentage of patients with symptomatic vitreomacular adhesion/vitreomacular traction reported clinically meaningful improvements in self-assessed visual function with ocriplasmin than sham.",2020,"A larger percentage of patients treated with ocriplasmin versus sham experienced a ≥5-point improvement in VFQ-25 composite and subscale scores at Month 24 regardless of baseline full-thickness macular hole status. ","['patients with symptomatic vitreomacular adhesion/vitreomacular traction including macular hole', '220 patients enrolled, 146 received']","['ocriplasmin', 'ocriplasmin through the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25', 'single intravitreal injection of ocriplasmin']","['percentage of patients with ≥5-point worsening', 'self-assessed visual function', 'VFQ-25 composite scores', 'VFQ-25 composite and subscale scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2748203', 'cui_str': 'Vitreomacular adhesion'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0024441', 'cui_str': 'Macular Holes'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}]","[{'cui': 'C0066522', 'cui_str': 'ocriplasmin'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}]",220.0,0.272427,"A larger percentage of patients treated with ocriplasmin versus sham experienced a ≥5-point improvement in VFQ-25 composite and subscale scores at Month 24 regardless of baseline full-thickness macular hole status. ","[{'ForeName': 'Calvin', 'Initials': 'C', 'LastName': 'Mein', 'Affiliation': 'Retinal Consultants of San Antonio, San Antonio, Texas.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix, Arizona.'}, {'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'Feiner', 'Affiliation': 'Hackensack University Medical Center, Hackensack, New Jersey.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Drenser', 'Affiliation': 'Associated Retinal Consultants P.C., Royal Oak, Michigan.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Miller', 'Affiliation': 'Cincinnati Eye Institute, Cincinnati, Ohio.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Benz', 'Affiliation': 'Retinal Consultants Houston, Houston, Texas.'}, {'ForeName': 'Esmeralda', 'Initials': 'E', 'LastName': 'Meunier', 'Affiliation': 'Oxurion (formerly ThromboGenics), Leuven, Belgium.'}, {'ForeName': 'Lionel', 'Initials': 'L', 'LastName': 'Moro', 'Affiliation': 'Oxurion (formerly ThromboGenics), Leuven, Belgium.'}, {'ForeName': 'Mitchell S', 'Initials': 'MS', 'LastName': 'Fineman', 'Affiliation': 'Mid Atlantic Retina, Philadelphia, Pennsylvania.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002599'] 860,31259813,"EFFICACY AND SAFETY OF A TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH TYPE 3 NEOVASCULARIZATION: A 52-Week, Single-Arm, Multicenter Trial.","PURPOSE To evaluate 52-week efficacy and safety of a treat-and-extend regimen of intravitreal aflibercept 2 mg on treatment-naive Type 3 neovascularization lesions. METHODS Phase IV, prospective, open-label, single-arm, multicenter trial including patients with untreated Stage I/II Type 3 neovascularization lesions and baseline best-corrected visual acuity between 78 and 23 Early Treatment Diabetic Retinopathy Study letters. Primary endpoint: mean change in best-corrected visual acuity from baseline at 52 weeks. RESULTS Thirty-two eyes from 32 patients were included (mean ± SD age: 78.2 ± 7.7 years, 68.8% females, baseline best-corrected visual acuity: 57.9 ± 15.4 [Snellen fraction 20/70]). Best-corrected visual acuity increased by 10.5 ± 15.9 Early Treatment Diabetic Retinopathy Study letters at Week 52 (P = 0.0001). The mean foveal and choroidal thickness decreased by 129.1 ± 80.1 µm (P < 0.0001) and 64.3 ± 96.5 (P = 0.0001), respectively. The proportion of patients with intraretinal/subretinal fluid decreased from 28 (87.5%) at baseline to 3 (11.5%) at Week 52 (P < 0.0001). Pigment epithelial detachment and lesion area showed nonsignificant changes over 52 weeks. The mean number of injections was 8.0 ± 2.0. Seven (21.9%) patients experienced treatment-related adverse events and two (6.3%) experienced serious adverse events; one (3.1%) ocular serious adverse event requiring treatment withdrawal, endophthalmitis, and one (3.1%) nonocular spontaneously resolved serious adverse event, palpitations. One (3.1%) patient experienced an APTC ATE: nonfatal stroke not related to trial treatment. CONCLUSION A treat-and-extend regimen of aflibercept improves visual acuity and retinal edema in eyes with Type 3 neovascularization over 52 weeks with good tolerability.",2020,Best-corrected visual acuity increased by 10.5 ± 15.9 Early Treatment Diabetic Retinopathy Study letters at Week 52 (P = 0.0001).,"['eyes with Type 3 neovascularization over 52 weeks with good tolerability', 'Thirty-two eyes from 32 patients were included (mean ± SD age: 78.2 ± 7.7 years, 68.8% females, baseline best-corrected visual acuity: 57.9 ± 15.4 [Snellen fraction 20/70', 'patients with untreated Stage I/II Type 3 neovascularization lesions and baseline best-corrected visual acuity between 78 and 23 Early Treatment Diabetic Retinopathy Study letters']","['aflibercept', 'intravitreal aflibercept']","['Best-corrected visual acuity', 'mean foveal and choroidal thickness', 'adverse events', 'proportion of patients with intraretinal/subretinal fluid', 'mean change in best-corrected visual acuity', 'serious adverse events', 'visual acuity and retinal edema', 'serious adverse event, palpitations']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0027686', 'cui_str': 'Pathologic Neovascularization'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0450357', 'cui_str': '32 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517860', 'cui_str': '7.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C4517579', 'cui_str': '15.4 (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1 (qualifier value)'}, {'cui': 'C0441731', 'cui_str': 'Type 3 (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0011884', 'cui_str': 'Diabetic Retinopathy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}]","[{'cui': 'C1134659', 'cui_str': 'aflibercept'}]","[{'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0242420', 'cui_str': 'Retinal Edema'}, {'cui': 'C0030252', 'cui_str': 'Palpitations (finding)'}]",32.0,0.115424,Best-corrected visual acuity increased by 10.5 ± 15.9 Early Treatment Diabetic Retinopathy Study letters at Week 52 (P = 0.0001).,"[{'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Arias', 'Affiliation': 'Department of Ophthalmology, Hospital Universitari de Bellvitge, Barcelona, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Cervera', 'Affiliation': 'Department of Ophthalmology, Hospital General de València, València, Spain.'}, {'ForeName': 'Jaume Crespí', 'Initials': 'JC', 'LastName': 'Vilimelis', 'Affiliation': 'Department of Ophthalmology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'José Juan', 'Initials': 'JJ', 'LastName': 'Escobar', 'Affiliation': 'Department of Ophthalmology, Hospital Dos de Maig, Barcelona, Spain.'}, {'ForeName': 'Antonio Gómez', 'Initials': 'AG', 'LastName': 'Escobar', 'Affiliation': 'Department of Ophthalmology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Zapata', 'Affiliation': ""Department of Ophthalmology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.""}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002582'] 861,30973547,Sustained Effect of a Community-based Behavioral and Nutrition Intervention on HIV-related Outcomes Among Women Living With HIV in Rural India: A Quasi-experimental Trial.,"BACKGROUND Women living with HIV (WLH) in rural communities face challenges to obtaining treatment and accurate disease-related information. Nutritional deficits exacerbate disease progression. SETTING WLH were recruited from primary health centers in rural India. METHOD A quasi-experimental trial of a comprehensive Accredited Social Health Activist (Asha)-supported intervention compared 4 distinct Asha-based programs [(1) standard education (SE) alone; (2) nutrition education (+NE); (3) nutrition supplements (+NS); or (4) nutrition education and nutrition supplements (+NENS)] on key disease and nutrition-related outcomes [CD4 count, body mass index (BMI), serum albumin, and hemoglobin]. Assessments occurred at baseline, and months 6 (immediately after intervention), 12, and 18. Multilevel modeling examined effects of program (group) over time. FINDINGS Among 600 WLH enrolled (n = 150 per arm), mean age, CD4 count, and BMI (kg/m) were 34.31, 447.42, and 20.09, respectively, at baseline. At 18-month follow-up, program 4 (+NENS) experienced greatest improvements in CD4 counts compared with program 1 (+SE) [adjusted difference = 223.81, 95% confidence interval (CI): 170.29 to 277.32]. For BMI, programs 3 (+NS; adjusted difference = 2.33, 95% CI: 1.39 to 3.26) and 4 (+NENS; adjusted difference = 2.14, 95% CI: 1.17 to 3.12) exhibited greater gains compared with program 1 (+SE). Programs 3 and 4 were not significantly different from each other (adjusted difference = -0.18, 95% CI: -1.12 to 0.76). Hemoglobin and serum albumin also improved over time; program 4 (+NENS) exhibited the greatest gains. CONCLUSIONS A low-cost Asha-supported behavioral and nutritional intervention improved outcomes for WLH. Gains were sustained at 18-month follow-up. Similar approaches may help improve HIV and other infectious disease-related outcomes in vulnerable populations.",2019,"For BMI, programs 3 (+NS; adjusted difference = 2.33, 95% CI: 1.39 to 3.26) and 4 (+NENS; adjusted difference = 2.14, 95% CI: 1.17 to 3.12) exhibited greater gains compared with program 1 (+SE).","['600 WLH enrolled (n = 150 per arm), mean age, CD4 count, and BMI (kg/m', 'WLH were recruited from primary health centers in rural India', 'Women Living With HIV in Rural India', 'Women living with HIV (WLH']","['comprehensive Accredited Social Health Activist (Asha)-supported intervention compared 4 distinct Asha-based programs [(1) standard education (SE) alone; (2) nutrition education (+NE); (3) nutrition supplements (+NS); or (4) nutrition education and nutrition supplements (+NENS', 'Community-based Behavioral and Nutrition Intervention']","['Hemoglobin and serum albumin', 'key disease and nutrition-related outcomes [CD4 count, body mass index (BMI), serum albumin, and hemoglobin', 'CD4 counts']","[{'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523465', 'cui_str': 'Albumin measurement, serum (procedure)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",600.0,0.0974018,"For BMI, programs 3 (+NS; adjusted difference = 2.33, 95% CI: 1.39 to 3.26) and 4 (+NENS; adjusted difference = 2.14, 95% CI: 1.17 to 3.12) exhibited greater gains compared with program 1 (+SE).","[{'ForeName': 'Adeline M', 'Initials': 'AM', 'LastName': 'Nyamathi', 'Affiliation': 'Sue & Bill Gross School of Nursing, University of California, Irvine, CA.'}, {'ForeName': 'Sanghyuk S', 'Initials': 'SS', 'LastName': 'Shin', 'Affiliation': 'Sue & Bill Gross School of Nursing, University of California, Irvine, CA.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Sinha', 'Affiliation': 'School of Medicine, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Carpenter', 'Affiliation': 'Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA.'}, {'ForeName': 'Dana Rose', 'Initials': 'DR', 'LastName': 'Garfin', 'Affiliation': 'Sue & Bill Gross School of Nursing, University of California, Irvine, CA.'}, {'ForeName': 'Padma', 'Initials': 'P', 'LastName': 'Ramakrishnan', 'Affiliation': 'School of Medicine, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Kartik', 'Initials': 'K', 'LastName': 'Yadav', 'Affiliation': 'Sue & Bill Gross School of Nursing, University of California, Irvine, CA.'}, {'ForeName': 'Maria L', 'Initials': 'ML', 'LastName': 'Ekstrand', 'Affiliation': 'School of Medicine, University of California, San Francisco, CA.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000002044'] 862,30497904,Effects of a sea buckthorn oil spray emulsion on dry eye.,"PURPOSE To investigate the effects of a sea buckthorn oil and sodium hyaluronate-containing eyelid spray emulsion (SB spray) on dry eye. METHODS A randomized controlled study was carried out. Adults (25-70 years) with Ocular Surface Disease Index (OSDI) ≥20 and moderate or severe dryness, burning or grittiness of the eyes were included. In study part one (n = 2), SB spray was used on both closed eyelids four times in one day. In part two (n = 10), SB spray was used on one randomized eyelid, and a commercial reference spray on the other for nine days. In part three (n = 40), eyes were randomized to one eye receiving SB spray and an untreated control for 1.5 months. Dry eye tests were carried out at baseline, during, and at the end of each study section. Symptoms were recorded in questionnaires and daily logs. RESULTS In part one, the SB spray was well tolerated. In part two, OSDI decreased significantly (P = 0.022) in the SB spray eye compared to the reference spray, indicating a beneficial effect on symptoms. In part three, OSDI in the SB spray eye decreased significantly compared to the untreated control (P = 0.0007). The scores for dryness at the study end were lower in the SB spray eye compared to control (P = 0.0070). Symptom sums and frequencies of dryness (sum P = 0.0046, frequency P = 0.0016) and watering (sum P = 0.0003, frequency P = 0.013) in the daily logs were lower in the eye treated with SB spray. CONCLUSIONS SB spray on closed eyelids relieved the symptoms of dry eye.",2019,"Symptom sums and frequencies of dryness (sum P = 0.0046, frequency P = 0.0016) and watering (sum P = 0.0003, frequency P = 0.013) in the daily logs were lower in the eye treated with SB spray. ",['Adults (25-70 years) with Ocular Surface Disease Index '],"['sea buckthorn oil and sodium hyaluronate-containing eyelid spray emulsion (SB spray', 'sea buckthorn oil spray emulsion', 'SB spray']","['OSDI', 'OSDI in the SB spray eye', 'tolerated', 'symptoms of dry eye', 'OSDI) ≥20 and moderate or severe dryness, burning or grittiness of the eyes', 'dry eye', 'scores for dryness', 'Symptom sums and frequencies of dryness']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C1013835', 'cui_str': 'Sea Buckthorn'}, {'cui': 'C0028908', 'cui_str': 'Oils'}, {'cui': 'C0087000', 'cui_str': 'Sodium Hyaluronate'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0015426', 'cui_str': 'Eyelids'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}]","[{'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0314719', 'cui_str': 'Dry eyes (finding)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",1.0,0.0298406,"Symptom sums and frequencies of dryness (sum P = 0.0046, frequency P = 0.0016) and watering (sum P = 0.0003, frequency P = 0.013) in the daily logs were lower in the eye treated with SB spray. ","[{'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Larmo', 'Affiliation': 'Aromtech Ltd, Tornio, Finland. Electronic address: petra.larmo@aromtech.com.'}, {'ForeName': 'Riikka', 'Initials': 'R', 'LastName': 'Järvinen', 'Affiliation': 'Finnsusp Ltd, Lieto, Finland.'}, {'ForeName': 'Jarmo', 'Initials': 'J', 'LastName': 'Laihia', 'Affiliation': 'Finnsusp Ltd, Lieto, Finland.'}, {'ForeName': 'Eliisa', 'Initials': 'E', 'LastName': 'Löyttyniemi', 'Affiliation': 'EL Statistics, Raisio, Finland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Maavirta', 'Affiliation': 'Turun Silmäexpertit Ltd, Turku, Finland.'}, {'ForeName': 'Baoru', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Food Chemistry and Food Development, Department of Biochemistry, University of Turku, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Kallio', 'Affiliation': 'Food Chemistry and Food Development, Department of Biochemistry, University of Turku, Finland.'}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Sandberg-Lall', 'Affiliation': 'Turun Silmäexpertit Ltd, Turku, Finland.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2018.11.011'] 863,31238061,Reduction in HbA1c with Exercise videogames among participants with elevated HbA1c: Secondary analysis of the Wii Heart Fitness trial.,"AIMS Physical activity plays an important role in blood glucose management, yet most adults with elevated blood glucose do not engage in regular physical activity. Exercise videogames (EVGs) may be an attractive alternative for persons who have not found standard exercise modalities appealing. METHODS This sub-study within a larger trial examined the effects of 12 weeks of EVGs versus standard exercise (e.g., treadmill, cycling) and a control condition among individuals with elevated HbA1c (100% prediabetic). This study was conducted at a university research lab. Outcomes included HbA1c and weekly minutes of moderate to vigorous physical activity (MVPA) assessed using self-report and accelerometer.Other health risk indices (e.g., lipids) and psychosocial constructs shown to influence exercise participation (e.g., intrinsic motivation) were assessed. RESULTS Participants (n = 84), averaged age 51.4 years (range 20-79), 80% were female, and 77.4% were non-Hispanic. Baseline HbA1c ranged from 5.7% to 6.4% (39-49 mmol/mol). At week 12, EVG participants demonstrated an average 2% reduction in HbA1c compared to a 0.6% reduction in Standard and Control groups (p's = 0.04 and 0.03). EVG participants engaged in significantly more MVPA than Standard (+17 min/week) and Controls (+54 min/week) (p's < 0.05), had reduced LDL cholesterol (p = 0.05) and trends suggesting reduced body fat (p = 0.10). EVG participants reported higher exercise enjoyment and motivation compared to other participants. CONCLUSIONS EVGs may be an attractive and effective tool to improve management of blood glucose that might contribute toward preventing the onset of type 2 diabetes among those with prediabetes.",2019,"EVG participants engaged in significantly more MVPA than Standard (+17 min/week) and Controls (+54 min/week) (p's < 0.05), had reduced LDL cholesterol (p = 0.05) and trends suggesting reduced body fat (p = 0.10).","['participants with elevated HbA1c', 'persons who have not found standard exercise modalities appealing', 'Participants (n\u202f=\u202f84), averaged age 51.4\u202fyears (range 20-79), 80% were female, and 77.4% were non-Hispanic', 'individuals with elevated HbA1c (100% prediabetic']","['EVGs versus standard exercise', 'Exercise videogames (EVGs', 'EVG']","['reduced LDL cholesterol', 'HbA1c and weekly minutes of moderate to vigorous physical activity (MVPA) assessed using self-report and accelerometer', 'exercise enjoyment and motivation', 'MVPA']","[{'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0442737', 'cui_str': 'Not detected (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",,0.0474691,"EVG participants engaged in significantly more MVPA than Standard (+17 min/week) and Controls (+54 min/week) (p's < 0.05), had reduced LDL cholesterol (p = 0.05) and trends suggesting reduced body fat (p = 0.10).","[{'ForeName': 'Beth C', 'Initials': 'BC', 'LastName': 'Bock', 'Affiliation': 'Centers for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, United States; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States; Department of Behavioral & Social Sciences, School of Public Health of Brown University, Providence, RI, United States. Electronic address: Beth_Bock@Brown.edu.'}, {'ForeName': 'Shira I', 'Initials': 'SI', 'LastName': 'Dunsiger', 'Affiliation': 'Centers for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, United States; Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States.'}, {'ForeName': 'Wen-Chih', 'Initials': 'WC', 'LastName': 'Wu', 'Affiliation': 'Department of Medicine, Alpert Medical School of Brown University and Department of Cardiology, Providence VA Medical Center, Providence, RI, United States.'}, {'ForeName': 'Joseph T', 'Initials': 'JT', 'LastName': 'Ciccolo', 'Affiliation': 'Department of Applied Physiology, Teachers College at Columbia University, New York, NY, United States.'}, {'ForeName': 'Eva R', 'Initials': 'ER', 'LastName': 'Serber', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Lantini', 'Affiliation': 'Centers for Behavioral & Preventive Medicine, The Miriam Hospital, Providence, RI, United States.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI, United States; Department of Behavioral & Social Sciences, School of Public Health of Brown University, Providence, RI, United States.'}]",Diabetes research and clinical practice,['10.1016/j.diabres.2019.06.011'] 864,31925721,Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVE Taxane-induced peripheral neuropathy (TIPN) is a main toxicity of taxanes with no effective treatment. This study aimed to compare the efficacy and safety of pregabalin (150 mg daily) and duloxetine (60 mg daily) for managing TIPN in breast cancer patients. METHODS This randomized, double-blind, Phase II clinical trial was carried out at a chemotherapy center affiliated to Mazandaran University of Medical Sciences. Patients with breast cancer who received paclitaxel or docetaxel and had a grade 1 or more neuropathy (based on the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI-CTCAE v4.03), and who had score 4 or higher neuropathic pain severity [based on the visual analog scale (VAS)] were enrolled. Response to treatment was assessed based on improvements in the VAS, NCI-CTCAE, and Patient Neurotoxicity Questionnaire (PNQ) scores during a 6-week trial. RESULTS Both interventions were effective in decreasing TIPN compared to baseline. At Week 6, the VAS scores were improved in 37/40 (92.5%) and 16/42 (38.1%) of the patients in the pregabalin and duloxetine groups, respectively (p < 0.001). Improvement in NCI-CTCAE sensory neuropathy was also more significant with pregabalin (37/40; 92.5%) in comparison to duloxetine (13/42; 31%) (p < 0.001). Pregabalin was also more beneficial than duloxetine in improving the PNQ scores by 36/40 (90%) and 13/42 (31%), respectively (p < 0.001). Both interventions were tolerated well with mild adverse events. CONCLUSIONS Both pregabalin and duloxetine were well tolerated and efficacious in relieving neuropathic pain, however a 60 mg dose of duloxetine is inferior to a 150 mg dose of pregabalin.",2020,"At Week 6, the VAS scores were improved in 37/40 (92.5%) and 16/42 (38.1%) of the patients in the pregabalin and duloxetine groups, respectively (p < 0.001).","['breast cancer patients', 'chemotherapy center affiliated to Mazandaran University of Medical Sciences', 'Taxane-Induced Sensory Neuropathy', 'Patients with breast cancer who received', 'and had a grade 1 or more neuropathy (based on the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI-CTCAE v4.03), and who had score 4 or higher neuropathic pain severity [based on the visual analog scale (VAS)] were enrolled']","['paclitaxel or docetaxel', 'Pregabalin and Duloxetine', 'pregabalin and duloxetine', 'pregabalin', 'Pregabalin', 'duloxetine']","['tolerated well with mild adverse events', 'efficacy and safety', 'VAS scores', 'tolerated and efficacious in relieving neuropathic pain', 'TIPN', 'NCI-CTCAE sensory neuropathy', 'PNQ scores', 'VAS, NCI-CTCAE, and Patient Neurotoxicity Questionnaire (PNQ) scores']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy (disorder)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1516728', 'cui_str': 'CTCAE (Common Terminology Criteria for Adverse Events)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0027796', 'cui_str': 'Neurodynia'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0657912', 'cui_str': 'pregabalin'}, {'cui': 'C0245561', 'cui_str': 'duloxetine'}]","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1301771', 'cui_str': 'Relieved'}, {'cui': 'C0027796', 'cui_str': 'Neurodynia'}, {'cui': 'C1513882', 'cui_str': 'National Cancer Institute'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.149526,"At Week 6, the VAS scores were improved in 37/40 (92.5%) and 16/42 (38.1%) of the patients in the pregabalin and duloxetine groups, respectively (p < 0.001).","[{'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Salehifar', 'Affiliation': 'Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Ghasem', 'Initials': 'G', 'LastName': 'Janbabaei', 'Affiliation': 'Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Narjes', 'Initials': 'N', 'LastName': 'Hendouei', 'Affiliation': 'Department of Pharmacotherapy, Faculty of Pharmacy, Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Alipour', 'Affiliation': 'Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Tabrizi', 'Affiliation': 'Department of Neurology, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Avan', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Medical Toxicology and Drug Abuse Research Center (MTDRC), Birjand University of Medical Sciences, Birjand, Iran. avanr91@gmail.com.'}]",Clinical drug investigation,['10.1007/s40261-019-00882-6'] 865,29940335,Group medical visits after heart failure hospitalization: Study protocol for a randomized-controlled trial.,"A primary goal of this research project is to better understand how shared medical appointments (SMAs) can improve the health status and decrease hospitalization and death for patients recently discharged with heart failure (HF) by providing education, disease state monitoring, medication titration, and social support to patients and their caregivers. We propose a 3-site randomized-controlled efficacy trial with mixed methods to test a SMA intervention, versus usual care. Patients within 12 weeks of a HF hospitalization will be randomized to receive either HF-SMA (intervention arm) with optional co-participation with their caregivers, versus usual care (control arm). The HF-SMA will be provided by a non-physician team composed of a nurse, a nutritionist, a health psychologist, a nurse practitioner and/or a clinical pharmacist and will consist of four sessions of 2-h duration that occur every other week for 8 weeks. Each session will start with an assessment of patient needs followed by theme-based disease self-management education, followed by patient-initiated disease management discussion, and conclude with break-out sessions of individualized disease monitoring and medication case management. The study duration will be 180 days for all patients from the day of randomization. The primary study hypothesis is that, compared with usual care, patients randomized to HF-SMA will experience better cardiac health status at 90 and 180 days follow-up. The secondary hypotheses are that, compared to usual care, patients randomized to HF-SMA will experience better overall health status, a combined endpoint of hospitalization and death, better HF self-care behavior, and lower B-type natriuretic peptide levels.",2018,"The secondary hypotheses are that, compared to usual care, patients randomized to HF-SMA will experience better overall health status, a combined endpoint of hospitalization and death, better HF self-care behavior, and lower B-type natriuretic peptide levels.",['Patients within 12\u202fweeks of a HF hospitalization'],"['HF-SMA', 'HF-SMA (intervention arm) with optional co-participation with their caregivers, versus usual care (control arm', 'SMA intervention']",['cardiac health status'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0018759', 'cui_str': 'Level of Health'}]",,0.0494785,"The secondary hypotheses are that, compared to usual care, patients randomized to HF-SMA will experience better overall health status, a combined endpoint of hospitalization and death, better HF self-care behavior, and lower B-type natriuretic peptide levels.","[{'ForeName': 'Wen-Chih', 'Initials': 'WC', 'LastName': 'Wu', 'Affiliation': 'Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA. Electronic address: Wen-Chih.Wu@va.gov.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Parent', 'Affiliation': 'Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA.'}, {'ForeName': 'Sandesh', 'Initials': 'S', 'LastName': 'Dev', 'Affiliation': 'Carl T. Hayden Medical Research Foundation, 650 E. Indian School Road 151A, Phoenix, AZ 85012-1892, USA.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Hearns', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Tracey H', 'Initials': 'TH', 'LastName': 'Taveira', 'Affiliation': 'Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cohen', 'Affiliation': 'Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI 02908, USA.'}, {'ForeName': 'Jeneen', 'Initials': 'J', 'LastName': 'Shell-Boyd', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Jeri', 'Initials': 'J', 'LastName': 'Jewett-Tennant', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Marshall', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Gee', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Schaub', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'LaForest', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Ball', 'Affiliation': 'Louis Stokes Cleveland VA Medical Center, 10701 East Boulevard, Cleveland, OH 44106, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2018.06.015'] 866,31469220,"Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.","AIM To determine the effects of individual and combined therapies on plasma insulin, glucagon, β-hydroxybutyrate (β-OH) and associated metabolites. MATERIALS AND METHODS In DURATION-8, the combination of once-weekly exenatide (EQW) + 10 mg dapagliflozin (Dapa) in patients with type 2 diabetes poorly controlled with metformin-reduced HbA1c levels and body weight (at weeks 28 and 52) was compared with EQW + placebo (Plb) or Dapa + Plb. The study included 678 patients randomized 1:1:1 to EQW + Dapa, EQW + Plb, or Dapa + Plb. Plasma insulin and glucagon were measured at fasting and 2 hours after a mixed meal. Fasting plasma free fatty acids (FFA) and β-OH concentrations were measured. RESULTS The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW + Plb only; postprandial I/Glg increased in all groups but significantly more with EQW + Plb. β-OH, FFA, and glycerol concentrations showed a parallel response: larger increments with Dapa + Plb, larger decrements with EQW + Plb, and intermediate changes with EQW + Dapa. β-OH levels and I/Glg were inversely related to one another. Patients in the top quartile of β-OH changes from baseline [median (interquartile range): +207 (305) vs. -65 (-154) μmol/L; P < .0001] were more frequently treated with Dapa + Plb, had higher urine glucose-to-creatinine ratios, and lower fasting insulin [52 (51) vs. 68 (53) pmol/L; P = .0013) and I/Glg [1.76 (1.49) vs. 2.23 (1.70) mol/mol; P = .0020]. Haematocrit increased only in the Dapa group. CONCLUSIONS The EQW + Dapa combination abolished the Dapa-induced rise in β-OH, reduced the EQW-induced increase in I/Glg, maintained glycosuria, and increased haematocrit in patients with poorly controlled type 2 diabetes. The drug combination may preserve any putative benefits while mitigating the risk of ketoacidosis.",2020,The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW+Plb only; postprandial I/Glg increased in all groups but significantly more with EQW+Plb.,"['678 patients randomized 1:1:1 to', 'patients with type 2 diabetes poorly controlled with', 'patients with poorly controlled type 2 diabetes']","['Exenatide Plus Dapagliflozin', 'exenatide (EQW)+10 mg dapagliflozin (Dapa', 'metformin', 'EQW+placebo (Plb) or Dapa+Plb', 'EQW+Dapa, EQW+Plb, or Dapa+Plb']","['glycated hemoglobin levels and body weight', 'fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW+Plb only; postprandial I/Glg', 'Fasting plasma free fatty acids (FFA) and β-OH concentrations', 'Plasma insulin and glucagon', 'β-OH levels and I/Glg', 'urine glucose-to-creatinine ratios', 'Hematocrit', 'β-OH, FFA, and glycerol concentrations', 'plasma insulin, glucagon, β-hydroxybutyrate (β-OH), and associated metabolites']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0373606', 'cui_str': 'Free fatty acids measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0004076', 'cui_str': 'Urine test for glucose'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0020332', 'cui_str': 'Hydroxybutyrates'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}]",678.0,0.0568795,The fasting insulin-to-glucagon molar ratio (I/Glg) increased with EQW+Plb only; postprandial I/Glg increased in all groups but significantly more with EQW+Plb.,"[{'ForeName': 'Ele', 'Initials': 'E', 'LastName': 'Ferrannini', 'Affiliation': 'CNR Institute of Clinical Physiology, Pisa, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Baldi', 'Affiliation': 'Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Frías', 'Affiliation': 'National Research Institute, Los Angeles, California.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Guja', 'Affiliation': 'Department of Diabetes, Nutrition and Metabolic Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Hardy', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Repetto', 'Affiliation': 'AstraZeneca, Gaithersburg, Maryland.'}, {'ForeName': 'Serge A', 'Initials': 'SA', 'LastName': 'Jabbour', 'Affiliation': 'Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Ralph A', 'Initials': 'RA', 'LastName': 'DeFronzo', 'Affiliation': 'Diabetes Division, University of Texas Health Science Center, San Antonio, Texas.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13870'] 867,30879881,Short Message Service Reminders to Parents for Increasing Adolescent Human Papillomavirus Vaccination Rates in a Secondary School Vaccine Program: A Randomized Control Trial.,"PURPOSE In Victoria (Australia), the human papillomavirus (HPV) vaccine is delivered within a state-wide secondary school vaccine program, administered by local government. This study aimed to test the hypothesis that sending a short message service (SMS) reminder to parents who had consented to their child's receiving the HPV vaccine would lead to greater uptake of the vaccine within the program. The secondary aim was to assess the effect of self-regulatory versus motivational message content in the SMS. METHODS A randomized control trial design was used across 31 schools within seven local government areas. Parents of 4,386 consented adolescents were randomized into three study conditions: motivational SMS versus self-regulatory SMS versus no SMS. Follow-up extended beyond the final school visit to the end of the calendar year to capture those who may have attended a catch-up vaccination session. RESULTS On the day of the final school visit, 85.71% of consented students in the control condition received the HPV vaccine, compared with 88.35% (2.64% point increase) in the motivational message condition, and 89.00% (3.29% point increase) in the self-regulatory message condition, χ 2 (2, N = 4,386) = 8.31, p = .016. Both intervention messages were similarly effective at increasing vaccination rates. This effect was maintained in the extended follow-up period. CONCLUSIONS The trial findings supported the hypothesis that SMS reminders to parents/guardians would lead to greater uptake of the HPV vaccine in adolescents participating in school-based vaccination. Also, this effect was observed whether we used a motivational or self-regulatory message framework. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ACTRN12617001307392). Registration Date: September 12, 2017. Retrospectively registered.",2019,"Parents of 4,386 consented adolescents were randomized into three study conditions: motivational SMS versus self-regulatory SMS versus no SMS.","['adolescents participating in school-based vaccination', 'Adolescent Human Papillomavirus Vaccination Rates in a Secondary School Vaccine Program', '31 schools within seven local government areas', 'Parents of 4,386 consented adolescents', ""parents who had consented to their child's receiving the""]","['sending a short message service (SMS) reminder', 'HPV vaccine', 'motivational SMS versus self-regulatory SMS versus no SMS']",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1997921', 'cui_str': 'Vaccination for human papillomavirus (procedure)'}, {'cui': 'C0036530', 'cui_str': 'Schools, Secondary'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0026788', 'cui_str': 'Local Government'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}]","[{'cui': 'C3178909'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}, {'cui': 'C0036588', 'cui_str': 'Self'}]",[],4386.0,0.0925751,"Parents of 4,386 consented adolescents were randomized into three study conditions: motivational SMS versus self-regulatory SMS versus no SMS.","[{'ForeName': 'Fraser', 'Initials': 'F', 'LastName': 'Tull', 'Affiliation': 'BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Victoria, Australia. Electronic address: fraser.tull@monash.edu.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Borg', 'Affiliation': 'BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Victoria, Australia.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Knott', 'Affiliation': 'Behavioural Insights Unit, Department of Premier and Cabinet, Victorian State Government, Melbourne, Australia.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Beasley', 'Affiliation': 'Immunisation Section, Health Protection Branch, Department of Health and Human Services, Victorian State Government, Melbourne, Australia.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Halliday', 'Affiliation': 'Public Sector Innovation, Department of Premier and Cabinet, Victorian State Government, Melbourne, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Faulkner', 'Affiliation': 'BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Victoria, Australia.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Sutton', 'Affiliation': 'Immunisation Section, Health Protection Branch, Department of Health and Human Services, Victorian State Government, Melbourne, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bragge', 'Affiliation': 'BehaviourWorks Australia, Monash Sustainable Development Institute, Monash University, Victoria, Australia.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2018.12.026'] 868,31233281,Efficacy and Safety of Long-Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate.,"OBJECTIVE To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy. METHODS This is a post hoc analysis of patients from the RA-BEGIN study who entered a long-term extension, RA-BEYOND, and were assessed for up to 24 weeks. In RA-BEGIN, MTX-naive patients with early active RA were randomized to MTX monotherapy, baricitinib 4 mg monotherapy, or baricitinib 4 mg plus MTX. At week 52, all patients entering RA-BEYOND received baricitinib 4 mg monotherapy. MTX could be prescribed during RA-BEYOND at the investigator's discretion. RESULTS Patients in RA-BEYOND who were not rescued in RA-BEGIN (n = 423) were evaluated. Of these, 47% continued baricitinib monotherapy and 53% added MTX, with similar proportions from the 3 original arms. Patients with lower disease activity at the RA-BEYOND baseline generally continued to do well with baricitinib monotherapy as assessed by the Simplified Disease Activity Index, the Clinical Disease Activity Index, and the Health Assessment Questionnaire disability index scores. Patients prescribed MTX had higher disease activity at the RA-BEYOND baseline and had improved disease activity after the addition of MTX. Safety outcomes were similar across treatment groups. CONCLUSION Many patients responded well to continued baricitinib monotherapy or to switching to baricitinib monotherapy from MTX monotherapy or baricitinib plus MTX, showing sustained or improved disease control. The groups of patients who had less disease control on their original therapies showed sustained or improved disease control with the addition of MTX to baricitinib.",2020,"Safety outcomes were similar across treatment groups. ","['rheumatoid arthritis', 'naïve patients with early active RA', 'patients with active rheumatoid arthritis (RA']","['MTX monotherapy or baricitinib plus MTX', 'MTX monotherapy, baricitinib 4-mg monotherapy, or baricitinib 4-mg plus MTX', 'MTX', 'baricitinib plus MTX', 'baricitinib 4-mg monotherapy', 'baricitinib monotherapy or switched from methotrexate (MTX', 'baricitinib monotherapy', 'long-term baricitinib with and without methotrexate', 'methotrexate monotherapy or baricitinib plus methotrexate']","['Safety outcomes', 'sustained or improved disease control', 'Simplified Disease Activity Index, Clinical Disease Activity Index, and Health Assessment Questionnaire-Disability Index scores', 'Efficacy and safety', 'disease activity']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C4044947', 'cui_str': 'baricitinib'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire (assessment scale)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",423.0,0.0574468,"Safety outcomes were similar across treatment groups. ","[{'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'Fleischmann', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Takeuchi', 'Affiliation': 'Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Schiff', 'Affiliation': 'University of Colorado, Denver.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Schlichting', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Xie', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Maher', 'Initials': 'M', 'LastName': 'Issa', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Ivaylo', 'Initials': 'I', 'LastName': 'Stoykov', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Lisse', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Pindaro', 'Initials': 'P', 'LastName': 'Martinez-Osuna', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Terence', 'Initials': 'T', 'LastName': 'Rooney', 'Affiliation': 'Eli Lilly and Company, Indianapolis, Indiana.'}, {'ForeName': 'Cristiano A F', 'Initials': 'CAF', 'LastName': 'Zerbini', 'Affiliation': 'Centro Paulista de Investigação Clinica, São Paulo, Brazil.'}]",Arthritis care & research,['10.1002/acr.24007'] 869,31420191,Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction.,"Angiotensin-converting enzyme inhibitors are beneficial in heart failure with reduced ejection fraction but are associated with acute declines in estimated glomerular filtration rate (eGFR). Prior studies evaluating thresholds of eGFR decline while using angiotensin-converting enzyme inhibitors in heart failure with reduced ejection have not taken into account this medication-driven decline. Here we used data from the Studies of Left Ventricular Dysfunction (SOLVD) trial of 6245 patients and performed Cox proportional hazards regression models to calculate hazard ratios of all-cause mortality and heart failure hospitalization-associated with percent eGFR decline at two- and six-weeks after randomization to enalapril versus placebo. In reference to placebo with equal degree of percent eGFR decline, any eGFR decline in the enalapril arm was associated with lower hazard of both outcomes. Under a conservative estimate using zero percent eGFR decline in the placebo arm as the reference, up to a 10% decline with enalapril was associated with mortality benefit (hazard ratio 0.87 [95% confidence interval 0.77, 0.99]) while up to a 35% decline was associated with decreased risk of heart failure hospitalization (0.78 [0.61, 0.98]). Under an intermediate estimate, up to a 15% decline with enalapril was associated with a mortality benefit (0.86 [0.77, 0.97]) and all levels of eGFR decline were associated with decreased risk of heart failure hospitalization. There was no percent eGFR decline, including up to 40%, in any models at either two- or six-weeks where enalapril was associated with higher mortality risk. Thus, in patients with reduced ejection fraction heart failure, enalapril is associated with decreased risk of mortality and heart failure hospitalizations. Hence, compelling reasons beyond moderate eGFR decline ought to be considered before its use is withdrawn.",2019,"There was no percent eGFR decline, including up to 40%, in any models at either two- or six-weeks where enalapril was associated with higher mortality risk.",['patients with heart failure with reduced ejection fraction'],"['enalapril versus placebo', 'angiotensin-converting enzyme inhibitors', 'Angiotensin-converting enzyme inhibitors', 'placebo', 'enalapril']","['risk of mortality and heart failure hospitalizations', 'mortality benefit', 'percent eGFR decline, any eGFR decline', 'risk of heart failure hospitalization', 'mortality risk', 'eGFR decline']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0003015', 'cui_str': 'ACE Inhibitors'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}]",6245.0,0.0819316,"There was no percent eGFR decline, including up to 40%, in any models at either two- or six-weeks where enalapril was associated with higher mortality risk.","[{'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'McCallum', 'Affiliation': 'Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Hocine', 'Initials': 'H', 'LastName': 'Tighiouart', 'Affiliation': 'Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts, USA.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Ku', 'Affiliation': 'Division of Nephrology and Pediatric Nephrology, University of California San Francisco, San Francisco, California, USA.'}, {'ForeName': 'Deeb', 'Initials': 'D', 'LastName': 'Salem', 'Affiliation': 'Division of Cardiology and the CardioVascular Center, Tufts Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Sarnak', 'Affiliation': 'Division of Nephrology, Tufts Medical Center, Boston, Massachusetts, USA. Electronic address: msarnak@tuftsmedicalcenter.org.'}]",Kidney international,['10.1016/j.kint.2019.05.019'] 870,30007300,A randomized clinical trial of the effectiveness of 0.018-inch and 0.022-inch slot orthodontic bracket systems: part 1-duration of treatment.,"OBJECTIVE To compare treatment duration between 0.018-inch and 0.022-inch slot systems and determine factors influencing treatment duration. SUBJECTS AND METHODS Eligible participants aged 12 years or over were allocated to the 0.018-inch or 0.022-inch slot MBT appliance (3M-Unitek, Monrovia, California, USA) using block randomization in groups of 10. Outcome measures included duration of: 1. overall treatment, 2. levelling and alignment, 3. working and finishing, and 4. appointment numbers and other treatment-related factors. Parametric tests (independent samples t-test) and non-parametric tests (chi-square with Fisher's exact tests and Mann-Whitney U-test) assessed differences between groups. A multiple linear regression analysis identified factors influencing treatment duration (P < 0.05). RESULTS Of the 187 participants randomized (1:1 ratio), 34 withdrew or were excluded (protocol deviations or poor cooperation). There were 77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years). Baseline characteristics were similar between groups (P > 0.05). The mean duration of treatment for the 0.018-inch and 0.022-inch slot groups was 29.3 and 31.2 months, respectively. There were no statistically significant differences between the two treatment groups in terms of treatment duration, duration of the key stages of treatment, and number of appointments (P > 0.05). The regression analysis revealed 33.0 per cent of variance in treatment duration was explained by age at bonding, Class II division 2 malocclusion, number of failed appointments, number of emergency appointments, and transfer to another clinician. There were no adverse events. LIMITATIONS It was impossible to blind clinicians or patients to allocation and oral hygiene and periodontal outcomes were not assessed. CONCLUSIONS There was no statistically or clinically significant difference in treatment duration between 0.018-inch and 0.022-inch slot bracket systems. Increasing patient age, Class II division 2 malocclusion, number of failed and emergency appointments, and multi-operator treatment all increase orthodontic treatment duration. REGISTRATION The trial was registered with ClinicalTrials.gov on 5 March 2014, registration number: NCT02080338. PROTOCOL The protocol was published at DOI: 10.1186/1745-6215-15-389.",2019,"There were no statistically significant differences between the two treatment groups in terms of treatment duration, duration of the key stages of treatment, and number of appointments (P > 0.05).","['Eligible participants aged 12 years or over were allocated to the 0.018-inch or 0.022-inch', '77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years', '187 participants randomized (1:1 ratio']","['slot MBT appliance (3M-Unitek, Monrovia, California, USA']","['duration of: 1. overall treatment, 2', 'treatment duration, duration of the key stages of treatment, and number of appointments', 'mean duration of treatment']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0450304', 'cui_str': '0.018""'}, {'cui': 'C0450305', 'cui_str': '0.022""'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]","[{'cui': 'C0243112'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment (qualifier value)'}]",187.0,0.151373,"There were no statistically significant differences between the two treatment groups in terms of treatment duration, duration of the key stages of treatment, and number of appointments (P > 0.05).","[{'ForeName': 'Yassir A', 'Initials': 'YA', 'LastName': 'Yassir', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'El-Angbawi', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'Grant T', 'Initials': 'GT', 'LastName': 'McIntyre', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'Gavin F', 'Initials': 'GF', 'LastName': 'Revie', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Bearn', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}]",European journal of orthodontics,['10.1093/ejo/cjy037'] 871,30007330,A randomized clinical trial of the effectiveness of 0.018-inch and 0.022-inch slot orthodontic bracket systems: part 3-biological side-effects of treatment.,"OBJECTIVE To compare orthodontically induced inflammatory root resorption (OIIRR) and patient perception of pain during orthodontic treatment between 0.018-inch and 0.022-inch slot bracket systems. SUBJECTS AND METHODS Eligible participants aged 12 years or above were allocated to treatment with the 0.018-inch or 0.022-inch slot MBT appliance (3M Unitek, Monrovia, California, USA) using block randomization in groups of 10. OIIRR was assessed radiographically using standardized periapical radiographs before and after 9 months from the start of treatment. Patient perception of pain was assessed using a validated patient questionnaire at 6 months from the start of treatment. Parametric tests (t-test) and non-parametric tests (chi-square with Fisher's exact tests and Kruskal-Wallis test) assessed differences between the groups (P < 0.05). The correlation between severity of OIIRR and abnormal root morphology, history of dental trauma, and pain during treatment was assessed. RESULTS Of the 187 participants randomized (1:1 ratio), 34 withdrew or were excluded (protocol deviations or poor cooperation). There were 77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years). Baseline characteristics were similar between groups (P > 0.05). There was no significant difference in the severity of the OIIRR nor patient perception of pain between the two study groups (P = 0.115 and P = 0.08 respectively). The correlation between the severity of OIIRR and abnormal root morphology or history of dental trauma was not statistically significant (P = 0.086 and P = 0.313). Moreover, there was no significant correlation between the severity of OIIRR and pain during treatment (R = 0.045, P = 0.617). LIMITATIONS It was impossible to blind clinicians or patients to allocation, and oral hygiene and periodontal outcomes were not assessed. CONCLUSIONS The effect of bracket slot size on the severity of OIIRR and patient perception of pain are not significant. TRIAL REGISTRATION The trial was registered with ClinicalTrials.gov on 5 March 2014, registration number: NCT02080338.",2019,There was no significant difference in the severity of the OIIRR nor patient perception of pain between the two study groups (P = 0.115 and P = 0.08 respectively).,"['77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years', '187 participants randomized (1:1 ratio', 'Eligible participants aged 12 years or above were allocated to treatment with the 0.018-inch or 0.022-inch']","['slot MBT appliance (3M Unitek, Monrovia, California, USA']","['Patient perception of pain', 'severity of OIIRR and abnormal root morphology, history of dental trauma, and pain', 'severity of the OIIRR nor patient perception of pain', 'inflammatory root resorption (OIIRR) and patient perception of pain', 'severity of OIIRR and abnormal root morphology or history of dental trauma', 'severity of OIIRR and patient perception of pain', 'severity of OIIRR and pain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450304', 'cui_str': '0.018""'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0450305', 'cui_str': '0.022""'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0243112'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C1301685', 'cui_str': 'Dental trauma'}, {'cui': 'C0035851', 'cui_str': 'Root Resorption'}]",187.0,0.228651,There was no significant difference in the severity of the OIIRR nor patient perception of pain between the two study groups (P = 0.115 and P = 0.08 respectively).,"[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'El-Angbawi', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'Yassir A', 'Initials': 'YA', 'LastName': 'Yassir', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'Grant T', 'Initials': 'GT', 'LastName': 'McIntyre', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'Gavin F', 'Initials': 'GF', 'LastName': 'Revie', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Bearn', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}]",European journal of orthodontics,['10.1093/ejo/cjy039'] 872,31478329,Striatal dopamine transporter changes after glucose loading in humans.,"AIMS The dopamine transporter (DAT) actively translocates dopamine that is released from the presynaptic neurons across the membranes of nerve terminals into the extracellular space. We hypothesized that glucose loading-induced changes in striatal DAT levels could be associated with food intake in humans. MATERIALS AND METHODS An intravenous bolus injection of 18 F-FP-CIT was administered after infusion of glucose or placebo (normal saline), and emission data were acquired over 90 minutes in 33 healthy males. For a volume-of-interest-based analysis, an atlas involving sub-striatal regions of ventral striatum (VST), caudate nucleus and putamen was applied. DAT availability and binding potential (BP ND ) were measured using a simplified reference tissue method with cerebellum as the reference. RESULTS The glucose-loaded BP ND from the VST negatively correlated with body mass index (BMI), whereas the placebo-loaded BP ND from the VST did not. After loading with glucose, there were substantial increases in BP ND s: 18.3%, 71.7% and 34.0% on average in the VST, caudate nucleus and putamen, respectively. CONCLUSION Striatal DAT changes after glucose loading, and BMI is associated with glucose-loaded DAT availability, not with placebo-loaded DAT availability. DAT might have a role in the reward system of eating behavior.",2020,"After loading with glucose, there were substantial increases in BP ND s: 18.3%, 71.7% and 34.0% on average in the VST, caudate nucleus and putamen, respectively. ","['33 healthy males', 'humans']","['glucose or placebo (normal saline), and emission data']","['DAT availability and binding potential (BP ND ', 'BP ND', 'glucose-loaded BP ND']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0233929', 'cui_str': 'Emission (finding)'}]","[{'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}]",33.0,0.0983813,"After loading with glucose, there were substantial increases in BP ND s: 18.3%, 71.7% and 34.0% on average in the VST, caudate nucleus and putamen, respectively. ","[{'ForeName': 'Kyoungjune', 'Initials': 'K', 'LastName': 'Pak', 'Affiliation': 'Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Seongho', 'Initials': 'S', 'LastName': 'Seo', 'Affiliation': 'Department of Neuroscience, College of Medicine, Gachon University, Incheon, Republic of Korea.'}, {'ForeName': 'Keunyoung', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Myung Jun', 'Initials': 'MJ', 'LastName': 'Lee', 'Affiliation': 'Department of Neurology, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Myung Jun', 'Initials': 'MJ', 'LastName': 'Shin', 'Affiliation': 'Department of Rehabilitation Medicine, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Sunghwan', 'Initials': 'S', 'LastName': 'Suh', 'Affiliation': 'Department of Internal Medicine, Dong-A University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Hyung-Jun', 'Initials': 'HJ', 'LastName': 'Im', 'Affiliation': 'Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Jung-Jun', 'Initials': 'JJ', 'LastName': 'Park', 'Affiliation': 'Division of Sport Science, Pusan National University, Busan, Republic of Korea.'}, {'ForeName': 'Seong-Jang', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.'}, {'ForeName': 'In Joo', 'Initials': 'IJ', 'LastName': 'Kim', 'Affiliation': 'Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13872'] 873,31202957,Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma.,"INTRODUCTION This study aimed to investigate the dose-response and pharmacology of a range of single doses of nebulised ensifentrine (RPL554), an inhaled dual phosphodiesterase (PDE) 3/4 inhibitor in patients with asthma. METHODS In this randomised, placebo-controlled, double-blind crossover study, patients received single nebulised doses of ensifentrine 0.4, 1.5, 6 and 24 mg, salbutamol 2.5 and 7.5 mg, and placebo. Eligible patients were adults with asthma, pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) 60-90% predicted and ≥1.5 L, with post-salbutamol FEV 1 increase ≥15%. The co-primary objectives were peak and average FEV 1 over 12 h for ensifentrine vs placebo and salbutamol. Secondary endpoints included: peak and average systolic and diastolic blood pressure, pulse rate and ECG heart rate; and safety and tolerability (adverse events [AEs], and serum potassium). ClinicalTrials.gov: NCT02427165. RESULTS A total of 29 patients were randomised, with 25 (89%) completing the study. For the two co-primary endpoints there was a clear ensifentrine dose-response relationship, with all treatments superior to placebo (p < 0.001). There was no relationship between the ensifentrine dose and AE incidence or blood pressure. Ensifentrine 0.4, 1.5 and 6 mg had significantly lower effects than both salbutamol doses on pulse and heart rates. Ensifentrine did not impact potassium, whereas there was a was a dose-related reduction for salbutamol. Inhalation of ensifentrine resulted in a dose-related increase in plasma exposure. CONCLUSIONS Single-dose ensifentrine demonstrated dose-dependent bronchodilation, and was as effective as a therapeutic dose of nebulised salbutamol. All ensifentrine doses were similarly well tolerated, and did not show the characteristic β 2 -agonist systemic adverse effects.",2019,"Ensifentrine 0.4, 1.5 and 6 mg had significantly lower effects than both salbutamol doses on pulse and heart rates.","['patients with asthma', 'asthma', 'A total of 29 patients were randomised, with 25 (89%) completing the study', 'Eligible patients were adults with asthma, pre-bronchodilator forced expiratory volume in 1\u202fs (FEV 1 ) 60-90% predicted and ≥1.5\u202fL, with post-salbutamol FEV 1 increase ≥15']","['nebulised salbutamol', 'placebo', 'Ensifentrine', 'salbutamol 2.5 and 7.5\u202fmg, and placebo', 'ensifentrine', 'nebulised ensifentrine (RPL554', 'salbutamol', 'first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol']","['peak and average systolic and diastolic blood pressure, pulse rate and ECG heart rate; and safety and tolerability (adverse events [AEs], and serum potassium', 'pulse and heart rates', 'Efficacy and safety', 'plasma exposure', 'clear ensifentrine dose-response relationship', 'ensifentrine dose and AE incidence or blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilators'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0860909', 'cui_str': 'FEV 1 increased'}]","[{'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C1744162', 'cui_str': 'RPL554'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0232117', 'cui_str': 'Pulse Rate'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0302353', 'cui_str': 'Serum potassium measurement'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",29.0,0.359591,"Ensifentrine 0.4, 1.5 and 6 mg had significantly lower effects than both salbutamol doses on pulse and heart rates.","[{'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Bjermer', 'Affiliation': 'Dept of Respiratory Medicine & Allergology, Skane University Hospital, Lund University, Lund, Sweden. Electronic address: leif.bjermer@med.lu.se.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Abbott-Banner', 'Affiliation': 'Verona Pharma plc, London, United Kingdom.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Newman', 'Affiliation': 'Verona Pharma plc, London, United Kingdom.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2019.101814'] 874,31222615,Effectiveness of Briefer Coping-Focused Psychotherapy for Common Mental Complaints on Work-Participation and Mental Health: A Pragmatic Randomized Trial with 2-Year Follow-Up.,"Purpose The aim of this study was to assess short and long-term effectiveness of brief coping-focused psychotherapy (Brief-PsT) compared with short-term psychotherapy (Short-PsT) on work-participation (WP) and mental health. Both treatments were preceded by group education. Methods All participants were on, or at risk of, sick leave due to common mental complaints. Patients were selected for inclusion in this study based on levels of self-reported symptoms ('some' or 'seriously affected') of anxiety and depression. They were randomized to Brief-PsT (n = 141) or Short-PsT with a more extended focus (n = 143). Primary outcome was the transition of WP-state from baseline to 3 months follow-up. In addition, WP at 12 and 24 months follow-up were assessed. The secondary outcome, clinical recovery rate (CR-rate) was obtained from the Beck Depression and Beck Anxiety Inventories, at 2-year follow-up. In addition, self-reported mental health symptom severity, self-efficacy, subjective health complaints and life satisfaction were assessed. Results At 3 months follow-up, the increase in WP was significantly greater in Brief-PsT than in Short-PsT (p = 0.039). At 3 months, 60% in Brief-PsT and 51% in Short-PsT was at work, partial or full. Thereafter, these differences diminished, 84% and 80% were at work at 2-year follow up. The 2-year follow-up of the secondary outcome measurements was completed by 53% in Brief-PsT and 57% in Short PsT. CR-rate was significantly greater in Brief-PsT compared with the Short-PsT (69% vs. 51%, p = 0.024). Furthermore, there was a greater reduction in the number of subjective health complaints in Brief-PsT (4.0 vs. 1.9 p = 0.012). All other measurements favoured Brief-PsT as well, but did not reach statistical significance. Conclusions Brief coping-focused psychotherapy added to group education for persons with depression or anxiety complaints seemed more effective in enhancing early work participation compared with additional short-term psychotherapy of standard duration with more extended focus. Clinical recovery rate and decline of comorbid subjective health complaints at 2-year follow-up were also in favour of the brief coping-focused program.",2020,"At 3 months follow-up, the increase in WP was significantly greater in Brief-PsT than in Short-PsT (p = 0.039).","['Methods All participants were on, or at risk of, sick leave due to common mental complaints', ""Patients were selected for inclusion in this study based on levels of self-reported symptoms ('some' or 'seriously affected') of anxiety and depression"", 'Common Mental Complaints on Work-Participation and Mental Health', 'persons with depression or anxiety complaints']","['brief coping-focused psychotherapy (Brief-PsT', 'Briefer Coping-Focused Psychotherapy', 'short-term psychotherapy (Short-PsT']","['Short PsT. CR-rate', 'Clinical recovery rate and decline of comorbid subjective health complaints', 'transition of WP-state', 'mental health symptom severity, self-efficacy, subjective health complaints and life satisfaction', 'Beck Depression and Beck Anxiety Inventories', 'increase in WP', 'work-participation (WP) and mental health', 'number of subjective health complaints', 'clinical recovery rate (CR-rate']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0027361', 'cui_str': 'Persons'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0033970', 'cui_str': 'Short-Term Psychotherapy'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2936631', 'cui_str': 'Subjective Health'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",,0.0788071,"At 3 months follow-up, the increase in WP was significantly greater in Brief-PsT than in Short-PsT (p = 0.039).","[{'ForeName': 'M E A', 'Initials': 'MEA', 'LastName': 'Wormgoor', 'Affiliation': 'Division Physical Medicine and Rehabilitation, Vestfold Hospital Trust, Stavern, Norway. marjon.wormgoor@siv.no.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Indahl', 'Affiliation': 'Division Physical Medicine and Rehabilitation, Vestfold Hospital Trust, Stavern, Norway.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Andersen', 'Affiliation': 'Division of Mental Health & Addiction, Vestfold Hospital Trust, Tønsberg, Norway.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Egeland', 'Affiliation': 'Division of Mental Health & Addiction, Vestfold Hospital Trust, Tønsberg, Norway.'}]",Journal of occupational rehabilitation,['10.1007/s10926-019-09841-6'] 875,31100535,Supplementing stuttering treatment with online cognitive behavior therapy: An experimental trial.,"PURPOSE It is now well established that adults who present to speech clinics for help with stuttering will have an increased risk of having an anxiety disorder, particularly social anxiety disorder. Concomitant psychological problems are known to interfere with the maintenance of the benefits of behavioral speech treatments for stuttering. The current team has developed and trialed a cognitive behavior therapy (CBT) program designed specifically to reduce anxiety in adults who stutter, and trials have shown promise for both an in-clinic version and a standalone internet-based version. The aim of the present study is to determine whether iGlebe, the internet-based version of the team's internet CBT treatment (previously known as CBTPsych), enhances the benefits of behavioral stuttering treatment. METHOD Participants were 32 adults seeking treatment for stuttering. The design was a two-arm randomized experimental trial with blinded outcome assessments at 6 and 12 months post-randomization. Both arms received basic speech-restructuring training to reduce stuttering, without any anxiolytic (anxiety reducing) components. The experimental arm also received 5 months access to iGlebe. RESULTS There was evidence that, at 12 months post-randomization, iGlebe added clinically significant improvements to self-reported stuttering severity and quality of life. The present experimental trial provides the first evidence that the addition of CBT to speech restructuring improves speech outcomes. CONCLUSIONS The present results will be the basis for the development of a comprehensive, internet-based treatment program for anxiety associated with stuttering. Ultimately, it may be possible for such an economical, scalable, and translatable comprehensive treatment model to supplement standard speech-language pathology treatment practices for those who stutter.",2019,"There was evidence that, at 12 months post-randomization, iGlebe added clinically significant improvements to self-reported stuttering severity and quality of life.","['Participants were 32 adults seeking treatment for stuttering', 'adults who present to speech clinics']","['basic speech-restructuring training to reduce stuttering, without any anxiolytic (anxiety reducing) components', 'cognitive behavior therapy (CBT) program', 'Supplementing stuttering treatment with online cognitive behavior therapy']",['self-reported stuttering severity and quality of life'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038506', 'cui_str': 'Stuttering'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0040616', 'cui_str': 'Anti-Anxiety Drugs'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0038506', 'cui_str': 'Stuttering'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0034380'}]",32.0,0.0437169,"There was evidence that, at 12 months post-randomization, iGlebe added clinically significant improvements to self-reported stuttering severity and quality of life.","[{'ForeName': 'Ross', 'Initials': 'R', 'LastName': 'Menzies', 'Affiliation': 'Australian Stuttering Research Centre, The University of Sydney, Australia. Electronic address: Ross.Menzies@uts.edu.au.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': ""O'Brian"", 'Affiliation': 'Australian Stuttering Research Centre, The University of Sydney, Australia. Electronic address: Susan.Obrian@uts.edu.au.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Packman', 'Affiliation': 'Australian Stuttering Research Centre, The University of Sydney, Australia. Electronic address: Ann.Packman@uts.edu.au.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'School of Public Health, The University of Queensland, Australia. Electronic address: majones@bond.edu.au.'}, {'ForeName': 'Fjóla Dögg', 'Initials': 'FD', 'LastName': 'Helgadóttir', 'Affiliation': 'Australian Stuttering Research Centre, The University of Sydney, Australia. Electronic address: fjola@ai-therapy.com.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Onslow', 'Affiliation': 'Australian Stuttering Research Centre, The University of Sydney, Australia. Electronic address: Mark.Onslow@uts.edu.au.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2019.04.003'] 876,31248461,A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.,"BACKGROUND Cancer vaccines require adjuvants to induce effective immune responses; however, there is no consensus on optimal adjuvants. We hypothesized that toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS), combined with CD4 T cell activation, would support strong and durable CD8 + T cell responses, whereas addition of an incomplete Freund's adjuvant (IFA) would reduce magnitude and persistence of immune responses. PATIENTS AND METHODS Participants with resected stage IIB-IV melanoma received a vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide (Tet). Participants were randomly assigned 2:1 to cohort 1 (LPS dose-escalation) or cohort 2 (polyICLC). Each cohort included 3 subgroups (a-c), receiving 12MP + Tet + TLR agonist without IFA (0), or with IFA in vaccine one (V1), or all six vaccines (V6). Toxicities were recorded (CTCAE v4). T cell responses were measured with IFNγ ELIspot assay ex vivo or after one in vitro stimulation (IVS). RESULTS Fifty-three eligible patients were enrolled, of which fifty-one were treated. Treatment-related dose-limiting toxicities (DLTs) were observed in 0/33 patients in cohort 1 and in 2/18 patients in cohort 2 (11%). CD8 T cell responses to 12MP were detected ex vivo in cohort 1 (42%) and in cohort 2 (56%) and in 18, 50, and 72% for subgroups V0, V1, and V6, respectively. T cell responses to melanoma peptides were more durable and of highest magnitude for IFA V6. CONCLUSIONS LPS and polyICLC are safe and effective vaccine adjuvants when combined with IFA. Contrary to the central hypothesis, IFA enhanced T cell responses to peptide vaccines when added to TLR agonists. Future studies will aim to understand mechanisms underlying the favorable effects with IFA. TRIAL REGISTRATION The clinical trial Mel58 was performed with IRB (#15781) and FDA approval and is registered with Clinicaltrials.gov on April 25, 2012 (NCT01585350). Patients provided written informed consent to participate. Enrollment started on June 24, 2012.",2019,"CD8 T cell responses to 12MP were detected ex vivo in cohort 1 (42%) and in cohort 2 (56%) and in 18, 50, and 72% for subgroups V0, V1, and V6, respectively.","['melanoma patients', 'Fifty-three eligible patients were enrolled, of which fifty-one were treated', 'Participants with resected stage IIB-IV melanoma received a']","['toll-like receptor (TLR)3 agonist polyICLC or TLR4 agonist lipopolysaccharide (LPS', 'vaccine comprised of 12 melanoma peptides restricted by Class I MHC (12MP), plus a tetanus helper peptide (Tet', 'multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC', '12MP\u2009+\u2009Tet\u2009+\u2009TLR agonist without IFA (0), or with IFA in vaccine one (V1), or all six vaccines (V6', 'LPS and polyICLC']","['CD8 T cell responses to 12MP', 'T cell responses', 'Toxicities', 'Treatment-related dose-limiting toxicities (DLTs']","[{'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0441769', 'cui_str': 'Stage 2B (qualifier value)'}]","[{'cui': 'C1534866', 'cui_str': 'Toll-Like Receptor 3'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0023810', 'cui_str': 'Lipoglycans'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C0443288', 'cui_str': 'Restricted (qualifier value)'}, {'cui': 'C0441885', 'cui_str': 'Class 1 (qualifier value)'}, {'cui': 'C0024518', 'cui_str': 'Histocompatibility Complex'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0670896'}]","[{'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}]",53.0,0.259038,"CD8 T cell responses to 12MP were detected ex vivo in cohort 1 (42%) and in cohort 2 (56%) and in 18, 50, and 72% for subgroups V0, V1, and V6, respectively.","[{'ForeName': 'Marit M', 'Initials': 'MM', 'LastName': 'Melssen', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA.'}, {'ForeName': 'Gina R', 'Initials': 'GR', 'LastName': 'Petroni', 'Affiliation': 'Department of Public Health Sciences/Division of Translational Research & Applied Statistics, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Chianese-Bullock', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA.'}, {'ForeName': 'Nolan A', 'Initials': 'NA', 'LastName': 'Wages', 'Affiliation': 'Department of Public Health Sciences/Division of Translational Research & Applied Statistics, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Grosh', 'Affiliation': 'Department of Medicine/Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Nikole', 'Initials': 'N', 'LastName': 'Varhegyi', 'Affiliation': 'Department of Public Health Sciences/Division of Translational Research & Applied Statistics, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Smolkin', 'Affiliation': 'Department of Public Health Sciences/Division of Translational Research & Applied Statistics, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Kelly T', 'Initials': 'KT', 'LastName': 'Smith', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA.'}, {'ForeName': 'Nadejda V', 'Initials': 'NV', 'LastName': 'Galeassi', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA.'}, {'ForeName': 'Donna H', 'Initials': 'DH', 'LastName': 'Deacon', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Gaughan', 'Affiliation': 'Department of Medicine/Division of Hematology/Oncology, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Craig L', 'Initials': 'CL', 'LastName': 'Slingluff', 'Affiliation': 'Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, 1352 Pinn Hall, P.O. Box 801457, Charlottesville, VA, 22908, USA. cls8h@virginia.edu.'}]",Journal for immunotherapy of cancer,['10.1186/s40425-019-0625-x'] 877,31221932,Effect of Music Therapy on Sleep Quality.,"Context One of the important functions of nurses is to prepare a relaxing environment for patients, for whom they look after and fulfill sleep needs. Today, music therapy, one of nonpharmacological treatment approaches, can be used for enhancing the sleep quality of individuals. The increase of individuals' sleep quality by using music therapy will enable nurses to intervene in problems associated with sleep disorders and prevent insomnia and other relevant problems. Objective This study was conducted to determine the effect of music therapy on sleep quality of the students. Design The research was an experimental pretest-posttest control group design. Setting The research was conducted among the students studying in the nursing department at a university in the east of Turkey in the spring term of the academic year of 2015-2016. Participant Students who (1) got a total score of 5 and higher according to the Pittsburgh Sleep Quality Index (PSQI), (2) had no neurological/psychiatric disorder, (3) had no hearing problem, (4) received no medical treatment regarding sleep, and (5) volunteered to participate in the study were included in the study. The students who were included in the study were divided into experimental and control groups. Invention Students in the experimental group were instructed to keep the volume of the personal MP3 player to be used for listening to the music therapy below 70% and to use it for 1 h/d at most. No intervention was applied to students in the control group. They were asked to sustain their normal sleeping habits. Outcome Measure To collect the data, a questionnaire prepared by the researchers for determining sociodemographic characteristics of the students and PSQI were used. Results As a result of the study, it was found that the posttest PSQI mean scores of students in the experimental group, listening to music therapy, were lower than the mean scores of the students in the control group, and the difference between the groups was statistically significant. Conclusions As a result of this study, it was determined that music therapy increased the sleep quality of students. Being one of the nonpharmacological treatment approaches intended for solving sleep problems, music therapy is a pain-free, safe, and affordable treatment method without any side effect that could be used in every area of health.",2020,No intervention was applied to students in the control group.,"['students studying in the nursing department at a university in the east of Turkey in the spring term of the academic year of 2015-2016', '2) had no neurological/psychiatric disorder, (3) had no hearing problem, (4) received no medical treatment regarding sleep, and (5) volunteered to participate in the study were included in the study']","['music therapy', 'Music Therapy']","['Pittsburgh Sleep Quality Index (PSQI', ""individuals' sleep quality"", 'Sleep Quality', 'sleep quality', 'posttest PSQI mean scores']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0028678', 'cui_str': 'nursing care'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0041400', 'cui_str': 'Turkey'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0011053', 'cui_str': 'Deafness'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0026868', 'cui_str': 'Music Therapy'}]","[{'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0168703,No intervention was applied to students in the control group.,"[{'ForeName': 'Mehtap', 'Initials': 'M', 'LastName': 'Kavurmaci', 'Affiliation': ''}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Dayapoğlu', 'Affiliation': ''}, {'ForeName': 'Mehtap', 'Initials': 'M', 'LastName': 'Tan', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 878,31227804,Fatty acid regio-specificity of triacylglycerol molecules may affect plasma lipid responses to dietary fats-a randomised controlled cross-over trial.,"BACKGROUND/OBJECTIVES Hypercholesterolaemic effects of saturated fatty acids (SFA) may be influenced not only by the chain length, but also by their specific location within the triacylglycerol (TAG) molecule. We examined the hypothesis that dietary fats rich in SFA, but containing mostly unsaturated fatty acids in the sn-2 position with most SFA in sn-1 and -3 (palm olein [PO] and cocoa butter [CB]) will have similar serum lipid outcomes to unsaturated olive oil (OO). SUBJECTS/METHODS Thirty-eight participants (20-40 yr, 18.5- ≤ 27.5 kg/m 2 ) completed a 4-week randomised 3 × 3 crossover feeding intervention, preceded by 2-week run-in and separated by 2-week washout periods. Background diet contained 35 percentage of total energy (%E) fat, 18%E protein, 48%E carbohydrates, differing in test fats only (palm olein (PO), CB, OO; 20%E). Total cholesterol (TC)/high density lipoprotein cholesterol (HDL-C) ratio and related variables; TC, HDL-C, low density lipoprotein cholesterol (LDL-C), TAG, apoA1, ApoB, ApoA1 (apolipoprotein A1)/ApoB (apolipoprotein B), lipoprotein (a) (Lp(a)), NEFA, LDL sub-fractions, were assessed pre- and post-intervention. Data were analysed using mixed effects longitudinal models with a P-value < 0.05 considered significant. RESULTS Changes in plasma fatty acids (P < 0.05) confirmed compliance; C18:1 increased with OO compared to PO and CB; C16:0 decreased with OO and C18:0 increased following CB. No differences were seen for TC/HDL-C (mean [95%CI] change for PO, 0.08[0.00, 0.15] mmol/L; CB, 0.06 [-0.05, 0.16] mmol/L; and OO, -0.01 [-0.15, 0.13] mmol/L; P = 0.53] or any other parameter including LDL sub-fractions. OO decreased IDL-A compared to PO (-2.2 [-4.31, -0.21] mg/dL, P = 0.03). CONCLUSION In healthy young participants, plasma lipid responses to PO and CB, enriched in SFA but having primarily unsaturated fatty acid in the sn-2 position of TAG, did not differ from OO.",2020,"RESULTS Changes in plasma fatty acids (P < 0.05) confirmed compliance; C18:1 increased with OO compared to PO and CB; C16:0 decreased with OO and C18:0 increased following CB.","['Thirty-eight participants (20-40\u2009yr, 18.5-\u2009≤\u200927.5', 'healthy young participants']",['saturated fatty acids (SFA'],"['plasma fatty acids', 'plasma lipid responses', 'TC/HDL-C', 'OO and C18:0', 'Total cholesterol (TC)/high density lipoprotein cholesterol (HDL-C) ratio and related variables; TC, HDL-C, low density lipoprotein cholesterol (LDL-C), TAG, apoA1, ApoB, ApoA1 (apolipoprotein A1)/ApoB (apolipoprotein B), lipoprotein (a) (Lp(a)), NEFA, LDL sub-fractions']","[{'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C4517611', 'cui_str': 'Eighteen point five'}, {'cui': 'C4517674', 'cui_str': '27.5'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}]","[{'cui': 'C0597423', 'cui_str': 'Fatty Acids, Saturated'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0015684', 'cui_str': 'Fatty Acids'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipids'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0065055', 'cui_str': 'lipoprotein cholesterol'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0037293', 'cui_str': 'Tag (morphologic abnormality)'}, {'cui': 'C0003593', 'cui_str': 'ApoB'}, {'cui': 'C0523476', 'cui_str': 'Apolipoprotein measurement (procedure)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0015688', 'cui_str': 'NEFA'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}]",38.0,0.0699815,"RESULTS Changes in plasma fatty acids (P < 0.05) confirmed compliance; C18:1 increased with OO compared to PO and CB; C16:0 decreased with OO and C18:0 increased following CB.","[{'ForeName': 'Welma', 'Initials': 'W', 'LastName': 'Stonehouse', 'Affiliation': 'Commonwealth Scientific Industrial Research Organisation, Health and Biosecurity, Adelaide, South Australia, Australia. welma.stonehouse@csiro.au.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Benassi-Evans', 'Affiliation': 'Commonwealth Scientific Industrial Research Organisation, Health and Biosecurity, Adelaide, South Australia, Australia.'}, {'ForeName': 'Genevieve', 'Initials': 'G', 'LastName': 'James-Martin', 'Affiliation': 'Commonwealth Scientific Industrial Research Organisation, Health and Biosecurity, Adelaide, South Australia, Australia.'}, {'ForeName': 'Mahinda', 'Initials': 'M', 'LastName': 'Abeywardena', 'Affiliation': 'Commonwealth Scientific Industrial Research Organisation, Health and Biosecurity, Adelaide, South Australia, Australia.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0452-7'] 879,31792878,"Oral morphine drops for prompt relief of breathlessness in patients with advanced cancer-a randomized, double blinded, crossover trial of morphine sulfate oral drops vs. morphine hydrochloride drops with ethanol (red morphine drops).","PURPOSE Episodic breathlessness is frequent in palliative cancer patients. Opioids are the only pharmacological agents with sufficient evidence in treatment. In Denmark, the main recommendation is red morphine drops (RMD), an off-label solution of morphine, ethanol, and red color (cochenille) described since 1893 (Pharmacopoea Danica). In 2015, the Danish Medicines Agency increased focus on off-label medicines and recommended registered morphine drops without ethanol instead. However, our palliative patients told us that RMD was better. For that reason, we conducted a clinical trial to clarify any perceived difference between the two types of drops. METHODS We conducted a randomized, double blinded, crossover trial. Patients were asked to perform standardized activity (2-min walk) aiming to provoke breathlessness. Primary endpoint (breathlessness NRS) and secondary endpoints (saturation, pulse, respiratory frequency) were measured before (t = 0) and after test medicine at t = 1, t = 3, t = 5, t = 10, and t = 20 min. After 2-4 days (washout period), the patients repeated the test, receiving the alternative drops in a blinded setup (crossover). RESULTS In the first 3 min, the relative drop in breathlessness for morphine drops with ethanol (RMD) was significant more than for morphine drops without ethanol. We found no significant difference in secondary endpoints. CONCLUSIONS A conclusion could be that ethanol might facilitate morphine absorption in the mouth. Our results needs further research of opioid absorption in the mouth as well as trials, testing morphine vs. more lipophilic opioids. The RMD drops are cheap, easy to use, and noninvasive and keep the patient independent of health care professionals.",2020,"In the first 3 min, the relative drop in breathlessness for morphine drops with ethanol (RMD) was significant more than for morphine drops without ethanol.","['palliative cancer patients', 'patients with advanced cancer']","['morphine drops without ethanol', 'ethanol', 'morphine drops with ethanol (RMD', 'morphine sulfate oral drops vs. morphine hydrochloride drops with ethanol (red morphine drops', 'morphine, ethanol, and red color (cochenille', 'Oral morphine']","['Primary endpoint (breathlessness NRS) and secondary endpoints (saturation, pulse, respiratory frequency']","[{'cui': 'C1285530', 'cui_str': 'Palliative'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}, {'cui': 'C0202304', 'cui_str': 'Alcohol measurement (procedure)'}, {'cui': 'C0066814', 'cui_str': 'Morphine Sulfate'}, {'cui': 'C0991577', 'cui_str': 'Oral drops'}, {'cui': 'C0770901', 'cui_str': 'Morphine hydrochloride'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}]",,0.392171,"In the first 3 min, the relative drop in breathlessness for morphine drops with ethanol (RMD) was significant more than for morphine drops without ethanol.","[{'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Aabom', 'Affiliation': 'Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 13.1, DK-4000, Roskilde, Denmark. bimaa@regionsjaelland.dk.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Laier', 'Affiliation': 'Department of Data and Innovation, Region Zealand, Alleen 15, DK-4180, Soroe, Denmark.'}, {'ForeName': 'Poul Lunau', 'Initials': 'PL', 'LastName': 'Christensen', 'Affiliation': 'Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 13.1, DK-4000, Roskilde, Denmark.'}, {'ForeName': 'Tine', 'Initials': 'T', 'LastName': 'Karlsson', 'Affiliation': 'Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 13.1, DK-4000, Roskilde, Denmark.'}, {'ForeName': 'May-Britt', 'Initials': 'MB', 'LastName': 'Jensen', 'Affiliation': 'Department of Clinical Oncology and Palliative Care, Zealand University Hospital, Vestermarksvej 13.1, DK-4000, Roskilde, Denmark.'}, {'ForeName': 'Birte', 'Initials': 'B', 'LastName': 'Hedal', 'Affiliation': 'Hospice Zealand, Tonsbergvej 61, DK-4000, Roskilde, Denmark.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05116-1'] 880,31213572,Impact of a Single Session of Inhalation Technique Training on Inhalation Skills and the Course of Asthma and COPD.,"BACKGROUND A significant percentage of patients with asthma and COPD do not use their inhalers properly. The aim of this study was to evaluate the impact of a single session of inhalation technique training on the frequency of inhalation errors and the course of asthma and COPD. METHODS This randomized controlled trial included adults who had been diagnosed with and treated for asthma or COPD with at least one inhaler use daily on a regular basis. All subjects were followed for 6 months, at which time their inhalation technique was assessed and an individual inhalation training (study group) or a sham procedure (control group) was applied. The number of mishandlings was calculated as the ratio of the number of errors to the number of inhalers used by an individual subject. The effect of training was evaluated after 3 months and again after 6 months. RESULTS 50 subjects with asthma and 50 subjects with COPD were enrolled. Only 20% of subjects made no critical errors before the intervention. Subjects who were trained in the proper inhalation technique made fewer errors after 3 months (32 of 50 vs 20 of 50). The relative risk was 1.63 (95% CI 1.1-2.4, P = .01) and the number needed to treat was 3.9 (95% CI 2.2-15). Despite the improvement in the inhalation technique, we found no reduction in the number of asthma/COPD exacerbations, symptom severity, or the quality of life. After 3 consecutive months, the efficacy of the intervention decreased, and only 66% of the former responders maintained the lower ratio of errors per inhaler. After 6 months, there was no difference in the number of subjects with better inhalation technique between intervention (24 of 50) and control group (27 of 50) ( P = .62). CONCLUSIONS Although a single inhalation training leads to a reduction in the number of errors made during inhalation, it does not influence the course of asthma and COPD. The positive effect of a single inhalation technique training is temporary. (ClinicalTrials.gov registration NCT02131454.).",2019,"The relative risk was 1.63 (95% CI 1.1-2.4, P = .01) and the number needed to treat was 3.9 (95% CI 2.2-15).","['50 subjects with asthma and 50 subjects with COPD were enrolled', 'adults who had been diagnosed with and treated for asthma or COPD with at least one inhaler use daily on a regular basis', 'patients with asthma and COPD']","['Inhalation Technique Training', 'individual inhalation training (study group) or a sham procedure (control group', 'inhalation technique training']","['Inhalation Skills and the Course of Asthma and COPD', 'frequency of inhalation errors', 'number of subjects with better inhalation technique', 'number of asthma/COPD exacerbations, symptom severity, or the quality of life', 'lower ratio of errors per inhaler', 'number needed to treat', 'relative risk']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for (contextual qualifier) (qualifier value)'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1998547', 'cui_str': 'Inhalation technique (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C1998547', 'cui_str': 'Inhalation technique (qualifier value)'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0021461', 'cui_str': 'Inhalators'}, {'cui': 'C3179138', 'cui_str': 'Numbers Needed To Treat'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}]",50.0,0.0458919,"The relative risk was 1.63 (95% CI 1.1-2.4, P = .01) and the number needed to treat was 3.9 (95% CI 2.2-15).","[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Dabrowska', 'Affiliation': 'Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Luczak-Wozniak', 'Affiliation': ""Students' Research Group Alveolus, Medical University of Warsaw, Poland. kasia.luczak1@gmail.com.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Miszczuk', 'Affiliation': ""Students' Research Group Alveolus, Medical University of Warsaw, Poland.""}, {'ForeName': 'Izabela', 'Initials': 'I', 'LastName': 'Domagala', 'Affiliation': ""Students' Research Group Alveolus, Medical University of Warsaw, Poland.""}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Lubanski', 'Affiliation': ""Students' Research Group Alveolus, Medical University of Warsaw, Poland.""}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Leszczynski', 'Affiliation': ""Students' Research Group Alveolus, Medical University of Warsaw, Poland.""}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Maskey-Warzechowska', 'Affiliation': 'Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Rubinsztajn', 'Affiliation': 'Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Hermanowicz-Salamon', 'Affiliation': 'Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland.'}, {'ForeName': 'Rafal', 'Initials': 'R', 'LastName': 'Krenke', 'Affiliation': 'Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Poland.'}]",Respiratory care,['10.4187/respcare.06740'] 881,31790639,Impact of mHealth technology on adherence to healthy PA after stroke: a randomized study.,"BACKGROUND Physical activity (PA) is a key health behavior in people with stroke including risk reduction of recurrent stroke. Despite the beneficial effects of PA, many community-dwelling stroke survivors are physically inactive. Information and communication technologies are emerging as a possible method to promote adherence to PA. OBJECTIVE The aim of this study is to investigate the effectiveness of a mobile-health (mHealth) App in improving levels of PA. METHODS Forty-one chronic stroke survivors were randomized into an intervention group (IG) n=24 and a control group (CG) n=17. Participants in the IG were engaged in the Multimodal Rehabilitation Program (MMRP) that consisted on supervising adherence to PA through a mHealth app, participating in an 8-week rehabilitation program that included: aerobic, task-oriented, balance and stretching exercises. Participants also performed an ambulation program at home. The CG received a conventional rehabilitation program. Outcome variables were: adherence to PA, (walking and sitting time/day), walking speed (10MWT); walking endurance (6MWT); risk of falling (TUG); ADLs (Barthel); QoL (Eq-5D5L) and participant's satisfaction. RESULTS At the end of the intervention, community ambulation increased more in IG (38.95 min; SD: 20.37) than in the CG (9.47 min; SD: 12.11) (p≤.05). Sitting time was reduced by 2.96 (SD 2.0) hours/day in the IG and by 0.53 (SD 0.24) hours in the CG (p≤.05). CONCLUSIONS The results suggest that mHealth technology provides a novel way to promote adherence to home exercise programs post stroke. However, frequent support and guidance of caregiver is required to ensure the use of mobile devices.",2020,Sitting time was reduced by 2.96 (SD 2.0) hours/day in the IG and by 0.53 (SD 0.24) hours in the CG (p≤.05).,"['n=24 and a control group (CG) n=17', 'healthy PA after stroke', 'people with stroke including risk reduction of recurrent stroke', 'Forty-one chronic stroke survivors']","[' : Physical activity (PA', 'mobile-health (mHealth) App', 'mHealth technology', 'Multimodal Rehabilitation Program (MMRP) that consisted on supervising adherence to PA through a mHealth app, participating in an 8-week rehabilitation program that included: aerobic, task-oriented, balance and stretching exercises', 'conventional rehabilitation program', 'intervention group (IG']","['Sitting time', 'community ambulation', ""adherence to PA, (walking and sitting time/day), walking speed (10MWT); walking endurance (6MWT); risk of falling (TUG); ADLs (Barthel); QoL (Eq-5D5L) and participant's satisfaction""]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0945826', 'cui_str': 'Ambulation'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0439511', 'cui_str': 'times/day (qualifier value)'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",41.0,0.0476273,Sitting time was reduced by 2.96 (SD 2.0) hours/day in the IG and by 0.53 (SD 0.24) hours in the CG (p≤.05).,"[{'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Grau-Pellicer', 'Affiliation': 'Rehabilitation Unit, Hospital-Consorci Sanitari de Terrassa , Barcelona, Spain.'}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Lalanza', 'Affiliation': 'Laboratory of Sport Psychology, Autonomous University of Barcelona , Bellaterra, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Jovell-Fernández', 'Affiliation': 'Department of Epidemiology, Hospital-Consorci Sanitari de Terrassa , Barcelona, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Capdevila', 'Affiliation': 'Laboratory of Sport Psychology, Autonomous University of Barcelona , Bellaterra, Spain.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1691816'] 882,31122797,Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.,"BACKGROUND Antiretroviral medication during pregnancy and breastfeeding substantially decreases the risk of HIV transmission from mothers to infants, but its effects on the child's neurodevelopment are unknown. This study compared neurodevelopmental outcomes of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children with HIV-unexposed and uninfected children at ages 12, 24, 48, and 60 months. METHODS For this study, a prospective cohort of HIV-exposed and uninfected children was identified from two research sites in the PROMISE-BF trial (at Blantyre, Malawi, and Kampala, Uganda), in which pregnant HIV-infected mothers were randomly assigned to triple antiretroviral prophylaxis (lopinavir-ritonavir plus either lamivudine and zidovudine or emtricitabine and tenofovir), versus zidovudine alone. Post partum, the mother-infant pairs were randomly assigned to maternal triple antiretroviral treatment or infant nevirapine during breastfeeding. HIV-unexposed and uninfected children matched for age, sex, and socioeconomic background were enrolled at vaccination and well-child clinics at the study sites. We included only children without a history of documented brain infection or injury or substantial malnutrition, and whose mothers were randomly assigned and maintained within their assigned ante-partum and post-partum phases throughout their treatment arm periods. Primary outcomes were the Mullen Scales of Early Learning (MSEL) cognitive composite score at age 12 months, 24 months, and 48 months; and the mental processing index for the Kaufman Assessment Battery for Children, second edition (KABC-II) global score at 48 months and 60 months. Repeated measures were analysed using a linear mixed-effects model controlling for data collection site. FINDINGS Between Aug 23, 2013, and Dec 17, 2014, we co-enrolled 861 children. For MSEL assessments, 738 were eligible for inclusion at age 12 months, 790 at age 24 months, and 692 at age 48 months. For KABC-II assessments, 685 were eligible for inclusion at age 48 months and 445 at age 60 months. There were no differences in MSEL cognitive composite scores according to exposure at age 12 and 24 months (p=0·19 and 0·24, respectively, for comparison of all groups). At 48 months, MSEL cognitive composite scores were worse for children of mothers who did not remain on triple antiretroviral treatment throughout both the ante-partum and post-partum treatment phases (adjusted means 80·64 [95% CI 77·74-83·54] and 81·34 [78·19-84·48], respectively), compared with those who did remain on triple treatment (adjusted mean 85·93, 95% CI 83·05-88·80; p=0·0486 for the comparison of all groups). The KABC-II composite scores (mental processing index) did not differ at 48 or 60 months according to exposure (p=0·81 and 0·89, respectively, for comparison of all groups). Scores for MSEL and KABC-II for children of mothers on triple antiretrovirals in both the ante-partum and post-partum treatment phases were similar to those for children in the HIV-unexposed and uninfected reference group at all timepoints. INTERPRETATION Maternal triple antiretroviral exposure during both the ante-partum and post-partum phases did not result in greater developmental risks for the mothers' HIV-exposed and uninfected children through age 60 months, compared with children who were HIV-unexposed and uninfected. This might be because ante-partum triple antiretroviral protection of the health of mothers with HIV during pregnancy might be neuroprotective for the child, and when continued post partum, could enhance the quality of caregiving for the child through better clinical care for the mother. FUNDING National Institutes of Health and Eunice Kennedy Shriver National Institute of Child Health and Human Development.",2019,"At 48 months, MSEL cognitive composite scores were worse for children of mothers who did not remain on triple antiretroviral treatment throughout both the ante-partum and post-partum treatment phases (adjusted means 80·64","['children without a history of documented brain infection or injury or substantial malnutrition, and whose mothers', 'Between Aug 23, 2013, and Dec 17, 2014, we co-enrolled 861 children', 'HIV-unexposed and uninfected children matched for age, sex, and socioeconomic background were enrolled at vaccination and well-child clinics at the study sites', 'HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi', '738 were eligible for inclusion at age 12 months, 790 at age 24 months, and 692 at age 48 months', 'pregnant HIV-infected mothers', '685 were eligible for inclusion at age 48 months and 445 at age 60 months', 'HIV-exposed and uninfected children with HIV-unexposed and uninfected children at ages 12, 24, 48, and 60 months', 'mother-infant pairs']","['maternal triple antiretroviral treatment or infant nevirapine', 'zidovudine alone', 'ante-partum and post-partum antiretroviral exposure', 'triple antiretroviral prophylaxis (lopinavir-ritonavir plus either lamivudine and zidovudine or emtricitabine and tenofovir']","['KABC-II composite scores (mental processing index', 'mental processing index for the Kaufman Assessment Battery for Children, second edition (KABC-II) global score', 'Mullen Scales of Early Learning (MSEL) cognitive composite score', 'MSEL cognitive composite scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0686744', 'cui_str': 'Well child (finding)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}, {'cui': 'C0024548', 'cui_str': 'Republic of Malawi'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0599685', 'cui_str': 'Anti-Retroviral Agents'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0132326', 'cui_str': 'Nevirapine'}, {'cui': 'C0043474', 'cui_str': 'Zidovudine'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0674432', 'cui_str': 'lopinavir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0582638', 'cui_str': 'Kaufman assessment battery for children (assessment scale)'}, {'cui': 'C0441795', 'cui_str': 'Second edition (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",861.0,0.101645,"At 48 months, MSEL cognitive composite scores were worse for children of mothers who did not remain on triple antiretroviral treatment throughout both the ante-partum and post-partum treatment phases (adjusted means 80·64","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Boivin', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, MI, USA; Department of Neurology & Ophthalmology, Michigan State University, East Lansing, MI, USA; Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA. Electronic address: boivin@msu.edu.'}, {'ForeName': 'Limbika', 'Initials': 'L', 'LastName': 'Maliwichi-Senganimalunje', 'Affiliation': 'Malawi College of Medicine, Johns Hopkins University Research Project, Blantyre, Malawi; Department of Psychology, Chancellor College, University of Malawi, Zomba, Malawi.'}, {'ForeName': 'Lillian W', 'Initials': 'LW', 'LastName': 'Ogwang', 'Affiliation': 'Department of Psychology, Chancellor College, University of Malawi, Zomba, Malawi.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kawalazira', 'Affiliation': 'Malawi College of Medicine, Johns Hopkins University Research Project, Blantyre, Malawi.'}, {'ForeName': 'Alla', 'Initials': 'A', 'LastName': 'Sikorskii', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, MI, USA; Department of Statistics & Probability, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Familiar-Lopez', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Agatha', 'Initials': 'A', 'LastName': 'Kuteesa', 'Affiliation': 'Makerere University-Johns Hopkins University, Kampala, Uganda.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Nyakato', 'Affiliation': 'Makerere University-Johns Hopkins University, Kampala, Uganda.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Mutebe', 'Affiliation': 'Makerere University-Johns Hopkins University, Kampala, Uganda.'}, {'ForeName': 'Jackie L', 'Initials': 'JL', 'LastName': 'Namukooli', 'Affiliation': 'Makerere University-Johns Hopkins University, Kampala, Uganda.'}, {'ForeName': 'MacPherson', 'Initials': 'M', 'LastName': 'Mallewa', 'Affiliation': 'Malawi College of Medicine, Johns Hopkins University Research Project, Blantyre, Malawi.'}, {'ForeName': 'Horacio', 'Initials': 'H', 'LastName': 'Ruiseñor-Escudero', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Aizire', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Taha E', 'Initials': 'TE', 'LastName': 'Taha', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Mary G', 'Initials': 'MG', 'LastName': 'Fowler', 'Affiliation': 'Department of Pathology, Johns Hopkins University Medical Institute, Baltimore, MD, USA.'}]",The lancet. HIV,['10.1016/S2352-3018(19)30083-9'] 883,31221941,Leukocytapheresis Therapy for Rheumatoid Arthritis: Results Compared with Control Trial.,"Context Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease, mainly characterized by synovitis and with symmetrical joint involvement. LCAP therapy for RA patients has been shown to be safe and efficacious in some developed countries for over a decade. Objective The study intended to evaluate the efficacy and safety of leukocytopheresis (LCAP) for treatment of rheumatoid arthritis (RA) and to study the influence of treatment on the levels of various serum cytokines. Design The study was a nonblinded, nonrandomized, controlled trial. Setting The study took place in the Department of Rheumatology and Immunology at Beijing Hospital at the National Center of Gerontology in Beijing, China. Participants Participants were 51 patients with RA at the hospital with a 28-joint disease activity score (DAS28) exceeding the 3.20 needed to fulfill the classification criteria of the American College of Rheumatology (ACR). Intervention Participants were divided into 2 groups. One group (intervention group) received LCAP therapy (n = 20), while the control group (n = 31) received disease-modifying antirheumatic drugs (DMARDs). Patients receiving the LCAP therapy were treated using a Cellsorba column every 5 days for a total of 5 treatments. Outcome Measures Clinical assessment of participants' symptoms included: (1) a tender-joint count, (2) a swollen-joint count, (3) erythrocyte sedimentation rates (ESR), (4) C-reactive protein levels (CRP), (5) a visual analog scale (VAS) for pain, (6) the DAS28 C-reactive protein (DAS28-CRP) scores, and the Health Assessment Questionnaire Disability Index (HAQ-DI). The study also evaluated participants' scores for the American College of Rheumatology (ACR) Core Data Set. Serum collected before and after therapy from both groups was analyzed for the levels of bradykinin, serotonin, heat shock protein 70, human CXC-chemokine ligand 16 (CXCL16), prostaglandin E2, and macrophage inflammation protein 1α. Results At week 4 for participants receiving the LCAP therapy, ACR20, ACR50, and ACR70 were observed in 55%, 30%, and 20% of patients, respectively, compared to 19.4%, 3.2%, and 0% for patients in the control group (P < .05). Also, at week 24 of LCAP therapy, ACR20, ACR50, and ACR70 were observed in 70%, 50%, and 30% of patients, respectively, which was significantly higher than the 25.8%, 12.9%, and 3.2% of patients in the control group (P < .05). The serum levels of CXCL16 and serotonin were significantly reduced in the LCAP group compared with control group. Conclusions This study indicated that LCAP therapy can significantly decrease RA disease activity and is a safe and effective alternative therapy. LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.",2020,"LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.","[""participants' scores for the American College of Rheumatology (ACR) Core Data Set"", 'rheumatoid arthritis (RA', 'Participants\n\n\nParticipants were 51 patients with RA at the hospital with a 28-joint disease activity score (DAS28) exceeding the 3.20 needed to fulfill the classification criteria of the American College of Rheumatology (ACR', 'Rheumatoid Arthritis', 'Department of Rheumatology and Immunology at Beijing Hospital at the National Center of Gerontology in Beijing, China']","['LCAP', 'disease-modifying antirheumatic drugs (DMARDs', 'leukocytopheresis (LCAP', 'Leukocytapheresis Therapy', 'LCAP therapy']","['ACR20, ACR50, and ACR70', ""Outcome Measures\n\n\nClinical assessment of participants' symptoms included: (1) a tender-joint count, (2) a swollen-joint count, (3) erythrocyte sedimentation rates (ESR), (4) C-reactive protein levels (CRP), (5) a visual analog scale (VAS) for pain, (6) the DAS28 C-reactive protein (DAS28-CRP) scores, and the Health Assessment Questionnaire Disability Index (HAQ-DI"", 'serum CXCL16 and serotonin levels', 'serum levels of CXCL16 and serotonin', 'RA disease activity']","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022408', 'cui_str': 'Arthropathy'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0152036', 'cui_str': 'Immunology'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205767', 'cui_str': 'Gerontology'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0242708', 'cui_str': 'Antirheumatic Drugs, Disease-Modifying'}, {'cui': 'C0023416', 'cui_str': 'Leukocytapheresis'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0451530', 'cui_str': 'Tender joint count (assessment scale)'}, {'cui': 'C0451521', 'cui_str': 'Swollen joint count (assessment scale)'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire (assessment scale)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0102923', 'cui_str': 'HAQ'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",51.0,0.0219527,"LCAP therapy significantly reduced serum CXCL16 and serotonin levels, offering a putative mechanism by which it improves the articular symptoms of RA.","[{'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Yongjing', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Yingjuan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Bingyao', 'Initials': 'B', 'LastName': 'Mu', 'Affiliation': ''}, {'ForeName': 'Rongwei', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Cibo', 'Initials': 'C', 'LastName': 'Huang', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 884,31787369,A randomized placebo-controlled trial of using B vitamins to prevent cognitive decline in older mild cognitive impairment patients.,"BACKGROUND & AIMS Mild cognitive impairment (MCI) patients are at risk of cognitive decline, while elevated serum homocysteine is also associated with cognitive impairment. Thus, older people with MCI and hyperhomocysteinemia may be under greater risk of cognitive decline. We therefore performed a randomized trial of homocysteine-lowering by B vitamins supplementation to prevent cognitive decline in older MCI patients with elevated serum homocysteine. METHODS 279 MCI outpatients aged ≥65 years with serum homocysteine ≥10.0 μmol/L were randomly assigned to take either methylcobalamin 500 μg and folic acid 400 μg once daily, or two placebo tablets for 24 months. All subjects were followed up at 12 monthly intervals. The primary outcome was cognitive decline as defined by an increase in clinical dementia rating scale (CDR) sum of boxes (CDR_SOB). The secondary outcomes were global CDR, memory Z score, executive function Z score and Hamilton depression rating scale (HDRS) score. RESULTS The clinical characteristics between two groups were well matched, except that the supplement group had better executive function. The supplement effectively lowered serum homocysteine (mean 13.9 ± sd 3.5 μmol at baseline to 9.3 ± 2.4 μmol/L at month 24). At month 24, there was no significant group difference in CDR_SOB or any secondary outcomes (mean changes in CDR_SOB 0.36 versus 0.22 in supplement and placebo groups respectively). At month 12, the supplement group significantly improved in executive function and had lower HDRS score (P = 0.004 and 0.012 respectively). Group difference was significant for HDRS, but borderline significant for executive function. (P = 0.01; 0.06 respectively) These effects were not significant at month 24. Subgroup analysis showed that aspirin use had significant interaction with B supplements in CDR_SOB at month 24 (Beta 0.189, P = 0.005). CONCLUSIONS Vitamin B 12 and folic acid supplementation did not reduce cognitive decline in older people with MCI and elevated serum homocysteine, though the cognitive decline over two years in placebo group was small. The supplement led to a significant reduction in depressive symptoms at month 12, though this effect was not sustained. Aspirin use had a negative interaction effect on cognitive functioning with B supplements. CLINICAL TRIAL REGISTRATION Centre for Clinical Research and Biostatistics (CCRB) Clinical Trials Registry: CUHK_CCT00373.",2020,"At month 12, the supplement group significantly improved in executive function and had lower HDRS score (P = 0.004 and 0.012 respectively).","['older people with MCI and hyperhomocysteinemia', 'older mild cognitive impairment patients', 'older MCI patients with elevated serum homocysteine', '279 MCI outpatients aged ≥65 years with serum homocysteine ≥10.0']","['Aspirin', 'placebo', 'B vitamins', 'methylcobalamin 500\xa0μg and folic acid 400\xa0μg once daily, or two placebo tablets', 'aspirin', 'Vitamin B 12 and folic acid supplementation', 'homocysteine-lowering by B vitamins supplementation']","['Mild cognitive impairment', 'HDRS', 'depressive symptoms', 'HDRS score', 'cognitive decline', 'cognitive functioning', 'executive function', 'serum homocysteine', 'global CDR, memory Z score, executive function Z score and Hamilton depression rating scale (HDRS) score', 'clinical dementia rating scale (CDR) sum of boxes (CDR_SOB']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0598608', 'cui_str': 'Hyperhomocysteinemia'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3714647', 'cui_str': 'B Vitamins'}, {'cui': 'C0065844', 'cui_str': 'methylcobalamin'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0042845', 'cui_str': 'cyanocobalamin'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplementation (product)'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}]","[{'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0234985', 'cui_str': 'Cognitive Decline'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0055351', 'cui_str': 'Chlordecone reductase'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0451074', 'cui_str': 'Dementia Rating Scale'}, {'cui': 'C1638312', 'cui_str': 'Boxes'}]",,0.458778,"At month 12, the supplement group significantly improved in executive function and had lower HDRS score (P = 0.004 and 0.012 respectively).","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Kwok', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. Electronic address: tkwok@cuhk.edu.hk.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. Electronic address: charliewyy@link.cuhk.edu.hk.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, Alice Ho Mui Ming Nethersole Hospital, Taipo, Hong Kong. Electronic address: jennylee@cuhk.edu.hk.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Lee', 'Affiliation': 'Department of Health, Hong Kong. Electronic address: ruby_sy_lee@dh.gov.hk.'}, {'ForeName': 'Cho Yiu', 'Initials': 'CY', 'LastName': 'Yung', 'Affiliation': 'Department of Medicine & Geriatrics, United Christian Hospital, Kowloon, Hong Kong. Electronic address: yungcy@ha.org.hk.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Choi', 'Affiliation': 'Department of Occupational Therapy, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. Electronic address: cwk637@ha.org.hk.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Lee', 'Affiliation': 'School of Pharmacy, The Chinese University of Hong Kong, Hong Kong. Electronic address: vivianlee@cuhk.edu.hk.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harrison', 'Affiliation': 'Alzheimer Center, VU Medical Center, Amsterdam, the Netherlands. Electronic address: john@metiscog.com.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Lam', 'Affiliation': 'Department of Psychiatry, The Chinese University of Hong Kong, Taipo Hospital, Taipo, Hong Kong. Electronic address: cwlam@cuhk.edu.hk.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Mok', 'Affiliation': 'Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong. Electronic address: vctmok@cuhk.edu.hk.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.11.005'] 885,31787562,A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation.,"We previously reported that fish oil in combination with cyclooxygenase (COX) inhibitors exerts enhanced hypolipidemic and anti-inflammatory effects in mice. Here, we sought to determine the effects of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in combination with naproxen (NX), a COX inhibitor, on dyslipidemia and gene expression in adipose tissue (AT) in humans. Obese dyslipidemic patients were randomly assigned to one of these interventions for 12 wk: 1) Standard nutrition counseling (control), 2) ω-3 PUFAs (2 g twice daily), 3) NX (220 mg twice daily), and 4) ω-3 PUFAs (2 g twice daily) + NX (220 mg twice daily). The serum triglycerides showed a trend towards a reduction and a significant reduction (P<0.05) in ω-3 and ω3 + NX-treated subjects, respectively, compared to control. The mRNA expression of vascular cell adhesion molecule-1 (Vcam1), an inflammatory marker, increased significantly in AT of ω-3 PUFA-treated subjects but not in ω-3 PUFAs+NX-treated group. The plasma level of glycine-conjugated hyodeoxycholic acid, a secondary bile acid with hypolipidemic property, increased significantly in ω-3 PUFAs + NX-treated group. Our data suggest that combining NX with ω-3 PUFAs increases their effectiveness in reducing serum TG and favorably altering AT gene expression and plasma bile acid profile.",2020,"(Vcam1), an inflammatory marker, increased significantly in AT of ω-3 PUFA-treated subjects but not in ω-3 PUFAs+NX-treated group.","['Obese dyslipidemic patients', 'humans']","['cyclooxygenase (COX) inhibitors', 'ω-3 PUFAs (2\u202fg twice daily)\u202f+\u202fNX', 'Omega-3 PUFAs and COX inhibitors', 'omega-3 polyunsaturated fatty acids (ω-3 PUFAs', 'naproxen (NX', 'Standard nutrition counseling (control), 2) ω-3 PUFAs (2\u202fg twice daily), 3) NX']","['mRNA expression of vascular cell adhesion molecule-1', 'serum TG and favorably altering AT gene expression and plasma bile acid profile', 'serum triglycerides']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0085387', 'cui_str': 'Prostaglandin Endoperoxide Synthase Inhibitors'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0442996', 'cui_str': 'Cox (qualifier value)'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated Fatty Acids'}, {'cui': 'C0027396', 'cui_str': 'Naproxen'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}]","[{'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0005390', 'cui_str': 'Bile Acids'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}]",,0.0233542,"(Vcam1), an inflammatory marker, increased significantly in AT of ω-3 PUFA-treated subjects but not in ω-3 PUFAs+NX-treated group.","[{'ForeName': 'Viswanathan', 'Initials': 'V', 'LastName': 'Saraswathi', 'Affiliation': 'Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, United States of America; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Heineman', 'Affiliation': 'Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, United States of America; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America.'}, {'ForeName': 'Yazen', 'Initials': 'Y', 'LastName': 'Alnouti', 'Affiliation': 'Pharmaceutical Sciences, University of Nebraska Medical Center, United States of America.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Shivaswamy', 'Affiliation': 'Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, United States of America; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America.'}, {'ForeName': 'Cyrus V', 'Initials': 'CV', 'LastName': 'Desouza', 'Affiliation': 'Internal Medicine, Division of Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, United States of America; VA Nebraska-Western Iowa Health Care System, Omaha, NE, United States of America. Electronic address: cdesouza@unmc.edu.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2019.107494'] 886,31521742,Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.,"OBJECTIVES To measure the effect of probenecid, fasting and fed, on flucloxacillin pharmacokinetic and pharmacodynamic endpoints. METHODS Flucloxacillin 1000 mg orally was given to 11 volunteers alone while fasting ('flucloxacillin alone'), and with probenecid 500 mg orally while fasting ('probenecid fasting') and with food ('probenecid fed'). Flucloxacillin pharmacokinetic and pharmacodynamic endpoints were compared. RESULTS Probenecid, fasting and fed, increased free plasma flucloxacillin area under the concentration-time curve (zero to infinity) ∼1.65-fold (p < 0.01) versus flucloxacillin alone. Probenecid fed prolonged time to peak flucloxacillin concentrations ∼2-fold versus the other two regimens (p < 0.01). Probenecid fasting or fed increased free flucloxacillin concentrations exceeding 30%, 50% and 70% of the first 6, 8 and 12 h post-dose by 1.58- to 5.48-fold compared with flucloxacillin alone. As an example of this pharmacodynamic improvement, the probability of target attainment of free concentrations above the minimum inhibitory concentration for Staphylococcus aureus (0.5 mg/L) for 50% of a 6-hour dose interval was > 80% for flucloxacillin plus probenecid (fasting or fed) and < 20% for flucloxacillin alone. CONCLUSIONS Probenecid increased flucloxacillin exposure, with predicted pharmacodynamic effects greater than pharmacokinetic effects because of the altered shape of the concentration-time curve. Probenecid may improve the applicability of oral flucloxacillin regimens.",2020,Probenecid fed prolonged time to peak flucloxacillin concentrations ∼2-fold versus the other two regimens (p<0.01).,['healthy volunteers'],"['probenecid', 'flucloxacillin plus probenecid', ""Flucloxacillin 1000 mg orally was given to 11 volunteers alone while fasting ('flucloxacillin alone'), and with probenecid 500 mg orally while fasting ('probenecid fasting') and with food ('probenecid fed"", 'flucloxacillin', 'Probenecid']","['free plasma flucloxacillin area under the concentration-time curve', 'free flucloxacillin concentrations', 'flucloxacillin pharmacokinetics and pharmacodynamics', 'Flucloxacillin pharmacokinetic and pharmacodynamic endpoints']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0033209', 'cui_str': 'Probenecid'}, {'cui': 'C0016267', 'cui_str': 'flucloxacillin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0989259', 'cui_str': 'Probenecid 500 MG'}, {'cui': 'C0016452', 'cui_str': 'Food'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0016267', 'cui_str': 'flucloxacillin'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}]",11.0,0.0756408,Probenecid fed prolonged time to peak flucloxacillin concentrations ∼2-fold versus the other two regimens (p<0.01).,"[{'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Everts', 'Affiliation': 'Department of Medicine, Nelson Hospital, Nelson, New Zealand. Electronic address: richard.everts@nmdhb.govt.nz.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Begg', 'Affiliation': 'Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Sharon J', 'Initials': 'SJ', 'LastName': 'Gardiner', 'Affiliation': 'Department of Infectious Diseases, Christchurch Hospital, Christchurch, New Zealand; Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand; Pharmacy Services, Christchurch Hospital, Christchurch, New Zealand.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand; Toxicology, Canterbury Health Laboratories, Christchurch, New Zealand.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Turnidge', 'Affiliation': 'Departments of Pathology, Paediatrics, and Molecular and Biomedical Sciences, University of Adelaide, Australia.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Chambers', 'Affiliation': 'Department of Infectious Diseases, Christchurch Hospital, Christchurch, New Zealand; Department of Pathology, University of Otago-Christchurch, Christchurch, New Zealand.'}, {'ForeName': 'Evan J', 'Initials': 'EJ', 'LastName': 'Begg', 'Affiliation': 'Department of Medicine, University of Otago-Christchurch, Christchurch, New Zealand; Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand.'}]",The Journal of infection,['10.1016/j.jinf.2019.09.004'] 887,31777409,Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.,"Depression is the leading cause of disability and a major cause of morbidity worldwide, with societal costs now upwards of 1 trillion dollars across the globe. Hence, extending current efforts to augment prevention outcomes is consistent with global public health interests. Although many prevention programs have been developed and have demonstrated efficacy, studies have yet to demonstrate that CBT is effective in preventing symptoms in populations at risk for developing depression induced by pharmacological substances. Using a randomized, controlled design, this pilot study reports on the feasibility and preliminary effects of a novel, guided symptom exposure augmented cognitive behavioral prevention intervention (GSE-CBT) in a sample diagnosed with Hepatitis C at risk for developing medication induced depression. Results demonstrated that the guided symptom exposure augmented CBT (GSE-CBT) was feasible in this population and was delivered with high integrity. Although not statistically different, we observed a pattern of lower depression levels in the GSE-CBT group versus those in the control group throughout. This pilot study demonstrates that a psychosocial prevention intervention is feasible for use in patients at risk for developing pharmacologically induced depression and that a guided symptom exposure augmented CBT protocol has the potential to prevent symptoms of depression that develop as a side effect to taking these medications. Results are preliminary and future studies should use larger samples and test the intervention in other populations.",2019,Results demonstrated that the guided symptom exposure augmented CBT (GSE-CBT) was feasible in this population and was delivered with high integrity.,"['sample diagnosed with Hepatitis C at risk for developing medication induced depression', 'patients at risk for developing pharmacologically induced depression']","['CBT', 'guided symptom exposure augmented cognitive behavior therapy protocol', 'psychosocial prevention intervention', 'GSE-CBT', 'guided symptom exposure augmented CBT (GSE-CBT', 'novel, guided symptom exposure augmented cognitive behavioral prevention intervention (GSE-CBT']","['symptoms of pharmacologically induced depression', 'depression levels']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0019196', 'cui_str': 'Parenterally-Transmitted Non-A, Non-B Hepatitis'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}]",,0.0179847,Results demonstrated that the guided symptom exposure augmented CBT (GSE-CBT) was feasible in this population and was delivered with high integrity.,"[{'ForeName': 'Lata K', 'Initials': 'LK', 'LastName': 'McGinn', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Albert Einstein College of Medicine; 1165 Morris Park Avenue, Bronx, NY, 10461 USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Van Meter', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Albert Einstein College of Medicine; 1165 Morris Park Avenue, Bronx, NY, 10461 USA.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Kronish', 'Affiliation': 'Mount Sinai Medical Center; 1468 Madison Avenue, New York, NY 10029, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gashin', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Albert Einstein College of Medicine; 1165 Morris Park Avenue, Bronx, NY, 10461 USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Burns', 'Affiliation': 'Ferkauf Graduate School of Psychology, Yeshiva University, Albert Einstein College of Medicine; 1165 Morris Park Avenue, Bronx, NY, 10461 USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Kil', 'Affiliation': 'Mount Sinai Medical Center; 1468 Madison Avenue, New York, NY 10029, USA.'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'McGinn', 'Affiliation': 'Mount Sinai Medical Center; 1468 Madison Avenue, New York, NY 10029, USA.'}]",Cognitive therapy and research,['10.1007/s10608-018-09990-7'] 888,31855202,Stenting of the carotid artery with CGuard and Acculink stents: interim results of a randomized trial.,"AIM The study was undertaken to evaluate safety and efficacy of carotid stents Acculink (open-cell carotid stent) and CGuard (closed-cell type stent) in treatment of patients presenting with atherosclerotic lesions of carotid arteries. PATIENTS AND METHODS The study enrolled a total of 50 patients diagnosed with haemodynamically significant stenosis of the carotid artery and divided into two groups of 25 patients each. Group One patients received Acculink stents and Group Two patients underwent implantation of CGuard stents. Ultrasonographic examination was performed in all patients before and after surgery, as well as at 6 and 12 months thereafter; magnetic resonance imaging of the brain was carried out before and after surgery (at 24-48 postoperative hours and on POD 30). The entire period of follow up included 5 examinations of each patient by a neurologist. The obtained findings were statistically analysed using the Statistica 12 software (StatSoft, USA). The level of deviation of the null hypothesis of the absence of differences between the groups was regarded as significant at p<0.05. RESULTS The technical success of the operation amounted to 100% in both groups. There were no complications (such as haematoma, arterial dissection, etc.) in the area of the approach in either group. The findings of ultrasonographic examination of the extracranial portion of the carotid arteries demonstrated a significant difference in the form of a decrease in the degree of narrowing of the operated vessel (p<0.05) as compared with its initial parameters. The number of the detected foci of acute cerebral ischaemia in the postoperative period (24-48 h) amounted to: in the Acculink group - 14 (56%), in the CGuard group - 12 (48%), p>0.77. Of these, multiple foci in Group One were encountered significantly more often than in Group Two (p=0.02). The patients with the Acculink stent implanted were found to develop 2 (4%) episodes of acute cerebral circulation impairment: the first one occurring after 24 hours and the second one at 28 days after stenting, with no such complications observed in Group Two patients. CONCLUSION Comparing the two stents (Acculink and CGuard) demonstrated no advantages with respect to safety and efficacy of either stent in endovascular treatment of patients with atherosclerotic lesions of brachiocephalic arteries.",2019,"There were no complications (such as haematoma, arterial dissection, etc.)","['50 patients diagnosed with haemodynamically significant stenosis of the carotid artery and divided into two groups of 25 patients each', 'patients presenting with atherosclerotic lesions of carotid arteries', 'patients with atherosclerotic lesions of brachiocephalic arteries']","['Acculink stents', 'Stenting of the carotid artery with CGuard and Acculink stents', 'carotid stents Acculink (open-cell carotid stent) and CGuard (closed-cell type stent', 'two stents (Acculink and CGuard', 'implantation of CGuard stents']","['number of the detected foci of acute cerebral ischaemia', 'degree of narrowing of the operated vessel', 'acute cerebral circulation impairment', 'technical success', 'safety and efficacy', 'Ultrasonographic examination']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0006094', 'cui_str': 'Innominate Artery'}]","[{'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0850458', 'cui_str': 'Carotid stent'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C2215101', 'cui_str': 'Acute cerebral ischemia (disorder)'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0007818', 'cui_str': 'Cerebral Circulation'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]",,0.0365262,"There were no complications (such as haematoma, arterial dissection, etc.)","[{'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'Bugurov', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Karpenko', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'P V', 'Initials': 'PV', 'LastName': 'Ignatenko', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'I V', 'Initials': 'IV', 'LastName': 'Popova', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'V B', 'Initials': 'VB', 'LastName': 'Starodubtsev', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'Sh B', 'Initials': 'SB', 'LastName': 'Saaia', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'G A', 'Initials': 'GA', 'LastName': 'Zeĭdlits', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'A S', 'Initials': 'AS', 'LastName': 'Brusianskaia', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'Sh Sh', 'Initials': 'SS', 'LastName': 'Fatulloeva', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'I V', 'Initials': 'IV', 'LastName': 'Bochkov', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}, {'ForeName': 'O S', 'Initials': 'OS', 'LastName': 'Osipova', 'Affiliation': 'Centre of Vascular and Hybrid Surgery, National Medical Research Centre named after Academician E.N. Meshalkin under the RF Ministry of Public Health, Novosibirsk, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGIO2019418'] 889,31910669,Clinical Outcomes of Dynamic Computed Tomography Myocardial Perfusion Imaging Combined With Coronary Computed Tomography Angiography Versus Coronary Computed Tomography Angiography-Guided Strategy.,"BACKGROUND Dynamic computed tomography (CT) myocardial perfusion imaging (MPI) provides quantitative myocardial blood flow for the precise assessment of myocardial ischemia. However, compared with coronary CT angiography (CCTA), whether this functional imaging modality can reduce invasive coronary angiography without revascularization remains unknown. We aimed to determine the clinical outcomes of a dynamic CT-MPI+CCTA-guided versus CCTA-guided strategy in patients with suspected coronary artery disease. METHODS Consecutive patients with intermediate pretest probability of coronary artery disease were prospectively enrolled and randomized to dynamic CT-MPI+CCTA-guided or CCTA-guided workup. The primary end point was the rate of invasive coronary angiography without revascularization within 3 months. The secondary end point was a composite of major adverse cardiac event at the 3-month, 6-month, and 1-year follow-up. RESULTS A total of 240 patients (mean age, 69.01±11.2 years; 173 men) were included. The total radiation dose and contrast media usage within 90 days were higher in the CT-MPI+CCTA group than in the CCTA group (10.3 versus 7.1 mSv, P =0.031; 134.5±40.6 versus 108.1±48.2 mL, P <0.0001). Compared with the CCTA-guided group, the CT-MPI+CCTA-guided group had significantly lower rates of invasive coronary angiography within 90 days (48.3% [58/120] versus 30.8% [37/120], P =0.006) and invasive coronary angiography without revascularization (50.0% [29/58] versus 10.8% [4/37], P <0.0001). There were no significant differences regarding the frequency of major adverse cardiac event between the 2 groups at the 3-month, 6-month, and 1-year follow-up. CONCLUSIONS In patients with intermediate pretest probability of coronary artery disease, CT-MPI+CCTA-guided patient management may be preferred over the CCTA-guided strategy as an approach to reduce unnecessary invasive procedures.",2020,"There were no significant differences regarding the frequency of major adverse cardiac event between the 2 groups at the 3-month, 6-month, and 1-year follow-up. ","['patients with suspected coronary artery disease', '240 patients (mean age, 69.01±11.2 years; 173 men) were included', 'Consecutive patients with intermediate pretest probability of coronary artery disease']","['CT-MPI+CCTA', 'Dynamic Computed Tomography Myocardial Perfusion Imaging Combined With Coronary Computed Tomography Angiography Versus Coronary Computed Tomography Angiography-Guided Strategy', 'Dynamic computed tomography (CT) myocardial perfusion imaging (MPI', 'dynamic CT-MPI+CCTA-guided or CCTA-guided workup', 'dynamic CT-MPI+CCTA-guided versus CCTA-guided strategy', 'CCTA', 'coronary CT angiography (CCTA']","['composite of major adverse cardiac event', 'rate of invasive coronary angiography without revascularization', 'total radiation dose and contrast media usage', 'frequency of major adverse cardiac event', 'rates of invasive coronary angiography', 'invasive coronary angiography without revascularization']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0428857', 'cui_str': 'Myocardial perfusion (observable entity)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C2350390', 'cui_str': 'Myocardial Perfusion Imaging'}, {'cui': 'C1536105', 'cui_str': 'Angiography, CT'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]",240.0,0.0400139,"There were no significant differences regarding the frequency of major adverse cardiac event between the 2 groups at the 3-month, 6-month, and 1-year follow-up. ","[{'ForeName': 'Mengmeng', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': ""Institute of Diagnostic and Interventional Radiology (M.Y., X.D., J.Z.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Chengxing', 'Initials': 'C', 'LastName': 'Shen', 'Affiliation': ""Department of Cardiology (C.S., Z.L.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Dai', 'Affiliation': ""Institute of Diagnostic and Interventional Radiology (M.Y., X.D., J.Z.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': ""Department of Cardiology (C.S., Z.L.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}, {'ForeName': 'Yining', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Radiology, Peking Union Medical College Hospital (Y.W.), Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': 'Department of Radiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Centre for Cardiovascular Diseases (B.L.), Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jiayin', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Institute of Diagnostic and Interventional Radiology (M.Y., X.D., J.Z.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.""}]",Circulation. Cardiovascular imaging,['10.1161/CIRCIMAGING.119.009775'] 890,30982761,The AAHKS Clinical Research Award: Prophylactic Tamsulosin Does Not Reduce the Risk of Urinary Retention Following Lower Extremity Arthroplasty: A Double-Blinded Randomized Controlled Trial.,"BACKGROUND Postoperative urinary retention (POUR) is common. Selective alpha-1 adrenergic antagonists, such as tamsulosin, are effective for treating urinary retention. The purpose of this study is to determine whether perioperative prophylactic tamsulosin reduces the incidence of POUR following total hip and knee arthroplasty. METHODS Male patients 35 years of age and older undergoing primary total hip or knee arthroplasty at a single center from 2015 to 2018 were eligible for inclusion. Patients were randomized to receive tamsulosin 0.4 mg or placebo daily for 5 days preoperatively, the morning of surgery, and the first postoperative day. The incidence of POUR was determined during the postoperative hospitalization. RESULTS A total of 176 patients were enrolled in the study. Two patients were withdrawn prior to randomization. The remaining 174 were randomized to tamsulosin (n = 87) or placebo (n = 87). After an additional 43 patients were withdrawn prior to surgery, 131 patients completed the study (tamsulosin, n = 64; placebo, n = 67). A total of 42 patients (32.1%) developed POUR, with 18 cases (28.1%) in the tamsulosin group and 24 cases (35.8%) in the placebo group (P = .345), resulting in an odds ratio of 0.701 and a risk difference of 7.69%. CONCLUSION Prophylactic tamsulosin did not reduce the incidence of POUR after hip and knee arthroplasty compared to placebo. The odds ratio indicates an approximately 30% decreased odds of developing POUR in the tamsulosin group, albeit not statistically significant. Tamsulosin does not appear to be effective as a prophylactic measure for reducing POUR in male hip and knee arthroplasty patients.",2019,Tamsulosin does not appear to be effective as a prophylactic measure for reducing POUR in male hip and knee arthroplasty patients.,"['male hip and knee arthroplasty patients', 'Lower Extremity Arthroplasty', '43 patients were withdrawn prior to surgery, 131 patients completed the study (tamsulosin, n\xa0= 64', 'Male patients 35 years of age and older undergoing primary total hip or knee arthroplasty at a single center from 2015 to 2018 were eligible for inclusion', 'A total of 176 patients were enrolled in the study']","['placebo', 'Prophylactic tamsulosin', 'perioperative prophylactic tamsulosin', 'Tamsulosin', 'tamsulosin 0.4 mg or placebo', 'tamsulosin']","['incidence of POUR', 'POUR', 'odds of developing POUR']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}]",2.0,0.311242,Tamsulosin does not appear to be effective as a prophylactic measure for reducing POUR in male hip and knee arthroplasty patients.,"[{'ForeName': 'Manuel F', 'Initials': 'MF', 'LastName': 'Schubert', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Jared R', 'Initials': 'JR', 'LastName': 'Thomas', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI; IHA Orthopaedic Surgery Associates, Saint Joseph Mercy Health System, Ypsilanti, MI.'}, {'ForeName': 'Joel J', 'Initials': 'JJ', 'LastName': 'Gagnier', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Caitlin M', 'Initials': 'CM', 'LastName': 'McCarthy', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI; Department of Orthopaedic Surgery, Southern California Permanente Medical Group, Kaiser Permanente, Baldwin Park, CA.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Urquhart', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Aidin Eslam', 'Initials': 'AE', 'LastName': 'Pour', 'Affiliation': 'Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, MI.'}]",The Journal of arthroplasty,['10.1016/j.arth.2019.03.039'] 891,31781755,Efficacy of JAK inhibitors in Crohn's Disease.,"Inhibition of Janus kinases [JAKs] in Crohn's disease [CD] patients has shown conflicting results in clinical trials. Tofacitinib, a pan-JAK inhibitor, showed efficacy in ulcerative colitis [UC] and has been approved for the treatment of patients with moderate to severe UC. In contrast, studies in CD patients were disappointing and the primary end point of clinical remission could not be met in the respective phase II induction and maintenance trials. Subsequently, the clinical development of tofacitinib was discontinued in CD. In contrast, efficacy of filgotinib, a selective JAK1 inhibitor, in CD patients was demonstrated in the randomized, double-blinded, placebo-controlled phase II FITZROY study. Upadacitinib also showed promising results in a phase II trial in moderate to severe CD. Subsequently, phase III programmes in CD have been initiated for both substances, which are still ongoing. Several newer molecules of this class of orally administrated immunosuppressants are being tested in clinical programmes. The concern of side effects of systemic JAK inhibition is addressed by either exclusively intestinal action or higher selectivity [Tyk2 inhibitors]. In general, JAK inhibitors constitute a new promising class of drugs for the treatment of CD.",2020,"Tofacitinib, a pan-JAK inhibitor showed efficacy in ulcerative colitis (UC) and has been approved for the treatment of patients with moderate to severe UC.","['CD patients', ""Crohn's disease (CD) patients"", 'patients with moderate to severe UC', ""Crohn's disease"", 'patients suffering from CD']","['placebo', 'filgotinib, a selective JAK1 inhibitor', 'Tofacitinib, a pan-JAK inhibitor']",['clinical remission'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4310256', 'cui_str': 'filgotinib'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C2930696', 'cui_str': 'tofacitinib'}, {'cui': 'C0085999', 'cui_str': 'Genus Pan (organism)'}, {'cui': 'C3854325', 'cui_str': 'JAK Inhibitors'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]",,0.0812242,"Tofacitinib, a pan-JAK inhibitor showed efficacy in ulcerative colitis (UC) and has been approved for the treatment of patients with moderate to severe UC.","[{'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Rogler', 'Affiliation': 'Department of Gastroenterology & Hepatology, University Hospital of Zürich, Switzerland.'}]",Journal of Crohn's & colitis,['10.1093/ecco-jcc/jjz186'] 892,31473932,Influence of an Implementation Support Intervention on Barriers and Facilitators to Delivery of a Substance Use Prevention Program.,"Implementation support interventions have helped organizations implement programs with quality and obtain intended outcomes. For example, a recent randomized controlled trial called Preparing to Run Effective Programs (PREP) showed that an implementation support intervention called Getting To Outcomes (GTO) improved implementation of an evidence-based substance use prevention program (CHOICE) run in community-based settings. However, more information is needed on how these interventions affect organizational barriers and facilitators of implementation. This paper aims to identify differences in implementation facilitators and barriers in sites conducting a substance use prevention program with and without GTO. PREP is a cluster-randomized controlled trial testing GTO, a two-year implementation support intervention, in Boys & Girls Clubs. The trial compares 15 Boys & Girls Club sites implementing CHOICE (control group), a five-session evidence-based alcohol and drug prevention program, with 14 Boys & Girls Club sites implementing CHOICE supported by GTO (intervention group). All sites received CHOICE training. Intervention sites also received GTO manuals, training, and onsite technical assistance to help practitioners complete implementation best practices specified by GTO (i.e., GTO steps). During the first year, technical assistance providers helped the intervention group adopt, plan, and deliver CHOICE, and then evaluate and make quality improvements to CHOICE implementation using feedback reports summarizing their data. Following the second year of CHOICE and GTO implementation, all sites participated in semi-structured interviews to identify barriers and facilitators to CHOICE implementation using the Consolidated Framework for Implementation Research (CFIR). This paper assesses the extent to which these facilitators and barriers differed between intervention and control group. Intervention sites had significantly higher average ratings than control sites for two constructs from the CFIR process domain: planning and reflecting and evaluating. At the same time, intervention sites had significantly lower ratings on the culture and available resources constructs. Findings suggest that strong planning, evaluation, and reflection-likely improved with GTO support-can facilitate implementation even in the face of perceptions of a less desirable implementation climate. These findings highlight that implementation support, such as GTO, is likely to help low-resourced community-based organizations improve program delivery through a focus on implementation processes. TRIAL REGISTRATION: This project is registered at ClinicalTrials.gov with number NCT02135991 (URL: https://clinicaltrials.gov/show/NCT02135991). The trial was first registered May 12, 2014.",2019,Intervention sites had significantly higher average ratings than control sites for two constructs from the CFIR process domain: planning and reflecting and evaluating.,"['15 Boys & Girls Club sites implementing CHOICE (control group), a', 'Boys & Girls Clubs']","['PREP', 'five-session evidence-based alcohol and drug prevention program, with 14 Boys & Girls Club sites implementing CHOICE supported by GTO (intervention group', 'Implementation Support Intervention']",['average ratings'],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]",[],,0.0574447,Intervention sites had significantly higher average ratings than control sites for two constructs from the CFIR process domain: planning and reflecting and evaluating.,"[{'ForeName': 'Jill S', 'Initials': 'JS', 'LastName': 'Cannon', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA. cannon@rand.org.'}, {'ForeName': 'Marylou', 'Initials': 'M', 'LastName': 'Gilbert', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Ebener', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Malone', 'Affiliation': 'Malone Quantitative, Durham, North Carolina, USA.'}, {'ForeName': 'Caitlin M', 'Initials': 'CM', 'LastName': 'Reardon', 'Affiliation': 'Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.'}, {'ForeName': 'Joie', 'Initials': 'J', 'LastName': 'Acosta', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Chinman', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-019-01037-x'] 893,31564057,Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.,"BACKGROUND Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13. International phase II and III studies have evaluated the efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis (AD), but the effects of dupilumab in Japanese patients have not been reported. OBJECTIVES To evaluate the efficacy and safety of dupilumab in Japanese patients with moderate-to-severe AD. METHODS We analysed the efficacy and safety of dupilumab in the Japanese cohorts of a 16-week, phase IIb dose-finding trial (AD-1021; NCT01859988); a 16-week, phase III, placebo-controlled monotherapy trial (LIBERTY AD SOLO 1; NCT02277743) and a 52-week, phase III, placebo-controlled study of dupilumab with topical corticosteroids (LIBERTY AD CHRONOS; NCT02260986). RESULTS Twenty-seven, 106 and 117 Japanese patients were enrolled in AD-1021, SOLO 1 and CHRONOS, respectively. Baseline disease severity was numerically higher in the Japanese cohort than in the overall study population. Generally, dupilumab significantly improved signs and symptoms of AD, including pruritus and patient quality of life, compared with placebo in the Japanese cohort, consistent with the overall study population. The combined safety profile of dupilumab in the Japanese cohort was similar to that in the total study populations; dupilumab was associated with an increased incidence of injection-site reactions and conjunctivitis compared with placebo. Dupilumab was associated with rapid reduction in thymus and activation-regulated chemokine and gradual IgE reductions. CONCLUSIONS Dupilumab alone or with topical corticosteroids improved signs and symptoms of AD, had an acceptable safety profile, and suppressed biomarkers of type 2 inflammation compared with placebo in Japanese adult patients with moderate-to-severe AD. What's already known about this topic? Differences in atopic dermatitis (AD) pathology have been reported between Asian and Western populations, in which distinct helper T-cell activation profiles have been observed. International clinical studies in adults with moderate-to-severe AD have evaluated the efficacy and safety of dupilumab, which blocks interleukin-4 and interleukin-13, key molecules in type 2 inflammation. The effects of dupilumab in Japanese patients specifically have not yet been reported. What does this study add? Dupilumab alone or with topical corticosteroids improved signs and symptoms of AD and had an acceptable safety profile compared with placebo in Japanese patients with moderate-to-severe AD. The effects were comparable with those observed in the overall study population. Reported immunological differences in AD pathology in Asian patients may be secondary to type 2 immune activation.",2020,"BACKGROUND Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13.","['Japanese adults with moderate-to-severe atopic dermatitis', 'Twenty-seven, 106, and 117 Japanese patients enrolled in AD-1021, SOLO 1 and CHRONOS, respectively', 'adults with moderate-to-severe atopic dermatitis (AD', 'Japanese adult patients with moderate-to-severe AD', 'Japanese patients with moderate-to-severe AD']","['placebo-controlled monotherapy', 'dupilumab with topical corticosteroids (TCS, LIBERTY AD', 'placebo', 'Dupilumab alone or with TCS', 'dupilumab']","['Baseline disease severity', 'efficacy and safety', 'signs and symptoms of AD, including pruritus, and patient quality of life', 'Efficacy and safety']","[{'cui': 'C1556094', 'cui_str': 'Japanese'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037088', 'cui_str': 'Signs and Symptoms'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034380'}]",117.0,0.0559352,"BACKGROUND Dupilumab, a human monoclonal antibody, blocks the shared receptor unit for interleukin-4 and interleukin-13.","[{'ForeName': 'N', 'Initials': 'N', 'LastName': 'Katoh', 'Affiliation': 'Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kataoka', 'Affiliation': 'Department of Dermatology, Osaka Habikino Medical Center, Osaka, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Saeki', 'Affiliation': 'Department of Dermatology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hide', 'Affiliation': 'Department of Dermatology, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kabashima', 'Affiliation': 'Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Etoh', 'Affiliation': 'Department of Dermatology, Tokyo Teishin Postal Services Agency Hospital, Tokyo, Japan.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Igarashi', 'Affiliation': 'Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Imafuku', 'Affiliation': 'Department of Dermatology, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kawashima', 'Affiliation': ""Department of Dermatology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ohtsuki', 'Affiliation': 'Department of Dermatology, Jichi Medical University, Tochigi, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Fujita', 'Affiliation': 'Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Arima', 'Affiliation': 'Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Takagi', 'Affiliation': 'Sanofi K.K., Tokyo, Japan.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Shumel', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ardeleanu', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, U.S.A.'}]",The British journal of dermatology,['10.1111/bjd.18565'] 894,30794083,Effect of Bilateral and Unilateral Plantarflexor Muscle Fatigue on Blind Navigation Precision and Gait Parameters.,"The objective was to evaluate the impact of bilateral and unilateral fatigue of the plantarflexor muscles on blind navigation. Thirty-eight young adults walked 8-m without vision before fatigue (pre-fatigue), then fatigued either one or both of their plantarflexor muscles by performing isometric contractions. After each fatigue, two blind navigation trials were performed (post-fatigue trials 1 and 2). Results revealed no effect of bilateral muscle fatigue on navigation precision and gait parameters. Unilateral muscle fatigue led to longer linear distance travelled during post-fatigue trial 2 compared to pre-fatigue and to a change in angular deviation between pre- and post-fatigue. In general, results suggest that participants were able to make adaptive changes to counter muscle fatigue during blind navigation.",2020,Unilateral muscle fatigue led to longer linear distance travelled during post-fatigue trial 2 compared to pre-fatigue and to a change in angular deviation between pre- and post-fatigue.,['Thirty-eight young adults walked 8-m without vision before fatigue (pre-fatigue'],['Bilateral and Unilateral Plantarflexor Muscle Fatigue'],"['Blind Navigation Precision and Gait Parameters', 'bilateral muscle fatigue on navigation precision and gait parameters', 'Unilateral muscle fatigue']","[{'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C0242979', 'cui_str': 'Muscular Fatigue'}]","[{'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0242979', 'cui_str': 'Muscular Fatigue'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}]",38.0,0.0429321,Unilateral muscle fatigue led to longer linear distance travelled during post-fatigue trial 2 compared to pre-fatigue and to a change in angular deviation between pre- and post-fatigue.,"[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Richer', 'Affiliation': 'Faculty of Health Sciences, School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Etienne J', 'Initials': 'EJ', 'LastName': 'Bisson', 'Affiliation': ""School of Rehabilitation Therapy, Faculty of Health Sciences, Queen's University, Kingston, ON, Canada.""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bilodeau', 'Affiliation': 'Faculty of Health Sciences, School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Paquet', 'Affiliation': 'Faculty of Health Sciences, School of Rehabilitation Sciences, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Lajoie', 'Affiliation': 'Faculty of Health Sciences, School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada.'}]",Journal of motor behavior,['10.1080/00222895.2019.1576157'] 895,31698965,Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.,"BACKGROUND A novel approach to determine the effect of a treatment is to calculate the delay of event, which estimates the gain of event-free time. The aim of this study was to estimate gains in event-free time for stroke or systemic embolism, death, bleeding events, and the composite of these events, in patients with atrial fibrillation randomized to either warfarin or apixaban in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial (ARISTOTLE). DESIGN The ARISTOTLE study was a randomized double-blind trial comparing apixaban with warfarin. METHODS Laplace regression was used to estimate the delay in time to the outcomes between the apixaban and the warfarin group in 6, 12, 18 and 22 months of follow-up. RESULTS The gain in event-free time for apixaban versus warfarin was 181 (95% confidence interval 76 to 287) days for stroke or systemic embolism and 55 (-4 to 114) days for death after 22 months of follow-up. The corresponding gains in event-free times for major and intracranial bleeding were 206 (130 to 281) and 392 (249 to 535) days, respectively. The overall gain for the composite of all these events was a gain of 116 (60 to 171) days. CONCLUSIONS In patients with atrial fibrillation, 22 months of treatment with apixaban, as compared with warfarin, provided gains of approximately 6 months in event-free time for stroke or systemic embolism, 7 months for major bleeding and 13 months for intracranial bleeding.",2020,The gain in event-free time for apixaban versus warfarin was 181 (95% confidence interval 76 to 287) days for stroke or systemic embolism and 55 (-4 to 114) days for death after 22 months of follow-up.,"['patients with atrial fibrillation, 22 months of treatment with', 'patients with atrial fibrillation randomized to either']","['warfarin or apixaban', 'apixaban versus warfarin', 'warfarin', 'apixaban with warfarin', 'apixaban']","['intracranial bleeding', 'gain in event-free time', 'corresponding gains in event-free times for major and intracranial bleeding', 'overall gain']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}]","[{'cui': 'C0524466', 'cui_str': 'Intracranial (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.179029,The gain in event-free time for apixaban versus warfarin was 181 (95% confidence interval 76 to 287) days for stroke or systemic embolism and 55 (-4 to 114) days for death after 22 months of follow-up.,"[{'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Berglund', 'Affiliation': 'Department of Public Health and Caring Sciences, Uppsala University, Sweden.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Wallentin', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Sweden.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Oldgren', 'Affiliation': 'Department of Medical Sciences, Cardiology, Uppsala University, Sweden.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Renlund', 'Affiliation': 'Uppsala Clinical Research Centre (UCR), Uppsala University, Sweden.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Duke Medicine, Durham, USA.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Granger', 'Affiliation': 'Duke Clinical Research Institute, Duke Medicine, Durham, USA.'}, {'ForeName': 'Stefan H', 'Initials': 'SH', 'LastName': 'Hohnloser', 'Affiliation': 'Department of Medicine, Division of Cardiology, Johann Wolfgang Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Elaine M', 'Initials': 'EM', 'LastName': 'Hylek', 'Affiliation': 'Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Duke Medicine, Durham, USA.'}, {'ForeName': 'John Jv', 'Initials': 'JJ', 'LastName': 'McMurray', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Lytsy', 'Affiliation': 'Department of Public Health and Caring Sciences, Uppsala University, Sweden.'}]",European journal of preventive cardiology,['10.1177/2047487319886959'] 896,31468247,Role of Organizational Support on Implementation of an Environmental Change Intervention to Improve Child Fruit and Vegetable Intake: a Randomized Cross-Over Design.,"Little is known about the role of organizational or administrative support in implementation of health promotion interventions, particularly outside of school settings. The purpose was to determine the change in fruit and vegetable (FV) intake among children living in residential children's homes (RCHs) and assess the relationships among change in organizational support, intervention implementation, and child nutrition outcomes. Data were collected from 29 RCHs and 614 children living in RCHs, as part of a group randomized design with delayed intervention, at three cross-sectional waves: 2004, 2006, and 2008. RCH staff made environmental changes to increase intake of FV. Implementation and organizational support data were collected from staff at the RCHs. Child FV intake were measured via 24-h dietary recalls. A two-way (condition by time) repeated measures ANOVA was conducted to test whether FV intake increased in response to the intervention. A two-level path analysis with a robust maximum likelihood estimator was used to explore the relationships among organizational support, intervention implementation fidelity, and child FV intake. There was a significant increase in FV intake within all RCHs from 2004 to 2006 (P = 0.022 for the intervention group, P = 0.015 for the control group). This increase was maintained in both groups from 2006 to 2008 (post-intervention mean servings: intervention = 3.2 vs control = 3.4). Increases in organizational support resulted in greater overall implementation fidelity. When RCH staff, supervisors, and the RCH CEO were perceived to be supportive of the intervention, more environmental changes were made to encourage eating FV. Fostering organizational support may improve implementation of interventions.",2019,"There was a significant increase in FV intake within all RCHs from 2004 to 2006 (P = 0.022 for the intervention group, P = 0.015 for the control group).","[""children living in residential children's homes (RCHs"", '614 children living in RCHs']",[],"['change in fruit and vegetable (FV) intake', 'FV intake', 'Child FV intake', 'overall implementation fidelity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442513', 'cui_str': ""Children's home (environment)""}]",[],"[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1271941', 'cui_str': 'Fruit and vegetable intake'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",614.0,0.0405036,"There was a significant increase in FV intake within all RCHs from 2004 to 2006 (P = 0.022 for the intervention group, P = 0.015 for the control group).","[{'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Gay', 'Affiliation': 'Department of Health Promotion & Behavior, University of Georgia, Athens, GA, USA. jlgay@uga.edu.'}, {'ForeName': 'Ruth P', 'Initials': 'RP', 'LastName': 'Saunders', 'Affiliation': 'Department of Health Promotion, Education and Behavior, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Rees-Punia', 'Affiliation': 'American Cancer Society, Atlanta, GA, USA.'}, {'ForeName': 'Marsha', 'Initials': 'M', 'LastName': 'Dowda', 'Affiliation': 'Department of Exercise Science, University of South Carolina, Columbia, SC, USA.'}, {'ForeName': 'Alexandra E', 'Initials': 'AE', 'LastName': 'van den Berg', 'Affiliation': 'Division of Health Promotion and Behavioral Sciences, UTHealth School of Public Health, Austin, TX, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-019-01043-z'] 897,31386073,The association of health-related quality of life and cognitive function in patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy.,"Background This study evaluated the association between health-related quality of life (HRQOL) and cognition in patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT). Methods Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine, 20 mg per day, within 3 days of initiating radiotherapy, for 24 weeks. The Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C) were completed in coordination with serial standardized tests of cognitive function. Results Of the 508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses. Evaluable patients at 24 weeks (n = 246) included surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments (n = 146, 59%) and patients alive at time of missed assessment (n = 100, 41%). Baseline cognitive function correlated significantly with FACT-Br and MOS-C self-reports. All domains of objective cognitive function showed declines over time. Neither FACT-Br nor MOS-C differed between the treatment arms. Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable. MOS-C scores declined over time. Conclusion Baseline cognitive function correlated significantly with FACT-Br and MOS-C scores. No by-arm differences in HRQOL were observed despite differences in objective cognitive function. Patient attrition and poor testing compliance remain significant problems in studies of cognitive function of brain metastases patients and further effort is needed to improve compliance with testing and sensitivity of patient-reported measures.",2019,Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable.,"['patients receiving memantine for the prevention of cognitive dysfunction during whole-brain radiotherapy', 'Adult patients with brain metastases', 'brain metastases patients', '508 eligible patients, 442 (87%) consented to participate in the HRQOL portion and contributed to baseline analyses', 'patients receiving memantine for prevention of cognitive dysfunction during whole-brain radiotherapy (WBRT']","['WBRT', 'placebo or memantine']","['Baseline cognitive function', 'FACT-Br nor MOS-C', 'Emotional and functional well-being subscales', 'objective cognitive function', 'Functional Assessment of Cancer Therapy-Brain module (FACT-Br) and Medical Outcomes Scale-Cognitive Functioning Scale (MOS-C', 'health-related quality of life (HRQOL) and cognition', 'MOS-C scores', 'HRQOL', 'surviving patients completing FACT-Br, MOS-C, and objective cognitive assessments']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C1520143', 'cui_str': 'Whole brain radiation therapy (regime/therapy)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0220650', 'cui_str': 'Secondary malignant neoplasm of brain (disorder)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}]","[{'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",508.0,0.044376,Emotional and functional well-being subscales of the FACT improved over time while the remainder of the FACT-Br domains remained stable.,"[{'ForeName': 'Nadia N', 'Initials': 'NN', 'LastName': 'Laack', 'Affiliation': 'Department of Radiation, Oncology Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Pugh', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Brown', 'Affiliation': 'The University of Texas, MD Anderson Cancer Center, Houston, USA.'}, {'ForeName': 'Sherry', 'Initials': 'S', 'LastName': 'Fox', 'Affiliation': ""Bon Secours Cullather Brain Tumor Quality of Life Center, St. Mary's Hospital, Richmond, Virginia, USA.""}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Wefel', 'Affiliation': 'The University of Texas, MD Anderson Cancer Center, Houston, USA.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Meyers', 'Affiliation': 'Department of Radiation, Oncology Mayo Clinic, Rochester, Minnesota, USA.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Choucair', 'Affiliation': 'Norton Healthcare System Neuroscience Institute, Louisville, Kentucky, USA.'}, {'ForeName': 'Deepak', 'Initials': 'D', 'LastName': 'Khuntia', 'Affiliation': 'Mills-Peninsula Health Services, Burlingame, California, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Suh', 'Affiliation': 'Cleveland Clinic Foundation, Ohio, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Roberge', 'Affiliation': 'McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Merideth M', 'Initials': 'MM', 'LastName': 'Wendland', 'Affiliation': 'US Oncology, Sugar Land, Texas.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Bruner', 'Affiliation': 'Emory University, Atlanta, Georgia, USA.'}]",Neuro-oncology practice,['10.1093/nop/npy038'] 898,31765987,"A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.","BACKGROUND This phase I/II study evaluated the feasibility and efficacy of S-1, leucovorin, oxaliplatin and gemcitabine (SLOG), a triplet regimen, for treating patients with metastatic pancreatic ductal adenocarcinoma (PDAC). METHODS Patients with chemo-naive, metastatic PDAC were eligible to receive fixed-rate infusion (10 mg/m 2 /min) of gemcitabine of 800 mg/m 2 followed by oxaliplatin of 85 mg/m 2 on day 1 plus oral S-1 and leucovorin (20 mg/m 2 ) twice daily from days 1 to 7 in a 2-week cycle. The dose of S-1 would be escalated from 20, 30, 35 to 40 mg/m2 in a 3 + 3 designed phase I part to determine the maximum tolerated dose (MTD) for phase II study, in which the primary end-point was objective response rate (ORR). The recommended dose of S-1 was from phase I. This trial is registered at ClinicalTrials.gov: NCT01415713. RESULTS Seventy-three patients were enrolled. In the phase I study (n = 19), the MTD of S-1 was 35 mg/m 2 twice daily. Of 54 patients in phase II, the ORR was 40.7% (95% confidence interval [CI], 28%-55%). The median progression-free survival and overall survival were 7.6 (95% CI, 5.6-11.0) and 11.4 (95% CI, 8.1-16.3) months, respectively. The most common grade III/IV adverse event was neutropenia (40.7%). Twenty-four percent of patients had SLOG treatment for more than 1 year. The mean relative dose intensities of gemcitabine, oxaliplatin, and S-1 were 92%, 92% and 89%, respectively. CONCLUSION Biweekly SLOG is a feasible regimen with promising activity and safety profiles. A randomised study comparing SLOG versus modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) in advanced PDAC is ongoing (ClinicalTrials.gov: NCT03443492).",2020,"The median progression-free survival and overall survival were 7.6 (95% CI, 5.6-11.0) and 11.4 (95% CI, 8.1-16.3) months, respectively.","['Patients with chemo-naive, metastatic PDAC were eligible to receive', 'metastatic pancreatic adenocarcinoma-TCOG T1211 study', 'Seventy-three patients were enrolled', 'patients with metastatic pancreatic ductal adenocarcinoma (PDAC']","['S-1, leucovorin, oxaliplatin and gemcitabine', 'fixed-rate infusion (10\xa0mg/m 2 /min) of gemcitabine of 800\xa0mg/m 2 followed by 85\xa0mg/m oxaliplatin of 85\xa0mg/m 2 on day 1 plus oral S-1 and leucovorin', 'SLOG versus modified folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX', 'S-1, leucovorin, oxaliplatin and gemcitabine (SLOG']","['median progression-free survival and overall survival', 'ORR', 'mean relative dose intensities of gemcitabine, oxaliplatin, and S-1', 'objective response rate (ORR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0281361', 'cui_str': 'Adenocarcinoma of pancreas'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}]","[{'cui': 'C0879262', 'cui_str': 'TS-1 cpd'}, {'cui': 'C2721771', 'cui_str': 'levoleucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0702093', 'cui_str': '/min'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0879262', 'cui_str': 'TS-1 cpd'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}]",73.0,0.0688427,"The median progression-free survival and overall survival were 7.6 (95% CI, 5.6-11.0) and 11.4 (95% CI, 8.1-16.3) months, respectively.","[{'ForeName': 'Nai-Jung', 'Initials': 'NJ', 'LastName': 'Chiang', 'Affiliation': 'Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.'}, {'ForeName': 'Kelvin K', 'Initials': 'KK', 'LastName': 'Tsai', 'Affiliation': 'National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan.'}, {'ForeName': 'Chin-Fu', 'Initials': 'CF', 'LastName': 'Hsiao', 'Affiliation': 'Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.'}, {'ForeName': 'Shih-Hung', 'Initials': 'SH', 'LastName': 'Yang', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Hui-Hua', 'Initials': 'HH', 'LastName': 'Hsiao', 'Affiliation': 'Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan.'}, {'ForeName': 'Wen-Chi', 'Initials': 'WC', 'LastName': 'Shen', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Chiun', 'Initials': 'C', 'LastName': 'Hsu', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Yu-Lin', 'Initials': 'YL', 'LastName': 'Lin', 'Affiliation': 'Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Jen-Shi', 'Initials': 'JS', 'LastName': 'Chen', 'Affiliation': 'Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan.'}, {'ForeName': 'Yan-Shen', 'Initials': 'YS', 'LastName': 'Shan', 'Affiliation': 'Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan.'}, {'ForeName': 'Li-Tzong', 'Initials': 'LT', 'LastName': 'Chen', 'Affiliation': 'National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan; Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan; Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: leochen@nhri.org.tw.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.023'] 899,31774380,Seeing Is Believing: Blind Putting Drills Confer No Advantage to the Novice Golfer.,"Purpose : Golf coaches may recommend ""blind"" putting drills in which golfers close their eyes to improve their feel. Research on specificity of learning suggests, however, that adding or removing a source of sensory information after practicing under differing circumstances can cause performance decrements. Specificity of learning is also dependent upon specific task requirements. The purpose of this study was to examine whether golf putting, requiring body positioning and aiming an implement, would benefit from blind training. Method : Novice golfers (n = 24) in Vision Training (VT) & No-Vision Training (NVT) groups completed 108 trials of a 10-ft putt. After a 24-hr delay, both groups completed sighted- and blind-putting tests. Results : Acquisition results revealed Group × Block interactions in RE ( p = .025) and y-VE ( p = .032). Post hoc procedures revealed significant differences between the groups on Block 2 ( p = .017), with the NVT group producing longer mean RE. During testing, RE and x-VE results revealed Group × Test interactions ( p = .027 & .041), such that performance of the VT group suffered when transferred to blind putting, while performance of the NVT group did not differ when transferred. Conclusion : NVT did not confer any advantage for subsequent performance with vision. Moreover, results were not consistent with the specificity of learning hypothesis and suggest that putting does not rely on complete sensory integration to support subsequent performance. Presumably, task requirements related to body positioning provided adequate sensory cues for successful performance.",2020,Acquisition results revealed Group × Block interactions in RE ( p = .025) and y-VE ( p = .032).,[],"['Vision Training (VT) ', 'NVT', 'No-Vision Training (NVT']",[],[],"[{'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",[],,0.0352187,Acquisition results revealed Group × Block interactions in RE ( p = .025) and y-VE ( p = .032).,"[{'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Fisher', 'Affiliation': 'Central Michigan University.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Fairbrother', 'Affiliation': 'University of Tennessee.'}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1674443'] 900,31774382,Can the Stereotype Threat and Lift Phenomenon Be Applicable to a Muscular Endurance Task?,"Purpose . Inducing a negative stereotype toward women usually leads to a decrease in women performance and an increase in men performance. These effects were observed during technical tasks. The purpose of the present study was to investigate the effect of this sex stereotype during a non-technical muscular endurance task. The perception of effort, closely related to endurance performance, was also recorded. Based on the type of task and the mere effort account, we predicted that both men and women in the negative stereotype toward women condition would perform better than participants in the two other groups. Method . Seventy-seven participants (38 women and 39 men) were randomly assigned to a negative stereotype toward women, a nullified-stereotype, or a control condition. Then, they performed a submaximal handgrip task until exhaustion at 50% of their maximal strength. Results . This study showed that performance at T2 was reduced for men and women in the nullified-stereotype and control conditions, but not in the negative stereotype toward women condition, revealing that participants in the negative stereotype toward women condition performed better than participants in the other conditions. No significant difference was observed concerning the perception of effort according to the conditions. Conclusion . As compared to technical tasks, inducing a negative stereotype toward women increased women's performance. The perception of effort could be responsible for this performance improvement. However, more research is needed to investigate the mechanisms involved. Concerning men, in line with the stereotype lift phenomenon, a performance increase was observed in this same condition.",2020,"This study showed that performance at T2 was reduced for men and women in the nullified-stereotype and control conditions, but not in the negative stereotype toward women condition, revealing that participants in the negative stereotype toward women condition performed better than participants in the other conditions.",['Seventy-seven participants (38 women and 39 men'],"['negative stereotype toward women, a nullified-stereotype, or a control condition', 'sex stereotype during a non-technical muscular endurance task']",['men performance'],"[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0038272', 'cui_str': 'Stereotyping'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}]",77.0,0.0306224,"This study showed that performance at T2 was reduced for men and women in the nullified-stereotype and control conditions, but not in the negative stereotype toward women condition, revealing that participants in the negative stereotype toward women condition performed better than participants in the other conditions.","[{'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Deshayes', 'Affiliation': ""Université Côte d'Azur.""}, {'ForeName': 'Raphaël', 'Initials': 'R', 'LastName': 'Zory', 'Affiliation': ""Université Côte d'Azur.""}, {'ForeName': 'Allison E', 'Initials': 'AE', 'LastName': 'Seitchik', 'Affiliation': 'Merrimack College.'}, {'ForeName': 'Aïna', 'Initials': 'A', 'LastName': 'Chalabaev', 'Affiliation': 'Université Grenoble Alpes.'}, {'ForeName': 'Corentin', 'Initials': 'C', 'LastName': 'Clément-Guillotin', 'Affiliation': ""Université Côte d'Azur.""}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1668518'] 901,31784217,Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.,"BACKGROUND Ivacaftor shows benefit in patients with cystic fibrosis (CF) and CFTR mutations associated with residual CF transmembrane conductance regulator (CFTR) function. Here we further assess the effect of ivacaftor in such patients using an N-of-1 study design. METHODS Patients aged ≥12 years with CF with clinical or molecular evidence of residual CFTR function were randomized to 1 of 4 treatment sequences for two 4-week, double-blind crossover cycles (each divided into 2 weeks of ivacaftor treatment and placebo) followed by 8 weeks of open-label ivacaftor treatment. The primary endpoint was absolute change from cycle baseline of percent predicted forced expiratory volume in 1 s (ppFEV 1 ) after 2 weeks of treatment with ivacaftor relative to placebo. RESULTS Absolute change (SD) from study baseline in ppFEV 1 favored ivacaftor by 2.3 (1.0) percentage points (95% credible interval, 0.4-4.1) after 2 weeks of treatment. Absolute mean change (SD) from open-label baseline (defined as day 1 of the open-label ivacaftor treatment period) in ppFEV 1 after 8 weeks of treatment was 4.7 (4.2) percentage points (P<.0001). Safety of ivacaftor was consistent with that observed in prior studies. CONCLUSIONS Ivacaftor improved lung function during the double-blind and open-label treatment periods in patients with CF and CFTR mutations associated with residual CFTR function (ClinicalTrials.gov, NCT01685801).",2020,"RESULTS Absolute change (SD) from study baseline in ppFEV 1 favored ivacaftor by 2.3 (1.0) percentage points (95% credible interval, 0.4-4.1) after 2 weeks of treatment.","['cystic fibrosis with residual function', 'patients with cystic fibrosis (CF) and CFTR mutations associated with residual CF transmembrane conductance regulator (CFTR) function', 'Patients aged ≥12 years with CF with clinical or molecular evidence of residual CFTR function']","['Ivacaftor', 'ivacaftor', 'ivacaftor treatment and placebo', 'open-label ivacaftor treatment']","['lung function', 'absolute change from cycle baseline of percent predicted forced expiratory volume in 1\xa0s (ppFEV 1 ', 'Absolute mean change (SD']","[{'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0855766', 'cui_str': 'Residual function'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C3264621', 'cui_str': 'ivacaftor'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]","[{'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.126125,"RESULTS Absolute change (SD) from study baseline in ppFEV 1 favored ivacaftor by 2.3 (1.0) percentage points (95% credible interval, 0.4-4.1) after 2 weeks of treatment.","[{'ForeName': 'Jerry A', 'Initials': 'JA', 'LastName': 'Nick', 'Affiliation': 'National Jewish Health, 1400 Jackson Street, Denver, CO 80206, United States. Electronic address: nickj@njhealth.org.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'St Clair', 'Affiliation': 'National Jewish Health, 1400 Jackson Street, Denver, CO 80206, United States. Electronic address: StClairC@njhealth.org.'}, {'ForeName': 'Marion C', 'Initials': 'MC', 'LastName': 'Jones', 'Affiliation': 'National Jewish Health, 1400 Jackson Street, Denver, CO 80206, United States. Electronic address: JonesM@NJHealth.org.'}, {'ForeName': 'Lan', 'Initials': 'L', 'LastName': 'Lan', 'Affiliation': 'Formerly of Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210, United States. Electronic address: lan012345@yahoo.com.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Higgins', 'Affiliation': 'Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London, W2 6BD, United Kingdom. Electronic address: mark_higgins@vrtx.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,['10.1016/j.jcf.2019.09.013'] 902,31726081,Gait-synchronized oscillatory brain stimulation modulates common neural drives to ankle muscles in patients after stroke: A pilot study.,"The present study aimed to investigate the long-term effects of gait intervention with transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency on the cortical control of muscle activity during gait, using coherence analyses, in patients after stroke. Eight chronic post-stroke patients participated in a single-blinded crossover study, and 7 patients completed the long-term intervention. Each patient received tACS over the primary motor cortex foot area on the affected side, which was synchronized with individual gait cycle frequency, and sham stimulation during treadmill gait in a random order. Electrical neuromuscular stimulation was used to assist the paretic ankle movement in both conditions. After gait intervention with tACS, beta band (15-35 Hz) coherence, which is considered to have a cortical origin, significantly increased in the paretic tibialis anterior (TA) muscle during 6-min of over-ground gait. The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance. These results indicate that gait intervention with tACS synchronized with gait cycle frequency may induce gait-specific plasticity that modulates the common neural drive to the TA motoneurons on the paretic side during gait and leads to changes in gait function in patients after stroke.",2020,The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance.,"['Eight chronic post-stroke patients', 'patients after stroke']","['tACS', 'Electrical neuromuscular stimulation', 'Gait-synchronized oscillatory brain stimulation', 'gait intervention with transcranial alternating current stimulation (tACS) synchronized with gait cycle frequency']","['gait distance', 'paretic tibialis anterior (TA) muscle', 'gait function', 'change in beta band coherence in the paretic TA muscle']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0442828', 'cui_str': 'Electrical (qualifier value)'}, {'cui': 'C0454448', 'cui_str': 'Neuromuscular stimulation (regime/therapy)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0870227', 'cui_str': 'Brain stimulation'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0242690', 'cui_str': 'Anterior Tibial Muscle'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}]",8.0,0.0293107,The change in beta band coherence in the paretic TA muscle was positively correlated with the change in gait distance.,"[{'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Kitatani', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Rehabilitation, Kansai Rehabilitation Hospital, Osaka, Japan. Electronic address: kitatani.ryosuke.88x@st.kyoto-u.ac.jp.'}, {'ForeName': 'Satoko', 'Initials': 'S', 'LastName': 'Koganemaru', 'Affiliation': 'Department of Physiology and Biological Information, Dokkyo Medical University, Tochigi, Japan.'}, {'ForeName': 'Ayaka', 'Initials': 'A', 'LastName': 'Maeda', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Mikami', 'Affiliation': 'Human Brain Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Masao', 'Initials': 'M', 'LastName': 'Matsuhashi', 'Affiliation': 'Department of Epilepsy, Movement Disorders and Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Tatsuya', 'Initials': 'T', 'LastName': 'Mima', 'Affiliation': 'Graduate School of Core Ethics and Frontier Sciences, Ritsumeikan University, Kyoto, Japan.'}, {'ForeName': 'Shigehito', 'Initials': 'S', 'LastName': 'Yamada', 'Affiliation': 'Department of Physical Therapy, Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}]",Neuroscience research,['10.1016/j.neures.2019.11.001'] 903,31172175,"Effect of different doses of supervised exercise on food intake, metabolism, and non-exercise physical activity: The E-MECHANIC randomized controlled trial.","BACKGROUND Exercise is recommended for weight management, yet exercise produces less weight loss than expected, which is called weight compensation. The mechanisms for weight compensation are unclear. OBJECTIVE The aim of this study was to identify the mechanisms responsible for compensation. METHODS In a randomized controlled trial conducted at an academic research center, adults (n = 198) with overweight or obesity were randomized for 24 wk to a no-exercise control group or 1 of 2 supervised exercise groups: 8 kcal/kg of body weight/wk (KKW) or 20 KKW. Outcome assessment occurred at weeks 0 and 24. Energy intake, activity, and resting metabolic rate (RMR) were measured with doubly labeled water (DLW; with and without adjustments for change in RMR), armband accelerometers, and indirect calorimetry, respectively. Appetite and compensatory health beliefs were measured by self-report. RESULTS A per-protocol analysis included 171 participants (72.5% women; mean ± SD baseline body mass index: 31.5 ± 4.7 kg/m2). Significant (P < 0.01) compensation occurred in the 8 KKW (mean: 1.5 kg; 95% CI: 0.9, 2.2 kg) and 20 KKW (mean: 2.7 kg; 95% CI: 2.0, 3.5 kg) groups, and compensation differed significantly between the exercise groups (P = 0.01). Energy intake by adjusted DLW increased significantly (P < 0.05) in the 8 KKW (mean: 90.7 kcal/d; 95% CI: 35.1, 146.4 kcal/d) and 20 KKW (mean: 123.6 kcal/d; 95% CI: 64.5, 182.7 kcal/d) groups compared with control (mean: -2.3 kcal/d; 95% CI: -58.0, 53.5 kcal/d). Results were similar without DLW adjustment. RMR and physical activity (excluding structured exercise) did not differentially change among the 3 groups. Participants with higher compared with lower compensation reported increased appetite ratings and beliefs that healthy behaviors can compensate for unhealthy behaviors. Furthermore, they increased craving for sweet foods, increased sleep disturbance, and had worsening bodily pain. CONCLUSIONS Compensation resulted from increased energy intake and concomitant increases in appetite, which can be treated with dietary or pharmacological interventions. Compensation was not due to activity or metabolic changes. This trial was registered at clinicaltrials.gov as NCT01264406.",2019,"Energy intake by adjusted DLW increased significantly (P < 0.05) in the 8 KKW (mean: 90.7 kcal/d; 95% CI: 35.1, 146.4 kcal/d) and 20 KKW (mean: 123.6 kcal/d; 95% CI: 64.5, 182.7 kcal/d) groups compared with control (mean: -2.3 kcal/d; 95% CI: -58.0, 53.5 kcal/d).","['academic research center, adults (n\xa0=\xa0198) with overweight or obesity', '171 participants (72.5% women; mean\xa0±\xa0SD baseline body mass index: 31.5\xa0±\xa04.7 kg/m2']","['no-exercise control group or 1 of 2 supervised exercise groups: 8 kcal/kg of body weight/wk (KKW) or 20 KKW', 'supervised exercise']","['Energy intake, activity, and resting metabolic rate (RMR', 'compensation', 'weight loss', 'Appetite and compensatory health beliefs', 'RMR and physical activity', 'craving for sweet foods, increased sleep disturbance', 'worsening bodily pain', 'food intake, metabolism, and non-exercise physical activity', 'energy intake', 'Energy intake by adjusted DLW', 'appetite ratings']","[{'cui': 'C0035168'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]","[{'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0152058', 'cui_str': 'Compensation (finding)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0814098', 'cui_str': 'Health belief'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0453865', 'cui_str': 'Sweet food (substance)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",198.0,0.204437,"Energy intake by adjusted DLW increased significantly (P < 0.05) in the 8 KKW (mean: 90.7 kcal/d; 95% CI: 35.1, 146.4 kcal/d) and 20 KKW (mean: 123.6 kcal/d; 95% CI: 64.5, 182.7 kcal/d) groups compared with control (mean: -2.3 kcal/d; 95% CI: -58.0, 53.5 kcal/d).","[{'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Johnson', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Candice A', 'Initials': 'CA', 'LastName': 'Myers', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Apolzan', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Conrad P', 'Initials': 'CP', 'LastName': 'Earnest', 'Affiliation': 'Texas A&M University, College Station, TX.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Thomas', 'Affiliation': 'United States Military Academy, West Point, NY.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Rood', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Neil M', 'Initials': 'NM', 'LastName': 'Johannsen', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Catrine', 'Initials': 'C', 'LastName': 'Tudor-Locke', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Harris', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Hsia', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Church', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, LA.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqz054'] 904,31773211,"A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.","RATIONALE Phosphodiesterase 10A inhibitor TAK-063 has shown effects that suggest efficacy in schizophrenia treatment. OBJECTIVE This randomized, double-blind, placebo-controlled, incomplete-crossover study investigated effects of single oral administration of TAK-063 on ketamine-induced changes in blood oxygen level-dependent (BOLD) signal in healthy males. METHODS Healthy men aged 18 to 45 years with normal magnetic resonance imaging (MRI) scans and electroencephalogram measurements at screening were eligible. Each subject was randomized to one of nine treatment schedules: all subjects received placebo and two of three doses of TAK-063 followed by ketamine. The primary endpoint was ketamine-induced brain activity in select regions of the brain during resting state. Secondary endpoints included pharmacokinetic parameters of TAK-063, proportion of subjects with treatment-emergent adverse events (AEs), and percentage of subjects meeting criteria for abnormal safety laboratory tests and vital sign measurements. RESULTS The study comprised 27 subjects. Prior to ketamine infusion, TAK-063 exerted region-specific effects on resting state functional MRI (fMRI) BOLD signal. After ketamine administration, TAK-063 reduced the Cohen's effect size for resting-state fMRI BOLD signal in key brain regions examined, and exerted similar effects on BOLD signal during the working memory task across all doses. TAK-063 was safe and well tolerated. CONCLUSIONS Our results are consistent with non-clinical studies of ketamine and TAK-063 and clinical studies of ketamine and risperidone. It is unknown whether these data are predictive of potential antipsychotic efficacy, and further analyses are required.",2020,"After ketamine administration, TAK-063 reduced the Cohen's effect size for resting-state fMRI BOLD signal in key brain regions examined, and exerted similar effects on BOLD signal during the working memory task across all doses.","['27 subjects', 'Healthy men aged 18 to 45 years with normal magnetic resonance imaging (MRI) scans and electroencephalogram measurements at screening were eligible', 'healthy males', 'healthy subjects']","['TAK-063', 'ketamine', 'placebo', 'TAK-063 followed by ketamine', 'ketamine and risperidone']","['fMRI BOLD signal', 'pharmacokinetic parameters of TAK-063, proportion of subjects with treatment-emergent adverse events (AEs), and percentage of subjects meeting criteria for abnormal safety laboratory tests and vital sign measurements', 'resting state functional MRI (fMRI) BOLD signal', 'safe and well tolerated', 'ketamine-induced brain activity in select regions of the brain during resting state', 'blood oxygen level-dependent (BOLD) signal', 'BOLD signal']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0441633'}, {'cui': 'C1527380', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3886479', 'cui_str': 'TAK-063'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0073393', 'cui_str': 'Risperidone'}]","[{'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C3886479', 'cui_str': 'TAK-063'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C2963216'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0443158', 'cui_str': 'Brain activity (observable entity)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0005768'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}]",27.0,0.179462,"After ketamine administration, TAK-063 reduced the Cohen's effect size for resting-state fMRI BOLD signal in key brain regions examined, and exerted similar effects on BOLD signal during the working memory task across all doses.","[{'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Yurgelun-Todd', 'Affiliation': 'The Brain Institute, University of Utah, 383 Colorow Drive, Salt Lake City, UT, 84108, USA. Deborah.Yurgelun-Todd@hsc.utah.edu.'}, {'ForeName': 'Perry F', 'Initials': 'PF', 'LastName': 'Renshaw', 'Affiliation': 'The Brain Institute, University of Utah, 383 Colorow Drive, Salt Lake City, UT, 84108, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Goldsmith', 'Affiliation': 'Takeda Development Center Europe, Ltd., 61 Aldwych, London, WC2B 4AE, UK.'}, {'ForeName': 'Tolga', 'Initials': 'T', 'LastName': 'Uz', 'Affiliation': 'Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL, 60015, USA.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Macek', 'Affiliation': 'Takeda Development Center Americas, Inc., One Takeda Parkway, Deerfield, IL, 60015, USA.'}]",Psychopharmacology,['10.1007/s00213-019-05366-1'] 905,31773210,Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [ 11 C]-(+)-PHNO.,"RATIONALE F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated in a randomized placebo-controlled clinical trial in patients with schizophrenia (Bitter et al. Neuropsychopharmacology 44(11):1917-1924, 2019). OBJECTIVE This open-label study in healthy male subjects aimed at characterizing F17464 binding to D3/D2 receptors and the time course of receptor occupancy using positron emission tomography (PET) imaging with a D3-preferring tracer, [ 11 C]-(+)-PHNO. METHODS PET scans were performed at baseline and following a single 30 mg or 15 mg dose of F17464 (3 subjects/dose), and blood samples were collected for pharmacokinetic analysis. Receptor occupancy was calculated based upon reduction in binding potential of the tracer following F17464 administration. The relationship between plasma F17464 concentration and D3/D2 receptor occupancy was modeled and the plasma concentration corresponding to 50% receptor occupancy (EC 50 ) calculated. RESULTS Both doses of F17464 robustly blocked [ 11 C]-(+)-PHNO D3 receptor binding, with substantial occupancy from 1 h post-administration, which increased at 6-9 h (89-98% and 79-87% for the 30 mg and 15 mg groups, respectively) and remained detectable at 22 h. In contrast, D2 binding was only modestly blocked at all time points (< 18%). F17464 exhibited a combination of rapid peripheral kinetics and hysteresis (persistence of binding 22 h post-dose despite low plasma concentration). The best estimate of the EC 50 was 19 ng ml -1 (~ 40 nM). CONCLUSION Overall, F17464 was strongly D3-selective in healthy volunteers, a unique profile for an antipsychotic candidate drug.",2020,"Both doses of F17464 robustly blocked [ 11 C]-(+)-PHNO D3 receptor binding, with substantial occupancy from 1 h post-administration, which increased at 6-9 h (89-98% and 79-87% for the 30 mg and 15 mg groups, respectively) and remained detectable at 22 h.","['healthy subjects with [ 11 C]-(+)-PHNO', 'patients with schizophrenia (Bitter et al', 'healthy male subjects', 'healthy volunteers']","['placebo', 'positron emission tomography']",['plasma F17464 concentration and D3/D2 receptor occupancy'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0302944', 'cui_str': '11C radioisotope'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}]",22.0,0.0770295,"Both doses of F17464 robustly blocked [ 11 C]-(+)-PHNO D3 receptor binding, with substantial occupancy from 1 h post-administration, which increased at 6-9 h (89-98% and 79-87% for the 30 mg and 15 mg groups, respectively) and remained detectable at 22 h.","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Slifstein', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, 11794, USA. mark.slifstein@stonybrookmedicine.edu.'}, {'ForeName': 'Anissa', 'Initials': 'A', 'LastName': 'Abi-Dargham', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, 11794, USA.'}, {'ForeName': 'Ragy R', 'Initials': 'RR', 'LastName': 'Girgis', 'Affiliation': 'New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.'}, {'ForeName': 'Raymond F', 'Initials': 'RF', 'LastName': 'Suckow', 'Affiliation': 'New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Cooper', 'Affiliation': 'Nathan Kline Research Institute, 140 Old Orangeburg Road, Orangeburg, New York, NY, 10962, USA.'}, {'ForeName': 'Chaitanya R', 'Initials': 'CR', 'LastName': 'Divgi', 'Affiliation': 'Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Sokoloff', 'Affiliation': 'PSAdvice, Impasse Larosa, F-56780, Ile-aux-Moines, France.'}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Leriche', 'Affiliation': 'Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Carberry', 'Affiliation': 'Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA.'}, {'ForeName': 'Shunichi', 'Initials': 'S', 'LastName': 'Oya', 'Affiliation': 'Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA.'}, {'ForeName': 'Simon K', 'Initials': 'SK', 'LastName': 'Joseph', 'Affiliation': 'Columbia University Medical Center Kreitchman PET Center, 772 W 168 Street, R-114, New York, NY, 10032, USA.'}, {'ForeName': 'Marlène', 'Initials': 'M', 'LastName': 'Guiraud', 'Affiliation': 'Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France.'}, {'ForeName': 'Agnès', 'Initials': 'A', 'LastName': 'Montagne', 'Affiliation': 'Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Brunner', 'Affiliation': 'IRIS Servier, 50 Rue Carnot, 92150, Suresnes, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Gaudoux', 'Affiliation': 'Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Tonner', 'Affiliation': 'Institut de Recherche Pierre Fabre (IRPF), 3 avenue Hubert Curien, 31100, Toulouse, France.'}]",Psychopharmacology,['10.1007/s00213-019-05387-w'] 906,31767788,"The effect of flavoured and non-flavoured tobacco on subjective experience, topography and toxicant exposure among waterpipe smokers.","INTRODUCTION Flavoured waterpipe (WP) tobacco is a major factor in the resurgence of WP smoking and a main attractant of WP use among youth. Yet, evidence of the effects of limiting flavour on WP smoker's experiences and exposures is limited. This study examined the impact of flavour manipulation on WP smokers' toxicant exposure and smoking experiences. METHOD A total of 144 WP smokers attended two, 45 min ad libitum smoking sessions (flavoured vs non-flavoured tobacco) in a crossover design study. Participants completed a battery of questions assessing subjective smoking experiences. Exhaled carbon monoxide (eCO) and plasma nicotine concentrations were measured before and after the smoking sessions. Puff topography was recorded throughout the smoking sessions. RESULTS Compared with the non-flavoured WP tobacco, participants reported enhanced subjective smoking measures of satisfaction and enjoyment following smoking flavoured WP tobacco (ps <0.05). Although participants spent a longer time smoking flavoured tobacco, they took on average larger puffs while smoking the non-flavoured tobacco (ps <0.05). Greater levels of eCO were recorded following the non-flavoured tobacco session (p<0.05) compared with flavoured tobacco. No significant differences were observed in plasma nicotine concentrations between the two tobacco conditions. WP harm perception was higher among participants after smoking non-flavoured WP tobacco compared with their preferred flavour (p<0.05). CONCLUSION Smoking the flavoured tobacco product was associated with enhanced subjective experiences compared with the non-flavoured, suggesting a potential role for flavour regulation in reducing WP use. Mixed results were observed for toxicants exposure in relation to smoking flavoured compared with non-flavoured products suggesting the need for a more comprehensive assessment of the effects of other tobacco constituents and additives on toxicant exposure in WP smokers.",2020,"Compared with the non-flavoured WP tobacco, participants reported enhanced subjective smoking measures of satisfaction and enjoyment following smoking flavoured WP tobacco (ps <0.05).","['waterpipe smokers', '144 WP smokers attended two, 45\u2009min ad']","['flavour manipulation', 'flavoured and non-flavoured tobacco', 'libitum smoking sessions (flavoured vs non-flavoured tobacco', 'Flavoured waterpipe (WP) tobacco']","['Puff topography', 'Exhaled carbon monoxide (eCO) and plasma nicotine concentrations', 'enhanced subjective smoking measures of satisfaction and enjoyment', 'WP harm perception', 'Greater levels of eCO', 'plasma nicotine concentrations']","[{'cui': 'C4302493', 'cui_str': 'Smoking Water Pipes'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C4505131', 'cui_str': 'Tobacco, Waterpipe'}]","[{'cui': 'C1533107', 'cui_str': 'Puffs'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0167816,"Compared with the non-flavoured WP tobacco, participants reported enhanced subjective smoking measures of satisfaction and enjoyment following smoking flavoured WP tobacco (ps <0.05).","[{'ForeName': 'Ziyad', 'Initials': 'Z', 'LastName': 'Ben Taleb', 'Affiliation': 'Kinesiology, University of Texas at Arlington, Arlington, Texas, USA.'}, {'ForeName': 'Mayra', 'Initials': 'M', 'LastName': 'Vargas', 'Affiliation': 'Epidemiology, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ebrahimi Kalan', 'Affiliation': 'Epidemiology, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Breland', 'Affiliation': 'Psychology, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Eissenberg', 'Affiliation': 'Psychology and Inst. for Drug/Alc. Studies, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Brown', 'Affiliation': 'Division of Family and College of Medicine Community Medicine, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Wasim', 'Initials': 'W', 'LastName': 'Maziak', 'Affiliation': 'Epidemiology, Florida International University, Miami, Florida, USA wmaziak@fiu.edu.'}]",Tobacco control,['10.1136/tobaccocontrol-2019-054972'] 907,31794848,"The Interaction Between Mild Cognitive Impairment with Vestibulo-ocular Reflex, Dynamic Visual Acuity and Postural Balance in Older Adults.","BACKGROUND Approximately 30% of the elderly population is falling each year, resulting in a major health problem. Cognitive decline is an independent risk factor for fall. Mild cognitive impairment (MCI) is a cognitive decline that is higher than expected in the subjects' age but does not affect the activities of daily living OBJECTIVE: In the study, vestibulo-ocular reflexes, dynamic visual acuities and postural balances of subjects with mild cognitive impairment were evaluated and compared with the healthy control group. METHODS For this purpose, 10 subjects with mild cognitive impairment and 10 healthy subjects from the same age group were included in the study. After the hearing test was applied to the subjects, videonistagmography, dynamic visual acuity and computerized dynamic posturography measurements were performed. RESULTS Computerized Dynamic Posturography VEST parameter, SOT (Sensory Organization Test) 2, SOT 3, SOT 6 and Composite Balance Scores were significantly lower in the MCI group. There was no significant difference between the two groups in terms of videonistagmographic measurements. Dynamic Visual Acuity Perception Time Test scores of the subjects with mild cognitive impairment were significantly longer compared to the control group (p < 0.05). CONCLUSION As a result of the study, it was concluded that subjects with mild cognitive impairment were more prone to fall compared to control group and that these subjects should be included in fall prevention rehabilitation programs.",2020,"Dynamic Visual Acuity Perception Time Test scores of the subjects with mild cognitive impairment were significantly longer compared to the control group (p < 0.05). ","['10 subjects with mild cognitive impairment and 10 healthy subjects from the same age group were included in the study', 'Older Adults', 'subjects with mild cognitive impairment']",['Computerized Dynamic Posturography'],"['vestibulo-ocular reflexes, dynamic visual acuities and postural balances', 'mild cognitive impairment', 'Dynamic Visual Acuity Perception Time Test scores', 'Mild cognitive impairment (MCI', 'VEST parameter, SOT (Sensory Organization Test) 2, SOT 3, SOT 6 and Composite Balance Scores', 'videonistagmographic measurements']","[{'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}]","[{'cui': 'C0034944', 'cui_str': 'Reflexes, Vestibo-Ocular'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1256755', 'cui_str': 'Postural Equilibrium'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0453884', 'cui_str': 'Waistcoat'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C4720873', 'cui_str': 'Sensory organization test (assessment scale)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",,0.0163818,"Dynamic Visual Acuity Perception Time Test scores of the subjects with mild cognitive impairment were significantly longer compared to the control group (p < 0.05). ","[{'ForeName': 'Mine', 'Initials': 'M', 'LastName': 'Baydan', 'Affiliation': 'Ankara University, Department of Audiology, Ankara, Turkey. Electronic address: mbaydan@hotmail.com.'}, {'ForeName': 'Hatice', 'Initials': 'H', 'LastName': 'Caliskan', 'Affiliation': 'Hacettepe University, Department of Geriatrics, Ankara, Turkey.'}, {'ForeName': 'Burcu', 'Initials': 'B', 'LastName': 'Balam-Yavuz', 'Affiliation': 'Hacettepe University, Department of Geriatrics, Ankara, Turkey.'}, {'ForeName': 'Songul', 'Initials': 'S', 'LastName': 'Aksoy', 'Affiliation': 'Hacettepe University, Department of Audiology, Ankara, Turkey.'}, {'ForeName': 'Bilgehan', 'Initials': 'B', 'LastName': 'Böke', 'Affiliation': 'Hacettepe University, Department of Audiology, Ankara, Turkey.'}]",Experimental gerontology,['10.1016/j.exger.2019.110785'] 908,31184938,CNR1 and FAAH variation and affective states induced by marijuana smoking.,"Background : Polymorphisms in cannabinoid receptor type 1 (encoded by CNR1 ) and fatty acid amide hydrolase (encoded by FAAH ) have been associated with cannabis dependence, but it remains unknown whether variation within these genes influences cannabis' acute effects on affect. Objective : Conduct a secondary data analysis study to determine whether previously observed acute effects of tetrahydrocannabinol (THC) on mood was dependent upon variation in CNR1 and FAAH . Methods : A balanced placebo design was used crossing marijuana administration (i.e., 0% THC vs. 2.8% THC) with stimulus expectancy. Participants (N = 118; 64% male) provided DNA and completed the Profile of Mood States questionnaire prior to and after smoking. Haplotypes were constructed from genotyped single nucleotide polymorphisms for CNR1 (rs1049353 and rs806368) and FAAH (rs4141964, rs324420, and rs11576941); rs2023239 ( CNR1 ) and rs6703669 ( FAAH ) were not part of a phased haplotype block. Analyses tested both main and interaction effects for genotype across CNR1 and FAAH , and drug, and expectancy effects. Results : THC increased levels of POMS Tension-Anxiety and Confusion-Bewilderment over and above the effects of variation in CNR1 and FAAH . Significant drug X genotype/haplotype and expectancy X genotype/haplotype interaction effects were observed for some but not all mood states [e.g., 'C' allele carriers of rs2023239 who received THC had higher levels of Anger-Hostility ( β = 0.29 (0.12), p = .02) compared to those who received placebo]. Conclusion : These preliminary findings suggest individual differences in mood states after using marijuana depend on genetic variation. Such information might be useful in understanding either motivation for use of marijuana and/or risk for associated behaviors.",2019,"Significant drug X genotype/haplotype and expectancy X genotype/haplotype interaction effects were observed for some but not all mood states [e.g., 'C' allele carriers of rs2023239 who received THC had higher levels of Anger-Hostility ( β = 0.29 (0.12), p = .02) compared to those who received placebo]. ",['Participants (N = 118; 64% male) provided DNA and completed the Profile of Mood States questionnaire prior to and after smoking'],"['tetrahydrocannabinol (THC', 'THC', 'placebo']","['Significant drug X genotype/haplotype and expectancy X genotype/haplotype interaction effects', 'levels of Anger-Hostility', 'CNR1 and FAAH variation and affective states', 'POMS Tension-Anxiety and Confusion-Bewilderment']","[{'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states (assessment scale)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1285573', 'cui_str': 'Genotype determination'}, {'cui': 'C0018591', 'cui_str': 'Haplotypes'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0002957', 'cui_str': 'Anger'}, {'cui': 'C0020039', 'cui_str': 'Hostility'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0233494', 'cui_str': 'Tension (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009676', 'cui_str': 'Confusional State'}, {'cui': 'C0813178', 'cui_str': 'Bewilderment'}]",,0.172903,"Significant drug X genotype/haplotype and expectancy X genotype/haplotype interaction effects were observed for some but not all mood states [e.g., 'C' allele carriers of rs2023239 who received THC had higher levels of Anger-Hostility ( β = 0.29 (0.12), p = .02) compared to those who received placebo]. ","[{'ForeName': 'Rohan H C', 'Initials': 'RHC', 'LastName': 'Palmer', 'Affiliation': 'a Department of Psychology at Emory University, Behavioral Genetics of Addiction Laboratory , Atlanta , GA , USA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'McGeary', 'Affiliation': 'b Providence Veterans Affairs Medical Center , Providence , RI , USA.'}, {'ForeName': 'Valerie S', 'Initials': 'VS', 'LastName': 'Knopik', 'Affiliation': 'e Human Development and Family Studies, Purdue University , West Lafayette , IN , USA.'}, {'ForeName': 'L Cinnamon', 'Initials': 'LC', 'LastName': 'Bidwell', 'Affiliation': 'f Institute for Cognitive Science, University of Colorado at Boulder , Boulder , CO , USA.'}, {'ForeName': 'Jane M', 'Initials': 'JM', 'LastName': 'Metrik', 'Affiliation': 'b Providence Veterans Affairs Medical Center , Providence , RI , USA.'}]",The American journal of drug and alcohol abuse,['10.1080/00952990.2019.1614596'] 909,31182369,Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis.,"BACKGROUND Eluforsen is an antisense oligonucleotide designed to bind to the mRNA region around the F508-encoding deletion and restore the cystic fibrosis transmembrane conductance regulator (CFTR) protein function in the airway epithelium. We assessed the safety and tolerability, pharmacokinetics and exploratory measures of efficacy of inhaled eluforsen in cystic fibrosis (CF) patients homozygous for the F508del-CFTR mutation. METHODS This randomised, double-blind, placebo-controlled, dose escalation 1b study recruited adult CF subjects with a FEV 1  > 70% predicted in four single ascending dose cohorts and four multiple ascending dose cohorts. Primary objectives were safety and tolerability. Secondary endpoints included pharmacokinetics, percent predicted forced expiratory volume in 1 s (ppFEV 1 ), and Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptom Score (RSS). RESULTS Single and multiple doses of inhaled eluforsen up to 50 mg were safe and well tolerated. A maximum tolerated dose was not established. Systemic exposure was low in all cohorts and lung function remained stable throughout the study. Three of four eluforsen-treated groups in the MAD study demonstrated an improvement in CFQ-R RSS at end of treatment with adjusted mean change from baseline values ranging from 6.4 to 12.7 points. In comparison, there was a mean decrease of 6.5 points in the placebo group from baseline to end of treatment. CONCLUSIONS Inhaled eluforsen up to 50 mg dosed 3 times per week for 4 weeks was safe and well tolerated, showed low systemic exposure, and demonstrated improvement in CFQ-R RSS, a relevant measure of clinical benefit in CF patients.",2020,Three of four eluforsen-treated groups in the MAD study demonstrated an improvement in CFQ-R RSS at end of treatment with adjusted mean change from baseline values ranging from 6.4 to 12.7 points.,"['adult CF subjects with a FEV 1 \u202f>\u202f70% predicted in four single ascending dose cohorts and four multiple ascending dose cohorts', 'cystic fibrosis (CF) patients homozygous for the F508del-CFTR mutation', 'F508DEL cystic fibrosis']","['placebo', 'inhaled eluforsen']","['safe and well tolerated', 'safety and tolerability', 'pharmacokinetics, percent predicted forced expiratory volume in 1\u202fs (ppFEV 1 ), and Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptom Score (RSS', 'CFQ-R RSS', 'Systemic exposure', 'safety and tolerability, pharmacokinetics and exploratory measures of efficacy']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205385', 'cui_str': 'Ascending (qualifier value)'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0037090', 'cui_str': 'Signs and Symptoms, Respiratory'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2699011', 'cui_str': 'Really Simple Syndication'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",,0.0838914,Three of four eluforsen-treated groups in the MAD study demonstrated an improvement in CFQ-R RSS at end of treatment with adjusted mean change from baseline values ranging from 6.4 to 12.7 points.,"[{'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Drevinek', 'Affiliation': 'Department of Medical Microbiology and Department of Paediatrics, Motol University Hospital and Second Faculty of Medicine, Charles University, V Uvalu, 84, Prague 15006, Czech Republic.'}, {'ForeName': 'Tacjana', 'Initials': 'T', 'LastName': 'Pressler', 'Affiliation': 'Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, Copenhagen 02100, Denmark.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Cipolli', 'Affiliation': 'Cystic Fibrosis Centre -Azienda, Ospedaliera Universitaria Integrata di Verona, P. le Stefani 1, Verona 37126, Italy; Cystic Fibrosis Centre, Azienda Ospedaliera Universitaria di Ancona, via Conca 71, Ancona 60020, Italy.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'De Boeck', 'Affiliation': 'University Hospital of Leuven, University of Leuven, Herestraat 49, 3000 Leuven, Belgium.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Schwarz', 'Affiliation': 'Charité Universitätsmedizin Berlin, Mittelallee 4, Augustenburger Platz 1, Berlin 13353, Germany.'}, {'ForeName': 'Florilene', 'Initials': 'F', 'LastName': 'Bouisset', 'Affiliation': ""Cytel, Route de Pre-Bois, 20, 1216 Geneva, Switzerland; GSK Consumer Health, Route de l'Etraz 2, 1260 Nyon, Switzerland.""}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Boff', 'Affiliation': 'Cytel, Route de Pre-Bois, 20, 1216 Geneva, Switzerland.'}, {'ForeName': 'Noreen', 'Initials': 'N', 'LastName': 'Henig', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands; Breath Therapeutics Inc., 633 Menlo Ave Ste 230, Menlo Park, CA, USA.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Paquette-Lamontagne', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands; Blueprint Medicines Corporation, 45 Sidney St., Cambridge, MA 02139, USA.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Montgomery', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands; Gyroscope Therapeutics, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Herts SG1 2FX, UK.'}, {'ForeName': 'Jaakko', 'Initials': 'J', 'LastName': 'Perquin', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Tomkinson', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.'}, {'ForeName': 'Wilhelmina', 'Initials': 'W', 'LastName': 'den Hollander', 'Affiliation': 'ProQR Therapeutics, Zernikedreef 9, 2333 CK Leiden, the Netherlands.'}, {'ForeName': 'J Stuart', 'Initials': 'JS', 'LastName': 'Elborn', 'Affiliation': 'Faculty of Medicine, Health & Life Sciences, 90 Lisburn Road, Belfast BT9 6AG, Northern Ireland. Electronic address: s.elborn@qub.ac.uk.'}]",Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,['10.1016/j.jcf.2019.05.014'] 910,31199555,Parent Psychological Distress: A Moderator of Behavioral Health Intervention Outcomes among Justice-Involved Adolescents.,"We examined whether pre-existing parent psychological distress moderated juvenile offenders' substance use, sexual risk, and mental health outcomes in a randomized trial. Forty-seven parent-adolescent dyads received either Family-based Affect Management Intervention (FAMI) for adolescent substance use and HIV prevention or adolescent-only Health Promotion Intervention (HPI). Parents' self-reported distress at baseline significantly moderated adolescents' self-reported marijuana use and alcohol use but not other outcomes at 3 months postintervention, producing crossover interactions. FAMI outperformed HPI when parents reported high-level distress, whereas HPI outperformed FAMI when parents reported low-level distress. This finding that the relative efficacy of interventions depends on the severity of parent psychological distress could inform efforts to match substance-using, justice-involved adolescents with the intervention most likely to benefit them.",2020,"Parents' self-reported distress at baseline significantly moderated adolescents' self-reported marijuana use and alcohol use but not other outcomes at 3 months postintervention, producing crossover interactions.","['Justice-Involved Adolescents', 'Forty-seven parent-adolescent dyads']",['Family-based Affect Management Intervention (FAMI) for adolescent substance use and HIV prevention or adolescent-only Health Promotion Intervention (HPI'],[],"[{'cui': 'C0022437', 'cui_str': 'Justice'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0018738', 'cui_str': 'Health Promotion'}]",[],47.0,0.0221786,"Parents' self-reported distress at baseline significantly moderated adolescents' self-reported marijuana use and alcohol use but not other outcomes at 3 months postintervention, producing crossover interactions.","[{'ForeName': 'Mei Yi', 'Initials': 'MY', 'LastName': 'Ng', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Tolou-Shams', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Galbraith', 'Affiliation': 'University of California, San Francisco.'}, {'ForeName': 'Larry K', 'Initials': 'LK', 'LastName': 'Brown', 'Affiliation': 'Alpert Medical School of Brown University.'}]",Journal of research on adolescence : the official journal of the Society for Research on Adolescence,['10.1111/jora.12512'] 911,31197218,Vitamin D supplementation has no effects on progression of motor dysfunction in amyotrophic lateral sclerosis (ALS).,"OBJECTIVES To investigate the effects of cholecalciferol supplementation on the progression of motor disability in a cohort of amyotrophic lateral sclerosis (ALS) patients with low blood 25-hydroxyvitamin D3 [25(OH)D] levels, on the basis of the hypothesis of potential neuroprotective effects of vitamin D supplementation. METHODS Forty-eight ALS patients, 34 with deficient (<20 ng/mL) and 14 with insufficient (20-29 ng/mL) serum levels of 25(OH)D, were randomized and treated by 3 different doses of cholecalciferol [50.000, 75.000 and 100.000 international units (IU) /month] and evaluated after 6-months. Assessment of motor dysfunction at baseline and after 6 months included ALS Functional Rating Scale-Revised (ALFRS-R) and upper motor neuron (UMN) scores and blood samples for 25(OH)D levels. RESULTS Clinical data of 33 patients were available after 6 months. Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol. Conversely, the treatment with 75.000 IU/month or 100.000 IU/month induced a significant increase in serum levels of 25(OH)D in comparison with the supplementation with 50.000 IU/month; no significant differences were found between 75.000 IU/month and 100.000 IU/month. CONCLUSIONS Our findings highlighted that 6-month supplementation of vitamin D in ALS patients had no significant effects on motor dysfunction. However, it is recommended to prevent medical complications of vitamin D deficiency in ALS patients as well as in other populations of neurodegenerative patients, characterized by low mobility and decreased sun exposure.",2020,"Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol.","['ALS patients', 'Forty-eight ALS patients, 34 with deficient (<20\u2009ng/mL) and 14 with insufficient (20-29\u2009ng/mL) serum levels of 25(OH)D', 'amyotrophic lateral sclerosis (ALS', 'amyotrophic lateral sclerosis (ALS) patients with low blood 25-hydroxyvitamin D3 [25(OH)D']","['vitamin D', 'vitamin D supplementation', 'Vitamin D supplementation', 'cholecalciferol supplementation', 'cholecalciferol']","['ALS Functional Rating Scale-Revised (ALFRS-R) and upper motor neuron (UMN) scores and blood samples for 25(OH)D levels', 'ALSFRS-R', 'motor dysfunction', 'serum levels of 25(OH)D']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0231180', 'cui_str': 'Insufficient'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0002736', 'cui_str': 'ALS (Amyotrophic Lateral Sclerosis)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0242215', 'cui_str': 'Cholecalciferols'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0524458', 'cui_str': 'Upper motor neuron (cell)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0521654', 'cui_str': 'Neurologic Deficits'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",48.0,0.0938312,"Analysis of Covariance (ANCOVA), with pre-treatment measurements included as covariate, did not show statistically significant differences in the ALSFRS-R (p > 0.05) and UMN (p > 0.05) among the patient groups who underwent 3 different doses of cholecalciferol.","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Trojsi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy. francesca.trojsi@unicampania.it.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Siciliano', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Passaniti', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Alvino', 'Initials': 'A', 'LastName': 'Bisecco', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Russo', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Lavorgna', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Esposito', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Ricciardi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Maria Rosaria', 'Initials': 'MR', 'LastName': 'Monsurrò', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Gioacchino', 'Initials': 'G', 'LastName': 'Tedeschi', 'Affiliation': 'Department of Advanced Medical and Surgical Sciences; MRI Research Centre ""SUN-FISM"", University of Campania ""Luigi Vanvitelli"", Naples, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Santangelo', 'Affiliation': 'Department of Psychology, University of Campania ""Luigi Vanvitelli"", Caserta, Italy.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0448-3'] 912,31178096,Effects of L-DOPA Monotherapy on Psychomotor Speed and [ 11 C]Raclopride Binding in High-Risk Older Adults With Depression.,"BACKGROUND A high-risk subgroup of older patients with depression has slowed processing and gait speeds. This study examined whether carbidopa/levodopa (L-DOPA) monotherapy increased dopamine availability, increased processing/gait speed, and relieved depressive symptoms. METHODS Adult outpatients with depression >59 years old underwent baseline [ 11 C]raclopride positron emission tomography followed by open L-DOPA for 3 weeks (1 week each of 150 mg, 300 mg, and 450 mg). Generalized estimating equations tested the pre- and post-L-DOPA differences in processing and gait speed measures, depressive symptoms, and reported side effects. The decrease in binding potential between the pre- and posttreatment scans indexed enhanced synaptic dopamine availability induced by L-DOPA treatment. RESULTS Thirty-six subjects participated (age, 75.3 ± 7.5 years; 44.4% male). Significant, dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: processing speed factor score effect size = 0.41, p = .001; dual-task gait speed effect size = 0.43, p = .002). [ 11 C]raclopride decrease in binding potential was significantly different from 0 in sensorimotor (t 24 = -4.85, p < .001) and associative striatum (t 24  = -2.52, p = .019) but not in limbic striatum (t 24  = 0.265, p = .793). Depressive symptoms decreased significantly on the Hamilton Rating Scale for Depression (effect size = -0.37, p = .002). Dropout rate was 8.3%, and nausea was the most frequently reported side effect. CONCLUSIONS By enhancing availability of dopamine, L-DOPA improved processing and gait speed in older adults with depression and significantly decreased [ 11 C]raclopride binding in selected striatal subregions.",2019,"Significant, dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: processing speed factor score effect size =","['Adult outpatients with depression', 'older patients with depression', 'older adults with depression', '59 years old underwent baseline [ 11', 'High-Risk Older Adults With Depression', 'Thirty-six subjects participated (age, 75.3 ± 7.5 years; 44.4% male']","['carbidopa/levodopa (L-DOPA', 'C]raclopride positron emission tomography followed by open L-DOPA', 'dopamine, L-DOPA', 'L-DOPA Monotherapy']","['binding potential', 'synaptic dopamine availability', 'limbic striatum', 'Depressive symptoms', 'processing and gait speed', 'associative striatum', 'Dropout rate', 'Hamilton Rating Scale for Depression (effect size\xa0', 'dopamine availability, increased processing/gait speed, and relieved depressive symptoms', 'nausea']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0353697', 'cui_str': 'Carbidopa / Levodopa'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0032743', 'cui_str': 'Positron-Emission Tomography'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}]","[{'cui': 'C1145667', 'cui_str': 'Binding - action (qualifier value)'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression (assessment scale)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C1301771', 'cui_str': 'Relieved'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",36.0,0.0336971,"Significant, dose-dependent increases in processing and gait speed were observed with L-DOPA (450-mg dose: processing speed factor score effect size =","[{'ForeName': 'Bret R', 'Initials': 'BR', 'LastName': 'Rutherford', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York. Electronic address: brr8@cumc.columbia.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Slifstein', 'Affiliation': 'Stony Brook University Renaissance College of Medicine, Stony Brook, New York.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.'}, {'ForeName': 'Anissa', 'Initials': 'A', 'LastName': 'Abi-Dargham', 'Affiliation': 'Stony Brook University Renaissance College of Medicine, Stony Brook, New York.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Brown', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.'}, {'ForeName': 'Melanie W', 'Initials': 'MW', 'LastName': 'Wall', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Vanegas-Arroyave', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York.'}, {'ForeName': 'Yaakov', 'Initials': 'Y', 'LastName': 'Stern', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Bailey', 'Affiliation': 'New York State Psychiatric Institute, New York, New York.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Valente', 'Affiliation': 'New York State Psychiatric Institute, New York, New York.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Roose', 'Affiliation': 'Columbia University Vagelos College of Physicians and Surgeons, New York, New York; New York State Psychiatric Institute, New York, New York.'}]",Biological psychiatry,['10.1016/j.biopsych.2019.04.007'] 913,30397735,Post-obturation pain following the use of carrier-based system with AH Plus or iRoot SP sealers: a randomized controlled clinical trial.,"OBJECTIVES The aim of this study was to compare the postoperative pain after root canal treatment using a carrier-based obturation system and two different sealers. MATERIALS AND METHODS In this prospective randomized clinical trial, 160 patients were selected. Patients with vital and devital teeth were randomized into four groups using a randomized block design with block sizes of 10 patients each. The groups were devital/vital teeth treated with iRoot SP sealer and devital/vital teeth treated with AH Plus sealer. Patients were prescribed ibuprofen, a 200-mg analgesic, if needed, and postoperative pain was recorded by visual analogue scale at 6, 12, 24, and 72 h after obturation. Pain score and frequency of tablet intake were recorded and statistically analyzed. RESULTS Results showed that there was no significant difference between groups in the incidence of postoperative pain; however, iRoot SP sealer was associated with less analgesic intake compared to AH Plus sealer. CONCLUSION The use of different sealers did not significantly affect pain levels. CLINICAL RELEVANCE iRoot SP sealer was associated with less analgesic intake compared to AH Plus sealer.",2019,"RESULTS Results showed that there was no significant difference between groups in the incidence of postoperative pain; however, iRoot SP sealer was associated with less analgesic intake compared to AH Plus sealer. ","['160 patients were selected', 'Patients with vital and devital teeth']","['ibuprofen', 'root canal treatment using a carrier-based obturation system and two different sealers', 'iRoot SP sealers', 'carrier-based system with AH', 'iRoot SP sealer and devital/vital teeth treated with AH Plus sealer']","['postoperative pain', 'Pain score and frequency of tablet intake', 'analgesic intake', 'incidence of postoperative pain', 'pain levels']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442732', 'cui_str': 'Vital (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}]","[{'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0086881', 'cui_str': 'Root Canal'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction (morphologic abnormality)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0449942', 'cui_str': 'Sealer (attribute)'}, {'cui': 'C4508447', 'cui_str': 'iRoot SP'}, {'cui': 'C0442732', 'cui_str': 'Vital (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0673096', 'cui_str': 'AH Plus'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",160.0,0.08484,"RESULTS Results showed that there was no significant difference between groups in the incidence of postoperative pain; however, iRoot SP sealer was associated with less analgesic intake compared to AH Plus sealer. ","[{'ForeName': 'Ayfer', 'Initials': 'A', 'LastName': 'Atav Ates', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey. ayfer.atav@okan.edu.tr.'}, {'ForeName': 'Aysin', 'Initials': 'A', 'LastName': 'Dumani', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Oguz', 'Initials': 'O', 'LastName': 'Yoldas', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Ilker', 'Initials': 'I', 'LastName': 'Unal', 'Affiliation': 'Department of Biostatistics, Faculty of Medicine, Cukurova University, Adana, Turkey.'}]",Clinical oral investigations,['10.1007/s00784-018-2721-6'] 914,31764011,Inflationary noninvasive blood pressure measurement reduces the incidence of subcutaneous hemorrhage.,"OBJECTIVE We verified the hypothesis that in noninvasive blood pressure (NIBP) measurement, inflationary NIBP measurement using the new type of cuff (YP-71xT series, Nihon Koden, Tokyo, Japan) might be associated with a reduced risk of subcutaneous hemorrhage. METHODS The study involved 30 healthy volunteers (15 males and 15 females). The blood pressure was measured by deflationary NIBP measurement + conventional cuff (control group), deflationary NIBP measurement + cuff (YP-71xT series) (deflationary measurement group), or inflationary NIBP measurement + cuff (YP-71xT series) (inflationary measurement group). NIBP measurement was performed five times in a row, then the presence or of subcutaneous hemorrhage was evaluated. The three different methods were used as cross-over design at 1-week interval for each subject so that all three methods were used for all the subjects. RESULTS The measurement time was significantly shorter in the inflationary measurement group than other groups. The incidence of subcutaneous hemorrhage significantly was lower in the inflationary measurement group (3%) than in control group (53%) (P < 0.001) and the deflationary measurement group (37%) (P = 0.002). CONCLUSION This study revealed that inflationary NIBP measurement was associated with a dramatically reduced incidence of subcutaneous hemorrhage. Synergistic effect of the newly designed cuff, short measurement time, and low inflation pressure may allow the risk of subcutaneous hemorrhage.",2020,"The incidence of subcutaneous hemorrhage significantly was lower in the inflationary measurement group (3%) than in control group (53%) (P < 0.001) and the deflationary measurement group (37%) (P = 0.002). ",['30 healthy volunteers (15 males and 15 females'],"['Inflationary noninvasive blood pressure measurement', 'deflationary NIBP measurement + conventional cuff (control group), deflationary NIBP measurement + cuff (YP-71xT series) (deflationary measurement group), or inflationary NIBP measurement + cuff (YP-71xT series) (inflationary measurement group']","['NIBP measurement', 'blood pressure', 'incidence of subcutaneous hemorrhage', 'subcutaneous hemorrhage', 'measurement time', 'noninvasive blood pressure (NIBP) measurement, inflationary NIBP measurement']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0005824', 'cui_str': 'Blood pressure taking (procedure)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205549', 'cui_str': 'Series (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking (procedure)'}]",30.0,0.019325,"The incidence of subcutaneous hemorrhage significantly was lower in the inflationary measurement group (3%) than in control group (53%) (P < 0.001) and the deflationary measurement group (37%) (P = 0.002). ","[{'ForeName': 'Shizuko', 'Initials': 'S', 'LastName': 'Nukita', 'Affiliation': 'Departments of Nursing.'}, {'ForeName': 'Sumie', 'Initials': 'S', 'LastName': 'Nakano', 'Affiliation': 'Departments of Nursing.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Morimoto', 'Affiliation': 'Anesthesia, Ube Industries Central Hospital, Ube, Japan.'}, {'ForeName': 'Hiroko', 'Initials': 'H', 'LastName': 'Shiramoto', 'Affiliation': 'Anesthesia, Ube Industries Central Hospital, Ube, Japan.'}]",Blood pressure monitoring,['10.1097/MBP.0000000000000418'] 915,31180608,Quality assessment of fetal middle cerebral and umbilical artery Doppler images using an objective scale within an international randomized controlled trial.,"OBJECTIVES To determine the quality of Doppler images of the fetal middle cerebral artery (MCA) and umbilical artery (UA) using an objective scale, and to determine the reliability of this scale, within a multicenter randomized controlled trial (Revealed versus concealed criteria for placental insufficiency in unselected obstetric population in late pregnancy (Ratio37)). METHODS The Ratio37 trial is an ongoing randomized, open-label, multicenter controlled study of women with a low-risk pregnancy recruited at 20 weeks. Doppler measurements of the fetal MCA and UA were performed at 37 weeks. Twenty patients from each of the six participating centers were selected randomly, with two images evaluated per patient (one each for the MCA and UA). The quality of a total of 240 images was evaluated by six experts, scored on an objective scale of six items. Inter- and intrarater reliability was assessed using the Fleiss-modified kappa statistic for ordinal scales. RESULTS On average, 89.2% of MCA images and 85.0% of UA images were rated as being of perfect (score of 6) or almost perfect (score of 5) quality. Kappa values for intrarater reliability of quality assessment were 0.90 (95% CI, 0.88-0.92) and 0.90 (95% CI, 0.88-0.93) for the MCA and UA, respectively. The corresponding inter-rater reliability values were 0.85 (95% CI, 0.81-0.89) and 0.84 (95% CI, 0.80-0.89), respectively. CONCLUSION The quality of MCA and UA Doppler ultrasound images can be evaluated reliably using an objective scale. Over 85% of images, which were obtained by operators from a broad range of clinical practices within a multicenter study, were rated as being of perfect or almost perfect quality. Intra- and inter-rater reliability of quality assessment was very good. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.",2020,"For MCA, 89.2% of the images were on average considered perfect (score of 6) or almost perfect (score of 5).","['unselected obstetric population in late pregnancy', ' 20 patients were randomly selected (2 images per patient, UA and MCA) from each of the 6 participating centres']","['middle cerebral artery and umbilical artery Doppler images', 'middle cerebral artery (MCA) and the umbilical artery (UA) Doppler evaluation']","['inter-rater reliabilities', 'inter- and intra-rater reliability']","[{'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0149566', 'cui_str': 'Middle Cerebral Artery'}, {'cui': 'C0041632', 'cui_str': 'Umbilical Arteries'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}]",240.0,0.164292,"For MCA, 89.2% of the images were on average considered perfect (score of 6) or almost perfect (score of 5).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rial-Crestelo', 'Affiliation': 'Fetal Medicine Research Center, BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetricia y Neonatología, IDIBAPS, Obstetrics and Gynecology, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Morales-Roselló', 'Affiliation': 'Department of Obstetrics and Gynecology, Hospital Universitario y Politécnico la Fe, Valencia, Spain.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hernández-Andrade', 'Affiliation': ""Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Wayne State University, Hutzel Women's Hospital, Perinatology Research Branch, NICHD/NIH/DHHS, Detroit, MI, USA.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Prefumo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Oros', 'Affiliation': 'Aragon Institute for Health Research (IIS Aragón), Obstetrics Department, Hospital Clínico Univeristario Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Caffici', 'Affiliation': 'Sociedad Argentina de Ultrasonografía en Medicina y Biología, Buenos Aires, Argentina.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sotiriadis', 'Affiliation': '2nd Department of Obstetrics and Gynecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Zohav', 'Affiliation': ""Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Lis Maternity and Women's Hospital University, Tel Aviv University, Tel Aviv, Israel.""}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Cruz-Martinez', 'Affiliation': ""Department of Fetal Medicine and Surgery, Children's and Women's Specialty Hospital of Querétaro, Querétaro, Mexico.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Parra-Cordero', 'Affiliation': 'Fetal Medicine Unit, Obstetrics and Gynecology, University of Chile Hospital, Santiago de Chile, Chile.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lubusky', 'Affiliation': 'Department of Obstetrics and Gynecology, Palacky University Olomouc, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kacerovsky', 'Affiliation': 'Charles University in Prague, Faculty of Medicine Hradec Kralove, Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Prague, Czech Republic.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Figueras', 'Affiliation': 'Fetal Medicine Research Center, BCNatal - Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clinic and Hospital Sant Joan de Déu), Institut Clínic de Ginecología, Obstetricia y Neonatología, IDIBAPS, Obstetrics and Gynecology, University of Barcelona, Barcelona, Spain.'}]",Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,['10.1002/uog.20370'] 916,30528222,Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.,"BACKGROUND Bone metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) are associated with debilitating pain and functional compromise. OBJECTIVE To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind phase 3 trial (COMET-2; NCT01522443) in men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with docetaxel and either abiraterone or enzalutamide. INTERVENTION Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m 2 every 3wk plus prednisone 5mg twice daily orally. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS The primary endpoint was pain response at week 6 confirmed at week 12 (≥30% decrease from baseline in patient-reported average daily worst pain score via the Brief Pain Inventory without increased narcotic use). The planned sample size was 246 to achieve ≥90% power. RESULTS AND LIMITATIONS Enrollment was terminated early because cabozantinib did not demonstrate a survival benefit in the companion COMET-1 trial. At study closure, 119 participants were randomized (cabozantinib: N=61; mitoxantrone-prednisone: N=58). Complete pain and narcotic use data were available at baseline, week 6, and week 12 for 73/106 (69%) patients. There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8). Barriers to accrual included pretreatment requirements for a washout period of prior anticancer therapy and a narcotic optimization period to maximize analgesic dosing. CONCLUSIONS Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. Future pain-palliation trials should incorporate briefer timelines from enrollment to treatment initiation. PATIENT SUMMARY Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases.",2019,"There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8).","['men with mCRPC and narcotic-dependent pain from bone metastases who had progressed after treatment with', 'patients with metastatic castration-resistant prostate cancer (mCRPC', 'Symptomatic Metastatic Castration-resistant Prostate Cancer', 'heavily pretreated patients with mCRPC and symptomatic bone metastases', '119 participants were randomized (cabozantinib: N=61', 'patients with castration-resistant prostate cancer and debilitating pain from bone metastases', 'men with mCRPC and symptomatic bone metastases using patient-reported outcome measures']","['docetaxel and either abiraterone or enzalutamide', 'mitoxantrone-prednisone', 'Cabozantinib Versus Mitoxantrone-prednisone', 'Cabozantinib 60mg once daily orally versus mitoxantrone 12mg/m 2 every 3wk plus prednisone 5mg twice daily orally']","['pain response', 'survival benefit', 'pain palliation', 'pain relief', 'Complete pain and narcotic use data']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0026259', 'cui_str': 'Mitoxantrone'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C4237943', 'cui_str': 'cabozantinib 60 MG'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1533720', 'cui_str': 'Prednisone 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0027415', 'cui_str': 'Narcotics'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",119.0,0.320849,"There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a -2% difference (95% confidence interval: -16% to 11%, p=0.8).","[{'ForeName': 'Ethan M', 'Initials': 'EM', 'LastName': 'Basch', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: ebasch@med.unc.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Scholz', 'Affiliation': 'Prostate Oncology Specialists, Marina del Rey, CA, USA.'}, {'ForeName': 'Johann S', 'Initials': 'JS', 'LastName': 'de Bono', 'Affiliation': 'Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, England, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Vogelzang', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'de Souza', 'Affiliation': 'Western Sydney University School of Medicine, Sydney, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Marx', 'Affiliation': 'Sydney Medical School, University of Sydney and Sydney Adventist Hospital, Wahroonga, Australia.'}, {'ForeName': 'Ulka', 'Initials': 'U', 'LastName': 'Vaishampayan', 'Affiliation': 'Karmanos Cancer Institute, Detroit, MI, USA.'}, {'ForeName': 'Saby', 'Initials': 'S', 'LastName': 'George', 'Affiliation': 'Roswell Park Cancer Institute, Buffalo, NY, USA.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Schwarz', 'Affiliation': 'University of Nebraska Medical Center, Omaha, NE, USA.'}, {'ForeName': 'Emmanuel S', 'Initials': 'ES', 'LastName': 'Antonarakis', 'Affiliation': 'The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': ""O'Sullivan"", 'Affiliation': 'Belfast City Hospital, Belfast, Northern Ireland, UK.'}, {'ForeName': 'Arash Rezazadeh', 'Initials': 'AR', 'LastName': 'Kalebasty', 'Affiliation': 'Norton Cancer Institute, Louisville, KY, USA.'}, {'ForeName': 'Kim N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, BC, Canada.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Dreicer', 'Affiliation': 'Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Hutson', 'Affiliation': 'Texas Oncology Sammons Cancer Center, Dallas, TX, USA.'}, {'ForeName': 'Amylou C', 'Initials': 'AC', 'LastName': 'Dueck', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA.'}, {'ForeName': 'Antonia V', 'Initials': 'AV', 'LastName': 'Bennett', 'Affiliation': 'Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Dayan', 'Affiliation': 'Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Mangeshkar', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Jaymes', 'Initials': 'J', 'LastName': 'Holland', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Aaron L', 'Initials': 'AL', 'LastName': 'Weitzman', 'Affiliation': 'Exelixis, Inc., Alameda, CA, USA.'}, {'ForeName': 'Howard I', 'Initials': 'HI', 'LastName': 'Scher', 'Affiliation': 'Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]",European urology,['10.1016/j.eururo.2018.11.033'] 917,29617180,Use of trunk muscle training and neuromuscular electrical stimulation to reduce pain and disability in an older adult with chronic low back pain: A case report.,"Among older adults, low back pain (LBP) is common, costly, and disabling. Trunk muscle training (TMT) and neuromuscular electrical stimulation (NMES) have both been found to be effective in reducing LBP, but studies among older adults have been limited. An 83-year-old female with left-sided chronic LBP participated in a randomized controlled trial consisting of supervised TMT and NMES to the paraspinal muscles two times per week for 12 weeks. She also participated in a home exercise program. At the end of the intervention, she reported reduced LBP and LBP-related disability per the modified Oswestry disability index (i.e., 60% at baseline to 40% at 12 weeks). Her Short Physical Performance Battery summary score improved from 4/12 at baseline to 10/12 at 12 weeks, while her Timed Up and Go test improved from 17.21 to 15.20 s and her Repetitive Trunk Rotation test from 2.72 to 1.93 s/right-left rotation. This case demonstrates a positive short-term treatment response to TMT supplemented with NMES of the paraspinal muscles in an older adult with chronic LBP. A packaged intervention of TMT plus NMES may be a means of addressing not only LBP, but also impaired physical function and resultant disability.",2019,"At the end of the intervention, she reported reduced LBP and LBP-related disability per the modified Oswestry disability index (i.e., 60% at baseline to 40% at 12 weeks).","['older adult with chronic low back pain', 'older adult with chronic LBP', '83-year-old female with left-sided chronic LBP', 'older adults', 'older adults, low back pain (LBP']","['trunk muscle training and neuromuscular electrical stimulation', 'TMT plus NMES', 'TMT supplemented with NMES', 'supervised TMT and NMES', 'Trunk muscle training (TMT) and neuromuscular electrical stimulation (NMES']","['LBP and LBP-related disability per the modified Oswestry disability index', 'Her Short Physical Performance Battery summary score', 'pain and disability', 'Repetitive Trunk Rotation test']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0024031', 'cui_str': 'Low Back Ache'}]","[{'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index (assessment scale)'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",,0.0465022,"At the end of the intervention, she reported reduced LBP and LBP-related disability per the modified Oswestry disability index (i.e., 60% at baseline to 40% at 12 weeks).","[{'ForeName': 'Jenifer M', 'Initials': 'JM', 'LastName': 'Pugliese', 'Affiliation': 'a Department of Physical Therapy , University of Delaware , Newark , DE , USA.'}, {'ForeName': 'J Megan', 'Initials': 'JM', 'LastName': 'Sions', 'Affiliation': 'a Department of Physical Therapy , University of Delaware , Newark , DE , USA.'}, {'ForeName': 'Teonette O', 'Initials': 'TO', 'LastName': 'Velasco', 'Affiliation': 'a Department of Physical Therapy , University of Delaware , Newark , DE , USA.'}, {'ForeName': 'Gregory E', 'Initials': 'GE', 'LastName': 'Hicks', 'Affiliation': 'a Department of Physical Therapy , University of Delaware , Newark , DE , USA.'}]",Physiotherapy theory and practice,['10.1080/09593985.2018.1457745'] 918,31178009,Efficacy of a Home-Based Parent Training-Focused Weight Management Intervention for Preschool Children: The DRIVE Randomized Controlled Pilot Trial.,"OBJECTIVES To pilot-test a home-based parent training intervention aimed at maintaining body weight among children at risk for obesity (> the 75th body mass index percentile). METHODS Sixteen parent-child dyads were randomized to a health education or Developing Relationships that Include Values of Eating and Exercise (DRIVE) intervention arm. The DRIVE curriculum was a structured parenting program to promote healthy weight in children by relying on behavioral principles to promote skill acquisition in the family's natural setting. Body weight and waist circumference were measured at baseline and weeks 9 and 19. RESULTS Body mass index z-score, body weight, and percent body weight increased in children in the health education arm vs DRIVE at weeks 9 and 19. Body weight, percent body weight, and waist circumference decreased in parents in DRIVE vs the health education arm at week 19, whereas no differences were shown at week 9. CONCLUSIONS AND IMPLICATIONS The DRIVE program mitigated weight gain in a small sample of at-risk children and showed promising results in reducing weight in parents. Home-based interventions emphasizing parent-child interactions are indicated as a practical model to deliver weight management in children.",2019,The DRIVE program mitigated weight gain in a small sample of at-risk children and showed promising results in reducing weight in parents.,"['children', 'children at risk for obesity (> the 75th body mass index percentile', 'Sixteen parent-child dyads', 'Preschool Children']","['Home-Based Parent Training-Focused Weight Management Intervention', 'home-based parent training intervention', 'health education or Developing Relationships that Include Values of Eating and Exercise (DRIVE) intervention arm']","['Body mass index z-score, body weight, and percent body weight', 'weight gain', 'Body weight and waist circumference', 'Body weight, percent body weight, and waist circumference']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0425119', 'cui_str': 'Child at risk (finding)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0018701'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}]",,0.0378361,The DRIVE program mitigated weight gain in a small sample of at-risk children and showed promising results in reducing weight in parents.,"[{'ForeName': 'Keely R', 'Initials': 'KR', 'LastName': 'Hawkins', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Apolzan', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA.'}, {'ForeName': 'Amanda E', 'Initials': 'AE', 'LastName': 'Staiano', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA.'}, {'ForeName': 'Jenelle R', 'Initials': 'JR', 'LastName': 'Shanley', 'Affiliation': 'School of Public Health, Georgia State University, Atlanta, GA.'}, {'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA. Electronic address: Corby.martin@pbrc.edu.'}]",Journal of nutrition education and behavior,['10.1016/j.jneb.2019.04.002'] 919,31176669,Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: A pilot study.,"In CF, pulmonary exacerbations (PEx) can lead to permanent loss in lung function and thus should be prevented. Previously, we identified a blood protein biosignature consisting of 6 proteins capable of predicting short-term PEx events in CF adults. In this study, we utilized blood samples from the placebo arm of a randomized controlled trial to assess whether this candidate protein biosignature was also capable of predicting short-term PEx events in CF children and adolescents. This pilot study provides preliminary evidence that blood inflammation can be monitored to predict short-term PEx risk in CF children and adolescents.",2020,This pilot study provides preliminary evidence that blood inflammation can be monitored to predict short-term PEx risk in CF children and adolescents.,"['CF children and adolescents', 'CF adults', 'children and adolescents with CF']",['placebo'],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.0445074,This pilot study provides preliminary evidence that blood inflammation can be monitored to predict short-term PEx risk in CF children and adolescents.,"[{'ForeName': 'Amrit', 'Initials': 'A', 'LastName': 'Singh', 'Affiliation': ""Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'He', 'Affiliation': 'Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Chen', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.""}, {'ForeName': 'Zsuzsanna', 'Initials': 'Z', 'LastName': 'Hollander', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.""}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Tebbutt', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.""}, {'ForeName': 'Raymond T', 'Initials': 'RT', 'LastName': 'Ng', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.""}, {'ForeName': 'Bruce M', 'Initials': 'BM', 'LastName': 'McManus', 'Affiliation': ""Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada.""}, {'ForeName': 'Don D', 'Initials': 'DD', 'LastName': 'Sin', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.""}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Ratjen', 'Affiliation': 'Division of Respiratory Medicine, Department of Pediatrics, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Bradley S', 'Initials': 'BS', 'LastName': 'Quon', 'Affiliation': ""Centre for Heart Lung Innovation, University of British Columbia and St. Paul's Hospital, Vancouver, BC, Canada; Prevention Of Organ Failure (PROOF) Centre of Excellence, Vancouver, BC, Canada; Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: bradley.quon@hli.ubc.ca.""}]",Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,['10.1016/j.jcf.2019.05.020'] 920,31126694,"Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.","PURPOSE This study assessed the tolerability and pharmacokinetic (PK) properties of a new-generation oxazolidinone, contezolid (MRX-I), and its major inactive metabolite, M2, after single oral administrations of 800, 1200, and 1600 mg in the fed state, and compared the efficacy of 3 dosing regimens in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection based on PK/pharmacodynamic (PD) analysis. METHODS A Phase I study at a single study center was conducted with 2 parts. In the first part, 20 healthy subjects received a single oral dose of 1200 or 1600 mg of contezolid or placebo in the fed state in a double-blind, placebo-controlled, dose-escalation tolerance study. In the second part of the study, 52 subjects received a single oral dose of 800 mg of contezolid in the fed state in a single-center, randomized, blinded, 4-period, crossover, thorough QT study. Noncompartmental analyses were used to evaluate the PK properties of contezolid and M2. Steady-state concentrations of contezolid following the 3 dosing regimens (800, 1200, and 1600 mg q12h) were simulated by employing a newly developed 2-compartmental PK model. The minimum inhibitory concentration (MIC) distributions of contezolid were analyzed in 178 Staphylococcus, Enterococcus, and Streptococcus clinical isolates. Monte Carlo simulations were conducted to predict the efficacy of the 3 dosing regimens to obtain probability of target attainment and cumulative fraction of response. FINDINGS Single-dose oral administrations of 800, 1200, and 1600 mg of contezolid were well tolerated in healthy subjects in the fed state, and nonlinear PK was observed. The mean plasma exposures to M2 exceeded 17.3% of contezolid exposure in the 3 groups. Both MIC 50 and MIC 90 (MICs that inhibit the growth of 50% and 90% of microorganisms, respectively) of contezolid against MRSA were 1 mg/L with clinical isolates from China. PK/PD analysis and Monte Carlo simulations predicted that 800 mg q12h of oral contezolid would be efficacious against MRSA infection, with a MIC of ≤4 mg/L (probability of target attainment, >90%; cumulative fraction of response, >90%). IMPLICATIONS Contezolid is a well-tolerated treatment option for MRSA infection, including at supratherapeutic doses up to 1600 mg. The regimen of 800 mg q12h could achieve efficacy in treating bacterial infection with MRSA. To our knowledge, this is the first PK study to predict that a dosing regimen of 800 mg q12h of oral contezolid is sufficient for treating MRSA infection, with a MIC of ≤4 mg/L. A Phase III study of this suggested dosing regimen is being conducted. Chinadrugtrials.org.cn identifier: CTR20161074.",2019,"Monte Carlo simulations were conducted to predict the efficacy of the 3 dosing regimens to obtain probability of target attainment and cumulative fraction of response. ","['20 healthy subjects', '52 subjects received a', 'Healthy Chinese Subjects', 'healthy subjects']","['single oral dose of 800\xa0mg of contezolid', 'contezolid or placebo']","['mean plasma exposures to M2', 'Tolerability and Pharmacokinetics', 'minimum inhibitory concentration (MIC) distributions of contezolid', 'tolerability and pharmacokinetic (PK) properties', 'PK properties of contezolid and M2']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0427978', 'cui_str': 'Minimum Inhibitory Concentration'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}]",20.0,0.0334892,"Monte Carlo simulations were conducted to predict the efficacy of the 3 dosing regimens to obtain probability of target attainment and cumulative fraction of response. ","[{'ForeName': 'Junzhen', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hailan', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yuancheng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Beining', 'Initials': 'B', 'LastName': 'Guo', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guoying', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jicheng', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Demei', 'Initials': 'D', 'LastName': 'Zhu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; MicuRx Pharmaceuticals, Inc, Hayward, CA, USA.'}, {'ForeName': 'Fupin', 'Initials': 'F', 'LastName': 'Hu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, National Health and Family Planning Commission, Shanghai, China; National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China; Phase I Unit, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: zhangj_fudan@aliyun.com.'}]",Clinical therapeutics,['10.1016/j.clinthera.2019.04.025'] 921,31154886,Comparison of the impact of single-port laparoscopic and conventional laparoscopic ovarian cystectomy on the ovarian reserve in adult patients with benign ovarian cysts.,"Objective: The surgical approach, hemostatic approach, histologic findings, and cyst size and location may have a role in reducing the ovarian reserve. The aim of this study was to investigate the impact of single-port laparoscopic cystectomy (SLC) and conventional laparoscopic cystectomy (CLC) on the ovarian reserve based on serum anti-Mullerian hormone (AMH) concentrations. Material and methods: This non-randomized concurrent control trial enrolled 79 female patients aged 18-45 years with benign ovarian cysts, including 47 patients in the SLC group and 32 patients in the CLC group. Outcome measures, including hospital stay, operative time, blood loss, analgesic use, body temperature, hospitalization cost, and serum AMH concentration, were evaluated preoperatively, two to three days postoperatively, and four to six weeks postoperatively. Results: The reduction in the AMH concentration after cystectomy was significantly different preoperatively, two to three days postoperatively ( p  < .001), and four weeks postoperatively ( p  < .001) regardless of the surgical approach (SLC or CLC) [F (1.00,31.00) = 0.026, p  = .873]. Moreover, the hemostatic approach and histologic findings yielded significant differences in the serum AMH concentration regardless of the surgical approach ( p  < .05). The serum AMH concentration was higher in unilateral cysts (2.70 ± 1.80 ng/mL) than in bilateral cysts (1.73 ± 1.11 ng/mL) postoperatively ( p  < .05). In the SLC group, the serum AMH concentration in the patients with ovarian endometriomas (1.58 ± 1.39 ng/mL) was significantly lower than that in the patients with other cysts (3.22 ± 1.68 ng/mL) postoperatively ( p  < .05). Conclusion: The serum AMH concentration decreased over time postoperatively but did not significantly differ between SLC and CLC.",2020,"The reduction in the AMH concentration after cystectomy was significantly different preoperatively, two to three days postoperatively ( p  < .001), and four weeks postoperatively ( p  < .001) regardless of the surgical approach (SLC or CLC) [F (1.00,31.00) = 0.026, p  = .873].","['adult patients with benign ovarian cysts', '79 female patients aged 18-45\u2009years with benign ovarian cysts, including 47 patients in the SLC group and 32 patients in the CLC group']","['single-port laparoscopic cystectomy (SLC) and conventional laparoscopic cystectomy (CLC', 'single-port laparoscopic and conventional laparoscopic ovarian cystectomy']","['serum AMH concentration', 'AMH concentration after cystectomy', 'serum anti-Mullerian hormone (AMH) concentrations', 'hospital stay, operative time, blood loss, analgesic use, body temperature, hospitalization cost, and serum AMH concentration']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740364', 'cui_str': 'Benign cyst of ovary'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0010651', 'cui_str': 'Cystectomy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0195488', 'cui_str': 'Removal of ovarian cyst (procedure)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0010651', 'cui_str': 'Cystectomy'}, {'cui': 'C0066928', 'cui_str': 'Anti-Muellerian Hormone'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0886414', 'cui_str': 'Body temperature'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",79.0,0.134527,"The reduction in the AMH concentration after cystectomy was significantly different preoperatively, two to three days postoperatively ( p  < .001), and four weeks postoperatively ( p  < .001) regardless of the surgical approach (SLC or CLC) [F (1.00,31.00) = 0.026, p  = .873].","[{'ForeName': 'Danying', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Haiyuan', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Qiu', 'Affiliation': 'Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Jianrong', 'Initials': 'J', 'LastName': 'Dai', 'Affiliation': 'Department of Obstetrics and Gynecology, Suzhou Municipal Hospital, Suzhou, China.'}, {'ForeName': 'Dawei', 'Initials': 'D', 'LastName': 'Sun', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.'}]",Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy,['10.1080/13645706.2019.1624575'] 922,31754697,Biomarkers of Docosahexaenoic Acid but Not Arachidonic Acid Reflect Dietary Intakes in Toddlers at Ages 1 and 2 Years Who Are Not Meeting Dietary Recommendations.,"BACKGROUND Long-chain n-6 and n-3 PUFAs are important for growth and development. However, little is known about requirements and current dietary intakes of these fatty acids in toddlers. OBJECTIVES This study assessed dietary intakes of n-6 and n-3 PUFAs and determined the relation to circulating PUFAs in toddlers at ages 1 and 2 y. METHODS This is a secondary analysis of data from toddlers enrolled in a double-blind randomized controlled trial of arachidonic acid (ARA) and DHA supplementation between ages 1 and 2 y. Dietary intakes of fatty acids were estimated by 3-d food records, and fatty acid composition in plasma total phospholipids, red blood cell phosphatidylethanolamine (PE), and phosphatidylcholine (PC) were assessed by GC at baseline in all subjects (n = 110; mean age 1.12 y; 64% male) and in the control subjects at 2 y (n = 43). RESULTS The dietary intakes of ARA, EPA, and DHA at age 1 y (baseline) were [mean (median)] 36.8 (30.0), 16.0 (0.00), and 31.1 (10.0) mg/d, respectively. Dietary intakes increased to 52.7 (45.0), 35.8 (0.00), and 64.8 (20.0) mg/d, respectively, at age 2 y (P < 0.05). The predominant dietary source of EPA and DHA was fish/seafood; eggs were an important source of ARA and DHA. Dietary DHA intakes were positively associated with plasma PE and PC DHA (P < 0.05). No relations between dietary ARA intakes and plasma PE and PC ARA (P > 0.05) were observed. CONCLUSIONS These findings suggest that most toddlers are not meeting the recommendation for dietary PUFA intakes and that higher dietary DHA intakes are reflected in plasma PE and PC DHA composition. Further work is required to investigate a biomarker for dietary ARA intake. This trial is registered at clinicaltrials.gov as NCT01263912.",2020,Dietary DHA intakes were positively associated with plasma PE and PC DHA (P < 0.05).,"['Toddlers at Ages 1 and 2 Years Who Are Not Meeting Dietary Recommendations', 'all subjects (n\xa0=\xa0110; mean age 1.12 y; 64% male) and in the control subjects at 2 y (n\xa0=\xa043', 'toddlers at ages 1 and 2 y.\nMETHODS']","['Arachidonic Acid', 'Docosahexaenoic Acid', 'n-6 and n-3 PUFAs', 'arachidonic acid (ARA) and DHA supplementation']","['plasma PE and PC DHA', 'Dietary intakes', 'dietary intakes of ARA, EPA, and DHA', 'plasma PE and PC DHA composition', 'plasma total phospholipids, red blood cell phosphatidylethanolamine (PE), and phosphatidylcholine (PC', 'dietary ARA intakes and plasma PE and PC ARA', 'Dietary DHA intakes']","[{'cui': 'C0682053', 'cui_str': 'Toddler (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}]","[{'cui': 'C0003701', 'cui_str': 'Arachidonic Acids'}, {'cui': 'C0556150', 'cui_str': 'docosahexaenoic acid'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1168488', 'cui_str': 'Total phospholipids'}, {'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0031618', 'cui_str': 'Phosphatidylethanolamines'}, {'cui': 'C1959616', 'cui_str': 'Phosphatidyl Cholines'}]",,0.0932511,Dietary DHA intakes were positively associated with plasma PE and PC DHA (P < 0.05).,"[{'ForeName': 'Alejandra M', 'Initials': 'AM', 'LastName': 'Wiedeman', 'Affiliation': ""Department of Pediatrics, The University of British Columbia and BC Children's Hospital Research Institute, Vancouver, Canada.""}, {'ForeName': 'Roger A', 'Initials': 'RA', 'LastName': 'Dyer', 'Affiliation': ""Department of Pediatrics, The University of British Columbia and BC Children's Hospital Research Institute, Vancouver, Canada.""}, {'ForeName': 'Deanna', 'Initials': 'D', 'LastName': 'McCarthy', 'Affiliation': 'DSM Nutritional Products, Columbia, MD, USA.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Yurko-Mauro', 'Affiliation': 'DSM Nutritional Products, Columbia, MD, USA.'}, {'ForeName': 'Sheila M', 'Initials': 'SM', 'LastName': 'Innis', 'Affiliation': ""Department of Pediatrics, The University of British Columbia and BC Children's Hospital Research Institute, Vancouver, Canada.""}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Devlin', 'Affiliation': ""Department of Pediatrics, The University of British Columbia and BC Children's Hospital Research Institute, Vancouver, Canada.""}]",The Journal of nutrition,['10.1093/jn/nxz280'] 923,31171470,Daily Passive Muscle Stretching Improves Flow-Mediated Dilation of Popliteal Artery and 6-minute Walk Test in Elderly Patients with Stable Symptomatic Peripheral Artery Disease.,"BACKGROUND Patients with peripheral arterial disease (PAD) often have walking impairment due to insufficient oxygen supply to skeletal muscle. In aged rats, we have shown that daily stretching of calf muscles improves endothelium-dependent dilation of arterioles from the soleus muscle and increases capillarity and muscle blood flow during exercise. Therefore, we hypothesized that daily muscle stretching of calf muscles would improve endothelium-dependent vasodilation of the popliteal artery and walking function in PAD patients. METHODS We performed a randomized, non-blinded, crossover study whereby 13 patients with stable symptomatic PAD were randomized to undergo either 4 weeks of passive calf muscle stretching (ankle dorsiflexion applied 30 min/d, 5 days/wk) followed by 4 weeks of no muscle stretching and vice versa. Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-induced dilation of the popliteal artery and 6 minute walk test (6MWT) were evaluated at baseline and after each 4 week interval. RESULTS After 4 weeks of muscle stretching, FMD and 6MWT improved significantly in the muscle stretching group vs. the control (FMD: 5.1 ± 0.5% vs. 3.7 ± 0.3%, P = 0.005; 6MWT continuous walking distance: 304 ± 43 m vs. 182 ± 34 m; P = 0.0006). No difference in nitroglycerin-induced dilation was found between groups (10.9 ± 1.2 vs. 9.9 ± 0.4%, P = 0.48). Post-stretching, 6MWT total walking distance was positively correlated with normalized FMD (R = 0.645, P = 0.02). CONCLUSIONS Passive calf muscle stretching enhanced vascular endothelial function and improved walking function in elderly patients with stable symptomatic PAD. These findings merit further investigation in a prospective randomized trial.",2019,"Post-stretching, 6MWT total walking distance was positively correlated with normalized FMD (R = 0.645, P = 0.02). ","['elderly patients with stable symptomatic PAD', 'PAD patients', 'Patients with peripheral arterial disease (PAD', 'aged rats', 'elderly patients with stable symptomatic peripheral artery disease', '13 patients with stable symptomatic PAD']","['Passive calf muscle stretching', 'Daily passive muscle stretching', 'passive calf muscle stretching (ankle dorsiflexion applied 30\u202fmin/d, 5\u202fdays/wk) followed by 4\u202fweeks of no muscle stretching and vice versa']","['normalized FMD', '6MWT total walking distance', 'Endothelium-dependent flow-mediated dilation (FMD) and endothelium-independent nitroglycerin-induced dilation of the popliteal artery and 6\u202fminute walk test (6MWT', 'muscle stretching, FMD and 6MWT', 'walking function', 'nitroglycerin-induced dilation', 'vascular endothelial function']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}, {'cui': 'C0034721', 'cui_str': 'Rats'}]","[{'cui': 'C0448482', 'cui_str': 'Posterior crural muscle structure'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0014257', 'cui_str': 'Endothelium'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0017887', 'cui_str': 'glyceryl trinitrate'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0032649', 'cui_str': 'Popliteal Artery'}, {'cui': 'C0430515', 'cui_str': '6-Minute Walk Test'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0031843', 'cui_str': 'function'}]",13.0,0.14241,"Post-stretching, 6MWT total walking distance was positively correlated with normalized FMD (R = 0.645, P = 0.02). ","[{'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Hotta', 'Affiliation': 'Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL, USA; Department of Physical Therapy, Niigata University of Health and Welfare, Niigata, Japan.'}, {'ForeName': 'Wayne B', 'Initials': 'WB', 'LastName': 'Batchelor', 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, VA, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Graven', 'Affiliation': 'Tallahassee Memorial Healthcare, Tallahassee, FL, USA.'}, {'ForeName': 'Vishal', 'Initials': 'V', 'LastName': 'Dahya', 'Affiliation': 'Summa Health Medical Group, Akron, OH, USA.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Noel', 'Affiliation': 'Southern Medical Group, P.A., Tallahassee, FL, USA.'}, {'ForeName': 'Akash', 'Initials': 'A', 'LastName': 'Ghai', 'Affiliation': 'Southern Medical Group, P.A., Tallahassee, FL, USA.'}, {'ForeName': 'John N', 'Initials': 'JN', 'LastName': 'Katopodis', 'Affiliation': 'Southern Medical Group, P.A., Tallahassee, FL, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Dixon', 'Affiliation': 'Southern Medical Group, P.A., Tallahassee, FL, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Andrews', 'Affiliation': 'Southern Medical Group, P.A., Tallahassee, FL, USA.'}, {'ForeName': 'Aimee', 'Initials': 'A', 'LastName': 'Pragle', 'Affiliation': 'Florida State University College of Medicine, Tallahassee, FL, USA.'}, {'ForeName': 'Jegghna', 'Initials': 'J', 'LastName': 'Chheda', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Florida State University College of Human Sciences, Tallahassee, FL, USA.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Liberatore', 'Affiliation': 'Department of Nutrition, Food and Exercise Sciences, Florida State University College of Human Sciences, Tallahassee, FL, USA.'}, {'ForeName': 'Brad J', 'Initials': 'BJ', 'LastName': 'Behnke', 'Affiliation': 'Department of Kinesiology, Kansas State University College of Human Ecology, Manhattan, KS, USA.'}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Muller-Delp', 'Affiliation': 'Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, FL, USA. Electronic address: judy.delp@med.fsu.edu.'}]",Cardiovascular revascularization medicine : including molecular interventions,['10.1016/j.carrev.2019.05.003'] 924,31165374,Sharing in care: engaging care partners in the care and communication of breast cancer patients.,"PURPOSE Family is often overlooked in cancer care. We developed a patient-family agenda setting intervention to engage family in cancer care communication. METHODS We conducted a pilot randomized controlled trial (NCT03283553) of patients on active treatment for breast cancer and their family ""care partner."" Intervention dyads (n = 69) completed a self-administered checklist to clarify care partner roles, establish a shared visit agenda, and facilitate MyChart patient portal access. Control dyads (n = 63) received usual care. We assessed intervention acceptability and initial effects from post-visit surveys and MyChart utilization at 6 weeks. RESULTS At baseline, most patients (89.4%) but few care partners (1.5%) were registered for MyChart. Most patients (79.4%) wanted their care partner to have access to their records and 39.4% of care partners reported accessing MyChart. In completing the checklist, patients and care partners endorsed active communication roles for the care partner and identified a similar visit agenda: most (> 90%) reported the checklist was easy, useful, and recommended it to others. At 6 weeks, intervention (vs control) care partners were more likely to be registered for MyChart (75.4% vs 1.6%; p < 0.001), to have logged in (43.5% vs 0%; p < 0.001) and viewed clinical notes (30.4% vs 0%; p < 0.001), but were no more likely to exchange direct messages with clinicians (1.5% vs 0%; p = 0.175). No differences in patients' MyChart use were observed, but intervention patients more often viewed clinical notes (50.7% vs 9.5%; p < 0.001). CONCLUSIONS A patient-family agenda setting intervention was acceptable and affected online practices of cancer patients and care partners.",2019,"No differences in patients' MyChart use were observed, but intervention patients more often viewed clinical notes (50.7% vs 9.5%; p < 0.001). ","['patients on active treatment for breast cancer and their family ""care partner', 'cancer patients and care partners', 'breast cancer patients']","[' Intervention dyads (n\u2009=\u200969) completed a self-administered checklist to clarify care partner roles, establish a shared visit agenda, and facilitate MyChart patient portal access', 'usual care']",['viewed clinical notes'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}, {'cui': 'C4277550', 'cui_str': 'Patient Internet Portals'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}]","[{'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]",,0.0418658,"No differences in patients' MyChart use were observed, but intervention patients more often viewed clinical notes (50.7% vs 9.5%; p < 0.001). ","[{'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Wolff', 'Affiliation': 'The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. jwolff2@jhu.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Aufill', 'Affiliation': 'The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Echavarria', 'Affiliation': 'The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'JaAlah-Ai', 'Initials': 'JA', 'LastName': 'Heughan', 'Affiliation': 'The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Kimberley T', 'Initials': 'KT', 'LastName': 'Lee', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Roisin M', 'Initials': 'RM', 'LastName': 'Connolly', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Fetting', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Danijela', 'Initials': 'D', 'LastName': 'Jelovac', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Papathakis', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Riley', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Vered', 'Initials': 'V', 'LastName': 'Stearns', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Elissa', 'Initials': 'E', 'LastName': 'Thorner', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Nelli', 'Initials': 'N', 'LastName': 'Zafman', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Howard P', 'Initials': 'HP', 'LastName': 'Levy', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Sydney M', 'Initials': 'SM', 'LastName': 'Dy', 'Affiliation': 'The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Antonio C', 'Initials': 'AC', 'LastName': 'Wolff', 'Affiliation': 'The Johns Hopkins University School of Medicine, Baltimore, MD, USA. awolff@jhmi.edu.'}]",Breast cancer research and treatment,['10.1007/s10549-019-05306-9'] 925,31078618,Morning stimulant administration reduces sleep and overnight working memory improvement.,"The goal of cognitive enhancement is to improve mental functions using interventions including cognitive training, brain stimulation and pharmacology. Indeed, psychostimulants, commonly used for cognitive enhancement purposes, while preventing sleep, have been shown to increase working memory (WM) and attention. Sleep, however, is also important for cognitive function; thus, understanding the interaction between stimulants, sleep and cognition may inform current approaches to cognitive enhancement. We used a double-blind, placebo controlled, repeated measure design to investigate the effect of morning administration of a commonly used stimulant, dextroamphetamine (DEX, 20 mg), on repeated, within-day and overnight WM performance, as well as on sleep in healthy young adults. Compared with placebo (PBO), we found no within-day benefit of DEX on WM. After sleep, DEX performed worse than PBO and the overnight improvement in performance in the PBO condition was absent in the DEX condition. Moreover, sleep quality was negatively affected by DEX administration. In summary, we found no cognitive boost from psychostimulants across a day of wake and a blockade of overnight WM increases with the stimulant, compared to PBO.",2019,"After sleep, DEX performed worse than PBO and the overnight improvement in performance in the PBO condition was absent in the DEX condition.",['healthy young adults'],"['DEX', 'dextroamphetamine (DEX', 'placebo', 'placebo (PBO']","['sleep and overnight working memory improvement', 'sleep quality', 'PBO condition']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0011812', 'cui_str': 'dexamfetamine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",,0.0525469,"After sleep, DEX performed worse than PBO and the overnight improvement in performance in the PBO condition was absent in the DEX condition.","[{'ForeName': 'Tenzin', 'Initials': 'T', 'LastName': 'Tselha', 'Affiliation': 'Department of Cognitive Science, University of California, Irvine, USA. Electronic address: ttselha@uci.edu.'}, {'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Whitehurst', 'Affiliation': 'Department of Psychology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Benjamin D', 'Initials': 'BD', 'LastName': 'Yetton', 'Affiliation': 'Department of Cognitive Science, University of California, Irvine, USA.'}, {'ForeName': 'Tina T', 'Initials': 'TT', 'LastName': 'Vo', 'Affiliation': 'Department of Psychology, University of California, Riverside, CA, USA.'}, {'ForeName': 'Sara C', 'Initials': 'SC', 'LastName': 'Mednick', 'Affiliation': 'Department of Cognitive Science, University of California, Irvine, USA.'}]",Behavioural brain research,['10.1016/j.bbr.2019.111940'] 926,31754836,Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy.,"The purpose of this pilot study was to determine whether photobiomodulation (PBM) might be effective for chemotherapy-induced palmo-plantar erythrodyesthesia (PPED), as it is for mucositis or radio dermatitis; no standard therapy exists for PPED. Patients were allocated to PBM or sham irradiation and were blindly assessed after 2 weeks. Pain and satisfaction with treatment were also evaluated. We found a significant benefit from PBM in comparison with sham treatment (p < 0.03) and a decrease of pain in 49% of the patients. No adverse reactions were observed. We concluded that PBM might represent a useful approach for the management of PPED.",2020,We found a significant benefit from PBM in comparison with sham treatment (p < 0.03) and a decrease of pain in 49% of the patients.,[],"['low-level laser therapy (LLLT) or photobiomodulation (PBM', 'photobiomodulation (PBM', 'PBM or sham irradiation', 'PBM']","['pain', 'Pain and satisfaction', 'adverse reactions']",[],"[{'cui': 'C0279027', 'cui_str': 'Low-Power Laser Therapy'}, {'cui': 'C0071006', 'cui_str': 'phytobacteriomycin'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}]",,0.0302752,We found a significant benefit from PBM in comparison with sham treatment (p < 0.03) and a decrease of pain in 49% of the patients.,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Latifyan', 'Affiliation': ""Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.""}, {'ForeName': 'M T', 'Initials': 'MT', 'LastName': 'Genot', 'Affiliation': ""Laser Therapy Unit, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.""}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Fernez', 'Affiliation': ""Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.""}, {'ForeName': 'M F', 'Initials': 'MF', 'LastName': 'Scharll', 'Affiliation': ""Laser Therapy Unit, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium.""}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Klastersky', 'Affiliation': ""Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles Centre des Tumeurs de l'ULB, Rue Héger-Bordet, 1, 1000, Brussels, Belgium. jean.klastersky@bordet.be.""}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05099-z'] 927,32410543,The Value of Low-dose Prospective Dual-energy Computed Tomography with Iodine Mapping in the Diagnosis of Gastric Cancer.,"OBJECTIVES This study investigated the radiation dose and value of prospective dualenergy computed tomography (DECT) in the diagnosis of gastric cancer. METHODS Sixty patients scheduled for computed tomography (CT) for preoperative staging were divided into two groups. Thirty patients (Group A) underwent a single contrast-enhanced abdominal CT acquisition using a dual-source mode (100 kV/140 kV). Weighted average images of the two-kilovolt acquisitions and iodine maps were created. The remaining 30 patients underwent a standard CT scan (Group B). Two observers performed a blinded read of the images for gastric lesions, evaluating the image quality and recording effective dose. RESULTS During the blinded read, observers found 90% (27/30) of the cancers in both groups. The mean imaging quality scores were 2.1±0.9 for Group A, and 2.3±1.1 for Group B. The effective mean doses were 6.59±0.59 mSv and 25.86±0.44 mSv for Groups A and B, respectively. Compared with the control group (B), the imaging quality in the low-dose group decreased a little, but the radiation dose substantially decreased by 74.6%. CONCLUSION The new DECT technique is valuable for examining gastric cancer patients. The dualkV scan mode can substantially reduce radiation dose while preserving good diagnostic image quality.",2020,"Compared with the control group (B), the imaging quality in the low-dose group decreased a little, but the radiation dose substantially decreased by 74.6%. ","['Thirty patients (Group A) underwent a', 'Sixty patients scheduled for computed tomography (CT) for preoperative staging', 'gastric cancer patients']","['Dual-energy Computed Tomography with Iodine Mapping', 'single contrast-enhanced abdominal CT acquisition using a dual-source mode', 'dualenergy computed tomography (DECT', 'standard CT scan']","['imaging quality', 'mean imaging quality scores']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0332305', 'cui_str': 'With staging'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}]","[{'cui': 'C4055114', 'cui_str': 'Dual energy computed tomography'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C1283195', 'cui_str': 'Mapping - action'}, {'cui': 'C0445261', 'cui_str': 'Single contrast technique'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}]","[{'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.014807,"Compared with the control group (B), the imaging quality in the low-dose group decreased a little, but the radiation dose substantially decreased by 74.6%. ","[{'ForeName': 'Lifeng', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Intervention, The First People's Hospital of Wujiang District, Suzhou, China.""}, {'ForeName': 'Xingxing', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': ""Department of Gastroenterology, the First People's Hospital of Yancheng, Yancheng, China.""}, {'ForeName': 'Zhenguo', 'Initials': 'Z', 'LastName': 'Qiao', 'Affiliation': ""Department of Gastroenterology, The First People's Hospital of Wujiang District, Suzhou, China.""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Xu', 'Affiliation': ""Department of Intervention, The First People's Hospital of Wujiang District, Suzhou, China.""}, {'ForeName': 'Jiaqing', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': 'Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, China.'}]",Current medical imaging,['10.2174/1573405614666181023114051'] 928,31167902,Effect of menthol cigarette and other menthol tobacco product bans on tobacco purchases in the RTI iShoppe virtual convenience store.,"OBJECTIVE To test how a potential US ban of menthol products or replacement with 'green' products and ads could influence tobacco purchases. METHODS US adult menthol smokers (N=1197) were recruited via an online panel and randomly assigned to complete a shopping task in one of four versions (experimental conditions) of the RTI iShoppe virtual store: (1) no ban, (2) replacement of menthol cigarettes and ads with green replacement versions, (3) menthol cigarette ban and (4) all menthol tobacco product ban. Logistic regressions assessed the effect of condition on tobacco purchases. RESULTS Participants in the menthol cigarette ban (OR=0.67, 95% CI 0.48 to 0.92) and all menthol product ban conditions (OR=0.60, 95% CI 0.43 to 0.83) were less likely to purchase cigarettes of any type than participants in the no ban condition. Participants in the green replacement (OR=1.74, 95% CI 1.13 to 2.70), menthol cigarette ban (OR=3.40, 95% CI 2.14 to 5.41) and all menthol product ban conditions (OR=3.14, 95% CI 1.97 to 5.01) were more likely to purchase a cigarette brand different from their usual brand than participants in the no ban condition. CONCLUSIONS Our findings suggest that menthol bans could have great public health impact by reducing cigarette purchases. However, tobacco marketing strategies, such as creating green (or other replacement) versions of menthol cigarettes, may undermine public health benefits of a menthol ban by prompting purchases of non-menthol cigarettes. Our findings highlight the importance of taking tobacco marketing tactics into consideration in tobacco product regulation.",2020,"Participants in the green replacement (OR=1.74, 95% CI 1.13 to 2.70), menthol cigarette ban (OR=3.40, 95% CI 2.14 to 5.41) and all menthol product ban conditions (OR=3.14, 95% CI 1.97 to 5.01) were more likely to purchase a cigarette brand different from their usual brand than participants in the no ban condition. ","['US adult menthol smokers (N=1197', 'tobacco purchases in the RTI iShoppe virtual convenience store']","['shopping task in one of four versions (experimental conditions) of the RTI iShoppe virtual store: (1) no ban, (2) replacement of menthol cigarettes and ads with green replacement versions, (3) menthol cigarette ban and (4) all menthol tobacco product ban', 'menthol cigarette and other menthol tobacco product']",['menthol cigarette'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0035243', 'cui_str': 'Infections, Respiratory'}]","[{'cui': 'C0150768', 'cui_str': 'Shopping (observable entity)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0035243', 'cui_str': 'Infections, Respiratory'}, {'cui': 'C0105185', 'cui_str': 'BANS'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332583', 'cui_str': 'Green color (qualifier value)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}]","[{'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]",1197.0,0.0670835,"Participants in the green replacement (OR=1.74, 95% CI 1.13 to 2.70), menthol cigarette ban (OR=3.40, 95% CI 2.14 to 5.41) and all menthol product ban conditions (OR=3.14, 95% CI 1.97 to 5.01) were more likely to purchase a cigarette brand different from their usual brand than participants in the no ban condition. ","[{'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Guillory', 'Affiliation': 'Prime Affect Research, Dublin, Ireland jamieguillory.contractor@rti.org.'}, {'ForeName': 'Annice E', 'Initials': 'AE', 'LastName': 'Kim', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Nonnemaker', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Bradfield', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Nathaniel Harlan', 'Initials': 'NH', 'LastName': 'Taylor', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Dutra', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Feld', 'Affiliation': 'Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2019-054997'] 929,31162530,Lung Ultrasound-Guided Dry-Weight Reduction in Hemodialysis Patients Does Not Affect Short-Term Blood Pressure Variability.,"BACKGROUND Increased short-term blood pressure (BP) variability (BPV) in hemodialysis is associated with increased cardiovascular and all-cause mortality. Studies on the impact of BP-lowering interventions on BPV are scarce. This study examined the effect of dry-weight reduction with a lung ultrasound-guided strategy on short-term BPV in hemodialysis patients with hypertension. METHODS This is a prespecified analysis of a randomized clinical trial in 71 hemodialysis patients with hypertension, assigned in a 1:1 ratio in the active group, following a strategy for dry-weight reduction guided by pre-hemodialysis lung ultrasound and the control group following standard-of-care treatment. All patients underwent 48-hour ambulatory BP monitoring at baseline and after 8 weeks. BPV was calculated with validated formulas for the 48-hour interval and the 2 daytime and nighttime periods. RESULTS Dry-weight changes were -0.71 ± 1.39 in active vs. +0.51 ± 0.98 kg in the control group (P < 0.001), generating a between-group difference of 5.9/3.5 mm Hg (P < 0.05) in 48-hour BP at study end. All brachial BPV indices [SD, weighted SD, coefficient of variation, and average real variability (ARV)] did not change significantly from baseline to study end in the active [systolic blood pressure (SBP)-ARV: 12.58 ± 3.37 vs. 11.91 ± 3.13, P = 0.117; diastolic blood pressure (DBP)-ARV: 9.14 ± 1.47 vs. 8.80 ± 1.96, P = 0.190] or control (SBP-ARV: 11.33 ± 2.76 vs. 11.07 ± 2.51, P = 0.544; DBP-ARV: 8.38 ± 1.50 vs. 8.15 ± 1.49, P = 0.295) group (between-group comparison P = 0.211/0.117). Aortic BPV indices followed a similar pattern. Likewise, no significant changes in BPV indices for the daytime and nighttime periods were noted in both groups during follow-up. CONCLUSIONS This study is the first to evaluate the effects of a nonpharmacological intervention on short-term BPV in hemodialysis, showing no effect of dry-weight reduction on BPV, despite BP decrease.",2019,"Likewise, no significant changes in BPV indices for the daytime and nighttime periods were noted in both groups during follow-up. ","['71 hemodialysis patients with hypertension, assigned in a 1:1 ratio in the active group, following a', 'hemodialysis patients with hypertension', 'Hemodialysis Patients']","['dry-weight reduction with a lung ultrasound-guided strategy', 'strategy for dry-weight reduction guided by pre-hemodialysis lung ultrasound and the control group following standard-of-care treatment', 'nonpharmacological intervention']","['blood pressure (BP) variability (BPV', 'active [systolic blood pressure', 'BPV', 'daytime and nighttime periods', 'BPV indices', 'All brachial BPV indices [SD, weighted SD, coefficient of variation, and average real variability (ARV', 'Aortic BPV indices', 'Dry-weight changes', 'diastolic blood pressure']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}]","[{'cui': 'C2709005', 'cui_str': 'Dry body weight (observable entity)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0531207', 'cui_str': 'bpV(phen)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C2709005', 'cui_str': 'Dry body weight (observable entity)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}]",71.0,0.0431758,"Likewise, no significant changes in BPV indices for the daytime and nighttime periods were noted in both groups during follow-up. ","[{'ForeName': 'Charalampos', 'Initials': 'C', 'LastName': 'Loutradis', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Pantelis A', 'Initials': 'PA', 'LastName': 'Sarafidis', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Marieta', 'Initials': 'M', 'LastName': 'Theodorakopoulou', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ekart', 'Affiliation': 'Department of Nephrology, University Clinical Centre Maribor, Maribor, Slovenia.'}, {'ForeName': 'Maria Eleni', 'Initials': 'ME', 'LastName': 'Alexandrou', 'Affiliation': 'Department of Nephrology, Papageorgiou Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Pyrgidis', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Angeloudi', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Tzanis', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Toumpourleka', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}, {'ForeName': 'Dorothea', 'Initials': 'D', 'LastName': 'Papadopoulou', 'Affiliation': 'Department of Nephrology, Papageorgiou Hospital, Thessaloniki, Greece.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Mallamaci', 'Affiliation': 'CNR-IFC Clinical Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.'}, {'ForeName': 'Carmine', 'Initials': 'C', 'LastName': 'Zoccali', 'Affiliation': 'CNR-IFC Clinical Epidemiology of Renal Diseases and Hypertension, Reggio Calabria, Italy.'}, {'ForeName': 'Aikaterini', 'Initials': 'A', 'LastName': 'Papagianni', 'Affiliation': 'Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Greece.'}]",American journal of hypertension,['10.1093/ajh/hpz064'] 930,31166248,A RANDOMIZED PAIRED-EYE TRIAL OF INTRAVITREAL DEXAMETHASONE IMPLANT FOR CYSTOID MACULAR EDEMA IN RETINITIS PIGMENTOSA.,"PURPOSE To evaluate the efficacy and safety of intravitreal dexamethasone (DEX) implant in retinitis pigmentosa patients with cystoid macular edema (CME). METHODS In this randomized, noncontrolled, paired-eye, single crossover clinical trial, one eye of retinitis pigmentosa patients with bilateral CME with central macular thickness of >250 µm was randomized to intravitreal DEX implant while the fellow eye was observed. Both eyes were started on topical dorzolamide. At Month 6, DEX implant was eligible for both eyes when CME was >250 µm. Patients were followed up until Month 12. Primary outcome measures were the central macular thickness and best-corrected visual acuity changes from baseline at Month 2. RESULTS Fourteen patients with bilateral RP-CME were included. Study eyes showed significant central macular thickness decrease (median, -147.5 µm; P = 0.001) and best-corrected visual acuity improvement (median, +6 letters; P = 0.001) at Month 2, but not at Month 6. Intravitreal DEX implant at Month 6 produced comparable efficacy to baseline treatment in 11 fellow eyes and 12 study eyes. Topical dorzolamide did not show significant therapeutic efficacy. During 12 months, elevated intraocular pressure of >21 mmHg and cataract progression were observed in 14.3% and 40.0% of study eyes. CONCLUSION Intravitreal DEX implant can both reduce macular thickness and improve vision in RP-CME, while repeated injection is required.",2020,"Study eyes showed significant central macular thickness decrease (median, -147.5 µm; P = 0.001) and best-corrected visual acuity improvement (median, +6 letters; P = 0.001) at Month 2, but not at Month 6.","['11 fellow eyes and 12 study eyes', 'retinitis pigmentosa patients with cystoid macular edema (CME', 'retinitis pigmentosa patients with bilateral CME with central macular thickness of >250 µm', 'Fourteen patients with bilateral RP-CME']","['Intravitreal DEX', 'DEX', 'intravitreal dexamethasone (DEX) implant', 'intravitreal DEX', 'topical dorzolamide', 'Topical dorzolamide']","['macular thickness', 'central macular thickness and best-corrected visual acuity changes', 'central macular thickness decrease', 'best-corrected visual acuity improvement', 'therapeutic efficacy', 'efficacy and safety', 'elevated intraocular pressure of >21 mmHg and cataract progression']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035334', 'cui_str': 'Pigmentary Retinopathy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024440', 'cui_str': 'Macular Dystrophy, Dominant Cystoid'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C3715152', 'cui_str': '14'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0165590', 'cui_str': 'dorzolamide'}]","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure (finding)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}]",14.0,0.0728424,"Study eyes showed significant central macular thickness decrease (median, -147.5 µm; P = 0.001) and best-corrected visual acuity improvement (median, +6 letters; P = 0.001) at Month 2, but not at Month 6.","[{'ForeName': 'Un Chul', 'Initials': 'UC', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Jung Hyun', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Dae Joong', 'Initials': 'DJ', 'LastName': 'Ma', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'In Hwan', 'Initials': 'IH', 'LastName': 'Cho', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Baek-Lok', 'Initials': 'BL', 'LastName': 'Oh', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}, {'ForeName': 'Hyeong Gon', 'Initials': 'HG', 'LastName': 'Yu', 'Affiliation': 'Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002589'] 931,31758324,Effects of a nutrition intervention on acute and late bowel symptoms and health-related quality of life up to 24 months post radiotherapy in patients with prostate cancer: a multicentre randomised controlled trial.,"PURPOSE Radiotherapy to the prostate gland and pelvic lymph nodes may cause acute and late bowel symptoms and diminish quality of life. The aim was to study the effects of a nutrition intervention on bowel symptoms and health-related quality of life, compared with standard care. METHODS Patients were randomised to a nutrition intervention (n = 92) aiming to replace insoluble fibres with soluble and reduce intake of lactose, or a standard care group (n = 88) who were recommended to maintain their habitual diet. Bowel symptoms, health-related quality of life and intake of fibre and lactose-containing foods were assessed up to 24 months after radiotherapy completion. Multiple linear regression was used to analyse the effects of the nutrition intervention on bowel symptoms during the acute (up to 2 months post radiotherapy) and the late (7 to 24 months post radiotherapy) phase. RESULTS Most symptoms and functioning worsened during the acute phase, and improved during the late phase in both the intervention and standard care groups. The nutrition intervention was associated with less blood in stools (p = 0.047), flatulence (p = 0.014) and increased loss of appetite (p = 0.018) during the acute phase, and more bloated abdomen in the late phase (p = 0.029). However, these associations were clinically trivial or small. CONCLUSIONS The effect of the nutrition intervention related to dietary fibre and lactose on bowel symptoms from pelvic RT was small and inconclusive, although some minor and transient improvements were observed. The results do not support routine nutrition intervention of this type to reduce adverse effects from pelvic radiotherapy.",2020,"The nutrition intervention was associated with less blood in stools (p = 0.047), flatulence (p = 0.014) and increased loss of appetite (p = 0.018) during the acute phase, and more bloated abdomen in the late phase (p = 0.029).","['Patients', 'patients with prostate cancer']","['nutrition intervention (n = 92) aiming to replace insoluble fibres with soluble and reduce intake of lactose, or a standard care group (n = 88) who were recommended to maintain their habitual diet', 'radiotherapy', 'nutrition intervention']","['bowel symptoms', 'bowel symptoms and health-related quality of life', 'acute and late bowel symptoms and health-related quality of life', 'loss of appetite', 'flatulence', 'Bowel symptoms, health-related quality of life and intake of fibre and lactose-containing foods', 'blood in stools']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}]","[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C3661726', 'cui_str': 'Insoluble dietary fiber'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}]","[{'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C1971624', 'cui_str': 'Loss of appetite (finding)'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C1321898', 'cui_str': 'Bloody stool'}]",,0.0473045,"The nutrition intervention was associated with less blood in stools (p = 0.047), flatulence (p = 0.014) and increased loss of appetite (p = 0.018) during the acute phase, and more bloated abdomen in the late phase (p = 0.029).","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Forslund', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. marina.forslund@igp.uu.se.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ottenblad', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Claes', 'Initials': 'C', 'LastName': 'Ginman', 'Affiliation': 'Department of Clinical Oncology, Central Hospital, Karlstad, Sweden.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Johansson', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Nygren', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Birgitta', 'Initials': 'B', 'LastName': 'Johansson', 'Affiliation': 'Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05182-5'] 932,31758326,Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial.,"PURPOSE Although topical agents are often provided during radiation therapy, there is limited consensus and evidence for their use prophylactically to prevent or reduce radiation dermatitis. METHODS This was a multi-site, randomized, placebo-controlled, blinded study of 191 breast cancer patients to compare the prophylactic effectiveness of three topical agents (Curcumin, HPR Plus™, and Placebo) for reducing radiation dermatitis and associated pain. Patients applied the topical agent to their skin in the radiation area site three times daily starting the first day of radiation therapy (RT) until 1 week after RT completion. RESULTS Of the 191 randomized patients, 171 patients were included in the final analyses (87.5% white females, mean age = 58 (range = 36-88)). Mean radiation dermatitis severity (RDS) scores did not significantly differ between study arms (Curcumin = 2.68 [2.49, 2.86]; HPR Plus™ = 2.64 [2.45, 2.82]; Placebo = 2.63 [2.44, 2.83]; p = 0.929). Logistic regression analyses showed that increased breast field separation positively correlated with increased radiation dermatitis severity (p = 0.018). In patients with high breast field separation (≥ 25 cm), RDS scores (Curcumin = 2.70 [2.21, 3.19]; HPR Plus™ = 3.57 [3.16, 4.00]; Placebo = 2.95 [2.60, 3.30]; p = 0.024) and pain scores (Curcumin = 0.52 [- 0.28, 1.33]; HPR Plus™ = 0.55 [- 0.19, 1.30]; Placebo = 1.73 [0.97, 2.50]; p = 0.046) significantly differed at the end of RT. CONCLUSIONS Although there were no significant effects of the treatment groups on the overall population, our exploratory subgroup analysis suggests that prophylactic treatment with topical curcumin may be effective for minimizing skin reactions and pain for patients with high breast separation (≥ 25 cm) who may have the worst skin reactions.",2020,Logistic regression analyses showed that increased breast field separation positively correlated with increased radiation dermatitis severity (p = 0.018).,"['radiation dermatitis and pain', '191 breast cancer patients', '191 randomized patients', '171 patients were included in the final analyses (87.5% white females, mean age = 58 (range = 36-88', 'patients with high breast separation (≥ 25 cm) who may have the worst skin reactions']","['placebo', 'topical agents', 'topical agents (Curcumin, HPR Plus™, and Placebo']","['pain scores', 'RDS scores', 'radiation dermatitis severity', 'prophylactic effectiveness', 'Mean radiation dermatitis severity (RDS) scores', 'skin reactions and pain', 'radiation dermatitis and associated pain']","[{'cui': 'C0034561', 'cui_str': 'Radiation-Induced Dermatitis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C4517896', 'cui_str': '87.5'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0237868', 'cui_str': 'Separation'}, {'cui': 'C0423754', 'cui_str': 'Poor skin condition (finding)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0034561', 'cui_str': 'Radiation-Induced Dermatitis'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}, {'cui': 'C0221743', 'cui_str': 'Skin reaction (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",191.0,0.2804,Logistic regression analyses showed that increased breast field separation positively correlated with increased radiation dermatitis severity (p = 0.018).,"[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Ryan Wolf', 'Affiliation': 'Department of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY, 14642, USA. julie_ryan@urmc.rochester.edu.'}, {'ForeName': 'Jennifer S', 'Initials': 'JS', 'LastName': 'Gewandter', 'Affiliation': 'Department of Anesthesiology, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Bautista', 'Affiliation': 'URCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'Heckler', 'Affiliation': 'URCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Strasser', 'Affiliation': 'Delaware/Christiana Care NCORP, Newark, DE, USA.'}, {'ForeName': 'Pawal', 'Initials': 'P', 'LastName': 'Dyk', 'Affiliation': 'Heartland Cancer Research NCORP, St. Louis, MO, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Anderson', 'Affiliation': 'Columbus NCORP, Columbus, OH, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Gross', 'Affiliation': 'Dayton Clinical Oncology Program, Dayton, OH, USA.'}, {'ForeName': 'Tod', 'Initials': 'T', 'LastName': 'Speer', 'Affiliation': 'Metro-Minnesota NCORP, St. Louis Park, MN, USA.'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Dolohanty', 'Affiliation': 'Department of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY, 14642, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Bylund', 'Affiliation': 'Department Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Alice P', 'Initials': 'AP', 'LastName': 'Pentland', 'Affiliation': 'Department of Dermatology, University of Rochester Medical Center, 601 Elmwood Ave, Box 697, Rochester, NY, 14642, USA.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Morrow', 'Affiliation': 'URCC NCORP Research Base, University of Rochester Medical Center, Rochester, NY, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05166-5'] 933,31149934,Further Examination of the Pain Stages of Change Questionnaires Among Chronic Low Back Pain Patients: Long-term Predictive Validity of Pretreatment and Posttreatment Change Scores and Stability of Posttreatment Scores.,"OBJECTIVES In order to maximize the therapeutic benefits of cognitive-behavioral therapy (CBT) for chronic pain, individuals need to be motivated to adopt a self-management approach. The Pain Stages of Change Questionnaire (PSOCQ) was developed to measure patients' readiness to adopt a self-management approach to chronic pain. The present study examined whether pretreatment and posttreatment PSOCQ change scores among chronic low back pain patients could predict 6- and 12-month follow-up outcomes, and the stability of posttreatment PSOCQ scores during follow-up. METHODS Participants were recruited from a VA primary care clinic. Data from 60 participants assigned to either regular CBT or a modified CBT (ie, PRIME CBT) condition were analyzed in the present study. Self-report measures including PSOCQ, pain severity, disability, and depressive symptom severity were administered at pretreatment, 10 weeks posttreatment, 6-month and follow-up assessments. RESULTS Multiple regression analyses showed that pretreatment and posttreatment changes in the Action/Maintenance scores significantly predicted pain severity at 6 months, and changes in the Precontemplation scores significantly predicted disability at 6 months. None of the PSOCQ change scores significantly predicted depressive symptom severity. Posttreatment Precontemplation and Action/Maintenance scores were quite stable, even at 12-month follow-up. CONCLUSIONS Changes in patients' attitudes toward adopting a pain self-management approach may serve as one of the therapeutic mechanisms and predict long-term function. This study also revealed that changed attitudes toward chronic pain self-management remain quite stable over time. Adoption of beliefs consistent with chronic pain self-management during treatment may promote sustained benefits.",2019,"Post-treatment Pre-contemplation and Action/Maintenance scores were quite stable, even at 12-month follow up. ","['chronic low back pain patients', '60 participants assigned to either', 'Participants were recruited from a VA primary care clinic', 'Chronic Low Back Pain Patients']","['cognitive behavioral therapy (CBT', 'regular CBT or a modified CBT']","['Pain Stages of Change Questionnaire (PSOCQ', 'Pain Stages of Change Questionnaires', 'PSOCQ, pain severity, disability, and depressive symptom severity', 'pain severity', 'depressive symptom severity']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",60.0,0.0256558,"Post-treatment Pre-contemplation and Action/Maintenance scores were quite stable, even at 12-month follow up. ","[{'ForeName': 'Chung Jung', 'Initials': 'CJ', 'LastName': 'Mun', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Otis', 'Affiliation': 'Department of Psychiatry, Boston University School of Medicine.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Concato', 'Affiliation': 'Departments of Internal Medicine.'}, {'ForeName': 'M Carringotn', 'Initials': 'MC', 'LastName': 'Reid', 'Affiliation': 'Division of Geriatrics and Palliative Medicine, Weill Cornell Medicine, New York, NY.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Burg', 'Affiliation': 'Departments of Internal Medicine.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Czlapinski', 'Affiliation': 'Pain Research, Informatics, Multimorbidities and Education (PRIME) Center, VA Connecticut Healthcare System.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Kerns', 'Affiliation': 'Pain Research, Informatics, Multimorbidities and Education (PRIME) Center, VA Connecticut Healthcare System.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000733'] 934,31757656,"Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial.","BACKGROUND Laparoscopy-assisted distal gastrectomy (LADG) is increasingly being used as an alternative to open distal gastrectomy (ODG) for gastric cancer treatment. Retrospective studies have shown equivalent survival with the two procedures, but these studies are limited by selection bias because LADG is more technically difficult than ODG. We aimed to evaluate whether LADG was non-inferior to ODG in terms of long-term survival outcomes. METHODS We did an open-label, multicentre, non-inferiority, phase 3 randomised controlled trial at 33 institutions in Japan. Patients aged 20-80 years with histologically confirmed gastric adenocarcinoma (T1N0, T1N1, or T2[MP]N0), clinical stage I, in the middle or lower third of the stomach, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with a body-mass index of less than 30 kg/m 2 , were randomly assigned (1:1) to receive ODG or LADG. Randomisation was done by telephone, fax, or with a web-based system in the Japan Clinical Oncology Group Data Center; a minimisation method with a random component was used to adjust for institution and clinical stage (IA or IB). Only study-accredited surgeons performed ODG and LADG. The primary endpoint was relapse-free survival and was analysed according to the intention-to-treat principle. The non-inferiority margin (LADG vs ODG) was set at a hazard ratio (HR) of 1·54. The trial was registered with the UMIN Clinical Trials Registry, UMIN000003319. FINDINGS Between March 15, 2010, and Nov 29, 2013, 921 patients were enrolled and randomly assigned to receive ODG (n=459) or LADG (n=462). 912 (99%) participants had the assigned surgery. 5-year relapse-free survival was 94·0% (95% CI 91·4-95·9) in the ODG group and 95·1% (92·7-96·8) in the LADG group. LADG was non-inferior to ODG for relapse-free survival (HR 0·84 [90% CI 0·56-1·27]), p=0·0075). The most common grade 3 or 4 adverse event was bowel obstruction, occurring in 11 (2%) of 455 patients in the ODG group and five (1%) of 457 patients in the LADG group. There were no treatment-related deaths. INTERPRETATION This trial supports the non-inferiority of LADG compared with ODG for clinical stage I gastric cancer relapse-free survival, suggesting that LADG should be considered a standard treatment option when performed by experienced surgeons. FUNDING Japan National Cancer Center, Ministry of Health, Labour and Welfare of Japan, Japan Agency for Medical Research and Development.",2020,"LADG was non-inferior to ODG for relapse-free survival (HR 0·84 [90% CI 0·56-1·27]), p=0·0075).","['Patients aged 20-80 years with histologically confirmed gastric adenocarcinoma (T1N0, T1N1, or T2[MP]N0), clinical stage I, in the middle or lower third of the stomach, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, with a body-mass index of less than 30 kg/m 2', '912 (99%) participants had the assigned surgery', '33 institutions in Japan', 'Between March 15, 2010, and Nov 29, 2013, 921 patients']","['ODG', 'laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection', 'LADG', 'Laparoscopy-assisted distal gastrectomy (LADG', 'ODG or LADG']","['Survival outcomes', '5-year relapse-free survival', 'relapse-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0205564', 'cui_str': 'Clinical stage I (finding)'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0442051', 'cui_str': 'Lower third (qualifier value)'}, {'cui': 'C3714551', 'cui_str': 'Stomach structure (body structure)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0031150', 'cui_str': 'Celioscopy'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0017118', 'cui_str': 'Gastrectomy'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0443268', 'cui_str': 'Nodal (qualifier value)'}, {'cui': 'C0012737', 'cui_str': 'Dissection'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]",921.0,0.318253,"LADG was non-inferior to ODG for relapse-free survival (HR 0·84 [90% CI 0·56-1·27]), p=0·0075).","[{'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Katai', 'Affiliation': 'Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan. Electronic address: hkatai@ncc.go.jp.'}, {'ForeName': 'Junki', 'Initials': 'J', 'LastName': 'Mizusawa', 'Affiliation': 'Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Katayama', 'Affiliation': 'Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Takanobu', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Department of Gastrointestinal Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan.'}, {'ForeName': 'Etsuro', 'Initials': 'E', 'LastName': 'Bando', 'Affiliation': 'Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Seiji', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Masakazu', 'Initials': 'M', 'LastName': 'Takagi', 'Affiliation': 'Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan.'}, {'ForeName': 'Akinori', 'Initials': 'A', 'LastName': 'Takagane', 'Affiliation': 'Department of Surgery, Hakodate Goryoukaku Hospital, Hakodate, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Teshima', 'Affiliation': 'Department of Surgery, National Hospital Organization, Sendai Medical Center, Sendai, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Koeda', 'Affiliation': 'Department of Surgery, Iwate Medical University, Morioka, Japan.'}, {'ForeName': 'Souya', 'Initials': 'S', 'LastName': 'Nunobe', 'Affiliation': 'Department of Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.'}, {'ForeName': 'Takaki', 'Initials': 'T', 'LastName': 'Yoshikawa', 'Affiliation': 'Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Terashima', 'Affiliation': 'Division of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Mitsuru', 'Initials': 'M', 'LastName': 'Sasako', 'Affiliation': 'Division of Upper Gastrointestinal Surgery, Department of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.'}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30332-2'] 935,31765028,Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.,"AIM Secondary hyperparathyroidism (SHPT), a complication of haemodialysis, is commonly treated with calcimimetics. The impact of dialysates containing different calcium (Ca) concentrations on clinical efficacy of calcimimetics are unclear. We examined whether dialysate Ca concentrations influence the efficacy and dosing of etelcalcetide with concomitant drugs. METHODS We performed post hoc analyses of a 52-week, open-label, multicentre study of etelcalcetide in Japanese SHPT patients to determine whether dialysate Ca influences the therapeutic effects of etelcalcetide with concomitant drugs. We evaluated the differences in serum intact parathyroid hormone (iPTH), corrected Ca (cCa) and phosphate levels among three dialysate Ca concentration groups (2.5, 2.75 or 3.0 mEq/L Ca). Tartrate-resistant acid phosphatase 5b (TRACP-5b) and bone alkaline phosphatase (BAP) levels were also compared. Since the dialysate Ca concentration may influence dose adjustment, we assessed the etelcalcetide and concomitant drug doses. RESULTS There were no clinically meaningful differences in iPTH, cCa and phosphate levels among the 2.5, 2.75 and 3.0 mEq/L groups (n = 34, 64 and 35, respectively) over 52 weeks. At Week 52, more than 82%, 71% and 67% of patients had iPTH, cCa and phosphate levels within target ranges (60-240 pg/mL, 8.4-10.0 mg/dL and 3.5-6.0 mg/dL, respectively) across the three groups. TRACP-5b and BAP levels decreased by Week 52 regardless of dialysate Ca. Changes in etelcalcetide and concomitant drug doses were generally similar in each group. CONCLUSION The efficacy and dosing of etelcalcetide with concomitant drugs were essentially unaffected by the dialysate Ca concentration. Patients showed improvements in bone hypermetabolism during treatment.",2020,"There were no clinically meaningful differences in iPTH, cCa and phosphate levels among the 2.5, 2.75, and 3.0 mEq/L groups (n=34, 64 and 35, respectively) over 52 weeks.","['patients with secondary hyperparathyroidism', 'Japanese SHPT patients']",[],"['TRACP-5b and BAP levels', 'dialysate Ca concentration', 'serum intact parathyroid hormone (iPTH), corrected Ca (cCa) and phosphate levels', 'Tartrate-resistant acid phosphatase 5b (TRACP-5b) and bone alkaline phosphatase (BAP) levels', 'bone hypermetabolism', 'iPTH, cCa and phosphate levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020503', 'cui_str': 'Hyperparathyroidism, Secondary'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]",[],"[{'cui': 'C0297331', 'cui_str': 'TRAcP'}, {'cui': 'C0908518', 'cui_str': '5-((76)Br)bromo-3-((2-azetidinyl)methoxy)pyridine'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0011947', 'cui_str': 'Dialyzates'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0030520', 'cui_str': 'Parathyroid Hormone'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0523826', 'cui_str': 'Phosphate measurement (procedure)'}, {'cui': 'C2106410', 'cui_str': 'Tartrate-resistant acid phosphatase'}, {'cui': 'C1868883', 'cui_str': 'Bone alkaline phosphatase'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0342952', 'cui_str': 'Hypermetabolism (finding)'}, {'cui': 'C0047008', 'cui_str': 'IPTHS'}]",,0.0263646,"There were no clinically meaningful differences in iPTH, cCa and phosphate levels among the 2.5, 2.75, and 3.0 mEq/L groups (n=34, 64 and 35, respectively) over 52 weeks.","[{'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Shigematsu', 'Affiliation': 'Department of Nephrology, Wakayama Medical University, Wakayama-city, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Fukagawa', 'Affiliation': 'Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara-shi, Japan.'}, {'ForeName': 'Keitaro', 'Initials': 'K', 'LastName': 'Yokoyama', 'Affiliation': 'Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Akiba', 'Affiliation': 'Tokyo Next Nephrology & Dialysis Clinic, Tokyo, Japan.'}, {'ForeName': 'Akifumi', 'Initials': 'A', 'LastName': 'Fujii', 'Affiliation': 'Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka-shi, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Shinoda', 'Affiliation': 'Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka-shi, Japan.'}, {'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.'}]","Nephrology (Carlton, Vic.)",['10.1111/nep.13682'] 936,32410152,Letter to the Editor Re: Sera of Obese Type 2 Diabetic Patients Undergoing Metabolic Surgery Instead of Conventional Treatment Exert Beneficial Effects on Beta Cell Survival and Function: Results of a Randomized Clinical Study.,,2020,,['Sera of Obese Type 2 Diabetic Patients Undergoing'],"['Metabolic Surgery', 'Letter to the Editor Re']",['Beta Cell Survival and Function'],"[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}]","[{'cui': 'C0030281', 'cui_str': 'Structure of beta Cell of islet'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0341806,,"[{'ForeName': 'Walter J', 'Initials': 'WJ', 'LastName': 'Pories', 'Affiliation': 'Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC, 27834, USA. poriesw@ecu.edu.'}, {'ForeName': 'G Lynis', 'Initials': 'GL', 'LastName': 'Dohm', 'Affiliation': 'Department of Surgery, Brody School of Medicine, East Carolina University, 600 Moye Blvd, Greenville, NC, 27834, USA.'}]",Obesity surgery,['10.1007/s11695-020-04665-3'] 937,31152080,"Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.","LESSONS LEARNED The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate cancer (mCRPC).The negative data underscore that, despite a sound biological rationale and supportive early-phase clinical results, adding antiangiogenic agents to docetaxel for mCRPC is a great challenge. BACKGROUND Inhibition of vascular endothelial growth factor (VEGF) signaling abrogates tumor-induced angiogenesis to constrain tumor growth, and can be exploited therapeutically by using cediranib, an oral tyrosine kinase inhibitor of VEGF receptor signaling. Our preliminary phase I trial data showed that adding cediranib to docetaxel plus prednisone (DP) was safe and feasible, with early evidence for efficacy in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS This multicenter phase II trial assessed whether adding cediranib to DP improves efficacy of DP in patients with mCRPC. Chemotherapy-naive patients with mCRPC were randomly assigned to receive either docetaxel (75 mg/m 2 intravenously every 3 weeks) with prednisone (5 mg twice daily) plus cediranib (30 mg once daily; the DP+C arm) or DP only (the DP arm). The primary endpoint was to compare 6-month progression-free survival (PFS) rate between the two arms. Secondary endpoints included 6-month overall survival (OS), objective tumor and prostate-specific antigen (PSA) response rates, biomarkers, and adverse events. RESULTS The 6-month PFS rate in a total of 58 patients was only numerically higher in the DP+C arm (61%) compared with the DP arm (57%). Similarly, the 6-month OS rate, objective tumor and PSA response rates, and biomarkers were not significantly different between the two arms. Increased baseline levels of interleukin 6 (IL-6), however, were significantly associated with increased risk of progression. Neutropenia was the only grade 4 toxicity (38% in the DP+C arm vs. 18% in the DP arm). CONCLUSION Combining cediranib with docetaxel + prednisone failed to demonstrate superior efficacy, compared with docetaxel + prednisone, and added toxicity. Our data do not support pursuing the combination further in patients with mCRPC.",2019,"Similarly, the 6-month OS rate, objective tumor and PSA response rates, and biomarkers were not significantly different between the two arms.","['patients with metastatic castrate-resistant prostate cancer (mCRPC', 'naive patients with mCRPC', 'patients with mCRPC', 'patients with metastatic castrate-resistant prostate cancer', 'Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer']","['Chemotherapy', 'Docetaxel plus Prednisone with or Without Cediranib', 'cediranib', 'docetaxel', 'cediranib to DP', 'prednisone', 'cediranib to docetaxel plus prednisone (DP', 'docetaxel + prednisone', 'docetaxel plus antiangiogenic agents']","['6-month overall survival (OS), objective tumor and prostate-specific antigen (PSA) response rates, biomarkers, and adverse events', '6-month OS rate, objective tumor and PSA response rates, and biomarkers', 'risk of progression', '6-month PFS rate', 'toxicity', 'Neutropenia', '6-month progression-free survival (PFS) rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1698364', 'cui_str': '4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline'}, {'cui': 'C0596087', 'cui_str': 'Inhibitors, Angiogenetic'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",58.0,0.0616348,"Similarly, the 6-month OS rate, objective tumor and PSA response rates, and biomarkers were not significantly different between the two arms.","[{'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Heath', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA heathe@karmanos.org.'}, {'ForeName': 'Lance', 'Initials': 'L', 'LastName': 'Heilbrun', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Mannuel', 'Affiliation': 'Division of Hematology/Oncology, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, Maryland, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, Wisconsin, USA.'}, {'ForeName': 'Primo', 'Initials': 'P', 'LastName': 'Lara', 'Affiliation': 'Division of Hematology/Oncology, University of California Davis School of Medicine and Cancer Center, Sacramento, California, USA.'}, {'ForeName': 'J Paul', 'Initials': 'JP', 'LastName': 'Monk', 'Affiliation': 'Division of Medical Oncology, Ohio State University School of Medicine and Cancer Center - James, Columbus, Ohio, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Flaig', 'Affiliation': 'Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Amado', 'Initials': 'A', 'LastName': 'Zurita', 'Affiliation': 'Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Mack', 'Affiliation': 'Division of Hematology/Oncology, University of California Davis School of Medicine and Cancer Center, Sacramento, California, USA.'}, {'ForeName': 'Ulka', 'Initials': 'U', 'LastName': 'Vaishampayan', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Stella', 'Affiliation': 'IHA Hematology/Oncology, Ypsilanti, Michigan, USA.'}, {'ForeName': 'Daryn', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Bolton', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.'}, {'ForeName': 'Arif', 'Initials': 'A', 'LastName': 'Hussain', 'Affiliation': 'Division of Hematology/Oncology, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, Maryland, USA.'}, {'ForeName': 'Anas', 'Initials': 'A', 'LastName': 'Al-Janadi', 'Affiliation': 'Michigan State University Breslin Cancer Center, Lansing, Michigan, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Silbiger', 'Affiliation': 'Case Western Reserve University School of Medicine University Hospitals, Cleveland, Ohio, USA.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Usman', 'Affiliation': 'Department of Oncology, Wayne State University School of Medicine and Karmanos Cancer Institute, Detroit, Michigan, USA.'}, {'ForeName': 'S Percy', 'Initials': 'SP', 'LastName': 'Ivy', 'Affiliation': 'National Institutes of Health National Cancer Institute, Bethesda, Maryland, USA.'}]",The oncologist,['10.1634/theoncologist.2019-0331'] 938,31741686,Individual gender and group gender composition as predictors of differential benefit from mindfulness-based relapse prevention for substance use disorders.,"Objectives Mindfulness-based relapse prevention (MBRP) is an effective group-based aftercare treatment for substance use disorders (SUDs), yet few studies have examined moderators of MBRP efficacy. This secondary data analysis evaluated individual gender and group gender composition (e.g., proportion of women relative to men in each therapy group) as treatment moderators of MBRP. Methods The analysis sample included 186 individuals with SUDs randomized to MBRP or relapse prevention (RP) as an aftercare treatment. Outcomes included number of heavy drinking days and drug use days at the 12-month follow-up. Results There were no treatment moderation effects for models with heavy drinking days as the outcome (all p s > .05). Group gender composition, but not individual gender, moderated the effect of treatment condition on drug use days ( p < .01). Individuals who received MBRP had significantly fewer drug use days at 12-months than those who received RP, but only among individuals in therapy groups comprising one-third or more women ( p <0 .0001). Specifically, all women and men who received MBRP in groups with one-third or more women were abstinent from drugs at month 12, whereas those in RP groups with one-third or more women had an average of about eight drug use days at month 12 (corresponding to a large between-treatment condition effect size). Conclusions Group-based MBRP may be more efficacious than group-based RP, particularly when women compose at least one-third of the therapy group. Further research is warranted on gender and group gender composition as moderators of MBRP.",2019,There were no treatment moderation effects for models with heavy drinking days as the outcome (all p s > .05).,['186 individuals with SUDs randomized to MBRP or relapse prevention (RP) as an aftercare treatment'],"['MBRP', 'Objectives\n\n\nMindfulness-based relapse prevention (MBRP']",['number of heavy drinking days and drug use days at the 12-month follow-up'],"[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0679867', 'cui_str': 'Relapse Prevention'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0679867', 'cui_str': 'Relapse Prevention'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0449889', 'cui_str': 'Drug used (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",186.0,0.0278333,There were no treatment moderation effects for models with heavy drinking days as the outcome (all p s > .05).,"[{'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Roos', 'Affiliation': 'Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque NM, 87131.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Stein', 'Affiliation': 'Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque NM, 87131.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bowen', 'Affiliation': 'School of Graduate Psychology, Pacific University, 190 SE 8th Avenue, Hillsboro OR 97123.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Witkiewitz', 'Affiliation': 'Department of Psychology, University of New Mexico, MSC 03-2220, Albuquerque NM, 87131.'}]",Mindfulness,['10.1007/s12671-019-01112-y'] 939,31134822,Vitamin D supplementation improves the metabolic syndrome risk profile in postmenopausal women.,"Objective: This study aimed to evaluate the effect of isolated vitamin D (VD) supplementation on the metabolic syndrome (MetS) risk profile in postmenopausal women. Methods: In this double-blind, placebo-controlled trial, 160 postmenopausal women aged 50-65 years were randomized into two groups: VD group, supplementation with 1000 IU vitamin D 3 /day ( n  = 80); or placebo group ( n  = 80). The intervention time was 9 months, and the women were assessed at baseline and endpoint. Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glucose, and insulin, were measured. The plasma concentration of 25-hydroxyvitamin D (25(OH)D) was measured by high-performance liquid chromatography. Results: After 9 months, there was a significant increase in the 25(OH)D levels for VD group (+45.4%, p  < 0.001), and a decrease (-18.5%, p  = 0.049) in the placebo group. In the VD group, a significant reduction was observed in triglycerides (-12.2%, p  = 0.001), insulin (-13.7%, p  = 0.008), and the homeostasis model assessment of insulin resistance (-17.9%, p  = 0.007). In the placebo group, there was an increase in glucose (+6.2%, p  = 0.009). Analysis of the risk adjusted for age, time since menopause, and body mass index showed that women supplemented with VD had a lower risk of MetS (odds ratio [OR] 0.42; 95% confidence interval [CI] 0.21-0.83), hypertriglyceridemia (OR 0.43; 95% CI 0.22-0.85), and hyperglycemia (OR 0.23; 95% CI 0.10-0.52) compared to the placebo group ( p  < 0.05). Conclusions: In postmenopausal women with VD deficiency, isolated supplementation with 1000 IU vitamin D 3 for 9 months was associated with a reduction in the MetS risk profile. Women undergoing VD supplementation had a lower risk of MetS, hypertriglyceridemia, and hyperglycemia.",2020,"In the placebo group, there was an increase in glucose (+6.2%, p  = 0.009).","['postmenopausal women', '160 postmenopausal women aged 50-65 years', 'postmenopausal women with VD deficiency, isolated supplementation with 1000']","['placebo', 'Vitamin D supplementation', 'isolated vitamin D (VD) supplementation', 'IU vitamin D', 'VD group, supplementation with 1000\u2009IU vitamin D']","['triglycerides', 'metabolic syndrome risk profile', 'total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glucose, and insulin', 'metabolic syndrome (MetS) risk profile', '25(OH)D levels', 'homeostasis model assessment of insulin resistance', 'glucose', 'hyperglycemia', 'MetS risk profile', 'risk of MetS', 'plasma concentration of 25-hydroxyvitamin D (25(OH)D', 'hypertriglyceridemia', 'lower risk of MetS, hypertriglyceridemia, and hyperglycemia']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0535968', 'cui_str': '25-hydroxyvitamin D'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}]",160.0,0.579366,"In the placebo group, there was an increase in glucose (+6.2%, p  = 0.009).","[{'ForeName': 'P P', 'Initials': 'PP', 'LastName': 'Ferreira', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Cangussu', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'F N', 'Initials': 'FN', 'LastName': 'Bueloni-Dias', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'C L', 'Initials': 'CL', 'LastName': 'Orsatti', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'E B', 'Initials': 'EB', 'LastName': 'Schmitt', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Nahas-Neto', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}, {'ForeName': 'E A P', 'Initials': 'EAP', 'LastName': 'Nahas', 'Affiliation': 'Department of Gynecology and Obstetrics, Botucatu Medical School, Sao Paulo State University - UNESP, Sao Paulo, Brazil.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1611761'] 940,31054015,"Application of tRNS to improve multiple sclerosis fatigue: a pilot, single-blind, sham-controlled study.","We evaluated the effects of transcranial random noise stimulation (tRNS) on fatigue in 17 subjects with relapsing-remitting multiple sclerosis with low physical disability. Two different patient groups underwent real or sham stimulation for 10 days, targeting the primary motor cortex of the dominant side or contralateral to the most compromised limb. In the 'real group', beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales 'change in health' (p = 0.006) and 'role limitations due to physical problems' (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue (p = 0.005).",2019,"In the 'real group', beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales 'change in health' (p = 0.006) and 'role limitations due to physical problems' (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue (p = 0.005).",['17 subjects with relapsing-remitting multiple sclerosis with low physical disability'],"['transcranial random noise stimulation (tRNS', 'tRNS']","['multiple sclerosis fatigue', ""subscales 'change in health"", 'Modified Fatigue Impact Scale', 'patient impression of perceived fatigue']","[{'cui': 'C0751967', 'cui_str': 'Multiple Sclerosis, Relapsing-Remitting'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0520817', 'cui_str': 'Physical handicap (finding)'}]","[{'cui': 'C3852967', 'cui_str': 'Transcranial Random Noise Stimulation'}]","[{'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale (assessment scale)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",17.0,0.0197881,"In the 'real group', beneficial effects were observed using the Modified Fatigue Impact Scale (p = 0.04; physical subscale: p = 0.03), the subscales 'change in health' (p = 0.006) and 'role limitations due to physical problems' (p = 0.001) of the Multiple Sclerosis Quality of Life-54, and by assessing the patient impression of perceived fatigue (p = 0.005).","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Salemi', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Vazzoler', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Ragonese', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy. paolo.ragonese@unipa.it.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Bianchi', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Cosentino', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Croce', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Gangitano', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Portera', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Realmuto', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Brigida', 'Initials': 'B', 'LastName': 'Fierro', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Brighina', 'Affiliation': 'Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, Via Gaetano La Loggia 1, 90129, Palermo, Italy.'}]","Journal of neural transmission (Vienna, Austria : 1996)",['10.1007/s00702-019-02006-y'] 941,31742221,Comparison between Patellar Resurfacing and Retention in Total Knee Arthroplasty Regarding the Postoperative Satisfaction of Patients and Patellar Crepitus.,"Background Patellar crepitus after total knee arthroplasty (TKA) is not uncommon. The choice between patellar resurfacing or retention in TKA has remained controversial. Therefore, this randomized controlled trial aimed to evaluate the impact of patellar resurfacing on the incidence of patellar crepitus. In addition, we compared the clinical outcomes and satisfaction between the patients who underwent patellar retention or resurfacing. Methods A total of 63 patients randomly received patellar resurfacing or non-resurfacing TKA by one surgeon at Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran during May 2014-February 2017. Finally, 29 patients in the resurfaced group and 44 subjects with retained patella were evaluated pre-op and in an average follow-up period of 8.68 months using the clinical Knee Society Score (KSS), functional KSS, and Knee injury and Osteoarthritis Outcome Score (KOOS). Results Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS. It was shown that the latter scores improved in both groups in the follow-up period. Nonetheless, patellar crepitus was not statistically different between the two groups. Conclusion According to the results of the present study, patellar resurfacing did not lead to decreased patellar crepitus or enhanced clinical outcomes of TKA.",2019,"Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS.","['Total Knee Arthroplasty Regarding the Postoperative Satisfaction of Patients and Patellar Crepitus', '29 patients in the resurfaced group and 44 subjects with retained patella', 'by one surgeon at Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Iran during May 2014-February 2017', '63 patients randomly received']","['patellar retention or resurfacing', '\n\n\nPatellar crepitus after total knee arthroplasty (TKA', 'patellar resurfacing or retention in TKA', 'patellar resurfacing', 'patellar resurfacing or non-resurfacing TKA', 'Patellar Resurfacing and Retention']","['satisfaction of patients, KSS, and KOOS', 'latter scores', 'clinical Knee Society Score (KSS), functional KSS, and Knee injury and Osteoarthritis Outcome Score (KOOS', 'patellar crepitus']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030647', 'cui_str': 'Kneecap'}, {'cui': 'C0582175', 'cui_str': 'Surgeon (occupation)'}, {'cui': 'C0521321', 'cui_str': 'Imam'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C1608424', 'cui_str': 'Patellar resurfacing'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0022744', 'cui_str': 'Knee Injuries'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}]",,0.0433543,"Our findings demonstrated no significant difference between the two groups regarding the satisfaction of patients, KSS, and KOOS.","[{'ForeName': 'Mohammad H', 'Initials': 'MH', 'LastName': 'Kaseb', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Mortazavi', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ayati Firoozabadi', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hesam', 'Initials': 'H', 'LastName': 'Toofan', 'Affiliation': 'Tehran University of Medical Sciences, Tehran, Iran.'}]",The archives of bone and joint surgery,[] 942,31747785,Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss.,"Objective: This study aimed to compare the efficacy and safety of ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC) for preventing bone loss during perimenopause in current clinical practice. Methods: The prospective, comparative, non-randomized, open-label study included 851 perimenopausal women with basal bone mineral density (BMD) T -score ≥-2 standard deviations (SDs). Participants received either OHC (712 mg calcium/day) or CC (1000 mg calcium/day) over 3 years. BMD was evaluated by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) at baseline and after 18 and 36 months of follow-up. Adverse drug reactions (ADRs) were also recorded. Results: In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11] g/cm 2 ). BMD in the CC arm decreased -3.1% (mean [SD] - 0.03 [0.11] g/cm 2 ). Between-group differences were statistically significant ( p  < 0.001) and favored OHC. ADRs were more frequent in the CC group (7.7% vs. 2.7% in the OHC group; p  = 0.001), affecting primarily the gastrointestinal system. Conclusion: OHC showed greater efficacy and tolerability than CC for bone loss prevention in perimenopausal women in real-world practice. As the daily dose of calcium was higher in the CC group, the differences might be linked to the ossein compound in OHC.",2020,"In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11]","['perimenopausal women in real-world practice', '851 perimenopausal women with basal bone mineral density (BMD']","['ossein-hydroxyapatite complex versus calcium carbonate', 'CC', 'OHC (712\u2009mg calcium/day) or CC', 'ossein-hydroxyapatite complex (OHC) versus calcium carbonate (CC']","['BMD', 'Adverse drug reactions (ADRs', 'bone loss', 'Efficacy and safety', 'OHC', 'T -score ≥-2 standard deviations (SDs', 'efficacy and tolerability', 'ADRs']","[{'cui': 'C3839366', 'cui_str': 'Perimenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]","[{'cui': 'C0115137', 'cui_str': 'Durapatite'}, {'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C0006681', 'cui_str': 'Calcium Carbonate'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0041755', 'cui_str': 'Drug Side Effects'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",,0.0252347,"In women receiving OHC, BMD at the L2-L4 site remained stable over the 3-year follow-up period (mean [SD] change 0.00 [0.11]","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Castelo-Branco', 'Affiliation': ""Clinic Institute of Gynecology, Obstetrics and Neonatology, Hospital Clinic-Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.""}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Cancelo Hidalgo', 'Affiliation': 'Obstetrics and Gynaecology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Palacios', 'Affiliation': ""Director of Palacios Institute of Woman's Health, Madrid, Spain.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ciria-Recasens', 'Affiliation': 'Rheumatology Department, Parc de Salud Mar, Hospital Universitari del Mar, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fernández-Pareja', 'Affiliation': 'CMSc, Departamento I de Prevención y Promoción de la Salud Hortaleza, Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Carbonell-Abella', 'Affiliation': 'Primary Care Health Centre Vía Roma, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Manasanch', 'Affiliation': 'Pierre Fabre Ibérica, Dep. Médico-Científico, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Haya-Palazuelos', 'Affiliation': 'Obstetrics and Gynaecology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1685488'] 943,30892615,Changes in pharyngeal airway dimensions following incremental and maximum bite advancement during Herbst-rapid palatal expander appliance therapy in late adolescent and young adult patients: a randomized non-controlled prospective clinical study.,"OBJECTIVES This was a parallel, assessor-blinded, randomized, non-controlled prospective trial with the objective to evaluate and compare the effects of maximum advancement (MA) and incremental advancement (IA) of mandible with cast-splint-type Herbst-rapid palatal expander (RPE) appliance on pharyngeal airway dimensions and hyoid bone position in skeletal Class II late adolescents and young adults. MATERIALS AND METHODS A total of 48 patients (19 male and 29 female, mean age: 15.45 ± 1.42 years) with skeletal Class II malocclusion were treated with cast-splint Herbst-RPE appliance. Inclusion criteria were skeletal Class II malocclusion, mandibular retrognathia, bilateral Class II molar and canine relationship, increased overjet, normal or decreased vertical dimensions, minimal crowding, and no missing teeth. Enrolled subjects were randomly allocated into two groups according to mandibular advancement type: IA and MA Herbst-RPE therapy. The outcome assessor was blinded. Advancement in MA group was adjusted until tête-à-tête incisor relationship or super Class I molar relationship was obtained. Initial forward movement in IA group was 4-5 mm and followed by bimonthly 2 mm of subsequent advancements. Skeletal, pharyngeal airway, and hyoid measurements were performed using lateral cephalometric films. Statistical significance was set at P value of less than 0.05. RESULTS Hypopharyngeal airway dimensions (P < 0.000), oropharyngeal airway dimensions (P < 0.001, P < 0.007), and PASmin values (P < 0.010, P < 0.009) were increased and soft palate angle (P < 0.018, P < 0.007) was decreased in MA and IA groups significantly. Hyoid bone measurements revealed a significant difference in H-Cv2 distance (MA: P < 0.002-P < 0.002; IA: P < 0.001-P < 0.043) and H-Cv3 distance (P < 0.005, P < 0.001) for both groups. However, all these changes did not differ among the MA and IA activation groups. ANB°, Wits, overjet, and overbite measurements decreased and SNB°, Co-Gn, Na-Me, ANS-Me, and S-Go increased with the treatment significantly in both mandibular advancement groups (P < 0.000-P < 0.040). CONCLUSIONS Herbst-RPE appliance provided a similar improvement in the oropharyngeal and hypopharyngeal airway dimensions and similar changes in sagittal and vertical hyoid position for both maximum and IA protocols in patients with skeletal Class II malocclusion. TRIAL REGISTRATION ISRCTN69743543.",2019,Hyoid bone measurements revealed a significant difference in H-Cv2 distance (MA: P < 0.002-P,"['skeletal Class II late adolescents and young adults', 'patients with skeletal Class II malocclusion', 'late adolescent and young adult patients', 'Inclusion criteria were skeletal Class II malocclusion, mandibular retrognathia, bilateral Class II molar and canine relationship, increased overjet, normal or decreased vertical dimensions, minimal crowding, and no missing teeth', '48 patients (19 male and 29 female, mean age: 15.45 ± 1.42 years) with skeletal Class II malocclusion']","['cast-splint Herbst-RPE appliance', 'maximum advancement (MA) and incremental advancement (IA) of mandible with cast-splint-type Herbst-rapid palatal expander (RPE) appliance', 'Herbst-RPE appliance', 'incremental and maximum bite advancement during Herbst-rapid palatal expander appliance therapy', 'mandibular advancement type: IA and MA Herbst-RPE therapy']","['oropharyngeal airway dimensions', 'H-Cv2 distance', 'Hypopharyngeal airway dimensions', 'PASmin values', 'H-Cv3 distance', 'soft palate angle', 'pharyngeal airway dimensions', 'oropharyngeal and hypopharyngeal airway dimensions']","[{'cui': 'C0441886', 'cui_str': 'Class 2 (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0399524', 'cui_str': 'Malocclusion, Angle Class II, Division 1'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C3494422', 'cui_str': 'Retrognathias'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0026367', 'cui_str': 'Molar'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0042569', 'cui_str': 'Vertical Dimension'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0441308', 'cui_str': 'Cast splint (physical object)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0243112'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}, {'cui': 'C0024687', 'cui_str': 'Mandible'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0005658', 'cui_str': 'Bites'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0376461', 'cui_str': 'Mandibular Advancement'}]","[{'cui': 'C0150694', 'cui_str': 'Oropharyngeal airway'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0450811', 'cui_str': 'CV2 (body structure)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0450812', 'cui_str': 'CV3 (body structure)'}, {'cui': 'C0030219', 'cui_str': 'Velum Palatinum'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}]",48.0,0.0597592,Hyoid bone measurements revealed a significant difference in H-Cv2 distance (MA: P < 0.002-P,"[{'ForeName': 'Nisa', 'Initials': 'N', 'LastName': 'Gul Amuk', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Erciyes University, Kayseri.'}, {'ForeName': 'Gokmen', 'Initials': 'G', 'LastName': 'Kurt', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Bezmialem University, Istanbul.'}, {'ForeName': 'Asli', 'Initials': 'A', 'LastName': 'Baysal', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Izmir Katip Çelebi University, Izmir.'}, {'ForeName': 'Gokhan', 'Initials': 'G', 'LastName': 'Turker', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Mersin University, Turkey.'}]",European journal of orthodontics,['10.1093/ejo/cjz011'] 944,31748198,Does telephone-delivered exercise advice and support by physiotherapists improve pain and/or function in people with knee osteoarthritis? Telecare randomised controlled trial.,"OBJECTIVE Evaluate a physiotherapist-led telephone-delivered exercise advice and support intervention for people with knee osteoarthritis. METHODS Participant-blinded, assessor-blinded randomised controlled trial. 175 people were randomly allocated to (1) existing telephone service (≥1 nurse consultation for self-management advice) or (2) exercise advice and support (5-10 consultations with a physiotherapist trained in behaviour change for a personalised strengthening and physical activity programme) plus the existing service. Primary outcomes were overall knee pain (Numerical Rating Scale, range 0-10) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index, range 0-68) at 6 months. Secondary outcomes, cost-effectiveness and 12-month follow-up were included. RESULTS 165 (94%) and 158 (90%) participants were retained at 6 and 12 months, respectively. At 6 months, exercise advice and support resulted in greater improvement in function (mean difference 4.7 (95% CI 1.0 to 8.4)), but not overall pain (0.7, 0.0 to 1.4). Eight of 14 secondary outcomes favoured exercise advice and support at 6 months, including pain on daily activities, walking pain, pain self-efficacy, global improvements across multiple domains (overall improvement, improved pain, improved function and improved physical activity) and satisfaction. By 12 months, most outcomes were similar between groups. Exercise advice and support cost $A514/participant and did not save other health service resources. CONCLUSION Telephone-delivered physiotherapist-led exercise advice and support modestly improved physical function but not the co-primary outcome of knee pain at 6 months. Functional benefits were not sustained at 12 months. The clinical significance of this effect is uncertain. TRIAL REGISTRATION NUMBER Australian New Zealand Clinical Trials Registry (#12616000054415).",2020,"Eight of 14 secondary outcomes favoured exercise advice and support at 6 months, including pain on daily activities, walking pain, pain self-efficacy, global improvements across multiple domains (overall improvement, improved pain, improved function and improved physical activity) and satisfaction.","['people with knee osteoarthritis', '175 people']","['physiotherapist-led telephone-delivered exercise advice and support intervention', 'Telephone-delivered physiotherapist-led exercise advice', 'existing telephone service (≥1 nurse consultation for self-management advice) or (2) exercise advice and support (5-10 consultations with a physiotherapist trained in behaviour change for a personalised strengthening and physical activity programme) plus the existing service', 'telephone-delivered exercise advice and support by physiotherapists']","['Functional benefits', 'function', 'physical function', 'overall pain', 'overall knee pain (Numerical Rating Scale, range 0-10) and physical function (Western Ontario and McMaster Universities Osteoarthritis Index, range 0-68', 'exercise advice and support at 6 months, including pain on daily activities, walking pain, pain self-efficacy, global improvements across multiple domains (overall improvement, improved pain, improved function and improved physical activity) and satisfaction', 'knee pain', 'cost-effectiveness and 12-month follow-up were included', 'pain and/or function']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C4517605', 'cui_str': '175'}]","[{'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231749', 'cui_str': 'Knee pain (finding)'}, {'cui': 'C0222045'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",175.0,0.203309,"Eight of 14 secondary outcomes favoured exercise advice and support at 6 months, including pain on daily activities, walking pain, pain self-efficacy, global improvements across multiple domains (overall improvement, improved pain, improved function and improved physical activity) and satisfaction.","[{'ForeName': 'Rana S', 'Initials': 'RS', 'LastName': 'Hinman', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Melbourne, Victoria, Australia ranash@unimelb.edu.au.'}, {'ForeName': 'Penny K', 'Initials': 'PK', 'LastName': 'Campbell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Belinda J', 'Initials': 'BJ', 'LastName': 'Lawford', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Briggs', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Western Australia, Australia.'}, {'ForeName': 'Janette', 'Initials': 'J', 'LastName': 'Gale', 'Affiliation': 'HealthChange Australia, Melbourne, Victoria, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Bills', 'Affiliation': 'HealthChange Australia, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Kasza', 'Affiliation': 'School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Harris', 'Affiliation': 'Centre for Health Economics, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Simon D', 'Initials': 'SD', 'LastName': 'French', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Bunker', 'Affiliation': 'Medibank Private, Melbourne, Victoria, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Forbes', 'Affiliation': 'School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Kim L', 'Initials': 'KL', 'LastName': 'Bennell', 'Affiliation': 'Centre for Health, Exercise and Sports Medicine, The University of Melbourne, Melbourne, Victoria, Australia.'}]",British journal of sports medicine,['10.1136/bjsports-2019-101183'] 945,31122843,Efficacy of an Ultrasound-Guided Erector Spinae Plane Block for Postoperative Analgesia Management After Video-Assisted Thoracic Surgery: A Prospective Randomized Study.,"OBJECTIVES Investigate whether an ultrasound-guided erector spinae plane block (ESPB) can be used to manage postoperative pain in video-assisted thoracic surgery (VATS) patients. DESIGN Prospective, randomized study. SETTING Single institution, academic university hospital. PARTICIPANTS Adult patients who underwent VATS under general anesthesia between September 2018 and March 2019. INTERVENTIONS This study was an interventional study. MEASUREMENTS AND MAIN RESULTS A total of 60 patients were randomly assigned into 2 groups (n = 30 per group): an ESPB group and a control group. In the ESPB group, a single-shot ultrasound-guided ESPB was administered preoperatively. The control group received no such intervention. All of the patients received intravenous patient-controlled postoperative analgesia, and they were assessed using visual analogue scale (VAS) scores, opioid consumption, and adverse events. There were no statistically significant intergroup differences with respect to the age, sex, weight, American Society of Anesthesiologists status, anesthesia duration, and surgery length (p > 0.05 for each). The opioid consumption at 1, 2, 4, 8, 16, and 24 hours and the active and passive VAS scores at 0, 2, 4, 8, 16, and 24 hours were statistically lower in the ESPB group at all of the time periods when compared with the control group (p < 0.05). In the control group, the nausea and itching rates were higher, but there were no intergroup differences in terms of other adverse effects. CONCLUSIONS A preemptive single-shot ESPB may provide effective analgesia management after VATS.",2020,"In the control group, the nausea and itching rates were higher, but there were no intergroup differences in terms of other adverse effects. ","['Adult patients who underwent VATS under general anesthesia between September 2018 and March 2019', '60 patients', 'video-assisted thoracic surgery (VATS) patients', 'Single institution, academic university hospital']","['Video-Assisted Thoracic Surgery', 'Ultrasound-Guided Erector Spinae Plane Block', 'ESPB group and a control group', 'ultrasound-guided erector spinae plane block (ESPB']","['opioid consumption', 'visual analogue scale (VAS) scores, opioid consumption, and adverse events', 'nausea and itching rates', 'adverse effects', 'active and passive VAS scores', 'Postoperative Analgesia Management', 'age, sex, weight, American Society of Anesthesiologists status, anesthesia duration, and surgery length']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",60.0,0.0625061,"In the control group, the nausea and itching rates were higher, but there were no intergroup differences in terms of other adverse effects. ","[{'ForeName': 'Bahadir', 'Initials': 'B', 'LastName': 'Ciftci', 'Affiliation': 'Istanbul Medipol University, School of Medicine, Mega Medipol University Hospital, Department of Anesthesiology and Reanimation, Istanbul, Turkey. Electronic address: bciftci@medipol.edu.tr.'}, {'ForeName': 'Mursel', 'Initials': 'M', 'LastName': 'Ekinci', 'Affiliation': 'Istanbul Medipol University, School of Medicine, Mega Medipol University Hospital, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}, {'ForeName': 'Erkan Cem', 'Initials': 'EC', 'LastName': 'Celik', 'Affiliation': 'Erzurum Regional Training and Research Hospital, Department of Anesthesiology and Reanimation, Yakutiye, Erzurum, Turkey.'}, {'ForeName': 'Ismail Cem', 'Initials': 'IC', 'LastName': 'Tukac', 'Affiliation': 'Istanbul Medipol University, School of Medicine, Mega Medipol University Hospital, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Bayrak', 'Affiliation': 'Istanbul Medipol University, Mega Medipol University Hospital, Department of Thoracic Surgery, Istanbul, Turkey.'}, {'ForeName': 'Yunus Oktay', 'Initials': 'YO', 'LastName': 'Atalay', 'Affiliation': 'Istanbul Medipol University, School of Medicine, Mega Medipol University Hospital, Department of Anesthesiology and Reanimation, Istanbul, Turkey.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2019.04.026'] 946,30659416,Exploring the feasibility of a mild and short 4-week combined upper limb and breathing exercise program as a possible home base program to decrease fatigue and improve quality of life in ambulatory and non-ambulatory multiple sclerosis individuals.,"PURPOSE To evaluate the feasibility of a combined upper limb and breathing exercise for a home-based program and to explore its effect on primary fatigue and quality of life in ambulatory and non-ambulatory individuals with multiple sclerosis (MS) in a short time. METHOD Nineteen individuals with MS were assigned into semi-controlled pre-post feasibility study based on Expanded Disability Status Scale (EDSS) status and divided into two groups: exercise (five ambulatory, five non-ambulatory; EDSS 1.0-8.0) and related control with no exercise (four ambulatory, five non-ambulatory; EDSS 1.0-7.5). Exercise group performed combined upper limb and breathing exercise in a controlled group (2 days/week, 60 min/session) accompanied by independent home exercise (3 days/week, ≥ 20 min/session). Participants underwent measures of fatigue impact (Modified Fatigue Impact Scale (MFIS) and quality of life (RAND Medical outcomes study 36-item short-form health survey (SF-36)) before and after a 4-week period. RESULTS The MFIS (physical, psychosocial, total) showed statistically significant group-by-time interaction in ambulatory (p = 0.033, d = 1.60; p = 0.039, d = 1.59; p = 0.033, d = 1.62) and non-ambulatory individuals (p = 0.009, d = 2.42; p = 0.018, d = 1.96; p = 0.0008, d = 3.92). Physical functioning (SF-36) showed statistically significant group-by-time interaction in ambulatory (p = 0.014, d = 2.14) but no significance in non-ambulatory (p = 0.368, d = 0.68) individuals. Despite the absent statistical significance, there were large intervention effects on MFIS cognitive scores for ambulatory (d = 1.28) and non-ambulatory (d = 1.47), and on other SF-36 scores for ambulatory (general health: d = 1.76 and pain: d = 1.02) and non-ambulatory (physical limitation: d = 1.03 and emotional well-being: d = 0.94) individuals. CONCLUSION Our 4-week program reduced some aspects of fatigue and improved some aspects of quality of life in a small group of ambulatory and non-ambulatory individuals with MS. Good feasibility and significant positive changes from baseline warrant further exploratory work. TRIAL REGISTRATION Name of the registry: The Impact of Exercise Training on Living Quality in Multiple Sclerosis. Registration: The study was registered at www.clinicaltrial.gov on July 14, 2017. First participant enrollment: August 28, 2017. URL: 602-01/17-01-147; Trial registration ID: NTC03222596.",2019,"Physical functioning (SF-36) showed statistically significant group-by-time interaction in ambulatory (p = 0.014, d = 2.14) but no significance in non-ambulatory (p = 0.368, d = 0.68) individuals.","['Nineteen individuals with MS', 'Registration', 'Multiple Sclerosis', 'ambulatory and non-ambulatory multiple sclerosis individuals', 'ambulatory and non-ambulatory individuals with multiple sclerosis (MS']","['Exercise Training', 'combined upper limb and breathing exercise', 'semi-controlled pre-post feasibility study based on Expanded Disability Status Scale (EDSS) status and divided into two groups: exercise (five ambulatory, five non-ambulatory; EDSS 1.0-8.0) and related control with no exercise (four ambulatory, five non-ambulatory; EDSS 1.0-7.5', 'mild and short 4-week combined upper limb and breathing exercise program', 'Exercise group performed combined upper limb and breathing exercise']","['fatigue and improve quality of life', 'MFIS cognitive scores', 'quality of life', 'Physical functioning (SF-36', 'MFIS (physical, psychosocial, total', 'primary fatigue and quality of life', 'fatigue impact (Modified Fatigue Impact Scale (MFIS) and quality of life (RAND Medical outcomes study 36-item short-form health survey (SF-36']","[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0006155', 'cui_str': 'Respiratory Muscle Training'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0015730', 'cui_str': 'Feasibility Studies'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4517859', 'cui_str': 'Seven point five'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale (assessment scale)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}]",19.0,0.0113876,"Physical functioning (SF-36) showed statistically significant group-by-time interaction in ambulatory (p = 0.014, d = 2.14) but no significance in non-ambulatory (p = 0.368, d = 0.68) individuals.","[{'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Grubić Kezele', 'Affiliation': 'Department of Physiology and Immunology, University of Rijeka Faculty of Medicine, B. Branchetta 20, 51000, Rijeka, Croatia. tanja.grubic@medri.uniri.hr.'}, {'ForeName': 'Matea', 'Initials': 'M', 'LastName': 'Babić', 'Affiliation': 'Department of Physiotherapy, University of Rijeka Faculty of Health Studies, Rijeka, Croatia.'}, {'ForeName': 'Dinko', 'Initials': 'D', 'LastName': 'Štimac', 'Affiliation': 'Department of Neurosurgery, Clinical Hospital Center, Rijeka, Croatia.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-019-3707-0'] 947,30995176,"Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.","PURPOSE A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab versus placebo plus rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) was terminated early because of superior efficacy of the IDELA-plus-rituximab (IDELA/R) arm. Patients in either arm could then enroll in an extension study to receive IDELA monotherapy. Here, we report the long-term efficacy and safety data for IDELA-treated patients across the primary and extension studies. PATIENTS AND METHODS Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety. RESULTS The long-term efficacy and safety of treatment with IDELA was assessed in 110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study. The IDELA/R-to-IDELA group had a median PFS of 20.3 months (95% CI, 17.3 to 26.3 months) after a median follow-up time of 18 months (range, 0.3 to 67.6 months). The ORR was 85.5% (94 of 110 patients; n = 1 complete response). The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively. Prolonged exposure to IDELA increased the incidence of all-grade, grade 2, and grade 3 or greater diarrhea (46.4%, 17.3%, and 16.4%, respectively), all-grade and grade 3 or greater colitis (10.9% and 8.2%, respectively) and all-grade and grade 3 or greater pneumonitis (10.0% and 6.4%, respectively) but did not increase the incidence of elevated hepatic aminotransferases. CONCLUSION IDELA improved PFS and OS compared with rituximab alone in patients with relapsed CLL. Long-term IDELA was effective and had an expected safety profile. No new IDELA-related adverse events were identified with longer exposure.",2019,"The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively.","['patients with relapsed chronic lymphocytic leukemia (CLL', 'Patients With Relapsed Chronic Lymphocytic Leukemia', 'Patients', '110 patients who received at least one dose of IDELA in the primary study, 75 of whom enrolled in the extension study', 'patients with relapsed CLL']","['IDELA', 'Rituximab With or Without Idelalisib', 'IDELA monotherapy', 'placebo plus rituximab', 'IDELA-plus-rituximab (IDELA/R', 'idelalisib (IDELA) plus rituximab', 'rituximab', 'rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo']","['PFS and OS', 'grade and grade 3 or greater colitis', 'pneumonitis', 'progression-free survival (PFS), overall response rate (ORR), overall survival (OS), and safety', 'diarrhea', 'median OS', 'ORR', 'median PFS', 'incidence of elevated hepatic aminotransferases']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]","[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C2698692', 'cui_str': 'idelalisib'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}]","[{'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C3714636', 'cui_str': 'Pulmonary Inflammation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferases'}]",110.0,0.412396,"The median OS was 40.6 months (95% CI, 28.5 to 57.3 months) and 34.6 months (95% CI, 16.0 months to not reached) for patients randomly assigned to the IDELA/R and placebo/R groups, respectively.","[{'ForeName': 'Jeff P', 'Initials': 'JP', 'LastName': 'Sharman', 'Affiliation': '1 Willamette Valley Cancer Institute and Research Center, US Oncology Research, Springfield, OR.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Coutre', 'Affiliation': '2 Stanford School of Medicine, Stanford, CA.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Furman', 'Affiliation': '3 Weill Cornell Medical College, New York, NY.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Cheson', 'Affiliation': '4 Georgetown University Hospital, Washington DC.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Pagel', 'Affiliation': '5 Swedish Cancer Institute, Seattle, WA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hillmen', 'Affiliation': ""6 St James's University Hospital, Leeds, United Kingdom.""}, {'ForeName': 'Jacqueline C', 'Initials': 'JC', 'LastName': 'Barrientos', 'Affiliation': '7 Zucher School of Medicine at Hofstra/Northwell, New Hyde Park, NY.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Zelenetz', 'Affiliation': '8 Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Kipps', 'Affiliation': '9 University of California, San Diego, Moores Cancer Center, La Jolla, CA.'}, {'ForeName': 'Ian W', 'Initials': 'IW', 'LastName': 'Flinn', 'Affiliation': '10 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Ghia', 'Affiliation': '11 Università Vita-Salute San Raffaele and Istituto Di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Eradat', 'Affiliation': '12 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ervin', 'Affiliation': '13 Venice Regional Bayfront Health, Venice, FL.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Lamanna', 'Affiliation': '14 Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Coiffier', 'Affiliation': '15 Centre Hospitalier Lyon-Sud, Pierre Benite, France.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Pettitt', 'Affiliation': '16 University of Liverpool, Liverpool, United Kingdom.'}, {'ForeName': 'Shuo', 'Initials': 'S', 'LastName': 'Ma', 'Affiliation': '17 Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.'}, {'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Tausch', 'Affiliation': '18 Ulm University, Ulm, Germany.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cramer', 'Affiliation': '19 University Hospital of Cologne, Cologne, Germany.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': '20 Gilead Sciences, Foster City, CA.'}, {'ForeName': 'Siddhartha', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': '20 Gilead Sciences, Foster City, CA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': '19 University Hospital of Cologne, Cologne, Germany.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': ""O'Brien"", 'Affiliation': '21 University of California, Irvine, Orange, CA.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': '18 Ulm University, Ulm, Germany.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.18.01460'] 948,31067369,Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.,"BACKGROUND The time to initiate intravenous thrombolysis for acute ischemic stroke is generally limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that the treatment window may be extended in patients who are shown to have ischemic but not yet infarcted brain tissue on imaging. METHODS We conducted a multicenter, randomized, placebo-controlled trial involving patients with ischemic stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion imaging. The patients were randomly assigned to receive intravenous alteplase or placebo between 4.5 and 9.0 hours after the onset of stroke or on awakening with stroke (if within 9 hours from the midpoint of sleep). The primary outcome was a score of 0 or 1 on the modified Rankin scale, on which scores range from 0 (no symptoms) to 6 (death), at 90 days. The risk ratio for the primary outcome was adjusted for age and clinical severity at baseline. RESULTS After 225 of the planned 310 patients had been enrolled, the trial was terminated because of a loss of equipoise after the publication of positive results from a previous trial. A total of 113 patients were randomly assigned to the alteplase group and 112 to the placebo group. The primary outcome occurred in 40 patients (35.4%) in the alteplase group and in 33 patients (29.5%) in the placebo group (adjusted risk ratio, 1.44; 95% confidence interval [CI], 1.01 to 2.06; P = 0.04). Symptomatic intracerebral hemorrhage occurred in 7 patients (6.2%) in the alteplase group and in 1 patient (0.9%) in the placebo group (adjusted risk ratio, 7.22; 95% CI, 0.97 to 53.5; P = 0.05). A secondary ordinal analysis of the distribution of scores on the modified Rankin scale did not show a significant between-group difference in functional improvement at 90 days. CONCLUSIONS Among the patients in this trial who had ischemic stroke and salvageable brain tissue, the use of alteplase between 4.5 and 9.0 hours after stroke onset or at the time the patient awoke with stroke symptoms resulted in a higher percentage of patients with no or minor neurologic deficits than the use of placebo. There were more cases of symptomatic cerebral hemorrhage in the alteplase group than in the placebo group. (Funded by the Australian National Health and Medical Research Council and others; EXTEND ClinicalTrials.gov numbers, NCT00887328 and NCT01580839.).",2019,"A secondary ordinal analysis of the distribution of scores on the modified Rankin scale did not show a significant between-group difference in functional improvement at 90 days. ","['A total of 113 patients', 'patients with ischemic stroke who had hypoperfused but salvageable regions of brain detected on automated perfusion imaging', 'After 225 of the planned 310 patients']","['Thrombolysis Guided by Perfusion Imaging', 'placebo', 'intravenous alteplase or placebo']","['ischemic stroke and salvageable brain tissue', 'Symptomatic intracerebral hemorrhage', 'neurologic deficits', 'symptomatic cerebral hemorrhage', 'functional improvement', 'risk ratio', 'score of 0 or 1 on the modified Rankin scale, on which scores range from 0 (no symptoms) to 6 (death', 'modified Rankin scale']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C2350393', 'cui_str': 'Perfusion Imaging'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}]","[{'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C2350393', 'cui_str': 'Perfusion Imaging'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}]","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0440746', 'cui_str': 'Brain tissue (substance)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C0521654', 'cui_str': 'Neurologic Deficits'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",113.0,0.653458,"A secondary ordinal analysis of the distribution of scores on the modified Rankin scale did not show a significant between-group difference in functional improvement at 90 days. ","[{'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Ma', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Bruce C V', 'Initials': 'BCV', 'LastName': 'Campbell', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Mark W', 'Initials': 'MW', 'LastName': 'Parsons', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Leonid', 'Initials': 'L', 'LastName': 'Churilov', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Levi', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Chung', 'Initials': 'C', 'LastName': 'Hsu', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Kleinig', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Tissa', 'Initials': 'T', 'LastName': 'Wijeratne', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Curtze', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Dewey', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Ferdinand', 'Initials': 'F', 'LastName': 'Miteff', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Chon-Haw', 'Initials': 'CH', 'LastName': 'Tsai', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Jiunn-Tay', 'Initials': 'JT', 'LastName': 'Lee', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Thanh G', 'Initials': 'TG', 'LastName': 'Phan', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Mahant', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Mu-Chien', 'Initials': 'MC', 'LastName': 'Sun', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Krause', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Sturm', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Rohan', 'Initials': 'R', 'LastName': 'Grimley', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Chih-Hung', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Chaur-Jong', 'Initials': 'CJ', 'LastName': 'Hu', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Wong', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Field', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'P Alan', 'Initials': 'PA', 'LastName': 'Barber', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Sabet', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Jannes', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Jiann-Shing', 'Initials': 'JS', 'LastName': 'Jeng', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Clissold', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Romesh', 'Initials': 'R', 'LastName': 'Markus', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Ching-Huang', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'Lien', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Christopher F', 'Initials': 'CF', 'LastName': 'Bladin', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Søren', 'Initials': 'S', 'LastName': 'Christensen', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Nawaf', 'Initials': 'N', 'LastName': 'Yassi', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Gagan', 'Initials': 'G', 'LastName': 'Sharma', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bivard', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Desmond', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Yan', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Mitchell', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Thijs', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Leeanne', 'Initials': 'L', 'LastName': 'Carey', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Atte', 'Initials': 'A', 'LastName': 'Meretoja', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Davis', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': 'Geoffrey A', 'Initials': 'GA', 'LastName': 'Donnan', 'Affiliation': ""From Florey Institute of Neuroscience and Mental Health (H.M., L. Churilov, N.Y., V.T., L. Carey, A.M., G.A.D.), the Department of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital (B.C.V.C., M.W.P., L. Churilov, S. Christensen, N.Y., G.S., A.B., B.Y., A.M., S.M.D., G.A.D.), and the Department of Radiology, Royal Melbourne Hospital (P.M.D., B.Y., P.J.M.), University of Melbourne, Parkville, the Department of Medicine, School of Clinical Science, Monash University, Clayton (H.M., T.G.P.), the Departments of Medicine and Neurology, Melbourne Medical School, University of Melbourne and Western Health, Sunshine Hospital, St. Albans (T.W.), the Department of Neurosciences, Eastern Health and Eastern Health Clinical School, Monash University, Box Hill (H.M.D., C.F.B.), the Department of Neurology, University Hospital Geelong, Deakin University, Geelong (B.C.), the Department of Neurology, Austin Hospital, Austin Health, Heidelberg (V.T.), and Occupational Therapy, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora (L. Carey), VIC, the Department of Neurology, Priority Research Centre for Brain and Mental Health Research, John Hunter Hospital (C.R.L., F.M.), University of Newcastle (J.S.), Newcastle, the Department of Neurology, Westmead Hospital (N.M.), the Department of Neurology, Royal North Shore Hospital and Kolling Institute, University of Sydney (M.K.), and the Department of Neurology, St. Vincent's Hospital Sydney (R.M.), Sydney, and the Department of Neurology, Gosford Hospital, Gosford (J.S.), NSW, the Department of Neurology, Royal Adelaide Hospital (T.J.K., J.J.), the Department of Neurology, Lyell McEwin Hospital (D.F.), and the Department of Neurology, Queen Elizabeth Hospital (J.J.), Adelaide, SA, the Department of Medicine, Sunshine Coast University Hospital, Nambour (R.G.), the Department of Neurology, Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane (A.A.W.), and the Department of Neurology, Gold Coast University Hospital, Southport (A.S.), and Australia and Griffith University, Gold Coast (A.S.), QLD - all in Australia; the Graduate Institute of Clinical Medical Science (C.H.) and the School of Medicine (C.-H.T.), China Medical University, and the Department of Neurology, China Medical University Hospital (C.-H.T.), Taichung, the Department of Neurology, Tri-Service General Hospital, National Defense Medical Center (J.-T.L.), the Department of Neurology, Shuang Ho Hospital (C.-J.H.), the Department of Neurology, En Chu Kong Hospital (Y.S.), the Stroke Center and Department of Neurology, National Taiwan University Hospital (J.-S.J.), and the Department of Neurology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei Medical University College of Medicine (L.-M.L.), Taipei, the Stroke Center and Department of Neurology, Changhua Christian Hospital, Changhua (M.-C.S.), the Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan (C.-H.C.), and the Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung (C.-H.L.) - all in Taiwan; the Department of Neurology, Helsinki University Hospital, Helsinki (S. Curtze, A.M.); the Department of Neurology, Auckland City Hospital, University of Auckland, Auckland, New Zealand (P.A.B.); and the Stanford Stroke Center, Stanford University, Stanford, CA (S. Christensen).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1813046'] 949,31113688,Effectiveness of personalized 3D printed models for patient education in degenerative lumbar disease.,"OBJECTIVE Three-dimensional printing may play an important role in patients' education. The objective of this study was to assess the effectiveness of personalized 3D printed models for increasing patient understanding of their medical condition and surgical plan. METHODS Forty-five patients with degenerative lumbar diseases were randomized by block design into three groups: educational program presented by CT & MRI imaging (care-as-usual), 3D reconstructions, or personalized 3D printed models. Patients' level of understanding and satisfaction were evaluated by two questionnaires one day after education. RESULTS Patients educated with personalized 3D printed models demonstrated an expanded level of understanding than patients educated with CT & MRI imaging (care-as-usual) (P ＜ 0.05) and 3D reconstructions (P ＜ 0.05). Personalized 3D printed models also resulted in a higher degree of patient satisfaction (P ＜ 0.05). CONCLUSIONS Personalized 3D printed models and 3D reconstructions can simplify and enhance understanding of lumbar anatomy, physiology, and patients' disease and surgical plan. Personalized 3D printed models also enhance patients' subjective satisfaction. PRACTICE IMPLICATIONS Personalized 3D printed models for patient education are feasible and could be generalized for degenerative lumbar diseases.",2019,"RESULTS Patients educated with personalized 3D printed models demonstrated an expanded level of understanding than patients educated with CT & MRI imaging (care-as-usual)","['Forty-five patients with degenerative lumbar diseases', 'patient education in degenerative lumbar disease', ""patients' education""]","['personalized 3D printed models', 'educational program presented by CT & MRI imaging (care-as-usual), 3D reconstructions, or personalized 3D printed models']",['patient satisfaction'],"[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}]","[{'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",45.0,0.0206324,"RESULTS Patients educated with personalized 3D printed models demonstrated an expanded level of understanding than patients educated with CT & MRI imaging (care-as-usual)","[{'ForeName': 'Yuan-Dong', 'Initials': 'YD', 'LastName': 'Zhuang', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China.'}, {'ForeName': 'Mao-Chao', 'Initials': 'MC', 'LastName': 'Zhou', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China.'}, {'ForeName': 'Shi-Chao', 'Initials': 'SC', 'LastName': 'Liu', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China.'}, {'ForeName': 'Jian-Feng', 'Initials': 'JF', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China.'}, {'ForeName': 'Chun-Mei', 'Initials': 'CM', 'LastName': 'Chen', 'Affiliation': 'Department of Neurosurgery, Union Hospital, Fujian Medical University, Fujian Institute of Neurosurgery, Fuzhou 350001, China. Electronic address: cmchen2009@sina.com.'}]",Patient education and counseling,['10.1016/j.pec.2019.05.006'] 950,31743094,Social Interaction in Walking Groups and Affective Responses Among Japanese Older Adults.,"This study examined whether satisfaction with social interactions and the number of people interacted with during walking groups is associated with affective responses among older adults. Twenty-six older adults were asked to participate in five walking group sessions. The participants walked together for 40-50 min. In every session, the participants reported their affective responses to walking (positive engagement, tranquility, and negative affect), their level of satisfaction with the social interactions experienced, and the number of people interacted with during the walk. The available data were from 107 person-sessions. Multilevel models revealed that, although a higher number of people interacted with was not significantly associated with improvements in any affective responses, higher satisfaction with the interactions was significantly associated with improvements in positive engagement at both the within- and between-person levels. This study found that higher satisfaction with the interactions was associated with desirable affective responses among older adults.",2020,"Multilevel models revealed that, although a higher number of people interacted with was not significantly associated with improvements in any affective responses, higher satisfaction with the interactions was significantly associated with improvements in positive engagement at both the within- and between-person levels.","['Twenty-six older adults', 'older adults', 'Japanese Older Adults']",[],['positive engagement'],"[{'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1556094', 'cui_str': 'Japanese'}]",[],"[{'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}]",26.0,0.017036,"Multilevel models revealed that, although a higher number of people interacted with was not significantly associated with improvements in any affective responses, higher satisfaction with the interactions was significantly associated with improvements in positive engagement at both the within- and between-person levels.","[{'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Harada', 'Affiliation': ''}, {'ForeName': 'Kouhei', 'Initials': 'K', 'LastName': 'Masumoto', 'Affiliation': ''}, {'ForeName': 'Ai', 'Initials': 'A', 'LastName': 'Fukuzawa', 'Affiliation': ''}, {'ForeName': 'Michiko', 'Initials': 'M', 'LastName': 'Touyama', 'Affiliation': ''}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Sato', 'Affiliation': ''}, {'ForeName': 'Narihiko', 'Initials': 'N', 'LastName': 'Kondo', 'Affiliation': ''}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Okada', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2018-0412'] 951,31530667,"Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.","OBJECTIVE To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin. RESEARCH DESIGN AND METHODS Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg ( N = 184), 7 mg ( N = 182), or 14 mg ( N = 181) or to placebo ( N = 184) in a 52-week, double-blind trial. End points were change from baseline to week 26 in HbA 1c (primary) and body weight (confirmatory secondary). Two estimands were defined: treatment policy (effect regardless of trial product discontinuation or rescue medication) and trial product (effect assuming trial product continuation without rescue medication) in randomized patients. RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment difference [ETD] -0.5% [95% CI -0.7, -0.3], -0.9% [-1.1, -0.7], and -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P < 0.001) and body weight (ETD -0.9 kg [95% CI -1.8, -0.0], -2.0 kg [-3.0, -1.0], and -3.3 kg [-4.2, -2.3]; P = 0.0392 for 3 mg, P ≤ 0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand). Significantly greater dose-dependent HbA 1c and body weight reductions versus placebo were achieved with oral semaglutide at weeks 26 and 52 (both estimands). The most frequent adverse event with oral semaglutide was nausea (11.4-23.2% of patients vs. 7.1% with placebo; mostly mild to moderate). CONCLUSIONS Oral semaglutide was superior to placebo in reducing HbA 1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.",2019,"RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment differences [ETD] [95% CI]: -0.5% [-0.7, -0.3], -0.9% [-1.1, -0.7], -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P <0.001) and body weight (ETD [95% CI]: -0.9 kg [-1.8, -0.0], -2.0 kg [-3.0, -1.0], -3.3 kg [-4.2, -2.3]; P =0.0392 for 3 mg, P ≤0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand).","['patients with type 2 diabetes', 'Patients with type 2 diabetes uncontrolled on insulin, ±', 'Patients with Type 2 Diabetes']","['insulin ± metformin', 'metformin', 'Insulin ± Metformin', 'oral semaglutide', 'Oral Semaglutide Versus Placebo', 'placebo', 'oral semaglutide added to insulin ± metformin']","['dose-dependent HbA 1c , and body weight reductions', 'HbA 1c and body weight', 'body weight', 'reducing HbA 1c', 'Efficacy, Safety and Tolerability', 'efficacy, safety and tolerability', 'nausea']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]","[{'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",,0.109896,"RESULTS Oral semaglutide was superior to placebo in reducing HbA 1c (estimated treatment differences [ETD] [95% CI]: -0.5% [-0.7, -0.3], -0.9% [-1.1, -0.7], -1.2% [-1.4, -1.0] for 3, 7, and 14 mg, respectively; P <0.001) and body weight (ETD [95% CI]: -0.9 kg [-1.8, -0.0], -2.0 kg [-3.0, -1.0], -3.3 kg [-4.2, -2.3]; P =0.0392 for 3 mg, P ≤0.0001 for 7 and 14 mg) at week 26 (treatment policy estimand).","[{'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada zinman@lunenfeld.ca.'}, {'ForeName': 'Vanita R', 'Initials': 'VR', 'LastName': 'Aroda', 'Affiliation': ""Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.""}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Division of Endocrinology and Metabolism, University of North Carolina School of Medicine, Chapel Hill, NC.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Cariou', 'Affiliation': ""Department of Endocrinology, L'Institut du Thorax, CIC INSERM 1413, CHU Nantes, Université de Nantes, Nantes, France.""}, {'ForeName': 'Stewart B', 'Initials': 'SB', 'LastName': 'Harris', 'Affiliation': 'Department of Family Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.'}, {'ForeName': 'Søren Tetens', 'Initials': 'ST', 'LastName': 'Hoff', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Karen Boje', 'Initials': 'KB', 'LastName': 'Pedersen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Mads Jeppe', 'Initials': 'MJ', 'LastName': 'Tarp-Johansen', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Eiichi', 'Initials': 'E', 'LastName': 'Araki', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0898'] 952,31530666,Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.,"OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg ( n = 412) or empagliflozin 25 mg ( n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA 1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA 1c versus empagliflozin at week 26 (treatment policy -1.3% vs. -0.9% [-14 vs. -9 mmol/mol], estimated treatment difference [ETD] -0.4% [95% CI -0.6, -0.3] [-5 mmol/mol (-6, -3)]; P < 0.0001). The treatment difference in HbA 1c significantly favored oral semaglutide at week 26 for the trial product estimand (-1.4% vs. -0.9% [-15 vs. -9 mmol/mol], ETD -0.5% [95% CI -0.7, -0.4] [-6 mmol/mol (-7, -5)]; P < 0.0001) and at week 52 for both estimands ( P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS Oral semaglutide was superior to empagliflozin in reducing HbA 1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA 1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.",2019,"Oral semaglutide provided superior reductions in HbA 1c versus empagliflozin at week 26 (treatment policy: -1.3% vs. -0.9% [-14 vs. -9 mmol/mol]; estimated treatment difference [ETD]: -0.4%, 95% CI -0.6, -0.3 [","['Patients', 'Patients with Type 2 Diabetes Uncontrolled on', 'patients with type 2 diabetes uncontrolled on metformin', 'patients with type 2 diabetes uncontrolled on']","['Oral Semaglutide versus Empagliflozin', 'Metformin', 'GLP-1 analog, oral semaglutide, and the SGLT-2 inhibitor, empagliflozin', 'metformin', 'daily open-label treatment with oral semaglutide 14 mg ( n = 412) or empagliflozin', 'empagliflozin']","['HbA 1c (primary) and body weight (confirmatory secondary', 'oral semaglutide', 'Superior weight loss', 'Gastrointestinal adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled (qualifier value)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C3273807', 'cui_str': 'Gliflozins'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3885068', 'cui_str': 'semaglutide'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",400.0,0.0679674,"Oral semaglutide provided superior reductions in HbA 1c versus empagliflozin at week 26 (treatment policy: -1.3% vs. -0.9% [-14 vs. -9 mmol/mol]; estimated treatment difference [ETD]: -0.4%, 95% CI -0.6, -0.3 [","[{'ForeName': 'Helena W', 'Initials': 'HW', 'LastName': 'Rodbard', 'Affiliation': 'Endocrine and Metabolic Consultants, Rockville, MD hrodbard@comcast.net.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosenstock', 'Affiliation': 'Dallas Diabetes Research Center at Medical City, Dallas, TX.'}, {'ForeName': 'Luis H', 'Initials': 'LH', 'LastName': 'Canani', 'Affiliation': 'Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Chaicharn', 'Initials': 'C', 'LastName': 'Deerochanawong', 'Affiliation': 'Rajavithi Hospital, Rangsit Medical School, Bangkok, Thailand.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Gumprecht', 'Affiliation': 'Medical University of Silesia, Katowice, Poland.'}, {'ForeName': 'Søren Østergaard', 'Initials': 'SØ', 'LastName': 'Lindberg', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Lingvay', 'Affiliation': 'Departments of Internal Medicine and Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX.'}, {'ForeName': 'Anette Luther', 'Initials': 'AL', 'LastName': 'Søndergaard', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Marianne Bach', 'Initials': 'MB', 'LastName': 'Treppendahl', 'Affiliation': 'Novo Nordisk A/S, Søborg, Denmark.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Montanya', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes care,['10.2337/dc19-0883'] 953,31548244,Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial.,"OBJECTIVE In type 2 diabetes, insulin resistance and progressive β-cell failure require treatment with high insulin doses, leading to weight gain. Our aim was to study whether a three-meal diet (3Mdiet) with a carbohydrate-rich breakfast may upregulate clock gene expression and, as a result, allow dose reduction of insulin, leading to weight loss and better glycemic control compared with an isocaloric six-meal diet (6Mdiet). RESEARCH DESIGN AND METHODS Twenty-eight volunteers with diabetes (BMI 32.4 ± 5.2 kg/m 2 and HbA 1c 8.1 ± 1.1% [64.5 ± 11.9 mmol/mol]) were randomly assigned to 3Mdiet or 6Mdiet. Body weight, glycemic control, continuous glucose monitoring (CGM), appetite, and clock gene expression were assessed at baseline, after 2 weeks, and after 12 weeks. RESULTS 3Mdiet, but not 6Mdiet, led to a significant weight loss (-5.4 ± 0.9 kg) ( P < 0.01) and decreased HbA 1c (-12 mmol/mol [-1.2%]) ( P < 0.0001) after 12 weeks. Fasting glucose and daily and nocturnal glucose levels were significantly lower on the 3Mdiet. CGM showed a significant decrease in the time spent in hyperglycemia only on the 3Mdiet. Total daily insulin dose was significantly reduced by 26 ± 7 units only on the 3Mdiet. There was a significant decrease in the hunger and cravings only in the 3Mdiet group. Clock genes exhibited oscillation, increased expression, and higher amplitude on the 3Mdiet compared with the 6Mdiet. CONCLUSIONS A 3Mdiet, in contrast to an isocaloric 6Mdiet, leads to weight loss and significant reduction in HbA 1c , appetite, and overall glycemia, with a decrease in daily insulin. Upregulation of clock genes seen in this diet intervention could contribute to the improved glucose metabolism.",2019,Fasting glucose and daily and nocturnal glucose levels were significantly lower on the 3Mdiet.,"['Twenty-eight volunteers with diabetes (BMI 32.4 ± 5.2 kg/m 2 and HbA 1c 8.1 ± 1.1% [64.5 ± 11.9 mmol/mol', 'Patients With Type']","['3Mdiet or 6Mdiet', 'isocaloric six-meal diet (6Mdiet', 'meal diet (3Mdiet) with a carbohydrate-rich breakfast', 'CGM']","['time spent in hyperglycemia', 'weight loss, significant reduction in HbA 1c , appetite, and overall glycemia', 'Body weight, glycemic control, continuous glucose monitoring (CGM), appetite, and clock gene expression', 'glucose metabolism', 'Fasting glucose and daily and nocturnal glucose levels', 'Total daily insulin dose', 'hunger and cravings', 'weight loss', 'daily insulin', 'Glycated Hemoglobin and Daily Insulin Dose']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C4517709', 'cui_str': '32.4 (qualifier value)'}, {'cui': 'C4517790', 'cui_str': '5.2 (qualifier value)'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4517875', 'cui_str': '8.1 (qualifier value)'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",28.0,0.0205284,Fasting glucose and daily and nocturnal glucose levels were significantly lower on the 3Mdiet.,"[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Jakubowicz', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel daniela.jak@gmail.com.'}, {'ForeName': 'Zohar', 'Initials': 'Z', 'LastName': 'Landau', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Shani', 'Initials': 'S', 'LastName': 'Tsameret', 'Affiliation': 'Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Wainstein', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Raz', 'Affiliation': 'Diabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, The Hebrew University of Jerusalem, Jerusalem, Israel.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Ahren', 'Affiliation': 'Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.'}, {'ForeName': 'Nava', 'Initials': 'N', 'LastName': 'Chapnik', 'Affiliation': 'Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel.'}, {'ForeName': 'Maayan', 'Initials': 'M', 'LastName': 'Barnea', 'Affiliation': 'Department of Molecular Genetics, Faculty of Biochemistry, Weizmann Institute of Science, Rehovot, Israel.'}, {'ForeName': 'Tali', 'Initials': 'T', 'LastName': 'Ganz', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Menaged', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Mor', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Yosefa', 'Initials': 'Y', 'LastName': 'Bar-Dayan', 'Affiliation': 'Diabetes Unit, Wolfson Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Holon, Israel.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Froy', 'Affiliation': 'Institute of Biochemistry, Food Science and Nutrition, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot, Israel oren.froy@mail.huji.ac.il.'}]",Diabetes care,['10.2337/dc19-1142'] 954,31743984,The effectiveness of superimposed neuromuscular electrical stimulation combined with strengthening exercises on patellofemoral pain: A randomized controlled pilot trial.,"BACKGROUND Patellofemoral pain (PFP) is one of the most common disorders of the knee. Neuromuscular electrical stimulation (NMES) is often assumed by clinicians to be an effective adjunctive therapy to quadriceps strengthening. OBJECTIVE The aim of this study was to assess the efficacy of superimposed NMES combined with strengthening exercises to improve the recovery of quadriceps strength and function in patients with PFP. METHODS This study was planned as a single blind randomized controlled pilot study. A total of twenty-seven patients diagnosed with PFP were randomly assigned into 2 groups. Patients received superimposed NMES in addition to the standardized program (Group I) or only the standardized program (Group II). The patients in both groups were treated 3 times a week for 6 weeks and followed at 12 weeks. Primary outcome measure was quadriceps isokinetic muscle strength. The changes in dependent variables before treatment, 6th, and 12th weeks were analyzed using a 2 × 3 mixed-model analysis of variance. RESULTS There were significant improvements in the within groups statistics of all parameters for both groups (p< 0.05). No differences in quadriceps strength, Kujala and Lysholm scores between groups were found at the different time points [F (2, 21) = 0.86; p= 0.12, F (2, 21) = 0.001; p= 0.97, F (2, 21) = 0.12; p= 0.73, respectively]. CONCLUSIONS The results indicate that superimposed NMES combined with the standardized rehabilitation program has no clinically significant superiority to standardized rehabilitation program alone.",2020,"No differences in quadriceps strength, Kujala and Lysholm scores between groups were found at the different time points [F (2, 21) = 0.86; p= 0.12, F (2, 21) = 0.001; p= 0.97, F (2, 21) = 0.12; p= 0.73, respectively]. ","['patellofemoral pain', 'A total of twenty-seven patients diagnosed with PFP', 'patients with PFP']","['superimposed NMES', 'superimposed neuromuscular electrical stimulation combined with strengthening exercises', 'Neuromuscular electrical stimulation (NMES', 'superimposed NMES combined with strengthening exercises']","['quadriceps strength, Kujala and Lysholm scores', 'quadriceps isokinetic muscle strength']","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise (regime/therapy)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]",,0.122387,"No differences in quadriceps strength, Kujala and Lysholm scores between groups were found at the different time points [F (2, 21) = 0.86; p= 0.12, F (2, 21) = 0.001; p= 0.97, F (2, 21) = 0.12; p= 0.73, respectively]. ","[{'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Celik', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Sezen Karaborklu', 'Initials': 'SK', 'LastName': 'Argut', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Nilgün', 'Initials': 'N', 'LastName': 'Türker', 'Affiliation': 'Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Onder Ismet', 'Initials': 'OI', 'LastName': 'Kilicoglu', 'Affiliation': 'Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-181339'] 955,30877851,Sudden gains in cognitive behavioral therapy among children and adolescents with obsessive compulsive disorder.,"BACKGROUND AND OBJECTIVES This study examined the occurrence of sudden gains (or reversal of gains) among children with obsessive-compulsive disorder (OCD) during the course of cognitive-behavioral therapy (CBT), as well as the association of sudden gains with treatment response, treatment group, and pre-treatment clinical characteristics. METHODS The sample consisted of 136 youth (ages 7-17) with a primary diagnosis of OCD who were randomized in a double-blinded fashion to 10 sessions of CBT with augmentation of either d-cycloserine or placebo. Sudden gain status was determined based on clinician-rated obsessive-compulsive symptom severity, which was collected on 9 occasions across the study period. RESULTS 42.6% of youth experienced at least one sudden gain, which tended to occur either after starting exposure and response prevention or towards the end of treatment. After applying the Benjamini-Hochberg procedure for multiple comparisons, there were no significant pre-treatment predictors of sudden gains and only reduced insight predicted the reversal of gains. Individuals with at least one sudden gain had improved overall treatment outcomes, measured both by reduction in OCD symptom severity, and by global illness severity. LIMITATIONS Several clinical constructs were not examined. Symptomatology was not assessed at every treatment session. Differences in those who achieved sudden gains and those who did not may be obscured. There is the possibility that a sudden gain reflected a scoring error generated by an optimistic or inaccurate report. Finally, a relatively homogenous sample may limit the generalizability of results. CONCLUSIONS The course of CBT for pediatric OCD is variable with many children experiencing sudden gains, but a sizable percentage experience a reversal of gains which was related to reduced insight. Sudden gains tended to occur after starting exposure and response prevention and towards the end of treatment. TRIALSREGISTRATION ClinicaltrialsgovRegistry:NCT00864123. https://www.clinicaltrials.gov/ct2/show/NCT00864123.",2019,"After applying the Benjamini-Hochberg procedure for multiple comparisons, there were no significant pre-treatment predictors of sudden gains and only reduced insight predicted the reversal of gains.","['children with obsessive-compulsive disorder (OCD', 'children and adolescents with obsessive compulsive disorder', '136 youth (ages 7-17) with a primary diagnosis of OCD']","['CBT with augmentation of either d-cycloserine or placebo', 'cognitive behavioral therapy', 'cognitive-behavioral therapy (CBT']","['sudden gain', 'OCD symptom severity, and by global illness severity', 'Sudden gains', 'Symptomatology', 'Sudden gain status', 'sudden gains']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028768', 'cui_str': 'Anankastic Personality'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C1276802', 'cui_str': 'Sudden onset'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",136.0,0.0840534,"After applying the Benjamini-Hochberg procedure for multiple comparisons, there were no significant pre-treatment predictors of sudden gains and only reduced insight predicted the reversal of gains.","[{'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Storch', 'Affiliation': 'Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, USA. Electronic address: eric.storch@bcm.edu.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'McGuire', 'Affiliation': 'Division of Child and Adolescent Psychiatry, Johns Hopkins University School of Medicine, USA.'}, {'ForeName': 'Sophie C', 'Initials': 'SC', 'LastName': 'Schneider', 'Affiliation': 'Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, USA.'}, {'ForeName': 'Brent J', 'Initials': 'BJ', 'LastName': 'Small', 'Affiliation': 'School of Aging Studies, University of South Florida, USA.'}, {'ForeName': 'Tanya K', 'Initials': 'TK', 'LastName': 'Murphy', 'Affiliation': 'Department of Pediatrics, University of South Florida, USA.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Wilhelm', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, USA.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Geller', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, USA.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.03.003'] 956,31733807,Effects of positive end-expiratory pressure/recruitment manoeuvres compared with zero end-expiratory pressure on atelectasis during open gynaecological surgery as assessed by ultrasonography: a randomised controlled trial.,"BACKGROUND During general anaesthesia, most patients develop atelectasis, which promotes postoperative pulmonary complications. RCTs that investigated perioperative lung protection have failed to reduce postoperative pulmonary complications consistently. Ultrasound imaging could help confirm the effects of different protective ventilatory strategies, but this has not been tested in trials. The objective of this study was to use ultrasonography to evaluate whether lung-protective ventilation measures reduce perioperative atelectasis. METHODS We conducted a prospective, randomised patient- and assessor-blinded controlled trial in women undergoing open gynaecological surgery. Subjects were randomised to either lung protection or zero end-expiratory pressure (ZEEP; with no recruitment manoeuvres [RMs]). Lung protection entailed PEEP (7 cm H 2 O) and RMs every 30 min. Lung ultrasonography was undertaken at five predefined time points. The primary outcome was the difference in lung ultrasonography score (LUS) between groups before emergence; a lower LUS indicates better lung aeration. RESULTS We recruited 45 women (34-85 yr old). Women randomised to lung protection had lower mean (standard deviation) LUS before emergence (6.1 [3.7]), compared with women randomised to ZEEP (11.7 [3.9]; 95% confidence interval for the difference between group means [-7.9 to -3.2]; P<0.0001). This difference did not persist after extubation, with similar mean LUSs in women who had received intraoperative lung protection (7.0 [4.1]), compared with women randomised to receive ZEEP (7.7 [3.1]). CONCLUSIONS As assessed by lung ultrasonography, intraoperative PEEP/RMs decreased aeration loss during general anaesthesia. However, similar degrees of aeration loss were observed after tracheal extubation regardless of intraoperative ventilatory strategy. CLINICAL TRIAL REGISTRATION NCT02055807.",2020,"Women randomised to lung protection had lower mean (standard deviation) LUS before emergence (6.1 [3.7]), compared with women randomised to ZEEP (11.7 [3.9]; 95% confidence interval for the difference between group means [-7.9 to -3.2]; P<0.0001).","['women who had received intraoperative lung protection (7.0 [4.1', '45 women (34-85 yr old', 'women undergoing open gynaecological surgery']","['positive end-expiratory pressure/recruitment manoeuvres compared with zero end-expiratory pressure', 'ZEEP', 'lung-protective ventilation', 'Lung protection entailed PEEP', 'lung protection or zero end-expiratory pressure (ZEEP; with no recruitment manoeuvres [RMs', 'ultrasonography']","['lung ultrasonography score (LUS', 'aeration loss']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C3494516', 'cui_str': 'Positive end expiratory pressure (observable entity)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0919414', 'cui_str': '0 (qualifier value)'}, {'cui': 'C0428720', 'cui_str': 'End-expiratory pressure'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0863179', 'cui_str': 'Peeping'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}]","[{'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",45.0,0.574347,"Women randomised to lung protection had lower mean (standard deviation) LUS before emergence (6.1 [3.7]), compared with women randomised to ZEEP (11.7 [3.9]; 95% confidence interval for the difference between group means [-7.9 to -3.2]; P<0.0001).","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Généreux', 'Affiliation': ""Department of Anaesthesiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Michaël', 'Initials': 'M', 'LastName': 'Chassé', 'Affiliation': ""Department of Medicine, Division of Critical Care, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Girard', 'Affiliation': ""Department of Anaesthesiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Massicotte', 'Affiliation': ""Department of Anaesthesiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Chartrand-Lefebvre', 'Affiliation': ""Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Department of Radiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Girard', 'Affiliation': ""Department of Anaesthesiology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Department of Medicine, Division of Critical Care, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. Electronic address: martin.girard@umontreal.ca.""}]",British journal of anaesthesia,['10.1016/j.bja.2019.09.040'] 957,31734568,Combining baseline characteristics to disentangle response differences to disorder-specific versus supportive psychotherapy in patients with persistent depressive disorder.,"Does the pre-treatment profile of individuals with persistent depressive disorder (PDD) moderate their benefit from disorder-specific Cognitive Behavioral System of Psychotherapy (CBASP) versus supportive psychotherapy (SP)? We investigated this question by analyzing data from a multi-center randomized clinical trial comparing the effectiveness of 48 weeks of CBASP to SP in n  =  237 patients with early-onset PDD who were not taking antidepressant medication. We statistically developed an optimal composite moderator as a weighted combination of 13 preselected baseline variables and used it for identifying and characterizing subgroups for which CABSP may be preferable to SP or vice versa. We identified two distinct subgroups: 58.65% of the patients had a better treatment outcome with CBASP, while the remaining 41.35% had a better outcome with SP. At baseline, patients responding more favorably to CBASP were more severely depressed and more likely affected by moderate-to-severe childhood trauma including early emotional, physical, or sexual abuse, as well as emotional or physical neglect. In contrast, patients responding more favorably to SP had a higher pre-treatment global and social functioning level, a higher life quality and more often a recurrent illness pattern without complete remission between the episodes. These findings emphasize the relevance of considering pre-treatment characteristics when selecting between disorder-specific CBASP and SP for treating PDD. The practical implementation of this approach would advance personalized medicine for PDD by supporting mental health practitioners in their selection of the most effective psychotherapy for an individual patient.",2020,"In contrast, patients responding more favorably to SP had a higher pre-treatment global and social functioning level, a higher life quality and more often a recurrent illness pattern without complete remission between the episodes.","['patients with persistent depressive disorder', 'in n \u202f= \u202f237 patients with early-onset PDD who were not taking antidepressant medication', 'individuals with persistent depressive disorder (PDD']","['supportive psychotherapy', 'Psychotherapy (CBASP) versus supportive psychotherapy (SP', 'CBASP to SP', 'CBASP']","['higher pre-treatment global and social functioning level', 'moderate-to-severe childhood trauma including early emotional, physical, or sexual abuse']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4087263', 'cui_str': 'Persistent depressive disorder'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0221295', 'cui_str': 'Supportive psychotherapy'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0282350', 'cui_str': 'Sexual abuse (event)'}]",237.0,0.0823288,"In contrast, patients responding more favorably to SP had a higher pre-treatment global and social functioning level, a higher life quality and more often a recurrent illness pattern without complete remission between the episodes.","[{'ForeName': 'Ilinca', 'Initials': 'I', 'LastName': 'Serbanescu', 'Affiliation': 'Center for Economics and Neuroscience, University of Bonn, Nachtigallenweg 86, D-53127, Bonn, Germany; Institute of Experimental Epileptology and Cognition Research, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany. Electronic address: ilinca.serbanescu@ukbonn.de.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Walter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Charité-University Medicine Berlin, Charitéplatz 1, D-10117, Berlin, Germany.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Schnell', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, vonsiebold Straße 5, D-37075, Göttingen, Germany.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Kessler', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, LWL University Hospital, Ruhr University Bochum, Alexandrinenstrasse 1-3, D-44791, Bochum, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Weber', 'Affiliation': 'Center for Economics and Neuroscience, University of Bonn, Nachtigallenweg 86, D-53127, Bonn, Germany; Institute of Experimental Epileptology and Cognition Research, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Drost', 'Affiliation': 'Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Groß', 'Affiliation': 'Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Neudeck', 'Affiliation': 'Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Klein', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Lübeck University, Ratzeburger Allee 160, D-23538, Lübeck, Germany.'}, {'ForeName': 'Nele', 'Initials': 'N', 'LastName': 'Assmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Lübeck University, Ratzeburger Allee 160, D-23538, Lübeck, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Zobel', 'Affiliation': 'Psychology School at the Fresenius University of Applied Sciences Berlin, Jägerstrasse 32, D-10117, Berlin, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Backenstrass', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Heidelberg, Hauptstrasse 47-51, D-69117, Heidelberg, Germany; Institute of Clinical Psychology, Hospital Stuttgart, Prießnitzweg 24, D-70374, Stuttgart, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hautzinger', 'Affiliation': 'Department of Psychology, Clinical Psychology and Psychotherapy, Eberhard Karls University Tübingen, Schleichstrasse 4, D-72076, Tübingen, Germany.'}, {'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Meister', 'Affiliation': 'Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Härter', 'Affiliation': 'Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246, Hamburg, Germany.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Schramm', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 5, D-79104, Freiburg, Germany.'}, {'ForeName': 'Dieter', 'Initials': 'D', 'LastName': 'Schoepf', 'Affiliation': 'Department of Psychiatry and Psychotherapy, CBASP Center of Competence, University of Bonn, Sigmund-Freud-Strasse 25, D-53127, Bonn, Germany; Department of Psychiatry and Psychotherapy, Vitos Weil-Lahn, Mönchberg 8, D-65589, Hadamar, Germany.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103512'] 958,31743982,Technological rehabilitation versus conventional rehabilitation following hip replacement: A prospective controlled study.,"BACKGROUND Among new technological rehabilitation systems, there are proprioceptive platforms. These could be useful to improve static and dynamic balance. OBJECTIVE To evaluate technological proprioceptive rehabilitation compared to conventional rehabilitation in patients after total hip arthroplasty (THA). METHODS Sixty-four patients after THA were divided in two groups: a conventional group (CG) and a technological group (TG) treated with proprioceptive platforms. Before (T0) and after 20 sessions (T1), we recorded static and dynamic balance. Clinical and disability scales (Modified Harris Hip Score, Barthel Index, Deambulation Index), pain scales (ID-PAIN, DN4, VAS) and QoL scale (SF-36) were administered to patients during T0 and T1. Mann-Whitney U test was used for stabilometric and dynamic assessments to detect differences between groups of patients and healthy subjects. The Wilcoxon signed-rank test was used for the within-group analysis and the ANCOVA test for the analysis between groups of patients. RESULTS All scales improved significantly in both groups after treatment (p< 0.05). Static balance improved in both groups, but there were greater improvements in the TG than in the CG. All dynamic balance indexes showed significant improvements only in the TG after treatment. CONCLUSIONS Both treatments improved the clinical, disability, pain, and QoL scales, as well as static balance, but only proprioceptive technological rehabilitation improved dynamic balance. Rehabilitation through proprioceptive platforms can indeed improve static and dynamic balance, which are both crucial for the patient's safety and autonomy.",2020,"Both treatments improved the clinical, disability, pain, and QoL scales, as well as static balance, but only proprioceptive technological rehabilitation improved dynamic balance.","['patients and healthy subjects', 'Sixty-four patients after THA', 'patients after total hip arthroplasty (THA', 'hip replacement']","['technological proprioceptive rehabilitation', 'conventional rehabilitation', 'Technological rehabilitation versus conventional rehabilitation', 'conventional group (CG) and a technological group (TG) treated with proprioceptive platforms']","['dynamic balance', 'Clinical and disability scales (Modified Harris Hip Score, Barthel Index, Deambulation Index), pain scales (ID-PAIN, DN4, VAS) and QoL scale (SF-36', 'Static balance', 'clinical, disability, pain, and QoL scales, as well as static balance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0642413', 'cui_str': 'THAS'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C0392806', 'cui_str': 'Hip Prosthesis Implantation'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0222045'}, {'cui': 'C2960598', 'cui_str': 'Modified Harris hip score'}, {'cui': 'C0451019', 'cui_str': 'Barthel index (assessment scale)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}]",64.0,0.0220917,"Both treatments improved the clinical, disability, pain, and QoL scales, as well as static balance, but only proprioceptive technological rehabilitation improved dynamic balance.","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Aprile', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Iacovelli', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Arianna', 'Initials': 'A', 'LastName': 'Cruciani', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Simbolotti', 'Affiliation': 'Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Loreti', 'Affiliation': 'Physical Medicine and Rehabilitation Unit, Sant\'Andrea Hospital, University of Rome - ""La Sapienza"", Rome, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Galli', 'Affiliation': 'IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.'}, {'ForeName': 'Maria Chiara', 'Initials': 'MC', 'LastName': 'Vulpiani', 'Affiliation': 'Physical Medicine and Rehabilitation Unit, Sant\'Andrea Hospital, University of Rome - ""La Sapienza"", Rome, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Padua', 'Affiliation': 'Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.'}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-181211'] 959,31093677,The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.,"BACKGROUND Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect. Ganglioside-monosialic acid (GM1) functions as a neuroprotective factor. We assessed the effects of GM1 on the prevention of TIPN in breast cancer patients. METHODS We conducted a randomized, double-blind, placebo-controlled trial including 206 patients with early-stage breast cancer planning to receive taxane-based adjuvant chemotherapy with a follow-up of more than 1 year. Subjects were randomly assigned to receive GM1 (80 mg, day -1 to day 2) or placebo. The primary endpoint was the Functional Assessment of Cancer Treatment Neurotoxicity subscale score after four cycles of chemotherapy. Secondary endpoints included neurotoxicity evaluated by National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale. All statistical tests were two-sided. RESULTS In 183 evaluable patients, the GM1 group reported better mean Functional Assessment of Cancer Treatment Neurotoxicity subscale scores than patients in the placebo group after four cycles of chemotherapy (43.27, 95% confidence interval [CI] = 43.05 to 43.49 vs 34.34, 95% CI = 33.78 to 34.89; mean difference = 8.96, 95% CI = 8.38 to 9.54, P < .001). Grade 1 or higher peripheral neurotoxicity in Common Terminology Criteria for Adverse Events v4.0 scale was statistically significantly lower in the GM1 group (14.3% vs 100.0%, P < .001). Additionally, the GM1 group had a statistically significantly lower incidence of grade 1 or higher neurotoxicity assessed by Eastern Cooperative Oncology Group neuropathy scale sensory neuropathy (26.4% vs 97.8%, P < .001) and motor neuropathy subscales (20.9% vs 81.5%, P < .001). CONCLUSIONS The treatment with GM1 resulted in a reduction in the severity and incidence of TIPN after four cycles of taxane-containing chemotherapy in patients with breast cancer.",2020,"In 183 evaluable patients, GM1 group reported better mean FACT-Ntx subscale scores than patients in the placebo group after 4-cycles of chemotherapy (43.27 [95% CI = 43.05 to 43.49] vs 34.34 [95% CI = 33.78 to 34.89]; mean difference = 8.96","['breast cancer patients', 'Patients with Breast Cancer', '206 patients with early-stage breast cancer planning to receive', 'with a follow-up of more than 1 year', 'patients with breast cancer']","['Taxane', 'placebo', 'taxane-containing chemotherapy', 'Ganglioside-Monosialic Acid', 'taxane-based adjuvant chemotherapy', 'GM1']","['motor neuropathy subscales', 'Peripheral Neurotoxicity', 'Functional Assessment of Cancer Treatment Neurotoxicity (FACT-Ntx) subscale score', 'incidence of grade ≥ 1 neurotoxicity assessed by ENS sensory neuropathy', 'neurotoxicity evaluated by CTCAE Version 4.0 and the Eastern Cooperative Oncology Group neuropathy scale (ENS', 'mean FACT-Ntx subscale scores', 'severity and incidence of TIPN', '1 peripheral neurotoxicity in CTCAE v4.0 scale', 'Grade ≥']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0017082', 'cui_str': 'Sialoglycosphingolipids'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0459443', 'cui_str': 'Subscale score (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy (disorder)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",206.0,0.482266,"In 183 evaluable patients, GM1 group reported better mean FACT-Ntx subscale scores than patients in the placebo group after 4-cycles of chemotherapy (43.27 [95% CI = 43.05 to 43.49] vs 34.34 [95% CI = 33.78 to 34.89]; mean difference = 8.96","[{'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jiajia', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Shusen', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Unger', 'Affiliation': 'Department of Health Services Research, Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Arias-Fuenzalida', 'Affiliation': 'Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Yanxia', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Jibin', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.'}, {'ForeName': 'Yongxiang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Medical Statistics and Epidemiology, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Shi', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xinyue', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Roujun', 'Initials': 'R', 'LastName': 'Peng', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'An', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Xue', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Xia', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Ruoxi', 'Initials': 'R', 'LastName': 'Hong', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yongyi', 'Initials': 'Y', 'LastName': 'Zhong', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Lin', 'Affiliation': 'Department of Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Huang', 'Affiliation': ""Department of Breast Surgery, Lianjiang People's Hospital, Lianjiang, Guangdong, China.""}, {'ForeName': 'Anqin', 'Initials': 'A', 'LastName': 'Zhang', 'Affiliation': ""Breast Disease Center, Guangdong Women and Children's Hospital, Guangzhou, Guangdong, China.""}, {'ForeName': 'Lehong', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Breast Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Cai', 'Affiliation': 'The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.'}, {'ForeName': 'Jinxin', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Medical Statistics and Epidemiology, Sun Yat-sen University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Zhongyu', 'Initials': 'Z', 'LastName': 'Yuan', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.'}]",Journal of the National Cancer Institute,['10.1093/jnci/djz086'] 960,31740092,Atomized intranasal vs intravenous fentanyl in severe renal colic pain management: A randomized single-blinded clinical trial.,"OBJECTIVES Renal colic is one of the most common painful disorders in patients referred to the emergency department. The main purpose of this study was to compare the efficiency of two methods of intravenous (IVF) and intranasal (INF) fentanyl administration in pain management in patients with severe renal colic. MATERIALS & METHODS This was a single-blind randomized clinical trial performed on patients with severe renal colic. The severity of pain was ≥8 based on the Numerical Rating Scale (NRS). The efficacy of pain management was compared within and between the IVF (intramuscular Ketorolac + intravenous fentanyl) and INF (intramuscular Ketorolac + intranasal fentanyl) groups at different times points. Oral consent was obtained from all the patients. RESULTS Of 220 individuals, 96 (43.60%) were women and 124 (56.40%) were men. There were no significant differences between the two groups regarding the baseline pain severity, age, sex, history of urolithiasis and body mass index (BMI). The pain severity showed a significant reducing trend in both groups (p < 0.0001). There was also a significant difference comparing the mean pain severity between groups at different times (p < 0.0001). In each group, the severity of pain showed significant reduction compared with its prior measurement (P < 0.0001). CONCLUSION Fentanyl is highly effective in controlling pain in patients with severe renal colic referring to the emergency department. Intranasal administration of fentanyl combination with ketorolac can be an appropriate, non-invasive, easy-to-use and fast alternative to the intravenous method to manage pain in these patients.",2020,"In each group, the severity of pain showed significant reduction compared with its prior measurement (P < 0.0001). ","['patients with severe renal colic referring to the emergency department', 'Of 220 individuals, 96 (43.60%) were women and 124 (56.40%) were men', 'severe renal colic pain management', 'patients with severe renal colic', 'patients referred to the emergency department']","['Fentanyl', 'Atomized intranasal vs intravenous fentanyl', 'fentanyl combination with ketorolac', 'IVF (intramuscular Ketorolac + intravenous fentanyl) and INF (intramuscular Ketorolac + intranasal fentanyl', 'intravenous (IVF) and intranasal (INF) fentanyl administration']","['efficacy of pain management', 'mean pain severity', 'baseline pain severity, age, sex, history of urolithiasis and body mass index (BMI', 'Numerical Rating Scale (NRS', 'severity of pain', 'pain severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0152169', 'cui_str': 'Acute Renal Colic'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}]","[{'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0073631', 'cui_str': 'Ketorolac'}, {'cui': 'C0015915', 'cui_str': 'Test-Tube Fertilization'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0451641', 'cui_str': 'Urinary Lithiasis'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0222045'}]",220.0,0.0731758,"In each group, the severity of pain showed significant reduction compared with its prior measurement (P < 0.0001). ","[{'ForeName': 'Narjes', 'Initials': 'N', 'LastName': 'Nazemian', 'Affiliation': 'Department of Emergency Medicine, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Torabi', 'Affiliation': 'Department of Emergency Medicine, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: me_torabi@kmu.ac.ir.'}, {'ForeName': 'Moghaddameh', 'Initials': 'M', 'LastName': 'Mirzaee', 'Affiliation': 'Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158483'] 961,31734591,Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.,"PURPOSE We recently showed that prophylactic breast irradiation (PBI) reduces the risk of contralateral breast cancer in BRCA mutation carriers undergoing treatment for early breast cancer. It has been suggested that Background Parenchymal Enhancement (BPE) may be a biomarker for increased risk of breast cancer. METHODS For participants in the trial we reviewed the MRI prior to enrollment and following radiation treatment and scored the contralateral breast for BPE and density. RESULTS Significant reduction of BPE was more commonly noted following PBI (p = 0.011) compared to the control group. CONCLUSION Reduction of BPE by PBI may contribute to its prophylactic effect.",2020,"RESULTS Significant reduction of BPE was more commonly noted following PBI (p = 0.011) compared to the control group. ",['BRCA mutation carriers undergoing treatment for early breast cancer'],"['prophylactic breast irradiation (PBI', 'Prophylactic breast irradiation']",['BPE'],"[{'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0560175', 'cui_str': 'Carrier State'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}]",[],,0.0274919,"RESULTS Significant reduction of BPE was more commonly noted following PBI (p = 0.011) compared to the control group. ","[{'ForeName': 'Merav A', 'Initials': 'MA', 'LastName': 'Ben-David', 'Affiliation': 'Department of Radiation Oncology, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Benjamin W', 'Initials': 'BW', 'LastName': 'Corn', 'Affiliation': 'Shaare Zedek Medical Center, Jerusalem, Israel; Hadassah Medical School, The Hebrew University, Jerusalem, Israel. Electronic address: ben.w.corn@gmail.com.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Evron', 'Affiliation': 'Oncology, Kaplan Medical Institute, Rehovot, Israel; Hadassah Medical School, The Hebrew University, Jerusalem, Israel.'}, {'ForeName': 'Hadassah', 'Initials': 'H', 'LastName': 'Goldberg', 'Affiliation': 'Oncology Institute, Galilee Medical Center, Naharia, Israel.'}, {'ForeName': 'Raphael M', 'Initials': 'RM', 'LastName': 'Pfeffer', 'Affiliation': 'Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Roxoliana', 'Initials': 'R', 'LastName': 'Abdah-Bortnyak', 'Affiliation': 'Oncology Division, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.'}, {'ForeName': 'Dianna', 'Initials': 'D', 'LastName': 'Matceyevsky', 'Affiliation': 'Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.'}, {'ForeName': 'Yuliana', 'Initials': 'Y', 'LastName': 'Weinstein', 'Affiliation': 'Assuta Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Orit', 'Initials': 'O', 'LastName': 'Golan', 'Affiliation': 'Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.'}, {'ForeName': 'Miri', 'Initials': 'M', 'LastName': 'Sklair-Levy', 'Affiliation': 'Department of Radiation Oncology, Sheba Medical Center, Ramat-Gan, Israel; Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2019.10.011'] 962,31362189,Cardiac output during targeted temperature management and renal function after out-of-hospital cardiac arrest.,"PURPOSE After resuscitation from out-of-hospital cardiac arrest (OHCA), renal injury and hemodynamic instability are common. We aimed to assess the association between low cardiac output during targeted temperature management (TTM) and acute kidney injury (AKI) after OHCA. MATERIALS AND METHODS Single-center substudy of 171 patients included in the prospective, randomized TTM-trial. Hemodynamic evaluation was performed with serial measurements by pulmonary artery catheter. AKI was the primary endpoint and was defined according to the KDIGO-criteria. RESULTS Of 152 patients with available hemodynamic data, 49 (32%) had AKI and 21 (14%) had AKI with need for renal replacement therapy (RRT) in the first three days. During targeted temperature management, patients with AKI had higher heart rate (11 beats/min, p group  < 0.0001), higher mean arterial pressure (MAP) (4 mmHg, p group  = 0.001) and higher lactate (1 mmol/L, p group  < 0.0001) compared to patients without AKI. However, there was no difference in cardiac index (p group  = 0.25). In a multivariate logistic regression model, adjusting for potential confounders, MAP (p = .03), heart rate (p = .01) and lactate (p = .006), but not cardiac output, were independently associated with AKI. CONCLUSIONS Blood pressure, heart rate and lactate, but not cardiac output, during 24 h of TTM were associated with AKI in comatose OHCA-patients.",2019,"During targeted temperature management, patients with AKI had higher heart rate (11 beats/min, p group  < 0.0001), higher mean arterial pressure (MAP) (4 mmHg, p group  = 0.001) and higher lactate (1 mmol/L, p group  < 0.0001) compared to patients without AKI.","['152 patients with available hemodynamic data, 49 (32%) had AKI and 21 (14%) had AKI with need for renal replacement therapy (RRT) in the first three days', 'Single-center substudy of 171 patients included in the prospective, randomized TTM-trial']",[],"['cardiac index', 'Blood pressure, heart rate and lactate', 'heart rate', 'higher lactate', 'mean arterial pressure (MAP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0206074', 'cui_str': 'Kidney Replacement Therapy'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]",[],"[{'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0024779', 'cui_str': 'Map'}]",171.0,0.0898083,"During targeted temperature management, patients with AKI had higher heart rate (11 beats/min, p group  < 0.0001), higher mean arterial pressure (MAP) (4 mmHg, p group  = 0.001) and higher lactate (1 mmol/L, p group  < 0.0001) compared to patients without AKI.","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Grand', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark. Electronic address: johannes.grand@regionh.dk.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bro-Jeppesen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Hassager', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Malin', 'Initials': 'M', 'LastName': 'Rundgren', 'Affiliation': 'Department of Clinical Sciences, Lund University, Intensive and Perioperative Care, Skåne University Hospital, Malmö, Sweden.'}, {'ForeName': 'Matilde', 'Initials': 'M', 'LastName': 'Winther-Jensen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Jakob Hartvig', 'Initials': 'JH', 'LastName': 'Thomsen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Niklas', 'Initials': 'N', 'LastName': 'Nielsen', 'Affiliation': 'Department of Anaesthesia and Intensive Care, Helsingborg Hospital, Helsingborg, Sweden.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Wanscher', 'Affiliation': 'Department of Cardiothoracic Anaesthesia 4142, Copenhagen University Hospital, Rigshospitalet, Denmark.'}, {'ForeName': 'Jesper', 'Initials': 'J', 'LastName': 'Kjærgaard', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Denmark.'}]",Journal of critical care,['10.1016/j.jcrc.2019.07.013'] 963,31608968,Effectiveness of Computer Assisted Training of Patients Undergoing Lumbar Disc Herniation Surgery.,"AIM To identify the effects of computer assisted training schemes provided to patients who have undergone surgical intervention for lumbar disc herniation on their level of knowledge, level of anxiety, problems experienced after discharge, and level of functional incapacity. MATERIAL AND METHODS The study was performed as a randomized controlled invasive study with a pre-testâ€'post-test design. The study was conducted with 62 patients, 31 of which were included in the intervention group and 31 in the control group. Training and counselling were provided to the patients included in the intervention group via a training web-site, while a training guidebook with the same content as the website for patients was given to the patients included in the control group. RESULTS The patients who have undergone a surgical intervention for lumbar disc herniation, those who were provided computer assisted training were better informed, had better functional capacity, and experienced less anxiety after discharge than those who were only informed through the training guidebook. CONCLUSION Computer-assisted training was efficient educational tool for patients undergoing lumbar disc herniation surgery.",2020,"The identify the effects of computer assisted training schemes provided to patients who have undergone surgical intervention for lumbar disc hernia on their level of knowledge, level of anxiety, problems experienced after discharge, and level of functional incapacity. ","['patients who have undergone a surgical intervention for lumbar disc hernia', 'patients undergoing lumbar disc hernia surgery', 'patients who have undergone surgical intervention for lumbar disc hernia on their level of knowledge, level of anxiety, problems experienced after discharge, and level of functional incapacity', 'Patients Undergoing Lumbar Disc Herniation Surgery', '62 patients, 31 of which were included in the intervention group and 31 in the control group']","['Computer Assisted Training', 'Computer-assisted training']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0549433', 'cui_str': 'Surgical intervention'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0281899', 'cui_str': 'Prolapsed lumbar intervertebral disc (disorder)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]",[],,0.0211383,"The identify the effects of computer assisted training schemes provided to patients who have undergone surgical intervention for lumbar disc hernia on their level of knowledge, level of anxiety, problems experienced after discharge, and level of functional incapacity. ","[{'ForeName': 'Zuhal', 'Initials': 'Z', 'LastName': 'Erdogan', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Nursing, Ankara, Turkey.'}, {'ForeName': 'Hulya', 'Initials': 'H', 'LastName': 'Bulut', 'Affiliation': ''}]",Turkish neurosurgery,['10.5137/1019-5149.JTN.26775-19.2'] 964,31071483,Imaginal retraining reduces alcohol craving in problem drinkers: A randomized controlled trial.,"BACKGROUND AND OBJECTIVES Retraining, a psychological intervention derived from the approach-avoidance paradigm, has yielded mixed results for the treatment of alcohol use disorder as well as other forms of addiction. The present study investigated the efficacy of an imaginal variant of retraining that allowed greater personalization of the content. METHODS Within the framework of a randomized controlled trial (RCT), 84 individuals with self-reported alcohol-related problems were recruited over the Internet and allocated to either imaginal retraining (treatment manual dispatched as a pdf-file via email) or a wait-list control group (with care-as-usual). The intervention period was four weeks. Alcohol craving, as measured with a visual analogue scale (VAS), served as the primary outcome. Other emotional (e.g. self-esteem) and drinking-related variables served as secondary outcomes. RESULTS Both per-protocol (PP) and intention-to-treat (ITT) analyses showed that imaginal retraining led to a significant reduction in alcohol craving compared to the control group at a large effect size. Self-esteem improved in the retraining condition relative to controls in the PP and one of the ITT analyses; 75% of the individuals in the treatment group reported less alcohol consumption in the treatment period, whereas drinking behavior remained essentially unchanged in the control group (p < .001) (the trial was registered at the German Clinical Trials Register, DRKS00015319). LIMITATIONS Whether the effects of imaginal retraining are sustained over time needs to be established. Attrition was significantly higher in the retraining group (40.5%) than in the control group (16.7%). Designs with an active control condition are needed as well as dismantling studies to explore which of the treatment's multiple components best predicts improvement. Future studies should verify participants' alcohol consumption levels using objective measures. CONCLUSION Imaginal retraining led to significant effects on the reduction of alcohol craving.",2019,"Self-esteem improved in the retraining condition relative to controls in the PP and one of the ITT analyses; 75% of the individuals in the treatment group reported less alcohol consumption in the treatment period, whereas drinking behavior remained essentially unchanged in the control group (p < .001) (the trial was registered at the German Clinical Trials Register, DRKS00015319). ","['84 individuals with self-reported alcohol-related problems', 'problem drinkers']","['Imaginal retraining', 'imaginal retraining', 'imaginal retraining (treatment manual dispatched as a pdf-file via email) or a wait-list control group (with care-as-usual']","['Self-esteem', 'alcohol consumption', 'alcohol craving', 'Attrition', 'visual analogue scale (VAS', 'Alcohol craving', 'drinking behavior']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0687725', 'cui_str': 'Alcoholics'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0180853', 'cui_str': 'File, device (physical object)'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0556385', 'cui_str': 'Craving for alcohol (finding)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0013124', 'cui_str': 'Drinking Behavior'}]",84.0,0.07061,"Self-esteem improved in the retraining condition relative to controls in the PP and one of the ITT analyses; 75% of the individuals in the treatment group reported less alcohol consumption in the treatment period, whereas drinking behavior remained essentially unchanged in the control group (p < .001) (the trial was registered at the German Clinical Trials Register, DRKS00015319). ","[{'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: moritz@uke.uni-hamburg.de.'}, {'ForeName': 'Alia Marie', 'Initials': 'AM', 'LastName': 'Paulus', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Hottenrott', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Weierstall', 'Affiliation': 'MSH Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Gallinat', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Kühn', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.04.001'] 965,31086947,"Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.","BACKGROUND The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase III clinical trial was conducted to evaluate the efficacy, safety, and immunogenicity of a novel Escherichia coli-produced bivalent HPV-16/18 vaccine. METHODS A multicenter, randomized, double-blind trial started on November 22, 2012 in China. In total, 7372 eligible women aged 18-45 years were age-stratified and randomly assigned to receive three doses of the test or control (hepatitis E) vaccine at months 0, 1, and 6. Co-primary endpoints included high-grade genital lesions and persistent infection (over 6 months) associated with HPV-16/18. The primary analysis was performed on a per-protocol susceptible population of individuals who were negative for relevant HPV type-specific neutralizing antibodies (at day 0) and DNA (at day 0 through month 7) and who received three doses of the vaccine. This report presents data from a prespecified interim analysis used for regulatory submission. RESULTS In the per-protocol cohort, the efficacies against high-grade genital lesions and persistent infection were 100.0% (95% confidence interval = 55.6% to 100.0%, 0 of 3306 in the vaccine group vs 10 of 3296 in the control group) and 97.8% (95% confidence interval = 87.1% to 99.9%, 1 of 3240 vs 45 of 3246), respectively. The side effects were mild. No vaccine-related serious adverse events were noted. Robust antibody responses for both types were induced and persisted for at least 42 months. CONCLUSIONS The E coli-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18-associated high-grade genital lesions and persistent infection in women.",2020,The Escherichia coli-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.,"['7372 eligible women aged 18-45 years were age-stratified', 'November 22, 2012, in China']","['novel Escherichia coli-produced bivalent HPV-16/18 vaccine', 'Escherichia coli-produced bivalent human papillomavirus vaccine', 'test or control (hepatitis E) vaccine', 'vaccine']","['efficacy, safety and immunogenicity', 'efficacies against high-grade genital lesions and persistent infection', 'Efficacy, safety, and immunogenicity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0085293', 'cui_str': 'Hepatitis, Water-Borne'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1962917', 'cui_str': 'High grade (lymphoma)'}, {'cui': 'C0744369', 'cui_str': 'Lesion of genitalia'}, {'cui': 'C1264606', 'cui_str': 'Persistent infection'}]",7372.0,0.594263,The Escherichia coli-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.,"[{'ForeName': 'You-Lin', 'Initials': 'YL', 'LastName': 'Qiao', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Rong-Cheng', 'Initials': 'RC', 'LastName': 'Li', 'Affiliation': 'Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China.'}, {'ForeName': 'Yue-Mei', 'Initials': 'YM', 'LastName': 'Hu', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Li-Hui', 'Initials': 'LH', 'LastName': 'Wei', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Chang-Gui', 'Initials': 'CG', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shou-Jie', 'Initials': 'SJ', 'LastName': 'Huang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Fang-Hui', 'Initials': 'FH', 'LastName': 'Zhao', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ming-Qiang', 'Initials': 'MQ', 'LastName': 'Li', 'Affiliation': 'Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China.'}, {'ForeName': 'Qin-Jing', 'Initials': 'QJ', 'LastName': 'Pan', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xun', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Shenzhen Maternity and Child Healthcare Hospital, Shenzhen, Guangdong, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Hong', 'Affiliation': 'The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Wen-Hua', 'Initials': 'WH', 'LastName': 'Zhang', 'Affiliation': 'National Cancer Center, National Center for Cancer Clinical Research, The Cancer Institute, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yan-Ping', 'Initials': 'YP', 'LastName': 'Li', 'Affiliation': 'Guangxi Center for Disease Control and Prevention, Nanning, Guangxi, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.'}, {'ForeName': 'Yun-Fei', 'Initials': 'YF', 'LastName': 'Jiang', 'Affiliation': 'The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Zhi-Jie', 'Initials': 'ZJ', 'LastName': 'Lin', 'Affiliation': 'Xiamen Innovax Biotech Company, Xiamen, Fujian, China.'}, {'ForeName': 'Xue-Lian', 'Initials': 'XL', 'LastName': 'Cui', 'Affiliation': 'Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China.'}, {'ForeName': 'Wen-Yu', 'Initials': 'WY', 'LastName': 'Liu', 'Affiliation': 'Funing Center for Disease Control and Prevention, Funing, Jiangsu, China.'}, {'ForeName': 'Cai-Hong', 'Initials': 'CH', 'LastName': 'Li', 'Affiliation': 'Xinmi Maternal and Child Health Hospital, Xinmi, Henan, China.'}, {'ForeName': 'Dong-Ping', 'Initials': 'DP', 'LastName': 'Guo', 'Affiliation': 'Yangcheng Maternal and Child Health Hospital, Yangcheng, Shanxi, China.'}, {'ForeName': 'Li-Dong', 'Initials': 'LD', 'LastName': 'Ke', 'Affiliation': 'Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Liuzhou Center for Disease Control and Prevention, Liuzhou, Guangxi, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Funing Center for Disease Control and Prevention, Funing, Jiangsu, China.'}, {'ForeName': 'Guo-Qi', 'Initials': 'GQ', 'LastName': 'Gao', 'Affiliation': 'Xinmi Maternal and Child Health Hospital, Xinmi, Henan, China.'}, {'ForeName': 'Ba-Yi', 'Initials': 'BY', 'LastName': 'Li', 'Affiliation': 'Yangcheng Maternal and Child Health Hospital, Yangcheng, Shanxi, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhao', 'Affiliation': 'Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei, China.'}, {'ForeName': 'Feng-Xian', 'Initials': 'FX', 'LastName': 'Zheng', 'Affiliation': 'Xinmi Maternal and Child Health Hospital, Xinmi, Henan, China.'}, {'ForeName': 'Cui-Hong', 'Initials': 'CH', 'LastName': 'Dai', 'Affiliation': 'Fengning Hospital of Traditional Chinese Medicine, Fengning, Hebei, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Guo', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Ying-Ying', 'Initials': 'YY', 'LastName': 'Su', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Jun-Zhi', 'Initials': 'JZ', 'LastName': 'Wang', 'Affiliation': 'National Institute for Food and Drug Control, Beijing, China.'}, {'ForeName': 'Feng-Cai', 'Initials': 'FC', 'LastName': 'Zhu', 'Affiliation': 'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.'}, {'ForeName': 'Shao-Wei', 'Initials': 'SW', 'LastName': 'Li', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Hui-Rong', 'Initials': 'HR', 'LastName': 'Pan', 'Affiliation': 'Xiamen Innovax Biotech Company, Xiamen, Fujian, China.'}, {'ForeName': 'Yi-Min', 'Initials': 'YM', 'LastName': 'Li', 'Affiliation': 'Xiamen Innovax Biotech Company, Xiamen, Fujian, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Ning-Shao', 'Initials': 'NS', 'LastName': 'Xia', 'Affiliation': 'The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health, Xiamen University, Xiamen, Fujian, China.'}]",Journal of the National Cancer Institute,['10.1093/jnci/djz074'] 966,31668839,"Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).","PURPOSE Gemcitabine-oxaliplatin (GEMOX) demonstrated mild toxicity and promising effectiveness in patients with advanced urothelial cell cancer (UCC). We investigated the activity and safety of first-line GEMOX compared with gemcitabine-carboplatin (GCb) in cisplatin-ineligible patients with advanced UCC. METHODS Treatment-naive, cisplatin-ineligible patients with advanced UCC were randomly assigned to GEMOX (gemcitabine 1000 mg/m 2 , oxaliplatin 100 mg/m 2 on day 1 [D1] every 2 weeks) or GCb (1000 mg/m 2 of gemcitabine on D1 and D8 and carboplatin area under the curve of 4.5 mg/mL/min on D1 every 3 weeks). We evaluated the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). RESULTS Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients were allocated to GCb and GEMOX arms, respectively. The ORR was 48.7% in the GCb arm and 55.0% in the GEMOX arm. The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months (95% confidence interval [CI], 4.8-6.2) vs. 4.4 months (95% CI, 2.7-6.1) and 9.1 months (95% CI, 5.2-13.0) vs. 11.0 months (95% CI, 6.9-15.0), respectively. ≥Leucopenia, neutropenia and fatigue of ≥ grade III were significantly more common in the GCb arm (26% vs. 3%, P = 0.003; 33% vs. 10%, P = 0.014; 15% vs. 3%, P = 0.012), whereas any-grade neuropathy was more common in the GEMOX arm (8% vs. 60%). CONCLUSIONS GEMOX showed similar efficacy with GCb and a favourable haematologic toxicity profile. GEMOX may be an additional chemotherapy option for patients with UCC ineligible for cisplatin-containing chemotherapy (NCT01487915).",2020,The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months,"['patients with UCC ineligible for cisplatin-containing chemotherapy (NCT01487915', 'Treatment-naive, cisplatin-ineligible patients with advanced UCC', 'Between January 2011 and March 2017, 80 patients were enrolled; 39 and 40 patients', 'patients with advanced urothelial cell cancer (UCC', 'unfit patients with advanced urothelial carcinoma', 'ineligible patients with advanced UCC']","['Gemcitabine-oxaliplatin (GEMOX', 'GCb and GEMOX', 'GCb', 'gemcitabine plus oxaliplatin', 'gemcitabine-carboplatin (GCb', 'GEMOX', 'cisplatin', 'GEMOX (gemcitabine 1000\xa0mg/m 2 , oxaliplatin 100\xa0mg/m 2 on day 1 [D1] every 2 weeks) or GCb (1000\xa0mg/m 2 of gemcitabine on D1 and D8\xa0and carboplatin', 'Gemcitabine plus carboplatin']","['haematologic toxicity profile', 'mild toxicity', 'median PFS and OS', '≥Leucopenia, neutropenia\xa0and fatigue of ≥ grade III', 'ORR', 'activity and safety', 'objective response rate (ORR), progression-free survival (PFS)\xa0and overall survival (OS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0007138', 'cui_str': 'Carcinoma, Transitional Cell'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C4057589', 'cui_str': 'gemcitabine 1000 MG'}, {'cui': 'C4081033', 'cui_str': 'oxaliplatin 100 MG'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",80.0,0.138573,The median follow-up duration was 37.8 months; the median PFS and OS in the GCb and GEMOX arms were 5.5 months,"[{'ForeName': 'Inkeun', 'Initials': 'I', 'LastName': 'Park', 'Affiliation': 'Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.'}, {'ForeName': 'Bong-Seog', 'Initials': 'BS', 'LastName': 'Kim', 'Affiliation': 'Division of Hemato-Oncology, Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Republic of Korea.'}, {'ForeName': 'Ho Yeong', 'Initials': 'HY', 'LastName': 'Lim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hee-Jun', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Hyo Jin', 'Initials': 'HJ', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea.'}, {'ForeName': 'Yoon Ji', 'Initials': 'YJ', 'LastName': 'Choi', 'Affiliation': 'Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Kyong Hwa', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung Hee', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Division of Hemato-oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Shinkyo', 'Initials': 'S', 'LastName': 'Yoon', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Bumsik', 'Initials': 'B', 'LastName': 'Hong', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jun Hyuk', 'Initials': 'JH', 'LastName': 'Hong', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hanjong', 'Initials': 'H', 'LastName': 'Ahn', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jae Lyun', 'Initials': 'JL', 'LastName': 'Lee', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: jaelyun@amc.seoul.kr.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.08.034'] 967,29878583,"Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers.","The orally available chymase inhibitor BAY 1142524 is currently being developed as a first-in-class treatment for left-ventricular dysfunction after myocardial infarction. Results from 3 randomized, single-center, phase 1 studies in healthy male volunteers examining the safety, tolerability, and pharmacokinetics of BAY 1142524 are summarized. In this first-in-human study, single oral doses of 1-200 mg were administered in fasted state as liquid service formulation or immediate release (IR) tablets. The relative bioavailability and the effect of a high-fat/high-calorie meal were investigated at the 5-mg dose. In a multiple-dose escalation study, doses of 5-50 mg twice daily and 100 mg once daily were given for 5 consecutive days. BAY 1142524 was safe and well tolerated and had no effects on heart rate or blood pressure compared with placebo. BAY 1142524 was absorbed with peak concentration 1-3 hours after administration for IR tablets; it was eliminated from plasma with a terminal half-life of 6.84-12.0 hours after administration of liquid service formulation or IR tablets. Plasma exposures appeared to be dose-linear, with a negligible food effect. There was only low accumulation of BAY 1142524 after multiple dosing. BAY 1142524 exhibited a pharmacokinetic profile allowing for once-daily dosing. The absence of blood pressure effects after administration of BAY 1142524 supports the combination of this novel anti-remodeling drug with existing standard of care in patients with left-ventricular dysfunction after acute myocardial infarction.",2019,BAY 1142524 was safe and well tolerated and had no effects on heart rate or blood pressure compared with placebo.,"['Healthy Male Volunteers', 'patients with left-ventricular dysfunction after acute myocardial infarction', 'healthy male volunteers']",['placebo'],"['safe and well tolerated', 'blood pressure effects', 'relative bioavailability', 'heart rate or blood pressure', 'Pharmacokinetics, Safety, and Tolerability', 'safety, tolerability, and pharmacokinetics']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242973', 'cui_str': 'Ventricular Dysfunction'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.07546,BAY 1142524 was safe and well tolerated and had no effects on heart rate or blood pressure compared with placebo.,"[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Kanefendt', 'Affiliation': 'Clinical Pharmacokinetics, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Thuß', 'Affiliation': 'Bioanalytics, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Becka', 'Affiliation': 'Research and Clinical Sciences Statistics, BAYER AG, Wuppertal, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Boxnick', 'Affiliation': 'CRS Clinical Research Services, Wuppertal GmbH, Wuppertal, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Berse', 'Affiliation': 'CRS Clinical Research Services, Berlin GmbH, Berlin, Germany.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Schultz', 'Affiliation': 'CRS Clinical Research Services, Mannheim GmbH, Mannheim, Germany.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Otto', 'Affiliation': 'Experimental Medicine Cardiovascular and Hematology, BAYER AG, Wuppertal, Germany.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.579'] 968,31732485,"Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.","BACKGROUND New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in the first 8 weeks of treatment of pulmonary tuberculosis. METHODS In this multicentre, open-label, partially randomised, phase 2b trial, we prospectively recruited patients with drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven sites in South Africa, two in Tanzania, and one in Uganda. Patients aged 18 years or older with sputum smear grade 1+ or higher were eligible for enrolment, and a molecular assay (GeneXpert or MTBDRplus) was used to confirm the diagnosis of tuberculosis and to distinguish between drug-susceptible and rifampicin-resistant tuberculosis. Patients who were HIV positive with a baseline CD4 cell count of less than 100 cells per uL were excluded. Patients with drug-susceptible tuberculosis were randomly assigned (1:1:1) using numbered treatment packs with sequential allocation by the pharmacist to receive 56 days of treatment with standard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or pretomanid (oral 200 mg daily) and pyrazinamide (oral 1500 mg daily) with either oral bedaquiline 400 mg daily on days 1-14 then 200 mg three times per week (B load PaZ) or oral bedaquiline 200 mg daily (B 200 PaZ). Patients with rifampicin-resistant tuberculosis received 56 days of the B 200 PaZ regimen plus moxifloxacin 400 mg daily (BPaMZ). All treatment groups were open label, and randomisation was not stratified. Patients, trial investigators and staff, pharmacists or dispensers, laboratory staff (with the exception of the mycobacteriology laboratory staff), sponsor staff, and applicable contract research organisations were not masked. The primary efficacy outcome was daily percentage change in time to sputum culture positivity (TTP) in liquid medium over days 0-56 in the drug-susceptible tuberculosis population, based on non-linear mixed-effects regression modelling of log 10 (TTP) over time. The efficacy analysis population contained patients who received at least one dose of medication and who had efficacy data available and had no major protocol violations. The safety population contained patients who received at least one dose of medication. This study is registered with ClinicalTrials.gov, NCT02193776, and all patients have completed follow-up. FINDINGS Between Oct 24, 2014, and Dec 15, 2015, we enrolled 180 patients with drug-susceptible tuberculosis (59 were randomly assigned to B load PaZ, 60 to B 200 PaZ, and 61 to HRZE) and 60 patients with rifampicin-resistant tuberculosis. 57 patients in the B load PaZ group, 56 in the B 200 PaZ group, and 59 in the HRZE group were included in the primary analysis. B 200 PaZ produced the highest daily percentage change in TTP (5·17% [95% Bayesian credibility interval 4·61-5·77]), followed by B load PaZ (4·87% [4·31-5·47]) and HRZE group (4·04% [3·67-4·42]). The bactericidal activity in B 200 PaZ and B load PaZ groups versus that in the HRZE group was significantly different. Higher proportions of patients in the B load PaZ (six [10%] of 59) and B 200 PaZ (five [8%] of 60) groups discontinued the study drug than in the HRZE group (two [3%] of 61) because of adverse events. Liver enzyme elevations were the most common grade 3 or 4 adverse events and resulted in the withdrawal of ten patients (five [8%] in the B load PaZ group, three [5%] in the B 200 PaZ group, and two [3%] in the HRZE group). Serious treatment-related adverse events affected two (3%) patients in the B load PaZ group and one (2%) patient in the HRZE group. Seven (4%) patients with drug-susceptible tuberculosis died and four (7%) patients with rifampicin-resistant tuberculosis died. None of the deaths were considered to be related to treatment. INTERPRETATION B 200 PaZ is a promising regimen to treat patients with drug-susceptible tuberculosis. The bactericidal activity of both these regimens suggests that they have the potential to shorten treatment, and the simplified dosing schedule of B 200 PaZ could improve treatment adherence in the field. However, these findings must be investigated further in a phase 3 trial assessing treatment outcomes. FUNDING TB Alliance, UK Department for International Development, Bill & Melinda Gates Foundation, US Agency for International Development, Directorate General for International Cooperation of the Netherlands, Irish Aid, Australia Department of Foreign Affairs and Trade, and the Federal Ministry for Education and Research of Germany.",2019,"B 200 PaZ produced the highest daily percentage change in TTP (5·17% [95% Bayesian credibility interval 4·61-5·77]), followed by B load PaZ (4·87% [4·31-5·47]) and HRZE group (4·04% [3·67-4·42]).","['57 patients in the B load PaZ group, 56 in the B 200 PaZ group, and 59 in the HRZE group were included in the primary analysis', 'Patients, trial investigators and staff, pharmacists or dispensers, laboratory staff (with the exception of the mycobacteriology laboratory staff), sponsor staff, and applicable contract research organisations were not masked', 'Patients with rifampicin-resistant tuberculosis', 'pulmonary tuberculosis', 'Patients aged 18 years or older with sputum smear grade 1+ or higher were eligible for enrolment, and a molecular assay (GeneXpert or MTBDRplus) was used to confirm the diagnosis of tuberculosis and to distinguish between drug-susceptible and rifampicin-resistant tuberculosis', 'Patients who were HIV positive with a baseline CD4 cell count of less than 100 cells per uL were excluded', 'Patients with drug-susceptible tuberculosis', 'Between Oct 24, 2014, and Dec 15, 2015, we enrolled 180 patients with drug-susceptible tuberculosis (59', 'patients with drug-susceptible or drug-resistant pulmonary tuberculosis', 'patients with drug-susceptible or rifampicin-resistant pulmonary tuberculosis from seven sites in South Africa, two in Tanzania, and one in Uganda', 'patients with drug-susceptible tuberculosis']","['oral bedaquiline', 'standard tuberculosis therapy (oral isoniazid, rifampicin, pyrazinamide, and ethambutol; HRZE), or pretomanid (oral 200 mg daily) and pyrazinamide (oral 1500 mg daily) with either oral bedaquiline', 'Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide', 'bedaquiline, pretomanid, moxifloxacin, and pyrazinamide', 'HRZE', 'rifampicin-resistant tuberculosis', 'moxifloxacin 400 mg daily (BPaMZ']","['Liver enzyme elevations', 'adverse events', 'daily percentage change in time to sputum culture positivity (TTP', 'bactericidal activity', 'TTP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0180463', 'cui_str': 'Dispenser'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0332522', 'cui_str': 'Contracts'}, {'cui': 'C0035168'}, {'cui': 'C0029237', 'cui_str': 'Organization (morphologic abnormality)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C1532782', 'cui_str': 'Rifampicin resistant tuberculosis'}, {'cui': 'C0041327', 'cui_str': 'Pulmonary Phthisis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0231204', 'cui_str': 'Susceptible (qualifier value)'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0243009', 'cui_str': 'CD4+ Counts'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C0039298', 'cui_str': 'United Republic of Tanzania'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1664205', 'cui_str': 'bedaquiline'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0041296', 'cui_str': 'Mycobacterium tuberculosis Infection'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0034239', 'cui_str': 'Pyrazinamide'}, {'cui': 'C0014964', 'cui_str': 'Ethambutol'}, {'cui': 'C4310440'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C1532782', 'cui_str': 'Rifampicin resistant tuberculosis'}, {'cui': 'C1592286', 'cui_str': 'moxifloxacin 400 MG [Avelox]'}]","[{'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0523174', 'cui_str': 'Microbial culture of sputum (procedure)'}, {'cui': 'C0034155', 'cui_str': 'Moschkowitz Disease'}, {'cui': 'C0544570', 'cui_str': 'Bactericidal activity (observable entity)'}]",180.0,0.193834,"B 200 PaZ produced the highest daily percentage change in TTP (5·17% [95% Bayesian credibility interval 4·61-5·77]), followed by B load PaZ (4·87% [4·31-5·47]) and HRZE group (4·04% [3·67-4·42]).","[{'ForeName': 'Conor D', 'Initials': 'CD', 'LastName': 'Tweed', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK. Electronic address: c.tweed@ucl.ac.uk.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Dawson', 'Affiliation': 'University of Cape Town Lung Institute, Cape Town, South Africa; Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Divan A', 'Initials': 'DA', 'LastName': 'Burger', 'Affiliation': 'Department of Statistics, University of Pretoria, Pretoria, South Africa.'}, {'ForeName': 'Almari', 'Initials': 'A', 'LastName': 'Conradie', 'Affiliation': 'TB Alliance, Pretoria, South Africa.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Crook', 'Affiliation': 'MRC Clinical Trials Unit at UCL, London, UK.'}, {'ForeName': 'Carl M', 'Initials': 'CM', 'LastName': 'Mendel', 'Affiliation': 'Global Alliance for TB Drug Development, New York, NY, USA.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Conradie', 'Affiliation': 'Clinical HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Andreas H', 'Initials': 'AH', 'LastName': 'Diacon', 'Affiliation': 'TASK Applied Science, Bellville, South Africa; Division of Physiology, Department of Medical Biochemistry, Stellenbosch University, Tygerberg, South Africa.'}, {'ForeName': 'Nyanda E', 'Initials': 'NE', 'LastName': 'Ntinginya', 'Affiliation': 'NIMR-Mbeya Medical Research Centre, Mbeya, Tanzania.'}, {'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Everitt', 'Affiliation': 'Global Alliance for TB Drug Development, New York, NY, USA.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Haraka', 'Affiliation': 'Ifakara Health Institute Bagamoyo Research and Training Center, Bagamoyo, Tanzania.'}, {'ForeName': 'Mengchun', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Global Alliance for TB Drug Development, New York, NY, USA.'}, {'ForeName': 'Christo H', 'Initials': 'CH', 'LastName': 'van Niekerk', 'Affiliation': 'TB Alliance, Pretoria, South Africa.'}, {'ForeName': 'Alphonse', 'Initials': 'A', 'LastName': 'Okwera', 'Affiliation': 'Uganda Case Western Reserve University Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Mohammed S', 'Initials': 'MS', 'LastName': 'Rassool', 'Affiliation': 'Clinical HIV Research Unit, Helen Joseph Hospital, Johannesburg, South Africa.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Reither', 'Affiliation': 'Ifakara Health Institute Bagamoyo Research and Training Center, Bagamoyo, Tanzania; Swiss Tropical and Public Health Institute, Basel, Switzerland.'}, {'ForeName': 'Modulakgotla A', 'Initials': 'MA', 'LastName': 'Sebe', 'Affiliation': 'The Aurum Institute, Tembisa Hospital, Tembisa, South Africa.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Staples', 'Affiliation': 'THINK, Durban, South Africa.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Variava', 'Affiliation': 'MDR Unit, Klerksdorp Tshepong Hospital, Klerksdorp, South Africa.'}, {'ForeName': 'Melvin', 'Initials': 'M', 'LastName': 'Spigelman', 'Affiliation': 'Global Alliance for TB Drug Development, New York, NY, USA.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30366-2'] 969,31053887,Effects of neurofeedback and working memory-combined training on executive functions in healthy young adults.,"Given the interest in improving executive functions, the present study examines a promising combination of two training techniques: neurofeedback training (NFT) and working memory training (WMT). NFT targeted increasing the amplitude of individual's upper Alpha frequency band at the parietal midline scalp location (Pz), and WMT consisted of an established computerized protocol with working memory updating and set-shifting components. Healthy participants (n = 140) were randomly allocated to five combinations of training, including visual search training used as an active control training for the WMT; all five groups were compared to a sixth silent control group receiving no training. All groups were evaluated before and after training for resting-state electroencephalogram (EEG) and behavioral executive function measures. The participants in the silent control group were unaware of this procedure, and received one of the training protocols only after study has ended. Results demonstrated significant improvement in the practice tasks in all training groups including non-specific influence of NFT on resting-state EEG spectral topography. There was only a near transfer effect (improvement in working memory task) for WMT, which remained significant in the delayed post-test (after 1 month), in comparison to silent control group but not in comparison to active control training group. The NFT + WMT combined group showed improved mental rotation ability both in the post-training and in the follow-up evaluations. This improvement, however, did not differ significantly from that in the silent control group. We conclude that the current training protocols, including their combination, have very limited influence on the executive functions that were assessed in this study.",2020,The NFT + WMT combined group showed improved mental rotation ability both in the post-training and in the follow-up evaluations.,"['Healthy participants (n\u2009=\u2009140', 'healthy young adults']","['visual search training used as an active control training for the WMT', 'NFT', 'sixth silent control group receiving no training', 'training techniques: neurofeedback training (NFT) and working memory training (WMT', 'neurofeedback and working memory-combined training']","['practice tasks', 'resting-state electroencephalogram (EEG) and behavioral executive function measures', 'mental rotation ability', 'executive functions']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205440', 'cui_str': 'Sixth (qualifier value)'}, {'cui': 'C0443304', 'cui_str': 'Silent (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0080236', 'cui_str': 'Training Technics'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C1527380', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",140.0,0.0120041,The NFT + WMT combined group showed improved mental rotation ability both in the post-training and in the follow-up evaluations.,"[{'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Gordon', 'Affiliation': 'Department of Psychology and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, 84105, Beersheba, Israel. Shirley.gordon@gmail.com.'}, {'ForeName': 'Doron', 'Initials': 'D', 'LastName': 'Todder', 'Affiliation': 'Mental Health Center, Beer Sheva, Ministry of Health, Beersheba, Zlotowski, Israel.'}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Deutsch', 'Affiliation': 'IDF Medical Corps, Tel Hashomer, Ramat Gan, Israel.'}, {'ForeName': 'Dror', 'Initials': 'D', 'LastName': 'Garbi', 'Affiliation': 'Department of Psychology and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, 84105, Beersheba, Israel.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Alkobi', 'Affiliation': 'Department of Cognitive and Brain Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Shriki', 'Affiliation': 'Department of Cognitive and Brain Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.'}, {'ForeName': 'Anat', 'Initials': 'A', 'LastName': 'Shkedy-Rabani', 'Affiliation': 'Department of Cognitive and Brain Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.'}, {'ForeName': 'Nitzan', 'Initials': 'N', 'LastName': 'Shahar', 'Affiliation': 'Department of Psychology and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, 84105, Beersheba, Israel.'}, {'ForeName': 'Nachshon', 'Initials': 'N', 'LastName': 'Meiran', 'Affiliation': 'Department of Psychology and Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, 84105, Beersheba, Israel.'}]",Psychological research,['10.1007/s00426-019-01170-w'] 970,31050809,Characterizing red blood cell age exposure in massive transfusion therapy: the scalar age of blood index (SBI).,"BACKGROUND The mortality of trauma patients requiring massive transfusion to treat hemorrhagic shock approaches 17% at 24 hours and 26% at 30 days. The use of stored RBCs is limited to less than 42 days, so older RBCs are delivered first to rapidly bleeding trauma patients. Patients who receive a greater quantity of older RBCs may have a higher risk for mortality. METHODS AND MATERIALS Characterizing blood age exposure requires accounting for the age of each RBC unit and the quantity of transfused units. To address this challenge, a novel Scalar Age of Blood Index (SBI) that represents the relative distribution of RBCs received is introduced and applied to a secondary analysis of the Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) randomized controlled trial (NCT01545232, https://clinicaltrials.gov/ct2/show/NCT01545232). The effect of the SBI is assessed on the primary PROPPR outcome, 24-hour and 30-day mortality. RESULTS The distributions of blood storage ages successfully maps to a parameter (SBI) that fully defines the blood age curve for each patient. SBI was a significant predictor of 24-hour and 30-day mortality in an adjusted model that had strong predictive ability (odds ratio, 1.15 [1.01-1.29], p = 0.029, C-statistic, 0.81; odds ratio, 1.14 [1.02-1.28], p = 0.019, C-statistic, 0.88, respectively). CONCLUSION SBI is a simple scalar metric of blood age that accounts for the relative distribution of RBCs among age categories. Transfusion of older RBCs is associated with 24-hour and 30-day mortality, after adjustment for total units and clinical covariates.",2019,"Transfusion of older RBCs is associated with 24-hour and 30-day mortality, after adjustment for total units and clinical covariates.",['trauma patients requiring massive transfusion'],"['SBI', 'stored RBCs']","['Blood Index', '24-hour and 30-day mortality', 'blood index (SBI', 'primary PROPPR outcome, 24-hour and 30-day mortality']","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0522501', 'cui_str': 'Massive (qualifier value)'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}]",[],"[{'cui': 'C0005768'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]",,0.092142,"Transfusion of older RBCs is associated with 24-hour and 30-day mortality, after adjustment for total units and clinical covariates.","[{'ForeName': 'Stacia M', 'Initials': 'SM', 'LastName': 'DeSantis', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Derek W', 'Initials': 'DW', 'LastName': 'Brown', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Allison R', 'Initials': 'AR', 'LastName': 'Jones', 'Affiliation': 'Department of Acute, Chronic and Continuing Care, School of Nursing, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Jose-Miguel', 'Initials': 'JM', 'LastName': 'Yamal', 'Affiliation': 'Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Jean-Francois', 'Initials': 'JF', 'LastName': 'Pittet', 'Affiliation': 'Department of Pathology and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Rakesh P', 'Initials': 'RP', 'LastName': 'Patel', 'Affiliation': 'Department of Pathology and Center for Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'Wade', 'Affiliation': 'Department of Surgery, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Holcomb', 'Affiliation': 'Department of Surgery, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Emergency Medicine, The University of Texas Health Science Center at Houston, Houston, Texas.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Transfusion,['10.1111/trf.15334'] 971,31728742,Encouraging Gamblers to Think Critically Using Generalised Analytical Priming is Ineffective at Reducing Gambling Biases.,"Gambling has been associated with an array of fallacious beliefs that foster risky gambling decisions. Research into other belief systems suggests that the endorsement of non-evidence based beliefs, such as the paranormal or conspiracy theories, can be reduced when people think more analytically. The purpose of this study was to explore whether an intervention designed to elicit analytical thinking was effective in altering the gambling beliefs and simulated gambling behaviour of 178 regular electronic gaming machine (EGM) gamblers (102 males, 76 female). Participants were randomly allocated to complete either an analytic or a neutral priming task, followed by completion of belief measures (erroneous and protective) and play on a simulated EGM game. Results failed to show that priming for analytical thinking changed betting on an EGM; including features of bet size, bet change, persistence and theoretical losses. Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs. In fact, priming people to think more critically might be counterproductive by contributing to greater positive expectations about gambling outcomes. The results further suggested that the number of times a player alters their bet is a good indicator of theoretical gambling losses and is associated with irrational gambling cognitions. Interventions designed to promote safer thinking in gamblers should be implemented with care, as results from our study suggest that encouraging critical thinking in at-risk or problem gamblers may not be effective in reducing risky gambling.",2020,"Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs.","['178 regular electronic gaming machine (EGM) gamblers (102 males, 76 female']","['analytic or a neutral priming task, followed by completion of belief measures (erroneous and protective) and play on a simulated EGM game']",['gambling beliefs and simulated gambling behaviour'],"[{'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0336779', 'cui_str': 'Machine, device (physical object)'}, {'cui': 'C0858352', 'cui_str': 'Gambler'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]","[{'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3541364', 'cui_str': 'Erroneous component'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0016995', 'cui_str': 'Gamblings'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",178.0,0.0422487,"Contrary to expectations, results suggest that priming analytical thinking using generalised interventions does not appear to be effective in altering peoples' simulated gambling involvement or gambling beliefs.","[{'ForeName': 'Tess', 'Initials': 'T', 'LastName': 'Armstrong', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, 44 Greenhill Road, Wayville, SA, 5034, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Rockloff', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, University Drive, Bundaberg, QLD, 4670, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Browne', 'Affiliation': 'School of Human, Medical, and Applied Sciences, Central Queensland University, University Drive, Bundaberg, QLD, 4670, Australia.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Blaszczynski', 'Affiliation': 'School of Psychology, The University of Sydney, M02F Mallett Street Campus, Sydney, NSW, 2006, Australia. alex.blaszczynski@sydney.edu.au.'}]",Journal of gambling studies,['10.1007/s10899-019-09910-8'] 972,30156758,"Pharmacokinetics, Safety, and Tolerability of the Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257, in Healthy Volunteers and Patients With Rheumatoid Arthritis.","The dual-variable domain immunoglobulin ABBV-257 binds tumor necrosis factor-α and interleukin 17A. Following single ascending doses ( 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously) in a randomized, double-blind, placebo-controlled study in healthy subjects (n = 40; n = 29 evaluated for pharmacokinetics), maximum observed serum concentration (C max ) increased dose-proportionally, whereas area under the serum concentration-versus-time curve trended to more than dose-proportional increase. Absolute subcutaneous bioavailability was ∼80%, and the time to C max (t max ) occurred 6 to 8 days after subcutaneous administration. The terminal-phase harmonic mean elimination half-life (t ½ ) ranged from 5.5 to 11 days following intravenous and subcutaneous administration. In another randomized, placebo-controlled study, rheumatoid arthritis (RA) patients (n = 8) received ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks. Following the fourth dose, C max was 7.69 μg/mL, and t max occurred ∼4 days after dosing; t ½ was ∼16 days. Most individuals (single-dose study, 97%; multiple-dose study, 83%) developed antidrug antibodies (ADAs). Generally, subjects with higher ADA titers had shorter ABBV-257 t ½ and lower exposure. One serious adverse event (cerebral ischemia, considered unrelated to treatment, resolved with interventions) occurred in an RA patient who received ABBV-257. Because of the high incidence of ADA-mediated drug clearance, ABBV-257 is no longer being developed.",2019,"Most individuals (single-dose study, 97%; multiple-dose study, 83%) developed antidrug antibodies (ADAs).","['rheumatoid arthritis (RA) patients (n\xa0=\xa08) received', 'Healthy Volunteers and Patients With Rheumatoid Arthritis', 'healthy subjects (n\xa0=\xa040; n\xa0=\xa029 evaluated for pharmacokinetics']","['ABBV-257 30\xa0mg/kg subcutaneously', 'Dual Inhibitor of Tumor Necrosis Factor-α and Interleukin 17A, ABBV-257', 'placebo']","['Absolute subcutaneous bioavailability', 'antidrug antibodies (ADAs', 'Pharmacokinetics, Safety, and Tolerability']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}]","[{'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C1705947', 'cui_str': 'CTLA8'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",97.0,0.138765,"Most individuals (single-dose study, 97%; multiple-dose study, 83%) developed antidrug antibodies (ADAs).","[{'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Othman', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Khatri', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Loebbert', 'Affiliation': 'AbbVie GmbH & Co KG, Ludwigshafen, Germany.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Peloso', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.611'] 973,31735538,Fatty acid profiles in erythrocyte membranes following the Mediterranean diet - data from a multicenter lifestyle intervention study in women with hereditary breast cancer (LIBRE).,"BACKGROUND & AIMS Evidence-based concepts to prevent breast cancer in women with BRCA1/2 mutations are limited. Adherence to a Mediterranean diet (MedD) has been associated with a lower risk for breast cancer, possibly due to a favorable fatty acid (FA) intake. Here, we studied in an at-risk population the effect of a lifestyle intervention that included the MedD on FA composition in red blood cell membranes (RBCM). METHODS Data derived from the German multicenter trial LIBRE, from which 68 women were randomized into an intervention group (IG) trained for MedD and increased physical activity for 12 months, and a usual care control group (CG). Adherence to the diet was assessed after 3 and 12 months using the validated Mediterranean Diet Adherence Screener (MEDAS) and a food frequency questionnaire. RBCM FA were analyzed by gas chromatography with mass spectrometry. RESULTS The MEDAS was increased in both groups after 3 months (IG: P < 0.001; CG: P = 0.004), and remained increased only in the IG after 12 months (P < 0.001). The food frequency questionnaire revealed an increased intake of omega-3 (n-3) FA at month 3 and month 12 in the IG (both P < 0.01), but not in the CG, in which intake of energy, protein and saturated FA decreased. In both groups n-6 FA in the RBCM decreased (P < 0.001), while n-9 FA increased (P < 0.001) and n-3 FA were unchanged. Women with higher consumption of fish had higher amounts of n-3 fatty acids in the RBCM. The MEDAS was inversely correlated with n-6 fatty acids. CONCLUSIONS The RBCM FA composition was associated with dietetic parameters related to the MedD. Adherence to the MedD resulted in an altered, likely favorable FA composition. Our data suggest selected FA as biomarkers to monitor compliance to a dietetic intervention such as the MedD. CLINICAL TRIAL REGISTRY The trial is registered at ClinicalTrials.gov (reference: NCT02087592).",2020,"In both groups n-6 FA in the RBCM decreased (P < 0.001), while n-9 FA increased (P < 0.001) and n-3 FA were unchanged.","['women with BRCA1/2 mutations', 'Data derived from the German multicenter trial LIBRE, from which 68 women', 'women with hereditary breast cancer (LIBRE']","['Mediterranean diet (MedD', 'intervention group (IG) trained for MedD and increased physical activity for 12 months, and a usual care control group (CG']","['MEDAS', 'n-9 FA', 'RBCM FA', 'validated Mediterranean Diet Adherence Screener (MEDAS', 'n-6 fatty acids', 'n-3 fatty acids', 'RBCM FA composition', 'FA composition in red blood cell membranes (RBCM', 'RBCM', 'n-3 FA', 'intake of omega-3 (n-3) FA']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C1556085', 'cui_str': 'Germans (ethnic group)'}, {'cui': 'C0206012', 'cui_str': 'Multicenter Trials'}, {'cui': 'C0439660', 'cui_str': 'Hereditary (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]","[{'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity (finding)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1138412', 'cui_str': 'Diet, Mediterranean'}, {'cui': 'C0133860', 'cui_str': 'Fatty Acids, Omega-6'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1277078', 'cui_str': 'Red blood cells, blood product'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}]",68.0,0.0361984,"In both groups n-6 FA in the RBCM decreased (P < 0.001), while n-9 FA increased (P < 0.001) and n-3 FA were unchanged.","[{'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Seethaler', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany. Electronic address: b.seethaler@uni-hohenheim.de.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Basrai', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany. Electronic address: m.basrai@uni-hohenheim.de.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Vetter', 'Affiliation': 'Institute of Food Chemistry, University of Hohenheim, Garbenstr. 28, 70593, Stuttgart, Germany. Electronic address: w-vetter@uni-hohenheim.de.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Lehnert', 'Affiliation': 'Institute of Food Chemistry, University of Hohenheim, Garbenstr. 28, 70593, Stuttgart, Germany. Electronic address: Katja.Lehnert@uni-hohenheim.de.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Engel', 'Affiliation': 'Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Haertelstrasse 16-18, 04107, Leipzig, Germany. Electronic address: christoph.engel@imise.uni-leipzig.de.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Siniatchkin', 'Affiliation': 'Institute for Medical Psychology and Sociology, University Hospital Schleswig-Holstein, Campus Kiel, Preusserstr. 1 - 9, 24105, Kiel, Germany. Electronic address: siniatchkin@med-psych.uni-kiel.de.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Halle', 'Affiliation': 'Department of Prevention and Sports Medicine, Klinikum Rechts der Isar, 6 Technical University Munich (TUM), Ismaninger Str. 22, 81675, Munich, Germany. Electronic address: Martin.Halle@mri.tum.de.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Kiechle', 'Affiliation': 'Department of Gynecology, Center for Hereditary Breast and Ovarian Cancer, Klinikum Rechts Der Isar, Technical University Munich (TUM) and Comprehensive Cancer Center Munich (CCCM), Ismaninger Str. 22, 81675, München, Germany. Electronic address: Marion.Kiechle@mri.tum.de.'}, {'ForeName': 'Stephan C', 'Initials': 'SC', 'LastName': 'Bischoff', 'Affiliation': 'Institute of Nutritional Medicine, University of Hohenheim, Fruwirthstr. 12, 70593, Stuttgart, Germany. Electronic address: bischoff.stephan@uni-hohenheim.de.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.10.033'] 974,30982972,Optimal reassessment time for treatment response in posterior canal benign paroxysmal positional vertigo.,"OBJECTIVES/HYPOTHESIS The present study aimed to evaluate the optimal reassessment time for treatment response in posterior canal benign paroxysmal positional vertigo (PC-BPPV) following the initial Epley maneuver. STUDY DESIGN Prospective, single-blinded, randomized study. METHODS One hundred eight patients with PC-BPPV agreed to participate. These patients received a single modified Epley maneuver (recommended by the 2008 American Academy of Otolaryngology-Head and Neck Surgery guidelines) daily until positional nystagmus disappeared during the Dix-Hallpike maneuver 24 hours after the treatment. Repeated Dix-Hallpike testing to reassess the treatment response was performed at 1 hour (post-1 hour), every 24 hours (post-24 hours) until the positional nystagmus resolved, 1 week (post-1 week), and 1 month (post-1 month) following the therapeutic maneuver. The difference in the resolution rates at post-1 hour and post-24 hours reassessment was analyzed, and the recurrence rates at post-1 week and post-1 month were evaluated. RESULTS The resolution rate was 67.6% at post-1 hour, which increased to 79.6% at post-24 hours reassessment. There was a statistically significant difference in the results of the Dix-Hallpike test between post-1 hour and post-24 hours follow-up. After complete resolution, nine out of 108 patients (8.3%) demonstrated recurrence within 1 month. CONCLUSIONS Reassessment after 24 hours following the initial Epley maneuver is more advantageous than a 1-hour follow-up in patients with PC-BPPV. This information may be helpful for clinicians in deciding the appropriate follow-up period after treatment for PC-BPPV. LEVEL OF EVIDENCE 1b Laryngoscope, 130:496-499, 2020.",2020,There was a statistically significant difference in the results of the Dix-Hallpike test between post-1 hour and post-24 hours follow-up.,"['posterior canal benign paroxysmal positional vertigo (PC-BPPV', 'One hundred eight patients with PC-BPPV agreed to participate', 'posterior canal benign paroxysmal positional vertigo']",['single modified Epley maneuver'],"['resolution rates', 'Dix-Hallpike test', 'recurrence', 'recurrence rates', 'resolution rate']","[{'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0442636', 'cui_str': 'Canal (environment)'}, {'cui': 'C0155502', 'cui_str': 'Vertigo, Benign Recurrent'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1279393', 'cui_str': 'Epley maneuver (procedure)'}]","[{'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",108.0,0.0791666,There was a statistically significant difference in the results of the Dix-Hallpike test between post-1 hour and post-24 hours follow-up.,"[{'ForeName': 'Mee Hyun', 'Initials': 'MH', 'LastName': 'Song', 'Affiliation': 'Department of Otorhinolaryngology, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.'}, {'ForeName': 'Tae Hoon', 'Initials': 'TH', 'LastName': 'Kong', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Yonsei University Wonju College of Medicine, Wonju, South Korea.'}, {'ForeName': 'Dae Bo', 'Initials': 'DB', 'LastName': 'Shim', 'Affiliation': 'Department of Otorhinolaryngology, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea.'}]",The Laryngoscope,['10.1002/lary.28005'] 975,31718499,Impact of a Design-Based Bike Exergame on Young Adults' Physical Activity Metrics and Situational Interest.,"Purpose : Despite the benefits of commercial exergames, in the practical application, players might not be spending sufficient time in physical activity levels compatible with health outcomes. We adopted a design-based exergame approach to build a bike exergame called Greedy Rabbit. The purpose of this study was to identify the impact of Greedy Rabbit on players' physical activity metrics and situational interest. Method : Sixty undergraduate students were assigned to two groups: an experimental group playing Greedy Rabbit (N = 41) and a control group playing a placebo version of Greedy Rabbit (N = 19). The physical activity metrics measured were maximum oxygen consumption, heart rate and cadence. Results : The experimental group reported higher scores for all physical activity metrics and for two dimensions of situational interest (instant enjoyment and attention demand). Furthermore, the physical activity metrics increased more during the exergame for the experimental group, reaching the standard guidelines for vigorous physical activity. Conclusion : This study demonstrated that a design-based bike exergame might be a good option to enhance players' health-related physical activity outcomes and situational interest.",2020,The experimental group reported higher scores for all physical activity metrics and for two dimensions of situational interest (instant enjoyment and attention demand).,"['Sixty undergraduate students', 'Young Adults']","['Design-Based Bike Exergame', 'control group playing a placebo version of Greedy Rabbit', 'experimental group playing Greedy Rabbit']","['maximum oxygen consumption, heart rate and cadence', 'Physical Activity Metrics and Situational Interest', 'situational interest (instant enjoyment and attention demand', 'physical activity metrics']","[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0005375', 'cui_str': 'Bicycle, device (physical object)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C3887509', 'cui_str': 'Rabbits'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0246847,The experimental group reported higher scores for all physical activity metrics and for two dimensions of situational interest (instant enjoyment and attention demand).,"[{'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Roure', 'Affiliation': 'University of Teacher Education.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Pasco', 'Affiliation': 'University of Bourgogne Franche-Comté.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Benoît', 'Affiliation': 'Université Catholique de Louvain.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Deldicque', 'Affiliation': 'Université Catholique de Louvain.'}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1665621'] 976,30693423,Methylphenidate modifies activity in the prefrontal and parietal cortex accelerating the time judgment.,"Methylphenidate produces its effects via actions on cortical areas involved with attention and working memory, which have a direct role in time estimation judgment tasks. In particular, the prefrontal and parietal cortex has been the target of several studies to understand the effect of methylphenidate on executive functions and time interval perception. However, it has not yet been studied whether acute administration of methylphenidate influences performance in time estimation task and the changes in alpha band absolute power in the prefrontal and parietal cortex. The current study investigates the influence of the acute use of methylphenidate in both performance and judgment in the time estimation interpretation through the alpha band absolute power activity in the prefrontal and parietal cortex. This is a double-blind, crossover study with a sample of 32 subjects under control (placebo) and experimental (methylphenidate) conditions with absolute alpha band power analysis during a time estimation task. We observed that methylphenidate does not influence task performance (p > 0.05), but it increases the time interval underestimation by over 7 s (p < 0.001) with a concomitant decrease in absolute alpha band power in the ventrolateral prefrontal cortex and dorsolateral prefrontal cortex and parietal cortex (p < 0.001). Acute use of methylphenidate increases the time interval underestimation, consistent with reduced accuracy of the internal clock mechanisms. Furthermore, acute use of methylphenidate influences the absolute alpha band power over the dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, and parietal cortex.",2019,"We observed that methylphenidate does not influence task performance (p > 0.05), but it increases the time interval underestimation by over 7 s (p < 0.001) with a concomitant decrease in absolute alpha band power in the ventrolateral prefrontal cortex and dorsolateral prefrontal cortex and parietal cortex (p < 0.001).",['32 subjects under'],"['methylphenidate', 'control (placebo) and experimental (methylphenidate', 'Methylphenidate']","['absolute alpha band power in the ventrolateral prefrontal cortex and dorsolateral prefrontal cortex and parietal cortex', 'absolute alpha band power over the dorsolateral prefrontal cortex, ventrolateral prefrontal cortex, and parietal cortex', 'executive functions and time interval perception', 'time interval underestimation', 'task performance']",[],"[{'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0185014', 'cui_str': 'Banding'}, {'cui': 'C3266730', 'cui_str': 'Ventrolateral'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C4019080', 'cui_str': 'Dorsolateral Prefrontal Cortex'}, {'cui': 'C0030560', 'cui_str': 'Parietal Cortex'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]",32.0,0.0320789,"We observed that methylphenidate does not influence task performance (p > 0.05), but it increases the time interval underestimation by over 7 s (p < 0.001) with a concomitant decrease in absolute alpha band power in the ventrolateral prefrontal cortex and dorsolateral prefrontal cortex and parietal cortex (p < 0.001).","[{'ForeName': 'Tiago Lopes', 'Initials': 'TL', 'LastName': 'Farias', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil. tiago_farias20@hotmail.com.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Marinho', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil. victormarinhophb@hotmail.com.'}, {'ForeName': 'Valécia', 'Initials': 'V', 'LastName': 'Carvalho', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Kaline', 'Initials': 'K', 'LastName': 'Rocha', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Paulo Ramiler Alves', 'Initials': 'PRA', 'LastName': 'da Silva', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Francisca', 'Initials': 'F', 'LastName': 'Silva', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Ariel Soares', 'Initials': 'AS', 'LastName': 'Teles', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Daya', 'Initials': 'D', 'LastName': 'Gupta', 'Affiliation': 'Department of Biology, Camden County College, Blackwood, NJ, USA.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Ribeiro', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Velasques', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Cagy', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Victor Hugo', 'Initials': 'VH', 'LastName': 'Bastos', 'Affiliation': 'Brain Mapping and Functionality Laboratory, Federal University of Piauí, Parnaíba, Brazil.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Silva-Junior', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}, {'ForeName': 'Silmar', 'Initials': 'S', 'LastName': 'Teixeira', 'Affiliation': 'Neuro-innovation Technology and Brain Mapping Laboratory, Federal University of Piauí, Av. São Sebastião, 2819, Bairro São Benedito, Parnaíba, Piauí, CEP: 64202-020, Brazil.'}]",Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,['10.1007/s10072-018-3699-1'] 977,31937137,Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial.,"BACKGROUND The long-term benefit of revascularization for intermittent claudication is poorly understood. The aim of this study was to investigate the long-term effectiveness and cost-effectiveness compared with a noninvasive approach. METHODS The IRONIC trial (Invasive Revascularization or Not in Intermittent Claudication) randomized patients with mild-to-severe intermittent claudication to either revascularization + best medical therapy + structured exercise therapy (the revascularization group) or best medical therapy + structured exercise therapy (the nonrevascularization group). The health-related quality of life short form 36 questionnaire was primary outcome and disease-specific health-related quality of life (vascular quality of life questionnaire) and treadmill walking distances were secondary end points. Health-related quality of life has previously been reported superior in the revascularization group at 1- and 2-year follow-up. In this study, the 5-year results were determined. The cost-effectiveness of the treatment options was analyzed from a payer/healthcare standpoint. RESULTS Altogether, 158 patients were randomized in a 1:1 ratio. Regarding the primary end point, no intergroup differences were observed for the short form 36 sum or domain scores from baseline to 5 years, except for the short form 36 role emotional domain score, with greater improvement in the nonrevascularization group (n=116, P =0.007). No intergroup differences were observed in the vascular quality of life questionnaire total and domain scores (n=116, NS) or in treadmill walking distances (n=91, NS). A revascularization strategy resulted in almost twice the cost per patient compared with a noninvasive treatment approach ($13 098 versus $6965, P =0.02). CONCLUSIONS After 5 years of follow-up, a revascularization strategy had lost its early benefit and did not result in any long-term improvement in health-related quality of life or walking capacity compared to a noninvasive treatment strategy. Revascularization was not a cost-effective treatment option from a payer/healthcare point of view. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT01219842.",2020,"Regarding the primary end point, no intergroup differences were observed for the short form 36 sum or domain scores from baseline to 5 years, except for the short form 36 role emotional domain score, with greater improvement in the nonrevascularization group (n=116, P =0.007).","['The IRONIC trial (Invasive Revascularization or Not in Intermittent Claudication) randomized patients with mild-to-severe intermittent claudication to either', 'Patients With Intermittent Claudication', '158 patients']",['revascularization + best medical therapy + structured exercise therapy (the revascularization group) or best medical therapy + structured exercise therapy'],"['vascular quality of life questionnaire total and domain scores', 'cost-effectiveness', 'health-related quality of life or walking capacity', 'disease-specific health-related quality of life (vascular quality of life questionnaire) and treadmill walking distances', 'long-term effectiveness and cost-effectiveness']","[{'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0021775', 'cui_str': 'Intermittent Claudication'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy (procedure)'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0034380'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}]",158.0,0.206277,"Regarding the primary end point, no intergroup differences were observed for the short form 36 sum or domain scores from baseline to 5 years, except for the short form 36 role emotional domain score, with greater improvement in the nonrevascularization group (n=116, P =0.007).","[{'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Djerf', 'Affiliation': 'Department of Vascular Surgery (H.D., J.M., J.N.), Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Johan', 'Initials': 'J', 'LastName': 'Millinger', 'Affiliation': 'Department of Vascular Surgery (H.D., J.M., J.N.), Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Mårten', 'Initials': 'M', 'LastName': 'Falkenberg', 'Affiliation': 'Department of Radiology, Institute of Clinical Science (H.D., M.F.), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.'}, {'ForeName': 'Lennart', 'Initials': 'L', 'LastName': 'Jivegård', 'Affiliation': 'HTA Centrum (Health Technology Assessment Center) Västra Götaland (L.J.), Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Svensson', 'Affiliation': 'Department of Public Health and Community Medicine (M.S.), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Nordanstig', 'Affiliation': 'Department of Vascular Surgery (H.D., J.M., J.N.), Sahlgrenska University Hospital, Gothenburg, Sweden.'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008450'] 978,31002578,Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.,"PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m 2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m 2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m 2 over 3 hours day 1, IP cisplatin 75 mg/m 2 day 2, and IP paclitaxel 60 mg/m 2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.",2019,"Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.","['1,560 participants were enrolled and had 84.8 months of follow-up', 'women with newly diagnosed advanced ovarian carcinoma', 'Advanced Ovarian Carcinoma', 'Eligible patients', '1,380 patients with stage II/III and residual disease of 1 cm or less']","['intraperitoneal (IP) chemotherapy regimens', 'bevacizumab', 'IV paclitaxel 80 mg/m 2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m 2 once per week with IP carboplatin area under the curve 6 (IP carboplatin', 'Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab', 'paclitaxel 135 mg/m 2 over 3 hours day 1, IP cisplatin 75 mg/m 2 day 2, and IP paclitaxel', 'IP cisplatin']","['Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores', 'progression-free survival (PFS', 'mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores', 'median PFS duration', 'duration of PFS', 'median overall survival', 'median PFS', 'Median overall survival', 'Median PFS']","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0029925'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0442120', 'cui_str': 'Intraperitoneal (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0029939', 'cui_str': 'Ovary'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",1560.0,0.234568,"Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.","[{'ForeName': 'Joan L', 'Initials': 'JL', 'LastName': 'Walker', 'Affiliation': '1 University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'ForeName': 'Mark F', 'Initials': 'MF', 'LastName': 'Brady', 'Affiliation': '2 Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Lari', 'Initials': 'L', 'LastName': 'Wenzel', 'Affiliation': '3 University of California, Irvine, Medical Center, Orange, CA.'}, {'ForeName': 'Gini F', 'Initials': 'GF', 'LastName': 'Fleming', 'Affiliation': '4 The University of Chicago Medicine, Chicago, IL.'}, {'ForeName': 'Helen Q', 'Initials': 'HQ', 'LastName': 'Huang', 'Affiliation': '2 Roswell Park Cancer Institute, Buffalo, NY.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'DiSilvestro', 'Affiliation': '5 Women and Infants Hospital, Providence, RI.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Fujiwara', 'Affiliation': '6 Saitama Medical University International Medical Center, Hidaka-Shi, Japan.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Alberts', 'Affiliation': '7 The University of Arizona Cancer Center, Tucson, AZ.'}, {'ForeName': 'Wenxin', 'Initials': 'W', 'LastName': 'Zheng', 'Affiliation': '8 The University of Arizona, Tucson, AZ.'}, {'ForeName': 'Krishnansu S', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': '3 University of California, Irvine, Medical Center, Orange, CA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Cohn', 'Affiliation': '9 The Ohio State University, Columbus, OH.'}, {'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Powell', 'Affiliation': '10 Washington University in St Louis, St Louis, MO.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Van Le', 'Affiliation': '11 University of North Carolina at Chapel Hill, Chapel Hill, NC.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Davidson', 'Affiliation': '12 University of Colorado, Aurora, CO.'}, {'ForeName': 'Heidi J', 'Initials': 'HJ', 'LastName': 'Gray', 'Affiliation': '13 University of Washington School of Medicine, Seattle, WA.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Rose', 'Affiliation': '14 Cleveland Clinic Foundation, Cleveland, OH.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': '15 Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Tashanna', 'Initials': 'T', 'LastName': 'Myers', 'Affiliation': '16 University of Connecticut, Storrs, CT.'}, {'ForeName': 'Angeles', 'Initials': 'A', 'LastName': 'Alvarez Secord', 'Affiliation': '17 Duke University Health System, Durham, NC.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Rubin', 'Affiliation': '18 University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Mannel', 'Affiliation': '1 University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.18.01568'] 979,31000508,Combined subconjunctival injection of dexamethasone for the management of acute primary angle closure: a randomised controlled trial.,"PURPOSE To investigate whether the combined subconjunctival injection of dexamethasone can accelerate the decrease in intraocular pressure (IOP) in acute primary angle closure (APAC)-affected eyes. METHODS 42 patients with APAC were recruited for a randomised controlled trial. These patients were separated into two groups: the injection group (21 patients) and the control group (21 patients). The injection group was subjected to a subconjunctival injection with 2.5 mg dexamethasone. Other drug treatments were the same with the control group. The follow-up was at 0, 3, 6, 12 and 24 hours after injection. The outcome measures include IOP and intraocular inflammation variables. RESULTS The IOP was significantly decreased in both groups after treatment. However, 24 hours after the initial treatment, the IOP of the injection group was significantly lower compared with the control group (p = 0.017). Kaplan-Meier survival curve analysis showed that the total success rate of the injection group and the control group were 79.7% and 54.9% at 24 hours after treatment (p = 0.027), respectively. For the comparison of anterior chamber inflammation, the severity of conjunctival erythema, ciliary flush and pain in the injection group was also lower than that in the control group at 24 hours after treatment(p = 0.012, p = 0.048 and p = 0.013, respectively). No statistical significance was found between the two groups regarding the anterior chamber cells, anterior chamber flare and photophobia. CONCLUSION The combined subconjunctival injection of dexamethasone for the management of APAC eyes can significantly accelerate the relief of high IOP, and therefore, improve the success rate of treatment.",2020,"No statistical significance was found between the two groups regarding the anterior chamber cells, anterior chamber flare and photophobia. ","['acute primary angle closure (APAC)-affected eyes', '42 patients with APAC', 'acute primary angle closure']","['subconjunctival injection with 2.5\u2009mg dexamethasone', 'dexamethasone']","['total success rate', 'IOP', 'severity of conjunctival erythema, ciliary flush and pain', 'anterior chamber cells, anterior chamber flare and photophobia', 'intraocular pressure (IOP', 'IOP and intraocular inflammation variables']","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0429528', 'cui_str': 'Angle closure'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0197180', 'cui_str': 'Subconjunctival injection (procedure)'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0016382', 'cui_str': 'Flushing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0423282', 'cui_str': 'Anterior chamber cells (finding)'}, {'cui': 'C0423281', 'cui_str': 'Anterior chamber flare (finding)'}, {'cui': 'C0085636', 'cui_str': 'Light Sensitivity'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C0042164', 'cui_str': 'Uveitis'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}]",42.0,0.0488493,"No statistical significance was found between the two groups regarding the anterior chamber cells, anterior chamber flare and photophobia. ","[{'ForeName': 'Wenbin', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, China.'}, {'ForeName': 'Xingyi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Gao', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, China.'}, {'ForeName': 'Xiulan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University Zhongshan Ophthalmic Center, Guangzhou, China zhangxl2@mail.sysu.edu.cn.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2018-313473'] 980,31028006,Intervention Increases Physical Activity and Healthful Diet Among South African Adolescents Over 54 Months: A Randomized Controlled Trial.,"PURPOSE Scant research has investigated whether health promotion interventions have sustained effects in increasing physical activity and healthful diet among adolescents in sub-Saharan Africa, which is experiencing an epidemiological transition from infectious diseases to noncommunicable diseases as leading causes of mortality. We examined whether an intervention increased adherence to 5-a-day diet and physical activity guidelines during a 54-month postintervention period among South African adolescents and whether its effects weakened at long-term (42 and 54 months postintervention) compared with short-term (3, 6, and 12 months postintervention) follow-up. METHODS We randomized 18 randomly selected schools serving grade 6 learners (mean age = 12.6) in a township and a semirural area in Eastern Cape Province, South Africa, to one of the two 12-hour interventions: health promotion, targeting healthful diet and physical activity; attention-matched control, targeting sexual risk behaviors. We tested the intervention's effects on adherence to 5-a-day diet and physical activity guidelines using generalized estimating equations logistic regression models adjusting for baseline behavior and clustering within schools. RESULTS Health promotion intervention participants had higher odds of meeting 5-a-day diet and physical activity guidelines than control participants. The effect on 5-a-day diet did not weaken at long-term compared with short-term follow-up, but the effect on physical activity guidelines was weaker at long-term follow-up, mainly because of a reduced effect on muscle-strengthening physical activity. The intervention also increased health promotion attitude and intention and health knowledge and reduced binge drinking compared with the control group. CONCLUSIONS A 12-hour intervention in grade 6 shows promise in increasing self-reported adherence to healthful diet and physical activity guidelines during a 4.5-year postintervention period among South African adolescents.",2019,"RESULTS Health promotion intervention participants had higher odds of meeting 5-a-day diet and physical activity guidelines than control participants.","['18 randomly selected schools serving grade 6 learners (mean age\xa0= 12.6) in a township and a semirural area in Eastern Cape Province, South Africa, to one of the two 12-hour interventions', 'South African Adolescents', 'South African adolescents']","['health promotion, targeting healthful diet and physical activity; attention-matched control, targeting sexual risk behaviors']","['Physical Activity and Healthful Diet', 'meeting 5-a-day diet and physical activity guidelines', 'physical activity guidelines', 'health promotion attitude and intention and health knowledge and reduced binge drinking']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517545', 'cui_str': 'Twelve point six'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0454728', 'cui_str': 'Cape Province (geographic location)'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C1292430', 'cui_str': '12 hours'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0556656', 'cui_str': 'Meetings (procedure)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}]",18.0,0.0322506,"RESULTS Health promotion intervention participants had higher odds of meeting 5-a-day diet and physical activity guidelines than control participants.","[{'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Jemmott', 'Affiliation': 'Annenberg School for Communication and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: jjemmott@asc.upenn.edu.'}, {'ForeName': 'Jingwen', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Communication, University of California, Davis, California.'}, {'ForeName': 'Loretta S', 'Initials': 'LS', 'LastName': 'Jemmott', 'Affiliation': 'College of Nursing and Health Professionals, Drexel University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Larry D', 'Initials': 'LD', 'LastName': 'Icard', 'Affiliation': 'College of Public Health, Temple University, Philadelphia, Pennsylvania.'}, {'ForeName': 'Zolani', 'Initials': 'Z', 'LastName': 'Ngwane', 'Affiliation': 'Department of Anthropology, Haverford College, Haverford, Pennsylvania.'}, {'ForeName': 'Monde', 'Initials': 'M', 'LastName': 'Makiwane', 'Affiliation': 'Human Sciences Research Council, Pretoria, South Africa.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': ""O'Leary"", 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2019.01.027'] 981,31552543,"Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical ""Pulse"" Dose.","INTRODUCTION This small pilot study is the first direct comparison of the currently marketed formulations of bromfenac (0.07% solution) and nepafenac (0.3% suspension) using identical dosing regimens and including an extra pre-surgical ""pulse"" dose in patients undergoing cataract surgery. METHODS Adults scheduled for unilateral phacoemulsification with intraocular lens implantation were randomly assigned to bromfenac 0.07% or nepafenac 0.3%, each given once-daily 1 day prior to surgery, on the day of surgery plus an extra dose 1 h before surgery, and for 14 days after surgery. Assessments included summed ocular inflammation score (SOIS), visual acuity (VA), and retinal thickness measured via optical coherence tomography. RESULTS The study population included 49 patients (bromfenac, n = 24; nepafenac, n = 25). The percentage of patients with a SOIS = 0 (no cells or flare) at post-surgical day 15 (primary efficacy endpoint) was statistically similar between the bromfenac (57.1%) and nepafenac (50.0%) treatment groups (intent-to-treat with last observation carried forward) (P = 0.6318). The proportions of patients with an SOIS of 0 at days 3 and 8 were significantly (P < 0.05) higher in the bromfenac group (23.8 and 52.4%, respectively) versus the nepafenac group (0.0 and 20.8%, respectively). Visual acuity was similar between groups at each study visit, as were mean retinal thickness and change from baseline in retinal thickness. Rescue medication (typically difluprednate) was given on or before day 15 to 13 patients in each treatment group (bromfenac, 54.2%; nepafenac, 52.0%). There were no adverse events considered to be related to either treatment. CONCLUSIONS The results of this small pilot study suggest that once-daily bromfenac 0.07% produces similar benefits with regard to postsurgical inflammation, VA, and retinal thickness as once-daily nepafenac 0.3%, and possibly has a faster onset of anti-inflammatory action, when compared using identical dosing regimens. FUNDING Bausch & Lomb Incorporated. TRIAL REGISTRATION NCT03886779.",2019,"Visual acuity was similar between groups at each study visit, as were mean retinal thickness and change from baseline in retinal thickness.","['49 patients (bromfenac, n\u2009=\u200924; nepafenac, n\u2009=\u200925', 'Adults scheduled for unilateral phacoemulsification with intraocular lens implantation', 'patients undergoing cataract surgery', 'Post-Cataract Surgery Inflammation']","['Nepafenac Ophthalmic Suspension', 'nepafenac', 'nepafenac (0.3% suspension']","['Visual acuity', 'summed ocular inflammation score (SOIS), visual acuity (VA), and retinal thickness measured via optical coherence tomography']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0054094', 'cui_str': 'bromfenac'}, {'cui': 'C0961209', 'cui_str': 'nepafenac'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C1276060', 'cui_str': 'Phacoemulsification of lens and insertion of prosthetic replacement (procedure)'}, {'cui': 'C2004600', 'cui_str': 'Cataract surgery specialty'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]","[{'cui': 'C3530973', 'cui_str': 'nepafenac Ophthalmic Suspension [Ilevro]'}, {'cui': 'C0961209', 'cui_str': 'nepafenac'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}]",49.0,0.10952,"Visual acuity was similar between groups at each study visit, as were mean retinal thickness and change from baseline in retinal thickness.","[{'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Silverstein', 'Affiliation': 'Silverstein Eye Centers, Kansas City, MO, USA. ssilverstein@silversteineyecenters.com.'}]",Ophthalmology and therapy,['10.1007/s40123-019-00215-y'] 982,31004521,Cognitive-behavioral therapy (CBT) for generalized anxiety disorder: Contrasting various CBT approaches in a randomized clinical trial.,"OBJECTIVE Cognitive-behavior therapy (CBT) is considered the ""golden standard"" psychotherapy for generalized anxiety disorder (GAD) but, at this point, we have little information about differences among various CBT approaches. METHOD We conducted a randomized controlled trial to compare three CBT protocols for GAD: (a) Cognitive Therapy/Borkovec's treatment package; (b) Rational Emotive Behavior Therapy, and (c) Acceptance and Commitment Therapy/Acceptance-based behavioral therapy. A number of 75 patients diagnosed with GAD, aged between 20 and 51 (m = 27.13; standard deviation = 7.50), 60 women and 11 men, were randomized to the three treatment arms. RESULTS All treatments were associated with large pre-post intervention reductions in GAD symptoms and dysfunctional automatic thoughts, with no significant differences between groups. Correlation analyses showed similar associations between changes in symptoms and changes in dysfunctional automatic thoughts. CONCLUSIONS All three approaches appear to be similarly effective. Implications for the theoretical models underlying each of the three cognitive-behavior therapy approaches are discussed.",2019,"All treatments were associated with large pre-post intervention reductions in GAD symptoms and dysfunctional automatic thoughts, with no significant differences between groups.","['75 patients diagnosed with GAD, aged between 20 and 51 (m = 27.13; standard deviation = 7.50), 60 women and 11 men', 'generalized anxiety disorder']","[""CBT protocols for GAD: (a) Cognitive Therapy/Borkovec's treatment package; (b) Rational Emotive Behavior Therapy, and (c) Acceptance and Commitment Therapy/Acceptance-based behavioral therapy"", 'Cognitive-behavior therapy (CBT', 'Cognitive-behavioral therapy (CBT']","['dysfunctional automatic thoughts', 'GAD symptoms and dysfunctional automatic thoughts']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}]","[{'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1704710', 'cui_str': 'Package'}, {'cui': 'C0004933', 'cui_str': 'Behavior Modification'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and Commitment Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C4319827', 'cui_str': 'Thought'}]",60.0,0.0434947,"All treatments were associated with large pre-post intervention reductions in GAD symptoms and dysfunctional automatic thoughts, with no significant differences between groups.","[{'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Stefan', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Babeş-Bolyai University, Cluj-Napoca, Romania.'}, {'ForeName': 'Ioana A', 'Initials': 'IA', 'LastName': 'Cristea', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Babeş-Bolyai University, Cluj-Napoca, Romania.'}, {'ForeName': 'Aurora', 'Initials': 'A', 'LastName': 'Szentagotai Tatar', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Babeş-Bolyai University, Cluj-Napoca, Romania.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'David', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy/International Institute for the Advanced Study of Psychotherapy and Applied Mental Health, Babeş-Bolyai University, No 37 Republicii Street, Cluj-Napoca, Romania.'}]",Journal of clinical psychology,['10.1002/jclp.22779'] 983,30982411,Effects of A Dual-Task Intervention in Postural Control and Cognitive Performance in Adolescents.,"The aim was to assess dual- versus single-task training for motor performance and cognitive performance in adolescents. Two experiments were performed. In the first, 30 adolescents were randomized to three groups to determine the effect of dual-task difficulty on postural control: α-scaling and root mean square (RMS). In the second, 20 adolescents were randomized to two groups to determine the effect of dual-task practice to improve working memory. RMS in the post-test was lower than the pre-test in both dual-task groups, while α-scaling was lower in post-test than pre-test only in the high-difficulty dual-task group. A practice effect was observed on the percentage of correct answers only in the dual-task group ( p  = 0.035). Thus, dual-task training could enhance motor and cognitive performance more than single-task training.",2020,A practice effect was observed on the percentage of correct answers only in the dual-task group (p = 0.035).,"['30 adolescents', '20 adolescents', 'Adolescents', 'adolescents']","['single-task training', 'Dual-Task Intervention', 'dual-task practice to improve working memory', 'dual-task difficulty on postural control: α-scaling and root mean square (RMS']","['motor performance and cognitive performance', 'Postural Control and Cognitive Performance', 'motor and cognitive performance']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205120', 'cui_str': 'Square (qualifier value)'}]","[{'cui': 'C0205278', 'cui_str': 'Postural (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",30.0,0.0143447,A practice effect was observed on the percentage of correct answers only in the dual-task group (p = 0.035).,"[{'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Bustillo-Casero', 'Affiliation': 'Department of Teaching of Musical, Visual and Corporal Expression, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Cebrian-Bou', 'Affiliation': 'Department of Teaching of Musical, Visual and Corporal Expression, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Cruz-Montecinos', 'Affiliation': 'Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Pardo', 'Affiliation': 'Department of Physical and Sports Education, University of Valencia, Valencia, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'García-Massó', 'Affiliation': 'Department of Teaching of Musical, Visual and Corporal Expression, University of Valencia, Valencia, Spain.'}]",Journal of motor behavior,['10.1080/00222895.2019.1600467'] 984,31029534,"The repeatability of subjective and objective tear ferning assessment and its association with lipid layer thickness, non-invasive tear break-up time and comfort.","PURPOSE To determine the repeatability of tear ferning (TF) grading analysed by subjective and objective techniques, and its correlation with lipid layer thickness (LLT), non-invasive keratograph break-up time (NIKBUT), and ocular surface disease index (OSDI) comfort scores with and without ocular lubricants. METHODS A prospective, randomised, controlled clinical study was conducted. Eighteen healthy non-contact lens wearers aged between 18 to 45 years attended a total of three visits. They were randomly allocated to receive no drops on two occasions to examine method repeatability (visits A and B) or a 60 μL drop of Refresh® (visit C). At each visit, LLT and NIKBUT were assessed followed by basal tear collection. The TF pattern was established by pipetting one μL volume of tears onto a glass slide that was allowed to air-dry and imaged under a microscope. The resulting tear ferning pattern was determined using subjective grading and a novel computerized objective analysis technique that measured the local contrast of ferning contours. RESULTS Paired t-tests found that all measurements collected between eyes, on different days for visit A and B were not significantly different (p >0.05). Eyes and days were averaged and compared to visit C. Paired t-tests between the averaged baseline visits and visit C for LLT, NIKBUT including subjective and objective TF scores showed no significant difference (p>0.05). No significant correlation was shown between the TF scoring and OSDI, LLT or NITBUT (p>0.05). There was however a high significant correlation and agreement between the subjective and objective analysis techniques for TF grading. CONCLUSIONS TF grade, LLT and NITBUT are repeatable. As with other ocular surface assessments, subjective and objective TF gradings did not significantly correlate with the measures of tear film stability or comfort. Lubricants had no effect on TF grade, LLT or NITBUT. The novel objective analysis technique is a promising candidate for a repeatable and unbiased assessment of tear ferning.",2019,"As with other ocular surface assessments, subjective and objective TF gradings did not significantly correlate with the measures of tear film stability or comfort.",['Eighteen healthy non-contact lens wearers aged between 18 to 45 years attended a total of three visits'],['60 μL drop of Refresh® (visit C'],"['TF scoring and OSDI, LLT or NITBUT (p>0.05', 'lipid layer thickness (LLT), non-invasive keratograph break-up time (NIKBUT), and ocular surface disease index (OSDI) comfort scores', 'subjective and objective TF scores', 'TF grade, LLT or NITBUT', 'tear film stability or comfort']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0920138', 'cui_str': 'Contact lens wearer'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]","[{'cui': 'C4318619', 'cui_str': 'Drop (unit of presentation)'}]","[{'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C4319646', 'cui_str': 'Film'}]",18.0,0.0189034,"As with other ocular surface assessments, subjective and objective TF gradings did not significantly correlate with the measures of tear film stability or comfort.","[{'ForeName': 'Debarun', 'Initials': 'D', 'LastName': 'Dutta', 'Affiliation': 'School of Optometry and Vision Science, University of New South Wales, Australia; Ophthalmic Research Group, Aston University, Birmingham, UK. Electronic address: d.dutta@aston.ac.uk.'}, {'ForeName': 'Juno', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'School of Optometry and Vision Science, University of New South Wales, Australia.'}, {'ForeName': 'Merna', 'Initials': 'M', 'LastName': 'Sarkes', 'Affiliation': 'School of Optometry and Vision Science, University of New South Wales, Australia.'}, {'ForeName': 'Suneeta', 'Initials': 'S', 'LastName': 'Nath', 'Affiliation': 'School of Optometry and Vision Science, University of New South Wales, Australia.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Markoulli', 'Affiliation': 'School of Optometry and Vision Science, University of New South Wales, Australia.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.04.003'] 985,31024092,Effects of full-fat dairy products on subclinical vascular function in adults with elevated blood pressure: a randomized clinical trial.,"BACKGROUND High consumption of low- and non-fat dairy products improves vascular dysfunction associated with elevated arterial blood pressure (BP). Currently, it is unknown if conventional full-fat dairy products improve vascular functions. OBJECTIVES To determine if adding whole milk and full-fat dairy products to the normal routine diet improves vascular function in adults with elevated BP. DESIGN Sixty adults (age ± SEM; 58 ± 2 years) with elevated BP (systolic/diastolic; 120-159/ < 99 mmHg) were randomized into a controlled crossover intervention trial consisting of two 4-week dietary periods. The high dairy condition consisted of adding four daily servings of whole milk or full-fat dairy products to the normal diet and eliminated all dairy intake during the control (no dairy) condition. A 2-week washout period separated the dietary conditions. RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec). The results were consistent when ultrasound-derived vascular distension measures (arterial compliance, beta-stiffness index, and elastic modulus) were evaluated. Cardiovagal baroreceptor sensitivity (via Valsalva maneuver) demonstrated no significant difference for either dietary condition. Brachial arterial flow-mediated dilation (FMD) did not differ significantly during the high dairy (5.7 ± 0.5 versus 5.4 ± 0.6%) and no dairy conditions (6.5 ± 0.5 versus 5.6 ± 0.6%). CONCLUSIONS The solitary addition of whole milk and full-fat dairy products has no effect on subclinical vascular function in adults with elevated BP.",2020,"RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec).","['adults with elevated BP', 'adults with elevated BP.\nDESIGN\n\n\nSixty adults (age\u2009±\u2009SEM; 58\u2009±\u20092 years) with elevated BP (systolic/diastolic; 120-159/\u2009<\u200999\u2009mmHg', 'adults with elevated blood pressure']","['whole milk and full-fat dairy products to the normal routine diet', 'full-fat dairy products']","['Cardiovagal baroreceptor sensitivity', 'Carotid-femoral pulse wave velocity (cfPWV', 'arterial blood pressure (BP', 'Brachial arterial flow-mediated dilation (FMD', 'ultrasound-derived vascular distension measures (arterial compliance, beta-stiffness index, and elastic modulus', 'vascular function', 'subclinical vascular function']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}]","[{'cui': 'C0452717', 'cui_str': 'Whole milk (substance)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0010947', 'cui_str': 'Dairy Products'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]","[{'cui': 'C0033093', 'cui_str': 'Stretch Receptors, Arterial'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0429856', 'cui_str': 'Arterial flow (observable entity)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C3714614', 'cui_str': 'Distention'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2350289', 'cui_str': 'Young Modulus'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0205211', 'cui_str': 'Subclinical (qualifier value)'}]",60.0,0.125608,"RESULTS Carotid-femoral pulse wave velocity (cfPWV) did not differ significantly between high dairy (11.3 ± 0.3 versus 10.9 ± 0.3 m/sec) and no dairy conditions (11.2 ± 0.3 versus 11.0 ± 0.3 m/sec).","[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Roy', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Brandon G', 'Initials': 'BG', 'LastName': 'Fico', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Brett D', 'Initials': 'BD', 'LastName': 'Baker', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Lapierre', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Jay A', 'Initials': 'JA', 'LastName': 'Shah', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Drew D', 'Initials': 'DD', 'LastName': 'Gourley', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Delfausse', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Tanaka', 'Affiliation': 'Cardiovascular Aging Research Laboratory, Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, USA. htanaka@austin.utexas.edu.'}]",European journal of clinical nutrition,['10.1038/s41430-019-0435-8'] 986,31036397,Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial.,"BACKGROUND Patients with diabetes and those with chronic kidney disease (CKD) are at increased risk of cardiovascular events. Everolimus eluting stents (EES) have been shown to be superior to paclitaxel eluting stents (PES) in patients with diabetes. However, it is not known if EES is as beneficial in diabetic patients with CKD compared with those without CKD. METHODS AND RESULTS Patients enrolled in the TUXEDO-India trial, which is a clinical trial of patients with diabetes and coronary artery disease (CAD) randomly assigned to EES vs. thin-strut PES (Taxus Element), with data on baseline renal function were selected. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m 2 using the Cockcroft-Gault formula. Primary outcome was target vessel failure (TVF-defined as cardiac death, TV myocardial infarction (MI) or ischemia driven TV revascularization) at 1 year. Various secondary outcomes including stent thrombosis were evaluated. Among the 1821 patients with diabetes included in this analysis, 344 (19%) had CKD. In a propensity score adjusted analysis, patients with CKD had a significant increase in MACE (HR = 2.02; 95% CI 1.17-3.50; P = 0.01); death/MI/TVR (HR = 1.99; 95% CI 1.18-3.34; P = 0.009); death/MI (HR = 2.31; 95% CI 1.30-4.08; P = 0.004); cardiac death/MI (HR = 2.40; 95% CI 1.31-4.42; P = 0.005); death (HR = 2.88; 95% CI 1.35-6.13; P = 0.006) driven by an increase in cardiac death (HR = 3.33; 95% CI 1.42-7.83; P = 0.006) when compared with those without CKD. However, stent related events (TV-MI, TVR, TLR and stent thrombosis) were not different between CKD and non CKD groups. A significant interaction between CKD status and stent type (EES vs. PES) was noted for the outcomes of TVF (P interaction  = 0.046), MACE (P interaction  = 0.02), cardiac death or MI (P interaction  = 0.05), non-target vessel related MI (P interaction  = 0.04), non-Q-wave MI (P interaction  = 0.03) and deaths/MI/TVR (P interaction  = 0.04) such that EES was superior to PES in the non-CKD cohort but not in the CKD cohort. CONCLUSIONS In subjects with diabetes, CKD is an independent predictor of adverse cardiovascular outcomes including increased risk of death driven largely by non-stent related events. While EES was superior to PES in patients without CKD, this was not the case in those with CKD (Clinical Trials Registry-India number, CTRI/2011/06/001830).",2019,"However, stent related events (TV-MI, TVR, TLR and stent thrombosis) were not different between CKD and non CKD groups.","['patients with diabetes', 'Patients with diabetes and those with chronic kidney disease (CKD', 'diabetic patients with CKD', '1821 patients with diabetes included in this analysis, 344 (19%) had CKD', 'Patients enrolled in the TUXEDO-India trial, which is a clinical trial of patients with diabetes and coronary artery disease (CAD) randomly assigned to', 'patients with diabetes mellitus and chronic kidney disease']","['EES', 'EES vs. thin-strut PES (Taxus Element', 'Everolimus eluting stents (EES', 'Everolimus eluting stents', 'paclitaxel eluting stents (PES']","['MACE', 'stent thrombosis', 'cardiac death', 'stent related events (TV-MI, TVR, TLR and stent thrombosis', 'glomerular filtration rate (eGFR', 'cardiac death or MI', 'target vessel failure (TVF-defined as cardiac death, TV myocardial infarction (MI) or ischemia driven TV revascularization', 'deaths/MI/TVR', 'cardiac death/MI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0332528', 'cui_str': 'Decreased thickness (finding)'}, {'cui': 'C0441295', 'cui_str': 'Strut (physical object)'}, {'cui': 'C0330199', 'cui_str': 'Taxus'}, {'cui': 'C0013879', 'cui_str': 'Elements'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}]",1821.0,0.16802,"However, stent related events (TV-MI, TVR, TLR and stent thrombosis) were not different between CKD and non CKD groups.","[{'ForeName': 'Sripal', 'Initials': 'S', 'LastName': 'Bangalore', 'Affiliation': 'New York University School of Medicine, New York, NY, USA. Electronic address: sripalbangalore@gmail.com.'}, {'ForeName': 'Rajpal', 'Initials': 'R', 'LastName': 'Abhaichand', 'Affiliation': 'Department of Cardiology, L.R.G. Naidu Cardiology Research Institute and Clinic, Kuppuswamy Naidu Memorial Hospital, Coimbatore, India.'}, {'ForeName': 'Ajit', 'Initials': 'A', 'LastName': 'Mullasari', 'Affiliation': 'Department of Cardiology, The Madras Medical Mission, Chennai, India.'}, {'ForeName': 'Rajneesh', 'Initials': 'R', 'LastName': 'Jain', 'Affiliation': 'Department of Cardiology, Sir Ganga Ram Hospitals, New Delhi, India.'}, {'ForeName': 'R K Prem', 'Initials': 'RKP', 'LastName': 'Chand', 'Affiliation': 'Department of Cardiology, Krishna Institute of Medical Sciences, Secunderabad, India.'}, {'ForeName': 'Priyadarshini', 'Initials': 'P', 'LastName': 'Arambam', 'Affiliation': 'Batra Hospital and Medical Research Center, New Delhi, India.'}, {'ForeName': 'Upendra', 'Initials': 'U', 'LastName': 'Kaul', 'Affiliation': 'Batra Hospital and Medical Research Center, New Delhi, India.'}]",Cardiovascular revascularization medicine : including molecular interventions,['10.1016/j.carrev.2019.02.017'] 987,31036563,"Distinct effects of acute exercise and breaks in sitting on working memory and executive function in older adults: a three-arm, randomised cross-over trial to evaluate the effects of exercise with and without breaks in sitting on cognition.","BACKGROUND Sedentary behaviour is associated with impaired cognition, whereas exercise can acutely improve cognition. OBJECTIVE We compared the effects of a morning bout of moderate-intensity exercise, with and without subsequent light-intensity walking breaks from sitting, on cognition in older adults. METHODS Sedentary overweight/obese older adults with normal cognitive function (n=67, 67±7 years, 31.2±4.1 kg/m 2 ) completed three conditions (6-day washout): SIT (sitting): uninterrupted sitting (8 hours, control); EX+SIT (exercise + sitting): sitting (1 hour), moderate-intensity walking (30 min), uninterrupted sitting (6.5 hours); and EX+BR (exercise + breaks): sitting (1 hour), moderate-intensity walking (30 min), sitting interrupted every 30 min with 3 min of light-intensity walking (6.5 hours). Cognitive testing (Cogstate) was completed at four time points assessing psychomotor function, attention, executive function, visual learning and working memory. Serum brain-derived neurotrophic growth factor (BDNF) was assessed at six time points. The 8-hour net area under the curve (AUC) was calculated for each outcome. RESULTS Working memory net AUC z-score·hour (95% CI) was improved in EX+BR with a z-score of +28 (-26 to +81), relative to SIT, -25 (-79 to +29, p=0.04 vs EX+BR). Executive function net AUC was improved in EX+SIT, -8 (- 71 to +55), relative to SIT, -80 (-142 to -17, p=0.03 vs EX+SIT). Serum BDNF net AUC ng/mL·hour (95% CI) was increased in both EX+SIT, +171 (-449 to +791, p=0.03 vs SIT), and EX+BR, +139 (-481 to +759, p=0.045 vs SIT), relative to SIT, -227 (-851 to +396). CONCLUSION A morning bout of moderate-intensity exercise improves serum BDNF and working memory or executive function in older adults, depending on whether or not subsequent sitting is also interrupted with intermittent light-intensity walking. TRIAL REGISTRATION NUMBER ACTRN12614000737639.",2020,"Executive function net AUC was improved in EX+SIT, -8 (- 71 to +55), relative to SIT, -80","['Sedentary overweight/obese older adults with normal cognitive function (n=67, 67±7 years, 31.2±4.1\u2009kg/m 2 ) completed three', 'older adults']","['morning bout of moderate-intensity exercise, with and without subsequent light-intensity walking breaks from sitting', 'moderate-intensity exercise', 'acute exercise and breaks in sitting', 'conditions (6-day washout): SIT (sitting): uninterrupted sitting (8\u2009hours, control); EX+SIT (exercise + sitting): sitting (1\u2009hour), moderate-intensity walking (30\u2009min), uninterrupted sitting (6.5\u2009hours); and EX+BR (exercise + breaks): sitting (1\u2009hour), moderate-intensity walking (30\u2009min), sitting interrupted every 30\u2009min with 3\u2009min of light-intensity walking']","['Serum BDNF net AUC ng/mL·hour', 'Cognitive testing (Cogstate', 'Serum brain-derived neurotrophic growth factor (BDNF', 'psychomotor function, attention, executive function, visual learning and working memory', 'serum BDNF and working memory or executive function', 'Working memory net AUC z-score·hour', 'Executive function net AUC', 'working memory and executive function', '8-hour net area under the curve (AUC']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0596836', 'cui_str': 'Low intensity'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1292429', 'cui_str': '8 hours (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C0443239', 'cui_str': 'Interrupted (qualifier value)'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C4704801', 'cui_str': 'Neurotrophic'}, {'cui': 'C0018284', 'cui_str': 'Growth factor (substance)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0582587', 'cui_str': 'Spatial Learning'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C1292429', 'cui_str': '8 hours (qualifier value)'}]",,0.054602,"Executive function net AUC was improved in EX+SIT, -8 (- 71 to +55), relative to SIT, -80","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Wheeler', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Western Australia, Australia michael.wheeler@baker.edu.au.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Green', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Ellis', 'Affiliation': 'Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Ester', 'Initials': 'E', 'LastName': 'Cerin', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Ilkka', 'Initials': 'I', 'LastName': 'Heinonen', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Louise H', 'Initials': 'LH', 'LastName': 'Naylor', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Larsen', 'Affiliation': 'Physical Activity, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Wennberg', 'Affiliation': 'Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.'}, {'ForeName': 'Carl-Johan', 'Initials': 'CJ', 'LastName': 'Boraxbekk', 'Affiliation': 'Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Jaye', 'Initials': 'J', 'LastName': 'Lewis', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, Western Australia, Australia.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Eikelis', 'Affiliation': 'Physical Activity, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Nicola T', 'Initials': 'NT', 'LastName': 'Lautenschlager', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Bronwyn A', 'Initials': 'BA', 'LastName': 'Kingwell', 'Affiliation': 'Metabolic and Vascular Physiology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Lambert', 'Affiliation': 'Iverson Health Innovation Research Institute and School of Health Science, Swinburne University of Technology, Melbourne, Victoria, Australia.'}, {'ForeName': 'Neville', 'Initials': 'N', 'LastName': 'Owen', 'Affiliation': 'Behavioural Epidemiology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Dunstan', 'Affiliation': 'Physical Activity, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.'}]",British journal of sports medicine,['10.1136/bjsports-2018-100168'] 988,31071484,Perfectly imperfect: The use of cognitive bias modification to reduce perfectionism.,"BACKGROUND AND OBJECTIVES Perfectionism is a transdiagnostic risk and maintenance factor for psychopathology. The current study developed and evaluated a cognitive bias modification, interpretation retraining (CBM-I) intervention targeting maladaptive perfectionistic beliefs. METHODS Participants were undergraduate students randomized to complete the perfectionism CBM-I (n = 33) or control condition task (n = 36) at two time points. Additionally, participants completed measures of perfectionistic interpretations and trait perfectionism, as well as an impossible anagram task designed to elicit perfectionistic concerns. RESULTS Results indicated that after the intervention, participants who completed the perfectionism CBM-I endorsed fewer perfectionistic interpretations than participants in the control condition. Furthermore, although the study groups self-reported comparably low confidence in their anagram task performance, participants who completed the perfectionism CBM-I reported wanting to re-do significantly fewer anagrams than participants in the control condition, suggesting greater acceptance of imperfect performance following the intervention. Moreover, supporting a key hypothesized mechanism of effect in CBM-I, reductions in perfectionistic interpretations mediated the effect of condition on the desire to re-do anagram task items. LIMITATIONS The study results should be viewed in light of limitations, including the short time-span of the study, and the use of a relatively small, non-clinical, and demographically homogenous convenience sample. CONCLUSIONS Further research and development of the perfectionism CBM-I intervention are needed, but the present findings add to a nascent evidence base that suggests CBM-I holds promise as an accessible and transdiagnostic intervention for perfectionism.",2019,"RESULTS Results indicated that after the intervention, participants who completed the perfectionism CBM-I endorsed fewer perfectionistic interpretations than participants in the control condition.",['Participants were undergraduate students randomized to complete the'],"['interpretation retraining (CBM-I) intervention', 'perfectionism CBM-I (n\u202f=\u202f33) or control condition task']",['perfectionistic interpretations'],"[{'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0459471', 'cui_str': 'Interpretation (attribute)'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0459471', 'cui_str': 'Interpretation (attribute)'}]",,0.053065,"RESULTS Results indicated that after the intervention, participants who completed the perfectionism CBM-I endorsed fewer perfectionistic interpretations than participants in the control condition.","[{'ForeName': 'Dorian R', 'Initials': 'DR', 'LastName': 'Dodd', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA. Electronic address: dodddr@miamioh.edu.'}, {'ForeName': 'E Marie', 'Initials': 'EM', 'LastName': 'Parsons', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}, {'ForeName': 'Elise M', 'Initials': 'EM', 'LastName': 'Clerkin', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}, {'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Forrest', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Velkoff', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}, {'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Kunstman', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}, {'ForeName': 'April R', 'Initials': 'AR', 'LastName': 'Smith', 'Affiliation': 'Department of Psychology, Miami University, 90 N. Patterson Ave., Oxford, OH, USA.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.04.002'] 989,29404948,A Randomized Trial on the Efficacy of Mastery Learning for Primary Care Provider Melanoma Opportunistic Screening Skills and Practice.,"BACKGROUND Early detection of melanoma represents an opportunity to reduce the burden of disease among people at increased risk for melanoma. OBJECTIVE To develop and demonstrate the efficacy of online training. DESIGN Randomized educational trial. PARTICIPANTS Primary care providers (PCPs). INTERVENTION Mastery learning course with visual and dermoscopic assessment, diagnosis and management, and deliberate practice with feedback to reach a minimum passing standard. MAIN MEASURES Pre-test/post-test diagnostic accuracy. Referral of concerning lesions for 3 months before and after the educational intervention. KEY RESULTS Among the 89 PCPs, 89.8% were internal medicine physicians, and the remainder were physician assistants embedded in internists' practices. There were no differences between control and intervention groups regarding gender, age, race, or percentage of full-time PCPs. The control group had more PCPs who reported less than 5 years of practice (n = 18) than the intervention group (n = 6) (χ 2 [6, n = 89] = 14.34, p = 0.03). PCPs in the intervention group answered more melanoma detection questions correctly on the post-test (M = 10.05, SE = 1.24) compared to control group PCPs (M = 7.11, SE = 0.24), and had fewer false-positive and no false-negative melanoma diagnoses (intervention, M = 1.09, SE = 0. 20; control, M = 3.1, SE = 0.23; ANCOVA, F[1,378] =27.86, p < 0.001; η p 2  = 0.26). PCPs who underwent training referred fewer benign lesions, including nevi, seborrheic keratoses, and dermatofibromas, than control PCPs (F[1,79] = 72.89, p < 0.001; η p 2  = 0.489; F[1,79] = 25.82, p < 0.001; η p 2  = 0.246; F[1,79] = 34.25, p < 0.001; η p 2  = 0.302; respectively). Those receiving training referred significantly more melanomas than controls (F[1,79] = 24.38, p < 0.001; η p 2  = 0.236). Referred melanomas (0.8  ± 0.07 per month for intervention, 0.17 ± 0.06 for control) were mostly located on the head and neck. CONCLUSIONS Mastery learning improved PCPs' ability to detect melanoma on a standardized post-test and may improve referral of patients with suspected melanoma. Further studies are needed to confirm this finding. ClinicalTrials.gov NCT02385253.",2018,"PCPs in the intervention group answered more melanoma detection questions correctly on the post-test (M = 10.05, SE = 1.24) compared to control group PCPs (M = 7.11, SE = 0.24), and had fewer false-positive and no false-negative melanoma diagnoses (intervention, M = 1.09, SE = 0.","['patients with suspected melanoma', 'Primary care providers (PCPs']","['online training', 'Mastery Learning', 'Mastery learning']","['false-positive and no false-negative melanoma diagnoses', 'benign lesions, including nevi, seborrheic keratoses, and dermatofibromas', 'melanoma detection questions']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider (occupation)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0205557', 'cui_str': 'False positive (qualifier value)'}, {'cui': 'C0205558', 'cui_str': 'False negative (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0376603', 'cui_str': 'Nevis'}, {'cui': 'C0022603', 'cui_str': 'Keratosis Seborrheica'}, {'cui': 'C0002991', 'cui_str': 'Dermatofibroma'}]",,0.110954,"PCPs in the intervention group answered more melanoma detection questions correctly on the post-test (M = 10.05, SE = 1.24) compared to control group PCPs (M = 7.11, SE = 0.24), and had fewer false-positive and no false-negative melanoma diagnoses (intervention, M = 1.09, SE = 0.","[{'ForeName': 'June K', 'Initials': 'JK', 'LastName': 'Robinson', 'Affiliation': 'Department of Dermatology , Northwestern University Feinberg School of Medicine, Chicago, IL, USA. june-robinson@northwestern.edu.'}, {'ForeName': 'Namita', 'Initials': 'N', 'LastName': 'Jain', 'Affiliation': 'Department of Dermatology , Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Ashfaq A', 'Initials': 'AA', 'LastName': 'Marghoob', 'Affiliation': 'Department of Dermatology, Memorial Sloan-Kettering Cancer Center, Hauppauge, NY, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'McGaghie', 'Affiliation': 'Department of Medical Education, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'MacLean', 'Affiliation': 'Department of Medical Education, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Pedram', 'Initials': 'P', 'LastName': 'Gerami', 'Affiliation': 'Department of Dermatology , Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Brittney', 'Initials': 'B', 'LastName': 'Hultgren', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Turrisi', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Mallett', 'Affiliation': 'Biobehavioral Health and Prevention Research Center, The Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Martin', 'Affiliation': 'Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}]",Journal of general internal medicine,['10.1007/s11606-018-4311-3'] 990,30977377,The value of prednisolone acetate provocative test before intravitreal triamcinolone acetonide injections.,"PURPOSE The aim of this study was to investigate the diagnostic value of a topical prednisolone acetate 1% provocative test for steroid-induced ocular hypertension before intravitreal triamcinolone acetonide injection. METHODS This is a prospective, single-center, randomized controlled study at Kasr El Aini Hospital, Cairo University. Patients scheduled for intravitreal triamcinolone acetonide were enrolled and randomly allocated in a ratio 2:1 to either Group A: received prednisolone acetate provocative test and those who did not develop SIOH proceeded with intravitreal triamcinolone acetonide or Group B: did not receive prednisolone acetate provocative test and proceeded directly to intravitreal triamcinolone acetonide. Intraocular pressures were measured weekly for 4 weeks following intravitreal triamcinolone acetonide. Steroid-induced ocular hypertension is defined as intraocular pressure increase of 5 mmHg or more from baseline after prednisolone acetate provocative test or intravitreal triamcinolone acetonide. RESULTS A total of 66 eyes (66 patients) were included. Of which, 10 eyes (23.8%) showed prednisolone acetate provocative test steroid-induced ocular hypertension during the 4-week period. Intravitreal triamcinolone acetonide steroid-induced ocular hypertension was less likely to develop in Group A (prednisolone acetate provocative test non-steroid-induced ocular hypertension, n = 32, 31.25%) than in group B (n = 24, 54.2%) (p = 0.006, odds ratio: 0.178, 95% CI: 0.53-0.596). Our test achieved a negative predictive value of 68.75%. CONCLUSION The topical prednisolone acetate provocative test may be a useful method to predict a steroid-induced ocular hypertension following intravitreal triamcinolone acetonide.",2020,"Intravitreal triamcinolone acetonide steroid-induced ocular hypertension was less likely to develop in Group A (prednisolone acetate provocative test non-steroid-induced ocular hypertension, n = 32, 31.25%) than in group B (n = 24, 54.2%) (p = 0.006, odds ratio: 0.178, 95% CI: 0.53-0.596).","['A total of 66 eyes (66 patients) were included', 'Kasr El Aini Hospital, Cairo University']","['triamcinolone acetonide', 'topical prednisolone acetate', 'prednisolone acetate provocative test', 'Intravitreal triamcinolone acetonide steroid', 'intravitreal triamcinolone acetonide', 'triamcinolone acetonide injections', 'prednisolone acetate provocative test and those who did not develop SIOH proceeded with intravitreal triamcinolone acetonide']","['ocular hypertension', 'Intraocular pressures', 'prednisolone acetate provocative test steroid-induced ocular hypertension']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone Acetonide'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0071839', 'cui_str': 'prednisolone acetate'}, {'cui': 'C0201784', 'cui_str': 'Provocative test (procedure)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}]","[{'cui': 'C0028840', 'cui_str': 'Ocular Hypertension'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C0071839', 'cui_str': 'prednisolone acetate'}, {'cui': 'C0201784', 'cui_str': 'Provocative test (procedure)'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]",,0.0141427,"Intravitreal triamcinolone acetonide steroid-induced ocular hypertension was less likely to develop in Group A (prednisolone acetate provocative test non-steroid-induced ocular hypertension, n = 32, 31.25%) than in group B (n = 24, 54.2%) (p = 0.006, odds ratio: 0.178, 95% CI: 0.53-0.596).","[{'ForeName': 'Aya Mohammed', 'Initials': 'AM', 'LastName': 'Saady', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Heba M', 'Initials': 'HM', 'LastName': 'Fouad', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Abdussalam M', 'Initials': 'AM', 'LastName': 'Abdullatif', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Youssef A H', 'Initials': 'YAH', 'LastName': 'Helmy', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Tamer A', 'Initials': 'TA', 'LastName': 'Macky', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Mansour', 'Affiliation': 'Department of Ophthalmology, Kasr El Aini Hospital, Cairo University, Cairo, Egypt.'}]",European journal of ophthalmology,['10.1177/1120672119842731'] 991,27225981,Interventions for female pattern hair loss.,"BACKGROUND Female pattern hair loss (FPHL), or androgenic alopecia, is the most common type of hair loss affecting women. It is characterised by progressive shortening of the duration of the growth phase of the hair with successive hair cycles, and progressive follicular miniaturisation with conversion of terminal to vellus hair follicles (terminal hairs are thicker and longer, while vellus hairs are soft, fine, and short). The frontal hair line may or may not be preserved. Hair loss can have a serious psychological impact on women. OBJECTIVES To determine the efficacy and safety of the available options for the treatment of female pattern hair loss in women. SEARCH METHODS We updated our searches of the following databases to July 2015: the Cochrane Skin Group Specialised Register, CENTRAL in the Cochrane Library (2015, Issue 6), MEDLINE (from 1946), EMBASE (from 1974), PsycINFO (from 1872), AMED (from 1985), LILACS (from 1982), PubMed (from 1947), and Web of Science (from 1945). We also searched five trial registries and checked the reference lists of included and excluded studies. SELECTION CRITERIA We included randomised controlled trials that assessed the efficacy of interventions for FPHL in women. DATA COLLECTION AND ANALYSIS Two review authors independently assessed trial quality, extracted data and carried out analyses. MAIN RESULTS We included 47 trials, with 5290 participants, of which 25 trials were new to this update. Only five trials were at 'low risk of bias', 26 were at 'unclear risk', and 16 were at 'high risk of bias'.The included trials evaluated a wide range of interventions, and 17 studies evaluated minoxidil. Pooled data from six studies indicated that a greater proportion of participants (157/593) treated with minoxidil (2% and one study with 1%) reported a moderate to marked increase in their hair regrowth when compared with placebo (77/555) (risk ratio (RR) = 1.93, 95% confidence interval (CI) 1.51 to 2.47; moderate quality evidence). These results were confirmed by the investigator-rated assessments in seven studies with 1181 participants (RR 2.35, 95% CI 1.68 to 3.28; moderate quality evidence). Only one study reported on quality of life (QoL) (260 participants), albeit inadequately (low quality evidence). There was an important increase of 13.18 in total hair count per cm² in the minoxidil group compared to the placebo group (95% CI 10.92 to 15.44; low quality evidence) in eight studies (1242 participants). There were 40/407 adverse events in the twice daily minoxidil 2% group versus 28/320 in the placebo group (RR 1.24, 95% CI 0.82 to 1.87; low quality evidence). There was also no statistically significant difference in adverse events between any of the individual concentrations against placebo.Four studies (1006 participants) evaluated minoxidil 2% versus 5%. In one study, 25/57 participants in the minoxidil 2% group experienced moderate to greatly increased hair regrowth versus 22/56 in the 5% group (RR 1.12, 95% CI 0.72 to 1.73). In another study, 209 participants experienced no difference based on a visual analogue scale (P = 0.062; low quality evidence). The assessments of the investigators based on three studies (586 participants) were in agreement with these findings (moderate quality evidence). One study assessed QoL (209 participants) and reported limited data (low quality evidence). Four trials (1006 participants) did not show a difference in number of adverse events between the two concentrations (RR 1.02, 95% CI 0.91 to 1.20; low quality evidence). Both concentrations did not show a difference in increase in total hair count at end of study in three trials with 631 participants (mean difference (MD) -2.12, 95% CI -5.47 to 1.23; low quality evidence).Three studies investigated finasteride 1 mg compared to placebo. In the finasteride group 30/67 participants experienced improvement compared to 33/70 in the placebo group (RR 0.95, 95% CI 0.66 to 1.37; low quality evidence). This was consistent with the investigators' assessments (RR 0.77, 95% CI 0.31 to 1.90; low quality evidence). QoL was not assessed. Only one study addressed adverse events (137 participants) (RR 1.03, 95% CI 0.45 to 2.34; low quality evidence). In two studies (219 participants) there was no clinically meaningful difference in change of hair count, whilst one study (12 participants) favoured finasteride (low quality evidence).Two studies (141 participants) evaluated low-level laser comb therapy compared to a sham device. According to the participants, the low-level laser comb was not more effective than the sham device (RR 1.54, 95% CI 0.96 to 2.49; and RR 1.18, 95% CI 0.74 to 1.89; moderate quality evidence). However, there was a difference in favour of low-level laser comb for change from baseline in hair count (MD 17.40, 95% CI 9.74 to 25.06; and MD 17.60, 95% CI 11.97 to 23.23; low quality evidence). These studies did not assess QoL and did not report adverse events per treatment arm and only in a generic way (low quality evidence). Low-level laser therapy against sham comparisons in two separate studies also showed an increase in total hair count but with limited further data.Single studies addressed the other comparisons and provided limited evidence of either the efficacy or safety of these interventions, or were unlikely to be examined in future trials. AUTHORS' CONCLUSIONS Although there was a predominance of included studies at unclear to high risk of bias, there was evidence to support the efficacy and safety of topical minoxidil in the treatment of FPHL (mainly moderate to low quality evidence). Furthermore, there was no difference in effect between the minoxidil 2% and 5% with the quality of evidence rated moderate to low for most outcomes. Finasteride was no more effective than placebo (low quality evidence). There were inconsistent results in the studies that evaluated laser devices (moderate to low quality evidence), but there was an improvement in total hair count measured from baseline.Further randomised controlled trials of other widely-used treatments, such as spironolactone, finasteride (different dosages), dutasteride, cyproterone acetate, and laser-based therapy are needed.",2016,"Both concentrations did not show a difference in increase in total hair count at end of study in three trials with 631 participants (mean difference (MD) -2.12, 95% CI -5.47 to 1.23; low quality evidence).Three studies investigated finasteride 1 mg compared to placebo.","['female pattern hair loss in women', 'Female pattern hair loss (FPHL', 'female pattern hair loss', 'women', '47 trials, with 5290 participants, of which 25 trials were new to this update']","['placebo', 'topical minoxidil', 'spironolactone, finasteride (different dosages), dutasteride, cyproterone acetate, and laser-based therapy', 'LILACS', 'Finasteride', 'minoxidil', 'Low-level laser therapy', 'finasteride']","['moderate to greatly increased hair regrowth', 'visual analogue scale', 'total hair count', 'adverse events', 'change of hair count', 'quality of life (QoL', 'total hair count per cm²', 'number of adverse events', 'efficacy and safety', 'hair regrowth']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0002170', 'cui_str': 'Hair Loss'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0026196', 'cui_str': 'Minoxidil'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0060389', 'cui_str': 'Finasteride'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C0754659', 'cui_str': 'Dutasteride'}, {'cui': 'C0056855', 'cui_str': 'Cyproterone Acetate'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0279027', 'cui_str': 'Low-Power Laser Therapy'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",5290.0,0.525014,"Both concentrations did not show a difference in increase in total hair count at end of study in three trials with 631 participants (mean difference (MD) -2.12, 95% CI -5.47 to 1.23; low quality evidence).Three studies investigated finasteride 1 mg compared to placebo.","[{'ForeName': 'Esther J', 'Initials': 'EJ', 'LastName': 'van Zuuren', 'Affiliation': 'Department of Dermatology, Leiden University Medical Center, PO Box 9600, B1-Q, Leiden, Netherlands, 2300 RC.'}, {'ForeName': 'Zbys', 'Initials': 'Z', 'LastName': 'Fedorowicz', 'Affiliation': ''}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Schoones', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD007628.pub4'] 992,30968431,Deep neuromuscular blockade for endolaryngeal procedures: A multicenter randomized study.,"OBJECTIVES/HYPOTHESIS The aim of the present study was to compare the surgical condition between deep neuromuscular blockade (NMB) and moderate NMB. STUDY DESIGN Multicenter, randomized, parallel intervention trial. METHODS One hundred two patients underwent microscopic endolaryngeal surgery at four university hospitals. The patients were randomized into moderate NMB (train-of-four 1-2) (M group) or deep NMB (post-tetanic count 1-2) (D group) with moderate or high doses of rocuronium, respectively. Surgical rating conditions (SRCs) were evaluated during the surgery. Sugammadex was given to the M group at 2 mg/kg and the D group at 4 mg/kg. Perioperative clinical signs and conditions were recorded until discharge from the postanesthesia care unit. RESULTS Clinically acceptable SRC was observed in 49 patients (100%) in the D group and 43 patients (89.6%) in the M group (P = .027). The frequency of notable vocal fold movement in the M group was significantly higher than the D group (70.8% vs. 32.7%). The patients in the M group required more additional doses of rocuronium (47.9%) than the D group (20.4%) to maintain full relaxation (P = .005). The median time (interquartile range) from administration of sugammadex to train-of-four ratio 0.9 in the D group was shorter than the M group (120 [109-180 minutes] vs. 180 minutes [120-240 minutes], P = .034). CONCLUSIONS Deep NMB with high doses of rocuronium combined with 4 mg/kg of sugammadex for reversal during endolaryngeal surgery provided better SRC and anesthetic conditions than moderate NMB of rocuronium with 2 mg/kg of sugammadex. LEVEL OF EVIDENCE 1b Laryngoscope, 130:437-441, 2020.",2020,The frequency of notable vocal fold movement in the M group was significantly higher than the D group (70.8% vs. 32.7%).,['One hundred two patients underwent microscopic endolaryngeal surgery at four university hospitals'],"['moderate NMB (train-of-four 1-2) (M group) or deep NMB', 'deep neuromuscular blockade (NMB', 'Sugammadex', 'rocuronium']","['Surgical rating conditions (SRCs', 'frequency of notable vocal fold movement', 'median time']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205288', 'cui_str': 'Microscopic (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0235062', 'cui_str': 'Neuromuscular Block'}, {'cui': 'C1700695', 'cui_str': 'Sugammadex'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0042930', 'cui_str': 'Vocal Fold'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",102.0,0.215599,The frequency of notable vocal fold movement in the M group was significantly higher than the D group (70.8% vs. 32.7%).,"[{'ForeName': 'Prok', 'Initials': 'P', 'LastName': 'Laosuwan', 'Affiliation': 'Department of Anesthesiology, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Thai Red Cross Society, Bangkok, Thailand.'}, {'ForeName': 'Phuriphong', 'Initials': 'P', 'LastName': 'Songarj', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Worawut', 'Initials': 'W', 'LastName': 'Lapisatepun', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Settapong', 'Initials': 'S', 'LastName': 'Boonsri', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Oraluxna', 'Initials': 'O', 'LastName': 'Rodanant', 'Affiliation': 'Department of Anesthesiology, King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University, Thai Red Cross Society, Bangkok, Thailand.'}, {'ForeName': 'Wirat', 'Initials': 'W', 'LastName': 'Wasinwong', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Wimonrat', 'Initials': 'W', 'LastName': 'Sriraj', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Jittiya', 'Initials': 'J', 'LastName': 'Watcharotayangul', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Mingkwan', 'Initials': 'M', 'LastName': 'Wongyingsinn', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",The Laryngoscope,['10.1002/lary.27956'] 993,30982953,Determination of the 90% effective dose of intranasal dexmedetomidine for sedation during electroencephalography in children.,"BACKGROUND The intranasal route of dexmedetomidine (DEX) administration is becoming increasingly popular for providing adequate sedation during short examinations in infants and children. However, data on the 90% effective dose (ED90) of intranasal DEX are rare in children under 3 years old. METHODS This is a double-blind trial using a biased coin design up-and-down sequential method (BCD-UDM). Fifty-three children aged under 3 years old requiring DEX for EEG were included in our study. The first patient received 2.5 μg kg -1 DEX, and the dose of DEX administered to the subsequent patient was determined by the response of the previous patient. The patient responses were recorded and analysed to calculate the ED90 by isotonic regression. The 95% confidence interval (CI) was estimated using a bootstrapping method. RESULTS Fifty-three patients were included in our study, of which 45 patients were successfully sedated, and the 8 instances of failed sedation were rescued using sevoflurane inhalation, allowing the completion of the procedure. The 90% effective dose of DEX was calculated to be 3.28 µg kg -1 , and the 95% CI was 2.74 ~ 3.39 µg kg -1 . No significant adverse events occurred in any of the patients. CONCLUSION The 90% effective dose of intranasal DEX sedation for EEG was 3.28 μg kg -1 in children under 3 years old.",2019,The 90% effective dose of intranasal DEX sedation for EEG was 3.28 μg kg -1 in children under 3 years old.,"['children', 'children under 3\xa0years old', 'Fifty-three patients were included in our study, of which 45 patients', 'Fifty-three children aged under 3\xa0years old requiring DEX for EEG were included in our study', 'infants and children']","['intranasal dexmedetomidine', 'intranasal DEX', 'dexmedetomidine (DEX', 'DEX']",['adverse events'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}]",53.0,0.14118,The 90% effective dose of intranasal DEX sedation for EEG was 3.28 μg kg -1 in children under 3 years old.,"[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Mang', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Qin', 'Initials': 'Q', 'LastName': 'Tian', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Yu', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Shangyingying', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}, {'ForeName': 'Shengfen', 'Initials': 'S', 'LastName': 'Tu', 'Affiliation': ""Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.""}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13372'] 994,30954675,Social incentives to encourage physical activity and understand predictors (STEP UP): Design and rationale of a randomized trial among overweight and obese adults across the United States.,"BACKGROUND Less than half of adults in the United States (US) obtain the recommended level of physical activity. Social incentives, the influences that impact individuals to adjust their behaviors based on social ties or connections, are ubiquitous and could be leveraged within gamification interventions to provide a scalable, low-cost approach to increase engagement. Gamification, or the use of game design in non-game situations, is commonly used in the real world, but in most cases has not appropriately leveraged principles from theories of health behavior. METHODS We are conducting a four-arm, randomized, controlled trial of 602 overweight and obese adults to evaluate the effectiveness of gamification interventions that leverage insights from behavioral economics to enhance either supportive, competitive, or collaborative social incentives. Daily step counts are monitored using wearable devices that transmit data to the study platform. Participants established a baseline step count, selected a step goal increase, and then were randomly assigned to control or one of three interventions for a 24-week intervention and 12-week follow-up period. To understand predictors of strong or poor performance, we had participants complete validated questionnaires on a range of areas including their personality, risk preferences, social network, and habits relating to physical activity, eating, and sleep. Trial enrollment was conducted in partnership with Deloitte Consulting and included employees from 40 states across the US. CONCLUSION The STEP UP Trial represents a scalable model and interventions found to be effective could be deployed more broadly to increase physical activity. TRIAL REGISTRATION Clinicaltrials.gov Identifier: NCT03311230.",2019,"Gamification, or the use of game design in non-game situations, is commonly used in the real world, but in most cases has not appropriately leveraged principles from theories of health behavior. ","['partnership with Deloitte Consulting and included employees from 40 states across the US', 'overweight and obese adults across the United States', '602 overweight and obese adults']",[],"['range of areas including their personality, risk preferences, social network, and habits relating to physical activity, eating, and sleep']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0599987', 'cui_str': 'Employee (person)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}]",602.0,0.0582004,"Gamification, or the use of game design in non-game situations, is commonly used in the real world, but in most cases has not appropriately leveraged principles from theories of health behavior. ","[{'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Harrison', 'Affiliation': 'The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Jeremy M', 'Initials': 'JM', 'LastName': 'Jones', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Dylan S', 'Initials': 'DS', 'LastName': 'Small', 'Affiliation': 'The Wharton School, University of Pennsylvania, Philadelphia, PA, United States; The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Charles A L', 'Initials': 'CAL', 'LastName': 'Rareshide', 'Affiliation': 'The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Szwartz', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Steier', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Guszcza', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'Pameljit', 'Initials': 'P', 'LastName': 'Kalra', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Torio', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Reh', 'Affiliation': 'Deloitte Consulting, United States.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Hilbert', 'Affiliation': 'The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Mitesh S', 'Initials': 'MS', 'LastName': 'Patel', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; The Wharton School, University of Pennsylvania, Philadelphia, PA, United States; The Penn Medicine Nudge Unit, University of Pennsylvania, Philadelphia, PA, United States; Crescenz Veterans Affairs Medical Center, Philadelphia, PA, United States. Electronic address: mpatel@pennmedicine.upenn.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.04.001'] 995,31714582,Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.,"CONTEXT Pretreatment with α-adrenergic receptor blockers is recommended to prevent hemodynamic instability during resection of a pheochromocytoma or sympathetic paraganglioma (PPGL). OBJECTIVE To determine which type of α-adrenergic receptor blocker provides the best efficacy. DESIGN Randomized controlled open-label trial (PRESCRIPT; ClinicalTrials.gov NCT01379898). SETTING Multicenter study including 9 centers in The Netherlands. PATIENTS 134 patients with nonmetastatic PPGL. INTERVENTION Phenoxybenzamine or doxazosin starting 2 to 3 weeks before surgery using a blood pressure targeted titration schedule. Intraoperative hemodynamic management was standardized. MAIN OUTCOME MEASURES Primary efficacy endpoint was the cumulative intraoperative time outside the blood pressure target range (ie, SBP >160 mmHg or MAP <60 mmHg) expressed as a percentage of total surgical procedure time. Secondary efficacy endpoint was the value on a hemodynamic instability score. RESULTS Median cumulative time outside blood pressure targets was 11.1% (interquartile range [IQR]: 4.3-20.6] in the phenoxybenzamine group compared to 12.2% (5.3-20.2)] in the doxazosin group (P = .75, r = 0.03). The hemodynamic instability score was 38.0 (28.8-58.0) and 50.0 (35.3-63.8) in the phenoxybenzamine and doxazosin group, respectively (P = .02, r = 0.20). The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P = .68). There was no mortality after 30 days. CONCLUSIONS The duration of blood pressure outside the target range during resection of a PPGL was not different after preoperative treatment with either phenoxybenzamine or doxazosin. Phenoxybenzamine was more effective in preventing intraoperative hemodynamic instability, but it could not be established whether this was associated with a better clinical outcome.",2020,"The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P=0.68).","['134 patients with non-metastatic PPGL', 'Multicenter study including 9 centers in The Netherlands']","['phenoxybenzamine', 'Phenoxybenzamine', 'doxazosin', 'α-blockers', 'phenoxybenzamine or doxazosin', 'α-adrenergic receptor blockers', 'phenoxybenzamine and doxazosin']","['mortality', '30-day cardiovascular complication rate', 'cumulative intraoperative time outside the blood pressure target range (i.e., SBP >160 mmHg or MAP <60 mmHg) expressed as a percentage of total surgical procedure time', 'duration of blood pressure', 'hemodynamic instability score', 'intraoperative hemodynamic instability', 'Median cumulative time outside blood pressure targets']","[{'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0031441', 'cui_str': 'Phenoxybenzamine'}, {'cui': 'C0114873', 'cui_str': 'Doxazosin'}, {'cui': 'C0034783', 'cui_str': 'Adrenoceptors'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0024779', 'cui_str': 'Map'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0948268', 'cui_str': 'Hemodynamic instability'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",134.0,0.097698,"The 30-day cardiovascular complication rate was 8.8% and 6.9% in the phenoxybenzamine and doxazosin group, respectively (P=0.68).","[{'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Buitenwerf', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Thamara E', 'Initials': 'TE', 'LastName': 'Osinga', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Henri J L M', 'Initials': 'HJLM', 'LastName': 'Timmers', 'Affiliation': 'Department of Internal Medicine, Section of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Jacques W M', 'Initials': 'JWM', 'LastName': 'Lenders', 'Affiliation': 'Department of Internal Medicine, Section of Vascular Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Feelders', 'Affiliation': 'Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Elisabeth M W', 'Initials': 'EMW', 'LastName': 'Eekhoff', 'Affiliation': 'Department of Internal Medicine, Endocrinology Section, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Harm R', 'Initials': 'HR', 'LastName': 'Haak', 'Affiliation': 'Department of Internal Medicine, Máxima Medical Center, Eindhoven, The Netherlands.'}, {'ForeName': 'Eleonora P M', 'Initials': 'EPM', 'LastName': 'Corssmit', 'Affiliation': 'Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Peter H L T', 'Initials': 'PHLT', 'LastName': 'Bisschop', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Gerlof D', 'Initials': 'GD', 'LastName': 'Valk', 'Affiliation': 'Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Ronald Groote', 'Initials': 'RG', 'LastName': 'Veldman', 'Affiliation': 'Department of Internal Medicine, Medical Spectrum Twente, Enschede, The Netherlands.'}, {'ForeName': 'Robin P F', 'Initials': 'RPF', 'LastName': 'Dullaart', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Thera P', 'Initials': 'TP', 'LastName': 'Links', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Magiel F', 'Initials': 'MF', 'LastName': 'Voogd', 'Affiliation': 'Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Götz J K G', 'Initials': 'GJKG', 'LastName': 'Wietasch', 'Affiliation': 'Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Michiel N', 'Initials': 'MN', 'LastName': 'Kerstens', 'Affiliation': 'Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz188'] 996,31714455,The Effect of Personal Protective Equipment on Firefighter Occupational Performance.,"Lesniak, AY, Bergstrom, HC, Clasey, JL, Stromberg, AJ, and Abel, MG. The effect of personal protective equipment on firefighter occupational performance. J Strength Cond Res 34(8): 2165-2172, 2020-The purpose of this study was to evaluate the effects of load carriage (LC) and LC plus respirator use (LC + self-contained breathing apparatus [SCBA]) on firefighters' work capacity to enhance our understanding of occupational demands. Twenty-one male structural firefighter recruits (age: 28.6 ± 4.3 years; height: 178.6 ± 7.2 cm; body mass: 94.1 ± 15.4 kg; body fat: 22.9 ± 6.1%) participated. Occupational performance was assessed by time to complete a simulated fire ground test (SFGT). After 2 familiarization trials, recruits performed the following SFGT conditions in a randomized order: PT (physical training clothes), LC only, and LC + SCBA. To describe within-group differences between SFGT conditions, relative difference scores were calculated as follows: % difference = ([experimental trial outcome - PT trial outcome]/PT trial outcome) × 100. Statistical differences between conditions were assessed with repeated-measures analysis of variance. The level of significance was set p < 0.01. Time to complete the LC + SCBA trial (345.9 ± 43.7 seconds; p < 0.001) and LC-only trial (331.2 ± 39.3 seconds; p < 0.001) were significantly greater than the PT trial (241.0 ± 33.3 seconds). Post-SFGT rating of perceived exertion was higher in the LC + SCBA trial (6.7 ± 1.7) and LC trial (6.4 ± 1.5) compared with the PT trial (4.7 ± 1.8; p < 0.001). Heart rate and lactate measures were similar across conditions (p = 0.488; p = 0.287). Personal protective equipment (PPE) significantly decreases the work capacity and increases the perceived effort of occupational tasks. Thus, these findings describe the additional physical demands produced by PPE and indicate that performance of firefighting tasks in an unloaded condition does not reflect work capacity in a bona fide condition.",2020,Time to complete the LC + SCBA trial (345.9 ± 43.7 seconds; p < 0.001) and LC-only trial (331.2 ± 39.3 seconds; p < 0.001) were significantly greater than the PT trial (241.0 ± 33.3 seconds).,['Twenty-one male structural firefighter recruits (age: 28.6 ± 4.3 years; height: 178.6 ± 7.2 cm; body mass: 94.1 ± 15.4 kg; body fat: 22.9 ± 6.1%) participated'],"['Personal protective equipment (PPE', 'PT (physical training clothes), LC only, and LC + SCBA', 'personal protective equipment', 'load carriage (LC) and LC plus respirator use (LC + self-contained breathing apparatus [SCBA', 'Personal Protective Equipment', 'J Strength Cond Res XX(X']","['Firefighter Occupational Performance', 'Post-SFGT rating of perceived exertion', 'firefighter occupational performance', 'Heart rate and lactate measures', 'perceived effort of occupational tasks', 'Occupational performance']","[{'cui': 'C3715213', 'cui_str': '21 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0221459', 'cui_str': 'Fire and Rescue Personnel'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517679', 'cui_str': '28.6'}, {'cui': 'C4517759', 'cui_str': 'Four point three'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517857', 'cui_str': '7.2 (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C4517579', 'cui_str': '15.4 (qualifier value)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}]","[{'cui': 'C1443871', 'cui_str': 'Personal protective equipment'}, {'cui': 'C0070932', 'cui_str': 'PPED'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0009072', 'cui_str': 'Garments'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0042497', 'cui_str': 'Respirators'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1443874', 'cui_str': 'Self-contained breathing apparatus'}]","[{'cui': 'C0221459', 'cui_str': 'Fire and Rescue Personnel'}, {'cui': 'C0521127', 'cui_str': 'Occupational (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",21.0,0.0610943,Time to complete the LC + SCBA trial (345.9 ± 43.7 seconds; p < 0.001) and LC-only trial (331.2 ± 39.3 seconds; p < 0.001) were significantly greater than the PT trial (241.0 ± 33.3 seconds).,"[{'ForeName': 'Ashley Y', 'Initials': 'AY', 'LastName': 'Lesniak', 'Affiliation': 'Department of Health Science, Lock Haven University, Lock Haven, Pennsylvania.'}, {'ForeName': 'Haley C', 'Initials': 'HC', 'LastName': 'Bergstrom', 'Affiliation': 'Departments of Kinesiology and Health Promotion.'}, {'ForeName': 'Jody L', 'Initials': 'JL', 'LastName': 'Clasey', 'Affiliation': 'Departments of Kinesiology and Health Promotion.'}, {'ForeName': 'Arnold J', 'Initials': 'AJ', 'LastName': 'Stromberg', 'Affiliation': 'Statistics, University of Kentucky, Lexington, Kentucky.'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Abel', 'Affiliation': 'Departments of Kinesiology and Health Promotion.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003384'] 997,31711748,Final Two-Year Outcomes for the Sentry Bioconvertible Inferior Vena Cava Filter in Patients Requiring Temporary Protection from Pulmonary Embolism.,"PURPOSE To report final 2-year outcomes with the Sentry bioconvertible inferior vena cava (IVC) filter in patients requiring temporary protection against pulmonary embolism (PE). MATERIALS AND METHODS In a prospective multicenter trial, the Sentry filter was implanted in 129 patients with documented deep vein thrombosis (DVT) and/or PE (67.5%) or who were at temporary risk of developing DVT/PE (32.6%). Patients were monitored and bioconversion status ascertained by radiography, computed tomography (CT), and CT venography through 2 years. RESULTS The composite primary 6-month endpoint of clinical success was achieved in 97.4% (111/114) of patients. The rate of new symptomatic PE was 0% (n = 126) through 1 year and 2.4% (n = 85) through the second year of follow-up, with 2 new nonfatal cases at 581 and 624 days that were adjudicated as not related to the procedure or device. Two patients (1.6%) developed symptomatic caval thrombosis during the first month and underwent successful interventions without recurrence. No other filter-related symptomatic complications occurred through 2 years. There was no filter tilting, migration, embolization, fracture, or caval perforation and no filter-related deaths through 2 years. Filter bioconversion was successful for 95.7% (110/115) of patients at 6 months, 96.4% (106/110) of patients at 12 months, and 96.5% (82/85) of patients at 24 months. Through 24 months of follow-up, there was no evidence of late-stage IVC obstruction or thrombosis after filter bioconversion or of thrombogenicity associated with retracted filter arms. CONCLUSIONS The Sentry IVC filter provided safe and effective protection against PE, with a high rate of intended bioconversion and a low rate of device-related complications, through 2 years of follow-up.",2020,"There was no filter tilting, migration, embolization, fracture, or caval perforation and no filter-related deaths through 2 years.","['patients requiring temporary protection against pulmonary embolism (PE', '129 patients with documented deep vein thrombosis (DVT) and/or PE (67.5%) or who were at temporary risk of developing DVT/PE (32.6', 'Patients Requiring Temporary Protection from Pulmonary Embolism']","['Sentry bioconvertible inferior vena cava (IVC) filter', 'radiography, computed tomography (CT), and CT venography through 2 years', 'Sentry Bioconvertible Inferior Vena Cava Filter']","['clinical success', 'late-stage IVC obstruction or thrombosis', 'symptomatic complications', 'filter tilting, migration, embolization, fracture, or caval perforation and no filter-related deaths', 'symptomatic caval thrombosis', 'rate of new symptomatic PE']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary Embolism'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0080306', 'cui_str': 'Inferior Vena Cava Filters'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C2317140', 'cui_str': 'CT venography'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C1279941', 'cui_str': 'Late stage (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0180860', 'cui_str': 'Filter, device (physical object)'}, {'cui': 'C1533574', 'cui_str': 'Migration, function (observable entity)'}, {'cui': 'C0013931', 'cui_str': 'Embolotherapy'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0549099', 'cui_str': 'Perforation (morphologic abnormality)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}]",129.0,0.0906457,"There was no filter tilting, migration, embolization, fracture, or caval perforation and no filter-related deaths through 2 years.","[{'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Dake', 'Affiliation': 'Department of Cardiothoracic Surgery, Stanford University School of Medicine, Falk Cardiovascular Research Center, 300 Pasteur Drive, Stanford, CA 94305. Electronic address: mddake@email.arizona.edu.'}, {'ForeName': 'Timothy P', 'Initials': 'TP', 'LastName': 'Murphy', 'Affiliation': 'Department of Vascular & Interventional Radiology, Rhode Island Hospital, Providence, Rhode Island.'}, {'ForeName': 'Albrecht H', 'Initials': 'AH', 'LastName': 'Krämer', 'Affiliation': 'Department of Vascular & Endovascular Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Darcy', 'Affiliation': 'Department of Vascular & Interventional Radiology, Washington University, St. Louis, Missouri.'}, {'ForeName': 'Luke E', 'Initials': 'LE', 'LastName': 'Sewall', 'Affiliation': 'Department of Vascular & Interventional Radiology, Adventist Midwest Health, Hinsdale, Illinois.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Curi', 'Affiliation': 'Department of Vascular Surgery, Rutgers-New Jersey Medical School, Newark, New Jersey.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Johnson', 'Affiliation': 'Department of Vascular & Interventional Radiology, Indiana University, Indianapolis, Indiana.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Arena', 'Affiliation': 'Department of Cardiac & Vascular Disease, Lakeview Regional Heart Center, Covington, Louisiana.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Swischuk', 'Affiliation': 'Department of Vascular & Interventional Radiology, OSF Saint Francis Medical Center, Peoria, Illinois.'}, {'ForeName': 'Gary M', 'Initials': 'GM', 'LastName': 'Ansel', 'Affiliation': 'Department of Interventional Cardiology & Vascular Medicine, Riverside Methodist Hospital, Columbus, Ohio.'}, {'ForeName': 'Mitchell J', 'Initials': 'MJ', 'LastName': 'Silver', 'Affiliation': 'Department of Interventional Cardiology &Vascular Medicine, OhioHealth Heart and Vascular Physicians, Columbus, Ohio.'}, {'ForeName': 'Souheil', 'Initials': 'S', 'LastName': 'Saddekni', 'Affiliation': 'Department of Interventional Radiology & Oncology, University of Alabama, Birmingham, Alabama.'}, {'ForeName': 'Jayson S', 'Initials': 'JS', 'LastName': 'Brower', 'Affiliation': 'Department of Vascular & Interventional Radiology, Providence Sacred Heart Medical Center, Spokane, Washington.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Mendes', 'Affiliation': 'Department of Vascular Surgery, UNC Rex Hospital, NC Heart and Vascular Research, Raleigh, North Carolina.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular and interventional radiology : JVIR,['10.1016/j.jvir.2019.08.036'] 998,30306222,"Acute continuous moderate-intensity exercise, but not low-volume high-intensity interval exercise, attenuates postprandial suppression of circulating osteocalcin in young overweight and obese adults.","Bone remodeling markers (BRMs) are suppressed following the consumption of a meal. Our findings indicate that a single session of continuous moderate-intensity exercise, but not low-volume high-intensity interval exercise, performed 1 h after a meal attenuates the postprandial suppression of BRMs. INTRODUCTION Acute exercise transiently increases BRMs including osteocalcin (tOC) and the undercarboxylated form of osteocalcin (ucOC), a hormone that is implicated in glucose regulation. The effects of acute exercise and exercise-intensity on postprandial levels of tOC and ucOC are unknown. METHODS Twenty-seven adults that were overweight or obese (age 30 ± 1 years; BMI 30 ± 1 kg∙m -2 ; mean ± SEM) were randomly allocated to perform a single session of low-volume high-intensity interval exercise (LV-HIIE; nine females, five males) or continuous moderate-intensity exercise (CMIE; eightfemales, five males) 1 h after consumption of a standard breakfast. Serum tOC, ucOC, and ucOC/tOC were measured at baseline, 1 h, and 3 h after breakfast consumption on a rest day (no exercise) and the exercise day (exercise 1 h after breakfast). RESULTS Compared to baseline, serum tOC and ucOC were suppressed 3 h after breakfast on the rest day (- 10 ± 1% and - 6 ± 2%, respectively; p < 0.05), whereas ucOC/tOC was elevated (2.5 ± 1%; p = 0.08). Compared to the rest day, CMIE attenuated the postprandial-induced suppression of tOC (rest day - 10 ± 2% versus CMIE - 5 ± 2%, p < 0.05) and ucOC (rest day - 6 ± 4% versus CMIE 11 ± 2%, p < 0.05), and increased postprandial ucOC/tOC (rest day 3 ± 2% versus CMIE 15 ± 1%, p < 0.05). In contrast, LV-HIIE did not alter postprandial tOC, ucOC, or ucOC/tOC (all p > 0.1). CONCLUSIONS Acute CMIE, but not LV-HIIE, attenuates the postprandial-induced suppression of tOC and ucOC. CMIE may be an effective tool to control the circulating levels of BRMs following meal consumption in overweight/obese adults.",2019,"In contrast, LV-HIIE did not alter postprandial tOC, ucOC, or ucOC","['young overweight and obese adults', 'overweight/obese adults', 'Twenty-seven adults that were overweight or obese (age 30\u2009±\u20091\xa0years; BMI 30\u2009±\u20091\xa0kg∙m -2 ; mean ± SEM']","['Acute continuous moderate-intensity exercise, but not low-volume high-intensity interval exercise', 'CMIE', 'acute exercise and exercise-intensity', 'single session of low-volume high-intensity interval exercise (LV-HIIE; nine females, five males) or continuous moderate-intensity exercise (CMIE; eightfemales, five males']","['postprandial tOC, ucOC, or ucOC', 'Serum tOC, ucOC, and ucOC/tOC', 'postprandial suppression of BRMs', 'Bone remodeling markers (BRMs', 'ucOC', 'postprandial ucOC/tOC', 'BRMs including osteocalcin (tOC', 'postprandial-induced suppression of tOC', 'ucOC/tOC', 'serum tOC and ucOC']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0373691', 'cui_str': 'Osteocalcin measurement (procedure)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]",27.0,0.0243907,"In contrast, LV-HIIE did not alter postprandial tOC, ucOC, or ucOC","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Parker', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia. lewan.parker@deakin.edu.au.'}, {'ForeName': 'C S', 'Initials': 'CS', 'LastName': 'Shaw', 'Affiliation': 'Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Byrnes', 'Affiliation': 'PathWest QEII Medical Centre, Perth, Australia.'}, {'ForeName': 'N K', 'Initials': 'NK', 'LastName': 'Stepto', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, Australia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Levinger', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, Australia.'}]",Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA,['10.1007/s00198-018-4719-y'] 999,31714444,Effects of psychological intervention and relevant influence factors on pregnant women undergoing interventional prenatal diagnosis.,"BACKGROUND This study aims to explore the effects of psychological intervention on eliminating anxiety and fear in pregnant women caused by interventional prenatal diagnosis, and the success rate of surgery. METHODS A total of 100 pregnant women who scheduled for interventional prenatal diagnosis were included in this study, and were randomly divided into two groups: control group and intervention group. Women in the control group were given routine nursing care, and women in the intervention group were given psychological intervention in different stages of the operation. Psychological status were assessed by the symptom checklist-90 (SCL-90), self-rating anxiety scale (SAS), self-rating depression scale (SDS), and visual analogue scale (VAS). Furthermore, the success rate of surgery and the incidence of postoperative complications were tracked. RESULTS Compared with the control group, the SCL-90 test scores of pregnant women in the intervention group were significantly lower in the following five factors: somatization, interpersonal sensitivity, depression, anxiety, and fear (p < 0.05). Furthermore, postoperative SAS, SDS, and VAS scores in the intervention group were significantly lower than in the control group; and the differences were statistically significant (p < 0.01). CONCLUSION Before pregnant women undergo interventional prenatal diagnosis, nurses should understand their psychological status and give psychological guidance in time, calm their anxiety, tension and fear, and help them build confidence to weather the pregnancy stages before and after the operation. This would improve the success rate of puncture and reduce the incidence of complications.",2020,"Compared with the control group, the SCL-90 test scores of pregnant women in the intervention group were significantly lower in the following five factors: somatization, interpersonal sensitivity, depression, anxiety and fear (p<0.05).","['100 pregnant women who scheduled for interventional prenatal diagnosis', 'pregnancy women', 'pregnant women undergoing interventional prenatal diagnosis']","['routine nursing care', 'control group and intervention group', 'psychological intervention']","['success rate of surgery and the incidence of postoperative complications', 'somatization, interpersonal sensitivity, depression, anxiety and fear (p<0.05', 'Furthermore, postoperative SAS, SDS, and VAS scores', 'Psychological status', 'success rate of puncture', 'anxiety and fear', 'symptom checklist-90 (SCL-90), self-rating anxiety scale (SAS), self-rating depression scale (SDS), and visual analogue scale (VAS', 'SCL-90 test scores']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0033053', 'cui_str': 'Intrauterine Diagnosis'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0028682', 'cui_str': 'Nursing Care'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0424139', 'cui_str': 'Anxiety and fear (finding)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist (assessment scale)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0222045'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",100.0,0.0208259,"Compared with the control group, the SCL-90 test scores of pregnant women in the intervention group were significantly lower in the following five factors: somatization, interpersonal sensitivity, depression, anxiety and fear (p<0.05).","[{'ForeName': 'Chun-Mei', 'Initials': 'CM', 'LastName': 'Kang', 'Affiliation': ''}]",Journal of the Chinese Medical Association : JCMA,['10.1097/JCMA.0000000000000220'] 1000,30846465,Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.,"INTRODUCTION The Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy of Sirolimus (MILES) trial revealed that sirolimus stabilised lung function in patients with moderately severe LAM. The purpose of this study was to further examine the MILES cohort for the effects of racial, demographic, clinical and physiological patient characteristics on disease progression and treatment response in LAM. METHODS MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian), bronchodilator responsiveness (present/absent), initial forced expiratory volume in 1 s (FEV 1 ; 51-70% versus ≤50% predicted) and tuberous sclerosis complex (TSC) association (yes/no). A linear mixed effects model was used to compare slope differences, and nonparametric tests were used to compare medians and proportions between treatment groups in each stratum. RESULTS In the MILES placebo group, pre-menopausal patients declined 5-fold faster than post-menopausal patients (mean±se FEV 1 slope -17±3 versus -3±3 mL·month -1 ; p=0.003). Upon treatment with sirolimus, both the pre-menopausal (-17±3 versus -1±2 mL·month -1 ; p<0.0001) and post-menopausal patients (-3±3 versus 6±3 mL·month -1 ; p=0.04) exhibited a beneficial response in mean±se FEV 1 slope compared with the placebo group. Race, LAM subtype, bronchodilator responsiveness or baseline FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group. Menopausal status and race had differential effects on the adverse event profile of sirolimus. Baseline serum vascular endothelial growth factor (VEGF)-D >600 pg·mL -1 identified subgroups of patients who were more likely to decline on placebo and respond to treatment with sirolimus. CONCLUSIONS In LAM patients, treatment with sirolimus is beneficial regardless of menopausal status, race, bronchodilator responsiveness, baseline FEV 1 or TSC association. Serum VEGF-D and menopausal status can help inform therapeutic decisions.",2019,FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group.,"['patients with moderately severe LAM', 'MILES subjects were stratified on the basis of menopausal status (pre-menopausal/post-menopausal), race (Asian/Caucasian']","['sirolimus', 'MILES placebo', 'placebo', 'Sirolimus (MILES', 'Lymphangioleiomyomatosis (LAM']","['rate of disease progression', 'Baseline serum vascular endothelial growth factor (VEGF)-D ', 'Serum VEGF-D and menopausal status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0751674', 'cui_str': 'Lymphangioleiomyomatosis'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}]","[{'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0664390', 'cui_str': 'Vascular Endothelial Growth Factor D'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",,0.156081,FEV 1 did not impact the rate of disease progression in the placebo group or treatment response in the sirolimus group.,"[{'ForeName': 'Nishant', 'Initials': 'N', 'LastName': 'Gupta', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Hye-Seung', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Young', 'Affiliation': 'Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Strange', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Moss', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Lianne G', 'Initials': 'LG', 'LastName': 'Singer', 'Affiliation': 'University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Koh', 'Initials': 'K', 'LastName': 'Nakata', 'Affiliation': 'Niigata University Medical and Dental Hospital, Niigata, Japan.'}, {'ForeName': 'Alan F', 'Initials': 'AF', 'LastName': 'Barker', 'Affiliation': 'Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Chapman', 'Affiliation': 'Cleveland Clinic, Abu Dhabi, United Arab Emirates.'}, {'ForeName': 'Mark L', 'Initials': 'ML', 'LastName': 'Brantly', 'Affiliation': 'University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Stocks', 'Affiliation': 'University of Texas Health Sciences Center, Tyler, TX, USA.'}, {'ForeName': 'Kevin K', 'Initials': 'KK', 'LastName': 'Brown', 'Affiliation': 'National Jewish Health and the University of Colorado, Denver, CO, USA.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'Lynch', 'Affiliation': 'University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Hilary J', 'Initials': 'HJ', 'LastName': 'Goldberg', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Gregory P', 'Initials': 'GP', 'LastName': 'Downey', 'Affiliation': 'National Jewish Health and the University of Colorado, Denver, CO, USA.'}, {'ForeName': 'Angelo M', 'Initials': 'AM', 'LastName': 'Taveira-DaSilva', 'Affiliation': 'National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Jeffrey P', 'Initials': 'JP', 'LastName': 'Krischer', 'Affiliation': 'University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Setchell', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.""}, {'ForeName': 'Bruce C', 'Initials': 'BC', 'LastName': 'Trapnell', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.'}, {'ForeName': 'Francis X', 'Initials': 'FX', 'LastName': 'McCormack', 'Affiliation': 'University of Cincinnati, Cincinnati, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.02066-2018'] 1001,30948271,"Understanding the Nature of Media Effects From Onscreen Exposure to Alcohol, Sex, and Their Combination.","PURPOSE Combinations of risk behaviors are common in popular media, which make it difficult to understand how exposure to risk content affects adolescent risk behaviors. The purpose of this study was to determine whether media effects associated with exposure to multiple risk behaviors (i.e., combined alcohol and sex, sex only, alcohol only, and no risk) in television content have specific or more general effects on attitudes and norms associated with performing these behaviors. METHODS Adolescents aged 14-17 years from an opt-in Qualtrics panel (n = 338) were randomized into one of four conditions, which varied the presence of risk behaviors (i.e., combined alcohol and sex, sex only, alcohol only, and no risk) that were featured in a brief video clip from a popular television show. We tested the content effects on behavioral attitudes and norms for performing each of the behaviors. RESULTS Analysis of variance analyses showed that exposure to combined alcohol and sex resulted in more positive attitudes toward engaging in combining alcohol and sex, drinking, and smoking. Exposure to the sex only, alcohol only, and no risk videos did not influence any attitudes or norms. CONCLUSIONS A brief exposure to combined risk behaviors in media may increase positive attitudes related to the combination behavior (alcohol and sex), a component behavior (alcohol), and also more general risk-taking behaviors (smoking).",2019,"RESULTS Analysis of variance analyses showed that exposure to combined alcohol and sex resulted in more positive attitudes toward engaging in combining alcohol and sex, drinking, and smoking.",['Adolescents aged 14-17\xa0years from an opt-in Qualtrics panel (n\xa0= 338'],[],"['positive attitudes toward engaging in combining alcohol and sex, drinking, and smoking']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0237428', 'cui_str': 'Optimism'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]",338.0,0.0124005,"RESULTS Analysis of variance analyses showed that exposure to combined alcohol and sex resulted in more positive attitudes toward engaging in combining alcohol and sex, drinking, and smoking.","[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Bleakley', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: ableakley@asc.upenn.edu.'}, {'ForeName': 'Morgan E', 'Initials': 'ME', 'LastName': 'Ellithorpe', 'Affiliation': 'Department of Advertising and Public Relations, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hennessy', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2019.01.023'] 1002,31761418,"Intensive multifactorial intervention improved renal impairment in short-duration type 2 diabetes: A randomized, controlled, 7-year follow-up trial.","AIMS To investigate the effect of multifactorial intervention on the urinary albumin to creatinine ratio (UACR) and the estimated glomerular filtration rate (eGFR) in short-duration type 2 diabetes. METHODS A total of 150 type 2 diabetes patients, with disease duration <1 year and with no evidence of atherosclerosis were randomized to either the intensive intervention group (IG, n = 75), or the conventional group (CG, n = 75) for 7 years. The predefined endpoint of microvascular complications was the progression of renal impairments (the development of albuminuria and the change of eGFR). RESULTS The incidence of progression to albuminuria (UACR ≥30 mg/g) was 12% in IG and 28% in CG (HR 0.37, 95% CI: 0.19-0.70, P = .0025). eGFR was significantly lower in IG than that in CG in the year 2 (P = .043) and 3 (P = .032) follow-up. Sex, fasting plasma glucose (FPG), HbA1c, and systolic blood pressure (SBP) were independently associated with the UACR (β = -5.112, P = .015; β = 0.908, P = .045; β = 2.087, P = .038; and β = 2.787, P = .002, respectively); aging was independently associated with eGFR (β = -0.447, P = .000). CONCLUSIONS Intensive multifactorial intervention delayed the progression to albuminuria, and reduced eGFR rapidly in early stage of intervention in short-duration type 2 diabetes. FPG, HbA1c, and SBP were risk factors for UACR increase; aging was a risk factor for eGFR decline.",2020,eGFR was significantly lower in IG than that in CG in the year 2 (P = .043) and 3 (P = .032) follow-up.,"['short-duration type 2 diabetes', '150 type 2 diabetes patients, with disease duration <1\u202fyear and with no evidence of atherosclerosis']","['Intensive multifactorial intervention', 'intensive intervention', 'multifactorial intervention']","['Sex, fasting plasma glucose (FPG), HbA1c, and systolic blood pressure (SBP', 'renal impairments (the development of albuminuria and the change of eGFR', 'FPG, HbA1c, and SBP', 'microvascular complications', 'glomerular filtration rate (eGFR', 'renal impairment', 'incidence of progression to albuminuria (UACR ≥30', 'eGFR', 'urinary albumin to creatinine ratio (UACR']","[{'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332125', 'cui_str': 'No evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}]",[],"[{'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",150.0,0.0625146,eGFR was significantly lower in IG than that in CG in the year 2 (P = .043) and 3 (P = .032) follow-up.,"[{'ForeName': 'Chunhong', 'Initials': 'C', 'LastName': 'Shi', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Bai', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Shanshan', 'Initials': 'S', 'LastName': 'Yu', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Guohua', 'Initials': 'G', 'LastName': 'Sun', 'Affiliation': 'Department of Laboratory, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Guirong', 'Initials': 'G', 'LastName': 'Song', 'Affiliation': 'Department of Statistics, Dalian Medical University, Dalian, PR China.'}, {'ForeName': 'Jianling', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, PR China. Electronic address: dujianlingcn@163.com.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2019.107468'] 1003,30947606,RETRACTED: A randomized comparison of ultrasound-guided versus landmark-based corticosteroid injection for trigger finger.,,2019,No significant differences between the two groups were observed in pain or QuickDASH scores at 24 weeks of follow-up.,['One hundred and four patients who had been diagnosed with trigger finger and were to be treated by corticosteroid injection'],"['Ultrasound-guided steroid injection', 'landmark-based injection and the other for ultrasound-guided injection', 'ultrasound-guided versus landmark-based corticosteroid injection']","['pain or QuickDASH scores', 'adverse events', 'visual analogue scale score for pain and the Quick Disability of the Arm, Shoulder, and Hand (QuickDASH) score']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0158328', 'cui_str': 'Trigger Digits'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C4305575', 'cui_str': 'Ultrasonography guided steroid injection'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0018563', 'cui_str': 'Hand'}]",,0.0500322,No significant differences between the two groups were observed in pain or QuickDASH scores at 24 weeks of follow-up.,"[{'ForeName': 'Young Hak', 'Initials': 'YH', 'LastName': 'Roh', 'Affiliation': 'Department of Orthopaedic Surgery, Ewha Womans University Medical Center, Ewha Womans University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sangwoo', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopaedic Surgery, Ewha Womans University Medical Center, Ewha Womans University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hyun Sik', 'Initials': 'HS', 'LastName': 'Gong', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Sungnam, South Korea.'}, {'ForeName': 'Goo Hyun', 'Initials': 'GH', 'LastName': 'Baek', 'Affiliation': 'Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.'}]","The Journal of hand surgery, European volume",['10.1177/1753193419839892'] 1004,31887743,Disease-Modifying Effects of a Novel Cathepsin K Inhibitor in Osteoarthritis: A Randomized Controlled Trial.,"Background MIV-711 is a novel selective cathepsin K inhibitor with beneficial effects on bone and cartilage in preclinical osteoarthritis models. Objective To evaluate the efficacy, safety, and tolerability of MIV-711 in participants with symptomatic, radiographic knee osteoarthritis. Design 26-week randomized, double-blind, placebo-controlled phase 2a study with a 26-week open-label safety extension substudy. (EudraCT: 2015-003230-26 and 2016-001096-73). Setting Six European sites. Participants 244 participants with primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3, and pain score of 4 to 10 on a numerical rating scale (NRS). Intervention MIV-711, 100 (n = 82) or 200 (n = 81) mg daily, or matched placebo (n = 77). Participants (46 who initially received 200 mg/d and 4 who received placebo) received 200 mg of MIV-711 daily during the extension substudy. Measurements The primary outcome was change in NRS pain score. The key secondary outcome was change in bone area on magnetic resonance imaging (MRI). Other secondary end points included cartilage thickness on quantitative MRI and type I and II collagen C-telopeptide biomarkers. Outcomes were assessed over 26 weeks. Results Changes in NRS pain scores with MIV-711 were not statistically significant (placebo, -1.4; MIV-711, 100 mg/d, -1.7; MIV-711, 200 mg/d, -1.5). MIV-711 significantly reduced medial femoral bone area progression (P = 0.002 for 100 mg/d and 0.004 for 200 mg/d) and medial femoral cartilage thinning (P = 0.023 for 100 mg/d and 0.125 for 200 mg/d) versus placebo and substantially reduced bone and cartilage biomarker levels. Nine serious adverse events occurred in 6 participants (1 in the placebo group, 3 in the 100 mg group, and 2 in the 200 mg group); none were considered to be treatment-related. Limitation The trial was relatively short. Conclusion MIV-711 was not more effective than placebo for pain, but it significantly reduced bone and cartilage progression with a reassuring safety profile. This treatment may merit further evaluation as a disease-modifying osteoarthritis drug. Primary Funding Source Medivir.",2020,MIV-711 significantly reduced medial femoral bone area progression (P = 0.002 for 100 mg/d and 0.004 for 200 mg/d) and medial femoral cartilage thinning (P = 0.023 for 100 mg/d and 0.125 for 200 mg/d) versus placebo and substantially reduced bone and cartilage biomarker levels.,"['Participants\n\n\n244 participants with primary knee osteoarthritis, Kellgren-Lawrence grade 2 or 3, and pain score of 4 to 10 on a numerical rating scale (NRS', 'Osteoarthritis', 'participants with symptomatic, radiographic knee osteoarthritis', 'Participants (46 who initially received 200 mg/d and 4 who received']","['placebo', 'Placebo', 'Novel Cathepsin K Inhibitor', 'MIV-711']","['Nine serious adverse events', 'medial femoral cartilage thinning', 'NRS pain score', 'cartilage thickness on quantitative MRI and type I and II collagen C-telopeptide biomarkers', 'medial femoral bone area progression', 'bone and cartilage progression', 'NRS pain scores', 'change in bone area on magnetic resonance imaging (MRI', 'efficacy, safety, and tolerability', 'bone and cartilage biomarker levels']","[{'cui': 'C4517660', 'cui_str': 'Two hundred and forty-four'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0222045'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0284930', 'cui_str': 'Cathepsin X'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0534110', 'cui_str': '(125I)mIV'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0007301', 'cui_str': 'Cartilage'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0631180', 'cui_str': 'C-telopeptide'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",244.0,0.588212,MIV-711 significantly reduced medial femoral bone area progression (P = 0.002 for 100 mg/d and 0.004 for 200 mg/d) and medial femoral cartilage thinning (P = 0.023 for 100 mg/d and 0.125 for 200 mg/d) versus placebo and substantially reduced bone and cartilage biomarker levels.,"[{'ForeName': 'Philip G', 'Initials': 'PG', 'LastName': 'Conaghan', 'Affiliation': 'Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (P.G.C., S.R.K.).'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Bowes', 'Affiliation': 'Imorphics, Manchester, United Kingdom (M.A.B., A.B., G.G.).'}, {'ForeName': 'Sarah R', 'Initials': 'SR', 'LastName': 'Kingsbury', 'Affiliation': 'Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom (P.G.C., S.R.K.).'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Brett', 'Affiliation': 'Imorphics, Manchester, United Kingdom (M.A.B., A.B., G.G.).'}, {'ForeName': 'Gwenael', 'Initials': 'G', 'LastName': 'Guillard', 'Affiliation': 'Imorphics, Manchester, United Kingdom (M.A.B., A.B., G.G.).'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Rizoska', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'Niclas', 'Initials': 'N', 'LastName': 'Sjögren', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'Philippa', 'Initials': 'P', 'LastName': 'Graham', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'Åsa', 'Initials': 'Å', 'LastName': 'Jansson', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Wadell', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bethell', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Öhd', 'Affiliation': 'Medivir, Huddinge, Sweden (B.R., N.S., P.G., Å.J., C.W., R.B., J.Ö.).'}]",Annals of internal medicine,['10.7326/M19-0675'] 1005,29908771,Cognitive-behavioral therapy improves weight loss and quality of life in women with polycystic ovary syndrome: a pilot randomized clinical trial.,"OBJECTIVE To compare the effects of cognitive-behavioral therapy (CBT) and lifestyle modification (LS) versus LS alone on weight, depressive and anxiety symptoms, and stress response in women with polycystic ovary syndrome (PCOS), overweight/obesity, and depressive symptoms. DESIGN A 16-week pilot randomized clinical trial. SETTING Tertiary-care PCOS center. PATIENT(S) Overweight/obese women with PCOS and depressive symptoms. INTERVENTION(S) Weekly CBT (n = 7) or contact only/no therapy (n = 8) for 8 weeks. Both groups received weekly LS for 16 weeks. MAIN OUTCOME MEASURE(S) Changes in weight, depression (Center for Epidemiologic Studies Depression Scale [CES-D]), anxiety (State-Trait Anxiety Inventory [STAI]), quality of life (Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire [PCOSQ]), laboratory tests, and response to a Trier Social Stress Test (TSST). RESULT(S) The CBT+LS group lost more weekly weight (-0.35 kg/wk vs. -0.16 kg/wk) compared with the LS group. Overall, the CBT+LS group lost 3.2 kg versus 1.8 kg for the LS group. The CBT+LS group had greater improvement in PCOSQ at 8 weeks (+3.7 vs. +1.2 points). In the overall cohort, STAI and CES-D decreased by -0.27 points per week and -0.31 points/wk, respectfully, and total and free T decreased at week 8. Heart rate response to TSST was lower at 15 minutes after stressor in the CBT+LS group. CONCLUSION(S) Weekly CBT+LS for 8 weeks compared with LS alone resulted in significant weight loss and improved quality of life in overweight/obese women with PCOS and depressive symptoms. These interventions were associated with a decreased autonomic response to a laboratory stressor, suggesting a potential link between CBT, weight loss, and modulation of the stress response. CLINICAL TRIAL REGISTRATION NUMBER NCT01899001.",2018,The CBT+LS group lost more weekly weight (-0.35 kg/wk vs. -0.16 kg/wk) compared with the LS group.,"['women with polycystic ovary syndrome', 'Tertiary-care PCOS center', 'women with polycystic ovary syndrome (PCOS), overweight/obesity, and depressive symptoms', '\n\n\nOverweight/obese women with PCOS and depressive symptoms']","['cognitive-behavioral therapy (CBT) and lifestyle modification (LS) versus LS alone', 'LS alone', 'CBT (n = 7) or contact only/no therapy', 'Cognitive-behavioral therapy', 'CBT+LS']","['PCOSQ', 'weight loss and quality of life', 'autonomic response', 'weight loss', 'Heart rate response to TSST', 'weight, depressive and anxiety symptoms, and stress response', 'CBT, weight loss, and modulation of the stress response', 'weekly weight', 'quality of life', 'State-Trait Anxiety Inventory [STAI]), quality of life (Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire [PCOSQ]), laboratory tests, and response to a Trier Social Stress Test (TSST', 'weight, depression (Center for Epidemiologic Studies Depression Scale [CES-D]), anxiety ', 'STAI and CES-D']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0034380'}, {'cui': 'C1997337', 'cui_str': 'Speed of heart rate response'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C0065404', 'cui_str': 'Tri (L)'}, {'cui': 'C0015260', 'cui_str': 'Exercise Test'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0222045'}]",,0.156927,The CBT+LS group lost more weekly weight (-0.35 kg/wk vs. -0.16 kg/wk) compared with the LS group.,"[{'ForeName': 'Laura G', 'Initials': 'LG', 'LastName': 'Cooney', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Lauren W', 'Initials': 'LW', 'LastName': 'Milman', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Liisa', 'Initials': 'L', 'LastName': 'Hantsoo', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kornfield', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Mary D', 'Initials': 'MD', 'LastName': 'Sammel', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, Philadelphia, Pennsylvania.'}, {'ForeName': 'Kelly C', 'Initials': 'KC', 'LastName': 'Allison', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'C Neill', 'Initials': 'CN', 'LastName': 'Epperson', 'Affiliation': 'Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Anuja', 'Initials': 'A', 'LastName': 'Dokras', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: adokras@obgyn.upenn.edu.'}]",Fertility and sterility,['10.1016/j.fertnstert.2018.03.028'] 1006,30946262,Reliability and Validity of a New Portable Tethered Sprint Running Test as a Measure of Maximal Anaerobic Performance.,"Limmer, M, Berkholz, A, de Marées, M, and Platen, P. Reliability and validity of a new portable tethered sprint running test as a measure of maximal anaerobic performance. J Strength Cond Res 34(8): 2197-2204, 2020-The purposes of this study were to develop a new portable tethered sprint running (PTSR) test for field-based anaerobic performance testing with restricted spatial conditions and the logistical challenge of carrying test equipment, and to determine reliability of the PTSR test. For validity, performance measures were compared with the cycle ergometer Wingate Anaerobic Test (WAnT) power outputs. Twelve recreationally active men and women (24.3 ± 1.6 years; 1.77 ± 0.07 m; 73.3 ± 12.5 kg) performed one familiarization trial followed by 3 randomly assigned experimental 60-second all-out effort trials consisting of one WAnT and 2 PTSR tests. All trials were performed in a randomized order on different days separated by at least 48 hours. Heart rate (HR) and maximum blood lactate concentration were recorded for each experimental trial to determine the physiological responses to the maximal efforts. Correlation coefficients indicated significant relationships between mean force (MF) and peak force (PF) in the PTSR test and mean power (MP) (r = 0.651, p = 0.022) and peak power (PP) (r = 0.877, p = 0.002) in the WAnT, but not for the fatigue index (r = 0.280, p = 0.379). In addition, both PTSR trials showed no significant differences (p > 0.05) between trials and a high reliability for the performance variables MF (intraclass correlation coefficient [ICC] = 0.98, coefficient of variation [%CV] = 7.7), PF (ICC = 0.98, %CV = 8.4), and HR (ICC = 0.92, %CV = 3.1). In conclusion, our results suggest that despite insufficient stimulation of anaerobic metabolism in some subjects resulting from poor implementation of test instructions, the PTSR is a reliable and valid test for an easy and practical assessment of maximal anaerobic performance under different field conditions.",2020,"Correlation coefficients indicated significant relationships between mean force (MF) and peak force (PF) in the PTSR test and mean power (MP) (r = 0.651, p = 0.022) and peak power (PP) (r = 0.877, p = 0.002) in the WAnT, but not for the fatigue index (r = 0.280, p = 0.379).",['Twelve recreationally active men and women (24.3 ± 1.6 years; 1.77 ± 0.07 m; 73.3 ± 12.5 kg'],"['J Strength Cond Res XX(X', 'new portable tethered sprint running (PTSR']","['Heart rate (HR) and maximum blood lactate concentration', 'Limmer, M, Berkholz, A, de Marées, M, and Platen, P. Reliability and validity', 'maximal anaerobic performance', 'Maximal Anaerobic Performance', 'mean force (MF) and peak force (PF) in the PTSR test and mean power (MP', 'peak power (PP']","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517508', 'cui_str': '1.6 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4518239', 'cui_str': '0.07'}, {'cui': 'C4517544', 'cui_str': '12.5 (qualifier value)'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0035036', 'cui_str': 'Reliability and Validity'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",,0.0740828,"Correlation coefficients indicated significant relationships between mean force (MF) and peak force (PF) in the PTSR test and mean power (MP) (r = 0.651, p = 0.022) and peak power (PP) (r = 0.877, p = 0.002) in the WAnT, but not for the fatigue index (r = 0.280, p = 0.379).","[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Limmer', 'Affiliation': 'Department of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Berkholz', 'Affiliation': 'Department of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'de Marées', 'Affiliation': 'Department of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Platen', 'Affiliation': 'Department of Sports Medicine and Sports Nutrition, Ruhr-University Bochum, Bochum, Germany.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003119'] 1007,30951609,Mental health stigma in depressed Latinos over the course of therapy: Results from a randomized controlled trial.,"OBJECTIVE The current study examined the course, correlates, and predictors of mental health stigma among depressed, Spanish-speaking Latinos that were receiving treatment. This population faces significant disparities in mental health treatment and carries high levels of mental health stigma. METHOD The study utilized data generated from a randomized clinical trial (N = 46) that evaluated the efficacy of Behavioral Activation and Supportive Counseling for depression among Latinos. RESULTS Mental health stigma decreased over time; these decreases were more pronounced among individuals who were randomized to Supportive Counseling. Mental health stigma was positively associated with depressive symptoms and therapeutic alliance over time. Mental health stigma was not related to treatment attrition. CONCLUSIONS These preliminary findings indicate that mental health stigma continues to be relevant among individuals who are actively participating in treatment. Receiving mental health treatment may be sufficient to dispel some of the stigmatizing views endorsed by underserved clinical populations.",2019,"Mental health stigma was not related to treatment attrition. ",['individuals who are actively participating in treatment'],['Behavioral Activation and Supportive Counseling'],"['Mental health stigma', 'mental health stigma']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C3697360', 'cui_str': 'Supportive counseling'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}]",,0.0479004,"Mental health stigma was not related to treatment attrition. ","[{'ForeName': 'Anahi', 'Initials': 'A', 'LastName': 'Collado', 'Affiliation': 'Department of Psychology, Cofrin Logan Center for Addiction Research and Treatment, University of Kansas, Lawrence, Kansas.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Zvolensky', 'Affiliation': 'Department of Psychology, University of Houston, Houston, Texas.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Lejuez', 'Affiliation': 'Department of Psychology, University of Kansas, Lawrence, Kansas.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'MacPherson', 'Affiliation': 'School of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland.'}]",Journal of clinical psychology,['10.1002/jclp.22777'] 1008,30921005,Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial.,"Whether prostate cancer (PCa) may be preventable by dietary interventions can be assessed in randomized trials using intermediate biomarkers of cancer risk or progression. We investigated whether lycopene or green tea modify circulating insulin-like growth factor (IGF) peptides in men at increased risk of PCa. Participants (aged 50-69 years) in one centre in the UK wide PCa testing and treatment trial (ProtecT) with prostate specific antigen between 2.0 and 2.95 ng/ml or negative biopsies, were randomized to daily lycopene (n = 44 assigned 15 mg capsules/day; 44 assigned a lycopene-rich diet; 45 assigned placebo) and green tea (n = 45 assigned 600 mg/day epigallocatechin gallate; 45 assigned green tea drink; 43 assigned placebo) for 6 months. The interventions significantly elevated the primary outcomes, serum epigallocatechin gallate and lycopene at 6 months of follow-up. We report here an exploratory analysis in which serum IGF-I, IGF-II, IGF binding protein (BP)-2 and IGFBP-3 were measured at baseline and 6 months of postintervention. A total of 133 men were randomized (34% of eligible men approached) and 130 had follow-up IGF peptides (98%). In intention-to-treat analyses, there was only weak evidence that lycopene or green tea influenced some aspects of serum IGF-I, IGF-II, IGFBP-2 or IGFBP-3. In men randomized to lycopene supplements, IGFBP-2 was nonsignificantly (50.9 ng/ml; 95% confidence interval: -51.2-152.9, P = 0.3) higher in comparison to placebo, whereas in men randomized to green tea supplements, IGFBP-3 was nonsignificantly (205.2 ng/ml; 95% confidence interval: -583.3-172.9, P = 0.3) lower than with placebo. In this small, pilot randomized controlled trial, there was little evidence that lycopene or green tea interventions influenced serum levels of IGF-I, IGF-II, IGFBBP-3 and IGFBP-2. However, the effects were imprecisely estimates and some observed trends may justify larger trials.",2019,"The interventions significantly elevated the primary outcomes, serum epigallocatechin gallate and lycopene at 6 months of follow-up.","['n=45 assigned 600', 'Participants (aged 50-69 years) in one centre in the UK wide PCa testing and treatment trial (ProtecT) with prostate specific antigen between 2.0 and 2.95\u2009ng/ml or negative biopsies', 'A total of 133 men were randomized (34% of eligible men approached) and 130 had follow-up IGF peptides (98', 'men at increased risk of PCa']","['placebo', 'lycopene-rich diet; 45 assigned placebo) and green tea', 'lycopene or green tea interventions', 'lycopene', 'green tea and lycopene', 'green tea supplements', 'daily lycopene', 'lycopene or green tea']","['IGFBP-2', 'insulin-like growth factor system', 'serum epigallocatechin gallate and lycopene', 'serum IGF-I, IGF-II, IGFBP-2 or IGFBP-3', 'serum IGF-I, IGF-II, IGF binding protein (BP)-2 and IGFBP-3', 'serum levels of IGF-I, IGF-II, IGFBBP-3 and IGFBP-2']","[{'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1384640', 'cui_str': 'Green Tea'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]","[{'cui': 'C0123257', 'cui_str': 'Insulin-Like Growth Factor Binding Protein 2'}, {'cui': 'C1328726', 'cui_str': 'Insulin-like growth factor'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0059438', 'cui_str': 'epigallocatechin gallate'}, {'cui': 'C0065331', 'cui_str': 'lycopene'}, {'cui': 'C0021665', 'cui_str': 'Somatomedin C'}, {'cui': 'C0021666', 'cui_str': 'insulin-like growth factor 2'}, {'cui': 'C0123707', 'cui_str': 'IGF-Binding Protein 3'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",133.0,0.728719,"The interventions significantly elevated the primary outcomes, serum epigallocatechin gallate and lycopene at 6 months of follow-up.","[{'ForeName': 'Kalina M', 'Initials': 'KM', 'LastName': 'Biernacka', 'Affiliation': 'IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Southmead Hospital.'}, {'ForeName': 'Jeff M P', 'Initials': 'JMP', 'LastName': 'Holly', 'Affiliation': 'IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Southmead Hospital.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Martin', 'Affiliation': 'National Institute for Health Research (NIHR) Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Frankow', 'Affiliation': 'IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Southmead Hospital.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Bull', 'Affiliation': 'IGFs & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Southmead Hospital.'}, {'ForeName': 'Freddie C', 'Initials': 'FC', 'LastName': 'Hamdy', 'Affiliation': 'Nuffield Department of Surgery, University of Oxford.'}, {'ForeName': 'Jenny L', 'Initials': 'JL', 'LastName': 'Donovan', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Neal', 'Affiliation': ""Department of Oncology, Addenbrooke's Hospital, University of Cambridge.""}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Metcalfe', 'Affiliation': 'Population Health Sciences, Bristol Medical School, University of Bristol.'}, {'ForeName': 'Athene', 'Initials': 'A', 'LastName': 'Lane', 'Affiliation': 'National Institute for Health Research (NIHR) Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol.'}]",European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP),['10.1097/CEJ.0000000000000502'] 1009,30794093,The Effectiveness of Driving Game on Trunk Control and Gait Ability in Stroke.,"Patients who require neurological rehabilitation often do not comply with conventional programs because they find the therapy uninteresting. As a result, specialized interactive video games have been designed to be more enjoyable than conventional therapy (CT) tasks. This study aimed to assess the trunk control and gait ability of patients with chronic stroke after participation in driving-based interactive video games (DBIVG). Participants included 24 chronic stroke patients allocated to an experimental group ( n  = 13, CT + DBIVG) or a control group ( n  = 11, CT + treadmill walking training). Both groups received CT five days/week; the experimental and control groups participated in DBIVG and treadmill walking training, respectively, three days/week for four weeks. The primary outcome of trunk control was measured by the trunk impairment scale (TISall) and TIS subscales, including static sitting balance (TISssb), dynamic sitting balance (TISdsb), and trunk co-ordination (TISco). Gait ability was measured by the dynamic gait index (DGI), timed walking test (TWT), and time up and go test (TUGT). Both groups demonstrated significant improvements in TISall, TISdsb, and TUGT results. The experimental group showed significantly greater improvement in TISssb, TISco, and DGI than the control group. Our findings indicate that DBIVG can improve trunk control and gait ability in patients with chronic stroke.",2020,"The experimental group showed significantly greater improvement in TISssb, TISco, and DGI than the control group.","['patients with chronic stroke', 'patients with chronic stroke after participation in driving-based interactive video games (DBIVG', 'Stroke', 'Patients who require neurological rehabilitation often do not comply with conventional programs because they find the therapy uninteresting', 'Participants included 24 chronic stroke patients']","['DBIVG', 'DBIVG and treadmill walking training', 'experimental group (n\u2009=\u200913, CT\u2009+\u2009DBIVG', 'Driving Game', 'control group (n\u2009=\u200911, CT\u2009+\u2009treadmill walking training']","['trunk impairment scale (TISall) and TIS subscales, including static sitting balance (TISssb), dynamic sitting balance (TISdsb), and trunk co-ordination (TISco', 'trunk control', 'trunk control and gait ability', 'dynamic gait index (DGI), timed walking test (TWT), and time up and go test (TUGT', 'TISall, TISdsb, and TUGT results', 'Gait ability', 'TISssb, TISco, and DGI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0204096', 'cui_str': 'Neurologic Rehabilitation'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0460005', 'cui_str': 'Torso'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0516712', 'cui_str': 'Balancing when sitting'}, {'cui': 'C0426971', 'cui_str': 'Trunk control (observable entity)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C2919794', 'cui_str': 'Dynamic gait index (assessment scale)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",24.0,0.0120447,"The experimental group showed significantly greater improvement in TISssb, TISco, and DGI than the control group.","[{'ForeName': 'Daegyun', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Graduate School, Gachon University, Incheon, Republic of Korea.'}, {'ForeName': 'Youngsook', 'Initials': 'Y', 'LastName': 'Bae', 'Affiliation': 'Department of Physical Therapy, Graduate School, Gachon University, Incheon, Republic of Korea.'}]",Journal of motor behavior,['10.1080/00222895.2019.1574259'] 1010,31847977,Effectiveness of two bundles in venous leg ulcer healing: A randomized controlled trial.,"The objective of this study was to compare the effectiveness of 2 bundles in venous leg ulcer healing. This study is a open, randomized, controlled clinical trial with parallel treatment, 1:1 allocation rate, and 24-week follow-up. Twenty-eight patients with venous leg ulcers of the lower limbs were allocated to 2 groups: group A (n = 14) and group B (n = 14). The mean age of the participants was 59.67 ± 11.95 years, and the mean ulcer surface area was 29.32 (±98.43) cm 2 . The primary outcome was ulcer healing. Secondary outcomes were wound area reduction rate, Pressure Ulcer Scale of Healing (PUSH) scores, and the presence and intensity of pain before, during and after dressing change. Two different bundles were applied in 2 phases to the randomized groups. All participants engaged in an educational activity, performed exercises, rested with legs elevated, received oral nutrition supplementation (Cubitan; Danone Nutricia), and had their ulcers cleaned with warm saline solution and biguanide polyhexanide solution (Prontosan; B. Braun). Topical therapy in the first phase was papain 2% or 4% for group A and 2% hydrogel for group B. Both groups received single-layer elastic compression therapy (SurePress; ConvaTec). In the second phase, group A received compression therapy with Unna boot (Viscopaste; Smith-Nephew) as the primary dressing, while group B received a cellulose membrane (Membracel; Vuelo Pharma) followed by the Unna boot (Viscopaste; Smith-Nephew).In group A, 71.42% of the ulcers healed; in group B, the figure was 64.28%. Wound area, PUSH scores, and the occurrence and intensity of pain decreased significantly and equivalently in groups A and B.Both bundles are effective in the treatment of venous leg ulcers and pain relief.",2019,"Wound area, PUSH scores, and the occurrence and intensity of pain decreased significantly and equivalently in groups A and B.Both bundles are effective in the treatment of venous leg ulcers and pain relief.","['The mean age of the participants was 59.67\xa0±', 'All participants engaged in an educational activity, performed exercises, rested with legs elevated, received', 'Twenty-eight patients with venous leg ulcers of the lower limbs', 'venous leg\xa0ulcer healing']","['oral nutrition supplementation (Cubitan; Danone Nutricia), and had their ulcers cleaned with warm saline solution and biguanide polyhexanide solution (Prontosan; B. Braun', 'compression therapy with Unna boot (Viscopaste; Smith-Nephew', 'single-layer elastic compression therapy (SurePress; ConvaTec', 'cellulose membrane (Membracel; Vuelo Pharma) followed by the Unna boot (Viscopaste; Smith-Nephew).In', 'Topical therapy']","['mean ulcer surface area', 'Wound area, PUSH scores, and the occurrence and intensity of pain', 'ulcer healing', 'wound area reduction rate, Pressure Ulcer Scale of Healing (PUSH) scores, and the presence and intensity of pain before, during and after dressing change', 'pain relief']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0013652', 'cui_str': 'Educational Activities'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C0023223', 'cui_str': 'Leg Ulcer'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0376892', 'cui_str': 'polihexanide'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0331794', 'cui_str': 'Boots (physical object)'}, {'cui': 'C0554249', 'cui_str': 'Smith (occupation)'}, {'cui': 'C0337579', 'cui_str': 'Nephew (person)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0007648', 'cui_str': 'Cellulose'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C1720549', 'cui_str': 'Push score'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0011127', 'cui_str': 'Pressure Ulcer'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0085671', 'cui_str': 'Dressing change'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}]",28.0,0.0334788,"Wound area, PUSH scores, and the occurrence and intensity of pain decreased significantly and equivalently in groups A and B.Both bundles are effective in the treatment of venous leg ulcers and pain relief.","[{'ForeName': 'Cynthia Assis de Barros', 'Initials': 'CAB', 'LastName': 'Nunes', 'Affiliation': 'Municipal Health Department, Nursing Graduate Program, Federal University of Goiás, Goiânia, GO, Brazil. Electronic address: cynthiaassisdebarros@gmail.com.'}, {'ForeName': 'Paulla Guimarães', 'Initials': 'PG', 'LastName': 'Melo', 'Affiliation': 'Health Sciences Graduate Program, Federal University of Goiás, Goiânia, GO, Brazil.'}, {'ForeName': 'Suelen Gomes', 'Initials': 'SG', 'LastName': 'Malaquias', 'Affiliation': 'Professor at the Faculty of Nursing, Federal University of Goiás, Goiânia, GO, Brazil.'}, {'ForeName': 'Kelle Vanessa Álvares', 'Initials': 'KVÁ', 'LastName': 'Amaral', 'Affiliation': 'Nursing Graduate Program, Federal University of Goiás, Goiânia, GO, Brazil.'}, {'ForeName': 'Gabriela Rodrigues', 'Initials': 'GR', 'LastName': 'Alves', 'Affiliation': 'FacUnicamps, Goiânia, GO, Brazil.'}, {'ForeName': 'Aline Antonelli', 'Initials': 'AA', 'LastName': 'Meira', 'Affiliation': 'Nursing Graduate Program, Federal University of Goiás, Goiânia, GO, Brazil.'}, {'ForeName': 'Alexandre Lamaro', 'Initials': 'AL', 'LastName': 'Cardoso', 'Affiliation': 'Health Sciences Graduate Program, Federal University of Goiás, Goiânia, GO, Brazil.'}, {'ForeName': 'Lílian Varanda', 'Initials': 'LV', 'LastName': 'Pereira', 'Affiliation': 'Federal University of Goiás, Nursing Graduate Program, Goiânia, GO, Brazil.'}, {'ForeName': 'Maria Márcia', 'Initials': 'MM', 'LastName': 'Bachion', 'Affiliation': 'Federal University of Goiás, Nursing Graduate Program, Goiânia, GO, Brazil.'}]",Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing,['10.1016/j.jvn.2019.09.004'] 1011,29746227,Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).,"Purpose Venous thromboembolism (VTE) is common in patients with cancer. Long-term daily subcutaneous low molecular weight heparin has been standard treatment for such patients. The purpose of this study was to assess if an oral factor Xa inhibitor, rivaroxaban, would offer an alternative treatment for VTE in patients with cancer. Patient and Methods In this multicenter, randomized, open-label, pilot trial in the United Kingdom, patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited. Allocation was to dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6) or rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months). The primary outcome was VTE recurrence over 6 months. Safety was assessed by major bleeding and clinically relevant nonmajor bleeding (CRNMB). A sample size of 400 patients would provide estimates of VTE recurrence to within ± 4.5%, assuming a VTE recurrence rate at 6 months of 10%. Results A total of 203 patients were randomly assigned to each group, 58% of whom had metastases. Twenty-six patients experienced recurrent VTE (dalteparin, n = 18; rivaroxaban, n = 8). The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99). The 6-month cumulative rate of major bleeding was 4% (95% CI, 2% to 8%) for dalteparin and 6% (95% CI, 3% to 11%) for rivaroxaban (HR, 1.83; 95% CI, 0.68 to 4.96). Corresponding rates of CRNMB were 4% (95% CI, 2% to 9%) and 13% (95% CI, 9% to 19%), respectively (HR, 3.76; 95% CI, 1.63 to 8.69). Conclusion Rivaroxaban was associated with relatively low VTE recurrence but higher CRNMB compared with dalteparin.",2018,"The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99).","['With Cancer With Venous Thromboembolism', '400 patients', 'A total of 203 patients', 'Patients', 'patients with active cancer who had symptomatic pulmonary embolism (PE), incidental PE, or symptomatic lower-extremity proximal deep vein thrombosis (DVT) were recruited', 'patients with cancer']","['Rivaroxaban', 'dalteparin', 'rivaroxaban', 'Oral Factor Xa Inhibitor With Low Molecular Weight Heparin', 'oral factor Xa inhibitor, rivaroxaban']","['Corresponding rates of CRNMB', 'VTE recurrence', 'low VTE recurrence', 'VTE recurrence rate', '6-month cumulative rate of major bleeding', 'major bleeding and clinically relevant nonmajor bleeding (CRNMB', '6-month cumulative VTE recurrence rate']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary Embolism'}, {'cui': 'C0444507', 'cui_str': 'Incidental (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0206461', 'cui_str': 'Dalteparin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4553708', 'cui_str': 'Factor Xa inhibitor'}, {'cui': 'C0019139', 'cui_str': 'LMWH'}]","[{'cui': 'C0630906', 'cui_str': 'triethoxyvinylsilane'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",203.0,0.493364,"The 6-month cumulative VTE recurrence rate was 11% (95% CI, 7% to 16%) with dalteparin and 4% (95% CI, 2% to 9%) with rivaroxaban (hazard ratio [HR], 0.43; 95% CI, 0.19 to 0.99).","[{'ForeName': 'Annie M', 'Initials': 'AM', 'LastName': 'Young', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Marshall', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Thirlwall', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Chapman', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Lokare', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Hill', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Hale', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Dunn', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Gary H', 'Initials': 'GH', 'LastName': 'Lyman', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Hutchinson', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'MacCallum', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Ajay', 'Initials': 'A', 'LastName': 'Kakkar', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'F D Richard', 'Initials': 'FDR', 'LastName': 'Hobbs', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Stavros', 'Initials': 'S', 'LastName': 'Petrou', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Dale', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Poole', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Maraveyas', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Levine', 'Affiliation': 'Annie M. Young, Andrea Marshall, Jenny Thirlwall, Catherine Hill, Danielle Hale, Janet A. Dunn, and Stavros Petrou, Warwick Clinical Trials Unit, University of Warwick; Oliver Chapman and Christopher J. Poole, University Hospitals Coventry and Warwickshire; Charles Hutchinson and Jeremy Dale, Warwick Medical School, University of Warwick, Coventry; Anand Lokare, Heart of England National Health Service Foundation Trust, Birmingham; Peter MacCallum, Queen Mary University of London; Ajay Kakkar, Thrombosis Research Institute, London; F.D. Richard Hobbs, University of Oxford, Oxford; Anthony Maraveyas, Hull York Medical School, Hull, United Kingdom; Gary H. Lyman, Fred Hutchinson Cancer Research Center, Seattle, WA; and Mark Levine, McMaster University, Hamilton, Ontario, Canada.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.2018.78.8034'] 1012,31648910,"The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?","HPV vaccines are highly immunogenic. A two-dose schedule for 9-14 year-old is recommended. However, no data exist regarding the impact of age, menarche status and body mass index (BMI) on the immune response to a two-dose schedule. In this post-hoc analysis, we present antibody titers to HPV6/11/16/18 in 9-13 year-old girls participating in a randomized clinical trial and assigned to receive two doses of quadrivalent HPV vaccine at 6 months interval (NCT00501137). Antibody titers were measured at month 7 and 24 of the study by using a competitive Luminex immunoassay (cLIA).Both, at Month 7 and 24 the GMTs for four HPV genotypes were similar across the age bands, and did not vary significantly by menarche status. Overweight and obese girls had lower GMTs. More than 99% of girls remained seropositive for HPV 6/11/16 and 89% for HPV18 at month 24. Comprehensive data in overweight and obese vaccines are warranted.",2019,More than 99% of girls remained seropositive for HPV 6/11/16 and 89% for HPV18 at month 24.,"['9-13\u202fyear-old girls', 'to HPV6/11/16/18 in 9-13\u202fyear-old girls participating', 'Overweight and obese girls had lower GMTs']","['HPV vaccines', 'quadrivalent HPV vaccine']","['antibody titers', 'Antibody titers']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C1512511', 'cui_str': 'HPV Vaccines'}]","[{'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}]",,0.0495155,More than 99% of girls remained seropositive for HPV 6/11/16 and 89% for HPV18 at month 24.,"[{'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Sauvageau', 'Affiliation': 'Quebec National Public Health Institute, Canada; Laval University, Canada; CHU de Québec Research Center, Canada. Electronic address: chantal.sauvageau@inspq.qc.ca.'}, {'ForeName': 'Vladimir', 'Initials': 'V', 'LastName': 'Gilca', 'Affiliation': 'Quebec National Public Health Institute, Canada; Laval University, Canada; CHU de Québec Research Center, Canada.'}, {'ForeName': 'Robine', 'Initials': 'R', 'LastName': 'Donken', 'Affiliation': ""BC Children's Hospital Research Institute, Vaccine Evaluation Center, Canada; University of British Columbia School of Population and Public Health, Canada; Women's Health Research Institute, Canada.""}, {'ForeName': 'Shu Yu', 'Initials': 'SY', 'LastName': 'Fan', 'Affiliation': ""BC Children's Hospital Research Institute, Vaccine Evaluation Center, Canada.""}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Ogilvie', 'Affiliation': ""University of British Columbia School of Population and Public Health, Canada; Women's Health Research Institute, Canada.""}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Dobson', 'Affiliation': ""BC Children's Hospital, Canada.""}]",Vaccine,['10.1016/j.vaccine.2019.09.089'] 1013,31847979,"The effect of the blended education program on treatment concordance of patients with hypertension: A single-blind randomized, controlled trial.","Poor treatment concordance is one of the major problems in patients with hypertension (HTN). An appropriate teaching method can help solving this problem. This study aimed to determine the effect of blended education program on treatment concordance in patients with HTN. This is a single-blind randomized controlled trial, and 60 patients with HTN who met inclusion criteria were selected by a convenience sampling and allocated into the control and intervention groups. A demographic information form and the questionnaires were used in this study. The questionnaires included questions addressing treatment concordance, which explored three dimensions: dietary adherence, medication adherence, physical activity plan. The blended educational intervention was carried out for 4 weeks in the intervention group. The control group only received traditional face-to-face education. The results showed that there was a significant increase in the total score of treatment concordance of the intervention group compared to the control group after the intervention (P < .001). In conclusion, using a blended education program is highly recommended to improve treatment concordance in patients with HTN. Consequently, it reduces patients' medical costs and enhances their health-related quality of life.",2019,The results showed that there was a significant increase in the total score of treatment concordance of the intervention group compared to the control group after the intervention (P < .001).,"['60 patients with HTN who met inclusion criteria were selected by a convenience sampling and allocated into the control and intervention groups', 'patients with HTN', 'patients with hypertension', 'patients with hypertension (HTN']","['traditional face-to-face education', 'blended education program', 'blended educational intervention']","[""patients' medical costs and enhances their health-related quality of life"", 'dietary adherence, medication adherence, physical activity plan', 'total score of treatment concordance']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.0257936,The results showed that there was a significant increase in the total score of treatment concordance of the intervention group compared to the control group after the intervention (P < .001).,"[{'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Aghakhani', 'Affiliation': 'Patient Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Naser', 'Initials': 'N', 'LastName': 'Parizad', 'Affiliation': 'Patient Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: nparizad@gmail.com.'}, {'ForeName': 'Behrouz', 'Initials': 'B', 'LastName': 'Soltani', 'Affiliation': 'Faculty of Nursing and Midwifery, Department of Nursing, Kermanshah University of Medical Science, Kermanshah, Iran.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Khademvatan', 'Affiliation': 'Patient Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Rahimi', 'Affiliation': 'Department of Nursing, Urmia University of Medical Sciences, Urmia, Iran.'}]",Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing,['10.1016/j.jvn.2019.08.001'] 1014,31707805,Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.,"BACKGROUND Among stented patients with atrial fibrillation, double therapy with a novel oral anticoagulant plus single antiplatelet therapy (SAPT) reduces bleeding or cardiovascular rehospitalizations compared with a vitamin K antagonist (VKA) based triple therapy regimen. A recent study demonstrated that apixaban based double therapy reduced bleeding compared with VKA based double therapy. However, it remains unknown whether rivaroxaban based double therapy is superior to a VKA based double therapy. METHODS Patient with stented atrial fibrillation (n=2124) were randomized to 3 groups: rivaroxaban 15 mg od plus a P2Y 12 inhibitor (Group 1, n=709); rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT; Group 2, n=709); and warfarin plus DAPT (Group 3, n=706). Before randomization, subjects were stratified according to a prespecified duration of DAPT (1, 6, or 12 months). After the prespecified DAPT duration, subjects in Group 2 were switched to rivaroxaban 15 mg plus low dose aspirin, and those in Group 3 were switched to VKA plus low dose aspirin. The Wei, Lin, and Weissfeld time to multiple events method was used to compare the occurrence of all bleeding and cardiovascular rehospitalizations among subjects on a novel oral anticoagulant versus VKA based double therapy. RESULTS A total of 906 subjects were prespecified to a 1 or 6 months DAPT duration and received at least one dose of study drug. Twenty subjects (3.3%) assigned to novel oral anticoagulant+SAPT, and 15 (5.1%) subjects assigned to VKA+SAPT experienced multiple rehospitalizations. In total, 124 (20.3%) events occurred among subjects on novel oral anticoagulant+SAPT compared with 87 (29.6%) among subjects on VKA+SAPT (hazard ratio=0.65 [95% CI, 0.45-0.93], P =0.008). CONCLUSIONS Among stented patients with atrial fibrillation, rivaroxaban plus SAPT was superior to warfarin plus SAPT in lowering total bleeding and cardiovascular rehospitalization. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT01830543.",2019,"Among stented patients with atrial fibrillation, rivaroxaban plus SAPT was superior to warfarin plus SAPT in lowering total bleeding and cardiovascular rehospitalization. ","['Twenty subjects (3.3%) assigned to novel oral anticoagulant+SAPT, and 15 (5.1%) subjects assigned to', 'Patient with stented atrial fibrillation (n=2124', '906 subjects were prespecified to a 1 or 6 months DAPT duration and received at least one dose of study drug', 'stented patients with atrial fibrillation', 'Stented Patients With Atrial Fibrillation']","['warfarin plus SAPT', 'rivaroxaban', 'VKA plus low dose aspirin', 'warfarin plus DAPT', 'Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy', 'rivaroxaban plus SAPT', 'novel oral anticoagulant plus single antiplatelet therapy (SAPT', 'rivaroxaban 15 mg od plus a P2Y 12 inhibitor', 'rivaroxaban 15 mg plus low dose aspirin', 'rivaroxaban 2.5 mg bid plus dual antiplatelet therapy (DAPT', 'VKA+SAPT', 'vitamin K antagonist (VKA', 'apixaban']",['total bleeding and cardiovascular rehospitalization'],"[{'cui': 'C4517688', 'cui_str': '3.3 (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulation Agents'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3653316', 'cui_str': 'Vitamin K antagonists'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C3248001', 'cui_str': 'rivaroxaban 15 MG [Xarelto]'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",906.0,0.102148,"Among stented patients with atrial fibrillation, rivaroxaban plus SAPT was superior to warfarin plus SAPT in lowering total bleeding and cardiovascular rehospitalization. ","[{'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Kerneis', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (M.K., M.K.Y., T.N., C.M.G.).'}, {'ForeName': 'Megan K', 'Initials': 'MK', 'LastName': 'Yee', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (M.K., M.K.Y., T.N., C.M.G.).'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, NY (R.M., J.L.H.).'}, {'ForeName': 'Tarek', 'Initials': 'T', 'LastName': 'Nafee', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (M.K., M.K.Y., T.N., C.M.G.).'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Bode', 'Affiliation': 'Heart Center, Department for Cardiology and Angiology I, University of Freiburg, Germany (C.B.).'}, {'ForeName': 'Jonathan L', 'Initials': 'JL', 'LastName': 'Halperin', 'Affiliation': 'Cardiovascular Institute, Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai, NY (R.M., J.L.H.).'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Peterson', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC (E.D.P.).'}, {'ForeName': 'Freek W A', 'Initials': 'FWA', 'LastName': 'Verheugt', 'Affiliation': 'Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, the Netherlands (F.W.A.V.).'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wildgoose', 'Affiliation': 'Janssen Pharmaceuticals, Inc, Beerse, Belgium, Inc, Titusville, NJ (P.W.).'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'van Eickels', 'Affiliation': 'Bayer Pharmaceuticals, Inc, Berlin, Germany (M.v.E.).'}, {'ForeName': 'Gregory Y H', 'Initials': 'GYH', 'LastName': 'Lip', 'Affiliation': 'Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark (G.Y.H.L.).'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Cohen', 'Affiliation': 'Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ (M.C.).'}, {'ForeName': 'Keith A A', 'Initials': 'KAA', 'LastName': 'Fox', 'Affiliation': 'Centre for Cardiovascular Science, University of Edinburgh and Royal Infirmary of Edinburgh, United Kingdom (K.A.A.F.).'}, {'ForeName': 'C Michael', 'Initials': 'CM', 'LastName': 'Gibson', 'Affiliation': 'Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (M.K., M.K.Y., T.N., C.M.G.).'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008160'] 1015,30921503,Effect of Food on the Pharmacokinetics of a Combination of Olanzapine and Samidorphan.,"ALKS 3831 is a combination of olanzapine and samidorphan (OLZ/SAM), intended to provide the antipsychotic efficacy of OLZ while mitigating its known weight gain and metabolic effects. This randomized, 2-way crossover study evaluated the effect of food on the pharmacokinetics (PK) of OLZ and SAM (both are Biopharmaceutics Classification System class 3 compounds) given in combination as OLZ/SAM. Thirty-six healthy volunteers were randomized to receive a single dose of OLZ/SAM (10 mg OLZ/10 mg SAM) in either fasted or fed conditions. After a 14-day washout period, study participants received the same OLZ/SAM dose in the opposite condition. PK profiles of OLZ and SAM were similar in fed and fasted conditions. The 90% confidence intervals (CIs) for the fed/fasted ratio of the geometric means for OLZ AUC 0-∞ and C max and SAM AUC 0-∞ were within the equivalence limit of 80%-125%. Although the lower bound of the 90%CI for the fed/fasted ratio of SAM C max (76%-94%) was slightly below the 80% equivalence limit, this slight decrease was not considered clinically meaningful. The results indicated that food does not have a clinically relevant impact on the PK of OLZ and SAM given as OLZ/SAM.",2019,The results indicated that food does not have a clinically relevant impact on the PK of OLZ and SAM given as OLZ/SAM.,['Thirty-six healthy volunteers'],"['OLZ and SAM', 'OLZ/SAM', 'OLZ/SAM (10 mg OLZ/10 mg SAM', 'olanzapine and samidorphan (OLZ/SAM', 'Olanzapine and Samidorphan', 'OLZ']",['PK profiles of OLZ and SAM'],"[{'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}, {'cui': 'C0171023', 'cui_str': 'olanzapine'}, {'cui': 'C4277369', 'cui_str': '3-carboxamido-4-hydroxynaltrexone'}]","[{'cui': 'C1563296', 'cui_str': 'Systolic anterior movement of mitral valve'}]",36.0,0.068632,The results indicated that food does not have a clinically relevant impact on the PK of OLZ and SAM given as OLZ/SAM.,"[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McDonnell', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Former employee of Alkermes, Inc., Waltham, MA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'von Moltke', 'Affiliation': 'Alkermes, Inc., Waltham, MA, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.688'] 1016,30914496,Impact of Gas Masks on the Work of Breathing and Breathing Pattern in Subjects With Stable COPD.,"BACKGROUND The gas mask constitutes the main respiratory protective equipment in a chemical, biological, radiological, or nuclear environment. The aim of the study was to evaluate the impact of the gas mask on respiratory pattern, gas exchange, and indexes of respiratory effort in patients with moderate to severe stable COPD. METHODS Crossover evaluation with 3 randomized-order, 10-min conditions: at rest and with and without a gas mask using 2 different filtered cartridges, each with a distinct inspiratory resistance (cartridge A = 3.5 cm H 2 O; cartridge B = 2.2 cm H 2 O, both at 1 L/s). The study involved 8 subjects with COPD, and breathing patterns, indexes of respiratory effort, and capillary blood gases were evaluated. Comparisons of these parameters were made between the tested conditions. RESULTS Mean subject age was 69 y, and mean FEV 1 = 1.3 L (47% predicted). Short-term utilization of the gas mask was associated with a significant increase in the indexes of effort in comparison to baseline without a mask. The esophageal product-time product significantly increased in comparison with baseline (cartridge A = 281 ± 65 cm H 2 O/s/min, cartridge B = 253 ± 47 cm H 2 O/s/min, and baseline = 184 ± 46 cm H 2 O/s/min, P < .001). There were negligible changes in the breathing pattern and gas exchange. CONCLUSIONS Indexes of respiratory effort increased slightly in subjects with stable COPD while using a gas mask. This effect was likely related to increased inspiratory resistance when the mask was worn. These data are reassuring for the potential short-duration use of such protection for patients with moderate to severe COPD.",2019,Short-term utilization of the gas mask was associated with a significant increase in the indexes of effort in comparison to baseline without a mask.,"['patients with moderate to severe stable COPD', 'Subjects With Stable COPD', '8 subjects with COPD, and breathing patterns, indexes of respiratory effort, and capillary blood gases were evaluated', 'subjects with stable COPD', 'patients with moderate to severe COPD']",['Gas Masks'],"['inspiratory resistance', 'respiratory pattern, gas exchange, and indexes of respiratory effort', 'breathing pattern and gas exchange', 'esophageal product-time product']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0425466', 'cui_str': 'Respiratory effort (observable entity)'}, {'cui': 'C0229666', 'cui_str': 'Capillary blood (substance)'}, {'cui': 'C0596601', 'cui_str': 'Gas'}]","[{'cui': 'C0017106', 'cui_str': 'Gas Masks'}]","[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0517967', 'cui_str': 'Respiratory pattern (observable entity)'}, {'cui': 'C0596601', 'cui_str': 'Gas'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0425466', 'cui_str': 'Respiratory effort (observable entity)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",8.0,0.0405633,Short-term utilization of the gas mask was associated with a significant increase in the indexes of effort in comparison to baseline without a mask.,"[{'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Bourassa', 'Affiliation': ""Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.""}, {'ForeName': 'Pierre-Alexandre', 'Initials': 'PA', 'LastName': 'Bouchard', 'Affiliation': ""Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada.""}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Lellouche', 'Affiliation': ""Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Quebec, Canada. francois.lellouche@criucpq.ulaval.ca.""}]",Respiratory care,['10.4187/respcare.06550'] 1017,31706658,Comparison of high-flow nasal cannula oxygen therapy and conventional reserve-bag oxygen therapy in carbon monoxide intoxication: A pilot study.,"BACKGROUND High-flow nasal cannula oxygen (HFNC) creates a positive pressure effect through high-flow rates compared to conventional oxygen therapy. The purpose of this human pilot study is to compare the effects of HFNC and conventional oxygen therapy on the rate of carbon monoxide (CO) clearance from the blood in patients with mild to moderate CO poisoning. METHODS CO-poisoned Patients randomly received 100% oxygen from a rebreathing reserve mask (NBO 2 , flow of 15 L/min) or HFNC (flow of 60 L/min). The fraction of COHb value (fCOHb) was measured in 30-min intervals until it fell to under 10%. We determined the Half-life time of fCOHb (fCOHb t 1/2 ). RESULTS A total of 22 patients had fCOHb levels ≥ 10% at the time of ED arrival, with 9 of them having fCOHb level ranging between 25% and 50%. There was no significant difference in the fCOHbt 1/2 between the HFNC group and NBO 2 group. However, the mean fCOHbt 1/2 in the HFNC group (48.5 ± 12.4 min) has a smaller standard deviation than that in the NBO 2 group (99.3 ± 93.38 min). There were significant between-group differences in the mean COHbt 1/2 among the patients with fCOHb levels less than 25% (HFNC 43.6 ± 10.6 vs. NBO 2 134.2 ± 111.3). CONCLUSIONS In this pilot randomized controlled trial study, HFNC therapy did not reduce fCOHbt 1/2 compared to NBO 2 therapy but could be beneficial in maintaining a constant fCOHbt 1/2 as well as in reducing fCOHbt 1/2 in mild CO poisoning patients compared to conventional NBO 2 therapy. However, further studies with a larger number of patients are needed to establish HFNC therapy as an alternative therapy for CO poisoning patients.",2020,There was no significant difference in the fCOHbt 1/2 between the HFNC group and NBO 2 group.,"['CO poisoning patients', 'patients with mild to moderate CO poisoning', 'mild CO poisoning patients', 'carbon monoxide intoxication', 'CO-poisoned Patients randomly received']","['HFNC therapy', 'HFNC', 'high-flow nasal cannula oxygen therapy and conventional reserve-bag oxygen therapy', 'HFNC and conventional oxygen therapy', '100% oxygen from a rebreathing reserve mask (NBO 2 , flow of 15\u202fL/min) or HFNC', 'High-flow nasal cannula oxygen (HFNC']","['fraction of COHb value (fCOHb', 'rate of carbon monoxide (CO) clearance']","[{'cui': 'C0032343', 'cui_str': 'Poisoning'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0728899', 'cui_str': 'Intoxication'}, {'cui': 'C0032344', 'cui_str': 'poisoning'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannula'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C1706249', 'cui_str': 'Bag - unit of product usage (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C0439393', 'cui_str': 'liter/minute'}]","[{'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}]",,0.0854453,There was no significant difference in the fCOHbt 1/2 between the HFNC group and NBO 2 group.,"[{'ForeName': 'Young-Min', 'Initials': 'YM', 'LastName': 'Kim', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea.'}, {'ForeName': 'Hyun-Jo', 'Initials': 'HJ', 'LastName': 'Shin', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea.'}, {'ForeName': 'Dong-Won', 'Initials': 'DW', 'LastName': 'Choi', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea.'}, {'ForeName': 'Ji-Min', 'Initials': 'JM', 'LastName': 'Kim', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea.'}, {'ForeName': 'Suk-Woo', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea; Department of Emergency Medicine, College of Medicine, Chungbuk National University, 1, Chungdae-ro, Seowon-gu, Cheongju, Republic of Korea.'}, {'ForeName': 'Seong-Hae', 'Initials': 'SH', 'LastName': 'Jeong', 'Affiliation': 'Department of Neurology, Chungnam National University Hospital, 282, Munhwa-ro, Jung-gu, Daejeon, Republic of Korea; Department of Neurology, Chungnam National University, School of Medicine, 282, Munhwa-ro, Jung-gu, Daejeon, Republic of Korea.'}, {'ForeName': 'Hoon', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Emergency Medicine, Chungbuk National University Hospital, 776, Sunhwan-ro, Seowon-gu, Cheongju, Republic of Korea; Department of Emergency Medicine, College of Medicine, Chungbuk National University, 1, Chungdae-ro, Seowon-gu, Cheongju, Republic of Korea. Electronic address: nichekh2000@chungbuk.ac.kr.'}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.158451'] 1018,31706805,Improved carotid intima-media thickness-induced high-intensity interval training associated with decreased serum levels of Dkk-1 and sclerostin in type 2 diabetes.,"AIMS Carotid intima-media thickness (cIMT) is a validated surrogate marker of atherosclerosis. Dickkopf-1 (Dkk-1) and sclerostin modulate wingless signaling, which is involved in atherosclerosis. The purpose of this study was to investigate whether 12 weeks of high-intensity interval training (HIIT) would improve cIMT and serum Dkk-1 and sclerostin levels in patients with type 2 diabetes. METHODS Seventy-four sedentary patients with type 2 diabetes were randomly divided into HIIT and control groups. The HIIT group intervention was 6 intervals (4 min) at 85%-90% HR max separated by 3 min at 45%-50% HR max in 3 sessions/week for 12 weeks. Before and after the intervention, cIMT, artery diameter and wall/lm ratio were recorded with high-resolution ultrasound. Serum sclerostin and Dkk-1 were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS cIMT decreased significantly in the HIIT group (0.83 ± 0.17 baseline, 0.71 ± 0.14 follow-up) compared to the control group (0.84 ± 0.20 baseline, 0.85 ± 0.19 follow-up) (P < .05). Dkk-1 and sclerostin decreased significantly after 12 weeks of HIIT (P < .01). In addition, VO 2peak was increased in the HIIT group than the control group (by 6.2 mL/kg/min) (P < .05). There was a positive correlation between percent changes in cIMT and percent changes in Dkk-1 and sclerostin (both P < .01). Additionally, there were a negative correlation between percent changes VO2peak and cIMT (r = - 0.740, P = .003), Dkk-1 (r = - 0.844, P < .001) and sclerostin (r = - 0.575, P = .001) in HIIT group. CONCLUSION Our results indicate that HIIT decreases cIMT, serum levels of Dkk-1 and sclerostin and improves VO 2peak in patients with type 2 diabetes.",2020,There was a positive correlation between percent changes in cIMT and percent changes in Dkk-1 and sclerostin (both P < .01).,"['patients with type 2 diabetes', 'Seventy-four sedentary patients with type 2 diabetes']","['high-intensity interval training (HIIT', 'Carotid intima-media thickness (cIMT', 'Dickkopf-1 (Dkk-1) and sclerostin']","['HIIT decreases cIMT, serum levels of Dkk-1 and sclerostin and improves VO 2peak', 'Serum sclerostin and Dkk-1 were measured by enzyme-linked immunosorbent assay (ELISA', 'cIMT and serum Dkk-1 and sclerostin levels', 'Dkk-1 and sclerostin', 'cIMT', 'VO 2peak', 'serum levels of Dkk-1 and sclerostin', 'sclerostin']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4517867', 'cui_str': 'Seventy-four'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}]","[{'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}]","[{'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0014441', 'cui_str': 'ELISA'}]",74.0,0.0198282,There was a positive correlation between percent changes in cIMT and percent changes in Dkk-1 and sclerostin (both P < .01).,"[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Ghardashi-Afousi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Exercise Sciences, University of Tehran, Tehran, IR, Iran. Electronic address: Ghardashi.a@ut.ac.ir.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Davoodi', 'Affiliation': 'Shiraz University of Medical Science, Shiraz, IR, Iran.'}, {'ForeName': 'Behnam Keshtkar-', 'Initials': 'BK', 'LastName': 'Hesamabadi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Education and Psychology, Shiraz University, Shiraz, IR, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Asvadi-Fard', 'Affiliation': 'Department of Medicine, Iran University of Medical Science, Tehran, IR, Iran.'}, {'ForeName': 'Mohammad Ali Babaee', 'Initials': 'MAB', 'LastName': 'Bigi', 'Affiliation': 'Cardiovascular Research Center, Shiraz University of Medical Science, Shiraz, IR, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Izadi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Exercise Sciences, University of Shahid Chamran, Ahvaz, IR, Iran.'}, {'ForeName': 'Abbas Ali', 'Initials': 'AA', 'LastName': 'Gaeini', 'Affiliation': 'Department of Exercise Physiology, Faculty of Physical Education and Exercise Sciences, University of Tehran, Tehran, IR, Iran. Electronic address: Aagaeini@ut.ac.ir.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2019.107469'] 1019,30898609,Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.,"BACKGROUND Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. OBJECTIVES This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease influenced risks of MACEs and death and their modification by alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy. METHODS Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. All-cause death was a secondary endpoint. RESULTS Median follow-up was 2.8 years. Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyvascular disease in 2 beds (coronary and peripheral artery or cerebrovascular), and 149 had polyvascular disease in 3 beds (coronary, peripheral artery, cerebrovascular). With placebo, the incidence of MACEs by respective vascular categories was 10.0%, 22.2%, and 39.7%. With alirocumab, the corresponding absolute risk reduction was 1.4% (95% confidence interval [CI]: 0.6% to 2.3%), 1.9% (95% CI: -2.4% to 6.2%), and 13.0% (95% CI: -2.0% to 28.0%). With placebo, the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab was 0.4% (95% CI: -0.1% to 1.0%), 1.3% (95% CI: -1.8% to 4.3%), and 16.2% (95% CI: 5.5% to 26.8%). CONCLUSIONS In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death. The large absolute reductions in those risks with alirocumab are a potential benefit for these patients. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]: NCT01663402).",2019,"With alirocumab, corresponding absolute risk reduction (ARR [95% confidence interval]) was 1.4% (0.6, 2.3), 1.9% (-2.4%, 6.2%), and 13.0% (-2.0, 28.0).","['Patients with Recent Acute Coronary Syndrome and Polyvascular Disease', 'Patients with acute coronary syndrome (ACS', 'patients with recent ACS and dyslipidemia despite intensive statin therapy', 'patients with recent ACS and dyslipidemia despite intensive statin therapy, polyVD', 'Patients', '18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyVD in two beds (coronary and peripheral artery or cerebrovascular), and 149 had polyVD in three beds (coronary, peripheral artery, cerebrovascular']","['alirocumab', 'lipid-lowering by proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibition', 'placebo', 'alirocumab or placebo', 'Alirocumab']","['composite of coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, or unstable angina requiring hospitalization', 'incidence of death by respective vascular categories', 'incidence of MACE by respective vascular categories']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}]","[{'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C1100660', 'cui_str': 'Proprotein Convertases'}, {'cui': 'C0038601', 'cui_str': 'Subtilisins'}, {'cui': 'C0165249', 'cui_str': 'kexin protein, S cerevisiae'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}]",18924.0,0.26158,"With alirocumab, corresponding absolute risk reduction (ARR [95% confidence interval]) was 1.4% (0.6, 2.3), 1.9% (-2.4%, 6.2%), and 13.0% (-2.0, 28.0).","[{'ForeName': 'J Wouter', 'Initials': 'JW', 'LastName': 'Jukema', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: j.w.jukema@lumc.nl.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Szarek', 'Affiliation': 'State University of New York, Downstate School of Public Health, Brooklyn, New York.'}, {'ForeName': 'Laurien E', 'Initials': 'LE', 'LastName': 'Zijlstra', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'H Asita', 'Initials': 'HA', 'LastName': 'de Silva', 'Affiliation': 'Clinical Trials Unit, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Vera A', 'Initials': 'VA', 'LastName': 'Bittner', 'Affiliation': 'Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'Latinoamerican Cardiological Studies, Cardiovascular Institute of Rosario, Rosario, Argentina.'}, {'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Edelberg', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Shaun G', 'Initials': 'SG', 'LastName': 'Goodman', 'Affiliation': ""Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Hanotin', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Harrington', 'Affiliation': 'Stanford Center for Clinical Research, Department of Medicine, Stanford University, Stanford, California.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Karpov', 'Affiliation': 'Russian Cardiological Scientific-Productive Complex, Moscow, Russian Federation.'}, {'ForeName': 'Angèle', 'Initials': 'A', 'LastName': 'Moryusef', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York.'}, {'ForeName': 'Juan C', 'Initials': 'JC', 'LastName': 'Prieto', 'Affiliation': 'University of Chile Clinical Hospital, Santiago, Chile.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Roe', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Harvey D', 'Initials': 'HD', 'LastName': 'White', 'Affiliation': 'Green Lane Cardiovascular Services Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Andreas M', 'Initials': 'AM', 'LastName': 'Zeiher', 'Affiliation': 'Department of Medicine III, Goethe University, Frankfurt am Main, Germany.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'P Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris and Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.03.013'] 1020,30747899,Association of Functional Screening Tests and Noncontact Injuries in Division I Women Student-Athletes.,"Warren, M, Lininger, M, Smith, CA, Copp, A, and Chimera, NJ. Association of functional screening tests and noncontact injuries in Division I women student-athletes. J Strength Cond Res 34(8): 2302-2311, 2020-To determine the association between functional screening tests and lower-body, noncontact injuries in Division I women basketball, soccer, and volleyball student-athletes (SA). Sixty-eight injury-free women SA (age: 19.1 ± 1.1 years, height: 171.3 ± 8.7 cm, and mass: 68.4 ± 9.5 kg) were tested preseason with single hop (SH), triple hop (TH), and crossover hop (XH) for distance, and isometric hip strength (abduction, extension, and external rotation) in randomized order. The first lower-body (spine and lower extremity), noncontact injury requiring intervention by the athletic trainer was abstracted from the electronic medical record. Receiver operating characteristic and area under the curve (AUC) were calculated to determine cut-points for each hopping test from the absolute value of between-limb difference. Body mass-adjusted strength was categorized into tertiles. Logistic regression determined the odds of injury with each functional screening test using the hopping tests cut-points and strength categories, adjusting for previous injury. Fifty-two SA were injured during the sport season. The cut-point for SH was 4 cm (sensitivity = 0.77, specificity = 0.43, and AUC = 0.53), and for TH and XH was 12 cm (sensitivity = 0.75 and 0.67, specificity = 0.71 and 0.57, AUC = 0.59 and 0.41, respectively). A statistically significant association with TH and injuries (adjusted odds ratio = 6.50 [95% confidence interval: 1.69-25.04]) was found. No significant overall association was found with SH or XH, nor with the strength tests. Using a clinically relevant injury definition, the TH showed the strongest predictive ability for noncontact injuries. This hopping test may be a clinically useful tool to help identify increased risk of injury in women SA participating in high-risk sports.",2020,A statistically significant association with TH and injuries (adjusted odds ratio = 6.50 [95% confidence interval: 1.69-25.04]) was found.,"['Sixty-eight injury-free women SA (age: 19.1 ± 1.1 years, height: 171.3 ± 8.7 cm, and mass: 68.4 ± 9.5 kg) were tested', ' 000-000, 2018-To determine the association between functional screening tests and lower-body, noncontact injuries in Division I women basketball, soccer, and volleyball student-athletes (SA', 'women SA participating in high-risk sports', 'I Women Student-Athletes', 'I women student-athletes']","['J Strength Cond Res XX(X', 'preseason with single hop (SH), triple hop (TH), and crossover hop (XH) for distance, and isometric hip strength (abduction, extension, and external rotation']",['Receiver operating characteristic and area under the curve (AUC'],"[{'cui': 'C0450387', 'cui_str': '68 (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517491', 'cui_str': 'One point one'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C4517899', 'cui_str': 'Nine point five'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0871311', 'cui_str': 'Screening test'}, {'cui': 'C1268088', 'cui_str': 'Lower body'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}, {'cui': 'C0004818', 'cui_str': 'Basketball'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C1956059', 'cui_str': 'Volleyball'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0038039', 'cui_str': 'Sports'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4018995', 'cui_str': 'Hop'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0231456', 'cui_str': 'Abduction, function (observable entity)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0231462', 'cui_str': 'Lateral rotation - action (qualifier value)'}]","[{'cui': 'C0376690', 'cui_str': 'AUC'}]",52.0,0.0209456,A statistically significant association with TH and injuries (adjusted odds ratio = 6.50 [95% confidence interval: 1.69-25.04]) was found.,"[{'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Warren', 'Affiliation': 'Department of Physical Therapy and Athletic Training, Northern Arizona University, Flagstaff, Arizona.'}, {'ForeName': 'Monica R', 'Initials': 'MR', 'LastName': 'Lininger', 'Affiliation': 'Department of Physical Therapy and Athletic Training, Northern Arizona University, Flagstaff, Arizona.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Smith', 'Affiliation': 'Department of Physical Therapy and Athletic Training, Northern Arizona University, Flagstaff, Arizona.'}, {'ForeName': 'Adam J', 'Initials': 'AJ', 'LastName': 'Copp', 'Affiliation': 'Advanced Travel Therapy, Rock Springs, Wyoming.'}, {'ForeName': 'Nicole J', 'Initials': 'NJ', 'LastName': 'Chimera', 'Affiliation': 'Daemen College, Amherst, New York.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003004'] 1021,30875541,Peer support and skills training through an eating club for people with psychotic disorders: A feasibility study.,"OBJECTIVE The HospitalitY (HY) intervention is a novel recovery oriented intervention for people with psychotic disorders in which peer support and home-based skill training are combined in an eating club. A feasibility study was conducted to inform a subsequent randomised trial. METHODS This study evaluated three eating clubs consisting of nine participants and three nurses. Semi-structured interviews and pre- and post-intervention measures (18 weeks) of personal recovery, quality of life and functioning were used to evaluate the intervention. Participants received individual skills training, guided by self-identified goals, while organising a dinner at their home. During each dinner, participants engaged in peer support, led by a nurse. RESULTS In personal interviews participants reported positive effects on social support, loneliness, and self-esteem. Nurses reported that participants became more independent during the intervention. Participants were satisfied with the HY-intervention (attendance rate = 93%). All were able to organise a dinner for their peers with practical support from a nurse. Pre- and post -intervention measures did not show important improvements. LIMITATIONS Outcome measures were not sensitive to change, likely due to a short intervention period (5 months) and a limited number of participants (N = 9). Using Goal Attainment Scaling to evaluate personal goals turned out to be unfeasible. CONCLUSIONS The HY-intervention is feasible for participants with psychotic disorders. This study refined intervention and research design for the upcoming multicentre randomised controlled trial. We expect that the Experience Sampling Method will be more sensitive to changes in recovery outcomes than regular pre-post intervention measures.",2019,The HospitalitY (HY) intervention is a novel recovery oriented intervention for people with psychotic disorders in which peer support and home-based skill training are combined in an eating club.,"['participants with psychotic disorders', 'people with psychotic disorders', 'Participants were satisfied with the HY-intervention (attendance rate\u202f=\u202f93', 'three eating clubs consisting of nine participants and three nurses']","['Peer support and skills training through an eating club', 'HospitalitY (HY) intervention', 'individual skills training, guided by self-identified goals, while organising a dinner at their home']","['personal recovery, quality of life and functioning', 'social support, loneliness, and self-esteem']","[{'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}]","[{'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0557971', 'cui_str': 'Identifying goals (procedure)'}, {'cui': 'C1300196', 'cui_str': 'Organized'}, {'cui': 'C4552592', 'cui_str': 'With dinner'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C0034380'}, {'cui': 'C0037438'}, {'cui': 'C0023974', 'cui_str': 'Loneliness'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}]",,0.0739179,The HospitalitY (HY) intervention is a novel recovery oriented intervention for people with psychotic disorders in which peer support and home-based skill training are combined in an eating club.,"[{'ForeName': 'Jelle Sjoerd', 'Initials': 'JS', 'LastName': 'Vogel', 'Affiliation': 'Lentis Psychiatric Institute, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Rob Giel Research Center, Groningen, the Netherlands; University of Groningen, Faculty of Behavioural and Social Sciences, Groningen, the Netherlands. Electronic address: js.vogel@lentis.nl.'}, {'ForeName': 'Marte', 'Initials': 'M', 'LastName': 'Swart', 'Affiliation': 'Lentis Psychiatric Institute, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Rob Giel Research Center, Groningen, the Netherlands.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Slade', 'Affiliation': 'University of Nottingham, School of Health Sciences, Nottingham, United Kingdom.'}, {'ForeName': 'Jojanneke', 'Initials': 'J', 'LastName': 'Bruins', 'Affiliation': 'Lentis Psychiatric Institute, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Rob Giel Research Center, Groningen, the Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'van der Gaag', 'Affiliation': 'VU University Amsterdam, Department of Clinical Psychology, Amsterdam, the Netherlands; EMGO + Institute of Health and Care Research, Amsterdam, the Netherlands; Parnassia Psychiatric Institute, Department of Psychiatry, The Hague, the Netherlands.'}, {'ForeName': 'Stynke', 'Initials': 'S', 'LastName': 'Castelein', 'Affiliation': 'Lentis Psychiatric Institute, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Rob Giel Research Center, Groningen, the Netherlands; University of Groningen, Faculty of Behavioural and Social Sciences, Groningen, the Netherlands.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.02.007'] 1022,31714322,Effects of Adding Oxycodone to Ropivacaine on Labor Analgesia: A Randomized Controlled Trial.,"BACKGROUND It has been reported that oxycodone is superior to the other opioids for the treatment of visceral pain. During the first stage of labor, pain is mainly caused by uterine contractions (visceral pain). It seems that oxycodone is more suitable for labor analgesia. During this study, we investigated the effects of adding oxycodone to ropivacaine on epidural analgesia during labor. MATERIALS AND METHODS Eighty nulliparous parturients were randomly divided into 2 groups. Group A received 0.2 mg/mL oxycodone plus 0.1% ropivacaine for epidural analgesia and group C (control group) received 0.1% ropivacaine alone for epidural analgesia. The onset time and duration of analgesia, duration of labor stages, delivery outcome, analgesic effect, Bromage scores, blood pressure, heart rate, and neonatal Apgar scores were recorded. Umbilical arterial blood was collected to analyze. Side effects, if any, were also recorded. RESULTS The visual analog scale of pain was lower at 2 and 4 hours after analgesia and 10 cm cervical dilatation in group A compared with group C (P=0.021, 0.018, and 0.009, respectively). The onset time of analgesia was shorter in group A than that in group C (13.3±2.8 vs. 14.9±3.6 min, P=0.032). There were no significant differences between the 2 groups in terms of the duration of labor stages, delivery outcome, Bromage score, neonatal Apgar score, or umbilical arterial blood pH. The duration of analgesia was significantly longer in group A than in group C (326.2±56.5 vs. 68.4±10.5 min, P=0.000), but the incidence of pruritus was higher in group A than in group C (10% vs. 0%, P=0.115). CONCLUSIONS This study demonstrates that epidural oxycodone may accelerate the onset of analgesia and obviously prolong the duration of analgesia during labor without increasing adverse effects associated with the neonate. However, it may cause a higher incidence of maternal pruritus (registration number: ChiCTR1800016483).",2020,"There were no significant differences between the two groups in terms of the duration of labor stages, delivery outcome, Bromage score, neonatal Apgar score and umbilical arterial blood pH. The duration of analgesia was significantly longer in group A than in group C (326.2±56.5 vs. 68.4±10.5▒min, P=0.000), but the incidence of pruritus was higher in group A than in group C (10% vs. 0%, P=0.115). ",['Eighty nulliparous parturients'],"['ropivacaine', 'mL oxycodone plus 0.1% ropivacaine', 'epidural oxycodone', 'Ropivacaine', 'Oxycodone', 'oxycodone']","['duration of labor stages, delivery outcome, Bromage score, neonatal Apgar score and umbilical arterial blood pH. The duration of analgesia', 'onset time and duration of analgesia, duration of labor stages, delivery outcome, analgesic effect, Bromage scores, blood pressure, heart rate and neonatal Apgar scores', 'Umbilical arterial blood', 'epidural analgesia', 'incidence of pruritus', 'Labor Analgesia', 'visual analogue scale (VAS) of pain', 'onset time of analgesia']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous (finding)'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}]","[{'cui': 'C0566679', 'cui_str': 'Duration of labor (observable entity)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0003533', 'cui_str': 'Apgar Score'}, {'cui': 'C0428199', 'cui_str': 'pH measurement, arterial (procedure)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0229665', 'cui_str': 'Arterial blood (substance)'}, {'cui': 'C0002769', 'cui_str': 'Analgesia, Epidural'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",80.0,0.0576194,"There were no significant differences between the two groups in terms of the duration of labor stages, delivery outcome, Bromage score, neonatal Apgar score and umbilical arterial blood pH. The duration of analgesia was significantly longer in group A than in group C (326.2±56.5 vs. 68.4±10.5▒min, P=0.000), but the incidence of pruritus was higher in group A than in group C (10% vs. 0%, P=0.115). ","[{'ForeName': 'Heying Y', 'Initials': 'HY', 'LastName': 'Zhong', 'Affiliation': ""Department of Anesthesiology, Huadu District People's Hospital, Southern Medical University.""}, {'ForeName': 'Zeyong Y', 'Initials': 'ZY', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai.'}, {'ForeName': 'Wangping', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Maternity and Child Health Hospital of Jiaxing University, Jiaxing, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'School of Nursing, Guangdong Pharmaceutical University, Guangzhou.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000777'] 1023,31714323,"The Benefit of Dexmedetomidine on Postoperative Cognitive Function Is Unrelated to the Modulation on Peripheral Inflammation: A Single-center, Prospective, Randomized Study.","BACKGROUND Dexmedetomidine potentially confers an advantage to reduce the incidence of postoperative delirium (POD) in surgical patients. Anti-inflammation is important effect of this sedative drug. In this study, we aimed to investigate whether the effect of dexmedetomidine on the postoperative cognitive function is via inhibiting peripheral inflammation. METHODS A prospective, randomized, controlled study was conducted with patients 65 years of age or above who received total knee arthroplasty from January 2019 to May 2019. The patients were randomly assigned to receive spinal anesthesia supplemented with propofol or dexmedetomidine for sedation. The incidence of POD was the primary endpoint and was evaluated with the Confusion Assessment Method, and incidence of postoperative cognitive dysfunction was assessed with the Mini-Mental State Examination. Blood samples were collected postoperatively to test the plasma concentrations of interleukin-6, tumor necrosis factor-α, and S100β. RESULTS A total of 366 patients were randomly assigned to 2 groups. Patients who received dexmedetomidine sedation had lower incidences of POD and better postoperative cognitive function than patients sedated with propofol. There was no difference in postoperative plasma concentrations of tumor necrosis factor-α and interleukin-6 between the 2 groups. The concentration of S100β 48 hours after surgery was higher in patients sedated with propofol than in patients who received dexmedetomidine sedation. CONCLUSION Intraoperative sedation with dexmedetomidine conferred better postoperative neurocognitive function for elderly patients who received total knee arthroplasty. This effect was unrelated to the modulation of dexmedetomidine on peripheral inflammation.",2020,"The concentration of S100β at 48 hours after surgery was higher in patients sedated with propofol than patients received dexmedetomidine sedation. ","['patients 65 years of age or older who received total knee hip arthroplasty from January 2019 to May 2019', 'elderly patients received total knee hip arthroplasty', 'Peripheral Inflammation', '366 patients', 'surgical patients']","['dexmedetomidine', 'dexmedetomidine sedation', 'Dexmedetomidine', 'spinal anesthesia supplemented with propofol or dexmedetomidine', 'propofol']","['peripheral inflammation', 'postoperative delirium', 'postoperative neurocognitive function', 'postoperative cognitive function', 'Confusion Assessment Method, and incidence of postoperative cognitive dysfunction', 'concentration of S100β', 'postoperative plasma concentrations of TNF-α and IL-6', 'Postoperative Cognitive Function', 'Incidence of postoperative delirium']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0235195', 'cui_str': 'Sedated (finding)'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1319200', 'cui_str': 'Postoperative confusion'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0009676', 'cui_str': 'Confusional State'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}]",366.0,0.0775105,"The concentration of S100β at 48 hours after surgery was higher in patients sedated with propofol than patients received dexmedetomidine sedation. ","[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Mei', 'Affiliation': 'Department of Anesthesiology, the Second Affiliated Hospital of Anhui Medical University.'}, {'ForeName': 'Guanghong', 'Initials': 'G', 'LastName': 'Xu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, the Second Affiliated Hospital of Anhui Medical University.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Luan Civil Hospital, Luan, Anhui Province, China.'}, {'ForeName': 'Ruihong', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Xinqi', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Shishou', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Erwei', 'Initials': 'E', 'LastName': 'Gu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Xuesheng', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, the First Affiliated Hospital of Anhui Medical University, Hefei.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, the Second Affiliated Hospital of Anhui Medical University.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Clinical journal of pain,['10.1097/AJP.0000000000000779'] 1024,30840307,Effect of different doses of ketamine with low-dose rocuronium on intubation conditions in children: prospective randomized double blind trial.,"OBJECTIVE The effect of ketamine on intubation condition, when used as an induction agent with low-dose rocuronium, is unknown. This study aimed to compare the effects of three doses of ketamine used with 0.3 mg/kg rocuronium and 1 µg/kg fentanyl on intubation conditions in children undergoing short elective surgery. PATIENTS AND METHODS The study was performed as a prospective, randomized double-blind clinical trial. A total of 60 children aged 2 to 12 years, who were scheduled for inguinal herniorrhaphy under general anesthesia, were randomly allocated into three groups on the basis of ketamine dose: 1 mg/kg (Group K1, n = 20), 1.5 mg/kg (Group K1.5, n = 20), and 2 mg/kg (Group K2, n = 20). The primary outcome was the intubation condition. Other assessments included hemodynamic data, recovery profile, adverse events in the postanesthetic care unit (PACU) and use of fentanyl as a rescue analgesic in the PACU were also assessed. RESULTS The occurrence of a clinically acceptable intubation condition increased with the use of an increased dose (≥ 1.5 mg/kg) (K1/K1.5/K2: 30%/65%/65%; p=0.038, for trends p=0.028). Hemodynamic data, recovery profile and adverse events in PACU showed no difference among groups. Fentanyl dose used in the PACU was higher in K1 than K2 and the number of patients requiring rescue analgesics in the PACU decreased in accordance with the dose of ketamine (K1/K1.5/K2: 30%/15%/0%; p=.031, for trends p=0.013). CONCLUSIONS Different intubation conditions were observed on the basis of ketamine dose used in conjunction with 0.3 mg/kg rocuronium and fentanyl 1 µg/kg. Ketamine dose ≥ 1.5 mg/kg with low-dose rocuronium should be used to improve intubation conditions in pediatrics.",2019,"Fentanyl dose used in the PACU was higher in K1 than K2 and the number of patients requiring rescue analgesics in the PACU decreased in accordance with the dose of ketamine (K1/K1.5/K2: 30%/15%/0%; p=.031, for trends p=0.013). ","['children', 'children undergoing short elective surgery', '60 children aged 2 to 12 years, who were scheduled for inguinal herniorrhaphy under general anesthesia']","['Fentanyl', 'ketamine', 'rocuronium and 1 µg/kg fentanyl', 'ketamine with low-dose rocuronium', 'rocuronium', 'Ketamine']","['intubation condition', 'intubation conditions', 'Hemodynamic data, recovery profile and adverse events', 'hemodynamic data, recovery profile, adverse events in the postanesthetic care unit (PACU) and use of fentanyl as a rescue analgesic in the PACU', 'acceptable intubation condition']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0021446', 'cui_str': 'Repair of inguinal hernia (procedure)'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}]","[{'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0445550', 'cui_str': 'Low dose (qualifier value)'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}]",60.0,0.551517,"Fentanyl dose used in the PACU was higher in K1 than K2 and the number of patients requiring rescue analgesics in the PACU decreased in accordance with the dose of ketamine (K1/K1.5/K2: 30%/15%/0%; p=.031, for trends p=0.013). ","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hwang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, Suwon, South Korea. lyrin01@gmail.com.'}, {'ForeName': 'Y J', 'Initials': 'YJ', 'LastName': 'Chae', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ha', 'Affiliation': ''}, {'ForeName': 'I K', 'Initials': 'IK', 'LastName': 'Yi', 'Affiliation': ''}]",European review for medical and pharmacological sciences,['10.26355/eurrev_201902_17144'] 1025,30833486,Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.,"BACKGROUND Mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis (mIAS) is a frequent adverse event (AE) associated with mTOR inhibitor therapy and can impact treatment adherence. The objectives are to evaluate two steroid-based mouthrinses for preventing/ameliorating mIAS in patients with metastatic breast cancer (MBC) treated with everolimus. MATERIALS AND METHODS This prospective, randomized phase II study enrolled 100 postmenopausal patients with hormone receptor-positive MBC within the US Oncology Network who were initiating therapy with an aromatase inhibitor + everolimus (AIE; 10 mg/day). Patients were randomized to prophylactic therapy with one of two oral rinses (Arm 1: Miracle Mouthwash [MMW] 480 mL recipe: 320 mL oral Benadryl [diphenhydramine; Johnson & Johnson, New Brunswick, NJ, USA], 2 g tetracycline, 80 mg hydrocortisone, 40 mL nystatin suspension, water; or Arm 2: prednisolone [P] 15 mg/5 mL oral solution, 1.8% alcohol). Patients were instructed to swish/expectorate 10 mL of the assigned rinse for 1-2 minutes four times daily starting with day 1 of AIE treatment, for the first 12 weeks. RESULTS A total of 100 patients received treatment (49 MMW; 51 P). The incidence of stomatitis/oral AEs during the first 12 weeks was 35% ( n  = 17/49) and 37% (19/51) in the MMW and P arms, respectively. The incidence of grade 2 oral AEs was 14% (7/49) and 12% (6/51) with MMW or P, respectively. There were two grade 3 oral AEs (MMW arm) and no grade 4 events. There was one everolimus dose reduction (MMW) and six dose delays (four MMW, two P) and one dose reduction + delay (MMW) during the first 12 weeks of treatment. No patients stopped steroid mouthwash therapy because of rinse-related toxicity. CONCLUSION Prophylactic use of steroid-containing oral rinses can prevent/ameliorate mIAS in patients with MBC treated with AIE. MMW + hydrocortisone is an affordable option, as is dexamethasone oral rinse. IMPLICATIONS FOR PRACTICE This prospective phase-II study showed that two steroid-containing mouthrinses substantially reduced incidences of all-grade and grade ≥2 stomatitis and related oral adverse events (AEs), and the number of everolimus dose-delays and/or dose-reduction in metastatic breast cancer (MBC) patients receiving everolimus treatment plus an aromatase inhibitor. Both oral rinses were well tolerated and demonstrated similar efficacy. Prophylactic use of steroid mouth rinse provides a cost-effective option that substantially decreases the incidence and severity of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis and related oral AEs as well as the need for dose modification in MBC patients undergoing treatment with an mTOR inhibitor.",2019,"The incidence of stomatitis/oral AEs during the first 12 weeks was 35% ( n  = 17/49) and 37% (19/51) in the MMW and P arms, respectively.","['100 postmenopausal patients with hormone receptor-positive MBC within the US Oncology Network who were initiating therapy with an aromatase inhibitor + everolimus (AIE; 10\u2009mg/day', 'metastatic breast cancer (MBC) patients receiving', 'MBC patients undergoing treatment with an mTOR inhibitor', 'patients with metastatic breast cancer (MBC) treated with everolimus', 'patients with MBC treated with AIE']","['tetracycline, 80\u2009mg hydrocortisone, 40\u2009mL nystatin suspension, water; or Arm 2: prednisolone [P] 15\u2009mg/5\u2009mL oral solution, 1.8% alcohol', 'steroid mouth rinse', 'prophylactic therapy with one of two oral rinses (Arm 1: Miracle Mouthwash [MMW', 'everolimus treatment plus an aromatase inhibitor', 'Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses', '480\u2009mL recipe: 320\u2009mL oral Benadryl [diphenhydramine; Johnson & Johnson, New Brunswick, NJ, USA', 'MMW\u2009+\u2009hydrocortisone', 'rapamycin (mTOR) inhibitor-associated stomatitis (mIAS', 'steroid-based mouthrinses']","['incidence of grade 2 oral AEs', 'incidences of all-grade and grade\u2009≥2 stomatitis and related oral adverse events (AEs), and the number of everolimus dose-delays and/or dose-reduction', 'incidence of stomatitis/oral AEs']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0593802', 'cui_str': 'Aromatase Inhibitors'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0439422', 'cui_str': 'mg/day'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer metastatic'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0039651', 'cui_str': 'Tetracyclines'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0028741', 'cui_str': 'Nystatin'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0991536', 'cui_str': 'Oral Solution'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0026647', 'cui_str': 'Oral Rinse'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0593802', 'cui_str': 'Aromatase Inhibitors'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0600194', 'cui_str': 'Recipes'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0700899', 'cui_str': 'Benadryl'}, {'cui': 'C0012522', 'cui_str': 'Diphenhydramine'}, {'cui': 'C0027963', 'cui_str': 'New Brunswick'}, {'cui': 'C0072980', 'cui_str': 'Sirolimus'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",100.0,0.0283019,"The incidence of stomatitis/oral AEs during the first 12 weeks was 35% ( n  = 17/49) and 37% (19/51) in the MMW and P arms, respectively.","[{'ForeName': 'Vicky E', 'Initials': 'VE', 'LastName': 'Jones', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Kristi J', 'Initials': 'KJ', 'LastName': 'McIntyre', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Devchand', 'Initials': 'D', 'LastName': 'Paul', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Sharon T', 'Initials': 'ST', 'LastName': 'Wilks', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Sharon M', 'Initials': 'SM', 'LastName': 'Ondreyco', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Scot', 'Initials': 'S', 'LastName': 'Sedlacek', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Melnyk', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Sanjay P', 'Initials': 'SP', 'LastName': 'Oommen', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Yunfei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Peck', 'Affiliation': 'McKesson Specialty Health, Inc., The Woodlands, Texas, USA.'}, {'ForeName': 'Joyce A', 'Initials': 'JA', 'LastName': ""O'Shaughnessy"", 'Affiliation': 'US Oncology Research, Inc., The Woodlands, Texas, USA joyce.oshaughnessy@usoncology.com.'}]",The oncologist,['10.1634/theoncologist.2018-0340'] 1026,30169298,"Effectiveness of Family Integrated Care in neonatal intensive care units on infant and parent outcomes: a multicentre, multinational, cluster-randomised controlled trial.","BACKGROUND Despite evidence suggesting that parent involvement was beneficial for infant and parent outcomes, the Family Integrated Care (FICare) programme was one of the first pragmatic approaches to enable parents to become primary caregivers in the neonatal intensive care unit (NICU). We aimed to analyse the effect of FICare on infant and parent outcomes, safety, and resource use. METHODS In this multicentre, cluster-randomised controlled trial, we stratified 26 tertiary NICUs from Canada, Australia, and New Zealand by country and size, and assigned them, using a computer-generated random allocation sequence, to provide FICare or standard NICU care. Eligible infants were born at 33 weeks' gestation or earlier, and had no or low-level respiratory support; parents gave written informed consent for enrolment. To be eligible, parents in the FICare group had to commit to be present for at least 6 h a day, attend educational sessions, and actively care for their infant. The primary outcome, analysed at the individual level, was infant weight gain at day 21 after enrolment. Secondary outcomes were weight gain velocity, high frequency breastfeeding (≥6 times a day) at hospital discharge, parental stress and anxiety at enrolment and day 21, NICU mortality and major neonatal morbidities, safety, and resource use (including duration of oxygen therapy and hospital stay). This trial is registered with ClinicalTrials.gov, number NCT01852695. FINDINGS From Oct 1, 2012, 26 sites were randomly assigned to provide FICare (n=14) or standard care (n=12). One site assigned to FICare discontinued because of poor site enrolment. Parents and infants were enrolled between April 1, 2013, and Aug 31, 2015, with 895 infants being eligible in the FICare group and 891 in the standard care group. At day 21, weight gain was greater in the FICare group than in the standard care group (mean change in Z scores -0·071 [SD 0·42] vs -0·155 [0·42]; p<0·0002). Average daily weight gain was significantly higher in infants receiving FICare than those receiving standard care (mean daily weight gain 26·7 g [SD 9·4] vs 24·8 g [9·5]; p<0·0001). The high-frequency exclusive breastmilk feeding rate at discharge was higher for infants in the FICare group (279 [70%] of 396) than those in the standard care group (394 [63%] of 624; p=0·016). At day 21, parents in the FICare group had lower mean stress scores than did parents in the standard care group (2·3 [SD 0·8] vs 2·5 [0·8]; p<0·00043), and lower mean anxiety scores (70·8 [20·1] vs 74·2 [19·9]; p=0·0045). There were no significant differences between groups in the rates of the secondary outcomes of mortality, major morbidity, duration of oxygen therapy, and duration of hospital stay. Although the safety assessment was not completed, there were no adverse events. INTERPRETATION FICare improved infant weight gain, decreased parent stress and anxiety, and increased high-frequency exclusive breastmilk feeding at discharge, which together suggest that FICare is an important advancement in neonatal care. Further research is required to examine if these results translate into better long-term outcomes for families. FUNDING Canadian Institutes of Health Research Partnerships for Health System Improvement, and Ontario Ministry of Health and Long-Term Care.",2018,"At day 21, parents in the FICare group had lower mean stress scores than did parents in the standard care group (2·3 [SD 0·8] vs 2·5","['stratified 26 tertiary NICUs from Canada, Australia, and New Zealand by country and size, and assigned them, using a computer-generated random allocation sequence, to provide FICare or standard NICU care', 'neonatal intensive care units on infant and parent outcomes', ""Eligible infants were born at 33 weeks' gestation or earlier, and had no or low-level respiratory support; parents gave written informed consent for enrolment"", 'Parents and infants were enrolled between April 1, 2013, and Aug 31, 2015, with 895 infants being eligible in the FICare group and 891 in the standard care group']","['provide FICare (n=14) or standard care', 'FICare', 'Family Integrated Care']","['mean anxiety scores', 'high-frequency exclusive breastmilk feeding rate at discharge', 'weight gain velocity, high frequency breastfeeding (≥6 times a day) at hospital discharge, parental stress and anxiety at enrolment and day 21, NICU mortality and major neonatal morbidities, safety, and resource use (including duration of oxygen therapy and hospital stay', 'mean stress scores', 'infant weight gain', 'weight gain', 'mortality, major morbidity, duration of oxygen therapy, and duration of hospital stay', 'Average daily weight gain']","[{'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0015576', 'cui_str': 'Family'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]",,0.131597,"At day 21, parents in the FICare group had lower mean stress scores than did parents in the standard care group (2·3 [SD 0·8] vs 2·5","[{'ForeName': 'Karel', 'Initials': 'K', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Paediatrics, Sinai Health System, Toronto, ON, Canada; Department of Paediatrics, University of Toronto, Toronto, ON, Canada; Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, ON, Canada. Electronic address: karel.obrien@sinaihealthsystem.ca.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Robson', 'Affiliation': 'Women and Babies Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Bracht', 'Affiliation': 'Department of Paediatrics, Sinai Health System, Toronto, ON, Canada.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Cruz', 'Affiliation': 'Miracle Babies Foundation, Chipping Norton, NSW, Australia.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Lui', 'Affiliation': ""Department of Newborn Care, Royal Hospital for Women and School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Alvaro', 'Affiliation': 'Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Orlando', 'Initials': 'O', 'LastName': 'da Silva', 'Affiliation': 'Department of Paediatrics, Western University, London, ON, Canada.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Monterrosa', 'Affiliation': 'Department of Pediatrics, Neonatal Division, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Narvey', 'Affiliation': 'Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Ng', 'Affiliation': 'Department of Paediatrics, University of Toronto, Toronto, ON, Canada; Women and Babies Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.'}, {'ForeName': 'Amuchou', 'Initials': 'A', 'LastName': 'Soraisham', 'Affiliation': ""Department of Pediatrics, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, Calgary, AB, Canada.""}, {'ForeName': 'Xiang Y', 'Initials': 'XY', 'LastName': 'Ye', 'Affiliation': 'Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, ON, Canada.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Mirea', 'Affiliation': ""Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Phoenix Children's Hospital, Phoenix, AZ, USA.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Tarnow-Mordi', 'Affiliation': 'WINNER Centre for Newborn Research, NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Infectious Diseases, Westmead Hospital, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Shoo K', 'Initials': 'SK', 'LastName': 'Lee', 'Affiliation': 'Department of Paediatrics, Sinai Health System, Toronto, ON, Canada; Department of Paediatrics, University of Toronto, Toronto, ON, Canada; Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Maternal-Infant Care Research Centre, Mount Sinai Hospital, Toronto, ON, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(18)30039-7'] 1027,31702015,Skeletal Effects of Levothyroxine for Subclinical Hypothyroidism in Older Adults: A TRUST Randomized Trial Nested Study.,"CONTEXT Both thyroid dysfunction and levothyroxine (LT4) therapy have been associated with bone loss, but studies on the effect of LT4 for subclinical hypothyroidism (SHypo) on bone yielded conflicting results. OBJECTIVE To assess the effect of LT4 treatment on bone mineral density (BMD), Trabecular Bone Score (TBS), and bone turnover markers (BTMs) in older adults with SHypo. DESIGN AND INTERVENTION Planned nested substudy of the double-blind placebo-controlled TRUST trial. Participants with SHypo were randomized to LT4 with dose titration versus placebo with computerized mock titration. SETTING AND PARTICIPANTS 196 community-dwelling adults over 65 years enrolled at the Swiss TRUST sites had baseline and 1-year follow-up bone examinations; 4 participants withdrew due to adverse events not related to treatment. MAIN OUTCOME MEASURES One-year percentage changes of BMD, TBS, and 2 serum BTMs (serum CTX-1 [sCTX] and procollagen type 1 N-terminal polypeptide [P1NP]). Student's t-test for unadjusted analyses and linear regression adjusted for clinical center and sex were performed. RESULTS Mean age was 74.3 years ± 5.7, 45.4% were women, and 19.6% were osteoporotic. The unadjusted 1-year change in lumbar spine BMD was similar between LT4 (+0.8%) and placebo-treated groups (-0.6%; between-groups difference +1.4%: 95% confidence interval [CI] -0.1 to 2.9, P = .059). Likewise, there were no between-group differences in 1-year change in TBS (-1.3%: 95% CI -3.1 to 0.6, P = .19), total hip BMD (-0.2%: 95% CI -1.1 to 0.1, P = .61), or BTMs levels (sCTX +24.1%: 95% CI -7.9 to 56.2, P = .14), or after adjustment for clinical centers and sex. CONCLUSIONS Over 1-year levothyroxine had no effect on bone health in older adults with SHypo. REGISTRATION ClinicalTrial.gov NCT01660126 and NCT02491008.",2020,"The unadjusted 1-year change in lumbar spine BMD was similar between LT4 (+0.8%) and placebo-treated groups (-0.6%; between-groups difference +1.4%: 95%CI -0.1 to 2.9, p=0.059).","['Participants with SHypo', '196 community-dwelling adults over 65 years enrolled at the Swiss TRUST sites had baseline and 1-year follow-up bone examinations; 4 participants withdrew due to adverse events not related to treatment', 'Older Adults', 'older adults with SHypo', 'Mean age was 74.3y ± 5.7, 45.4% were women, and 19.6% were osteoporotic']","['Levothyroxine', 'levothyroxine therapy', 'LT4', 'placebo', 'LT4 with dose titration vs. placebo', 'levothyroxine']","['total hip BMD', 'bone health', 'lumbar spine BMD', 'BMD, TBS, and two serum BTMs (sCTX and P1NP', '1-year change in TBS', 'bone mineral density (BMD), Trabecular Bone Score (TBS), and bone turnover markers (BTMs', 'BTMs levels']","[{'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0241315', 'cui_str': 'Swiss (ethnic group)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn (finding)'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C1881373', 'cui_str': ""L-3,5,3',5'-Tetraiodothyronine""}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3887615', 'cui_str': 'Lumbar spine structure (body structure)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0222660', 'cui_str': 'Spongy Bone'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0085268', 'cui_str': 'Bone Turnover'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",196.0,0.653512,"The unadjusted 1-year change in lumbar spine BMD was similar between LT4 (+0.8%) and placebo-treated groups (-0.6%; between-groups difference +1.4%: 95%CI -0.1 to 2.9, p=0.059).","[{'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Gonzalez Rodriguez', 'Affiliation': 'Center of Bone Diseases, Rheumatology Unit, Bone and Joint Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Mirah', 'Initials': 'M', 'LastName': 'Stuber', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}, {'ForeName': 'Cinzia', 'Initials': 'C', 'LastName': 'Del Giovane', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Feller', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}, {'ForeName': 'Tinh-Hai', 'Initials': 'TH', 'LastName': 'Collet', 'Affiliation': 'Service of Endocrinology, Diabetes and Metabolism, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Axel L', 'Initials': 'AL', 'LastName': 'Löwe', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}, {'ForeName': 'Manuel R', 'Initials': 'MR', 'LastName': 'Blum', 'Affiliation': 'Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Nicolien A', 'Initials': 'NA', 'LastName': 'van Vliet', 'Affiliation': 'Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'van Heemst', 'Affiliation': 'Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Kearney', 'Affiliation': 'School of Public Health, University College Cork, Cork, Ireland.'}, {'ForeName': 'Jacobijn', 'Initials': 'J', 'LastName': 'Gussekloo', 'Affiliation': 'Departments of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Mooijaart', 'Affiliation': 'Departments of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Rudi G J', 'Initials': 'RGJ', 'LastName': 'Westendorp', 'Affiliation': 'Department of Public Health and Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Stott', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Aeberli', 'Affiliation': 'Department of Rheumatology and Clinical Immunology/Allergology, Inselspital, Bern University Hospital, Bern, Switzerland.'}, {'ForeName': 'Douglas C', 'Initials': 'DC', 'LastName': 'Bauer', 'Affiliation': 'Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, US.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Hans', 'Affiliation': 'Center of Bone Diseases, Rheumatology Unit, Bone and Joint Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rodondi', 'Affiliation': 'Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz058'] 1028,30088055,Adjunctive left anterior line ablation induced left atrial dysfunction and dyssynchrony in atrial fibrillation ablation.,"We evaluated the effects of adjunctive left anterior line (LAL) ablation on LA dyssynchrony and function using real-time three-dimensional echocardiography (3DE) in connection with thromboembolic complications and tachyarrhythmia recurrence in patients with persistent atrial fibrillation (AF). We randomly and prospectively assigned consecutive persistent AF patients to the LAL (n = 52, 65 ± 7 years) and control groups (n = 50, 64 ± 10 years). In the LAL group, extensive encircling pulmonary vein isolation (EEPVI), roof line ablation, and LAL ablation regardless of the extent of the low-voltage area (LVA) were performed. The control group underwent EEPVI and roof line ablation. After ablation, 3DE demonstrated LA dyssynchrony in 23 (46%) and 4 patients (8%, P < 0.001) of the LAL and control groups, respectively. Baseline LA LVAs were relatively small in most patients and there were no significant differences in extent of LVA between control and LAL groups or between patients with and without dyssynchrony. During the follow-up periods (771 ± 121 days), patients with LA dyssynchrony in the LAL group did not show significant differences in symptomatic thromboembolic events (0%) and atrial tachyarrhythmia recurrence (39%) from patients without LA dyssynchrony in the LAL (0% and 30%) and control groups (0% and 32%, respectively). LA ejection fraction and active emptying fraction were lower by 9% on average in the LAL group than in the control group (P < 0.0001). Similarly, in the LAL group, LA ejection fraction, active emptying fraction, and expansion index were significantly lower by approximately 7%, 8%, and 15%, respectively, in LA with dyssynchrony than those in LA without dyssynchrony. In conclusion, LA dyssynchrony and LA hypofunction were induced by LAL ablation in patients with persistent AF and relatively mild LVA. LAL ablation with or without LA dyssynchrony is thought not to affect thromboembolic complications or atrial tachyarrhythmia recurrence.",2019,LAL ablation with or without LA dyssynchrony is thought not to affect thromboembolic complications or atrial tachyarrhythmia recurrence.,"['atrial fibrillation ablation', 'patients with persistent atrial fibrillation (AF']","['LAL ablation with or without LA dyssynchrony', 'EEPVI and roof line ablation', 'real-time three-dimensional echocardiography (3DE', 'adjunctive left anterior line (LAL) ablation', 'LAL', 'Adjunctive left anterior line ablation']","['LA dyssynchrony and LA hypofunction', 'LA ejection fraction, active emptying fraction, and expansion index', 'symptomatic thromboembolic events', 'thromboembolic complications or atrial tachyarrhythmia recurrence', 'extensive encircling pulmonary vein isolation (EEPVI), roof line ablation, and LAL ablation', 'LA ejection fraction and active emptying fraction', 'tachyarrhythmia recurrence', 'LA dyssynchrony', 'LVA', 'atrial tachyarrhythmia recurrence', 'Baseline LA LVAs']","[{'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2585653', 'cui_str': 'Persistent atrial fibrillation'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0557685', 'cui_str': 'Roof'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0203378', 'cui_str': 'Echocardiography, 3D'}, {'cui': 'C0441998', 'cui_str': 'Left anterior (qualifier value)'}]","[{'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolism'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0080203', 'cui_str': 'Tachyarrhythmia'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0205231', 'cui_str': 'Extensive (qualifier value)'}, {'cui': 'C3544330', 'cui_str': 'Pulmonary vein isolation'}, {'cui': 'C0557685', 'cui_str': 'Roof'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}]",,0.0239776,LAL ablation with or without LA dyssynchrony is thought not to affect thromboembolic complications or atrial tachyarrhythmia recurrence.,"[{'ForeName': 'Hirosuke', 'Initials': 'H', 'LastName': 'Yamaji', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan. yamaji2@mac.com.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Murakami', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Hina', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Shunichi', 'Initials': 'S', 'LastName': 'Higashiya', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Kawamura', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Murakami', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Shigeshi', 'Initials': 'S', 'LastName': 'Kamikawa', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Hirohata', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}, {'ForeName': 'Shozo', 'Initials': 'S', 'LastName': 'Kusachi', 'Affiliation': 'Heart Rhythm Center, Okayama Heart Clinic, Takeda 54-1, Naka-ku, Okayama, Okayama, 703-8251, Japan.'}]",Heart and vessels,['10.1007/s00380-018-1238-x'] 1029,30870245,Predictors of Exercise Training and Physical Activity Adherence in People Recently Hospitalized With Heart Failure: A BRIEF REPORT.,"PURPOSE For individuals with heart failure (HF), frequent attendance at exercise training programs and meeting physical activity (PA) guidelines are significantly associated with improvements in 6-min walk distance. Despite the evidence, adherence to exercise interventions remains poor. The aim of this study was to identify predictors of these 2 variables in patients recently hospitalized with HF. METHODS In this substudy of the Exercise Joins Education: Combined Therapy to Improve Outcomes in Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk. Intervention group participants additionally undertook twice weekly supervised exercise training. Primary outcomes were frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines (150 min/wk of moderate intensity exercise) at 12 wk. Participant and clinical characteristics were analyzed using a logistic regression model to identify significant predictors of each outcome. RESULTS A total of 278 participants provided PA data and 140 contributed attendance data. New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03). Predictors of meeting PA guidelines at follow-up included new HF diagnosis (OR = 2.4; 95% CI, 1.2-4.8, P = .013), and being physically active at baseline (OR = 2.7; 95% CI, 1.3-5.6; P = .007). Gender, symptom severity, multimorbidity, and disability were not significantly associated with either outcome in multivariate analysis. CONCLUSION To improve adherence, specific strategies may be required for patients with decompensated HF and those physically inactive at time of referral.",2019,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","['278 participants provided PA data and 140 contributed attendance data', 'Newly-discharged Heart Failure (EJECTION-HF) trial, all participants were enrolled in a HF disease management program, including weekly review of a home exercise program for 12 wk', 'individuals with heart failure (HF', 'patients with decompensated HF and those physically inactive at time of referral', 'People Recently Hospitalized With Heart Failure']","['Exercise Training and Physical Activity Adherence', 'supervised exercise training']","['Gender, symptom severity, multimorbidity, and disability', 'frequent exercise training program attendance (≥12 sessions) and attainment of PA guidelines', 'frequent program attendance']","[{'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0336969', 'cui_str': 'Ejection (qualifier value)'}, {'cui': 'C1303150', 'cui_str': 'Disease management program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0699752', 'cui_str': 'Review of (contextual qualifier) (qualifier value)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}]",278.0,0.0700865,"New diagnosis of HF was a significant predictor of frequent program attendance (OR = 2.3; 95% CI, 1.1-4.7; P = .03).","[{'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Adsett', 'Affiliation': ""Heart Support Service (Ms Adsett) and Departments of Physiotherapy (Ms Adsett) and Internal Medicine and Aged Care (Dr Mudge), Royal Brisbane and Women's Hospital, Brisbane, Australia; School of Allied Health Sciences, Griffith University, Gold Coast, Australia (Ms Adsett and Dr Morris); Menzies Health Institute, Queensland, Australia (Ms Adsett and Dr Morris); Metro North Hospital and Health Service, The Prince Charles Hospital, Allied Health Research Collaborative, Queensland, Australia (Dr Morris); and University of Queensland Faculty of Medicine, Brisbane, Queensland, Australia (Dr Mudge).""}, {'ForeName': 'Norman R', 'Initials': 'NR', 'LastName': 'Morris', 'Affiliation': ''}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Mudge', 'Affiliation': ''}]",Journal of cardiopulmonary rehabilitation and prevention,['10.1097/HCR.0000000000000407'] 1030,30870252,"Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial: Comparative Feasibility Study in GOUt, CHerry Extract Versus Diet Modification (Mini-GOUCH).","OBJECTIVE The aim of this study was to report patient-centered outcomes and finalization of key study procedures from a 9-month pilot internet randomized controlled trial of cherry extract versus diet modification. METHODS We randomized 84 people with physician-confirmed gout in an internet study to cherry extract (n = 41) or dietitian-assisted diet modification for gout (n = 43). All study outcomes were collected via internet and phone calls. We finalized key study procedures. We assessed acceptability and feasibility of the intervention and satisfaction with study website. RESULTS Study participant satisfaction with the intervention was high. The intervention was perceived as easy, enjoyable, understandable, and helpful (scores 65-88 for all; higher = better). The amount of time spent for the study was acceptable. Participant satisfaction with website interaction and content was very high; 85% or more were moderately to extremely satisfied. Significantly lower total calories, total carbohydrate, and saturated fat intake were noted at 6 months in the diet modification versus cherry extract group; differences were insignificant at 9 months. Six of the 8 Health Assessment Questionnaire sections/domains improved significantly from baseline to 9 months in cherry extract versus 2 Health Assessment Questionnaire sections/domains in the diet modification group. Key study procedures were finalized for a future trial, including an internet diet assessment tool, gout flare assessment, provider confirmation of gout diagnosis, patient reporting of classification criteria, and centralized laboratory-assisted serum urate testing. CONCLUSIONS High patient acceptability and feasibility of study/intervention and finalization of key study procedures indicate that hypothesis-testing internet gout trials of cherry extract and/or diet modification can be conducted in the future.",2020,Six of the 8 Health Assessment Questionnaire sections/domains improved significantly from baseline to 9 months in cherry extract versus 2 Health Assessment Questionnaire sections/domains in the diet modification group.,['84 people with physician-confirmed gout in an internet study to cherry extract (n = 41) or dietitian-assisted diet modification for gout (n = 43'],"['cherry extract versus diet modification', 'GOUt, CHerry Extract Versus Diet Modification (Mini-GOUCH']","['total calories, total carbohydrate, and saturated fat intake']","[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0330657', 'cui_str': 'Pie Cherry'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general) (occupation)'}, {'cui': 'C0086153', 'cui_str': 'Dietary Modification'}]","[{'cui': 'C0330657', 'cui_str': 'Pie Cherry'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0086153', 'cui_str': 'Dietary Modification'}, {'cui': 'C0018099', 'cui_str': 'Gout'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0556120', 'cui_str': 'Saturated fat intake (observable entity)'}]",84.0,0.0403927,Six of the 8 Health Assessment Questionnaire sections/domains improved significantly from baseline to 9 months in cherry extract versus 2 Health Assessment Questionnaire sections/domains in the diet modification group.,"[{'ForeName': 'Jasvinder A', 'Initials': 'JA', 'LastName': 'Singh', 'Affiliation': 'From the Medicine Service, VA Medical Center, Birmingham, AL.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Willig', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine at School of Medicine.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Darnell', 'Affiliation': 'Departments of Nutrition, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Candace', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': 'Division of Clinical Immunology and Rheumatology, Department of Medicine at School of Medicine.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Morgan', 'Affiliation': 'Division of Clinical Immunology and Rheumatology, Department of Medicine at School of Medicine.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Weiss', 'Affiliation': 'Viocare, Princeton, NJ.'}, {'ForeName': 'Kenneth G', 'Initials': 'KG', 'LastName': 'Saag', 'Affiliation': 'Division of Clinical Immunology and Rheumatology, Department of Medicine at School of Medicine.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cutter', 'Affiliation': 'Biostatistics, University of Alabama at Birmingham, Birmingham, AL.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'McGwin', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine at School of Medicine.'}]",Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,['10.1097/RHU.0000000000001018'] 1031,30851653,Is the hierarchy necessary? Gradual versus variable exposure intensity in the treatment of unacceptable obsessional thoughts.,"BACKGROUND AND OBJECTIVES Although research suggests that introducing varying levels of fear during exposure enhances outcomes for some anxiety-related problems, this has not been examined in the context of obsessions. The current preliminary study tested the hypothesis that introducing variability in exposure intensity would improve long-term outcomes relative to traditional gradual (hierarchical) exposure METHODS: Adults (N = 40) with a moderately distressing unacceptable obsessional thought were randomly assigned in parallel to four twice-weekly sessions of: (a) gradual exposure (EXP-G; n = 19) emphasizing hierarchical exposure completion, or (b) variable exposure (EXP-V; n = 21) emphasizing variability in exposure intensity RESULTS: There were no significant differences in pre to post changes between groups using self-report, interview, or behavioral outcomes (as evaluated by an independent assessor blind to treatment condition). Group comparisons at 3-month follow-up did not reach statistical significance but were moderate in magnitude. Specifically, as measured by clinical interview (the Yale-Brown Obsessive-Compulsive Scale; primary outcome) and self-report, individuals in the EXP-G group maintained gains at 3-month follow-up, while the EXP-V group continued to improve. Treatment expectancies and satisfaction were comparable for both groups. Five participants withdrew from the EXP-G condition, and none withdrew from the EXP-V condition. In contrast to previous studies, variability in subjective and physiological fear during exposure did not predict outcomes LIMITATIONS: The study employed an analogue sample with moderate unacceptable obsessions, and results should be replicated in clinical samples CONCLUSIONS: Variable exposure warrants future study to understand the mechanisms, moderators, and implications of this novel approach.",2019,Treatment expectancies and satisfaction were comparable for both groups.,[' Adults (N\u202f=\u202f40) with a moderately distressing unacceptable obsessional thought'],[],['Treatment expectancies and satisfaction'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0233697', 'cui_str': 'Obsessions'}]",[],"[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",40.0,0.050237,Treatment expectancies and satisfaction were comparable for both groups.,"[{'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Jacoby', 'Affiliation': 'University of North Carolina at Chapel Hill, Davie Hall, Campus Box 3270, Chapel Hill, NC, 27599, United States; Massachusetts General Hospital / Harvard Medical School, 185 Cambridge St, Boston, MA, 02114, United States. Electronic address: rjjacoby@mgh.harvard.edu.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Abramowitz', 'Affiliation': 'University of North Carolina at Chapel Hill, Davie Hall, Campus Box 3270, Chapel Hill, NC, 27599, United States. Electronic address: jabramowitz@unc.edu.'}, {'ForeName': 'Shannon M', 'Initials': 'SM', 'LastName': 'Blakey', 'Affiliation': 'University of North Carolina at Chapel Hill, Davie Hall, Campus Box 3270, Chapel Hill, NC, 27599, United States. Electronic address: sblakey@unc.edu.'}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Reuman', 'Affiliation': 'University of North Carolina at Chapel Hill, Davie Hall, Campus Box 3270, Chapel Hill, NC, 27599, United States. Electronic address: reuman@unc.edu.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.02.008'] 1032,30797045,"C-reactive protein, Epstein-Barr virus, and cortisol trajectories in refugee and non-refugee youth: Links with stress, mental health, and cognitive function during a randomized controlled trial.","Experiencing childhood adversity has been associated with significant changes in inflammation, cell-mediated immunocompetence, and cortisol secretion. Relatively few studies have examined, longitudinally, alterations to inflammatory processes during adolescence, especially outside Western contexts; none have evaluated biomarker trajectories for at-risk youth in response to a structured behavioral intervention. We conducted a randomized controlled trial evaluating the efficacy of a humanitarian intervention targeting stress-alleviation, with 12-18 year-old Syrian refugees (n = 446) and Jordanian non-refugees (n = 371) living side-by-side in war-affected communities in Jordan. We measured C-reactive protein (CRP), Epstein-Barr virus antibodies (EBV), and hair cortisol concentration (HCC) at three timepoints (pre/post intervention and 11 month follow-up), and assessed three main outcomes (psychosocial stress, mental health, and cognitive function). Using growth mixture models, regressions, and growth curve models, we identified three distinct trajectories for CRP, two for EBV, and three for HCC, and examined their associations with age, gender, BMI, poverty, and trauma. We found associations with BMI for CRP, refugee status for EBV, and BMI and gender with HCC trajectory. In terms of health outcomes, we found associations between rising CRP levels and perceived stress (B =  -2.92, p = .007), and between HCC hypersecretion and insecurity (B = 7.21, p = .017). In terms of responses to the intervention, we observed no differential impacts by CRP or EBV trajectories, unlike HCC. These results suggest that commonly-assayed biomarkers do not associate with health outcomes and respond to targeted interventions in straightforward ways. Our study is the first to examine multiple biomarker trajectories in war-affected adolescents, in order to better evaluate the extent, timing, and malleability of the biological signatures of poverty, conflict, and forced displacement.",2020,"Experiencing childhood adversity has been associated with significant changes in inflammation, cell-mediated immunocompetence, and cortisol secretion.",['12-18\u202fyear-old Syrian refugees (n\u202f=\u202f446) and Jordanian non-refugees (n\u202f=\u202f371) living side-by-side in war-affected communities in Jordan'],['humanitarian intervention'],"['main outcomes (psychosocial stress, mental health, and cognitive function', 'C-reactive protein, Epstein-Barr virus, and cortisol trajectories', 'C-reactive protein (CRP), Epstein-Barr virus antibodies (EBV), and hair cortisol concentration (HCC', 'rising CRP levels and perceived stress', 'HCC hypersecretion and insecurity']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0337819', 'cui_str': 'Syrians (ethnic group)'}, {'cui': 'C0034961', 'cui_str': 'Refugees'}, {'cui': 'C0043027', 'cui_str': 'War'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0022418', 'cui_str': 'Jordan'}]",[],"[{'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0014644', 'cui_str': 'Epstein-Barr Virus'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0236525', 'cui_str': 'Epstein-Barr virus antibody (substance)'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0233497', 'cui_str': 'Insecurity (finding)'}]",,0.0231915,"Experiencing childhood adversity has been associated with significant changes in inflammation, cell-mediated immunocompetence, and cortisol secretion.","[{'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Panter-Brick', 'Affiliation': 'Department of Anthropology, Yale University, New Haven, USA. Electronic address: catherine.panter-brick@yale.edu.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Wiley', 'Affiliation': 'Department of Anthropology, Yale University, New Haven, USA.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Sancilio', 'Affiliation': 'Department of Anthropology, Yale University, New Haven, USA.'}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Dajani', 'Affiliation': 'Department of Biology and Biotechnology, Hashemite University, Zarqa, Jordan.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Hadfield', 'Affiliation': 'Department of Biological and Experimental Psychology, Queen Mary University of London, UK.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2019.02.015'] 1033,30511879,Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.,"BACKGROUND Patients with active cancer have an increased risk of venous thromboembolism, which results in substantial morbidity, mortality, and health care expenditures. The Khorana score (range, 0 to 6, with higher scores indicating a higher risk of venous thromboembolism) has been validated to identify patients with cancer at elevated risk for this complication and may help select those who could benefit from thromboprophylaxis. METHODS We conducted a randomized, placebo-controlled, double-blind clinical trial assessing the efficacy and safety of apixaban (2.5 mg twice daily) for thromboprophylaxis in ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (Khorana score, ≥2) and were initiating chemotherapy. The primary efficacy outcome was objectively documented venous thromboembolism over a follow-up period of 180 days. The main safety outcome was a major bleeding episode. RESULTS Of the 574 patients who underwent randomization, 563 were included in the modified intention-to-treat analysis. Venous thromboembolism occurred in 12 of 288 patients (4.2%) in the apixaban group and in 28 of 275 patients (10.2%) in the placebo group (hazard ratio, 0.41; 95% confidence interval [CI], 0.26 to 0.65; P<0.001). In the modified intention-to-treat analysis, major bleeding occurred in 10 patients (3.5%) in the apixaban group and in 5 patients (1.8%) in the placebo group (hazard ratio, 2.00; 95% CI, 1.01 to 3.95; P = 0.046). During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo group (hazard ratio, 1.89; 95% CI, 0.39 to 9.24). CONCLUSIONS Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. (Funded by the Canadian Institutes of Health Research and Bristol-Myers Squibb-Pfizer Alliance; AVERT ClinicalTrials.gov number, NCT02048865.).",2019,"During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo group (hazard ratio, 1.89; 95% CI, 0.39 to 9.24). ","['Patients with active cancer', '574 patients who underwent randomization', 'ambulatory patients with cancer who were at intermediate-to-high risk for venous thromboembolism (Khorana score, ≥2) and were initiating chemotherapy', 'Patients with Cancer']","['apixaban', 'Apixaban therapy', 'placebo', 'Apixaban']","['Venous Thromboembolism', 'major bleeding episode', 'Khorana score', 'rate of major bleeding episodes', 'Venous thromboembolism', 'major bleeding', 'rate of venous thromboembolism', 'efficacy and safety', 'venous thromboembolism']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",574.0,0.540304,"During the treatment period, major bleeding occurred in 6 patients (2.1%) in the apixaban group and in 3 patients (1.1%) in the placebo group (hazard ratio, 1.89; 95% CI, 0.39 to 9.24). ","[{'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Abou-Nassar', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Ranjeeta', 'Initials': 'R', 'LastName': 'Mallick', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Tagalakis', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Sudeep', 'Initials': 'S', 'LastName': 'Shivakumar', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Ariah', 'Initials': 'A', 'LastName': 'Schattner', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Kuruvilla', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Hill', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Spadafora', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Katerine', 'Initials': 'K', 'LastName': 'Marquis', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Mateya', 'Initials': 'M', 'LastName': 'Trinkaus', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Tomiak', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Agnes Y Y', 'Initials': 'AYY', 'LastName': 'Lee', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Gross', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Lazo-Langner', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'El-Maraghi', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Glenwood', 'Initials': 'G', 'LastName': 'Goss', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Gregoire', 'Initials': 'G', 'LastName': 'Le Gal', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Stewart', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Ramsay', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Rodger', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Witham', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': 'Philip S', 'Initials': 'PS', 'LastName': 'Wells', 'Affiliation': ""From the Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa (M.C., R.M., G.G., G.L.G., D.S., T.R., M.R., D.W., P.S.W.), Centre Intégré de Santé et des Services Sociaux de l'Outaouais, Gatineau, QC (K.A.-N.), Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal (V.T.), Nova Scotia Health Authority, Halifax (S. Shivakumar), Lakeridge Health, Oshawa, ON (A.S.), William Osler Health Centre, Brampton, ON (P.K.), Sault Area Hospital, Sault Ste. Marie, ON (D.H., S. Spadafora), Hôpital Régional de Rimouski, Rimouski, QC (K.M.), Markham Stouffville Hospital, Markham, ON (M.T.), Kingston General Hospital, Kingston, ON (A.T.), University of British Columbia, British Columbia Cancer Agency, Vancouver (A.Y.Y.L.), Hamilton Health Sciences, Hamilton, ON (P.L.G.), London Health Sciences Centre, London, ON (A.L.-L.), and Royal Victoria Regional Health Centre, Barrie, ON (R.E.-M.) - all in Canada.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1814468'] 1034,30876673,Dual prophylaxis with teicoplanin and cefazolin in the prevention of prosthetic joint infection.,"INTRODUCTION There is a growing increase in prosthetic joint infection (PJI) incidence due to cephalosporin-resistant bacteria, used in surgical prophylaxis. The replacement of these with glycopeptides has not been shown to improve the results, but they have been shown to improve with their combination. METHODS Comparative study of combination of teicoplanin and cefazolin before arthroplasty surgery against cefazolin alone from a previous control group. RESULTS During the control period, there were 16 PJIs from 585 surgeries, while in the intervention group there were 6 from 579 (incidence 2.7% vs. 1.03%, RR 0.4, P=.04). In control group, 11 of the infections were caused by Gram-positive bacteria versus 4 in the intervention group (1.8% vs. 0.7%, P=.08). CONCLUSIONS The addition of teicoplanin to cefazolin in the prophylaxis of arthroplasty surgery was associated with a reduction in the incidence of PJI, thanks to a decrease in infections caused by Gram-positive bacteria.",2019,"The addition of teicoplanin to cefazolin in the prophylaxis of arthroplasty surgery was associated with a reduction in the incidence of PJI, thanks to a decrease in infections caused by Gram-positive bacteria.",[],"['teicoplanin and cefazolin', 'cefazolin', 'teicoplanin']","['Gram-positive bacteria', 'prosthetic joint infection', 'prosthetic joint infection (PJI) incidence']",[],"[{'cui': 'C0145106', 'cui_str': 'Teicoplanin'}, {'cui': 'C0007546', 'cui_str': 'Cefazolin'}]","[{'cui': 'C0018154', 'cui_str': 'Gram-Positive Bacteria'}, {'cui': 'C0410808', 'cui_str': 'Prosthetic joint infection (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.0413945,"The addition of teicoplanin to cefazolin in the prophylaxis of arthroplasty surgery was associated with a reduction in the incidence of PJI, thanks to a decrease in infections caused by Gram-positive bacteria.","[{'ForeName': 'José María', 'Initials': 'JM', 'LastName': 'Barbero-Allende', 'Affiliation': 'Servicio de Medicina Interna, Hospital Universitario Príncipe de Asturias, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España. Electronic address: j_m_barbero@yahoo.es.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'García-Sánchez', 'Affiliation': 'Servicio de Medicina Interna, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Montero-Ruiz', 'Affiliation': 'Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, Madrid, España.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Vallés-Purroy', 'Affiliation': 'Servicio de Cirugía Ortopédica y Traumatológica, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España.'}, {'ForeName': 'Miguel Ángel', 'Initials': 'MÁ', 'LastName': 'Plasencia-Arriba', 'Affiliation': 'Servicio de Cirugía Ortopédica y Traumatológica, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Sanz-Moreno', 'Affiliation': 'Servicio de Medicina Interna, Hospital Universitario Príncipe de Asturias, Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Alcalá de Henares, Madrid, España.'}]",Enfermedades infecciosas y microbiologia clinica,['10.1016/j.eimc.2018.12.013'] 1035,30791963,Day hospital versus intensive out-patient mentalisation-based treatment for borderline personality disorder: multicentre randomised clinical trial.,"BACKGROUND Two types of mentalisation-based treatment (MBT) have been developed and empirically evaluated for borderline personality disorder (BPD): day hospital MBT (MBT-DH) and intensive out-patient MBT (MBT-IOP). No trial has yet compared their efficacy. AIMS To compare the efficacy of MBT-DH and MBT-IOP 18 months after start of treatment. MBT-DH was hypothesised to be superior to MBT-IOP because of its higher treatment intensity. METHOD In a multicentre randomised controlled trial (Nederlands Trial Register: NTR2292) conducted at three sites in the Netherlands, patients with BPD were randomly assigned to MBT-DH (n = 70) or MBT-IOP (n = 44). The primary outcome was symptom severity (Brief Symptom Inventory). Secondary outcome measures included borderline symptomatology, personality functioning, interpersonal functioning, quality of life and self-harm. Patients were assessed every 6 months from baseline to 18 months after start of treatment. Data were analysed using multilevel modelling based on intention-to-treat principles. RESULTS Significant improvements were found on all outcome measures, with moderate to very large effect sizes for both groups. MBT-DH was not superior to MBT-IOP on the primary outcome measure, but MBT-DH showed a clear tendency towards superiority on secondary outcomes. CONCLUSIONS Although MBT-DH was not superior to MBT-IOP on the primary outcome measure despite its greater treatment intensity, MBT-DH showed a tendency to be more effective on secondary outcomes, particularly in terms of relational functioning. Patients receiving MBT-DH and MBT-IOP, thus, seem to follow different trajectories of change, which may have important implications for clinical decision-making. Longer-term follow-up and cost-effectiveness considerations may ultimately determine the optimal intensity of specialised treatments such as MBT for patients with BPD.",2020,"Although MBT-DH was not superior to MBT-IOP on the primary outcome measure despite its greater treatment intensity, MBT-DH showed a tendency to be more effective on secondary outcomes, particularly in terms of relational functioning.",['patients with BPD'],"['MBT-IOP', 'MBT-DH and MBT-IOP', 'Day hospital versus intensive out-patient mentalisation-based treatment', 'mentalisation-based treatment (MBT', 'MBT-DH']","['borderline symptomatology, personality functioning, interpersonal functioning, quality of life and self-harm', 'symptom severity (Brief Symptom Inventory']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0587438', 'cui_str': 'Day hospital (environment)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0031208', 'cui_str': 'Personality'}, {'cui': 'C0034380'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",,0.201301,"Although MBT-DH was not superior to MBT-IOP on the primary outcome measure despite its greater treatment intensity, MBT-DH showed a tendency to be more effective on secondary outcomes, particularly in terms of relational functioning.","[{'ForeName': 'Maaike L', 'Initials': 'ML', 'LastName': 'Smits', 'Affiliation': 'Health Care Psychologist and PhD Student, de Viersprong and the Viersprong Institute for Studies on Personality Disorders, the Netherlands.'}, {'ForeName': 'Dine J', 'Initials': 'DJ', 'LastName': 'Feenstra', 'Affiliation': 'Clinical Psychologist and Principal Investigator, de Viersprong, the Netherlands.'}, {'ForeName': 'Hester V', 'Initials': 'HV', 'LastName': 'Eeren', 'Affiliation': 'PhD Student, de Viersprong, the Netherlands.'}, {'ForeName': 'Dawn L', 'Initials': 'DL', 'LastName': 'Bales', 'Affiliation': 'Clinical Psychologist and Director Expertcentre MBT-Netherlands, de Viersprong; and Expertcentre MBT-Netherlands, the Netherlands.'}, {'ForeName': 'Elisabeth M P', 'Initials': 'EMP', 'LastName': 'Laurenssen', 'Affiliation': 'PhD Student, de Viersprong, the Netherlands.'}, {'ForeName': 'Matthijs', 'Initials': 'M', 'LastName': 'Blankers', 'Affiliation': 'Senior Researcher, Netherlands Psychoanalytic Institute, the Netherlands.'}, {'ForeName': 'Mirjam B J', 'Initials': 'MBJ', 'LastName': 'Soons', 'Affiliation': 'Psychiatrist and Clinical Psychologist, Netherlands Psychoanalytic Institute, the Netherlands.'}, {'ForeName': 'Jack J M', 'Initials': 'JJM', 'LastName': 'Dekker', 'Affiliation': 'Professor, Department of Clinical Psychology, dr. Vrije University Amsterdam; and Netherlands Psychoanalytic Institute, the Netherlands.'}, {'ForeName': 'Zwaan', 'Initials': 'Z', 'LastName': 'Lucas', 'Affiliation': 'Clinical Psychologist and Psychotherapist, Lentis, the Netherlands.'}, {'ForeName': 'Roel', 'Initials': 'R', 'LastName': 'Verheul', 'Affiliation': 'de Viersprong, the Netherlands.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Luyten', 'Affiliation': 'Professor, Doctor, Faculty of Psychology and Educational Sciences, University of Leuven, Belgium; and Research Department of Clinical, Educational and Health Psychology, University College London, UK.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2019.9'] 1036,31702409,Is there an app for that? A cluster randomised controlled trial of a mobile app-based mental health intervention.,"Demand for the use of mobile apps in mental health interventions has grown in recent years, particularly among adolescents who experience elevated levels of distress. However, there is a scarcity of evidence for the effectiveness of these tools within this population. The aim of this study was to test the effectiveness of CopeSmart, a mental health mobile app, using a multicentre cluster randomised controlled trial design. Participants were 15-18-years-olds (N = 560) recruited from 10 schools randomly assigned to an intervention or control condition. Intervention participants used the app over a 4-week period. Multi-level modelling analyses revealed no significant changes in the intervention group from pre-test to post-test, when compared to the control group, in terms of emotional distress, well-being, emotional self-awareness or coping strategies. Findings suggest that a 4-week app-based intervention may not be enough to elicit intra-personal changes in mental health outcomes in a general adolescent population.",2020,"Multi-level modelling analyses revealed no significant changes in the intervention group from pre-test to post-test, when compared to the control group, in terms of emotional distress, well-being, emotional self-awareness or coping strategies.","['general adolescent population', 'Participants were 15-18-years-olds (N = 560) recruited from 10 schools randomly assigned to an']","['intervention or control condition', 'mobile app-based mental health intervention']","['emotional distress, well-being, emotional self-awareness or coping strategies']","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C3146223', 'cui_str': 'Awareness of self (observable entity)'}]",560.0,0.17612,"Multi-level modelling analyses revealed no significant changes in the intervention group from pre-test to post-test, when compared to the control group, in terms of emotional distress, well-being, emotional self-awareness or coping strategies.","[{'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kenny', 'Affiliation': 'University College Dublin, Ireland.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Fitzgerald', 'Affiliation': 'University College Dublin, Ireland.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Segurado', 'Affiliation': 'University College Dublin, Ireland.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Dooley', 'Affiliation': 'University College Dublin, Ireland.'}]",Health informatics journal,['10.1177/1460458219884195'] 1037,29611171,Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial.,"BACKGROUND Renal denervation (RDN) is as an effective treatment for heart failure (HF), but its effects on cardiac function of patients with HF are not well documented. Here, the aim was to investigate RDN's effect on patients with chronic systolic HF, by conducting a single-center, prospective, randomized, and controlled study. METHODS Sixty patients with chronic systolic HF were randomly assigned to the RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment, respectively. All patients performed a 6-minute walk test, echocardiography, blood pressure measurement, and biochemical test, at both baseline and in a 6-month follow up. RESULTS Over 6-month follow up, patients in RDN group showed a decrease in N-terminal pro-B-type natriuretic peptide (440.1 ± 226.5 pg/mL vs. 790.8 ± 287.0 pg/mL, p < 0.001, Cohen's d = 1.14), an increase in left ventricular ejection fraction (39.1 ± 7.3% vs. 35.6 ± 3.3%, p = 0.017, Cohen's d = 0.61), improved New York Heart Association class assessment (p = 0.01, Cohen's d = 0.66), and decreased blood pressures (p < 0.001, Cohen's d = 0.91), without reporting hypotension and syncope amaurosis. No significant between-group difference was observed for glomerular filtration rate and heart rate. CONCLUSIONS Renal denervation which effectively and safely improves patient's cardiac function as well as exercise tolerance, could be considered as an effective treatment for chronic systolic HF.",2019,"No significant between-group difference was observed for glomerular filtration rate and heart rate. ","['Sixty patients with chronic systolic HF', 'patients with chronic systolic heart failure', 'patients with heart failure (HF', 'patients with chronic systolic HF, by conducting a single-center']","['Percutaneous renal artery denervation', 'RDN or control groups, receiving percutaneous catheter-based RDN with radiofrequency ablation and drug treatment respectively']","['blood pressures', 'NT-proBNP (440.1 ±', 'left ventricular ejection fraction', '6-minute walk test, echocardiography, blood pressure measurement, and biochemical test', 'glomerular filtration rate and heart rate', 'improved NYHA class assessment']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1135194', 'cui_str': 'Chronic systolic heart failure'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C3544270', 'cui_str': 'Renal artery denervation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1963813', 'cui_str': 'NT-proBNP'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0430515', 'cui_str': '6-Minute Walk Test'}, {'cui': 'C0013516', 'cui_str': 'Transthoracic Echocardiography'}, {'cui': 'C0005824', 'cui_str': 'Blood pressure taking (procedure)'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0017654', 'cui_str': 'Glomerular Filtration Rate'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",60.0,0.0970672,"No significant between-group difference was observed for glomerular filtration rate and heart rate. ","[{'ForeName': 'Jun-Qing', 'Initials': 'JQ', 'LastName': 'Gao', 'Affiliation': ""Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yang', 'Affiliation': ""Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.""}, {'ForeName': 'Zong-Jun', 'Initials': 'ZJ', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China. lzj160507@163.com.""}]",Cardiology journal,['10.5603/CJ.a2018.0028'] 1038,31494019,Evaluation of a technology assisted physical activity intervention among hospitalised patients: A randomised study.,"BACKGROUND Physical inactivity is common during hospitalisation and poses a threat to functional capacity and independency in the elderly. AIM We aimed to assess the effect of physical activity measurements with visual feedback about time spent in various activities on the average daily time spent out of bed during hospitalisation. METHODS We recorded physical activity during hospitalisation by accelerometers and compared the effect of the visual feedback (intervention) with no feedback (control) on time spent out of bed. Patients admitted to the pulmonary ward were invited and assigned to intervention with feedback or control with no feedback in 6 alternating waves of approximately 18 patients each. The order of feedback/no feedback was randomised at the outset of the study. The visual feedback intervention group was provided with visual feedback of the daily time spent in bed, sitting, standing, and walking. The control group did not receive feedback. RESULTS 93 patients completed the study with a median length of stay of 5 days. Across all patients there were no statistically significant group differences in daily time out of bed; however, patients with independent mobility spent 51 minutes (95% CI 0 to 102; P = .049) more out of bed when provided with visual feedback compared to no feedback. CONCLUSIONS A simple technology assisted physical activity intervention with visual feedback to encourage mobility was not effective at increasing time spent out of bed among hospitalised patients. With feedback, a subgroup of patients with independent walking abilities increased time out of bed and may benefit from this type of intervention. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01945749.",2019,A simple technology assisted physical activity intervention with visual feedback to encourage mobility was not effective at increasing time spent out of bed among hospitalised patients.,"['hospitalised patients', 'Patients admitted to the pulmonary ward', '93 patients completed the study with a median length of stay of 5 days']","['visual feedback (intervention) with no feedback (control', 'visual feedback intervention', 'technology assisted physical activity intervention', 'intervention with feedback or control with no feedback']",['daily time out of bed'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0004916', 'cui_str': 'Beds'}]",93.0,0.0776366,A simple technology assisted physical activity intervention with visual feedback to encourage mobility was not effective at increasing time spent out of bed among hospitalised patients.,"[{'ForeName': 'Christian Have', 'Initials': 'CH', 'LastName': 'Dall', 'Affiliation': 'Department of Physical and Occupational Therapy, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark; Department of Cardiology, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark; The Parker Institute, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark. Electronic address: christian.have.dall@regionh.dk.'}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Andersen', 'Affiliation': 'Department of Physical and Occupational Therapy, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark.'}, {'ForeName': 'Tina Myung', 'Initials': 'TM', 'LastName': 'Povlsen', 'Affiliation': 'VihTek, Rigshospitalet, Valdemar Hansens Vej 2, 2600 Glostrup, Denmark.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Henriksen', 'Affiliation': 'Department of Physical and Occupational Therapy, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark; The Parker Institute, Bispebjerg Frederiksberg University Hospital, Copenhagen and University of Copenhagen, Denmark.'}]",European journal of internal medicine,['10.1016/j.ejim.2019.08.019'] 1039,31503245,[Clinical study of efficacy and safety of Aducil in patients with chronic lower limb ischaemia].,"AIM The study was aimed at assessing efficacy and safety of treatment with Aducil® (cilostazol) compared with Trental® 400 in patients with moderate-to-severe intermittent claudication due to peripheral atherosclerosis. PATIENTS AND METHODS The study included a total of one hundred and forty-five 36-to-75-year-old patients. The participants were distributed into 2 groups according to the inclusion/exclusion criteria in a 2 to 1 proportion: patients in group 1 received Aducil® 100 mg BID, in group 2 - Trental® 400 TID for 12 weeks. 142 subjects completed the protocol. RESULTS Analysis of the effectiveness of treatment according to the primary criterion showed a better effectiveness of Aducil® as compared with Trental® 400. Subjects who received Aducil® had a higher increase in the absolute maximum walking distance after 12 weeks of treatment as compared with those taking Trental® 400: 126±110 m versus 45±39 m, respectively (р<0.001). Subjects who received Aducil® had a statistically significant improvement in quality of life parameters such as physical and mental health components according to the SF-36 questionnaire after 12 weeks of treatment (р≤0.01). Subjects in Aducil® group had better quality of life with an increase from 34 to 40 points according to the physical component score, while patients in Trental® 400 group demonstrated minor positive changes (from 35 to 37 points); mean mental component score increased from 45 to 48 points in Aducil® group as compared with an increase from 45 to 47 points in Trental® 400 group. While self-reported physical health status was similar between the groups at baseline, subjects in Aducil® group reported better physical functioning after treatment (р=0.016). Two adverse events were registered in two subjects in Aducil® group. CONCLUSION Analysis of the study endpoints demonstrated that Aducil® had better treatment effectiveness in patients with chronic lower limb ischemia stage IIB according to the classification of A.V. Pokrovsky-Fontaine as compared with Trental® 400, while the safety profile and drug tolerance were similar between the two.",2019,Subjects who received Aducil® had a statistically significant improvement in quality of life parameters such as physical and mental health components according to the SF-36 questionnaire after 12 weeks of treatment (р≤0.01).,"['142 subjects completed the protocol', 'total of one hundred and forty-five 36-to-75-year-old patients', 'patients with chronic lower limb ischaemia', 'patients with moderate-to-severe intermittent claudication due to peripheral atherosclerosis', 'patients with chronic lower limb ischemia stage IIB']","['Aducil® (cilostazol', 'Aducil', 'Trental® 400', 'Aducil®', 'Aducil® 100 mg BID']","['safety profile and drug tolerance', 'quality of life', 'physical health status', 'efficacy and safety', 'physical functioning', 'absolute maximum walking distance', 'mean mental component score', 'quality of life parameters such as physical and mental health components']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0340565', 'cui_str': 'Lower limb ischemia (disorder)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0021775', 'cui_str': 'Intermittent Claudication'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0441769', 'cui_str': 'Stage 2B (qualifier value)'}]","[{'cui': 'C0055729', 'cui_str': 'cilostazol'}, {'cui': 'C0699487', 'cui_str': 'Trental'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0048106', 'cui_str': 'BIDS'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0013220', 'cui_str': 'Drug Tolerance'}, {'cui': 'C0034380'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",400.0,0.0391438,Subjects who received Aducil® had a statistically significant improvement in quality of life parameters such as physical and mental health components according to the SF-36 questionnaire after 12 weeks of treatment (р≤0.01).,"[{'ForeName': 'I A', 'Initials': 'IA', 'LastName': 'Suchkov', 'Affiliation': 'Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Russia.'}, {'ForeName': 'R E', 'Initials': 'RE', 'LastName': 'Kalinin', 'Affiliation': 'Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Russia.'}, {'ForeName': 'R U', 'Initials': 'RU', 'LastName': 'Gadzhimuradov', 'Affiliation': 'Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia.'}, {'ForeName': 'R N', 'Initials': 'RN', 'LastName': ""Lar'kov"", 'Affiliation': 'Moscow Regional Research and Clinical Institute named after M.F. Vladimirsky, Moscow, Russia.'}, {'ForeName': 'I G', 'Initials': 'IG', 'LastName': 'Uchkin', 'Affiliation': ""N.A. Semashko Central Clinical Hospital #2 of the Open Joint Stock Company 'Russian Railways', Moscow, Russia.""}, {'ForeName': 'A V', 'Initials': 'AV', 'LastName': 'Chupin', 'Affiliation': 'Federal Research and Clinical Center of Federal Medical Biological Agency, Moscow, Russia.'}, {'ForeName': 'P Iu', 'Initials': 'PI', 'LastName': 'Parshin', 'Affiliation': 'Federal Research and Clinical Center of Federal Medical Biological Agency, Moscow, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Kamaev', 'Affiliation': 'Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Russia.'}, {'ForeName': 'E V', 'Initials': 'EV', 'LastName': 'Porsheneva', 'Affiliation': 'Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGIO2019305'] 1040,31503258,[Immediate results of three methods of surgical myocardial revascularization in multivessel lesion of the coronary bed].,"INTRODUCTION Percutaneous coronary intervention (PTI) and coronary artery bypass grafting (CABG) are currently the most commonly used techniques of myocardial revascularization. However, each of the methods has its own advantages and disadvantages. The creation of hybrid coronary revascularization (HCR) was based on an attempt to combine the benefits of CABG and PTI. AIM The study was aimed at assessing the immediate results of three methods of surgical myocardial revascularization in patients with multivessel lesions of the coronary bed in stable ischaemic heart disease. PATIENTS AND METHODS The study enrolled a total of 155 patients randomized into three groups of myocardial revascularization: HCR, CABG and PTI. In the HCR group, the first stage consisted in minimally invasive myocardial revascularization with the anterior descending artery (ADA) followed by PTI (within 1-3 days) with implantation of drug-eluting second-generation stents Xience to other coronary vessels. In the CABG and PTI groups we performed CABG and PTI, respectively, using the Xience stents. In all three groups we assessed the procedural success, frequency of major adverse cardiovascular events and bleeding. RESULTS Full myocardial revascularization was achieved in all three groups in more than 90% of cases. No statistically significant differences in either the procedural success rate or frequency of major adverse cardiovascular events between the CABG, PTI and HCR were revealed. The PTI group was characterized by the lowest frequency of bleeding, need for rehabilitation, and length of hospital stay. CONCLUSION Hybrid revascularization with the use of minimally invasive direct myocardial revascularization with the ADA followed by PTI with second-generation drug-eluting stents to other coronary arteries is a method of choice in treatment of patients with multivessel lesions of coronary arteries.",2019,"No statistically significant differences in either the procedural success rate or frequency of major adverse cardiovascular events between the CABG, PTI and HCR were revealed.","['patients with multivessel lesions of coronary arteries', '155 patients randomized into three groups of', 'patients with multivessel lesions of the coronary bed in stable ischaemic heart disease']","['surgical myocardial revascularization', 'Percutaneous coronary intervention (PTI) and coronary artery bypass grafting (CABG', 'myocardial revascularization: HCR, CABG and PTI', 'hybrid coronary revascularization (HCR']","['Full myocardial revascularization', 'procedural success rate or frequency of major adverse cardiovascular events', 'procedural success, frequency of major adverse cardiovascular events and bleeding', 'lowest frequency of bleeding, need for rehabilitation, and length of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0027056', 'cui_str': 'Myocardial Revascularization'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C0391072', 'cui_str': 'platinum (bis(acetato))(ethylenediamine) diiodide'}, {'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}]","[{'cui': 'C0027056', 'cui_str': 'Myocardial Revascularization'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",155.0,0.0184364,"No statistically significant differences in either the procedural success rate or frequency of major adverse cardiovascular events between the CABG, PTI and HCR were revealed.","[{'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Shilov', 'Affiliation': 'Kemerovo Regional Clinical Cardiological Dispensary named after Academician L.S. Barbarash, Kemerovo, Russia.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Kochergin', 'Affiliation': 'Scientific Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia.'}, {'ForeName': 'V I', 'Initials': 'VI', 'LastName': 'Ganyukov', 'Affiliation': 'Scientific Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Kozyrin', 'Affiliation': 'Scientific Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia.'}, {'ForeName': 'O L', 'Initials': 'OL', 'LastName': 'Barbarash', 'Affiliation': 'Scientific Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo, Russia.'}]",Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery,['10.33529/ANGI02019314'] 1041,30741744,"Comparative effects of high-dose atorvastatin versus rosuvastatin on lipid parameters, oxidized low-density lipoprotein, and proprotein convertase subtilisin kexin 9 in acute coronary syndrome.","AIM Current guidelines recommend administration of high-dose statins in acute coronary syndrome (ACS). It has been reported that statins upregulate proprotein convertase subtilisin kexin 9 (PCSK9) mRNA expression and increase circulating PCSK9 levels. We aimed to compare the effects of high-dose atorvastatin and rosuvastatin on serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels in statin-naive patients with ACS. PATIENTS AND METHODS One hundred and six patients with ACS were enrolled in this study. The patients were assigned randomly to receive atorvastatin (80 mg/day) or rosuvastatin (40 mg/day) by using a ratio of 1 : 1 in randomization. The levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, LDL-cholesterol, oxidized-LDL, and PCSK9 were compared between groups after a 4-week treatment. RESULTS Our study population included 53 patients in the atorvastatin group (age: 58.13±11.30 years, 11.32% female) and 53 patients in the rosuvastatin group (age: 59.08±12.44 years, 15.09% female). In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment. High-dose atorvastatin and rosuvastatin induced similar decreases in LDL-cholesterol, oxidized-LDL, and triglyceride levels and similarly increased in high-density lipoprotein cholesterol and PCSK9 levels (P>0.05). CONCLUSION We showed that atorvastatin and rosuvastatin treatment regimens have comparable effects on lipid parameters and PCSK9 levels in ACS patients.",2019,"In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment.","['ACS patients', 'acute coronary syndrome', '53 patients in the atorvastatin group (age: 58.13±11.30 years, 11.32% female) and 53 patients in the rosuvastatin group (age: 59.08±12.44 years, 15.09% female', 'acute coronary syndrome (ACS', 'statin-naive patients with ACS', 'One hundred and six patients with ACS']","['high-dose statins', 'atorvastatin and rosuvastatin', 'atorvastatin versus rosuvastatin', 'atorvastatin', 'rosuvastatin']","['LDL-cholesterol, oxidized-LDL, and triglyceride levels', 'lipid parameters, oxidized-LDL, and PCSK9 values', 'lipid parameters and PCSK9 levels', 'levels of total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol, LDL-cholesterol, oxidized-LDL, and PCSK9', 'high-density lipoprotein cholesterol and PCSK9 levels', 'serum oxidized low-density lipoprotein (oxidized-LDL) and PCSK9 levels']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0286651', 'cui_str': 'atorvastatin'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0428475', 'cui_str': 'Triglyceride level - finding'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023822', 'cui_str': 'High Density Lipoprotein Cholesterol'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",106.0,0.0265308,"In both groups, lipid parameters, oxidized-LDL, and PCSK9 values changed significantly according to the baseline following treatment.","[{'ForeName': 'Bulent B', 'Initials': 'BB', 'LastName': 'Altunkeser', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Abdullah', 'Initials': 'A', 'LastName': 'Tuncez', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Bahadir', 'Initials': 'B', 'LastName': 'Ozturk', 'Affiliation': 'Biochemistry, Faculty of Medicine, Selcuk University, Konya, Turkey.'}, {'ForeName': 'Huseyin', 'Initials': 'H', 'LastName': 'Tezcan', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Muhammet S', 'Initials': 'MS', 'LastName': 'Ates', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Canan', 'Initials': 'C', 'LastName': 'Yilmaz', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Muhammed U', 'Initials': 'MU', 'LastName': 'Yalcin', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Nazif', 'Initials': 'N', 'LastName': 'Aygul', 'Affiliation': 'Departments of Cardiology.'}, {'ForeName': 'Kenan', 'Initials': 'K', 'LastName': 'Demir', 'Affiliation': 'Departments of Cardiology.'}]",Coronary artery disease,['10.1097/MCA.0000000000000715'] 1042,30826468,The effect of content and tone of maternal evaluative feedback on self-cognitions and affect in young children.,"Feedback that young children receive from others can affect their emotions and emerging self-views. The current experiment tested the effect of negative content (criticism) and negative tone (hostile) of the feedback on children's affect, self-evaluations, and attributions. We also explored whether maternal history of depression and children's temperament moderated these relations. Participants were 152 mothers and children (48% girls) aged 4 and 5 years (M = 61.6 months, SD = 6.83). The task involved three scenarios enacted by dolls; a child doll made something (e.g., picture, house, numbers) that had a mistake (e.g., no windows on the house) and proudly showed it to the mother doll, who then gave feedback (standardized, audio recorded) to the child. Children were randomized to one of four maternal feedback conditions: negative or neutral content in either a negative or neutral tone. Negative content (criticism) produced significantly more negative affect and lower self-evaluations than neutral content. When the tone of the feedback was hostile, children of mothers who had been depressed during the children's lifetimes were significantly more likely to make internal attributions for mistakes than children of nondepressed mothers. In addition, among children with low temperamental negative affectivity, in the presence of negative tone, negative content significantly predicted more internal attributions for the errors. Findings are discussed in terms of understanding the role of evaluative feedback in children's emerging social cognitions and affect.",2019,Negative content (criticism) produced significantly more negative affect and lower self-evaluations than neutral content.,"['young children', 'Participants were 152 mothers and children (48% girls) aged 4 and 5\u202fyears (M\u202f=\u202f61.6\u202fmonths, SD\u202f=\u202f6.83']","['maternal evaluative feedback', 'negative content (criticism) and negative tone (hostile', 'maternal feedback conditions: negative or neutral content in either a negative or neutral tone']",['internal attributions'],"[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}]",152.0,0.0149701,Negative content (criticism) produced significantly more negative affect and lower self-evaluations than neutral content.,"[{'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Garber', 'Affiliation': 'Department of Psychology and Human Development, Vanderbilt University, Nashville, TN 37203, USA. Electronic address: Judy.Garber@Vanderbilt.edu.'}, {'ForeName': 'Sherryl H', 'Initials': 'SH', 'LastName': 'Goodman', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA 30322, USA.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'Brunwasser', 'Affiliation': 'School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Frankel', 'Affiliation': 'Department of Psychiatry, Columbia University, New York, NY 10032, USA.'}, {'ForeName': 'Catherine G', 'Initials': 'CG', 'LastName': 'Herrington', 'Affiliation': 'School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2019.01.017'] 1043,31764165,Parents Reliably Identify Pain Dismissal by Pediatric Providers.,"OBJECTIVES Approximately 40% of children and adolescents with chronic pain report at least 1 dismissal experience, citing medical providers and parents as the primary and most distressing dismissers. Previous research indicates sex differences in pain dismissal experience and observer pain perception. This study examined parental reactions to dismissive provider-child scenarios and the influence of provider and patient sex on perceptions. METHODS Community parents (N=326) completed an online survey. Parents were randomized to listen to 1 of 8 vignettes of a provider-child chronic pain scenario. Vignettes varied by type of scenario (appropriate vs. dismissive)×provider sex×patient sex. RESULTS Overall, parents rated the dismissive scenario more negatively. There was a significant interaction between provider sex and scenario regarding likelihood to bring their own child to this provider and a significant 3-way interaction regarding provider belief of the pain complaint. When asked how they would feel if this was their own child, parents who heard the dismissive scenario reported more negative reactions. When asked what they would say to the provider, parents in the dismissive condition were more likely to defend their child and request a second opinion. DISCUSSION Parents consistently identified the dismissive language in a child and provider scenario. Female providers and sex-matched dyads seem to be more polarizing in terms of likelihood to bring their child to the provider and belief of pain, respectively. Providers within these groups may need to be especially cautious with their language when responding to pediatric chronic pain complaints.",2020,"When asked what they would say to the provider, parents in the dismissive condition were more likely to defend their child and request a second opinion. ","['Community parents (N=326) completed an online survey', 'children and adolescents with chronic pain report at least one dismissal experience, citing medical providers and parents as the primary and most distressing dismissers']",[],['pain dismissal experience and observer pain perception'],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}]",[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain Perception'}]",,0.0296932,"When asked what they would say to the provider, parents in the dismissive condition were more likely to defend their child and request a second opinion. ","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Igler', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Lang', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Balistreri', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Sejkora', 'Affiliation': ""Nationwide Children's Hospital, Columbus, OH.""}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Drendel', 'Affiliation': 'Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'William H', 'Initials': 'WH', 'LastName': 'Davies', 'Affiliation': 'Department of Psychology, University of Wisconsin-Milwaukee.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000776'] 1044,31672143,A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria.,"BACKGROUND Acute seizures are common in pediatric cerebral malaria (CM), but usual care with phenobarbital risks respiratory suppression. We undertook studies of enteral levetiracetam (eLVT) to evaluate pharmacokinetics (PK), safety and efficacy including an open-label, randomized controlled trial (RCT) comparing eLVT to phenobarbital. METHODS Children 24-83 months old with CM were enrolled in an eLVT dose-finding study starting with standard dose (40 mg/kg load, then 30 mg/kg Q12 hours) titrated upward until seizure freedom was attained in 75% of subjects. The RCT that followed randomized children to eLVT vs. phenobarbital for acute seizures and compared the groups on minutes with seizures based upon continuous electroencephalogram. Due to safety concerns, midway through the study children allocated to phenobarbital received the drug only if they continued to have seizures (either clinically or electrographically) after benzodiazepine treatment. Secondary outcomes were treatment failure requiring cross over, coma duration and neurologic sequelae at discharge. PK and safety assessments were also undertaken. RESULTS Among 30 comatose CM children, eLVT was rapidly absorbed and well-tolerated. eLVT clearance was lower in patients with higher admission serum creatinine (SCr), but overall PK parameters were similar to prior pediatric PK studies. Within 4 h of the first dose, 90% reached therapeutic levels (> 20 μg/mL) and all were above 6 μg/mL. 7/7 children achieved seizure freedom on the initial eLVT dose. Comparing 23 eLVT to 21 phenobarbital patients among whom 15/21 received phenobarbital, no differences were seen for minutes with seizure, seizure freedom, coma duration, neurologic sequelae or death, but eLVT was safer (p = 0.019). Phenobarbital was discontinued in 3/15 due to respiratory side effects. CONCLUSION Enteral LVT offers an affordable option for seizure control in pediatric CM and is safer than phenobarbital. TRIAL REGISTRATION NCT01660672 . NCT01982812 .",2019,"eLVT clearance was lower in patients with higher admission serum creatinine (SCr), but overall PK parameters were similar to prior pediatric PK studies.","['Children 24-83\u2009months old with CM were enrolled in an', '30 comatose CM children', 'acute seizures in pediatric cerebral malaria']","['Phenobarbital', 'benzodiazepine', 'Enteral LVT', 'eLVT vs. phenobarbital', 'eLVT', 'enteral levetiracetam (eLVT', 'enteral Levetiracetam']","['therapeutic levels', 'eLVT clearance', 'minutes with seizure, seizure freedom, coma duration, neurologic sequelae or death', 'treatment failure requiring cross over, coma duration and neurologic sequelae at discharge', 'pharmacokinetics (PK), safety and efficacy', 'seizure freedom']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0009421', 'cui_str': 'Comatose'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0024534', 'cui_str': 'Malaria, Cerebral'}]","[{'cui': 'C0031412', 'cui_str': 'Phenobarbital'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C1304890', 'cui_str': 'Enteral (qualifier value)'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0009421', 'cui_str': 'Comatose'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0243088', 'cui_str': 'sequelae'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0162643'}, {'cui': 'C0010366', 'cui_str': 'Crossing Over, Genetic'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.178529,"eLVT clearance was lower in patients with higher admission serum creatinine (SCr), but overall PK parameters were similar to prior pediatric PK studies.","[{'ForeName': 'Gretchen L', 'Initials': 'GL', 'LastName': 'Birbeck', 'Affiliation': 'Department of Neurology, University of Rochester, 265 Crittenden Blvd, Rochester, NY, 14642, USA. gretchen_birbeck@urmc.rochester.edu.'}, {'ForeName': 'Susan T', 'Initials': 'ST', 'LastName': 'Herman', 'Affiliation': 'Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.'}, {'ForeName': 'Edmund V', 'Initials': 'EV', 'LastName': 'Capparelli', 'Affiliation': 'University of California San Diego, Center for Research in Paediatric and Developmental Pharmacology, La Jolla, CA, USA.'}, {'ForeName': 'Fraction K', 'Initials': 'FK', 'LastName': 'Dzinjalamala', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Samah G', 'Initials': 'SG', 'LastName': 'Abdel Baki', 'Affiliation': 'Bio-Signal Group Co., Acton, MA, USA.'}, {'ForeName': 'Macpherson', 'Initials': 'M', 'LastName': 'Mallewa', 'Affiliation': 'Department of Paediatrics, Queen Elizabeth Central Hospital, Blantyre, Malawi.'}, {'ForeName': 'Neema M', 'Initials': 'NM', 'LastName': 'Toto', 'Affiliation': 'Malawi-Liverpool-Wellcome Trust Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Douglas G', 'Initials': 'DG', 'LastName': 'Postels', 'Affiliation': ""Department of Neurology, Children's National Medical Center, Washington, DC, USA.""}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Gardiner', 'Affiliation': 'Department of Epidemiology & Biostatistics, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'Terrie E', 'Initials': 'TE', 'LastName': 'Taylor', 'Affiliation': 'Blantyre Malaria Project, Blantyre, Malawi.'}, {'ForeName': 'Karl B', 'Initials': 'KB', 'LastName': 'Seydel', 'Affiliation': 'Blantyre Malaria Project, Blantyre, Malawi.'}]",BMC pediatrics,['10.1186/s12887-019-1766-2'] 1045,30799266,The James A. Rand Young Investigator's Award: Large Opioid Prescriptions Are Unnecessary After Total Joint Arthroplasty: A Randomized Controlled Trial.,"BACKGROUND The purpose of this randomized controlled trial is to determine whether the quantity of opioid pills prescribed at discharge is associated with the number of opioid pills consumed or unused by patients after primary hip and knee arthroplasty within 30 days after discharge. METHODS A total of 304 opioid-naïve patients were randomized to receive either 30 or 90 5-mg oxycodone immediate-release (OxyIR) pills at discharge. Daily opioid consumption, number of unused pills, and pain scores were calculated for 30 days with a patient-completed medication diary. Statistical analysis involved t-test, rank-sum, chi-squared tests, and multiple linear regression with alpha = 0.05. RESULTS Of the 304 patients randomized, 161 patients were randomized to receive 30 pills and 143 to receive 90. In the first 30 days after discharge, the median number of unused pills was 15 in the 30 group vs 73 in the 90 group (P < .001). Within 90 days of discharge, 26.7% of the 30 group and 10.5% of the 90 group requested a refill (P < .001), leading to a mean of 777.1 ± 414.2 morphine equivalents vs 1089.7 ± 536.4 prescribed (P < .0001). There was no difference between groups in mean morphine equivalents consumed. Regression analysis demonstrated that being prescribed 90 OxyIR pills was independently associated with taking more OxyIR pills (P = .028). There was no difference in pain scores within the first 30 days and in patient-reported outcome scores at 6 weeks postoperatively. CONCLUSION Prescribing fewer OxyIR pills is associated with a significant reduction in unused opioid pills and decreased opioid consumption with no increase in pain scores and no difference in patient-reported outcomes. LEVEL OF EVIDENCE Level I. Randomized controlled trial.",2019,"There was no difference in pain scores within the first 30 days and in patient-reported outcome scores at 6 weeks postoperatively. ","['304 opioid-naïve patients', 'After Total Joint Arthroplasty', '304 patients randomized', '161 patients were randomized to receive 30 pills and 143 to receive 90', 'patients after primary hip and knee arthroplasty within 30 days after discharge']",['oxycodone immediate-release (OxyIR) pills at discharge'],"['opioid consumption', 'median number of unused pills', 'Daily opioid consumption, number of unused pills, and pain scores', 'pain scores']","[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C4517573', 'cui_str': 'One hundred and forty-three'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]","[{'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}]","[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0994475', 'cui_str': 'Pill (basic dose form)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",304.0,0.519344,"There was no difference in pain scores within the first 30 days and in patient-reported outcome scores at 6 weeks postoperatively. ","[{'ForeName': 'Charles P', 'Initials': 'CP', 'LastName': 'Hannon', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Tyler E', 'Initials': 'TE', 'LastName': 'Calkins', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Jefferson', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Culvern', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Darrith', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Nam', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Tad L', 'Initials': 'TL', 'LastName': 'Gerlinger', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Asokumar', 'Initials': 'A', 'LastName': 'Buvanendran', 'Affiliation': 'Department of Anesthesiology, Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Craig J', 'Initials': 'CJ', 'LastName': 'Della Valle', 'Affiliation': 'Adult Reconstruction Division, Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.'}]",The Journal of arthroplasty,['10.1016/j.arth.2019.01.065'] 1046,30864000,The effects of early schema acquisition on mathematical problem solving.,"The current paper explores the effects of providing people with schema training at the outset of learning (compared to at later stages) on mathematical word problems modeled after problems from the Graduate Record Examination. Additionally, the ratio of worked examples to problem-solving practice was manipulated. Participants were randomly assigned to one of four conditions and were tested on near and far transfer problems. Participants provided schema training at the outset of learning outperformed those provided schema training after problem-solving practice, particularly on far transfer problems. Likewise, participants provided with a higher ratio of worked examples to problem-solving practice demonstrated better performance during testing than those provided with more problem-solving practice and fewer worked examples. These findings extend the worked example effect to far transfer problems and suggest that providing schema training prior to learning solution strategies may be effective in improving mathematical problem solving.",2020,"Participants provided schema training at the outset of learning outperformed those provided schema training after problem-solving practice, particularly on far transfer problems.",[],['schema training at the outset of learning outperformed those provided schema training'],[],[],"[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]",[],,0.0238118,"Participants provided schema training at the outset of learning outperformed those provided schema training after problem-solving practice, particularly on far transfer problems.","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Corral', 'Affiliation': 'Department of Psychology, Iowa State University, W112 Lagomarcino Hall 901 Stange Rd, Ames, IA, 50011, USA. dcorral@iastate.edu.'}, {'ForeName': 'Jill L', 'Initials': 'JL', 'LastName': 'Quilici', 'Affiliation': 'Department of Psychology, California State University Northridge, 18111 Nordhoff St., Northridge, CA, 91330-8255, USA.'}, {'ForeName': 'Abraham M', 'Initials': 'AM', 'LastName': 'Rutchick', 'Affiliation': 'Department of Psychology, California State University Northridge, 18111 Nordhoff St., Northridge, CA, 91330-8255, USA.'}]",Psychological research,['10.1007/s00426-019-01164-8'] 1047,30284018,Differential effect of concomitant antidiabetic agents on carotid atherosclerosis: a subgroup analysis of the PROLOGUE study.,"Accumulated evidence shows that some antidiabetic agents attenuate the progression of carotid atherosclerosis assessed as intima-media thickness (IMT). Although some studies have demonstrated an inhibitory effect of dipeptidyl peptidase-4 inhibitors on carotid IMT progression, in the PROLOGUE study sitagliptin failed to slow progression relative to conventional therapy for 24 months. We hypothesized that differences in the concomitant antidiabetic agents between the groups have influenced the progression of carotid IMT. We performed a post hoc analysis of the PROLOGUE study using subgroups stratified by concomitant antidiabetic agents. Although no subgroup with any combination of agents in the overall patients showed a significant difference between sitagliptin group and conventional therapy group in the changes from baseline in mean common carotid artery (CCA)-IMT at 24 months, a significant attenuation of mean CCA-IMT progression was observed in the sitagliptin group relative to conventional therapy group only in three combination subgroups aged < 70 years, namely no thiazolidinedione; no thiazolidinedione or biguanide; and no thiazolidinedione, biguanide or α-glucosidase inhibitor, even after adjustment for multiple confounding factors. In the three subgroups, no significant difference between sitagliptin group and conventional therapy group in the changes from baseline in HbA1c at 24 months was detected. Our data suggest that some concomitant agents, whose prescription frequencies were increased in the conventional therapy group, may have masked the inhibitory effect of sitagliptin on carotid IMT progression in the PROLOGUE study.",2019,"In the three subgroups, no significant difference between sitagliptin group and conventional therapy group in the changes from baseline in HbA1c at 24 months was detected.",[],['concomitant antidiabetic agents'],"['carotid IMT progression', 'carotid atherosclerosis', 'mean CCA-IMT progression']",[],"[{'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0935929', 'cui_str': 'Antidiabetics'}]","[{'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0577631', 'cui_str': 'Carotid Atherosclerosis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0274855,"In the three subgroups, no significant difference between sitagliptin group and conventional therapy group in the changes from baseline in HbA1c at 24 months was detected.","[{'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Tanaka', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan. tanakaa2@cc.saga-u.ac.jp.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Kawaguchi', 'Affiliation': 'Clinical Research Center, Saga University, Saga, Japan.'}, {'ForeName': 'Jun-Ichi', 'Initials': 'JI', 'LastName': 'Oyama', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Ishizu', 'Affiliation': 'Department of Clinical Laboratory Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Ito', 'Affiliation': 'Department of Cardiovascular and Respiratory Medicine, Akita University Graduate School of Medicine, Akita, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Fukui', 'Affiliation': 'Division of Cardiology, Hokusho Central Hospital, Sasebo, Japan.'}, {'ForeName': 'Taizo', 'Initials': 'T', 'LastName': 'Kondo', 'Affiliation': 'Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Japan.'}, {'ForeName': 'Shigetaka', 'Initials': 'S', 'LastName': 'Kuroki', 'Affiliation': 'Division of Internal Medicine, Eguchi Hospital, Ogi, Japan.'}, {'ForeName': 'Mamoru', 'Initials': 'M', 'LastName': 'Nanasato', 'Affiliation': 'Cardiovascular Center, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.'}, {'ForeName': 'Yukihito', 'Initials': 'Y', 'LastName': 'Higashi', 'Affiliation': 'Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Kaku', 'Affiliation': 'Department of General Internal Medicine, Kawasaki Medical School, Kurashiki, Japan.'}, {'ForeName': 'Teruo', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Japan.'}, {'ForeName': 'Toyoaki', 'Initials': 'T', 'LastName': 'Murohara', 'Affiliation': 'Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Node', 'Affiliation': 'Department of Cardiovascular Medicine, Saga University, Saga, Japan. node@cc.saga-u.ac.jp.'}]",Heart and vessels,['10.1007/s00380-018-1275-5'] 1048,26621682,"Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.","BACKGROUND Relapses of multiple sclerosis decrease during pregnancy, when the hormone estriol is increased. Estriol treatment is anti-inflammatory and neuroprotective in preclinical studies. In a small single-arm study of people with multiple sclerosis estriol reduced gadolinium-enhancing lesions and was favourably immunomodulatory. We assessed whether estriol treatment reduces multiple sclerosis relapses in women. METHODS We did a randomised, double-blind, placebo-controlled phase 2 trial at 16 academic neurology centres in the USA, between June 28, 2007, and Jan 9, 2014. Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly assigned (1:1) with a random permuted block design to either daily oral estriol (8 mg) or placebo, each in combination with injectable glatiramer acetate 20 mg daily. Patients and all study personnel, except for pharmacists and statisticians, were masked to treatment assignment. The primary endpoint was annualised relapse rate after 24 months, with a significance level of p=0.10. Relapses were confirmed by an increase in Expanded Disability Status Scale score assessed by an independent physician. Analysis was by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00451204. FINDINGS We enrolled 164 patients: 83 were allocated to the estriol group and 81 were allocated to the placebo group. The annualised confirmed relapse rate was 0.25 relapses per year (95% CI 0.17-0.37) in the estriol group versus 0.37 relapses per year (0.25-0.53) in the placebo group (adjusted rate ratio 0.63, 95% CI 0.37-1.05; p=0.077). The proportion of patients with serious adverse events did not differ substantially between the estriol group and the placebo group (eight [10%] of 82 patients vs ten [13%] of 76 patients). Irregular menses were more common in the estriol group than in the placebo group (19 [23%] vs three [4%], p=0.0005), but vaginal infections were less common (one [1%] vs eight [11%], p=0.0117). There were no differences in breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as assessed by clinical examination, mammogram, uterine ultrasound, or endometrial lining biopsy. INTERPRETATION Estriol plus glatiramer acetate met our criteria for reducing relapse rates, and treatment was well tolerated over 24 months. These results warrant further investigation in a phase 3 trial. FUNDING National Institutes of Health, National Multiple Sclerosis Society, Conrad N Hilton Foundation, Jack H Skirball Foundation, Sherak Family Foundation, and the California Community Foundation.",2016,"The annualised confirmed relapse rate was 0.25 relapses per year (95% CI 0.17-0.37) in the estriol group versus 0.37 relapses per year (0.25-0.53) in the placebo group (adjusted rate ratio 0.63, 95% CI 0.37-1.05; p=0.077).","['women', 'We enrolled 164 patients: 83 were allocated to the', '16 academic neurology centres in the USA, between June 28, 2007, and Jan 9, 2014', 'Women aged 18-50 years with relapsing-remitting multiple sclerosis', 'people with multiple sclerosis estriol reduced gadolinium-enhancing lesions', 'women with relapsing-remitting multiple sclerosis']","['estriol treatment', 'estriol', 'placebo', 'daily oral estriol (8 mg) or placebo, each in combination with injectable glatiramer acetate 20 mg daily', 'Estriol treatment', 'Estriol combined with glatiramer acetate']","['vaginal infections', 'relapse rate', 'Irregular menses', 'annualised relapse rate', 'Expanded Disability Status Scale score', 'breast fibrocystic disease, uterine fibroids, or endometrial lining thickness as assessed by clinical examination, mammogram, uterine ultrasound, or endometrial lining biopsy', 'proportion of patients with serious adverse events', 'multiple sclerosis relapses']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027855', 'cui_str': 'Neurology'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0751967', 'cui_str': 'Multiple Sclerosis, Relapsing-Remitting'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0014927', 'cui_str': 'Estriol'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]","[{'cui': 'C0014927', 'cui_str': 'Estriol'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0289884', 'cui_str': 'glatiramer acetate'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0404521', 'cui_str': 'Infective vaginitis (disorder)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0156404', 'cui_str': 'Irregular Menses'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0016034', 'cui_str': 'Mammary Dysplasia'}, {'cui': 'C0042133', 'cui_str': 'Fibroid Uterus'}, {'cui': 'C0031809', 'cui_str': 'Physical Examination'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}]",164.0,0.598455,"The annualised confirmed relapse rate was 0.25 relapses per year (95% CI 0.17-0.37) in the estriol group versus 0.37 relapses per year (0.25-0.53) in the placebo group (adjusted rate ratio 0.63, 95% CI 0.37-1.05; p=0.077).","[{'ForeName': 'Rhonda R', 'Initials': 'RR', 'LastName': 'Voskuhl', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: rvoskuhl@ucla.edu.'}, {'ForeName': 'HeJing', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'T C Jackson', 'Initials': 'TC', 'LastName': 'Wu', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Sicotte', 'Affiliation': 'Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Kunio', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Kurth', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Itoh', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Bardens', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Jacqueline T', 'Initials': 'JT', 'LastName': 'Bernard', 'Affiliation': 'University of Chicago Medical Center, Chicago, IL, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Corboy', 'Affiliation': 'University of Colorado Denver, Aurora, CO, USA.'}, {'ForeName': 'Anne H', 'Initials': 'AH', 'LastName': 'Cross', 'Affiliation': 'Washington University School of Medicine, St Louis, MO, USA.'}, {'ForeName': 'Suhayl', 'Initials': 'S', 'LastName': 'Dhib-Jalbut', 'Affiliation': 'Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.'}, {'ForeName': 'Corey C', 'Initials': 'CC', 'LastName': 'Ford', 'Affiliation': 'University of New Mexico Health Sciences Center, Albuquerque, NM, USA.'}, {'ForeName': 'Elliot M', 'Initials': 'EM', 'LastName': 'Frohman', 'Affiliation': 'University of Texas Southwestern, Dallas, TX, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Giesser', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Jacobs', 'Affiliation': 'University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.'}, {'ForeName': 'Lloyd H', 'Initials': 'LH', 'LastName': 'Kasper', 'Affiliation': 'Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Lynch', 'Affiliation': 'University of Kansas Medical Center, Kansas City, KS, USA.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Parry', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Racke', 'Affiliation': 'Wexner Medical Center, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Anthony T', 'Initials': 'AT', 'LastName': 'Reder', 'Affiliation': 'University of Chicago Medical Center, Chicago, IL, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rose', 'Affiliation': 'Salt Lake City VA Medical Center, Salt Lake City, UT, USA.'}, {'ForeName': 'Dean M', 'Initials': 'DM', 'LastName': 'Wingerchuk', 'Affiliation': 'Mayo Clinic Scottsdale, Scottsdale, AZ, USA.'}, {'ForeName': 'Allan J', 'Initials': 'AJ', 'LastName': 'MacKenzie-Graham', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Arnold', 'Affiliation': 'McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Chi Hong', 'Initials': 'CH', 'LastName': 'Tseng', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Elashoff', 'Affiliation': 'David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, CA, USA.'}]",The Lancet. Neurology,['10.1016/S1474-4422(15)00322-1'] 1049,30811881,A randomised controlled trial of bag-valve-mask teaching techniques.,"BACKGROUND Bag-valve-mask (BVM) ventilation is a vital skill in the management of the collapsed patient; however, the quality of BVM ventilation is a cause for concern. Modified techniques, designed to be easier for the novice practitioner, offer an opportunity to improve quality. One such modification is the 'LASOO' (Lift, Apply, Slide, Oppose, Observe) approach, which offers theoretical benefits over the traditionally taught 'CE' (finger shapes) technique. We conducted a randomised controlled trial (RCT) to determine whether LASOO was superior to CE in terms of tidal volume, when taught to novices in the skills-lab setting. We conducted a randomised controlled trial (RCT) to determine whether LASOO was superior to CE in terms of tidal volume, when taught to novices in the skills-lab setting METHODS: A total of 76 undergraduate health care students received a manikin-based teaching session on LASOO or CE. They then delivered 20 breaths (10 with each hand) to a modified airway manikin. The primary outcome was mean tidal volume; secondary outcomes were the proportion of breaths that achieved 150-mL and 400-mL threshold volumes. Subgroup analyses and statistical modelling were conducted for time-point, hand dominance and hand size. RESULTS The mean tidal volume was 320 mL for CE and 304 mL for LASOO. The median percentage of attempts that exceeded 150 mL was 85 for CE and 82.5 for LASOO. The median percentage of attempts that exceeded 400 mL was 20 for CE and 20 for LASOO. The differences recorded between the techniques were not statistically significant. There was a small, statistically significant increase in tidal volume across both techniques with time-point and holding the mask with the non-dominant hand. DISCUSSION LASOO is a viable alternative to CE. Educators may opt to teach either or both techniques, allowing students to choose the technique that they prefer.",2020,"There was a small, statistically significant increase in tidal volume across both techniques with time-point and holding the mask with the non-dominant hand. ",['76 undergraduate health care students'],"['Bag-valve-mask ', 'LASOO', 'bag-valve-mask teaching techniques', 'manikin-based teaching session on LASOO or CE', 'BVM) ventilation']","['proportion of breaths that achieved 150-mL and 400-mL threshold volumes', 'tidal volume', 'mean tidal volume']","[{'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C1706249', 'cui_str': 'Bag - unit of product usage (qualifier value)'}, {'cui': 'C3888056', 'cui_str': 'Valve (physical object)'}, {'cui': 'C0024861', 'cui_str': 'Masks'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0024722', 'cui_str': 'Mannequins'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}]","[{'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0040210', 'cui_str': 'Tidal Volume'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.0804109,"There was a small, statistically significant increase in tidal volume across both techniques with time-point and holding the mask with the non-dominant hand. ","[{'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Strzelecki', 'Affiliation': 'Health Education England North West, Manchester, UK.'}, {'ForeName': 'Cliff L', 'Initials': 'CL', 'LastName': 'Shelton', 'Affiliation': 'Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Cunningham', 'Affiliation': 'Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Dean', 'Affiliation': 'Health Education England North West, Manchester, UK.'}, {'ForeName': 'Sameera', 'Initials': 'S', 'LastName': 'Naz-Thomas', 'Affiliation': 'Department of Perioperative Practice, Edge Hill University, Manchester, UK.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Stocking', 'Affiliation': 'Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Dobson', 'Affiliation': 'Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.'}]",The clinical teacher,['10.1111/tct.13008'] 1050,30155865,"Does the use of cardiopulmonary resuscitation feedback devices improve the quality of chest compressions performed by doctors? A prospective, randomized, cross-over simulation study.","BACKGROUND The aim of the study was to compare the quality of chest compressions (CCs) carried out with and without the use of the TrueCPR device during simulated cardiopulmonary resuscitations conducted by trainee doctors. METHODS The study was a prospective, randomized, cross-over simulation study. The study involved 65 trainee doctors who were tasked with performing a 2-min cycle of uninterrupted CCs under conditions of a simulated cardiopulmonary resuscitation of adults. CC were carried out in two scenarios: with and without TrueCPR chest compression support. Participants did not have experience in the use of CCs prior to this study. RESULTS The depth of compressions in regard to CC techniques were varied by 45 mm (IQR 43-48) for manual CC and 53 mm (IQR 51-55) for the TrueCPR device (p < 0.001). The incidence of CCs with and without TrueCPR was: 112 (IQR 103-113) vs. 129 (IQR 122-135) compressions (p = 0.002). The degree of complete chest relaxation with the TrueCPR device was 95% (IQR 76-99) and without the device, 33% (IQR 29-38) (p < 0.001). CONCLUSIONS In the simulation study performed, the use of the TrueCPR device resulted in a significant improvement in the quality of CCs in relation to frequency and depth of CCs and correctness of chest relaxation.",2019,The depth of compressions in regard to CC techniques were varied by 45 mm (IQR 43-48) for manual CC and 53 mm (IQR 51-55) for the TrueCPR device (p < 0.001).,['65 trainee doctors who were tasked with performing a 2-min cycle of uninterrupted CCs under conditions of a simulated cardiopulmonary resuscitation of adults'],"['cardiopulmonary resuscitation feedback devices', 'TrueCPR device']","['incidence of CCs with and without TrueCPR', 'quality of CCs in relation to frequency and depth of CCs and correctness of chest relaxation', 'depth of compressions in regard to CC techniques', 'degree of complete chest relaxation']","[{'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0817096', 'cui_str': 'Chest'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",65.0,0.0393551,The depth of compressions in regard to CC techniques were varied by 45 mm (IQR 43-48) for manual CC and 53 mm (IQR 51-55) for the TrueCPR device (p < 0.001).,"[{'ForeName': 'Jolanta', 'Initials': 'J', 'LastName': 'Majer', 'Affiliation': 'Polish Society of Disaster Medicine, Warsaw, Poland.'}, {'ForeName': 'Milosz J', 'Initials': 'MJ', 'LastName': 'Jaguszewski', 'Affiliation': 'I Department of Cardiology, Medical University of Gdansk, Poland.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Frass', 'Affiliation': 'Department of Medicine I, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Leskiewicz', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Smereka', 'Affiliation': 'Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland.'}, {'ForeName': 'Jerzy R', 'Initials': 'JR', 'LastName': 'Ładny', 'Affiliation': 'Department of Emergency Medicine and Disaster, Medical University Bialystok, Bialystok, Poland.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Robak', 'Affiliation': 'Department of Medicine I, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Łukasz', 'Initials': 'Ł', 'LastName': 'Szarpak', 'Affiliation': 'Lazarski University, Warsaw, Poland. lukasz.szarpak@gmail.com.'}]",Cardiology journal,['10.5603/CJ.a2018.0091'] 1051,31694410,Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study.,"BACKGROUND In the ARCTIC trial (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting), treatment adjustment following platelet function testing failed to improve clinical outcomes. However, high-on-treatment platelet reactivity (HPR) is considered as a predictor of poor ischemic outcome. This prespecified substudy evaluated clinical outcomes according to the residual platelet reactivity status after antiplatelet therapy adjustment. METHODS We analyzed the 1213 patients assigned to the monitoring arm of the ARCTIC trial in whom platelet reactivity was evaluated by the VerifyNow P2Y 12 test before percutaneous coronary intervention and during the maintenance phase (at 14 days). HPR was defined as platelet reaction unit≥235U. The primary ischemic end point, a composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization and the safety end point of major bleeding were assessed according to the platelet reactivity status. RESULTS Before percutaneous coronary intervention, 35.7% of patients displayed HPR (n=419). During the acute phase, between percutaneous coronary intervention and the 14-day platelet function testing, ischemic (adjusted hazard ratio, 0.94 [95% CI, 0.74-1.18]; P =0.58) and safety outcomes (hazard ratio, 1.28 [95% CI, 0.22-7.59]; P =0.78) were similar in HPR and non-HPR patients. During the maintenance phase, the proportion of HPR patients (n=186, 17.4%) decreased by 56%. At 1-year, there was no difference for the ischemic end point (5.9% versus 6.0%; adjusted hazard ratio, 0.79 [95% CI, 0.40-1.58]; P =0.51) and a nonsignificant higher rate of major bleedings (2.7% versus 1.0%, hazard ratio, 2.83 [95% CI, 0.96-8.41]; P =0.06) in HPR versus non-HPR patients. CONCLUSIONS The proportion of HPR was halved after platelet function testing and treatment adjustment but without significant ischemic benefit at 1 year. HPR seems more as a modifiable risk marker than a risk factor of ischemic outcome. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT00827411.",2019,The proportion of HPR was halved after platelet function testing and treatment adjustment but without significant ischemic benefit at 1 year.,['1213 patients assigned to the monitoring arm of the ARCTIC trial in whom platelet reactivity was evaluated by the VerifyNow P2Y 12 test before percutaneous coronary intervention and during the maintenance phase (at 14 days'],[],"['platelet reactivity status', 'composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization and the safety end point of major bleeding', 'proportion of HPR', 'HPR', 'safety outcomes', 'rate of major bleedings', 'platelet reaction unit≥235U']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",[],"[{'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}]",1213.0,0.104207,The proportion of HPR was halved after platelet function testing and treatment adjustment but without significant ischemic benefit at 1 year.,"[{'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Lattuca', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).'}, {'ForeName': 'Johanne', 'Initials': 'J', 'LastName': 'Silvain', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Pouillot', 'Affiliation': 'Cardiology Department, Sainte Clotilde Clinic, St. Denis de la Réunion, France (C.P.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Cuisset', 'Affiliation': 'ACTION Study Group, Cardiology Department, La Timone Hospital, Marseille, France (T.C.).'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Cayla', 'Affiliation': 'Cardiology Department, Caremeau University Hospital, ACTION Study Group, Montpellier University, Nîmes, France (B.L., G.C.).'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Henry', 'Affiliation': 'Cardiology Department (P.H.), Lariboisière University Hospital, Paris, France.'}, {'ForeName': 'Abdourahmane', 'Initials': 'A', 'LastName': 'Diallo', 'Affiliation': 'ACTION Study Group, Epidemiology and Clinic Research Unit (A.D., E.V.), Lariboisière University Hospital, Paris, France.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Elhadad', 'Affiliation': 'Cardiology department, Lagny-Marne la Vallée Hospital, France (S.E.).'}, {'ForeName': 'Grégoire', 'Initials': 'G', 'LastName': 'Rangé', 'Affiliation': 'Cardiology department, Chartres Hospital, Le Coudray, France (G.R.).'}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Lhermusier', 'Affiliation': 'Cardiology Department, Rangueil University Hospital, Toulouse, France (T.L., D.C.).'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Boueri', 'Affiliation': 'Cardiology Department, Bastia Hospital, France (Z.B.).'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Motreff', 'Affiliation': 'Cardiology Department, Gabriel Montpied University Hospital, Clermont-Ferrand, France (P.M.).'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Carrié', 'Affiliation': 'Cardiology Department, Rangueil University Hospital, Toulouse, France (T.L., D.C.).'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vicaut', 'Affiliation': 'ACTION Study Group, Epidemiology and Clinic Research Unit (A.D., E.V.), Lariboisière University Hospital, Paris, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Montalescot', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Collet', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Cardiology Institute, Pitié-Salpêtrière (AP-HP) University Hospital, Paris, France (B.L., J.S., Y.Y., G.M., J.-P.C.).'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.118.007749'] 1052,30679877,"The impact of theory-based educational intervention on improving helmet use behavior among workers of cement factory, Iran.","Background The occurrence of occupational accidents is a serious public health issue in industrial workers and may impose life jeopardizing complications. The aim of the study was to assess the effect of a training intervention based on the theory of planned behavior (TPB) on helmet use of workers in cement factories in Khoy and Urmia, Northwest of Iran. Materials and methods This study was a controlled quasi-experimental investigation (before and after) which was conducted on 170 workers employed in Khoy and Urmia cement factories, Northwest of Iran. Eighty-five eligible subjects from Khoy (as intervention group) and 85 similar samples from Urmia (as control group) were selected and recruited. A valid and reliable four-part questionnaire was used to collect the data including socio demographic information, awareness, the theory constructs, and the behavior. After completing the study questionnaire and needs assessment, a specific educational program was implemented on the intervention group only. The effects of education were compared between the groups before and after intervention. The posttest was applied 1 month after educational intervention. Results The mean age of workers in the intervention and control groups was 34.32 ± 8.19 and 33.62 ± 6.17 years, respectively. Before education, the mean score of awareness and helmet use behavior of intervention group was 6.15 ± 3.4 and 5.35 ± 2.8, but after education, those changed into 13.61 ± 3.10 and 9.15 ± 1.65, and the differences were significant ( p  < 0.01). In addition, before education, the mean score of attitude, subjective norm, behavioral control, and behavioral intention of intervention group was 27 ± 5.17, 37.74 ± 6.92, 29.56 ± 6.17, and 17.65 ± 4.90, respectively. After education, the mean score of those changed into 37.26 ± 4.76, 48.34 ± 5.64, 42 ± 8.07, and 24.79 ± 5.33, respectively, and changes were statistically significant ( p  < 0.01), while no statistically significant differences were observed in awareness, the behavior, and the theory constructs in the control group after the intervention. Conclusion and recommendations The TPB-based educational approach had a remarkable effect on helmet use of workers. Applying this theory to improve workers' personal protective behaviors is recommended and emphasized.",2019,"After education, the mean score of those changed into 37.26 ± 4.76, 48.34 ± 5.64, 42 ± 8.07, and 24.79 ± 5.33, respectively, and changes were statistically significant ( p  < 0.01), while no statistically significant differences were observed in awareness, the behavior, and the theory constructs in the control group after the intervention. ","['170 workers employed in Khoy and Urmia cement factories, Northwest of Iran', 'workers in cement factories in Khoy and Urmia, Northwest of Iran', 'workers of cement factory, Iran', 'Eighty-five eligible subjects from Khoy (as intervention group) and 85 similar samples from Urmia (as control group) were selected and recruited']","['theory-based educational intervention', 'planned behavior (TPB', 'training intervention']","['awareness, the behavior, and the theory constructs', 'mean score of awareness and helmet use behavior', 'mean score of attitude, subjective norm, behavioral control, and behavioral intention']","[{'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C1704479', 'cui_str': 'Cement'}, {'cui': 'C0442614', 'cui_str': 'Factory (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0004448', 'cui_str': 'Situational Awareness'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0018884', 'cui_str': 'Helmets'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",170.0,0.0163784,"After education, the mean score of those changed into 37.26 ± 4.76, 48.34 ± 5.64, 42 ± 8.07, and 24.79 ± 5.33, respectively, and changes were statistically significant ( p  < 0.01), while no statistically significant differences were observed in awareness, the behavior, and the theory constructs in the control group after the intervention. ","[{'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Jafaralilou', 'Affiliation': 'Health Education and Promotion, Khoy Faculty of Medical Sciences, Khoy, Iran.'}, {'ForeName': 'Iraj', 'Initials': 'I', 'LastName': 'Zareban', 'Affiliation': '2Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Hajaghazadeh', 'Affiliation': '3Department of Occupational Health, Faculty of Health Sciences, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Habibeh', 'Initials': 'H', 'LastName': 'Matin', 'Affiliation': 'Health Education and Promotion, Department of Health Sciences, Khoy Faculty of Medical Sciences, Khoy, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Didarloo', 'Affiliation': '5Social Determinants of Health Research Center, Department of Public Health, Faculty of Health Sciences, Urmia University of Medical Sciences, P. O. Box: 57561-15111, Urmia, Iran.'}]",The Journal of the Egyptian Public Health Association,['10.1186/s42506-018-0001-6'] 1053,30143885,Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?,"Interventions targeting the serum eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio could be useful for the prevention of coronary artery disease (CAD). Few data exist regarding the effects of administration of EPA on the serum levels of soluble thrombomodulin (sTM) as a marker of endothelial damage, or on the relationship between the sTM and EPA/AA ratio in patients with CAD receiving statin treatment. We assigned stable CAD patients already receiving statin therapy to an EPA group (1800 mg/day: n = 50) or control group (n = 50). A significant increase of the sTM level was observed in the EPA group as compared to that in the control group 0.40 (0.10/0.70) FU/mL vs. 0.20 (0/0.40) FU/mL, p = 0.004 at the 6-month follow-up examination. Multivariate regression analysis after adjustments for coronary risk factors and changes of the serum lipid levels identified an increased EPA/AA ratio as an independent predictor of increased serum sTM level (β = 0.244, p = 0.02). The results suggest that an increased sTM level caused by additional administration of EPA to statin might be associated with an increased EPA/AA ratio. The increase of the serum sTM after administration of EPA might reflect an increase of the TM expression on the endothelial surface rather than endothelial damage in CAD patients under statin treatment.Clinical Trial Registration Information UMIN ( http://www.umin.ac.jp/ ), Study ID: UMIN000010452.",2019,A significant increase of the sTM level was observed in the EPA group as compared to that in the control group 0.40 (0.10/0.70) FU/mL vs. 0.20,"['statin-treated patients with stable coronary artery disease', 'patients with CAD receiving statin treatment']","['eicosapentaenoic acid', 'EPA']","['soluble thrombomodulin level', 'serum sTM level', 'EPA/AA ratio', 'sTM level', 'serum eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio', 'serum lipid levels']","[{'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic Acid'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}]","[{'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0059057', 'cui_str': 'EPA (prealbumin)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic Acid'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C1287373', 'cui_str': 'Finding of serum lipid levels (finding)'}]",,0.103176,A significant increase of the sTM level was observed in the EPA group as compared to that in the control group 0.40 (0.10/0.70) FU/mL vs. 0.20,"[{'ForeName': 'Shigemasa', 'Initials': 'S', 'LastName': 'Tani', 'Affiliation': 'Department of Health Planning Center, Nihon University Hospital, 1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-8309, Japan. tani.shigemasa@nihon-u.ac.jp.'}, {'ForeName': 'Rei', 'Initials': 'R', 'LastName': 'Matsuo', 'Affiliation': 'Department of Cardiology, Nihon University Hospital, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Hirayama', 'Affiliation': 'Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.'}]",Heart and vessels,['10.1007/s00380-018-1240-3'] 1054,30824040,"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).","BACKGROUND Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial. METHODS In this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting on day 5 at 15 mg/kg three times daily not to exceed 1 g from day 5 to day 35); tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m 2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc 300 mg orally twice daily from day -3 to day 30 after HCT). Methotrexate was administered as a 15 mg/m 2 intravenous bolus on day 1 and 10 mg/m 2 intravenous bolus on days 3, 6, and 11 after HCT; tacrolimus was given intravenously at a dose of 0·05 mg/kg twice daily (or oral equivalent) starting on day -3 (except the post-transplantation cyclophosphamide, as indicated), with a target level of 5-15 ng/mL. Tacrolimus was continued at least until day 90 and was tapered off by day 180. Each study group was compared separately to a contemporary non-randomised prospective cohort of patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with tacrolimus and methotrexate at centres not participating in the trial. The primary endpoint (GvHD-free, relapse-free survival [GRFS]) was defined as the time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death. The study was analysed by modified intention to treat. The study is closed to accrual and this is the planned analysis. This trial is registered with ClinicalTrials.gov, number NCT02208037. FINDINGS Between Nov 17, 2014, and May 18, 2016, 273 patients from 31 US centres were randomly assigned to the three study arms: 89 to tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; and six were excluded. Between Aug 1, 2014, and Sept 14, 2016, 224 controls received tacrolimus and methotrexate. Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used. Compared with controls, the hazard ratio for GRFS was 0·72 (90% CI 0·54-0·94; p=0·044) for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide, 0·98 (0·76-1·27; p=0·92) for tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41; p=0·49) for tacrolimus, methotrexate, and maraviroc. 238 patients experienced grade 3 or 4 toxicities: 12 (13%) had grade 3 and 67 (73%) grade 4 events with tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; ten (11%) had grade 3 and 68 (76%) had grade 4 events with tacrolimus, methotrexate, and bortezomib; and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc. The most common toxicities were haematological (77 [84%] for tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide; 73 [82%] for tacrolimus, methotrexate, and bortezomib; and 78 [85%] for tacrolimus, methotrexate, and maraviroc) and cardiac (43 [47%], 44 [49%], and 43 [47%], respectively). INTERPRETATION Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide was the most promising intervention, yielding the best GRFS; this regimen is thus being prospectively compared with tacrolimus and methotrexate in a phase 3 randomised trial. FUNDING US National Health, Lung, and Blood Institute; National Cancer Institute; National Institute of Allergy and Infectious Disease; and Millennium Pharmaceuticals.",2019,Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used.,"['patients (control group) who fulfilled the same eligibility criteria as the trial, but who were treated with', 'Between Nov 17, 2014, and May 18, 2016', 'and 18 (20%) had grade 3 and 63 (68%) had grade 4 events with tacrolimus, methotrexate, and maraviroc', 'adult patients aged 18-75 years who received reduced-intensity conditioning HCT', '238 patients experienced', '273 patients from 31 US centres', 'at centres not participating in the trial']","['tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate', 'Methotrexate', 'tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide', 'tacrolimus, methotrexate, and bortezomib (bortezomib 1·3 mg/m 2 intravenously on days 1, 4, and 7 after HCT); or tacrolimus, methotrexate, and maraviroc (maraviroc', 'Tacrolimus', 'tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide (cyclophosphamide 50 mg/kg on days 3 and 4, followed by tacrolimus starting on day 5 and mycophenolate mofetil starting', 'tacrolimus, methotrexate, and maraviroc', 'tacrolimus and methotrexate', 'HCT; tacrolimus', 'tacrolimus, methotrexate, and bortezomib', 'Tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide', 'tacrolimus, methotrexate, and bortezomib; 92 to tacrolimus, methotrexate, and maraviroc; 92 to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide', 'haemopoietic cell transplantation with reduced-intensity conditioning', 'allogeneic haemopoietic cell transplantation (HCT', 'tacrolimus, methotrexate, and bortezomib, and 1·10 (0·86-1·41', 'tacrolimus, mycophenolate mofetil', 'maraviroc, bortezomib, or post-transplantation cyclophosphamide']","['tacrolimus, methotrexate, and maraviroc) and cardiac', 'grade 3 or 4 toxicities', 'hazard ratio for GRFS', 'time from HCT to onset of grade 3-4 acute GvHD, chronic GvHD requiring systemic immunosuppression, disease relapse, or death', 'primary endpoint (GvHD-free, relapse-free survival [GRFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1667052', 'cui_str': 'maraviroc'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C1667052', 'cui_str': 'maraviroc'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0985263', 'cui_str': 'Cyclophosphamide 50 MG'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0206153', 'cui_str': 'Cell Transplantation'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1667052', 'cui_str': 'maraviroc'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0021080', 'cui_str': 'Immunosuppression (Physiology)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.131255,Controls were generally well matched except for more frequent comorbidities than the intervention groups and a different distribution of types of conditioning regimens used.,"[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Bolaños-Meade', 'Affiliation': 'Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. Electronic address: fbolano2@jhmi.edu.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Reshef', 'Affiliation': 'Department of Medicine, Columbia University Medical Center, New York, NY, USA.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Fraser', 'Affiliation': 'Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Mingwei', 'Initials': 'M', 'LastName': 'Fei', 'Affiliation': 'Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Abhyankar', 'Affiliation': 'Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA.'}, {'ForeName': 'Zaid', 'Initials': 'Z', 'LastName': 'Al-Kadhimi', 'Affiliation': 'Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Amin M', 'Initials': 'AM', 'LastName': 'Alousi', 'Affiliation': 'Department of Stem Cell Transplant and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Joseph H', 'Initials': 'JH', 'LastName': 'Antin', 'Affiliation': 'Department of Medicial Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Arai', 'Affiliation': 'Department of Medicine, Stanford University, Palo Alto, CA, USA.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Bickett', 'Affiliation': 'The Emmes Corporation, Rockville, MD, USA.'}, {'ForeName': 'Yi-Bin', 'Initials': 'YB', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, Massachusetts General, Hospital, Boston, MA, USA.'}, {'ForeName': 'Lloyd E', 'Initials': 'LE', 'LastName': 'Damon', 'Affiliation': 'Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Yvonne A', 'Initials': 'YA', 'LastName': 'Efebera', 'Affiliation': 'Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Geller', 'Affiliation': 'Office of Biostatistics Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Sergio A', 'Initials': 'SA', 'LastName': 'Giralt', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Parameswaran', 'Initials': 'P', 'LastName': 'Hari', 'Affiliation': 'Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Shernan G', 'Initials': 'SG', 'LastName': 'Holtan', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Horowitz', 'Affiliation': 'Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Jacobsohn', 'Affiliation': ""Department of Pediatrics at George Washington University, Children's National Medical Center, Washington, DC, USA.""}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Jones', 'Affiliation': 'Department of Oncology, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, Johns Hopkins University, Baltimore, MD, USA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Jane L', 'Initials': 'JL', 'LastName': 'Liesveld', 'Affiliation': 'Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Brent R', 'Initials': 'BR', 'LastName': 'Logan', 'Affiliation': 'Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Margaret L', 'Initials': 'ML', 'LastName': 'MacMillan', 'Affiliation': 'Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Mielcarek', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Noel', 'Affiliation': 'Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Pidala', 'Affiliation': 'Blood and Marrow Transplantation and Cellular Immunotherapy, H Lee Moffitt Cancer Center, Tampa, FL, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Porter', 'Affiliation': 'Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Iskra', 'Initials': 'I', 'LastName': 'Pusic', 'Affiliation': 'Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Sobecks', 'Affiliation': 'Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Scott R', 'Initials': 'SR', 'LastName': 'Solomon', 'Affiliation': 'Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Weisdorf', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'The Emmes Corporation, Rockville, MD, USA.'}, {'ForeName': 'Marcelo C', 'Initials': 'MC', 'LastName': 'Pasquini', 'Affiliation': 'Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Koreth', 'Affiliation': 'Department of Medicial Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.'}]",The Lancet. Haematology,['10.1016/S2352-3026(18)30221-7'] 1055,31691621,"Effectiveness of the short-term use of Cimicifuga racemosa in the endothelial function of postmenopausal women: a double-blind, randomized, controlled trial.","Objective: This study aimed to assess the effects of daily use of Cimicifuga racemosa on endothelial function through flow-mediated dilation of the brachial artery, when used for 28 days by healthy postmenopausal women. Methods: The double-blind, randomized, placebo-controlled study included two groups of postmenopausal women ( n  = 31 each). The subjects were clinically assessed and flow-mediated dilation of the brachial artery was measured before and after 28 days of treatment. Patients received dry extract corresponding to 160 mg C. racemosa (extract with 4 mg of triterpene glycosides) or placebo. Results: Mean age, time since menopause, and body mass index in the two groups were similar. The measurements of flow-mediated dilation of the brachial artery, pre and post treatment, respectively, showed a significant increase in patients who used C. racemosa ( p  = 0.006), unlike patients who used placebo, who did not present changes in the outcome of flow-mediated dilation of the brachial artery after 28 days of use ( p  ≥ 0.05). When comparing the number of women in both groups who showed an increase in flow-mediated dilation, a significant difference was found in the measurements of the treated group after the use of the medication ( p  = 0.018). Conclusions: Daily use of 160 mg C. racemosa extract by postmenopausal women for 28 days beneficially influences endothelial function by promoting elasticity of the brachial artery.",2020,"The measurements of flow-mediated dilation of the brachial artery, pre and post treatment, respectively, showed a significant increase in patients who used C. racemosa ( p  = 0.006), unlike patients who used placebo, who did not present changes in the outcome of flow-mediated dilation of the brachial artery after 28 days of use ( p  ≥ 0.05).","['160', 'postmenopausal women', '28\u2009days by healthy postmenopausal women', 'two groups of postmenopausal women ( n \u2009=\u200931 each']","['dry extract corresponding to 160', 'mg C. racemosa (extract with 4\u2009mg of triterpene glycosides) or placebo', 'Cimicifuga racemosa', 'placebo', 'short-term use of Cimicifuga racemosa']","['outcome of flow-mediated dilation of the brachial artery', 'flow-mediated dilation', 'flow-mediated dilation of the brachial artery', 'Mean age, time since menopause, and body mass index', 'endothelial function']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1720167', 'cui_str': 'Dry extract (qualifier value)'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0041113', 'cui_str': 'Triterpenes'}, {'cui': 'C0007158', 'cui_str': 'Cardiotonic Steroids'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0885226', 'cui_str': 'Cimicifuga racemosa'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}]","[{'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0567312', 'cui_str': 'Menopause present (finding)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.342591,"The measurements of flow-mediated dilation of the brachial artery, pre and post treatment, respectively, showed a significant increase in patients who used C. racemosa ( p  = 0.006), unlike patients who used placebo, who did not present changes in the outcome of flow-mediated dilation of the brachial artery after 28 days of use ( p  ≥ 0.05).","[{'ForeName': 'E S', 'Initials': 'ES', 'LastName': 'Fernandes', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'M F S', 'Initials': 'MFS', 'LastName': 'Celani', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Fistarol', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Geber', 'Affiliation': 'Department of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1682542'] 1056,29396643,"A randomized controlled clinical trial on the effectiveness of three different mouthrinses (chlorhexidine with or without alcohol and C31G), adjunct to periodontal surgery, in early wound healing.","OBJECTIVES The use of chlorhexidine (CHX) with or without alcohol has been recommended for a number of clinical applications. On the other hand, there is a plethora of widely subscribed antiseptics, such as agent C31G (alkyl dimethyl glycine/alkyl dimethyl amine oxide), which has not yet been evaluated postsurgically. The effectiveness of three different mouthrinses (CHX with and without alcohol, C31G) in plaque control and early wound healing was compared postoperatively. MATERIALS AND METHODS In this, randomized, double-blind, controlled clinical trial 42 patients were allocated to three groups assigned to 2 weeks rinsing after non-regenerative periodontal flap surgery with or without osseous surgery with C31G (group A), alcohol-free CHX 0.12% (group B) or alcohol-based CHX 0.12% (group C). At days 7 and 14, plaque and early wound healing indices were recorded. At day 14, total bacterial counts were estimated utilizing real-time quantitative polymerase chain reaction (qPCR). Statistics included linear and generalized linear mixed models. RESULTS At day 7, healing response was not significantly different among groups. At day 14, group A revealed the highest while group C demonstrated the lowest plaque index values (B vs A, odds ratio-OR = 0.18, p = 0.012; C vs A, OR = 0.01, p < 0.001; C vs B, OR = 0.06, p < 0.001). Group C demonstrated the lowest bacterial counts levels at day 14 (38.470 × 10 6 , 48.190 × 10 6 , and 3.020 × 10 6 for groups A, B, and C, respectively). At day 14, healing was significantly better in group C compared to B (p = 0.007). Group A showed no significant differences compared to other groups. CONCLUSIONS (1) The presence of alcohol may increase the effectiveness of CHX in early wound healing, (2) C31G might be an alternative solution prescribed during early postoperative period after non-regenerative periodontal flap surgery. CLINICAL RELEVANCE The present study found that active agent C31G displayed no significant differences to CHX formulations regarding periodontal wound healing improvement and might be used alternatively after non-regenerative periodontal flap surgery. In addition, an alcohol based 0.12% CHX mouthwash was more effective than an alcohol-free 0.12% CHX and C31G mouthrinse on plaque control in the absence of mechanical oral hygiene.",2018,The present study found that active agent C31G displayed no significant differences to CHX formulations regarding periodontal wound healing improvement and might be used alternatively after non-regenerative periodontal flap surgery.,['42 patients'],"['chlorhexidine (CHX) with or without alcohol', 'mouthrinses (chlorhexidine with or without alcohol and C31G', 'mouthrinses (CHX with and without alcohol, C31G', 'C31G mouthrinse', 'CHX', 'rinsing after non-regenerative periodontal flap surgery with or without osseous surgery with C31G (group A), alcohol-free CHX 0.12% (group B) or alcohol-based CHX']","['lowest bacterial counts levels', 'healing response', 'lowest plaque index values', 'plaque control and early wound healing', 'plaque and early wound healing indices', 'healing']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0054368', 'cui_str': 'C31G'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0441835', 'cui_str': 'Group A (qualifier value)'}, {'cui': 'C4517426', 'cui_str': '0.12 (qualifier value)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0004618', 'cui_str': 'Bacterial Count'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}]",42.0,0.0519657,The present study found that active agent C31G displayed no significant differences to CHX formulations regarding periodontal wound healing improvement and might be used alternatively after non-regenerative periodontal flap surgery.,"[{'ForeName': 'Anastasios M', 'Initials': 'AM', 'LastName': 'Gkatzonis', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, National and Kapodistrian University of Athens, 2 Thivon Str, 115 27, Athens, Greece. gkatzonis.tasos@gmail.com.'}, {'ForeName': 'Spyridon I', 'Initials': 'SI', 'LastName': 'Vassilopoulos', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, National and Kapodistrian University of Athens, 2 Thivon Str, 115 27, Athens, Greece.'}, {'ForeName': 'Ioannis K', 'Initials': 'IK', 'LastName': 'Karoussis', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, National and Kapodistrian University of Athens, 2 Thivon Str, 115 27, Athens, Greece.'}, {'ForeName': 'Archontia', 'Initials': 'A', 'LastName': 'Kaminari', 'Affiliation': 'Institute of Biosciences and Applications, National Center for Scientific Research ""Demokritos"", Athens, Greece.'}, {'ForeName': 'Phoebus N', 'Initials': 'PN', 'LastName': 'Madianos', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, National and Kapodistrian University of Athens, 2 Thivon Str, 115 27, Athens, Greece.'}, {'ForeName': 'Ioannis A', 'Initials': 'IA', 'LastName': 'Vrotsos', 'Affiliation': 'Department of Periodontology, School of Dental Medicine, National and Kapodistrian University of Athens, 2 Thivon Str, 115 27, Athens, Greece.'}]",Clinical oral investigations,['10.1007/s00784-018-2357-6'] 1057,32407827,A simulation approach to measure critical safety behaviors when evaluating training methods for respirator education in healthcare workers.,"BACKGROUND The N95 respirator is the most common safety tool used in hospitals to protect health care workers (HCW) from inhaling airborne particles. Focusing on HCW behavior related to respirator use is an effective route to improve HCW safety and respiratory health. METHODS Participants were asked to perform the donning and doffing of an N95 respirator to camera. Then they were randomized to a video alone or a reflective practice intervention. After the intervention they repeated the donning and doffing to camera. A critical safety behavior scoring tool (CSBST) was developed to compare the performance of the participants over time at pretest, post-test and 1 month later for follow-up. RESULTS The reflective practice intervention group was found to have significantly higher scores on the CSBST at post-test and follow-up than the video alone group. In the reflective practice intervention group, the participants perceived they were better at performing the N95 donning and doffing than the experts scored them. CONCLUSIONS The CSBST is a tool to measure the performance of HCWs on a specific targeted safety behaviors. The addition of a reflective practice intervention may result in a measurable and sustained improvement in the safety behaviors demonstrated when using the N95 respirator.",2020,The reflective practice intervention group was found to have significantly higher scores on the CSBST at post-test and follow-up than the video alone group.,"['Participants were asked to perform the donning and doffing of an N95 respirator to camera', 'hospitals to protect healthcare workers (HCW) from inhaling airborne particles', 'healthcare workers']","['video alone or a reflective practice intervention', 'CSBST']","['safety behaviors', 'HCW safety and respiratory health']","[{'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0429406', 'cui_str': 'Pattern ERG N95'}, {'cui': 'C0035208', 'cui_str': 'Air-purifying respirator'}, {'cui': 'C0179533', 'cui_str': 'Camera'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1321226', 'cui_str': 'Safety behavior'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C1321226', 'cui_str': 'Safety behavior'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.036832,The reflective practice intervention group was found to have significantly higher scores on the CSBST at post-test and follow-up than the video alone group.,"[{'ForeName': 'Elizabeth L', 'Initials': 'EL', 'LastName': 'Beam', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, NE; Nebraska Biocontainment Unit, Omaha, NE. Electronic address: ebeam@unmc.edu.'}, {'ForeName': 'Jocelyn J', 'Initials': 'JJ', 'LastName': 'Herstein', 'Affiliation': 'Nebraska Biocontainment Unit, Omaha, NE; Department of Environmental, Agricultural, and Occupational Health, University of Nebraska Medical Center, College of Public Health, Omaha, NE.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Kupzyk', 'Affiliation': 'College of Nursing, University of Nebraska Medical Center, Omaha, NE.'}, {'ForeName': 'Shawn G', 'Initials': 'SG', 'LastName': 'Gibbs', 'Affiliation': 'Texas A & M School of Public Health, College Station, TX.'}]",American journal of infection control,['10.1016/j.ajic.2020.05.005'] 1058,30628511,Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.,"Phase II data suggest a benefit to autotransplantation for aggressive T-cell non-Hodgkin lymphoma (T-NHL) in first remission; randomized trials have yet to validate this. We performed a retrospective analysis of aggressive T-NHL patients in the intergroup randomized consolidative autotransplant trial (SWOG 9704). Of the 370 enrolled, 40 had T-NHL: 12 were not randomized due to ineligibility ( n  = 1), choice ( n  = 2), or progression ( n  = 9), leaving 13 randomized to control and 15 to autologous stem cell transplantation (ASCT). Two ASCT patients refused transplant and one failed mobilization. The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% ( p  = .56), and 40% vs. 45% ( p  = .98), respectively. No difference was seen based on IPI, or histologic subtype. Only 1/7 receiving BCNU-based therapy survived vs. 4/5 receiving TBI. Aggressive T-NHL autotransplanted in first remission did not appear to benefit from consolidative ASCT. This and the 30% who dropped out pre-randomization mostly to progression, suggests that improved induction regimens be developed.",2019,"The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p = .56), and 40% vs. 45% (p = .98), respectively.","['370 enrolled, 40 had T-NHL: 12']","['control and 15 to autologous stem cell transplantation (ASCT', 'Autologous transplantation']","['IPI, or histologic subtype', '5-year landmark PFS/OS estimates']","[{'cui': 'C4517743', 'cui_str': 'Three hundred and seventy'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C1504389', 'cui_str': 'Stem Cell Transplantation'}, {'cui': 'C0040736', 'cui_str': 'Autotransplantation'}]","[{'cui': 'C0668760', 'cui_str': ""P(1),P(5)-di(inosine-5')pentaphosphate""}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0449560', 'cui_str': 'Subtype (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}]",2.0,0.103798,"The 5-year landmark PFS/OS estimates for ASCT vs. control groups were 40% vs. 38% (p = .56), and 40% vs. 45% (p = .98), respectively.","[{'ForeName': 'Zeina', 'Initials': 'Z', 'LastName': 'Al-Mansour', 'Affiliation': 'a Cardinal Bernardin Cancer Center, Loyola University Medical Center , Maywood , IL , USA.'}, {'ForeName': 'Hongli', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'b SWOG Statistical Center , Seattle , WA , USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Cook', 'Affiliation': 'c Cleveland Clinic , Cleveland , OH , USA.'}, {'ForeName': 'Louis S', 'Initials': 'LS', 'LastName': 'Constine', 'Affiliation': 'd University of Rochester , Rochester , NY , USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Couban', 'Affiliation': 'e Queen Elizabeth II Health Sciences Centre and Dalhousie University , Halifax , Canada.'}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Stewart', 'Affiliation': 'f Tom Baker Cancer Centre, University of Calgary , Calgary , Canada.'}, {'ForeName': 'Thomas C', 'Initials': 'TC', 'LastName': 'Shea', 'Affiliation': 'g University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Pierluigi', 'Initials': 'P', 'LastName': 'Porcu', 'Affiliation': 'h Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , PA , USA.'}, {'ForeName': 'Jane N', 'Initials': 'JN', 'LastName': 'Winter', 'Affiliation': 'i Northwestern University , Chicago , IL , USA.'}, {'ForeName': 'Brad S', 'Initials': 'BS', 'LastName': 'Kahl', 'Affiliation': 'j University of Wisconsin , Madison , WI , USA.'}, {'ForeName': 'Sonali M', 'Initials': 'SM', 'LastName': 'Smith', 'Affiliation': 'k University of Chicago , Chicago , IL , USA.'}, {'ForeName': 'Deborah C', 'Initials': 'DC', 'LastName': 'Marcellus', 'Affiliation': 'l Juravinski Hospital and Cancer Centre , Hamilton , Canada.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Barton', 'Affiliation': 'a Cardinal Bernardin Cancer Center, Loyola University Medical Center , Maywood , IL , USA.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Mills', 'Affiliation': 'm Louisiana State University Health Sciences Center , Shreveport , LA , USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'LeBlanc', 'Affiliation': 'b SWOG Statistical Center , Seattle , WA , USA.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Rimsza', 'Affiliation': 'n Mayo Clinic , Scottsdale , AZ , USA.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Forman', 'Affiliation': 'o City of Hope Medical Center , Duarte , CA , USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Leonard', 'Affiliation': 'p Weill Cornell Medicine , New York , NY , USA.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Fisher', 'Affiliation': 'q q Temple University School of Medicine, Fox Chase Cancer Center - Temple Health , Philadelphia , PA , USA.'}, {'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Friedberg', 'Affiliation': 'd University of Rochester , Rochester , NY , USA.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Stiff', 'Affiliation': 'a Cardinal Bernardin Cancer Center, Loyola University Medical Center , Maywood , IL , USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2018.1563691'] 1059,29423713,Effects of a sodium fluoride- and phytate-containing dentifrice on remineralisation of enamel erosive lesions-an in situ randomised clinical study.,"OBJECTIVE The objective of this work was to evaluate effects of a dentifrice containing sodium fluoride (1150 ppm F) and the organic polyphosphate phytate (0.85% w/w of the hexa-sodium salt) on in situ remineralisation of early enamel erosive lesions and resistance to subsequent demineralisation. MATERIALS AND METHODS Subjects (n = 62) wore palatal appliances holding eight bovine enamel specimens with pre-formed erosive lesions. They brushed their natural teeth with the phytate test dentifrice (TD); a positive control dentifrice (PC, 1150 ppm fluoride as NaF); a reference dentifrice (RD, disodium pyrophosphate + 1100 ppm fluoride as NaF) or a negative control dentifrice (NC, fluoride-free) in a randomised, double-blind, crossover design. Specimens were removed at 2, 4 and 8 h post-brushing and exposed to an ex vivo acid challenge. Surface microhardness (Knoop) was measured at each stage. The primary efficacy variable was relative erosion resistance (RER); other variables included the surface microhardness recovery (SMHR), acid resistance ratio (ARR) and enamel fluoride uptake (EFU). RESULTS After 4 h, the results for RER, ARR and EFU were in the order PC > TD = RD > NC with PC > TD = RD = NC for SMHR. Results at 2 and 8 h were generally consistent with the 4 h data. Mineralisation progressed over time. Dentifrices were generally well-tolerated. CONCLUSIONS In this in situ model, addition of phytate or pyrophosphate to a fluoride dentifrice inhibited the remineralising effect of fluoride. Both formulations still delivered fluoride to the enamel and inhibited demineralisation, albeit to a lesser extent than a polyphosphate-free dentifrice. CLINICAL RELEVANCE Addition of phytate or pyrophosphate to a fluoride dentifrice may reduce its net anti-erosive properties.",2018,"Both formulations still delivered fluoride to the enamel and inhibited demineralisation, albeit to a lesser extent than a polyphosphate-free dentifrice. ",['Subjects (n\u2009=\u200962) wore palatal appliances holding eight bovine enamel specimens with pre-formed erosive lesions'],"['phytate test dentifrice (TD); a positive control dentifrice (PC, 1150\xa0ppm fluoride as NaF); a reference dentifrice (RD, disodium pyrophosphate\u2009+\u20091100\xa0ppm fluoride as NaF) or a negative control dentifrice (NC, fluoride-free', 'pyrophosphate', 'organic polyphosphate phytate (0.85% w/w of the hexa-sodium salt', 'sodium fluoride- and phytate-containing dentifrice', 'dentifrice containing sodium fluoride']","['remineralisation of enamel erosive lesions', 'tolerated', 'surface microhardness recovery (SMHR), acid resistance ratio (ARR) and enamel fluoride uptake (EFU', 'RER, ARR and EFU', 'relative erosion resistance (RER']","[{'cui': 'C0700374', 'cui_str': 'Palate'}, {'cui': 'C0243112'}, {'cui': 'C1553387', 'cui_str': 'Hold'}, {'cui': 'C1265545', 'cui_str': 'Family Bovidae'}, {'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0439679', 'cui_str': 'Erosive (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]","[{'cui': 'C0086808', 'cui_str': 'Phytate'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439187', 'cui_str': 'parts per million'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0888195', 'cui_str': 'sodium acid pyrophosphate'}, {'cui': 'C4517537', 'cui_str': 'One thousand one hundred'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C3252566', 'cui_str': 'Pyrophosphate'}, {'cui': 'C0032575', 'cui_str': 'Polyphosphates'}, {'cui': 'C4517483', 'cui_str': '0.85 (qualifier value)'}, {'cui': 'C2919747', 'cui_str': 'Weight/weight ratio'}, {'cui': 'C0351302', 'cui_str': 'Sodium salts (substance)'}, {'cui': 'C3652487', 'cui_str': 'sodium fluoride (18F)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0011350', 'cui_str': 'Enamel'}, {'cui': 'C0439679', 'cui_str': 'Erosive (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205148', 'cui_str': 'Surface (attribute)'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer (morphologic abnormality)'}]",,0.135711,"Both formulations still delivered fluoride to the enamel and inhibited demineralisation, albeit to a lesser extent than a polyphosphate-free dentifrice. ","[{'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Creeth', 'Affiliation': ""GSK Consumer Healthcare, St George's Avenue, Weybridge, Surrey, KT13 0DE, UK. jonathan.e.creeth@gsk.com.""}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Parkinson', 'Affiliation': ""GSK Consumer Healthcare, St George's Avenue, Weybridge, Surrey, KT13 0DE, UK.""}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Burnett', 'Affiliation': ""GSK Consumer Healthcare, St George's Avenue, Weybridge, Surrey, KT13 0DE, UK.""}, {'ForeName': 'Susmita', 'Initials': 'S', 'LastName': 'Sanyal', 'Affiliation': 'Syneos Health, Hyderabad, India.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Lippert', 'Affiliation': 'Oral Health Research Institute, Indiana University School of Dentistry, Indianapolis, IN, USA.'}, {'ForeName': 'Domenick T', 'Initials': 'DT', 'LastName': 'Zero', 'Affiliation': 'Oral Health Research Institute, Indiana University School of Dentistry, Indianapolis, IN, USA.'}, {'ForeName': 'Anderson T', 'Initials': 'AT', 'LastName': 'Hara', 'Affiliation': 'Oral Health Research Institute, Indiana University School of Dentistry, Indianapolis, IN, USA.'}]",Clinical oral investigations,['10.1007/s00784-018-2351-z'] 1060,30706746,"Group leader and participant perceptions of Balancing Everyday Life, a group-based lifestyle intervention for mental health service users.","Background: There exist few recovery and occupation-based interventions for mental health service users. Balancing Everyday Life (BEL) is a new occupation-based lifestyle intervention that was created to fill this need. Aim: To gain group leaders' and participants' perspectives of the BEL intervention content and format, including factors that helped, hindered, and could be improved. Methods: A constructivist grounded theory method guided data collection and analysis. Interviews took place with 12 BEL group leaders and 19 BEL participants from out-patient psychiatry settings and community-based day centers in Sweden. Results: BEL's structure and content were appreciated, yet flexibility was desired to adapt to participant needs. BEL could act as a bridge, helping participants connect with others, and to a more engaged and balanced everyday life. Facilitating factors included a person-focused (versus illness-focused) approach, physical and emotional environments, and connection. Barriers included room resources. More sessions were desired for the intervention. Conclusion: Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives. The combination of a positive person-focused approach and group support was appreciated. These results could inform future research, evaluation, and development of occupation-focused lifestyle interventions for mental health service users.",2020,"CONCLUSION Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives.","['Interviews took place with 12 BEL group leaders and 19 BEL participants from out-patient psychiatry settings and community-based day centers in Sweden', 'mental health service users']","['Balancing Everyday Life, a group-based lifestyle intervention']",[],"[{'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C1704765', 'cui_str': 'Place - dosing instruction imperative'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0025355', 'cui_str': 'Mental Hygiene Services'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]",[],,0.110859,"CONCLUSION Group leaders and participants experienced BEL as a useful tool to instigate meaningful change and connection in the participants' lives.","[{'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Lund', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Hultqvist', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Bejerholm', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Argentzell', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Eklund', 'Affiliation': 'Department of Health Sciences/Mental Health, Activity and Participation, Lund University, Lund, Sweden.'}]",Scandinavian journal of occupational therapy,['10.1080/11038128.2018.1551419'] 1061,28750548,"A feasibility study of a novel, task-specific movement training intervention for women with patellofemoral pain.","OBJECTIVE To investigate whether a novel, task-specific training intervention that focused on correcting pain-producing movement patterns was feasible and whether it would improve hip and knee kinematics, pain, and function in women with patellofemoral pain. DESIGN Prospective, non-randomized, within-group, double baseline, feasibility intervention study. SUBJECTS A total of 25 women with patellofemoral pain were enrolled. INTERVENTION The intervention, delivered 2×/week for six weeks, consisted of supervised, high-repetition practice of daily weight-bearing and recreational activities. Activities were selected and progressed based on participants' interest and ability to maintain optimal alignment without increasing pain. MAIN MEASURES Primary feasibility outcomes were recruitment, retention, adherence, and treatment credibility (Credibility/Expectancy Questionnaire). Secondary outcomes assessing intervention effects were hip and knee kinematics, pain (visual analog scale: current, average in past week, maximum in past week), and function (Patient-Specific Functional Scale). RESULTS A total of 25 participants were recruited and 23 were retained (92% retention). Self-reported average daily adherence was 79% and participants were able to perform their prescribed home program correctly (reduced hip and knee frontal plane angles) by the second intervention visit. On average, treatment credibility was rated 25 (out of 27) and expectancy was rated 22 (out of 27). Hip and knee kinematics, pain, and function improved following the intervention when compared to the control phase. CONCLUSION Based on the feasibility outcomes and preliminary intervention effects, this task-specific training intervention warrants further investigation and should be evaluated in a larger, randomized clinical trial.",2018,"Hip and knee kinematics, pain, and function improved following the intervention when compared to the control phase. ","['25 women with patellofemoral pain were enrolled', 'women with patellofemoral pain', 'A total of 25 participants were recruited and 23 were retained (92% retention']","['novel, task-specific training intervention', 'novel, task-specific movement training intervention', 'task-specific training intervention']","['Hip and knee kinematics, pain, and function', 'recruitment, retention, adherence, and treatment credibility (Credibility/Expectancy Questionnaire', 'Self-reported average daily adherence', 'hip and knee kinematics, pain, and function', 'hip and knee kinematics, pain (visual analog scale: current, average in past week, maximum in past week), and function (Patient-Specific Functional Scale']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0333118', 'cui_str': 'Retained (qualifier value)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0026649', 'cui_str': 'Movement'}]","[{'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale (assessment scale)'}]",25.0,0.0592801,"Hip and knee kinematics, pain, and function improved following the intervention when compared to the control phase. ","[{'ForeName': 'Gretchen B', 'Initials': 'GB', 'LastName': 'Salsich', 'Affiliation': '1 Program in Physical Therapy, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Yemm', 'Affiliation': '1 Program in Physical Therapy, Saint Louis University, St. Louis, MO, USA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Steger-May', 'Affiliation': '2 Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Catherine E', 'Initials': 'CE', 'LastName': 'Lang', 'Affiliation': '3 Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, USA.'}, {'ForeName': 'Linda R', 'Initials': 'LR', 'LastName': 'Van Dillen', 'Affiliation': '3 Program in Physical Therapy, Washington University School of Medicine, St. Louis, MO, USA.'}]",Clinical rehabilitation,['10.1177/0269215517723055'] 1062,29450737,Correlation between plaque control and gingival health using short and extended oral hygiene intervals.,"OBJECTIVES To evaluate the correlation between dental plaque formation and gingival health in subjects performing high oral hygiene standards over short or extended intervals. MATERIALS AND METHODS Fifty-two non-dental students volunteered for this study. The subjects, trained to perform high oral hygiene standards, were randomized to perform oral hygiene at 12-, 24-, 48-, or 72-h interval over 30 days. The plaque index (PlI) and the gingival index (GI) were evaluated at baseline, 15, and 30 days. For the statistical analysis, oral hygiene intervals were collapsed into daily (12 and 24 h; G12/24) and extended (48 and 72 h; G48/72) intervals. Summary statistics (mean ± SD) and Spearman correlations between the PlI and the GI at baseline, 15, and 30 days were estimated. RESULTS At baseline, correlation coefficients between PlI and GI were positive for both groups (r = 0.29 and r = 0.25). At day 15 and 30, correlation was maintained with similar baseline values for the G48/72 group. GI levels did not increase despite an increase in PlI for the G12/24 group, and the correlation was lower than that observed at baseline (r = 0.13 vs. r = 0.29). CONCLUSIONS In subjects with high oral hygiene standards, the oral hygiene frequency governs the correlation between dental plaque formation and gingival health. Subjects performing high oral hygiene standards at daily intervals will maintain gingival health in difference to subjects using extended hygiene intervals. CLINICAL RELEVANCE Subjects performing high oral hygiene standards at daily intervals will maintain gingival health in difference to subjects using extended hygiene intervals.",2018,"In subjects with high oral hygiene standards, the oral hygiene frequency governs the correlation between dental plaque formation and gingival health.","['Fifty-two non-dental students volunteered for this study', 'subjects performing high oral hygiene standards over short or extended intervals']",[],"['GI levels', 'plaque index (PlI) and the gingival index (GI', 'PlI']","[{'cui': 'C4319570', 'cui_str': 'Fifty-two'}, {'cui': 'C0038493', 'cui_str': 'Students, Dental'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1272386', 'cui_str': 'Mouth care management'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",[],"[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}]",,0.100879,"In subjects with high oral hygiene standards, the oral hygiene frequency governs the correlation between dental plaque formation and gingival health.","[{'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'De David', 'Affiliation': 'Division of Periodontology, Department of Stomatology, School of Dentistry, Federal University of Santa Maria, Santa Maria, Brazil.'}, {'ForeName': 'T G', 'Initials': 'TG', 'LastName': 'Mário', 'Affiliation': 'Division of Periodontology, Department of Stomatology, School of Dentistry, Federal University of Santa Maria, Santa Maria, Brazil.'}, {'ForeName': 'G C', 'Initials': 'GC', 'LastName': 'De Freitas', 'Affiliation': 'Division of Periodontology, Department of Stomatology, School of Dentistry, Federal University of Santa Maria, Santa Maria, Brazil.'}, {'ForeName': 'K Z', 'Initials': 'KZ', 'LastName': 'Kantorski', 'Affiliation': 'Division of Periodontology, Department of Stomatology, School of Dentistry, Federal University of Santa Maria, Santa Maria, Brazil.'}, {'ForeName': 'U M E', 'Initials': 'UME', 'LastName': 'Wikesjö', 'Affiliation': 'Laboratory for Applied Periodontal & Craniofacial Regeneration, Dental College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'Carlos Heitor Cunha', 'Initials': 'CHC', 'LastName': 'Moreira', 'Affiliation': 'Division of Periodontology, Department of Stomatology, School of Dentistry, Federal University of Santa Maria, Santa Maria, Brazil. carlosheitormoreira@gmail.com.'}]",Clinical oral investigations,['10.1007/s00784-018-2358-5'] 1063,31683467,Effects of dexmedetomidine on cerebral oxygen saturation and postoperative cognitive function in elderly patients undergoing minimally invasive coronary artery bypass surgery.,"OBJECTIVE This study aimed to investigate the effects of dexmedetomidine on cerebral oxygen saturation [Sct(O2)] and postoperative cognitive function in elderly patients undergoing minimally invasive coronary artery bypass graft surgery. METHODS Sixty elderly patients who received minimally invasive coronary artery bypass graft surgery were randomly equally divided into dexmedetomidine group (group D) and control group (group N). The patients in group D were pumped with 1 μg/kg dexmedetomidine for 15 min before incision, followed by continuous pumping at 0.3-0.5 μg/(kg·h) till the end of the operation. The patients in group N received same dose of normal saline during the operation. Sct(O2) was monitored at pre-induction (T0), post-induction (T1), 30 min (T2) after single-lung ventilation, and after surgery (T3). Mini-mental state examination (MMSE) was used to assess the cognitive function at 1 day before, 72 hour and 7 days after surgery. RESULTS Sct(O2) level in group D was significantly higher than that in group N at T2 (P < 0.05). Sct(O2) level was statistically lower at T2 than that at T0, T1 and T3 in the same group N (P < 0.05). At 72 h and 7d after operation, the incidence of cognitive dysfunction in group D was markedly lower than that in group N (P < 0.05), the MMSE score in group D was markedly higher than those in group N, but was significantly lower than that before surgery (P < 0.05). CONCLUSION Dexmedetomidine can alleviate the decrease of Sct(O2) during single-lung ventilation, improve postoperative cognitive function, and reduce the incidence of POCD in elderly patients with minimally invasive coronary artery bypass surgery.",2020,"Sct(O2) level was statistically lower at T2 than that at T0, T1 and T3 in the same group N (P < 0.05).","['Sixty elderly patients who received minimally invasive coronary artery bypass graft surgery', 'elderly patients undergoing minimally invasive coronary artery bypass surgery', 'elderly patients undergoing minimally invasive coronary artery bypass graft surgery', 'elderly patients with minimally invasive coronary artery bypass surgery']","['Dexmedetomidine', 'dexmedetomidine', 'Mini-mental state examination (MMSE', 'normal saline']","['incidence of cognitive dysfunction', 'Sct(O2', 'incidence of POCD', 'cognitive function', 'postoperative cognitive function', 'cerebral oxygen saturation [Sct(O2', 'MMSE score', 'Sct(O2) level', 'cerebral oxygen saturation and postoperative cognitive function']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation (observable entity)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",60.0,0.0237976,"Sct(O2) level was statistically lower at T2 than that at T0, T1 and T3 in the same group N (P < 0.05).","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Imaging Center, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.'}, {'ForeName': 'Lining', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.'}, {'ForeName': 'Jinliang', 'Initials': 'J', 'LastName': 'Teng', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.'}, {'ForeName': 'Fulong', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.'}]",Clinical hemorheology and microcirculation,['10.3233/CH-190590'] 1064,30685963,A prospective randomized clinical study evaluating the efficacy and compliance of oral sulfate solution and 2-L ascorbic acid plus polyethylene glycol.,"BACKGROUND/AIMS Oral sulfate solution (OSS) is an emerging cleansing agent for bowel preparation. However, data comparing OSS to other conventional bowel preparations in Asian patients are limited. Therefore, the objective of this study was to compare the efficacy and tolerability of OSS to ascorbic acid plus polyethylene glycol (AA + PEG) in Asian patients. METHODS This was a prospective, randomized, parallel, investigator-blind study performed in two university hospitals in Korea. Bowel preparation efficacy was evaluated using both the Ottawa Bowel Preparation Scale (OBPS) and Boston Bowel Preparation Scale (BBPS). RESULTS Among 173 patients, 86 received OSS while 87 received AA + PEG for bowel preparation. Total OBPS score was 2.80 ± 2.48 in the OSS group and 4.49 ± 3.08 in the AA + PEG group, indicating significantly (p < 0.001) better efficacy with OSS. Total BBPS was higher in the OSS group (7.43 ± 1.49 vs. 6.51 ± 1.76, p < 0.001), indicating superior bowel preparation quality with OSS. Preparation-related adverse events were generally acceptable. Patients receiving OSS had more nausea (1.92 ± 0.94 vs. 1.54 ± 0.76, p = 0.004) and abdominal cramping (1.45 ± 0.78 vs. 1.17 ± 0.51, p = 0.006) than those receiving AA + PEG. However, overall satisfaction and taste were similar between the two groups. CONCLUSION OSS had a non-inferior bowel cleansing efficacy than AA + PEG regardless of colon segment.",2020,"Patients receiving OSS had more nausea (1.92 ± 0.94 vs. 1.54 ± 0.76, p = 0.004) and abdominal cramping (1.45 ± 0.78 vs. 1.17 ± 0.51, p = 0.006) than those receiving AA + PEG.","['Asian patients', '173 patients', 'two university hospitals in Korea']","['ascorbic acid plus polyethylene glycol (AA + PEG', 'AA + PEG', 'Oral sulfate solution (OSS', 'OSS', 'oral sulfate solution and 2-L ascorbic acid plus polyethylene glycol']","['Total OBPS score', 'Total BBPS', 'efficacy and tolerability', 'overall satisfaction and taste', 'nausea', 'abdominal cramping', 'Bowel preparation efficacy', 'Ottawa Bowel Preparation Scale (OBPS) and Boston Bowel Preparation Scale (BBPS']","[{'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0022771', 'cui_str': 'Korea'}]","[{'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0032483', 'cui_str': 'polyethylene oxide'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038720', 'cui_str': 'Sulfates, Inorganic'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0449206', 'cui_str': 'OSS (body structure)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure (procedure)'}, {'cui': 'C0222045'}, {'cui': 'C4302285', 'cui_str': 'Boston bowel preparation scale (assessment scale)'}]",173.0,0.096813,"Patients receiving OSS had more nausea (1.92 ± 0.94 vs. 1.54 ± 0.76, p = 0.004) and abdominal cramping (1.45 ± 0.78 vs. 1.17 ± 0.51, p = 0.006) than those receiving AA + PEG.","[{'ForeName': 'Ki Hwan', 'Initials': 'KH', 'LastName': 'Kwon', 'Affiliation': 'Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.'}, {'ForeName': 'Ji Ae', 'Initials': 'JA', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Yun Jeong', 'Initials': 'YJ', 'LastName': 'Lim', 'Affiliation': 'Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.'}, {'ForeName': 'Beom Jae', 'Initials': 'BJ', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Moon Kyung', 'Initials': 'MK', 'LastName': 'Joo', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Yu Ra', 'Initials': 'YR', 'LastName': 'Sim', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Wonjae', 'Initials': 'W', 'LastName': 'Choi', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Taehyun', 'Initials': 'T', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}, {'ForeName': 'Ji Yoon', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.'}, {'ForeName': 'Ei Rie', 'Initials': 'ER', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.'}, {'ForeName': 'Yoon Tae', 'Initials': 'YT', 'LastName': 'Jeen', 'Affiliation': 'Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.'}, {'ForeName': 'Jong-Jae', 'Initials': 'JJ', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.'}]",The Korean journal of internal medicine,['10.3904/kjim.2017.275'] 1065,31821151,Effectiveness and Cost-Effectiveness of a Self-Guided Internet Intervention for Social Anxiety Symptoms in a General Population Sample: Randomized Controlled Trial.,"BACKGROUND Many people are accessing digital self-help for mental health problems, often with little evidence of effectiveness. Social anxiety is one of the most common sources of mental distress in the population, and many people with symptoms do not seek help for what represents a significant public health problem. OBJECTIVE This study aimed to evaluate the effectiveness of a self-guided cognitive behavioral internet intervention for people with social anxiety symptoms in the general population. METHODS We conducted a two-group randomized controlled trial in England between May 11, 2016, and June 27, 2018. Adults with social anxiety symptoms who were not receiving treatment for social anxiety were recruited using online advertisements. All participants had unrestricted access to usual care and were randomized in a 1:1 ratio to either a Web-based unguided self-help intervention based on cognitive behavioral principles or a waiting list control group. All outcomes were collected through self-report online questionnaires. The primary outcome was the change in 17-item Social Phobia Inventory (SPIN-17) score from baseline to 6 weeks using a linear mixed-effect model that used data from all time points (6 weeks, 3 months, 6 months, and 12 months). RESULTS A total of 2122 participants were randomized, and 6 were excluded from analyses because they were ineligible. Of the 2116 eligible randomized participants (mean age 37 years; 80.24%, 1698/2116 women), 70.13% (1484/2116) had follow-up data available for analysis, and 56.95% (1205/2116) had data on the primary outcome, although attrition was higher in the intervention arm. At 6 weeks, the mean (95% CI) adjusted difference in change in SPIN-17 score in the intervention group compared with control was -1.94 (-3.13 to -0.75; P=.001), a standardized mean difference effect size of 0.2. The improvement was maintained at 12 months. Given the high dropout rate, sensitivity analyses explored missing data assumptions, with results that were consistent with those of the primary analysis. The economic evaluation demonstrated cost-effectiveness with a small health status benefit and a reduction in health service utilization. CONCLUSIONS For people with social anxiety symptoms who are not receiving other forms of help, this study suggests that the use of an online self-help tool based on cognitive behavioral principles can provide a small improvement in social anxiety symptoms compared with no intervention, although dropout rates were high. TRIAL REGISTRATION ClinicalTrials.gov NCT02451878; https://clinicaltrials.gov/ct2/show/NCT02451878.",2020,"At 6 weeks, the mean (95% CI) adjusted difference in change in SPIN-17 score in the intervention group compared with control was -1.94","['Adults with social anxiety symptoms who were not receiving treatment for social anxiety were recruited using online advertisements', 'people with social anxiety symptoms who are not receiving other forms of help', '2116 eligible randomized participants (mean age 37 years; 80.24%, 1698/2116 women), 70.13% (1484/2116) had follow-up data available for analysis, and 56.95% (1205/2116) had data on the primary outcome, although attrition was higher in the intervention arm', 'England between May 11, 2016, and June 27, 2018', 'A total of 2122 participants were randomized, and 6 were excluded from analyses because they were ineligible', 'people with social anxiety symptoms in the general population', 'All participants had unrestricted access to usual care', 'Social Anxiety Symptoms in a General Population Sample']","['Self-Guided Internet Intervention', 'Web-based unguided self-help intervention based on cognitive behavioral principles or a waiting list control group', 'self-guided cognitive behavioral internet intervention']","['SPIN-17 score', 'Effectiveness and Cost-Effectiveness', 'social anxiety symptoms', 'change in 17-item Social Phobia Inventory (SPIN-17) score']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C2919658', 'cui_str': 'Social phobia inventory'}]",2122.0,0.256543,"At 6 weeks, the mean (95% CI) adjusted difference in change in SPIN-17 score in the intervention group compared with control was -1.94","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Powell', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Williams', 'Affiliation': 'School of Nursing, Faculty of Education and Professional Studies, Nipissing University, North Bay, ON, Canada.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Atherton', 'Affiliation': 'Unit of Academic Primary Care, Warwick Medical School, University of Warwick, Coventry, United Kingdom.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Bennett', 'Affiliation': 'eHub Health Pty Ltd, Goulburn NSW, Australia.'}, {'ForeName': 'Yaling', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Davoudianfar', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Hellsing', 'Affiliation': 'Research School of Psychology, Australian National University, Canberra, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Mollison', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Milensu', 'Initials': 'M', 'LastName': 'Shanyinde', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Ly-Mee', 'Initials': 'LM', 'LastName': 'Yu', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Griffiths', 'Affiliation': 'Research School of Psychology, Australian National University, Canberra, Australia.'}]",Journal of medical Internet research,['10.2196/16804'] 1066,32408253,Effect of amino acids on IGF1 gene expression in human myotubes and skeletal muscle.,"OBJECTIVE Insulin-like growth factor I (IGF1) is an important regulator of collagen and extracellular matrix protein expression. We aimed to evaluate the effect of amino acids (AAs) on expression of IGF1 and IGF1-dependent genes in human myotubes and skeletal muscle and supposed that AAs administration increases IGF1 levels in blood and expression of IGF1 and IGF1-dependent genes in trained skeletal muscle, thereby reducing training-induced muscle damage. DESIGN Human myotubes were incubated with Arg and Leu for 24 h. Then, the effects of long-term branched chain AAs administration (10 weeks, 0.1 g/kg body mass/day) to volunteers (six subjects per AAs and placebo groups) performing large training volumes regularly (cross country skiers, training twice a day) were examined. RESULTS Incubating the myotubes with AAs increases expression of IGF1 mRNA isoforms and IGF1 secretion by 2-3 times. In athletes, long-term AAs administration increased basal blood levels of IGF1 (~50%) and expression of IGF1Ea mRNA slightly in skeletal muscle. There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration. However, expression of these genes in the combined group (placebo + AAs; n = 12) significantly correlated with the expression of IGF1Ea mRNA in muscle and did not correlate with IGF1 levels in the blood. CONCLUSIONS AAs administration increases IGF1 expression in vitro and in vivo. To obtain more pronounced changes in expression of IGF1 and IGF1-dependent genes in skeletal muscle, it may be necessary to increase the dose and/or duration of AAs administration.",2020,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","['human myotubes and skeletal muscle', 'Human myotubes were incubated with Arg and Leu for 24\xa0h']","['Insulin-like growth factor', 'amino acids', 'amino acids (AAs']","['IGF1 gene expression', 'IGF1 expression', 'basal blood levels of IGF1', 'expression of IGF1 mRNA isoforms and IGF1 secretion', 'expression of IGF1Ea mRNA', 'expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle', 'IGF1 levels']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1704336', 'cui_str': 'Skeletal muscle fiber'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}]","[{'cui': 'C0037657', 'cui_str': 'Somatomedin'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C0202220', 'cui_str': 'Somatomedin-C measurement'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0597298', 'cui_str': 'Isoforms'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0972255', 'cui_str': 'type I collagen alpha 1'}, {'cui': 'C0024375', 'cui_str': 'Protein-lysine 6-oxidase'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}]",,0.0302591,"There is no marked increase in expression of COL1A1, COL3A1, COL5A1, and LOX genes in skeletal muscle after AAs administration.","[{'ForeName': 'Egor M', 'Initials': 'EM', 'LastName': 'Lednev', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation. Electronic address: ledhauz@gmail.com.'}, {'ForeName': 'Irina V', 'Initials': 'IV', 'LastName': 'Kravchenko', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Vladimir A', 'Initials': 'VA', 'LastName': 'Furalyov', 'Affiliation': 'Federal Research Centre «Fundamentals of Biotechnology» of the Russian Academy of Sciences, 33 build 2, Leninsky prospect, Moscow 119071, Russian Federation.'}, {'ForeName': 'Evgeny A', 'Initials': 'EA', 'LastName': 'Lysenko', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Iulia S', 'Initials': 'IS', 'LastName': 'Lemesheva', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Alexandr A', 'Initials': 'AA', 'LastName': 'Grushin', 'Affiliation': 'Russian Olympic Committee, Luzhnetskaya Embankment 8, Russia, Moscow 119991, Russian Federation.'}, {'ForeName': 'Vadim E', 'Initials': 'VE', 'LastName': 'Dubrov', 'Affiliation': 'Lomonosov Moscow State University, Faculty of Fundamental Medicine, 27 build. 1, Lomonosovsky Prospekt, Moscow 119991, Russian Federation.'}, {'ForeName': 'Olga L', 'Initials': 'OL', 'LastName': 'Vinogradova', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}, {'ForeName': 'Daniil V', 'Initials': 'DV', 'LastName': 'Popov', 'Affiliation': 'Institute of Biomedical Problems of the RAS, 76A Khoroshevskoye Shosse, Moscow 123007, Russian Federation.'}]",Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,['10.1016/j.ghir.2020.101323'] 1067,30264178,Photobiomodulation therapy before futsal matches improves the staying time of athletes in the court and accelerates post-exercise recovery.,"This study aimed to analyze PBMT effects on futsal player's performance and recovery in a non-controlled field environment. It is a randomized, triple-blinded, placebo-controlled, crossover clinical trial. The research included six professional athletes and in each match phototherapy treatments were performed before matches (40 minutes), blood samples were collected before treatments, and samples immediately after the end of the matches and 48 h after. Furthermore, videos were analyzed to quantify the time athletes spent on the pitch and the distance they covered. PBMT was performed at 17 sites of each lower limb (40 mins before matches), employing a cluster with 12 diodes (4 laser diodes of 905 nm, 4 LEDs of 875 nm, and 4 LEDs of 640 nm, 30 J per site). The performance of the athlete could be quantified considering the time on the pitch and the distance covered; the biochemical markers evaluated were creatine kinase, lactate dehydrogenase, blood lactate, and oxidative damage to lipids and proteins. PBMT significantly increased the time of staying in the pitch and a significant improvement in all the biochemical markers evaluated. No statistically significant difference was found for the distance covered. Pre-exercise PBMT can enhance performance and accelerate recovery of high-level futsal players.",2019,No statistically significant difference was found for the distance covered.,[],"['exercise PBMT', 'Photobiomodulation therapy', 'placebo', 'PBMT']","['staying time', 'creatine kinase, lactate dehydrogenase, blood\xa0lactate, and oxidative damage to lipids and proteins', 'time of staying']",[],"[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4019433', 'cui_str': 'LLLT'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}, {'cui': 'C0022917', 'cui_str': 'L-Lactate Dehydrogenase'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]",6.0,0.0994139,No statistically significant difference was found for the distance covered.,"[{'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'De Marchi', 'Affiliation': 'Laboratory of Oxidative Stress and Antioxidants, Biotechnology Institute, University of Caxias do Sul, Caxias do Sul, RS, Brazil. thiagomarchi@gmail.com.'}, {'ForeName': 'Ernesto Cesar Pinto', 'Initials': 'ECP', 'LastName': 'Leal-Junior', 'Affiliation': 'Postgraduate Program in Rehabilitation Sciences, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil.'}, {'ForeName': 'Kalvin Comin', 'Initials': 'KC', 'LastName': 'Lando', 'Affiliation': 'Academic Physical Therapy, Faculty Cenecista of Bento Gonçalves (CNEC), Bento Gonçalves, RS, Brazil.'}, {'ForeName': 'Fabiane', 'Initials': 'F', 'LastName': 'Cimadon', 'Affiliation': 'Academic Physical Therapy, Faculty Cenecista of Bento Gonçalves (CNEC), Bento Gonçalves, RS, Brazil.'}, {'ForeName': 'Adriane Aver', 'Initials': 'AA', 'LastName': 'Vanin', 'Affiliation': 'Laboratory of Phototherapy and Innovative Technologies in Health, Nove de Julho University (UNINOVE), São Paulo, SP, Brazil.'}, {'ForeName': 'Darlan Pase', 'Initials': 'DP', 'LastName': 'da Rosa', 'Affiliation': 'Faculty Cenecista of Bento Gonçalves (CNEC), Bento Gonçalves, RS, Brazil.'}, {'ForeName': 'Mirian', 'Initials': 'M', 'LastName': 'Salvador', 'Affiliation': 'Laboratory of Oxidative Stress and Antioxidants, Biotechnology Institute, University of Caxias do Sul, Caxias do Sul, RS, Brazil.'}]",Lasers in medical science,['10.1007/s10103-018-2643-1'] 1068,30689293,Use of an Elbow Brace During Repetitive Pitching Does Not Cause an Increased Mechanical Burden on the Throwing Arm.,"BACKGROUND Repetitive pitching induces an increase in medial elbow joint space gapping and may consequently lead to local tissue stress and injury. Use of an elbow brace may prevent this from occurring by preventing an increase of medial elbow joint space gapping. However, an elbow brace adds weight to the limb and may increase the burden on the throwing arm. OBJECTIVE To investigate whether use of an elbow brace during repetitive pitching reduces shoulder and arm range of motion and grip strength. DESIGN Prospective crossover study. SETTING University campus. PARTICIPANTS Twenty-five healthy high school baseball players. METHODS Each participant pitched 100 times under two conditions: without an elbow brace (control) and wearing an elbow brace. MAIN OUTCOME MEASUREMENTS Shoulder and elbow range of motion (ROM) before pitching and after every block of 20 pitches. Grip strength before pitching and after 100 pitches. RESULTS There was no significant main effect and interaction for ROM between the two conditions and between pitching sets. In both conditions, grip strength after 100 pitches was significantly lower than that before pitching (P < .05). When the two conditions were compared, there was no significant difference before pitching or after 100 pitches. CONCLUSIONS Use of elbow brace does not alter shoulder and elbow ROM or decrease grip strength after repetitive pitching up to 100 times compared with a no brace condition. An elbow brace can be used during repetitive pitching without causing an increased mechanical burden on the throwing arm. LEVEL OF EVIDENCE II.",2019,"CONCLUSIONS Use of elbow brace does not alter shoulder and elbow ROM or decrease grip strength after repetitive pitching up to 100 times compared with a no brace condition.","['University campus', 'Twenty-five healthy high school baseball players']","['Elbow Brace', 'elbow brace', 'elbow brace (control) and wearing an elbow brace']","['grip strength', 'Mechanical Burden', 'Grip strength', 'Shoulder and elbow range of motion (ROM']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0004795', 'cui_str': 'Baseball'}]","[{'cui': 'C0438899', 'cui_str': 'Elbow brace (physical object)'}]","[{'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0575649', 'cui_str': 'Joint movement: elbow'}]",25.0,0.0336172,"CONCLUSIONS Use of elbow brace does not alter shoulder and elbow ROM or decrease grip strength after repetitive pitching up to 100 times compared with a no brace condition.","[{'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Hattori', 'Affiliation': 'Department of Physical Therapy, Saitama Medical University Graduate School of Medicine, Moroyama, Saitama, Japan.'}, {'ForeName': 'Kiyokazu', 'Initials': 'K', 'LastName': 'Akasaka', 'Affiliation': 'Department of Physical Therapy, Saitama Medical University Graduate School of Medicine, Moroyama, Saitama, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Otsudo', 'Affiliation': 'Department of Physical Therapy, Saitama Medical University Graduate School of Medicine, Moroyama, Saitama, Japan.'}, {'ForeName': 'Toby', 'Initials': 'T', 'LastName': 'Hall', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Katsuya', 'Initials': 'K', 'LastName': 'Amemiya', 'Affiliation': 'Department of Rehabilitation, Kawagoe Clinic, Saitama Medical University, Kawagoe, Saitama, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Mori', 'Affiliation': 'Department of Rehabilitation, Kawagoe Clinic, Saitama Medical University, Kawagoe, Saitama, Japan.'}]","PM & R : the journal of injury, function, and rehabilitation",['10.1002/pmrj.12083'] 1069,30688120,Effect of spinal anesthesia on the QT interval in term and post-term pregnancies scheduled for elective cesarean section: a prospective study.,"Objectives: In this study, we aimed to investigate the effects of spinal anesthesia on the QT interval in patients with term and post-term pregnancy that were scheduled for elective cesarean section. Materials and methods: Forty pregnant women scheduled for elective cesarean section under spinal anesthesia were assigned into two groups: Post-term group (Group P) ( n  = 20) and Term group (Group T) ( n  = 20). After entering the operation room, standard monitoring [electrocardiography (ECG), noninvasive blood pressure, heart rate, respiratory rate, and peripheral oxygen saturation] was performed. The patient was placed in the sitting position and spinal anesthesia was performed with a median approach at the L3-L4a level using a 25G Quincke-type spinal needle. After cerebrospinal fluid was viewed, 12.5 mg (2.5 mL) hyperbaric bupivacaine was administered intrathecally over 1 min. Other ECG records were made at min 1 (T1), 5 (T2), and 10 (T3) after the induction of spinal anesthesia and after skin closure (T4). QT and QT dispersion were measured from ECG. Heart rate-corrected QT (QTc) and QT dispersion (QTcd) values were calculated using the Bazett formula. Results: Demographic characteristics of the patients were similar in both groups. Postoperative QTc, QTd, and QTcd values were significantly increased in Group P compared to those in Group T ( p  < .05). Conclusion: Spinal anesthesia led to increased postoperative QTc, QTd, and QTcd values in the patients with a gestational age of ≥42 weeks who underwent cesarean section. Accordingly, it is advisable to perform postoperative strict cardiac monitoring particularly in post-term pregnant women undergoing spinal anesthesia.",2020,"Postoperative QTc, QTd, and QTcd values were significantly increased in Group P compared to those in Group T (p < .05). ","['patients with term and post-term pregnancy that were scheduled for elective cesarean section', 'pregnant women undergoing spinal anesthesia', 'term and post-term pregnancies scheduled for elective cesarean section', 'patients with a gestational age of ≥42 weeks who underwent cesarean section', 'Forty pregnant women scheduled for elective cesarean section under spinal anesthesia']","['spinal anesthesia', 'hyperbaric bupivacaine']","['QT and QT dispersion', 'QT interval', 'standard monitoring [electrocardiography (ECG), noninvasive blood pressure, heart rate, respiratory rate, and peripheral oxygen saturation', 'postoperative QTc, QTd, and QTcd values', 'Heart rate-corrected QT (QTc) and QT dispersion (QTcd', 'Postoperative QTc, QTd, and QTcd values']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032993', 'cui_str': 'Pregnancy, Prolonged'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}]","[{'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0332624', 'cui_str': 'Dispersion'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C1623258', 'cui_str': 'ECG'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0231832', 'cui_str': 'Respiration Rate'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}]",40.0,0.0198039,"Postoperative QTc, QTd, and QTcd values were significantly increased in Group P compared to those in Group T (p < .05). ","[{'ForeName': 'Mahmut Alp', 'Initials': 'MA', 'LastName': 'Karahan', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Incebiyik', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}, {'ForeName': 'Evren', 'Initials': 'E', 'LastName': 'Buyukfirat', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Altay', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}, {'ForeName': 'Orhan', 'Initials': 'O', 'LastName': 'Binici', 'Affiliation': 'Department of Anesthesiology and Reanimation, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}, {'ForeName': 'Feyzullah', 'Initials': 'F', 'LastName': 'Besli', 'Affiliation': 'Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, Turkey.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2019.1569620'] 1070,30681754,Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.,"BACKGROUND AND PURPOSE The aim was to evaluate the efficacy of the catechol-O-methyltransferase inhibitor opicapone (25 and 50 mg) as adjunct therapy to levodopa in a pooled population of Parkinson's disease patients who participated in the pivotal double-blind trials of opicapone and their 1-year open-label extensions. METHODS Data (placebo, opicapone 25 mg and opicapone 50 mg) from the BIPARK-1 and BIPARK-2 double-blind and open-label studies were combined. The studies had similar designs, eligibility criteria and assessment methods. The primary efficacy variable in both double-blind studies was the change from baseline in absolute OFF time based on patient diaries. RESULTS Double-blind treatment with opicapone (25 and 50 mg) significantly reduced absolute daily OFF time from a baseline of 6.1-6.6 h. The mean (and 95% confidence interval) treatment effect versus placebo was -35.1 (-62.1, -8.2) min (P = 0.0106) for the 25 mg dose and -58.1 (-84.5, -31.7) min (P < 0.0001) for the 50 mg dose. Reductions in OFF time were mirrored by significant increases in ON time without troublesome dyskinesia (P < 0.05 and P < 0.0001 for the 25 and 50 mg doses, respectively). No significant differences were observed for ON time with troublesome dyskinesia. Patient diary results from the open-label phase indicated a maintenance of effect for patients previously treated with opicapone 50 mg. The group previously treated with the 25 mg dose benefitted with further optimization of therapy during the open-label phase, whilst switching from placebo to opicapone led to significant reductions in OFF time and increased ON time. CONCLUSIONS Over at least 1 year of open-label therapy, opicapone consistently reduced OFF time and increased ON time without increasing the frequency of troublesome dyskinesia.",2019,"RESULTS Double-blind treatment with opicapone (25 and 50 mg) significantly reduced absolute daily OFF time from a baseline of 6.1-6.6 h.","[""fluctuating Parkinson's disease patients"", ""pooled population of Parkinson's disease patients who participated in the pivotal double-blind trials of opicapone and their 1-year open-label extensions""]","['placebo', 'levodopa', 'catechol-O-methyltransferase inhibitor opicapone', 'placebo, opicapone 25 mg and opicapone', 'opicapone']","['OFF time', 'OFF time and increased ON time', 'ON time without troublesome dyskinesia', 'absolute OFF time', 'frequency of troublesome dyskinesia', 'absolute daily OFF time', 'ON time with troublesome dyskinesia']","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0337051', 'cui_str': 'Pool (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C2933912', 'cui_str': '2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C4521910', 'cui_str': 'Catechol-O-methyltransferase inhibitor'}, {'cui': 'C2933912', 'cui_str': '2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine 1-oxide'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C1869094', 'cui_str': 'Dyskinesia (SMQ)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]",,0.328549,"RESULTS Double-blind treatment with opicapone (25 and 50 mg) significantly reduced absolute daily OFF time from a baseline of 6.1-6.6 h.","[{'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Ferreira', 'Affiliation': 'Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Torres Vedras, Portugal.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lees', 'Affiliation': 'Reta Lila Weston Institute, University College London, London, UK.'}, {'ForeName': 'J-F', 'Initials': 'JF', 'LastName': 'Rocha', 'Affiliation': 'Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Rascol', 'Affiliation': 'Clinical Investigation Centre CIC1436, Departments of Clinical Pharmacology and Neurosciences, NS-Park/FCRIN Network, University Hospital of Toulouse, INSERM, University Toulouse 3, Toulouse, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Soares-da-Silva', 'Affiliation': 'Department of Research and Development, BIAL - Portela & Ca SA, S. Mamede do Coronado, Portugal.'}]",European journal of neurology,['10.1111/ene.13914'] 1071,31784300,Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.,"BACKGROUND & AIMS Disease-associated factors influence parenteral support (PS) reduction in response to teduglutide in patients with intestinal failure associated-short bowel syndrome (SBS-IF). We sought to determine correlative relationships between plasma citrulline levels, small bowel length, and PS volume. METHODS A post hoc analysis of plasma citrulline levels from patients in the STEPS 24-week study of teduglutide in patients with SBS-IF. Plasma citrulline was assessed in all patients; patients were stratified 3 times into subgroups based on bowel anatomy, cause of SBS-IF, and baseline PS volumes. Correlation analyses used simple linear regression models. Statistical comparisons between study groups were conducted using 2-sided t tests for 2 independent mean differences. RESULTS Baseline plasma citrulline correlated with remnant small bowel length (r = 0.355, P = 0.002), but not with baseline PS volume (r = -0.167, P = 0.14), in the overall population. There was a robust correlation between the baseline and Week 24 citrulline (r = 0.705, P < 0.0001), and an inverse correlation between change from baseline in citrulline and PS volume from baseline to Week 24 (r = -0.359, P = 0.001). In all subgroups, patients treated with teduglutide showed numerically greater increases in plasma citrulline at Week 24 compared with placebo. CONCLUSION Baseline plasma citrulline showed significant correlations with small bowel length in patients with ≥50% colon remaining/no stoma/colon-in-continuity, and patients with SBS-IF causes other than IBD/vascular disease. Citrulline levels may correlate with PS changes in response to teduglutide and more research may reveal a relationship between citrulline levels within the heterogeneous population of patients with SBS-IF. ClinicalTrials.gov NCT00798967, ClinicalTrialsRegister.eu 2008-006193-15.",2020,"In all subgroups, patients treated with teduglutide showed numerically greater increases in plasma citrulline at Week 24 compared with placebo. ","['patients with ≥50% colon remaining', 'patients with SBS-IF', 'patients with intestinal failure associated-short bowel syndrome (SBS-IF']",['ClinicalTrialsRegister.eu'],"['plasma citrulline levels, small bowel length, and PS volume', 'citrulline and PS volume', 'plasma citrulline', 'plasma citrulline levels', 'small bowel length', 'Citrulline correlations', 'Plasma citrulline']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0036992', 'cui_str': 'Short Bowel Syndrome'}]",[],"[{'cui': 'C1271643', 'cui_str': 'Plasma citrulline level'}, {'cui': 'C0021852', 'cui_str': 'Intestines, Small'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}]",,0.132453,"In all subgroups, patients treated with teduglutide showed numerically greater increases in plasma citrulline at Week 24 compared with placebo. ","[{'ForeName': 'Palle Bekker', 'Initials': 'PB', 'LastName': 'Jeppesen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Rigshospitalet, Copenhagen, Denmark. Electronic address: Palle.Bekker.Jeppesen@regionh.dk.'}, {'ForeName': 'Simon M', 'Initials': 'SM', 'LastName': 'Gabe', 'Affiliation': ""Lennard Jones Intestinal Failure Unit, St. Mark's Hospital, Northwick Park, London, UK.""}, {'ForeName': 'Douglas L', 'Initials': 'DL', 'LastName': 'Seidner', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Hak-Myung', 'Initials': 'HM', 'LastName': 'Lee', 'Affiliation': 'Shire Human Genetic Therapies, Inc., Lexington, MA, USA.'}, {'ForeName': 'Clément', 'Initials': 'C', 'LastName': 'Olivier', 'Affiliation': 'Shire International GmbH, Zug, Switzerland.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.11.001'] 1072,31253718,Evidence that an intervention weakens the relationship between adolescent electronic cigarette use and tobacco smoking: a 24-month prospective study.,"BACKGROUND The electronic cigarette (e-cigarette) use to subsequent smoking relationship in adolescents has received much attention. Whether an intervention to reduce smoking initiation attenuated this relationship was assessed. METHOD Data were from 3994 adolescent never smokers (aged 13-14 years at baseline) as part of a cluster randomised controlled trial. Self-report measures of smoking, e-cigarette use and covariates were assessed and used to predict ever smoked cigarettes, any recent tobacco smoking and regularly smoked cigarettes at 24-month follow-up. RESULTS Baseline ever use of e-cigarettes was associated with ever smoked cigarettes (OR=4.03, 95% CI 3.33 to 4.88; controlling for covariates, OR=2.78, 95% CI 2.20 to 3.51), any recent tobacco smoking (OR=3.38, 95% CI 2.72 to 4.21; controlling for covariates, OR=2.17, 95% CI 1.76 to 2.69) and regularly smoked cigarettes (OR=3.60, 95% CI 2.35 to 5.51; controlling for covariates, OR=1.27, 95% CI 1.17 to 1.39) at follow-up. For ever smoked cigarettes only, the impact of e-cigarette use was attenuated in the intervention (OR=1.83) compared with control (OR=4.53) condition. For ever smoked cigarettes and any recent tobacco smoking, the impact of e-cigarette use was attenuated among those with friends who smoked (OR=2.05 (ever smoked); 1·53 (any tobacco use)) compared with those without friends who smoked (OR=3.32 (ever smoked); 2·17 (any tobacco use)). CONCLUSIONS This is one of the first studies to show that e-cigarette use was robustly associated with measures of smoking over 24 months and the first to show an intervention to attenuate the relationship. Further research with a broader age range of adolescents is required.",2020,"For ever smoked cigarettes and any recent tobacco smoking, the impact of e-cigarette use was attenuated among those with friends who smoked (OR=2.05 (ever smoked); 1·53 (any tobacco use)) compared with those without friends who smoked (OR=3.32 (ever smoked); 2·17 (any tobacco use)). ",['Data were from 3994 adolescent never smokers (aged 13-14 years at baseline'],[],"['adolescent electronic cigarette use and tobacco smoking', 'regularly smoked cigarettes', 'recent tobacco smoking']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4280017', 'cui_str': 'E-Cig Use'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]",,0.0288669,"For ever smoked cigarettes and any recent tobacco smoking, the impact of e-cigarette use was attenuated among those with friends who smoked (OR=2.05 (ever smoked); 1·53 (any tobacco use)) compared with those without friends who smoked (OR=3.32 (ever smoked); 2·17 (any tobacco use)). ","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Conner', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK m.t.conner@leeds.ac.uk.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Grogan', 'Affiliation': 'Department of Psychology, Manchester Metropolitan University, Manchester, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Simms-Ellis', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Keira', 'Initials': 'K', 'LastName': 'Flett', 'Affiliation': 'Faculty of Health Sciences, Staffordshire University, Staffordshire, UK.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Sykes-Muskett', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Cowap', 'Affiliation': 'Faculty of Health Sciences, Staffordshire University, Staffordshire, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Lawton', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Armitage', 'Affiliation': 'Psychology, University of Manchester, Manchester, Greater Manchester, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Meads', 'Affiliation': 'Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Laetitia', 'Initials': 'L', 'LastName': 'Schmitt', 'Affiliation': 'Academic Centre for Health Economics, University of York, York, UK.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Torgerson', 'Affiliation': 'Education, Durham University, Durham, Durham, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Institute of Health Sciences, University of Leeds, Leeds, UK.'}, {'ForeName': 'Kamran', 'Initials': 'K', 'LastName': 'Siddiqi', 'Affiliation': 'Institute of Health Sciences, University of York, York, North Yorkshire, UK.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054905'] 1073,30375187,A 5-week randomized clinical evaluation of a novel electric toothbrush head with regular and tapered bristles versus a manual toothbrush for reduction of gingivitis and plaque.,"OBJECTIVE To evaluate the efficacy of an oscillating-rotating (O-R) electric rechargeable toothbrush with a novel round brush head comprised of regular and tapered bristles in reducing plaque and gingivitis versus a manual toothbrush. METHODS This was a randomized, examiner-blind, parallel group, five-week study. Participants with mild-to-moderate plaque and gingivitis received an oral examination and were evaluated for baseline plaque (Rustogi Modified Navy Index), gingivitis (Modified Gingival Index) and gingival bleeding (Gingival Bleeding Index). Qualifying participants were randomly assigned to the novel Oral-B sensitive brush head (EB60) on an Oral-B Vitality O-R handle (D12) or an ADA manual toothbrush. Participants brushed twice daily with the assigned brush and a standard fluoride dentifrice for 5 weeks before returning for an oral examination and plaque and gingivitis evaluations. RESULTS A total of 150 participants were randomized to treatment and completed the study (mean age = 45.7 years). Both brushes demonstrated a statistically significant reduction in number of bleeding sites versus baseline (P < 0.001). At Week 5, the number of bleeding sites was reduced from baseline by 11.15 (52.2%) for the O-R brush and 5.04 (23.6%) for the manual brush. The treatment difference was statistically significant (P < 0.001). Significant reductions versus baseline (P < 0.001) were also seen for both brushes for MGI, GBI and Rustogi plaque measures (whole mouth, gingival margin and proximal), but the O-R brush produced significantly greater reductions versus the manual brush (P < 0.001). CONCLUSION The O-R handle and round brush head with tapered and regular bristles produced greater plaque and gingivitis reductions than the manual brush.",2019,Both brushes demonstrated a statistically significant reduction in number of bleeding sites versus baseline (P < 0.001).,"['A total of 150 participants were randomized to treatment and completed the study (mean age\xa0=\xa045.7\xa0years', 'Participants with mild-to-moderate plaque and gingivitis']","['standard fluoride dentifrice', 'oscillating-rotating (O-R) electric rechargeable toothbrush', 'novel Oral-B sensitive brush head (EB60) on an Oral-B Vitality O-R handle (D12) or an ADA manual toothbrush', 'novel electric toothbrush head with regular and tapered bristles versus a manual toothbrush']","['baseline plaque (Rustogi Modified Navy Index), gingivitis (Modified Gingival Index) and gingival bleeding (Gingival Bleeding Index', 'MGI, GBI and Rustogi plaque measures (whole mouth, gingival margin and proximal', 'number of bleeding sites', 'plaque and gingivitis reductions']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0016327', 'cui_str': 'Fluorides'}, {'cui': 'C0040462', 'cui_str': 'Toothpaste'}, {'cui': 'C0231458', 'cui_str': 'Rotated (qualifier value)'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush, device (physical object)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C0443165', 'cui_str': 'Brushing, function (observable entity)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0018578', 'cui_str': 'Handling'}, {'cui': 'C0490733', 'cui_str': 'Manual toothbrush (physical object)'}, {'cui': 'C1740271', 'cui_str': 'Electric toothbrush'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}]","[{'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017574', 'cui_str': 'Gingivitis'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C0017565', 'cui_str': 'Gingival Hemorrhage'}, {'cui': 'C4521854', 'cui_str': 'Gingival (intended site)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0205284', 'cui_str': 'Marginal (qualifier value)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",150.0,0.0790993,Both brushes demonstrated a statistically significant reduction in number of bleeding sites versus baseline (P < 0.001).,"[{'ForeName': 'Renzo Alberto', 'Initials': 'RA', 'LastName': 'Ccahuana-Vasquez', 'Affiliation': 'Clinical Operations, Procter & Gamble, Kronberg, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Adam', 'Affiliation': 'Clinical Operations, Procter & Gamble, Kronberg, Germany.'}, {'ForeName': 'Erinn', 'Initials': 'E', 'LastName': 'Conde', 'Affiliation': 'Clinical Operations, Procter & Gamble, Mason, Ohio.'}, {'ForeName': 'Julie M', 'Initials': 'JM', 'LastName': 'Grender', 'Affiliation': 'Clinical Statistics and Data Management, Procter & Gamble, Mason, Ohio.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Cunningham', 'Affiliation': 'Clinical Operations, Procter & Gamble, Mason, Ohio.'}, {'ForeName': 'C Ram', 'Initials': 'CR', 'LastName': 'Goyal', 'Affiliation': 'All Sum Research Center Ltd, Mississauga, Ontario, Canada.'}, {'ForeName': 'Jimmy', 'Initials': 'J', 'LastName': 'Qaqish', 'Affiliation': 'All Sum Research Center Ltd, Mississauga, Ontario, Canada.'}]",International journal of dental hygiene,['10.1111/idh.12372'] 1074,30375301,Predicting first-episode psychosis patients who will never relapse over 10 years.,"BACKGROUND Although relapse in psychosis is common, a small proportion of patients will not relapse in the long term. We examined the proportion and predictors of patients who never relapsed in the 10 years following complete resolution of positive symptoms from their first psychotic episode. METHOD Patients who previously enrolled in a 12-month randomized controlled trial on medication discontinuation and relapse following first-episode psychosis (FEP) were followed up after 10 years. Relapse of positive symptoms was operationalized as a change from a Clinical Global Impression scale positive score of <3 for at least 3 consecutive months to a score of ⩾3 (mild or more severe). Baseline predictors included basic demographics, premorbid functioning, symptoms, functioning, and neurocognitive functioning. RESULTS Out of 178 first-episode patients, 37 (21%) never relapsed during the 10-year period. Univariate predictors (p ⩽ 0.1) of patients who never relapsed included a duration of untreated psychosis (DUP) ⩽30 days, diagnosed with non-schizophrenia spectrum disorders, having less severe negative symptoms, and performing better in logical memory immediate recall and verbal fluency tests. A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders. CONCLUSIONS Treatment delay and neurocognitive function are potentially modifiable predictors of good long-term prognosis in FEP. These predictors are informative as they can be incorporated into an optimum risk prediction model in the future, which would help with clinical decision making regarding maintenance treatment in FEP.",2019,"A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders. ","['patients who never relapsed in the 10 years following complete resolution of positive symptoms from their first psychotic episode', 'Patients who previously enrolled in a 12-month randomized controlled trial on medication discontinuation and relapse following first-episode psychosis (FEP) were followed up after 10 years', 'episode psychosis patients who will never relapse over 10 years']",[],"['basic demographics, premorbid functioning, symptoms, functioning, and neurocognitive functioning', 'logical memory immediate recall and verbal fluency tests', 'Relapse of positive symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0338614'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1096777', 'cui_str': 'Randomized Controlled Trial'}, {'cui': 'C0439615', 'cui_str': 'First episode (qualifier value)'}, {'cui': 'C0033975', 'cui_str': 'Psychoses'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]",[],"[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0242393', 'cui_str': 'Immediate Recall'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}]",178.0,0.0356821,"A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders. ","[{'ForeName': 'Christy Lm', 'Initials': 'CL', 'LastName': 'Hui', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Honer', 'Affiliation': 'Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Edwin Hm', 'Initials': 'EH', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'W C', 'Initials': 'WC', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'Sherry Kw', 'Initials': 'SK', 'LastName': 'Chan', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'Emily Sm', 'Initials': 'ES', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'Edwin Pf', 'Initials': 'EP', 'LastName': 'Pang', 'Affiliation': 'Department of Psychiatry, United Christian Hospital, Hong Kong.'}, {'ForeName': 'Simon Sy', 'Initials': 'SS', 'LastName': 'Lui', 'Affiliation': 'Department of Psychiatry, Castle Peak Hospital, Hong Kong.'}, {'ForeName': 'Dicky Ws', 'Initials': 'DW', 'LastName': 'Chung', 'Affiliation': 'Department of Psychiatry, Tai Po Hospital, Hong Kong.'}, {'ForeName': 'W S', 'Initials': 'WS', 'LastName': 'Yeung', 'Affiliation': 'Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Hong Kong.'}, {'ForeName': 'Roger Mk', 'Initials': 'RM', 'LastName': 'Ng', 'Affiliation': 'Department of Psychiatry, Kowloon Hospital, Hong Kong.'}, {'ForeName': 'William Tl', 'Initials': 'WT', 'LastName': 'Lo', 'Affiliation': 'Department of Psychiatry, Kwai Chung Hospital, Hong Kong.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, England.'}, {'ForeName': 'Pak', 'Initials': 'P', 'LastName': 'Sham', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}, {'ForeName': 'Eric Yh', 'Initials': 'EY', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, University of Hong Kong, Hong Kong.'}]",Psychological medicine,['10.1017/S0033291718003070'] 1075,30653372,Occupational therapy and activity pacing with hospital-associated deconditioned older adults: a randomised controlled trial.,"Purpose: To examine the efficacy of an occupational therapy activity pacing intervention with deconditioned older adults in rehabilitation. Method: Randomised, single-blind controlled trial of deconditioned older adults admitted for rehabilitation following treatment of an acute medical condition, allocated to intervention [ n  = 51, males = 14, mean age = 80(8)] or control [ n  = 49, males = 12, mean age = 81(7)] group. The intervention group received individual and group activity pacing education with practice and application of techniques to daily activities and the home environment, while the control group received a typical occupational therapy program, which included brief activity pacing education. Outcomes included participation in daily living skills, health status (including pain and fatigue symptoms), self-efficacy in daily activities and activity pacing techniques using the Australian Therapy Outcome Measures-Occupational Therapy (AusTOMs-OT), Short Form-36 Health Survey (SF-36), Self-Efficacy Gauge and Activity Pacing Assessment. Results: No differences in groups at admission. Comparison at discharge and three months post discharge using 2 × 2 mixed ANOVA demonstrated small differences in only one scale of the activity limitation domain of the AusTOMs-OT. No significant differences were found in other scales or domains of the AusTOMs-OT, nor secondary outcome measures. Conclusion: Activity pacing in addition to typical occupational therapy during inpatient rehabilitation did not demonstrate benefits to participants in the management of their daily activities on returning home post hospitalisation.Implications for rehabilitationActivity pacing has been identified as one of the commonly used occupational therapy interventions utilised with deconditioned older adults in rehabilitation.An activity pacing intervention in conjunction with typical occupational therapy demonstrated no benefits for deconditioned older adults over typical occupational therapy which included basic education on this topic.Continuation of the activity pacing intervention into the outpatient setting may be of benefit to older adults and requires further investigation.",2020,An activity pacing intervention in conjunction with typical occupational therapy demonstrated no benefits for deconditioned older adults over typical occupational therapy which included basic education on this topic.,"['deconditioned older adults', 'with hospital-associated deconditioned older adults', 'deconditioned older adults admitted for rehabilitation following treatment of an acute medical condition, allocated to intervention [n\u2009=\u200951, males\u2009=\u200914, mean age\u2009=\u200980(8)] or control [n\u2009=\u200949, males\u2009=\u200912, mean age\u2009=\u200981(7)] group', 'older adults', 'deconditioned older adults in rehabilitation']","['rehabilitation Activity pacing', 'Occupational therapy and activity pacing', 'individual and group activity pacing education with practice and application of techniques to daily activities and the home environment, while the control group received a typical occupational therapy program, which included brief activity pacing education', 'Activity pacing', 'activity pacing intervention', 'occupational therapy activity pacing intervention']","['participation in daily living skills, health status (including pain and fatigue symptoms), self-efficacy in daily activities and activity pacing techniques using the Australian Therapy Outcome Measures-Occupational Therapy (AusTOMs-OT), Short Form-36 Health Survey (SF-36), Self-Efficacy Gauge and Activity Pacing Assessment']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439053', 'cui_str': 'Fatigue - symptom (finding)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0562458', 'cui_str': 'Pacing up and down (finding)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C2586282', 'cui_str': 'Therapy outcome measure'}, {'cui': 'C1318464', 'cui_str': 'Occupational Therapy'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0456564', 'cui_str': 'Gauges (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",,0.0149108,An activity pacing intervention in conjunction with typical occupational therapy demonstrated no benefits for deconditioned older adults over typical occupational therapy which included basic education on this topic.,"[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Timmer', 'Affiliation': 'School of Health Medical and Applied Sciences, Central Queensland University, Melbourne, Australia.'}, {'ForeName': 'Carolyn A', 'Initials': 'CA', 'LastName': 'Unsworth', 'Affiliation': 'School of Health Medical and Applied Sciences, Central Queensland University, Melbourne, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Browne', 'Affiliation': 'School of Health Medical and Applied Sciences, Central Queensland University, Melbourne, Australia.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1535630'] 1076,30632455,Napping Improves HRV in Older Patients With Cardiovascular Risk Factors.,"Heart rate variability (HRV), especially increased high frequency (HF), has been reported to provide clinically useful prognostic information regarding cardiovascular disease. Napping is an excellent sleep management strategy in older adults. This study was conducted to clarify the effect of napping on HRV in older adult patients with cardiovascular risk factors. The patients were divided into two groups: one group of 32 patients who reported napping (nap group) and another group of 45 patients who did not report napping (nonnap group). The HRV was calculated in terms of the HF component over 24 hr during wakefulness, sleep, and 1 hr after sleep onset. The HF in the nap group was significantly higher than that in the nonnap group during all times measured. In addition, napping was a significant predictor of increased HF. This study shows the effectiveness of napping in the daily lives of patients with cardiovascular risk factors.",2019,The HF in the nap group was significantly higher than that in the nonnap group during all times measured.,"['older adult patients with cardiovascular risk factors', 'patients with cardiovascular risk factors', 'Older Patients With Cardiovascular Risk Factors', 'older adults']",['reported napping (nap group) and another group of 45 patients who did not report napping (nonnap group'],"['HRV', 'HF', 'Heart rate variability (HRV']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]","[{'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0067518', 'cui_str': 'NAPS'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",45.0,0.019108,The HF in the nap group was significantly higher than that in the nonnap group during all times measured.,"[{'ForeName': 'Natsuki', 'Initials': 'N', 'LastName': 'Nakayama', 'Affiliation': '1 Nagoya University Graduate School of Medicine, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Hayashi', 'Affiliation': '1 Nagoya University Graduate School of Medicine, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Miyachi', 'Affiliation': '2 Chutoen General Medical Center, Kakegawa, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Negi', 'Affiliation': '3 Negi Clinic, Inazawa, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': '4 Watanabe Medical Clinic, Taketoyo, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Hirai', 'Affiliation': '5 Sugiyama Jogakuen University, Nagoya, Japan.'}]",Western journal of nursing research,['10.1177/0193945918824603'] 1077,30604197,"International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients.","BACKGROUND The oral administration of drug β-D-mannuronic acid (M2000) showed a potent therapeutic effect in phase I/II study in rheumatoid arthritis (RA) patients. Here, our aim is to assess the efficacy and safety of this new drug in RA patients under a multinational, randomized placebo-controlled phase III clinical trial. METHOD Patients (n = 288) with active disease at baseline and inadequate response to conventional drugs were randomly allocated to three groups; (1) receiving mannuronic acid at a dose of two capsules (500 mg) per day orally for 12 weeks, (2) placebo-controlled, and (3) conventional. The primary endpoints were the America College of Rheumatology 20 response (ACR20), 28-joint disease activity score (DAS28) and Modified Health Assessment Questionnaire-Disability Index (M-HAQ-DI). In addition, the participants were followed-up for safety assessment. RESULTS In this phase III trial, after 12 weeks of treatment, there was a significant reduction in ACR20 between mannuronic-treated patients compared to placebo and conventional groups. Moreover, there was a similar significant improvement for DAS28 following mannuronic therapy. The statistical analysis showed a significant reduction in the swollen and tender joint count in mannuronic-treated patients compared with the placebo group. On the other side, mannuronic acid showed no-to-very low adverse events in comparison to placebo. CONCLUSION The results of this multinational, phase III clinical trial provided a potent evidence base for the use of β-D-mannuronic acid as a new highly safe and efficient drug in the treatment of RA.",2019,The statistical analysis showed a significant reduction in the swollen and tender joint count in mannuronic-treated patients compared with the placebo group.,"['rheumatoid arthritis patients', 'Patients (n\u2009=\u2009288) with active disease at baseline and inadequate response to conventional drugs', 'RA patients under a multinational, randomized', 'rheumatoid arthritis (RA) patients']","['placebo', 'drug β-D-mannuronic acid (M2000', 'mannuronic acid', 'β-D-mannuronic acid', 'placebo-controlled, and (3) conventional']","['ACR20', 'swollen and tender joint count', 'efficacy and safety', 'DAS28', 'America College of Rheumatology 20 response (ACR20), 28-joint disease activity score (DAS28) and Modified Health Assessment Questionnaire-Disability Index (M-HAQ-DI']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid Arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0162988', 'cui_str': 'mannuronic acid'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0451530', 'cui_str': 'Tender joint count (assessment scale)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002454', 'cui_str': 'Americas'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0022408', 'cui_str': 'Arthropathy'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451209', 'cui_str': 'Modified health assessment questionnaire (assessment scale)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0102923', 'cui_str': 'HAQ'}]",,0.239027,The statistical analysis showed a significant reduction in the swollen and tender joint count in mannuronic-treated patients compared with the placebo group.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Rezaieyazdi', 'Affiliation': 'Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Abid', 'Initials': 'A', 'LastName': 'Farooqi', 'Affiliation': 'Department of Rheumatology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Soleymani-Salehabadi', 'Affiliation': 'Department of Rheumatology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Ahmadzadeh', 'Affiliation': 'Department of Rheumatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Aslani', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Saiedeh', 'Initials': 'S', 'LastName': 'Omidian', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Arezoo', 'Initials': 'A', 'LastName': 'Sadoughi', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Vahidi', 'Affiliation': 'Inflammation and Inflammatory Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mandana', 'Initials': 'M', 'LastName': 'Khodashahi', 'Affiliation': 'Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Shazia', 'Initials': 'S', 'LastName': 'Zamurrad', 'Affiliation': 'Department of Rheumatology, Pakistan Institute of Medical Sciences, Islamabad, Pakistan.'}, {'ForeName': 'Seyed Shahabeddin', 'Initials': 'SS', 'LastName': 'Mortazavi-Jahromi', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Fallahzadeh', 'Affiliation': 'Research Center of Prevention and Epidemiology of Non-Communicable Disease, Departments of Biostatistics and Epidemiology, Faculty of Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Hosseini', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Aghazadeh', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Ekhtiari', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran.'}, {'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Matsuo', 'Affiliation': 'Nagasaki National Hospital, Sakuragi-cho 6-41, Nagasaki, Japan.'}, {'ForeName': 'Bernd H A', 'Initials': 'BHA', 'LastName': 'Rehm', 'Affiliation': 'Centre for Cell Factories and Biopolymers, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, Australia.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Cuzzocrea', 'Affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.'}, {'ForeName': 'Antimo', 'Initials': 'A', 'LastName': ""D'Aniello"", 'Affiliation': 'Laboratory of Neurobiology, Zoological Station of Naples ""Anton Dohrn"", Villa Comunale, Naples, Italy.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Mirshafiey', 'Affiliation': 'Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Box: 14155-6446, Tehran, Iran. mirshafiey@tums.ac.ir.'}]",Inflammopharmacology,['10.1007/s10787-018-00557-2'] 1078,25922327,Efficacy of prophylactic dexamethasone in prevention of postoperative nausea and vomiting.,"OBJECTIVE Many trials have been conducted with regard to the relative benefits of prophylactic anti-emetic interventions given alone or in combination, yet the results remain unknown. This study reviewed the efficacy of a single prophylactic dose of dexamethasone on postoperative nausea or vomiting (PONV) after abdominal hysterectomy. METHODS In a prospective study of 100 women undergoing total abdominal hysterectomy (TAH) under general anesthesia, the dexamethasone group (n=50) received a single dose (8 mg) immediately after the operation, and the saline group (n=50) received a dose of saline as a placebo, in addition to conventional management. The incidence of nausea, vomiting, the need for an anti-emetic and patient satisfaction with the management of PONV were evaluated during the first 24 postoperative hours. RESULTS The overall frequency of nausea during the initial postoperative 24 in the dexamethasone and saline groups were 12% and 18%, respectively, and vomiting was 10% and 16%, respectively (P=0.001). However, there was a lower need for a rescue anti-emetic drugs in the dexamethasone group (18% vs 24%), but it was not statistically significant (P=0.06). CONCLUSION The results of this study indicate that a single prophylactic dose of dexamethasone after an operation can reduce postoperative nausea and vomiting.",2015,"The incidence of nausea, vomiting, the need for an anti-emetic and patient satisfaction with the management of PONV were evaluated during the first 24 postoperative hours. ","['100 women undergoing total abdominal hysterectomy (TAH) under general anesthesia, the dexamethasone group (n=50']","['saline as a placebo', 'prophylactic dexamethasone', 'dexamethasone']","['overall frequency of nausea', 'vomiting', 'postoperative nausea or vomiting (PONV', 'nausea, vomiting, the need for an anti-emetic and patient satisfaction', 'postoperative nausea and vomiting']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0404079', 'cui_str': 'Total abdominal hysterectomy (procedure)'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445202', 'cui_str': 'Prophylactic (qualifier value)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0520904', 'cui_str': 'Postoperative Nausea'}, {'cui': 'C0520909', 'cui_str': 'PONV'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic Drugs'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}]",100.0,0.179388,"The incidence of nausea, vomiting, the need for an anti-emetic and patient satisfaction with the management of PONV were evaluated during the first 24 postoperative hours. ","[{'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Sekhavat', 'Affiliation': 'Obstetrics & Gynecologist, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Robab', 'Initials': 'R', 'LastName': 'Davar', 'Affiliation': 'Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Electronic address: sekhavat@ssu.ac.ir.'}, {'ForeName': 'Shekoufeh', 'Initials': 'S', 'LastName': 'Behdad', 'Affiliation': 'Department of Anesthesia, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}]",Journal of epidemiology and global health,['10.1016/j.jegh.2014.07.004'] 1079,23440811,Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis.,"BACKGROUND Wegener's granulomatosis (WG) is a necrotizing small-vessel vasculitis that can affect any organ in the body but mainly affects the upper and lower respiratory tract, the kidneys, joints, skin and eyes. The current mainstay of remission induction therapy is systemic corticosteroids in combination with oral daily cyclophosphamide (CYC) which induces remission in 75% to 100% of cases. Although standard therapy is effective in inducing partial or complete remission, 50% of complete remissions are followed by at least one relapse. This is an update of a review first published in 2009. OBJECTIVES To determine if intravenous immunoglobulin (IVIg) adjuvant therapy provides a therapeutic advantage over and above treatment with systemic corticosteroids in combination with immunosuppressants for the treatment of WG. SEARCH METHODS For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) searched the Specialised Register (last searched November 2012) and CENTRAL (2012, Issue 11). Trial databases were searched by the TSC for details of ongoing and unpublished studies. No date or language restrictions were applied. SELECTION CRITERIA Randomized controlled trials (RCTs), or quasi RCTs, or randomized cross-over trials. Participants had to be adults with a confirmed diagnosis of WG. DATA COLLECTION AND ANALYSIS Two authors independently extracted data and assessed trial quality. Relative risk was used to analyze dichotomous variables, and mean difference (MD) was used to analyze continuous variables. MAIN RESULTS We included one RCT with 34 participants who were randomly assigned to receive IVIg or placebo once daily in addition to azathioprine and prednisolone for remission maintenance. There were no significant differences between adjuvant IVIg and adjuvant placebo in mortality, serious adverse events, time to relapse, open-label rescue therapy, and infection rates. The fall in disease activity score, derived from patient-reported symptoms, was slightly greater in the IVIg group than in the placebo group at one month (MD 2.30; 95% Confidence interval (CI) 1.12 to 3.48, P < 0.01) and three months (MD 1.80; 95% CI 0.35 to 3.25, P = 0.01). There was a significant increase in total adverse events in the IVIg group (relative risk (RR) 3.50; 95% CI 1.44 to 8.48, P < 0.01). AUTHORS' CONCLUSIONS There is insufficient evidence from one RCT that IVIg adjuvant therapy provides a therapeutic advantage compared with the combination of steroids and immunosuppressants for patients with WG. Given the high cost of IVIg (one dose at 2 g/kg for a 70 kg patient = $8,400), it should be limited to treat WG in the context of a well conducted RCT powered to detect patient-relevant outcomes.",2013,"There were no significant differences between adjuvant IVIg and adjuvant placebo in mortality, serious adverse events, time to relapse, open-label rescue therapy, and infection rates.","[""Wegener's granulomatosis"", 'patients with WG', 'Participants had to be adults with a confirmed diagnosis of WG']","['Intravenous immunoglobulin', 'azathioprine and prednisolone', 'IVIg or placebo', 'placebo', 'intravenous immunoglobulin (IVIg) adjuvant therapy', 'cyclophosphamide (CYC']","['total adverse events', 'fall in disease activity score', 'mortality, serious adverse events, time to relapse, open-label rescue therapy, and infection rates']","[{'cui': 'C3495801', 'cui_str': 'Wegener Granulomatosis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0085297', 'cui_str': 'Immunoglobulins, Intravenous'}, {'cui': 'C0004482', 'cui_str': 'Azathioprine'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",1.0,0.449267,"There were no significant differences between adjuvant IVIg and adjuvant placebo in mortality, serious adverse events, time to relapse, open-label rescue therapy, and infection rates.","[{'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Fortin', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada. patricia@ti.ubc.ca.'}, {'ForeName': 'Aaron M', 'Initials': 'AM', 'LastName': 'Tejani', 'Affiliation': ''}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Bassett', 'Affiliation': ''}, {'ForeName': 'Vijaya M', 'Initials': 'VM', 'LastName': 'Musini', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD007057.pub3'] 1080,31679170,Presession attention affects the acquisition of tacts and intraverbals.,"This study examined the effects of presession attention on the acquisition of tacts (Experiment 1) and intraverbals (Experiment 2) in children diagnosed with autism. Each participant experienced 3 conditions. In the first 2 conditions, participants experienced a 15-min interval of either presession attention (PA) or no presession attention (NPA) followed by a teaching session. The third condition was a control condition. Across experiments, all participants acquired the verbal operants assigned to the NPA condition, whereas only 4 of the 6 participants acquired the verbal operants assigned to the PA condition. Five of the 6 participants required fewer sessions to meet the mastery criterion and a shorter duration of training for the verbal operants assigned to the NPA condition as compared to the PA condition. These outcomes suggest that antecedent manipulations traditionally reserved for mand training can positively affect the acquisition of other verbal operants. Theoretical implications are discussed.",2020,Five of the 6 participants required fewer sessions to meet the mastery criterion and a shorter duration of training for the verbal operants assigned to the NPA condition as compared to the PA condition.,['children diagnosed with autism'],"['presession attention (PA) or no presession attention (NPA', 'presession attention']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}]",[],,0.0160894,Five of the 6 participants required fewer sessions to meet the mastery criterion and a shorter duration of training for the verbal operants assigned to the NPA condition as compared to the PA condition.,"[{'ForeName': 'Mirela', 'Initials': 'M', 'LastName': 'Cengher', 'Affiliation': 'UMBC.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Fienup', 'Affiliation': 'Teachers College, Columbia University.'}]",Journal of applied behavior analysis,['10.1002/jaba.657'] 1081,31634512,Financial incentives and proactive calling for reducing barriers to tobacco treatment among socioeconomically disadvantaged women: A factorial randomized trial.,"Improved strategies and scalable interventions to engage low-socioeconomic status (SES) smokers in tobacco treatment are needed. We tested an intervention designed to connect low-SES smokers to treatment services, implemented through Minnesota's National Breast and Cervical Cancer Early Detection Program (Sage) in 2017; the trial was designed to last 3 months (July through October). Participants were female smokers who were 250% below the federal poverty level (randomized N = 3723; analyzed N = 3365). Using a factorial design, participants were randomized to six intervention groups consisting of a proactive call (no call vs call) and/or a financial incentive offered for being connected to treatment services ($0 vs $10 vs $20). Simple randomization was conducted using Stata v.13. All individuals received direct mail. Participants and staff were blinded to allocation. The outcome was connection via phone to QUITPLAN Services®, Minnesota's population-based cessation services. Groups that received $10 or $20 incentives had higher odds of treatment engagement compared to the no incentive group [respectively, OR = 1.94; 95% CI (1.19-3.14); OR = 2.18; 95% CI (1.36-3.51)]. Individuals that received proactive calls had higher odds of treatment engagement compared to individuals not called [OR = 1.59; 95% CI (1.11-2.29)]. Economic evaluation revealed that the $10 incentive, no call group had the best cost-benefit ratio compared to the no incentive, no call group. Direct mail with moderate incentives or proactive calling can successfully encourage connections to population-based tobacco treatment services among low-SES smokers. The intervention could be disseminated to similar programs serving low-SES populations. This trial is registered at ClinicalTrials.gov (NCT03760107).",2019,Groups that received proactive calls had higher odds of treatment engagement compared to groups not called [OR = 1.50; 95% CI (1.04-2.17)].,"['Participants were female smokers who were 250% below the federal poverty level (randomized N\u202f=\u202f3723', 'socioeconomically disadvantaged women']","[""connect low-SES smokers to treatment services, implemented through Minnesota's National Breast and Cervical Cancer Early Detection Program (Sage"", 'Financial incentives and proactive calling', 'Direct mail with moderate incentives or proactive calling', 'proactive call (no call vs call) and/or a financial incentive offered for being connected to treatment services ']",['cost-benefit ratio'],"[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0032854', 'cui_str': 'Poverty'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1122976', 'cui_str': 'Sage (substance)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1444648', 'cui_str': 'Offered'}]","[{'cui': 'C0010187', 'cui_str': 'Cost Benefit'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",20.0,0.106601,Groups that received proactive calls had higher odds of treatment engagement compared to groups not called [OR = 1.50; 95% CI (1.04-2.17)].,"[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Parks', 'Affiliation': 'University of Minnesota, 1100 S. Washington Ave., Minneapolis, MN 55415, USA; Minnesota Department of Health, 85 East 7th Place, St. Paul, MN 55164, USA. Electronic address: park0614@umn.edu.'}, {'ForeName': 'Kelly D', 'Initials': 'KD', 'LastName': 'Hughes', 'Affiliation': 'Minnesota Department of Health, 85 East 7th Place, St. Paul, MN 55164, USA.'}, {'ForeName': 'Paula A', 'Initials': 'PA', 'LastName': 'Keller', 'Affiliation': 'ClearWay Minnesota(SM), 8011 34th Ave S, Suite 400, Minneapolis, MN 55425, USA.'}, {'ForeName': 'Randi B', 'Initials': 'RB', 'LastName': 'Lachter', 'Affiliation': 'ClearWay Minnesota(SM), 8011 34th Ave S, Suite 400, Minneapolis, MN 55425, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Kingsbury', 'Affiliation': 'Minnesota Department of Health, 85 East 7th Place, St. Paul, MN 55164, USA.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Nelson', 'Affiliation': 'Minnesota Department of Health, 85 East 7th Place, St. Paul, MN 55164, USA.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Slater', 'Affiliation': 'Minnesota Department of Health, 85 East 7th Place, St. Paul, MN 55164, USA.'}]",Preventive medicine,['10.1016/j.ypmed.2019.105867'] 1082,30648520,The Effect of Methylphenidate on Reed Scaling in Benzodiazepine Poisoning: A Prospective Trial.,"BACKGROUND Benzodiazepine is one of the most important causes of substance abuse and intoxication throughout the world and Iran. OBJECTIVE The aim of our study is to determine the role of stimulants in reversing CNS level in acute Benzodiazepine poisoning patients who were hospitalized at referral poison center. METHOD This was a randomized double-blind placebo-controlled trial study on 32 cases with pure acute Benzodiazepine poisoning from March 2016 to February 2017. Diagnosis of pure acute poisoning was based on history, and laboratory confirmation. We gathered the demographics, clinical data, laboratory data, hospitalization and outcome. Participants were randomized into two groups: Methylphenidate Group (MPH) and Placebo Group (PBO). RESULTS The randomized sample consisted of 32 participants who were predominately female (83%). The majority of the PBO group and the MPH group reported improvement in their consciousness with a significant difference between the two groups (p = .005). Paired sample t-test analyses on Reed Scale data revealed an increase in the probability of improvement during the trial for the MPH group compared to the PBO group. Furthermore, the HCo3 (bicarbonate) level has a significant p-value with respect to age groups (p = .02). None of our cases required either the ICU facility or intubation. CONCLUSION Our study provided the MPH superiority over PBO in reversing CNS symptoms in loss of consciousness in acute BZD poisoned patients. Thus, this trial provides concrete evidence that improvement in consciousness levels (Reed Scale rated) among those patients receiving MPH was associated with a methylphenidate use.",2020,The majority of the PBO group and the MPH group reported improvement in their consciousness with a significant difference between the two groups (p = .005).,"['32 cases with pure acute Benzodiazepine poisoning from March 2016 to February 2017', '32 participants who were predominately female (83', 'acute Benzodiazepine poisoning patients who were hospitalized a referral poison center', 'acute BZD poisoned patients']","['Benzodiazepine', 'Methylphenidate Group (MPH) and Placebo Group (PBO', 'methylphenidate', 'placebo']","['HCo3 (bicarbonate) level', 'consciousness levels']","[{'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0412862', 'cui_str': 'Benzodiazepine poisoning'}, {'cui': 'C0332251', 'cui_str': 'Predominate (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034927', 'cui_str': 'Referral'}, {'cui': 'C0032344', 'cui_str': 'poisoning'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0025810', 'cui_str': 'Methylphenidate'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}]",32.0,0.146873,The majority of the PBO group and the MPH group reported improvement in their consciousness with a significant difference between the two groups (p = .005).,"[{'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Latifi-Pour', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Hassanian-Moghaddam', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}, {'ForeName': 'Helya-Sadat', 'Initials': 'HS', 'LastName': 'Mortazavi', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}, {'ForeName': 'Shahin', 'Initials': 'S', 'LastName': 'Shadnia', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}, {'ForeName': 'Nasim', 'Initials': 'N', 'LastName': 'Zamani', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}, {'ForeName': 'Mitra', 'Initials': 'M', 'LastName': 'Rahimi', 'Affiliation': 'Toxicological Research Center and Excellence Center of Clinical Toxicology, Department of Clinical Toxicology, Loghman Hakim Hospital Poison Center, Shahid Beheshti University of Medical Sciences, Kamali Avenue, South Karegar Street, Tehran, Iran.'}]",Current clinical pharmacology,['10.2174/1574884714666190112153157'] 1083,30565793,Donepezil for gait and falls in mild cognitive impairment: a randomized controlled trial.,"BACKGROUND AND PURPOSE Cognitive enhancers are commonly prescribed to people with Alzheimer's disease and related dementias to improve cognition and function. However, their effectiveness for individuals in the pre-stages of dementia, particularly in functional motor outcomes, remains unknown. We aimed to determine the efficacy of donepezil, a cognitive enhancer that improves cholinergic neurotransmission, on gait performance in mild cognitive impairment (MCI). METHODS This was a double-blind, placebo-controlled trial including 60 older adults with MCI, randomized to receive donepezil (10 mg/daily, maximal dose) or placebo. Primary outcome was gait speed (cm/s) under single and three dual-task conditions (counting backwards by 1 or 7 and naming animals) measured using an electronic walkway. Dual-task gait cost (DTC), a valid measure of motor-cognitive interaction, was calculated as the percentage change between single (S) and dual-task (D) gait speeds: [(S - D)/S] × 100. Secondary outcomes included attention, executive function, balance and falls. RESULTS After 6 months, the donepezil group experienced an improvement in dual-task gait speed (range 4-11 cm/s), although this was not statistically significant. The donepezil group showed a significant reduction in DTC (improvement) by counting backwards by 1 and 7 compared with placebo (10.25% vs. 1.75%, P = 0.048; 21.38% vs. 14.64%, P = 0.037, intention-to-treat analysis). Per-protocol analyses showed that all three DTCs improved in the donepezil group, along with a non-significant reduction of rate of falls. CONCLUSIONS Donepezil treatment improved dual-task gait speed and DTC in elderly patients with MCI. Our results support the concept of reducing falls in MCI by targeting the motor-cognitive interface.",2019,"The donepezil group showed a significant reduction in DTC (improvement) by counting backwards by 1 and 7 compared with placebo (10.25% vs. 1.75%, P = 0.048; 21.38% vs. 14.64%, P = 0.037, intention-to-treat analysis).","['60 older adults with MCI', 'elderly patients with MCI', 'mild cognitive impairment (MCI', 'mild cognitive impairment']","['donepezil', 'Donepezil', 'placebo']","['dual-task gait speed and DTC', 'gait speed (cm/s) under single and three dual-task conditions (counting backwards by 1 or 7 and naming animals) measured using an electronic walkway', 'rate of falls', 'Dual-task gait cost (DTC', 'dual-task gait speed', 'DTC', 'percentage change between single (S) and dual-task (D) gait speeds: [(S - D)/S', 'attention, executive function, balance and falls']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}]","[{'cui': 'C0527316', 'cui_str': 'donepezil'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0439392', 'cui_str': 'cm/s'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C4522128', 'cui_str': 'Name (property)'}, {'cui': 'C0003062', 'cui_str': 'Animals'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}]",60.0,0.467072,"The donepezil group showed a significant reduction in DTC (improvement) by counting backwards by 1 and 7 compared with placebo (10.25% vs. 1.75%, P = 0.048; 21.38% vs. 14.64%, P = 0.037, intention-to-treat analysis).","[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Montero-Odasso', 'Affiliation': 'Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, University of Western Ontario, London, ON.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Speechley', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Chertkow', 'Affiliation': 'Jewish General Hospital Memory Clinic, McGill University, Montreal, QC.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Sarquis-Adamson', 'Affiliation': 'Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, University of Western Ontario, London, ON.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Wells', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Borrie', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vanderhaeghe', 'Affiliation': ""Pharmacy Services, St Joseph's Health Care, London, ON.""}, {'ForeName': 'G Y', 'Initials': 'GY', 'LastName': 'Zou', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Fraser', 'Affiliation': 'Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, QC.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Bherer', 'Affiliation': 'Department of Medicine, Université de Montréal and Montreal Heart Institute, Montreal, QC.'}, {'ForeName': 'S W', 'Initials': 'SW', 'LastName': 'Muir-Hunter', 'Affiliation': 'Gait and Brain Lab, Parkwood Institute and Lawson Health Research Institute, University of Western Ontario, London, ON.'}]",European journal of neurology,['10.1111/ene.13872'] 1084,30472778,High-frequency repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation for spasticity management in secondary progressive multiple sclerosis.,"BACKGROUND AND PURPOSE The spasticity phenomenon is a significant factor in the development of disability. Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment method for this disorder. Our aim was to compare the effects of two protocols of rTMS - the high-frequency (HF) rTMS (20 Hz) and the intermittent theta-burst stimulation (iTBS) - on the level of spasticity and concomitant symptoms in patients with secondary progressive multiple sclerosis with an analysis of the duration of the effects up to 12 weeks after the stimulation course. METHODS Thirty-four patients with secondary progressive multiple sclerosis and lower spastic paraparesis were randomized into three groups: (i) HF-rTMS (20 Hz); (ii) iTBS; (iii) sham stimulation. Spasticity and spasticity-associated symptoms were assessed by the Modified Ashworth Scale, the Subjective Evaluating Spasticity Scale (SESS), the numerical analog scale, the Modified Fatigue Impact Scale and the pain level scale. RESULTS The Modified Ashworth Scale was significantly reduced after the stimulation course in the HF-rTMS and iTBS groups. The SESS was reduced post-intervention and at the two follow-ups in the iTBS group, whilst HF-rTMS produced an SESS reduction only at the 2-week follow-up, with no effects in the sham group. Conversely, reduction in pain and fatigue was found in the HF-rTMS group. CONCLUSIONS The results show that HF-rTMS and iTBS significantly reduce spasticity measured by the Modified Ashworth Scale, in contrast to sham stimulation. Some evidence was found in favor of a longer-lasting effect of iTBS on the SESS and of a reduction in pain and fatigue after HF-rTMS.",2019,"The results show that HF-rTMS and iTBS significantly reduce spasticity measured by the Modified Ashworth Scale, in contrast to sham stimulation.","['patients with secondary progressive multiple sclerosis with an analysis of the duration of the effects up to 12\xa0weeks after the stimulation course', 'secondary progressive multiple sclerosis', 'Thirty-four patients with secondary progressive multiple sclerosis and lower spastic paraparesis']","['High-frequency repetitive transcranial magnetic stimulation and intermittent theta-burst stimulation', 'rTMS - the high-frequency (HF) rTMS', 'HF-rTMS (20\xa0Hz); (ii) iTBS; (iii) sham stimulation', 'Repetitive transcranial magnetic stimulation (rTMS', 'HF-rTMS and iTBS', 'intermittent theta-burst stimulation (iTBS) ']","['pain and fatigue', 'Modified Ashworth Scale', 'Spasticity and spasticity-associated symptoms', 'SESS reduction', 'spasticity', 'Modified Ashworth Scale, the Subjective Evaluating Spasticity Scale (SESS), the numerical analog scale, the Modified Fatigue Impact Scale and the pain level scale']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0751965', 'cui_str': 'Multiple Sclerosis, Secondary Progressive'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0037771', 'cui_str': 'Spastic Lower Extremity Weakness'}]","[{'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale (assessment scale)'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom (finding)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0222045'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale (assessment scale)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",34.0,0.0234381,"The results show that HF-rTMS and iTBS significantly reduce spasticity measured by the Modified Ashworth Scale, in contrast to sham stimulation.","[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Korzhova', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Bakulin', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Sinitsyn', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Poydasheva', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Suponeva', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Zakharova', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Piradov', 'Affiliation': 'Research Center of Neurology (RCN), Moscow, Russia.'}]",European journal of neurology,['10.1111/ene.13877'] 1085,31525581,Transcranial direct current stimulation in patients with obsessive compulsive disorder: A randomized controlled trial.,"BACKGROUND Obsessive-compulsive disorder (OCD) is a severe mental disorder with poor response to the available treatments. Neuroimaging studies have identified dysfunctions within the orbito-fronto-striato-pallido-thalamic network in patients with OCD. Here, we assessed the efficacy and safety of transcranial direct current stimulation (tDCS) applied with the cathode over the orbitofrontal cortex (OFC) and the anode over the right cerebellum to decrease OCD symptoms in patients with treatment-resistant OCD. METHODS In a randomized sham-controlled double-blind study, 21 patients with OCD were assigned to receive ten 20-min sessions (two sessions per day) of either active (2 mA) or sham tDCS. The clinical symptoms were measured using the Yale-Brown Obsessive and Compulsive Scale (YBOCS). Acute effects on the symptoms were measured from baseline to immediately after the 10 tDCS sessions. Long-lasting effects were measured 1 and 3 months after the 10th tDCS session. RESULTS Compared with the sham tDCS, active tDCS significantly decreased OCD symptoms immediately after the 10th tDCS session (F (1,19)  = 5.26, p = 0.03). However, no significant differences were observed between the active and sham groups in terms of changes in YBOCS score or the number of responders one and 3 months after tDCS. CONCLUSION Despite significant acute effects, tDCS with the cathode placed over the left OFC and the anode placed over the right cerebellum was not significantly effective in inducing a long-lasting reduction of symptoms in patients with treatment-resistant OCD.",2019,"However, no significant differences were observed between the active and sham groups in terms of changes in YBOCS score or the number of responders one and 3 months after tDCS. ","['patients with OCD', 'patients with obsessive compulsive disorder', 'patients with treatment-resistant OCD', '21 patients with OCD']","['transcranial direct current stimulation (tDCS', 'Transcranial direct current stimulation', 'active (2\u202fmA) or sham tDCS']","['YBOCS score', 'Yale-Brown Obsessive and Compulsive Scale (YBOCS', 'efficacy and safety', 'OCD symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0028768', 'cui_str': 'Anankastic Personality'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0678579', 'cui_str': 'Brown'}, {'cui': 'C0222045'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.203964,"However, no significant differences were observed between the active and sham groups in terms of changes in YBOCS score or the number of responders one and 3 months after tDCS. ","[{'ForeName': 'Rémy', 'Initials': 'R', 'LastName': 'Bation', 'Affiliation': 'INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, Lyon, France; Centre Hospitalier Le Vinatier, Bron, France; Psychiatric Unit, Wertheimer Neurologic Hospital, CHU Lyon, F69500, Bron, France. Electronic address: remy.bation@chu-lyon.fr.'}, {'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Mondino', 'Affiliation': 'INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, Lyon, France; Centre Hospitalier Le Vinatier, Bron, France.'}, {'ForeName': 'Florent', 'Initials': 'F', 'LastName': 'Le Camus', 'Affiliation': 'INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, Lyon, France; Centre Hospitalier Le Vinatier, Bron, France.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Saoud', 'Affiliation': 'INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, Lyon, France; Centre Hospitalier Le Vinatier, Bron, France; Psychiatric Unit, Wertheimer Neurologic Hospital, CHU Lyon, F69500, Bron, France.'}, {'ForeName': 'Jerome', 'Initials': 'J', 'LastName': 'Brunelin', 'Affiliation': 'INSERM U1028, CNRS UMR5292, PSYR2 Team, Lyon Neuroscience Research Center, Université Claude Bernard Lyon 1, Lyon, France; Centre Hospitalier Le Vinatier, Bron, France.'}]",European psychiatry : the journal of the Association of European Psychiatrists,['10.1016/j.eurpsy.2019.08.011'] 1086,29074043,Change in lymphocyte to neutrophil ratio predicts acute rejection after heart transplantation.,"AIMS Most immunosuppressive drugs provide targeted immunosuppression by selective inhibition of lymphocyte activation and proliferation. This study evaluated whether a change in the lymphocyte to neutrophil ratio (LNR) is related to acute rejection. METHODS In 74 cardiac transplant recipients peripheral blood lymphocyte and neutrophil counts were measured soon after (baseline) and three, six, and 12months after heart transplantation. The primary endpoint was the incidence of acute rejection. RESULTS Significant acute rejection after heart transplantation occurred in 20 patients (27%) during a median follow-up of 49.4 [IQR 37.4-61.1] months. LNR significantly increased over time (0.1149±0.1354 at baseline, 0.2330±0.2266 at 3months, 0.2961±0.2849 at 6months, and 0.3521±0.2383 at 12months; P<0.001), especially during the first 3months in the group without acute rejection. The area under the curve of the change in LNR during the first three months (ΔLNR) for acute rejection was 0.565 (95% CI 0.420 to 0.710, P=0.380) on ROC curve analysis. The best cutoff value of Δ LNR to differentiate those with and without acute rejection was ≤0.046 by ROC curve analysis. Kaplan-Meier analysis revealed that the low ΔLNR group (≤0.046) had a significantly higher rate of acute rejection than the high ΔLNR group (>0.046) (37.5% vs. 19.0%, log-rank: P=0.0358). The low ΔLNR for the first 3months was an independent predictor of clinically significant acute rejection after adjusting for cytomegalovirus donor seropositive and recipient seronegative. CONCLUSIONS The results of this study suggest that ΔLNR over the first 3months after heart transplantation is a strong and independent predictor of acute rejection after heart transplantation. ΔLNR can be used as an early biomarker for predicting of acute rejection after heart transplantation.",2018,"LNR significantly increased over time (0.1149±0.1354 at baseline, 0.2330±0.2266 at 3months, 0.2961±0.2849 at 6months, and 0.3521±0.2383 at 12months; P<0.001), especially during the first 3months in the group without acute rejection.",['74 cardiac transplant recipients'],['ΔLNR'],"['peripheral blood lymphocyte and neutrophil counts', 'LNR', 'rate of acute rejection', 'lymphocyte to neutrophil ratio (LNR', 'incidence of acute rejection', 'acute rejection', 'acute rejection after heart transplantation']","[{'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}]",[],"[{'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0200633', 'cui_str': 'Neutrophil count (procedure)'}, {'cui': 'C0035015', 'cui_str': 'Rejection'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}]",,0.0255037,"LNR significantly increased over time (0.1149±0.1354 at baseline, 0.2330±0.2266 at 3months, 0.2961±0.2849 at 6months, and 0.3521±0.2383 at 12months; P<0.001), especially during the first 3months in the group without acute rejection.","[{'ForeName': 'Dong-Hyun', 'Initials': 'DH', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA; Department of Internal Medicine, Chosun University School of Medicine, Gwangju, Republic of Korea.'}, {'ForeName': 'Yuhei', 'Initials': 'Y', 'LastName': 'Kobayashi', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Nishi', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Luikart', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sadia', 'Initials': 'S', 'LastName': 'Dimbil', 'Affiliation': 'Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Kobashigawa', 'Affiliation': 'Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Kiran', 'Initials': 'K', 'LastName': 'Khush', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Fearon', 'Affiliation': 'Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA. Electronic address: wfearon@stanford.edu.'}]",International journal of cardiology,['10.1016/j.ijcard.2017.10.060'] 1087,29398160,"Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.","PURPOSE This study was designed to evaluate the safety and pharmacokinetic profiles of MRX-I tablet, an oxazolidinone antibacterial agent, in healthy Chinese subjects. METHODS The study was composed of 3 sequential periods. Period 1 was a randomized, double-blind, placebo-controlled, sequential ascending dose (50 to 1800 mg) study. Period 2 included one arm as a randomized, open-label, 3-period, 3 × 3 Latin square single-dose study of 300, 600, and 900 mg MRX-I administration and another arm as a crossover study to evaluate high-fat diet effect. Period 3 was a randomized, double-blind, placebo-controlled multiple-dose study with 600 or 800 mg, q12h regimens over 15 days. FINDINGS MRX-I was rapidly absorbed and reached peak plasma concentration at about 2 hours post dose. The C max was 8.07, 12.24, and 15.25 mg/L and the corresponding AUC 0-∞ 29.21, 48.27, and 59.60 mg/h/L, in 300-, 600-, and 900-mg dosing groups, respectively. High-fat diet increased the exposure of MRX-I. No discernable drug accumulation was observed after 15 days of continuous drug administration. About 2% of MRX-I was excreted via kidneys in unchanged form. No obvious hematologic toxicity by MRX-I was observed during the entire study. Based on Monte Carlo simulation, 600 or 800 mg BID can produce satisfactory efficacy against methicillin-resistant Staphylococcus aureus. IMPLICATIONS MRX-I was well tolerated in healthy Chinese subjects (50-1800 mg). No serious or severe adverse effects were observed. MRX-I 600 or 800 mg BID up to 15 days can be recommended in future clinical trials. Chinese Clinical Trial Registration (http://www.chinadrugtrials.org.cn) identifier: CTR20131214.",2018,High-fat diet increased the exposure of MRX-I. No discernable drug accumulation was observed after 15 days of continuous drug administration.,"['healthy Chinese subjects (50-1800 mg', 'healthy Chinese subjects', 'Healthy Chinese Subjects', 'I 600 or 800']","['placebo', 'MRX', 'MRX-I tablet', 'Oxazolidinone Antibacterial Agent', 'oxazolidinone antibacterial agent']","['hematologic toxicity', 'peak plasma concentration', 'No serious or severe adverse effects', 'exposure of MRX-I. No discernable drug accumulation']","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0887953', 'cui_str': 'Oxazolidinones'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]","[{'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]",,0.115183,High-fat diet increased the exposure of MRX-I. No discernable drug accumulation was observed after 15 days of continuous drug administration.,"[{'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Yunfei', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China. Electronic address: zhangj_fudan@aliyun.com.'}, {'ForeName': 'Yingyuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Jicheng', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Guoying', 'Initials': 'G', 'LastName': 'Cao', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Yuancheng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Beining', 'Initials': 'B', 'LastName': 'Guo', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Yaoguo', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Yuran', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Xiaofang', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Jufang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China; Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.'}, {'ForeName': 'Mikhail Fedorovich', 'Initials': 'MF', 'LastName': 'Gordeev', 'Affiliation': 'MicuRx Pharmaceuticals, Inc, Hayward, California.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'MicuRx Pharmaceuticals, Inc, Hayward, California.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'MicuRx Pharmaceuticals, Inc, Hayward, California.'}]",Clinical therapeutics,['10.1016/j.clinthera.2017.12.017'] 1088,30883686,Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU)-Protocol for a randomised clinical trial comparing a lower vs a higher oxygenation target in adults with acute hypoxaemic respiratory failure.,"BACKGROUND Acutely ill adults with hypoxaemic respiratory failure are at risk of life-threatening hypoxia, and thus oxygen is often administered liberally. Excessive oxygen use may, however, increase the number of serious adverse events, including death. Establishing the optimal oxygenation level is important as existing evidence is of low quality. We hypothesise that targeting an arterial partial pressure of oxygen (PaO 2 ) of 8 kPa is superior to targeting a PaO 2 of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure. METHODS The Handling Oxygenation Targets in the ICU (HOT-ICU) trial is an outcome assessment blinded, multicentre, randomised, parallel-group trial targeting PaO 2 in acutely ill adults with hypoxaemic respiratory failure within 12 hours after ICU admission. Patients are randomised 1:1 to one of the two PaO 2 targets throughout ICU stay until a maximum of 90 days. The primary outcome is 90-day mortality. Secondary outcomes are serious adverse events in the ICU, days alive without organ support and days alive out of hospital in the 90-day period; mortality, health-related quality-of-life at 1-year follow-up as well as 1-year cognitive and pulmonary function in a subgroup; and an overall health economic analysis. To detect or reject a 20% relative risk reduction, we aim to include 2928 patients. An interim analysis is planned after 90-day follow-up of 1464 patients. CONCLUSION The HOT-ICU trial will test the hypothesis that a lower oxygenation target reduces 90-day mortality compared with a higher oxygenation target in adult ICU patients with acute hypoxaemic respiratory failure.",2019,"We hypothesise that targeting an arterial partial pressure of oxygen (PaO 2 ) of 8 kPa is superior to targeting a PaO 2 of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure. ","['adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure', 'adult ICU patients with acute hypoxaemic respiratory failure', 'acutely ill adults with hypoxaemic respiratory failure within 12\xa0hours after ICU admission', '2928 patients', 'adults with acute hypoxaemic respiratory failure', 'Acutely ill adults with hypoxaemic respiratory failure', '1464 patients']",[],"['serious adverse events in the ICU, days alive without organ support and days alive out of hospital in the 90-day period; mortality, health-related quality-of-life at 1-year follow-up as well as 1-year cognitive and pulmonary function', '90-day mortality', 'overall health economic analysis']","[{'cui': 'C0587445', 'cui_str': 'Adult intensive care unit (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0340194', 'cui_str': 'Respiratory failure without hypercapnia (disorder)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C1292430', 'cui_str': '12 hours'}]",[],"[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0013557', 'cui_str': 'economics'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]",2928.0,0.378923,"We hypothesise that targeting an arterial partial pressure of oxygen (PaO 2 ) of 8 kPa is superior to targeting a PaO 2 of 12 kPa in adult intensive care unit (ICU) patients with acute hypoxaemic respiratory failure. ","[{'ForeName': 'Olav L', 'Initials': 'OL', 'LastName': 'Schjørring', 'Affiliation': 'Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Perner', 'Affiliation': 'Centre for Research in Intensive Care (CRIC), Copenhagen, Denmark.'}, {'ForeName': 'Jørn', 'Initials': 'J', 'LastName': 'Wetterslev', 'Affiliation': 'Centre for Research in Intensive Care (CRIC), Copenhagen, Denmark.'}, {'ForeName': 'Theis', 'Initials': 'T', 'LastName': 'Lange', 'Affiliation': 'Centre for Research in Intensive Care (CRIC), Copenhagen, Denmark.'}, {'ForeName': 'Frederik', 'Initials': 'F', 'LastName': 'Keus', 'Affiliation': 'Department of Critical Care, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Jon H', 'Initials': 'JH', 'LastName': 'Laake', 'Affiliation': 'Division of Emergencies and Critical Care, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Marjatta', 'Initials': 'M', 'LastName': 'Okkonen', 'Affiliation': 'Department of Perioperative, Intensive Care and Pain Medicine, Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siegemund', 'Affiliation': 'Department of Anaesthesia and Intensive Care, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Morgan', 'Affiliation': 'Critical Care Research, University Hospital of Wales, Cardiff, UK.'}, {'ForeName': 'Katrin M', 'Initials': 'KM', 'LastName': 'Thormar', 'Affiliation': 'Department of Anaesthesia and Intensive Care, University Hospital Reykjavik, Landspitali, Reykjavik, Iceland.'}, {'ForeName': 'Bodil S', 'Initials': 'BS', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Anaesthesia and Intensive Care Medicine, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13356'] 1089,31545636,Affinity between us: Examining how psychopathic traits influence the stigmatization of psychiatric disorders.,"Psychopathy is a personality disorder that is often stigmatized in both the general population and in legal settings. Although individuals with psychopathy face significant stigma, individuals with elevated psychopathic traits may hold fewer stigmatizing beliefs about this population. It is unclear, however, if this relationship stems from feelings of similarity or from traits of fearlessness that are commonly observed in some psychopathic individuals. In this study, 661 participants from the community were recruited online and completed the Triarchic Psychopathy Measure. They were then randomly assigned to read a description of either a nonviolent or violent psychopath, as well as either a nonviolent or violent person with schizophrenia. All participants also read a vignette of a nondangerous person with depression. For each description, participants completed the Attribution Questionnaire to measure stigmatizing attributes based on the vignette. Psychopathic traits were negatively associated with the stigmatization of individuals presented as either dangerous or nondangerous psychopaths, but were not associated with either forms of schizophrenia or with depression. Findings are explained in terms of identification with psychopaths. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,"Psychopathic traits were negatively associated with the stigmatization of individuals presented as either dangerous or nondangerous psychopaths, but were not associated with either forms of schizophrenia or with depression.","['All participants also read a vignette of a nondangerous person with depression', '661 participants from the community were recruited online and completed the Triarchic Psychopathy Measure']","['nonviolent or violent psychopath, as well as either a nonviolent or violent person with schizophrenia']",['Psychopathic traits'],"[{'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]","[{'cui': 'C0242151', 'cui_str': 'Violent'}, {'cui': 'C0003431', 'cui_str': 'Psychopathic Personality'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]",[],661.0,0.0428052,"Psychopathic traits were negatively associated with the stigmatization of individuals presented as either dangerous or nondangerous psychopaths, but were not associated with either forms of schizophrenia or with depression.","[{'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Durand', 'Affiliation': 'Department of Psychiatry and Neuropsychology.'}, {'ForeName': 'Robyn E', 'Initials': 'RE', 'LastName': 'Metcalfe', 'Affiliation': 'Department of Counseling and Human Services.'}, {'ForeName': 'Ioana-Smărăndita', 'Initials': 'IS', 'LastName': 'Arbone', 'Affiliation': 'Department of Public Health.'}]",Personality disorders,['10.1037/per0000362'] 1090,30377243,Evidence of compensation among waterpipe smokers using harm reduction components.,"OBJECTIVES We examined two waterpipe tobacco smoking components advertised to reduce harm to determine if they result in lower levels of biomarkers of acute exposure. METHODS We conducted a crossover study of 34 experienced waterpipe smokers smoking a research-grade waterpipe in three configurations ad libitum in a controlled chamber: control (quick-light charcoal), electric (electric heating) and bubble diffuser (quick-light charcoal and bubble diffuser). We collected data on smoking topography, environmental carbon monoxide (CO), subjective effects, heart rate, plasma nicotine and exhaled CO and benzene. RESULTS Smokers' mean plasma nicotine, heart rate, and exhaled benzene and CO boost were all significantly lower for electric compared with control. However, smokers puffed more intensely and took significantly more and larger volume puffs for a larger total puffing volume (2.0 times larger, p<0.0001) when smoking electric; machine yields indicate this was likely due to lower mainstream nicotine. Smokers rated electric smoking experience less satisfying and less pleasant. For charcoal heating, the mean mass of CO emitted into the chamber was ~1 g when participants smoked for a mean of 32 minutes at a typical residential ventilation rate (2.3 hr -1 ). CONCLUSION Waterpipe smokers engaged in compensation (i.e., increased and more intense puffing) to make up for decreased mainstream nicotine delivery from the same tobacco heated two ways. Waterpipe components can affect human puffing behaviours, exposures and subjective effects. Evidence reported here supports regulation of waterpipe components, smoking bans in multifamily housing and the use of human studies to evaluate modified or reduced risk claims.",2020,"RESULTS Smokers' mean plasma nicotine, heart rate, and exhaled benzene and CO boost were all significantly lower for electric compared with control.",['34 experienced waterpipe smokers smoking a research-grade waterpipe in three configurations ad'],"['libitum in a controlled chamber: control (quick-light charcoal), electric (electric heating) and bubble diffuser (quick-light charcoal and bubble diffuser']","['typical residential ventilation rate', 'mean plasma nicotine, heart rate, and exhaled benzene and CO boost', 'smoking topography, environmental carbon monoxide (CO), subjective effects, heart rate, plasma nicotine and exhaled CO and benzene']","[{'cui': 'C4302493', 'cui_str': 'Smoking Water Pipes'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0035168'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0007955', 'cui_str': 'Charcoal'}, {'cui': 'C0018851', 'cui_str': 'Heating'}]","[{'cui': 'C2945579', 'cui_str': 'Ventilation, function (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0053291', 'cui_str': 'benzyl chloride'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",34.0,0.0136421,"RESULTS Smokers' mean plasma nicotine, heart rate, and exhaled benzene and CO boost were all significantly lower for electric compared with control.","[{'ForeName': 'Marielle C', 'Initials': 'MC', 'LastName': 'Brinkman', 'Affiliation': 'College of Public Health, The Ohio State University, Columbus, Ohio, USA.'}, {'ForeName': 'Hyoshin', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Battelle, Seattle, Washington, USA.'}, {'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Buehler', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Battelle, Columbus, Ohio, USA.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Adetona', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Battelle, Columbus, Ohio, USA.'}, {'ForeName': 'Sydney M', 'Initials': 'SM', 'LastName': 'Gordon', 'Affiliation': 'Battelle Public Health Center for Tobacco Research, Battelle, Columbus, Ohio, USA.'}, {'ForeName': 'Pamela I', 'Initials': 'PI', 'LastName': 'Clark', 'Affiliation': 'School of Public Health, Tobacco Center of Regulatory Science, University of Maryland, College Park, Maryland, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054502'] 1091,30047096,Eye Movement Desensitization and Reprocessing (EMDR) Therapy as a Feasible and Potential Effective Treatment for Adults with Autism Spectrum Disorder (ASD) and a History of Adverse Events.,"The study investigated whether EMDR is a feasible therapy for adults with ASD and a history of adverse events, and whether it is associated with reductions in symptoms of PTSD, psychological distress and autism. Participants received 6 to 8 weeks treatment as usual (TAU), followed by a maximum of 8 sessions EMDR added to TAU, and a follow-up of 6-8 weeks with TAU only. Results showed a significant reduction of symptoms of post-traumatic stress (IES-R: d = 1.16), psychological distress (BSI: d = 0.93) and autistic features (SRS-A: d = 0.39). Positive results were maintained at follow-up. The results suggest EMDR therapy to be a feasible and potentially effective treatment for individuals with ASD who suffer from the consequences of exposure to distressing events.",2019,"Results showed a significant reduction of symptoms of post-traumatic stress (IES-R: d = 1.16), psychological distress (BSI: d = 0.93) and autistic features (SRS-A: d = 0.39).","['Adults with Autism Spectrum Disorder (ASD', 'individuals with ASD', 'adults with ASD']","['Eye Movement Desensitization and Reprocessing (EMDR) Therapy', 'EMDR']","['psychological distress', 'symptoms of post-traumatic stress']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0015413', 'cui_str': 'Eye Movements'}, {'cui': 'C0556520', 'cui_str': 'Desensitization (Psychology)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0870535', 'cui_str': 'EMDR'}]","[{'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0332663', 'cui_str': 'Traumatic (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",,0.0269767,"Results showed a significant reduction of symptoms of post-traumatic stress (IES-R: d = 1.16), psychological distress (BSI: d = 0.93) and autistic features (SRS-A: d = 0.39).","[{'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Lobregt-van Buuren', 'Affiliation': 'Centre for Developmental Disorders, Dimence Institute of Mental Health, Nico Bolkesteinlaan 1, 7416 SB, Deventer, The Netherlands. e.lobregt@dimence.nl.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Sizoo', 'Affiliation': 'Centre for Developmental Disorders, Dimence Institute of Mental Health, Nico Bolkesteinlaan 1, 7416 SB, Deventer, The Netherlands.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Mevissen', 'Affiliation': 'Accare, Centre for Child and Adolescent Psychiatry, Pluryn, Nijmegen, The Netherlands.'}, {'ForeName': 'Ad', 'Initials': 'A', 'LastName': 'de Jongh', 'Affiliation': 'Department of Social Dentistry and Behavioral Sciences, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University, Amsterdam, The Netherlands.'}]",Journal of autism and developmental disorders,['10.1007/s10803-018-3687-6'] 1092,30623683,The effect of Tai Chi on balance and functional mobility in children with congenital sensorineural hearing loss.,"Background: The aim of the study was to examine the effect of Tai Chi on balance and functional mobility in children with congenital sensorineural hearing loss. Methods: The study included 39 children, aged 10-14 years, with congenital sensorineural hearing loss. The participants were divided into three groups as the Tai Chi group, conventional exercise group, and control group. The Tai Chi group and the conventional exercise group received a 1-h exercise program twice a week for 10 weeks. The balance function of the children was assessed using the Pediatric Balance Scale, the balance subtest of Bruininks-Oseretsky Test 2-Short Form, and the Functional Reach Test. The Timed Up and Go Test and the Timed Up and Down Stairs Test were used to assess functional mobility. The Wilcoxon rank, Kruskal-Wallis. and Mann-Whitney U-tests were used for statistical analyses. Results: When the pre-training values of the groups were compared, with the exception of the Timed Up and Go test, there was no statistically significant difference with respect to demographic data, balance, and functional mobility parameters ( p  > 0.05). After training, the overall balance and functional mobility tests improved compared to pre-training values in both the Tai Chi and conventional exercise groups ( p  < 0.05). When the post-training values were compared between the groups, with the exception of the Functional Reach Test and the Timed Up and Down Stairs Test, the results of both exercise groups were superior to those of the control group ( p  < 0.05). Conclusions: The results of this study indicate that Tai Chi and conventional exercise programs have positive effects on balance and functional mobility in children with congenital sensorineural hearing loss. However, no superiority of Tai Chi or the conventional exercise programs was determined over the other. Both Tai Chi and conventional exercise programs could be used to improve balance and functional mobility in children with congenital sensorineural hearing loss.Implications for rehabilitationTai Chi and conventional exercises are effective on balance in children with congenital sensorineural hearing loss.Tai Chi and conventional exercises are effective on functional mobility in children with congenital sensorineural hearing loss.Tai Chi may be added to the rehabilitation program for children with congenital sensorineural hearing loss.",2020,"After training, the overall balance and functional mobility tests improved compared to pre-training values in both the Tai Chi and conventional exercise groups (p < 0.05).","['children with congenital sensorineural hearing loss', '39 children, aged 10-14 years, with congenital sensorineural hearing loss']","['Tai Chi and conventional exercise programs', 'Tai Chi group, conventional exercise group, and control group', 'Tai Chi', 'conventional exercise group received a 1-h exercise program', 'rehabilitation Tai Chi and conventional exercises', 'Tai Chi and conventional exercises']","['balance and functional mobility', 'demographic data, balance, and functional mobility parameters', 'functional mobility', 'overall balance and functional mobility tests']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1865866', 'cui_str': 'Congenital sensorineural hearing loss (disorder)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0700308', 'cui_str': 'Protium (substance)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",39.0,0.0178706,"After training, the overall balance and functional mobility tests improved compared to pre-training values in both the Tai Chi and conventional exercise groups (p < 0.05).","[{'ForeName': 'Sebahat Yaprak', 'Initials': 'SY', 'LastName': 'Cetin', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Health Sciences Faculty, Akdeniz University, Antalya, Turkey.'}, {'ForeName': 'Suat', 'Initials': 'S', 'LastName': 'Erel', 'Affiliation': 'School of Physical Therapy and Rehabilitation, Pamukkale University, Denizli, Turkey.'}, {'ForeName': 'Ummuhan', 'Initials': 'U', 'LastName': 'Bas Aslan', 'Affiliation': 'School of Physical Therapy and Rehabilitation, Pamukkale University, Denizli, Turkey.'}]",Disability and rehabilitation,['10.1080/09638288.2018.1535629'] 1093,30660574,Divergence of subjective and performance-based cognitive gains following cognitive training in schizophrenia.,"BACKGROUND Cognitive training is effective for improving cognitive performance among people with schizophrenia. An individual's perception of their own cognition is dissociable from performance on objective cognitive tests. Since subjective cognitive benefit may impact engagement, motivation, and satisfaction with time-intensive cognitive interventions, this study aimed to determine whether subjective cognitive difficulties improve in conjunction with cognitive gains following 30 h of cognitive training. METHODS Patients with schizophrenia or schizoaffective disorder (N = 46) were randomized to treatment as usual (TAU) or TAU augmented with auditory-targeted cognitive training (TCT). All participants completed assessment batteries at baseline and follow-up. As previously reported, the TCT group showed significant improvements in verbal learning and memory and reductions in auditory hallucinations relative to the TAU group. RESULTS Subjective cognitive difficulties did not significantly improve following TCT, even among TCT participants who showed improvements in cognitive performance (all ps > 0.05). Subjective cognitive difficulties were significantly associated with severity of depressive symptoms and hallucinations (r = 0.48 and r = 0.28, p < 0.001), but not global or specific domains of cognition (all rs < 0.1) at baseline. There were no significant relationships between change in subjective cognitive difficulties and change in cognitive or clinical variables (all ps > 0.05). DISCUSSION Patients with schizophrenia do not detect change in their cognition following cognitive training, even among those who showed robust gains in cognitive performance. Failure to detect improvement may undermine treatment engagement, motivation, and satisfaction. Translating score improvements on the cognitive exercises into tangible metrics, and providing ongoing, clinician-delivered feedback on performance may facilitate patient ability to detect improvements and improve motivation to engage with cognitive training interventions.",2019,"RESULTS Subjective cognitive difficulties did not significantly improve following TCT, even among TCT participants who showed improvements in cognitive performance (all ps > 0.05).","['people with schizophrenia', 'schizophrenia', 'Patients with schizophrenia or schizoaffective disorder (N\u202f=\u202f46']","['usual (TAU) or TAU augmented with auditory-targeted cognitive training (TCT', 'cognitive training', 'Cognitive training']","['subjective cognitive difficulties and change in cognitive or clinical variables', 'verbal learning and memory and reductions in auditory hallucinations', 'severity of depressive symptoms and hallucinations', 'Divergence of subjective and performance-based cognitive gains', 'Subjective cognitive difficulties', 'cognitive performance']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036337', 'cui_str': 'Schizoaffective Disorder'}]","[{'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0677634', 'cui_str': 'Reptilase Time'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0233762', 'cui_str': 'Hallucinations, Auditory'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0018524', 'cui_str': 'Hallucinations'}, {'cui': 'C0443204', 'cui_str': 'Divergence (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]",46.0,0.050842,"RESULTS Subjective cognitive difficulties did not significantly improve following TCT, even among TCT participants who showed improvements in cognitive performance (all ps > 0.05).","[{'ForeName': 'Emily B H', 'Initials': 'EBH', 'LastName': 'Treichler', 'Affiliation': 'VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Thomas', 'Affiliation': 'Department of Psychology, Colorado State University, Fort Collins, CO, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Bismark', 'Affiliation': 'VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Hochberger', 'Affiliation': 'VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tarasenko', 'Affiliation': 'VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nungaray', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Cardoso', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Yash B', 'Initials': 'YB', 'LastName': 'Joshi', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sprock', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Swerdlow', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Amy N', 'Initials': 'AN', 'LastName': 'Cohen', 'Affiliation': 'VA Desert Pacific MIRECC, VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States; Department of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, Los Angeles, CA, United States.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Light', 'Affiliation': 'VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; Department of Psychiatry, University of California San Diego, La Jolla, CA, United States. Electronic address: glight@ucsd.edu.'}]",Schizophrenia research,['10.1016/j.schres.2018.12.034'] 1094,31680028,Reconstructive burden and financial implications of wider excision margins for invasive primary cutaneous melanoma.,"BACKGROUND For invasive primary cutaneous melanoma, wider excision is advocated to reduce local recurrence risk and improve patient outcomes. Excision detail is controversial, especially in intermediate- and high-risk primary melanoma (AJCC pT2-pT4). Guidance varies from sizes 1 to 3 cm (translating into large defects of 2-6 cm). The aim of this study was to determine the reconstructive and resource burden of wider excision margins (EMs). METHODS Data analysis from our prospective database (2008-2017) included 1184 patients (563F:621 M) with cutaneous melanoma (pT1b-pT4b). Procedure tariff data were sourced from our financial services department. RESULTS Two hundred twenty-nine patients had a narrower EM (1 cm) and 995 (80.7%) had a wider EM (2-3 cm). Reconstructive requirement significantly increased with a wider EM collectively (11.3% vs 29.3%, odds ratio (OR) = 3.2; p < 0.0001), in the extremities (15.2% vs 42.0%; p < 0.0001), and in the head and neck (H&N) (23.5 % vs 64.7%; p < 0.0001). Reconstruction significantly increased hospitalisation rates (26.6% vs 63.0%, OR = 4.7; p < 0.0001) collectively, in the H&N (26.8 % vs 53.9%), and in the upper (18.9 % vs 42.3%) and lower extremities (34.8% vs 77.3%). Narrower EMs significantly reduced hospitalisation rates in the upper and lower extremities (7.1% vs 28.5%; p = 0.004, 37.9% vs 58.5%; p = 0.005, respectively). Overall procedure cost significantly increased by £180 (mean, p < 0.0001) and £346 (median, p = 0.0004) per patient when reconstruction was required. CONCLUSIONS Our data suggest substantial impact of wider EM on patients, which more than doubled in the functionally and cosmetically sensitive extremities and the H&N region. Reconstructions add significant financial and healthcare service burden. Without randomised controlled trial (RCT) evidence demonstrating increased efficacy of wider EM, narrower EM is advocated whilst awaiting future planned RCT results specifically investigating on this.",2020,"Reconstruction significantly increased hospitalisation rates (26.6% vs 63.0%, OR = 4.7; p < 0.0001) collectively, in the H&N (26.8 % vs 53.9%), and in the upper (18.9 % vs 42.3%) and lower extremities (34.8% vs 77.3%).","['Two hundred twenty-nine patients had a narrower EM (1\xa0cm) and 995 (80.7%) had a wider EM (2-3\xa0cm', 'invasive primary cutaneous melanoma', 'Data analysis from our prospective database (2008-2017) included 1184 patients (563F:621\xa0M) with cutaneous melanoma (pT1b-pT4b']",[],"['Overall procedure cost', 'hospitalisation rates', 'lower extremities']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450351', 'cui_str': '29 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3854333', 'cui_str': 'Narrowing'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0010992', 'cui_str': 'Data Analysis'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}]",1184.0,0.318379,"Reconstruction significantly increased hospitalisation rates (26.6% vs 63.0%, OR = 4.7; p < 0.0001) collectively, in the H&N (26.8 % vs 53.9%), and in the upper (18.9 % vs 42.3%) and lower extremities (34.8% vs 77.3%).","[{'ForeName': 'Michelle Chin', 'Initials': 'MC', 'LastName': 'Lo', 'Affiliation': 'Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital, Norwich NR4 7UY, UK. Electronic address: michelle.lo@nhs.net.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Heaton', 'Affiliation': 'Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital, Norwich NR4 7UY, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Snelling', 'Affiliation': 'Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital, Norwich NR4 7UY, UK.'}, {'ForeName': 'Marc Ds', 'Initials': 'MD', 'LastName': 'Moncrieff', 'Affiliation': 'Department of Plastic & Reconstructive Surgery, Norfolk & Norwich University Hospital, Norwich NR4 7UY, UK; Norwich Medical School, University of East Anglia, UK.'}]","Journal of plastic, reconstructive & aesthetic surgery : JPRAS",['10.1016/j.bjps.2019.09.035'] 1095,30952795,Insular and anterior cingulate cortex deep stimulation for central neuropathic pain: Disassembling the percept of pain.,"OBJECTIVE To compare the analgesic effects of stimulation of the anterior cingulate cortex (ACC) or the posterior superior insula (PSI) against sham deep (d) repetitive (r) transcranial magnetic stimulation (TMS) in patients with central neuropathic pain (CNP) after stroke or spinal cord injury in a randomized, double-blinded, sham-controlled, 3-arm parallel study. METHODS Participants were randomly allocated into the active PSI-rTMS, ACC-rTMS, sham-PSI-rTMS, or sham-ACC-rTMS arms. Stimulations were performed for 12 weeks, and a comprehensive clinical and pain assessment, psychophysics, and cortical excitability measurements were performed at baseline and during treatment. The main outcome of the study was pain intensity (numeric rating scale [NRS]) after the last stimulation session. RESULTS Ninety-eight patients (age 55.02 ± 12.13 years) completed the study. NRS score was not significantly different between groups at the end of the study. Active rTMS treatments had no significant effects on pain interference with daily activities, pain dimensions, neuropathic pain symptoms, mood, medication use, cortical excitability measurements, or quality of life. Heat pain threshold was significantly increased after treatment in the PSI-dTMS group from baseline (1.58, 95% confidence interval [CI] 0.09-3.06]) compared to sham-dTMS (-1.02, 95% CI -2.10 to 0.04, p = 0.014), and ACC-dTMS caused a significant decrease in anxiety scores (-2.96, 95% CI -4.1 to -1.7]) compared to sham-dTMS (-0.78, 95% CI -1.9 to 0.3; p = 0.018). CONCLUSIONS ACC- and PSI-dTMS were not different from sham-dTMS for pain relief in CNP despite a significant antinociceptive effect after insular stimulation and anxiolytic effects of ACC-dTMS. These results showed that the different dimensions of pain can be modulated in humans noninvasively by directly stimulating deeper SNC cortical structures without necessarily affecting clinical pain per se. CLINICALTRIALSGOV IDENTIFIER NCT01932905.",2019,"Active rTMS treatments had no significant effects on pain interference with daily activities, pain dimensions, neuropathic pain symptoms, mood, medication use, cortical excitability measurements, or quality of life.","['patients with central neuropathic pain (CNP) after stroke or spinal cord injury', 'Ninety-eight patients (age 55.02 ± 12.13 years) completed the study', 'central neuropathic pain', 'Participants']","['PSI-dTMS', 'Active rTMS', 'active PSI-rTMS, ACC-rTMS, sham-PSI-rTMS, or sham-ACC-rTMS', 'Insular and anterior cingulate cortex deep stimulation', 'anterior cingulate cortex (ACC) or the posterior superior insula (PSI) against sham deep (d) repetitive (r) transcranial magnetic stimulation (TMS']","['Heat pain threshold', 'pain interference with daily activities, pain dimensions, neuropathic pain symptoms, mood, medication use, cortical excitability measurements, or quality of life', 'comprehensive clinical and pain assessment, psychophysics, and cortical excitability measurements', 'anxiety scores', 'pain relief', 'NRS score', 'pain intensity (numeric rating scale [NRS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4087506', 'cui_str': 'Central neuropathic pain'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0037929', 'cui_str': 'Spinal Cord Trauma'}, {'cui': 'C4319627', 'cui_str': 'Ninety-eight'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1706489', 'cui_str': 'Psi'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0021640', 'cui_str': 'Insula of Reil'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162703', 'cui_str': 'Pain Threshold'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0027796', 'cui_str': 'Neurodynia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C4277734', 'cui_str': 'Cortical Excitability'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0034380'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0030198', 'cui_str': 'Nociception Tests'}, {'cui': 'C0033930', 'cui_str': 'Psychophysics'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0222045'}]",98.0,0.54129,"Active rTMS treatments had no significant effects on pain interference with daily activities, pain dimensions, neuropathic pain symptoms, mood, medication use, cortical excitability measurements, or quality of life.","[{'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Galhardoni', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Valquíria', 'Initials': 'V', 'LastName': 'Aparecida da Silva', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'García-Larrea', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Dale', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Abrahão F', 'Initials': 'AF', 'LastName': 'Baptista', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Luciana Mendonça', 'Initials': 'LM', 'LastName': 'Barbosa', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Luciana Mendes Bahia', 'Initials': 'LMB', 'LastName': 'Menezes', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Silvia R D T', 'Initials': 'SRDT', 'LastName': 'de Siqueira', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Valério', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Jefferson', 'Initials': 'J', 'LastName': 'Rosi', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Antonia Lilian', 'Initials': 'AL', 'LastName': 'de Lima Rodrigues', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Diego Toledo', 'Initials': 'DT', 'LastName': 'Reis Mendes Fernandes', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Priscila Mara', 'Initials': 'PM', 'LastName': 'Lorencini Selingardi', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Marco Antônio', 'Initials': 'MA', 'LastName': 'Marcolin', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Fábio Luís de Souza', 'Initials': 'FLS', 'LastName': 'Duran', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Carla Rachel', 'Initials': 'CR', 'LastName': 'Ono', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Leandro Tavares', 'Initials': 'LT', 'LastName': 'Lucato', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Ana Mércia B L', 'Initials': 'AMBL', 'LastName': 'Fernandes', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Fábio E F', 'Initials': 'FEF', 'LastName': 'da Silva', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Lin T', 'Initials': 'LT', 'LastName': 'Yeng', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'André R', 'Initials': 'AR', 'LastName': 'Brunoni', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Buchpiguel', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Manoel J', 'Initials': 'MJ', 'LastName': 'Teixeira', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Ciampi de Andrade', 'Affiliation': 'From the Pain Center (L.M.B., L.M.B.M., R.D.T.d.S., F.V., J.R., M.J.T., D.C.d.A.), Instituto do Câncer do Estado de São Paulo; Pain Center (R.G.G., V.S., A.L.d.L.R., D.T.R.M.F., P.M.L.S., M.A.M., S.R.D.T.d.S., A.M.B.L.F., M.J.T., D.C.d.A.), LIM62 Neurosurgery LIM, Department of Neurology, Instituto de Ortopedia e Traumatologia (L.T.Y.), Division of Physical Medicine and Rehabilitation, and Laboratory of Psychiatric Neuroimaging (LIM-21) (F.L.d.S.D.), Department and Institute of Psychiatry, School of Medicine, University of São Paulo; Service of Interdisciplinary Neuromodulation (R.G.G., V.S., A.R.B., M.J.T., D.C.d.A.), Laboratory of Neuroscience (LIM27) and National Institute of Biomarkers in Neuropsychiatry, Department and Institute of Psychiatry, Neuroradiology Section (L.T.L., F.E.F.d.S.), Instituto de Radiologia, and Department of Radiology (C.R.O., C.A.B.), University of São Paulo School of Medicine; Center for Mathematics, Computation and Cognition (A.F.B.), Federal University of ABC, São Bernardo do Campo; School of Medicine (R.G.G.), University of City of São Paulo; Department of Anatomy (C.D.), Institute of Biomedical Sciences of University of São Paulo, Brazil; and Central Integration of Pain (NeuroPain) (L.G.-L.), Lyon Centre for Neurosciences, Inserm U1028, University Claude Bernard Lyon 1, and Hospices Civils de Lyon, France. ciampi@usp.br.'}]",Neurology,['10.1212/WNL.0000000000007396'] 1096,31662717,Financial Education and Coaching: A Lifestyle Medicine Approach to Addressing Financial Stress.,"Economic stability is a well-documented social determinant of health, and financial stress is an important driver for the health disparities observed in the poor. Persons under financial stress are more likely to engage in smoking, alcohol consumption, overspending, poor diet, and reduced exercise. Financial education and coaching is one strategy that can be used to reduce financial stress and potentially improve engagement in healthy lifestyle behaviors, quality of life, and objective health outcomes. A conceptual model describing the link between financial education/coaching and health is described along with preliminary data from a randomized controlled trial evaluating this intervention.",2019,"Financial education and coaching is one strategy that can be used to reduce financial stress and potentially improve engagement in healthy lifestyle behaviors, quality of life, and objective health outcomes.",[],['Financial Education and Coaching'],[],[],"[{'cui': 'C0013621', 'cui_str': 'Education'}]",[],,0.020852,"Financial education and coaching is one strategy that can be used to reduce financial stress and potentially improve engagement in healthy lifestyle behaviors, quality of life, and objective health outcomes.","[{'ForeName': 'Nicole D', 'Initials': 'ND', 'LastName': 'White', 'Affiliation': 'Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska (NW, KP).'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Packard', 'Affiliation': 'Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska (NW, KP).'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Kalkowski', 'Affiliation': 'Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska (NW, KP).'}]",American journal of lifestyle medicine,['10.1177/1559827619865439'] 1097,28440853,Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.,"BACKGROUND Respiratory tract infection with Pseudomonas aeruginosa occurs in most people with cystic fibrosis. Once chronic infection is established, Pseudomonas aeruginosa is virtually impossible to eradicate and is associated with increased mortality and morbidity. Early infection may be easier to eradicate.This is an update of a Cochrane review first published in 2003, and previously updated in 2006, 2009 and 2014. OBJECTIVES To determine whether antibiotic treatment of early Pseudomonas aeruginosa infection in children and adults with cystic fibrosis eradicates the organism, delays the onset of chronic infection, and results in clinical improvement. To evaluate whether there is evidence that a particular antibiotic strategy is superior to or more cost-effective than other strategies and to compare the adverse effects of different antibiotic strategies (including respiratory infection with other micro-organisms). SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 10 October 2016. SELECTION CRITERIA We included randomised controlled trials of people with cystic fibrosis, in whom Pseudomonas aeruginosa had recently been isolated from respiratory secretions. We compared combinations of inhaled, oral or intravenous antibiotics with placebo, usual treatment or other combinations of inhaled, oral or intravenous antibiotics. We excluded non-randomised trials, cross-over trials, and those utilising historical controls. DATA COLLECTION AND ANALYSIS Both authors independently selected trials, assessed risk of bias and extracted data. MAIN RESULTS The search identified 60 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion. Three of the trials are over 10 years old and their results may be less applicable today given the changes in standard treatment. Some of the trials had low numbers of participants and most had relatively short follow-up periods; however, there was generally a low risk of bias from missing data. In most trials it was difficult to blind participants and clinicians to treatment given the interventions and comparators used. Two trials were supported by the manufacturers of the antibiotic used.Evidence from two trials (38 participants) at the two-month time-point showed treatment of early Pseudomonas aeruginosa infection with inhaled tobramycin results in microbiological eradication of the organism from respiratory secretions more often than placebo, odds ratio 0.15 (95% confidence interval (CI) 0.03 to 0.65) and data from one of these trials, with longer follow up, suggested that this effect may persist for up to 12 months.One randomised controlled trial (26 participants) compared oral ciprofloxacin and nebulised colistin versus usual treatment. Results after two years suggested treatment of early infection results in microbiological eradication of Pseudomonas aeruginosa more often than no anti-pseudomonal treatment, odds ratio 0.12 (95% CI 0.02 to 0.79).One trial comparing 28 days to 56 days treatment with nebulised tobramycin solution for inhalation in 88 participants showed that both treatments were effective and well-tolerated, with no notable additional improvement with longer over shorter duration of therapy. However, this trial was not powered to detect non-inferiority or equivalence .A trial of oral ciprofloxacin with inhaled colistin versus nebulised tobramycin solution for inhalation alone (223 participants) failed to show a difference between the two strategies, although it was underpowered to show this. A further trial of inhaled colistin with oral ciprofloxacin versus nebulised tobramycin solution for inhalation with oral ciprofloxacin also showed no superiority of the former, with increased isolation of Stenotrophomonas maltophilia in both groups.A recent, large trial in 306 children aged between one and 12 years compared cycled nebulised tobramycin solution for inhalation to culture-based therapy and also ciprofloxacin to placebo. The primary analysis showed no difference in time to pulmonary exacerbation or proportion of Pseudomonas aeruginosa positive cultures. An analysis performed in this review (not adjusted for age) showed fewer participants in the cycled therapy group with one or more isolates of Pseudomonas aeruginosa, odds ratio 0.51 (95% CI 0.31 to 0.28). Using GRADE, the quality of evidence for outcomes was downgraded to moderate to very low. Downgrading decisions for Pseudomonas aeruginosa eradication and lung function were based on applicability (participants mostly children) and limitations in study design, with imprecision an additional limitation for lung function, growth parameters and adverse effects. AUTHORS' CONCLUSIONS We found that nebulised antibiotics, alone or in combination with oral antibiotics, were better than no treatment for early infection with Pseudomonas aeruginosa. Eradication may be sustained for up to two years. There is insufficient evidence to determine whether antibiotic strategies for the eradication of early Pseudomonas aeruginosa decrease mortality or morbidity, improve quality of life, or are associated with adverse effects compared to placebo or standard treatment. Four trials comparing two active treatments have failed to show differences in rates of eradication of Pseudomonas aeruginosa. There have been no published randomised controlled trials that investigate the efficacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic fibrosis. Overall, there is still insufficient evidence from this review to state which antibiotic strategy should be used for the eradication of early Pseudomonas aeruginosa infection in cystic fibrosis.",2017,There have been no published randomised controlled trials that investigate the efficacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic fibrosis.,"['children and adults with cystic fibrosis eradicates', '306 children aged between one and 12 years compared', 'early infection with Pseudomonas aeruginosa', 'people with cystic fibrosis', '2006, 2009 and 2014', '60 trials; seven trials (744 participants) with a duration between 28 days and 27 months were eligible for inclusion', 'people with cystic fibrosis, in whom Pseudomonas aeruginosa had recently been isolated from respiratory secretions']","['oral ciprofloxacin and nebulised colistin versus usual treatment', 'inhaled, oral or intravenous antibiotics with placebo, usual treatment or other combinations of inhaled, oral or intravenous antibiotics', 'ciprofloxacin with inhaled colistin versus nebulised tobramycin solution', 'tobramycin', 'cycled nebulised tobramycin solution', 'placebo', 'Antibiotic strategies', 'antibiotic treatment', 'nebulised tobramycin solution', 'ciprofloxacin versus nebulised tobramycin solution', 'intravenous antibiotics', 'nebulised antibiotics, alone or in combination with oral antibiotics', 'ciprofloxacin to placebo', 'ciprofloxacin']","['mortality and morbidity', 'time to pulmonary exacerbation or proportion of Pseudomonas aeruginosa positive cultures', 'microbiological eradication of Pseudomonas aeruginosa', 'microbiological eradication of the organism from respiratory secretions', 'quality of life', 'rates of eradication of Pseudomonas aeruginosa', 'effective and well-tolerated']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C1532372', 'cui_str': 'Respiratory secretion'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0009316', 'cui_str': 'Colistin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0029235', 'cui_str': 'Organism - attribute'}, {'cui': 'C1532372', 'cui_str': 'Respiratory secretion'}, {'cui': 'C0034380'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",306.0,0.335337,There have been no published randomised controlled trials that investigate the efficacy of intravenous antibiotics to eradicate Pseudomonas aeruginosa in cystic fibrosis.,"[{'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Langton Hewer', 'Affiliation': 'Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, Upper Maudlin Street, Bristol, Avon, UK, BS2 8BJ.'}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Smyth', 'Affiliation': 'Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine, University of Nottingham, Queens Medical Centre, Derby Road, Nottingham, UK, NG7 2UH.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD004197.pub5'] 1098,29766750,Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.,"BACKGROUND Combination antiplatelet therapy with clopidogrel and aspirin may reduce the rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has shown a reduction in the risk of recurrent stroke. We tested this combination in an international population. METHODS In a randomized trial, we assigned patients with minor ischemic stroke or high-risk TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. The dose of aspirin in each group was selected by the site investigator. The primary efficacy outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 90 days. RESULTS A total of 4881 patients were enrolled at 269 international sites. The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days. Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event. Major hemorrhage occurred in 23 patients (0.9%) receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P=0.02). CONCLUSIONS In patients with minor ischemic stroke or high-risk TIA, those who received a combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk of major hemorrhage at 90 days than those who received aspirin alone. (Funded by the National Institute of Neurological Disorders and Stroke; POINT ClinicalTrials.gov number, NCT00991029 .).",2018,"Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event.","['patients with minor ischemic stroke or high-risk TIA to receive either', '4881 patients were enrolled at 269 international sites', 'patients with minor ischemic stroke or high-risk TIA']","['clopidogrel plus aspirin', 'aspirin', 'aspirin plus placebo', 'aspirin alone', 'Clopidogrel and Aspirin', 'clopidogrel and aspirin', 'clopidogrel']","['Major hemorrhage', 'time-to-event analysis was the risk of a composite of major ischemic events, which was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 90 days', 'Major ischemic events', 'rate of recurrent stroke', 'risk of major ischemic events', 'major hemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0026193', 'cui_str': 'Minors'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]",4881.0,0.260721,"Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P=0.02), with most events occurring during the first week after the initial event.","[{'ForeName': 'S Claiborne', 'Initials': 'SC', 'LastName': 'Johnston', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'J Donald', 'Initials': 'JD', 'LastName': 'Easton', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Farrant', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Barsan', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Robin A', 'Initials': 'RA', 'LastName': 'Conwit', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Jordan J', 'Initials': 'JJ', 'LastName': 'Elm', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Anthony S', 'Initials': 'AS', 'LastName': 'Kim', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Anne S', 'Initials': 'AS', 'LastName': 'Lindblad', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': 'Yuko Y', 'Initials': 'YY', 'LastName': 'Palesch', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology, University of California, San Francisco, San Francisco (J.D.E., M.F., A.S.K.); the Department of Emergency Medicine, University of Michigan, Ann Arbor (W.B.); the Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda (R.A.C.), and Emmes, Rockville (A.S.L.) - both in Maryland; and the Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston (J.J.E., Y.Y.P.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1800410'] 1099,31561981,Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry.,"INTRODUCTION AND OBJECTIVES Renal denervation is a percutaneous intervention for the treatment of resistant hypertension. Randomized studies have shown contradictory results on its efficacy. We present the results of a renal denervation registry for the treatment of resistant hypertension in real-life patients in Spain. METHODS Multicenter registry of consecutive patients with resistant hypertension treated with renal denervation in Spain between 2009 and 2018. RESULTS We included 125 patients (mean age, 56 years; 41% female; mean onset of hypertension 14±9 years previously). Office systolic and diastolic blood pressure and ambulatory blood pressure monitoring decreased 6 months after the intervention (166±20/95±16 to 149±22/87±16 mmHg and 151±14/89±12 to 143±15/84±11, both P <.0001). At 12 months, the blood pressure reduction was maintained and the number of antihypertensive drugs decreased from 4.9±1.2 to 4.4±1.5 (P=.0001). There were no significant procedure-related complications. The response rate to denervation at 1 year was 80%, but there were wide differences between centers. CONCLUSIONS In patients with resistant hypertension, treatment with renal denervation was related to a decrease in office blood pressure and, more importantly, in ambulatory blood pressure monitoring, with a significant reduction in pharmacological treatment.",2020,There were no significant procedure-related complications.,"['consecutive patients with resistant hypertension treated with renal denervation in Spain between 2009 and 2018', 'patients with resistant hypertension', 'resistant hypertension in real-life patients in Spain', '125 patients (mean age, 56 years; 41% female; mean onset of hypertension 14±9 years previously', 'resistant hypertension in Spain']",[],"['response rate to denervation', 'blood pressure reduction', 'Office systolic and diastolic blood pressure and ambulatory blood pressure monitoring', 'office blood pressure', 'number of antihypertensive drugs']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C1321798', 'cui_str': 'Muscle denervation'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C4319551', 'cui_str': 'One hundred and twenty-five'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0332162', 'cui_str': 'Onset of (contextual qualifier) (qualifier value)'}]",[],"[{'cui': 'C1321798', 'cui_str': 'Muscle denervation'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0242876', 'cui_str': 'Blood Pressure Monitoring, Ambulatory'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}]",125.0,0.0283963,There were no significant procedure-related complications.,"[{'ForeName': 'Oriol', 'Initials': 'O', 'LastName': 'Rodriguez-Leor', 'Affiliation': 'Institut del Cor (ICOR), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Institut per la Recerca Germans Trias i Pujol, Badalona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: oriolrodriguez@gmail.com.'}, {'ForeName': 'Julián', 'Initials': 'J', 'LastName': 'Segura', 'Affiliation': 'Departamento de Nefrología, Hospital 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'García Donaire', 'Affiliation': 'Departamento de Nefrología, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Gutiérrez-Ibañes', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Cardiología, Hospital Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Oliveras', 'Affiliation': 'Departamento de Nefrología, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Juan Diego', 'Initials': 'JD', 'LastName': 'Mediavilla', 'Affiliation': 'Departamento de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Serrador', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Cardiología, Hospital Clínico, Valladolid, Spain.'}, {'ForeName': 'José Carlos', 'Initials': 'JC', 'LastName': 'Prado', 'Affiliation': 'Departamento de Nefrología, Hospital 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Iván', 'Initials': 'I', 'LastName': 'Nuñez-Gil', 'Affiliation': 'Departamento de Cardiología, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Díez-Delhoyo', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Cardiología, Hospital Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Clarà Velasco', 'Affiliation': 'Departamento de Cirugía Vascular, Hospital del Mar, Barcelona, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Jaén Águila', 'Affiliation': 'Departamento de Medicina Interna, Hospital Virgen de las Nieves, Granada, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Amat-Santos', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; Departamento de Cardiología, Hospital Clínico, Valladolid, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Bayes-Genis', 'Affiliation': 'Institut del Cor (ICOR), Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Institut per la Recerca Germans Trias i Pujol, Badalona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.'}, {'ForeName': 'María Isabel', 'Initials': 'MI', 'LastName': 'Troya Saborido', 'Affiliation': 'Institut per la Recerca Germans Trias i Pujol, Badalona, Barcelona, Spain; Departamento de Nefrología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.'}]",Revista espanola de cardiologia (English ed.),['10.1016/j.rec.2019.08.001'] 1100,24206796,Providing detailed information about latent tuberculosis and compliance with the PPD test among healthcare workers in Israel: a randomized controlled study.,"BACKGROUND The compliance of screening for latent tuberculosis (TB) with the tuberculin purified protein derivative (PPD) test is very low among healthcare workers (HCWs) in Israel. METHODS This randomized controlled study uses the Health Belief Model (HBM) as a conceptual framework to examine whether providing more information about latent TB and the PPD test increases the response rate for PPD screening among HCWs. All candidate HCWs for latent TB screening were randomly allocated to one of the following two invitations to perform the PPD test: regular letter (control group, n=97), and a letter with information about latent TB and the PPD test (intervention group, n=196). RESULTS 293 HCWs were included (185 nurses, and 108 physicians). Overall, 36 (12.3%) HCWs were compliant with the PPD test screening. Compliance with PPD testing in the intervention group was not statistically different from the control group, RR 0.87 (95% CI, 0.46-1.65). CONCLUSIONS Compliance for latent TB screening is low among HCWs in northeastern Israel. Providing detailed information about latent TB was not associated with increased test compliance. Understanding existing disparities in screening rates and potential barriers to latent TB screening among HCWs is important in order to move forward and successfully increase screening rates.",2013,"Compliance with PPD testing in the intervention group was not statistically different from the control group, RR 0.87","['293 HCWs were included (185 nurses, and 108 physicians', 'healthcare workers in Israel', 'All candidate HCWs for latent TB screening', 'group, n=196']","['tuberculin purified protein derivative (PPD) test', 'PPD test: regular letter (control group, n=97), and a letter with information about latent TB and the PPD test (intervention', 'Health Belief Model (HBM']",[],"[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0018724', 'cui_str': 'Healthcare Workers'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0205275', 'cui_str': 'Latent (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205275', 'cui_str': 'Latent (qualifier value)'}, {'cui': 'C3714363', 'cui_str': 'Health belief model (qualifier value)'}]",[],293.0,0.0929227,"Compliance with PPD testing in the intervention group was not statistically different from the control group, RR 0.87","[{'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Taubman', 'Affiliation': 'Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, MI, United States. Electronic address: dtaubman@umich.edu.'}, {'ForeName': 'Nava', 'Initials': 'N', 'LastName': 'Titler', 'Affiliation': ''}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Edelstein', 'Affiliation': ''}, {'ForeName': 'Mazen', 'Initials': 'M', 'LastName': 'Elias', 'Affiliation': ''}, {'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Saliba', 'Affiliation': ''}]",Journal of epidemiology and global health,['10.1016/j.jegh.2013.06.003'] 1101,24534331,"Socioeconomic status and obesity in Cairo, Egypt: a heavy burden for all.","Studies have generally shown a positive association between socioeconomic status (SES) and obesity in low-income countries, but few have tested this relationship in the Middle East where obesity prevalence is extraordinarily high and the nutrition profile more closely resembles developed world contexts. The objective of this study is to examine the SES-obesity association in Cairo, Egypt. Multinomial regression analyses were conducted and predicted probabilities were found for overweight and obesity status among adult men and women in a stratified analysis. Data were taken from the 2007 Cairo Urban Inequity Study which collected information on 3993 individuals from 50 neighborhoods in the Cairo Governorate. Five different measures of SES were utilized - education, household expenditures, household assets, subjective wealth, and father's education. No significant associations were found between most measures of SES and overweight/obesity in this population. Overweight and obesity are prevalent across the SES spectrum. These findings suggest that obesity programs and policies should be targeted at all SES groups in Cairo, although specific mechanisms may vary by SES and should be explored further in future studies.",2014,No significant associations were found between most measures of SES and overweight/obesity in this population.,['2007 Cairo Urban Inequity Study which collected information on 3993 individuals from 50 neighborhoods in the Cairo Governorate'],[],['SES and overweight/obesity'],"[{'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}]",[],"[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",3993.0,0.016875,No significant associations were found between most measures of SES and overweight/obesity in this population.,"[{'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Mowafi', 'Affiliation': 'Harvard School of Public Health, Department of Social and Behavioral Sciences, 677 Huntington Avenue, Boston, MA 02115, United States. Electronic address: mmowafi@post.harvard.edu.'}, {'ForeName': 'Zeinab', 'Initials': 'Z', 'LastName': 'Khadr', 'Affiliation': 'American University in Cairo, Social Research Center, AUC Ave., P.O. Box 74, New Cairo 11835, Egypt.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Kawachi', 'Affiliation': 'Harvard School of Public Health, Department of Social and Behavioral Sciences, 677 Huntington Avenue, Boston, MA 02115, United States.'}, {'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'Subramanian', 'Affiliation': 'Harvard School of Public Health, Department of Social and Behavioral Sciences, 677 Huntington Avenue, Boston, MA 02115, United States.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Hill', 'Affiliation': 'Harvard School of Public Health, Department of Global Health and Population, 677 Huntington Avenue, Boston, MA 02115, United States.'}, {'ForeName': 'Gary G', 'Initials': 'GG', 'LastName': 'Bennett', 'Affiliation': 'Duke University, Department of Psychology and Neuroscience, Box 90086, Durham, NC 27708, United States.'}]",Journal of epidemiology and global health,['10.1016/j.jegh.2013.09.001'] 1102,31930845,"Effects of Olive Leaf Extract on Metabolic Response, Liver and Kidney Functions and Inflammatory Biomarkers in Hypertensive Patients.","BACKGROUND AND OBJECTIVE Hypertension is a long-term medical condition in which the blood pressure is gradually elevated. In this project, the effects of olive leaf extract (OLE) were evaluated on metabolic response, liver and kidney functions and also biomarkers of inflammation in hypertensive patients. MATERIALS AND METHODS In this randomized double-blind placebo controlled clinical trial, 60 hypertensive patients, aged 30-60 years old had participated. Patients were randomly assigned into two groups to receive either OLE or placebo tablets for 12 weeks. At the beginning and end of the intervention, metabolic parameters and biomarkers of liver, kidney and inflammation were measured in sera of the participants using available laboratory methods. RESULTS Compared with the placebo, changes in parameters associated with glucose metabolism were not statistically significant (p>0.05). The OLE tablets did not have significant effect on liver enzymes, total protein, albumin, urea and creatinine (p>0.05), but significantly decreased interleukin-6, interleukin-8 and tumor necrosis factor alpha as inflammatory biomarkers (p<0.05) in OLE group compared to the placebo group. CONCLUSION The results concluded that inflammation as a major cause of hypertension was significantly decreased in patients using OLE tablets.",2019,"Compared with the placebo, changes in parameters associated with glucose metabolism were not statistically significant (p>0.05).","['Hypertensive Patients', 'hypertensive patients', '60 hypertensive patients, aged 30-60 years old had participated']","['placebo', 'Olive Leaf Extract', 'olive leaf extract (OLE', 'OLE or placebo tablets']","['liver enzymes, total protein, albumin, urea and creatinine (p>0.05', 'inflammation as a major cause of hypertension', 'interleukin-6, interleukin-8 and tumor necrosis factor alpha as inflammatory biomarkers', 'metabolic parameters and biomarkers of liver, kidney and inflammation', 'Metabolic Response, Liver and Kidney Functions and Inflammatory Biomarkers', 'glucose metabolism', 'metabolic response, liver and kidney functions']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1364955', 'cui_str': 'Olive Leaf Extract'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0443764', 'cui_str': 'Liver enzyme (substance)'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0070525', 'cui_str': 'phenacemide'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}]",,0.266156,"Compared with the placebo, changes in parameters associated with glucose metabolism were not statistically significant (p>0.05).","[{'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Javadi', 'Affiliation': ''}, {'ForeName': 'Hayedeh', 'Initials': 'H', 'LastName': 'Yaghoobzadeh', 'Affiliation': ''}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Esfahani', 'Affiliation': ''}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Reza Memarzadeh', 'Affiliation': ''}, {'ForeName': 'Seyyed', 'Initials': 'S', 'LastName': 'Mehdi Mirhashemi', 'Affiliation': ''}]",Pakistan journal of biological sciences : PJBS,['10.3923/pjbs.2019.342.348'] 1103,30806856,Effect of flaxseed poultice compress application on pain and hand functions of patients with hand osteoarthritis.,"INTRODUCTION/OBJECTIVES This randomized controlled intervention study investigated the effect of flaxseed poultice compress application on pain and hand functions in patients with primary interphalangeal hand osteoarthritis (OA). METHOD The study sample consisted of 82 patients who met the inclusion criteria in the Rheumatology Outpatient Clinic at a University Hospital between January 15, 2017, and May 15, 2018. Patients included in the sample groups were selected randomly. Three sample groups were formed: intervention group I (flaxseed poultice compress) (n = 33), intervention group II (hot compress) (n = 29), and control group (n = 20). The interventions were applied once a day for 7 days in a row. These patients also continued their routine pharmacological treatment. descriptive characteristics identification form, visual analog scale (VAS), Australian-Canadian (AUSCAN) Osteoarthritis (OA) Hand Index, and side effect evaluation form were used as data collection tools. RESULTS The means of VAS scores of patients in the intervention group I were 6.03 ± 0.25 on day 0, 2.2 ± 0.30 on day 8, and 3.39 ± 0.32 on day 15. The means of AUSCAN total scores of patients in the intervention group I were 40.84 ± 1.76 on day 0, 14.03 ± 1.66 on day 8, and 15.78 ± 1.66 on day 15. The present study showed that pain significantly decreased and the hand function efficiency increased in patients treated with flaxseed poultice compress compared with the hot compress and control groups. CONCLUSIONS In addition to pharmacological treatment, flaxseed poultice compress intervention is recommended to be used as a nursing intervention for reducing pain and increasing hand functions for patients with hand OA in cooperation with the physicians and other health professionals.",2019,The means of AUSCAN total scores of patients in the intervention group,"['82 patients who met the inclusion criteria in the Rheumatology Outpatient Clinic at a University Hospital between January 15, 2017, and May 15, 2018', 'patients with hand osteoarthritis', 'patients with hand OA in cooperation with the physicians and other health professionals', 'patients with primary interphalangeal hand osteoarthritis (OA']","['intervention group I (flaxseed poultice compress', 'flaxseed poultice compress application']","['hand function efficiency', 'pain', 'VAS scores', 'pain and hand functions', 'visual analog scale (VAS), Australian-Canadian (AUSCAN) Osteoarthritis (OA']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0263746', 'cui_str': 'Degenerative joint disease of hand (disorder)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0441843', 'cui_str': 'Group I (qualifier value)'}, {'cui': 'C0023753', 'cui_str': 'Flaxseed'}, {'cui': 'C4551917', 'cui_str': 'Poultice'}, {'cui': 'C0332260', 'cui_str': 'Compressing (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0562230', 'cui_str': 'Hand functions (observable entity)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}]",,0.0185595,The means of AUSCAN total scores of patients in the intervention group,"[{'ForeName': 'Burcu Babadağ', 'Initials': 'BB', 'LastName': 'Savaş', 'Affiliation': 'Department of Nursing, Faculty of Health Science, Eskisehir Osmangazi University, Meşelik Campus, 26480, Eskisehir, Turkey. burcubabadag1@gmail.com.'}, {'ForeName': 'Güler Balcı', 'Initials': 'GB', 'LastName': 'Alparslan', 'Affiliation': 'Department of Nursing, Faculty of Health Science, Eskisehir Osmangazi University, Meşelik Campus, 26480, Eskisehir, Turkey.'}, {'ForeName': 'Cengiz', 'Initials': 'C', 'LastName': 'Korkmaz', 'Affiliation': 'Department of Internal Medicine and Rheumatology, School of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.'}]",Clinical rheumatology,['10.1007/s10067-019-04484-7'] 1104,30227718,Effect of a participatory patient education programme ( NE xt ED ucation) in group-based patient education among Danes with type 2 diabetes.,"OBJECTIVE To assess the effect of a participatory group-based education programme for individuals with type 2 diabetes, Next Education. METHOD In a quasi-experimental study, individuals with type 2 diabetes were recruited from 14 Danish municipalities with a patient education programme. Eight municipalities using Next Education were intervention sites; six control sites used usual group-based education programmes. Data were collected through questionnaires at baseline and at 3 and 12 months after programmes ended. Changes in quality of life (EQ-5D-5L), diabetes-related emotional distress (PAID-5), physical activity, diet, foot care and sense of coherence (SOC-13) were assessed in generalised linear mixed models. RESULTS At baseline, 310 participants (52.6% females, mean age 62.5 years [SD = 10.7] and a mean duration of type 2 diabetes of 6.9 years [SD = 8.4]) participated in Next Education ( n  = 234) or group-based education ( n  = 76) at control sites. Compared with participants at control sites, participants at intervention sites had significantly larger sense of coherence scores at 3 (9.4%, p  = 0.03) and 12 (9.8%, p  = 0.02) months of follow-up. Other measures did not differ significantly between groups. DISCUSSION It is likely that person-centeredness and high degrees of user participation at the intervention sites improved sense of coherence among Danes with type 2 diabetes.",2020,Other measures did not differ significantly between groups.,"['individuals with type 2 diabetes, Next Education', 'group-based patient education among Danes with type 2 diabetes', 'individuals with type 2 diabetes were recruited from 14 Danish municipalities with a patient education programme', '310 participants (52.6% females, mean age 62.5 years [SD\u2009=\u200910.7] and a mean duration of type 2 diabetes of 6.9 years [SD\u2009=\u20098.4]) participated in Next Education ( n\u2009=\u2009234) or group-based education ( n\u2009=\u200976) at control sites']","['participatory patient education programme (NExt EDucation', 'participatory group-based education programme', 'control sites used usual group-based education programmes']","['quality of life (EQ-5D-5L), diabetes-related emotional distress (PAID-5), physical activity, diet, foot care and sense of coherence (SOC-13', 'larger sense of coherence scores']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0337800', 'cui_str': 'Danes (ethnic group)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0600182'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517836', 'cui_str': '62.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C4517826', 'cui_str': 'Six point nine'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}]","[{'cui': 'C0034380'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0150240', 'cui_str': 'Foot care'}, {'cui': 'C3178983', 'cui_str': 'Salutogeneses'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",310.0,0.0209646,Other measures did not differ significantly between groups.,"[{'ForeName': 'Lea An', 'Initials': 'LA', 'LastName': 'Christoffersen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Anne K', 'Initials': 'AK', 'LastName': 'Hansen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Regitze As', 'Initials': 'RA', 'LastName': 'Pals', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Willaing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Volkert', 'Initials': 'V', 'LastName': 'Siersma', 'Affiliation': 'The Research Unit for General Practice and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Olesen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}]",Chronic illness,['10.1177/1742395318799843'] 1105,30559030,"Acute and 30-Day Safety and Effectiveness Evaluation of Eximo Medical's B-Laser™, a Novel Atherectomy Device, in Subjects Affected With Infrainguinal Peripheral Arterial Disease: Results of the EX-PAD-03 Trial.","BACKGROUND B-Laser™ is a novel atherectomy device that uses a solid-state third harmonic pulsed Nd:YAG laser with an output of 355 nm. Early data showed that the B-Laser™ is safe in treating a broad range of infrainguinal arterial lesions. We present the results of the EX-PAD-03 U.S. pivotal trial of the EXIMO B-Laser™. METHODS EX-PAD-03 is a prospective, single-arm, multi-center, international, open-label, clinical study. The study enrolled patients in the United States and Europe. The primary efficacy endpoint was the average reduction in residual diameter stenosis of >20% from baseline prior to any adjunctive therapy achieved by the B-Laser™ catheter alone. The primary safety endpoint was freedom from major adverse events (MAEs) defined as: unplanned target limb amputation above the ankle, clinically driven target lesion revascularization (CD-TLR) and cardiovascular related death. RESULTS A total of 97 subjects (107 lesions) were enrolled. Mean age was 70.5 years and 51% were males. Diabetes mellitus was present in 42.3%. Mean lesion length was 53.96 ± 43.18 mm and 26.2% had severe calcification. Lesions were de novo (79.4%), followed by in-stent restenosis (ISR) (15.9%) and non in-stent restenosis (4.7%). The mean percent stenosis at the target lesion as assessed by the Core lab was 85.7% ± 12.2 (femoro-popliteal 85.6 ± 12.8%; tibials 86.0 ± 9.6%). Post B-Laser™ and prior to adjunctive therapy, the mean percent stenosis at the target lesion was 52.1%. This resulted in a mean reduction from baseline to post B-Laser™ of 33.6% ± 14.2% meeting the primary efficacy endpoint goal. The freedom from MAE through the 30-day follow-up period after intervention was 98.9%. Per Core lab, there was no device-related distal embolization, dissections that required additional therapy, perforation, or pseudoaneurysm. Bailout stenting was 0.9%. A significant improvement from baseline in ABI (0.24 ± 0.18), Rutherford category (-1.79 ± 1.22) and WIQ (0.26 ± 0.28) were noted at 1 month. There was no target lesion revascularization and the patency was 96.8% by duplex ultrasound criteria at 30-day follow up. CONCLUSION The Eximo B-Laser™ is effective and safe in ablating atherosclerotic and restenotic tissue for both above and below the knee obstructive arterial disease. The device has a high safety profile including a low risk of distal embolization.",2020,"CONCLUSION The Eximo B-Laser™ is effective and safe in ablating atherosclerotic and restenotic tissue for both above and below the knee obstructive arterial disease.","['97 subjects (107 lesions) were enrolled', 'Mean age was 70.5\u202fyears and 51% were males', 'study enrolled patients in the United States and Europe', 'subjects affected with infrainguinal peripheral arterial disease']","['Bailout stenting', ""Eximo Medical's B-Laser™, a novel atherectomy device"", 'EXIMO B-Laser™', 'Eximo B-Laser']","['target lesion revascularization and the patency', 'severe calcification', 'Diabetes mellitus', 'freedom from major adverse events (MAEs) defined as: unplanned target limb amputation above the ankle, clinically driven target lesion revascularization (CD-TLR) and cardiovascular related death', 'average reduction in residual diameter stenosis', 'ABI', 'mean percent stenosis', 'Mean lesion length']","[{'cui': 'C4517529', 'cui_str': 'One hundred and seven'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Artery Disease'}]","[{'cui': 'C0336968', 'cui_str': 'Sky-diving (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0522642', 'cui_str': 'Atherectomy device (physical object)'}]","[{'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0002689', 'cui_str': 'Amputation of limb'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",97.0,0.0549364,"CONCLUSION The Eximo B-Laser™ is effective and safe in ablating atherosclerotic and restenotic tissue for both above and below the knee obstructive arterial disease.","[{'ForeName': 'Nicolas W', 'Initials': 'NW', 'LastName': 'Shammas', 'Affiliation': 'Midwest Cardiovascular Research Foundation, Davenport, IA, USA. Electronic address: shammas@mchsi.com.'}, {'ForeName': 'Pradeep', 'Initials': 'P', 'LastName': 'Chandra', 'Affiliation': 'St. Louis Heart and Vascular, St Louis, MO, USA.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Brodmann', 'Affiliation': 'Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Weinstock', 'Affiliation': 'Orlando Heart Specialists, Orlando, FL, USA.'}, {'ForeName': 'Gino', 'Initials': 'G', 'LastName': 'Sedillo', 'Affiliation': 'Cardiovascular Solutions Institute, Bradenton, USA.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Cawich', 'Affiliation': 'Arkansas Heart Hospital, Little Rock, AR, USA.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Micari', 'Affiliation': 'Maria Cecilia Hospital, Cotignola, Italy and Gavazzeni Humanitas Hospital, Bergamo, Italy.'}, {'ForeName': 'Arthur', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'North Florida Regional Medical Center, Gainesville, FL, USA.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Metzger', 'Affiliation': 'Wellmont CVA Heart Institute, Kingsport, USA.'}, {'ForeName': 'Luis Mariano', 'Initials': 'LM', 'LastName': 'Palena', 'Affiliation': 'Policlinico Abano Terme, Abano Terme, Italy.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rundback', 'Affiliation': 'Holy Name Medical Center, Teaneck, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Cardiovascular revascularization medicine : including molecular interventions,['10.1016/j.carrev.2018.11.022'] 1106,30361170,"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.","BACKGROUND Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. METHODS In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAF V600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505. FINDINGS Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis. INTERPRETATION The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma. FUNDING Bristol-Myers Squibb.",2018,The hazard ratio for death for the combination versus ipilimumab was 0·54,"['eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAF V600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1', 'patients with advanced melanoma', 'group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation', 'advanced melanoma (CheckMate 067', 'Between July 3, 2013, and March 31, 2014, 945 patients']","['placebo', 'Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone', 'nivolumab versus ipilimumab', 'nivolumab plus ipilimumab', 'nivolumab (n=316), or ipilimumab', 'ipilimumab', 'nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab', 'intravenous nivolumab 1 mg/kg plus ipilimumab']","['hazard ratio for progression-free survival', 'colitis', 'progression-free survival and overall survival', 'diarrhoea', 'objective responses, progression-free survival, and overall survival', 'hazard ratio for death', 'median overall survival', 'deaths', 'Median progression-free survival', 'Serious adverse events', 'lipase']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0441772', 'cui_str': 'Stage level 4 (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathies'}, {'cui': 'C0151798', 'cui_str': 'Hepatic necrosis (disorder)'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0347646', 'cui_str': 'Perforation of colon (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0009319', 'cui_str': 'Colitis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023764', 'cui_str': 'Lipase'}]",945.0,0.431166,The hazard ratio for death for the combination versus ipilimumab was 0·54,"[{'ForeName': 'Frank Stephen', 'Initials': 'FS', 'LastName': 'Hodi', 'Affiliation': 'Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: stephen_hodi@dfci.harvard.edu.'}, {'ForeName': 'Vanna', 'Initials': 'V', 'LastName': 'Chiarion-Sileni', 'Affiliation': 'Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Gonzalez', 'Affiliation': 'University of Colorado Cancer Center, Denver, CO, USA.'}, {'ForeName': 'Jean-Jacques', 'Initials': 'JJ', 'LastName': 'Grob', 'Affiliation': 'Aix-Marseille University and APHM Hospital CHU Timone, Marseille, France.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Rutkowski', 'Affiliation': 'Maria Skłodowska-Curie Institute - Oncology Centre, Warsaw, Poland.'}, {'ForeName': 'Charles Lance', 'Initials': 'CL', 'LastName': 'Cowey', 'Affiliation': 'Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Lao', 'Affiliation': 'Department of Oncology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University of Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wagstaff', 'Affiliation': 'The College of Medicine, Swansea University, Swansea, UK.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Dummer', 'Affiliation': 'Department of Dermatology, Universitäts Spital, Zürich, Switzerland.'}, {'ForeName': 'Pier Francesco', 'Initials': 'PF', 'LastName': 'Ferrucci', 'Affiliation': 'European Institute of Oncology, Milan, Italy.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Smylie', 'Affiliation': 'Cross Cancer Institute, Edmonton, AB, Canada.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hill', 'Affiliation': 'Tasman Oncology Research, Southport, QLD, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hogg', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, ON, Canada.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Marquez-Rodas', 'Affiliation': 'General University Hospital Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Rizzo', 'Affiliation': 'Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'The Royal Marsden NHS Foundation Trust, London, UK.'}, {'ForeName': 'Jedd D', 'Initials': 'JD', 'LastName': 'Wolchok', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(18)30700-9'] 1107,30055883,Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care.,"Computerized targeted cognitive training (TCT) of auditory processing has been shown to improve verbal learning in several clinical trials of schizophrenia outpatients. Less is known, however, about the effectiveness of this promising intervention in more chronic, treatment-refractory patients who are treated in non-academic settings. This study aimed to determine whether TCT improves auditory processing, verbal learning, and clinical symptoms in SZ patients mandated to receive care at a locked residential rehabilitation center. Secondarily, potential factors that moderate TCT's effectiveness including age, symptom severity, antipsychotic medication load, and duration of illness were examined. Schizophrenia patients were randomized to treatment as usual (TAU; n = 22) or TAU augmented with TCT (TAU + TCT; n = 24). Outcomes included a measure of auditory perception (Word-In-Noise test, WIN), verbal learning domain scores from the MATRICS Consensus Cognitive Battery (MCCB), and clinical symptoms (Scale for the Assessment of Positive Symptoms, SAPS; Scale for the Assessment of Negative Symptoms, SANS). TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64). TCT's effects were only weakly, and mostly non-significantly, moderated by age, clinical symptoms, medication, and illness duration. These findings indicate that even highly symptomatic, functionally disabled patients with chronic illness benefit from this emerging treatment. Ongoing studies will examine the predictive utility of neurophysiological biomarkers and other characteristics assessed at baseline.",2018,TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64).,"['schizophrenia outpatients', 'treatment refractory schizophrenia patients mandated to residential care', 'Schizophrenia patients', 'SZ patients mandated to receive care at a locked residential rehabilitation center']","['TAU augmented with TCT (TAU\u202f+\u202fTCT', 'Computerized targeted cognitive training (TCT) of auditory processing', 'cognitive training', 'TCT']","[""TCT's effects"", 'measure of auditory perception (Word-In-Noise test, WIN), verbal learning domain scores from the MATRICS Consensus Cognitive Battery (MCCB), and clinical symptoms (Scale for the Assessment of Positive Symptoms, SAPS; Scale for the Assessment of Negative Symptoms, SANS', 'verbal learning', 'auditory perception', 'auditory and verbal outcomes', 'auditory processing, verbal learning, and clinical symptoms', 'auditory hallucinations']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034993', 'cui_str': 'Rehabilitation Centers'}]","[{'cui': 'C1720655', 'cui_str': 'Tau'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0677634', 'cui_str': 'Reptilase Time'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}]","[{'cui': 'C0677634', 'cui_str': 'Reptilase Time'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0042531', 'cui_str': 'Verbal Learning'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0222045'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0233762', 'cui_str': 'Hallucinations, Auditory'}]",,0.0298067,TCT produced significant improvements in auditory perception (d = 0.67) and verbal learning (d = 0.65); exploratory analyses revealed a statistically significant reduction in auditory hallucinations (d = -0.64).,"[{'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Thomas', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Bismark', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Yash B', 'Initials': 'YB', 'LastName': 'Joshi', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tarasenko', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Emily B H', 'Initials': 'EBH', 'LastName': 'Treichler', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Hochberger', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'San Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program (JDP) in Clinical Psychology, San Diego, CA, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Nungaray', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sprock', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Cardoso', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Tiernan', 'Affiliation': 'Alpine Special Treatment Center Inc., Alpine, CA, United States.'}, {'ForeName': 'Mouna', 'Initials': 'M', 'LastName': 'Attarha', 'Affiliation': 'Posit Science Corporation, 160 Pine St Suite 200, San Francisco, CA 94111, United States.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Braff', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Vinogradov', 'Affiliation': 'Department of Psychiatry, University of Minnesota, Minneapolis, MN, United States.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Swerdlow', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Light', 'Affiliation': 'Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States; San Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program (JDP) in Clinical Psychology, San Diego, CA, United States. Electronic address: glight@ucsd.edu.'}]",Schizophrenia research,['10.1016/j.schres.2018.07.025'] 1108,31663831,Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: A Multicenter randomized clinical Trial (DIRECT-MT)-Protocol.,"RATIONALE Intravenous thrombolysis combined with mechanical thrombectomy (MT) has been proven safe and clinical effective in patients with acute ischemic stroke of anterior circulation large vessel occlusion. However, despite reperfusion, a considerable proportion of patients do not recover. Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis. Conversely, intravenous thrombolysis may be beneficial in patients with small clots occluding intracranial arteries with underlying intracranial atherosclerotic disease, not accessible for MT. AIM To assess whether direct MT is non-inferior compared to combined intravenous thrombolysis plus MT in patients with AIS due to an anterior circulation large vessel occlusion, and to assess treatment effect modification by presence of intracranial atherosclerotic disease. SAMPLE SIZE Aim to randomize 636 patients 1:1 to receive direct MT (intervention) or combined intravenous thrombolysis plus MT (control). DESIGN This is a multicenter, prospective, open label parallel group trial with blinded outcome assessment (PROBE design) assessing non-inferiority of direct MT compared to combined intravenous thrombolysis plus MT. OUTCOMES The primary outcome is the score on the modified Rankin Scale assessed blindly at 90 (±14) days. An common odds ratio, adjusted for the prognostic factors (age, NIHSS, collateral score), representing the shift on the 6-category mRS scale measured at three months, estimated with ordinal logistic regression, will be the primary effect parameter. Non-inferiority is established if the lower boundary of the 95% confidence interval does not cross 0.8. DISCUSSION DIRECT-MT could result in improved therapeutic efficiency and cost reduction in treatment of anterior circulation large vessel occlusion stroke.",2020,"Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis.","['Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals', 'patients with acute ischemic stroke of anterior circulation large vessel occlusion', '636 patients 1:1 to receive', 'patients with small clots occluding intracranial arteries with underlying intracranial atherosclerotic disease', 'patients with AIS due to an anterior circulation large vessel occlusion']","['Direct Intra-arterial thrombectomy', 'direct MT (intervention) or combined intravenous thrombolysis plus MT (control', 'mechanical thrombectomy (MT', 'direct MT']","['therapeutic efficiency', '6-category mRS scale', 'score on the modified Rankin Scale assessed blindly at 90 (±14) days', 'symptomatic intracerebral hemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0225990', 'cui_str': 'Large vessel'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0302148', 'cui_str': 'Blood coagulum'}, {'cui': 'C1947917', 'cui_str': 'Occluded (qualifier value)'}, {'cui': 'C0447028', 'cui_str': 'Structure of intracranial artery'}, {'cui': 'C0524466', 'cui_str': 'Intracranial (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0694634', 'cui_str': 'Intra-arterial (qualifier value)'}, {'cui': 'C0162578', 'cui_str': 'Thrombectomy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}]",636.0,0.161536,"Incidence of symptomatic intracerebral hemorrhage was similar between patients treated with the combination of intravenous thrombolysis and MT, as compared to intravenous thrombolysis alone, suggesting that this complication should be attributed to pre-treatment with intravenous thrombolysis.","[{'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Kilian M', 'Initials': 'KM', 'LastName': 'Treurniet', 'Affiliation': 'Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yongwei', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Zifu', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Xing', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Yongxin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Hong', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Diederik Wj', 'Initials': 'DW', 'LastName': 'Dippel', 'Affiliation': 'Erasmus MC University Medical Center, Neurology and Stroke Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Yvo Bwem', 'Initials': 'YB', 'LastName': 'Roos', 'Affiliation': 'Neurology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Charles Blm', 'Initials': 'CB', 'LastName': 'Majoie', 'Affiliation': 'Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Benqiang', 'Initials': 'B', 'LastName': 'Deng', 'Affiliation': 'Neurology, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': 'Jianmin', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Neurosurgery, Changhai Hospital - Naval Medical University, Shanghai, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",International journal of stroke : official journal of the International Stroke Society,['10.1177/1747493019882837'] 1109,30222208,Eccentric cycling is more efficient in reducing fat mass than concentric cycling in adolescents with obesity.,"The benefits of eccentric (ECC) training on fat mass (FM) remain underexplored. We hypothesized that in obese adolescents, ECC cycling training is more efficient for decreasing whole-body FM percentage compared to concentric (CON) performed at the same oxygen consumption (VO 2 ). Twenty-four adolescents aged 13.4 ± 1.3 years (BMI > 90th percentile) were randomized to ECC or CON. They performed three cyclo-ergometer sessions per week (30 min per session) for 12 weeks: two habituation, 5 at 50% VO 2peak , and 5 at 70% VO 2peak . Anthropometric measurements, body composition, maximal incremental CON tests, strength tests, and blood samples were assessed pre- and post-training. Whole-body FM percentage decreased significantly after compared to pretraining in both groups, though to a larger extent in the ECC group (ECC: -10% vs CON: -4.2%, P < 0.05). Whole-body lean mass (LM) percentage increased significantly in both groups after compared to pretraining, with a greater increase in the ECC group (ECC: 3.8% vs CON: 1.5%, P <0.05). The improvements in leg FM and LM percentages were greater in the ECC group (-6.5% and 3.0%, P = 0.01 and P < 0.01). Quadriceps isometric and isokinetic ECC strength increased significantly more in the ECC group (28.3% and 21.3%, P < 0.05). Both groups showed similar significant VO 2peak improvement (ECC: 15.4% vs CON: 10.3%). The decrease in homeostasis model assessment of insulin resistance index was significant in the ECC group (-19.9%). In conclusion, although both ECC and CON cycling trainings are efficient to decrease FM, ECC induces greater FM reduction, strength gains, and insulin resistance improvements and represents an optimal modality to recommend for obese adolescents.",2019,"Quadriceps isometric and isokinetic ECC strength increased significantly more in the ECC group (28.3% and 21.3%, P < 0.05).","['adolescents with obesity', 'obese adolescents', 'Twenty-four adolescents aged 13.4\xa0±\xa01.3\xa0years']","['ECC group (ECC', 'Eccentric cycling', 'eccentric (ECC) training', 'CON']","['FM reduction, strength gains, and insulin resistance improvements', 'Quadriceps isometric and isokinetic ECC strength', 'leg FM and LM percentages', 'Whole-body lean mass (LM) percentage', 'homeostasis model assessment of insulin resistance index', 'Whole-body FM percentage', 'Anthropometric measurements, body composition, maximal incremental CON tests, strength tests, and blood samples']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517558', 'cui_str': 'Thirteen point four'}, {'cui': 'C4517499', 'cui_str': '1.3 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C4077283', 'cui_str': '(67Ga)ECC'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C4077283', 'cui_str': '(67Ga)ECC'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}]",24.0,0.0213134,"Quadriceps isometric and isokinetic ECC strength increased significantly more in the ECC group (28.3% and 21.3%, P < 0.05).","[{'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Julian', 'Affiliation': 'Department of Sport Medicine and Functional Explorations, Diet and Musculoskeletal Health Team, CRNH, INRA, University Teaching Hospital of Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Thivel', 'Affiliation': 'Laboratory AME2P, University of Clermont Auvergne, Aubière, France.'}, {'ForeName': 'Maud', 'Initials': 'M', 'LastName': 'Miguet', 'Affiliation': 'Laboratory AME2P, University of Clermont Auvergne, Aubière, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Pereira', 'Affiliation': 'Department of Biostatistics, University Teaching Hospital of Clermont-Ferrand, Clermont-Ferrand, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Costes', 'Affiliation': 'Department of Sport Medicine and Functional Explorations, Diet and Musculoskeletal Health Team, CRNH, INRA, University Teaching Hospital of Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Coudeyre', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Diet and Musculoskeletal Health Team, CRNH, INRA, University Teaching Hospital of Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Duclos', 'Affiliation': 'Department of Sport Medicine and Functional Explorations, Diet and Musculoskeletal Health Team, CRNH, INRA, University Teaching Hospital of Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'Ruddy', 'Initials': 'R', 'LastName': 'Richard', 'Affiliation': 'Department of Sport Medicine and Functional Explorations, Diet and Musculoskeletal Health Team, CRNH, INRA, University Teaching Hospital of Clermont-Ferrand, University of Clermont Auvergne, Clermont-Ferrand, France.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13301'] 1110,30453852,Intensive Patients' Education and Lifestyle Improving Program in CAD Patients.,"The objective of this article is to investigate the effects of intensive patients' education and lifestyle improving program (IPEL) on anxiety, depression, and overall survival (OS) in coronary artery disease (CAD) patients with anxiety and depression. In all, 224 CAD patients with anxiety and depression were randomly assigned to IPEL or control group. In Stage I, the IPEL group received IPEL and usual care, while the control group only received usual care. In Stage II, patients were further followed up and OS analysis was performed. Hospital Anxiety and Depression Scale-anxiety (HADS-A) and HADS-depression (HADS-D) were used to assess anxiety and depression. IPEL reduced HADS-A score at Month 9 (M9)/M12, and the percentage of anxiety at M12 and HADS-A score changed. IPEL reduced HADS-D score at M12, and the percentage of depression at M12 and HADS-D score changed compared with control. Patients with nonanxiety/nondepression at M12 in the IPEL group showed better OS. IPEL reduces anxiety and depression and improves OS in CAD patients.",2019,"IPEL reduced HADS-D score at M12, and the percentage of depression at M12 and HADS-D score changed compared with control.","[""Intensive Patients' Education and Lifestyle Improving Program in CAD Patients"", '224 CAD patients with anxiety and depression', 'coronary artery disease (CAD) patients with anxiety and depression', 'CAD patients']","['IPEL', ""intensive patients' education and lifestyle improving program (IPEL"", 'control group only received usual care']","['anxiety, depression, and overall survival (OS', 'anxiety and depression and improves OS', 'OS', 'Hospital Anxiety and Depression Scale-anxiety (HADS-A) and HADS-depression (HADS-D', 'anxiety and depression', 'percentage of depression at M12 and HADS-D score', 'IPEL reduced HADS-A score', 'IPEL reduced HADS-D score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C4319560', 'cui_str': '224'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",224.0,0.0288189,"IPEL reduced HADS-D score at M12, and the percentage of depression at M12 and HADS-D score changed compared with control.","[{'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Nie', 'Affiliation': '1 Department of Geriatrics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Tianzhu', 'Initials': 'T', 'LastName': 'Li', 'Affiliation': '2 Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Xiaoxia', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': '3 Department of Nursing, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.'}]",Western journal of nursing research,['10.1177/0193945918810205'] 1111,31654350,"Capsule Commentary on Hastings, et. al., Discharge Information and Support for Patients Discharged from the Emergency Department: Results from a Randomized Controlled Trial.",,2020,,['Discharged from the Emergency Department'],[],[],"[{'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}]",[],[],,0.258667,,"[{'ForeName': 'Timothy F', 'Initials': 'TF', 'LastName': 'Simpson', 'Affiliation': 'Oregon Health & Science University, Portland, USA. simpsont@ohsu.edu.'}]",Journal of general internal medicine,['10.1007/s11606-019-05387-8'] 1112,31654125,"Effect of therapeutic exercise routine on pain, disability, posture, and health status in dentists with chronic neck pain: a randomized controlled trial.","PURPOSE To investigate the effect of therapeutic exercise (TE) on pain, disability, posture, and health status in female dentists suffering from chronic neck pain (NP). METHODS 48 female dentists (40-45 years) suffering from NP were randomly divided into two experimental (n = 24) and control (n = 24) groups. Experimental group received 8 weeks of TE aimed to improve (1) muscle coordination and proprioception, (2) muscular endurance, and (3) muscle strength. Control group received no specific exercises. The pain, disability, posture (forward head and protracted shoulder angles), and health status were assessed at baseline and after an 8-week TE by visual analogue scale (VAS), neck disability index (NDI), photogrammetry, and self-rated general health questionnaire, respectively. Wilcoxon and Mann-Whitney non-parametric tests were used for statistical analysis. RESULTS There were significant between-group differences in neck pain [p = 0.003, 0.86 (0.09-1.65)], disability [p = 0.009, ES (95% CI) = 0.78 (0.020-1.37)], forward head angle [p = 0.039, ES (95% CI) = 0.61 (0.034-1.19)], protracted shoulder angle [p = 0.031, ES (95% CI) = 0.64 (0.062-1.22)], and health status [p = 0.022, ES (95% CI) = 0.68 (0.102-1.26)] favoring the corrective exercise group. There were significant within-group changes in pain, disability, posture, and health status in the experimental group. However, there were no within group changes in the control group. CONCLUSIONS TEs successfully alleviated pain, disability, posture, and health status in female dentists suffering from chronic NP. Considering the extremely large effect size of TEs, this intervention was recommended to neck pain treatment in patients suffering from chronic NP, poor posture, and health problem.",2020,"There were significant between-group differences in neck pain [p = 0.003, 0.86 (0.09-1.65)], disability [p = 0.009, ES (95% CI) = 0.78 (0.020-1.37)], forward head angle [p = 0.039, ES (95% CI) = 0.61 (0.034-1.19)], protracted shoulder angle [p = 0.031, ES (95% CI) = 0.64 (0.062-1.22)], and health status [p = 0.022, ES (95% CI) = 0.68 (0.102-1.26)] favoring the corrective exercise group.","['patients suffering from chronic NP, poor posture, and health problem', 'female dentists suffering from chronic neck pain (NP', 'female dentists suffering from chronic NP', 'dentists with chronic neck pain', '48 female dentists (40-45 years) suffering from NP']","['Control group received no specific exercises', 'therapeutic exercise (TE', 'therapeutic exercise routine', 'TE aimed to improve (1) muscle coordination and proprioception, (2) muscular endurance, and (3) muscle strength']","['pain, disability, posture, and health status', 'pain, disability, posture (forward head and protracted shoulder angles), and health status', 'protracted shoulder angle', 'disability', 'visual analogue scale (VAS), neck disability index (NDI), photogrammetry, and self-rated general health questionnaire', 'neck pain', 'health status']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0426976', 'cui_str': 'Poor posture (finding)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0011441', 'cui_str': 'Dentist'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0242414', 'cui_str': 'Coordination (observable entity)'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1262869', 'cui_str': 'Posture'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0439780', 'cui_str': 'Forward (qualifier value)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0031747', 'cui_str': 'Photogrammetry'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0451182', 'cui_str': 'General health questionnaire (assessment scale)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}]",48.0,0.0536114,"There were significant between-group differences in neck pain [p = 0.003, 0.86 (0.09-1.65)], disability [p = 0.009, ES (95% CI) = 0.78 (0.020-1.37)], forward head angle [p = 0.039, ES (95% CI) = 0.61 (0.034-1.19)], protracted shoulder angle [p = 0.031, ES (95% CI) = 0.64 (0.062-1.22)], and health status [p = 0.022, ES (95% CI) = 0.68 (0.102-1.26)] favoring the corrective exercise group.","[{'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Letafatkar', 'Affiliation': 'Sport Injury and Corrective Exercises, Faculty of Physical Education and Sports Sciences, Kharazmi University, Tehran, Iran. letafatkaramir@yahoo.com.'}, {'ForeName': 'Pouya', 'Initials': 'P', 'LastName': 'Rabiei', 'Affiliation': 'Department of Physical Education and Sports Sciences, Karaj Branch, Islamic Azad University, Karaj, Iran.'}, {'ForeName': 'Gelareh', 'Initials': 'G', 'LastName': 'Alamooti', 'Affiliation': 'Sport Injury and Corrective Exercises, Faculty of Physical Education and Sports Sciences, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Bertozzi', 'Affiliation': 'Department of Physiotherapy, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Niloufar', 'Initials': 'N', 'LastName': 'Farivar', 'Affiliation': 'Sport Injury and Corrective Exercises, Faculty of Physical Education and Sports Sciences, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Afshari', 'Affiliation': 'Sport Injury and Corrective Exercises, Faculty of Physical Education and Sports Sciences, Kharazmi University, Tehran, Iran.'}]",International archives of occupational and environmental health,['10.1007/s00420-019-01480-x'] 1113,31652226,Efficacy of Intralesional Cryosurgery in the Treatment of Multiple Extragenital Cutaneous Warts: A Randomized Controlled Study.,"BACKGROUND The efficacy of intralesional (IL) cryosurgery in the treatment of cutaneous warts has not been previously studied. OBJECTIVE To compare the efficacy and safety of IL cryosurgery versus electrosurgery in multiple extragenital warts and investigate their effect on serum interleukin (IL)-12 and interferon-gamma (IFN-γ). MATERIALS AND METHODS Thirty-one patients were included; 18 received IL cryosurgery, and 13 had electrosurgery. Treatment was performed for the largest or few (2-3) small warts (target) until cleared, leaving the remaining (distant) warts untreated. Clinical response of the target and distant warts and adverse effects were evaluated. Serum IL-12 and IFN-γ levels were assessed before and after treatment. RESULTS All patients had complete clearing of the treated wart in both groups. IL cryosurgery was well tolerated; infection, ulceration, and recurrence occurred only with electrosurgery. Complete/near-complete resolution of the distant untreated warts was seen in 33.3% versus none of patients in the IL cryosurgery and electrosurgery groups, respectively (p = .003). Furthermore, IL-12 and IFN-γ levels showed a tendency to increase after IL cryosurgery, and their increase correlated with distant wart response. CONCLUSION Intralesional cryosurgery is effective not only in clearing treated warts but also resolving untreated warts and possibly enhances human papillomavirus-directed immune response.",2020,"Complete/near-complete resolution of the distant untreated warts was seen in 33.3% versus none of patients in the IL cryosurgery and electrosurgery groups, respectively (p = .003).","['Thirty-one patients were included; 18 received IL cryosurgery, and 13 had electrosurgery', 'Multiple Extragenital Cutaneous Warts']","['intralesional (IL', 'Intralesional Cryosurgery', 'IL cryosurgery versus electrosurgery']","['Complete/near-complete resolution of the distant untreated warts', 'Furthermore, IL-12 and IFN-γ levels', 'efficacy and safety', 'serum interleukin (IL)-12 and interferon-gamma (IFN-γ', 'Serum IL-12 and IFN-γ levels', 'tolerated; infection, ulceration, and recurrence']","[{'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0010408', 'cui_str': 'Cryoablation'}, {'cui': 'C0013873', 'cui_str': 'Electrosurgery'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C4521174', 'cui_str': 'Cutaneous'}, {'cui': 'C3665596', 'cui_str': 'Verruca'}]","[{'cui': 'C0010408', 'cui_str': 'Cryoablation'}, {'cui': 'C0013873', 'cui_str': 'Electrosurgery'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0475806', 'cui_str': 'Nr - Near'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C3665596', 'cui_str': 'Verruca'}, {'cui': 'C0123759', 'cui_str': 'Interleukin-12'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021745', 'cui_str': 'interferon gamma'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C3887532', 'cui_str': 'Ulceration (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",31.0,0.0564542,"Complete/near-complete resolution of the distant untreated warts was seen in 33.3% versus none of patients in the IL cryosurgery and electrosurgery groups, respectively (p = .003).","[{'ForeName': 'Sara M', 'Initials': 'SM', 'LastName': 'Awad', 'Affiliation': 'Department of Dermatology, Venereology and Andrology, Assiut University Hospital, Assiut, Egypt.'}, {'ForeName': 'Omnia', 'Initials': 'O', 'LastName': 'El-Badawy', 'Affiliation': 'Department of Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Doaa A E', 'Initials': 'DAE', 'LastName': 'Abou-Taleb', 'Affiliation': 'Department of Dermatology, Venereology and Andrology, Assiut University Hospital, Assiut, Egypt.'}]",Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],['10.1097/DSS.0000000000002217'] 1114,31652109,Cold-Water Immersion Does Not Accelerate Performance Recovery After 10-km Street Run: Randomized Controlled Clinical Trial.,"The use of strategies to assure better post-effort recovery is frequent in sports settings. There are several interventions available for exercise induced muscle damage recovery, but cold-water immersion (CWI) stands out among them. The effects of CWI are unclear in the literature and, although the number of street runners has been growing, there is a gap in the scientific evidence regarding the use of CWI to recover runners' performance after a 10-km street run. Purpose: The goal of our study was to analyze the effects of CWI on the recovery of muscle damage markers after a 10-km street run. Method: We randomly assigned thirty male recreational street runners, immediately after a 10-km street run, into three recovery groups: control (rest for 10 minutes), immersion (10 min immersed in water without ice at room temperature) and CWI (10 min immersed in water with ice at 10ºC). We assessed pain, triple hop distance, extensor peak torque and blood creatine kinase levels pre- and post-run, post-intervention and 24 hours after the run. Results: The 10-km run was enough to decrease triple hop distance and extensor peak torque, and increase levels of creatine kinase ( p < 0.05); however, we found no time/group interactions in any of the assessed variables after we applied the appropriate interventions ( p > 0.05). Conclusion: 10-min CWI at 10°C was no more effective than water immersion and rest in recovering muscle damage markers after 10-km runs.",2020,"The 10-km run was enough to decrease triple hop distance and extensor peak torque, and increase levels of creatine kinase ( p < 0.05); however, we found no time/group interactions in any of the assessed variables after we applied the appropriate interventions ( p > 0.05). ","['thirty male recreational street runners, immediately after a 10-km street run, into three recovery groups']","['Cold-water Immersion', 'control (rest for 10 minutes), immersion (10 min immersed in water without ice at room temperature) and CWI', 'CWI']","['pain, triple hop distance, extensor peak torque and blood creatine kinase levels pre- and post-run, post-intervention and 24 hours after the run', 'triple hop distance and extensor peak torque, and increase levels of creatine kinase']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0442658', 'cui_str': 'Street (environment)'}, {'cui': 'C0052080', 'cui_str': '3-((phenylacetyl)amino)-2,6-piperidinedione'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C4708833', 'cui_str': 'Cold water'}, {'cui': 'C0020940', 'cui_str': 'Immersion'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0349714', 'cui_str': 'Icing (substance)'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C4018995', 'cui_str': 'Hop'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0853178', 'cui_str': 'Blood creatine'}, {'cui': 'C4521566', 'cui_str': 'Kinase'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0201973', 'cui_str': 'Creatine kinase measurement (procedure)'}]",30.0,0.0695893,"The 10-km run was enough to decrease triple hop distance and extensor peak torque, and increase levels of creatine kinase ( p < 0.05); however, we found no time/group interactions in any of the assessed variables after we applied the appropriate interventions ( p > 0.05). ","[{'ForeName': 'Glauko', 'Initials': 'G', 'LastName': 'Dantas', 'Affiliation': 'Federal University of São Carlos.'}, {'ForeName': 'Alef', 'Initials': 'A', 'LastName': 'Barros', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Silva', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Belém', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Vitoria', 'Initials': 'V', 'LastName': 'Ferreira', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Fonseca', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Castro', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Santos', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Telma', 'Initials': 'T', 'LastName': 'Lemos', 'Affiliation': 'Federal University of Rio Grande do Norte.'}, {'ForeName': 'Wouber', 'Initials': 'W', 'LastName': 'Hérickson', 'Affiliation': 'Federal University of Rio Grande do Norte.'}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1659477'] 1115,30552829,Breast lesion detection and characterization with contrast-enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T.,"BACKGROUND Contrast-enhanced magnetic resonance imaging (CE-MRI) of the breast is highly sensitive for breast cancer detection. Multichannel coils and 3T scanners can increase signal, spatial, and temporal resolution. In addition, the T 1 -reduction effect of a gadolinium-based contrast agent (GBCA) is higher at 3T. Thus, it might be possible to reduce the dose of GBCA at 3T without losing diagnostic information. PURPOSE To compare a three-quarter (0.075 mmol/kg) dose of the high-relaxivity GBCA gadobenate dimeglumine, with a 1.5-fold higher than on-label dose (0.15 mmol/kg) of gadoterate meglumine for breast lesion detection and characterization at 3T CE-MRI. STUDY TYPE Prospective, randomized, intraindividual comparative study. POPULATION Eligible were patients with imaging abnormalities (BI-RADS 0, 4, 5) on conventional imaging. Each patient underwent two examinations, 24-72 hours apart, one with 0.075 mmol/kg gadobenate and the other with 0.15 mmol/kg gadoterate administered in a randomized order. In all, 109 patients were prospectively recruited. FIELD STRENGTH/SEQUENCE 3T MRI with a standard breast protocol (dynamic-CE, T 2 w-TSE, STIR-T 2 w, DWI). ASSESSMENT Histopathology was the standard of reference. Three blinded, off-site breast radiologists evaluated the examinations using the BI-RADS lexicon. STATISTICAL TESTS Lesion detection, sensitivity, specificity, and diagnostic accuracy were calculated per-lesion and per-region, and compared by univariate and multivariate analysis (Generalized Estimating Equations, GEE). RESULTS Five patients were excluded, leaving 104 women with 142 histologically verified breast lesions (109 malignant, 33 benign) available for evaluation. Lesion detection with gadobenate (84.5-88.7%) was not inferior to gadoterate (84.5-90.8%) (P ≥ 0.165). At per-region analysis, gadobenate demonstrated higher specificity (96.4-98.7% vs. 92.6-97.3%, P ≤ 0.007) and accuracy (96.3-97.8% vs. 93.6-96.1%, P ≤ 0.001) compared with gadoterate. Multivariate analysis demonstrated superior, reader-independent diagnostic accuracy with gadobenate (odds ratio = 1.7, P < 0.001 using GEE). DATA CONCLUSION A 0.075 mmol/kg dose of the high-relaxivity contrast agent gadobenate was not inferior to a 0.15 mmol/kg dose of gadoterate for breast lesion detection. Gadobenate allowed increased specificity and accuracy. LEVEL OF EVIDENCE 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;49:1157-1165.",2019,"Multivariate analysis demonstrated superior, reader-independent diagnostic accuracy with gadobenate (odds ratio = 1.7, P < 0.001 using GEE). ","['Five patients were excluded, leaving 104 women with 142 histologically verified breast lesions (109 malignant, 33 benign) available for evaluation', '109 patients were prospectively recruited', 'Eligible were patients with imaging abnormalities (BI-RADS 0, 4, 5) on conventional imaging']","['gadolinium-based contrast agent (GBCA', 'contrast-enhanced magnetic resonance imaging', 'Contrast-enhanced magnetic resonance imaging (CE-MRI', 'gadoterate meglumine', 'high-relaxivity GBCA gadobenate dimeglumine', 'gadobenate dimeglumine', 'Multichannel coils and 3T scanners']","['Lesion detection with gadobenate', 'specificity', 'specificity and accuracy', 'accuracy', 'signal, spatial, and temporal resolution', 'Lesion detection, sensitivity, specificity, and diagnostic accuracy']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205282', 'cui_str': 'Malignant (qualifier value)'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0556643', 'cui_str': 'rad (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009924', 'cui_str': 'Contrast Agents'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0118538', 'cui_str': 'gadoterate meglumine'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0209453', 'cui_str': 'Gadobenate dimeglumine'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil (physical object)'}, {'cui': 'C1097281', 'cui_str': '3-(DMP)-T'}, {'cui': 'C0183115', 'cui_str': 'Scanner'}]","[{'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1875994', 'cui_str': 'Gadobenate'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0428763', 'cui_str': 'Temporal resolution (observable entity)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}]",109.0,0.0808301,"Multivariate analysis demonstrated superior, reader-independent diagnostic accuracy with gadobenate (odds ratio = 1.7, P < 0.001 using GEE). ","[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Clauser', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Helbich', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Kapetas', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Pinker', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Bernathova', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Woitek', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Kaneider', 'Affiliation': 'Diagnose Zentrum Urania, Vienna, Austria.'}, {'ForeName': 'Pascal A T', 'Initials': 'PAT', 'LastName': 'Baltzer', 'Affiliation': 'Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Vienna, Austria.'}]",Journal of magnetic resonance imaging : JMRI,['10.1002/jmri.26335'] 1116,30316564,[Primary Care and oral health promotion: Assessment of an educational intervention in school children].,"OBJECTIVE To evaluate the short and medium term effectiveness of a Primary Care-driven oral health promotion intervention. DESIGN A non-randomised community intervention trial. SETTING Three socio-demographically similar primary schools of a deprived neighborhood in Granada, Spain. PARTICIPANTS Eighty-two intervention and 109 control students aged 5 to 6, as well as the teachers and the parent's association of the intervention school (IS) participated in the study. INTERVENTION School-based health promotion activities aimed at students, and regular meetings with the teachers and parents of the IS during 2 consecutive years. MAIN MEASUREMENTS Students' oral health-related knowledge and behavior, assessed via questionnaires distributed before the intervention, and 6 and 18 months afterwards. RESULTS Compared to the control groups at 18 months, students belonging to the IS reported enhanced oral health knowledge (OR 3.54; 95% CI 1.46-8.58), and an increased consumption of healthy food at breakfast (OR 2.95; 95% CI 1.26-6.89) and during mid-afternoon snack (OR 3.67; 95% CI 1.49-9.05). A significant decrease was seen in the intake of pastries (OR 4.05; 95% CI 1.68-9.81) and sweetened soft drinks and juices (OR 3.79; 95% CI 1.57-9.12) amongst intervention compared to control students in the medium term (18 months). No significant improvements were observed concerning oral hygiene in the IS. CONCLUSIONS School-based educational interventions, when developed through an intersectoral and participative approach and considering the socio-economic context, appear to be effective in improving students' diet-related knowledge and behaviors.",2019,A significant decrease was seen in the intake of pastries (OR 4.05; 95% CI 1.68-9.81) and sweetened soft drinks and juices (OR 3.79; 95% CI 1.57-9.12) amongst intervention compared to control students in the medium term (18 months).,"['Three socio-demographically similar primary schools of a deprived neighborhood in Granada, Spain', ""Eighty-two intervention and 109 control students aged 5 to 6, as well as the teachers and the parent's association of the intervention school (IS) participated in the study"", 'school children']","['educational intervention', 'School-based health promotion activities aimed at students, and regular meetings with the teachers and parents of the IS during 2 consecutive years', 'Primary Care-driven oral health promotion intervention']","['oral hygiene', 'oral health-related knowledge and behavior, assessed via questionnaires', 'oral health knowledge', 'increased consumption of healthy food at breakfast', 'intake of pastries']","[{'cui': 'C0033145', 'cui_str': 'Primary Schools'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0556656', 'cui_str': 'Meetings (procedure)'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0004379', 'cui_str': 'Drivings, Automobile'}, {'cui': 'C0150290', 'cui_str': 'Oral health promotion (regime/therapy)'}]","[{'cui': 'C1272386', 'cui_str': 'Mouth care management'}, {'cui': 'C0029162'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}, {'cui': 'C0452703', 'cui_str': 'Pastry (substance)'}]",,0.0323525,A significant decrease was seen in the intake of pastries (OR 4.05; 95% CI 1.68-9.81) and sweetened soft drinks and juices (OR 3.79; 95% CI 1.57-9.12) amongst intervention compared to control students in the medium term (18 months).,"[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Calderón Larrañaga', 'Affiliation': 'Centro de Salud Cartuja, Granada, España. Electronic address: sarakalde@gmail.com.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Expósito Ruiz', 'Affiliation': 'Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO), Granada, España.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Cruz Vela', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Cuadrado Conde', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}, {'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Alquézar Villarroya', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Garach Gómez', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Ruiz Hernández', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Toral López', 'Affiliation': 'Centro de Salud Cartuja, Granada, España.'}]",Atencion primaria,['10.1016/j.aprim.2018.05.003'] 1117,30246926,A multicentre prospective randomised controlled comparative parallel study of dehydrated human umbilical cord (EpiCord) allograft for the treatment of diabetic foot ulcers.,"The aim of this study was to determine the safety and effectiveness of dehydrated human umbilical cord allograft (EpiCord) compared with alginate wound dressings for the treatment of chronic, non-healing diabetic foot ulcers (DFU). A multicentre, randomised, controlled, clinical trial was conducted at 11 centres in the United States. Individuals with a confirmed diagnosis of Type 1 or Type 2 diabetes presenting with a 1 to 15 cm 2 ulcer located below the ankle that had been persisting for at least 30 days were eligible for the 14-day study run-in phase. After 14 days of weekly debridement, moist wound therapy, and off-loading, those with ≤30% wound area reduction post-debridement (n = 155) were randomised in a 2:1 ratio to receive a weekly application of EpiCord (n = 101) or standardised therapy with alginate wound dressing, non-adherent silicone dressing, absorbent non-adhesive hydropolymer secondary dressing, and gauze bandage roll (n = 54). All wounds continued to have appropriate off-loading during the treatment phase of the study. Study visits were conducted for 12 weeks. At each weekly visit, the DFU was cleaned and debrided as necessary, with the wound photographed pre- and post-debridement and measured before the application of treatment group-specific dressings. A follow-up visit was performed at week 16. The primary study end point was the percentage of complete closure of the study ulcer within 12 weeks, as assessed by Silhouette camera. Data for randomised subjects meeting study inclusion criteria were included in an intent-to-treat (ITT) analysis. Additional analysis was conducted on a group of subjects (n = 134) who completed the study per protocol (PP) (EpiCord, n = 86, alginate, n = 48) and for those subjects receiving adequate debridement (EpiCord, n = 67, alginate, n = 40). ITT analysis showed that DFUs treated with EpiCord were more likely to heal within 12 weeks than those receiving alginate dressings, 71 of 101 (70%) vs 26 of 54 (48%) for EpiCord and alginate dressings, respectively, P = 0.0089. Healing rates at 12 weeks for subjects treated PP were 70 of 86 (81%) for EpiCord-treated and 26 of 48 (54%) for alginate-treated DFUs, P = 0.0013. For those DFUs that received adequate debridement (n = 107, ITT population), 64 of 67 (96%) of the EpiCord-treated ulcers healed completely within 12 weeks, compared with 26 of 40 (65%) of adequately debrided alginate-treated ulcers, P < 0.0001. Seventy-five subjects experienced at least one adverse event, with a total of 160 adverse events recorded. There were no adverse events related to either EpiCord or alginate dressings. These results demonstrate the safety and efficacy of EpiCord as a treatment for non-healing DFUs.",2019,"ITT analysis showed that DFUs treated with EpiCord were more likely to heal within 12 weeks than those receiving alginate dressings, 71 of 101 (70%) vs 26 of 54 (48%) for EpiCord and alginate dressings, respectively, P = 0.0089.","['Individuals with a confirmed diagnosis of Type 1 or Type 2 diabetes presenting with a 1 to 15\u2009cm 2 ulcer located below the ankle that had been persisting for at least 30\u2009days were eligible for the 14-day study run-in phase', 'n\u2009=\u2009155', 'chronic, non-healing diabetic foot ulcers (DFU', 'diabetic foot ulcers', 'group of subjects (n\u2009=\u2009134) who completed the study per protocol (PP) (EpiCord, n\u2009=\u200986, alginate, n\u2009=\u200948) and for those subjects receiving adequate debridement (EpiCord, n\u2009=\u200967, alginate, n\u2009=\u200940', '11 centres in the United States']","['moist wound therapy, and off-loading, those with ≤30% wound area reduction post-debridement', 'weekly application of EpiCord (n\u2009=\u2009101) or standardised therapy with alginate wound dressing, non-adherent silicone dressing, absorbent non-adhesive hydropolymer secondary dressing, and gauze bandage roll', 'dehydrated human umbilical cord (EpiCord) allograft', 'alginate wound dressings', 'dehydrated human umbilical cord allograft (EpiCord']","['safety and effectiveness', 'safety and efficacy', 'percentage of complete closure of the study ulcer', 'Healing rates']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}, {'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0102137', 'cui_str': 'alginate'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0205381', 'cui_str': 'Wet (qualifier value)'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0102137', 'cui_str': 'alginate'}, {'cui': 'C0013119', 'cui_str': 'Dressings'}, {'cui': 'C0460757', 'cui_str': 'Non-adherent silicone dressing (physical object)'}, {'cui': 'C3873692', 'cui_str': 'Absorbent (physical object)'}, {'cui': 'C0001516', 'cui_str': 'Adhesives'}, {'cui': 'C3266202', 'cui_str': 'Secondary dressing (physical object)'}, {'cui': 'C0590323', 'cui_str': 'Gauzes (physical object)'}, {'cui': 'C0150468', 'cui_str': 'Application of bandage (procedure)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0041633', 'cui_str': 'Umbilical Cord'}, {'cui': 'C0450127', 'cui_str': 'Allogeneic Grafts'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0043240', 'cui_str': 'Wound Healing'}]",,0.0427692,"ITT analysis showed that DFUs treated with EpiCord were more likely to heal within 12 weeks than those receiving alginate dressings, 71 of 101 (70%) vs 26 of 54 (48%) for EpiCord and alginate dressings, respectively, P = 0.0089.","[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Tettelbach', 'Affiliation': 'Wound Care & Hyperbaric Medicine Clinical Services, Intermountain Healthcare, Salt Lake City, Utah.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Cazzell', 'Affiliation': 'Limb Preservation Platform, Inc., Fresno, California.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sigal', 'Affiliation': 'Foot and Ankle Clinic, Los Angeles, California.'}, {'ForeName': 'Joseph M', 'Initials': 'JM', 'LastName': 'Caporusso', 'Affiliation': 'Futuro Clinical Trials, McAllen, Texas.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Agnew', 'Affiliation': 'Coastal Podiatry, Inc, Virginia Beach, Virginia.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Hanft', 'Affiliation': 'Miami Foot and Ankle, Miami, Florida.'}, {'ForeName': 'Cyaandi', 'Initials': 'C', 'LastName': 'Dove', 'Affiliation': 'Advanced Foot & Ankle Center, Las Vegas, Nevada.'}]",International wound journal,['10.1111/iwj.13001'] 1118,31664441,Effect of Weight Loss via Severe vs Moderate Energy Restriction on Lean Mass and Body Composition Among Postmenopausal Women With Obesity: The TEMPO Diet Randomized Clinical Trial.,"Importance Severely energy-restricted diets are the most effective dietary obesity treatment. However, there are concerns regarding potential adverse effects on body composition. Objective To compare the long-term effects of weight loss via severe vs moderate energy restriction on lean mass and other aspects of body composition. Design, Setting, and Participants The Type of Energy Manipulation for Promoting Optimum Metabolic Health and Body Composition in Obesity (TEMPO) Diet Trial was a 12-month, single-center, randomized clinical trial. A total of 101 postmenopausal women, aged 45 to 65 years with body mass index (calculated as weight in kilograms divided by height in meters squared) from 30 to 40, who were at least 5 years after menopause, had fewer than 3 hours of structured physical activity per week, and lived in the Sydney metropolitan area of New South Wales, Australia, were recruited between March 2013 and July 2016. Data analysis was conducted between October 2018 and August 2019. Intervention Participants were randomized to either 12 months of moderate (25%-35%) energy restriction with a food-based diet (moderate intervention) or 4 months of severe (65%-75%) energy restriction with a total meal replacement diet followed by moderate energy restriction for an additional 8 months (severe intervention). Both interventions had a prescribed protein intake of 1.0 g/kg of actual body weight per day, and physical activity was encouraged but not supervised. Main Outcomes and Measures The primary outcome was whole-body lean mass at 12 months after commencement of intervention. Secondary outcomes were body weight, thigh muscle area and muscle function (strength), bone mineral density, and fat mass and distribution, measured at 0, 4, 6, and 12 months. Results A total of 101 postmenopausal women were recruited (mean [SD] age, 58.0 [4.2] years; mean [SD] weight, 90.8 [9.1] kg; mean [SD] body mass index, 34.4 [2.5]). Compared with the moderate group at 12 months, the severe group lost more weight (effect size, -6.6 kg; 95% CI, -8.2 to -5.1 kg), lost more whole-body lean mass (effect size, -1.2 kg; 95% CI, -2.0 to -0.4 kg), and lost more thigh muscle area (effect size, -4.2 cm2; 95% CI, -6.5 to -1.9 cm2). However, decreases in whole-body lean mass and thigh muscle area were proportional to total weight loss, and there was no difference in muscle (handgrip) strength between groups. Total hip bone mineral density (effect size, -0.017 g/cm2; 95% CI, -0.029 to -0.005 g/cm2), whole-body fat mass (effect size, -5.5 kg; 95% CI, -7.1 to -3.9 kg), abdominal subcutaneous adipose tissue (effect size, -1890 cm3; 95% CI, -2560 to -1219 cm3), and visceral adipose tissue (effect size, -1389 cm3; 95% CI, -1748 to -1030 cm3) loss were also greater for the severe group than for the moderate group at 12 months. Conclusions and Relevance Severe energy restriction had no greater adverse effect on relative whole-body lean mass or handgrip strength compared with moderate energy restriction and was associated with 2-fold greater weight and fat loss over 12 months. However, there was significantly greater loss of total hip bone mineral density with severe vs moderate energy restriction. Therefore, caution is necessary when implementing severe energy restriction in postmenopausal women, particularly those with osteopenia or osteoporosis. Trial Registration anzctr.org.au Identifier: 12612000651886.",2019,"Total hip bone mineral density (effect size, -0.017 g/cm2; 95% CI, -0.029 to -0.005 g/cm2), whole-body fat mass (effect size, -5.5 kg; 95% CI, -7.1 to -3.9 kg), abdominal subcutaneous adipose tissue (effect size, -1890 cm3; 95% CI, -2560 to -1219 cm3), and visceral adipose tissue (effect size, -1389 cm3; 95% CI, -1748 to -1030 cm3) loss were also greater for the severe group than for the moderate group at 12 months. ","['Postmenopausal Women With Obesity', 'postmenopausal women, particularly those with osteopenia or osteoporosis', '101 postmenopausal women were recruited (mean [SD] age, 58.0 [4.2] years', '101 postmenopausal women, aged 45 to 65 years with body mass index (calculated as weight in kilograms divided by height in meters squared) from 30 to 40, who were at least 5 years after menopause, had fewer than 3 hours of structured physical activity per week, and lived in the Sydney metropolitan area of New South Wales, Australia, were recruited between March 2013 and July 2016']","['Weight Loss via Severe vs Moderate Energy Restriction', 'moderate (25%-35%) energy restriction with a food-based diet (moderate intervention) or 4 months of severe (65%-75%) energy restriction with a total meal replacement diet followed by moderate energy restriction for an additional 8 months (severe intervention', 'weight loss via severe vs moderate energy restriction']","['Total hip bone mineral density', 'thigh muscle area', 'weight and fat loss', 'whole-body lean mass', 'visceral adipose tissue', 'total weight loss', 'Optimum Metabolic Health and Body Composition in Obesity (TEMPO', 'muscle (handgrip) strength', 'total hip bone mineral density', 'weight', 'abdominal subcutaneous adipose tissue', 'Lean Mass and Body Composition', 'body weight, thigh muscle area and muscle function (strength), bone mineral density, and fat mass and distribution, measured at 0, 4, 6, and 12 months']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517758', 'cui_str': 'Four point two'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0475209', 'cui_str': 'm'}, {'cui': 'C0205120', 'cui_str': 'Square (qualifier value)'}, {'cui': 'C0587113', 'cui_str': 'After menopause (qualifier value)'}, {'cui': 'C0205388', 'cui_str': 'Few (qualifier value)'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0559897', 'cui_str': 'Diet followed (observable entity)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0039866', 'cui_str': 'Thigh'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C1563740', 'cui_str': 'Visceral Fat'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0076084', 'cui_str': '2,2,6,6-tetramethyl-4-piperidine-N-oxide'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1563741', 'cui_str': 'Subcutaneous Fat, Abdominal'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0231484', 'cui_str': 'Muscular activity'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]",101.0,0.155129,"Total hip bone mineral density (effect size, -0.017 g/cm2; 95% CI, -0.029 to -0.005 g/cm2), whole-body fat mass (effect size, -5.5 kg; 95% CI, -7.1 to -3.9 kg), abdominal subcutaneous adipose tissue (effect size, -1890 cm3; 95% CI, -2560 to -1219 cm3), and visceral adipose tissue (effect size, -1389 cm3; 95% CI, -1748 to -1030 cm3) loss were also greater for the severe group than for the moderate group at 12 months. ","[{'ForeName': 'Radhika V', 'Initials': 'RV', 'LastName': 'Seimon', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Anthony L', 'Initials': 'AL', 'LastName': 'Wild-Taylor', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'School of Human Movement and Nutrition Sciences, Centre for Research on Exercise, Physical Activity and Health, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'McClintock', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Harper', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Alice A', 'Initials': 'AA', 'LastName': 'Gibson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Johnson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Hamish A', 'Initials': 'HA', 'LastName': 'Fernando', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Tania P', 'Initials': 'TP', 'LastName': 'Markovic', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Jacqueline R', 'Initials': 'JR', 'LastName': 'Center', 'Affiliation': ""Bone Biology Program, Garvan Institute of Medical Research, St Vincent's Hospital Clinical School, University of New South Wales, Sydney, New South Wales, Australia.""}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Franklin', 'Affiliation': 'Metabolism and Obesity Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Peter Y', 'Initials': 'PY', 'LastName': 'Liu', 'Affiliation': 'Division of Endocrinology, Department of Medicine, Harbor-University of California Los Angeles Medical Center and Los Angeles BioMedical Research Institute, Los Angeles.'}, {'ForeName': 'Stuart M', 'Initials': 'SM', 'LastName': 'Grieve', 'Affiliation': 'Sydney Translational Imaging Laboratory, Heart Research Institute, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Lagopoulos', 'Affiliation': 'Sunshine Coast Mind and Neuroscience-Thompson Institute, University of the Sunshine Coast, Queensland, Australia.'}, {'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Caterson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Nuala M', 'Initials': 'NM', 'LastName': 'Byrne', 'Affiliation': 'School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, Tasmania, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Sainsbury', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise, and Eating Disorders, Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia.'}]",JAMA network open,['10.1001/jamanetworkopen.2019.13733'] 1119,30326551,Dynamic stretching is not detrimental to neuromechanical and sensorimotor performance of ankle plantarflexors.,"The acute effects of two dynamic stretching (DS) protocols on changes in the ankle range of motion (RoM), neuromechanical, and sensorimotor properties of the plantarflexor muscle group were examined. Eighteen participants received slow (SDS) or fast dynamic stretching (FDS) on two separate days. Outcome measures were assessed pre- and 2 minutes post-interventions, and included maximum dorsiflexion angle, maximum isometric torque at neutral ankle position, maximum concentric and eccentric torques, force matching capacity, joint position sense and medial gastrocnemius muscle and tendon strain. Possibly and likely small increases in dorsiflexion RoM were observed after SDS (mean ± 90% confidence intervals; 1.8 ± 1.2°) and FDS (2.1 ± 1.2°), respectively. Very likely moderate decreases in muscle strain after SDS (-38.0 ± 20.6%) and possibly small decrease after FDS (-13.6 ± 21.2%) were observed. SDS resulted in a likely beneficial small increase in tendon strain (25.3 ± 29.7%) and a likely beneficial moderate increase after FDS (41.4 ± 44.9%). Effects on strength were inconsistent. Possibly small effect on positional error after SDS (-27.1 ± 37.5%), but no clear effect after FDS was observed. Both DS protocols increased RoM, and this was more due to an increase in tendon elongation rather than the muscle. However, SDS showed greater improvement than FDS in both neuromechanical and sensorimotor performance, and hence, SDS can be recommended as part of warm-up in sporting contexts.",2019,"Possibly small effect on positional error after SDS (-27.1 ± 37.5%), but no clear effect after FDS was observed.",['Eighteen participants received'],"['Dynamic stretching', 'SDS', 'dynamic stretching (DS) protocols', 'slow (SDS) or fast dynamic stretching (FDS']","['dorsiflexion RoM', 'maximum dorsiflexion angle, maximum isometric torque at neutral ankle position, maximum concentric and eccentric torques, force matching capacity, joint position sense and medial gastrocnemius muscle and tendon strain', 'tendon elongation rather', 'tendon strain', 'ankle range of motion (RoM), neuromechanical, and sensorimotor properties', 'positional error', 'muscle strain']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0600080', 'cui_str': 'Stretching procedure (procedure)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}]","[{'cui': 'C0205143', 'cui_str': 'Angular (qualifier value)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0423561', 'cui_str': 'Joint position sense, function (observable entity)'}, {'cui': 'C0205098', 'cui_str': 'Medial (qualifier value)'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius Muscle'}, {'cui': 'C0434303', 'cui_str': 'Tendon strain (disorder)'}, {'cui': 'C0856439', 'cui_str': 'Tendon elongation'}, {'cui': 'C0576183', 'cui_str': 'Joint movement: ankle'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}]",,0.0630846,"Possibly small effect on positional error after SDS (-27.1 ± 37.5%), but no clear effect after FDS was observed.","[{'ForeName': 'George M', 'Initials': 'GM', 'LastName': 'Pamboris', 'Affiliation': 'Centre for Human Performance, Exercise and Rehabilitation, Brunel University London, Uxbridge, UK.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Noorkoiv', 'Affiliation': 'Centre for Human Performance, Exercise and Rehabilitation, Brunel University London, Uxbridge, UK.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Baltzopoulos', 'Affiliation': 'Research Institute for Sport and Exercise Sciences (RISES), Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'Amir A', 'Initials': 'AA', 'LastName': 'Mohagheghi', 'Affiliation': 'Centre for Human Performance, Exercise and Rehabilitation, Brunel University London, Uxbridge, UK.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13321'] 1120,30264179,Surface electromyography after lower level laser therapy application on skeletal muscles in individuals with heart failure.,"The purpose of this study was to investigate the effects of low-level laser therapy (LLLT) applied before a fatigue protocol through the effects on the electrical activation in the quadriceps muscle in patients with HF. Fourteen patients with the diagnosis of heart failure (HF) were selected for this double-blind, crossover type clinical trial. These participants have attended to a familiarization, LLLT, and placebo sessions, totaling three visits. The LLLT was applied in the quadriceps muscle (850 nm, 5 J per diode). The fatigue protocol consisted of concentric and eccentric isokinetic contractions (cc/ec) until exhaustion or up to 50 cc/ec. The muscular fatigue was evaluated with surface electromyography, by the analysis of integral, median frequency, and entropy. Only one application of LLLT is not able to decrease skeletal muscle activation in patients with HF. There was no reduction of muscle fatigue among the proposed protocols. Single LLLT session has no effect on the reduction of skeletal muscle fatigue in patients with HF.",2019,There was no reduction of muscle fatigue among the proposed protocols.,"['Fourteen patients with the diagnosis of heart failure (HF', 'individuals with heart failure', 'patients with HF']","['concentric and eccentric isokinetic contractions (cc/ec) until exhaustion or up to 50\xa0cc/ec', 'Single LLLT session', 'low-level laser therapy (LLLT', 'Surface electromyography after lower level laser therapy application', 'LLLT']","['muscular fatigue', 'skeletal muscle fatigue', 'muscle fatigue', 'skeletal muscle activation']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric (qualifier value)'}, {'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C1140999', 'cui_str': 'Contraction (finding)'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion (finding)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C4019433', 'cui_str': 'LLLT'}, {'cui': 'C0279027', 'cui_str': 'Low-Power Laser Therapy'}, {'cui': 'C0430815', 'cui_str': 'Surface Electromyography'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0242979', 'cui_str': 'Muscular Fatigue'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",14.0,0.0439623,There was no reduction of muscle fatigue among the proposed protocols.,"[{'ForeName': 'Fernanda B C', 'Initials': 'FBC', 'LastName': 'Delacoste', 'Affiliation': 'Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite 245, Porto Alegre, RS, 90050-170, Brazil.'}, {'ForeName': 'Anelise', 'Initials': 'A', 'LastName': 'Sonza', 'Affiliation': 'Physical Therapy Department, Universidade do Estado de Santa Catarina (UDESC), Florianópolis, SC, Brazil.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Mochizuki', 'Affiliation': 'Escola de Artes, Ciências e Humanidades, Universidade do Estado de São Paulo (USP), São Paulo, SP, Brazil.'}, {'ForeName': 'Marília Lambrecht', 'Initials': 'ML', 'LastName': 'da Silva', 'Affiliation': 'Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite 245, Porto Alegre, RS, 90050-170, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Dal Lago', 'Affiliation': 'Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Rua Sarmento Leite 245, Porto Alegre, RS, 90050-170, Brazil. pdallago@ufcspa.edu.br.'}]",Lasers in medical science,['10.1007/s10103-018-2611-9'] 1121,30149417,Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes.,"AIM To evaluate the effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes. METHODS A randomized, double-blind, placebo-controlled clinical trial was carried out in 24 adults diagnosed with prediabetes and without pharmacological treatment. Patients were randomly assigned into two groups of 12 patients each to receive 10 mg of oral dapagliflozin or placebo once a day during 12 weeks. At baseline and at the end of the study, anthropometric and metabolic measurements were evaluated, including the first phase of insulin secretion, total insulin secretion, and insulin sensitivity. RESULTS After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.",2020,"After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.","['24 adults diagnosed with prediabetes and without pharmacological treatment', 'patients with prediabetes', 'Patients with Prediabetes']","['placebo', 'Dapagliflozin', 'dapagliflozin', 'oral dapagliflozin or placebo']","['insulin sensitivity', 'waist circumference', 'uric acid', 'fasting glucose', 'insulin secretion, total insulin secretion, and insulin sensitivity', 'body weight, body mass index, waist circumference, fasting glucose, and uric acid', 'body mass index', 'Insulin Secretion and Insulin Sensitivity', 'body weight', 'insulin secretion and insulin sensitivity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0205464', 'cui_str': 'Pharmacologic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",24.0,0.204756,"After dapagliflozin administration, there were significant decreases in body weight (80.8±16.3 vs. 77.8±14.9 kg, p=0.019), body mass index (30.3±3.5 vs. 29.2±3.1 kg/m 2 , p=0.023), waist circumference (100.6±13.5 vs. 96.2±11.8 cm, p=0.003), fasting glucose (5.9±0.4 vs. 5.1±0.3 mmol/L, p<0.001) and uric acid (334.3±70.8 vs. 262.9±60.7 mmol/L, p=0.032), with a tendency to increase the insulin sensitivity (1.94±0.72 vs. 2.63±1.04, p=0.064). CONCLUSION Dapagliflozin administration in patients with prediabetes decreased body weight, body mass index, waist circumference, fasting glucose, and uric acid, with a tendency to increase the insulin sensitivity without changes in insulin secretion.","[{'ForeName': 'Alejandra M', 'Initials': 'AM', 'LastName': 'Ramírez-Rodríguez', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'González-Ortiz', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}, {'ForeName': 'Esperanza', 'Initials': 'E', 'LastName': 'Martínez-Abundis', 'Affiliation': 'Institute of Experimental and Clinical Therapeutics, Department of Physiology, Health Sciences University Center, University of Guadalajara, Guadalajara, Jalisco, Mexico.'}]","Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association",['10.1055/a-0664-7583'] 1122,30189025,The course and predictors of perceived unsupportive responses by family and friends among women newly diagnosed with gynecological cancers.,"Perceived unsupportive responses from close others play an important role in psychological adaptation of patients with cancer. Little is known about whether these negative responses change after someone experiences a serious life event, and even less is known about the individual characteristics and related factors that might contribute to both the levels of and changes in perceived unsupportive responses over the course of adaptation to an experience. This longitudinal study aimed to evaluate changes in perceived unsupportive behavior from family and friends among women newly with gynecologic cancer as well as initial demographic, disease, and psychological factors that predict the course of perceived unsupportive behavior over time. Women (N = 125) assigned to the usual care arm of a randomized clinical trial comparing a coping and communication intervention with a supportive counseling intervention to usual care completed six surveys over an 18 month period. Growth models using multilevel modeling were used to predict unsupportive responses over time. Average levels of perceived unsupportive responses from family and friends were low. Unsupportive responses varied from patient to patient, but patients did not report a systematic change in perceived unsupportive responses over time. Cultivating meaning and peace and coping efficacy were associated with fewer perceived unsupportive responses as well as reductions in perceived unsupportive responses over time. Emotional distress, cancer concerns, functional impairment, holding back sharing concerns, and cognitive and behavioral avoidance predicted higher perceived unsupportive responses over time. The findings are discussed in terms of the self-presentation theory and social network responses to persons undergoing difficult life events.",2019,"Unsupportive responses varied from patient to patient, but patients did not report a systematic change in perceived unsupportive responses over time.","['women newly diagnosed with gynecological cancers', 'family and friends among women newly with gynecologic cancer', 'patients with cancer']",['coping and communication intervention with a supportive counseling intervention to usual care completed six surveys over an 18 month period'],"['Emotional distress, cancer concerns, functional impairment, holding back sharing concerns, and cognitive and behavioral avoidance', 'Unsupportive responses', 'Cultivating meaning and peace and coping efficacy']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0079382', 'cui_str': 'Friend (person)'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1274143', 'cui_str': 'Communication treatments and procedures'}, {'cui': 'C3697360', 'cui_str': 'Supportive counseling'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0700361', 'cui_str': 'Emotional distress'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C1553387', 'cui_str': 'Hold'}]",125.0,0.0181031,"Unsupportive responses varied from patient to patient, but patients did not report a systematic change in perceived unsupportive responses over time.","[{'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Manne', 'Affiliation': 'Department of Medicine, Rutgers Robert Wood Johnson Medical School, Section of Population Science, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Kashy', 'Affiliation': 'Department of Psychology, Michigan State University, East Lansing, MI, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Kissane', 'Affiliation': 'Department of Psychiatry, Monash University, Melbourne, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Ozga', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Shannon Myers', 'Initials': 'SM', 'LastName': 'Virtue', 'Affiliation': 'Clinical Psychology, Helen Graham Cancer Center, Christiana Care Health System, Wilmington, DE, USA.'}, {'ForeName': 'Carolyn J', 'Initials': 'CJ', 'LastName': 'Heckman', 'Affiliation': 'Cancer Prevention and Control Program, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.'}]",Translational behavioral medicine,['10.1093/tbm/iby087'] 1123,30191265,Cardiac rehabilitation therapy for coronary slow flow phenomenon.,"OBJECTIVE To evaluate the effectiveness of cardiac rehabilitation on coronary slow flow phenomenon. METHOD Included were 30 consecutive patients from June 2015 to June 2017. A thrombolysis in myocardial infarction (TIMI) frame evaluation was used to estimate coronary blood flow velocity. All coronary angiography diameters were normal, but blood flow levels did not reach the TIMI level 3. All patients were treated with aspirin and rosuvastatin. Patients were randomly assigned to an experimental group (cardiac rehabilitation treatment group, n = 15) or a control group (normal treatment without cardiac rehabilitation, n = 15). Plasma low density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-sensitivity C reactive protein (hs-CRP), homocysteine (Hcy) and arginine (Arg) expression levels were collected after admission. These indices were reviewed again after 20-30 weeks, improved subjective symptoms were evaluated by multiple outcome criteria (MOCs), and coronary angiography was used to evaluate the velocity of coronary artery blood flow. RESULT The expression levels of LDL-C and TG in the experimental group were significantly lower than those of the control group (both P < 0.01). The plasma levels of hs-CRP, Hcy and Arg were lower than those in the control group (all P < 0.01). In the experimental group, subjective symptoms of chest pain were significantly improved and the coronary artery blood flow velocity was significantly increased compared with the control group (P < 0.01). CONCLUSION Cardiac rehabilitation can reduce the plasma levels of LDL-C, TG, hs-CRP, Hcy and Arg, significantly improve the symptoms of coronary slow flow phenomenon and accelerate the speed of coronary artery blood flow.",2020,"The plasma levels of hs-CRP, Hcy and Arg were lower than those in the control group (all P < 0.01).",['Included were 30\xa0consecutive patients from June 2015 to June 2017'],"['Cardiac rehabilitation', 'cardiac rehabilitation', 'Cardiac rehabilitation therapy', 'experimental group (cardiac rehabilitation treatment group, n\u202f=\u200915) or a\xa0control group (normal treatment without cardiac rehabilitation, n\u202f=\u200915', 'aspirin and rosuvastatin']","['plasma levels of hs-CRP, Hcy and Arg', 'speed of coronary artery blood flow', 'Plasma low density lipoprotein cholesterol (LDL-C), triglyceride (TG), high-sensitivity C\xa0reactive protein (hs-CRP), homocysteine (Hcy) and arginine (Arg) expression levels', 'expression levels of LDL-C and TG', 'coronary artery blood flow velocity', 'subjective symptoms of chest pain', 'velocity of coronary artery blood flow', 'plasma levels of LDL-C, TG, hs-CRP, Hcy and Arg', 'coronary blood flow velocity', 'blood flow levels', 'subjective symptoms']","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0019878', 'cui_str': '2-amino-4-mercaptobutyric acid'}, {'cui': 'C0968133', 'cui_str': 'alpha-(trifluoromethyl)arginine'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0005798', 'cui_str': 'Blood Flow Velocity'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0008031', 'cui_str': 'Chest Pain'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}]",,0.0133583,"The plasma levels of hs-CRP, Hcy and Arg were lower than those in the control group (all P < 0.01).","[{'ForeName': 'W', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Department of Cardiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Cardiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'She', 'Affiliation': 'Department of Cardiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Fang', 'Affiliation': 'Department of Cardiology, First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. whuwangzhuo@163.com.'}]",Herz,['10.1007/s00059-018-4742-y'] 1124,31629691,A genetic risk score predicts recurrent events after myocardial infarction in young adults.,"INTRODUCTION AND OBJECTIVES To evaluate whether a genetic risk score (GRS) improves prediction of recurrent events in young nondiabetic patients presenting with an acute myocardial infarction (AMI) and identifies a more aggressive form of atherosclerosis. METHODS We conducted a prospective study with consecutive nondiabetic patients aged <55 years presenting with AMI. We performed a genetic test, cardiac computed tomography, and analyzed several biomarkers. We studied the association of a GRS composed of 11 genetic variants and a primary composite endpoint (cardiovascular mortality, a recurrent event, and cardiac hospitalization). RESULTS A total of 81 patients were studied and followed up for a median of 4.1 years. There were 24 recurrent cardiovascular events. Compared with the general population, study participants had a higher prevalence of 9 out of 11 risk alleles. The GRS was significantly associated with recurrent cardiovascular events, especially when baseline low-density lipoprotein cholesterol (LDL-C) levels were elevated. Compared with the low-risk GRS tertile, the multivariate-adjusted HR for recurrences was 10.2 (95%CI, 1.1-100.3; P=.04) for the intermediate-risk group and was 20.7 (2.4-181.0; P=.006) for the high-risk group when LDL-C was≥2.8mmol/L (≥ 110mg/dL). Inclusion of the GRS improved the C-statistic (ΔC-statistic=0.086), cNRI (continuous net reclassification improvement) (30%), and the IDI (integrated discrimination improvement) index (0.05). Cardiac computed tomography frequently detected coronary calcified atherosclerosis but had limited value for prediction of recurrences. No association was observed between metalloproteinases, GRS and recurrences. CONCLUSIONS A multilocus GRS may identify individuals at increased risk of long-term recurrences among young nondiabetic patients with AMI and improve clinical risk stratification models, particularly among patients with high baseline LDL-C levels.",2020,"The GRS was significantly associated with recurrent cardiovascular events, especially when baseline low-density lipoprotein cholesterol (LDL-C) levels were elevated.","['81 patients were studied and followed up for a median of 4.1 years', 'young nondiabetic patients with AMI', 'young adults', 'consecutive nondiabetic patients aged <55 years presenting with AMI', 'young nondiabetic patients presenting with an acute myocardial infarction (AMI']",['genetic risk score (GRS'],"['recurrent cardiovascular events', '24 recurrent cardiovascular events', 'baseline low-density lipoprotein cholesterol (LDL-C) levels', 'primary composite endpoint (cardiovascular mortality, a recurrent event, and cardiac hospitalization', 'metalloproteinases, GRS and recurrences']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}]","[{'cui': 'C0017399', 'cui_str': 'genetics'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}]",81.0,0.0331771,"The GRS was significantly associated with recurrent cardiovascular events, especially when baseline low-density lipoprotein cholesterol (LDL-C) levels were elevated.","[{'ForeName': 'Luis M', 'Initials': 'LM', 'LastName': 'Rincón', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Electronic address: lmrincon@secardiologia.es.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Sanmartín', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.'}, {'ForeName': 'Gonzalo L', 'Initials': 'GL', 'LastName': 'Alonso', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'Rodríguez', 'Affiliation': 'Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Laboratorio de Aterotrombosis. Centro de Investigación Médica Aplicada (CIMA)-Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Navarra, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Muriel', 'Affiliation': 'Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Casas', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Navarro', 'Affiliation': 'Servicio de Radiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Carbonell', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Lázaro', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Hospital de Torrejón, Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Fernández', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.'}, {'ForeName': 'Paz', 'Initials': 'P', 'LastName': 'González', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.'}, {'ForeName': 'Macarena', 'Initials': 'M', 'LastName': 'Rodríguez', 'Affiliation': 'Unidad Central de Apoyo en Biomarcadores y Dianas Terapéuticas, EATRIS Biomarkers Platform, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Jiménez-Mena', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Hospital La Moraleja, Madrid, Spain.'}, {'ForeName': 'Covadonga', 'Initials': 'C', 'LastName': 'Fernández-Golfín', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.'}, {'ForeName': 'Amparo', 'Initials': 'A', 'LastName': 'Esteban', 'Affiliation': 'Servicio de Radiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Hospital La Moraleja, Madrid, Spain.'}, {'ForeName': 'María Laura', 'Initials': 'ML', 'LastName': 'García-Bermejo', 'Affiliation': 'Unidad Central de Apoyo en Biomarcadores y Dianas Terapéuticas, EATRIS Biomarkers Platform, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.'}, {'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Zamorano', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; Hospital La Zarzuela, Madrid, Spain.'}]",Revista espanola de cardiologia (English ed.),['10.1016/j.rec.2019.08.006'] 1125,29955889,Web-based versus in-person methods for training lay community health advisors to implement health promotion workshops: participant outcomes from a cluster-randomized trial.,"Project HEAL (Health through Early Awareness and Learning) is an implementation trial that compared two methods of training lay peer community health advisors (CHAs)-in-person (""Traditional"") versus web-based (""Technology"")-to conduct a series of three evidence-based cancer educational workshops in African American churches. This analysis reports on participant outcomes from Project HEAL. Fifteen churches were randomized to the two CHA training methods and the intervention impact was examined over 24 months. This study was conducted in Prince George's County, MD, and enrolled 375 church members age 40-75. Participants reported on knowledge and screening behaviors for breast, prostate, and colorectal cancer. Overall, cancer knowledge in all areas increased during the study period (p < .001). There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group. Mammography maintenance (56% overall) was evidenced by women reporting multiple mammograms within the study period. Participants attending all three workshops were more likely to report a fecal occult blood test or colonoscopy at 24 months (p < .05) than those who attended only one. These findings suggest that lay individuals can receive web-based training to successfully implement an evidence-based health promotion intervention that results in participant-level outcomes comparable with (a) people trained using the traditional classroom method and (b) previous efficacy trials. Findings have implications for resources and use of technology to increase widespread dissemination of evidence-based health promotion interventions through training lay persons in community settings.",2019,"There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group.","[""Prince George's County, MD, and enrolled 375 church members age 40-75"", 'Fifteen churches', 'African American churches']","['training lay peer community health advisors (CHAs)-in-person (""Traditional"") versus web-based (""Technology"")-to conduct a series of three evidence-based cancer educational workshops']","['fecal occult blood test', 'digital rectal exam', 'Mammography maintenance', 'knowledge and screening behaviors for breast, prostate, and colorectal cancer', 'Overall, cancer knowledge', 'fecal occult blood test or colonoscopy']","[{'cui': 'C4517745', 'cui_str': '375 (qualifier value)'}, {'cui': 'C0562324', 'cui_str': 'Church (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0600261', 'cui_str': 'Lying'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205549', 'cui_str': 'Series (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}]","[{'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces (procedure)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0009378', 'cui_str': 'Endoscopy of colon'}]",375.0,0.0807391,"There were significant increases in digital rectal exam (p < .05), fecal occult blood test (p < .001), and colonoscopy (p < .01) at 24 months; however, this did not differ by study group.","[{'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Holt', 'Affiliation': 'Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Erin K', 'Initials': 'EK', 'LastName': 'Tagai', 'Affiliation': 'Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Sherie Lou Zara', 'Initials': 'SLZ', 'LastName': 'Santos', 'Affiliation': 'Department of Behavioral and Community Health, School of Public Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Mary Ann', 'Initials': 'MA', 'LastName': 'Scheirer', 'Affiliation': 'Scheirer Consulting, Princeton, NJ, USA.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Bowie', 'Affiliation': 'Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Muhiuddin', 'Initials': 'M', 'LastName': 'Haider', 'Affiliation': 'School of Public Health, Institute for Applied Environmental Health, University of Maryland, College Park, MD, USA.'}, {'ForeName': 'Jimmie', 'Initials': 'J', 'LastName': 'Slade', 'Affiliation': ""Community Ministry of Prince George's County, Upper Marlboro, MD, USA.""}]",Translational behavioral medicine,['10.1093/tbm/iby065'] 1126,29616236,"Effects of water quality, sanitation, handwashing, and nutritional interventions on child development in rural Kenya (WASH Benefits Kenya): a cluster-randomised controlled trial.","Background Poor nutrition and infectious diseases can prevent children from reaching their developmental potential. We aimed to assess the effects of improvements in water, sanitation, handwashing, and nutrition on early child development in rural Kenya. Methods In this cluster-randomised controlled trial, we enrolled pregnant women in their second or third trimester from three counties (Kakamega, Bungoma, and Vihiga) in Kenya's western region, with an average of 12 households per cluster. Groups of nine geographically adjacent clusters were block-randomised, using a random number generator, into the six intervention groups (including monthly visits to promote target behaviours), a passive control group (no visits), or a double-sized active control group (monthly household visits to measure child mid-upper arm circumference). The six intervention groups were: chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition. Here we report on the prespecified secondary child development outcomes: gross motor milestone achievement assessed with the WHO module at year 1, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ) at year 2. Masking of participants was not possible, but data assessors were masked. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01704105. Findings Between Nov 27, 2012, and May 21, 2014, 8246 women residing in 702 clusters were enrolled. No clusters were lost to follow-up, but 2212 households with 2279 children were lost to follow-up by year 2. 5791 (69%) children were measured at year 1 and 6107 (73%) at year 2. At year 1, compared with the active control group, the combined water, sanitation, handwashing, and nutrition group had greater rates of attaining the standing with assistance milestone (hazard ratio 1·23, 95% CI 1·09-1·40) and the walking with assistance milestone (1·32, 1·17-1·50), and the handwashing group had a greater rate of attaining the standing alone milestone (1·15, 1·01-1·31). There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1. At year 2, there were no differences among groups for the communication, gross motor, personal social, or combined EASQ scores. Interpretation The handwashing and combined water, sanitation, handwashing, and nutrition interventions might have improved child motor development after 1 year, although after 2 years there were no other differences between groups. Future research should examine ways to make community health and nutrition programmes more effective at supporting child development. Funding Bill & Melinda Gates Foundation.",2018,There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1.,"[""enrolled pregnant women in their second or third trimester from three counties (Kakamega, Bungoma, and Vihiga) in Kenya's western region, with an average of 12 households per cluster"", '2212 households with 2279 children', 'rural Kenya', 'Findings\n\n\nBetween Nov 27, 2012, and May 21, 2014, 8246 women residing in 702 clusters were enrolled', 'child development in rural Kenya (WASH Benefits Kenya']","['passive control group (no visits), or a double-sized active control group', 'water quality, sanitation, handwashing, and nutritional interventions', 'chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition']","['rates of attaining the standing with assistance milestone', 'communication, gross motor, personal social, or combined EASQ scores', 'rate of attaining the standing alone milestone', 'motor milestone achievement assessed with the WHO module at year 1, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0032981', 'cui_str': 'Last Trimester'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C1704764', 'cui_str': 'Per'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",8246.0,0.135414,There were no differences when comparing the other intervention groups with the active control group on any of the motor milestone measures at year 1.,"[{'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA. Electronic address: cpstewart@ucdavis.edu.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Kariger', 'Affiliation': 'School of Public Health, University of California, Davis, CA, USA.'}, {'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Fernald', 'Affiliation': 'Community Health Sciences, University of California, Davis, CA, USA.'}, {'ForeName': 'Amy J', 'Initials': 'AJ', 'LastName': 'Pickering', 'Affiliation': 'Department of Civil and Environmental Engineering, Stanford University, Stanford, CA, USA; Department of Civil and Environmental Engineering, Tufts University, Medford, MA, USA.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Arnold', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Alan E', 'Initials': 'AE', 'LastName': 'Hubbard', 'Affiliation': 'Division of Biostatistics, University of California, Davis, CA, USA.'}, {'ForeName': 'Holly N', 'Initials': 'HN', 'LastName': 'Dentz', 'Affiliation': 'Department of Nutrition, University of California, Davis, CA, USA.'}, {'ForeName': 'Audrie', 'Initials': 'A', 'LastName': 'Lin', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Theodora J', 'Initials': 'TJ', 'LastName': 'Meerkerk', 'Affiliation': 'Department of Nutrition and Health, Wageningen University, Wageningen, Netherlands.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Milner', 'Affiliation': 'Environmental Health Sciences, University of California, Davis, CA, USA.'}, {'ForeName': 'Jenna', 'Initials': 'J', 'LastName': 'Swarthout', 'Affiliation': 'Innovations for Poverty Action, New Haven, CT, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'Division of Epidemiology, University of California, Davis, CA, USA.'}, {'ForeName': 'Clair', 'Initials': 'C', 'LastName': 'Null', 'Affiliation': 'Innovations for Poverty Action, New Haven, CT, USA; Center for International Policy Research and Evaluation, Mathematica Policy Research, Washington DC, USA.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(18)30025-7'] 1127,29461422,Eight Weeks of Strength and Power Training Improves Club Head Speed in Collegiate Golfers.,"Oranchuk, DJ, Mannerberg, JM, Robinson, TL, and Nelson, MC. Eight weeks of strength and power training improves club head speed in collegiate golfers. J Strength Cond Res 34(8): 2205-2213, 2020-Club head speed (CHS) is a major determinant of drive distance, a key component of golf performance. The purpose of this study was to determine the indirect effects of an 8-week strength and power program on CHS. Twelve (6 men, 6 women) NCAA Division II golfers (20.3 ± 1.5 years) randomly assigned to an intervention or control group underwent either a periodized strength and power program consisting of high-load barbell movements or a bodyweight and rotational movement focused resistance training program. Outcomes were CHS, countermovement jump (CMJ) height, and 1RM back squat (BS), power clean (PC), and deadlift (DL). Dependent t-tests were used to assess differences in outcome variables pre-to-post for each group, independent t-tests were used to assess differences between groups, and Pearson correlations were used to assess associations between CHS and outcome variables. On average, the intervention group experienced improvements in all outcome variables except peak CHS (p = 0.60); the control group displayed no changes in any outcome variable except a decrease in average CHS (p = 0.028). Compared with the control group, the intervention group experienced greater improvements in average CHS, BS, PC, and average and peak CMJ height (p ≤ 0.05). Additionally, CHS had large associations with PC (r = 0.70, p = 0.012), BS (r = 0.64, p = 0.025), DL (r = 0.54, p = 0.068) and CMJ (r = 0.73, p = 0.007). These results suggest that improving muscular strength and power by increasing PC, BS, and CMJ is associated with increased CHS in collegiate golfers. Integrating a high-load, barbell-focused strength and power program may be beneficial for improving CHS and indirectly, golf performance.",2020,"On average, the intervention group experienced improvements in all outcome variables except peak CHS (p=0.60); the control group displayed no changes in any outcome variable except a decrease in average CHS (p=0.028).","['Twelve (6 male, 6 female) NCAA Division II golfers (20.3±1.5 years) randomly assigned to an']","['Strength and Power Training', 'Club head speed (CHS', 'intervention or control group, underwent either a periodized strength and power program consisting of high-load barbell movements or a bodyweight and rotational movement focused resistance training program']","['CHS, countermovement jump (CMJ) height, and 1RM back squat (BS), power clean (PC), and deadlift (DL', 'muscular strength and power by increasing PC, BS, and CMJ', 'average CHS', 'average CHS, BS, PC, and average and peak CMJ height (p<0.05', 'BS']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1293097', 'cui_str': 'Division - action (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0149651', 'cui_str': 'Clubbing (morphologic abnormality)'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0445237', 'cui_str': 'Rotational (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",12.0,0.0277418,"On average, the intervention group experienced improvements in all outcome variables except peak CHS (p=0.60); the control group displayed no changes in any outcome variable except a decrease in average CHS (p=0.028).","[{'ForeName': 'Dustin J', 'Initials': 'DJ', 'LastName': 'Oranchuk', 'Affiliation': 'Department of Human Performance & Physical Education, Adams State University, Alamosa, Colorado.'}, {'ForeName': 'Jason M', 'Initials': 'JM', 'LastName': 'Mannerberg', 'Affiliation': 'Department of Human Performance & Physical Education, Adams State University, Alamosa, Colorado.'}, {'ForeName': 'Tracey L', 'Initials': 'TL', 'LastName': 'Robinson', 'Affiliation': 'Department of Human Performance & Physical Education, Adams State University, Alamosa, Colorado.'}, {'ForeName': 'Megan C', 'Initials': 'MC', 'LastName': 'Nelson', 'Affiliation': 'Department of Human Performance & Physical Education, Adams State University, Alamosa, Colorado.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002505'] 1128,31647384,Long-Term Effects in the EXERDIET-HTA Study: Supervised Exercise Training vs . Physical Activity Advice.,"Purpose : To determine whether improvements in cardiorespiratory fitness (CRF), blood pressure (BP) and body composition previously seen after a 16-week exercise intervention (POST) with hypocaloric diet are maintained following six months (6M) of unsupervised exercise time. Methods : Overweight/obese, physically inactive participants with primary hypertension (HTN) (n = 190) were randomly assigned into an attention control group (physical activity recommendations) or one of three supervised exercise groups. After POST, all participants received diet and physical activity advice for the following 6M but no supervision. All anthropometric and physiological measurements were taken pre and post the 16-week supervised intervention period, as well as after 6M of no supervision. Results : After 6M: 1) body mass (BM) (Δ = 2.5%) and waist circumference (Δ = 1.8%) were higher ( P < .005) than POST, but lower ( P < .005) than pre-intervention (BM, Δ = -5.1%; waist circumference, Δ = -4.7%), with high-volume and high-intensity interval training group revealing a higher BM reduction (Δ = -6.4 kg) compared to control group (Δ = -3.5 kg); 2) BP variables were higher ( P < .001) compared to POST with no change from pre-intervention; and 3) CRF was higher compared to pre-intervention (Δ = 17.1%, P < .001) but lower than POST (Δ = -5.7%, P < .001). Conclusions : When an overweight/obese population with HTN attains significant improvements in cardiometabolic health POST intervention with diet restriction, there is a significant reduction following 6M when exercise and diet supervision is removed, and only recommendations were applied. These results suggest the need for a regular, systematic and supervised diet and exercise programs to avoid subsequent declines in cardiometabolic health.",2020,"P < .001) compared to POST with no change from pre-intervention; and 3) CRF was higher compared to pre-intervention (Δ = 17.1%, P < .001) but lower than POST (","['Overweight/obese, physically inactive participants with primary hypertension (HTN) (n = 190']","['attention control group (physical activity recommendations) or one of three supervised exercise groups', 'Supervised Exercise Training vs ', 'exercise intervention (POST) with hypocaloric diet']","['BM reduction', 'waist circumference', 'Physical Activity Advice', 'cardiorespiratory fitness (CRF), blood pressure (BP) and body composition']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0085580', 'cui_str': 'Essential Hypertension'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0012155', 'cui_str': 'Diet'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}]",,0.0224371,"P < .001) compared to POST with no change from pre-intervention; and 3) CRF was higher compared to pre-intervention (Δ = 17.1%, P < .001) but lower than POST (","[{'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Corres', 'Affiliation': 'University of the Basque Country (UPV/EHU).'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'MartinezAguirre-Betolaza', 'Affiliation': 'University of the Basque Country (UPV/EHU).'}, {'ForeName': 'Simon M', 'Initials': 'SM', 'LastName': 'Fryer', 'Affiliation': 'University of Gloucestershire.'}, {'ForeName': 'Ilargi', 'Initials': 'I', 'LastName': 'Gorostegi-Anduaga', 'Affiliation': 'University of the Basque Country (UPV/EHU).'}, {'ForeName': 'Iñaki', 'Initials': 'I', 'LastName': 'Arratibel-Imaz', 'Affiliation': 'University of the Basque Country (UPV/EHU).'}, {'ForeName': 'G Rodrigo', 'Initials': 'GR', 'LastName': 'Aispuru', 'Affiliation': 'Igualatorio Médico Quirúrgico (IMQ-Amárica).'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Maldonado-Martín', 'Affiliation': 'University of the Basque Country (UPV/EHU).'}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1656794'] 1129,31512365,"Efficacy of metformin in preventing progression to diabetes in a Chinese population with impaired glucose regulation: Protocol for a multicentre, open-label, randomized controlled clinical study.","AIM To investigate the effectiveness of metformin in delaying or preventing progression to diabetes in a Chinese population with impaired glucose regulation (IGR). MATERIALS AND METHODS This multicentre, randomized, open-label, controlled study (NCT03441750) will assess the efficacy of metformin in preventing diabetes over ≥2 years. Eligible participants will be randomly assigned (1:1) to lifestyle intervention (LSI) or metformin plus LSI, with stratification based on blood pressure, anti-hypertensive medication use and isolated/non-isolated impaired fasting glucose. All participants will receive LSI advice. Participants in the metformin plus LSI group will receive metformin 850 mg once daily for the first 2 weeks, and twice daily thereafter, according to tolerability. RESULTS The primary objective is to compare rates of newly diagnosed diabetes in the two intervention groups. Changes in glycaemia, blood pressure, body weight, insulin resistance, and safety outcomes will also be evaluated. CONCLUSIONS This large clinical trial in a Chinese population with IGR aims to provide critical information to guide clinical decision-making in order to alleviate the current diabetes epidemic.",2020,"Primary prevention, by identifying individuals with impaired glucose regulation (IGR), including impaired glucose tolerance (IGT) and isolated impaired fasting glucose (IFG), and intervening to improve glucose regulation, is desirable to reduce morbidity, mortality and healthcare costs.","['diabetes over ≥2\u2009years', 'Chinese subjects with IGR', 'Chinese subjects with impaired glucose regulation', 'Eligible subjects']","['metformin', 'lifestyle intervention (LSI', 'Metformin+LSI', 'LSI or metformin+LSI, with stratification based on blood pressure, antihypertensive medication use and isolated/non-isolated IFG']","['morbidity, mortality and healthcare costs', 'impaired glucose regulation (IGR), including impaired glucose tolerance (IGT) and isolated impaired fasting glucose (IFG', 'rates of newly diagnosed diabetes', 'glycemia, blood pressure, body weight, insulin resistance, and safety outcomes', 'progression to diabetes']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0085552', 'cui_str': 'Healthcare Costs'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0205409', 'cui_str': 'Isolated (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1320655', 'cui_str': 'Newly diagnosed diabetes'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]",,0.04742,"Primary prevention, by identifying individuals with impaired glucose regulation (IGR), including impaired glucose tolerance (IGT) and isolated impaired fasting glucose (IFG), and intervening to improve glucose regulation, is desirable to reduce morbidity, mortality and healthcare costs.","[{'ForeName': 'Linong', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': ""Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Ningling', 'Initials': 'N', 'LastName': 'Sun', 'Affiliation': ""Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Yunliang', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology and Metabolism, Baoding First Central Hospital, Baoding, Hebei, China.'}, {'ForeName': 'Lihui', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Endocrinology and Metabolism, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.'}, {'ForeName': ""Sheng'ai"", 'Initials': 'S', 'LastName': 'Shen', 'Affiliation': 'Department of Endocrinology and Metabolism, Yanji Hospital, Yanji, Yanbian Korean Autonomous Prefecture, Jilin, China.'}, {'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology and Metabolism, Jinzhou Central Hospital, Jinzhou, Liaoning, China.'}, {'ForeName': 'Qiuyun', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology and Metabolism, Kailuan General Hospital, Tangshan, Hebei Province, China.'}, {'ForeName': 'Luling', 'Initials': 'L', 'LastName': 'Dong', 'Affiliation': 'Department of Endocrinology and Metabolism, Zhangjiakou First Hospital, Zhangjiakou, Hebei, China.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Ren', 'Affiliation': 'Department of Endocrinology and Metabolism, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Department of Endocrinology and Metabolism, Beijing Yanhua Hospital, Beijing, China.'}, {'ForeName': 'Yufeng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology and Metabolism, Beijing Pinggu Hospital, Beijing, China.'}, {'ForeName': 'Shuang', 'Initials': 'S', 'LastName': 'Yan', 'Affiliation': 'Department of Endocrinology and Metabolism, Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.'}, {'ForeName': 'Wenli', 'Initials': 'W', 'LastName': 'Cheng', 'Affiliation': 'Department of Hypertension, Beijing Anzhen Hospital, Beijing, China.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Kuang', 'Affiliation': 'Department of Endocrinology and Metabolism, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.'}, {'ForeName': 'Guangwei', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of Endocrinology, Fuwai Hospital & Chinese Academy of Medical Sciences, Beijing, China.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13884'] 1130,29616235,"Effect of water quality, sanitation, hand washing, and nutritional interventions on child development in rural Bangladesh (WASH Benefits Bangladesh): a cluster-randomised controlled trial.","Background Poor nutrition and hygiene make children vulnerable to delays in growth and development. We aimed to assess the effects of water quality, sanitation, handwashing, and nutritional interventions individually or in combination on the cognitive, motor, and language development of children in rural Bangladesh. Methods In this cluster-randomised controlled trial, we enrolled pregnant women in their first or second trimester from rural villages of Gazipur, Kishoreganj, Mymensingh, and Tangail districts of central Bangladesh, with an average of eight women per cluster. Groups of eight geographically adjacent clusters were block-randomised, using a random number generator, into six intervention groups (all of which received weekly visits from a community health promoter for the first 6 months and every 2 weeks for the next 18 months) and a double-sized control group (no intervention or health promoter visit). The six intervention groups were: chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition. Here, we report on the prespecified secondary child development outcomes: gross motor milestone achievement assessed with the WHO module at age 1 year, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ) at age 2 years. Masking of participants was not possible. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01590095. Findings Between May 31, 2012, and July 7, 2013, 5551 pregnant women residing in 720 clusters were enrolled. Index children of 928 (17%) enrolled women were lost to follow-up in year 1 and an additional 201 (3%) in year 2. 4757 children were assessed at 1 year and 4403 at 2 years. At year 1, compared with the control group, the combined water, sanitation, handwashing, and nutrition group had a higher rate of attaining the standing alone milestone (hazard ratio 1·19, 95% CI 1·01-1 ·40), and the nutrition group had a higher rate of attaining the walking alone milestone (1·32, 95% CI 1·07-1·62). The combined water, sanitation, handwashing, and nutrition group had a higher rate of attaining the walking alone milestone than those in the water, sanitation, and handwashing group (1·29, 1·01-1·65). At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). Interpretation Improvements in water quality, handwashing, sanitation, or nutrition supported by intensive interpersonal communication, when delivered either individually or in combination, contributed to improvements in child development. A crucial next step is to establish whether similar effects can be achieved with reduced intensity of promoter contacts that could be supported in large-scale interventions. Funding Bill & Melinda Gates Foundation.",2018,"At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). ","['Index children of 928 (17%) enrolled women were lost to follow-up in year 1 and an additional 201 (3%) in year 2', 'child development in rural Bangladesh (WASH Benefits Bangladesh', '5551 pregnant women residing in 720 clusters were enrolled', 'enrolled pregnant women in their first or second trimester from rural villages of Gazipur, Kishoreganj, Mymensingh, and Tangail districts of central Bangladesh, with an average of eight women per cluster', '4757 children were assessed at 1 year and 4403 at 2 years', 'children in rural Bangladesh']","['double-sized control group (no intervention or health promoter visit', 'water quality, sanitation, hand washing, and nutritional interventions', 'water quality, sanitation, handwashing, and nutritional interventions', 'chlorinated drinking water; improved sanitation; handwashing with soap; combined water, sanitation, and handwashing; improved nutrition through counselling and provision of lipid-based nutrient supplements; and combined water, sanitation, handwashing, and nutrition']","['higher rate of attaining the walking alone milestone', 'higher rate of attaining the standing alone milestone', 'rate of attaining the walking alone milestone', 'motor milestone achievement assessed with the WHO module at age 1 year, and communication, gross motor, personal social, and combined scores measured by the Extended Ages and Stages Questionnaire (EASQ', 'water quality, handwashing, sanitation, or nutrition supported by intensive interpersonal communication']","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0680063', 'cui_str': 'Child of (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1302313', 'cui_str': 'Lost to Follow-Up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008071', 'cui_str': 'Child Development'}, {'cui': 'C0004732', 'cui_str': 'Bangladesh'}, {'cui': 'C1547959', 'cui_str': 'Wash - dosing instruction imperative'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C4517865', 'cui_str': 'Seven hundred and twenty'}, {'cui': 'C0032980', 'cui_str': 'Midtrimester'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1704764', 'cui_str': 'Per'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0018581', 'cui_str': 'Hand Washing'}, {'cui': 'C0599638', 'cui_str': 'Drinking Water'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0597680', 'cui_str': 'Water Quality'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]",5551.0,0.142212,"At 2 years, we noted beneficial effects in the combined EASQ score in all intervention groups, with effect sizes smallest in the water treatment group (difference 0·15, 95% CI 0·04 to 0·26 vs control) and largest in the combined water, sanitation, handwashing, and nutrition treatment group (0·37, 0·27-0·46). ","[{'ForeName': 'Fahmida', 'Initials': 'F', 'LastName': 'Tofail', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh. Electronic address: ftofail@icddrb.org.'}, {'ForeName': 'Lia Ch', 'Initials': 'LC', 'LastName': 'Fernald', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Kishor K', 'Initials': 'KK', 'LastName': 'Das', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Mahbubur', 'Initials': 'M', 'LastName': 'Rahman', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Tahmeed', 'Initials': 'T', 'LastName': 'Ahmed', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Kaniz K', 'Initials': 'KK', 'LastName': 'Jannat', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Unicomb', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Benjamin F', 'Initials': 'BF', 'LastName': 'Arnold', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Sania', 'Initials': 'S', 'LastName': 'Ashraf', 'Affiliation': 'International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Winch', 'Affiliation': 'Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Kariger', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Christine P', 'Initials': 'CP', 'LastName': 'Stewart', 'Affiliation': 'Department of Nutrition, University of California Davis, Davis, CA, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Colford', 'Affiliation': 'School of Public Health, University of California Berkeley, Berkeley, CA USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Luby', 'Affiliation': 'Division of Infectious Diseases and Geographic Medicine, Stanford University Stanford, CA USA.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(18)30031-2'] 1131,31987998,Just a very expensive breathing training? Risk of respiratory artefacts in functional connectivity-based real-time fMRI neurofeedback.,"Real-time functional magnetic resonance imaging neurofeedback (rtfMRI NFB) is a promising method for targeted regulation of pathological brain processes in mental disorders. But most NFB approaches so far have used relatively restricted regional activation as a target, which might not address the complexity of the underlying network changes. Aiming towards advancing novel treatment tools for disorders like schizophrenia, we developed a large-scale network functional connectivity-based rtfMRI NFB approach targeting dorsolateral prefrontal cortex and anterior cingulate cortex connectivity with the striatum. In a double-blind randomized yoke-controlled single-session feasibility study with N ​= ​38 healthy controls, we identified strong associations between our connectivity estimates and physiological parameters reflecting the rate and regularity of breathing. These undesired artefacts are especially detrimental in rtfMRI NFB, where the same data serves as an online feedback signal and offline analysis target. To evaluate ways to control for the identified respiratory artefacts, we compared model-based physiological nuisance regression and global signal regression (GSR) and found that GSR was the most effective method in our data. Our results strongly emphasize the need to control for physiological artefacts in connectivity-based rtfMRI NFB approaches and suggest that GSR might be a useful method for online data correction for respiratory artefacts.",2020,Real-time functional magnetic resonance imaging neurofeedback (rtfMRI NFB) is a promising method for targeted regulation of pathological brain processes in mental disorders.,"['disorders like schizophrenia', 'N\u202f=\u202f38 healthy controls']",['Real-time functional magnetic resonance imaging neurofeedback (rtfMRI NFB'],['rate and regularity of breathing'],"[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C2713543', 'cui_str': 'Neurofeedback'}]","[{'cui': 'C0449581', 'cui_str': 'Regularity (attribute)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}]",38.0,0.0503571,Real-time functional magnetic resonance imaging neurofeedback (rtfMRI NFB) is a promising method for targeted regulation of pathological brain processes in mental disorders.,"[{'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Weiss', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany. Electronic address: franziska.weiss@zi-mannheim.de.'}, {'ForeName': 'Vera', 'Initials': 'V', 'LastName': 'Zamoscik', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany; Department of Psychology, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Stephanie N L', 'Initials': 'SNL', 'LastName': 'Schmidt', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany; Department of Psychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Halli', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Kirsch', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany; Department of Psychology, Heidelberg University, Heidelberg, Germany; Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.'}, {'ForeName': 'Martin Fungisai', 'Initials': 'MF', 'LastName': 'Gerchen', 'Affiliation': 'Department of Clinical Psychology, Central Institute of Mental Health, University of Heidelberg/Medical Faculty Mannheim, Mannheim, Germany; Department of Psychology, Heidelberg University, Heidelberg, Germany; Bernstein Center for Computational Neuroscience Heidelberg/Mannheim, Mannheim, Germany.'}]",NeuroImage,['10.1016/j.neuroimage.2020.116580'] 1132,30137607,Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]).,"Genetic variations of breast cancer survivors (BCS) may contribute to level of residual symptoms, such as depression, stress, fatigue, and cognitive impairment. The objective of this study was to investigate whether particular single-nucleotide polymorphisms (SNPs) moderated symptom improvement resulting from the Mindfulness-Based Stress Reduction for Breast Cancer (MBSR[BC]) program. An overarching goal of personalized medicine is to identify individuals as risk for disease and tailor interventions based on genetic profiles of patients with diseases including cancer. BCS were recruited from Moffitt Cancer Center and University of South Florida's Breast Health Program and were randomized to either the 6-week MBSR(BC) program (n = 92) or Usual Care (n = 93). Measures of symptoms, demographic, and clinical history data were attained at baseline, 6 weeks, and 12 weeks. A total of 10 SNPs from eight genes known to be related to these symptoms were studied using genomic DNA extracted from blood. Our results were examined for effect sizes, consistency, and statistical significance (p < .05). Three SNPs (rs4680 in COMT, rs6314 in HTR2A, and rs429358 in APOE) emerged as having the strongest (though relatively weak) and most consistent effects in moderating the impact of the MBSR program on symptom outcomes. Although effects were generally weak, with only one effect withstanding multiple comparisons correction for statistical significance, this translational behavioral research may help start the identification of genetic profiles that moderate the impact of MBSR(BC). The ultimate goal of this study is the development of personalized treatment programs tailored to the genetic profile of each patient.",2019,"Although effects were generally weak, with only one effect withstanding multiple comparisons correction for statistical significance, this translational behavioral research may help start the identification of genetic profiles that moderate the impact of MBSR(BC).","[""BCS were recruited from Moffitt Cancer Center and University of South Florida's Breast Health Program"", 'patients with diseases including cancer', 'breast cancer survivors (BCS', 'Breast Cancer']",['Usual Care'],"['symptoms, demographic, and clinical history data']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]",[],"[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}]",93.0,0.0139761,"Although effects were generally weak, with only one effect withstanding multiple comparisons correction for statistical significance, this translational behavioral research may help start the identification of genetic profiles that moderate the impact of MBSR(BC).","[{'ForeName': 'Jong Y', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Cecile A', 'Initials': 'CA', 'LastName': 'Lengacher', 'Affiliation': 'University of South Florida College of Nursing, Tampa, FL, USA.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Reich', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Carissa B', 'Initials': 'CB', 'LastName': 'Alinat', 'Affiliation': 'University of South Florida College of Nursing, Tampa, FL, USA.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Ramesar', 'Affiliation': 'University of South Florida College of Nursing, Tampa, FL, USA.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Le', 'Affiliation': 'University of South Florida College of Nursing, Tampa, FL, USA.'}, {'ForeName': 'Carly L', 'Initials': 'CL', 'LastName': 'Paterson', 'Affiliation': 'National Cancer Institute, National Institutes of Health, Rockville, MD, USA.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Pleasant', 'Affiliation': 'University of South Florida College of Nursing, Tampa, FL, USA.'}, {'ForeName': 'Hyun Y', 'Initials': 'HY', 'LastName': 'Park', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kiluk', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Hyo', 'Initials': 'H', 'LastName': 'Han', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Roohi', 'Initials': 'R', 'LastName': 'Ismail-Khan', 'Affiliation': 'Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Kip', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of South Florida, College of Public Health, Tampa, FL, USA.'}]",Translational behavioral medicine,['10.1093/tbm/iby061'] 1133,31638455,"Huperzine A for the treatment of cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI): results of a Phase II randomized controlled pilot study: implications for understanding the placebo effect.","Objective : To investigate the effect of Huperzine A on memory and learning in individuals with moderate-severe traumatic brain injury (TBI). Design : Randomized, double-blind, placebo-controlled Phase II clinical trial. Methods : Subjects were randomly assigned to receive Huperzine A or placebo for 12 weeks and were assessed during in-person visits at screening/baseline, and 6, 12, 24, and 52 weeks post-injury. Changes in memory and learning scores on the California Verbal Learning Test - 2nd Edition (CVLT-II) from baseline to week 12 were assessed using permutation tests and regression analyses. Results : There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment. In the placebo group, significant improvements were noted in learning and memory scores. Both groups showed clinically important improvements in depression on the Beck Depression Index. Conclusions : The clinically important improvements in cognitive and emotional outcomes observed in both the placebo and active treatment arms of this clinical trial of Huperzine A are best understood in the context of a placebo effect. Future trials involving patients with moderate-severe TBI in the subacute to chronic phases of recovery should be designed to account for placebo effects as failure to do so may lead to spurious conclusions.",2020,There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment.,"['cognitive, mood, and functional deficits after moderate and severe TBI (HUP-TBI', 'individuals with moderate-severe traumatic brain injury (TBI', 'patients with moderate-severe TBI']","['Huperzine', 'placebo', 'Huperzine A or placebo', 'Huperzine A']","['Changes in memory and learning scores on the California Verbal Learning Test - 2nd Edition (CVLT-II', 'cognitive and emotional outcomes', 'memory and learning', 'depression on the Beck Depression Index', 'learning and memory scores', 'memory performance']","[{'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0063033', 'cui_str': 'huperzine A'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0589055', 'cui_str': 'TOMAL'}, {'cui': 'C0205436', 'cui_str': 'Second - ordinal'}, {'cui': 'C0441792', 'cui_str': 'Editions (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1285654', 'cui_str': 'Ability to remember'}]",,0.535423,There was no difference between the Huperzine A and placebo groups in memory performance after 12 weeks of treatment.,"[{'ForeName': 'Ross D', 'Initials': 'RD', 'LastName': 'Zafonte', 'Affiliation': 'Department of Physical Medicine Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': 'Department of Physical Medicine Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Michael J G', 'Initials': 'MJG', 'LastName': 'Bergin', 'Affiliation': 'Department of Physical Medicine Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Goldstein', 'Affiliation': 'Department of Physical Medicine Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Boudreau', 'Affiliation': 'Spaulding Research Institute, Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Monge', 'Affiliation': 'Spaulding Research Institute, Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Luz', 'Affiliation': 'Spaulding Research Institute, Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Frazier', 'Affiliation': 'Spaulding Research Institute, Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Joseph T', 'Initials': 'JT', 'LastName': 'Giacino', 'Affiliation': 'Department of Physical Medicine Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA.'}]",Brain injury,['10.1080/02699052.2019.1677941'] 1134,30117760,A Feasibility Study of Restorative Yoga Versus Vigorous Yoga Intervention for Sedentary Breast and Ovarian Cancer Survivors.,"Yoga has been shown to improve cancer survivors' quality of life, yet regular yoga practice is a challenge for those who are sedentary. We conducted a pilot randomized controlled study to assess feasibility and adherence of two types of yoga intervention among sedentary cancer survivors. Sedentary breast and ovarian cancer survivors were randomized to practice either restorative yoga (minimal physical exertion, Group R) or vigorous yoga (considerable physical exertion, Group V) in three 60-minute supervised sessions a week for 12 weeks, followed by 12 weeks of home practice. Accrual, adherence, and attendance rates were assessed. Of the 226 eligible patients, 175 (77%) declined to participate in the study, citing time commitment and travel as the most common barriers. Forty-two subjects consented to participate in the study. Of the 35 participants who began the intervention (20 in Group R and 15 in Group V), adherence rate (percentage remaining in the study at week 12) was 100% and 87%, respectively. Rate of adequate attendance (more than 66% of the scheduled supervised sessions) was 85% and 73%, respectively. Rate of completion of the home practice period was 85% and 77%, respectively. In this study, sedentary cancer survivors were able to adhere to a long-term, regular yoga regimen. The rate of adequate attendance was higher for restorative yoga. Future studies for sedentary patients should focus on reducing time commitment and travel requirements to improve recruitment, and on using restorative yoga as a more feasible intervention for this population.",2018,The rate of adequate attendance was higher for restorative yoga.,"['sedentary patients', 'Sedentary Breast and Ovarian Cancer Survivors', 'Forty-two subjects consented to participate in the study', 'sedentary cancer survivors', 'Sedentary breast and ovarian cancer survivors', '226 eligible patients, 175 (77%) declined to participate in the study, citing time commitment and travel as the most common barriers']","['Restorative Yoga Versus Vigorous Yoga Intervention', 'restorative yoga (minimal physical exertion, Group R) or vigorous yoga (considerable physical exertion, Group V', 'yoga intervention']","['Rate of adequate attendance', 'rate of adequate attendance', 'adherence rate', 'Accrual, adherence, and attendance rates']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0040802', 'cui_str': 'Travel (event)'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0031807', 'cui_str': 'Physical Effort'}, {'cui': 'C0441852', 'cui_str': 'Group R (qualifier value)'}, {'cui': 'C0441855', 'cui_str': 'Group V (qualifier value)'}]","[{'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}]",226.0,0.045079,The rate of adequate attendance was higher for restorative yoga.,"[{'ForeName': 'Kaitlyn', 'Initials': 'K', 'LastName': 'Lapen', 'Affiliation': '1. College of Medicine, University of Illinois, Chicago.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Benusis', 'Affiliation': '2. Department of Biobehavioral Sciences, Columbia University, New York.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Pearson', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Search', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Marci', 'Initials': 'M', 'LastName': 'Coleton', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Q Susan', 'Initials': 'QS', 'LastName': 'Li', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Sjoberg', 'Affiliation': '4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Konner', 'Affiliation': '5. Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Jun J', 'Initials': 'JJ', 'LastName': 'Mao', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Deng', 'Affiliation': '3. Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York.'}]",International journal of yoga therapy,['10.17761/2018-00039'] 1135,30894009,Iodine load reduction in dual-energy spectral CT portal venography with low energy images combined with adaptive statistical iterative reconstruction.,"OBJECTIVE To study the application of using low energy images combined with adaptive statistical iterative reconstruction (ASiR) in dual-energy spectral CT portal venography (CTPV) to reduce iodine load. METHODS 41 patients for CTPV were prospectively and randomly divided into two groups. Group A ( n = 21) used conventional 120 kVp scanning protocol with contrast dose at 0.6 gI/kg while group B ( n = 20) used dual-energy spectral imaging with reduced contrast dose at 0.3 gI/kg. The 120 kVp images in Group A and 50 keV images in Group B were reconstructed with 40% ASiR. The contrast-to-noise ratio of portal vein was calculated. The image quality and the numbers of intrahepatic portal vein branches were evaluated by two experienced radiologists using a 5-point scoring system. RESULTS Group B reduced iodine load by 52% compared to Group A (17.21 ± 3.30 gI vs 35.80 ± 6.18 gI, p < 0.001). All images in both groups were acceptable for diagnosis. CT values and standard deviations in portal veins of Group B were higher than Group A (all p < 0.05); There were no statistical differences in contrast-to-noise ratio, image quality score and the number of observed portal vein branches between the two groups (all p > 0.05), and the two observers had excellent agreement in image quality assessment (all κ > 0.75). CONCLUSION The use of 50 keV images in dual-energy spectral CTPV with ASiR reduces total iodine load by 52% while maintaining good image quality. ADVANCES IN KNOWLEDGE Spectral CT images combined with ASiR can be used in low contrast dose CTPV portal venography to maintain image quality and reduce contrast dose.",2019,"CT values and standard deviations in portal veins of Group B were higher than Group A (all p < 0.05); There were no statistical differences in CNR, image quality score and the number of observed portal vein branches between the two groups (all p > 0.05), and the two observers had excellent agreement in image quality assessment (all kappa  > 0.75). ",['\n\n\n41 patients for CTPV'],"['conventional 120kVp scanning protocol with contrast dose at 0.6 \u2009gI/kg while group B ( n = 20) used dual-energy spectral imaging with reduced contrast dose at 0.3 \u2009gI/kg', '40%ASiR', 'low energy images combined with adaptive statistical iterative reconstruction (ASiR) in dual-energy spectral CT portal venography (CTPV']","['CNR, image quality score and the number of observed portal vein branches', 'image quality assessment', 'total iodine load', 'image quality and the numbers of intrahepatic portal vein branches', 'iodine load', 'CT values and standard deviations in portal veins']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4068883', 'cui_str': 'Zero point six'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0524865', 'cui_str': 'Reconstructive Surgery'}, {'cui': 'C0205054', 'cui_str': 'Portal (qualifier value)'}, {'cui': 'C0031545', 'cui_str': 'Venography'}]","[{'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C0032718', 'cui_str': 'Portal Vein'}, {'cui': 'C0205384', 'cui_str': 'Branching (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0021968', 'cui_str': 'molecular iodine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]",,0.0172268,"CT values and standard deviations in portal veins of Group B were higher than Group A (all p < 0.05); There were no statistical differences in CNR, image quality score and the number of observed portal vein branches between the two groups (all p > 0.05), and the two observers had excellent agreement in image quality assessment (all kappa  > 0.75). ","[{'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Han', 'Affiliation': '1 Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}, {'ForeName': 'Xiaoxia', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': '1 Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}, {'ForeName': 'Yuxin', 'Initials': 'Y', 'LastName': 'Lei', 'Affiliation': '1 Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}, {'ForeName': 'Chunling', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': '1 Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}, {'ForeName': 'Jieli', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""2 Department of Ultrasound, Xijing Hospital, Xi'an, Shaanxi, China.""}, {'ForeName': 'Yingcong', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': '3 Department of Ultrasound, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': '1 Department of Radiology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China.'}]",The British journal of radiology,['10.1259/bjr.20180414'] 1136,30024485,"Effects of Endurance Exercise Bouts in Hypoxia, Hyperoxia, and Normoxia on mTOR-Related Protein Signaling in Human Skeletal Muscle.","Przyklenk, A, Aussieker, T, Gutmann, B, Schiffer, T, Brinkmann, C, Strüder, HK, Bloch, W, Mierau, A, and Gehlert, S. Effects of endurance exercise bouts in hypoxia, hyperoxia, and normoxia on mTOR-related protein signaling in human skeletal muscle. J Strength Cond Res 34(8): 2276-2284, 2020-This study investigated the effects of short-term hypoxia (HY), hyperoxia (PER), and normoxia on anabolic signaling proteins in response to an acute bout of moderate endurance exercise (EEX) before and after an endurance exercise training intervention. Eleven healthy male subjects conducted one-legged cycling endurance exercise (3 × 30 min·wk for 4 weeks). One leg was trained under hypoxic (12% O2) or hyperoxic conditions (in a randomized cross-over design), and the other leg was trained in normoxia (20.9% O2) at the same relative workload. Musculus vastus lateralis biopsies were taken at baseline (T0) as well as immediately after the first (T1) and last (T2) training session to analyze anabolic signaling proteins and the myofiber cross-sectional area (FCSA). No significant differences were detected for FCSA between T0 and T2 under all oxygen conditions (p > 0.05). No significant differences (p > 0.05) were observed for BNIP3, phosphorylated RSK1, ERK1/2, FoxO3a, mTOR, and S6K1 between all conditions and time points. Phosphorylated Akt/PKB decreased significantly (p < 0.05) at T1 in PER and at T2 in HY and PER. Phosphorylated rpS6 decreased significantly (p < 0.05) at T1 only in PER, whereas nonsignificant increases were shown in HY at T2 (p = 0.10). Despite no significant regulations, considerable reductions in eEF2 phosphorylation were detected in HY at T1 and T2 (p = 0.11 and p = 0.12, respectively). Short-term hypoxia in combination with moderate EEX induces favorable acute anabolic signaling responses in human skeletal muscle.",2020,"No significant differences (p > 0.05) were observed for BNIP3, phosphorylated RSK1, ERK1/2, FoxO3a, mTOR, and S6K1 between all conditions and time points.","[' 000-000', 'Human Skeletal Muscle', 'human skeletal muscle', 'Eleven healthy male subjects conducted one']","['J Strength Cond Res XX(X', 'endurance exercise training intervention', 'short-term hypoxia (HY), hyperoxia (PER), and normoxia', 'Endurance Exercise', 'legged cycling endurance exercise']","['FCSA between T0 and T2 under all oxygen conditions', 'Przyklenk, A, Aussieker, T, Gutmann, B, Schiffer, T, Brinkmann, C, Strüder, HK, Bloch, W, Mierau, A, and Gehlert, S. Effects of endurance exercise bouts in hypoxia, hyperoxia, and normoxia on mTOR-related protein signaling', 'BNIP3, phosphorylated RSK1, ERK1/2, FoxO3a, mTOR, and S6K1 between all conditions and time points', 'Phosphorylated Akt/PKB', 'eEF2 phosphorylation', 'Phosphorylated rpS6']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise (regime/therapy)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise (regime/therapy)'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0031715', 'cui_str': 'Phosphorylation'}]",11.0,0.0204772,"No significant differences (p > 0.05) were observed for BNIP3, phosphorylated RSK1, ERK1/2, FoxO3a, mTOR, and S6K1 between all conditions and time points.","[{'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Przyklenk', 'Affiliation': 'Department of Molecular and Cellular Sport Medicine, Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Thorben', 'Initials': 'T', 'LastName': 'Aussieker', 'Affiliation': 'Department of Molecular and Cellular Sport Medicine, Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Gutmann', 'Affiliation': 'Institute of Movement and Neuroscience, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Schiffer', 'Affiliation': 'Outpatient Clinic for Sports Traumatology and Public Health Consultation, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Brinkmann', 'Affiliation': 'Department of Molecular and Cellular Sport Medicine, Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Heiko K', 'Initials': 'HK', 'LastName': 'Strüder', 'Affiliation': 'Institute of Movement and Neuroscience, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Bloch', 'Affiliation': 'Department of Molecular and Cellular Sport Medicine, Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Mierau', 'Affiliation': 'Institute of Movement and Neuroscience, German Sport University Cologne, Cologne, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Gehlert', 'Affiliation': 'Department of Molecular and Cellular Sport Medicine, Institute of Cardiovascular Research and Sport Medicine, German Sport University Cologne, Cologne, Germany.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002753'] 1137,31647280,Virtual grocery shopping and cookie consumption following intranasal insulin or placebo application.,"Insulin receptors are present in brain areas that are involved in the control of hunger and satiety, and intranasal insulin is assumed to have an anorexigenic effect. This known influence of insulin on satiety encouraged us to investigate the effect of intranasal insulin on feeding-related behaviors. The aim of the current study was to explore the influence of 40 IU of intranasal insulin on the grocery shopping behavior and cookie consumption in a group of 30 healthy young men, using a crossover randomized double-blind design. Using a virtual mock supermarket, we tested whether the intranasal administration of insulin influences purchase behavior in comparison to a placebo or control condition. The participants also provided hedonic ratings of food pictures, as well as their subjective feeling of hunger. We calculated an objective measure of hunger from the amount of cookies eaten. In contradiction to our hypotheses, no significant differences regarding ratings, calorie content of purchased food products, and cookie consumption were found between the treatment conditions. Our conclusion is that 40 IU intranasal insulin had no influence on the evaluation of pictured foods in healthy young men in our task. Acknowledging that previous studies have found effects for intranasal insulin and food cue processing, we suggest that future research should focus on chemosensory stimulation or cognitive tasks in behavioral experiments and carefully consider the doses of intranasal insulin. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Our conclusion is that 40 IU intranasal insulin had no influence on the evaluation of pictured foods in healthy young men in our task.,"['30 healthy young men', 'healthy young men']","['intranasal insulin', 'placebo', 'intranasal insulin or placebo application']","['ratings, calorie content of purchased food products, and cookie consumption', 'hedonic ratings of food pictures, as well as their subjective feeling of hunger']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C3853210', 'cui_str': 'Cookie (substance)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441469', 'cui_str': 'Picture (physical object)'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}]",2019.0,0.228854,Our conclusion is that 40 IU intranasal insulin had no influence on the evaluation of pictured foods in healthy young men in our task.,"[{'ForeName': 'Rea', 'Initials': 'R', 'LastName': 'Rodriguez-Raecke', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology.'}, {'ForeName': 'Miriam', 'Initials': 'M', 'LastName': 'Sommer', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology.'}, {'ForeName': 'Yvonne Felicitas', 'Initials': 'YF', 'LastName': 'Brünner', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology.'}, {'ForeName': 'Franziska Sonja', 'Initials': 'FS', 'LastName': 'Müschenich', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology.'}, {'ForeName': 'Rik', 'Initials': 'R', 'LastName': 'Sijben', 'Affiliation': 'Department of Diagnostic and Interventional Neuroradiology.'}]",Experimental and clinical psychopharmacology,['10.1037/pha0000330'] 1138,31647379,Communicating Dynamic Behaviors in Basketball: The Role of Verbal Instructions and Arrow Symbols.,"Purpose: Guided by cognitive load theory and cognitive theory of multimedia learning, the purpose of this study was to evaluate players' ability to integrate dynamic information presented under different conditions: a verbal condition, in which instructions were given orally; a visual condition, in which instructions were shown using arrow symbols; and a redundant condition, in which both visual and verbal instructions were presented simultaneously. Method: In a 2 × 3 design, we asked basketball players with varied levels of skill (less-skilled, skilled) to rate their invested mental effort and to perform a recall test after learning from either the verbal, visual or redundant condition. Results: Results demonstrated that the less-skilled players benefited more from the redundant condition, whereas the skilled participants benefited more from the visual condition. Conclusion: Recommendations for improving instructional design techniques aimed at the transmission of tactical instructions in team games are proposed.",2020,"Results demonstrated that the less-skilled players benefited more from the redundant condition, whereas the skilled participants benefited more from the visual condition. ",['Basketball'],"['basketball players with varied levels of skill (less-skilled, skilled) to rate their invested mental effort and to perform a recall test after learning from either the verbal, visual or redundant condition', 'cognitive load theory and cognitive theory of multimedia learning']",[],"[{'cui': 'C0004818', 'cui_str': 'Basketball'}]","[{'cui': 'C0004818', 'cui_str': 'Basketball'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}]",[],,0.0237597,"Results demonstrated that the less-skilled players benefited more from the redundant condition, whereas the skilled participants benefited more from the visual condition. ","[{'ForeName': 'Aïmen', 'Initials': 'A', 'LastName': 'Khacharem', 'Affiliation': 'Paris-East Créteil University.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Trabelsi', 'Affiliation': 'University of Sfax.'}, {'ForeName': 'Bachir', 'Initials': 'B', 'LastName': 'Zoudji', 'Affiliation': 'University of Polytechnique Hautes-de-France.'}, {'ForeName': 'Slava', 'Initials': 'S', 'LastName': 'Kalyuga', 'Affiliation': 'University of New South Wales.'}]",Research quarterly for exercise and sport,['10.1080/02701367.2019.1657553'] 1139,31560027,Lower-Extremity Torque Capacity and Physical Function in Mobility-Limited Older Adults.,"OBJECTIVES Skeletal muscle weakness and an increase in fatigability independently contribute to age-related functional decline. The objective of this study was to examine the combined contribution of these deficiencies (i.e., torque capacity) to physical function, and then to assess the functional implications of progressive resistance training (PRT) mediated-torque capacity improvements in mobility-limited older adults. DESIGN Randomized controlled trial. SETTING Exercise laboratory on the Health Sciences campus of an urban university. PARTICIPANTS Seventy mobility-limited (Short Physical Performance Battery (SPPB) ≤9) older adults (~79 yrs). INTERVENTION Progressive resistance training or home-based flexibility 3 days/week for 12 weeks. MEASUREMENTS Torque capacity was defined as the sum of peak torques from an isokinetic knee extension fatigue test. Relationships between torque capacity and performance-based and patient-reported functional measures before and after PRT were examined using partial correlations adjusted for age, sex, and body mass index. RESULTS Torque capacity explained (P<0.05) 10 and 28% of the variance in six-minute walk distance and stair climb time, respectively. PRT-mediated torque capacity improvements were paralleled by increases (P<0.05) in self-reported activity participation (+20%) and advanced lower extremity function (+7%), and associated (P<0.05) with a reduction in activity limitations (r=0.44) and an improved SPPB score (r=0.32). CONCLUSION Skeletal muscle torque capacity, a composite of strength and fatigue, may be a proximal determinant of physical function in mobility-limited older individuals. To more closely replicate the musculoskeletal demands of real-life tasks, future studies are encouraged to consider the combined interaction of distinct skeletal muscle faculties to overall functional ability in older adults.",2019,"RESULTS Torque capacity explained (P<0.05) 10 and 28% of the variance in six-minute walk distance and stair climb time, respectively.","['Seventy mobility-limited (Short Physical Performance Battery (SPPB) ≤9) older adults (~79 yrs', 'older adults', 'Exercise laboratory on the Health Sciences campus of an urban university', 'mobility-limited older adults', 'Mobility-Limited Older Adults']","['Progressive resistance training or home-based flexibility 3 days/week for 12 weeks', 'progressive resistance training (PRT']","['activity participation', 'Torque capacity', 'PRT-mediated torque capacity improvements', 'activity limitations', 'advanced lower extremity function', 'SPPB score', 'Lower-Extremity Torque Capacity and Physical Function', 'peak torques from an isokinetic knee extension fatigue test']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0677547', 'cui_str': 'days/week (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0376590', 'cui_str': 'Torque'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0449295', 'cui_str': 'Limitation (attribute)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",70.0,0.0312026,"RESULTS Torque capacity explained (P<0.05) 10 and 28% of the variance in six-minute walk distance and stair climb time, respectively.","[{'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Grosicki', 'Affiliation': 'Gregory J. Grosicki, Ph.D., Department of Health Sciences and Kinesiology, Biodynamics and Human Performance Center, Georgia Southern University (Armstrong Campus), 11935 Abercorn Street, Savannah, GA, 31419. Phone: (912) 344-3317. Fax: (912) 344-3490. Email: ggrosicki@georgiasouthern.edu.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Englund', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Price', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Iwai', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kashiwa', 'Affiliation': ''}, {'ForeName': 'K F', 'Initials': 'KF', 'LastName': 'Reid', 'Affiliation': ''}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Fielding', 'Affiliation': ''}]","The journal of nutrition, health & aging",['10.1007/s12603-019-1232-8'] 1140,31637452,Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.,"RATIONALE Animal studies have found robust sex differences in the pharmacokinetics and pharmacodynamics of Δ 9 -tetrahydrocannabinol (THC). However, the human evidence remains equivocal, despite findings that women may experience more severe consequences of cannabis use than men. OBJECTIVES The objective of this secondary analysis was to examine sex differences in THC pharmacokinetics and in acute subjective, physiological, and cognitive effects of smoked cannabis in a sample of regular cannabis users (use 1-4 days per week) aged 19-25 years. METHODS Ninety-one healthy young adults were randomized to receive active (12.5% THC; 17 females, 43 males) or placebo (< 0.1% THC; 9 females, 21 males) cannabis using a 2:1 allocation ratio. Blood samples to quantify concentrations of THC, 11-OH-THC, and 11-Nor-carboxy-THC (THC-COOH), as well as measures of subjective drug effects, vital signs, and cognition were collected over a period of 6 h following ad libitum smoking of a 750-mg cannabis cigarette. RESULTS Females smoked less of the cannabis cigarette than males (p = 0.008) and had a lower peak concentration of THC and THC-COOH than males (p ≤ 0.01). Blood THC concentrations remained lower in females even when adjusting for differences in estimated dose of THC inhaled. There was very little evidence of sex differences in visual analog scale (VAS) ratings of subjective drug effects, mood, heart rate, blood pressure, or cognitive effects of cannabis. CONCLUSIONS Females experienced the same acute effects of smoked cannabis as males at a lower observed dose, highlighting the need for more research on sex differences in the pharmacology of THC, especially when administered by routes in which titrating to the desired effect is more difficult (e.g., cannabis edibles).",2020,"RESULTS Females smoked less of the cannabis cigarette than males (p = 0.008) and had a lower peak concentration of THC and THC-COOH than males (p ≤ 0.01).","['young adults', 'Ninety-one healthy young adults were randomized to receive active (12.5% THC; 17 females, 43 males) or', 'smoked cannabis in a sample of regular cannabis users (use 1-4\xa0days per week) aged 19-25\xa0years']",['placebo'],"['Blood samples to quantify concentrations of THC, 11-OH-THC, and 11-Nor-carboxy-THC (THC-COOH', 'visual analog scale (VAS) ratings of subjective drug effects, mood, heart rate, blood pressure, or cognitive effects of cannabis', 'peak concentration of THC and THC-COOH', 'Blood THC concentrations']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C4517544', 'cui_str': '12.5 (qualifier value)'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0677547', 'cui_str': 'days/week (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0728867', 'cui_str': 'Drug action (finding)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0678449', 'cui_str': 'Cannabis'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0005768'}]",91.0,0.168615,"RESULTS Females smoked less of the cannabis cigarette than males (p = 0.008) and had a lower peak concentration of THC and THC-COOH than males (p ≤ 0.01).","[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Matheson', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario, M5S 3H7, Canada. justin.matheson@camh.ca.""}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Sproule', 'Affiliation': 'Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, M5S 3M2, Canada.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Di Ciano', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario, M5S 3H7, Canada.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fares', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario, M5S 3H7, Canada.""}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Le Foll', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario, M5S 3H7, Canada.""}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Mann', 'Affiliation': 'Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, M5S 2S1, Canada.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Brands', 'Affiliation': ""Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, 27 King's College Circle, Toronto, Ontario, M5S 3H7, Canada.""}]",Psychopharmacology,['10.1007/s00213-019-05369-y'] 1141,31553108,Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.,"In hereditary cancer, multigene panel testing is currently replacing older single-gene approaches. Patients whose tests were previously uninformative could benefit from updated testing. Research suggests that patients desire to be recontacted about updated genetic testing, but few studies have tested the efficacy of recontact efforts. This study investigated the outcomes of a recontact effort in a hereditary cancer clinic and explored the impact of four different recontact letters, randomized in a 2X2 factorial design. Patients who had negative genetic testing for single genes or conditions were mailed letters inviting them to schedule an appointment to discuss updated testing. Patients were randomized to receive one of four letters and each letter emphasized different implications of updated multigene genetic testing: (a) personal medical management implications, (b) implications for family members, (c) both personal and family implications or (d) a control letter. The proportion of patients who arrived for appointments was assessed approximately 7 months after mailing along with associations with patient demographics and type of letter received. Letters were mailed to 586 patients who had initial testing between 2001 and 2015. Most patients were white (78%) and female (97%) with private insurance (65%). At 7 months, 25 patients (4.3%, 95% CI: 2.6% to 5.9%) had arrived for an appointment. Older age was significantly associated with response rate (p = .01), while type of recontact letter was not (p = .54). This study suggests that recontacting patients about updated genetic testing by mail does not yield a large response. It also suggests that personal and/or familial implications do not seem to be significant factors that determine response rate. Nevertheless, results provide meaningful information for cancer clinics about the outcomes of recontact efforts via informational letter.",2019,"Older age was significantly associated with response rate (p = .01), while type of recontact letter was not (p = .54).","['Recontacting patients for multigene panel testing in hereditary cancer', 'Most patients were white (78%) and female (97%) with private insurance (65', 'Patients who had negative genetic testing for single genes or conditions', '586 patients who had initial testing between 2001 and 2015']","['letter emphasized different implications of updated multigene genetic testing: (a) personal medical management implications, (b) implications for family members, (c) both personal and family implications or (d) a control letter']",['response rate'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439660', 'cui_str': 'Hereditary (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C0021672', 'cui_str': 'Insurance'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0679560', 'cui_str': 'Genetic Testing'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}]","[{'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0679560', 'cui_str': 'Genetic Testing'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],586.0,0.0563042,"Older age was significantly associated with response rate (p = .01), while type of recontact letter was not (p = .54).","[{'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Sawyer', 'Affiliation': 'Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Creswick', 'Affiliation': 'Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Lewandowski', 'Affiliation': 'Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Quillin', 'Affiliation': 'Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA.'}]",Journal of genetic counseling,['10.1002/jgc4.1173'] 1142,31648851,Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).,"BACKGROUND The present study (VINGEM) is the first randomised trial comparing vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG) in patients with advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin. PATIENTS AND METHODS Patients with aUC, creatinine clearance 30-60 ml/min, performance status ≤1 and no prior chemotherapy for metastatic disease were randomised to the experimental arm (vinflunine 280 or 250 mg/m 2 day 1, gemcitabine 1000 mg/m 2 days 1 and 8, q21 days) or the control arm (carboplatin AUC 4.5 day 1, gemcitabine 1000 mg/m 2 days 1 and 8, q21 days). Primary end-point was progression-free survival (PFS). RESULTS Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30 CG). There was no significant difference in PFS between the treatment arms: median 6.2 months for VG versus 6.3 months for CG (hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.44-1.28; P = 0.293). Median overall survival was 12.5 months for VG versus 10.6 months for CG. The overall response rate (ORR) was higher in the VG arm than in the CG arm (63% versus 40%) but was not statistically significant in the intention-to-treat analysis. Furthermore, VG showed a high complete response (CR) rate, 22% versus 3% in CG. In the per-protocol group, both ORR and CR were significantly higher for VG than for CG. The most common adverse events (AEs) were fatigue, haematological toxicities, gastrointestinal disorders and nausea/vomiting. Common grade III/IV AEs were neutropenia (VG 62%, CG 43%), thrombocytopenia (VG 7%, CG 37%) and febrile neutropenia (VG 31%, CG 7%). CONCLUSIONS The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment. The response rate of VG indicates, however, an active regimen and warrants further studies. CLINICALTRIALS. GOV NUMBER NCT02665039.",2020,The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment.,"['patients unfit for cisplatin due to renal impairment', 'Patients with aUC, creatinine clearance 30-60\xa0ml/min, performance status ≤1 and no prior chemotherapy for metastatic disease', 'Sixty-two patients were randomised; a total of 59 patients were treated (29 VG, 30 CG', 'cisplatin-ineligible patients with advanced urothelial carcinoma', 'patients with advanced urothelial carcinoma (aUC) ineligible for treatment with cisplatin']","['experimental arm (vinflunine 280 or 250\xa0mg/m 2 day 1, gemcitabine 1000\xa0mg/m 2 days 1 and 8, q21 days) or the control arm (carboplatin AUC 4.5 day 1', 'vinflunine/gemcitabine (VG) to standard carboplatin/gemcitabine (CG', 'gemcitabine 1000', 'Vinflunine/gemcitabine versus carboplatin/gemcitabine']","['complete response (CR) rate', 'fatigue, haematological toxicities, gastrointestinal disorders and nausea/vomiting', 'progression-free survival (PFS', 'neutropenia', 'febrile neutropenia', 'ORR and CR', 'Median overall survival', 'PFS', 'overall response rate (ORR', 'thrombocytopenia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine (procedure)'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C2939420', 'cui_str': 'Metastatic disease'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0007138', 'cui_str': 'Carcinoma, Transitional Cell'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0672663', 'cui_str': 'vinflunine'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4057589', 'cui_str': 'gemcitabine 1000 MG'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}]",30.0,0.161964,The combination of VG did not improve PFS compared with standard treatment with CG in patients unfit for cisplatin due to renal impairment.,"[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Holmsten', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. Electronic address: karin.holmsten@ki.se.'}, {'ForeName': 'Niels Viggo', 'Initials': 'NV', 'LastName': 'Jensen', 'Affiliation': 'Department of Oncology, Odense Universitetshospital, Odense, Denmark.'}, {'ForeName': 'Lene Sonne', 'Initials': 'LS', 'LastName': 'Mouritsen', 'Affiliation': 'Department of Oncology, Herlev Gentofte Hospital, Herlev, Denmark.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Jonsson', 'Affiliation': 'Department of Oncology, Norrlands Universitetssjukhus, Umeå, Sweden.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Mellnert', 'Affiliation': 'Department of Oncology, Skånes Universitetssjukhus, Lund, Sweden.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Agerbæk', 'Affiliation': 'Department of Oncology, Aarhus Universitetshospital, Aarhus, Denmark.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nilsson', 'Affiliation': 'Department of Oncology, Västmanlands Sjukhus, Västerås, Sweden.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Moe', 'Affiliation': 'Department of Oncology, Aalborg Universitetshospital, Aalborg, Denmark.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Carus', 'Affiliation': 'Department of Oncology, Aalborg Universitetshospital, Aalborg, Denmark.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Öfverholm', 'Affiliation': 'Department of Oncology, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden.'}, {'ForeName': 'Outi', 'Initials': 'O', 'LastName': 'Lahdenperä', 'Affiliation': 'Department of Oncology, Åbo Universitetscentralsjukhus, Åbo, Finland.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Brandberg', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Hemming', 'Initials': 'H', 'LastName': 'Johansson', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Hellström', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Hans von der', 'Initials': 'HV', 'LastName': 'Maase', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Pappot', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Ullén', 'Affiliation': 'PO Bäckencancer, Tema Cancer, Karolinska Universitetssjukhuset and Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.08.033'] 1143,31641769,Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.,"AIMS The Hygia Chronotherapy Trial, conducted within the clinical primary care setting, was designed to test whether bedtime in comparison to usual upon awakening hypertension therapy exerts better cardiovascular disease (CVD) risk reduction. METHODS AND RESULTS In this multicentre, controlled, prospective endpoint trial, 19 084 hypertensive patients (10 614 men/8470 women, 60.5 ± 13.7 years of age) were assigned (1:1) to ingest the entire daily dose of ≥1 hypertension medications at bedtime (n = 9552) or all of them upon awakening (n = 9532). At inclusion and at every scheduled clinic visit (at least annually) throughout follow-up, ambulatory blood pressure (ABP) monitoring was performed for 48 h. During the 6.3-year median patient follow-up, 1752 participants experienced the primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke). Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio-adjusted for significant influential characteristics of age, sex, type 2 diabetes, chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event-of the primary CVD outcome [0.55 (95% CI 0.50-0.61), P < 0.001] and each of its single components (P < 0.001 in all cases), i.e. CVD death [0.44 (0.34-0.56)], myocardial infarction [0.66 (0.52-0.84)], coronary revascularization [0.60 (0.47-0.75)], heart failure [0.58 (0.49-0.70)], and stroke [0.51 (0.41-0.63)]. CONCLUSION Routine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events. TRIAL REGISTRATION ClinicalTrials.gov, number NCT00741585.",2019,"Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio-adjusted for significant influential characteristics of age, sex, type 2 diabetes, chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event-of the primary CVD outcome [0.55","['19 084 hypertensive patients (10 614 men/8470 women, 60.5\u2009±\u200913.7\u2009years of age']",['Bedtime hypertension treatment'],"['chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event-of the primary CVD outcome', 'cardiovascular risk reduction', 'asleep BP and increased sleep-time relative BP decline, i.e. BP dipping', 'ABP control', 'primary CVD outcome (CVD death, myocardial infarction, coronary revascularization, heart failure, or stroke', 'CVD death', 'myocardial infarction', 'coronary revascularization', 'heart failure', 'ambulatory blood pressure (ABP) monitoring', 'cardiovascular disease (CVD) risk reduction']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0521112', 'cui_str': 'Bedtime (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol, HDL2'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0378785', 'cui_str': 'DIPS'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0242876', 'cui_str': 'Blood Pressure Monitoring, Ambulatory'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]",1752.0,0.186905,"Patients of the bedtime, compared with the upon-waking, treatment-time regimen showed significantly lower hazard ratio-adjusted for significant influential characteristics of age, sex, type 2 diabetes, chronic kidney disease, smoking, HDL cholesterol, asleep systolic blood pressure (BP) mean, sleep-time relative systolic BP decline, and previous CVD event-of the primary CVD outcome [0.55","[{'ForeName': 'Ramón C', 'Initials': 'RC', 'LastName': 'Hermida', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Crespo', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Domínguez-Sardiña', 'Affiliation': 'Estructura de Xestión Integrada de Vigo, Servicio Galego de Saúde (SERGAS), Vigo, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Otero', 'Affiliation': 'Servicio de Nefrología, Complejo Hospitalario Universitario, Estructura de Xestión Integrada de Ourense, Verín e O Barco de Valdeorras, Servicio Galego de Saúde (SERGAS), Ourense 32005, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Moyá', 'Affiliation': 'Estructura de Xerencia Integrada Pontevedra e O Salnés, Servicio Galego de Saúde (SERGAS), Pontevedra, Spain.'}, {'ForeName': 'María T', 'Initials': 'MT', 'LastName': 'Ríos', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Sineiro', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'María C', 'Initials': 'MC', 'LastName': 'Castiñeira', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Pedro A', 'Initials': 'PA', 'LastName': 'Callejas', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Pousa', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'José L', 'Initials': 'JL', 'LastName': 'Salgado', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Durán', 'Affiliation': 'Estructura de Xestión Integrada de Vigo, Servicio Galego de Saúde (SERGAS), Vigo, Spain.'}, {'ForeName': 'Juan J', 'Initials': 'JJ', 'LastName': 'Sánchez', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'José R', 'Initials': 'JR', 'LastName': 'Fernández', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Artemio', 'Initials': 'A', 'LastName': 'Mojón', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': 'Diana E', 'Initials': 'DE', 'LastName': 'Ayala', 'Affiliation': 'Bioengineering & Chronobiology Laboratories, Atlantic Research Center for Information and Communication Technologies (AtlantTIC), University of Vigo, E.I. Telecomunicación, Campus Universitario, Vigo 36310, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European heart journal,['10.1093/eurheartj/ehz754'] 1144,29107709,"IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.",,2017,,[],"['IFNL4', 'Sofosbuvir, Velpatasvir, and Voxilaprevir']",['Virologic Relapse'],[],"[{'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C4079582', 'cui_str': 'velpatasvir'}, {'cui': 'C4507236', 'cui_str': 'voxilaprevir'}]","[{'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]",,0.0147234,,"[{'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': ""O'Brien"", 'Affiliation': 'Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.'}, {'ForeName': 'Shyam', 'Initials': 'S', 'LastName': 'Kottilil', 'Affiliation': 'Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Ruth M', 'Initials': 'RM', 'LastName': 'Pfeiffer', 'Affiliation': 'Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.'}]",Gastroenterology,['10.1053/j.gastro.2017.06.069'] 1145,29609480,Adherence and retention of African Americans in a randomized controlled trial with a yoga-based intervention: the effects of health promoting programs on cardiovascular disease risk study.,"Objectives: Sedentary lifestyle is a risk factor for cardiovascular disease (CVD). Few alternative lifestyle interventions, such as yoga practice, focus on African Americans (AA), the population most vulnerable to CVD. Our objective is to compare the retention and adherence rates between yoga, walking, and health education interventions while providing information about the acceptance of various yoga regimens. Design: Three hundred seventy-five AA participants were recruited exclusively from an active cohort study and randomized into a 48-week study (24 weeks intervention, 24 weeks follow-up) with 5 health promotion interventions: high frequency yoga, moderate frequency yoga, low frequency yoga, guided walking, and health education. In addition to examining the separate yoga interventions, a pooled yoga intervention is considered for comparison to guided walking and health education. Participant retention, adherence, and vitals were monitored at each intervention session. Participants were also scheduled for four clinic visits throughout the study where blood panels, health behavior, and medication surveys were administered. Results: Of the 375 participants recruited, 31.7% did not complete the study. At baseline, in both the guided walking group and the high frequency yoga group, there were significant differences between those who completed the study and those who did not. Although intervention retention in the pooled yoga program (78.3%) was higher compared to the walking (60%) and education programs (74.3%) ( p  = 0.007), differences in post-intervention retention was not significant. Median adherence rates for the pooled yoga program exceeded rates for guided walking and education with moderate frequency yoga out performing high and low frequency yoga. Conclusion: Study-defined retention success rates were not reached by all health promotion programs. However, retention and adherence rates for the pooled yoga program show that older African Americans are receptive to participating in yoga-based health promotion practices.",2020,"Although intervention retention in the pooled yoga program (78.3%) was higher compared to the walking (60%) and education programs (74.3%) (p = 0.007), differences in post-intervention retention was not significant.","['African Americans (AA', 'African Americans', 'older African Americans', 'Three hundred seventy-five AA participants', '375 participants recruited, 31.7% did not complete the study', 'Participants were also scheduled for four clinic visits throughout the study where blood panels, health behavior, and medication surveys were administered']","['5 health promotion interventions: high frequency yoga, moderate frequency yoga, low frequency yoga, guided walking, and health education', 'yoga-based intervention', 'health promoting programs']","['Median adherence rates', 'Participant retention, adherence, and vitals', 'retention success rates', 'retention and adherence rates']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4319621', 'cui_str': 'Seventy-five'}, {'cui': 'C4517745', 'cui_str': '375 (qualifier value)'}, {'cui': 'C4708784', 'cui_str': '31.7 (qualifier value)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0005768'}, {'cui': 'C0018687'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1621583', 'cui_str': 'Administer'}]","[{'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C0205212', 'cui_str': 'High frequency (qualifier value)'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0205213', 'cui_str': 'Low frequency (qualifier value)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0018701'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0442732', 'cui_str': 'Vital (qualifier value)'}]",375.0,0.0257851,"Although intervention retention in the pooled yoga program (78.3%) was higher compared to the walking (60%) and education programs (74.3%) (p = 0.007), differences in post-intervention retention was not significant.","[{'ForeName': 'Victoria I', 'Initials': 'VI', 'LastName': 'Okhomina', 'Affiliation': 'Department of Data Science, John D.\xa0Bower School of Population Health, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Samantha R', 'Initials': 'SR', 'LastName': 'Seals', 'Affiliation': 'Department of Mathematics and Statistics, Hal Marcus College of Science and Engineering, University of West Florida, Pensacola, FL, USA.'}, {'ForeName': 'Pramod', 'Initials': 'P', 'LastName': 'Anugu', 'Affiliation': 'Department of Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Godwin', 'Initials': 'G', 'LastName': 'Adu-Boateng', 'Affiliation': 'Department of Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Sims', 'Affiliation': 'Department of Medicine, School of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}, {'ForeName': 'Gailen D', 'Initials': 'GD', 'LastName': 'Marshall', 'Affiliation': 'Division of Clinical Immunology and Allergy, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.'}]",Ethnicity & health,['10.1080/13557858.2018.1458073'] 1146,31651426,"Does Repeated Painful Stimuli Change Cerebral Near-Infrared Spectroscopy Response in Healthy, Term, Large for Gestational Age Newborns?","OBJECTIVE The objective of this study was to evaluate the effect of repeated painful stimuli on short-term pain response in healthy, term, large for gestational age newborns by measuring the regional cerebral oxygen saturation (rScO2), and behavioral and physiological responses. METHODS We compared term large for gestational age infants who received repeated painful stimuli (study group) with term, appropriate for gestational age infants (control group). A pulse oximeter and a near-infrared spectroscopy probe were connected to babies during the study period, and the responses of the babies were recorded by video, from which the crying time and the Neonatal Infant Pain Scale were obtained. The heart rate, peripheral oxygen saturation (SpO2), and rScO2 data were sampled every 1 second and exported to a personal computer via digital output during the study period. The maximum heart rate, the minimum SpO2, and peak, baseline, and mean rScO2 measurements following skin puncture were recorded. Data were compared within 1 group and between the 2 groups. RESULTS After the heel prick, crying time (P<0.001) and Neonatal Infant Pain Scale scores (P=0.024) increased, and SpO2 levels decreased significantly (P=0.012) in the study group versus the control group. Although mean rScO2 increased significantly within 1 group (P<0.001), it was not significant between the 2 groups. The percent change in rScO2 was greater in the study group (5.2 [2.5 to 9.3]) compared with the control group (2.8 [1.1 to 8.2], P=0.037). CONCLUSION We showed that rScO2 values changed significantly within the first few days of life in babies who received more painful stimuli compared with the control group, similar to behavioral and physiological responses.",2020,"Although mean rScO2 increased significantly within one group (P<0.001), it was not significant between the two groups.","['Healthy Term Large for Gestational Age Newborns', 'healthy, term, large for gestational age (LGA) newborns', 'LGA infants who received repeated painful stimuli (study group) to term, appropriate for gestational age (AGA) infants (control group']","['Painful Stimuli Change Cerebral Near-infrared Spectroscopy Response', 'repeated painful stimuli']","['crying time, and Neonatal Infant Pain Scale (NIPS', 'SpO2 levels', 'mean rScO2', 'NIPS scores', 'rScO2', 'regional cerebral oxygen saturation (rScO2), behavioral and physiological responses', 'heart rate (HR), peripheral oxygen saturation (SpO2) and rScO2 data', 'crying time', 'maximum HR, the minimum SpO2, peak, baseline and mean rScO2 measurements', 'rScO2 values']","[{'cui': 'C4304643', 'cui_str': 'Large for gestational age newborn'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0376519', 'cui_str': 'Spectrometry, Near-Infrared'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0234402', 'cui_str': 'Stimulus, function (observable entity)'}]","[{'cui': 'C0010399', 'cui_str': 'Cryings'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0645782', 'cui_str': 'NIPS'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C4273907', 'cui_str': 'Cerebral oxygen saturation (observable entity)'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.0309688,"Although mean rScO2 increased significantly within one group (P<0.001), it was not significant between the two groups.","[{'ForeName': 'Hulya', 'Initials': 'H', 'LastName': 'Ozdemir', 'Affiliation': 'Department of Pediatrics, Division of Neonatology Marmara University Faculty of Medicine, Istanbul.'}, {'ForeName': 'Hulya', 'Initials': 'H', 'LastName': 'Bilgen', 'Affiliation': 'Department of Pediatrics, Division of Neonatology Marmara University Faculty of Medicine, Istanbul.'}, {'ForeName': 'Gamze', 'Initials': 'G', 'LastName': 'Gokulu', 'Affiliation': 'Department of Pediatric Emergency, Faculty of Medicine, Cukurova University, Adana, Turkey.'}, {'ForeName': 'Asli', 'Initials': 'A', 'LastName': 'Memisoglu', 'Affiliation': 'Department of Pediatrics, Division of Neonatology Marmara University Faculty of Medicine, Istanbul.'}, {'ForeName': 'Eren', 'Initials': 'E', 'LastName': 'Ozek', 'Affiliation': 'Department of Pediatrics, Division of Neonatology Marmara University Faculty of Medicine, Istanbul.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000774'] 1147,30063554,Acute Effects of Interset Rest Duration on Physiological and Perceptual Responses to Resistance Exercise in Hypoxia.,"Lockhart, C, Scott, BR, Thoseby, B, and Dascombe, BJ. Acute effects of interset rest duration on physiological and perceptual responses to resistance exercise in hypoxia. J Strength Cond Res 34(8): 2241-2249, 2020-This study aimed to determine whether manipulating interset rest periods during resistance training in hypoxia impacts on physiological and perceptual responses to exercise. Twelve healthy males completed 1 repetition maximum (1RM) testing for the bilateral leg extension, before completing 4 separate randomized trials comprising 5 × 10 repetitions of leg extensions at 70% 1RM. Experimental trials were completed in both moderate hypoxia (FIO2 = 15%) and normoxia (FIO2 = 21%), using interset rest periods of both 60 and 180 seconds for each environmental condition. Near-infrared spectroscopy was used to quantify muscle oxygenation of vastus lateralis , and surface electromyography assessed the activation of vastus lateralis and medialis. Blood lactate concentration ([BLa]) and midthigh circumference were assessed before and immediately after each trial. Heart rate (HR) responses, blood oxygen saturation, and rating of perceived exertion (RPE) were also assessed after each set and the whole session RPE (sRPE). Perceived quadriceps soreness was reported before, immediately after, and at 24 and 48 hours after each trial. Muscle activation (sets 4-5), RPE (sets 3-5), and sRPE were significantly (p < 0.05) higher in the 60-second trials of the resistance exercise protocol. Significant increases (p < 0.01) were observed for [BLa] and midthigh circumference across sets within each condition. No significant main effect was observed for interset rest duration or environmental condition for muscle oxygenation, HR, or perceived quadriceps soreness. These findings indicate that performing resistance exercise in hypoxia or normoxia with shortened interset rest periods increases muscle activation and perceived exertion, without exacerbating muscle soreness.",2020,"No significant main effect was observed for interset rest duration or environmental condition for muscle oxygenation, HR, or perceived quadriceps soreness.","['hypoxia', 'Hypoxia', 'Twelve healthy males completed 1']","['J Strength Cond Res XX(X', 'repetition maximum (1RM) testing for the bilateral leg extension', 'Interset Rest Duration', 'interset rest duration']","['Muscle activation', 'Lockhart, C, Scott, BR, Thoseby, B, and Dascombe, BJ', 'Heart rate (HR) responses, blood oxygen saturation, and rating of perceived exertion (RPE', 'Blood lactate concentration ([BLa]) and midthigh circumference', 'interset rest duration or environmental condition for muscle oxygenation, HR, or perceived quadriceps soreness', 'Perceived quadriceps soreness']","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C1997337', 'cui_str': 'Speed of heart rate response'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen (observable entity)'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0445208', 'cui_str': 'RPE'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0234233', 'cui_str': 'Tenderness (finding)'}]",12.0,0.100923,"No significant main effect was observed for interset rest duration or environmental condition for muscle oxygenation, HR, or perceived quadriceps soreness.","[{'ForeName': 'Catriona', 'Initials': 'C', 'LastName': 'Lockhart', 'Affiliation': 'Department of Rehabilitation, Nutrition and Sport, School of Allied Health, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Brendan R', 'Initials': 'BR', 'LastName': 'Scott', 'Affiliation': 'School of Psychology and Exercise Science, Murdoch University, Perth, Western Australia, Australia.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Thoseby', 'Affiliation': 'Department of Rehabilitation, Nutrition and Sport, School of Allied Health, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Dascombe', 'Affiliation': 'Department of Rehabilitation, Nutrition and Sport, School of Allied Health, La Trobe University, Bundoora, Victoria, Australia.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002755'] 1148,29995670,"Preventing Exercise-Associated Collapse Using Online Runner Education: A Randomized, Controlled Trial.","OBJECTIVE To determine whether online exercise-associated collapse (EAC) prevention education decreases medical tent EAC visits among first-time marathoners. DESIGN A prospective controlled study, with age- and sex-stratified randomization, evaluated rates of medical tent diagnosed EAC among runners randomized to the intervention group and intervention participants, compared with a control group. SETTING Grandma's Marathon Medical Tent in Duluth, MN, June 2016. PARTICIPANTS Runners in the 2016 Grandma's Marathon who never previously ran a marathon (n = 2943), randomized into control (n = 1482) and intervention (n = 1461) groups. Intervention participants opened the EAC prevention video (n = 590). INTERVENTIONS Online EAC education included an introductory webpage and 5-minute professional video describing EAC and prevention. MAIN OUTCOME MEASURES Medical tent visit with EAC diagnosis. RESULTS Intervention participants had no decreased likelihood of EAC, compared with controls [odds ratio (OR), 0.88, 95% confidence interval (CI), 0.46-1.69]. Exercise-associated collapse occurred less frequently in those with longer race times (OR, 0.58, 95% CI, 0.43-0.79). Intervention participation was associated with longer race times (OR, 1.12, 95% CI, 1.10-1.23). CONCLUSIONS Those opening the EAC prevention video and controls had similar EAC rates. Slower running speed was associated with lower EAC rates. Video viewing was a predictor of slower running pace.",2020,"Intervention participation was associated with longer race times (OR, 1.12, 95% CI, 1.10-1.23). ","[""Grandma's Marathon Medical Tent in Duluth, MN, June 2016"", ""Runners in the 2016 Grandma's Marathon who never previously ran a marathon (n = 2943), randomized into control (n = 1482) and intervention (n = 1461) groups""]","['control group', 'Exercise-Associated Collapse Using Online Runner Education', 'EAC prevention video', 'online exercise-associated collapse (EAC) prevention education', 'Online EAC education included an introductory webpage and 5-minute professional video describing EAC and prevention']","['longer race times', 'likelihood of EAC', 'EAC rates', 'Exercise-associated collapse']","[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0677506', 'cui_str': 'Tent, device (physical object)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0392748', 'cui_str': 'Collapsed (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C1633748', 'cui_str': 'Prevention education'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0392748', 'cui_str': 'Collapsed (qualifier value)'}]",2943.0,0.0912051,"Intervention participation was associated with longer race times (OR, 1.12, 95% CI, 1.10-1.23). ","[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Worley', 'Affiliation': 'Health Services, University of Minnesota Duluth, Duluth, MN.'}, {'ForeName': 'Colleen M', 'Initials': 'CM', 'LastName': 'Renier', 'Affiliation': 'Essentia Institute of Rural Health, Duluth, MN.'}, {'ForeName': 'Theo A', 'Initials': 'TA', 'LastName': 'Woehrle', 'Affiliation': 'Essentia Institute of Rural Health, Duluth, MN.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Stovitz', 'Affiliation': 'Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Benjamin D', 'Initials': 'BD', 'LastName': 'Nelson', 'Affiliation': 'Department of Orthopedics and Sports Medicine, Essentia Health-Duluth Clinic, Duluth, MN.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000607'] 1149,30024482,Effects of an Upper-Body Training Program Involving Resistance Exercise and High-Intensity Arm Cranking on Peak Handcycling Performance and Wheelchair Propulsion Efficiency in Able-Bodied Men.,"Chaikhot, D, Reed, K, Petroongrad, W, Athanasiou, F, van Kooten, D, and Hettinga, FJ. Effects of an upper-body training program involving resistance exercise and high-intensity arm cranking on peak handcycling performance and wheelchair propulsion efficiency in able-bodied men. J Strength Cond Res 34(8): 2267-2275, 2020-The aim of this study was to determine the training effects of an upper-body training program involving resistance exercise and high-intensity arm cranking on peak handcycling performance, propulsion efficiency, and biomechanical characteristics of wheelchair propulsion in able-bodied men. The training group (n = 10) received a 4-week upper-body resistance training (RT), 70% of 1 repetition maximum, 3 sets of 10 repetitions, 8 exercise stations, 2 times per week, combined with high-intensity interval training (HIIT) 2 times per week. High-intensity interval training consisted of arm-crank exercise, 7 intervals of 2 minutes at 80-90% of peak heart rate (HRpeak) with 2-minute active rest at 50-60% of HRpeak. The control group (n = 10) received no training. Both groups performed a preincremental and postincremental handcycling test until volitional exhaustion to evaluate fitness and a 4-minute submaximal wheelchair propulsion test at comfortable speed (CS), 125 and 145% of CS, to evaluate gross mechanical efficiency (GE), fraction of effective force (FEF), percentage of peak oxygen consumption (% V[Combining Dot Above]O2peak), and propulsion characteristics. Repeated-measures analysis of variance was performed (p < 0.05). Training resulted in a 28.2 ± 16.5% increase in peak power output, 13.3 ± 7.5% increase in V[Combining Dot Above]O2peak, 5.6 ± 0.9% increase in HRpeak, and 3.8 ± 1.5% decrease in HRrest. No training effects on FEF, GE, % V[Combining Dot Above]O2peak, and push characteristics were identified. In conclusion, the combined RT and arm-cranking HIIT improved fitness. However, it seems that this training did not result in improvements in propulsion efficiency and push characteristics. Additional wheelchair skill training may be needed to fully benefit from this advantage in daily life propulsion.",2020,"No training effects on FEF, GE, %","['able-bodied men', 'Able-Bodied Men']","['Resistance Exercise and High-Intensity Arm Cranking', 'V[Combining', 'J Strength Cond Res XX(X', 'upper-body training program involving resistance exercise and high-intensity arm cranking', '4-week upper-body resistance training (RT', 'Upper-Body Training Program', 'High-intensity interval training consisted of arm-crank exercise', 'no training', 'Additional wheelchair skill training']","['V[Combining', 'Peak Handcycling Performance and Wheelchair Propulsion Efficiency', 'peak power output', 'peak handcycling performance, propulsion efficiency, and biomechanical characteristics of wheelchair propulsion', 'propulsion efficiency and push characteristics', 'HRrest', 'gross mechanical efficiency (GE), fraction of effective force (FEF), percentage of peak oxygen consumption', 'Chaikhot, D, Reed, K, Petroongrad, W, Athanasiou, F, van Kooten, D, and Hettinga, FJ. Effects', 'peak handcycling performance and wheelchair propulsion efficiency']","[{'cui': 'C1299581', 'cui_str': 'Able'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1268087', 'cui_str': 'Upper body'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4277545', 'cui_str': 'High-Intensity Intermittent Exercise'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0559197', 'cui_str': 'Skills training (procedure)'}]","[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0043143', 'cui_str': 'Wheel Chairs'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0445194', 'cui_str': 'Power output (qualifier value)'}, {'cui': 'C1719958', 'cui_str': 'Push'}, {'cui': 'C0439806', 'cui_str': 'Gross (qualifier value)'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C1264633', 'cui_str': 'Fractions of (qualifier value)'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0557775', 'cui_str': 'Van (physical object)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.0236011,"No training effects on FEF, GE, %","[{'ForeName': 'Dhissanuvach', 'Initials': 'D', 'LastName': 'Chaikhot', 'Affiliation': 'School of Sports, Rehabilitation and Exercise Science, University of Essex, Colchester, United Kingdom.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Reed', 'Affiliation': ''}, {'ForeName': 'Wannakarn', 'Initials': 'W', 'LastName': 'Petroongrad', 'Affiliation': ''}, {'ForeName': 'Fotios', 'Initials': 'F', 'LastName': 'Athanasiou', 'Affiliation': ''}, {'ForeName': 'Daan', 'Initials': 'D', 'LastName': 'van Kooten', 'Affiliation': ''}, {'ForeName': 'Florentina J', 'Initials': 'FJ', 'LastName': 'Hettinga', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002738'] 1150,31647585,Exercise Maintenance in Older Adults 1 Year After Completion of a Supervised Training Intervention.,"BACKGROUND/OBJECTIVE Barriers and facilitators of exercise maintenance and residual effects of exercise training intervention on physical and cognitive function after the cessation of training are inadequately described in older adults. DESIGN AND SETTING One year after the cessation of a supervised exercise training intervention, a mixed methods approach employed a quantitative phase that assessed body composition and physical and cognitive function and a qualitative phase that explored determinants of exercise maintenance after participation in the intervention. PARTICIPANTS Community-dwelling older Irish adults (aged >65 years) who had completed 12 weeks of supervised exercise training 1 year previously. MEASUREMENTS Fifty-three participants (male/female ratio = 30:23; age = 70.8 ± 3.9 years) completed the follow-up testing comprising body composition and physical and cognitive function. Semistructured interviews were conducted with 12 participants (male/female ratio = 6:6) using the Theoretical Domains Framework to inform the interview guide. RESULTS At 1 year follow-up, body fat increased (mean = 4.3%; 95% confidence limit = 2.2% to 6.3%), while lean body mass (mean = -0.6%; 95% confidence limit = -1.2% to -0.1%), strength (leg press, mean = -5.6%; 95% confidence limit = -8.3% to -2.8%; chest press, mean = -11.0%; 95% confidence limit = -14.8% to -7.8%), and cognitive function (mean = -3.7%; 95% confidence limit = -5.7% to -1.8%) declined (all P < .05). Interviews revealed key facilitators (social aspects and beliefs about benefits of exercise) and barriers (affordability and general aversion to gyms) to exercise maintenance in this population. CONCLUSION Key barriers and facilitators to exercise maintenance were identified, which will inform the development of future behavior change interventions to support exercise participation and maintenance in older adults to mitigate adverse changes in body composition and physical and cognitive function with advancing age. J Am Geriatr Soc 68:163-169, 2019.",2020,"At 1 year follow-up, body fat increased (mean = 4.3%; 95% confidence limit = 2.2% to 6.3%), while lean body mass (mean = -0.6%; 95% confidence limit = -1.2% to -0.1%), strength (leg press, mean = -5.6%; 95% confidence limit = -8.3% to -2.8%; chest press, mean = -11.0%; 95% confidence limit = -14.8% to -7.8%), and cognitive function (mean = -3.7%; 95% confidence limit = -5.7% to -1.8%) declined (all P < .05).","['12 participants (male/female ratio = 6:6) using the Theoretical Domains Framework to inform the interview guide', 'older adults', 'Older Adults 1 Year', 'Fifty-three participants (male/female ratio = 30:23; age = 70.8\u2009±\u20093.9\u2009years', 'Community-dwelling older Irish adults (aged >65\u2009years) who had completed 12\u2009weeks of']","['Supervised Training Intervention', 'Exercise Maintenance', 'supervised exercise training intervention', 'supervised exercise training 1 year previously', 'exercise training intervention']","['body fat', 'key facilitators (social aspects and beliefs about benefits of exercise) and barriers (affordability and general aversion to gyms', 'cognitive function', 'physical and cognitive function', 'lean body mass']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0700287', 'cui_str': 'Informing (procedure)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0422794', 'cui_str': 'Irish (NMO) (ethnic group)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0814630', 'cui_str': 'Affordabilities'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0233496', 'cui_str': 'Aversion (finding)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}]",53.0,0.0253965,"At 1 year follow-up, body fat increased (mean = 4.3%; 95% confidence limit = 2.2% to 6.3%), while lean body mass (mean = -0.6%; 95% confidence limit = -1.2% to -0.1%), strength (leg press, mean = -5.6%; 95% confidence limit = -8.3% to -2.8%; chest press, mean = -11.0%; 95% confidence limit = -14.8% to -7.8%), and cognitive function (mean = -3.7%; 95% confidence limit = -5.7% to -1.8%) declined (all P < .05).","[{'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Timmons', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Griffin', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Karl E', 'Initials': 'KE', 'LastName': 'Cogan', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Matthews', 'Affiliation': 'School of Public Health, Physiotherapy and Sports Science, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Brendan', 'Initials': 'B', 'LastName': 'Egan', 'Affiliation': 'School of Health and Human Performance, Dublin City University, Dublin, Ireland.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16209'] 1151,29952869,Physiological Adaptations to High-Intensity Interval and Continuous Training in Kayak Athletes.,"Papandreou, A, Philippou, A, Zacharogiannis, E, and Maridaki, M. Physiological adaptations to high-intensity interval and continuous training in kayak athletes. J Strength Cond Res 34(8): 2258-2266, 2020-High-intensity interval training (HIIT) seems to be more effective than continuous training (CT) for the improvement of physical condition and sports performance. This study compared physiological adaptations with HIIT and CT in flat water kayak athletes. Twenty-four national-class kayakists were divided into 3 groups (n = 8 per group), 2 of which participated in an 8-week CT or HIIT program, whereas the third one served as control (C). An incremental maximum oxygen uptake (V[Combining Dot Above]O2max), a maximal anaerobic Wingate-type, as well as 1,000-m (T1,000 m) and 200-m (T200 m) time test were performed before and after the training period on a kayak ergometer, to determine changes in V[Combining Dot Above]O2max, peak blood lactate ([La]peak), paddling speed at V[Combining Dot Above]O2max ((Equation is included in full-text article.)), heart rate at V[Combining Dot Above]O2max (HRpeak), paddling economy speed (PEs; speed at 75% of V[Combining Dot Above]O2max), paddling speed at anaerobic ventilatory threshold (PSVT2), maximal paddling speed (PSpeak), and reduction of PSpeak (PSR). V[Combining Dot Above]O2max, [La]peak, HRpeak, and PSR did not change after the 8-week training compared with baseline in either training group (p > 0.05). However, significant changes were found in PSVT2 and T200 m (HIIT), (Equation is included in full-text article.), PEs, PSpeak, and T1,000 m (CT and HIIT) (p < 0.05-0.0001) as compared to baseline. Moreover, percent changes were different between the training groups in PEs, and between control and training groups in PSpeak and (Equation is included in full-text article.)(p < 0.05-0.01). Both training programs improved physiological and performance variables; however, HIIT resulted in significant changes of PSVT2 and T200 m and higher improvement of PEs with 15 times less training time compared with CT. Thus, HIIT seems more time-efficient than CT for improving paddling economy of kayaking performance.",2020,"However, significant changes were found in PSVT2 and T200 m (HIIT), PSVO2max, PEs, PSpeak, and T1,000 m (CT and HIIT) (p < 0.05-0.0001) as compared to baseline.","['Kayak Athletes', 'flat water kayak athletes', 'kayak athletes', 'Twenty-four national-class kayakists']","['continuous training (CT', 'Dot Above]O2max', 'V[Combining', 'HIIT and CT', 'CT']","['PSVO2max), heart rate at V[Combining', 'incremental maximum oxygen uptake ', 'Dot Above]O2max (HRpeak), paddling economy speed (PEs; speed', 'paddling speed at anaerobic ventilatory threshold (PSVT2), maximal paddling speed (PSpeak), and reduction of PSpeak (PSR', 'physiological and performance variables', 'PSVT2 and T200 m (HIIT), PSVO2max, PEs, PSpeak, and T1,000 m (CT and HIIT', 'Dot Above]O2max, peak blood lactate ([La]peak), paddling speed at V[Combining', 'PSVT2 and T200 m and higher improvement of PEs', 'Dot Above]O2max, [La]peak, HRpeak, and PSR']","[{'cui': 'C4316800', 'cui_str': 'Kayaking'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205324', 'cui_str': 'Flat (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C3715070', 'cui_str': '24 (qualifier value)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0429693', 'cui_str': 'Maximum oxygen uptake (observable entity)'}, {'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",,0.0132211,"However, significant changes were found in PSVT2 and T200 m (HIIT), PSVO2max, PEs, PSpeak, and T1,000 m (CT and HIIT) (p < 0.05-0.0001) as compared to baseline.","[{'ForeName': 'Apostolos', 'Initials': 'A', 'LastName': 'Papandreou', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Anastassios', 'Initials': 'A', 'LastName': 'Philippou', 'Affiliation': 'Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Zacharogiannis', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Maridaki', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002710'] 1152,31641913,Effects of quadratus lumborum block regional anesthesia on postoperative pain after colorectal resection: a randomized controlled trial.,"INTRODUCTION Postoperative pain following colorectal surgery is associated with a significant use of opioids. Recently, regional anesthesia, such as the posterior quadratus lumborum block (QL2), has been proposed to improve pain relief and reduce opioid use. However, the benefit of the QL2 on postoperative pain control remains controversial. METHODS We conducted a randomized controlled trial of patients undergoing colorectal surgery at the CHU de Québec-Université Laval. Patients were randomized to regional QL2 anesthesia with 150 mg of ropivacaine combined with standard analgesia or to QL2 with a sham intervention and standard analgesia. Our primary outcome was postoperative opioid administration at 24 h. Secondary outcomes included opioid administration in the post-anesthesia care unit (PACU), at 48 h and at hospital discharge, postoperative pain scores, delay in resumption of intestinal transit, nausea and vomiting, and hospital length of stay. RESULTS A total of 62 patients were enrolled from November 2017 to February 2018. QL2 regional anesthesia compared with a sham intervention was not associated with a reduction in postoperative morphine dose equivalent (100.2 mg, 95% CI 68.9-131.5 versus 88.7 mg, 95% CI 59.3-118.0, p = 0.81, respectively). Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points. Other secondary outcomes were comparable between both groups. CONCLUSION We did not observe a reduction in postoperative opioid administration at 24 h with a posterior quadratus lumborum block regional anesthesia in patients undergoing elective colorectal surgery.",2020,"Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points.","['62 patients were enrolled from November 2017 to February 2018', 'patients undergoing colorectal surgery at the CHU de Québec-Université Laval', 'patients undergoing elective colorectal surgery', 'after colorectal resection']","['posterior quadratus lumborum block regional anesthesia', 'quadratus lumborum block regional anesthesia', 'regional QL2 anesthesia with 150\xa0mg of ropivacaine combined with standard analgesia or to QL2 with a sham intervention and standard analgesia', 'QL2']","['postoperative pain', 'QL2 regional anesthesia', 'postoperative opioid administration', 'QL2 regional anesthesia, postoperative pain scores', 'pain relief', 'opioid administration in the post-anesthesia care unit (PACU), at 48\xa0h and at hospital discharge, postoperative pain scores, delay in resumption of intestinal transit, nausea and vomiting, and hospital length of stay']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009369', 'cui_str': 'Colon and Rectal Surgery Specialty'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}, {'cui': 'C0555952', 'cui_str': 'Colorectal (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}]","[{'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",,0.245417,"Compared to QL2 regional anesthesia, postoperative pain scores in the control group were lower although statistical significance was not consistent for all postoperative time points.","[{'ForeName': 'Mélissa', 'Initials': 'M', 'LastName': 'Boulianne', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada. melissa.boulianne.1@ulaval.ca.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Paquet', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Veilleux', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Drolet', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Meunier', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Frigault', 'Affiliation': 'Department of Surgery, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Simonyan', 'Affiliation': 'CHU de Québec - Université Laval Research Centre, Clinical and Evaluative Research Platform, Québec City, QC, Canada.'}, {'ForeName': 'Alexis F', 'Initials': 'AF', 'LastName': 'Turgeon', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine, Université Laval, Québec City, QC, Canada.'}]",Surgical endoscopy,['10.1007/s00464-019-07184-0'] 1153,29781936,Influence of Adding Single-Joint Exercise to a Multijoint Resistance Training Program in Untrained Young Women.,"Barbalho, M, Gentil, P, Raiol, R, Fisher, J, Steele, J, and Coswig, V. Influence of adding single-joint exercise to a multijoint resistance training program in untrained young women. J Strength Cond Res 34(8): 2214-2219, 2020-The aim of the present study was to investigate the effects of adding single-joint (SJ) exercises to a multijoint (MJ) resistance training (RT) program on muscle strength and anthropometric measures of young women. Twenty untrained women were divided into a group that performed only MJ exercises or a group that performed both SJ and MJ exercises (MJ + SJ). Before and after 8 weeks of training, the participants were tested for 10 repetition maximum (10RM). Flexed arm circumference and triceps and biceps skinfold thickness were also measured. Both groups significantly decreased biceps (-3.60% for MJ and -3.55% for MJ + SJ) and triceps skinfold (-3.05% for MJ and -2.98% for MJ + SJ), with no significant difference between them. Flexed arm circumference significantly increased in both groups; however, increases in MJ + SJ (4.39%) were significantly greater than MJ (3.50%). Increases in 10RM load in elbow extension (28.2% for MJ and 28.0% for MJ + SJ), elbow flexion (29.8% for MJ and 28.7% for MJ + SJ), and knee extension (26.92% for MJ and 23.86% for MJ + SJ) were all significant and not different between groups. The results showed that adding SJ exercises to an MJ RT program resulted in no additional benefits in muscle performance, whilst differences in flexed arm circumference were small, but significant, in untrained women.",2020,"Both groups significantly decreased biceps (-3.60% for MJ and -3.55% for MJ + SJ) and triceps skinfold (-3.05% for MJ and -2.98% for MJ + SJ), with no significant difference between them.","['untrained young women', 'Twenty untrained women', 'untrained women', 'young women', 'Untrained Young Women']","['MJ exercises or a group that performed both SJ and MJ exercises (MJ + SJ', 'J Strength Cond Res XX(X', 'MJ RT program', 'Multijoint Resistance Training Program', 'single-joint (SJ) exercises to a multijoint (MJ) resistance training (RT) program', 'Single-Joint Exercise', 'SJ exercises']","['10RM load in elbow extension', 'muscle performance or anthropometric changes', 'muscle strength and anthropometric measures', 'knee extension', 'Flexed arm circumference and triceps and biceps skinfold thickness', 'MJ + SJ', 'Flexed arm circumference', 'Barbalho, M, Gentil, P, Raiol, R, Fisher, J, Steele, J, and Coswig, V. Influence of adding single-joint exercise', 'triceps skinfold', 'biceps', 'elbow flexion']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0022417', 'cui_str': 'Joints'}]","[{'cui': 'C0013769', 'cui_str': 'Elbow'}, {'cui': 'C0231448', 'cui_str': 'Extension (qualifier value)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0037302', 'cui_str': 'Skinfold Thickness'}, {'cui': 'C0325045', 'cui_str': 'Martes pennanti (organism)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0231452', 'cui_str': 'Flexion, function (observable entity)'}]",20.0,0.0160546,"Both groups significantly decreased biceps (-3.60% for MJ and -3.55% for MJ + SJ) and triceps skinfold (-3.05% for MJ and -2.98% for MJ + SJ), with no significant difference between them.","[{'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Barbalho', 'Affiliation': 'Center for Biological and Health Sciences, University of the Amazon, Belém, Pará, Brazil.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Gentil', 'Affiliation': 'College of Physical Education and Dance, Federal University of Goiás, Goiânia, Goiás, Brazil.'}, {'ForeName': 'Rodolfo', 'Initials': 'R', 'LastName': 'Raiol', 'Affiliation': 'Group of Studies in Physical and Sports Training - GET, Federal University of Pará, Castanhal, Pará, Brazil.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Fisher', 'Affiliation': 'Center for Health, Exercise and Sport Science, Southampton Solent University, Southampton, United Kingdom.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Steele', 'Affiliation': 'Center for Health, Exercise and Sport Science, Southampton Solent University, Southampton, United Kingdom.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Coswig', 'Affiliation': 'Group of Studies in Physical and Sports Training - GET, Federal University of Pará, Castanhal, Pará, Brazil.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002624'] 1154,31634870,Investigations of Silymarine Effects on Prognosis of Patients With Severe and Moderate Traumatic Brain Injury.,"Objective The purpose of this study was to evaluate Silymarine effects on prognosis of patients with severe and moderate traumatic brain injury. Study Design This double blind, placebo-controlled clinical trial. Setting Valiasr hospital hospital in Arak, Iran. Subjects and Methods Research was performed among patients between 15 and 65 years of age with severe moderate (Glasgow Coma Scale score 9 to 12) and moderate (GCS 3 to 8) traumatic brain injury (TBI). Patients were divided into two groups (Each group: 40 patients). Patients assigned to the control groupwere receiving all standard treatments. Patients in case groups were administered 140 mg of silymarin every 8 hours for 7 days. We Checked the Glasgow Outcome Scale (GOS), GCS, age, gender, location, mechanism of trauma, site of accident and the incidence time of accident to arrival at emergency unite. Statistical analysis was conducted using SPSS (SPSS version 18; Chicago, IL). Results Our findings suggested that there was no a significant difference between intervention group and control in terms of parameters as GOS, GCS, age, gender, location, mechanism of trauma, and site of accident and the incidence time of accident to arrival at emergency unite (P > .05). Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. Conclusions Silymarin did not reveal a significant effect for improving prognosis of patients with moderate and severe TBI.",2020,"Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. ","['patients between 15 and 65 years of age with severe moderate (Glasgow Coma Scale score 9 to 12) and moderate (GCS 3 to 8) traumatic brain injury (TBI', 'Setting\n\n\nValiasr hospital hospital in Arak, Iran', 'Patients With Severe and Moderate Traumatic Brain Injury', 'patients with severe and moderate traumatic brain injury']","['placebo', 'Silymarine', 'silymarin']","['Glasgow Outcome Scale (GOS), GCS, age, gender, location, mechanism of trauma, site of accident and the incidence time of accident to arrival at emergency unite', 'GOS, GCS, age, gender, location, mechanism of trauma, and site of accident and the incidence time of accident to arrival at emergency unite']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0037135', 'cui_str': 'Silymarin'}]","[{'cui': 'C0701887', 'cui_str': 'Glasgow Outcome Scale'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms (qualifier value)'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C1961149', 'cui_str': 'Accidental physical contact (event)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0175673', 'cui_str': 'Emergency (qualifier value)'}]",,0.096076,"Brain CT in two groups showed a significant difference (P = .002), where in the silymarin group there were more normal cases when comparing with control group. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Nazemi Rafi', 'Affiliation': ''}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Jafari', 'Affiliation': ''}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Solhi', 'Affiliation': ''}, {'ForeName': 'Jila', 'Initials': 'J', 'LastName': 'Mohseni', 'Affiliation': ''}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Kamali', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 1155,31608934,Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease.,"CONTEXT The insulin-stimulating and glucagon-regulating effects of the 2 incretin hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), contribute to maintain normal glucose homeostasis. Impaired glucose tolerance occurs with high prevalence among patients with end-stage renal disease (ESRD). OBJECTIVE To evaluate the effect of the incretin hormones on endocrine pancreatic function in patients with ESRD. DESIGN AND SETTING Twelve ESRD patients on chronic hemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included. On 3 separate days, a 2-hour euglycemic clamp followed by a 2-hour hyperglycemic clamp (3 mM above fasting level) was performed with concomitant infusion of GLP-1 (1 pmol/kg/min), GIP (2 pmol/kg/min), or saline administered in a randomized, double-blinded fashion. A 30% lower infusion rate was used in the ESRD group to obtain comparable incretin hormone plasma levels. RESULTS During clamps, comparable plasma glucose and intact incretin hormone concentrations were achieved. The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (50 [8-72]%, P = 0.03). Similarly, the effect of GIP relative to placebo levels tended to be lower during euglycemia in ESRD and was significantly reduced during hyperglycemia (34 [13-50]%, P = 0.005). Glucagon was suppressed in both groups, with controls reaching lower concentrations than ESRD patients. CONCLUSIONS The effect of incretin hormones to increase insulin release is reduced in ESRD, which, together with elevated glucagon levels, could contribute to the high prevalence of impaired glucose tolerance among ESRD patients.",2020,"The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (50 [8-72]%, P=0.03).","['end-stage renal disease', 'patients with ESRD', 'and Setting: Twelve ESRD patients on chronic haemodialysis and 12 matched healthy controls, all with normal oral glucose tolerance test, were included', 'patients with end-stage renal disease (ESRD']","['GIP (2 pmol/kg/min) or saline', 'incretin hormones', 'euglycaemic clamp followed by a 2 h hyperglycaemic clamp']","['plasma glucose and intact incretin hormone concentrations', 'hyperglycaemia', 'Glucagon', 'Impaired glucose tolerance (IGT', 'endocrine pancreatic function']","[{'cui': 'C0022661', 'cui_str': 'End-Stage Kidney Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C1740835', 'cui_str': 'Chronic haemodialysis'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1702020', 'cui_str': '37-epsilon-palmitoyl-Lys-GIP'}, {'cui': 'C0439192', 'cui_str': 'pmol'}, {'cui': 'C1532757', 'cui_str': 'kg/min'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1562292', 'cui_str': 'Glucose-Dependent Insulin-Releasing Hormone'}, {'cui': 'C0079318', 'cui_str': 'Glucose Clamp'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0011744', 'cui_str': 'Hydrogen-2'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}]","[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C1562292', 'cui_str': 'Glucose-Dependent Insulin-Releasing Hormone'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0876232', 'cui_str': 'glucagon recombinant'}, {'cui': 'C0271650', 'cui_str': 'Glucose Intolerance'}, {'cui': 'C0232786', 'cui_str': 'Pancreatic function'}]",,0.0990271,"The effect of GLP-1 to increase insulin concentrations relative to placebo levels tended to be lower during euglycaemia in ESRD and was significantly reduced during hyperglycaemia (50 [8-72]%, P=0.03).","[{'ForeName': 'Morten B', 'Initials': 'MB', 'LastName': 'Jørgensen', 'Affiliation': 'Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Idorn', 'Affiliation': 'Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Casper', 'Initials': 'C', 'LastName': 'Rydahl', 'Affiliation': 'Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Henrik P', 'Initials': 'HP', 'LastName': 'Hansen', 'Affiliation': 'Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Bressendorff', 'Affiliation': 'Department of Cardiology, Endocrinology and Nephrology, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.'}, {'ForeName': 'Lisbet', 'Initials': 'L', 'LastName': 'Brandi', 'Affiliation': 'Department of Cardiology, Endocrinology and Nephrology, Nordsjællands Hospital, University of Copenhagen, Hillerød, Denmark.'}, {'ForeName': 'Nicolai J', 'Initials': 'NJ', 'LastName': 'Wewer Albrechtsen', 'Affiliation': 'Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Gerrit', 'Initials': 'G', 'LastName': 'van Hall', 'Affiliation': 'Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mads', 'Initials': 'M', 'LastName': 'Hornum', 'Affiliation': 'Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Feldt-Rasmussen', 'Affiliation': 'Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz048'] 1156,31628860,Nonsteroidal anti-inflammatory drugs for assisted reproductive technology.,"BACKGROUND Despite substantial improvements in the success of treatments through assisted reproduction technologies (ART), live birth rates remain constantly low, and practitioners are seeking aetiologic treatments to improve the outcomes.Local inflammatory response is believed to contribute to implantation failure, where prostaglandins may increase uterine contractions and decrease uterine receptivity, decreasing the possibility of an IVF cycle leading to successful embryo transfer. In this context, nonsteroidal anti-inflammatory drugs (NSAIDs) have been employed to inhibit the negative prostaglandin effect. They are often offered in clinical practice to improve ART outcomes, but current robust evidence on their efficacy is lacking. OBJECTIVES To evaluate the effectiveness and safety of nonsteroidal anti-inflammatory drugs as co-treatments in infertile women undergoing assisted reproduction, in terms of improving live birth and miscarriage rates. SEARCH METHODS We designed the search using standard Cochrane methods and performed it on databases from their inception to 20 February 2019.We searched the Cochrane Gynaecology and Fertility Group Specialised Register of controlled trials, CENTRAL via the Cochrane Central Register of Studies Online, MEDLINE, Embase, CINAHL, and the trial registers for ongoing and registered trials, grey literature and treatment guidelines. We handsearched reference lists of relevant systematic reviews and RCTs, and PubMed and Google for any recent trials. There were no restrictions by language or country of origin. SELECTION CRITERIA All RCTs on the use of NSAIDs as co-treatment during an ART cycle compared with no use or the use of placebo or any other similar drug, along with the comparison of any NSAID to another. DATA COLLECTION AND ANALYSIS We used standard methodological procedures recommended by Cochrane. Our primary outcomes were live birth/ongoing pregnancy and miscarriage. We performed statistical analysis using Review Manager 5. We assessed evidence quality using GRADE methods. MAIN RESULTS We found 11 RCTs (1884 women) suitable for inclusion in the review. Most studies were at unclear or high risk of bias. The main limitations in the overall quality of the evidence were high risk of bias, unexplained heterogeneity and serious imprecision and indirectness.There were no data on our primary outcome - live birth per woman randomised - in any review comparisons.NSAIDs vs. placebo/no treatmentWe are uncertain of an effect on ongoing pregnancy when NSAIDs were compared to placebo/no treatment (risk ratio (RR) 1.06, 95% confidence interval (CI) 0.71 to 1.59; 4 studies, 1159 participants; I² = 53%; very low quality evidence). Results suggest that if the chance of ongoing pregnancy following placebo or no treatment is assumed to be 15%, the chance following the use of NSAIDs is estimated to be between 12% and 24%. Subgroup analysis according to the type of NSAID yielded similar results.We are also uncertain of an effect on miscarriage rates when NSAIDs were compared to placebo/no treatment (RR 0.62, 95% CI 0.33 to 1.16; 4 studies, 525 participants; I² = 43%; very low quality evidence). Results suggest that if the chance of miscarriage following placebo or no treatment is assumed to be 21%, the chance following the use of NSAIDs is estimated to be between 7% and 27%. The results were similar when two studies were excluded due to high risk of bias.Concerning the secondary outcomes, we are uncertain of an effect on clinical pregnancy rates (RR 1.23, 95% CI 1.00 to 1.52; 6 studies, 1570 participants; I² = 49%; low-quality evidence); on ectopic pregnancy (RR 0.56, 95% CI 0.05 to 5.89; 1 study, 72 participants); on multiple pregnancy (RR 2.00, 95% CI 0.18 to 21.67; 1 study, 180 participants); and on side effects (RR 1.39, 95% CI 0.02 to 119.35; 3 studies, 418 participants; I² = 79%). The evidence suggests that if the chance of clinical pregnancy following placebo or no treatment is assumed to be 30%, the chance following the use of NSAIDs is estimated to be between 31% and 45%. If the chance of ectopic pregnancy following placebo or no treatment is assumed to be 5%, the chance following the use of NSAIDs is estimated to be between 0.3% and 31%. If the chance of multiple pregnancy following placebo or no treatment is assumed to be 1%, the chance following the use of NSAIDs is estimated to be between 0.2 % and 24%.There were no cases of congenital anomalies during antenatal ultrasound screening of the women in one study.NSAID vs. another NSAIDOnly one study compared piroxicam with indomethacin: we are uncertain of an effect on ongoing pregnancy (RR 1.12, 95% CI 0.63 to 2.00; 1 study, 170 participants; very low quality evidence); and on miscarriage (RR 1.00, 95% CI 0.44 to 2.28; 1 study, 170 participants; very low quality evidence). The evidence suggests that if the chance of ongoing pregnancy following indomethacin is assumed to be 20%, the chance following the use of piroxicam is estimated to be between 13% and 40%; while for miscarriage, the evidence suggests that if the chance following indomethacin is assumed to be 12%, the chance following the use of piroxicam is estimated to be between 5% and 27%.Similar results were reported for clinical pregnancy (RR 1.07, 95% CI 0.71 to 1.63; 1 study, 170 participants; very low quality evidence).There were no data for the other outcomes specified in this review.NSAID vs. aspirinNo study reported this comparison. AUTHORS' CONCLUSIONS Currently we are uncertain of an effect of the routine use of NSAIDs as co-treatments in infertile women undergoing assisted reproduction in order to improve ongoing pregnancy and miscarriage rates. This is based on available data from RCTs, where very low quality evidence showed that there is no single outcome measure demonstrating a benefit with their use. Further large, well-designed randomised placebo-controlled trials reporting on live births are required to clarify the exact role of NSAIDs.",2019,": we are uncertain of an effect on ongoing pregnancy (RR 1.12, 95% CI 0.63 to 2.00; 1 study, 170 participants; very low quality evidence); and on miscarriage (RR 1.00, 95% CI 0.44 to 2.28; 1 study, 170 participants; very low quality evidence).","['11 RCTs (1884 women) suitable for inclusion in the review', 'infertile women undergoing assisted reproduction']","['Nonsteroidal anti-inflammatory drugs', 'piroxicam', 'nonsteroidal anti-inflammatory drugs', 'placebo', 'indomethacin', 'NSAIDs vs. placebo']","['clinical pregnancy', 'clinical pregnancy rates', 'side effects', 'live birth/ongoing pregnancy and miscarriage', 'live birth and miscarriage rates', 'effectiveness and safety', 'multiple pregnancy', 'ectopic pregnancy', 'miscarriage rates']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0031990', 'cui_str': 'Piroxicam'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0021246', 'cui_str': 'Indomethacin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0000786', 'cui_str': 'Vaginal expulsion of product of conception'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032989', 'cui_str': 'Multiple Pregnancy'}, {'cui': 'C0032987', 'cui_str': 'Ectopic Pregnancy'}]",525.0,0.454739,": we are uncertain of an effect on ongoing pregnancy (RR 1.12, 95% CI 0.63 to 2.00; 1 study, 170 participants; very low quality evidence); and on miscarriage (RR 1.00, 95% CI 0.44 to 2.28; 1 study, 170 participants; very low quality evidence).","[{'ForeName': 'Atunga', 'Initials': 'A', 'LastName': 'Nyachieo', 'Affiliation': 'Reproductive health and Biology, Institute of Primate Research, POBox 24481-00502, Karen, Nairobi, Kenya.'}, {'ForeName': 'Charalampos S', 'Initials': 'CS', 'LastName': 'Siristatidis', 'Affiliation': ''}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Vaidakis', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD007618.pub2'] 1157,31257642,Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents' perspective.,"AIM Remote monitoring with continuous glucose monitoring (CGM) in children with Type 1 diabetes mellitus has recently become available, but little is known about caregivers' experiences of its use, particularly in younger children. The aim of this study was to explore parents' everyday experiences of using this technology. METHODS The parents of children with Type 1 diabetes diagnosed for > 1 year, aged 2-12 years were invited to participate in a semi-structured interview. Interviews were the second phase of a randomized cross-over study using standard insulin therapy with or without CGM and remote monitoring for two 3-month periods. Open-ended questions were used to explore parents' real-life experiences of the remote monitoring and CGM system. Interviews were analysed using thematic analysis. RESULTS Five themes related to remote monitoring emerged: (i) impact on sleep quality for the parents, (ii) peace of mind, (iii) impact on anxiety, (iv) freedom and confidence for the parents and children, and (v) impact on relationships. Furthermore, parents reported on themes related to CGM in general, such as better understanding of how to manage and control their child's diabetes and experiences related to physical or technical aspects. CONCLUSION Overall, parents of primary school children reported that using remote monitoring and CGM was a mostly beneficial experience. However, negative aspects within the themes were also reported. These findings will help to provide a structure to discuss parent and child expectations and provide targeted education at the start of using remote monitoring and CGM.",2019,"RESULTS Five themes related to remote monitoring emerged: (i) impact on sleep quality for the parents, (ii) peace of mind, (iii) impact on anxiety, (iv) freedom and confidence for the parents and children, and (v) impact on relationships.","['young children with Type 1 diabetes', 'parents of children with Type 1 diabetes diagnosed for >\xa01 year, aged 2-12\xa0years', 'children with Type 1 diabetes mellitus']","['remote monitoring with continuous glucose monitoring', 'standard insulin therapy with or without CGM', 'continuous glucose monitoring (CGM']","['sleep quality for the parents, (ii) peace of mind, (iii) impact on anxiety, (iv) freedom and confidence']","[{'cui': 'C0337547', 'cui_str': 'Younger child (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C4523945', 'cui_str': 'Continuous glucose monitoring'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0237529', 'cui_str': 'Self Confidence'}]",,0.0121364,"RESULTS Five themes related to remote monitoring emerged: (i) impact on sleep quality for the parents, (ii) peace of mind, (iii) impact on anxiety, (iv) freedom and confidence for the parents and children, and (v) impact on relationships.","[{'ForeName': 'M-A', 'Initials': 'MA', 'LastName': 'Burckhardt', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Fried', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bebbington', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hancock', 'Affiliation': 'Division of Paediatrics, The University of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Nicholas', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Roberts', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Abraham', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'E A', 'Initials': 'EA', 'LastName': 'Davis', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}, {'ForeName': 'T W', 'Initials': 'TW', 'LastName': 'Jones', 'Affiliation': ""Children's Diabetes Centre, Telethon Kids Institute, Perth, WA, Australia.""}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14061'] 1158,29382367,Effects of automated smartphone mobile recovery support and telephone continuing care in the treatment of alcohol use disorder: study protocol for a randomized controlled trial.,"BACKGROUND New smartphone communication technology provides a novel way to provide personalized continuing care support following alcohol treatment. One such system is the Addiction version of the Comprehensive Health Enhancement Support System (A-CHESS), which provides a range of automated functions that support patients. A-CHESS improved drinking outcomes over standard continuing care when provided to patients leaving inpatient treatment. Effective continuing care can also be delivered via telephone calls with a counselor. Telephone Monitoring and Counseling (TMC) has demonstrated efficacy in two randomized trials with alcohol-dependent patients. A-CHESS and TMC have complementary strengths. A-CHESS provides automated 24/7 recovery support services and frequent assessment of symptoms and status, but does not involve regular contact with a counselor. TMC provides regular and sustained contact with the same counselor, but no ongoing support between calls. The future of continuing care for alcohol use disorders is likely to involve automated mobile technology and counselor contact, but little is known about how best to integrate these services. METHODS/DESIGN To address this question, the study will feature a 2 × 2 design (A-CHESS for 12 months [yes/no] × TMC for 12 months [yes/no]), in which 280 alcohol-dependent patients in intensive outpatient programs (IOPs) will be randomized to one of the four conditions and followed for 18 months. We will determine whether adding TMC to A-CHESS produces fewer heavy drinking days than TMC or A-CHESS alone and test for TMC and A-CHESS main effects. We will determine the costs of each of the four conditions and the incremental cost-effectiveness of the three active conditions. Analyses will also examine secondary outcomes, including a biological measure of alcohol use, and hypothesized moderation and mediation effects. DISCUSSION The results of the study will yield important information on improving patient alcohol use outcomes by integrating mobile automated recovery support and counselor contact. TRIAL REGISTRATION ClinicalTrials.gov, NCT02681406 . Registered on 2 September 2016.",2018,"The future of continuing care for alcohol use disorders is likely to involve automated mobile technology and counselor contact, but little is known about how best to integrate these services. ","['for 12\xa0months [yes/no]), in which 280 alcohol-dependent patients in intensive outpatient programs (IOPs']","['Telephone Monitoring and Counseling (TMC', 'TMC', 'automated smartphone mobile recovery support and telephone continuing care', 'no]\u2009×\u2009TMC']","['drinking outcomes', 'biological measure of alcohol use, and hypothesized moderation and mediation effects']","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1298907', 'cui_str': 'Yes'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0581116', 'cui_str': 'Dependent patient (finding)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol Drinking'}, {'cui': 'C0680727', 'cui_str': 'Negotiation'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.0589807,"The future of continuing care for alcohol use disorders is likely to involve automated mobile technology and counselor contact, but little is known about how best to integrate these services. ","[{'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'McKay', 'Affiliation': 'Center on Continuum of Care in Addictions, Perelman School of Medicine, University of Pennsylvania, Philadelphia VAMC, Philadelphia, PA, 19104, USA. jimrache@pennmedicine.upenn.edu.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Gustafson', 'Affiliation': 'Center for Health Enhancement System Studies, University of Wisconsin-Madison, Madison, WI, 53706, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Ivey', 'Affiliation': 'Center on Continuum of Care in Addictions, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'McTavish', 'Affiliation': 'Center for Health Enhancement System Studies, University of Wisconsin-Madison, Madison, WI, 53706, USA.'}, {'ForeName': 'Klaren', 'Initials': 'K', 'LastName': 'Pe-Romashko', 'Affiliation': 'Center for Health Enhancement System Studies, University of Wisconsin-Madison, Madison, WI, 53706, USA.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Curtis', 'Affiliation': 'Center on Continuum of Care in Addictions, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Oslin', 'Affiliation': 'Center for the Study of Addictions, Perelman School of Medicine, University of Pennsylvania, Philadelphia VAMC, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Polsky', 'Affiliation': 'Leonard Davis Institute of Health Economics and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Quanbeck', 'Affiliation': 'Department of Family Medicine & Community Health, and Center for Health Enhancement Systems Studies, University of Wisconsin-Madison, Madison, WI, 53706, USA.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Lynch', 'Affiliation': 'Center on Continuum of Care in Addictions, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}]",Trials,['10.1186/s13063-018-2466-1'] 1159,31886591,Effect of a pharmacist-led intervention on adherence among patients with a first-time prescription for a cardiovascular medicine: a randomized controlled trial in Norwegian pharmacies.,"OBJECTIVE To examine whether a pharmacist-led intervention improves medication adherence among patients who have filled a first-time prescription for a cardiovascular medicine. METHODS Design: Unblinded randomized controlled trial. SETTING 67 Norwegian pharmacies, October 2014-June 2015. PARTICIPANTS 1480 adults with a first-time prescription for a cardiovascular medicine. INTERVENTION Participants in the intervention group received two consultations with a pharmacist 1-2 and 3-5 weeks after filling the prescription. Participants in the control group received care according to usual practice. MAIN OUTCOME MEASURE The primary outcome was self-reported adherence as measured by the 8-item Morisky Medication Adherence Scale (MMAS-8), at 7 and 18 weeks after filling the prescription. Adherence from baseline to week 52 was estimated using data from the Norwegian Prescription Database (NPD). KEY FINDINGS Data from MMAS-8 showed that 91.3% of the patients in the intervention group were adherent after 7 weeks versus 86.8% in the control group (4.5% difference, 95% CI 0.8-8.2, P = 0.017). The corresponding proportions were 88.7% versus 83.7% after 18 weeks (5.0% difference, 95% CI 0.8-9.2, P = 0.021). NPD data (n = 1294) showed no significant difference in adherence after 52 weeks (95% CI -2.0 to 7.8, P = 0.24). However, adherence among statin users (n = 182) was 66.5% in the intervention group versus 57.4% among new statin users in the general population (n = 1500) (difference 9.1%, 95% CI 1.5-16.0, P = 0.019). CONCLUSION The main outcome measure indicates that a short, structured pharmacist-led intervention may increase medication adherence for patients starting on chronic cardiovascular medication. However, these findings could not be confirmed by the NPD data analysis.",2020,"(difference 9.1%, 95% CI 1.5-16.0, P = 0.019). ","['Design', '67 Norwegian pharmacies, October 2014-June 2015', 'patients who have filled a first-time prescription for a cardiovascular medicine', 'patients with a first-time prescription for a cardiovascular medicine', '1480 adults with a first-time prescription for a cardiovascular medicine']","['pharmacist-led intervention', 'care according to usual practice']","['adherence', 'medication adherence', 'self-reported adherence as measured by the 8-item Morisky Medication Adherence Scale (MMAS-8']","[{'cui': 'C0337812', 'cui_str': 'Norwegians (ethnic group)'}, {'cui': 'C0031322', 'cui_str': 'Pharmacies'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}]",1480.0,0.216021,"(difference 9.1%, 95% CI 1.5-16.0, P = 0.019). ","[{'ForeName': 'Ragnar', 'Initials': 'R', 'LastName': 'Hovland', 'Affiliation': 'Apokus, National Centre for Development of Pharmacy Practice, Oslo, Norway.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Bremer', 'Affiliation': 'Apokus, National Centre for Development of Pharmacy Practice, Oslo, Norway.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Frigaard', 'Affiliation': 'Apokus, National Centre for Development of Pharmacy Practice, Oslo, Norway.'}, {'ForeName': 'Solveig', 'Initials': 'S', 'LastName': 'Henjum', 'Affiliation': 'Norwegian Pharmacy Association, Oslo, Norway.'}, {'ForeName': 'Per Kristian', 'Initials': 'PK', 'LastName': 'Faksvåg', 'Affiliation': 'Norwegian Pharmacy Association, Oslo, Norway.'}, {'ForeName': 'Erik Magnus', 'Initials': 'EM', 'LastName': 'Saether', 'Affiliation': 'Oslo Economics, Oslo, Norway.'}, {'ForeName': 'Ivar Sønbø', 'Initials': 'IS', 'LastName': 'Kristiansen', 'Affiliation': 'Oslo Economics, Oslo, Norway.'}]",The International journal of pharmacy practice,['10.1111/ijpp.12598'] 1160,31502749,"Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).","AIMS The aim of this study was to compare the effect of gemigliptin, a dipeptidyl peptidase-4 inhibitor, and dapagliflozin, a sodium glucose co-transporter-2 inhibitor, on glycaemic variability in type 2 diabetes patients. MATERIALS AND METHODS In this randomized, blinded end point, multicentre clinical trial, we enrolled 71 patients with type 2 diabetes who were inadequately controlled with metformin alone or were drug naïve. The participants were randomized to receive gemigliptin 50 mg (n = 35) or dapagliflozin 10 mg (n = 36) daily for 12 weeks. Glycaemic variability was estimated by mean amplitude of glycaemic excursions (MAGE), standard deviation (SD) and coefficient of variation (CV) using a 6-day continuous glucose monitoring system. The primary efficacy endpoint was change in MAGE after 12 weeks compared to baseline. RESULTS Intergroup differences in baseline characteristics were not significant. The adjusted mean change (± standard error) in MAGE after 12 weeks in the gemigliptin and dapagliflozin groups was -27.2 ± 4.4 mg/dL and -7.9 ± 4.9 mg/dL, respectively. Between-group comparisons showed a significantly larger reduction in MAGE in the gemigliptin group (-19.2 mg/dL; 95% CI, -31.3 to -7.2; P = .002). Measures of SD and CV also showed a significantly larger reduction in the gemigliptin group. Average glycaemic control, estimated by HbA1c, fasting glucose and safety profiles, was comparable between the two groups. CONCLUSIONS Compared to dapagliflozin, gemigliptin significantly improved glycaemic variability, with similar glucose-lowering efficacy and safety profiles in patients with type 2 diabetes who were inadequately controlled with metformin alone or were drug naïve.",2020,"Average glycemic control estimated by HbA1c, and fasting glucose and safety profiles were comparable between the two groups. ","['type 2 diabetes patients', 'Type 2 Diabetes', 'patients with type 2 diabetes inadequately controlled with', '71 patients with type 2 diabetes inadequately controlled with metformin alone or who were drug naïve']","['gemigliptin 50 mg (n\xa0=\xa035) or dapagliflozin', 'gemigliptin, a dipeptidyl peptidase-4 inhibitor, and dapagliflozin, a sodium glucose co-transporter-2 inhibitor', 'metformin', 'Gemigliptin and Dapagliflozin', 'dapagliflozin, gemigliptin']","['glycemic variability', 'SD and CV', 'mean amplitude of glycemic excursions (MAGE), standard deviation (SD), and coefficient of variation (CV', 'change in MAGE', 'Glycemic variability', 'larger reduction in MAGE', 'Glycemic Variability', 'Average glycemic control estimated by HbA1c, and fasting glucose and safety profiles']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C3501981'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",71.0,0.0630842,"Average glycemic control estimated by HbA1c, and fasting glucose and safety profiles were comparable between the two groups. ","[{'ForeName': 'Soo Heon', 'Initials': 'SH', 'LastName': 'Kwak', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.'}, {'ForeName': 'You-Cheol', 'Initials': 'YC', 'LastName': 'Hwang', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.'}, {'ForeName': 'Jong Chul', 'Initials': 'JC', 'LastName': 'Won', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Sanggye Paik Hospital, Cardiovascular and Metabolic Disease Center, Inje University School of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ji Cheol', 'Initials': 'JC', 'LastName': 'Bae', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.'}, {'ForeName': 'Hyun Jin', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Republic of Korea.'}, {'ForeName': 'Sunghwan', 'Initials': 'S', 'LastName': 'Suh', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Republic of Korea.'}, {'ForeName': 'Eun Young', 'Initials': 'EY', 'LastName': 'Lee', 'Affiliation': ""Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Subin', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Clinical Development Team, LG Chem, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-Yong', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Chosun University, Gwangju, Republic of Korea.'}, {'ForeName': 'Jae Hyeon', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13882'] 1161,29174323,"Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.","BACKGROUND Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in UK infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 schedule and to assess the potential effect on population protection. METHODS In this multicentre, parallel group, randomised controlled trial, we recuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations by information booklets mailed out via the NHS Child Health Information Service and the UK National Health Application and Infrastructure Services. Eligible infants were randomly assigned (1:1) to receive PCV13 at 2, 4, and 12 months (2 + 1 schedule) or 3 and 12 months of age (1 + 1 schedule) delivered with other routine vaccinations. Randomisation was done by computer-generated permuted block randomisation, with a block size of six. Participants and clinical trial staff were not masked to treatment allocation. The primary endpoint was serotype-specific immunoglobulin G concentrations values (geometric mean concentrations [GMC] in μg/mL) measured in blood samples collected at 13 months of age. Analysis was by modified intention to treat with all individuals included by randomised group if they had a laboratory result. This trial is registered on the EudraCT clinical trial database, number 2015-000817-32, and ClinicalTrials.gov, number NCT02482636. FINDINGS Between September, 2015, and June, 2016, 376 infants were assessed for eligibility. 81 infants were excluded for not meeting the inclusion criteria (n=50) or for other reasons (n=31). 213 eligible infants were enrolled and randomly allocated to group 1 (n=106; 2 + 1 schedule) or to group 2 (n=107; 1 + 1 schedule). In group 1, 91 serum samples were available for analysis 1 month after booster immunisation versus 86 in group 2. At month 13, post-booster, GMCs were equivalent between schedules for serotypes 3 (0·61 μg/mL in group 1 vs 0·62 μg/mL in group 2), 5 (1·74 μg/mL vs 2·11 μg/mL), 7F (3·98 μg/mL vs 3·36 μg/mL), 9V (2·34 μg/mL vs 2·50 μg/mL), and 19A (8·38 μg/mL vs 8·83 μg/mL). Infants given the 1 + 1 schedule had significantly greater immunogenicity post-booster than those given the 2 + 1 schedule for serotypes 1 (8·92 μg/mL vs 3·07 μg/mL), 4 (3·43 μg/mL vs 2·55 μg/mL), 14 (16·9 μg/mL vs 10·49 μg/mL), and 19F (14·76 μg/mL vs 11·12 μg/mL; adjusted p value range <0·001 to 0·047). The 2 + 1 schedule was superior for serotypes 6A, 6B, 18C and 23F (adjusted p value range <0·0001 to 0·017). In a predefined numerical subset of all of the infants recruited to the study (n=40 [20%]), functional serotype-specific antibody was similar between schedules. 26 serious adverse events were recorded in 21 (10%) infants across the study period; 18 (n=13) were in the 2 + 1 group and eight (n=8) in the 1 + 1 group. Only one serious adverse event, a high temperature and refusal to feed after the first vaccination visit in a child on the 2+1 schedule was considered related to vaccine. INTERPRETATION Our findings show that for nine of the 13 serotypes in PCV13, post-booster responses in infants primed with a single dose are equivalent or superior to those seen following the standard UK 2 + 1 schedule. Introducing a 1 + 1 schedule in countries with a mature PCV programme and established herd immunity is likely to maintain population control of vaccine-type pneumococcal disease. FUNDING NIHR and the Bill & Melinda Gates Foundation.",2018,"Infants given the 1 + 1 schedule had significantly greater immunogenicity post-booster than those given the 2 + 1 schedule for serotypes 1 (8·92 μg/mL vs 3·07 μg/mL), 4 (3·43 μg","['376 infants were assessed for eligibility', 'Eligible infants', 'UK infants', '81 infants were excluded for not meeting the inclusion criteria (n=50) or for other reasons (n=31', '213 eligible infants', 'Between September, 2015, and June, 2016', 'recuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations by information booklets mailed out via the NHS Child Health Information Service and the UK National Health Application and Infrastructure Services']","['PCV13', 'pneumococcal conjugate vaccine (PCV7']","['functional serotype-specific antibody', '26 serious adverse events', 'immunogenicity post-booster', 'serotype-specific immunoglobulin G concentrations values (geometric mean concentrations [GMC']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C1328526', 'cui_str': 'Primary immunization'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0439787', 'cui_str': 'Out (qualifier value)'}, {'cui': 'C0008078', 'cui_str': 'Childrens Health'}, {'cui': 'C0021425', 'cui_str': 'Information Services'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C1579319', 'cui_str': 'Streptococcus pneumoniae conjugate vaccine'}]","[{'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody (substance)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1697762', 'cui_str': 'Booster'}, {'cui': 'C0358334', 'cui_str': 'Specific immunoglobulins'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",213.0,0.406071,"Infants given the 1 + 1 schedule had significantly greater immunogenicity post-booster than those given the 2 + 1 schedule for serotypes 1 (8·92 μg/mL vs 3·07 μg/mL), 4 (3·43 μg","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Goldblatt', 'Affiliation': 'Immunobiology Unit, UCL Great Ormond Street Institute of Child Health, London, UK. Electronic address: d.goldblatt@ucl.ac.uk.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Southern', 'Affiliation': 'Immunisation Hepatitis and Blood Safety Department, Public Health England, Colindale, London UK.'}, {'ForeName': 'Nick J', 'Initials': 'NJ', 'LastName': 'Andrews', 'Affiliation': 'Statitstics, Modelling and Economics Department, Public Health England, Colindale, London UK.'}, {'ForeName': 'Polly', 'Initials': 'P', 'LastName': 'Burbidge', 'Affiliation': 'Immunobiology Unit, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Partington', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Roalfe', 'Affiliation': 'Immunobiology Unit, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Valente Pinto', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Vasilli', 'Initials': 'V', 'LastName': 'Thalasselis', 'Affiliation': 'Immunobiology Unit, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Plested', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'Richardson', 'Affiliation': 'Immunobiology Unit, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Snape', 'Affiliation': 'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Miller', 'Affiliation': 'Immunisation Hepatitis and Blood Safety Department, Public Health England, Colindale, London UK.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(17)30654-0'] 1162,29189583,Modeling Fitness Variable Responses to Training in Prepubescent Children.,"Alves, AR, Marta, C, Neiva, HP, Nunes, C, Izquierdo, M, and Marques, MC. Modeling fitness variable responses to training in prepubescent children. J Strength Cond Res 34(8): 2352-2359, 2020-The aim of this study was to determine strength and oxygen uptake (V[Combining Dot Above]O2max) performances according to different training program intervention design with 8-week duration in prepubescent children through a multiple linear regression models. Two hundred forty-five healthy prepubescent children (aged 10.9 ± 0.5 years) were randomly assigned to a specific training program (strength training only-S; aerobic training only-A; intrasession aerobic and strength training-AS; intrasession strength and aerobic training-SA; or concurrent training performed in different sessions-CT) or a control group (no training regimen-C). It was possible to develop indirect predictive models for each training method, by including each variable pretraining, body fat percentage and body mass index. The models provided explained 82% of variance in the V[Combining Dot Above]O2max, 98% in the 1 kg ball-throw, 96% in the 3 kg ball-throw, 92% in the countermovement jump, 93% in the standing long jump and 98% in the 20 m sprint performances. This novel approach to training evaluation and control aims to provide a tool to allow professionals to calculate changes with a high confidence level (CI 95%), to control gains and to choose the best training methodology to apply according to the defined purposes. The results of this study could be a great support to teachers, coaches, and professionals providing important tools to improve the efficacy and individualization of training.",2020,"The models provided explained 82% of variance in the VO2max, 98% in the 1kg ball-throw, 96% in the 3kg ball-throw, 92% in the counter-movement jump, 93% in the standing long jump and 98% in the 20m sprint performances.",['Two hundred and forty-five healthy prepubescent children (aged 10.9 ± 0.5 years'],['specific training program (strength training only - S; aerobic training only - A; intra-session aerobic and strength training - AS; intra-session strength and aerobic training - SA; or concurrent training performed in different sessions - CT) or a control group (no training regimen - C'],['strength and oxygen uptake (VO2max) performances'],"[{'cui': 'C4517661', 'cui_str': '245'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0429627', 'cui_str': 'Oxygen uptake (observable entity)'}]",245.0,0.0152703,"The models provided explained 82% of variance in the VO2max, 98% in the 1kg ball-throw, 96% in the 3kg ball-throw, 92% in the counter-movement jump, 93% in the standing long jump and 98% in the 20m sprint performances.","[{'ForeName': 'Ana R', 'Initials': 'AR', 'LastName': 'Alves', 'Affiliation': 'Department of Sport Sciences, University of Beira Interior, Covilhã, Portugal.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Marta', 'Affiliation': 'Department of Sport Sciences, Guarda Polytechnique Institute, Guarda, Portugal.'}, {'ForeName': 'Henrique P', 'Initials': 'HP', 'LastName': 'Neiva', 'Affiliation': 'Department of Sport Sciences, University of Beira Interior, Covilhã, Portugal.'}, {'ForeName': 'Célia', 'Initials': 'C', 'LastName': 'Nunes', 'Affiliation': 'Department of Mathematics, University of Beira Interior, Covilhã, Portugal.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Department of Health Sciences, Public University of Navarre, Navarre, Spain.'}, {'ForeName': 'Mário C', 'Initials': 'MC', 'LastName': 'Marques', 'Affiliation': 'Department of Sport Sciences, University of Beira Interior, Covilhã, Portugal.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002201'] 1163,31489188,"Postprandial amino acid, glucose and insulin responses among healthy adults after a single intake of Lemna minor in comparison with green peas: a randomised trial.","A high protein content combined with its enormous growth capacity make duckweed an interesting alternative protein source, but information about postprandial responses in humans is lacking. The present study aimed to assess the postprandial serum amino acid profile of Lemna minor in healthy adults in comparison with green peas. A secondary objective was to obtain insights regarding human safety. A total of twelve healthy volunteers participated in a randomised, cross-over trial. Subjects received two protein sources in randomised order with a 1-week washout period. After an overnight fast, subjects consumed L. minor or peas (equivalent to 20 g of protein). After a baseline sample, blood samples were taken 15, 30, 45, 60, 75, 90, 120, 150 and 180 min after consumption to assess amino acid, glucose and insulin levels. Heart rate, blood pressure and aural temperature were measured before and after consumption, and subjects reported on gastrointestinal discomfort for four subsequent days. Compared with green peas, significantly lower blood concentrations of amino acids from L. minor were observed, indicating lower digestibility. L. minor consumption resulted in lower plasma glucose and insulin levels compared with peas, probably due to different glucose content. There were no significant differences concerning the assessed health parameters or the number of gastrointestinal complaints, indicating that a single bolus of L. minor - grown under controlled conditions - did not induce acute adverse effects in humans. Further studies need to investigate effects of repeated L. minor intake and whether proteins purified from L. minor can be digested more easily.",2019,"L. minor consumption resulted in lower plasma glucose and insulin levels compared with peas, probably due to different glucose content.","['healthy adults after a single intake of', 'twelve healthy volunteers', 'healthy adults in comparison with green peas']",[],"['plasma glucose and insulin levels', 'amino acid, glucose and insulin levels', 'Postprandial amino acid, glucose and insulin responses', 'blood concentrations of amino acids', 'Heart rate, blood pressure and aural temperature', 'gastrointestinal discomfort', 'acute adverse effects']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030738', 'cui_str': 'Peas'}]",[],"[{'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C3539946', 'cui_str': 'Amino acids'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C1313904', 'cui_str': 'Blood concentration, test strip measurement'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1532039', 'cui_str': 'Tympanic temperature'}, {'cui': 'C1096250', 'cui_str': 'Gastrointestinal discomfort'}, {'cui': 'C0001688', 'cui_str': 'side effects'}]",,0.0892596,"L. minor consumption resulted in lower plasma glucose and insulin levels compared with peas, probably due to different glucose content.","[{'ForeName': 'Gertrude G', 'Initials': 'GG', 'LastName': 'Zeinstra', 'Affiliation': 'Wageningen University and Research, Wageningen Food and Biobased Research, Food, Health & Consumer Research, Bornse Weilanden 9, 6708 WG Wageningen, The Netherlands.'}, {'ForeName': 'Dianne', 'Initials': 'D', 'LastName': 'Somhorst', 'Affiliation': 'Wageningen University and Research, Wageningen Food and Biobased Research, Food, Health & Consumer Research, Bornse Weilanden 9, 6708 WG Wageningen, The Netherlands.'}, {'ForeName': 'Els', 'Initials': 'E', 'LastName': 'Oosterink', 'Affiliation': 'Wageningen University and Research, Wageningen Food and Biobased Research, Food, Health & Consumer Research, Bornse Weilanden 9, 6708 WG Wageningen, The Netherlands.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Fick', 'Affiliation': 'Wageningen University and Research, Division of Human Nutrition & Health, Stippeneng 4, 6708 WE Wageningen, The Netherlands.'}, {'ForeName': 'Ineke', 'Initials': 'I', 'LastName': 'Klopping-Ketelaars', 'Affiliation': 'Wageningen University and Research, Division of Human Nutrition & Health, Stippeneng 4, 6708 WE Wageningen, The Netherlands.'}, {'ForeName': 'Ingrid M', 'Initials': 'IM', 'LastName': 'van der Meer', 'Affiliation': 'Wageningen University and Research, Wageningen Plant Research, Bioscience, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands.'}, {'ForeName': 'Jurriaan J', 'Initials': 'JJ', 'LastName': 'Mes', 'Affiliation': 'Wageningen University and Research, Wageningen Food and Biobased Research, Food, Health & Consumer Research, Bornse Weilanden 9, 6708 WG Wageningen, The Netherlands.'}]",Journal of nutritional science,['10.1017/jns.2019.26'] 1164,31594195,The application of the Neurac technique vs. manual therapy in patients during the acute phase of subacromial impingement syndrome: A randomized single-blinded controlled trial.,"BACKGROUD Although the effect of exercise in patients during the subacute and/or chronic subacromial impingement syndrome has been reported, only a few studies have examined the effect of pain free exercise in the acute phase of this disorder. OBJECTIVE To compare the effect of training using the Neurac technique which combines body segments suspension and vibration vs. manual therapy, on various relevant outcome parameters in patients with acute subacromial impingement syndrome (PASIS). METHOD Twenty-six patients underwent a 4 week intervention program. Using random assignment, half of the patients were treated using the Neurac device while the other half was treated using manual therapy. The outcome parameters consisted of shoulder pain, shoulder function, range of motion (ROM) and the isokinetic strength of the external and internal rotators at 60 and 180∘/s. RESULTS Following either modes of interventions, the pain, function, and ROM improved significantly compared to pre-intervention levels in both groups. Time-by-group interaction was observed for the rotational strength which increased significantly and exclusively in the Neurac group. CONCLUSIONS Given its positive effect on shoulder pain, function, ROM and the isokinetic strength of the external and internal rotators, we recommend the application of the Neurac technique in PASIS.",2020,"The outcome parameters consisted of shoulder pain, shoulder function, range of motion (ROM) and the isokinetic strength of the external and internal rotators at 60 and 180∘/s. ","['patients during the acute phase of subacromial impingement syndrome', 'patients during the subacute and/or chronic subacromial impingement syndrome', 'patients with acute subacromial impingement syndrome (PASIS', 'Twenty-six patients underwent a 4 week intervention program']","['Neurac technique vs. manual therapy', 'training using the Neurac technique which combines body segments suspension and vibration vs. manual therapy']","['shoulder pain, function, ROM and the isokinetic strength of the external and internal rotators', 'shoulder pain, shoulder function, range of motion (ROM) and the isokinetic strength of the external and internal rotators at 60 and 180∘/s', 'rotational strength', 'pain, function, and ROM']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439557', 'cui_str': 'Acute phase (qualifier value)'}, {'cui': 'C4255192', 'cui_str': 'Coracohumeral Impingement'}, {'cui': 'C0205365', 'cui_str': 'Subacute course'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0454525', 'cui_str': 'Manual Therapies'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C0459800', 'cui_str': 'Vibration'}]","[{'cui': 'C0037011', 'cui_str': 'Shoulder Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0080078', 'cui_str': 'Range of Motion'}, {'cui': 'C0445237', 'cui_str': 'Rotational (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0271859,"The outcome parameters consisted of shoulder pain, shoulder function, range of motion (ROM) and the isokinetic strength of the external and internal rotators at 60 and 180∘/s. ","[{'ForeName': 'Soo-Yong', 'Initials': 'SY', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Pusan National University Yangsan Hospital, Yangsan, Gyeongsangsam-do, Korea.'}, {'ForeName': 'Zeevi', 'Initials': 'Z', 'LastName': 'Dvir', 'Affiliation': 'Department of Physical Therapy, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Jae-Seop', 'Initials': 'JS', 'LastName': 'Oh', 'Affiliation': 'Department of Physical Therapy, College of Biomedical Science and Engineering, Inje University, Gimhae, Korea.'}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-170884'] 1165,31594198,The effect of neuromuscular electrical stimulation with different electrode positions on swallowing in stroke patients with oropharyngeal dysphagia: A randomized trial.,"OBJECTIVE To examine the effects of neuromuscular electrical stimulation (NMES) on oropharyngeal swallowing function according to 2 types of placement, acting as assistance and as resistance, in stroke patients with dysphagia. METHODS Thirty-eight stroke patients with dysphasia were randomly assigned to the suprahyoid group (SMG), or infrahyoid muscle group (IMG); 26 patients completed the intervention and were included in the analysis. In the SMG, the electrodes were placed on the region between the jaw and the hyoid bone, whereas in the IMG, the electrodes were placed on the region below the hyoid for the targeted infrahyoid muscles. Both groups received NMES for 30 min/d, 5 d/wk, for 4 weeks and conventional dysphagia therapy. Swallowing function was measured using the Videofluoroscopic Dysphagia Scale and Penetration-Aspiration Scale based on videofluoroscopic swallowing study. Oral dietary intake was measured using the Functional Oral Intake Scale. RESULTS Both groups showed significant improvements in oropharyngeal function and level of functional oral intake, but there was no significant difference between the two groups. However, the SMG showed a more reduced penetration-aspiration, compared with the IMG. CONCLUSIONS Altogether, these data demonstrate that 2 types of NMES placements have a similar effect on improving swallowing function and oral diet intake in patients with dysphagia.",2020,"Both groups showed significant improvements in oropharyngeal function and level of functional oral intake, but there was no significant difference between the two groups.","['stroke patients with oropharyngeal dysphagia', 'patients with dysphagia', '26 patients completed the intervention and were included in the analysis', 'Thirty-eight stroke patients with dysphasia', 'stroke patients with dysphagia']","['NMES', 'neuromuscular electrical stimulation with different electrode positions', 'suprahyoid group (SMG), or infrahyoid muscle group (IMG', 'neuromuscular electrical stimulation (NMES', 'conventional dysphagia therapy']","['oropharyngeal swallowing function', 'oropharyngeal function and level of functional oral intake', 'Videofluoroscopic Dysphagia scale and Penetration-Aspiration scale', 'Swallowing function', 'Functional Oral Intake Scale', 'swallowing function and oral diet intake', 'Oral dietary intake', 'reduced penetration-aspiration']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0267071', 'cui_str': 'Oropharyngeal Dysphagia'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C0973461', 'cui_str': 'Dysphasia'}]","[{'cui': 'C0013786', 'cui_str': 'Electrical Stimulation'}, {'cui': 'C0013812', 'cui_str': 'Electrode, device (physical object)'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0224161', 'cui_str': 'Structure of infrahyoid muscle'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1522409', 'cui_str': 'Oropharyngeal route (qualifier value)'}, {'cui': 'C0326374', 'cui_str': 'Swallows'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0222045'}, {'cui': 'C0349707', 'cui_str': 'Aspiration - action (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",,0.0333356,"Both groups showed significant improvements in oropharyngeal function and level of functional oral intake, but there was no significant difference between the two groups.","[{'ForeName': 'Dong-Hwan', 'Initials': 'DH', 'LastName': 'Oh', 'Affiliation': 'Department of Occupational Therapy, Kyung-Dong University, Korea.'}, {'ForeName': 'Ji-Su', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Advanced Human Resource Development Project Group for Health Care in Aging Friendly Industry, DongSeo University, Korea.'}, {'ForeName': 'Hee-Jeong', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Occupational Therapy, Kyung-Dong University, Korea.'}, {'ForeName': 'Moon-Young', 'Initials': 'MY', 'LastName': 'Chang', 'Affiliation': 'Department of Occupational Therapy, College of Healthcare Medical Science and Engineering, Inje University, Korea.'}, {'ForeName': 'Na-Kyoung', 'Initials': 'NK', 'LastName': 'Hwang', 'Affiliation': 'Department of Occupational Therapy, Seoul North Municipal Hospital, Korea.'}]",Journal of back and musculoskeletal rehabilitation,['10.3233/BMR-181133'] 1166,30382743,Development and pilot study of a suicide prevention intervention delivered by peer support specialists.,"Suicide rates in the United States have been increasing in recent years, and the period after an inpatient psychiatric hospitalization is one of especially high risk for death by suicide. Peer support specialists may play an important role in addressing recommendations that suicide prevention activities focus on protective factors by improving hope and connectedness. The present study developed a peer specialist intervention titled Peers for Valued Living (PREVAIL) to reduce suicide risk, incorporating components of motivational interviewing and psychotherapies targeting suicide risk into recovery-based peer support. A randomized controlled pilot study was conducted to assess the acceptability, feasibility, and fidelity of the intervention. A total of 70 adult psychiatric inpatients at high risk for suicide were enrolled into the study. Participants were randomized to usual care (n = 36) or to the 12-week PREVAIL peer support intervention (n = 34). Those in the PREVAIL arm completed an average of 6.1 (SD = 5.0) peer sessions over the course of 12 weeks. Fidelity was rated for 20 peer support sessions, and 85% of the peer specialist sessions demonstrated adequate fidelity to administering a conversation tool regarding hope, belongingness, or safety, and 72.5% of general support skills (e.g., validation) were performed with adequate fidelity. Participants' qualitative responses (n = 23) were highly positive regarding peer specialists' ability to relate, listen, and advise and to provide support specifically during discussions about suicide. Findings demonstrate that a peer support specialist suicide prevention intervention is feasible and acceptable for patients at high risk for suicide. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,"Participants' qualitative responses (n = 23) were highly positive regarding peer specialists' ability to relate, listen, and advise and to provide support specifically during discussions about suicide.","['70 adult psychiatric inpatients at high risk for suicide were enrolled into the study', 'patients at high risk for suicide']","['peer support specialist suicide prevention intervention', 'peer specialist intervention titled Peers for Valued Living (PREVAIL) to reduce suicide risk, incorporating components of motivational interviewing and psychotherapies targeting suicide risk into recovery-based peer support', 'usual care (n = 36) or to the 12-week PREVAIL peer support intervention', 'suicide prevention intervention delivered by peer support specialists']","['Suicide rates', 'acceptability, feasibility, and fidelity']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric inpatient'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C0204732', 'cui_str': 'Suicide prevention (procedure)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0563664', 'cui_str': 'Suicide risk'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3152857', 'cui_str': 'Prevail'}]","[{'cui': 'C0852733', 'cui_str': 'Suicide (accomplished)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",23.0,0.050229,"Participants' qualitative responses (n = 23) were highly positive regarding peer specialists' ability to relate, listen, and advise and to provide support specifically during discussions about suicide.","[{'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Pfeiffer', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'King', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Ilgen', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}, {'ForeName': 'Dara', 'Initials': 'D', 'LastName': 'Ganoczy', 'Affiliation': 'VA Center for Clinical Management Research.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Clive', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Garlick', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Abraham', 'Affiliation': 'VA Center for Clinical Management Research.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'VA Center for Clinical Management Research.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Vega', 'Affiliation': 'Recovery, Action! International.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Ahmedani', 'Affiliation': 'Henry Ford Health System.'}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Valenstein', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School.'}]",Psychological services,['10.1037/ser0000257'] 1167,28877862,Effectiveness of a Web-Based Tailored Intervention With Virtual Assistants Promoting the Acceptability of HPV Vaccination Among Mothers of Invited Girls: Randomized Controlled Trial.,"BACKGROUND In 2010, the human papillomavirus (HPV) vaccination was introduced in the Dutch National Immunization Program for 12-year-old girls, aiming to reduce the incidence of cervical cancer in women. HPV vaccination uptake turned out to be lower than expected: 61% versus 70%, respectively. Mothers were shown to play the most important role in the immunization decision about this vaccination. They had also expressed their need for interactive personal information about the HPV vaccination over and above the existing universal general information. To improve the effectiveness of the existing education about the HPV vaccination, we systematically developed a Web-based tailored intervention with virtual assistants providing mothers of girls to be invited with tailored feedback on their decision making about the HPV vaccination. OBJECTIVE The aim of this study was to evaluate the effectiveness of the Web-based tailored intervention for promoting HPV vaccination acceptance by means of a randomized controlled trial (RCT). METHODS Mothers were recruited via the Dutch vaccination register (Praeventis) (n=36,000) and three Web-based panels (n=2483). Those who gave informed consent (N=8062) were randomly assigned to the control (n=4067) or intervention condition (n=3995). HPV vaccination uptake, as registered by Praeventis once the HPV vaccination round was completed, was used as the primary outcome. Secondary outcomes were differential scores across conditions between baseline (before the provided access to the new tailored intervention) and follow-up (just before the first vaccination) regarding the mothers' degree of informed decision making (IDM), decisional conflict, and critical determinants of HPV vaccination uptake among which are intention, attitude, risk perception, and outcome beliefs. RESULTS Intention-to-treat analysis (N=8062) showed a significant positive effect of the intervention on IDM, decisional conflict, and nearly all determinants of HPV vaccination uptake (P<.001). No effect was found on uptake (P=.60). This may be attributed to the overall high uptake rates in both conditions. Mothers evaluated the intervention as highly positive, including the website as well as the virtual assistants that were used to deliver the tailored feedback. CONCLUSIONS This computer-tailored intervention has the potential to improve HPV vaccination acceptability and IDM and to decrease decisional conflict among mothers of invited girls. Implications for future research are discussed. TRIAL REGISTRATION Trialregister.nl NTR4935; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4935 (Archived by WebCite at http://www.webcitation.org/6srT7l9EM).",2017,This computer-tailored intervention has the potential to improve HPV vaccination acceptability and IDM and to decrease decisional conflict among mothers of invited girls.,"['Mothers were recruited via the Dutch vaccination register (Praeventis) (n=36,000) and three Web-based panels (n=2483', 'Mothers of Invited Girls', 'mothers of invited girls']",['Web-based tailored intervention'],"['HPV vaccination acceptability and IDM', 'decisional conflict', 'HPV vaccination uptake', 'IDM, decisional conflict, and nearly all determinants of HPV vaccination uptake', ""mothers' degree of informed decision making (IDM), decisional conflict, and critical determinants of HPV vaccination uptake among which are intention, attitude, risk perception, and outcome beliefs"", 'Vaccination', 'Acceptability of HPV']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0013331', 'cui_str': 'Dutch (ethnic group)'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}]",,0.0895052,This computer-tailored intervention has the potential to improve HPV vaccination acceptability and IDM and to decrease decisional conflict among mothers of invited girls.,"[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Pot', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Theo Gwm', 'Initials': 'TG', 'LastName': 'Paulussen', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Robert Ac', 'Initials': 'RA', 'LastName': 'Ruiter', 'Affiliation': 'Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Eekhout', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Hester E', 'Initials': 'HE', 'LastName': 'de Melker', 'Affiliation': 'National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, Netherlands.'}, {'ForeName': 'Maxine Ea', 'Initials': 'ME', 'LastName': 'Spoelstra', 'Affiliation': 'Department of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Hilde M', 'Initials': 'HM', 'LastName': 'van Keulen', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/jmir.7449'] 1168,31491583,Additive effectiveness of contingency management on cognitive behavioural treatment for smokers with depression: Six-month abstinence and depression outcomes.,"BACKGROUND Depression and smoking co-occur at high rates and there is a lack of evidence on the efficacy of treatments specifically tailored to this population. This randomized controlled trial sought to compare the effectiveness of cognitive behavioural treatment (CBT) combined with behavioural activation (BA) and the same treatment protocol plus contingency management (CM). METHODS A sample of 120 adult smokers (70.8%: females) with severe depressive symptoms were randomly allocated to: CBT + BA (n = 60) or CBT + BA + CM (n = 60). Smoking and depression outcomes were reported at end of treatment, 1-, 2-, 3-, and 6-month follow-ups. Self-reported smoking status was biochemically verified, and depression was assessed using the Beck Depression Inventory-II. RESULTS At end of treatment, the overall quit rate was 69.2% (83/120). CM showed an additive effect on CBT + BA in enhancing abstinence rates. The significant effect of group [F(1,155) = 9.55, p =  .0024], time [F(4,96) = 7.93, p < .0001], and group by time interaction [F(4,96) = 6.12, p =  .0002], indicated that CM is more effective for generating longer durations of abstinence beyond those of CBT+BA. All treatment conditions equally promoted sustained reductions in depression across time [F(1,111) = 0.53, p =  .4665]. A greater number of days of continuous abstinence and lower depressive symptoms mutually influenced each other. CONCLUSIONS Depressed smokers achieve high cessation rates without suffering negative mood changes. Quitting smoking is not detrimental and adding CM to CBT + BA enhances long-lasting abstinence rates while promoting large depression improvements.",2019,"The significant effect of group [F(1,155) = 9.55, p =  .0024], time [F(4,96) = 7.93, p < .0001], and group by time interaction [F(4,96) = 6.12, p =  .0002], indicated that CM is more effective for generating longer durations of abstinence beyond those of CBT+BA.","['smokers with depression', '120 adult smokers (70.8%: females) with severe depressive symptoms']","['cognitive behavioural treatment (CBT) combined with behavioural activation (BA) and the same treatment protocol plus contingency management (CM', 'CBT\u202f+\u202fBA (n\u202f=\u202f60) or CBT\u202f+\u202fBA\u202f+\u202fCM', 'contingency management']","['Smoking and depression outcomes', 'number of days of continuous abstinence and lower depressive symptoms', 'overall quit rate']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0040808', 'cui_str': 'Treatment Protocols'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",120.0,0.0940232,"The significant effect of group [F(1,155) = 9.55, p =  .0024], time [F(4,96) = 7.93, p < .0001], and group by time interaction [F(4,96) = 6.12, p =  .0002], indicated that CM is more effective for generating longer durations of abstinence beyond those of CBT+BA.","[{'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Secades-Villa', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'González-Roz', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain. Electronic address: albagroz@cop.es.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Vallejo-Seco', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Weidberg', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'García-Pérez', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Alonso-Pérez', 'Affiliation': 'Department of Psychology. University of Oviedo, Plaza Feijoo, s/n, 33003 Oviedo, Spain.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2019.06.003'] 1169,29654506,Evaluating the Training of Chinese-Speaking Community Health Workers to Implement a Small-Group Intervention Promoting Mammography.,"This study evaluated the training of Chinese American Community Health Workers (CHWs) to implement a small-group mammography video and discussion program as part of a randomized controlled trial that had the goal to increase adherence to mammography screening guidelines among Chinese American women. A total of 26 Chinese American CHWs in the metropolitan Washington DC area, Southern California, and New York City participated in a 4-h training workshop and completed surveys before and after the workshop to assess their knowledge regarding mammography screening guidelines and human subjects protection rules. The results showed significantly increased knowledge of mammography screening guidelines and human subjects protection rules (both p < 0.01) after the training. CHWs were also trained to lead a discussion of the video, including screening benefits and misconceptions. Forty-three audio recordings of discussions led by 13 active CHWs were transcribed and qualitatively analyzed to assess implementation fidelity. Ten out of 13 active CHWs fully addressed about 3 of the 5 benefit items, and 11 out of 13 CHWs fully addressed more than 5 of the 9 misconception items. Chinese CHWs can be trained to implement research-based intervention programs. However, a one-time training resulted in moderate adherence to the discussion protocol. Ongoing or repeat trainings throughout the intervention period may be needed to enhance implementation fidelity.",2019,The results showed significantly increased knowledge of mammography screening guidelines and human subjects protection rules (both p < 0.01) after the training.,"['Chinese American women', 'Chinese American Community Health Workers (CHWs', '26 Chinese American CHWs in the metropolitan Washington DC area, Southern California, and New York City']",['small-group mammography video and discussion program'],"['moderate adherence', 'knowledge of mammography screening guidelines and human subjects protection rules']","[{'cui': 'C0008121', 'cui_str': 'Chinese Americans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0009467', 'cui_str': 'Community Health Aides'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0027977', 'cui_str': 'New York City'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}]",43.0,0.0191563,The results showed significantly increased knowledge of mammography screening guidelines and human subjects protection rules (both p < 0.01) after the training.,"[{'ForeName': 'Jiayan', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'Department of Oncology, Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA.'}, {'ForeName': 'Annette E', 'Initials': 'AE', 'LastName': 'Maxwell', 'Affiliation': 'Fielding School of Public Health and Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Grace X', 'Initials': 'GX', 'LastName': 'Ma', 'Affiliation': 'Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Xiaokun', 'Initials': 'X', 'LastName': 'Qian', 'Affiliation': 'Department of Oncology, Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Tan', 'Affiliation': 'Center for Asian Health, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.'}, {'ForeName': 'Hsing-Chuan', 'Initials': 'HC', 'LastName': 'Hsieh', 'Affiliation': 'Department of Oncology, Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA.'}, {'ForeName': 'Shin-Ping', 'Initials': 'SP', 'LastName': 'Tu', 'Affiliation': 'Division of General Internal Medicine, Geriatrics, and Bioethics, University of California Davis, Sacramento, CA, USA.'}, {'ForeName': 'Judy Huei-Yu', 'Initials': 'JH', 'LastName': 'Wang', 'Affiliation': 'Department of Oncology, Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington D.C., USA. jw235@georgetown.edu.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-018-1361-5'] 1170,31615934,Submucosal Saline Injection Followed by Endoscopic Ultrasound versus Endoscopic Ultrasound Only for Distinguishing between T1a and T1b Esophageal Cancer.,"PURPOSE To examine whether submucosal saline injection (SSI) can improve traditional endoscopic ultrasound (EUS) accuracy in distinguishing between T1a and T1b stage esophageal squamous cell carcinoma (ESCC). EXPERIMENTAL DESIGN Patients with T1N0M0 stage ESCC ( n = 180) ages 18 to 85 years were enrolled between February 14, 2012 to June 4, 2018 at Sun Yat-sen University Cancer Center (Guangdong, China). They were randomly assigned (1:1) to receive either EUS examination after 3-5 mL SSI or EUS only examination. All the patients were referred to thoracic surgeons to receive endoscopic resection (ER) or esophagectomy 5 to 10 days after EUS examination. Standard EUS criteria were used to preoperatively stage the ESCC cases, and surgical pathology reports after referral were used to postoperatively stage the cases. The primary endpoint was the diagnostic accuracy of T1b staging [defined as the sum of the true positive (T1b) and true negative (T1a) cases divided by the total number of cases]. RESULTS Among the per-protocol population, the SSI+EUS group ( n = 81) was superior to the EUS-only group ( n = 85) in terms of the diagnostic accuracy for T1b staging [93.8% (95% confidence interval (CI), 88.6-99.1) vs. 65.9% (95% CI, 55.8-76.0); P < 0.001]. The positive predictive value of SSI+EUS for diagnosing T1b ESCC reached 90.9% (95% CI, 81.1-100), which was significantly superior to that of EUS only [0.576 (0.450-0.702), P = 0.001]. CONCLUSIONS SSI significantly improves the diagnostic accuracy of EUS in distinguishing between T1a and T1b ESCC, which might help avoid unnecessary esophagectomy and diagnostic ER.",2020,"CONCLUSIONS SSI significantly improves the diagnostic accuracy of EUS in distinguishing between T1a and T1b ESCC, which might help avoid unnecessary esophagectomy and diagnostic ER.","['180 T1N0M0 stage ESCC patients aged 18-85 years old were enrolled between February 14, 2012 to June 4, 2018 at Sun Yat-sen University Cancer Center in China', 'distinguishing between T1a and T1b stage esophageal squamous cell carcinoma (ESCC']","['submucosal saline injection (SSI', 'Submucosal saline injection followed by endoscopic ultrasound versus endoscopic ultrasound', 'endoscopic resection (ER) or esophagectomy', 'EUS examination after 3-5 ml submucosal saline injection (SSI) or EUS only examination']","['diagnostic accuracy of T1b staging (defined as the sum of the true positive [T1b] and true negative [T1a] cases divided by the total number of cases', 'diagnostic accuracy of EUS', 'diagnostic accuracy for T1b staging']","[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0279626', 'cui_str': 'Esophageal Squamous Cell Carcinoma'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0376443', 'cui_str': 'Ultrasonography, Endoscopic'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0085198', 'cui_str': 'Esophagectomy'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}]","[{'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0205559', 'cui_str': 'True positive (qualifier value)'}, {'cui': 'C0205560', 'cui_str': 'True negative (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]",,0.0438942,"CONCLUSIONS SSI significantly improves the diagnostic accuracy of EUS in distinguishing between T1a and T1b ESCC, which might help avoid unnecessary esophagectomy and diagnostic ER.","[{'ForeName': 'Long-Jun', 'Initials': 'LJ', 'LastName': 'He', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Chuanbo', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': 'Cancer Prevention Cancer, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Zi-Xian', 'Initials': 'ZX', 'LastName': 'Wang', 'Affiliation': 'Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Yi-Tai', 'Initials': 'YT', 'LastName': 'Xiao', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Xiao-Yan', 'Initials': 'XY', 'LastName': 'Gao', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Hong-Bo', 'Initials': 'HB', 'LastName': 'Shan', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Lin-Na', 'Initials': 'LN', 'LastName': 'Luo', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'Chen', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Guang-Yu', 'Initials': 'GY', 'LastName': 'Luo', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Yang', 'Affiliation': 'Department of Pathology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Shuo-Chun', 'Initials': 'SC', 'LastName': 'Zeng', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China.'}, {'ForeName': 'Guo-Liang', 'Initials': 'GL', 'LastName': 'Xu', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China. lijj@sysucc.org.cn xugl@sysucc.org.cn.'}, {'ForeName': 'Jian-Jun', 'Initials': 'JJ', 'LastName': 'Li', 'Affiliation': 'Department of Endoscopy, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Guangzhou, China. lijj@sysucc.org.cn xugl@sysucc.org.cn.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-1722'] 1171,31613965,Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.,"CONTEXT Increased prevalence of asthma has been reported from epidemiological studies in women with polycystic ovary syndrome (PCOS). OBJECTIVE To investigate respiratory function in women with PCOS compared with controls in a clinical setting. DESIGN An 8-year clinical follow-up study including self-reported asthma diagnoses and spirometry of women with PCOS randomized to metformin or placebo during pregnancy in the original studies (the Pilot and the PregMet-study), compared with matched controls from a population-based cohort study (The HUNT Study). SETTING Secondary and tertiary care centers. PARTICIPANTS A total of 145 women with PCOS (54% of original cohort) were matched 1:3 to controls, on gender, age, and smoking-status. MAIN OUTCOMES AND MEASURES Self-reported doctor-diagnosed asthma (DDA), percentage of predicted forced expiratory volume in the first second of expiration (FEV1 % predicted), percentage of predicted forced vital capacity (FVC % predicted). RESULTS Women with PCOS reported more DDA compared with controls (19% vs 9%; P < 0.01). Spirometry indicated a combined obstructive (FEV1 % predicted, 93.7 vs 102.0; P < 0.01) and restrictive (FVC % predicted, 94.5 vs 103.7; P < 0.01) respiratory impairment in PCOS compared with controls. Metformin in pregnancy did not affect respiratory function at follow-up. CONCLUSION Women with PCOS reported higher prevalence of DDA compared with controls matched for age and smoking status. In addition, respiratory function was decreased, with both obstructive and restrictive components. Further insight to the underlying pathogenesis of these observations is needed. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov: The PregMet study: NCT00159536. The Pilot study: NCT03259919.",2020,"RESULTS Women with PCOS reported more DDA compared to controls (19% vs 9%, p<0.01).","['Secondary and tertiary care centers', 'women with PCOS compared to controls in a clinical setting', '145 women with PCOS (54% of original cohort) were matched 1:3 to controls, on gender, age and smoking-status', 'matched controls from a population-based cohort study (The HUNT Study', '8-year clinical follow-up including self-reported asthma diagnoses and spirometry of women with PCOS randomized to', 'women with PCOS']","['metformin or placebo', 'Metformin']","['Self-reported doctor diagnosed asthma (DDA), FEV1 % predicted, FVC % predicted', 'DDA', 'respiratory function', 'respiratory impairment in PCOS', 'prevalence of DDA']","[{'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0587437', 'cui_str': 'Tertiary Hospital'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4517577', 'cui_str': '145'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4255216', 'cui_str': 'Hunting'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0106487', 'cui_str': 'DDA'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",145.0,0.20856,"RESULTS Women with PCOS reported more DDA compared to controls (19% vs 9%, p<0.01).","[{'ForeName': 'Maria Othelie', 'Initials': 'MO', 'LastName': 'Underdal', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Salvesen', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Anne Hildur', 'Initials': 'AH', 'LastName': 'Henriksen', 'Affiliation': 'Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Andersen', 'Affiliation': 'Department of Internal Medicine, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Vanky', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz053'] 1172,29271282,Implementation of a Psychosocial Intervention Program for Working Caregivers.,"The overall aim of this pilot study was to examine the feasibility and acceptability of a multicomponent, psychosocial intervention specifically designed to meet the unique needs of caregivers who are balancing caregiving duties with work responsibilities. Seventy-one family caregivers employed at a private, nonprofit institution in South Florida were randomized to either the Caregiver Workstation condition ( n = 35) or a control condition ( n = 36). Sixty-two caregivers completed the 5-month follow-up. Our results indicate that an intervention tailored to the time demands of a working caregiver is feasible, acceptable to caregivers, and has the potential to have positive long-term effects. Currently, there are limited data available regarding the benefits of employer programs for caregivers or the type of programs caregivers find most useful. This pilot study is the first step in developing a working caregiver intervention program that can be implemented on a broad-scale basis.",2019,"The overall aim of this pilot study was to examine the feasibility and acceptability of a multicomponent, psychosocial intervention specifically designed to meet the unique needs of caregivers who are balancing caregiving duties with work responsibilities.","['Seventy-one family caregivers employed at a private, nonprofit institution in South Florida', 'caregivers who are balancing caregiving duties with work responsibilities', 'Working Caregivers']","['Psychosocial Intervention Program', 'multicomponent, psychosocial intervention', 'control condition', 'Caregiver Workstation condition']",[],"[{'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0086279', 'cui_str': 'Family Caregivers'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C4521534', 'cui_str': 'US Military enlisted E1'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0016253', 'cui_str': 'Florida'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0043227', 'cui_str': 'Work'}]","[{'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C1736830', 'cui_str': 'Workstation (physical object)'}]",[],71.0,0.0313891,"The overall aim of this pilot study was to examine the feasibility and acceptability of a multicomponent, psychosocial intervention specifically designed to meet the unique needs of caregivers who are balancing caregiving duties with work responsibilities.","[{'ForeName': 'Daniel E', 'Initials': 'DE', 'LastName': 'Jimenez', 'Affiliation': '1 University of Miami, FL, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schulz', 'Affiliation': '2 University of Pittsburgh, PA, USA.'}, {'ForeName': 'Dolores', 'Initials': 'D', 'LastName': 'Perdomo', 'Affiliation': '1 University of Miami, FL, USA.'}, {'ForeName': 'Chin Chin', 'Initials': 'CC', 'LastName': 'Lee', 'Affiliation': '1 University of Miami, FL, USA.'}, {'ForeName': 'Sara J', 'Initials': 'SJ', 'LastName': 'Czaja', 'Affiliation': '1 University of Miami, FL, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464817748777'] 1173,31862436,Communicating health information and improving coordination with primary care (CHIIP): Rationale and design of a randomized cardiovascular health promotion trial for adult survivors of childhood cancer.,"BACKGROUND Long-term survival for children diagnosed with cancer exceeds 80%. Notably, premature cardiovascular disease has become the leading non-cancer cause of late mortality among these survivors. METHODS/DESIGN This randomized controlled trial (RCT; NCT03104543) focuses on adult participants in the Childhood Cancer Survivor Study identified as high risk for ischemic heart disease or heart failure due to their cancer treatment. Participants undergo a home-based evaluation of blood pressure and laboratory tests to determine the prevalence of undiagnosed and/or undertreated hypertension, dyslipidemia, and diabetes. Those with abnormal values are then enrolled in an RCT to test the efficacy of a 12-month personalized, remotely delivered survivorship care plan (SCP) intervention designed to reduce undertreatment of these three target conditions. The intervention approximates a clinical encounter and is based on chronic disease self-management strategies. RESULTS With a goal of 750, currently 342 out of 742 eligible participants approached have enrolled (46.1%). Initially, we randomized participants to different recruitment strategies, including shorter approach packets and a tiered consent, but did not find significant differences in participation rates (40.7% to 42.9%; p = .95). Subsequently, slightly greater participation was seen with larger upfront unconditional incentive checks ($50 vs. $25: 50.7% vs. 44.1%; p = .10). Overall, the financial impact of the $50 upfront incentive was cost neutral, and possibly cost-saving, vs. a $25 upfront incentive. CONCLUSION The overall study will determine if a National Academy of Medicine-recommended SCP intervention can improve cardiovascular outcomes among long-term survivors of childhood cancer. Modifications to the recruitment strategy may improve participation rates over time.",2020,"Overall, the financial impact of the $50 upfront incentive was cost neutral, and possibly cost-saving, vs. a $25 upfront incentive. ","['Participants undergo a home-based evaluation of blood pressure and laboratory tests to determine the prevalence of undiagnosed and/or undertreated hypertension, dyslipidemia, and diabetes', 'adult participants in the Childhood Cancer Survivor Study identified as high risk for ischemic heart disease or heart failure due to their cancer treatment', '750, currently 342 out of 742 eligible participants approached have enrolled (46.1', 'children diagnosed with cancer exceeds 80', 'adult survivors of childhood cancer']","['survivorship care plan (SCP) intervention', 'primary care (CHIIP', 'Medicine-recommended SCP intervention']","['participation rates', 'cardiovascular outcomes']","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0022885', 'cui_str': 'Laboratory test (procedure)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231335', 'cui_str': 'Childhood (finding)'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C4517868', 'cui_str': '750 (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0038955'}, {'cui': 'C0178916', 'cui_str': 'Care plan (record artifact)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C1145610', 'cui_str': 'Cellulose sodium phosphate'}]",[],742.0,0.163255,"Overall, the financial impact of the $50 upfront incentive was cost neutral, and possibly cost-saving, vs. a $25 upfront incentive. ","[{'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Chow', 'Affiliation': ""Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, United States of America. Electronic address: ericchow@uw.edu.""}, {'ForeName': 'Laura-Mae', 'Initials': 'LM', 'LastName': 'Baldwin', 'Affiliation': 'Department of Family Medicine, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Anna M', 'Initials': 'AM', 'LastName': 'Hagen', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.'}, {'ForeName': 'Melissa M', 'Initials': 'MM', 'LastName': 'Hudson', 'Affiliation': ""Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States of America; Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Gibson', 'Affiliation': ""Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Komal', 'Initials': 'K', 'LastName': 'Kochar', 'Affiliation': ""Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'McDonald', 'Affiliation': ""Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Nathan', 'Affiliation': 'Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Syrjala', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Taylor', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.'}, {'ForeName': 'Emily S', 'Initials': 'ES', 'LastName': 'Tonorezos', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Yasui', 'Affiliation': ""Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Gregory T', 'Initials': 'GT', 'LastName': 'Armstrong', 'Affiliation': ""Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, United States of America.""}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Oeffinger', 'Affiliation': 'Department of Medicine, Duke University, Durham, NC, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.105915'] 1174,29302609,Effectiveness of the Healthy Lifestyles Programme (HeLP) to prevent obesity in UK primary-school children: a cluster randomised controlled trial.,"Background Although childhood overweight and obesity prevalence has increased substantially worldwide in the past three decades, scarce evidence exists for effective preventive strategies. We aimed to establish whether a school-based intervention for children aged 9-10 years would prevent excessive weight gain after 24 months. Methods This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England. All state-run primary and junior schools in Devon and Plymouth (UK) with enough pupils for at least one year-5 class were eligible. Schools were assigned (1:1) using a computer-generated sequence to either intervention or control, stratified by the number of year-5 classes (one vs more than one) and the proportion of children eligible for free school meals (<19% [the national average] vs ≥19%). HeLP was delivered to year-5 children (ages 9-10 years) over 1 year, and included dynamic and interactive activities such as physical activity workshops, education sessions delivered by teachers with short homework tasks, drama sessions, and setting goals to modify behaviour (with parental support and one-to-one discussions with HeLP coordinators). The primary outcome was change in body-mass index (BMI) standard deviation score (SDS) between baseline and 24 months, analysed in children with BMI data available for both timepoints. This study is registered with the International Standard Randomised Controlled Trial register, number ISRCTN15811706, and the trial status is complete. Findings Between March 21, 2012, and Sept 30, 2013, 32 eligible schools with 1324 children were recruited, of which 16 schools (676 children) were randomly assigned to the HeLP intervention and 16 schools (648 children) to control. All schools that began the trial completed the intervention, and 1244 children (628 in intervention group and 616 in control group) had BMI data at both baseline and 24 months for the primary outcome analysis. Mean BMI SDS was 0·32 (SD 1·16) at baseline and 0·35 (1·25) at 24 months in the intervention group, and 0·18 (1·14) at baseline and 0·22 (1·22) at 24 months in the control group. With adjustment for school-level clustering, baseline BMI scores, sex, cohort, and number of year-5 classes and socioeconomic status of each school, the mean difference in BMI SDS score (intervention-control) at 24 months was -0·02 (95% CI -0·09 to 0·05), p=0·57. One parent reported an adverse event related to their child's eating and activity behaviours, but agreed for the child to continue trial participation after discussion with the chief investigator. Interpretation Despite a theoretically informed and extensively piloted intervention that achieved high levels of engagement, follow-up, and fidelity of delivery, we found no effect of the intervention on preventing overweight or obesity. Although schools are an ideal setting in which to deliver population-based interventions, school-based interventions might not be sufficiently intense to affect both the school and the family environment, and hence the weight status of children. Future research should focus on more upstream determinants of obesity and use whole-systems approaches. Funding UK National Institute for Health Research, Public Health Research Programme.",2018,"This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England.","['UK primary-school children', 'children aged 9-10 years', '32 schools in southwest England', 'All state-run primary and junior schools in Devon and Plymouth (UK) with enough pupils for at least one year-5 class were eligible', 'Findings\n\n\nBetween March 21, 2012, and Sept 30, 2013, 32 eligible schools with 1324 children were recruited, of which 16 schools (676 children']","['HeLP intervention', 'dynamic and interactive activities such as physical activity workshops, education sessions delivered by teachers with short homework tasks, drama sessions, and setting goals to modify behaviour (with parental support and one-to-one discussions with HeLP coordinators', 'school-based intervention', 'Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention', 'Healthy Lifestyles Programme (HeLP']","['BMI SDS score', 'overweight or obesity', 'Mean BMI SDS', 'change in body-mass index (BMI) standard deviation score (SDS', 'BMI data', 'excessive weight gain']","[{'cui': 'C0033145', 'cui_str': 'Primary Schools'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0557793', 'cui_str': 'Junior school (environment)'}, {'cui': 'C0454849', 'cui_str': 'Devonshire (geographic location)'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0589414', 'cui_str': 'Homework, function (observable entity)'}, {'cui': 'C0013109', 'cui_str': 'Drama'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0418946', 'cui_str': 'Parental support (regime/therapy)'}, {'cui': 'C0557061', 'cui_str': 'Discussion (procedure)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0000765', 'cui_str': 'Excessive weight gain (finding)'}]",1324.0,0.0875582,"This pragmatic cluster randomised controlled trial of the Healthy Lifestyles Programme (HeLP), a school-based obesity prevention intervention, was done in 32 schools in southwest England.","[{'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Lloyd', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK. Electronic address: j.j.lloyd@exeter.ac.uk.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Creanor', 'Affiliation': 'Peninsula Clinical Trials Unit and Medical Statistics, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Logan', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Green', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Sarah G', 'Initials': 'SG', 'LastName': 'Dean', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Melvyn', 'Initials': 'M', 'LastName': 'Hillsdon', 'Affiliation': 'Sport and Health Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Abraham', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Tomlinson', 'Affiliation': 'Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Pearson', 'Affiliation': 'Public Health Devon, Devon County Council Commissioning Headquarters, Exeter, UK.'}, {'ForeName': 'Rod S', 'Initials': 'RS', 'LastName': 'Taylor', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Ryan', 'Affiliation': 'ISCA Academy, Earl Richards Road South, Exeter, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Price', 'Affiliation': 'Sport and Health Sciences, University of Exeter, Exeter, UK.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Streeter', 'Affiliation': 'Peninsula Clinical Trials Unit and Medical Statistics, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.'}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Wyatt', 'Affiliation': 'Institute of Health Research, University of Exeter Medical School, University of Exeter, Exeter, UK.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(17)30151-7'] 1175,30007333,A randomized clinical trial of the effectiveness of 0.018-inch and 0.022-inch slot orthodontic bracket systems: part 2-quality of treatment.,"OBJECTIVE To compare the quality of orthodontic treatment between 0.018-inch and 0.022-inch slot bracket systems. SUBJECTS AND METHODS Eligible participants aged 12 years or over were allocated to the 0.018-inch or 0.022-inch slot MBT appliance (3M-Unitek, Monrovia, California, USA) using block randomization in groups of 10. Outcome measures included: 1. ABO cast-radiograph evaluation (CR-EVAL), 2. peer assessment rating (PAR) scores, 3. incisor inclination, and 4. patient perception using the Index of Orthodontic Treatment Need aesthetic component (IOTN AC) and three validated questionnaires before, during and after treatment. Parametric tests [independent samples t-test and two-way analysis of variance (ANOVA)] and non-parametric tests (chi-square with Fisher's exact tests and Mann-Whitney U-test) assessed differences between groups (P < 0.05). RESULTS Of the 187 participants randomized (1:1 ratio), 34 withdrew or were excluded (protocol deviations or poor cooperation). There were 77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years). Baseline characteristics were similar between groups (P > 0.05). The mean total ABO CR-EVAL scores were 34.7 and 34.5; mean percentage PAR score reduction 74.1 per cent and 77.1 per cent; mean change for maxillary incisor inclination 2.9 degrees and 1.6 degrees and for mandibular incisor inclination 2.7 degrees and 1.4 degrees for the 0.018-inch and 0.022-inch groups, respectively. Improvement in patient perception of aesthetics after treatment was statistically significant for both groups (P < 0.05). However, there were no statistically significant differences between the two treatment groups for ABO CR-EVAL, percentage PAR score reduction, incisor inclination, and patient perception of treatment (P > 0.05). No adverse events were observed during treatment. LIMITATIONS It was impossible to blind clinicians or patients to allocation and oral hygiene and periodontal outcomes were not assessed. CONCLUSIONS There were no statistically or clinically significant differences in the quality of occlusal outcomes, incisor inclination and patient perception of treatment between 0.018-inch and 0.022-inch slot bracket systems. REGISTRATION The trial was registered with ClinicalTrials.gov on 5 March 2014, registration number: NCT02080338. PROTOCOL The protocol was published at DOI: 10.1186/1745-6215-15-389.",2019,"There were no statistically or clinically significant differences in the quality of occlusal outcomes, incisor inclination and patient perception of treatment between 0.018-inch and 0.022-inch slot bracket systems. ","['Eligible participants aged 12 years or over were allocated to the 0.018-inch or 0.022-inch', '77 patients in the 0.018-inch slot group and 76 patients in the 0.022-inch slot group (overall mean age: 19.1 years', '187 participants randomized (1:1 ratio']","['slot MBT appliance (3M-Unitek, Monrovia, California, USA']","[' 1. ABO cast-radiograph evaluation (CR-EVAL), 2. peer assessment rating (PAR) scores, 3. incisor inclination, and 4', 'adverse events', 'ABO CR-EVAL, percentage PAR score reduction, incisor inclination, and patient perception of treatment', 'mean total ABO CR-EVAL scores', 'PAR score reduction', 'patient perception of aesthetics', 'quality of occlusal outcomes, incisor inclination and patient perception of treatment']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0450304', 'cui_str': '0.018""'}, {'cui': 'C0450305', 'cui_str': '0.022""'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4517618', 'cui_str': '187 (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]","[{'cui': 'C0243112'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}, {'cui': 'C1306645', 'cui_str': 'Plain x-ray'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0429164', 'cui_str': 'Peer assessment rating (orthodontic index)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0021156', 'cui_str': 'Incisor'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0014901', 'cui_str': 'Esthetics'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1947917', 'cui_str': 'Occluded (qualifier value)'}]",187.0,0.191767,"There were no statistically or clinically significant differences in the quality of occlusal outcomes, incisor inclination and patient perception of treatment between 0.018-inch and 0.022-inch slot bracket systems. ","[{'ForeName': 'Yassir A', 'Initials': 'YA', 'LastName': 'Yassir', 'Affiliation': 'Orthodontic Department, School of Dentistry, University of Dundee, UK.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'El-Angbawi', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'Grant T', 'Initials': 'GT', 'LastName': 'McIntyre', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'Gavin F', 'Initials': 'GF', 'LastName': 'Revie', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Bearn', 'Affiliation': 'Orthodontic Department, College of Dentistry, University of Baghdad, Iraq.'}]",European journal of orthodontics,['10.1093/ejo/cjy038'] 1176,31611624,Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.,,2020,,['non-high-risk acute promyelocytic leukemia'],['trans retinoic acid and arsenic trioxide'],[],"[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0023487', 'cui_str': 'Myeloid Leukemia, Acute, M3'}]","[{'cui': 'C0040845', 'cui_str': 'retinoic acid'}, {'cui': 'C0052416', 'cui_str': 'arsenic trioxide'}]",[],,0.0553994,,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cicconi', 'Affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Platzbecker', 'Affiliation': 'Universitätsklinikum Leipzig, Leipzig, Germany.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Avvisati', 'Affiliation': 'Ematologia e Trapianto di cellule staminali, Università Campus Bio-Medico, Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Paoloni', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Thiede', 'Affiliation': 'Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Vignetti', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Fazi', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Felicetto', 'Initials': 'F', 'LastName': 'Ferrara', 'Affiliation': 'Dipartimento di Ematologia e Trapianto di Cellule Staminali, Ospedale Cardarelli, Napoli, Italy.'}, {'ForeName': 'Mariadomenica', 'Initials': 'M', 'LastName': 'Divona', 'Affiliation': 'Laboratorio di Oncoematologia, Policlinico Tor Vergata, Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Albano', 'Affiliation': 'Dipartimento di Ematologia, Università di Bari, Bari, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Efficace', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Sborgia', 'Affiliation': 'U.O. di Ematologia Clinica, Pescara, Italy.'}, {'ForeName': 'Eros', 'Initials': 'E', 'LastName': 'Di Bona', 'Affiliation': 'Dipartimento di Terapie cellulari ed Ematologia, Unità Operativa di Ematologia, Ospedale S. Bortolo, Vicenza, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Breccia', 'Affiliation': 'Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Borlenghi', 'Affiliation': 'Dipartimento di Ematologia, Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cairoli', 'Affiliation': 'Grande Ospedale Metropolitano Niguarda, SC Ematologia, Milan, Italy.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Rambaldi', 'Affiliation': 'Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.'}, {'ForeName': 'Lorella', 'Initials': 'L', 'LastName': 'Melillo', 'Affiliation': 'Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'La Nasa', 'Affiliation': 'Centro Trapianti Midollo Osseo, Ospedale R. Binaghi, Università di Cagliari, Cagliari, Italy.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Fiedler', 'Affiliation': 'University Hospital Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brossart', 'Affiliation': 'Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, CIO Bonn, Bonn, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Hertenstein', 'Affiliation': 'Klinikum Bremen Mitte, Bremen, Germany.'}, {'ForeName': 'Helmut R', 'Initials': 'HR', 'LastName': 'Salih', 'Affiliation': 'University Hospital Tubingen, Tubingen, Germany.'}, {'ForeName': 'Ombretta', 'Initials': 'O', 'LastName': 'Annibali', 'Affiliation': 'Ematologia e Trapianto di cellule staminali, Università Campus Bio-Medico, Rome, Italy.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Wattad', 'Affiliation': 'Kliniken Essen Süd, Essen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lubbert', 'Affiliation': 'University Medical Center, Freiburg, Germany.'}, {'ForeName': 'Christian H', 'Initials': 'CH', 'LastName': 'Brandts', 'Affiliation': 'Goethe University Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Hanel', 'Affiliation': 'Klinikum Chemnitz gGmbH, Chemnitz, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Rollig', 'Affiliation': 'Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Schmitz', 'Affiliation': 'Asklepios Klinik St Georg Hamburg, Hamburg, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Link', 'Affiliation': 'Klinik für Innere Medizin I, Westpfalz-Klinikum, Kaiserslautern, Germany.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Frairia', 'Affiliation': 'Città della Salute e della Scienza, Hematology, Torino, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Fozza', 'Affiliation': 'University of Sassari, Sassari, Italy.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': ""Maria D'Arco"", 'Affiliation': 'U.O. Medicina Interna e Onco-Ematologica P.O. Umberto I, Nocera Inferiore, Nocera Inferiore, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Di Renzo', 'Affiliation': 'Ospedale Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Agostino', 'Initials': 'A', 'LastName': 'Cortelezzi', 'Affiliation': ""Foundation Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy.""}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Fabbiano', 'Affiliation': 'Divisione di Ematologia e Unità di Trapianti di Midollo Osseo, Ospedale Riuniti Villa Sofia-Cervello, Palermo, Italy.'}, {'ForeName': 'Konstanze', 'Initials': 'K', 'LastName': 'Dohner', 'Affiliation': 'University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Ganser', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Dohner', 'Affiliation': 'University Hospital Ulm, Ulm, Germany.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Amadori', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Mandelli', 'Affiliation': 'GIMEMA Data Center, Rome, Italy.'}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Voso', 'Affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy. voso@med.uniroma2.it.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Ehninger', 'Affiliation': 'Universitätsklinikum Carl Gustav Carus der Technischen Universität, Dresden, Germany.'}, {'ForeName': 'Richard F', 'Initials': 'RF', 'LastName': 'Schlenk', 'Affiliation': 'NCT Trial Center, National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Lo-Coco', 'Affiliation': 'Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.'}]",Leukemia,['10.1038/s41375-019-0589-3'] 1177,31611626,T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol.,"The NOPHO ALL2008 is a population-based study using an unmodified pediatric protocol in patients 1-45 years of age with acute lymphoblastic leukemia. Patients with T-ALL were given a traditional pediatric scheme if fast responding (minimal residual disease (MRD) < 0.1% day 29), or intensive block-based chemotherapy if slow responding (MRD > 0.1% day 29). Both treatment arms included pediatric doses of high-dose methotrexate and asparaginase. If MRD ≥ 5% on day 29 or ≥0.1% after consolidation, patients were assigned to allogeneic hematopoietic stem cell transplantation. The 5-year overall survival of the 278 T-ALL patients was 0.75 (95% CI 0.69-0.81), being 0.82 (0.74-0.88) for patients 1.0-9.9 years, 0.76 (0.66-0.86) for those 10.0-17.9 years, and 0.65 (0.55-0.75) for the older patients. The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%). The MRD responses in the three age groups were similar, and only a nonsignificant increase in relapse risk was found in adults. In conclusion, an unmodified pediatric protocol in patients 1-45 years is effective in all age groups. The traditional pediatric treatment schedule was safe for all patients, but the intensive block therapy led to a high toxic death rate in adults.",2020,The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%).,['patients 1-45 years of age with acute lymphoblastic leukemia'],"['intensive block-based chemotherapy', 'methotrexate and asparaginase', 'allogeneic hematopoietic stem cell transplantation']","['T-cell acute lymphoblastic leukemia', 'MRD responses', 'toxic death rate', 'relapse risk', '5-year overall survival', 'risk of death in first remission']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}]","[{'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0472699', 'cui_str': 'Hematopoietic Stem Cell Transplantation'}]","[{'cui': 'C1961099', 'cui_str': 'Leukemia, Lymphocytic, Acute, T-Cell'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}]",278.0,0.042444,The risk of death in first remission was significantly higher in adults (12%) compared with the 1-9 years group (4%).,"[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Quist-Paulsen', 'Affiliation': ""Department of Hematology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. Petter.Quist-Paulsen@ntnu.no.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Toft', 'Affiliation': 'Department of Hematology, Herlev University Hospital, University of Copenhagen, Herlev, Denmark.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Heyman', 'Affiliation': ""Childhood Cancer Research Unit, Karolinska Institute, Astrid Lindgren's Childrens' Hospital, Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Abrahamsson', 'Affiliation': 'Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Griškevičius', 'Affiliation': 'Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hallböök', 'Affiliation': 'Department of Medical Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Ó G', 'Initials': 'ÓG', 'LastName': 'Jónsson', 'Affiliation': ""Children's Hospital, Landspitali University Hospital, Reykjavík, Iceland.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Palk', 'Affiliation': 'Department of Hematology, North Estonia Medical Centre, Tallinn, Estonia.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Vaitkeviciene', 'Affiliation': ""Centre for Pediatric Oncology and Hematology, Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius University, Vilnius, Lithuania.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Vettenranta', 'Affiliation': 'Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Åsberg', 'Affiliation': ""Department of Pediatrics, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.""}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Frandsen', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Opdahl', 'Affiliation': 'Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNU, Trondheim, Norway.'}, {'ForeName': 'H V', 'Initials': 'HV', 'LastName': 'Marquart', 'Affiliation': 'Department of Clinical Immunology, Section 7631, University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Siitonen', 'Affiliation': 'Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland.'}, {'ForeName': 'L T', 'Initials': 'LT', 'LastName': 'Osnes', 'Affiliation': 'Department of Immunology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hultdin', 'Affiliation': 'Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.'}, {'ForeName': 'U M', 'Initials': 'UM', 'LastName': 'Overgaard', 'Affiliation': 'Department of Hematology, The University Hospital Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Wartiovaara-Kautto', 'Affiliation': 'Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Schmiegelow', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.'}]",Leukemia,['10.1038/s41375-019-0598-2'] 1178,31603121,Prospective randomized trial of standard antiemetic therapy with yoga versus standard antiemetic therapy alone for highly emetogenic chemotherapy-induced nausea and vomiting in South Asian population.,"Aim/Background Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects of highly emetogenic chemotherapy regimens. There have been continuous efforts in the direction to control CINV by many investigators. Materials and Methods Randomly selected patients were those receiving highly emetogenic chemotherapy regimen grouped into yoga and standard antiemetic therapy (n = 50) just before receiving chemotherapy and continued for the following days and other group (n = 50) received only the standard antiemetic agent. Both the groups were assessed, followed for acute and delayed onset of chemotherapy-induced and anticipatory nausea and vomiting using radiation therapy oncology group grading for the same. We also assessed the quality of life of the patient using the Functional Assessment of Cancer Therapy-General questionnaire. Results The median age group of the patients was 51 years with male:female ratio 2:1, The Eastern Cooperative Oncology Group (ECOG) performance status was 0/1 in 38% of the selected population, while ECOG 2 in 62% of the patients. In yoga arm, insignificant reduction in chemotherapy-induced nausea (90% vs. 78%, P = 0.35) and but significant reduction in vomiting (42% vs. 22%, P =0.01) was observed as compared to the standard antiemetics only arm. There was a significant reduction in Grade 2 and 3 nausea (84% vs. 38% P < 0.01) and vomiting (14% vs. 0% P < 0.01). Quality of life is also significantly improved in the yoga arm, especially in the ECOG 2 performance status. Conclusions This study concludes that yoga along with standard antiemetic medication should be a part of the management plan for the cancer patients receiving highly emetogenic chemotherapy.",2019,There was a significant reduction in Grade 2 and 3 nausea (84% vs. 38% P < 0.01) and vomiting (14% vs. 0% P < 0.01).,"['South Asian population', 'The median age group of the patients was 51 years with male:female ratio 2:1, The Eastern Cooperative Oncology Group (ECOG) performance status was 0/1 in 38% of the selected population, while ECOG 2 in 62% of the patients', 'cancer patients receiving highly emetogenic chemotherapy']","['standard antiemetic agent', 'standard antiemetic therapy with yoga versus standard antiemetic therapy alone', 'emetogenic chemotherapy regimen grouped into yoga and standard antiemetic therapy']","['chemotherapy-induced nausea', 'Grade 2 and 3 nausea', 'Quality of life', 'quality of life', 'nausea and vomiting', 'vomiting', 'nausea and vomiting (CINV', 'anticipatory nausea and vomiting']","[{'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0027362', 'cui_str': 'Age Groups'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0430797', 'cui_str': 'Intracranial EEG'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic Drugs'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting (disorder)'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C3854611', 'cui_str': 'Anticipatory nausea'}]",,0.0243449,There was a significant reduction in Grade 2 and 3 nausea (84% vs. 38% P < 0.01) and vomiting (14% vs. 0% P < 0.01).,"[{'ForeName': 'Trupti O', 'Initials': 'TO', 'LastName': 'Kothari', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Jakhar', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}, {'ForeName': 'Dhirendra', 'Initials': 'D', 'LastName': 'Bothra', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}, {'ForeName': 'Neeti', 'Initials': 'N', 'LastName': 'Sharma', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}, {'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Kumar', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Baradia', 'Affiliation': 'Department of Radiation Oncology, Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_860_16'] 1179,31018018,Daily Use of Bilateral Custom-Made Ankle-Foot Orthoses for Fall Prevention in Older Adults: A Randomized Controlled Trial.,"OBJECTIVE To examine the effects of bilateral custom-made ankle-foot orthoses (AFOs) to prevent falls for older adults with concern about or at risk for falling over 12-month daily use. DESIGN Secondary analysis of a randomized controlled trial. SETTING Community-dwelling older adults. INTERVENTION Half of the participants were randomly allocated to an intervention group (IG) that received fitted walking shoes and bilateral custom-made AFOs, and the other half were randomly allocated to a control group (CG) that only received fitted walking shoes. MEASUREMENTS Self-reported fall history of 12-month duration was investigated at baseline and 12-month follow-up for both groups. Fall incidence rate and proportion of fallers were used as outcome measures to determine effects of 12-month footwear intervention in either group. PARTICIPANTS Adults aged 65 years and older with concern about or at risk for falling (n = 44). RESULTS No significant between-group differences in participant characteristics were observed at the baseline (P = .144-.882). Within the IG, significant reductions were found in the fall incidence rate (P = .039) and the proportion of fallers (P = .036) at the 12-month follow-up compared to the baseline. Within the CG, no significant change was found at the 12-month follow-up compared to the baseline for the fall incidence rate (P = .217) or the proportion of fallers (P = .757). When comparing the IG with the CG, there was no significant difference in the change from the baseline to the 12-month follow-up for the fall incidence rate (P = .572) or the proportion of fallers (P = .080). CONCLUSION This study failed to demonstrate a significant benefit of bilateral custom-made AFOs to reduce falls compared to fitted walking shoes. However, the AFO users had significant reductions in falls compared to the preceding year. A future study with a larger sample size is recommended to confirm these observations. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT02819011. J Am Geriatr Soc 67:1656-1661, 2019.",2019,No significant between-group differences in participant characteristics were observed at the baseline (P = .144-.882).,"['older adults with concern about or at risk for falling over 12-month daily use', 'Community-dwelling older adults', 'Adults aged 65\u2009years and older with concern about or at risk for falling (n\u2009=\u200944', 'Older Adults']","['bilateral custom-made ankle-foot orthoses (AFOs', 'intervention group (IG) that received fitted walking shoes and bilateral custom-made AFOs, and the other half were randomly allocated to a control group (CG) that only received fitted walking shoes', 'Bilateral Custom-Made Ankle-Foot Orthoses']","['proportion of fallers', 'Self-reported fall history of 12-month duration', 'Fall incidence rate and proportion of fallers', 'fall incidence rate']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1268740', 'cui_str': 'Fall risk'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0162343', 'cui_str': 'Customs'}, {'cui': 'C0003086', 'cui_str': 'Regio tarsalis'}, {'cui': 'C1283250', 'cui_str': 'Foot Orthotic Devices'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0185506', 'cui_str': 'Shoeing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.055343,No significant between-group differences in participant characteristics were observed at the baseline (P = .144-.882).,"[{'ForeName': 'Changhong', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Interdisciplinary Consortium on Advanced Motion Performance, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Rahul', 'Initials': 'R', 'LastName': 'Goel', 'Affiliation': 'Interdisciplinary Consortium on Advanced Motion Performance, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Qianzi', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Lepow', 'Affiliation': 'Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Najafi', 'Affiliation': 'Interdisciplinary Consortium on Advanced Motion Performance, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.15929'] 1180,28860128,Opioid Receptor Activation Impairs Hypoglycemic Counterregulation in Humans.,"Although intensive glycemic control improves outcomes in type 1 diabetes mellitus (T1DM), iatrogenic hypoglycemia limits its attainment. Recurrent and/or antecedent hypoglycemia causes blunting of protective counterregulatory responses, known as hypoglycemia-associated autonomic failure (HAAF). To determine whether and how opioid receptor activation induces HAAF in humans, 12 healthy subjects without diabetes (7 men, age 32.3 ± 2.2 years, BMI 25.1 ± 1.0 kg/m 2 ) participated in two study protocols in random order over two consecutive days. On day 1, subjects received two 120-min infusions of either saline or morphine (0.1 μg/kg/min), separated by a 120-min break (all euglycemic). On day 2, subjects underwent stepped hypoglycemic clamps (nadir 60 mg/dL) with evaluation of counterregulatory hormonal responses, endogenous glucose production (EGP, using 6,6-D2-glucose), and hypoglycemic symptoms. Morphine induced an ∼30% reduction in plasma epinephrine response together with reduced EGP and hypoglycemia-associated symptoms on day 2. Therefore, we report the first studies in humans demonstrating that pharmacologic opioid receptor activation induces some of the clinical and biochemical features of HAAF, thus elucidating the individual roles of various receptors involved in HAAF's development and suggesting novel pharmacologic approaches for safer intensive glycemic control in T1DM.",2017,Morphine induced an ∼30% reduction in plasma epinephrine response together with reduced EGP and hypoglycemia-associated symptoms on day 2.,"['12 healthy subjects without diabetes (7 men, age 32.3 ± 2.2 years, BMI 25.1 ± 1.0 kg/m 2 ) participated in two study protocols in random order over two consecutive days', 'Humans']","['Opioid Receptor Activation', 'stepped hypoglycemic clamps', 'intensive glycemic control', 'opioid receptor activation induces HAAF', 'Morphine', 'saline or morphine']","['plasma epinephrine response', 'counterregulatory hormonal responses, endogenous glucose production (EGP, using 6,6-D2-glucose), and hypoglycemic symptoms']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C0034801', 'cui_str': 'Receptors, Opiate'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic Drugs'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0458083', 'cui_str': 'Hormonal (qualifier value)'}, {'cui': 'C0205227', 'cui_str': 'Endogenous (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0033268'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic Drugs'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",12.0,0.0211095,Morphine induced an ∼30% reduction in plasma epinephrine response together with reduced EGP and hypoglycemia-associated symptoms on day 2.,"[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Carey', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Rebekah', 'Initials': 'R', 'LastName': 'Gospin', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Akankasha', 'Initials': 'A', 'LastName': 'Goyal', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Tomuta', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Oana', 'Initials': 'O', 'LastName': 'Sandu', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Armand', 'Initials': 'A', 'LastName': 'Mbanya', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lontchi-Yimagou', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Hulkower', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Shamoon', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Ilan', 'Initials': 'I', 'LastName': 'Gabriely', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Hawkins', 'Affiliation': 'Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY meredith.hawkins@einstein.yu.edu.'}]",Diabetes,['10.2337/db16-1478'] 1181,28670677,A Randomized Control Trial Comparing Combined Glandular Lidocaine Injection and Intraurethral Lidocaine Gel with Intraurethral Lidocaine Gel Alone in Cystoscopy and Urethral Dilatation.,"PURPOSE Cystoscopy is one of the most common urologic procedures. The aim of this study is to investigate the combined effect of intraurethral lidocaine gel and intraglandular injection of lidocaine 2% on pain during and after cystoscopy. Materials & Methods: In this double-blind, parallel group randomized clinical trial, 156 patients referred for double J removal, urethral dilatation, or cystoscopy were enrolled. The patients were divided into two groups, A and B. All patients received 20 cc of intraurethral lidocaine gel 2%. In group A (N = 75), lidocaine 2% was also injected into the glans penis. The patients in group B (N = 81) only received the intraurethral lidocaine gel. Cystoscopy was performed 10 minutes later. The primary outcome of interest was measured in terms of pain score (visual analogue scale) during and 5 minutes after cystoscopy. RESULTS Immediate pain score after the procedure was 3.4 ± 3 and 4.6 ± 3 in groups A and B, respectively (P = .011). CONCLUSION Based on the findings of the present study, lidocaine injection into the glans penis significantly reducedpain perception.",2017,"RESULTS Immediate pain score after the procedure was 3.4 ± 3 and 4.6 ± 3 in groups A and B, respectively (P = .011). ","['pain during and after cystoscopy', 'Cystoscopy and Urethral Dilatation', '156 patients referred for double J removal, urethral dilatation, or cystoscopy were enrolled']","['lidocaine', 'intraurethral lidocaine gel and intraglandular injection of lidocaine', 'intraurethral lidocaine gel', 'Combined Glandular Lidocaine Injection and Intraurethral Lidocaine Gel with Intraurethral Lidocaine Gel Alone']","['pain score (visual analogue scale', 'Immediate pain score']","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0010702', 'cui_str': 'Cystoscopy'}, {'cui': 'C1457917', 'cui_str': 'Urethral dilatation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0225353', 'cui_str': 'Glandular (qualifier value)'}, {'cui': 'C4081145', 'cui_str': 'Lidocaine Injection [Xylocaine]'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}]",156.0,0.0880202,"RESULTS Immediate pain score after the procedure was 3.4 ± 3 and 4.6 ± 3 in groups A and B, respectively (P = .011). ","[{'ForeName': 'Shahram', 'Initials': 'S', 'LastName': 'Gooran', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran.'}, {'ForeName': 'Pejman', 'Initials': 'P', 'LastName': 'Pourfakhr', 'Affiliation': 'Department of Anesthesiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Bahrami', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran.'}, {'ForeName': 'Ali Mohammad', 'Initials': 'AM', 'LastName': 'Fakhr Yasseri', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran. yasseri_2006@yahoo.com.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Javid', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran.'}, {'ForeName': 'Negar', 'Initials': 'N', 'LastName': 'Behtash', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Pourmand', 'Affiliation': 'Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Hassan-Abad Sq., Tehran, Iran.'}]",Urology journal,[] 1182,31618127,"Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer.","PURPOSE Oral mucositis (OM) remains a common, debilitating toxicity of radiation therapy (RT) for head and neck cancer. The goal of this phase IIb, multi-institutional, randomized, double-blind trial was to compare the efficacy and safety of GC4419, a superoxide dismutase mimetic, with placebo to reduce the duration, incidence, and severity of severe OM (SOM). PATIENTS AND METHODS A total of 223 patients (from 44 institutions) with locally advanced oral cavity or oropharynx cancer planned to be treated with definitive or postoperative intensity-modulated RT (IMRT; 60 to 72 Gy [≥ 50 Gy to two or more oral sites]) plus cisplatin (weekly or every 3 weeks) were randomly assigned to receive 30 mg (n = 73) or 90 mg (n = 76) of GC4419 or to receive placebo (n = 74) by 60-minute intravenous administration before each IMRT fraction. WHO grade of OM was assessed biweekly during IMRT and then weekly for up to 8 weeks after IMRT. The primary endpoint was duration of SOM tested for each active dose level versus placebo (intent-to-treat population, two-sided α of .05). The National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03, was used for adverse event grading. RESULTS Baseline patient and tumor characteristics as well as treatment delivery were balanced. With 90 mg GC4419 versus placebo, SOM duration was significantly reduced ( P = .024; median, 1.5 v 19 days). SOM incidence (43% v 65%; P = .009) and severity (grade 4 incidence, 16% v 30%; P = .045) also were improved. Intermediate improvements were seen with the 30-mg dose. Safety was comparable across arms, with no significant GC4419-specific toxicity nor increase of known toxicities of IMRT plus cisplatin. The 2-year follow-up for tumor outcomes is ongoing. CONCLUSION GC4419 at a dose of 90 mg produced a significant, clinically meaningful reduction of SOM duration, incidence, and severity with acceptable safety. A phase III trial (ROMAN; ClinicalTrials.gov identifier: NCT03689712) has begun.",2019,"With 90 mg GC4419 versus placebo, SOM duration was significantly reduced ( P = .024; median, 1.5 v 19 days).","['223 patients (from 44 institutions) with locally advanced oral cavity or oropharynx cancer planned to be treated with', 'For Head and Neck Cancer', 'head and neck cancer']","['definitive or postoperative intensity-modulated RT (IMRT; 60 to 72 Gy [≥ 50 Gy to two or more oral sites]) plus cisplatin', 'Radiotherapy and Cisplatin', 'GC4419, a superoxide dismutase mimetic, with placebo', 'GC4419 Versus Placebo', 'radiation therapy (RT', 'placebo', 'GC4419 or to receive placebo']","['SOM duration, incidence, and severity with acceptable safety', 'Safety', 'WHO grade of OM', 'efficacy and safety', 'duration, incidence, and severity of severe OM (SOM', 'SOM duration', 'Severe Oral Mucositis', 'GC4419-specific toxicity', 'SOM incidence', 'duration of SOM']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0226896', 'cui_str': 'Cavitas Oris'}, {'cui': 'C2349952', 'cui_str': 'Cancer of Oropharnyx'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0278996', 'cui_str': 'Cancer of Head and Neck'}]","[{'cui': 'C0443196', 'cui_str': 'Definitive (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0443264', 'cui_str': 'Modulated (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C0069638', 'cui_str': 'orgotein'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1568868', 'cui_str': 'Oral Mucositis'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",223.0,0.508431,"With 90 mg GC4419 versus placebo, SOM duration was significantly reduced ( P = .024; median, 1.5 v 19 days).","[{'ForeName': 'Carryn M', 'Initials': 'CM', 'LastName': 'Anderson', 'Affiliation': 'University of Iowa Hospitals and Clinics, Iowa City, IA.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Lee', 'Affiliation': 'Cancer Care Northwest, Spokane, WA.'}, {'ForeName': 'Deborah P', 'Initials': 'DP', 'LastName': 'Saunders', 'Affiliation': 'North East Cancer Centre, Health Sciences North, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.'}, {'ForeName': 'Amarinthia', 'Initials': 'A', 'LastName': 'Curtis', 'Affiliation': 'Spartanburg Medical Center, Spartanburg, SC.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Dunlap', 'Affiliation': 'University of Louisville/James Graham Brown Cancer Center, Louisville, KY.'}, {'ForeName': 'Chaitali', 'Initials': 'C', 'LastName': 'Nangia', 'Affiliation': 'University of California Irvine Medical Center, Orange, CA.'}, {'ForeName': 'Arielle S', 'Initials': 'AS', 'LastName': 'Lee', 'Affiliation': 'HOPE Cancer Center of East Texas, Tyler, TX.'}, {'ForeName': 'Sharon M', 'Initials': 'SM', 'LastName': 'Gordon', 'Affiliation': 'East Carolina University, Greenville, NC.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Kovoor', 'Affiliation': 'Texas Oncology, Plano West, Plano, TX.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Arevalo-Araujo', 'Affiliation': 'Pasco Pinellas Cancer Center, Holiday, FL.'}, {'ForeName': 'Voichita', 'Initials': 'V', 'LastName': 'Bar-Ad', 'Affiliation': 'Thomas Jefferson University, Philadelphia, PA.'}, {'ForeName': 'Abhinand', 'Initials': 'A', 'LastName': 'Peddada', 'Affiliation': 'Renown Regional Medical Center, Reno, NV.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Colvett', 'Affiliation': 'Mountain States Health Alliance, Johnson City, TN.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Miller', 'Affiliation': 'Jersey Shore University Medical Center, Neptune, NJ.'}, {'ForeName': 'Anshu K', 'Initials': 'AK', 'LastName': 'Jain', 'Affiliation': 'Ashland-Bellefonte Cancer Center, Ashland, KY.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wheeler', 'Affiliation': 'Goshen Center for Cancer Care, Goshen, IN.'}, {'ForeName': 'Dukagjin', 'Initials': 'D', 'LastName': 'Blakaj', 'Affiliation': 'James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Bonomi', 'Affiliation': 'James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH.'}, {'ForeName': 'Sanjiv S', 'Initials': 'SS', 'LastName': 'Agarwala', 'Affiliation': ""St Luke's Cancer Center and Temple University, Easton, PA.""}, {'ForeName': 'Madhur', 'Initials': 'M', 'LastName': 'Garg', 'Affiliation': 'Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Worden', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Holmlund', 'Affiliation': 'Galera Therapeutics, Malvern, PA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Brill', 'Affiliation': 'Galera Therapeutics, Malvern, PA.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Downs', 'Affiliation': 'Statistics Collaborative, Washington, DC.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Sonis', 'Affiliation': 'Primary Endpoint Solutions, Watertown, MA.'}, {'ForeName': 'Sanford', 'Initials': 'S', 'LastName': 'Katz', 'Affiliation': 'Willis-Knighton Cancer Center, Shreveport, LA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Buatti', 'Affiliation': 'University of Iowa Hospitals and Clinics, Iowa City, IA.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.01507'] 1183,31616932,"A Moderate-Fat Diet with One Avocado per Day Increases Plasma Antioxidants and Decreases the Oxidation of Small, Dense LDL in Adults with Overweight and Obesity: A Randomized Controlled Trial.","BACKGROUND Avocados are a nutrient-dense source of MUFAs and are rich in antioxidants. Avocados have an additional LDL cholesterol (LDL-C) lowering effect beyond that observed when their MUFAs are substituted for SFAs, especially on small, dense LDL (sdLDL) particles, which are susceptible to in vivo oxidation and associated with increased risk of cardiovascular disease (CVD). OBJECTIVES We investigated whether a healthy diet with 1 avocado daily decreased the following secondary outcomes: circulating oxidized LDL (oxLDL) and related oxidative stress markers. METHODS A randomized, crossover, controlled feeding trial was conducted with 45 men and women, aged 21-70 y, with overweight or obesity and elevated LDL-C (25th-90th percentile). Three cholesterol-lowering diets were provided (5 wk each) in random sequences: a lower-fat (LF) diet (24% calories from fat-7% SFAs, 11% MUFAs, 6% PUFAs) and 2 moderate-fat (MF) diets (34% calories from fat-6% SFAs, 17% MUFAs, 9% PUFAs): the avocado (AV) diet included 1 Hass avocado (∼136 g) per day, and the MF diet used high oleic acid oils to match the fatty acid profile of 1 avocado. A general linear mixed model was used to analyze the treatment effects. RESULTS Compared with baseline, the AV diet significantly decreased circulating oxLDL (-7.0 U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05). The change in oxLDL caused by the AV diet was significantly correlated with the changes in the number of sdLDL particles (r = 0.32, P = 0.0002) but not large, buoyant LDL particles. CONCLUSIONS One avocado a day in a heart-healthy diet decreased oxLDL in adults with overweight and obesity, and the effect was associated with the reduction in sdLDL. This trial was registered at http://www.clinicaltrials.gov as NCT01235832.",2020,"U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05).","['45 men and women, aged 21-70 y, with overweight or obesity and elevated LDL-C (25th-90th percentile', 'Adults with Overweight and Obesity']","['oxidized LDL (oxLDL', 'avocado (AV) diet included 1 Hass avocado (∼136 g) per day, and the MF diet used high oleic acid oils']","['plasma lutein concentration', 'number of sdLDL particles', 'circulating oxLDL', 'Oxidation of Small, Dense LDL']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0330230', 'cui_str': 'Avocado'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0028929', 'cui_str': 'Oleic Acids'}, {'cui': 'C0028908', 'cui_str': 'Oils'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0348035', 'cui_str': 'oxidized low density lipoprotein'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]",,0.0615617,"U/L, -8.8%, P = 0.0004) and increased plasma lutein concentration (19.6 nmol/L, 68.7%, P < 0.0001), and both changes differed significantly from that after the MF and LF diets (P ≤ 0.05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Tao', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Hao', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Todd H', 'Initials': 'TH', 'LastName': 'Stanley', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Kuan-Hsun', 'Initials': 'KH', 'LastName': 'Huang', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Lambert', 'Affiliation': 'Department of Food Science, Pennsylvania State University, University Park, PA, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, Pennsylvania State University, University Park, PA, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz231'] 1184,29165000,Building Better Caregivers: A Pragmatic 12-Month Trial of a Community-Based Workshop for Caregivers of Cognitively Impaired Adults.,"Building Better Caregivers (BBC), a community 6-week, peer-led intervention, targets family caregivers of those with cognitive impairments. BBC was implemented in four geographically scattered areas. Self-report data were collected at baseline, 6 months, and 1 year. Primary outcome were caregiver strain and depression. Secondary outcomes included caregiver burden, stress, fatigue, pain, sleep, self-rated health, exercise, self-efficacy, and caregiver and care partner health care utilization. Paired t tests examined 6 month and 1-year improvements. General linear models examined associations between baseline and 6-month changes in self-efficacy and 12-month primary outcomes. Eighty-three participants (75% of eligible) completed 12-month data. Caregiver strain and depression improved significantly (Effect Sizes = .30 and .41). All secondary outcomes except exercise and caregiver health care utilization improved significantly. Baseline and 6-month improvements in self-efficacy were associated with improvements in caregiver strain and depression. In this pilot pragmatic study, BBC appears to assist caregivers while reducing care partner health care utilization. Self-efficacy appears to moderate these outcomes.",2019,Caregiver strain and depression improved significantly (Effect Sizes = .30 and .41).,"['Building Better Caregivers', 'Eighty-three participants (75% of eligible) completed 12-month data', 'Caregivers of Cognitively Impaired Adults']",['Community-Based Workshop'],"['BBC', 'caregiver burden, stress, fatigue, pain, sleep, self-rated health, exercise, self-efficacy, and caregiver and care partner health care utilization', 'exercise and caregiver health care utilization', 'Caregiver strain and depression', 'caregiver strain and depression', 'Self-efficacy', 'self-efficacy']","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C4517888', 'cui_str': '83'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}]","[{'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0030672', 'cui_str': 'Patient Acceptance of Healthcare'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]",83.0,0.0432217,Caregiver strain and depression improved significantly (Effect Sizes = .30 and .41).,"[{'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Lorig', 'Affiliation': '1 Stanford University, CA, USA.'}, {'ForeName': 'Philip L', 'Initials': 'PL', 'LastName': 'Ritter', 'Affiliation': '1 Stanford University, CA, USA.'}, {'ForeName': 'Diana D', 'Initials': 'DD', 'LastName': 'Laurent', 'Affiliation': '1 Stanford University, CA, USA.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Yank', 'Affiliation': '2 University of California, San Francisco, USA.'}]",Journal of applied gerontology : the official journal of the Southern Gerontological Society,['10.1177/0733464817741682'] 1185,29293361,"The Effectiveness of Platelet-Rich Plasma Injections in Gluteal Tendinopathy: A Randomized, Double-Blind Controlled Trial Comparing a Single Platelet-Rich Plasma Injection With a Single Corticosteroid Injection.","BACKGROUND Gluteus medius/minimus tendinopathy is a common cause of lateral hip pain or greater trochanteric pain syndrome. HYPOTHESIS There would be no difference in the modified Harris Hip Score (mHHS) between a single platelet-rich plasma (PRP) injection compared with a corticosteroid injection in the treatment of gluteal tendinopathy. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS There were 228 consecutive patients referred with gluteal tendinopathy who were screened to enroll 80 participants; 148 were excluded (refusal: n = 42; previous surgery or sciatica: n = 50; osteoarthritis, n = 17; full-thickness tendon tear, n = 17; other: n = 22). Participants were randomized (1:1) to receive either a blinded glucocorticoid or PRP injection intratendinously under ultrasound guidance. A pain and functional assessment was performed using the mHHS questionnaire at 0, 2, 6, and 12 weeks and the patient acceptable symptom state (PASS) and minimal clinically important difference (MCID) at 12 weeks. RESULTS Participants had a mean age of 60 years, a ratio of female to male of 9:1, and mean duration of symptoms of >14 months. Pain and function measured by the mean mHHS showed no difference at 2 weeks (corticosteroid: 66.95 ± 15.14 vs PRP: 65.23 ± 11.60) or 6 weeks (corticosteroid: 69.51 ± 14.78 vs PRP: 68.79 ± 13.33). The mean mHHS was significantly improved at 12 weeks in the PRP group (74.05 ± 13.92) compared with the corticosteroid group (67.13 ± 16.04) ( P = .048). The proportion of participants who achieved an outcome score of ≥74 at 12 weeks was 17 of 37 (45.9%) in the corticosteroid group and 25 of 39 (64.1%) in the PRP group. The proportion of participants who achieved the MCID of more than 8 points at 12 weeks was 21 of 37 (56.7%) in the corticosteroid group and 32 of 39 (82%) in the PRP group ( P = .016). CONCLUSION Patients with chronic gluteal tendinopathy >4 months, diagnosed with both clinical and radiological examinations, achieved greater clinical improvement at 12 weeks when treated with a single PRP injection than those treated with a single corticosteroid injection. Registration: ACTRN12613000677707 (Australian New Zealand Clinical Trials Registry).",2018,The mean mHHS was significantly improved at 12 weeks in the PRP group (74.05 ± 13.92) compared with the corticosteroid group (67.13 ± 16.04) ( P = .048).,"['Gluteal Tendinopathy', 'Registration', 'Participants had a mean age of 60 years, a ratio of female to male of 9:1, and mean duration of symptoms of >14 months', '228 consecutive patients referred with gluteal tendinopathy who were screened to enroll 80 participants; 148 were excluded (refusal: n = 42; previous surgery or sciatica: n = 50; osteoarthritis, n = 17; full-thickness tendon tear, n = 17; other: n = 22']","['Platelet-Rich Plasma Injections', 'Single Platelet-Rich Plasma Injection With a Single Corticosteroid Injection', 'blinded glucocorticoid or PRP injection intratendinously under ultrasound guidance', 'corticosteroid injection']","['Pain and function', 'modified Harris Hip Score (mHHS', 'mean mHHS']","[{'cui': 'C1568272', 'cui_str': 'Tendinopathy'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts (observable entity)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0036396', 'cui_str': 'Sciatic Neuralgia'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0439809', 'cui_str': 'Full thickness (qualifier value)'}, {'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0039409', 'cui_str': 'Tears'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma (substance)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure (procedure)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C2919875', 'cui_str': 'Harris hip score (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",228.0,0.238652,The mean mHHS was significantly improved at 12 weeks in the PRP group (74.05 ± 13.92) compared with the corticosteroid group (67.13 ± 16.04) ( P = .048).,"[{'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Fitzpatrick', 'Affiliation': 'School of Surgery, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Max K', 'Initials': 'MK', 'LastName': 'Bulsara', 'Affiliation': 'Institute for Health Research, University of Notre Dame, Fremantle, Western Australia, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': ""O'Donnell"", 'Affiliation': 'Hip Arthroscopy Australia, Richmond, Victoria, Australia.'}, {'ForeName': 'Paul Robert', 'Initials': 'PR', 'LastName': 'McCrory', 'Affiliation': 'Melbourne Brain Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia.'}, {'ForeName': 'Ming Hao', 'Initials': 'MH', 'LastName': 'Zheng', 'Affiliation': 'School of Surgery, University of Western Australia, Crawley, Western Australia, Australia.'}]",The American journal of sports medicine,['10.1177/0363546517745525'] 1186,31607604,Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB).,"BACKGROUND The RV3-BB human neonatal rotavirus vaccine was developed to provide protection from severe rotavirus disease from birth. The aim of this study was to investigate the potential for mutual interference in the immunogenicity of oral polio vaccine (OPV) and RV3-BB. METHODS A randomized, placebo-controlled trial involving 1649 participants was conducted from January 2013 to July 2016 in Central Java and Yogyakarta, Indonesia. Participants received three doses of oral RV3-BB, with the first dose given at 0-5 days (neonatal schedule) or ~8 weeks (infant schedule), or placebo. Two sub-studies assessed the immunogenicity of RV3-BB when co-administered with either trivalent OPV (OPV group, n = 282) or inactivated polio vaccine (IPV group, n = 333). Serum samples were tested for antibodies to poliovirus strains 1, 2 and 3 by neutralization assays following doses 1 and 4 of OPV. RESULTS Sero-protective rates to poliovirus type 1, 2 or 3 were similar (range 0.96-1.00) after four doses of OPV co-administered with RV3-BB compared with placebo. Serum IgA responses to RV3-BB were similar when co-administered with either OPV or IPV (difference in proportions OPV vs IPV: sIgA responses; neonatal schedule 0.01, 95% CI -0.12 to 0.14; p = 0.847; infant schedule -0.10, 95% CI -0.21 to -0.001; p = 0.046: sIgA GMT ratio: neonatal schedule 1.23, 95% CI 0.71-2.14, p = 0.463 or infant schedule 1.20, 95% CI 0.74-1.96, p = 0.448). CONCLUSIONS The co-administration of OPV with RV3-BB rotavirus vaccine in a birth dose strategy did not reduce the immunogenicity of either vaccine. These findings support the use of a neonatal RV3-BB vaccine where either OPV or IPV is used in the routine vaccination schedule.",2019,"Serum samples were tested for antibodies to poliovirus strains 1, 2 and 3 by neutralization assays following doses 1 and 4 of OPV. ","['1649 participants was conducted from January 2013 to July 2016 in Central Java and Yogyakarta, Indonesia']","['RV3-BB rotavirus vaccine', 'oral poliovirus vaccine', 'oral polio vaccine (OPV) and RV3-BB', 'oral RV3-BB', 'placebo', 'OPV or IPV ', 'trivalent OPV (OPV group, n\u202f=\u202f282) or inactivated polio vaccine (IPV']","['Immunogenicity', 'Serum IgA responses to RV3-BB', 'immunogenicity of RV3-BB']","[{'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205803', 'cui_str': 'Java'}, {'cui': 'C0021247', 'cui_str': 'East Indies'}]","[{'cui': 'C0674210', 'cui_str': 'R(t)V3'}, {'cui': 'C0597418', 'cui_str': 'Rotavirus Vaccines'}, {'cui': 'C0032375', 'cui_str': 'Sabin Vaccine'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0032371', 'cui_str': 'Poliomyelitis Infection'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517681', 'cui_str': '282'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0674210', 'cui_str': 'R(t)V3'}]",1649.0,0.341991,"Serum samples were tested for antibodies to poliovirus strains 1, 2 and 3 by neutralization assays following doses 1 and 4 of OPV. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Cowley', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.""}, {'ForeName': 'Rini Mulia', 'Initials': 'RM', 'LastName': 'Sari', 'Affiliation': 'Bio Farma PT, Bandung, Indonesia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Handley', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Medicines Development for Global Health, Melbourne, Victoria, Australia.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Watts', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Novilia S', 'Initials': 'NS', 'LastName': 'Bachtiar', 'Affiliation': 'Bio Farma PT, Bandung, Indonesia.'}, {'ForeName': 'Jarir', 'Initials': 'J', 'LastName': 'At Thobari', 'Affiliation': 'Departments of Pharmacology and Therapy, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Cahya Dewi', 'Initials': 'CD', 'LastName': 'Satria', 'Affiliation': 'Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Bogdanovic-Sakran', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Hera', 'Initials': 'H', 'LastName': 'Nirwati', 'Affiliation': 'Departments of Microbiology, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Orsini', 'Affiliation': ""Clinical Epidemiology and Biostatistics Unit and the Melbourne Children's Trials Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Lee', 'Affiliation': ""Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Clinical Epidemiology and Biostatistics Unit and the Melbourne Children's Trials Centre, Murdoch Children's Research Institute, Parkville, Victoria, Australia.""}, {'ForeName': 'Carl D', 'Initials': 'CD', 'LastName': 'Kirkwood', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Bill and Melinda Gates Foundation, Seattle, WA, USA.""}, {'ForeName': 'Yati', 'Initials': 'Y', 'LastName': 'Soenarto', 'Affiliation': 'Paediatric Research Office, Department of Paediatrics Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Bines', 'Affiliation': ""Enteric Diseases, Murdoch Children's Research Institute, Parkville, Victoria, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia; Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Parkville, Victoria, Australia. Electronic address: jebines@unimelb.edu.au.""}]",Vaccine,['10.1016/j.vaccine.2019.09.071'] 1187,31407866,Effects of sodium-glucose cotransporter-2 inhibitors on the cardiovascular and renal complications of type 2 diabetes.,"Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have been shown to mitigate the risks of cardiovascular (CV) and renal complications in patients with type 2 diabetes (T2D) and CV risk factors or CV disease (CVD). In CV outcomes trials (CVOTs) of patients with T2D and established CVD or multiple CV risk factors, empagliflozin and canagliflozin were associated with significant reductions in the risks of major adverse CV events (MACE), hospitalization for heart failure (HF) and kidney disease progression. In the DECLARE-TIMI 58 study, in which the majority of patients did not have established CVD, dapagliflozin was associated with significant reductions in the composite end point of CV death or hospitalization for HF and was noninferior to placebo with regard to MACE; although patients had relatively good renal function, dapagliflozin also showed renal benefits similar to those seen with empagliflozin and canagliflozin. This article reviews the increased risk of CVD and renal disease in patients with T2D and discusses the potential mechanisms of the cardioprotective and renoprotective effects of SGLT-2i therapy. The observed improvements in CV and renal outcomes with SGLT-2is in CVOTs suggest a class effect in this patient population and have influenced treatment guidelines for the way add-on therapy to metformin is initiated in patients with T2D and high CV risk. The overall cardioprotective and renoprotective effects of SGLT-2is in patients with T2D and high CV risk are most likely attributable to multiple mechanisms, including cardiac, haemodynamic, metabolic, anti-inflammatory and renal effects.",2020,"The overall cardioprotective and renoprotective effects of SGLT-2is in patients with T2D and high CV risk are most likely attributable to multiple mechanisms, including cardiac, haemodynamic, metabolic, anti-inflammatory and renal effects.","['type 2 diabetes', 'patients with T2D and high CV risk', 'patients with type 2 diabetes (T2D) and CV risk factors or CV disease (CVD', 'patients with T2D']","['sodium-glucose cotransporter-2 inhibitors', 'empagliflozin', 'placebo', 'Sodium-glucose cotransporter-2 inhibitors (SGLT-2is', 'metformin']","['cardiovascular and renal complications', 'risks of major adverse CV events (MACE), hospitalization for heart failure (HF) and kidney disease progression', 'CV and renal outcomes', 'CV death or hospitalization']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0017739', 'cui_str': 'Sodium-Glucose Transport Proteins'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",58.0,0.0276799,"The overall cardioprotective and renoprotective effects of SGLT-2is in patients with T2D and high CV risk are most likely attributable to multiple mechanisms, including cardiac, haemodynamic, metabolic, anti-inflammatory and renal effects.","[{'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Chilton', 'Affiliation': 'Division of Cardiology, University of Texas Health Science Center, San Antonio, Texas.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13854'] 1188,28853107,A Comparative Study on the Clinical Efficacy of Two Different Disposable Circumcision Suture Devices in Adult Males.,"PURPOSE We evaluated the safety and efficacy of two different kinds of disposable circumcision suture devices in adult men. MATERIALS AND METHODS Adult male patients (n = 179; mean age: 23.7 years) with redundant prepuce and/or phimosis were included in a clinical trial from July 2015 to August 2016. Patients were divided into 2 groups: group A using the Langhe disposable circumcision suture device (n = 89), and group B using the Daming disposable circumcision suture device (n = 94). RESULTS Intraoperative and postoperative bleeding were more serious in the group A of disposable circumcision suture device compared with the group B of disposable circumcision suture device (4.21 ± 1.31 ml) versus (2.56 ± 1.45 ml). Patients in the group B of disposable circumcision suture device had a longer swelling time (group A versus group B: 11.7 ± 0.9 days versus 14.5 ± 1.4 days), the postoperative pain score in the 7 days after surgery (group A versus group B: 2.9 ± 0.9 versus 3.8 ± 1.5), and higher postoperative infection rate (group A versus group B: 4.7% versus 13.8%), the differences were statistically significant (p < 0.05). CONCLUSION postoperative complications of the two kinds of disposable circumcision suture devices are different. We should pay attention to the risk of postoperative bleeding when the patients use the Langhe disposable circumcision suture device, while the patients who use the Langhe disposable circumcision suture device will have a longer healing time, and postoperative pain and the risk of infection cannot be ignored after the surgery.",2017,"RESULTS Intraoperative and postoperative bleeding were more serious in the group A of disposable circumcision suture device compared with the group B of disposable circumcision suture device (4.21 ± 1.31 ml) versus (2.56 ± 1.45 ml).","['Adult Males', 'and/or phimosis were included in a clinical trial from July 2015 to August 2016', 'Adult male patients (n = 179; mean age: 23.7 years) with redundant prepuce', 'adult men']","['disposable circumcision suture devices', 'disposable circumcision suture device', 'Daming disposable circumcision suture device', 'Two Different Disposable Circumcision Suture Devices', 'Langhe disposable circumcision suture device']","['longer swelling time', 'safety and efficacy', 'postoperative infection rate', 'postoperative pain score', 'Intraoperative and postoperative bleeding']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0031538', 'cui_str': 'Phimosis'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0345325', 'cui_str': 'Redundant prepuce (disorder)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0403327', 'cui_str': 'Ritual circumcision (procedure)'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture (procedure)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0038999', 'cui_str': 'Bulging (morphologic abnormality)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0392618', 'cui_str': 'Postoperative infection (disorder)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0032788', 'cui_str': 'Blood Loss, Postoperative'}]",,0.0253598,"RESULTS Intraoperative and postoperative bleeding were more serious in the group A of disposable circumcision suture device compared with the group B of disposable circumcision suture device (4.21 ± 1.31 ml) versus (2.56 ± 1.45 ml).","[{'ForeName': 'Junwen', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China. wind-301@163.com.""}, {'ForeName': 'Jihan', 'Initials': 'J', 'LastName': 'Shi', 'Affiliation': ""Departments of anesthesiology, the first people's hospital of Huzhou, Zhejiang province, China.""}, {'ForeName': 'Jianguo', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}, {'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}, {'ForeName': 'Jianer', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}, {'ForeName': 'Weigao', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}, {'ForeName': 'Rongjiang', 'Initials': 'R', 'LastName': 'Wang', 'Affiliation': ""Departments of Urology, the first people's hospital of Huzhou, Zhejiang province,China.""}]",Urology journal,[] 1189,31712211,"A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.","Infection of long-term central venous catheters (CVCs) remains a challenge in the clinical management of cancer patients. We aimed to determine whether a lock solution with taurolidine-citrate-heparin would be more effective than placebo for preventing nontunneled CVC infection in high-risk neutropenic hematologic patients. We performed a prospective, multicenter, randomized (1:1), double-blind, parallel, superiority, placebo-controlled trial involving 150 hematological patients with neutropenia carrying nontunneled CVCs who were assigned to receive CVC lock solution with taurolidine-citrate-heparin or heparin alone. The primary endpoint was bacterial colonization of the CVC hubs. Secondary endpoints were the incidence of catheter-related bloodstream infection (CRBSI), CVC removal, adverse events related to the lock solution, and the 30-day case fatality rate. CVC lock solution with taurolidine-citrate-heparin was associated with less colonization of the CVC hubs than that with placebo, with no statistically significant differences: 4.1%, versus 10.1% (relative risk [RR] = 0.41, 95% confidence interval [CI] = 0.11 to 1.52), with a cumulative incidence of 4.17 (95% CI = 0.87 to 11.70) and 10.14 (95% CI = 4.18 to 19.79), respectively. There were no significant differences regarding the secondary endpoints. Only three episodes of CRBSI occurred during the study period. No adverse events related to the administration of the lock solution occurred. In this trial involving high-risk patients carrying nontunneled CVCs, the use of taurolidine-citrate-heparin did not show a benefit over the use of placebo. Nevertheless, the safety of this prevention strategy and the trend toward less hub colonization in the taurolidine-citrate-heparin group raise the interest in assessing its efficacy in centers with higher rates of CRBSI. (This study has been registered in ISRCTN under identifier ISRCTN47102251.).",2020,No adverse events related to the administration of the lock solution occurred.,"['cancer patients', '150 hematological patients with neutropenia carrying non-tunnelled CVCs', 'high-risk neutropenic hematologic patients', 'neutropenic hematological patients']","['CVC lock solution with taurolidine-citrate-heparin or heparin alone', 'long-term central venous catheters (CVCs', 'Taurolidine-citrate lock solution', 'placebo', 'taurolidine-citrate-heparin']","['CRBSI', 'colonization of the CVC', 'incidence of catheter-related bloodstream infection (CRBSI), CVC removal, adverse events related to the lock solution, and 30-day case-fatality rate', 'bacterial colonization of the CVC hubs']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0205488', 'cui_str': 'Hematologic (qualifier value)'}]","[{'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0144567', 'cui_str': 'taurolidine'}, {'cui': 'C0376259', 'cui_str': 'Citrate'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C1145640', 'cui_str': 'Central Venous Catheters'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0282250', 'cui_str': 'Case Fatality Rate'}, {'cui': 'C2747813', 'cui_str': 'Bacterial colonisation'}]",150.0,0.559102,No adverse events related to the administration of the lock solution occurred.,"[{'ForeName': 'Carlota', 'Initials': 'C', 'LastName': 'Gudiol', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain carlotagudiol@gmail.com.""}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Arnan', 'Affiliation': ""Hematology Department, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Aguilar-Guisado', 'Affiliation': 'Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Royo-Cebrecos', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Sánchez-Ortega', 'Affiliation': ""Hematology Department, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Montero', 'Affiliation': 'Deparment of Hematology, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Martín-Gandul', 'Affiliation': 'Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.'}, {'ForeName': 'Júlia', 'Initials': 'J', 'LastName': 'Laporte-Amargós', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Adaia', 'Initials': 'A', 'LastName': 'Albasanz-Puig', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Sermed', 'Initials': 'S', 'LastName': 'Nicolae', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Perayre', 'Affiliation': ""Pharmacy Department, Clinical Trial Unit, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Damaris', 'Initials': 'D', 'LastName': 'Berbel', 'Affiliation': ""Microbiology Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Tebe', 'Affiliation': ""Biostatistics Unit, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Riera', 'Affiliation': ""Hematology Department, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Sureda', 'Affiliation': ""Hematology Department, Institut Català d'Oncologia, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'José Miguel', 'Initials': 'JM', 'LastName': 'Cisneros', 'Affiliation': 'Department of Infectious Diseases, Microbiology, and Preventive Medicine, University Hospital Virgen del Rocío-Institute of Biomedicine of Seville, Seville, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Carratalà', 'Affiliation': ""Infectious Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.""}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.01521-19'] 1190,27576880,Percutaneous Nephrolithotomy Using Split Amplatz Sheath: A Randomized Clinical Trial.,"PURPOSE To compare the outcome of percutaneous nephrolithotomy (PCNL) using split or intact Amplatz sheath. MATERIALS AND METHODS Seventy two patients who underwent PCNL were randomly divided into two groups; PCNL using intact (group 1) and split (group 2) Amplatz sheath. Preoperative data, operative time, largest extracted stone size, fluoroscopy and lithotripsy time, and serum biochemistry tests before and after PCNL were evaluated. RESULTS Preoperative features and stone size were not significantly different between the groups. There were no significant differences in complications and postoperative changes in hemoglobin and serum electrolytes. Stone free rate in group 2 (88.1%) was insignificantly higher than group 1 (83.3%) (p = .05), but in staghorn stones and stones larger than 1000 mm2, stone free rate in group 2 was significantly higher than group 1 (82% vs. 72%). The mean extracted stone size in group 2 (150 ± 49) was significantly larger than group 1 (40 ± 16 mm2) (p < .005). The mean operative, lithotripsy and fluoroscopy times were significantly longer in group 1. CONCLUSION Using split Amplatz sheath in PCNL facilitates extraction of larger stone fragments which could contribute to shorter fluoroscopy, lithotripsy and operative times. .",2016,"The mean operative, lithotripsy and fluoroscopy times were significantly longer in group 1. ",['Seventy two patients who underwent PCNL'],"['percutaneous nephrolithotomy (PCNL) using split or intact Amplatz sheath', 'Percutaneous Nephrolithotomy Using Split Amplatz Sheath', 'PCNL using intact (group 1) and split (group 2) Amplatz sheath']","['complications and postoperative changes in hemoglobin and serum electrolytes', 'mean extracted stone size', 'Preoperative data, operative time, largest extracted stone size, fluoroscopy and lithotripsy time, and serum biochemistry tests', 'stone size', 'mean operative, lithotripsy and fluoroscopy times', 'stone free rate', 'staghorn stones and stones larger', 'Stone free rate']","[{'cui': 'C4319632', 'cui_str': 'Seventy-two'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0009653', 'cui_str': 'Condoms'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}]","[{'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0587355', 'cui_str': 'Electrolytes measurement, serum (procedure)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0023878', 'cui_str': 'Litholapaxy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0332249', 'cui_str': 'Staghorn (qualifier value)'}]",72.0,0.0204349,"The mean operative, lithotripsy and fluoroscopy times were significantly longer in group 1. ","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Tabibi', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran,Iran.'}, {'ForeName': 'Amir Reza', 'Initials': 'AR', 'LastName': 'Abedi', 'Affiliation': 'Urology and Nephrology Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Hadi', 'Initials': 'MH', 'LastName': 'Radfar', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran,Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Kamranmanesh', 'Affiliation': 'Anesthesiology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Hormoz', 'Initials': 'H', 'LastName': 'Karami', 'Affiliation': 'Yazd University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Davood', 'Initials': 'D', 'LastName': 'Arab', 'Affiliation': 'Semnan University of Medical Sciences, Semnan, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Pakmanesh', 'Affiliation': 'Kerman University of Medical Sciences, Kerman, Iran.'}]",Urology journal,[] 1191,31419353,Preserved brain functional plasticity after upper limb task-oriented rehabilitation in progressive multiple sclerosis.,"BACKGROUND AND PURPOSE Limited research has been dedicated to upper limb (UL) rehabilitation in progressive multiple sclerosis (PMS). The objective in this pilot study was to investigate the effect of task-oriented UL rehabilitation in PMS and to perform explorative analyses of the magnetic resonance imaging (MRI) correlates of changes in motor performance. METHODS Twenty-six PMS patients with mild UL impairment were prospectively enrolled and randomized into two groups: an active treatment group (ATG, n = 13) and a passive treatment group (PTG, n = 13). At baseline and after training, patients underwent MRI scans with structural and functional imaging and were evaluated with the action research arm test, the nine-hole peg test, the ABILHAND scale and the modified fatigue impact scale (MFIS). Measures of motor finger performance were obtained by engineered glove measuring. RESULTS After rehabilitation, the ATG improved in several finger motor tasks (0.001 ≤ P ≤ 0.03, 0.72 ≤ Cohen's d ≤ 1.22) and showed reduced MFIS scores compared with the PTG (P = 0.03). The ATG showed increased functional connectivity within the cerebellar and thalamic resting state networks compared with the PTG (P < 0.05). Correlations were found between several measures of motor improvement and thalamic and sensorimotor networks (0.87 ≤ r ≤ 0.93, 0.001 ≤ P ≤ 0.03). No changes in cerebral volumes and diffusion tensor imaging derived measures were detected. CONCLUSIONS Progressive multiple sclerosis patients with mild UL dysfunction benefit from task-oriented UL rehabilitation, which seems to be more efficient than simple passive mobilization. Despite a high burden of disability and brain damage, functional adaptive capacities seem to be preserved, thus providing a rationale for the use of rehabilitative treatments in late PMS.",2020,ATG showed increased functional connectivity within the cerebellar and thalamic resting state networks compared to PTG (p<0.05).,"['PMS patients with mild ULD', 'progressive multiple sclerosis', 'Twenty-six PMS patients with mild UL impairment']","['active treatment group (ATG, n=13) and passive treatment group (PTG', 'task-oriented UL rehabilitation', 'upper limb task-oriented rehabilitation']","['motor finger performance', 'motor improvement and thalamic and sensorimotor networks', 'functional connectivity', 'several finger motor tasks', 'MFIS scores', 'scale and modified fatigue impact scale (MFIS', 'cerebral volumes and diffusion-tensor-imaging derived measures']","[{'cui': 'C0033046', 'cui_str': 'PMS - Premenstrual syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0016129', 'cui_str': 'Fingers'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale (assessment scale)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",,0.0249136,ATG showed increased functional connectivity within the cerebellar and thalamic resting state networks compared to PTG (p<0.05).,"[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Boffa', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tacchino', 'Affiliation': 'Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Sbragia', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Schiavi', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Droby', 'Affiliation': 'Department of Neurology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Piaggio', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bommarito', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Girardi', 'Affiliation': 'Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.'}, {'ForeName': 'G L', 'Initials': 'GL', 'LastName': 'Mancardi', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Brichetto', 'Affiliation': 'Scientific Research Area, Italian Multiple Sclerosis Foundation, Genoa, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Inglese', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy.'}]",European journal of neurology,['10.1111/ene.14059'] 1192,28549471,The Shared Health Appointments and Reciprocal Enhanced Support (SHARES) study: study protocol for a randomized trial.,"BACKGROUND Diabetes shared medical appointments (SMAs) and reciprocal peer support programs have been found in efficacy trials to help adults with diabetes improve their self-management and achieve short-term gains in clinical and patient-centered outcomes. In order to translate this evidence to system-level interventions, there is a need for large-scale, pragmatic trials that examine the effectiveness, implementation, and costs of SMAs and reciprocal peer support across diverse settings. METHODS The Shared Health Appointments and Reciprocal Enhanced Support (SHARES) study is a multisite, cluster randomized trial that is evaluating the effectiveness and implementation of SMAs with and without an additional reciprocal Peer-to-Peer (P2P) support program, when compared to usual care. The P2P program comprises periodic peer support group sessions and telephone contact between SMA participant pairs to promote more effective diabetes self-management. We will examine outcomes across three different treatment groups: (1) SMAs, (2) SMAs plus P2P, and (3) usual care. We will collect and analyze data over a 2.5-year implementation period at five geographically diverse Veterans Affairs (VA) health systems. The primary outcome is the relative change in hemoglobin A1c over time. Secondary outcomes are changes in systolic blood pressure, antihypertensive medication use, statin use, and insulin initiation over the study period. The unit of analysis is the individual, adjusted by the individual's SMA group (the cluster). We will use mixed methods to rigorously evaluate processes and costs of implementing these programs in each of the clinic settings. DISCUSSION We hypothesize that patients will experience improved outcomes immediately following participation in SMAs and that augmenting SMAs with reciprocal peer support will help to maintain these gains over time. The results of this study will be among the first to examine the effects of diabetes SMAs alone and in conjunction with P2P in a range of real-life clinical settings. In addition, the study will provide important information on contextual factors associated with successful program implementation. TRIAL REGISTRATION ClinicalTrials.gov, ID: NCT02132676 . Registered on 21 August 2013.",2017,"We will examine outcomes across three different treatment groups: (1) SMAs, (2) SMAs plus P2P, and (3) usual care.",[],[],"['relative change in hemoglobin A1c over time', 'systolic blood pressure, antihypertensive medication use, statin use, and insulin initiation over the study period']",[],[],"[{'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0003364', 'cui_str': 'Anti-Hypertensive Drugs'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",,0.0927824,"We will examine outcomes across three different treatment groups: (1) SMAs, (2) SMAs plus P2P, and (3) usual care.","[{'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Heisler', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA. mheisler@umich.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Burgess', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Cass', 'Affiliation': 'VA Northern California Health Care System, 10535 Hospital Way, Mather, CA, 95655, USA.'}, {'ForeName': 'John F', 'Initials': 'JF', 'LastName': 'Chardos', 'Affiliation': 'Veterans Affairs Center for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road, Menlo Park, CA, 94025, USA.'}, {'ForeName': 'Alexander B', 'Initials': 'AB', 'LastName': 'Guirguis', 'Affiliation': 'VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT, 06516, USA.'}, {'ForeName': 'Sean M', 'Initials': 'SM', 'LastName': 'Jeffery', 'Affiliation': 'University of Connecticut School of Pharmacy, 69 North Eagleville Road, Storrs, CT, 06269, USA.'}, {'ForeName': 'Lorrie A', 'Initials': 'LA', 'LastName': 'Strohecker', 'Affiliation': 'VA Northern California Health Care System, 10535 Hospital Way, Mather, CA, 95655, USA.'}, {'ForeName': 'Adam S', 'Initials': 'AS', 'LastName': 'Tremblay', 'Affiliation': 'Veterans Affairs Center for Clinical Management Research, VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA.'}, {'ForeName': 'Wen-Chih', 'Initials': 'WC', 'LastName': 'Wu', 'Affiliation': 'Providence VA Medical Center, 830 Chalkstone Avenue, Providence, RI, 02908, USA.'}, {'ForeName': 'Donna M', 'Initials': 'DM', 'LastName': 'Zulman', 'Affiliation': 'Veterans Affairs Center for Innovation to Implementation, VA Palo Alto Health Care System, 795 Willow Road, Menlo Park, CA, 94025, USA.'}]",Trials,['10.1186/s13063-017-1959-7'] 1193,31578169,"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.","BACKGROUND At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of the lung. We aimed to assess the efficacy and safety of pirfenidone in patients with progressive fibrosing unclassifiable ILD. METHODS We did a multicentre, double-blind, randomised, placebo-controlled phase 2 trial at 70 centres in Australia, Belgium, Canada, Czech Republic, Denmark, Germany, Greece, Ireland, Israel, Italy, Poland, Portugal, Spain, and the UK. Eligible patients (aged ≥18-85 years) had progressive fibrosing unclassifiable ILD, a percent predicted forced vital capacity (FVC) of 45% or higher and percent predicted carbon monoxide diffusing capacity (DLco) of 30% or higher, more than 10% fibrosis on high-resolution CT, and a high-resolution CT from the previous 12 months. Patients were randomly assigned (1:1) to 2403 mg oral pirfenidone daily or placebo using a central validated interactive voice or web-based response system, stratified by concomitant mycophenolate mofetil use and presence or absence of interstitial pneumonia with autoimmune features. Investigators, site personnel, and patients were masked to treatment assignment. The primary endpoint was mean predicted change in FVC from baseline over 24 weeks, measured by daily home spirometry. Secondary endpoints were change in FVC measured by site spirometry, proportion of patients who had a more than 5% or more than 10% absolute or relative decline in percent predicted FVC measured by clinic-based spirometry, change in percent predicted DLco, change in 6-min walk distance (6MWD), change in University of California San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) score, change in Leicester Cough Questionnaire score, change in cough visual analogue scale, and changes in total and subscores of the St George's Respiratory Questionnaire (SGRQ), all of which were compared with baseline. Additional secondary endpoints included proportion of patients who had non-elective hospitalisation (respiratory and all-cause) and acute exacerbations, and progression-free survival. Efficacy was analysed in the intention-to-treat (ITT) population, which included all randomly assigned patients. Safety was assessed in the safety analysis set, which included all randomly assigned patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03099187, and is no longer recruiting. FINDINGS Between May 15, 2017, and June 5, 2018, 253 patients were randomly assigned to receive 2403 mg pirfenidone (n=127) or placebo (n=126) and were included in the ITT analysis set. Analysis of the primary endpoint was affected by intraindividual variability in home spirometry values, which prevented application of the prespecified statistical model. Over 24 weeks, predicted median change in FVC measured by home spirometry was -87·7 mL (Q1-Q3 -338·1 to 148·6) in the pirfenidone group versus -157·1 mL (-370·9 to 70·1) in the placebo group. Over 24 weeks, predicted mean change in FVC measured by site spirometry was lower in patients given pirfenidone than placebo (treatment difference 95·3 mL [95% CI 35·9 to 154·6], p=0·002). Compared with the placebo group, patients in the pirfenidone group were less likely to have a decline in FVC of more than 5% (odds ratio [OR] 0·42 [95% CI 0·25 to 0·69], p=0·001) or more than 10% (OR 0·44 [0·23 to 0·84], p=0·011). At week 24, mean change in DLco from baseline was -0·7% (SD 7·1) for the pirfenidone group and -2·5% (8·8) for the placebo group, and mean change in 6MWD from baseline was -2·0 m (68·1) for the pirfenidone group and -26·7 m (79·3) for the placebo group. Changes from baseline in UCSD-SOBQ, Leicester Cough Questionnaire score, cough visual analogue scale, and SGRQ scores were similar between the pirfenidone and placebo groups at week 24. Analysis of acute exacerbations, hospital admissions, and time to death from respiratory causes during the study yielded no meaningful results due to a small number of events. No differences in progression-free survival were identified between the pirfenidone and placebo groups, irrespective of the definition of progression-free survival used. Treatment-emergent adverse events were reported in 120 (94%) of 127 patients in the pirfenidone group and 101 (81%) of 124 patients in the placebo group. Serious treatment-emergent adverse events were reported in 18 (14%) patients in the pirfenidone group and 20 (16%) patients in the placebo group. The most common treatment-related treatment-emergent adverse events were gastrointestinal disorders (60 [47%] in the pirfenidone group vs 32 [26%] in the placebo group), fatigue (16 [13%] vs 12 [10%]), and rash (13 [10%] vs nine [7%]). INTERPRETATION Although the planned statistical model could not be applied to the primary endpoint data, analysis of key secondary endpoints suggests that patients with progressive fibrosing unclassifiable ILD could benefit from pirfenidone treatment, which has an acceptable safety and tolerability profile. These findings support further investigation of pirfenidone as an effective treatment for patients with progressive fibrotic unclassifiable ILD. FUNDING F Hoffmann-La Roche.",2020,"Over 24 weeks, predicted mean change in FVC measured by site spirometry was lower in patients given pirfenidone than placebo (treatment difference","['70 centres in Australia, Belgium, Canada, Czech Republic, Denmark, Germany, Greece, Ireland, Israel, Italy, Poland, Portugal, Spain, and the UK', 'patients with progressive fibrotic unclassifiable ILD', 'Between May 15, 2017, and June 5, 2018, 253 patients', 'patients with unclassifiable progressive fibrosing interstitial lung disease', 'patients with progressive fibrosing unclassifiable ILD', 'Eligible patients (aged ≥18-85 years) had progressive fibrosing unclassifiable ILD, a percent predicted forced vital capacity (FVC) of 45% or higher and percent predicted carbon monoxide diffusing capacity (DLco) of 30% or higher, more than 10% fibrosis on high-resolution CT, and a high-resolution CT from the previous 12 months', '95·3']","['pirfenidone', 'pirfenidone daily or placebo using a central validated interactive voice or web-based response system, stratified by concomitant mycophenolate mofetil', 'placebo', 'mL', 'Pirfenidone']","['mean change in FVC measured by site spirometry', 'FVC', 'Safety', 'UCSD-SOBQ, Leicester Cough Questionnaire score, cough visual analogue scale, and SGRQ scores', 'progression-free survival', 'efficacy and safety', 'mean predicted change in FVC', ""6-min walk distance (6MWD), change in University of California San Diego-Shortness of Breath Questionnaire (UCSD-SOBQ) score, change in Leicester Cough Questionnaire score, change in cough visual analogue scale, and changes in total and subscores of the St George's Respiratory Questionnaire (SGRQ"", 'Efficacy', 'median change in FVC', 'rash', 'mean change in DLco', 'Serious treatment-emergent adverse events', 'change in FVC', 'proportion of patients who had non-elective hospitalisation (respiratory and all-cause) and acute exacerbations, and progression-free survival', 'mean change in 6MWD', 'fatigue', 'intraindividual variability in home spirometry values']","[{'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0206578', 'cui_str': 'Czech Republic'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0022067', 'cui_str': 'Ireland, Republic of'}, {'cui': 'C0022271', 'cui_str': 'Israel'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0032356', 'cui_str': 'Republic of Poland'}, {'cui': 'C0032729', 'cui_str': 'Portuguese Republic'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C1869044', 'cui_str': 'Interstitial lung disease (SMQ)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C3714541', 'cui_str': 'Forced Vital Capacity'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0199525', 'cui_str': 'Carbon monoxide diffusing capacity measurement (procedure)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous (qualifier value)'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0429886', 'cui_str': 'Walking distance (observable entity)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0745036', 'cui_str': 'Elective hospitalization'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",253.0,0.690512,"Over 24 weeks, predicted mean change in FVC measured by site spirometry was lower in patients given pirfenidone than placebo (treatment difference","[{'ForeName': 'Toby M', 'Initials': 'TM', 'LastName': 'Maher', 'Affiliation': 'Inflammation, Repair, and Development Section, National Heart and Lung Institute, Imperial College London, London, UK; National Institute for Health Research Respiratory Clinical Research Facility, Royal Brompton Hospital, London, UK. Electronic address: t.maher@rbht.nhs.uk.'}, {'ForeName': 'Tamera J', 'Initials': 'TJ', 'LastName': 'Corte', 'Affiliation': 'Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Medical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Aryeh', 'Initials': 'A', 'LastName': 'Fischer', 'Affiliation': 'University of Colorado School of Medicine, Denver, CO, USA; Bristol-Myers Squibb, Princeton, NJ, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kreuter', 'Affiliation': 'Center for Interstitial and Rare Lung Diseases, Department of Pulmonology and Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lederer', 'Affiliation': 'Divison of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, NY, USA; Regeneron Pharmaceuticals, New York, NY, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Molina-Molina', 'Affiliation': 'Respiratory Department, Unit of Interstitial Lung Diseases, University Hospital of Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Madrid, Spain.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Axmann', 'Affiliation': 'F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Klaus-Uwe', 'Initials': 'KU', 'LastName': 'Kirchgaessler', 'Affiliation': 'F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Katerina', 'Initials': 'K', 'LastName': 'Samara', 'Affiliation': 'F Hoffmann-La Roche, Athens, Greece.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Gilberg', 'Affiliation': 'F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Cottin', 'Affiliation': 'National Reference Coordinating Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France; Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30341-8'] 1194,31901782,The effects of Pythagorean Self-Awareness Intervention on breast cancer patients undergoing adjuvant therapy: A pilot randomized controlled trial.,"INTRODUCTION Breast cancer patients undergo extended treatments that affect their psychological state and quality of life. There is a lack of studies examining the effects of holistic stress management interventions (that combine stress perception, cognitive and lifestyle interventions) on mental health and biological indices (e.g. cortisol concentrations) of breast cancer patients. MATERIALS AND METHODS This pilot randomized controlled trial provided the first assessment of the effects of a novel, cognitive-based intervention, the Pythagorean Self-Awareness Intervention (PSAI), on psychological symptoms, quality of life, sleep quality and lifestyle as well as on stress-related biological measures of breast cancer patients undergoing adjuvant therapy. Standardized questionnaires were administered at baseline and 8-weeksafter the intervention to evaluate quality of life, stress, depression, and anxiety (primary outcomes). Sleep quality, lifestyle and hair cortisol concentrations were also assessed (secondary outcomes). RESULTS Forty-five breast cancer patients undergoing adjuvant therapy were randomly assigned to the PSAI group (n = 25) or the control group (n = 20).Women in the PSAI group reported significant improvements post-intervention in total Quality of Life, specific aspects of Quality of Life [Physical well-being, Social well-being, Emotional well-being, Functional well-being, Breast cancer concerns] as well as Perceived stress, depression, anxiety and stress. Improvements in secondary outcomes included increase in sleep quality, empowerment for healthy lifestyle and reduction of hair cortisol concentrations. CONCLUSIONS The PSAI was beneficial as complementary therapy in the women studied. Larger randomized controlled trials with longer follow-up are needed to ascertain these findings.",2020,"20).Women in the PSAI group reported significant improvements post-intervention in total Quality of Life, specific aspects of Quality of Life [Physical well-being, Social well-being, Emotional well-being, Functional well-being, Breast cancer concerns] as well as Perceived stress, depression, anxiety and stress.","['breast cancer patients undergoing adjuvant therapy', 'Breast cancer patients', 'breast cancer patients', 'Forty-five breast cancer patients undergoing adjuvant therapy']","['control group (n\xa0', 'Pythagorean Self-Awareness Intervention', 'PSAI', 'novel, cognitive-based intervention, the Pythagorean Self-Awareness Intervention (PSAI', 'holistic stress management interventions']","['psychological symptoms, quality of life, sleep quality and lifestyle as well as on stress-related biological measures', 'quality of life, stress, depression, and anxiety (primary outcomes', 'psychological state and quality of life', 'Sleep quality, lifestyle and hair cortisol concentrations', 'Perceived stress, depression, anxiety and stress', 'sleep quality, empowerment for healthy lifestyle and reduction of hair cortisol concentrations', 'total Quality of Life, specific aspects of Quality of Life [Physical well-being, Social well-being, Emotional well-being, Functional well-being, Breast cancer concerns']","[{'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C4319567', 'cui_str': '45'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3146223', 'cui_str': 'Awareness of self (observable entity)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}]","[{'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0034380'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C4277664', 'cui_str': 'Healthy Life Styles'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}]",45.0,0.040658,"20).Women in the PSAI group reported significant improvements post-intervention in total Quality of Life, specific aspects of Quality of Life [Physical well-being, Social well-being, Emotional well-being, Functional well-being, Breast cancer concerns] as well as Perceived stress, depression, anxiety and stress.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Charalampopoulou', 'Affiliation': 'Postgraduate Course of Stress Management and Health Promotion, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: xarmar@msn.com.'}, {'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Bacopoulou', 'Affiliation': ""Center for Adolescent Medicine and UNESCO Chair on Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens, Greece; Unit of Clinical and Translational Research in Endocrinology, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'Konstantinos N', 'Initials': 'KN', 'LastName': 'Syrigos', 'Affiliation': 'Oncology Unit, 3rd Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece.'}, {'ForeName': 'Evaggelos', 'Initials': 'E', 'LastName': 'Filopoulos', 'Affiliation': 'Breast Cancer Department, General Anti-Cancer Hospital Agios Savvas, Athens, Greece.'}, {'ForeName': 'George P', 'Initials': 'GP', 'LastName': 'Chrousos', 'Affiliation': ""Postgraduate Course of Stress Management and Health Promotion, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Center for Adolescent Medicine and UNESCO Chair on Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens, Greece; Unit of Clinical and Translational Research in Endocrinology, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Darviri', 'Affiliation': 'Postgraduate Course of Stress Management and Health Promotion, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2019.12.012'] 1195,28167545,"Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.","A multipart phase 1 study was conducted to determine the safety, tolerability, pharmacokinetics, and food effect of the novel oral oxazolidinone, MRX-I, in healthy adults, as well as the tolerability of longer-term exposure of both oral MRX-I and linezolid. Thirty subjects in part 1 received single ascending doses of MRX-I or placebo under fasting or fed condition in a double-blind crossover design. Twelve subjects in part 2 received MRX-I at 800 mg every 12 h (q12h) for 14 days in a double-blind, placebo-controlled design. In part 3, 24 subjects were randomized to receive 28 days of MRX-I at 800 mg q12h or oral linezolid at 600 mg q12h for 28 days in a double-blind, double-dummy design. Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration. Oral MRX-I was well tolerated at single doses of up to 1,200 and 800 mg q12h for up to 28 days; all adverse events were mild to moderate in severity, and there was no drug discontinuation due to adverse events. These data support further clinical development of oral MRX-I in the treatment of resistant Gram-positive bacterial infections.",2017,"Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration.","['24 subjects', 'healthy adults', 'Thirty subjects in part 1 received', 'Healthy Adult Subjects']","['MRX-I at 800 mg q12h or oral linezolid', 'Oral MRX-I versus Linezolid', 'placebo', 'single ascending doses of MRX-I or placebo', 'MRX', 'novel oral oxazolidinone, MRX-I', 'oral MRX-I and linezolid']","['Safety, Tolerability, Pharmacokinetics, and Food Effect', 'safety, tolerability, pharmacokinetics, and food effect']","[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0663241', 'cui_str': 'linezolid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0887953', 'cui_str': 'Oxazolidinones'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",24.0,0.135031,"Oral MRX-I was associated with a greater bioavailability and exposure when administered with food, and minimal accumulation of MRX-I occurred after multiple-dose administration.","[{'ForeName': 'Paul B', 'Initials': 'PB', 'LastName': 'Eckburg', 'Affiliation': 'MicuRx Pharmaceuticals, Inc., Hayward, California, USA peckburg@gmail.com.'}, {'ForeName': 'Yigong', 'Initials': 'Y', 'LastName': 'Ge', 'Affiliation': 'MicuRx Pharmaceuticals, Inc., Hayward, California, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Hafkin', 'Affiliation': 'MicuRx Pharmaceuticals, Inc., Hayward, California, USA.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.02181-16'] 1196,32413431,Anchor vs suture for the attachment of vaginal mesh in a robotic-assisted sacrocolpopexy: a randomized clinical trial.,"BACKGROUND Vaginal mesh attachment can be one of the most time-consuming components of a minimally invasive sacrocolpopexy. OBJECTIVE To assess the impact on the duration vaginal mesh attachment of using absorbable anchors compared to interrupted sutures for vaginal mesh attachment in robotic-assisted sacrocolpopexy. STUDY DESIGN This was a single-masked, randomized clinical trial of women with pelvic organ prolapse that underwent a robotic-assisted sacrocolpopexy at 2 clinical sites. The participants were randomized to receive either interrupted delayed absorbable anchors or sutures during the vaginal mesh attachment portion of the surgery. The participants completed validated questionnaires at baseline and at 6 weeks, 6 months, and 12 months after the surgery. A certified examiner, masked to the attachment technique that was used, performed a clinical examination using the Pelvic Organ Prolapse Quantification system and also assessed for mesh exposure and the overall appearance of the vaginal walls using a 10-cm visual analog scale at each follow-up visit. The primary outcome was the vaginal mesh attachment time. The categorical variables were compared using chi-square or Fischer's Exact test, whereas the continuous variables were compared using Student's t-test or Mann-Whitney U test where appropriate. An intention-to-treat analysis was performed. RESULTS Fifty-three participants were randomized, 26 to mesh attachment with anchor, 27 to mesh attachment with suture, and 81% (21/26) and 93% (25/27) had 12-month follow up respectively. There were no significant differences between the groups with regard to age (P=.12), body mass index (P=.23), stage of prolapse (P=.97), or other preoperative factors. Mesh attachment interval time was faster in the anchor compared to suturing study arm (12.2±7.8 vs 21.2±5.2 minutes; P<.001), while sacrocolpopexy times (107.6±33.2 vs 109.8±21.2 minutes; P=.774) were not different. The ease of placement for the surgeon based on a visual analog scale (P=.16), the appearance of the mesh attachment (P=.07), and the overall satisfaction with the use of the specific attachment type (P=.65) were similar for the arms. There was no difference in perioperative adverse events rates between arms and by 12 months follow-up there were no sacrocolpopexy mesh, anchor, or suture exposures. There was no difference in outcomes at 12 months including composite failure (10% vs 12%; P=.79), patient global impression of improvement (1.06 vs 1.19; P=.27), or patient pelvic pain (9.81 vs 9.67; P=.56). CONCLUSION In patients undergoing a robotic-assisted sacrocolpopexy, the anchor vaginal mesh attachment technique required significantly less time than suturing. There was no difference between techniques in complications, failure, surgeon, or patient-reported outcomes through 12 months of follow-up. Mesh attachment during sacrocolpopexy can be performed in less time by using the anchor technique, providing surgeons with an alternative surgical technique for this procedure.",2020,"There was no difference between techniques in complications, failure, surgeon or patient-reported outcomes through 12 months of follow-up.","['patients undergoing', 'women with pelvic organ prolapse undergoing robotic-assisted sacrocolpopexy', 'Fifty-three participants']","['robotic-assisted sacrocolpopexy the anchor vaginal mesh attachment technique', 'VAS', 'Anchor versus Suture for Attachment of Vaginal Mesh in Robotic-Assisted Sacrocolpopexy', 'interrupted delayed-absorbable anchors or sutures', 'absorbable anchors compared to interrupted sutures']","['Mesh attachment interval time', 'patient global impression of improvement', 'patient pelvic pain', 'composite failure', 'vaginal mesh attachment time', 'BMI (p=0.23), stage of prolapse', 'perioperative adverse events rates', 'global satisfaction', 'appearance of mesh attachment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0554325', 'cui_str': 'Sacrocolpopexy'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0554325', 'cui_str': 'Sacrocolpopexy'}, {'cui': 'C1293132', 'cui_str': 'Anchoring'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0443239', 'cui_str': 'Interrupted'}]","[{'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C4706333', 'cui_str': 'Patient Global Impression of Improvement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030794', 'cui_str': 'Pain in pelvis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}]",53.0,0.29178,"There was no difference between techniques in complications, failure, surgeon or patient-reported outcomes through 12 months of follow-up.","[{'ForeName': 'Alexander A', 'Initials': 'AA', 'LastName': 'Berger', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente San Diego Medical Center, San Diego, CA; Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics, Gynecology and Reproductive Science, University of California San Diego, San Diego, CA. Electronic address: alexanderbergermd@gmail.com.'}, {'ForeName': 'Jasmine', 'Initials': 'J', 'LastName': 'Tan-Kim', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente San Diego Medical Center, San Diego, CA.'}, {'ForeName': 'Shawn A', 'Initials': 'SA', 'LastName': 'Menefee', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, Kaiser Permanente San Diego Medical Center, San Diego, CA.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.05.018'] 1197,27734422,Retrograde Intrarenal Surgery Versus Shock Wave Lithotripsy for Renal Stones Smaller Than 2 cm: A Randomized Clinical Trial.,"PURPOSE To compare outcomes of retrograde intrarenal surgery (RIRS) with extracorporeal shock wave lithotripsy (SWL) for stones ≤ 2 cm. MATERIALS AND METHODS Patients who were diagnosed with kidney stones of ≤ 2 cm underwent RIRS or SWL in a parallel group randomized clinical trial with balanced randomization [1:1] from 2011 to 2014. The primary outcome of interest was stone free rate after a single session intervention. Patients were evaluated by ultrasonography and KUB at 1 and 3 months after the intervention for the presence of residual stone by a radiologist who was blinded to the study. RESULTS The stone free rate one month after a single session intervention in the RIRS group was higher than the SWL group (90% versus 75%, P = .03). The success rates after two sessions of RIRS versus SWL were 96.7% versus 88.3% respectively. (P = .08) Patients in the RIRS group had significantly lower postoperative visual analogue pain score compared to the SWL group (5.2 ± 2.8 versus 3.1 ± 2.7, P < .001). Steinstrasse formation and renal hematoma were observed in 4 and one patient in the SWL group versus no patient in the RIRS group. Postoperative hospital stay was significantly shorter in the SWL group (6.7 ± 1.3 versus18.9 ± 4.3 hours, P < .001). CONCLUSION The RIRS procedure is a safe treatment option for renal stones of ≤2cm with less pain and higher success rate at first session compared to SWL. .",2016,"The stone free rate one month after a single session intervention in the RIRS group was higher than the SWL group (90% versus 75%, P = .03).","['Patients who were diagnosed with kidney stones of &le', 'Renal Stones', 'Smaller Than 2 cm']","['retrograde intrarenal surgery (RIRS', 'RIRS or SWL', 'extracorporeal shock wave lithotripsy (SWL', 'Retrograde Intrarenal Surgery Versus Shock Wave Lithotripsy', 'SWL']","['Postoperative hospital stay', 'success rates', 'Steinstrasse formation and renal hematoma', 'postoperative visual analogue pain score', 'stone free rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022650', 'cui_str': 'Kidney Stones'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}]","[{'cui': 'C0439784', 'cui_str': 'Retrograde direction (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal Shockwave Lithotripsy'}, {'cui': 'C1869063', 'cui_str': 'Shock (SMQ)'}, {'cui': 'C0023878', 'cui_str': 'Litholapaxy'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0403718', 'cui_str': 'Steinstrasse (disorder)'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0475022', 'cui_str': 'Hematoma of kidney (disorder)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}]",,0.0730112,"The stone free rate one month after a single session intervention in the RIRS group was higher than the SWL group (90% versus 75%, P = .03).","[{'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Javanmard', 'Affiliation': 'Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drbabakjavanmard@gmail.com.'}, {'ForeName': 'Amir Hossein', 'Initials': 'AH', 'LastName': 'Kashi', 'Affiliation': 'Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Mohsen', 'Initials': 'MM', 'LastName': 'Mazloomfard', 'Affiliation': 'Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Ansari Jafari', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Arefanian', 'Affiliation': 'Department of Surgery, School of Medicine, Washington University in St. Louis, Saint Louis, Missouri, United States.'}]",Urology journal,[] 1198,31586244,Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial.,"INTRODUCTION Total mesorectal excision (TME) is the standard procedure for middle lower rectal cancer, and transanal total mesorectal excision (taTME) was founded as a valid alternative to the open and laparoscopic TME. The quality of the procedure performed is important for prognosis of patients. This study was designed to compare the pathological results of taTME with those of laparoscopic TME (laTME), based on the data from a randomized control trial (RCT: NCT02966483). METHODS Between April 2016 and November 2018, all rectal cancer patients who underwent taTME or laTME in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and enrolled in the RCT were included in this study. The data from all participants were prospectively input in a standardized database. RESULTS In total 128 patients were included in the taTME group and 133 patients were included in the laTME group. The demographics and tumor characteristics were not significantly different between the two group. T3 or N0 lesions were most common in both groups. The mesorectum specimen was complete or nearly complete in all patients. The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745). The positive circumferential resection margin was detected in 2 cases in each group (P = 0.674). The median number of resected lymph nodes was 15.0 in taTME group versus 16.0 in the laTME group (P = 0.069). CONCLUSION The pathological outcomes between transanal and laparoscopic total mesorectal excision are similar. The rate of positive resection margin could not be significant decreased, nonetheless the decrease trend could be shown.",2020,"The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745).","['In total 128 patients were included in the taTME group and 133 patients were included in the laTME group', 'Between April 2016 and November 2018, all rectal cancer patients who underwent taTME or laTME in the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) and enrolled in the RCT were included in this study']","['Total mesorectal excision (TME', 'laTME', 'transanal versus laparoscopic total mesorectal excision', 'laparoscopic TME (laTME', 'transanal and laparoscopic total mesorectal excision']","['demographics and tumor characteristics', 'rate of positive resection margin', 'median number of resected lymph nodes', 'positive circumferential resection margin', 'positive distal resection margin (DRM']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C0007113', 'cui_str': 'Cancer of Rectum'}, {'cui': 'C0205440', 'cui_str': 'Sixth (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0589371', 'cui_str': 'Transanal approach (qualifier value)'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0229985', 'cui_str': 'Margins of Excision'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0024204', 'cui_str': 'Lymphatic gland'}, {'cui': 'C1300632', 'cui_str': 'Surgical circumferential margin finding'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}]",128.0,0.0585214,"The positive distal resection margin (DRM) was detected in 2 (1.5%) cases in the laTME group versus no cases in the taTME group (P = 0.498), and the distance between the tumor and DRM in the taTME group (1.4 ± 1.1) may have the longer tendency than that in the laTME group (1.3 ± 0.9) (P = 0.745).","[{'ForeName': 'Ziwei', 'Initials': 'Z', 'LastName': 'Zeng', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Shuangling', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Yonghua', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Xingwei', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China.""}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Kang', 'Affiliation': ""Department of Colorectal Surgery, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510655, Guangdong, People's Republic of China. kangl@mail.sysu.edu.cn.""}]",Surgical endoscopy,['10.1007/s00464-019-07167-1'] 1199,32413812,Effects of a mindfulness based behavioral intervention for young adults with childhood maltreatment history on hippocampal morphometry: a pilot MRI study with voxel-based morphometry.,"Childhood maltreatment has long lasting impacts on neural development of the hippocampus, which is important for learning and memory. The present study aimed to assess the effects of a mindfulness based intervention on hippocampal morphometry and episodic memory in this population. We administered MRI, psychological questionnaires and an episodic memory task to 21 participants (5 males) before and after a mindfulness-based behavioral intervention, compared to 21 participants (7 males) on the waiting list. Changes in Gray Matter Volume (GMV) in bilateral hippocampi were analyzed with Voxel-Based Morphometry (VBM). One cluster was identified in the right hippocampus with a group by time interaction effect that consisted of 130 contiguous voxels but fell short of significance with full FDR correction (p = 0.077). GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group. Within the mindfulness group, changes in hippocampal GMV were negatively associated with changes in perceived stress and depression severity and positively associated with enhancement in performance accuracy on the episodic memory task. Findings from this pilot study suggest that a mindfulness-based intervention may lead to an increase in partial hippocampal GMV with associated symptom reduction and improvement in episodic memory.",2020,GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group.,"['21 participants (5 males) before and after a', 'young adults with childhood maltreatment history on hippocampal morphometry']","['mindfulness based intervention', 'mindfulness-based behavioral intervention', 'mindfulness based behavioral intervention']","['perceived stress and depression severity', 'GMV', 'hippocampal morphometry and episodic memory', 'episodic memory', 'hippocampal GMV', 'partial hippocampal GMV', 'Gray Matter Volume (GMV']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0200760', 'cui_str': 'Morphometric analysis'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0200760', 'cui_str': 'Morphometric analysis'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0728938', 'cui_str': 'Partial'}]",130.0,0.0170544,GMV in this cluster increased by 0.76% in the mindfulness group and decreased by 0.78% in the control group.,"[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Joss', 'Affiliation': 'Developmental Biopsychiatry Research Program, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Massachusetts General Hospital, USA; Department of Psychiatry, Harvard Medical School, Boston, USA. Electronic address: djoss@mclean.harvard.edu.'}, {'ForeName': 'Sara W', 'Initials': 'SW', 'LastName': 'Lazar', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, USA; Department of Psychiatry, Harvard Medical School, Boston, USA.'}, {'ForeName': 'Martin H', 'Initials': 'MH', 'LastName': 'Teicher', 'Affiliation': 'Developmental Biopsychiatry Research Program, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, USA.'}]",Psychiatry research. Neuroimaging,['10.1016/j.pscychresns.2020.111087'] 1200,28219612,"Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.","BACKGROUND There is insufficient research into the use of mechanical ventilation with increased inspiratory oxygen concentration (FiO 2 ) and fluid resuscitation with hypertonic saline solution in patients with septic shock. We tested whether these interventions are associated with reduced mortality. METHODS This two-by-two factorial, multicentre, randomised, clinical trial (HYPERS2S) recruited patients aged 18 years and older with septic shock who were on mechanical ventilation from 22 centres in France. Patients were randomly assigned 1:1:1:1 to four groups by a computer generated randomisation list stratified by site and presence or absence of acute respiratory distress syndrome by use of permuted blocks of random sizes. Patients received, in an open-labelled manner, mechanical ventilation either with FiO 2 at 1·0 (hyperoxia) or FiO 2 set to target an arterial haemoglobin oxygen saturation of 88-95% (normoxia) during the first 24 h; patients also received, in a double-blind manner, either 280 mL boluses of 3·0% (hypertonic) saline or 0·9% (isotonic) saline for fluid resuscitation during the first 72 h. The primary endpoint was mortality at day 28 after randomisation in the intention-to-treat population. This study was registered with ClinicalTrials.gov, number NCT01722422. FINDINGS Between Nov 3, 2012, and June 13, 2014, 442 patients were recruited and assigned to a treatment group (normoxia [n=223] or hyperoxia [n=219]; isotonic [n=224] or hypertonic [n=218]). The trial was stopped prematurely for safety reasons. 28 day mortality was recorded for 434 patients; 93 (43%) of 217 patients had died in the hyperoxia group versus 77 (35%) of 217 patients in the normoxia group (hazard ratio [HR] 1·27, 95% CI 0·94-1·72; p=0·12). 89 (42%) of 214 patients had died in the hypertonic group versus 81 (37%) of 220 patients in the isotonic group (HR 1·19, 0·88-1·61; p=0·25). We found a significant difference in the overall incidence of serious adverse events between the hyperoxia (185 [85%]) and normoxia groups (165 [76%]; p=0·02), with a clinically relevant doubling in the hyperoxia group of the number of patients with intensive care unit-acquired weakness (24 [11%] vs 13 [6%]; p=0·06) and atelectasis (26 [12%] vs 13 [6%]; p=0·04) compared with the normoxia group. We found no statistical difference for serious adverse events between the two saline groups (p=0·23). INTERPRETATION In patients with septic shock, setting FiO 2 to 1·0 to induce arterial hyperoxia might increase the risk of mortality. Hypertonic (3%) saline did not improve survival. FUNDING The French Ministry of Health.",2017,"We found no statistical difference for serious adverse events between the two saline groups (p=0·23). ","['patients with septic shock (HYPERS2S', 'patients aged 18 years and older with septic shock who were on mechanical ventilation from 22 centres in France', 'patients with septic shock', 'Between Nov 3, 2012, and June 13, 2014, 442 patients were recruited and assigned to a treatment group (normoxia [n=223] or hyperoxia [n=219']","['isotonic [n=224] or hypertonic', 'mechanical ventilation', '280 mL boluses of 3·0% (hypertonic) saline or 0·9% (isotonic) saline', 'hypertonic saline solution', 'Hypertonic (3%) saline', 'open-labelled manner, mechanical ventilation either with FiO 2 at 1·0 (hyperoxia) or FiO 2 set to target an arterial haemoglobin oxygen saturation', 'Hyperoxia and hypertonic saline']","['survival', 'risk of mortality', '28 day mortality', 'overall incidence of serious adverse events', 'serious adverse events', 'mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C1097282', 'cui_str': '2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523807', 'cui_str': 'Oximetry'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",442.0,0.60947,"We found no statistical difference for serious adverse events between the two saline groups (p=0·23). ","[{'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Asfar', 'Affiliation': 'Département de Réanimation Médicale et de Médecine Hyperbare, Angers, France. Electronic address: piasfar@chu-angers.fr.'}, {'ForeName': 'Frédérique', 'Initials': 'F', 'LastName': 'Schortgen', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Henri Mondor, APHP, Créteil, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Boisramé-Helms', 'Affiliation': 'Service de Réanimation Médicale, Nouvel Hôpital Civil, Centre Hospitalo-Universitaire, Strasbourg, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Charpentier', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Cochin, APHP, Paris, France.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Guérot', 'Affiliation': 'Service de Réanimation Médicale, Hôpital Européen Georges Pompidou, APHP, Paris, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Megarbane', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Lariboisière, APHP, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Grimaldi', 'Affiliation': 'Service de Réanimation, Centre Hospitalier Angré Mignot, Le Chesnay, France.'}, {'ForeName': 'Fabien', 'Initials': 'F', 'LastName': 'Grelon', 'Affiliation': 'Service de Réanimation, Centre hospitalier, Le Mans, France.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Anguel', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Le Kremlin Bicêtre, APHP, France.'}, {'ForeName': 'Sigismond', 'Initials': 'S', 'LastName': 'Lasocki', 'Affiliation': ""Département d'Anesthésie Réanimation, Centre Hospitalo-Universitaire, Angers, France.""}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Henry-Lagarrigue', 'Affiliation': 'Service de Réanimation, Centre Hospitalier, La Roche sur Yon, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Gonzalez', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Avicenne, APHP, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Legay', 'Affiliation': 'Service de Réanimation, Centre Hospitalier, Saint Brieuc, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Guitton', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Nantes, France.'}, {'ForeName': 'Maleka', 'Initials': 'M', 'LastName': 'Schenck', 'Affiliation': 'Service de Réanimation Médicale, Hôpital de Hautepierre, Centre Hospitalo-Universitaire, Strasbourg, France.'}, {'ForeName': 'Jean Marc', 'Initials': 'JM', 'LastName': 'Doise', 'Affiliation': 'Service de Réanimation, Centre Hospitalier, Chalon sur Saône, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Devaquet', 'Affiliation': 'Service de Réanimation, Hôpital Foch, Suresnes, France.'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Van Der Linden', 'Affiliation': 'Service de Réanimation, Centre Hospitalier Saint Philibert, Lomme, France.'}, {'ForeName': 'Delphine', 'Initials': 'D', 'LastName': 'Chatellier', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire, Poitiers, Paris, France.'}, {'ForeName': 'Jean Philippe', 'Initials': 'JP', 'LastName': 'Rigaud', 'Affiliation': 'Service de Réanimation, Centre Hospitalier, Dieppe, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Dellamonica', 'Affiliation': 'Service de Réanimation, Centre Hospitalier-Universitaire, Nice, France.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Tamion', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalier-Universitaire, Rouen, France.'}, {'ForeName': 'Ferhat', 'Initials': 'F', 'LastName': 'Meziani', 'Affiliation': 'Service de Réanimation Médicale, Nouvel Hôpital Civil, Centre Hospitalo-Universitaire, Strasbourg, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Mercat', 'Affiliation': 'Département de Réanimation Médicale et de Médecine Hyperbare, Angers, France.'}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Dreyfuss', 'Affiliation': 'Service de Réanimation Médicale, Centre Hospitalo-Universitaire Louis Mourier, APHP, Paris, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Seegers', 'Affiliation': ""Department of Statistics, Institut de Cancérologie de l'Ouest, Angers, France.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Radermacher', 'Affiliation': 'Institut für anesthesiologische Pathophysiologie und Verfahrensentwicklung, Universitätklinikum Ulm, Ulm, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(17)30046-2'] 1201,31568829,Effect of Acoustic Cardiography-guided Management on 1-year Outcomes in Patients With Acute Heart Failure.,"BACKGROUND The electromechanical activation time (EMAT) normalized by cardiac cycle length (%EMAT) and the third heart sound (S3) strength, as measured by automated acoustic cardiography, are predictive of postdischarge adverse events in patients with acute heart failure (AHF). The aim of this study was to evaluate whether the acoustic cardiography-guided management improves outcomes in patients with AHF when it is compared with the conventional therapy. METHODS AND RESULTS This prospective single-blind study randomized 225 patients with AHF (74.1 ± 14.5 years of age, 26.2% women, and left ventricular ejection fraction 38.4 ± 14.4%) before discharge to the EMAT-guided group (n = 114) with the postdischarge treatment goals to reduce %EMAT to < 15% and S3 < 5, and the symptom-guided group (n = 111) to adjust medications without knowledge of the results of acoustic cardiography. The primary endpoints were rehospitalization for heart failure and total mortality during 1-year follow-up. The 2 groups were well matched in age and predischarge %EMAT and S3 strength. After a mean follow-up period of 238.1 ± 140.8 days, a significant reduction in the primary endpoints was seen in the EMAT-guided group compared with the symptom-guided group (43 events vs 61 events, P = 0.0095). Kaplan-Meier curves demonstrated significant differences in the time to first event, favoring the EMAT-guided group in the total study population (n = 225, hazard ratio and 95% confidence interval: 0.61, 0.42-0.91, log-rank P = 0.0129), as well as in the prespecified subgroup of patients with predischarge %EMAT > 15% (n = 85; 0.32, 0.16-0.65, P = 0.0008). CONCLUSIONS In patients hospitalized due to AHF, EMAT-guided postdischarge management was superior to the conventional symptoms-driven therapy in terms of 1-year outcomes (ClinicalTrials.gov number NCT01298232).",2020,"In patients hospitalized due to AHF, EMAT-guided post-discharge management was superior to the conventional symptoms-driven therapy in terms of one-year outcomes.","['225 AHF patients (age 74.1±14.5 years, 26.2% women, and left ventricular ejection fraction 38.4±14.4%) before discharge to the EMAT-guided group (n=114) with the post-discharge treatment goals to reduce %EMAT to <15% and S 3 <5, and the symptom-guided group (n=111) to adjust medications without the knowledge of the results of acoustic cardiography', 'Patients with Acute Heart Failure', 'patients with acute heart failure (AHF', 'patients with AHF when compared with the conventional therapy']","['Acoustic Cardiography-guided Management', 'acoustic cardiography-guided management']",['re-hospitalization for heart failure and total mortality'],"[{'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0015506', 'cui_str': 'coagulation factor VIII'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure (disorder)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",225.0,0.0615763,"In patients hospitalized due to AHF, EMAT-guided post-discharge management was superior to the conventional symptoms-driven therapy in terms of one-year outcomes.","[{'ForeName': 'Shih-Hsien', 'Initials': 'SH', 'LastName': 'Sung', 'Affiliation': 'Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Chi-Jung', 'Initials': 'CJ', 'LastName': 'Huang', 'Affiliation': 'Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Hao-Min', 'Initials': 'HM', 'LastName': 'Cheng', 'Affiliation': 'Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Wei-Ming', 'Initials': 'WM', 'LastName': 'Huang', 'Affiliation': 'Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Wen-Chung', 'Initials': 'WC', 'LastName': 'Yu', 'Affiliation': 'Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Chen-Huan', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan; Cardiovascular Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Public Health, National Yang-Ming University School of Medicine, Taipei, Taiwan. Electronic address: chchen3@ym.edu.tw.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2019.09.012'] 1202,27582089,Vilanterol and fluticasone furoate for asthma.,"BACKGROUND Vilanterol (VI) is a long-acting beta 2 -agonist (LABA) that binds to the beta 2 -adrenoceptor on the airway smooth muscle, producing bronchodilation. LABA therapy, which is well established in adults as part of the British Thoracic Society (BTS) Guidelines for the Management of Asthma, leads to improvement in symptoms and lung function and reduction in exacerbations. At present, the commonly used LABAs licensed for use in asthma management (formoterol and salmeterol) require twice-daily administration, whereas VI is a once-daily therapy.Fluticasone furoate (FF) is an inhaled corticosteroid (ICS), and ICS therapy is recommended by the BTS asthma guidelines. ICSs, the mainstay of asthma treatment, lead to a reduction in both airway inflammation and airway hyper-responsiveness. Regular use leads to improvement in symptoms and lung function. ICSs are currently recommended as 'preventer' therapy for patients who use a 'reliever' medication (e.g. short-acting beta 2 agonist (SABA), salbutamol) three or more times per week. Most of the commonly used ICS treatments are twice-daily medications, although two once-daily products are currently licensed (ciclesonide and mometasone).At the present time, only one once-daily ICS/LABA combination (FF/VI) is available, and several other combination inhalers are recommended for twice-daily administration. OBJECTIVES To compare effects of VI and FF in combination versus placebo, or versus other ICSs and/or LABAs, on acute exacerbations and on health-related quality of life (HRQoL) in adults and children with chronic asthma. SEARCH METHODS We searched the Cochrane Airways Group Register of trials, clinical trial registries, manufacturers' websites and reference lists of included studies up to June 2016. SELECTION CRITERIA We included randomised controlled trials (RCTs) of adults and children with a diagnosis of asthma. Included studies compared VI and FF combined versus placebo, or versus other ICSs and/or LABAs. Our primary outcomes were health-related quality of life, severe asthma exacerbation, as defined by hospital admissions or treatment with a course of oral corticosteroids, and serious adverse events. DATA COLLECTION AND ANALYSIS Two review authors independently extracted data and analysed outcomes using a fixed-effect model. We used standard Cochrane methods. MAIN RESULTS We identified 14 studies that met our inclusion criteria, with a total of 6641 randomised participants, of whom 5638 completed the study. All studies lasted between two and 78 weeks and showed good methodological quality overall.We included 10 comparisons in this review, seven for which the dose of VI and FF was 100/25 mcg (VI/FF 100/25 mcg vs placebo; VI/FF 100/25 mcg vs same dose of FF; VI/FF 100/25 mcg vs same dose of VI; VI/FF 100/25 mcg vs fluticasone propionate (FP) 500 mcg twice-daily; VI/FF 100/25 mcg vs fluticasone propionate/salmeterol (FP/SAL) 250/50 mcg twice-daily; VI/FF 100/25 mcg vs FP/SAL 250/25 mcg twice-daily; FF/VI 100/25 vs FP/SAL500/50) and three for which the dose of VI and FF was 200/25 mcg (VI/FF 200/25 mcg vs placebo; VI/FF 200/25 mcg vs FP 500 mcg; VI/FF 200/25 mcg vs same dose of FF).We found very few opportunities to combine results from the 14 included studies in meta-analyses. We tabulated the data for our pre-specified primary outcomes. In particular, we found insufficient information to assess whether once-daily VI/FF was better or worse than twice-daily FP/SAL in terms of efficacy or safety.Only one of the 14 studies looked at health-related quality of life when comparing VI and FF 100/25 mcg versus placebo and identified a significant advantage of VI/FF 100/25 mcg (mean difference (MD) 0.30, 95% confidence interval (CI) 0.14 to 0.46; 329 participants); we recognised this as moderate-quality evidence. Only two studies compared VI/FF 100/25 mcg versus placebo with respect to exacerbations; both studies reported no exacerbations in either treatment arm. Five studies (VI/FF 100/25 mcg vs placebo) sought information on serious adverse events; all five studies reported no serious adverse events in the VI/FF 100/25 mcg or placebo arms. We found no comparison relevant to our primary outcomes for VI/FF at a higher dose (200/25 mcg) versus placebo.The small number of studies contributing to each comparison precludes the opportunity to draw robust conclusions for clinical practice. These studies were not of sufficient duration to allow conclusions about long-term side effects. AUTHORS' CONCLUSIONS Some evidence suggests clear advantages for VI/FF, in combination, compared with placebo, particularly for forced expiratory volume in one second (FEV 1 ) and peak expiratory flow; however, the variety of questions addressed in the included studies did not allow review authors to draw firm conclusions. Information was insufficient for assessment of whether once-daily VI/FF was better or worse than twice-daily FP/SAL in terms of efficacy or safety. It is clear that more research is required to reduce the uncertainties that surround interpretation of these studies. It will be necessary for these findings to be replicated in other work before more robust conclusions are revealed. Only five of the 13 included studies provided data on health-related quality of life, and only six recorded asthma exacerbations. Only one study focused on paediatric patients, so no conclusions can be drawn for the paediatric population. More research is needed, particularly in the primary outcome areas selected for this review, so that we can draw firmer conclusions in the next update of this review.",2016,We found no comparison relevant to our primary outcomes for VI/FF at a higher dose (200/25 mcg) versus placebo.,"['asthma', 'adults and children with chronic asthma', '14 studies that met our inclusion criteria, with a total of 6641 randomised participants, of whom 5638 completed the study', 'adults and children with a diagnosis of asthma']","['placebo', 'fluticasone propionate/salmeterol (FP/SAL', 'VI and FF in combination versus placebo, or versus other ICSs and/or LABAs', 'fluticasone propionate (FP', 'LABA therapy', 'Fluticasone furoate (FF', 'LABA', '2 -agonist', 'Vilanterol and fluticasone furoate', 'VI and FF combined versus placebo', 'FF 100/25 mcg vs FP/SAL']","['health-related quality of life', 'efficacy or safety', 'symptoms and lung function', 'health-related quality of life, severe asthma exacerbation, as defined by hospital admissions or treatment with a course of oral corticosteroids, and serious adverse events', 'acute exacerbations and on health-related quality of life (HRQoL']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0117996', 'cui_str': 'Fluticasone propionate'}, {'cui': 'C0073992', 'cui_str': 'salmeterol'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1948374', 'cui_str': 'fluticasone furoate'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C3700389', 'cui_str': 'vilanterol and fluticasone furoate'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439211', 'cui_str': 'microgram'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}]",6641.0,0.737983,We found no comparison relevant to our primary outcomes for VI/FF at a higher dose (200/25 mcg) versus placebo.,"[{'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Dwan', 'Affiliation': 'Cochrane Central Executive, St Albans House, 57-59 Haymarket, London, England, UK, SW1Y 4QX.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Milan', 'Affiliation': ''}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Bax', 'Affiliation': ''}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Walters', 'Affiliation': ''}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Powell', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD010758.pub2'] 1203,28441894,Self-directed exercise in multiple sclerosis: Evaluation of a home automated tele-management system.,"Introduction Physical rehabilitation is one of the few non-pharmaceutical therapies for maintaining or improving walking ability for patients with multiple sclerosis. However, travel distance to rehabilitation clinics, neurological disability and insurance coverage often limit access to specialised rehabilitation services. To address these issues, we utilised a web-based system to support a home-based self-directed exercise programme. Methods Patients ( n = 24) were randomised to either routine home rehabilitation or to the multiple sclerosis home automated tele-management system for a six-month period. The study group had a mean age of 50.4 years, 56% of patients were male, and 67% had progressive multiple sclerosis with an overall mean Patient Determined Disease Steps score of 4.4 (cane or crutch required for walking). Key outcomes included the timed 25-foot-walk, six-minute-walk and the Berg Balance Scale. Results There was no statistically significant difference in the change of the primary walking outcome measure, timed 25-foot-walk, at six months between the home automated tele-management intervention and control groups ( p = 0.44). Similarly, change scores for the six-minute-walk were not significantly different between the home automated tele-management or control groups at six months. Discussion Maintaining overall gait abilities in this group of predominantly progressive multiple sclerosis patients is notable. Exercise adherence was positively associated with higher multiple sclerosis disability and self-reported walking ability. Study engagement and participation in routine home-based exercise for the entire study period was challenging. Further research using clinical video telerehabilitation techniques that optimise patient involvement warrants further study.",2018,"There was no statistically significant difference in the change of the primary walking outcome measure, timed 25-foot-walk, at six months between the home automated tele-management intervention and control groups ( p = 0.44).","['The study group had a mean age of 50.4 years, 56% of patients were male, and 67% had progressive multiple sclerosis with an overall mean Patient Determined Disease Steps score of 4.4 (cane or crutch required for walking', 'Methods Patients ( n\u2009=\u200924', 'patients with multiple sclerosis']","['routine home rehabilitation or to the multiple sclerosis home automated tele-management system', 'Self-directed exercise']","['Exercise adherence', 'gait abilities', 'multiple sclerosis disability and self-reported walking ability', 'timed 25-foot-walk, six-minute-walk and the Berg Balance Scale', 'primary walking outcome measure, timed 25-foot-walk']","[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1261552', 'cui_str': 'Step'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0006856', 'cui_str': 'Walking Sticks'}, {'cui': 'C0010397', 'cui_str': 'Crutches'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}]","[{'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0026769', 'cui_str': 'MS (Multiple Sclerosis)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0559964', 'cui_str': 'Ambulation ability'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0016504', 'cui_str': 'Foot'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}]",,0.0407919,"There was no statistically significant difference in the change of the primary walking outcome measure, timed 25-foot-walk, at six months between the home automated tele-management intervention and control groups ( p = 0.44).","[{'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Conroy', 'Affiliation': '1 Rehabilitation Research and Development Service, VA Maryland Health Care System, USA.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhan', 'Affiliation': '2 Department of Epidemiology, University of Maryland School of Medicine, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Culpepper', 'Affiliation': '3 VA Multiple Sclerosis Center of Excellence-East, Veterans Health Administration, USA.'}, {'ForeName': 'Walter', 'Initials': 'W', 'LastName': 'Royal', 'Affiliation': '1 Rehabilitation Research and Development Service, VA Maryland Health Care System, USA.'}, {'ForeName': 'Mitchell T', 'Initials': 'MT', 'LastName': 'Wallin', 'Affiliation': '1 Rehabilitation Research and Development Service, VA Maryland Health Care System, USA.'}]",Journal of telemedicine and telecare,['10.1177/1357633X17702757'] 1204,32412952,Trends in Costs of Care and Utilization for Medicaid Patients With Diabetes in Accountable Care Communities.,"BACKGROUND/OBJECTIVES Medicaid beneficiaries with diabetes have complex care needs. The Accountable Care Communities (ACC) Program is a practice-level intervention implemented by UnitedHealthcare to improve care for Medicaid beneficiaries. We examined changes in costs and utilization for Medicaid beneficiaries with diabetes assigned to ACC versus usual care practices. RESEARCH DESIGN Interrupted time series with concurrent control group analysis, at the person-month level. The ACC was implemented in 14 states, and we selected comparison non-ACC practices from those states to control for state-level variation in Medicaid program. We adjusted the models for age, sex, race/ethnicity, comorbidities, seasonality, and state-by-year fixed effects. We examined the difference between ACC and non-ACC practices in changes in the time trends of expenditures and hospital and emergency room utilization, for the 4 largest categories of Medicaid eligibility [Temporary Assistance to Needy Families, Supplemental Security Income (without Medicare), Expansion, Dual-Eligible]. SUBJECTS/MEASURES Eligibility and claims data from Medicaid adults with diabetes from 14 states between 2010 and 2016, before and after ACC implementation. RESULTS Analyses included 1,200,460 person-months from 66,450 Medicaid patients with diabetes. ACC implementation was not associated with significant changes in outcome time trends, relative to comparators, for all Medicaid categories. CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices. The ACC program may not reduce costs or utilization for Medicaid patients with diabetes.",2020,"CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices.","['66,450 Medicaid patients with diabetes', 'Medicaid beneficiaries with diabetes', 'Medicaid adults with diabetes from 14 states between 2010 and 2016, before and after ACC implementation', 'Medicaid patients with diabetes', 'Medicaid Patients With Diabetes in Accountable Care Communities', 'Medicaid beneficiaries with diabetes assigned to ACC versus usual care practices']",[],"['Costs of Care and Utilization', 'cost or utilization', 'costs or utilization', 'costs and utilization']","[{'cui': 'C0025071', 'cui_str': 'Medicaid coverage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]",[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",66450.0,0.0160042,"CONCLUSIONS Medicaid patients assigned to ACC practices had no changes in cost or utilization over 3 years of follow-up, compared with patients assigned to non-ACC practices.","[{'ForeName': 'Tannaz', 'Initials': 'T', 'LastName': 'Moin', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Harwood', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Carol M', 'Initials': 'CM', 'LastName': 'Mangione', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Jackson', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Ho', 'Affiliation': 'UnitedHealthcare, Minnetonka, MN.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Ettner', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}, {'ForeName': 'O Kenrik', 'Initials': 'OK', 'LastName': 'Duru', 'Affiliation': 'David Geffen School of Medicine at UCLA.'}]",Medical care,['10.1097/MLR.0000000000001318'] 1205,31548680,A randomized controlled trial of restorative justice-informed treatment for domestic violence crimes.,"Recent innovation in domestic violence (DV) treatment suggests that when a batterer intervention programme (BIP) is combined with clinical elements, including motivational or readiness to change strategies, subsequent incidents of violence can be reduced. Prompted by previous research on restorative justice in reducing recidivism in crimes other than DV, a randomized controlled trial in Utah, USA, compared a typical BIP with one that included restorative justice-informed treatment, called circles of peace (CP). The findings reveal that the 'hybrid' BIP-plus-CP resulted in statistically significant reductions in both new arrests (53%) and crime severity scores (52%) for all offences, including DV, over a 24-month period. We conclude that a hybrid BIP-plus-CP programme should be considered as a viable treatment option for DV offenders. Implications for DV victims are discussed, as are the study's limitations, including the fact that some elements typical of restorative justice programmes could not be attained in this DV context.",2019,"The findings reveal that the 'hybrid' BIP-plus-CP resulted in statistically significant reductions in both new arrests (53%) and crime severity scores (52%) for all offences, including DV, over a 24-month period.","['DV offenders', 'domestic violence crimes']",['hybrid BIP-plus-CP programme'],['crime severity scores'],"[{'cui': 'C0206073', 'cui_str': 'Domestic Violence'}, {'cui': 'C0010325', 'cui_str': 'Crime'}]","[{'cui': 'C0020205', 'cui_str': 'Hybrids'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0010325', 'cui_str': 'Crime'}, {'cui': 'C0457451', 'cui_str': 'Severity score (qualifier value)'}]",,0.0252923,"The findings reveal that the 'hybrid' BIP-plus-CP resulted in statistically significant reductions in both new arrests (53%) and crime severity scores (52%) for all offences, including DV, over a 24-month period.","[{'ForeName': 'Linda G', 'Initials': 'LG', 'LastName': 'Mills', 'Affiliation': 'Center on Violence and Recovery, New York University, New York, NY, USA. linda.mills@nyu.edu.'}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Barocas', 'Affiliation': 'Center on Violence and Recovery, New York University, New York, NY, USA. briana.barocas@nyu.edu.'}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Butters', 'Affiliation': 'School of Social Work, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Barak', 'Initials': 'B', 'LastName': 'Ariel', 'Affiliation': 'Institute of Criminology, University of Cambridge, Cambridge, UK.'}]",Nature human behaviour,['10.1038/s41562-019-0724-1'] 1206,28299762,Comparison of Success Rate in Complete Supine Versus Semi Supine Percutaneous Nephrolithotomy: (The first pilot study in randomized clinical trial).,"PURPOSE To compare outcomes and complications of percutaneous nephrolithotomy (PCNL) in the complete supine versus semi supine position in order to select the best position. MATERIALS AND METHODS In this clinical trial, between July 2011 and May 2014, a total of 44 patients who presented for PCNL were prospectively enrolled and randomly divided into 2 groups [complete supine (n=22), andsemi supine (n = 22)]. The results in both positions were compared regarding the complexity and outcomes. Stonefree rate was considered as a main target of the study. However, it was the first study to focus on overlapping the vertebral density during the access. RESULTS The two groups were comparable in age, gender, body mass index, and preoperative glomerular filtration rate, hemoglobin and creatinine. The mean operative time was significantly shorter for complete supine versus semi supine (36.68 ± 14.12 min versus 47.50 ± 16.45 min, P = .024). At the angle of 0?, overlapping with the spine occurred in 7 patients (31.8%) in semi supine group and just in 1 patient (4.5%) in complete supine group. Also, overlapping with the edge of bed occurred in 10 cases (45.5%) of complete supine and 1 (4.5%) of semi supine; the differences were statistically significant (P = .023, P = .002, respectively). No significant difference was found between the two groups in terms of stone free rate and complications. CONCLUSION Although, we had to convert two cases from semi supine into the complete supine position but we have demonstrated that PCNL in both positions is safe, effective and suitable for the patients. The stone free rate was similar in both groups. But the complete supine position is associated with a significantly shorter postoperative hospital stay and operative time, which may improve ease and safety of PCNL for patients.",2017,"No significant difference was found between the two groups in terms of stone free rate and complications. ","['July 2011 and May 2014, a total of 44 patients who presented for PCNL']","['Complete Supine Versus Semi Supine Percutaneous Nephrolithotomy', 'andsemi supine', 'percutaneous nephrolithotomy (PCNL']","['stone free rate and complications', 'mean operative time', 'stone free rate', 'Stonefree rate', 'postoperative hospital stay and operative time']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}]","[{'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",44.0,0.030303,"No significant difference was found between the two groups in terms of stone free rate and complications. ","[{'ForeName': 'Siavash', 'Initials': 'S', 'LastName': 'Falahatkar', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ghasemi', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}, {'ForeName': 'Keivan', 'Initials': 'K', 'LastName': 'Gholamjani Moghaddam', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Esmaeili', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences. samaneh_815@yahoo.com.'}, {'ForeName': 'Ehsan', 'Initials': 'E', 'LastName': 'Kazemnezhad', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}, {'ForeName': 'Seyed Naser', 'Initials': 'SN', 'LastName': 'Seyed Esmaeili', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Motiee', 'Affiliation': 'Urology Research Center, School of Medicine, Guilan University of Medical Sciences.'}]",Urology journal,[] 1207,28299764,Bolus Injection Versus Infusion of Furosemide in Kidney Transplantation: A Randomized Clinical Trial.,"PURPOSE Furosemide is commonly administered to increase the urinary output in patients with transplanted kidneys. This study compared the two administration routes of furosemide (bolus versus infusion) in kidney transplanted patients. MATERIALS AND METHODS Fifty patients who had undergone kidney transplantation in 2015 in a hospital in Tabriz, Iran, were included in this clinical trial. They were divided into two groups: bolus (120 mg stat) and infusion (4 mg/minute) groups. The primary outcome was urine onset time. Secondary outcomes were urine output volume, vital signs (blood pressure, heart rate), and electrolyte level (creatinine, blood urea nitrogen, sodium and potassium). After arterial and venous anastomoses, arterial clamp removal time and diuresis onset were recorded. Finally, theurinary output volumes of both groups were measured with regular urine bags for an hour after anastomosis. Then it was repeated each three hours for 24 hours, and eventually two and three days thereafter. Finally, all data were statistically analyzed. RESULTS Around 72% of the patients were men (mean age of 37.15 ± 14.67 years). Urine output was higher in bolus group but it was not statistically significant. Diuresis duration was measured after arterial declamping and its averages were 5.41 ± 3.7 minutes and 9.36 ± 7.65 minutes in bolus and infusion groups, respectively (P = .040). Furosemide bolus injection and infusion had no significant effect on creatinine, blood urea nitrogen, sodium and potassium. CONCLUSION Furosemide bolus injection can reduce diuresis onset time compared to furosemide infusion.",2017,"Furosemide bolus injection and infusion had no significant effect on creatinine, blood urea nitrogen, sodium and potassium. ","['patients with transplanted kidneys', 'Fifty patients who had undergone kidney transplantation in 2015 in a hospital in Tabriz, Iran, were included in this clinical trial', 'kidney transplanted patients', 'Kidney Transplantation']","['Furosemide', 'furosemide']","['urine output volume, vital signs (blood pressure, heart rate), and electrolyte level (creatinine, blood urea nitrogen, sodium and potassium', 'Diuresis duration', 'urinary output', 'creatinine, blood urea nitrogen, sodium and potassium', 'urine onset time', 'arterial clamp removal time and diuresis onset', 'diuresis onset time', 'Urine output']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0022671', 'cui_str': 'Grafting, Kidney'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}]","[{'cui': 'C0016860', 'cui_str': 'Furosemide'}]","[{'cui': 'C1287298', 'cui_str': 'UO - Urine output'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0518766'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0428284', 'cui_str': 'Finding of electrolyte levels (finding)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0600137', 'cui_str': 'Blood urea nitrogen (substance)'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0304475', 'cui_str': 'Potassium supplement'}, {'cui': 'C0012797', 'cui_str': 'Diuresis'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0232856', 'cui_str': 'Urinary output'}, {'cui': 'C0042037'}, {'cui': 'C1299997', 'cui_str': 'Onsets'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",50.0,0.334448,"Furosemide bolus injection and infusion had no significant effect on creatinine, blood urea nitrogen, sodium and potassium. ","[{'ForeName': 'Afshar', 'Initials': 'A', 'LastName': 'Zomorrodi', 'Affiliation': 'Department of Urology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Mohammadipoor Anvari', 'Affiliation': 'Department of Anesthesiology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Farzad', 'Initials': 'F', 'LastName': 'Kakaei', 'Affiliation': 'Department of Surgery, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Farzin', 'Initials': 'F', 'LastName': 'Solymanzadeh', 'Affiliation': 'Department of Urology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Esmaeil', 'Initials': 'E', 'LastName': 'Khanlari', 'Affiliation': 'Department of Urology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Bagheri', 'Affiliation': 'Department of Urology, Emam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Urology journal,[] 1208,32054513,"""I was seen by a radiologist, but unfortunately I can't remember the name and I still have questions. What should I do?"" Radiologists should give thoughts to improve service professionalism and patient esteem.","BACKGROUND The aim of the study is to investigate how well patients remember the radiologist's name after a radiological examination, and whether giving the patient a business card improves the patient's perception of the radiologist's professionalism and esteem. METHODS In this prospective and randomized two-centre study, a total of 141 patients with BI-RADS 1 and 2 scores were included. After screening examination comprising mammography and ultrasound by a radiologist, 71 patients received a business card (group 1), while 70 received no business card (group 2). Following the examination, patients were questioned about their experiences. RESULTS The patients in group 1 could remember the name of the radiologist in 85% of cases. The patients in group 2, in contrast, could only remember the name in 7% of cases (p < 0.001). 90% of the patients in group 1 believed it was very important that they are able to contact the radiologist at a later time, whereas only 76% of patients in group 2 felt that this was a very important service (p < 0.025). A total of 87% of the patients in group 1 indicated that they would contact the radiologist if they had any questions whereas 73% of the patients in group 2 would like to contact the radiologist but were not able to do so, because they could not remember the name (p < 0.001). All questions were analysed with a Cochran-Mantel-Haenszel (CMH) test that took study centre as stratification into account. In some cases, two categories were collapsed to avoid zero cell counts. CONCLUSIONS Using business cards significantly increased the recall of the radiologist's name and could be an important tool in improving the relationships between patients and radiologists and enhancing service professionalism. TRIAL REGISTRATION We have a general approval from our ethics committee. The patients have given their consent to this study.",2020,"90% of the patients in group 1 believed it was very important that they are able to contact the radiologist at a later time, whereas only 76% of patients in group 2 felt that this was a very important service (p < 0.025).",['141 patients with BI-RADS 1 and 2 scores were included'],"['business card (group 1), while 70 received no business card']",[],"[{'cui': 'C4517572', 'cui_str': 'One hundred and forty-one'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0556643', 'cui_str': 'rad (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0085936', 'cui_str': 'Business'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}]",[],141.0,0.0289319,"90% of the patients in group 1 believed it was very important that they are able to contact the radiologist at a later time, whereas only 76% of patients in group 2 felt that this was a very important service (p < 0.025).","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Gutzeit', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria. andreas.gutzeit@hirslanden.ch.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Fischmann', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Rosemarie', 'Initials': 'R', 'LastName': 'Forstner', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Romana', 'Initials': 'R', 'LastName': 'Goette', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Herzog', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Kurtz', 'Affiliation': 'Institute of Radiology and Nuclear Medicine, Kantonsspital Luzern, Lucerne, Switzerland.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Hebler', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Ladinger', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Johannes M', 'Initials': 'JM', 'LastName': 'Froehlich', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Janusch', 'Initials': 'J', 'LastName': 'Blautzik', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Orpheus', 'Initials': 'O', 'LastName': 'Kolokythas', 'Affiliation': 'Department of Radiology, University of Washington, 1959 NE Pacific St, Seattle, WA, 98190, USA.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Matoori', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Kos', 'Affiliation': 'Institute of Radiology and Nuclear Medicine and Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Reischauer', 'Affiliation': 'Department of Medicine, University of Fribourg, Fribourg, Switzerland.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'Schefer', 'Affiliation': 'Department of Oncology, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Dubsky', 'Affiliation': 'Breast Center St. Anna, Hirslanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Lucerne, Switzerland.'}, {'ForeName': 'Simon Peter', 'Initials': 'SP', 'LastName': 'Gampenrieder', 'Affiliation': 'Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University Salzburg, Muellner Hauptstraße 48, 5020, Salzburg, Austria.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Hergan', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Gaissmaier', 'Affiliation': 'Department of Psychology, University of Konstanz, P.O. Box 43, D-78457, Konstanz, Germany.'}, {'ForeName': 'Dow-Mu', 'Initials': 'DM', 'LastName': 'Koh', 'Affiliation': 'Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research, Sutton, Surrey, UK.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Meissnitzer', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}]",Cancer imaging : the official publication of the International Cancer Imaging Society,['10.1186/s40644-020-0292-7'] 1209,31905097,"Effectiveness of Cervical Spine High-Velocity, Low-Amplitude Thrust Added to Behavioral Education, Soft Tissue Mobilization, and Exercise for People With Temporomandibular Disorder With Myalgia: A Randomized Clinical Trial.","OBJECTIVE To determine the immediate and short-term effects of adding cervical spine high-velocity, low-amplitude thrust (HVLAT) to behavioral education, soft tissue mobilization, and a home exercise program on pain and dysfunction for people with a primary complaint of temporomandibular disorder (TMD) with myalgia. DESIGN Randomized clinical trial. METHODS Fifty individuals with TMD were randomly assigned to receive cervical HVLAT or sham manipulation for 4 visits over 4 weeks. Participants in both groups received other treatments, including standardized behavioral education, soft tissue mobilization, and a home exercise program. Primary outcomes included maximal mouth opening, the numeric pain-rating scale, the Jaw Functional Limitation Scale (JFLS), the Tampa Scale of Kinesiophobia for TMD (TSK-TMD), and a global rating of change (GROC). Self-report and objective measurements were taken at baseline, immediately after initial treatment, and follow-ups of 1 week and 4 weeks. A 2-by-4 mixed-model analysis of variance was used, with intervention group as the between-subjects factor and time as the within-subject factor. Separate analyses of variance were performed for dependent variables, and the hypothesis of interest was the group-by-time interaction. RESULTS There was no significant interaction for maximal mouth opening, the numeric pain-rating scale, or secondary measures. There were significant 2-way interactions for the JFLS ( d = 0.60) and TSK-TMD ( d = 0.80). The HVLAT group had lower fear at 4 weeks and improved jaw function earlier (1 week). The GROC favored the HVLAT group, with significant differences in successful outcomes noted immediately after baseline treatment (thrust, 6/25; sham, 0/25) and at 4 weeks (thrust, 17/25; sham, 10/25). CONCLUSION Both groups improved over time; however, differences between groups were small. There were significant differences between groups for the JFLS, TSK-TMD, and GROC. The additive clinical effect of cervical HVLAT to standard care remains unclear for treating TMD. J Orthop Sports Phys Ther 2020;50(8):455-465. Epub 6 Jan 2020. doi:10.2519/jospt.2020.9175 .",2020,Significant 2-way interactions were noted in JFLS (d=0.60) and TSK-TMD (d=0.80).,"['Individuals With Temporomandibular Disorder (TMD) With Myalgia', 'individuals with a primary complaint of temporomandibular disorder (TMD) with myalgia', 'Fifty individuals with TMD (n=50']","['cervical HVLAT or sham manipulation', 'Cervical Spine High Velocity Low Amplitude Thrust Added to Behavioral Education, Soft Tissue Mobilization, and Exercise', 'HVLAT', 'standardized behavioral education, soft tissue mobilization, and a HEP', 'cervical spine high velocity low amplitude thrust (HVLAT) added to behavioral education, soft tissue mobilization, and a home exercise program (HEP', 'JFLS']","['JFLS, TSK-TMD, and GROC', 'TSK-TMD), and Global Rating of Change (GROC', 'lower fear at 4-weeks and improved jaw function', 'pain and dysfunction', 'maximal mouth opening (MMO), Numeric Pain Rating Scale (NPRS), Jaw Functional Limitation Scale (JFLS), Tampa Scale of Kinesiophobia', 'successful outcomes', 'GROC']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0039494', 'cui_str': 'TMJ Diseases'}, {'cui': 'C0231528', 'cui_str': 'Muscle Pain'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}]","[{'cui': 'C0205064', 'cui_str': 'Cervical (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0947647', 'cui_str': 'Manipulation - action (qualifier value)'}, {'cui': 'C0728985', 'cui_str': 'Cervical spine'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1720086', 'cui_str': 'Add - dosing instruction fragment'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0686940', 'cui_str': 'Soft tissue mobilization'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449198', 'cui_str': 'HEP (body structure)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449295', 'cui_str': 'Limitation (attribute)'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C1272703', 'cui_str': 'Successful'}]",50.0,0.0853835,Significant 2-way interactions were noted in JFLS (d=0.60) and TSK-TMD (d=0.80).,"[{'ForeName': 'Breanna', 'Initials': 'B', 'LastName': 'Reynolds', 'Affiliation': ''}, {'ForeName': 'Emilio J', 'Initials': 'EJ', 'LastName': 'Puentedura', 'Affiliation': ''}, {'ForeName': 'Morey J', 'Initials': 'MJ', 'LastName': 'Kolber', 'Affiliation': ''}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Cleland', 'Affiliation': ''}]",The Journal of orthopaedic and sports physical therapy,['10.2519/jospt.2020.9175'] 1210,27928809,Efficacy of Medical Expulsive Therapy in Renal Calculi Less than or Equal to 5 Millimetres in Size.,"PURPOSE Natural history and modality of treatment for asymptomatic renal calculi less than or equal to 5 millimetres in size is still unknown. Many options are available ranging from medical expulsive therapy to minimally invasive surgery. Till date no study has focussed on this very common but asymptomatic issue. Hence, this study is undertaken to evaluate efficacy of medical expulsive therapy in renal calculi less than or equal to 5mm in size. MATERIALS AND METHODS A prospective, parallel group, randomized study was carried out from 1st June 2014 to 31st May 2015, with total of 100 patients, 50 patients in each group. Patients with renal stones less than or equal to 5mm were included in the study. Group A Patients were administered medical expulsive therapy which included  tamsulosin 0.4 mg daily at night time, furosemide 20mg, spironolactone 50mg in a single morning dose, and syrup potassium magnesium citrate 20Meq per dose three times a day for 12 weeks while group B patients were given placebo. The primary outcome variable was number of patients achieving clearance of stone during 12-week treatment period in both groups. RESULTS No statistically significant differences in age, gender, stone size, and calyceal stone location was found between the two treatment arms. A spontaneous stone expulsion rate of 50% (at 6 weeks) and 86 %( at 12 weeks) was noted in group A versus 28% (at 6 weeks) and 38 % (at 12 weeks) in group B. Less number of pain episodes and less analgesic medication was required in group A as compared to group B. CONCLUSION Medical Expulsive therapy for 12 weeks significantly improves stone free rates in renal calyceal calculi less than or equal to 5mm.",2016,Medical Expulsive therapy for 12 weeks significantly improves stone free rates in renal calyceal calculi less than or equal to 5mm.,"['Renal Calculi Less than or Equal to 5 Millimetres in Size', 'Patients with renal stones less than or equal to 5mm were included in the study', '1st June 2014 to 31st May 2015, with total of 100 patients, 50 patients in each group', 'renal calculi less than or equal to 5mm in size']","['medical expulsive therapy which included \xa0tamsulosin 0.4 mg daily at night time, furosemide 20mg, spironolactone 50mg in a single morning dose, and syrup potassium magnesium citrate 20Meq', 'Medical Expulsive Therapy', 'medical expulsive therapy', 'placebo']","['analgesic medication', 'stone free rates', 'number of pain episodes', 'spontaneous stone expulsion rate', 'number of patients achieving clearance of stone', 'age, gender, stone size, and calyceal stone location']","[{'cui': 'C0022650', 'cui_str': 'Kidney Stones'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0439200', 'cui_str': 'mm'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205435', 'cui_str': 'First (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0240526', 'cui_str': 'Night time (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0986198', 'cui_str': 'Furosemide 20 MG'}, {'cui': 'C0992989', 'cui_str': 'Spironolactone 50 MG'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0332170', 'cui_str': 'Morning (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0458173', 'cui_str': 'Syrup (substance)'}, {'cui': 'C0084141', 'cui_str': 'potassium-magnesium citrate'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C1293107', 'cui_str': 'Expulsion (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}, {'cui': 'C0403714', 'cui_str': 'Calyceal renal calculus (disorder)'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}]",100.0,0.0226357,Medical Expulsive therapy for 12 weeks significantly improves stone free rates in renal calyceal calculi less than or equal to 5mm.,"[{'ForeName': 'Sudarshan', 'Initials': 'S', 'LastName': 'Daga', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}, {'ForeName': 'Vinayak G', 'Initials': 'VG', 'LastName': 'Wagaskar', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}, {'ForeName': 'Harshawardhan', 'Initials': 'H', 'LastName': 'Tanwar', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Shelke', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}, {'ForeName': 'Bhushan', 'Initials': 'B', 'LastName': 'Patil', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}, {'ForeName': 'Sujata', 'Initials': 'S', 'LastName': 'Patwardhan', 'Affiliation': ""Department of Urology, King's Edward Memorial Hospital, Mumbai, India.""}]",Urology journal,[] 1211,27928815,Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial.,"PURPOSE To compare monotherapy with tadalafil or tamsulosin and their combination therapy in men with benignprostatic hyperplasia and erectile dysfunction by comparing IPSS score, prostate volume and Qmax and someother outcomes. MATERIALS AND METHODS This randomized, single-blind, paralleled group clinical trial was done in 2013 on patientswho had referred to our hospital in Tehran. All patients with lower urinary tract symptoms, benign prostatichyperplasia and any grade of erectile dysfunction were recruited. They were randomly divided into three groups(61 participants in each group): Group A received 20 mg/daily tadalafil; Group B received 0.4 mg/daily tamsulosin;Group C receieved a combination of 0.4 mg/daily tamsulosin and 20 mg/daily tadalafil. Primary outcomeswere prostate volume, prostate specific antigen, post-void residual volume, IPSS score, LUTS severity, Qmax,IIEF and erectile dysfunction severity and secondary outcome was complications. RESULTS The mean ± SD of ultrasonographic prostate volume was 61.4 ± 15.1 mL and prostate specific antigenlevel was 2.4 ± 1.9 ng/dl. Post-void residual level was significantly different before and after the treatment, exceptfor group A. Also, this group had no meaningful difference compared to the other groups in this regard (P > 0.05).There were significant differences between pre- and post-treatment international prostate symptom scores in eachgroup (P < 0.05). CONCLUSION Combination of tamsulosin and tadalafil can improve international prostate symptom scores, internationalindex of erectile function questionnaire scores and Qmax in patients with lower urinary tract symptoms andbenign prostatic hyperplasia to more degrees than their separate use. This combination is recommended becauseof its synergistic effects, well toleration and safety.",2016,"0.05).There were significant differences between pre- and post-treatment international prostate symptom scores in eachgroup (P < 0.05). ","['Men with Benign Prostatic Hyperplasia', 'patients with lower urinary tract symptoms andbenign prostatic hyperplasia', '2013 on patientswho had referred to our hospital in Tehran', 'All patients with lower urinary tract symptoms, benign prostatichyperplasia and any grade of erectile dysfunction were recruited', 'men with benignprostatic hyperplasia and erectile dysfunction by comparing IPSS score, prostate volume and Qmax and someother outcomes']","['tamsulosin;Group C receieved a combination of 0.4 mg/daily tamsulosin and 20 mg/daily tadalafil', '20 mg/daily tadalafil', 'tamsulosin and tadalafil', 'Tadalafil or Tamsulosin and Their Combination Therapy', 'tadalafil or tamsulosin and their combination therapy']","['mean ± SD of ultrasonographic prostate volume', 'Primary outcomeswere prostate volume, prostate specific antigen, post-void residual volume, IPSS score, LUTS severity, Qmax,IIEF and erectile dysfunction severity and secondary outcome was complications', 'Post-void residual level', 'international prostate symptom scores, internationalindex of erectile function questionnaire scores and Qmax']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C2937421', 'cui_str': 'Prostatic Hyperplasia'}, {'cui': 'C0019982', 'cui_str': 'Hospital Referral'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0242350', 'cui_str': 'Male Sexual Impotence'}, {'cui': 'C0020507', 'cui_str': 'Hyperplasia'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}]","[{'cui': 'C4517457', 'cui_str': 'Zero point four'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C1176316', 'cui_str': 'tadalafil'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0242350', 'cui_str': 'Male Sexual Impotence'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0412489,"0.05).There were significant differences between pre- and post-treatment international prostate symptom scores in eachgroup (P < 0.05). ","[{'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Karami', 'Affiliation': 'Laser application in medical sciences research center, Shohadaye Tajrish hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. karami_hosein@yahoo.com.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Hassanzadeh-Hadad', 'Affiliation': 'Laser application in medical sciences research center, Shohadaye Tajrish hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Morteza', 'Initials': 'M', 'LastName': 'Fallah-Karkan', 'Affiliation': 'Laser application in medical sciences research center, Shohadaye Tajrish hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Urology journal,[] 1212,32412991,An Exploration of Health Behaviors in a Mind-Body Resilience Intervention for Parents of Children with Developmental Disabilities.,"OBJECTIVE Parents of children with special needs such as learning and attentional disabilities (LADs) and autism spectrum disorder (ASD) are at high risk for stress-related disorders. The demands of parenting may compete with time for self-care behaviors such as physical activity, healthy eating, and adequate sleep. The objective was to describe health behaviors among this understudied population and assess the changes after a resilience intervention. METHODS This was a secondary data analysis of a randomized controlled pilot virtual mind-body resilience intervention (Stress Management and Resiliency Training: A Relaxation Response Resiliency Program) trial for parents of children with LADs (n = 52) and ASD (n = 47). Parents completed self-report questionnaires about their weekly physical activity, eating behaviors, sleep duration, and fatigue before and after the 8-week intervention. Descriptive statistics and pre-post intervention effect sizes (Cohen's d) were calculated. RESULTS Both parent groups reported suboptimal levels of health behaviors at baseline, but ASD parents reported lower health behaviors than LAD parents. LAD parents improved more on physical activity, with a higher percentage meeting recommendations at postintervention follow-up (d = 0.71) than ASD parents (d = 0.01). Eating behaviors showed small effect size improvements for both groups. Although sleep duration improved only with small or medium effect sizes for both groups, ASD parents rated their fatigue lower after the intervention (d = 0.81). CONCLUSION Parents of children with special needs who participated in a virtual resilience intervention demonstrated suboptimal health behaviors. There is a need for targeted interventions for health behaviors that can promote resilience in these high-stress populations.",2020,"Although sleep duration improved only with small or medium effect sizes for both groups, ASD parents rated their fatigue lower after the intervention (d = 0.81). ","['parents of children with LADs (n = 52) and ASD (n = 47', 'Parents of Children with Developmental Disabilities', 'Parents of children with special needs such as learning and attentional disabilities (LADs) and autism spectrum disorder (ASD', 'Parents of children with special needs who participated in a']","['body resilience intervention (Stress Management and Resiliency Training', 'Mind-Body Resilience Intervention', 'virtual resilience intervention']","['self-report questionnaires about their weekly physical activity, eating behaviors, sleep duration, and fatigue', 'sleep duration', 'physical activity', 'suboptimal health behaviors', 'health behaviors', 'suboptimal levels of health behaviors']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0008073', 'cui_str': 'Developmental disorder'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0424574', 'cui_str': 'Duration of sleep'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018759', 'cui_str': 'Health status'}]",52.0,0.0551803,"Although sleep duration improved only with small or medium effect sizes for both groups, ASD parents rated their fatigue lower after the intervention (d = 0.81). ","[{'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Millstein', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Olivia J', 'Initials': 'OJ', 'LastName': 'Lindly', 'Affiliation': 'Department of Health Sciences, Northern Arizona University, Tucson, AZ.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Luberto', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Giselle K', 'Initials': 'GK', 'LastName': 'Perez', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Gabrielle N', 'Initials': 'GN', 'LastName': 'Schwartz', 'Affiliation': 'Health Policy Research Center, Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Kuhlthau', 'Affiliation': 'Division of General Academic Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}, {'ForeName': 'Elyse R', 'Initials': 'ER', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA.'}]",Journal of developmental and behavioral pediatrics : JDBP,['10.1097/DBP.0000000000000813'] 1213,31735542,"Effects of weight stigma in news media on physical activity, dietary and weight loss intentions and behaviour.","OBJECTIVES To investigate the effect of weight stigma in news media on (a) intentions to increase physical activity (PA), improve diet quality and lose weight, and (b) changes in PA, diet quality and body mass index (BMI) over one month, in (i) women of all weight categories and (ii) a subsample of women living with obesity. METHODS UK-based women (N=172; subgroup with obesity N=81) were assigned to read an experimental (weight stigma; N=75) or control (smoking stigma; N=97) news article. Questionnaires were administered immediately after, and one month subsequently to collect information on BMI, PA, diet quality, intentions, past stigma, and diet and PA self-efficacy. Logistic and linear regression analyses were used to assess the effect of weight stigma on all outcome variables. RESULTS In the whole sample, there was no significant effect of weight stigma on any primary or secondary outcome. In women with obesity, there was no significant effect of weight stigma on diet quality (0.26 units, 95% CI: -0.36 to 0.87) or PA (-1.83 units, 95% CI: -11.11 to 7.44) at follow up, but exposure to weight stigma was associated with a significant increase in BMI at 1-month follow-up (1.15kg/m 2 , 95% CI: 0.38 to 1.92) compared with the control group. CONCLUSIONS In people with obesity, exposure to weight-stigmatising media may contribute to increased BMI over time. Larger trials with longer follow-up are needed to confirm these findings.",2019,"In women with obesity, there was no significant effect of weight stigma on diet quality (0.26 units, 95% CI: -0.36 to 0.87) or PA (-1.83 units, 95% CI: -11.11 to 7.44) at follow up, but exposure to weight stigma was associated with a significant increase in BMI at 1-month follow-up (1.15kg/m 2 , 95% CI: 0.38 to 1.92) compared with the control group. ","['women living with obesity', 'UK-based women ', 'N=172; subgroup with obesity N=81']",[],"['weight stigma on diet quality', 'physical activity, dietary and weight loss intentions and behaviour', 'physical activity (PA), improve diet quality and lose weight, and (b) changes in PA, diet quality and body mass index (BMI) over one month, in (i) women of all weight categories and (ii', 'BMI', 'BMI, PA, diet quality, intentions, past stigma, and diet and PA self-efficacy', 'weight stigma']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0178499', 'cui_str': 'Base'}]",[],"[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0277787', 'cui_str': 'Stigma (finding)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4082115', 'cui_str': 'One month (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.0285905,"In women with obesity, there was no significant effect of weight stigma on diet quality (0.26 units, 95% CI: -0.36 to 0.87) or PA (-1.83 units, 95% CI: -11.11 to 7.44) at follow up, but exposure to weight stigma was associated with a significant increase in BMI at 1-month follow-up (1.15kg/m 2 , 95% CI: 0.38 to 1.92) compared with the control group. ","[{'ForeName': 'Ellen R', 'Initials': 'ER', 'LastName': 'Lambert', 'Affiliation': ""Department of Behavioural Science and Health, University College London, London, UK; Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.""}, {'ForeName': 'Dimitrios A', 'Initials': 'DA', 'LastName': 'Koutoukidis', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Jackson', 'Affiliation': 'Department of Behavioural Science and Health, University College London, London, UK. Electronic address: s.e.jackson@ucl.ac.uk.'}]",Obesity research & clinical practice,['10.1016/j.orcp.2019.09.001'] 1214,27576882,Comparison of the Efficacy and Safety of Laparoendoscopic Single-Site Surgery with Conventional Laparoscopic Surgery for Upper Ureter or Renal Pelvis Stones in a Single Institution: A Randomized Controlled Study.,"PURPOSE To evaluate the utility and safety of laparoendoscopic single-site surgery (LESS) in comparison with conventional laparoscopic (CL) surgery for the treatment of upper urinary tract stones. MATERIAL AND METHODS Between June 2011 and May 2012, 20 patients with upper urinary tract stones were included in this prospective randomized study. The patients were assigned into the LESS group or CL group in a one-on-one manner using a random table. The clinical parameters were evaluated in the immediate postoperative period, and the stone clearance rate was evaluated via non-contrast computer tomography at one month postoperatively. RESULTS There were no significant differences in patient demographics or preoperative stone sizes between the two groups. The perioperative parameters, including operative time, estimated blood loss, postoperative pain scores, length of hospital stay, and changes in renal function, were comparable. No transfusions or open conversions were required in either group. The incidence of residual stones was lower in the LESS group (1 case) than in the CL group (2 cases). However, this difference was not statistically significant. CONCLUSIONS For large and impacted upper ureteral stones, the effectiveness and safety of LESS were equivalent to those of CL. Further randomized control trials with larger sample sizes are needed to strengthen the conclusions of this study. .",2016,The incidence of residual stones was lower in the LESS group (1 case) than in the CL group (2 cases).,"['Upper Ureter or Renal Pelvis Stones in a Single Institution', 'Between June 2011 and May 2012, 20 patients with upper urinary tract stones']","['Laparoendoscopic Single-Site Surgery with Conventional Laparoscopic Surgery', 'laparoendoscopic single-site surgery (LESS', 'LESS group or CL', 'conventional laparoscopic (CL) surgery', 'LESS']","['stone clearance rate', 'effectiveness and safety of LESS', 'incidence of residual stones', 'operative time, estimated blood loss, postoperative pain scores, length of hospital stay, and changes in renal function', 'patient demographics or preoperative stone sizes']","[{'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0041951', 'cui_str': 'Ureter'}, {'cui': 'C0227666', 'cui_str': 'Kidney Pelvis'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042018', 'cui_str': 'Urinary Tract Stones'}]","[{'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}]",20.0,0.0526568,The incidence of residual stones was lower in the LESS group (1 case) than in the CL group (2 cases).,"[{'ForeName': 'Juhyun', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Seung Bae', 'Initials': 'SB', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Sung Yong', 'Initials': 'SY', 'LastName': 'Cho', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Chang Wook', 'Initials': 'CW', 'LastName': 'Jeong', 'Affiliation': 'Department of Urology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Hwancheol', 'Initials': 'H', 'LastName': 'Son', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Yong Hyun', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': ""Department of Urology, Seoul St. Mary's Hospital, Seoul, Korea.""}, {'ForeName': 'Hyeon Hoe', 'Initials': 'HH', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'IslahMunjih Ab', 'Initials': 'IA', 'LastName': 'Rashid', 'Affiliation': 'Urology Unit, Department of Surgery, International Islamic University Malaysia, Kuala Lumpur, Malasyia.'}, {'ForeName': 'Hyeon', 'Initials': 'H', 'LastName': 'Jeong', 'Affiliation': 'Department of Urology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea. drjh@brm.co.kr.'}]",Urology journal,[] 1215,31818329,ELEMENT TRIAL: study protocol for a randomized controlled trial on endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs. endoscopic retrograde cholangio-pancreatography in the management of malignant distal biliary obstruction.,"BACKGROUND & AIMS Endoscopic ultrasound guided-biliary drainage (EUS-BD) is a promising alternative to endoscopic retrograde cholangiopancreatography (ERCP); however, its growth has been limited by a lack of multicenter randomized controlled trials (RCT) and dedicated devices. A dedicated EUS-BD lumen- apposing metal stent (LAMS) has recently been developed with the potential to greatly facilitate the technique and safety of the procedure. We aim to compare a first intent approach with EUS-guided choledochoduodenostomy with a dedicated biliary LAMS vs. standard ERCP in the management of malignant distal biliary obstruction. METHODS The ELEMENT trial is a multicenter single-blinded RCT involving 130 patients in nine Canadian centers. Patients with unresectable, locally advanced, or borderline resectable malignant distal biliary obstruction meeting the inclusion and exclusion criteria will be randomized to EUS-choledochoduodenostomy using a LAMS or ERCP with traditional metal stent insertion in a 1:1 proportion in blocks of four. Patients with hilar obstruction, resectable cancer, or benign disease are excluded. The primary endpoint is the rate of stent dysfunction needing re-intervention. Secondary outcomes include technical and clinical success, interruptions in chemotherapy, rate of surgical resection, time to stent dysfunction, and adverse events. DISCUSSION The ELEMENT trial is designed to assess whether EUS-guided choledochoduodenostomy using a dedicated LAMS is superior to conventional ERCP as a first-line endoscopic drainage approach in malignant distal biliary obstruction, which is an important and timely question that has not been addressed using an RCT study design. TRIAL REGISTRATION Registry name: ClinicalTrials.gov. Registration number: NCT03870386. Date of registration: 03/12/2019.",2019,"The ELEMENT trial is designed to assess whether EUS-guided choledochoduodenostomy using a dedicated LAMS is superior to conventional ERCP as a first-line endoscopic drainage approach in malignant distal biliary obstruction, which is an important and timely question that has not been addressed using an RCT study design. ","['malignant distal biliary obstruction', '130 patients in nine Canadian centers', 'Patients with hilar obstruction, resectable cancer, or benign disease are excluded', 'Patients with unresectable, locally advanced, or borderline resectable malignant distal biliary obstruction meeting the inclusion and exclusion criteria']","['EUS-BD lumen- apposing metal stent (LAMS', 'EUS-guided choledochoduodenostomy', 'endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs. endoscopic retrograde cholangio-pancreatography', 'LAMS or ERCP with traditional metal stent insertion', 'EUS-guided choledochoduodenostomy with a dedicated biliary LAMS vs. standard ERCP', 'endoscopic retrograde cholangiopancreatography (ERCP', 'Endoscopic ultrasound guided-biliary drainage (EUS-BD']","['rate of stent dysfunction needing re-intervention', 'technical and clinical success, interruptions in chemotherapy, rate of surgical resection, time to stent dysfunction, and adverse events']","[{'cui': 'C0205282', 'cui_str': 'Malignant (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0205150', 'cui_str': 'Hilar'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205183', 'cui_str': 'Benign (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0441290', 'cui_str': 'Metal stent (physical object)'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0008342', 'cui_str': 'Choledochoduodenostomy'}, {'cui': 'C0376443', 'cui_str': 'Ultrasonography, Endoscopic'}, {'cui': 'C0400745', 'cui_str': 'Biliary drainage (procedure)'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C0439784', 'cui_str': 'Retrograde direction (qualifier value)'}, {'cui': 'C0581480', 'cui_str': 'Pancreatic contrast procedure (procedure)'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",130.0,0.294254,"The ELEMENT trial is designed to assess whether EUS-guided choledochoduodenostomy using a dedicated LAMS is superior to conventional ERCP as a first-line endoscopic drainage approach in malignant distal biliary obstruction, which is an important and timely question that has not been addressed using an RCT study design. ","[{'ForeName': 'Yen-I', 'Initials': 'YI', 'LastName': 'Chen', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada. yen-i.chen@mcgill.ca.'}, {'ForeName': 'Kashi', 'Initials': 'K', 'LastName': 'Callichurn', 'Affiliation': ""Division of Gastroenterology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Avijit', 'Initials': 'A', 'LastName': 'Chatterjee', 'Affiliation': 'Division of Gastroenterology and Hepatology, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Desilets', 'Affiliation': 'Division of Gastroenterology, Hôpital Charles-Le Moyne, University of Sherbrooke, Greenfield Park, QC, Canada.'}, {'ForeName': 'Donnellan', 'Initials': 'D', 'LastName': 'Fergal', 'Affiliation': 'Division of Gastroenterology and Hepatology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Nauzer', 'Initials': 'N', 'LastName': 'Forbes', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Gan', 'Affiliation': 'Division of Gastroenterology and Hepatology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Sana', 'Initials': 'S', 'LastName': 'Kenshil', 'Affiliation': 'Division of Gastroenterology and Hepatology, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Mouen A', 'Initials': 'MA', 'LastName': 'Khashab', 'Affiliation': 'Division of Gastroenterology and Hepatology, Johns Hopkins Hospital, Baltimore, MD, USA.'}, {'ForeName': 'Rastislav', 'Initials': 'R', 'LastName': 'Kunda', 'Affiliation': 'Department of Surgery, Department of Gastroenterology and Hepatology, Department of Advanced Interventional Endoscopy, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Lam', 'Affiliation': ""Division of Gastroenterology and Hepatology, St-Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.""}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'May', 'Affiliation': ""Division of Gastroenterology and Hepatology, St-Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Rachid', 'Initials': 'R', 'LastName': 'Mohamed', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Jeff', 'Initials': 'J', 'LastName': 'Mosko', 'Affiliation': ""Division of Gastroenterology and Hepatology, St-Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Sarto C', 'Initials': 'SC', 'LastName': 'Paquin', 'Affiliation': ""Division of Gastroenterology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Sahai', 'Affiliation': ""Division of Gastroenterology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Gurpal', 'Initials': 'G', 'LastName': 'Sandha', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of Alberta Hospital, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Teshima', 'Affiliation': ""Division of Gastroenterology and Hepatology, St-Michael's Hospital, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Barkun', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Barkun', 'Affiliation': 'Department of Surgery, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Bessissow', 'Affiliation': 'Department of Radiology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Candido', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Martel', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Corey', 'Initials': 'C', 'LastName': 'Miller', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Waschke', 'Affiliation': 'Division of Gastroenterology and Hepatology, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Zogopoulos', 'Affiliation': 'Department of Surgery, McGill University Health Centre, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Clarence', 'Initials': 'C', 'LastName': 'Wong', 'Affiliation': 'Division of Gastroenterology and Hepatology, Royal Alexandra Hospital, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-019-3918-y'] 1216,27530654,Stress Management and Health Promotion in a Sample of Women With Intimate Partner Violence: A Randomized Controlled Trial.,"The aim of the present study was to investigate the effectiveness of a stress management program regarding mitigating psychological repercussions in women who experience intimate partner violence (IPV). This randomized controlled trial took place from January 2015 to June 2015, in Attica, Greece. A total of 60 women were randomly assigned into an intervention and control group, with the intervention group ( n = 30) receiving stress management and a lifestyle program. Self-reported measures were used to assess stress, depression and anxiety levels, daily routine, severity of abuse, self-esteem, health locus of control, and self-efficacy. Statistical analysis showed a significant improvement in measures of stress, depression, anxiety, self-esteem, and self-efficacy in the intervention group. Daily routine and physical exercise also improved. Based on these findings, we strongly encourage health professionals to advise women experiencing current and past IPV to adopt stress management techniques to their daily program, as a further means of empowerment.",2019,"Statistical analysis showed a significant improvement in measures of stress, depression, anxiety, self-esteem, and self-efficacy in the intervention group.","['A total of 60 women', 'January 2015 to June 2015, in Attica, Greece', 'Women With Intimate Partner Violence', 'women who experience intimate partner violence (IPV']","['stress management program', 'Stress Management and Health Promotion', 'intervention group ( n = 30) receiving stress management and a lifestyle program']","['stress, depression and anxiety levels, daily routine, severity of abuse, self-esteem, health locus of control, and self-efficacy', 'measures of stress, depression, anxiety, self-esteem, and self-efficacy']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}]","[{'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018738', 'cui_str': 'Health Promotion'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1546935', 'cui_str': 'Abuse (event)'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023953', 'cui_str': 'Locus of Control'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",60.0,0.0411965,"Statistical analysis showed a significant improvement in measures of stress, depression, anxiety, self-esteem, and self-efficacy in the intervention group.","[{'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Kokka', 'Affiliation': '1 Postgraduate Course Science of Stress and Health Promotion, School of Medicine, University of Athens, Athens, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Mikelatou', 'Affiliation': '1 Postgraduate Course Science of Stress and Health Promotion, School of Medicine, University of Athens, Athens, Greece.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Fouka', 'Affiliation': '2 Technological Educational Institute of Athens, Athens, Greece.'}, {'ForeName': 'Liza', 'Initials': 'L', 'LastName': 'Varvogli', 'Affiliation': '1 Postgraduate Course Science of Stress and Health Promotion, School of Medicine, University of Athens, Athens, Greece.'}, {'ForeName': 'George P', 'Initials': 'GP', 'LastName': 'Chrousos', 'Affiliation': '1 Postgraduate Course Science of Stress and Health Promotion, School of Medicine, University of Athens, Athens, Greece.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Darviri', 'Affiliation': '1 Postgraduate Course Science of Stress and Health Promotion, School of Medicine, University of Athens, Athens, Greece.'}]",Journal of interpersonal violence,['10.1177/0886260516658759'] 1217,31296525,Carotid CTA at the Lowest Tube Voltage (70 kV) in Comparison with Automated Tube Voltage Adaption.,"BACKGROUND AND PURPOSE CTA is the imaging modality of choice in many institutions for the evaluation of the supraaortic vessels, but radiation exposure remains a matter of concern. Our aim was to evaluate a 70-kV protocol for CT angiography of the carotid arteries with respect to image quality and radiation exposure compared with automated tube voltage adaption. MATERIALS AND METHODS A total of 90 consecutive patients were included in this prospective study and randomized to the study group ( n = 45, 70 kV) or control group ( n = 45, automated tube voltage adaptation). Volume CT dose indices and dose-length products were recorded in the examination protocol. Image quality was assessed as arterial vessel contrast, signal-to-noise ratio, contrast-to-noise ratio, and contrast-to-noise ratio in reference to the radiation dose. Subjective overall image-quality analysis, image-artifact analysis, and diagnostic evaluation were performed by 2 observers by using a 4-point Likert scale. RESULTS Radiation exposure was significantly lower in the study group (volume CT dose index reduced by 22%, dose-length product reduction by 20%; each P < .001). Contrast ( P = .15), SNR ( P = .4), and contrast-to-noise ratio ( P = .5) did not show significant differences between the groups. The contrast-to-noise ratio in reference to the radiation dose was not significantly increased using the study protocol ( P = .2). Subjective image quality and visualization of pathologic findings did not differ significantly between the groups. CONCLUSIONS Carotid CTA using the lowest available voltage (70 kV) is feasible at very-low-dose levels, while overall image quality is comparable with protocols using automated tube voltage selection.",2019,"RESULTS Radiation exposure was significantly lower in the study group (volume CT dose index reduced by 22%, dose-length product reduction by 20%; each P < .001).",['90 consecutive patients'],"['automated tube voltage adaption', 'control group ( n = 45, automated tube voltage adaptation']","['Subjective image quality and visualization of pathologic findings', 'arterial vessel contrast, signal-to-noise ratio, contrast-to-noise ratio, and contrast-to-noise ratio', 'Volume CT dose indices and dose-length products', 'Radiation exposure', 'Image quality', 'SNR', 'Subjective overall image-quality analysis, image-artifact analysis, and diagnostic evaluation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392673', 'cui_str': 'Adaptation, function (observable entity)'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C1521733', 'cui_str': 'Pathologic (qualifier value)'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C2986823', 'cui_str': 'Signal-To-Noise Ratio'}, {'cui': 'C0028263', 'cui_str': 'Noise'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1956110', 'cui_str': 'Cone-Beam Computerized Tomography'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation (event)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1297895', 'cui_str': 'Computer assisted image analysis for image quality'}, {'cui': 'C0085089', 'cui_str': 'Artifacts'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",90.0,0.0281792,"RESULTS Radiation exposure was significantly lower in the study group (volume CT dose index reduced by 22%, dose-length product reduction by 20%; each P < .001).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Eller', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Wiesmüller', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Wüst', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Heiss', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kopp', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Saake', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Brand', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uder', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'May', 'Affiliation': 'From the Department of Radiology (A.E., M.W., W.W., R.H., M.K., M.S., M.B., M.U., M.M.M.), University Hospital Erlangen, Erlangen, Germany Matthias.May@uk-erlangen.de.'}]",AJNR. American journal of neuroradiology,['10.3174/ajnr.A6108'] 1218,32416442,"Acute inspiratory muscle exercise effect on glucose levels, glucose variability and autonomic control in patients with type 2 diabetes: A crossover randomized trial.","Inspiratory muscle exercise (IME) can be an alternative to conventional exercise. We aimed to evaluate the effect of IME on glucose, glucose variability, and autonomic cardiovascular control in type 2 diabetes. Fourteen diabetic subjects were randomly assigned to IME with 2% maximal inspiratory pressure (PImax) or 60% PImax wearing a continuous glucose monitoring system for three days. Glucose variability [glucose variance (VAR), glucose coefficient of variation (CV%), glucose standard deviation (SD), and mean amplitude of glycemic excursions (MAGE)] were evaluated. Glucose reduction was observed in 5 min (60% of PImax 33.2% and 2% of PImax 32.0%), 60 min (60% of PImax 29.6% and 2% of PImax 31.4%) and 120 min (60% of PImax 21.4% and 2% of PImax 24.0%) after IME (vs.1 h before the exercise), with no difference between loads. This reduction in glucose levels was observed in all moments of the IME protocol. Glucose variability was reduced after 12 h and 18 h of the IME (ΔCV: P < 0.001, ΔSD: P < 0.001 and ΔVAR: P < 0.001) for both loads. No difference was found in MAGE (P = 0.594) after IME. Mean arterial pressure and heart rate rose during the exercise session with 60% of PImax. Although sufficiently strong to induce cardiovascular changes, an inspiratory muscle exercise session with 60% of PImax in subjects with type 2 diabetes has failed to induce any significant improvement in glucose, glucose variability and autonomic control, compared to the 2% Plmax exercise session.",2020,"Glucose variability was reduced after 12 h and 18 h of the IME (ΔCV: P < 0.001, ΔSD:","['2 diabetes', 'subjects with type 2 diabetes', 'Fourteen diabetic subjects', 'type 2 diabetes', 'patients with type']","['Acute inspiratory muscle exercise', 'Inspiratory muscle exercise (IME', 'IME with 2% maximal inspiratory pressure (PImax) or 60% PImax wearing a continuous glucose monitoring system', 'IME']","['glucose, glucose variability and autonomic control', 'Glucose reduction', 'MAGE', 'Glucose variability [glucose variance (VAR), glucose coefficient of variation (CV%), glucose standard deviation (SD), and mean amplitude of glycemic excursions (MAGE', 'Mean arterial pressure and heart rate', 'glucose, glucose variability, and autonomic cardiovascular control', 'glucose levels', 'Glucose variability', 'glucose levels, glucose variability and autonomic control']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement'}]",14.0,0.0238522,"Glucose variability was reduced after 12 h and 18 h of the IME (ΔCV: P < 0.001, ΔSD:","[{'ForeName': 'Andressa S O', 'Initials': 'ASO', 'LastName': 'Schein', 'Affiliation': 'Postgraduate Program in Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Exercise Pathophysiology Research Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Electronic address: andressasilveiradeoliveira@yahoo.com.br.'}, {'ForeName': 'Ana P S', 'Initials': 'APS', 'LastName': 'Corrêa', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}, {'ForeName': 'Aline C P', 'Initials': 'ACP', 'LastName': 'Macedo', 'Affiliation': 'Postgraduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Exercise Pathophysiology Research Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.'}, {'ForeName': 'Daniela R', 'Initials': 'DR', 'LastName': 'Dartora', 'Affiliation': 'Sainte-Justine University Hospital Research Center, University of Montreal Depatment of pediatrics, Montreal, Quebec, Canada.'}, {'ForeName': 'Anderson Donelli', 'Initials': 'AD', 'LastName': 'da Silveira', 'Affiliation': 'Postgraduate Program in Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Mateus Dornelles', 'Initials': 'MD', 'LastName': 'Severo', 'Affiliation': 'Postgraduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}, {'ForeName': 'Karina R', 'Initials': 'KR', 'LastName': 'Casali', 'Affiliation': 'Institute of Science and Technology, Universidade Federal de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Beatriz D', 'Initials': 'BD', 'LastName': 'Schaan', 'Affiliation': 'Postgraduate Program in Cardiology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Postgraduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil; Exercise Pathophysiology Research Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.'}]",Autonomic neuroscience : basic & clinical,['10.1016/j.autneu.2020.102669'] 1219,32415846,Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial.,"Cryptococcal antigen (CrAg) screening in HIV-infected persons with CD4 < 100 cells/µl can reduce meningitis and death, yet preemptive fluconazole therapy fails in ∼25%. Sertraline has in vitro and in vivo activity against Cryptococcus and is synergistic with fluconazole in mice. We evaluated the efficacy and safety of sertraline in asymptomatic cryptococcal antigenemia. We conducted a randomized trial of asymptomatic CrAg-positive Ugandans from November 2017 to February 2018. All subjects received WHO standard therapy of fluconazole 800 mg for 2 weeks, then 400 mg for 10 weeks, then 200 mg through 24 weeks. Participants were randomized to receive adjunctive sertraline or placebo, given in once-weekly escalating 100 mg/day doses up to 400 mg/day, which was then given for 8 weeks, then tapered. The primary endpoint was meningitis-free 6-month survival. The data and safety monitoring board halted the trial after 21 subjects were enrolled due to safety concerns. Meningitis-free 6-month survival occurred in 9 of 11 of placebo participants and 10 of 10 of sertraline participants. However, seven serious adverse events (SAEs) occurred (n = 4 sertraline group; n = 3 placebo group). Three SAEs in the sertraline group presented with psychosis and aggressive behavioral changes with one meeting Hunter's criteria for serotonin syndrome while receiving 200 mg/day sertraline. Two transient psychoses were associated with antecedent fluconazole and sertraline interruption. The serotonin syndrome resolved within 1 day, but psychosis persisted for 4 months after sertraline discontinuation. Sertraline was associated with excess SAEs of psychosis. Due to early stopping, we were unable to determine any efficacy for cryptococcal antigenemia.",2020,Meningitis-free 6-month survival occurred in 9 of 11 of placebo participants and 10 of 10 of sertraline participants.,"['HIV-infected persons with CD4', 'asymptomatic cryptococcal antigenemia', 'asymptomatic CrAg-positive Ugandans from November 2017 to February 2018', '21 subjects were enrolled due to safety concerns']","['fluconazole', 'sertraline', 'adjunctive sertraline or placebo', 'Sertraline', 'Adjunctive sertraline', 'placebo']","['meningitis-free 6-month survival', 'efficacy and safety', 'meningitis and death', 'Meningitis-free 6-month survival']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0010415', 'cui_str': 'Cryptococcus'}, {'cui': 'C0522281', 'cui_str': 'Cryptococcal antigen'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0016277', 'cui_str': 'Fluconazole'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0025289', 'cui_str': 'Meningitis'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",21.0,0.245246,Meningitis-free 6-month survival occurred in 9 of 11 of placebo participants and 10 of 10 of sertraline participants.,"[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Nalintya', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kirumira', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Naluyima', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Turya', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Namanda', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Morris K', 'Initials': 'MK', 'LastName': 'Rutakingirwa', 'Affiliation': 'Infectious Diseases Institute, Makerere University, Uganda.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Yofesi', 'Initials': 'Y', 'LastName': 'Nikweri', 'Affiliation': 'Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM), Uganda Research Unit, Masaka Station.'}, {'ForeName': 'Kathy Huppler', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Meya', 'Affiliation': 'University of Minnesota, Minneapolis, MN, USA.'}]",Medical mycology,['10.1093/mmy/myaa033'] 1220,27351320,Efficacy of Silodosin in Expulsive Therapy for Distal Ureteral Stones: A Randomized Double-blinded Controlled Trial.,"PURPOSE To evaluate the efficacy of silodosin in the medical expulsive therapy for symptomatic distal ureteral stones. MATERIALS AND METHODS This prospectively randomized controlled trial was carried out from May 2011 to December 2014. In all, 198 patients with radiopaque distal ureteral stones <10 mm in size were eligible: 61 patients in the control group and 62 patients in the silodosin group. The silodosin group received silodosin 8 mg daily, and the control group received lactose tablets. The primary outcome was the expulsion rate. The secondary outcomes the expulsion time, analgesic consumption, lower urinary tract symptoms, colic episodes, and adverse effects. Statistical analyses were performed using a Mann-Whitney U-test and chi-square test. RESULTS The final analysis was conducted with 61 control and 62 silodosin patients as the denominator in each randomization arm. The average expulsion times were 6.31 ± 2.13 days for the silodosin group and 9.73 ± 2.76 days for the control group (P < .001). CONCLUSION Treatment with silodosin proved to be safe and effective, as demonstrated by the increased stone expulsion rate, the reduced expulsion time, and the reduced analgesics consumption. .",2016,"CONCLUSION Treatment with silodosin proved to be safe and effective, as demonstrated by the increased stone expulsion rate, the reduced expulsion time, and the reduced analgesics consumption. .","['symptomatic distal ureteral stones', 'Distal Ureteral Stones', 'May 2011 to December 2014', '198 patients with radiopaque distal ureteral stones <10 mm in size were eligible: 61 patients in the control group and 62 patients in the silodosin group']","['lactose tablets', 'silodosin', 'Silodosin']","['average expulsion times', 'safe and effective', 'expulsion time, analgesic consumption, lower urinary tract symptoms, colic episodes, and adverse effects', 'stone expulsion rate', 'expulsion rate']","[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0041952', 'cui_str': 'Ureterolithiasis'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1870115', 'cui_str': 'silodosin'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1870115', 'cui_str': 'silodosin'}]","[{'cui': 'C1293107', 'cui_str': 'Expulsion (procedure)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0232488', 'cui_str': 'Colic'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}]",198.0,0.178092,"CONCLUSION Treatment with silodosin proved to be safe and effective, as demonstrated by the increased stone expulsion rate, the reduced expulsion time, and the reduced analgesics consumption. .","[{'ForeName': 'Chung Jing', 'Initials': 'CJ', 'LastName': 'Wang', 'Affiliation': 'Department of Surgery, Division of Urology, Saint Martin De Porres Hospital, Chiayi, Taiwan, R.O.C.'}, {'ForeName': 'Po Chao', 'Initials': 'PC', 'LastName': 'Tsai', 'Affiliation': 'Department of Surgery, Division of Urology, Saint Martin De Porres Hospital, Chiayi, Taiwan, R.O.C.'}, {'ForeName': 'Chien Hsing', 'Initials': 'CH', 'LastName': 'Chang', 'Affiliation': 'Department of Surgery, Division of Urology, Saint Martin De Porres Hospital, Chiayi, Taiwan, R.O.C.'}]",Urology journal,[] 1221,32492293,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.,"BACKGROUND Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown. METHODS We conducted a randomized, double-blind, placebo-controlled trial across the United States and parts of Canada testing hydroxychloroquine as postexposure prophylaxis. We enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure). Within 4 days after exposure, we randomly assigned participants to receive either placebo or hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 additional days). The primary outcome was the incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days. RESULTS We enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 821) reported a high-risk exposure to a confirmed Covid-19 contact. The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P = 0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. CONCLUSIONS After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. (Funded by David Baszucki and Jan Ellison Baszucki and others; ClinicalTrials.gov number, NCT04308668.).",2020,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","['United States and parts of Canada testing', '821 asymptomatic participants', 'enrolled adults who had household or occupational exposure to someone with confirmed Covid-19 at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield (high-risk exposure) or while wearing a face mask but no eye shield (moderate-risk exposure']","['placebo', 'Hydroxychloroquine', 'placebo or hydroxychloroquine', 'hydroxychloroquine']","['Side effects', 'incidence of new illness compatible with Covid-19', 'incidence of either laboratory-confirmed Covid-19 or illness compatible with Covid-19 within 14 days', 'serious adverse reactions']","[{'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0454979', 'cui_str': 'Part of Canada'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0028798', 'cui_str': 'Exposure, Occupational'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0183251', 'cui_str': 'Shield'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",821.0,0.751633,"Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported. ","[{'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'LaBar', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marten', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'From the University of Minnesota (D.R.B., M.F.P., A.S.B., K.A.P., S.M.L., E.C.O., C.P.S., A.A.N., M.R.N., M.A., N.W.E., R.R., K.H.H.) and M Health Fairview Investigational Drug Service Pharmacy (D.L.), Minneapolis; and the Research Institute of the McGill University Health Centre and the Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal (M.P.C., E.G.M., T.C.L.), the Department of Internal Medicine, University of Manitoba (S.A.L., L.J.M., G.D., N.M., R.Z.), the Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba (R.Z.), and the George and Fay Yee Centre for Healthcare Innovation (L.E.K.), Winnipeg, and the University of Alberta, Edmonton (I.S.S.) - all in Canada.'}]",The New England journal of medicine,['10.1056/NEJMoa2016638'] 1222,31913967,A Randomized Study Comparing the Short-Term Neurocognitive Outcome of Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation in the Treatment of Patients With Depression.,"BACKGROUND Studies have compared electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) with regard to their clinical efficacy in the treatment of depression, but only a few studies have addressed their differential impact on cognition. The purpose of this study was to compare the neurocognitive side effects of both treatment modalities. METHODS In this comparative study, 40 patients with major depressive disorder referred for ECT were randomly assigned either to a course of 25 sessions of rTMS to the left dorsolateral prefrontal cortex or to a course of ECT ranging from 4 to 8 sessions. The primary outcome measures were the results of a cognitive battery that assessed different aspects of cognitive functioning. The cognitive battery comprised the Digit Span Subtest from the Wechsler Adult Intelligence Scale, the Stroop Color-Word Test-Victoria version, the Color Trails Test Trials 1 and 2, and the Rey-Osterrieth Complex Figure Test. RESULTS At the end of treatment, scores on the Digit Span Subtest, the Stroop Color-Word Test-Victoria version, and the Color Trails Test showed statistically significant better results in the rTMS group compared with the ECT group. CONCLUSIONS rTMS was well tolerated with less negative impact on cognitive functioning than ECT.",2020,"At the end of treatment, scores on the Digit Span Subtest, the Stroop Color-Word Test-Victoria version, and the Color Trails Test showed statistically significant better results in the rTMS group compared with the ECT group. ","['Patients With Depression', '40 patients with major depressive disorder referred for ECT']","['electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS', 'rTMS', 'Electroconvulsive Therapy Versus Repetitive Transcranial Magnetic Stimulation', 'ECT']","['neurocognitive side effects', 'cognitive functioning', 'Digit Span Subtest, the Stroop Color-Word Test-Victoria version', 'cognitive battery that assessed different aspects of cognitive functioning']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}]","[{'cui': 'C0013806', 'cui_str': 'Electroshock Therapy'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0582675', 'cui_str': 'Stroop neuropsychological screening test (assessment scale)'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}]",40.0,0.0243072,"At the end of treatment, scores on the Digit Span Subtest, the Stroop Color-Word Test-Victoria version, and the Color Trails Test showed statistically significant better results in the rTMS group compared with the ECT group. ","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Abdel Latif', 'Affiliation': 'LATIF, NASRELDIN, FATHY, MOUSSA, ELSHEIKH, and MADBOULY: Department of Psychiatry, Cairo University, Cairo, Egypt KADER, BASHEER: Department of Neurophysiology, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Nasreldin', 'Affiliation': ''}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Abdel Kader', 'Affiliation': ''}, {'ForeName': 'Heba', 'Initials': 'H', 'LastName': 'Fathy', 'Affiliation': ''}, {'ForeName': 'Suaad', 'Initials': 'S', 'LastName': 'Moussa', 'Affiliation': ''}, {'ForeName': 'Mye', 'Initials': 'M', 'LastName': 'Basheer', 'Affiliation': ''}, {'ForeName': 'Adly', 'Initials': 'A', 'LastName': 'Elsheikh', 'Affiliation': ''}, {'ForeName': 'Nagwan', 'Initials': 'N', 'LastName': 'Madbouly', 'Affiliation': ''}]",Journal of psychiatric practice,['10.1097/PRA.0000000000000436'] 1223,31818310,"Psychosomatic therapy for patients frequently attending primary care with medically unexplained symptoms, the CORPUS trial: study protocol for a randomised controlled trial.","BACKGROUND Medically unexplained symptoms (MUS) are highly prevalent and pose a burden both on patients and on health care. In a pilot study psychosomatic therapy delivered by specialised therapists for patients with MUS showed promising results with regard to patient's acceptability, feasibility and effects on symptoms. The aim of this study is to establish whether psychosomatic therapy by specialised psychosomatic exercise therapists is cost- effective in decreasing symptoms and improving functioning in patients who frequently consult their general practitioner (GP) with MUS. METHODS A randomised effectiveness trial with an economic evaluation in primary care with 158 patients aged 18 years and older who are frequently consulting their GP with MUS. Patients will be assigned to psychosomatic therapy in addition to usual care or usual care only. Psychosomatic therapy is a multi-component and tailored intervention, aiming to empower patients by applying psycho-education, relaxation techniques, mindfulness, cognitive approaches and/or graded activity. Patients assigned to the psychosomatic therapy receive 6 to 12 sessions of psychosomatic therapy, of 30-45 min each, delivered by a specialised exercise or physical therapist. Primary outcome measure is patient-specific functioning and disability, measured with the Patient-Specific Functional Scale (PSFS). Secondary outcome measures are symptom severity, consultation frequency and referrals to secondary care, patient satisfaction, quality of life and costs. Assessments will be carried out at baseline, and after 4 and 12 months. An economic evaluation alongside the trial will be conducted from a societal perspective, with quality-adjusted life years (QALYs) as outcome measure. Furthermore, a mixed-methods process evaluation will be conducted. DISCUSSION We expect that psychosomatic therapy in primary care for patients who frequently attend the GP for MUS will improve symptoms and daily functioning and disability, while reducing consultation frequency and referrals to secondary care. We expect that the psychosomatic therapy provides value for money for patients with MUS. TRIAL REGISTRATION Netherlands Trial Register, ID: NL7157 (NTR7356). Registered 13 July 2018.",2019,"In a pilot study psychosomatic therapy delivered by specialised therapists for patients with MUS showed promising results with regard to patient's acceptability, feasibility and effects on symptoms.","['158 patients aged 18\u2009years and older who are frequently consulting their GP with MUS', 'patients who frequently consult their general practitioner (GP) with MUS', 'patients frequently attending primary care with medically unexplained symptoms, the CORPUS trial', 'patients with MUS']","['economic evaluation', 'psychosomatic therapy', 'psychosomatic therapy by specialised psychosomatic exercise therapists', 'psychosomatic therapy in addition to usual care or usual care only', 'psychosomatic therapy receive 6 to 12 sessions of psychosomatic therapy, of 30-45\u2009min each, delivered by a specialised exercise or physical therapist', 'Psychosomatic therapy']","['symptom severity, consultation frequency and referrals to secondary care, patient satisfaction, quality of life and costs', 'patient-specific functioning and disability, measured with the Patient-Specific Functional Scale (PSFS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0026809', 'cui_str': 'Mice'}, {'cui': 'C0017319', 'cui_str': 'Physicians, General Practice'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C3839861', 'cui_str': 'Medically Unexplained Symptoms'}]","[{'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}]","[{'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C3494402', 'cui_str': 'Secondary Care'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0034380'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale (assessment scale)'}]",,0.131561,"In a pilot study psychosomatic therapy delivered by specialised therapists for patients with MUS showed promising results with regard to patient's acceptability, feasibility and effects on symptoms.","[{'ForeName': 'Margreet S H', 'Initials': 'MSH', 'LastName': 'Wortman', 'Affiliation': 'ACHIEVE - Centre of Applied Research, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands. m.s.h.wortman@hva.nl.'}, {'ForeName': 'Johannes C', 'Initials': 'JC', 'LastName': 'van der Wouden', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.'}, {'ForeName': 'Janneke P C', 'Initials': 'JPC', 'LastName': 'Grutters', 'Affiliation': 'Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'Visser', 'Affiliation': 'ACHIEVE - Centre of Applied Research, Faculty of Health, Amsterdam University of Applied Sciences, Amsterdam, The Netherlands.'}, {'ForeName': 'Willem J J', 'Initials': 'WJJ', 'LastName': 'Assendelft', 'Affiliation': 'Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Henriëtte E', 'Initials': 'HE', 'LastName': 'van der Horst', 'Affiliation': 'Department of General Practice and Elderly Care Medicine, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.'}, {'ForeName': 'Tim C', 'Initials': 'TC', 'LastName': 'Olde Hartman', 'Affiliation': 'Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, The Netherlands.'}]",Trials,['10.1186/s13063-019-3913-3'] 1224,29633630,"Authors' reply: Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019).",,2019,,[],[],[],[],[],[],,0.0227568,,"[{'ForeName': 'Moonseong', 'Initials': 'M', 'LastName': 'Heo', 'Affiliation': '1 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Meissner', 'Affiliation': '2 Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Alain H', 'Initials': 'AH', 'LastName': 'Litwin', 'Affiliation': '3 Department of Medicine, University of South Carolina School of Medicine at Greenville, Greenville, SC, USA.'}, {'ForeName': 'M Diane', 'Initials': 'MD', 'LastName': 'McKee', 'Affiliation': '2 Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Karasz', 'Affiliation': '2 Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Earle C', 'Initials': 'EC', 'LastName': 'Chambers', 'Affiliation': '2 Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Ming-Chin', 'Initials': 'MC', 'LastName': 'Yeh', 'Affiliation': '4 Nutrition Program, Hunter College, City University of New York, New York, NY, USA.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Wylie-Rosett', 'Affiliation': '1 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.'}]",Statistical methods in medical research,['10.1177/0962280218767707'] 1225,31566666,Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.,"BACKGROUND Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration. Gemcitabine plus S-1 (GS) reportedly has equal to, or better, efficacy and an acceptable toxicity profile. We aimed to confirm the non-inferiority of GS to GC for patients with advanced/recurrent BTC in terms of overall survival (OS). PATIENTS AND METHODS We undertook a phase III randomized trial in 33 institutions in Japan. Eligibility criteria included chemotherapy-naïve patients with recurrent or unresectable BTC, an Eastern Cooperative Oncology Group Performance Status of 0 - 1, and adequate organ function. The calculated sample size was 350 with a one-sided α of 5%, a power of 80%, and non-inferiority margin hazard ratio (HR) of 1.155. The primary end point was OS, while the secondary end points included progression-free survival (PFS), response rate (RR), adverse events (AEs), and clinically significant AEs defined as grade ≥2 fatigue, anorexia, nausea, vomiting, oral mucositis, or diarrhea. RESULTS Between May 2013 and March 2016, 354 patients were enrolled. GS was found to be non-inferior to GC [median OS: 13.4 months with GC and 15.1 months with GS, HR, 0.945; 90% confidence interval (CI), 0.78-1.15; P = 0.046 for non-inferiority]. The median PFS was 5.8 months with GC and 6.8 months with GS (HR 0.86; 95% CI 0.70-1.07). The RR was 32.4% with GC and 29.8% with GS. Both treatments were generally well-tolerated. Clinically significant AEs were observed in 35.1% of patients in the GC arm and 29.9% in the GS arm. CONCLUSIONS GS, which does not require hydration, should be considered a new, convenient standard of care option for patients with advanced/recurrent BTC. CLINICAL TRIAL NUMBER This trial has been registered with the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr/index.htm), number UMIN000010667.",2019,"The median PFS was 5.8 months with GC and 6.8 months with GS (HR, 0.86, 95% CI, 0.70-1.07).","['Eligibility criteria included chemotherapy-naïve patients with recurrent or unresectable BTC, an Eastern Cooperative Oncology Group Performance Status of 0-1, and adequate organ function', '33 institutions in Japan', 'Between May 2013 and March 2016, 354 patients were enrolled', 'advanced/recurrent biliary tract cancer', 'patients with advanced/recurrent BTC in terms of overall survival (OS', 'advanced biliary tract cancer (BTC', 'patients with advanced/recurrent']","['Gemcitabine plus cisplatin (GC', 'Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin', 'Gemcitabine plus S-1']","['progression-free survival (PFS), response rate (RR), adverse events (AEs), and clinically significant AEs defined as grade ≥2 fatigue, anorexia, nausea, vomiting, oral mucositis, or diarrhea', 'tolerated', 'median PFS']","[{'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1520224', 'cui_str': 'Eastern Cooperative Oncology Group performance status'}, {'cui': 'C0205411', 'cui_str': 'Adequate (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0750952', 'cui_str': 'Biliary Tract Cancer'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0879262', 'cui_str': 'TS-1 cpd'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1971624', 'cui_str': 'Loss of appetite (finding)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C1568868', 'cui_str': 'Oral Mucositis'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",354.0,0.139934,"The median PFS was 5.8 months with GC and 6.8 months with GS (HR, 0.86, 95% CI, 0.70-1.07).","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Morizane', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, Tokyo. Electronic address: cmorizan@ncc.go.jp.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Okusaka', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, Tokyo.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mizusawa', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Katayama', 'Affiliation': 'JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ueno', 'Affiliation': 'Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ikeda', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ozaka', 'Affiliation': 'Hepato-Biliary-Pancreatic Medicine Department, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Okano', 'Affiliation': 'Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Sugimori', 'Affiliation': 'Gastroenterological Center, Yokohama City University Medical Center, Yokohama.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Fukutomi', 'Affiliation': 'Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Hara', 'Affiliation': 'Department of Gastroenterology, Saitama Cancer Center, Saitama.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Mizuno', 'Affiliation': 'Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Yanagimoto', 'Affiliation': 'Department of Surgery, Kansai Medical University Hospital, Hirakata.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Wada', 'Affiliation': 'Department of Surgery, Teikyo University School of Medicine, Tokyo.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Tobimatsu', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine Kobe University Graduate School of Medicine, Kobe.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Yane', 'Affiliation': 'Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Nakamori', 'Affiliation': 'Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Clinical Oncology, Jichi Medical University, Shimotsuke.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Asagi', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Yukisawa', 'Affiliation': 'Department of Medical Oncology, Tochigi Cancer Center, Utsunomiya.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kojima', 'Affiliation': 'Department of Gastroenterology, National Center for Global Health and Medicine, Tokyo.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kawabe', 'Affiliation': 'Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kawamoto', 'Affiliation': 'Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Sugimoto', 'Affiliation': 'Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Iwai', 'Affiliation': 'Department of Gastroenterology, Kitasato University Hospital, Sagamihara.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nakamura', 'Affiliation': 'Division of Gastroenterology, Chiba Cancer Center, Chiba.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Miyakawa', 'Affiliation': 'Department of Bilio-Pancreatology, Sapporo Kousei General Hospital, Sapporo.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yamashita', 'Affiliation': 'Department of Gastroenterology, Kanazawa University, Kanazawa.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Hosokawa', 'Affiliation': 'Department of Gastroenterology and Hematology, University of Toyama, Faculty of Medicine, Toyama.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ioka', 'Affiliation': 'Department of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Kato', 'Affiliation': 'Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Shioji', 'Affiliation': 'Department of Internal medicine, Niigata Cancer Center Hospital, Niigata.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Shimizu', 'Affiliation': ""Department of Gastroenterology, Tokyo Women's Medical University, Tokyo.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nakagohri', 'Affiliation': 'Gastroenterological Surgery, Tokai University School of Medicine, Isehara.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kamata', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ishii', 'Affiliation': 'Clinical Research Center, Chiba Cancer Center, Chiba, Japan.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Furuse', 'Affiliation': 'Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz402'] 1226,27207526,Central Regulation of Glucose Production May Be Impaired in Type 2 Diabetes.,"The challenges of achieving optimal glycemic control in type 2 diabetes highlight the need for new therapies. Inappropriately elevated endogenous glucose production (EGP) is the main source of hyperglycemia in type 2 diabetes. Because activation of central ATP-sensitive potassium (KATP) channels suppresses EGP in nondiabetic rodents and humans, this study examined whether type 2 diabetic humans and rodents retain central regulation of EGP. The KATP channel activator diazoxide was administered in a randomized, placebo-controlled crossover design to eight type 2 diabetic subjects and seven age- and BMI-matched healthy control subjects. Comprehensive measures of glucose turnover and insulin sensitivity were performed during euglycemic pancreatic clamp studies following diazoxide and placebo administration. Complementary rodent clamp studies were performed in Zucker Diabetic Fatty rats. In type 2 diabetic subjects, extrapancreatic KATP channel activation with diazoxide under fixed hormonal conditions failed to suppress EGP, whereas matched control subjects demonstrated a 27% reduction in EGP (P = 0.002) with diazoxide. Diazoxide also failed to suppress EGP in diabetic rats. These results suggest that suppression of EGP by central KATP channel activation may be lost in type 2 diabetes. Restoration of central regulation of glucose metabolism could be a promising therapeutic target to reduce hyperglycemia in type 2 diabetes.",2016,Diazoxide also failed to suppress EGP in diabetic rats.,"['Zucker Diabetic Fatty rats', 'diabetic rats', 'eight type 2 diabetic subjects and seven age- and BMI-matched healthy control subjects', 'Type 2 Diabetes']","['placebo', 'KATP channel activator diazoxide', 'diazoxide', 'Diazoxide', 'diazoxide and placebo']","['glucose turnover and insulin sensitivity', 'extrapancreatic KATP channel activation', 'EGP']","[{'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0034721', 'cui_str': 'Rats'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1955862', 'cui_str': 'ATP-Sensitive Potassium Channels'}, {'cui': 'C0012022', 'cui_str': 'Diazoxide'}]","[{'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0443331', 'cui_str': 'Turnover technique (qualifier value)'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C1955862', 'cui_str': 'ATP-Sensitive Potassium Channels'}]",,0.0279822,Diazoxide also failed to suppress EGP in diabetic rats.,"[{'ForeName': 'Yonah B', 'Initials': 'YB', 'LastName': 'Esterson', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Carey', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Boucai', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Akankasha', 'Initials': 'A', 'LastName': 'Goyal', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Raghavan', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Kehao', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Deeksha', 'Initials': 'D', 'LastName': 'Mehta', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Daorong', 'Initials': 'D', 'LastName': 'Feng', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Licheng', 'Initials': 'L', 'LastName': 'Wu', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Kehlenbrink', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Sudha', 'Initials': 'S', 'LastName': 'Koppaka', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Preeti', 'Initials': 'P', 'LastName': 'Kishore', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.'}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Hawkins', 'Affiliation': 'Diabetes Research and Training Center and Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY meredith.hawkins@einstein.yu.edu.'}]",Diabetes,['10.2337/db15-1465'] 1227,32416251,Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.,"BACKGROUND Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is approved in multiple countries for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer following progression on or after endocrine therapy. A detailed understanding of alpelisib's safety profile should inform adverse event (AE) management and enhance patient care. PATIENTS AND METHODS AEs in the phase III SOLAR-1 trial were assessed in patients with and without PIK3CA mutations. The impact of protocol-specified AE-management recommendations was evaluated, including an amendment to optimize hyperglycemia and rash management. RESULTS Patients were randomly assigned to receive fulvestrant plus alpelisib (n = 284) or placebo (n = 287). The most common grade 3/4 AEs with alpelisib were hyperglycemia (grade 3, 32.7%; grade 4, 3.9%), rash (grade 3, 9.9%), and diarrhea (grade 3, 6.7%). Median time to onset of grade ≥3 toxicity was 15 days (hyperglycemia, based on fasting plasma glucose), 13 days (rash), and 139 days (diarrhea). Metformin alone or in combination with other antidiabetic agents was used by most patients (87.1%) with hyperglycemia. Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% versus 64.1%) and severity of rash (grade 3, 11.6% versus 22.7%) versus no preventative medication. Discontinuations due to grade ≥3 AEs were lower following more-detailed AE management guidelines (7.9% versus 18.1% previously). Patients with PIK3CA mutations had a median alpelisib dose intensity of 248 mg/day. Median progression-free survival with alpelisib was 12.5 and 9.6 months for alpelisib dose intensities of ≥248 mg/day and <248 mg/day, respectively, compared with 5.8 months with placebo. CONCLUSIONS Hyperglycemia and rash occurred early during alpelisib treatment, while diarrhea occurred at a later time point. Early identification, prevention, and intervention, including concomitant medications and alpelisib dose modifications, resulted in less severe toxicities. Reductions in treatment discontinuations and improved progression-free survival at higher alpelisib dose intensities support the need for optimal AE management. CLINICALTRIALS. GOV ID NCT02437318.",2020,"Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% vs 64.1%) and severity of rash (grade 3, 11.6% vs 22.7%) vs no preventative medication.","['Patients With HR-Positive Advanced Breast Cancer', 'AEs in the phase 3 SOLAR-1 trial were assessed in patients with and without PIK3CA mutations', 'multiple countries for men and post-menopausal women with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer following progression on or after endocrine therapy']","['Metformin', 'Alpelisib (α-selective PI3K inhibitor) plus fulvestrant', 'fulvestrant plus alpelisib', 'PI3K Inhibitor Alpelisib Plus Fulvestrant', 'placebo']","['diarrhea', 'median alpelisib dose intensity', 'PFS', 'Hyperglycemia and rash', 'Time Course and Management of Key Adverse Events', 'Median time to onset of grade ≥3 toxicity', 'Median progression-free survival (PFS', 'rash', 'severe toxicities', 'hyperglycemia', 'severity of rash']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1451005', 'cui_str': 'PIK3CA protein, human'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0044602', 'cui_str': '1-phosphatidylinositol 3-kinase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0935916', 'cui_str': 'fulvestrant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4055478', 'cui_str': 'alpelisib'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.111823,"Preventive anti-rash medication resulted in lower incidence (any grade, 26.7% vs 64.1%) and severity of rash (grade 3, 11.6% vs 22.7%) vs no preventative medication.","[{'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Department of Medicine, Division of Hematology and Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA. Electronic address: Hope.Rugo@ucsf.edu.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'André', 'Affiliation': 'Department of Medical Oncology, INSERM U981, Gustave Roussy, Université Paris-Sud, Villejuif, France.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Yamashita', 'Affiliation': 'Department of Breast and Endocrine Surgery, Kanagawa Cancer Center Hospital, Yokohama, Japan.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Cerda', 'Affiliation': 'Clinica RedSalud Vitacura, Santiago, Chile.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Toledano', 'Affiliation': 'Institut Curie, Paris, France.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Stemmer', 'Affiliation': 'Institute of Oncology, Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Jurado', 'Affiliation': 'Hospital Universitario Canarias, S/C Tenerife, Islas Canarias, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Juric', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Mayer', 'Affiliation': 'Department of Medicine, Hematology and Oncology, Vanderbilt University, Nashville, USA.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Ciruelos', 'Affiliation': 'Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Iwata', 'Affiliation': 'Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Conte', 'Affiliation': 'Department of Surgery, Oncology and Gastroenterology, University of Padua and Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padua, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Campone', 'Affiliation': ""Department of Medical Oncology, Institut de Cancérologie de l'Ouest, St Herblain, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wilke', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Mills', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Lteif', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Miller', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, USA.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gaudenzi', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'Department of Medicine and Research, German Breast Group, Neu-Isenburg; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.05.001'] 1228,31554765,Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study.,"AIM Posterior circulation stroke (PCS) has different clinical features and prognosis compared with anterior circulation stroke (ACS), and whether the effect of statin therapy on stroke prevention differs according to infarction location remains unclear. This post hoc analysis of the J-STARS study aimed to compare the usefulness of statin at different infarction locations (i.e., ACS and PCS). METHODS In the J-STARS study, 1578 patients were randomly assigned to the pravastatin or control group. The subjects were divided into two subgroups (ACS and PCS groups) based on the arteries responsible for the infarction. Cox proportional hazards models were used to investigate whether the all stroke recurrence rate was different between the ACS and PCS groups. RESULTS The PCS group (n=499) had a significantly higher prevalence of diabetes than the ACS group (n=1022) (30.7% vs. 19.8%, P＜0.001). During the follow-up (4.9±1.4 years), the incidence of all stroke was significantly lower in the pravastatin group than in the control group among patients with PCS (adjusted hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.83, P=0.009); however, the stroke recurrence rates were not significantly different between both groups among patients with ACS (adjusted HR 1.32, 95% CI 0.93-1.88,P=0.123). A significant interaction between the ACS and PCS groups in terms of pravastatin effects was noted (P=0.003 for interaction). CONCLUSIONS Pravastatin significantly reduced the recurrence rate of all stroke among patients with PCS. Thus, the effect of statin on the recurrence of stroke may differ according to infarction location.",2020,"During the follow-up (4.9±1.4 years), the incidence of all stroke was significantly lower in the pravastatin group than in the control group among patients with PCS (adjusted hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.83, P=0.009); however, the stroke recurrence rates were not significantly different between both groups among patients with ACS (adjusted HR 1.32, 95% CI 0.93-1.88,P=0.123).","['at Different Infarction Locations', '1578 patients', 'patients with PCS']","['Statin', 'pravastatin', 'Pravastatin', 'statin therapy', 'PCS', 'Posterior circulation stroke (PCS', 'ACS', 'statin']","['Stroke Recurrence Prevention', 'stroke recurrence rate', 'incidence of all stroke', 'prevalence of diabetes', 'stroke recurrence rates', 'recurrence rate', 'pravastatin effects']","[{'cui': 'C0021308', 'cui_str': 'Infarction'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0085542', 'cui_str': 'Pravastatin'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0085542', 'cui_str': 'Pravastatin'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",1578.0,0.0441505,"During the follow-up (4.9±1.4 years), the incidence of all stroke was significantly lower in the pravastatin group than in the control group among patients with PCS (adjusted hazard ratio [HR] 0.46, 95% confidence interval [CI] 0.25-0.83, P=0.009); however, the stroke recurrence rates were not significantly different between both groups among patients with ACS (adjusted HR 1.32, 95% CI 0.93-1.88,P=0.123).","[{'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Nezu', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.'}, {'ForeName': 'Naohisa', 'Initials': 'N', 'LastName': 'Hosomi', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kitagawa', 'Affiliation': ""Department of Neurology, Tokyo Women's Medical University School of Medicine.""}, {'ForeName': 'Yoji', 'Initials': 'Y', 'LastName': 'Nagai', 'Affiliation': 'Center for Clinical Research, Kobe University Hospital.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Nakagawa', 'Affiliation': 'Division of Medical Statistics, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation.'}, {'ForeName': 'Shiro', 'Initials': 'S', 'LastName': 'Aoki', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Kagimura', 'Affiliation': 'Division of Medical Statistics, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Maruyama', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Origasa', 'Affiliation': 'Division of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Minematsu', 'Affiliation': 'National Cerebral and Cardiovascular Center.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Uchiyama', 'Affiliation': 'Clinical Research Center for Medicine, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center.'}, {'ForeName': 'Masayasu', 'Initials': 'M', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of atherosclerosis and thrombosis,['10.5551/jat.51391'] 1229,31499240,Self-efficacy as a pathway to long-term smoking cessation among low-income parents in the multilevel Kids Safe and Smokefree intervention.,"BACKGROUND This study investigated the effects of a multi-level smoking intervention on mediators of long-term abstinence in parental smokers, including smoking cessation self-efficacy, smoking urge coping, and perceived support to quit smoking. METHODS This is a secondary analysis of data from a randomized trial that recruited parental smokers from pediatric clinics in low-income communities (N = 327, 83% women, 83% African American, 79% below poverty level). Following clinical practice guidelines for tobacco intervention (""Ask, Advise, Refer"" [AAR]), pediatricians asked all parents about child tobacco smoke exposure (TSE), advised about TSE harms and benefits of reducing TSE, and referred smokers to cessation resources. Eligible parents were then randomized to additional telephone-based smoking behavior counseling (AAR + counseling) or nutrition education (AAR + control). Bioverified 7-day point prevalence smoking abstinence and perceived counselor support were assessed at 12-month follow-up; cessation self-efficacy and urge coping were assessed at 3-month follow-up. RESULTS Relative to AAR + control, AAR + counseling was associated with higher self-efficacy, urge coping, and perceived support to quit (all p's<.001). Self-efficacy, but no other mediators, had a significant positive effect on 12-month bioverified smoking abstinence (p < .001). The indirect effect of intervention on 12-month abstinence via self-efficacy suggested mediation via this pathway (p = .002). CONCLUSION Results suggest that all putative treatment pathways were improved more by the multi-level AAR + counseling than the clinic-level AAR + control intervention. Further, self-efficacy at end-of-treatment prospectively predicted long-term cessation, suggesting that building of self-efficacy through treatment may be key to sustained cessation.",2019,"Self-efficacy, but no other mediators, had a significant positive effect on 12-month bioverified smoking abstinence (p < .001).","['parental smokers', 'recruited parental smokers from pediatric clinics in low-income communities (N\u2009=\u2009327, 83% women, 83% African American, 79% below poverty level', 'low-income parents in the multilevel Kids Safe and Smokefree intervention', 'Eligible parents']","['telephone-based smoking behavior counseling (AAR\u2009+\u2009counseling) or nutrition education (AAR\u2009+\u2009control', 'multi-level smoking intervention']","['cessation self-efficacy and urge coping', 'higher self-efficacy, urge coping, and perceived support to quit', 'smoking cessation self-efficacy, smoking urge coping', '12-month bioverified smoking abstinence', 'Self-efficacy']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C3839701', 'cui_str': 'Pediatric clinic (environment)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0032854', 'cui_str': 'Poverty'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1519383', 'cui_str': 'Smoking Behaviors'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]",,0.0254556,"Self-efficacy, but no other mediators, had a significant positive effect on 12-month bioverified smoking abstinence (p < .001).","[{'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Lepore', 'Affiliation': 'Department of Social and Behavioral Sciences, College of Public Health, Temple University, 1301 Cecil B. Moore Ave, 9th Floor Ritter Annex, Philadelphia, PA 19122, USA. Electronic address: slepore@temple.edu.'}, {'ForeName': 'Bradley N', 'Initials': 'BN', 'LastName': 'Collins', 'Affiliation': 'Department of Social and Behavioral Sciences, College of Public Health, Temple University, 1301 Cecil B. Moore Ave, 9th Floor Ritter Annex, Philadelphia, PA 19122, USA. Electronic address: collinsb@temple.edu.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Sosnowski', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University, 806 W. Franklin St, Box 842018, Richmond, VA 23284, USA. Electronic address: sosnowskid@mymail.vcu.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2019.05.027'] 1230,26671216,A Clinically Relevant Method of Analyzing Continuous Change in Robotic Upper Extremity Chronic Stroke Rehabilitation.,"BACKGROUND Robots designed for rehabilitation of the upper extremity after stroke facilitate high rates of repetition during practice of movements and record precise kinematic data, providing a method to investigate motor recovery profiles over time. OBJECTIVE To determine how motor recovery profiles during robotic interventions provide insight into improving clinical gains. METHODS A convenience sample (n = 22), from a larger randomized control trial, was taken of chronic stroke participants completing 12 sessions of arm therapy. One group received 60 minutes of robotic therapy (Robot only) and the other group received 45 minutes on the robot plus 15 minutes of translation-to-task practice (Robot + TTT). Movement time was assessed using the robot without powered assistance. Analyses (ANOVA, random coefficient modeling [RCM] with 2-term exponential function) were completed to investigate changes across the intervention, between sessions, and within a session. RESULTS Significant improvement (P < .05) in movement time across the intervention (pre vs post) was similar between the groups but there were group differences for changes between and within sessions (P < .05). The 2-term exponential function revealed a fast and slow component of learning that described performance across consecutive blocks. The RCM identified individuals who were above or below the marginal model. CONCLUSIONS The expanded analyses indicated that changes across time can occur in different ways but achieve similar goals and may be influenced by individual factors such as initial movement time. These findings will guide decisions regarding treatment planning based on rates of motor relearning during upper extremity stroke robotic interventions.",2016,"RESULTS Significant improvement (P < .05) in movement time across the intervention (pre vs post) was similar between the groups but there were group differences for changes between and within sessions (P < .05).","['A convenience sample (n = 22', 'Robotic Upper Extremity Chronic Stroke Rehabilitation']",['robotic therapy (Robot only) and the other group received 45 minutes on the robot plus 15 minutes of translation-to-task practice (Robot + TTT'],"['Movement time', 'movement time']","[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0336537', 'cui_str': 'Robot, device (physical object)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1442463', 'cui_str': 'Forty-five minutes (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes (qualifier value)'}, {'cui': 'C0040712', 'cui_str': 'Translations'}]","[{'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",,0.0304675,"RESULTS Significant improvement (P < .05) in movement time across the intervention (pre vs post) was similar between the groups but there were group differences for changes between and within sessions (P < .05).","[{'ForeName': 'Crystal L', 'Initials': 'CL', 'LastName': 'Massie', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, MD, USA Indiana University, Indianapolis, IN, USA massiec@iu.edu.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'University of Maryland College Park, College Park, MD, USA.'}, {'ForeName': 'Susan S', 'Initials': 'SS', 'LastName': 'Conroy', 'Affiliation': 'VA Maryland Health Care System, Baltimore, MD, USA.'}, {'ForeName': 'H Igo', 'Initials': 'HI', 'LastName': 'Krebs', 'Affiliation': 'Massachusetts Institute of Technology, Cambridge, MA, USA.'}, {'ForeName': 'George F', 'Initials': 'GF', 'LastName': 'Wittenberg', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, MD, USA VA Maryland Health Care System, Baltimore, MD, USA.'}, {'ForeName': 'Christopher T', 'Initials': 'CT', 'LastName': 'Bever', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, MD, USA VA Maryland Health Care System, Baltimore, MD, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Whitall', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, MD, USA University of Southampton, Southampton, UK.'}]",Neurorehabilitation and neural repair,['10.1177/1545968315620301'] 1231,32419245,Prediction of the output factor using machine and deep learning approach in uniform scanning proton therapy.,"PURPOSE The purpose of this work is to develop machine and deep learning-based models to predict output and MU based on measured patient quality assurance (QA) data in uniform scanning proton therapy (USPT). METHODS This study involves 4,231 patient QA measurements conducted over the last 6 years. In the current approach, output and MU are predicted by an empirical model (EM) based on patient treatment plan parameters. In this study, two MATLAB-based machine and deep learning algorithms - Gaussian process regression (GPR) and shallow neural network (SNN) - were developed. The four parameters from patient QA (range, modulation, field size, and measured output factor) were used to train these algorithms. The data were randomized with a training set containing 90% and a testing set containing remaining 10% of the data. The model performance during training was accessed using root mean square error (RMSE) and R-squared values. The trained model was used to predict output based on the three input parameters: range, modulation, and field size. The percent difference was calculated between the predicted and measured output factors. The number of data sets required to make prediction accuracy of GPR and SNN models' invariable was also evaluated. RESULTS The prediction accuracy of machine and deep learning algorithms is higher than the EM. The output predictions with [GPR, SNN, and EM] within ± 2% and ± 3% difference were [97.16%, 97.64%, and 92.95%] and [99.76%, 99.29%, and 97.18%], respectively. The GPR model outperformed the SNN with a smaller number of training data sets. CONCLUSION The GPR and SNN models outperformed the EM in terms of prediction accuracy. Machine and deep learning algorithms predicted the output factor and MU for USPT with higher predictive accuracy than EM. In our clinic, these models have been adopted as a secondary check of MU or output factors.",2020,The GPR and SNN models outperformed the EM in terms of prediction accuracy.,"['4,231 patient QA measurements conducted over the last 6\xa0years']",['scanning proton therapy (USPT'],"['patient QA (range, modulation, field size, and measured output factor']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0436226', 'cui_str': 'Proton therapy'}, {'cui': 'C0205375', 'cui_str': 'Uniform'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0204709', 'cui_str': 'Measuring output'}]",,0.0491469,The GPR and SNN models outperformed the EM in terms of prediction accuracy.,"[{'ForeName': 'Hardev S', 'Initials': 'HS', 'LastName': 'Grewal', 'Affiliation': 'Oklahoma Proton Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Chacko', 'Affiliation': 'Oklahoma Proton Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Salahuddin', 'Initials': 'S', 'LastName': 'Ahmad', 'Affiliation': 'Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}, {'ForeName': 'Hosang', 'Initials': 'H', 'LastName': 'Jin', 'Affiliation': 'Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.'}]",Journal of applied clinical medical physics,['10.1002/acm2.12899'] 1232,26945658,A Prospective Randomized Trial Comparing a Combined Regimen of Amikacin and Levofloxacin to Levofloxacin Alone as Prophylaxis in Transrectal Prostate Needle Biopsy.,"PURPOSE We investigated whether addition of amikacin to levofloxacin-based antimicrobial prophylaxis reduces febrile urinary tract infections after transrectal ultrasound-guided prostate needle biopsy (TRUSB). MATERIALS AND METHODS A total of 447 patients undergoing TRUSB were prospectively randomized into two groups. The 230 patients in Group A were given one oral dose of levofloxacin 400 mg prior to TRUSB; the 217 patients in Group B each received the same dose of levofloxacin and one 200 mg intravenous dose of amikacin. Patients' characteristics were assessed prior to TRUSB and their symptoms were checked after the TRUSB. RESULTS Both regimens were well tolerated with no side effects. No statistically significant difference in patients' characteristics, or in incidence of inflammation- or infection-related symptoms was seen between the two groups; nor any significant difference among those who developed fever and those who did not. Two Group A patients and one Group B patient developed febrile urinary tract infections. Accountable pathogens determined by urine and blood cultures were fluoroquinolone-resistant E.coli and extended-spectrum β-lactamase-producing E.coli. All pathogens isolated were levofloxacin-resistant, amikacin-susceptible species. CONCLUSION Although the present study was under-powered by unexpectedly low overall incidence of febrile urinary tract infections, addition of one intravenous administration of amikacin to one oral administration of levofloxacin showed no advantage compared with levofloxacin alone as antimicrobial prophylaxis in TRUSB. Strikingly, all pathogens isolated from febrile patients were sensitive to amikacin in vitro. Therefore, further understanding of amikacin's drug kinetics in the prostate is necessary to develop a more efficient drug delivery system for amikacin.",2016,"No statistically significant difference in patients' characteristics, or in incidence of inflammation- or infection-related symptoms was seen between the two groups; nor any significant difference among those who developed fever and those who did not.","['Transrectal Prostate Needle Biopsy', '447 patients undergoing TRUSB']","['levofloxacin 400 mg prior to TRUSB', 'Amikacin and Levofloxacin to Levofloxacin Alone', 'amikacin', 'amikacin to levofloxacin-based antimicrobial prophylaxis', 'levofloxacin', 'levofloxacin and one 200 mg intravenous dose of amikacin', 'transrectal ultrasound-guided prostate needle biopsy (TRUSB']","['febrile urinary tract infections', 'incidence of inflammation- or infection-related symptoms']","[{'cui': 'C0205518', 'cui_str': 'Transrectal approach (qualifier value)'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005560', 'cui_str': 'Biopsy, Needle'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0002499', 'cui_str': 'Amikacin'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005560', 'cui_str': 'Biopsy, Needle'}]","[{'cui': 'C3875265', 'cui_str': 'Febrile urinary tract infection'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",447.0,0.0303011,"No statistically significant difference in patients' characteristics, or in incidence of inflammation- or infection-related symptoms was seen between the two groups; nor any significant difference among those who developed fever and those who did not.","[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Miyazaki', 'Affiliation': 'Department of Urology, Japanese Red Cross Otsu Hospital, 1-35 Nagara 1-Chome Otsu City, Shiga, 520-8511, Japan.'}, {'ForeName': 'Shusuke', 'Initials': 'S', 'LastName': 'Akamatsu', 'Affiliation': 'Department of Urology, Kyoto University Graduate School of Medicine, 54 Shougoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. akamats@kuhp.kyoto-u.ac.jp.'}, {'ForeName': 'Sojun', 'Initials': 'S', 'LastName': 'Kanamaru', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Kamiyama', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Sengiku', 'Affiliation': 'Department of Urology, Japanese Red Cross Otsu Hospital, 1-35 Nagara 1-Chome Otsu City, Shiga, 520-8511, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Iguchi', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Sano', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Takahashi', 'Affiliation': 'Department of Urology, Japanese Red Cross Otsu Hospital, 1-35 Nagara 1-Chome Otsu City, Shiga, 520-8511, Japan.'}, {'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Ito', 'Affiliation': 'Department of Urology, Japanese Red Cross Otsu Hospital, 1-35 Nagara 1-Chome Otsu City, Shiga, 520-8511, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Takenawa', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Noriyuki', 'Initials': 'N', 'LastName': 'Ito', 'Affiliation': 'Department of Urology, Nishi-Kobe Medical Center, 7-1 Kojidai 5-Chome, Nishi-Ku, Kobe City, Hyogo, 651-2273, Japan.'}, {'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Ogura', 'Affiliation': 'Department of Urology, Japanese Red Cross Otsu Hospital, 1-35 Nagara 1-Chome Otsu City, Shiga, 520-8511, Japan.'}]",Urology journal,[] 1233,26945662,"Effect of Preoperative Finasteride on the Volume or Length Density of Prostate Vessels, Intraoperative, Postoperative Blood Loss during and after Monopolar Transurethral Resection of Prostate: A Dose Escalation Randomized Clinical Trial Using Stereolog Methods.","PURPOSE To evaluate the effects of two preoperative treatment courses with Finasteride on intraoperative and postoperative bleeding complications and prostate blood vessel characteristics in men who underwent transurethral resection of prostate (TURP) using monopolar energy. MATERIALS AND METHODS Men scheduled for TURP were randomized into group 1 (control n = 25, no medication), group 2 and 3 (n = 20 in each, 5 mg Finasteride daily for 2 and 4 weeks before TURP; respectively). Hematocrit level in the irrigation fluid, weight of the resected prostate chips, decreases in blood hemoglobin (Hb) level 6 and 24 hours after the operation together with volume and length density of prostate vessels using stereological methods were compared. RESULTS The three groups were matched regarding preoperative demographic data, resection time and weight of the resected tissue. Men who received preoperative Finasteride (groups 2 and 3) had significantly lower hematocrit levels in irrigation fluid than control group (control, 0.59 ± 0.85, group 2, 0.25 ± 0.4, group 3, 0.175 ± 0.16; P = .028; Power = .80). However, no statistically significant difference was found in hematocrit level in irrigation fluid between groups 2 and 3 (0.25 ± 0.4 vs. 0.175 ± 0.16, 95% confidence interval (CI) = -0.28-0.42; P = .68). These values were independent of the weight of the resected tissue and resection time. There were no significant differences between the three groups in the decrease in Hb 6 hours (P = .58) and 24 hours after TURP (P = .65). The stereological and histological characteristics of blood vessels in suburethral prostate tissue were similar in all three groups. CONCLUSION A 2-week preoperative course of daily Finasteride seems sufficient to significantly reduce intraoperative blood loss; this effect was independent of the weight of the resected tissue and resection time. Neither the 2-week nor the 4-week presurgical Finasteride regimen could significantly decrease postoperative blood loss, and neither regimen induced significant changes in characteristics of prostate tissue blood vessels.",2016,"Neither the 2-week nor the 4-week presurgical Finasteride regimen could significantly decrease postoperative blood loss, and neither regimen induced significant changes in characteristics of prostate tissue blood vessels.","['Men scheduled for TURP', 'men who underwent']","['transurethral resection of prostate (TURP', 'preoperative Finasteride', 'Finasteride', 'Preoperative Finasteride', 'Monopolar Transurethral Resection of Prostate']","['weight of the resected tissue and resection time', 'Volume or Length Density of Prostate Vessels, Intraoperative, Postoperative Blood Loss', 'postoperative blood loss', 'hematocrit levels in irrigation fluid', 'hematocrit level in irrigation fluid', 'intraoperative blood loss', 'characteristics of prostate tissue blood vessels', 'preoperative demographic data, resection time and weight of the resected tissue', 'Hematocrit level', 'blood hemoglobin (Hb) level']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}]","[{'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0060389', 'cui_str': 'Finasteride'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0032788', 'cui_str': 'Blood Loss, Postoperative'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2746010', 'cui_str': 'Irrigating solution'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0005847', 'cui_str': 'Blood Vessel'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0005768'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",,0.0262159,"Neither the 2-week nor the 4-week presurgical Finasteride regimen could significantly decrease postoperative blood loss, and neither regimen induced significant changes in characteristics of prostate tissue blood vessels.","[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Aminsharifi', 'Affiliation': 'Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran. aminsharifi_ar@yahoo.com.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Salehi', 'Affiliation': 'Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Noorafshan', 'Affiliation': 'Department of Histomorphometry and Stereology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amirhossein', 'Initials': 'A', 'LastName': 'Aminsharifi', 'Affiliation': 'General Internal Medicine, Toronto General Hospital, Toronto, Canada.'}, {'ForeName': 'Khalil', 'Initials': 'K', 'LastName': 'Alnajar', 'Affiliation': 'Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran. aminsharifi_ar@yahoo.com.'}]",Urology journal,[] 1234,27085561,Effect of Music on Reducing Anxiety for Patients Undergoing Transrectal Ultrasound-Guided Prostate Biopsies: Randomized Prospective Trial.,"PURPOSE The purpose of this study was to assess the impact of music on anxiety and perceived pain during transrectal ultrasound-guided prostate biopsy. MATERIALS AND METHODS Forty consecutive men with an elevated serum prostate specific antigen (PSA) level and/ or an abnormal digital rectal examination referred for transrectal ultrasound-guided prostate biopsy were recruited and allocated to a music (n = 20) or a non-music (n = 20) group. Anxiety was assessed prior to and after biopsy and pain was assessed after biopsy in each patient using visual analog scales (VAS) in the same setting, and group anxiety scores were compared. RESULTS Patients in the music group experienced less anxiety (P = .046) during the procedure, but group pain scores were not significantly different. CONCLUSION Music was found to decrease anxiety effectively during transrectal ultrasound-guided prostate biopsy.",2016,"RESULTS Patients in the music group experienced less anxiety (P = .046) during the procedure, but group pain scores were not significantly different. ","['Forty consecutive men with an elevated serum prostate specific antigen (PSA) level and/ or an abnormal digital rectal examination referred for transrectal ultrasound-guided prostate biopsy were recruited and allocated to a music (n = 20) or a non-music (n = 20) group', 'Patients Undergoing Transrectal Ultrasound-Guided Prostate Biopsies']","['Music', 'transrectal ultrasound-guided prostate biopsy']","['anxiety and perceived pain', 'anxiety', 'anxiety effectively', 'pain scores', 'Anxiety']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C1384593', 'cui_str': 'Digital Rectal Examination'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",40.0,0.138147,"RESULTS Patients in the music group experienced less anxiety (P = .046) during the procedure, but group pain scores were not significantly different. ","[{'ForeName': 'Seong Whi', 'Initials': 'SW', 'LastName': 'Cho', 'Affiliation': 'Department of Radiology, Kangwon National University Hospital, Chuncheon, Korea.'}, {'ForeName': 'Hyuck Jae', 'Initials': 'HJ', 'LastName': 'Choi', 'Affiliation': 'Department of Radiology, Kangwon National University Hospital, Chuncheon, Korea.'}]",Urology journal,[] 1235,27085565,Comparing the Effectiveness of Dietary Vitamin C and Exercise Interventions on Fertility Parameters in Normal Obese Men.,"PURPOSE Comparing the effectiveness of dietary vitamin C and weight loss exercises interventions for weight loss on semen characteristics in normal obese man. MATERIALS AND METHODS A total number of 200 men were randomly allocated into two groups based on body mass index, exercise and vitamin C groups. Also, 50 men with normal spermogram were placed in a control group. In exercise group, a 6 months intensive exercise program was designed under a coach's supervision to reduce the body weight. In vitamin C group, 1,000 mg of vitamin C were given every other day as supplement. RESULTS Weight loss increased the volume of semen in participants with 25-30 (P = .02) and more than 30 body mass index (P = .001). The increased concentration of sperm per mL of semen in body mass index (BMI) 25-30 group (P = .01) and more than 30 (P = .003) BMI was significant. Improving sperm motility after two hours in participants with more than 30 (P = .01) BMI was significant. In vitamin C group, the improvement of sperm concentration in participants who had less than 25 (P = .01), between 25 and 30 (P = .01), more than 30 (P = .02) BMI was significant. Sperm motility improved in all three groups (P = .001, P = .02 and P = .003, respectively). CONCLUSION Weight loss can significantly increase semen volume, its concentration, its mobility and percentage of normal morphology. Consuming vitamin C significantly improves sperm concentration and mobility, but the semen volume and the percentage of normal morphology will not change significantly.",2016,"Sperm motility improved in all three groups (P = .001, P = .02 and P = .003, respectively). ","['Normal Obese Men', 'normal obese man', 'A total number of 200 men', '50 men with normal spermogram']","['intensive exercise program', 'Consuming vitamin C', 'Dietary Vitamin C and Exercise Interventions', 'vitamin C', 'dietary vitamin C and weight loss exercises interventions']","['Improving sperm motility', 'Weight loss', 'semen volume, its concentration, its mobility and percentage of normal morphology', 'sperm concentration and mobility', 'concentration of sperm per mL of semen in body mass index', 'Fertility Parameters', 'BMI', 'sperm concentration', 'Sperm motility']","[{'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0037848', 'cui_str': 'Sperm Motility'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C1261167', 'cui_str': 'Sperm concentration'}, {'cui': 'C4048707', 'cui_str': 'Concentration of sperm'}, {'cui': 'C2756969', 'cui_str': 'Semen'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015895', 'cui_str': 'Fecundity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",50.0,0.0627947,"Sperm motility improved in all three groups (P = .001, P = .02 and P = .003, respectively). ","[{'ForeName': 'Bahare', 'Initials': 'B', 'LastName': 'Rafiee', 'Affiliation': 'Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Morowvat', 'Affiliation': 'Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Rahimi-Ghalati', 'Affiliation': 'Bagherian Industrial School, Ministry of Education and Training, Shiraz, Iran.'}]",Urology journal,[] 1236,27085566,"Prevention of Urinary Tract Infection with Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins: A Pre-Clinical Double-Blind Controlled Study.","PURPOSE Urinary tract infections (UTIs) are widespread and affect a large portion of the human population. Cranberry juices and extracts have been used for UTI prevention due to their content of bioactive proanthocyanidins (PACs), particularly of the A type (PAC-A). Controversial clinical results obtained with cranberry are often due to a lack of precise determination and authentication of the PAC-A content. This study used Oximacro (Biosfered S.r.l., Turin, Italy), a cranberry extract with a high content of PAC-A, to prevent UTIs in female and male volunteers. MATERIALS AND METHODS The Oximacro PACs content was assayed using the Brunswick Laboratories 4-dimethylaminocinnamaldehyde (BL-DMAC) method, and the dimer and trimer PACs-A and PACs-B percentages were determined via high-performance liquid chromatography/electrospray ionization tandem mass spectrometry (HPLC/ESI-MS/MS). A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 51 years) was divided into two groups. The experimental group received 1 capsule containing Oximacro (36 mg PACs-A) twice per day (morning and evening) for 7 days, and the placebo group was given the same number of capsules with no PACs. RESULTS Analysis of Oximacro revealed a high total PAC content (372.34 mg/g ± 2.3) and a high percentage of PAC-A dimers and trimers (86.72% ± 1.65). After 7 days of Oximacro administration, a significant difference was found between the placebo and Oximacro groups for both females (Mann-Whitney U-test = 875; P < .001; n = 60) and males (Mann-Whitney U-test = 24; P = .016; n = 10). When the female and male age ranges were analysed separately, the female age range 31-35 showed only slightly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 20.5; P = .095; n = 10), whereas all other female age ranges showed highly significant differences between the placebo and Oximacro groups (Mann-Whitney U-test = 25; P = .008; n = 10). Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < .001, Bonferroni Adjusted P < .001). CONCLUSION Careful determination of the total PAC content using the BL-DMAC method and the authentication of PACs-A with mass spectrometry in cranberry extracts are necessary to prepare effective doses for UTI prevention. A dose of 112 mg Oximacro containing 36 mg PACs-A was found to be effective in preventing UTIs when used twice per day for 7 days.",2016,"Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < .001, Bonferroni Adjusted P < .001). ","['A balanced group of female (ranging from 19 to over 51 years) and male volunteers (over 51 years', 'female and male volunteers']","['1 capsule containing Oximacro', 'Oximacro, A Cranberry Extract with a High Content of A-Type Proanthocyanidins', 'placebo', 'cranberry extract']","['Oximacro PACs content', 'high total PAC content']","[{'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C4319574', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0936050', 'cui_str': 'Cranberry'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0072018', 'cui_str': 'proanthocyanidin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0182281', 'cui_str': 'Picture Archiving and Communication Systems'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",,0.163796,"Furthermore, colony forming unit/mL counts from the urine cultures showed a significant difference (P < .001) between the experimental and the placebo groups (SD difference = 51688; df = 34, t = -10.27; Dunn-Sidak Adjusted P < .001, Bonferroni Adjusted P < .001). ","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Occhipinti', 'Affiliation': 'Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/A, Turin, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Germano', 'Affiliation': 'Farmacia Antoniana, Viale Cesare Balbo, 3, 10040 San Gillio (TO), Italy.'}, {'ForeName': 'Massimo E', 'Initials': 'ME', 'LastName': 'Maffei', 'Affiliation': 'Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/A, Turin, Italy.'}]",Urology journal,[] 1237,31556078,Influence of Postoperative Patient-Controlled Analgesia on Hemorheology in Patients Undergoing Hip Arthroplasty.,"OBJECTIVE To test the hypothesis that patient-controlled analgesia (PCA) contributes to improvement of hemorheology in patients undergoing hip arthroplasty. METHODS 120 patients, aged 60 - 75 years old, undergoing hip arthroplasty under spinal anesthesia, were randomly divided into group PCA (n = 60) and control group (n = 60). Patients in PCA group received PCA in postoperative 3 days. Blood samples from the median cubital vein were collected at five time points: before anesthesia (T1), after surgery (T2), 6 h after surgery (T3), 24 h after surgery (T4), 48 h after surgery (T5). Hemorheological parameters were measured, including whole blood viscosity at a high shear rate (Hηb), whole blood viscosity at a low shear rate (Lηb), reduced viscosity (ηr), plasma viscosity (ηp), hematocrit (Hct), erythrocyte aggregation index(EAI) and erythrocyte deformation index (EDI). Noninvasive blood pressure and heart rate at T1-5 and pain scoring of visual analogue scale (VAS) score at T2-5 were recorded. RESULTS (1) Compared with T1, Hηb, Lηb, ηp, ηr decreased significantly at T3-5 with EAI decreased significantly at T5 in group PCA (p < 0.05), EDI increased significantly at T5 in group C (p < 0.05). (2) Compared with group C, Hηb, Lηb, ηp, ηr, EAI decreased significantly at T5 with Lηb concurrently decreased at T4 in group PCA (p < 0.05). CONCLUSION Postoperative pain may increase blood viscosity in patients undergoing hip arthroplasty, mainly via plasma viscosity, erythrocyte aggregation and rigidity, and which could be improved by postoperative PCA.",2020,"(1) Compared with T1, Hηb, Lηb, ηp, ηr decreased significantly at T3-5 with EAI decreased significantly at T5 in group PCA (p < 0.05), EDI increased significantly at T5 in group C (p < 0.05).","['patients undergoing hip arthroplasty', '120 patients, aged 60\u200a-\u200a75 years old, undergoing hip arthroplasty under spinal anesthesia', 'Patients Undergoing Hip Arthroplasty']","['PCA', 'Postoperative Patient-Controlled Analgesia', 'patient-controlled analgesia (PCA']","['whole blood viscosity at a high shear rate (Hηb), whole blood viscosity at a low shear rate (Lηb), reduced viscosity (ηr), plasma viscosity (ηp), hematocrit (Hct), erythrocyte aggregation index(EAI) and erythrocyte deformation index (EDI', 'EDI', 'blood viscosity', 'Hemorheological parameters', 'Noninvasive blood pressure and heart rate at T1-5 and pain scoring of visual analogue scale (VAS) score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0186193', 'cui_str': 'Arthroplasty of coxofemoral joint'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}]","[{'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}]","[{'cui': 'C0427691', 'cui_str': 'Whole blood viscosity measurement'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4301986', 'cui_str': 'Viscosity (property) (qualifier value)'}, {'cui': 'C1287278', 'cui_str': 'Finding of plasma viscosity (finding)'}, {'cui': 'C0518014', 'cui_str': 'Hematocrit - finding'}, {'cui': 'C1608880', 'cui_str': 'Erythrocyte aggregation (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0014792', 'cui_str': 'Blood Corpuscles, Red'}, {'cui': 'C0005848', 'cui_str': 'Blood Viscosity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",120.0,0.0363218,"(1) Compared with T1, Hηb, Lηb, ηp, ηr decreased significantly at T3-5 with EAI decreased significantly at T5 in group PCA (p < 0.05), EDI increased significantly at T5 in group C (p < 0.05).","[{'ForeName': 'Yiping', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': 'Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, China.'}, {'ForeName': 'Liqun', 'Initials': 'L', 'LastName': 'Mo', 'Affiliation': 'Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, China.'}, {'ForeName': 'Liming', 'Initials': 'L', 'LastName': 'Luan', 'Affiliation': 'Vanderbilt University Medical Center, Department of Anesthesiology, Nashville, United States.'}, {'ForeName': 'Daiying', 'Initials': 'D', 'LastName': 'Zhang', 'Affiliation': 'Department of Operating Room, Affiliated Hospital of Southwest Medical University, Luzhou, China.'}]",Zeitschrift fur Orthopadie und Unfallchirurgie,['10.1055/a-0918-6603'] 1238,26571323,Effect of Preoperative Forced-Air Warming on Hypothermia in Elderly Patients Undergoing Transurethral Resection of the Prostate.,"PURPOSE Elderly patients under spinal anesthesia are vulnerable to hypothermia, leading to increased morbidity. The aim of this study was to investigate the effects of preoperative forced-air warming on perioperative hypothermia and shivering in elderly patients undergoing transurethral resection of the prostate (TURP) under spinal anesthesia. MATERIALS AND METHODS Patients (> 65-year-old) scheduled for TURP under spinal anesthesia were randomly assigned to receive preoperative forced-air skin warming for 20 min (the pre-warmed group, n = 25) or not (control group, n = 25). Core temperatures were measured at 15-min intervals after spinal anesthesia, and intra- and post-operative shivering were also assessed. RESULTS Incidences of intraoperative hypothermia (< 36 ºC) in the pre-warmed and control groups were not significantly different (10/25 [40%] vs. 15/24 [62.5%], P = .259). However, severities of hypothermia were significantly different (P = .019). No patient in the pre-warmed group showed moderate or profound hypothermia, whereas of patients in control group 21% and 13% did so, respectively. CONCLUSION This study demonstrated that a brief period of preoperative forced-air warming did not completely prevent intraoperative hypothermia or shivering, but it could significantly reduce its severity in elderly male patients under spinal anesthesia.",2015,"RESULTS Incidences of intraoperative hypothermia (< 36 ºC) in the pre-warmed and control groups were not significantly different (10/25 [40%] vs. 15/24 [62.5%], P = .259).","['elderly male patients under spinal anesthesia', 'elderly patients undergoing transurethral resection of the prostate (TURP) under spinal anesthesia', 'Elderly Patients Undergoing Transurethral Resection of the Prostate', 'Patients (> 65-year-old) scheduled for TURP under spinal anesthesia', 'Elderly patients under spinal anesthesia']","['preoperative forced-air skin warming for 20 min (the pre-warmed group, n = 25) or not (control', 'Preoperative Forced-Air Warming', 'preoperative forced-air warming']","['severities of hypothermia', 'moderate or profound hypothermia', 'intraoperative hypothermia']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0002928', 'cui_str': 'Spinal Anesthesia'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0235218', 'cui_str': 'Warm skin (finding)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0413252', 'cui_str': 'Hypothermia due to exposure'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0445200', 'cui_str': 'Profound hypothermia (qualifier value)'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}]",,0.0180554,"RESULTS Incidences of intraoperative hypothermia (< 36 ºC) in the pre-warmed and control groups were not significantly different (10/25 [40%] vs. 15/24 [62.5%], P = .259).","[{'ForeName': 'Youn Yi', 'Initials': 'YY', 'LastName': 'Jo', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.'}, {'ForeName': 'Young Jin', 'Initials': 'YJ', 'LastName': 'Chang', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.'}, {'ForeName': 'Yong Beom', 'Initials': 'YB', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.'}, {'ForeName': 'Sehwan', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Gachon University, Gil Medical Center, Incheon, South Korea.'}, {'ForeName': 'Hyun Jeong', 'Initials': 'HJ', 'LastName': 'Kwak', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Gachon University, Gil Medical Center, Incheon, South Korea. hyun615@gilhospital.com.'}]",Urology journal,[] 1239,26571324,Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device.,"PURPOSE Thermobalancing therapy, provided by Therapeutic Device, which contains a natural thermoelement, and is applied topically in the projection ofthe prostate,was aimed to improve blood circulation in the affected organ. We evaluated the effectiveness of new Therapeutic Device for the treatment of patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS We performed a clinical non-randomized controlled trial before and after 6-month treatment. Therapeutic Device was administered to 124 patients with BPH as mono-therapy. The dynamic of the patients' condition was assessed by the International Prostate Symptom Score (IPSS), ultrasound measurement of prostate volume (PV) and uroflowmetry. The control-group comprised 124 men who did not receive any treatment. The IPSS score, maximum flow rate (Qmax), and PV were compared between the groups. RESULTS Baseline evaluation (pre-treatment) for both groups were comparable to each other with no clinically significant difference regarding age, IPSS score, Qmax and PV volume. Overall, thermobalancing therapy resulted in significant improvements from baseline to endpoint in IPSS (P = .001), IPSS storage and voiding subscores (both P = .001), and IPSS quality of life index (QoL) (P = .001) compared with control group. Moreover, comparison of parameters after 6 months treatment showed that thermobalancing therapy also improved the Qmax (P = .001), and PV (P = .001). CONCLUSION Two years clinical trial demonstrated that thermobalancing therapy administered for 6 months provides a marked improvement in patients presenting with symptomatic BPH not only on lower urinary tract symptoms (LUTS) but also in QoL and Qmax. Thus urologists should be aware about thermobalancing therapy as a non-invasive physiotherapeutic treatment option for treatment of BPH.",2015,"Overall, thermobalancing therapy resulted in significant improvements from baseline to endpoint in IPSS (P = .001), IPSS storage and voiding subscores (both P = .001), and IPSS quality of life index (QoL)","['patients with benign prostatic hyperplasia (BPH', 'Benign Prostatic Hyperplasia Treatment with New Physiotherapeutic Device', '124 men who did not receive any treatment', '124 patients with BPH as mono-therapy']","['thermobalancing therapy', 'new Therapeutic Device']","['IPSS score, maximum flow rate (Qmax), and PV', 'urinary tract symptoms (LUTS', 'blood circulation', 'IPSS score, Qmax and PV volume', 'IPSS quality of life index (QoL', 'IPSS storage and voiding subscores', 'IPSS', 'International Prostate Symptom Score (IPSS), ultrasound measurement of prostate volume (PV) and uroflowmetry', 'Qmax']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0540173', 'cui_str': 'MonoS'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0042027'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0005775', 'cui_str': 'Blood Circulation'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0451498', 'cui_str': 'Spitzer quality of life index (assessment scale)'}, {'cui': 'C1698986', 'cui_str': 'Storage (procedure)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0200008', 'cui_str': 'Uroflowmetry (procedure)'}]",124.0,0.0375124,"Overall, thermobalancing therapy resulted in significant improvements from baseline to endpoint in IPSS (P = .001), IPSS storage and voiding subscores (both P = .001), and IPSS quality of life index (QoL)","[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Allen', 'Affiliation': 'Fine Treatment, 29 Rewley Road, Oxford, OX1 2RA, United Kingdom. info@finetreatment.com.'}, {'ForeName': 'Ivan Gerasimovich', 'Initials': 'IG', 'LastName': 'Aghajanyan', 'Affiliation': 'Department of Urology, Yerevan State Medical University, Institute of Surgery Mikaelyan, Republic of Armenia.'}]",Urology journal,[] 1240,26571315,Diagnostic Yield and Complications Using a 20 Gauge Prostate Biopsy Needle versus a Standard 18 Gauge Needle: A Randomized Controlled Study.,"PURPOSE To compare and evaluate whether a 20 gauge (20G) biopsy needle maintains a similar detection rate as that of the commonly used 18G needle for transrectal ultrasound-guided prostate biopsy (TRUSPB) aimed at assessing prostate cancer (PCa) and decreasing pain and complications. MATERIALS AND METHODS A total of 122 cases with indications of PCa were randomly allocated into two groups for this randomized controlled study. TRUSPB was performed randomly using either an 18G or 20G needle for core biopsies (62 cases with 18G and 60 cases with 20G). Detection rate, pain, and complications were assessed after the procedure. RESULTS The cancer detection rate in the 18G group (40.3%) did not differ from that in the 20G group (35.0%). However, the number of patients with pain was significantly lower in 20G group (P < 0.05). The number of patients with self-limiting hematuria decreased in both groups after the biopsy procedure (18G: 38 cases; 20G: 16 cases; P < .0001). Hematochezia occurred in 11 cases (9 cases [14.5%] in the 18G group; 2 cases [3.4%] in the 20G group). The number of patients with infection, dysuria, and urinary retention tended to be lower in 20G group. CONCLUSION Use of a 20G needle for TRUSPB yielded a comparable cancer detection rate to that of an 18G needle and led to less local injury, pain, and complications. A larger and more sensitive study is needed to verify our results.",2015,The cancer detection rate in the 18G group (40.3%) did not differ from that in the 20G group (35.0%).,['122 cases with indications of PCa'],"['20 Gauge Prostate Biopsy Needle versus a Standard 18 Gauge Needle', 'TRUSPB', '20 gauge (20G) biopsy needle', 'transrectal ultrasound-guided prostate biopsy (TRUSPB']","['Hematochezia', 'cancer detection rate', 'number of patients with self-limiting hematuria', 'Detection rate, pain, and complications', 'local injury, pain, and complications', 'number of patients with pain', 'Diagnostic Yield and Complications', 'number of patients with infection, dysuria, and urinary retention']","[{'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C0030625', 'cui_str': 'PCA'}]","[{'cui': 'C0456564', 'cui_str': 'Gauges (qualifier value)'}, {'cui': 'C3878906', 'cui_str': 'Prostate biopsy needle'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C0181960', 'cui_str': 'Biopsy needle, device (physical object)'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0018932', 'cui_str': 'Hematochezia'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C0018965', 'cui_str': 'Hematuria'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0013428', 'cui_str': 'Dysuria'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}]",122.0,0.0245237,The cancer detection rate in the 18G group (40.3%) did not differ from that in the 20G group (35.0%).,"[{'ForeName': 'Jianlong', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Urology, Beijing Hospital, Beijing, China.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Wan', 'Affiliation': 'Department of Urology, Beijing Hospital, Beijing, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Tongji Hospital, Shanghai, China.'}, {'ForeName': 'Jianye', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Urology, Beijing Hospital, Beijing, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': ""Department of Urology, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, China.""}, {'ForeName': 'Weixin', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Kaile', 'Initials': 'K', 'LastName': 'Zhang', 'Affiliation': 'Department of Urology, Tongji Hospital, Shanghai, China.'}]",Urology journal,[] 1241,26571321,980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study.,"PURPOSE We compared the effectiveness and complications of 980-nm diode laser vaporization and transurethral resection of the prostate (TURP) in patients with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS In total, 72 consecutive patients with BPH entered the study. All patients underwent general and urological evaluations. The primary outcome was improvement in the International Prostate Symptom Score (IPSS). The secondary outcomes were IPSS quality of life (QoL), maximum urinary flow rate (Qmax), residual volume, and complications. Patients were allocated randomly to the TURP and laser groups. The Ceralas HPD120, a diode laser system emitting at a wavelength of 980 nm, was used for photoselective vaporization of the prostate (PVP). TURP was performed with a monopolar 26 French resectoscope. Preoperative and operative parameters and surgical outcomes were compared. RESULTS In total, 36 patients in each group underwent PVP and TURP. The mean age ± standard deviation was 63.1 ± 9.1 years and 64.7 ± 10.2 years in the PVP and TURP groups, respectively. There were no statistically significant differences in age, prostate size, prostate-specific antigen concentration, Qmax, preoperative IPSS, or preoperative Qmax between the two groups. The operation duration was also similar between the groups (P = .36). The catheterization time was 1.45 ± 0.75 and 2.63 ± 0.49 days in the PVP and TURP groups, respectively (P < .01). The PVP group had a shorter hospital stay than the TURP group. The 3-month postoperative Qmax increased to 9.90 ± 3.61 and 6.59 ± 6.06 mL/s from baseline in the TURP and PVP groups, respectively; there was no difference in the increases between the groups (P = .08). The IPSS and IPSS-QoL were significantly improved with the operation (P < .01), and this improvement was similar in both groups P = .3 and P = .8, respectively . The complication rate was also similar between the two groups. CONCLUSIONS PVP with a diode laser is as safe and effective as TURP in the treatment of BPH, and the techniques have similar complication rates and functional results. PVP has the advantage of shorter hospitalization and catheter indwelling times and no need for discontinuation of anticoagulant therapy.",2015,"There were no statistically significant differences in age, prostate size, prostate-specific antigen concentration, Qmax, preoperative IPSS, or preoperative Qmax between the two groups.","['Benign Prostatic Hyperplasia', 'The mean age ± standard deviation was 63.1 ± 9.1 years and 64.7 ± 10.2 years in the PVP and TURP groups, respectively', 'All patients underwent general and urological evaluations', '72 consecutive patients with BPH entered the study', 'patients with benign prostatic hyperplasia (BPH']","['980-Nm Diode Laser Vaporization versus Transurethral Resection', '980-nm diode laser vaporization and transurethral resection of the prostate (TURP', 'PVP with a diode laser', 'PVP', 'PVP and TURP', 'TURP']","['3-month postoperative Qmax', 'IPSS quality of life (QoL), maximum urinary flow rate (Qmax), residual volume, and complications', 'operation duration', 'catheterization time', 'age, prostate size, prostate-specific antigen concentration, Qmax, preoperative IPSS, or preoperative Qmax', 'IPSS and IPSS-QoL', 'International Prostate Symptom Score (IPSS', 'complication rate', 'shorter hospital stay']","[{'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C3653764', 'cui_str': 'UROLOGICALS'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0392254', 'cui_str': 'Semiconductor Diode Lasers'}, {'cui': 'C0581699', 'cui_str': 'Vaporization'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach (qualifier value)'}, {'cui': 'C0728940', 'cui_str': 'Surgical removal - action'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}]","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0034380'}, {'cui': 'C0429783', 'cui_str': 'Urinary flow rate (observable entity)'}, {'cui': 'C0035190', 'cui_str': 'Residual respiratory volume (observable entity)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0426731', 'cui_str': 'Prostate size'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",72.0,0.0289914,"There were no statistically significant differences in age, prostate size, prostate-specific antigen concentration, Qmax, preoperative IPSS, or preoperative Qmax between the two groups.","[{'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Cetinkaya', 'Affiliation': 'Department of Urology, School of Medicine, Mugla Sitki Kocman University, Mugla, Turkey. drmemoly@yahoo.com.'}, {'ForeName': 'Kadir', 'Initials': 'K', 'LastName': 'Onem', 'Affiliation': 'Department of Urology, Ondokuz Mayis Medical Faculty, Ondokuz Mayis University, Samsun, Turkey.'}, {'ForeName': 'Mehmet Murat', 'Initials': 'MM', 'LastName': 'Rifaioglu', 'Affiliation': 'Department of Urology, Medical Faculty, Mustafa Kemal University, Hatay, Turkey.'}, {'ForeName': 'Veli', 'Initials': 'V', 'LastName': 'Yalcin', 'Affiliation': 'Department of Urology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.'}]",Urology journal,[] 1242,30876680,Pro-cognitive effect of a prebiotic in psychosis: A double blind placebo controlled cross-over study.,,2019,,['psychosis'],['placebo'],[],"[{'cui': 'C0033975', 'cui_str': 'Psychoses'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]",[],,0.198492,,"[{'ForeName': 'Amy Chia-Ching', 'Initials': 'AC', 'LastName': 'Kao', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Safarikova', 'Affiliation': 'Research & Development Department, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, United Kingdom.'}, {'ForeName': 'Tahnee', 'Initials': 'T', 'LastName': 'Marquardt', 'Affiliation': 'Research & Development Department, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, United Kingdom.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Mullins', 'Affiliation': 'Research & Development Department, Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford OX3 7JX, United Kingdom.'}, {'ForeName': 'Belinda R', 'Initials': 'BR', 'LastName': 'Lennox', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom.'}, {'ForeName': 'Philip W J', 'Initials': 'PWJ', 'LastName': 'Burnet', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford OX3 7JX, United Kingdom. Electronic address: phil.burnet@psych.ox.ac.uk.'}]",Schizophrenia research,['10.1016/j.schres.2019.03.003'] 1243,26148507,Luteal phase support for assisted reproduction cycles.,"BACKGROUND Progesterone prepares the endometrium for pregnancy by stimulating proliferation in response to human chorionic gonadotropin(hCG) produced by the corpus luteum. This occurs in the luteal phase of the menstrual cycle. In assisted reproduction techniques(ART), progesterone and/or hCG levels are low, so the luteal phase is supported with progesterone, hCG or gonadotropin-releasing hormone (GnRH) agonists to improve implantation and pregnancy rates. OBJECTIVES To determine the relative effectiveness and safety of methods of luteal phase support provided to subfertile women undergoing assisted reproduction. SEARCH METHODS We searched databases including the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and trial registers. We conducted searches in November 2014, and further searches on 4 August 2015. SELECTION CRITERIA Randomised controlled trials (RCTs) of luteal phase support using progesterone, hCG or GnRH agonist supplementation in ART cycles. DATA COLLECTION AND ANALYSIS Three review authors independently selected trials, extracted data and assessed risk of bias. We calculated odds ratios (ORs) and 95%confidence intervals (CIs) for each comparison and combined data when appropriate using a fixed-effect model. Our primary out come was live birth or ongoing pregnancy. The overall quality of the evidence was assessed using GRADE methods. MAIN RESULTS Ninety-four women RCTs (26,198 women) were included. Most studies had unclear or high risk of bias in most domains. The main limitations in the evidence were poor reporting of study methods and imprecision due to small sample sizes.1. hCG vs placebo/no treatment (five RCTs, 746 women)There was no evidence of differences between groups in live birth or ongoing pregnancy (OR 1.67, 95% CI 0.90 to 3.12, three RCTs,527 women, I2 = 24%, very low-quality evidence, but I2 of 61% was found for the subgroup of ongoing pregnancy) with a random effects model. hCG increased the risk of ovarian hyperstimulation syndrome (OHSS) (1 RCT, OR 4.28, 95% CI 1.91 to 9.6, low quality evidence).2. Progesterone vs placebo/no treatment (eight RCTs, 875 women)Evidence suggests a higher rate of live birth or ongoing pregnancy in the progesterone group (OR 1.77, 95% CI 1.09 to 2.86, five RCTs, 642 women, I2 = 35%, very low-quality evidence). OHSS was not reported.3. Progesterone vs hCG regimens (16 RCTs, 2162 women)hCG regimens included comparisons of progesterone versus hCG and progesterone versus progesterone + hCG. No evidence showed differences between groups in live birth or ongoing pregnancy (OR 0.95, 95% CI 0.65 to 1.38, five RCTs, 833 women, I2 = 0%, low quality evidence) or in the risk of OHSS (four RCTs, 615 women, progesterone vs hCG OR 0.54, 95% CI 0.22 to 1.34; four RCTs,678 women; progesterone vs progesterone plus hCG, OR 0.34, 95% CI 0.09 to 1.26, low-quality evidence).4. Progesterone vs progesterone with oestrogen (16 RCTs, 2577 women)No evidence was found of differences between groups in live birth or ongoing pregnancy (OR 1.12, 95% CI 0.91 to 1.38, nine RCTs,1651 women, I2 = 0%, low-quality evidence) or OHSS (OR 0.56, 95% CI 0.2 to 1.63, two RCTs, 461 women, I2 = 0%, low-quality evidence).5. Progesterone vs progesterone + GnRH agonist (seven RCTs, 1708 women)Live birth or ongoing pregnancy rates were lower in the progesterone-only group and increased in women who received progester one and one or more GnRH agonist doses (OR 0.62, 95% CI 0.48 to 0.81, nine RCTs, 2861 women, I2 = 55%, random effects, low quality evidence). Statistical heterogeneity for this comparison was high because of unexplained variation in the effect size, but the direction of effect was consistent across studies. OHSS was reported in one study only (OR 1.00, 95% CI 0.33 to 3.01, 1 RCT, 300 women, very low quality evidence).6. Progesterone regimens (45 RCTs, 13,814 women)The included studies reported nine different comparisons between progesterone regimens. Findings for live birth or ongoing pregnancy were as follows: intramuscular (IM) versus oral: OR 0.71, 95% CI 0.14 to 3.66 (one RCT, 40 women, very low-quality evidence);IM versus vaginal/rectal: OR 1.24, 95% CI 1.03 to 1.5 (seven RCTs, 2309 women, I2 = 71%, very low-quality evidence); vaginal/rectal versus oral: OR 1.19, 95% CI 0.83 to 1.69 (four RCTs, 857 women, I2 = 32%, low-quality evidence); low-dose versus high-dose vaginal: OR 0.97, 95% CI 0.84 to 1.11 (five RCTs, 3720 women, I2 = 0%, moderate-quality evidence); short versus long protocol:OR 1.04, 95% CI 0.79 to 1.36 (five RCTs, 1205 women, I2 = 0%, low-quality evidence); micronised versus synthetic: OR 0.9, 95%CI 0.53 to 1.55 (two RCTs, 470 women, I2 = 0%, low-quality evidence); vaginal ring versus gel: OR 1.09, 95% CI 0.88 to 1.36 (oneRCT, 1271 women, low-quality evidence); subcutaneous versus vaginal gel: OR 0.92, 95% CI 0.74 to 1.14 (two RCTs, 1465 women,I2 = 0%, low-quality evidence); and vaginal versus rectal: OR 1.28, 95% CI 0.64 to 2.54 (one RCT, 147 women, very low-quality evidence). OHSS rates were reported for only two of these comparisons: IM versus oral, and low versus high-dose vaginal. No evidence showed a difference between groups.7. Progesterone and oestrogen regimens (two RCTs, 1195 women)The included studies compared two different oestrogen protocols. No evidence was found to suggest differences in live birth or ongoing pregnancy rates between a short and a long protocol (OR 1.08, 95% CI 0.81 to 1.43, one RCT, 910 women, low-quality evidence) or between a low dose and a high dose of oestrogen (OR 0.65, 95% CI 0.37 to 1.13, one RCT, 285 women, very low-quality evidence).Neither study reported OHSS. AUTHORS' CONCLUSIONS Both progesterone and hCG during the luteal phase are associated with higher rates of live birth or ongoing pregnancy than placebo.The addition of GnRHa to progesterone is associated with an improvement in pregnancy outcomes. OHSS rates are increased with hCG compared to placebo (only study only). The addition of oestrogen does not seem to improve outcomes. The route of progester one administration is not associated with an improvement in outcomes.",2015,"No evidence was found to suggest differences in live birth or ongoing pregnancy rates between a short and a long protocol (OR 1.08, 95% CI 0.81 to 1.43, one RCT, 910 women, low-quality evidence) or between a low dose and a high dose of oestrogen (OR 0.65, 95% CI 0.37 to 1.13, one RCT, 285 women, very low-quality evidence).Neither study reported OHSS. ","['subfertile women undergoing assisted reproduction', 'Cochrane Menstrual Disorders and Subfertility Group (MDSG', 'November 2014, and further searches on 4 August 2015', 'Ninety-four women RCTs (26,198 women) were included']","['placebo', 'Progesterone vs progesterone with oestrogen', 'progesterone and hCG', 'Progesterone vs hCG', 'progesterone, hCG or gonadotropin-releasing hormone (GnRH) agonists', 'Progesterone vs progesterone + GnRH agonist', 'Progesterone', 'hCG vs placebo', 'Progesterone and oestrogen regimens', 'hCG', 'progesterone versus hCG and progesterone versus progesterone + hCG', 'Progesterone vs placebo', 'progesterone, hCG or GnRH agonist supplementation']","['rates of live birth or ongoing pregnancy', 'live birth or ongoing pregnancy rates', 'rate of live birth or ongoing pregnancy', 'women)Live birth or ongoing pregnancy rates', 'OHSS rates', 'risk of ovarian hyperstimulation syndrome (OHSS', 'odds ratios (ORs) and 95%confidence intervals (CIs', 'live birth or ongoing pregnancy', 'OHSS']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0025345', 'cui_str': 'Menstruation Disorders'}, {'cui': 'C0729353', 'cui_str': 'Sub-Fertility'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3816959', 'cui_str': 'Ninety'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0373705', 'cui_str': 'Progesterone measurement (procedure)'}, {'cui': 'C0202006', 'cui_str': 'Estrogen measurement (procedure)'}, {'cui': 'C1141639', 'cui_str': 'Human Chorionic Gonadotropin'}, {'cui': 'C4543260', 'cui_str': 'Gonadotropin'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}]","[{'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0085083', 'cui_str': 'Ovarian Hyperstimulation Syndrome'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",3.0,0.500998,"No evidence was found to suggest differences in live birth or ongoing pregnancy rates between a short and a long protocol (OR 1.08, 95% CI 0.81 to 1.43, one RCT, 910 women, low-quality evidence) or between a low dose and a high dose of oestrogen (OR 0.65, 95% CI 0.37 to 1.13, one RCT, 285 women, very low-quality evidence).Neither study reported OHSS. ","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'van der Linden', 'Affiliation': 'Department of Obstetrics and Gynaecology, Radboud University Medical Center, PO Box 9101, Nijmegen, Netherlands, 6500 HB.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Buckingham', 'Affiliation': ''}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Farquhar', 'Affiliation': ''}, {'ForeName': 'Jan A M', 'Initials': 'JA', 'LastName': 'Kremer', 'Affiliation': ''}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Metwally', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD009154.pub3'] 1244,23879752,Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design.,"BACKGROUND Ischemic stroke and other vascular outcomes occur in 10-20% of patients in the three-months following a transient ischemic attack or minor ischemic stroke, and many are disabling. The highest risk period for these outcomes is the early hours and days immediately following the ischemic event. Aspirin is the most common antithrombotic treatment used for these patients. AIM The aim of POINT is to determine whether clopidogrel plus aspirin taken <12 h after transient ischemic attack or minor ischemic stroke symptom onset is more effective in preventing major ischemic vascular events at 90 days in the high-risk, and acceptably safe, compared with aspirin alone. DESIGN POINT is a prospective, randomized, double-blind, multicenter trial in patients with transient ischemic attack or minor ischemic stroke. Subjects are randomized to clopidogrel (600 mg loading dose followed by 75 mg/day) or matching placebo, and all will receive open-label aspirin 50-325 mg/day, with a dose of 162 mg daily for five-days followed by 81 mg daily strongly recommended. STUDY OUTCOMES The primary efficacy outcome is the composite of new ischemic vascular events - ischemic stroke, myocardial infarction, or ischemic vascular death - by 90 days. The primary safety outcome is major hemorrhage, which includes symptomatic intracranial hemorrhage. DISCUSSION Aspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.",2013,"The primary efficacy outcome is the composite of new ischemic vascular events - ischemic stroke, myocardial infarction, or ischemic vascular death - by 90 days.","['patients with a stroke or transient ischemic attack', 'patients with transient ischemic attack or minor ischemic stroke']","['aspirin', 'clopidogrel', 'matching placebo, and all will receive open-label aspirin', 'Aspirin', 'clopidogrel plus aspirin']","['composite of new ischemic vascular events - ischemic stroke, myocardial infarction, or ischemic vascular death - by 90 days', 'major hemorrhage, which includes symptomatic intracranial hemorrhage']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0026193', 'cui_str': 'Minors'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]","[{'cui': 'C0004057', 'cui_str': 'acetylsalicylic acid'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0151699', 'cui_str': 'Intracranial Hemorrhage'}]",,0.255927,"The primary efficacy outcome is the composite of new ischemic vascular events - ischemic stroke, myocardial infarction, or ischemic vascular death - by 90 days.","[{'ForeName': 'S Claiborne', 'Initials': 'SC', 'LastName': 'Johnston', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA, USA. clay.johnston@ucsfmedctr.org'}, {'ForeName': 'J Donald', 'Initials': 'JD', 'LastName': 'Easton', 'Affiliation': ''}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Farrant', 'Affiliation': ''}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Barsan', 'Affiliation': ''}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Battenhouse', 'Affiliation': ''}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Conwit', 'Affiliation': ''}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Dillon', 'Affiliation': ''}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Elm', 'Affiliation': ''}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Lindblad', 'Affiliation': ''}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Morgenstern', 'Affiliation': ''}, {'ForeName': 'Sharon N', 'Initials': 'SN', 'LastName': 'Poisson', 'Affiliation': ''}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Palesch', 'Affiliation': ''}]",International journal of stroke : official journal of the International Stroke Society,['10.1111/ijs.12129'] 1245,31842232,Hospital-Level Care at Home for Acutely Ill Adults: A Randomized Controlled Trial.,"Background Substitutive hospital-level care in a patient's home may reduce cost, health care use, and readmissions while improving patient experience, although evidence from randomized controlled trials in the United States is lacking. Objective To compare outcomes of home hospital versus usual hospital care for patients requiring admission. Design Randomized controlled trial. (ClinicalTrials.gov: NCT03203759). Setting Academic medical center and community hospital. Patients 91 adults (43 home and 48 control) admitted via the emergency department with selected acute conditions. Intervention Acute care at home, including nurse and physician home visits, intravenous medications, remote monitoring, video communication, and point-of-care testing. Measurements The primary outcome was the total direct cost of the acute care episode (sum of costs for nonphysician labor, supplies, medications, and diagnostic tests). Secondary outcomes included health care use and physical activity during the acute care episode and at 30 days. Results The adjusted mean cost of the acute care episode was 38% (95% CI, 24% to 49%) lower for home patients than control patients. Compared with usual care patients, home patients had fewer laboratory orders (median per admission, 3 vs. 15), imaging studies (median, 14% vs. 44%), and consultations (median, 2% vs. 31%). Home patients spent a smaller proportion of the day sedentary (median, 12% vs. 23%) or lying down (median, 18% vs. 55%) and were readmitted less frequently within 30 days (7% vs. 23%). Limitation The study involved 2 sites, a small number of home physicians, and a small sample of highly selected patients (with a 63% refusal rate among potentially eligible patients); these factors may limit generalizability. Conclusion Substitutive home hospitalization reduced cost, health care use, and readmissions while increasing physical activity compared with usual hospital care. Primary Funding Source Partners HealthCare Center for Population Health and internal departmental funds.",2020,"Home patients spent a smaller proportion of the day sedentary (median, 12% vs. 23%) or lying down (median, 18% vs. 55%) and were readmitted less frequently within 30 days (7% vs. 23%). ","['Acutely Ill Adults', '2 sites, a small number of home physicians, and a small sample of highly selected patients (with a 63% refusal rate among potentially eligible patients', 'Patients\n\n\n91 adults (43 home and 48 control) admitted via the emergency department with selected acute conditions', 'patients requiring admission']",['home hospital versus usual hospital care'],"['health care use and physical activity during the acute care episode and at 30 days', 'laboratory orders', 'cost, health care use, and readmissions while increasing physical activity', 'adjusted mean cost of the acute care episode', 'total direct cost of the acute care episode (sum of costs for nonphysician labor, supplies, medications, and diagnostic tests', 'smaller proportion of the day sedentary']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0085554', 'cui_str': 'Patient Care Episodes'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C4302923', 'cui_str': 'Laboratory order (record artifact)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}, {'cui': 'C1875802', 'cui_str': 'Healthcare supplies'}, {'cui': 'C0086143'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}]",91.0,0.165426,"Home patients spent a smaller proportion of the day sedentary (median, 12% vs. 23%) or lying down (median, 18% vs. 55%) and were readmitted less frequently within 30 days (7% vs. 23%). ","[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Levine', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.M.L., K.O., B.B., A.S., J.L.S.).""}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Ouchi', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.M.L., K.O., B.B., A.S., J.L.S.).""}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Blanchfield', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.M.L., K.O., B.B., A.S., J.L.S.).""}, {'ForeName': 'Agustina', 'Initials': 'A', 'LastName': 'Saenz', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.M.L., K.O., B.B., A.S., J.L.S.).""}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Burke', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (K.B., M.P.).""}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Paz', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (K.B., M.P.).""}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Diamond', 'Affiliation': 'Partners HealthCare at Home, Waltham, Massachusetts (K.D.).'}, {'ForeName': 'Charles T', 'Initials': 'CT', 'LastName': 'Pu', 'Affiliation': 'Harvard Medical School, Massachusetts General Hospital, and Partners HealthCare System Center for Population Health, Boston, Massachusetts (C.T.P.).'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Schnipper', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.M.L., K.O., B.B., A.S., J.L.S.).""}]",Annals of internal medicine,['10.7326/M19-0600'] 1246,30964335,Videogames That Encourage Healthy Behavior Did Not Alter Fasting Insulin or Other Diabetes Risks in Children: Randomized Clinical Trial.,"Background: Previous research indicates games for health have substantial promise in promoting change in children's diet and physical activity (PA) behavior for obesity and diabetes prevention, but the research has generally not been rigorous. The study reported here was an efficacy trial of two role-playing videogames played in sequence, ""Escape from Diab"" (hereinafter called Diab) and ""Nanoswarm: Invasion from Inner Space"" (hereinafter called Nano), on diabetes and obesity risk factors: fasting insulin and body mass index (BMI), and risk-related behaviors: diet, PA, and sedentary behavior (SB). Design: A two-group (treatment vs. wait list control) randomized clinical trial was used with baseline, immediate postintervention (∼3 months postbaseline), and 2 months postassessments. Intervention: Diab and Nano were desktop or laptop role-playing videogames with nine sessions (each episode/session lasting ∼60 minutes). Two storylines attempted to immerse players and used ethnically diverse characters to model desired behaviors. Tailored goal setting, problem solving, and motivational statements were used. Methods: A sample of 200 overweight or obese children (ages 10-12 years from 85th to 99th BMI percentile [%ile]) was recruited, primarily using a volunteer list. Fasting insulin was the primary dependent variable. BMI, fruit, vegetable and sweetened beverage intakes, PA, and SBs were secondary outcomes. Generalized linear mixed models were used to test for the treatment effects. Results: No significant differences were detected in any of the tested outcome variables. Conclusions: The lack of differences may indicate that games cannot change dietary behaviors and thereby not change-related clinical outcomes. Alternatively, there seem to have been changes in (1) the types of videogames children expect and like to play since a pilot study was conducted, (2) productization challenges, and/or (3) problems in staff management of the trial. All may have contributed to the lack of effect.",2019,"No significant differences were detected in any of the tested outcome variables. ","['Children', '200 overweight or obese children (ages 10-12 years from 85th to 99th']",['Diab and Nano were desktop or laptop role-playing videogames with nine sessions'],"['Healthy Behavior', 'BMI, fruit, vegetable and sweetened beverage intakes, PA, and SBs', 'Fasting Insulin', 'Fasting insulin']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0035822', 'cui_str': 'Role Playings'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}]",200.0,0.0414878,"No significant differences were detected in any of the tested outcome variables. ","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Baranowski', 'Affiliation': ""1Department of Pediatrics, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Baranowski', 'Affiliation': ""1Department of Pediatrics, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Tzu-An', 'Initials': 'TA', 'LastName': 'Chen', 'Affiliation': '2HEALTH Research Institute, University of Houston, Houston, Texas.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Buday', 'Affiliation': '3Archimage, Inc., Houston, Texas.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Beltran', 'Affiliation': ""1Department of Pediatrics, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Hafza', 'Initials': 'H', 'LastName': 'Dadabhoy', 'Affiliation': ""1Department of Pediatrics, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Ryan', 'Affiliation': ""1Department of Pediatrics, USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, Texas.""}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Lu', 'Affiliation': '4Health Technology Lab, Department of Communication Studies, College of Arts, Media & Design, Northeastern University, Boston, Massachusetts.'}]",Games for health journal,['10.1089/g4h.2018.0097'] 1247,31549793,Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis.,"OBJECTIVE High magnetic resonance imaging (MRI)-detected inflammation is associated with greater progression and poorer outcomes in rheumatoid arthritis (RA). This analysis aimed to determine if baseline MRI inflammation was related to clinical response and remission in the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study. METHODS AVERT was a phase IIIb, randomized, controlled trial with a 12-month, double-blind treatment period enrolling patients with early (≤2 years' duration), anti-citrullinated peptide-positive methotrexate (MTX)-naive RA. In this post hoc analysis, patients in the abatacept plus MTX (n = 114) and MTX (n = 111) arms with available MRI results were stratified into low and high baseline MRI inflammation groups based on previously developed cutoffs of synovitis and osteitis on unilateral hand-wrist contrast-enhanced MRI. Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score in 28 joints using the C-reactive protein level (<2.6) were assessed. RESULTS Overall, 100 of 225 patients (44.4%) had high baseline MRI inflammation. In patients with high baseline MRI inflammation, a significantly greater proportion achieved remission at 12 months with abatacept plus MTX versus MTX across SDAI (45.1% versus 16.3%; P = 0.0022), CDAI (47.1% versus 20.4%; P = 0.0065), and Boolean indices (39.2% versus 16.3%; P = 0.0156). In patients with low baseline MRI inflammation, remission rates were not significantly different with abatacept plus MTX versus MTX (SDAI: 39.7% versus 32.3%; P = 0.4961). CONCLUSION In seropositive, MTX-naive patients with early RA and presence of objectively measured high inflammation by MRI, indicating poor prognosis, remission rates were higher with abatacept plus MTX treatment versus MTX.",2020,"Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score in 28 joints (C-reactive protein)","[""enrolling patients with early (≤2 years' duration), anti-citrullinated peptide-positive methotrexate (MTX)-naïve RA""]","['MTX', 'abatacept+MTX treatment versus MTX', 'Magnetic Resonance Imaging', 'magnetic resonance imaging', 'abatacept+MTX versus MTX', 'abatacept+MTX']","['Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score', 'remission rates', 'Boolean indices', 'CDAI', 'remission']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}]",,0.295007,"Simplified Disease Activity Index (SDAI) remission (≤3.3), Clinical Disease Activity Index (CDAI) remission (≤2.8), Boolean remission, and Disease Activity Score in 28 joints (C-reactive protein)","[{'ForeName': 'Harris A', 'Initials': 'HA', 'LastName': 'Ahmad', 'Affiliation': 'Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'Joshua F', 'Initials': 'JF', 'LastName': 'Baker', 'Affiliation': 'University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Mikkel', 'Initials': 'M', 'LastName': 'Østergaard', 'Affiliation': 'Rigshospitalet, Glostrup, Denmark, and University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Emery', 'Affiliation': 'University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Durez', 'Affiliation': 'Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'June', 'Initials': 'J', 'LastName': 'Ye', 'Affiliation': 'Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'Subhashis', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Bristol Myers Squibb, Princeton, New Jersey.'}, {'ForeName': 'Philip G', 'Initials': 'PG', 'LastName': 'Conaghan', 'Affiliation': 'University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, UK.'}]",Arthritis care & research,['10.1002/acr.24072'] 1248,26341763,"Combined Dietary Recommendations, Desmopressin, and Behavioral Interventions May Be Effective First-Line Treatment in Resolution of Enuresis.","PURPOSE Nocturnal enuresis (NE) is a very common multifactorial pediatric disorder and in children with­out any other lower urinary tract symptoms is defined as monosymptomatic NE (MNE). Pharmacologi­cal, psychological/behavioral, and alternative interventions are commonly used and the first-line drug ther­apy for patients with MNE is desmopressin (dDAVP) but the response rate is less than 40-60% and the relapse rate is about 50-80% after treatment. Many studies show that some foods and beverages can promote diuresis or bladder irritability, which in some people can exacerbate bladder symptoms and NE. The pres­ent study aimed to compare the efficacy of combined specific dietary advices and dDAVP vs dDAVP alone. MATERIALS AND METHODS We enrolled in the study 172 patients affected by MNE between January 2013 and May 2014, of these 35 were excluded. The inclusion criterion was primary MNE and exclusion criteria included non-MNE, secondary MNE and lactose intolerance. Children were treated with dDAVP at a dose of 120 μg a day and were randomized to receive dietary recommendations. They were asked to fill out a char­ter depicting their wet and dry nights for the period of treatment. Sixty-seven patients were randomly as­signed to receive dDAVP and dietary advices (group A) and 70 patients to receive dDAVP alone (group B). RESULTS We included in our study 137 children, 102 (74.5%) male, and 35 (25.5%) female, aged be­tween 5 and 14 years. Our results show a higher response rate and a lower number of relapse in group A vs group B with 67.2% of responders in group A vs 58.6% in group B, after 3 months of ther­apy and 31.1% of relapse in group A vs 46.3% in group B one month, after the end of treatment. CONCLUSION Our results show the effectiveness of specific dietary advices in the manage­ment of primary MNE. However further studies are needed to determine whether the differ­ence between therapy with combined dietary recommendations and dDAVP vs dDAVP alone.",2015,"Our results show a higher response rate and a lower number of relapse in group A vs group B with 67.2% of responders in group A vs 58.6% in group B, after 3 months of ther­apy and 31.1% of relapse in group A vs 46.3% in group B one month, after the end of treatment. ","['We enrolled in the study 172 patients affected by MNE between January 2013 and May 2014, of these 35 were excluded', 'Sixty-seven patients', '137 children, 102 (74.5%) male, and 35 (25.5%) female, aged be\xadtween 5 and 14 years']","['dDAVP and dietary advices', 'dDAVP alone', 'desmopressin (dDAVP', 'dDAVP', 'Combined Dietary Recommendations, Desmopressin, and Behavioral Interventions', 'combined specific dietary advices and dDAVP vs dDAVP alone']","['relapse rate', 'response rate', 'number of relapse', 'diuresis or bladder irritability']","[{'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}, {'cui': 'C0522476', 'cui_str': 'Patient affected (contextual qualifier) (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517569', 'cui_str': 'One hundred and thirty-seven'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C4517663', 'cui_str': 'Twenty-five point five'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0701195', 'cui_str': 'DDAVP'}, {'cui': 'C0204932', 'cui_str': 'Diet education (procedure)'}, {'cui': 'C0011701', 'cui_str': 'desmopressin'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205369', 'cui_str': 'Specified'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0012797', 'cui_str': 'Diuresis'}, {'cui': 'C2945586', 'cui_str': 'Bladder irritability (finding)'}]",67.0,0.0327511,"Our results show a higher response rate and a lower number of relapse in group A vs group B with 67.2% of responders in group A vs 58.6% in group B, after 3 months of ther­apy and 31.1% of relapse in group A vs 46.3% in group B one month, after the end of treatment. ","[{'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Ferrara', 'Affiliation': 'Institute of Pediatrics, Catholic University of Sacred Heart, Rome, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Del Volgo', 'Affiliation': 'Service of Pediatrics, Campus Bio-Medico University, Rome, Italy.'}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Romano', 'Affiliation': 'Institute of Pediatrics, Catholic University of Sacred Heart, Rome, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Scarpelli', 'Affiliation': 'Food Sciences and Human Nutrition Unit, Campus Bio-Medico University, Rome, Italy. scarpelli.valentina1@gmail.com.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'De Gara', 'Affiliation': 'Food Sciences and Human Nutrition Unit, Campus Bio-Medico University, Rome, Italy.'}, {'ForeName': 'Giacinto Abele Donato', 'Initials': 'GA', 'LastName': 'Miggiano', 'Affiliation': 'Service of Clinical Nutrition, Catholic University of Sacred Heart, Rome, Italy.'}]",Urology journal,[] 1249,26341762,"Minilaparoscopy vs. standard laparoscopic donor nephrectomy: comparison of safety, efficacy and cosmetic outcomes in a randomized clinical trial.","PURPOSE This study was conducted to compare safety, efficacy and cosmetic outcome between standard laparoscopic live donor nephrectomy (sLDN) and mini-laparoscopic donor nephrectomy (mLDN) in a randomized clinical trial. MATERIALS AND METHODS From March 2012 to June 2013, 100 consecutive kidney donors were randomly assigned to two equal groups for laparoscopic donor nephrectomy. mLDN: Six to eight centimeters Pfannenstiel incision was made slightly above pubis symphysis and 11 millimeters trocar was fixed through exposed fascia using open technique. Five mm port was placed under direct vision at the umbilicus for camera insertion and two 3.5 mm ports were placed in subxiphoid and paraumbilical area. sLDN: Ten mm port was placed at umbilicus using open access technique for camera insertion. Five mm trocar for grasping and 11 mm trocar for vascular clipping were placed at subxiphoid and paraumbilical areas under direct vision, respectively. The second 5 mm trocar was placed in suprapubic area. Cosmetic appearance was assessed three months after surgery by using the Patient Scar Assessment Questionnaire (PSAQ). RESULTS Demographic data of the patients was not significantly different between two groups. Total operative time and ischemic time was nearly similar in both groups (104 ± 21 vs. 114 ± 24 min; P = .327 and 4.03 vs. 4.07 min; P = .592). There were no cases of conversion to open surgery. Mean hospital stay was similar between the two groups [2.1 (2-5) vs. 2.4 (2-5) days; P = .346]. Kidney graft function assessed by serum creatinine val­ues (mg/dL) of recipients, was equivalent in both groups (1.58 vs. 1.86: P = .206). Mean appearance score (34 vs. 29) and consciousness score (22 vs. 18) in PSAQ showed significantly better results in the mLDN group. CONCLUSION Our experience in this study revealed that peri- and post-operative findings were comparable between sLDN and mLDN, but mLDN has significant better cosmetic appearance than standard laparoscopic approach.",2015,Mean hospital stay was similar between the two groups [2.1 (2-5) vs. 2.4 (2-5) days; P = .346].,"['From March 2012 to June 2013, 100 consecutive kidney donors']","['laparoscopic donor nephrectomy', 'Pfannenstiel incision', 'sLDN', 'standard laparoscopic live donor nephrectomy (sLDN) and mini-laparoscopic donor nephrectomy (mLDN', 'Minilaparoscopy vs. standard laparoscopic donor nephrectomy']","['Mean hospital stay', 'Total operative time and ischemic time', 'safety, efficacy and cosmetic outcome', 'Kidney graft function assessed by serum creatinine val\xadues', 'Patient Scar Assessment Questionnaire (PSAQ', 'Mean appearance score', 'consciousness score', 'Cosmetic appearance', 'cosmetic appearance']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1313935', 'cui_str': 'Kidney donor'}]","[{'cui': 'C0411257', 'cui_str': 'Donor nephrectomy (procedure)'}, {'cui': 'C0457819', 'cui_str': 'Pfannenstiel incision (procedure)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C4039558', 'cui_str': 'Laparoscopic live donor nephrectomy'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0442965', 'cui_str': 'Cosmetic procedure (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}]",,0.105353,Mean hospital stay was similar between the two groups [2.1 (2-5) vs. 2.4 (2-5) days; P = .346].,"[{'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Simforoosh', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed Hossein', 'Initials': 'SH', 'LastName': 'Hosseini Sharifi', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Valipour', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Narouie', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Kamranmanesh', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Soltani', 'Affiliation': 'Shahid Labbafinejad Medical Center, Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.. mhsoltani60@gmail.com.'}]",Urology journal,[] 1250,26341769,Comparison between Microsurgical Subinguinal Varicocelectomy with and without Testicular Delivery for Infertile Men: Is Testicular Delivery an Unnecessary Procedure.,"PURPOSE Controversy still exists as to whether testicular delivery during microsurgical subinguinal varicocelecto­my (MSV) provides benefit to the patient or not. This study specifically compared the therapeutic effect of MSV with and without testicular delivery for the treatment of varicocele in a cohort of infertile men. MATERIALS AND METHODS We conducted a prospective, randomized, controlled study to evaluate the therapeutic efficacy of MSV with and without testicular delivery for the treatment of varicocele in infertile men. A total of 100 patients were specifically recruited using strict inclusion criteria to undergo MSV with testicular delivery (group 1, n = 50) or MSV without testicular delivery (group 2, n = 50). All patients were followed-up at 3, 6 and 12 months following surgery. Semen parameters, pregnancy and recurrence rates, and complications were monitored. RESULTS Mean surgical time for group 1 was significantly longer than group 2 (90.50 ± 15.60 min vs. 84.30 ± 15.58 min; P = .001). Sperm count and motility were significantly improved at the 12-month follow-up appoint­ment in both groups compared with pre-operative values, but were not significantly different at 3, 6, and 12 months when compared between the two treatment groups. The incidence of scrotal edema, and spermatic/testicular en­gorgement were higher in group 1 (both P = .001), although natural pregnancy rate was not significantly different between the two groups at the 12 month follow-up appointment (46% vs. 42%) (P = .817). CONCLUSION MSV with testicular delivery did not reduce the risk of recurrence and led to improved semen quality compared with MSV without testicular delivery. However, there was a higher risk of complication with this tech­nique, which must be borne in mind when considering the clinical implications of our dataset.",2015,"CONCLUSION MSV with testicular delivery did not reduce the risk of recurrence and led to improved semen quality compared with MSV without testicular delivery.","['A total of 100 patients were specifically recruited using strict inclusion criteria to undergo MSV with testicular delivery (group 1, n = 50) or MSV without testicular delivery (group 2, n = 50', 'varicocele in a cohort of infertile men', 'varicocele in infertile men', 'Infertile Men']","['Microsurgical Subinguinal Varicocelectomy with and without Testicular Delivery', 'MSV with and without testicular delivery', 'microsurgical subinguinal varicocelecto\xadmy (MSV']","['natural pregnancy rate', 'risk of recurrence', 'incidence of scrotal edema, and spermatic/testicular en\xadgorgement', 'semen quality', 'Semen parameters, pregnancy and recurrence rates, and complications', 'Sperm count and motility', 'Mean surgical time']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0560133', 'cui_str': 'mSv'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0441861', 'cui_str': 'Group 1 (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0042341', 'cui_str': 'Varicocele'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0194985', 'cui_str': 'Excision of varicocele (procedure)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0560133', 'cui_str': 'mSv'}]","[{'cui': 'C0205296', 'cui_str': 'Natural (qualifier value)'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0151609', 'cui_str': 'Edema of scrotum (disorder)'}, {'cui': 'C2717747', 'cui_str': 'Semen Quality'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0037842', 'cui_str': 'Sperm Count'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}]",100.0,0.0557626,"CONCLUSION MSV with testicular delivery did not reduce the risk of recurrence and led to improved semen quality compared with MSV without testicular delivery.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Hou', 'Affiliation': 'Department of Urology, China and Japan union hospital of Jilin University, 126 Xiantai Street, Changchun City, Jilin province, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Urology, China and Japan union hospital of Jilin University, 126 Xiantai Street, Changchun City, Jilin province, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Urology, China and Japan union hospital of Jilin University, 126 Xiantai Street, Changchun City, Jilin province, China. 986062616@qq.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Huo', 'Affiliation': 'Department of Urology, China and Japan union hospital of Jilin University, 126 Xiantai Street, Changchun City, Jilin province, China.'}, {'ForeName': 'Hai', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Urology, China and Japan union hospital of Jilin University, 126 Xiantai Street, Changchun City, Jilin province, China.'}]",Urology journal,[] 1251,29633654,"Comment to the reply letter: Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019).",,2019,,[],[],[],[],[],[],,0.0188753,,"[{'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Walter', 'Affiliation': '1 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Macaskill', 'Affiliation': '2 School of Public Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Turner', 'Affiliation': ""3 Biostatistics Unit, Dean's Office, School of Medicine, University of Otago, Dunedin, New Zealand.""}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Guyatt', 'Affiliation': '1 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Cook', 'Affiliation': '4 Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada.'}, {'ForeName': 'Kameshwar', 'Initials': 'K', 'LastName': 'Prasad', 'Affiliation': '5 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.'}]",Statistical methods in medical research,['10.1177/0962280218768107'] 1252,26154829,Educational intervention to improve oral health beliefs and behaviors during pregnancy: a randomized-controlled trial.,"BACKGROUND Oral and dental health is one of the most important aspects of public health, which becomes more important during pregnancy. Health education may effectively prevent a considerable percent of oral and dental diseases. OBJECTIVE This study was designed to evaluate the effects of an oral and dental health educational intervention during pregnancy on the beliefs and behaviors of pregnant women on oral and dental health. PARTICIPANTS AND METHODS In this randomized-controlled clinical trial, 160 pregnant women were allocated randomly to intervention and control groups (80 in each group). The intervention group received six education sessions over 3 weeks on oral health issues, whereas the control group received no education. Beliefs and behaviors of pregnant women on oral health were evaluated before, immediately, and 2 months after the educational intervention using a self-administered questionnaire containing 13 Likert scale belief statements and nine practice items. RESULTS There were no significant differences in the scores of behaviors between the two groups, whereas the scores of beliefs of the educated group were lower than the controls at baseline. The scores of beliefs and behaviors were significantly higher in the educated group than the controls immediately and 2 months after the education program (P<0.05). CONCLUSION AND RECOMMENDATIONS The results of the present study indicated the positive effects of oral health training during pregnancy in promoting the beliefs and behaviors of pregnant women on oral health. More attention to oral and dental education programs is recommended during pregnancy.",2015,"The scores of beliefs and behaviors were significantly higher in the educated group than the controls immediately and 2 months after the education program (P<0.05). ","['160 pregnant women', 'pregnant women on oral health', 'pregnant women on oral and dental health']","['control group received no education', 'six education sessions', 'oral health training', 'Educational intervention', 'oral and dental health educational intervention']","['scores of beliefs and behaviors', 'Beliefs and behaviors of pregnant women on oral health', 'scores of behaviors', 'scores of beliefs', 'oral health beliefs and behaviors']","[{'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0029162'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0029162'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0029162'}]",160.0,0.0590819,"The scores of beliefs and behaviors were significantly higher in the educated group than the controls immediately and 2 months after the education program (P<0.05). ","[{'ForeName': 'Narjes', 'Initials': 'N', 'LastName': 'Bahri', 'Affiliation': 'Departments of aMidwifery bPublic Health, Gonabad University of Medical Sciences cSocial Development & Health Promotion Research Centre, Gonabad University of Medical Sciences, Gonabad Departments of dEpidemiology and Biostatistics eHealth Education, Tehran University of Medical Sciences, Tehran fHealth Center Number 3, Vice Chancellery of Health, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran.'}, {'ForeName': 'Hamid R', 'Initials': 'HR', 'LastName': 'Tohidinik', 'Affiliation': ''}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Bahri', 'Affiliation': ''}, {'ForeName': 'Hamid R', 'Initials': 'HR', 'LastName': 'Iliati', 'Affiliation': ''}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Moshki', 'Affiliation': ''}, {'ForeName': 'Fateme', 'Initials': 'F', 'LastName': 'Darabi', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000464139.06374.a4'] 1253,32417348,Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.,"BACKGROUND Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. METHODS Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT. The primary endpoint was locoregional progression (LRP). RESULTS 188 patients were randomized: 85% oropharynx and 73% stage IVa. P16 status was documented for 137 oropharyngeal tumors with P16+ in 53 (39%) patients; and 90% were smokers. Median follow-up was 60.5 months. Xerostomia was markedly decreased in arm B (p < 0.0001). The 1-year grade ≥2 xerostomia (RTOG criteria) was 63% vs 23% and 3-year 45% vs 11% in arms A and B, respectively. Xerostomia LENT-SOMA scale was also reduced in arm B. Dose-escalated IMRT did not reduce LRP with an adjusted HR of 1.13 [95%CI = 0.64-1.98] (p = 0.68). Survival was not different (adjusted HR: 1.19 [95%CI = 0.78-1.81], p = 0.42). No interaction between p16 and treatment effect was found. CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.",2020,"CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT.","['locally advanced (LA) head and neck squamous cell carcinomas (HNSCC', '188 patients were randomized: 85% oropharynx and 73% stage IVa', 'patients', 'locally advanced head and neck squamous cell carcinomas (HNSCC']","['Concurrent chemoradiotherapy (CRT', 'radiotherapy', 'Concurrent cisplatin and Dose escalation with Intensity-modulated radiotherapy (IMRT', 'cisplatin', 'conventional radiotherapy', 'IMRT and cisplatin', '75Gy/35F with IMRT']","['1-year grade ≥ 2 xerostomia (RTOG criteria', 'Xerostomia LENT-SOMA scale', 'Survival', 'P16 status', 'Xerostomia', 'locoregional progression (LRP', 'xerostomia']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1168401', 'cui_str': 'Squamous cell carcinoma of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0441773', 'cui_str': 'Stage IVa'}]","[{'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0702216', 'cui_str': 'Soma'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0249880', 'cui_str': 'Cdk4-Associated Protein p16'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",188.0,0.356655,"CONCLUSION Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT.","[{'ForeName': 'Yungan', 'Initials': 'Y', 'LastName': 'Tao', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address: yungan.tao@gustaveroussy.fr.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Auperin', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Blanchard', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Alfonsi', 'Affiliation': 'Institut Sainte Catherine, Avignon, France.'}, {'ForeName': 'Xu-Shan', 'Initials': 'XS', 'LastName': 'Sun', 'Affiliation': 'Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Rives', 'Affiliation': 'Institut Claudius Regaud, Toulouse, France.'}, {'ForeName': 'Yoann', 'Initials': 'Y', 'LastName': 'Pointreau', 'Affiliation': 'Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Joël', 'Initials': 'J', 'LastName': 'Castelli', 'Affiliation': 'Centre Eugène Marquis, Rennes, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Graff', 'Affiliation': 'Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.'}, {'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Wong Hee Kam', 'Affiliation': 'AP-HM Hôpital de la Timone, Marseille, France.'}, {'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Thariat', 'Affiliation': 'Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.'}, {'ForeName': 'Ovidiu', 'Initials': 'O', 'LastName': 'Veresezan', 'Affiliation': 'Centre Henri Becquerel, Rouen, France.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Heymann', 'Affiliation': 'Clinique Sainte Anne, Strasbourg, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Renard-Oldrini', 'Affiliation': 'Centre Alexis Vautrin, Nancy, France.'}, {'ForeName': 'Cédrik', 'Initials': 'C', 'LastName': 'Lafond', 'Affiliation': 'Centre Jean Bernard, Le Mans, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Cornely', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Casiraghi', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Boisselier', 'Affiliation': 'Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Lapeyre', 'Affiliation': 'Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Biau', 'Affiliation': 'Centre Jean Perrin, Clermont-Ferrand, France.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Bourhis', 'Affiliation': 'Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne, Switzerland. Electronic address: jean.bourhis@chuv.ch.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.05.021'] 1254,25703908,A comparison of the effects of morphine and sublingual desmopressin combination therapy with morphine alone in treatment of renal colic: a controlled clinical trial.,"PURPOSE To compare the therapeutic efficacy of combined desmopressin and morphine with morphine and placebo on acute renal colic. MATERIALS AND METHODS In a single blind case-control clinical trial 81 consecutive patients, 54 males and 27 females with the mean age of 30.12 ± 9.88 years, presenting with acute renal colic to the urology emergency unit were studied. The patients were randomly assigned into two groups. The 40 cases were treated with 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt; whereas the 41 controls received the same dose of morphine beside a placebo. RESULTS There were no significant statistical differences regarding the mean age, gender, stone size, location and affected side between the two groups. Our results showed a significantly higher acuity of pain in the study group in comparison to the controls at 10, 20 and 30 minutes of receiving the medication (P = .06, .017 and P = .008, respectively). CONCLUSION No superiority was found in adding desmopressin to morphine compared to the traditional treatments (opioids only) in relieving the pain of acute renal colic cases.",2015,"There were no significant statistical differences regarding the mean age, gender, stone size, location and affected side between the two groups.","['81 consecutive patients, 54 males and 27 females with the mean age of 30.12 ± 9.88 years, presenting with acute renal colic to the urology emergency unit were studied']","['morphine', 'combined desmopressin and morphine with morphine and placebo', 'IM morphine', 'morphine beside a placebo', 'morphine alone', 'morphine and sublingual desmopressin combination therapy', 'sublingual desmopressin melt']","['acuity of pain', 'pain of acute renal colic cases', 'renal colic', 'therapeutic efficacy', 'acute renal colic']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0152169', 'cui_str': 'Acute Renal Colic'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0011701', 'cui_str': 'desmopressin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521982', 'cui_str': 'Sublingual'}, {'cui': 'C0556895', 'cui_str': 'Combination therapy (regime/therapy)'}, {'cui': 'C0599882', 'cui_str': 'Melting'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0152169', 'cui_str': 'Acute Renal Colic'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",81.0,0.0272566,"There were no significant statistical differences regarding the mean age, gender, stone size, location and affected side between the two groups.","[{'ForeName': 'Maliheh', 'Initials': 'M', 'LastName': 'Keshvari Shirvani', 'Affiliation': 'Department of Urology, Mashhad University of Medical Sciences, Mashhad, Iran.. Keshvarim@mums.ac.ir.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Darabi Mahboub', 'Affiliation': ''}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Ghazi', 'Affiliation': ''}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Delijani', 'Affiliation': ''}]",Urology journal,[] 1255,32417629,"Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial.","OBJECTIVE This study was performed to evaluate the impact of melatonin supplementation on clinical and metabolic profiles in people with Parkinson's disease (PD). METHODS This randomized, double-blind, placebo-controlled clinical trial was conducted among 60 patients with PD. Participants were randomly divided into two groups to intake either 10 mg melatonin (two melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day, 1 h before bedtime for 12 weeks. RESULTS Melatonin supplementation significantly reduced the Unified Parkinson's Disease Rating Scale (UPDRS) part I score (β -2.33; 95% CI, -3.57, -1.09; P < 0.001), Pittsburgh Sleep Quality Index (PSQI) (β -1.82; 95% CI, -3.36, -0.27; P = 0.02), Beck Depression Inventory (BDI) (β -3.32; 95% CI, -5.23, -1.41; P = 0.001) and Beck Anxiety Inventory (BAI) (β -2.22; 95% CI, -3.84, -0.60; P = 0.008) compared with the placebo treatment. Compared with the placebo, melatonin supplementation resulted in a significant reduction in serum high sensitivity C-reactive protein (hs-CRP) (β -0.94 mg/L; 95% CI, -1.55, -0.32; P = 0.003) and a significant elevation in plasma total antioxidant capacity (TAC) (β 108.09 mmol/L; 95% CI, 78.21, 137.97; P < 0.001) and total glutathione (GSH) levels (β 77.08 μmol/L; 95% CI, 44.29, 109.86; P < 0.001). Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β -13.16 mg/dL; 95% CI, -25.14, -1.17; P = 0.03) and LDL- (β -10.44 mg/dL; 95% CI, -20.55, -0.34; P = 0.04) compared with the placebo. CONCLUSIONS Overall, melatonin supplementation for 12 weeks to patients with PD had favorable effects on the UPDRS part I score, PSQI, BDI, BAI, hs-CRP, TAC, GSH, insulin levels, HOMA-IR, total-, LDL-cholesterol, and gene expression of TNF-α, PPAR-γ and LDLR, but did not affect other metabolic profiles.",2020,"Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β","[""Parkinson's disease"", ""people with Parkinson's disease (PD"", '60 patients with PD']","['melatonin supplementation', 'Melatonin supplementation', 'placebo, melatonin supplementation', 'melatonin (two melatonin capsules', 'placebo']","['Pittsburgh Sleep Quality Index (PSQI', 'homeostasis model of assessment-insulin resistance (HOMA-IR', 'UPDRS part I score, PSQI, BDI, BAI, hs-CRP, TAC, GSH, insulin levels, HOMA-IR, total-, LDL-cholesterol, and gene expression of TNF-α, PPAR-γ and LDLR', 'serum high sensitivity C-reactive protein (hs-CRP', 'plasma total antioxidant capacity (TAC', 'total glutathione (GSH) levels', 'LDL', 'Beck Anxiety Inventory (BAI) ', 'Beck Depression Inventory (BDI', 'serum insulin levels', ""Unified Parkinson's Disease Rating Scale (UPDRS) part I score (β""]","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006448', 'cui_str': 'Burundi'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0166418', 'cui_str': 'PPAR'}, {'cui': 'C0034821', 'cui_str': 'LDL receptor'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}]",60.0,0.782673,"Additionally, consuming melatonin significantly decreased serum insulin levels (β -1.79 μIU/mL; 95% CI, -3.12, -0.46; P = 0.009), homeostasis model of assessment-insulin resistance (HOMA-IR) (β -0.47; 95% CI, -0.80, -0.13; P = 0.007), total- (β","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Daneshvar Kakhaki', 'Affiliation': 'Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Vahidreza', 'Initials': 'V', 'LastName': 'Ostadmohammadi', 'Affiliation': 'Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Kouchaki', 'Affiliation': 'Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran; Department of Neurology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Esmat', 'Initials': 'E', 'LastName': 'Aghadavod', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Bahmani', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Omid Reza', 'Initials': 'OR', 'LastName': 'Tamtaji', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Russel', 'Initials': 'R', 'LastName': 'J Reiter', 'Affiliation': 'Department of Cellular and Structural Biology, University of Texas Health Science, Center, San Antonio, TX, USA.'}, {'ForeName': 'Mohammad Ali', 'Initials': 'MA', 'LastName': 'Mansournia', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: asemi_z@Kaums.ac.ir.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.105878'] 1256,32418145,Peri-transplant aminophylline in pediatric kidney transplant recipients of donation after brain death: a double-blinded placebo-controlled randomized clinical trial.,"BACKGROUND During kidney transplantation, the transplanted kidney undergoes ischemia reperfusion injury, with adenosine being a major mediator. This study aimed to assess whether aminophylline, an adenosine receptor antagonist, improves early graft function and reduces incidence of delayed graft function (DGF) and slow graft function (SGF). METHODS Single center, double-blinded, placebo-controlled randomized clinical trial. Pediatric patients admitted for renal transplantation from donation after brain death donors were randomized into a treatment arm receiving aminophylline and a placebo arm receiving normal saline infusions. Primary outcome was estimated glomerular filtration rate (eGFR) at 5 days post-transplant. Secondary outcomes were rates of DGF/SGF and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels. RESULTS Twenty-three patients were randomized to aminophylline and 27 to placebo. There was no difference in day 5 eGFR, rate of DGF/SGF, or urine NGAL/Creatinine level between aminophylline vs. placebo arm (eGFR 67.39 ± 38.9 ml/min/1.73m 2 vs. 80.48 ± 52.1 ml/min/1.73m 2 p = 0.32; DGF/SGF 5/23 (21.7%) vs. 3/27 (11.1%) p = 0.31; urine NGAL/creatinine 300.5 ng/mg IQR 105.5-1464.5 ng/mg vs. 425.4 ng/mg IQR 140.3-1126.2 ng/mg, p = 0.95; respectively). At 12 months, there was 100% patient survival and 98% graft survival. eGFR at 12 months was similar between the two arms. CONCLUSIONS There was no benefit in peri-transplant aminophylline administration. Our results are limited by small sample size, since sample calculations were based on primary outcome of day 5 eGFR and low rate of DGF/SGF, which may have precluded us from demonstrating efficacy. Further clinical studies are necessary to determine any benefit of aminophylline in kidney transplant recipients, particularly from high-risk donors.",2020,"There was no difference in day 5 eGFR, rate of DGF/SGF, or urine NGAL/Creatinine level between aminophylline vs. placebo arm (eGFR 67.39 ± 38.9 ","['kidney transplant recipients, particularly from high-risk donors', 'pediatric kidney transplant recipients of donation after brain death', 'Pediatric patients admitted for renal transplantation from donation after brain death donors', 'Twenty-three patients']","['aminophylline', 'placebo arm receiving normal saline infusions', 'aminophylline vs. placebo', 'Peri-transplant aminophylline', 'placebo']","['delayed graft function (DGF) and slow graft function (SGF', 'day 5 eGFR, rate of DGF/SGF, or urine NGAL/Creatinine level', 'eGFR', 'glomerular filtration rate (eGFR', 'patient survival and 98% graft survival', 'rates of DGF/SGF and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C4049936', 'cui_str': 'Patient status determination, deceased and body donated'}, {'cui': 'C0006110', 'cui_str': 'Brain death'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0450348', 'cui_str': '23'}]","[{'cui': 'C0002575', 'cui_str': 'Aminophylline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}]","[{'cui': 'C1566590', 'cui_str': 'Delayed graft function'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0018131', 'cui_str': 'Graft Survival'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",23.0,0.796399,"There was no difference in day 5 eGFR, rate of DGF/SGF, or urine NGAL/Creatinine level between aminophylline vs. placebo arm (eGFR 67.39 ± 38.9 ","[{'ForeName': 'Orly', 'Initials': 'O', 'LastName': 'Haskin', 'Affiliation': 'Department of Pediatrics (Nephrology), Stanford University School of Medicine, Stanford, CA, USA. orly.haskin@gmail.com.'}, {'ForeName': 'Weiwen', 'Initials': 'W', 'LastName': 'Shih', 'Affiliation': 'Department of Pediatrics (Nephrology), Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Wong', 'Affiliation': 'Department of Pediatrics (Nephrology), Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Axelrod', 'Affiliation': 'Department of Pediatrics (Cardiology), Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Grimm', 'Affiliation': 'Department of Pediatrics (Nephrology), Stanford University School of Medicine, Stanford, CA, USA.'}]","Pediatric nephrology (Berlin, Germany)",['10.1007/s00467-020-04561-z'] 1257,25853544,Prevalence of cardiovascular disease risk factors among Egyptian and Saudi medical students: a comparative study.,"BACKGROUND Results from recent reports suggest that the mortality and the morbidity from coronary heart disease (CHD) is leveling, especially in younger adults. Studies conducted in both Saudi Arabia and Egypt, aiming at the estimation of the prevalence of cardiovascular risk factors among the young population, demonstrated a high prevalence of risk factors. OBJECTIVE The aim of this study was to compare the prevalence of cardiovascular risk factors among medical students aged 18-25 years in two Middle East countries (Egypt and Saudi Arabia). PARTICIPANTS AND METHODS This was a cross-sectional comparative study involving a sample of 360 medical students of both sexes randomly selected from students enrolled into two medical colleges in Saudi Arabia and Egypt. RESULTS The prevalence of risk factors for cardiovascular disease was relatively high among both Saudi and Egyptian medical students, particularly a sedentary life style, obesity, and abdominal obesity. Smoking was practiced by 29.7% of both populations. A significantly higher prevalence of obesity and a reported family history of premature CHD were observed among the Saudi students and a significantly higher prevalence of hypertension was found among male Egyptian students as compared with male Saudi students. A relatively high proportion of both populations (23.9% of Saudi students and 16.7% of the Egyptian students) was at an increased risk of developing fatal cardiovascular disease within 10 years. CONCLUSION Apart from the higher prevalence of obesity and reported family history of premature CHD among the Saudi students and the significantly higher prevalence of hypertension among the Egyptian students, there was no statistically significant difference between the risk profiles of both populations. Participatory behavior change programs in medical schools for the adoption of healthy lifestyles, particularly involvement in regular physical activity and smoking cessation are highly recommended.",2015,"The prevalence of risk factors for cardiovascular disease was relatively high among both Saudi and Egyptian medical students, particularly a sedentary life style, obesity, and abdominal obesity.","['This was a cross-sectional comparative study involving a sample of 360 medical students of both sexes randomly selected from students enrolled into two medical colleges in Saudi Arabia and Egypt', 'male Egyptian students as compared with male Saudi students', 'Egyptian and Saudi medical students', 'medical students aged 18-25 years in two Middle East countries (Egypt and Saudi Arabia', 'younger adults']",[],"['premature CHD', 'risk of developing fatal cardiovascular disease', 'cardiovascular risk factors', 'prevalence of hypertension']","[{'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C0205203', 'cui_str': 'Crossed (qualifier value)'}, {'cui': 'C0205155', 'cui_str': 'Sectional (qualifier value)'}, {'cui': 'C0009491', 'cui_str': 'Comparative Study'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0038495', 'cui_str': 'Students, Medical'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0557806', 'cui_str': 'College (environment)'}, {'cui': 'C0036243', 'cui_str': 'Kingdom of Saudi Arabia'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0026068', 'cui_str': 'Middle East'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]",[],"[{'cui': 'C0205252', 'cui_str': 'Immature (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]",360.0,0.0157313,"The prevalence of risk factors for cardiovascular disease was relatively high among both Saudi and Egyptian medical students, particularly a sedentary life style, obesity, and abdominal obesity.","[{'ForeName': 'Alaa-El-Dine H', 'Initials': 'AE', 'LastName': 'Mahmoud', 'Affiliation': 'aCommunity Medicine Department, Ibn Sina National College for Medical Sciences, Jeddah, KSA bCommunity Medicine Department, Faculty of Medicine, Beni Suef University, Beni Suef, Egypt.'}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000460969.93981.c2'] 1258,32100445,Effect of training provided to patients with chronic obstructive pulmonary disease on drug management.,"AIM Wrong use of an inhaler arising from a lack of knowledge can negatively affect treatment management. Therefore, this study was performed with the aim of determining the effects on treatment management of inhaler training carried out under the leadership of a nurse in individuals with medium and advanced stage chronic obstructive pulmonary disease (COPD). METHODS This was an experimentally designed pre-test post-test study with a control group. Participants were interviewed four times in 1 year. The experimental group performed inhaler training. A Patient Description and Follow-Up Form, an Inhaler Drug Use Skill Chart, the Morisky eight-item Medication Adherence Scale, the COPD Assessment Test, and the St. George Respiration Questionnaire were used to collect data. Data analysis was performed by SPSS, using nonparametric tests. RESULTS Although there was no significant difference between the groups, a reduction in hospital visits and admissions because of attacks was seen in the experimental group (p = .239, p = .492). It was found there was a greater increase in the correct use of the inhaler in the experimental group than in the control group, and that correct use of the handihaler increased significantly (p = .008). Also, the increases in adherence to treatment (p = .006) and quality of life (p = .010) in the experimental group were significantly different from the control group. In the control group, the annual decline in forced expiratory volume in 1 s increased significantly (p = .016). CONCLUSIONS It was seen that long-term inhaler training given by nurses at regular intervals made a significant contribution to treatment management.",2020,"In the control group, the annual decline in forced expiratory volume in 1 s increased significantly (p = .016). ","['patients with chronic obstructive pulmonary disease on drug management', 'individuals with medium and advanced stage chronic obstructive pulmonary disease (COPD']",[],"['hospital visits and admissions because of attacks', 'correct use', 'quality of life', 'annual decline in forced expiratory volume']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}]",[],"[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0034380'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}]",,0.0208525,"In the control group, the annual decline in forced expiratory volume in 1 s increased significantly (p = .016). ","[{'ForeName': 'Sevda', 'Initials': 'S', 'LastName': 'Efil', 'Affiliation': 'Nursing Department, Faculty of Health Sciences, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.'}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Enç', 'Affiliation': 'Department of Internal Diseases Nursing, Cerrahpasa Florence Nightingale Faculty of Nursing, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Turhan', 'Initials': 'T', 'LastName': 'Ece', 'Affiliation': 'Department of Chest Diseases, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12333'] 1259,25703911,Novel approach for pain control in patients undergoing prostate biopsy: iliohypogastric nerve block with or without topical application of prilocaine-lidocaine: a randomized controlled trial.,"PURPOSE To investigate the efficacy of a novel anesthetic technique called iliohypogastric nerve block (INB) for pain control in patients undergoing prostate biopsy. MATERIALS AND METHODS A total of 59 consecutive patients who underwent transrectal ultrasound guided prostates biopsies were included in the study. Patients were randomized into four groups: (1) control, no method of anesthesia was administered, (2) intrarectal prilocaine-lidocaine cream application, (3) INB and (4) INB + intrarectal prilocaine-lidocaine cream application (combined group). Patients were asked to use a scale of 0-10 in a Visual Analogue Scale (VAS) questionnaire about pain during probe insertion (VAS 1) and prostate biopsy (VAS 2). RESULTS The mean VAS 1 and VAS 2 scores were 0.7 and 4.9 for controls, 0.5 and 1.8 for INB, 0.5 and 2.6 for the intrarectal cream group, and 0.4 and 1.8 for the combined group. The mean VAS 1 scores were not different between groups. However, the mean VAS 2 scores were significantly lower in INB, prilocaine-lidocaine cream and combined groups compared to the control group (P < .001). In addition, the INB group had significantly lower VAS 2 scores compared to the cream application group (P = .03). On the other hand, there was no difference between the INB and combined groups (P = .8). CONCLUSION Any form of anesthesia was superior to none. However, INB alone seemed to be superior to prilocaine-lidocaine cream application in patients undergoing prostate biopsy. Addition of prilocaine-lidocaine cream application to INB may not provide better analgesia. ",2015,"However, the mean VAS 2 scores were significantly lower in INB, prilocaine-lidocaine cream and combined groups compared to the control group (P < .001).","['patients undergoing prostate biopsy', '59 consecutive patients who underwent']","['transrectal ultrasound guided prostates biopsies', 'novel anesthetic technique called iliohypogastric nerve block (INB', 'prilocaine-lidocaine', 'prilocaine-lidocaine cream application, (3) INB and (4) INB + intrarectal prilocaine-lidocaine cream application', 'prilocaine-lidocaine cream', 'prilocaine-lidocaine cream application']","['mean VAS 1 scores', 'mean VAS 1 and VAS 2 scores', 'VAS 2 scores', 'mean VAS 2 scores', 'Visual Analogue Scale (VAS) questionnaire about pain during probe insertion (VAS 1) and prostate biopsy (VAS 2']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0002930', 'cui_str': 'Anesthesiology'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0394767', 'cui_str': 'Local anesthetic block of iliohypogastric nerve (procedure)'}, {'cui': 'C0033124', 'cui_str': 'Prilocaine'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0148052', 'cui_str': 'VA 2'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]",59.0,0.0273349,"However, the mean VAS 2 scores were significantly lower in INB, prilocaine-lidocaine cream and combined groups compared to the control group (P < .001).","[{'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Hizli', 'Affiliation': 'Department of Urology, Oncology Training and Research Hospital, 06530 Demetevler, Ankara, Turkey. fatihhizli33@yahoo.com.'}, {'ForeName': 'Güldeniz', 'Initials': 'G', 'LastName': 'Argun', 'Affiliation': ''}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Özkul', 'Affiliation': ''}, {'ForeName': 'Oguz', 'Initials': 'O', 'LastName': 'Güven', 'Affiliation': ''}, {'ForeName': 'Ali Ihsan', 'Initials': 'AI', 'LastName': 'Arik', 'Affiliation': ''}, {'ForeName': 'Sinan', 'Initials': 'S', 'LastName': 'Başay', 'Affiliation': ''}, {'ForeName': 'Aydin', 'Initials': 'A', 'LastName': 'Köşüş', 'Affiliation': ''}, {'ForeName': 'Halil', 'Initials': 'H', 'LastName': 'Günaydin', 'Affiliation': ''}, {'ForeName': 'Halil', 'Initials': 'H', 'LastName': 'Başar', 'Affiliation': ''}]",Urology journal,[] 1260,32420511,Study within a trial (SWAT) protocol. Investigating the effect of personalised versus non-personalised study invitations on recruitment: An embedded randomised controlled recruitment trial.,"Introduction Recruitment into clinical trials is a common challenge experienced by healthcare researchers. Currently, there is little evidence regarding strategies to improve recruitment into clinical trials. However, preliminary research suggests the personalisation of study invitation letters may increase recruitment rates. As such, there is a need to investigate the effectiveness of personalisation strategies on trial recruitment rates. This study within a trial (SWAT) will investigate the effect of personalised versus non-personalised study invitation letters on recruitment rates into the host trial ENGAGE, a feasibility study of an internet-administered, guided, Cognitive-Behavioural Therapy (CBT) based self-help intervention for parents of children previously treated for cancer. Methods An embedded randomised controlled trial (RCT) will investigate the effectiveness of a personalised study invitation letter including the potential participant's name and address compared with a standard, non-personalised letter without name or address, on participant recruitment rates into the ENGAGE study. The primary outcome is differences in the proportion of participants recruited, examined using logistic regression. Results will be reported as adjusted odds ratios with 95% confidence intervals. Discussion Even moderate effects of the personalisation of study invitation letters on recruitment rates could be of significant value by shortening study length, saving resources, and providing a faster answer to the clinical question posed by the study. This protocol can be used as a template for other researchers who wish to contribute to the evidence base for trial decision-making, by embedding a similar SWAT into their trial. Trial registration ISRCTN 57233429; ISRCTN 18404129; SWAT 112, Northern Ireland Hub for Trials Methodology Research SWAT repository (2018 OCT 1 1231).",2020,"Even moderate effects of the personalisation of study invitation letters on recruitment rates could be of significant value by shortening study length, saving resources, and providing a faster answer to the clinical question posed by the study.",['parents of children previously treated for cancer'],"['personalised versus non-personalised study invitation letters', 'internet-administered, guided, Cognitive-Behavioural Therapy (CBT) based self-help intervention', 'personalised versus non-personalised study invitations']",[],"[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.298338,"Even moderate effects of the personalisation of study invitation letters on recruitment rates could be of significant value by shortening study length, saving resources, and providing a faster answer to the clinical question posed by the study.","[{'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Woodford', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Psychosocial Care Programme (U-CARE), Uppsala University, Sweden.""}, {'ForeName': 'Kajsa', 'Initials': 'K', 'LastName': 'Norbäck', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Psychosocial Care Programme (U-CARE), Uppsala University, Sweden.""}, {'ForeName': 'Josefin', 'Initials': 'J', 'LastName': 'Hagström', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Psychosocial Care Programme (U-CARE), Uppsala University, Sweden.""}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Grönqvist', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Psychosocial Care Programme (U-CARE), Uppsala University, Sweden.""}, {'ForeName': 'Adwoa', 'Initials': 'A', 'LastName': 'Parker', 'Affiliation': 'Department of Health Sciences, Faculty of Sciences, York Trials Unit, University of York, United Kingdom.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Arundel', 'Affiliation': 'Department of Health Sciences, Faculty of Sciences, York Trials Unit, University of York, United Kingdom.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'von Essen', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University Psychosocial Care Programme (U-CARE), Uppsala University, Sweden.""}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100572'] 1261,32420695,"A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia.","Accumulating evidence suggests that adipose-derived stem cell constituent extract (ADSC-CE) helps hair regrowth in patients with androgenetic alopecia (AGA). However, the effects of ADSC-CE have not been demonstrated in a randomized, double-blind, vehicle-controlled clinical trial. In this randomized, double-blind, vehicle-controlled clinical trial, 38 patients (29 men) with AGA were assigned to an intervention group (IG), with twice-daily self-application of the ADSC-CE topical solution over the scalp with fingers, or to a control group (CG). Changes in hair count and thickness at 16 weeks from the baseline were evaluated using a phototrichogram. Overall, 34 (89%) patients (mean age, 45.3 years) completed the study. The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively. Similarly, a significant improvement in hair diameter was observed in the IG (14.2%) after 16 weeks when compared with hair diameter in the CG (6.3%). Our findings suggest that the application of the ADSC-CE topical solution has enormous potential as an alternative therapeutic strategy for hair regrowth in patients with AGA, by increasing both hair density and thickness while maintaining adequate treatment safety.",2020,"The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively.","['patients with androgenetic alopecia (AGA', 'androgenetic alopecia', '38 patients (29 men) with AGA']","['hair regeneration using adipose-derived stem cell constituent extract', 'adipose-derived stem cell constituent extract (ADSC-CE', 'ADSC-CE', 'intervention group (IG), with twice-daily self-application of the ADSC-CE topical solution over the scalp with fingers, or to a control group (CG']","['hair count and thickness', 'hair count', 'change of hair count', 'hair diameter']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0034963', 'cui_str': 'Regeneration'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0729650', 'cui_str': 'Constituents'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0991555', 'cui_str': 'Cutaneous solution'}, {'cui': 'C0036270', 'cui_str': 'Scalp structure'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}]",38.0,0.46629,"The phototrichogram at week 8 showed more increase in hair count in the IG than in the CG, and intergroup differences in the change of hair count remained significant until week 16 with overall changes of 28.1% vs 7.1%, respectively.","[{'ForeName': 'Young Jin', 'Initials': 'YJ', 'LastName': 'Tak', 'Affiliation': 'Department of Family Medicine, Pusan National University School of Medicine, Yangsan, South Korea.'}, {'ForeName': 'Sang Yeoup', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, South Korea.'}, {'ForeName': 'A Ra', 'Initials': 'AR', 'LastName': 'Cho', 'Affiliation': 'Department of Family Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.'}, {'ForeName': 'Young Sil', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'T-Stem, Co., Ltd, Changwon-si, South Korea.'}]",Stem cells translational medicine,['10.1002/sctm.19-0410'] 1262,26116459,Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.,"We compared an angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB) and the combination of NEB/VAL with respect to 24-hour myocardial oxygen consumption (determined by 24-hour ambulatory heart rate-central systolic pressure product [ACRPP]) and its components. Subjects with hypertension (systolic blood pressure >140 or diastolic blood pressure >90; n = 26) were studied in a double-blinded, double-dummy, forced-titration, crossover design with 3 random-order experimental periods: VAL 320 mg, NEB 40 mg, and NEB/VAL 320/40 mg daily. After 4 weeks of each drug, ambulatory pulse wave analysis (MobilOGraph) was performed every 20 minutes for 24 hours. All three treatments resulted in nearly identical brachial and central systolic blood pressures. NEB alone or in combination with VAL resulted in lower ACRPP (by 11%-14%; P < .001 each) and heart rate (by 18%-20%; P < .001 each) compared with VAL, but stroke work (ACRPP per beat) was lower with VAL. Relative and adjusted variability (standard deviation and coefficient of variation) of heart rate were also lower with NEB and NEB/VAL than VAL. Results in African Americans, the majority subpopulation, were similar to those of the entire treatment group. We conclude that the rate-slowing effects of NEB cause ambulatory cardiac myocardial oxygen consumption to be lower with NEB monotherapy or NEB/VAL combination therapy than with VAL monotherapy. NEB/VAL is not superior to NEB alone in controlling heart rate, blood pressure, or ACRPP. Heart rate variability but not ACRPP variability is reduced by NEB or the combination NEB/VAL. There is no attenuation of beta-blocker-induced rate-slowing effects of in African Americans.",2015,"NEB alone or in combination with VAL resulted in lower ACRPP (by 11%-14%; P < .001 each) and heart rate (by 18%-20%; P < .001 each) compared with VAL, but stroke work (ACRPP per beat) was lower with VAL.","['African Americans', '90; n\xa0=\xa026', 'Subjects with hypertension (systolic blood pressure >140 or diastolic blood pressure']","['NEB alone or in combination with VAL', 'NEB/VAL', 'angiotensin receptor blocker (valsartan; VAL), a beta-blocker (nebivolol; NEB', 'VAL 320 mg, NEB 40 mg, and NEB/VAL 320/40', 'nebivolol and valsartan']","['heart rate', 'lower ACRPP', 'heart rate, blood pressure, or ACRPP', '24-hour myocardial oxygen consumption', 'Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects', 'Relative and adjusted variability (standard deviation and coefficient of variation) of heart rate', 'nearly identical brachial and central systolic blood pressures']","[{'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}]","[{'cui': 'C1529218', 'cui_str': 'Vals'}, {'cui': 'C0815017', 'cui_str': 'Angiotensin Receptor Blockers'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0068475', 'cui_str': 'nebivolol'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0428863', 'cui_str': 'Myocardial oxygen consumption (observable entity)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",26.0,0.138588,"NEB alone or in combination with VAL resulted in lower ACRPP (by 11%-14%; P < .001 each) and heart rate (by 18%-20%; P < .001 each) compared with VAL, but stroke work (ACRPP per beat) was lower with VAL.","[{'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Izzo', 'Affiliation': 'Department of Medicine, State University of New York at Buffalo, Erie County Medical Center, Buffalo, NY, USA. Electronic address: jizzo@buffalo.edu.'}, {'ForeName': 'Safi U', 'Initials': 'SU', 'LastName': 'Khan', 'Affiliation': 'Department of Medicine, State University of New York at Buffalo, Erie County Medical Center, Buffalo, NY, USA.'}, {'ForeName': 'Osman', 'Initials': 'O', 'LastName': 'Saleem', 'Affiliation': 'Department of Medicine, State University of New York at Buffalo, Erie County Medical Center, Buffalo, NY, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Osmond', 'Affiliation': 'Department of Medicine, State University of New York at Buffalo, Erie County Medical Center, Buffalo, NY, USA.'}]",Journal of the American Society of Hypertension : JASH,['10.1016/j.jash.2015.03.009'] 1263,25194079,Combination of sacral neuromodulation and tolterodine for treatment of idiopathic overactive bladder in women: a clinical trial.,"PURPOSE To evaluate the efficacy of intermittent percutaneous needle sacral nerve stimulation (IPN-SNS) in women with idiopathic overactive bladder (IOAB) treated with tolterodine. MATERIALS AND METHODS A total of 240 female patients diagnosed with IOAB were randomized to receive tolterodine only treatment (group 1, n = 120) or tolterodine combined with IPN-SNS (group 2, n = 120). Each group included 120 participants, who were divided into subgroups depending on whether they had dry OAB (urinary frequency and urgency) or wet OAB (urinary frequency and urgency with urgency incontinence). In the treatment group, patients received percutaneous IPN-SNS plus tolterodine (2 mg once daily), while in the control group, only tolterodine (2 mg once daily) was administered for 3 months. The voiding diary and urodynamic parameters were monitored, and patients' psychological depression and anxiety scores were recorded before and after treatment. RESULTS There were significantly greater improvements in the conditions of first desire to void (FDV), max­imum cystometric capacity (MCC), and daily average volumes, as well as the daily single maximum voided volumes in group 2 (P = .001) than in group 1. In addition, there were significantly greater decreases in self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores in group 2 compared with group 1 (P < .001). CONCLUSION Combined treatment with tolterodine plus IPN-SNS can not only improve the symptoms of voiding dysfunction but can also reduce the concomitant depression and anxiety in women with IOAB, there­by improving patients' quality of life.",2014,"In addition, there were significantly greater decreases in self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores in group 2 compared with group 1 (P < .001). ","['120 participants, who were divided into subgroups depending on whether they had dry OAB (urinary frequency and urgency) or wet OAB (urinary frequency and urgency with urgency incontinence', '240 female patients diagnosed with IOAB', 'idiopathic overactive bladder in women', 'women with idiopathic overactive bladder (IOAB) treated with tolterodine']","['tolterodine combined with IPN-SNS', 'percutaneous IPN-SNS plus tolterodine', 'intermittent percutaneous needle sacral nerve stimulation (IPN-SNS', 'tolterodine plus IPN-SNS', 'sacral neuromodulation and tolterodine', 'tolterodine']","['conditions of first desire to void (FDV), max\xadimum cystometric capacity (MCC), and daily average volumes, as well as the daily single maximum voided volumes', 'symptoms of voiding dysfunction', 'voiding diary and urodynamic parameters', 'psychological depression and anxiety scores', 'self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0042023', 'cui_str': 'Increased frequency of urination (finding)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0021167', 'cui_str': 'Incontinence (finding)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0388753', 'cui_str': 'tolterodine'}]","[{'cui': 'C0388753', 'cui_str': 'tolterodine'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0398296', 'cui_str': 'Cannulation of vascular fistula, graft or prosthetic device (procedure)'}, {'cui': 'C2609267', 'cui_str': 'Sacral nerve stimulation'}]","[{'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0429826', 'cui_str': 'Dysfunctional voiding of urine (finding)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0222045'}]",240.0,0.0492577,"In addition, there were significantly greater decreases in self-rating depression scale (SDS) and self-rating anxiety scale (SAS) scores in group 2 compared with group 1 (P < .001). ","[{'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Tang', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China. tanghuaBM@163.com.""}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.""}, {'ForeName': 'Yongfu', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.""}, {'ForeName': 'Ting', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.""}, {'ForeName': 'Changping', 'Initials': 'C', 'LastName': 'Guo', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.""}, {'ForeName': 'Xiaoqi', 'Initials': 'X', 'LastName': 'Liao', 'Affiliation': ""Department of Urinary Surgery, The Second Hospital of Sanming, Yong'an, 366000, Fujian Province, China.""}]",Urology journal,[] 1264,25453536,Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.,"OBJECTIVES The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during symptom-limited exercise in patients with ischemic cardiomyopathy and angina. These patients may have increased vulnerability to prolongation of the systolic ejection time. BACKGROUND Omecamtiv mecarbil is a selective cardiac myosin activator that augments cardiac contractility in patients with systolic heart failure through a dose-dependent increase in systolic ejection time. METHODS In this double-blind, placebo-controlled study, patients with chronic heart failure were randomized 2:1 to receive omecamtiv mecarbil or placebo in 2 sequential cohorts of escalating doses designed to achieve plasma concentrations previously shown to increase systolic function. Patients underwent 2 symptom-limited exercise treadmill tests (ETTs) at baseline (ETT1 and ETT2) and again before the end of a 20-h infusion of omecamtiv mecarbil (ETT3). RESULTS The primary pre-defined safety endpoint (i.e., the proportion of patients who stopped ETT3 because of angina at a stage earlier than baseline) was observed in 1 patient receiving placebo and none receiving omecamtiv mecarbil. No dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of adverse events. CONCLUSIONS Doses of omecamtiv mecarbil producing plasma concentrations previously shown to increase systolic function were well tolerated during exercise in these study patients with ischemic cardiomyopathy and angina. There was no indication that treatment increased the likelihood of myocardial ischemia in this high-risk population. (Pharmacokinetics [PK] and Tolerability of Intravenous [IV] and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina; NCT00682565).",2015,"No dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of adverse events. ","['patients with chronic heart failure', 'patients with ischemic cardiomyopathy and angina', 'patients with systolic heart failure', 'Patients With Ischemic Cardiomyopathy and Angina']","['omecamtiv mecarbil during exercise', 'omecamtiv mecarbil treatment', 'placebo', 'omecamtiv mecarbil or placebo', 'Intravenous [IV] and Oral CK-1827452', '2 symptom-limited exercise treadmill tests (ETTs) at baseline (ETT1 and ETT2) and again before the end of a 20-h infusion of omecamtiv mecarbil (ETT3']","['Pharmacokinetics [PK] and Tolerability', 'Safety and tolerability', 'systolic ejection time', 'likelihood of myocardial ischemia', 'safety and tolerability', 'systolic function']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0349782', 'cui_str': 'Generalized ischemic myocardial dysfunction (disorder)'}, {'cui': 'C0002962', 'cui_str': 'Stenocardia'}, {'cui': 'C1135191', 'cui_str': 'Heart Failure, Systolic'}]","[{'cui': 'C2932035', 'cui_str': 'omecamtiv mecarbil'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C2932036', 'cui_str': 'CK 1827452'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0087110', 'cui_str': 'Treadmill Test'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0336969', 'cui_str': 'Ejection (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}, {'cui': 'C0031843', 'cui_str': 'function'}]",,0.0673008,"No dose-dependent differences emerged in the proportion of patients stopping ETT3 for any reason or in the pattern of adverse events. ","[{'ForeName': 'Barry H', 'Initials': 'BH', 'LastName': 'Greenberg', 'Affiliation': 'University of California at San Diego, San Diego, California. Electronic address: bgreenberg@ucsd.edu.'}, {'ForeName': 'Willis', 'Initials': 'W', 'LastName': 'Chou', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Khalil G', 'Initials': 'KG', 'LastName': 'Saikali', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Escandón', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Jacqueline H', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Chen', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Tatyana', 'Initials': 'T', 'LastName': 'Treshkur', 'Affiliation': 'Almazov Federal Heart Blood and Endocrinology Centre, St. Petersburg, Russia.'}, {'ForeName': 'Irakli', 'Initials': 'I', 'LastName': 'Megreladze', 'Affiliation': 'Cardiology Clinic, Tbilisi, Georgia.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Wasserman', 'Affiliation': 'Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Eisenberg', 'Affiliation': 'Amgen Inc., Thousand Oaks, California.'}, {'ForeName': 'Fady I', 'Initials': 'FI', 'LastName': 'Malik', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'Wolff', 'Affiliation': 'Cytokinetics, Inc., South San Francisco, California.'}, {'ForeName': 'Tamaz', 'Initials': 'T', 'LastName': 'Shaburishvili', 'Affiliation': 'Diagnostic Services Clinic, Tbilisi, Georgia.'}]",JACC. Heart failure,['10.1016/j.jchf.2014.07.009'] 1265,25194077,Diode laser ablation of prostate and channel transurethral resection of prostate in patients with prostate cancer and bladder outlet obstruction symptoms.,"PURPOSE To evaluate the efficacy of diode laser ablation of prostate for treating lower urinary tract symptoms (LUTS) in patients with locally advanced prostate cancer and comparing results with palli­ative transurethral resection of prostate (pTURP). MATERIALS AND METHODS Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study. Patients were randomized into two groups. The first group underwent pTURP and for the second group diode laser ablation of prostate was done. In 6 months post-operative follow up, patients were evaluated for IPSS, post void residual (PVR) urine volume, Qmax and possible complications such as urethral stricture or urinary incontinence. RESULTS Postoperatively, mean IPSS was 11.1 ± 4.1 in TURP group and 11.7 ± 3.6 in laser group (P = .64). Mean PVR was 18.4 ± 3.5 mL in TURP group and 17.7 ± 6.3 mL in laser group (P = .68). Mean Qmax in TURP and laser groups were measured 20.1 ± 4.5 mL/s and 19.4 ± 2.6 mL/s, respectively (P = .57). While there was a significant improvement in IPSS and Qmax and PVR in both groups, statisti­cal analysis did not show any significant difference postoperatively between pTURP and laser groups. CONCLUSION Diode laser ablation of prostate and pTURP, both improved significantly IPSS, PVR and Qmax. But hospital stay and post-operative catheterization time was less in laser group.",2014,"While there was a significant improvement in IPSS and Qmax and PVR in both groups, statisti­cal analysis did not show any significant difference postoperatively between pTURP and laser groups. ","['patients with prostate cancer and bladder outlet obstruction symptoms', 'Thirty-six known cases of locally advanced prostate cancer with a maximum urinary flow rate (Qmax) of 12 mL per second or less and an International Prostate Symptom Score (IPSS) of 20 or more were included in this study', 'patients with locally advanced prostate cancer']","['Diode laser ablation of prostate and channel transurethral resection of prostate', 'palli\xadative transurethral resection of prostate (pTURP', 'diode laser ablation of prostate', 'pTURP', 'TURP', 'Diode laser ablation of prostate and pTURP']","['IPSS, post void residual (PVR) urine volume, Qmax and possible complications such as urethral stricture or urinary incontinence', 'IPSS, PVR and Qmax', 'Mean PVR', 'But hospital stay and post-operative catheterization time', 'mean IPSS', 'Mean Qmax', 'IPSS and Qmax and PVR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C0005694', 'cui_str': 'Bladder Outlet Obstruction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4319606', 'cui_str': 'Thirty-six'}, {'cui': 'C0205309', 'cui_str': 'Known (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0429783', 'cui_str': 'Urinary flow rate (observable entity)'}, {'cui': 'C0565930', 'cui_str': '/s'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score (assessment scale)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}]","[{'cui': 'C0392254', 'cui_str': 'Semiconductor Diode Lasers'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0033572', 'cui_str': 'Prostate'}, {'cui': 'C0439799', 'cui_str': 'Channel (qualifier value)'}, {'cui': 'C0040771', 'cui_str': 'Prostatectomy, Transurethral'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0429774', 'cui_str': 'Residual urine volume (observable entity)'}, {'cui': 'C0332149', 'cui_str': 'Possible (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C4551691', 'cui_str': 'Urethral stricture (disorder)'}, {'cui': 'C0042024', 'cui_str': 'Urinary Incontinence'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C1632851', 'cui_str': 'Times'}]",36.0,0.0288237,"While there was a significant improvement in IPSS and Qmax and PVR in both groups, statisti­cal analysis did not show any significant difference postoperatively between pTURP and laser groups. ","[{'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Javanmard', 'Affiliation': 'Department of Laser Application in Medical Sciences Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences.Tehran, Iran. dr_javanmard@yahoo.com.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Hassanzadeh Haddad', 'Affiliation': 'Department of Laser Application in Medical Sciences Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences.Tehran, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Yaghoobi', 'Affiliation': 'Department of Laser Application in Medical Sciences Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences.Tehran, Iran.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Lotfi', 'Affiliation': 'Department of Laser Application in Medical Sciences Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences.Tehran, Iran.'}]",Urology journal,[] 1266,31888709,"A randomised controlled trial of an exercise intervention promoting activity, independence and stability in older adults with mild cognitive impairment and early dementia (PrAISED) - A Protocol.","BACKGROUND People with dementia progressively lose cognitive and functional abilities. Interventions promoting exercise and activity may slow decline. We developed a novel intervention to promote activity and independence and prevent falls in people with mild cognitive impairment (MCI) or early dementia. We successfully undertook a feasibility randomised controlled trial (RCT) to refine the intervention and research delivery. We are now delivering a multi-centred RCT to evaluate its clinical and cost-effectiveness. METHODS We will recruit 368 people with MCI or early dementia (Montreal Cognitive Assessment score 13-25) and a family member or carer from memory assessment clinics, other community health or social care venues or an online register (the National Institute for Health Research Join Dementia Research). Participants will be randomised to an individually tailored activity and exercise programme delivered using motivational theory to promote adherence and continued engagement, with up to 50 supervised sessions over one year, or a brief falls prevention assessment (control). The intervention will be delivered in participants' homes by trained physiotherapists, occupational therapists and therapy assistants. We will measure disabilities in activities of daily living, physical activity, balance, cognition, mood, quality of life, falls, carer strain and healthcare and social care use. We will use a mixed methods approach to conduct a process evaluation to assess staff training and delivery of the intervention, and to identify individual- and context-level mechanisms affecting intervention engagement and activity maintenance. We will undertake a health economic evaluation to determine if the intervention is cost-effective. DISCUSSION We describe the protocol for a multi-centre RCT that will evaluate the clinical and cost-effectiveness of a therapy programme designed to promote activity and independence amongst people living with dementia. TRIAL REGISTRATION ISRCTN, ISRCTN15320670. Registered on 4 September 2018.",2019,We developed a novel intervention to promote activity and independence and prevent falls in people with mild cognitive impairment (MCI) or early dementia.,"['people living with dementia', ""participants' homes by trained physiotherapists, occupational therapists and therapy assistants"", '368 people with MCI or early dementia (Montreal Cognitive Assessment score 13-25) and a family member or carer from memory assessment clinics, other community health or social care venues or an online register (the National Institute for Health Research Join Dementia Research', 'people with mild cognitive impairment (MCI) or early dementia', 'older adults with mild cognitive impairment and early dementia (PrAISED) - A Protocol']","['individually tailored activity and exercise programme delivered using motivational theory to promote adherence and continued engagement, with up to 50 supervised sessions over one year, or a brief falls prevention assessment (control', 'exercise intervention']","['disabilities in activities of daily living, physical activity, balance, cognition, mood, quality of life, falls, carer strain and healthcare and social care use']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist (occupation)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0560005', 'cui_str': 'millicurie'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0439045', 'cui_str': 'Memory assessment finding'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0419189', 'cui_str': 'Social care (regime/therapy)'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035168'}, {'cui': 'C1270972', 'cui_str': 'Mild Neurocognitive Disorder'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention (procedure)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0034380'}, {'cui': 'C0000921', 'cui_str': 'Falls'}, {'cui': 'C1305660', 'cui_str': 'Carer (occupation)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0419189', 'cui_str': 'Social care (regime/therapy)'}, {'cui': 'C1947944', 'cui_str': 'Use'}]",,0.15019,We developed a novel intervention to promote activity and independence and prevent falls in people with mild cognitive impairment (MCI) or early dementia.,"[{'ForeName': 'Rupinder K', 'Initials': 'RK', 'LastName': 'Bajwa', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK. Rupinder.Bajwa@nottingham.ac.uk.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Goldberg', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Van der Wardt', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Burgon', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Di Lorito', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Godfrey', 'Affiliation': 'Patient and Public Involvement Collaborator, Nottingham, UK.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Dunlop', 'Affiliation': 'Patient and Public Involvement Collaborator, Nottingham, UK.'}, {'ForeName': 'Pip', 'Initials': 'P', 'LastName': 'Logan', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Tahir', 'Initials': 'T', 'LastName': 'Masud', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gladman', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Smith', 'Affiliation': 'Mental Health Services for Older People, Nottinghamshire Healthcare NHS Foundation Trust, Highbury Hospital, Nottingham, NG6 9RD, UK.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Hood-Moore', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Booth', 'Affiliation': 'Divison of Rehabilitation, Ageing and Wellbeing, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'Das Nair', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, NG8 1BB, UK.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Pollock', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Vedhara', 'Affiliation': 'Division of Primary Care, University of Nottingham, Nottingham, NG7 2RD, UK.'}, {'ForeName': 'Rhiannon Tudor', 'Initials': 'RT', 'LastName': 'Edwards', 'Affiliation': 'Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, LL57 2PZ, UK.'}, {'ForeName': 'Carys', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, LL57 2PZ, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Hoare', 'Affiliation': 'North Wales Organisation for Randomised Trials in Health Clinical Trials Unit (NWORTH CTU), Bangor University, Bangor, LL57 2PZ, Wales, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Brand', 'Affiliation': 'North Wales Organisation for Randomised Trials in Health Clinical Trials Unit (NWORTH CTU), Bangor University, Bangor, LL57 2PZ, Wales, UK.'}, {'ForeName': 'Rowan H', 'Initials': 'RH', 'LastName': 'Harwood', 'Affiliation': 'School of Health Sciences, University of Nottingham, Nottingham, NG7 2UH, UK.'}]",Trials,['10.1186/s13063-019-3871-9'] 1267,31400231,Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.,"BACKGROUND AND PURPOSE Chronic inflammatory demyelinating polyneuropathy (CIDP) causes weakness which adversely impacts function and quality of life (QOL). CIDP often requires long-term management with intravenous or subcutaneous immunoglobulin. The Polyneuropathy and Treatment with Hizentra® (PATH) study showed that subcutaneous immunoglobulin (SCIG) was efficacious in CIDP maintenance. Here, patient-reported outcomes in patients on SCIG are assessed. METHODS Subjects stabilized on intravenous immunoglobulin were randomly allocated to receive weekly 0.2 or 0.4 g/kg bodyweight of 20% SCIG (IgPro20) or placebo. Overall QOL/health status was assessed using the EuroQoL 5-Dimension (EQ-5D) health profile and visual analog scale, treatment satisfaction was assessed with the Treatment Satisfaction Questionnaire for Medicine (TSQM) and work-related impact was assessed with the Work Productivity and Activity Impairment Questionnaire for General Health (WPAI-GH). The EQ-5D health profile was assessed in terms of the percentage of subjects maintained or improved at week 25 of SCIG therapy on each of the EQ-5D domains versus baseline after intravenous immunoglobulin stabilization. TSQM and WPAI-GH were assessed by median score changes from baseline to week 25. RESULTS In total, 172 subjects were randomized to placebo (n = 57), 0.2 g/kg IgPro20 (n = 57) and 0.4 g/kg IgPro20 (n = 58). Significantly higher proportions of IgPro20-treated subjects improved/maintained their health status on the EQ-5D usual activities dimension, and in additional dimensions (mobility and pain/discomfort) in sensitivity analyses. TSQM and WPAI-GH scores were more stable with IgPro20 treatment compared with placebo. CONCLUSIONS IgPro20 maintained or improved QOL in most subjects with CIDP, consistent with the PATH study findings that both IgPro20 doses were efficacious in maintaining CIDP.",2020,"Significantly higher proportions of IgPro20-treated subjects improved/maintained their health status on the EQ-5D usual activities dimension, and in additional dimensions (mobility and pain/discomfort) in sensitivity analyses.","['172 subjects', 'Subjects stabilised on IVIG', 'chronic inflammatory demyelinating polyneuropathy']","['subcutaneous immunoglobulin (SCIG', 'kg bodyweight of 20% SCIG (IgPro20) or placebo', 'placebo', 'subcutaneous immunoglobulin', 'IgPro20-treated', 'intravenous or subcutaneous immunoglobulin']","['EQ-5D health profile', 'TSQM and WPAI-GH scores', 'Overall QOL/health status', 'TSQM and WPAI-GH', 'EQ-5D usual activities dimension, and in additional dimensions (mobility and pain/discomfort', 'quality of life (QOL', 'EuroQoL 5-Dimension Questionnaire (EQ-5D) health profile and visual analog scale (VAS), treatment satisfaction with the Treatment Satisfaction Questionnaire for Medicine (TSQM), and work-related impact with the Work Productivity and Activity Impairment Questionnaire for General Health']","[{'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}, {'cui': 'C0085297', 'cui_str': 'Immunoglobulins, Intravenous'}, {'cui': 'C0393819', 'cui_str': 'Inflammatory Polyradiculopathy, Chronic'}]","[{'cui': 'C1522438', 'cui_str': 'SC use'}, {'cui': 'C0021027', 'cui_str': 'Immune Globulins'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3181507', 'cui_str': 'IgPro20'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0018759', 'cui_str': 'Level of Health'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0439534', 'cui_str': 'Dimensions (qualifier value)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C0684336', 'cui_str': 'Impairment (finding)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",172.0,0.135729,"Significantly higher proportions of IgPro20-treated subjects improved/maintained their health status on the EQ-5D usual activities dimension, and in additional dimensions (mobility and pain/discomfort) in sensitivity analyses.","[{'ForeName': 'H-P', 'Initials': 'HP', 'LastName': 'Hartung', 'Affiliation': 'Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Mallick', 'Affiliation': 'CSL Behring LLC, King of Prussia, PA, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Bril', 'Affiliation': 'Ellen and Martin Prosserman Centre for Neuromuscular Diseases, Division of Neurology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada.'}, {'ForeName': 'R A', 'Initials': 'RA', 'LastName': 'Lewis', 'Affiliation': 'Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Sobue', 'Affiliation': 'Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.'}, {'ForeName': 'J-P', 'Initials': 'JP', 'LastName': 'Lawo', 'Affiliation': 'CSL Behring, Marburg, Germany.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Mielke', 'Affiliation': 'CSL Behring, Marburg, Germany.'}, {'ForeName': 'B L', 'Initials': 'BL', 'LastName': 'Durn', 'Affiliation': 'CSL Behring LLC, King of Prussia, PA, USA.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Cornblath', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'I S J', 'Initials': 'ISJ', 'LastName': 'Merkies', 'Affiliation': 'Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'ForeName': 'I N', 'Initials': 'IN', 'LastName': 'van Schaik', 'Affiliation': 'Department of Neurology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of neurology,['10.1111/ene.14056'] 1268,25529904,Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation.,"Blockade of the inflammatory cytokine tumor necrosis factor (TNF) in depressed patients with increased inflammation has been associated with decreased depressive symptoms. Nevertheless, the impact of TNF blockade on sleep in depressed patients has not been examined. Accordingly, sleep parameters were measured using polysomnography in 36 patients with treatment resistant major depression at baseline and 2weeks after 3 infusions (week 8) of either the TNF antagonist infliximab (n=19) or placebo (n=17). Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors were also assessed along with depression measured by the 17-item Hamilton Depression Rating Scale. No differences in sleep parameters were found as a function of infliximab treatment over time. Nevertheless, wake after sleep onset (WASO), the spontaneous arousal index and sleep period time significantly decreased, and sleep efficiency significantly increased, from baseline to week 8 in infliximab-treated patients with high (CRP>5mg/L) (n=9) versus low inflammation (CRP⩽5mg/L) (n=10), controlling for changes in scores of depression. Stage 2 sleep also significantly decreased in infliximab-treated patients with high versus low inflammation. Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation. Placebo-treated subjects exhibited no sleep changes as a function of inflammation, and no correlations between inflammatory markers and sleep parameters in placebo-treated patients were found. These data suggest that inhibition of inflammation may be a viable strategy to improve sleep alterations in patients with depression and other disorders associated with increased inflammation.",2015,Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation.,"['36 patients with treatment resistant major depression at baseline and 2weeks after 3 infusions (week 8) of either the', 'patients with depression and other disorders associated with increased inflammation', 'patients with treatment resistant depression and high inflammation']","['Placebo', 'TNF antagonist infliximab', 'TNF blockade', 'placebo']","['sleep parameters', 'sleep alterations', 'soluble TNF receptor 1 (sTNFR1', 'spontaneous arousal index and sleep period time', '17-item Hamilton Depression Rating Scale', 'WASO', 'Markers of inflammation including c-reactive protein (CRP) and TNF and its soluble receptors', 'inflammatory markers and sleep parameters', 'sleep efficiency', 'Stage 2 sleep']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0243076', 'cui_str': 'antagonists'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0147226', 'cui_str': 'tumor necrosis factor receptor type I, P55 soluble fragment'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}]",36.0,0.0227431,Decreases in soluble TNF receptor 1 (sTNFR1) significantly correlated with decreases in WASO and increases in sleep efficiency in infliximab-treated subjects with high inflammation.,"[{'ForeName': 'Jeremy F', 'Initials': 'JF', 'LastName': 'Weinberger', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Charles L', 'Initials': 'CL', 'LastName': 'Raison', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Rye', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Amy R', 'Initials': 'AR', 'LastName': 'Montague', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Bobbi J', 'Initials': 'BJ', 'LastName': 'Woolwine', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Felger', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Haroon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Department of Neurology, Emory University School of Medicine, Atlanta, GA 30322, United States. Electronic address: amill02@emory.edu.'}]","Brain, behavior, and immunity",['10.1016/j.bbi.2014.12.016'] 1269,31664479,The effects of alcohol on sequential decision-making biases during gambling.,"RATIONALE Gambling and alcohol use are recreational behaviours that share substantial commonalities at a phenomenological, clinical and neurobiological level. Past studies have shown that alcohol can have a disinhibiting effect on gambling behaviour, in terms of bet size and persistence. OBJECTIVES This study was conducted in order to characterise how alcohol affects biases in judgment and decision-making that occur during gambling, with a focus on sequential decision-making including the gambler's fallacy. METHODS Sequential biases were elicited via a roulette-based gambling task. Using a standard between-groups alcohol challenge procedure, male participants played the roulette task 20 min after receiving an alcoholic (0.8 g/kg; n = 22) or placebo (n = 16) beverage. The task measured colour choice decisions (red/black) and bet size, in response to varying lengths of colour runs and winning/losing feedback streaks. RESULTS Across both groups, a number of established sequential biases were observed. On colour choice, there was an effect of run length in line with the gambler's fallacy, which further varied by previous feedback (wins vs losses). Bet size increased with feedback streaks, especially for losing streaks. Compared to placebo, the alcohol group placed higher bets following losses compared to wins. CONCLUSIONS Increased bet size after losses following alcohol consumption may reflect increased loss chasing that may amplify gambling harms. Our results do not fit a simple pattern of enhanced gambling distortions or reward sensitivity, but help contextualise the effects of alcohol on gambling to research on decision-making biases.",2020,"Compared to placebo, the alcohol group placed higher bets following losses compared to wins. ",['male participants played the roulette task 20 min after receiving an alcoholic (0.8 g/kg; n = 22) or'],"['placebo', 'alcohol']","['Bet size increased with feedback streaks', 'task measured colour choice decisions (red/black) and bet size, in response to varying lengths of colour runs and winning/losing feedback streaks']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0687725', 'cui_str': 'Alcoholics'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C1300563', 'cui_str': 'ug/mg'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}]","[{'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0332575', 'cui_str': 'Red color (finding)'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}]",,0.0488115,"Compared to placebo, the alcohol group placed higher bets following losses compared to wins. ","[{'ForeName': 'Juliette', 'Initials': 'J', 'LastName': 'Tobias-Webb', 'Affiliation': 'Department of Psychology, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK.'}, {'ForeName': 'Eve H', 'Initials': 'EH', 'LastName': 'Limbrick-Oldfield', 'Affiliation': 'Department of Psychology, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Vearncombe', 'Affiliation': 'Cambridgeshire and Peterborough NHS Foundation Trust, Elizabeth House, Fulbourn Hospital, Cambridge, CB21 5EF, UK.'}, {'ForeName': 'Theodora', 'Initials': 'T', 'LastName': 'Duka', 'Affiliation': 'Behavioural and Clinical Neuroscience, School of Psychology, University of Sussex, Pevensey I Building, Falmer, Brighton, BN1 9QH, UK.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Clark', 'Affiliation': 'Department of Psychology, University of Cambridge, Downing Street, Cambridge, CB2 3EB, UK. luke.clark@psych.ubc.ca.'}]",Psychopharmacology,['10.1007/s00213-019-05376-z'] 1270,31122890,Understanding of different front-of-package labels by the Spanish population: Results of a comparative study.,"BACKGROUND AND OBJECTIVES Increased prevalence of obesity and its comorbidities has shown the need to implement social policies to help curb this trend. Nutritional risk factors are recognized as key drivers of obesity and other chronic diseases in Spain and in other Western countries. Front-of-package labels (FoPLs) are efficient tools to help consumers make healthier choices. To be useful in purchasing situations, consumers need to understand the information provided by FoPLs. The study objective was to assess objective understanding by consumers of five types of FoPLs, i.e. Health Star Rating system (HSR), Multiple Traffic Lights (MTL), Nutri-Score, Reference Intakes (RIs), and Warning symbol in Spain. METHODS In 2018, 1,000 Spanish participants were recruited and requested to rank three sets of label-free products (one set of three pizzas, one set of three cakes, and one set of three breakfast cereals) according to their nutritional quality in an on-line survey. Participants were then randomized to one of the five types of FoPLs, and were requested to rank the same sets of products again, this time with a given FoPL displayed on the package. Changes in ability to correctly rank products according to FoPLs were compared between both tasks using ordinal logistic regression. RESULTS For all three food categories, Nutri-Score performed significantly better, followed by MTL, the Warning symbol, HSR and RIs. CONCLUSIONS Nutri-Score emerged as the most efficient FoPL in conveying information on the nutritional quality of foods among Spanish consumers.",2020,"For all three food categories, Nutri-Score performed significantly better, followed by MTL, the Warning symbol, HSR and RIs. ","['Spanish population', 'In 2018, 1,000 Spanish participants were recruited and requested to rank three sets of label-free products (one set of three pizzas, one set of three cakes, and one set of three breakfast cereals) according to their nutritional quality in an on-line survey']",['Front-of-package labels (FoPLs'],"['Health Star Rating system (HSR), Multiple Traffic Lights (MTL), Nutri-Score, Reference Intakes (RIs), and Warning symbol in Spain']","[{'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0699794', 'cui_str': 'Rank (attribute)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0453577', 'cui_str': 'Pizza (substance)'}, {'cui': 'C0452597', 'cui_str': 'Cake (substance)'}, {'cui': 'C0452557', 'cui_str': 'Breakfast cereal (substance)'}, {'cui': 'C3489446', 'cui_str': 'Nutritional Quality'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C1704710', 'cui_str': 'Package'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0442664', 'cui_str': 'Traffic light (physical object)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]",1000.0,0.0259254,"For all three food categories, Nutri-Score performed significantly better, followed by MTL, the Warning symbol, HSR and RIs. ","[{'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Galan', 'Affiliation': 'Sorbonne Paris Cité Epidemiology and Statistics Research Center (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, Francia. Electronic address: galan@uren.smbh.univ-paris13.fr.'}, {'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Egnell', 'Affiliation': 'Sorbonne Paris Cité Epidemiology and Statistics Research Center (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, Francia.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': ""Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, España; Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Hospital Universitari San Joan de Reus, Institut d'Investigació Pere Virgili (IISPV), Reus, España.""}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Babio', 'Affiliation': ""Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Madrid, España; Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Hospital Universitari San Joan de Reus, Institut d'Investigació Pere Virgili (IISPV), Reus, España.""}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Pettigrew', 'Affiliation': 'School of Psychology, Curtin University, Bentley, Australia.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Hercberg', 'Affiliation': 'Sorbonne Paris Cité Epidemiology and Statistics Research Center (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, Francia; Public Health Department, Avicenne Hospital, AP-HP, Bobigny, Francia.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Julia', 'Affiliation': 'Sorbonne Paris Cité Epidemiology and Statistics Research Center (CRESS), Nutritional Epidemiology Research Team (EREN), Bobigny, Francia; Public Health Department, Avicenne Hospital, AP-HP, Bobigny, Francia.'}]","Endocrinologia, diabetes y nutricion",['10.1016/j.endinu.2019.03.013'] 1271,25194085,A prospective interventional study in chronic prostatitis with emphasis to clinical features.,"PURPOSE Chronic bacterial prostatitis displays a variety of symptoms (mainly local pain exhibiting vari­ability in origin and intensity). These symptoms often persist despite bacterial eradication. The purpose of this article is to exam the role of phytotherapeutic agents as complementary treatment in patients with bacterial prostatitis. MATERIALS AND METHODS The material consisted of individuals with reported pelvic discomfort and genital pain with or without lower urinary tract symptoms (LUTS) and sexual dysfunction visiting our department from March 2009 to March 2011. Patients underwent Stamey-Meares test (several cases underwent the two glass test). Depending on history and specific symptoms urethral smear and semen cultures were additionally obtained from several patients. All patients were randomized into two groups. Subjects in the first group (72 patients) received appropriate antibiotic (according to the sensitivity test) for 15 days, while subjects in the second group (72 patients) received phytotherapeutic agents for 30 days, additionally the conventional 15 days antibiotic treatment. The response was tested using laboratory and clinical criteria. RESULTS We found no statistically significant differences between the two groups regarding bacterial and symptom persistence rate, however, symptoms burden was lower in patients receiving combinational treatment. CONCLUSION Phytotherapeutic agents may improve pain and prostatitis related difficulty in urination. Further randomized, placebo-controlled studies are needed to substantiate safer conclusions.",2014,"We found no statistically significant differences between the two groups regarding bacterial and symptom persistence rate, however, symptoms burden was lower in patients receiving combinational treatment. ","['patients with bacterial prostatitis', 'individuals with reported pelvic discomfort and genital pain with or without lower urinary tract symptoms (LUTS) and sexual dysfunction visiting our department from March 2009 to March 2011']","['appropriate antibiotic', 'phytotherapeutic agents', 'placebo']","['bacterial and symptom persistence rate', 'symptoms burden']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0748023', 'cui_str': 'Prostatitis caused by bacteria'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C1535975', 'cui_str': 'Pelvic discomfort'}, {'cui': 'C0239725', 'cui_str': 'Genital pain'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder (disorder)'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0546816', 'cui_str': 'Persistence (finding)'}]",,0.013775,"We found no statistically significant differences between the two groups regarding bacterial and symptom persistence rate, however, symptoms burden was lower in patients receiving combinational treatment. ","[{'ForeName': 'Konstantinos Nikolaos', 'Initials': 'KN', 'LastName': 'Stamatiou', 'Affiliation': 'Department of Urology, Tzaneio Hospital, Pireas, Greece. stamatiouk@gmail.com.'}, {'ForeName': 'Hippocrates', 'Initials': 'H', 'LastName': 'Moschouris', 'Affiliation': 'Department of Urology, Tzaneio Hospital, Pireas,Greece.'}]",Urology journal,[] 1272,24078509,Autologous fibrin sealant in tubeless percutaneous nephrolithotomy; a prospective study.,"PURPOSE To evaluate the efficacy of autologous single-donor fibrin glue after tubeless percutaneous nephrolithotomy (PCNL). MATERIALS AND METHODS Forty-three patients were planned for tubeless PCNL in a prospective cohort study and randomized in two groups with or without using fibrin glue. Randomization method was based on the computer-generated random numbers. RESULTS Transfusion, urinary leakage, or major complications were found in neither of the groups. There was no difference between two groups in stone free rate (P = .53), and changes in hemoglobin (P = .61) and serum creatinine (P = .63) level. CONCLUSION Although autologous fibrin glue did not play any significant role in improving results or decreasing complications after tubeless PCNL in our study, its use was safe and did not increase complications.",2013,"There was no difference between two groups in stone free rate (P = .53), and changes in hemoglobin (P = .61) and serum creatinine (P = .63) level. CONCLUSION ","['tubeless percutaneous nephrolithotomy', 'Forty-three patients were planned for']","['Autologous fibrin sealant', 'fibrin glue', 'autologous single-donor fibrin glue after tubeless percutaneous nephrolithotomy (PCNL', 'tubeless PCNL', 'autologous fibrin glue']","['Transfusion, urinary leakage, or major complications', 'changes in hemoglobin', 'serum creatinine', 'stone free rate']","[{'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1301732', 'cui_str': 'Planned'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0016004', 'cui_str': 'Fibrin Glue'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}]","[{'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum (procedure)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}]",43.0,0.0179847,"There was no difference between two groups in stone free rate (P = .53), and changes in hemoglobin (P = .61) and serum creatinine (P = .63) level. CONCLUSION ","[{'ForeName': 'Seyyed Amir Mohsen', 'Initials': 'SA', 'LastName': 'Ziaee', 'Affiliation': 'Urology and Nephrology Research Center, No. 103, 9th Boustan St., Pasdaran Ave., Tehran, Iran. nouralizadeh@yahoo.com.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Sarhangnejad', 'Affiliation': ''}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Abolghasemi', 'Affiliation': ''}, {'ForeName': 'Peyman', 'Initials': 'P', 'LastName': 'Eshghi', 'Affiliation': ''}, {'ForeName': 'Mohammad Hadi', 'Initials': 'MH', 'LastName': 'Radfar', 'Affiliation': ''}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahanian', 'Affiliation': ''}, {'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Kardoust Parizi', 'Affiliation': ''}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Amirizadeh', 'Affiliation': ''}, {'ForeName': 'Akbar', 'Initials': 'A', 'LastName': 'Nouralizadeh', 'Affiliation': ''}]",Urology journal,[] 1273,24807748,Blind versus fluoroscopy-guided percutaneous nephrolithotomy: a randomized clinical trial.,"PURPOSE Due to the negative impact of radiation on the patient and the surgical team during percutaneous nephrolithotomy (PCNL), we aimed to evaluate success rate and complications of blind access for PCNL using lumbar notch landmark and compare with conventional fluoroscopy-guided access. MATERIALS AND METHODS In a clinical trial, 100 patients who were candidate for PCNL, were randomly assigned into blind group (1) and fluoroscopy-guided group (2). In group 1 the lumbar notch was used to guide percutaneous access and in group 2 fluoroscopy performed after needle insertion, Amplatz placement and at the end of surgery. If the access failed, we would repeat puncturing up to 5 times. In group 2, access was achieved using full fluoroscopy guidance. All patients underwent postoperative assessment including kidney-ureter-bladder X-ray and ultrasonography. RESULTS Both mean access time and mean operation time were statically similar in group 1 and group 2 (3.3 ± 0.5 vs. 3.6 ± 0.7 min and 35.2 ± 4.6 vs. 38.9 ± 4.1 min, respectively). A successful puncture was achieved in 86% and 94% of the patients in groups 1 and 2, respectively (P = .18). Total success rate of procedure was 80% and 88% of the patients in groups 1 and 2, respectively (P = .27). CONCLUSION According to this study, it seems that blind access is a safe and effective PCNL method, and we recommend employment of this technique by skilled endourologist in urology centers especially for patient with large hydronephrotic kidney.",2014,"A successful puncture was achieved in 86% and 94% of the patients in groups 1 and 2, respectively (P = .18).","['100 patients who were candidate for PCNL', 'patient with large hydronephrotic kidney']","['conventional fluoroscopy-guided access', 'percutaneous nephrolithotomy (PCNL', 'postoperative assessment including kidney-ureter-bladder X-ray and ultrasonography', 'fluoroscopy-guided percutaneous nephrolithotomy', 'fluoroscopy-guided group']","['successful puncture', 'mean access time and mean operation time', 'Total success rate of procedure']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0041951', 'cui_str': 'Ureter'}, {'cui': 'C0005682', 'cui_str': 'Bladder'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]",100.0,0.0641436,"A successful puncture was achieved in 86% and 94% of the patients in groups 1 and 2, respectively (P = .18).","[{'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Karami', 'Affiliation': 'Urology and Nephrology Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. karami_hosein@yahoo.com.'}, {'ForeName': 'Mohammad Mohsen', 'Initials': 'MM', 'LastName': 'Mazloomfard', 'Affiliation': 'Department of Urology, Medical Laser Application Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. mazloomfard@yahoo.com.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Moeini', 'Affiliation': 'Infertility and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Mohammadhosseini', 'Affiliation': 'Urology and Nephrology Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. drmohammadhosseini@yahoo.com.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Rezaei', 'Affiliation': 'Urology and Nephrology Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences,Tehran,Iran.'}, {'ForeName': 'Behzad', 'Initials': 'B', 'LastName': 'Lotfi', 'Affiliation': 'Department of Urology, Medical Laser Application Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}]",Urology journal,[] 1274,32075612,The effect of educational intervention program on promoting preventive behaviors of urinary tract infection in girls: a randomized controlled trial.,"BACKGROUND Urinary tract infection is one of the most common infectious diseases in children, which can lead to serious complications for a child. The purpose of this study was to investigate the impact of Theory Planned Behavior (TPB) -based education on the promotion of preventive behaviors of urinary tract infection in mothers with a daughter under age two. METHODS The present study is an educational randomized controlled trial that its sample consisted of 100 mothers who had a daughter under age two. They were selected through convenience sampling and then were randomly assigned to the intervention and control groups (each group included 50 participants). The data collection tool was a reliable and valid questionnaire based on TPB constructs. First, in both groups, the pre-test was administrated and then the educational intervention in the intervention group was conducted in the form of four educational sessions in 1 month (based on the pre-test need assessment) and then 3 months after the intervention (according to the ideas of Panel of Experts), post-test in both groups was administrated and then the data were analyzed through SPSS version 23 software with inferential statistics (independent t-test, paired t-test, and chi-square). The significance level was considered 0.05. RESULTS Three months after the intervention, the mean score of the constructs of TPB in the intervention group was significantly higher than the control group. The performance of prevention of urinary tract infection in the intervention group before the education increased from 2.85 ± 0.51 to 3.74 ± 0.29 (out of 4) (p = 0.001). CONCLUSIONS TPB-based education with active and interventional follow-up was effective in promoting the preventive behaviors of urinary tract infection. Therefore, due to the side effects of UTI, especially in vulnerable periods such as childhood, it is recommended that trainings based on this model be carried out in other health care centers in order to maintain children health. TRIAL REGISTRATION This trial has been registered at IRCT, IRCT2017031533090N1. Registered on 9 July 2017, https://en.irct.ir/trial/25621.",2020,"Three months after the intervention, the mean score of the constructs of TPB in the intervention group was significantly higher than the control group.","['mothers with a daughter under age two', '100 mothers who had a daughter under age two', 'urinary tract infection in girls']","['Theory Planned Behavior (TPB) -based education', 'educational intervention program']","['mean score of the constructs of TPB', 'performance of prevention of urinary tract infection']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0011011', 'cui_str': 'Daughter'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}]",,0.0536381,"Three months after the intervention, the mean score of the constructs of TPB in the intervention group was significantly higher than the control group.","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Health Education, Faculty of Health, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Shamsi', 'Affiliation': 'Department of Health Education and Health Promotion, Faculty of Health, Arak University of Medical Sciences, Arak, Iran. mohsen_shamsi1360@yahoo.com.'}, {'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Roozbahani', 'Affiliation': 'Department of Health Education and Health Promotion, Faculty of Health, Arak University of Medical Sciences, Arak, Iran.'}, {'ForeName': 'Rahmatollah', 'Initials': 'R', 'LastName': 'Moradzadeh', 'Affiliation': 'Department of Epidemiology, Faculty of Health, Arak University of Medical Sciences, Arak, Iran.'}]",BMC pediatrics,['10.1186/s12887-020-1981-x'] 1275,24595939,Success rate and patients' satisfaction following intradetrusor dysport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity.,"PURPOSE To evaluate the efficacy of intradetrusor Dysport (a type of botulinum toxin type A) injection in patients with idiopathic or neurogenic detrusor overactivity, who were refractory to antimuscarinic drugs, and to compare the efficacy of Dysport injection in both groups. MATERIALS AND METHODS Twelve patients with neurogenic detrusor overactivity (NDO) and 18 patients with idiopathic detrusor overactivity (IDO) participated in this study. All the patients received intravesical injection of 500 units of Dysport. They were followed up for 3 months after injection with maximum cystometric capacity, maximum detrusor filling pressure, and number of catheterization or pad usage. RESULTS After 3 months, the mean maximum cystometric capacity increased from 109.36 ± 24.11 mL to 266.81 ± 97.18 mL (P = .000) in the NDO group and from 192.24 ± 36.21 mL to 272.61 ± 63.37 mL (P = .000) in the IDO group. The mean maximum detrusor filling pressure decreased from 48.14 ± 26.51 cmH2O to 28.91 ± 9.01 cmH2O (P = .005) in the NDO group and from 39.22 ± 9.92 cmH2O to 29.64 ± 10.14 cmH2O (P = .003) in the IDO group. CONCLUSION Intradetrusor Dysport injection improved urodynamic parameters and quality of life (QoL) in both groups significantly. We did not find significant difference in QoL or urodynamic parameters between both groups.",2014,We did not find significant difference in QoL or urodynamic parameters between both groups.,"['Twelve patients with neurogenic detrusor overactivity (NDO) and 18 patients with idiopathic detrusor overactivity (IDO) participated in this study', 'patients with detrusor overactivity', 'patients with idiopathic or neurogenic detrusor overactivity, who were refractory to antimuscarinic drugs']","['intradetrusor Dysport', 'botulinum toxin type A) injection']","['maximum detrusor filling pressure, and number of catheterization or pad usage', 'mean maximum detrusor filling pressure', 'urodynamic parameters and quality of life (QoL', 'QoL or urodynamic parameters', 'mean maximum cystometric capacity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1536696', 'cui_str': 'Overactivity'}, {'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C4521482', 'cui_str': 'Antimuscarinic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0591427', 'cui_str': 'Dysport'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0441601', 'cui_str': 'Padding (qualifier value)'}, {'cui': 'C0457083', 'cui_str': 'Usage (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0034380'}, {'cui': 'C0429809', 'cui_str': 'Maximum cystometric capacity (observable entity)'}]",12.0,0.0371964,We did not find significant difference in QoL or urodynamic parameters between both groups.,"[{'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Shakeri', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Mohammadian', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Aminsharifi', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ariafar', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Jalal', 'Initials': 'J', 'LastName': 'Vaghedashti', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Yazdani', 'Affiliation': 'Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Mahnaz', 'Initials': 'M', 'LastName': 'Yadollahi', 'Affiliation': 'Trauma research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Emadmarvasti', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Baharikhoob', 'Affiliation': 'Urology and Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Urology journal,[] 1276,24595941,"Percutaneous nerve evaluation (PNE) for treatment of non-obstructive urinary retention: urodynamic changes, placebo effects, and response rates.","PURPOSE To evaluate the results of percutaneous nerve evaluation (PNE) implantation in the treatment of non-obstructive urinary retention and report the changes in the urodynamic parameters. MATERIALS AND METHODS Patients with non-obstructive urinary retention or incomplete bladder emptying were included. All patients filled a 7 days voiding diary chart and underwent PNE for one week, and the patient was asked to record the second voiding diary chart and repeat urodynamic study in this period. Then the PNE lead was removed from the S3 foramen, but the connections remained fixed in place for another 3 days to exclude the placebo effects and the third voiding diary chart was completed by the patient. The patient wasn't aware of lead removal. Success was defined as, more than 50% improvement in at least one of the urinary tract symptoms. RESULTS Forty five patients with a mean age of 37.1 years (ranged 9-83 years) were treated with PNE for refractory, non-obstructive urinary retention. Of study subjects 28 complained from complete urinary retention, and 17 had incomplete emptying. Of participants, 28 (62.2%) demonstrated greater than 50% improvement in the urinary symptoms. Urodynamic data, showed a statistically significant increase in maximum flow rate (8 ± 2.2 mL/sec to 16 ± 3.6 mL/sec, P = .06) and voided volume (35 mL to 187 mL, P = .032) in the responders. Any placebo effects in PNE have not been seen. CONCLUSION Patients with complete non obstructive urinary retention were good responders to PNE. The placebo effect in sacral nerve stimulation was negligible.",2014,"Urodynamic data, showed a statistically significant increase in maximum flow rate (8 ± 2.2 mL/sec to 16 ± 3.6 mL/sec, P = .06) and voided volume (35 mL to 187 mL, P = .032) in the responders.","['Forty five patients with a mean age of 37.1 years (ranged 9-83 years', 'Of study subjects 28 complained from complete urinary retention, and 17 had incomplete emptying', 'Patients with non-obstructive urinary retention or incomplete bladder emptying were included']","['PNE', 'placebo', 'percutaneous nerve evaluation (PNE) implantation', 'Percutaneous nerve evaluation (PNE']","['obstructive urinary retention', 'maximum flow rate', 'urinary symptoms', 'voided volume', 'urinary tract symptoms', 'sacral nerve stimulation']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C0205257', 'cui_str': 'Incomplete (qualifier value)'}, {'cui': 'C0205304', 'cui_str': 'Non-obstructive (qualifier value)'}, {'cui': 'C0344365', 'cui_str': 'Incomplete emptying of bladder (finding)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0027740', 'cui_str': 'Nerve structure'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}]","[{'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C0426359', 'cui_str': 'Urinary symptoms (finding)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0042027'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2609267', 'cui_str': 'Sacral nerve stimulation'}]",28.0,0.111949,"Urodynamic data, showed a statistically significant increase in maximum flow rate (8 ± 2.2 mL/sec to 16 ± 3.6 mL/sec, P = .06) and voided volume (35 mL to 187 mL, P = .032) in the responders.","[{'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Sharifiaghdas', 'Affiliation': 'Department of Urology, Shaheed Labbafinejad Medical Center, Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences Tehran, Iran.'}, {'ForeName': 'Mahboubeh', 'Initials': 'M', 'LastName': 'Mirzaei', 'Affiliation': 'Department of Urology, Shaheed Labbafinejad Medical Center, Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences Tehran, Iran.mirzaeimahboubeh@yahoo.com.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Ahadi', 'Affiliation': 'Department of Urology, Shaheed Labbafinejad Medical Center, Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences Tehran, Iran.'}]",Urology journal,[] 1277,24595942,The effect of garlic powder on human urinary cytokine excretion.,"PURPOSE To evaluate the effects of orally administered dehydrated garlic powder on cytokine excretion in the urinary tract. MATERIALS AND METHODS A total of 60 healthy volunteers, randomized into 3 groups, were given a single oral dose of 1 g or 3 g of dehydrated garlic powder or placebo. Urine samples were obtained 6.0 and 24.0 h after garlic intake and assayed for interleukin-8 (IL-8), interleukin- 12 (IL-12), tumor necrosis factor-alpha (TNF-α), diallyl disulfide (DADS) and diallyl sulfide (DAS). RESULTS Significant increases in IL-12 levels over baseline were noted in urine samples obtained after oral intake of 1 g and 3 g of garlic powder (P < .001). In the 1 g and 3 g garlic powder treatment groups, time-dependent variations in IL-12 levels over the study period were significantly different from the placebo group (P < .001). In both garlic treatment groups, urinary levels of IL-8 and TNF-α were not significantly different from baseline and placebo levels (P > .017). DADS and DAS were not detected in the urine samples at any time after garlic powder intake. CONCLUSION Oral intake of doses of garlic traditionally used for daily supplementation increases urinary levels of IL-12, which is a potent stimulator of T helper cell 1 (Th-1) immune responses. This observation encourages further studies investigating the immunostimulatory role of garlic in the urinary tract.",2014,"In both garlic treatment groups, urinary levels of IL-8 and TNF-α were not significantly different from baseline and placebo levels (P > .017).",['60 healthy volunteers'],"['dehydrated garlic powder', 'placebo', 'garlic powder', 'garlic', 'dehydrated garlic powder or placebo']","['DADS and DAS', 'IL-12 levels', 'interleukin-8 (IL-8), interleukin- 12 (IL-12), tumor necrosis factor-alpha (TNF-α), diallyl disulfide (DADS) and diallyl sulfide (DAS', 'urinary levels of IL-12', 'cytokine excretion', 'urinary levels of IL-8 and TNF-α', 'human urinary cytokine excretion', 'time-dependent variations in IL-12 levels']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1119842', 'cui_str': 'GARLIC POWDER'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0885057', 'cui_str': 'Garlic preparation'}]","[{'cui': 'C0051767', 'cui_str': 'DASD'}, {'cui': 'C0123759', 'cui_str': 'Interleukin-12'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0057693', 'cui_str': 'allyl disulfide'}, {'cui': 'C0051235', 'cui_str': 'allyl sulfide'}, {'cui': 'C0243173', 'cui_str': 'urinary levels'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}]",60.0,0.235471,"In both garlic treatment groups, urinary levels of IL-8 and TNF-α were not significantly different from baseline and placebo levels (P > .017).","[{'ForeName': 'Ergun', 'Initials': 'E', 'LastName': 'Alma', 'Affiliation': 'Department of Urology, Ceyhan State Hospital, Ceyhan, Adana, Turkey.almaerim@yahoo.com.'}, {'ForeName': 'Alper', 'Initials': 'A', 'LastName': 'Eken', 'Affiliation': 'Department of Urology, Acibadem Adana Hospital, Adana, Turkey.'}, {'ForeName': 'Hakan', 'Initials': 'H', 'LastName': 'Ercil', 'Affiliation': 'Department of Urology, Adana Numune Education and Research Hospital, Adana, Turkey.'}, {'ForeName': 'Kazim', 'Initials': 'K', 'LastName': 'Yelsel', 'Affiliation': 'Department of Urology, Viransehir State Hospital, Viransehir, Urfa, Turkey.'}, {'ForeName': 'Nebile', 'Initials': 'N', 'LastName': 'Daglioglu', 'Affiliation': 'Department of Forensic Medicine, Cukurova University Adana, Turkey.'}]",Urology journal,[] 1278,24626145,Daily Automated Telephone Assessment and Intervention Improved 1-Month Outcome in Paroled Offenders.,"This randomized trial evaluates whether automated telephony could be used to perform daily assessments in paroled offenders ( N = 108) during their first 30 days after leaving prison. All subjects were called daily and answered assessment questions. Based on the content of their daily assessments, subjects in the intervention group received immediate feedback and a recommendation by automated telephony, and their probation officers also received a daily report by email. The outcome variables were analyzed using linear mixed models. The intervention group showed greater improvement than the control group in the summary scores ( M = 9.6, 95% confidence interval [CI] = [0.5, 18.7], p = .038), in mental symptoms ( M = 4.6, CI = [0.2, 9.0], p = .042), in alcohol drinking ( M = 0.8, CI = [0.1, 1.4], p = .031), in drug use ( M = 1.0, CI = [0.5, 1.6], p = .000), and in most stressful daily event ( M = 1.9, CI = [1.1, 2.7], p = .000). In conclusion, automated telephony may be used to follow up and to give interventions, resulting in reduced stress and drug use, in paroled offenders.",2020,"The intervention group showed greater improvement than the control group in the summary scores (M = 9.6, 95% confidence interval [CI] = [0.5, 18.7], p = .038), in mental symptoms (M = 4.6, CI = [0.2, 9.0], p = .042), in alcohol drinking (M = 0.8, CI = [0.1, 1.4], p = .031), in drug use (M = 1.0, CI = [0.5, 1.6], p = .000), and in most stressful daily event (M = 1.9, CI = [1.1, 2.7], p = .000).",['paroled offenders (N = 108) during their first 30 days after leaving prison'],"['automated telephony', 'immediate feedback and a recommendation by automated telephony, and their probation officers also received a daily report by email', 'Daily Automated Telephone Assessment and Intervention']",['mental symptoms'],"[{'cui': 'C0699726', 'cui_str': 'Offenders'}, {'cui': 'C4517530', 'cui_str': 'One hundred and eight'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0401946', 'cui_str': 'Probation officer (occupation)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0498334,"The intervention group showed greater improvement than the control group in the summary scores (M = 9.6, 95% confidence interval [CI] = [0.5, 18.7], p = .038), in mental symptoms (M = 4.6, CI = [0.2, 9.0], p = .042), in alcohol drinking (M = 0.8, CI = [0.1, 1.4], p = .031), in drug use (M = 1.0, CI = [0.5, 1.6], p = .000), and in most stressful daily event (M = 1.9, CI = [1.1, 2.7], p = .000).","[{'ForeName': 'Claes', 'Initials': 'C', 'LastName': 'Andersson', 'Affiliation': 'Malmö University, Sweden.'}, {'ForeName': 'Zoran', 'Initials': 'Z', 'LastName': 'Vasiljevic', 'Affiliation': 'Malmö University, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Höglund', 'Affiliation': 'Lund University, Sweden.'}, {'ForeName': 'Agneta', 'Initials': 'A', 'LastName': 'Öjehagen', 'Affiliation': 'Lund University, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Berglund', 'Affiliation': 'Lund University, Sweden.'}]",International journal of offender therapy and comparative criminology,['10.1177/0306624X14526800'] 1279,24469649,Mini-laparoscopic live donor nephrectomy: initial series.,"PURPOSE To present the safety and surgical outcomes of the initial series of mini-laparoscopic live donor nephrectomy and graft outcomes in related recipients. MATERIALS AND METHODS From January 2012 through July 2012, fifty patients underwent minilaparoscopic live donor nephrectomy. Two 3.5 mm trocars were inserted above and lateral to the umbilicus for grasping and scissoring. One 5 mm trocar with a camera was inserted in the umbilicus and an 11 mm trocar was inserted through fascia from a 6-8 cm Pfannenstiel incision for bipolar coagulation, kidney extraction, and vascular clip applier. RESULTS Mean age of donors was 28 ± 4.2 (range, 21-39) years. Mean operative time from trocar insertion was 145.8 (range, 85-210) minutes. No major perioperative or postoperative complications occurred. The average decrease in hemoglobin level was 1.14 (range, 0.32-1.8) mg/dL and no one required blood transfusion. Mean warm ischemia time was 4.41 (range, 2.35- 9) minutes. Mean hospital stay was 2.2 (range, 2-5) days. Mean follow-up time of the recipients was 215 (range, 130-270) days. The mean serum creatinine level of the recipients at discharge time and the last follow-up visit was 1.38 mg/dL and 1.22 mg/dL, respectively. CONCLUSIONS While the primary purpose of this technique is to make donor nephrectomy less invasive and more cosmetic, it is also comfortable for the laparoscopist surgeons because it is nearly similar to standard laparoscopy. A randomized controlled trial with a large sample size, long-term follow-up, and comparison with standard laparoscopy are necessary to present more definitive data about this technique.",2014,No major perioperative or postoperative complications occurred.,"['From January 2012 through July 2012, fifty patients underwent', 'Mean age of donors was 28 ± 4.2 (range, 21-39) years', 'related recipients']","['standard laparoscopy', 'One 5 mm trocar with a camera was inserted in the umbilicus and an 11 mm trocar was inserted through fascia from a 6-8 cm Pfannenstiel incision for bipolar coagulation, kidney extraction, and vascular clip applier', 'Mini-laparoscopic live donor nephrectomy', 'mini-laparoscopic live donor nephrectomy', 'minilaparoscopic live donor nephrectomy']","['Mean warm ischemia time', 'Mean hospital stay', 'major perioperative or postoperative complications', 'hemoglobin level', 'Mean operative time from trocar insertion', 'blood transfusion', 'mean serum creatinine level']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C4517758', 'cui_str': 'Four point two'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031150', 'cui_str': 'Celioscopy'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0179533', 'cui_str': 'Camera'}, {'cui': 'C1881217', 'cui_str': 'Insert - unit of product usage'}, {'cui': 'C0041638', 'cui_str': 'Umbilicus'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0457819', 'cui_str': 'Pfannenstiel incision (procedure)'}, {'cui': 'C0443156', 'cui_str': 'Bipolar (qualifier value)'}, {'cui': 'C0441509', 'cui_str': 'Coagulation - action (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0185115', 'cui_str': 'Extraction - action (qualifier value)'}, {'cui': 'C0179992', 'cui_str': 'Vascular clip'}, {'cui': 'C0445542', 'cui_str': 'Mini (qualifier value)'}, {'cui': 'C4039558', 'cui_str': 'Laparoscopic live donor nephrectomy'}, {'cui': 'C0401187', 'cui_str': 'Donation of kidney'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1563923', 'cui_str': 'Warm Ischemic Time'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}, {'cui': 'C0600061', 'cui_str': 'Serum creatinine level - finding'}]",,0.0618621,No major perioperative or postoperative complications occurred.,"[{'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Simforoosh', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences. simforoosh@iurtc.org.ir.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Soltani', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Seyed Hossein', 'Initials': 'SH', 'LastName': 'Hosseini Sharifi', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ahanian', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Lashay', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Davood', 'Initials': 'D', 'LastName': 'Arab', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}, {'ForeName': 'Samad', 'Initials': 'S', 'LastName': 'Zare', 'Affiliation': 'Urology and Nephrology Research Center, Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences.'}]",Urology journal,[] 1280,24078500,Comparative study between three analgesic agents for the pain management during extracorporeal shock wave lithotripsy.,"PURPOSE To compare the clinical efficacy between locally applied diclofenac diethylamine gel, EMLA cream and systemically given diclofenac sodium for the pain relief during extracorporeal shock wave lithotripsy (SWL) using Dornier Delta Compact Lithotripter. MATERIAL AND METHODS One hundred five patients with renal stones were randomly divided in to 3 groups. Group A was given intramuscular diclofenac sodium (1 mg/kg), 45 minutes before the procedure. In group B, 10 gm of eutectic mixture of local anesthetic (EMLA) cream and in group C, 15 gm of diclofenac diethylamine gel was applied locally 45 minutes before the procedure. Ten-score linear and visual analogue scale (VAS) was used to assess the severity of pain during the procedure. Analysis of variance (ANOVA) test was used to compare various parameters and analyzed statistically. RESULTS All the three groups were not statistically different with respect to age, weight, stone size, number of shock wave delivered and maximum voltage used (P > .05). The mean pain score in group A was 4.48, in group B was 3.60 and in group C was 3.95, which were not significantly different (P = 1.34). Complication like skin lesion was found only in injection diclofenac sodium group whereas cold sensation at the local site was typically found in diclofenac diethylamine gel group. CONCLUSION Although not statistically significant, the mean pain score in locally applied analgesic agents (EMLA and diclofenac diethylamine gel) is lower as compared to intramuscularly given diclofenac sodium. Among these two locally acting drugs, diclofenac diethylamine gel is an equally effective alternative to EMLA.",2013,"All the three groups were not statistically different with respect to age, weight, stone size, number of shock wave delivered and maximum voltage used (P > .05).",['One hundred five patients with renal stones'],"['intramuscular diclofenac sodium', 'diclofenac diethylamine gel', 'eutectic mixture of local anesthetic (EMLA) cream', 'diclofenac sodium', 'diclofenac diethylamine gel, EMLA cream', 'extracorporeal shock wave lithotripsy']","['severity of pain', 'mean pain score', 'pain relief', 'Complication like skin lesion', 'cold sensation', 'visual analogue scale (VAS']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022650', 'cui_str': 'Kidney Stones'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0700583', 'cui_str': 'Diclofenac Sodium'}, {'cui': 'C0771369', 'cui_str': 'diclofenac diethylammonium'}, {'cui': 'C0017243', 'cui_str': 'Gel (basic dose form)'}, {'cui': 'C0059079', 'cui_str': 'EMLA'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0360032', 'cui_str': 'EMLA Cream'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal Shockwave Lithotripsy'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0037284', 'cui_str': 'Skin lesion (disorder)'}, {'cui': 'C0009443', 'cui_str': 'Common Cold'}, {'cui': 'C0036658', 'cui_str': 'Sensory Function'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",105.0,0.0117417,"All the three groups were not statistically different with respect to age, weight, stone size, number of shock wave delivered and maximum voltage used (P > .05).","[{'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Yun-Jiang Zang, Department of Urologic Surgery, Weifang People's Hospital, 151 Guangwen Street, Kuiwen District, Weifang, Shandong, China. yunshanzang@gmail.com.""}, {'ForeName': 'Yun-Jiang', 'Initials': 'YJ', 'LastName': 'Zang', 'Affiliation': ''}]",Urology journal,[] 1281,24078507,Unwanted intra-operative penile erection during pediatric hypospadiasis repair. Comparison of propofol and halothane.,"PURPOSE To compare the erectile effect of propofol and halothane on unwanted intraoperative penile erection (UIOPE) during pediatric hypospadiasis repair. MATERIALS AND METHODS One hundred and seventeen boys who were in the age range of 6 months to 6 years and referred for hypospadiasis repair to our referral teaching hospital were included in this randomized clinical trial. Patients were randomly assigned to one of the two study groups before anesthesia induction. Anesthesia was maintained with a continuous intravenous infusion of propofol and inhalational halothane in the propofol (P) and halothane (H) groups, respectively. Data regarding the patients’ age, weight, pre- and intra-operative chordee, UIOPE, anesthesia time, surgery time, hematoma formation, and wound infection were collected. The Chi-Square and Fisher’s exact tests were used for comparison. RESULTS No statistically significant differences were noted regarding age, weight, and pre and intra-operative chordee between the two groups. The incidence of UIOPE (10.34% versus 57.63%; P = .000), anesthesia time (174.15 +/- 15.02 versus 181.26 +/- 15.19; P =.012), and surgery time (162.34 +/- 12.99 versus 167.69 +/- 13.90 +/- 13.90; P = .034) were significantly lower in group P compared with group H. CONCLUSION The use of propofol during hypospadiasis surgical repair is more safe and effective than halothane in preventing UIOPE and reducing surgery and anesthesia time.",2013,"No statistically significant differences were noted regarding age, weight, and pre and intra-operative chordee between the two groups.","['pediatric hypospadiasis repair', 'One hundred and seventeen boys who were in the age range of 6 months to 6 years and referred for hypospadiasis repair to our referral teaching hospital']","['halothane', 'propofol and halothane', 'propofol and inhalational halothane', 'propofol (P) and halothane (H', 'propofol']","['patients’ age, weight, pre- and intra-operative chordee, UIOPE, anesthesia time, surgery time, hematoma formation, and wound infection', 'age, weight, and pre and intra-operative chordee', 'anesthesia time', 'incidence of UIOPE', 'surgery time', 'intraoperative penile erection (UIOPE']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0020027', 'cui_str': 'Teaching Hospitals'}]","[{'cui': 'C0018549', 'cui_str': 'Halothane'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0221182', 'cui_str': 'Chordee (disorder)'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0043241', 'cui_str': 'Wound Infection'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative (qualifier value)'}, {'cui': 'C0030847', 'cui_str': 'Penile Erection'}]",117.0,0.0299388,"No statistically significant differences were noted regarding age, weight, and pre and intra-operative chordee between the two groups.","[{'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Abbasi', 'Affiliation': 'Department of Anesthesiology and Critical Care Medicine, Parsian Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. mr-hajiesmaeili@razi.tums.ac.ir.'}, {'ForeName': 'Seyed Soheil', 'Initials': 'SS', 'LastName': 'Ben Razavi', 'Affiliation': ''}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Hajiesmaeili', 'Affiliation': ''}, {'ForeName': 'Shekoufeh', 'Initials': 'S', 'LastName': 'Behdad', 'Affiliation': ''}, {'ForeName': 'Mohammad Mehdi', 'Initials': 'MM', 'LastName': 'Ghiamat', 'Affiliation': ''}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Eghbali', 'Affiliation': ''}]",Urology journal,[] 1282,24717394,"The effectiveness of the WHO training course on complementary feeding counseling in a primary care setting, Ismailia, Egypt.","BACKGROUND The adequacy and timing of complementary feeding of the breastfed child are critical for optimal child growth and development.Considerable efforts have been made to improve complementary feeding in the first 2 years of life. One of them was the WHO complementary feeding counseling course (CFC). OBJECTIVES To evaluate the effectiveness of the WHO CFC on knowledge and counseling abilities of primary healthcare physicians; on caretaker's knowledge and adherence to physicians' recommendations and their feeding practices; and on children's growth. PARTICIPANTS AND INTERVENTIONS A single-blinded randomized-controlled study was carried out in 40 primary healthcare centers divided into matched pairs according to their location, either in rural or urban areas, and training of the selected physicians on integrated management of childhood illness. One center from each pair was selected randomly for its physician to receive CFC training in nutrition counseling and the matched center was selected as a control. Forty primary healthcare center physicians and 480 mother-child (6-18 months) pairs were included in the study. The mother-child pairs recruited were visited at home within 2 weeks, 90, and 180 days after the initial consultation with trained health workers. Special questionnaires were used to collect information on healthcare providers' knowledge of nutrition counseling and practice (counseling skills); maternal knowledge of basic nutrition-counseling recommendations, maternal compliance with the recommended feeding practice; child dietary intake; and gains in weight and length. RESULTS CFC-trained physicians were more likely to engage in nutrition counseling and to deliver more appropriate advice. This was reflected in improvements in maternal recall of complementary feeding messages, which were higher in the intervention group compared with the control group. Six months after the consultation, children in the intervention group had significantly greater weight gains compared with the control group (0.96 vs. 0.78 kg; P=0.038). Children in the intervention group, who were 12-18 months of age at the time of recruitment, had significantly less faltering in length gain compared with the control group (height/age Z-score; 0.23 vs. 0.04; P=0.004). CONCLUSION AND RECOMMENDATIONS Nutrition counseling training improved counseling abilities of primary healthcare physicians and led to improvements in mothers' knowledge and practices of complementary feeding. In turn, this led to improved growth of children. We recommend wide and regular utilization of the CFC course to improve the knowledge and skills of health workers who provide counseling to mothers for complementary feeding.",2014,Nutrition counseling training improved counseling abilities of primary healthcare physicians and led to improvements in mothers' knowledge and practices of complementary feeding.,"['primary healthcare physicians', '40 primary healthcare centers divided into matched pairs according to their location, either in rural or urban areas, and training of the selected physicians on integrated management of childhood illness', 'mother-child pairs recruited were visited at home within 2 weeks, 90, and 180 days after the initial consultation with trained health workers', 'Forty primary healthcare center physicians and 480 mother-child (6-18 months) pairs were included in the study']","['nutrition counseling and practice (counseling skills); maternal knowledge of basic nutrition-counseling recommendations, maternal compliance with the recommended feeding practice; child dietary intake', 'CFC training in nutrition counseling', 'Nutrition counseling training', 'WHO CFC']","['weight gains', ""mothers' knowledge and practices of complementary feeding"", 'counseling abilities', 'maternal recall of complementary feeding messages', 'faltering in length gain']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C3714365', 'cui_str': 'Counseling about nutrition'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0038847', 'cui_str': 'Complementary Feeding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C1444754', 'cui_str': 'Length property'}]",40.0,0.0224969,Nutrition counseling training improved counseling abilities of primary healthcare physicians and led to improvements in mothers' knowledge and practices of complementary feeding.,"[{'ForeName': 'Hesham', 'Initials': 'H', 'LastName': 'El-Sayed', 'Affiliation': 'Departments of aPediatrics bFamily Medicine, Faculty of Medicine, Suez Canal University, Ismailia cMinistry of Health and Population, Cairo, Egypt dDepartment of Child and Adolescent Health and Development, World Health Organization (WHO), Geneva, Switzerland.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Martines', 'Affiliation': ''}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Rakha', 'Affiliation': ''}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Zekry', 'Affiliation': ''}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Abdel-Hak', 'Affiliation': ''}, {'ForeName': 'Hanan', 'Initials': 'H', 'LastName': 'Abbas', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000443990.46047.a6'] 1283,24717395,"Efficacy of a psychosocial intervention for parents of children with attention deficit hyperactivity disorder, Alexandria, Egypt.","BACKGROUND Childhood attention deficit hyperactivity disorder (ADHD) is a chronic disorder that carries an immense amount of suffering for its victims, their families, and communities. The efficacy of behavioral parent training in the treatment of ADHD has been supported in several studies. OBJECTIVE To evaluate the efficacy of a predesigned culturally sensitive psychosocial intervention program for parents of ADHD children in Alexandria, Egypt. PARTICIPANTS AND METHODS A pretest-post-test intervention study was carried out at the Child Mental Health Clinic for School Students affiliated to the Health Insurance Organization, Alexandria. The intervention aimed at improving parents' knowledge of ADHD, building their skills in effective parenting, stress management and problem-solving, as well as providing social support. All the participants (50 parents) were assigned to groups, each of five to eight parents. They received a total of eight sessions on a weekly basis. The program was evaluated immediately after completion and 2 months later using the Arabic Version of Conners' Rating Scale to identify ADHD and to assess its severity, Home Situations Questionnaire, Parenting Scale, the Arabic Version of Depression Anxiety Stress Scales (DASS), and parental ADHD-related knowledge questionnaire were used. RESULTS There was a statistically significant decrease in the mean total scores recorded by parents on Conners' Rating Scale (P<0.001), Home Situations Questionnaire (P<0.05), Parenting Scale (P<0.001), and DASS (P<0.001) immediately after program completion and 2 months later compared with that reported before program initiation. The total scores of participants on the ADHD-related knowledge questionnaire increased significantly after attending the program (P<0.001). CONCLUSION AND RECOMMENDATIONS Provision of a psychosocial intervention program for parents of ADHD children proved to be effective in reducing perceived severity of the symptoms and problem situations, as well as improving parents' knowledge, discipline practices, and psychological well-being.",2014,"The total scores of participants on the ADHD-related knowledge questionnaire increased significantly after attending the program (P<0.001). ","['parents of ADHD children', 'A pretest-post-test intervention study was carried out at the Child Mental Health Clinic for School Students affiliated to the Health Insurance Organization, Alexandria', 'parents of ADHD children in Alexandria, Egypt', 'parents of children with attention deficit hyperactivity disorder, Alexandria, Egypt', 'participants (50 parents']","['behavioral parent training', 'predesigned culturally sensitive psychosocial intervention program', 'psychosocial intervention']","['total scores of participants on the ADHD-related knowledge questionnaire', ""Arabic Version of Conners' Rating Scale to identify ADHD and to assess its severity, Home Situations Questionnaire, Parenting Scale, the Arabic Version of Depression Anxiety Stress Scales (DASS), and parental ADHD-related knowledge questionnaire"", ""Conners' Rating Scale (P<0.001), Home Situations Questionnaire (P<0.05), Parenting Scale (P<0.001), and DASS"", 'mean total scores']","[{'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}, {'cui': 'C3839912', 'cui_str': 'Mental health clinic'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}]","[{'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0222045'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",50.0,0.0162963,"The total scores of participants on the ADHD-related knowledge questionnaire increased significantly after attending the program (P<0.001). ","[{'ForeName': 'Zeinab N', 'Initials': 'ZN', 'LastName': 'Shata', 'Affiliation': 'aMental Health bSchool Health Specialty, Department of Family Health, High Institute of Public Health, Alexandria, Egypt.'}, {'ForeName': 'Mervat W', 'Initials': 'MW', 'LastName': 'Abu-Nazel', 'Affiliation': ''}, {'ForeName': 'Sawsan I', 'Initials': 'SI', 'LastName': 'Fahmy', 'Affiliation': ''}, {'ForeName': 'Amira A', 'Initials': 'AA', 'LastName': 'El-Dawaiaty', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000443989.38424.d4'] 1284,24717399,"Zinc status and dietary intake of pregnant women, Alexandria, Egypt.","BACKGROUND AND OBJECTIVES Deficiencies of protein, energy, and micronutrients are highly prevalent in developing countries and have major effects on pregnancy outcome. Low dietary intake is the most common reason for zinc deficiency. The present research is part of a larger double-blind randomized-controlled trial to evaluate the effect of zinc supplementation on the pregnancy outcome. The aim of the present study was to assess the zinc status and dietary intake of zinc and other macronutrients and micronutrients among pregnant women in Alexandria, Egypt. PARTICIPANTS AND METHODS Participants were pregnant women attending two antenatal care centers that serve low-income and middle-income pregnant populations. A total of 1055 healthy pregnant women aged 20-45 years were assessed for eligibility. Of these, only 675 had serum zinc level below the median for the gestational age. They were assigned randomly to one of three parallel groups. Zinc supplements were provided from 16 weeks until delivery. A subsample of 100 women was assessed for their dietary intake. A questionnaire interview was used to collect basic socioeconomic and data on current pregnancy and labor. Dietary data were collected using the 24-h recall method and a food frequency questionnaire. The nutritive value of the daily diet was computed using the Egyptian food composition tables. The blood hemoglobin level, serum zinc level, and fasting blood sugar were determined. RESULTS Zinc deficiency was detected among 53.5% of the sample. Dietary intake of zinc was low, representing 59.4, 59.4, and 62% of the recommended dietary allowance (RDA) for the zinc group, zinc plus multivitamins, and the placebo group, respectively. The iron intake was below 50% of the RDA. Protein intake was less than 70% of the RDA. The mean intakes of fat were 191.97, 211.8, and 196.3 g/day for the three groups. The mean energy intake represented 51.1, 53.5, and 49.8% of the RDA. CONCLUSION AND RECOMMENDATIONS Except for carbohydrate intake, the dietary intake of all macronutrients and micronutrients was low. The lowest intake was of iron (below 50% of the RDA). Zinc and protein intake represented less than 70% of the RDA. The overall energy intake was around 50% of the RDA. Nutritional health education should be used as a preventive approach to allow the large sector of the low-income population to maximize the use of the limited resources in the best way. In women at high risk of zinc deficiency, zinc supplementation should be added to the routine supplements.",2014,"The mean intakes of fat were 191.97, 211.8, and 196.3 g/day for the three groups.","['pregnant women in Alexandria, Egypt', 'Participants were pregnant women attending two antenatal care centers that serve low-income and middle-income pregnant populations', '1055 healthy pregnant women aged 20-45 years', 'A subsample of 100 women was assessed for their dietary intake', 'pregnant women, Alexandria, Egypt']","['zinc and other macronutrients and micronutrients', 'placebo', 'zinc supplementation']","['Zinc and protein intake', 'iron intake', 'blood hemoglobin level, serum zinc level, and fasting blood sugar', 'Protein intake', 'Dietary intake of zinc', 'overall energy intake', 'mean energy intake', 'serum zinc level', 'Zinc deficiency', 'Zinc status and dietary intake', 'mean intakes of fat']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]","[{'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0282575', 'cui_str': 'Micronutrients'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}]","[{'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0518043', 'cui_str': 'Iron intake (observable entity)'}, {'cui': 'C0005768'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1318315', 'cui_str': 'Serum zinc measurement'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0235950', 'cui_str': 'Zinc deficiency (disorder)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}]",1055.0,0.0629994,"The mean intakes of fat were 191.97, 211.8, and 196.3 g/day for the three groups.","[{'ForeName': 'Noha E', 'Initials': 'NE', 'LastName': 'Naem', 'Affiliation': 'aMinistry of Health (MOH) bDepartments of Nutrition cFamily Health, High Institute of Public Health, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Nawal M', 'Initials': 'NM', 'LastName': 'El-Sayed', 'Affiliation': ''}, {'ForeName': 'Samia A', 'Initials': 'SA', 'LastName': 'Nossier', 'Affiliation': ''}, {'ForeName': 'Azza A', 'Initials': 'AA', 'LastName': 'Abu Zeid', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000443987.44261.9b'] 1285,25015597,Percutaneous nephrolithotomy: is distilled water as safe as saline for irrigation?,"PURPOSE To compare dilutional effect of distilled water with saline solution as an irrigation fluid in percutaneous nephrolithotomy (PCNL). MATERIALS AND METHODS Three hundred twenty eight adult patients (191 men, 137 women) who were candidates for PCNL were randomly assigned into two groups (distilled water, n = 158, group 1; saline solution, n = 162, group 2). Stone size, operation time, irrigation fluid volume, blood hemoglobin level, urea nitrogen, creatinine, sodium and potassium levels were checked before and at 6 and 12 hours after operation. RESULTS The mean age of the patients was 37.8 years, and the mean stone diameter was 31.5 mm. There was no clinical case of transurethral resection (TUR) syndrome. Serum sodium depletion was significantly more in group 1 than group 2 (P < .0001). Group 1 had significant decreased post-operative serum sodium levels (P < .0003). Similarly in group 2, postoperative serum sodium levels were significantly lower than the preoperative concentration (P < .01), but it was not the same 6 hours after the operation (P = .23). Serum sodium concentrations remained within normal limits in all cases, without causing clinical signs and symptoms of hyponatremia. CONCLUSION We found that distilled water is safe irrigation fluid for PCNL in adults. In addition, it is more available and cost effective.",2014,"Similarly in group 2, postoperative serum sodium levels were significantly lower than the preoperative concentration (P < .01), but it was not the same 6 hours after the operation (P = .23).","['percutaneous nephrolithotomy (PCNL', 'adults', 'Three hundred twenty eight adult patients (191 men, 137 women) who were candidates for PCNL']","['distilled water with saline solution', 'Percutaneous nephrolithotomy', 'saline solution']","['post-operative serum sodium levels', 'postoperative serum sodium levels', 'mean stone diameter', 'Serum sodium concentrations', 'Stone size, operation time, irrigation fluid volume, blood hemoglobin level, urea nitrogen, creatinine, sodium and potassium levels', 'transurethral resection (TUR) syndrome', 'Serum sodium depletion']","[{'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4517569', 'cui_str': 'One hundred and thirty-seven'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0790233', 'cui_str': 'Distilled water'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0162428', 'cui_str': 'Nephrolithotomy, Percutaneous'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0523891', 'cui_str': 'Sodium measurement, serum (procedure)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0006736', 'cui_str': 'Biliary or Urinary Stones'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0449454', 'cui_str': 'Stone size'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C2746010', 'cui_str': 'Irrigating solution'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0005768'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1291218', 'cui_str': 'Urea nitrogen (substance)'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0428289', 'cui_str': 'Finding of potassium level (finding)'}, {'cui': 'C0349610', 'cui_str': 'TUR syndrome'}, {'cui': 'C0333668', 'cui_str': 'Depletion (morphologic abnormality)'}]",328.0,0.0194401,"Similarly in group 2, postoperative serum sodium levels were significantly lower than the preoperative concentration (P < .01), but it was not the same 6 hours after the operation (P = .23).","[{'ForeName': 'Mohammad Mehdi', 'Initials': 'MM', 'LastName': 'Hosseini', 'Affiliation': 'Department of Urology, Endourology Division, Urology Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Hassanpour', 'Affiliation': 'Department of Urology, Endourology Division, Urology Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. hassanpour74@yahoo.com.'}, {'ForeName': 'Farhad', 'Initials': 'F', 'LastName': 'Manaheji', 'Affiliation': 'Department of Urology, Endourology Division, Urology Nephrology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Yousefi', 'Affiliation': 'Department of Urology,Jahrom University of Medical Sciences, Jahrom, Iran.'}, {'ForeName': 'Mohammad Hassan', 'Initials': 'MH', 'LastName': 'Damshenas', 'Affiliation': 'Department of Anesthesiology, Jahrom University of Medical Sciences, Jahrom, Iran.'}, {'ForeName': 'Sezaneh', 'Initials': 'S', 'LastName': 'Haghpanah', 'Affiliation': 'Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Urology journal,[] 1286,25015615,Is the double dose alpha-blocker treatment superior than the single dose in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia?,"PURPOSE To compare the efficacy and safety of single (tamsulosin) and double dose (tamsulosin + alfuzosin) alpha-blocker therapy for treating catheterized patients with acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH). MATERIALS AND METHODS Seventy patients with AUR due to BPH were catheterized and randomized into two groups: the single dose group (0.4 mg tamsulosin, 35 patients) and the double dose group (0.4 mg tamsulosin + 10 mg alfuzosin, 35 patients). The catheter was removed after 3 days, and the patients were put on trial without catheter (TWOC). RESULTS Seventy males (mean age, 71.2 years) were randomly assigned to receive double or single dose alpha-blocker (35 patients per group). The intent-to-treat population consisted of 70 males. Twenty-seven individuals in the double dose group and 19 in the single dose group did not require re-catheterization on the day of the TWOC (77% and 54%, respectively; P = .003). Success using free-flow variables was also higher in the males who received double dose alpha-blocker compared with single dose therapy (48% vs. 40%; P = .017). CONCLUSION TWOC was more successful in males treated with double dose alpha-blockers, and the subsequent need for re-catheterization was also reduced. The side-effect profiles were similar in the single and double dose alpha-blocker groups and were consistent with the known pharmacology. These results state that double dose alpha-blocker treatment can be recommended for treating males after catheterization for AUR, which may reduce the need for re-catheterization.",2014,"Success using free-flow variables was also higher in the males who received double dose alpha-blocker compared with single dose therapy (48% vs. 40%; P = .017). ","['Seventy males (mean age, 71.2 years', 'patients suffering from acute urinary retention caused by benign prostatic hyperplasia', 'Seventy patients with AUR due to BPH', 'catheterized patients with acute urinary retention (AUR) due to benign prostatic hyperplasia (BPH']","['tamsulosin', 'tamsulosin + 10 mg alfuzosin', 'single (tamsulosin) and double dose (tamsulosin + alfuzosin) alpha-blocker therapy', 'double or single dose alpha-blocker']","['efficacy and safety', 'require re-catheterization']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0341742', 'cui_str': 'Acute retention of urine (disorder)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C1704272', 'cui_str': 'Benign Prostatic Hyperplasia'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0005001', 'cui_str': 'Benign enlargement of prostate'}]","[{'cui': 'C0257343', 'cui_str': 'tamsulosin'}, {'cui': 'C0051150', 'cui_str': 'alfuzosin'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}]",70.0,0.082796,"Success using free-flow variables was also higher in the males who received double dose alpha-blocker compared with single dose therapy (48% vs. 40%; P = .017). ","[{'ForeName': 'Onder', 'Initials': 'O', 'LastName': 'Kara', 'Affiliation': 'Department of Urology, Hacettepe University School of Medicine, 06100, Ankara, Turkey. onerkara@yahoo.com.'}, {'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Yazici', 'Affiliation': 'Department of Anesthesiology and Reanimation, Ankara University School of Medicine, 06100, Ankara, Turkey.'}]",Urology journal,[] 1287,31077299,A Prospective Study of Serum Vitamin E and 28-Year Risk of Lung Cancer.,"BACKGROUND Epidemiologic data are inconsistent regarding the vitamin E-lung cancer association, and no study to our knowledge has examined serologic changes in vitamin E status in relation to subsequent risk. METHODS In a cohort of 22 781 male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, we ascertained 3184 lung cancer cases during up to 28 years of observation. Cox proportional hazards models examined whether higher serum alpha-tocopherol concentrations at baseline, 3 years, or the interval change were associated with lower lung cancer risk. All statistical tests were two-sided. RESULTS After adjustment for age, body mass index, smoking intensity and duration, serum total cholesterol, and trial intervention group, we found lower lung cancer risk in men with high baseline alpha-tocopherol (fifth quintile [Q5] vs Q1, hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.66 to 0.87, Ptrend < .001). A similar reduction in risk was seen for serum alpha-tocopherol at 3 years (Q5 vs Q1, HR = 0.78, 95% CI = 0.67 to 0.91, Ptrend = .004). The inverse risk association appeared stronger for younger men and those who had smoked fewer years but was similar across trial intervention groups. We also found reduced risk among men not supplemented with vitamin E who had a lower serum alpha-tocopherol at baseline and greater increases in concentrations at 3 years (third tertile vs first tertile of serum alpha-tocopherol change, HR = 0.74, 95% CI = 0.59 to 0.91, P = .005). CONCLUSIONS Higher vitamin E status, as measured by serum alpha-tocopherol concentration, as well as repletion of a low vitamin E state, was related to decreased lung cancer risk during a 28-year period. Our findings provide evidence supporting the importance of adequate physiological vitamin E status for lung cancer risk reduction.",2020,"The inverse risk association appeared stronger for younger men and those having smoked fewer years, but was similar across trial intervention groups.","['22,781 male smokers in the ATBC Study, we ascertained 3,184 lung cancer cases during up to 28 years of observation', 'Lung Cancer']",['Serum Vitamin E'],"['serum alpha-tocopherol concentrations', 'serum alpha-tocopherol', 'serum alpha-tocopherol concentration', 'lung cancer risk']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0042874', 'cui_str': 'Vitamin E'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0969677', 'cui_str': 'd-alpha tocopherol'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",22781.0,0.0172966,"The inverse risk association appeared stronger for younger men and those having smoked fewer years, but was similar across trial intervention groups.","[{'ForeName': 'Jiaqi', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Weinstein', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Yu', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.'}, {'ForeName': 'Satu', 'Initials': 'S', 'LastName': 'Männistö', 'Affiliation': 'Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.'}, {'ForeName': 'Demetrius', 'Initials': 'D', 'LastName': 'Albanes', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.'}]",Journal of the National Cancer Institute,['10.1093/jnci/djz077'] 1288,30483971,Randomized trial of a web-based survivor intervention on melanoma prevention behaviors of first-degree relatives.,"OBJECTIVES Melanoma can be prevented through reducing sun exposure and detected early by increasing examination of skin for lesions. First-degree relatives of melanoma cases have higher risk than the general population and, therefore, could be targets of behavioral interventions through families. We tested the effects of a family-based web delivered intervention to melanoma families on the melanoma risk reduction behaviors of first-degree relatives of melanoma cases. METHODS A total of 313 families that included one first-degree relative were recruited to join this randomized trial. All intervention families received access to the Suntalk website developed to promote family communication and behavioral risk reduction among families of melanoma survivors. RESULTS First degree relatives in the intervention arm significantly increased their yearly performance of both skin self examination and thorough provider examination from baseline to 12-month follow-up while the control FDRs decreased their yearly performance of both of those behaviors (p's = 0.006 and 0.005, respectively). Several sun protection behaviors increased significantly in FDRs in the intervention arm but not the control arm, including wearing a covering on the head (p = 0.005), staying in available shade (p = 0.008), and avoiding sun exposure during peak hours (p = 0.010). Some of these changes were mediated by perceptions of risk and other process variables. CONCLUSIONS A web-based intervention can reduce risk of melanoma through changes in relevant behaviors among first-degree relatives of melanoma survivors. Future research should identify methods for making this type of intervention accessible to more families and for broadening the reach to other types of cancer families. PRACTICE IMPLICATIONS This program can be provided to melanoma families to improve their sun protection and screening behaviors, at the point of diagnosis.",2019,"All intervention families received access to the Suntalk website developed to promote family communication and behavioral risk reduction among families of melanoma survivors. ","['313 families that included one first-degree relative', 'melanoma prevention behaviors of first-degree relatives']",['web-based survivor intervention'],"['yearly performance of both skin self examination and thorough provider examination', 'Several sun protection behaviors', 'avoiding sun exposure']","[{'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0444502', 'cui_str': 'First degree (qualifier value)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0025202', 'cui_str': 'Malignant Melanoma'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C1444170', 'cui_str': 'Skin self-examination'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0038817', 'cui_str': 'Sunshine'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}]",313.0,0.0533124,"All intervention families received access to the Suntalk website developed to promote family communication and behavioral risk reduction among families of melanoma survivors. ","[{'ForeName': 'Deborah J', 'Initials': 'DJ', 'LastName': 'Bowen', 'Affiliation': 'Bioethics and Humanities, University of Washington, Seattle, WA, 98195, USA. dbowen@uw.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hay', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Hendrika', 'Initials': 'H', 'LastName': 'Meischke', 'Affiliation': 'Health Services, University of Washington, Seattle, WA, 98195, USA.'}, {'ForeName': 'Joni A', 'Initials': 'JA', 'LastName': 'Mayer', 'Affiliation': 'Graduate School of Public Health, San Diego State University, San Diego, CA, 92182, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Harris-Wai', 'Affiliation': 'University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Wylie', 'Initials': 'W', 'LastName': 'Burke', 'Affiliation': 'Bioethics and Humanities, University of Washington, Seattle, WA, 98195, USA.'}]",Cancer causes & control : CCC,['10.1007/s10552-018-1096-y'] 1289,23618052,Exploring the value of mixed methods within the At Home/Chez Soi housing first project: a strategy to evaluate the implementation of a complex population health intervention for people with mental illness who have been homeless.,"OBJECTIVE This paper is a methodological case study that describes the At Home/Chez Soi (Housing First) Initiative's mixed-methods strategy for implementation evaluation and discusses the value of these methods in evaluating the implementation of such complex population health interventions. TARGET POPULATION The Housing First (HF) model is being implemented in five cities: Vancouver, Winnipeg, Toronto, Montréal and Moncton. INTERVENTION At Home/Chez Soi is an intervention trial that aims to address the issue of homelessness in people with mental health issues. The HF model emphasizes choices, hopefulness and connecting people with resources that make a difference to their quality of life. A component of HF is supported housing, which provides a rent subsidy and rapid access to housing of choice in private apartments; a second component is support. Quantitative and qualitative methods were used to evaluate HF implementation. OUTCOMES The findings of this case study illustrate how the critical ingredients of complex interventions, such as HF, can be adapted to different contexts while implementation fidelity is maintained at a theoretical level. The findings also illustrate how the project's mixed methods approach helped to facilitate the adaptation process. Another value of this approach is that it identifies systemic and organizational factors (e.g., housing supply, discrimination, housing procurement strategy) that affect implementation of key elements of HF. CONCLUSION In general, the approach provides information about both whether and how key aspects of the intervention are implemented effectively across different settings. It thus provides implementation data that are rigorous, contextually relevant and practical.",2012,At Home/Chez Soi is an intervention trial that aims to address the issue of homelessness in people with mental health issues.,['people with mental illness who have been homeless'],"['complex population health intervention', 'Chez Soi (Housing First']",[],"[{'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0237154', 'cui_str': 'Homelessness'}]","[{'cui': 'C0439855', 'cui_str': 'Complex (qualifier value)'}, {'cui': 'C3242284', 'cui_str': 'Population Health'}, {'cui': 'C0676803', 'cui_str': 'styrene oxide isomerase'}, {'cui': 'C0020056', 'cui_str': 'Housing'}]",[],,0.0854203,At Home/Chez Soi is an intervention trial that aims to address the issue of homelessness in people with mental health issues.,"[{'ForeName': 'Eric L', 'Initials': 'EL', 'LastName': 'Macnaughton', 'Affiliation': 'At Home/Chez Soi Project, Mental Health Commission of Canada, Calgary, Alberta. emacnaug@shaw.ca'}, {'ForeName': 'Paula N', 'Initials': 'PN', 'LastName': 'Goering', 'Affiliation': ''}, {'ForeName': 'Geoffrey B', 'Initials': 'GB', 'LastName': 'Nelson', 'Affiliation': ''}]",Canadian journal of public health = Revue canadienne de sante publique,[] 1290,23618054,Evaluation of an educational policing strategy to reduce alcohol-related crime associated with licensed premises.,"OBJECTIVES Licensed premises are associated with a considerable level of alcohol-related harm. This study examined the effectiveness of an educational policing strategy, implemented as routine policing practice, to reduce the number of patrons of licensed premises involved in police-recorded incidents of violence, disorder and motor vehicle crashes. PARTICIPANTS The educational policing strategy targeted on-licensed premises registered as operating in 2003. The strategy was delivered by police and was overseen by the research team. SETTING The intervention was conducted in 21 non-metropolitan New South Wales Police Force commands. INTERVENTION On the basis of routinely collected and recorded police data, premises received one of three levels of police response on three separate occasions from December 2002 to July 2003. The police responses were letters, incident reports, covert audits and feedback meetings. OUTCOMES The rate of patrons who had last consumed alcohol on licensed premises before being involved in police-recorded incidents decreased from 1.24 per premises in the 4-month baseline period to 1.11 in the 4-month follow-up period (p=0.08). There was a significant reduction, from 7.08 to 5.65 patrons (p=0.03), in such a rate for high-risk premises that received the most intensive police response. High-risk premises also recorded a significant reduction in the rate of intoxicated patrons involved in such incidents, from 5.50 to 4.40 (p=0.05). CONCLUSION The findings suggest a potential benefit of an educational policing strategy in reducing alcohol-related harm associated with licensed premises. Further implementation of this strategy concurrent with rigorous evaluation is warranted.",2012,"There was a significant reduction, from 7.08 to 5.65 patrons (p=0.03), in such a rate for high-risk premises that received the most intensive police response.","['21 non-metropolitan New South Wales Police Force commands', 'The educational policing strategy targeted on-licensed premises registered as operating in 2003']",['educational policing strategy'],['rate of intoxicated patrons'],"[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0086824', 'cui_str': 'Police Force'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]",[],[],,0.0254022,"There was a significant reduction, from 7.08 to 5.65 patrons (p=0.03), in such a rate for high-risk premises that received the most intensive police response.","[{'ForeName': 'Shelley C', 'Initials': 'SC', 'LastName': 'Rowe', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, and Hunter New England Population Health, New South Wales, Australia. shelley.rowe@hnehealth.nsw.gov.au'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wiggers', 'Affiliation': ''}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Wolfenden', 'Affiliation': ''}, {'ForeName': 'J Lynn', 'Initials': 'JL', 'LastName': 'Francis', 'Affiliation': ''}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Freund', 'Affiliation': ''}]",Canadian journal of public health = Revue canadienne de sante publique,[] 1291,32421353,Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.,"Rationale: Pleural infection is frequently encountered in clinical practice and is associated with high morbidity and mortality. Limited evidence exists regarding the optimal treatment. Although both early medical thoracoscopy (MT) and tube thoracostomy with intrapleural instillation of tissue plasminogen activator and human recombinant deoxyribonuclease are acceptable treatments for patients with complicated pleural infection, there is a lack of comparative data for these modes of management. Objectives: The aim of this study was to compare the safety and efficacy of early MT versus intrapleural fibrinolytic therapy (IPFT) in selected patients with multiloculated pleural infection and empyema. Methods: This was a prospective multicenter, randomized controlled trial involving patients who underwent MT or IPFT for pleural infection. The primary outcome was the length of hospital stay after either intervention. Secondary outcomes included the total length of hospital stay, treatment failure, 30-day mortality, and adverse events. Results: Thirty-two patients with pleural infection were included in the study. The median length of stay after an intervention was 4 days in the IPFT arm and 2 days in the MT arm ( P  = 0.026). The total length of hospital stay was 6 days in the IPFT arm and 3.5 days in MT arm ( P  = 0.12). There was no difference in treatment failure, mortality, or adverse events between the treatment groups, and no serious complications related to either intervention were recorded. Conclusions: When used early in the course of a complicated parapneumonic effusion or empyema, MT is safe and might shorten hospital stays for selected patients as compared with IPFT therapy. A multicenter trial with a larger sample size is needed to confirm these findings.Clinical trial registered with ClinicalTrials.gov (NCT02973139).",2020,"There was no difference in treatment failure, mortality or adverse events between treatment groups, and no serious complications related to either interventions were recorded. ","['patients with complicated pleural infection', 'selected patients with multiloculated pleural infection and empyema', 'Pleural Infection', '32 patients with pleural infection', 'patients who underwent MT or IPFT for pleural infection']","['Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy', 'IPFT therapy', 'Medical thoracoscopy', 'medical thoracoscopy (MT) and tube thoracostomy with intrapleural instillation of tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase', 'early MT versus intrapleural fibrinolytic therapy (IPFT']","['treatment failure, mortality or adverse events', 'median length of stay', 'total length of hospital stay, treatment failure, 30-day mortality and adverse events', 'length of hospital stay', 'safety and efficacy', 'total length of hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0014009', 'cui_str': 'Empyema'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039989', 'cui_str': 'Thoracoscopy'}, {'cui': 'C0595451', 'cui_str': 'Intrapleural route'}, {'cui': 'C0040044', 'cui_str': 'Thrombolytic therapy'}]","[{'cui': 'C0595451', 'cui_str': 'Intrapleural route'}, {'cui': 'C0040044', 'cui_str': 'Thrombolytic therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039989', 'cui_str': 'Thoracoscopy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0189476', 'cui_str': 'Insertion of pleural tube drain'}, {'cui': 'C0184959', 'cui_str': 'Instillation'}, {'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1135662', 'cui_str': 'Dornase Alfa'}, {'cui': 'C0011522', 'cui_str': 'Deoxyribonucleases'}]","[{'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",32.0,0.0949974,"There was no difference in treatment failure, mortality or adverse events between treatment groups, and no serious complications related to either interventions were recorded. ","[{'ForeName': 'Fayez', 'Initials': 'F', 'LastName': 'Kheir', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Sanket', 'Initials': 'S', 'LastName': 'Thakore', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Hiren', 'Initials': 'H', 'LastName': 'Mehta', 'Affiliation': 'Division of Pulmonary Diseases and Critical Care, University of Florida Health, Gainesville, Florida; and.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jantz', 'Affiliation': 'Division of Pulmonary Diseases and Critical Care, University of Florida Health, Gainesville, Florida; and.'}, {'ForeName': 'Mihir', 'Initials': 'M', 'LastName': 'Parikh', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Chee', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Upendra', 'Initials': 'U', 'LastName': 'Kaphle', 'Affiliation': 'Division of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Sisnega', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Fernandez-Bussy', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville, Florida.'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Majid', 'Affiliation': 'Division of Thoracic Surgery and Interventional Pulmonology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.'}]",Annals of the American Thoracic Society,['10.1513/AnnalsATS.202001-076OC'] 1292,31287192,The effect of xenon-augmented sevoflurane anesthesia on intra-operative hemodynamics and postoperative neurocognitive function in children undergoing cardiac catheterization: A 1-year follow-up of a randomized controlled pilot trial.,,2019,[IQR 1.80-2.22]) resulted in short-lasting neurocognitive deficits when compared to a non-randomized group of healthy control children matched for age and gender.,"['children between 4 and 12 years of age, suffering from congenital heart disease and undergoing cardiac catheterization, combining xenon with sevoflurane was safe and feasible.(1', 'children undergoing cardiac catheterization']","['xenon-augmented sevoflurane-anaesthesia', 'sevoflurane', 'propofol-fentanyl-rocuronium']",['short-lasting neurocognitive deficits'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease (disorder)'}, {'cui': 'C0018795', 'cui_str': 'Catheterization, Heart'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0043339', 'cui_str': 'Xenon'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0043339', 'cui_str': 'Xenon'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002903', 'cui_str': 'Anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}]","[{'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C4552512', 'cui_str': 'Neurocognitive deficit'}]",,0.134647,[IQR 1.80-2.22]) resulted in short-lasting neurocognitive deficits when compared to a non-randomized group of healthy control children matched for age and gender.,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Devroe', 'Affiliation': 'Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Jurgen', 'Initials': 'J', 'LastName': 'Lemiere', 'Affiliation': 'Department of Child and Adolescent Psychiatry, University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Rex', 'Affiliation': 'Department of Anesthesiology, University Hospitals Leuven, Leuven, Belgium.'}]",Paediatric anaesthesia,['10.1111/pan.13696'] 1293,31855907,Oral Hypertonic Saline Is Effective in Reversing Acute Mild-to-Moderate Symptomatic Exercise-Associated Hyponatremia.,"OBJECTIVES To determine whether oral administration of 3% hypertonic saline (HTS) is as efficacious as intravenous (IV) 3% saline in reversing symptoms of mild-to-moderate symptomatic exercise-associated hyponatremia (EAH) in athletes during and after a long-distance triathlon. DESIGN Noninferiority, open-label, parallel-group, randomized control trial to IV or oral HTS. We used permuted block randomization with sealed envelopes, containing the word either ""oral"" or ""IV."" SETTING Annual long-distance triathlon (3.8-km swim, 180-km bike, and 42-km run) at Mont-Tremblant, Quebec, Canada. PARTICIPANTS Twenty race finishers with mild to moderately symptomatic EAH. INDEPENDENT VARIABLES Age, sex, race finish time, and 9 clinical symptoms. MAIN OUTCOME MEASURES Time from treatment to discharge. METHODS We successfully randomized 20 participants to receive either an oral (n = 11) or IV (n = 9) bolus of HTS. We performed venipuncture to measure serum sodium (Na) at presentation to the medical clinic and at time of symptom resolution after the intervention. RESULTS The average time from treatment to discharge was 75.8 minutes (SD 29.7) for the IV treatment group and 50.3 minutes (SD 26.8) for the oral treatment group (t test, P = 0.02). Serum Na before and after treatment was not significantly different in both groups. There was no difference on presentation between groups in age, sex, or race finish time, both groups presented with an average of 6 symptoms. CONCLUSIONS Oral HTS is effective in reversing symptoms of mild-to-moderate hyponatremia in EAH.",2020,"There was no difference on presentation between groups in age, sex, or race finish time, both groups presented with an average of 6 symptoms. ","['Annual long-distance triathlon (3.8-km swim, 180-km bike, and 42-km run) at Mont-Tremblant, Quebec, Canada', 'Twenty race finishers with mild to moderately symptomatic EAH']","['Oral Hypertonic Saline', 'sealed envelopes, containing the word either ""oral"" or ""IV', 'HTS', 'oral HTS', '3% hypertonic saline (HTS']",['average time'],"[{'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0005375', 'cui_str': 'Bicycle, device (physical object)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0034390', 'cui_str': 'Quebec'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}]",20.0,0.145485,"There was no difference on presentation between groups in age, sex, or race finish time, both groups presented with an average of 6 symptoms. ","[{'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Bridges', 'Affiliation': 'Department of Emergency Medicine, McGill University Health Centre, Montreal, QC, Canada.'}, {'ForeName': 'Tawfeeq', 'Initials': 'T', 'LastName': 'Altherwi', 'Affiliation': 'EM FRCP Program-McGill University, Montreal, QC, Canada.'}, {'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Correa', 'Affiliation': 'Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Hew-Butler', 'Affiliation': 'Oakland University, Rochester, Michigan.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000573'] 1294,32492933,Caffeine and Gastric Emptying Time in Very Preterm Neonates.,"BACKGROUND Caffeine has been commonly used for prevention and treatment of apnea-related symptoms in premature infants. However, its side effects have not been thoroughly studied. We investigated whether caffeine affects gastric motility in very-preterm (VP) neonates. METHODS The study is a randomized crossover clinical trial. Twenty-two neonates with mean birth weight (BW) (standard deviation-SD) 1077 (229) g and mean gestational age (GA) (SD) 28.6 (2.1) weeks were recruited. Each neonate had its gastric emptying time checked twice with ultrasound assessment of changes in antral cross sectional area (ACSA). All neonates were sequentially allocated to the caffeine group (A) and the control group (B). Complications from the gastrointestinal tract were documented throughout the study. RESULTS Statistically significant difference was found with regards to the gastric emptying time [median, (range)] between caffeine and control group (p = 0.040). Additionally, in the neonates with BW 1000-1500 g and GA ≥ 28 weeks, the gastric emptying time (minutes) was significantly longer during caffeine treatment [44.5 (36-68.2)] and [40 (34.5-66.5)] respectively, as compared to the gastric emptying time during no caffeine treatment [27 (24.2-30)] ( p = 0.002) and [27 (24.5-30)] ( p = 0.001). The incidence of gastrointestinal (GI) complications was significantly greater in neonates receiving caffeine [6 (27.%)] as compared with those without caffeine treatment [1 (4.6%)] ( p = 0.039). CONCLUSIONS During caffeine treatment, a significantly delayed gastric emptying time was noted in all study neonates, especially in these with BW 1000-1500 g and those with GA ≥ 28 weeks. Further larger studies are necessary in order to confirm this interesting finding.",2020,"Statistically significant difference was found with regards to the gastric emptying time [median, (range)] between caffeine and control group (p = 0.040).","['g and mean gestational age (GA) (SD) 28.6 (2.1) weeks were recruited', 'Twenty-two neonates with mean birth weight (BW) (standard deviation-SD) 1077 (229', 'very-preterm (VP) neonates', 'premature infants', 'Very Preterm Neonates']","['caffeine', 'Caffeine']","['gastric emptying time', 'incidence of gastrointestinal (GI) complications', 'gastric motility', 'gastric emptying time checked twice with ultrasound assessment of changes in antral cross sectional area (ACSA', 'delayed gastric emptying time']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4517679', 'cui_str': '28.6'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0161819', 'cui_str': 'Gastrointestinal complication'}, {'cui': 'C0232572', 'cui_str': 'Gastric motility'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0293352', 'cui_str': 'Antral'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",22.0,0.0751421,"Statistically significant difference was found with regards to the gastric emptying time [median, (range)] between caffeine and control group (p = 0.040).","[{'ForeName': 'Antonios K', 'Initials': 'AK', 'LastName': 'Gounaris', 'Affiliation': 'Neonatal Clinic-NICU, University General Hospital, 41222 Larissa, Greece.'}, {'ForeName': 'Ioanna N', 'Initials': 'IN', 'LastName': 'Grivea', 'Affiliation': 'Neonatal Clinic-NICU, University General Hospital, 41222 Larissa, Greece.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Baltogianni', 'Affiliation': 'Neonatal Clinic-NICU, University General Hospital, 451 10 Ioannina, Greece.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Gounari', 'Affiliation': ""NICU, Royal Alexandra Children's Hospital Brighton, Eastern Road, Brighton, East Sussex BN2 5BE, UK.""}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Antonogeorgos', 'Affiliation': 'Neonatal Clinic-NICU, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}, {'ForeName': 'Fedra', 'Initials': 'F', 'LastName': 'Kokori', 'Affiliation': 'Department of Radiology, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}, {'ForeName': 'Polytimi', 'Initials': 'P', 'LastName': 'Panagiotounakou', 'Affiliation': 'Neonatal Clinic-NICU, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Theodoraki', 'Affiliation': 'Neonatal Clinic-NICU, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}, {'ForeName': 'Aikaterini', 'Initials': 'A', 'LastName': 'Konstantinidi', 'Affiliation': 'Neonatal Clinic-NICU, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}, {'ForeName': 'Rozeta', 'Initials': 'R', 'LastName': 'Sokou', 'Affiliation': 'Neonatal Clinic-NICU, General Hospital ""Agios Panteleimon"", 18454 Piraeus, Greece.'}]",Journal of clinical medicine,['10.3390/jcm9061676'] 1295,31855906,"Efficacy of Intra-Articular Polynucleotides Associated With Hyaluronic Acid Versus Hyaluronic Acid Alone in the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Clinical Trial.","OBJECTIVE Pain and range of motion loss are the main clinical features of osteoarthritis (OA). Hyaluronic acid (HA) is one of the infiltrative therapies for OA treatment; however, its effectiveness is a matter of an ongoing debate in clinical practice. Polynucleotides (PNs), a DNA-derived macromolecule with natural origin and trophic activity, were found to favor cell growth and collagen production, in preclinical and clinical studies regarding cartilage regeneration. This study aimed at evaluating whether injection of PNs, in combination with HA [PNs associated with HA (PNHA)], can ameliorate pain and function of knees affected by OA, more than HA alone. DESIGN A randomized, double-blind, controlled clinical trial. PATIENTS The study enrolled 100 patients, then randomized to receive PNHA or HA alone (3 weekly knee I.A. injections). INTERVENTIONS AND MAIN OUTCOME MEASURES Pain reduction, decrease of proinflammatory synovial fluid (SF) factors, and improvement in knee function were evaluated by Knee Society Score and WOMAC scores, after 2, 6, and 12 months and by biochemical and immunoenzymatic analyses of SF at the end of the treatment. RESULTS Knee Society Score total score and pain item significantly ameliorated in both groups, showing better results in PNHA- than in the HA-treated group. A significant reduction in the WOMAC score was observed over time for both groups. No significant adverse events were reported in either group. CONCLUSIONS These findings suggest that I.A. injection of PNs, in combination with HA, is more effective in improving knee function and pain, in a joint affected by OA, compared with HA alone.",2020,"RESULTS Knee Society Score total score and pain item significantly ameliorated in both groups, showing better results in PNHA- than in the HA-treated group.","['100 patients', 'Knee Osteoarthritis']","['PNHA or HA alone', 'Hyaluronic Acid Versus Hyaluronic Acid Alone', 'Hyaluronic acid (HA', 'HA [PNs associated with HA (PNHA']","['knee function and pain', 'WOMAC score', 'Knee Society Score and WOMAC scores', 'Pain reduction, decrease of proinflammatory synovial fluid (SF) factors, and improvement in knee function', 'adverse events', 'Knee Society Score total score and pain item']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}]","[{'cui': 'C1141990', 'cui_str': 'Hyaluronic acid'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}]","[{'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0039097', 'cui_str': 'Synovia'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",100.0,0.245541,"RESULTS Knee Society Score total score and pain item significantly ameliorated in both groups, showing better results in PNHA- than in the HA-treated group.","[{'ForeName': 'Dante', 'Initials': 'D', 'LastName': 'Dallari', 'Affiliation': 'Conservative Orthopedic Surgery and Innovative Techniques, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Sabbioni', 'Affiliation': 'Conservative Orthopedic Surgery and Innovative Techniques, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Nicolandrea', 'Initials': 'N', 'LastName': 'Del Piccolo', 'Affiliation': 'Conservative Orthopedic Surgery and Innovative Techniques, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Carubbi', 'Affiliation': 'Conservative Orthopedic Surgery and Innovative Techniques, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Veronesi', 'Affiliation': 'Laboratory of Preclinical and Surgical Studies, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Torricelli', 'Affiliation': 'Laboratory of Preclinical and Surgical Studies, Rizzoli Orthopedic Institute, Bologna, Italy.'}, {'ForeName': 'Milena', 'Initials': 'M', 'LastName': 'Fini', 'Affiliation': 'Laboratory of Preclinical and Surgical Studies, Rizzoli Orthopedic Institute, Bologna, Italy.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000569'] 1296,31355878,Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis.,"Importance The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that a systolic blood pressure (BP) target less than 120 mm Hg was superior to less than 140 mm Hg for preventing vascular events. This trial excluded patients with prior stroke; therefore, the ideal BP target for secondary stroke prevention remains unknown. Objective To assess whether intensive BP control would achieve fewer recurrent strokes vs standard BP control. Design, Setting, and Participants Randomized clinical trial (RCT) of standard vs intensive BP control in an intent-to-treat population of patients who had a history of stroke. Patients were enrolled between October 20, 2010, and December 7, 2016. For an updated meta-analysis, PubMed and the Cochrane Central Library database were searched through September 30, 2018, using the Medical Subject Headings and relevant search terms for cerebrovascular disease and for intensive BP lowering. This was a multicenter trial that included 140 hospitals in Japan; 1514 patients who had a history of stroke within the previous 3 years were approached, but 234 refused to give informed consent. Interventions In total, 1280 patients were randomized 1:1 to BP control to less than 140/90 mm Hg (standard treatment) (n = 640) or to less than 120/80 mm Hg (intensive treatment) (n = 640). However, 17 patients never received intervention; therefore, 1263 patients assigned to standard treatment (n = 630) or intensive treatment (n = 633) were analyzed. Main Outcomes and Measures The primary outcome was stroke recurrence. Results The trial was stopped early. Among 1263 analyzed patients (mean [SD] age, 67.2 [8.8] years; 69.4% male), 1257 of 1263 (99.5%) completed a mean (SD) of 3.9 (1.5) years of follow-up. The mean BP at baseline was 145.4/83.6 mm Hg. Throughout the overall follow-up period, the mean BP was 133.2/77.7 (95% CI, 132.5-133.8/77.1-78.4) mm Hg in the standard group and 126.7/77.4 (95% CI, 125.9-127.2/73.8-75.0) mm Hg in the intensive group. Ninety-one first recurrent strokes occurred. Nonsignificant rate reductions were seen for recurrent stroke in the intensive group compared with the standard group (hazard ratio [HR], 0.73; 95% CI, 0.49-1.11; P = .15). When this finding was pooled in 3 previous relevant RCTs in a meta-analysis, the risk ratio favored intensive BP control (relative risk, 0.78; 95% CI, 0.64-0.96; P = .02; absolute risk difference, -1.5%; 95% CI, -2.6% to -0.4%; number needed to treat, 67; 95% CI, 39-250). Conclusions and Relevance Intensive BP lowering tended to reduce stroke recurrence. The updated meta-analysis supports a target BP less than 130/80 mm Hg in secondary stroke prevention. Trial Registration ClinicalTrials.gov identifier: NCT01198496.",2019,"Nonsignificant rate reductions were seen for recurrent stroke in the intensive group compared with the standard group (hazard ratio [HR], 0.73; 95% CI, 0.49-1.11; P = .15).","['1280 patients were randomized 1:1 to BP control to less than 140/90 mm Hg (standard treatment', 'included 140 hospitals in Japan; 1514 patients who had a history of stroke within the previous 3 years were approached, but 234 refused to give informed consent', '17 patients never received intervention; therefore, 1263 patients assigned to standard treatment (n\u2009=\u2009630) or intensive treatment (n\u2009=\u2009633) were analyzed', '1263 analyzed patients (mean [SD] age, 67.2 [8.8] years; 69.4% male), 1257 of 1263 (99.5%) completed a mean (SD) of 3.9 (1.5) years of follow-up', 'patients with prior stroke', 'Patients were enrolled between October 20, 2010, and December 7, 2016', 'patients who had a history of stroke']","['standard vs intensive BP control', 'Standard vs Intensive Blood Pressure Control', 'intensive BP control']","['Risk of Recurrent Stroke', 'recurrent stroke', 'stroke recurrence', 'mean BP', 'systolic blood pressure (BP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C1705116', 'cui_str': 'Refused (qualifier value)'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C4708165', 'cui_str': 'Six hundred and thirty'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517882', 'cui_str': '8.8 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C4517912', 'cui_str': '99.5 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4517698', 'cui_str': '3.9 (qualifier value)'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}]",1263.0,0.301075,"Nonsignificant rate reductions were seen for recurrent stroke in the intensive group compared with the standard group (hazard ratio [HR], 0.73; 95% CI, 0.49-1.11; P = .15).","[{'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kitagawa', 'Affiliation': ""Department of Neurology, Tokyo Women's Medical University, Shinjuku, Tokyo, Japan.""}, {'ForeName': 'Yasumasa', 'Initials': 'Y', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Neurology, Kyoto Katsura Hospital, Nishikyo, Kyoto, Japan.'}, {'ForeName': 'Hisatomi', 'Initials': 'H', 'LastName': 'Arima', 'Affiliation': 'Department of Preventive Medicine and Public Health, Fukuoka University Faculty of Medicine, Jyonan, Fukuoka, Japan.'}, {'ForeName': 'Toshiki', 'Initials': 'T', 'LastName': 'Maeda', 'Affiliation': 'Department of Preventive Medicine and Public Health, Fukuoka University Faculty of Medicine, Jyonan, Fukuoka, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Sunami', 'Affiliation': 'Department of Neurosurgery, Fukuzumi Hospital, Matsuyama, Ehime, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Kanzawa', 'Affiliation': 'Department of Stroke Medicine, Institute of Brain and Blood Vessel, Mihara Memorial Hospital, Isesaki, Gunnma, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Eguchi', 'Affiliation': 'Department of Internal Medicine, Hanyu General Hospital, Hanyu, Saitama, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Kamiyama', 'Affiliation': 'Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Minematsu', 'Affiliation': 'General of the Hospital, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.'}, {'ForeName': 'Shinichiro', 'Initials': 'S', 'LastName': 'Ueda', 'Affiliation': 'Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus School of Medicine, Nakagamigunn, Okinawa, Japan.'}, {'ForeName': 'Hiromi', 'Initials': 'H', 'LastName': 'Rakugi', 'Affiliation': 'Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Ohya', 'Affiliation': 'Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine, Nakagamigunn, Okinawa, Japan.'}, {'ForeName': 'Takahide', 'Initials': 'T', 'LastName': 'Kohro', 'Affiliation': 'Department of Cerebrovascular Medicine, Jichi Medical School, Shimotsuke, Tochigi, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Yonemoto', 'Affiliation': 'Department of Environmental Health, University of the Ryukyus School of Medicine, Nakagamigunn, Okinawa, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Okada', 'Affiliation': 'Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center Clinical Research Institute, Chuo, Fukuoka, Japan.'}, {'ForeName': 'Jitsuo', 'Initials': 'J', 'LastName': 'Higaki', 'Affiliation': 'Minami-Matsuyama Hospital, Matsuyama, Ehime, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Tanahashi', 'Affiliation': 'Department of Neurology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.'}, {'ForeName': 'Genjiro', 'Initials': 'G', 'LastName': 'Kimura', 'Affiliation': 'Cardio-renal and Health Research Institute, Nagoya, Aichi, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Umemura', 'Affiliation': 'Yokohama Rosai Hospital, Yokohama, Kanagawa, Japan.'}, {'ForeName': 'Masayasu', 'Initials': 'M', 'LastName': 'Matsumoto', 'Affiliation': 'Sakai City Medical Center, Sakai, Osaka, Japan.'}, {'ForeName': 'Kazuaki', 'Initials': 'K', 'LastName': 'Shimamoto', 'Affiliation': 'Japan Health Care College, Sapporo, Hokkaido, Japan.'}, {'ForeName': 'Sadayoshi', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Department of Nephrology Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Miyagi, Japan.'}, {'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Saruta', 'Affiliation': 'Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kazuyuki', 'Initials': 'K', 'LastName': 'Shimada', 'Affiliation': 'Shin-Oyama City Hospital, Oyama, Tochigi, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA neurology,['10.1001/jamaneurol.2019.2167'] 1297,22972448,Score Study Report 12: Development of venous collaterals in the Score Study.,"PURPOSE To investigate the prevalence of venous collaterals after branch and central retinal vein occlusion, assess the association of venous collaterals with other clinical features (including visual acuity), and determine if treatment with intravitreal corticosteroids influences the development of new venous collaterals. METHODS Review of data from two multicenter randomized clinical trials in the Standard of Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study. RESULTS Statistically significant associations of venous collaterals and visual acuity at baseline or at follow-up were not found. Treatment with intravitreal triamcinolone acetonide did not appear to influence the development of venous collaterals. CONCLUSION In contrast to some previous reports, development of venous collaterals did not demonstrate an independent association with visual acuity in eyes with branch retinal vein occlusion or central retinal vein occlusion in the SCORE Study. Intravitreal steroid effects do not appear to influence the development of venous collaterals.",2013,"Treatment with intravitreal triamcinolone acetonide did not appear to influence the development of venous collaterals. ",[],"['intravitreal triamcinolone acetonide', 'intravitreal corticosteroids', 'Care versus COrticosteroid']","['venous collaterals and visual acuity', 'development of venous collaterals']",[],"[{'cui': 'C0040866', 'cui_str': 'Triamcinolone Acetonide'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C1275670', 'cui_str': 'Collateral'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0243107', 'cui_str': 'development'}]",,0.122913,"Treatment with intravitreal triamcinolone acetonide did not appear to influence the development of venous collaterals. ","[{'ForeName': 'David V', 'Initials': 'DV', 'LastName': 'Weinberg', 'Affiliation': 'Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Aimee E', 'Initials': 'AE', 'LastName': 'Wahle', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0b013e318263d106'] 1298,31996186,Lactoferrin infant feeding trial_Canada (LIFT_Canada): protocol for a randomized trial of adding lactoferrin to feeds of very-low-birth-weight preterm infants.,"BACKGROUND In Canada alone, almost 3000 VLBW infants are born and treated annually with almost 1200 going onto death or survival with severe brain injury, chronic lung disorders, aggressive retinopathy of prematurity, late-onset sepsis, or significant necrotizing enterocolitis. Lactoferrin is an antimicrobial, antioxidant, anti-inflammatory iron-carrying, bifidogenic glycoprotein found in all vertebrates and in mammalian milk, leukocytes and exocrine secretions. Lactoferrin aids in creating an environment for growth of beneficial bacteria in the gut, thus reducing colonization with pathogenic bacteria. It is hypothesized that oral bovine lactoferrin (bLF), through its antimicrobial, antioxidant and anti-inflammatory properties, will reduce the rate of mortality or major morbidity in very low birth weight preterm infants. METHOD Lactoferrin Infant Feeding Trial_Canada (LIFT_Canada) is a multi-centre, double-masked, randomized controlled trial with the aim to enroll 500 infants whose data will be combined with the data of the 1542 infants enrolled from Lactoferrin Infant Feeding Trial_Australia/New Zealand (LIFT_ANZ) in a pooled intention-to-treat analysis. Eligible infants will be randomized and allocated to one of two treatment groups: 1) a daily dose of 200 mg/kg bLF in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier; 2) no bLF with daily feeds. The primary outcome will be determined at 36 weeks corrected gestation for the presence of neonatal morbidity and at discharge for survival and treated retinopathy of prematurity. The duration of the trial is expected to be 36 months. DISCUSSION Currently, there continues to be no clear answer related to the benefit of bLF in reducing mortality or any or all of the significant neonatal morbidities in very low birth weight infants. LIFT_Canada is designed with the hope that the pooled results from Australia, New Zealand, and Canada may help to clarify the situation. TRIAL REGISTRATION Clinical Trials.Gov, Identifier: NCT03367013, Registered December 8, 2017.",2020,"Lactoferrin aids in creating an environment for growth of beneficial bacteria in the gut, thus reducing colonization with pathogenic bacteria.","['very low birth weight preterm infants', 'very low birth weight infants', '3000 VLBW infants are born and treated annually with almost 1200 going onto death or survival with severe brain injury, chronic lung disorders', 'enroll 500 infants whose data will be combined with the data of the 1542 infants enrolled from', 'Eligible infants', 'very-low-birth-weight preterm infants']","['Lactoferrin Infant Feeding Trial_Australia/New Zealand (LIFT_ANZ', 'Lactoferrin', 'Lactoferrin aids', 'Lactoferrin Infant Feeding Trial_Canada (LIFT_Canada', 'LIFT_Canada', 'bLF', 'lactoferrin', 'daily dose of 200\u2009mg/kg bLF in breast/donor human milk or formula milk until 34\u2009weeks corrected gestation or for a minimum of 2\u2009weeks, whichever is longer, or until discharge home or transfer, if earlier; 2) no bLF with daily feeds', 'oral bovine lactoferrin (bLF', 'Lactoferrin infant feeding trial_Canada (LIFT_Canada']",['neonatal morbidity and at discharge for survival and treated retinopathy of prematurity'],"[{'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0282667', 'cui_str': 'Infant, Very Low Birth Weight'}, {'cui': 'C0470279', 'cui_str': 'Three thousand'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C4517548', 'cui_str': 'One thousand two hundred'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0270611', 'cui_str': 'Brain Injuries'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0024115', 'cui_str': 'Pulmonary Diseases'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0022942', 'cui_str': 'Lactoferrin'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2987508', 'cui_str': 'Feeding (observable entity)'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0026140', 'cui_str': 'Breast Milk'}, {'cui': 'C0452742', 'cui_str': 'Formula milk (substance)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1440867', 'cui_str': 'lactoferrin, bovine'}]","[{'cui': 'C2939425', 'cui_str': 'Neonatal (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0035344', 'cui_str': 'Retrolental Fibroplasia'}]",1542.0,0.400141,"Lactoferrin aids in creating an environment for growth of beneficial bacteria in the gut, thus reducing colonization with pathogenic bacteria.","[{'ForeName': 'Elizabeth V', 'Initials': 'EV', 'LastName': 'Asztalos', 'Affiliation': 'Department of Newborn and Developmental Paediatrics, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, M4-230, 2075 Bayview Ave., Toronto, ON, M4N 3M5, Canada. elizabeth.asztalos@sunnybrook.ca.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Barrington', 'Affiliation': 'Department of Pediatrics, Université de Montréal, Montréal, PQ, Canada.'}, {'ForeName': 'Abhay', 'Initials': 'A', 'LastName': 'Lodha', 'Affiliation': 'Department of Pediatrics, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Tarnow-Mordi', 'Affiliation': 'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.'}]",BMC pediatrics,['10.1186/s12887-020-1938-0'] 1299,31505954,Hip abductor strength-based exercise therapy in treating women with moderate-to-severe knee osteoarthritis: a randomized controlled trial.,"OBJECTIVE To investigate whether hip abductor strength-based exercise therapy could result in further function improvement and more pain relief in women with knee osteoarthritis. DESIGN Randomized controlled trial. SETTINGS Rehabilitation department of Affiliated Hospital of Southwest Medical University from years 2016 to 2018. SUBJECTS In total, 82 women aged 50-70 years, with knee osteoarthritis grade II-IV on the Kellgren-Lawrence scale. INTERVENTION The experimental group engaged in hip abductor strength-based exercises under the supervision of physical therapists (once a day for six weeks), while the control group engaged in quadriceps femoris strength-based exercises. MAIN MEASURES Osteoarthritis severity measured by the Western Ontario and McMaster Universities Osteoarthritis Index, pain on a visual analogue scale and three objective functional tests were assessed at the sixth and 12th week. Repeated measures analysis of variance and multivariable analysis were applied. RESULTS Finally, 72 participants completed the study: 35 in the experimental group and 37 in the control group. The self-reported functional difficulties score in the experimental group was significantly lower than that in the control group both at the sixth week and at the 12th week ( P < 0.001). There were significant differences between groups in the stair ascent/descent task and Figure of 8 Walk test, but not in the Five Times Sit-to-Stand Test. The pain in the experimental group decreased compared with that in the control group at the sixth week ( P < 0.05), but not at the 12th week ( P > 0.05). CONCLUSION Hip abductor strength-based exercises could result in better performance and higher self-reported function in women with symptomatic knee osteoarthritis.",2020,"There were significant differences between groups in the stair ascent/descent task and Figure of 8 Walk test, but not in the Five Times Sit-to-Stand Test.","['treating women with moderate-to-severe knee osteoarthritis', '72 participants completed the study: 35 in the experimental group and 37 in the control group', 'women with knee osteoarthritis', '82 women aged 50-70 years, with knee osteoarthritis grade II-IV on the Kellgren-Lawrence scale', 'Rehabilitation department of Affiliated Hospital of Southwest Medical University from years 2016 to 2018', 'women with symptomatic knee osteoarthritis']","['Hip abductor strength-based exercise therapy', 'control group engaged in quadriceps femoris strength-based exercises', 'hip abductor strength-based exercise therapy', 'Hip abductor strength-based exercises', 'hip abductor strength-based exercises under the supervision of physical therapists']","['self-reported functional difficulties score', 'pain', 'pain relief', 'Osteoarthritis severity measured by the Western Ontario and McMaster Universities Osteoarthritis Index, pain on a visual analogue scale and three objective functional tests', 'stair ascent/descent task and Figure of 8 Walk test']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis, Knee'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0587478', 'cui_str': 'Rehabilitation department (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}]","[{'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0452240', 'cui_str': 'Rehabilitation Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapists'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3472647', 'cui_str': 'WOMAC index'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",72.0,0.0458777,"There were significant differences between groups in the stair ascent/descent task and Figure of 8 Walk test, but not in the Five Times Sit-to-Stand Test.","[{'ForeName': 'Jianxiong', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Yujie', 'Initials': 'Y', 'LastName': 'Xie', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Lei', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Liao', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'ShiQi', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'YaQian', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Fangyuan', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}, {'ForeName': 'Chi', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': ""Department of Rehabilitation Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.""}]",Clinical rehabilitation,['10.1177/0269215519875328'] 1300,32091560,Assessment and Management of Somatic Dysfunctions in Patients With Patellofemoral Pain Syndrome.,"Context Patellofemoral pain syndrome (PFPS) is one of the most common determinants of knee pain. The causes of PFPS are multifactorial, and most treatment approaches are conservative. There are many kinds of therapy for this syndrome, which are based on building strength, flexibility, proprioception, and endurance. Training is functional and progression is gradual. Our hypothesis is that total-body osteopathic manipulative therapy (OMTh; manipulative care provided by foreign-trained osteopaths) focused on the management of somatic dysfunctions could be useful for managing the pain of patients with PFPS. Objective To investigate the effect of OMTh on pain reduction in patients with PFPS. Methods This pilot study was randomized, controlled, and single-blinded with 2 months of follow-up. Qualified participants were randomly assigned to 1 of 2 groups: OMTh group or placebo group. Each participant received either 4 sessions of OMTh or 4 sessions of manual placebo intervention that consisted of passive touching without joint mobilization in a protocolled order. A visual analogue scale (VAS) was used to assess general knee pain, peripatellar pain, pain after prolonged sitting, pain during the patellar compression test, and pain during stair ascent and descent. Pain assessment was performed before the baseline (T0), second (T1), third (T2), and fourth (T3) sessions, and follow-up (T4) was performed 8 weeks after T3. Results Thirty-five participants were enrolled the study. The VAS score was significantly reduced and clinically relevant in the OMTh group after each treatment and after 2 months of follow-up. The change in the VAS score before each treatment indicates that the most improved areas at T1 compared with T0 were lumbar and sacral with improvements in 83% and 40% of patients, respectively. At T2 compared with T1, the most improved areas were cervical and sacral with improvements found in 58% and 36% of patients, respectively. The number of dysfunctions that were diagnosed decreased during the baseline to T3 period (40% change). The correlation analysis showed significant results for the dysfunction and the compression test at T2 (P=.01, ρ=0.543). Conclusion Significant differences in VAS scores were found between the OMTh and placebo groups. These findings underline how OMTh can lead to reduced pain in patients with PFPS.",2020,The VAS score was significantly reduced and clinically relevant in the OMTh group after each treatment and after 2 months of follow-up.,"['patients with PFPS', 'Patients With Patellofemoral Pain Syndrome', 'Thirty-five participants were enrolled the study']","['placebo', 'OMTh group or placebo', 'OMTh or 4 sessions of manual placebo intervention that consisted of passive touching without joint mobilization', 'OMTh']","['VAS score', 'number of dysfunctions', 'Pain assessment', 'pain reduction', 'VAS scores', 'visual analogue scale (VAS', 'general knee pain, peripatellar pain, pain after prolonged sitting, pain during the patellar compression test, and pain during stair ascent and descent']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0877149', 'cui_str': 'Patellofemoral Pain Syndrome'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0152054', 'cui_str': 'Therapeutic Touch'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization (observable entity)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0030198', 'cui_str': 'Nociception Tests'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0231749', 'cui_str': 'Knee pain (finding)'}, {'cui': 'C0439590', 'cui_str': 'Prolonged (qualifier value)'}, {'cui': 'C3669211', 'cui_str': 'Patellar compression test'}]",35.0,0.139301,The VAS score was significantly reduced and clinically relevant in the OMTh group after each treatment and after 2 months of follow-up.,"[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Tramontano', 'Affiliation': ''}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Pagnotta', 'Affiliation': ''}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Lunghi', 'Affiliation': ''}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Manzo', 'Affiliation': ''}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Manzo', 'Affiliation': ''}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Consolo', 'Affiliation': ''}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Manzo', 'Affiliation': ''}]",The Journal of the American Osteopathic Association,['10.7556/jaoa.2020.029'] 1301,23624296,Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression.,"The tumor necrosis factor (TNF) antagonist infliximab was recently found to reduce depressive symptoms in patients with increased baseline inflammation as reflected by a plasma C-reactive protein concentration >5 mg/L. To further explore predictors and targets of response to infliximab, differential gene expression was examined in peripheral blood mononuclear cells from infliximab responders (n=13) versus non-responders (n=14) compared to placebo at baseline and 6 h, 24 h, and 2 weeks after the first infliximab infusion. Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. One-hundred-forty-eight gene transcripts were significantly associated (1.2-fold, adjusted p≤0.01) with response to infliximab and were distinct from placebo responders. Transcripts predictive of infliximab response were associated with gluconeogenesis and cholesterol transport, and were enriched in a network regulated by hepatocyte nuclear factor (HNF)4-alpha, a transcription factor involved in gluconeogenesis and cholesterol and lipid homeostasis. Of the 148 transcripts differentially expressed at baseline, 48% were significantly regulated over time in infliximab responders, including genes related to gluconeogenesis and the HNF4-alpha network, indicating that these predictive genes were responsive to infliximab. Responders also demonstrated inhibition of genes related to apoptosis through TNF signaling at 6 h and 24 h after infusion. Transcripts down-regulated in responders 2 weeks after infliximab were related to innate immune signaling and nuclear factor-kappa B. Thus, baseline transcriptional signatures reflective of alterations in glucose and lipid metabolism predicted antidepressant response to infliximab, and infliximab response involved regulation of metabolic genes and inhibition of genes related to innate immune activation.",2013,Transcripts down-regulated in responders 2 weeks after infliximab were related to innate immune signaling and nuclear factor-kappa B.,['patients with treatment-resistant depression'],['placebo'],"['depressive symptoms', 'peripheral blood mononuclear cells']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",148.0,0.0289673,Transcripts down-regulated in responders 2 weeks after infliximab were related to innate immune signaling and nuclear factor-kappa B.,"[{'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Mehta', 'Affiliation': 'Max Planck Institute of Psychiatry, Munich, Germany.'}, {'ForeName': 'Charles L', 'Initials': 'CL', 'LastName': 'Raison', 'Affiliation': ''}, {'ForeName': 'Bobbi J', 'Initials': 'BJ', 'LastName': 'Woolwine', 'Affiliation': ''}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Haroon', 'Affiliation': ''}, {'ForeName': 'Elisabeth B', 'Initials': 'EB', 'LastName': 'Binder', 'Affiliation': ''}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Felger', 'Affiliation': ''}]","Brain, behavior, and immunity",['10.1016/j.bbi.2013.04.004'] 1302,21440942,SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.,"PURPOSE To investigate in The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study: (1) incidences of neovascular events and retinal capillary nonperfusion (abbreviated as ""nonperfusion""), and their relationship with treatment groups; (2) neovascular incidences by nonperfusion status; and (3) pertinent baseline factors for their potential risk for neovascular events. DESIGN Two multicenter, randomized clinical trials, 1 evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). PARTICIPANTS At 36 months, data were available for 81 participants with CRVO and 128 with BRVO. INTERVENTION Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone. MAIN OUTCOME MEASURES Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion. RESULTS The cumulative 36-month incidences for CRVO and BRVO eyes, respectively, were 8.5% and 2.4% for NVI or NVG; 8.8% and 7.6% for NVD/NVE or PRH/VH. There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases. For CRVO at 36 months, 16.6% of eyes with ≥5.5 disc areas of nonperfusion versus 4.0% of eyes with <5.5 disc areas of nonperfusion developed NVG (P = 0.0003); for BRVO at 36 months, 14.6% versus 2.4% developed NVD/NVE (P<0.0001). Similar results were noted for most other neovascular events. Nonperfusion was the only significant baseline factor for neovascularization in BRVO, with the risk of a neovascular event increasing with greater disc areas of nonperfusion, and the highest risk noted at ≥5.5 disc areas. CONCLUSIONS In the SCORE Study, triamcinolone treatment was not associated with lower incidences of neovascular events or nonperfusion status compared with observation or grid photocoagulation. Cumulative 36-month incidences for most neovascular events were significantly higher for nonperfused than perfused eyes. Greater baseline disc areas of nonperfusion increased the risk of neovascularization in BRVO but not CRVO eyes, possibly owing to obscuration of retinal capillary details caused by dense hemorrhage at baseline for CRVO eyes. Increased risk of neovascularization was noted below the historical threshold of 10 disc areas of nonperfusion for retinal vein occlusion.",2011,There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases.,"['eyes with retinal vein occlusion', 'participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO', 'At 36 months, data were available for 81 participants with CRVO and 128 with BRVO']","['triamcinolone', 'Standard care (observation or grid photocoagulation) versus 1 or 4 mg intravitreal triamcinolone', 'Standard Care versus COrticosteroid']","['Increased risk of neovascularization', 'neovascular events', 'Neovascularization of the iris (NVI), neovascular glaucoma (NVG), disc or retinal neovascularization (NVD/NVE), preretinal or vitreous hemorrhage (PRH/VH), and nonperfusion', 'neovascular events or risk of nonperfusion', 'cumulative 36-month incidences for CRVO and BRVO eyes']","[{'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0470187', 'cui_str': 'Availability of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C1302035', 'cui_str': 'Grid photocoagulation'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0027686', 'cui_str': 'Pathologic Neovascularization'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0022077', 'cui_str': 'Iris'}, {'cui': 'C0017609', 'cui_str': 'Glaucoma, Neovascular'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0035320', 'cui_str': 'Retinal Neovascularization'}, {'cui': 'C0042909', 'cui_str': 'Vitreous Hemorrhage'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]",81.0,0.036906,There were no differences in incidences of neovascular events or risk of nonperfusion when comparing the 3 treatment groups within diseases.,"[{'ForeName': 'Clement K', 'Initials': 'CK', 'LastName': 'Chan', 'Affiliation': 'Southern California Desert Retina Consultants, Palm Springs, CA, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Vanveldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Tolentino', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2010.11.020'] 1303,22415333,"Famotidine in the treatment of functional dyspepsia: a randomized double-blind, placebo-controlled trial.","AIM In the present study, we aimed to investigate patients with a documented diagnosis of functional dyspepsia (FD) who had been admitted to our outpatient Gastroenterology Clinic and provided consent to participate in this randomized, double-blind, placebo-controlled trial of the therapeutic impact of famotidine on the symptoms and quality of life of FD patients. PARTICIPANTS AND METHODS A total of 160 patients attending our outpatient clinic with a diagnosis of FD according to Rome III criteria were enrolled in this double-blind study. They were randomized into case (famotidine treatment) and placebo groups; patients were asked to refill the Honk Kong dyspepsia index (a self global assessment tool) before the start of the study as well as after 3 months of treatment. RESULTS Both famotidine and placebo led to significant improvements in dyspepsia symptoms, except for vomiting in both groups and loss of appetite in the placebo control group. However, the extent of these improvements was not different between the two study groups for most of the study parameters, whereas belching, feeling of acid regurgitation, heartburn, and the total score for the Hong Kong dyspepsia index were significantly more responsive to famotidine than placebo. No significant effectiveness of famotidine therapy was found regarding quality of life. CONCLUSION AND RECOMMENDATIONS This study showed a significant improvement in the total dyspepsia scores of FD, with a marked effect on belching, heartburn, and the feeling of acid regurgitation. These findings suggest that famotidine may be administered in certain FD patients who have significantly more symptoms of belching, heartburn, and acid regurgitation.",2012,"Both famotidine and placebo led to significant improvements in dyspepsia symptoms, except for vomiting in both groups and loss of appetite in the placebo control group.","['A total of 160 patients attending our outpatient clinic with a diagnosis of FD according to Rome III criteria', 'functional dyspepsia', 'patients with a documented diagnosis of functional dyspepsia (FD) who had been admitted to our outpatient Gastroenterology Clinic and provided consent']","['famotidine', 'Famotidine', 'placebo']","['dyspepsia symptoms', 'vomiting', 'symptoms of belching, heartburn, and acid regurgitation', 'quality of life', 'belching, heartburn, and the feeling of acid regurgitation', 'total dyspepsia scores of FD', 'belching, feeling of acid regurgitation, heartburn, and the total score for the Hong Kong dyspepsia index']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0730261', 'cui_str': 'Attends outpatients'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C3834491', 'cui_str': 'Gastroenterology clinic (environment)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}]","[{'cui': 'C0015620', 'cui_str': 'Famotidine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0014724', 'cui_str': 'Belching'}, {'cui': 'C0018834', 'cui_str': 'Pyrosis'}, {'cui': 'C0001128', 'cui_str': 'Acids'}, {'cui': 'C0460152', 'cui_str': 'Regurgitation - mechanism (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0019907', 'cui_str': 'Hongkong'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",160.0,0.412435,"Both famotidine and placebo led to significant improvements in dyspepsia symptoms, except for vomiting in both groups and loss of appetite in the placebo control group.","[{'ForeName': 'Mohsen', 'Initials': 'M', 'LastName': 'Amini', 'Affiliation': 'Baqiyatallah University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Ebrahim', 'Initials': 'ME', 'LastName': 'Ghamar Chehreh', 'Affiliation': ''}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Khedmat', 'Affiliation': ''}, {'ForeName': 'Ghasem', 'Initials': 'G', 'LastName': 'Valizadegan', 'Affiliation': ''}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Babaei', 'Affiliation': ''}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Darvishi', 'Affiliation': ''}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Taheri', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,['10.1097/01.EPX.0000410948.64665.66'] 1304,31843246,Elastic compression after ultrasound-guided foam sclerotherapy in overweight patients does not improve primary venous hemodynamics outcomes.,"OBJECTIVE Lower extremity varicose veins have a high prevalence and can be associated with significant morbidity in their more advanced presentations; overweight patients tend to present with more severe clinical symptoms and conventional surgical treatment remains challenging. Although the advent of ultrasound-guided foam sclerotherapy (UGFS) increased the treatment options for these patients, the need for elastic compression after UGFS remains controversial. METHODS Overweight patients with lower extremity varicose veins secondary to great saphenous vein reflux were treated with UGFS and then randomized to use or no use of a 3-week treatment of elastic compression stockings. Follow-up was performed by clinical evaluation and duplex ultrasound examination. The primary outcome measure was the absence of venous reflux in the great saphenous vein. RESULTS One hundred thirty-five lower limbs were treated; 72 limbs were randomized to elastic compression and 63 limbs to the control group. There were no statistically significant differences in the number of procedures (P = .64) or the mean foam volume per procedure (P = .27) between groups. There was no difference in the reflux rate at either 3 weeks (26% vs 35%; P = .16) or 3 months (25% vs 21%; P = .85). Major complications were venous deep thrombosis (n = 2), neurologic event (n = 1), and ischemic ulceration (n = 1); the overall rate was 3% in both groups-2 of 62 in control patients and 2 of 69 in compression patients (P = .45). Venous diameter reduction was noted in both groups during treatment (P < .05) but with greater decrease in greater saphenous vein diameter in patients treated with compression. CONCLUSIONS Elastic compression stockings for 3 consecutive weeks after UGFS in overweight patients did not decrease great saphenous vein reflux, need for repeat procedures, or the volume of foam injected. However, UGFS was associated with a greater and uniform reduction in saphenous vein diameter at all times after the procedure.",2020,There was no difference in the reflux rate at either 3 weeks (26% vs 35%; P = .16) or 3 months (25% vs 21%; P = .85).,"['One hundred thirty-five lower limbs were treated; 72 limbs', 'overweight patients', 'Overweight patients with lower extremity varicose veins secondary to great saphenous vein reflux were treated with']","['Elastic compression after ultrasound-guided foam sclerotherapy', 'UGFS', 'elastic compression stockings', 'ultrasound-guided foam sclerotherapy (UGFS', 'elastic compression', 'Elastic compression stockings']","['saphenous vein diameter', 'reflux rate', 'Venous diameter reduction', 'number of procedures', 'absence of venous reflux in the great saphenous vein', 'neurologic event', 'ischemic ulceration', 'great saphenous vein reflux', 'overall rate']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0042345', 'cui_str': 'Varices'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0991510', 'cui_str': 'Foam (basic dose form)'}, {'cui': 'C0036435', 'cui_str': 'Sclerotherapy'}, {'cui': 'C0038348', 'cui_str': 'Compression Stockings'}]","[{'cui': 'C0036186', 'cui_str': 'Saphenous Vein'}, {'cui': 'C1301886', 'cui_str': 'Diameter (qualifier value)'}, {'cui': 'C0348013', 'cui_str': 'Venous (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C2363955', 'cui_str': 'Venous reflux'}, {'cui': 'C0392907', 'cui_str': 'Great saphenous vein structure'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C3887532', 'cui_str': 'Ulceration (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",135.0,0.0432575,There was no difference in the reflux rate at either 3 weeks (26% vs 35%; P = .16) or 3 months (25% vs 21%; P = .85).,"[{'ForeName': 'Cristiane Vilaça', 'Initials': 'CV', 'LastName': 'Campos Gomes', 'Affiliation': 'Department of Cardiovascular, Division of Vascular Surgery, University Hospital of Sergipe, Federal University of Sergipe, Aracaju, Brazil. Electronic address: cristianevilaca@gmail.com.'}, {'ForeName': 'Marco Antônio', 'Initials': 'MA', 'LastName': 'Prado Nunes', 'Affiliation': 'Department of Cardiovascular, Division of Vascular Surgery, University Hospital of Sergipe, Federal University of Sergipe, Aracaju, Brazil.'}, {'ForeName': 'Tulio Pinho', 'Initials': 'TP', 'LastName': 'Navarro', 'Affiliation': 'Department of Surgery, Vascular Surgery Unit, Federal University of Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Dardik', 'Affiliation': 'Department of Surgery, Division of Vascular Surgery, Yale University School of Medicine, New Haven, Conn.'}]",Journal of vascular surgery. Venous and lymphatic disorders,['10.1016/j.jvsv.2019.07.008'] 1305,31855909,Changes on Tendon Stiffness and Clinical Outcomes in Athletes Are Associated With Patellar Tendinopathy After Eccentric Exercise.,"OBJECTIVE Eccentric exercise is commonly used as a form of loading exercise for individuals with patellar tendinopathy. This study investigated the change of mechanical properties and clinical outcomes and their interrelationships after a 12-week single-legged decline-board exercise with and without extracorporeal shockwave therapy (ESWT). DESIGN Randomized controlled trial. SETTING Outpatient clinic of a university. PARTICIPANTS Thirty-four male in-season athletes with patellar tendinopathy for more than 3 months were randomized into exercise and combined groups. INTERVENTIONS The exercise group received a 12-week single-legged decline-squat exercise, and the combined group performed an identical exercise program in addition to a weekly session of ESWT in the initial 6 weeks. MAIN OUTCOME MEASURES Tendon stiffness and strain were examined using ultrasonography and dynamometry. Visual analog scale and Victoria Institute of Sports Assessment-patella (VISA-p) score were used to assess pain and dysfunction. These parameters were measured at preintervention and postintervention. RESULTS Significant time effect but no significant group effect on the outcome measures; significant reduction in tendon stiffness (P = 0.02) and increase in tendon strain (P = 0.00); and reduction of intensity of pain (P = 0.00) and dysfunction (P = 0.00) were observed. Significant correlations between changes in tendon stiffness and VISA-p score (ρ = -0.58, P = 0.05); alteration in tendon strain, pain intensity (ρ = -0.63, P = 0.03); and VISA-p score (ρ = 0.60, P = 0.04) were detected after the exercise program. CONCLUSIONS Eccentric exercise-induced modulation on tendon mechanical properties and clinical symptoms are associated in athletes with patellar tendinopathy.",2020,"RESULTS Significant time effect but no significant group effect on the outcome measures; significant reduction in tendon stiffness (P = 0.02) and increase in tendon strain (P = 0.00); and reduction of intensity of pain (P = 0.00) and dysfunction (P = 0.00) were observed.","['Outpatient clinic of a university', 'athletes with patellar tendinopathy', 'individuals with patellar tendinopathy', 'Thirty-four male in-season athletes with patellar tendinopathy for more than 3 months']","['Eccentric exercise', 'single-legged decline-board exercise with and without extracorporeal shockwave therapy (ESWT', 'Eccentric exercise-induced modulation', '12-week single-legged decline-squat exercise, and the combined group performed an identical exercise program in addition to a weekly session of ESWT']","['Tendon Stiffness and Clinical Outcomes', 'pain and dysfunction', 'Visual analog scale and Victoria Institute of Sports Assessment-patella (VISA-p) score', 'Tendon stiffness and strain', 'reduction of intensity of pain', 'tendon stiffness and VISA-p score', 'tendon stiffness', 'tendon mechanical properties and clinical symptoms', 'tendon strain', 'tendon strain, pain intensity']","[{'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C1568272', 'cui_str': 'Tendinopathy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1737238', 'cui_str': 'Extracorporeal Shockwave Therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C0039508', 'cui_str': 'Tendons'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0030647', 'cui_str': 'Kneecap'}, {'cui': 'C1318881', 'cui_str': 'Infection due to vancomycin intermediate Staphylococcus aureus'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0871161', 'cui_str': 'Property (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0434303', 'cui_str': 'Tendon strain (disorder)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",34.0,0.0305104,"RESULTS Significant time effect but no significant group effect on the outcome measures; significant reduction in tendon stiffness (P = 0.02) and increase in tendon strain (P = 0.00); and reduction of intensity of pain (P = 0.00) and dysfunction (P = 0.00) were observed.","[{'ForeName': 'Wai-Chun', 'Initials': 'WC', 'LastName': 'Lee', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.'}, {'ForeName': 'Gabriel Yin-Fat', 'Initials': 'GY', 'LastName': 'Ng', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.'}, {'ForeName': 'Zhi-Jie', 'Initials': 'ZJ', 'LastName': 'Zhang', 'Affiliation': 'Department of Physical Therapy, Luoyang Orthopedic Hospital of Henan Province, Luoyang, Henan, China.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Malliaras', 'Affiliation': 'Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Lorenzo', 'Initials': 'L', 'LastName': 'Masci', 'Affiliation': 'Pure Sports Medicine, London, United Kingdom.'}, {'ForeName': 'Siu-Ngor', 'Initials': 'SN', 'LastName': 'Fu', 'Affiliation': 'Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong SAR, China.'}]",Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine,['10.1097/JSM.0000000000000562'] 1306,31969108,A telehealth approach to improving clinical trial access for infants with tuberous sclerosis complex.,"BACKGROUND Research in rare genetic syndromes associated with ASD is often hampered by the wide geographic distribution of families and the presence of medical comorbidities, such as epilepsy, that may preclude travel to clinical sites. These challenges can limit the sample size and generalizability of the cohorts included in both natural history studies and clinical trials. Tuberous sclerosis complex (TSC) is a rare genetic syndrome that confers an elevated risk for autism spectrum disorder (ASD), with social communication delays identified in this population as early as 12 months of age. Early identification of risk necessitates parallel testing of early intervention, prompting the first randomized controlled clinical trial of behavioral intervention for infants with TSC (NCT03422367). However, considerable early recruitment challenges have mandated the systematic identification of enrollment barriers followed by modification of the study design to address these barriers. METHODS Caregivers were interviewed regarding barriers to enrollment (phase 1). Adaptations to the intervention were made to address these barriers (phase 2). Outcomes based on this modification to the study design were defined by enrollment rate and participant demographics. RESULTS Qualitative reports from caregivers indicated that distance and time were the primary barriers to clinical trial enrollment. The intervention was then modified to a remote model, with at-home, parent-delivered intervention, and weekly video conferencing with interventionists at the study sites. Enrollment increased 10-fold (from 3 to 30 participants) within 1 year and included a more diverse and clinically representative cohort of infants. CONCLUSION The design and implementation of more scalable methods to disseminate research remotely can substantially improve access to clinical trials in rare neurodevelopmental disorders. The lessons learned from this trial can serve as a model for future studies not only in rare conditions, but in other populations that lack adequate access, such as families with limited financial or clinical resources. Continued efforts will further refine delivery methods to enhance efficiency and ease of these delivery systems for families.",2020,"Early identification of risk necessitates parallel testing of early intervention, prompting the first randomized controlled clinical trial of behavioral intervention for infants with TSC (NCT03422367).","['infants with TSC (NCT03422367', 'infants with tuberous sclerosis complex', 'Caregivers were interviewed regarding barriers to enrollment (phase 1']",['behavioral intervention'],[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0041341', 'cui_str': 'Sclerosis Tuberosa'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0439559', 'cui_str': 'Phase 1 (qualifier value)'}]",[],[],30.0,0.103292,"Early identification of risk necessitates parallel testing of early intervention, prompting the first randomized controlled clinical trial of behavioral intervention for infants with TSC (NCT03422367).","[{'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Hyde', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, 90095, USA. chyde@mednet.ucla.edu.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pizzano', 'Affiliation': 'UCLA Graduate School of Education and Information Studies, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'McDonald', 'Affiliation': 'UCLA Semel Institute, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Nelson', 'Affiliation': ""Boston Children's Hospital and Harvard Medical School, Harvard Graduate School of Education, Boston, MA, 02115, USA.""}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Kasari', 'Affiliation': 'UCLA Semel Institute, Los Angeles, CA, 90095, USA.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Thiele', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, Herscot Center for Tuberous Sclerosis Complex, Boston, MA, 02114, USA.'}, {'ForeName': 'Shafali S', 'Initials': 'SS', 'LastName': 'Jeste', 'Affiliation': 'UCLA Semel Institute, Los Angeles, CA, 90095, USA.'}]",Journal of neurodevelopmental disorders,['10.1186/s11689-019-9302-0'] 1307,31625041,A Systems-Level Approach to Improving Medication Adherence in Hypertensive Latinos: a Randomized Control Trial.,"BACKGROUND Despite numerous interventions targeting medication adherence in patients with uncontrolled hypertension, practice-based trials in Latino patients are scant. OBJECTIVE To evaluate the effect of a systems-level adherence intervention, delivered by medical assistants (MAs), versus a comparison condition on medication adherence and blood pressure (BP) in 119 hypertensive Latino patients who were initially non-adherent to their antihypertensive medications. STUDY DESIGN Randomized control trial. PARTICIPANTS Patients (50% women; mean age, 61 years) were recruited from April 2013 to August 2015 in a community-based practice in New York. INTERVENTION Systems-level approach that included an office system component built into the electronic health record and a provider support component consisting of nine MA-delivered health coaching sessions for improving medication adherence. The comparison group received the standard health coaching procedures followed at the clinic. MAIN OUTCOME MEASURES The primary outcome was rate of medication adherence measured by an electronic monitoring device (EMD) across 6 months. The secondary outcomes were self-reported medication adherence measured by the eight-item Morisky Medication Adherence Scale (MMAS-8) and BP reduction from baseline to 6 months. KEY RESULTS Adherence as measure by EMD worsened for both groups (p = 0.04) with no between-group difference (- 9.6% intervention and - 6.6% control, p = 0.66). While systolic BP improved in both groups, the difference between groups was not significant (- 6 mmHg in intervention vs. - 2.7 mmHg in control, p = 0.34). In contrast, the intervention group had a greater improvement in self-reported adherence (mean change 1.98 vs. 1.26, p = 0.03) when measured using the MMAS-8. CONCLUSIONS Among Latinos with poorly controlled BP who were non-adherent to their antihypertensive medications, a systems-level intervention did not improve adherence as measured by EMD nor blood pressure. However, many patients reported challenges to using the EMD. Improvements in self-reported adherence suggest that this measure captures different aspects of adherence behavior than EMD. CLINICAL TRIAL REGISTRATION NCT03560596.",2020,"Adherence as measure by EMD worsened for both groups (p = 0.04) with no between-group difference (- 9.6% intervention and - 6.6% control, p = 0.66).","['Hypertensive Latinos', 'patients with uncontrolled hypertension, practice-based trials in Latino patients', '119 hypertensive Latino patients who were initially non-adherent to their antihypertensive medications', 'Patients (50% women; mean age, 61 years) were recruited from April 2013 to August 2015 in a community-based practice in New York']","['standard health coaching procedures', 'systems-level adherence intervention, delivered by medical assistants (MAs', 'Systems-level approach that included an office system component built into the electronic health record and a provider support component consisting of nine MA-delivered health coaching sessions']","['self-reported medication adherence measured by the eight-item Morisky Medication Adherence Scale (MMAS-8) and BP reduction', 'medication adherence and blood pressure (BP', 'EMD', 'EMD nor blood pressure', 'self-reported adherence', 'rate of medication adherence measured by an electronic monitoring device (EMD', 'systolic BP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027976', 'cui_str': 'New York'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0334914', 'cui_str': 'Medical assistant (occupation)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C2362543', 'cui_str': 'Electronic Medical Record'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0340861', 'cui_str': 'PEA - Pulseless electrical activity'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",,0.0737003,"Adherence as measure by EMD worsened for both groups (p = 0.04) with no between-group difference (- 9.6% intervention and - 6.6% control, p = 0.66).","[{'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Schoenthaler', 'Affiliation': 'Department of Population Health, Center for Healthful Behavior Change, New York University School of Medicine, New York, NY, USA. Antoinette.Schoenthaler@nyumc.org.'}, {'ForeName': 'Franzenith', 'Initials': 'F', 'LastName': 'de la Calle', 'Affiliation': 'Department of Population Health, Center for Healthful Behavior Change, New York University School of Medicine, New York, NY, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Pitaro', 'Affiliation': 'Union Health Center, New York, NY, USA.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Lum', 'Affiliation': 'Union Health Center, New York, NY, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Chaplin', 'Affiliation': 'Department of Psychology, St. Johns University, Jamaica, NY, USA.'}, {'ForeName': 'Jazmin', 'Initials': 'J', 'LastName': 'Mogavero', 'Affiliation': 'Department of Psychology, St. Johns University, Jamaica, NY, USA.'}, {'ForeName': 'Milagros C', 'Initials': 'MC', 'LastName': 'Rosal', 'Affiliation': 'Preventive and Behavioral Medicine, Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05419-3'] 1308,31916648,"The beneficial health effects of Nigella sativa on Helicobacter pylori eradication, dyspepsia symptoms, and quality of life in infected patients: A pilot study.","The aim of this study was to evaluate the effects of Nigella sativa (N. sativa) in addition to quadruple-therapy on Helicobacter pylori eradication, dyspepsia, biochemical-markers, and quality of life in infected patients. In this double-blind placebo-controlled clinical-trial, 51 H. pylori infected patients with functional dyspepsia were randomly assigned to treatment (quadruple-therapy with 2 g/day N. sativa) or placebo groups (quadruple-therapy with 2 g/day placebo) for 8 weeks. Serum levels of interleukin-8 (IL-8), high-sensitivity C-reactive protein (hs-CRP) and malondialdehyde, quality of life, dyspepsia, food-intake, body-weight, and body mass index (BMI) were evaluated at the baseline and at the end of the study. H. pylori eradication was evaluated at the end of the intervention. At the end of the study, H. pylori eradication was more in the N. sativa group compared with the placebo (p = .01). Weight, BMI, and dietary-intake (p < .05) increased significantly as compared with placebo. A significant improvement was also observed in patients' quality of life in the treatment group compared with the placebo (p < .05). The differences of biochemical-markers and dyspepsia between the two groups were not significant. So, N. sativa supplementation with medical treatment may have beneficial effects on H. pylori eradication, weight, BMI, dietary-intake, and quality of life in infected patients.",2020,A significant improvement was also observed in patients' quality of life in the treatment group compared with the placebo (p < .05).,"['infected patients', '51 H. pylori infected patients with functional dyspepsia']","['placebo', 'placebo groups (quadruple-therapy with 2\u2009g/day placebo', 'Nigella sativa', 'Nigella sativa (N. sativa']","['Helicobacter pylori eradication, dyspepsia symptoms, and quality of life', 'Weight, BMI, and dietary-intake', 'pylori eradication', ""patients' quality of life"", 'Helicobacter pylori eradication, dyspepsia, biochemical-markers, and quality of life', 'H. pylori eradication, weight, BMI, dietary-intake, and quality of life', 'H. pylori eradication', 'Serum levels of interleukin-8 (IL-8), high-sensitivity C-reactive protein (hs-CRP) and malondialdehyde, quality of life, dyspepsia, food-intake, body-weight, and body mass index (BMI', 'biochemical-markers and dyspepsia']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205175', 'cui_str': 'Quadruple (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439417', 'cui_str': 'g/day'}, {'cui': 'C1140702', 'cui_str': 'Cumin, Black'}]","[{'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0034380'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Marker'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}]",,0.184888,A significant improvement was also observed in patients' quality of life in the treatment group compared with the placebo (p < .05).,"[{'ForeName': 'Mahvash', 'Initials': 'M', 'LastName': 'Alizadeh-Naini', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Hedieh', 'Initials': 'H', 'LastName': 'Yousefnejad', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}, {'ForeName': 'Najmeh', 'Initials': 'N', 'LastName': 'Hejazi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.'}]",Phytotherapy research : PTR,['10.1002/ptr.6610'] 1309,32423512,"Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial.","OBJECTIVE. The aim of this fixed-dose study was to evaluate the efficacy and safety of dasotraline in the treatment of patients with binge-eating disorder (BED). METHODS. Patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for BED were randomized to 12 weeks of double-blind treatment with fixed doses of dasotraline (4 and 6 mg/d), or placebo. The primary efficacy endpoint was change in number of binge-eating (BE) days per week at week 12. Secondary efficacy endpoints included week 12 change on the BE CGI-Severity Scale (BE-CGI-S) and the Yale-Brown Obsessive-Compulsive Scale Modified for BE (YBOCS-BE). RESULTS. At week 12, treatment with dasotraline was associated with significant improvement in number of BE days per week on the dose of 6 mg/d (N = 162) vs placebo (N = 162; -3.47 vs -2.92; P = .0045), but not 4 mg/d (N = 161; -3.21). Improvement vs placebo was observed for dasotraline 6 and 4 mg/d, respectively, on the BE-CGI-S (effect size [ES]: 0.37 and 0.27) and on the YBOCS-BE total score (ES: 0.43 and 0.29). The most common adverse events on dasotraline were insomnia, dry mouth, headache, decreased appetite, nausea, and anxiety. Changes in blood pressure and pulse were minimal. CONCLUSION. Treatment with dasotraline 6 mg/d (but not 4 mg/d) was associated with significantly greater reduction in BE days per week. Both doses of dasotraline were generally safe and well-tolerated and resulted in global improvement on the BE-CGI-S, as well as improvement in BE related obsessional thoughts and compulsive behaviors on the YBOCS-BE. These results confirm the findings of a previous flexible dose study.",2020,,['Adults with Binge-Eating Disorder'],"['Placebo', 'Dasotraline']",['Efficacy and Safety'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0596170', 'cui_str': 'Binge eating disorder'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4276542', 'cui_str': '4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.635752,,"[{'ForeName': 'Carlos M', 'Initials': 'CM', 'LastName': 'Grilo', 'Affiliation': 'Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'McElroy', 'Affiliation': 'Lindner Center of HOPE, Mason, Ohio, USA.'}, {'ForeName': 'James I', 'Initials': 'JI', 'LastName': 'Hudson', 'Affiliation': 'Biological Psychiatry Laboratory McLean Hospital, Belmont, Massachusetts, USA.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Tsai', 'Affiliation': 'Global Clinical Research, Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}, {'ForeName': 'Bradford', 'Initials': 'B', 'LastName': 'Navia', 'Affiliation': 'Global Clinical Research, Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Goldman', 'Affiliation': 'Global Clinical Research, Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Deng', 'Affiliation': 'Biostatistics, Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Kent', 'Affiliation': 'Global Clinical Research, Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}, {'ForeName': 'Antony', 'Initials': 'A', 'LastName': 'Loebel', 'Affiliation': 'Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts, USA.'}]",CNS spectrums,['10.1017/S1092852920001406'] 1310,22301525,NIDCAP improves brain function and structure in preterm infants with severe intrauterine growth restriction.,"OBJECTIVE The effect of NIDCAP (Newborn Individualized Developmental Care and Assessment Program) was examined on the neurobehavioral, electrophysiological and neurostructural development of preterm infants with severe intrauterine growth restriction (IUGR). STUDY DESIGN A total of 30 infants, 27-33 weeks gestation, were randomized to control (C; N=17) or NIDCAP/experimental (E; N=13) care. Baseline health and demographics were assessed at intake; electroencephalography (EEG) and magnetic resonance imaging (MRI) at 35 and 42 weeks postmenstrual age; and health, growth and neurobehavior at 42 weeks and 9 months corrected age (9 months). RESULTS C and E infants were comparable in health and demographics at baseline. At follow-up, E infants were healthier, showed significantly improved brain development and better neurobehavior. Neurobehavior, EEG and MRI discriminated between C and E infants. Neurobehavior at 42 weeks correlated with EEG and MRI at 42 weeks and neurobehavior at 9 months. CONCLUSION NIDCAP significantly improved IUGR preterm infants' neurobehavior, electrophysiology and brain structure. Longer-term outcome assessment and larger samples are recommended.",2012,"At follow-up, E infants were healthier, showed significantly improved brain development and better neurobehavior.","['preterm infants with severe intrauterine growth restriction (IUGR', 'preterm infants with severe intrauterine growth restriction', 'A total of 30 infants, 27-33 weeks gestation']","['NIDCAP', 'NIDCAP (Newborn Individualized Developmental Care and Assessment Program']","['intake; electroencephalography (EEG) and magnetic resonance imaging (MRI', 'brain development and better neurobehavior', 'brain function and structure', 'Neurobehavior, EEG and MRI', ""IUGR preterm infants' neurobehavior, electrophysiology and brain structure""]","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0015934', 'cui_str': 'Intrauterine Growth Restriction'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0204796', 'cui_str': 'Special care of premature baby (regime/therapy)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0013865', 'cui_str': 'Electrophysiology'}]",30.0,0.0550992,"At follow-up, E infants were healthier, showed significantly improved brain development and better neurobehavior.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Als', 'Affiliation': ""Department of Psychiatry, Children's Hospital Boston and Harvard Medical School, Boston, MA 02115, USA. heidelise.als@childrens.harvard.edu""}, {'ForeName': 'F H', 'Initials': 'FH', 'LastName': 'Duffy', 'Affiliation': ''}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'McAnulty', 'Affiliation': ''}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Butler', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lightbody', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kosta', 'Affiliation': ''}, {'ForeName': 'N I', 'Initials': 'NI', 'LastName': 'Weisenfeld', 'Affiliation': ''}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Robertson', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Parad', 'Affiliation': ''}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Ringer', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Blickman', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Zurakowski', 'Affiliation': ''}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Warfield', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/jp.2011.201'] 1311,32423348,Associations Between Dietary Patterns and Subclinical Cardiac Injury: An Observational Analysis From the DASH Trial.,"BACKGROUND The DASH diet has been found to lower blood pressure (BP) and low-density lipoprotein cholesterol levels. OBJECTIVE To compare diets rich in fruits and vegetables with a typical American diet in their effects on cardiovascular injury in middle-aged adults without known preexisting cardiovascular disease (CVD). DESIGN Observational study based on a 3-group, parallel-design, randomized trial conducted in the United States from 1994 to 1996. (ClinicalTrials.gov: NCT00000544). SETTING 3 of the 4 original clinical trial centers. PARTICIPANTS 326 of the original 459 trial participants with available stored specimens. INTERVENTION Participants were randomly assigned to 8 weeks of monitored feeding with a control diet typical of what many Americans eat; a diet rich in fruits and vegetables but otherwise similar to the control diet; or the DASH diet, which is rich in fruits, vegetables, low-fat dairy, and fiber and has low levels of saturated fat and cholesterol. Weight was kept constant throughout feeding. MEASUREMENTS Biomarkers collected at baseline and 8 weeks: high-sensitivity cardiac troponin I (hs-cTnI), N -terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity C-reactive protein (hs-CRP). RESULTS The mean age of participants was 45.2 years, 48% were women, 49% were black, and mean baseline BP was 131/85 mm Hg. Compared with the control diet, the fruit-and-vegetable diet reduced hs-cTnI levels by 0.5 ng/L (95% CI, -0.9 to -0.2 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.1 pg/mL). Compared with the control diet, the DASH diet reduced hs-cTnI levels by 0.5 ng/L (CI, -0.9 to -0.1 ng/L) and NT-proBNP levels by 0.3 pg/mL (CI, -0.5 to -0.04 pg/mL). Levels of hs-CRP did not differ among diets. None of the markers differed between the fruit-and-vegetable and DASH diets. LIMITATION Short duration, missing specimens, and an inability to isolate the effects of specific foods or micronutrients. CONCLUSION Diets rich in fruits and vegetables given over 8 weeks were associated with lower levels of markers for subclinical cardiac damage and strain in adults without preexisting CVD. PRIMARY FUNDING SOURCE National Institutes of Health, National Heart, Lung, and Blood Institute.",2020,"Diets rich in fruits and vegetables given over 8 weeks were associated with lower levels of markers for subclinical cardiac damage and strain in adults without preexisting CVD. ","['middle-aged adults without known preexisting cardiovascular disease (CVD', '3 of the 4 original clinical trial centers', '326 of the original 459 trial participants with available stored specimens', 'United States from 1994 to 1996', 'The mean age of participants was 45.2 years, 48% were women, 49% were black, and mean baseline BP was 131/85 mm Hg', 'adults without preexisting CVD']","['diets rich in fruits and vegetables with a typical American diet', 'control diet typical of what many Americans eat; a diet rich in fruits and vegetables but otherwise similar to the control diet; or the DASH diet']","['blood pressure (BP) and low-density lipoprotein cholesterol levels', 'cardiovascular injury', 'NT-proBNP levels', 'hs-cTnI levels', 'Weight', 'Levels of hs-CRP', 'high-sensitivity cardiac troponin']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C5191353', 'cui_str': '326'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement'}, {'cui': 'C0560570', 'cui_str': 'Cardiovascular injury'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1096316', 'cui_str': 'Cardiac troponin'}]",,0.0964925,"Diets rich in fruits and vegetables given over 8 weeks were associated with lower levels of markers for subclinical cardiac damage and strain in adults without preexisting CVD. ","[{'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Juraschek', 'Affiliation': 'Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (S.P.J., K.J.M.).'}, {'ForeName': 'Lara C', 'Initials': 'LC', 'LastName': 'Kovell', 'Affiliation': 'University of Massachusetts Medical School, Worcester, Massachusetts (L.C.K.).'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Appel', 'Affiliation': 'The Johns Hopkins University School of Medicine, The Johns Hopkins Bloomberg School of Public Health, and The Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland (L.J.A., E.R.M.).'}, {'ForeName': 'Edgar R', 'Initials': 'ER', 'LastName': 'Miller', 'Affiliation': 'The Johns Hopkins University School of Medicine, The Johns Hopkins Bloomberg School of Public Health, and The Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland (L.J.A., E.R.M.).'}, {'ForeName': 'Frank M', 'Initials': 'FM', 'LastName': 'Sacks', 'Affiliation': ""Harvard T.H. Chan School of Public Health, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts (F.M.S.).""}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Christenson', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, Maryland (R.H.C., H.R.).'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Rebuck', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, Maryland (R.H.C., H.R.).'}, {'ForeName': 'Alexander R', 'Initials': 'AR', 'LastName': 'Chang', 'Affiliation': 'Geisinger Health System, Danville, Pennsylvania (A.R.C.).'}, {'ForeName': 'Kenneth J', 'Initials': 'KJ', 'LastName': 'Mukamal', 'Affiliation': 'Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (S.P.J., K.J.M.).'}]",Annals of internal medicine,['10.7326/M20-0336'] 1312,31843251,Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis.,"BACKGROUND After deep venous thrombosis (DVT), many patients have impaired quality of life (QOL). We aimed to assess whether pharmacomechanical catheter-directed thrombolysis (PCDT) improves short-term or long-term QOL in patients with proximal DVT and whether QOL is related to extent of DVT. METHODS The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial was an assessor-blinded randomized trial that compared PCDT with no PCDT in patients with DVT of the femoral, common femoral, or iliac veins. QOL was assessed at baseline and 1 month, 6 months, 12 months, 18 months, and 24 months using the Venous Insufficiency Epidemiological and Economic Study on Quality of Life/Symptoms (VEINES-QOL/Sym) disease-specific QOL measure and the 36-Item Short Form Health Survey (SF-36) physical component summary (PCS) and mental component summary general QOL measures. Change in QOL scores from baseline to assessment time were compared in the PCDT and no PCDT treatment groups overall and in the iliofemoral DVT and femoral-popliteal DVT subgroups. RESULTS Of 692 ATTRACT patients, 691 were analyzed (mean age, 53 years; 62% male; 57% iliofemoral DVT). VEINES-QOL change scores were greater (ie, better) in PCDT vs no PCDT from baseline to 1 month (difference, 5.7; P = .0006) and from baseline to 6 months (5.1; P = .0029) but not for other intervals. SF-36 PCS change scores were greater in PCDT vs no PCDT from baseline to 1 month (difference, 2.4; P = .01) but not for other intervals. Among iliofemoral DVT patients, VEINES-QOL change scores from baseline to all assessments were greater in the PCDT vs no PCDT group; this was statistically significant in the intention-to-treat analysis at 1 month (difference, 10.0; P < .0001) and 6 months (8.8; P < .0001) and in the per-protocol analysis at 18 months (difference, 5.8; P = .0086) and 24 months (difference, 6.6; P = .0067). SF-36 PCS change scores were greater in PCDT vs no PCDT from baseline to 1 month (difference, 3.2; P = .0010) but not for other intervals. In contrast, in femoral-popliteal DVT patients, change scores from baseline to all assessments were similar in the PCDT and no PCDT groups. CONCLUSIONS Among patients with proximal DVT, PCDT leads to greater improvement in disease-specific QOL than no PCDT at 1 month and 6 months but not later. In patients with iliofemoral DVT, PCDT led to greater improvement in disease-specific QOL during 24 months.",2020,"Among patients with proximal DVT, PCDT leads to greater improvement in disease-specific QOL than no PCDT at 1 month and 6 months but not later.","['patients with DVT of the femoral, common femoral, or iliac veins', 'proximal deep venous thrombosis', 'Of 692 ATTRACT patients, 691 were analyzed (mean age', '53\xa0years; 62% male; 57% iliofemoral DVT', 'patients with proximal DVT and whether QOL']","['PCDT with no PCDT', 'pharmacomechanical catheter-directed thrombolysis', 'pharmacomechanical catheter-directed thrombolysis (PCDT', 'PCDT']","['QOL scores', 'disease-specific QOL', 'Quality of life', 'VEINES-QOL change scores', 'Quality of Life/Symptoms (VEINES-QOL/Sym) disease-specific QOL measure and the 36-Item Short Form Health Survey (SF-36) physical component summary (PCS) and mental component summary general QOL measures', 'SF-36 PCS change scores', 'QOL']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0020888', 'cui_str': 'Iliac Vein'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis, function (observable entity)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0034380'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",691.0,0.105402,"Among patients with proximal DVT, PCDT leads to greater improvement in disease-specific QOL than no PCDT at 1 month and 6 months but not later.","[{'ForeName': 'Susan R', 'Initials': 'SR', 'LastName': 'Kahn', 'Affiliation': 'Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: susan.kahn@mcgill.ca.'}, {'ForeName': 'Jim A', 'Initials': 'JA', 'LastName': 'Julian', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada; Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Kearon', 'Affiliation': 'Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Chu-Shu', 'Initials': 'CS', 'LastName': 'Gu', 'Affiliation': 'Department of Oncology, McMaster University, Hamilton, Ontario, Canada; Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Cohen', 'Affiliation': ""Department of Medicine, University of Missouri-Kansas City, Kansas City, Mo; St. Luke's Mid America Heart Institute, Kansas City, Mo.""}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Magnuson', 'Affiliation': ""St. Luke's Mid America Heart Institute, Kansas City, Mo.""}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Comerota', 'Affiliation': 'Inova Heart and Vascular Institute, Inova Alexandria Hospital, Alexandria, Va.'}, {'ForeName': 'Samuel Z', 'Initials': 'SZ', 'LastName': 'Goldhaber', 'Affiliation': ""Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Jaff', 'Affiliation': 'Harvard Medical School, Boston, Mass; Newton-Wellesley Hospital, Newton, Mass.'}, {'ForeName': 'Mahmood K', 'Initials': 'MK', 'LastName': 'Razavi', 'Affiliation': ""St. Joseph's Hospital, Orange, Calif.""}, {'ForeName': 'Andrei L', 'Initials': 'AL', 'LastName': 'Kindzelski', 'Affiliation': 'Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.'}, {'ForeName': 'Joseph R', 'Initials': 'JR', 'LastName': 'Schneider', 'Affiliation': 'Vascular Surgery and Interventional Radiology Partners/VSIR, Northwestern Medicine, Chicago, Ill.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Maine Medical Center, Portland, Me.'}, {'ForeName': 'Rabih', 'Initials': 'R', 'LastName': 'Chaer', 'Affiliation': 'Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.'}, {'ForeName': 'Akhilesh K', 'Initials': 'AK', 'LastName': 'Sista', 'Affiliation': 'Department of Radiology, New York University, New York, NY.'}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'McLafferty', 'Affiliation': 'Department of Surgery, Portland Veterans Administration, Portland, Me.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Kaufman', 'Affiliation': 'Department of Interventional Radiology, Dotter Interventional Institute, Oregon Health & Science University, Portland.'}, {'ForeName': 'Brandt C', 'Initials': 'BC', 'LastName': 'Wible', 'Affiliation': ""Department of Radiology, St. Luke's Hospital, Kansas City, Mo.""}, {'ForeName': 'Morey', 'Initials': 'M', 'LastName': 'Blinder', 'Affiliation': 'Department of Medicine, Washington University in St. Louis, St. Louis, Mo.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Vedantham', 'Affiliation': 'Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Mo.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular surgery. Venous and lymphatic disorders,['10.1016/j.jvsv.2019.03.023'] 1313,30876922,The use of dispatcher assistance in improving the quality of cardiopulmonary resuscitation: A randomised controlled trial.,"AIMS The introduction of dispatcher assistance (DA) services has led to increased bystander cardiopulmonary resuscitation (CPR) participation rates. However, the extent to which DA improves CPR quality remains unclear. This study aimed to evaluate the efficacy of DA in improving CPR quality among healthcare professionals and laypersons within a multi-ethnic Southeast Asian population. METHODS A parallel, randomised controlled, open label trial was performed. Four hundred and twelve participants were recruited via convenience sampling in a public location. In a simulated cardiac-arrest scenario, the participants were randomised to perform CPR with DA over the phone (DA+) or CPR without DA (DA-). The ratio of participant assignment to DA+ and DA- was 1:1. The primary outcomes were CPR compression depth, compression rate, no-flow time, complete release of pressure between compressions, and hand location. The assessment involved CPR manikins and human assessors. RESULTS A larger proportion of participants in DA + achieved the correct compression rate (34.3% vs 18.1%, p < 0.001). There was no difference in the other primary outcomes. A subgroup analysis revealed that healthcare professionals in DA+ had a higher proportion of correct hand location compared to those in DA- (82.1% vs. 53.5%, p < 0.05). There was no significant difference in CPR quality among laypersons with valid CPR certification regardless of whether they received DA. CONCLUSION DA should be provided to laypersons without valid CPR certification, as well as healthcare professionals. The identification of gaps in the current DA protocol highlights areas where specific changes can be made to improve CPR quality.",2019,"A subgroup analysis revealed that healthcare professionals in DA+ had a higher proportion of correct hand location compared to those in DA- (82.1% vs. 53.5%, p < 0.05).","['healthcare professionals and laypersons within a multi-ethnic Southeast Asian population', 'Four hundred and twelve participants were recruited via convenience sampling in a public location']","['dispatcher assistance (DA) services', 'dispatcher assistance', 'DA', 'CPR with DA over the phone (DA+) or CPR without DA (DA']","['quality of cardiopulmonary resuscitation', 'CPR quality', 'CPR compression depth, compression rate, no-flow time, complete release of pressure between compressions, and hand location', 'correct compression rate']","[{'cui': 'C1704312', 'cui_str': 'Healthcare professional (occupation)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0078988', 'cui_str': 'Asians'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C3816746', 'cui_str': 'Four hundred'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}]","[{'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}]","[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0450429', 'cui_str': 'Location (attribute)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}]",412.0,0.0482514,"A subgroup analysis revealed that healthcare professionals in DA+ had a higher proportion of correct hand location compared to those in DA- (82.1% vs. 53.5%, p < 0.05).","[{'ForeName': 'Ming Hao Nelson', 'Initials': 'MHN', 'LastName': 'Teo', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore.'}, {'ForeName': 'Wen En Joseph', 'Initials': 'WEJ', 'LastName': 'Wong', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore. Electronic address: josephwong5@hotmail.com.'}, {'ForeName': 'Peter Chen-Yang Nikhil', 'Initials': 'PCN', 'LastName': 'Daniel', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore.'}, {'ForeName': 'Ren Hao Clement', 'Initials': 'RHC', 'LastName': 'Kweh', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore.'}, {'ForeName': 'Ren Yi Jonas', 'Initials': 'RYJ', 'LastName': 'Ho', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore.'}, {'ForeName': 'Jia Hong', 'Initials': 'JH', 'LastName': 'Koh', 'Affiliation': 'Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block Level 11, 119228, Singapore.'}, {'ForeName': 'Sieu-Hon Benjamin', 'Initials': 'SB', 'LastName': 'Leong', 'Affiliation': 'Emergency Medicine Department, National University Hospital, National University Health System, 5 Lower Kent Ridge Road, 119074, Singapore.'}, {'ForeName': 'Junxiong', 'Initials': 'J', 'LastName': 'Pang', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, #10-01, 117549, Singapore.'}, {'ForeName': 'Yi-Fu Jeff', 'Initials': 'YJ', 'LastName': 'Hwang', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, 12 Science Drive 2, #10-01, 117549, Singapore. Electronic address: jeff_yf_hwang@nuhs.edu.sg.'}]",Resuscitation,['10.1016/j.resuscitation.2019.03.003'] 1314,32430189,Experience of an upper limb training program with a non-immersive virtual reality system in patients after stroke: a qualitative study.,"OBJECTIVES The YouGrabber (YG) is a new virtual reality training system that focuses on unilateral and bimanual activities. This nested study was part of a larger multicenter randomized controlled trial and explored experiences of people with chronic stroke during a 4 weeks intensive upper limb training with YG. DESIGN A qualitative design using semi-structured, face-to-face interviews. A phenomenological descriptive approach was used, with data coded, categorized and summarized using a thematic analysis. Topics investigated included: the experience of YG training, perceived impact of YG training on arm function, and the role of the treating therapist. RESULTS Five people were interviewed (one female, age range 55 to 75 years, 1 to 6 years poststroke). Seven main themes were identified: (1) general experience, (2) expectations, (3) feedback, (4) arm function, (5) physiotherapist's role, (6) fatigue, (7) motivation. Key experiences reported included feelings of motivation and satisfaction, with positive factors identified as challenge, competition, fun and effort. The YG training appeared to trigger greater effort, however fatigue was experienced at the end of the training. Overall, patients described positive changes in upper limb motor function and activity level, e.g. automatic arm use. While the opportunity for self-practice was appreciated, input from the therapist at the start of the intervention was deemed important for safety and confidence. CONCLUSIONS Reported experiences were mostly positive and the participants were motivated to practice intensively. They enjoyed the challenging component of the games.",2020,The YouGrabber (YG) is a new virtual reality training system that focuses on unilateral and bimanual activities.,"['people with chronic stroke during a 4 weeks intensive upper limb training with YG', 'Five people were interviewed (one female, age range 55 to 75 years, 1 to 6 years poststroke', 'patients after stroke']","['upper limb training program with a non-immersive virtual reality system', 'YG training']","[""general experience, (2) expectations, (3) feedback, (4) arm function, (5) physiotherapist's role, (6) fatigue, (7) motivation"", 'upper limb motor function and activity level, e.g. automatic arm use', 'feelings of motivation and satisfaction']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0556501', 'cui_str': 'Upper limb training'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0556501', 'cui_str': 'Upper limb training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",5.0,0.0277916,The YouGrabber (YG) is a new virtual reality training system that focuses on unilateral and bimanual activities.,"[{'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Lehmann', 'Affiliation': 'Department of Physiotherapy, Inselspital, Bern University Hospital, Bern, Switzerland. Electronic address: isabelle.lehmann@insel.ch.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Baer', 'Affiliation': 'School of Health Sciences, Queen Margaret University, Edinburgh EH21 6UU, United Kingdom. Electronic address: gbaer@qmu.ac.uk.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Schuster-Amft', 'Affiliation': 'Research Department, Reha Rheinfelden, Rheinfelden, Switzerland; Institute for Rehabilitation and Performance Technology, Bern University of Applied Sciences, Burgdorf, Switzerland.'}]",Physiotherapy,['10.1016/j.physio.2017.03.001'] 1315,31350894,The Experimental Tobacco Marketplace: Demand and Substitutability as a Function of Cigarette Taxes and e-Liquid Subsidies.,"INTRODUCTION The experimental tobacco marketplace (ETM) approximates real-world situations by estimating the effects of several, concurrently available products and policies on budgeted purchasing. Although the effects of increasing cigarette price on potentially less harmful substitutability are well documented, the effects of other, nuanced pricing policies remain speculative. This study used the ETM as a tool to assess the effects of two pricing policies, conventional cigarette taxation and e-liquid subsidization, on demand and substitutability. METHODS During sampling periods, participants were provided 2-day samples of 24 mg/mL e-liquid, after which ETM purchase sessions occurred. Across two ETM sessions, conventional cigarettes were taxed or e-liquid was subsidized in combination with increasing cigarette price. The other four available products were always price constant and not taxed or subsidized. RESULTS E-liquid functioned as a substitute for conventional cigarettes across all conditions. Increasing cigarette taxation and e-liquid subsidization increased the number of participants for which e-liquid functioned as a substitute. Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability). E-liquid subsidization resulted in large increases in the initial intensity of e-liquid substitution, but did not affect e-liquid substitutability nor cigarette demand. IMPLICATIONS 24 mg/mL e-cigarette e-liquid was the only product to significantly substitute for cigarettes in at least one condition throughout the experiment; it functioned as a significant substitute throughout all four tax and all four subsidy conditions. Increasing cigarette taxes decreased cigarette demand through decreases in demand intensity but did not affect e-cigarette substitution. Increasing e-liquid subsidies increased e-liquid initial intensity of substitution but did not affect cigarette demand. CONCLUSIONS This study extended research on the behavioral economics of conventional cigarette demand and e-liquid substitutability in a complex marketplace. The results suggest that the most efficacious method to decrease conventional cigarette purchasing and increase e-liquid purchasing may involve greatly increasing cigarette taxes while also increasing the value of e-liquid through potentially less harmful product subsidization or differential taxation.",2020,"Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability).",[],[],"['Increasing cigarette taxation and e-liquid subsidization', 'initial intensity of e-liquid substitution']",[],[],"[{'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0039370', 'cui_str': 'Taxation'}, {'cui': 'C4543628', 'cui_str': 'Electronic cigarette liquid (physical object)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}]",,0.0121748,"Cigarette taxation decreased cigarette demand, by decreasing demand intensity, and marginally increased the initial intensity of e-liquid substitution, but did not affect the functions' slopes (substitutability).","[{'ForeName': 'Derek A', 'Initials': 'DA', 'LastName': 'Pope', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Lindsey', 'Initials': 'L', 'LastName': 'Poe', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Stein', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Brent A', 'Initials': 'BA', 'LastName': 'Kaplan', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'William B', 'Initials': 'WB', 'LastName': 'DeHart', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Alexandra M', 'Initials': 'AM', 'LastName': 'Mellis', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}, {'ForeName': 'Bryan W', 'Initials': 'BW', 'LastName': 'Heckman', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Chaloupka', 'Affiliation': 'Department of Economics, University of Illinois at Chicago, Chicago, IL.'}, {'ForeName': 'Warren K', 'Initials': 'WK', 'LastName': 'Bickel', 'Affiliation': 'Addiction Recovery Research Center, Fralin Biomedical Research Institute at VTC, Roanoke, VA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntz116'] 1316,31825075,A Carbohydrate Beverage Reduces Monocytes Expressing TLR4 in Children with Overweight or Obesity.,"BACKGROUND Childhood obesity is increasing, with about one-third of children overweight or obese. Obesity is characterized by a state of chronic low-grade inflammation that is related to cardiometabolic comorbidities. Inflammatory monocytes, which are classified into 3 different groups-classical, intermediate, and nonclassical monocytes, with Toll-like receptor 4 (TLR4+) expression indicating a proinflammatory state-underlie several obesity-associated morbidities. OBJECTIVES This study aimed to assess the responses of monocyte populations to beverages of differing macronutrient composition in children with healthy weight (HW) or overweight/obesity (OW/OB). METHODS Ten HW children (5th to 84.9th percentile; mean age 12.29 ± 2.5 y) and 7 children with OW/OB (85th to 99.99th percentile; mean age 11.96 ± 3.8 y) completed the study. Adiposity was determined via DXA. Using a double-blinded, randomized, crossover design, participants consumed either a high-carbohydrate (CHO; 210 kcal; 0 g fat/56 g carbohydrates/0 g protein) or a whole-egg-based high-protein/fat (EGG; 210 kcal; 15 g fat/0 g carbohydrates/18 g protein) beverage. Venous blood was collected at baseline and 2 h postprandially for evaluation of metabolic and inflammatory responses. Repeated measures ANOVA and Pearson correlations were conducted. RESULTS Consuming the CHO beverage significantly reduced the primary outcome: TLR4+ expression on classical monocytes in children with OW/OB only (25.60% decrease from baseline in OW/OB compared with 1.61% increase in HW). Children with OW/OB had significantly less percentages of TLR4+ nonclassical monocytes than HW (47.66% lower after CHO). Insulin and glucose (secondary outcomes), were significantly higher after the CHO condition compared with baseline (230.61% and 9.93% increase, respectively). Changes in glucose were significantly and negatively related to changes in monocyte populations in the CHO condition. CONCLUSIONS These data suggest that high-carbohydrate beverages alter monocyte populations in the blood in children with OW/OB, which is related to glucose metabolism. These findings have implications for nutritional recommendations in children with overweight/obesity. National Clinical Trial registry trial number: NCT03597542.",2020,Children with OW/OB had significantly less percentages of TLR4+ nonclassical monocytes than HW (47.66% lower after CHO).,"['children with OW/OB', 'Children with Overweight or Obesity', 'children with overweight/obesity', ' mean age 12.29\xa0±\xa02.5 y) and 7 children with OW/OB (85th to 99.99th percentile; mean age 11.96\xa0±\xa03.8 y) completed the study', 'Ten HW children ', 'children overweight or obese', 'children with healthy weight (HW) or overweight/obesity (OW/OB']","['Carbohydrate Beverage', 'high-carbohydrate (CHO; 210 kcal; 0\xa0g fat/56\xa0g carbohydrates/0\xa0g protein) or a whole-egg-based high-protein/fat (EGG; 210 kcal; 15\xa0g fat/0\xa0g carbohydrates/18\xa0g protein) beverage']","['Changes in glucose', 'Adiposity', 'Insulin and glucose', 'classical monocytes', 'TLR4+ nonclassical monocytes', 'Venous blood']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0005329', 'cui_str': 'Beverages'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0439259', 'cui_str': 'kilocalorie'}, {'cui': 'C0530867', 'cui_str': 'G13 Protein'}, {'cui': 'C0029974', 'cui_str': 'Egg, Unfertilized'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fats'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0443177', 'cui_str': 'Classical (qualifier value)'}, {'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C0229667', 'cui_str': 'VB - Venous blood'}]",10.0,0.0405511,Children with OW/OB had significantly less percentages of TLR4+ nonclassical monocytes than HW (47.66% lower after CHO).,"[{'ForeName': 'Grace M', 'Initials': 'GM', 'LastName': 'Niemiro', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Chiarlitti', 'Affiliation': 'School of Human Kinetics, Brain and Mind Institute, Centre on Neuromuscular Disease, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Naiman A', 'Initials': 'NA', 'LastName': 'Khan', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'De Lisio', 'Affiliation': 'Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, Urbana, IL, USA.'}]",The Journal of nutrition,['10.1093/jn/nxz294'] 1317,20837797,Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study system for evaluation of stereoscopic color fundus photographs and fluorescein angiograms: SCORE Study Report 9.,"OBJECTIVE To describe the procedures and reproducibility for grading stereoscopic color fundus photographs and fluorescein angiograms of participants in the SCORE Study. METHODS Standardized stereoscopic fundus photographs and fluorescein angiograms taken at 84 clinical centers were evaluated by graders at a central reading center. Type of retinal vein occlusion (RVO), area of retinal thickening, and area of retinal hemorrhage are evaluated from fundus photographs; area of fluorescein leakage and area of capillary nonperfusion are measured on fluorescein angiography. Temporal reproducibility consisted of annual regrading of a randomly selected dedicated subset of fundus photographs (60 subjects) and fluorescein angiograms (40 subjects) for 3 successive years. Contemporaneous reproducibility involved monthly regrading of a 5% random selection of recently evaluated fundus photographs (n = 73). RESULTS The intergrader agreement for RVO type and presence of retinal thickening was greater than 90% in the 3 annual regrades. The intraclass correlation (ICC) for area of retinal thickening in the 3 years ranged from 0.39 to 0.64 and for area of retinal hemorrhage, 0.87 to 0.96. The ICC for area of fluorescein leakage ranged from 0.66 to 0.75 and for capillary nonperfusion, 0.94 to 0.97. The contemporaneous reproducibility results were similar to those of temporal reproducibility for all variables except area of retinal thickening (ICC, 0.84). CONCLUSIONS The fundus photography and fluorescein angiography grading procedures for the SCORE Study are reproducible and can be used for multicenter longitudinal studies of RVO. A systematic temporal drift occurred in evaluating area of retinal thickening.",2010,The intergrader agreement for RVO type and presence of retinal thickening was greater than 90% in the 3 annual regrades.,"['Standardized stereoscopic fundus photographs and fluorescein angiograms taken at 84 clinical centers were evaluated by graders at a central reading center', 'participants in the SCORE Study']","['Standard Care vs Corticosteroid', 'randomly selected dedicated subset of fundus photographs (60 subjects) and fluorescein angiograms']","['fluorescein leakage', 'intraclass correlation (ICC) for area of retinal thickening', 'Type of retinal vein occlusion (RVO), area of retinal thickening, and area of retinal hemorrhage', 'RVO type and presence of retinal thickening']","[{'cui': 'C0227817', 'cui_str': 'Uterine Fundus'}, {'cui': 'C0441468', 'cui_str': 'Photograph (physical object)'}, {'cui': 'C0016313', 'cui_str': 'Fluorescein Angiography'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0227817', 'cui_str': 'Uterine Fundus'}, {'cui': 'C0441468', 'cui_str': 'Photograph (physical object)'}, {'cui': 'C0016313', 'cui_str': 'Fluorescein Angiography'}]","[{'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1302690', 'cui_str': 'Retinal thickening'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0035317', 'cui_str': 'Retinal Hemorrhage'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]",,0.0380307,The intergrader agreement for RVO type and presence of retinal thickening was greater than 90% in the 3 annual regrades.,"[{'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53705-3611, USA.'}, {'ForeName': 'Amitha', 'Initials': 'A', 'LastName': 'Domalpally', 'Affiliation': ''}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Julee', 'Initials': 'J', 'LastName': 'Elledge', 'Affiliation': ''}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Warren', 'Affiliation': ''}, {'ForeName': 'Michael M', 'Initials': 'MM', 'LastName': 'Altaweel', 'Affiliation': ''}, {'ForeName': 'Judy E', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Van Veldhuisen', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Archives of ophthalmology (Chicago, Ill. : 1960)",['10.1001/archophthalmol.2010.193'] 1318,32130025,Angiotensin II-mediated nondipping during sleep in healthy humans: effects on baroreflex function at subsequent daytime.,"Blood pressure dipping at night is mediated by sleep-inherent, active downregulation of sympathetic vascular tone. Concomitantly, activity of the renin-angiotensin system is reduced, which might contribute to the beneficial effect of baroreflex downward resetting on daytime blood pressure homeostasis. To evaluate whether experimental nondipping mediated by angiotensin II during sleep would alter blood pressure and baroreflex function the next day in healthy humans, angiotensin-II or placebo (saline) was infused for a 7-h period at night, preventing blood pressure dipping in 11 sleeping normotensive individuals (5 males, balanced, crossover design). Baroreflex function was assessed about 1 h upon awakening and stop of infusion via microneurographic recordings of muscle sympathetic nerve activity (MSNA), showing that resting MSNA was significantly increased following angiotensin II nondipping compared with placebo ( P = 0.029), whereas blood pressure and heart rate remained unchanged. Baroreflex sensitivity in response to vasoactive drug challenge was preserved, and neuroendocrine markers of fluid balance and electrolytes did not differ between conditions. Ambulatory blood pressure during subsequent daytime was not altered. Data were compared with analog experiments previously performed within the same subjects during awake daytime (ANCOVA). We conclude that angiotensin-II mediated nocturnal nondipping did not induce blood pressure elevation at subsequent daytime in healthy humans but was linked to increased vasoconstrictive sympathetic activity. This is in contrast to a prolonged increase in blood pressure in corresponding daytime experiments of the same individuals. Evidently, sleep strongly preserves normotensive blood pressure homeostasis in healthy humans.",2020,Ambulatory blood pressure during subsequent daytime was not altered.,"['healthy humans', 'eleven sleeping normotensive individuals (5 males, balanced, cross-over design']","['placebo', 'Angiotensin-II or placebo (saline', 'Angiotensin-II-mediated non-dipping', 'Angiotensin-II during sleep']","['Baroreflex sensitivity', 'Ambulatory blood pressure', 'blood pressure elevation', 'Blood pressure', 'baroreflex function', 'blood pressure and heart rate', 'blood pressure', 'blood pressure and baroreflex function', 'normotensive blood pressure homeostasis', 'Baroreflex function', 'vasoconstrictive sympathetic activity']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0242817', 'cui_str': 'Cross-Over Design'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0373546', 'cui_str': 'Angiotensin II measurement (procedure)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0378785', 'cui_str': 'DIPS'}, {'cui': 'C0587116', 'cui_str': 'During sleep (qualifier value)'}]","[{'cui': 'C0206162', 'cui_str': 'Reflex, Baroreceptor'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",11.0,0.0295353,Ambulatory blood pressure during subsequent daytime was not altered.,"[{'ForeName': 'Friedhelm', 'Initials': 'F', 'LastName': 'Sayk', 'Affiliation': 'Department of Internal Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Twesten', 'Affiliation': 'Department of Internal Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Adametz', 'Affiliation': 'Institute of Radiology, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Klaas', 'Initials': 'K', 'LastName': 'Franzen', 'Affiliation': 'Department of Internal Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Vonthein', 'Affiliation': 'Institute of Medical Biometry and Statistics, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Dodt', 'Affiliation': 'Department of Emergency Medicine, München-Bogenhausen Hospital, München, Germany.'}, {'ForeName': 'Moritz', 'Initials': 'M', 'LastName': 'Meusel', 'Affiliation': 'Department of Cardiology and Angiology, University Heart Center Lübeck, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00355.2019'] 1319,20926135,Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.,"OBJECTIVE To investigate baseline factors associated with visual acuity and central retinal thickness outcomes in patients with macular edema secondary to retinal vein occlusion in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study. DESIGN Two multicenter, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and one evaluating participants with branch retinal vein occlusion (BRVO). PARTICIPANTS Participants with follow-up data of 1 year or more, including 238 with CRVO and 367 with BRVO. METHODS Visual acuity was measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) method, and central retinal thickness was measured by optical coherence tomography (OCT). Regression analysis related these outcomes to 20 baseline measures. Multiple P values were adjusted to control the false discovery rate. MAIN OUTCOME MEASURES Outcome measures of visual acuity letter score included absolute change from baseline, a gain of ≥ 15 from baseline, and a loss of ≥ 15 from baseline. Outcome measures of center point thickness included absolute change from baseline, a measurement of ≤ 250 μm, and a measurement of ≥ 500 μm. Outcomes were assessed at 1 and 2 years. RESULTS For CRVO and BRVO, younger age was associated with improved visual acuity and central retinal thickness outcomes. For CRVO, triamcinolone treatment and less severe anatomic abnormalities of the retina (center point thickness and areas of retinal hemorrhage, thickening, and fluorescein leakage) were predictive of better visual acuity outcomes. For BRVO, no history of coronary artery disease was predictive of improved visual acuity outcomes. For center point thickness outcomes, shorter duration of macular edema was associated with improvement in both disease entities. For CRVO, higher baseline visual acuity letter score was predictive of favorable OCT outcomes. For BRVO, lower baseline visual acuity letter score, presence of dense macular hemorrhage, and no prior grid photocoagulation were predictive of favorable OCT outcomes. CONCLUSIONS Several factors were predictive of better visual acuity outcomes and more favorable OCT outcomes, including younger age and shorter duration of macular edema, respectively. These factors may assist clinicians in predicting disease course for patients with CRVO and BRVO.",2011,"For BRVO, no history of coronary artery disease was predictive of improved visual acuity outcomes.","['patients with macular edema secondary to retinal vein occlusion in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study', 'Participants with follow-up data of 1 year or more, including 238 with CRVO and 367 with BRVO', 'participants with central retinal vein occlusion (CRVO) and one evaluating participants with branch retinal vein occlusion (BRVO', 'patients with CRVO and BRVO', 'patients with retinal vein occlusion']","['Standard Care Versus COrticosteroid', 'CRVO, triamcinolone', 'BRVO']","['baseline visual acuity letter score', 'electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) method, and central retinal thickness', 'visual acuity letter score included absolute change from baseline, a gain of ≥ 15 from baseline, and a loss of ≥ 15 from baseline', 'severe anatomic abnormalities of the retina (center point thickness and areas of retinal hemorrhage, thickening, and fluorescein leakage', 'visual acuity and retinal thickness outcomes', 'shorter duration of macular edema', 'center point thickness included absolute change from baseline, a measurement of ≤ 250 μm, and a measurement of ≥ 500 μm', 'For BRVO, lower baseline visual acuity letter score, presence of dense macular hemorrhage', 'visual acuity outcomes', 'visual acuity and central retinal thickness outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0011884', 'cui_str': 'Diabetic Retinopathy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0220784', 'cui_str': 'Anatomic (qualifier value)'}, {'cui': 'C0000769', 'cui_str': 'anomalies'}, {'cui': 'C0035298', 'cui_str': 'Retina'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0035317', 'cui_str': 'Retinal Hemorrhage'}, {'cui': 'C0205400', 'cui_str': 'Thickened (qualifier value)'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C0439593', 'cui_str': 'Short duration (qualifier value)'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}]",,0.341791,"For BRVO, no history of coronary artery disease was predictive of improved visual acuity outcomes.","[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Mary Elizabeth', 'Initials': 'ME', 'LastName': 'Hartnett', 'Affiliation': ''}, {'ForeName': 'Geoff', 'Initials': 'G', 'LastName': 'Cohen', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2010.06.034'] 1320,31653476,The importance of relationship processes for lowering BMI over time in women with type 2 diabetes in a randomized controlled trial.,"OBJECTIVE Weight change may be affected by dyadic processes within couple relationships. The aim of this secondary data analysis was to explore trends in BMI across time, and assess whether relationship processes (i.e., relationship satisfaction, positive problem-solving), predict BMI trajectories in men and women. METHODS Data are from 268 participants in the Diabetes Support Project, a randomized trial of behavioral intervention for individuals with type 2 diabetes (T2D) in poor glycemic control. For secondary analyses, BMI was measured at pre-treatment (baseline), 4 months (post-treatment), 8 months, and 12 months. Multiple relationship variables were measured at all time points and were modeled as predictors and correlates of change in BMI across time. RESULTS In general, BMI trajectories had higher starting values (intercepts) for females than for males in the sample (b = -2.51, p < .05), and slopes trended downward from pre-treatment to 12 months (b = -.09, p <  .05). Downward trajectories of BMI were more pronounced for women with higher relationship satisfaction (b = .05, p <  .05) and higher positive problem solving skills (b = .06, p < .05) at baseline. Change in relationship processes were not correlated with change in BMI across time. CONCLUSION For women with T2D in this behavioral intervention study, relationship process scores at the beginning of treatment predicted changes in BMI over time, with better problem solving and higher relationship satisfaction at baseline related to steeper decreases in BMI across treatment. Additional research is needed to understand how improving relationship interaction prior to diabetes treatment may positively influence weight loss during treatment.",2019,"Downward trajectories of BMI were more pronounced for women with higher relationship satisfaction (b = .05, p <  .05) and higher positive problem solving skills (b = .06, p < .05) at baseline.","['individuals with type 2 diabetes (T2D) in poor glycemic control', 'men and women', '268 participants in the Diabetes Support Project', 'women with type 2 diabetes']",['behavioral intervention'],"['relationship satisfaction', 'BMI', 'positive problem solving skills', 'weight loss']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control (disorder)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]",[],"[{'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3669643', 'cui_str': 'Problem solving (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]",268.0,0.206139,"Downward trajectories of BMI were more pronounced for women with higher relationship satisfaction (b = .05, p <  .05) and higher positive problem solving skills (b = .06, p < .05) at baseline.","[{'ForeName': 'Jeremy B', 'Initials': 'JB', 'LastName': 'Yorgason', 'Affiliation': 'School of Family Life, Brigham Young University, Provo, UT United States. Electronic address: jeremy_yorgason@byu.edu.'}, {'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Sandberg', 'Affiliation': 'School of Family Life, Brigham Young University, Provo, UT United States.'}, {'ForeName': 'Ruth S', 'Initials': 'RS', 'LastName': 'Weinstock', 'Affiliation': 'The State University of New York Upstate Medical University, Syracuse, NY United States.'}, {'ForeName': 'Paula M', 'Initials': 'PM', 'LastName': 'Trief', 'Affiliation': 'The State University of New York Upstate Medical University, Syracuse, NY United States.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Fisher', 'Affiliation': 'The University of California, San Francisco, CA United States.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Hessler', 'Affiliation': 'The University of California, San Francisco, CA United States.'}]",Obesity research & clinical practice,['10.1016/j.orcp.2019.08.003'] 1321,31801814,Extremely Preterm Infants Have Significant Alterations in Their Conventional T Cell Compartment during the First Weeks of Life.,"Extremely preterm neonates are particularly susceptible to infections, likely because of severely impaired immune function. However, little is known on the composition of the T cell compartment in early life in this vulnerable population. We conducted a comprehensive phenotypic flow cytometry-based longitudinal analysis of the peripheral conventional T cell compartment of human extremely low gestational age neonates (ELGAN) with extremely low birth weight (ELBW; <1000 g) participating in a randomized placebo-controlled study of probiotic supplementation. PBMCs from ELGAN/ELBW neonates were collected at day 14, day 28, and postmenstrual week 36. Comparisons were made with full-term 14-d-old neonates. Total CD4 + and CD8 + T cell frequencies were markedly lower in the preterm neonates. The reduction was more pronounced among the CD8 + population, resulting in an increased CD4/CD8 ratio. The preterm infants were also more Th2 skewed than the full-term infants. Although the frequency of regulatory T cells seemed normal in the ELGAN/ELBW preterm neonates, their expression of the homing receptors α4β7, CCR4, and CCR9 was altered. Notably, ELGAN/ELBW infants developing necrotizing enterocolitis before day 14 had higher expression of CCR9 in CD4 + T cells at day 14. Chorioamnionitis clearly associated with reduced T regulatory cell frequencies and functional characteristics within the preterm group. Finally, probiotic supplementation with Lactobacillus reuteri did not impose any phenotypic changes of the conventional T cell compartment. In conclusion, notable immaturities of the T cell compartment in ELGAN/ELBW neonates may at least partially explain their increased susceptibility to severe immune-mediated morbidities.",2020,"Notably, ELGAN/ELBW infants developing necrotizing enterocolitis before day 14 had higher expression of CCR9 in CD4 + T cells at day 14.",['human extremely low gestational age neonates (ELGAN) with extremely low birth weight (ELBW; <1000 g) participating in a randomized'],"['placebo', 'probiotic supplementation']","['necrotizing enterocolitis', 'Total CD4 + and CD8 + T cell frequencies', 'CD4/CD8 ratio', 'reduced T regulatory cell frequencies and functional characteristics']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0205403', 'cui_str': 'Extreme (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0456065', 'cui_str': 'Infant, Extremely Low Birth Weight'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}]","[{'cui': 'C0520459', 'cui_str': 'Necrotizing Enterocolitis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1267822', 'cui_str': 'T lymphocyte positive for both CD4 antigen and CD25 antigen'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}]",,0.122672,"Notably, ELGAN/ELBW infants developing necrotizing enterocolitis before day 14 had higher expression of CCR9 in CD4 + T cells at day 14.","[{'ForeName': 'Khaleda Rahman', 'Initials': 'KR', 'LastName': 'Qazi', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden; qazi.khaleda.rahman@su.se.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Bach Jensen', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, 581 83 Linköping, Sweden.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'van der Heiden', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}, {'ForeName': 'Sophia', 'Initials': 'S', 'LastName': 'Björkander', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Holmlund', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}, {'ForeName': 'Yeneneh', 'Initials': 'Y', 'LastName': 'Haileselassie', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}, {'ForeName': 'Efthymia', 'Initials': 'E', 'LastName': 'Kokkinou', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Marchini', 'Affiliation': ""Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden.""}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Jenmalm', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, 581 83 Linköping, Sweden.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Abrahamsson', 'Affiliation': 'Department of Clinical and Experimental Medicine, Linköping University, 581 83 Linköping, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Sverremark-Ekström', 'Affiliation': 'Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, 106 91 Stockholm, Sweden.'}]","Journal of immunology (Baltimore, Md. : 1950)",['10.4049/jimmunol.1900941'] 1322,20673563,"Improvement of knowledge, attitudes and practices of health care workers towards the transmission of blood-borne pathogens: an intervention study.","BACKGROUND Health care workers (HCW) are at risk of occupational infection with blood-borne pathogens (BBP). AIM OF THE STUDY 1) to assess the knowledge, attitude and practice (KAP) of nurses, lab technicians and housekeepers working in nine Primary Health Care centers in Cairo and Giza governorates in Egypt concerning BBP; 2) to apply a health education intervention on BBP; 3) to assess the effectiveness of the health education intervention on the level of KAP of the study population. METHODS A total of 130 study participants were enrolled and received the health education intervention, only 86 participants came back for the post-intervention evaluation (drop-out rate = 33.8%). RESULTS It was found that 34% of participants were exposed to one or more needle stick injuries during the 3 months preceding the intervention, and only 13.8% received the hepatitis B immunization. Comparison of the pre- and post-intervention scores for the total study population showed a significant increase in the post-intervention cumulative KAP score, as well as the knowledge, attitude and practice scores by about 13, 12, 11 and 20% respectively (p<0.001). The housekeepers, compared to nurses and lab technicians, were the best recipients to the health education intervention with a significantly higher percent change of the KAP score (27.7, 16.9 and 9.5% respectively, p=0.005). Reasons for non-compliance to the application of preventive measures to protect against BBP were lack of resources, work overload and lack of training. CONCLUSION AND RECOMMENDATIONS Continuous education and in-service training on prevention of BBP transmission is mandatory to protect HCW.",2009,"Reasons for non-compliance to the application of preventive measures to protect against BBP were lack of resources, work overload and lack of training. ","['A total of 130 study participants were enrolled and received the', 'nurses, lab technicians and housekeepers working in nine Primary Health Care centers in Cairo and Giza governorates in Egypt concerning BBP']","['health education intervention', 'hepatitis B immunization']","['KAP score', 'post-intervention cumulative KAP score', 'needle stick injuries', 'knowledge, attitude and practice scores']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}, {'cui': 'C0914447', 'cui_str': 'BBP'}]","[{'cui': 'C0018701'}, {'cui': 'C0474232', 'cui_str': 'Hepatitis B vaccination (procedure)'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0085178', 'cui_str': 'Needle-Stick Injuries'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",130.0,0.017588,"Reasons for non-compliance to the application of preventive measures to protect against BBP were lack of resources, work overload and lack of training. ","[{'ForeName': ""Doa'a A"", 'Initials': 'DA', 'LastName': 'Saleh', 'Affiliation': 'Department of Community Medicine, Faculty of Medicine, Cairo, Egypt. doa_a_saleh@yahoo.com.'}, {'ForeName': 'Laila M', 'Initials': 'LM', 'LastName': 'Elghorory', 'Affiliation': ''}, {'ForeName': 'Maged R', 'Initials': 'MR', 'LastName': 'Shafik', 'Affiliation': ''}, {'ForeName': 'Enayat E', 'Initials': 'EE', 'LastName': 'Elsherbini', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1323,20651694,Is the Newborn Individualized Developmental Care and Assessment Program (NIDCAP) effective for preterm infants with intrauterine growth restriction?,"OBJECTIVE This study investigates the effectiveness of the Newborn Individualized Developmental Care and Assessment Program (NIDCAP) on neurobehavioral and electrophysiological functioning of preterm infants with severe intrauterine growth restriction (IUGR). STUDY DESIGN Thirty IUGR infants, 28 to 33 weeks gestational age, randomized to standard care (control/C=18), or NIDCAP (experimental/E=12), were assessed at 2 weeks corrected age (2wCA) and 9 months corrected age (9mCA) in regard to health, anthropometrics, and neurobehavior, and additionally at 2wCA in regard to electrophysiology (EEG). RESULT The two groups were comparable in health and anthropometrics at 2wCA and 9mCA. The E-group at 2wCA showed significantly better autonomic, motor, and self-regulation functioning, improved motility, intensity and response thresholds, and reduced EEG connectivity among several adjacent brain regions. At 9mCA, the E-group showed significantly better mental performance. CONCLUSION This is the first study to show NIDCAP effectiveness for IUGR preterm infants.",2011,"The E-group at 2wCA showed significantly better autonomic, motor, and self-regulation functioning, improved motility, intensity and response thresholds, and reduced EEG connectivity among several adjacent brain regions.","['IUGR preterm infants', 'preterm infants with severe intrauterine growth restriction (IUGR', 'Thirty IUGR infants, 28 to 33 weeks gestational age, randomized to standard care (control/C=18), or NIDCAP (experimental/E=12), were assessed at 2 weeks corrected age (2wCA) and 9 months corrected age (9mCA) in regard to health, anthropometrics, and neurobehavior, and additionally at 2wCA in regard to electrophysiology (EEG', 'preterm infants with intrauterine growth restriction']",['Newborn Individualized Developmental Care and Assessment Program (NIDCAP'],"['mental performance', 'autonomic, motor, and self-regulation functioning, improved motility, intensity and response thresholds, and reduced EEG connectivity']","[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0015934', 'cui_str': 'Intrauterine Growth Restriction'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013865', 'cui_str': 'Electrophysiology'}, {'cui': 'C0013819', 'cui_str': 'EEG'}]","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0204796', 'cui_str': 'Special care of premature baby (regime/therapy)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0684274', 'cui_str': 'Self Regulation'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1510470', 'cui_str': 'Motility (observable entity)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}]",30.0,0.0270818,"The E-group at 2wCA showed significantly better autonomic, motor, and self-regulation functioning, improved motility, intensity and response thresholds, and reduced EEG connectivity among several adjacent brain regions.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Als', 'Affiliation': ""Department of Psychiatry, Children's Hospital Boston, Boston, MA 02115 USA. heidelise.als@childrens.harvard.edu""}, {'ForeName': 'F H', 'Initials': 'FH', 'LastName': 'Duffy', 'Affiliation': ''}, {'ForeName': 'G B', 'Initials': 'GB', 'LastName': 'McAnulty', 'Affiliation': ''}, {'ForeName': 'C B', 'Initials': 'CB', 'LastName': 'Fischer', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kosta', 'Affiliation': ''}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Butler', 'Affiliation': ''}, {'ForeName': 'R B', 'Initials': 'RB', 'LastName': 'Parad', 'Affiliation': ''}, {'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Blickman', 'Affiliation': ''}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Zurakowski', 'Affiliation': ''}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Ringer', 'Affiliation': ''}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/jp.2010.81'] 1324,21244813,"Effectiveness of health education program for type 2 diabetes mellitus patients attending zagazig university diabetes clinic, egypt.","BACKGROUND Diabetes mellitus is a major public health problem. OBJECTIVES To i) assess knowledge, attitude, random blood sugar and glycosylated hemoglobin (HbA1c) levels in type 2 diabetics, ii) investigate the effect of different socio-demographic factors on acquiring knowledge about diabetes, iii) assess the effectiveness of health education on knowledge, attitude, blood sugar and HbA1c levels in type 2 diabetics. METHODS This intervention study was carried out on 122 randomly selected type 2 diabetics attending diabetes outpatient clinic in Zagazig University, from January 2009 to April 2009. A questionnaire (pretest) was used to collect data on socio-demographic characteristics, knowledge and attitude, then a blood sample was taken for testing random blood sugar and HbA1c. Patients were subjected to the first health education session where information about diabetes was provided. In the second visit patients were informed about the results of their investigations, and the remaining part of the educational message was delivered. In the 3rd visit, patients were subjected to the post test and blood samples were tested for random blood sugar and HbA1c. RESULTS The majority of patients had low levels of knowledge regarding different aspects of diabetes (Correct answers ranged from 16.39% to 49.18%). Knowledge level was significantly poor, among females, not educated, low social class, and rural residence and of older age group. After implementation of the educational message, a significant improvement was revealed in patients' knowledge and attitude with lowering of their mean levels of blood sugar and HbA 1c. CONCLUSION AND RECOMMENDATIONS Health education was an effective tool that implicated change in diabetic patients' knowledge, attitude towards diabetes, random blood sugar and HbA1c levels. Training of health care providers working in outpatient diabetes clinic regarding different aspects of type 2 diabetes is highly needed.",2010,The majority of patients had low levels of knowledge regarding different aspects of diabetes (Correct answers ranged from 16.39% to 49.18%).,"['122 randomly selected type 2 diabetics attending diabetes outpatient clinic in Zagazig University, from January 2009 to April 2009', 'type 2 diabetics', 'type 2 diabetes mellitus patients attending zagazig university diabetes clinic, egypt']",['health education program'],"['Knowledge level', ""patients' knowledge and attitude with lowering of their mean levels of blood sugar and HbA 1c"", 'knowledge, attitude, random blood sugar and glycosylated hemoglobin (HbA1c) levels', 'knowledge, attitude, blood sugar and HbA1c levels']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3839636', 'cui_str': 'Diabetes clinic'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}]","[{'cui': 'C0018701'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0871796', 'cui_str': 'Knowledge level'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}]",122.0,0.0166845,The majority of patients had low levels of knowledge regarding different aspects of diabetes (Correct answers ranged from 16.39% to 49.18%).,"[{'ForeName': 'Naglaa M', 'Initials': 'NM', 'LastName': 'Abdo', 'Affiliation': 'Community Medicine Department and Clinical Pathology, Faculty of Medicine, Zagazig University, Egypt. nagla_abdo@hotmail.com.'}, {'ForeName': 'Mohamed E', 'Initials': 'ME', 'LastName': 'Mohamed', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1325,31448116,Postprandial changes in gene expression of cholesterol influx and efflux mediators after intake of SFA compared with n -6 PUFA in subjects with and without familial hypercholesterolaemia: secondary outcomes of a randomised controlled trial.,,2019,,['subjects with and without familial hypercholesterolaemia'],[],[],"[{'cui': 'C0020445', 'cui_str': 'Hyperbetalipoproteinemia'}]",[],[],,0.191481,,"[{'ForeName': 'Linn K L', 'Initials': 'LKL', 'LastName': 'Øyri', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Ingunn', 'Initials': 'I', 'LastName': 'Narverud', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Martin P', 'Initials': 'MP', 'LastName': 'Bogsrud', 'Affiliation': 'Norwegian National Advisory Unit on Familial Hypercholesterolemia, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Aker Hospital, Building 6, 6th floor, Trondheimsveien 232, 0586 Oslo, Norway.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Hansson', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Leder', 'Affiliation': 'Mills AS, Sofienberggt. 19, 0558 Oslo, Norway.'}, {'ForeName': 'Marte G', 'Initials': 'MG', 'LastName': 'Byfuglien', 'Affiliation': 'Mills AS, Sofienberggt. 19, 0558 Oslo, Norway.'}, {'ForeName': 'Marit B', 'Initials': 'MB', 'LastName': 'Veierød', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Magne', 'Initials': 'M', 'LastName': 'Thoresen', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Stine M', 'Initials': 'SM', 'LastName': 'Ulven', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}, {'ForeName': 'Kirsten B', 'Initials': 'KB', 'LastName': 'Holven', 'Affiliation': 'Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Sognsvannsveien 9, 0372 Oslo, Norway.'}]",Journal of nutritional science,['10.1017/jns.2019.25'] 1326,31523425,The ConsuMEER study: a randomised trial towards the effectiveness of protein-rich ready-made meals and protein-rich dairy products in increasing protein intake of community-dwelling older adults after switching from self-prepared meals towards ready-made meals.,"The risk of undernutrition in older community-dwelling adults increases when they are no longer able to shop or cook themselves. Home-delivered products could then possibly prevent them from becoming undernourished. This single-blind randomised trial tested the effectiveness of home-delivered protein-rich ready-made meals and dairy products in reaching the recommended intake of 1·2 g protein/kg body weight (BW) per d and ≥25 g of protein per meal. Community-dwelling older adults ( n 98; mean age 80·4 (sd 6·8) years) switched from self-prepared to home-delivered hot meals and dairy products for 28 d. The intervention group received ready-made meals and dairy products high in protein; the control group received products lower in protein. Dietary intake was measured at baseline, after 2 weeks (T1), and after 4 weeks (T2). Multilevel analyses (providing one combined outcome for T1 and T2) and logistic regressions were performed. Average baseline protein intake was 1·09 (se 0·05) g protein/kg BW per d in the intervention group and 0·99 (se 0·05) g protein/kg BW per d in the control group. During the trial, protein intake of the intervention group was 1·12 (se 0·05) g protein/kg BW per d compared with 0·87 (se 0·03) g protein/kg BW per d in the control group (between-group differences P < 0·05). More participants of the intervention group reached the threshold of ≥25 g protein at dinner compared with the control group (intervention T1: 84·8 %, T2: 88·4 % v. control T1: 42·9 %, T2: 40·5 %; P < 0·05), but not at breakfast and lunch. Our findings suggest that switching from self-prepared meals to ready-made meals carries the risk of a decreasing protein intake, unless extra attention is given to protein-rich choices.",2019,The risk of undernutrition in older community-dwelling adults increases when they are no longer able to shop or cook themselves.,"['mean age 80·4', 'community-dwelling older adults after switching from self-prepared meals towards ready-made meals', '1·2 g protein/kg body weight (BW) per d and ≥25 g of protein per meal', 'older community-dwelling adults', 'Community-dwelling older adults ( n 98']","['home-delivered protein-rich ready-made meals and dairy products', 'ready-made meals and dairy products high in protein; the control group received products lower in protein', 'protein-rich ready-made meals and protein-rich dairy products']","['Dietary intake', 'risk of undernutrition']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0530867', 'cui_str': 'G13 Protein'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0010947', 'cui_str': 'Dairy Products'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}]","[{'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0162429', 'cui_str': 'Malnutrition'}]",,0.0255632,The risk of undernutrition in older community-dwelling adults increases when they are no longer able to shop or cook themselves.,"[{'ForeName': 'Jos W', 'Initials': 'JW', 'LastName': 'Borkent', 'Affiliation': 'Department of Nutrition and Health, HAN University of Applied Sciences, Faculty of Health and Social Studies, Nijmegen, the Netherlands.'}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Beelen', 'Affiliation': 'Department of Nutrition and Health, HAN University of Applied Sciences, Faculty of Health and Social Studies, Nijmegen, the Netherlands.'}, {'ForeName': 'Joost O', 'Initials': 'JO', 'LastName': 'Linschooten', 'Affiliation': ""Department of Food Science & Technology, HAS University of Applied Sciences, 's-Hertogenbosch, The Netherlands.""}, {'ForeName': 'Annet J C', 'Initials': 'AJC', 'LastName': 'Roodenburg', 'Affiliation': ""Department of Food Science & Technology, HAS University of Applied Sciences, 's-Hertogenbosch, The Netherlands.""}, {'ForeName': 'Marian A E', 'Initials': 'MAE', 'LastName': 'de van der Schueren', 'Affiliation': 'Department of Nutrition and Health, HAN University of Applied Sciences, Faculty of Health and Social Studies, Nijmegen, the Netherlands.'}]",Journal of nutritional science,['10.1017/jns.2019.27'] 1327,20919760,The Treatment Advocacy Program: a randomized controlled trial of a peer-led safer sex intervention for HIV-infected men who have sex with men.,"OBJECTIVE Primary care may be an effective venue for delivering behavioral interventions for sexual safety among HIV-positive men who have sex with men (MSM); however, few studies show efficacy for such an approach. We tested the efficacy of the Treatment Advocacy Program (TAP), a 4-session, primary-care-based, individual counseling intervention led by HIV-positive MSM ""peer advocates"" in reducing unprotected sex with HIV-negative or unknown partners (HIV transmission risk). METHOD We randomized 313 HIV-positive MSM to TAP or standard care. HIV transmission risk was assessed at baseline, 6 months, and 12 months (251 participants completed all study waves). We conducted intent-to-treat analyses using general estimating equations to test the interaction of group (TAP vs. standard care) by follow-up period. RESULTS At study completion, TAP participants reported greater transmission risk reduction than did those receiving standard care, χ2(2, N = 249) = 6.6, p = .04. Transmission risk among TAP participants decreased from 34% at baseline to about 20% at both 6 and 12 months: Transmission risk ranged from 23% to 25% among comparison participants. CONCLUSIONS TAP reduced transmission risk among HIV-positive MSM, although results are modest. Many participants and peer advocates commented favorably on the computer structure of the program. We feel that the key elements of TAP-computer-based and individually tailored session content, delivered by peers, in the primary care setting-warrant further exploration.",2010,Transmission risk among TAP participants decreased from 34% at baseline to about 20% at both 6 and 12 months:,"['HIV-positive men who have sex with men (MSM', 'HIV-infected men who have sex with men']","['behavioral interventions', 'peer-led safer sex intervention', 'TAP', 'Treatment Advocacy Program (TAP), a 4-session, primary-care-based, individual counseling intervention led by HIV-positive MSM ""peer advocates']","['HIV transmission risk', 'Transmission risk', 'transmission risk reduction']","[{'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}]","[{'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0597728', 'cui_str': 'Responsible Sex'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0150446', 'cui_str': 'Advocacy (regime/therapy)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0019699', 'cui_str': 'HTLV-III Seroconversion'}]","[{'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0040722', 'cui_str': 'transmission'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]",313.0,0.0414,Transmission risk among TAP participants decreased from 34% at baseline to about 20% at both 6 and 12 months:,"[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'McKirnan', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, IL 60607, USA. davidmck@uic.edu'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Tolou-Shams', 'Affiliation': ''}, {'ForeName': 'Cari', 'Initials': 'C', 'LastName': 'Courtenay-Quirk', 'Affiliation': ''}]",Journal of consulting and clinical psychology,['10.1037/a0020759'] 1328,31529097,Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.,"CONTEXT Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone (GH), which can result in increased visceral adiposity (VAT) and impaired vascular function. GH-releasing hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion. OBJECTIVE We tested the hypothesis that DPP4 inhibition increases GH and improves glucose levels and vascular function in women with PCOS. METHODS Eighteen women with PCOS participated in a double-blind, crossover study. They received sitagliptin either 100 mg or placebo daily for 1 month, with crossover treatments separated by an 8-week washout. During each treatment, women underwent a 75-gram oral glucose tolerance test (OGTT) and assessments of vascular function and body composition. Overnight GH secretion was assessed via venous sampling every 10 minutes for 12 hours and analyzed using an automated deconvolution algorithm. RESULTS During OGTT, sitagliptin increased glucagon-like peptide-1 (P < 0.001), early insulin secretion (from mean [± SD] insulinogenic index 1.9 ± 1.2 to 3.2 ± 3.1; P = 0.02), and decreased peak glucose (mean -17.2 mg/dL [95% CI, -27.7 to -6.6]; P < 0.01). At 1 month, sitagliptin decreased VAT (from 1141.9 ± 700.7 to 1055.1 ± 710.1 g; P = 0.02) but did not affect vascular function. Sitagliptin increased GH half-life (from 13.9 ± 3.6 to 17.0 ± 6.8 min, N = 16; P = 0.04) and interpulse interval (from 53.2 ± 20.0 to 77.3 ± 38.2 min, N = 16; P < 0.05) but did not increase mean overnight GH (P = 0.92 vs placebo). CONCLUSIONS Sitagliptin decreased the maximal glucose response to OGTT and VAT. Sitagliptin did not increase overnight GH but increased GH half-life and the interpulse interval. CLINICAL TRIAL REGISTRATION This study was registered at www.clinicaltrials.gov as NCT02122380 prior to enrollment of the first participant.",2020,"During OGTT, sitagliptin increased GLP-1 (p<0.001), early insulin secretion (from mean insulinogenic index 1.9±1.2 (SD) to 3.2±3.1; p=0.02) and decreased peak glucose (mean -17.2 mg/dL","['Women with polycystic ovarian syndrome (PCOS', 'women with PCOS', 'women with polycystic ovarian syndrome', 'Eighteen women with PCOS participated in a double-blinded, cross-over study']","['75-gram oral glucose tolerance test (OGTT', 'Sitagliptin', 'sitagliptin 100 mg vs. placebo']","['GLP-1 (p<0.001), early insulin secretion', 'visceral fat and blood glucoses', 'maximal glucose response', 'overnight GH levels', 'peak glucose', 'Overnight GH secretion', 'glucose levels and vascular function', 'mean overnight GH', 'interpulse interval', 'sitagliptin decreased VAT', 'Sitagliptin increased GH half-life']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C1812980', 'cui_str': 'sitagliptin 100 MG'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C1563740', 'cui_str': 'Visceral Fat'}, {'cui': 'C0005802', 'cui_str': 'Blood Sugar'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0036537', 'cui_str': 'Secretions'}, {'cui': 'C0428548', 'cui_str': 'Glucose level - finding'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0752151', 'cui_str': 'VATS'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}]",18.0,0.187824,"During OGTT, sitagliptin increased GLP-1 (p<0.001), early insulin secretion (from mean insulinogenic index 1.9±1.2 (SD) to 3.2±3.1; p=0.02) and decreased peak glucose (mean -17.2 mg/dL","[{'ForeName': 'Jessica K', 'Initials': 'JK', 'LastName': 'Devin', 'Affiliation': 'Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Nian', 'Affiliation': 'Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Celedonio', 'Affiliation': 'Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Wright', 'Affiliation': 'Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Nancy J', 'Initials': 'NJ', 'LastName': 'Brown', 'Affiliation': 'Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz028'] 1329,31526557,"A Pilot, Double-Blind, Randomized, Controlled Trial of High-Dose Intravenous Vitamin C for Vasoplegia After Cardiac Surgery.","OBJECTIVE To conduct a pilot feasibility and physiologic efficacy study of high-dose vitamin C in patients with vasoplegia after cardiac surgery. DESIGN Prospective, double-blind, randomized, controlled trial. SETTING Two tertiary intensive care units (ICUs). PARTICIPANTS Post-cardiac surgery patients with vasoplegia. INTERVENTIONS The authors randomly assigned the patients to receive either high-dose intravenous vitamin C (1,500 mg every 6 hours) or placebo. The primary outcome was time from randomization to resolution of vasoplegia. Secondary outcomes included total norepinephrine equivalent dose in the first 2 days, ICU length of stay, ICU mortality, and in-hospital mortality. MEASUREMENTS AND MAIN RESULTS The authors studied 50 patients (25 patients in each arms). The mean (standard deviation) time to resolution of vasoplegia was 27.0 (16.5) hours in the vitamin C group versus 34.7 (41.1) hours in the placebo group (mean decrease with vitamin C of 7.7 hours, 95% confidence interval -10.5 to 25.9, p = 0.40). The median (interquartile range) norepinephrine equivalent dose in the first 2 days was 64.9 (23.5-236.5) µg/kg versus 47.4 (21.4-265.9) µg/kg in the vitamin C and placebo group (p = 0.75). The median duration of ICU admission was similar (1.4 [0.5-2.5] days and 1.5 [0.5-3.3] days in the vitamin C and placebo group; p = 0.36). Only 1 patient, in the vitamin C arm, died. CONCLUSION In patients with post-cardiac surgery vasoplegia, high-dose vitamin C infusion was feasible, appeared safe, and, within the limitations of a pilot study, did not achieve statistically faster resolution of vasoplegia.",2020,"In patients with post-cardiac surgery vasoplegia, high-dose vitamin C infusion was feasible, appeared safe, and, within the limitations of a pilot study, did not achieve statistically faster resolution of vasoplegia.","['patients with vasoplegia after cardiac surgery', 'Two tertiary intensive care units (ICUs', '50 patients (25 patients in each arms', 'Post-cardiac surgery patients with vasoplegia']","['vitamin C infusion', 'vitamin C', 'placebo', 'High-Dose Intravenous Vitamin C', 'high-dose intravenous vitamin C', 'high-dose vitamin C']","['died', 'time from randomization to resolution of vasoplegia', 'median duration of ICU admission', 'mean (standard deviation) time to resolution of vasoplegia', 'total norepinephrine equivalent dose in the first 2 days, ICU length of stay, ICU mortality, and in-hospital mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2717957', 'cui_str': 'Vasoplegia'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]","[{'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C2717957', 'cui_str': 'Vasoplegia'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0202145', 'cui_str': 'Norepinephrine measurement (procedure)'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}]",,0.764927,"In patients with post-cardiac surgery vasoplegia, high-dose vitamin C infusion was feasible, appeared safe, and, within the limitations of a pilot study, did not achieve statistically faster resolution of vasoplegia.","[{'ForeName': 'Fumitaka', 'Initials': 'F', 'LastName': 'Yanase', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia; Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Bitker', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia; Service de médecine intensive et réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Hessels', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia; Department of Critical Care, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Osawa', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Thummaporn', 'Initials': 'T', 'LastName': 'Naorungroj', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia; Department of Intensive Care, Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Salvatore L', 'Initials': 'SL', 'LastName': 'Cutuli', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Young', 'Affiliation': 'Department of Intensive Care, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Ritzema', 'Affiliation': 'Department of Intensive Care, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Hill', 'Affiliation': 'Department of Intensive Care, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Latimer-Bell', 'Affiliation': 'Department of Intensive Care, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hunt', 'Affiliation': 'Department of Intensive Care, Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Glenn M', 'Initials': 'GM', 'LastName': 'Eastwood', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Hilton', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia; Australian and New Zealand Intensive Care Research Centre, Monash University School of Public Health and Preventive Medicine, Melbourne, Australia; Centre for Integrated Critical Care, Department of Medicine & Radiology, University of Melbourne, Melbourne, Australia. Electronic address: rinaldo.bellomo@austin.org.au.'}]",Journal of cardiothoracic and vascular anesthesia,['10.1053/j.jvca.2019.08.034'] 1330,31865336,Study of Biocompatibility of Membranes in Online Hemodiafiltration.,"BACKGROUND The biocompatibility of dialysis membranes is a determining factor in avoiding chronic microinflammation in patients under haemodialysis. Lower biocompatibility has been related to increased inflammatory status, which is known to be associated with cardiovascular events. Classically, cellulose membranes have been considered bioincompatible. A new-generation of asymmetric cellulose triacetate (CTA) membranes allows the performance of high convective transport techniques, but there have been no studies of their biocompatibility. The aim of the present study was to analyze and compare the biocompatibility characteristics of 4 membranes, including CTA, in online hemodiafiltration (OL-HDF) patients. METHODS We included 15 patients in -OL-HDF. After a 2-week washout period with helixone membrane, each patient was treated with the 4 membranes (polyamide, polynephron, helixone and CTA) for 4 weeks in a randomized order. The other dialysis parameters were kept stable throughout the study. We studied changes in markers of the activation of the complement system, monocytes, platelets, and adhesion molecules with the 4 membranes, as well as inflammatory parameters. RESULTS Biocompatibility was similar among the membranes. There were no sustained differences in complement activation, measured by C3a and C5a levels, or in platelet activation, determined by levels of P-selectin and platelet-derived microparticles (CD41a+). No differences were observed in activated monocyte levels (CD14+/CD16+) or in plasma levels of interleukin (IL)-1, IL-6, IL-10 or high-sensitivity C-reactive protein, although tumour necrosis factor-α levels decreased when the patients were dialyzed with CTA. No significant differences were found in markers of endothelial damage, assessed by levels of plasminogen activator inhibitor-1 and adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1). CONCLUSION The 4 membranes evaluated in this study in stable patients on OL-HDF, including the new-generation CTA, show similar biocompatibility with the methods applied.",2020,"No significant differences were found in markers of endothelial damage, assessed by levels of plasminogen activator inhibitor-1 and adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1). ","['15 patients in -OL-HDF', 'patients under haemodialysis']","['asymmetric cellulose triacetate (CTA) membranes', 'helixone membrane, each patient was treated with the 4 membranes (polyamide, polynephron, helixone and CTA']","['complement activation', 'C3a and C5a levels, or in platelet activation, determined by levels of P-selectin and platelet-derived microparticles (CD41a', 'activated monocyte levels (CD14+/CD16+) or in plasma levels of interleukin (IL)-1, IL-6, IL-10 or high-sensitivity C-reactive protein, although tumour necrosis factor-α levels', 'markers of endothelial damage, assessed by levels of plasminogen activator inhibitor-1 and adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1', 'Biocompatibility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0055048', 'cui_str': 'triacetylcellulose'}, {'cui': 'C0025255', 'cui_str': 'Membranes'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0028736', 'cui_str': 'Polyamides'}]","[{'cui': 'C0009528', 'cui_str': 'Complement Activation'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0032173', 'cui_str': 'Platelet Activation'}, {'cui': 'C0521095', 'cui_str': 'Determined by (contextual qualifier) (qualifier value)'}, {'cui': 'C0134835', 'cui_str': 'Platelet alpha-Granule Membrane Protein'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0021755', 'cui_str': 'T Helper Factor'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0030190', 'cui_str': 'SERPINE1 Protein'}, {'cui': 'C0001511', 'cui_str': 'Tissue Adhesions'}, {'cui': 'C0567416', 'cui_str': 'Molecule (substance)'}, {'cui': 'C0063695', 'cui_str': 'CD54 Antigens'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}]",,0.06035,"No significant differences were found in markers of endothelial damage, assessed by levels of plasminogen activator inhibitor-1 and adhesion molecules (intercellular adhesion molecule-1 and vascular cell adhesion molecule-1). ","[{'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Ojeda', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Arias-Guillén', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Gómez', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'Vera', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Néstor', 'Initials': 'N', 'LastName': 'Fontseré', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lida', 'Initials': 'L', 'LastName': 'Rodas', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Filella', 'Affiliation': 'Department of Biochemistry, Hospital Clínic Barcelona, Barcelona, Spain.'}, {'ForeName': 'Juan Carlos', 'Initials': 'JC', 'LastName': 'Reverter', 'Affiliation': 'Department of Haemotherapy and Haemostasis, Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Lozano', 'Affiliation': 'Department of Inmunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Neus', 'Initials': 'N', 'LastName': 'Villamor', 'Affiliation': ""Department of Pathology, Haematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.""}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Maduell', 'Affiliation': 'Department of Nephrology, Hospital Clínic Barcelona, Barcelona, Spain, fmaduell@clinic.cat.'}]",Blood purification,['10.1159/000504954'] 1331,31527558,"Stereological analysis of terminal villi, intervillous space and fibrinoid of adolescent placentas and birth weight of newborns.","Aim To determine stereological structural parameters of the parenchymal part of the placenta, placental weight and volume of adolescent pregnant women and their correlation with newborns' birth weight. Methods This prospective study was conducted on a total of 60 human placentas of term pregnancy, divided into two groups according to the age of pregnant women. Experimental group consisted of 30 placentas of pregnant women aged 13-19 years. Control group consisted of 30 placentas of pregnant women aged 20-35 years. Stereological analysis was performed. Results Volumetric density of terminal villi of adolescent placentas was significantly higher than the one of control group (p <0.0001). The volumetric density of fibrinoid of adolescent placentas was significantly lower than of the control group (p <0.0001). Total volume of terminal villi of adolescent placentas was significantly higher than of the control group (p<0.0001). The total volume of fibrinoid of adolescent placentas was significantly lower than of the control group (p<0.0001). Newborns of adolescent pregnancies had in average lower birth weight of 439.01 g compared to the newborns of the control group (p <0.00001). Conclusion Adolescent pregnancy affects placental structure, weight and volume. Newborns of adolescent pregnancy have optimal body weight.",2020,The total volume of fibrinoid of adolescent placentas was significantly lower than of the control group (p<0.0001).,"['adolescent placentas and birth weight of newborns', 'pregnant women aged 13-19 years', '60 human placentas of term pregnancy, divided into two groups according to the age of pregnant women', 'pregnant women aged 20-35 years', ""adolescent pregnant women and their correlation with newborns' birth weight""]",[],"['Total volume of terminal villi of adolescent placentas', 'volumetric density of fibrinoid of adolescent placentas', 'total volume of fibrinoid of adolescent placentas', 'placental structure, weight and volume', 'birth weight', 'Volumetric density of terminal villi of adolescent placentas']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0032043', 'cui_str': 'Placentome'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0232991', 'cui_str': 'Term pregnancy (finding)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]",[],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0445383', 'cui_str': 'Volumetric (qualifier value)'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0032043', 'cui_str': 'Placentome'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005612', 'cui_str': 'Birth Weight'}]",60.0,0.0188143,The total volume of fibrinoid of adolescent placentas was significantly lower than of the control group (p<0.0001).,"[{'ForeName': 'Sergije', 'Initials': 'S', 'LastName': 'Marković', 'Affiliation': 'Department of Histology and Embryology, School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Anis', 'Initials': 'A', 'LastName': 'Cerovac', 'Affiliation': 'Department of Gynaecology and Obstetrics, General Hospital Tešanj, Tešanj, Bosnia and Herzegovina.'}, {'ForeName': 'Suad', 'Initials': 'S', 'LastName': 'Kunosić', 'Affiliation': 'Department of Physics, School of Natural Sciences and Mathematics, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Suada', 'Initials': 'S', 'LastName': 'Ramić', 'Affiliation': 'Department of Histology and Embryology, School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Emir', 'Initials': 'E', 'LastName': 'Bećirović', 'Affiliation': 'Clinic for Internal Diseases, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1055-20'] 1332,32076003,Short-term and long-term effects of a social network intervention on friendships among university students.,"Informal social relations, such as friendships, are crucial for the well-being and success of students at all levels of education. Network interventions can aim at providing contact opportunities in school settings to prevent the social isolation of individuals and facilitate integration between otherwise segregated social groups. We investigate the short-term and long-term effects of one specific network intervention in an undergraduate cohort freshly admitted to an engineering department ([Formula: see text]). In this intervention, we randomly assigned students into small groups at an introduction event two months prior to their first day at university. The groups were designed to increase mixed-gender contact opportunities. Two months after the intervention, we find a higher rate of friendships, common friends, and mixed-gender friendships in pairs of students who were assigned to the same group than in pairs from different groups (short-term effects). These effects gradually diminish over the first academic year (long-term effects). Using stochastic actor-oriented models, we investigate the long-term trajectory of the intervention effects, while considering alternative network processes, such as reciprocity, transitivity, homophily, and popularity. The results suggest that even though the induced friendship ties are less stable than other friendships, they may serve as early seeds for complex social network processes. Our study shows that simple network interventions can have a pronounced short-term effect and indirect long-term effects on the evolution and structure of student communities.",2020,"Informal social relations, such as friendships, are crucial for the well-being and success of students at all levels of education.","['undergraduate cohort freshly admitted to an engineering department ([Formula', 'friendships among university students']","['specific network intervention', 'social network intervention']",[],"[{'cui': 'C0014279', 'cui_str': 'Engineerings'}, {'cui': 'C0178647', 'cui_str': 'Friendship'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}]","[{'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]",[],,0.0271311,"Informal social relations, such as friendships, are crucial for the well-being and success of students at all levels of education.","[{'ForeName': 'Zsófia', 'Initials': 'Z', 'LastName': 'Boda', 'Affiliation': 'Chair of Social Networks, Department of Humanities, Social and Political Sciences, ETH Zürich, Weinbergstrasse 109, Zürich, 8006, Switzerland. zsofia.boda@gess.ethz.ch.'}, {'ForeName': 'Timon', 'Initials': 'T', 'LastName': 'Elmer', 'Affiliation': 'Chair of Social Networks, Department of Humanities, Social and Political Sciences, ETH Zürich, Weinbergstrasse 109, Zürich, 8006, Switzerland.'}, {'ForeName': 'András', 'Initials': 'A', 'LastName': 'Vörös', 'Affiliation': 'Chair of Social Networks, Department of Humanities, Social and Political Sciences, ETH Zürich, Weinbergstrasse 109, Zürich, 8006, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Stadtfeld', 'Affiliation': 'Chair of Social Networks, Department of Humanities, Social and Political Sciences, ETH Zürich, Weinbergstrasse 109, Zürich, 8006, Switzerland. christoph.stadtfeld@ethz.ch.'}]",Scientific reports,['10.1038/s41598-020-59594-z'] 1333,31825067,Matched Weight Loss Through Intermittent or Continuous Energy Restriction Does Not Lead To Compensatory Increases in Appetite and Eating Behavior in a Randomized Controlled Trial in Women with Overweight and Obesity.,"BACKGROUND Continuous energy restriction (CER) is purported to be problematic because of reductions in fat-free mass (FFM), compensatory motivation to overeat, and weakened satiety. Intermittent energy restriction (IER) is an alternative behavioral weight loss (WL) strategy that may mitigate some of these limitations. OBJECTIVE The objective of the DIVA study was to compare the effects of CER and IER on appetite when the degree of WL (≥5%) is matched. METHODS Women with overweight/obesity (BMI 25.0-34.9 kg/m2; age 18-55 y) were recruited for this controlled-feeding RCT via CER (25% daily energy restriction) or IER (alternating ad libitum and 75% energy restriction days). Probe days were conducted at baseline and post-intervention to assess body composition, ad libitum energy intake and subjective appetite in response to a fixed-energy breakfast, and eating behavior traits. After baseline measurements, participants were allocated to CER (n = 22) or IER (n = 24). Per protocol analyses (≥5% WL within 12 wk) were conducted with use of repeated measures ANOVA. RESULTS Thirty of 37 completers reached ≥5% WL [CER (n = 18): 6.3 ± 0.8% in 57 ± 16 d, IER (n = 12): 6.6 ± 1.1% in 67 ± 13 d; % WL P = 0.43 and days P = 0.10]. Fat mass [-3.9 (95% CI: -4.3, -3.4) kg] and FFM [-1.3 (95% CI: -1.6, -1.0) kg] were reduced post-WL (P < 0.001), with no group differences. Self-selected meal size decreased post-WL in CER (P = 0.03) but not in IER (P = 0.19). Hunger AUC decreased post-WL (P < 0.05), with no group differences. Satiety quotient remained unchanged and was similar in both groups. Both interventions improved dietary restraint, craving control, susceptibility to hunger, and binge eating (P < 0.001). CONCLUSIONS Controlled ≥5% WL via CER or IER did not differentially affect changes in body composition, reductions in hunger, and improvements in eating behavior traits. This suggests that neither CER nor IER lead to compensatory adaptations in appetite in women with overweight/obesity. This trial was registered at clinicaltrials.gov as NCT03447600.",2020,Self-selected meal size decreased post-WL in CER (P = 0.03) but not in IER (P = 0.19).,"['Women with overweight/obesity (BMI 25.0-34.9\xa0kg/m2; age 18-55 y', 'women with overweight/obesity', 'Women with Overweight and Obesity']","['CER and IER', 'CER', 'Intermittent energy restriction (IER', 'IER', 'Continuous energy restriction (CER']","['Satiety quotient', 'Appetite and Eating Behavior', 'dietary restraint, craving control, susceptibility to hunger, and binge eating', 'FFM', 'Hunger AUC', 'body composition, reductions in hunger, and improvements in eating behavior traits', 'Fat mass']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0237504', 'cui_str': 'CER (body structure)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C0036239', 'cui_str': 'Satiations'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0015745', 'cui_str': 'Eating Behavior'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1264642', 'cui_str': 'Susceptibility (property) (qualifier value)'}, {'cui': 'C0020175', 'cui_str': 'Hunger'}, {'cui': 'C0596170', 'cui_str': 'Binge overeating'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}]",,0.283,Self-selected meal size decreased post-WL in CER (P = 0.03) but not in IER (P = 0.19).,"[{'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Beaulieu', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Nuno', 'Initials': 'N', 'LastName': 'Casanova', 'Affiliation': 'School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Oustric', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Jake', 'Initials': 'J', 'LastName': 'Turicchi', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Gibbons', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Hopkins', 'Affiliation': 'School of Food Science and Nutrition, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Krista', 'Initials': 'K', 'LastName': 'Varady', 'Affiliation': 'Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Blundell', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'School of Psychology, University of Leeds, Leeds, LS2 9JT, UK.'}]",The Journal of nutrition,['10.1093/jn/nxz296'] 1334,30946919,The effect of an International competitive leaderboard on self-motivated simulation-based CPR practice among healthcare professionals: A randomized control trial.,"BACKGROUND Little is known about how best to motivate healthcare professionals to engage in frequent cardiopulmonary resuscitation (CPR) refresher skills practice. A competitive leaderboard for simulated CPR can encourage self-directed practice on a small scale. The study aimed to determine if a large-scale, multi-center leaderboard improved simulated CPR practice frequency and CPR performance among healthcare professionals. METHODS This was a multi-national, randomized cross-over study among 17 sites using a competitive online leaderboard to improve simulated practice frequency and CPR performance. All sites placed a Laerdal® ResusciAnne or ResusciBaby QCPR manikin in 1 or more clinical units - emergency department, ICU, etc. - in easy reach for 8 months. These simulators provide visual feedback during 2-minute compressions-only CPR and a performance score. Sites were randomly assigned to the intervention for the first 4-months or the second 4-months. Following any CPR practice by a healthcare professional, participants uploaded scores and an optional 'selfie' photo to the leaderboard. During the intervention phase, the leaderboard displayed ranked scores and high scores earned digital badges. The leaderboard did not display control phase participants. Outcomes included CPR practice frequency and mean compression score, using non-parametric statistics for analyses. RESULTS Nine-hundred nineteen participants completed 1850 simulated CPR episodes. Exposure to the leaderboard yielded 1.94 episodes per person compared to 2.14 during the control phase (p = 0.99). Mean CPR performance participants did not differ between phases: 90.7 vs. 89.3 (p = 0.19). CONCLUSION A competitive leaderboard was not associated with an increase in self-directed simulated CPR practice or improved performance.",2019,"Mean CPR performance participants did not differ between phases: 90.7 vs. 89.3 (p = 0.19). ","['healthcare professionals', 'Nine-hundred nineteen participants completed 1850 simulated CPR episodes']","['Laerdal® ResusciAnne or ResusciBaby QCPR manikin', 'International competitive leaderboard']","['Mean CPR performance', 'CPR practice frequency and mean compression score, using non-parametric statistics for analyses', 'simulated CPR practice frequency and CPR performance']","[{'cui': 'C1704312', 'cui_str': 'Healthcare professional (occupation)'}, {'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]","[{'cui': 'C0024722', 'cui_str': 'Mannequins'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0007203', 'cui_str': 'Cardio-Pulmonary Resuscitation'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0332459', 'cui_str': 'Compression (morphologic abnormality)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0242932', 'cui_str': 'Non-Parametric Statistics'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]",919.0,0.0344866,"Mean CPR performance participants did not differ between phases: 90.7 vs. 89.3 (p = 0.19). ","[{'ForeName': 'Todd P', 'Initials': 'TP', 'LastName': 'Chang', 'Affiliation': ""Division of Emergency Medicine & Transport, Children's Hospital Los Angeles, Keck School of Medicine at University of Southern California, United States. Electronic address: dr.toddchang@gmail.com.""}, {'ForeName': 'Tia', 'Initials': 'T', 'LastName': 'Raymond', 'Affiliation': ""Pediatric Cardiac Critical Care, Medical City Children's Hospital, Dallas, TX, United States.""}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Dewan', 'Affiliation': ""Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States; Division of Critical Care, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.""}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'MacKinnon', 'Affiliation': ""Department of Paediatric Anaesthesia, Royal Manchester Children's Hospital, Manchester, United Kingdom.""}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Whitfill', 'Affiliation': 'Departments of Pediatrics and Emergency Medicine, Yale University School, Division of Medicine, New Haven CT, United States.'}, {'ForeName': 'Ilana', 'Initials': 'I', 'LastName': 'Harwayne-Gidansky', 'Affiliation': ""Department of Pediatrics, Division of Pediatric Critical Care Medicine, Stony Brook Children's Hospital, Stony Brook, NY, United States.""}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Doughty', 'Affiliation': ""Department of Pediatrics, Section of Pediatric Emergency Medicine, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, United States.""}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Frisell', 'Affiliation': 'Anestesikliniken Mälarsjukhuset, Eskilstuna, Sweden.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kessler', 'Affiliation': 'Department of Emergency Medicine, Columbia University Vagelos College of Physicians and Surgeons, United States.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Wolfe', 'Affiliation': ""Department of Anesthesiology and Critical Care Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, United States.""}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Auerbach', 'Affiliation': 'Departments of Pediatrics and Emergency Medicine, Yale University School, Division of Medicine, New Haven CT, United States.'}, {'ForeName': 'Chrystal', 'Initials': 'C', 'LastName': 'Rutledge', 'Affiliation': 'Division of Pediatric Critical Care, University of Alabama at Birmingham, Birmingham, AL, United States.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Mitchell', 'Affiliation': ""Department of Pediatrics, Section of Critical Care Medicine, Comer Children's Hospital, The University of Chicago Medicine, Chicago, IL, United States.""}, {'ForeName': 'Priti', 'Initials': 'P', 'LastName': 'Jani', 'Affiliation': ""Department of Pediatrics, Section of Critical Care Medicine, Comer Children's Hospital, The University of Chicago Medicine, Chicago, IL, United States.""}, {'ForeName': 'Catharine M', 'Initials': 'CM', 'LastName': 'Walsh', 'Affiliation': 'Department of Paediatrics, the Research and Learning Institutes, Hospital for Sick Children, University of Toronto, Toronto, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Resuscitation,['10.1016/j.resuscitation.2019.02.050'] 1335,31797549,Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.,"AIM To compare the efficacy and safety of Gla-300 versus Gla-100 in insulin-naïve people with type 2 diabetes in Asia Pacific. MATERIALS AND METHODS In this open-label, randomized, active-controlled, 26-week study, insulin-naïve participants with type 2 diabetes inadequately controlled with non-insulin antihyperglycaemic drugs were randomized (2:1) to Gla-300 or Gla-100. The initial daily dose of basal insulin was 0.2 U/kg and was adjusted at least weekly for 8-12 weeks to a target fasting self-monitored plasma glucose (SMPG) of 4.4-5.6 mmol/L. RESULTS Of the 604 participants randomized, 570 (Gla-300, n = 375; Gla-100, n = 195) completed the study. Non-inferiority of Gla-300 versus Gla-100 in HbA1c reduction from baseline to week 26 was confirmed. In the Gla-300 and Gla-100 groups, 51.1% and 52.2% of participants achieved the HbA1c target of <7.0% (rate ratio [95% CI]: 0.98 [0.84 to 1.14]) and 19.1% and 21.9% achieved the target without hypoglycaemia during the last 12 weeks of treatment (rate ratio [95% CI]: 0.87 [0.63 to 1.20]). Changes in fasting plasma glucose and 24-hour average eight-point SMPG were comparable between groups. Incidence of hypoglycaemia at any time of day was similar between treatment groups at week 26, but incidence of any nocturnal hypoglycaemia was numerically lower with Gla-300 than Gla-100 over the initial 12-week titration period and 26-week on-treatment period. Rates of adverse events were similar between groups and low for serious adverse events. CONCLUSIONS Glycaemic control of Gla-300 is non-inferior to Gla-100 with a similar or lower incidence and proportion of hypoglycaemia in people with type 2 diabetes in Asia Pacific, reinforcing the results in the global EDITION programme.",2020,inferiority of Gla-300 versus Gla-100 in HbA 1c reduction from baseline to week 26 was confirmed.,"['naïve participants with T2DM inadequately controlled with non-insulin antihyperglycaemic drugs', 'Asia Pacific Insulin-Naïve People with Type 2 Diabetes', '604 participants randomised, 570 (Gla-300 n=375; Gla-100 n=195) completed the study', 'insulin-naïve people with type 2 diabetes mellitus (T2DM) in Asia Pacific']","['Gla-300 or Gla-100', 'basal insulin', 'Gla-300 versus Gla-100', 'Insulin Glargine 300 U/mL versus Insulin Glargine 100', 'insulin']","['fasting plasma glucose and 24-hour average 8-point SMPG', 'efficacy and safety', 'target without hypoglycaemia', 'Rates of adverse events', 'Efficacy and Safety', 'Incidence of hypoglycaemia', 'anynocturnal hypoglycaemia']","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0205112', 'cui_str': 'Basal (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C2945590', 'cui_str': 'unit/mL'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",604.0,0.075098,inferiority of Gla-300 versus Gla-100 in HbA 1c reduction from baseline to week 26 was confirmed.,"[{'ForeName': 'Linong', 'Initials': 'L', 'LastName': 'Ji', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Eun Seok', 'Initials': 'ES', 'LastName': 'Kang', 'Affiliation': 'Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea.'}, {'ForeName': 'XiaoLin', 'Initials': 'X', 'LastName': 'Dong', 'Affiliation': 'Jinan Central Hospital Affiliated to Shandong University, Shandong, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Shengjing Hospital of China Medical University, Shenyang, China.'}, {'ForeName': 'GuoYue', 'Initials': 'G', 'LastName': 'Yuan', 'Affiliation': 'Affiliated Hospital of Jiangsu University, Zhenjiang, China.'}, {'ForeName': 'Shuhua', 'Initials': 'S', 'LastName': 'Shang', 'Affiliation': 'Sanofi, Shanghai, China.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Niemoeller', 'Affiliation': 'Sanofi, Frankfurt, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Diabetes, obesity & metabolism",['10.1111/dom.13936'] 1336,19889356,"The Effect of a Training Program in Communication Skills on Primary Health Care Physicians' Knowledge, Attitudes and Self-efficacy.","UNLABELLED Communication has been identified as one of the core clinical skills for all health care providers, but it is especially important for primary health care disciplines. Findings suggest the need for more attention to communication skills in continued physician education. This work aims at evaluating the effect of a communication skills training program on physicians' knowledge, attitude and self efficacy related to communication. In this pretest- posttest intervention study, a three-day, 18-hour training program was developed and implemented. The teaching method was learner-centered and includes theoretical information, practical applications and attitude change. A self administered questionnaire was used to evaluate the program. The results showed significant improvement in physicians' knowledge about communication where those having good knowledge increased from 13.1% before the intervention to 82% after the intervention. Physicians reported significantly higher confidence levels in their ability to build rapport with patients, counsel patients for smoking cessation and medication adherence after the intervention. CONCLUSION Overall, in this study we found that training in communication skills improves clinicians' knowledge, changes some negative attitudes and enhances assessment of physicians' own ability to perform specific communication tasks.",2009,"Physicians reported significantly higher confidence levels in their ability to build rapport with patients, counsel patients for smoking cessation and medication adherence after the intervention. ",[],"['Training Program', 'communication skills training program']","['smoking cessation and medication adherence', ""physicians' knowledge about communication"", ""physicians' knowledge, attitude and self efficacy""]",[],"[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0588407', 'cui_str': 'Communication skills training (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}, {'cui': 'C2364172', 'cui_str': 'Medication Adherence'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.0108488,"Physicians reported significantly higher confidence levels in their ability to build rapport with patients, counsel patients for smoking cessation and medication adherence after the intervention. ","[{'ForeName': 'Mona E', 'Initials': 'ME', 'LastName': 'Shama', 'Affiliation': 'Department of Health Administration and Behavioral Sciences, High Institute of Public Health, Alexandria University, Alexandria, Egypt. monashama@gmail.com.'}, {'ForeName': 'Fatma A', 'Initials': 'FA', 'LastName': 'Meky', 'Affiliation': ''}, {'ForeName': 'Nagwa Y', 'Initials': 'NY', 'LastName': 'Abou El Enein', 'Affiliation': ''}, {'ForeName': 'Mohamed Y', 'Initials': 'MY', 'LastName': 'Mahdy', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1337,31856954,Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment.,"BACKGROUND Patients recovering from opioid use disorders (OUD) may be prone to relapse and opioid misuse in the postoperative period due to re-exposure to prescription opioids for pain control. This retrospective study analyzed the incidence of confirmed opioid misuse in the postoperative period in patients with OUDs enrolled in an opioid agonist treatment (OAT) program. METHODS The study population was US veterans with a diagnosis of OUD who enrolled in the OAT program at VA Maryland Health Care System (Baltimore, Maryland, USA) between 1/1/2000 and 12/31/2016. The patients were excluded if they were enrolled in OAT for less than a year, or if they had surgery within the first 180 days after OAT admission. The surgical group consisted of veterans who had surgery or an invasive procedure during their enrollment in the OAT program. The control (reference) group consisted of enrolled veterans who did not have any invasive procedure. The primary outcome was the first opioid misuse within 365 days after surgery date in the surgical group or a randomly assigned sham surgery date in controls. Opioid misuse was defined as either inappropriate use of opioids detected via urinalysis or admission with a diagnosis of an opioid overdose. RESULTS From a total of 1352 patients enrolled in the OAT program, 413 were excluded because they were enrolled for less than a year, and 26 were excluded because they had surgery within the first 180 days after admission to the OAT program. Of the 923 eligible patients, 87 had surgery while enrolled and 836 did not. Using propensity scores, all 87 of the surgical cases were matched to 249 of the control cases. In the matched groups, surgery was positively associated with postoperative opioid misuse (odds ratio (OR) of 1.91, 95% CI 1.05-3.48, p = 0.034) in logistic regression. CONCLUSION Among patients with a history of opioid use disorders, the postoperative period was associated with an increased risk of opioid misuse. Moreover, opioid misuse among patients in an opioid agonist treatment program may well be considered a surgical hazard.",2020,"In the matched groups, surgery was positively associated with postoperative opioid misuse (odds ratio (OR) of 1.91, 95% CI 1.05-3.48, p = 0.034) in logistic regression. ","['patients with a history of opioid use disorders', 'patients were excluded if they were enrolled in OAT for less than a year, or if they had surgery within the first 180 days after OAT admission', '923 eligible patients, 87 had surgery while enrolled and 836 did not', 'veterans who had surgery or an invasive procedure during their enrollment in the OAT program', 'enrolled veterans who did not have any invasive procedure', 'Patients recovering from opioid use disorders (OUD', '1352 patients enrolled in the OAT program, 413 were excluded because they were enrolled for less than a year, and 26 were excluded because they had surgery within the first 180\u202fdays after admission to the OAT program', 'patients with OUDs enrolled in an opioid agonist treatment (OAT) program', 'study population was US veterans with a diagnosis of OUD who enrolled in the OAT program at VA Maryland Health Care System (Baltimore, Maryland, USA) between 1/1/2000 and 12/31/2016', 'patients with opioid use disorders maintained on opioid agonist treatment']",[],"['postoperative opioid misuse', 'risk of opioid misuse']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C0028753', 'cui_str': 'Oats (substance)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0348025', 'cui_str': 'Open approach - access (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0521108', 'cui_str': 'Recovering from (contextual qualifier) (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0024858', 'cui_str': 'Maryland'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}]",[],"[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",1352.0,0.0472194,"In the matched groups, surgery was positively associated with postoperative opioid misuse (odds ratio (OR) of 1.91, 95% CI 1.05-3.48, p = 0.034) in logistic regression. ","[{'ForeName': 'Khodadad', 'Initials': 'K', 'LastName': 'Namiranian', 'Affiliation': 'VA Maryland Health Care System, Baltimore, MD, United States of America; Department of Anesthesiology, University of Maryland, Baltimore, MD, United States of America. Electronic address: Khodadad.namiranian@va.gov.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Siglin', 'Affiliation': 'School of Medicine, University of Maryland, Baltimore, MD, United States of America.'}, {'ForeName': 'John David', 'Initials': 'JD', 'LastName': 'Sorkin', 'Affiliation': 'Baltimore VA Medical Center Geriatric Research, Education and Clinical Center, VA Maryland Health Care System, Baltimore, MD, United States of America; Division of Gerontology and Geriatric Medicine, University of Maryland, Baltimore, MD, United States of America.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Norris', 'Affiliation': 'VA Maryland Health Care System, Baltimore, MD, United States of America; Department of Anesthesiology, University of Maryland, Baltimore, MD, United States of America.'}, {'ForeName': 'Minu', 'Initials': 'M', 'LastName': 'Aghevli', 'Affiliation': 'VA Maryland Health Care System, Baltimore, MD, United States of America.'}, {'ForeName': 'Edward C', 'Initials': 'EC', 'LastName': 'Covington', 'Affiliation': 'Neurological Institute (Emeritus), Cleveland Clinic, Cleveland, OH, United States of America.'}]",Journal of substance abuse treatment,['10.1016/j.jsat.2019.10.007'] 1338,19901211,The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study system for evaluation of optical coherence tomograms: SCORE study report 4.,"OBJECTIVE To describe grading procedures for optical coherence tomographic (OCT) images of participants in the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. METHODS Optical coherence tomograms were taken at clinical sites with the Stratus OCT using fast macular and crosshair scan protocols. Paper prints of images were evaluated at a central reading center. Quality evaluation identified the accuracy of OCT-measured retinal thickness data and was categorized as good, fair, borderline, or ungradable. Manual measurement of center point thickness was performed on borderline images. Morphological evaluation identified cystoid spaces, subretinal fluid, and vitreoretinal interface abnormalities. Reproducibility of grading was assessed through formal quality control exercises. RESULTS A randomly selected set of 106 images was identified for quality control. The first 2 annual regrades showed 91% and 89% intergrader agreement for OCT quality. Intraclass correlation for manually measured center point thickness was 0.99 per year. For morphological variables, intergrader agreement for cystoid spaces was 83% and 76%. Reproducibility for subretinal fluid and vitreoretinal interface abnormalities could not be interpreted owing to their limited presence in the sample. CONCLUSION Optical coherence tomogram evaluation procedures used in the SCORE Study are reproducible and can be used for multicenter longitudinal studies of retinal vein occlusion.",2009,"For morphological variables, intergrader agreement for cystoid spaces was 83% and 76%.",['participants in the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study'],['Standard Care vs Corticosteroid'],"['OCT quality', 'cystoid spaces']","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}]","[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}]",,0.0253388,"For morphological variables, intergrader agreement for cystoid spaces was 83% and 76%.","[{'ForeName': 'Amitha', 'Initials': 'A', 'LastName': 'Domalpally', 'Affiliation': 'University of Wisconsin Madison, Madison, WI 53705-3611, USA.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Andreas K', 'Initials': 'AK', 'LastName': 'Lauer', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Archives of ophthalmology (Chicago, Ill. : 1960)",['10.1001/archophthalmol.2009.277'] 1339,32429983,Development of an intervention to facilitate implementation and uptake of diabetic retinopathy screening.,"BACKGROUND 'Implementation interventions' refer to methods used to enhance the adoption and implementation of clinical interventions such as diabetic retinopathy screening (DRS). DRS is effective, yet uptake is often suboptimal. Despite most routine management taking place in primary care and the central role of health care professionals (HCP) in referring to DRS, few interventions have been developed for primary care. We aimed to develop a multifaceted intervention targeting both professionals and patients to improve DRS uptake as an example of a systematic development process combining theory, stakeholder involvement, and evidence. METHODS First, we identified target behaviours through an audit in primary care of screening attendance. Second, we interviewed patients (n = 47) and HCP (n = 30), to identify determinants of uptake using the Theoretical Domains Framework, mapping these to behaviour change techniques (BCTs) to develop intervention content. Thirdly, we conducted semi-structured consensus groups with stakeholders, specifically users of the intervention, i.e. patients (n = 15) and HCPs (n = 16), regarding the feasibility, acceptability, and local relevance of selected BCTs and potential delivery modes. We consulted representatives from the national DRS programme to check intervention 'fit' with existing processes. We applied the APEASE criteria (affordability, practicability, effectiveness, acceptability, side effects, and equity) to select the final intervention components, drawing on findings from the previous steps, and a rapid evidence review of operationalised BCT effectiveness. RESULTS We identified potentially modifiable target behaviours at the patient (consent, attendance) and professional (registration) level. Patient barriers to consent/attendance included confusion between screening and routine eye checks, and fear of a negative result. Enablers included a recommendation from friends/family or professionals and recognising screening importance. Professional barriers to registration included the time to register patients and a lack of readily available information on uptake in their local area/practice. Most operationalised BCTs were acceptable to patients and HCPs while the response to feasibility varied. After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. CONCLUSIONS Using the example of an intervention to improve DRS uptake, this study illustrates an approach to integrate theory with user involvement. This process highlighted tensions between theory-informed and stakeholder suggestions, and the need to apply the Theoretical Domains Framework (TDF)/BCT structure flexibly. The final intervention draws on the trusted professional-patient relationship, leveraging existing services to enhance implementation of the DRS programme. Intervention feasibility in primary care will be evaluated in a randomised cluster pilot trial.",2020,"After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. ",[],['HCPs'],[],[],[],[],47.0,0.0559924,"After considering APEASE, the core intervention, incorporating a range of BCTs, involved audit/feedback, electronic prompts targeting professionals, HCP-endorsed reminders (face-to-face, by phone and letter), and an information leaflet for patients. ","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Riordan', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland. fiona.riordan@ucc.ie.'}, {'ForeName': 'Emmy', 'Initials': 'E', 'LastName': 'Racine', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Eunice T', 'Initials': 'ET', 'LastName': 'Phillip', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Bradley', 'Affiliation': 'Department of General Practice, University College Cork, Cork, Ireland.'}, {'ForeName': 'Fabiana', 'Initials': 'F', 'LastName': 'Lorencatto', 'Affiliation': 'Centre for Behaviour Change, University College London, London, England.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Murphy', 'Affiliation': 'Department of General Practice, Royal College of Surgeons of Ireland, Dublin, Ireland.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Murphy', 'Affiliation': 'Department of Economics, Cork University Business School, University College Cork, Cork, Ireland.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Browne', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Smith', 'Affiliation': 'Department of General Practice, Royal College of Surgeons of Ireland, Dublin, Ireland.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Kearney', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}, {'ForeName': 'Sheena M', 'Initials': 'SM', 'LastName': 'McHugh', 'Affiliation': 'School of Public Health, University College Cork, Western Gateway Building, Western Rd, Cork, Ireland.'}]",Implementation science : IS,['10.1186/s13012-020-00982-4'] 1340,31455824,"Morphine compared to placebo for procedural pain in preterm infants: safety, efficacy and equipoise.",,2019,,['preterm infants'],"['placebo', 'Morphine']",[],"[{'cui': 'C4048294', 'cui_str': 'Preterm Infant'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",[],,0.11121,,"[{'ForeName': 'Omri David', 'Initials': 'OD', 'LastName': 'Soffer', 'Affiliation': ""Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA. Omri.soffer@childrens.harvard.edu.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cornelissen', 'Affiliation': ""Division of Pain Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Christy', 'Initials': 'C', 'LastName': 'Cummings', 'Affiliation': ""Division of Newborn Medicine, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Berde', 'Affiliation': ""Division of Pain Medicine, Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, MA, USA.""}]",Journal of perinatology : official journal of the California Perinatal Association,['10.1038/s41372-019-0476-9'] 1341,31180819,Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA Trial.,"PURPOSE The International Union Against Cancer highlighted tumor budding as a tumor-related prognostic factor. International assessment criteria for tumor budding were recently defined by the 2016 International Tumor Budding Consensus Conference (ITBCC2016). This study aimed to clarify the prognostic and predictive values of tumor budding in a randomized controlled trial evaluating the superiority of adjuvant chemotherapy with oral tegafur-uracil over surgery alone for stage II colon cancer (SACURA trial; ClinicalTrials.gov identifier: NCT00392899). PATIENTS AND METHODS Between 2006 and 2010, we enrolled 991 patients from 123 institutions with stage II colon cancer. Tumor budding was diagnosed by central review on the basis of the criteria adopted in the ITBCC2016. We prospectively recorded all clinical and pathologic data, including the budding grade, and performed prognostic analyses after 5 years of completing the patients' registration. RESULTS Of 991 tumors, 376, 331, and 284 were classified as BD1, BD2, and BD3, respectively; the 5-year relapse-free survival (RFS) rate was 90.9%, 85.1%, and 74.4%, respectively ( P < .001), and ranged widely in T4 tumors (86.6% to 53.3%). The budding grade significantly correlated with recurrence in the liver, lungs, lymph nodes, and peritoneum ( P < .001 to .01). Multivariable analysis revealed that budding and T stage exerted an independent impact on RFS, and on the basis of the Harrell concordance index, these two factors substantially contributed to the improvement of the Cox model for predicting RFS. Both the BD2 and BD3 groups demonstrated greater improvement in the 5-year recurrence rate in the adjuvant chemotherapy group than the surgery-alone group by approximately 5%, but the difference was statistically nonsignificant. CONCLUSION Tumor budding grade on the basis of the ITBCC2016 criteria should be routinely evaluated in pathologic practice and could improve the benefit of adjuvant chemotherapy for stage II colon cancer.",2019,"Both the BD2 and BD3 groups demonstrated greater improvement in the 5-year recurrence rate in the adjuvant chemotherapy group than the surgery-alone group by approximately 5%, but the difference was statistically nonsignificant. ","['991 patients from 123 institutions with stage II colon cancer', 'Stage II Colon Cancer', 'Between 2006 and 2010']",['adjuvant chemotherapy with oral tegafur-uracil over surgery alone'],"['5-year recurrence rate', 'BD1, BD2, and BD3', '5-year relapse-free survival (RFS) rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1272753', 'cui_str': 'Institution'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2 (qualifier value)'}, {'cui': 'C0007102', 'cui_str': 'Cancer of Colon'}]","[{'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0016778', 'cui_str': 'Tegafur'}, {'cui': 'C0041917', 'cui_str': 'Uracil'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",991.0,0.175321,"Both the BD2 and BD3 groups demonstrated greater improvement in the 5-year recurrence rate in the adjuvant chemotherapy group than the surgery-alone group by approximately 5%, but the difference was statistically nonsignificant. ","[{'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Ueno', 'Affiliation': '1National Defense Medical College, Saitama, Japan.'}, {'ForeName': 'Megumi', 'Initials': 'M', 'LastName': 'Ishiguro', 'Affiliation': '2Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Nakatani', 'Affiliation': '3Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Hyogo, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Ishikawa', 'Affiliation': '2Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Uetake', 'Affiliation': '2Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Chu', 'Initials': 'C', 'LastName': 'Matsuda', 'Affiliation': '4Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Yoshihiko', 'Initials': 'Y', 'LastName': 'Nakamoto', 'Affiliation': '5Kobe City Medical Center West Hospital, Hyogo, Japan.'}, {'ForeName': 'Masanori', 'Initials': 'M', 'LastName': 'Kotake', 'Affiliation': '6Kouseiren Takaoka Hospital, Toyama, Japan.'}, {'ForeName': 'Kiyotaka', 'Initials': 'K', 'LastName': 'Kurachi', 'Affiliation': '7Hamamatsu University School of Medicine, Shizuoka, Japan.'}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Egawa', 'Affiliation': '8Saiseikai Yokohamashi Tobu Hospital, Kanagawa, Japan.'}, {'ForeName': 'Keigo', 'Initials': 'K', 'LastName': 'Yasumasa', 'Affiliation': '9Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Murata', 'Affiliation': '10Suita Municipal Hospital, Osaka, Japan.'}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Ikawa', 'Affiliation': '11Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.'}, {'ForeName': 'Seiichi', 'Initials': 'S', 'LastName': 'Shinji', 'Affiliation': '12Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Murotani', 'Affiliation': '13Kurume University, Fukuoka, Japan.'}, {'ForeName': 'Shigeyuki', 'Initials': 'S', 'LastName': 'Matsui', 'Affiliation': '14Nagoya University, Aichi, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Teramukai', 'Affiliation': '15Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Naohiro', 'Initials': 'N', 'LastName': 'Tomita', 'Affiliation': '16Hyogo College of Medicine, Hyogo, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Sugihara', 'Affiliation': '2Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.18.02059'] 1342,32044182,"Study validity depends on the study design and bias. Comment on ""Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia"" by Bajpai et al. (The Breast. 2019 December 12. Doi: 10.1016/j.breast.2019.12.004 [Epub ahead of print]).",,2020,,"['Doi', '2019 December 12']",['scalp cooling'],[],[],"[{'cui': 'C0036270', 'cui_str': 'Scalp'}]",[],,0.031076,,"[{'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas 77030, USA. Electronic address: appatel3@texaschildrens.org.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.01.040'] 1343,19493511,The efficacy of different regimens of chlorhexidine as an antimicrobial agent for a group of egyptians.,"UNLABELLED This study was conducted to evaluate different regimens of 0.12% chlohexidine (CHX) rinse on the salivary parameters and Mutans Streptococci (MS) for a group of Egyptians. Twenty one females were recruited based on inclusive exclusive criteria. They were assigned to three different groups according to the CHX regimen specified. Salivary parameters (unstimulated salivary flow rate, stimulated salivary flow rate, pH and buffering capacity) and salivary mutans streptococci were evaluated at base line for all participants. Diet recording was done for 4 days in a supplied chart. DMFS and DS scores were also determined. This was followed by the use of 0.12% CHX mouth rinse once daily for 60 seconds before bedtime for either 3,7 or 14 days. Salivary parameters were re-evaluated in the early morning after the use of the mouth rinse, after 1 month and 3months. Mutans Streptococci (MS) were also evaluated at the same intervals. The salivary parameters did not show any difference throughout the study. The majority of the participants belonged to the moderate low fermentable CHO diet content category and they consumed five meals of cariogenic intake per day. Their DMFS scores ranged between 2 and 50 whereas the DS scores ranged between 2 and 10. The 3 day regimen was not statistically significantly different from the 7 and 14 days regimens and the maximum efficacy of CHX was obtained immediately after its use and lasted throughout the first week after stopping it. The effect of the CHX disappeared after 1 month and gradually reached the base line and surpassed this level sometimes. CONCLUSION AND RECOMMENDATIONS A regimen of once daily use of 15 ml of 0.12% CHX mouth rinse for 3 days is effective in reducing MS below critical values. It is recommended to reuse the CHX rinse after 1 month owing to the cessation of its effect. Patients who start using CHX should not discontinue it.",2008,The 3 day regimen was not statistically significantly different from the 7 and 14 days regimens and the maximum efficacy of CHX was obtained immediately after its use and lasted throughout the first week after stopping it.,['Twenty one females were recruited based on inclusive exclusive criteria'],"['chlohexidine (CHX) rinse', 'CHX', 'chlorhexidine']","['Mutans Streptococci (MS', 'salivary parameters and Mutans Streptococci (MS', 'DMFS scores', 'maximum efficacy of CHX', 'DMFS and DS scores', 'Salivary parameters (unstimulated salivary flow rate, stimulated salivary flow rate, pH and buffering capacity) and salivary mutans streptococci']","[{'cui': 'C3715213', 'cui_str': '21 (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439819', 'cui_str': 'Unstimulated (qualifier value)'}, {'cui': 'C0429177', 'cui_str': 'Salivary flow rate (observable entity)'}]",21.0,0.0215556,The 3 day regimen was not statistically significantly different from the 7 and 14 days regimens and the maximum efficacy of CHX was obtained immediately after its use and lasted throughout the first week after stopping it.,"[{'ForeName': 'Suzan M', 'Initials': 'SM', 'LastName': 'Hassan', 'Affiliation': 'Operative Dentistry Department, Faculty of Dentistry, MSA University, Egypt. enasmobark@yahoo.de.'}, {'ForeName': 'Enas H', 'Initials': 'EH', 'LastName': 'Mobarak', 'Affiliation': ''}, {'ForeName': 'Elham M', 'Initials': 'EM', 'LastName': 'Fawzi', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1344,19493514,The Role of Museum Education in Developining Some Healthy Behaviours among Preschool Children.,"An intervention study was done to evaluate the effects of museum education on developing healthy behavior in preschool children. The study was performed between June and August 2006. The sample was 111 children; 45 children as experimental group and 66 as control group. All children were subjected to the following: 1) Goudenough test, 2) Socioeconomic assessment, 3) Intervention program by using museum education, 4) Test for health behaviour for children before and after the museum education, 5) Observation checklist for teachers and mothers to evaluate the health behaviour of children before and after museum education. There was significant difference between experimental group (mean = 9.53) and control group (mean = 6.36) in post test of health behavior (p < 0.01). There was significant difference between the post test of experimental group (mean = 17.67) and post test for control group (mean = 12.29) as regard the observation checklist for mothers (p < 0.01). There was significant differences between the post test (mean= (8.29) of experimental group and post test (mean= (6.52) of control group as regard the observation checklist for teachers (p < 0.01) CONCLUSION AND RECOMMENDATIONS: There was significant improvement in healthy behaviour of children after museum education. Museum education is a suitable tool for health education. Kinder garten programs should include museum education as well as health education.",2008,There was significant difference between experimental group (mean = 9.53) and control group (mean = 6.36) in post test of health behavior (p < 0.01).,"['Preschool Children', '111 children; 45 children as experimental group and 66 as control group', 'preschool children']",['museum education'],"['health behavior', 'healthy behavior', 'healthy behaviour']","[{'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C4517538', 'cui_str': '111 (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0026863', 'cui_str': 'Museums'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0018687'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",,0.0130122,There was significant difference between experimental group (mean = 9.53) and control group (mean = 6.36) in post test of health behavior (p < 0.01).,"[{'ForeName': 'Faten I', 'Initials': 'FI', 'LastName': 'Abd El-Latif', 'Affiliation': 'Department of Basic Sciences, Kinder Garten College, University of Alexandria, Alexandria, Egypt. fatenabdellatif@yahoo.com.'}, {'ForeName': 'Hala I', 'Initials': 'HI', 'LastName': 'Elgarawany', 'Affiliation': ''}, {'ForeName': 'Soulaf A', 'Initials': 'SA', 'LastName': 'Al Hamarawy', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1345,19427708,[Repeat prescription management systems: strategy for optimising their use].,"OBJECTIVE To improve patient compliance with a repeat prescription system. To evaluate the reasons for not being punctual in collecting prescriptions and the non-compliance declared by the patients themselves. DESIGN Quasi-experimental study before and after intervention including a control group. SETTING Primary health care centre which serves a population of 62,981 inhabitants. PARTICIPANTS Patients with chronic diseases included in the repeat prescription management system (100 in the control group and 100 in the intervention group) who were unpunctual in collecting their prescriptions. INTERVENTIONS An informative-educational session consisting of a short interview with the pharmacist from Primary Health Care Centre, in which the patient was educated on compliance of the repeat prescription system and treatment. The reasons for the unpunctuality were identified and the Moriskey-Green test was performed. MAIN MEASUREMENTS Punctuality of the patients in collecting their prescriptions after the intervention. Reasons for unpunctuality recorded at recruitment. Therapeutic compliance according to the Moriskey-Green test. RESULTS There was an overall absolute improvement of 17% in punctuality in the intervention group (60% of the patients in the intervention group and 43% in the control group were punctual in the first as well as in the second follow up. Women were more punctual in the intervention group. There were no differences seen due to age, number of medications or reason for unpunctuality. CONCLUSIONS It is possible to improve patient compliance with the prescription renewal system using a simple informative-educational intervention.",2009,There was an overall absolute improvement of 17% in punctuality in the intervention group (60% of the patients in the intervention group and 43% in the control group were punctual in the first as well as in the second follow up.,"['Patients with chronic diseases included in the repeat prescription management system (100 in the control group and 100 in the intervention group) who were unpunctual in collecting their prescriptions', 'Primary health care centre which serves a population of 62,981 inhabitants']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008679', 'cui_str': 'Chronic Illness'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0420263', 'cui_str': 'Repeated prescription'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],[],62981.0,0.0157332,There was an overall absolute improvement of 17% in punctuality in the intervention group (60% of the patients in the intervention group and 43% in the control group were punctual in the first as well as in the second follow up.,"[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Llobet Traveset', 'Affiliation': 'CAP Rambla, Unidad de Farmacia de Atención Primaria, Mútua de Terrassa, Terrassa, Barcelona, España. Electronic address: ellobet@mutuaterrassa.es.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Madridejos Mora', 'Affiliation': 'CAP Rambla, Unidad de Farmacia de Atención Primaria, Mútua de Terrassa, Terrassa, Barcelona, España.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Tomás Sanz', 'Affiliation': 'CAP Rambla, Unidad de Farmacia de Atención Primaria, Mútua de Terrassa, Terrassa, Barcelona, España.'}]",Atencion primaria,['10.1016/j.aprim.2008.09.021'] 1346,32017597,Pulse Wave Velocity in Chronic Obstructive Pulmonary Disease and the Impact of Inhaled Therapy (SUMMIT): A Randomized Double-Blind Clinical Trial.,,2020,,[],['Inhaled Therapy (SUMMIT'],[],[],"[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",[],,0.735713,,"[{'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Crim', 'Affiliation': 'GlaxoSmithKline plcResearch Triangle Park, North Carolina.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Anderson', 'Affiliation': 'GlaxoSmithKline plcMiddlesex, United Kingdom.'}, {'ForeName': 'Peter M A', 'Initials': 'PMA', 'LastName': 'Calverley', 'Affiliation': 'University Hospital AintreeLiverpool, United Kingdom.'}, {'ForeName': 'Bartolome R', 'Initials': 'BR', 'LastName': 'Celli', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical SchoolBoston, Massachusetts.""}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Cowans', 'Affiliation': 'Veramed Ltd.Twickenham, United Kingdom.'}, {'ForeName': 'Fernando J', 'Initials': 'FJ', 'LastName': 'Martinez', 'Affiliation': 'Weill Cornell MedicineNew York, New York.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Newby', 'Affiliation': 'University of EdinburghEdinburgh, United Kingdom.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Vestbo', 'Affiliation': 'The University of Manchester Manchester, United Kingdom.'}, {'ForeName': 'Julie C', 'Initials': 'JC', 'LastName': 'Yates', 'Affiliation': 'GlaxoSmithKline plcResearch Triangle Park, North Carolina.'}, {'ForeName': 'Robert D', 'Initials': 'RD', 'LastName': 'Brook', 'Affiliation': 'University of MichiganAnn Arbor, Michigan.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201908-1639LE'] 1347,32027841,A trial for post-exposure prophylaxis against henipaviruses.,,2020,,[],[],[],[],[],[],,0.0267004,,"[{'ForeName': 'Hossain M S', 'Initials': 'HMS', 'LastName': 'Sazzad', 'Affiliation': 'The Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia; icddr,b, Dhaka, Bangladesh. Electronic address: hsazzad@kirby.unsw.edu.au.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30687-5'] 1348,19752419,A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.,"OBJECTIVE To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with observation for eyes with vision loss associated with macular edema secondary to perfused central retinal vein occlusion (CRVO). METHODS Multicenter, randomized, clinical trial of 271 participants. MAIN OUTCOME MEASURE Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS Seven percent, 27%, and 26% of participants achieved the primary outcome in the observation, 1-mg, and 4-mg groups, respectively. The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P = .001) and 5.0 times greater in 4-mg group than the observation group (OR, 5.0; 95% CI, 1.8-14.4; P = .001); there was no difference identified between the 1-mg and 4-mg groups (OR, 1.0; 95% CI, 0.5-2.1; P = .97). The rates of elevated intraocular pressure and cataract were similar for the observation and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial. The 1-mg dose has a safety profile superior to that of the 4-mg dose. Application to Clinical Practice Intravitreal triamcinolone in a 1-mg dose, following the retreatment criteria applied in the SCORE Study, should be considered for up to 1 year, and possibly 2 years, for patients with characteristics similar to those in the SCORE-CRVO trial. Trial Registration clinicaltrials.gov Identifier: NCT00105027.",2009,"The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P =","['macular edema secondary to central retinal vein occlusion', '271 participants', 'eyes with vision loss associated with macular edema secondary to perfused central retinal vein occlusion (CRVO']","['preservative-free intravitreal triamcinolone', 'intravitreal triamcinolone', 'triamcinolone']","['efficacy and safety', 'visual acuity letter score', 'rates of elevated intraocular pressure and cataract']","[{'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C3665346', 'cui_str': 'Unspecified visual loss'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure (finding)'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}]",271.0,0.145422,"The odds of achieving the primary outcome were 5.0 times greater in the 1-mg group than the observation group (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.8-14.1; P =","[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': 'EMMES Corporation, Rockville, MD 20850, USA.'}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Fisher', 'Affiliation': ''}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Singerman', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tolentino', 'Affiliation': ''}, {'ForeName': 'Clement K', 'Initials': 'CK', 'LastName': 'Chan', 'Affiliation': ''}, {'ForeName': 'Victor H', 'Initials': 'VH', 'LastName': 'Gonzalez', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Archives of ophthalmology (Chicago, Ill. : 1960)",['10.1001/archophthalmol.2009.234'] 1349,19712661,"Impact of A Health Education Intervention Program about Breast Cancer among Women in a Semi-urban Area in Alexandria, Egypt.","UNLABELLED Breast cancer is the most common cancer and the second principal cause of cancer deaths in women worldwide as well as in Egypt. The present work aimed to assess the impact of a health education intervention program about breast cancer (BC) among women in a semi-urban area in Alexandria. The study was carried out through pre-post test design in three phases; pre intervention phase, intervention phase, and post intervention phase. A total number of 139 females accepted to be included in the study, their mean age was 39.94 +/-13.5 years, about 23% had secondary and university education. Intervention health education program was administrated to 96 women, those were subjected to post test, and the total number of drop-outs group was 43 women. The results showed that there was a highly significant improvement in all knowledge items of the intervention group from pre to post-test. After the intervention program, eleven women (11.6%) had good knowledge. About, 75.0% practiced breast self examination (BSE) in post-test compared to 70.0% who did not practiced it in pre-test. Age was the only factor affecting BC knowledge significantly. Women's education and knowledge score were significantly associated with the practice of BSE. CONCLUSION AND RECOMMENDATIONS data from this study re-enforce the continuing need for more BC education programs that are intended to attract the attention of women with low literacy skills.",2009,Age was the only factor affecting BC knowledge significantly.,"['women in a semi-urban area in Alexandria', 'A total number of 139 females accepted to be included in the study, their mean age was 39.94 +/-13.5', 'about Breast Cancer among Women in a Semi-urban Area in Alexandria, Egypt']","['Health Education Intervention Program', 'Intervention health education program', 'health education intervention program']","['knowledge items', 'good knowledge']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517559', 'cui_str': '13.5 (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}]","[{'cui': 'C0018701'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}]",,0.0292732,Age was the only factor affecting BC knowledge significantly.,"[{'ForeName': 'Hanan M', 'Initials': 'HM', 'LastName': 'Abd El Aziz', 'Affiliation': 'Family Health Department, High Institute of Public Health, Alexandria University, Egypt. hnnmourad@yahoo.com.'}, {'ForeName': 'Ola A', 'Initials': 'OA', 'LastName': 'Akl', 'Affiliation': ''}, {'ForeName': 'Hala K', 'Initials': 'HK', 'LastName': 'Ibrahim', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1350,19167078,SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.,"OBJECTIVE To investigate the relationship between baseline center point retinal thickness measured by optical coherence tomography (OCT) and best-corrected visual acuity in eyes with macular edema associated with retinal vein occlusion and to investigate other factors associated with baseline visual acuity letter score. DESIGN The Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study includes 2 multicenter, randomized clinical trials: one evaluating participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO). PARTICIPANTS After omitting 17 participants with missing or unreliable OCT measurements, analyses proceeded with 665 enrolled SCORE Study participants (665 eyes), including 262 with CRVO and 403 with BRVO. METHODS At baseline, center point thickness was measured by OCT (Stratus OCT 3 [n=663] and OCT2 [n=2]; Carl Zeiss Meditech, Dublin, CA), and visual acuity was measured by the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) methodology. MAIN OUTCOME MEASURES Center point thickness and best-corrected E-ETDRS visual acuity letter score. RESULTS The correlation coefficient for the association between baseline OCT-measured center point thickness and best-corrected E-ETDRS visual acuity letter score is -0.27 (95% confidence limit: -0.38 to -0.16) for participants in the CRVO trial and -0.28 (95% confidence limit: -0.37 to -0.19) in the BRVO trial. Regression modeling estimated the following decrease in baseline visual acuity letter score for every 100-microm increase in OCT-measured center point thickness: 1.7 letters (P=0.0007) for CRVO and 1.9 letters (P<0.0001) for BRVO. On the basis of multivariate regression models, baseline factors significantly associated (P<0.05, after adjusting for multiple testing) with baseline visual acuity letter score include age and duration of macular edema for CRVO participants and center point thickness and presence of cystoid spaces for BRVO participants. CONCLUSIONS The correlation between OCT-measured center point thickness and visual acuity letter score is modest. OCT-measured center point thickness represents a useful tool for the detection and monitoring of macular edema in retinal vein occlusion, but it cannot reliably substitute for visual acuity measurements.",2009,"OCT-measured center point thickness represents a useful tool for the detection and monitoring of macular edema in retinal vein occlusion, but it cannot reliably substitute for visual acuity measurements.","['After omitting 17 participants with missing or unreliable OCT measurements, analyses proceeded with 665 enrolled SCORE Study participants (665 eyes), including 262 with CRVO and 403 with BRVO.\nMETHODS', 'participants with central retinal vein occlusion (CRVO) and the other evaluating participants with branch retinal vein occlusion (BRVO', 'eyes with macular edema associated with retinal vein occlusion', 'patients with retinal vein occlusion']","['optical coherence tomography (OCT) and best-corrected visual acuity', 'Standard Care versus COrticosteroid for REtinal Vein Occlusion']","['baseline visual acuity letter score', 'OCT-measured center point thickness and visual acuity letter score', 'central retinal thickness and visual acuity', 'Center point thickness and best-corrected E-ETDRS visual acuity letter score', 'Carl Zeiss Meditech, Dublin, CA), and visual acuity']","[{'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C4517848', 'cui_str': '665'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0454777', 'cui_str': 'Dublin (geographic location)'}]",17.0,0.279993,"OCT-measured center point thickness represents a useful tool for the detection and monitoring of macular edema in retinal vein occlusion, but it cannot reliably substitute for visual acuity measurements.","[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'J Michael', 'Initials': 'JM', 'LastName': 'Jumper', 'Affiliation': ''}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Figueroa', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2008.10.017'] 1351,31928034,Impact of risk assessment on judges' fairness in sentencing relatively poor defendants.,"OBJECTIVE Use of risk assessment instruments in the criminal justice system is controversial. Advocates emphasize that risk assessments are more transparent, consistent, and accurate in predicting re-offending than judicial intuition. Skeptics worry that risk assessments will increase socioeconomic disparities in incarceration. Ultimately, judges make decisions-not risk assessments. This study tests whether providing risk assessment information interacts with a defendant's socioeconomic class to influence judges' sentencing decisions. HYPOTHESES Tentatively, socioeconomic status was expected to have a main effect; without an interaction with risk assessment information. METHOD Judges (N = 340) with sentencing experience were randomly assigned to review 1 of 4 case vignettes and sentence the defendant to probation, jail, or prison. Information in the vignettes was held constant, except the defendant's socioeconomic status and whether risk assessment information was provided. RESULTS Risk assessment information reduced the likelihood of incarceration for relatively affluent defendants, but the same information increased the likelihood of incarceration for relatively poor defendants. This finding held after controlling for the sex, race, political orientation, and jurisdiction of the judge. CONCLUSIONS Cuing judges to focus on risk may re-frame how they process socioeconomic status-a variable with opposite effects on perceptions of blameworthiness for past crime versus perceptions of risk for future crime. Providing risk assessment information may have transformed low socioeconomic status from a circumstance that reduced the likelihood of incarceration (by mitigating perceived blameworthiness) to a factor that increased the likelihood of incarceration (by increasing perceived risk). Under some circumstances, risk assessment information may increase sentencing disparities. (PsycINFO Database Record (c) 2020 APA, all rights reserved).",2020,"RESULTS Risk assessment information reduced the likelihood of incarceration for relatively affluent defendants, but the same information increased the likelihood of incarceration for relatively poor defendants.","['Judges (N = 340) with sentencing experience', ""judges' fairness in sentencing relatively poor defendants""]",[],['likelihood of incarceration'],"[{'cui': 'C0221191', 'cui_str': 'Judge (occupation)'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}]",[],"[{'cui': 'C0205255', 'cui_str': 'Imprisonment (finding)'}]",2020.0,0.017923,"RESULTS Risk assessment information reduced the likelihood of incarceration for relatively affluent defendants, but the same information increased the likelihood of incarceration for relatively poor defendants.","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Skeem', 'Affiliation': 'School of Social Welfare, University of California, Berkeley.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Scurich', 'Affiliation': 'School of Social Ecology, University of California, Irvine.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Monahan', 'Affiliation': 'School of Law, University of Virginia.'}]",Law and human behavior,['10.1037/lhb0000360'] 1352,19674727,SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design.,"PURPOSE To evaluate the incidence of intravitreal silicone oil (SO) droplets associated with intravitreal injections using a staked-on vs luer cone syringe design in the SCORE (Standard Care vs COrticosteroid in REtinal Vein Occlusion) Study. DESIGN Prospective, randomized, phase III clinical trial. METHODS The incidence of intravitreal SO was compared among participants exposed to the staked-on syringe design, the luer cone syringe design, or both of the syringe designs in the SCORE Study, which evaluated intravitreal triamcinolone acetonide injection(s) for vision loss secondary to macular edema associated with central or branch retinal vein occlusion. Injections were given at baseline and 4-month intervals, based on treatment assignment and study-defined retreatment criteria. Because intravitreal SO was observed following injections in some participants, investigators were instructed, on September 22, 2006, to look for intravitreal SO at all study visits. On November 1, 2007, the luer cone syringe design replaced the staked-on syringe design. RESULTS A total of 464 participants received a total of 1,205 injections between November 4, 2004 and February 28, 2009. Intravitreal SO was noted in 141 of 319 participants (44%) exposed only to staked-on syringes, 11 of 87 (13%) exposed to both syringe designs, and 0 of 58 exposed only to luer cone syringes (P < .0001). Among participants with first injections after September 22, 2006, intravitreal SO was noted in 65 of 114 (57%) injected only with staked-on syringes compared with 0 of 58 injected only with luer cone syringes. Differential follow-up is unlikely to explain these results. CONCLUSION In the SCORE Study, luer cone syringe design is associated with a lower frequency of intravitreal SO droplet occurrence compared with the staked-on syringe design, likely attributable to increased residual space in the needle hub with the luer cone design.",2009,"Intravitreal SO was noted in 141 of 319 participants (44%) exposed only to staked-on syringes, 11 of 87 (13%) exposed to both syringe designs, and 0 of 58 exposed only to luer cone syringes (P < .0001).","['464 participants received a total of 1,205 injections between November 4, 2004 and February 28, 2009']","['triamcinolone acetonide injection(s', 'intravitreal silicone oil (SO']",['Intravitreal SO'],"[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1272883', 'cui_str': 'Injection'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone Acetonide'}, {'cui': 'C0037111', 'cui_str': 'Silicone Oils'}]",[],464.0,0.0264493,"Intravitreal SO was noted in 141 of 319 participants (44%) exposed only to staked-on syringes, 11 of 87 (13%) exposed to both syringe designs, and 0 of 58 exposed only to luer cone syringes (P < .0001).","[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA.'}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Andrew N', 'Initials': 'AN', 'LastName': 'Antoszyk', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of ophthalmology,['10.1016/j.ajo.2009.06.004'] 1353,19619896,SCORE Study report 3: study design and baseline characteristics.,"OBJECTIVE To describe the baseline characteristics of the participants in the Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE) Study and to compare with cohorts from other retinal vein occlusion trials. The design of the SCORE Study is also described. DESIGN Two, multicenter, Phase III, randomized clinical trials, one involving participants with central retinal vein occlusion (CRVO) and one involving participants with branch retinal vein occlusion (BRVO). PARTICIPANTS A total of 682 participants, including 271 with CRVO and 411 with BRVO. METHODS Demographic and study eye characteristics are summarized and compared between the CRVO and BRVO study participants. MAIN OUTCOME MEASURES Baseline ophthalmic characteristics, including visual acuity and duration of macular edema before enrollment, and medical history characteristics, including diabetes mellitus and hypertension. RESULTS In the CRVO trial, at baseline, mean visual acuity letter score was 51 ( approximately 20/100), mean optical coherence tomography (OCT)-measured central subfield thickness was 595 microns, mean area of retinal thickening in the macular grid on color photography was 12.3 disc areas (DA), and mean area of fluorescein leakage was 11.0 DA. In the BRVO trial, at baseline, mean visual acuity letter score was 57 ( approximately 20/80), mean OCT-measured central subfield thickness was 491 microns, mean area of retinal thickening in the macular grid on color photography was 7.5 DA, and the mean area of fluorescein leakage was 6.1 DA. CONCLUSIONS Differences observed in baseline visual acuity, OCT-measured retinal thickness, area of retinal thickening on color photography, and area of fluorescein leakage support the evaluation of CRVO and BRVO in separate trials. FINANCIAL DISCLOSURE(S) The authors have no proprietary or commercial interest in any of the materials discussed in this article.",2009,"mean area of retinal thickening in the macular grid on color photography was 7.5 DA, and the mean area of fluorescein leakage was 6.1 DA. ","['participants with central retinal vein occlusion (CRVO) and one involving participants with branch retinal vein occlusion (BRVO', 'A total of 682 participants, including 271 with CRVO and 411 with BRVO']",['Standard Care versus COrticosteroid for REtinal Vein Occlusion (SCORE'],"['mean visual acuity letter score', 'mean optical coherence tomography (OCT)-measured central subfield thickness', 'mean OCT-measured central subfield thickness', 'baseline visual acuity, OCT-measured retinal thickness, area of retinal thickening on color photography, and area of fluorescein leakage', 'mean area of fluorescein leakage', 'visual acuity and duration of macular edema before enrollment, and medical history characteristics, including diabetes mellitus and hypertension', 'mean area of retinal thickening']","[{'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1302690', 'cui_str': 'Retinal thickening'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0031749', 'cui_str': 'Photography'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0015376', 'cui_str': 'Extravasation (morphologic abnormality)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0019665', 'cui_str': 'historical aspects'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]",682.0,0.37671,"mean area of retinal thickening in the macular grid on color photography was 7.5 DA, and the mean area of fluorescein leakage was 6.1 DA. ","[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': 'University of Wisconsin Fundus Photograph Reading Center, Madison, WI, USA.'}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Figueroa', 'Affiliation': ''}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Antoszyk', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Elman', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2009.03.022'] 1354,30914378,Integrative analysis of the intestinal metabolome of childhood asthma.,"BACKGROUND The intestinal metabolome reflects the biological consequences of diverse exposures and might provide insight into asthma pathophysiology. OBJECTIVE We sought to perform an untargeted integrative analysis of the intestinal metabolome of childhood asthma in this ancillary study of the Vitamin D Antenatal Asthma Reduction Trial. METHODS Metabolomic profiling was performed by using mass spectrometry on fecal samples collected from 361 three-year-old subjects. Adjusted logistic regression analyses identified metabolites and modules of highly correlated metabolites associated with asthma diagnosis by age 3 years. Sparse canonical correlation analysis identified associations relevant to asthma between the intestinal metabolome and other ""omics"": the intestinal microbiome as measured by using 16S rRNA sequencing, the plasma metabolome as measured by using mass spectrometry, and diet as measured by using food frequency questionnaires. RESULTS Several intestinal metabolites were associated with asthma at age 3 years, including inverse associations between asthma and polyunsaturated fatty acids (adjusted logistic regression β = -6.3; 95% CI, -11.3 to -1.4; P = .01) and other lipids. Asthma-associated intestinal metabolites were significant mediators of the inverse relationship between exclusive breast-feeding for the first 4 months of life and asthma (P for indirect association = .04) and the positive association between a diet rich in meats and asthma (P = .03). Specific intestinal bacterial taxa, including the family Christensenellaceae, and plasma metabolites, including γ-tocopherol/β-tocopherol, were positively associated with asthma and asthma-associated intestinal metabolites. CONCLUSION Integrative analyses revealed significant interrelationships between the intestinal metabolome and the intestinal microbiome, plasma metabolome, and diet in association with childhood asthma. These findings require replication in future studies.",2019,"RESULTS Several intestinal metabolites were associated with asthma at age 3 years, including inverse associations between asthma and polyunsaturated fatty acids (adjusted logistic regression β = -6.3; 95% CI, -11.3 to -1.4; P = .01) and other lipids.","['361 three-year-old subjects', 'childhood asthma']",[],[],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0264408', 'cui_str': 'Childhood asthma'}]",[],[],,0.0267051,"RESULTS Several intestinal metabolites were associated with asthma at age 3 years, including inverse associations between asthma and polyunsaturated fatty acids (adjusted logistic regression β = -6.3; 95% CI, -11.3 to -1.4; P = .01) and other lipids.","[{'ForeName': 'Kathleen A', 'Initials': 'KA', 'LastName': 'Lee-Sarwar', 'Affiliation': ""Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass. Electronic address: klee-sarwar@partners.org.""}, {'ForeName': 'Rachel S', 'Initials': 'RS', 'LastName': 'Kelly', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Lasky-Su', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Zeiger', 'Affiliation': 'Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif.'}, {'ForeName': 'George T', 'Initials': 'GT', 'LastName': ""O'Connor"", 'Affiliation': 'Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, Mass.'}, {'ForeName': 'Megan T', 'Initials': 'MT', 'LastName': 'Sandel', 'Affiliation': 'Department of Pediatrics, Boston Medical Center, Boston, Mass.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Bacharier', 'Affiliation': ""Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, and St Louis Children's Hospital, St Louis, Mo.""}, {'ForeName': 'Avraham', 'Initials': 'A', 'LastName': 'Beigelman', 'Affiliation': ""Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, and St Louis Children's Hospital, St Louis, Mo.""}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Laranjo', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Diane R', 'Initials': 'DR', 'LastName': 'Gold', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Mass.""}, {'ForeName': 'Scott T', 'Initials': 'ST', 'LastName': 'Weiss', 'Affiliation': ""Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Augusto A', 'Initials': 'AA', 'LastName': 'Litonjua', 'Affiliation': ""Division of Pediatric Pulmonary Medicine, Golisano Children's Hospital at Strong, University of Rochester Medical Center, Rochester, NY. Electronic address: augusto_litonjua@urmc.rochester.edu.""}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2019.02.032'] 1355,32007087,Stockholm preterm interaction-based intervention (SPIBI) - study protocol for an RCT of a 12-month parallel-group post-discharge program for extremely preterm infants and their parents.,"BACKGROUND Improved neonatal care has resulted in increased survival rates among infants born after only 22 gestational weeks, but extremely preterm children still have an increased risk of neurodevelopmental delays, learning disabilities and reduced cognitive capacity, particularly executive function deficits. Parent-child interaction and parental mental health are associated with infant development, regardless of preterm birth. There is a need for further early interventions directed towards extremely preterm (EPT) children as well as their parents. The purpose of this paper is to describe the Stockholm Preterm Interaction-Based Intervention (SPIBI), the arrangements of the SPIBI trial and the chosen outcome measurements. METHODS The SPIBI is a randomized clinical trial that includes EPT infants and their parents upon discharge from four neonatal units in Stockholm, Sweden. Inclusion criteria are EPT infants soon to be discharged from a neonatal intensive care unit (NICU), with parents speaking Swedish or English. Both groups receive three initial visits at the neonatal unit before discharge during the recruitment process, with a strengths-based and development-supportive approach. The intervention group receives ten home visits and two telephone calls during the first year from a trained interventionist from a multi-professional team. The SPIBI intervention is a strengths-based early intervention programme focusing on parental sensitivity to infant cues, enhancing positive parent-child interaction, improving self-regulating skills and supporting the infant's next small developmental step through a scaffolding process and parent-infant co-regulation. The control group receives standard follow-up and care plus extended assessment. The outcomes of interest are parent-child interaction, child development, parental mental health and preschool teacher evaluation of child participation, with assessments at 3, 12, 24 and 36 months corrected age (CA). The primary outcome is emotional availability at 12 months CA. DISCUSSION If the SPIBI shows positive results, it could be considered for clinical implementation for child-support, ethical and health-economic purposes. Regardless of the outcome, the trial will provide valuable information about extremely preterm children and their parents during infancy and toddlerhood after regional hospital care in Sweden. TRIAL REGISTRATION The study was registered in ClinicalTrials.gov in October 2018 (NCT03714633).",2020,"BACKGROUND Improved neonatal care has resulted in increased survival rates among infants born after only 22 gestational weeks, but extremely preterm children still have an increased risk of neurodevelopmental delays, learning disabilities and reduced cognitive capacity, particularly executive function deficits.","['extremely preterm infants and their parents', 'infants born after only 22 gestational weeks', 'EPT infants and their parents upon discharge from four neonatal units in Stockholm, Sweden', 'Inclusion criteria are EPT infants soon to be discharged from a neonatal intensive care unit (NICU), with parents speaking Swedish or English', 'preterm children and their parents during infancy and toddlerhood after regional hospital care in Sweden']","['SPIBI intervention', 'standard follow-up and care plus extended assessment', 'Stockholm preterm interaction-based intervention (SPIBI) - study protocol']","['emotional availability at 12\u2009months CA', 'survival rates']","[{'cui': 'C3494262', 'cui_str': 'Extremely Preterm Infants'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439671', 'cui_str': 'Gestational (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0039512', 'cui_str': 'Teniposide'}, {'cui': 'C1720176', 'cui_str': 'Upon'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0021709', 'cui_str': 'Newborn ICU'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0231290', 'cui_str': 'Status post (contextual qualifier) (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0687133', 'cui_str': 'Drug Interactions'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1096775', 'cui_str': 'Intervention Study'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.155134,"BACKGROUND Improved neonatal care has resulted in increased survival rates among infants born after only 22 gestational weeks, but extremely preterm children still have an increased risk of neurodevelopmental delays, learning disabilities and reduced cognitive capacity, particularly executive function deficits.","[{'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Baraldi', 'Affiliation': 'Department of Special Education, Specialpedagogiska institutionen Stockholms universitet, Stockholm University, Frescati Hagväg 10, 106 91, Stockholm, Sweden. erika.baraldi@specped.su.se.'}, {'ForeName': 'Mara Westling', 'Initials': 'MW', 'LastName': 'Allodi', 'Affiliation': 'Department of Special Education, Specialpedagogiska institutionen Stockholms universitet, Stockholm University, Frescati Hagväg 10, 106 91, Stockholm, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Löwing', 'Affiliation': ""Department of Women's and Children's Health, Institutionen för kvinnors och barns hälsa, Karolinska Institutet, Karolinska Institutet, 171 77, Stockholm, Sweden.""}, {'ForeName': 'Ann-Charlotte', 'Initials': 'AC', 'LastName': 'Smedler', 'Affiliation': 'Department of Psychology, Psykologiska institutionen Stockholms universitet, Stockholm University, Frescati Hagväg 8, 106 91, Stockholm, Sweden.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Westrup', 'Affiliation': ""Department of Women's and Children's Health, Institutionen för kvinnors och barns hälsa, Karolinska Institutet, Karolinska Institutet, 171 77, Stockholm, Sweden.""}, {'ForeName': 'Ulrika', 'Initials': 'U', 'LastName': 'Ådén', 'Affiliation': ""Department of Women's and Children's Health, Institutionen för kvinnors och barns hälsa, Karolinska Institutet, Karolinska Institutet, 171 77, Stockholm, Sweden.""}]",BMC pediatrics,['10.1186/s12887-020-1934-4'] 1356,18209165,"Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.","OBJECTIVE To determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris (PV). DESIGN A randomized, double-blind, placebo-controlled study with a crossover arm for those who failed treatment. SETTING A US multicenter outpatient study. Patients A total of 19 subjects enrolled among 5 centers, 9 randomized to receive dapsone and 10 to receive placebo. Inclusion criteria were biopsy and direct immunofluorescence-proven PV controlled with glucocorticoids and/or cytotoxic agents, disease in maintenance phase, and aged 18 to 80 years. Physicians had tried at least 2 tapers of glucocorticoids unsuccessfully and had 30 days of stable steroid dosage. Treatment for any patient unable to taper glucocorticoids by more than 25% within 4 months was declared a failure, and the patient was allowed to switch to the opposite medication while maintaining the double-blind. Main Outcome Measure The ability of patients to taper to 7.5 mg/d or less within 1 year of reaching the maximum dosage of the study drug. RESULTS Of the 9 patients receiving dapsone, 5 were successfully treated, 3 failed treatment, and 1 dropped out of the study. Of the 10 patients receiving placebo, 3 were successfully treated, and 7 failed treatment. This primary end point favored the dapsone-treated group but was not statistically significant (P = .37). Four patients who failed treatment while receiving placebo were switched to treatment with dapsone. Of these, 3 were successfully treated after switching to dapsone treatment, and 1 failed treatment. We found that, overall, 8 of 11 patients (73%) receiving dapsone vs 3 of 10 (30%) receiving placebo reached the primary outcome of a prednisone dosage of 7.5 mg/d or less. CONCLUSION This trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug in maintenance-phase PV.",2008,This primary end point favored the dapsone-treated group but was not statistically significant (P = .37).,"['Inclusion criteria were biopsy and direct immunofluorescence-proven PV controlled with glucocorticoids and/or cytotoxic agents, disease in maintenance phase, and aged 18 to 80 years', '19 subjects enrolled among 5 centers', 'Patients', '10 patients receiving', 'maintenance-phase pemphigus vulgaris']","['glucocorticoid-sparing agent', 'placebo', 'dapsone']",[],"[{'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0282648', 'cui_str': 'Direct tissue immunofluorescence procedure'}, {'cui': 'C0456369', 'cui_str': 'Proven (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic drug'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030809', 'cui_str': 'Pemphigus Vulgaris'}]","[{'cui': 'C3540778', 'cui_str': 'Glucocorticoids'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0010980', 'cui_str': 'Dapsone'}]",[],19.0,0.316299,This primary end point favored the dapsone-treated group but was not statistically significant (P = .37).,"[{'ForeName': 'Victoria P', 'Initials': 'VP', 'LastName': 'Werth', 'Affiliation': 'Department of Dermatology, University of Pennsylvania, 2 Rhodes Pavilion, 3600 Spruce St, Philadelphia, PA 19119, USA. werth@mail.med.upenn.edu'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fivenson', 'Affiliation': ''}, {'ForeName': 'Amit G', 'Initials': 'AG', 'LastName': 'Pandya', 'Affiliation': ''}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'M Joyce', 'Initials': 'MJ', 'LastName': 'Rico', 'Affiliation': ''}, {'ForeName': 'Joerg', 'Initials': 'J', 'LastName': 'Albrecht', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jacobus', 'Affiliation': ''}]",Archives of dermatology,['10.1001/archderm.144.1.25'] 1357,19752420,A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6.,"OBJECTIVE To compare the efficacy and safety of 1-mg and 4-mg doses of preservative-free intravitreal triamcinolone with standard care (grid photocoagulation in eyes without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS Multicenter, randomized clinical trial of 411 participants. Main Outcome Measure Gain in visual acuity letter score of 15 or more from baseline to month 12. RESULTS Twenty-nine percent, 26%, and 27% of participants achieved the primary outcome in the standard care, 1-mg, and 4-mg groups, respectively. None of the pairwise comparisons between the 3 groups was statistically significant at month 12. The rates of elevated intraocular pressure and cataract were similar for the standard care and 1-mg groups, but higher in the 4-mg group. CONCLUSIONS There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group. Application to Clinical Practice Grid photocoagulation as applied in the SCORE Study remains the standard care for patients with vision loss associated with macular edema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial. Grid photocoagulation should remain the benchmark against which other treatments are compared in clinical trials for eyes with vision loss associated with macular edema secondary to BRVO. Trial Registration clinicaltrials.gov Identifier: NCT00105027.",2009,"There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group.","['macular Edema secondary to branch retinal vein occlusion', 'eyes without dense macular hemorrhage and deferral of photocoagulation until hemorrhage clears in eyes with dense macular hemorrhage) for eyes with vision loss associated with macular edema secondary to branch retinal vein occlusion (BRVO', '411 participants', 'patients with vision loss associated with macular edema secondary to BRVO who have characteristics similar to participants in the SCORE-BRVO trial']","['preservative-free intravitreal triamcinolone with standard care (grid photocoagulation', 'intravitreal triamcinolone', 'Clinical Practice Grid photocoagulation', 'triamcinolone', 'Grid photocoagulation']","['efficacy and safety', 'visual acuity', 'rates of elevated intraocular pressure and cataract', 'rates of adverse events (particularly elevated intraocular pressure and cataract', 'visual acuity letter score']","[{'cui': 'C0271051', 'cui_str': 'Macular Edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary (qualifier value)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0023694', 'cui_str': 'Photocoagulation'}, {'cui': 'C2963144', 'cui_str': 'Clear (qualifier value)'}, {'cui': 'C3665346', 'cui_str': 'Unspecified visual loss'}, {'cui': 'C0332281', 'cui_str': 'Associated with (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1302035', 'cui_str': 'Grid photocoagulation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0234708', 'cui_str': 'Raised intraocular pressure (finding)'}, {'cui': 'C0856347', 'cui_str': 'Right cataract'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0021888', 'cui_str': 'Ocular Tension'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",411.0,0.114414,"There was no difference identified in visual acuity at 12 months for the standard care group compared with the triamcinolone groups; however, rates of adverse events (particularly elevated intraocular pressure and cataract) were highest in the 4-mg group.","[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'EMMES Corporation, Rockville, MD 20850, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'VanVeldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Fisher', 'Affiliation': ''}, {'ForeName': 'Clement K', 'Initials': 'CK', 'LastName': 'Chan', 'Affiliation': ''}, {'ForeName': 'Victor H', 'Initials': 'VH', 'LastName': 'Gonzalez', 'Affiliation': ''}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Singerman', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tolentino', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Archives of ophthalmology (Chicago, Ill. : 1960)",['10.1001/archophthalmol.2009.233'] 1358,30712814,"N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study.",,2019,,['schizophrenia'],['N-acetylcysteine'],['EEG measures of auditory deviance detection and neural synchronization'],"[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}]",,0.0579665,,"[{'ForeName': 'Yvonne S', 'Initials': 'YS', 'LastName': 'Yang', 'Affiliation': 'VISN22 MIRECC Greater Los Angeles Veterans Affairs Healthcare System, United States of America. Electronic address: ysyang@mednet.ucla.edu.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Davis', 'Affiliation': 'Division of Psychiatry Products, US Food and Drug Administration.'}, {'ForeName': 'Jonathan K', 'Initials': 'JK', 'LastName': 'Wynn', 'Affiliation': 'VISN22 MIRECC Greater Los Angeles Veterans Affairs Healthcare System, United States of America.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Hellemann', 'Affiliation': 'Biostatistics Core, Semel Institute for Neuroscience and Human Behavior, UCLA.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Green', 'Affiliation': 'VISN22 MIRECC Greater Los Angeles Veterans Affairs Healthcare System, United States of America.'}, {'ForeName': 'Stephen R', 'Initials': 'SR', 'LastName': 'Marder', 'Affiliation': 'VISN22 MIRECC Greater Los Angeles Veterans Affairs Healthcare System, United States of America.'}]",Schizophrenia research,['10.1016/j.schres.2019.01.036'] 1359,19344824,SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.,"OBJECTIVE To evaluate interobserver agreement between investigator and Reading Center classification of retinal vein occlusion. DESIGN The Standard Care versus COrticosteroid in REtinal Vein Occlusion (SCORE) Study includes 2 multicenter phase 3 randomized clinical trials evaluating the efficacy and safety of intravitreal triamcinolone: one involves participants with central retinal vein occlusion (CRVO) and one for participants with branch retinal vein occlusion (BRVO). Eyes with hemiretinal vein occlusion (HRVO) were classified as BRVO. PARTICIPANTS A total of 682 SCORE Study participants, including 271 with CRVO and 411 with BRVO. METHODS Participants were enrolled in each trial on the basis of investigator classification of retinal vein occlusion. Definitions of CRVO, BRVO, and HRVO based on clinical findings were specified in the study protocol. At baseline, 7-field color stereoscopic fundus photographs of the study eye of each participant were forwarded to the University of Wisconsin Fundus Photograph Reading Center (Reading Center) for evaluation. MAIN OUTCOME MEASURES Percent agreement and kappa statistics comparing investigator and Reading Center classification of retinal vein occlusion type. RESULTS With HRVO categorized as BRVO (consistent with the SCORE Study design), there was 98.0% agreement between investigator and Reading Center classification (641/654 eyes; kappa = 0.96; 95% confidence interval, 0.94-0.98). Disagreements were fairly evenly divided between classification of an eye as CRVO by the investigator and as BRVO by the Reading Center (7/13 disagreements) and vice versa (6 disagreements). When all 3 disease categories (CRVO, BRVO, and HRVO) were compared, there was 92.2% agreement (603/654; unweighted kappa = 0.86; 95% confidence interval, 0.83-0.90). Most disagreements (38/51, or 74.5%) were between BRVO and HRVO, with 9 between CRVO and BRVO, and 4 between HRVO and CRVO. In univariate analyses, baseline factors significantly associated with disagreement include larger area of capillary loss and black race; black race was the only significant factor in a multivariate analysis. CONCLUSIONS Investigator and Reading Center agreement was excellent in the SCORE Study; disease classification would have been altered in only 13 eyes (2.0%) had Reading Center eligibility been required. Interobserver agreement was least for classification between BRVO and HRVO.",2009,"Most disagreements (38/51, or 74.5%) were between BRVO and HRVO, with 9 between CRVO and BRVO, and 4 between HRVO and CRVO.","['A total of 682 SCORE Study participants, including 271 with CRVO and 411 with BRVO', 'Eyes with hemiretinal vein occlusion (HRVO', 'participants with central retinal vein occlusion (CRVO) and one for participants with branch retinal vein occlusion (BRVO', 'Participants were enrolled in each trial on the basis of investigator classification of retinal vein occlusion']","['Standard Care versus COrticosteroid in REtinal Vein Occlusion', 'intravitreal triamcinolone']","['efficacy and safety', 'BRVO and HRVO', 'larger area of capillary loss and black race; black race', 'disease categories (CRVO, BRVO, and HRVO', 'kappa statistics comparing investigator and Reading Center classification of retinal vein occlusion type', 'CRVO, BRVO, and HRVO']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C1735356', 'cui_str': 'Hemiretinal vein occlusion'}, {'cui': 'C0154841', 'cui_str': 'Central retinal vein occlusion (disorder)'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion (disorder)'}, {'cui': 'C1626935', 'cui_str': 'Base'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0006901', 'cui_str': 'Capillaries'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439099', 'cui_str': 'Kappa'}, {'cui': 'C0600673', 'cui_str': 'Statistics'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0035328', 'cui_str': 'Retinal Vein Occlusion'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}]",682.0,0.0840636,"Most disagreements (38/51, or 74.5%) were between BRVO and HRVO, with 9 between CRVO and BRVO, and 4 between HRVO and CRVO.","[{'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': ''}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': ''}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Vanveldhuisen', 'Affiliation': ''}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Oden', 'Affiliation': ''}, {'ForeName': 'Clement K', 'Initials': 'CK', 'LastName': 'Chan', 'Affiliation': ''}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Gonzalez', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2008.11.015'] 1360,17212003,Controlled trial with interferon alfa 2-b in chronic hepatitis C patients.,"Thirty-eight chronic hepatitis C (CHC) Egyptian patients with persistently elevated serum alanine aminotransferase (ALT) for 6 months were randomly allocated into 2 groups: Group I (19 patients) received 3 million units (MU) of interferon alpha - 2b (Intron-A) subcutaneously thrice weekly for 6 months. In group I, complete response (normalization of ALT by the end of treatment) was achieved in 8 patients (42.1%), partial response (decrease of ALT by at least 50% of the pretreatment values) in 7 patients (36.8%) and no response in 4 (21.1%). Sustained response for 6 months after the end of therapy was attained in 4 of the 8 (50%) complete responders. Thus attaining an overall sustained response in 4 of the 19 patients (21.1%). In group II, spontaneous normalization of ALT was established in 1 patient (5.3%). Repeat liver biopsies in 16 patients of the interferon group, revealed moderate improvement in the degree of lobular inflammation, hepatocyte necrosis and portal inflammation. We conclude from this study that treatment of CHC with 3 MU of IFN-alfa 2b thrice weekly for 6 months is associated with a low response rate (21.1%). To improve the results, escalation of the IFN dose and/or prolongation of the treatment period should be considered.",1994,"Repeat liver biopsies in 16 patients of the interferon group, revealed moderate improvement in the degree of lobular inflammation, hepatocyte necrosis and portal inflammation.","['Thirty-eight chronic hepatitis C (CHC) Egyptian patients with persistently elevated serum alanine aminotransferase (ALT) for 6 months', 'chronic hepatitis C patients']","['interferon alfa', '3 million units (MU) of interferon alpha - 2b (Intron-A) subcutaneously thrice weekly for 6 months']","['degree of lobular inflammation, hepatocyte necrosis and portal inflammation', 'Repeat liver biopsies', 'overall sustained response', 'partial response', 'complete response (normalization of ALT', 'Sustained response', 'low response rate', 'spontaneous normalization of ALT']","[{'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C0524910', 'cui_str': 'Hepatitis C, Chronic'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0201836', 'cui_str': 'Alanine aminotransferase measurement (procedure)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0002199', 'cui_str': 'Interferon, Lymphoblastoid'}, {'cui': 'C1306898', 'cui_str': 'mU'}, {'cui': 'C0751600', 'cui_str': 'Intron A'}, {'cui': 'C0556987', 'cui_str': 'Three times weekly (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0205417', 'cui_str': 'Lobular (qualifier value)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0227525', 'cui_str': 'Hepatic Cells'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0205054', 'cui_str': 'Portal (qualifier value)'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver (procedure)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}]",,0.0356853,"Repeat liver biopsies in 16 patients of the interferon group, revealed moderate improvement in the degree of lobular inflammation, hepatocyte necrosis and portal inflammation.","[{'ForeName': 'A R', 'Initials': 'AR', 'LastName': 'El-Zayadi', 'Affiliation': '""Cairo Liver Center"", Dokki, Cairo, Egypt.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Selim', 'Affiliation': ''}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'El-Haddad', 'Affiliation': ''}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ahdy', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1361,32434884,HIV RNA Rebound in Seminal Plasma after Antiretroviral Treatment Interruption.,"If strategies currently in development succeed in eradicating HIV reservoirs in peripheral blood and lymphoid tissues, residual sources of virus may remain in anatomic compartments. Paired blood and semen samples were collected from 12 individuals enrolled in a randomized, double-blind, placebo-controlled therapeutic vaccine clinical trial in people with HIV (PWH) who began antiretroviral therapy (ART) during acute or early infection (ClinicalTrials registration no. NCT01859325). After the week 56 visit (postintervention), all participants interrupted ART. At the first available time points after viral rebound, we sequenced HIV-1 env (C2-V3), gag (p24), and pol (reverse transcriptase) regions amplified from cell-free HIV RNA in blood and seminal plasma using the MiSeq Illumina platform. Comprehensive sequence and phylogenetic analyses were performed to evaluate viral population structure, compartmentalization, and viral diversity in blood and seminal plasma. Compared to that in blood, HIV RNA rebound in semen occurred significantly later (median of 66 versus 42 days post-ART interruption, P < 0.01) and reached lower levels (median 164 versus 16,090 copies/ml, P < 0.01). Three of five participants with available sequencing data presented compartmentalized viral rebound between blood and semen in one HIV coding region. Despite early ART initiation, HIV RNA molecular diversity was higher in semen than in blood in all three coding regions for most participants. Higher HIV RNA molecular diversity in the genital tract (compared to that in blood plasma) and evidence of compartmentalization illustrate the distinct evolutionary dynamics between these two compartments after ART interruption. Future research should evaluate whether the genital compartment might contribute to viral rebound in some PWH interrupting ART. IMPORTANCE To cure HIV, we likely need to target the reservoirs in all anatomic compartments. Here, we used sophisticated statistical and phylogenetic methods to analyze blood and semen samples collected from 12 persons with HIV who began antiretroviral therapy (ART) during very early HIV infection and who interrupted their ART as part of a clinical trial. First, we found that HIV RNA rebound in semen occurred significantly later and reached lower levels than in blood. Second, we found that the virus in semen was genetically different in some participants compared to that in blood. Finally, we found increased HIV RNA molecular diversity in semen compared to that in blood in almost all study participants. These data suggest that the HIV RNA populations emerging from the genital compartment after ART interruption might not be the same as those emerging from blood plasma. Future research should evaluate whether the genital compartment might contribute to viral rebound in some people with HIV (PWH) interrupting ART.",2020,"Despite early ART initiation, HIV RNA molecular diversity was higher in semen compared to blood in all three coding regions for most participants.","['clinical trial in people with HIV (PWH) who began ART during acute or early infection (NCT01859325', '12 individuals enrolled', '12 persons with HIV who began antiretroviral therapy (ART) during very early HIV-infection and who interrupted their ART as part of a clinical trial']","['placebo-controlled therapeutic vaccine', 'antiretroviral therapy (ART']","['sequenced HIV-1 env ( C2-V3 ), gag (p24), and pol ( reverse transcriptase) regions amplified from cell-free HIV RNA in blood and seminal plasma', 'viral population structure, compartmentalization and viral diversity in blood and seminal plasma', 'HIV RNA rebound in semen', 'blood, HIV RNA rebound in semen', 'HIV RNA molecular diversity']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0443239', 'cui_str': 'Interrupted'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042210', 'cui_str': 'Vaccine'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0017343', 'cui_str': 'ENV gene'}, {'cui': 'C0016927', 'cui_str': 'Gagging'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0035379', 'cui_str': 'RNA-directed DNA polymerase'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0242499', 'cui_str': 'Seminal plasma'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0877595', 'cui_str': 'HIV RNA rebound'}]",5.0,0.115519,"Despite early ART initiation, HIV RNA molecular diversity was higher in semen compared to blood in all three coding regions for most participants.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Gianella', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA gianella@ucsd.edu.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Chaillon', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA.'}, {'ForeName': 'Tae-Wook', 'Initials': 'TW', 'LastName': 'Chun', 'Affiliation': 'National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Sneller', 'Affiliation': 'National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Ignacio', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA.'}, {'ForeName': 'Milenka V', 'Initials': 'MV', 'LastName': 'Vargas-Meneses', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Caballero', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA.'}, {'ForeName': 'Ronald J', 'Initials': 'RJ', 'LastName': 'Ellis', 'Affiliation': 'University of California, San Diego, La Jolla, California, USA.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Kovacs', 'Affiliation': 'Maple Leaf Medical Clinic, Toronto, Ontario, Canada.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Benko', 'Affiliation': 'Maple Leaf Medical Clinic, Toronto, Ontario, Canada.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Huibner', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Kaul', 'Affiliation': 'Department of Medicine, University of Toronto, Toronto, Ontario, Canada.'}]",Journal of virology,['10.1128/JVI.00415-20'] 1362,17382085,Impact evaluation of nutrition education intervention for an elementary school in riyadh city.,"A nutritional education intervention (NEI) was conducted to assess its impact and suitability for the 5th and 6th graders at a governmental girls' elementary school in Riyadh city. The study design was a randomized posttest only control group. The results revealed that the mean knowledge score of the first posttest for intervention classes was higher than that of their controls (F=91.147, p<0.001). This score increased markedly among all classes at the post-posttest. The mean self-efficacy (SE) score of the control class of 5th graders and intervention class of 6th graders at posttest were much lower than that of their comparable classes and both classes showed significant increase of SE in the post-posttest (paired t=2.819 and 4.561, p<0.01 and p<0.001 respectively). The mean practice score of the posttest was lower among intervention class of the 5th graders than their control, but both means were much higher than that of both classes of the 6th graders (F=6.856, p<0.001). Only control class of the 6th graders showed increased mean practice score at the post-posttest. Stepwise linear regression models reveal that exposure to NEI session was a major predictor of students knowledge at posttest (R(2)=.345). Knowledge score was a predictor of students' dietary SE and practices scores at posttest (R(2)=.041 & .136). Self efficacy was a predictor of students' dietary practices at posttest and post-posttest (R(2)=.107 & .162) as well as lower body mass index (R(2)=.048). The study recommends the replication of such a program among diverse population of school students to have more improvement in students' dietary knowledge, SE and practices.",2006,Self efficacy was a predictor of students' dietary practices at posttest and post-posttest (R(2)=.107 & .162) as well as lower body mass index (R(2)=.048).,"['elementary school in riyadh city', 'diverse population of school students', ""5th and 6th graders at a governmental girls' elementary school in Riyadh city""]","['nutrition education intervention', 'nutritional education intervention (NEI']","['mean self-efficacy (SE) score', 'mean practice score', 'SE', 'Self efficacy', 'mean knowledge score']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0204934', 'cui_str': 'Nutritional education'}, {'cui': 'C1955969', 'cui_str': 'NEI (US)'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.0140489,Self efficacy was a predictor of students' dietary practices at posttest and post-posttest (R(2)=.107 & .162) as well as lower body mass index (R(2)=.048).,"[{'ForeName': 'Ensaf S', 'Initials': 'ES', 'LastName': 'Abdel Gawwad', 'Affiliation': 'Health Administration and Behavioral Sciences Dept., High Institute of Public Health, Alexandria University, Alexandria, Egypt. ensafabdel@hotmail.com.'}, {'ForeName': 'Ebtisam M', 'Initials': 'EM', 'LastName': 'Fetohy', 'Affiliation': ''}, {'ForeName': 'Lamiaa', 'Initials': 'L', 'LastName': 'Fiala', 'Affiliation': ''}, {'ForeName': 'Saada M', 'Initials': 'SM', 'LastName': 'Al Orf', 'Affiliation': ''}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Al Saif', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1363,32434761,A School-Based Intervention for Mental Illness Stigma: A Cluster Randomized Trial.,"OBJECTIVES To determine the effectiveness of a school-based curriculum, Eliminating the Stigma of Differences (ESD), in improving attitudinal and/or behavioral contexts regarding mental illness in schools and increasing the likelihood that youth seek treatment for mental health problems when needed. METHODS We conducted a cluster randomized trial in sixth-grade classes from 14 schools in 2011 and 2012 with follow-up at 6-month intervals through 24 months (2012-2015). Using a fully crossed 2 × 2 × 2 factorial design, we compared ESD to a no-intervention control and to 2 comparator interventions: (1) contact with 2 young adults with a history of mental illness and (2) exposure to antistigma printed materials. We implemented interventions in classrooms in an ethnically and socioeconomically diverse school district. There were 416 youth who participated in the follow-up, and 312 (75%) of these participated for the full 2 years. Outcome measures were knowledge and positive attitudes, social distance from peers with mental illness, and mental health treatment seeking. RESULTS Youth assigned to ESD reported greater knowledge and positive attitudes and reduced social distance (Cohen's d = 0.35 and 0.16, respectively) than youth in the comparator interventions and no-intervention groups across the 2-year follow-up. Youth with high levels of mental health symptoms were more likely (odds ratio = 3.51; confidence interval = 1.08-11.31) to seek treatment during follow-up if assigned to ESD than if they were assigned to comparator interventions or no intervention. CONCLUSIONS ESD shows potential for improving the social climate related to mental illnesses in schools and increasing treatment seeking when needed. ESD and interventions like it show promise as part of a public mental health response to youth with mental health needs in schools.",2020,"Youth with high levels of mental health symptoms were more likely (odds ratio = 3.51; confidence interval = 1.08-11.31) to seek treatment during follow-up if assigned to ESD than if they were assigned to comparator interventions or no intervention. ","['416 youth who participated in the follow-up, and 312 (75%) of these participated for the full 2 years', 'sixth-grade classes from 14 schools in 2011 and 2012 with follow-up at 6-month intervals through 24 months (2012-2015', 'classrooms in an ethnically and socioeconomically diverse school district', 'Mental Illness Stigma']",['ESD to a no-intervention control and to 2 comparator interventions: (1) contact with 2 young adults with a history of mental illness and (2) exposure to antistigma printed materials'],"['mental health symptoms', 'knowledge and positive attitudes, social distance from peers with mental illness, and mental health treatment seeking', 'knowledge and positive attitudes and reduced social distance']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C4517706', 'cui_str': '312'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205440', 'cui_str': 'Sixth'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}]","[{'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0034036', 'cui_str': 'Printed material'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0037412', 'cui_str': 'Social Distance'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0184647', 'cui_str': 'Mental health treatment'}]",2.0,0.0591902,"Youth with high levels of mental health symptoms were more likely (odds ratio = 3.51; confidence interval = 1.08-11.31) to seek treatment during follow-up if assigned to ESD than if they were assigned to comparator interventions or no intervention. ","[{'ForeName': 'Bruce G', 'Initials': 'BG', 'LastName': 'Link', 'Affiliation': 'Department of Sociology, School of Public Policy, University of California, Riverside, Riverside, California; bruce.link@ucr.edu.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'DuPont-Reyes', 'Affiliation': 'Latino Research Institute, The University of Texas at Austin, Austin, Texas.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Barkin', 'Affiliation': 'Mental Health Connection of Tarrant County, Fort Worth, Texas.'}, {'ForeName': 'Alice P', 'Initials': 'AP', 'LastName': 'Villatoro', 'Affiliation': 'Latino Research Institute, The University of Texas at Austin, Austin, Texas.'}, {'ForeName': 'Jo C', 'Initials': 'JC', 'LastName': 'Phelan', 'Affiliation': 'Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York; and.'}, {'ForeName': 'Kris', 'Initials': 'K', 'LastName': 'Painter', 'Affiliation': 'School of Social Work, University of Texas Arlington, Arlington, Texas.'}]",Pediatrics,['10.1542/peds.2019-0780'] 1364,32434637,[Application of vacuum stretcher combined with feeding in cranial magnetic resonance imaging examination for neonates: a prospective randomized controlled study].,"OBJECTIVE To study the effect and safety of vacuum stretcher combined with feeding in cranial magnetic resonance imaging (MRI) examination for neonates. METHODS A prospective study was performed for the neonates with hyperbilirubinemia, with a gestational age of >34 weeks and stable vital signs, who needed cranial MRI examination and did not need oxygen inhalation hospitalized in the Department of Neonatology, Children's Hospital of Zhejiang University School of Medicine, from September to November, 2019. The neonates were randomly divided into a vacuum stretcher combined with feeding group and a conventional sedation group. Vital signs were monitored before, during, and after MRI examination. The success rate of MRI procedure was recorded. RESULTS A total of 80 neonates were enrolled in the study, with 40 neonates in the vacuum stretcher combined with feeding group and 40 in the conventional sedation group. The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05). As for the neonates who underwent successful MRI examination, the fastest heart rate after examination in the vacuum stretcher combined with feeding group was significantly lower than that in the conventional sedation group (P<0.05), while there were no significant differences between the two groups in transcutaneous oxygen saturation, respiratory rate, and body temperature before and after MRI examination (P>0.05). No complications, such as apnea, acute allergic reactions, and malignant fever, were observed. CONCLUSIONS Vacuum stretcher combined with feeding can improve the success rate of MRI procedure and reduce the use of sedatives, and meanwhile, it does not increase related risks.",2020,The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05).,"['neonates', '80 neonates were enrolled in the study, with 40 neonates in the vacuum stretcher combined with feeding group and 40 in the conventional sedation group', ""neonates with hyperbilirubinemia, with a gestational age of >34 weeks and stable vital signs, who needed cranial MRI examination and did not need oxygen inhalation hospitalized in the Department of Neonatology, Children's Hospital of Zhejiang University School of Medicine, from September to November, 2019""]","['vacuum stretcher combined with feeding group and a conventional sedation group', 'cranial magnetic resonance imaging examination', 'vacuum stretcher combined with feeding in cranial magnetic resonance imaging (MRI) examination', 'vacuum stretcher combined with feeding']","['fastest heart rate', 'transcutaneous oxygen saturation, respiratory rate, and body temperature', 'No complications, such as apnea, acute allergic reactions, and malignant fever', 'success rate of MRI procedure']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0150789', 'cui_str': 'Stretcher'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0027621', 'cui_str': 'Neonatology'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0150789', 'cui_str': 'Stretcher'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}]","[{'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0413234', 'cui_str': 'Acute allergic reaction'}, {'cui': 'C0024591', 'cui_str': 'Malignant hyperthermia'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]",80.0,0.058861,The vacuum stretcher combined with feeding group had a significantly higher success rate of MRI procedure than the conventional sedation group (P<0.05).,"[{'ForeName': 'Xiao-Xia', 'Initials': 'XX', 'LastName': 'Shen', 'Affiliation': ""Department of Neonatal Intensive Care Unit, Children's Hospital, Zhejiang University School of Medicine, Hangzhou 310051, China. maxiaolu_zjuch@zju.edu.cn.""}, {'ForeName': 'Ting-Ting', 'Initials': 'TT', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Fu-Sheng', 'Initials': 'FS', 'LastName': 'Gao', 'Affiliation': ''}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Li-Zhong', 'Initials': 'LZ', 'LastName': 'DU', 'Affiliation': ''}, {'ForeName': 'Xiao-Lu', 'Initials': 'XL', 'LastName': 'Ma', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1365,17216957,Developing and testing of an Egyptian version of Children's Health Locus of Control scale.,"The purpose of this study is to develop and test the reliability and validity of an Egyptian version of the Children's Health Locus of Control scale. A cross sectional study design was applied using a stratified random sample of 930 students from the final two grades of primary and all grades of the preparatory schools. A further convenience sample of 120 students was selected to examine test-retest reliability of the scale. A preliminary instrument was developed and consisted of 40 statements having one of two response forms; a Yes/No format and a 4-point Likert scale format From data analysis the later format showed higher validity and reliability than the former one. Construct validity of the scale is evidenced by the factor analysis which revealed five factors (Internal, Chance, Powerful Others, Fate and Self blame) consistent with the previous theoretical model of HLC. As indicated by eta coefficient the scale and the subscales showed strong discriminating power between subjects. The known group comparison indicated a good criterion validity of the scale and the subscales. The scale showed a considerable reliability as alpha coefficient was 0.73 with test-retest reliability of 0.65. Comparison of different groups of students indicated that the scale could be used with confidence for all age groups, though it was more reliable for the preparatory phase, for private and governmental schools for males and females and for different social strata. Further testing of the developed scale is indicated among Egyptian children in different cultures.",1999,"Comparison of different groups of students indicated that the scale could be used with confidence for all age groups, though it was more reliable for the preparatory phase, for private and governmental schools for males and females and for different social strata.","['120 students', 'stratified random sample of 930 students from the final two grades of primary and all grades of the preparatory schools', 'Egyptian children in different cultures']",[],[],"[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0557794', 'cui_str': 'Preparatory school (environment)'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0220814', 'cui_str': 'culture'}]",[],[],930.0,0.0165838,"Comparison of different groups of students indicated that the scale could be used with confidence for all age groups, though it was more reliable for the preparatory phase, for private and governmental schools for males and females and for different social strata.","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Abdel Gawwad', 'Affiliation': 'Department of Health Administration And Behavioral Sciences, High Institute of Public Health, Alexandria University, Egypt.'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Ahmed', 'Affiliation': ''}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Kamal', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1366,32069113,One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention: The T-TIME Randomized Trial.,,2020,,[],[],[],[],[],[],,0.0288112,,"[{'ForeName': 'Annette M', 'Initials': 'AM', 'LastName': 'Maznyczka', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'McCartney', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Hany', 'Initials': 'H', 'LastName': 'Eteiba', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Greenwood', 'Affiliation': 'Leeds University and Leeds Teaching Hospitals NHS Trust, United Kingdom (J.P.G.).'}, {'ForeName': 'Douglas F', 'Initials': 'DF', 'LastName': 'Muir', 'Affiliation': 'James Cook University Hospital NHS Trust, Middlesbrough, United Kingdom (D.F.M., C.M.).'}, {'ForeName': 'Saqib', 'Initials': 'S', 'LastName': 'Chowdhary', 'Affiliation': 'Manchester University NHS Foundation Trust, United Kingdom (S.C.).'}, {'ForeName': 'Anthony H', 'Initials': 'AH', 'LastName': 'Gershlick', 'Affiliation': 'Leicester University Hospitals NHS Trust, United Kingdom (A.H.G.).'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Appleby', 'Affiliation': 'Liverpool Heart and Chest Hospital NHS Foundation Trust, United Kingdom (C.A.).'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Cotton', 'Affiliation': 'Wolverhampton University Hospital NHS Trust, United Kingdom (J.M.C.).'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wragg', 'Affiliation': 'Barts and The London Hospital, London, United Kingdom (A.W.).'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Curzen', 'Affiliation': 'University Hospital Southampton Foundation Trust and School of Medicine, University of Southampton, United Kingdom (N.C.).'}, {'ForeName': 'Keith G', 'Initials': 'KG', 'LastName': 'Oldroyd', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Mitchell', 'Initials': 'M', 'LastName': 'Lindsay', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'McEntegart', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'J Paul', 'Initials': 'JP', 'LastName': 'Rocchiccioli', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Aadil', 'Initials': 'A', 'LastName': 'Shaukat', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Good', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Watkins', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Robertson', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Malkin', 'Affiliation': 'James Cook University Hospital NHS Trust, Middlesbrough, United Kingdom (D.F.M., C.M.).'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Martin', 'Affiliation': 'West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Glasgow, United Kingdom (A.M.M., P.J.M., H.E., K.G.O., M.L., M.M., J.P.R., A.S., R.G., S.W., K.R., L.M., M.C.P., C.B.).'}, {'ForeName': 'Lynsey', 'Initials': 'L', 'LastName': 'Gillespie', 'Affiliation': 'Greater Glasgow and Clyde Health Board, United Kingdom (L.G.).'}, {'ForeName': 'Robin A', 'Initials': 'RA', 'LastName': 'Weir', 'Affiliation': 'University Hospital Hairmyres, East Kilbride, United Kingdom (R.A.W.).'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Ford', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Mark C', 'Initials': 'MC', 'LastName': 'Petrie', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Aengus', 'Initials': 'A', 'LastName': 'Murphy', 'Affiliation': 'University Hospital Monklands, NHS Lanarkshire, United Kingdom (A.M., C.J.P.).'}, {'ForeName': 'Colin J', 'Initials': 'CJ', 'LastName': 'Petrie', 'Affiliation': 'University Hospital Monklands, NHS Lanarkshire, United Kingdom (A.M., C.J.P.).'}, {'ForeName': 'Nitish', 'Initials': 'N', 'LastName': 'Ramparsad', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing (N.R., K.W., I.F., A.M.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Wetherall', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing (N.R., K.W., I.F., A.M.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Fox', 'Affiliation': 'Centre for Cardiovascular Science, University of Edinburgh, United Kingdom (K.A.F.).'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Ford', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing (N.R., K.W., I.F., A.M.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'McConnachie', 'Affiliation': 'Robertson Centre for Biostatistics, Institute of Health and Wellbeing (N.R., K.W., I.F., A.M.), University of Glasgow, United Kingdom.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Berry', 'Affiliation': 'British Heart Foundation Glasgow Cardiovascular Research Centre (A.M.M., P.J.M., K.G.O., T.J.F., M.C.P., C.B.), University of Glasgow, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008855'] 1367,32434638,[Sedative effect of intranasal midazolam in neonates undergoing magnetic resonance imaging: a prospective single-blind randomized controlled study].,"OBJECTIVE To compare intranasal midazolam and intramuscular phenobarbital sodium for their sedative effect in neonates undergoing magnetic resonance imaging (MRI). METHODS A total of 70 neonates who underwent cranial MRI from September 2017 to March 2019 were randomized into an observation group and a control group, with 35 cases in each group. The observation group received intranasal drops of midazolam (0.3 mg/kg), and the control group received intramuscular injection of phenobarbital sodium (10 mg/kg). The sedation status of the neonates was evaluated using the Ramsay Sedation Scale. Meanwhile, the two groups were compared for the success rate of MRI procedure and incidence of adverse reactions. RESULTS In the observation group, the sedation score was the highest at 20 minutes post administration, then was gradually decreasing, and decreased to the lowest level at 70 minutes post administration. In the control group, the sedation score was the lowest at 10 minutes post administration, then was gradually increasing, and increased to the highest level at 40 minutes and 50 minutes post administration, followed by a gradual decrease. Comparison of the sedation score at each time period suggested that the sedation score was significantly higher in the observation group than in the control group within 40 minutes post administration (P<0.05), while there were no significant differences between the two groups in the sedation score after 40 minutes post administration (P>0.05). The success rate of MRI procedure was significantly higher in the observation group than in the control group (89% vs 69%, P<0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). CONCLUSIONS Intranasal midazolam is superior to intramuscular phenobarbital sodium in the sedative effect in neonates undergoing MRI, with the benefits of being fast, convenient, safe, and effective.",2020,"There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). ","['70 neonates who underwent cranial MRI from September 2017 to March 2019', 'neonates undergoing magnetic resonance imaging (MRI', 'neonates undergoing MRI', 'neonates undergoing magnetic resonance imaging']","['intramuscular injection of phenobarbital sodium', 'intranasal drops of midazolam', 'intranasal midazolam', 'midazolam and intramuscular phenobarbital sodium', 'midazolam']","['success rate of MRI procedure and incidence of adverse reactions', 'incidence of adverse reactions', 'sedation score', 'Ramsay Sedation Scale', 'success rate of MRI procedure']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0021492', 'cui_str': 'Intramuscular injection'}, {'cui': 'C0282303', 'cui_str': 'Phenobarbital sodium'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559295', 'cui_str': 'Ramsay sedation scale'}]",70.0,0.0813785,"There was no significant difference between the two groups in the incidence of adverse reactions (P>0.05). ","[{'ForeName': 'Fang-Hui', 'Initials': 'FH', 'LastName': 'Wang', 'Affiliation': ""Department of Neonatology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. zhouxih@mail.xjtu.edu.cn.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Xiao', 'Affiliation': ''}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': ''}, {'ForeName': 'Xi-Hui', 'Initials': 'XH', 'LastName': 'Zhou', 'Affiliation': ''}]",Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics,[] 1368,32434744,Risk for Delayed Graft Function in Deceased Donor Renal Transplant Patients: A Single-Center Experience From North India.,"OBJECTIVES Delayed graft function (DGF) in renal allograft transplantation refers to the need for dialysis in the first week after renal transplantation. This study analyzed the causes of DGF in deceased donor transplantation. METHODS Data from January 2018 to July 2019 was reviewed with regard to donor and recipient characteristics such as demographics, biochemical parameters, organ dysfunction, and preterminal management. The recipients were divided into 2 groups: group I: patients without DGF and group II: patients with DGF. RESULTS Kidneys were retrieved from 49 deceased donors (male:female = 41:8) and transplanted to 95 recipients (male:female = 60:35). Mean age of the donors and recipients was 35.34 ± 18.2 and 40.72 ± 13.30 years, respectively. The most common cause of brain death was central nervous system trauma (45 out of 49, 91%). In total, 20/95 (21%) recipients had DGF. Twelve recipients had received kidneys from donors who had circulatory arrest. Two patients were re-explored on postoperative day 1 for bleeding from renal artery anastomosis. The mean age in group I and group II was 28.65 ± 10.2 and 37.38 ± 12.28 years, respectively. The mean cold ischemia time in group I and group II was 398.73 ± 187.19 and 333.24 ± 115.49 minutes, respectively. The mean hospital stay of donor before donation in group I and group II was 4.34 ± 1.27 and 6 ± 2.95 days, respectively. The terminal donor creatinine in group I and group II was 0.88 ± 0.47 and 2.33 ± 1.73 mg/dL, respectively. CONCLUSION DGF in deceased donor transplantation may be attributed to donation after circulatory death, prolonged donor hospital stay, high donor leukocyte count, and high terminal creatinine.",2020,"The mean hospital stay of donor before donation in group I and group II was 4.34 ± 1.27 and 6 ± 2.95 days, respectively.","['Mean age of the donors and recipients was 35.34 ± 18.2 and 40.72 ± 13.30 years, respectively', 'Deceased Donor Renal Transplant Patients', 'Data from January 2018 to July 2019 was reviewed with regard to donor and recipient characteristics such as demographics, biochemical parameters, organ dysfunction, and preterminal management', 'deceased donor transplantation', 'Twelve recipients had received kidneys from donors who had circulatory arrest', 'Kidneys were retrieved from 49 deceased donors (male:female\xa0= 41:8) and transplanted to 95 recipients (male:female\xa0= 60:35', 'and group II: patients with DGF']","['Delayed graft function (DGF', 'DGF']","['mean hospital stay of donor before donation', 'mean cold ischemia time']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0730392', 'cui_str': 'Donor renal transplantation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0444720', 'cui_str': 'Circulatory arrest'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1566590', 'cui_str': 'Delayed graft function'}]","[{'cui': 'C1566590', 'cui_str': 'Delayed graft function'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C4049936', 'cui_str': 'Patient status determination, deceased and body donated'}, {'cui': 'C1563922', 'cui_str': 'Cold Ischemic Time'}]",2.0,0.0250709,"The mean hospital stay of donor before donation in group I and group II was 4.34 ± 1.27 and 6 ± 2.95 days, respectively.","[{'ForeName': 'Abhinav', 'Initials': 'A', 'LastName': 'Seth', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Deepesh Benjamin', 'Initials': 'DB', 'LastName': 'Kenwar', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Shivakumar S', 'Initials': 'SS', 'LastName': 'Patil', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Gaurav Shankar', 'Initials': 'GS', 'LastName': 'Pandey', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Vidyasagar', 'Initials': 'V', 'LastName': 'Kallepalli', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sahil', 'Initials': 'S', 'LastName': 'Rally', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Thakur', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Milind', 'Initials': 'M', 'LastName': 'Mandwar', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sarbpreet', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Renal Transplant Surgery, Nehru Building, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: drsarbpreet@yahoo.com.'}]",Transplantation proceedings,['10.1016/j.transproceed.2020.04.003'] 1369,17214176,Controlled trial with human lymphoblastoid interferon among HBeAg and anti-HBe-positive chronic hepatitis B patients in Egypt.,"In a randomized controlled trial, sixty chronic hepatitis B liver disease patients (HBsAg +ve and HBV-DNA +ve) were randomly allocated into 2 groups. The first group comprised of 30 patients who were subdivided into 2 subgroups according to the HBeAg/anti-HBe system. One subgroup was HBeAg-positive (12 patients) and the other was anti-HBe-positive (18 patients). All were given human lymphoblastoid IFN alpha (Wellferon-R) at a dosage of 5 MU, thrice weekly for 4 months. The other 30 patients served as a control group, six of whom were lost during the study. The initial response was loss of HBV-DNA in 66.6% of the HBeAg +ve subgroup (8/12 patients), 33% in the anti-HBe subgroup (6/18 patients) and in 8% in the control group (2/24 patients). Patients and controls were followed up for 8 months after the end of IFN therapy. A sustained response (loss of HBV-DNA) 8 months after discontinuation of IFN was attained in 5/12 patients (41.6%) of the HBeAg-positive subgroup compared to none (0/24) in the control group (p < 0.05). In the anti-HBe subgroup, a sustained response in 2/18 patients (11%) compared to none (0/24) in the controls was not significant. We conclude from this study that (Wellferon-R) at a dosage of 5 MU given thrice weekly for 4 months was significantly better (p < 0.05) than no treatment in producing a sustained response among the HBeAg +ve subgroup of patients. On the other hand, in the anti-HBe subgroup the outcome of the previous schedule was not significantly better than in controls due to the small numbers involved although 2 patients did have a sustained response.",1995,A sustained response (loss of HBV-DNA) 8 months after discontinuation of IFN was attained in 5/12 patients (41.6%) of the HBeAg-positive subgroup compared to none (0/24) in the control group (p < 0.05).,"['30 patients who were subdivided into 2 subgroups according to the HBeAg/anti-HBe system', 'positive chronic hepatitis B patients in Egypt', 'sixty chronic hepatitis B liver disease patients (HBsAg +ve and HBV-DNA +ve', '30 patients served as a control group, six of whom were lost during the study']","['human lymphoblastoid IFN alpha (Wellferon-R', 'human lymphoblastoid interferon among HBeAg and anti-HBe']",['HBV-DNA'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C0312634', 'cui_str': 'Antibody to hepatitis Be antigen (substance)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0524909', 'cui_str': 'Chronic Hepatitis B Virus Infection'}, {'cui': 'C0013715', 'cui_str': 'Arab Republic of Egypt'}, {'cui': 'C0023895', 'cui_str': 'Disorder of liver (disorder)'}, {'cui': 'C0201477', 'cui_str': 'Hepatitis B surface antigen measurement (procedure)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0043112', 'cui_str': 'Wellferon'}, {'cui': 'C0002199', 'cui_str': 'Interferon, Lymphoblastoid'}, {'cui': 'C0019167', 'cui_str': 'e Antigens'}, {'cui': 'C0312634', 'cui_str': 'Antibody to hepatitis Be antigen (substance)'}]","[{'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}]",60.0,0.0349438,A sustained response (loss of HBV-DNA) 8 months after discontinuation of IFN was attained in 5/12 patients (41.6%) of the HBeAg-positive subgroup compared to none (0/24) in the control group (p < 0.05).,"[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'El-Zayadi', 'Affiliation': 'Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Osaima', 'Affiliation': ''}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Haseeb', 'Affiliation': ''}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Dabbous', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1370,32436655,"Novel, digital, chest drainage system in cardiac surgery.","BACKGROUND A new, self-contained, digital, continuous pump-driven chest drainage system is compared in a randomized control trial to a traditional wall-suction system in cardiac surgery. METHODS One hundred and twenty adult elective cardiac patients undergoing coronary artery bypass graft and/or valve surgery were randomized to the study or control group. Both groups had similar pre/intra-operative demographics: age 67.8 vs 67.0 years, Euroscore 2.3 vs 2.2, and body surface area 1.92 vs 1.91 m 2 . Additionally, a satisfaction assessment score (0-10) was performed by 52 staff members. RESULTS Given homogenous intra-operative variables, total chest-tube drainage was comparable among groups (566 vs 640 mL; ns), but the study group showed more efficient fluid collection during the early postoperative phase due to continuous suction (P = .01). Blood, cell saver transfusions and postoperative hemoglobin values were similar in both groups. The study group experienced drain removal after 29.8 vs 38.4 hours in the control group (ns). Seven crossovers from the Study to the Control group were registered but no patient had drain-related complications. The Personnel Satisfaction Assessment scored above 5 for all questions asked. CONCLUSIONS The new, digital, chest drainage system showed better early drainage of the chest cavity and was as reliable as conventional systems. Quicker drain removal might impact on intensive care unit (ICU) stay and reduce costs. Additional advantages are portable size, battery operation, patient mobility, noiseless function, digital indications and alarms. The satisfaction assessment of the new system by the staff revealed a higher score when compared to the traditional wall suction chest drainage system.",2020,"The new, digital, chest drainage system showed better early drainage of the chest cavity and was as reliable as conventional systems.","['Both groups had similar pre/intra-operative demographics: age 67.8 vs 67.0 years, Euroscore 2.3 vs 2.2, and body surface area 1.92 vs 1.91 m 2 ', 'and/or valve surgery', 'One hundred and twenty adult elective cardiac patients undergoing', 'cardiac surgery']",['coronary artery bypass graft'],"['drain-related complications', 'drain removal', 'Blood, cell saver transfusions and postoperative hemoglobin values', 'total chest-tube drainage', 'intensive care unit (ICU) stay and reduce costs', 'satisfaction assessment score', 'efficient fluid collection']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3164744', 'cui_str': 'European system for cardiac operative risk evaluation'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}]","[{'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}]","[{'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008034', 'cui_str': 'Chest drain'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0442799', 'cui_str': 'Efficient'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0600644', 'cui_str': 'Collection'}]",120.0,0.0347734,"The new, digital, chest drainage system showed better early drainage of the chest cavity and was as reliable as conventional systems.","[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Barozzi', 'Affiliation': 'Division of Cardiac Surgery, University of Verona, Verona, Italy.'}, {'ForeName': 'Livio San', 'Initials': 'LS', 'LastName': 'Biagio', 'Affiliation': 'Division of Cardiac Surgery, University of Verona, Verona, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Meneguzzi', 'Affiliation': 'Division of Cardiac Surgery, University of Verona, Verona, Italy.'}, {'ForeName': 'Delphine S', 'Initials': 'DS', 'LastName': 'Courvoisier', 'Affiliation': 'Quality of Care Unit, University Hospital, Geneva, Switzerland.'}, {'ForeName': 'Beat H', 'Initials': 'BH', 'LastName': 'Walpoth', 'Affiliation': 'Department of Cardiovascular Surgery, University Hospital, Geneva, Switzerland.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Faggian', 'Affiliation': 'Division of Cardiac Surgery, University of Verona, Verona, Italy.'}]",Journal of cardiac surgery,['10.1111/jocs.14629'] 1371,17187741,Health education program for mothers of children suffering from iron deficiency anemia in United Arab Emirates.,"The present study was designed to assess knowledge, beliefs and practices of mothers regarding factors leading to iron deficiency anemia among children, to develop a health education (HE) program according to the needs of the target group, to determine the effect of the program in terms of changes in mothers' knowledge, practices and beliefs using Health Belief Model (HBM), and to determine the hemoglobin and hematocrite levels of the children of the target group before and after the program. The sample size was 200 anemic children aged 6-24 months and their mothers, 100 of them were randomly assigned to face to face intervention program (experimental group) (I), the other 100 were the control group (II). Only 16% of mothers of group I and 18% of mothers of group II got satisfactory level of knowledge. After the conduction of HE program, the mothers' knowledge was significantly increased among group I, while almost there was no change of the knowledge's level among group II. Only 7% of mothers of group I and 27% of those of group II had high perceived severity. Only 8% of mothers of group I and 14% of those of group II had low perceived barriers. After the program, 58% of mothers in group I got low perceived barriers. Only 28% of mothers of group I and 21% of those of group II had good dietary practice. After the program, 74% of mothers in group I showed good dietary practice. There were highly significant increases in the levels of hemoglobin and hematocrite of children of group I after the program, while the increases were not significant in group II.",2005,"There were highly significant increases in the levels of hemoglobin and hematocrite of children of group I after the program, while the increases were not significant in group II.","['200 anemic children aged 6-24 months and their mothers, 100 of them', 'mothers of children suffering from iron deficiency anemia in United Arab Emirates']","['Health education program', 'face intervention program (experimental group']","['good dietary practice', 'levels of hemoglobin and hematocrite', 'satisfactory level of knowledge']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia (disorder)'}, {'cui': 'C0282540', 'cui_str': 'Arabs'}]","[{'cui': 'C0018701'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",200.0,0.0228032,"There were highly significant increases in the levels of hemoglobin and hematocrite of children of group I after the program, while the increases were not significant in group II.","[{'ForeName': 'Aisha E', 'Initials': 'AE', 'LastName': 'Hassan', 'Affiliation': 'Health Administration and Behavioral Sciences Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Mofida M', 'Initials': 'MM', 'LastName': 'Kamal', 'Affiliation': ''}, {'ForeName': 'Ebtisam M', 'Initials': 'EM', 'LastName': 'Fetohy', 'Affiliation': ''}, {'ForeName': 'Gamil M', 'Initials': 'GM', 'LastName': 'Turky', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1372,31488402,Nebulised hypertonic saline in moderate-to-severe bronchiolitis: a randomised clinical trial.,"OBJECTIVES To investigate whether nebulised hypertonic saline (HS) treatment would decrease length of hospital stay (LOS) among infants with moderate-to severe-bronchiolitis compared with standard supportive care (SC). METHODS We conducted an open, multicentre, randomised clinical trial from 1 April 2013 to 31 March 2016, in Swiss children's hospitals. Patients aged 6 weeks to 24 months with a primary diagnosis of moderate or severe bronchiolitis were included. Children with previous episodes of wheezing, cardiac disease, chronic respiratory disease, immunodeficiency, prematurity (gestational age <34 weeks), corticotherapy in the preceding 2 weeks or inhaled bronchodilators within 24 hours before presentation were excluded. Patients were randomised to receive standard SC with nebulisation of 4 mL of 3% sodium chloride every 6 hours versus SSC. Main outcomes and measures were LOS duration of oxygen therapy, transfer to intensive care unit (ICU), readmission within 7 days following discharge and adverse events. RESULTS 121 children were randomised. No statistically significant differences were found between treatment groups at baseline (age, Wang Score, atopic history, smoking exposure). Children in the HS group had a non-significant difference in length of stay -2.8 hours (-10; 16) compared with the SC group. There were no differences in oxygen therapy duration, transfer to ICU, readmission rate or adverse events. The intervention was discontinued at the parents' request in 16% of the cases. CONCLUSION Our study does not support the use of HS nebulisation in children with moderate to severe bronchiolitis. TRIAL REGISTRATION NUMBER NCT01812525.",2020,"No statistically significant differences were found between treatment groups at baseline (age, Wang Score, atopic history, smoking exposure).","['Children with previous episodes of wheezing, cardiac disease, chronic respiratory disease, immunodeficiency, prematurity (gestational age <34 weeks), corticotherapy in the preceding 2 weeks or inhaled bronchodilators within 24\u2009hours before presentation were excluded', 'moderate-to-severe bronchiolitis', ""1 April 2013 to 31 March 2016, in Swiss children's hospitals"", 'Patients aged 6 weeks to 24 months with a primary diagnosis of moderate or severe bronchiolitis were included', 'infants with moderate-to severe-bronchiolitis compared with standard supportive care (SC', 'children with moderate to severe bronchiolitis', '121 children']","['standard SC with nebulisation of 4\u2009mL of 3% sodium chloride every 6\u2009hours versus SSC', 'Nebulised hypertonic saline', 'HS nebulisation', 'nebulised hypertonic saline (HS']","['length of hospital stay (LOS', 'LOS duration of oxygen therapy, transfer to intensive care unit (ICU), readmission within 7 days following discharge and adverse events', 'oxygen therapy duration, transfer to ICU, readmission rate or adverse events', 'length of stay']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}, {'cui': 'C0043144', 'cui_str': 'Wheezing'}, {'cui': 'C0018799', 'cui_str': 'Cardiac Diseases'}, {'cui': 'C0264220', 'cui_str': 'Chronic disease of respiratory system'}, {'cui': 'C0021051', 'cui_str': 'Immunological Deficiency Syndromes'}, {'cui': 'C0728731', 'cui_str': 'Prematurity of fetus (disorder)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0006280', 'cui_str': 'Bronchodilators'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0449450', 'cui_str': 'Presentation (attribute)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0006271', 'cui_str': 'Bronchiolitis'}, {'cui': 'C0241315', 'cui_str': 'Swiss (ethnic group)'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C1292428', 'cui_str': '6 hours (qualifier value)'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}]","[{'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0040671', 'cui_str': 'Transfer'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1275717', 'cui_str': 'Transfer to ICU'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",121.0,0.251162,"No statistically significant differences were found between treatment groups at baseline (age, Wang Score, atopic history, smoking exposure).","[{'ForeName': 'Raphaelle', 'Initials': 'R', 'LastName': 'Jaquet-Pilloud', 'Affiliation': 'Department of Medical and Surgical Pediatrics, University Hospital of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Marie-Elise', 'Initials': 'ME', 'LastName': 'Verga', 'Affiliation': 'Department of Medical and Surgical Pediatrics, University Hospital of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Russo', 'Affiliation': 'Pediatrics & Neonatal Medicine Department Hospital, Sion, Valais, Switzerland.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Gehri', 'Affiliation': 'Department of Medical and Surgical Pediatrics, University Hospital of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Pauchard', 'Affiliation': 'Department of Medical and Surgical Pediatrics, University Hospital of Lausanne, Lausanne, Switzerland Jean-Yves.Pauchard@chuv.ch.'}]",Archives of disease in childhood,['10.1136/archdischild-2019-317160'] 1373,31366999,The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trial.,"BACKGROUND Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight women. METHODS Overweight or obese (n = 243) and normal weight (n = 166) women were randomised to a three-month unsupervised home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes. RESULTS Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control mean (95% CI); weight -2.3 (-3.5, -1.0) kg, body fat -1.6 (-2.6, -0.7) kg, community vs. control; weight -2.4 (-3.6, -1.1) kg, body fat -1.4 (-2.4, -0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective. CONCLUSIONS The programmes were equally effective for weight control, but the community programme had additional benefits. CLINICAL TRIAL REGISTRATION ISRCTN68576140.",2019,Both programmes reduced weight and body fat: home vs. control,"['overweight or obese women and prevent gains in normal-weight women', 'Forty-three percent of eligible women were recruited', 'Overweight or obese (n\u2009=\u2009243) and normal weight (n\u2009', '166) women', 'breast cancer diagnosis']","['home versus community-based weight control programmes', 'supervised community weight control programme (community) or to standard written advice (control']","['change in weight and body fat', 'acceptability and effectiveness', 'change in insulin, cardiovascular risk markers, quality of life and cost-effectiveness of the programmes', 'physical activity, reduced insulin, cardiovascular disease risk markers, increased QOL and was cost-effective', 'weight and body fat']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen (regime/therapy)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0034380'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}]",,0.108066,Both programmes reduced weight and body fat: home vs. control,"[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Harvie', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK. michelle.harvie@manchester.ac.uk.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Pegington', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'McMullan', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Bundred', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Livingstone', 'Affiliation': 'The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Campbell', 'Affiliation': 'School of Applied Sciences, Edinburgh Napier University, Edinburgh, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Wolstenholme', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Eleanora', 'Initials': 'E', 'LastName': 'Lovato', 'Affiliation': 'Nuffield Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Campbell', 'Affiliation': 'National Perinatal Epidemiology Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Adams', 'Affiliation': 'Clinical Radiology, Faculty of Medicine Biology and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Speed', 'Affiliation': 'The School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Morris', 'Affiliation': 'Department of Medical Statistics, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Howell', 'Affiliation': 'Manchester Breast Centre, Manchester Cancer Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Howell', 'Affiliation': 'Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, UK.'}]",British journal of cancer,['10.1038/s41416-019-0522-6'] 1374,31383985,Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.,"Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC) significantly increased non-progression rate in advanced ovarian cancer (OC) patients. We report final overall survival (OS) results to further strengthen the efficacy of DD-EPIC in the front-line therapy. In this phase 2 trial, 218 patients with FIGO IIIC-IV OC were randomly allocated to receive DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone (IV group). The study was prespecified to detect differences in progression-free survival (PFS) and OS. At a median follow-up period of 69.1 months, the median OS was 67.5 and 46.3 months in the DD-EPIC and IV group, respectively. The probability rate of OS at 5 years was 61.0% with DD-EPIC, and 38.2% with IV (hazard ratio [HR] for death from OC, 0.70; 95% confidence interval [CI], 0.49-1.00). DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86). DD-EPIC was associated with a longer OS than IV chemotherapy alone. It may be considered as a valuable option of the front-line therapy for advanced ovarian cancer.Trial registration: ClinicalTrials.gov, NCT01669226 (date of registration: August 20, 2012).",2019,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","['advanced ovarian cancer (OC) patients', 'advanced ovarian cancer', '218 patients with FIGO IIIC-IV OC']","['dose-dense early postoperative intraperitoneal chemotherapy', 'Dose-dense early postoperative intraperitoneal chemotherapy (DD-EPIC', 'DD-EPIC followed by intravenous (IV) chemotherapy (DD-EPIC group), or IV chemotherapy alone']","['median OS', 'probability rate of OS', 'Survival benefits', 'progression-free survival (PFS) and OS']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1140680', 'cui_str': 'Ovary Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517647', 'cui_str': 'Two hundred and eighteen'}]","[{'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0439794', 'cui_str': 'Dense (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0442120', 'cui_str': 'Intraperitoneal (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0413365', 'cui_str': 'Intravenous chemotherapy (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",218.0,0.207204,"DD-EPIC was associated with a prolonged PFS compared with the IV group (the estimated rate of PFS at 5 years, 26.0% vs. 8.5%; HR for disease progression, 0.64; 95% CI, 0.47-0.86).","[{'ForeName': 'Tingyan', 'Initials': 'T', 'LastName': 'Shi', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Pu', 'Affiliation': 'Department of Obstetrics and Gynecology, Wuxi Caner Hospital, Jiangsu, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': ""Department of Mathematics and Statistics, Queen's University, Kingston, Canada.""}, {'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Dai', 'Affiliation': 'Department of Obstetrics and Gynecology, Suzhou Municipal Hospital, Jiangsu, China.'}, {'ForeName': 'Yunlang', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': 'Department of Obstetrics and Gynecology, Zhongda Hospital Southeast University, Jiangsu, China.'}, {'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Cheng', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Huixun', 'Initials': 'H', 'LastName': 'Jia', 'Affiliation': 'Clinical Statistics Center, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Ruiqin', 'Initials': 'R', 'LastName': 'Tu', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Huaying', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Luan', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Shumo', 'Initials': 'S', 'LastName': 'Cai', 'Affiliation': 'Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China.'}, {'ForeName': 'Rongyu', 'Initials': 'R', 'LastName': 'Zang', 'Affiliation': 'Ovarian Cancer Program, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai, China. ryzang@yahoo.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",British journal of cancer,['10.1038/s41416-019-0543-1'] 1375,32494976,"A daily study of stressors, continuously measured glucose, and diabetes symptoms in latinos with type 2 diabetes.","This study examined whether daily stressors and continuously monitored glucose levels and glucose variability predict daily diabetes symptoms. Fifty Latinos with type 2 diabetes were randomized to either diabetes education (DE-only; N = 23) or DE plus stress management and relaxation training (DE + SMR; N = 32). After treatment, for 7 days they wore 'blinded' continuous glucose monitors and reported common stressors and diabetes symptoms twice daily. Between individuals, participants with more numerous overall stressors and more time in hyperglycemia reported higher symptoms. Within individuals, symptoms were higher during intervals of greater than usual stressors. Yet, diabetes symptoms did not covary with changes in glucose levels or glucose variability. The within-person stressor-symptom association was stronger among older individuals and non-significant for participants in DE + SMR condition. Diabetes symptoms were associated with recent stressor exposure, but not recent glucose level or changes in glucose. CLINICAL TRIAL NUMBER: ClinicalTrials.gov Identifier (No. NCT01578096).",2020,The within-person stressor-symptom association was stronger among older individuals and non-significant for participants in DE + SMR condition.,"['Fifty Latinos with type 2 diabetes', 'latinos with type 2 diabetes']",['diabetes\xa0education (DE-only; N\u2009=\u200923) or\xa0DE plus stress management and relaxation training (DE\u2009+\u2009SMR; N\u2009=\u200932'],[],"[{'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0282333', 'cui_str': 'Relaxation training therapy'}, {'cui': 'C0036154', 'cui_str': 'San Marino'}]",[],50.0,0.0350559,The within-person stressor-symptom association was stronger among older individuals and non-significant for participants in DE + SMR condition.,"[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Wagner', 'Affiliation': 'Division of Behavioral Sciences and Community Health and Department of Psychiatry, UConn Schools of Dental Medicine and Medicine, UConn Health, 263 Farmington Ave, Farmington, CT, 06030, USA. juwagner@uchc.edu.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Armeli', 'Affiliation': 'Department of Psychology, Farleigh Dickinson University, Teaneck, NJ, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Tennen', 'Affiliation': 'Department of Public Health Sciences, UConn School of Medicine, Farmington, CT, USA.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Bermudez-Millan', 'Affiliation': 'Department of Public Health Sciences, UConn School of Medicine, Farmington, CT, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Wolpert', 'Affiliation': 'Harvard Medical School, Joslin Diabetes Center, Boston, MA, USA.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Pérez-Escamilla', 'Affiliation': 'Yale School of Public Health, New Haven, CT, USA.'}]",Journal of behavioral medicine,['10.1007/s10865-020-00162-1'] 1376,32436048,Is intracytoplasmic sperm (ICSI) better than traditional in vitro fertilization (IVF): confirmation of higher blastocyst rates per oocyte using a split insemination design.,"PURPOSE To explore the effects of traditional vs. intracytoplasmic sperm injection (ICSI) insemination method on the outcome of high-quality blastocyst development in a split sibling oocyte cohort. METHODS In this retrospective cohort study, we analyzed 62 ICSI/IVF split cycles. Sibling oocytes were randomly assigned to ICSI or IVF insemination. Two hundred thirty-four ICSI-only cycles and 152 IVF-only cycles were also analyzed for comparison. Blastocysts were graded by Gardner's embryo grading and were considered a high-quality blastocyst if 3BB or better (Gardner 1999). RESULTS In the ICSI/IVF split group, (1) ICSI oocytes had a higher fertilization rate per oocyte allocated (73% vs 62%, p < 0.001), (2) more high-quality day 2 embryos (69% vs 55%, p < 0.005), (3) ICSI oocytes had a lower blastulation rate per 2PN (46% vs 54%, p < 0.05), but a higher blastulation rate when calculated per oocyte allocated (40% vs 32%, p < 0.05). The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05). The total high-quality blastulation rate was higher for the IVF-only group per 2PN (49% vs 43%, p < 0.05) and per oocyte retrieved (34% vs 28%, p < 0.05). CONCLUSIONS This distinctive IVF/ICSI sibling oocyte split design demonstrated a higher-quality blastulation rate in the IVF group compared to the ICSI group when calculated per 2PN, but not per oocyte allocated to each insemination procedure.",2020,"The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05).","['Sibling oocytes', 'a split sibling oocyte cohort']","['ICSI', 'ICSI or IVF insemination', '2PN', 'traditional vs. intracytoplasmic sperm injection (ICSI) insemination method']","['fertilization rate', 'high-quality day 2 embryos', 'blastulation rate', 'quality blastulation rate', 'blastulation rate per 2PN', 'total high-quality blastulation rate']","[{'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0021586', 'cui_str': 'Insemination'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.207194,"The ICSI-only group had a lower fertilization rate (65% vs 70%, p < 0.001) but more high-quality day 2 embryos in comparison to the IVF-only group (68% vs 64%, p < .05).","[{'ForeName': 'May-Tal', 'Initials': 'MT', 'LastName': 'Sauerbrun-Cutler', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA. msauerbruncutle@wihri.org.'}, {'ForeName': 'Warren J', 'Initials': 'WJ', 'LastName': 'Huber', 'Affiliation': 'The Fertility Institute of New Orleans, 4770 S I-10 Service Rd W Ste 201, Metairie, LA, 94087, USA.'}, {'ForeName': 'Phinnara', 'Initials': 'P', 'LastName': 'Has', 'Affiliation': 'Division of Research, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 Plain Street, Providence, RI, 02905, USA.'}, {'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Shen', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Hackett', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Alvero', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford Medical School, 1195 W Fremont Ave, Sunnyvale, CA, 94087, USA.'}, {'ForeName': 'Shunping', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women & Infants Hospital, 90 plain street, Providence, RI, 02905, USA.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-020-01819-1'] 1377,32436733,Quality of life of women using the etonogestrel long-acting reversible contraceptive implant after abortion for unplanned pregnancy.,"OBJECTIVES The aims of the study were to investigate the effect of a subcutaneous etonogestrel-containing contraceptive implant on the quality of life (QoL) and sexual function of women who had undergone termination of an unplanned pregnancy. METHODS At pregnancy termination 140 women received contraceptive counselling on the etonogestrel implant. The Short Form-36 questionnaire, the Female Sexual Function Index and the Female Sexual Distress Scale were used to investigate, respectively, the QoL, sexual function and sexual distress of the women at baseline and at 6, 12, 24 and 36 months of follow-up. RESULTS The study group comprised 86 (61.4%) women who chose to use the contraceptive implant. The control group comprised 28 (20.0%) women who chose to use short-acting reversible contraception (SARC) and 26 (18.6%) women who chose not to use hormonal contraception. In the women not using hormonal contraception there were 23 (88.5%) unintended pregnancies before the end of the 3 year study period. QoL, sexual function and sexual distress improved in the study group from the 6 months follow-up until the end of the study ( p  < 0.001). QoL ( p  < 0.02) and sexuality ( p  < 0.001) gradually improved in the control group after 24 and 12 months of follow-up, respectively. None of the women using the etonogestrel implant became pregnant during the study. Inter-group analysis showed better improvement in QoL, sexual function and sexual distress in the study group than in the control group from 6 months ( p  < 0.004) until the end of the study ( p  < 0.001). CONCLUSION Compared with SARC and non-hormonal contraception, the contraceptive implant promoted better QoL and sexuality in users and reduced the incidence of unplanned pregnancy. However, the women who opted for SARC or non-hormonal contraception did so because of the lower cost compared with that of the contraceptive implant.",2020,"Inter-group analysis showed better improvement in QoL, sexual function and sexual distress in the study group than in the control group from 6 months ( p  < 0.004) until the end of the study ( p  < 0.001).","['28 (20.0%) women who chose to use short-acting reversible contraception (SARC) and 26 (18.6%) women who chose not to use hormonal contraception', 'of women using the etonogestrel long-acting reversible contraceptive implant after abortion for unplanned pregnancy', '86 (61.4%) women who chose to use the contraceptive implant', 'women who had undergone termination of an unplanned pregnancy']","['SARC and non-hormonal contraception', 'contraceptive counselling', 'subcutaneous etonogestrel-containing contraceptive implant']","['QoL', 'sexuality', 'quality of life (QoL) and sexual function', 'QoL, sexual function and sexual distress', 'QoL and sexuality', 'Quality of life', 'Short Form-36 questionnaire, the Female Sexual Function Index and the Female Sexual Distress Scale', 'incidence of unplanned pregnancy']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0205343', 'cui_str': 'Reversible'}, {'cui': 'C0700589', 'cui_str': 'Contraception'}, {'cui': 'C2985296', 'cui_str': 'Hormonal contraception'}, {'cui': 'C0047683', 'cui_str': 'Etonogestrel'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1657106', 'cui_str': 'Contraceptive implant'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0041747', 'cui_str': 'Unplanned pregnancy'}]","[{'cui': 'C2985296', 'cui_str': 'Hormonal contraception'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0047683', 'cui_str': 'Etonogestrel'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1657106', 'cui_str': 'Contraceptive implant'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0041747', 'cui_str': 'Unplanned pregnancy'}]",,0.0453151,"Inter-group analysis showed better improvement in QoL, sexual function and sexual distress in the study group than in the control group from 6 months ( p  < 0.004) until the end of the study ( p  < 0.001).","[{'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Caruso', 'Affiliation': 'Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.'}, {'ForeName': 'Salvatore Giovanni', 'Initials': 'SG', 'LastName': 'Vitale', 'Affiliation': 'Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Fava', 'Affiliation': 'Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.'}, {'ForeName': 'Salvatore Di', 'Initials': 'SD', 'LastName': 'Pasqua', 'Affiliation': 'Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.'}, {'ForeName': 'Agnese Maria Chiara', 'Initials': 'AMC', 'LastName': 'Rapisarda', 'Affiliation': 'Sexology Research Group, Gynaecology Clinic, Department of General Surgery and Medical Surgical Specialties, School of Medicine, University of Catania, Catania, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Cianci', 'Affiliation': ""Department of Woman, Child and General and Specialised Surgery, University of Campania 'Luigi Vanvitelli', Naples, Italy.""}]",The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,['10.1080/13625187.2020.1760240'] 1378,16918151,"Impact of a simple health education program about antenatal care on knowledge, attitudes, subjective norms and intention of pregnant women.","The aim of this study was to identify pregnant women practices and to assess the impact of simple health education program on knowledge attitudes, subjective norms and intentions to antenatal care of pregnant women The randomized post-test only control group design was used among 200 pregnant women attending Maternal and Child Health (MCH) centers. One hundred women represented the intervention group who received a simple health eduction program and another 100 women constituted the control group. The study demonstated that nearly the intervention and control group women were equal in sociodemographic characteristics as there was no statistically significant difference in any item studied. It was found that 92% of the intervention group women had high outcome belief that attending Ante-Natal Care (ANC) leads to early detection of dangerous signs of pregnancy compared to 77% of the control group. Also 88% of the intervention group women perceived the importance of early detection of dangerous signs compared to 75% of the control group. Also 95% of the intervention group women had high normative belief that their physician believe that they must go for check up during pregnancy compared to 87% of the control group. The study also clarified that 85% of the intervention group had high motivation to comply with their physicians compared to 73% of the control group. Only 43% of the control group had regular medical check up. The mean scores of indirect attitude, subjective norms, indirect subjective norms, intention and practice were highest for the intervention and control groups among those having more than 12 years of education. The mean score of indirect attitudes increased with increasing level of knowledge among both the intervention and control groups. The mean score of practice was highest among those having positive indirect attitudes among both the intervention and control group. The mean score of practice was highest among those having high indirect subjective norm either in the intervention or the control group.",2004,"The mean scores of indirect attitude, subjective norms, indirect subjective norms, intention and practice were highest for the intervention and control groups among those having more than 12 years of education.","['pregnant women', '200 pregnant women attending Maternal and Child Health (MCH) centers', 'pregnant women practices', 'One hundred women represented the intervention group who received a']","['simple health education program', 'simple health eduction program']","['importance of early detection of dangerous signs', 'mean score of indirect attitudes', 'knowledge attitudes, subjective norms and intentions to antenatal care', 'regular medical check', 'knowledge, attitudes, subjective norms and intention', 'mean scores of indirect attitude, subjective norms, indirect subjective norms, intention and practice', 'mean score of practice']","[{'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0008078', 'cui_str': 'Childrens Health'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0205352', 'cui_str': 'Simple (qualifier value)'}, {'cui': 'C0018701'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439852', 'cui_str': 'Indirect (qualifier value)'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]",200.0,0.0201829,"The mean scores of indirect attitude, subjective norms, indirect subjective norms, intention and practice were highest for the intervention and control groups among those having more than 12 years of education.","[{'ForeName': 'Ebtisam M', 'Initials': 'EM', 'LastName': 'Fetohy', 'Affiliation': 'Health Administration and Behavioral Sciences Department (Health Education), High Institute of Public Health, University of Alexandria.'}]",The Journal of the Egyptian Public Health Association,[] 1379,16916051,Blood count profile in chronic active hepatitis (C) Egyptian patients.,"Hepatitis C virus (HCV) is one of the most important causes of chronic hepatitis globally, and particularly in Egypt. Abnormal blood counts have been noted in clinics among patients with HCV infection. The present work is a case control study conducted in Damanhour Medical National Institute (DMNI) to evaluate the frequency and severity of peripheral blood cell abnormalities in HCV- infected Egyptian patients. Two groups of individuals were randomly selected, group 1 comprised 100 patients suffering from chronic active hepatitis C with positive RNA PCR, and group 2 comprised 100 healthy persons and represented the control group. Low neutrophil and platelet counts, but not anemia were noticed in the first group and were significantly different when compared to the control group (<2.1x10(9)/L in 27% of patients versus 10% of controls and <175x10(9)/L in patients versus 11% of controls respectively at p<0.01). Obesity, advanced age and anti HCV seropositivity were independently associated with neutropenia, while advanced age and female gender and anti HCV seropositivity were associated with thrombocytopenia among HCV infected patients.",2004,not anemia were noticed in the first group and were significantly different when compared to the control group (<2.1x10(9)/L in 27% of patients versus 10% of controls and <175x10(9)/L in patients versus 11% of controls respectively at p<0.01).,"['chronic active hepatitis (C) Egyptian patients', '100 patients suffering from chronic active hepatitis C with positive RNA PCR, and group 2 comprised 100 healthy persons and represented the control group', 'HCV- infected Egyptian patients', 'patients with HCV infection']",['Hepatitis C virus (HCV'],"['not anemia', 'Obesity, advanced age and anti HCV seropositivity', 'Low neutrophil and platelet counts', 'Abnormal blood counts']","[{'cui': 'C0520463', 'cui_str': 'Chronic active hepatitis (disorder)'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3872662', 'cui_str': 'Chronic active hepatitis C (disorder)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0441865', 'cui_str': 'Group 2 (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]","[{'cui': 'C0220847', 'cui_str': 'Hepatitis C virus'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0166049', 'cui_str': 'Hepatitis C Virus Antibodies'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear Leukocytes'}, {'cui': 'C1287267', 'cui_str': 'Finding of platelet count (finding)'}, {'cui': 'C0205161', 'cui_str': 'Abnormal (qualifier value)'}, {'cui': 'C0005771', 'cui_str': 'Blood Cell Number'}]",,0.0159345,not anemia were noticed in the first group and were significantly different when compared to the control group (<2.1x10(9)/L in 27% of patients versus 10% of controls and <175x10(9)/L in patients versus 11% of controls respectively at p<0.01).,"[{'ForeName': 'Khaled A', 'Initials': 'KA', 'LastName': 'Farrag', 'Affiliation': 'Tropical Medicine and Hygiene Department, Damanhour Medical National Institute, General Organization for Teaching Hospitals and Institutes.'}, {'ForeName': 'Talaat A', 'Initials': 'TA', 'LastName': 'Elkemary', 'Affiliation': ''}, {'ForeName': 'Saneya A', 'Initials': 'SA', 'LastName': 'Saleh', 'Affiliation': ''}, {'ForeName': 'Hoda', 'Initials': 'H', 'LastName': 'Mangoud', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 1380,31253441,Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.,"BACKGROUND AND AIMS Elevated lipoprotein(a) [Lp(a)] levels are considered a causal factor for cardiovascular disease. In phase 3 ODYSSEY trials, alirocumab reduced levels of low-density lipoprotein cholesterol (LDL-C) and Lp(a), with concomitant reductions in the risk of major adverse cardiovascular events (MACE). We assessed whether lower on-study and greater percentage reductions in Lp(a) are associated with a lower risk of MACE. METHODS Post-hoc analysis of data pooled from 10 phase 3 ODYSSEY trials comparing alirocumab with control (placebo or ezetimibe) in patients (n = 4983) with cardiovascular disease and/or risk factors, and hypercholesterolemia despite statin/other lipid-lowering therapies. RESULTS Median (Q1, Q3) baseline Lp(a) levels were 23.5 (8.0, 67.0) mg/dL. Median Lp(a) changes from baseline with alirocumab were -25.6% vs. -2.5% with placebo (absolute reductions 6.8 vs. 0.5 mg/dL) in placebo-controlled trials, and -21.4% vs. 0.0% with ezetimibe (4.5 vs. 0.0 mg/dL) in ezetimibe-controlled trials. During follow-up (6699 patient-years), 104 patients experienced MACE. A 12% relative risk reduction in MACE per 25% reduction in Lp(a) (p=0.0254) was no longer significant after adjustment for LDL-C changes: hazard ratio per 25% reduction: 0.89 (95% confidence interval, 0.79-1.01; p=0.0780). In subgroup analysis, the association between Lp(a) reduction and MACE remained significant in a fully adjusted model among participants with baseline Lp(a) ≥50 mg/dL (p-interaction vs. Lp(a) < 50 mg/dL: 0.0549). CONCLUSIONS In this population, Lp(a) reductions were not significantly associated with MACE independently of LDL-C reductions. Reducing the risk of MACE by targeting Lp(a) may require greater reductions in Lp(a) with more potent therapies and/or higher initial Lp(a) levels.",2019,"(p=0.0254) was no longer significant after adjustment for LDL-C changes: hazard ratio per 25% reduction: 0.89 (95% confidence interval, 0.79-1.01; p=0.0780).","['≥50', 'patients (n\u202f=\u202f4983) with cardiovascular disease and/or risk factors, and hypercholesterolemia despite statin/other lipid-lowering therapies', 'participants with baseline Lp(a']","['MACE', 'placebo', 'alirocumab with control (placebo or ezetimibe', 'ezetimibe', 'Lp(a']","['baseline Lp(a) levels', 'risk of major adverse cardiovascular events (MACE', 'Median (Q1, Q3', 'low-density lipoprotein cholesterol (LDL-C) and Lp(a', 'Lp(a']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0585943', 'cui_str': 'Lipid-lowering therapy (procedure)'}]","[{'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}]",,0.382512,"(p=0.0254) was no longer significant after adjustment for LDL-C changes: hazard ratio per 25% reduction: 0.89 (95% confidence interval, 0.79-1.01; p=0.0780).","[{'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care & Public Health, School of Public Health, Imperial College, London, UK.'}, {'ForeName': 'Antonio J', 'Initials': 'AJ', 'LastName': 'Vallejo-Vaz', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care & Public Health, School of Public Health, Imperial College, London, UK. Electronic address: a.vallejo-vaz@imperial.ac.uk.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Davidson', 'Affiliation': 'Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Louie', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Maja', 'Initials': 'M', 'LastName': 'Bujas-Bobanovic', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Minini', 'Affiliation': 'Biostatistics and Programming, Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Eckel', 'Affiliation': 'University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Cardiovascular Medicine Innovation, Brigham and Women's Hospital, Boston, MA, USA.""}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.06.896'] 1381,32436277,"Stress-reducing effects of a brief mindfulness intervention in palliative care: Results from a randomised, crossover study.","OBJECTIVE Mindfulness-based interventions are a widely used and highly accepted adjunct treatment in oncology. Due to a paucity of research in advanced cancer and other terminal illnesses, we aimed to evaluate the stress-reducing effects of a brief, standardised mindfulness intervention for use in palliative care. METHODS This study was a randomised, crossover trial where patients participated in both a single mindfulness intervention and a resting state control condition. The order of the conditions was randomised. Study outcomes encompassed self-report data on stress and well-being and measures of heart rate variability. All outcome data were measured at four times per day. RESULTS Forty-two patients participated in this study. We found significantly stronger reductions in self-rated stress and mean heart rate as well as an increase in heart rate variability after the mindfulness intervention. Psychophysiological effects were strongest in the immediate pre- to post-intervention comparison, while the effect on subjective stress persisted after 20 to 40 min. No significant differences were found for self-rated well-being. CONCLUSIONS Despite the rather small magnitude of effects, the brief mindfulness intervention showed to be effective and accepted by patients in very advanced stages of a disease and could be offered by trained healthcare professionals in palliative care.",2020,We found significantly stronger reductions in self-rated stress and mean heart rate as well as an increase in heart rate variability after the mindfulness intervention.,"['patients participated in both a single mindfulness intervention and a resting state control condition', 'palliative care', 'Forty-two patients participated in this study']",['brief mindfulness intervention'],"['self-rated well-being', 'Psychophysiological effects', 'subjective stress', 'heart rate variability', 'self-report data on stress and well-being and measures of heart rate variability', 'self-rated stress and mean heart rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",42.0,0.0486242,We found significantly stronger reductions in self-rated stress and mean heart rate as well as an increase in heart rate variability after the mindfulness intervention.,"[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Warth', 'Affiliation': 'Institute of Medical Psychology, Center for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Koehler', 'Affiliation': 'Institute of Medical Psychology, Center for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Aguilar-Raab', 'Affiliation': 'Institute of Medical Psychology, Center for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Hubert J', 'Initials': 'HJ', 'LastName': 'Bardenheuer', 'Affiliation': 'Center of Pain Therapy and Palliative Care Medicine, Department of Anesthesiology, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Ditzen', 'Affiliation': 'Institute of Medical Psychology, Center for Psychosocial Medicine, University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Kessler', 'Affiliation': 'Center of Pain Therapy and Palliative Care Medicine, Department of Anesthesiology, University Hospital Heidelberg, Heidelberg, Germany.'}]",European journal of cancer care,['10.1111/ecc.13249'] 1382,32436800,Effect of a mobile phone-assisted postpartum family planning service on the use of long-acting reversible contraception: a randomised controlled trial.,"OBJECTIVE The aim of the study was to evaluate the effect of adding mobile phone call reminders to a postpartum family planning service on the initiation of long-acting reversible contraception (LARC). METHODS A randomised, open-label controlled trial (ClinicalTrials.gov NCT03135288) was carried out at a university hospital between July 2017 and March 2019. The study comprised women who delivered a live birth at >28 weeks' gestation and who requested birth spacing for ≥1 year. Eligible women were recruited and randomised to two groups. The study group received contraceptive counselling and two reminders of their first postpartum appointment, one week and again 48 h before the appointment. The control group received contraceptive counselling but no mobile phone reminders of their first postpartum appointment. The primary outcome was the rate of initiation of a LARC method in the first 6 months postpartum. RESULTS The study comprised 500 participants in each group. The rate of initiation and continuation of a LARC method was significantly higher in the study group compared with the control group (30.2% vs 8.4% and 95.4% vs 83.3%, respectively; p < .001). In the study group, 382 (76.4%) women had started using a contraceptive method during the first 6 months, compared with 218 (43.6%) women in the control group ( p < .001). CONCLUSION Using mobile phone reminders as part of the postpartum service increases the frequency of women who attends family planning clinics and initiates contraception, including a LARC methods, as well as the proportion who continue LARC use through the first 6 months postpartum.",2020,"The rate of initiation and continuation of a LARC method was significantly higher in the study group compared with the control group (30.2% vs 8.4% and 95.4% vs 83.3%, respectively; ","['long-acting reversible contraception', '500 participants in each group', 'Eligible women', 'university hospital between July 2017 and March 2019', ""women who delivered a live birth at >28 weeks' gestation and who requested birth spacing for ≥1 year""]","['mobile phone call reminders', 'contraceptive counselling but no mobile phone reminders of their first postpartum appointment', 'contraceptive counselling', 'mobile phone-assisted postpartum family planning service']","['rate of initiation and continuation of a LARC method', 'rate of initiation of a LARC method']","[{'cui': 'C4505307', 'cui_str': 'Long-Acting Reversible Contraception'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0009861', 'cui_str': 'Family planning service'}]","[{'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0025663', 'cui_str': 'Method'}]",,0.188632,"The rate of initiation and continuation of a LARC method was significantly higher in the study group compared with the control group (30.2% vs 8.4% and 95.4% vs 83.3%, respectively; ","[{'ForeName': 'Omar M', 'Initials': 'OM', 'LastName': 'Shaaban', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Treza', 'Initials': 'T', 'LastName': 'Saber', 'Affiliation': 'Department of Obstetrics and Gynaecological Nursing, Faculty of Nursing, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Entisar', 'Initials': 'E', 'LastName': 'Youness', 'Affiliation': 'Department of Obstetrics and Gynaecological Nursing, Faculty of Nursing, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Manal', 'Initials': 'M', 'LastName': 'Farouk', 'Affiliation': 'Department of Obstetrics and Gynaecological Nursing, Faculty of Nursing, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Abbas', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}]",The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,['10.1080/13625187.2020.1764528'] 1383,31326727,Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.,"BACKGROUND AND AIMS Atherosclerosis in obesity and type 2 diabetes (T2DM) is associated with low-grade inflammation (LGI) and dyslipidemia, where especially small, dense lipoprotein particles are atherogenic. The glucagon-like peptide-1 receptor agonist, liraglutide, reduces cardiovascular events by poorly understood mechanisms. We investigated the effect of liraglutide combined with metformin on LGI and lipoprotein density profiles in patients with stable coronary artery disease (CAD) and newly diagnosed T2DM. METHODS We conducted a randomized, double-blind, placebo-controlled, cross-over trial over a 12 + 12-week period, with ≥2-week wash-out. INTERVENTION liraglutide/metformin vs. placebo/metformin. Lipoproteins were separated by continuous density gradient ultracentrifugation, and LDL divided into five subfractions between 226 and 270 Å, considering particle size ≤255 Å as the atherogenic pattern. Plasma C-reactive protein and tumor necrosis factor-α were assessed by the enzyme-linked immunosorbent-assay. RESULTS 28 out of 41 randomized patients completed all visits. Intention-to-treat analysis was performed but one patient had statin dosage and was excluded from the analysis. 95% of the patients were on statin therapy. Overall, liraglutide did not affect lipid subfractions or markers of LGI compared to placebo. The combination of liraglutide and metformin reduced the total LDL subfractions, primarily by reducing the most atherogenic subfraction LDL 5 , and reduced CRP but not TNF-α. Explorative analyses suggested that the subfraction LDL 5 during the wash-out period rebounded significantly at least in a per-protocol analysis of the sub-group of patients starting the liraglutide therapy. CONCLUSIONS In patients with CAD and newly diagnosed T2DM on stable statin therapy, liraglutide combined with metformin may improve the atherogenic LDL lipid profile and CRP.",2019,"Overall, liraglutide did not affect lipid subfractions or markers of LGI compared to placebo.","['statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes', 'patients with stable coronary artery disease (CAD) and newly diagnosed T2DM', 'patients with CAD and newly diagnosed T2DM on stable statin therapy']","['Liraglutide', 'liraglutide', 'placebo', 'metformin', 'liraglutide/metformin vs. placebo/metformin', 'liraglutide and metformin', 'liraglutide combined with metformin']","['total LDL subfractions', 'lipid subfractions or markers of LGI', 'atherogenic LDL lipid profile and CRP', 'Plasma C-reactive protein and tumor necrosis factor-α', 'atherogenic lipid profile and decrease C-reactive protein level', 'LGI and lipoprotein density profiles']","[{'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1956346', 'cui_str': 'Coronary Artery Disease'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}]","[{'cui': 'C1456408', 'cui_str': 'liraglutide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0336789', 'cui_str': 'Combine'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}]",41.0,0.154719,"Overall, liraglutide did not affect lipid subfractions or markers of LGI compared to placebo.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Anholm', 'Affiliation': 'Department of Internal Medicine, Copenhagen University Hospital, Glostrup, Denmark; Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark. Electronic address: canholm@youmail.dk.'}, {'ForeName': 'Preman', 'Initials': 'P', 'LastName': 'Kumarathurai', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Lene Rørholm', 'Initials': 'LR', 'LastName': 'Pedersen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Amirsalar', 'Initials': 'A', 'LastName': 'Samkani', 'Affiliation': 'Department of Endocrinology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Rosemary L', 'Initials': 'RL', 'LastName': 'Walzem', 'Affiliation': 'Department of Poultry Science and Faculty of Nutrition, Texas A&M University, Texas, USA.'}, {'ForeName': 'Olav Wendelboe', 'Initials': 'OW', 'LastName': 'Nielsen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Ole Peter', 'Initials': 'OP', 'LastName': 'Kristiansen', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Mogens', 'Initials': 'M', 'LastName': 'Fenger', 'Affiliation': 'Department of Clinical Biochemistry, Copenhagen University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Sten', 'Initials': 'S', 'LastName': 'Madsbad', 'Affiliation': 'Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Denmark.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Sajadieh', 'Affiliation': 'Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark.'}, {'ForeName': 'Steen Bendix', 'Initials': 'SB', 'LastName': 'Haugaard', 'Affiliation': 'Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark; Department of Endocrinology, Copenhagen University Hospital, Bispebjerg, Denmark.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.07.007'] 1384,31349086,Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.,"BACKGROUND AND AIMS Guidelines recommend high-intensity statins for patients with atherosclerotic cardiovascular disease (ASCVD). Subgroups with comorbidities that increase cardiovascular risk, such as diabetes mellitus (DM), chronic kidney disease (CKD) or polyvascular disease (PoVD), may derive greater absolute benefit from addition of non-statin therapies. We assessed the relationship between lower low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) risk reduction during alirocumab phase III ODYSSEY trials among these subgroups. METHODS Patient data were pooled from nine trials comparing alirocumab with control (placebo/ezetimibe), predominantly on background maximally tolerated statin. Patients with baseline ASCVD were stratified into subgroups with DM, CKD or PoVD, or without comorbidities, and between-group relative and absolute benefits were compared. RESULTS Among 3505 patients with ASCVD, 1573 had no comorbidities, 981 had DM, 660 had CKD and 943 had PoVD, with overlap between comorbidities; mean baseline LDL-C levels were 119 (ASCVD overall), 123, 117, 114 and 113 mg/dL, respectively. Overall, each 39 mg/dL lower on-study LDL-C was associated with a 25% lower MACE risk, hazard ratio 0.75 (95% confidence interval, 0.62-0.90, p = 0.0023), with a similar lower risk observed in each very high-risk subgroup (DM, CKD or PoVD; 30-35%) but not in the subgroup without these comorbidities (9%). Absolute benefits were greater for very high-risk subgroups; lowering LDL-C from 120 to 40 mg/dL would result in 2.76-4.35 fewer MACE/100 patient-years versus 0.3 for no comorbidities. CONCLUSIONS Among patients with ASCVD and mean baseline LDL-C >100 mg/dL, patients with DM, CKD or PoVD appeared to derive greater absolute cardiovascular benefits from further LDL-C reduction than those without.",2019,"Overall, each 39 mg/dL lower on-study LDL-C was associated with a 25% lower MACE risk, hazard ratio 0.75 (95% confidence interval, 0.62-0.90, p = 0.0023), with a similar lower risk observed in each very high-risk subgroup (DM, CKD or PoVD; 30-35%) but not in the subgroup without these comorbidities (9%).","['Patients with baseline', 'patients with atherosclerotic cardiovascular disease (ASCVD', 'Patient data were pooled from nine trials comparing', '3505 patients with ASCVD, 1573 had no comorbidities, 981 had DM', 'very high-risk patients']","['alirocumab with control (placebo/ezetimibe', 'alirocumab']","['cardiovascular risk, such as diabetes mellitus (DM), chronic kidney disease (CKD) or polyvascular disease (PoVD', 'LDL-C levels', 'Absolute benefits', 'low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) risk reduction', 'low-density lipoprotein cholesterol and cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0337051', 'cui_str': 'Pool (environment)'}, {'cui': 'C0442804', 'cui_str': 'Very high (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1142985', 'cui_str': 'ezetimibe'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1273410', 'cui_str': 'Cardiovascular event risk'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",3505.0,0.117266,"Overall, each 39 mg/dL lower on-study LDL-C was associated with a 25% lower MACE risk, hazard ratio 0.75 (95% confidence interval, 0.62-0.90, p = 0.0023), with a similar lower risk observed in each very high-risk subgroup (DM, CKD or PoVD; 30-35%) but not in the subgroup without these comorbidities (9%).","[{'ForeName': 'Antonio J', 'Initials': 'AJ', 'LastName': 'Vallejo-Vaz', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK. Electronic address: a.vallejo-vaz@imperial.ac.uk.'}, {'ForeName': 'Kausik K', 'Initials': 'KK', 'LastName': 'Ray', 'Affiliation': 'Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK.'}, {'ForeName': 'Henry N', 'Initials': 'HN', 'LastName': 'Ginsberg', 'Affiliation': 'Columbia University, New York, NY, USA.'}, {'ForeName': 'Michael H', 'Initials': 'MH', 'LastName': 'Davidson', 'Affiliation': 'Department of Medicine, University of Chicago Medicine, Chicago, IL, USA.'}, {'ForeName': 'Robert H', 'Initials': 'RH', 'LastName': 'Eckel', 'Affiliation': 'University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.'}, {'ForeName': 'L Veronica', 'Initials': 'LV', 'LastName': 'Lee', 'Affiliation': 'Sanofi, Bridgewater, NJ, USA.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Bessac', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.'}, {'ForeName': 'Alexia', 'Initials': 'A', 'LastName': 'Letierce', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.""}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.07.008'] 1385,31357039,Impact of late stent malapposition after drug-eluting stent implantation on long-term clinical outcomes.,"BACKGROUND AND AIMS The impact of late drug-eluting stent (DES) malapposition detected by optical coherence tomography (OCT) on long-term clinical outcomes has not been clearly established. We evaluated long-term clinical outcomes of late stent malapposition (LSM) detected by OCT in a qualified study population. METHODS A total of 428 patients were selected from previous randomized OCT studies that evaluated the degree of strut coverage of different DESs at a 3-12-month follow-up OCT examination. These patients were assigned to one of two groups based on the presence (n = 136) or absence (n = 292) of LSM on follow-up OCT images (performed at 7.0 ± 3.4 months after DES implantation). The cumulative rates of composite events (cardiac death, target-vessel-related myocardial infarction, target-vessel revascularization, and stent thrombosis) were compared between the two groups. RESULTS During 73.7 ± 18.3 months of follow-up, cardiac death or (very) late stent thrombosis did not occur in either group. The cumulative rate of composite events was similar among the patients in each group (6.2% in patients with LSM vs. 11.7% in those without LSM) [hazard ratio (HR) = 0.569, 95% confidence interval (CI) = 0.257-1.257, p = 0.163]. Target vessel-related myocardial infarction occurred in 0.7% of patients with LSM vs. 1.5% of those without LSM (HR = 0.521, 95% CI = 0.058-4.670, p = 0.560). Target-vessel revascularization was performed in 5.4% of patients with LSM vs. 10.2% of those without LSM (HR = 0.574, 95% CI = 0.246-1.343, p = 0.201). CONCLUSIONS Cardiac death or (very) late stent thrombosis did not occur in patients with OCT-detected LSM during long-term follow-up. The presence of OCT-detected LSM was not associated with adverse clinical events.",2019,"The cumulative rates of composite events (cardiac death, target-vessel-related myocardial infarction, target-vessel revascularization, and stent thrombosis) were compared between the two groups. ",['428 patients'],"['late stent malapposition after drug-eluting stent implantation', 'LSM', 'late stent malapposition (LSM', 'late drug-eluting stent (DES) malapposition detected by optical coherence tomography (OCT']","['Target vessel-related myocardial infarction', 'Cardiac death or (very) late stent thrombosis', 'hazard ratio (HR', 'Target-vessel revascularization', 'cumulative rates of composite events (cardiac death, target-vessel-related myocardial infarction, target-vessel revascularization, and stent thrombosis', 'cumulative rate of composite events', 'cardiac death or (very) late stent thrombosis']","[{'cui': 'C4517775', 'cui_str': 'Four hundred and twenty-eight'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C2363858', 'cui_str': 'Stent malapposition'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}]","[{'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}]",428.0,0.189931,"The cumulative rates of composite events (cardiac death, target-vessel-related myocardial infarction, target-vessel revascularization, and stent thrombosis) were compared between the two groups. ","[{'ForeName': 'Eui', 'Initials': 'E', 'LastName': 'Im', 'Affiliation': 'Yongin Severance Hospital, Yonsei University Health System, Yongin, South Korea.'}, {'ForeName': 'Seung-Yul', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Sanbon Hospital, Wonkwang University College of Medicine, Gunpo, South Korea.'}, {'ForeName': 'Sung-Jin', 'Initials': 'SJ', 'LastName': 'Hong', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Chul-Min', 'Initials': 'CM', 'LastName': 'Ahn', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Jung-Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Byeong-Keuk', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Young-Guk', 'Initials': 'YG', 'LastName': 'Ko', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Choi', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Yangsoo', 'Initials': 'Y', 'LastName': 'Jang', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea.'}, {'ForeName': 'Myeong-Ki', 'Initials': 'MK', 'LastName': 'Hong', 'Affiliation': 'Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea. Electronic address: mkhong61@yuhs.ac.'}]",Atherosclerosis,['10.1016/j.atherosclerosis.2019.07.014'] 1386,31515735,Impact of a Patient-Centered Behavioral Economics Intervention on Hypertension Control in a Highly Disadvantaged Population: a Randomized Trial.,"BACKGROUND Uncontrolled hypertension contributes to disparities in cardiovascular outcomes. Patient intervention strategies informed by behavioral economics and social psychology could improve blood pressure (BP) control in disadvantaged minority populations. OBJECTIVE To assess the impact on BP control of an intervention combining short-term financial incentives with promotion of intrinsic motivation among highly disadvantaged patients. DESIGN Randomized controlled trial. PARTICIPANTS Two hundred seven adults (98% African American or Latino) aged 18 or older with uncontrolled hypertension attending Federally Qualified Health Centers. INTERVENTION Six-month intervention, combining financial incentives for measuring home BP, recording medication use, BP improvement, and achieving target BP values with counseling linking hypertension control efforts to participants' personal reasons to stay healthy. MAIN MEASURES Primary outcomes: percentage achieving systolic BP (SBP) < 140 mmHg, percentage achieving diastolic BP (DBP) < 90 mmHg, and changes in SBP and DBP, all after 6 months. Priority secondary outcomes were SBP < 140 mmHg, DBP < 90 mmHg, and BP change at 12 months, 6 months after the intervention ended. KEY RESULTS After 6 months, rates of achieving target BP values for intervention and control subjects respectively was 57.1% vs. 40.2% for SBP < 140 mmHg (adjusted odds ratio (AOR) 2.53 (1.13-5.70)), 79.8% vs 70.1% for DBP < 90 mmHg (AOR 2.50 (0.84-7.44)), and 53.6% vs 40.2% for achieving both targets (AOR 2.04 (0.92-4.52)). However, at 12 months, the groups did not differ significantly in these 3 measures: 39.5% vs 35.0% for SBP (AOR 1.20 (0.51-2.83)), 68.4% vs 75.0% for DBP (AOR 0.70 (0.24-2.09)), and 35.5% vs 33.8% for both (AOR 1.03 (0.44-2.42)). Change in absolute SBP and DBP did not differ significantly between the groups at 6 or 12 months. Exploratory post hoc analysis revealed intervention benefit only occurred among individuals whose providers intensified their regimens, but not among those with intensification but no intervention. CONCLUSIONS The intervention achieved short-term improvement in SBP control in a highly disadvantaged population. Despite attempts to enhance intrinsic motivation, the effect was not sustained after incentives were withdrawn. Future research should evaluate combined patient/provider strategies to enhance such interventions and sustain their benefit. TRIAL REGISTRATION NCT01402453; http://clinicaltrials.gov/show/NCT01402453.",2020,"However, at 12 months, the groups did not differ significantly in these 3 measures: 39.5% vs 35.0% for SBP (AOR 1.20 (0.51-2.83)), 68.4% vs 75.0% for DBP (AOR 0.70 (0.24-2.09)), and 35.5% vs 33.8% for both (AOR 1.03 (0.44-2.42)).","['Two hundred seven adults (98% African American or Latino) aged 18 or older with uncontrolled hypertension attending Federally Qualified Health Centers', 'disadvantaged minority populations', 'Hypertension Control in a Highly Disadvantaged Population', 'highly disadvantaged patients']","[""Six-month intervention, combining financial incentives for measuring home BP, recording medication use, BP improvement, and achieving target BP values with counseling linking hypertension control efforts to participants' personal reasons to stay healthy"", 'Patient-Centered Behavioral Economics Intervention']","['absolute SBP and DBP', 'SBP control', 'SBP and DBP', 'SBP <\u2009140\xa0mmHg, DBP <\u200990\xa0mmHg, and BP change', 'rates of achieving target BP values', 'percentage achieving diastolic BP (DBP', 'blood pressure (BP) control', 'systolic BP (SBP']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}, {'cui': 'C0439475', 'cui_str': 'torr (qualifier value)'}, {'cui': 'C0439087', 'cui_str': '<90 (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",207.0,0.0636395,"However, at 12 months, the groups did not differ significantly in these 3 measures: 39.5% vs 35.0% for SBP (AOR 1.20 (0.51-2.83)), 68.4% vs 75.0% for DBP (AOR 0.70 (0.24-2.09)), and 35.5% vs 33.8% for both (AOR 1.03 (0.44-2.42)).","[{'ForeName': 'Martin F', 'Initials': 'MF', 'LastName': 'Shapiro', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA. mfs2004@med.cornell.edu.'}, {'ForeName': 'Suzanne B', 'Initials': 'SB', 'LastName': 'Shu', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Noah J', 'Initials': 'NJ', 'LastName': 'Goldstein', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Ronald G', 'Initials': 'RG', 'LastName': 'Victor', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Craig R', 'Initials': 'CR', 'LastName': 'Fox', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Chi-Hong', 'Initials': 'CH', 'LastName': 'Tseng', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Sitaram', 'Initials': 'S', 'LastName': 'Vangala', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Braden K', 'Initials': 'BK', 'LastName': 'Mogler', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Stewart B', 'Initials': 'SB', 'LastName': 'Reed', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'Estivali', 'Initials': 'E', 'LastName': 'Villa', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'José J', 'Initials': 'JJ', 'LastName': 'Escarce', 'Affiliation': 'Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05269-z'] 1387,30231750,"""Partner in Prime""? Effects of repeated mobile security priming on attachment security and perceived stress in daily life.","Lacking secure attachment representations is associated with vulnerability to mental and physical health problems, perhaps mediated by increased susceptibility to stress and impaired emotion regulation. Even though cognitive representations of self and others tend to favor confirmation over information, research has shown that adult attachment security can be positively influenced. In a randomized control trial using a mixed between- and within-subjects design, participants ( N  = 112) were mobile primed with attachment security stimulating visualization tasks, over a 7-day period. Self-reported attachment security was unchanged; however, reduced attachment avoidance and perceived stress and increased resilience and self-compassion scores were obtained up to one week after the last prime. Participants who reported less effort and more pleasure in carrying out the visualization tasks experienced the highest gains. Results highlight the potential of mobile attachment security priming for intervention, but also the differential potential of such intervention for people with different attachment orientations.",2019,"Self-reported attachment security was unchanged; however, reduced attachment avoidance and perceived stress and increased resilience and self-compassion scores were obtained up to one week after the last prime.",[],"['mobile primed with attachment security stimulating visualization tasks', 'repeated mobile security priming']","['reduced attachment avoidance and perceived stress and increased resilience and self-compassion scores', 'attachment security and perceived stress in daily life']",[],"[{'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",112.0,0.0332411,"Self-reported attachment security was unchanged; however, reduced attachment avoidance and perceived stress and increased resilience and self-compassion scores were obtained up to one week after the last prime.","[{'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Oehler', 'Affiliation': 'Department of Psychology, Lund University , Lund , Sweden.'}, {'ForeName': 'Elia', 'Initials': 'E', 'LastName': 'Psouni', 'Affiliation': 'Department of Psychology, Lund University , Lund , Sweden.'}]",Attachment & human development,['10.1080/14616734.2018.1517811'] 1388,31349003,Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study.,"PURPOSE Various mechanisms, including oxidative stress, inflammation, and protease-antiprotease imbalance are proposed for the progressive decline in lung function in chronic obstructive pulmonary disease (COPD). Doxycycline, a broad spectrum tetracycline antibiotic, is reported to have non-antimicrobial matrix metalloproteinases (MMP) inhibitory action in various inflammatory conditions. The effect of doxycycline in COPD is hereby assessed in the present randomized prospective study. PATIENTS AND METHODS The first group of COPD patients (n = 30; mild (n = 3), moderate (n = 6), severe (n = 7), very severe (n = 14) as per GOLD II & III criteria was prescribed the standard therapy, a combination of (i) short acting anti-muscarinic agent (SAMA) + short acting β2 agonist (SABA) inhaled and (ii) corticosteroid inhaled (ICS) + long acting β2 agonist (LABA) (iii) ICS + LABA + LAMA. Whereas doxycycline (100 mg), was used daily once or twice as per Body Mass Index (BMI), as an add-on to existing standard therapy for the second group of patients (n = 30; mild (n = 2), moderate (n = 7), severe (n = 8), very severe (n = 13). All recruited patients were followed-up after 3 months of treatment. Lung function index FEV1(%) predicted, FEV1/FVC (%), quality of life status including COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ) were assessed. Routine blood cell count also was performed. RESULTS Biochemical analysis included estimation of oxidative stress markers, inflammatory cytokines and proteases in plasma of both the groups. Reduction in oxidative stress is evidenced by a significant decrease in Lipid hydro peroxides (LPO), total oxidative stress (TOS) and increase in glutathione peroxidase (GSH-PX), reduced glutathione (GSH) and total anti-oxidant capacity (TAO) nitrite and nitrate (NOx) along with peroxynitrate following 3 months of add-on doxycycline treatment. Reduced levels of cytokines such as interleukin IL-6, TNF-α, IL-8 were also observed. Multivariate analysis identified TNF-α major effective discriminant among pre and post doxycycline treated COPD patients. The expression of TNF-α was inversely correlated with FEV1/FVC (%) changes. The levels of MMP-2 and MMP-9/tissue inhibitors of metalloproteinases (TIMP)-1 ratio (MMP-9/ TIMP-1), also decreased significantly and the decline could be associated with TOS. A significant increase in bilirubin and reduced glutathione (GSH) level was noticed in standard therapy group. CONCLUSION These data suggest that the improvement in lung function and quality of life in COPD patients may probably be attributed to the antioxidant, anti-inflammatory and anti-MMP activity of doxycycline. The potential therapeutic role of long-term doxycycline, in addition to its traditional antibiotic effect, definitely warrants further attention.",2019,"Reduction in oxidative stress is evidenced by a significant decrease in Lipid hydro peroxides (LPO), total oxidative stress (TOS) and increase in glutathione peroxidase (GSH-PX), reduced glutathione (GSH) and total anti-oxidant capacity (TAO) nitrite and nitrate (NOx) along with peroxynitrate following 3 months of add-on doxycycline treatment.","['treated COPD patients', 'COPD patients', 'chronic obstructive pulmonary disease - An exploratory study', 'chronic obstructive pulmonary disease (COPD']","['Doxycycline', 'combination of (i) short acting anti-muscarinic agent (SAMA)\xa0+\xa0short acting β2 agonist (SABA) inhaled and (ii) corticosteroid inhaled (ICS)\xa0+\xa0long acting β2 agonist (LABA', 'doxycycline', 'doxycyline', 'LABA\xa0+\xa0LAMA', 'ICS\xa0']","['lung function and quality of life', 'oxidative stress markers, inflammatory cytokines and proteases in plasma', 'Routine blood cell count', 'levels of MMP-2 and MMP-9/tissue inhibitors of metalloproteinases (TIMP)-1 ratio (MMP-9/ TIMP-1', 'Lipid hydro peroxides (LPO), total oxidative stress (TOS) and increase in glutathione peroxidase (GSH-PX), reduced glutathione (GSH) and total anti-oxidant capacity (TAO) nitrite and nitrate (NOx', 'bilirubin and reduced glutathione (GSH) level', 'levels of cytokines such as interleukin IL-6, TNF-α, IL-8', 'expression of TNF-α', ""FEV1/FVC (%), quality of life status including COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ"", 'oxidative stress']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0013090', 'cui_str': 'Doxycycline'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0026815', 'cui_str': 'Muscarinic Agents'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0999593', 'cui_str': 'Lama'}]","[{'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0034380'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0030940', 'cui_str': 'Peptide Hydrolases'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C0005771', 'cui_str': 'Blood Cell Number'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0145947', 'cui_str': 'TIMP-1'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0017822', 'cui_str': 'Glutathione:hydrogen-peroxide oxidoreductase'}, {'cui': 'C0034917', 'cui_str': 'Reduced Glutathione'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0028137', 'cui_str': 'Nitrites'}, {'cui': 'C0028125', 'cui_str': 'Nitrates'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.033449,"Reduction in oxidative stress is evidenced by a significant decrease in Lipid hydro peroxides (LPO), total oxidative stress (TOS) and increase in glutathione peroxidase (GSH-PX), reduced glutathione (GSH) and total anti-oxidant capacity (TAO) nitrite and nitrate (NOx) along with peroxynitrate following 3 months of add-on doxycycline treatment.","[{'ForeName': 'Brajesh', 'Initials': 'B', 'LastName': 'Singh', 'Affiliation': 'School of Medical Science and Technology, Indian Institute of Technology Kharagpur, West Bengal, India.'}, {'ForeName': 'Nilanjana', 'Initials': 'N', 'LastName': 'Ghosh', 'Affiliation': 'School of Medical Science and Technology, Indian Institute of Technology Kharagpur, West Bengal, India.'}, {'ForeName': 'Dipanjan', 'Initials': 'D', 'LastName': 'Saha', 'Affiliation': 'Institute of Pulmocare and Research, Kolkata, India.'}, {'ForeName': 'Surita', 'Initials': 'S', 'LastName': 'Sarkar', 'Affiliation': 'Department of Applied Physics, University of Calcutta, Kolkata, India.'}, {'ForeName': 'Parthasarathi', 'Initials': 'P', 'LastName': 'Bhattacharyya', 'Affiliation': 'Institute of Pulmocare and Research, Kolkata, India.'}, {'ForeName': 'Koel', 'Initials': 'K', 'LastName': 'Chaudhury', 'Affiliation': 'School of Medical Science and Technology, Indian Institute of Technology Kharagpur, West Bengal, India. Electronic address: koel@smst.iitkgp.ernet.in.'}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2019.101831'] 1389,31501880,"Parental perceptions, attitudes and knowledge on European preschool children's total screen time: the ToyBox-study.","BACKGROUND Preschool children spend a significant proportion of their waking hours being sedentary. Parents play a critical role in developing and shaping their children's lifestyle behaviours, particularly in the early years of life. This study aims to assess parental perceptions, attitudes and knowledge of their preschool children's sedentary behaviours and the association with children's television (TV)/video/DVDs viewing and total screen time. METHODS Data were obtained from a sample of 4836 children (3.5-5.5 years), participating in the multi-centre ToyBox-study at baseline (T0) and at 1-year follow-up (T1) periods. Data on children's sedentary behaviours were collected via a standardized proxy-administered primary caregiver's questionnaire. RESULTS Regarding total screen time, 66.6% of the children at T0 and 71.8% at T1 in the control group exceeded the recommendations, whereas the proportion in the intervention group varied from 69.7% at T0 to 72.5% at T1. The odds of exceeding total screen time recommendations were significantly higher when parental perceptions towards limiting the total screen time were negative [(both T0 and T1 and in the intervention and control groups (P < 0.05)]. Similarly, the odds of exceeding TV/video/DVDs viewing recommendations were significantly higher (both T0 and T1 is observed in both groups) when parental knowledge of recommendation were absent. CONCLUSIONS Preschool children whose caregivers stated rules limiting their sedentary screen time were less likely to spend a high amount of time watching TV/video/DVDs. Interventions to increase parental practices may be a promising approach to decrease total screen time of preschool children but studies are needed to confirm this.",2020,"Parents play a critical role in developing and shaping their children's lifestyle behaviours, particularly in the early years of life.","[""European preschool children's total screen time"", 'preschool children', 'Preschool children', ""preschool children's sedentary behaviours and the association with children's"", ""children's sedentary behaviours"", 'Data were obtained from a sample of 4836 children (3.5-5.5 years), participating in the multi-centre ToyBox-study at baseline (T0) and at 1-year follow-up (T1) periods']",['television (TV)/video/DVDs viewing and total screen time'],"['odds of exceeding TV/video/DVDs viewing recommendations', 'odds of exceeding total screen time recommendations', 'Parental perceptions, attitudes and knowledge', 'total screen time']","[{'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]","[{'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C0449911', 'cui_str': 'View (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4704787', 'cui_str': 'Screen Time'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",4836.0,0.0336471,"Parents play a critical role in developing and shaping their children's lifestyle behaviours, particularly in the early years of life.","[{'ForeName': 'María L', 'Initials': 'ML', 'LastName': 'Miguel-Berges', 'Affiliation': 'Growth, Exercise, Nutrition and Development (GENUD) Research Group, University of Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Alba M', 'Initials': 'AM', 'LastName': 'Santaliestra-Pasias', 'Affiliation': 'Growth, Exercise, Nutrition and Development (GENUD) Research Group, University of Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Theodora', 'Initials': 'T', 'LastName': 'Mouratidou', 'Affiliation': 'Growth, Exercise, Nutrition and Development (GENUD) Research Group, University of Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Paloma', 'Initials': 'P', 'LastName': 'Flores-Barrantes', 'Affiliation': 'Growth, Exercise, Nutrition and Development (GENUD) Research Group, University of Zaragoza, Zaragoza, Spain.'}, {'ForeName': 'Odysseas', 'Initials': 'O', 'LastName': 'Androutsos', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'De Craemer', 'Affiliation': 'Department of Movement and Sports Sciences, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Galcheva', 'Affiliation': 'Medical University Varna, Varna, Bulgaria.'}, {'ForeName': 'Berthold', 'Initials': 'B', 'LastName': 'Koletzko', 'Affiliation': ""Dr von Hauner Children's Hospital, University of Munich Medical Centre, Munich, Germany.""}, {'ForeName': 'Zbigniew', 'Initials': 'Z', 'LastName': 'Kulaga', 'Affiliation': ""The Children's Memorial Health Institute, Warsaw, Poland.""}, {'ForeName': 'Yannis', 'Initials': 'Y', 'LastName': 'Manios', 'Affiliation': 'Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, Greece.'}, {'ForeName': 'Luis A', 'Initials': 'LA', 'LastName': 'Moreno', 'Affiliation': 'Growth, Exercise, Nutrition and Development (GENUD) Research Group, University of Zaragoza, Zaragoza, Spain.'}]",European journal of public health,['10.1093/eurpub/ckz151'] 1390,31246555,Effects of dynamic arm and leg exercise on muscle sympathetic nerve activity and vascular conductance in the inactive leg.,"The influence of muscle sympathetic nerve activity (MSNA) responses on local vascular conductance during exercise are not well established. Variations in exercise mode and active muscle mass can produce divergent MSNA responses. Therefore, we sought to examine the effects of small- versus large-muscle mass dynamic exercise on vascular conductance and MSNA responses in the inactive limb. Thirty-five participants completed two study visits in a randomized order. During visit 1 , superficial femoral artery (SFA) blood flow (Doppler ultrasound) was assessed at rest and during steady-state rhythmic handgrip (RHG; 1:1 duty cycle, 40% maximal voluntary contraction), one-leg cycling (17 ± 3% peak power output), and concurrent exercise at the same intensities. During visit 2 , MSNA (contralateral fibular nerve microneurography) was acquired successfully in 12/35 participants during the same exercise modes. SFA blood flow increased during RHG ( P < 0.0001) and concurrent exercise ( P = 0.03) but not cycling ( P = 0.91). SFA vascular conductance was unchanged during RHG ( P = 0.88) but reduced similarly during concurrent and cycling exercise (both P < 0.003). RHG increased MSNA burst frequency ( P = 0.04) without altering burst amplitude ( P = 0.69) or total MSNA ( P = 0.26). In contrast, cycling and concurrent exercise had no effects on MSNA burst frequency (both P ≥ 0.10) but increased burst amplitude (both P ≤ 0.001) and total MSNA (both P ≤ 0.007). Across all exercise modes, the changes in MSNA burst amplitude and SFA vascular conductance were correlated negatively ( r  = -0.43, P = 0.02). In summary, the functional vascular consequences of alterations in sympathetic outflow to skeletal muscle are most closely associated with changes in MSNA burst amplitude, but not frequency, during low-intensity dynamic exercise. NEW & NOTEWORTHY Low-intensity small- versus large-muscle mass exercise can elicit divergent effects on muscle sympathetic nerve activity (MSNA). We examined the relationships between changes in MSNA (burst frequency and amplitude) and superficial femoral artery (SFA) vascular conductance during rhythmic handgrip, one-leg cycling, and concurrent exercise in the inactive leg. Only changes in MSNA burst amplitude were inversely associated with SFA vascular conductance responses. This result highlights the functional importance of measuring MSNA burst amplitude during exercise.",2019,SFA blood flow increased during RHG ( P <0.0001) and concurrent exercise ( P =0.03) but not cycling ( P =0.91).,['Thirty-five participants completed two study visits in a randomized order'],"['dynamic arm and leg exercise', 'small vs. large muscle mass dynamic exercise', 'muscle sympathetic nerve activity (MSNA']","['SFA blood flow', 'burst amplitude (Both, P ≤0.001) and total MSNA', 'total MSNA', 'vascular conductance and MSNA responses', 'changes in MSNA burst amplitude and SFA vascular conductance', 'RHG increased MSNA burst frequency', 'MSNA burst frequency', 'muscle sympathetic nerve activity and vascular conductance', 'SFA vascular conductance', 'superficial femoral artery (SFA) blood flow (Doppler ultrasound']","[{'cui': 'C4319605', 'cui_str': 'Thirty-five'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0454361', 'cui_str': 'Lower limb exercises (regime/therapy)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure (body structure)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure (body structure)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0447106', 'cui_str': 'Superficial femoral artery (body structure)'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}]",35.0,0.0536675,SFA blood flow increased during RHG ( P <0.0001) and concurrent exercise ( P =0.03) but not cycling ( P =0.91).,"[{'ForeName': 'Connor J', 'Initials': 'CJ', 'LastName': 'Doherty', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Trevor J', 'Initials': 'TJ', 'LastName': 'King', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Anthony V', 'Initials': 'AV', 'LastName': 'Incognito', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Jordan B', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Andrew D', 'Initials': 'AD', 'LastName': 'Shepherd', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Cacoilo', 'Affiliation': 'Department of Kinesiology, University of Guelph-Humber, Toronto, Ontario, Canada.'}, {'ForeName': 'Joshua T', 'Initials': 'JT', 'LastName': 'Slysz', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Jamie F', 'Initials': 'JF', 'LastName': 'Burr', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Millar', 'Affiliation': 'Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00997.2018'] 1391,31520255,Proactive Tobacco Treatment in a Behavioral Health Home.,"Tobacco use is rarely addressed in community mental healthcare despite high patient smoking prevalence. Community mental health centers have systems in place that could be used to comprehensively address tobacco use. This study tested feasibility of, satisfaction with, and safety of proactive tobacco treatment (tobacco outreach to offer connection to tobacco cessation treatment). Behavioral health home patients who smoke were randomly assigned to usual care (UC; N = 11) or proactive care (PC; N = 9). All participants were called 3-months post-randomization for follow-up. PC patients reported high satisfaction with the program and experienced no adverse events or mental health symptom exacerbation during treatment. PC patients reported greater reductions in cigarettes per day, more quit attempts, and more cessation medication utilization than UC patients. Proactive outreach for tobacco cessation is feasible in a behavioral health home, acceptable to patients, and may reduce smoking heaviness and promote quit attempts.",2020,"PC patients reported greater reductions in cigarettes per day, more quit attempts, and more cessation medication utilization than UC patients.",['Behavioral health home patients who smoke'],"['Proactive Tobacco Treatment', 'Proactive outreach for tobacco cessation', 'proactive tobacco treatment (tobacco outreach', 'usual care (UC; N\u2009=\u200911) or proactive care (PC; N\u2009=\u20099']","['adverse events or mental health symptom exacerbation', 'smoking heaviness', 'cessation medication utilization']","[{'cui': 'C0870196', 'cui_str': 'Behavioral health (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}]","[{'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0042153', 'cui_str': 'use'}]",,0.0314057,"PC patients reported greater reductions in cigarettes per day, more quit attempts, and more cessation medication utilization than UC patients.","[{'ForeName': 'Sandra J', 'Initials': 'SJ', 'LastName': 'Japuntich', 'Affiliation': 'Hennepin Healthcare Research Institute, 701 Park Ave. S.9.303, Minneapolis, MN, 55415, USA. Sandra.Japuntich@hcmed.org.'}, {'ForeName': 'Eugene M', 'Initials': 'EM', 'LastName': 'Dunne', 'Affiliation': 'Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA.'}, {'ForeName': 'Naomi H', 'Initials': 'NH', 'LastName': 'Krieger', 'Affiliation': 'Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA.'}, {'ForeName': 'Patricia M', 'Initials': 'PM', 'LastName': 'Ryan', 'Affiliation': 'Gateway Healthcare, Providence, RI, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Rogers', 'Affiliation': 'VA New York Harbor Healthcare System, New York City, NY, USA.'}, {'ForeName': 'Scott E', 'Initials': 'SE', 'LastName': 'Sherman', 'Affiliation': 'VA New York Harbor Healthcare System, New York City, NY, USA.'}, {'ForeName': 'Steven S', 'Initials': 'SS', 'LastName': 'Fu', 'Affiliation': 'VA HSR&D Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, Minneapolis, MN, 55417, USA.'}]",Community mental health journal,['10.1007/s10597-019-00458-w'] 1392,31515713,Sex Differences on Quality of Life and Mental Health Outcomes When Using a Brief Cognitive-Behavioral Skill Building Intervention with Adolescent Syrian Refugees: A Secondary Analysis.,"Little is known about how sex as a biological variable may contribute to differences in quality of life (QOL) and mental health outcomes following a brief intervention among adolescent Syrian refugees. This paper explores the results of a secondary data analysis to investigate differences by sex on self-reported QOL and mental health outcomes among Syrian refugees who participated in a 7-session cognitive behavioral skills building intervention. A one group pretest-posttest design was used to deliver the intervention to 31 adolescent refugees (13-17 years; 15 male, and 16 female). At baseline, there were no significant differences between males and females on mean scores of depression, anxiety, or QOL. Post-intervention, self-reported scores for QOL and mental health were significantly different between sexes. Males demonstrated a significant decrease in anxiety scores compared to females. Among males only, significant decreases in depression and anxiety scores were observed with significant improvement in total QOL.",2020,"Post-intervention, self-reported scores for QOL and mental health were significantly different between sexes.","['Syrian refugees who participated in a 7-session cognitive behavioral skills building intervention', '31 adolescent refugees (13-17\xa0years; 15 male, and 16 female']",[],"['mean scores of depression, anxiety, or QOL', 'depression and anxiety scores', 'Quality of Life and Mental Health Outcomes', 'QOL and mental health', 'anxiety scores', 'quality of life (QOL) and mental health outcomes', 'total QOL']","[{'cui': 'C0337819', 'cui_str': 'Syrians (ethnic group)'}, {'cui': 'C0034961', 'cui_str': 'Refugees'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0034380'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}]",31.0,0.0166603,"Post-intervention, self-reported scores for QOL and mental health were significantly different between sexes.","[{'ForeName': 'Chant', 'Initials': 'C', 'LastName': 'Kazandjian', 'Affiliation': 'American University of Beirut, Lebanon, P.O. box: 11-0236, Beirut, Lebanon.'}, {'ForeName': 'Lisa K', 'Initials': 'LK', 'LastName': 'Militello', 'Affiliation': 'Martha S. Pitzer Center for Women, Children & Youth, The Ohio State University, 1585 Neil Avenue, Columbus, OH, 43210, USA.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Doumit', 'Affiliation': 'Alice Ramez Chagoury School of Nursing, Lebanese American University, P.O. box 36, Byblos Campus, Byblos, Lebanon. rita.doumit@lau.edu.lb.'}]",Community mental health journal,['10.1007/s10597-019-00453-1'] 1393,31985516,Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.,"PURPOSE NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. METHODS Eligibility-within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180. Gemcitabine arm-6 cycles of gemcitabine. Gemcitabine+erlotinib arm-gemcitabine and erlotinib 100 mg/d. Two hundred deaths provided 90% power (1-sided α=0.15) to detect the hypothesized OS signal (hazard ratio=0.72) in favor of the arm 2. RESULTS From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2. Median age was 63 (39 to 86) years. CA19-9 ≤90 in 93%. Arm 1: 32 patients (20%) grade 4 and 2 (1%) grade 5 adverse events; arm 2, 27 (17%) grade 4 and 3 (2%) grade 5. GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, (P=0.22). The median follow-up (surviving patients) was 42.5 months (min-max: <1 to 75). With 203 deaths, the median and 3-year OS (95% confidence interval) are 29.9 months (21.7, 33.4) and 39% (30, 45) for arm 1 and 28.1 months (20.7, 30.9) and 39% (31, 47) for arm 2 (log-rank P=0.62). Hazard ratio (95% confidence interval) comparing OS of arm 2 to arm 1 is 1.04 (0.79, 1.38). CONCLUSIONS The addition of adjuvant erlotinib to gemcitabine did not provide a signal for increased OS in this trial.",2020,"GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, (P=0.22).","['Resected Cancer of the Pancreatic Head', 'From November 17, 2009 to February 28, 2014, 163 patients were randomized and evaluable for arm 1 and 159 for arm 2', 'Median age was 63 (39 to 86) years', 'patients with resected pancreatic head adenocarcinoma', 'Eligibility-within 10 weeks of curative intent pancreaticoduodenectomy with postoperative CA19-9<180']","['Gemcitabine', 'fluoropyrimidine', 'gemcitabine and erlotinib', 'Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine', 'gemcitabine-based adjuvant chemotherapy', 'gemcitabine', 'Gemcitabine+erlotinib arm-gemcitabine and erlotinib']","['median and 3-year OS', 'survival', 'Hazard ratio', 'hypothesized OS signal']","[{'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001418', 'cui_str': 'Adenoma, Malignant'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1276305', 'cui_str': 'Curative procedure'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C0085162', 'cui_str': 'Pancreatoduodenectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1135135', 'cui_str': 'erlotinib'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",163.0,0.114886,"GI adverse events, arm 1: 22% grade ≥3 and arm 2: 28%, (P=0.22).","[{'ForeName': 'Ross A', 'Initials': 'RA', 'LastName': 'Abrams', 'Affiliation': 'Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Winter', 'Affiliation': 'NRG Oncology Statistics and Data Management Center.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Safran', 'Affiliation': 'Rhode Island Hospital.'}, {'ForeName': 'Karyn A', 'Initials': 'KA', 'LastName': 'Goodman', 'Affiliation': 'University of Colorado Cancer Center, Denver, CO.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Regine', 'Affiliation': 'University of Maryland/Greenebaum Cancer Center, Baltimore, MD.'}, {'ForeName': 'Adam C', 'Initials': 'AC', 'LastName': 'Berger', 'Affiliation': 'Thomas Jefferson University Hospital, Philadelphia, PA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Gillin', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Philip', 'Affiliation': 'Wayne State University/Karmanos Cancer Institute, Detroit, MI.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Lowy', 'Affiliation': 'UC San Diego Moores Cancer Center, San Diego.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Wu', 'Affiliation': 'Memorial Sloan Kettering Cancer, New York.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'DiPetrillo', 'Affiliation': 'Rush University Medical Center, Chicago, IL.'}, {'ForeName': 'Benjamin W', 'Initials': 'BW', 'LastName': 'Corn', 'Affiliation': 'Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.'}, {'ForeName': 'Samantha A', 'Initials': 'SA', 'LastName': 'Seaward', 'Affiliation': 'Department of Radiation Oncology.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Haddock', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Suisui', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'USC/Norris Comprehensive Cancer Center, Los Angeles, CA.'}, {'ForeName': 'Yixing', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'University of Maryland/Greenebaum Cancer Center, Baltimore, MD.'}, {'ForeName': 'Barbara J', 'Initials': 'BJ', 'LastName': 'Fisher', 'Affiliation': 'London Regional Cancer Program, London, ON, Canada.'}, {'ForeName': 'Alan W', 'Initials': 'AW', 'LastName': 'Katz', 'Affiliation': 'University of Rochester, Rochester, NY.'}, {'ForeName': 'Sharmila', 'Initials': 'S', 'LastName': 'Mehta', 'Affiliation': 'Spartanburg Regional Medical Center, Spartanburg, SC.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Willett', 'Affiliation': 'Duke University Medical Center, Durham, NC.'}, {'ForeName': 'Christopher H', 'Initials': 'CH', 'LastName': 'Crane', 'Affiliation': 'Memorial Sloan Kettering Cancer, New York.'}]",American journal of clinical oncology,['10.1097/COC.0000000000000633'] 1394,31500524,Cerebrovascular effects of endothelin-1 investigated using high-resolution magnetic resonance imaging in healthy volunteers.,"Endothelin-1 (ET-1) is a highly potent vasoconstrictor peptide released from vascular endothelium. ET-1 plays a major role in cerebrovascular disorders and likely worsens the outcome of acute ischaemic stroke and aneurismal subarachnoid haemorrhage through vasoconstriction and cerebral blood flow (CBF) reduction. Disorders that increase the risk of stroke, including hypertension, diabetes mellitus, and acute myocardial infarction, are associated with increased plasma levels of ET-1. The in vivo human cerebrovascular effects of systemic ET-1 infusion have not previously been investigated. In a two-way crossover, randomized, double-blind design, we used advanced 3 tesla MRI methods to investigate the effects of high-dose intravenous ET-1 on intra- and extracranial artery circumferences, global and regional CBF, and cerebral metabolic rate of oxygen (CMRO 2 ) in 14 healthy volunteers. Following ET-1 infusion, we observed a 14% increase of mean arterial blood pressure, a 5% decrease of middle cerebral artery (MCA) circumference, but no effects on extracerebral arteries and no effects on CBF or CMRO 2 . Collectively, the findings indicate MCA constriction secondarily to blood pressure increase and not due to a direct vasoconstrictor effect of ET-1. We suggest that, as opposed to ET-1 in the subarachnoid space, intravascular ET-1 does not exert direct cerebrovascular effects in humans.",2020,"Following ET-1 infusion, we observed a 14% increase of mean arterial blood pressure, a 5% decrease of middle cerebral artery (MCA) circumference, but no effects on extracerebral arteries and no effects on CBF or CMRO 2 .","['14 healthy volunteers', 'healthy volunteers']","['Endothelin-1 (ET-1', 'endothelin-1 investigated using high-resolution magnetic resonance imaging']","['blood pressure increase', 'intra- and extracranial artery circumferences, global and regional CBF, and cerebral metabolic rate of oxygen (CMRO 2 ', 'risk of stroke, including hypertension, diabetes mellitus, and acute myocardial infarction', 'mean arterial blood pressure', 'middle cerebral artery (MCA) circumference']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0079281', 'cui_str': 'Endothelin Type 1'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1552358', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}, {'cui': 'C0347985', 'cui_str': 'During values (qualifier value)'}, {'cui': 'C0580586', 'cui_str': 'Extracranial (qualifier value)'}, {'cui': 'C0003842', 'cui_str': 'Arteries'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction (disorder)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0149566', 'cui_str': 'Middle Cerebral Artery'}]",14.0,0.171039,"Following ET-1 infusion, we observed a 14% increase of mean arterial blood pressure, a 5% decrease of middle cerebral artery (MCA) circumference, but no effects on extracerebral arteries and no effects on CBF or CMRO 2 .","[{'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Hougaard', 'Affiliation': 'Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Samaira', 'Initials': 'S', 'LastName': 'Younis', 'Affiliation': 'Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Afrim', 'Initials': 'A', 'LastName': 'Iljazi', 'Affiliation': 'Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Kristian A', 'Initials': 'KA', 'LastName': 'Haanes', 'Affiliation': 'Department of Clinical Experimental Research, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Lindberg', 'Affiliation': 'Department of Clinical Physiology, Functional Imaging Unit, Nuclear Medicine and PET, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Mark B', 'Initials': 'MB', 'LastName': 'Vestergaard', 'Affiliation': 'Department of Clinical Physiology, Functional Imaging Unit, Nuclear Medicine and PET, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Faisal M', 'Initials': 'FM', 'LastName': 'Amin', 'Affiliation': 'Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Sugimoto', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.'}, {'ForeName': 'Lars S', 'Initials': 'LS', 'LastName': 'Kruse', 'Affiliation': 'Department of Clinical Experimental Research, Rigshospitalet Glostrup, Glostrup, Denmark.'}, {'ForeName': 'Cenk', 'Initials': 'C', 'LastName': 'Ayata', 'Affiliation': 'Stroke Service, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.'}, {'ForeName': 'Messoud', 'Initials': 'M', 'LastName': 'Ashina', 'Affiliation': 'Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Glostrup, Denmark.'}]",Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,['10.1177/0271678X19874295'] 1395,31492485,Prospective randomized placebo-controlled double-blind clinical study of adjuvant dexamethasone with surgery for chronic subdural haematoma with post-operative subdural drainage: Interim analysis.,"Most chronic subdural haematomas (CSDH) are successfully treated neurosurgically. However, operative recurrences occur with a frequency 3-30%, consume resources and potentially prolong length-of stay (LOS). The only adjuvant factor proven to significantly decrease CSDH recurrence rate (RR) is post-operative subdural drainage. Corticosteroids have been used to conservatively manage CSDH. One non-randomised study also compared dexamethasone (DX) as an adjunct to surgery without post-operative drainage: whilst a null effect was observed, the 'surgery-alone' group consisted of only n = 13. We present an interim analysis of the first registered prospective randomised placebo-controlled trial (PRPCT) of adjuvant DX on RR and outcome after CSDH surgery with post-operative drainage. Participants were randomised to either placebo or a reducing DX regime over 2 weeks, with CSDH evacuation and post-operative drainage. Post-operative mortality (POMT) and RR were determined at 30 days and 6 months; modified Rankin Score (mRS) at discharge and 6 months. Post-operative morbidity (POMB) and adverse events (AEs) were determined at 30 days. Interim analysis at approximately 50% estimated sample size was performed (n = 47). Recurrences were not observed with DX: only with placebo (0/23 [0%] v 5/24 [20.83%], P = 0.049). There was no significant between-group differences in POMT, POMB, LOS, mRS or AEs. CONCLUSIONS: In this first registered PRPCT, interim analysis suggested that adjuvant DX with post-operative drainage is both safe and may significantly decrease recurrences. A 12.5% point between-groups difference may be reasonable to power a final sample size of approximately n = 89. Future studies could consider adjuvant DX for longer than the arbitrarily-chosen 2 weeks.",2020,"There was no significant between-group differences in POMT, POMB, LOS, mRS or AEs.",['chronic subdural haematoma with post-operative subdural drainage'],"['adjuvant dexamethasone', 'CSDH surgery with post-operative drainage', 'placebo', 'Corticosteroids', 'dexamethasone (DX', 'placebo or a reducing DX regime over 2\u202fweeks, with CSDH evacuation and post-operative drainage', 'adjuvant DX']","['Recurrences', 'Post-operative mortality', 'POMT, POMB, LOS, mRS or AEs', 'POMT) and RR', 'Post-operative morbidity (POMB) and adverse events (AEs', 'CSDH recurrence rate (RR', 'length-of stay (LOS']","[{'cui': 'C0749095', 'cui_str': 'Hemorrhage, Subdural, Chronic'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1282573', 'cui_str': 'Evacuation procedure'}]","[{'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",,0.560342,"There was no significant between-group differences in POMT, POMB, LOS, mRS or AEs.","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Mebberson', 'Affiliation': 'Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Colditz', 'Affiliation': 'Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia.'}, {'ForeName': 'L A G', 'Initials': 'LAG', 'LastName': 'Marshman', 'Affiliation': 'Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia; School of Medicine and Dentistry, James Cook University, Douglas, Townsville 4810, Queensland, Australia. Electronic address: l.a.g.marshman@btinternet.com.'}, {'ForeName': 'P A W', 'Initials': 'PAW', 'LastName': 'Thomas', 'Affiliation': 'Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia; School of Medicine and Dentistry, James Cook University, Douglas, Townsville 4810, Queensland, Australia.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Mitchell', 'Affiliation': 'Department of Neurosurgery, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Robertson', 'Affiliation': 'School of Medicine and Dentistry, James Cook University, Douglas, Townsville 4810, Queensland, Australia; Department of Pharmacy, Medical Services Group, The Townsville Hospital, Douglas, Townsville 4810, Queensland, Australia.'}]",Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,['10.1016/j.jocn.2019.08.095'] 1396,31830211,Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials.,"Importance For men with metastatic castration-resistant prostate cancer (mCRPC) whose condition is responding to enzalutamide, new unconfirmed bone lesions detected at posttreatment scinitigraphy may reflect an osteoblastic reaction that represents healing, known as pseudoprogression, which can lead to premature discontinuation of therapy. Objective To determine the association between new unconfirmed lesions detected on a follow-up bone scintigram (bone scan) and outcomes in enzalutamide-treated men with mCRPC. Design, Setting, and Participants This post hoc, retrospective secondary analysis of 1672 enzalutamide-treated men from 2 phase 3, randomized mCRPC studies (PREVAIL and AFFIRM) before or after treatment with docetaxel was conducted from April 12, 2018, to July 25, 2019. Participants were men from the enzalutamide groups of the 2 studies with a decrease in prostate-specific antigen level at any time or with stable disease or soft-tissue disease responding to treatment based onradiologic findings. Intervention Enzalutamide, 160 mg once daily. Main Outcomes and Measures The clinical significance of new lesions detected on the first (early) or second (late) posttreatment bone scan, without an unfavorable change in prostate-specific antigen level or soft-tissue progression, was investigated. Associations of new unconfirmed lesions with radiographic progression-free survival, overall survival, decrease in prostate-specific antigen level, objective response in soft tissue, and quality of life were evaluated. Results Among the 643 men (median age, 72 years [range, 43-93 years]) in PREVAIL, early and late unconfirmed lesions were observed in 177 men (27.5%) with stable disease or disease responding to enzalutamide. Among the 404 men (median age, 70 years [range, 41-88 years]) in AFFIRM, early and late unconfirmed lesions were observed in 73 men (18.1%) with stable disease or disease responding to enzalutamide. In PREVAIL, men with new unconfirmed lesions had median radiographic progression-free survival (hazard ratio [HR], 1.37 [95% CI, 0.81-2.30]; P = .23) and median overall survival (HR, 1.25 [95% CI, 0.85-1.83]) in the chemotherapy-naive setting similar to men those of men without such new lesions. In AFFIRM, the median overall survival (HR, 1.94 [95% CI, 1.10-3.44]) was reduced among men with unconfirmed bone lesions, but the median radiographic progression-free survival was not reduced (HR, 1.21 [95% CI, 0.83-1.75]; P = .32). Quality of life over time was similar regardless of the presence of new unconfirmed lesions detected on a follow-up bone scan in either setting. Conclusions and Relevance These results suggest that new unconfirmed lesions detected on follow-up bone scans may represent pseudoprogression in men with mCRPC and are indicative of a favorable treatment response to enzalutamide. The detection of new unconfirmed bone lesions in men with mCRPC that responded to treatment with enzalutamide after docetaxel appears to be associated with worse overall survival and may represent true progression, thus highlighting the need for improved functional bone metastasis imaging. Trial Registration ClinicalTrials.gov identifier: NCT01212991 and NCT00974311.",2019,"In AFFIRM, the median overall survival (HR, 1.94 [95% CI, 1.10-3.44]) was reduced among men with unconfirmed bone lesions, but the median radiographic progression-free survival was not reduced (HR, 1.21 [95% CI, 0.83-1.75]; P = .32).","['treated men with mCRPC.\nDesign, Setting, and Participants', 'Men', 'Participants were men from the enzalutamide groups of the 2 studies with a decrease in prostate-specific antigen level at any time or with stable disease or soft-tissue disease responding to treatment based onradiologic findings', 'men with mCRPC', 'men with metastatic castration-resistant prostate cancer (mCRPC', '1672 enzalutamide-treated men from 2 phase 3, randomized mCRPC studies (PREVAIL and AFFIRM) before or after treatment with', '643 men (median age, 72 years [range, 43-93 years]) in PREVAIL, early and late unconfirmed lesions were observed in 177 men (27.5%) with stable disease or disease responding to enzalutamide', '404 men (median age, 70 years [range, 41-88 years]) in AFFIRM, early and late unconfirmed lesions were observed in 73 men (18.1%) with stable disease or disease responding to enzalutamide']","['Enzalutamide', 'enzalutamide after docetaxel', 'enzalutamide', 'docetaxel', 'Enzalutamide, 160 mg once daily']","['median overall survival', 'median radiographic progression-free survival', 'radiographic progression-free survival, overall survival, decrease in prostate-specific antigen level, objective response in soft tissue, and quality of life', 'Quality of life', 'overall survival']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2607943', 'cui_str': 'findings'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C3152857', 'cui_str': 'Prevail'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C3875135', 'cui_str': 'Observes (attribute)'}, {'cui': 'C4517674', 'cui_str': '27.5'}]","[{'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C0246415', 'cui_str': 'docetaxel'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0556983', 'cui_str': 'Once daily (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0034380'}]",,0.0974355,"In AFFIRM, the median overall survival (HR, 1.94 [95% CI, 1.10-3.44]) was reduced among men with unconfirmed bone lesions, but the median radiographic progression-free survival was not reduced (HR, 1.21 [95% CI, 0.83-1.75]; P = .32).","[{'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Armstrong', 'Affiliation': 'Division of Medical Oncology and Urology, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, North Carolina.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Al-Adhami', 'Affiliation': 'Biostatistics, Pfizer Inc, Cambridge, Massachusetts.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Lin', 'Affiliation': 'Biostatistics, Pfizer Inc, San Francisco, California.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Parli', 'Affiliation': 'Clinical Development, Pfizer Inc, San Francisco, California.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Sugg', 'Affiliation': 'Biostatistics, Astellas Pharma Inc, Northbrook, Illinois.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Steinberg', 'Affiliation': 'Clinical Development, Astellas Pharma Inc, Northbrook, Illinois.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Tombal', 'Affiliation': 'Division of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Cora N', 'Initials': 'CN', 'LastName': 'Sternberg', 'Affiliation': 'Medical Oncology, Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'de Bono', 'Affiliation': 'Division of Clinical Studies, The Institute of Cancer Research, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Howard I', 'Initials': 'HI', 'LastName': 'Scher', 'Affiliation': 'Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.'}, {'ForeName': 'Tomasz M', 'Initials': 'TM', 'LastName': 'Beer', 'Affiliation': 'Division of Hematology/Medical Oncology, OHSU Knight Cancer Institute, Oregon Health & Science University, Portland.'}]",JAMA oncology,['10.1001/jamaoncol.2019.4636'] 1397,31812686,Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial.,"INTRODUCTION Clinical research and management of postmenopausal vaginal symptoms have been limited by the lack of validated measures for assessing symptom impact. AIM To evaluate convergent-divergent validity of the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire among postmenopausal women with moderate-to-severe vulvovaginal symptoms and identify demographic and clinical factors associated with greater symptom impact. METHODS We examined baseline data from postmenopausal women with moderate-to-severe vulvovaginal itching, pain, irritation, dryness, or pain with intercourse in a randomized trial of vaginal estradiol, moisturizer, or placebo. In addition to completing the DIVA questionnaire, participants rated the severity of their most bothersome vulvovaginal symptom, underwent assessment of vaginal pH and epithelial cytology, and completed other self-report measures including the Female Sexual Function Index (FSFI), Female Sexual Distress Scale (FSDS), and Patient Health Questionnaire-8 for depression (PHQ-8). MAIN OUTCOME MEASURE The main outcome measures were the unadjusted correlations and multivariable-adjusted associations with 4 DIVA domain scales designed to assess symptom impact on day-to-day activities, sexual functioning, emotional well-being, and body image/self-concept on a scale of 0 to 4. RESULTS Among 301 women, we detected moderately strong correlations between the DIVA emotional well-being scale and PHQ-8 scores (Pearson correlation coefficient [r] = 0.39) and strong correlations between the DIVA sexual functioning scale and FSFI and FSDS scores (r > 0.50). No significant correlations were detected between any DIVA scales and vaginal pH or epithelial cytology. In adjusted linear-regression analyses, greater vulvovaginal symptom severity was associated with worse DIVA scores for emotional well-being, sexual functioning, and self-concept/body image (average 0.3- to 0.5-point higher DIVA score for each 1-point difference in vulvovaginal symptom severity). Depression symptoms were associated with worse DIVA scores for activities of daily living and emotional well-being (0.2- to 0.4-point higher DIVA score for each 5- point worsening of PHQ-8 score). Women reporting recent sexual activity had lower symptom impact on sexual functioning and self-concept/body image domains (-0.3- to -0.4-point lower DIVA score with weekly sexual activity). CLINICAL IMPLICATIONS Findings suggest that the impact of postmenopausal vaginal symptoms on functioning and well-being is greater in women with co-morbid depression symptoms and less frequent sexual activity, independent of symptom severity. STRENGTHS & LIMITATIONS Strengths include the multicenter sample and wide array of measures. Results may not generalize to women with mild symptoms. CONCLUSION Our results support the construct validity of the DIVA questionnaire for clinical practice and research and indicate that depression and lower frequency of sexual activity are markers of greater impact of postmenopausal vaginal symptoms on multiple dimensions of functioning and quality of life. Hunter MM, Guthrie KA, Larson JC, et al. Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial. J Sex Med 2020;17:117-125.",2020,Depression symptoms were associated with worse DIVA scores for activities of daily living and emotional well-being (0.2- to 0.4-point higher DIVA score for each 5- point worsening of PHQ-8 score).,"['postmenopausal women with moderate-to-severe vulvovaginal symptoms', 'women with mild symptoms', '301 women', 'postmenopausal women with moderate-to-severe vulvovaginal itching, pain, irritation, dryness, or pain with intercourse']","['Vaginal Aging (DIVA) questionnaire', 'vaginal estradiol, moisturizer, or placebo']","['DIVA scores for emotional well-being, sexual functioning, and self-concept/body image', 'DIVA sexual functioning scale and FSFI and FSDS scores', 'worse DIVA scores for activities of daily living and emotional well-being', 'severity of their most bothersome vulvovaginal symptom', 'DIVA scales and vaginal pH or epithelial cytology', 'vulvovaginal symptom severity', 'Female Sexual Function Index (FSFI), Female Sexual Distress Scale (FSDS), and Patient Health Questionnaire-8 for depression (PHQ-8', 'symptom impact on day-to-day activities, sexual functioning, emotional well-being, and body image/self-concept on a scale of 0 to\xa04', 'DIVA emotional well-being scale and PHQ-8 scores', 'Depression symptoms']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441723', 'cui_str': 'Irritation (qualifier value)'}, {'cui': 'C0009253', 'cui_str': 'Sexual Intercourse'}]","[{'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0036594', 'cui_str': 'Self Concept'}, {'cui': 'C0005891', 'cui_str': 'Body Image'}, {'cui': 'C0222045'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0429263', 'cui_str': 'Vaginal pH (observable entity)'}, {'cui': 'C0010820', 'cui_str': 'cytology'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C1879301', 'cui_str': 'Patient Health Questionnaire'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",301.0,0.0763158,Depression symptoms were associated with worse DIVA scores for activities of daily living and emotional well-being (0.2- to 0.4-point higher DIVA score for each 5- point worsening of PHQ-8 score).,"[{'ForeName': 'Mary M', 'Initials': 'MM', 'LastName': 'Hunter', 'Affiliation': 'School of Nursing, University of California San Francisco, San Francisco, CA. Electronic address: mary.hunter@ucsf.edu.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Guthrie', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Larson', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA.'}, {'ForeName': 'Susan D', 'Initials': 'SD', 'LastName': 'Reed', 'Affiliation': 'Obstetrics and Gynecology, University of Washington, Seattle, WA.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Mitchell', 'Affiliation': 'Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA.'}, {'ForeName': 'Susan J', 'Initials': 'SJ', 'LastName': 'Diem', 'Affiliation': 'Department of Medicine, University of Minnesota, Minneapolis, MN.'}, {'ForeName': 'Andrea Z', 'Initials': 'AZ', 'LastName': 'LaCroix', 'Affiliation': 'Family Medicine and Public Health, University of California San Diego, La Jolla, CA.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Huang', 'Affiliation': 'School of Medicine, University of California San Francisco, San Francisco, CA.'}]",The journal of sexual medicine,['10.1016/j.jsxm.2019.10.010'] 1398,31552706,CD4 + T cell activation and associated susceptibility to HIV-1 infection in vitro increased following acute resistance exercise in human subjects.,"Early studies in exercise immunology suggested acute bouts of exercise had an immunosuppressive effect in human subjects. However, recent data, show acute bouts of combined aerobic and resistance training increase both lymphocyte activation and proliferation. We quantified resistance exercise-induced changes in the activation state of CD4 + T lymphocytes via surface protein expression and using a medically relevant model of infection (HIV-1). Using a randomized cross-over design, 10 untrained subjects completed a control and exercise session. The control session consisted of 30-min seated rest while the exercise session entailed 3 sets × 10 repetitions of back squat, leg press, and leg extensions at 70% 1-RM with 2-min rest between each set. Venous blood samples were obtained pre/post each session. CD4 + T lymphocytes were isolated from whole blood by negative selection. Expression of activation markers (CD69 & CD25) in both nonstimulated and stimulated (costimulation through CD3 + CD28) cells were assessed by flow cytometry. Resistance exercised-induced effects on intracellular activation was further evaluated via in vitro infection with HIV-1. Nonstimulated CD4 + T lymphocytes obtained postexercise exhibited elevated CD25 expression following 24 h in culture. Enhanced HIV-1 replication was observed in cells obtained postexercise. Our results demonstrate that an acute bout of resistance exercise increases the activation state of CD4 + T lymphocytes and results in a greater susceptibility to HIV-1 infection in vitro. These findings offer further evidence that exercise induces activation of T lymphocytes and provides a foundation for the use of medically relevant pathogens as indirect measures of intracellular activation.",2019,Expression of activation markers (CD69 & CD25) in both nonstimulated and stimulated (costimulation through CD3 + CD28) cells were assessed by flow cytometry.,"['10 untrained subjects completed a', 'human subjects']",['control and exercise session'],"['lymphocyte activation and proliferation', 'Enhanced HIV-1 replication', 'Expression of activation markers (CD69 & CD25', 'CD25 expression', 'CD4 + T lymphocytes', 'activation state of CD4 + T lymphocytes', 'Venous blood samples']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0024262', 'cui_str': 'Lymphoblast Transformation'}, {'cui': 'C0334094', 'cui_str': 'Proliferation (morphologic abnormality)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0039215', 'cui_str': 'CD4-Positive Lymphocytes'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0444255', 'cui_str': 'Venous blood specimen'}]",,0.0409718,Expression of activation markers (CD69 & CD25) in both nonstimulated and stimulated (costimulation through CD3 + CD28) cells were assessed by flow cytometry.,"[{'ForeName': 'Alexander K', 'Initials': 'AK', 'LastName': 'Holbrook', 'Affiliation': 'Department of Medical Microbiology and Immunology, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Hunter D', 'Initials': 'HD', 'LastName': 'Peterson', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Samantha A', 'Initials': 'SA', 'LastName': 'Bianchi', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Brad W', 'Initials': 'BW', 'LastName': 'Macdonald', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Eric C', 'Initials': 'EC', 'LastName': 'Bredahl', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Belshan', 'Affiliation': 'Department of Medical Microbiology and Immunology, Creighton University, Omaha, Nebraska.'}, {'ForeName': 'Jacob A', 'Initials': 'JA', 'LastName': 'Siedlik', 'Affiliation': 'Department of Exercise Science and Pre-Health Professions, Creighton University, Omaha, Nebraska.'}]",Physiological reports,['10.14814/phy2.14234'] 1399,31490861,Early Self-directed Home Exercise Program After Anterior Cervical Discectomy and Fusion: A Pilot Study.,"STUDY DESIGN Pilot randomized controlled trial. OBJECTIVE To examine the acceptability and preliminary safety and outcome effects of an early self-directed home exercise program (HEP) performed within the first 6 weeks after anterior cervical discectomy and fusion (ACDF). SUMMARY OF BACKGROUND DATA Little is known regarding optimal postoperative management after ACDF. METHODS Thirty patients (mean ± standard deviation, age = 50.6 ± 11.0 years, 16 women) undergoing ACDF were randomized to receive an early HEP (n = 15) or usual care (n = 15). The early HEP was a 6-week self-directed program with weekly supportive telephone calls to reduce pain and improve activity. Treatment acceptability was assessed after the intervention period (6 weeks after surgery). Safety (adverse events, radiographic fusion, revision surgery) was determined at routine postoperative visits. Disability (Neck Disability Index), pain intensity (Numeric Rating Scale for neck and arm pain), physical and mental health (SF-12), and opioid use were assessed preoperatively, and at 6 weeks and 6 and 12 months after surgery by an evaluator blinded to group assignment. RESULTS Participants reported high levels of acceptability and no serious adverse events with the early HEP. No difference in fusion rate was observed between groups (P > 0.05) and no participants underwent revision surgery. The early self-directed HEP group reported lower 6-week neck pain than the usual care group (F = 3.3, P = 0.04, r = 0.3, mean difference = -1.7 [-3.4; -0.05]) and lower proportion of individuals (13% vs. 47%) using opioids at 12 months (P = 0.05). No other between-group outcome differences were observed (P > 0.05). CONCLUSION An early self-directed HEP program was acceptable to patients and has the potential to be safely administered to patients immediately after ACDF. Benefits were noted for short-term neck pain and long-term opioid utilization. However, larger trials are needed to confirm safety with standardized and long-term radiograph assessment and treatment efficacy. LEVEL OF EVIDENCE 2.",2020,"The early self-directed HEP group reported lower 6-week neck pain than the usual care group (F = 3.3, p = 0.04, r2 = 0.3, mean difference = -1.7 [-3.4; -0.05]) and lower proportion of individuals (13% vs. 47%) using opioids at 12 months (p = 0.05).","['Thirty patients (mean\u200a±\u200aSD age\u200a=\u200a50.6\u200a±\u200a11.0 years, 16 females) undergoing ACDF']","['Early Self-Directed Home Exercise Program', 'early HEP (n\u200a=\u200a15) or usual care', 'early self-directed home exercise program (HEP']","['high levels of acceptability and no serious adverse events', 'Disability (Neck Disability Index), pain intensity (Numeric Rating Scale for neck and arm pain), physical and mental health (SF-12), and opioid use', 'Safety (adverse events, radiographic fusion, revision surgery', 'fusion rate', '6-week neck pain', 'pain and improve activity', 'Treatment acceptability']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C4552416', 'cui_str': 'Anterior cervical discectomy with fusion'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program (regime/therapy)'}, {'cui': 'C0449198', 'cui_str': 'HEP (body structure)'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0027536', 'cui_str': 'Necking (finding)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0222045'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C1293131', 'cui_str': 'Fusion procedure (procedure)'}, {'cui': 'C0035110', 'cui_str': 'Revision Surgery'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",30.0,0.111701,"The early self-directed HEP group reported lower 6-week neck pain than the usual care group (F = 3.3, p = 0.04, r2 = 0.3, mean difference = -1.7 [-3.4; -0.05]) and lower proportion of individuals (13% vs. 47%) using opioids at 12 months (p = 0.05).","[{'ForeName': 'Rogelio A', 'Initials': 'RA', 'LastName': 'Coronado', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Clinton J', 'Initials': 'CJ', 'LastName': 'Devin', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Jacquelyn S', 'Initials': 'JS', 'LastName': 'Pennings', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Susan W', 'Initials': 'SW', 'LastName': 'Vanston', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Dana E', 'Initials': 'DE', 'LastName': 'Fenster', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Hills', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Oran S', 'Initials': 'OS', 'LastName': 'Aaronson', 'Affiliation': 'Howell Allen Clinic, Saint Thomas Medical Partners, Nashville, TN.'}, {'ForeName': 'Jacob P', 'Initials': 'JP', 'LastName': 'Schwarz', 'Affiliation': 'Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Byron F', 'Initials': 'BF', 'LastName': 'Stephens', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Kristin R', 'Initials': 'KR', 'LastName': 'Archer', 'Affiliation': 'Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN.'}]",Spine,['10.1097/BRS.0000000000003239'] 1400,31858966,Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT.,"BACKGROUND Motivational interviewing (MI) enhanced with behaviour change techniques (BCTs) and deployed by health trainers targeting multiple risk factors for cardiovascular disease (CVD) may be more effective than interventions targeting a single risk factor. OBJECTIVES The clinical effectiveness and cost-effectiveness of an enhanced lifestyle motivational interviewing intervention for patients at high risk of CVD in group settings versus individual settings and usual care (UC) in reducing weight and increasing physical activity (PA) were tested. DESIGN This was a three-arm, single-blind, parallel randomised controlled trial. SETTING A total of 135 general practices across all 12 South London Clinical Commissioning Groups were recruited. PARTICIPANTS A total of 1742 participants aged 40-74 years with a ≥ 20.0% risk of a CVD event in the following 10 years were randomised. INTERVENTIONS The intervention was designed to integrate MI and cognitive-behavioural therapy (CBT), delivered by trained healthy lifestyle facilitators in 10 sessions over 1 year, in group or individual format. The control group received UC. RANDOMISATION Simple randomisation was used with computer-generated randomisation blocks. In each block, 10 participants were randomised to the group, individual or UC arm in a 4 : 3 : 3 ratio. Researchers were blind to the allocation. MAIN OUTCOME MEASURES The primary outcomes are change in weight (kg) from baseline and change in PA (average number of steps per day over 1 week) from baseline at the 24-month follow-up, with an interim follow-up at 12 months. An economic evaluation estimates the relative cost-effectiveness of each intervention. Secondary outcomes include changes in low-density lipoprotein cholesterol and CVD risk score. RESULTS The mean age of participants was 69.75 years (standard deviation 4.11 years), 85.5% were male and 89.4% were white. At the 24-month follow-up, the group and individual intervention arms were not more effective than UC in increasing PA [mean 70.05 steps, 95% confidence interval (CI) -288 to 147.9 steps, and mean 7.24 steps, 95% CI -224.01 to 238.5 steps, respectively] or in reducing weight (mean -0.03 kg, 95% CI -0.49 to 0.44 kg, and mean -0.42 kg, 95% CI -0.93 to 0.09 kg, respectively). At the 12-month follow-up, the group and individual intervention arms were not more effective than UC in increasing PA (mean 131.1 steps, 95% CI -85.28 to 347.48 steps, and mean 210.22 steps, 95% CI -19.46 to 439.91 steps, respectively), but there were reductions in weight for the group and individual intervention arms compared with UC (mean -0.52 kg, 95% CI -0.90 to -0.13 kg, and mean -0.55 kg, 95% CI -0.95 to -0.14 kg, respectively). The group intervention arm was not more effective than the individual intervention arm in improving outcomes at either follow-up point. The group and individual interventions were not cost-effective. CONCLUSIONS Enhanced MI, in group or individual formats, targeted at members of the general population with high CVD risk is not effective in reducing weight or increasing PA compared with UC. Future work should focus on ensuring objective evidence of high competency in BCTs, identifying those with modifiable factors for CVD risk and improving engagement of patients and primary care. TRIAL REGISTRATION Current Controlled Trials ISRCTN84864870. FUNDING This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 23, No. 69. See the NIHR Journals Library website for further project information. This research was part-funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.",2019,"At the 24-month follow-up, the group and individual intervention arms were not more effective than UC in increasing PA [mean 70.05 steps, 95% confidence interval (CI)","['adults with high cardiovascular risk', 'A total of 135 general practices across all 12 South London Clinical Commissioning Groups were recruited.\nPARTICIPANTS\n\n\nA total of 1742 participants aged 40-74 years with a ≥\u200920.0% risk of a CVD event in the following 10 years were randomised', 'patients at high risk of CVD in group settings versus', 'The mean age of participants was 69.75 years (standard deviation 4.11 years), 85.5% were male and 89.4% were white']","['Enhanced motivational interviewing', 'enhanced lifestyle motivational interviewing intervention', 'individual settings and usual care (UC', 'Motivational interviewing (MI) enhanced with behaviour change techniques (BCTs', 'integrate MI and cognitive-behavioural therapy (CBT), delivered by trained healthy lifestyle facilitators', 'UC']","['clinical effectiveness and cost-effectiveness', 'cost-effective', 'weight and increasing physical activity', 'weight and increasing physical activity (PA', 'changes in low-density lipoprotein cholesterol and CVD risk score', 'reductions in weight', 'change in weight (kg) from baseline and change in PA', 'reducing weight', 'PA']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C0086343', 'cui_str': 'General Practice'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0043157', 'cui_str': 'Whites'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational Interviewing'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C4277664', 'cui_str': 'Healthy Life Styles'}]","[{'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4039165', 'cui_str': 'Increased physical activity (finding)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",1742.0,0.123281,"At the 24-month follow-up, the group and individual intervention arms were not more effective than UC in increasing PA [mean 70.05 steps, 95% confidence interval (CI)","[{'ForeName': 'Khalida', 'Initials': 'K', 'LastName': 'Ismail', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Stahl', 'Affiliation': ""Department of Biostatistics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Bayley', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Twist', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Kurtis', 'Initials': 'K', 'LastName': 'Stewart', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Ridge', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Britneff', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Ashworth', 'Affiliation': ""Department of Primary Care and Public Health Sciences, King's College London, London, UK.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'de Zoysa', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Rundle', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Cook', 'Affiliation': ""Population Health Research Institute, St George's, University of London, London, UK.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Whincup', 'Affiliation': ""Population Health Research Institute, St George's, University of London, London, UK.""}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Treasure', 'Affiliation': ""Department of Health Services and Population Research, Institute of Psychiatry, King's College London, London, UK.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'McCrone', 'Affiliation': ""Section of Eating Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Greenough', 'Affiliation': ""Division of Asthma, Allergy and Lung Biology, King's College London, Guy's Hospital, London, UK.""}, {'ForeName': 'Kirsty', 'Initials': 'K', 'LastName': 'Winkley', 'Affiliation': ""Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]","Health technology assessment (Winchester, England)",['10.3310/hta23690'] 1401,31490257,"Intravenous Lidocaine for the Prevention of Postoperative Catheter-Related Bladder Discomfort in Male Patients Undergoing Transurethral Resection of Bladder Tumors: A Randomized, Double-Blind, Controlled Trial.","BACKGROUND Male patients undergoing transurethral resection of bladder tumors (TURBT) are prone to suffer from catheter-related bladder discomfort (CRBD). Lidocaine administration has been widely performed to reduce postoperative pain. Here, the effect of intravenous lidocaine administration on moderate-to-severe CRBD was evaluated in male patients undergoing TURBT. METHODS Patients were randomly allocated to receive intravenous lidocaine (1.5 mg/kg bolus dose followed by a 2 mg/kg/h continuous infusion during the intraoperative period, which was continued for 1 hour postsurgery; group L) or placebo (normal saline; group C). The primary outcome was moderate-to-severe CRBD at 0 hour postsurgery (on admission to the postanesthetic care unit), analyzed using the χ test. The secondary outcome was opioid requirement during the 24-hour postoperative period. None, mild, and moderate-to-severe CRBD at 1, 2, and 6 hours postsurgery, postoperative pain, patient satisfaction, side effects of lidocaine and rescue medications (tramadol and fentanyl), and surgical complications were also assessed. RESULTS A total of 132 patients were included in the study (66 patients in each group). The incidence of moderate-to-severe CRBD at 0 hour postsurgery was significantly lower in group L than in group C (25.8% vs 66.7%, P < .001, relative risk: 0.386, 95% confidence interval: 0.248-0.602). Opioid requirements during the 24-hour postoperative period were significantly lower in group L than in group C (10.0 mg [interquartile range (IQR), 5.0-15.0 mg] vs 13.8 mg [IQR, 10.0-20.0 mg], P = .005). At 1 and 2 hours postsurgery (but not at 6 hours), the incidence of moderate-to-severe CRBD was significantly lower in group L than in group C (1 hour: 10.6% vs 27.3%, P = .026; 2 hours: 0.0% vs 15.2%, P = .003). Patient satisfaction was significantly greater in group L than in group C (5.0 [IQR, 4.8-6.0] vs 4.0 [IQR, 4.0-5.0], P < .001). No lidocaine-related side effects were reported. Rescue medication-related side effects and surgical complications did not differ significantly between the 2 groups. CONCLUSIONS Intravenous lidocaine administration resulted in lower incidence of moderate-to-severe CRBD, lower opioid requirement, and higher patient satisfaction in male patients undergoing TURBT without evidence of significant side effects.",2020,"Patient satisfaction was significantly greater in group L than in group C (5.0 [IQR, 4.8-6.0] vs 4.0 [IQR, 4.0-5.0], P < .001).","['Patients', 'male patients undergoing TURBT', 'Male Patients Undergoing Transurethral Resection of Bladder Tumors', '132 patients were included in the study (66 patients in each group', 'male patients undergoing', 'Male patients undergoing']","['lidocaine', 'transurethral resection of bladder tumors (TURBT', 'placebo (normal saline', 'TURBT', 'intravenous lidocaine', 'Lidocaine', 'Intravenous Lidocaine']","['postoperative pain', 'postoperative pain, patient satisfaction, side effects of lidocaine and rescue medications (tramadol and fentanyl), and surgical complications', 'side effects', 'incidence of moderate-to-severe CRBD', 'Patient satisfaction', 'moderate-to-severe CRBD', 'Opioid requirements', 'opioid requirement during the 24-hour postoperative period', 'Rescue medication-related side effects and surgical complications']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}]","[{'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}]",132.0,0.45349,"Patient satisfaction was significantly greater in group L than in group C (5.0 [IQR, 4.8-6.0] vs 4.0 [IQR, 4.0-5.0], P < .001).","[{'ForeName': 'Doo-Hwan', 'Initials': 'DH', 'LastName': 'Kim', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jun-Young', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jihion', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sang-A', 'Initials': 'SA', 'LastName': 'Lee', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sooin', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jai-Hyun', 'Initials': 'JH', 'LastName': 'Hwang', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Gi-Ho', 'Initials': 'GH', 'LastName': 'Koh', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Gwangju, Republic of Korea.'}, {'ForeName': 'Young-Kug', 'Initials': 'YK', 'LastName': 'Kim', 'Affiliation': 'From the Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.'}]",Anesthesia and analgesia,['10.1213/ANE.0000000000004405'] 1402,31475791,Comparison of the results of two chest tube managements during an enhanced recovery program after video-assisted thoracoscopic lobectomy: A randomized trial.,"BACKGROUND This study compared the results of the application of two different chest tube management systems; a drainage ball with low negative pressure and the more commonly used chest tube with water-sealed bottle, after video-assisted thoracoscopic (VATS) lobectomy. METHODS A total of 60 patients undergoing lobectomy were enrolled into this prospective open label randomized clinical trial and equally divided into two groups. The data collected in the trial included age, gender, forced expiratory volume in 1 second (FEV1), blood loss, operation time, drainage volume, drainage time, length of stay, postoperative pain score according to the Visual Analogue Scale (VAS) within 24 hours after surgery and chest tube removal. This study was registered at ClinicalTrials.gov (NCT03598296). RESULTS The characteristics of the patients were similar in both groups. Group ball patients had a lower pain score (after operation: 3.47 ± 1.80 vs. 6.20 ± 1.56, P < 0.001; after removal of chest tube: 1.47 ± 1.28 vs. 3.00 ± 1.29, P < 0.001); less analgesic used (2.83 ± 2.09 times vs. 5.00 ± 3.24 times, P = 0.003); less drainage time (upper tube: 3.89 ± 1.63 days vs. 5.10 ± 2.02 days, P = 0.048; lower tube: upper lobe 4.84 ± 1.61 days vs. 5.90 ± 1.52 days, P = 0.041; lower lobe: 3.82 ± 1.08 days vs. 5.70 ± 2.63 days, P = 0.042) and shorter length of stay (5.40 ± 1.65 days vs. 6.37 ± 1.99 days, P = 0.045). All other related parameters were similar in both groups. CONCLUSIONS For patients undergoing lobectomy, using a drainage ball with negative pressure could reduce hospitalization days and postoperative pain compared with the more commonly used chest tube with water-sealed bottle when a strict postoperative curative procedure was performed.",2019,"Group ball patients had a lower pain score (after operation: 3.47 ± 1.80 vs. 6.20 ± 1.56, P < 0.001; after removal of chest tube: 1.47 ± 1.28 vs. 3.00 ± 1.29, P < 0.001); less analgesic used (2.83 ± 2.09 times vs. 5.00 ± 3.24 times, P = 0.003); less drainage time (upper tube: 3.89 ± 1.63 days vs. 5.10 ± 2.02 days, P = 0.048; lower tube: upper lobe 4.84 ± 1.61 days vs. 5.90 ± 1.52 days, P = 0.041; lower lobe: 3.82 ± 1.08 days vs. 5.70 ± 2.63 days, P = 0.042) and shorter length of stay (5.40 ± 1.65 days vs. 6.37 ± 1.99 days, P = 0.045).",['A total of 60 patients undergoing lobectomy'],"['video-assisted thoracoscopic (VATS) lobectomy', 'video-assisted thoracoscopic lobectomy']","['drainage time', 'lower pain score', 'shorter length of stay', 'hospitalization days and postoperative pain', 'forced expiratory volume in 1\u2009second (FEV1), blood loss, operation time, drainage volume, drainage time, length of stay, postoperative pain score according to the Visual Analogue Scale (VAS']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0405532', 'cui_str': 'Lobectomy of thyroid gland (procedure)'}]","[{'cui': 'C0042655', 'cui_str': 'Videotapes'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0405532', 'cui_str': 'Lobectomy of thyroid gland (procedure)'}]","[{'cui': 'C0013103', 'cui_str': 'Drainage'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",60.0,0.126945,"Group ball patients had a lower pain score (after operation: 3.47 ± 1.80 vs. 6.20 ± 1.56, P < 0.001; after removal of chest tube: 1.47 ± 1.28 vs. 3.00 ± 1.29, P < 0.001); less analgesic used (2.83 ± 2.09 times vs. 5.00 ± 3.24 times, P = 0.003); less drainage time (upper tube: 3.89 ± 1.63 days vs. 5.10 ± 2.02 days, P = 0.048; lower tube: upper lobe 4.84 ± 1.61 days vs. 5.90 ± 1.52 days, P = 0.041; lower lobe: 3.82 ± 1.08 days vs. 5.70 ± 2.63 days, P = 0.042) and shorter length of stay (5.40 ± 1.65 days vs. 6.37 ± 1.99 days, P = 0.045).","[{'ForeName': 'Zihan', 'Initials': 'Z', 'LastName': 'Cui', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Yuejuan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Chun', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Ding', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Medical college of Soochow University, Suzhou, China.'}]",Thoracic cancer,['10.1111/1759-7714.13183'] 1403,31480897,"Effect of proprioceptive stimulation induced by footplate during center of pressure movement tracking training on the balance abilities of patients with chronic hemiplegic stroke: a randomized, controlled, pilot study.","Background : Balance requires highly complex interactions involving muscle strength, joint flexibility, visual, vestibular, and proprioceptive senses. Objective : The purpose of this pilot study was to compare the effects of COP (center of pressure) movement tracking training conducted using the Biodex Balance System SD® in static and dynamic modes on balance ability in stroke patients. Methods : Twenty-six stroke patients were randomly assigned to a control group (COP movement tracking training in static mode ; stable; n = 13 or an experimental group (COP movement tracking training in dynamic mode; unstable; n = 13). Both groups underwent neurodevelopmental therapy followed by an additional 15 min of COP movement training three times a week for 6 consecutive weeks. The timed-up and go test, COP pathway velocity, COP pathway length, and limit of stability were measured before and after intervention. Results : The experimental group showed greater reductions in COP pathway length and COP pathway velocity than the control group (5%, F (1, 24) = 6.125, p = .021, η 2 = .203; 5.4%, F (1, 24) = 6.661, p = .016, η 2 = .217, respectively). No significant intergroup difference was observed for the timed-up and go test or limit of stability results. Conclusion : COP movement tracking training in dynamic mode was found to be a more effective intervention for improving the static balancing abilities of stroke patients than training in static mode.",2020,COP movement tracking training in dynamic mode was found to be a more effective intervention for improving the static balancing abilities of stroke patients than training in static mode.,"['patients with chronic hemiplegic stroke', 'stroke patients', 'Methods : Twenty-six stroke patients']","['control group (COP movement tracking training in static mode ; stable; n = 13 or an experimental group (COP movement tracking training', 'neurodevelopmental therapy', 'COP movement tracking training', 'Biodex Balance System SD®', ' ', 'proprioceptive stimulation', 'pressure movement tracking training', 'COP (center of pressure) movement tracking training']","['timed-up and go test, COP pathway velocity, COP pathway length, and limit of stability', 'COP pathway length and COP pathway velocity', 'timed-up and go test or limit of stability results']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0450349', 'cui_str': '26 (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0441463', 'cui_str': 'Static (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C1319201', 'cui_str': 'Timed up and go'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0125662,COP movement tracking training in dynamic mode was found to be a more effective intervention for improving the static balancing abilities of stroke patients than training in static mode.,"[{'ForeName': 'Ju-Hyeong', 'Initials': 'JH', 'LastName': 'Cha', 'Affiliation': 'Department of Physical Therapy, Graduate School of Daejeon University, Daejeon, Republic of Korea.'}, {'ForeName': 'Nan-Hyang', 'Initials': 'NH', 'LastName': 'Kim', 'Affiliation': 'Department of Physical Therapy, Graduate School of Daejeon University, Daejeon, Republic of Korea.'}, {'ForeName': 'Yong-Jun', 'Initials': 'YJ', 'LastName': 'Cha', 'Affiliation': 'Department of Physical Therapy, College of Health and Medical Science, Daejeon University, Daejeon, Republic of Korea.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1661699'] 1404,31474161,A study protocol of vaginal laser therapy in gynecological cancer survivors.,"Objectives: Sexual dysfunction and radiation cystitis are common adverse events following radiotherapy for gynecological cancer (GC). This study aims to assess the efficacy of intravaginal CO 2 laser on GC survivors with dyspareunia following pelvic radiation and/or brachytherapy. Methods: This is the study protocol of a randomized double-blind placebo-controlled trial. All participants will receive five therapies (active or placebo) at monthly intervals. Outcomes will include a 10-cm visual analog scale measuring dyspareunia, vaginal dryness, and other symptom intensity, 3-day voiding diary, Day-to Day Impact of Vaginal Aging questionnaire, Female Sexual Function Index, European Organization for Research and Treatment of Cancer Quality of Life questionnaire cervical cancer module, Urogenital Distress Inventory short form, King's Health Questionnaire, International Consultation on Incontinence Questionnaire short form/female lower urinary tract symptoms, patient perception of improvement, sexual satisfaction of male partners, vaginal maturation value, and Vaginal Health Index. Differences between groups will be assessed at baseline and 1, 3, 6, 9, and 12 months following the five laser therapies. Results: As this is a study protocol, the study is ongoing with an expected end of recruitment and analysis date of 2021. Conclusion: Pelvic radiotherapy for GC increases the 5-year survival rate but with a negative impact on women's quality of life due to sexual dysfunction and radiation cystitis onset. With this study, CO 2 laser therapy will be evaluated for the first time in GC survivors treated with radiotherapy. ClinicalTrials.gov registration number: NCT03714581.",2020,increases the 5-year survival rate but with a negative impact on women's quality of life due to sexual dysfunction and radiation cystitis onset.,"['gynecological cancer survivors', 'gynecological cancer (GC', 'GC survivors with dyspareunia following pelvic radiation and/or brachytherapy']","['intravaginal CO 2 laser', 'five therapies (active or placebo', 'Pelvic radiotherapy for GC', 'placebo', 'radiotherapy', 'vaginal laser therapy']","['5-year survival rate', ""10-cm visual analog scale measuring dyspareunia, vaginal dryness, and other symptom intensity, 3-day voiding diary, Day-to Day Impact of Vaginal Aging questionnaire, Female Sexual Function Index, European Organization for Research and Treatment of Cancer Quality of Life questionnaire cervical cancer module, Urogenital Distress Inventory short form, King's Health Questionnaire, International Consultation on Incontinence Questionnaire short form/female lower urinary tract symptoms, patient perception of improvement, sexual satisfaction of male partners, vaginal maturation value, and Vaginal Health Index""]","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse (finding)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0030797', 'cui_str': 'Pelvic Region'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0006098', 'cui_str': 'Radioisotope Brachytherapy'}]","[{'cui': 'C0442122', 'cui_str': 'Intravaginal (qualifier value)'}, {'cui': 'C0023089', 'cui_str': 'Lasers'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0030797', 'cui_str': 'Pelvic Region'}, {'cui': 'C0243005', 'cui_str': 'Radiation Oncology'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C1955835', 'cui_str': 'Laser Therapy'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0013394', 'cui_str': 'Pain in female genitalia on intercourse (finding)'}, {'cui': 'C0241633', 'cui_str': 'Vaginal dryness (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function (observable entity)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix (disorder)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire (assessment scale)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0574785', 'cui_str': 'Lower Urinary Tract Symptoms'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0871356', 'cui_str': 'Sexual Satisfaction'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.524912,increases the 5-year survival rate but with a negative impact on women's quality of life due to sexual dysfunction and radiation cystitis onset.,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Athanasiou', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Pitsouni', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Grigoriadis', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Michailidis', 'Affiliation': ""Department of Radiation Oncology, 'Alexandra' Hospital, Athens, Greece.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tsiveleka', 'Affiliation': ""Cytological Department, 'Alexandra' Hospital, Athens, Greece.""}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Rodolakis', 'Affiliation': ""Oncologic Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Loutradis', 'Affiliation': ""1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1646720'] 1405,31486272,Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men.,"Sodium-glucose co-transporter-2 (SGLT2) inhibitors prevent cardiovascular complications in type 2 diabetes. We aimed to study whether they have similar effects in women and men by summarizing the effects of SGLT2 inhibitors compared to placebo on vascular and safety outcomes stratified by sex. We included patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58 and CREDENCE trials. There were no differences in the risk ratios between men and women, SGLT2 versus control (placebo), for vascular efficacy outcomes or death (all P for interaction ≥.12), with clear protection shown against major adverse cardiovascular events, heart failure, vascular death and total mortality. SGLT2 inhibitor treatment was also associated with similar relative risks in women and men for the safety outcomes of amputation, fracture, genital infection and urinary tract infection (all P for interaction ≥.17). SGLT2 inhibition provided similar protection against vascular risks and death, and similar risks of serious adverse events, for women and men.",2020,"There were no differences in the risk ratios between men and women, SGLT2 versus control (placebo), for vascular efficacy outcomes or death (all P for interaction ≥.12), with clear protection shown against major adverse cardiovascular events, heart failure, vascular death and total mortality.","['type 2 diabetes', 'women and men', 'patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58 and CREDENCE trials', 'type 2 diabetes in women versus men']","['SGLT2', 'Sodium-glucose co-transporter-2 (SGLT2) inhibitors', 'placebo', 'SGLT2 inhibitors', 'sodium-glucose co-transporter-2 inhibitors', 'SGLT2 versus control (placebo']","['vascular efficacy outcomes or death', 'major adverse cardiovascular events, heart failure, vascular death and total mortality', 'risk ratios', 'safety outcomes of amputation, fracture, genital infection and urinary tract infection', 'cardiovascular complications']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3273807', 'cui_str': 'Gliflozins'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0028873', 'cui_str': 'Risk Ratio'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C0729552', 'cui_str': 'Infectious disease of genitopelvic system'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",,0.182402,"There were no differences in the risk ratios between men and women, SGLT2 versus control (placebo), for vascular efficacy outcomes or death (all P for interaction ≥.12), with clear protection shown against major adverse cardiovascular events, heart failure, vascular death and total mortality.","[{'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Rådholm', 'Affiliation': 'Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.'}, {'ForeName': 'Zien', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Clemens', 'Affiliation': 'Division of Endocrinology and Metabolism, Department of Medicine, Western University, London, Ontario, Canada.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Neal', 'Affiliation': 'George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Woodward', 'Affiliation': 'George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13876'] 1406,32439860,A randomized trial evaluating virus-specific effects of a combination probiotic in children with acute gastroenteritis.,"Gastroenteritis accounts for nearly 500,000 deaths in children younger than 5 years annually. Although probiotics have been touted as having the potential to expedite diarrhea resolution, recent clinical trials question their effectiveness. A potential explanation is a shift in pathogens following the introduction of a rotavirus vaccine. Here, we report the results of a multi-center, double-blind trial of 816 children with acute gastroenteritis who completed follow-up and provided multiple stool specimens. Participants were randomized to receive a probiotic containing Lactobacillus rhamnosus and Lactobacillus helveticus or placebo. We report no virus-specific beneficial effects attributable to the probiotic, either in reducing clinical symptoms or viral nucleic acid clearance from stool specimens collected up to 28 days following enrollment. We provide pathophysiological and microbiologic evidence to support the clinical findings and conclude that our data do not support routine probiotic administration to children with acute gastroenteritis, regardless of the infecting virus.",2020,"We report no virus-specific beneficial effects attributable to the probiotic, either in reducing clinical symptoms or viral nucleic acid clearance from stool specimens collected up to 28 days following enrollment.","['children younger than 5 years annually', '816 children with acute gastroenteritis who completed follow-up and provided multiple stool specimens', 'children with acute gastroenteritis']","['combination probiotic', 'probiotic containing Lactobacillus rhamnosus and Lactobacillus helveticus or placebo']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0267446', 'cui_str': 'Acute gastroenteritis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0317597', 'cui_str': 'Lactobacillus casei rhamnosus'}, {'cui': 'C0317592', 'cui_str': 'Lactobacillus helveticus'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],816.0,0.233591,"We report no virus-specific beneficial effects attributable to the probiotic, either in reducing clinical symptoms or viral nucleic acid clearance from stool specimens collected up to 28 days following enrollment.","[{'ForeName': 'Stephen B', 'Initials': 'SB', 'LastName': 'Freedman', 'Affiliation': ""Alberta Children's Hospital Foundation Professor in Child Health and Wellness, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada. Stephen.freedman@ahs.ca.""}, {'ForeName': 'Jianling', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': ""Alberta Children's Hospital Foundation Professor in Child Health and Wellness, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Nettel-Aguirre', 'Affiliation': ""Alberta Children's Hospital Foundation Professor in Child Health and Wellness, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.""}, {'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Pang', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Chui', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Williamson-Urquhart', 'Affiliation': ""Alberta Children's Hospital Foundation Professor in Child Health and Wellness, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, 28 Oki Drive NW, Calgary, AB, T3B 6A8, Canada.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Schnadower', 'Affiliation': 'University of Cincinnati, 3333 Burnet Ave, Cincinnati, OH, UCA 45229, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Schuh', 'Affiliation': 'University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Sherman', 'Affiliation': 'University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.'}, {'ForeName': 'Bonita E', 'Initials': 'BE', 'LastName': 'Lee', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Gouin', 'Affiliation': 'Université de Montréal, 3175 Chemin de la Côte-Sainte-Catherine, Montréal, QC, H3T 1C5, Canada.'}, {'ForeName': 'Ken J', 'Initials': 'KJ', 'LastName': 'Farion', 'Affiliation': 'University of Ottawa, 401 Smyth Rd, Ottawa, ON, K1H 8L1, Canada.'}, {'ForeName': 'Naveen', 'Initials': 'N', 'LastName': 'Poonai', 'Affiliation': 'University of Western Ontario, 800 Commissioners Road E, London, ON, N6A 5W9, Canada.'}, {'ForeName': 'Katrina F', 'Initials': 'KF', 'LastName': 'Hurley', 'Affiliation': 'Dalhousie University, 5980 University Avenue, PO Box 9700, Halifax, NS, B3K 6R8, Canada.'}, {'ForeName': 'Yuanyuan', 'Initials': 'Y', 'LastName': 'Qiu', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Binal', 'Initials': 'B', 'LastName': 'Ghandi', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Lloyd', 'Affiliation': 'University of Alberta, 116 St & 85 Ave., Edmonton, AB, T6G 2R3, Canada.'}, {'ForeName': 'Yaron', 'Initials': 'Y', 'LastName': 'Finkelstein', 'Affiliation': 'University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Nature communications,['10.1038/s41467-020-16308-3'] 1407,31667992,Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis: A randomized controlled trial.,"BACKGROUND Transfusion of blood components prior to invasive procedures in cirrhosis patients is high and associated with adverse events. OBJECTIVES We compared three transfusion strategies prior to central venous catheterization in cirrhosis patients. PATIENTS/METHODS Single center randomized trial that included critically ill cirrhosis patients with indication for central venous line in a tertiary private hospital in Brazil. INTERVENTIONS Restrictive protocol, thromboelastometry-guided protocol, or usual care (based on coagulogram). The primary endpoint was the proportion of patients transfused with any blood component (ie, fresh frozen plasma, platelets, or cryoprecipitate). The secondary endpoints included incidence of bleeding and transfusion-related adverse events. RESULTS A total of 57 patients (19 per group; 64.9% male; mean age, 53.4 ± 11.3 years) were enrolled. Prior to catheterization, 3/19 (15.8%) in the restrictive arm, 13/19 (68.4%) in the thromboelastometry-guided arm, and 14/19 (73.7%) in the coagulogram-guided arm received blood transfusion (odds ratio [OR], 0.07; 95% confidence interval [CI], 0.01-0.45; P = .002 for restrictive versus coagulogram-guided arm; OR, 0.09; 95% CI, 0.01-0.56; P = .006 for restrictive versus thromboelastometry-guided arm; and OR, 0.77; 95% CI, 0.14-4.15; P = .931 for thromboelastometry-guided versus coagulogram-guided arm). The restrictive protocol was cost saving. No difference in bleeding, length of stay, mortality, and transfusion-related adverse events was found. CONCLUSIONS The use of a restrictive strategy is associated with a reduction in transfusion prior to central venous catheterization and costs in critically ill cirrhosis patients. No effect on bleeding was found among the groups.",2020,The use of a restrictive strategy is associated with a reduction in transfusion prior to central venous catheterization and costs in critically ill cirrhosis patients.,"['57 patients (19 per group; 64.9% male; mean age, 53.4 ± 11.3 years) were enrolled', 'cirrhosis patients', 'critically ill cirrhosis patients with indication for central venous line in a tertiary private hospital in Brazil', 'patients with cirrhosis', 'critically ill cirrhosis patients']","['transfusion protocols prior to central venous catheterization', 'Restrictive protocol, thromboelastometry-guided protocol, or usual care (based on coagulogram']","['incidence of bleeding and transfusion-related adverse events', 'bleeding, length of stay, mortality, and transfusion-related adverse events', 'blood transfusion', 'proportion of patients transfused with any blood component (i.e. fresh frozen plasma, platelets or cryoprecipitate', 'bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0392360', 'cui_str': 'Reason for (attribute)'}, {'cui': 'C1145640', 'cui_str': 'Central Venous Catheters'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0033173', 'cui_str': 'Hospitals, Private'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}]","[{'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0007435', 'cui_str': 'Central Catheterization'}, {'cui': 'C3661505', 'cui_str': 'Thromboelastometry'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0450129', 'cui_str': 'Blood component (substance)'}, {'cui': 'C0016709', 'cui_str': 'Fresh frozen plasma (product)'}, {'cui': 'C0005821', 'cui_str': 'Platelets'}, {'cui': 'C0443121', 'cui_str': 'Cryoprecipitate (product)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}]",,0.0818077,The use of a restrictive strategy is associated with a reduction in transfusion prior to central venous catheterization and costs in critically ill cirrhosis patients.,"[{'ForeName': 'Leonardo L', 'Initials': 'LL', 'LastName': 'Rocha', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Ary S', 'Initials': 'AS', 'LastName': 'Neto', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Camila M S', 'Initials': 'CMS', 'LastName': 'Pessoa', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Márcio D', 'Initials': 'MD', 'LastName': 'Almeida', 'Affiliation': 'Liver Transplant Program, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Nicole P', 'Initials': 'NP', 'LastName': 'Juffermans', 'Affiliation': 'Department of Intensive Care, Academic Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Tomaz', 'Initials': 'T', 'LastName': 'Crochemore', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Roseny R', 'Initials': 'RR', 'LastName': 'Rodrigues', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Roberto R', 'Initials': 'RR', 'LastName': 'Filho', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Renato Carneiro', 'Initials': 'RC', 'LastName': 'de Freitas Chaves', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Cavalheiro', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Rogério R', 'Initials': 'RR', 'LastName': 'Prado', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Murillo S C', 'Initials': 'MSC', 'LastName': 'Assunção', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Bianca D', 'Initials': 'BD', 'LastName': 'Guardia', 'Affiliation': 'Liver Transplant Program, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Eliézer', 'Initials': 'E', 'LastName': 'Silva', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Thiago D', 'Initials': 'TD', 'LastName': 'Corrêa', 'Affiliation': 'Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14672'] 1408,31515972,Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia.,"AIM This exploratory post hoc analysis of a randomized, double-blind (DB), multicentre, non-inferiority study (NCT01515423) evaluated the effects of the long-acting injectable antipsychotic therapies once-monthly paliperidone palmitate (PP1M) and once-every-3-months paliperidone palmitate (PP3M) on symptom severity and functional remission in patients with schizophrenia with differing durations of illness (≤5, 6-10 and >10 years). METHODS Endpoints included Personal and Social Performance (PSP) scale and Positive and Negative Syndrome Scale (PANSS) total scores during the DB phase (DB baseline and DB endpoint) and the proportion of patients meeting PSP or PANSS remission criteria at any time during the open-label (OL) or DB phases that were maintained for ≥3, ≥6, ≥9 or ≥12 months. RESULTS In both the OL and DB phases, significant improvements in PSP scale and PANSS scores were observed from baseline in all duration-of-illness groups, with significantly greater improvements observed in the ≤5-year and 6-10-year groups compared with the >10-year group. The proportion of patients who maintained PSP or PANSS remission criteria for ≥3, ≥6, ≥9 and ≥12 months was higher in the ≤5-year and 6-10-year groups than in the >10-year group. Safety profiles were similar across duration-of-illness groups in the DB phase. CONCLUSIONS Symptomatic and functional improvements were observed with PP1M/PP3M in patients with differing durations of schizophrenia, but the magnitude of the effects was greater in those with early illness vs chronic illness. These findings advocate implementation of PP1M and PP3M in all stages of schizophrenia, including early illness.",2020,"In both the OL and DB phases, significant improvements in PSP scale and PANSS scores were observed from baseline in all duration-of-illness groups, with significantly greater improvements observed in the ≤5-year and 6-10-year groups compared with the >10-year group.","['patients with schizophrenia with differing durations of illness (≤5, 6-10 and >10\u2009years', 'patients with schizophrenia']","['paliperidone palmitate long-acting injectable antipsychotic therapy', 'paliperidone palmitate (PP1M) and once-every-3-months paliperidone palmitate (PP3M']","['PSP scale and PANSS scores', 'symptom severity and functional remission', 'Personal and Social Performance (PSP) scale and Positive and Negative Syndrome Scale (PANSS) total scores during the DB phase (DB baseline and DB endpoint) and the proportion of patients meeting PSP or PANSS remission criteria at any time during the open-label (OL) or DB phases']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0221423', 'cui_str': 'Illness (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C2719626', 'cui_str': 'paliperidone palmitate'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C1868193', 'cui_str': 'PSP'}, {'cui': 'C0222045'}, {'cui': 'C0451383', 'cui_str': 'Positive and negative syndrome scale (assessment scale)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}]",,0.0677623,"In both the OL and DB phases, significant improvements in PSP scale and PANSS scores were observed from baseline in all duration-of-illness groups, with significantly greater improvements observed in the ≤5-year and 6-10-year groups compared with the >10-year group.","[{'ForeName': 'Brianne', 'Initials': 'B', 'LastName': 'Brown', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, New Jersey.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Turkoz', 'Affiliation': 'Janssen Research and Development, LLC, Titusville, New Jersey.'}, {'ForeName': 'Branislav', 'Initials': 'B', 'LastName': 'Mancevski', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, New Jersey.'}, {'ForeName': 'Maju', 'Initials': 'M', 'LastName': 'Mathews', 'Affiliation': 'Janssen Research and Development, LLC, Titusville, New Jersey.'}]",Early intervention in psychiatry,['10.1111/eip.12868'] 1409,31302339,"First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis.","BACKGROUND ENaC inhibition has been investigated as a CF treatment; however, small molecule inhibitors of ENaC lack efficacy and/or have shown dose-limiting hyperkalemia. SPX-101 is a novel, investigational small peptide (SPLUNC1 mimetic) that regulates ENaC density with the potential for efficacy without systemic effects. METHODS Two trials are presented: The first was a Phase 1, 2-part, randomized, double-blind, placebo-controlled, ascending-dose study of nebulized SPX-101 in healthy adults. Part 1 evaluated 4 single doses of SPX-101 ranging from 20 to 240 mg. Part 2 evaluated a 14-day regimen of SPX-101 at 4 doses of SPX-101 ranging from 10 to 120 mg BID. Pharmacokinetics, adverse events, spirometry, vital signs, electrocardiograms, pulse oximetry, and clinical laboratory values were assessed. The second trial was a tolerability-confirming, Phase 1b, open-label study conducted in 5 adult subjects with CF. Ascending doses of SPX-101 inhalation solution (10 mg-120 mg BID) were administered for 7 days. Safety was assessed as described above. RESULTS All 64 healthy volunteers (32 in each Part) completed the single and multiple dose study. SPX-101 was well tolerated with little/no systemic exposure and with no hyperkalemia. Adverse events were generally mild with reported respiratory events associated with the purported pharmacological activity of SPX-101. Tolerability of SPX-101 was similarly observed in adults with CF; all 5 subjects treated with SPX-101 completed the study. CONCLUSIONS SPX-101 was well-tolerated across a range of doses and had little/no systemic exposure in healthy adults and adults with CF, thus supporting further study in patients with CF. CLINICALTRIAL. GOV REGISTRATION NCT03056989.",2019,"Tolerability of SPX-101 was similarly observed in adults with CF; all 5 subjects treated with SPX-101 completed the study. ","['5 adult subjects with CF', 'adults with CF; all 5 subjects treated with SPX-101 completed the study', '64 healthy volunteers (32 in each Part) completed the single and multiple dose study', 'healthy adults', 'healthy volunteers and adults with cystic fibrosis', 'healthy adults and adults with CF']","['SPX-101 inhalation solution', 'placebo', 'SPX-101', 'nebulized SPX-101']","['Adverse events', 'Tolerability', 'Pharmacokinetics, adverse events, spirometry, vital signs, electrocardiograms, pulse oximetry, and clinical laboratory values', 'Safety']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}]","[{'cui': 'C1154181', 'cui_str': 'Inhalation Solution'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0518766'}, {'cui': 'C0034108', 'cui_str': 'Oximetry, Pulse'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",64.0,0.123326,"Tolerability of SPX-101 was similarly observed in adults with CF; all 5 subjects treated with SPX-101 completed the study. ","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Couroux', 'Affiliation': 'Inflamax Research Limited, Mississauga, Ontario, Canada.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Farias', 'Affiliation': 'Spyryx Biosciences, Inc, Durham, NC, USA.'}, {'ForeName': 'Leena', 'Initials': 'L', 'LastName': 'Rizvi', 'Affiliation': ""Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Griffin', 'Affiliation': ""Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Ontario, Canada.""}, {'ForeName': 'Christie', 'Initials': 'C', 'LastName': 'Hudson', 'Affiliation': 'Spyryx Biosciences, Inc, Durham, NC, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Crowder', 'Affiliation': 'Spyryx Biosciences, Inc, Durham, NC, USA. Electronic address: tcrowder@spyryxbio.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Tarran', 'Affiliation': 'Marsico Lung Institute, Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Tullis', 'Affiliation': ""Toronto Adult Cystic Fibrosis Centre, St. Michael's Hospital, Toronto, Ontario, Canada; Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto, Toronto, Canada.""}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2019.101819'] 1410,30859515,High Prevalence of Undiagnosed Hyperglycemia in Low-Income Overweight and Obese Hispanic Women in Oregon.,"BACKGROUND Overweight Hispanic women are at high risk for type 2 diabetes. A clinical diagnosis of hyperglycemia is often necessary to access interventions. We examined the prevalence of undiagnosed hyperglycemia among a group of low-income overweight or obese Hispanic women, who were receiving care at a Federally Qualified Health Center (FQHC). METHODS Among 196 overweight or obese Hispanic women (mean age 44 ± 10 years, mean weight 86.8 ± 16.5 kg, mean body mass index [BMI] 36.5 ± 6.4 kg/m 2 ) enrolled in a randomized clinical weight-loss trial, we compared A1C and fasting blood glucose (FBG) obtained at baseline with women's existing diabetes and prediabetes diagnoses in the medical record. RESULTS According to the information in participants' medical records, 36% (70/196) had diagnosed diabetes, 20% (39/196) had a diagnosis of prediabetes, and the remaining 44% (87/196) had neither diagnosis. Among participants without a diagnosis of diabetes or prediabetes during the baseline screening for our study, 63% (55/87) had at least one test in the prediabetes range (baseline A1C and FBG were in prediabetes range for 39 and 55 participants, respectively), and 13% (11/87) had at least one test in the diabetic range (baseline A1C and FBG values in diabetes range for 3 and 11 participants, respectively). DISCUSSION We found substantial prevalence of undiagnosed hyperglycemia among a sample of overweight and obese Hispanic women. It is possible that limited awareness of diabetes risk may be a barrier to patient compliance with screening recommendations.",2019,"According to the information in participants' medical records, 36% (70/196) had diagnosed diabetes, 20% (39/196) had a diagnosis of prediabetes, and the remaining 44% (87/196) had neither diagnosis.","['undiagnosed hyperglycemia among a group of low-income overweight or obese Hispanic women, who were receiving care at a Federally Qualified Health Center (FQHC', 'participants without a diagnosis of diabetes or prediabetes during the baseline screening for our study, 63% (55/87) had at least one test in the', 'Overweight Hispanic women', 'Low-Income Overweight and Obese Hispanic Women in Oregon', 'overweight and obese Hispanic women', '196 overweight or obese Hispanic women (mean age 44\u2009±\u200910\xa0years, mean weight 86.8\u2009±\u200916.5\xa0kg, mean body mass index', ""participants' medical records, 36% (70/196) had diagnosed diabetes, 20% (39/196) had a diagnosis of prediabetes, and the remaining 44% (87/196) had neither diagnosis""]",[],"['prediabetes range (baseline A1C and FBG', 'diabetic range (baseline A1C and FBG values', 'undiagnosed hyperglycemia', 'Undiagnosed Hyperglycemia', 'A1C and fasting blood glucose (FBG']","[{'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0475309', 'cui_str': 'Health center (environment)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0025102', 'cui_str': 'Medical Records'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}]",[],"[{'cui': 'C0362046', 'cui_str': 'Prediabetes'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C4521595', 'cui_str': 'Lcpl'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0020456', 'cui_str': 'Hyperglycemia'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}]",196.0,0.0531146,"According to the information in participants' medical records, 36% (70/196) had diagnosed diabetes, 20% (39/196) had a diagnosis of prediabetes, and the remaining 44% (87/196) had neither diagnosis.","[{'ForeName': 'Nangel M', 'Initials': 'NM', 'LastName': 'Lindberg', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA. Nangel.M.Lindberg@kpchr.org.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Vega-López', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'LeBlanc', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Leo', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Victor J', 'Initials': 'VJ', 'LastName': 'Stevens', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Gille', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Mayra', 'Initials': 'M', 'LastName': 'Arias-Gastélum', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Shuster', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Meenan', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Vaughn', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Meagan C', 'Initials': 'MC', 'LastName': 'Shaw', 'Affiliation': 'Kaiser Permanente Northwest Center for Health Research, 3800 N. Interstate Ave., Portland, OR, 97227, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Turner', 'Affiliation': 'Virginia Garcia Memorial Health Center, Cornelius, OR, USA.'}]",Journal of racial and ethnic health disparities,['10.1007/s40615-019-00578-9'] 1411,32439248,Derivation and validation of a new nutritional index for predicting 90 days mortality after ICU admission in a Korean population.,"BACKGROUND/PURPOSE Predicting the mortality in patients admitted to the ICU is important for determining a treatment strategy and public health policy. Although many scores have been developed to predict the mortality, these scores were based on Caucasian population. We aimed to develop a new prognostic index, the New nutritional index (NNI), to predict 90-days mortality after ICU admission based on Korean population. METHODS Patients (1453) who admitted intensive care unit (ICU) of the Gangnam Severance hospital were analyzed. After exclusion, 984 patients were randomly divided into internal (n = 702) and external validation (n = 282) data set. The new nutritional index (NNI) was developed using univariate and multivariate logistic regression with backward selection of predictors. Receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC) verified the better predictor of 90 days-mortality after ICU admission. RESULTS The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858 (SE: 0.015, 95% CI: 0.829-0.887), respectively. The calibration plots using external data set for validation showed a close approximation to the logistic calibration of each nomogram, and p-value of Hosmer and Lemeshow test was 0.1804. CONCLUSION The NNI has advantages as a predictor of 90 days mortality based on nutritional status in the Korean population.",2020,"The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858","['Patients (1453) who admitted intensive care unit (ICU) of the Gangnam Severance hospital were analyzed', '90 days mortality after ICU admission in a Korean population', '984 patients', 'patients admitted to the ICU']",[],"['modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets', 'Receiver operating characteristic (ROC) curve analysis and comparison of the area under the curve (AUC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0032659', 'cui_str': 'Population'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0489438', 'cui_str': 'APACHE II score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0555903', 'cui_str': 'Total protein measurement'}, {'cui': 'C0201838', 'cui_str': 'Albumin measurement'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",984.0,0.0138512,"The NNI better predicted 90 days-mortality compared to modified NUTRIC score, APACHE II scores, SOFA scores, CRP, glucose, total protein, and albumin level in internal and external data sets, with AUC of 0.862 (SE: 0.017, 95% CI: 0.829-0.895) and 0.858","[{'ForeName': 'Da-Hye', 'Initials': 'DH', 'LastName': 'Son', 'Affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyung-Sub', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hye-Sun', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Biostatistics Collaboration Unit, Department of Research Affairs, Yonsei University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Ji-Won', 'Initials': 'JW', 'LastName': 'Lee', 'Affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: indi5645@yuhs.ac.'}, {'ForeName': 'Cheung-Soo', 'Initials': 'CS', 'LastName': 'Shin', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: cheung56@yuhs.ac.'}]",Journal of the Formosan Medical Association = Taiwan yi zhi,['10.1016/j.jfma.2020.05.007'] 1412,32093625,Beat osteoporosis - nourish and exercise skeletons (BONES): a group randomized controlled trial in children.,"BACKGROUND Lifelong healthy habits developed during childhood may prevent chronic diseases in adulthood. Interventions to promote these habits must begin early. The BONES (Beat Osteoporosis - Nourish and Exercise Skeletons) project assessed whether early elementary school children participating in a multifaceted health behavior change, after-school based intervention would improve bone quality and muscular strength and engage in more bone-strengthening behaviors. METHODS The 2-year BONES (B) intervention included bone-strengthening physical activity (85 min/week), educational materials (2 days/week), and daily calcium-rich snacks (380 mg calcium/day) delivered by after-school program leaders. BONES plus Parent (B + P) included an additional parent education component. From 1999 to 2004, n = 83 after-school programs (N = 1434 children aged 6-9 years) in Massachusetts and Rhode Island participated in a group randomized trial with two intervention arms (B only, n = 25 programs; B + P, n = 33) and a control arm (C, n = 25). Outcome measures (primary: bone quality (stiffness index of the calcaneus) and muscular strength (grip strength and vertical jump); secondary: bone-strengthening behaviors (calcium-rich food knowledge, preference, and intake; and physical activity level (metabolic equivalent time (MET) score, and weight-bearing factor (WBF) score)) were recorded at baseline, and after years one and two. Analyses followed an intent-to-treat protocol, and focused on individual subjects' trajectories along the three time points adjusting for baseline age and race via a mixed-effects regression framework. Analyses were performed with and without sex stratification. RESULTS Children in B + P increased bone stiffness compared to C (p = 0.05); No significant changes were observed in muscle strength, food knowledge, or vertical jump. Children in B + P showed significant improvement in their MET and WBF scores compared to C (p < 0.01) with a stronger effect in boys in both B and B + P (all p < 0.01). CONCLUSION After-school programs, coupled with parental engagement, serving early elementary school children are a potentially feasible platform to deliver bone-strengthening behaviors to prevent osteoporosis in adulthood, with some encouraging bone and physical activity outcomes. TRIAL REGISTRATION ClinicalTrials.gov NCT00065247. Retrospectively registered. First posted July 22, 2003.",2020,"RESULTS Children in B + P increased bone stiffness compared to C (p = 0.05); No significant changes were observed in muscle strength, food knowledge, or vertical jump.","['From 1999 to 2004, n\u2009=\u200983 after-school programs (N\u2009=\u20091434 children aged 6-9\u2009years) in Massachusetts and Rhode Island participated', 'early elementary school children participating in a multifaceted health behavior change, after-school based intervention', 'children']","['bone-strengthening physical activity (85\u2009min/week), educational materials (2\u2009days/week), and daily calcium-rich snacks (380\u2009mg calcium/day) delivered by after-school program leaders', 'Beat osteoporosis\xa0-\xa0nourish and exercise skeletons (BONES']","['MET and WBF scores', 'bone stiffness', 'muscle strength, food knowledge, or vertical jump', 'bone quality and muscular strength and engage in more bone-strengthening behaviors', 'bone quality (stiffness index of the calcaneus) and muscular strength (grip strength and vertical jump); secondary: bone-strengthening behaviors (calcium-rich food knowledge, preference, and intake; and physical activity level (metabolic equivalent time (MET) score, and weight-bearing factor (WBF) score']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0035487', 'cui_str': 'Rhode Island'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0205291', 'cui_str': 'Multifaceted (qualifier value)'}, {'cui': 'C0018687'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0556975', 'cui_str': 'mins/week'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0677547', 'cui_str': 'days/week (qualifier value)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C3494314', 'cui_str': 'Snacking'}, {'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0816871', 'cui_str': 'Skeleton'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205128', 'cui_str': 'Vertical (qualifier value)'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0006655', 'cui_str': 'Heel Bone'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0453861', 'cui_str': 'Rich food (substance)'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C2355577', 'cui_str': 'Metabolic Equivalent'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0085086', 'cui_str': 'Finding of weight-bearing'}]",1434.0,0.0486644,"RESULTS Children in B + P increased bone stiffness compared to C (p = 0.05); No significant changes were observed in muscle strength, food knowledge, or vertical jump.","[{'ForeName': 'Christina D', 'Initials': 'CD', 'LastName': 'Economos', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, 150 Harrison Avenue, Boston, MA, 02111, USA. Christina.Economos@tufts.edu.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Hennessy', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, 150 Harrison Avenue, Boston, MA, 02111, USA.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Chui', 'Affiliation': 'Tufts University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Dwyer', 'Affiliation': 'Frances Stern Nutrition Center, Tufts Medical Center, Boston, MA, USA.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Marcotte', 'Affiliation': 'Boston Public Schools, Boston, MA, USA.'}, {'ForeName': 'Aviva', 'Initials': 'A', 'LastName': 'Must', 'Affiliation': 'Tufts University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Elena N', 'Initials': 'EN', 'LastName': 'Naumova', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, 150 Harrison Avenue, Boston, MA, 02111, USA.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Goldberg', 'Affiliation': 'Friedman School of Nutrition Science and Policy, Tufts University, 150 Harrison Avenue, Boston, MA, 02111, USA.'}]",BMC pediatrics,['10.1186/s12887-020-1964-y'] 1413,29633629,"Letter to the Editor: Preference option randomized design (PORD) for comparative effectiveness research: Statistical power for testing comparative effect, preference effect, selection effect, intent-to-treat effect, and overall effect (SMMR, Vol. 28, Issue 2, 2019).",,2019,,[],['Letter to the Editor'],[],[],"[{'cui': 'C1096774', 'cui_str': 'Letter'}]",[],,0.0201527,,"[{'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Walter', 'Affiliation': '1 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Macaskill', 'Affiliation': '2 School of Public Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Turner', 'Affiliation': ""3 Biostatistics Unit, Dean's Office, School of Medicine, University of Otago, Dunedin, New Zealand.""}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Guyatt', 'Affiliation': '1 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Cook', 'Affiliation': '4 Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada.'}, {'ForeName': 'Kameshwar', 'Initials': 'K', 'LastName': 'Prasad', 'Affiliation': '5 Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.'}]",Statistical methods in medical research,['10.1177/0962280218767691'] 1414,32095502,Comparison of a Behavioral Versus an Educational Weight Management Intervention After Renal Transplantation: A Randomized Controlled Trial.,"Background In the first year following renal transplantation, preventing weight gain to minimize overweight or obesity is particularly important. The aim of this study is to test the effect of an 8-month behavioral intervention BMI and physical activity. Methods This randomized controlled study included 123 adult kidney or kidney-pancreas recipients. Patients were randomized to usual (1 educational session, then weight self-monitoring) and intervention care (usual care plus 7-8 counseling sessions). Alongside weight, body composition, and physical activity, satisfaction and perceptions regarding care were measured at weeks 2-6 (baseline), then at months 8 and 12. Results Both groups reported comparably high satisfaction. The intervention group (IG) reported more chronic care-related activities. In patients with BMIs ≥ 18.5, mean weight gain (from baseline) was unexpectedly low in both groups: at month 8, +0.04 kg/m 2 in IG patients and +0.14 kg/m 2 in the control group ( P = 0.590), and respectively, +0.03 kg/m 2 and +0.19 kg/m 2 at month 12 ( P = 0.454). Both groups were physically active, walking averages of 10 807 (IG) and 11 093 (control group) steps per day at month 8 ( P = 0.823), and respectively 9773 and 11 217 at month 12 ( P = 0.195). Conclusions The behavioral intervention had high patient acceptance and supported patients in maintaining their weight, but had no superior effect on a single educational session. Further research is needed to assess patient weight gain risk profiles to stratify the intervention.",2019,"In patients with BMIs ≥ 18.5, mean weight gain (from baseline) was unexpectedly low in both groups: at month 8, +0.04 kg/m 2 in IG patients and +0.14 kg/m 2 in the control group ( P = 0.590), and respectively, +0.03 kg/m 2 and +0.19 kg/m 2 at month 12 ( P = 0.454).","['123 adult kidney or kidney-pancreas recipients', 'Both groups were physically active, walking averages of 10 807 (IG) and 11 093']","['usual (1 educational session, then weight self-monitoring) and intervention care (usual care plus 7-8 counseling sessions', 'Behavioral Versus an Educational Weight Management Intervention']","['weight gain', 'Alongside weight, body composition, and physical activity, satisfaction and perceptions regarding care', 'mean weight gain', 'chronic care-related activities']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0556453', 'cui_str': 'Physically active (finding)'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",123.0,0.109104,"In patients with BMIs ≥ 18.5, mean weight gain (from baseline) was unexpectedly low in both groups: at month 8, +0.04 kg/m 2 in IG patients and +0.14 kg/m 2 in the control group ( P = 0.590), and respectively, +0.03 kg/m 2 and +0.19 kg/m 2 at month 12 ( P = 0.454).","[{'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Schmid-Mohler', 'Affiliation': 'Center of Clinical Nursing Science, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Zala', 'Affiliation': 'Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Graf', 'Affiliation': 'Graf biostatistics, Winterthur, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Witschi', 'Affiliation': 'Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Mueller', 'Affiliation': 'Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Peter Wüthrich', 'Affiliation': 'Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Huber', 'Affiliation': 'Center of Clinical Nursing Science, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Fehr', 'Affiliation': 'Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Spirig', 'Affiliation': 'Directorate of Nursing and Allied Health Professionals, University Hospital Zurich, Zurich, Switzerland.'}]",Transplantation direct,['10.1097/TXD.0000000000000936'] 1415,32439205,"Intraoperative application of inactivated Pseudomonas aeruginosa in patients undergoing lateral neck dissection for metastatic thyroid cancer: A randomized, parallel group, placebo-controlled trial.","BACKGROUND We hypothesize that the intraoperative, prophylactic application of Pseudomonas aeruginosa can decrease postoperative chylous fistula and enhance recovery after surgery in patients with thyroid cancer undergoing lateral neck lymph node dissection. METHOD In this single-center trial, we assigned randomly 200 patients with thyroid cancer who had proven lateral lymph node metastasis to groups receiving either 2 mL Pseudomonas aeruginosa spray (Pseudomonas aeruginosa group) or 2 mL saline spray (control group) in the lateral cervical surgical field. The primary end points were the rate of chylous fistula, mean difference in the duration and volume of drainage fluid, days of postoperative hospital stay, and overall cost. The secondary end points included the red blood cell count and triglyceride level in the drainage, the white blood cell count in the blood, fever, local pain, development of a pleural effusion, and tumor recurrence. RESULTS Patients treated with Pseudomonas aeruginosa had a decrease in macroscopic chylous fistula compared with controls (0 vs 6%, P = .025). There were fewer days to drain-tube removal, a less volume of drainage fluid, fewer postoperative days of hospital stay, and a lesser red blood cell count in the drainage fluid in the Pseudomonas aeruginosa group than in the control group (all P < .05). No severe side effects of the Pseudomonas aeruginosa spray with respect to fever, pain, or pleural effusion were observed. Pseudomonas aeruginosa spraying did not affect postoperative recurrence of the thyroid cancer. CONCLUSION Intraoperative spraying of inactivated Pseudomonas aeruginosa in the lateral neck compartment can decrease the development of chylous fistula and enhance postoperative recovery.",2020,"There were fewer days to drain-tube removal, a less volume of drainage fluid, fewer postoperative days of hospital stay, and a lesser red blood cell count in the drainage fluid in the Pseudomonas aeruginosa group than in the control group (all P < .05).","['patients undergoing lateral neck dissection for metastatic thyroid cancer', 'patients with thyroid cancer undergoing lateral neck lymph node dissection', '200 patients with thyroid cancer who had proven lateral lymph node metastasis to groups receiving either']","['Intraoperative application of inactivated Pseudomonas aeruginosa', '2 mL Pseudomonas aeruginosa spray (Pseudomonas aeruginosa group) or 2 mL saline spray (control group) in the lateral cervical surgical field', 'placebo']","['macroscopic chylous fistula', 'red blood cell count', 'postoperative recurrence', 'severe side effects', 'red blood cell count and triglyceride level in the drainage, the white blood cell count in the blood, fever, local pain, development of a pleural effusion, and tumor recurrence', 'rate of chylous fistula, mean difference in the duration and volume of drainage fluid, days of postoperative hospital stay, and overall cost', 'volume of drainage fluid, fewer postoperative days of hospital stay', 'fever, pain, or pleural effusion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0398395', 'cui_str': 'Block dissection of cervical lymph nodes'}, {'cui': 'C1096666', 'cui_str': 'Thyroid cancer metastatic'}, {'cui': 'C0007115', 'cui_str': 'Malignant tumor of thyroid gland'}, {'cui': 'C0588054', 'cui_str': 'Cervical lymph node group'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0686619', 'cui_str': 'Secondary malignant neoplasm of lymph node'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0033809', 'cui_str': 'Pseudomonas aeruginosa'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C1066168', 'cui_str': 'Pseudomonas aeruginosa group'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0443174', 'cui_str': 'Chylous'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0032227', 'cui_str': 'Pleural effusion'}, {'cui': 'C0521158', 'cui_str': 'Recurrent tumor'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205388', 'cui_str': 'Few'}]",200.0,0.224468,"There were fewer days to drain-tube removal, a less volume of drainage fluid, fewer postoperative days of hospital stay, and a lesser red blood cell count in the drainage fluid in the Pseudomonas aeruginosa group than in the control group (all P < .05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Genpeng', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Jinen', 'Affiliation': 'State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tao', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhihui', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Gong', 'Initials': 'G', 'LastName': 'Rixiang', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Jianyong', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China. Electronic address: leijianyong11@163.com.'}, {'ForeName': 'Zhu', 'Initials': 'Z', 'LastName': 'Jingqiang', 'Affiliation': 'Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, China.'}]",Surgery,['10.1016/j.surg.2020.03.020'] 1416,31410633,"Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent.","The effects of contezolid (MRX-I, an oxazolidinone antibacterial agent) on cardiac repolarization were evaluated retrospectively using a population modeling approach in a Phase I study incorporating single ascending dose, multiple ascending dose, and food effect assessments. Linear mixed effect models were used to assess the relationships between MRX-I plasma concentrations and QT/QTc/∆QTc (baseline-adjusted), in which different correction methods for heart rate have been included. The upper bound of the one-sided 95% confidence interval (CI) for predicted ∆∆QTc was < 10 ms (ms) at therapeutic doses of MRX-I. Model performance/suitability was determined using diagnostic evaluations, which indicated rationality of one-stage concentration-QT model, as well as C-QT model suggested by Garnett et al. The finding demonstrated that MRX-I may have no clinical effects on the QT interval. Concentration-QT model may be an alternative to conventional thorough QT studies.",2019,"The upper bound of the one-sided 95% confidence interval (CI) for predicted ∆∆QTc was < 10 ms (ms) at therapeutic doses of MRX-I. Model performance/suitability was determined using diagnostic evaluations, which indicated rationality of one-stage concentration-QT model, as well as C-QT model suggested by Garnett et al.",[],"['contezolid (MRX-I, an oxazolidinone antibacterial agent']","['MRX-I plasma concentrations and QT/QTc/∆QTc', 'cardiac repolarization']",[],"[{'cui': 'C2931498', 'cui_str': 'Mental Retardation, X-Linked 1'}, {'cui': 'C0887953', 'cui_str': 'Oxazolidinone'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C2931498', 'cui_str': 'Mental Retardation, X-Linked 1'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]",,0.0329148,"The upper bound of the one-sided 95% confidence interval (CI) for predicted ∆∆QTc was < 10 ms (ms) at therapeutic doses of MRX-I. Model performance/suitability was determined using diagnostic evaluations, which indicated rationality of one-stage concentration-QT model, as well as C-QT model suggested by Garnett et al.","[{'ForeName': 'Junzhen', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Certara Strategic Consulting China, Shanghai, 200122, China.'}, {'ForeName': 'Yuancheng', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Yuan', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. zhangj_fudan@aliyun.com.'}]",Journal of pharmacokinetics and pharmacodynamics,['10.1007/s10928-019-09650-7'] 1417,31468664,"Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.","AIMS To determine the effects of the dipeptidyl peptidase-4 inhibitor, sitagliptin, on gastric emptying (GE) of a high-carbohydrate meal and associated glycaemic and blood pressure (BP) responses in type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS Fourteen patients with T2DM (nine men, five women; age 67.8 ± 1.5 years; body mass index 31.2 ± 0.9 kg/m 2 ; T2DM duration: 4.2 ± 0.9 years; glycated haemoglobin: 46 ± 1.8 mmol/mol [6.4% ± 0.2%]), managed by diet and/or metformin, underwent concurrent measurements of GE, BP and plasma glucose for 240 minutes after ingestion of a radiolabelled mashed potato meal after receiving sitagliptin (100 mg) or placebo in randomized, double-blind, crossover fashion on 2 consecutive days. RESULTS Sitagliptin reduced postprandial plasma glucose (P < .005) without affecting GE (P = .88). The magnitude of the glucose-lowering effect (change in incremental area under the curve 0-240 min from placebo to sitagliptin) was related to GE (kcal/min) on placebo (r = 0.68, P = .008) There was a comparable fall in systolic BP (P = .80) following the meal, with no difference between the 2 days. CONCLUSIONS In T2DM, while sitagliptin has no effect on either GE or postprandial BP, its ability to lower postprandial glucose are dependent on the basal rate of GE.",2020,"RESULTS Sitagliptin reduced postprandial plasma glucose (P<0.005), without affecting gastric emptying (P=0.88).","['type 2 diabetes', 'type 2 diabetes mellitus', 'Fourteen patients with type 2 diabetes (9 male, 5 female; age: 67.8±1.5\u2009years; BMI: 31.2±0.9 kg/m 2 ; diabetes duration: 4.2±0.9\u2009years; HbA 1 c: 46±1.8\u2009mmol/mol (6.4±0.2%), managed by']","['dipeptidyl peptidase-4 inhibitor, sitagliptin', 'placebo', 'carbohydrate meal', 'sitagliptin', 'diet and/or metformin, underwent concurrent measurements of gastric emptying, blood pressure and plasma glucose for 240 min after ingestion of a radiolabelled a mashed potato meal after receiving sitagliptin (100 mg) or placebo']","['gastric emptying of, and the glycaemic and blood pressure responses', 'systolic blood pressure', 'postprandial plasma glucose', 'gastric emptying or postprandial blood pressure', 'gastric emptying', 'glycaemic and blood pressure responses']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}]","[{'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0017127', 'cui_str': 'Gastric Emptyings'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0032846', 'cui_str': 'Potato'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0017127', 'cui_str': 'Gastric Emptyings'}, {'cui': 'C1997183', 'cui_str': 'Speed of blood pressure response (observable entity)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}]",240.0,0.129258,"RESULTS Sitagliptin reduced postprandial plasma glucose (P<0.005), without affecting gastric emptying (P=0.88).","[{'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Stevens', 'Affiliation': 'School of Health and Biomedical Sciences, RMIT University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Buttfield', 'Affiliation': 'Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}, {'ForeName': 'Tongzhi', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Seva', 'Initials': 'S', 'LastName': 'Hatzinikolas', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Hung', 'Initials': 'H', 'LastName': 'Pham', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Lange', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Christopher K', 'Initials': 'CK', 'LastName': 'Rayner', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'Adelaide Medical School and NHMRC Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, South Australia, Australia.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Jones', 'Affiliation': 'Division of Health Sciences, University of South Australia, Adelaide, South Australia, Australia.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13864'] 1418,31468249,Comparison of the Effectiveness of Two Cognitive-Behavioral Group Therapy Programs for Schizophrenia: Results of a Short-Term Randomized Control Trial.,"This study aimed to compare the effectiveness of two different cognitive-behavioural therapy programs in patients with schizophrenia and clarify which techniques are more effective on psychotic symptoms. With this purpose, 39 schizophrenia outpatients-assessed by independent assessors using Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative Symptoms and by researchers using Psychotic Symptoms Rating Scales-were randomly assigned to routine care (RC), RC plus COPE-CBT or RC plus CBT groups. The repeated measures ANOVA results show that there was a significant reduction in the severity and frequency of hallucinations in CBT group and delusions in COPE-CBT group. Both CBT programs were found to be superior to RC group on some measures at post-treatment, as well as 3 months follow-up.",2020,The repeated measures ANOVA results show that there was a significant reduction in the severity and frequency of hallucinations in CBT group and delusions in COPE-CBT group.,"['Schizophrenia', 'patients with schizophrenia', '39 schizophrenia outpatients']","['Two Cognitive-Behavioral Group Therapy Programs', 'cognitive-behavioural therapy programs']","['psychotic symptoms', 'Psychotic Symptoms Rating Scales', 'severity and frequency of hallucinations']","[{'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C1527374', 'cui_str': 'Group Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}, {'cui': 'C2959702', 'cui_str': 'Psychotic symptom rating scale (assessment scale)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0018524', 'cui_str': 'Hallucinations'}]",39.0,0.0186596,The repeated measures ANOVA results show that there was a significant reduction in the severity and frequency of hallucinations in CBT group and delusions in COPE-CBT group.,"[{'ForeName': 'Oya', 'Initials': 'O', 'LastName': 'Mortan Sevi', 'Affiliation': 'Department of Psychology, Faculty of Economics, Administrative and Social Sciences, Bahcesehir University, Yıldız Mh., Çırağan Cd., Beşiktaş, 34349, Istanbul, Turkey. oya.mortansevi@eas.bau.edu.tr.'}, {'ForeName': 'Serap', 'Initials': 'S', 'LastName': 'Tekinsav Sutcu', 'Affiliation': 'Department of Psychology, Faculty of Letters, Ege University, Izmir, Turkey.'}, {'ForeName': 'Sema', 'Initials': 'S', 'LastName': 'Yesilyurt', 'Affiliation': 'Safa Hospital Group, Istanbul, Turkey.'}, {'ForeName': 'Sultan', 'Initials': 'S', 'LastName': 'Turan Eroglu', 'Affiliation': 'Biruni University, Istanbul, Turkey.'}, {'ForeName': 'Busra', 'Initials': 'B', 'LastName': 'Gunes', 'Affiliation': 'Humanity Psychiatry Clinic, Istanbul, Turkey.'}]",Community mental health journal,['10.1007/s10597-019-00448-y'] 1419,32004567,Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study.,"BACKGROUND Scientific rationale and encouraging first clinical results suggest the interest of using apremilast for treating vitiligo. OBJECTIVE This study aimed to compare the efficacy of apremilast in combination therapy with narrowband (NB)-UVB versus placebo and NB-UVB treatment for repigmentation in patients with nonsegmental vitiligo. DESIGN This was a 52-week prospective randomized placebo-controlled study. PARTICIPANTS Adult patients with vitiligo participated. INTERVENTIONS Group A received, in addition to phototherapy, apremilast at the label dosage, and group B received placebo. After 24 weeks, patients who responded (decreased Vitiligo Area Scoring Index >30%) were rerandomized to receive apremilast or placebo, combined with twice-weekly NB-UVB for 24 additional weeks. Main outcome and measure: The primary outcome measure was the comparison between the two groups of the Vitiligo Area Scoring Index score at 24 weeks. RESULTS Eighty patients were randomized (40 in each group). After 24 weeks, the mean Vitiligo Area Scoring Index score decreased from 23.63 to 19.49 (P = 0.011) in the apremilast + UVB group and from 21.57 to 15.25 (P < 0.0001) in the placebo + UVB group. The difference between the two groups was not statistically significant (P = 0.18). No statistically significant differences were observed between the two groups after an additional 24 weeks of treatment. CONCLUSIONS AND RELEVANCE Apremilast does not bring any benefit to NB-UVB for treating vitiligo.",2020,"After 24 weeks, the mean VASI score decreased from 23.63 to 19.49 (p=0.011) in apremilast+UVB group and from 21.57 to 15.25 (p<0.0001) in the placebo+UVB group.","['80 patients', 'After 24 weeks, patients who responded (decreased VASI>30', 'Adult patients with vitiligo', 'patients with non-segmental vitiligo']","['narrowband UVB', 'apremilast or placebo', 'narrowband (NB)-UVB versus placebo and NB-UVB treatment', 'placebo', 'placebo+UVB']","['VASI score', 'mean VASI score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C1274648', 'cui_str': 'Segmental vitiligo'}]","[{'cui': 'C1678805', 'cui_str': 'apremilast'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",80.0,0.280086,"After 24 weeks, the mean VASI score decreased from 23.63 to 19.49 (p=0.011) in apremilast+UVB group and from 21.57 to 15.25 (p<0.0001) in the placebo+UVB group.","[{'ForeName': 'Abdallah', 'Initials': 'A', 'LastName': 'Khemis', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Fontas', 'Affiliation': ""Department of Research and Innovation, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Moulin', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Henri', 'Initials': 'H', 'LastName': 'Montaudié', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France; Université Côte d'Azur, INSERM U1065, Team 12, C3M, Nice, France.""}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Lacour', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France.""}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Passeron', 'Affiliation': ""Department of Dermatology, University Hospital Center of Nice, University of Côte d'Azur, Nice, France; Université Côte d'Azur, INSERM U1065, Team 12, C3M, Nice, France. Electronic address: passeron@unice.fr.""}]",The Journal of investigative dermatology,['10.1016/j.jid.2019.11.031'] 1420,31468636,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial.","AIMS To evaluate the safety and pharmacokinetics of naringenin in healthy adults consuming whole-orange (Citrus sinensis) extract. METHODS AND METHODS In a single-ascending-dose randomized crossover trial, 18 adults ingested doses of 150 mg (NAR150), 300 mg (NAR300), 600 mg (NAR600) and 900 mg (NAR900) naringenin or placebo. Each dose or placebo was followed by a wash-out period of at least 1 week. Blood safety markers were evaluated pre-dose and 24 hours post-dose. Adverse events (AEs) were recorded. Serum naringenin concentrations were measured before and over 24 hours following ingestion of placebo, NAR150 and NAR600. Four- and 24-hour serum measurements were obtained after placebo, NAR300 and NAR900 ingestion. Data were analysed using a mixed-effects linear model. RESULTS There were no relevant AEs or changes in blood safety markers following ingestion of any of the naringenin doses. The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600). Naringenin half-life was 3.0 hours (NAR150) and 2.65 hours (NAR600). After NAR300 ingestion, serum concentrations were 10.67 ± 5.74 μM (4 hours) and 0.35 ± 0.30 μM (24 hours). After NAR900 ingestion, serum concentrations were 43.11 ± 5.26 μM (4 hours) and 0.24 ± 0.30 μM (24 hours). CONCLUSIONS Ingestion of 150 to 900 mg doses of naringenin is safe in healthy adults, and serum concentrations are proportional to the dose administered. Since naringenin (8 μM) is effective in primary human adipocytes, ingestion of 300 mg naringenin twice/d will likely elicit a physiological effect.",2020,"Serum naringenin concentrations were measured before and over 24 hours following ingestion of placebo, NAR150, and NAR600.","['18 adults', 'healthy adults', 'healthy adults, consuming a whole orange (Citrus Sinensis) extract']","['ingested 150mg (NAR150), 300mg (NAR300), 600mg (NAR600), and 900mg (NAR900) doses of naringenin or placebo', 'Naringenin', 'placebo', 'naringenin']","['serum concentrations', 'Maximal concentration: 15.76±7.88μM (NAR150) and 48.45±7.88μM (NAR600); Time to peak: 3.17±0.74h (NAR150) and 2.41±0.74h (NAR600); Area under the 24-hour concentration-time curve: 67.61±24.36μM×h (NAR150) and 199.06±24.36μM×h (NAR600); and Apparent oral clearance', 'Adverse events', 'Serum naringenin concentrations', 'Blood safety markers', 'blood safety markers']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0440277', 'cui_str': 'Oranges'}, {'cui': 'C0522462', 'cui_str': 'Orange Tree'}, {'cui': 'C2752151', 'cui_str': 'Extract (qualifier value)'}]","[{'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C4517900', 'cui_str': '900 (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0068450', 'cui_str': 'naringenin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205289', 'cui_str': 'Maximal (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0068450', 'cui_str': 'naringenin'}, {'cui': 'C2936496', 'cui_str': 'Blood Supply Safety'}]",18.0,0.205889,"Serum naringenin concentrations were measured before and over 24 hours following ingestion of placebo, NAR150, and NAR600.","[{'ForeName': 'Candida J', 'Initials': 'CJ', 'LastName': 'Rebello', 'Affiliation': 'Pharmacology Clinical Trials, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'Biostatistics, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'Juan J L', 'Initials': 'JJL', 'LastName': 'Lertora', 'Affiliation': 'Clinical Pharmacology, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'Greenway', 'Affiliation': 'Pharmacology Clinical Trials, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ravussin', 'Affiliation': 'Human Translational Physiology, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Ribnicky', 'Affiliation': 'Rutgers University Botanical Centre, New Brunswick, New Jersey.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Poulev', 'Affiliation': 'Rutgers University Botanical Centre, New Brunswick, New Jersey.'}, {'ForeName': 'Brandon J', 'Initials': 'BJ', 'LastName': 'Kennedy', 'Affiliation': 'Department of Chemistry, University of Tennessee, Knoxville, Tennessee.'}, {'ForeName': 'Hector F', 'Initials': 'HF', 'LastName': 'Castro', 'Affiliation': 'Department of Chemistry, University of Tennessee, Knoxville, Tennessee.'}, {'ForeName': 'Shawn R', 'Initials': 'SR', 'LastName': 'Campagna', 'Affiliation': 'Department of Chemistry, University of Tennessee, Knoxville, Tennessee.'}, {'ForeName': 'Ann A', 'Initials': 'AA', 'LastName': 'Coulter', 'Affiliation': 'Pharmacology Clinical Trials, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Redman', 'Affiliation': 'Reproductive Endocrinology, Pennington Biomedical Research Centre, Baton Rouge, Louisiana.'}]","Diabetes, obesity & metabolism",['10.1111/dom.13868'] 1421,30552595,Healthcare service utilization and work-related productivity in reflexology intervention for advanced breast cancer women.,"PURPOSE This project's purpose was to determine the effects of a home-based reflexology intervention on symptom-related use of health services and work-related productivity during the 11-week study. METHODS A total of 256 patients were randomized to four weekly reflexology sessions (each lasting 30 min, delivered by lay caregivers who received two training sessions by a professional reflexologist) or attention control. The Conventional Health Service and Productivity Costs Form was used to collect information on health service utilization and out-of-pocket expenditure of symptom management. The Health and Work Performance Questionnaire was used to measure workplace performance for patients during the study period. We used weighted and unweighted logistic and linear regression analyses. RESULTS Patients in the reflexology group were less likely to have hospital visits compared to the control group in the weighted unadjusted (odds ratio [OR] = 0.49; 95% confidence interval [CI] = [0.25, 0.97]), unweighted adjusted (OR = 0.35; 95% CI = [0.16, 0.75]), and weighted adjusted (OR = 0.30, 95% CI = [0.13, 0.66]) logistic regressions. Compared to attention control, patients in the reflexology group had lower relative absenteeism in the unweighted adjusted (- 0.32; 95% CI = [- 0.60, - 0.03]) linear regressions and less absolute presenteeism (15.42, 95% CI = [0.87, 29.98]) in the weighted unadjusted analysis. CONCLUSION The reflexology intervention delivered by lay caregivers reduced hospital visits and increased workplace productivity in a short-term period, which has potential for cost saving for health care systems and employers. TRIAL REGISTRATION NCT01582971.",2019,"Compared to attention control, patients in the reflexology group had lower relative absenteeism in the unweighted adjusted (- 0.32; 95% CI = [- 0.60, - 0.03]) linear regressions and less absolute presenteeism (15.42, 95% CI = [0.87, 29.98]) in the weighted unadjusted analysis. ","['advanced breast cancer women', 'A total of 256 patients']","['reflexology intervention', 'reflexology sessions (each lasting 30\xa0min, delivered by lay caregivers who received two training sessions by a professional reflexologist) or attention control', 'home-based reflexology intervention', 'reflexology intervention delivered by lay caregivers reduced hospital visits']","['workplace performance', 'hospital visits', 'relative absenteeism', 'workplace productivity']","[{'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0034945', 'cui_str': 'Reflexology'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]","[{'cui': 'C0162579', 'cui_str': 'Job Site'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}]",256.0,0.0521911,"Compared to attention control, patients in the reflexology group had lower relative absenteeism in the unweighted adjusted (- 0.32; 95% CI = [- 0.60, - 0.03]) linear regressions and less absolute presenteeism (15.42, 95% CI = [0.87, 29.98]) in the weighted unadjusted analysis. ","[{'ForeName': 'Zhehui', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, 48824, USA. zluo@msu.edu.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, 48824, USA.'}, {'ForeName': 'Alla', 'Initials': 'A', 'LastName': 'Sikorskii', 'Affiliation': 'Department of Psychiatry, Department of Statistics and Probability, Michigan State University, East Lansing, MI, 48824, USA.'}, {'ForeName': 'Gwen', 'Initials': 'G', 'LastName': 'Wyatt', 'Affiliation': 'College of Nursing, Michigan State University, East Lansing, MI, 48824, USA.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-018-4592-4'] 1422,32440935,"Correction to: A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.",The original article unfortunately has a missing acknowledgement.,2020,The original article unfortunately has a missing acknowledgement.,[],['corifollitropin-α late-start (day 4) versus standard administration'],[],[],"[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",[],,0.0221903,The original article unfortunately has a missing acknowledgement.,"[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Revelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy. alberto.revelli@unito.it.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Gennarelli', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Sestero', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Canosa', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Carosso', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Salvagno', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Pittatore', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Filippini', 'Affiliation': 'Clinical Statistics, Department of Surgical Sciences, University of Torino, Corso Bramante 88, Turin, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Benedetto', 'Affiliation': 'Gynecology and Obstetrics 1, Physiopathology of Reproduction and IVF Unit, Department of Surgical Sciences, S. Anna Hospital, University of Torino, Via Ventimiglia 3, 10126, Turin, Italy.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-020-01823-5'] 1423,31031097,Comparison of the efficacy of an education program for people with diabetes and insulin pump treatment (INPUT) in a randomized controlled trial setting and the effectiveness in a routine care setting: Results of a comparative effectiveness study.,"OBJECTIVE To compare the efficacy of an education program for people with diabetes and insulin pump treatment (INPUT) in a randomized controlled trial (RCT) to the effectiveness in an implementation trial (IT). METHODS 135 people with diabetes on insulin pump treatment (CSII) underwent structured education with INPUT under RCT-conditions, 191 people with diabetes on CSII underwent structured education with INPUT under IT-conditions. Baseline characteristics and treatment outcomes at the 6-month follow-up were compared. RESULTS At baseline, RCT-participants were younger (42.7 ± 14.2 vs. 47.2 ± 14.1 years, p = 0.005), had higher HbA1c-values (8.3 ± 0.8% vs. 7.8 ± 1.2%, p = 0.001) and had more diabetes-related distress (27.8 ± 16.4 vs 22.4 ± 14.4, p = 0.002). At follow-up, INPUT results were comparable under the RCT and IT settings. After adjustment for baseline HbA1c, reduction of HbA1c in the IT was significantly greater than in the RCT (Δ0.17%; 95% CI 0.023-0.319%, p = 0.024). Participants with higher HbA1c-levels, more diabetes-related distress and more hypoglycemia problems were most likely to benefit from INPUT regardless of the trial setting. CONCLUSIONS Efficacy of the INPUT program for people with CSII was demonstrated under RCT- and routine care conditions. PRACTICE IMPLICATIONS Education with the INPUT program is effective not only under standardized RCT conditions but also under conditions of routine care.",2019,"After adjustment for baseline HbA1c, reduction of HbA1c in the IT was significantly greater than in the RCT (Δ0.17%; 95% CI 0.023-0.319%, p = 0.024).","['135 people with diabetes on insulin pump treatment', '191 people with diabetes on CSII underwent structured education with INPUT under IT-conditions', 'people with diabetes and']","['insulin pump treatment (INPUT', 'education program', 'INPUT program']","['diabetes-related distress', 'hypoglycemia problems', 'reduction of HbA1c in the IT']","[{'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C4087542', 'cui_str': 'Hypoglycaemia (SMQ)'}, {'cui': 'C0033213', 'cui_str': 'Problem (finding)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0202054', 'cui_str': 'HbA1C'}]",191.0,0.135681,"After adjustment for baseline HbA1c, reduction of HbA1c in the IT was significantly greater than in the RCT (Δ0.17%; 95% CI 0.023-0.319%, p = 0.024).","[{'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Bergis', 'Affiliation': 'Division of Endocrinology & Diabetes, Department of Internal Medicine 1, Goethe-University Hospital, 60590, Frankfurt am Main, Germany. Electronic address: dominik.bergis@kgu.de.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Ehrmann', 'Affiliation': 'Research Institute of the Diabetes Academy Mergentheim (FIDAM), 97980, Bad Mergentheim, Germany; Otto-Friedrich-University of Bamberg, Department of Clinical Psychology and Psychotherapy, Bamberg, Germany.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Albrecht', 'Affiliation': 'Research Institute of the Diabetes Academy Mergentheim (FIDAM), 97980, Bad Mergentheim, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Haak', 'Affiliation': 'Research Institute of the Diabetes Academy Mergentheim (FIDAM), 97980, Bad Mergentheim, Germany; Diabetes Centre Mergentheim, Diabetes Clinic, 97980, Bad Mergentheim, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Kulzer', 'Affiliation': 'Research Institute of the Diabetes Academy Mergentheim (FIDAM), 97980, Bad Mergentheim, Germany; Diabetes Centre Mergentheim, Diabetes Clinic, 97980, Bad Mergentheim, Germany; Otto-Friedrich-University of Bamberg, Department of Clinical Psychology and Psychotherapy, Bamberg, Germany.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Hermanns', 'Affiliation': 'Research Institute of the Diabetes Academy Mergentheim (FIDAM), 97980, Bad Mergentheim, Germany; Diabetes Centre Mergentheim, Diabetes Clinic, 97980, Bad Mergentheim, Germany; Otto-Friedrich-University of Bamberg, Department of Clinical Psychology and Psychotherapy, Bamberg, Germany.'}]",Patient education and counseling,['10.1016/j.pec.2019.04.021'] 1424,31371165,A Pragmatic Trial of Symptom-Based Inhaled Corticosteroid Use in African-American Children with Mild Asthma.,"BACKGROUND Symptom-based adjustment (SBA) of inhaled corticosteroids may be an alternative patient-centered approach in which day-to-day inhaled corticosteroid use is adjusted by symptoms and short-acting β-agonist need. OBJECTIVE To evaluate the effectiveness of SBA in the primary care setting. METHODS We conducted a randomized, open-label, pragmatic equivalence trial in African-American children (6-17 years old) with mild asthma managed by 12 primary care providers (PCPs). A total of 206 participants were randomized to SBA (as-needed beclomethasone 80 μg with rescue short-acting β-agonist) or provider-based guideline-directed adjustment (PBA): maintenance beclomethasone 80 μg/d (6-11 years old), 160 μg/d (12-17 years old), with subsequent guideline-based dose adjustment by PCPs. PCPs implemented both treatment assignments, with outcomes measured by blinded staff. All participants received symptom recognition and albuterol use education from peer educators. Primary outcome was change in asthma control (measured by Asthma Control Test [ACT]/childhood ACT [cACT]) over 12 months. RESULTS Participants had adequately controlled asthma (mean ACT or cACT score = 21.6 ± 2.8) at baseline. After 1 year, there was no significant between-group difference in change in ACT scores (SBA - PBA): ACT: -0.88 (95% CI, -2.19 to 0.42), cACT: -0.73 (-2.09 to 0.62), or combined ACT and cACT (P = .10), and was within the predefined statistical clinical equivalence. The proportion with an exacerbation and measures of lung function were similar between groups. Compared with PBA, SBA led to less beclomethasone use (SBA: 526 μg/mo [95% CI, 412-639 μg] vs PBA: 1961 μg/mo [95% CI, 1681-2241]; P < .0001). More parents in the SBA arm felt they were managing their child's asthma. CONCLUSIONS SBA in African-American children with mild asthma was similar to PBA in asthma control and events when implemented by PCPs with lower inhaled corticosteroid exposure.",2020,"After 1 year, there was no significant between-group difference in change in ACT scores (SBA - PBA):","['African-American Children with Mild Asthma', 'Participants had adequately controlled asthma (mean ACT or cACT score\xa0= 21.6 ± 2.8) at baseline', 'African-American children (6-17 years old) with mild asthma managed by 12 primary care providers (PCPs', 'African-American children with mild asthma', '206 participants']","['beclomethasone', 'beclomethasone 80 μg with rescue short-acting β-agonist) or provider-based guideline-directed adjustment (PBA): maintenance beclomethasone', 'PBA, SBA', 'SBA', 'PBA', 'Symptom-Based Inhaled Corticosteroid Use']","['ACT scores (SBA\xa0- PBA', 'change in asthma control (measured by Asthma Control Test [ACT]/childhood ACT [cACT', 'proportion with an exacerbation and measures of lung function']","[{'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1264638', 'cui_str': 'Catalytic activity'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider (occupation)'}]","[{'cui': 'C0004905', 'cui_str': 'Beclomethasone'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0220845', 'cui_str': 'guidelines'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test (assessment scale)'}, {'cui': 'C1264638', 'cui_str': 'Catalytic activity'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}]",206.0,0.234069,"After 1 year, there was no significant between-group difference in change in ACT scores (SBA - PBA):","[{'ForeName': 'Kaharu', 'Initials': 'K', 'LastName': 'Sumino', 'Affiliation': 'Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Mo. Electronic address: ksumino@wustl.edu.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Bacharier', 'Affiliation': 'Department of Pediatrics, Washington University School of Medicine, Saint Louis, Mo; Division of Allergy, Immunology and Pulmonary Medicine, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Juanita', 'Initials': 'J', 'LastName': 'Taylor', 'Affiliation': 'Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Kelley', 'Initials': 'K', 'LastName': 'Chadwick-Mansker', 'Affiliation': 'Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Curtis', 'Affiliation': 'Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Nash', 'Affiliation': 'Department of Pediatrics, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Shawni', 'Initials': 'S', 'LastName': 'Jackson-Triggs', 'Affiliation': 'Department of Medicine, Division of Biostatistics, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Moen', 'Affiliation': 'Department of Medicine, Division of Biostatistics, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Kenneth B', 'Initials': 'KB', 'LastName': 'Schechtman', 'Affiliation': 'Department of Medicine, Division of Biostatistics, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Garbutt', 'Affiliation': 'Department of Pediatrics, Washington University School of Medicine, Saint Louis, Mo; Department of Medicine, Division of General Medical Sciences, Washington University School of Medicine, Saint Louis, Mo.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Castro', 'Affiliation': 'Department of Medicine, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Mo.'}]",The journal of allergy and clinical immunology. In practice,['10.1016/j.jaip.2019.06.030'] 1425,31464152,Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.,"Aim: Utilize the Bucher indirect treatment comparison (ITC) method to compare valbenazine and deutetrabenazine efficacy using clinical trial data. Methods: Outcomes included mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes. Data were pooled by trial and dose; outcomes were analyzed at multiple time points. Results: ITC of AIMS score improvement significantly favored valbenazine 80 mg/day at 6 weeks versus deutetrabenazine 36 mg/day at 8 weeks, while valbenazine 40 mg/day was statistically similar to all doses of deutetrabenazine at all time points. No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. Conclusion: In this ITC of pooled trial data, valbenazine was generally favorable over deutetrabenazine, although dose titration and equivalency should be considered when interpreting results.",2019,No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. ,['tardive dyskinesia'],"['valbenazine and deutetrabenazine', 'valbenazine', 'deutetrabenazine']","['Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes', 'AIMS and clinical global impression of change responses and safety outcomes']","[{'cui': 'C3714760', 'cui_str': 'TD - Tardive dyskinesia'}]","[{'cui': 'C4078701', 'cui_str': 'valbenazine'}, {'cui': 'C4277781', 'cui_str': 'deutetrabenazine'}]","[{'cui': 'C0450978', 'cui_str': 'Abnormal Involuntary Movement Scale'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0529868,No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. ,"[{'ForeName': 'Saurabh', 'Initials': 'S', 'LastName': 'Aggarwal', 'Affiliation': 'Novel Health Strategies, Columbia, MD 21044, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Serbin', 'Affiliation': 'Neurocrine Biosciences, Inc., San Diego, CA 92130, USA.'}, {'ForeName': 'Chuck', 'Initials': 'C', 'LastName': 'Yonan', 'Affiliation': 'Neurocrine Biosciences, Inc., San Diego, CA 92130, USA.'}]",Journal of comparative effectiveness research,['10.2217/cer-2019-0059'] 1426,32048205,Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.,"Ocrelizumab is indicated for relapsing remitting and primary progressive multiple sclerosis (RRMS and PPMS, respectively). In an appraisal undertaken by the National Institute for Health and Care Excellence (NICE), the company Roche presented the evidence for ocrelizumab used in patients with PPMS, which came from one single randomised controlled trial (RCT) comparing ocrelizumab versus placebo. Based on results from this trial, the licensed indication was restricted to patients with early PPMS in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. Overall, the Evidence Review Group (ERG) found that the RCT had a low risk of bias. In the post-hoc defined magnetic resonance imaging (MRI) active subgroup, matching the label indication, the risk of confirmed disability progression sustained for 12 weeks (CDP-12) was significantly delayed in the ocrelizumab group compared to placebo. However, considering the same risk with progression sustained for 24 weeks (CDP-24), which was deemed the most clinically relevant, the benefit from ocrelizumab did not reach statistical significance. In the same MRI active subgroup, benefits from ocrelizumab on functional outcomes and on health-related quality of life were not clearly demonstrated. A de novo Markov model was used to estimate the cost-effectiveness of ocrelizumab versus best supportive care (BSC) for treating patients with PPMS. Health states were defined by the Expanded Disability Status Scale (EDSS), ranging from 0 to 9. Disability progression was based on the MSBase natural history cohort that exhibited disease progression in the absence of disease-modifying therapy. Treatment with ocrelizumab delayed disability progression, with evidence of its clinical effectiveness obtained from the RCT. The economic analysis was undertaken from the National Health Service and Personal Social Services perspective, and the outcomes were reported in terms of life years gained and quality-adjusted life years (QALYs), with the overall results reported in terms of an incremental cost-effectiveness ratio (ICER), expressed as cost per QALY gained over a 50-year time horizon. Both costs and effects were discounted at 3.5% per annum. The company undertook deterministic one-way sensitivity analyses and scenario analyses, including probabilistic sensitivity analysis (PSA). The ERG raised several concerns, which were discussed at the appraisal committee meetings, resulting in the committee's preferences being applied and a revised economic analysis from the company. Under an approved patient access scheme with appraisal committee preferences applied, analyses yielded an ICER of approximately £78,300 per QALY. Sensitivity analysis results indicated that the treatment effect on CDP-12 had the greatest impact. Results for the PSA showed that at a willingness-to-pay threshold of £30,000 per QALY gained, ocrelizumab versus BSC had a zero probability of being cost-effective. Following new analyses submitted by the company, with a revised confidential patient access scheme, NICE recommended ocrelizumab in the treatment of early PPMS in adults with imaging features characteristic of inflammatory activity.",2020,"In the same MRI active subgroup, benefits from ocrelizumab on functional outcomes and on health-related quality of life were not clearly demonstrated.","['patients with PPMS', 'Patients with Primary Progressive Multiple Sclerosis']","['Ocrelizumab', 'ocrelizumab versus placebo', 'placebo', 'ocrelizumab versus best supportive care (BSC', 'RCT']","['Disability progression', 'incremental cost-effectiveness ratio (ICER', 'health-related quality of life', 'Expanded Disability Status Scale (EDSS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0751964', 'cui_str': 'Multiple Sclerosis, Primary Progressive'}]","[{'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale (assessment scale)'}]",,0.0482329,"In the same MRI active subgroup, benefits from ocrelizumab on functional outcomes and on health-related quality of life were not clearly demonstrated.","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Auguste', 'Affiliation': 'Warwick Evidence, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK. P.Auguste@warwick.ac.uk.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Colquitt', 'Affiliation': 'Effective Evidence, Coventry, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Connock', 'Affiliation': 'Warwick Evidence, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Loveman', 'Affiliation': 'Effective Evidence, Coventry, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Court', 'Affiliation': 'Warwick Evidence, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Ciccarelli', 'Affiliation': 'University College London (UCL) Queen Square Institute of Neurology, London, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Counsell', 'Affiliation': 'Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Armoiry', 'Affiliation': 'Warwick Evidence, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.'}]",PharmacoEconomics,['10.1007/s40273-020-00889-4'] 1427,32437393,"Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial.","OBJECTIVES Systemic sclerosis (SSc) is an auto-immune, multi organ disease marked by severe gastrointestinal (GI) involvement and gut dysbiosis. Here, we aimed to determine the safety and efficacy of fecal microbiota transplantation (FMT) using commercially-available anaerobic cultivated human intestinal microbiota (ACHIM) in SSc. METHODS Ten patients with SSc were randomized to ACHIM (n = 5) or placebo (n = 5) in a double-blind, placebo-controlled 16-week pilot. All patients had mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence at baseline. Gastroduodenoscopy transfer of ACHIM or placebo was performed at weeks 0 and 2. Primary endpoints were safety and clinical efficacy on GI symptoms assessed at weeks 4 and 16. Secondary endpoints included changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing. RESULTS ACHIM side effects were mild and transient. Two placebo controls experienced procedure-related serious adverse events; one developed laryngospasms at week 0 gastroduodenoscopy necessitating study exclusion whilst one encountered duodenal perforation during gastroduodenoscopy at the last study visit (week 16). Decreased bloating, diarrhea and/or fecal incontinence was observed in four of five patients in the FMT group (week 4 or/and 16) and in two of four in the placebo group (week 4 or 16). Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. CONCLUSIONS FMT of commercially-available ACHIM is associated with gastroduodenoscopy complications but reduces lower GI symptoms by possibly altering the gut microbiota in patients with SSc.",2020,"Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. ","['Ten patients with SSc', 'systemic sclerosis', 'patients with SSc']","['fecal microbiota transplantation (FMT', 'FMT', 'ACHIM or placebo', 'ACHIM', 'Fecal microbiota transplantation', 'placebo']","['safety and clinical efficacy on GI symptoms', 'changes in relative abundance of total, immunoglobulin (Ig) A- and IgM-coated fecal bacteria measured by 16s rRNA sequencing', 'procedure-related serious adverse events', 'mild to severe upper and lower GI symptoms including diarrhea, distention/bloating and/or fecal incontinence', 'Decreased bloating, diarrhea and/or fecal incontinence', 'Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036421', 'cui_str': 'Systemic sclerosis'}]","[{'cui': 'C2242628', 'cui_str': 'Fecal microbiota transplantation'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020835', 'cui_str': 'Immunoglobulin A'}, {'cui': 'C0020861', 'cui_str': 'Immunoglobulin M'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0035701', 'cui_str': 'Ribosomal RNA'}, {'cui': 'C0162801', 'cui_str': 'Analysis, Sequence'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0231241', 'cui_str': 'Fluctuating'}]",10.0,0.365308,"Relative abundance, richness and diversity of total and IgA-coated and IgM-coated bacteria fluctuated more after FMT, than after placebo. ","[{'ForeName': 'Håvard', 'Initials': 'H', 'LastName': 'Fretheim', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Brian K', 'Initials': 'BK', 'LastName': 'Chung', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Didriksen', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Espen S', 'Initials': 'ES', 'LastName': 'Bækkevold', 'Affiliation': 'Department of Pathology and Centre for Immune Regulation, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Midtvedt', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Cathrine', 'Initials': 'C', 'LastName': 'Brunborg', 'Affiliation': 'Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Holm', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Valeur', 'Affiliation': 'Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway.'}, {'ForeName': 'Anders Heiervang', 'Initials': 'AH', 'LastName': 'Tennøe', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Torhild', 'Initials': 'T', 'LastName': 'Garen', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Tore', 'Initials': 'T', 'LastName': 'Midtvedt', 'Affiliation': 'Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Trøseid', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Hasse', 'Initials': 'H', 'LastName': 'Zarè', 'Affiliation': 'Clinical Trial Unit, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'May Brit', 'Initials': 'MB', 'LastName': 'Lund', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Johannes R', 'Initials': 'JR', 'LastName': 'Hov', 'Affiliation': 'Institute of Clinical Medicine, University of Oslo, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Knut E A', 'Initials': 'KEA', 'LastName': 'Lundin', 'Affiliation': 'Department of Gastroenterology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Molberg', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Hoffmann-Vold', 'Affiliation': 'Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}]",PloS one,['10.1371/journal.pone.0232739'] 1428,31356125,Associations between driving under the influence or riding with an impaired driver and future substance use among adolescents.,"Objective: Risky driving behaviors among adolescents, such as riding with a drinking or impaired driver (RWID) or driving while under the influence (DUI) of alcohol or drugs, are significant public health concerns. Few studies have examined associations of RWID and DUI with future substance use and problems after controlling for baseline substance use. Given that the DUI/RWDD event may be a teachable moment to prevent future consequences (e.g., when injured or arrested), it is important to understand how this risk behavior relates to subsequent use and problems. This study therefore examined characteristics of adolescents who reported DUI and RWID and assessed their risk of future alcohol and marijuana use and consequences 6 months later. Methods: Participants were 668 adolescents aged 12 to 18 (inclusive) recruited at 1 of 4 primary care clinics in Pittsburgh and Los Angeles as part of a larger randomized controlled trial. They completed surveys about their health behaviors at baseline and 6 months after baseline. We examined baseline characteristics of adolescents who reported DUI and RWID and then assessed whether past-year DUI and RWID at baseline were associated with alcohol and marijuana use and consequences 6 months after baseline. Results: Fifty-eight percent of participants were female, 56% were Hispanic, 23% were Black, 14% were White, 7% were multiethnic or other, and the average age was 16 years (SD = 1.9). At baseline, participants who reported RWID or DUI were more likely to be older, report past-year use of alcohol and marijuana, and more likely to have an alcohol use disorder or cannabis use disorder versus those who did not report RWID or DUI, respectively. At 6-month follow-up and after controlling for baseline demographics and baseline alcohol use, RWID was associated with more frequent drinking episodes in the past 3 months and greater number of drinks in the past month when they drank heavily. DUI at baseline was associated with more frequent heavy drinking episodes and alcohol and marijuana consequences 6 months later. Conclusions: RWID and DUI are significantly associated with greater alcohol and marijuana use over time. This study highlights that teens may be at higher risk for problem substance use in the future even if they ride with someone who is impaired. Prevention and intervention efforts for adolescents need to address both driving under the influence and riding with an impaired driver to prevent downstream consequences.",2019,DUI at baseline was associated with more frequent heavy drinking episodes and alcohol and marijuana consequences 6 months later. ,"['Fifty-eight percent of participants were female, 56% were Hispanic, 23% were Black, 14% were White, 7% were multiethnic or other, and the average age was 16 years (SD\u2009=\u20091.9', 'adolescents', 'adolescents, such as riding with a drinking or impaired driver (RWID) or driving while under the influence (DUI) of alcohol or drugs', 'Participants were 668 adolescents aged 12 to 18 (inclusive) recruited at 1 of 4 primary care clinics in Pittsburgh and Los Angeles as part of a larger randomized controlled trial']",[],[],"[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0439165', 'cui_str': 'Percent (property) (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517517', 'cui_str': '1.9 (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0684271', 'cui_str': 'Drinkings'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0001975', 'cui_str': 'Alcohols'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],[],668.0,0.0393686,DUI at baseline was associated with more frequent heavy drinking episodes and alcohol and marijuana consequences 6 months later. ,"[{'ForeName': 'Karen Chan', 'Initials': 'KC', 'LastName': 'Osilla', 'Affiliation': 'a RAND Corporation , Santa Monica , California.'}, {'ForeName': 'Rachana', 'Initials': 'R', 'LastName': 'Seelam', 'Affiliation': 'a RAND Corporation , Santa Monica , California.'}, {'ForeName': 'Layla', 'Initials': 'L', 'LastName': 'Parast', 'Affiliation': 'a RAND Corporation , Santa Monica , California.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': ""D'Amico"", 'Affiliation': 'a RAND Corporation , Santa Monica , California.'}]",Traffic injury prevention,['10.1080/15389588.2019.1615620'] 1429,31439215,Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.,"BACKGROUND Addition of ezetimibe to statin therapy reduces the risk of recurrent cardiovascular (CV) events in patients with prior acute coronary syndrome (ACS). The role of biomarkers in identifying subsets of patients who may derive greater clinical benefit with ezetimibe is unknown. OBJECTIVES This study sought to evaluate the role of established CV biomarkers in assessing likely benefit with ezetimibe added to statin therapy in post-ACS patients. METHODS In a pre-specified nested analysis within a randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROVE-IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, growth-differentiation factor-15, and high-sensitivity C-reactive protein was measured in 7,195 patients stabilized (1 month post-randomization) after ACS. A multimarker approach based on biomarker values was used to examine the risk of recurrent CV events and clinical benefit with ezetimibe. RESULTS Elevated levels of each biomarker were independently associated with higher risks of CV death/myocardial infarction/stroke and CV death/heart failure (p trend  < 0.001 for each). There was a pattern of greater absolute risk reduction in CV death/myocardial infarction/stroke with the addition of ezetimibe to statin therapy in patients at higher risk on the basis of biomarker levels. High-risk patients (≥3 biomarkers ""positive""; n = 1,437) had an absolute risk difference of -7.3% (95% confidence interval: -13.8% to -0.8%; p = 0.02) with ezetimibe, and intermediate-risk patients (1 to 2 biomarkers positive; n = 3,842) had an absolute risk difference of -4.4% (95% confidence interval: -9.7% to 0.8%), translating into numbers needed to treat at 7 years of 14 and 23, respectively. Low-risk patients (0 biomarkers positive; n = 1,916) did not appear to benefit from the addition of ezetimibe to statin therapy. CONCLUSIONS A biomarker-based strategy identifies a gradient of risk among patients post-ACS, offering the potential to identify higher-risk patients with a correspondingly high absolute benefit from the addition of ezetimibe to statin therapy.",2019,"RESULTS Elevated levels of each biomarker were independently associated with higher risks of CV death/myocardial infarction/stroke and CV death/heart failure (p trend  < 0.001 for each).","['post-ACS patients', 'Low-risk patients (0 biomarkers positive; n\xa0=\xa01,916', 'patients with prior acute coronary syndrome (ACS', '7,195 patients stabilized (1\xa0month post-randomization) after ACS']","['ezetimibe', 'ezetimibe to statin therapy', 'ezetimibe/simvastatin versus placebo/simvastatin', 'statin therapy', 'Ezetimibe']","['risks of CV death/myocardial infarction/stroke and CV death/heart failure', 'CV death/myocardial infarction/stroke', 'risk of recurrent cardiovascular (CV) events']","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}, {'cui': 'C0184512', 'cui_str': 'Stabilized (qualifier value)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}, {'cui': 'C1532737', 'cui_str': 'ezetimibe / Simvastatin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.295763,"RESULTS Elevated levels of each biomarker were independently associated with higher risks of CV death/myocardial infarction/stroke and CV death/heart failure (p trend  < 0.001 for each).","[{'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Qamar', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/AqamarMD.""}, {'ForeName': 'Robert P', 'Initials': 'RP', 'LastName': 'Giugliano', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/rgiugliano.""}, {'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'Bohula', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Jeong-Gun', 'Initials': 'JG', 'LastName': 'Park', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Jarolim', 'Affiliation': ""Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Sabina A', 'Initials': 'SA', 'LastName': 'Murphy', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Blazing', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Califf', 'Affiliation': 'Duke Forge, Duke University School of Medicine, Durham, North Carolina; Verily Life Sciences (Alphabet), South San Francisco, California; Department of Medicine, Stanford University, Stanford, California. Electronic address: https://twitter.com/califf001.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Cannon', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Braunwald', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Morrow', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: dmorrow@bwh.harvard.edu.""}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.06.038'] 1430,31377534,Randomized controlled trial of the Child Protection Unit: Grade and gender as moderators of CSA prevention concepts in elementary students.,"BACKGROUND Despite the importance of child sexual abuse (CSA) prevention, there are few recent randomized controlled trials of school-based CSA prevention programs. OBJECTIVES (1) To evaluate the effects of the Second Step Child Protection Unit (CPU) on students' CSA prevention concept knowledge, ability to recognize, report, and refuse unsafe touches, and perceptions of teacher-student relations and (2) investigate the moderating role of age and gender on program effectiveness. PARTICIPANTS AND SETTING Eight elementary schools in a large suburban school district in the northeast United States were randomly assigned to the intervention or control condition, with analyses conducted on a total of 2172 students. METHODS Students in intervention schools received the 6-week CPU and those in the control schools were exposed to business as usual. Students were administered assessments at baseline and then at post-test. RESULTS Univariate Analyses of Covariance revealed that students in the intervention schools had significantly higher scores on all outcomes than students in the control schools at post-test, even after controlling for baseline scores. Children in younger grades made greater gains from the program, and girls scored higher than boys in CSA knowledge and ability to recognize, refuse, and report unsafe touches, but both boys and girls made significant gains. CONCLUSIONS Results support the importance of beginning early with school-based CSA prevention efforts. Although boys are still at a relative disadvantage in terms of their knowledge and ability in this area, they are able to make gains at the same rate as girls.",2019,"RESULTS Univariate Analyses of Covariance revealed that students in the intervention schools had significantly higher scores on all outcomes than students in the control schools at post-test, even after controlling for baseline scores.","['Eight elementary schools in a large suburban school district in the northeast United States were randomly assigned to the intervention or control condition, with analyses conducted on a total of 2172 students', 'elementary students', 'Students in intervention schools received the 6-week', 'child sexual abuse (CSA) prevention']","['CPU', 'Second Step Child Protection Unit (CPU']",[],"[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0008062', 'cui_str': 'Molestation, Sexual, Child'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0337542', 'cui_str': 'Stepchild (person)'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}]",[],,0.0238781,"RESULTS Univariate Analyses of Covariance revealed that students in the intervention schools had significantly higher scores on all outcomes than students in the control schools at post-test, even after controlling for baseline scores.","[{'ForeName': 'Amanda B', 'Initials': 'AB', 'LastName': 'Nickerson', 'Affiliation': 'University at Buffalo, State University of New York, United States. Electronic address: nickersa@buffalo.edu.'}, {'ForeName': 'Jenine', 'Initials': 'J', 'LastName': 'Tulledge', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Manges', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Kesselring', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Parks', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Livingston', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Dudley', 'Affiliation': 'University at Buffalo, State University of New York, United States.'}]",Child abuse & neglect,['10.1016/j.chiabu.2019.104101'] 1431,31444252,FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.,"On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (CALASP), an asparagine-specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years. Efficacy was determined on the basis of achievement and maintenance of steady-state nadir serum asparaginase activity (NSAA) above 0.1 U/mL when using CALASP, 2,500 U/m 2 intravenously, every 3 weeks. In a randomized comparison to pegaspargase (PEGASP) every 2 weeks, treatment with CALASP every 3 weeks had a similar safety profile and no substantial impairment in event-free survival. The pharmacokinetics of CALASP were studied when administered in combination with multiagent chemotherapy in 124 patients with B-cell ALL in Study AALL07P4 and Study DFCI 11-001. The results showed that 123 [99%, 95% confidence interval (CI), 96%-100%] of the 124 patients maintained NSAA >0.1 U/mL at weeks 6, 12, 18, 24, and 30 of post-induction phase. Maintaining adequate NSAA levels is critical to successful treatment of ALL. Herein, we describe the FDA review and approval of CALASP. See related commentary by Lew, p. 325 .",2020,"The results showed that 123 (99%, 95% confidence interval (CI): 96%-100%) of the 124 patients maintained NSAA > 0.1 U/mL at weeks 6, 12, 18, 24 and 30 of post-induction phase.","['124 patients with B-cell ALL in Study AALL07P4 and Study DFCI 11-001', 'acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years', 'Acute Lymphoblastic Leukemia in Children and Young Adults']","['multiagent chemotherapy', 'CALASP', ' Calaspargase Pegol-mknl', 'pegaspargase (PEGASP']","['Efficacy', 'achievement and maintenance of steady-state nadir serum asparaginase activity (NSAA']","[{'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0004561', 'cui_str': 'B-Cells'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1961102', 'cui_str': 'Lymphocytic Leukemia, Acute'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C2699709', 'cui_str': 'calaspargase pegol'}, {'cui': 'C0071568', 'cui_str': 'pegaspargase'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}]",124.0,0.0357791,"The results showed that 123 (99%, 95% confidence interval (CI): 96%-100%) of the 124 patients maintained NSAA > 0.1 U/mL at weeks 6, 12, 18, 24 and 30 of post-induction phase.","[{'ForeName': 'Ruo-Jing', 'Initials': 'RJ', 'LastName': 'Li', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. ruojing.li@fda.hhs.gov.'}, {'ForeName': 'Runyan', 'Initials': 'R', 'LastName': 'Jin', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Xianhua', 'Initials': 'X', 'LastName': 'Cao', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Manning', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Xu Michael', 'Initials': 'XM', 'LastName': 'Di', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Przepiorka', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Namuswe', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Deisseroth', 'Affiliation': 'Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Kirsten B', 'Initials': 'KB', 'LastName': 'Goldberg', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Gideon M', 'Initials': 'GM', 'LastName': 'Blumenthal', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Pazdur', 'Affiliation': 'Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-1255'] 1432,31434552,Development and Assessment of a Social Network Service-Based Lifestyle-Modification Program for Workers at High Risk of Developing Cardiovascular Disease.,"Cardiovascular disease is a leading cause of mortality in the United States. This study examined the cardiovascular disease risk factors and health beliefs of workers for the purpose of developing a social network service (SNS)-based (e.g., Facebook and KakaoTalk) lifestyle-modification program for workers. Participants included 68 hospital workers (aged 25-60 years), with more than two metabolic syndrome or cardiovascular disease risk factors. Participants were randomly assigned to one of three groups: SNS intervention group ( n = 23), education-only intervention group ( n = 19), or nonintervention group ( n = 26). Data were collected to compare changes in risk indicators according to the intervention method and time and analyzed using repeated-measures analyses of variance. Compared to the education and nonintervention groups, the SNS intervention group demonstrated significant improvements in waist circumference, body mass index, total cholesterol, low-density lipoprotein cholesterol, health promotion behaviors, and self-efficacy. This type of program has potential for allowing occupational health professionals to work with workers to improve lifestyle behaviors that promote health and reduce the risk of cardiovascular disease.",2020,"Compared to the education and nonintervention groups, the SNS intervention group demonstrated significant improvements in waist circumference, body mass index, total cholesterol, low-density lipoprotein cholesterol, health promotion behaviors, and self-efficacy.","['workers', 'Participants included 68 hospital workers (aged 25-60 years), with more than two metabolic syndrome or cardiovascular disease risk factors', 'Workers at High Risk of Developing Cardiovascular Disease']","['Social Network Service-Based Lifestyle-Modification Program', 'SNS intervention group ( n = 23), education-only intervention group', 'social network service (SNS)-based (e.g., Facebook and KakaoTalk) lifestyle-modification program', 'SNS intervention']","['waist circumference, body mass index, total cholesterol, low-density lipoprotein cholesterol, health promotion behaviors, and self-efficacy']","[{'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}]","[{'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0517496', 'cui_str': 'Health promotion behavior'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",68.0,0.0239888,"Compared to the education and nonintervention groups, the SNS intervention group demonstrated significant improvements in waist circumference, body mass index, total cholesterol, low-density lipoprotein cholesterol, health promotion behaviors, and self-efficacy.","[{'ForeName': 'Soo Hee', 'Initials': 'SH', 'LastName': 'Woo', 'Affiliation': ""Department of Nursing, Kyung-In Women's University.""}, {'ForeName': 'Eui Geum', 'Initials': 'EG', 'LastName': 'Oh', 'Affiliation': 'College of Nursing Mo-Im Kim Nursing Research Institute, Yonsei University.'}, {'ForeName': 'Kyung-Soo', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': ""Department of Family Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University.""}, {'ForeName': 'Sang Hui', 'Initials': 'SH', 'LastName': 'Chu', 'Affiliation': 'College of Nursing Mo-Im Kim Nursing Research Institute, Yonsei University.'}, {'ForeName': 'Gwang Suk', 'Initials': 'GS', 'LastName': 'Kim', 'Affiliation': 'College of Nursing Mo-Im Kim Nursing Research Institute, Yonsei University.'}, {'ForeName': 'Chung Mo', 'Initials': 'CM', 'LastName': 'Nam', 'Affiliation': 'Department of Preventive Medicine, College of Medicine, Yonsei University Seoul.'}]",Workplace health & safety,['10.1177/2165079919864976'] 1433,31402638,Premature and preterm premature rupture of membranes in adolescent compared to adult pregnancy.,"Aim To compare the prevalence of premature rupture of membranes (PROM) and preterm premature rupture of membranes (PPROM) between adolescent and adult pregnancies, and the influence of gestational age and adolescent pregnancy on the frequency of occurrence of PROM and PPROM. Methods This prospective study included 300 pregnant patients, 13 to 35 years of age, divided into two groups. The first group consisted of 150 pregnant women aged 13-19 (experimental group) and the second group consisted of 150 pregnant women aged 20-35 (control group). Results There was a statistically significant higher incidence of both PPROM and PROM in the group of adolescent pregnant women compared to adult pregnant women (p<0.000001). Preterm delivery with PPROM was significantly more common in the group of adolescent pregnant women (p<0.004). Term delivery with PROM was statistically significantly more common in the adolescent pregnancy group than in the adult pregnancy group (p<0.001). Term delivery with PROM was statistically significantly more common than preterm delivery with PPROM in the group of adolescent pregnant women (p<0.0001). Conclusion Adolescent pregnancy has a greater impact on the frequency of PROM and PPROM.",2020,Preterm delivery with PPROM was significantly more common in the group of adolescent pregnant women (p<0.004).,"['150 pregnant women aged 13-19 (experimental group) and the second group consisted of 150 pregnant women aged 20-35 (control group', '300 pregnant patients, 13 to 35 years of age, divided into two groups', 'adolescent and adult pregnancies']",[],"['frequency of PROM and PPROM', 'Preterm delivery with PPROM', 'Term delivery with PROM', 'PPROM and PROM']","[{'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}]",[],"[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0015944', 'cui_str': 'Premature Rupture of Membrane (Pregnancy)'}, {'cui': 'C0729264', 'cui_str': 'PPROM'}, {'cui': 'C0151526', 'cui_str': 'Premature Birth'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}]",300.0,0.0438153,Preterm delivery with PPROM was significantly more common in the group of adolescent pregnant women (p<0.004).,"[{'ForeName': 'Sergije', 'Initials': 'S', 'LastName': 'Marković', 'Affiliation': 'Department of Histology and Embryology, School of Medicine, University of Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Gordana', 'Initials': 'G', 'LastName': 'Bogdanović', 'Affiliation': 'Clinic for Gynaecology and Obstetrics, University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina.'}, {'ForeName': 'Anis', 'Initials': 'A', 'LastName': 'Cerovac', 'Affiliation': 'Department of Gynaecology and Obstetrics, General Hospital Tešanj, Tešanj, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1052-20'] 1434,31327131,Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.,"OBJECTIVES Management options for PCOS, as the most prevalent endocrine disorder in women of reproductive age, using natural supplements have a high priority for physicians, especially based on the etiological pathways. Therefore, this study was conducted to describe the effect of resveratrol on the angiogenesis pathway, for management of PCOS through assessing VEGF, HIF1 gene expression, and laboratory parameters. METHODS In this triple-blind RCT, PCOS was confirmed in ICSI candidates based on the Rotterdam criteria. Sixty-two patients that met the inclusion criteria were randomly assigned to two groups. All patients took resveratrol 800 mg/day or placebo for 40 days orally from the beginning of their previous menstruation cycle until the oocyte retrieval day. The serum levels of different hormones were measured, and the expression of HIF1 & VEGF genes was quantified by real-time PCR. RESULTS As for the laboratory hormone assay in 61 PCOS patients, a significant mean difference was seen in the FSH, LH, TSH, and testosterone between the two groups (P < 0.05). The results showed a reduction in the expression of VEGF & HIF1 genes under the effect of resveratrol in the granulosa cells (P = 0.0001). The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05). CONCLUSIONS Based on the results, resveratrol may improve some outcomes of PCOS patients, probably through changing the serum levels of some sex hormones and expression of VEGF & HIF1 genes in the angiogenesis pathway of granulosa cells.",2019,"The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05). ","['61 PCOS patients', 'Sixty-two patients that met the inclusion criteria', 'polycystic ovary syndrome']",['placebo'],"['number of mature oocytes, cleavage rate, fertilization rate, and fertility rate', 'expression of VEGF & HIF1 genes', 'FSH, LH, TSH, and testosterone', 'high-quality oocyte rate and high-quality embryo rate', 'serum levels of different hormones', 'expression of HIF1 & VEGF genes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517835', 'cui_str': '62 (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0205286', 'cui_str': 'Mature (qualifier value)'}, {'cui': 'C0029045', 'cui_str': 'Ovocytes'}, {'cui': 'C0015914', 'cui_str': 'Fertilization'}, {'cui': 'C0015912', 'cui_str': 'Fertility Rate'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0733758', 'cui_str': 'Follicle Stimulating Hormone'}, {'cui': 'C0202230', 'cui_str': 'Thyroid stimulating hormone measurement (procedure)'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0013935', 'cui_str': 'Embryo'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0019932', 'cui_str': 'Hormones'}]",61.0,0.197923,"The number of mature oocytes, cleavage rate, fertilization rate, and fertility rate were not significantly different between the two groups (P > 0.05), but the high-quality oocyte rate and high-quality embryo rate were higher in the resveratrol group (P < 0.05). ","[{'ForeName': 'Mojdeh', 'Initials': 'M', 'LastName': 'Bahramrezaie', 'Affiliation': 'Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fardin', 'Initials': 'F', 'LastName': 'Amidi', 'Affiliation': 'Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. famidi@sina.tums.ac.ir.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Aleyasin', 'Affiliation': 'Faculty of Medicine, Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'AboTaleb', 'Initials': 'A', 'LastName': 'Saremi', 'Affiliation': ""Sarem Fertility and Infertility Research Center (SAFIR), Sarem Cell Research Center (SCRC), Sarem Women's Hospital, Tehran, Iran.""}, {'ForeName': 'Marzieh', 'Initials': 'M', 'LastName': 'Aghahoseini', 'Affiliation': 'Faculty of Medicine, Department of Infertility, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Samaneh', 'Initials': 'S', 'LastName': 'Brenjian', 'Affiliation': 'Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mahshad', 'Initials': 'M', 'LastName': 'Khodarahmian', 'Affiliation': 'Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Pooladi', 'Affiliation': 'Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.'}]",Journal of assisted reproduction and genetics,['10.1007/s10815-019-01461-6'] 1435,31433997,Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1).,"In patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa) results in disease progression, frequent pulmonary exacerbations and lung function decline. However, at present, no inhaled antibiotics have been approved for the treatment of these patients. Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate. We aimed to assess effective and well-tolerated doses and regimens of TIP in BE patients with Pa infection. In this phase II, double-blind, placebo-controlled, randomised study, three different daily doses of TIP are administered either as continuous or cyclical regimens. The study protocol comprises 7-28 days of screening, 112 days of double-blind treatment and 56 days of follow-up. The plan was to enrol 180 patients (aged ≥18 years) with BE, documented Pa infection and a history of exacerbations. The primary outcome is change in sputum Pa density from baseline. Key secondary outcomes include number of pulmonary exacerbations, use of antipseudomonal antibiotics, serum and sputum tobramycin concentrations, quality of life and safety. Exploratory endpoints include lung clearance index, sputum inflammatory markers and microbiome analysis. As of October 2018, 107/180 patients were enrolled at 34 sites (six countries) following which recruitment was closed for administrative reasons unrelated to safety findings. Despite a reduced sample size from initially planned enrolment, the unique design may inform the benefit-risk profile of TIP in BE patients with chronic Pa infection. Moreover, several novel and exploratory endpoints (lung clearance index, inflammatory biomarkers, lung microbiome), will contribute to the advancement of research in this area.",2019,"Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate.","['180 patients (aged ≥18 years) with BE, documented Pa infection and a history of exacerbations', 'BE patients with chronic Pa infection', '107/180 patients were enrolled at 34 sites (six countries) following which recruitment was closed for administrative reasons unrelated to safety findings', 'bronchiectasis patients with P. aeruginosa infection', 'BE patients with Pa infection', 'patients with bronchiectasis (BE), infection with Pseudomonas aeruginosa (Pa']","['placebo', 'tobramycin inhalation powder', 'Tobramycin inhalation powder (TIP', 'TIP']","['lung clearance index, sputum inflammatory markers and microbiome analysis', 'number of pulmonary exacerbations, use of antipseudomonal antibiotics, serum and sputum tobramycin concentrations, quality of life and safety', 'several novel and exploratory endpoints (lung clearance index, inflammatory biomarkers, lung microbiome', 'change in sputum Pa density', 'Efficacy and safety']","[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0262926', 'cui_str': 'History of (contextual qualifier) (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0587267', 'cui_str': 'Closed (qualifier value)'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0445356', 'cui_str': 'Unrelated (finding)'}, {'cui': 'C0581560', 'cui_str': 'Safety finding'}, {'cui': 'C0006267', 'cui_str': 'Bronchiectasis'}, {'cui': 'C0033808', 'cui_str': 'Flavimonas'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}]","[{'cui': 'C0231990', 'cui_str': 'Lung clearance index (observable entity)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0034380'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}]",180.0,0.14046,"Tobramycin inhalation powder (TIP), approved for treatment of Pa infection in cystic fibrosis, could be a promising candidate.","[{'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Loebinger', 'Affiliation': 'Host Defence Unit, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; Imperial College London, London, United Kingdom. Electronic address: M.Loebinger@rbht.nhs.uk.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Polverino', 'Affiliation': ""Respiratory Disease Department, Vall d' Hebron University Hospital - VHIR, CIBER, Barcelona, Spain.""}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Blasi', 'Affiliation': 'Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Elborn', 'Affiliation': ""Halo Research Group, Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom; Imperial College and Royal Brompton Hospital and Harefield NHS Foundation Trust, London, United Kingdom.""}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Chalmers', 'Affiliation': 'Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom.'}, {'ForeName': 'Harm Awm', 'Initials': 'HA', 'LastName': 'Tiddens', 'Affiliation': ""Department of Paediatric Pulmonology and Allergology, Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Sophia Children's Hospital, Rotterdam, the Netherlands.""}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Goossens', 'Affiliation': 'Department of Clinical Microbiology, University Hospital Antwerp, Antwerp, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Tunney', 'Affiliation': ""Halo Research Group, School of Pharmacy, Queen's University Belfast, Belfast, United Kingdom.""}, {'ForeName': 'Wenchun', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Novartis Pharma, AG, Basel, Switzerland.'}, {'ForeName': 'Gerhild', 'Initials': 'G', 'LastName': 'Angyalosi', 'Affiliation': 'Novartis Pharma, AG, Basel, Switzerland.'}, {'ForeName': 'Adam T', 'Initials': 'AT', 'LastName': 'Hill', 'Affiliation': 'Respiratory Medicine, Royal Infirmary of Edinburgh, and University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Charles S', 'Initials': 'CS', 'LastName': 'Haworth', 'Affiliation': 'Cambridge Centre for Lung Infection, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pulmonary pharmacology & therapeutics,['10.1016/j.pupt.2019.101834'] 1436,31444861,"Efficacy and safety of a new resilient hyaluronic acid dermal filler, in the correction of moderate-to-severe nasolabial folds: A 64-week, prospective, multicenter, controlled, randomized, double-blind and within-subject study.","BACKGROUND Injectables that behave similarly to native tissue and preserve facial expressiveness represent a new frontier in aesthetic medicine. A range of fillers made of high molecular weight hyaluronic acid (HA) chains with low crosslinking have been specifically developed to complement facial dynamics. AIMS The efficacy and safety of one of these resilient HA fillers, and its noninferiority to an effective comparator available in the US, were tested in the treatment of dynamic wrinkles. METHODS A 15-month, prospective, multicenter, controlled, randomized, double-blind, within-subject (split-face) clinical trial was conducted on 140 subjects with moderate-to-severe nasolabial folds (NLF). Study endpoints included improvement on a proprietary Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale, according to Blind Live Evaluators (BLE), subjects, and treating investigators (TI). Subject perception was evaluated with FACE-Q and satisfaction scales. RESULTS The per-protocol population included 88 subjects (92% women) of all Fitzpatrick phototypes, with a mean age of 57 years. WSRS improvement was significantly greater with the resilient HA than its comparator over 15 months, including at week 24 (primary endpoint), as rated by BLE and TI. Results demonstrated the noninferiority of the resilient HA filler to its comparator. Aesthetic improvement and subject satisfaction were durably high, with an overall trend toward higher scores for the resilient HA filler. Both treatments were safe and well tolerated. CONCLUSION The resilient HA filler made of long chains lightly crosslinked is at least equivalent to a well-established comparator for the correction of NLF in subjects of diverse skin phototypes.",2019,"Study endpoints included improvement on a proprietary Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale, according to Blind Live Evaluators (BLE), subjects, and treating investigators (TI).","['88 subjects (92% women) of all Fitzpatrick phototypes, with a mean age of 57\xa0years', 'moderate-to-severe nasolabial folds', '140 subjects with moderate-to-severe nasolabial folds (NLF']",['new resilient hyaluronic acid dermal filler'],"['proprietary Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale, according to Blind Live Evaluators (BLE), subjects, and treating investigators (TI', 'WSRS improvement', 'safe and well tolerated', 'Efficacy and safety', 'efficacy and safety', 'Aesthetic improvement and subject satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0221328', 'cui_str': 'Nasolabial Fold'}, {'cui': 'C4319553', 'cui_str': '140 (qualifier value)'}]","[{'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1141990', 'cui_str': 'Hyaluronic acid'}, {'cui': 'C4042850', 'cui_str': 'Skin Fillers'}]","[{'cui': 'C0037301', 'cui_str': 'Skin Wrinkling'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0014901', 'cui_str': 'Esthetics'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",88.0,0.104576,"Study endpoints included improvement on a proprietary Wrinkle Severity Rating Scale (WSRS) and Global Aesthetic Improvement Scale, according to Blind Live Evaluators (BLE), subjects, and treating investigators (TI).","[{'ForeName': 'Joely', 'Initials': 'J', 'LastName': 'Kaufman-Janette', 'Affiliation': 'Skin Research Institute, Coral Gables, FL, USA.'}, {'ForeName': 'Susan C', 'Initials': 'SC', 'LastName': 'Taylor', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Sue Ellen', 'Initials': 'SE', 'LastName': 'Cox', 'Affiliation': 'Aesthetic Solutions P.A., Chapel Hill, NC, USA.'}, {'ForeName': 'Susan H', 'Initials': 'SH', 'LastName': 'Weinkle', 'Affiliation': 'Bay Area Medical Complex, Bradenton, FL, USA.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'California Dermatology & Clinical Research Institute, Encinitas, CA, USA.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Kinney', 'Affiliation': 'Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13100'] 1437,32080218,Effectiveness of the GumChucks flossing system compared to string floss for interdental plaque removal in children: a randomized clinical trial.,"Flossing, an important oral hygiene skill, is technique-sensitive and challenging for children with developing manual dexterity. GumChucks is a novel flossing device designed to assist children with proper flossing technique. The aim of this study was to assess the efficacy of the GumChucks flossing device compared to string floss (SF). We conducted a randomized trial with 40 children aged 4-15 years at the UCLA Children's Dental Center from January- April 2017. Participants were randomly assigned to either GumChucks or SF. Interdental plaque score (IPS) and gingival index (GI) were recorded at baseline and 4-week post-usage. Flossing speed and interdental plaque reduction were also determined immediately after first use. In addition, questionnaires were completed by children, parents and dentists. Overall, children flossed significantly faster (p < 0.001) and achieved greater IPS reduction after first use (47.0% vs. 26.8%) with GumChucks compared to SF. After 4-week post-usage, children ages 10-15 in the GumChucks group demonstrated significantly greater improvement in GI and IPS from baseline (p < 0.01) and greater efficacy in interdental plaque removal compared to the SF group (p < 0.01). Children ages 4-9 flossed more effectively (p < 0.01) with GumChucks after first use, but no significant IPS and GI improvement after 4-week post-usage. Children preferred GumChucks (92.5%) over SF, with a similar positive attitude reported by parents and dentists. GumChucks is an effective alternative interdental plaque removal aid that allows children to floss with greater speed and efficacy, with recommended parental supervision for children under age 10.",2020,"Children ages 4-9 flossed more effectively (p < 0.01) with GumChucks after first use, but no significant IPS and GI improvement after 4-week post-usage.","['children under age 10', ""40 children aged 4-15 years at the UCLA Children's Dental Center from January- April 2017"", 'children with developing manual dexterity', 'children']","['string floss', 'GumChucks flossing system', 'GumChucks flossing device', 'string floss (SF', 'GumChucks or SF']","['IPS reduction', 'Interdental plaque score (IPS) and gingival index (GI', 'GI and IPS', 'efficacy in interdental plaque removal', 'IPS and GI improvement', 'Flossing speed and interdental plaque reduction']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4522313', 'cui_str': 'Dental (intended site)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities (observable entity)'}]","[{'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C3540771', 'cui_str': 'String'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0442104', 'cui_str': 'Interdental (qualifier value)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0017569', 'cui_str': 'Gingival Index'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",40.0,0.035326,"Children ages 4-9 flossed more effectively (p < 0.01) with GumChucks after first use, but no significant IPS and GI improvement after 4-week post-usage.","[{'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Lin', 'Affiliation': 'University of California, Los Angeles School of Dentistry | Section of Pediatric Dentistry, California, USA.'}, {'ForeName': 'Márcia', 'Initials': 'M', 'LastName': 'Dinis', 'Affiliation': 'University of California, Los Angeles School of Dentistry | Section of Pediatric Dentistry, California, USA.'}, {'ForeName': 'Chi-Hong', 'Initials': 'CH', 'LastName': 'Tseng', 'Affiliation': 'University of California, Los Angeles | Department of Medicine, Statistics Core, California, USA.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Agnello', 'Affiliation': 'University of California, Los Angeles School of Dentistry | Section of Oral Biology, California, USA.'}, {'ForeName': 'Xuesong', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'The Forsyth Institute| Microbiology, Cambridge, USA.'}, {'ForeName': 'Daniela R', 'Initials': 'DR', 'LastName': 'Silva', 'Affiliation': 'University of California, Los Angeles School of Dentistry | Section of Pediatric Dentistry, California, USA.'}, {'ForeName': 'Nini C', 'Initials': 'NC', 'LastName': 'Tran', 'Affiliation': 'University of California, Los Angeles School of Dentistry | Section of Pediatric Dentistry, California, USA. ninic@dentistry.ucla.edu.'}]",Scientific reports,['10.1038/s41598-020-59705-w'] 1438,31325288,"A Smart and Multifaceted Mobile Health System for Delivering Evidence-Based Secondary Prevention of Stroke in Rural China: Design, Development, and Feasibility Study.","BACKGROUND Mobile health (mHealth) technologies hold great promise in improving the delivery of high-quality health care services. Yet, there has been little research so far applying mHealth technologies in the context of delivering stroke care in resource-limited rural regions. OBJECTIVE This study aimed to introduce the design and development of an mHealth system targeting primary health care providers and to ascertain its feasibility in supporting the delivery of a System-Integrated techNology-Enabled Model of cAre (SINEMA) service for strengthening secondary prevention of stroke in rural China. METHODS The SINEMA mHealth system was designed by a multidisciplinary team comprising public health researchers, neurologists, and information and communication technology experts. The iterative co-design and development of the mHealth system involved the following 5 steps: (1) assessing the needs of relevant end users through in-depth interviews of stakeholders, (2) designing the functional modules and evidence-based care content, (3) designing and building the system and user interface, (4) improving and enhancing the system through a 3-month pilot test in 4 villages, and (5) finalizing the system and deploying it in field trial, and finally, evaluating its feasibility through a survey of the dominant user group. RESULTS From the in-depth interviews of 49 relevant stakeholders, we found that village doctors had limited capacity in caring for village-dwelling stroke patients in rural areas. Primary health care workers demonstrated real needs in receiving appropriate training and support from the mHealth system as well as great interests in using the mHealth technologies and tools. Using these findings, we designed a multifaceted mHealth system with 7 functional modules by following the iterative user-centered design and software development approach. The mHealth system, aimed at 3 different types of users (village doctors, town physicians, and county managers), was developed and utilized in a cluster-randomized controlled trial by 25 village doctors in a resource-limited county in rural China to manage 637 stroke patients between July 2017 and July 2018. In the end, a survey on the usability and functions of the mHealth system among village doctors (the dominant group of users, response rate=96%, 24/25) revealed that most of them were satisfied with the essential functions provided (71%) and were keen to continue using it (92%) after the study. CONCLUSIONS The mHealth system was feasible for assisting primary health care providers in rural China in delivering the SINEMA service on the secondary prevention of stroke. Further research and initiatives in scaling up the SINEMA approach and this mHealth system to other resource-limited regions in China and beyond will likely enhance the quality and accessibility of essential secondary prevention among stroke patients. CLINICALTRIAL ClinicalTrials.gov NCT03185858; https://clinicaltrials.gov/ct2/show/NCT03185858. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.1016/j.ahj.2018.08.015.",2019,The mHealth system was feasible for assisting primary health care providers in rural China in delivering the SINEMA service on the secondary prevention of stroke.,"['stroke patients', 'From the in-depth interviews of 49 relevant stakeholders', 'village-dwelling stroke patients in rural areas', 'stroke in rural China', 'users (village doctors, town physicians, and county managers), was developed and utilized in a cluster-randomized controlled trial by 25 village doctors in a resource-limited county in rural China to manage 637 stroke patients between July 2017 and July 2018']",[],[],"[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0557750', 'cui_str': 'Towns'}, {'cui': 'C0335141', 'cui_str': 'Manager (occupation)'}, {'cui': 'C1096777', 'cui_str': 'Randomized Controlled Trial'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0439801', 'cui_str': 'Limited (qualifier value)'}]",[],[],49.0,0.0942861,The mHealth system was feasible for assisting primary health care providers in rural China in delivering the SINEMA service on the secondary prevention of stroke.,"[{'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Wu', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}, {'ForeName': 'Enying', 'Initials': 'E', 'LastName': 'Gong', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Kunshan, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}, {'ForeName': 'Wanbing', 'Initials': 'W', 'LastName': 'Gu', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Kunshan, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Ding', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}, {'ForeName': 'Zhuoran', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}, {'ForeName': 'Mengyao', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}, {'ForeName': 'Lijing L', 'Initials': 'LL', 'LastName': 'Yan', 'Affiliation': 'Global Health Research Center, Duke Kunshan University, Kunshan, China.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'School of Population and Global Health, The University of Melbourne, Victoria, Australia.'}, {'ForeName': 'Li-Qun', 'Initials': 'LQ', 'LastName': 'Xu', 'Affiliation': 'Center of Excellence for mHealth and Smart Healthcare, China Mobile Research Institute, China Mobile Communications Corporation, Beijing, China.'}]",JMIR mHealth and uHealth,['10.2196/13503'] 1439,31448950,The Effect of t'ai chi on Quality of Life in Centrally Obese Adults with Depression.,"Objectives: The aim of this pilot study was to assess the effects of a t'ai chi program on health-related quality of life (HR-QOL) in centrally obese adults with depression. Methods: Two hundred thirteen participants were randomly allocated to either a t'ai chi intervention group ( n  = 106) or a usual medical care control group ( n  = 107). The t'ai chi group involved 3 × 1.5 h supervised and group-based training sessions per week for 24 weeks. Indicators of HR-QOL were assessed by questionnaire at baseline, 12 weeks, and 24 weeks. Results: There were significant improvements in favor of the t'ai chi group for the SF-36 subscales of physical functioning ( p  < 0.01), role physical ( p  < 0.01), and role emotional ( p  < 0.01) at 12 and 24 weeks. Scores for bodily pain were improved in the control group at 12 weeks ( p  < 0.01) and 24 weeks ( p  < 0.05), but not in the t'ai chi group. There was also a significant improvement in favor of the control group in general health ( p  < 0.05) at 12 weeks, but not at 24 weeks. A further analysis showed clinically significant changes in favor of the t'ai chi group in physical functioning ( p  < 0.05 or p  = 0.05), role physical ( p  < 0.05), and role emotional ( p  < 0.05), and in favor of the control group in bodily pain ( p  < 0.05) at 12 and 24 weeks. Conclusions: The findings show that t'ai chi exercise improved indicators of HR-QOL including physical functioning, role physical, and role emotional in centrally obese adults with depression.",2019,"Scores for bodily pain were improved in the control group at 12 weeks ( p  < 0.01) and 24 weeks ( p  < 0.05), but not in the t'ai chi group.","['Two hundred thirteen participants', 'centrally obese adults with depression', 'Centrally Obese Adults with Depression']","[""t'ai chi program"", ""t'ai chi"", ""t'ai chi exercise"", ""t'ai chi intervention group ( n \u2009=\u2009106) or a usual medical care control group""]","['Scores for bodily pain', 'general health', 'indicators of HR-QOL including physical functioning, role physical, and role emotional', 'Indicators of HR-QOL', 'physical functioning', 'SF-36 subscales of physical functioning', 'bodily pain', 'health-related quality of life (HR-QOL', 'role emotional', 'Quality of Life', 'role physical']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0376403', 'cui_str': 'Taiji'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}]",213.0,0.0697349,"Scores for bodily pain were improved in the control group at 12 weeks ( p  < 0.01) and 24 weeks ( p  < 0.05), but not in the t'ai chi group.","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Williams', 'Affiliation': 'The University of Queensland School of Public Health, Brisbane, Australia.'}, {'ForeName': 'Karam', 'Initials': 'K', 'LastName': 'Kostner', 'Affiliation': 'The University of Queensland School of Medicine, Brisbane, Australia.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Brown', 'Affiliation': 'The University of Queensland School of Human Movement and Nutrition Sciences, Brisbane, Australia.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2019.0050'] 1440,31070807,Bayesian hierarchical EMAX model for dose-response in early phase efficacy clinical trials.,"A primary goal of a phase II dose-ranging trial is to identify a correct dose before moving forward to a phase III confirmatory trial. A correct dose is one that is actually better than control. A popular model in phase II is an independent model that puts no structure on the dose-response relationship. Unfortunately, the independent model does not efficiently use information from related doses. One very successful alternate model improves power using a pre-specified dose-response structure. Past research indicates that EMAX models are broadly successful and therefore attractive for designing dose-response trials. However, there may be instances of slight risk of nonmonotone trends that need to be addressed when planning a clinical trial design. We propose to add hierarchical parameters to the EMAX model. The added layer allows information about the treatment effect in one dose to be ""borrowed"" when estimating the treatment effect in another dose. This is referred to as the hierarchical EMAX model. Our paper compares three different models (independent, EMAX, and hierarchical EMAX) and two different design strategies. The first design considered is Bayesian with a fixed trial design, and it has a fixed schedule for randomization. The second design is Bayesian but adaptive, and it uses response adaptive randomization. In this article, a randomized trial of patients with severe traumatic brain injury is provided as a motivating example.",2019,"The second design is Bayesian but adaptive, and it uses response adaptive randomization.",['patients with severe traumatic brain injury'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}]",[],[],,0.0235633,"The second design is Bayesian but adaptive, and it uses response adaptive randomization.","[{'ForeName': 'Byron J', 'Initials': 'BJ', 'LastName': 'Gajewski', 'Affiliation': 'Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Caitlyn', 'Initials': 'C', 'LastName': 'Meinzer', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Berry', 'Affiliation': 'Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Gaylan L', 'Initials': 'GL', 'LastName': 'Rockswold', 'Affiliation': 'Hennepin County Medical Center, Minneapolis, Minnesota.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Barsan', 'Affiliation': 'Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Frederick K', 'Initials': 'FK', 'LastName': 'Korley', 'Affiliation': 'Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': ""Renee' H"", 'Initials': 'RH', 'LastName': 'Martin', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina.'}]",Statistics in medicine,['10.1002/sim.8167'] 1441,32134279,Disrupting the path to craving: Acting without awareness mediates the link between negative affect and craving.,"Low treatment utilization, relapse, and chronicity are characteristic of substance use disorders (SUDs). Craving is an important predictor of relapse. Individuals with an SUD report using various coping strategies in response to negative affect, two of which are investigated in the current study: suppression and acting with awareness. Suppression is typically understood to be avoidance of unwanted experience through turning attention away from unwanted stimuli. Acting with awareness (AWA) is a facet of mindfulness, which includes turning toward experience with kindness and curiosity, even when the experience is unwanted. Evidence suggests mindfulness may reduce craving, while suppression has been associated with increased craving. In the current study, participants ( N = 210) had recently completed inpatient or intensive outpatient SUD treatment followed by a randomized controlled trial of aftercare. Participants completed measures within 2 weeks following the completion of the aftercare intervention. Negative affect and severity of dependence were both positively associated with craving. Structural equation modeling evaluated AWA and suppression as partial mediators of the link between negative affect and craving. Suppression was positively associated and AWA was negatively associated with craving. Mediation analyses revealed the indirect effect of negative affect on craving through AWA was significant, but the path through suppression was not. These findings suggest that AWA may inhibit the development of craving from negative affect, but further research is needed. Future research should investigate the path from negative affect to craving with greater temporal resolution to evaluate how these phenomena function with increased ecological validity. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Suppression was positively associated and AWA was negatively associated with craving.,['participants ( N = 210) had recently completed inpatient or intensive outpatient SUD treatment followed by a randomized controlled trial of aftercare'],[],[],"[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}]",[],[],,0.0252668,Suppression was positively associated and AWA was negatively associated with craving.,"[{'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Enkema', 'Affiliation': 'Department of Psychology, University of Washington.'}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Hallgren', 'Affiliation': 'Department of Psychiatry, University of Washington.'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Neilson', 'Affiliation': 'Department of Psychology, Morehead State University.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bowen', 'Affiliation': 'Department of Psychology, Pacific University.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Bird', 'Affiliation': 'Department of Psychology, University of Washington.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Larimer', 'Affiliation': 'Department of Psychiatry, University of Washington.'}]",Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors,['10.1037/adb0000565'] 1442,31421395,"Daidzein and genistein have differential effects in decreasing whole body bone mineral density but had no effect on hip and spine density in premenopausal women: A 2-year randomized, double-blind, placebo-controlled study.","Soy isoflavones are potentially beneficial phytoestrogens, but their tissue-selective effects in women are poorly understood. We tested the hypothesis that soy isoflavones affect bone mineral density (BMD), which may be influenced by individual differences in isoflavone metabolism and serum calcium levels. Ninety-nine healthy premenopausal women were randomized to isoflavones (136.6 mg aglycone equivalence) and 98 to placebo for 5 days per week for up to 2 years. BMD, serum calcium, and urinary excretion of daidzein and genistein were measured before and during treatment. In 129 adherent subjects, we found that isoflavone exposure, determined by urinary excretion levels, but not by dose assignment, interacted with serum calcium in affecting whole body BMD, but not hip and spine BMD. The regression coefficient was -0.042 for genistein excretion (GE) and 0.091 for the interaction between GE and serum calcium (all P < .05). Daidzein excretion had similar but marginal effect. Genistein significantly decreased whole body BMD only at low normal serum calcium levels but increased whole body BMD at higher serum calcium levels. Comparing maximum to minimum GE, mean changes in whole body BMD were +0.033 and -0.113 g/cm 2 at serum calcium levels of 10 and 8.15 mg/dL, respectively. These associations were not evident by intention-to-treat analysis, which could not model for inter-individual differences in isoflavone metabolism. In summary, soy isoflavones decrease whole body BMD only when serum calcium is low. Isoflavones are dietary substances that may influence calcium homeostasis by releasing calcium from bone while sparing the common fracture risk sites hip and spine.",2019,Genistein significantly decreased whole body BMD only at low normal serum calcium levels but increased whole body BMD at higher serum calcium levels.,"['Ninety-nine healthy premenopausal women', 'premenopausal women', '129 adherent subjects']","['Daidzein and genistein', 'placebo', 'soy isoflavones', 'isoflavones', 'Isoflavones', 'Genistein', 'Soy isoflavones']","['whole body BMD', 'body BMD', 'whole body bone mineral density', 'bone mineral density (BMD', 'urinary excretion levels', 'BMD, serum calcium, and urinary excretion of daidzein and genistein', 'Daidzein excretion']","[{'cui': 'C3828813', 'cui_str': 'Ninety-nine'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C0057090', 'cui_str': 'diadzein'}, {'cui': 'C0061202', 'cui_str': 'Genistein'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4076257', 'cui_str': 'Soy isoflavone (substance)'}, {'cui': 'C0022179', 'cui_str': 'Isoflavone Derivatives'}]","[{'cui': 'C0444584', 'cui_str': 'Whole body (qualifier value)'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0057090', 'cui_str': 'diadzein'}, {'cui': 'C0061202', 'cui_str': 'Genistein'}]",99.0,0.0742129,Genistein significantly decreased whole body BMD only at low normal serum calcium levels but increased whole body BMD at higher serum calcium levels.,"[{'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Nayeem', 'Affiliation': 'Department of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: fanayeem@utmb.edu.'}, {'ForeName': 'Nai-Wei', 'Initials': 'NW', 'LastName': 'Chen', 'Affiliation': 'Department of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: Nai-Wei.Chen@beaumont.org.'}, {'ForeName': 'Manubai', 'Initials': 'M', 'LastName': 'Nagamani', 'Affiliation': 'Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: mnagaman@gmail.com.'}, {'ForeName': 'Karl E', 'Initials': 'KE', 'LastName': 'Anderson', 'Affiliation': 'Department of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: kanderso@utmb.edu.'}, {'ForeName': 'Lee-Jane W', 'Initials': 'LW', 'LastName': 'Lu', 'Affiliation': 'Department of Preventive Medicine and Community Health The University of Texas Medical Branch, Galveston, TX 77555. Electronic address: llu@utmb.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2019.06.007'] 1443,32438301,Preoperative fasting abbreviation (Enhanced Recovery After Surgery protocol) and its effects on the metabolism of patients undergoing gynecologic surgeries under spinal anesthesia: A randomized clinical trial.,"OBJECTIVES Recommended perioperative nutritional interventions may contribute to satisfactory surgical outcomes. Each moment in the course of a surgical pathologic condition may be a window of opportunity for an intervention with a positive impact on postoperative recovery. Based on the idea of accelerating postoperative recovery, the objective of this study was to evaluate the effectiveness of a nutritional intervention with preoperative fasting abbreviation (Enhanced Recovery After Surgery recommendations) on the metabolism of patients undergoing gynecologic surgeries under spinal anesthesia. METHODS This randomized clinical trial was performed at a hospital of medium complexity. After Human Research Ethics Committee approval on August 24, 2015, 80 women who had gynecologic surgery in the period from January to June 2016 and signed the consent form were randomly allocated into two groups: a control group (n = 42) and a juice group (n = 38). They received 200 mL of inert solution (control group) or liquid enriched with carbohydrate and protein (juice group) 4 h before surgery. The variables studied were serum glucose, insulin, insulin resistance evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR), C-reactive protein, and albumin in the pre- and postoperative periods. The statistical analysis was performed with SPSS 20.0. RESULTS There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. CONCLUSIONS Preoperative fasting abbreviation with liquid containing carbohydrate and protein before gynecologic surgeries may provide metabolic stability with lower variation in insulin resistance than inert solution.",2020,"There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. ","['80 women who had gynecologic surgery in the period from January to June 2016 and signed the consent', 'patients undergoing gynecologic surgeries under spinal anesthesia']",['200 mL of inert solution (control group) or liquid enriched with carbohydrate and protein (juice group) 4 h before surgery'],"['serum glucose, insulin, insulin resistance evaluated by the homeostatic model assessment of insulin resistance (HOMA-IR), C-reactive protein, and albumin in the pre- and postoperative periods', 'Preoperative fasting abbreviation', 'HOMA-IR index']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}]","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1268568', 'cui_str': 'Juice'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0000723', 'cui_str': 'Abbreviation'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0703072,"There was a statistically significant difference in the coefficient of variation for the HOMA-IR index in the control group (17.27%; P < 0.01) compared with the juice group (8.46%; P < 0.05), which remained stable from the pre- to the postoperative period. ","[{'ForeName': 'Gisele Vissoci', 'Initials': 'GV', 'LastName': 'Marquini', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil. Electronic address: giselemarquini@gmail.com.'}, {'ForeName': 'Francisco Edes', 'Initials': 'FE', 'LastName': 'da Silva Pinheiro', 'Affiliation': 'Hospital and Municipal Maternity Dr. Odelmo Leão Carneiro, Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Alfredo Urbano', 'Initials': 'AU', 'LastName': 'da Costa Vieira', 'Affiliation': 'Hospital and Municipal Maternity Dr. Odelmo Leão Carneiro, Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Rogério Melo', 'Initials': 'RM', 'LastName': 'da Costa Pinto', 'Affiliation': 'Faculty of Maths, Nucleus of Statistical and Biometrical Studies, Federal University of Uberlândia, Minas Gerais, Brazil.'}, {'ForeName': 'Maria Gabriela Baumgarten', 'Initials': 'MGB', 'LastName': 'Kuster Uyeda', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Manoel João Batista Castello', 'Initials': 'MJBC', 'LastName': 'Girão', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Marair Gracio Ferreira', 'Initials': 'MGF', 'LastName': 'Sartori', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo, São Paulo, Brazil.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110790'] 1444,31208714,A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease.,"OBJECTIVE Assess whether treatment with probiotics improve gastrointestinal symptoms in patients with systemic sclerosis (SSc). METHODS In this double-blind randomized placebo-controlled parallel-group phase II trial, SSc subjects with total score ≥ 0.1 on a validated SSc-specific gastrointestinal tract (GIT) questionnaire were randomized (1:1) to receive 60 days of high dose multi-strain probiotics (Vivomixx® 1800 billion units/day) or identical placebo, followed by an additional 60 days of probiotics in both groups. Between group differences in GIT score change were assessed after 60 days (primary outcome, time-point T1) and 120 days (secondary outcome, time-point, T2) by an intention-to-treat approach. Stool samples at three time-points were subjected to 16S next generation sequencing. RESULTS Forty subjects were randomized to placebo-probiotics (n = 21) or probiotics-probiotics (n = 19). At T1, no significant improvement was observed between the two groups, reported as mean ± SE for total GIT score (placebo 0.14 ± 0.06 versus probiotics 0.13 ± 0.07; p = 0.85) or its subdomains. At T2, whilst there was no significant improvement in total GIT score (placebo-probiotics -0.05±0.06; probiotics-probiotics -0.18 ± 0.07; p = 0.14), there was significant improvement of GIT-reflux in the probiotic group (-0.22 ± 0.05 versus placebo-probiotics 0.05 ± 0.07; p = 0.004). Subjects on probiotics exhibited increasing stool microbiota alpha diversity compared to the placebo-probiotics group. Adverse events (AEs) were mild, with similar proportion of subjects with AEs and serious AEs in both groups. CONCLUSION Whilst there was no clear improvement in overall GI symptoms after 60 days, we observed significantly improved GI reflux after 120 days of probiotics. The trial confirmed safety of multi-strain probiotics in SSc patients. TRIAL REGISTRATION Clinicaltrials.gov; NCT01804959.",2019,"At T1, no significant improvement was observed between the two groups, reported as mean ± SE for total GIT score (placebo 0.14 ± ","['SSc subjects with total score ≥\xa00.1 on a validated SSc-specific gastrointestinal tract (GIT) questionnaire', 'patients with systemic sclerosis (SSc', 'Forty subjects', 'systemic sclerosis associated gastrointestinal disease', 'SSc patients']","['multi-strain probiotics', 'placebo', 'probiotics', 'placebo-probiotics', 'high dose multi-strain probiotics (Vivomixx® 1800 billion units/day) or identical placebo', 'probiotics-probiotics']","['gastrointestinal symptoms', 'overall GI symptoms', 'total GIT score', 'GIT-reflux', 'GI reflux', 'mean\xa0±\xa0SE for total GIT score', 'stool microbiota alpha diversity', 'GIT score change']","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4517420', 'cui_str': 'Zero point one'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal Tract'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0036421', 'cui_str': 'Systemic Scleroderma'}, {'cui': 'C0017178', 'cui_str': 'Gastrointestinal Diseases'}]","[{'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0080194', 'cui_str': 'Strains'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0456683', 'cui_str': 'unit/day'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}]","[{'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",40.0,0.672162,"At T1, no significant improvement was observed between the two groups, reported as mean ± SE for total GIT score (placebo 0.14 ± ","[{'ForeName': 'Andrea Hsiu Ling', 'Initials': 'AHL', 'LastName': 'Low', 'Affiliation': 'Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road 169856, Singapore; Duke-National University of Singapore Medical School, 8 College Road 169857, Singapore. Electronic address: andrea.low.h.l@singhealth.com.sg.'}, {'ForeName': 'Gim Gee', 'Initials': 'GG', 'LastName': 'Teng', 'Affiliation': 'Division of Rheumatology, National University Hospital, National University Health System, 5 Lower Kent Ridge Road 119074, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road 119228, Singapore.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Pettersson', 'Affiliation': 'Lee Kong Chian School of Medicine, Nanyang Technological University, 59 Nanyang Drive, Experimental Medicine Building 636921, Singapore; Singapore Centre for Environmental Life Sciences Engineering Microbiome Centre, Nanyang Technological University, 60 Nanyang Drive 637551, Singapore.'}, {'ForeName': 'Paola Florez', 'Initials': 'PF', 'LastName': 'de Sessions', 'Affiliation': 'Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street 138672, Singapore.'}, {'ForeName': 'Eliza Xin Pei', 'Initials': 'EXP', 'LastName': 'Ho', 'Affiliation': 'Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street 138672, Singapore.'}, {'ForeName': 'Qiao', 'Initials': 'Q', 'LastName': 'Fan', 'Affiliation': 'Centre for Quantitative Medicine, Duke-NUS Medical School, 8 College Road 169857, Singapore.'}, {'ForeName': 'Collins Wenhan', 'Initials': 'CW', 'LastName': 'Chu', 'Affiliation': 'Genome Institute of Singapore, Agency for Science, Technology and Research, 60 Biopolis Street 138672, Singapore.'}, {'ForeName': 'Annie Hui Nee', 'Initials': 'AHN', 'LastName': 'Law', 'Affiliation': 'Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road 169856, Singapore.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Santosa', 'Affiliation': 'Division of Rheumatology, National University Hospital, National University Health System, 5 Lower Kent Ridge Road 119074, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road 119228, Singapore.'}, {'ForeName': 'Anita Yee Nah', 'Initials': 'AYN', 'LastName': 'Lim', 'Affiliation': 'Division of Rheumatology, National University Hospital, National University Health System, 5 Lower Kent Ridge Road 119074, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road 119228, Singapore.'}, {'ForeName': 'Yu Tien', 'Initials': 'YT', 'LastName': 'Wang', 'Affiliation': 'Gastroenterology and Hepatology, Singapore General Hospital, 20 College Road Singapore 169856.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Haaland', 'Affiliation': 'Centre for Quantitative Medicine, Duke-NUS Medical School, 8 College Road 169857, Singapore.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Thumboo', 'Affiliation': 'Department of Rheumatology and Immunology, Singapore General Hospital, The Academia, Level 4, 20 College Road 169856, Singapore; Duke-National University of Singapore Medical School, 8 College Road 169857, Singapore.'}]",Seminars in arthritis and rheumatism,['10.1016/j.semarthrit.2019.05.006'] 1445,31404177,Blood Flow Restriction Therapy after Closed Treatment of Distal Radius Fractures.,"Background  Blood flow restriction (BFR) therapy is an innovative rehabilitative program that enables patients to increase strength at a fraction of the weight typically necessary in endurance exercises. Therefore, we conducted a pilot study evaluating patient outcomes with a BFR therapy program for closed management after a distal radius fracture compared to a traditional rehabilitation protocol. Literature review  A randomized-controlled study was conducted comparing a standardized hand therapy rehabilitation protocol alone to a combined protocol with the use of BFR therapy in patients who were initially treated with closed reduction and short arm cast immobilization for a displaced distal radius fracture between May 1, 2015 and August 1, 2016. BFR therapy was performed with a restrictive tourniquet applied to the upper brachium, performing the same strengthening exercises as the control group but with the restrictive tourniquet in place. Clinical assessment was conducted at 6, 10, and 14 weeks from the date of initial cast immobilization. Outcome measures collected included wrist range of motion; grip strength; pinch strength; visual analogue scale for pain with activity and at rest; patient-rated wrist evaluation (PRWE) scores; and disabilities of the arm, shoulder, and hand scores. Results  Thirteen patients were enrolled and randomized between the BFR ( n  = 6) and control ( n  = 7) groups. The BFR group noted significantly greater reduction in pain with activity compared to the control group after 8 weeks of therapy (Δ -4.0 vs. -2.3, p  = 0.03). Similarly, patients in the BFR group displayed greater reduction in PRWE scores compared to the control group after 8 weeks of BFR therapy (Δ -57.9 vs. 30.8, p  = 0.01). The two groups did not demonstrate any significant difference in radiographic outcomes at any time point or throughout the course of the study. All patients tolerated the BFR therapy program and there were no complications. Clinical relevance  The addition of BFR therapy to the rehabilitative program after closed management of a distal radius fracture is safe, well tolerated by patients, without any deleterious effects on radiographic outcomes. This pilot study noted that BFR therapy in patients with nonoperative distal radius fractures may result in a larger reduction in pain with activity and greater improvement in overall self-perceived function.",2019,The two groups did not demonstrate any significant difference in radiographic outcomes at any time point or throughout the course of the study.,"['patients who were initially treated with closed reduction and short arm cast immobilization for a displaced distal radius fracture between May 1, 2015 and August 1, 2016', 'Distal Radius Fractures', 'Thirteen patients were enrolled and randomized between the BFR ( n \u2009=\u20096) and control ( n \u2009=\u20097) groups', 'patients with nonoperative distal radius fractures']","['Blood Flow Restriction Therapy', 'BFR therapy program', ' \u2003Blood flow restriction (BFR) therapy', 'BFR therapy']","['wrist range of motion; grip strength; pinch strength; visual analogue scale for pain with activity and at rest; patient-rated wrist evaluation (PRWE) scores; and disabilities of the arm, shoulder, and hand scores', 'pain with activity', 'PRWE scores', 'radiographic outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0426857', 'cui_str': 'Short arm (finding)'}, {'cui': 'C0302143', 'cui_str': 'Casts (qualifier value)'}, {'cui': 'C0020944', 'cui_str': 'Immobilization'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0575717', 'cui_str': 'Joint movement: wrist'}, {'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}]",,0.0207569,The two groups did not demonstrate any significant difference in radiographic outcomes at any time point or throughout the course of the study.,"[{'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Cancio', 'Affiliation': 'Center for the Intrepid, Department of Rehabilitation Medicine, Brooke Army Medical Center, San Antonio Military Medical Center, JBSA Ft. Sam Houston, Texas; Extremity Trauma and Amputation Center of Excellence, JBSA Ft. Sam Houston, Texas.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Sgromolo', 'Affiliation': 'San Antonio Military Medical Center, Fort Sam Houston, Texas; Department of Orthopaedic Surgery.'}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Rhee', 'Affiliation': 'Mayo Clinic, Orthopedic Surgery, Rochester, Minnesota.'}]",Journal of wrist surgery,['10.1055/s-0039-1685455'] 1446,31346923,Implementation of Early Intervention Protocol in Australia for 'High Risk' Injured Workers is Associated with Fewer Lost Work Days Over 2 Years Than Usual (Stepped) Care.,"Purpose To evaluate whether a protocol for early intervention addressing the psychosocial risk factors for delayed return to work in workers with soft tissue injuries would achieve better long-term outcomes than usual (stepped) care. Methods The study used a controlled, non-randomised prospective design to compare two case management approaches. For the intervention condition, workers screened within 1-3 weeks of injury as being at high risk of delayed returned to work by the Örebro Musculoskeletal Pain Screening Questionnaire-short version (ÖMPSQ-SF) were offered psychological assessment and a comprehensive protocol to address the identified obstacles for return to work. Similarly identified injured workers in the control condition were managed under usual (stepped) care arrangements. Results At 2-year follow-up, the mean lost work days for the Intervention group was less than half that of the usual care group, their claim costs were 30% lower, as was the growth trajectory of their costs after 11 months. Conclusions The findings supported the hypothesis that brief psychological risk factor screening, combined with a protocol for active collaboration between key stakeholders to address identified psychological and workplace factors for delayed return to work, can achieve better return on investment than usual (stepped) care.",2020,", the mean lost work days for the Intervention group was less than half that of the usual care group, their claim costs were 30% lower, as was the growth trajectory of their costs after 11 months.","['workers with soft tissue injuries', ""Australia for 'High Risk' Injured Workers""]",[],['claim costs'],"[{'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0037578', 'cui_str': 'Soft Tissue Injuries'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}]",[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0372678,", the mean lost work days for the Intervention group was less than half that of the usual care group, their claim costs were 30% lower, as was the growth trajectory of their costs after 11 months.","[{'ForeName': 'M K', 'Initials': 'MK', 'LastName': 'Nicholas', 'Affiliation': 'Sydney Medical School - Northern, University of Sydney & Royal North Shore Hospital, St Leonards, NSW, Australia. michael.nicholas@sydney.edu.au.'}, {'ForeName': 'D S J', 'Initials': 'DSJ', 'LastName': 'Costa', 'Affiliation': 'Sydney Medical School - Northern, University of Sydney & Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Linton', 'Affiliation': 'Center for Health And Medical Psychology, Department of Law, Psychology, and Social Work, Örebro University, Örebro, Sweden.'}, {'ForeName': 'C J', 'Initials': 'CJ', 'LastName': 'Main', 'Affiliation': 'Arthritis Care UK Primary Care Centre, Keele University, Keele, North Staffordshire, UK.'}, {'ForeName': 'W S', 'Initials': 'WS', 'LastName': 'Shaw', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Pearce', 'Affiliation': 'Sydney Medical School - Northern, University of Sydney & Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gleeson', 'Affiliation': 'Sydney Medical School - Northern, University of Sydney & Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'R Z', 'Initials': 'RZ', 'LastName': 'Pinto', 'Affiliation': 'Sydney Medical School - Northern, University of Sydney & Royal North Shore Hospital, St Leonards, NSW, Australia.'}, {'ForeName': 'F M', 'Initials': 'FM', 'LastName': 'Blyth', 'Affiliation': 'School of Public Health, Concord Clinical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'J H', 'Initials': 'JH', 'LastName': 'McAuley', 'Affiliation': 'Neuroscience Research Australia and School of Medical Sciences, University of NSW, Sydney, NSW, Australia.'}, {'ForeName': 'R J E M', 'Initials': 'RJEM', 'LastName': 'Smeets', 'Affiliation': 'Department of Rehabilitation Medicine, Caphri, Maastricht University, Maastricht, The Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'McGarity', 'Affiliation': 'Injury Management Health & Safety Branch, NSW Fire and Safety, Sydney, Australia.'}]",Journal of occupational rehabilitation,['10.1007/s10926-019-09849-y'] 1447,31527919,Randomized control trial of Tools of the Mind: Marked benefits to kindergarten children and their teachers.,"The kindergarten program, Tools of the Mind (Tools), has been shown to improve executive functions (as assessed by laboratory measures) and academic performance. The objective here was to see if Tools can improve executive functions in the real world (in the classroom), academic outcomes not previously investigated, reduce bullying and peer ostracism, and increase teachers' and students' joy in being in the classroom. This first randomized controlled trial of Tools in Canada included 351 kindergarten children (mean age 5.2 years at entry; 51% female) in 18 public schools. Stratified randomization resulted in teachers and students in both groups being closely matched. Teachers in both groups received the same number of training hours and same funds for new materials. Outcome measures were pre and post standardized academic skill assessments and teacher online survey responses. This study replicated that Tools improves reading and shows for the first time that it improves writing (far exceeding levels the school districts had seen before), self-control and attention-regulation in the real world (e.g., time on task without supervision), reduces teacher burnout and children being ostracized or excluded, and increases the joy students and teachers experience in school. By Spring, Tools teachers were still enthusiastic about teaching; control teachers were exhausted. These results were not only better than the control group but also better than Tools teachers experienced the year before Tools. Thus, children in a kindergarten curriculum that emphasized play, improving self-regulation, working together and helping one another, and hands-on learning performed better academically, showed less bullying and peer ostracism and more kindness and helping behavior than students in more traditional classes, and teacher enthusiasm for teaching soared. Tools reduced initial disparities separating children, schools, and teachers.",2019,"The kindergarten program, Tools of the Mind (Tools), has been shown to improve executive functions (as assessed by laboratory measures) and academic performance.","['kindergarten children and their teachers', '351 kindergarten children (mean age 5.2 years at entry; 51% female) in 18 public schools']",[],"['pre and post standardized academic skill assessments and teacher online survey responses', 'executive functions']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517790', 'cui_str': '5.2 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0557800', 'cui_str': 'Public school (environment)'}]",[],"[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0221457', 'cui_str': 'Teacher (occupation)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",18.0,0.0240006,"The kindergarten program, Tools of the Mind (Tools), has been shown to improve executive functions (as assessed by laboratory measures) and academic performance.","[{'ForeName': 'Adele', 'Initials': 'A', 'LastName': 'Diamond', 'Affiliation': 'Program in Developmental Cognitive Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Lee', 'Affiliation': 'Program in Developmental Cognitive Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Senften', 'Affiliation': 'Program in Developmental Cognitive Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Lam', 'Affiliation': 'Program in Developmental Cognitive Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Abbott', 'Affiliation': 'Program in Developmental Cognitive Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver, Canada.'}]",PloS one,['10.1371/journal.pone.0222447'] 1448,32148106,Don't skip the methods section! Randomized controlled trials are not all the same.,,2020,,[],[],[],[],[],[],,0.120931,,"[{'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Bell', 'Affiliation': ""Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.""}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2020.1732916'] 1449,32437690,Effect of Anodal Transcranial Direct Current Stimulation at the Right Dorsolateral Prefrontal Cortex on the Cognitive Function in Patients With Mild Cognitive Impairment: A Randomized Double-Blind Controlled Trial.,"OBJECTIVES To study the effect of anodal transcranial direct stimulation (atDCS) of the right dorsolateral prefrontal cortex (DLPFC) on cognitive function and side effects in patients with mild cognitive impairment. DESIGN Experimental double-blind randomized, sham-controlled trial. SETTING Department of Rehabilitation Medicine, King Chulalongkorn Memorial Hospital PARTICIPANTS: Volunteers (N=45) with mild cognitive impairment. INTERVENTIONS Not applicable. MAIN OUTCOME MEASURES The atDCS group (n=23) were stimulated at 2 mA for 20 minutes with the anode on the right DLPFC and the cathode on the left supraorbital area. The control group (n=22) received placebo stimulation. Baseline cognitive function was assessed using the Cambridge Neuropsychological Test Automated Battery test. Participants were treated 3 times per week for 4 weeks (12 sessions). Cognitive function and side effects were assessed immediately after the first stimulation, the last session, and 4 weeks after treatment. RESULTS Cambridge Neuropsychological Test Automated Battery results revealed a significant improvement in the accuracy of the visual sustained attention (VSA) in the atDCS group at all 3 time points, the spatial working memory and visual memory (VM) immediately after the first stimulation, and a decreased VM reaction time after 12 sessions. A long-lasting effect on VSA and VM were found 4 weeks after treatment. CONCLUSIONS Anodal tDCS over the right DLPFC enhanced the VSA, spatial working memory, and VM accuracy after the first stimulation and reduced the reaction time of VM after 12 sessions. A long-lasting effect on VSA and VM was found 4 weeks after treatment. This study corroborated atDCS as a safe technique to improve cognitive function.",2020,"Anodal tDCS over the right DLPFC enhanced the VSA, SWM and VM accuracy after the first stimulation and reduced the reaction time of VM after 12 sessions.","[' Participants (45) who met the inclusion criteria', 'patients with mild cognitive impairment', 'Department of Rehabilitation Medicine, Tertiary Hospital SUBJECTS', 'patients with mild cognitive impairment (MCI']","['anodal transcranial direct current stimulation', 'anodal transcranial direct stimulation (atDCS) of the right dorsolateral prefrontal cortex (DLPFC', 'placebo stimulation']","['Baseline cognitive function', 'reaction time of VM', 'VSA, SWM and VM accuracy', 'spatial working memory (SWM) and visual memory (VM', 'Cognitive function and side effects', 'VM reaction time', 'cognitive function', 'accuracy of the visual sustained attention (VSA', 'VSA and VM', 'Cambridge Neuropsychological Test Automated Battery (CANTAB) test', 'cognitive function and side effects']","[{'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0542316', 'cui_str': 'Visual memory'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C4505411', 'cui_str': 'CANTAB'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",45.0,0.0855784,"Anodal tDCS over the right DLPFC enhanced the VSA, SWM and VM accuracy after the first stimulation and reduced the reaction time of VM after 12 sessions.","[{'ForeName': 'Chernkhuan', 'Initials': 'C', 'LastName': 'Stonsaovapak', 'Affiliation': 'Department of Rehabilitation Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}, {'ForeName': 'Solaphat', 'Initials': 'S', 'LastName': 'Hemrungroj', 'Affiliation': 'Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Terachinda', 'Affiliation': 'Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Krisna', 'Initials': 'K', 'LastName': 'Piravej', 'Affiliation': 'Department of Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Electronic address: Krisna.P@chula.ac.th.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.03.023'] 1450,32495974,Double recurrence of double cancers: Rhabdomyosarcoma and secondary AML.,,2020,,[],[],[],[],[],[],,0.361475,,"[{'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Kajita', 'Affiliation': 'Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.'}, {'ForeName': 'Yuya', 'Initials': 'Y', 'LastName': 'Saito', 'Affiliation': 'Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Makimoto', 'Affiliation': 'Division of Pathology and Laboratory Medicine, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Miyahara', 'Affiliation': 'Division of Pathology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Yuza', 'Affiliation': 'Division of Hematology/Oncology, Tokyo Metropolitan Children Medical Center, Tokyo, Japan.'}]",Pediatrics international : official journal of the Japan Pediatric Society,['10.1111/ped.14172'] 1451,32437664,"First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.","BACKGROUND Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety and activity of pembrolizumab in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer. METHODS This study was an investigator-initiated, open-label, non-randomised, single-arm, single centre, phase 2 trial in patients aged 18 years or older with HER2-positive metastatic oesophagogastric cancer. Eligible patients had measurable or evaluable non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular ejection fraction of at least 53%. Patients were eligible to receive an initial induction cycle of 200 mg flat dose of intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab. For subsequent cycles, patients received 130 mg/m 2 of intravenous oxaliplatin or 80 mg/m 2 of cisplatin on day 1, 850 mg/m 2 of oral capecitabine twice a day for 2 weeks followed by 1 week off (or intravenous 5-fluorouracil, 800 mg/m 2 per day on days 1-5), and a 200 mg flat dose of intravenous pembrolizumab, and 6 mg/kg of trastuzumab, administered on day 1 of each 3-week cycle. The primary endpoint was 6-month progression-free survival, defined as the proportion of patients alive and free of progression at 6 months, assessed in patients who received at least one dose of trastuzumab and pembrolizumab. The regimen would be considered worthy of further investigation if 26 or more of 37 patients were progression-free at 6 months. This trial is registered with ClinicalTrials.gov, NCT02954536, and is ongoing, but closed to enrolment. FINDINGS Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled. At the time of data cutoff on Aug 6, 2019, median follow-up among survivors was 13·0 months (IQR 11·7-23·5). The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months. The most common treatment-related adverse event of any grade was neuropathy, which was reported in 36 (97%) of 37 patients. The most common grade 3 or 4 adverse events were lymphocytopenia (seven [19%] patients with grade 3 and two [5%] with grade 4), grade 3 decreased electrolytes (six [16%] patients), and grade 3 anaemia (four [11%] patients). Serious adverse events occurred in two patients patients (both grade 3 nephritis leading to treatment discontinuation). Four patients discontinued pembrolizumab because of immune-related adverse events. There were no treatment-related deaths. INTERPRETATION Pembrolizumab can be safely combined with trastuzumab and chemotherapy and has promising activity in HER2-positive metastatic oesophagogastric cancer. A randomised phase 3 clinical trial assessing the efficacy and safety of pembrolizumab versus placebo in combination with trastuzumab and chemotherapy in first-line HER2-positive metastatic oesophagogastric cancer is underway. FUNDING Merck & Co.",2020,The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months.,"['HER2-positive metastatic oesophagogastric cancer', 'Eligible patients had measurable or evaluable non-measurable disease, Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and left ventricular ejection fraction of at least 53', 'patients aged 18 years or older with HER2-positive metastatic oesophagogastric cancer', 'first-line HER2-positive metastatic oesophagogastric cancer', 'HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer', 'Between Nov 11, 2016, and Jan 23, 2019, 37 patients were enrolled', 'first-line HER2-positive metastatic oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer', 'patients with HER2-positive metastatic gastric cancer']","['oxaliplatin', 'intravenous pembrolizumab and 8 mg/kg loading dose of intravenous trastuzumab', 'trastuzumab and pembrolizumab', 'trastuzumab to first-line chemotherapy', 'trastuzumab and chemotherapy', 'capecitabine', 'cisplatin', 'pembrolizumab, and 6 mg/kg of trastuzumab', 'pembrolizumab versus placebo', 'First-line pembrolizumab and trastuzumab', '5-fluorouracil', 'pembrolizumab']","['safety and activity', '6-month progression-free survival, defined as the proportion of patients alive and free of progression', 'overall survival', 'grade 3 decreased electrolytes', 'grade 3 anaemia', 'efficacy and safety', 'Serious adverse events']","[{'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0475468', 'cui_str': 'Esophagogastric'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C0278498', 'cui_str': 'Gastric cancer stage IV'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3658706', 'cui_str': 'pembrolizumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0740464', 'cui_str': 'Electrolytes NOS decreased'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",37.0,0.193351,The primary endpoint was achieved; 26 (70%; 95% CI 54-83) of 37 patients were progression-free at 6 months.,"[{'ForeName': 'Yelena Y', 'Initials': 'YY', 'LastName': 'Janjigian', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: janjigiy@mskcc.org.'}, {'ForeName': 'Steven B', 'Initials': 'SB', 'LastName': 'Maron', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Walid K', 'Initials': 'WK', 'LastName': 'Chatila', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Tri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Brittanie', 'Initials': 'B', 'LastName': 'Millang', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Shweta S', 'Initials': 'SS', 'LastName': 'Chavan', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Carly', 'Initials': 'C', 'LastName': 'Alterman', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Joanne F', 'Initials': 'JF', 'LastName': 'Chou', 'Affiliation': 'Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Michal F', 'Initials': 'MF', 'LastName': 'Segal', 'Affiliation': 'Department of Nursing, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marc Z', 'Initials': 'MZ', 'LastName': 'Simmons', 'Affiliation': 'Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Momtaz', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Shcherba', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Geoffrey Y', 'Initials': 'GY', 'LastName': 'Ku', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Zervoudakis', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Elizabeth S', 'Initials': 'ES', 'LastName': 'Won', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Kelsen', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Ilson', 'Affiliation': 'Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Nagy', 'Affiliation': 'Guardant Health, Redwood City, CA, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lanman', 'Affiliation': 'Guardant Health, Redwood City, CA, USA.'}, {'ForeName': 'Ryan N', 'Initials': 'RN', 'LastName': 'Ptashkin', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Mark T A', 'Initials': 'MTA', 'LastName': 'Donoghue', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Marinela', 'Initials': 'M', 'LastName': 'Capanu', 'Affiliation': 'Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Barry S', 'Initials': 'BS', 'LastName': 'Taylor', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Solit', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Schultz', 'Affiliation': 'Marie-Josée & Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Jaclyn F', 'Initials': 'JF', 'LastName': 'Hechtman', 'Affiliation': 'Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30169-8'] 1452,32438483,Telemonitoring versus standard care in heart failure: a randomised multicentre trial.,"AIMS The aim was to assess the effect of a telemonitoring programme vs. standard care (SC) in preventing all-cause deaths or unplanned hospitalisations in heart failure (HF) at 18 months. METHODS AND RESULTS OSICAT was a randomised, multicentre, open-label French study in 937 patients hospitalised for acute HF ≤12 months before inclusion. Patients were randomised to telemonitoring (daily body weight measurement, daily recording of HF symptoms, and personalised education) (n = 482) or to SC (n = 455). Mean ± standard deviation number of events for the primary outcome was 1.30 ± 1.85 for telemonitoring and 1.46 ± 1.98 for SC [rate ratio 0.97, 95% confidence interval (CI) 0.77-1.23; P = 0.80]. In New York Heart Association (NYHA) class III or IV HF, median time to all-cause death or first unplanned hospitalisation was 82 days in the telemonitoring group and 67 days in the SC group (P = 0.03). After adjustment for known predictive factors, telemonitoring was associated with a 21% relative risk reduction in first unplanned hospitalisation for HF [hazard ratio (HR) 0.79, 95% CI 0.62-0.99; P = 0.044); the relative risk reduction was 29% in patients with NYHA class III or IV HF (HR 0.71, 95% CI 0.53-0.95; P = 0.02), 38% in socially isolated patients (HR 0.62, 95% CI 0.39-0.98; P = 0.043), and 37% in patients who were ≥70% adherent to body weight measurement (HR 0.63, 95% CI 0.45-0.88; P = 0.006). CONCLUSION Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients. The pre-specified subgroup results suggest the telemonitoring approach improves clinical outcomes in selected populations but need further confirmation.",2020,Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients.,"['all-cause deaths or unplanned hospitalisations in heart failure (HF) at 18\u2009months', '937 patients hospitalised for acute HF ≤12\u2009months before inclusion', 'in heart failure']","['telemonitoring (daily body-weight measurement, daily recording of HF symptoms, and personalised education) (n\xa0=\xa0482) or to SC', 'telemonitoring programme versus standard care (SC', 'Telemonitoring versus standard of care']","['Mean\u2009±\u2009standard deviation number of events', 'median time to all-cause death or first unplanned hospitalisation', 'rate of all-cause deaths or unplanned hospitalisations', 'relative risk reduction']","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0264714', 'cui_str': 'Acute heart failure'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",937.0,0.224831,Telemonitoring did not result in a significantly lower rate of all-cause deaths or unplanned hospitalisations in HF patients.,"[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Galinier', 'Affiliation': 'Cardiology, Toulouse Rangueil University Hospital (CHU), Toulouse, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Roubille', 'Affiliation': 'PhyMedExp, Université de Montpellier, INSERM, CNRS, Cardiology Department, University Hospital of Montpellier, Montpellier, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Berdague', 'Affiliation': 'Beziers Hospital Centre, Beziers, France.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Brierre', 'Affiliation': ""Intercommunal Hospital Centre des Vallées de l'Ariege, Foix, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Cantie', 'Affiliation': 'Intercommunal Hospital Centre Castres-Mazamet, Castres, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Dary', 'Affiliation': 'Private Practice, Saint Yrieix La Perche, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Ferradou', 'Affiliation': 'Cardiology Aftercare and Rehabilitation Centre, Beaumont de Lomagne, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Fondard', 'Affiliation': 'Pasteur Clinic, Toulouse, France.'}, {'ForeName': 'Jean Philippe', 'Initials': 'JP', 'LastName': 'Labarre', 'Affiliation': 'Pont de Chaume Clinic, Montauban, France.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Mansourati', 'Affiliation': 'CHRU Brest, Brest, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Picard', 'Affiliation': ""Unité d'Insuffisance Cardiaque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.""}, {'ForeName': 'Jean-Etienne', 'Initials': 'JE', 'LastName': 'Ricci', 'Affiliation': 'University Hospital of Nimes, Nimes, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Salvat', 'Affiliation': 'University Hospital of Grenoble, Grenoble, France.'}, {'ForeName': 'Lamia', 'Initials': 'L', 'LastName': 'Tartière', 'Affiliation': 'Leon Berard Hospital, Hyeres, France.'}, {'ForeName': 'Jean-Bernard', 'Initials': 'JB', 'LastName': 'Ruidavets', 'Affiliation': 'INSERM UMR - U1027, Toulouse, France.'}, {'ForeName': 'Vanina', 'Initials': 'V', 'LastName': 'Bongard', 'Affiliation': 'USMR - CHU Toulouse, Toulouse, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Delval', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Guila', 'Initials': 'G', 'LastName': 'Lancman', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Pasche', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Juan Fernando', 'Initials': 'JF', 'LastName': 'Ramirez-Gil', 'Affiliation': 'Air Liquide Santé International, Loges en Josas, France.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Pathak', 'Affiliation': 'Department of Cardiovascular Medicine, Princess Grace Hospital, Monaco, Monaco.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of heart failure,['10.1002/ejhf.1906'] 1453,31422458,Oral versus patient-controlled intravenous administration of oxycodone for pain relief after cesarean section.,"PURPOSE The optimal postoperative analgesia after cesarean section (CS) remains to be determined. The primary objective of this study was to assess whether oral oxycodone provides the same or better pain control and satisfaction with pain relief as oxycodone given intravenously using a patient-controlled analgesia (PCA) infusion device. The secondary objectives were to compare the gastrointestinal symptoms and postsurgical recovery of the two groups. METHODS This prospective randomized trial was conducted at a University Hospital between February 2015 and June 2017. Altogether 270 CS patients were randomly assigned to receive postoperative oxycodone pain relief by IV PCA (n = 133) or orally (n = 137). Pain control and satisfaction with pain treatment were assessed by a numeric rating scale (NRS) at 2, 4, 8, and 24 h postoperatively. RESULTS No differences were found in NRS pain scores or satisfaction between the groups except at 24 h pain when coughing; there was a statistically significant difference favoring the IV PCA group (p = 0.006). In the IV PCA group, the patients experienced more nausea at 4 h (p = 0.001) and more vomiting at 8 h (p = 0.010). Otherwise, postoperative recovery was similar in both groups. The equianalgesic dose of oxycodone was significantly smaller in the oral group (p = 0.003). CONCLUSIONS This study indicates that oral oxycodone provides pain control and satisfaction with pain relief equal to IV oxycodone PCA for postoperative analgesia after cesarean section. Satisfaction with pain treatment was high in both groups, and both methods were well tolerated. Early nausea was less common with oral medication.",2019,No differences were found in NRS pain scores or satisfaction between the groups except at 24 h pain when coughing; there was a statistically significant difference favoring the IV PCA group (p = 0.006).,"['postoperative analgesia after cesarean section', 'pain relief after cesarean section', 'University Hospital between February 2015 and June 2017', 'Altogether 270 CS patients']","['oxycodone PCA', 'oral oxycodone', 'oxycodone', 'postoperative oxycodone pain relief by IV PCA', 'oxycodone given intravenously using a patient-controlled analgesia (PCA) infusion device']","['vomiting', 'Pain control and satisfaction with pain treatment', 'numeric rating scale (NRS', 'Satisfaction with pain treatment', 'Early nausea', 'equianalgesic dose of oxycodone', 'postoperative recovery', 'pain control and satisfaction with pain relief', 'tolerated', 'nausea', 'gastrointestinal symptoms and postsurgical recovery', 'NRS pain scores or satisfaction']","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C4319603', 'cui_str': '270 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0030625', 'cui_str': 'PCA'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0222045'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0030049', 'cui_str': 'Oxycodone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]",270.0,0.0949123,No differences were found in NRS pain scores or satisfaction between the groups except at 24 h pain when coughing; there was a statistically significant difference favoring the IV PCA group (p = 0.006).,"[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Mäkelä', 'Affiliation': 'Department of Obstetrics and Gynecology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland. katja.makela@pshp.fi.'}, {'ForeName': 'Outi', 'Initials': 'O', 'LastName': 'Palomäki', 'Affiliation': 'Department of Obstetrics and Gynecology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.'}, {'ForeName': 'Satu', 'Initials': 'S', 'LastName': 'Pokkinen', 'Affiliation': 'Department of Anesthesia, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.'}, {'ForeName': 'Arvi', 'Initials': 'A', 'LastName': 'Yli-Hankala', 'Affiliation': 'Department of Anesthesia, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Helminen', 'Affiliation': 'Research, Development and Innovation Centre, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.'}, {'ForeName': 'Jukka', 'Initials': 'J', 'LastName': 'Uotila', 'Affiliation': 'Department of Obstetrics and Gynecology, Tampere University Hospital, PL 2000, 33521, Tampere, Finland.'}]",Archives of gynecology and obstetrics,['10.1007/s00404-019-05260-3'] 1454,31343947,Cellular and morphological changes with EAA supplementation before and after total knee arthroplasty.,"Investigate the underlying cellular basis of muscle atrophy (Placebo) and atrophy reduction (essential amino acid supplementation, EAAs) in total knee arthroplasty (TKA) patients by examining satellite cells and other key histological markers of inflammation, recovery, and fibrosis. Forty-one subjects (53-76 yr) scheduled for TKA were randomized into two groups, ingesting 20 g of EAAs or placebo, twice-daily, for 7 days before TKA and for 6 wk after surgery. A first set of muscle biopsies was obtained from both legs before surgery in the operating room, and patients were randomly assigned and equally allocated to have two additional biopsies at either 1 or 2 wk after surgery. Biopsies were processed for gene expression and immunohistochemistry. Satellite cells were significantly higher in patients ingesting 20 g of essential amino acids twice daily for the 7 days leading up to surgery compared with Placebo (operative leg P = 0.03 for satellite cells/fiber and P = 0.05 for satellite cell proportions for Type I-associated cells and P = 0.05 for satellite cells/fiber for Type II-associated cells.) Myogenic regulatory factor gene expression was different between groups, with the Placebo Group having elevated MyoD expression at 1 wk and EAAs having elevated myogenin expression at 1 wk. M1 macrophages were more prevalent in Placebo than the EAAs Group. IL-6 and TNF-α transcripts were elevated postsurgery in both groups; however, TNF-α declined by 2 wk in the EAAs Group. EAAs starting 7 days before surgery increased satellite cells on the day of surgery and promoted a more favorable inflammatory environment postsurgery. NEW & NOTEWORTHY Clinical studies by our group indicate that the majority of muscle atrophy after total knee arthroplasty (TKA) in older adults occurs rapidly, within the first 2 wks. We have also shown that essential amino acid supplementation (EAAs) before and after TKA mitigates muscle atrophy; however, the mechanisms are unknown. These results suggest that satellite cell numbers are elevated with EAA ingestion before surgery, and after surgery, EAA ingestion positively influences markers of inflammation. Combined, these data may help inform further studies designed to address the accelerated sarcopenia that occurs in older adults after major surgery.",2019,"M1 macrophages were more prevalent in Placebo than the EAAs Group. IL-6 and TNF-α transcripts were elevated postsurgery in both groups; however, TNF-α declined by 2 wk in the EAAs Group.","['total knee arthroplasty (TKA) patients', 'total knee arthroplasty', 'Forty-one subjects (53-76 yr) scheduled for TKA', 'older adults after major surgery']","['muscle atrophy (Placebo) and atrophy reduction (essential amino acid supplementation, EAAs', 'ingesting 20 g of EAAs or placebo', 'Placebo', 'total knee arthroplasty (TKA']","['satellite cells', 'M1 macrophages', 'TNF-α', 'Satellite cells', 'Myogenic regulatory factor gene expression', 'IL-6 and TNF-α transcripts', 'elevated MyoD expression']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0026846', 'cui_str': 'Atrophy, Muscle'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0556083', 'cui_str': 'Essential amino acid supplementation (product)'}, {'cui': 'C0450403', 'cui_str': '20G (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}]","[{'cui': 'C0332221', 'cui_str': 'Satellite (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0206474', 'cui_str': 'Myogenic Regulatory Factors'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",41.0,0.162478,"M1 macrophages were more prevalent in Placebo than the EAAs Group. IL-6 and TNF-α transcripts were elevated postsurgery in both groups; however, TNF-α declined by 2 wk in the EAAs Group.","[{'ForeName': 'Jonathan B', 'Initials': 'JB', 'LastName': 'Muyskens', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, Oregon.'}, {'ForeName': 'Douglas M', 'Initials': 'DM', 'LastName': 'Foote', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, Oregon.'}, {'ForeName': 'Nathan J', 'Initials': 'NJ', 'LastName': 'Bigot', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, Oregon.'}, {'ForeName': 'Lisa A', 'Initials': 'LA', 'LastName': 'Strycker', 'Affiliation': 'Oregon Research Institute, Eugene, Oregon.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Smolkowski', 'Affiliation': 'Oregon Research Institute, Eugene, Oregon.'}, {'ForeName': 'Tessa K', 'Initials': 'TK', 'LastName': 'Kirkpatrick', 'Affiliation': 'Slocum Research and Education Foundation, Eugene, Oregon.'}, {'ForeName': 'Brick A', 'Initials': 'BA', 'LastName': 'Lantz', 'Affiliation': 'Slocum Center for Orthopedics and Sports Medicine, Eugene, Oregon.'}, {'ForeName': 'Steven N', 'Initials': 'SN', 'LastName': 'Shah', 'Affiliation': 'Slocum Center for Orthopedics and Sports Medicine, Eugene, Oregon.'}, {'ForeName': 'Craig G', 'Initials': 'CG', 'LastName': 'Mohler', 'Affiliation': 'Slocum Center for Orthopedics and Sports Medicine, Eugene, Oregon.'}, {'ForeName': 'Brian A', 'Initials': 'BA', 'LastName': 'Jewett', 'Affiliation': 'Slocum Center for Orthopedics and Sports Medicine, Eugene, Oregon.'}, {'ForeName': 'Erin C', 'Initials': 'EC', 'LastName': 'Owen', 'Affiliation': 'Slocum Research and Education Foundation, Eugene, Oregon.'}, {'ForeName': 'Hans C', 'Initials': 'HC', 'LastName': 'Dreyer', 'Affiliation': 'Department of Human Physiology, University of Oregon, Eugene, Oregon.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00869.2018'] 1455,32134320,Factors contributing to symptom change in standardized and individualized Internet-based interventions for depression: A randomized-controlled trial.,"Research suggests 4 categories of outcome predictors in face-to-face therapy (i.e., treatment expectations, extratherapeutic factors, relationship factors, and factors specific to a treatment approach/technique). However, it is unclear whether these factors are relevant in standardized and individualized Internet-based interventions. To investigate this question, a secondary analysis of data from 1,089 mildly to moderately depressed adults undergoing 6 weeks of cognitive-behavioral Internet-based intervention for depression randomized to receive either weekly written feedback individualized by a counselor or automated and fully standardized feedback was performed. The following variables corresponding to the 4 categories were tested regarding associations with depressive symptom change during multiple treatment periods within a multigroup structural equation model: (a) outcome expectations, (b) extratherapeutic stressors and stress change during treatment, (c) midtreatment working alliance (task/goal and bond), and (d) uptake of treatment-specific components (logins and specific tool use). Results suggest similar regressive associations across treatment conditions: Previous symptom change was the most important predictor for subsequent symptom developments. Stress at baseline and the uptake of specific treatment components only played a minor role, and stronger task/goal ratings were associated with later symptom improvements. Early symptom improvements predicted stronger midtreatment task/goal and bond ratings, whereas only stronger task/goal ratings were associated with later symptom improvements. Outcome expectations were only indirectly related with symptom change mediated through goal/task ratings. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Early symptom improvements predicted stronger midtreatment task/goal and bond ratings, whereas only stronger task/goal ratings were associated with later symptom improvements.","['1,089 mildly to moderately depressed adults undergoing 6 weeks of cognitive-behavioral Internet-based intervention for depression randomized to receive either']",['weekly written feedback individualized by a counselor or automated and fully standardized feedback'],"['stronger task/goal ratings', 'stronger midtreatment task/goal and bond ratings', 'symptom change mediated through goal/task ratings', 'extratherapeutic stressors and stress change during treatment, (c) midtreatment working alliance (task/goal and bond), and (d) uptake of treatment-specific components (logins and specific tool use', 'depressive symptom change']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}]","[{'cui': 'C0442821', 'cui_str': 'Strong (qualifier value)'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}]",,0.056975,"Early symptom improvements predicted stronger midtreatment task/goal and bond ratings, whereas only stronger task/goal ratings were associated with later symptom improvements.","[{'ForeName': 'Pavle', 'Initials': 'P', 'LastName': 'Zagorscak', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Heinrich', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Schulze', 'Affiliation': 'Department of Psychological Assessment, Differential and Personality Psychology, Freie Universität Berlin.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Böttcher', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, Freie Universität Berlin.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Knaevelsrud', 'Affiliation': 'Department of Clinical-Psychological Intervention, Freie Universität Berlin.'}]","Psychotherapy (Chicago, Ill.)",['10.1037/pst0000276'] 1456,32688225,Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study.,"Exercise may be beneficial for individuals in substance use disorder (SUD) treatment given the higher rates of both medical and psychiatric comorbidity, namely mood and anxiety disorders, compared to the general population. Gender and/or racial/ethnic differences in health benefits and response to prescribed exercise have been reported and may have implications for designing exercise interventions in SUD programs. METHOD Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN) Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial. Gender differences across racial/ethnic groups in physiological responses and stimulant withdrawal severity across time were analyzed using linear mixed effects models. RESULTS Males completed significantly more exercise sessions than females and were more adherent to the prescribed exercise dose of 12 Kcal/Kg/Week. Controlling for age, race/ethnicity, treatment group and stimulant withdrawal severity, there was a significant gender by time interaction for body mass index (BMI) (p < 0.001), waist circumference (p < 0.001) and heart rate measured prior to exercise sessions (p < 0.01). For females, body mass index (BMI) and waist circumference increased over time while for males BMI and waist circumference stayed unchanged or slightly decreased with time. Heart rate over time significantly increased for females at a higher rate than in males. Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not. Although baseline differences were observed, there were no time by race/ethnicity differences in physiologic responses. DISCUSSION Gender differences in response to exercise may have implications for developing gender specific exercise interventions in SUD programs.",2020,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,['Data are from the National Drug Abuse Treatment Clinical Trials Network (NIDA/CTN'],['Stimulant Reduction Intervention'],"['waist circumference', 'heart rate', 'time interaction for body mass index (BMI', 'Heart rate over time', 'Stimulant withdrawal severity', 'body mass index (BMI) and waist circumference', 'exercise sessions']","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0013146', 'cui_str': 'Drug abuse'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]","[{'cui': 'C0002763', 'cui_str': 'Central stimulant'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1997739', 'cui_str': 'Psychostimulant withdrawal'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0431347,Stimulant withdrawal severity was similar in males and females at baseline but males exhibited a significant decrease over time while females did not.,"[{'ForeName': 'T K', 'Initials': 'TK', 'LastName': 'Killeen', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA. Electronic address: killeent@musc.edu.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wolf', 'Affiliation': 'Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'T L', 'Initials': 'TL', 'LastName': 'Greer', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Carmody', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Rethorst', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'University of Texas Southwestern Medical Center, Dallas, TX, USA.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106546'] 1457,32688368,Thymus size in children with moderate malnutrition: a cohort study from Burkina Faso.,"BACKGROUND Moderate acute malnutrition (MAM) affects millions of children, increasing their risk of dying from infections. Thymus atrophy may be a marker of malnutrition-associated immunodeficiency, but factors associated with thymus size in children with MAM are unknown, as is the effect of nutritional interventions on thymus size. METHODS Thymus size was measured by ultrasound in 279 children in Burkina Faso with MAM, diagnosed by low mid-upper arm circumference (MUAC) and/or low weight-for-length z-score (WLZ), who received 12 weeks treatment with different food supplements as part of a randomized trial. Correlates of thymus size and of changes in thymus size after treatment, and after another 12 weeks of follow-up were identified. RESULTS Thymus size correlated positively with age, anthropometry and blood haemoglobin, and was smaller in children with malaria. Children with malnutrition diagnosed using MUAC had a smaller thymus than children diagnosed based on WLZ. Thymus size increased during and after treatment, similarly across the different food supplement groups. CONCLUSIONS In children with MAM, the thymus is smaller in children with anaemia or malaria, and grows with recovery. Assuming that thymus size reflects vulnerability, low MUAC seems to identify more vulnerable children than low WLZ in children with MAM. IMPACT Thymus atrophy is known to be a marker of the immunodeficiency associated with malnutrition in children.In children with moderate malnutrition, we found the thymus to be smaller in children with anaemia or malaria.Assuming that thymus size reflects vulnerability, low MUAC seems to identify more vulnerable children than low weight for length.Thymus atrophy appears reversible with recovery from malnutrition, with similar growth seen in children randomized to treatment with different nutritional supplements.",2020,"Thymus size increased during and after treatment, similarly across the different food supplement groups. ","['279 children in Burkina Faso with MAM, diagnosed by low mid-upper arm circumference (MUAC) and/or low weight-for-length z-score (WLZ), who received 12 weeks treatment with different food supplements as part of a randomized trial', 'Children with malnutrition diagnosed using', 'children with moderate malnutrition']","['MUAC', 'WLZ']",['Thymus size'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0006409', 'cui_str': 'Burkina Faso'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}]","[{'cui': 'C0040112', 'cui_str': 'Thymus Extracts'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",279.0,0.033117,"Thymus size increased during and after treatment, similarly across the different food supplement groups. ","[{'ForeName': 'Maren J H', 'Initials': 'MJH', 'LastName': 'Rytter', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark. marenrytter@hotmail.com.'}, {'ForeName': 'Bernardette', 'Initials': 'B', 'LastName': 'Cichon', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Fabiansen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Charles W', 'Initials': 'CW', 'LastName': 'Yameogo', 'Affiliation': 'Institut de Recherche en Sciences de la Santé, Ouagadougou, 03 BP:7048, Ouagadougou 03, Burkina Faso.'}, {'ForeName': 'Sylvain Z', 'Initials': 'SZ', 'LastName': 'Windinmi', 'Affiliation': 'Centre Médical Chirurgicale Pédiatrique, Ouahigouya, Burkina Faso.'}, {'ForeName': 'Kim F', 'Initials': 'KF', 'LastName': 'Michaelsen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Filteau', 'Affiliation': 'London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Dorthe L', 'Initials': 'DL', 'LastName': 'Jeppesen', 'Affiliation': 'Department of Paediatrics, Copenhagen University Hospital Hvidovre, Kettergårds allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Friis', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Briend', 'Affiliation': 'Department of Nutrition, Exercise and Sports, University of Copenhagen, Rolighedsvej 30, 1958, Frederiksberg C, Denmark.'}, {'ForeName': 'Vibeke B', 'Initials': 'VB', 'LastName': 'Christensen', 'Affiliation': 'Médecins Sans Frontières-Denmark, Strandlodsvej 44, 2. 2300, København S, Denmark.'}]",Pediatric research,['10.1038/s41390-020-1057-5'] 1458,31809403,Noninvasive Hemodynamic Monitoring of Cocaine-Induced Changes in Cardiac Output and Systemic Vascular Resistance in Subjects With Chronic Cocaine Use Disorder.,"BACKGROUND Cocaine use disorder (CUD) is a common problem in the United States and worldwide. The mechanisms by which cocaine induces acute cardiovascular toxicity are various. When systemically absorbed through inhaled or intravenous routes, cocaine induces an acute rise in the heart rate (HR) and blood pressure (BP) leading to a significant increase in the cardiac output (CO) and myocardial oxygen demand. Subjects with chronic CUD represent a special population that has experienced long-term cocaine exposure, often without showing signs of cardiovascular disease. We herein present prospectively collected data on the acute hemodynamic effects of intravenous cocaine in a cohort of nontreatment-seeking individuals with CUD without cardiovascular disease. METHODS AND RESULTS Baseline physiologic data were collected while participants underwent infusion of escalating doses of cocaine (10, 20, and 40 mg administered over 2 minutes) at baseline and after receiving single-blind placebo treatment. Continuous noninvasive hemodynamic monitoring was performed throughout the infusion sessions using the ccNexfin finger cuffs (Edwards Lifesciences Corp, Irvine, CA). The recorded arterial BP tracings allowed for the measurement of beat-to-beat changes in HR, BP, stroke volume, CO, and systemic vascular resistance (SVR). None of the subjects experienced a treatment-related serious adverse event. Cocaine produced significant dose-dependent increases in median HR, BP, CO, and +dP/dt (a measure of cardiac contractility) and a significant dose-dependent reduction in median SVR. CONCLUSIONS Intravenous cocaine in a cohort of otherwise healthy subjects with CUD produced dose-dependent increases in CO, largely explained by an increase in HR, accompanied by a dose-dependent decrease in SVR.",2019,"Cocaine produced significant dose-dependent increases in median HR, BP, CO, and +dP/dt (a measure of cardiac contractility) and a significant dose-dependent reduction in median SVR. ","['Subjects with chronic CUD', 'Subjects With Chronic Cocaine Use Disorder', 'cohort of nontreatment-seeking individuals with CUD without cardiovascular disease']","['placebo', 'Cocaine', 'cocaine']","['SVR', 'heart rate (HR) and blood pressure (BP', 'HR, BP, stroke volume, CO, and systemic vascular resistance (SVR', 'cardiac output (CO) and myocardial oxygen demand', 'median SVR', 'Cardiac Output and Systemic Vascular Resistance', 'recorded arterial BP tracings', 'acute cardiovascular toxicity', 'median HR, BP, CO, and +dP/dt (a measure of cardiac contractility']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0038455', 'cui_str': 'Stroke Volume'}, {'cui': 'C1258192', 'cui_str': 'Total Peripheral Resistance'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",,0.0741744,"Cocaine produced significant dose-dependent increases in median HR, BP, CO, and +dP/dt (a measure of cardiac contractility) and a significant dose-dependent reduction in median SVR. ","[{'ForeName': 'Benjamin W', 'Initials': 'BW', 'LastName': 'Van Tassell', 'Affiliation': 'Wright Center for Clinical and Translational Research, Richmond, VA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Westman', 'Affiliation': 'Pauley Heart Center, School of Medicine, Richmond, VA.'}, {'ForeName': 'Cory', 'Initials': 'C', 'LastName': 'Trankle', 'Affiliation': 'Pauley Heart Center, School of Medicine, Richmond, VA.'}, {'ForeName': 'Sade', 'Initials': 'S', 'LastName': 'Johns', 'Affiliation': 'Wright Center for Clinical and Translational Research, Richmond, VA.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Kadariya', 'Affiliation': 'Institute of Drug and Alcohol Studies.'}, {'ForeName': 'Leo', 'Initials': 'L', 'LastName': 'Buckley', 'Affiliation': 'Department of Pharmacotherapy, School of Pharmacy, Richmond, VA.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Carbone', 'Affiliation': 'Institute of Drug and Alcohol Studies.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Abbate', 'Affiliation': 'Wright Center for Clinical and Translational Research, Richmond, VA.'}, {'ForeName': 'Frederick Gerard', 'Initials': 'FG', 'LastName': 'Moeller', 'Affiliation': 'Wright Center for Clinical and Translational Research, Richmond, VA.'}]",Journal of cardiovascular pharmacology,['10.1097/FJC.0000000000000740'] 1459,32496074,"Effects of the COVID-19 pandemic and nationwide lockdown on trust, attitudes toward government, and well-being.","The contagiousness and deadliness of COVID-19 have necessitated drastic social management to halt transmission. The immediate effects of a nationwide lockdown were investigated by comparing matched samples of New Zealanders assessed before (N prelockdown = 1,003) and during the first 18 days of lockdown (N lockdown = 1,003). Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being. Applying propensity score matching to approximate the conditions of a randomized controlled experiment, the study found that people in the pandemic/lockdown group reported higher trust in science, politicians, and police, higher levels of patriotism, and higher rates of mental distress compared to people in the prelockdown prepandemic group. Results were confirmed in within-subjects analyses. The study highlights social connectedness, resilience, and vulnerability in the face of adversity and has applied implications for how countries face this global challenge. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being.,[],"['COVID-19 pandemic and nationwide lockdown', 'nationwide lockdown']","['institutional trust and attitudes toward the nation and government and (b) health and well-being', 'mental distress']",[],"[{'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}]","[{'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0235109', 'cui_str': 'Mental distress'}]",,0.0275454,Two categories of outcomes were examined: (a) institutional trust and attitudes toward the nation and government and (b) health and well-being.,"[{'ForeName': 'Chris G', 'Initials': 'CG', 'LastName': 'Sibley', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Lara M', 'Initials': 'LM', 'LastName': 'Greaves', 'Affiliation': 'School of Social Sciences, University of Auckland.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Satherley', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Marc S', 'Initials': 'MS', 'LastName': 'Wilson', 'Affiliation': 'School of Psychology, Victoria University of Wellington.'}, {'ForeName': 'Nickola C', 'Initials': 'NC', 'LastName': 'Overall', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Carol H J', 'Initials': 'CHJ', 'LastName': 'Lee', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Petar', 'Initials': 'P', 'LastName': 'Milojev', 'Affiliation': 'School of Humanities, University of Auckland.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Bulbulia', 'Affiliation': 'School of Humanities, University of Auckland.'}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Osborne', 'Affiliation': 'School of Psychology, University of Auckland.'}, {'ForeName': 'Taciano L', 'Initials': 'TL', 'LastName': 'Milfont', 'Affiliation': 'School of Psychology, Victoria University of Wellington.'}, {'ForeName': 'Carla A', 'Initials': 'CA', 'LastName': 'Houkamau', 'Affiliation': 'Department of Management and International Business, University of Auckland.'}, {'ForeName': 'Isabelle M', 'Initials': 'IM', 'LastName': 'Duck', 'Affiliation': 'Silverdale Medical.'}, {'ForeName': 'Raine', 'Initials': 'R', 'LastName': 'Vickers-Jones', 'Affiliation': 'School of Psychology, University of Queensland.'}, {'ForeName': 'Fiona Kate', 'Initials': 'FK', 'LastName': 'Barlow', 'Affiliation': 'School of Psychology, University of Queensland.'}]",The American psychologist,['10.1037/amp0000662'] 1460,31815642,KONTAKT© for Australian adolescents on the autism spectrum: protocol of a randomized control trial.,"BACKGROUND Individuals diagnosed with autism spectrum disorder (ASD) experience impairing challenges in social communication and interaction across multiple contexts. While social skills group training (SSGT) has shown moderate effects on various sociability outcomes in ASD, there is a need for (1) replication of effects in additional clinical and cultural contexts, (2) designs that employ active control groups, (3) calculation of health economic benefits, (4) identification of the optimal training duration, and (5) measurement of individual goals and quality of life outcomes. METHOD/DESIGN With the aim of investigating the efficacy and cost-effectiveness of a SSGT, KONTAKT©, a two-armed randomized control trial with adolescents aged 12-17 years (N = 90) with ASD and an intelligence quotient (IQ) of over 70 will be undertaken. Following stratification for centre and gender, participants will be randomly assigned to either KONTAKT© or to an active control group, a group-based cooking programme. Participants will attend both programmes in groups of 6-8 adolescents, over 16 one-and-a-half-hour sessions. The primary outcome examined is adolescent self-rated achievement of personally meaningful social goals as assessed via the Goal Attainment Scaling during an interview with a blinded clinician. Secondary outcomes include adolescent self-reported interpersonal efficacy, quality of life, social anxiety, loneliness, face emotion recognition performance and associated gaze behaviour, and parent proxy reports of autistic traits, quality of life, social functioning, and emotion recognition and expression. Cost-effectiveness will be investigated in relation to direct and indirect societal and healthcare costs. DISCUSSION The primary outcomes of this study will be evidenced in the anticipated achievement of adolescents' personally meaningful social goals following participation in KONTAKT© as compared to the active control group. This design will enable rigorous evaluation of the efficacy of KONTAKT©, exercising control over the possibly confounding effect of exposure to a social context of peers with a diagnosis of ASD. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry (ANZCTR). ACTRN12617001117303. Registered on 31 July 2017. anzctr.org.au ClinicalTrials.gov, NCT03294668. Registered on 22 September 2017. https://clinicaltrials.gov.",2019,"Secondary outcomes include adolescent self-reported interpersonal efficacy, quality of life, social anxiety, loneliness, face emotion recognition performance and associated gaze behaviour, and parent proxy reports of autistic traits, quality of life, social functioning, and emotion recognition and expression.","['Individuals diagnosed with autism spectrum disorder (ASD', 'adolescents aged 12-17 years (N\u2009=\u200990) with ASD and an intelligence quotient (IQ) of over 70 will be undertaken', 'Australian adolescents on the autism spectrum', 'peers with a diagnosis of ASD']","['KONTAKT© or to an active control group, a group-based cooking programme', 'SSGT, KONTAKT', 'KONTAKT', 'social skills group training (SSGT']","[""anticipated achievement of adolescents' personally meaningful social goals following participation in KONTAKT©"", 'Cost-effectiveness', 'efficacy and cost-effectiveness', 'adolescent self-rated achievement of personally meaningful social goals as assessed via the Goal Attainment Scaling during an interview with a blinded clinician', 'adolescent self-reported interpersonal efficacy, quality of life, social anxiety, loneliness, face emotion recognition performance and associated gaze behaviour, and parent proxy reports of autistic traits, quality of life, social functioning, and emotion recognition and expression']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0456149', 'cui_str': 'Intelligence quotient (observable entity)'}, {'cui': 'C0041666', 'cui_str': 'Undertaking'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0335326', 'cui_str': 'Cookery'}, {'cui': 'C4521834', 'cui_str': 'United States Military enlisted E6'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0222045'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0424166', 'cui_str': 'Social Anxiety'}, {'cui': 'C0023974', 'cui_str': 'Loneliness'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0013987', 'cui_str': 'Emotions'}, {'cui': 'C0524637', 'cui_str': 'Recognition (Psychology)'}, {'cui': 'C0553544', 'cui_str': 'Gaze (finding)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0600420', 'cui_str': 'Proxy'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C3854321', 'cui_str': 'Expression'}]",8.0,0.0963691,"Secondary outcomes include adolescent self-reported interpersonal efficacy, quality of life, social anxiety, loneliness, face emotion recognition performance and associated gaze behaviour, and parent proxy reports of autistic traits, quality of life, social functioning, and emotion recognition and expression.","[{'ForeName': 'Bahareh', 'Initials': 'B', 'LastName': 'Afsharnejad', 'Affiliation': 'School of Occupational Therapy, Social Works and Speech pathology, Curtin University, Kent street, Bentley, Perth, WA, 6102, Australia.'}, {'ForeName': 'Marita', 'Initials': 'M', 'LastName': 'Falkmer', 'Affiliation': 'School of Occupational Therapy, Social Works and Speech pathology, Curtin University, Kent street, Bentley, Perth, WA, 6102, Australia.'}, {'ForeName': 'Melissa H', 'Initials': 'MH', 'LastName': 'Black', 'Affiliation': 'School of Occupational Therapy, Social Works and Speech pathology, Curtin University, Kent street, Bentley, Perth, WA, 6102, Australia.'}, {'ForeName': 'Tasha', 'Initials': 'T', 'LastName': 'Alach', 'Affiliation': 'Autism Association of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Lenhard', 'Affiliation': ""Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Division of Neuropsychiatry, Department of Women's and Children's Health, Karolinska Institutet & Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fridell', 'Affiliation': ""Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Division of Neuropsychiatry, Department of Women's and Children's Health, Karolinska Institutet & Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.""}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Coco', 'Affiliation': ""Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Division of Neuropsychiatry, Department of Women's and Children's Health, Karolinska Institutet & Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.""}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Milne', 'Affiliation': 'Autism Association of Western Australia, Perth, WA, Australia.'}, {'ForeName': 'Nigel T M', 'Initials': 'NTM', 'LastName': 'Chen', 'Affiliation': 'Curtin Autism Research Group (CARG), Curtin University, Perth, WA, Australia.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Bölte', 'Affiliation': 'School of Occupational Therapy, Social Works and Speech pathology, Curtin University, Kent street, Bentley, Perth, WA, 6102, Australia.'}, {'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Girdler', 'Affiliation': 'School of Occupational Therapy, Social Works and Speech pathology, Curtin University, Kent street, Bentley, Perth, WA, 6102, Australia. Sonya.girdler@curtin.edu.au.'}]",Trials,['10.1186/s13063-019-3721-9'] 1461,31427751,"Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders.","Activation of the innate immune system is commonly associated with depression. Immunomodulatory drugs may have efficacy for depressive symptoms that are co-morbidly associated with inflammatory disorders. We report a large-scale re-analysis by standardized procedures (mega-analysis) of patient-level data combined from 18 randomized clinical trials conducted by Janssen or GlaxoSmithKline for one of nine disorders (N = 10,743 participants). Core depressive symptoms (low mood, anhedonia) were measured by the Short Form Survey (SF-36) or the Hospital Anxiety and Depression Scale (HADS), and participants were stratified into high (N = 1921) versus low-depressive strata based on baseline ratings. Placebo-controlled change from baseline after 4-16 weeks of treatment was estimated by the standardized mean difference (SMD) over all trials and for each subgroup of trials targeting one of 7 mechanisms (IL-6, TNF-α, IL-12/23, CD20, COX2, BLγS, p38/MAPK14). Patients in the high depressive stratum showed modest but significant effects on core depressive symptoms (SMD = 0.29, 95% CI [0.12-0.45]) and related SF-36 measures of mental health and vitality. Anti-IL-6 antibodies (SMD = 0.8, 95% CI [0.20-1.41]) and an anti-IL-12/23 antibody (SMD = 0.48, 95% CI [0.26-0.70]) had larger effects on depressive symptoms than other drug classes. Adjustments for physical health outcome marginally attenuated the average treatment effect on depressive symptoms (SMD = 0.20, 95% CI: 0.06-0.35), but more strongly attenuated effects on mental health and vitality. Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment. Novel immune-therapeutics can produce antidepressant effects in depressed patients with primary inflammatory disorders that are not entirely explained by treatment-related changes in physical health.",2020,Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment.,"['depressed patients with primary inflammatory disorders', 'for one of nine disorders (N\u2009=\u200910,743 participants']","['Placebo', 'placebo', 'immunomodulatory drugs', 'Janssen or GlaxoSmithKline']","['depressive symptoms', 'Anti-IL-6 antibodies', 'mental health and vitality', 'core depressive symptoms', 'related SF-36 measures of mental health and vitality', 'Core depressive symptoms (low mood, anhedonia', 'Hospital Anxiety and Depression Scale (HADS']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1290884', 'cui_str': 'Inflammatory disorder'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0344315', 'cui_str': 'Depressed'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0451221', 'cui_str': 'Hospital anxiety and depression scale (assessment scale)'}, {'cui': 'C0048008', 'cui_str': 'Benzenamine, 4-((4-aminophenyl)sulfonyl)-N-hydroxy-'}]",,0.398153,Effects of anti-IL-12/23 remained significant and anti-IL-6 antibodies became a trend after controlling for physical response to treatment.,"[{'ForeName': 'Gayle M', 'Initials': 'GM', 'LastName': 'Wittenberg', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA. gwittenb@its.jnj.com.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Stylianou', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Ashutosh', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Bangalore, India.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Jagannatha', 'Affiliation': 'Clinical Statistics, GlaxoSmithKline R&D, Bangalore, India.'}, {'ForeName': 'Dai', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Hsu', 'Affiliation': 'Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Curran', 'Affiliation': 'Immunology, Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Khan', 'Affiliation': 'ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, La Jolla, CA, USA.'}, {'ForeName': 'Edward T', 'Initials': 'ET', 'LastName': 'Bullmore', 'Affiliation': 'ImmunoPsychiatry, Immuno-Inflammation Therapeutic Area Unit, GlaxoSmithKline R&D, Stevenage, UK.'}, {'ForeName': 'Wayne C', 'Initials': 'WC', 'LastName': 'Drevets', 'Affiliation': 'Neuroscience, Janssen Research & Development, LLC, La Jolla, CA, USA.'}]",Molecular psychiatry,['10.1038/s41380-019-0471-8'] 1462,31815647,Fecal microbiome as determinant of the effect of diet on colorectal cancer risk: comparison of meat-based versus pesco-vegetarian diets (the MeaTIc study).,"BACKGROUND Convincing evidence suggests that the risk of colorectal cancer (CRC) is increased by the typical Western diet characterized by high consumption of red and processed meat. In addition, some epidemiological studies suggest a reduction in the risk of CRC associated with fish consumption. The role of the gut microbiome in this diet-associated risk is not well understood. METHODS/DESIGN This is a randomized parallel open clinical trial comprising a total of 150 clinically healthy subjects randomly assigned to three groups: a meat-based diet of which 4 portions per week are red meat (1 portion = 150 g), 3 portions per week are processed meat (1 portion = 50 g), and 1 portion per week is poultry (1 portion = 150 g), for a total amount of 900 g per week of meat and derivatives; a meat-based diet supplemented with alpha-tocopherol; and a pesco-vegetarian diet excluding fresh and processed meat and poultry, but which includes 3 portions per week of fish for a total amount of 450 g per week. Each intervention will last 3 months. The three diets will be isocaloric and of three different sizes according to specific energy requirements. Anthropometric measurements, body composition, and blood and fecal samples will be obtained from each participant at the beginning and end of each intervention phase. The measure of the primary outcome will be the change from baseline in DNA damage induced by fecal water using the comet assay in a cellular model. Secondary outcome measures will be changes in the profile of fecal microbiomes, global fecal and urinary peroxidation markers, and neoplastic biomarkers. DISCUSSION Although epidemiological data support the promoting role of meat and the possible protective role of fish in colon carcinogenesis, no study has directly compared dietary profiles characterized by the presence of these two food groups and the role of the gut microbiome in these diet-associated CRC risks. This study will test the effect of these dietary profiles on validated CRC risk biomarkers. TRIAL REGISTRATION ClinicalTrials.gov, NCT03416777. Registered on 3 May 2018.",2019,The measure of the primary outcome will be the change from baseline in DNA damage induced by fecal water using the comet assay in a cellular model.,['150 clinically healthy subjects'],"['meat-based versus pesco-vegetarian diets', 'meat-based diet of which 4 portions per week are red meat', 'total amount of 900\u2009g per week of meat and derivatives; a meat-based diet supplemented with alpha-tocopherol; and a pesco-vegetarian diet excluding fresh and processed meat and poultry']","['DNA damage induced by fecal water using the comet assay in a cellular model', 'Anthropometric measurements, body composition, and blood and fecal samples', 'profile of fecal microbiomes, global fecal and urinary peroxidation markers, and neoplastic biomarkers']","[{'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0311164', 'cui_str': 'Vegetarian diet'}, {'cui': 'C0012155', 'cui_str': 'Diet'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0452848', 'cui_str': 'Red Meat'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0665509', 'cui_str': 'OF 900'}, {'cui': 'C0243072', 'cui_str': 'derivatives'}, {'cui': 'C0969677', 'cui_str': 'd-alpha tocopherol'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0443224', 'cui_str': 'Fresh (qualifier value)'}, {'cui': 'C0452956', 'cui_str': 'Processed meat (substance)'}, {'cui': 'C0452888', 'cui_str': 'Poultry (substance)'}]","[{'cui': 'C0012860', 'cui_str': 'DNA Injury'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0751980', 'cui_str': 'Gel Electrophoresis, Single-Cell'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0005768'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",150.0,0.0337447,The measure of the primary outcome will be the change from baseline in DNA damage induced by fecal water using the comet assay in a cellular model.,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sofi', 'Affiliation': 'Department of Experimental and Clinical Medicine, School of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy. francesco.sofi@unifi.it.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Dinu', 'Affiliation': 'Department of Experimental and Clinical Medicine, School of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.'}, {'ForeName': 'Giuditta', 'Initials': 'G', 'LastName': 'Pagliai', 'Affiliation': 'Department of Experimental and Clinical Medicine, School of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.'}, {'ForeName': 'Fabrice', 'Initials': 'F', 'LastName': 'Pierre', 'Affiliation': 'INRA, ToxAlim (Research Centre in Food Toxicology), Universitè de Toulouse, ENVT, INP-Purpan, UPS, Toulouse, France.'}, {'ForeName': 'Francoise', 'Initials': 'F', 'LastName': 'Gueraud', 'Affiliation': 'INRA, ToxAlim (Research Centre in Food Toxicology), Universitè de Toulouse, ENVT, INP-Purpan, UPS, Toulouse, France.'}, {'ForeName': 'Jildau', 'Initials': 'J', 'LastName': 'Bowman', 'Affiliation': 'Netherlands Organisation for Applied Scientific Research (TNO) Research group: Microbiology and Systems Biology (MSB), Amsterdam, The Netherlands.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gerard', 'Affiliation': 'Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Longo', 'Affiliation': 'Institute of Agricultural Biology and Biotechnology (IBBA), National Research Council (CNR), Pisa, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Giovannelli', 'Affiliation': ""Department of Neuroscience, Psychology, Drug Research and Children's Health, University of Florence, Florence, Italy.""}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Caderni', 'Affiliation': ""Department of Neuroscience, Psychology, Drug Research and Children's Health, University of Florence, Florence, Italy.""}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'de Filippo', 'Affiliation': 'Institute of Agricultural Biology and Biotechnology (IBBA), National Research Council (CNR), Pisa, Italy.'}]",Trials,['10.1186/s13063-019-3801-x'] 1463,32134683,Effects of exercise training and sex on dynamic responses of O 2 uptake in type 2 diabetes.,"Effects of training and sex on oxygen uptake dynamics during exercise in type 2 diabetes mellitus (T2DM) are not well established. We tested the hypotheses that exercise training improves the time constant of the primary phase of oxygen uptake (τ p oxygen uptake) and with greater effect in males than females. Forty-one subjects with T2DM were assigned to 2 training groups (T male , T female ) and 2 control groups (C male , C female ), and were assessed before and after a 12-week intervention period. Twelve weeks of aerobic/resistance training was performed 3 times per week, 60-90 min per session. Assessments included ventilatory threshold (VT), peak oxygen uptake, τ p oxygen uptake (80%VT), and dynamic responses of cardiac output, mean arterial pressure and systemic vascular conductance (80%VT). Training significantly decreased τ p oxygen uptake in males by a mean of 20% (T male = 42.7 ± 6.2 to 34.3 ± 7.2 s) and females by a mean of 16% (T female = 42.2 ± 9.3 to 35.4 ± 8.6 s); whereas τ p oxygen uptake was not affected in controls (C male = 41.6 ± 9.8 to 42.9 ± 7.6 s; C female = 40.4 ± 12.2 to 40.6 ± 13.4 s). Training increased peak oxygen uptake in both sexes (12%-13%) but did not alter systemic cardiovascular dynamics in either sex. Training improved oxygen uptake dynamics to a similar extent in males and females in the absence of changes in systemic cardiovascular dynamics. Novelty Similar training improvements in oxygen uptake dynamics were observed in males and females with T2DM. In both sexes these improvements occurred without changes in systemic cardiovascular dynamics.",2020,Training increased V̇O2peak in both sexes (12-13 %) but did not alter systemic cardiovascular dynamics in either sex.,"['males than females', 'Forty-one subjects with T2DM', 'type 2 diabetes', 'males and females with type 2 diabetes', 'type 2 diabetes mellitus (T2DM']","['training and sex', 'aerobic/resistance training', 'exercise training']","['taupV̇O2', 'systemic cardiovascular dynamics', 'ventilatory threshold (VT), V̇O2peak, taupV̇O2 (80 %VT) and dynamic responses of cardiac output, mean arterial pressure and systemic vascular conductance', 'time constant of the primary phase of V̇O2 (taupV̇O2', 'V̇O2 dynamics']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0449864', 'cui_str': 'Threshold (property) (qualifier value)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}]",41.0,0.016161,Training increased V̇O2peak in both sexes (12-13 %) but did not alter systemic cardiovascular dynamics in either sex.,"[{'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Green', 'Affiliation': 'School of Science and Health, Western Sydney University, Sydney 2567, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Kiely', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Eamonn', 'Initials': 'E', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Norita', 'Initials': 'N', 'LastName': 'Gildea', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}, {'ForeName': 'Donal', 'Initials': 'D', 'LastName': ""O'Shea"", 'Affiliation': ""Endocrinology, St Columcille's and St Vincent's Hospitals, Dublin, Dublin 18, Ireland.""}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Egaña', 'Affiliation': 'Department of Physiology, School of Medicine, Trinity College Dublin, Dublin 2, Ireland.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0636'] 1464,31113857,A Randomized Controlled Trial Comparing Two Lung Expansion Therapies After Upper Abdominal Surgery.,"BACKGROUND Lung expansion therapy is often ordered after surgery to improve alveolar ventilation and reduce risks of postoperative pulmonary complications. The impact of lung expansion therapy at altering ventilation in patients who are not intubated has not been described. The primary purpose of this study was to determine if there is a difference in dorsal redistribution of ventilation and incidences of postoperative pulmonary complications when comparing incentive spirometry (IS) with EzPAP lung expansion therapy after upper abdominal surgery. Our a priori null hypothesis was that there are no differences. METHODS This randomized controlled trial enrolled adult human subjects after upper- abdominal surgery from January 2017 to November 2018. The subjects were allocated to receive IS or EzPAP 3 times a day on postoperative days 1-5. An electrical impedance tomography device was connected to the subjects for a single lung expansion therapy session on postoperative days 1, 3, and 5 to measure the change in post-lung expansion therapy dorsal end-expiratory lung impedance (ΔEELI%). Lung expansion therapy sessions with electrical impedance tomography included 2 min of normal breathing, 3 cycles of 10 breaths, and 2 min of normal breathing after cycle 3. Postoperative pulmonary complications were screened until hospital discharge. Mann-Whitney, chi-square, and Fisher exact tests were applied. Data were reported as count ( n ), percentage, and median (interquartile range) for primary and secondary outcomes. Alpha (2-tailed) was < 0.05. RESULTS A total of 112 subjects were enrolled to receive IS ( n = 56) or EzPAP ( n = 56). Baseline characteristics were equal. Post-lung expansion therapy dorsal ΔEELI% increased for both groups, but the dorsal ΔEELI% for IS versus EzPAP on postoperative day 1 (16% versus 12%, P = .39), postoperative day 3 (6% versus 6%, P = .68), and postoperative day 5 (9% versus 6%, P = .46) was not significantly different. Hospital length of stay (4 d; P = .30) and incidence of postoperative pulmonary complications (3.6% versus 7.1%, P = .19) were similar. CONCLUSIONS There was no significant post-lung expansion therapy dorsal ΔEELI% or postoperative pulmonary complications among the adults who received IS or EzPAP 3 times a day after upper abdominal surgery. (ClinicalTrials.gov registration NCT02892773.).",2019,"Hospital stay (4 d; P = .30) and incidence of postoperative pulmonary complications (3.6% versus 7.1%, P = .19) were similar. ","['112 subjects were enrolled to receive IS ( n = 56) or', 'patients who are not intubated has not been described', 'adult human subjects after upper-abdominal surgery from January 2017 to November 2018', 'after upper abdominal surgery']","['Two Lung Expansion Therapies', 'lung expansion therapy', 'incentive spirometry (IS) with Ez-PAP lung expansion therapy', 'EzPAP']","['Postoperative pulmonary complications', 'postoperative pulmonary complications', 'Post-lung expansion therapy dorsal ΔEELI', 'incidence of postoperative pulmonary complications', 'Hospital stay', 'normal breathing, 3 cycles of 10 breaths, and 2 min of normal breathing', 'α (2-tailed']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0445105', 'cui_str': 'Not intubated (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}]","[{'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0454512', 'cui_str': 'Incentive spirometry (regime/therapy)'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205095', 'cui_str': 'Behind (qualifier value)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0231795', 'cui_str': 'Normal respiratory function (finding)'}, {'cui': 'C0225386', 'cui_str': 'Breath (substance)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0039259', 'cui_str': 'Tail'}]",112.0,0.135743,"Hospital stay (4 d; P = .30) and incidence of postoperative pulmonary complications (3.6% versus 7.1%, P = .19) were similar. ","[{'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Rowley', 'Affiliation': 'Pulmonary Diagnostics and Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, Virginia. ddr8a@virginia.edu.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Malinowski', 'Affiliation': 'Pulmonary Diagnostics and Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, Virginia.'}, {'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Di Peppe', 'Affiliation': 'Pulmonary Diagnostics and Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, Virginia.'}, {'ForeName': 'Ryan M', 'Initials': 'RM', 'LastName': 'Sharkey', 'Affiliation': 'Pulmonary Diagnostics and Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, Virginia.'}, {'ForeName': 'Daniel U', 'Initials': 'DU', 'LastName': 'Gochenour', 'Affiliation': 'Pulmonary Diagnostics and Respiratory Therapy Services, University of Virginia Medical Center, Charlottesville, Virginia.'}, {'ForeName': 'Kyle B', 'Initials': 'KB', 'LastName': 'Enfield', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia.'}]",Respiratory care,['10.4187/respcare.06812'] 1465,31815645,Acupuncture for patients with insomnia disorder using resting-state functional magnetic resonance imaging: a protocol for a randomized controlled trial.,"BACKGROUND Insomnia is among the most prevalent of the sleep-related disorders. Insomnia disorder is associated with a brain hyperarousal state manifested by abnormal regional brain activity and resting state functional connectivity. Acupuncture improves sleep quality and modulates the hyperarousal state; however, the underlying neurobiological basis for improved sleep quality is poorly understood. The purpose of this clinical trial is to study the efficacy of acupuncture in the treatment of insomnia disorder. In addition, the neural mechanism by which acupuncture affects insomnia disorder will be explored using resting-state functional magnetic resonance imaging (rs-fMRI) and neuropsychological parameters. METHODS AND DESIGN A randomized, patient- and assessor-blinded trial will be conducted. We will randomize (in a 1:1 ratio) 60 eligible patients with insomnia disorder into a real acupuncture group or a sham acupuncture group. Interventions will be administered three times per week over a 4-week period, with an 8-week follow-up period. The healthy control group will consist of 30 age- and sex-matched healthy individuals who sleep well without any treatment intervention. All participants will undergo neuropsychological and rs-fMRI evaluations. The change in Pittsburgh Sleep Quality Index (PSQI) scores is the primary outcome parameter. The secondary outcome parameters include the Hyperarousal scale (HAS), rs-fMRI measurements, the Fatigue scale-14 (FS-14), the Hamilton depression scale (HAMD), the Hamilton anxiety scale (HAMA), a sleep diary, and an actigraph. Assessment of all parameters will be performed at baseline, post-treatment, and during follow-up. Analyses will be implemented based on intention-to-treat. DISCUSSION The study results will be used to clarify the effectiveness and elucidate the mechanism by which acupuncture improves sleep quality in patients with insomnia disorder. TRIAL REGISTRATION Chinese Clinical Trials Register, ChiCTR1800015282. Registered on 20 March 2018.",2019,"The secondary outcome parameters include the Hyperarousal scale (HAS), rs-fMRI measurements, the Fatigue scale-14 (FS-14), the Hamilton depression scale (HAMD), the Hamilton anxiety scale (HAMA), a sleep diary, and an actigraph.","['60 eligible patients with insomnia disorder into a real acupuncture group or a sham acupuncture group', '30 age- and sex-matched healthy individuals who sleep well without any treatment intervention', 'patients with insomnia disorder', 'patients with insomnia disorder using resting-state functional magnetic resonance imaging', 'insomnia disorder']","['acupuncture', 'Acupuncture']","['sleep quality', 'Hyperarousal scale (HAS), rs-fMRI measurements, the Fatigue scale-14 (FS-14), the Hamilton depression scale (HAMD), the Hamilton anxiety scale (HAMA), a sleep diary, and an actigraph', 'Pittsburgh Sleep Quality Index (PSQI) scores', 'hyperarousal state']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}, {'cui': 'C0222045'}, {'cui': 'C0376335', 'cui_str': 'fMRI'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0376660', 'cui_str': 'Diary'}, {'cui': 'C4545801', 'cui_str': 'PSQI (Pittsburgh Sleep Quality Index) score'}, {'cui': 'C1301808', 'cui_str': 'State'}]",60.0,0.116066,"The secondary outcome parameters include the Hyperarousal scale (HAS), rs-fMRI measurements, the Fatigue scale-14 (FS-14), the Hamilton depression scale (HAMD), the Hamilton anxiety scale (HAMA), a sleep diary, and an actigraph.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Art Museum Backstreet, Dongcheng District, Beijing, 100010, China. guojing_2002@163.com.'}, {'ForeName': 'Siyi', 'Initials': 'S', 'LastName': 'Yu', 'Affiliation': ""Chengdu University of Traditional Chinese Medicine, 37 Shi'er Qiao Road, Jinniu District, Chengdu, 610072, Sichuan, China.""}, {'ForeName': 'Chunhong', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, 23 Meishuguanhou Street, Dongcheng District, Beijing, 100010, China.'}, {'ForeName': 'Guiling', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Art Museum Backstreet, Dongcheng District, Beijing, 100010, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Acupuncture and Moxibustion Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, 23 Art Museum Backstreet, Dongcheng District, Beijing, 100010, China.'}]",Trials,['10.1186/s13063-019-3836-z'] 1466,32139090,A randomized control trial evaluating efficacy of antimicrobial impregnated hospital privacy curtains in an intensive care setting.,"BACKGROUND Acquisition of pathogens into health care settings from prior room occupants has been documented. Hospital room privacy curtains are at high risk for pathogenic bacterial contamination. Antimicrobial impregnated curtains could be effective in reducing contamination. METHODS Rooms within an intensive care unit at The University of Iowa Hospitals and Clinics were randomized to 3 arms. The 2 intervention arms: (1) halamine antimicrobial curtains (BioSmart curtain [BSC]) and (2) halamine antimicrobial curtains sprayed twice weekly with a sodium hypochlorite-based disinfecting spray (BSC-pre and BSC-post) and a third control arm (standard curtain [SC]). Samples were collected twice weekly for 3 weeks to assess pathogenic bacterial contamination. RESULTS The likelihood of remaining uncontaminated was 38% for SC, 37% for BSC, and 60% for the BSC-pre group. Time to event (contamination) analysis found no statistically significant difference between pathogenic contamination between the SC, BSC, and BSC-pre groups (P value = .1921). There was a decrease in average colony count for BSC curtains compared with control, however, this difference was not statistically significant. Hypochlorite spray was found to transiently decontaminate curtains, but effects dissipated after 72 hours. CONCLUSIONS BSC did not show a significant reduction in pathogenic contamination compared with control. Antimicrobial curtains could have a role in reducing environmental contamination in the health care setting. Future studies should be done to determine the long-term effects of using antimicrobial curtains in health care.",2020,"There was a decrease in average colony count for BSC curtains compared with control, however, this difference was not statistically significant.",['Rooms within an intensive care unit at The University of Iowa Hospitals and Clinics'],"['halamine antimicrobial curtains (BioSmart curtain [BSC]) and (2) halamine antimicrobial curtains sprayed twice weekly with a sodium hypochlorite-based disinfecting spray (BSC-pre and BSC-post) and a third control arm (standard curtain [SC', 'antimicrobial impregnated hospital privacy curtains']","['average colony count for BSC curtains', 'pathogenic contamination']","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0022037', 'cui_str': 'Iowa'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C1136254', 'cui_str': 'Microbicides'}, {'cui': 'C0180239', 'cui_str': 'Curtain (physical object)'}, {'cui': 'C4521772', 'cui_str': 'Spray'}, {'cui': 'C0556985', 'cui_str': 'Two times a week'}, {'cui': 'C0037518', 'cui_str': 'Sodium Hypochlorite'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0080048', 'cui_str': 'Privacy'}]","[{'cui': 'C0368993', 'cui_str': 'Colony count'}, {'cui': 'C0180239', 'cui_str': 'Curtain (physical object)'}]",,0.0368638,"There was a decrease in average colony count for BSC curtains compared with control, however, this difference was not statistically significant.","[{'ForeName': 'Geneva', 'Initials': 'G', 'LastName': 'Wilson', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA. Electronic address: geneva-wilson@uiowa.edu.'}, {'ForeName': 'Virgil', 'Initials': 'V', 'LastName': 'Jackson', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Boyken', 'Affiliation': 'Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; Internal Medicine and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.'}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Puig-Asensio', 'Affiliation': 'Internal Medicine and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.'}, {'ForeName': 'Alexandre R', 'Initials': 'AR', 'LastName': 'Marra', 'Affiliation': 'Internal Medicine and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA; Division of Medical Practice, Hospital Israelita Albert Einstein, São Paulo, Brazil.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Perencevich', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; Center for Access and Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA; Internal Medicine and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.'}, {'ForeName': 'Marin L', 'Initials': 'ML', 'LastName': 'Schweizer', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA; Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; Center for Access and Delivery Research and Evaluation (CADRE), Iowa City VA Health Care System, Iowa City, IA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Diekema', 'Affiliation': 'Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA; Internal Medicine and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Breheny', 'Affiliation': 'Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Petersen', 'Affiliation': 'Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA; Center for Emerging Infectious Diseases, University of Iowa Research Park, Coralville, IA.'}]",American journal of infection control,['10.1016/j.ajic.2019.12.024'] 1467,32134882,The Efficacy of PowerPoint-based CBT Delivered Through Email: Breaking the Barriers to Treatment for Generalized Anxiety Disorder.,"OBJECTIVE A lack of resources and cultural stigma associated with mental health treatment necessitate the development of innovative and economical individualized treatments. This study evaluated the efficacy of delivering computer-based cognitive behavioral therapy (e-CBT) presented through Microsoft PowerPoint and delivered via email in the treatment of generalized anxiety disorder (GAD) to Iranian patients, as a means of overcoming treatment barriers. METHODS Participants (N=80) of Iranian descent were recruited through announcements on psychology websites, Iranian organization websites, weblogs, and in flyers. Participants were randomly assigned to either an e-CBT or a control group. The e-CBT group received 12 weekly modules and homework assignments through email, presented using PowerPoint. The control group received no treatment (individuals in the control group were able to pursue another treatment, but would then be excluded from the study although they could continue with the program). All emails were sent by an attending or resident psychiatrist, who also provided feedback on weekly homework via email. The Beck Anxiety Inventory was used to measure levels of anxiety before study onset and changes in levels of anxiety upon completion of the program at 12 weeks, and at 6-month and 1-year follow-up in both groups. RESULTS Beck Anxiety Inventory scores were significantly reduced in the group who received PowerPoint e-CBT modules delivered via email, compared with the control group, following 12 weeks of treatment, and the reductions were maintained at both follow-up points. CONCLUSIONS Delivery of PowerPoint e-CBT modules via email was found to be a viable method for delivering CBT to individuals with GAD and a simple method for overcoming language, cultural, and travel barriers to accessing mental health resources. This simplified approach to the individualization and delivery of treatment modules has the potential to improve access to CBT as a treatment option throughout the world.",2020,"RESULTS Beck Anxiety Inventory scores were significantly reduced in the group who received PowerPoint e-CBT modules delivered via email, compared with the control group, following 12 weeks of treatment, and the reductions were maintained at both follow-up points. ","['Generalized Anxiety Disorder', 'Participants (N=80) of Iranian descent were recruited through announcements on psychology websites, Iranian organization websites, weblogs, and in flyers', 'generalized anxiety disorder (GAD) to Iranian patients']","['PowerPoint-based CBT', 'e-CBT', 'delivering computer-based cognitive behavioral therapy (e-CBT']","['Beck Anxiety Inventory', 'Beck Anxiety Inventory scores']","[{'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder (disorder)'}, {'cui': 'C0554962', 'cui_str': 'Iranian (NMO) (ethnic group)'}, {'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0220885', 'cui_str': 'organization'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C4274492', 'cui_str': 'Beck Anxiety Inventory score (observable entity)'}]",,0.0249523,"RESULTS Beck Anxiety Inventory scores were significantly reduced in the group who received PowerPoint e-CBT modules delivered via email, compared with the control group, following 12 weeks of treatment, and the reductions were maintained at both follow-up points. ","[{'ForeName': 'Nazanin', 'Initials': 'N', 'LastName': 'Alavi', 'Affiliation': ""ALAVI: Queen's University Department of Psychiatry, Providence Care Hospital, Kingston, ON, Canada and University of Toronto Department of Psychiatry, Toronto, ON, Canada HIRJI: Queen's University Department of Psychology, Kingston, ON, Canada.""}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Hirji', 'Affiliation': ''}]",Journal of psychiatric practice,['10.1097/PRA.0000000000000455'] 1468,32266406,"Corrigendum for Struik et al. Very Low and Higher Carbohydrate Diets Promote Differential Appetite Responses in Adults with Type 2 Diabetes: A Randomized Trial. J Nutr 2020; nxz344, https://doi.org/10.1093/jn/nxz344.",,2020,,['Adults with Type 2 Diabetes'],['Carbohydrate Diets'],[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0301577', 'cui_str': 'Carbohydrate diet'}]",[],,0.0202625,,[],The Journal of nutrition,['10.1093/jn/nxaa047'] 1469,31815655,Chinese pediatric Tuina on children with acute diarrhea: study protocol for a randomized sham-controlled trial.,"BACKGROUND Acute pediatric diarrhea is one of the most common causes of morbidity and mortality worldwide and seriously affects the health of children. Previous studies have shown that pediatric Tuina, a traditional Chinese medicine therapy, has potential therapeutic benefits for acute pediatric diarrhea. However, the evidence for its effectiveness is insufficient due to the lack of high-quality clinical studies. Our aim is to evaluate the efficacy of Chinese pediatric Tuina for children aged 0-6 years with acute diarrhea. METHODS/DESIGN This study is a randomized, double-blind, sham-controlled trial. We will include 122 children with acute diarrhea from Dongguan Kanghua Hospital in Guangdong province, China. The patients will be allocated into either the pediatric Tuina group or the sham Tuina group in a 1:1 ratio. The treatment will last for 3 days followed by an 11-day follow-up period. Both groups will receive usual care. In addition, the experimental group will receive 15-25 min of Chinese pediatric Tuina, while the control group will receive 15-25 min of sham pediatric Tuina. Both groups will receive treatments once per day, for 3 consecutive days. Primary outcome measures are diarrhea days from baseline and diarrhea times on the third day. Secondary outcome measures are the global change rating and period of days when the stool character changes to normal. Safety assessments will be monitored during each visit. DISCUSSION This clinical trial is designed to evaluate the efficacy of pediatric Tuina for children with acute diarrhea. We expect results to provide solid evidence and support for pediatric Tuina as an appropriate treatment for children with acute diarrhea. TRIAL REGISTRATION ClinicalTrials.gov, NCT03005821. Registered on 29 December 2016.",2019,"Previous studies have shown that pediatric Tuina, a traditional Chinese medicine therapy, has potential therapeutic benefits for acute pediatric diarrhea.","['122\xa0children with acute diarrhea from Dongguan Kanghua Hospital in Guangdong province, China', 'children with acute diarrhea', 'Chinese pediatric Tuina on children with acute diarrhea', 'children aged 0-6\u2009years with acute diarrhea']",['Chinese pediatric Tuina'],"['diarrhea days from baseline and diarrhea times', 'global change rating and period of days when the stool character changes to normal']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0740441', 'cui_str': 'Acute diarrhea (disorder)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0235181', 'cui_str': 'Character change in'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}]",,0.354539,"Previous studies have shown that pediatric Tuina, a traditional Chinese medicine therapy, has potential therapeutic benefits for acute pediatric diarrhea.","[{'ForeName': 'Taoying', 'Initials': 'T', 'LastName': 'Lu', 'Affiliation': 'Program for Outcome Assessment in TCM, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Huiyan', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Lingjia', 'Initials': 'L', 'LastName': 'Yin', 'Affiliation': 'Program for Outcome Assessment in TCM, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Jianxiong', 'Initials': 'J', 'LastName': 'Cai', 'Affiliation': 'Program for Outcome Assessment in TCM, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.'}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Li', 'Affiliation': 'Gastroenterology Department, Guangzhou Hospital of TCM, Guangzhou, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Dai', 'Affiliation': 'Acupuncture and Tuina Department, Wenzhou Hospital of Chinese medicine, Wenzhou, China.'}, {'ForeName': 'Conghao', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Pediatric Department, Dongguan Kanghua hospital, Dongguan, China.'}, {'ForeName': 'Yongping', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Pediatric Department, Dongguan Kanghua hospital, Dongguan, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Xiang', 'Affiliation': 'Pediatric Department, Dongguan Kanghua hospital, Dongguan, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Pediatric Department, Dongguan Kanghua hospital, Dongguan, China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Pediatric Department, Dongguan Kanghua hospital, Dongguan, China.'}, {'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Tuina, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China.'}, {'ForeName': 'Darong', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Program for Outcome Assessment in TCM, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. darongwu@163.com.'}]",Trials,['10.1186/s13063-019-3818-1'] 1470,31815661,"Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial.","BACKGROUND Much evidence is available demonstrating that both vitamin D and omega-3 fatty acids block the development and progression of colonic carcinogenesis. The results of animal studies have shown that the consumption of omega-3 fatty acids can decrease inflammatory biomarkers, enhance the efficacy of chemotherapy, and decrease the side effects of chemotherapy or cancer. Also, observational studies propose that higher levels of 25(OH)D are related to improved survival of colorectal cancer patients. This study will aim to evaluate the effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in colorectal cancer patients. METHODS/DESIGN We will carry out an 8-week double-blind randomized, placebo-controlled clinical trial to evaluate the effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with stage ӀӀ or ӀӀӀ colorectal cancer undergoing chemotherapy. DISCUSSION Because of the important effects of vitamin D and omega-3 fatty acids on molecular pathways involved in cancer development and progression, it seems that both vitamin D and omega-3 fatty acids may provide a new adjuvant therapy by decreasing inflammatory biomarkers and resistance to cancer treatment in patients with colorectal cancer. TRIAL REGISTRATION Iranian Registry of Clinical Trials IRCT20180306038979N1. Registered on 16 March 2018.",2019,"Also, observational studies propose that higher levels of 25(OH)D are related to improved survival of colorectal cancer patients.","['colorectal cancer patients', 'patients with stage ӀӀ or ӀӀӀ colorectal cancer undergoing chemotherapy', 'patients with colorectal cancer']","['vitamin D and omega-3 fatty acids co-supplementation', 'vitamin D and omega-3 fatty acids', 'vitamin D and omega-3 fatty acids block', 'placebo']","['inflammatory biomarkers, tumor marker CEA, and nutritional status']","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C1719844', 'cui_str': 'Greek letter omega'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0041365', 'cui_str': 'Biomarkers, Cancer'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}]",,0.165205,"Also, observational studies propose that higher levels of 25(OH)D are related to improved survival of colorectal cancer patients.","[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Haidari', 'Affiliation': 'Department of Nutrition, Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Behnaz', 'Initials': 'B', 'LastName': 'Abiri', 'Affiliation': 'Department of Nutrition, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Masood', 'Initials': 'M', 'LastName': 'Iravani', 'Affiliation': 'Department of Oncology and Hematology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed-Mohsen', 'Initials': 'SM', 'LastName': 'Razavi', 'Affiliation': 'Department of Oncology and Hematology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Parvin', 'Initials': 'P', 'LastName': 'Sarbakhsh', 'Affiliation': 'Department of Statistics and Epidemiology, School of Public Health, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Kambiz', 'Initials': 'K', 'LastName': 'Ahmadi-Angali', 'Affiliation': 'Faculty of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Mohammadreza', 'Initials': 'M', 'LastName': 'Vafa', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran. vafa.m@iums.ac.ir.'}]",Trials,['10.1186/s13063-019-3719-3'] 1471,31026216,Why Does Prevention of Recurrent Urinary Tract Infection not Result in Less Renal Scarring? A Deeper Dive into the RIVUR Trial.,"PURPOSE The RIVUR (Randomized Intervention for Children with Vesicoureteral Reflux) trial reported that antibiotic prophylaxis reduced recurrent urinary tract infection but antibiotic prophylaxis was not associated with decreased new renal scarring. However, the original reports did not assess the relationship among recurrent urinary tract infection, new renal scarring and antibiotic prophylaxis in detail. Therefore, we investigated the relationship among these issues. MATERIALS AND METHODS We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial. The primary outcome was recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan. Due to a low number of events, propensity score was used to adjust for confounders. Multivariate logistic regression was fitted to investigate the associations between the covariates and the outcome. RESULTS A total of 489 patients (91% female, mean age 20.3 months) were included in the study. Any new renal scarring was more common among those with recurrent urinary tract infection (OR 4.1, 95% CI 2.0-8.5, p <0.01) after adjusting for age, sex, index urinary tract infection, duplication, bowel bladder dysfunction and antibiotic prophylaxis. Recurrent urinary tract infection associated new renal scarring occurred in 5 of 244 (2%) patients on antibiotic prophylaxis and 13 of 245 (5%) on placebo. Compared to antibiotic prophylaxis, placebo was associated with a higher risk of recurrent urinary tract infection associated new renal scarring (OR 3.1, 95% CI 1.0-8.8, p=0.04) after adjusting for age, sex, race, index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring. There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. CONCLUSIONS Recurrent urinary tract infection was associated with new renal scarring in the RIVUR trial. When limited to recurrent urinary tract infection associated new renal scarring, antibiotic prophylaxis was associated with a decreased risk of this outcome. It remains unclear why new renal scarring developed in a proportion of subjects without recurrent urinary tract infection. The results should be carefully interpreted due to the inherent limitations.",2019,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","['Children with Vesicoureteral Reflux', 'We included subjects with dimercaptosuccinic acid scan within 6 months of enrollment and at least 1 followup dimercaptosuccinic acid scan from the RIVUR trial', '489 patients (91% female, mean age 20.3 months) were included in the study']","['antibiotic prophylaxis', 'antibiotic prophylaxis, placebo', 'placebo']","['higher risk of recurrent urinary tract infection associated new renal scarring', 'index urinary tract infection, bowel bladder dysfunction, duplication, hydronephrosis, vesicoureteral reflux grade and baseline renal scarring', 'recurrent urinary tract infection associated new renal scarring, defined as recurrent urinary tract infection and new changes on dimercaptosuccinic acid scan', 'scar severity at final dimercaptosuccinic acid scan', 'Recurrent urinary tract infection associated new renal scarring']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0332285', 'cui_str': 'In (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0282638', 'cui_str': 'Premedication, Antibiotic'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection (disorder)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1700247', 'cui_str': 'Renal scarring'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C0232841', 'cui_str': 'Bladder dysfunction (finding)'}, {'cui': 'C0332597', 'cui_str': 'Duplication (finding)'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0042580', 'cui_str': 'Vesicoureteral Reflux'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C1875873', 'cui_str': '2,3-Dimercaptosuccinic Acid'}, {'cui': 'C0441633'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}]",489.0,0.0321717,"There were no differences in scar severity at final dimercaptosuccinic acid scan (p=0.88) or change from baseline (p=0.53) between antibiotic prophylaxis and placebo. ","[{'ForeName': 'Hsin-Hsiao', 'Initials': 'HH', 'LastName': 'Wang', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kurtz', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Logvinenko', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}, {'ForeName': 'Caleb', 'Initials': 'C', 'LastName': 'Nelson', 'Affiliation': ""Department of Urology, Boston Children's Hospital , Boston , Massachusetts.""}]",The Journal of urology,['10.1097/JU.0000000000000292'] 1472,31408686,Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.,"BACKGROUND No oral systemic treatments are approved for pediatric patients with psoriasis. OBJECTIVE To evaluate the pharmacokinetics and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in pediatric patients with psoriasis. METHODS This phase 2, multicenter, open-label study enrolled pediatric patients with moderate to severe plaque psoriasis. Patients received apremilast twice daily without titration for 2 weeks (group 1 [age, 12-17 years; weight, ≥35 kg]: apremilast 20 or 30 mg; group 2 [age, 6-11 years; weight, ≥15 kg]: apremilast 20 mg), followed by a 48-week extension. Primary endpoints were pharmacokinetics and safety. Other endpoints were taste/acceptability and change from baseline in score on the Psoriasis Area and Severity Index. RESULTS A total of 42 enrolled patients (21 adolescents [age, 12-17 years] and 21 children [age, 6-11 years]) received apremilast. Pharmacokinetics modeling and noncompartmental analyses showed that weight-based dosing with apremilast 20 mg twice daily in children or apremilast 20 or 30 mg twice daily in adolescents provides exposure (area under the concentration-time curve from time 0 to 12 hours after the dose) that is comparable to that achieved with apremilast 30 mg twice daily in adults. The safety profile was generally similar to that in adults. Most study participants liked the taste of the tablet. Improvements from baseline in mean Psoriasis Area and Severity Index score were 68% for adolescents (overall) and 79% for children. LIMITATIONS No children weighing less than 20 kg were enrolled. CONCLUSIONS This first-time-in-children phase 2 study supports weight-based apremilast dosing for future phase 3 studies of pediatric plaque psoriasis.",2020,"Improvements from baseline in mean PASI score were 68% for adolescents (overall) and 79% for children). ","['pediatric patients with moderate to severe plaque psoriasis', 'pediatric psoriasis patients', '42 enrolled patients (21 adolescents [age 12‒17 years] and 21 children [age 6‒11 years', 'Pediatric Patients With Moderate to Severe Plaque Psoriasis', 'No children weighing <20 kg were enrolled']",[],"['taste/acceptability and change from baseline in PASI score', 'mean PASI score', 'safety profile', 'PK and safety']","[{'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0406317', 'cui_str': 'Plaque psoriasis (disorder)'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]",[],"[{'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",42.0,0.0383809,"Improvements from baseline in mean PASI score were 68% for adolescents (overall) and 79% for children). ","[{'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Paller', 'Affiliation': 'Northwestern University Feinberg Medical School, Chicago, Illinois. Electronic address: apaller@northwestern.edu.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Hong', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Emily M', 'Initials': 'EM', 'LastName': 'Becker', 'Affiliation': 'University of Texas Health Science Center-San Antonio, San Antonio, Texas.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'de Lucas', 'Affiliation': 'Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Paris', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Zuoshun', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Barcellona', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Maes', 'Affiliation': 'Celgene Corporation, Summit, New Jersey.'}, {'ForeName': 'Loretta', 'Initials': 'L', 'LastName': 'Fiorillo', 'Affiliation': 'Pediatric Department, University of Alberta, Edmonton, Canada.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2019.08.019'] 1473,31815656,Cognitive-behavioral intervention via interactive multimedia online video game for active aging: study protocol for a randomized controlled trial.,"BACKGROUND Due to the progressive aging of the population, programs to promote active aging have been recommended. However, older adults have difficulty accessing them. Interventions administered through online video games may increase their accessibility, and complementing these with a smartphone app will likely increase adherence and allow for ongoing professional monitoring. The objective of this study is to evaluate the efficacy of a cognitive-behavioral intervention for active aging administered through an online interactive multimedia video game that includes a smartphone app companion. The secondary objectives are to analyze the moderators and mediators of the change in the outcome variables and to evaluate the adherence to the intervention. METHODS/DESIGN A randomized controlled clinical trial will be conducted. Adults 45 years and older will be randomly assigned to a cognitive-behavioral intervention administered through an online multimedia video game that includes a smartphone app companion or to a control group that will receive online information on active aging (274 participants per group). The intervention will be administered in eight weekly 45-min modules. An investigator-blinded evaluation will be conducted using online self-administered tests at baseline, post-intervention, and 6- and 12-month follow-ups. The primary outcome will be mental health status as evaluated using the 36-item Short-Form Health Survey (SF-36) at post-intervention. Secondary outcomes will be emotional well-being, depressive symptoms, reinforcement, negative thoughts, self-reported memory, cognitive task performance, sleep hygiene behaviors, physical activity, eating habits, body mass index, social support, dropout, treatment adherence, and satisfaction with the intervention. DISCUSSION If the results are favorable, this study would involve the development of the first evidence-based active aging promotion intervention based on a video game that includes a smartphone app companion, providing evidence on its efficacy, accessibility, and clinical utility. TRIAL REGISTRATION ClinicalTrials.gov, NCT03643237. Registered 27 August 2018.",2019,Adults 45 years and older will be randomly assigned to a cognitive-behavioral intervention administered through an online multimedia video game that includes a smartphone app companion or to a control group that will receive online information on active aging (274 participants per group).,"['Adults 45\u2009years and older', 'older adults']","['Cognitive-behavioral intervention via interactive multimedia online video game', 'cognitive-behavioral intervention administered through an online multimedia video game that includes a smartphone app companion or to a control group that will receive online information on active aging', 'cognitive-behavioral intervention']","['emotional well-being, depressive symptoms, reinforcement, negative thoughts, self-reported memory, cognitive task performance, sleep hygiene behaviors, physical activity, eating habits, body mass index, social support, dropout, treatment adherence, and satisfaction with the intervention', 'mental health status as evaluated using the 36-item Short-Form Health Survey (SF-36']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C1621583', 'cui_str': 'Administer'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0335343', 'cui_str': 'Companions'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0035007', 'cui_str': 'Reinforcement'}, {'cui': 'C1142075', 'cui_str': 'Negative thoughts'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C4277672', 'cui_str': 'Sleep Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1266864', 'cui_str': 'Eating habit'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037438'}, {'cui': 'C4505265', 'cui_str': 'Treatment Adherence'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}]",274.0,0.186762,Adults 45 years and older will be randomly assigned to a cognitive-behavioral intervention administered through an online multimedia video game that includes a smartphone app companion or to a control group that will receive online information on active aging (274 participants per group).,"[{'ForeName': 'Fernando L', 'Initials': 'FL', 'LastName': 'Vázquez', 'Affiliation': 'Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain. fernandolino.vazquez@usc.es.'}, {'ForeName': 'Ángela J', 'Initials': 'ÁJ', 'LastName': 'Torres', 'Affiliation': 'Department of Psychiatry, Radiology, Public Health, Nursing and Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Otero', 'Affiliation': 'Department of Psychology, University of A Coruña, A Coruña, Spain.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Blanco', 'Affiliation': 'Department of Evolutive and Educational Psychology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'López', 'Affiliation': 'Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'García-Casal', 'Affiliation': 'Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Arrojo', 'Affiliation': 'Department of Psychiatry, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.'}]",Trials,['10.1186/s13063-019-3859-5'] 1474,32229469,Assessing Real-Time Moderation for Developing Adaptive Mobile Health Interventions for Medical Interns: Micro-Randomized Trial.,"BACKGROUND Individuals in stressful work environments often experience mental health issues, such as depression. Reducing depression rates is difficult because of persistently stressful work environments and inadequate time or resources to access traditional mental health care services. Mobile health (mHealth) interventions provide an opportunity to deliver real-time interventions in the real world. In addition, the delivery times of interventions can be based on real-time data collected with a mobile device. To date, data and analyses informing the timing of delivery of mHealth interventions are generally lacking. OBJECTIVE This study aimed to investigate when to provide mHealth interventions to individuals in stressful work environments to improve their behavior and mental health. The mHealth interventions targeted 3 categories of behavior: mood, activity, and sleep. The interventions aimed to improve 3 different outcomes: weekly mood (assessed through a daily survey), weekly step count, and weekly sleep time. We explored when these interventions were most effective, based on previous mood, step, and sleep scores. METHODS We conducted a 6-month micro-randomized trial on 1565 medical interns. Medical internship, during the first year of physician residency training, is highly stressful, resulting in depression rates several folds higher than those of the general population. Every week, interns were randomly assigned to receive push notifications related to a particular category (mood, activity, sleep, or no notifications). Every day, we collected interns' daily mood valence, sleep, and step data. We assessed the causal effect moderation by the previous week's mood, steps, and sleep. Specifically, we examined changes in the effect of notifications containing mood, activity, and sleep messages based on the previous week's mood, step, and sleep scores. Moderation was assessed with a weighted and centered least-squares estimator. RESULTS We found that the previous week's mood negatively moderated the effect of notifications on the current week's mood with an estimated moderation of -0.052 (P=.001). That is, notifications had a better impact on mood when the studied interns had a low mood in the previous week. Similarly, we found that the previous week's step count negatively moderated the effect of activity notifications on the current week's step count, with an estimated moderation of -0.039 (P=.01) and that the previous week's sleep negatively moderated the effect of sleep notifications on the current week's sleep with an estimated moderation of -0.075 (P<.001). For all three of these moderators, we estimated that the treatment effect was positive (beneficial) when the moderator was low, and negative (harmful) when the moderator was high. CONCLUSIONS These findings suggest that an individual's current state meaningfully influences their receptivity to mHealth interventions for mental health. Timing interventions to match an individual's state may be critical to maximizing the efficacy of interventions. TRIAL REGISTRATION ClinicalTrials.gov NCT03972293; http://clinicaltrials.gov/ct2/show/NCT03972293.",2020,We found that the previous week's mood negatively moderated the effect of notifications on the current week's mood with an estimated moderation of -0.052 (P=.001).,"['Medical Interns', '1565 medical interns']",['Mobile health (mHealth) interventions'],['activity notifications'],"[{'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}]","[{'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0422202', 'cui_str': 'Notifications (procedure)'}]",1565.0,0.0508285,We found that the previous week's mood negatively moderated the effect of notifications on the current week's mood with an estimated moderation of -0.052 (P=.001).,"[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'NeCamp', 'Affiliation': 'Department of Statistics, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Srijan', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': 'Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Frank', 'Affiliation': 'Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Maureen A', 'Initials': 'MA', 'LastName': 'Walton', 'Affiliation': 'Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Ionides', 'Affiliation': 'Department of Statistics, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': 'Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Ambuj', 'Initials': 'A', 'LastName': 'Tewari', 'Affiliation': 'Department of Statistics, University of Michigan, Ann Arbor, MI, United States.'}, {'ForeName': 'Zhenke', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Biostatistics, University of Michigan, Ann Arbor, MI, United States.'}]",Journal of medical Internet research,['10.2196/15033'] 1475,30387538,Measuring epidermal effects of ostomy skin barriers.,"BACKGROUND Ostomy barriers are adhesive devices designed to hold pouching systems to the abdomen and protect the peristomal skin from stoma effluent. The objective of this study was to determine differences in the extent of skin trauma resulting from serially applying and removing two types of ostomy barriers. METHODS The study was a randomized, prospective, repeated measure trial involving healthy volunteers. The ostomy skin barriers were applied to the abdomen and changed every 3-4 days over a 17-day period. Skin observations (erythema, stripping, edge irritation and overall comparisons) were completed by a trained (blinded) observer. Transepidermal water loss (TEWL) measurements were completed by a separate (blinded) technician. TEWL was measured in a designated site and again in the most visually traumatized location at termination. RESULTS Statistically significant differences were found between the two test devices in all assessments but visual observation of erythema. Highly significant differences in TEWL were found between the test products when measured at termination from the most visually traumatized sites. CONCLUSIONS The ostomy barrier with ceramide was significantly less disruptive to the epidermis than the ostomy barrier without ceramide. TEWL measurements were more sensitive to changes in the barrier function of the skin than visual observation of erythema.",2019,The ostomy barrier with ceramide was significantly less disruptive to the epidermis than the ostomy barrier without ceramide.,['healthy volunteers'],[],"['TEWL', 'visual observation of erythema', 'Skin observations (erythema, stripping, edge irritation and overall comparisons', 'Transepidermal water loss (TEWL) measurements']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0199219', 'cui_str': 'Visual observation'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0455205', 'cui_str': 'Skin finding'}, {'cui': 'C0205154', 'cui_str': 'Along edge (qualifier value)'}, {'cui': 'C0441723', 'cui_str': 'Irritation (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}]",,0.0694067,The ostomy barrier with ceramide was significantly less disruptive to the epidermis than the ostomy barrier without ceramide.,"[{'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Grove', 'Affiliation': 'cyberDERM inc., Broomall, Pennsylvania.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Houser', 'Affiliation': 'cyberDERM inc., Broomall, Pennsylvania.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Sibbald', 'Affiliation': 'Toronto Regional (Dermatology) & Wound Healing Clinic, Mississauga, Ontario.'}, {'ForeName': 'Ginger', 'Initials': 'G', 'LastName': 'Salvadalena', 'Affiliation': 'Hollister Incorporated, Libertyville, Illinois.'}]",Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),['10.1111/srt.12630'] 1476,32493720,Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials.,"A maternal vaccine capable of boosting neutralizing antibody (NAb) responses directed against circulating viruses in HIV-infected pregnant women could effectively decrease mother-to-child transmission of HIV. However, it is not known if an HIV envelope (Env) vaccine administered to infected pregnant women could enhance autologous virus neutralization and thereby reduce this risk of vertical HIV transmission. Here, we assessed autologous virus NAb responses in maternal plasma samples obtained from AIDS Vaccine Evaluation Group (AVEG) protocols 104 and 102, representing historical phase I safety and immunogenicity trials of recombinant HIV Env subunit vaccines administered to HIV-infected pregnant women (ClinicalTrials registration no. NCT00001041). Maternal HIV Env-specific plasma binding and neutralizing antibody responses were characterized before and after vaccination in 15 AVEG 104 ( n  = 10 vaccine recipients, n  = 5 placebo recipients) and 2 AVEG 102 ( n  = 1 vaccine recipient, n  = 1 placebo recipient) participants. Single-genome amplification (SGA) was used to obtain HIV env gene sequences of autologous maternal viruses for pseudovirus production and neutralization sensitivity testing in pre- and postvaccination plasma of HIV-infected pregnant vaccine recipients ( n  = 6 gp120, n  = 1 gp160) and placebo recipients ( n  = 3). We detected an increase in Env subunit MN gp120-specific IgG binding in the group of vaccine recipients between the first immunization visit and the last visit at delivery ( P  = 0.027, 2-sided Wilcoxon test). While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy. Immunization strategies capable of further enhancing these autologous virus NAb responses in pregnant women will be important to block vertical transmission of HIV. IMPORTANCE Maternal antiretroviral therapy (ART) has effectively reduced but not eliminated the burden of mother-to-child transmission of HIV across the globe, as an estimated 160,000 children were newly infected with HIV in 2018. Thus, additional preventive strategies beyond ART will be required to close the remaining gap and end the pediatric HIV epidemic. A maternal active immunization strategy that synergizes with maternal ART could further reduce infant HIV infections. In this study, we found that two historic HIV Env vaccines did not enhance the ability of HIV-infected pregnant women to neutralize autologous viruses. Therefore, next-generation maternal HIV vaccine candidates must employ alternate approaches to achieve potent neutralizing antibody and perhaps nonneutralizing antibody responses to effectively impede vertical virus transmission. Moreover, these approaches must reflect the broad diversity of HIV strains and widespread availability of ART worldwide.",2020,"While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy.","['160,000 children were newly infected with HIV in 2018', 'HIV-infected pregnant women', 'HIV-infected pregnant women (ClinicalTrials registration no', 'pregnant women']","['Maternal antiretroviral therapy (ART', 'Single-genome amplification (SGA', 'recombinant HIV Env subunit vaccines', 'AVEG 102 ( n \u2009=\u20091 vaccine recipient, n \u2009=\u20091 placebo', 'placebo']","['Env subunit MN gp120-specific IgG binding', 'levels of autologous virus neutralization potency', 'Maternal HIV Env-specific plasma binding and neutralizing antibody responses']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0887892', 'cui_str': 'Vaccines, Subunit'}, {'cui': 'C0085432', 'cui_str': 'AIDS Vaccines'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0019691', 'cui_str': 'env Protein gp120, HIV'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0282682', 'cui_str': 'Blocking antibody'}]",160000.0,0.230413,"While no difference was observed in the levels of autologous virus neutralization potency between groups, in both groups maternal plasma collected at delivery more effectively neutralized autologous viruses from early pregnancy than late pregnancy.","[{'ForeName': 'Eliza D', 'Initials': 'ED', 'LastName': 'Hompe', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Jesse F', 'Initials': 'JF', 'LastName': 'Mangold', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Eudailey', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'McGuire', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Barton F', 'Initials': 'BF', 'LastName': 'Haynes', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'M Anthony', 'Initials': 'MA', 'LastName': 'Moody', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Peter F', 'Initials': 'PF', 'LastName': 'Wright', 'Affiliation': 'Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.'}, {'ForeName': 'Genevieve G', 'Initials': 'GG', 'LastName': 'Fouda', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Elena E', 'Initials': 'EE', 'LastName': 'Giorgi', 'Affiliation': 'Los Alamos National Laboratory, Los Alamos, New Mexico, USA.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.'}, {'ForeName': 'Sallie R', 'Initials': 'SR', 'LastName': 'Permar', 'Affiliation': 'Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA sallie.permar@duke.edu.'}]",mSphere,['10.1128/mSphere.00254-20'] 1477,31603996,"Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.","We recently showed that zoledronate prevented fractures in older women with osteopenia (hip T-scores between -1.0 and -2.5). In addition to fewer fractures, this study also suggested that women randomized to zoledronate had fewer vascular events, a lower incidence of cancer, and a trend to lower mortality. The present analysis provides a more detailed presentation of the adverse event data from that study, a 6-year, double-blind trial of 2000 women aged >65 years recruited using electoral rolls. They were randomly assigned to receive four infusions of either zoledronate 5 mg or normal saline at 18-month intervals. Supplements of vitamin D, but not calcium, were provided. There were 1017 serious adverse events in 443 participants in the placebo group, and 820 events in 400 participants in those randomized to zoledronate (relative risk = 0.90; 95% CI, 0.81 to 1.00). These events included fractures resulting in hospital admission. Myocardial infarction occurred in 39 women (43 events) in the placebo group and in 24 women (25 events) in the zoledronate group (hazard ratio 0.60 [95% CI, 0.36 to 1.00]; rate ratio 0.58 [95% CI, 0.35 to 0.94]). For a prespecified composite cardiovascular endpoint (sudden death, myocardial infarction, coronary artery revascularization, or stroke) 69 women had 98 events in the placebo group, and 53 women had 71 events in the zoledronate group (hazard ratio 0.76 [95% CI, 0.53 to 1.08]; rate ratio 0.72 [95% CI, 0.53 to 0.98]). Total cancers were significantly reduced with zoledronate (hazard ratio 0.67 [95% CI, 0.51 to 0.89]; rate ratio 0.68 [95% CI, 0.52 to 0.89]), and this was significant for both breast cancers and for non-breast cancers. Eleven women had recurrent or second breast cancers during the study, all in the placebo group. The hazard ratio for death was 0.65 (95% CI, 0.40 to 1.06; p = 0.08), and 0.51 (95% CI, 0.30 to 0.87) in those without incident fragility fracture. These apparent beneficial effects justify further appropriately powered trials of zoledronate with these nonskeletal conditions as primary endpoints. © 2019 American Society for Bone and Mineral Research.",2020,Total cancers were significantly reduced with zoledronate (hazard ratio 0.67,"['© 2019 American Society for Bone and Mineral Research', 'Eleven women had recurrent or second breast cancers', 'Osteopenic Older Women', '2000 women aged >65\u2009years recruited using electoral rolls', '69 women had 98 events in the placebo group, and 53 women had 71 events in the zoledronate group (hazard ratio 0.76', 'older women with osteopenia (hip T-scores between -1.0 and -2.5']","['zoledronate 5\u2009mg or normal saline', 'Zoledronate', 'placebo', 'zoledronate', 'vitamin D']","['Myocardial infarction', 'vascular events', 'composite cardiovascular endpoint (sudden death, myocardial infarction, coronary artery revascularization, or stroke', 'Total cancers', 'Cancer, Cardiac Events, and Mortality', 'hazard ratio for death']","[{'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0026162', 'cui_str': 'Minerals'}, {'cui': 'C0035168'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate (substance)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C0392938', 'cui_str': 'Zoledronate (substance)'}, {'cui': 'C0445115', 'cui_str': '0.9% NaCl'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042866', 'cui_str': 'Vitamin D'}]","[{'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0011071', 'cui_str': 'Sudden death (event)'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",443.0,0.62402,Total cancers were significantly reduced with zoledronate (hazard ratio 0.67,"[{'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Reid', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Horne', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Borislav', 'Initials': 'B', 'LastName': 'Mihov', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Stewart', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Garratt', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Bastin', 'Affiliation': 'Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Gamble', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.'}]",Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,['10.1002/jbmr.3860'] 1478,32234296,Evaluating bio-burden of frequently touched surfaces using Adenosine Triphosphate bioluminescence (ATP): Results from the Researching Effective Approaches to Cleaning in Hospitals (REACH) trial.,"BACKGROUND Environmental cleaning is an important approach to reducing healthcare-associated infection. The aim of this short research paper is to describe changes in the efficacy of post-discharge cleaning by examining the amount of bio-burden on frequent touch points (FTPs) in patient areas, using a validated Adenosine Triphosphate (ATP) bioluminescence sampling method. In so doing, we present findings from a secondary outcome of a recent trial, the Researching Effective Approaches to Cleaning in Hospitals (REACH) study. METHODS The REACH study used a prospective, stepped-wedge randomised cluster design. Cross sectional ATP sampling was conducted at three of the 11 participating hospitals. At each hospital, during the control and intervention phase of the study, six Frequent Touch Points (FTPs) were sampled: toilet flush, bathroom tap, inside bathroom door handle, patient call button, over bed tray table, and bed rails. RESULTS Across the three hospitals, 519 surfaces in 49 rooms (control phase) and 2856 surfaces in 251 rooms (intervention phase) were sampled. Bedroom FTP cleaning improved across all three hospitals. The cleaning of bathroom FTPs was generally high from the outset and remained consistent throughout the whole study period. Average cleaning outcomes for bathroom FTPs were consistently high during the control period however outcomes varied between individual FTP. Changes in cleaning performance over time reflected variation in intervention effectiveness at the hospital level. CONCLUSION Findings confirm improvement in cleaning in the FTPs in bedrooms, demonstrating improvements in discharge cleaning aligned with the improvements seen when using fluorescent marking technology as a marker of performance.",2020,Average cleaning outcomes for bathroom FTPs were consistently high during the control period however outcomes varied between individual FTP.,[],['Adenosine Triphosphate bioluminescence (ATP'],"['cleaning of bathroom FTPs', 'Bedroom FTP cleaning']",[],"[{'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}]","[{'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0040364', 'cui_str': 'Lavatory'}, {'cui': 'C0557652', 'cui_str': 'Bedroom'}, {'cui': 'C0542277', 'cui_str': 'Cleans drug injection equipment'}]",6.0,0.0480273,Average cleaning outcomes for bathroom FTPs were consistently high during the control period however outcomes varied between individual FTP.,"[{'ForeName': 'Brett G', 'Initials': 'BG', 'LastName': 'Mitchell', 'Affiliation': 'School of Nursing and Midwifery, University of Newcastle, Ourimbah, NSW, 2258, Australia. Electronic address: Brett.mitchell@newcastle.edu.au.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'McGhie', 'Affiliation': 'Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Whiteley', 'Affiliation': 'Whiteley Corporation, North Sydney, NSW, 2060, Australia; Western Sydney University, School of Medicine, Liverpool, NSW, 2010, Australia.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Farrington', 'Affiliation': 'Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia; School of Public Health and Social Work, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hall', 'Affiliation': 'School of Public Health, University of Queensland, Herston, Qld, 4006, Australia.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Halton', 'Affiliation': 'Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'White', 'Affiliation': 'Institute of Health and Biomedical Innovation, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia; School of Public Health and Social Work, Queensland University of Technology, GPO Box 2434, Brisbane, QLD, 4001, Australia.'}]","Infection, disease & health",['10.1016/j.idh.2020.02.001'] 1479,32418886,Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.,"BACKGROUND The ALEX study demonstrated significantly improved progression-free survival (PFS) with alectinib versus crizotinib in treatment-naive ALK-positive non-small-cell lung cancer (NSCLC) at the primary data cut-off (9 February 2017). We report mature PFS (cut-off: 30 November 2018) and overall survival (OS) data up to 5 years (cut-off: 29 November 2019). PATIENTS AND METHODS Patients with stage III/IV ALK-positive NSCLC were randomized to receive twice-daily alectinib 600 mg (n = 152) or crizotinib 250 mg (n = 151) until disease progression, toxicity, withdrawal or death. Primary end point: investigator-assessed PFS. Secondary end points included objective response rate, OS and safety. RESULTS Mature PFS data showed significantly prolonged investigator-assessed PFS with alectinib [hazard ratio (HR) 0.43, 95% confidence interval (CI) 0.32-0.58; median PFS 34.8 versus 10.9 months crizotinib]. Median duration of OS follow-up: 48.2 months alectinib, 23.3 months crizotinib. OS data remain immature (37% of events). Median OS was not reached with alectinib versus 57.4 months with crizotinib (stratified HR 0.67, 95% CI 0.46-0.98). The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 8.6% of patients still on study treatment, respectively. The OS benefit of alectinib was seen in patients with central nervous system metastases at baseline [HR 0.58 (95% CI 0.34-1.00)] and those without [HR 0.76 (95% CI 0.45-1.26)]. Median treatment duration was longer with alectinib (28.1 versus 10.8 months), and no new safety signals were observed. CONCLUSIONS Mature PFS data from ALEX confirmed significant improvement in PFS for alectinib over crizotinib in ALK-positive NSCLC. OS data remain immature, with a higher 5-year OS rate with alectinib versus crizotinib. This is the first global randomized study to show clinically meaningful improvement in OS for a next-generation tyrosine kinase inhibitor versus crizotinib in treatment-naive ALK-positive NSCLC. CLINICAL TRIALS NUMBER NCT02075840.",2020,"The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 9.3% of patients still on study treatment, respectively.","['patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study', 'patients with central nervous system metastases at baseline (HR 0.58', 'Patients with stage III/IV ALK-positive NSCLC']","['twice-daily alectinib 600 mg (n = 152) or crizotinib', 'alectinib versus crizotinib']","['overall survival (OS) data', 'Median duration of OS', 'Median OS', 'Updated overall survival and final progression-free survival data', 'Median treatment duration', 'objective response rate, OS and safety', '5-year OS rate', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1663627', 'cui_str': 'ALK protein, human'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0279130', 'cui_str': 'CNS metastases'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4517463', 'cui_str': '0.58'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C3853921', 'cui_str': 'alectinib'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C2974289', 'cui_str': 'crizotinib'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.315613,"The 5-year OS rate was 62.5% (95% CI 54.3-70.8) with alectinib and 45.5% (95% CI 33.6-57.4) with crizotinib, with 34.9% and 9.3% of patients still on study treatment, respectively.","[{'ForeName': 'T', 'Initials': 'T', 'LastName': 'Mok', 'Affiliation': 'State Key Laboratory of Translational Oncology, Chinese University of Hong Kong, Shatin, NT, Hong Kong.'}, {'ForeName': 'D R', 'Initials': 'DR', 'LastName': 'Camidge', 'Affiliation': 'University of Colorado, Denver, USA.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Gadgeel', 'Affiliation': 'Department of Internal Medicine, Rogel Cancer Center/University of Michigan, Ann Arbor, USA.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Rosell', 'Affiliation': 'Catalan Institute of Oncology, Barcelona, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Dziadziuszko', 'Affiliation': 'Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.'}, {'ForeName': 'D-W', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Seoul National University Hospital, Seoul, South Korea.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Pérol', 'Affiliation': 'Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.'}, {'ForeName': 'S-H I', 'Initials': 'SI', 'LastName': 'Ou', 'Affiliation': 'Chao Family Comprehensive Cancer Center, University of California, Irvine, USA.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'A T', 'Initials': 'AT', 'LastName': 'Shaw', 'Affiliation': 'Massachusetts General Hospital, Boston, USA.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Bordogna', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Smoljanović', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Hilton', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ruf', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Noé', 'Affiliation': 'F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Peters', 'Affiliation': 'Lausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.04.478'] 1480,32503194,Acupuncture Treatment Modulates the Connectivity of Key Regions of the Descending Pain Modulation and Reward Systems in Patients with Chronic Low Back Pain.,"Chronic low back pain (cLBP) is a common disorder with unsatisfactory treatment options. Acupuncture has emerged as a promising method for treating cLBP. However, the mechanism underlying acupuncture remains unclear. In this study, we investigated the modulation effects of acupuncture on resting state functional connectivity (rsFC) of the periaqueductal gray (PAG) and ventral tegmental area (VTA) in patients with cLBP. Seventy-nine cLBP patients were recruited and assigned to four weeks of real or sham acupuncture. Resting state functional magnetic resonance imaging data were collected before the first and after the last treatment. Fifty patients completed the study. We found remission of pain bothersomeness in all treatment groups after four weeks, with greater pain relief after real acupuncture compared to sham acupuncture. We also found that real acupuncture can increase VTA/PAG rsFC with the amygdala, and the increased rsFC was associated with decreased pain bothersomeness scores. Baseline PAG-amygdala rsFC could predict four-week treatment response. Our results suggest that acupuncture may simultaneously modulate the rsFC of key regions in the descending pain modulation (PAG) and reward systems (VTA), and the amygdala may be a key node linking the two systems to produce antinociceptive effects. Our findings highlight the potential of acupuncture for chronic low back pain management.",2020,"We found remission of pain bothersomeness in all treatment groups after four weeks, with greater pain relief after real acupuncture compared to sham acupuncture.","['Patients with Chronic Low Back Pain', 'Fifty patients completed the study', 'patients with cLBP', 'Seventy-nine cLBP patients']","['acupuncture', 'real or sham acupuncture', 'Acupuncture']","['remission of pain bothersomeness', 'pain relief', 'resting state functional connectivity (rsFC) of the periaqueductal gray (PAG) and ventral tegmental area (VTA', 'Chronic low back pain (cLBP', 'pain bothersomeness scores', 'Connectivity of Key Regions of the Descending Pain Modulation and Reward Systems', 'VTA/PAG rsFC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3816957', 'cui_str': '70'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0228398', 'cui_str': 'Structure of periaqueductal gray matter'}, {'cui': 'C0175405', 'cui_str': 'Ventral Tegmental Area of Tsai'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]",79.0,0.121085,"We found remission of pain bothersomeness in all treatment groups after four weeks, with greater pain relief after real acupuncture compared to sham acupuncture.","[{'ForeName': 'Siyi', 'Initials': 'S', 'LastName': 'Yu', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Randy L', 'Initials': 'RL', 'LastName': 'Gollub', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gerber', 'Affiliation': 'Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Yiting', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Shen', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Suk-Tak', 'Initials': 'ST', 'LastName': 'Chan', 'Affiliation': 'Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Ajay D', 'Initials': 'AD', 'LastName': 'Wasan', 'Affiliation': 'Department of Anesthesiology, Center for Pain Research, University of Pittsburgh, Pittsburgh, PA 15206, USA.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'Edwards', 'Affiliation': ""Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02467, USA.""}, {'ForeName': 'Vitaly', 'Initials': 'V', 'LastName': 'Napadow', 'Affiliation': 'Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Ted J', 'Initials': 'TJ', 'LastName': 'Kaptchuk', 'Affiliation': 'Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Rosen', 'Affiliation': 'Department of Radiology, Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.'}]",Journal of clinical medicine,['10.3390/jcm9061719'] 1481,32497599,"Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial.","OBJECTIVE To compare the efficacy and safety of MT10107 (Coretox) with those of onabotulinum toxin A (Botox) in patients with poststroke upper limb spasticity DESIGN: Prospective, randomized, double-blind, active drug-controlled, multicenter, phase III clinical trial. SETTING Seven university hospitals in the Republic of Korea. PARTICIPANTS Patients (N=220) with poststroke upper limb spasticity. INTERVENTIONS All participants received a single injection of either MT10107 (Coretox group) or onabotulinum toxin A (Botox group). MAIN OUTCOME MEASURES The primary outcome was change in wrist flexor spasticity from baseline to week 4, which was assessed using the modified Ashworth scale (MAS). The secondary outcomes were MAS scores for wrist, elbow, and finger flexors; percentage of treatment responders (response rate); Disability Assessment Scale (DAS) score, and global assessment of treatment. Safety was evaluated based on adverse events, vital signs, physical examination findings, and laboratory test results. The efficacy and safety were evaluated at 4, 8, and 12 weeks postintervention. RESULTS The primary outcome was found to be -1.32±0.69 and -1.40±0.69 for the Coretox and Botox groups, respectively. MT10107 showed a non-inferior efficacy compared with onabotulinum toxin A, as the 95% confidence interval for between-group differences was -0.10 to 0.27 and the upper limit was less than the non-inferiority margin of 0.45. Regarding the secondary outcomes, MAS scores for all muscles and DAS scores showed a significant improvement at all time points in both groups, with no significant between-group difference. No significant between-group differences were observed regarding response rate, global assessment of treatment, and safety measures. CONCLUSIONS MT10107 showed no significant difference in efficacy and safety compared with onabotulinum toxin A in poststroke upper limb spasticity treatment.",2020,"Regarding the secondary outcomes, MAS scores for all muscles and DAS scores showed a significant improvement at all time points in both groups, with no significant between-group difference.","['post-stroke upper limb spasticity treatment', '220 patients with post-stroke upper limb spasticity', 'Seven university hospitals in the Republic of Korea PARTICIPANTS', 'patients with post-stroke upper limb spasticity DESIGN']","['onabotulinum toxin A (Botox®', 'MT10107 (Coretox group) or onabotulinum toxin A (Botox group', 'MT10107 (Coretox®']","['modified Ashworth scale (MAS', 'adverse events, vital signs, physical examination findings, and laboratory test results', 'Efficacy and safety', 'MAS scores for all muscles and DAS scores', 'response rate, global assessment of treatment, and safety measures', 'change in wrist flexor spasticity', 'efficacy and safety', 'MAS scores for wrist, elbow, and finger flexors; percentage of treatment responders (response rate); Disability Assessment Scale (DAS) score, and global assessment of treatment']","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1273957', 'cui_str': 'Upper limb spasticity'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C4743433', 'cui_str': 'onabotulinum toxin A'}, {'cui': 'C0700702', 'cui_str': 'Botox'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0587081', 'cui_str': 'Laboratory test finding'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C3854497', 'cui_str': 'Disability assessment scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",220.0,0.288437,"Regarding the secondary outcomes, MAS scores for all muscles and DAS scores showed a significant improvement at all time points in both groups, with no significant between-group difference.","[{'ForeName': 'Junekyung', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.'}, {'ForeName': 'Min Ho', 'Initials': 'MH', 'LastName': 'Chun', 'Affiliation': 'Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul. Electronic address: mhchun@amc.seoul.kr.'}, {'ForeName': 'Young Jin', 'Initials': 'YJ', 'LastName': 'Ko', 'Affiliation': ""Department of Rehabilitation Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul.""}, {'ForeName': 'Shi-Uk', 'Initials': 'SU', 'LastName': 'Lee', 'Affiliation': 'Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Boramae Medical Center, Seoul.'}, {'ForeName': 'Deog Young', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul.'}, {'ForeName': 'Nam-Jong', 'Initials': 'NJ', 'LastName': 'Paik', 'Affiliation': 'Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.'}, {'ForeName': 'Bum Sun', 'Initials': 'BS', 'LastName': 'Kwon', 'Affiliation': 'Department of Rehabilitation Medicine, Dongguk University Ilsan Hospital, Goyang.'}, {'ForeName': 'Yoon Ghil', 'Initials': 'YG', 'LastName': 'Park', 'Affiliation': 'Department of Rehabilitation Medicine, Gangnam Severance Hospital Yonsei University College of Medicine, Seoul, Republic of Korea.'}]",Archives of physical medicine and rehabilitation,['10.1016/j.apmr.2020.03.025'] 1482,32497693,Habit tracking of sunscreen use in National Collegiate Athletics Association cross country athletes: A randomized pilot study.,,2020,,['NCAA Cross Country Athletes'],[],[],"[{'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]",[],[],,0.030267,,"[{'ForeName': 'Mary P', 'Initials': 'MP', 'LastName': 'List', 'Affiliation': 'Department of Internal Medicine, The Christ Hospital, Cincinnati, Ohio. Electronic address: marylist23@gmail.com.'}, {'ForeName': 'Mary B', 'Initials': 'MB', 'LastName': 'Carter', 'Affiliation': 'Department of Global Education, School of Medicine, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Brian B', 'Initials': 'BB', 'LastName': 'Adams', 'Affiliation': 'Department of Dermatology, College of Medicine, University of Cincinnati, Cincinnati, Ohio.'}]",Journal of the American Academy of Dermatology,['10.1016/j.jaad.2020.05.108'] 1483,32504715,Rehabilitation Posture Does Not Affect the Outcome of Arthroscopically Treated Acromioclavicular Dislocation.,"PURPOSE To assess the effect of the patient's posture (erect or supine) during rehabilitation sessions on pain, function, and the coracoclavicular (CC) distance after arthroscopic treatment of acromioclavicular joint dislocation. METHODS Sixty patients with acute type III or V acromioclavicular dislocation injuries were randomly allocated into 2 groups according to their posture during the rehabilitation phase: supine rehabilitation group (SRG) or erect rehabilitation group (ERG). Arthroscopic stabilization with a suspensory fixation device was used in all patients. The visual analog scale (VAS) score was assessed on the first postoperative day and at 1, 3, and 6 months postoperatively. The Constant-Murley score (CMS) was recorded preoperatively and at 3, 6, 12, and 24 months postoperatively. The CC distance was assessed preoperatively; on the first postoperative day; and at 6, 12, and 24 months postoperatively. RESULTS No significant differences were found between the 2 groups in terms of the VAS score, CMS, and CC distance changes. A significant improvement over the follow-up phase was identified in the VAS score and CMS in both groups. The CC distance in both groups was significantly reduced from preoperatively (29.34 mm in the ERG and 28.65 mm in the SRG) to the first postoperative day (10.44 mm and 10.11 mm, respectively). However, a statistically significant re-widening of the CC distance (P < .001) occurred within the first 6 months after surgery (13.55 mm in the ERG and 13.50 mm in the SRG) and at 12 months (15.51 mm and 15.80 mm, respectively). CONCLUSIONS The patient's posture during early postoperative rehabilitation does not affect the CC distance changes. LEVEL OF EVIDENCE Level I, randomized prospective comparative study.",2020,"No significant differences were found between the two groups in terms of the VAS, CMS scores, and CC distance changes.","['Sixty patients with acute AC dislocation injury types, III and V']","['Arthroscopic stabilization with a suspensory fixation device', ""patient's posture (erect or supine"", 'posture during the rehabilitation phase (Supine Rehabilitation Group; SRG, or Erect Rehabilitation Group; ERG']","['coracoclavicular (CC) distance', 'Constant-Murley Score (CMS', 'CC distance', 'Visual Analogue Scale (VAS', 'coracoclavicular distance changes', 'VAS, CMS scores, and CC distance changes', 'pain, function and the CC (Coracoclavicular) distance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0012691', 'cui_str': 'Dislocation'}, {'cui': 'C0449499', 'cui_str': 'Type of injury'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0441254', 'cui_str': 'Fixation device'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013867', 'cui_str': 'Electroretinography'}]","[{'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",60.0,0.018762,"No significant differences were found between the two groups in terms of the VAS, CMS scores, and CC distance changes.","[{'ForeName': 'Amr', 'Initials': 'A', 'LastName': 'Ibrahim', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Saleh', 'Initials': 'S', 'LastName': 'Gameel', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Abdelghafar', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Tarek Mohamed', 'Initials': 'TM', 'LastName': 'Ghandour', 'Affiliation': 'Orthopedic Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Electronic address: tarekghndr@yahoo.com.'}, {'ForeName': 'Begad M', 'Initials': 'BM', 'LastName': 'Samy Abbas', 'Affiliation': 'Physical Medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}]",Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association,['10.1016/j.arthro.2020.05.043'] 1484,32233747,Exploring gender differences among treatment-seekers who use opioids versus alcohol and other drugs.,"Identifying clinical differences between opioid users (OU) and alcohol and other drug users (AOD) may help to tailor treatment to OU, particularly among the majority of OU who are not on opioid agonist treatments. Given the dearth of research on these differences, this study explored gender differences in demographic and clinical characteristics between OU and AOD. Participants (N = 506) were from a multisite, randomized controlled clinical trial of an Internet-delivered psychosocial intervention conducted in 2010-2011. Logistic regression models explored differences in demographic and clinical characteristics by substance use category within and between women and men. Women OU were more likely to be younger, White, employed, benzodiazepine users, and less likely to have children or use cocaine and cannabis than women AOD. Men OU, compared to men AOD, were more likely to be younger, White, younger at first abuse/dependence, benzodiazepine users, and reported greater psychological distress, but were less likely to be involved in criminal justice or use stimulants. Interactions by gender and substance use were also detected for age of first abuse/dependence, employment, and criminal justice involvement. These findings provide a nuanced understanding of gender differences within substance use groups to inform providers for OU seeking treatment.",2020,"Men OU, compared to men AOD, were more likely to be younger, White, younger at first abuse/dependence, benzodiazepine users, and reported greater psychological distress, but were less likely to be involved in criminal justice or use stimulants.",['Participants (N\xa0=\xa0506'],"['Internet-delivered psychosocial intervention', 'benzodiazepine']",['psychological distress'],[],"[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}]","[{'cui': 'C0815107', 'cui_str': 'Emotional Distress'}]",506.0,0.053569,"Men OU, compared to men AOD, were more likely to be younger, White, younger at first abuse/dependence, benzodiazepine users, and reported greater psychological distress, but were less likely to be involved in criminal justice or use stimulants.","[{'ForeName': 'Tanya C', 'Initials': 'TC', 'LastName': 'Saraiya', 'Affiliation': 'Derner School of Psychology, Adelphi University , Garden City, NY, USA.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University , New York, NY, USA.'}, {'ForeName': 'Mei-Chen', 'Initials': 'MC', 'LastName': 'Hu', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health, Columbia University , New York, NY, USA.'}, {'ForeName': 'Edward V', 'Initials': 'EV', 'LastName': 'Nunes', 'Affiliation': 'Department of Psychiatry and New York State Psychiatric Institute, Columbia University Medical Center , New York, NY, USA.'}, {'ForeName': 'Denise A', 'Initials': 'DA', 'LastName': 'Hien', 'Affiliation': 'Center of Alcohol Studies, Graduate School of Applied and Professional Psychology, Rutgers, The State University of New Jersey , Piscataway Township, NJ, USA.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'Department of Psychiatry and New York State Psychiatric Institute, Columbia University Medical Center , New York, NY, USA.'}]",Women & health,['10.1080/03630242.2020.1746952'] 1485,31815653,Short or Long Antibiotic Regimes in Orthopaedics (SOLARIO): a randomised controlled open-label non-inferiority trial of duration of systemic antibiotics in adults with orthopaedic infection treated operatively with local antibiotic therapy.,"BACKGROUND Orthopaedic infections, such as osteomyelitis, diabetic foot infection and prosthetic joint infection, are most commonly treated by a combination of surgical debridement and a prolonged course of systemic antibiotics, usually for at least 4-6 weeks. Use of local antibiotics, implanted directly into the site of infection at the time of surgery, may improve antibiotic delivery and allow us to shorten the duration of systemic antibiotic therapy, thereby limiting the frequency of side effects, cost and selection pressure for antimicrobial resistance. METHODS SOLARIO is a multicentre open-label randomised controlled non-inferiority trial comparing short and long systemic antibiotic therapy alongside local antibiotic therapy. Adult patients with orthopaedic infection, who have given informed consent, will be eligible to participate in the study provided that no micro-organisms identified from deep tissue samples are resistant to locally implanted antibiotics. Participants will be randomised in a 1:1 ratio to receive either a short course (≤ 7 days) or currently recommended long course (≥ 4 weeks) of systemic antibiotics. The primary outcome will be treatment failure by 12 months after surgery, as ascertained by an independent Endpoint Committee blinded to treatment allocation. An absolute non-inferiority margin of 10% will be used for both per-protocol and intention-to-treat populations. Secondary outcomes will include probable and definite treatment failure, serious adverse events, treatment side effects, quality of life scores and cost analysis. DISCUSSION This study aims to assess a treatment strategy that may enable the reduction of systemic antibiotic use for patients with orthopaedic infection. If this strategy is non-inferior, this will be to the advantage of patients and contribute to antimicrobial stewardship. TRIAL REGISTRATION Clinicaltrials.gov, NCT03806166. Registered on 11 November 2019.",2019,"The primary outcome will be treatment failure by 12 months after surgery, as ascertained by an independent Endpoint Committee blinded to treatment allocation.","['adults with orthopaedic infection treated operatively with local antibiotic therapy', 'Adult patients with orthopaedic infection', 'Orthopaedics (SOLARIO', 'patients with orthopaedic infection']","['systemic antibiotic therapy alongside local antibiotic therapy', 'systemic antibiotics', 'short course (≤ 7\u2009days) or currently recommended long course (≥ 4\u2009weeks) of systemic antibiotics']","['probable and definite treatment failure, serious adverse events, treatment side effects, quality of life scores and cost analysis']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0338237', 'cui_str': 'Antibiotic therapy (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0338237', 'cui_str': 'Antibiotic therapy (procedure)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}]","[{'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C0439544', 'cui_str': 'Definite (qualifier value)'}, {'cui': 'C0162643'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0034380'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0010171', 'cui_str': 'Cost Analysis'}]",,0.347972,"The primary outcome will be treatment failure by 12 months after surgery, as ascertained by an independent Endpoint Committee blinded to treatment allocation.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Dudareva', 'Affiliation': 'Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, UK. maria.dudareva@ouh.nhs.uk.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Kümin', 'Affiliation': 'Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Vach', 'Affiliation': 'Department of Orthopaedics and Traumatology, Universitätsspital Basel, Basel, Switzerland.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Kaier', 'Affiliation': 'Institute of Medical Biometry and Medical Informatics, Universitätsklinikums Freiburg, Freiburg, Germany.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Ferguson', 'Affiliation': 'Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'McNally', 'Affiliation': 'Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Scarborough', 'Affiliation': 'Bone Infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, UK.'}]",Trials,['10.1186/s13063-019-3832-3'] 1486,32496922,Three-dimensionally printed non-biological simulator for percutaneous nephrolithotomy training.,"Objective : We sought to improve the educational and pre-operative training on various stages of percutaneous nephrolithotomy (PCNL) under fluoroscopic and ultrasound guidance. We developed a three-dimensional (3D) printed simulator (3D-printed PCNL model) for urological trainees. Methods : 40 s year urology residents were randomly assigned into two groups, completing PCNL surgical steps on a URO Mentor™ surgical simulator (Group A) or on our new 3D-printed PCNL model (Group B). Following the training, both groups completed a standardized questionnaire (Likert scale from 0 to 10) which we used to asses the learning curve associated with PCNL training. Results : The mean score of Group A was 65.2/80 while Group B was 76.1/80. Mann-Whitney U-test showed no significant difference between the groups ( U  = 16, p  < 0.05). Conclusion : The 3D-printed PCNL model developed is a novel and highly effective tool that can facilitate enhanced endourological education and personalized pre-operative planning for urolithiasis cases. According to the criteria tested, residents who used our 3D-printed PCNL models performed better under all metrics.",2020,The 3D-printed PCNL model developed is a novel and highly effective tool that can facilitate enhanced endourological education and personalized pre-operative planning for urolithiasis cases.,"['s year urology residents', '40']","['percutaneous nephrolithotomy (PCNL) under fluoroscopic and ultrasound guidance', 'PCNL surgical steps on a URO Mentor™ surgical simulator (Group A) or on our new 3D-printed PCNL model', 'PCNL training', 'percutaneous nephrolithotomy training']",[],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042077', 'cui_str': 'Urology'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}]","[{'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0025369', 'cui_str': 'Mentors'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",[],,0.0185617,The 3D-printed PCNL model developed is a novel and highly effective tool that can facilitate enhanced endourological education and personalized pre-operative planning for urolithiasis cases.,"[{'ForeName': 'Stanislav', 'Initials': 'S', 'LastName': 'Ali', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Evgenii', 'Initials': 'E', 'LastName': 'Sirota', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Ali', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Evgenii', 'Initials': 'E', 'LastName': 'Bezrukov', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Zhamshid', 'Initials': 'Z', 'LastName': 'Okhunov', 'Affiliation': 'Department of Urology, University of California, Irvine, Irvine, CA, USA.'}, {'ForeName': 'Mikhail', 'Initials': 'M', 'LastName': 'Bukatov', 'Affiliation': 'LLC «VERITEL», Moscow, Russia.'}, {'ForeName': 'Alexandr', 'Initials': 'A', 'LastName': 'Letunovskiy', 'Affiliation': 'LLC «VERITEL», Moscow, Russia.'}, {'ForeName': 'Nikolai', 'Initials': 'N', 'LastName': 'Grygoriev', 'Affiliation': 'European Medical Center, Moscow, Russia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Taratkin', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Stanislav', 'Initials': 'S', 'LastName': 'Vovdenko', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}, {'ForeName': 'Andyshea', 'Initials': 'A', 'LastName': 'Afyouni', 'Affiliation': 'Department of Urology, University of California, Irvine, Irvine, CA, USA.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Alyaev', 'Affiliation': 'Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.'}]",Scandinavian journal of urology,['10.1080/21681805.2020.1773529'] 1487,32506665,The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial.,"BACKGROUND Intraprostatic inflammation is an emerging prostate cancer risk factor. Estrogens are pro-inflammatory while androgens are anti-inflammatory. Thus, we investigated whether serum sex steroid hormone concentrations are associated with intraprostatic inflammation to inform mechanistic links among hormones, inflammation, and prostate cancer. METHODS We conducted a cross-sectional study among 247 men in the placebo arm of the Prostate Cancer Prevention Trial who had a negative end-of-study biopsy, most (92.7%) performed without clinical indication per trial protocol. Serum estradiol, estrone, and testosterone were previously measured by immunoassay in pooled baseline and Year 3 serum. Free estradiol and free testosterone were calculated. Inflammation was visually assessed (median of three prostate biopsy cores per man). Polytomous or logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) of some or all cores inflamed (both vs none) or any core inflamed (vs none) by hormone tertile, adjusting for age, race, and family history. We evaluated effect modification by waist circumference and body mass index (BMI). RESULTS In all, 51.4% had some and 26.3% had all cores inflamed. Free (P-trend = .11) but not total estradiol was suggestively inversely associated with all cores inflamed. In men with waist circumference greater than or equal to 102 cm (P-trend = .021) and BMI ≥ 27.09 kg/m 2 (P-trend = .0037) free estradiol was inversely associated with any core inflamed. Estrone was inversely associated with all cores inflamed (T3: OR = 0.36, 95% CI 0.14-0.95, P-trend = .036). Total (T3: OR = 1.91, 95% CI 0.91-4.02, P-trend = .11) and free (T3: OR = 2.19, 95% CI 1.01-4.74, P-trend = .05) testosterone were positively associated with any core inflamed, especially free testosterone in men with waist circumference less than 102 cm (T3: OR = 3.51, 95% CI 1.03-12.11, P-trend = .05). CONCLUSIONS In this first study in men without prostate cancer and irrespective of clinical indication for biopsy, contrary to the hypothesis, circulating estrogens appeared to be inversely associated, especially in heavy men, whereas androgens appeared to be positively associated with intraprostatic inflammation.",2020,"Total (T3: OR = 1.91, 95% CI 0.91-4.02, P-trend = .11) and free (T3: OR = 2.19, 95% CI 1.01-4.74, P-trend = .05)","['247 men in the placebo arm of the Prostate Cancer Prevention Trial who had a negative end-of-study biopsy, most (92.7%) performed without clinical indication per trial protocol', 'men without prostate cancer']",[],"['Free estradiol and free testosterone', 'testosterone', 'Inflammation', 'total estradiol', 'waist circumference and body mass index (BMI', 'Serum estradiol, estrone, and testosterone', 'Estrone']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}]",[],"[{'cui': 'C0369189', 'cui_str': 'Free estradiol'}, {'cui': 'C0202228', 'cui_str': 'Testosterone measurement, unbound'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C0014942', 'cui_str': 'Estrone'}]",247.0,0.209464,"Total (T3: OR = 1.91, 95% CI 0.91-4.02, P-trend = .11) and free (T3: OR = 2.19, 95% CI 1.01-4.74, P-trend = .05)","[{'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Chadid', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Barber', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'William G', 'Initials': 'WG', 'LastName': 'Nelson', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.'}, {'ForeName': 'Bora', 'Initials': 'B', 'LastName': 'Gurel', 'Affiliation': 'The Institute of Cancer Research, The Royal Marsden, London, UK.'}, {'ForeName': 'M Scott', 'Initials': 'MS', 'LastName': 'Lucia', 'Affiliation': 'Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Thompson', 'Affiliation': 'The Cancer Therapy and Research Center, CHRISTUS Santa Rosa Hospital-Medical Center, San Antonio, Texas.'}, {'ForeName': 'Phyllis J', 'Initials': 'PJ', 'LastName': 'Goodman', 'Affiliation': 'SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.'}, {'ForeName': 'Frank Z', 'Initials': 'FZ', 'LastName': 'Stanczyk', 'Affiliation': 'Departments of Obstetrics and Gynecology, and Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California.'}, {'ForeName': 'Howard L', 'Initials': 'HL', 'LastName': 'Parnes', 'Affiliation': 'Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Lippman', 'Affiliation': 'Moores Cancer Center, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Angelo M', 'Initials': 'AM', 'LastName': 'De Marzo', 'Affiliation': 'Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Platz', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}]",The Prostate,['10.1002/pros.24023'] 1488,32507672,"Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87.",,2020,,"['2020, Pages 79-87']","['istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine', 'placebo']",[],"[{'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}]","[{'cui': 'C3641662', 'cui_str': 'MM-141'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0987186,,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kundranda', 'Affiliation': 'Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA.'}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Gracian', 'Affiliation': 'Medical Oncology, Centro Integral Oncologico Clara Campal, Universidad CEU San Pablo, Madrid, Spain; Departamento de Ciencias Médicas Clínicas, Universidad CEU San Pablo, Madrid, Spain.'}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Zafar', 'Affiliation': 'Hematology and Oncology, Florida Cancer Specialists, Fort Myers, USA.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Meiri', 'Affiliation': 'Medical Oncology, Comprehensive Care and Research Center, Atlanta, USA.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Bendell', 'Affiliation': 'GI Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Algül', 'Affiliation': 'TUM School of Medicine, Klinikum rechts der Isar, Medizinische Klinik II, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Rivera', 'Affiliation': 'Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain.'}, {'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'Ahn', 'Affiliation': 'Medical Oncology, Cancer Treatment Centers of America Chicago, Zion, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Watkins', 'Affiliation': 'Department of Medicine, Royal Marsden Hospital, Sutton, UK.'}, {'ForeName': 'U', 'Initials': 'U', 'LastName': 'Pelzer', 'Affiliation': 'Charité - Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Charu', 'Affiliation': 'Hematology/Oncology, Pacific Cancer Medical Center, Anaheim, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Zalutskaya', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Kuesters', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Pipas', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Santillana', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Askoxylakis', 'Affiliation': 'Clinical Development, Merrimack Pharmaceuticals, Inc., Cambridge, USA.'}, {'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'Ko', 'Affiliation': 'Hematology/Oncology, University of California San Francisco Cancer Center, San Francisco, USA. Electronic address: andrew.ko@ucsf.edu.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.05.011'] 1489,32502730,Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins.,"BACKGROUND Sclerotherapy is considered to be the method of choice for the treatment of telangiectatic varicose veins (C1 veins). Whereas the use of compression stockings after sclerotherapy is recommended, little is known about the impact of compression on the outcome of sclerotherapy. The aim of this study was to assess the influence of compression on the outcome of injection sclerotherapy of C1 varicose veins. METHODS There were 100 legs of 50 consecutive patients with chronic venous insufficiency (C1) included. After randomization per patient, both legs were treated with sclerotherapy in a predefined area of the thigh (measuring 100 cm 2 ), followed by eccentric compression for 24 hours. Group A received no further compression, whereas group B was additionally equipped with compression stockings of 18 to 20 mm Hg above the ankle and continued wearing these for 1 week. Photodocumentation was performed before, 1 week after, and 4 weeks after sclerotherapy, and the clinical outcome was assessed at these postprocedure follow-up dates. The photographs were reviewed by an internal unblinded rater and an independent blinded external rater. RESULTS There was no discernible difference between the groups in terms of clinical outcome or side effects after 4 weeks. Whereas inter-rater reliability was high, there was no correlation between the raters and patients in terms of outcome. In 55% of the treated legs, the patients deemed the result of the treatment to be good; in 27% of the treated legs, fair; and in 18%, poor. Postprocedure hyperpigmentation occurred in 13% of patients and was comparable in both groups. Compression therapy was found to be comfortable by the majority (58%) of patients. CONCLUSIONS One week of postinterventional compression therapy had no clinical benefit compared with no compression.",2020,There was no discernable difference between the groups in terms of clinical outcome or side effects after 4 weeks.,"['100 legs of 50 consecutive patients with chronic venous insufficiency (C1', 'teleangiectatic varicose veins']","['sclerotherapy', 'compression stockings post sclerotherapy', 'Compression therapy', 'compression stockings']","['Post procedure hyperpigmentation', 'clinical outcome or side effects']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1306557', 'cui_str': 'Venous insufficiency (chronic) (peripheral)'}, {'cui': 'C0042345', 'cui_str': 'Phlebectasia'}]","[{'cui': 'C0036435', 'cui_str': 'Injection of sclerosing agent'}, {'cui': 'C0038348', 'cui_str': 'Compression stocking'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",50.0,0.0228149,There was no discernable difference between the groups in terms of clinical outcome or side effects after 4 weeks.,"[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Bayer', 'Affiliation': 'Department of Surgery, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany; Institute of Anatomy, Christian-Albrechts-University of Kiel, Kiel, Germany. Electronic address: a.bayer@anat.uni-kiel.de.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Kuznik', 'Affiliation': 'Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}, {'ForeName': 'Ewan Andrew', 'Initials': 'EA', 'LastName': 'Langan', 'Affiliation': 'Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany; Division of Musculoskeletal and Dermatological Sciences, University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Recke', 'Affiliation': 'Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}, {'ForeName': 'Anna-Lena', 'Initials': 'AL', 'LastName': 'Recke', 'Affiliation': 'Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Faerber', 'Affiliation': 'Center for Vascular Medicine, Hamburg, Germany.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Kaschwich', 'Affiliation': 'Department of Surgery, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Kleemann', 'Affiliation': 'Department of Surgery, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}, {'ForeName': 'Birgit', 'Initials': 'B', 'LastName': 'Kahle', 'Affiliation': 'Department of Dermatology, University Medical Centre Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.'}]",Journal of vascular surgery. Venous and lymphatic disorders,['10.1016/j.jvsv.2020.05.015'] 1490,32507404,Presentation and short-term evaluation of an all-in-one patient-specific implant for cranial reconstruction: A randomized controlled trial.,"Cranial reconstruction after bone graft harvesting remains a challenge. A patient-specific implant (PSI) to guide harvesting and reconstruction was evaluated and compared with the use of a free-hand procedure with calcium phosphate cement (C). Patients were randomized to either the PSI or C group. The outcome was measured clinically and radiographically as the primary endpoint. Secondary endpoints were ease of application, patient and surgeon satisfaction, and the complication rate. Twenty patients were randomized to the PSI (n=10) and C (n=10) groups. Two PSI patients were switched to the cement group due to a poor fit of the PSI. There was a non-significant trend towards more successful outcomes in the PSI group. Two PSI patients presented palpable screws, and one cement patient had a palpable dimple. Cone beam computed tomography showed a significantly lower median volume discrepancy in the PSI group (P<0.0001). The total surgical manipulation time was significantly higher in the PSI group. At 10 days postoperative, three PSI and two C patients presented with minor postoperative complications. There was no significant difference in patient or surgeon satisfaction. PSIs are a reliable alternative to cement. This PSI is novel as it also serves as a guide for harvesting the bone blocks required for reconstructive purposes.",2020,Cone beam computed tomography showed a significantly lower median volume discrepancy in the PSI group (P<0.0001).,"['cranial reconstruction', 'Twenty patients were randomized to the PSI (n=10) and C (n=10) groups']",['calcium phosphate cement (C'],"['patient or surgeon satisfaction', 'total surgical manipulation time', 'ease of application, patient and surgeon satisfaction, and the complication rate', 'postoperative complications', 'successful outcomes', 'median volume discrepancy']","[{'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0006711', 'cui_str': 'calcium phosphate'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C1290905', 'cui_str': 'Discrepancy'}]",20.0,0.029954,Cone beam computed tomography showed a significantly lower median volume discrepancy in the PSI group (P<0.0001).,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'De Cuyper', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium. Electronic address: brecht.decuyper@gmail.com.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Pottel', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Würsching', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Abeloos', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'De Ceulaer', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Neyt', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Lamoral', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Swennen', 'Affiliation': 'Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge-Oostende, Bruges, Belgium.'}]",International journal of oral and maxillofacial surgery,['10.1016/j.ijom.2020.04.002'] 1491,32511226,"Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study.","In Haiti, 22 communes still require mass drug administration (MDA) to eliminate lymphatic filariasis (LF) as a public health problem. Several clinical trials have shown that a single oral dose of ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) (IDA) is more effective than DEC plus ALB (DA) for clearing Wuchereria bancrofti microfilariae (Mf). We performed a cluster-randomized community study to compare the safety and efficacy of IDA and DA in an LF-endemic area in northern Haiti. Ten localities were randomized to receive either DA or IDA. Participants were monitored for adverse events (AE), parasite antigenemia, and microfilaremia. Antigen-positive participants were retested one year after MDA to assess treatment efficacy. Fewer participants (11.0%, 321/2917) experienced at least one AE after IDA compared to DA (17.3%, 491/2844, P<0.001). Most AEs were mild, and the three most common AEs reported were headaches, dizziness and abdominal pain. Serious AEs developed in three participants who received DA. Baseline prevalence for filarial antigenemia was 8.0% (239/3004) in IDA localities and 11.5% (344/2994) in DA localities (<0.001). Of those with positive antigenemia, 17.6% (42/239) in IDA localities and 20.9% (72/344, P = 0.25) in DA localities were microfilaremic. One year after treatment, 84% percent of persons with positive filarial antigen tests at baseline could be retested. Clearance rates for filarial antigenemia were 20.5% (41/200) after IDA versus 25.4% (74/289) after DA (P = 0.3). However, 94.4% (34/36) of IDA recipients and 75.9% (44/58) of DA recipients with baseline microfilaremia were Mf negative at the time of retest (P = 0.02). Thus, MDA with IDA was at least as well tolerated and significantly more effective for clearing Mf compared to the standard DA regimen in this study. Effective MDA coverage with IDA could accelerate the elimination of LF as a public health problem in the 22 communes that still require MDA in Haiti.",2020,Baseline prevalence for filarial antigenemia was 8.0% (239/3004) in IDA localities and 11.5% (344/2994) in DA localities (<0.001).,"['lymphatic filariasis in Haiti', 'LF-endemic area in northern Haiti']","['IDA and DA', 'ivermectin (IVM), diethylcarbamazine (DEC) and albendazole (ALB) (IDA', 'DA or IDA', 'diethylcarbamazine, albendazole and ivermectin', 'DEC plus ALB (DA']","['Clearance rates for filarial antigenemia', 'filarial antigenemia', 'Safety and efficacy', 'headaches, dizziness and abdominal pain', 'adverse events (AE), parasite antigenemia, and microfilaremia']","[{'cui': 'C0013884', 'cui_str': 'Lymphatic filariasis'}, {'cui': 'C0018510', 'cui_str': 'Haiti'}, {'cui': 'C0243130', 'cui_str': 'endemics'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0020789', 'cui_str': 'Idarubicin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0001909', 'cui_str': 'Albania'}, {'cui': 'C0022322', 'cui_str': 'Ivermectin'}, {'cui': 'C0012191', 'cui_str': 'Diethylcarbamazine'}, {'cui': 'C0001911', 'cui_str': 'Albendazole'}]","[{'cui': 'C0025515', 'cui_str': 'Metabolic clearance rate'}, {'cui': 'C1621857', 'cui_str': 'Filarial worm'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0030498', 'cui_str': 'Parasite'}]",10.0,0.218718,Baseline prevalence for filarial antigenemia was 8.0% (239/3004) in IDA localities and 11.5% (344/2994) in DA localities (<0.001).,"[{'ForeName': 'Christine L', 'Initials': 'CL', 'LastName': 'Dubray', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Anita D', 'Initials': 'AD', 'LastName': 'Sircar', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Valery Madsen', 'Initials': 'VM', 'LastName': 'Beau de Rochars', 'Affiliation': 'University of Florida, Gainsville, Florida, United States of America.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Bogus', 'Affiliation': 'Washington University in St. Louis, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Abdel N', 'Initials': 'AN', 'LastName': 'Direny', 'Affiliation': 'RTI International, Washington, District of Columbia, United States of America.'}, {'ForeName': 'Jean Romuald', 'Initials': 'JR', 'LastName': 'Ernest', 'Affiliation': 'IMA World Health, Port-au-Prince, Haiti.'}, {'ForeName': 'Carl R', 'Initials': 'CR', 'LastName': 'Fayette', 'Affiliation': 'IMA World Health, Port-au-Prince, Haiti.'}, {'ForeName': 'Charles W', 'Initials': 'CW', 'LastName': 'Goss', 'Affiliation': 'Washington University in St. Louis, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Hast', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Kobie', 'Initials': 'K', 'LastName': ""O'Brian"", 'Affiliation': 'Washington University in St. Louis, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Guy Emmanuel', 'Initials': 'GE', 'LastName': 'Pavilus', 'Affiliation': 'IMA World Health, Port-au-Prince, Haiti.'}, {'ForeName': 'Daniel Frantz', 'Initials': 'DF', 'LastName': 'Sabin', 'Affiliation': 'IMA World Health, Port-au-Prince, Haiti.'}, {'ForeName': 'Ryan E', 'Initials': 'RE', 'LastName': 'Wiegand', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Gary J', 'Initials': 'GJ', 'LastName': 'Weil', 'Affiliation': 'Washington University in St. Louis, St. Louis, Missouri, United States of America.'}, {'ForeName': 'Jean Frantz', 'Initials': 'JF', 'LastName': 'Lemoine', 'Affiliation': 'Ministère de la Santé et de la Population, Port-au-Prince, Haïti.'}]",PLoS neglected tropical diseases,['10.1371/journal.pntd.0008298'] 1492,32502559,Optimal timing of a second postoperative voiding trial in women with incomplete bladder emptying after vaginal reconstructive surgery: a randomized trial.,"BACKGROUND Rates of postoperative incomplete bladder emptying vary significantly after pelvic reconstructive surgery. With enhanced recovery protocols the paradigm is shifting towards same-day discharge and the rates of incomplete bladder emptying are expected to increase. The optimal length of time for postoperative catheter drainage has not been clearly established. There are no current studies that assess the optimal timing of a repeat voiding trial in women who have unsuccessful same day voiding trials. OBJECTIVE This study aimed to compare the outcomes of a second voiding trial performed 2-4 days (earlier group) vs 7 days (later group) postoperatively in women with incomplete bladder emptying after vaginal prolapse surgery. Secondary aims included postoperative urinary tract infection rates, total days with a catheter, and patient-reported catheter bother between groups. STUDY DESIGN Across 2 sites, women undergoing multicompartment vaginal repair were enrolled. Within 6 hours postoperatively, subjects had an active retrograde voiding trial. Those who passed this voiding trial exited the study; those who had persistent incomplete bladder emptying (postvoid residual >100 mL) had a transurethral indwelling catheter placed and were randomized to return for an earlier (postoperative day 2-4) vs later (postoperative day 7) follow-up office voiding trial. Subjects were followed for 6 weeks after surgery. The primary outcome was the rate of unsuccessful repeat office voiding trial. Secondary outcomes included rates of urinary tract infection, total days with a catheter, and subjective catheter bother. A power calculation based on a projected 31% difference, a power of 0.8, and an alpha of 0.05 revealed that 30 subjects were needed in each group. RESULTS A total of 102 subjects were enrolled; 38 exited on postoperative day 0, leaving 64 subjects for randomization (4 of whom withdrew after randomization). A comparison of data revealed that randomization was effective, with no differences between the earlier and later groups in terms of demographic data or surgical procedures. Using an intention-to-treat analysis, women in the earlier group were more likely to be unsuccessful in their follow-up office voiding trial (23.3%) than the later group (3.3%), with a risk difference of 20% (95% confidence interval, 3.56-36.44) and a relative risk of 7.00 (95% confidence interval, 0.92-53.47; P=.02). A number-needed-to-treat calculation found that for every 5 patients using a catheter for 7 days postoperatively, 1 case of persistent postoperative incomplete bladder emptying was prevented. Rates of catheter bother did not differ between groups at the time of the follow-up office voiding trial or at 6 weeks (P=.09 and P=.20, respectively). Urinary tract infection rates were higher in the earlier group but did not reach statistical significance (23% vs 7%, P=.07). Regression analysis revealed that subjects who required additional pain medication refills were 9.6 times (95% confidence interval, 1.24-73.77) more likely to have persistent incomplete bladder emptying after the follow-up office voiding trial. CONCLUSION Women with incomplete bladder emptying after multicompartment prolapse repair had a 7-fold higher risk of an unsuccessful repeat office voiding trial if performed within 4 days of surgery than when performed within 7 days of surgery. In addition, requiring additional prescriptions for analgesia increased the risk of an unsuccessful follow-up office voiding trial.",2020,A comparison of data revealed that randomization was effective with no differences between the earlier and later groups in terms of demographic data or surgical procedures.,"['women with incomplete bladder emptying following vaginal prolapse surgery', 'women with incomplete bladder emptying after vaginal reconstructive surgery', 'women undergoing multi-compartment vaginal repair were enrolled', 'Those who passed this VT exited the study; those who had persistent incomplete bladder emptying (postvoid residual >100ml) had a', '102 subjects were enrolled: 38 exited on post-operative day 0, leaving 64 subjects for randomization (4 of whom withdrew after randomization']",['transurethral indwelling catheter placed'],"['rates of urinary tract infection, total days with a catheter and subjective catheter bother', 'additional pain medication refills', 'incomplete bladder emptying', 'post-operative urinary tract infection (UTI) rates, total days with a catheter, and patient reported catheter bother between groups', 'rate of unsuccessful repeat office VT', 'Rates of catheter bother', 'UTI rates']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0344365', 'cui_str': 'Incomplete emptying of bladder'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205990', 'cui_str': 'Vaginal wall prolapse'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0524865', 'cui_str': 'Reconstruction - action'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1288276', 'cui_str': 'Vaginoplasty'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0337094', 'cui_str': 'Exit'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}]","[{'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0007439', 'cui_str': 'In-Dwelling Catheters'}, {'cui': 'C0442504', 'cui_str': 'Place'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0344365', 'cui_str': 'Incomplete emptying of bladder'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1272705', 'cui_str': 'Unsuccessful'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",102.0,0.290319,A comparison of data revealed that randomization was effective with no differences between the earlier and later groups in terms of demographic data or surgical procedures.,"[{'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Schachar', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Departments of Urology and Obstetrics and Gynecology, Wake Forest Baptist Health, Winston-Salem, NC.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ossin', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Department of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Andre R', 'Initials': 'AR', 'LastName': 'Plair', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Departments of Urology and Obstetrics and Gynecology, Wake Forest Baptist Health, Winston-Salem, NC.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Hurtado', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Department of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Candace', 'Initials': 'C', 'LastName': 'Parker-Autry', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Departments of Urology and Obstetrics and Gynecology, Wake Forest Baptist Health, Winston-Salem, NC.'}, {'ForeName': 'Gopal', 'Initials': 'G', 'LastName': 'Badlani', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Departments of Urology and Obstetrics and Gynecology, Wake Forest Baptist Health, Winston-Salem, NC.'}, {'ForeName': 'G Willy', 'Initials': 'GW', 'LastName': 'Davila', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Department of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Matthews', 'Affiliation': 'Female Pelvic Medicine and Reconstructive Surgery, the Departments of Urology and Obstetrics and Gynecology, Wake Forest Baptist Health, Winston-Salem, NC. Electronic address: CAMatthe@wakehealth.edu.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.06.001'] 1493,31353364,Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma.,"Talimogene laherparepvec (T-VEC) has demonstrated efficacy for unresectable melanoma. We explored response patterns from a phase 2 study evaluating patients with unresectable stage IIIB-IVM1c malignant melanoma who received T-VEC plus ipilimumab or ipilimumab alone. Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response). Patients without pseudo-progression were classified by whether they responded within or after 6 months of treatment start; those with pseudo-progression were classified by whether pseudo-progression was due to increase in existing lesions or development of new lesions. Overall, 39% (n = 38/98) in the combination arm and 18% (n = 18/100) in the ipilimumab arm had an objective response. Eight responders (combination, n = 7 [18.4%]; ipilimumab, n = 1 [5.6%]) had pseudo-progression; most occurred by week 12 and were caused by an increase in existing lesions. These data reinforce use of T-VEC through initial progression when combined with checkpoint inhibitors.Trial Registration NCT01740297 (ClinicalTrials.gov; date of registration, December 4, 2012); 2012-000307-32 (ClinicalTrialsRegister.eu; date of registration, May 13, 2014).",2019,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"['metastatic unresectable melanoma', 'patients with unresectable stage IIIB-IVM1c malignant melanoma who received']","['ipilimumab or ipilimumab alone', 'Talimogene laherparepvec (T-VEC', 'T-VEC plus ipilimumab or ipilimumab alone']","['objective response', 'pseudo-progression']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C1831828', 'cui_str': 'talimogene laherparepvec'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0205237', 'cui_str': 'False'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",,0.159882,Patients with objective response per modified irRC were evaluated for pseudo-progression (single ≥25% increase in tumour burden before response).,"[{'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Chesney', 'Affiliation': 'James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. jason.chesney@louisville.edu.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Puzanov', 'Affiliation': 'Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Collichio', 'Affiliation': 'The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Mohammed M', 'Initials': 'MM', 'LastName': 'Milhem', 'Affiliation': 'University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'University of Kiel, Kiel, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Amgen Inc., Thousand Oaks, CA, USA.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Parminder', 'Initials': 'P', 'LastName': 'Singh', 'Affiliation': 'Mayo Clinic, Phoenix, AZ, USA.'}, {'ForeName': 'Janice M', 'Initials': 'JM', 'LastName': 'Mehnert', 'Affiliation': 'Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.'}]",British journal of cancer,['10.1038/s41416-019-0530-6'] 1494,32507057,"Effect of a Spinomed orthosis on balance performance, spinal alignment, joint position sense and back muscle endurance in elderly people with hyperkyphotic posture: A randomized controlled trial.","BACKGROUND Hyperkyphosis may cause balance impairment in elderly people. Although the effectiveness of orthoses for improving balance in hyperkyphotic elderly people has received much attention, the mechanisms by which devices affect balance remain unknown. OBJECTIVES The objective of this study was to evaluate changes in balance performance, thoracic kyphosis angle, craniovertebral angle, back muscle endurance and joint position sense after 3 months of wearing a Spinomed orthosis. The study also included a secondary exploratory analysis to determine whether changes in any of the above-mentioned outcome measures can predict balance performance improvement in elderly people with hyperkyphosis. STUDY DESIGN Parallel group randomized controlled trial. METHODS In total, 44 hyperkyphotic elderly people were randomly allocated to an experimental group, who wore a Spinomed orthosis and a control group, who did not. No other treatment or change in physical activity was permitted during the study. A blinded assessor evaluated thoracic kyphosis angle, joint position sense, craniovertebral angle, back muscle endurance, Timed Up and Go Test time and Berg Balance Scale score at baseline and after 5, 9 and 13 weeks. All dependent variables were measured without the orthosis and analyzed separately using a 2 × 4 (time × group) mixed model analysis of variance. Based on the results of correlation analysis, thoracic kyphosis angle, back muscle endurance and joint position sense were selected as independent variables in a stepwise multiple regression model. RESULTS The two-way (group × time) interactions were significant in terms of Berg Balance Scale ( F  = 11.6, P  ⩽ 0.001, η p 2 = 0 . 59 ), Timed Up and Go Test ( F  = 3.74, P  = 0.013, η p 2 = 0 . 46 ), thoracic kyphosis angle ( F  = 43.39, P  ⩽ 0.001, η p 2 = 0 . 96 ), craniovertebral angle ( F  = 5.245, P  = 0.002, η p 2 = 0 . 59 ) and joint position sense ( F  = 4.44, P  = 0.005, [Formula: see text] ). The two-way interaction was not significant in terms of back muscle endurance; however, the main effect of group was significant for this variable ( F  = 3.85, P  = 0.025). Stepwise multiple regression showed that thoracic kyphosis angle and joint position sense were significant determinants of Timed Up and Go Test time ( R 2  = 0.155, P  = 0.037 and R 2  = 0.292, P  = 0.012, respectively). CONCLUSION Wearing a Spinomed orthosis for 3 months improved the posture, position sense and muscle performance of hyperkyphotic elderly people. Orthoses may improve balance performance by correcting spinal alignment and increasing proprioceptive information.",2020,"Stepwise multiple regression showed that thoracic kyphosis angle and joint position sense were significant determinants of Timed Up and Go Test time ( R 2  = 0.155, P  = 0.037 and R 2  = 0.292, P  = 0.012, respectively). ","['hyperkyphotic elderly people', '44 hyperkyphotic elderly people', 'elderly people', 'elderly people with hyperkyphotic posture', 'elderly people with hyperkyphosis']",['Spinomed orthosis'],"['thoracic kyphosis angle, back muscle endurance and joint position sense', 'Timed Up and Go Test', 'thoracic kyphosis angle and joint position sense', 'Timed Up and Go Test time', 'balance performance, spinal alignment, joint position sense and back muscle endurance', 'Berg Balance Scale', 'posture, position sense and muscle performance', 'balance performance, thoracic kyphosis angle, craniovertebral angle, back muscle endurance and joint position sense', 'balance performance', 'joint position sense', 'physical activity', 'craniovertebral angle', 'back muscle endurance', 'thoracic kyphosis angle', 'thoracic kyphosis angle, joint position sense, craniovertebral angle, back muscle endurance, Timed Up and Go Test time and Berg Balance Scale score']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0022821', 'cui_str': 'Kyphosis deformity of spine'}]","[{'cui': 'C0006086', 'cui_str': 'Brace'}]","[{'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0022821', 'cui_str': 'Kyphosis deformity of spine'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0224334', 'cui_str': 'Skeletal muscle structure of back'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0423561', 'cui_str': 'Joint position sense'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0429928', 'cui_str': 'Test time'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0234219', 'cui_str': 'Postural sense'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.10268,"Stepwise multiple regression showed that thoracic kyphosis angle and joint position sense were significant determinants of Timed Up and Go Test time ( R 2  = 0.155, P  = 0.037 and R 2  = 0.292, P  = 0.012, respectively). ","[{'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Hosseinabadi', 'Affiliation': 'Department of Orthotics and Prosthetics, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Kamyab', 'Affiliation': 'Department of Orthotics and Prosthetics, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Azadinia', 'Affiliation': 'Department of Orthotics and Prosthetics, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Sarrafzadeh', 'Affiliation': 'Department of Physiotherapy, School of Rehabilitation Sciences, Iran University of Medical Sciences, Tehran, Iran.'}]",Prosthetics and orthotics international,['10.1177/0309364620923816'] 1495,32507989,[Timing of androgen-deprivation therapy and radical radiotherapy in localized prostate cancer: a phase III randomized controlled trial].,,2020,,['localized prostate cancer'],['androgen-deprivation therapy and radical radiotherapy'],[],"[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}]","[{'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]",[],,0.0915835,,"[{'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Nieder', 'Affiliation': 'Dept. of Oncology and Palliative Medicine, Nordland Hospital Trust, P.O. Box 1480, 8092, Bodø, Norwegen. carsten.nieder@nlsh.no.'}]",Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],['10.1007/s00066-020-01645-5'] 1496,32505378,[Impact of post-thoracotomy analgesia with dexmedetomidine and morphine on immunocytes: a randomized clinical trial].,"OBJECTIVE This study aimed to investigate the impact of post-thoracotomy analgesia with dexmedetomidine and morphine on immunocytes. METHODS A total of 118 patients with post-thoracotomy Patient-Controlled Intravenous Analgesia (PCIA) in our hospital from March 2016 to July 2018 were randomly selected and divided into the Composite (COM) Group (57 patients administered with dexmedetomidine [1.0 μg.kg -1 body weight] and morphine [0.48 mg.kg -1 body weight]) and the Morphine (MOR) Group (61 patients administered with morphine [0.48 mg.kg -1 ]). The values of lymphocyte subsets (CD3+, CD4+, and CD8+) and Natural Killer cells in the peripheral blood of these two groups were detected by FACSCalibur flow cytometry at different time points (before anesthesia induction [T0], immediately after tracheal extubation [T1], 12 hours after surgery [T2], 24 hours after surgery [T3], 48 hours after surgery [T4], 72 hours after surgery [T5], and 7 days after surgery [T6]). The doses of morphine at T3 to T5 and the adverse reactions between the two groups were also recorded and compared. RESULTS The CD3+ level and the CD4+/CD8+ ratio at T2 to T5 and the CD4+ level and NK cells at T3 to T5 were significantly higher in the COM Group than in the MOR Group (p < 0.05). The postoperative morphine dose and the incidence of postoperative itching, nausea, and vomiting were significantly lower in the COM Group than in the MOR Group (p < 0.05). CONCLUSIONS Dexmedetomidine combined with morphine for post-thoracotomy PCIA can improve the function of immunocytes, reduce morphine consumption, and reduce the adverse reactions during analgesia induction.",2020,"The postoperative morphine dose and the incidence of postoperative itching, nausea, and vomiting were significantly lower in the COM Group than in the MOR Group (p < 0.05). ",['118\xa0patients with post-thoracotomy Patient-Controlled Intravenous Analgesia (PCIA) in our hospital from March\xa02016 to July\xa02018'],"['Dexmedetomidine', 'Morphine (MOR', 'COM', 'dexmedetomidine and morphine', 'dexmedetomidine', 'morphine']","['CD4+ level and NK cells', 'function of immunocytes, reduce morphine consumption', 'postoperative itching, nausea, and vomiting', 'CD3+ level and the CD4+/CD8+ ratio', 'adverse reactions', 'values of lymphocyte subsets (CD3+, CD4+, and CD8+) and Natural Killer cells', 'immunocytes']","[{'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039991', 'cui_str': 'Chest wall incision'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C1138348', 'cui_str': 'moira protein, Drosophila'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]","[{'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0312737', 'cui_str': 'Immunologic cell'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0079720', 'cui_str': 'Lymphocyte Subpopulations'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}]",,0.073553,"The postoperative morphine dose and the incidence of postoperative itching, nausea, and vomiting were significantly lower in the COM Group than in the MOR Group (p < 0.05). ","[{'ForeName': 'Pengfei', 'Initials': 'P', 'LastName': 'Lei', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.""}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.""}, {'ForeName': 'Shan', 'Initials': 'S', 'LastName': 'Gao', 'Affiliation': 'Shenzhen University General Hospital, Operation Department, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.""}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.""}, {'ForeName': 'Weichun', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.""}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Shi', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China. Electronic address: cnpengfeilei@163.com.""}, {'ForeName': 'Aijun', 'Initials': 'A', 'LastName': 'Shan', 'Affiliation': ""Department of Emergency, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China. Electronic address: abv236@126.com.""}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2019.12.017'] 1497,32502908,Effects of 1 mA and 2 mA transcranial direct current stimulation on working memory performance in healthy participants.,"Anodal transcranial current stimulation (tDCS) to the left dorsolateral prefrontal cortex (DLPFC) has been shown to enhance working memory (WM) in neuropsychiatric patients. In healthy populations, however, tDCS obtains inconclusive results, mostly due to heterogeneous study and stimulation protocols. Here, we approached these issues by investigating effects of tDCS intensity on simultaneous WM performance with three cognitive loads by directly comparing findings of two double-blind, cross-over, sham-controlled experiments. TDCS was administrated to the left DLPFC at intensity of 1 mA (Experiment 1) or 2 mA (Experiment 2), while participants completed a verbal n-back paradigm (1-, 2-, 3-back). Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load. The present study suggests that cognitive load rather than tDCS intensity could be a decisive factor for effects on WM. Moreover, it emphasizes the need of thorough investigation on study parameters to develop more efficient stimulation protocols.",2020,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","['healthy participants', 'neuropsychiatric patients']","['1\xa0mA and 2\xa0mA transcranial direct current stimulation', 'TDCS', 'Anodal transcranial current stimulation (tDCS']",['working memory performance'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1172076', 'cui_str': '1-(1-phenylethyl)-2-methyleneaziridine'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",,0.0450811,"Analysis showed no overall effects of tDCS on WM, but a significant interaction with cognitive load.","[{'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Papazova', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany. Electronic address: Irina.papazova@med.uni-muenchen.de.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Strube', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Wienert', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Henning', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Schwippel', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Andreas J', 'Initials': 'AJ', 'LastName': 'Fallgatter', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Padberg', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Falkai', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Plewnia', 'Affiliation': 'Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Germany.'}, {'ForeName': 'Alkomiet', 'Initials': 'A', 'LastName': 'Hasan', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University, München, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, BKH Augsburg, Medical Faculty, University of Augsburg, Germany.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102959'] 1498,32506733,Methylene blue vs methyl aminolevulinate photodynamic therapy in combination with oral terbinafine in the treatment of severe dermatophytic toenail onychomycosis: Short- and long-term effects.,"BACKGROUND Photodynamic therapy (PDT) kills target microorganisms via reactive oxygen species (ROS) production. PDT seems to be a good alternative treatment option for onychomycosis. OBJECTIVE To compare the efficacy of combined therapies based on oral terbinafine (TN) plus adjunctive PDT mediated by methylene blue (MB) (TN + MB/PDT) or methyl aminolevulinate (MAL) (TN + MAL/PDT) in the treatment of onychomycosis. METHODS Twenty patients affected by severe dermatophyte onychomycosis in the nails of the big toe (>60% disease involvement of target nail) received oral TN for 12 weeks and concomitantly were randomly allocated to receive nine sessions, separated by 2-week intervals, of urea (40%) plus a PDT protocol mediated by MB (TN + MB/PDT: group I) or mediated by MAL (TN + MAL/PDT: group II). Clinical and mycological efficacy was evaluated at 16-, 40- and 52-week follow-up. RESULTS Both protocols showed a significant decrease in Onychomycosis Severity Index (OSI) scores (P < .05), from 24.2 ± 4.6 to 0.7 ± 0.6 (group I)) and from 18.5 ± 10.1 to 2.1 ± 2.0 (group II). No side effects or complications were reported in any of the combinations used. Mycological cure rates were significantly higher during the last third of the evaluated period of time, reaching 100% and 90% in group I and group II, respectively, at the 52-week follow-up. In both modalities, complete cure was achieved in 70% of the patients at the 52-week follow-up. CONCLUSIONS TN + MB/PDT and TN + MAL/PDT show similar outcomes in the treatment of toenails with severe onychomycosis. PDT is an effective method to accelerate the TN-mediated healing process.",2020,"Both protocols showed a significant decrease in Onychomycosis Severity Index (OSI) scores (p<0.05), from 24.2±4.6 to 0.7±0.6 (group I)) and from 18.5±10.1 to 2.1±2.0 (group II).","['toenails with severe onychomycosis', 'severe dermatophytic toenail onychomycosis', 'Twenty patients affected by severe dermatophyte onychomycosis in the nails of the big toe (>60% disease involvement of target nail) received oral TN for 12 weeks and concomitantly']","['PDT protocol mediated by MB (TN+MB/PDT: group I) or mediated by MAL (TN+MAL/PDT', 'Photodynamic therapy (PDT', 'TN+MB/PDT and TN+MAL/PDT', 'terbinafine', 'PDT', 'Methylene blue vs. methyl aminolevulinate photodynamic therapy', 'terbinafine (TN) plus adjunctive PDT mediated by methylene blue (MB) (TN+MB/PDT) or methyl aminolevulinate (MAL) (TN+MAL/PDT']","['Onychomycosis Severity Index (OSI) scores', 'Mycological cure rates', 'complete cure', 'Clinical and mycological efficacy', 'side effects or complications']","[{'cui': 'C0222007', 'cui_str': 'Toenails'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040261', 'cui_str': 'Onychomycosis'}, {'cui': 'C0522476', 'cui_str': 'Patient affected'}, {'cui': 'C0011635', 'cui_str': 'Arthrodermataceae'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0018534', 'cui_str': 'Hallux structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0076110', 'cui_str': 'terbinafine'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C1134467', 'cui_str': 'methyl 5-aminolevulinate'}, {'cui': 'C0600157', 'cui_str': 'Aminolevulinate'}, {'cui': 'C0076110', 'cui_str': 'terbinafine'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0040261', 'cui_str': 'Onychomycosis'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205467', 'cui_str': 'Mycologic'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",20.0,0.0247545,"Both protocols showed a significant decrease in Onychomycosis Severity Index (OSI) scores (p<0.05), from 24.2±4.6 to 0.7±0.6 (group I)) and from 18.5±10.1 to 2.1±2.0 (group II).","[{'ForeName': 'Enrique', 'Initials': 'E', 'LastName': 'Alberdi', 'Affiliation': 'Private clinic of Dr. Alberdi, Madrid, Spain.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Gómez', 'Affiliation': 'Institute of Physical Chemistry Rocasolano, CSIC, Madrid, Spain.'}]",Mycoses,['10.1111/myc.13125'] 1499,32511251,Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea.,"BACKGROUND Anemia is the most common and serious cancer-related complication. This study aimed to evaluate the efficacy of administration of ferric carboxymaltose without erythropoiesis-stimulating agents for treating anemia in cancer patients. Moreover, we identified the biomarkers of hemoglobin response to predict the need for iron therapy. METHODS AND FINDINGS We enrolled patients with solid cancers who were treated at a single institute (Samsung Medical Center, South Korea), from April 2015 to July 2017, in this prospective single-arm Phase II clinical trial. Patients received intravenous ferric carboxymaltose (1,000 mg) infusion on the first day (visit 1) of treatment. The primary end point was the number of hemoglobin responders, defined as patients with an increase in hemoglobin level ≥ 1.0 g/dL from the baseline, a hemoglobin level ≥ 11.0 g/dL, or both, within an 8-week observation period (week 3, 6, or 8). Secondary end points included changes in transferrin saturation and levels of soluble transferrin receptors, hepcidin, erythropoietin, interleukin-6, and C-reactive protein (CRP) at each visit. Of the 103 recruited patients, 92 were eligible for analysis. The mean patient age was 57.3 ± 12.5 years, and 54.3% of the patients were women. The most common diagnoses were breast cancer (n = 23, 25.1%), lung cancer (n = 21, 22.9%), gastrointestinal cancer (n = 20, 20.9%), and lymphoma (n = 16, 17.7%). A hemoglobin response was observed in 36 (39.1%), 53 (57.6%), and 61 (66.3%) patients in the third, fifth, and eighth weeks, respectively. The mean increase in hemoglobin levels from the baseline to the end of treatment was 1.77 ± 1.30 g/dL. Baseline values of hepcidin (p = 0.008), total iron binding capacity (p = 0.014), ferritin (p = 0.048), and CRP (p = 0.044) were significantly different between the responder and nonresponder groups. Multiple logistic regression analysis for baseline anemia-related biochemical variable significantly associated with the hemoglobin response showed that only baseline hepcidin level was a significant factor for hemoglobin response (odds ratio = 0.95, 95% confidence interval 0.90-1.0, p = 0.045). Hemoglobin responders had significantly lower hepcidin levels than nonresponders (mean [±standard deviation], 13.45 [±14.71] versus 35.22 [±40.470 ng/ml]; p = 0.007). However, our analysis had some limitations such as the different patient characteristics in the studies that were included, institutional differences in the measurement of hepcidin level, and missing data on long-term safety. Therefore, our findings need further validation. CONCLUSIONS Intravenous ferric carboxymaltose (1,000 mg) monotherapy increases hemoglobin levels without serious adverse events in patients with cancer. Hepcidin is a useful biomarker for predicting iron requirement in cancer patients. TRIAL REGISTRATION Clinicaltrials.gov NCT02599012.",2020,"Secondary end points included changes in transferrin saturation and levels of soluble transferrin receptors, hepcidin, erythropoietin, interleukin-6, and C-reactive protein (CRP) at each visit.","['103 recruited patients, 92 were eligible for analysis', 'patients with cancer', 'The mean patient age was 57.3 ± 12.5 years, and 54.3% of the patients were women', 'cancer patients', 'chemotherapy-induced anemia', 'enrolled patients with solid cancers who were treated at a single institute (Samsung Medical Center, South Korea), from April 2015 to July 2017']","['Hepcidin', 'ferric carboxymaltose without erythropoiesis-stimulating agents', 'Intravenous ferric carboxymaltose', 'intravenous ferric carboxymaltose', 'intravenous iron treatment']","['CRP', 'lung cancer', 'hepcidin levels', 'gastrointestinal cancer', 'Efficacy', 'hemoglobin levels', 'total iron binding capacity', 'hemoglobin level', 'changes in transferrin saturation and levels of soluble transferrin receptors, hepcidin, erythropoietin, interleukin-6, and C-reactive protein (CRP', 'number of hemoglobin responders', 'hemoglobin response']","[{'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C2001867', 'cui_str': 'ferric carboxymaltose'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0700379', 'cui_str': 'Total iron binding capacity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C1116139', 'cui_str': 'Transferrin receptor, soluble'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",103.0,0.0792099,"Secondary end points included changes in transferrin saturation and levels of soluble transferrin receptors, hepcidin, erythropoietin, interleukin-6, and C-reactive protein (CRP) at each visit.","[{'ForeName': 'Jun Ho', 'Initials': 'JH', 'LastName': 'Jang', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Youjin', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': ""Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Kihyun', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seok Jin', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Won Seog', 'Initials': 'WS', 'LastName': 'Kim', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chul Won', 'Initials': 'CW', 'LastName': 'Jung', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jeeyun', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Se-Hoon', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University of School of Medicine, Seoul, South Korea.'}]",PLoS medicine,['10.1371/journal.pmed.1003091'] 1500,32512477,"Effect of a maximal exercise test on serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium in athletes.","AIM This study aims to determine the changes induced by a maximal exercise test until exhaustion on the serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr) in athletes (AG) and sedentary students (SG). METHODS Fifty subjects participated in the study divided into two groups. In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students. Both groups performed an exercise test until exhaustion, starting at 8 or 10 km/h respectively, and increasing the speed at 1 km/h every 400 m. Serum and urine samples were obtained from all participants before and after the test. RESULTS Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG. Comparing the pre and post-test values, corrected or non-corrected for hemoconcentration in serum and for creatinine in urine, AG showed a decrease in serum Mg (p < 0.05), in serum P (p < 0.01) and in urinary Sr (p < 0.01) while an increase was observed in urinary P (p < 0.05) and in urinary Rb (p < 0.05). CONCLUSIONS It can be concluded that a treadmill test until exhaustion leads to changes in serum and urinary concentrations of minerals in both AG and SG males. This may reflect an adaptive response of the body to overcome the physical stress and, in some cases, to avoid loss of these elements.",2020,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","['athletes', 'athletes (AG) and sedentary students (SG', 'In AG there were twenty-five male athletes and in SG there were twenty-five male sedentary students', 'Fifty subjects participated in the study divided into two groups']",['maximal exercise test'],"['urinary Rb', 'serum and urinary concentrations of Magnesium (Mg), Phosphorous (P), Rubidium (Rb) and Strontium (Sr', 'urinary Sr', 'serum and urinary concentrations of magnesium, phosphorous, rubidium and strontium']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0035930', 'cui_str': 'Rubidium'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0232827', 'cui_str': 'Urinary concentration'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0038467', 'cui_str': 'Strontium'}]",25.0,0.0207851,"Regarding the basal status, AG showed lower values of Mg in serum (p < 0.05) and urine (p < 0.01), but higher concentrations of serum P (p < 0.05) in comparison to SG.","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: diegomun@unex.es.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Grijota', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: fgrijota@gmail.com.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Siquier-Coll', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: jsiquier@alumnos.unex.es.'}, {'ForeName': 'Víctor', 'Initials': 'V', 'LastName': 'Toro-Román', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: vtororom@alumnos.unex.es.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Bartolomé', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: ignbs.1991@gmail.com.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Maynar-Mariño', 'Affiliation': 'Exercise Physiology Lab, Sport Sciences Faculty, University of Extremadura, Avenida De La Universidad s/n, 10003, Cáceres, Spain. Electronic address: mmaynar@unex.es.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126572'] 1501,32514060,"Commentary on ""A pragmatic randomized controlled trial testing the effects of the international scientific SCI exercise guidelines on SCI chronic pain: protocol for the EPIC-SCI trial"".",,2020,,[],['international scientific SCI exercise guidelines'],['SCI chronic pain'],[],"[{'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}]","[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}]",,0.242921,,"[{'ForeName': 'Sara J', 'Initials': 'SJ', 'LastName': 'Mulroy', 'Affiliation': 'Rancho Los Amigos National Rehabilitation Center, Downey, CA, USA. smulroy@dhs.lacounty.gov.'}]",Spinal cord,['10.1038/s41393-020-0494-7'] 1502,32506498,Negative-pressure wound therapy does not reduce superficial SSI in pancreatectomy and hepatectomy procedures.,"INTRODUCTION Surgical site infections (SSIs) lead to increased morbidity and cost. Negative-pressure wound therapy (NPWT) removes wound exudate and improves local blood flow, but its effect on SSI is unproven following hepatectomy and pancreatectomy. The aim of this trial was to evaluate the effect of NPWT on SSI in this population. METHODS Patients were randomized to incisional NPWT or sterile island dressing following surgery. SSI predictive factors were recorded as well as patient comorbidities. Wound complications and type of SSI were recorded prospectively. RESULTS Forty patients received the standardized perioperative bundle. Twenty patients received sterile island: 11 hepatic and 9 pancreatic resections; 20 patients received NPWT: 11 hepatic and 9 pancreatic resections; 23 patients were male; mean age 60.8 years (SD ±10.3); mean BMI 31.7 (SD ±7.0). There were three incisional wound infections: two with sterile island, one with NPWT; six organ space infections: four sterile island and two NPWT. There were no significant differences in SSI rates between groups (P = .57). CONCLUSION NPWT does not improve SSI rates over simple sterile dressing following hepatectomy or pancreatectomy. Improvements in SSI must be directed toward organ-space infections, which are unaffected by NPWT.",2020,"There were no significant differences in SSI rates between groups (P = .57). ","['Twenty patients received sterile island: 11 hepatic and 9 pancreatic resections; 20 patients received NPWT: 11 hepatic and 9 pancreatic resections; 23 patients were male; mean age 60.8 years (SD ±10.3); mean BMI 31.7 (SD ±7.0', 'Forty patients received the standardized perioperative bundle', 'Patients']","['Negative-pressure wound therapy', 'NPWT', 'Negative-pressure wound therapy (NPWT', 'incisional NPWT or sterile island dressing following surgery']","['incisional wound infections', 'SSI rates', 'superficial SSI', 'Wound complications and type of SSI', 'local blood flow', 'SSI predictive factors']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0022130', 'cui_str': 'Island'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0854522', 'cui_str': 'Pancreatic resection'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4708784', 'cui_str': '31.7'}]","[{'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0022130', 'cui_str': 'Island'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}]",23.0,0.083828,"There were no significant differences in SSI rates between groups (P = .57). ","[{'ForeName': 'Conor H', 'Initials': 'CH', 'LastName': ""O'Neill"", 'Affiliation': 'Hiram Polk Jr. MD, Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Robert C G', 'Initials': 'RCG', 'LastName': 'Martin', 'Affiliation': 'Hiram Polk Jr. MD, Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, Kentucky.'}]",Journal of surgical oncology,['10.1002/jso.25980'] 1503,32507490,WITHDRAWN: Comparison of Preadministered and Coadministered Lidocaine for Treating Pain and Distress Associated With Intranasal Midazolam Administration in Children: A Randomized Clinical Trial.,This article has been withdrawn at the request of the authors and editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/policies/article-withdrawal.,2020,Coadministered lidocaine is noninferior to preadministered lidocaine for decreasing pain and distress associated with intranasal midazolam administration and was preferred by clinicians.,"['Fifty-one patients were analyzed, with a median age of 2 years', 'Children', 'Children aged 6 months to 7 years undergoing laceration repair received']","['midazolam (preadministered lidocaine', 'Midazolam', 'intranasal lidocaine', 'lidocaine', 'Coadministered lidocaine', 'Preadministered and Coadministered Lidocaine', 'preadministered lidocaine', 'midazolam', 'lidocaine with midazolam', 'intranasal midazolam with preadministered or coadministered lidocaine']","[""Children's Hospital of Eastern Ontario Pain Scale (CHEOPS); Faces, Legs, Activity, Cry, Consolability (FLACC) scale; and cry duration (secondary outcomes"", 'OSBD-R, CHEOPS, FLACC scores, and cry duration', 'OSBD-R scores', 'pain and distress', 'Observational Scale of Behavioral Distress-Revised (OSBD-R', 'CHEOPS and FLACC scores and cry duration', 'adverse events, clinician and caregiver satisfaction, and pain and distress associated with intranasal lidocaine administration', 'Pain and distress']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C3701948', 'cui_str': 'Laceration repair'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}]","[{'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1319173', 'cui_str': 'Caregiver wellbeing status'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",51.0,0.201182,Coadministered lidocaine is noninferior to preadministered lidocaine for decreasing pain and distress associated with intranasal midazolam administration and was preferred by clinicians.,"[{'ForeName': 'Nicole C', 'Initials': 'NC', 'LastName': ""O'Connell"", 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY; Department of Emergency Medicine, Westchester Medical Center, Valhalla, NY.'}, {'ForeName': 'Hilary A', 'Initials': 'HA', 'LastName': 'Woodward', 'Affiliation': ""Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY; NewYork-Presbyterian Morgan Stanley Children's Hospital, New York, NY.""}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Flores-Sanchez', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Son H', 'Initials': 'SH', 'LastName': 'McLaren', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ieni', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Kenneth W', 'Initials': 'KW', 'LastName': 'McKinley', 'Affiliation': ""Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY; Division of Emergency Medicine, Children's National Hospital, Washington, DC.""}, {'ForeName': 'Sripriya T', 'Initials': 'ST', 'LastName': 'Shen', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Dayan', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}, {'ForeName': 'Daniel S', 'Initials': 'DS', 'LastName': 'Tsze', 'Affiliation': 'Department of Emergency Medicine, Division of Pediatric Emergency Medicine, Columbia University College of Physicians and Surgeons, New York, NY.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2020.04.025'] 1504,32505861,The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial.,"BACKGROUND The OPTION trial results showed that premenopausal women with early stage breast cancer (EBC) receiving chemotherapy benefited from ovarian function protection with goserelin. The impact of treatments on patient reported Quality of Life (QoL) were also examined. PATIENTS AND METHODS 227 pre-menopausal women with EBC, were randomly assigned to chemotherapy±goserelin (C±G); 132 (58%) were ER-ve. Patients were stratified by age (≤40 years and >40 years). QoL was assessed with the Functional Assessment of Cancer Therapy - Breast, and Endocrine Symptom checklist at baseline (pre-treatment), 3, 6, 12, 18 and 24 months, then annually to 5 years. Treatment Outcome Index (TOI) score was the primary outcome. RESULTS 213 patients were available for QoL analysis. There was a significant decrease in TOI scores for both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then continued to increase reflecting improved QoL. By 3 months there was a significant difference from baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing hot flushes at any time. The C + G group experienced higher levels of vasomotor symptoms generally during the treatment phase; by 24 months, the short-term negative effect of goserelin was reversed, with hot flushes twice as frequent in the chemotherapy only group (40.9% vs 21.3%). CONCLUSIONS These results show that young women diagnosed with breast cancer experienced only a short-term decrease in QoL from the addition of goserelin, in order to preserve ovarian function during chemotherapy treatment.",2020,"There was a significant decrease in TOI scores for both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then continued to increase reflecting improved QoL. By 3 months there was a significant difference from baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing hot flushes at any time.","['213 patients were available for QoL analysis', 'Patients were stratified by age (≤40 years and >40 years', 'women having chemotherapy for EBC', '227 pre-menopausal women with EBC', 'young women diagnosed with breast cancer', 'premenopausal women with early stage breast cancer (EBC) receiving']","['chemotherapy', 'chemotherapy±goserelin (C±G', 'goserelin']","['Functional Assessment of Cancer Therapy - Breast, and Endocrine Symptom checklist', 'Quality of Life (QoL', 'ovarian function', 'vasomotor symptoms', 'TOI scores', 'Treatment Outcome Index (TOI) score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0120107', 'cui_str': 'Goserelin'}]","[{'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0014136', 'cui_str': 'Structure of endocrine system'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",213.0,0.103562,"There was a significant decrease in TOI scores for both treatment groups at 3 and 6 months that returned to pre-treatment levels at 12 months, then continued to increase reflecting improved QoL. By 3 months there was a significant difference from baseline in both groups for menopausal symptoms, and between groups in the proportion experiencing hot flushes at any time.","[{'ForeName': 'Leonard', 'Initials': 'L', 'LastName': 'R', 'Affiliation': 'Department of Surgery and Cancer, Imperial College, London, United Kingdom.'}, {'ForeName': 'Yellowlees', 'Initials': 'Y', 'LastName': 'A', 'Affiliation': 'Quantics Consulting Ltd, Edinburgh, United Kingdom.'}, {'ForeName': 'Mansi', 'Initials': 'M', 'LastName': 'J', 'Affiliation': ""Department of Oncology, Guy's and St Thomas' NHS Foundation Hospital, London, United Kingdom.""}, {'ForeName': 'Fallowfield', 'Initials': 'F', 'LastName': 'L', 'Affiliation': 'Sussex Health Outcomes Research & Education in Cancer (SHORE -C) University of Sussex, United Kingdom.'}, {'ForeName': 'Jenkins', 'Initials': 'J', 'LastName': 'V', 'Affiliation': 'Sussex Health Outcomes Research & Education in Cancer (SHORE -C) University of Sussex, United Kingdom. Electronic address: val@sussex.ac.uk.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.05.009'] 1505,32505866,"Compared to Facebook, Instagram use causes more appearance comparison and lower body satisfaction in college women.","The current experiment tested the effect of social media use on college women's appearance comparisons, mood, and body satisfaction. We randomly assigned 308 undergraduate women (aged 18-26) to use Facebook, use Instagram, or play a matching game (the control condition) on an iPad for seven minutes. Compared to the Facebook condition, Instagram users retrospectively reported spending more time viewing images or videos containing people. Participants in both the Facebook and Instagram conditions also retrospectively reported engaging in more appearance comparisons relative to those in the control condition, but Instagram users reported significantly more appearance comparisons than those in the Facebook condition. Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect. Results are consistent with previous research suggesting social media use influences body satisfaction and social comparison, and that Instagram may be a particularly harmful platform when it comes to body image because of its focus on photos over text.",2020,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[""college women's"", '308 undergraduate women (aged 18-26) to use', 'college women']","['Facebook, use Instagram, or play a matching game (the control condition']","['body satisfaction', 'appearance comparisons, mood, and body satisfaction']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0026516', 'cui_str': 'Mood'}]",308.0,0.0383295,"Those who used Instagram, but not Facebook, showed decreased body satisfaction, decreased positive affect, and increased negative affect.","[{'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Engeln', 'Affiliation': 'Department of Psychology, Northwestern University, United States. Electronic address: rengeln@northwestern.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Loach', 'Affiliation': 'Department of Psychology, Northwestern University, United States.'}, {'ForeName': 'Megan N', 'Initials': 'MN', 'LastName': 'Imundo', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, United States.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zola', 'Affiliation': 'Oxford Internet Institute, University of Oxford, United Kingdom.'}]",Body image,['10.1016/j.bodyim.2020.04.007'] 1506,32511792,"Prophylactic clipping not effective in preventing post-polypectomy bleeding for < 20-mm colon polyps: A multicenter, open-label, randomized controlled trial.","BACKGROUND AND AIM Prophylactic clipping (PC) after polypectomy has the potential to prevent post-polypectomy bleeding (PPB). We aimed to evaluate the effectiveness of PC in preventing PPB for < 20-mm polyps. METHODS This multicenter, open-label, randomized controlled trial conducted from December 2013 to June 2017 at 10 institutions randomly assigned 1080 patients with < 20-mm colon polyps to the non-PC and PC groups. Allocation factors were institution, antiplatelet drug use, and polyp number. The primary endpoint was differences in PPB rates between the groups. The severity of PPB and post-procedural abdominal symptoms were also investigated. These endpoints in intention-to-treat and per-protocol (PP) analyses were evaluated. RESULTS We investigated 1039 patients with 2960 lesions. There was no significant difference between the groups in characteristics including age, sex, hypertension, diabetes, hyperlipidemia, antiplatelet drug use, and lesion characteristics such as type and size. Excluding the clip used in the non-PC group, intraoperative bleeding, and deviation of protocol, 903 patients were investigated in PP analysis. There was no significant difference in the PPB rate between the non-PC and PC groups (2.7% vs 2.3%, P = 0.6973 [intention-to-treat analysis]; 3.0 vs 2.4%, P = 0.7353 [PP analysis]). Severe PPB (≥ grade 3) was similar between the groups. Total procedure time was significantly shorter in the non-PC group than in the PC group (31 vs 36 min, P = 0.0002). Post-procedural abdominal fullness was less common in the non-PC group than in the PC group (20.8% vs 25.6%, P = 0.0833). CONCLUSION Prophylactic clipping is not effective in preventing PBB for < 20-mm colon polyps (UMIN000012163).",2020,"Total procedure time was significantly shorter in the non-PC group than in the PC group (31 min vs. 36 min, p=0.0002).","['1039 patients with 2960 lesions', 'from December 2013 to June 2017 at 10 institutions randomly assigned 1080 patients with <20-mm colon polyps to the non-PC and PC groups']","['PC', 'Prophylactic clipping', 'Prophylactic clipping (PC']","['intraoperative bleeding', 'PPB rates', 'Total procedure time', 'severity of PPB and post-procedure abdominal symptoms', 'PPB rate', 'Post-procedure abdominal fullness', 'intention-to-treat (ITT) and per-protocol (PP) analyses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0591126', 'cui_str': 'AT-10'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C5192768', 'cui_str': '1080'}, {'cui': 'C0009376', 'cui_str': 'Polyp of colon'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0521210', 'cui_str': 'Resection of polyp'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0740651', 'cui_str': 'Abdominal symptom'}, {'cui': 'C0235318', 'cui_str': 'Fullness abdominal'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]",1080.0,0.158608,"Total procedure time was significantly shorter in the non-PC group than in the PC group (31 min vs. 36 min, p=0.0002).","[{'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Ryu', 'Initials': 'R', 'LastName': 'Ishihara', 'Affiliation': 'Department of Gastrointestinal Oncology, Osaka International Cancer Center, Osaka, Japan.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Nishida', 'Affiliation': 'Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan.'}, {'ForeName': 'Tomofumi', 'Initials': 'T', 'LastName': 'Akasaka', 'Affiliation': 'Department of Gastrointestinal Oncology, Osaka International Cancer Center, Osaka, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Hayashi', 'Affiliation': 'Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Dai', 'Initials': 'D', 'LastName': 'Nakamatsu', 'Affiliation': 'Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan.'}, {'ForeName': 'Hideharu', 'Initials': 'H', 'LastName': 'Ogiyama', 'Affiliation': 'Department of Gastroenterology, Itami City Hospital, Itami, Japan.'}, {'ForeName': 'Shinjiro', 'Initials': 'S', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Gastroenterology, Kansai Rosai Hospital, Amagasaki, Japan.'}, {'ForeName': 'Katsumi', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Gastroenterology, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Mukai', 'Affiliation': 'Department of Gastroenterology, Sumitomo Hospital, Osaka, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Gastroenterology, Otemae Hospital, Osaka, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yakushijin', 'Affiliation': 'Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Iijima', 'Affiliation': 'Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.'}, {'ForeName': 'Tetsuo', 'Initials': 'T', 'LastName': 'Takehara', 'Affiliation': 'Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.15134'] 1507,32513646,Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial.,"BACKGROUND Pulmonary rehabilitation is one of the main interventions to reduce the use of health resources, and it promotes a reduction in chronic obstructive pulmonary disease (COPD) costs. mHealth systems in COPD aim to improve adherence to maintenance programs after pulmonary rehabilitation by promoting the change in attitude and behavior necessary for patient involvement in the management of the disease. OBJECTIVE This study aimed to assess the effects of an integrated care plan based on an mHealth web-based platform (HappyAir) on adherence to a 1-year maintenance program applied after pulmonary rehabilitation in COPD patients. METHODS COPD patients from three hospitals were randomized to a control group or an intervention group (HappyAir group). Patients from both groups received an 8-week program of pulmonary rehabilitation and educational sessions about their illness. After completion of the process, only the HappyAir group completed an integrated care plan for 10 months, supervised by an mHealth system and therapeutic educator. The control group only underwent the scheduled check-ups. Adherence to the program was rated using a respiratory physiotherapy adherence self-report (CAP FISIO) questionnaire. Other variables analyzed were adherence to physical activity (Morisky-Green Test), quality of life (Chronic Obstructive Pulmonary Disease Assessment Test, St. George's Respiratory Questionnaire, and EuroQOL-5D), exercise capacity (6-Minute Walk Test), and lung function. RESULTS In total, 44 patients were recruited and randomized in the control group (n=24) and HappyAir group (n=20). Eight patients dropped out for various reasons. The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HappyAir group, which was statistically different compared with the control group at 12 months (56.1 [SD 4.0] vs 44.0 [SD 13.6]; P=.004) after pulmonary rehabilitation. CONCLUSIONS mHealth systems designed for COPD patients improve adherence to maintenance programs as long as they are accompanied by disease awareness and patient involvement in management. TRIAL REGISTRATION ClinicalTrials.gov NCT04479930; https://clinicaltrials.gov/ct2/show/NCT04479930.",2020,"The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HG, which was statistically different compared to the CG at 12 months (56.1±4 vs 44±13.6; P=.004) after PR. ","['44 patients were recruited and randomized in the CG (n=24) and HG (n=20', 'COPD patients from three hospitals', 'COPD patients', 'COPD Patients']","['control group (CG) or an intervention group (HappyAir™ group [HG', 'mHealth Web-based Platform (HappyAir™', 'integrated care plan based on an mHealth web-based platform (HappyAir™', 'Maintenance Program', 'Pulmonary rehabilitation (PR']","['adherence to physical activity (Morisky-Green Test), quality of life (CAT, SGRQ and EuroQOL-5D), exercise capacity (6MWT) and lung function', 'adherence', 'Adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",44.0,0.0421553,"The CAP FISIO questionnaire results showed an improvement in adherence during follow-up period for the HG, which was statistically different compared to the CG at 12 months (56.1±4 vs 44±13.6; P=.004) after PR. ","[{'ForeName': 'Begoña', 'Initials': 'B', 'LastName': 'Jiménez-Reguera', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Maroto López', 'Affiliation': 'Lovexair Foundation, Madrid, Spain.'}, {'ForeName': 'Shane', 'Initials': 'S', 'LastName': 'Fitch', 'Affiliation': 'Lovexair Foundation, Madrid, Spain.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'Juarros', 'Affiliation': 'Hospital Universitario 12 de octubre, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Sánchez Cortés', 'Affiliation': 'Hospital Universitario 12 de octubre, Madrid, Spain.'}, {'ForeName': 'Juan Luis', 'Initials': 'JL', 'LastName': 'Rodríguez Hermosa', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Calle Rubio', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'María Teresa', 'Initials': 'MT', 'LastName': 'Hernández Criado', 'Affiliation': 'Hospital Universitario de La Princesa, Madrid, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'López', 'Affiliation': 'Hospital Universitario de La Princesa, Madrid, Spain.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Angulo-Díaz-Parreño', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Martín-Pintado-Zugasti', 'Affiliation': 'Departamento de Fisioterapia, Facultad de Medicina, Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Vilaró', 'Affiliation': 'Ramon Llull University, Barcelona, Spain.'}]",JMIR mHealth and uHealth,['10.2196/18465'] 1508,32517192,Effect of Magnesium Supplementation on Circulating Biomarkers of Cardiovascular Disease.,"(1) Background: Magnesium supplementation may be effective for the prevention of cardiometabolic diseases, but the mechanisms are unclear. Proteomic approaches can assist in identifying the underlying mechanisms. (2) Methods: We collected repeated blood samples from 52 individuals enrolled in a double-blind trial which randomized participants 1:1 to oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo for 10 weeks. Plasma levels of 91 proteins were measured at baseline with follow-up samples using the Olink Cardiovascular Disease III proximity extension assay panel and were modeled as arbitrary units in a log 2 scale. We evaluated the effect of oral magnesium supplementation for changes in protein levels and the baseline association between serum magnesium and protein levels. The Holm procedure was used to adjust for multiple comparisons. (3) Results: Participants were 73% women, 94% white, and had a mean age of 62. Changes in proteins did not significantly differ between the two intervention groups after correction for multiple comparisons. The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029). Similarly, none of the associations of baseline serum magnesium with protein levels were significant after correction for multiple comparisons. (4) Conclusions: Although we did not identify statistically significant effects of oral magnesium supplementation in this relatively small study, this study demonstrates the value of proteomic approaches for the investigation of mechanisms underlying the beneficial effects of magnesium supplementation. Clinical Trials Registration: ClinicalTrials.gov NCT02837328.",2020,"The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029).","['Participants were 73% women, 94% white, and had a mean age of 62', '52 individuals enrolled']","['Magnesium Supplementation', 'oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide) or a matching placebo', 'oral magnesium supplementation', 'Magnesium supplementation']","['Plasma levels of 91 proteins', 'Circulating Biomarkers of Cardiovascular Disease', 'ST2 protein', 'tartrate-resistant acid phosphatase type']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1096534', 'cui_str': 'Magnesium supplement therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0024477', 'cui_str': 'Magnesium Oxide'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0450499', 'cui_str': 'ST2'}, {'cui': 'C0297331', 'cui_str': 'Acid phosphatase bone isoenzyme'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",73.0,0.469746,"The most statistically significant effects were on myoglobin [difference -0.319 log 2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 (-0.187, (-0.328, -0.045), p = 0.011), tumor necrosis factor ligand superfamily member 13B (-0.181, (-0.332, -0.031), p = 0.019), ST2 protein (-0.198, (-0.363, -0.032), p = 0.020), and interleukin-1 receptor type 1 (-0.144, (-0.273, -0.015), p = 0.029).","[{'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Alonso', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA.'}, {'ForeName': 'Lin Y', 'Initials': 'LY', 'LastName': 'Chen', 'Affiliation': 'Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Kyle D', 'Initials': 'KD', 'LastName': 'Rudser', 'Affiliation': 'Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Faye L', 'Initials': 'FL', 'LastName': 'Norby', 'Affiliation': 'Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.'}, {'ForeName': 'Mary R', 'Initials': 'MR', 'LastName': 'Rooney', 'Affiliation': 'Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA.'}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Lutsey', 'Affiliation': 'Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454, USA.'}]",Nutrients,['10.3390/nu12061697'] 1509,32519599,Patients' and caregivers' experiences of driving with chronic breathlessness before and after regular low-dose sustained-release morphine: A qualitative study.,"BACKGROUND Chronic breathlessness is a disabling syndrome that profoundly impacts patients' and caregivers' lives. Driving is important for most people, including those with advanced disease. Regular, low-dose, sustained-release morphine safely reduces breathlessness, but little is known about its impact on driving. AIM To understand patients' and caregivers' (1) perspectives and experiences of driving with chronic breathlessness; and (2) perceived impact of regular, low-dose, sustained-release morphine on driving. DESIGN A qualitative study embedded in a pragmatic, phase III, randomised, placebo-controlled trial of low-dose, sustained-release morphine (⩽32 mg/24 h) for chronic breathlessness. Semi-structured interviews were conducted immediately after participants withdrew or completed the randomised, placebo-controlled trial. Informed by grounded theory, a constant comparative approach to analysis was adopted. SETTING/PARTICIPANTS Participants were recruited from an outpatients palliative care service in Adelaide, Australia. Participants included patients ( n  = 13) with severe breathlessness associated with chronic obstructive pulmonary disease and their caregivers ( n  = 9). RESULTS Participants were interviewed at home. Eleven received morphine 8-32 mg. Three themes emerged: (1) independence; (2) breathlessness' impact on driving; and (3) driving while taking regular, low-dose, sustained-release morphine. CONCLUSION Driving contributed to a sense of identity and independence. Being able to drive increased the physical and social space available to patients and caregivers, their social engagement and well-being. Patients reported breathlessness at rest may impair driving skills, while the introduction of sustained-release morphine seemed to have no self-reported impact on driving. Investigating this last perception objectively, especially in terms of safety, is the subject of ongoing work.",2020,"Being able to drive increased the physical and social space available to patients and caregivers, their social engagement and well-being.","['Participants included patients ( n \u2009=\u200913) with severe breathlessness associated with chronic obstructive pulmonary disease and their caregivers ( n \u2009=\u20099', 'Participants were interviewed at home', ""Patients' and caregivers' experiences of driving with chronic breathlessness before and after regular low-dose sustained-release"", 'Participants were recruited from an outpatients palliative care service in Adelaide, Australia']","['placebo', 'sustained-release morphine', 'morphine']","[""independence; (2) breathlessness' impact on driving; and (3) driving while taking regular, low-dose, sustained-release morphine""]","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",,0.0508524,"Being able to drive increased the physical and social space available to patients and caregivers, their social engagement and well-being.","[{'ForeName': 'Diana H', 'Initials': 'DH', 'LastName': 'Ferreira', 'Affiliation': 'Palliative and Supportive Services, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Jason W', 'Initials': 'JW', 'LastName': 'Boland', 'Affiliation': 'Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK.'}, {'ForeName': 'Slavica', 'Initials': 'S', 'LastName': 'Kochovska', 'Affiliation': 'IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Honson', 'Affiliation': 'Palliative and Supportive Services, Flinders University, Bedford Park, SA, Australia.'}, {'ForeName': 'Jane L', 'Initials': 'JL', 'LastName': 'Phillips', 'Affiliation': 'IMPACCT, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Currow', 'Affiliation': 'Palliative and Supportive Services, Flinders University, Bedford Park, SA, Australia.'}]",Palliative medicine,['10.1177/0269216320929549'] 1510,32521284,The effect of vibration therapy on neck myofascial trigger points: A randomized controlled pilot study.,"BACKGROUND The purpose of this study was to evaluate the effect of low-frequency self-administered vibration therapy into myofascial trigger points in the upper trapezius and levator scapulae on patients with chronic non-specific neck pain. METHODS Twenty-eight patients with chronic non-specific neck pain were randomly assigned into a vibration group, receiving 10 self-applied sessions of vibration therapy in the upper trapezius and levator scapulae trigger points; or a control group, receiving no intervention. Self-reported neck pain and disability (Neck Disability Index) and pressure pain threshold were assessed at baseline and after the first, fifth and 10th treatment sessions. FINDINGS Significant differences were found in the vibration group when compared to the control group after the treatment period: the vibration group reached lower Neck Disability Index scores (F = 4.74, P = .033, η 2  = 0.07) and greater pressure pain threshold values (F = 7.56, P = .01, η 2  = 0.10) than the control group. The vibration group reported a significant reduction in Neck Disability Index scores (χ2 = 19,35, P = .00, Kendall's W = 0.28) and an increase in pressure pain threshold (χ2 = 87,10, P = .00, Kendall's W = 0.73) between the assessment times over the course of the treatment. The mean increase in pressure pain threshold in the vibration group after the 10 sessions was 8.54 N/cm2, while the mean reduction in Neck Disability Index scores was 4.53 points. INTERPRETATION Vibration therapy may be an effective intervention for reducing self-reported neck pain and disability and pressure pain sensitivity in patients with chronic non-specific neck pain. This tool could be recommended for people with non-specific neck pain.",2020,"INTERPRETATION Vibration therapy may be an effective intervention for reducing self-reported neck pain and disability and pressure pain sensitivity in patients with chronic non-specific neck pain.","['people with non-specific neck pain', 'patients with chronic non-specific neck pain', 'Twenty-eight patients with chronic non-specific neck pain']","['low-frequency self-administered vibration therapy', 'vibration group, receiving 10 self-applied sessions of vibration therapy in the upper trapezius and levator scapulae trigger points; or a control group, receiving no intervention', 'vibration therapy']","['Neck Disability Index scores', 'Self-reported neck pain and disability (Neck Disability Index) and pressure pain threshold', 'pressure pain threshold', 'neck myofascial trigger points', 'pressure pain threshold values']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0224368', 'cui_str': 'Structure of levator scapulae muscle'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2959538', 'cui_str': 'Neck disability index score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",28.0,0.0224475,"INTERPRETATION Vibration therapy may be an effective intervention for reducing self-reported neck pain and disability and pressure pain sensitivity in patients with chronic non-specific neck pain.","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Dueñas', 'Affiliation': 'Department of Physical Therapy, University of Valencia, Gascó Oliag 5, 46010, Valencia, Spain. Electronic address: lirios.duenas@uv.es.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Zamora', 'Affiliation': 'European Sleep Care Institute, San Vicente 16, 46023, Valencia, Spain. Electronic address: innovation@escinstitute.com.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Lluch', 'Affiliation': 'Department of Physical Therapy, University of Valencia, Gascó Oliag 5, 46010, Valencia, Spain; ""Pain in Motion"" international research group, Belgium. Electronic address: enrique.lluch@uv.es.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Artacho-Ramírez', 'Affiliation': 'Department of Engineering Projects, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain. Electronic address: miarra@dpi.upv.es.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Mayoral', 'Affiliation': 'Physical Therapy Unit, Hospital Provincial de Toledo, Toledo, Spain. Electronic address: orlando.mayoral@uclm.es.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Balasch', 'Affiliation': 'Departamento de Estadística e Investigación Operativa Aplicadas y Calidad, Universitat Politècnica de València, Camí de Vera s/n, 46022 València, Spain. Electronic address: sbalasch@eio.upv.es.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Balasch-Bernat', 'Affiliation': 'Department of Physical Therapy, University of Valencia, Gascó Oliag 5, 46010, Valencia, Spain. Electronic address: merce.balasch@uv.es.'}]","Clinical biomechanics (Bristol, Avon)",['10.1016/j.clinbiomech.2020.105071'] 1511,32522591,Mothers' DASH diet adherence and food purchases after week-long episodic future thinking intervention.,"Prospection has helped participants forego the temptation to buy and eat higher calorie nutrient poor foods in favor of buying and eating fewer calories and healthier macronutrient profiles in laboratory tasks and brief field studies. This pilot study examines whether episodic future thinking (EFT) improves mothers' dietary behavior and food purchasing over a longer 7-10-day period. The study utilized a 2 × 2 factorial design with mothers (N = 60) randomized to EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control. Participants listened to their cues (e.g., recordings of themselves imagining a future event or recalling a past episode) using a mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts. Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group. When considering food purchases for the family, there was an EFT effect on milligrams of sodium purchased (η p 2  = 0.07, p < .05) and a trend towards a decrease in grams of fat purchased (η p 2  = 0.06, p = .06), however, these findings were no longer significant after correcting for multiple comparisons. There were no DASH education effects and no DASH by EFT interactions observed. The dietary intake and food purchasing results should be replicated in larger more representative samples.",2020,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.",['2\u202f×\u202f2 factorial design with mothers (N\u202f=\u202f60) randomized to'],"['episodic future thinking (EFT', 'EFT or standardized episodic thinking (SET) crossed with dietary approaches to stop hypertension (DASH) diet education or a food safety education control', 'mobile ecological momentary intervention (EMI) tool and returned to complete a follow-up dietary recall and submit food receipts']","['DASH education effects', ""mothers' dietary behavior and food purchasing"", 'grams of fat purchased']","[{'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C1456535', 'cui_str': 'Food Safety'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0016452', 'cui_str': 'Foods'}]","[{'cui': 'C4053458', 'cui_str': 'Dietary Approaches to Stop Hypertension diet'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]",60.0,0.0401892,"Results showed diets of mothers in the EFT groups became more concordant with the DASH diet (η p 2  = 0.08, p < .05) than mothers in the SET group.","[{'ForeName': 'Kelseanna', 'Initials': 'K', 'LastName': 'Hollis-Hansen', 'Affiliation': 'Department of Population Health, University of Texas at Austin, Dell Medical School, Austin, TX, USA; University of Texas at Austin, Steve Hicks School of Social Work, Austin, TX, USA. Electronic address: kelseanna.hollishansen@austin.utexas.edu.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Seidman', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': ""O'Donnell"", 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, Division of Behavioral Medicine, University at Buffalo, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.'}]",Appetite,['10.1016/j.appet.2020.104757'] 1512,32525410,Optical Coherence Tomography for Coronary Bioresorbable Vascular Scaffold Implantation: A Randomized Controlled Trial.,"BACKGROUND We investigated whether optical coherence tomography (OCT) guidance would reduce nonoptimal bioresorbable vascular scaffold (BVS) deployment. METHODS This was a randomized controlled trial. Patients who required percutaneous coronary intervention for ischemic heart disease were recruited from 2 centers in Korea. The enrolled patients were randomly assigned to receive either OCT-guided BVS (Absorb; Abbott Vascular) implantation or angiography-guided BVS implantation using an optimized technique. The primary outcome was nonoptimal deployment, which was a composite outcome of the following parameters assessed by OCT: a minimal scaffold area <5 mm 2 , residual area stenosis >20%, incomplete apposition of the scaffold struts >5%, major edge dissection, or scaffold disruption. The secondary outcome was a procedural complication defined by the occurrence of no reflow, coronary perforation, or flow-limiting dissection. RESULTS Between September 2016 and January 2018, 88 patients (90 lesions) were assigned to OCT guidance, while 88 patients (89 lesions) were assigned to angiography guidance. The recruitment was prematurely terminated in March 2018 because the manufacturer stopped supplying BVS. Postprocedural OCT data were available for 88 lesions with OCT guidance and for 88 lesions with angiography guidance. There was nonoptimal BVS deployment postprocedurally in 35.2% of patients in the OCT-guidance group and in 38.6% in the angiography-guidance group (absolute difference, -3.7% [95% CI, -19.0% to 11.6%]; P =0.64). There were no procedural complications in either group. CONCLUSIONS OCT-guided BVS implantation did not reduce the incidence of nonoptimal deployment compared to that of angiography-guided BVS implantation (using optimized techniques). CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT02894697.",2020,"There was nonoptimal BVS deployment postprocedurally in 35.2% of patients in the OCT-guidance group and in 38.6% in the angiography-guidance group (absolute difference, -3.7% [95% CI, -19.0% to 11.6%]; P =0.64).","['Patients who required percutaneous coronary intervention for ischemic heart disease were recruited from 2 centers in Korea', 'Coronary Bioresorbable Vascular Scaffold Implantation', 'Between September 2016 and January 2018', '88 patients (90 lesions) were assigned to OCT guidance, while 88 patients (89 lesions']","['OCT-guided BVS (Absorb; Abbott Vascular) implantation or angiography-guided BVS implantation using an optimized technique', 'Optical Coherence Tomography', 'OCT-guided BVS implantation', 'angiography guidance', 'optical coherence tomography (OCT) guidance', 'angiography-guided BVS implantation']","['nonoptimal BVS deployment', 'incidence of nonoptimal deployment', 'nonoptimal deployment, which was a composite outcome of the following parameters assessed by OCT: a minimal scaffold area <5 mm 2 , residual area stenosis >20%, incomplete apposition of the scaffold struts >5%, major edge dissection, or scaffold disruption', 'procedural complication defined by the occurrence of no reflow, coronary perforation, or flow-limiting dissection', 'procedural complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0337143', 'cui_str': 'Scaffold'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0337143', 'cui_str': 'Scaffold'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0337143', 'cui_str': 'Scaffold'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0441295', 'cui_str': 'Strut'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0012737', 'cui_str': 'Dissection - action'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C1141861', 'cui_str': 'Procedural complication'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0549099', 'cui_str': 'Perforation'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]",,0.308663,"There was nonoptimal BVS deployment postprocedurally in 35.2% of patients in the OCT-guidance group and in 38.6% in the angiography-guidance group (absolute difference, -3.7% [95% CI, -19.0% to 11.6%]; P =0.64).","[{'ForeName': 'Seung-Yul', 'Initials': 'SY', 'LastName': 'Lee', 'Affiliation': 'Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea (S.-Y.L.).'}, {'ForeName': 'Do-Yoon', 'Initials': 'DY', 'LastName': 'Kang', 'Affiliation': 'Department of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea (D.-Y.K., J.-M.A., D.-W.P., S.-J.P.).'}, {'ForeName': 'Sung-Jin', 'Initials': 'SJ', 'LastName': 'Hong', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Jung-Min', 'Initials': 'JM', 'LastName': 'Ahn', 'Affiliation': 'Department of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea (D.-Y.K., J.-M.A., D.-W.P., S.-J.P.).'}, {'ForeName': 'Chul-Min', 'Initials': 'CM', 'LastName': 'Ahn', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Duk-Woo', 'Initials': 'DW', 'LastName': 'Park', 'Affiliation': 'Department of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea (D.-Y.K., J.-M.A., D.-W.P., S.-J.P.).'}, {'ForeName': 'Jung-Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Byeong-Keuk', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Young-Guk', 'Initials': 'YG', 'LastName': 'Ko', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Yangsoo', 'Initials': 'Y', 'LastName': 'Jang', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}, {'ForeName': 'Seung-Jung', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Cardiology, Heart Institute, Asan Medical Center, University of Ulsan, Seoul, Korea (D.-Y.K., J.-M.A., D.-W.P., S.-J.P.).'}, {'ForeName': 'Myeong-Ki', 'Initials': 'MK', 'LastName': 'Hong', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (S.-J.H., C.-M.A., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.).'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008383'] 1513,32533800,Building consensus: thresholds for delivery in TRUFFLE-2 randomized intervention study.,,2020,,[],[],[],[],[],[],,0.0379308,,"[{'ForeName': 'B', 'Initials': 'B', 'LastName': 'Mylrea-Foley', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Bhide', 'Affiliation': ""Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust and Molecular & Clinical Sciences Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Mullins', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Thornton', 'Affiliation': 'School of Clinical Sciences, University of Nottingham, Division of Obstetrics and Gynaecology, Maternity Department, City Hospital, Nottingham, UK.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Marlow', 'Affiliation': ""UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Stampalija', 'Affiliation': 'Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Napolitano', 'Affiliation': ""UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, UK.""}, {'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Lees', 'Affiliation': 'Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.'}]",Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology,['10.1002/uog.22124'] 1514,32406064,Short-term skin reactions following use of N95 respirators and medical masks.,"BACKGROUND In the context of the COVID-19 pandemic, cases of adverse skin reactions related to the wearing of masks have been observed. OBJECTIVES To analyze the short-term effects of N95 respirators and medical masks, respectively, on skin physiological properties and to report adverse skin reactions caused by the protective equipment. METHODS This study used a randomized crossover design with repeated measurements. Twenty healthy Chinese volunteers were recruited. Skin parameters were measured on areas covered by the respective masks and on uncovered skin 2 and 4 hours after donning, and 0.5 and 1 hour after removing the masks, including skin hydration, transepidermal water loss (TEWL), erythema, pH, and sebum secretion. Adverse reactions were clinically assessed, and perceived discomfort and non-compliance measured. RESULTS Skin hydration, TEWL, and pH increased significantly with wearing the protective equipment. Erythema values increased from baseline. Sebum secretion increased both on the covered and uncovered skin with equipment-wearing. There was no significant difference in physiological values between the two types of equipment. More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and non-compliance. CONCLUSIONS This study demonstrates that skin biophysical characters change as a result of wearing a mask or respirator. N95 respirators were associated with more skin reactions than medical masks.",2020,"More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and",['Twenty healthy Chinese volunteers'],['N95 respirators and medical masks'],"['skin reactions', 'Sebum secretion', 'Skin hydration, TEWL, and pH increased significantly with wearing the protective equipment', 'perceived discomfort and non-compliance measured', 'physiological values', 'Erythema values', 'adverse reactions', 'Skin parameters', 'Adverse reactions', 'skin hydration, transepidermal water loss (TEWL), erythema, pH, and sebum secretion']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0429406', 'cui_str': 'Pattern ERG N95'}, {'cui': 'C0035208', 'cui_str': 'Air-purifying respirator'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0024861', 'cui_str': 'Mask'}]","[{'cui': 'C0221743', 'cui_str': 'Skin reaction'}, {'cui': 'C0232436', 'cui_str': 'Sebaceous gland activity'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0221106', 'cui_str': 'Alkalemia'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0457432', 'cui_str': 'Non-compliant'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0031845', 'cui_str': 'Physiological process'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",20.0,0.0210399,"More adverse reactions were reported following a N95 mask use than the use of a medical mask, with a higher score of discomfort and","[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hua', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zuo', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Ruoyu', 'Initials': 'R', 'LastName': 'Wan', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Lidan', 'Initials': 'L', 'LastName': 'Xiong', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Shu', 'Affiliation': 'Cosmetic Safety and Efficacy Evaluation Center of West China Hospital, Sichuan University, Chengdu, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.'}]",Contact dermatitis,['10.1111/cod.13601'] 1515,31820274,Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial.,"This was a substudy of a randomized, double-blind, placebo-controlled trial originally designed to explore the effect of dalfampridine on information processing speed (2013-002558-64 EU Clinical Trials Register) in patients with multiple sclerosis (MS). A total of 120 patients were originally randomized in a 2:1 ratio to receive dalfampridine 10 mg or placebo twice daily for 12 weeks. Here, we sought to explore the effect of dalfampridine on static balance in single-task and dual-task conditions in a subgroup of 41 patients. They underwent static posturography in quiet standing (single-task) and while performing the Stroop test (dual-task) at randomization (baseline), after 12 weeks and after a 4-week wash-out period. Baseline characteristics of active group (n = 27) did not differ from those of placebo group (n = 14). Dalfampridine treatment was associated with better balance control than placebo in both single-task (F = 4.80, p = 0.034) and dual-task (F = 6.42, p = 0.015) conditions, with small-to-moderate effect sizes (Cohen's f 2 = 0.122-0.162). The beneficial effect of dalfampridine was not retained 4 weeks after its discontinuation. The rate of accidental falls per month did not differ between the two groups (p = 0.12). Our preliminary findings suggest that dalfampridine can be considered a potential option to treat balance impairment due to MS. Larger sample sizes are needed to verify if the beneficial effect of dalfampridine on balance can be translated into a reduced risk of accidental falls.",2020,"Dalfampridine treatment was associated with better balance control than placebo in both single-task (F = 4.80, p = 0.034) and dual-task (F = 6.42, p = 0.015) conditions, with small-to-moderate effect sizes (Cohen's f 2 = 0.122-0.162).","['A total of 120 patients', 'a subgroup of 41 patients', 'patients with multiple sclerosis (MS', 'Multiple Sclerosis']","['Placebo', 'static posturography in quiet standing (single-task) and while performing the Stroop test (dual-task', 'dalfampridine 10 mg or placebo', 'dalfampridine', 'Dalfampridine', 'placebo']","['balance control', 'rate of accidental falls', 'static balance']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0919611', 'cui_str': 'Posturography'}, {'cui': 'C0439654', 'cui_str': 'Quiet'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C2732148', 'cui_str': 'dalfampridine 10 MG'}, {'cui': 'C0000477', 'cui_str': 'dalfampridine'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0441463', 'cui_str': 'Static'}]",120.0,0.478695,"Dalfampridine treatment was associated with better balance control than placebo in both single-task (F = 4.80, p = 0.034) and dual-task (F = 6.42, p = 0.015) conditions, with small-to-moderate effect sizes (Cohen's f 2 = 0.122-0.162).","[{'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Prosperini', 'Affiliation': 'Dept. of Neurosciences, S. Camillo-Forlanini Hospital, C.ne Gianicolense 87, 00152, Rome, Italy. luca.prosperini@gmail.com.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Castelli', 'Affiliation': 'Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Don Carlo Gnocchi, -, Piazzale Morandi 6, 20121, Milano, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'De Giglio', 'Affiliation': 'Neurology Unit, S. Filippo Neri Hospital, Via G. Martinotti 20, 00135, Rome, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Bonanno', 'Affiliation': 'S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Gasperini', 'Affiliation': 'Dept. of Neurosciences, S. Camillo-Forlanini Hospital, C.ne Gianicolense 87, 00152, Rome, Italy.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Pozzilli', 'Affiliation': 'S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.'}]",Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,['10.1007/s13311-019-00813-5'] 1516,32524605,An integrated approach to improve maternal and perinatal outcomes in rural Guatemala: A stepped-wedge cluster randomized trial.,"OBJECTIVE To evaluate the impact of an intervention package on maternal and newborn health indicators. METHODS A randomized stepped-wedge non-blind trial was conducted across six subdistricts within two districts in Guatemala from January 2014 to January 2017. Data on outcomes were collected on all deliveries in all 33 health centers. The intervention package included distribution of promotional materials encouraging health center delivery; education for traditional birth attendants about the importance of health center delivery; and provider capacity building using simulation training. Main outcomes were number of health center deliveries, maternal morbidity, and perinatal morbidity and mortality. RESULTS Overall, there were 24 412 deliveries. Health center deliveries per 1000 live births showed an overall increase, although after adjustment for secular trends and clustering, the relative risk for the treatment effect was not statistically significant (aRR, 1.04; 95% confidence interval [CI], 0.97-1.11, P=0.242). Although not statistically significant, maternal morbidity (aRR, 0.78; 95% CI, 0.60-1.02; P=0.068) and perinatal morbidity (aRR, 0.84; 95% CI, 0.68-1.05; P=0.133) showed a tendency toward a decrease. CONCLUSION The present study represents one of the few randomized evaluations of an integrated approach to improve birth outcomes in a low-income setting. ClinicalTrials.gov: NCT0315107.",2020,"Although not statistically significant, maternal morbidity (aRR, 0.78; 95% CI, 0.60-1.02; P=0.068) and perinatal morbidity (aRR, 0.84; 95% CI, 0.68-1.05; P=0.133) showed a tendency toward a decrease.","['six subdistricts within two districts in Guatemala from January 2014 to January 2017', 'rural Guatemala']","['promotional materials encouraging health center delivery; education for traditional birth attendants about the importance of health center delivery; and provider capacity building using simulation training', 'intervention package']","['maternal morbidity', 'perinatal morbidity', 'birth outcomes', 'number of health center deliveries, maternal morbidity, and perinatal morbidity and mortality']","[{'cui': 'C0018367', 'cui_str': 'Guatemala'}]","[{'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0040600', 'cui_str': 'Traditional Birth Attendant'}, {'cui': 'C2718026', 'cui_str': 'Capacity Building'}, {'cui': 'C4042947', 'cui_str': 'Simulation Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",24412.0,0.143651,"Although not statistically significant, maternal morbidity (aRR, 0.78; 95% CI, 0.60-1.02; P=0.068) and perinatal morbidity (aRR, 0.84; 95% CI, 0.68-1.05; P=0.133) showed a tendency toward a decrease.","[{'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Kestler', 'Affiliation': 'Epidemiological Research Center in Sexual and Reproductive Health, Guatemala City, Guatemala.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Ambrosio', 'Affiliation': 'Epidemiological Research Center in Sexual and Reproductive Health, Guatemala City, Guatemala.'}, {'ForeName': 'Karla', 'Initials': 'K', 'LastName': 'Hemming', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Hughes', 'Affiliation': 'University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Matute', 'Affiliation': 'Centro de Investigaciones en Nutrición y Salud, Guatemala City, Guatemala.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Moreno', 'Affiliation': 'USAID, Guatemala Monitoring and Evaluation Program, Guatemala City, Guatemala.'}, {'ForeName': 'Solange', 'Initials': 'S', 'LastName': 'Madriz', 'Affiliation': 'University of California, San Francisco, CA, USA.'}, {'ForeName': 'Dilys', 'Initials': 'D', 'LastName': 'Walker', 'Affiliation': 'University of California, San Francisco, CA, USA.'}]",International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,['10.1002/ijgo.13262'] 1517,32682929,"Antioxidant supplementation, redox deficiencies and exercise performance: A falsification design.","The aim of the present study was to validate the idea of personalized redox supplementation by subjecting individuals to targeted and non-targeted antioxidant supplementation schemes. Seventy-three volunteers were screened for plasma vitamin C and erythrocyte glutathione levels. Three groups were formed: i) the ""low vitamin C″ group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels). The three groups received 1 g of vitamin C or 1.2 g of NAC daily for 30 days in a crossover design with a wash-out period of 30 days. Both antioxidant treatments reduced the increased resting systemic oxidative stress levels, assessed via urine F 2 -isoprostanes, in the Low VitC and Low GSH groups (P < .05). A significant group × time interaction (P < .05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively). A significant group × time interaction (P < .05) was found for fatigue index after NAC treatment, but not after vitamin C treatment. No interaction was found for the Wingate test after both treatments. Most of the evidence verifies the idea that antioxidant supplementation increases performance when a particular deficiency is reversed. This indicates that the presence of oxidative stress per se does not rationalize the use of antioxidants and emphasizes the need to identify ""responsive"" phenotypes.",2020,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).",[],"['low vitamin C"" group (12 individuals with the lowest vitamin C levels; Low VitC), ii) the ""low glutathione"" group (12 individuals with the lowest glutathione levels; Low GSH) and iii) a control group (12 individuals with moderate vitamin C and glutathione levels', 'antioxidant supplementation', 'personalized redox supplementation', 'vitamin C or 1.2g of NAC']","['Antioxidant supplementation, redox deficiencies and exercise performance', 'fatigue index', 'resting systemic oxidative stress levels', 'VO 2 max and isometric peak torque', 'plasma vitamin C and erythrocyte glutathione levels']",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0201898', 'cui_str': 'Ascorbic acid measurement'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0030012', 'cui_str': 'Oxidation-reduction'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0202053', 'cui_str': 'Glutathione measurement'}]",73.0,0.0729379,"A significant group × time interaction (P<.05) was found for VO 2 max and isometric peak torque after both treatments, with the Low VitC and Low GSH groups exhibiting improved performance only after the targeted treatment (vitamin C and NAC, respectively).","[{'ForeName': 'Nikos V', 'Initials': 'NV', 'LastName': 'Margaritelis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece; Dialysis Unit, 424 General Military Hospital of Thessaloniki, Thessaloniki, Greece. Electronic address: nvmargar@auth.gr.'}, {'ForeName': 'Vassilis', 'Initials': 'V', 'LastName': 'Paschalis', 'Affiliation': 'School of Physical Education and Sport Science, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: vpaschalis@phed.uoa.gr.'}, {'ForeName': 'Anastasios A', 'Initials': 'AA', 'LastName': 'Theodorou', 'Affiliation': 'Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus. Electronic address: a.theodorou@euc.ac.cy.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Kyparos', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: akyparos@auth.gr.'}, {'ForeName': 'Michalis G', 'Initials': 'MG', 'LastName': 'Nikolaidis', 'Affiliation': 'Department of Physical Education and Sport Science at Serres, Aristotle University of Thessaloniki, Serres, Greece. Electronic address: nikolaidis@auth.gr.'}]",Free radical biology & medicine,['10.1016/j.freeradbiomed.2020.06.029'] 1518,32533548,The Effectiveness of Acceptance and Commitment Therapy on Pain Acceptance and Pain Perception in Patients with Painful Diabetic Neuropathy: A Randomized Controlled Trial.,"INTRODUCTION Neuropathic pain is a complex phenomenon in patients with diabetes. These patients have many problems, such as psychological problems, high-level pain perception, and pain acceptance. This study aimed to evaluate the effectiveness of acceptance and commitment therapy on pain acceptance and pain perception in patients with painful diabetic neuropathy. METHODS This study was performed according to the clinical trial method. The sample size was 50 participants. In this study, participants were divided into interventional and control groups. According to the diagnosis of neurologists, all participants received conventional medications to manage neuropathic pain. The intervention group received acceptance and commitment therapy for eight sessions. The results in the three phases of pre-test, post-test, and follow-up were evaluated. After completing the study, to comply with ethical standards, the control group received psycho-education. The tools used were the McGill Pain Questionnaire (MPQ) and the Chronic Pain Acceptance Questionnaire (CPAQ). Statistical analysis includes mean, standard deviation, and repeated-measures (ANOVA) conducted by SPSS software version 22. RESULTS The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). CONCLUSION The results indicated that acceptance and commitment therapy could be used as a psychological intervention besides pharmacotherapy to improve pain acceptance and reduce pain perception in patients with painful diabetic neuropathy. CLINICAL TRAIL REGISTRATION This study was registered at the Iranian Registry of Clinical Trials (IRCT20180205038630N4).",2020,"The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). ","['patients with diabetes', 'Patients with Painful Diabetic Neuropathy', 'patients with painful diabetic neuropathy']","['psycho-education', 'acceptance and commitment therapy', 'conventional medications', 'Acceptance and Commitment Therapy']","['pain acceptance and reduce pain perception', 'Pain Acceptance and Pain Perception', 'McGill Pain Questionnaire (MPQ) and the Chronic Pain Acceptance Questionnaire (CPAQ', 'pain\xa0acceptance and pain perception']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751074', 'cui_str': 'Neuralgia, Diabetic'}]","[{'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",50.0,0.0546189,"The results demonstrated that in the post-test and follow-up phases, acceptance and commitment therapy could improve pain acceptance and reduce pain perception in the intervention group compared to the control group (P < 0.01). ","[{'ForeName': 'Amir Abbas', 'Initials': 'AA', 'LastName': 'Taheri', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Foroughi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran. aliakbar.Foroughi@kums.ac.ir.'}, {'ForeName': 'Youkhabeh', 'Initials': 'Y', 'LastName': 'Mohammadian', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Seyed Mojtaba', 'Initials': 'SM', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Khatereh', 'Initials': 'K', 'LastName': 'Heshmati', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Leila Afshar', 'Initials': 'LA', 'LastName': 'Hezarkhani', 'Affiliation': 'Department of Neurology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}, {'ForeName': 'Ali Akbar', 'Initials': 'AA', 'LastName': 'Parvizifard', 'Affiliation': 'Department of Clinical Psychology, Kermanshah University of Medical Sciences, Kermanshah, Iran.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00851-9'] 1519,32532705,Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men.,"BACKGROUND Compulsive sexual behavior disorder (CSBD) is a common disorder affecting different areas of life, although studies focusing on pharmacological treatment are sparse. AIM To investigate whether the opioid receptor antagonist naltrexone is feasible and tolerable and can provide symptom reduction in CSBD. METHODS Twenty men aged 27-60 years (mean = 38.8 years, standard deviation = 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of naltrexone 25-50 mg. Measurements were made before, during, and four weeks after treatment. OUTCOMES The self-assessment Hypersexual Disorder: Current Assessment Scale (HD: CAS) score was the primary outcome measure, and secondary outcomes were the Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts. RESULTS There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone. Even though some of the effects remained after treatment, the increased scores on HD: CAS indicated worsening of CSBD symptoms. The most reported side effects were fatigue (55%), nausea (30%), vertigo (30%), and abdominal pain (30%). However, there were no serious adverse effects leading to discontinuation of naltrexone. CLINICAL IMPLICATIONS Despite side effects being common, naltrexone seems to be feasible in the treatment of CSBD. STRENGTHS & LIMITATIONS Being the first nonforensic prospective trial on naltrexone in CSBD, this study provides novel insights on a pharmacological intervention. However, owing to the small sample size and the lack of a control group, conclusions of effectiveness should be interpreted with caution. CONCLUSION Naltrexone is feasible and tolerable and may reduce symptoms of CSBD; nevertheless, future studies should ensure a randomized controlled procedure to evaluate possible effectiveness. Savard J, Öberg KG, Chatzittofis A, et al. Naltrexone in Compulsive Sexual Behavior Disorder: A Feasibility Study of Twenty Men. J Sex Med 2020;17:1544-1552.",2020,There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone.,"['Twenty men aged 27-60 years (mean\xa0= 38.8 years, standard deviation\xa0= 10.3) with CSBD seeking treatment in an outpatient nonforensic clinic received four weeks of', 'Twenty Men', 'Compulsive Sexual Behavior Disorder']","['opioid receptor antagonist naltrexone', 'naltrexone', 'Naltrexone', 'naltrexone 25-50 mg']","['self-assessment Hypersexual Disorder', 'CSBD symptoms', 'Current Assessment Scale (HD: CAS) score', 'Hypersexual Behavior Inventory (HBI) score, reported adverse effects, adherence to treatment, and dropouts', 'vertigo', 'nausea', 'abdominal pain', 'HD: CAS and HBI scores']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4517519', 'cui_str': '10.3'}, {'cui': 'C0312420', 'cui_str': 'Hypersexuality state'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0027410', 'cui_str': 'Opioid receptor antagonist'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}]","[{'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0312420', 'cui_str': 'Hypersexuality state'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042571', 'cui_str': 'Vertigo'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}]",20.0,0.0529634,There was significant decrease on both HD: CAS and HBI scores during treatment with naltrexone.,"[{'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Savard', 'Affiliation': 'Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden; Anova, Karolinska University Hospital, Stockholm, Sweden. Electronic address: josephine.savard@umu.se.'}, {'ForeName': 'Katarina Görts', 'Initials': 'KG', 'LastName': 'Öberg', 'Affiliation': 'Anova, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Chatzittofis', 'Affiliation': 'Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden; Medical School, University of Cyprus, Nicosia, Cyprus.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Dhejne', 'Affiliation': 'Anova, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Arver', 'Affiliation': 'Anova, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Jussi', 'Initials': 'J', 'LastName': 'Jokinen', 'Affiliation': 'Department of Clinical Sciences/Psychiatry, Umeå University, Umeå, Sweden; Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}]",The journal of sexual medicine,['10.1016/j.jsxm.2020.04.318'] 1520,32505485,Neuroplastic changes in resting-state functional connectivity after rTMS intervention for methamphetamine craving.,"Amphetamine-type stimulants are the second most commonly abused illicit drug worldwide, with no effective medical treatments currently available. Previous studies have demonstrated that high frequency repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) reduced cue-induced craving in patients with methamphetamine dependence. However, the neuroplastic mechanism underlying rTMS intervention in methamphetamine users remains to be elucidated. Sixty participants (40 males) with severe methamphetamine use disorder according to DSM-5 were randomized to receive either intermittent theta burst protocols (iTBS) (short bursts of 50 Hz rTMS repeated at a rate in the theta range (5 Hz), 2-sec on, 8-sec off for 5 min; 900 pulses) or sham rTMS over the DLPFC over four weeks (20 daily sessions). Resting state functional connectivity magnetic resonance imaging was acquired before and after rTMS intervention. Participants received drug related cue exposure and rated their craving before and after stimulation. Seed-based functional connectivity analysis was performed to probe rTMS-induced neuroplastic reorganization of brain functional networks. Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus. Moreover, the increase of functional connectivity between DLPFC and inferior parietal lobule correlated with craving reduction. This study suggests that neuroplastic changes of frontoparietal functional connectivity contributes to craving reduction, shedding light on the therapeutic effect of rTMS on methamphetamine use disorder. This article is part of the special issue on Stress, Addiction and Plasticity.",2020,"Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus.","['patients with methamphetamine dependence', 'Sixty participants (40 males) with severe methamphetamine use disorder according to DSM-5']","['intermittent theta burst protocols (iTBS) (short bursts of 50\u202fHz rTMS repeated at a rate in the theta range (5\u202fHz), 2-sec on, 8-sec off for 5\u202fmin; 900 pulses) or sham rTMS', 'rTMS', 'rTMS intervention', 'repetitive transcranial magnetic stimulation (rTMS', 'Amphetamine-type stimulants']","['craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus', 'functional connectivity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1533217', 'cui_str': 'Methamphetamine dependence'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0059387', 'cui_str': 'staphylococcal enterotoxin C'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0002763', 'cui_str': 'Central stimulant'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0152304', 'cui_str': 'Inferior parietal lobule structure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0039485', 'cui_str': 'Temporal lobe structure'}]",60.0,0.0225991,"Results showed that twenty daily rTMS sessions decreased craving, increased functional connectivity between left DLPFC and inferior parietal lobule, and decreased functional connectivity between insula and inferior parietal lobule, medial temporal lobe and precuneus.","[{'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Su', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Yilin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China.'}, {'ForeName': 'Dazhi', 'Initials': 'D', 'LastName': 'Yin', 'Affiliation': 'School of Psychology and Cognitive Science, East China Normal University, Shanghai, China.'}, {'ForeName': 'Tianzhen', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xiaotong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhong', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Haifeng', 'Initials': 'H', 'LastName': 'Jiang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jijun', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Du', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Xiao', 'Affiliation': 'Shanghai Drug Rehabilitation Administration Bureau, Shanghai, China.'}, {'ForeName': 'Ding', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Shanghai Drug Rehabilitation Administration Bureau, Shanghai, China.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Zeljic', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Wang', 'Affiliation': 'Institute of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, State Key Laboratory of Neuroscience, CAS Key Laboratory of Primate Neurobiology, Chinese Academy of Sciences, Shanghai, China; University of Chinese Academy of Sciences, Beijing, China; CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China. Electronic address: zheng.wang@ion.ac.cn.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhao', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China; Institute of Psychological and Behavioral Science, Shanghai Jiao Tong University, Shanghai, China. Electronic address: drminzhao@smhc.org.cn.'}]",Neuropharmacology,['10.1016/j.neuropharm.2020.108177'] 1521,32505660,Frontal-midline theta frequency and probabilistic learning: A transcranial alternating current stimulation study.,"Probabilistic learning is a fundamental cognitive ability that extracts and represents regularities of our environment enabling predictive processing during perception and acquisition of perceptual, motor, cognitive, and social skills. Previous studies show competition between neural networks related to executive function/working memory vs. probabilistic learning. Theta synchronization has been associated with the former while desynchronization with the latter in correlational studies. In the present paper our aim was to test causal relationship between fronto-parietal midline theta synchronization and probabilistic learning with non-invasive transcranial alternating current (tACS) stimulation. We hypothesize that theta synchronization disrupts probabilistic learning performance by modulating the competitive relationship. Twenty-six young adults performed the Alternating Serial Reaction Time (ASRT) task to assess probabilistic learning in two sessions that took place one week apart. Stimulation was applied in a double-blind cross-over within-subject design with an active theta tACS and a sham stimulation in a counter-balanced order between participants. Sinusoidal current was administered with 1 mA peak-to-peak intensity throughout the task (approximately 20 min) for the active stimulation and 30 s for the sham. We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation. To influence probabilistic learning, we suggest applying higher current intensity and stimulation parameters more precisely aligned to endogenous brain activity for future studies.",2020,We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation.,['Twenty-six young adults'],"['fronto-parietal midline theta synchronization and probabilistic learning with non-invasive transcranial alternating current (tACS) stimulation', 'probabilistic learning', 'fronto-parietal midline theta tACS', 'Probabilistic learning', 'Alternating Serial Reaction Time (ASRT) task to assess probabilistic learning']",['probabilistic learning performance'],"[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}]",26.0,0.103353,We did not find an effect of fronto-parietal midline theta tACS on probabilistic learning comparing performance during active and sham stimulation.,"[{'ForeName': 'Zsófia', 'Initials': 'Z', 'LastName': 'Zavecz', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.'}, {'ForeName': 'Kata', 'Initials': 'K', 'LastName': 'Horváth', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.'}, {'ForeName': 'Péter', 'Initials': 'P', 'LastName': 'Solymosi', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Janacsek', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; Centre of Thinking and Learning, Institute for Lifecourse Development, School of Human Sciences, University of Greenwich, London, United Kingdom.'}, {'ForeName': 'Dezso', 'Initials': 'D', 'LastName': 'Nemeth', 'Affiliation': 'Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Brain, Memory and Language Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; Lyon Neuroscience Research Center (CRNL), INSERM, CNRS, Université Claude Bernard Lyon 1, Lyon, France. Electronic address: dezso.nemeth@univ-lyon1.fr.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112733'] 1522,32512184,"Accelerated iTBS treatment applied to the left DLPFC in depressed patients results in a rapid volume increase in the left hippocampal dentate gyrus, not driven by brain perfusion.","BACKGROUND Accelerated intermittent Theta Burst Stimulation (aiTBS) has been shown to be an effective antidepressant treatment. Although neurobiological changes shortly after this intervention have been reported, whether aiTBS results in structural brain changes must still be determined. Furthermore, it possible that rapid volumetric changes are driven by factors other than neurotrophic processes. OBJECTIVES We examined whether possible grey matter volumetric (GMV) increases after aiTBS treatment could be driven by increased brain perfusion, measured by Arterial Spin Labeling (ASL). METHODS 46 treatment-resistant depressed patients were randomized to receive 20 sessions of active or sham iTBS applied to the left dorsolateral prefrontal cortex. All sessions were delivered over 4 days at 5 sessions per day (trial registration: http://clinicaltrials.gov/show/NCT01832805). Patients were scanned the day before starting stimulation and three days after aiTBS. RESULTS There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation. These GMV increases became more pronounced when accounting for changes in cerebral perfusion. CONCLUSIONS Active, but not sham, aiTBS, resulted in acute volumetric changes in parts of the left dentate gyrus, suggesting a connection with adult neurogenesis. Furthermore, taking cerebral perfusion measurements into account impacts on detection of the GMV changes. Whether these hippocampal volumetric changes produced by active aiTBS are necessary for long-term clinical improvement remains to be determined.",2020,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.",['46 treatment-resistant depressed patients'],"['Accelerated intermittent Theta Burst Stimulation (aiTBS', '20 sessions of active or sham iTBS']","['Arterial Spin Labeling (ASL', 'left hippocampal GMV']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0445383', 'cui_str': 'Volumetric'}]",46.0,0.102893,"There was a significant cluster of increased left hippocampal GMV in the dentate gyrus related to HRSD changes after active aiTBS, but not after sham stimulation.","[{'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Baeken', 'Affiliation': 'Ghent University, Department of Psychiatry and Medical Psychology, Ghent Experimental Psychiatry (GHEP) Lab, Ghent, Belgium; Vrije Universiteit Brussel (VUB), Department of Psychiatry, Universitair Ziekenhuis Brussel (UZBrussel), Laarbeeklaan 101, 1090, Brussels, Belgium; Eindhoven University of Technology, Department of Electrical Engineering, Eindhoven, the Netherlands.'}, {'ForeName': 'GuoRong', 'Initials': 'G', 'LastName': 'Wu', 'Affiliation': 'Key Laboratory of Cognition and Personality, Faculty of Psychology, Southwest University, Chongqing, China. Electronic address: guorongwu@swu.edu.cn.'}, {'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Columbia University, Department of Psychiatry, New York, NY, USA; Columbia University, Department of Radiology, New York, NY, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.05.015'] 1523,32512234,Oxygen supplementation increases the total work and muscle damage markers but reduces the inflammatory response in COPD patients.,"INTRODUCTION Oxygen supplementation (O 2 -Suppl) is recommended for pulmonary rehabilitation with higher exercise intensities. However, high-intensity exercise tends toward muscle damage and a greater inflammatory response. We aimed to investigate the effect of O 2 -Suppl during exercise test (EET) on CRP level and muscle damage (CPK, LDH, lactate) in non-hypoxemic COPD patients. METHODS Eleven non-depleted patients with COPD (FEV 1 65.5 ± 4.3 %) performed two EET (room-air or O 2 -Suppl-100 %), through a blind, randomized, and placebo-controlled crossover design. CPK, LDH and CRP were measured before, immediately after and 24 h after EET. RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3 %; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L). The O 2 -Suppl protocol resulted in a lower increase in CRP (92.1 ± 112.4 % vs. 400.1 ± 384.9 %; p = 0.003). CONCLUSIONS O 2 -Suppl increases exercise-tolerance, resulting in increased muscle injury markers in COPD. However, oxygen supplementation attenuates the inflammatory response, even upon increased physical exercise.",2020,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","['Eleven non-depleted patients with COPD (FEV 1 65.5\u2009±\u20094.3%) performed two EET (room-air or O 2 -Suppl-100', 'COPD patients', 'non-hypoxemic COPD patients']","['oxygen supplementation', 'Oxygen supplementation (O 2 -Suppl', 'O 2 -Suppl during exercise test (EET', 'Oxygen supplementation', 'placebo']","['Exercise time', 'CRP', 'CPK and LDH', 'CPK, LDH and CRP', 'total work and muscle damage markers', 'physical exercise', 'exercise-tolerance', 'CRP level and muscle damage (CPK, LDH, lactate', 'inflammatory response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517759', 'cui_str': '4.3'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0919655', 'cui_str': 'Oxygen supplementation'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}]",11.0,0.185322,"RESULTS Exercise time was higher with O 2 -Suppl (49.9 ± 37.3%; p = 0.001) and increases in CPK and LDH were observed compared to basal values in the O 2 -Suppl (28.4UI/L and 28.3 UI/L).","[{'ForeName': 'Daniela Rodrigues', 'Initials': 'DR', 'LastName': 'Andrade', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Kelly Critine', 'Initials': 'KC', 'LastName': 'Pinto', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Julia Sampel', 'Initials': 'JS', 'LastName': 'de Castro', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Daniela Kuguimoto', 'Initials': 'DK', 'LastName': 'Andaku', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Viviani Aparecida', 'Initials': 'VA', 'LastName': 'Lara', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Fabio Augusto', 'Initials': 'FA', 'LastName': 'de Luca', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gun', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil.'}, {'ForeName': 'Felipe Augusto Rodrigues', 'Initials': 'FAR', 'LastName': 'Mendes', 'Affiliation': 'Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil.'}, {'ForeName': 'Mayron F', 'Initials': 'MF', 'LastName': 'Oliveira', 'Affiliation': 'Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; VO2Care Research Group, Research Physiotherapy Coordinator of Vila Nova Star Hospital, São Paulo, SP, Brazil.'}, {'ForeName': 'Wladimir Musetti', 'Initials': 'WM', 'LastName': 'Medeiros', 'Affiliation': 'Laboratory of Exercise Physiology and Cardiac Rehabilitation (GERFE), Department of Medicine and Physiotherapy, Santo Amaro University (UNISA), São Paulo, Brazil; Department of Physiotherapy, Ibirapuera University (UNIB), São Paulo, Brazil; Pulmonary Function and Clinical Exercise Physiology Unit (SEFICE), Respiratory Division, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil; HEART - Institute of Cardiology, Department of Education and Research, São Paulo, Brazil. Electronic address: wmusettimedeiros@hotmail.com.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103475'] 1524,32517453,[A Prospective Study of Da Vinci Surgical Robotic System with Chest Wall External Nursing Interventions].,"BACKGROUND Minimally invasive and rapid recovery are trends in surgical treatment of lung cancer, and Da Vinci Surgical Robotic System plays an important role in them. This study was planned to explore the effect of chest wall external nursing interventions on reducing postoperative thoracic drainage and promoting rapid recovery of patients. METHODS The patients who underwent robotic radical lung cancer resection in our hospital from November 2017 to April 2018were randomly divided into two groups. The control group received robotic radical lung cancer resection with abdominal bands wrapped around the chest. The experimental group underwent Da Vinci robotic radical lung cancer surgery and assisted chest wall external nursing interventions after surgery. RESULTS The total and average daily drainage of the experimental group were less than those of the control group. Both the extubation time and the hospitalization time were shorter than those of the control group, but there was no significant difference. The pain score in the second days after operation of the experimental group was slightly higher than that of the control group, with no significant statistical difference. For patients whose chest wall thickness is less than 4 cm, mirabilite external application can significantly reduce the average daily and total drainage volume, but there is no significant difference in extubation time and hospitalization time. CONCLUSIONS Chest wall external nursing interventions are beneficial to the recovery of patients undergoing Vinci robotic lung cancer surgery. Especially for patients with thinner chest wall. It can reduce postoperative drainage, shorten tube retention time and accelerate discharge. Further improvement is expected to achieve better clinical results.",2020,"The pain score in the second days after operation of the experimental group was slightly higher than that of the control group, with no significant statistical difference.","['patients', 'patients with thinner chest wall', 'patients undergoing Vinci robotic lung cancer surgery']","['chest wall external nursing interventions', 'Da Vinci robotic radical lung cancer surgery and assisted chest wall external nursing interventions after surgery', 'Da Vinci Surgical Robotic System with Chest Wall External Nursing Interventions', 'Chest wall external nursing interventions', 'robotic radical lung cancer resection with abdominal bands wrapped around the chest', 'robotic radical lung cancer resection']","['extubation time and the hospitalization time', 'postoperative drainage, shorten tube retention time and accelerate discharge', 'postoperative thoracic drainage', 'total and average daily drainage', 'average daily and total drainage volume', 'extubation time and hospitalization time', 'pain score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205076', 'cui_str': 'Chest wall structure'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0302912', 'cui_str': 'Radical'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}]","[{'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.0110548,"The pain score in the second days after operation of the experimental group was slightly higher than that of the control group, with no significant statistical difference.","[{'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Meng', 'Affiliation': 'The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Xinxing', 'Initials': 'X', 'LastName': 'Sun', 'Affiliation': 'The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.'}, {'ForeName': 'Jiaqi', 'Initials': 'J', 'LastName': 'Tao', 'Affiliation': 'The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.'}]",Zhongguo fei ai za zhi = Chinese journal of lung cancer,['10.3779/j.issn.1009-3419.2020.101.07'] 1525,31973631,"Effects of graduated compression stockings, local vibration and their combination on popliteal venous blood velocity.","OBJECTIVES The purpose of this pilot study was to examine and compare the effects of graduated compression stockings, local vibration, and combined graduated compression stockings and local vibration on popliteal venous blood velocity. METHOD Twenty-four healthy subjects received four 15 min interventions (control, graduated compression stockings alone, local vibration alone, and combined graduated compression stockings and local vibration), while resting inactive in the prone position. Popliteal vein blood velocity was investigated before (PRE) and at the end (POST) of each intervention using Doppler ultrasound. RESULTS At POST, peak velocity was reported to be 26.3 ± 53.5% ( p  <   0.05) greater for local vibration than control (CONT). Peak velocity was 46.2 ± 54.6% ( p  <   0.001) and 21.1 ± 37.6% ( p  <   0.01) higher for graduated compression stockings than CONT and local vibration, respectively. Graduated compression stockings + local vibration presented 64.1 ± 58.0% ( p  <   0.001), 38.4 ± 52.4% ( p  <   0.001) and 15.0 ± 31.6% ( p  <   0.05) greater values than CONT, local vibration and graduated compression stockings, respectively. CONCLUSIONS This study demonstrated an increase in popliteal venous blood velocity after graduated compression stockings and local vibration application. Their combination provided the greatest effects.",2020,"Graduated compression stockings + local vibration presented 64.1 ± 58.0% ( p  <   0.001), 38.4 ± 52.4% ( p  <   0.001) and 15.0 ± 31.6% ( p  <   0.05) greater values than CONT, local vibration and graduated compression stockings, respectively. ",['Twenty-four healthy subjects'],"['graduated compression stockings, local vibration, and combined graduated compression stockings and local vibration', '15\u2009min interventions (control, graduated compression stockings alone, local vibration alone, and combined graduated compression stockings and local vibration', 'graduated compression stockings, local vibration and their combination']","['Popliteal vein blood velocity', 'peak velocity', 'Peak velocity', 'popliteal venous blood velocity', 'local vibration']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0588053', 'cui_str': 'Graduate'}, {'cui': 'C0038348', 'cui_str': 'Compression stocking'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0032652', 'cui_str': 'Structure of popliteal vein'}, {'cui': 'C1531610', 'cui_str': 'Blood velocity'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0442037', 'cui_str': 'Popliteal'}, {'cui': 'C0229667', 'cui_str': 'Venous blood'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}]",24.0,0.0238083,"Graduated compression stockings + local vibration presented 64.1 ± 58.0% ( p  <   0.001), 38.4 ± 52.4% ( p  <   0.001) and 15.0 ± 31.6% ( p  <   0.05) greater values than CONT, local vibration and graduated compression stockings, respectively. ","[{'ForeName': 'Loïc', 'Initials': 'L', 'LastName': 'Espeit', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Lapole', 'Affiliation': 'Univ Lyon, UJM Saint-Etienne, Laboratoire Interuniversitaire de Biologie de la Motricité, Saint-Etienne, France.'}]",Phlebology,['10.1177/0268355520902000'] 1526,32430908,Changes in perampanel levels during de-induction: Simulations following carbamazepine discontinuation.,"OBJECTIVE To evaluate the time course of changes in perampanel levels when co-administered with carbamazepine, and following carbamazepine discontinuation, using a physiologically based pharmacokinetic (PBPK) model. METHODS The PBPK model was developed, verified using clinical PK data, and used to simulate the effect of abrupt discontinuation and down-titration (75 mg twice daily [bid]/wk) of co-administered carbamazepine 300 mg bid on the PK of perampanel once daily (qd). Perampanel dose tapering (8-4 mg) and up-titration (2-6 mg) were simulated during abrupt carbamazepine 300 mg bid discontinuation to identify a titration schedule that minimizes changes in perampanel plasma concentrations. RESULTS The PBPK model accurately reproduced perampanel plasma concentration-time profiles from clinical studies in single- and multiple-dose regimen simulations, including multiple-dose carbamazepine co-administration. The time course of return to pre-induced perampanel levels occurred more slowly following carbamazepine down-titration (~48 days after first down-titration) vs abrupt discontinuation (~25 days). Perampanel dose tapering (8-4 mg) at abrupt carbamazepine discontinuation produced minimal changes in steady-state concentrations, which returned to the levels observed during carbamazepine co-administration in ~15 days from the time of carbamazepine discontinuation. When perampanel was up-titrated in the presence of carbamazepine, return to steady state occurred more slowly when carbamazepine was down-titrated weekly (~45 days) vs abrupt discontinuation (~24 days). CONCLUSION This PBPK model simulated and predicted optimal perampanel dose tapering and up-titration schedules for maintaining perampanel levels during conversion to monotherapy. These results may guide physicians when managing conversion from perampanel polytherapy with concomitant enzyme-inducing anti-seizure medications to monotherapy.",2020,The time course of return to pre-induced perampanel levels occurred more slowly following carbamazepine down-titration (~48 days after first down-titration) vs abrupt discontinuation (~25 days).,[],"['carbamazepine', 'carbamazepine 300\xa0mg bid on the PK of perampanel', 'Perampanel', 'perampanel']","['time course of return to pre-induced perampanel levels', 'steady-state concentrations', 'perampanel levels']",[],"[{'cui': 'C0006949', 'cui_str': 'Carbamazepine'}, {'cui': 'C0984515', 'cui_str': 'Carbamazepine 300 MG'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}, {'cui': 'C2698764', 'cui_str': 'perampanel'}]","[{'cui': 'C0449247', 'cui_str': 'Time course'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0293076,The time course of return to pre-induced perampanel levels occurred more slowly following carbamazepine down-titration (~48 days after first down-titration) vs abrupt discontinuation (~25 days).,"[{'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Schuck', 'Affiliation': 'Eisai Inc., Woodcliff Lake, NJ, USA.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Ferry', 'Affiliation': 'Eisai Inc., Woodcliff Lake, NJ, USA.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Gidal', 'Affiliation': 'School of Pharmacy, University of Wisconsin, Madison, WI, USA.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Hussein', 'Affiliation': 'Eisai Ltd., Hatfield, Hertfordshire, UK.'}]",Acta neurologica Scandinavica,['10.1111/ane.13286'] 1527,32530426,Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.,"BACKGROUND WHO recommends that men who have sex with men (MSM) receive gonorrhoea and chlamydia testing, but many evidence-based preventive services are unaffordable. The pay-it-forward strategy offers an individual a gift (eg, a test for sexually transmitted diseases) and then asks whether they would like to give a gift (eg, a future test) to another person. This study examined the effectiveness of a pay-it-forward programme to increase gonorrhoea and chlamydia testing among MSM in China. METHODS We did a randomised controlled superiority trial at three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China. We included MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing. Restricted randomisation was done using computer-generated permuted blocks. 30 groups were randomised into three arms (1:1:1): a pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing and then asked whether they would like to donate for testing of prospective participants, a pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing was offered at ¥150 (US$22). There was no masking to arm assignment. The primary outcome was gonorrhoea and chlamydia test uptake ascertained by administrative records. We used generalised estimating equations to estimate intervention effects with one-sided 95% CIs and a prespecified superiority margin of 20%. The trial is registered with ClinicalTrials.gov, NCT03741725. FINDINGS Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis. 101 were randomly assigned to the pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group. Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm. The estimated difference in test uptake between the pay-it-forward and standard-of-care group was 38·4% (95% CI lower bound 28·4%). Among men in the pay-it-forward arm, 54 of 57 (95%) chose to donate to support testing for others. INTERPRETATION The pay-it-forward strategy can increase gonorrhoea and chlamydia testing uptake among Chinese MSM and could be a useful tool for scaling up preventive services that carry a mandatory fee. FUNDING US National Institute of Health; Special Programme for Research and Training in Tropical Diseases, sponsored by UNICEF, UNDP, World Bank, and WHO; the National Key Research and Development Program of China; Doris Duke Charitable Foundation; and Social Entrepreneurship to Spur Health.",2020,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","['MSM aged 16 years or older who were seeking HIV testing and met indications for gonorrhoea and chlamydia testing', 'men who have sex with men in China', 'MSM in China', 'three HIV testing sites run by MSM community-based organisations in Guangzhou and Beijing, China', 'Between Dec 8, 2018, and Jan 19, 2019, 301 men were recruited and included in the analysis', 'men who have sex with men (MSM']","['pay-it-forward arm in which men were offered free gonorrhoea and chlamydia testing', 'pay-it-forward group, 100 to the pay-what-you-want group, and 100 to the standard-of-care group', 'Pay-it-forward gonorrhoea and chlamydia testing', 'pay-it-forward programme', 'pay-what-you-want arm in which men were offered free testing and given the option to pay any desired amount for the test, and a standard-of-care arm in which testing']",['gonorrhoea and chlamydia test uptake'],"[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0459958', 'cui_str': 'HIV screening'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}]","[{'cui': 'C0018081', 'cui_str': 'Gonorrhea'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",301.0,0.098425,"Test uptake for gonorrhoea and chlamydia was 56% (57 of 101 participants) in the pay-it-forward arm, 46% (46 of 100 participants) in the pay-what-you-want arm, and 18% (18 of 100 participants) in the standard-of-care arm.","[{'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Tiange P', 'Initials': 'TP', 'LastName': 'Zhang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.'}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China; University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Jason J', 'Initials': 'JJ', 'LastName': 'Ong', 'Affiliation': 'Central Clinical School, Monash University, Melbourne, VIC, Australia; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Alexander', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Forastiere', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA; Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Navin', 'Initials': 'N', 'LastName': 'Kumar', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Katherine T', 'Initials': 'KT', 'LastName': 'Li', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Zou', 'Affiliation': 'Department of Biostatistics, University of North Carolina at Chapel Hill, NC, USA.'}, {'ForeName': 'Ligang', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Guodong', 'Initials': 'G', 'LastName': 'Mi', 'Affiliation': 'Blued, Beijing, China.'}, {'ForeName': 'Yehua', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China.'}, {'ForeName': 'Weizan', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Danyang', 'Initials': 'D', 'LastName': 'Luo', 'Affiliation': 'Zhitong Guangzhou LGBT Center, Guangzhou, China.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vickerman', 'Affiliation': 'School of Social and Community Medicine, University of Bristol, Bristol, UK.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Dermatology Hospital of Southern Medical University, Guangzhou, China.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Christakis', 'Affiliation': 'Yale Institute for Network Science, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Tucker', 'Affiliation': 'University of North Carolina at Chapel Hill, Project-China, Guangzhou, China; London School of Hygiene and Tropical Medicine, London, UK. Electronic address: jdtucker@med.unc.edu.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30172-9'] 1528,32538267,Naltrexone during pain conditioning: A double-blind placebo-controlled experimental trial.,"Naltrexone reversibly blocks the effects of opioids and has been shown to decrease placebo analgesia. However, it is not clear (1) to what extent naltrexone affects pain modulation in a nontreatment context, for example, in response to pain cues or (2) how naltrexone given prior to pain-cue learning shapes pain responses. In a double-blind procedure prior to pain-cue conditioning, 30 healthy participants were randomized to receive an oral dose of naltrexone (50 mg) or inert pill. During functional magnetic resonance imaging, high and low pain pressures were paired with two different visual cues: a high pain cue and a low pain cue (learning sequence). During a test sequence, medium levels of pressure were used for both cues and the difference in subjective pain ratings following high and low pain cues was calculated. Results showed significant conditioned pain responses across groups ( P  <   .001); however, no significant difference between participants receiving naltrexone or inert pill ( P  =   .193). There was a significant correlation between the difference in high and low pain ratings during the learning sequence and the effect of high and low pain cues during the test sequence (r = .575, P  =   .002). Functional magnetic resonance imaging analyses revealed no significant difference in brain activation between groups. Here, we demonstrate comparable learning of pain responses in participants treated with naltrexone or inert pill. The results point to the possibility that associative learning, and conditional responding to pain cues, is not dependent on endogenous opioids. Our results, using pain-cue conditioning to create reduced pain responses, contrast previous studies where opioid antagonists significantly reduced the placebo effect in treatment of pain.",2020,"Results showed significant conditioned pain responses across groups ( P  <   .001); however, no significant difference between participants receiving naltrexone or inert pill ( P  =   .193).","['participants treated with', '30 healthy participants']","['naltrexone', 'naltrexone (50\u2009mg) or inert pill', 'naltrexone or inert pill', 'Naltrexone', 'placebo']","['pain modulation', 'conditioned pain responses', 'brain activation', 'high and low pain ratings', 'effect of high and low pain cues', 'subjective pain ratings', 'pain responses']","[{'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0424543', 'cui_str': 'Response to pain'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}]",30.0,0.262936,"Results showed significant conditioned pain responses across groups ( P  <   .001); however, no significant difference between participants receiving naltrexone or inert pill ( P  =   .193).","[{'ForeName': 'Moa', 'Initials': 'M', 'LastName': 'Pontén', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Fust', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Kosek', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Joar', 'Initials': 'J', 'LastName': 'Guterstam', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Jensen', 'Affiliation': 'Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}]",Molecular pain,['10.1177/1744806920927625'] 1529,32540337,Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study.,"BACKGROUND AND PURPOSE Preclinical data suggest that cetuximab should be continued after end of concurrent radiotherapy+cetuximab due to its efficacy against residual tumor cells in the irradiated tumor bed. Based on this concept the phase II add-on cetuximab (AOC) study was designed. MATERIALS AND METHODS Altogether 63 patients with advanced head and neck cancer were treated with radiochemotherapy (70 Gy, cisplatin 40 mg/m 2 weekly) in combination with concurrent cetuximab (loading dose 400 mg/m 2 , then 250 mg/m 2 weekly). Thereafter patients were randomized to cetuximab consolidation (500 mg/m 2 biweekly × 6) or no further treatment. The primary endpoint was the 2-year locoregional control (LRC) rate. As translational research endpoints serum markers were analyzed before and during treatment and CT-based quantitative image analysis (radiomics) was performed. RESULTS Median follow-up was 24 months. The 2-year LRC rates were 67.9% and 67.7% in the treatment arms with and without consolidation cetuximab, respectively. Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p ≤ 0.05). A radiomics model consisting of two radiomics features could be built showing that higher entropy and higher complexity of tumor Hounsfield unit distribution indicates worse LRC (concordance index 0.66). No correlation was found between biological and imaging markers. CONCLUSIONS There was no evidence that consolidation cetuximab would improve the 2-year LRC rate. Prognostic biological and imaging markers could be identified for the overall patient cohort. Studies with larger patient numbers are needed to correlate biological and imaging markers.",2020,"Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).","['Altogether 63 patients with advanced head and neck cancer', 'patients with advanced head and neck cancer']","['radiochemotherapy + cetuximab', 'radiochemotherapy (70 Gy, cisplatin 40mg/m2 weekly) in combination with concurrent cetuximab', 'Consolidation cetuximab', 'radiotherapy + cetuximab', 'cetuximab consolidation']","['2-year LRC rates', '2-year LRC rate', '2-year locoregional control (LRC) rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}]","[{'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0521530', 'cui_str': 'Lung consolidation'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",63.0,0.0261113,"Higher than median levels of three serum markers were negatively associated with the 2-year LRC rate in the overall patient cohort: Osteopontin, IL8 and FasL2 (p≤0.05).","[{'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Riesterer', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Center for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Switzerland. Electronic address: oliver.riesterer@ksa.ch.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Pruschy', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Bender', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Laboratory for Molecular Radiobiology, University of Zurich, Switzerland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Bogowicz', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Tanadini-Lang', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Stieb', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Kaja', 'Initials': 'K', 'LastName': 'Bertogg', 'Affiliation': 'Clinical Trials Center, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Weber', 'Affiliation': 'Clinical Trials Center, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Ikenberg', 'Affiliation': 'Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Huber', 'Affiliation': 'Department of Otorhinolaryngology, University Hospital Zurich, University of Zurich, Switzerland; Department of Otorhinolaryngology, Cantonal Hospital St. Gallen, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Schmid', 'Affiliation': 'Otorhinolaryngology Clinic Bethanien, Zurich, Switzerland.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Bredell', 'Affiliation': 'Clinic for Oral and Maxillofacial Surgery, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Veit-Haibach', 'Affiliation': 'Department of Nuclear Medicine, University Hospital Zurich, Switzerland; Department of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Rordorf', 'Affiliation': 'Department of Medical Oncology, University Hospital Zurich, University of Zurich, Switzerland.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Held', 'Affiliation': 'Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Switzerland.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Glanzmann', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, Cantonal Hospital Lucerne, Switzerland.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Studer', 'Affiliation': 'Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland; Department of Radiation Oncology, Cantonal Hospital Lucerne, Switzerland.'}]",Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,['10.1016/j.radonc.2020.06.011'] 1530,32541132,Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer.,"Chemotherapy, targeted therapy, and immunotherapy are used against advanced non-small cell lung cancer. A clinically efficacious method for relieving the adverse events associated of such therapies is lacking. Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs. Twenty patients who refused drug treatment were assigned equally and randomly to a hydrogen (H 2 )-only group and a control group. According to the results of tumor-gene mutations and drug-sensitivity tests, 10, 18, and 10 patients were enrolled into chemotherapy, targeted therapy, and immunotherapy groups in which these therapies were combined with H 2 -therapy, respectively. Patients underwent H 2 inhalation for 4-5 hours per day for 5 months or stopped when cancer recurrence. Before study initiation, the demographics (except for tumor-mutation genes) and pulmonary symptoms (except for moderate cough) of the five groups showed no significant difference. During the first 5 months of treatment, the prevalence of symptoms of the control group increased gradually, whereas that of the four treatment groups decreased gradually. After 16 months of follow-up, progression-free survival of the control group was lower than that of the H 2 -only group, and significantly lower than that of H 2 + chemotherapy, H 2 + targeted therapy, and H 2 + immunotherapy groups. In the combined-therapy groups, most drug-associated adverse events decreased gradually or even disappeared. H 2 inhalation was first discovered in the clinic that can be used to control tumor progression and alleviate the adverse events of medications for patients with advanced non-small cell lung cancer. This study was approved by the Ethics Committee of Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval No. Fuda20181207), and was registered at ClinicalTrials.gov (Identifier: NCT03818347) on January 28, 2019.",2020,"After 16 months of follow-up, progression-free survival of the control group was lower than that of the H 2 -only group, and significantly lower than that of H 2 + chemotherapy, H 2 + targeted therapy, and H 2 + immunotherapy groups.","['patients with advanced non-small cell lung cancer', 'Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs', 'Fuda Cancer Hospital of Jinan University on December 7, 2018 (approval No. Fuda20181207), and was registered at ClinicalTrials.gov (Identifier: NCT03818347) on January 28, 2019', 'Twenty patients who refused drug treatment']","['Hydrogen therapy', 'hydrogen (H 2 )-only group and a control group', 'Chemotherapy, targeted therapy, and immunotherapy']","['pulmonary symptoms', 'adverse events', 'progression-free survival', 'prevalence of symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0019999', 'cui_str': 'Cancer hospital'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0600091', 'cui_str': 'Identifier'}, {'cui': 'C0017095', 'cui_str': 'Trash'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0037090', 'cui_str': 'Respiratory symptom'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",58.0,0.0176589,"After 16 months of follow-up, progression-free survival of the control group was lower than that of the H 2 -only group, and significantly lower than that of H 2 + chemotherapy, H 2 + targeted therapy, and H 2 + immunotherapy groups.","[{'ForeName': 'Ji-Bing', 'Initials': 'JB', 'LastName': 'Chen', 'Affiliation': 'Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Xiao-Feng', 'Initials': 'XF', 'LastName': 'Kong', 'Affiliation': 'Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Mu', 'Affiliation': 'Fuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.'}, {'ForeName': 'Tian-Yu', 'Initials': 'TY', 'LastName': 'Lu', 'Affiliation': 'Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.'}, {'ForeName': 'You-Yong', 'Initials': 'YY', 'LastName': 'Lu', 'Affiliation': 'Central Lab, Beijing Cancer Hospital, Beijing, China.'}, {'ForeName': 'Ke-Cheng', 'Initials': 'KC', 'LastName': 'Xu', 'Affiliation': 'Fuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.'}]",Medical gas research,['10.4103/2045-9912.285560'] 1531,32541143,A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society.,"BACKGROUND Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined. METHODS In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patients were randomized 1:1 to either TEM in a dose of 25 mg i.v. once a week or SUN with 50 mg p.o. daily for 4 weeks on and 2 weeks off. Primary endpoint was progression-free survival (PFS). In total, 22 patients were included with predominantly papillary RCC (16/22) followed by chromophobe RCC and others. RESULTS The male to female ratio was 16:6. The tumor control rate (CR + PR + SD) was 58% for TEM and 90% for SUN-treated patients. There was also a trend for improved PFS with 9.3 versus 13.2 months (HR 1.64; 95% CI 0.65-4.18) in favor of SUN. There was no trend for overall survival. CONCLUSIONS Despite this trial had to be terminated earlier due to low recruitment, the results match the other studies published so far with the mTOR inhibitor everolimus and SUN, which show a trend in favor of SUN for ORR and PFS.",2020,The tumor control rate (CR + PR + SD) was 58% for TEM and 90% for SUN-treated patients.,"['patients with metastatic nccRCC', 'Advanced Non-Clear Cell Renal Cell Carcinoma', '22 patients were included with predominantly papillary RCC (16/22) followed by chromophobe RCC and others']","['TEM', 'temsirolimus (TEM) versus sunitinib (SUN', 'Temsirolimus versus Sunitinib']","['progression-free survival (PFS', 'overall survival', 'PFS', 'tumor control rate (CR + PR + SD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0279702', 'cui_str': 'Clear cell carcinoma of kidney'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0007134', 'cui_str': 'Renal cell carcinoma'}, {'cui': 'C0450329', 'cui_str': '16/22'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C1707080', 'cui_str': 'temsirolimus'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",22.0,0.176986,The tumor control rate (CR + PR + SD) was 58% for TEM and 90% for SUN-treated patients.,"[{'ForeName': 'Lothar', 'Initials': 'L', 'LastName': 'Bergmann', 'Affiliation': 'Medical Clinic II, J.W. Goethe University, Frankfurt, Germany, L.Bergmann@em.uni-frankfurt.de.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Grünwald', 'Affiliation': 'Hematology and Medical Oncology, Medizinische Hochschule Hannover, Hannover, Germany.'}, {'ForeName': 'Luise', 'Initials': 'L', 'LastName': 'Maute', 'Affiliation': 'Medical Clinic II, J.W. Goethe University, Frankfurt, Germany.'}, {'ForeName': 'Marc-Oliver', 'Initials': 'MO', 'LastName': 'Grimm', 'Affiliation': 'Clinic for Urology, Friedrich-Schiller University, Jena, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Weikert', 'Affiliation': 'Clinic for Urology, Vivantes Humboldt-Klinikum, Berlin, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Schleicher', 'Affiliation': 'Clinic for Hematology and Oncology, Klinikum Stuttgart, Stuttgart, Germany.'}, {'ForeName': 'Theodor', 'Initials': 'T', 'LastName': 'Klotz', 'Affiliation': 'Clinic for Urology and Andrology, Kliniken Nordoberpfalz AG, Weiden, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Greiner', 'Affiliation': 'Clinic for Hematology and Oncology, Diakonie Klinikum, Stuttgart, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Flörcken', 'Affiliation': 'Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Virchow-Klinikum, Berlin, Germany.'}, {'ForeName': 'Arndt', 'Initials': 'A', 'LastName': 'Hartmann', 'Affiliation': 'Institut for Pathology, University Hospital, Erlangen-Nürnberg, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Gauler', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen of the University Duisburg-Essen, Essen, Germany.'}]",Oncology research and treatment,['10.1159/000508450'] 1532,32542431,"Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.","INTRODUCTION Diabetic macular edema (DME) threatens daily life activities such as reading and driving and reduces the patients' quality-of-life. Recently, anti-vascular endothelial growth factor (VEGF) agents have become a first-line therapy in DME. However, therapy with anti-VEGF agents has several problems: repeated invasive injections are required; medical costs are high; and a certain proportion of patients with DME are resistant to treatment with anti-VEGF agents. While sodium-glucose co-transporter 2 (SGLT2) inhibitors have been widely used for the treatment of type 2 diabetes mellitus (T2DM), the effects of a combination therapy with anti-VEGF agent and SGLT2 inhibitor on DME are not yet known. METHODS This study enrolls subjects with T2DM and DME, randomizes them into either a study agent treatment group (treated with ranibizumab as anti-VEGF agent and luseogliflozin as SGLT2 inhibitor) or a control group (treated with ranibizumab and glimepiride), and observes the subjects for 52 weeks after initiation of treatment. Planned outcomes: The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48. Secondary and exploratory endpoints include safety and ophthalmologic and internal medical clinical parameters. REGISTRATION This study is registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000033961) and Japan Registry of Clinical Trials (jRCTs031180210).",2020,The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48.,"['Patients with Diabetic Macular Edema', 'enrolls subjects with T2DM and DME, randomizes them into either a study agent treatment group (treated with']","['sodium-glucose co-transporter\xa02 (SGLT2) inhibitors', 'ranibizumab as anti-VEGF agent and luseogliflozin as SGLT2 inhibitor) or a control group (treated with ranibizumab and glimepiride', 'Ranibizumab and Luseogliflozin Combination Therapy']","['safety and ophthalmologic and internal medical clinical parameters', 'Safety and Efficacy', 'number of intravitreal anti-VEGF injections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598849', 'cui_str': 'Co-Transporters'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C2933904', 'cui_str': '1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol'}, {'cui': 'C4301634', 'cui_str': 'Sodium-glucose co-transporter 2 (SGLT2) inhibitors'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",,0.0283211,The primary endpoint is intergroup difference in the number of intravitreal anti-VEGF injections to the study eye from baseline to week 48.,"[{'ForeName': 'Ryoichi', 'Initials': 'R', 'LastName': 'Ishibashi', 'Affiliation': 'Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu, Chiba, 292-8535, Japan. ishibashi-cib@umin.net.'}, {'ForeName': 'Yoko', 'Initials': 'Y', 'LastName': 'Takatsuna', 'Affiliation': 'Department of Ophthalmology, Chiba Rosai Hospital, 2-16 Tatsumidai-Higashi, Ichihara, Chiba, 290-0003, Japan.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Koshizaka', 'Affiliation': 'Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Tomoaki', 'Initials': 'T', 'LastName': 'Tatsumi', 'Affiliation': 'Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Takahashi', 'Affiliation': 'Clinical Research Support Center, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Nagashima', 'Affiliation': 'Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, 10-3 Midori-cho, Tachikawa, Tokyo, 190-8562, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Asaumi', 'Affiliation': 'Department of Ophthalmology, Kimitsu Chuo Hospital, 1010 Sakurai, Kisarazu, Chiba, 292-8535, Japan.'}, {'ForeName': 'Miyuki', 'Initials': 'M', 'LastName': 'Arai', 'Affiliation': 'Department of Ophthalmology, National Hospital Organization Chiba Medical Center, Tsubakimori 4-1-2, Chuo-ku, Chiba, Chiba, 260-8606, Japan.'}, {'ForeName': 'Fumio', 'Initials': 'F', 'LastName': 'Shimada', 'Affiliation': 'Department of Diabetes and Metabolism, National Hospital Organization Chiba Medical Center, Tsubakimori 4-1-2, Chuo-ku, Chiba, Chiba, 260-8606, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Tachibana', 'Affiliation': 'Department of Diabetes, Metabolic Diseases, Endocrinology, Japanese Red Cross Narita Hospital, 90-1, Iida-cho, Narita, Chiba, 286-8523, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Watanabe', 'Affiliation': 'Department of Ophthalmology, Japanese Red Cross Narita Hospital, 90-1, Iida-cho, Narita, Chiba, 286-8523, Japan.'}, {'ForeName': 'Ko', 'Initials': 'K', 'LastName': 'Ishikawa', 'Affiliation': 'Department of Internal Medicine, Chiba Rosai Hospital, Tatsumidai-Higashi 2-16, Ichihara, Chiba, 290-0003, Japan.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Hoshino', 'Affiliation': 'Department of Ophthalmology, Chiba Aoba Municipal Hospital, Aoba-cho 1273-2, Chuo-ku, Chiba, Chiba, 260-0852, Japan.'}, {'ForeName': 'Kyohei', 'Initials': 'K', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Internal Medicine, Chiba Aoba Municipal Hospital, Aoba-cho 1273-2, Chuo-ku, Chiba, Chiba, 260-0852, Japan.'}, {'ForeName': 'Mariko', 'Initials': 'M', 'LastName': 'Kubota-Taniai', 'Affiliation': 'Department of Ophthalmology, Chiba Kaihin Municipal Hospital, Isobe 3-31-1, Mihama-ku, Chiba, Chiba, 261-0012, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Mayama', 'Affiliation': 'Department of Internal Medicine, Chiba Kaihin Municipal Hospital, Isobe 3-31-1, Mihama-ku, Chiba, Chiba, 261-0012, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}, {'ForeName': 'Koutaro', 'Initials': 'K', 'LastName': 'Yokote', 'Affiliation': 'Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Chiba, 260-8677, Japan.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00854-6'] 1533,32536527,Arthroscopic Remnant-Preserving Anterior Talofibular Ligament Reconstruction does not Improve Mid-term Function in Chronic Ankle Instability.,"BACKGROUND Anterior talofibular ligament (ATFL) reconstruction is routinely undertaken to manage chronic lateral ankle instability (CLAI). This study evaluated the effects on clinical outcome of preserving or not preserving the ATFL remnant when reconstructing the ATFL. METHODS From January 2015 to July 2017, 53 CLAI patients with ATFL injury were randomized to undergo either a remnant-preserving (preservation of ATFL) or a non-preserving (no preservation of ATFL) anatomic reconstruction of the ATFL using an ipsilateral free semitendinosus tendon autograft. The Visual Analogue Scale (VAS) score, the American Orthopedic Foot and Ankle Society (AOFAS) score, Karlsson Ankle Functional Score (KAFS), Anterior Talar Translation (ATT), and ankle proprioceptive recovery in both groups were compared. RESULTS All patients were followed up for at least 2 years, VAS, AOFAS, KAFS, ATT and ankle proprioception between two the groups were not statistically significant different. CONCLUSION There are no differences at 2.5 years in postoperative ankle function, stability and proprioceptive recovery when an ipsilateral free semitendinosus tendon autograft is used to manage CLAI regardless of preservation of the remnant ATFL.",2020,"There are no differences at 2.5 years in postoperative ankle function, stability and proprioceptive recovery when an ipsilateral free semitendinosus tendon autograft is used to manage CLAI regardless of preservation of the remnant ATFL.","['From January 2015 to July 2017, 53 CLAI patients with ATFL injury']","['Arthroscopic Remnant-Preserving Anterior Talofibular Ligament Reconstruction', 'Anterior talofibular ligament (ATFL) reconstruction', 'remnant-preserving (preservation of ATFL) or a non-preserving (no preservation of ATFL) anatomic reconstruction of the ATFL using an ipsilateral free semitendinosus tendon autograft']","['Visual Analogue Scale (VAS) score, the American Orthopedic Foot and Ankle Society (AOFAS) score, Karlsson Ankle Functional Score (KAFS), Anterior Talar Translation (ATT), and ankle proprioceptive recovery', 'postoperative ankle function, stability and proprioceptive recovery', 'VAS, AOFAS, KAFS, ATT and ankle proprioception']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0277851', 'cui_str': 'Ankle instability'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0225166', 'cui_str': 'Structure of anterior talofibular ligament'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0225166', 'cui_str': 'Structure of anterior talofibular ligament'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0921292', 'cui_str': 'Tendon of semitendinosus'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0040712', 'cui_str': 'Translations'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}]",,0.0344146,"There are no differences at 2.5 years in postoperative ankle function, stability and proprioceptive recovery when an ipsilateral free semitendinosus tendon autograft is used to manage CLAI regardless of preservation of the remnant ATFL.","[{'ForeName': 'Shi-Ming', 'Initials': 'SM', 'LastName': 'Feng', 'Affiliation': 'Hand and Foot Microsurgery Department, Xuzhou Central Hospital, Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, 221009, PR China; Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, 221009, PR China.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Maffulli', 'Affiliation': 'Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery, University of Salerno, Salerno, Italy; Centre for Sports and Exercise Medicine, Barts and The London School of Medicine and Dentistry, Mile End Hospital, 275 Bancroft Road, London, E1 4DG, England. Electronic address: n.maffulli@qmul.ac.uk.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Oliva', 'Affiliation': 'Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery, University of Salerno, Salerno, Italy.'}, {'ForeName': 'Ai-Guo', 'Initials': 'AG', 'LastName': 'Wang', 'Affiliation': 'Hand and Foot Microsurgery Department, Xuzhou Central Hospital, Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, 221009, PR China.'}, {'ForeName': 'Qing-Qing', 'Initials': 'QQ', 'LastName': 'Sun', 'Affiliation': 'Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, 221009, PR China.'}]",Injury,['10.1016/j.injury.2020.05.011'] 1534,32544700,Time course of drug-related treatment-emergent adverse side effects of brivaracetam.,"OBJECTIVE Treatment-emergent adverse events (TEAEs) in clinical trials are typically reported for the full duration of the treatment period including titration and maintenance. Drug-related central nervous system (CNS) TEAEs are common with antiseizure medications (ASMs) and can affect drug tolerability. In this report, we test the hypothesis that drug-related CNS TEAEs have early onset and decrease with time. Unlike prior ASM clinical trials, a novel design was used for brivaracetam (BRV) without initial drug titration allowing assessment of habituation to TEAEs separate from dose titration. METHODS Data were pooled from three studies (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) in adult patients (≥16 years of age) with focal seizures receiving BRV adjunctive therapy. This post hoc analysis reports data on the prevalence and incidence of all drug-related CNS TEAEs and all TEAEs over time in patients who received BRV doses of 50-200 mg/day (without titration) vs. placebo during a 12-week treatment period. RESULTS A total of 1262 patients received the following: placebo (n = 459), BRV 50 mg/day (n = 200), BRV 100 mg/day (n = 353), and BRV 200 mg/day (n = 250). Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. CONCLUSIONS Drug-related CNS TEAEs occurred early and substantially habituated over several weeks. TEAEs of ASMs might be better represented by division into early and late phases to guide clinician monitoring and patient expectations.",2020,"Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. ","['1262 patients', 'adult patients (≥16\u202fyears of age) with focal seizures receiving BRV adjunctive therapy']","['Drug-related central nervous system (CNS', 'brivaracetam', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],1262.0,0.10034,"Both the incidence (p < .0001) and prevalence (p < .0001) of drug-related CNS TEAEs (all with frequency ≥ 5%) changed across time with peak TEAEs in week 1 then significantly reducing over the first 6 weeks for prevalence and the first 3 weeks for incidence. ","[{'ForeName': 'Kimford J', 'Initials': 'KJ', 'LastName': 'Meador', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: kmeador@stanford.edu.'}, {'ForeName': 'Cedric', 'Initials': 'C', 'LastName': 'Laloyaux', 'Affiliation': 'UCB Pharma, Brussels, Belgium. Electronic address: cedric.laloyaux@ucb.com.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, Raleigh, NC, USA. Electronic address: sami.elmoufti@ucb.com.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Gasalla', 'Affiliation': 'UCB Pharma, Monheim am Rhein, Germany. Electronic address: teresa.gasalla@ucb.com.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Fishman', 'Affiliation': 'UCB Pharma, Smyrna, GA, USA. Electronic address: jfishman@its.jnj.com.'}, {'ForeName': 'Melinda S', 'Initials': 'MS', 'LastName': 'Martin', 'Affiliation': 'UCB Pharma, Smyrna, GA, USA. Electronic address: melinda.martin@ucb.com.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Klein', 'Affiliation': 'Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. Electronic address: kleinp@epilepsydc.com.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107212'] 1535,32544794,Acute aerobic exercise enhances pleasant compared to unpleasant visual scene processing.,"Although acute aerobic exercise benefits different aspects of emotional functioning, it is unclear how exercise influences the processing of emotional stimuli and which brain mechanisms support this relationship. We assessed the influence of acute aerobic exercise on valence biases (preferential processing of negative/positive pictures) by performing source reconstructions of participants' brain activity after they viewed emotional scenes. Twenty-four healthy participants (12 women) were tested in a randomized and counterbalanced design that consisted of three experimental protocols, each lasting 30 min: low-intensity exercise (Low-Int); moderate-intensity exercise (Mod-Int); and a seated rest condition (REST). After each of the protocols, participants viewed negative and positive pictures, during which event-related magnetic fields were recorded. Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset. Brain activity in this cluster showed that a negativity bias at REST (negative > positive picture processing) diminished after the Low-Int condition (positive = negative) and even reversed to a positivity bias after the Mod-Int condition (positive > negative). Thus, acute aerobic exercise of low and moderate intensities induces a positivity bias which is reflected in early, automatic processes.",2020,Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset.,"['Twenty-four healthy participants (12 women', ""participants' brain activity after they viewed emotional scenes""]","['Acute aerobic exercise enhances pleasant', 'lasting 30\xa0min: low-intensity exercise (Low-Int); moderate-intensity exercise (Mod-Int); and a seated rest condition (REST', 'acute aerobic exercise']","['valence processing of emotional scenes', 'Brain activity']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}]",24.0,0.139816,Analyses revealed that exercise strongly impacted the valence processing of emotional scenes within a widely distributed left hemispheric spatio-temporal cluster between 190 and 310 ms after picture onset.,"[{'ForeName': 'Tomasz S', 'Initials': 'TS', 'LastName': 'Ligeza', 'Affiliation': 'Psychophysiology Laboratory, Institute of Psychology, Jagiellonian University, Kraków, Poland. Electronic address: tomasz.ligeza@uj.edu.pl.'}, {'ForeName': 'Marcin', 'Initials': 'M', 'LastName': 'Maciejczyk', 'Affiliation': 'Department of Physiology and Biochemistry, Faculty of Physical Education and Sport, University of Physical Education, Kraków, Poland.'}, {'ForeName': 'Miroslaw', 'Initials': 'M', 'LastName': 'Wyczesany', 'Affiliation': 'Psychophysiology Laboratory, Institute of Psychology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Wagner', 'Affiliation': 'Institute for Sports Science, University of Muenster, Muenster, Germany; Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany.'}, {'ForeName': 'Kati', 'Initials': 'K', 'LastName': 'Roesmann', 'Affiliation': 'Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany; Institute for Clinical Psychology, University of Siegen, Siegen, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Junghofer', 'Affiliation': 'Institute for Biomagnetism and Biosignalanalysis, University of Muenster, Muenster, Germany; Otto Creutzfeldt Center for Cognitive and Behavioral Neuroscience, University of Muenster, Muenster, Germany.'}]",Brain and cognition,['10.1016/j.bandc.2020.105595'] 1536,32520718,Dose-Response Relationship of a Web-Based Tailored Intervention Promoting Human Papillomavirus Vaccination: Process Evaluation of a Randomized Controlled Trial.,"BACKGROUND In the Netherlands, human papillomavirus (HPV) vaccination uptake remains low. To improve informed decision making (IDM) and HPV vaccination acceptability, we systematically developed an interactive, web-based tailored intervention to which mothers of Dutch girls were invited to participate. OBJECTIVE The aim of this study was to provide insight into the intervention's working mechanisms by evaluating (1) program use, (2) program acceptability, and (3) the relationship of program use with program acceptability and intervention effects (ie, dose-response relationship). METHODS Only mothers from the intervention arm of a randomized controlled trial that assessed the effectiveness of the web-based, tailored intervention were included in this study. They were invited to visit the website of the web-based intervention between baseline (January 2015, just before access to the intervention) and follow up (March 2015, prior to the first HPV vaccination). Indicators for program use were time of website use (ie, duration of intervention exposure) and completeness (ie, proportion of all available web pages visited). HPV vaccination uptake registered by Praeventis was used as the primary outcome. Secondary outcomes were IDM, decisional conflict, and social-psychological determinants of HPV vaccination uptake. RESULTS Among the 3995 invited mothers, 2509 (62.80%) logged on to the website, 2239 of whom (89.24%) visited at least one page of the intervention components. On average, mothers spent 21.39 minutes (SD 12.41) on the website and completed 50.04% (SD 26.18%) of the website components. Participants rated the website 7.64 (SD 1.39) on a 10-point scale. Program acceptability was significantly associated with completeness (β=4.36, P<.001), but not with time of website use (β=-.07, P=.77). Intention-to-treat analysis (N=3995) showed a significant positive effect of completeness on all outcome measures (all P<.003; Bonferroni-corrected α=.05/15 factors), including on HPV vaccination uptake. Time of website use had a significant positive effect on all outcomes (all P<.003), except for uptake (P=.20), risk perception when not vaccinated (P=.14), subjective norms (P=.03), and habit (P=.01). CONCLUSIONS Program use and acceptability of the intervention were adequate. Completeness was positively associated with acceptability. Furthermore, positive effects (ie, dose-response effects) were found for completeness and time of website use on the mothers' IDM, decisional conflict, and almost all of the social-psychological determinants of HPV vaccination acceptability. In addition, the extent to which mothers completed the intervention had a positive impact on their daughters' vaccination uptake. This indicates that the web-based, tailored intervention fits well with the mothers' needs, and that completeness of use is essential for improving HPV vaccination uptake, acceptability, and IDM. Program use should therefore be promoted. TRIAL REGISTRATION Netherlands Trial Register NTR4795; https://www.trialregister.nl/trial/4795.",2020,"Time of website use had a significant positive effect on all outcomes (P's <.003), except for uptake (P = .195), risk perception when not vaccinated (P = .144), subjective norms (P = .032), and habit (P = .013). ","['mothers of Dutch girls to-be-invited', '3995 invited mothers, 2509 mothers (62.80%) logged in', '2239 mothers (89.24%) visited at least one page of the intervention components']",[],"['decision-making (IDM), decisional conflict, and social psychological determinants of HPV vaccination uptake', 'Program acceptability', 'risk perception', 'HPV vaccination uptake', 'HPV vaccination uptake, acceptability, and IDM', 'completeness and time of website use on the mothers IDM, decisional conflict, and almost all of the social-psychological determinants of HPV vaccination acceptability', 'subjective norms']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013862', 'cui_str': 'Polyacrylamide gel electrophoresis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",[],"[{'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",3995.0,0.0847614,"Time of website use had a significant positive effect on all outcomes (P's <.003), except for uptake (P = .195), risk perception when not vaccinated (P = .144), subjective norms (P = .032), and habit (P = .013). ","[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Pot', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Theo Gwm', 'Initials': 'TG', 'LastName': 'Paulussen', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Robert Ac', 'Initials': 'RA', 'LastName': 'Ruiter', 'Affiliation': 'Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Liesbeth', 'Initials': 'L', 'LastName': 'Mollema', 'Affiliation': 'National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, Netherlands.'}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Hofstra', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}, {'ForeName': 'Hilde M', 'Initials': 'HM', 'LastName': 'Van Keulen', 'Affiliation': 'Child Health, Netherlands Organization for Applied Scientific Research (TNO), Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/14822'] 1537,32527501,[Influence of methylprednisolone on the reversal time of sugammadex: a randomized clinical trial].,"BACKGROUND AND OBJECTIVES Sugammadex is a modified gamma-cyclodextrin that reverses the effects of aminosteroidal neuromuscular blocking agents. Likewise, some steroid molecules, such as toremifene, fusidic acid, and flucloxacillin, can also be encapsulated by sugammadex. Methylprednisolone, which is a synthetic steroid used commonly for airway oedema prophylaxis, can also be encapsulated by sugammadex. The objective of this study was to compare the recovery times of sugammadex for reversing rocuronium-induced moderate neuromuscular blockade in those who received intraoperative 1 mg.kg -1 methylprednisolone or saline. METHOD This single-centered, randomized, controlled, prospective study included 162 adult patients undergoing elective ear-nose-throat procedures (aged from 18-65, an ASA physical status I-II, a BMI less than 30 kg.m -2 , and not taking steroid drug medication) with propofol, remifentanyl, rocuronium and sevoflurane. Neuromuscular monitoring was performed using calibrated acceleromyography. The Control Group (Group C) received 5 mL of saline, while the Methylprednisolone Group (Group M) received 1 mg.kg -1 of methylprednisolone in 5mL of saline just after induction. After the completion of surgery, regarding the TOF count, two reappeared spontaneously and 2 mg.kg -1 sugammadex was administered to all patients. Recovery of the TOF ratio to 0.9 was recorded for both groups, and the estimated recovery time to reach a TOF ratio (TOFr) of 0.9 was the primary outcome of the study. RESULTS Median time to TOFr = 0.9 was for 130.00 s (range of 29-330) for Group C and 181.00 s (100-420) for Group M (p < 0.001). The differences between the two groups were statistically significant. CONCLUSION When using 2 mg.kg -1 of sugammadex to reverse rocuronium-induced neuromuscular blockade in patients who received 1 mg.kg -1 of intraoperative methylprednisolone, demonstrated delayed recovery times.",2020,"The differences between the two groups were statistically significant. ","['162 adult patients undergoing elective ear-nose-throat procedures (aged from 18-65, an ASA physical status I-II, a BMI less than 30 kg.m']","['intraoperative 1 mg.kg -1 methylprednisolone or saline', '5 mL of saline, while the Methylprednisolone', 'methylprednisolone', 'propofol, remifentanyl, rocuronium and sevoflurane', 'Methylprednisolone']","['delayed recovery times', 'TOF count', 'estimated recovery time to reach a TOF ratio (TOFr', 'TOF ratio', 'reversal time of sugammadex']","[{'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0150934', 'cui_str': 'Ear, nose and throat structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439092', 'cui_str': '<'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039685', 'cui_str': 'Tetralogy of Fallot'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1700695', 'cui_str': 'Sugammadex'}]",162.0,0.465584,"The differences between the two groups were statistically significant. ","[{'ForeName': 'Merve Hayriye', 'Initials': 'MH', 'LastName': 'Kocaoğlu', 'Affiliation': 'Turkish Ministry of Health Ankara 29 Mayis State Hospital, Department of Anesthesiology and Intensive Care, Ankara, Turkey. Electronic address: mervearal@yahoo.com.'}, {'ForeName': 'Başak Ceyda', 'Initials': 'BC', 'LastName': 'Meço', 'Affiliation': 'Ankara University Faculty of Medicine, Department of Anesthesiology and Intensive Care, Ankara, Turkey.'}, {'ForeName': 'Menekşe', 'Initials': 'M', 'LastName': 'Özçelik', 'Affiliation': 'Ankara University Faculty of Medicine, Department of Anesthesiology and Intensive Care, Ankara, Turkey.'}, {'ForeName': 'Yeşim', 'Initials': 'Y', 'LastName': 'Batislam', 'Affiliation': 'Ankara University Faculty of Medicine, Department of Anesthesiology and Intensive Care, Ankara, Turkey.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2020.01.002'] 1538,32530760,Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.,"PURPOSE Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma. PATIENTS AND METHODS The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012. Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts. The survival outcomes were compared with the published American Joint Committee on Cancer version 8 (AJCCv8) stage III survival data. RESULTS For the CMMR stage III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 67% versus 77%, and at 10 years were 56% versus 69%, respectively. For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%. The MSS rates of the EORTC studies either overlapped with or were lower than, the CMMR data. CONCLUSION The MSS rates in the CMMR and EORTC cohorts over the entire stage III are less favorable than those published in AJCCv8. This is particularly true for substages IIIA and IIIB.",2020,"For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%.","['573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts', 'Patients With Stage III Melanoma', 'patients with stage III melanoma', 'The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012']",[],"['MSS rates', 'survival probabilities', 'melanoma-specific survival (MSS) rates', 'survival outcomes', 'Cancer version 8 (AJCCv8) stage III survival data']","[{'cui': 'C4708164', 'cui_str': '573'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0332137', 'cui_str': 'Principal diagnosis'}, {'cui': 'C0470277', 'cui_str': '2000'}]",[],"[{'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]",1553.0,0.101388,"For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%.","[{'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Garbe', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Keim', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Suciu', 'Affiliation': 'European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Amaral', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Eigentler', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Gesierich', 'Affiliation': 'Department of Dermatology, University Hospital Wuerzburg, Wuerzburg, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Hauschild', 'Affiliation': 'Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Heinzerling', 'Affiliation': 'Department of Dermatology, University Hospital Erlangen, Erlangen, Germany.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Kiecker', 'Affiliation': 'Skin Cancer Center, Department of Dermatology, Charité Berlin, Berlin, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Schadendorf', 'Affiliation': 'Department of Dermatology, University Hospital Essen, Essen, & German Cancer Consortium, Heidelberg, Germany.'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Stadler', 'Affiliation': 'Department of Dermatology, Johannes Wesling Hospital Minden, Ruhr-University of Bochum, Minden, Germany.'}, {'ForeName': 'Cord', 'Initials': 'C', 'LastName': 'Sunderkötter', 'Affiliation': 'Department of Dermatology and Venereology, University Hospital Halle, Halle, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Tüting', 'Affiliation': 'Department of Dermatology, University Hospital Magdeburg, Magdeburg, Germany.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Utikal', 'Affiliation': 'Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Wollina', 'Affiliation': 'Department of Dermatology and Allergology, Municipal Hospital of Dresden, Dresden, Germany.'}, {'ForeName': 'Christos C', 'Initials': 'CC', 'LastName': 'Zouboulis', 'Affiliation': 'Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane, Dessau, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Keilholz', 'Affiliation': 'Charité, Campus Benjamin Franklin, Berlin, Germany.'}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Testori', 'Affiliation': 'Department of Dermatology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Martus', 'Affiliation': 'Institute of Clinical Epidemiology and Applied Biostatistics, Eberhard-Karls-University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Leiter', 'Affiliation': 'Center for Dermatooncology, Department of Dermatology, Eberhard Karls University of Tuebingen, Tuebingen, Germany.'}, {'ForeName': 'Alexander M M', 'Initials': 'AMM', 'LastName': 'Eggermont', 'Affiliation': 'Princess Máxima Center, Utrecht, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03034'] 1539,32530769,International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct.,"PURPOSE To compare cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel in chemotherapy-naïve advanced anal cancer to establish the optimal regimen. PATIENTS AND METHODS Patients who had not received systemic therapy for advanced anal cancer were randomly assigned 1:1 to intravenous cisplatin 60 mg/m 2 (day 1) plus FU 1,000 mg/m 2 (days 1-4) every 21 days or carboplatin (area under the curve, 5; day 1) plus paclitaxel 80 mg/m 2 (days 1, 8, and 15) every 28 days for 24 weeks, until disease progression, intolerable toxicity, or withdrawal of consent. Primary end point was objective response rate (ORR). Primary and secondary end points were assessed in a hierarchic model to compare the regimens and pick the winner. RESULTS We conducted an international multicenter randomized phase II study in 60 centers between December 2013 and November 2017. Median follow-up was 28.6 months. A total of 91 patients were randomly assigned: 46 to cisplatin plus FU and 45 to carboplatin plus paclitaxel. ORR was 57% (95% CI, 39.4% to 73.7%) for cisplatin plus FU versus 59% (95% CI, 42.1% to 74.4%) for carboplatin plus paclitaxel. More serious adverse events were noted in the cisplatin plus FU arm (62%) compared with the carboplatin plus paclitaxel arm (36%; P = .016). Median progression-free survival was 5.7 months (95% CI, 3.3 to 9.0 months) for cisplatin plus FU compared with 8.1 months (95% CI, 6.6 to 8.8 months) for carboplatin plus paclitaxel. Median overall survival was 12.3 months for cisplatin plus FU (95% CI, 9.2 to 17.7 months) compared with 20 months (95% CI, 12.7 months to not reached) for carboplatin plus paclitaxel (hazard ratio, 2.00; 95% CI, 1.15 to 3.47; P = .014). CONCLUSION This is the first international randomized trial to our knowledge conducted in chemotherapy-naïve advanced anal cancer. Although there was no difference in ORR, the association with clinically relevant reduced toxicity and a trend toward longer survival suggest that carboplatin plus paclitaxel should be considered as a new standard of care.",2020,Median overall survival was 12.3 months for cisplatin plus FU,"['60 centers between December 2013 and November 2017', 'Advanced Anal Cancer', 'International Rare Cancers Initiative', 'A total of 91 patients were randomly assigned: 46 to', 'chemotherapy-naïve advanced anal cancer', 'Patients who had not received systemic therapy for advanced anal cancer']","['paclitaxel', 'cisplatin plus fluorouracil (FU) versus carboplatin plus paclitaxel', 'carboplatin', 'carboplatin plus paclitaxel', 'cisplatin plus FU', 'Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel', 'intravenous cisplatin 60 mg/m 2 (day 1) plus FU 1,000 mg/m 2', 'cisplatin plus FU and 45 to carboplatin plus paclitaxel']","['Median overall survival', 'Median progression-free survival', 'objective response rate (ORR', 'toxicity', 'ORR', 'hierarchic model to compare the regimens and pick the winner', 'serious adverse events']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0153446', 'cui_str': 'Malignant tumor of anus'}, {'cui': 'C0521114', 'cui_str': 'Infrequent'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",91.0,0.183791,Median overall survival was 12.3 months for cisplatin plus FU,"[{'ForeName': 'Sheela', 'Initials': 'S', 'LastName': 'Rao', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sclafani', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Eng', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX.'}, {'ForeName': 'Richard A', 'Initials': 'RA', 'LastName': 'Adams', 'Affiliation': 'Velindre Cancer Centre, Cardiff, Wales.'}, {'ForeName': 'Marianne G', 'Initials': 'MG', 'LastName': 'Guren', 'Affiliation': 'Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sebag-Montefiore', 'Affiliation': 'Leeds Cancer Centre, Leeds, United Kingdom.'}, {'ForeName': 'Al', 'Initials': 'A', 'LastName': 'Benson', 'Affiliation': 'Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Bryant', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Peckitt', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Segelov', 'Affiliation': 'Monash Health and Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Amitesh', 'Initials': 'A', 'LastName': 'Roy', 'Affiliation': 'Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Matt T', 'Initials': 'MT', 'LastName': 'Seymour', 'Affiliation': 'Leeds Cancer Centre, Leeds, United Kingdom.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Welch', 'Affiliation': 'National Cancer Institute, Bethesda, MD.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Saunders', 'Affiliation': 'Christie Cancer Centre, Manchester, United Kingdom.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Muirhead', 'Affiliation': 'University of Oxford, Oxford, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': ""O'Dwyer"", 'Affiliation': 'Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bridgewater', 'Affiliation': 'University College Hospital, London, United Kingdom.'}, {'ForeName': 'Shree', 'Initials': 'S', 'LastName': 'Bhide', 'Affiliation': 'Institute of Cancer Research, London, United Kingdom.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Glynne-Jones', 'Affiliation': 'Hamburg University Medical Centre, Hamburg, Germany.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Arnold', 'Affiliation': 'Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Philadelphia, PA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Royal Marsden Hospital, London, United Kingdom.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03266'] 1540,32540553,Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).,"BACKGROUND The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosphamide (HEX) as first-line therapy in HER-2 positive ABC.
Methods. Patients at first relapse or with synchronous metastasis were treated with trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily). Primary endpoint was objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR + CR + SD for ≥ 24 weeks) and tolerability. Optimal two-stage design was applied. RESULTS Sixty patients with measurable ABC, tumors scored as +3 for HER-2 or FISH +, untreated for advanced disease were enrolled. Median age was 62.5 years, visceral metastases were present in most patients (57.9%). Median number of cycles was 16 (range 1-98). ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%). Fifteen patients had SD (25%). The CBR was 78.2%. Nine progressions were observed (15%). Median PFS was 11 months. One year PFS was 47.7%. Median OS was 45.9 months. Worst toxicities were grade 3 hand-foot syndrome in 2 pts (3.3%), grade 3 anaemia in 2 pts (3.3%), grade 2 nausea in 2 pts (3.3%) and grade 3-4 diarrhea in 2 pts (3.3%). Cardiac toxicity grade 1 was reported in 1 pt. CONCLUSIONS Combination of trastuzumab and metronomic oral chemotherapy has clinical activity. The tolerability was excellent and allowed the prolonged delivery of treatment.",2020,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","['Patients at first relapse or with synchronous metastasis', 'HER-2 positive advanced breast cancer', 'HER-2 positive advanced breast cancer (ABC) therapy', 'Sixty patients with measurable ABC, tumors scored as\xa0+3 for HER-2 or FISH\xa0+, untreated for advanced disease were enrolled', 'Fifteen patients had SD (25']","['trastuzumab', 'cyclophosphamide', 'chemotherapy plus anti HER-2 agents', 'trastuzumab and metronomic capecitabine/cyclophosphamide (HEX', 'trastuzumab and metronomic oral chemotherapy', 'oral capecitabine', 'Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX']","['Median PFS', 'grade 2 nausea', 'Median OS', 'Worst toxicities', 'grade 3 anaemia', 'ORR', 'objective response rate (ORR), secondary endpoints progression-free survival (PFS), clinical benefit rate (CBR; PR\xa0+\xa0CR\xa0+\xa0SD for\xa0≥\xa024 weeks) and tolerability', 'Cardiac toxicity grade 1', 'tolerability', 'Median number of cycles', 'visceral metastases', 'grade 3-4 diarrhea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}]","[{'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0419073', 'cui_str': 'Oral chemotherapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",9.0,0.0480206,"ORR was 56.7% (95% CI, 44.1-68.4%), with 5 CR (8.3%) and 29 PR (48.3%).","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Orlando', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy. Electronic address: laura.orlando68@gmail.com.'}, {'ForeName': 'Vito', 'Initials': 'V', 'LastName': 'Lorusso', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giotta', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Di Maio', 'Affiliation': 'Department of Oncology, University of Turin at Ordine Mauriziano Hospital, Turin, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Schiavone', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Palma', 'Initials': 'P', 'LastName': 'Fedele', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Annamaria', 'Initials': 'A', 'LastName': 'Quaranta', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Caliolo', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Mariangela', 'Initials': 'M', 'LastName': 'Ciccarese', 'Affiliation': 'Medical Oncology, Ospedale Vito Fazzi, Lecce, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': 'Cinefra', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}, {'ForeName': 'Sante', 'Initials': 'S', 'LastName': 'Romito', 'Affiliation': 'Medical Oncology, Ospedali Riuniti, Foggia, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Pisconti', 'Affiliation': 'Medical Oncology, Ospedale Moscato, Taranto, Italy.'}, {'ForeName': 'Salvatore Del', 'Initials': 'SD', 'LastName': 'Prete', 'Affiliation': 'Medical Oncology, Ospedale San Giovanni di Dio, Frattamaggiore, Napoli, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Aieta', 'Affiliation': 'Medical Oncology, Ospedale Oncologico Regionale, Rionero in Vulture, Potenza, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Rizzi', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Evaristo', 'Initials': 'E', 'LastName': 'Maiello', 'Affiliation': 'Medical Oncology, Ospedale Sollievo Della Sofferenza, IRCCS, San Giovanni Rotondo, Foggia, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Colucci', 'Affiliation': 'Medical Oncology, Istituto Tumori Giovanni Paolo II, IRCCS, Bari, Italy.'}, {'ForeName': 'Saverio', 'Initials': 'S', 'LastName': 'Cinieri', 'Affiliation': 'Medical Oncology, Antonio Perrino Hospital, Brindisi, Italy.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.002'] 1541,32540624,Effects of night-time bicycling visibility aids on vehicle passing distance.,"Bicycling at night is dangerous, with vehicle passing distances being a key concern, given that the main cause of night-time bicycling fatalities is from motorists hitting bicyclists from behind. However, little is known about vehicle passing distances at night or how they are affected by bicyclist visibility. This study assessed the impact of different bicyclist visibility configurations on vehicle passing distances at night-time. Fourteen licenced drivers with normal vision (age 24.2 ± 3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night. Each lap involved passing two bicyclists displaying one of four visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles). Participants were instructed to pass each bicyclist at a distance of 1-metre at a speed no greater than 50 km/hr, consistent with Queensland's Minimum Passing Distance rule. Participants completed eight laps, two for each configuration, in a randomised sequence. Passing distance was measured using a vehicle-mounted ultra-sonic sensor (ToughSonic14; Senix). Following each lap, participants rated the difficulty level in judging the 1-metre passing distance, as well as their estimated passing distance. Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other. There was also a significant effect of visibility configuration on difficulty rating (p = 0.035), with the Control rated as the most difficult, followed by Helmet, Handlebars and Leg Retro-reflectors. Overall, additional visibility aids resulted in wider vehicle passing distances, likely due to enhanced visual cues for drivers. The findings suggest that bicyclists should incorporate additional visibility aids to encourage safer passing distances of vehicles at night-time.",2020,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.",['Fourteen licenced drivers with normal vision (age 24.2\u202f±\u202f3.7 years) drove an experimental vehicle with low-beam headlights around a 1-km section of a closed-road circuit at night'],"['visibility configurations: Control (red rear-facing light and reflector), Handlebars (control plus two red rear-facing lights on each handlebar), Helmet (control plus one red rear-facing light on the helmet), and Leg Retro-reflectors (control plus retro-reflective strips positioned on the knees and ankles', 'night-time bicycling visibility aids']","['visibility configuration on difficulty rating', 'Leg Retro-reflectors']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0234622', 'cui_str': 'Normal vision'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517696', 'cui_str': '3.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0442650', 'cui_str': 'Road'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332575', 'cui_str': 'Red color'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0018884', 'cui_str': 'Helmet'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0005375', 'cui_str': 'Bicycle'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0449830', 'cui_str': 'With configuration'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}]",,0.0635457,"Visibility configuration significantly affected passing distance (p = 0.001), with wider passing distances for the Handlebar configuration (1.54 ± 0.62 m), followed by the Helmet (1.51 ± 0.63 m), Leg Retro-reflectors (1.50 ± 0.62 m) which were all significantly greater than the Control (1.42 ± 0.57 m), but not significantly different from each other.","[{'ForeName': 'Alex A', 'Initials': 'AA', 'LastName': 'Black', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia. Electronic address: aa.black@qut.edu.au.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Duff', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Hutchinson', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Ng', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Kirby', 'Initials': 'K', 'LastName': 'Phillips', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Rose', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Abby', 'Initials': 'A', 'LastName': 'Ussher', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'Wood', 'Affiliation': 'Queensland University of Technology (QUT), Centre for Vision and Eye Research, Institute of Health and Biomedical Innovation, Kelvin Grove, Brisbane, QLD 4059, Australia.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105636'] 1542,32541618,A Comparison of Bilateral vs. Unilateral-Biased Strength and Power Training Interventions on Measures of Physical Performance in Elite Youth Soccer Players.,"Stern, D, Gonzalo-Skok, O, Loturco, I, Turner, A, and Bishop, C. A comparison of bilateral vs. unilateral-biased strength and power training interventions on measures of physical performance in elite youth soccer players. J Strength Cond Res 34(8): 2105-2111, 2020-The aim of the present study was to compare the effects of bilateral and unilateral-biased strength and power training programs on measures of physical performance in male youth soccer players. Twenty-three elite youth players (age: 17.6 ± 1.2 years) were randomly assigned to either a unilateral (n = 11) or a bilateral (n = 12) group, who completed a strength and power intervention, twice per week for 6 weeks. The unilateral group completed rear foot elevated split squats (RFESS), single-leg countermovement jumps (SLCMJs), single-leg drop jumps (SLDJs), and single-leg broad jumps (SLBJs). The bilateral group intervention performed back squats, CMJs, drop jumps (DJ), and broad jumps (BJ). A 2 × 2 repeated measures analysis of variance showed no between-group differences. However, within-group differences were evident. The bilateral training group showed significant (p < 0.05) improvements in back squat strength (d = 1.27; %Δ = 26.01), RFESS strength (d = 1.64; %Δ = 23.34), BJ (d = 0.76; %Δ = 5.12), 10-m (d = -1.17; %Δ = 4.29), and 30-m (d = -0.88; %Δ = 2.10) performance. The unilateral group showed significant (p < 0.05) improvements in RFESS strength (d = 1.40; %Δ = 33.29), SLCMJ on the left leg (d = 0.76; %Δ = 9.84), SLBJ on the left leg (d = 0.97; %Δ = 6.50), 10 m (d = -1.50; %Δ = 5.20), and 505 on the right leg (d = -0.78; %Δ = 2.80). Standardized mean differences showed that bilateral training favored improvements in back squat strength and unilateral training favored improvements in RFESS strength, SLDJ on the right leg and 505 on the right leg. These results show that although both training interventions demonstrated trivial-to-large improvements in physical performance, the notion of training specificity was evident with unilateral training showing greater improvements in unilateral test measures.",2020,"Standardized mean differences showed that bilateral training favored improvements in back squat strength and unilateral training favored improvements in RFESS strength, SLDJ on the right leg and 505 on the right leg.","['Twenty-three elite youth players (age: 17.6 ± 1.2 years', 'male youth soccer players', 'elite youth soccer players', 'Elite Youth Soccer Players']","['SLCMJ', 'J Strength Cond Res XX(X', 'unilateral group completed rear foot elevated split squats (RFESS), single-leg countermovement jumps (SLCMJs), single-leg drop jumps (SLDJs), and single-leg broad jumps (SLBJs', 'bilateral group intervention performed back squats, CMJs, drop jumps (DJ), and broad jumps (BJ', 'Bilateral vs. Unilateral-Biased Strength and Power Training Interventions', 'bilateral and unilateral-biased strength and power training programs']","['left leg', 'SLBJ on the left leg', 'RFESS strength', 'back squat strength and unilateral training favored improvements in RFESS strength, SLDJ on the right leg and 505 on the right leg', 'RFESS strength ', 'back squat strength', 'physical performance', 'unilateral test measures', 'Physical Performance']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0230443', 'cui_str': 'Structure of left lower leg'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0230415', 'cui_str': 'Structure of right lower limb'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0151728,"Standardized mean differences showed that bilateral training favored improvements in back squat strength and unilateral training favored improvements in RFESS strength, SLDJ on the right leg and 505 on the right leg.","[{'ForeName': 'Darren', 'Initials': 'D', 'LastName': 'Stern', 'Affiliation': 'Millwall Football Club Academy, Calmont Road, Bromley, United Kingdom.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Gonzalo-Skok', 'Affiliation': 'Return to Play Department, Sevilla Football Club, Seville, Spain.'}, {'ForeName': 'Irineu', 'Initials': 'I', 'LastName': 'Loturco', 'Affiliation': 'Department of Sport Science and Research, Nucleus of High Performance in Sport, Sao Paulo, Brazil.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Turner', 'Affiliation': 'Faculty of Science and Technology, London Sports Institute, Middlesex University, London, United Kingdom.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Bishop', 'Affiliation': 'Faculty of Science and Technology, London Sports Institute, Middlesex University, London, United Kingdom.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003659'] 1543,32535742,Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects.,"INTRODUCTION Ultra rapid lispro (URLi) is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. The aims of this study were to demonstrate the bioequivalence (BE) of a concentrated formulation (U200) of URLi to the U100 formulation of URLi after subcutaneous (SC) administration and to evaluate the glucodynamics (GD) of these formulations. METHODS This phase 1, randomized, two-sequence, four-period, double-blind, replicate crossover study was conducted in 68 healthy subjects. At each dosing visit, subjects received a 15-U SC dose of either U100 URLi or U200 URLi followed by a 10-h euglycemic clamp procedure. Serum insulin lispro and blood glucose concentrations were measured, and the glucose infusion rate was continuously adjusted during the clamp to maintain the target blood glucose. RESULTS Bioequivalence of U200 URLi relative to U100 URLi was demonstrated. The 90% confidence intervals (CIs) of the ratios of geometric least squares (LS) means for the maximum insulin concentration and total exposure were within the BE limits of 0.80-1.25. Additionally, the 90% CIs for the ratios of geometric LS means for maximum glucose infusion rate and total glucose infused were within the BE limits. The early 50% t max occurred at approximately the same time for the U100 and U200 URLi formulations, and the insulin exposure within the first 15 min was similar for both formulations. The tolerability of the two URLi formulations was comparable. CONCLUSIONS This study demonstrated that the U100 and U200 URLi formulations are bioequivalent. The accelerated insulin absorption observed for the U100 formulation was maintained with the U200 URLi formulation. Further, the GD were similar for both formulations, supporting the ability of individuals to transfer from U100 to U200 URLi in a 1:1 unit conversion. TRIAL REGISTRATION NCT03616977.",2020,"The tolerability of the two URLi formulations was comparable. ","['68 healthy subjects', 'Healthy Subjects']","['Ultra Rapid Lispro (URLi) U100 and U200 Formulations', 'Ultra rapid lispro (URLi', '15-U SC dose of either U100 URLi or U200 URLi followed by a 10-h euglycemic clamp procedure']","['accelerated insulin absorption', 'maximum glucose infusion rate and total glucose', 'Serum insulin lispro and blood glucose concentrations', 'glucose infusion rate']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0052080', 'cui_str': 'antineoplaston A10'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}]",68.0,0.0625239,"The tolerability of the two URLi formulations was comparable. ","[{'ForeName': 'Helle', 'Initials': 'H', 'LastName': 'Linnebjerg', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Elizabeth Smith', 'Initials': 'ES', 'LastName': 'LaBell', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Mary Anne', 'Initials': 'MA', 'LastName': 'Dellva', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Coutant', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Leohr', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA. leohr_jennifer_k@lilly.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00848-4'] 1544,32682996,THR1VE! Positive psychology intervention to treat diabetes distress in teens with type 1 diabetes: Rationale and trial design.,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control. Building on effective positive psychology interventions to improve adherence in adults, as well as our pilot work to adapt these interventions for adolescents, we developed a positive psychology intervention for adolescents with T1D. The goal of THR1VE! is to reduce diabetes distress in adolescents with T1D and improve their diabetes outcomes. This multi-site randomized controlled trial compares a Diabetes Education + text-message-based Positive Affect intervention, to a Diabetes Education control condition. In the ongoing trial, we are evaluating the effects of the intervention on adolescents' diabetes distress, self-management, and glycemic control. This paper describes the rationale, trial design, and methodology of the THR1VE! Study.",2020,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","['Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress', 'teens with type 1 diabetes', 'adolescents with T1D']","['Diabetes Education + text-message-based Positive Affect intervention', 'Positive psychology intervention']","[""adolescents' diabetes distress, self-management, and glycemic control"", 'diabetes distress']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0231303', 'cui_str': 'Distress'}]","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}]","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0417244,"Adolescents with type 1 diabetes (T1D) experience high rates of diabetes distress, which negatively influence self-management and glycemic control.","[{'ForeName': 'Sarah S', 'Initials': 'SS', 'LastName': 'Jaser', 'Affiliation': 'Vanderbilt University Medical Center, USA. Electronic address: sarah.jaser@vumc.org.'}, {'ForeName': 'Karishma', 'Initials': 'K', 'LastName': 'Datye', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Troy', 'Initials': 'T', 'LastName': 'Morrow', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Sinisterra', 'Affiliation': ""Children's National Hospital, USA.""}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'LeStourgeon', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Fayo', 'Initials': 'F', 'LastName': 'Abadula', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'Bell', 'Affiliation': 'Vanderbilt University Medical Center, USA.'}, {'ForeName': 'Randi', 'Initials': 'R', 'LastName': 'Streisand', 'Affiliation': ""Children's National Hospital, USA.""}]",Contemporary clinical trials,['10.1016/j.cct.2020.106086'] 1545,32545583,Effectiveness of Percutaneous Electrolysis in Supraspinatus Tendinopathy: A Single-Blinded Randomized Controlled Trial.,"Supraspinatus tendinopathy is one of the most common causes of shoulder pain. Many studies support conservative treatments such as exercise, trigger point dry needling or corticosteroid injections. Otherwise, a minimally invasive approach with percutaneous electrolysis (PE) has also been used successfully in shoulder pain, although evidence about its long-term effects is scarce. The aim of this trial was to determine the effects of PE on supraspinatus tendinopathy compared with trigger point dry needling (TDN). Thirty-six patients with supraspinatus tendinopathy were randomly assigned to either a PE group ( n = 18) or a TDN group ( n = 18). Both groups also performed eccentric exercises. The main outcome to be measured was the Numerical Pain Rating Scale (NPRS), but the shoulder range of motion (ROM) and trigger point pressure pain threshold (PPT) were also considered. A one-year follow-up was conducted. Significant differences favoring the PE group were found regarding pain at one-year follow-up ( p = 0.002). The improvement achieved in the PE group was greater in the NPRS ( p < 0.001), proximal PPT, middle PPT, distal PPT (all p < 0.001) and ranges of movement. PE seems to be more effective than TDN in relieving pain and improving ROM and PPT supraspinatus values in patients with supraspinatus tendinopathy, both right after treatment and at one-year follow-up.",2020,"PE seems to be more effective than TDN in relieving pain and improving ROM and PPT supraspinatus values in patients with supraspinatus tendinopathy, both right after treatment and at one-year follow-up.","['Thirty-six patients with supraspinatus tendinopathy', 'Supraspinatus Tendinopathy']","['TDN', 'eccentric exercises', 'PE', 'percutaneous electrolysis (PE', 'Percutaneous Electrolysis', 'trigger point dry needling (TDN']","['NPRS', 'proximal PPT, middle PPT, distal PPT', 'Numerical Pain Rating Scale (NPRS), but the shoulder range of motion (ROM) and trigger point pressure pain threshold (PPT', 'pain', 'relieving pain and improving ROM and PPT supraspinatus values']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0584869', 'cui_str': 'Supraspinatus muscle structure'}, {'cui': 'C0151936', 'cui_str': 'Disorder of tendon'}]","[{'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0394648', 'cui_str': 'Dry needle acupuncture'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0013829', 'cui_str': 'Electrolysis - action'}]","[{'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0032334', 'cui_str': 'podofilox'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0575545', 'cui_str': 'Shoulder joint - range of movement'}, {'cui': 'C0458343', 'cui_str': 'Trigger point'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0948106', 'cui_str': 'Amniorrhexis'}, {'cui': 'C0584869', 'cui_str': 'Supraspinatus muscle structure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",36.0,0.118885,"PE seems to be more effective than TDN in relieving pain and improving ROM and PPT supraspinatus values in patients with supraspinatus tendinopathy, both right after treatment and at one-year follow-up.","[{'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Rodríguez-Huguet', 'Affiliation': 'Department of Nursing and Physiotherapy, University of Cádiz, 11009 Cádiz, Spain. manuel.rodriguez@uca.es.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Góngora-Rodríguez', 'Affiliation': 'Policlínica Santa María Clinic, 11008 Cádiz, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Rodríguez-Huguet', 'Affiliation': 'Andalusian Regional Public Health Service Hospital of Jerez de la Frontera, 11407 Cadiz, Spain.'}, {'ForeName': 'Alfonso Javier', 'Initials': 'AJ', 'LastName': 'Ibañez-Vera', 'Affiliation': 'Department of Health Sciences, University of Jaén, Campus las Lagunillas, 23071 Jaen, Spain.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Rodríguez-Almagro', 'Affiliation': 'Department of Health Sciences, University of Jaén, Campus las Lagunillas, 23071 Jaen, Spain.'}, {'ForeName': 'Rocío', 'Initials': 'R', 'LastName': 'Martín-Valero', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, University of Málaga, 29071 Málaga, Spain.'}, {'ForeName': 'Ángeles', 'Initials': 'Á', 'LastName': 'Díaz-Fernández', 'Affiliation': 'Department of Health Sciences, University of Jaén, Campus las Lagunillas, 23071 Jaen, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Lomas-Vega', 'Affiliation': 'Department of Health Sciences, University of Jaén, Campus las Lagunillas, 23071 Jaen, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9061837'] 1546,32683106,Effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status.,"OBJECTIVES There is some evidence for beneficial effects of exercise on cytokines in people with multiple sclerosis (MS), but it is unclear if such effects differ by disability status (i.e., stage of the disease). This study investigated the effect of combined exercise training on pentraxins and pro- inflammatory cytokines in people with multiple sclerosis as a function of disability status. METHODS This randomized control trial included 94 women with MS who were randomly assigned into exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS < 4.5), moderate (4.5 ≤ EDSS ≤ 6), or high (EDSS ≥ 6.5) disability. The exercise program lasted 12 weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed? days/week; the control condition involved a waitlist control. We measured resting levels of inflammatory factors, functional capacity, and lipid profile before and after the 12-week intervention period. RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status. 1RM for lat pull-down, knee extension, and seated row and 6MWT (i.e., walking further) significantly increased and TUG performance significantly decreased (i.e., faster performance) (all, p < 0.001) after combined exercise compared with control, and this too was independent of disability status. CONCLUSIONS Exercise may stimulate anti-inflammatory effects in MS, and this is generally not influenced by disability status. Exercise training may be an adjuvant for disease-modifying therapy among people with MS, and such effects might not be moderated by disability status.",2020,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","['people with multiple sclerosis', '94 women with MS', 'people with multiple sclerosis (MS']","['Combined exercise training', 'exercise or control conditions with randomization stratified by Expanded Disability Status Scale (EDSS) scores of low (EDSS\xa0<\xa04.5), moderate (4.5\xa0≤', 'exercise program lasted 12\xa0weeks and comprised resistance, endurance, Pilates, balance and stretch exercises performed', 'Exercise training', 'combined exercise training']","['Fibrin D-dimer (FDD', 'resting levels of inflammatory factors, functional capacity, and lipid profile', 'faster performance', 'TUG performance', 'pentraxins and pro- inflammatory cytokines', 'PTX-3', 'IL-6', 'hs-CRP']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451246', 'cui_str': 'Kurtzke multiple sclerosis rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]",94.0,0.0328348,"RESULTS Combined exercise training significantly decreased hs-CRP (p = 0.029) and IL-6 (p = 0.001) and increased PTX-3 (p = 0.001) and IFN-ƴ (p = 0.001), but there was no significant change in Fibrin D-dimer (FDD) (p = 0.876) compared with control, and those effects were independent of disability status.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Faramarzi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran. Electronic address: farmarzi@sku.ac.ir.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Banitalebi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Raisi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Masoumeh', 'Initials': 'M', 'LastName': 'Samieyan', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Saberi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Mardaniyan Ghahfarrokhi', 'Affiliation': 'Department of Sport Sciences, Shahrekord University, Shahrekord, Iran.'}, {'ForeName': 'Raoof', 'Initials': 'R', 'LastName': 'Negaresh', 'Affiliation': 'Department of Physical Education & Sport Sciences, Faculty of Humanities, Tarbiat Modares University, Tehran, Iran.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Motl', 'Affiliation': 'Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, USA.'}]",Cytokine,['10.1016/j.cyto.2020.155196'] 1547,32553024,Exercise Intervention Outcomes with Cannabis Users and Nonusers Aged 60 and Older.,"Objectives: Cannabis use is increasing among older adults. We examined whether cannabis use impacted results of an intervention to increase physical activity in sedentary adults aged 60 and over. Methods: We measured differences in body mass index (BMI), exercise behavior, and cardiovascular fitness between older adult cannabis users (N = 28) and nonusers (N = 136) participating in an exercise intervention trial. Results: BMI of cannabis users was significantly lower than non-users (p = .007). Cannabis users reported .70 more days of exercise on the Stanford 7-Day Physical Activity Recall than non-users at the 8-week timepoint (p = .068) and were 4.1 points higher on the exercise subscale of the Community Healthy Activities Model Program for Seniors at 16-weeks (p = .045). Neither baseline nor post-intervention fitness differed by cannabis use status, and cardiovascular fitness improved after intervention in the full sample. Conclusion: These preliminary data suggest that current cannabis use status is not associated with a negative impact on fitness and efforts to increase exercise in sedentary older adults. Future studies should collect more detailed information on patterns and forms of cannabis use to understand their potential health effects for older adults.",2020,"Neither baseline nor post-intervention fitness differed by cannabis use status, and cardiovascular fitness improved after intervention in the full sample. ","['older adult cannabis users (N = 28) and nonusers (N = 136) participating in an exercise intervention trial', 'older adults', 'Aged 60 and Older', 'sedentary adults aged 60 and over', 'sedentary older adults', 'Cannabis Users and Nonusers']",[],"['body mass index (BMI), exercise behavior, and cardiovascular fitness', 'physical activity', 'BMI of cannabis users', 'cannabis use status, and cardiovascular fitness', 'Stanford 7-Day Physical Activity Recall']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}]",136.0,0.0641099,"Neither baseline nor post-intervention fitness differed by cannabis use status, and cardiovascular fitness improved after intervention in the full sample. ","[{'ForeName': 'Sophie L', 'Initials': 'SL', 'LastName': 'YorkWilliams', 'Affiliation': 'Sophie L. YorkWilliams, Department of Psychology & Neuroscience, University of Colorado Boulder, Boulder, CO;, Email: sophie.yorkwilliams@colorado.edu.'}, {'ForeName': 'Laurel P', 'Initials': 'LP', 'LastName': 'Gibson', 'Affiliation': 'Laurel P. Gibson, Department of Psychology & Neuroscience, University of Colorado Boulder, Boulder, CO.'}, {'ForeName': 'Charleen J', 'Initials': 'CJ', 'LastName': 'Gust', 'Affiliation': 'Charleen J. Gust, Department of Psychology & Neuroscience, University of Colorado Boulder, Boulder, CO.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Giordano', 'Affiliation': 'Gregory Giordano, Department of Psychology & Neuroscience, University of Colorado Boulder, Boulder, CO.'}, {'ForeName': 'Kent E', 'Initials': 'KE', 'LastName': 'Hutchison', 'Affiliation': 'Kent E. Hutchison, Department of Psychology & Neuroscience , University of Colorado Boulder, Boulder, CO.'}, {'ForeName': 'Angela D', 'Initials': 'AD', 'LastName': 'Bryan', 'Affiliation': 'Angela D. Bryan, Department of Psychology & Neuroscience, University of Colorado Boulder, Boulder, CO.'}]",American journal of health behavior,['10.5993/AJHB.44.4.5'] 1548,32517847,Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy.,"Background: Epicutaneous immunotherapy is a potential novel immunotherapy that utilizes unique cutaneous immunologic properties. In a phase III, randomized, double-blind, placebo controlled clinical trial, an epicutaneous patch (DBV712) with 250 µg of peanut protein applied once daily for 12-months was statistically superior to placebo in desensitizing children with peanut allergy (ages 4-11 years) (N = 356). Objective: To assess the relationship between the hours of daily application time and the efficacy of DBV712 250 µg. Methods: DBV712 250 µg was applied to 30 nonallergic volunteers for various durations from 2 to 24 hours and then assayed for residual peanut protein. Patch application data from the phase III clinical trial were analyzed post hoc according to prespecified responder rates and changes in the eliciting dose (ED), as measured by the geometric mean (GM) ED ratio (12 months/baseline). Results: Following application, there was a marked decrease in peanut protein on the patches from 2 to 12 hours. After 12 hours, the median peanut protein recovered was below quantification limits. The median daily patch application duration in subjects from the phase III clinical trial was 21.1 hours (DBV712 250 µg) and 22.4 hours (placebo). Ninety-five percent of the treated population achieved >10 hours per day mean application. Response rates and GM ED ratios were similar among subjects across a range of application durations; e.g. , in those with a mean duration of >10 hours, the response rate was 36.6% and the GM ED ratio was 3.8, comparable with 42.6% and 4.0, respectively, in those with a mean duration of >20 hours. In DBV712 250 µg subjects with >16 hours mean application duration (84.5% of the treated population), the response rate was 38.8% versus 13.4% for placebo (difference, 24.4% [95% confidence interval, 15.5-34.0%]; p < 0.001). Conclusion: An evaluation of residual peanut protein on patches following application and post hoc analysis of phase III data strongly suggest that allergen delivery is attained with 12-16 hours of daily patch application time, sufficient to drive clinically meaningful desensitization to peanut after 12 months.",2020,"In DBV712 250 micrograms subjects with >16 hours mean application duration (84.5% of the treated population), the response rate was 38.8% versus 13.4% for placebo (difference, 24.4% [95% confidence interval, 15.5-34.0%]; p < 0.001). ","['desensitizing children with peanut allergy (ages 4-11 years', '30 nonallergic volunteers for various durations from 2 to 24 hours and thenassayed for residual peanut protein', 'peanut allergy']","['epicutaneous patch (DBV712) with 250 micrograms of peanut protein', 'DBV712 250 micrograms', 'placebo']","['geometric mean (GM) ED ratio (12months/baseline', 'response rate', 'median peanut protein', 'median daily patch application duration', 'peanut protein', 'Response rates and GM ED ratios']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0559470', 'cui_str': 'Allergy to peanut'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}]","[{'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449265', 'cui_str': 'Elicited by'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0030736', 'cui_str': 'Arachis hypogaea'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",356.0,0.140751,"In DBV712 250 micrograms subjects with >16 hours mean application duration (84.5% of the treated population), the response rate was 38.8% versus 13.4% for placebo (difference, 24.4% [95% confidence interval, 15.5-34.0%]; p < 0.001). ","[{'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Fleischer', 'Affiliation': ""From the Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado.""}, {'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Spergel', 'Affiliation': ""Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Edwin H', 'Initials': 'EH', 'LastName': 'Kim', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, North Carolina.'}, {'ForeName': 'Dianne E', 'Initials': 'DE', 'LastName': 'Campbell', 'Affiliation': 'DBV Technologies, Montrouge, France.'}, {'ForeName': 'Todd D', 'Initials': 'TD', 'LastName': 'Green', 'Affiliation': 'DBV Technologies, Montrouge, France.'}, {'ForeName': 'Katharine J', 'Initials': 'KJ', 'LastName': 'Bee', 'Affiliation': 'DBV Technologies, Montrouge, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Lambert', 'Affiliation': 'DBV Technologies, Montrouge, France.'}, {'ForeName': 'Terrance', 'Initials': 'T', 'LastName': 'Ocheltree', 'Affiliation': 'Certara, Princeton, New Jersey; and.'}, {'ForeName': 'Hugh A', 'Initials': 'HA', 'LastName': 'Sampson', 'Affiliation': 'DBV Technologies, Montrouge, France.'}]",Allergy and asthma proceedings,['10.2500/aap.2020.41.200045'] 1549,32521556,A Randomized Trial of Voice-Generated Inpatient Progress Notes: Effects on Professional Fee Billing.,"BACKGROUND Prior evaluations of automated speech recognition (ASR) to create hospital progress notes have not analyzed its effect on professional revenue billing codes. As ASR becomes a more common method of entering clinical notes, clinicians, hospital administrators, and payers should understand whether this technology alters charges associated with inpatient physician services. OBJECTIVES This study aimed to measure the difference in professional fee charges between using voice and keyboard to create inpatient progress notes. METHODS In a randomized trial of a novel voice with ASR system, called voice-generated enhanced electronic note system (VGEENS), to generate physician notes, we compared 1,613 notes created using intervention (VGEENS) or control (keyboard with template) created by 31 physicians. We measured three outcomes, as follows: (1) professional fee billing levels assigned by blinded coders, (2) number of elements within each note domain, and (3) frequency of organ system evaluations documented in review of systems (ROS) and physical exam. RESULTS Participants using VGEENS generated a greater portion of high-level (99233) notes than control users (31.8 vs. 24.3%, p  < 0.01). After adjustment for clustering by author, the finding persisted; intervention notes were 1.43 times more likely (95% confidence interval [CI]: 1.14-1.79) to receive a high-level code. Notes created using voice contained an average of 1.34 more history of present illness components (95% CI: 0.14-2.54) and 1.62 more review of systems components (95% CI: 0.48-2.76). The number of physical exam components was unchanged. CONCLUSION Using this voice with ASR system as tested slightly increases documentation of patient symptom details without reliance on copy and paste and may raise physician charges. Increased provider reimbursement may encourage hospital and provider group to offer use of voice and ASR to create hospital progress notes as an alternative to usual methods.",2020,Notes created using voice contained an average of 1.34 more history of present illness components (95% CI: 0.14-2.54) and 1.62 more review of systems components (95% CI: 0.48-2.76).,[],"['1,613 notes created using intervention (VGEENS) or control (keyboard with template) created by 31 physicians', 'novel voice with ASR system, called voice-generated enhanced electronic note system (VGEENS', 'automated speech recognition (ASR']","['professional fee billing levels assigned by blinded coders, (2) number of elements within each note domain, and (3) frequency of organ system evaluations documented in review of systems (ROS) and physical exam', 'greater portion of high-level', 'number of physical exam components']",[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4317132', 'cui_str': 'Template'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0015751', 'cui_str': 'Fees'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013879', 'cui_str': 'Chemical element'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0460002', 'cui_str': 'Body system structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0489633', 'cui_str': 'Review of systems'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449432', 'cui_str': 'Component'}]",99233.0,0.0952634,Notes created using voice contained an average of 1.34 more history of present illness components (95% CI: 0.14-2.54) and 1.62 more review of systems components (95% CI: 0.48-2.76).,"[{'ForeName': 'Andrew A', 'Initials': 'AA', 'LastName': 'White', 'Affiliation': 'Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Lee', 'Affiliation': 'Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States.'}, {'ForeName': 'Michelle M', 'Initials': 'MM', 'LastName': 'Garrison', 'Affiliation': 'Department of Health Services, University of Washington School of Public Health, and Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, United States.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Payne', 'Affiliation': 'Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States.'}]",Applied clinical informatics,['10.1055/s-0040-1713134'] 1550,32524985,Results of Coronary Artery Bypass Grafting Alone Versus Combined Surgical Revascularization and Mitral Repair In Patients with Moderate Ischemic Mitral Regurgitation,"BACKGROUND This is a prospective randomized-controlled study done to evaluate the best surgical option for moderate ischemic mitral regurgitation through either coronary artery bypass grafting only or by performing additional mitral repair. METHODS Over a nine-month period, 60 patients with ischemic heart disease associated with moderate ischemic mitral regurgitation were equally divided into two groups. Group 1 included 30 patients who had coronary artery bypass grafting with mitral valve repair; Group 2 included 30 patients who had only coronary artery bypass grafting. RESULTS There were no significant differences between the study groups, regarding operative data, apart from the cardiopulmonary bypass time and aortic cross-clamp time, which were significantly longer in group 1 (P < 0.001). Only one patient died in group 1 due to severe myocardial dysfunction. During the follow up, the NYHA class improved in group 1, from 2.7 to 1.35 (P < 0.004), compared with group 2, where the NYHA class improved from 2.6 to 1.72 (P = 0.07). The degree of MR improved in 28 patients (93%) in group 1 and 22 patients (73%) in group 2 (P < 0.0001). CONCLUSION The study revealed many advantages of adding mitral repair to surgical revascularization in patients with moderate ischemic mitral regurgitation, with improvement in the degree of MR and NYHA functional class. On the other hand there were no significant differences between the groups, regarding the postoperative course and incidence of mortality.",2020,"The degree of MR improved in 19 patients (95%) in Group 1 compared with 15 (75%) patients in Group 2 (P < .0001). ","['patients with ischemic heart disease and moderate ischemic mitral regurgitation', 'Between April 2014 and November 2014', '40 patients with ischemic heart disease associated with moderate ischemic mitral regurgitation at our University hospitals', 'Patients With Moderate Ischemic Mitral Regurgitation']","['coronary artery bypass grafting alone', 'mitral-valve repair to CABG', 'coronary artery bypass grafting surgery together with mitral valve repair, while Group 2 underwent coronary artery bypass grafting surgery alone', 'Surgical Coronary Revascularization Alone Versus Combined Surgical Revascularization and Mitral Valve Repair']","['degree of MR', 'postoperative coarse and in-hospital mortality', 'operative data, except for cardiopulmonary bypass time and aortic cross-clamp time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4087284', 'cui_str': 'Ischaemic mitral regurgitation'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0396849', 'cui_str': 'Mitral valvuloplasty'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205194', 'cui_str': 'Coarse'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0332300', 'cui_str': 'Except for'}, {'cui': 'C0429123', 'cui_str': 'Cardiopulmonary bypass time'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0175721', 'cui_str': 'Clamp'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",40.0,0.013605,"The degree of MR improved in 19 patients (95%) in Group 1 compared with 15 (75%) patients in Group 2 (P < .0001). ","[{'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Khallaf', 'Affiliation': 'Department of Cardiothoracic Surgery, Fayoum University, Fayoum, Egypt.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Elzayadi', 'Affiliation': 'Department of Cardiothoracic Surgery, Fayoum University, Fayoum, Egypt.'}, {'ForeName': 'Hesham', 'Initials': 'H', 'LastName': 'Alkady', 'Affiliation': 'Department of Cardiothoracic Surgery, Cairo University, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'El Naggar', 'Affiliation': 'Department of Cardiothoracic Surgery, Cairo University, Egypt.'}]",The heart surgery forum,['10.1532/hsf.2773'] 1551,32524991,Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.,"BACKGROUND Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. OBJECTIVE Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2). METHODS Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score. Secondary end points included change from baseline to week 24 in Sino-Nasal Outcome Test-22 (SNOT-22) score, University of Pennsylvania Smell Identification Test, sense of smell, postnasal drip, runny nose, and adverse events. RESULTS Patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) exhibited severe CRSwNP and substantial quality of life impairment evidenced by a mean NPS higher than 6 and SNOT-22 score of approximately 60. Both studies met both the coprimary end points. SNOT-22 score, University of Pennsylvania Smell Identification Test score, sense of smell, postnasal drip, and runny nose were also significantly improved for omalizumab versus placebo. In POLYP 1 and POLYP 2, the mean changes from baseline at week 24 for omalizumab versus placebo were as follows: NPS, -1.08 versus 0.06 (P < .0001) and -0.90 versus -0.31 (P = .0140); Nasal Congestion Score, -0.89 versus -0.35 (P = .0004) and -0.70 versus -0.20 (P = .0017); and SNOT-22 score, -24.7 versus -8.6 (P < .0001) and -21.6 versus -6.6 (P < .0001). Adverse events were similar between groups. CONCLUSION Omalizumab significantly improved endoscopic, clinical, and patient-reported outcomes in severe CRSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.",2020,"The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. ","['nasal polyposis', 'Adults with CRSwNP with inadequate response to intranasal corticosteroids', 'Chronic rhinosinusitis with nasal polyps (CRSwNP', 'patients with CRSwNP and comorbid asthma previously', 'Patients in POLYP 1']","['omalizumab or placebo and intranasal mometasone', 'CRSwNP', 'Omalizumab', 'omalizumab', 'placebo']","['change from baseline to week 24 in Sino-Nasal Outcome Test-22 (SNOT-22), University of Pennsylvania Smell Identification Test (UPSIT), sense of smell, postnasal drip, runny nose, and adverse events (AEs', 'tolerated', 'Efficacy and safety', 'SNOT-22, UPSIT, sense of smell, postnasal drip and runny nose', 'Nasal Polyp Score (NPS) and Nasal Congestion Score (NCS', 'severe CRSwNP and substantial quality-of-life impairment']","[{'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}]","[{'cui': 'C0966225', 'cui_str': 'omalizumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0360564', 'cui_str': 'Mometasone'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0030853', 'cui_str': 'Pennsylvania'}, {'cui': 'C0037361', 'cui_str': 'Sense of smell, function'}, {'cui': 'C0020792', 'cui_str': 'Identification - mental defense mechanism'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0032781', 'cui_str': 'Posterior rhinorrhea'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027424', 'cui_str': 'Nasal congestion'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}]",,0.169777,"The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. ","[{'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Gevaert', 'Affiliation': 'Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Theodore A', 'Initials': 'TA', 'LastName': 'Omachi', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif. Electronic address: omachi.theodore@gene.com.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Corren', 'Affiliation': 'Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, Calif.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Mullol', 'Affiliation': 'Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Han', 'Affiliation': 'Eastern Virginia Medical School, Norfolk, Va.'}, {'ForeName': 'Stella E', 'Initials': 'SE', 'LastName': 'Lee', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh, Pittsburgh, Pa.'}, {'ForeName': 'Derrick', 'Initials': 'D', 'LastName': 'Kaufman', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Ligueros-Saylan', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ.'}, {'ForeName': 'Monet', 'Initials': 'M', 'LastName': 'Howard', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Owen', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif.'}, {'ForeName': 'Kit', 'Initials': 'K', 'LastName': 'Wong', 'Affiliation': 'Genentech, Inc, South San Francisco, Calif.'}, {'ForeName': 'Lutaf', 'Initials': 'L', 'LastName': 'Islam', 'Affiliation': 'Roche, Welwyn Garden City, United Kingdom.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Bachert', 'Affiliation': 'Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium; Division of ENT Diseases, CLINTEC, Karolinska Institute, Stockholm, Sweden.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.05.032'] 1552,32525863,"Energy-dense vs routine enteral nutrition in New Zealand Europeans, Māori, and Pacific Peoples who are critically ill.","AIMS To evaluate the effect of energy-dense vs routine enteral nutrition on day-90 mortality by ethnic group in critically ill adults. METHODS Pre-planned subgroup analysis of the 1,257 New Zealanders in a 4,000-participant randomised trial comparing energy-dense enteral nutrition (1.5kcal/mL) with routine enteral nutrition (1kcal/mL) in mechanically ventilated intensive care unit (ICU) patients. The primary purpose of this analysis was to evaluate responses to study treatment by ethnic group (European, Māori, and Pacific Peoples) using ethnicity data recorded in the clinical records. The secondary purpose was to compare the characteristics and outcomes of patients by ethnic group. The primary outcome was day-90 mortality. RESULTS Among 1,138 patients included in the primary outcome analysis, 165 of 569 (29.0%) assigned to energy-dense nutrition and 156 of 569 patients (27.4%) assigned to routine nutrition died by day 90 (odds ratio; 1.06; 95% CI, 0.92-1.22). There was no statistically significant interaction between treatment allocation and ethnicity with respect to day-90 mortality. Day-90 mortality rates did not vary statistically significantly by ethnic group. CONCLUSIONS Among mechanically ventilated adults in New Zealand ICUs, the effect on day-90 mortality of energy-dense vs routine enteral nutrition did not vary by ethnicity.",2020,"Day-90 mortality rates did not vary statistically significantly by ethnic group. ","['mechanically ventilated intensive care unit (ICU) patients', 'critically ill adults', '1,138 patients', 'mechanically ventilated adults in New Zealand ICUs', 'patients by ethnic group']","['Energy-dense vs routine enteral nutrition', 'energy-dense enteral nutrition (1.5kcal/mL) with routine enteral nutrition (1kcal/mL', 'energy-dense vs routine enteral nutrition']","['Day-90 mortality rates', 'day-90 mortality']","[{'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}]","[{'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.201762,"Day-90 mortality rates did not vary statistically significantly by ethnic group. ","[{'ForeName': 'Alice L', 'Initials': 'AL', 'LastName': 'Reid', 'Affiliation': 'Research Fellow, Medical Research Institute of New Zealand, Wellington.'}, {'ForeName': 'Marianne J', 'Initials': 'MJ', 'LastName': 'Chapman', 'Affiliation': 'Research Director, Intensive Care Unit, Royal Adelaide Hospital, Adelaide, SA, Australia; Professor, Faculty of Health and Medical Sciences, The University of Adelaide, SA, Australia; Adjunct Associate Professor, School of Epidemiology and Preventive Medicine, Monash University, VIC, Australia.'}, {'ForeName': 'Sandra L', 'Initials': 'SL', 'LastName': 'Peake', 'Affiliation': 'Director, Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville South, SA, Australia; Professor, Faculty of Health and Medical Sciences, University of Adelaide, SA, Australia; Adjunct Associate Professor, School of Epidemiology and Preventive Medicine, Monash University, VIC, Australia.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Intensive Care Specialist, Intensive Care Unit, Austin Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Davies', 'Affiliation': 'Intensive Care Specialist, Intensive Care Unit, Frankston, VIC, Australia.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Deane', 'Affiliation': 'Principal Research Fellow, The University of Melbourne, Melbourne Medical School, Department of Medicine and Radiology, Royal Melbourne Hospital, Parkville, VIC, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'Professor of Medicine & Head Endocrine Unit, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hurford', 'Affiliation': 'ICU Trials Project Manager, Medical Research Institute of New Zealand, Wellington.'}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Lange', 'Affiliation': 'Biostatistician, Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, SA, Australia.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Little', 'Affiliation': 'Project Manager, School of Epidemiology and Preventive Medicine, Monash University, VIC, Australia.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Mackle', 'Affiliation': 'ICU Programme Manager, Medical Research Institute of New Zealand, Wellington.'}, {'ForeName': 'Stephanie N', 'Initials': 'SN', 'LastName': ""O'Connor"", 'Affiliation': 'ICU Clinical Research Manager, Royal Adelaide Hospital, Adelaide, SA, Australia; Affiliate Senior Lecturer, Acute Care Medicine, The University of Adelaide, SA, Australia.'}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Ridley', 'Affiliation': 'Senior Research Fellow, Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Patricia J', 'Initials': 'PJ', 'LastName': 'Williams', 'Affiliation': 'Research Coordinator, Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville South, SA, Australia; Affiliate Lecturer, Acute Care Medicine, The University of Adelaide, SA, Australia; Adjunct Research Fellow, Department of Epidemiology and Preventative Medicine, Monash University, VIC, Australia.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Young', 'Affiliation': 'Deputy Director, Medical Research Institute of New Zealand, Wellington; Intensive Care Specialist, Wellington Hospital, Wellington.'}]",The New Zealand medical journal,[] 1553,32533295,Internet-Delivered Parent Training for Preschoolers with Conduct Problems: Do Callous-Unemotional Traits Moderate Efficacy and Engagement?,"Recent efforts to improve access to evidence-based parent training programs using online delivery have largely neglected findings that young children with callous-unemotional (CU)-type conduct problems receive less benefit from parent training than children with conduct problems alone. The current study aimed to examine the moderating effect of child CU traits on efficacy and engagement outcomes associated with Internet-delivered Parent-Child Interaction Therapy (iPCIT) versus standard, clinic-based PCIT. Forty families (57.6% non-Hispanic Caucasian) with a 3-5 year-old (M = 3.95 years, SD = 0.9; 83.5% boys) child with a disruptive behavior disorder were randomized to either iPCIT or clinic-based PCIT. Families participated in four assessments across time; child conduct problems, global functioning and treatment responder status, and parent-rated treatment satisfaction were measured. Analyses revealed that the negative influence of CU traits on functional gains was not uniform across treatment formats. Specifically, the detrimental effect of CU traits on functional gains was significantly more pronounced among children treated with iPCIT than clinic-based PCIT. CU traits also predicted lower parental treatment satisfaction across delivery formats, but this effect was more pronounced among iPCIT parents. In contrast, CU traits did not moderate differential effects across iPCIT and clinic-based PCIT for conduct problem severity or treatment response status. Findings suggest that iPCIT is a promising treatment option for early conduct problems, particularly when access-to-care barriers exist, but that further research is needed to determine whether strategic adaptations to online programs can more optimally address the distinct needs of children with clinically significant CU traits.",2020,"In contrast, CU traits did not moderate differential effects across iPCIT and clinic-based PCIT for conduct problem severity or treatment response status.","['Preschoolers with Conduct Problems', 'young children with callous-unemotional (CU)-type conduct problems', 'Forty families (57.6% non-Hispanic Caucasian) with a 3-5\xa0year-old (M\u2009=\u20093.95\xa0years, SD\u2009=\u20090.9; 83.5% boys) child with a disruptive behavior disorder']","['Internet-delivered Parent-Child Interaction Therapy (iPCIT) versus standard, clinic-based PCIT', 'iPCIT or clinic-based PCIT', 'iPCIT', 'Internet-Delivered Parent Training']","['time; child conduct problems, global functioning and treatment responder status, and parent-rated treatment satisfaction', 'functional gains']","[{'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0376154', 'cui_str': 'Callosity'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0012734', 'cui_str': 'Disruptive behavior disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0030542', 'cui_str': 'Parent-Child Relationship'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",40.0,0.054209,"In contrast, CU traits did not moderate differential effects across iPCIT and clinic-based PCIT for conduct problem severity or treatment response status.","[{'ForeName': 'Georgette E', 'Initials': 'GE', 'LastName': 'Fleming', 'Affiliation': 'School of Psychology, The University of New South Wales, Sydney, New South Wales, Australia. g.fleming@unsw.edu.au.'}, {'ForeName': 'Eva R', 'Initials': 'ER', 'LastName': 'Kimonis', 'Affiliation': 'School of Psychology, The University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jami M', 'Initials': 'JM', 'LastName': 'Furr', 'Affiliation': 'Center for Children and Families, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Comer', 'Affiliation': 'Center for Children and Families, Florida International University, Miami, Florida, USA.'}]",Journal of abnormal child psychology,['10.1007/s10802-020-00660-5'] 1554,32538550,"Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.","AIM To report the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) versus standard-of-care basal insulin analogues (SOC-BI) at 12 months in the ACHIEVE Control trial, which is a prospective pragmatic randomized real-life study in insulin-naïve adults with type 2 diabetes (T2D). METHODS A total of 3304 insulin-naïve adults with T2D and glycated haemoglobin (HbA1c) concentration of 64 to 97 mmol/mol (8.0% to 11.0%) after ≥1 year of treatment with two or more antihyperglycaemic agents were randomized to Gla-300 or SOC-BI. Key secondary endpoints included HbA1c target attainment without documented symptomatic (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia at 12 months. RESULTS At 12 months, 26.1% (Gla-300) and 23.7% (SOC-BI) of adults achieved HbA1c targets without documented symptomatic (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia (odds ratio [OR] 1.14, 95% confidence interval [CI] 0.97-1.35); 33.0% and 29.5%, respectively, achieved HbA1c targets without documented symptomatic (<3.0 mmol/L [<54 mg/dL]) or severe hypoglycaemia (OR 1.19, 95% CI 1.02-1.38). The OR for HbA1c target achievement was 1.15 (95% CI 0.99-1.34), and favoured Gla-300 versus SOC-BI for absence of documented symptomatic or severe hypoglycaemia at 12 months for both ≤3.9 mmol/L (≤70 mg/dL; OR 1.21, 95% CI 1.05-1.40) and < 3.0 mmol/L (<54 mg/dL; OR 1.26, 95% CI 1.07-1.48). CONCLUSION Gla-300 tended to be associated with lower hypoglycaemia risk than SOC-BI in real-world clinical practice during the 12-month follow-up.",2020,Odds ratio for HbA1c target achievement was 1.15 (95% CI 0.99-1.34) and favoured Gla-300 versus SOC-BI for absence of documented symptomatic or severe hypoglycaemia at 12 months for both ≤3.9 mmol/L (≤70 mg/dL),"['3304 insulin-naïve adults with T2D and HbA1c 8%-11% after ≥1 year of treatment with ≥2 antihyperglycaemic agents', 'insulin-naïve adults with type 2 diabetes (T2D', 'insulin-naïve adults with type 2 diabetes']","['Gla-300 versus SOC-BI', 'Insulin glargine 300 U/mL versus first-generation basal insulin analogues', 'Gla-300 or SOC-BI', 'insulin glargine 300 U/mL (Gla-300) over first-generation standard-of-care basal insulin analogues (SOC-BI; insulin glargine 100 U/mL or insulin detemir']","['Odds ratio for HbA1c target achievement', 'severe hypoglycaemia', 'HbA1c target attainment without documented symptomatic or severe hypoglycaemia', 'symptomatic or severe hypoglycaemia', 'hypoglycemia risk']","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439340', 'cui_str': 'kU/L'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0537270', 'cui_str': 'insulin detemir'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C1318607', 'cui_str': 'HBA1c target'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",3304.0,0.161478,Odds ratio for HbA1c target achievement was 1.15 (95% CI 0.99-1.34) and favoured Gla-300 versus SOC-BI for absence of documented symptomatic or severe hypoglycaemia at 12 months for both ≤3.9 mmol/L (≤70 mg/dL),"[{'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Meneghini', 'Affiliation': 'Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Blonde', 'Affiliation': 'Frank Riddick Diabetes Institute, Endocrinology Department, Ochsner Medical Center, New Orleans, Louisiana, USA.'}, {'ForeName': 'Jasvinder', 'Initials': 'J', 'LastName': 'Gill', 'Affiliation': 'Sanofi, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Dauchy', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Andrius', 'Initials': 'A', 'LastName': 'Bacevicius', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Jodi', 'Initials': 'J', 'LastName': 'Strong', 'Affiliation': 'Ascension Health, Stevens Point, Wisconsin, USA.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Bailey', 'Affiliation': 'AMCR Institute, Escondido, California, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14116'] 1555,32540179,Comparing the usefulness of a fluoroscopic navigation system in femoral trochanteric fracture for orthopaedic residents with the conventional method.,"INTRODUCTION Lag screw insertion into the ideal position is essential to obtain good results in open reduction and internal fixation for femoral trochanteric fracture. Tip-apex distance (TAD) is a widely adopted method for evaluating the risk of lag screw cut-out. Adaptive positioning technology (ADAPT) is a fluoroscopic computer-assisted surgery system that enables orthopaedic surgeons to guide the screw into a proper position intraoperatively. A randomized control study concluded that ADAPT resulted in excellent TAD. However, it was not significantly better than conventional methods when performed by fellowship-trained traumatologists. Therefore, we hypothesised that ADAPT would be useful to orthopaedic residents and evaluated this usefulness. METHODS We reviewed 102 patients who underwent open reduction and internal fixation for femoral trochanteric fracture from May 2017 to March 2019 using Gamma-3 intertrochanteric nails. Two residents performed all procedures; 51 patients underwent surgery using ADAPT and the others underwent surgery without navigation. The number of attempts to drill guide-wire, operation time, lag screw insertion time, radiation exposure time, TAD, and lag screw position were evaluated for each surgeon. RESULTS In one resident, when using the ADAPT system, the number of attempts to drill guide-wire (p=0.001), lag screw insertion time (p=0.000), radiational exposure time (p=0.009) and TAD (p=0.007) were lower, and the percentage of ideal lag screw position (p=0.035) were better than that in the conventional method. However, there was no significant difference in the performance of another resident with respect to the aforementioned factors, whether using ADAPT or not. CONCLUSION One resident showed better results with the ADAPT system than with conventional osteosynthesis. However, another resident received no benefit from ADAPT. The efficiency may not apply to everyone as individual competence can influence efficiency when using ADAPT system. Therefore, as a new device, it must be used cautiously because skill or experience may influence its use, especially by orthopaedic residents.",2020,Adaptive positioning technology (ADAPT) is a fluoroscopic computer-assisted surgery system that enables orthopaedic surgeons to guide the screw into a proper position intraoperatively.,"['102 patients who underwent open reduction and internal fixation for femoral trochanteric fracture from May 2017 to March 2019 using Gamma-3 intertrochanteric nails', 'femoral trochanteric fracture for orthopaedic residents with the conventional method']","['surgery using ADAPT and the others underwent surgery without navigation', 'conventional osteosynthesis', 'fluoroscopic navigation system', 'Tip-apex distance (TAD', 'Adaptive positioning technology (ADAPT']","['radiational exposure time', 'number of attempts to drill guide-wire, operation time, lag screw insertion time, radiation exposure time, TAD, and lag screw position', 'excellent TAD', 'percentage of ideal lag screw position', 'lag screw insertion time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0185373', 'cui_str': 'Open reduction of fracture'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0162387', 'cui_str': 'Trochanteric Fractures'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0017011', 'cui_str': 'Gamma radiation'}, {'cui': 'C0027342', 'cui_str': 'Nail plate structure'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C4075648', 'cui_str': 'Navigation system'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}, {'cui': 'C0012751', 'cui_str': 'Distance'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0324815', 'cui_str': 'Mandrillus leucophaeus'}, {'cui': 'C0181089', 'cui_str': 'Guide wire'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0015333', 'cui_str': 'Exposure to radiation'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0439165', 'cui_str': 'Percent'}]",102.0,0.0170369,Adaptive positioning technology (ADAPT) is a fluoroscopic computer-assisted surgery system that enables orthopaedic surgeons to guide the screw into a proper position intraoperatively.,"[{'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Takai', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan. Electronic address: hirokazoid@hotmail.co.jp.'}, {'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Mizuta', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Murayama', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Nakayama', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}, {'ForeName': 'Sakumo', 'Initials': 'S', 'LastName': 'Kii', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}, {'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Hayai', 'Affiliation': 'Imaging Diagnostic Center, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}, {'ForeName': 'Tomoki', 'Initials': 'T', 'LastName': 'Takahashi', 'Affiliation': 'Department of Orthopaedic Surgery, Kumamoto Kinoh Hospital, Kumamoto, Japan.'}]",Injury,['10.1016/j.injury.2020.06.001'] 1556,32540277,High blood pressure responders show largest increase in heartbeat perception accuracy after post-learning stress following a cardiac interoceptive learning task.,"Mental disorders with physical symptoms, e.g. somatic symptom disorder, are characterized by altered interoceptive accuracy (IAc), which can be explained by individual differences in interoceptive learning (IL). We investigated if stress facilitates IL. Seventy-three healthy participants performed a heartbeat counting task (HCT: T1) and a heartbeat perception training (HBPT). After exposure to a socially-evaluated cold pressor stress test (SECPT; n = 48) or a control condition (n = 25), two more HCTs were performed (T2: 30 min after SECPT; T3: 24 h later). After the HBPT, all participants showed an increase in IAc. We separated the stress group into high vs. low systolic blood pressures (SBP) responders (n = 24 each), with high SBP responders showing the largest IAc increases. Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2. Our results indicate that post-learning autonomic stress response facilitates IL, whereas the HPA axis response may be less important for this effect.",2020,"Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2.","['Seventy-three healthy participants', 'Mental disorders with physical symptoms, e.g. somatic symptom disorder']","['heartbeat counting task (HCT: T1) and a heartbeat perception training (HBPT', 'SECPT']","['HPA axis response', 'IAc', 'systolic blood pressures (SBP) responders', 'heartbeat perception accuracy']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4087321', 'cui_str': 'Somatic symptom disorder'}]","[{'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0085355', 'cui_str': 'Platelet-specific antigen'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0425583', 'cui_str': 'Heart beat'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",73.0,0.014762,"Only SBP, but not cortisol responsiveness significantly predicted IAc increase from T1 to T2.","[{'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Schenk', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Jean T M', 'Initials': 'JTM', 'LastName': 'Fischbach', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Ruta', 'Initials': 'R', 'LastName': 'Müller', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Vögele', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Witthöft', 'Affiliation': 'Division of Clinical Psychology, Department of Psychology, Johannes Gutenberg University of Mainz, Mainz, Germany.'}, {'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Van Diest', 'Affiliation': 'Department of Health Psychology, Catholic University of Leuven, Leuven, Belgium.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Schulz', 'Affiliation': 'Clinical Psychophysiology Laboratory, Department of Behavioural and Cognitive Sciences, University of Luxembourg, Esch-sur-Alzette, Luxembourg. Electronic address: andre.schulz@uni.lu.'}]",Biological psychology,['10.1016/j.biopsycho.2020.107919'] 1557,32534843,Gabapentin as an adjunct to paracervical block for perioperative pain management for first-trimester uterine aspiration: a randomized controlled trial.,"BACKGROUND Pain management approaches during uterine aspiration vary, which include local anesthetic, oral analgesics, moderate sedation, deep sedation, or a combination of approaches. For local anesthetic approaches specifically, we continue to have suboptimal pain control. Gabapentin as an adjunct to pain management has proven to be beneficial in gynecologic surgery. We sought to evaluate the impact of gabapentin on perioperative pain during surgical management of first-trimester abortion or early pregnancy loss with uterine aspiration under local anesthesia. OBJECTIVE We hypothesized that adding gabapentin to local anesthesia will reduce perioperative and postoperative pain associated with uterine aspiration. Secondary outcomes included tolerability of gabapentin and postoperative pain, nausea, vomiting, and anxiety. STUDY DESIGN We conducted a randomized double-blinded placebo-controlled trial of gabapentin 600 mg given 1 to 2 hours preoperatively among subjects receiving a first-trimester uterine aspiration under paracervical block in an outpatient ambulatory surgery center. There were 111 subjects randomized. The primary outcome was pain at time of uterine aspiration as measured on a 100-mm visual analog scale. Secondary outcomes included pain at other perioperative time points. To assess changes in pain measures, an intention to treat mixed effects model was fit with treatment groups (gabapentin vs control) as a between-subjects factor and time point as a within-subjects factor plus their interaction term. Because of a non-normal distribution of pain scores, the area under the curve was calculated for secondary outcomes with comparison of groups utilizing Mann-Whitney U tests. RESULTS Among the 111 randomized, most subjects were Black or African American (69.4%), mean age was 26 years (±5.5), and mean gestational age was 61.3 days (standard deviation, 14.10). Mean pain scores at time of uterine aspiration were 66.77 (gabapentin) vs 71.06 (placebo), with a mean difference of -3.38 (P=.51). There were no significant changes in pain score preoperatively or intraoperatively. Subjects who received gabapentin had significantly lower levels of pain at 10 minutes after surgery (mean difference [standard error (SE)]=-13.0 [-5.0]; P=.01) and 30 minutes after surgery (mean difference [SE]=-10.8 [-5.1]; P=.03) compared with subjects who received placebo. Median nausea scores and incidence of emesis pre- and postoperatively did not differ between groups. Similarly, anxiety scores did not differ between groups, before or after the procedure. At 10 and 30 minutes after the procedure, most participants reported no side effects or mild side effects, and this did not differ between groups. CONCLUSION Preoperative gabapentin did not reduce pain during uterine aspiration. However, it did reduce postoperative pain, which may prove to be a desired attribute of its use, particularly in cases where postoperative pain may be a greater challenge.",2020,"At 10 and 30 minutes post-procedure, most participants reported no or mild side effects and this did not differ between groups. ","['First Trimester Uterine Aspiration', '111 subjects randomized', '111 randomized, most subjects were Black/African American (69.4%), mean age was 26 years (+/-5.5), and mean gestational age was 61.3 days, (SD 14.10', 'first trimester abortion or early pregnancy loss with uterine aspiration under local anesthesia', 'subjects receiving a 1 st trimester uterine aspiration under paracervical block in an outpatient ambulatory surgery center']","['gabapentin', 'Paracervical Block', 'Gabapentin', 'placebo']","['pain at other perioperative time points', 'levels of pain', 'perioperative pain', 'postoperative pain', 'tolerability of gabapentin, and postoperative pain, nausea, vomiting, and anxiety', 'Median nausea scores and incidence of emesis pre', 'mild side effects', 'pain', 'pain at time of uterine aspiration as measured on a 100-mm visual analog scale (VAS', 'pain score', 'pain measures', 'anxiety scores', 'Mean pain scores at time of uterine aspiration']","[{'cui': 'C0032979', 'cui_str': 'First trimester pregnancy'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844008', 'cui_str': '5.5'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C3830362', 'cui_str': 'Early Pregnancy Loss'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}, {'cui': 'C0032982', 'cui_str': 'Trimesters'}, {'cui': 'C0030401', 'cui_str': 'Paracervical block anesthesia'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1321139', 'cui_str': 'Ambulatory surgery center'}]","[{'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0030401', 'cui_str': 'Paracervical block anesthesia'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0060926', 'cui_str': 'gabapentin'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",111.0,0.647974,"At 10 and 30 minutes post-procedure, most participants reported no or mild side effects and this did not differ between groups. ","[{'ForeName': 'Tiffany P', 'Initials': 'TP', 'LastName': 'Hailstorks', 'Affiliation': 'Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA. Electronic address: tiffany.p.hailstorks@emory.edu.'}, {'ForeName': 'Sarah M D', 'Initials': 'SMD', 'LastName': 'Cordes', 'Affiliation': 'Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Carrie A', 'Initials': 'CA', 'LastName': 'Cwiak', 'Affiliation': 'Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA.'}, {'ForeName': 'Beverly A', 'Initials': 'BA', 'LastName': 'Gray', 'Affiliation': 'Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Ge', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Biostatistics Collaboration Core, Emory University, Atlanta, GA.'}, {'ForeName': 'Reneé H', 'Initials': 'RH', 'LastName': 'Moore', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Biostatistics Collaboration Core, Emory University, Atlanta, GA.'}, {'ForeName': 'Lisa B', 'Initials': 'LB', 'LastName': 'Haddad', 'Affiliation': 'Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.06.011'] 1558,32536000,Impact of inferior caval valve implantation on severity of tricuspid regurgitation and right heart function.,"AIMS Severe tricuspid regurgitation (TR) is a common finding in heart failure patients and associated with increased mortality. New interventional therapeutic options are needed as many heart failure patients are unfit for surgery. The TRICAVAL study compared valve implantation into the inferior vena cava (CAVI) with optimal medical therapy (OMT) in patients with severe TR. Here, we report details on the impact of CAVI on TR severity as well as right heart function and morphology. METHODS AND RESULTS We randomized 28 patients with severe TR to CAVI (n = 14) with transfemoral implantation of an Edwards Sapien XT valve into the inferior vena cava or OMT (n = 14). Inclusion and exclusion criteria were based on anatomical and clinical parameters. Echocardiographic measurements were performed at baseline, at the first postoperative day and one, three, and twelve months after randomization. As proof of concept of an effective sealing of the inferior vena cava, we detected a significant decrease in systolic hepatic vein reflux volume (11.0 [6.2-21.9] mL vs 3.5 [0.6-8.5] mL, P = .016) and hepatic vein diameter (11.5 [10.0-14.8] mm vs 10.0 [9.3-11.8] mm, P = .034) at thirty-day follow-up. However, CAVI had no significant impact on TR, cardiac function, and morphology. CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.",2020,"CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.","['heart failure patients', 'patients with severe TR', '28 patients with severe TR to CAVI (n\xa0=\xa014) with', 'n\xa0=\xa014']","['valve implantation into the inferior vena cava (CAVI) with optimal medical therapy (OMT', 'inferior caval valve implantation', 'transfemoral implantation of an Edwards Sapien XT valve into the inferior vena cava or OMT']","['Echocardiographic measurements', 'hepatic vein diameter', 'Severe tricuspid regurgitation (TR', 'systolic reflux', 'severity of tricuspid regurgitation and right heart function', 'systolic hepatic vein reflux volume', 'TR, cardiac function, and morphology', 'cardiac function, morphology, or TR severity']","[{'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040961', 'cui_str': 'Tricuspid valve regurgitation'}, {'cui': 'C0085979', 'cui_str': 'Genus Cavia'}]","[{'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0042458', 'cui_str': 'Inferior vena cava structure'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0152096', 'cui_str': 'Complete trisomy 18 syndrome'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0019155', 'cui_str': 'Structure of hepatic vein'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040961', 'cui_str': 'Tricuspid valve regurgitation'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C4317146', 'cui_str': 'Acid reflux'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0225808', 'cui_str': 'Structure of right side of heart'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0332437', 'cui_str': 'Associated morphology'}]",28.0,0.0584031,"CONCLUSIONS Caval valve implantation significantly reduced systolic reflux into the hepatic veins but was not associated with an improvement in cardiac function, morphology, or TR severity.","[{'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Mattig', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Knebel', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Hewing', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Stangl', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Stangl', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Laule', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Henryk', 'Initials': 'H', 'LastName': 'Dreger', 'Affiliation': 'Medizinische Klinik mit Schwerpunkt Kardiologie und Angiologie, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}]","Echocardiography (Mount Kisco, N.Y.)",['10.1111/echo.14760'] 1559,32548724,"Health economic evaluation of an internet intervention for depression (deprexis), a randomized controlled trial.","BACKGROUND Depressive disorders often remain undiagnosed or are treated inadequately. Online-based programs may reduce the present treatment gap for depressive disorders and reduce disease-related costs. This study aimed to examine the potential of the internet intervention ""deprexis"" to reduce the total costs of statutory health insurance. Changes in depression severity, health-related quality of life and impairment in functioning were also examined. METHOD A total of 3805 participants with, at minimum, mild depressive symptoms were randomized to either a 12-week online intervention (deprexis) or a control condition. The primary outcome measure was statutory health insurance costs, estimated using health insurers' administrative data. Secondary outcomes were: depression severity, health-related quality of life, and impairment in functioning; assessed on patient's self-report at baseline, post-treatment, and three-months' and nine-months' follow-up. RESULTS In both groups, total costs of statutory health insurance decreased during the study period, but changes from baseline differed significantly. In the intervention group total costs decreased by 32% from 3139€ per year at baseline to 2119€ in the study year (vs. a mean reduction in total costs of 13% in the control group). In comparison to the control group, the intervention group also showed a significantly greater reduction in depression severity, and impairment in functioning and a significantly greater increase in health-related quality of life. CONCLUSION The study underlines the potential of innovative internet intervention programs in treating depressive disorders. The results suggest that the use of deprexis over a period of 12 weeks leads to a significant improvement in symptoms with a simultaneous reduction in the costs of statutory health insurance.",2020,"In comparison to the control group, the intervention group also showed a significantly greater reduction in depression severity, and impairment in functioning and a significantly greater increase in health-related quality of life. ","['3805 participants with, at minimum, mild depressive symptoms']","['innovative internet intervention programs', 'internet intervention', 'online intervention (deprexis) or a control condition']","['total costs of statutory health insurance', 'depression severity, health-related quality of life and impairment in functioning', 'total costs', 'depression severity, and impairment in functioning', 'health-related quality of life', ""statutory health insurance costs, estimated using health insurers' administrative data"", 'costs of statutory health insurance', ""depression severity, health-related quality of life, and impairment in functioning; assessed on patient's self-report at baseline, post-treatment, and three-months' and nine-months' follow-up""]","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]","[{'cui': 'C3898714', 'cui_str': 'Internet Intervention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0027452', 'cui_str': 'National Health Insurance'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0021675', 'cui_str': 'Insurers'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",3805.0,0.0841955,"In comparison to the control group, the intervention group also showed a significantly greater reduction in depression severity, and impairment in functioning and a significantly greater increase in health-related quality of life. ","[{'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Gräfe', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany. viola.graefe@uni-bielefeld.de.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Greiner', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany.'}]",Health economics review,['10.1186/s13561-020-00273-0'] 1560,32683215,Intensive upper extremity training improved whole body movement control for children with unilateral spastic cerebral palsy.,"BACKGROUND Children with unilateral spastic cerebral palsy (USCP) exhibit impaired bimanual coordination, gait control, and whole body movement control. Intensive upper extremity training has been found to be effective for improving upper extremity function. However, the effectiveness of the intensive upper extremity training on whole body movement control is not known. RESEARCH QUESTION The present study aimed to evaluate the effects of Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT) on bimanual coordination and gait control during a complex whole body task. METHODS Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS: I-II, MACS: I-II) were randomly assigned to either CIMT or HABIT for 6 h per day training for 15 days. Children were asked to perform two whole body tasks (walking with and without a tray carrying) while 3-D kinematic analysis was performed before and after training. RESULTS After training, the HABIT group increased the symmetry in height of their hands during tray carrying (more leveled tray). Both CIMT and HABIT groups decreased the lateral motion of the tray. The CIMT group increased speed and stride length after training in both the walking and tray carrying tasks. Both groups also increased their minimum toe clearance (all p < 0.05). SIGNIFICANCE Two types of intensive upper extremity training have provided significant improvements to whole body movement control for children with USCP. Adhering to the specificity of practice concept, HABIT improved bimanual coordination after training during the whole body tray carrying tasks. Given extensive interactions between the upper and lower extremities in real-world activities, future studies should focus on the effects of such combined training.",2020,"Both groups also increased their minimum toe clearance (all p < 0.05). ","['children with unilateral spastic cerebral palsy', 'Children with unilateral spastic cerebral palsy (USCP', 'children with USCP', 'Sixteen children with congenital hemiplegia (age 6-12 years; GMFCS']","['CIMT or HABIT', 'Intensive upper extremity training improved whole body movement control', 'CIMT', 'Constraint Induced Movement Therapy (CIMT) and Hand Arm Bimanual Intensive Therapy (HABIT', 'intensive upper extremity training', 'Intensive upper extremity training']","['bimanual coordination and gait control', 'symmetry in height of their hands', 'speed and stride length', 'lateral motion of the tray', 'minimum toe clearance']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0454279', 'cui_str': 'Movement therapy'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0427083', 'cui_str': 'Control of movement'}]","[{'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0184054', 'cui_str': 'Tray'}, {'cui': 'C0040357', 'cui_str': 'Toe structure'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}]",16.0,0.0108967,"Both groups also increased their minimum toe clearance (all p < 0.05). ","[{'ForeName': 'Ya-Ching', 'Initials': 'YC', 'LastName': 'Hung', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA. Electronic address: yaching.hung@qc.cuny.edu.'}, {'ForeName': 'Fawzia', 'Initials': 'F', 'LastName': 'Shirzad', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Saleem', 'Affiliation': 'Department of Family, Nutrition, and Exercise Sciences, Queens College, City University of New York, 65-30 Kissena Blvd, Flushing, NY 11367, USA.'}, {'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Gordon', 'Affiliation': 'Department of Biobehavioral Sciences, Teachers College, Columbia University, 525 West 120th Street, Box 199, NY 10027, USA.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.009'] 1561,32554380,"Effectiveness of an 8-Week Web-Based Mindfulness Virtual Community Intervention for University Students on Symptoms of Stress, Anxiety, and Depression: Randomized Controlled Trial.","BACKGROUND A student mental health crisis is increasingly acknowledged and will only intensify with the COVID-19 crisis. Given accessibility of methods with demonstrated efficacy in reducing depression and anxiety (eg, mindfulness meditation and cognitive behavioral therapy [CBT]) and limitations imposed by geographic obstructions and localized expertise, web-based alternatives have become vehicles for scaled-up delivery of benefits at modest cost. Mindfulness Virtual Community (MVC), a web-based program informed by CBT constructs and featuring online videos, discussion forums, and videoconferencing, was developed to target depression, anxiety, and experiences of excess stress among university students. OBJECTIVE The aim of this study was to assess the effectiveness of an 8-week web-based mindfulness and CBT program in reducing symptoms of depression, anxiety, and stress (primary outcomes) and increasing mindfulness (secondary outcome) within a randomized controlled trial (RCT) with undergraduate students at a large Canadian university. METHODS An RCT was designed to assess undergraduate students (n=160) who were randomly allocated to a web-based guided mindfulness-CBT condition (n=80) or to a waitlist control (WLC) condition (n=80). The 8-week intervention consisted of a web-based platform comprising (1) 12 video-based modules with psychoeducation on students' preidentified life challenges and applied mindfulness practice; (2) anonymous peer-to-peer discussion forums; and (3) anonymous, group-based, professionally guided 20-minute live videoconferences. The outcomes (depression, anxiety, stress, and mindfulness) were measured via an online survey at baseline and at 8 weeks postintervention using the Patient Health Questionnaire-9 (PHQ9), the Beck Anxiety Inventory (BAI), the Perceived Stress Scale (PSS), and the Five Facets Mindfulness Questionnaire Short Form (FFMQ-SF). Analyses employed generalized estimation equation methods with AR(1) covariance structures and were adjusted for possible covariates (gender, age, country of birth, ethnicity, English as first language, paid work, unpaid work, relationship status, physical exercise, self-rated health, and access to private mental health counseling). RESULTS Of the 159 students who provided T1 data, 32 were males and 125 were females with a mean age of 22.55 years. Participants in the MVC (n=79) and WLC (n=80) groups were similar in sociodemographic characteristics at T1 with the exception of gender and weekly hours of unpaid volunteer work. At postintervention follow-up, according to the adjusted comparisons, there were statistically significant between-group reductions in depression scores (β=-2.21, P=.01) and anxiety scores (β=-4.82, P=.006), and a significant increase in mindfulness scores (β=4.84, P=.02) compared with the WLC group. There were no statistically significant differences in perceived stress for MVC (β=.64, P=.48) compared with WLC. CONCLUSIONS With the MVC intervention, there were significantly reduced depression and anxiety symptoms but no significant effect on perceived stress. Online mindfulness interventions can be effective in addressing common mental health conditions among postsecondary populations on a large scale, simultaneously reducing the current burden on traditional counseling services. TRIAL REGISTRATION ISRCTN Registry ISRCTN12249616; http://www.isrctn.com/ISRCTN12249616.",2020,"There were no statistically significant differences in perceived stress for MVC (β = .64, P = .48) compared to WLC. ","['32 were males and 125 were females with a mean age of 22.55 years', 'undergraduate students at a large Canadian university', 'undergraduate students (n = 160', '159 students who provided T1 data', 'Participants in the MVC (n = 79) and WLC (n = 80) groups were similar in sociodemographic characteristics at T1 with the exception of gender and weekly hours of unpaid volunteer work', 'University Students on Symptoms of Stress, Anxiety, and Depression', 'university students']","['web-based guided mindfulness-CBT condition (n = 80) or to a waitlist control condition (WLC', 'Eight-Week Web-Based Mindfulness Virtual Community Intervention', 'mindfulness meditation and cognitive behavioural therapy [CBT', 'Mindfulness Virtual Community (MVC), a web-based program informed by cognitive behavioral therapy (CBT) constructs and featuring online videos, discussion forums, and videoconferencing', 'eight-week web-based mindfulness and cognitive behavioural therapy (CBT) program', 'Online mindfulness interventions', ""web-based platform consisting of (1) 12 video-based modules with psycho-education on students' preidentified life challenges and applied mindfulness practice; (2) anonymous peer-to-peer discussion forums; and (3) anonymous, group-based, professionally guided 20-minute live videoconferences""]","['mindfulness scores', 'outcomes (depression, anxiety, stress, and mindfulness', 'depression scores', 'Patient Health Questionniare-9 (PHQ9), the Beck Anxiety Inventory (BAI), the Perceived Stress Scale (PSS), and the Five Facets Mindfulness Questionnaire Short Form (FFMQ-SF', 'depression and anxiety symptoms', 'anxiety scores', 'symptoms of depression, anxiety, and stress (primary outcomes', 'perceived stress for MVC']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0700287', 'cui_str': 'Informing'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0582653', 'cui_str': 'Perceived stress scale'}, {'cui': 'C0222679', 'cui_str': 'Structure of articular surface of bone'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",160.0,0.0566538,"There were no statistically significant differences in perceived stress for MVC (β = .64, P = .48) compared to WLC. ","[{'ForeName': 'Christo', 'Initials': 'C', 'LastName': 'El Morr', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Ritvo', 'Affiliation': 'School of Kinesiology and Health Science, York University, Toronto, ON, Canada.'}, {'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Ahmad', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}, {'ForeName': 'Rahim', 'Initials': 'R', 'LastName': 'Moineddin', 'Affiliation': 'Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'School of Health Policy and Management, York University, Toronto, ON, Canada.'}]",JMIR mental health,['10.2196/18595'] 1562,32561426,Recombinant human thrombopoietin in critically ill patients with sepsis-associated thrombocytopenia: A clinical study.,"BACKGROUND Sepsis causes varying degrees of thrombocytopenia that are closely related to the likelihood of patient mortality. This study analysed the effect of recombinant human thrombopoietin (rhTPO) on the platelet count in critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment. MATERIAL/METHODS The study was a retrospective analysis of the clinical data of patients. Patients were divided into an rhTPO group and control group according to rhTPO use during treatment. Demographical and clinical data (age, sex, history of hypertension, diabetes, platelet counts, mortality rate, etc.) of the patients were collected and analysed using statistical software; p < 0.05 was considered statistically significant. RESULTS Of 213 patients, 84 constituted the rhTPO group and 129 constituted the control group. The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01 ± 18.23 × 10 9 /L vs. 36.31 ± 14.17 × 10 9 /L, p = 0.003), fifth day (71.51 ± 39.59 × 10 9 /L vs. 42.95 ± 20.48 × 10 9 /L, p < 0.001) and seventh day (115.36 ± 69.41 × 10 9 /L vs. 62.54 ± 42.70 × 10 9 /L, p < 0.001). Further statistical analysis of the data of patients with platelet counts ≤30 × 10 9 /L and >30 × 10 9 /L and APACHE II scores >15 and ≤15 at the time of diagnosis showed that the increase in platelet counts in the rhTPO group was greater. There was no significant between-group difference in volume of platelet transfusions (rhTPO group 15.42 ± 17.20 vs. control group 10.93 ± 17.48, p = 0.068). The cost of ICU treatment in patients with rhTPO was higher (RMB 126,936.21 ± 86,548.27 vs. 101,685.28 ± 77,291.75, p = 0.027); however, the ICU stay time was shorter (9.20 ± 5.38 vs. 10.88 ± 6.82, p = 0.047). There was no significant difference in 28-day mortality (rhTPO group: 25.0% vs. control group: 34.1%, p = 0.158) between the two groups. CONCLUSION For patients with severe thrombocytopenia or severe sepsis, rhTPO was efficacious in increasing their platelet counts, resulting in a shorter ICU stay time.",2020,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"['patients with severe thrombocytopenia or patients with severe sepsis', 'patients with platelet counts', 'critically ill patients with sepsis-associated thrombocytopenia and provided a reference for its treatment', '213 patients', '84 patients constituted the rhTPO group and 129 constituted the control group', 'critically ill patients with sepsis-associated thrombocytopenia', '≤30×10 9']","['recombinant human thrombopoietin (rhTPO', 'Recombinant human thrombopoietin', 'rhTPO']","['ICU stay time', 'platelet counts', 'volume of platelet transfusions', 'cost of ICU treatment', '28-days mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040034', 'cui_str': 'Thrombocytopenic disorder'}, {'cui': 'C1719672', 'cui_str': 'Severe Sepsis'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0036690', 'cui_str': 'Septicaemia, unspecified'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040052', 'cui_str': 'Thrombopoietin'}]","[{'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0086818', 'cui_str': 'Platelet transfusion'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",213.0,0.0258731,The increase in platelet counts was significantly higher in the rhTPO group than in the control group on the third day (43.01±18.23×10 9,"[{'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Jin', 'Affiliation': ""Emergency Department, Xi'an Aerospace General Hospital, Xi'an, China.""}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.""}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: wangxuejd2008@126.com.""}, {'ForeName': 'Litao', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': ""Department of Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Electronic address: glt2002@xjtu.edu.cn.""}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.06.045'] 1563,32563606,A phase 2 study of the bivalent VLP norovirus vaccine candidate in older adults; impact of MPL adjuvant or a second dose.,"INTRODUCTION Acute norovirus gastroenteritis causes significant morbidity and in uncommon cases fatality in older adults. We investigated the safety and immunogenicity of bivalent virus-like particle (VLP) vaccine candidate formulations with and without monophosphoryl lipid A (adjuvant MPL) in this population. METHODS In this phase II, double-blind, controlled trial 294 healthy adults, ≥ 60 years of age, were randomized (1:1:1:1) to four groups to receive one or two intramuscular immunizations 28 days apart, with 26 18-49 year-old controls who received one MPL-free dose. One-dose groups received placebo on Day 1. Vaccine formulations contained 15 μg GI.1 and 50 μg GII.4c VLP antigens and 500 μg Al(OH) 3 , with or without 15 μg MPL. We measured histo-blood group antigen blocking (HBGA) antibodies and ELISA Ig at Days 1, 8, 29, 57, 211 and 393, and avidity indices and cell-mediated immunity (CMI). Solicited local and systemic adverse events (AE) were assessed for 7 days and unsolicited AEs for 28 days after each injection. RESULTS After one dose HBGA antibodies to both VLP antigens increased with similar kinetics and magnitude in all groups; geometric mean titres (GMTs) persisted above baseline through Day 393. GMTs were similar across age strata (18-49, 60-74, 75-84 and ≥ 85 years of age) and unaffected by a second vaccination or MPL. Total Ig showed similar responses. No clinically relevant differences or changes in avidity or CMI were observed between formulations. Both formulations were well tolerated with no vaccine-related SAEs, the most frequent AEs being mild injection site pain and fatigue. CONCLUSIONS Adults over 60 years of age displayed no safety concerns and had similar immune responses to the norovirus VLP vaccine candidate as younger adults, unaffected by increasing age, a second dose or inclusion of MPL. This data supports the further development of the MPL-free vaccine candidate for older adults.",2020,After one dose HBGA antibodies to both VLP antigens increased with similar kinetics and magnitude in all groups; geometric mean titres (GMTs) persisted above baseline through Day 393.,"['294 healthy adults, ≥ 60\xa0years of age', 'older adults']","['intramuscular immunizations 28\xa0days apart, with 26 18-49\xa0year-old controls who received one MPL-free dose', 'bivalent virus-like particle (VLP) vaccine candidate formulations with and without monophosphoryl lipid A (adjuvant MPL', 'placebo']","['Solicited local and systemic adverse events (AE', 'avidity indices and cell-mediated immunity (CMI', 'geometric mean titres (GMTs', 'avidity or CMI']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0020971', 'cui_str': 'Immunization'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0066776', 'cui_str': 'monophosphoryl lipid A'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0333785', 'cui_str': 'Virus-like particles'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0020966', 'cui_str': 'Cell-Mediated Immunity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}]",294.0,0.41082,After one dose HBGA antibodies to both VLP antigens increased with similar kinetics and magnitude in all groups; geometric mean titres (GMTs) persisted above baseline through Day 393.,"[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Treanor', 'Affiliation': 'University of Rochester Medical Center, School of Medicine and Dentistry, Rochester NY, USA.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Sherwood', 'Affiliation': 'Takeda Pharmaceuticals International AG, Zurich, Switzerland. Electronic address: Jim.Sherwood@takeda.com.'}, {'ForeName': 'Jakob P', 'Initials': 'JP', 'LastName': 'Cramer', 'Affiliation': 'Takeda Pharmaceuticals International AG, Zurich, Switzerland.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Le Cam Bouveret', 'Affiliation': 'Takeda Pharmaceuticals International AG, Zurich, Switzerland.'}, {'ForeName': 'Stella', 'Initials': 'S', 'LastName': 'Lin', 'Affiliation': 'Takeda Vaccines Inc., Cambridge, MA, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Baehner', 'Affiliation': 'Takeda Pharmaceuticals International AG, Zurich, Switzerland.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Borkowski', 'Affiliation': 'Takeda Pharmaceuticals International AG, Zurich, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Vaccine,['10.1016/j.vaccine.2020.06.011'] 1564,32564334,Long-Term Cilostazol Treatment and Predictive Factors on Outcomes of Endovascular Intervention in Patients with Diabetes Mellitus and Critical Limb Ischemia.,"INTRODUCTION Despite improvements in endovascular interventions and multidisciplinary approaches, improving clinical outcomes and increasing limb salvage have become increasingly challenging. This prospective study investigated the associations of cilostazol treatment with clinical outcomes and predictive factors in patients with diabetes mellitus (DM) and critical limb ischemia (CLI) after endovascular revascularization of the affected angiosome. METHODS In this study, 172 consecutive patients with CLI (Fontaine levels III-IV) received cilostazol treatment after successful endovascular intervention according to the angiosome concept, and their primary patency rates and cardiovascular and amputation events during a 24-month follow-up period were assessed. RESULT The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014). Weighted multivariate Cox analyses with a propensity scoring-based method showed that long-term cilostazol treatment [hazard ratio (HR) 0.2, 95% confidence interval (CI) 0.11-0.36, P < 0.001], direct revascularization (DR) (HR 0.46, 95% CI 0.28-0.74, P = 0.002), and supervised exercise (HR 0.4, 95% CI 0.24-0.66, P < 0.001) were independently associated with primary patency. Patients with lower-extremity amputation (LEA) had a higher risk of coronary artery disease (CAD) and mortality. Cellulitis and neuropathy were independently associated with LEA events (cellulitis: HR 2.89, 95% CI 1.66-5.05, P < 0.001; neuropathy: HR 2.2, 95% CI 1.31-3.7, P = 0.003). CONCLUSION Our results showed that patients with DM who received cilostazol treatment for more than 3 months had significantly better outcomes and decreased amputation and mortality rates after DR, and cellulitis and neuropathy were highly associated with the risk of limb loss. A large-scale randomized trial should be conducted in the future to confirm these results. TRIAL REGISTRATION Taipei Veterans General Hospital (TVGH) IRB no. 2013-08-020B. Registered 30 August 2013.",2020,"The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014).","['2013-08-020B', '172 consecutive patients with CLI (Fontaine levels\xa0III-IV) received', 'Patients with lower-extremity amputation (LEA', 'Patients with Diabetes Mellitus and Critical Limb Ischemia', 'Taipei Veterans General Hospital', 'patients with diabetes mellitus (DM) and critical limb ischemia (CLI) after endovascular revascularization of the affected angiosome']","['cilostazol', 'TVGH', 'cilostazol treatment', 'Endovascular Intervention']","['supervised exercise', 'direct revascularization (DR', 'risk of coronary artery disease (CAD) and mortality', 'Cellulitis and neuropathy', 'amputation and mortality rates after DR, and cellulitis and neuropathy', '24-month primary patency rate, mortality rate, and amputation rate', 'risk of limb loss']","[{'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C0441927', 'cui_str': 'Level III'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}]","[{'cui': 'C0055729', 'cui_str': 'cilostazol'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0411282', 'cui_str': 'Endovascular radiological intervention'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0002695', 'cui_str': 'Amputee'}]",172.0,0.0628399,"The 24-month primary patency rate, mortality rate, and amputation rate were better in the patients under long-term cilostazol treatment (P < 0.001, P = 0.029, and P = 0.014).","[{'ForeName': 'Chiu-Yang', 'Initials': 'CY', 'LastName': 'Lee', 'Affiliation': 'Division of Cardiovascular Surgery, Department of Surgery, Taipei Veterans General Hospital, No. 201, Section\xa02 Shih-Pai Road, Beitou District, Taipei, 11217, Taiwan.'}, {'ForeName': 'Tao-Cheng', 'Initials': 'TC', 'LastName': 'Wu', 'Affiliation': 'Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. dcwu@vghtpe.gov.tw.'}, {'ForeName': 'Shing-Jong', 'Initials': 'SJ', 'LastName': 'Lin', 'Affiliation': 'Institute of Clinical Medicine, School of Medicine, National Yang Ming University, Taipei, Taiwan. shingjong88@gmail.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00860-8'] 1565,32564804,An RCT of Fecal Immunochemical Test Colorectal Cancer Screening in Veterans Without Recent Primary Care.,"INTRODUCTION The use of screening can prevent death from colorectal cancer, yet people without regular healthcare visits may not realize the benefits of this preventive intervention. The objective of this study was to determine the effectiveness of a mailed screening invitation or mailed fecal immunochemical test in increasing colorectal cancer screening uptake in veterans without recent primary care encounters. STUDY DESIGN Three-arm pragmatic randomized trial. SETTING/PARTICIPANTS Participants were screening-eligible veterans aged 50-75 years, without a recent primary care visit who accessed medical services at the Corporal Michael J. Crescenz Veteran Affairs Medical Center between January 1, 2017, and July 31, 2017. All data were analyzed from March 1, 2018, to July 31, 2018. INTERVENTION Participants were randomized to (1) usual opportunistic screening during a healthcare visit (n=260), (2) mailed invitation to screen and reminder phone calls (n=261), or (3) mailed fecal immunochemical test outreach plus reminder calls (n=61). MAIN OUTCOME MEASURES The main outcome under investigation was the completion of colorectal cancer screening within 6 months after randomization. RESULTS Of 782 participants in the trial, 53.9% were aged 60-75 years and 59.7% were African American. The screening rate was higher in the mailed fecal immunochemical test group (26.1%) compared with usual care (5.8%) (rate difference=20.3%, 95% CI=14.3%, 26.3%; RR=4.52, 95% CI=2.7, 7.7) or screening invitation (7.7%) (rate difference=18.4%, 95% CI=12.2%, 24.6%; RR=3.4, 95% CI=2.1, 5.4). Screening completion rates were similar between invitation and usual care (rate difference=1.9%, 95% CI= -2.4%, 6.2%; RR=1.3, 95% CI=0.7, 2.5). CONCLUSIONS Mailed fecal immunochemical test screening promotes colorectal cancer screening participation among veterans without a recent primary care encounter. Despite the addition of reminder calls, an invitation letter was no more effective in screening participation than screening during outpatient appointments. TRIAL REGISTRATION This study is registered at clinicaltrials.gov NCT02584998.",2020,"Screening completion rates were similar between invitation and usual care (rate difference=1.9%, 95% CI= -2.4%, 6.2%; RR=1.3, 95% CI=0.7, 2.5). ","['782 participants in the trial, 53.9% were aged 60-75 years and 59.7% were African American', 'Veterans Without Recent Primary Care', 'Participants were screening-eligible veterans aged 50-75 years, without a recent primary care visit who accessed medical services at the Corporal Michael J. Crescenz Veteran Affairs Medical Center between January 1, 2017, and July 31, 2017', 'veterans without a recent primary care encounter', 'veterans without recent primary care encounters']","['usual opportunistic screening during a healthcare visit (n=260), (2) mailed invitation to screen and reminder phone calls (n=261), or (3) mailed fecal immunochemical test outreach plus reminder calls (n=61', 'mailed screening invitation or mailed fecal immunochemical test']","['screening invitation', 'Screening completion rates', 'completion of colorectal cancer screening', 'screening rate']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C4521398', 'cui_str': 'US Military enlisted E4'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}]","[{'cui': 'C0422389', 'cui_str': 'Opportunistic screening'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",,0.289727,"Screening completion rates were similar between invitation and usual care (rate difference=1.9%, 95% CI= -2.4%, 6.2%; RR=1.3, 95% CI=0.7, 2.5). ","[{'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Goldshore', 'Affiliation': 'Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: matthew.goldshore@pennmedicine.upenn.edu.'}, {'ForeName': 'Shivan J', 'Initials': 'SJ', 'LastName': 'Mehta', 'Affiliation': 'Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}, {'ForeName': 'Woodrow', 'Initials': 'W', 'LastName': 'Fletcher', 'Affiliation': 'Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Tzanis', 'Affiliation': 'Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Chyke A', 'Initials': 'CA', 'LastName': 'Doubeni', 'Affiliation': 'Center for Health Equity and Community Engagement Research, Mayo Clinic, Rochester, Minnesota; Department of Family Medicine, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'E Carter', 'Initials': 'EC', 'LastName': 'Paulson', 'Affiliation': 'Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",American journal of preventive medicine,['10.1016/j.amepre.2020.02.014'] 1566,32569678,Ovulation inhibition with a new vaginal ring containing trimegestone.,"OBJECTIVES The primary objective was to determine the lowest trimegestone (TMG) dose, administered via a vaginal ring, that effectively inhibited ovulation. STUDY DESIGN Single-centre, open-label, single-dose, parallel-group clinical trial with adaptive design. Eighty healthy female volunteers with proven ovulatory cycles were allocated to treatment with a vaginal ring during 28 days, with an average daily release rate of either 46 µg, 94 µg, 147 µg, or 184 µg TMG (20 women/group). Ultrasound measurements of follicular growth and endometrial thickness, and blood sampling for follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone determinations were performed every 3rd (±1) day from treatment day 4 (±1) until day 28 (±1), and in a follow-up phase after ring removal, until study day 39 (±1). Trimegestone concentrations were measured at each visit in the treatment phase. RESULTS Mean age and body mass index were 28.8 years and 23.15 kg/m 2 . One subject in the lowest dose group (46 µg/day) ovulated, no ovulations were seen in the higher dose groups. The degree of ovarian suppression increased with the dose. Median estradiol levels were 119, 36.5, 33.2 and 27.2 pg/mL in the 46, 94, 147 and 184 µg/day groups, respectively. Ovarian activity was resumed in the follow-up phase. Plasma TMG levels gradually declined over the treatment period and showed dose proportionality. The study treatment was safe and well tolerated. CONCLUSION The release rate of 94 µg TMG per day was the lowest effective dose for ovulation inhibition. The study results justify further development of the TMG-ring as progestogen-only contraceptive. IMPLICATIONS The vaginal ring releasing TMG seems to be an effective new progestogen-only contraceptive preparation, having the advantage of once-a-month vaginal insertion.",2020,"One subject in the lowest dose group (46 µg/day) ovulated, no ovulations were seen in the higher dose groups.","['Mean age and body mass index were 28.8 years and 23.15 kg/m 2 ', 'Eighty healthy female volunteers with proven ovulatory cycles']","['TMG-ring as progestogen-only contraceptive', 'lowest trimegestone (TMG', 'trimegestone']","['Plasma TMG levels', 'Ovulation inhibition', 'degree of ovarian suppression', 'Median estradiol levels', 'Trimegestone concentrations', 'release rate', 'safe and well tolerated', 'Ovarian activity', 'Ultrasound measurements of follicular growth and endometrial thickness, and blood sampling for follicle-stimulating hormone, luteinizing hormone, estradiol and progesterone determinations']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0429470', 'cui_str': 'Ovulatory'}]","[{'cui': 'C0628822', 'cui_str': 'trimegestone'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0009871', 'cui_str': 'Contraceptive agent'}, {'cui': 'C0205251', 'cui_str': 'Low'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0628822', 'cui_str': 'trimegestone'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029968', 'cui_str': 'Ovulation Suppression'}, {'cui': 'C0677922', 'cui_str': 'Ovarian ablation'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0337434', 'cui_str': 'Estradiol measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0439682', 'cui_str': 'Follicular'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0202022', 'cui_str': 'Follicle stimulating hormone measurement'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0033308', 'cui_str': 'Progesterone'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}]",80.0,0.0599633,"One subject in the lowest dose group (46 µg/day) ovulated, no ovulations were seen in the higher dose groups.","[{'ForeName': 'Ingrid J M', 'Initials': 'IJM', 'LastName': 'Duijkers', 'Affiliation': 'Dinox Consultancy BV, Marktstraat 19, 9712 PB Groningen, the Netherlands. Electronic address: id@dinoxconsultancy.com.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Klipping', 'Affiliation': 'Dinox Consultancy BV, Marktstraat 19, 9712 PB Groningen, the Netherlands; Dinox GmbH, Anklamer Strasse 38, 10115 Berlin, Germany. Electronic address: ck@dinoxconsultancy.com.'}, {'ForeName': 'Corinna', 'Initials': 'C', 'LastName': 'Draeger', 'Affiliation': 'Dinox GmbH, Anklamer Strasse 38, 10115 Berlin, Germany. Electronic address: corinna.draeger@dinox.de.'}, {'ForeName': 'Barbara S', 'Initials': 'BS', 'LastName': 'Schug', 'Affiliation': 'SocraTec R&D GmbH, Im Setzling 35, 61440 Oberursel, Germany. Electronic address: Barbara.Schug@socratec-pharma.de.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Dax', 'Affiliation': 'SocraTec R&D GmbH, Im Setzling 35, 61440 Oberursel, Germany. Electronic address: Annika.Dax@socratec-pharma.de.'}, {'ForeName': 'Maika', 'Initials': 'M', 'LastName': 'Friedrich', 'Affiliation': 'Evestra GmbH, Britzer Straße 26, 12439 Berlin, Germany. Electronic address: mfriedrich@evestra.com.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Nickisch', 'Affiliation': 'Evestra GmbH, Britzer Straße 26, 12439 Berlin, Germany. Electronic address: knickisch@evestra.com.'}]",Contraception,['10.1016/j.contraception.2020.06.006'] 1567,32521448,Design cues for tobacco communication: Heuristic interpretations and usability of online health information about harmful chemicals.,"OBJECTIVE Many people have a poor understanding of the numerous chemicals in tobacco products that cause severe health harms. The US government must display a list of these harmful chemicals for the public. Online disclosures are one promising solution, but evidence is needed for effective design strategies to encourage interpretation and use of information as intended. METHOD To examine the impact of website designs for the activation of heuristics and usability perceptions, a national probability sample of US adolescents and adults (n = 1441) was randomized in a 3 (chemical format) × 2 (webpage layout) between-subjects online experiment. Chemicals were displayed as names only, with a visual risk indicator, or with numerical ranges. Layouts displayed health harms at the top of the webpage separate from chemicals or the chemicals grouped by associated health harms. Participants viewed a webpage and reported activated heuristics, usability (perceived ease of use and usefulness), and intentions to use the website. RESULTS Displaying risk indicators increased website usability by encouraging users to rely on colors to interpret the risk of the chemicals (all p < .01). Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). CONCLUSION Assessing heuristics gives insights for how US adolescents and adults interpret chemical information and the impact of design strategies on usability. Public disclosures of chemicals in tobacco products could be optimized with color-coded risk indicators and layouts placing chemicals near the harms they cause.",2020,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ",['US adolescents and adults (n = 1441'],[],['website usability'],"[{'cui': 'C0002838', 'cui_str': 'Andorra'}]",[],[],1441.0,0.0625486,"Website designs that grouped chemicals with harms allowed users to link the chemicals to harms they cause and increased perceived usability and intentions to use the website (all p < .001). ","[{'ForeName': 'Allison J', 'Initials': 'AJ', 'LastName': 'Lazard', 'Affiliation': 'School of Media and Journalism, University of North Carolina at Chapel Hill, NC 27599-3365, United States; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599-3365, United States. Electronic address: lazard@unc.edu.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104177'] 1568,32526490,Creativity on tap 2: Investigating dose effects of alcohol on cognitive control and creative cognition.,"This preregistered study aimed to replicate and extend research on the role of cognitive control in creative cognition by examining dose effects of alcohol in a randomized controlled trial. A sample of 125 participants was randomly assigned to three experimental groups, either drinking alcoholic beer (BAC = 0.03 or 0.06) or drinking non-alcoholic beer (placebo-control group). Before and after the alcohol intervention, participants completed two tests of cognitive control and two established creative thinking tasks. A BAC of 0.06 led to an impairment of verbal fluency, while working memory performance was unaffected at both alcohol levels. Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity. These results indicate that moderate alcohol levels have dose-dependent, selective effects on cognitive control, and that minor impairments of cognitive control do not generally increase or attenuate creative thinking performance.",2020,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.",['A sample of 125 participants'],"['drinking alcoholic beer (BAC\xa0=\xa00.03 or 0.06) or drinking non-alcoholic beer (placebo-control group', 'alcohol', 'cognitive control and two established creative thinking tasks']","['creative thinking performance', 'verbal fluency, while working memory performance', 'RAT performance, divergent thinking fluency or divergent thinking creativity', 'cognitive control and creative cognition']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0687725', 'cui_str': 'Problem drinker'}, {'cui': 'C0004922', 'cui_str': 'Beer'}, {'cui': 'C0004599', 'cui_str': 'Bacitracin'}, {'cui': 'C4517402', 'cui_str': '0.03'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]","[{'cui': 'C0010297', 'cui_str': 'Creative thought'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",125.0,0.0319793,"Alcohol had no facilitative or detrimental effects on creative thinking performance, neither in terms of RAT performance, divergent thinking fluency or divergent thinking creativity.","[{'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Benedek', 'Affiliation': 'Institute of Psychology, University of Graz, Austria. Electronic address: mathias.benedek@uni-graz.at.'}, {'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Zöhrer', 'Affiliation': 'Institute of Psychology, University of Graz, Austria.'}]",Consciousness and cognition,['10.1016/j.concog.2020.102972'] 1569,32682992,Characterizing the analgesic effects of real and imagined acupuncture using functional and structure MRI.,"Acupuncture and imagery interventions for pain management have a long history. The present study comparatively investigated whether acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture on the participant's own body while imagining it being applied) could modulate brain regional connectivity to produce analgesic effects. The study also examined whether pre-intervention brain functional and structural features could be used to predict the magnitude of analgesic effects. Twenty-four healthy participants were recruited and received four different interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control) in random order using a cross-over design. Pain thresholds and magnetic resonance imaging (MRI) data were collected before and after each intervention. We first compared the modulatory effects of real acupuncture and VGAIT on intra- and inter-regional intrinsic brain connectivity and found that real acupuncture decreased regional homogeneity (ReHo) and functional connectivity (FC) in sensorimotor areas, whereas VGAIT increased ReHo in basal ganglia (BG) (i.e., putamen) and FC between the BG subcortical network and default mode network. The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively. A multimodality fusion approach with pre-intervention ReHo and gray matter volume (GMV) as features was used to explore the brain profiles underlying individual variability of pain threshold changes by real acupuncture and VGAIT. Variability in acupuncture responses was associated with ReHo and GMV in BG, whereas VGAIT responses were associated with ReHo and GMV in the anterior insula. These results suggest that, through different pathways, both real acupuncture and VGAIT can modulate brain systems to produce analgesic effects.",2020,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.",['Twenty-four healthy participants'],"['real acupuncture and VGAIT', 'acupuncture and video-guided acupuncture imagery treatment (VGAIT, watching a video of acupuncture', 'pre-intervention ReHo and grey matter volume (GMV', 'interventions (real acupuncture, sham acupuncture, VGAIT, and VGAIT control', 'Acupuncture and imagery interventions']","['pain threshold', 'Pain thresholds and magnetic resonance imaging (MRI) data', 'regional homogeneity (ReHo) and functional connectivity (FC']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",24.0,0.0799386,"The altered ReHo and FC were associated with changes in pain threshold after real acupuncture and VGAIT, respectively.","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Cao', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Yiheng', 'Initials': 'Y', 'LastName': 'Tu', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Wilson', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Scott P', 'Initials': 'SP', 'LastName': 'Orr', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Kong', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States; Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States. Electronic address: jkong2@mgh.harvard.edu.'}]",NeuroImage,['10.1016/j.neuroimage.2020.117176'] 1570,32534120,Effect of traditional Chinese medicine formula GeGen decoction on primary dysmenorrhea: A randomized controlled trial study.,"ETHNOPHARMACOLOGICAL RELEVANCE GeGen Decoction, a well-known Chinese herbal formula, is widely used in China and other Asian countries to treat gynecological diseases, including primary dysmenorrhea. Pharmacological studies have confirmed that GeGen Decoction is able to inhibit spasmodic contractions of the uterus in vivo and in vitro. AIM OF THE STUDY The objective of this study is to examine the efficacy and safety of GeGen Decoction on primary dysmenorrheic patients. METHODS This was a randomized, double-blinded, placebo-controlled trial. GeGen Decoction or placebo was administered a week before the expected start of each cycle for three consecutive menstrual periods. Between-group differences in pain intensity were detected by visual analogue scale (VAS). In addition, serum levels of arginine vasopressin (AVP) and estrogen (E) were examined by enzyme-linked immunosorbent assay. Metabolomic analysis was further used to evaluate the influence of GeGen Decoction on the metabolomics of primary dysmenorrheic patients. RESULTS A total of 71 primary dysmenorrheic women were recruited and 30 participants met the criteria were randomized into GeGen Decoction or placebo group. After three consecutive menstrual cycles' treatments, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group. Both serum levels of AVP and E decreased after GeGen Decoction administration, while the placebo seemed to have little effect on either of the index. Moreover, after GeGen Decoction treatment, seven important metabolites were identified by metabolomic analysis compared to the placebo group. No abnormalities in blood biochemical and routine physical examination pre and post GeGen Decoction intervention were observed. CONCLUSIONS GeGen Decoction can remarkably relieve the severity of menstrual pain without obvious adverse effects. Its therapeutic effect on primary dysmenorrhea might be related to the regulation of pituitary hypothalamic ovarian hormones, and interfering with the metabolic change.",2020,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","['primary dysmenorrhea', 'primary dysmenorrheic patients', '71 primary dysmenorrheic women were recruited and 30 participants met the criteria']","['GeGen Decoction', 'traditional Chinese medicine formula GeGen decoction', 'GeGen Decoction or placebo', 'placebo']","['VAS score', 'pain intensity', 'blood biochemical and routine physical examination pre and post GeGen Decoction intervention', 'visual analogue scale (VAS', 'serum levels of arginine vasopressin (AVP) and estrogen (E', 'serum levels of AVP and E', 'efficacy and safety', 'severity of menstrual pain']","[{'cui': 'C0149875', 'cui_str': 'Primary dysmenorrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003779', 'cui_str': 'Argipressin'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0013390', 'cui_str': 'Dysmenorrhea'}]",71.0,0.369829,"After three consecutive menstrual cycles' treatment, the VAS score of the GeGen Decoction group was significantly lower than that of the placebo group.","[{'ForeName': 'Chengzhi', 'Initials': 'C', 'LastName': 'Chai', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Hong', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Shanxi University, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Zong', 'Affiliation': 'Hospital Affiliated to Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi Province, PR China.'}, {'ForeName': 'Changsong', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China.'}, {'ForeName': 'Zhigang', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'Department of Traditional Chinese Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu Province, PR China. Electronic address: liuzhigang729@seu.edu.cn.'}, {'ForeName': 'Boyang', 'Initials': 'B', 'LastName': 'Yu', 'Affiliation': 'Jiangsu Provincial Key Laboratory for TCM Evaluation and Translational Development, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China. Electronic address: boyangyu59@163.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113053'] 1571,32538835,Impact of Serum Calcium Levels on Alzheimer's Disease: A Mendelian Randomization Study.,"BACKGROUND Altered calcium homeostasis is hypothesized to underlie Alzheimer's disease (AD). However, it remains unclear whether serum calcium levels are genetically associated with AD risk. OBJECTIVE To develop effective therapies, we should establish the causal link between serum calcium levels and AD. METHODS Here, we performed a Mendelian randomization study to investigate the causal association of increased serum calcium levels with AD risk using the genetic variants from a large-scale serum calcium genome-wide association study (GWAS) dataset (61,079 individuals of European descent) and a large-scale AD GWAS dataset (54,162 individuals including 17,008 AD cases and 37,154 controls of European descent). Here, we selected the inverse-variance weighted (IVW) as the main analysis method. Meanwhile, we selected other three sensitivity analysis methods to examine the robustness of the IVW estimate. RESULTS IVW analysis showed that the increased serum calcium level (per 1 standard deviation (SD) increase 0.5 mg/dL) was significantly associated with a reduced AD risk (OR = 0.57, 95% CI 0.35-0.95, p = 0.031). Meanwhile, all the estimates from other sensitivity analysis methods were consistent with the IVW estimate in terms of direction and magnitude. CONCLUSION In summary, we provided evidence that increased serum calcium levels could reduce the risk of AD. Meanwhile, randomized controlled study should be conducted to clarify whether diet calcium intake or calcium supplement, or both could reduce the risk of AD.",2020,"Meanwhile, all the estimates from other sensitivity analysis methods were consistent with the IVW estimate in terms of direction and magnitude. ","['61,079 individuals of European descent) and a large-scale AD GWAS dataset (54,162 individuals including 17,008 AD cases and 37,154 controls of European descent', ""Alzheimer's Disease""]",['diet calcium intake or calcium supplement'],"['serum calcium level', 'reduced AD risk', 'serum calcium levels']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C2350277', 'cui_str': 'Genome Wide Association Studies'}, {'cui': 'C0150098', 'cui_str': 'Data Set'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0301595', 'cui_str': 'Calcium diet'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C3540037', 'cui_str': 'Calcium supplement'}]","[{'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.0667333,"Meanwhile, all the estimates from other sensitivity analysis methods were consistent with the IVW estimate in terms of direction and magnitude. ","[{'ForeName': 'Yating', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Department of Neurology and Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.'}, {'ForeName': 'Haihua', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wang', 'Affiliation': 'Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China.'}, {'ForeName': 'Zhifa', 'Initials': 'Z', 'LastName': 'Han', 'Affiliation': 'School of Medicine, School of Pharmaceutical Sciences, THU-PKU Center for Life Sciences, Tsinghua University, Beijing, China.'}, {'ForeName': 'Qing-Bin', 'Initials': 'QB', 'LastName': 'Ni', 'Affiliation': 'Postdoctoral Workstation, Taian City Central Hospital, Taian, Shandong, China.'}, {'ForeName': 'Kun', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Postdoctoral Workstation, Taian City Central Hospital, Taian, Shandong, China.'}, {'ForeName': 'Longcai', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Weifang Medical University, Weifang, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Pathology, The Affiliated Hospital of Weifang Medical University, Weifang, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'School of Life Science and Technology, Harbin Institute of Technology, Harbin, China.'}, {'ForeName': 'Shuilin', 'Initials': 'S', 'LastName': 'Jin', 'Affiliation': 'Department of Mathematics, Harbin Institute of Technology, Harbin, China.'}, {'ForeName': 'Bao-Liang', 'Initials': 'BL', 'LastName': 'Sun', 'Affiliation': 'Department of Neurology, The Second Affiliated Hospital; Key Laboratory of Cerebral Microcirculation in Universities of Shandong; Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, Shandong, China.'}, {'ForeName': 'Guiyou', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China.'}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-191249'] 1572,32534628,"Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.","BACKGROUND In animal models, immunity to mosquito salivary proteins protects animals against mosquito-borne disease. These findings provide a rationale to vaccinate against mosquito saliva instead of the pathogen itself. To our knowledge, no vector salivary protein-based vaccine has been tested for safety and immunogenicity in humans. We aimed to assess the safety and immunogenicity of Anopheles gambiae saliva vaccine (AGS-v), a peptide-based vaccine derived from four A gambiae salivary proteins, in humans. METHODS In this randomised, placebo-controlled, double-blind, phase 1 trial, participants were enrolled at the National Institutes of Health Clinical Center in Bethesda, MD, USA. Participants were eligible if they were healthy adults, aged 18-50 years with no history of severe allergic reactions to mosquito bites. Participants were randomly assigned (1:1:1), using block randomisation and a computer-generated randomisation sequence, to treatment with either 200 nmol of AGS-v vaccine alone, 200 nmol of AGS-v with adjuvant (Montanide ISA 51), or sterile water as placebo. Participants and clinicians were masked to treatment assignment. Participants were given a subcutaneous injection of their allocated treatment at day 0 and day 21, followed by exposure to feeding by an uninfected Aedes aegypti mosquito at day 42 to assess subsequent risk to mosquito bites in a controlled setting. The primary endpoints were safety and immunogenicity at day 42 after the first immunisation. Participants who were given at least one dose of assigned treatment were assessed for the primary endpoints and analysis was by intention to treat. The trial was registered with ClinicalTrials.gov, NCT03055000, and is closed for accrual. FINDINGS Between Feb 15 and Sept 10, 2017, we enrolled and randomly assigned 49 healthy adult participants to the adjuvanted vaccine (n=17), vaccine alone (n=16), or placebo group (n=16). Five participants did not complete the two-injection regimen with mosquito feeding at day 42, but were included in the safety analyses. No systemic safety concerns were identified; however, one participant in the adjuvanted vaccine group developed a grade 3 erythematous rash at the injection site. Pain, swelling, erythema, and itching were the most commonly reported local symptoms and were significantly increased in the adjuvanted vaccine group compared with both other treatment groups (nine [53%] of 17 participants in the adjuvanted vaccine group, two [13%] of 16 in the vaccine only group, and one [6%] of 16 in the placebo group; p=0·004). By day 42, participants who were given the adjuvanted vaccine had a significant increase in vaccine-specific total IgG antibodies compared with at baseline than did participants who were give vaccine only (absolute difference of log 10 -fold change of 0·64 [95% CI 0·39 to 0·89]; p=0·0002) and who were given placebo (0·62 [0·34 to 0·91]; p=0·0001). We saw a significant increase in IFN-γ production by peripheral blood mononuclear cells at day 42 in the adjuvanted vaccine group compared with in the placebo group (absolute difference of log 10 ratio of vaccine peptide-stimulated vs negative control 0·17 [95% CI 0·061 to 0·27]; p=0·009) but we saw no difference between the IFN-γ production in the vaccine only group compared with the placebo group (0·022 [-0·072 to 0·116]; p=0·63). INTERPRETATION AGS-v was well tolerated, and, when adjuvanted, immunogenic. These findings suggest that vector-targeted vaccine administration in humans is safe and could be a viable option for the increasing burden of vector-borne disease. FUNDING Office of the Director and the Division of Intramural Research at the National Institute of Allergy and Infectious Diseases, and National Institutes of Health.",2020,We saw a significant increase in IFN-γ production by peripheral blood mononuclear cells at day 42 in the adjuvanted vaccine group compared with in the placebo group (absolute difference of log 10 ratio of vaccine peptide-stimulated vs negative control 0·17,"['Participants were eligible if they were healthy adults, aged 18-50 years with no history of severe allergic reactions to mosquito bites', '49 healthy adult participants to the adjuvanted vaccine (n=17', 'Between Feb 15 and Sept 10, 2017', 'participants were enrolled at the National Institutes of Health Clinical Center in Bethesda, MD, USA']","['AGS-v vaccine alone, 200 nmol of AGS-v with adjuvant (Montanide ISA 51), or sterile water as placebo', 'vaccine alone', 'Anopheles gambiae saliva vaccine (AGS-v), a peptide-based vaccine', 'mosquito saliva peptide-based vaccine', 'placebo']","['Safety and immunogenicity', 'vaccine-specific total IgG antibodies', 'Pain, swelling, erythema, and itching', 'grade 3 erythematous rash', 'IFN-γ production', 'safety and immunogenicity', 'IFN-γ production by peripheral blood mononuclear cells']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332122', 'cui_str': 'No history of'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0417744', 'cui_str': 'Mosquito bite'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0027468', 'cui_str': 'United States National Institutes of Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439191', 'cui_str': 'nmol'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C1311732', 'cui_str': 'montanide ISA 51'}, {'cui': 'C0359299', 'cui_str': 'sterile water'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4047355', 'cui_str': 'Mosquito saliva'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0234913', 'cui_str': 'Rash erythematous'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}]",49.0,0.7465,We saw a significant increase in IFN-γ production by peripheral blood mononuclear cells at day 42 in the adjuvanted vaccine group compared with in the placebo group (absolute difference of log 10 ratio of vaccine peptide-stimulated vs negative control 0·17,"[{'ForeName': 'Jessica E', 'Initials': 'JE', 'LastName': 'Manning', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA. Electronic address: jessica.manning@nih.gov.'}, {'ForeName': 'Fabiano', 'Initials': 'F', 'LastName': 'Oliveira', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Iliano V', 'Initials': 'IV', 'LastName': 'Coutinho-Abreu', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Herbert', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Meneses', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Shaden', 'Initials': 'S', 'LastName': 'Kamhawi', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Holly Ann', 'Initials': 'HA', 'LastName': 'Baus', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Han', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Czajkowski', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Luz Angela', 'Initials': 'LA', 'LastName': 'Rosas', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Cervantes-Medina', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Rani', 'Initials': 'R', 'LastName': 'Athota', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Reed', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Allyson', 'Initials': 'A', 'LastName': 'Mateja', 'Affiliation': 'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, sponsored by the National Cancer Institute, National Institutes of Health, Frederick, MD, USA.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hunsberger', 'Affiliation': 'Biostatistics Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'James', 'Affiliation': 'SEEK, PepTcell, London, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Pleguezuelos', 'Affiliation': 'SEEK, PepTcell, London, UK.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Stoloff', 'Affiliation': 'SEEK, PepTcell, London, UK.'}, {'ForeName': 'Jesus G', 'Initials': 'JG', 'LastName': 'Valenzuela', 'Affiliation': 'Laboratory of Malaria and Vector Research, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Memoli', 'Affiliation': 'LID Clinical Studies Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)31048-5'] 1573,32536680,Erratum for A Comparison of the Weight Loss Effect between a Low-carbohydrate Diet and a Calorie-restricted Diet in Combination with Intragastric Balloon Therapy.,,2020,,[],['Low-carbohydrate Diet and a Calorie-restricted Diet in Combination with Intragastric Balloon Therapy'],[],[],"[{'cui': 'C0259836', 'cui_str': 'Carbohydrate restricted diet'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}, {'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],,0.0105694,,"[{'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Maekawa', 'Affiliation': 'Nagano Matsushiro General Hospital, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Niizawa', 'Affiliation': 'Nagano Matsushiro General Hospital, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Harada', 'Affiliation': 'Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.'}]","Internal medicine (Tokyo, Japan)",['10.2169/internalmedicine.E002-20'] 1574,32544846,"A fructose-based meal challenge to assess metabotypes and their metabolic risk profile: A randomized, crossover, controlled trial.","OBJECTIVES The first aim of this study was to determine the metabolic type of individuals based on the postprandial metabolic response after the ingestion of a meal challenge that was high protein and either high glucose (high GI) or fructose (low GI). The second aim was to compare the baseline characteristics between the different metabolic types (metabotypes). The third aim was to assess whether the inclusion of fructose or glucose in a high-protein breakfast modulated the glucose, insulin, and TG response over a 4-h period. METHODS The study included 46 Asian women with a body mass index between 17 and 28 kg/m 2 in a randomized crossover design. Metabolic typing was based on the assessment of the postprandial glycemic, insulin and triacylglycerol (TG) response after the ingestion of two high-protein meal challenges either high in fructose or glucose. Baseline characteristics were compared between the different metabolic types. Baseline and 4-h postprandial blood samples were collected and glucose, insulin, and TG levels were analyzed. Cluster analysis was used to phenotype the participants in distinct groups. Baseline characteristics including anthropometry, glycemic, and lipid profiles and resting metabolic rate were compared among the metabolic types. RESULTS Cluster analysis revealed that women could be grouped into three metabolic types based on postprandial glucose, insulin, and TG response after the fructose meal challenge: cluster 1 with an average glucose + high TG response (highTG; n = 12), cluster 2 with a high glucose + average TG response (highGLU; n = 8), and cluster 3 with an average glucose + average TG response (Avg; n = 26). Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. CONCLUSIONS Three metabolic types with a distinct metabolic response could be distinguished after a high fructose meal. The results suggest a different risk profile and may indicate why some people develop diabetes in an obesogenic environment. Improved metabolic-type assessments will enable us to develop and optimize nutritional and medical interventions for individuals with differing diabetes risk.",2020,"Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. ","['46 Asian women with a body mass index between 17 and 28 kg/m 2', 'individuals with differing diabetes risk']","['high glucose (high GI) or fructose (low GI', 'fructose-based meal challenge']","['waist-to-hip ratio', 'fasting blood glucose, body mass index, fat percentage, and hip circumference', 'glucose, insulin, and TG levels', 'glucose, insulin, and TG response', 'postprandial glycemic, insulin and triacylglycerol (TG) response', 'Baseline and 4-h postprandial blood samples', 'postprandial glucose, insulin, and TG response', 'anthropometry, glycemic, and lipid profiles and resting metabolic rate', 'postprandial metabolic response']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0860803', 'cui_str': 'Glucose increased'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0016745', 'cui_str': 'Fructose'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}]",46.0,0.0341195,"Post hoc analysis revealed significantly greater waist-to-hip ratio and a worse lipid profile for the highTG cluster and a higher fasting blood glucose, body mass index, fat percentage, and hip circumference in the highGLU cluster. ","[{'ForeName': 'Stefan Gerardus', 'Initials': 'SG', 'LastName': 'Camps', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Huann Rong', 'Initials': 'HR', 'LastName': 'Koh', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Nan Xin', 'Initials': 'NX', 'LastName': 'Wang', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore.'}, {'ForeName': 'Christiani Jeyakumar', 'Initials': 'CJ', 'LastName': 'Henry', 'Affiliation': 'Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research and National University Health System, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: jeya_henry@sifbi.a-star.edu.sg.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110799'] 1575,32544854,Effect of ZNF804A gene polymorphism (rs1344706) on the plasticity of the functional coupling between the right dorsolateral prefrontal cortex and the contralateral hippocampal formation.,"ZNF804A has now been recognized as a schizophrenia risk gene by multiple genome-wide association studies with its intronic polymorphism rs1344706 being reported as the first genome-wide significant risk variant for schizophrenia. Although the functional impact of this gene is still unknown, rs1344706's contribution to the functional coupling between the right dorsolateral prefrontal cortex (DLPFC) and the contralateral hippocampal formation (HF) has been reported by several studies. The current study tested whether the right DLPFC-left HF functional coupling showed plasticity during cognitive training (Study I) and whether rs1344706 affected the plasticity (Study II). In Study I, we conducted a randomized controlled trial with 30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group). All subjects were scanned using fMRI before and after the training. Analyses of resting-state and task-state fMRI data consistently showed that the adaptive memory span training significantly strengthened the right DLPFC-left HF functional coupling. In Study II, we conducted a genetic association study with 101 subjects (combining the data from the training group in Study I with those from an additional subsequent sample of 71 subjects who received the same training and fMRI scans). Results showed that rs1344706 was significantly associated with training-induced changes in functional coupling. Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes. These findings expanded our current understanding of the functional impact of the schizophrenia risk variant of ZNF804A gene and suggested that the ZNF804A gene could be used as a prospective target for future antipsychotic drugs and clinical research.",2020,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"['101 subjects (combining the data from the training group in Study', '71 subjects who received the same training and fMRI scans', '30 subjects receiving 20 sessions of adaptive training on a memory span task (the training group) and 30 subjects practicing on a non-adaptive easy version of the same memory span task for 20 sessions (the control group']","['ZNF804A', 'ZNF804A gene polymorphism (rs1344706']",['functional coupling'],"[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}]",101.0,0.0118036,Subjects carrying the non-risk allele (C) of rs1344706 showed greater training-induced plasticity than the risk allele (A) homozygotes.,"[{'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiongying', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qiumei', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China; School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Boqi', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Xiaoxiang', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'School of Mental Health, Jining Medical University, 45# Jianshe South Road, Jining 272013, Shandong Province, PR China.'}, {'ForeName': 'Yu-Tao', 'Initials': 'YT', 'LastName': 'Xiang', 'Affiliation': 'Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, PR China.'}, {'ForeName': 'Chuanyue', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders & Beijing Institute for Brain Disorders Center of Schizophrenia, Beijing Anding Hospital, Capital Medical University, Beijing 100088, PR China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China.'}, {'ForeName': 'Chuansheng', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Psychological Science, University of California, Irvine, CA 92697, United States.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, PR China. Electronic address: lijundp@bnu.edu.cn.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102279'] 1576,32556960,Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial.,"BACKGROUND To evaluate the efficacy of adjuvant systemic corticosteroids in reducing kidney scarring. A previous study suggested that use of adjuvant systemic corticosteroids reduces kidney scarring in children radiologically confirmed to have extensive pyelonephritis. Efficacy of corticosteroids for children with febrile urinary tract infection (UTI) has not been studied. METHODS Children aged 2 months to 6 years with their first febrile UTI were randomized to corticosteroids or placebo for 3 days (both arms received antimicrobial therapy); kidney scarring was assessed using 99m Tc-dimercaptosuccinic acid kidney scan 5-24 months after the initial UTI. RESULTS We randomized 546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned). Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1). CONCLUSION While children randomized to adjuvant corticosteroids tended to develop fewer kidney scars than children who were randomized to receive placebo, a statistically significant difference was not achieved. However, the study was limited by not reaching its intended sample size. CLINICAL TRIAL REGISTRATION Clinicaltrials.gov, NCT01391793, Registered 7/12/2011 Graphical abstract.",2020,"Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1). ","['children with febrile urinary tract infection (UTI', 'Children aged 2\xa0months to 6\xa0years with their first febrile UTI', 'children with a febrile urinary tract infection', '546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned']","['adjuvant systemic corticosteroids', 'corticosteroids or placebo', 'corticosteroids', 'Corticosteroids', 'antimicrobial therapy); kidney scarring was assessed using 99m', 'placebo']","['kidney scarring', 'kidney scars', 'Rates of kidney scarring']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3875265', 'cui_str': 'Febrile urinary tract infection'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C4517751', 'cui_str': '385'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0412412', 'cui_str': 'Kidney imaging with function study'}, {'cui': 'C4517711', 'cui_str': '320'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0017658', 'cui_str': 'Glomerulonephritis'}]","[{'cui': 'C0017658', 'cui_str': 'Glomerulonephritis'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}]",546.0,0.616011,"Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1). ","[{'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Shaikh', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. nader.shaikh@chp.edu.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Shope', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Hoberman', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Gysella B', 'Initials': 'GB', 'LastName': 'Muniz', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Sonika', 'Initials': 'S', 'LastName': 'Bhatnagar', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Nowalk', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Hickey', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Marian G', 'Initials': 'MG', 'LastName': 'Michaels', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Kearney', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Howard E', 'Initials': 'HE', 'LastName': 'Rockette', 'Affiliation': 'Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Charron', 'Affiliation': 'Department of Radiology, Virginia Commonwealth University, Richmond, VA, USA.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Lim', 'Affiliation': 'Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Massoud', 'Initials': 'M', 'LastName': 'Majd', 'Affiliation': ""Children's National Health System, Washington, DC, USA.""}, {'ForeName': 'Eglal', 'Initials': 'E', 'LastName': 'Shalaby-Rana', 'Affiliation': ""Children's National Health System, Washington, DC, USA.""}, {'ForeName': 'Marcia', 'Initials': 'M', 'LastName': 'Kurs-Lasky', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Cohen', 'Affiliation': ""Nationwide Children's Hospital, Columbus, OH, USA.""}, {'ForeName': 'Ellen R', 'Initials': 'ER', 'LastName': 'Wald', 'Affiliation': 'University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Lockhart', 'Affiliation': ""Hasbro Children's Hospital, Alpert Medical School, Providence, RI, USA.""}, {'ForeName': 'Hans G', 'Initials': 'HG', 'LastName': 'Pohl', 'Affiliation': ""Children's National Health System, Washington, DC, USA.""}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Martin', 'Affiliation': 'University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.'}]","Pediatric nephrology (Berlin, Germany)",['10.1007/s00467-020-04622-3'] 1577,32552310,A randomised phase II trial testing the acceptability and feasibility of a narrative approach to public health communication to increase community engagement with palliative care.,"BACKGROUND Communities have limited understanding of palliative care, creating barriers to informed choice around consideration of a full range of care options in the event of serious illness. Few empirically tested interventions are available to educate community about palliative care, and ultimately improve timely access to these services. AIM To test the acceptability (primary outcome), and feasibility of a narrative approach to public health communication seeking to improve attitudes to possible access to palliative care in the event of serious illness. DESIGN Randomised phase II trial with six parallel experimental conditions. Outcomes tested included measures of acceptability, feasibility and change in attitudes to possible access to palliative care post-intervention. Contrasts planned for exploratory testing included format, message content and narrator. SETTING/PARTICIPANTS Community-based sample of consecutive English-speaking adults who volunteered their participation in response to a study advertisement distributed online through established community groups. RESULTS A narrative approach to public health communication was found to be acceptable to community members, and feasible to deliver online. Exploratory data suggested it immediately improved attitudes towards possible access to palliative care in the event of serious illness, with the narrative detailing a description of the evidence delivered by a healthcare professional appearing to be the most promising strategy. CONCLUSIONS This study provides preliminary data to inform a future, longitudinal trial evaluating effectiveness and ultimately other evidence-based, public health approaches to improve community engagement with palliative care. Further studies are required to confirm the generalisability of findings to a broader representative sample and other settings including internationally.",2020,"Exploratory data suggested it immediately improved attitudes towards possible access to palliative care in the event of serious illness, with the narrative detailing a description of the evidence delivered by a healthcare professional appearing to be the most promising strategy. ",['Community-based sample of consecutive English-speaking adults who volunteered their participation in response to a study advertisement distributed online through established community groups'],"['narrative approach to public health communication seeking', 'narrative approach to public health communication']","['acceptability, feasibility and change in attitudes to possible access to palliative care post-intervention']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1135957', 'cui_str': 'Narration'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0332149', 'cui_str': 'Possible'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",6.0,0.0851889,"Exploratory data suggested it immediately improved attitudes towards possible access to palliative care in the event of serious illness, with the narrative detailing a description of the evidence delivered by a healthcare professional appearing to be the most promising strategy. ","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Collins', 'Affiliation': ""Department of Medicine, St Vincent's Hospital, The University of Melbourne, Fitzroy, VIC, Australia.""}, {'ForeName': 'Sue-Anne', 'Initials': 'SA', 'LastName': 'McLachlan', 'Affiliation': ""Medical Oncology, St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia.""}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Hill', 'Affiliation': 'Moonshine Agency, Cremorne, VIC, Australia.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Collins', 'Affiliation': 'Moonshine Agency, Cremorne, VIC, Australia.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Philip', 'Affiliation': ""Department of Medicine, St Vincent's Hospital, The University of Melbourne, Fitzroy, VIC, Australia.""}]",Palliative medicine,['10.1177/0269216320932766'] 1578,32556595,Preliminary evidence of effects of potassium chloride on a metabolomic path to diabetes and cardiovascular disease.,"INTRODUCTION Low potassium intake can affect cardiovascular disease (CVD) risk and cardiometabolic risk factors. OBJECTIVE We hypothesize that potassium chloride (KCl) supplementation can improve cardiovascular risk metabolomic profile. METHODS In this secondary analysis of a pilot randomized clinical trial (RCT) of 26 participants with prediabetes randomized to KCl or placebo, we performed targeted mass-spectrometry-based metabolomic profiling on baseline and 12-week (end-of-study) plasma samples. Principal component analysis (PCA) was used to reduce the many correlated metabolites into fewer, independent factors that retain most of the information in the original data. RESULTS Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11). CONCLUSIONS KCl supplementation may improve circulating BCAA levels, which may reflect improvements in overall cardiometabolic risk profile. CLINICAL TRIALS REGISTRY Clinicaltrials.gov identifier: NCT02236598; https://clinicaltrials.gov/ct2/show/NCT02236598.",2020,"Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11). ",['26 participants with prediabetes randomized to'],"['potassium chloride (KCl) supplementation', 'potassium chloride', 'KCl supplementation', 'KCl or placebo']","['circulating BCAA levels', 'short-chain acylcarnitines (SCA) factor', 'metabolomic path to diabetes and cardiovascular disease', 'cardiovascular risk metabolomic profile', 'overall cardiometabolic risk profile', 'valine levels']","[{'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}]","[{'cui': 'C0032825', 'cui_str': 'Potassium Chloride'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0002521', 'cui_str': 'Branched-chain amino acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0368608', 'cui_str': 'Acylcarnitine'}, {'cui': 'C1328813', 'cui_str': 'Metabolomics'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0042285', 'cui_str': 'Valine'}]",26.0,0.492144,"Those taking KCl had significant reductions (corresponding to lower cardiovascular risk) in the branched-chain amino acids (BCAA) factor (P = 0.004) and in valine levels (P = 0.02); and non-significant reductions in short-chain acylcarnitines (SCA) factor (P = 0.11). ","[{'ForeName': 'Ranee', 'Initials': 'R', 'LastName': 'Chatterjee', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA. ranee.chatterjee@duke.edu.'}, {'ForeName': 'Clemontina A', 'Initials': 'CA', 'LastName': 'Davenport', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Kwee', 'Affiliation': 'Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': ""D'Alessio"", 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Laura P', 'Initials': 'LP', 'LastName': 'Svetkey', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Pao-Hwa', 'Initials': 'PH', 'LastName': 'Lin', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Cris A', 'Initials': 'CA', 'LastName': 'Slentz', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Ilkayeva', 'Affiliation': 'Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Johnson', 'Affiliation': 'Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Edelman', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}, {'ForeName': 'Svati H', 'Initials': 'SH', 'LastName': 'Shah', 'Affiliation': 'Department of Medicine, Duke University, 200 Morris Street, 3rd Floor, Durham, NC, 27701, USA.'}]",Metabolomics : Official journal of the Metabolomic Society,['10.1007/s11306-020-01696-w'] 1579,32554133,A video-game based cognitive training for breast cancer survivors with cognitive impairment: A prospective randomized pilot trial.,"INTRODUCTION We investigated whether a web-based cognitive training video game is an effective approach to improve cognitive decline in combination with our standard of care for rehabilitation of breast cancer (BC) patients. MATERIALS AND METHODS Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied. The patients received access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™). The early intervention group (n = 23) had a training program of 6 months of at least three times a week for a minimum of 60 min of game playing per week at home in addition to standard of care rehabilitation. The delayed intervention (n = 23) received standard of care for three months, followed by three months of similar MyCQ training. Outcome measures were the MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests. RESULTS At baseline the means for CFQ (a measure of self-reported cognitive failure), anxiety, PSQI and self-reflectiveness were beyond normal range in both groups. CFQ improved significantly better in the intervention group (p = 0.029). Combining the evolution over time in the entire population a significant improvement was seen for overall MyCQ score, level of fear, physical and emotional role limitation, and health change (all p < 0.05), but self-reflectivess deteriorated (p < 0.05)). Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N back 1 and 2 (all p < 0.05). CONCLUSION A program of cognitive training improves cognitive functioning over time. ""Aquasnap"" has a beneficial effect on the perception of subjective cognitive functioning (CFQ) but the exact role of video gaming in this process remains uncertain.",2020,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","['Self-selected BC patients between 18 and 71 years old complaining of disturbing cognitive impairment were studied', 'breast cancer (BC) patients', 'breast cancer survivors with cognitive impairment']","['video-game based cognitive training', 'cognitive training', 'web-based cognitive training video game', 'MyCQ training', 'access to a web-based internet video game and online cognitive assessments (Aquasnap, Cambridge, MyCQ™']","['speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N', 'cognitive failure), anxiety, PSQI and self-reflectiveness', 'cognitive functioning', 'MyCQ (sub)scores and Activity of Daily Life (ADL), mood, subjective cognition and functional cognitive status measured by classic neuropsychological tests', 'overall MyCQ score, level of fear, physical and emotional role limitation, and health change', 'CFQ']","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0542316', 'cui_str': 'Visual memory'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319227', 'cui_str': 'Level of fear'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.0411642,"Significant differences in the various MyCQ subtests over time were: improved speed in choice reaction time, visual memory recognition, N back 1 and 2, coding, trail making test B, improved accuracy of N","[{'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bellens', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Roelant', 'Affiliation': 'Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, B2650, Belgium; StatUa, Center for Statistics, University of Antwerp, Antwerp, B2000, Belgium.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Sabbe', 'Affiliation': 'Department of Psychiatry, Antwerp University, Wilrijk, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Peeters', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'van Dam', 'Affiliation': 'Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, B2650, Belgium; Centre for Oncological Research (CORE), University of Antwerp, Wilrijk, B2610, Belgium. Electronic address: peter.vandam@telenet.be.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.003'] 1580,32554173,Neuroendocrine biomarkers of prolonged exposure treatment response in military-related PTSD.,"Posttraumatic stress disorder (PTSD) is associated with dysregulation of the neuroendocrine system, including cortisol, allopregnanolone, and pregnanolone. Preliminary evidence from animal models suggests that baseline levels of these biomarkers may predict response to PTSD treatment. We report the change in biomarkers over the course of PTSD treatment. Biomarkers were sampled from individuals participating in (1) a randomized controlled trial comparing a web-version of Prolonged Exposure (Web-PE) therapy to in-person Present-Centered Therapy (PCT) and (2) from individuals participating in a nonrandomized effectiveness study testing PE delivered in-person as part of an intensive outpatient PTSD program. We found that higher cortisol reactivity during script-driven imagery was associated with higher baseline PTSD severity and that baseline allopregnanolone, pregnanolone, and cortisol reactivity were associated with degree of symptom change over the course of intensive outpatient treatment. These findings demonstrate that peripherally assessed biomarkers are associated with PTSD severity and likelihood of successful treatment outcome of PE delivered daily over two weeks. These assessments could be used to determine which patients are likely to respond to treatment and which patients require augmentation to increase the likelihood of optimal response to PTSD treatment.",2020,"Posttraumatic stress disorder (PTSD) is associated with dysregulation of the neuroendocrine system, including cortisol, allopregnanolone, and pregnanolone.","['military-related PTSD', 'Posttraumatic stress disorder (PTSD']","['web-version of Prolonged Exposure (Web-PE) therapy to in-person Present-Centered Therapy (PCT', 'pregnanolone']",['higher cortisol reactivity'],"[{'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033008', 'cui_str': '3 alpha, 5 beta-Tetrahydroprogesterone'}]","[{'cui': 'C0541847', 'cui_str': 'Cortisol increased'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}]",,0.0279829,"Posttraumatic stress disorder (PTSD) is associated with dysregulation of the neuroendocrine system, including cortisol, allopregnanolone, and pregnanolone.","[{'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA, 30033, USA; Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: sheila.a.m.rauch@emory.edu.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Sripada', 'Affiliation': 'VA Ann Arbor Healthcare System, 2215 Fuller Road, Ann Arbor, MI, 48105, USA; University of Michigan, Department of Psychiatry, 4250 Plymouth Road, Ann Arbor, MI, 48109, USA. Electronic address: rekaufma@med.umich.edu.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Burton', 'Affiliation': 'Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: mark.steven.burton@emory.edu.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Michopoulos', 'Affiliation': 'Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: vmichop@emory.edu.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Kerley', 'Affiliation': 'Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: kimberly.kerley@emory.edu.'}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Marx', 'Affiliation': 'Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, 40 Duke Medicine Circle, Durham, NC, 27710, USA; Durham Veterans Administration Medical Center and VA Mid-Atlantic MIRECC, 508 Fulton Street, Durham, NC, 27705, USA. Electronic address: christine.marx@duke.edu.'}, {'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Kilts', 'Affiliation': 'Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, 40 Duke Medicine Circle, Durham, NC, 27710, USA; Durham Veterans Administration Medical Center and VA Mid-Atlantic MIRECC, 508 Fulton Street, Durham, NC, 27705, USA. Electronic address: jason.kilts@duke.edu.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Naylor', 'Affiliation': 'Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, 40 Duke Medicine Circle, Durham, NC, 27710, USA; Durham Veterans Administration Medical Center and VA Mid-Atlantic MIRECC, 508 Fulton Street, Durham, NC, 27705, USA. Electronic address: jennifer.naylor@duke.edu.'}, {'ForeName': 'Barbara O', 'Initials': 'BO', 'LastName': 'Rothbaum', 'Affiliation': 'Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, 12 Executive Park, 3rd Floor, Atlanta, GA, 30029, USA. Electronic address: brothba@emory.edu.'}, {'ForeName': 'Carmen P', 'Initials': 'CP', 'LastName': 'McLean', 'Affiliation': 'National Center for PTSD, Dissemination and Training Division, VA Palo Alto Health Care System, 795 Willow Rd, Menlo Park, CA, 94025, USA; Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, 291 Campus Dr., Stanford, CA, 94305, USA. Electronic address: Carmen.McLean4@va.gov.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Smith', 'Affiliation': 'Emory University School of Medicine, Department of Obstetrics and Gynecology, 101 Woodruff Circle NE, Ste 4217, Atlanta, 30322, USA. Electronic address: alicia.smith@emory.edu.'}, {'ForeName': 'Seth D', 'Initials': 'SD', 'LastName': 'Norrholm', 'Affiliation': 'Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA, 30033, USA; Wayne State University, 3901 Chrysler Dr, Detroit, MI, 48201, USA. Electronic address: SNorrholm@wayne.edu.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Jovanovic', 'Affiliation': 'Wayne State University, 3901 Chrysler Dr, Detroit, MI, 48201, USA. Electronic address: tjovanovic@med.wayne.edu.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Liberzon', 'Affiliation': 'Texas A&M University, 8447 Riverside Parkway, Bryan, TX, 77808-3260, USA. Electronic address: liberzon@tamu.edu.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Williamson', 'Affiliation': 'Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, 40 Duke Medicine Circle, Durham, NC, 27710, USA; Durham Veterans Administration Medical Center and VA Mid-Atlantic MIRECC, 508 Fulton Street, Durham, NC, 27705, USA. Electronic address: douglas.williamson@duke.edu.'}, {'ForeName': 'Col Jeffrey S', 'Initials': 'CJS', 'LastName': 'Yarvis', 'Affiliation': 'Carl R. Darnall Army Medical Center, Department of Behavioral Health, 36065 Santa Fe Ave., Fort Hood, TX, 76544, USA. Electronic address: jeffrey.s.yarvis.mil@mail.mil.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Dondanville', 'Affiliation': 'University of Texas Health Science Center at San Antonio, Department of Psychiatry and Behavioral Sciences, 7703 Floyd Curl Dr., San Antonio, TX, 78229, USA. Electronic address: Dondanville@uthscsa.edu.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Young-McCaughan', 'Affiliation': 'University of Texas Health Science Center at San Antonio, Department of Psychiatry and Behavioral Sciences, 7703 Floyd Curl Dr., San Antonio, TX, 78229, USA. Electronic address: youngs1@uthscsa.edu.'}, {'ForeName': 'Terence M', 'Initials': 'TM', 'LastName': 'Keane', 'Affiliation': 'VA Boston Healthcare System, National Center for PTSD (116B-2), 150 South Huntington Avenue, Boston, MA, 02130, USA; Boston University School of Medicine, Department of Psychiatry, 720 Harrison Avenue, Room 906, Boston, MA, 02118, USA. Electronic address: Terry.Keane@va.gov.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Peterson', 'Affiliation': 'University of Texas Health Science Center at San Antonio, Department of Psychiatry and Behavioral Sciences, 7703 Floyd Curl Dr., San Antonio, TX, 78229, USA; South Texas Veterans Health Care System, Research and Development Service, 7400 Merton Minter, San Antonio, TX, 78229, USA; University of Texas at San Antonio, Department of Psychology, One UTSA Circle, San Antonio, TX, 78249, USA. Electronic address: petersona3@uthscsa.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104749'] 1581,32578279,Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07).,"OBJECTIVE We compared patients' preferences for intravenous (IV-t) versus subcutaneous (SC-t) trastuzumab administration. METHODS Phase III, open-label, multicentre study in HER2-positive metastatic breast cancer. Patients were receiving IV-t for at least 4 months without progression. Randomisation was 1:1 to administer 2 cycles of SC-t with vial followed by 2 cycles with single injection device (SID) or the reverse sequence (600mg SC-t every 3 weeks for 4 cycles). PRIMARY OBJECTIVE patients' preference for IV-t versus SC-t; secondary objectives: patients' preference for vial versus SID, healthcare professional (HCP) preference and safety. RESULTS We randomised 166 patients in 26 sites. Median number of previous lines of chemotherapy and/or endocrine therapy was 1 (1-7). Median duration of prior IV-t was 1.8 years (0.3-14). Of the159 patients completing the questionnaires, 86.2% preferred SC-t, 6.9% preferred IV-t, and 6.9% had no preference. Patients preferred SID (59.2%) over vial (26.3%). Most (87.2%) HCP preferred SC-t of whom 51.3% and 28.2% preferred SID and vial respectively. Related adverse events included G1-2 injection site reactions in 18 patients (10.8%), G1 pain in 8 (4.8%), G1-2 allergic reaction in 2 (1.2%), one G3 heart failure and 1 G2 ejection fraction decrease. CONCLUSIONS SC-t is preferred with no safety impact.",2020,"Related adverse events included G1-2 injection site reactions in 18 patients (10.8%), G1 pain in 8 (4.8%), G1-2 allergic reaction in 2 (1.2%), one G3 heart failure and 1 G2 ejection fraction decrease. ","['HER2-positive metastatic breast cancer patients', 'HER2-positive metastatic breast cancer', '166 patients in 26 sites']","['chemotherapy and/or endocrine therapy', 'intravenous (IV-t) versus subcutaneous (SC-t) trastuzumab administration', 'subcutaneous versus intravenous trastuzumab']","['G1-2 allergic reaction', ' preference for vial versus SID, healthcare professional (HCP) preference and safety', 'Median duration of prior IV-t', 'G1 pain', 'G3 heart failure and 1 G2 ejection fraction decrease']","[{'cui': 'C4721209', 'cui_str': 'Metastatic human epidermal growth factor 2 positive carcinoma of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C5191361', 'cui_str': '166'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0728747', 'cui_str': 'trastuzumab'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C1706398', 'cui_str': 'Vial - unit of product usage'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0794888', 'cui_str': 'Injection device'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0743400', 'cui_str': 'Ejection fraction decreased'}]",,0.0805355,"Related adverse events included G1-2 injection site reactions in 18 patients (10.8%), G1 pain in 8 (4.8%), G1-2 allergic reaction in 2 (1.2%), one G3 heart failure and 1 G2 ejection fraction decrease. ","[{'ForeName': 'Eva M', 'Initials': 'EM', 'LastName': 'Ciruelos', 'Affiliation': 'Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Montaño', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'César A', 'Initials': 'CA', 'LastName': 'Rodríguez', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Encarnación', 'Initials': 'E', 'LastName': 'González-Flores', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Lluch', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Laia', 'Initials': 'L', 'LastName': 'Garrigós', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Vanesa', 'Initials': 'V', 'LastName': 'Quiroga', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Antón', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Malón', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Chacón', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Velasco', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Gonzalez-Cortijo', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Jolis', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'María J', 'Initials': 'MJ', 'LastName': 'Echarri', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Montse', 'Initials': 'M', 'LastName': 'Muñoz', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Pascual', 'Affiliation': 'Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Amigo', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Maribel', 'Initials': 'M', 'LastName': 'Casas', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Carrasco', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Casas', 'Affiliation': 'GEICAM Spanish Breast Cancer Group, Madrid, Spain.'}]",European journal of cancer care,['10.1111/ecc.13253'] 1582,32683565,"Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).","PURPOSE Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). In the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC. Here, we present the final overall survival (OS) and updated safety results. METHODS Postmenopausal women with ER+/HER2- ABC were randomized 1:1 to receive either palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous) or letrozole alone (2.5 mg/day, continuous). The primary endpoint was investigator-assessed PFS; secondary endpoints included OS and safety. RESULTS A total of 165 patients were randomized. At the data cutoff date of December 30, 2016 (median duration of follow-up, 64.7 months), the stratified hazard ratio for OS was 0.897 (95% CI 0.623-1.294; P = 0.281); median OS in the palbociclib plus letrozole and letrozole alone arms was 37.5 and 34.5 months, respectively. The median time from randomization to first subsequent chemotherapy use was longer with palbociclib plus letrozole than letrozole alone (26.7 and 17.7 months, respectively). The most frequently reported adverse event in the palbociclib plus letrozole arm was neutropenia (any grade, 75%; grade 3 or 4, 59%). CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).",2020,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","['women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC', '165 patients were randomized', 'postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC', 'Postmenopausal women with ER+/HER2- ABC']","['letrozole versus letrozole', 'endocrine therapy', 'letrozole', 'palbociclib', 'letrozole alone', 'palbociclib plus letrozole', 'Palbociclib plus letrozole']","['median time', 'neutropenia', 'median OS', 'Overall survival', 'stratified hazard ratio for OS', 'investigator-assessed PFS; secondary endpoints included OS and safety', 'final overall survival (OS) and updated safety results', 'prolonged progression-free survival (PFS']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C4319555', 'cui_str': '165'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0279754', 'cui_str': 'ESR1 positive'}]","[{'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy'}, {'cui': 'C3853822', 'cui_str': 'palbociclib'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]",165.0,0.0903289,"CONCLUSIONS Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS.","[{'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Finn', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu.'}, {'ForeName': 'Katalin', 'Initials': 'K', 'LastName': 'Boer', 'Affiliation': 'Onkologia, Szent Margit Korhaz, Budapest, Hungary.'}, {'ForeName': 'Igor', 'Initials': 'I', 'LastName': 'Bondarenko', 'Affiliation': 'Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.'}, {'ForeName': 'Ravindranath', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Comprehensive Blood and Cancer Center, Bakersfield, CA, USA.'}, {'ForeName': 'Tamas', 'Initials': 'T', 'LastName': 'Pinter', 'Affiliation': 'Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Schmidt', 'Affiliation': 'Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.'}, {'ForeName': 'Yaroslav V', 'Initials': 'YV', 'LastName': 'Shparyk', 'Affiliation': 'Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Thummala', 'Affiliation': 'Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.'}, {'ForeName': 'Nataliia', 'Initials': 'N', 'LastName': 'Voitko', 'Affiliation': 'Kyiv City Clinical Oncology Center, Kyiv, Ukraine.'}, {'ForeName': 'Eustratios', 'Initials': 'E', 'LastName': 'Bananis', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'McRoy', 'Affiliation': 'Pfizer Inc, New York, NY, USA.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Wilner', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Sindy', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Pfizer Inc, San Diego, CA, USA.'}, {'ForeName': 'Dennis J', 'Initials': 'DJ', 'LastName': 'Slamon', 'Affiliation': 'David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Ettl', 'Affiliation': 'Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05755-7'] 1583,32442673,Salivary oxytocin after oxytocin administration: Examining the moderating role of childhood trauma.,"Although oxytocin administration influences behavior, its effects on peripheral oxytocin concentrations are mixed and derived from studies on healthy subjects. Additionally, trauma attenuates the behavioral effects of oxytocin, but it is unknown whether it also influences its effect on peripheral circulation. This study examined whether salivary oxytocin increased after oxytocin administration and whether trauma attenuated this effect. We conducted a randomized, double-blind, placebo-controlled, within-subjects study in 100 male adolescents living in residential youth care facilities. Participants self-administered intranasally 24 IU of oxytocin and placebo (one week later) and provided a saliva sample before and 15 min after administration. Salivary oxytocin increased significantly after oxytocin administration, but this effect might be inflated by exogenous oxytocin reaching the throat. Trauma did not moderate this effect. Our findings suggest that trauma did not attenuate the effect of oxytocin administration on salivary oxytocin, but more robust methodologies are recommended to draw more solid conclusions.",2020,Trauma did not moderate this effect.,"['100 male adolescents living in residential youth care facilities', 'healthy subjects']","['oxytocin', 'salivary oxytocin', 'Salivary oxytocin', 'oxytocin and placebo', 'placebo']","['Salivary oxytocin', 'peripheral oxytocin concentrations']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",100.0,0.442201,Trauma did not moderate this effect.,"[{'ForeName': 'Iro', 'Initials': 'I', 'LastName': 'Fragkaki', 'Affiliation': 'Radboud University, Behavioural Science Institute, Montessorilaan 3, 6525 HR, Nijmegen, the Netherlands. Electronic address: i.fragkaki@pwo.ru.nl.'}, {'ForeName': 'Jeffrey C', 'Initials': 'JC', 'LastName': 'Glennon', 'Affiliation': 'Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands.'}, {'ForeName': 'Maaike', 'Initials': 'M', 'LastName': 'Cima', 'Affiliation': 'Radboud University, Behavioural Science Institute, Montessorilaan 3, 6525 HR, Nijmegen, the Netherlands.'}]",Biological psychology,['10.1016/j.biopsycho.2020.107903'] 1584,30123942,Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.,"BACKGROUND AND OBJECTIVES Risankizumab is a humanized anti-interleukin-23 monoclonal antibody in development for the treatment of several inflammatory diseases. This work characterized the pharmacokinetics of risankizumab and evaluated covariates that may affect its exposures using phase I and II trial data in subjects with psoriasis and Crohn's disease. METHODS Plasma concentration measurements from a phase I study and a phase II study in subjects with psoriasis (n = 157; single doses of 0.01-5 mg/kg intravenously, 0.25-1 mg/kg subcutaneously, and 18 mg subcutaneously, and multiple doses of 90 and 180 mg subcutaneously), and a phase II study in subjects with Crohn's disease (n = 115; doses of 200 or 600 mg intravenously every 4 weeks followed by 180 mg subcutaneously every 8 weeks) were analyzed using non-linear mixed-effects modeling. The model was qualified using bootstrap and simulation-based diagnostics. RESULTS A two-compartment model with first-order absorption and elimination described the pharmacokinetics of risankizumab. Considering the body weight and baseline albumin central tendency differences between disease populations, risankizumab clearance, steady-state volume of distribution, and terminal-phase elimination half-life were estimated to be approximately 0.35 L/day, 11.7 L, and 27 days, respectively, for a typical 90-kg subject with psoriasis with an albumin level of 42 g/L, and 0.31 L/day, 8.45 L, and 22 days, respectively, for a typical 65-kg subject with Crohn's disease with an albumin level of 37 g/L. Risankizumab absolute subcutaneous bioavailability and absorption rate constant were 72% and 0.18 day -1 , respectively. Inter-individual variability for clearance was 37%. CONCLUSIONS Risankizumab displayed pharmacokinetic characteristics typical for an IgG1 monoclonal antibody with no apparent target-mediated disposition. Accounting for the effects of body weight and baseline albumin explained the small differences in the pharmacokinetics of risankizumab between psoriasis and Crohn's disease, with no further differences between the patient populations.",2019,"Inter-individual variability for clearance was 37%. ","[""subjects with psoriasis and Crohn's disease"", ""Subjects with Psoriasis and Crohn's Disease"", 'subjects with psoriasis (n\u2009=\u2009157']","['single doses of 0.01-5\xa0mg/kg intravenously, 0.25-1\xa0mg/kg subcutaneously, and 18\xa0mg subcutaneously, and multiple doses of 90 and 180\xa0mg subcutaneously', 'Interleukin-23 Inhibitor Risankizumab']","['risankizumab clearance, steady-state volume of distribution, and terminal-phase elimination half-life', 'Risankizumab absolute subcutaneous bioavailability and absorption rate constant']","[{'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C4505511', 'cui_str': 'risankizumab'}]","[{'cui': 'C4505511', 'cui_str': 'risankizumab'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0205361', 'cui_str': 'Steady'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C1720529', 'cui_str': 'Constant'}]",,0.0558151,"Inter-individual variability for clearance was 37%. ","[{'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Suleiman', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen am Rhein, Germany.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Khatri', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.'}, {'ForeName': 'Mukul', 'Initials': 'M', 'LastName': 'Minocha', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Othman', 'Affiliation': 'Clinical Pharmacology and Pharmacometrics, AbbVie Inc., 1 North Waukegan Road, North Chicago, IL, 60064, USA. ahmed.othman@abbvie.com.'}]",Clinical pharmacokinetics,['10.1007/s40262-018-0704-z'] 1585,32534250,External trigeminal nerve stimulation for drug resistant epilepsy: A randomized controlled trial.,"BACKGROUND External trigeminal nerve stimulation (ETNS) is an emergent, non-invasive neurostimulation therapy delivered bilaterally with adhesive skin electrodes. In previous studies, ETNS was associated to a decrease in seizure frequency in patients with focal drug-resistant epilepsy (DRE). OBJECTIVE To determine the long-term efficacy and tolerability of ETNS in patients with focal DRE. Moreover, to explore whether its efficacy depends on the epileptogenic zone (frontal or temporal), and its impact on mood, cognitive function, quality of life, and trigeminal nerve excitability. METHODS Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery, were randomized to ETNS or usual medical treatment. Participants were evaluated at 3, 6 and 12 months for efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability. RESULTS Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs. At 12 months, percentage of responders was 50% in ETNS group and 0% in control group. Seizure frequency in ETNS group decreased by -43.5% from baseline. Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively). Median stimulation intensity was 6.2 mA. ETNS improved quality of life, but not anxiety or depression. Long-term ETNS affected neither neuropsychological function, nor trigeminal nerve excitability. No relevant adverse events were observed. CONCLUSIONS ETNS is an effective and well-tolerated therapy for focal DRE. Patients with temporal epilepsy showed a better response than those with frontal epilepsy. Future studies with larger populations may define its role compared to other neurostimulation techniques. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that ETNS reduces seizure frequency in patients with focal DRE.",2020,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","['Patients with temporal epilepsy', 'Subjects had a median of 15 seizures per month and had tried a median of 12.5 antiepileptic drugs', 'patients with focal drug-resistant epilepsy (DRE', 'drug resistant epilepsy', 'Forty consecutive patients with frontal or temporal DRE, unsuitable for surgery', 'patients with focal DRE']","['ETNS or usual medical treatment', 'External trigeminal nerve stimulation (ETNS', 'ETNS', 'External trigeminal nerve stimulation']","['quality of life', 'seizure frequency', 'neuropsychological function, nor trigeminal nerve excitability', 'efficacy, side effects, mood scales, neuropsychological tests and trigeminal nerve excitability', 'Seizure frequency', 'Median stimulation intensity', 'adverse events', 'anxiety or depression', 'mood, cognitive function, quality of life, and trigeminal nerve excitability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C1096063', 'cui_str': 'Refractory epilepsy'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040996', 'cui_str': 'Trigeminal nerve structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",40.0,0.130105,"Temporal epilepsy subgroup responded better than frontal epilepsy subgroup (55.56% vs. 45.45%, respectively).","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Gil-López', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: fran.gil.lopez@gmail.com.""}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Boget', 'Affiliation': 'Epilepsy Unit, Department of Neuropsychology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Manzanares', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Donaire', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Estefanía', 'Initials': 'E', 'LastName': 'Conde-Blanco', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Baillés', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Pintor', 'Affiliation': 'Epilepsy Unit, Department of Psychiatry, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Setoaín', 'Affiliation': 'Epilepsy Unit, Department of Nuclear Medicine, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Núria', 'Initials': 'N', 'LastName': 'Bargalló', 'Affiliation': 'Epilepsy Unit, Department of Neurorradiology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Navarro', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Casanova', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Valls', 'Affiliation': 'Electromyography Unit, Neurophysiology, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Roldán', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Rumià', 'Affiliation': 'Epilepsy Unit, Department of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Casanovas', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Gema', 'Initials': 'G', 'LastName': 'Domenech', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Ferrán', 'Initials': 'F', 'LastName': 'Torres', 'Affiliation': 'Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Carreño', 'Affiliation': ""Epilepsy Unit, Department of Neurology, Hospital Clínic de Barcelona, Barcelona, Spain, Institut D'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.""}]",Brain stimulation,['10.1016/j.brs.2020.06.005'] 1586,32534252,"Two weeks of image-guided left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation improves smoking cessation: A double-blind, sham-controlled, randomized clinical trial.","BACKGROUND Previous studies have found that repetitive transcranial magnetic stimulation (rTMS) to the left dorsal lateral prefrontal cortex (LDLPFC) transiently reduces smoking craving, decreases cigarette consumption, and increases abstinence rates. OBJECTIVE We investigated whether 10 daily MRI-guided rTMS sessions over two weeks to the LDLPFC paired with craving cues could reduce cigarette consumption and induce smoking cessation. METHODS We enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day) in a randomized, double-blind, sham-controlled trial. Participants received 10 daily sessions over 2 weeks of either active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues. The primary outcome was a reduction in biochemically confirmed cigarette consumption with a secondary outcome of abstinence on the target quit date. We also recorded cue-induced craving and withdrawal symptoms. RESULTS Compared to sham (n = 17), participants receiving active rTMS (n = 21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P < .005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P < .001). Active rTMS participants were also more likely to quit by their target quit rate (23.81%vs. 0%, OR 11.67, 90% CL, 0.96-141.32, x 2  = 4.66, P = .031). Furthermore, rTMS significantly reduced mean craving throughout the treatments and at follow-up (29.93[13.12] vs. 25.01[14.45], P < .001). Interestingly across the active treatment sample, more lateral coil location was associated with more success in quitting (-43.43[0.40] vs. -41.79[2.24], P < .013). CONCLUSIONS Daily MRI-guided rTMS to the LDLPFC for 10 days reduces cigarette consumption and cued craving for up to one month and also increases the likelihood of smoking cessation. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02401672.",2020,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).",['enrolled 42 treatment-seeking nicotine-dependent smokers (≥10 cigarettes per day'],"['rTMS', 'Image-guided Left Dorsolateral Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation Improves Smoking Cessation', 'active rTMS', 'repetitive transcranial magnetic stimulation (rTMS', 'LDLPFC paired with craving cues', 'active or sham MRI-guided rTMS (10Hz, 3000 pulses each session) to the LDLPFC concurrently with video smoking cues']","['abstinence on the target quit date', 'likelihood of smoking cessation', 'lateral coil location', 'cigarette consumption and cued craving', 'mean craving', 'likely to quit by their target quit rate']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}]","[{'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}]",42.0,0.428626,"Compared to sham (n=17), participants receiving active rTMS (n=21) smoked significantly fewer cigarettes per day during the 2-week treatment (mean [SD], 13.73[9.18] vs. 11.06[9.29], P<.005) and at 1-month follow-up (12.78[9.53] vs. 7.93[7.24], P<.001).","[{'ForeName': 'Xingbao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA. Electronic address: lixi@musc.edu.'}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Hartwell', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Henderson', 'Affiliation': 'Center for Biomedical Imaging, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Bashar W', 'Initials': 'BW', 'LastName': 'Badran', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA.'}, {'ForeName': 'Kathleen T', 'Initials': 'KT', 'LastName': 'Brady', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'George', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29401, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.007'] 1587,32534376,Fatty acid desaturation in red blood cell membranes of patients with type 2 diabetes is improved by zinc supplementation.,"BACKGROUND/OBJECTIVE Membrane flexibility can be a determining factor in pathophysiological mechanisms of type 2 diabetes (T2D). As a cofactor of delta-5 desaturase (D5D) and delta-6 desaturase (D6D), and gene expression regulator, zinc may play a role modulating membrane flexibility by increasing membrane polyunsaturated fatty acids (PUFA) abundance. The objective of this study was to evaluate the effect of a 24-month zinc supplementation (30 mg elemental zinc) on membrane fatty acid composition in patients with T2D. SUBJECTS/METHODS Sixty patients with T2D were evaluated. Thirty were randomly assigned to the zinc supplemented group and thirty to the placebo group. Fatty acid composition in red blood cell (RBC) membranes was determined by gas chromatography. Expression of gene encoding for D5D (FADS1), and D6D (FADS2) were evaluated in peripheral blood mononuclear cells by real-time polymerase chain reaction. RESULTS After 24 months of supplementation, a greater abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA was found (p = 0.001, p = 0.007, p = 0.033, p = 0.048, respectively). The unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index was increased in the zinc supplemented group at month 24 (p = 0.003 and p  = 0.000, respectively). FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). CONCLUSIONS Supplementation with 30 mg/d elemental zinc during 24 months in patients with T2D had an effect on the composition of RBC membranes increasing PUFA abundance and in turn, improving membrane flexibility. This effect may be mediated by induction of D5D gene expression.",2020,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","['patients with T2D', 'Sixty patients with T2D were evaluated', 'patients with type 2 diabetes']","['Fatty acid desaturation', 'zinc supplementation (30\u202fmg elemental zinc', 'placebo']","['membrane flexibility', 'Expression of gene encoding for D5D (FADS1), and D6D (FADS2', 'Fatty acid composition in red blood cell (RBC) membranes', 'abundance of docosapentaenoic acid (C22:5 n-3), arachidonic acid (C20:4 n-6), adrenic acid (C22:4 n-6), and total n-6 PUFA', 'FADS1 gene', 'unsaturated fatty acids/saturated fatty acids ratio, and unsaturation index', 'membrane fatty acid composition']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0057338', 'cui_str': 'delta-5 fatty acid desaturase'}, {'cui': 'C0065017', 'cui_str': 'Linoleoyl-CoA desaturase'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0058624', 'cui_str': 'docosapentaenoic acid'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C0050877', 'cui_str': 'adrenic acid'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1276035', 'cui_str': 'Pena-Shokeir syndrome type I'}, {'cui': 'C0015690', 'cui_str': 'Unsaturated fatty acid'}, {'cui': 'C0597423', 'cui_str': 'Saturated fat'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",60.0,0.126956,"FADS1 gene was upregulated in the zinc group in relation to placebo at month 12 (p = 0.020). ","[{'ForeName': 'María Catalina', 'Initials': 'MC', 'LastName': 'Hernández', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Rojas', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Carrasco', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basfi-Fer', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Valenzuela', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Codoceo', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Inostroza', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Ruz', 'Affiliation': 'From the Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile. Electronic address: mruz@med.uchile.cl.'}]",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),['10.1016/j.jtemb.2020.126571'] 1588,32540134,Event-related desynchronization of alpha and beta band neural oscillations predicts speech and limb motor timing deficits in normal aging.,"Normal aging is associated with decline of motor timing mechanisms implicated in planning and execution of movement. Evidence from previous studies has highlighted the relationship between neural oscillatory activities and motor timing processing in neurotypical younger adults; however, it remains unclear how normal aging affects the underlying neural mechanisms of movement in older populations. In the present study, we recorded EEG activities in two groups of younger and older adults while they performed randomized speech and limb motor reaction time tasks cued by temporally predictable and unpredictable sensory stimuli. Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli. This behavioral effect was accompanied by significant desynchronization of alpha (7-12 Hz) and beta (13-25 Hz) band neural oscillatory activities in older compared with younger adults, primarily during the preparatory pre-motor phase of responses for speech production and limb movement. In addition, we found that faster motor reaction times in younger adults were significantly correlated with weaker desynchronization of pre-motor alpha and beta band neural activities irrespective of stimulus timing and response modality. However, the pre-motor components of alpha and beta activities were timing-specific in older adults and were more strongly desynchronized in response to temporally predictable sensory stimuli. These findings highlight the role of alpha and beta band neural oscillations in motor timing processing mechanisms and reflect their functional deficits during the planning phase of speech production and limb movement in normal aging.",2020,"Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli.","['Normal Aging', 'neurotypical younger adults', 'two groups of younger and older adults', 'older adults']",['randomized speech and limb motor reaction time tasks cued by temporally predictable and unpredictable sensory stimuli'],['faster motor reaction times'],"[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0320888,"Our data showed that older adults were significantly slower than their younger counterparts during speech production and limb movement, especially in response to temporally unpredictable sensory stimuli.","[{'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Johari', 'Affiliation': 'Speech Neuroscience Lab, Department of Communication Sciences and Disorders, University of South Carolina, Columbia, SC, United States; Department of Psychology, University of South Carolina, Columbia, SC, United States.'}, {'ForeName': 'Roozbeh', 'Initials': 'R', 'LastName': 'Behroozmand', 'Affiliation': 'Speech Neuroscience Lab, Department of Communication Sciences and Disorders, University of South Carolina, Columbia, SC, United States. Electronic address: r-behroozmand@sc.edu.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112763'] 1589,32535263,Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial.,"BACKGROUND Postoperative cognitive dysfunction (POCD) is a complication of central nervous system in patients after surgery. Edaravone as a brain-protective agent may have protective effect on postoperative cognitive function. The study was designed to explore the effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery and potential mechanism. PATIENTS AND METHODS Patients undergoing hip joint replacement surgery were randomly allocated into 2 groups: the edaravone group (group E) and the control group (group C). Group E received intravenous edaravone at a dose of 0.5 mg/kg after induction of anesthesia, while group C received normal saline. The cognitive function was evaluated with the Mini-Mental State Examination (MMSE) 1day before surgery,3 days and the 7 days after surgery. Patients' plasma samples were collected to detect the levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA) before the induction of anesthesia, at the end of surgery and on postoperative day 3. RESULTS The MMSE scores in group E were higher than those of group C 3 days after surgery (25.98 ± 1.99 vs 24.86 ± 1.86, p = 0.003). There were remarkable rises (p < 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p < 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03 ± 2.46U/ml vs. 13.65 ± 2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01 ± 2.37 nmol/ml vs. 11.34 ± 3.18 nmol/ml, p = 0.0001). CONCLUSION The results indicated that preoperative intervention with edaravone may improve the postoperative cognitive function in elderly patients undergoing hip joint replacement surgery.",2020,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","['eldely patients undergoing hip joint replacement surgery and potential mechanism', 'Patients undergoing hip joint replacement surgery', 'patients after surgery', 'elderly patients undergoing hip joint replacement surgery']","['intravenous edaravone', 'normal saline', 'edaravone', 'Edaravone']","['MDA level', 'MMSE scores', 'cognitive function', 'SOD concentration', 'levels of S100β protein (S100β), interleukin-6 (IL-6), matrix metalloproteinase-9 (MMP-9), superoxide dismutase (SOD) and malondialdehyde (MDA', 'postoperative cognitive function', 'plasma IL-6, S100βand MMP-9 levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0070694', 'cui_str': 'edaravone'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0165519', 'cui_str': 'Gelatinase B'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",,0.097904,"There were remarkable rises (p< 0.05) in plasma IL-6, S100βand MMP-9 levels at the end of surgery and on postoperative day 3 in the two groups, however, edaravone pretreatment could reduce these levels to a certain extent compared with group C (p< 0.05).In group E, the SOD concentration was higher at the end of surgery (16.03±2.46U/ml vs. 13.65±2.53U/ml, p = 0.0001), while the MDA level was lower on postoperative day 3 than those in group C (7.01±2.37nmol/ml vs. 11.34±3.18nmol/ml, p = 0.0001). ","[{'ForeName': 'Nan-Nan', 'Initials': 'NN', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Sun', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China. Electronic address: sun_long2@163.com.'}, {'ForeName': 'Wen-Ting', 'Initials': 'WT', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesiology, Shuguang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, 528 Zhangheng Road, Pudong, Shanghai, 201203, China.'}, {'ForeName': 'Yang-Liang', 'Initials': 'YL', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China.'}, {'ForeName': 'Yi-Ming', 'Initials': 'YM', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, 2800 Gongwei Road, Huinan Town, Pudong, Shanghai, 201399, China. Electronic address: nange1984@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.05.092'] 1590,32535338,A serious-game for child sexual abuse prevention: An evaluation of orbit.,"BACKGROUND Greater public and professional awareness of the extent and impact of child sexual abuse (CSA) has prompted the inclusions of prevention initiatives within school curricula. However CSA education is not always soundly grounded in empirical evidence, and evaluations of the impact of programs often inadequate. OBJECTIVE This paper reports on a randomized-control trial of an empirically informed serious-game for CSA prevention, for children aged 8-10 years. The study also evaluates the impact on learning of complementary classroom lessons and part completion of the Orbit game. PARTICIPANTS AND SETTING The evaluation involved 139 students (female = 78; male = 61) aged 8-10 years (Mage = 9.64, SD = 0.33), from an elementary school in Queensland, Australia. METHOD All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit . Children were assigned to one of three groups; i) play Orbit (n = 50); ii) play Orbit and CSA lessons (n = 55); and iii) control (n = 34). RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not. Furthermore, those children who completed all of Orbit significantly (p < .001) increased their post-test CKAQ scores, whereas those who didn't complete the game did not. CONCLUSIONS This study shows the strength of a serious-games approach for school CSA prevention whilst reporting how child completion can impact learnings.",2020,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","['child sexual abuse (CSA', 'child sexual abuse prevention', ""All children were pre-tested and post-tested (at 3 months) for knowledge of abuse prevention using the Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R-III), and a short form (SF) mapped to the learning objectives of Orbit "", 'The evaluation involved 139 students (female\u202f=\u202f78; male\u202f=\u202f61) aged 8-10 years (Mage\u202f=\u202f9.64, SD\u202f=\u202f0.33), from an elementary school in Queensland, Australia', 'children aged 8-10 years']",['play Orbit (n\u202f=\u202f50); ii) play Orbit and CSA lessons (n\u202f=\u202f55); and iii) control'],"['post-test CKAQ scores', 'CKAQ SF scores']","[{'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1261558', 'cui_str': 'Abuse prevention'}, {'cui': 'C0562381', 'cui_str': 'Victim of abuse'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0024779', 'cui_str': 'Maps'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C5191072', 'cui_str': '139'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517449', 'cui_str': '0.33'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]","[{'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0029180', 'cui_str': 'Orbital cavity'}, {'cui': 'C0008062', 'cui_str': 'Sexual Abuse of Child'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",139.0,0.0282223,"RESULTS Children in the Orbit play, and Orbit play and lesson groups, significantly (p < .001) increased their CKAQ SF scores, whereas those in the control group did not.","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'School of Social Sciences, University of the Sunshine Coast, Queensland, Australia. Electronic address: cmjones@usc.edu.au.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Scholes', 'Affiliation': 'Institute for Learning Sciences & Teacher Education, Australian Catholic University, Queensland, Australia. Electronic address: laura.scholes@acu.edu.au.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Rolfe', 'Affiliation': 'Ecoludology Games, Queensland, Australia. Electronic address: ben@ecoludology.com.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Stieler-Hunt', 'Affiliation': 'School of Creative Industries, University of the Sunshine Coast, Queensland, Australia. Electronic address: cstieler@usc.edu.au.'}]",Child abuse & neglect,['10.1016/j.chiabu.2020.104569'] 1591,32549898,Thickening of the axillary recess capsule on ultrasound correlates with magnetic resonance imaging signs of adhesive capsulitis.,"Objective To correlate the thickness of the axillary recess capsule measured by ultrasound with magnetic resonance imaging signs of adhesive capsulitis in patients with shoulder pain. Materials and methods We prospectively evaluated 193 consecutive patients (141 women and 52 men, aged 40-69 years) with shoulder pain lasting 1-9 months from January 2015 to December 2016 who underwent shoulder ultrasound. All participants had routine shoulder ultrasound with additional measurement of axillary recess capsule thickness. After examinations, two groups were formed: negative ultrasound group, composed of patients with a capsule thickness of 2.0 mm or less, and positive ultrasound group, composed of individuals with a capsule thickness greater than 2.0 mm. All patients from the positive ultrasound group and 27 randomly chosen patients from the negative ultrasound group underwent shoulder magnetic resonance imaging. Results In all, 169/193 patients (88%) had an axillary recess capsule thickness of 2.0 mm or less (negative ultrasound group) and 24/193 patients (12%) had a capsule thickness greater than 2.0 mm (positive ultrasound group). Twenty-seven patients from negative ultrasound group (27/169) were randomly selected to undergo shoulder magnetic resonance imaging. None of them had magnetic resonance imaging criteria for adhesive capsulitis. All patients from positive ultrasound group (24/24) underwent shoulder magnetic resonance imaging and 23 of them (23/24) had magnetic resonance imaging signs of adhesive capsulitis, with a sensitivity of 100% and a specificity of 96%. Conclusion In patients with shoulder pain, a thickness greater than 2.0 mm of the axillary recess capsule measured by ultrasound correlates to magnetic resonance imaging signs of adhesive capsulitis with good sensitivity and specificity.",2019,"In all, 169/193 patients (88%) had an axillary recess capsule thickness of 2.0 mm or less (negative ultrasound group) and 24/193 patients (12%) had a capsule thickness greater than 2.0 mm (positive ultrasound group).","['patients with shoulder pain', 'Twenty-seven patients from negative ultrasound group (27/169', 'All participants had routine shoulder ultrasound with additional measurement of axillary recess capsule thickness', '193 consecutive patients (141 women and 52 men, aged 40-69 years) with shoulder pain lasting 1-9 months from January 2015 to December 2016 who underwent shoulder ultrasound']","['negative ultrasound group underwent shoulder magnetic resonance imaging', 'shoulder magnetic resonance imaging']","['axillary recess capsule thickness', 'capsule thickness', 'magnetic resonance imaging signs of adhesive capsulitis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0158300', 'cui_str': 'Capsulitis, Adhesive'}]",193.0,0.0848339,"In all, 169/193 patients (88%) had an axillary recess capsule thickness of 2.0 mm or less (negative ultrasound group) and 24/193 patients (12%) had a capsule thickness greater than 2.0 mm (positive ultrasound group).","[{'ForeName': 'Renato A', 'Initials': 'RA', 'LastName': 'Sernik', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Vidal Leão', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Luis Bizetto', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Sanford Damasceno', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}, {'ForeName': 'Natally', 'Initials': 'N', 'LastName': 'Horvat', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Guido Cerri', 'Affiliation': 'Department of Radiology, Hospital Sírio-Libanês, São Paulo, Brazil.'}]","Ultrasound (Leeds, England)",['10.1177/1742271X19840063'] 1592,32556324,Dry Cupping Therapy for Improving Nonspecific Neck Pain and Subcutaneous Hemodynamics.,"CONTEXT Dry cupping therapy is a noninvasive treatment commonly used to reduce pain and promote the healing process in various populations, including those with nonspecific neck pain; however, no data are available to support most of this method's true physiological benefits. OBJECTIVE To determine if dry cupping therapy decreased pain and increased subcutaneous blood flow compared with sham cupping and control conditions. DESIGN Controlled laboratory study. SETTING Laboratory. PATIENTS OR OTHER PARTICIPANTS A total of 32 participants (age = 22.5 ± 2.8 years, height = 173.3 ± 10.1 cm, mass = 76.6 ± 18.7 kg) with self-reported nonspecific neck pain. INTERVENTION(S) We used dry cupping and sham cupping interventions and a control condition. For the dry cupping intervention, 1 stationary cup was placed directly over the most painful area for 8 minutes. The sham cupping intervention followed the same procedures as the dry cupping intervention except a sham cup was applied. For the control condition, participants received no treatment. MAIN OUTCOME MEASURE(S) Subjective pain intensity (visual analog scale); pain-pressure threshold; subcutaneous hemodynamics, including superficial and deep oxygenated, deoxygenated, and total hemoglobin levels; and tissue saturation index. RESULTS We observed differences in the visual analog scale score and the superficial and deep oxygenated and total hemoglobin levels (P values ≤ .002) immediately postintervention compared with baseline. Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008). No differences were found between baseline and 24 hours postintervention. CONCLUSIONS A single session of dry cupping therapy may be an effective short-term treatment method for immediately reducing pain and increasing oxygenated and total hemoglobin levels in patients with nonspecific neck pain.",2020,Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008).,"['patients with nonspecific neck pain', 'A total of 32 participants (age = 22.5 ± 2.8 years, height = 173.3 ± 10.1 cm, mass = 76.6 ± 18.7 kg) with self-reported nonspecific neck pain']","['dry cupping and sham cupping interventions', 'Dry Cupping Therapy', 'sham cupping intervention']","['higher superficial and deep oxygenated and total hemoglobin levels', 'Subcutaneous Hemodynamics and Pain Associated With Nonspecific Neck Pain', 'Subjective pain intensity (visual analog scale); pain-pressure threshold; subcutaneous hemodynamics, including superficial and deep oxygenated, deoxygenated, and total hemoglobin levels; and tissue saturation index', 'pain and increased subcutaneous blood flow', 'pain and increasing oxygenated and total hemoglobin levels', 'pain', 'visual analog scale score and the superficial and deep oxygenated and total hemoglobin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517649', 'cui_str': '22.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]","[{'cui': 'C0011682', 'cui_str': 'Desiccation - action'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C5197695', 'cui_str': 'Cupping Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0475206', 'cui_str': '% total hemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",32.0,0.0555464,Post hoc tests revealed that the dry cupping group had less pain than the sham cupping and control groups and higher superficial and deep oxygenated and total hemoglobin levels (P values ≤ .008).,"[{'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Stephens', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}, {'ForeName': 'Noelle M', 'Initials': 'NM', 'LastName': 'Selkow', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}, {'ForeName': 'Nicole L', 'Initials': 'NL', 'LastName': 'Hoffman', 'Affiliation': 'School of Kinesiology and Recreation, Illinois State University, Normal.'}]",Journal of athletic training,['10.4085/1062-6050-236-19'] 1593,32553888,Effect of practical hyperoxic high-intensity interval training on exercise performance.,"This study investigated the effect of a practical hyperoxic high-intensity interval training (HIIT) on aerobic and anaerobic exercise capacity. Sixteen male athletes were randomized into 2 groups: normoxic HIIT (NHIIT, n = 8) group or hyperoxic HIIT (HHIIT, n = 8) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia. All training sessions were performed until exhaustion. Participants performed maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests before and after the training period. Maximal oxygen uptake (P < 0.01) increased significantly in both groups. Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P < 0.01). Mean power output during maximal exercise increased significantly only in the HHIIT group (P = 0.02). This study demonstrated that a practical hyperoxic HHIIT might be effective for improving aerobic capacity and anaerobic performance.",2020,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,['Sixteen male athletes'],"['normoxic HIIT (NHIIT, n\u2009=\u20098) group or hyperoxic HIIT (HHIIT, n\u2009=\u20098) group and trained for 3 weeks (2 days/week) on a cycle ergometer (2-min intervals, with 2-min rest between intervals) at maximal workload, which was obtained during a maximal graded exercise test under normoxia', 'maximal graded exercise, submaximal exercise, and 90-s maximal exercise tests', 'practical hyperoxic high-intensity interval training', 'practical hyperoxic high-intensity interval training (HIIT']","['Mean power output during maximal exercise', 'Blood lactate curve during submaximal exercise', 'Maximal oxygen uptake', 'aerobic capacity and anaerobic performance', 'aerobic and anaerobic exercise capacity', 'exercise performance']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",16.0,0.0253253,Blood lactate curve during submaximal exercise improved significantly only in the HHIIT group (P <  0.01).,"[{'ForeName': 'Michihiro', 'Initials': 'M', 'LastName': 'Kon', 'Affiliation': 'School of International Liberal Studies, Chukyo University, 101-2 Yagotohonmachi, Showa-ku, Nagoya, 466-8666, Japan; Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan. Electronic address: kon.michihiro@gmail.com.'}, {'ForeName': 'Kohei', 'Initials': 'K', 'LastName': 'Nakagaki', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan; Department of Sports Sciences, Yamanashi Gakuin University, 2-4-5 Sakaori, Kofu, Yamanashi, 400-8575, Japan.'}, {'ForeName': 'Yoshiko', 'Initials': 'Y', 'LastName': 'Ebi', 'Affiliation': 'Department of Sports Sciences, Japan Institute of Sports Sciences, 3-15-1 Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103481'] 1594,32559463,Dynamic trial fitting by an expanding trial cup does not jeopardize primary acetabular component stability.,"BACKGROUND Trial fitting of the acetabular component in uncemented total hip replacement is traditionally done by trial cups. Since trial cups do not resemble the real press-fit obtained by the definitive cup, a dynamic trial inserter, called the X-pander ®, was developed to mimic the real amount of press-fit. However, the concern is raised of losing the initial press-fit by using the X-pander® due to pre-expansion of the acetabulum. The purpose of this study was to assess if there is a difference in primary stability between both methods. METHODS A biomechanical randomized study was performed with bovine calf acetabula, with randomization between either using the X-pander® or the traditional trial cups to assess primary stability. The primary outcome was the force needed to achieve lever out of the implanted cup (Anexys, Mathys or Trident, Stryker), measured in Newton meter (Nm) with a biomechanical testing set up. FINDINGS In total, 54 cups (19 Anexys, 35 Trident) were inserted and tested after randomized trial fitting. Overall mean lever out was 45.1 Nm (SD 14.6) for the X-pander® group and 45.0 Nm (SD 14.5) for the trial cups group. After adjustment for potential confounders (cup size and type) mixed model analysis did not reveal a significant difference in lever out force between both testing devices (mean 1.0 Nm, 95%CI (-5.9; 8.0), p = .77). INTERPRATION Initial press-fit of the implanted cup is not lost by pre-expansion as done with dynamic trial fitting with the X-pander®.",2020,"After adjustment for potential confounders (cup size and type) mixed model analysis did not reveal a significant difference in lever out force between both testing devices (mean 1.0 Nm, 95%CI (-5.9; 8.0), p = .77). ",[],"['INTERPRATION', 'bovine calf acetabula']","['force needed to achieve lever out of the implanted cup (Anexys, Mathys or Trident, Stryker), measured in Newton meter (Nm) with a biomechanical testing set up']",[],"[{'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0000962', 'cui_str': 'Bone structure of acetabulum'}]","[{'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C1430904', 'cui_str': 'FOXM1 protein, human'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0542569', 'cui_str': 'newton'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]",54.0,0.260371,"After adjustment for potential confounders (cup size and type) mixed model analysis did not reveal a significant difference in lever out force between both testing devices (mean 1.0 Nm, 95%CI (-5.9; 8.0), p = .77). ","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Hoornenborg', 'Affiliation': 'Xpert Orthopedie Amsterdam/SCORE (Specialized Center of Orthopedic Research and Education), Laarderhoogtweg 12, 1101EA Amsterdam, the Netherlands. Electronic address: d.hoornenborg@xpertorthopedie.nl.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'van Loon', 'Affiliation': 'Xpert Orthopedie Amsterdam/SCORE (Specialized Center of Orthopedic Research and Education), Laarderhoogtweg 12, 1101EA Amsterdam, the Netherlands; Academic Medical Center Amsterdam, Department of Orthopedic Surgery, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands. Electronic address: justin.vanloon@amc.uva.nl.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'de Waard', 'Affiliation': 'Xpert Orthopedie Amsterdam/SCORE (Specialized Center of Orthopedic Research and Education), Laarderhoogtweg 12, 1101EA Amsterdam, the Netherlands.'}, {'ForeName': 'I N', 'Initials': 'IN', 'LastName': 'Sierevelt', 'Affiliation': 'Xpert Orthopedie Amsterdam/SCORE (Specialized Center of Orthopedic Research and Education), Laarderhoogtweg 12, 1101EA Amsterdam, the Netherlands. Electronic address: i.n.sierevelt@score-amsterdam.nl.'}, {'ForeName': 'K T M', 'Initials': 'KTM', 'LastName': 'Opdam', 'Affiliation': 'Academic Medical Center Amsterdam, Department of Orthopedic Surgery, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands. Electronic address: k.t.opdam@amc.uva.nl.'}, {'ForeName': 'G M M J', 'Initials': 'GMMJ', 'LastName': 'Kerkhoffs', 'Affiliation': 'Academic Medical Center Amsterdam, Department of Orthopedic Surgery, Meibergdreef 15, 1105 AZ Amsterdam, the Netherlands. Electronic address: g.m.kerkhoffs@amc.uva.nl.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Haverkamp', 'Affiliation': 'Xpert Orthopedie Amsterdam/SCORE (Specialized Center of Orthopedic Research and Education), Laarderhoogtweg 12, 1101EA Amsterdam, the Netherlands. Electronic address: d.haverkamp@xpertorthopedie.nl.'}]","Clinical biomechanics (Bristol, Avon)",['10.1016/j.clinbiomech.2020.105077'] 1595,32559515,Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.,"Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-release fampridine (PR-fampridine) improves walking ability in some PwMS. Associated fampridine-induced changes in the walking pattern are still poorly understood but may provide a better understanding of the mechanisms underlying the beneficial drug effects. 61 PwMS were treated with PR-fampridine in a randomized, monocentric, double-blind and placebo-controlled clinical trial with crossover design (FAMPKIN). Drug-induced improvements in walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT) were quantified. In this sub-study of the FAMPKIN trial, fampridine-induced changes in kinetic gait patterns were analyzed by pressure-based foot print analysis during treadmill walking. Vertical ground reaction forces were analyzed during different gait phases. Kinetic data of 44 PwMS was eligible for analysis. During double-blind treatment with PR-fampridine, patients performed significantly better in the T25FW and 6MWT than during placebo treatment (p < 0.0001 for both). At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo. However, we found relevant changes of walking kinetics regarding forces during loading, single limb and pre-swing phase in a patient sub-group (n = 8). Interestingly, this sub-group demonstrated superior responsiveness to PR-fampridine in the clinical walking tests compared to those patients without any fampridine-induced changes in kinetics (n = 36). Our results demonstrate fampridine-induced changes in gait kinetics in a sub-group of PwMS. These gait pattern changes were accompanied by improved clinical walking performance under PR-fampridine. These results shed some light on the biomechanical changes in walking patterns underlying enhanced fampridine-induced gait performance.",2020,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","['patients with multiple sclerosis', 'patients with multiple sclerosis (PwMS']","['PR-fampridine', 'prolonged-release fampridine (PR-fampridine', 'placebo']","['clinical walking performance', 'Vertical ground reaction forces', 'walking kinetics', 'gait kinetics', 'Gait dysfunction', 'walking speed (Timed-25-Foot Walk; T25FW) and endurance (6-Minute Walk Test; 6MWT', 'kinetic gait patterns', 'T25FW and 6MWT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C0000477', 'cui_str': 'dalfampridine'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0022702', 'cui_str': 'Kinetics'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}]",61.0,0.124543,"At the group level (n = 44), there were no significant changes of gait kinetics under PR-fampridine vs. placebo.","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Lörincz', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Sutter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reuter', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Linnebank', 'Affiliation': 'Department of Neurology, University Witten/Herdecke and Evangelische Kliniken Gelsenkirchen, Munckelstraße 32, 45879 Gelsenkirchen, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Zörner', 'Affiliation': 'Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Filli', 'Affiliation': 'Department of Neurology, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland; Spinal Cord Injury Center, Balgrist University Hospital, Forchstrasse 340, 8008 Zurich, Switzerland; Swiss Center for clinical Movement Analysis (SCMA), Balgrist Campus AG, Lengghalde 5, 8008 Zurich, Switzerland. Electronic address: linard.filli@balgrist.ch.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.116978'] 1596,32559601,Cardiovascular responses to pelvic floor muscle contraction in healthy women: Prospective study.,"OBJECTIVE Analyze the acute heart rate and blood pressure responses to two protocols of pelvic floor muscles contractions in premenopausal and postmenopausal women. METHODS Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal. The groups underwent two protocols and the pelvic floor muscle endurance, heart rate, and blood pressure values were monitored. Both protocols included 10 pelvic floor muscles contractions; one series contained contractions lasting 5 s with 5 s of rest between each contraction and the other series contained contractions lasting 10 s with 10 s of rest. RESULTS In both groups, there was a significant increase in the heart rate during pelvic floor muscles contractions (premenopausal: 71.0 ± 7.3 and 80.3 ± 7.7; postmenopausal: 65.4 ± 6.6 and 73.6 ± 6.6, at rest and contractions peak, respectively) and in systolic blood pressure immediately after the contractions. The observed values during exercise returned to basal values seconds after the contractions. A positive correlation between heart rate and vaginal squeeze pressure (r = 0.45, p = 0.0007 and r = 0.48, p = 0.0003, 5- and 10-s series, respectively) was observed. CONCLUSION The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.",2020,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"['premenopausal and postmenopausal women', 'healthy women', 'healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions', 'Fifty-four women without pelvic floor muscles disorders were eligible and allocated into two groups: premenopausal and postmenopausal']",['pelvic floor muscles contractions'],"['heart rate and blood pressure', 'pelvic floor muscle endurance, heart rate, and blood pressure values', 'heart rate', 'Cardiovascular responses', 'systolic blood pressure', 'heart rate and vaginal squeeze pressure']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026848', 'cui_str': 'Disorder of muscle'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0413258', 'cui_str': 'Barotrauma of descent'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}]",54.0,0.0281104,The proposed protocol of isometric pelvic floor muscles contractions caused an increase in heart rate and blood pressure within the normal range and might not represent a cardiovascular risk for healthy postmenopausal women without urinary incontinence and without cardiovascular dysfunctions.,"[{'ForeName': 'Alana Maria G', 'Initials': 'AMG', 'LastName': 'Bastos', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Aparecida M', 'Initials': 'AM', 'LastName': 'Catai', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Soraia P', 'Initials': 'SP', 'LastName': 'Jürgensen', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Grasiela N', 'Initials': 'GN', 'LastName': 'Correia', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Vanessa S', 'Initials': 'VS', 'LastName': 'Pereira-Baldon', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Perseguini', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Borghi-Silva', 'Affiliation': 'Cardiovascular Physical Therapy Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Driusso', 'Affiliation': ""Women's Health Research Laboratory, Physical Therapy Department, Federal University of São Carlos, São Carlos, São Paulo State, Brazil. Electronic address: pdriusso@ufscar.br.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.050'] 1597,32560911,"Effect of mental rotation skills training on ultrasound-guided regional anaesthesia task performance by novice operators: a rater-blinded, randomised, controlled study.","BACKGROUND The effect of mental rotation training on ultrasound-guided regional anaesthesia (UGRA) skill acquisition is currently unknown. In this study we aimed to examine whether mental rotation skill training can improve UGRA task performance by novice operators. METHODS We enrolled 94 volunteers with no prior experience of UGRA in this randomised controlled study. After a baseline mental rotation test, their performance in a standardised UGRA needling task was independently assessed by two raters using the composite error score (CES) and global rating scale (GRS). Volunteers with low baseline mental rotation ability were randomised to a mental rotation training group or a no training group, and the UGRA needling task was repeated to determine the impact of the training intervention on task performance. The study primary outcome measure was UGRA needling task CES measured before and after the training intervention. RESULTS Multivariate analyses controlling for age, gender, and previous performance showed that participants exposed to the training intervention made significantly fewer errors (CES B=-0.66 [standard error, se=0.17]; P<0.001; 95% confidence interval [CI], -0.92 to -0.26) and displayed improved overall performance (GRS B=6.15 [se=2.99], P=0.048, 95% CI=0.06 to 12.13) when undertaking the UGRA needling task. CONCLUSIONS A simple training intervention, based on the manipulation and rotation of three-dimensional models, results in improved technical performance of a UGRA needling task in operators with low baseline mental rotation skills.",2020,"A simple training intervention, based on the manipulation and rotation of three-dimensional models, results in improved technical performance of a UGRA needling task in operators with low baseline mental rotation skills.","['94 volunteers with no prior experience of UGRA', 'in operators with low baseline mental rotation skills', 'Volunteers with low baseline mental rotation ability', 'ultrasound-guided regional anaesthesia task performance by novice operators']","['UGRA needling task', 'mental rotation training group or a no training group, and the UGRA needling task', 'mental rotation skills training', 'mental rotation training', 'mental rotation skill training']","['UGRA task performance', 'composite error score (CES) and global rating scale (GRS', 'UGRA needling task CES', 'overall performance']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}]","[{'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",94.0,0.202241,"A simple training intervention, based on the manipulation and rotation of three-dimensional models, results in improved technical performance of a UGRA needling task in operators with low baseline mental rotation skills.","[{'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Hewson', 'Affiliation': 'Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham, UK. Electronic address: david.hewson@nottingham.ac.uk.'}, {'ForeName': 'Rasmus', 'Initials': 'R', 'LastName': 'Knudsen', 'Affiliation': 'Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Sanjeevan', 'Initials': 'S', 'LastName': 'Shanmuganathan', 'Affiliation': 'Department of Anaesthesia, Royal National Orthopaedic Hospital, Stanmore, UK.'}, {'ForeName': 'Eamonn', 'Initials': 'E', 'LastName': 'Ferguson', 'Affiliation': 'Personality, Social Psychology and Health Research Group, School of Psychology, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Hardman', 'Affiliation': 'Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Nigel M', 'Initials': 'NM', 'LastName': 'Bedforth', 'Affiliation': 'Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Rob A', 'Initials': 'RA', 'LastName': 'McCahon', 'Affiliation': 'Department of Anaesthesia, Nottingham University Hospitals NHS Trust, Nottingham, UK.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.04.090'] 1598,32566130,Toward a paradigm shift from deficit-based to proactive speech and language treatment: Randomized pilot trial of the Babble Boot Camp in infants with classic galactosemia.,"Background: Speech and language therapy is typically initiated reactively after a child shows delays. Infants with classic galactosemia (CG), a metabolic disease with a known high risk for both speech and language disorders, hold the keys towards evaluating whether preventive treatment is effective when the risks are known at birth. We present pilot data from a randomized parallel trial of an innovative proactive speech and language intervention program, the Babble Boot Camp (BBC).  Method : Five children with CG, otherwise healthy, participated in the study from approximately 2 to 24 months of age. One of these was randomly selected as control receiving conventional management, which typically starts at age 2-3 years. A pediatric speech-language pathologist met weekly via telepractice with the parents in the treatment cohort. Parents implemented the prespeech, speech, and language stimulation and expansion activities according to the intervention protocol. The control child was still too young for conventional treatment. Primary outcome measures were speech sound production complexity in babble and speech and expressive vocabulary size. Secondary outcome measures were vocalization rates and developmental milestones in communication, motor, and cognition. The trial is ongoing. Results :  All four treated children had higher speech sound skills in babble, three had higher speech sound skills in meaningful speech, two had higher expressive vocabularies, three had higher global developmental scores, and two had higher vocalization rates, compared to the control child with CG. Discussion: Given the high risk for speech and language delays in children with CG, finding on-schedule abilities in two or more of the treated children but not the untreated child is unexpected under random conditions. The trends toward beneficial effects of the BBC on speech sound production, expressive language, and communication milestones warrant appropriately powered larger clinical trials with full randomization. Trial registration: ClinicalTrials.gov NCT03838016 (12 th February 2019).",2019,"All four treated children had higher speech sound skills in babble, three had higher speech sound skills in meaningful speech, two had higher expressive vocabularies, and three had higher communication and personal-social skills, compared to the control child with CG. ","['infants with classic galactosemia', 'children with CG', 'Infants with classic galactosemia (CG', 'Method : Five children with CG, otherwise healthy, participated in the BBC from approximately 2 to 24 months of age']","['Babble Boot Camp', 'proactive speech and language treatment', 'control receiving conventional management', 'innovative proactive speech and language intervention program, the Babble Boot Camp (BBC', ': Speech or language therapy']","['speech sound production, expressive language, and communication milestones', 'developmental milestones in communication, motor, and cognition', 'speech sound production complexity in babble and speech and expressive vocabulary size', 'higher communication and personal-social skills', 'higher speech sound skills', 'prespeech, speech, and language stimulation and expansion activities']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0268151', 'cui_str': 'Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0856983', 'cui_str': 'Babbling'}, {'cui': 'C0331794', 'cui_str': 'Boots'}, {'cui': 'C0001455', 'cui_str': 'Cyclic AMP'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0023017', 'cui_str': 'Language therapy'}]","[{'cui': 'C0037829', 'cui_str': 'Speech Sounds'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0856983', 'cui_str': 'Babbling'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0589217', 'cui_str': 'Language stimulation'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",5.0,0.032084,"All four treated children had higher speech sound skills in babble, three had higher speech sound skills in meaningful speech, two had higher expressive vocabularies, and three had higher communication and personal-social skills, compared to the control child with CG. ","[{'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Peter', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Potter', 'Affiliation': 'Department of Speech and Hearing Sciences, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Davis', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Donenfeld-Peled', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Lizbeth', 'Initials': 'L', 'LastName': 'Finestack', 'Affiliation': 'Department of Speech-Language-Hearing Services, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Stoel-Gammon', 'Affiliation': 'Department of Speech and Hearing Sciences, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Lien', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Bruce', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Vose', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, Syracuse, NY, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Eng', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Hanako', 'Initials': 'H', 'LastName': 'Yokoyama', 'Affiliation': 'Speech and Hearing Science, College of Health Solutions, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Olds', 'Affiliation': 'Department of Speech and Hearing Sciences, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'VanDam', 'Affiliation': 'Department of Speech and Hearing Sciences, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.'}]",F1000Research,['10.12688/f1000research.18062.5'] 1599,32450083,Randomized matrix games in a finite population: Effect of stochastic fluctuations in the payoffs on the evolution of cooperation.,"A diffusion approximation for a randomized 2 × 2-matrix game in a large finite population is ascertained in the case of random payoffs whose expected values, variances and covariances are of order given by the inverse of the population size N. Applying the approximation to a Randomized Prisoner's Dilemma (RPD) with independent payoffs for cooperation and defection in random pairwise interactions, conditions on the variances of the payoffs for selection to favor the evolution of cooperation, favor more the evolution of cooperation than the evolution of defection, and disfavor the evolution of defection are deduced. All these are obtained from probabilities of ultimate fixation of a single mutant. It is shown that the conditions are lessened with an increase in the variances of the payoffs for defection against cooperation and defection and a decrease in the variances of the payoffs for cooperation against cooperation and defection. A RPD game with independent payoffs whose expected values are additive is studied in detail to support the conclusions. Randomized matrix games with non-independent payoffs, namely the RPD game with additive payoffs for cooperation and defection based on random cost and benefit for cooperation and the repeated RPD game with Tit-for-Tat and Always-Defect as strategies in pairwise interactions with a random number of rounds, are studied under the assumption that the population-scaled expected values, variances and covariances of the payoffs are all of the same small enough order. In the first model, the conditions in favor of the evolution of cooperation hold only if the covariance between the cost and the benefit is large enough, while the analysis of the second model extends the results on the effects of the variances of the payoffs for cooperation and defection found for the one-round RPD game.",2020,It is shown that the conditions are lessened with an increase in the variances of the payoffs for defection against cooperation and defection and a decrease in the variances of the payoffs for cooperation against cooperation and defection.,[],[],[],[],[],[],,0.0254081,It is shown that the conditions are lessened with an increase in the variances of the payoffs for defection against cooperation and defection and a decrease in the variances of the payoffs for cooperation against cooperation and defection.,"[{'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Département de mathématiques et de statistique, Université de Montréal, Montréal, Québec, H3C 3J7, Canada.'}, {'ForeName': 'Sabin', 'Initials': 'S', 'LastName': 'Lessard', 'Affiliation': 'Département de mathématiques et de statistique, Université de Montréal, Montréal, Québec, H3C 3J7, Canada. Electronic address: lessards@dms.umontreal.ca.'}]",Theoretical population biology,['10.1016/j.tpb.2020.04.006'] 1600,32459129,Consolidation of Reward Memory during Sleep Does Not Require Dopaminergic Activation.,"Sleep enhances memories, especially if they are related to future rewards. Although dopamine has been shown to be a key determinant during reward learning, the role of dopaminergic neurotransmission for amplifying reward-related memories during sleep remains unclear. In this study, we scrutinize the idea that dopamine is needed for the preferential consolidation of rewarded information. We impaired dopaminergic neurotransmission, thereby aiming to wipe out preferential sleep-dependent consolidation of high- over low-rewarded memories during sleep. Following a double-blind, balanced, crossover design, 17 young healthy men received the dopamine d2-like receptor blocker sulpiride (800 mg) or placebo, after learning a motivated learning task. The task required participants to memorize 80 highly and 80 lowly rewarded pictures. Half of them were presented for a short (750 msec) and a long (1500 msec) duration, respectively, which permitted dissociation of the effects of reward on sleep-associated consolidation from those of mere encoding depth. Retrieval was tested after a retention interval of approximately 22 hr that included 8 hr of nocturnal sleep. As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo. However, there was no evidence for an effect of reducing dopaminergic neurotransmission with sulpiride during sleep on this differential retention of rewarded information. This result indicates that dopaminergic activation likely is not required for the preferential consolidation of reward-associated memory. Rather, it appears that dopaminergic activation only tags such memories at encoding for intensified reprocessing during sleep.",2020,"As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo.",['17 young healthy men'],"['dopamine d2-like receptor blocker sulpiride (800 mg) or placebo', 'dopamine', 'placebo']",[],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0038803', 'cui_str': 'Sulpiride'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],17.0,0.110276,"As expected, at retrieval, highly rewarded memories were remembered better than lowly rewarded memories, under placebo.","[{'ForeName': 'Marjan Alizadeh', 'Initials': 'MA', 'LastName': 'Asfestani', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Brechtmann', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Santiago', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Peter', 'Affiliation': 'German Center for Diabetes Research (DZD), Tübingen, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Born', 'Affiliation': 'University of Tübingen.'}, {'ForeName': 'Gordon Benedikt', 'Initials': 'GB', 'LastName': 'Feld', 'Affiliation': 'University of Tübingen.'}]",Journal of cognitive neuroscience,['10.1162/jocn_a_01585'] 1601,32454191,Patient Perceptions in a Nonblinded Randomized Trial of Radiation Therapy Technologies: A Novel Survey Study Exploring Therapeutic Misconception.,"PURPOSE Therapeutic misconception is the tendency for a clinical trial participant to overlook the scientific objective of a clinical trial and instead believe that an experimental intervention is intended for personal therapeutic benefit. We sought to evaluate this tendency in the setting of a clinical trial of a new radiation therapy technology. METHODS Patients with left-sided, node positive breast cancer enrolled in a randomized clinical trial evaluating intensity modulated radiation therapy with deep inspiration breath hold (IMRT-DIBH) versus 3-dimensional conformal radiation therapy (3DCRT). Patients who enrolled completed surveys at baseline, after randomization, and upon completion of radiation therapy to evaluate expectations, satisfaction, and experiences. RESULTS Forty women participated in the survey study, with 20 in each arm. Most participants endorsed the perception that participation in the trial might result in better treatment than the current standard treatment (77%) and more medical attention than being off trial (54%). At baseline, most women (74%) believed that a new treatment technology is superior than an established one. Before randomization, 43% of participants believed IMRT-DIBH would be more effective than standard treatment with 3DCRT, none believed that 3DCRT would be more effective, 23% believed that they would be the same, and 34% did not know. None believed that IMRT-DIBH would cause worse long-term side effects, whereas 37% thought that 3DCRT would. Most (71%) reported that they would choose to be treated with IMRT-DIBH; none would have elected 3DCRT if given a choice. Nearly half (44%) in the 3DCRT arm wished that they had been assigned to the IMRT-DIBH arm; none in the IMRT-DIBH arm expressed a wish for crossover. CONCLUSIONS Most participants reported the perception that trial participation would result in better treatment and more medical attention than off trial, hallmarks of therapeutic misconception. Our observations provide empirical evidence of a fixed belief in the superiority of new technology and highlight the importance of adjusting expectations through informed consent to mitigate therapeutic misconception.",2020,"Nearly half (44%) in the 3DCRT arm wished that they had been assigned to the IMRT-DIBH arm; none in the IMRT-DIBH arm expressed a wish for crossover. ","['35 women surveyed', 'Patients with breast cancer enrolled']","['3DCRT', 'Radiotherapy Technologies', 'intensity modulated radiotherapy with deep inspiration breath hold (IMRT-DIBH) versus 3-dimensional conformal radiotherapy (3DCRT']",['medical attention'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0600521', 'cui_str': 'Conformal radiotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0235744', 'cui_str': 'Interrupted breathing'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",35.0,0.156869,"Nearly half (44%) in the 3DCRT arm wished that they had been assigned to the IMRT-DIBH arm; none in the IMRT-DIBH arm expressed a wish for crossover. ","[{'ForeName': 'Dean A', 'Initials': 'DA', 'LastName': 'Shumway', 'Affiliation': 'Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Motomura', 'Affiliation': 'Center for Law and the Biosciences and Stanford Program in Neuroscience and Society, Stanford Law School, Stanford, California.'}, {'ForeName': 'Kent A', 'Initials': 'KA', 'LastName': 'Griffith', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Hayman', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Lori J', 'Initials': 'LJ', 'LastName': 'Pierce', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Reshma', 'Initials': 'R', 'LastName': 'Jagsi', 'Affiliation': 'Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: rjagsi@med.umich.edu.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2020.05.021'] 1602,32458391,Temporal Deployment of Attention by Mental Training: an fMRI Study.,"In this study, we employed a visuo-motor imagery task of alertness as a mental training to examine temporal processing of motor responses within healthy young adults. Participants were divided into two groups (group 1; n = 20 who performed the mental training before the real physical task and a control group who performed the physical task without mental training). We vary the time interval between the imperative stimulus and the preceding one (fore-period) in which temporal preparation and arousal increase briefly. Our behavioural results provide clear evidence that mental training reinforces both temporal preparation and arousal, by shortening reaction time (RT), especially for the shortest fore-periods (FP) within exogenous ""FP 250 ms"" (p = 0.008) and endogenous alertness ""FP 650 ms"" (p = 0.001). We investigated how the brain controls such small temporal changes. We focus our neural hypothesis on three brain regions: anterior insula, dorsolateral prefrontal cortex, and anterior cingulate cortex and three putative circuits: one top-down (from dorsolateral prefrontal cortex to anterior cingulate cortex) and two bottom-up (from anterior insula to dorsolateral prefrontal cortex and anterior cingulate cortex). In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05). We suggest that attentional reinforcement induced by an intensive and short session of mental training induces a temporal deployment of attention and allow optimizing the time pressure by maintaining a high state of arousal and ameliorating temporal preparation.",2020,"In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05).",['healthy young adults'],"['Temporal Deployment of Attention by Mental Training', 'mental training before the real physical task and a control group who performed the physical task without mental training', 'visuo-motor imagery task of alertness as a mental training']","['anterior insula and cingulate cortex', 'endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex', 'shortening reaction time (RT']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}]","[{'cui': 'C0228259', 'cui_str': 'Anterior insula'}, {'cui': 'C0598179', 'cui_str': 'Cingulate Cortex'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0441636', 'cui_str': 'Surgical shortening - action'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",,0.0136049,"In fMRI, effective connectivity is strengthened during exogenous alertness between anterior insula and dorsolateral prefrontal cortex (p = 0.001), between anterior insula and cingulate cortex (p = 0.01), and during endogenous alertness between dorsolateral prefrontal cortex and anterior cingulate cortex (p = 0.05).","[{'ForeName': 'Souhir', 'Initials': 'S', 'LastName': 'Daly', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France. souhir.daly91@gmail.com.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Thai', 'Affiliation': 'Clinical Research & Imaging Centre (CRICBristol), Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Chama', 'Initials': 'C', 'LastName': 'Belkhiria', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}, {'ForeName': 'Chistelle', 'Initials': 'C', 'LastName': 'Langley', 'Affiliation': 'Clinical Research & Imaging Centre (CRICBristol), Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, UK.'}, {'ForeName': 'Alain Le', 'Initials': 'AL', 'LastName': 'Blanche', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'de Marco', 'Affiliation': 'LINP2 (Interdisciplinary Laboratory in Neurosciences, Physiology and Psychology), Université Paris Nanterre, 200 Avenue de la république, 92000, Nanterre, France.'}]","Cognitive, affective & behavioral neuroscience",['10.3758/s13415-020-00795-4'] 1603,32458393,Correction to: Conservative Sinusectomy vs. excision and primary off-midline closure for pilonidal disease: a randomized controlled trial.,"The original version of this article, unfortunately, contained an error. The given names and family names of the authors were interchanged and are now presented correctly. The original article has been corrected.].",2020,"The original version of this article, unfortunately, contained an error.",['pilonidal disease'],['Conservative Sinusectomy vs. excision and primary off-midline closure'],[],"[{'cui': 'C2317114', 'cui_str': 'Pilonidal disease'}]","[{'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}]",[],,0.0503036,"The original version of this article, unfortunately, contained an error.","[{'ForeName': 'Sotirios Georgios', 'Initials': 'SG', 'LastName': 'Popeskou', 'Affiliation': 'Department of Visceral Surgery and Transplantation, Geneva University Hospitals, Geneva, Switzerland. salvator10@yahoo.com.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Pravini', 'Affiliation': 'Depatment of Surgery, Regional Hospital of Lugano, Lugano, Switzerland.'}, {'ForeName': 'Sofoklis', 'Initials': 'S', 'LastName': 'Panteleimonitis', 'Affiliation': 'School of Health Sciences and social work, University of Portsmouth, Portsmouth, UK.'}, {'ForeName': 'Antoniacopo', 'Initials': 'A', 'LastName': 'Ferrario di Tor Vajana', 'Affiliation': 'Department of Surgery, Regional Hospital of Bellinzona, Bellinzona, Switzerland.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Vanoni', 'Affiliation': 'Department of Visceral Surgery, Lausanne University Hospital, Lausanne, Switzerland.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Schmalzbauer', 'Affiliation': 'Depatment of Surgery, Regional Hospital of Lugano, Lugano, Switzerland.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Posabella', 'Affiliation': 'Department of Surgery, Standort Unispital Clarunis, Universitäres Bauchzentrum Basel, Basel, Switzerland.'}, {'ForeName': 'Dimitri', 'Initials': 'D', 'LastName': 'Christoforidis', 'Affiliation': 'Depatment of Surgery, Regional Hospital of Lugano, Lugano, Switzerland. dimitri.christoforidis@eoc.ch.'}]",International journal of colorectal disease,['10.1007/s00384-020-03620-z'] 1604,32548299,Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer.,"This retrospective study examined magnetic resonance imaging (MRI)-derived tumor sphericity (SPH) as a quantitative measure of breast tumor morphology, and investigated the association between SPH and reader-assessed morphological pattern (MP). In addition, association of SPH with pathologic complete response was evaluated in patients enrolled in an adaptively randomized clinical trial designed to rapidly identify new agents for breast cancer. All patients underwent MRI examinations at multiple time points during the treatment. SPH values from pretreatment (T0) and early-treatment (T1) were investigated in this study. MP on T0 dynamic contrast-enhanced MRI was ranked from 1 to 5 in 220 patients. Mean SPH values decreased with the increased order of MP. SPH was higher in patients with pathologic complete response than in patients without (difference at T0: 0.04, 95% confidence interval [CI]: 0.02-0.05, P < .001; difference at T1: 0.03, 95% CI: 0.02-0.04, P < .001). The area under the receiver operating characteristic curve was estimated as 0.61 (95% CI, 0.57-0.65) at T0 and 0.58 (95% CI, 0.55-0.62) at T1. When the analysis was performed by cancer subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, highest area under the receiver operating characteristic curve were observed in HR-/HER2+: 0.67 (95% CI, 0.54-0.80) at T0, and 0.63 (95% CI, 0.51-0.76) at T1. Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.",2020,Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.,['Invasive Breast Cancer'],"['Neoadjuvant Chemotherapy', 'magnetic resonance imaging (MRI)-derived tumor sphericity (SPH']","['SPH', 'MP on T0 dynamic contrast-enhanced MRI', 'SPH values', 'area under the receiver operating characteristic curve', 'Mean SPH values', 'hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, highest area under the receiver operating characteristic curve']","[{'cui': 'C0853879', 'cui_str': 'Invasive carcinoma of breast'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0543482', 'cui_str': 'morphology'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0034772', 'cui_str': 'Receiver Operating Characteristic'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0242957', 'cui_str': 'Genes, erbb2'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0205250', 'cui_str': 'High'}]",220.0,0.0801601,Tumor SPH showed promise to quantify MRI MPs and as a biomarker for predicting treatment outcome at pre- or early-treatment time points.,"[{'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Newitt', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Bo La', 'Initials': 'B', 'LastName': 'Yun', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Ella F', 'Initials': 'EF', 'LastName': 'Jones', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Vignesh', 'Initials': 'V', 'LastName': 'Arasu', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Lisa J', 'Initials': 'LJ', 'LastName': 'Wilmes', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Gibbs', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Alex Anh-Tu', 'Initials': 'AA', 'LastName': 'Nguyen', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Natsuko', 'Initials': 'N', 'LastName': 'Onishi', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kornak', 'Affiliation': 'Departments of Epidemiology and Biostatistics; and.'}, {'ForeName': 'Bonnie N', 'Initials': 'BN', 'LastName': 'Joe', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Esserman', 'Affiliation': 'Surgery, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Nola M', 'Initials': 'NM', 'LastName': 'Hylton', 'Affiliation': 'Department of Radiology & Biomedical Imaging, University of California, San Francisco, San Francisco, CA.'}]","Tomography (Ann Arbor, Mich.)",['10.18383/j.tom.2020.00016'] 1605,32553417,Postoperative Pain after Treatment Using the GentleWave System: A Randomized Controlled Trial.,"INTRODUCTION Cleaning and shaping are necessary to allow for the delivery of irrigants and medicaments to the apical third of the canal. Standard treatment irrigation generally uses a conventional needle and some frequency of sonic activation. The GentleWave System (GWS; Sonendo, Inc, Laguna Hills, CA) combines irrigant delivery with multisonic activation. This randomized clinical trial aimed to determine if the GWS significantly decreases the incidence and intensity of postoperative pain. METHODS Patients used a numeric rating scale to record their pain level at the 6-hour time point before treatment. All participants were randomly divided into 2 groups and were blind to the treatment they received. The standard (control) group received endodontic treatment with conventional side-vented needle irrigation and ultrasonic activation. The second group received treatment with the GWS. Following treatment, patients used a numeric rating scale to record their pain level at 6, 24, 72, and 168 hours. RESULTS In the standard treatment group, 72.2% of patients experienced at least 1 occurrence of postoperative pain, whereas in the GWS group, 83.3% of patients experienced at least 1 occurrence of postoperative pain. The highest pain intensity level for both treatments occurred at the 6-hour posttreatment time point. All pain decreased with time after the 6-hour posttreatment time point (P < 1.237e -7 ). CONCLUSIONS There was no significant difference in the incidence or intensity of postoperative pain after either treatment group. However, both groups reported a statistically significant decrease in pain with time.",2020,"All pain decreased with time after the 6-hour posttreatment time point (P < 1.237e -7 ). ",[],"['GWS', 'GentleWave System', 'endodontic treatment with conventional side-vented needle irrigation and ultrasonic activation']","['All pain', 'postoperative pain', 'pain with time', 'highest pain intensity level', 'Postoperative Pain', 'incidence or intensity of postoperative pain', 'numeric rating scale to record their pain level']",[],"[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0700632', 'cui_str': 'Endodontic procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0181988', 'cui_str': 'Medication transfer needle, vented'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0332311', 'cui_str': 'With time'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}]",,0.0471475,"All pain decreased with time after the 6-hour posttreatment time point (P < 1.237e -7 ). ","[{'ForeName': 'Daryl', 'Initials': 'D', 'LastName': 'Grigsby', 'Affiliation': 'Division of Endodontics, School of Dentistry, University of Minnesota, Minneapolis, Minnesota. Electronic address: grigs029@umn.edu.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Ordinola-Zapata', 'Affiliation': 'Division of Endodontics, School of Dentistry, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Scott B', 'Initials': 'SB', 'LastName': 'McClanahan', 'Affiliation': 'Division of Endodontics, School of Dentistry, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Fok', 'Affiliation': 'Minnesota Dental Research Center for Biomaterials and Biomechanics, School of Dentistry, University of Minnesota, Minneapolis, Minnesota.'}]",Journal of endodontics,['10.1016/j.joen.2020.04.004'] 1606,32551817,Machine Learning Classifier Models Can Identify ARDS Phenotypes Using Readily Available Clinical Data.,"RATIONALE Two distinct phenotypes of ARDS with differential clinical outcomes and responses to randomly assigned treatment have consistently been identified in randomized controlled trial (RCT) cohorts using latent class analysis (LCA). Plasma biomarkers, key components in phenotype identification, currently lack point-of-care assays and represent a barrier to the clinical implementation of phenotypes. The objective of this study was to develop models to classify ARDS phenotypes using readily-available clinical data only. METHODS Three RCT cohorts served as the training dataset (ARMA, ALVEOLI, and FACTT, n=2022), and a fourth as the validation dataset (SAILS, n = 745). A gradient-boosted machine algorithm was used to develop classifier models using 24 variables (demographics, vital signs, laboratory, and respiratory variables) at enrollment. As secondary analyses, ALVEOLI and FACTT each served as the validation dataset and the remaining combined cohorts formed the training dataset for each analysis. Model performance was evaluated against LCA-derived phenotype. RESULTS For the primary analysis, the model accurately classified phenotypes in the validation cohort (AUC 0.95, CI:0.94-0.96). Using a probability cut-off of 0.5 to assign class, inflammatory biomarkers (Interleukin-6, Interleukin-8, Protein C, and sTNFR-1; p<0.0001) and 90-day mortality (38% vs 24%, p=0.0002) were significantly higher in the hyperinflammatory phenotype as classified by the model. Model accuracy was similar when ALVEOLI (AUC 0.94, CI:0.92-0.96) and FACTT (AUC 0.94, CI:0.92-0.95) were the validation cohorts. Significant treatment interactions were observed with the clinical-classifier model assigned phenotypes in both ALVEOLI (p=0.0113) and FACTT (p=0.0072). CONCLUSION ARDS phenotypes can be accurately identified using machine learning models based on readily-available clinical data and may enable rapid phenotype identification at the bedside.",2020,"Model accuracy was similar when ALVEOLI (AUC 0.94, CI:0.92-0.96) and FACTT (AUC 0.94, CI:0.92-0.95) were the validation cohorts.",[],[],"['inflammatory biomarkers (Interleukin-6, Interleukin-8, Protein C, and sTNFR-1; p<0.0001) and 90-day mortality', 'Model accuracy']",[],[],"[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0033621', 'cui_str': 'Protein C'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.0627125,"Model accuracy was similar when ALVEOLI (AUC 0.94, CI:0.92-0.96) and FACTT (AUC 0.94, CI:0.92-0.95) were the validation cohorts.","[{'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Sinha', 'Affiliation': 'University of California San Francisco Medical Center at Parnassus, 43166, Division of Pulmonary and Critical Care, San Francisco, California, United States; pratik.sinha@ucsf.edu.'}, {'ForeName': 'Matthew M', 'Initials': 'MM', 'LastName': 'Churpek', 'Affiliation': 'University of Wisconsin Madison, 5228, Madison, Wisconsin, United States.'}, {'ForeName': 'Carolyn S', 'Initials': 'CS', 'LastName': 'Calfee', 'Affiliation': 'UCSF, Medicine, San Francisco, California, United States.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.202002-0347OC'] 1607,32559602,Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.,"OBJECTIVE To assess the efficacy of vilaprisan compared with placebo in the management of the symptoms of uterine fibroids (UF), with a secondary objective to provide a descriptive comparison with ulipristal acetate. STUDY DESIGN The randomized, parallel-group, double-blind, placebo- and active-controlled, multicenter ASTEROID 2 trial assessed the efficacy and safety of vilaprisan versus placebo and ulipristal acetate for two 12-week treatment periods in women with ≥1 UF experiencing heavy menstrual bleeding (HMB). The primary endpoint compared the efficacy of vilaprisan with placebo at 12 weeks, assessed as the absence of bleeding/spotting by bleeding diary. Secondary endpoints compared the efficacy of vilaprisan with ulipristal acetate. Results of the first 12-week treatment period are reported here. RESULTS Women (mean age 42.5 years) were enrolled from 1 June 2015. At baseline, mean menstrual blood loss per 28 days was 214.1 mL and the volume of the three largest UF was 106.2 mL. In total, 155 women completed the initial 12-week treatment period. Complete absence of bleeding/spotting until the end of the 12-week treatment period was achieved by 62.9 % of women receiving vilaprisan versus 0.0 % with placebo (p < .001); 55.4 % of women treated with ulipristal acetate reported absence of bleeding/spotting. The predefined HMB response (<80 mL and >50 % reduction from baseline during the last 28 days of treatment) was observed in 95.7 % of subjects treated with vilaprisan and 86.5 % of subjects treated with ulipristal acetate. Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group. No safety concerns, including multiple laboratory parameters, were identified. CONCLUSION Daily administration of vilaprisan 2 mg induced amenorrhea, controlled bleeding, decreased UF size, and was well tolerated in women with HMB associated with UF. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov number: NCT02465814 https://clinicaltrials.gov/ct2/show/NCT02465814.",2020,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","['women with ≥1 UF experiencing heavy menstrual bleeding (HMB', 'women with uterine fibroids', 'Women (mean age 42.5 years) were enrolled from 1 June 2015', '155 women completed the initial 12-week treatment period']","['Vilaprisan and ulipristal acetate', 'ulipristal acetate', 'vilaprisan versus placebo and ulipristal acetate', 'vilaprisan', 'placebo']","['mean menstrual blood loss', 'HMB response', 'Efficacy and safety', 'absence of bleeding/spotting by bleeding diary', 'Complete absence of bleeding/spotting', 'efficacy and safety', 'amenorrhea, controlled bleeding, decreased UF size', 'efficacy of vilaprisan', 'efficacy of vilaprisan with ulipristal acetate', 'absence of bleeding/spotting']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0025323', 'cui_str': 'Menorrhagia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0694689', 'cui_str': 'Menstrual blood'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0149533', 'cui_str': 'Control of hemorrhage'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C4508937', 'cui_str': 'vilaprisan'}, {'cui': 'C2723461', 'cui_str': 'Ulipristal acetate'}]",155.0,0.413833,"Vilaprisan and ulipristal acetate treatment reduced the sum of the volume of the three largest UF by 29.9 % and 23.8 %, respectively, whereas an increase of 6.3 % was observed in the placebo group.","[{'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, and Karolinska University Hospital, S-171 76, Stockholm, Sweden. Electronic address: Kristina.Gemzell@ki.se.""}, {'ForeName': 'Oskari', 'Initials': 'O', 'LastName': 'Heikinheimo', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, PO Box 140, 00029-HUS, Helsinki, Finland. Electronic address: oskari.heikinheimo@helsinki.fi.'}, {'ForeName': 'Janos', 'Initials': 'J', 'LastName': 'Zatik', 'Affiliation': 'Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Magan Rendelo, 48 Szent Anna utca, Debrecen, Hungary. Electronic address: jzatik@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Poka', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary. Electronic address: pokar@med.unideb.hu.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Rechberger', 'Affiliation': 'II Department of Gynecology, Medical University of Lublin, Racławickie 1 Street, 20-059, Lublin, Poland. Electronic address: rechbergt@yahoo.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hudecek', 'Affiliation': 'Department of Obstetrics and Gynecology, Brno University Hospital and Masaryk University Medical School, Jihlavská 20, CZ - 625 00, Brno, Czech Republic. Electronic address: hudecek.robert@fnbrno.cz.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Petersdorf', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Kathrin.petersdorf@bayer.com.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Ramirez', 'Affiliation': 'Syneos Health, Frankfurter StraBe 233 Triforum, Haus C1 Neu-Isenburg, 63263, Germany. Electronic address: francisco.ramirez1.ext@bayer.com.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Faustmann', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: thomas.faustmann@bayer.com.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Groettrup-Wolfers', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Esther.groettrup-wolfers@bayer.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Seitz', 'Affiliation': 'Bayer AG, Müllerstraße 178, 13342, Berlin, Germany. Electronic address: Christian.seitz@bayer.com.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.043'] 1608,32567065,Effectiveness of the WeChat-based smoking cessation intervention ('WeChat WeQuit' program) in China: study protocol for a randomized controlled trial.,"BACKGROUND AND AIMS Since its first release in 2011, WeChat (Chinese pinyin: Wei Xin) has been widely used to promote health. As the most popular all-in-one social media application providing free instant messaging, voice, text, pictures, videos and location information exchange via smartphone, WeChat holds promise for delivering smoking cessation services to a large number of people at low unit cost in China, a country with more than 300 million smokers. This protocol is for a study that aims to assess the efficacy of a WeChat-based smoking cessation intervention ('WeChat WeQuit') for treatment-seeking smokers in China. DESIGN In this two-arm randomized controlled trial (RCT), the control group will receive only a digital version of a booklet of 'Happy Quit'. The intervention group will also receive the 2 weeks pre- and 12 weeks post-quit 'WeChat WeQuit' intervention. Both groups will be followed-up to 26 weeks (6 months) after quit day. SETTING This on-line trial has no restrictions on setting or location. PARTICIPANTS Chinese-speaking current smokers (have smoked ≥100 cigarettes in their life-time and currently smoke cigarettes) aged 18+ years willing to make a quit attempt within 1 month (n = 2000) will be recruited by on- and off-line advertising. Potential participants will register their interest by sending WeChat messages or text messages, or making a voice call. MEASUREMENTS The primary outcome measure is self-reported 26-week continuous smoking abstinence with biological verification [test by clinic visit: expired carbon monoxide concentration <10 parts per million (p.p.m.) or by mailing cotinine urine dipsticks: urine cotinine <200 ng/ml]. Secondary outcome measures include: 7-day point prevalence abstinence at weeks 1, 4, 8, 12, 16, 20 and 26 after-quit day; self-reported 12-week continuous smoking abstinence and 26-week continuous smoking abstinence; reductions in number of cigarettes smoked per day; and rates of participation in and completion of the smoking-cessation program. CONCLUSIONS If the 'WeChat WeQuit' program is found to be effective, it will be an accessible, affordable and widely implementable intervention to help cigarette smokers to quit. The potential public health impact of its expansion into underserved regions or communities is considerable.",2020,"In this two-arm randomized controlled trial (RCT), the control group will receive only a digital version of a booklet of ""Happy Quit"".","['Chinese-speaking current smokers (smoked ≥ 100 cigarettes in the lifetime and currently smokes cigarettes) aged 18+, willing to make a quit attempt within 1 month (n = 2000) will be recruited by on-line and off-line advertising', 'treatment seeking smokers in China']","['WeChat-based smoking cessation intervention (""WeChat WeQuit', 'WeChat-based Smoking Cessation intervention (""WeChat WeQuit"" program']","[' 7-day point prevalence abstinence', 'continuous smoking abstinence and 26-week continuous smoking abstinence; reductions in number of cigarettes smoked per day; and rates of participation in and completion of smoking-cessation program', 'self-reported 26-week continuous smoking abstinence with biological verification (test by clinic visit: expired carbon monoxide concentration < 10 ppm or by mailing cotinine urine dipsticks: urine cotinine < 200 ng/ml']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0600109', 'cui_str': 'Willing'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0001690', 'cui_str': 'Advertising as Topic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0010194', 'cui_str': 'Cotinine'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0441090', 'cui_str': 'Dipstick'}, {'cui': 'C1697737', 'cui_str': 'Urine cotinine test'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}]",,0.0682711,"In this two-arm randomized controlled trial (RCT), the control group will receive only a digital version of a booklet of ""Happy Quit"".","[{'ForeName': 'Yanhui', 'Initials': 'Y', 'LastName': 'Liao', 'Affiliation': 'Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.'}, {'ForeName': 'Yunfei', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Yueheng', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Psychiatry, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'McNeill', 'Affiliation': ""Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jinsong', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.'}]","Addiction (Abingdon, England)",['10.1111/add.15166'] 1609,32563378,"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.","BACKGROUND Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. METHODS We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. FINDINGS Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82-1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). INTERPRETATION We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial. FUNDING UK National Institute for Health Research Health Technology Assessment Programme.",2020,Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977;,"['patients with gastrointestinal bleeding', 'Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding', 'patients with trauma', '164 hospitals in 15 countries', 'patients with acute gastrointestinal bleeding (HALT-IT', 'Between July 4, 2013, and June 21, 2019, we randomly allocated 12\u2008009 patients to receive']","['Tranexamic acid', 'placebo', 'matching placebo', 'tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9', 'tranexamic acid', '0·9% sodium chloride']","['death due to bleeding', 'death and thromboembolic events', 'Venous thromboembolic events (deep vein thrombosis or pulmonary embolism', 'Arterial thromboembolic events (myocardial infarction or stroke', 'Death due to bleeding', 'death from gastrointestinal bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}, {'cui': 'C1273518', 'cui_str': 'Responsible to'}, {'cui': 'C0087130', 'cui_str': 'Uncertain'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0024050', 'cui_str': 'Lower gastrointestinal hemorrhage'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0266807', 'cui_str': 'Acute gastrointestinal hemorrhage'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0454287', 'cui_str': 'Isotonic exercise'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C4707055', 'cui_str': 'Infuse'}, {'cui': 'C0104485', 'cui_str': 'AT 125'}, {'cui': 'C0439421', 'cui_str': 'mg/h'}, {'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0017181', 'cui_str': 'Gastrointestinal hemorrhage'}]",12009.0,0.734066,Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977;,"[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30848-5'] 1610,32564453,Profiling ocular surface responses to preserved and non-preserved topical glaucoma medications: A 2-year randomized evaluation study.,"BACKGROUND Use of topical glaucoma medications has been reported to cause ocular surface (OS) discomfort and inflammation. This study explores the profile of inflammatory cytokines and OS symptoms induced in response to preserved and non-preserved drops. METHODS Prospective, randomized evaluation on 36 treatment-naïve patients over 24 months of three differently preserved glaucoma drop preparations: Preservative-free (PF), polyquad (PQ) and benzalkonium chloride (BAK). Study participants were evaluated at baseline and then at 1, 3, 6, 12 and 24 months while on medication. At each visit, participants completed the OS disease index (OSDI) questionnaire, had basal tear sampling and impression cytology (IC) of the conjunctival epithelium. Quantitative polymerase chain reaction was performed to measure the gene expression of inflammatory cytokines [interleukin (IL)-6, IL-8, IL-10, IL-12A, IL-12B, IL-17A, IL-1β and tumour necrosis factor-α] in the IC samples. Corresponding protein expression of cytokines in tear samples was assessed by the Becton-Dickinson cytometric bead arrays. RESULTS Compared to PF and PQ groups, mRNA and protein expression of IL-6, IL-8 and IL-1β increased in samples from the BAK group in a time-dependent fashion, whereas all other cytokines showed a non-significant increase. In the BAK group, there was a strong correlation between OSDI and the levels of IC/IL-1β (r = .832, R 2 = .692 and P = .040); IC/IL-10 (r = .925, R 2 = .856 and P = .008) and tear/IL-1β (r = .899, R 2 = .808 and P = .014). CONCLUSIONS BAK-preserved topical drops stimulate a sterile inflammatory response on the OS within 3 months which is maintained thereafter, whereas PF-drops and PQ-preserved drops showed no significant OS inflammation.",2020,"In the BAK group, there was a strong correlation between OSDI and the levels of IC/IL-1β (r=0.832, R squared=0.692 and p=0.040); IC/IL-10 (r=0.925, R squared=0.856 and p=0.008) and tear/IL-1β",['thirty-six treatment-naïve patients over 24 months of three differently preserved glaucoma drop preparations'],"['Preservative-free (PF), Polyquad (PQ), and Benzalkonium chloride (BAK']","['mRNA and protein expression of IL-6, IL-8, and IL-1β', 'tear/IL-1β', 'OSDI and the levels of IC/IL-1β', 'OS inflammation', 'gene expression of inflammatory cytokines (Interleukin (IL)-6, IL-8, IL-10, IL-12A, IL-12B, IL-17A, IL-1β, and tumour necrosis factor (TNF)-α', 'Ocular Surface disease index (OSDI) questionnaire, had basal tear sampling and impression cytology (IC) of the conjunctival epithelium']","[{'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}]","[{'cui': 'C0033086', 'cui_str': 'Drug preservative'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0071668', 'cui_str': 'polyquaternium 1'}, {'cui': 'C0005026', 'cui_str': 'Benzalkonium chloride'}]","[{'cui': 'C0035696', 'cui_str': 'Messenger RNA'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0010818', 'cui_str': 'Cytology'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1121403', 'cui_str': 'IL-12p35'}, {'cui': 'C1099914', 'cui_str': 'IL12B protein, human'}, {'cui': 'C1701790', 'cui_str': 'IL17A protein, human'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action'}, {'cui': 'C0014609', 'cui_str': 'Epithelium'}]",,0.0697721,"In the BAK group, there was a strong correlation between OSDI and the levels of IC/IL-1β (r=0.832, R squared=0.692 and p=0.040); IC/IL-10 (r=0.925, R squared=0.856 and p=0.008) and tear/IL-1β","[{'ForeName': 'Imran', 'Initials': 'I', 'LastName': 'Mohammed', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Bina', 'Initials': 'B', 'LastName': 'Kulkarni', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Lana A', 'Initials': 'LA', 'LastName': 'Faraj', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Abbas', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Harminder S', 'Initials': 'HS', 'LastName': 'Dua', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'King', 'Affiliation': 'Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13814'] 1611,32565333,In Vivo Evaluation of Effect of Preoperative Ibuprofen on Proinflammatory Mediators in Irreversible Pulpitis Cases.,"INTRODUCTION Preoperative administration of nonsteroidal anti-inflammatory drugs has been suggested as a method for increasing the efficacy of local anesthetics and decreasing postoperative pain in symptomatic irreversible pulpitis cases. However, the effects of ibuprofen at the molecular level are still unknown. Hence, the purpose of this study was to compare the levels of proinflammatory mediators in the dental pulp of teeth with irreversible pulpitis in patients who medicated with preoperative ibuprofen versus those who did not. METHODS Thirty-four patients undergoing conventional endodontic therapy for teeth with irreversible pulpitis were selected and randomly assigned into either the ibuprofen or nonibuprofen group. Four patients undergoing endodontic therapy for prosthodontic reasons served as controls. Patients in the ibuprofen group were instructed to take 600 mg ibuprofen 1 hour before treatment, whereas patients in the nonibuprofen and control groups were asked to avoid analgesics before treatment. Blood samples obtained from the pulp upon access were tested for levels of prostaglandin E2, tumor necrosis efactor alpha, interleukin (IL)-6, IL-1β, and interferon gamma using high-sensitivity enzyme-linked immunosorbent assay. Postoperative pain levels were recorded for the groups. Data for the cytokine levels and postoperative pain were analyzed using statistical analysis. RESULTS There was a significant decrease in the levels of prostaglandin E2, tumor necrosis factor alpha, IL-6, and interferon gamma in the ibuprofen group compared with the nonibuprofen group. No significant differences were noted in the postoperative pain levels between these groups. CONCLUSIONS The data showed that preoperative ibuprofen significantly decreased the levels of most proinflammatory cytokines in the dental pulp, which could possibly help with anesthesia in irreversible cases.",2020,"There was a significant decrease in the levels of PGE2, TNF-α, IL-6, and IFN-γ in the ibuprofen group as compared to the non-ibuprofen group.","['irreversible pulpitis cases', 'Four patients undergoing', 'Thirty-four patients undergoing', 'for teeth with irreversible pulpitis', 'dental pulp of teeth with irreversible pulpitis in patients who medicated with pre-operative ibuprofen versus those who did not']","['pre-operative ibuprofen', 'ibuprofen or non-ibuprofen', 'conventional endodontic therapy', 'endodontic therapy', 'ibuprofen']","['post-operative pain levels', 'levels of PGE2, TNF-α, IL-6, and IFN-γ', 'levels of PGE2, TNF-α, IL-6, IL-1β and IFN-γ using high sensitivity ELISAs', 'Post-operative pain levels', 'cytokine levels and post-operative pain', 'levels of most pro-inflammatory cytokines']","[{'cui': 'C0399406', 'cui_str': 'Irreversible pulpitis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0011399', 'cui_str': 'Structure of pulp of tooth'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0332274', 'cui_str': 'Endodontic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]",4.0,0.0251917,"There was a significant decrease in the levels of PGE2, TNF-α, IL-6, and IFN-γ in the ibuprofen group as compared to the non-ibuprofen group.","[{'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Nguyen', 'Affiliation': 'Department of Endodontics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Yen-Wei', 'Initials': 'YW', 'LastName': 'Chen', 'Affiliation': 'Department of Restorative Dentistry, University of Washington, Seattle, Washington.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Johnson', 'Affiliation': 'Department of Endodontics, University of Washington, Seattle, Washington.'}, {'ForeName': 'Avina', 'Initials': 'A', 'LastName': 'Paranjpe', 'Affiliation': 'Department of Endodontics, University of Washington, Seattle, Washington. Electronic address: avina@uw.edu.'}]",Journal of endodontics,['10.1016/j.joen.2020.06.009'] 1612,32576320,"Dietary nitrate improves skeletal muscle microvascular oxygenation in HIV-infected patients receiving highly active antiretroviral therapy: a randomised, double-blind, cross-over, placebo-controlled study.","HIV-1 proteins and highly active antiretroviral therapy (HAART) have been associated with microvascular endothelial dysfunction. Although nitrate-rich beetroot juice (NR-BJ) consumption has been shown to improve endothelial function in clinical population, its effects in HIV-infected patients has not been addressed. We investigated the effect of a single dose of NR-BJ on muscle oxygen saturation parameters in response to a handgrip exercise in HIV-infected patients. Fifteen HIV-infected patients received NR-BJ or nitrate-depleted beetroot juice (ND-BJ) in a double-blind cross-over design. Near-IR spectroscopy was utilised to assess muscle oxygen saturation parameters during rhythmic handgrip exercise after NR-BJ or ND-BJ supplementation. A significant faster muscle oxygen desaturation rate during exercise (-7·97 (sd 5·00) v. -5·45 (3·94) %/s, P = 0·005) and muscle oxygen resaturation rate during exercise recovery (0·43 (0·24) v. 0·28 (0·24) %/s, P = 0·030) after NR-BJ ingestion was found. However, no significant difference in exercise time until fatigue was observed. Salivary nitrite and urinary nitrate concentration were analysed after NR-BJ or ND-BJ. A significant increase in salivary nitrite and urinary nitrate in NR-BJ was observed compared with ND-BJ (P < 0·05). Our findings suggest that NR-BJ consumption may acutely improve muscle oxygen saturation during exercise and exercise recovery in HIV-infected patients undergoing HAART and who are expected to present microvascular damage. Thus, future studies investigating the chronic effects of NR-BJ are warranted to delineate a better nutritional strategy based on nitrate-rich foods.",2020,A significant faster muscle oxygen desaturation rate during exercise (-7.97±5.00 vs -5.45±3.94 %.s-1; p=0.005) and the muscle oxygen resaturation rate during exercise recovery (0.43±0.24 vs 0.28±0.24 %.s-1; p=0.030) after NR-BJ ingestion was found.,"['HIV-infected patients receiving highly active antiretroviral therapy', 'Fifteen HIV-infected patients received', 'HIV-infected patients']","['NR-BJ', 'nitrate-rich beetroot juice (NR-BJ) consumption', 'Dietary nitrate', 'Human immunodeficiency virus-1 (HIV-1) proteins and highly active antiretroviral therapy (HAART', 'NR-BJ or nitrate-depleted beetroot juice', 'placebo']","['endothelial function', 'muscle oxygen saturation', 'muscle oxygen desaturation rate', 'muscle oxygen resaturation rate during exercise recovery', 'salivary nitrite and urinary nitrate in NR-BJ condition', 'Salivary nitrite and urinary nitrate concentration', 'skeletal muscle microvascular oxygenation', 'exercise time until fatigue']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0887947', 'cui_str': 'Highly active anti-retroviral therapy'}]","[{'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0887947', 'cui_str': 'Highly active anti-retroviral therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}]",15.0,0.164489,A significant faster muscle oxygen desaturation rate during exercise (-7.97±5.00 vs -5.45±3.94 %.s-1; p=0.005) and the muscle oxygen resaturation rate during exercise recovery (0.43±0.24 vs 0.28±0.24 %.s-1; p=0.030) after NR-BJ ingestion was found.,"[{'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Barros-Santos', 'Affiliation': 'Nutrition and Exercise Metabolism Research Group, Nutrition Institute, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, 27979-000, Brazil.'}, {'ForeName': 'Gustavo Vieira', 'Initials': 'GV', 'LastName': 'de Oliveira', 'Affiliation': 'Nutrition and Exercise Metabolism Research Group, Nutrition Institute, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, 27979-000, Brazil.'}, {'ForeName': 'Mônica', 'Initials': 'M', 'LastName': 'Volino-Souza', 'Affiliation': 'Nutrition and Exercise Metabolism Research Group, Nutrition Institute, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, 27979-000, Brazil.'}, {'ForeName': 'Thiago Silveira', 'Initials': 'TS', 'LastName': 'Alvares', 'Affiliation': 'Nutrition and Exercise Metabolism Research Group, Nutrition Institute, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, 27979-000, Brazil.'}]",The British journal of nutrition,['10.1017/S0007114520002226'] 1613,32576090,Telemedicine Cognitive Behavioral Therapy for Anxiety After Stroke: Proof-of-Concept Randomized Controlled Trial.,"BACKGROUND AND PURPOSE Disabling anxiety affects a quarter of stroke survivors but access to treatment is poor. We developed a telemedicine model for delivering guided self-help cognitive behavioral therapy (CBT) for anxiety after stroke (TASK-CBT). We aimed to evaluate the feasibility of TASK-CBT in a randomized controlled trial workflow that enabled all trial procedures to be carried out remotely. In addition, we explored the feasibility of wrist-worn actigraphy sensor as a way of measuring objective outcomes in this clinical trial. METHODS We recruited adult community-based stroke patients (n=27) and randomly allocated them to TASK-CBT (n=14) or relaxation therapy (TASK-Relax), an active comparator (n=13). RESULTS In our sample (mean age 65 [±10]; 56% men; 63% stroke, 37% transient ischemic attacks), remote self-enrolment, electronic signature, intervention delivery, and automated follow-up were feasible. All participants completed all TASK-CBT sessions (14/14). Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20. Mean actigraphy sensor wearing-time was 33 days (±15). CONCLUSIONS Our preliminary feasibility data from the current study support a larger definitive clinical trial and the use of wrist-worn actigraphy sensor in anxious stroke survivors. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT03439813.",2020,Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20.,"['anxious stroke survivors', 'In our sample (mean age 65 [±10]; 56% men; 63% stroke, 37% transient ischemic attacks), remote self-enrolment, electronic signature, intervention delivery, and automated follow-up were feasible', 'adult community-based stroke patients (n=27']","['telemedicine model for delivering guided self-help cognitive behavioral therapy (CBT', 'Telemedicine Cognitive Behavioral Therapy', 'TASK-CBT', 'relaxation therapy (TASK-Relax), an active comparator (n=13', 'wrist-worn actigraphy sensor']","['Mean actigraphy sensor wearing-time', 'Lower levels of anxiety', 'Anxiety']","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C2733435', 'cui_str': 'Guided self-help cognitive behavioral therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0282333', 'cui_str': 'Relaxation training therapy'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.157782,Lower levels of anxiety were observed in TASK-CBT when compared with TASK-Relax at both weeks 6 and 20.,"[{'ForeName': 'Ho-Yan Yvonne', 'Initials': 'HY', 'LastName': 'Chun', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Carson', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Tsanas', 'Affiliation': 'Centre for Medical Informatics, Usher Institute (A.T.), University of Edinburgh, UK.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Dennis', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Gillian E', 'Initials': 'GE', 'LastName': 'Mead', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}, {'ForeName': 'Clementina', 'Initials': 'C', 'LastName': 'Calabria', 'Affiliation': 'Royal Infirmary of Edinburgh (C.C.), National Health Service Lothian, Edinburgh, UK.'}, {'ForeName': 'William N', 'Initials': 'WN', 'LastName': 'Whiteley', 'Affiliation': 'Centre for Clinical Brain Sciences (H.Y.Y.C., A.J.C., M.S.D., G.E.M., W.N.W.), University of Edinburgh, UK.'}]",Stroke,['10.1161/STROKEAHA.120.029042'] 1614,32453759,"Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: A randomized, controlled, double-blind trial.","BACKGROUND Postoperative depression is one of the most common mental disorders in patients undergoing cancer surgery and it often delays postoperative recovery. We investigated whether dezocine, an analgesic with inhibitory effect on the serotonin and norepinephrine reuptake, could relieve postoperative depressive symptoms in patients undergoing colorectal cancer surgery. METHODS This randomized, controlled, single-center, double-blind trial was performed in the Second Affiliated Hospital of the Army Medical University. A total of 120 patients were randomly assigned to receive either sufentanil (1.3 μg/kg) with dezocine (1 mg/kg) (dezocine group; n = 60) or only sufentanil (2.3 μg/kg) (control group; n = 60) for patient-controlled intravenous analgesia after colorectal cancer surgery. The primary outcome was the Beck Depression Inventory score at 2 days after surgery. The secondary outcomes included the Beck Anxiety Inventory, sleep quality, and quality of recovery scores. RESULTS Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001). No significant difference was found in other outcomes between the two groups. CONCLUSIONS Intravenous analgesia using dezocine can relieve postoperative depression symptoms and improve sleep quality in patients undergoing colorectal cancer surgery.",2020,"Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001).","['patients undergoing colorectal cancer surgery', 'A total of 120 patients', 'patients undergoing cancer surgery', 'alleviates depressive symptoms after colorectal cancer surgery', 'Second Affiliated Hospital of the Army Medical University']","['dezocine (1 mg/kg) (dezocine group; n = 60) or only sufentanil (2.3 μg/kg) (control group; n = 60) for patient-controlled intravenous analgesia after colorectal cancer surgery', 'sufentanil', 'dezocine', 'serotonin and norepinephrine reuptake']","['night sleep quality', 'lower depression scores', 'postoperative depressive symptoms', 'Beck Anxiety Inventory, sleep quality, and quality of recovery scores', 'postoperative depression symptoms', 'sleep quality', 'Beck Depression Inventory score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0057626', 'cui_str': 'dezocine'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0028351', 'cui_str': 'Norepinephrine'}]","[{'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0362037', 'cui_str': 'Postoperative depression'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}]",120.0,0.70306,"Compared with those in the control group, patients in the dezocine group had lower depression scores (7.3±3.4 vs. 9.9±3.5, mean difference 2.6, 95% CI: 1.4-3.9; P<0.001) at 2 days after surgery and better night sleep quality at the day of surgery (P = 0.010) and at 1 day after the surgery (P<0.001).","[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Zhuoxi', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Chunrui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Guiying', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Jinping', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Mingming', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Lijuan', 'Initials': 'L', 'LastName': 'Feng', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Guangyou', 'Initials': 'G', 'LastName': 'Duan', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Second Affiliated Hospital, Army Medical University, Chongqing, China.'}]",PloS one,['10.1371/journal.pone.0233412'] 1615,32453774,"Effect of guided counseling on dietary practices of pregnant women in West Gojjam Zone, Ethiopia.","BACKGROUND In Ethiopia, although nutrition education has been given during pregnancy, most women have inadequate nutrient intakes. As a result, the prevalence of malnutrition is high during pregnancy. In this study, we set out to evaluate the effect of guided counseling based on the health belief model and the theory of planned behavior on the dietary practices of pregnant women. METHODS A two-arm parallel cluster randomized controlled community trial was carried out among pregnant women in West, Gojjam Zone, Ethiopia from May 1, 2018, to April 30, 2019. A total of 346 and 348 pregnant women were recruited from the intervention and control clusters, respectively. Of which endline data were collected from 313 and 332 pregnant women in the intervention and control groups, respectively. Each woman in the intervention group attended four counseling sessions. Women in the control group attended the routine nutrition education given by the health care system. Data were collected using a structured questionnaire. McNemar test and Generalized Estimating Equations were used to evaluate the intervention effect. RESULTS The average difference of appropriate dietary practice between the two groups was 30.7%. After controlling for the possible confounders, women in the intervention group had 7.2 times [AOR = 7.187, 95% CI: (4.49, 11.49)] higher odds of having appropriate dietary practices compared with the control group. Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. CONCLUSION Counseling based on the health belief model and the theory of planned behavior is an effective approach in increasing the proportion of women who had appropriate dietary practices. Thus, these findings suggest the need for employing trimester based counseling using the HBM and the TPB to improve the dietary practices of pregnant women. TRIAL REGISTRATION The trial was registered in Clinical Trials.gov (NCT03627156).",2020,"Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. ","['A total of 346 and 348 pregnant women', '313 and 332 pregnant women in the intervention and control groups, respectively', 'pregnant women in West, Gojjam Zone, Ethiopia from May 1, 2018, to April 30, 2019', 'pregnant women in West Gojjam Zone, Ethiopia', 'women who had appropriate dietary practices', 'pregnant women']","['routine nutrition education', 'guided counseling']",['Dietary diversity and meal frequency'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C4517707', 'cui_str': '313'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037769', 'cui_str': 'West syndrome'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.0585045,"Dietary diversity and meal frequency of counseled women were 7 [AOR = 6.994, 95% CI: (4.59, 10.66)] and 8 [AOR = 8.146, 95% CI: (5.377, 12.341)] times higher than dietary diversity and meal frequency of women in the control group, respectively. ","[{'ForeName': 'Yeshalem Mulugeta', 'Initials': 'YM', 'LastName': 'Demilew', 'Affiliation': 'School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.'}, {'ForeName': 'Getu Degu', 'Initials': 'GD', 'LastName': 'Alene', 'Affiliation': 'School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.'}, {'ForeName': 'Tefera', 'Initials': 'T', 'LastName': 'Belachew', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Public Health, Jimma University, Jimma, Ethiopia.'}]",PloS one,['10.1371/journal.pone.0233429'] 1616,32458282,EEG Theta/Beta Ratio Neurofeedback Training in Healthy Females.,A growing number of studies suggest that EEG theta/beta ratio (TBR) is inversely related to executive cognitive control. Neurofeedback training aimed at reducing TBR (TBR NFT) might provide a tool to study causality in this relation and might enhance human performance. To investigate whether TBR NFT reduces TBR in healthy participants. Twelve healthy female participants were assigned (single blind) to one of three groups. Groups differed on baseline durations and one group received only sham NFT. TBR NFT consisted of eight or fourteen 25-min sessions. No evidence was found that TBR NFT had any effect on TBR. The current TBR NFT protocol is possibly ineffective. This is in line with a previous study with a different protocol.,2020,No evidence was found that TBR NFT had any effect on TBR.,"['healthy participants', 'Healthy Females', 'Twelve healthy female participants']","['sham NFT', 'Neurofeedback training aimed at reducing TBR (TBR NFT', 'TBR NFT']","['TBR', 'EEG Theta/Beta Ratio Neurofeedback Training', 'EEG theta/beta ratio (TBR']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0085400', 'cui_str': 'Neurofibrillary degeneration'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]","[{'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",12.0,0.0266986,No evidence was found that TBR NFT had any effect on TBR.,"[{'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'van Son', 'Affiliation': 'Institute of Psychology, Leiden University, Leiden, The Netherlands. dana.vanson@yale.edu.'}, {'ForeName': 'Willem', 'Initials': 'W', 'LastName': 'van der Does', 'Affiliation': 'Institute of Psychology, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Guido P H', 'Initials': 'GPH', 'LastName': 'Band', 'Affiliation': 'Institute of Psychology, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Putman', 'Affiliation': 'Institute of Psychology, Leiden University, Leiden, The Netherlands.'}]",Applied psychophysiology and biofeedback,['10.1007/s10484-020-09472-1'] 1617,31388184,Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.,"BACKGROUND An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS. METHODS This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual. RESULTS The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1-2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe. CONCLUSIONS The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed.",2019,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","['For Type II cases (~80% were HGS', '49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis']",[],[],"[{'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C1568891', 'cui_str': 'HGS protein, human'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],[],49.0,0.0221786,"The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Russell', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ciaren', 'Initials': 'C', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK.'}, {'ForeName': 'Alfonsina', 'Initials': 'A', 'LastName': ""D'Amato"", 'Affiliation': 'Department of Pharmaceutical Sciences, University of Milan, Milano, Lombardy, Italy.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Gentry-Maharaj', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Ryan', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Jatinderpal K', 'Initials': 'JK', 'LastName': 'Kalsi', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Whetton', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Usha', 'Initials': 'U', 'LastName': 'Menon', 'Affiliation': 'MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Faculty of Population Health Sciences, University College London, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jacobs', 'Affiliation': 'Stoller Biomarker Discovery Centre and Manchester Molecular Pathology Innovation Centre, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK. i.jacobs@unsw.edu.au.'}, {'ForeName': 'Robert L J', 'Initials': 'RLJ', 'LastName': 'Graham', 'Affiliation': 'School of Biological Sciences, Queens University Belfast, Chlorine Gardens, Belfast, BT9 5DL, UK. r.graham@qub.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0544-0'] 1618,31388185,Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence by tumour and nodal stage.,"BACKGROUND Intratumoural T-cell infiltrate intensity cortes wrelaith clinical outcome in stage II/III colorectal cancer (CRC). We aimed to determine whether this association varies across this heterogeneous group. METHODS We performed a pooled analysis of 1804 CRCs from the QUASAR2 and VICTOR trials. Intratumoural CD8 + and CD3 + densities were quantified by immunohistochemistry in tissue microarray (TMA) cores, and their association with clinical outcome analysed by Cox regression. We validated our results using publicly available gene expression data in a pooled analysis of 1375 CRCs from seven independent series. RESULTS In QUASAR2, intratumoural CD8 + was a stronger predictor of CRC recurrence than CD3 + and showed similar discriminative ability to both markers in combination. Pooled multivariable analysis of both trials showed increasing CD8 + density was associated with reduced recurrence risk independent of confounders including DNA mismatch repair deficiency, POLE mutation and chromosomal instability (multivariable hazard ratio [HR] for each two-fold increase = 0.92, 95%CI = 0.87-0.97, P = 3.6 × 10 -3 ). This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090. Analysis of tumour CD8A expression in the independent validation cohort revealed similar variation in prognostic value across risk strata (P INTERACTION  = 0.048). CONCLUSIONS The prognostic value of intratumoural CD8 + cell infiltration in stage II/III CRC varies across tumour and nodal risk strata.",2019,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.",['stage II/III colorectal cancer (CRC'],[],"['tumour CD8A expression', 'CRC recurrence', 'Tumour-infiltrating CD8 + lymphocytes and colorectal cancer recurrence', 'CD8 + density', 'DNA mismatch repair deficiency, POLE mutation and chromosomal instability', 'Intratumoural CD8 + and CD3 + densities']","[{'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}]",[],"[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1155661', 'cui_str': 'DNA mismatch repair'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1257806', 'cui_str': 'Chromosome Instability'}, {'cui': 'C0108779', 'cui_str': 'Lymphocyte antigen CD3'}]",1804.0,0.198792,"This association was not uniform across risk strata defined by tumour and nodal stage: absent in low-risk (pT3,N0) cases (HR = 1.03, 95%CI = 0.87-1.21, P = 0.75), modest in intermediate-risk (pT4,N0 or pT1-3,N1-2) cases (HR = 0.92, 95%CI = 0.86-1.0, P = 0.046) and strong in high-risk (pT4,N1-2) cases (HR = 0.87, 95%CI = 0.79-0.97, P = 9.4 × 10 -3 ); P INTERACTION  = 0.090.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Glaire', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Enric', 'Initials': 'E', 'LastName': 'Domingo', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Sveen', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Jarle', 'Initials': 'J', 'LastName': 'Bruun', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Arild', 'Initials': 'A', 'LastName': 'Nesbakken', 'Affiliation': 'Department of Gastroenterological Surgery & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nicholson', 'Affiliation': 'Department of Statistics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Novelli', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Lawson', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Dahmane', 'Initials': 'D', 'LastName': 'Oukrif', 'Affiliation': 'Department of Histopathology, UCL, Rockefeller Building, University Street, London, WC1E 6JJ, UK.'}, {'ForeName': 'Wanja', 'Initials': 'W', 'LastName': 'Kildal', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Havard E', 'Initials': 'HE', 'LastName': 'Danielsen', 'Affiliation': 'Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kerr', 'Affiliation': 'Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals Foundation NHS Trust, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kerr', 'Affiliation': 'Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, OX3 9 DU, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Tomlinson', 'Affiliation': 'Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.'}, {'ForeName': 'Ragnhild A', 'Initials': 'RA', 'LastName': 'Lothe', 'Affiliation': 'Department of Molecular Oncology, Institute for Cancer Research & K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Church', 'Affiliation': 'Cancer Genomics and Immunology Group, The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK. dchurch@well.ox.ac.uk.'}]",British journal of cancer,['10.1038/s41416-019-0540-4'] 1619,32461138,High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial.,"BACKGROUND & AIMS Vitamin D deficiency is common in Crohn's disease (CD). High-dose vitamin D had anti-inflammatory effects in preclinical studies and trials of patients with CD. We performed a randomized trial to determine whether high-dose vitamin D prevents postoperative recurrence of CD after ileocolonic resection. METHODS Patients with CD after ileocolonic resection with ileocolonic anastomosis were assigned randomly to groups given weekly 25,000 IU oral vitamin D (n = 72) or placebo (n = 71) for 26 weeks, at 17 hospitals in The Netherlands and Belgium, from February 2014 through June 2017. Patients were assessed at baseline and at weeks 2, 6, 12, and 26 for laboratory and clinical parameters, and underwent ileocolonoscopy at 26 weeks. The primary end point was endoscopic recurrence (modified Rutgeerts score, ≥i2b, as assessed by blinded readers) at 26 weeks. Secondary end points included clinical recurrence (Crohn's disease activity index, ≥220), quality of life (measured by the 36-Item Short Form Health Survey, Inflammatory Bowel Disease Questionnaire, and EuroQol, a 5-dimension questionnaire), and outcomes associated with the baseline serum concentration of vitamin D. RESULTS In the vitamin D group, serum levels of 25-hydroxy vitamin D increased from a median of 42 nmol/L at baseline to 81 nmol/L at week 26 (P < .00001), whereas levels did not change significantly in the placebo group and remained unchanged at 43 nmol/L. In the intention-to-treat analysis, the proportion of patients with endoscopic recurrence at 26 weeks did not differ significantly between the vitamin D vs the placebo group (58% vs 66%; P = .37). The cumulative rate of clinical recurrence did not differ significantly between the groups (18.1% in the vitamin D group vs 18.3% in the placebo group; P = .91). Quality of life improved slightly over time in both groups, but did not differ significantly between groups (P = .07). There were few adverse events in either group. CONCLUSIONS High-dose vitamin D, compared with placebo, did not reduce the incidence of postoperative endoscopic or clinical recurrence of CD in patients who underwent ileocolonic resection with ileocolonic anastomosis. ClinicalTrials.gov no: NCT02010762.",2020,Quality of life improved slightly over time in both groups but did not differ significantly between groups (P=.07).,"['patients who underwent ileocolonic resection with ileocolonic anastomosis', 'n=71) for 26 weeks, at 17 hospitals in the Netherlands and Belgium from February 2014 through June 2017', ""Crohn's disease (CD"", 'patients with CD', 'Patients with CD following ileocolonic resection with ileocolonic anastomosis']","['High-dose vitamin D', 'ileocolonoscopy', 'oral vitamin D', 'vitamin D', 'placebo']","[""clinical recurrence (Crohn's disease activity index ≥ 220), quality of life (measured by SF-36, IBD-Q and EQ-5D) and outcomes associated with baseline serum concentration of vitamin D"", 'endoscopic recurrence', 'proportion of patients with endoscopic recurrence', 'incidence of postoperative endoscopic or clinical recurrence of CD', 'Quality of life', 'postoperative recurrence of CD', 'cumulative rate of clinical recurrence', 'serum levels of 25-hydroxy vitamin D']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0740369', 'cui_str': 'Ileocolonic anastomosis'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0104487', 'cui_str': 'AT 17'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0004950', 'cui_str': 'Belgium'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0451071', 'cui_str': ""Crohn's disease activity index""}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.751718,Quality of life improved slightly over time in both groups but did not differ significantly between groups (P=.07).,"[{'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'de Bruyn', 'Affiliation': 'Department of Gastroenterology and Hepatology.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bossuyt', 'Affiliation': 'Department of Gastroenterology and Hepatology, Imeldaziekenhuis Bonheiden, Bonheiden, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ferrante', 'Affiliation': 'Department of Gastroenterology and Hepatology.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'West', 'Affiliation': 'Department of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Dijkstra', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, The Netherlands.'}, {'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Wildenberg', 'Affiliation': 'Department of Gastroenterology and Hepatology.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Hoentjen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Franchimont', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasme Hospital, Brussels, Belgium.'}, {'ForeName': 'Esmé', 'Initials': 'E', 'LastName': 'Clasquin', 'Affiliation': 'Department of Gastroenterology and Hepatology.'}, {'ForeName': 'Jarmila D', 'Initials': 'JD', 'LastName': 'van der Bilt', 'Affiliation': 'Department of Surgery, Flevoziekenhuis, Almere, The Netherlands.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Tollens', 'Affiliation': 'Department of General and Abdominal Surgery, Imelda Hospital, Bonheiden, Belgium.'}, {'ForeName': 'Willem A', 'Initials': 'WA', 'LastName': 'Bemelman', 'Affiliation': 'Department of Surgery, Amsterdam Inflammatory Bowel Disease Center, Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': ""D'Hoore"", 'Affiliation': 'Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Marjolijn', 'Initials': 'M', 'LastName': 'Duijvestein', 'Affiliation': 'Department of Gastroenterology and Hepatology.'}, {'ForeName': 'Geert R', 'Initials': 'GR', 'LastName': ""D'Haens"", 'Affiliation': 'Department of Gastroenterology and Hepatology. Electronic address: g.dhaens@amsterdamumc.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.05.037'] 1620,32468646,"Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.","OBJECTIVE Preclinical evidence with nilotinib, a US Food and Drug Administration (FDA)-approved drug for leukemia, indicates improvement in Alzheimer's disease phenotypes. We investigated whether nilotinib is safe, and detectable in cerebrospinal fluid, and alters biomarkers and clinical decline in Alzheimer's disease. METHODS This single-center, phase 2, randomized, double-blind, placebo-controlled study investigated the safety, tolerability, and pharmacokinetics of nilotinib, and measured biomarkers in participants with mild to moderate dementia due to Alzheimer's disease. The diagnosis was supported by cerebrospinal fluid or amyloid positron emission tomography biomarkers. Nilotinib 150 mg versus matching placebo was taken orally once daily for 26 weeks followed by nilotinib 300 mg versus placebo for another 26 weeks. RESULTS Of the 37 individuals enrolled, 27 were women and the mean (SD) age was 70.7 (6.48) years. Nilotinib was well-tolerated, although more adverse events, particularly mood swings, were noted with the 300 mg dose. In the nilotinib group, central nervous system (CNS) amyloid burden was significantly reduced in the frontal lobe compared to the placebo group. Cerebrospinal fluid Aβ40 was reduced at 6 months and Aβ42 was reduced at 12 months in the nilotinib group compared to the placebo. Hippocampal volume loss was attenuated (-27%) at 12 months and phospho-tau-181 was reduced at 6 months and 12 months in the nilotinib group. INTERPRETATION Nilotinib is safe and achieves pharmacologically relevant cerebrospinal fluid concentrations. Biomarkers of disease were altered in response to nilotinib treatment. These data support a larger, longer, multicenter study to determine the safety and efficacy of nilotinib in Alzheimer's disease. ANN NEUROL 2020 ANN NEUROL 2020;88:183-194.",2020,Cerebrospinal fluid Aβ40 was reduced at 6 months and Aβ42 was reduced at 12 months in the nilotinib group compared to the placebo.,"[""participants with mild to moderate dementia due to Alzheimer's disease"", ' 27 were women and the mean (SD) age was 70.7 (6.48) years', '37 individuals enrolled', ""Alzheimer's disease""]","['Nilotinib 150 mg versus matching placebo', 'nilotinib 300 mg versus placebo', 'placebo']","['safety, tolerability, and pharmacokinetics of nilotinib, and measured biomarkers', ""Safety, Tolerability, and Biomarkers in Alzheimer's Disease"", 'Hippocampal volume loss', 'central nervous system (CNS) amyloid burden', 'Cerebrospinal fluid Aβ40', 'safety and efficacy']","[{'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C3665464', 'cui_str': ""Dementia in Alzheimer's disease, unspecified""}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}]","[{'cui': 'C2920193', 'cui_str': 'nilotinib 150 MG'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1721377', 'cui_str': 'nilotinib'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C1721377', 'cui_str': 'nilotinib'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0002716', 'cui_str': 'Amyloid Substance'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",27.0,0.589561,Cerebrospinal fluid Aβ40 was reduced at 6 months and Aβ42 was reduced at 12 months in the nilotinib group compared to the placebo.,"[{'ForeName': 'Raymond S', 'Initials': 'RS', 'LastName': 'Turner', 'Affiliation': 'Memory Disorders Program, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Michaeline L', 'Initials': 'ML', 'LastName': 'Hebron', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Lawler', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Elizabeth E', 'Initials': 'EE', 'LastName': 'Mundel', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Yusuf', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'J Nathan', 'Initials': 'JN', 'LastName': 'Starr', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Anjum', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Pagan', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Yasar', 'Initials': 'Y', 'LastName': 'Torres-Yaghi', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.'}, {'ForeName': 'Wangke', 'Initials': 'W', 'LastName': 'Shi', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Sanjana', 'Initials': 'S', 'LastName': 'Mulki', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Dalila', 'Initials': 'D', 'LastName': 'Ferrante', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Matar', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Xiaoguang', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Esposito', 'Affiliation': 'Division of Nuclear Medicine, Washington, DC, USA.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Berkowitz', 'Affiliation': 'Department of Radiology, MedStar Georgetown Hospital, Washington, DC, USA.'}, {'ForeName': 'Xiong', 'Initials': 'X', 'LastName': 'Jiang', 'Affiliation': 'Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Jaeil', 'Initials': 'J', 'LastName': 'Ahn', 'Affiliation': 'Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.'}, {'ForeName': 'Charbel', 'Initials': 'C', 'LastName': 'Moussa', 'Affiliation': 'Translational Neurotherapeutics Program, Laboratory for Dementia and Parkinsonism, Department of Neurology, Georgetown University Medical Center, Washington, DC, USA.'}]",Annals of neurology,['10.1002/ana.25775'] 1621,32558052,The effect of mirabegron on energy expenditure and brown adipose tissue in healthy lean South Asian and Europid men.,"AIM To compare the effects of cold exposure and the β3-adrenergic receptor agonist mirabegron on plasma lipids, energy expenditure and brown adipose tissue (BAT) activity in South Asians versus Europids. MATERIALS AND METHODS Ten lean Dutch South Asian (aged 18-30 years; body mass index [BMI] 18-25 kg/m 2 ) and 10 age- and BMI-matched Europid men participated in a randomized, double-blinded, cross-over study consisting of three interventions: short-term (~ 2 hours) cold exposure, mirabegron (200 mg one dose p.o.) and placebo. Before and after each intervention, we performed lipidomic analysis in serum, assessed resting energy expenditure (REE) and skin temperature, and measured BAT fat fraction by magnetic resonance imaging. RESULTS In both ethnicities, cold exposure increased the levels of several serum lipid species, whereas mirabegron only increased free fatty acids. Cold exposure increased lipid oxidation in both ethnicities, while mirabegron increased lipid oxidation in Europids only. Cold exposure and mirabegron enhanced supraclavicular skin temperature in both ethnicities. Cold exposure decreased BAT fat fraction in both ethnicities. After the combination of data from both ethnicities, mirabegron decreased BAT fat fraction compared with placebo. CONCLUSIONS In South Asians and Europids, cold exposure and mirabegron induced beneficial metabolic effects. When combining both ethnicities, cold exposure and mirabegron increased REE and lipid oxidation, coinciding with a higher supraclavicular skin temperature and lower BAT fat fraction.",2020,"In both ethnicities, cold exposure increased levels of many serum lipid species, whereas mirabegron only increased free fatty acids.","['healthy lean South Asian and Europid men', 'South Asians versus Europids', 'Ten lean Dutch South Asian (age 18-30\u2009years']","['β3-adrenergic receptor agonist mirabegron', 'mirabegron', 'three interventions; short-term (approx. 2\u2009hours) cold exposure, mirabegron (200\u2009mg one dose p.o.) and placebo']","['supraclavicular skin temperature', 'lipidomic analysis in serum, assessed resting energy expenditure (REE) and skin temperature, and measured BAT fat fraction by MRI', 'plasma lipids, energy expenditure and brown adipose tissue (BAT) activity', 'free fatty acids', 'lipid oxidation', 'levels of many serum lipid species', 'BAT fat fraction', 'REE and lipid oxidation, coinciding with a higher supraclavicular skin temperature and lower BAT fat fraction', 'beneficial metabolic effects']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0001648', 'cui_str': 'Adrenergic receptor agonist'}, {'cui': 'C2983812', 'cui_str': 'mirabegron'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1292425', 'cui_str': '2 hours'}, {'cui': 'C0231275', 'cui_str': 'Cold exposure'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0589496', 'cui_str': 'Supraclavicular approach'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C4727082', 'cui_str': 'Lipidomics'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0006298', 'cui_str': 'Brown fat'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",10.0,0.0787891,"In both ethnicities, cold exposure increased levels of many serum lipid species, whereas mirabegron only increased free fatty acids.","[{'ForeName': 'Kimberly J', 'Initials': 'KJ', 'LastName': 'Nahon', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Laura G M', 'Initials': 'LGM', 'LastName': 'Janssen', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Aashley S D', 'Initials': 'ASD', 'LastName': 'Sardjoe Mishre', 'Affiliation': 'Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands.'}, {'ForeName': 'Manu P', 'Initials': 'MP', 'LastName': 'Bilsen', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Jari A', 'Initials': 'JA', 'LastName': 'van der Eijk', 'Affiliation': 'Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands.'}, {'ForeName': 'Kani', 'Initials': 'K', 'LastName': 'Botani', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Lisanne A', 'Initials': 'LA', 'LastName': 'Overduin', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Jonatan R', 'Initials': 'JR', 'LastName': 'Ruiz', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sport Sciences, PROFITH ""PROmoting FITness and Health through physical activity"" research group, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.'}, {'ForeName': 'Jedrzej', 'Initials': 'J', 'LastName': 'Burakiewicz', 'Affiliation': 'Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands.'}, {'ForeName': 'Oleh', 'Initials': 'O', 'LastName': 'Dzyubachyk', 'Affiliation': 'Department of Radiology, Division of Image Processing (LKEB), Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Andrew G', 'Initials': 'AG', 'LastName': 'Webb', 'Affiliation': 'Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands.'}, {'ForeName': 'Hermien E', 'Initials': 'HE', 'LastName': 'Kan', 'Affiliation': 'Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden, the Netherlands.'}, {'ForeName': 'Jimmy F P', 'Initials': 'JFP', 'LastName': 'Berbée', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Jan-Bert', 'Initials': 'JB', 'LastName': 'van Klinken', 'Affiliation': 'Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Ko Willems', 'Initials': 'KW', 'LastName': 'van Dijk', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'van Weeghel', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Frédéric M', 'Initials': 'FM', 'LastName': 'Vaz', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology and Metabolism, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.'}, {'ForeName': 'Tamer', 'Initials': 'T', 'LastName': 'Coskun', 'Affiliation': 'Department of Diabetes/Endocrine, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Ingrid M', 'Initials': 'IM', 'LastName': 'Jazet', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Sander', 'Initials': 'S', 'LastName': 'Kooijman', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Borja', 'Initials': 'B', 'LastName': 'Martinez-Tellez', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Mariëtte R', 'Initials': 'MR', 'LastName': 'Boon', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Patrick C N', 'Initials': 'PCN', 'LastName': 'Rensen', 'Affiliation': 'Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14120'] 1622,32553642,Love at first taste: Activation in reward-related brain regions during single-trial naturalistic appetitive conditioning in humans.,"Palatable food can trigger appetitive responses, such as salivation and approach tendencies. Though evolutionarily functional, these conditioned responses can encourage overeating and obesity when food is abundant. The current study examines the neural correlates of 'denovo' Pavlovian appetitive conditioning, pairing one class of unknown objects (conditioned stimuli, CS) with their sweet taste (unconditioned stimulus, US) during a single trial. To do so, 23 participants consumed unknown (marzipan) objects of one particular color (CS+) while only interacting with control stimuli of different color and shape (CS-). After this single-trial conditioning procedure, participants viewed and rated images of the marzipan figures and the control objects during functional magnetic resonance imaging (fMRI). Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling. Furthermore, conditioning effects in subjective 'craving', defined as increased palatability and desire to eat, were observed, and these were positively related to conditioning effects in the amygdala, a brain region associated with the need-dependent value of a reward. Thus, the study identified reward-related brain regions involved in single-trial appetitive learning, thereby providing a potential mechanism that contributes to the etiology of food craving. These findings might help to understand clinically relevant food cravings in individuals with eating or weight related concerns and might support the development of extinction based treatments.",2020,"Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling.","['23 participants consumed unknown (marzipan) objects of one particular color (CS+) while only interacting with control stimuli of different color and shape (CS', 'humans']","[""denovo' Pavlovian appetitive conditioning, pairing one class of unknown objects (conditioned stimuli, CS) with their sweet taste (unconditioned stimulus, US""]","[""subjective 'craving"", 'palatability and desire to eat']","[{'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0234404', 'cui_str': 'Conditioned stimulus'}, {'cui': 'C0858600', 'cui_str': 'Taste sweet'}, {'cui': 'C0234403', 'cui_str': 'Unconditioned stimulus'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}]",23.0,0.0298472,"Relative to the CS-, the CS+ elicited stronger activation in the dorsal striatum, a brain region associated with cue-reward coupling.","[{'ForeName': 'Lender', 'Initials': 'L', 'LastName': 'A', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria. Electronic address: anja.lender@sbg.ac.at.'}, {'ForeName': 'Miedl', 'Initials': 'M', 'LastName': 'Sf', 'Affiliation': 'Department of Psychology, Division of Clinical Psychology and Psychopathology, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 15020 Salzburg, Austria.'}, {'ForeName': 'Wilhelm', 'Initials': 'W', 'LastName': 'Fh', 'Affiliation': 'Department of Psychology, Division of Clinical Psychology and Psychopathology, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 15020 Salzburg, Austria.'}, {'ForeName': 'Miller', 'Initials': 'M', 'LastName': 'J', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria.'}, {'ForeName': 'Blechert', 'Initials': 'B', 'LastName': 'J', 'Affiliation': 'Department of Psychology, Centre for Cognitive Neuroscience, Paris-Lodron-University of Salzburg, Hellbrunner Str. 34, 5020 Salzburg, Austria.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113014'] 1623,32553717,Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.,"OBJECTIVES The aim was to fully characterize the plasma and urine washout pharmacokinetics of tenofovir (TFV) in adults following 6 weeks of controlled levels of tenofovir disoproxil fumarate (TDF) adherence, in order to inform the utility of clinic-based adherence testing. DESIGN This was a three-arm, randomized, open-label study in adult volunteers. Participants were randomized to receive TDF 300 mg/emtricitabine (FTC) 200 mg as (1) 7 doses/week (perfect adherence), (2) 4 doses/week (moderate adherence), or (3) 2 doses/week (low adherence). Plasma and urine samples were collected regularly during the 6-week dosing phase and for 4 weeks following drug cessation. RESULTS Twenty-eight adults were included in this analysis. Median (range) age was 33 (20-49) years. No differences in TFV pharmacokinetic parameters during the washout were observed across the study arms. Small differences in TFV plasma concentrations occurred across arms between 4 and 10 h post-dose. The cumulative amount of TFV excreted in urine was not different at 24 h post-dose, but at 148 h it was 24.8 mg, 21.0 mg, and 17.2 mg for the perfect, moderate, and low adherence arms, respectively (p = 0.043). CONCLUSIONS Among adults with different TDF adherence patterns, relative differences in plasma concentrations and cumulative urine extraction of TFV were minor following cessation. TFV measurement in plasma or urine is more indicative of last drug ingestion, rather than prior dose patterns.",2020,"The cumulative amount of TFV excreted in urine was not different 24 hours post-dose, but at 148 hours was 24.8, 21.0 and 17.2 mg for the Perfect, Moderate and Low Adherence arms, respectively (p = 0.043). ","['Adults with Controlled Levels of Adherence to', 'adult volunteers', 'adults with different TDF adherence patterns', 'Median (range) age was 33 (20-49) years', 'Twenty-eight adults']","['Tenofovir Disoproxil Fumarate', 'TDF 300\u2009mg/emtricitabine (FTC']","['Plasma and urine samples', 'cumulative amount of TFV excreted in urine', 'TFV PK parameters', 'Plasma Pharmacokinetics and Urinary Excretion of Tenofovir', 'plasma concentrations and cumulative urine extraction of TFV', 'TFV measurement in plasma or urine', 'TFV plasma concentrations']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0619283', 'cui_str': 'IS 33'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",28.0,0.0747984,"The cumulative amount of TFV excreted in urine was not different 24 hours post-dose, but at 148 hours was 24.8, 21.0 and 17.2 mg for the Perfect, Moderate and Low Adherence arms, respectively (p = 0.043). ","[{'ForeName': 'Tim R', 'Initials': 'TR', 'LastName': 'Cressey', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Immunology and Infectious Diseases, Boston, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. Electronic address: tim.cressey@phpt.org.'}, {'ForeName': 'Oraphan', 'Initials': 'O', 'LastName': 'Siriprakaisil', 'Affiliation': 'Sanpatong Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Rachel W', 'Initials': 'RW', 'LastName': 'Kubiak', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Virat', 'Initials': 'V', 'LastName': 'Klinbuayaem', 'Affiliation': 'Sanpatong Hospital, Chiang Mai, Thailand.'}, {'ForeName': 'Pra-Ornsuda', 'Initials': 'PO', 'LastName': 'Sukrakanchana', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Justice', 'Initials': 'J', 'LastName': 'Quame-Amaglo', 'Affiliation': 'Department of Global Health, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Okochi', 'Affiliation': 'Department of Medicine, University of California-San Francisco (UCSF), San Francisco, CA, USA.'}, {'ForeName': 'Yardpiroon', 'Initials': 'Y', 'LastName': 'Tawon', 'Affiliation': 'PHPT/IRD UMI 174, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Ratchada', 'Initials': 'R', 'LastName': 'Cressey', 'Affiliation': 'Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Jared M', 'Initials': 'JM', 'LastName': 'Baeten', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Gandhi', 'Affiliation': 'Department of Medicine, University of California-San Francisco (UCSF), San Francisco, CA, USA.'}, {'ForeName': 'Paul K', 'Initials': 'PK', 'LastName': 'Drain', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, USA.'}]",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,['10.1016/j.ijid.2020.06.037'] 1624,32554025,swCRTdesign: An R Package for Stepped Wedge Trial Design and Analysis.,"BACKGROUND AND OBJECTIVE Stepped wedge trials (SWTs) are a type of cluster-randomized trial that are commonly used to evaluate health care interventions. Most SWT-related software packages have restrictive assumptions about the study design and correlation structure of the data. The objective of this paper is to present a package and corresponding web-based graphical user interface (GUI) that provide researchers with another, more flexible option for SWT design and analysis. METHODS We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design. Possible sources of correlation include clusters, time within clusters, and treatment within clusters. RESULTS swCRTdesign allows a user to calculate power, simulate SWT data to streamline simulation studies (e.g. to estimate power), and create descriptive summaries and plots. Additionally, a GUI, developed using shiny, is available to calculate power and create power curves and design plots. CONCLUSIONS The swCRTdesign package accommodates a wide variety of SWT designs, and makes it easy to account for some sources of correlation which are not found in other packages. The user-friendly web-based GUI makes some swCRTdesign features accessible to researchers not familiar with R. These two resources will make appropriately complex SWT calculations more accessible to scientists from a wide variety of backgrounds.",2020,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.",[],['swCRTdesign'],[],[],[],[],,0.150645,"We developed an R package swCRTdesign ('stepped wedge Cluster Randomized Trial design'), which uses a random effects model to account for correlation in the data induced by a SWT design.","[{'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Voldal', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States. Electronic address: voldal@uw.edu.'}, {'ForeName': 'Navneet R', 'Initials': 'NR', 'LastName': 'Hakhu', 'Affiliation': 'Department of Statistics, University of California, Irvine, Irvine, CA 92697, United States.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Xia', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Heagerty', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Hughes', 'Affiliation': 'Department of Biostatistics, University of Washington, Box 357232, Seattle, WA 98195, United States.'}]",Computer methods and programs in biomedicine,['10.1016/j.cmpb.2020.105514'] 1625,32560714,On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial.,"BACKGROUND Non-specific neck pain and headache are major economic and individual burden in office-workers. The aim of this study is to investigate the effect of a multi-component intervention combining workstation ergonomics, health promotion information group workshops, neck exercises, and an app to enhance intervention adherence to assess possible reductions in the economic and individual burden of prevalent and incident neck pain and headache in office workers. METHODS/DESIGN This study is a stepped wedge cluster-randomized controlled trial. Eligible participants will be any office-worker aged 18-65 years from two Swiss organisations in the Cantons of Zurich and Aargau, working more than 25 h a week in predominantly sedentary office work and without serious health conditions of the neck. One hundred twenty voluntary participants will be assigned to 15 clusters which, at randomly selected time steps, switch from the control to the intervention group. The intervention will last 12 weeks and comprises workstation ergonomics, health promotion information group workshops, neck exercises and an adherence app. The primary outcome will be health-related productivity losses (presenteeism, absenteeism) using the Work Productivity and Activity Impairment Questionnaire. Secondary outcomes are neck disability and pain (measured by the Neck Disability Index, and muscle strength and endurance measures), headache (measured by the short-form headache impact test), psychosocial outcomes (e.g. job-stress index, Fear-Avoidance Beliefs Questionnaire), workplace outcomes (e.g. workstation ergonomics), adherence to intervention, and additional measures (e.g. care-seeking). Measurements will take place at baseline, 4 months, 8 months, and 12 months after commencement. Data will be analysed on an intention to treat basis and per protocol. Primary and secondary outcomes will be examined using linear mixed-effects models. DISCUSSION To the authors' knowledge, this study is the first that investigates the impact of a multi-component intervention combining current evidence of effective interventions with an adherence app to assess the potential benefits on productivity, prevalent and incident neck pain, and headache. The outcomes will impact the individual, their workplace, as well as private and public policy by offering evidence for treatment and prevention of neck pain and headache in office-workers. TRIAL REGISTRATION ClinicalTrials.gov, NCT04169646. Registered 15 November 2019 - Retrospectively registered.",2020,"The primary outcome will be health-related productivity losses (presenteeism, absenteeism) using the Work Productivity and Activity Impairment Questionnaire.","['One hundred twenty voluntary participants', 'Registered 15 November 2019 - Retrospectively registered', 'Swiss office-workers (NEXpro', 'Eligible participants will be any office-worker aged 18-65\u2009years from two Swiss organisations in the Cantons of Zurich and Aargau, working more than 25\u2009h a week in predominantly sedentary office work and without serious health conditions of the neck']","['workstation ergonomics, health promotion information group workshops, neck exercises and an adherence app']","['neck disability and pain (measured by the Neck Disability Index, and muscle strength and endurance measures), headache (measured by the short-form headache impact test), psychosocial outcomes (e.g. job-stress index, Fear-Avoidance Beliefs Questionnaire), workplace outcomes (e.g. workstation ergonomics), adherence to intervention, and additional measures (e.g. care-seeking', 'health-related productivity losses (presenteeism, absenteeism) using the Work Productivity and Activity Impairment Questionnaire', 'productivity, prevalent and incident neck pain, and headache']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C1306056', 'cui_str': 'Worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}]","[{'cui': 'C1736830', 'cui_str': 'Workstation'}, {'cui': 'C0086246', 'cui_str': 'Human Engineering'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0454347', 'cui_str': 'Neck exercises'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0814090', 'cui_str': 'Job-related Stress'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C1736830', 'cui_str': 'Workstation'}, {'cui': 'C0086246', 'cui_str': 'Human Engineering'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0033269', 'cui_str': 'Productivity'}, {'cui': 'C4042785', 'cui_str': 'Sickness Presence'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]",120.0,0.182642,"The primary outcome will be health-related productivity losses (presenteeism, absenteeism) using the Work Productivity and Activity Impairment Questionnaire.","[{'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Aegerter', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland. andrea.aegerter@zhaw.ch.'}, {'ForeName': 'Manja', 'Initials': 'M', 'LastName': 'Deforth', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Venerina', 'Initials': 'V', 'LastName': 'Johnston', 'Affiliation': 'The University of Queensland, School of Health and Rehabilitation Sciences, Brisbane, Queensland, Australia.'}, {'ForeName': 'Markus J', 'Initials': 'MJ', 'LastName': 'Ernst', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Volken', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Luomajoki', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Brunner', 'Affiliation': 'ZHAW School of Management and Law, Winterthur Institute of Health Economics, Gertrudstrasse 15, 8401, Winterthur, Switzerland.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Dratva', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Gisela', 'Initials': 'G', 'LastName': 'Sjøgaard', 'Affiliation': 'University of Southern Denmark, Department of Sport Sciences and Clinical Biomechanics, Odense, Denmark.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Elfering', 'Affiliation': 'University of Bern, Institute of Psychology, Fabrikstrasse 8, 3012, Bern, Switzerland.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Melloh', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03388-x'] 1626,32567290,Combination of vitamin A and D supplementation for ischemic stroke: effects on interleukin-1ß and clinical outcome.,"Aim Accumulated evidence suggests that vitamin A and D agonists can alleviate the development of atherosclerosis. Therefore, the aim of this study was to determine the effect of vitamin A and D combination supplement on interleukin-1β (IL-1β) and clinical outcome in ischemic stroke. Methods A single-blind, randomized controlled trial was conducted on ischemic stroke patients at Adam Malik Hospital between March 2018 to February 2019. The patients were randomized into 4 groups of the treatment consisting of supplementation using vitamin A or D only, combination of vitamin A and D, and placebo group, all given for 12 weeks. Clinical outcome was determined using the National Institute of Health Stroke Scale (NIHSS). At the time of admission and after the treatment was completed, all patients were measured for vitamin A, vitamin D, and IL-1β serum level, and NIHSS score. Results From the total of 120 patients, in the combination group there were significant increments on both vitamin A (p=0.04) and vitamin D (p=0.01) serum level after 12 weeks of the treatment, compared to the other groups. In conjunction, IL-1β serum level showed a significant decrement in the combination group (p<0.001). Lastly, the biggest improvement of NIHSS could be seen in the combination group, which was marked by the highest decrement of NIHSS score (p<0.001). Conclusion Administration of combination of vitamin A and D supplementation can significantly increase vitamin A and D serum level, decrease IL-1β serum level, and ultimately improve clinical outcome in ischemic stroke patients.",2020,"in the combination group there were significant increments on both vitamin A (p=0.04) and vitamin D (p=0.01) serum level after 12 weeks of the treatment, compared to the other groups.","['ischemic stroke patients', 'ischemic stroke patients at Adam Malik Hospital between March 2018 to February 2019', 'ischemic stroke', '120 patients']","['vitamin A and D agonists', 'supplementation using vitamin A or D only, combination of vitamin A and D, and placebo', 'vitamin A and D combination supplement', 'vitamin A and D supplementation']","['IL-1β serum level', 'National Institute of Health Stroke Scale (NIHSS', 'NIHSS score', 'vitamin D (p=0.01) serum level', 'vitamin A, vitamin D, and IL-1β serum level, and NIHSS score', 'vitamin A and D serum level, decrease IL-1β serum level']","[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1529905', 'cui_str': '(123I)ADAM'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0310589', 'cui_str': 'Vitamin A- and vitamin D-containing product'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C3653679', 'cui_str': 'Combinations of vitamins'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}]","[{'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0310589', 'cui_str': 'Vitamin A- and vitamin D-containing product'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}]",120.0,0.31388,"in the combination group there were significant increments on both vitamin A (p=0.04) and vitamin D (p=0.01) serum level after 12 weeks of the treatment, compared to the other groups.","[{'ForeName': 'Alfansuri', 'Initials': 'A', 'LastName': 'Kadri', 'Affiliation': 'Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Indonesia.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Sjahrir', 'Affiliation': 'Department of Neurology, Faculty of Medicine, Universitas Sumatera Utara, Indonesia.'}, {'ForeName': 'Rosita', 'Initials': 'R', 'LastName': 'Juwita Sembiring', 'Affiliation': 'Department of Clinical Pathology, Faculty of Medicine, Universitas Sumatera Utara, Indonesia.'}, {'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Ichwan', 'Affiliation': 'Department of Pharmacology, Faculty of Medicine, Universitas Sumatera Utara, Indonesia.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1137-20'] 1627,32568433,Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack.,"OBJECTIVE To understand the changes in functional connectivity between brain areas of potential importance in migraine during different phases of the attack. BACKGROUND Migraine is a symptomatically heterogeneous disorder. Understanding the possible changes in brain function and, therefore, neurobiology during different phases of the migraine attack is important in developing disease biomarkers and advancing therapeutics. DESIGN Randomized, double-blind, placebo-controlled, multi-visit experimental study. METHODS Subjects aged 18-50 years with migraine with and without aura (≤22 headache days per month) were recruited from across the UK using advertising, from both population and hospital clinic samples (n = 53). Consented subjects had a 0.5 µg/kg/min nitroglycerin infusion or to placebo over 20 minutes during the period February 2015-July 2017. All subjects were exposed to a nitroglycerin infusion at least on 1 occasion at screening. For those subjects who consented to participate in imaging visits (n = 25), structural T1, T2 and FLAIR sequences and resting state blood oxygen level dependant contrast (rsBOLD) time series, using a multiecho EPI sequence, were conducted over 30-40 minutes at baseline and rsBOLD during premonitory symptoms and migraine headache on a 3T General Electric MR750 MRI scanner. For the placebo visit, the imaging was conducted at the same times following infusion in the absence of symptoms. RESULTS Montreal Neurological Institute (MNI) coordinates were used to characterize brain areas of connectivity change identified. Using repeated measures ANOVA models with time (visit number) and trigger substance (nitroglycerin/placebo) as factors, significant positive functional coupling was found between the thalami bilaterally and the right precuneus and cuneus regions during the nitroglycerin-triggered premonitory phase (T = 3.23, peak connectivity change at [-6, -68, 40] for left thalamus, P = .012 and [-4, -68, 40] for right thalamus, P = .019). The nitroglycerin-triggered premonitory phase was associated with a change in the direction of connectivity from positive to negative between the pons and the limbic lobe (T = 3.47, peak connectivity change at [2, 8, 50], P < .001). The headache phase of the nitroglycerin-triggered migraine attack was associated with ongoing negative functional coupling between the pons and the cingulate and frontal cortices, and positive functional coupling between the pons and the cerebellar tonsils and medulla (T = 3.47, peak connectivity change at [-8, -52, -58], P = .007). CONCLUSIONS Understanding the functional reorganization between subcortical and cortical brain areas in different phases of the migraine attack provides novel insights into the abnormal sensory processing and integration during migraine, as well as functional correlation with clinical symptoms displayed during each phase.",2020,"The headache phase of the nitroglycerin-triggered migraine attack was associated with ongoing negative functional coupling between the pons and the cingulate and frontal cortices, and positive functional coupling between the pons and the cerebellar tonsils and medulla (T = 3.47, peak connectivity change at [-8, -52, -58], P = .007). ","['Montreal Neurological Institute (MNI', 'Subjects aged 18-50\xa0years with migraine with and without aura (≤22 headache days per month) were recruited from across the UK using advertising, from both population and hospital clinic samples (n\xa0=\xa053']","['substance (nitroglycerin/placebo', 'nitroglycerin infusion or to placebo', 'nitroglycerin', 'placebo']","['Functional Connectivity', 'positive functional coupling', 'structural T1, T2 and FLAIR sequences and resting state blood oxygen level']","[{'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0556971', 'cui_str': 'days/month'}, {'cui': 'C0001690', 'cui_str': 'Advertising as Topic'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0587906', 'cui_str': 'Hospital clinic'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.063712,"The headache phase of the nitroglycerin-triggered migraine attack was associated with ongoing negative functional coupling between the pons and the cingulate and frontal cortices, and positive functional coupling between the pons and the cerebellar tonsils and medulla (T = 3.47, peak connectivity change at [-8, -52, -58], P = .007). ","[{'ForeName': 'Nazia', 'Initials': 'N', 'LastName': 'Karsan', 'Affiliation': ""Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Pyari R', 'Initials': 'PR', 'LastName': 'Bose', 'Affiliation': ""Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': ""O'Daly"", 'Affiliation': ""Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Fernando O', 'Initials': 'FO', 'LastName': 'Zelaya', 'Affiliation': ""Department of Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Goadsby', 'Affiliation': ""Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]",Headache,['10.1111/head.13865'] 1628,32573927,Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.,"AIMS To test whether a long-acting GLP-1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to determine whether the drug would affect beta cell function. METHODS We performed a randomized placebo-controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C-peptide. Seventy-nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C-peptide levels. The primary outcome was the difference in glycated haemoglobin (HbA1c) levels at 24 weeks. Participants were followed for another 6 months off study drug. RESULTS At week 24, the time of the primary outcome, the least squares (LS) mean HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER group versus 8.0% (95% CI 7.64, 8.35) in the placebo group (P = 0.08). At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group (P = 0.01). The improvement at week 12 was driven mainly by those with detectable levels of C-peptide. Those treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated with placebo (P <0.001 and P = 0.007). The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production. Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased. CONCLUSION Treatment with exenatide ER may have short-term benefits in some individuals with T1D who are overweight or who have detectable levels of C-peptide, but short-term improvements were not sustained.",2020,Those treated with exenatide ER lost weight at 12 and 24 weeks compared to placebo (p < 0.001 and p = 0.007).,"['patients with Type 1 diabetes (T1D', 'participants with T1D with and without detectable levels of C-peptide', 'Seventy-nine participants', 'patients with Type 1 diabetes with and without residual insulin production']","['exenatide ER 2 mcg weekly or placebo', 'Exenatide ER', 'Glucagon-like peptide-1 receptor agonists (GLP1RA', 'exenatide ER', 'placebo']","['Adverse events', 'hypoglycemia', 'HbA1c level', 'total dose of insulin', 'HbA1c levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0439211', 'cui_str': 'mcg'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]",79.0,0.485484,Those treated with exenatide ER lost weight at 12 and 24 weeks compared to placebo (p < 0.001 and p = 0.007).,"[{'ForeName': 'Kevan C', 'Initials': 'KC', 'LastName': 'Herold', 'Affiliation': 'Departments of Immunobiology, Yale University, New Haven, Connecticut.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Reynolds', 'Affiliation': 'Biostatics, Yale University, New Haven, Connecticut.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': 'Internal Medicine (Endocrinology), Yale University, New Haven, Connecticut.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Baidal', 'Affiliation': 'Department of Medicine (Endocrinology), University of Miami, Miami, Florida.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Gaglia', 'Affiliation': 'Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Gitelman', 'Affiliation': 'Department of Pediatrics (Endocrinology), University of California, San Francisco, California.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Gottlieb', 'Affiliation': 'Barbara Davis Diabetes Center, University of Colorado, Anschutz, Colorado.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Marks', 'Affiliation': 'Department of Medicine (Endocrinology), University of Miami, Miami, Florida.'}, {'ForeName': 'Louis H', 'Initials': 'LH', 'LastName': 'Philipson', 'Affiliation': 'Department of Medicine (Endocrinology), The University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Rodica', 'Initials': 'R', 'LastName': 'Pop-Busui', 'Affiliation': 'Department of Medicine (Endocrinology), The University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Ruth S', 'Initials': 'RS', 'LastName': 'Weinstock', 'Affiliation': 'Department of Medicine (Endocrinology), SUNY Upstate Medical University, Syracuse, New York.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14121'] 1629,32571570,A consensus checklist to help clinicians interpret clinical trial results analysed by Bayesian methods.,"INTRODUCTION In the context of an increasing number of publications of trial data analysed by Bayesian methods, clinicians need support to better understand Bayesian statistical methods. The existing checklists are intended for people who already know these methods. We aimed to establish and validate a checklist that contains a group of items considered crucial in interpreting the results of a phase III RCT analysed with Bayesian methods. METHODS A team of biostatisticians created a checklist of previously reported items and additional items identified from a literature review. Using three different articles in three rounds, the items were then validated by residents in anaesthesiology with no skills in statistics. RESULTS Based on an initial item list, three rounds led to a consensus checklist. Eleven items were considered important information to be specified for understanding the validity of the results. Of these, three were considered essential: specification of the prior, source of the prior (when prior is informative), and the effect size point estimate with its credible interval. CONCLUSION The checklist can help clinicians interpret the results of a phase III randomised clinical trial analysed by Bayesian methods, even clinicians with no particular knowledge of statistics, to ensure that the major elements of the statistical section are present and valid. Care should be taken in interpreting the results of a trial analysed by Bayesian methods that are not reported with these three essential items because the validity of the results cannot be established.",2020,"Using three different articles in three rounds, the items were then validated by residents in anaesthesiology with no skills in statistics. ",[],[],[],[],[],[],11.0,0.0629078,"Using three different articles in three rounds, the items were then validated by residents in anaesthesiology with no skills in statistics. ","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ferreira', 'Affiliation': 'Anesthesiology and Intensive Care Department, CHU Besançon, Besançon, France; Université de Strasbourg, iCUBE, UMR7357, Illkirch Cedex, France. Electronic address: dferreira@chu-besancon.fr.'}, {'ForeName': 'Mael', 'Initials': 'M', 'LastName': 'Barthoulot', 'Affiliation': ""Institut Pasteur de Lille, Unité d'Epidémiologie et de Santé Publique, Inserm-U1167, Lille, France.""}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Pottecher', 'Affiliation': 'Anesthesiology and Intensive Care Department, CHU de Strasbourg, IHU-Strasbourg, Strasbourg, France.'}, {'ForeName': 'Klaus D', 'Initials': 'KD', 'LastName': 'Torp', 'Affiliation': 'Department of Anesthesiology, Mayo Clinic, Jacksonville, FL, USA.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Diemunsch', 'Affiliation': 'Anesthesiology and Intensive Care Department, CHU de Strasbourg, IHU-Strasbourg, Strasbourg, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Meyer', 'Affiliation': 'Université de Strasbourg, iCUBE, UMR7357, Illkirch Cedex, France; Public Health Department, CHU de Strasbourg, GMRC, Strasbourg, France.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.04.093'] 1630,32574657,The Feasibility and Acceptability of a Cognitive Behavioral Therapy-Based Intervention for Patients With Advanced Colorectal Cancer.,"CONTEXT Advanced colorectal cancer and its treatment can bring about challenges associated with psychological distress. OBJECTIVES The primary aims of this study were to examine the feasibility and acceptability of a cognitive behavioral therapy (CBT)-based intervention to improve coping with the disease. The secondary aim is to evaluate preliminary intervention efficacy. METHODS Patients with advanced colorectal cancer in Singapore (N = 60) were randomized to either receive a four-session CBT intervention immediately or be waitlisted. Intervention feasibility (i.e., recruitment and intervention adherence) and acceptability (i.e., participant satisfaction and cultural sensitivity) were assessed. Changes in psychological distress and self-efficacy were examined. RESULTS The study successfully recruited the intended sample (mean age 61; 62% men). A proportion (12%) reported Hospital Anxiety and Depression Scale scores indicative of distress at baseline. Most (88%) completed all sessions. Participants reported high rates of satisfaction (97%), helpfulness (96%), and cultural sensitivity (95%) of the intervention. The intervention group did not show decrease in psychological distress; however, self-efficacy in cancer-related coping (information seeking: effect size [ES] = 0.64; 95% CI = 0.17, 0.85; coping with side effects: ES = 0.69; 95% CI = 0.33, 0.82; and maintaining positive attitude: ES = 0.45; 95% CI = 0.19, 0.79) increased in the intervention group compared with the waitlisted group. CONCLUSION The CBT-based intervention was feasible and acceptable to patients in Singapore. There is no sufficient evidence to warrant a larger trial in this sample with low baseline distress. Future work should identify and target those who are most in need of support.",2020,"The intervention group did not show decrease in psychological distress; however, self-efficacy in cancer-related coping (information seeking, effect size (ES) = 0.64, 95%CI [0.17, 0.85]; coping with side effects, ES=0.69, 95%CI [0.33, 0.82]; and maintaining positive attitude, ES=0.45, 95%CI [0.19, 0.79]) increased in the intervention group compared to the waitlisted group. ","['Patients with advanced colorectal cancer in Singapore (N = 60', 'The study successfully recruited the intended sample (M age = 61, 62% men', 'Patients with Advanced Colorectal Cancer']","['Cognitive Behavioral Therapy-based intervention', 'cognitive behavioral therapy (CBT)-based intervention', '4-session CBT intervention immediately or be waitlisted']","['Intervention feasibility (i.e., recruitment and intervention adherence) and acceptability (i.e., participant satisfaction and cultural sensitivity', 'psychological distress and self-efficacy', 'cultural sensitivity', 'feasibility and acceptability', 'rates of satisfaction', 'Hospital Anxiety and Depression Scale (HADS) scores indicative of distress', 'self-efficacy in cancer-related coping (information seeking, effect size (ES', 'psychological distress']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0037173', 'cui_str': 'Singapore'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}]",60.0,0.0706234,"The intervention group did not show decrease in psychological distress; however, self-efficacy in cancer-related coping (information seeking, effect size (ES) = 0.64, 95%CI [0.17, 0.85]; coping with side effects, ES=0.69, 95%CI [0.33, 0.82]; and maintaining positive attitude, ES=0.45, 95%CI [0.19, 0.79]) increased in the intervention group compared to the waitlisted group. ","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Teo', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore; Department of Psychosocial Oncology, National Cancer Centre Singapore, Singapore; Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore. Electronic address: irene.teo@duke-nus.edu.sg.'}, {'ForeName': 'Yee Pin', 'Initials': 'YP', 'LastName': 'Tan', 'Affiliation': 'Department of Psychosocial Oncology, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Finkelstein', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore; Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Grace Meijuan', 'Initials': 'GM', 'LastName': 'Yang', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore; Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Fang Ting', 'Initials': 'FT', 'LastName': 'Pan', 'Affiliation': 'Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Henry Yuen Foong', 'Initials': 'HYF', 'LastName': 'Lew', 'Affiliation': 'Department of Psychology, Singapore General Hospital, Singapore.'}, {'ForeName': 'Emile Kwong Wei', 'Initials': 'EKW', 'LastName': 'Tan', 'Affiliation': 'Department of Colorectal Surgery, Singapore General Hospital, Singapore.'}, {'ForeName': 'Simon Yew Kuang', 'Initials': 'SYK', 'LastName': 'Ong', 'Affiliation': 'Division of Medical Oncology, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Yin Bun', 'Initials': 'YB', 'LastName': 'Cheung', 'Affiliation': 'Programme in Health Services & Systems Research, Duke-NUS Medical School, Singapore; Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore; Centre for Child Health Research, Tampere University, Finland.'}]",Journal of pain and symptom management,['10.1016/j.jpainsymman.2020.06.016'] 1631,32574722,HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.,"BACKGROUND A common polymorphism (1245A>C) in the HSD3B1 gene is associated with increased de novo synthesis of androgens and worse outcomes in men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer. The objective of the study was to determine whether this polymorphism is associated with outcomes for metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. PATIENTS AND METHODS A total of 547 patients treated with abiraterone or enzalutamide from two prospective cohorts were evaluated. The HSD3B1 genotype was determined by targeted sequencing and/or TaqMan single-nucleotide polymorphism genotyping. In cohort 1, patients were randomized to receive abiraterone + prednisone or enzalutamide. In cohort 2, patients received either agent according to investigator's choice. Prostate-specific antigen (PSA) response rate, time to PSA progression (TTPP), time to progression (TTP) and overall survival were determined. Associations between HSD3B1 genotypes and outcomes were evaluated via univariate Cox regression. Multivariable Cox model was used to determine the independent association of each covariate. RESULTS The HSD3B1 variant genotype (CC) was present in 15% of patients and was associated with worse TTP [hazard ratio (HR) 1.31, 95% confidence interval (CI) 1.02-1.67, P = 0.032] and PSA response rates (48% for CC versus 62% and 65% for AA and AC, respectively [P = 0.019]), with no significant difference in TTPP (HR 1.28, 95% CI 0.99-1.66, P = 0.064). The effect of genotype was similar for treatment with abiraterone or enzalutamide with a negative test for interaction for TTPP (P = 0.997) and TTP (P = 0.749). Multivariable analysis did not show a significant association between genotype and TTP or TTPP. CONCLUSIONS The HSD3B1 (CC) genotype was associated with shorter TTP and lower PSA response rate in patients with mCRPC treated with abiraterone or enzalutamide. However, the CC genotype did not provide prognostic information beyond that conferred by standard clinical variables, suggesting that it may not be a suitable stand-alone biomarker in mCRPC.",2020,"CONCLUSIONS HSD3B1 (CC) genotype was associated with shorter TTP and lower PSA response rate in mCRPC patients treated with abiraterone or enzalutamide.","['metastatic castration-resistant prostate cancer (mCRPC) treated with', 'metastatic castration-resistant prostate cancer patients treated with', 'men treated with androgen-deprivation therapy for metastatic castration-sensitive prostate cancer', '547 patients treated with']","['abiraterone + prednisone or enzalutamide', 'abiraterone and enzalutamide', 'abiraterone or enzalutamide']","['PSA response rate', 'PSA response rates', 'PSA response rate, time to PSA progression (TTPP), time to progression (TTP) and overall survival (OS', 'HSD3B1 variant genotype (CC', 'TTPP']","[{'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C4302896', 'cui_str': 'Hormone sensitive prostate cancer'}]","[{'cui': 'C0754011', 'cui_str': 'abiraterone'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C3496793', 'cui_str': 'enzalutamide'}]","[{'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0178415', 'cui_str': 'Raised prostate specific antigen'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}]",547.0,0.123766,"CONCLUSIONS HSD3B1 (CC) genotype was associated with shorter TTP and lower PSA response rate in mCRPC patients treated with abiraterone or enzalutamide.","[{'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Khalaf', 'Affiliation': 'BC Cancer Vancouver, Vancouver, BC, Canada.'}, {'ForeName': 'I M', 'Initials': 'IM', 'LastName': 'Aragón', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Annala', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Lozano', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Taavitsainen', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Lorente', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Hospital General Universitari de Castelló, Castellon, Spain.'}, {'ForeName': 'D L', 'Initials': 'DL', 'LastName': 'Finch', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada; BC Cancer Kelowna, Kelowna, BC, Canada.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Romero-Laorden', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Vergidis', 'Affiliation': 'BC Cancer Victoria, Victoria, BC, Canada.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Cendón', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Oja', 'Affiliation': 'BC Cancer Surrey, Surrey, BC, Canada.'}, {'ForeName': 'M I', 'Initials': 'MI', 'LastName': 'Pacheco', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Zulfiqar', 'Affiliation': 'BC Cancer Abbotsford, Abbotsford, BC, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'M E', 'Initials': 'ME', 'LastName': 'Gleave', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'A W', 'Initials': 'AW', 'LastName': 'Wyatt', 'Affiliation': 'Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Olmos', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain.'}, {'ForeName': 'K N', 'Initials': 'KN', 'LastName': 'Chi', 'Affiliation': 'BC Cancer Vancouver, Vancouver, BC, Canada; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Castro', 'Affiliation': 'Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Genitourinary Cancer Translational Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Malaga, Spain; Medical Oncology Department, Hospital Universitario Virgen de la Victoria y Regional de Málaga, Malaga, Spain. Electronic address: elena.castro@ibima.eu.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1016/j.annonc.2020.06.006'] 1632,32442353,A randomized controlled clinical trial comparing the use of displacement cords and aluminum chloride paste.,"OBJECTIVES This clinical study measured the change in opening and height of the displaced gingiva using paste and cord retraction materials for definitive impression making of natural teeth and assessed if they were comparable and clinically acceptable. METHODS Impressions of 4 maxilla premolars from 10 participants were taken using a split-mouth protocol. All participants were free of periodontal disease, had a thick biotype, a minimal of 3 mm height of keratinized gingival tissue and gingival sulci depths of 2 mm. The bleeding index (BI), gingival index (GI) plaque index (PI), sulcular depth, level of attachment and tooth sensitivity were recorded at baseline, just after retraction, at 24 hours and at 2 weeks. Impressions were poured in stone and then after initial analysis were cross-sectioned to allow measurements of the gingival height change and gap size to be recorded. RESULTS The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively. Gingival height with the paste was 0.047 mm lower than that achieved by the cord (P = .208). CONCLUSIONS Cord and paste retraction produced comparable clinically acceptable gingival gaps, with the cord producing statistically larger gap size. CLINICAL SIGNIFICANCE The cord and paste retraction materials produced comparable clinically acceptable gingival retraction.",2020,"The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively.","['All participants were free of periodontal disease, had a thick biotype, a minimal of 3\u2009mm height of keratinized gingival tissue and gingival sulci depths of 2\u2009mm', 'Impressions of 4 maxilla premolars from 10 participants were taken using a split-mouth protocol']",['displacement cords and aluminum chloride paste'],"['bleeding index (BI), gingival index (GI) plaque index (PI), sulcular depth, level of attachment and tooth sensitivity', 'acceptable gingival retraction', 'Gingival height']","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0441707', 'cui_str': 'Biotyping'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0317562', 'cui_str': 'Eubacterium sulci'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0051512', 'cui_str': 'Aluminum chloride hexahydrate'}, {'cui': 'C0030634', 'cui_str': 'Pastes'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0332523', 'cui_str': 'Retraction'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}]",10.0,0.0760322,"The paste produced a slightly smaller gap compared to the cord (0.041 mm less, P = .014) whilst the mean displacement for the cord was 0.282 mm and paste was 0.241 mm respectively.","[{'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Bennani', 'Affiliation': 'Department of Oral Rehabilitation, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Aarts', 'Affiliation': 'Department of Oral Rehabilitation, Faculty of Dentistry, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Brunton', 'Affiliation': 'Pro Vice Chancellor Health Sciences, University of Otago, Dunedin, New Zealand.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12581'] 1633,32444132,Early Steroid Withdrawal Protocol With Basiliximab and Rituximab in ABO-Incompatible Kidney Transplant Recipients.,"OBJECTIVES Corticosteroids remain an important component of immunosuppressive regimens in high-risk kidney transplants. In this study, we investigated the efficacy of early steroid withdrawal with basiliximab and rituximab in ABO-blood type incompatible (ABO-i) recipients of kidney transplants. METHODS Between 2008 and 2019, 15 patients underwent ABO-i kidney transplantation. Seven of the 15 patients were treated with a steroid maintenance protocol and the remaining 8 with an early steroid withdrawal protocol. The immunosuppressive protocol consisted of tacrolimus, mycophenolate mofetil, and methylprednisolone (MP), with basiliximab administered as induction therapy. Rituximab was administered as a single 200-mg dose 1 to 4 weeks before kidney transplantation. Two to 4 sessions of either double-filtration plasmapheresis or regular plasmapheresis or both were performed to remove anti-AB antibodies before transplantation. During surgery, MP was administered at a dose of 500 mg; thereafter, the dosage was tapered rapidly, and the drug was discontinued on day 14 post transplant. RESULTS In the steroid maintenance group, 2 patients experienced acute antibody-mediated rejection (AMR). One patient with severe AMR had graft loss on postoperative day 4. Patient and graft survival rates in the steroid maintenance group were 100% and 86%, respectively. MP was successfully withdrawn in the steroid withdrawal group. In this group, there was no biopsy-proven rejection. Patient and graft survival rates were 100%, and when last measured, serum creatinine level ± SD was 1.6 ± 0.8 mg/dL. CONCLUSIONS Our protocol successfully enabled the early withdrawal of steroids in recipients of ABO-i grafts; however, further follow-up is necessary to confirm our results.",2020,"Patient and graft survival rates were 100%, and when last measured, serum creatinine level ± SD was 1.6 ± 0.8 mg/dL. CONCLUSIONS Our protocol successfully enabled the early withdrawal of steroids in recipients of ABO-i grafts; however, further follow-up is necessary to confirm our results.","['high-risk kidney transplants', 'ABO-Incompatible Kidney Transplant Recipients', '15 patients underwent ABO-i kidney transplantation', 'Between 2008 and 2019', 'Seven of the 15 patients were treated with a steroid maintenance protocol and the remaining 8 with an early steroid withdrawal protocol', 'ABO-blood type incompatible (ABO-i) recipients of kidney transplants']","['Basiliximab and Rituximab', 'Rituximab', 'basiliximab and rituximab', 'double-filtration plasmapheresis or regular plasmapheresis', 'tacrolimus, mycophenolate mofetil, and methylprednisolone (MP), with basiliximab']","['acute antibody-mediated rejection (AMR', 'biopsy-proven rejection', 'serum creatinine level ± SD', 'graft loss', 'graft survival rates']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0078140', 'cui_str': 'VBM protocol'}, {'cui': 'C0013184', 'cui_str': 'Drug Incompatibility'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0200499', 'cui_str': 'ABO blood grouping'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}]","[{'cui': 'C0676831', 'cui_str': 'basiliximab'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C5200809', 'cui_str': 'Double Filtration Plasmapheresis'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0032134', 'cui_str': 'Plasmapheresis'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1608421', 'cui_str': 'Antibody-mediated rejection'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0877042', 'cui_str': 'Graft loss'}, {'cui': 'C0018131', 'cui_str': 'Graft Survival'}]",15.0,0.0245331,"Patient and graft survival rates were 100%, and when last measured, serum creatinine level ± SD was 1.6 ± 0.8 mg/dL. CONCLUSIONS Our protocol successfully enabled the early withdrawal of steroids in recipients of ABO-i grafts; however, further follow-up is necessary to confirm our results.","[{'ForeName': 'Tamotsu', 'Initials': 'T', 'LastName': 'Tojimbara', 'Affiliation': 'Department of Transplant Surgery, International University of Health and Welfare, Atami Hospital, Shizuoka, Japan. Electronic address: tojimbara@iuhw.ac.jp.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yashima', 'Affiliation': 'Department of Transplant Surgery, International University of Health and Welfare, Atami Hospital, Shizuoka, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Shirai', 'Affiliation': 'Department of Transplant Surgery, International University of Health and Welfare, Atami Hospital, Shizuoka, Japan.'}, {'ForeName': 'Tomotaka', 'Initials': 'T', 'LastName': 'Yamazaki', 'Affiliation': 'Department of Transplant Surgery, International University of Health and Welfare, Atami Hospital, Shizuoka, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Koyama', 'Affiliation': ""Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.""}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Nakajima', 'Affiliation': ""Department of Surgery, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.""}]",Transplantation proceedings,['10.1016/j.transproceed.2020.01.139'] 1634,32470217,Randomized clinical trial to evaluate mometasone lavage vs spray for patients with chronic rhinosinusitis without nasal polyps who have not undergone sinus surgery.,"BACKGROUND There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS). The study objective of this work was to compare the impact of mometasone furoate nasal spray (MFNS) vs mometasone nasal irrigation in the management of CRS patients who have not undergone sinus surgery. METHODS A double-blind, placebo-controlled, randomized clinical trial was conducted in adults with CRS. Individuals with nasal polyps and/or history of sinus surgery were excluded. Patients were randomized to receive 8 weeks of either MFNS or mometasone nasal irrigation. The primary outcome measure was change in the 22-item Sino-Nasal Outcome Test (SNOT-22) score between the 2 groups. Secondary outcome measures included patient global response to treatment and Lund-Kennedy endoscopy scores. RESULTS A total of 43 participants completed the study (n = 22, MFNS; n = 21,mometasone nasal irrigation). Fourteen (64%) participants in the MFNS group and 17 (81%) in the mometasone lavage group had a clinically meaningful improvement in SNOT-22 scores with a proportion difference of 17% (95% confidence interval [CI], -9% to 44%). The least-squares (LS) mean difference between the 2 groups for SNOT-22 was -8.6 (95% CI, -17.7 to 0.58; p = 0.07), whereas the LS mean difference between the 2 groups for Lund-Kennedy endoscopy scores was 0.16 (95% CI, -0.84 to 1.15; p = 0.75). No adverse events were associated with the study. CONCLUSION Both MFNS and mometasone nasal irrigations are beneficial in symptom management of CRS. Our study suggests that patients who perform mometasone lavage do better in a clinically meaningful way, but our results are not definitive and further studies are warranted.",2020,There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS).,"['Individuals with nasal polyps and/or history of sinus surgery', '43 participants completed the study (n = 22, MFNS; n = 21,mometasone nasal irrigation', 'chronic rhinosinusitis (CRS', 'adults with CRS', 'patients with chronic rhinosinusitis without nasal polyps who have not undergone sinus surgery', 'CRS patients who have not undergone sinus surgery']","['MFNS and mometasone nasal irrigations', 'mometasone lavage vs spray', 'MFNS', 'corticosteroids', 'mometasone furoate nasal spray (MFNS) vs mometasone nasal irrigation', 'mometasone lavage', 'MFNS or mometasone nasal irrigation', 'placebo']","['patient global response to treatment and Lund-Kennedy endoscopy scores', 'Lund-Kennedy endoscopy scores', 'adverse events', '22-item Sino-Nasal Outcome Test (SNOT-22) score', 'SNOT-22 scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027430', 'cui_str': 'Polyp of nasal cavity'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C2350442', 'cui_str': 'Nasal irrigation'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0066700', 'cui_str': 'Mometasone furoate'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C0717925', 'cui_str': 'Mometasone-containing product in nasal dose form'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0360564', 'cui_str': 'Mometasone'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C5197689', 'cui_str': 'Sinonasal Outcome Test'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}]",43.0,0.259522,There is no consensus regarding the best route of intranasal delivery of corticosteroids in the treatment of chronic rhinosinusitis (CRS).,"[{'ForeName': 'Pawina', 'Initials': 'P', 'LastName': 'Jiramongkolchai', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Peterson', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Dorina', 'Initials': 'D', 'LastName': 'Kallogjeri', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Jake J', 'Initials': 'JJ', 'LastName': 'Lee', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kukuljan', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Liebendorfer', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'John S', 'Initials': 'JS', 'LastName': 'Schneider', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Cristine N', 'Initials': 'CN', 'LastName': 'Klatt-Cromwell', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Drescher', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}, {'ForeName': 'Jay F', 'Initials': 'JF', 'LastName': 'Piccirillo', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St. Louis, MO.'}]",International forum of allergy & rhinology,['10.1002/alr.22586'] 1635,32470486,"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.","BACKGROUND Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as therapeutic targets warranting rapid investigation. OBJECTIVE This study evaluated the efficacy and safety of ruxolitinib, a JAK1/2 inhibitor, for coronavirus disease 2019. METHODS We conducted a prospective, multicenter, single-blind, randomized controlled phase II trial involving patients with severe coronavirus disease 2019. RESULTS Forty-three patients were randomly assigned (1:1) to receive ruxolitinib plus standard-of-care treatment (22 patients) or placebo based on standard-of-care treatment (21 patients). After exclusion of 2 patients (1 ineligible, 1 consent withdrawn) from the ruxolitinib group, 20 patients in the intervention group and 21 patients in the control group were included in the study. Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical improvement in severe patients with coronavirus disease 2019, although ruxolitinib recipients had a numerically faster clinical improvement. Eighteen (90%) patients from the ruxolitinib group showed computed tomography improvement at day 14 compared with 13 (61.9%) patients from the control group (P = .0495). Three patients in the control group died of respiratory failure, with 14.3% overall mortality at day 28; no patients died in the ruxolitinib group. Ruxolitinib was well tolerated with low toxicities and no new safety signals. Levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group. CONCLUSIONS Although no statistical difference was observed, ruxolitinib recipients had a numerically faster clinical improvement. Significant chest computed tomography improvement, a faster recovery from lymphopenia, and favorable side-effect profile in the ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.",2020,"Significant chest CT improvement, a faster recovery from lymphopenia and favorable side-effect profile in ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.","['severe coronavirus disease 2019 (COVID-19', 'patients with severe COVID-19', 'Forty-three patients']","['ruxolitinib plus SoC', 'placebo based on SoC treatment', 'ruxolitinib plus SoC treatment']","['tolerated with low toxicities and no new safety signals', 'overall mortality', 'died of respiratory failure', 'CT improvement', 'Levels of 7 cytokines']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450368', 'cui_str': '43'}]","[{'cui': 'C2931926', 'cui_str': 'ruxolitinib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}]",43.0,0.116984,"Significant chest CT improvement, a faster recovery from lymphopenia and favorable side-effect profile in ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.","[{'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Cao', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Zou', 'Affiliation': 'Department of Hematology, Wuhan No. 1 Hospital, Wuhan, China.'}, {'ForeName': 'Tiebin', 'Initials': 'T', 'LastName': 'Jiang', 'Affiliation': 'Hematology Department of The Third Xiangya Hospital Central South University, Changsha, China.'}, {'ForeName': 'Gaoxiang', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Liting', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Liang', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Fankai', 'Initials': 'F', 'LastName': 'Meng', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Xiaoxi', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Zekai', 'Initials': 'Z', 'LastName': 'Mao', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Xing', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jungang', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Site of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Hematology Department of The Third Xiangya Hospital Central South University, Changsha, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Cheng', 'Affiliation': 'Department of Hematology, Wuhan No. 1 Hospital, Wuhan, China.'}, {'ForeName': 'Jianping', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key Site of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Huang', 'Affiliation': ""Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: Gang.Huang@cchmc.org.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: wwang@vip.126.com.'}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Clincal Trial and Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: jfzhou@tjh.tjmu.edu.cn.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2020.05.019'] 1636,31875646,GDF15 mediates the effects of metformin on body weight and energy balance.,"Metformin, the world's most prescribed anti-diabetic drug, is also effective in preventing type 2 diabetes in people at high risk 1,2 . More than 60% of this effect is attributable to the ability of metformin to lower body weight in a sustained manner 3 . The molecular mechanisms by which metformin lowers body weight are unknown. Here we show-in two independent randomized controlled clinical trials-that metformin increases circulating levels of the peptide hormone growth/differentiation factor 15 (GDF15), which has been shown to reduce food intake and lower body weight through a brain-stem-restricted receptor. In wild-type mice, oral metformin increased circulating GDF15, with GDF15 expression increasing predominantly in the distal intestine and the kidney. Metformin prevented weight gain in response to a high-fat diet in wild-type mice but not in mice lacking GDF15 or its receptor GDNF family receptor α-like (GFRAL). In obese mice on a high-fat diet, the effects of metformin to reduce body weight were reversed by a GFRAL-antagonist antibody. Metformin had effects on both energy intake and energy expenditure that were dependent on GDF15, but retained its ability to lower circulating glucose levels in the absence of GDF15 activity. In summary, metformin elevates circulating levels of GDF15, which is necessary to obtain its beneficial effects on energy balance and body weight, major contributors to its action as a chemopreventive agent.",2020,"In wild-type mice, oral metformin increased circulating GDF15, with GDF15 expression increasing predominantly in the distal intestine and the kidney.",[],"['oral metformin', 'Metformin', 'metformin']","['circulating GDF15, with GDF15 expression', 'body weight', 'weight gain', 'energy intake and energy expenditure', 'body weight and energy balance']",[],"[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C1431343', 'cui_str': 'GDF15 protein, human'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",,0.0132908,"In wild-type mice, oral metformin increased circulating GDF15, with GDF15 expression increasing predominantly in the distal intestine and the kidney.","[{'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'Coll', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK. apc36@cam.ac.uk.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'NGM Biopharmaceuticals, South San Francisco, CA, USA.'}, {'ForeName': 'Pranali', 'Initials': 'P', 'LastName': 'Taskar', 'Affiliation': 'NGM Biopharmaceuticals, South San Francisco, CA, USA.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Rimmington', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Satish', 'Initials': 'S', 'LastName': 'Patel', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Tadross', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Cimino', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Welsh', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Virtue', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Goldspink', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Emily L', 'Initials': 'EL', 'LastName': 'Miedzybrodzka', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Adam R', 'Initials': 'AR', 'LastName': 'Konopka', 'Affiliation': 'Division of Endocrinology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Raul Ruiz', 'Initials': 'RR', 'LastName': 'Esponda', 'Affiliation': 'Division of Endocrinology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Jeffrey T-J', 'Initials': 'JT', 'LastName': 'Huang', 'Affiliation': 'Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, UK.'}, {'ForeName': 'Y C Loraine', 'Initials': 'YCL', 'LastName': 'Tung', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Rodriguez-Cuenca', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Rute A', 'Initials': 'RA', 'LastName': 'Tomaz', 'Affiliation': 'Wellcome -Medical Research Council Cambridge Stem Cell Institute, Department of Surgery, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Heather P', 'Initials': 'HP', 'LastName': 'Harding', 'Affiliation': 'Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Melvin', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Giles S H', 'Initials': 'GSH', 'LastName': 'Yeo', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Preiss', 'Affiliation': 'MRC Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Vidal-Puig', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Vallier', 'Affiliation': 'Wellcome -Medical Research Council Cambridge Stem Cell Institute, Department of Surgery, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'K Sreekumaran', 'Initials': 'KS', 'LastName': 'Nair', 'Affiliation': 'Division of Endocrinology, Mayo Clinic, Rochester, MN, USA.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Wareham', 'Affiliation': 'MRC Epidemiology Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ron', 'Affiliation': 'Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Fiona M', 'Initials': 'FM', 'LastName': 'Gribble', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Reimann', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Naveed', 'Initials': 'N', 'LastName': 'Sattar', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Savage', 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Bernard B', 'Initials': 'BB', 'LastName': 'Allan', 'Affiliation': 'NGM Biopharmaceuticals, South San Francisco, CA, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': ""O'Rahilly"", 'Affiliation': 'MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK. so104@medschl.cam.ac.uk.'}]",Nature,['10.1038/s41586-019-1911-y'] 1637,32473959,A randomised controlled trial of the effect of providing online risk information and lifestyle advice for the most common preventable cancers.,"Few trial data are available concerning the impact of personalised cancer risk information on behaviour. This study assessed the short-term effects of providing personalised cancer risk information on cancer risk beliefs and self-reported behaviour. We randomised 1018 participants, recruited through the online platform Prolific, to either a control group receiving cancer-specific lifestyle advice or one of three intervention groups receiving their computed 10-year risk of developing one of the five most common preventable cancers either as a bar chart, a pictograph or a qualitative scale alongside the same lifestyle advice. The primary outcome was change from baseline in computed risk relative to an individual with a recommended lifestyle (RRI) 1 at three months. Secondary outcomes included: health-related behaviours, risk perception, anxiety, worry, intention to change behaviour, and a newly defined concept, risk conviction. After three months there were no between-group differences in change in RRI (p = 0.71). At immediate follow-up, accuracy of absolute risk perception (p < 0.001), absolute and comparative risk conviction (p < 0.001) and intention to increase fruit and vegetables (p = 0.026) and decrease processed meat (p = 0.033) were higher in all intervention groups relative to the control group. The increases in accuracy and conviction were only seen in individuals with high numeracy and low baseline conviction, respectively. These findings suggest that personalised cancer risk information alongside lifestyle advice can increase short-term risk accuracy and conviction without increasing worry or anxiety but has little impact on health-related behaviour. Trial registration: ISRCTN17450583. Registered 30 January 2018.",2020,"At immediate follow-up, accuracy of absolute risk perception (p < 0.001), absolute and comparative risk conviction (p < 0.001) and intention to increase fruit and vegetables (p = 0.026) and decrease processed meat (p = 0.033) were higher in all intervention groups relative to the control group.","['1018 participants, recruited through the online platform Prolific, to either a']","['control group receiving cancer-specific lifestyle advice or one of three intervention groups receiving their computed 10-year risk of developing one of the five most common preventable cancers either as a bar chart, a pictograph or a qualitative scale alongside the same lifestyle advice', 'personalised cancer risk information', 'online risk information and lifestyle advice']","['computed risk relative to an individual with a recommended lifestyle (RRI', 'accuracy and conviction', 'health-related behaviours, risk perception, anxiety, worry, intention to change behaviour, and a newly defined concept, risk conviction', 'accuracy of absolute risk perception', 'absolute and comparative risk conviction', 'change in RRI', 'intention to increase fruit and vegetables', 'cancer risk beliefs and self-reported behaviour']",[],"[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205447', 'cui_str': '1'}, {'cui': 'C1547273', 'cui_str': 'Preventable'}, {'cui': 'C0684240', 'cui_str': 'Chart'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0237121', 'cui_str': 'Health-related behavior'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",1018.0,0.105156,"At immediate follow-up, accuracy of absolute risk perception (p < 0.001), absolute and comparative risk conviction (p < 0.001) and intention to increase fruit and vegetables (p = 0.026) and decrease processed meat (p = 0.033) were higher in all intervention groups relative to the control group.","[{'ForeName': 'Golnessa', 'Initials': 'G', 'LastName': 'Masson', 'Affiliation': 'The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. Electronic address: gh453@medschl.cam.ac.uk.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Mills', 'Affiliation': 'The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. Electronic address: kmills@medschl.cam.ac.uk.'}, {'ForeName': 'Simon J', 'Initials': 'SJ', 'LastName': 'Griffin', 'Affiliation': 'The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. Electronic address: profgp@medschl.cam.ac.uk.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Sharp', 'Affiliation': 'MRC Epidemiology Unit, University of Cambridge, Institute of Metabolic Science, Cambridge CB2 0QQ, UK. Electronic address: stephen.sharp@mrc-epid.cam.ac.uk.'}, {'ForeName': 'William M P', 'Initials': 'WMP', 'LastName': 'Klein', 'Affiliation': 'National Cancer Institute, Rockville, MD, USA. Electronic address: kleinwm@mail.nih.gov.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Sutton', 'Affiliation': 'The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. Electronic address: srs34@medschl.cam.ac.uk.'}, {'ForeName': 'Juliet A', 'Initials': 'JA', 'LastName': 'Usher-Smith', 'Affiliation': 'The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge School of Clinical Medicine, Box 113, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK. Electronic address: jau20@medschl.cam.ac.uk.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106154'] 1638,32482541,"Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.","BACKGROUND In the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed. PATIENTS AND METHODS Eligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m 2 ) and dexamethasone (20 mg) for 8 cycles with or without daratumumab (16 mg/kg) until disease progression. RESULTS Of 498 patients in the intent-to-treat (ITT) population (D-Vd, n = 251; Vd, n = 247), 47% had 1 prior line of treatment (1PL; D-Vd, n = 122; Vd, n = 113). Median progression-free survival (PFS) was significantly prolonged with D-Vd versus Vd in the ITT population (16.7 vs. 7.1 months; hazard ratio [HR], 0.31; 95% confidence interval [CI], 0.25-0.40; P < .0001) and the 1PL subgroup (27.0 vs. 7.9 months; HR, 0.22; 95% CI, 0.15-0.32; P < .0001). In lenalidomide-refractory patients, the median PFS was 7.8 versus 4.9 months (HR, 0.44; 95% CI, 0.28-0.68; P = .0002) for D-Vd (n = 60) versus Vd (n = 81). Minimal residual disease (MRD)-negativity rates (10 -5 ) were greater with D-Vd versus Vd (ITT: 14% vs. 2%; 1PL: 20% vs. 3%; both P < .0001). PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001). No new safety concerns were observed. CONCLUSION After 3 years, D-Vd maintained significant benefits in patients with relapsed or refractory multiple myeloma with a consistent safety profile. D-Vd provided the greatest benefit at first relapse and increased MRD-negativity rates.",2020,"PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001).","['Patients With Previously Treated Multiple Myeloma', 'patients with relapsed or refractory multiple myeloma', '498 patients in the intent-to-treat (ITT) population (D-Vd, n\xa0= 251; Vd, n\xa0= 247', 'Eligible patients had received\xa0≥ 1 line of treatment and were\xa0administered']","['Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone', 'bortezomib', 'dexamethasone']","['MRD-negativity rates', 'PFS2', 'Median progression-free survival (PFS', 'Minimal residual disease (MRD)-negativity rates', 'median PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0242596', 'cui_str': 'Minimal residual disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",-5.0,0.0659076,"PFS2 was significantly prolonged with D-Vd versus Vd (ITT: HR, 0.48; 95% CI, 0.38-0.61; 1PL: HR, 0.35; 95% CI, 0.24-0.51; P < .0001).","[{'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Department of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Sonneveld', 'Affiliation': 'Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.'}, {'ForeName': 'Vania', 'Initials': 'V', 'LastName': 'Hungria', 'Affiliation': 'Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Nooka', 'Affiliation': 'Winship Cancer Institute, Emory University, Atlanta, GA.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Estell', 'Affiliation': 'Haematology Department, Concord Cancer Centre, Concord Hospital, University of Sydney, Concord NSW, Australia.'}, {'ForeName': 'Wolney', 'Initials': 'W', 'LastName': 'Barreto', 'Affiliation': 'Hospital Santa Marcelina, São Paulo, Brazil.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Corradini', 'Affiliation': 'Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy.'}, {'ForeName': 'Chang-Ki', 'Initials': 'CK', 'LastName': 'Min', 'Affiliation': ""Seoul St. Mary's Hospital, Seoul, The Republic of Korea.""}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Medvedova', 'Affiliation': 'Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Chiu', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Jordan M', 'Initials': 'JM', 'LastName': 'Schecter', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ.'}, {'ForeName': 'Himal', 'Initials': 'H', 'LastName': 'Amin', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Ukropec', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kobos', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Spencer', 'Affiliation': 'Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia. Electronic address: aspencer@netspace.net.au.'}]","Clinical lymphoma, myeloma & leukemia",['10.1016/j.clml.2019.09.623'] 1639,32566276,Banded Sleeve Gastrectomy Improves Weight Loss Compared to Nonbanded Sleeve: Midterm Results from a Prospective Randomized Study.,"Background Weight regain after laparoscopic sleeve gastrectomy (LSG) is nowadays a growing concern. Sleeve dilatation and loss of food restriction is considered the main mechanism. The placement of a silicon ring around the gastric tube seems to give benefits in the short term. We report the results of a randomized study comparing LSG and laparoscopic banded sleeve gastrectomy (LBSG) over a 4-year follow-up. Objectives To evaluate the efficacy of banded sleeve gastrectomy compared to standard sleeve in the midterm. Methods Between 01/2014 and 01/2015, we randomly assigned 50 patients to receive one of the two procedures. Patients' management was exactly the same, apart from the band placement. We analyzed differences in weight loss, operative time, complication rate, and mortality, with a median follow-up of 4 years. Results Twenty five patients were assigned to receive LSG (Group A) and 25 LBSG (Group B). The mean preoperative BMI (body mass index) was 47.3 ± 6.58 kg/m 2 and 45.95 ± 5.85 kg/m 2 , respectively. There was no significant difference in the operative time. No intraoperative or postoperative complications occurred. At 12-month follow-up, the mean BMI was 29.72 ± 4.40 kg/m 2 in Group A and 27.42 ± 4.47 kg/m 2 in Group B ( p =0.186). After a median follow-up of 4 years, the mean BMI in Group B was significantly lower than Group A (24.10 ± 4.52 kg/m 2 vs 28.80 ± 4.62 kg/m 2 ; p =0.00199). Conclusions LBSG is a safe procedure, with no impact on postoperative complications. The banded sleeve showed a significant greater weight loss in the midterm follow-up. Considering the issue of weight regain observed after LSG, the placement of a perigastric ring during the first procedure may be a strategy to improve the results. This trial is registered with NCT04228185.",2020,No intraoperative or postoperative complications occurred.,['Twenty five patients'],"['laparoscopic sleeve gastrectomy (LSG', 'banded sleeve gastrectomy', 'LSG and laparoscopic banded sleeve gastrectomy (LBSG', 'Nonbanded Sleeve', 'Banded Sleeve Gastrectomy', 'LSG']","['intraoperative or postoperative complications', 'weight loss, operative time, complication rate, and mortality, with a median follow-up of 4 years', 'Weight Loss', 'Sleeve dilatation and loss of food restriction', 'mean preoperative BMI (body mass index', 'weight loss', 'operative time', 'mean BMI', 'postoperative complications']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0183336', 'cui_str': 'Sleeve'}]","[{'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0183336', 'cui_str': 'Sleeve'}, {'cui': 'C0002940', 'cui_str': 'Aneurysm'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",50.0,0.0494765,No intraoperative or postoperative complications occurred.,"[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Gentileschi', 'Affiliation': 'Department of Surgery, Obesity Unit, Tor Vergata University Hospital, Viale Oxford 81-00133, Rome, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Bianciardi', 'Affiliation': 'Department of Systems Medicine, Tor Vergata University Hospital, Viale Oxford 81-00133, Rome, Italy.'}, {'ForeName': 'Leandro', 'Initials': 'L', 'LastName': 'Siragusa', 'Affiliation': 'Department of Surgery, Tor Vergata University Hospital, Viale Oxford 81-00133, Rome, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Tognoni', 'Affiliation': 'Department of Surgery, Tor Vergata University Hospital, Viale Oxford 81-00133, Rome, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Benavoli', 'Affiliation': 'Department of Surgery, Tor Vergata University Hospital, Viale Oxford 81-00133, Rome, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': ""D'Ugo"", 'Affiliation': 'Department of General Surgery, ""Vito Fazzi"" Hospital, Piazza Muratore 1-73100, Lecce, Italy.'}]",Journal of obesity,['10.1155/2020/9792518'] 1640,32567124,Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial.,"OBJECTIVE The 5-hydroxytryptamine-3 receptor antagonist palonosetron (PALO) is approved (United States/Europe) as an oral formulation for prevention of chemotherapy-induced nausea and vomiting in adult cancer patients undergoing moderately emetogenic chemotherapy (MEC) for the acute phase only, in the United States, or as intravenous (IV) formulation in patients undergoing MEC or highly emetogenic chemotherapy. This phase III study compares the efficacy/safety of oral versus IV PALO in Chinese patients. METHODS Chemotherapy-naive patients with solid tumours scheduled for MEC received oral PALO 0.50 mg or IV PALO 0.25 mg. The primary objective was to demonstrate non-inferiority in terms of patients with complete response in the acute phase (0-24 hr post-chemotherapy). RESULTS Complete response rates (acute phase), evaluated in 318/320 randomised patients, were 84.6% and 85.9% for oral and IV PALO respectively. Non-inferiority was demonstrated; the two formulations showed similar efficacy/safety. CONCLUSION Non-inferiority of oral versus IV PALO in the acute phase was demonstrated in Chinese patients. CLINICAL TRIAL REGISTRATION CTR20140711.",2020,"Non-inferiority was demonstrated; the two formulations showed similar efficacy/safety. ","['Chinese cancer patients receiving moderately emetogenic chemotherapy', 'Chinese patients', 'adult cancer patients undergoing moderately', 'patients undergoing MEC or highly emetogenic chemotherapy', 'Chemotherapy-naive patients with solid tumours scheduled for']","['MEC received oral PALO 0.50\xa0mg or IV PALO 0.25\xa0mg', 'Oral versus intravenous palonosetron', 'oral versus IV PALO', 'emetogenic chemotherapy (MEC', '5-hydroxytryptamine-3 receptor antagonist palonosetron (PALO']","['efficacy/safety', 'nausea and vomiting']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0220578', 'cui_str': 'palonosetron'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C4691686', 'cui_str': 'palonosetron 0.25 MG'}, {'cui': 'C0360055', 'cui_str': '5-HT3 receptor antagonist'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}]",,0.216724,"Non-inferiority was demonstrated; the two formulations showed similar efficacy/safety. ","[{'ForeName': 'Jiuwei', 'Initials': 'J', 'LastName': 'Cui', 'Affiliation': 'The First Hospital of Jilin University, Changchun, Jilin, China.'}, {'ForeName': 'Qingyuan', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.'}, {'ForeName': 'Hongyu', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China.'}, {'ForeName': 'Tulla', 'Initials': 'T', 'LastName': 'Spinelli', 'Affiliation': 'Helsinn Healthcare SA, Pambio-Noranco, Switzerland.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Nicolas', 'Affiliation': 'Helsinn Healthcare SA, Pambio-Noranco, Switzerland.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'The First Hospital of Jilin University, Changchun, Jilin, China.'}]",European journal of cancer care,['10.1111/ecc.13245'] 1641,32568198,Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression.,"BACKGROUND By the time Alzheimer's disease and related disorders (ADRD) are diagnosed, efficacy of treatments is limited. Preventive interventions are urgently needed. OBJECTIVE To design a randomized controlled trial to assess a novel intervention that aims to prevent ADRD in high-risk groups. METHODS We report on the rationale and describe the design of a multisite randomized controlled trial that aims to prevent ADRD in older persons with: (1) mild cognitive impairment (MCI); (2) remitted major depressive disorder (MDD) without MCI; or (3) remitted MDD with MCI. RESULTS PACt-MD (Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression) is a trial that randomized 375 older participants with MCI, MDD, or MCI + MDD to cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) or sham-CR + sham-tDCS for 5 days/week for 8 weeks followed by boosters for 5 days/week once every 6 months until participants progress to MCI or ADRD, or the end of the study. Between boosters, participants are asked to train on CR daily. At baseline, end of 8 weeks, and yearly from baseline, participants undergo clinical, cognitive, and functional assessments. The primary aims are to compare the efficacy of CR + tDCS versus sham + sham in preventing: 1) long-term cognitive decline; and 2) incidence of ADRD or MCI. The secondary aim is to assess for cognitive improvement after the 8-week course. We will also explore the moderating and mediating effects of several biomarkers collected from the participants. CONCLUSION PACt-MD is unique in combining brain stimulation and a psychosocial intervention to prevent ADRD. PACt-MD is also a platform for studying multi-domain biomarkers that will advance our understanding of the relationships among MCI, MDD, and ADRD.",2020,"RESULTS PACt-MD (Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression) is a trial that randomized 375 older participants with MCI, MDD, or MCI + MDD to cognitive remediation (CR) and transcranial direct current stimulation (tDCS) or sham-CR + sham-tDCS for 5 days/week for 8 weeks followed by boosters for 5 days/week once every 6 months until participants progress to MCI or ADRD, or the end of the study.","['Mild cognitive impairment and Depression', '375 older participants with MCI, MDD, or MCI\u200a+\u200aMDD to cognitive remediation (CR) and', 'older persons with: (1) mild cognitive impairment (MCI); (2) remitted major depressive disorder (MDD) without MCI; or (3) remitted MDD with MCI', ""Alzheimer's dementia with""]","['Cognitive remediation plus transcranial direct current stimulation', 'CR\u200a+\u200atDCS versus sham\u200a+\u200asham', 'transcranial direct current stimulation (tDCS) or sham-CR\u200a+\u200asham-tDCS']",['cognitive improvement'],"[{'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4517745', 'cui_str': '375'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439600', 'cui_str': 'Remitting'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}]","[{'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]",[],375.0,0.420069,"RESULTS PACt-MD (Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression) is a trial that randomized 375 older participants with MCI, MDD, or MCI + MDD to cognitive remediation (CR) and transcranial direct current stimulation (tDCS) or sham-CR + sham-tDCS for 5 days/week for 8 weeks followed by boosters for 5 days/week once every 6 months until participants progress to MCI or ADRD, or the end of the study.","[{'ForeName': 'Tarek K', 'Initials': 'TK', 'LastName': 'Rajji', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bowie', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Herrmann', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Bruce G', 'Initials': 'BG', 'LastName': 'Pollock', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Marom', 'Initials': 'M', 'LastName': 'Bikson', 'Affiliation': 'Department of Biomedical Engineering, The City College of New York, NY, USA.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Blumberger', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Meryl A', 'Initials': 'MA', 'LastName': 'Butters', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Zafiris J', 'Initials': 'ZJ', 'LastName': 'Daskalakis', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Corinne E', 'Initials': 'CE', 'LastName': 'Fischer', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Alastair J', 'Initials': 'AJ', 'LastName': 'Flint', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Angela C', 'Initials': 'AC', 'LastName': 'Golas', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Graff-Guerrero', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Sanjeev', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Lourenco', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mah', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Shima', 'Initials': 'S', 'LastName': 'Ovaysikia', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Thorpe', 'Affiliation': 'Dalla Lana School of Public Health, University of Toronto.'}, {'ForeName': 'Aristotle N', 'Initials': 'AN', 'LastName': 'Voineskos', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Ontario, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of Alzheimer's disease : JAD,['10.3233/JAD-200141'] 1642,32563858,Capitalizing on cross-language similarities in intervention with bilingual children.,"PURPOSE This study examined the effects of a vocabulary intervention for bilingual children that was conducted in children's first language, Spanish, and included explicit instruction on cognates. We measured effects in terms of change from pre- to post-intervention in Spanish as well as associations with the non-target language, English. METHOD Participants were 12 Spanish-English bilingual children, aged 6-8 years, with and without Developmental Language Disorder. Children completed the intervention in pairs (one child with DLD and a typically developing peer) for 70-minute sessions, 3 days a week, for four weeks. Intervention targeted 32 words (16 cognates, 16 non-cognates) using four storybooks (8 words/book) and interactive activities that highlighted similarities across languages. Pre- and post-intervention measures in Spanish and English included tasks of word definition and cognate facilitation. RESULTS As a group, children showed improvement in definition quality and cognate naming in Spanish. There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD. All children showed positive cross-language correlations on post-intervention measures. CONCLUSIONS Bilingual children, with and without DLD, have the capacity to improve in their awareness and use of cognates. Explicit teaching of cognates can be an effective tool for building vocabulary skills. Children with DLD may need additional time and support to apply their knowledge of cognates to vocabulary learning.",2020,"There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD.","[""bilingual children that was conducted in children's first language, Spanish, and included explicit instruction on cognates"", 'Children with DLD', 'Participants were 12 Spanish-English bilingual children, aged 6-8 years, with and without Developmental Language Disorder', 'Spanish and English']",['vocabulary intervention'],"['included tasks of word definition and cognate facilitation', 'definition quality and cognate naming', 'positive cross-language correlations']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0557073', 'cui_str': 'First language'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023014', 'cui_str': 'Developmental language disorder'}]","[{'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0023008', 'cui_str': 'Language'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}]",,0.0437372,"There was a positive correlation between definition quality and cognate naming for the typically developing children, but not for the children with DLD.","[{'ForeName': 'Quynh', 'Initials': 'Q', 'LastName': 'Dam', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States; University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, United States. Electronic address: qdam@sdsu.edu.'}, {'ForeName': 'Giang T', 'Initials': 'GT', 'LastName': 'Pham', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: gpham@sdsu.edu.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Pruitt-Lord', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: spruitt@sdsu.edu.'}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Limon-Hernandez', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: jlimon-hernandez@sdsu.edu.'}, {'ForeName': 'Carrie', 'Initials': 'C', 'LastName': 'Goodwiler', 'Affiliation': 'San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, United States. Electronic address: cgoodwiler@sdsu.edu.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106004'] 1643,32564499,Reduced pain and analgesic use after acoustic binaural beats therapy in chronic pain - A double-blind randomized control cross-over trial.,"BACKGROUND Binaural Beats (BB) consist of two artificial acoustic stimuli with different frequency, presented simultaneously but independently to each ear. The human brain perceives and synchronizes to this frequency difference (entrainment). Aim of this study was to test the hypothesis that brain entrainment to a lower function rhythm, with BB application, can decrease pain perception and analgesic medication use, in chronic pain patients. METHODS In a double blind, randomized, cross-over trial, BB at 5Hz (theta rhythm) were applied for 30 minutes, under simultaneous electroencephalogram recordings, followed by liberal, on demand use by chronic pain patients for a week, compared to sham stimulation (SS). Pain as the main outcome (numeric scale, NRS), stress (STAI) and medication usage (defined daily doses, DDD) were assessed at baseline, 30 minutes and week's end. RESULTS Perceived pain (NRS) was significantly reduced in BB intervention (5.6±2.3 to 3.4±2.6, p<0.001), compared to SS (5.2±2.1 to 4.8±2.3, p=0.78), during the first 30-minute phase, as well as at the week's end (to 3.9±2.5 compared to 5.5±2.6 respectively, p<0.001). The mean EEG theta power at 5Hz was significantly increased only during BB application. Stress was significantly reduced at 30 minutes in both interventions but remained reduced only in the BB group at the week's end. Analgesic medication consumption (DDD, g) during the week was significantly less in the BB intervention (3.9±3.7 vs. 4.6±4.1, p<0.05), while reporting equal to SS mean levels of pain. CONCLUSIONS Acoustic BB reduced pain intensity, stress and analgesic use, compared to SS, in chronic pain patients. SIGNIFICANCE This study provides evidence that theta rhythm binaural beats can alleviate pain intensity, both after a brief 30 minute and a longer one week on-demand intervention. The subsequent significant reduction in analgesic medication consumption in chronic pain patients' daily living could offer a valuable tool, augmenting the effect of existing pain therapies.",2020,Stress was significantly reduced at 30 minutes in both interventions but remained reduced only in the BB group at the week's end.,['chronic pain patients'],"['acoustic binaural beats therapy', 'Acoustic BB']","['pain intensity, stress and analgesic use', 'Stress', 'pain and analgesic use', 'Perceived pain (NRS', 'Pain as the main outcome (numeric scale, NRS), stress (STAI) and medication usage (defined daily doses, DDD', 'Analgesic medication consumption (DDD, g', 'mean EEG theta power at 5Hz']","[{'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0011037', 'cui_str': 'DDD'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0439101', 'cui_str': 'Theta'}]",,0.0804744,Stress was significantly reduced at 30 minutes in both interventions but remained reduced only in the BB group at the week's end.,"[{'ForeName': 'Vasileios', 'Initials': 'V', 'LastName': 'Gkolias', 'Affiliation': 'Laboratory of Clinical Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Aikaterini', 'Initials': 'A', 'LastName': 'Amaniti', 'Affiliation': 'AHEPA University Hospital, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Areti', 'Initials': 'A', 'LastName': 'Triantafyllou', 'Affiliation': '3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Panagiota', 'Initials': 'P', 'LastName': 'Papakonstantinou', 'Affiliation': 'AHEPA University Hospital, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Kartsidis', 'Affiliation': 'Laboratory of Medical Physics, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Paraskevopoulos', 'Affiliation': 'Laboratory of Medical Physics, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Panagiotis D', 'Initials': 'PD', 'LastName': 'Bamidis', 'Affiliation': 'Laboratory of Medical Physics, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Leontios', 'Initials': 'L', 'LastName': 'Hadjileontiadis', 'Affiliation': 'Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Kouvelas', 'Affiliation': 'Laboratory of Clinical Pharmacology, Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.'}]","European journal of pain (London, England)",['10.1002/ejp.1615'] 1644,32565123,An acute bout of swimming increases post-exercise energy intake in young healthy men and women.,"Single bouts of land-based exercise (for example, walking, running, cycling) do not typically alter post-exercise energy intake on the day of exercise. However, anecdotal and preliminary empirical evidence suggests that swimming may increase appetite and energy intake. This study compared the acute effects of swimming on appetite, energy intake, and food preference and reward, versus exertion-matched cycling and a resting control. Thirty-two men (n = 17; mean ± SD age 24 ± 2 years, body mass index [BMI] 25.0 ± 2.6 kg/m 2 ) and women (n = 15; age 22 ± 3 years, BMI 22.8 ± 2.3 kg/m 2 ) completed three experimental trials (swimming, cycling, control) in a randomised, crossover design. The exercise trials involved 60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast. Food preference and reward were assessed via the Leeds Food Preference Questionnaire 15-min after exercise, whilst ad libitum energy intake was determined 30-min after exercise. The control trial involved identical procedures except no exercise was performed. Compared with control (3259 ± 1265 kJ), swimming increased ad libitum energy intake (3857 ± 1611 kJ; ES = 0.47, 95% CI of the mean difference between trials 185, 1010 kJ, P = 0.005); the magnitude of increase was smaller after cycling (3652 ± 1619 kJ; ES = 0.31, 95% CI -21, 805 kJ, P = 0.062). Ad libitum energy intake was similar between swimming and cycling (ES = 0.16, 95% CI -207, 618 kJ, P = 0.324). This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control. This study has identified an orexigenic effect of swimming. Further research is needed to identify the responsible mechanism(s), including the relevance of water immersion and water temperature per se.",2020,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"['young healthy men and women', 'Thirty-two men (n\u202f=\u202f17; mean\u202f±\u202fSD age 24\u202f±\u202f2 years, body mass index [BMI] 25.0\u202f±\u202f2.6\u202fkg/m 2 ) and women (n\u202f=\u202f15', 'age 22\u202f±\u202f3 years, BMI 22.8\u202f±\u202f2.3\u202fkg/m 2 ']","[""60-min of 'hard' exercise (self-selected rating of perceived exertion: 15) performed 90-min after a standardised breakfast"", 'Single bouts of land-based exercise']","['appetite, energy intake, and food preference and reward, versus exertion-matched cycling', 'Ad libitum energy intake', 'appetite and energy intake']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517633', 'cui_str': '2.6'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0016483', 'cui_str': 'Food Preferences'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]",,0.135485,This effect was consistent across sexes and unrelated to food preference and reward which were similar after swimming and cycling compared with control.,"[{'ForeName': 'Alice E', 'Initials': 'AE', 'LastName': 'Thackray', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.E.Thackray@lboro.ac.uk.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Willis', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: S.Willis2@lboro.ac.uk.'}, {'ForeName': 'Aron P', 'Initials': 'AP', 'LastName': 'Sherry', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: A.P.Sherry@lboro.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Clayton', 'Affiliation': 'School of Science and Technology, Nottingham Trent University, UK. Electronic address: David.Clayton@ntu.ac.uk.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Broom', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Coventry University, UK. Electronic address: ad5173@coventry.ac.uk.'}, {'ForeName': 'Mayada', 'Initials': 'M', 'LastName': 'Demashkieh', 'Affiliation': 'Department of Physical Education and Sport Science, Nanyang Technological University, Singapore. Electronic address: Mayada.Demashkieh@nie.edu.sg.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Sargeant', 'Affiliation': 'National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK; Diabetes Research Centre, University of Leicester, UK. Electronic address: js928@leicester.ac.uk.'}, {'ForeName': 'Lewis J', 'Initials': 'LJ', 'LastName': 'James', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK. Electronic address: L.James@lboro.ac.uk.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Finlayson', 'Affiliation': 'Faculty of Medicine and Health, University of Leeds, UK. Electronic address: G.S.Finlayson@leeds.ac.uk.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Stensel', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: D.J.Stensel@lboro.ac.uk.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'King', 'Affiliation': 'National Centre for Sport and Exercise Medicine, School of Sport Exercise and Health Sciences, Loughborough University, UK; National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, UK. Electronic address: j.a.king@lboro.ac.uk.'}]",Appetite,['10.1016/j.appet.2020.104785'] 1645,32568867,Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-naïve chronic hepatitis B patients: a prospective and randomized controlled trial.,"BACKGROUND The efficacy of entecavir (ETV) add-on peg-interferon therapy compared with ETV monotherapy in treatment-naïve hepatitis B virus (HBV) patients remains controversial. We investigated whether adding peg-interferon to ongoing ETV treatment leads to a better curative effect or not. METHODS All patients have been recruited between August 2013 and January 2015 from the Shanghai Public Health Clinical Center and Zhongshan Hospital (China). Eligible HBV patients (n = 144) were randomly divided (1:1) to receive either ETV monotherapy (n = 70) or peg-interferon add-on therapy from week 26 to 52 (n = 74). Patients were followed-up for at least 2 years. Indexes including hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion rate, sustained virologic response, transient elastography value, and histological scores were evaluated every 3 months until the end of the study. The rate of patients with HBsAg loss was defined as the primary endpoint criteria. RESULTS At week 26, no patient achieved HBsAg seroconversion in either group. At week 52, one patient in the monotherapy group was HBsAg-negative but there was none in the combination therapy group. The monotherapy group showed significantly better liver function recovery results than the combination therapy group. At week 78, one patient in the combination group had HBsAg seroconverted. At week 104, only three patients in the combination therapy group were HBsAg-negative compared with one patient in monotherapy. The mean alanine aminotransferase and aspartate aminotransferase levels and transient elastography values decreased significantly compared with baseline. Both groups showed a favorable decrease in alpha-fetoprotein (monotherapy: 4.5 [2.8, 7.1] vs. 2.2 [1.8, 3.1] ng/mL, P < 0.001; combination therapy: 5.7 [3.0, 18.8] vs. 3.2 [2.0, 4.3] ng/mL, P < 0.001) and an improved result of liver biopsy examination scores. The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028). But there was no significant difference in HBsAg conversion rate (1.8% [1/56] vs. 4.1% [3/73], P = 0.809) and HBeAg conversion rate (12.5% [7/56] vs. 11.0% [8/73], P = 0.787), as well as HBV-DNA, sustained virologic response (93.2% vs. 98.5%, P = 0.150) between the two groups. CONCLUSIONS Both therapies supported liver function recovery and histology improvement. Combination therapy did not show better anti-viral efficacy in HBsAg or HBeAg seroconversion compared with monotherapy. However, combination therapy played a more positive role in reversing hepatic fibrosis compared with monotherapy. TRIAL REGISTRATION ClinicalTrials.gov: NCT02849132; https://clinicaltrials.gov/ct2/show/NCT02849132.",2020,"The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028).","['treatment-naïve chronic hepatitis B patients', 'All patients have been recruited between August 2013 and January 2015 from the Shanghai Public Health Clinical Center and Zhongshan Hospital (China', 'Eligible HBV patients (n = 144']","['Entecavir', 'entecavir (ETV', 'ETV monotherapy (n\u200a=\u200a70) or peg-interferon add-on therapy', 'ETV monotherapy']","['mean alanine aminotransferase and aspartate aminotransferase levels and transient elastography values', 'hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) seroconversion rate, sustained virologic response, transient elastography value, and histological scores', 'HBsAg seroconversion', 'HBsAg-negative', 'hepatic fibrosis', 'histology', 'rate of patients with HBsAg loss', 'HBeAg conversion rate', 'liver function recovery', 'alpha-fetoprotein', 'HBV-DNA, sustained virologic response', 'liver biopsy examination scores', 'HBsAg conversion rate']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C4760627', 'cui_str': '144'}]","[{'cui': 'C0971023', 'cui_str': 'entecavir'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0428339', 'cui_str': 'Aspartate transaminase level'}, {'cui': 'C2748260', 'cui_str': 'Transient elastography'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C0019167', 'cui_str': 'Hepatitis B e antigen'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0919711', 'cui_str': 'Hepatitis B surface antigen negative'}, {'cui': 'C0239946', 'cui_str': 'Hepatic fibrosis'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0002210', 'cui_str': 'Alpha fetoprotein'}, {'cui': 'C0369332', 'cui_str': 'Hepatitis B virus DNA'}, {'cui': 'C0193388', 'cui_str': 'Biopsy of liver'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",144.0,0.0480929,"The combination group showed a better improvement in histology compared with the monotherapy group (mean transient elastography value 6.6 [4.9, 9.8] vs. 7.8 [5.4, 11.1] kPa, P = 0.028).","[{'ForeName': 'Jing-Mao', 'Initials': 'JM', 'LastName': 'Yang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Li-Ping', 'Initials': 'LP', 'LastName': 'Chen', 'Affiliation': 'Shanghai Medical College of Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Ya-Jie', 'Initials': 'YJ', 'LastName': 'Wang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Jinshan Hospital, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Lyu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhao', 'Affiliation': ""Department of Gastroenterology and Hepatology, Dongyang People's Hospital, Dongyang, Zhejiang 322100, China.""}, {'ForeName': 'Zhi-Yin', 'Initials': 'ZY', 'LastName': 'Shang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Zhen-Yu', 'Initials': 'ZY', 'LastName': 'Fan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Sheng-Di', 'Initials': 'SD', 'LastName': 'Wu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Ming', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Shao-Ping', 'Initials': 'SP', 'LastName': 'Huang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}, {'ForeName': 'Ji-Lin', 'Initials': 'JL', 'LastName': 'Cheng', 'Affiliation': 'Department of Gastroenterology and Hepatology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201500, China.'}]",Chinese medical journal,['10.1097/CM9.0000000000000857'] 1646,31181395,Distinguishing between demographic and contextual factors linked to early childhood physical discipline and physical maltreatment among Black families.,"BACKGROUND Despite persistent discouragement from professionals, U.S. parents, especially Black parents, highly endorse physical discipline, which also is a risk factor for physical maltreatment. Few studies have examined physical discipline heterogeneity or maltreatment, and predictive demographic and contextual factors within the same population. OBJECTIVE This exploratory study aimed to identify subgroups of Black parents' use of early childhood physical discipline. It also examined whether demographic and contextual factors' relations with physical discipline were similar or different from those with physical maltreatment. PARTICIPANTS AND SETTING 310 Black parents from three geographically-distinct high-risk U.S. communities participated in home-based interview and survey data collection. METHODS We conducted latent class analyses to identify sub-groups among Black parents characterized by physical discipline frequency and type. Bolck, Croon, and Hagenaars method and binary logistic regression were conducted to examine relations between demographic and contextual factors (child gender, family income, marital status, parental education, family stress and perceived neighborhood safety), discipline and maltreatment. RESULTS Three physical discipline classes, which differed in frequency and type, were identified among Black parents. Only income was significantly related to both discipline (x 2  = 18.97, p < .001) and maltreatment (OR = 1.03, p < .01). Child gender (x 2  = 6.66, p < .01), never-married status (x 2  = 13.94, p < .001), parental education (x 2  = 10.32, p < .001), and neighborhood safety (x 2  = 7.57, p < .01) also significantly related to discipline. Family stress was significantly related to physical maltreatment (OR = 1.42, p < .001). CONCLUSIONS Differing demographic and contextual factor relations with physical discipline and maltreatment within a Black population should be considered when identifying parents at-risk.",2019,"Family stress was significantly related to physical maltreatment (OR = 1.42, p < .001). ","['Black families', ""subgroups of Black parents' use of early childhood physical discipline"", '310 Black parents from three geographically-distinct high-risk U.S. communities participated in home-based interview and survey data collection', 'Black parents characterized by physical discipline frequency and type']",[],"['Family stress', 'neighborhood safety', 'parental education', 'demographic and contextual factors (child gender, family income, marital status, parental education, family stress and perceived neighborhood safety), discipline and maltreatment']","[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C5191352', 'cui_str': '310'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0010995', 'cui_str': 'Data Collection'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]",[],"[{'cui': 'C0577730', 'cui_str': 'Family tension'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",310.0,0.0129974,"Family stress was significantly related to physical maltreatment (OR = 1.42, p < .001). ","[{'ForeName': 'Judith C', 'Initials': 'JC', 'LastName': 'Scott', 'Affiliation': 'School of Social Work, Boston University, 264 Bay State Road, Boston, MA, 02215, United States. Electronic address: jcscott@bu.edu.'}, {'ForeName': 'Ellen E', 'Initials': 'EE', 'LastName': 'Pinderhughes', 'Affiliation': 'Eliot-Pearson Department of Child Study and Human Development, Tufts University, 105 College Avenue, Medford, MA, 02155, United States.'}]",Child abuse & neglect,['10.1016/j.chiabu.2019.05.013'] 1647,32578685,Pharmacological treatment of female sexual dysfunction: a critical analysis of the placebo and nocebo effects.,,2020,,['female sexual dysfunction'],['placebo'],[],"[{'cui': 'C1112442', 'cui_str': 'Female sexual dysfunction'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.101458,,"[{'ForeName': 'Lucia Alves da Silva', 'Initials': 'LADS', 'LastName': 'Lara', 'Affiliation': 'Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.'}]","Einstein (Sao Paulo, Brazil)",['10.31744/einstein_journal/2020ED5616'] 1648,32442198,No-flip ShangRing circumcision in 10-12 year old boys: Results from randomized clinical trials in Kenya.,"BACKGROUND Attention has recently turned toward the use of device-assisted male circumcision to help scale up male circumcision services in sub-Saharan Africa, with increasing emphasis on younger age groups. We assessed the use of the ShangRing for circumcising the subset of boys aged 10 to 12 years who were enrolled in two randomized clinical trials in Kenya. METHODS We performed a sub-analysis of outcomes in 197 boys aged 10 to 12 years; a subset who were enrolled in two randomized clinical trials to assess the use of the no-flip ShangRing circumcision technique in men and boys. One trial assessed spontaneous detachment vs. planned removal of the ShangRing 7 days post-circumcision. The second trial compared the use of topical vs. injectable anesthesia with ShangRing circumcision. Aside from baseline characteristics, data was collected and analyzed for each trial separately. RESULTS All participants were successfully circumcised. Duration of circumcision, participants requiring a dorsal slit, rate of adverse events, time to complete wound healing, and participant satisfaction were similar between the two groups in each trial. Mean time required for spontaneous ShangRing detachment was 14.82±3.76 days. Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001). Median dwell time of the topical anesthetic was 43 (IQR: 35.5-60) minutes, while the median time it took the injectable anesthetic to take effect was 2.04 (IQR: 1.72-3.09) minutes. CONCLUSION No-flip ShangRing circumcision had a positive safety profile among young adolescent boys, specifically ages 10-12 years. The use of spontaneous device detachment and topical anesthesia with the procedure have shown promising outcomes in this age group. This may have the potential to further increase the acceptability of ShangRing circumcision, and therefore accelerate the scle up of male circumcision services in sub-Saharan Africa. TRIAL REGISTRATION ClinicalTrials.gov registration # NCT02390310.",2020,"Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001).","['boys aged 10 to 12 years who were enrolled in two randomized clinical trials in Kenya', 'young adolescent boys, specifically ages 10-12 years', '10-12 year old boys', '197 boys aged 10 to 12 years', 'in men and boys']","['topical vs. injectable anesthesia with ShangRing circumcision', 'no-flip ShangRing circumcision technique', 'Topical anesthesia']","['Duration of circumcision, participants requiring a dorsal slit, rate of adverse events, time to complete wound healing, and participant satisfaction', 'Median dwell time of the topical anesthetic', 'positive safety profile', 'mean pain score', 'Mean time required for spontaneous ShangRing detachment']","[{'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001589', 'cui_str': 'Adolescents, Male'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0540654', 'cui_str': 'Casper Protein'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0472473', 'cui_str': 'Topical local anesthetic'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0008819', 'cui_str': 'Circumcision'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0184904', 'cui_str': 'Slitting'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0429659', 'cui_str': 'Dwell time'}, {'cui': 'C0040464', 'cui_str': 'Topical anesthetic'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0541879', 'cui_str': 'Detachment psychological'}]",197.0,0.304241,"Topical anesthesia showed a significantly lower mean pain score at the time of application (0.64±1.71 vs. 1.55± 2.21, p = 0.03) as well as postoperatively (0.54±0.88 vs. 1.72±1.56, p<0.0001).","[{'ForeName': 'Omar', 'Initials': 'O', 'LastName': 'Al Hussein Alawamlh', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Quentin D', 'Initials': 'QD', 'LastName': 'Awori', 'Affiliation': 'EngenderHealth, Nairobi, Kenya.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Barone', 'Affiliation': 'EngenderHealth, Washington, DC, NY, United States of America.'}, {'ForeName': 'Soo-Jeong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Goldstein', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Philip S', 'Initials': 'PS', 'LastName': 'Li', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, James Buchanan Brady Foundation, Center for Male Reproductive Medicine and Microsurgery, Weill Cornell College of Cornell University, New York, NY, United States of America.'}]",PloS one,['10.1371/journal.pone.0233150'] 1649,32442205,No effect of repetitive tDCS on daily smoking behaviour in light smokers: A placebo controlled EMA study.,"INTRODUCTION The effectiveness of repetitive transcranial Direct Current Stimulation (tDCS) on reducing smoking behaviour has been studied with mixed results. Smoking behaviour is influenced by affect and context, therefore we choose to use mobile ecological momentary assessments (EMA) to measure changes in smoking behaviour after tDCS. METHODS In a randomized, placebo-controlled, between subject study, we applied tDCS bilaterally with the anodal electrode targeting the right DLPFC (https://clinicaltrials.gov/ct2/show/NCT03027687). Smokers were allocated to six sessions of either active tDCS (n = 35) or sham tDCS (n = 36) and received two sessions on three different days in one week. They were asked to keep track of their daily cigarette consumption, craving and affect in an application on their mobile phones for three months starting one week before the first tDCS session. RESULTS Number of smoked cigarettes a day progressively decreased up to one week after the last tDCS session in both conditions. Active treatment had no additional effect on cigarette consumption, craving and affect. CONCLUSIONS In this exploratory study, repetitive bilateral tDCS over the DLPFC had no effect on daily smoking behaviour. Future research needs to investigate how motivation to quit smoking and the number of tDCS sessions affect the efficacy of repetitive tDCS.",2020,"Active treatment had no additional effect on cigarette consumption, craving and affect. ",['light smokers'],"['repetitive transcranial Direct Current Stimulation (tDCS', 'sham tDCS', 'active tDCS', 'repetitive tDCS', 'placebo']","['daily smoking behaviour', 'cigarette consumption, craving and affect']","[{'cui': 'C3494624', 'cui_str': 'Light tobacco smoker'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0459840', 'cui_str': 'Cigarette consumption'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0001721', 'cui_str': 'Affect'}]",36.0,0.0277547,"Active treatment had no additional effect on cigarette consumption, craving and affect. ","[{'ForeName': 'Ilse', 'Initials': 'I', 'LastName': 'Verveer', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioural Sciences, Erasmus University, Rotterdam, The Netherlands.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Remmerswaal', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioural Sciences, Erasmus University, Rotterdam, The Netherlands.'}, {'ForeName': 'Joran', 'Initials': 'J', 'LastName': 'Jongerling', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioural Sciences, Erasmus University, Rotterdam, The Netherlands.'}, {'ForeName': 'Frederik M', 'Initials': 'FM', 'LastName': 'van der Veen', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioural Sciences, Erasmus University, Rotterdam, The Netherlands.'}, {'ForeName': 'Ingmar H A', 'Initials': 'IHA', 'LastName': 'Franken', 'Affiliation': 'Department of Psychology, Education and Child Studies, Erasmus School of Social and Behavioural Sciences, Erasmus University, Rotterdam, The Netherlands.'}]",PloS one,['10.1371/journal.pone.0233414'] 1650,32445952,"Low-Fat, High-Fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in Patients With Ulcerative Colitis.","BACKGROUND & AIMS A high-fat diet has been associated with an increased risk of ulcerative colitis (UC). We studied the effects of a low-fat, high-fiber diet (LFD) vs an improved standard American diet (iSAD, included higher quantities of fruits, vegetables, and fiber than a typical SAD). We collected data on quality of life, markers of inflammation, and fecal markers of intestinal dysbiosis in patients with UC. METHODS We analyzed data from a parallel-group, cross-over study of 17 patients with UC in remission or with mild disease (with a flare within the past 18 mo), from February 25, 2015, through September 11, 2018. Participants were assigned randomly to 2 groups and received a LFD (10% of calories from fat) or an iSAD (35%-40% of calories from fat) for the first 4-week period, followed by a 2-week washout period, and then switched to the other diet for 4 weeks. All diets were catered and delivered to patients' homes, and each participant served as her or his own control. Serum and stool samples were collected at baseline and week 4 of each diet and analyzed for markers of inflammation. We performed 16s ribosomal RNA sequencing and untargeted and targeted metabolomic analyses on stool samples. The primary outcome was quality of life, which was measured by the short inflammatory bowel disease (IBD) questionnaire at baseline and week 4 of the diets. Secondary outcomes included changes in the Short-Form 36 health survey, partial Mayo score, markers of inflammation, microbiome and metabolome analysis, and adherence to the diet. RESULTS Participants' baseline diets were unhealthier than either study diet. All patients remained in remission throughout the study period. Compared with baseline, the iSAD and LFD each increased quality of life, based on the short IBD questionnaire and Short-Form 36 health survey scores (baseline short IBD questionnaire score, 4.98; iSAD, 5.55; LFD, 5.77; baseline vs iSAD, P = .02; baseline vs LFD, P = .001). Serum amyloid A decreased significantly from 7.99 mg/L at baseline to 4.50 mg/L after LFD (P = .02), but did not decrease significantly compared with iSAD (7.20 mg/L; iSAD vs LFD, P = .07). The serum level of C-reactive protein decreased numerically from 3.23 mg/L at baseline to 2.51 mg/L after LFD (P = .07). The relative abundance of Actinobacteria in fecal samples decreased from 13.69% at baseline to 7.82% after LFD (P = .017), whereas the relative abundance of Bacteroidetes increased from 14.6% at baseline to 24.02% on LFD (P = .015). The relative abundance of Faecalibacterium prausnitzii was higher after 4 weeks on the LFD (7.20%) compared with iSAD (5.37%; P = .04). Fecal levels of acetate (an anti-inflammatory metabolite) increased from a relative abundance of 40.37 at baseline to 42.52 on the iSAD and 53.98 on the LFD (baseline vs LFD, P = .05; iSAD vs LFD, P = .09). The fecal level of tryptophan decreased from a relative abundance of 1.33 at baseline to 1.08 on the iSAD (P = .43), but increased to a relative abundance of 2.27 on the LFD (baseline vs LFD, P = .04; iSAD vs LFD, P = .08); fecal levels of lauric acid decreased after LFD (baseline, 203.4; iSAD, 381.4; LFD, 29.91; baseline vs LFD, P = .04; iSAD vs LFD, P = .02). CONCLUSIONS In a cross-over study of patients with UC in remission, we found that a catered LFD or iSAD were each well tolerated and increased quality of life. However, the LFD decreased markers of inflammation and reduced intestinal dysbiosis in fecal samples. Dietary interventions therefore might benefit patients with UC in remission. ClinicalTrials.gov no: NCT04147598.",2020,"Compared to baseline, the iSAD and LFD each increased quality of life, based on the short IBD questionnaire and short-form 36 health survey scores (baseline short IBD questionnaire score, 4.98; iSAD, 5.55; LFD, 5.77; baseline vs iSAD P=.02; baseline vs LFD P=.001).","['patients with UC in remission', '17 patients with UC in remission or mild disease (with a flare within the last 18 months), from February 25, 2015 through September 11, 2018', 'Patients', 'patients with UC']","['Low-fat, High-fiber Diet', 'low-fat, high-fiber diet (LFD) vs an improved standard American diet (iSAD', 'LFD (10% of calories from fat) or an iSAD']","['relative abundance of Bacteroidetes', 'quality of life, based on the short IBD questionnaire and short-form 36 health survey scores (baseline short IBD questionnaire score', 'Serum amyloid', 'LFD decreased markers of inflammation and reduced intestinal dysbiosis', 'quality of life, markers of inflammation, and fecal markers of intestinal dysbiosis', 'Serum and stool samples', 'risk of ulcerative colitis (UC', 'Inflammation and Dysbiosis and Improves Quality of Life', 'changes in short-form 36 health survey, partial Mayo score, markers of inflammation, microbiome and metabolome analysis, and adherence to the diet', 'Serum level of C-reactive protein', 'Relative abundance of Actinobacteria in fecal samples', 'Relative abundance of Faecalibacterium prausnitzii', 'quality of life, which was measured by the short inflammatory bowel disease (IBD) questionnaire', 'Fecal levels of acetate (an anti-inflammatory metabolite', 'Fecal level of tryptophan', 'fecal levels of lauric acid', 'tolerated and increased quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3697010', 'cui_str': 'Ulcerative colitis in remission'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}]","[{'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0301568', 'cui_str': 'High residue diet'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0021390', 'cui_str': 'Inflammatory bowel disease'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0002723', 'cui_str': 'Serum amyloid A protein'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0301568', 'cui_str': 'High residue diet'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C4287543', 'cui_str': 'Intestinal dysbiosis'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1550661', 'cui_str': 'Stool specimen'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C3658208', 'cui_str': 'Dysbiosis'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C1956108', 'cui_str': 'Microbiome'}, {'cui': 'C2350399', 'cui_str': 'Metabolome'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0600148', 'cui_str': 'Class Actinobacteria'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0317558', 'cui_str': 'Faecalibacterium prausnitzii'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0000975', 'cui_str': 'Acetate'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0023139', 'cui_str': 'Lauric acid'}]",17.0,0.0684843,"Compared to baseline, the iSAD and LFD each increased quality of life, based on the short IBD questionnaire and short-form 36 health survey scores (baseline short IBD questionnaire score, 4.98; iSAD, 5.55; LFD, 5.77; baseline vs iSAD P=.02; baseline vs LFD P=.001).","[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Fritsch', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida; Department of Microbiology and Immunology, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Garces', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Quintero', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Pignac-Kobinger', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Santander', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Irina', 'Initials': 'I', 'LastName': 'Fernández', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Yuguang J', 'Initials': 'YJ', 'LastName': 'Ban', 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Deukwoo', 'Initials': 'D', 'LastName': 'Kwon', 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami-Leonard Miller School of Medicine, Miami, Florida; Division of Biostatistics, Department of Public Health Sciences, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Phillips', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Knight', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Qingqing', 'Initials': 'Q', 'LastName': 'Mao', 'Affiliation': 'Department of Food Science and Nutrition, University of Minnesota, St Paul, Minnesota.'}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'Santaolalla', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Xi S', 'Initials': 'XS', 'LastName': 'Chen', 'Affiliation': 'Sylvester Comprehensive Cancer Center, University of Miami-Leonard Miller School of Medicine, Miami, Florida; Division of Biostatistics, Department of Public Health Sciences, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Mukil', 'Initials': 'M', 'LastName': 'Maruthamuthu', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Norma', 'Initials': 'N', 'LastName': 'Solis', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Oriana M', 'Initials': 'OM', 'LastName': 'Damas', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Kerman', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Amar R', 'Initials': 'AR', 'LastName': 'Deshpande', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Lewis', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Miami-Leonard Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Chi', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Food Science and Nutrition, University of Minnesota, St Paul, Minnesota.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Abreu', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida; Department of Microbiology and Immunology, University of Miami-Leonard Miller School of Medicine, Miami, Florida. Electronic address: Mabreu1@med.miami.edu.'}]",Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,['10.1016/j.cgh.2020.05.026'] 1651,32446323,Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.,"BACKGROUND Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhibitors) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional therapy consisting of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and β blockers. Each class was previously studied with different background therapies and the expected treatment benefits with their combined use are not known. Here, we used data from three previously reported randomised controlled trials to estimate lifetime gains in event-free survival and overall survival with comprehensive therapy versus conventional therapy in patients with chronic HFrEF. METHODS In this cross-trial analysis, we estimated treatment effects of comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACE inhibitor or ARB and β blocker) in patients with chronic HFrEF by making indirect comparisons of three pivotal trials, EMPHASIS-HF (n=2737), PARADIGM-HF (n=8399), and DAPA-HF (n=4744). Our primary endpoint was a composite of cardiovascular death or first hospital admission for heart failure; we also assessed these endpoints individually and assessed all-cause mortality. Assuming these relative treatment effects are consistent over time, we then projected incremental long-term gains in event-free survival and overall survival with comprehensive disease-modifying therapy in the control group of the EMPHASIS-HF trial (ACE inhibitor or ARB and β blocker). FINDINGS The hazard ratio (HR) for the imputed aggregate treatment effects of comprehensive disease-modifying therapy versus conventional therapy on the primary endpoint of cardiovascular death or hospital admission for heart failure was 0·38 (95% CI 0·30-0·47). HRs were also favourable for cardiovascular death alone (HR 0·50 [95% CI 0·37-0·67]), hospital admission for heart failure alone (0·32 [0·24-0·43]), and all-cause mortality (0·53 [0·40-0·70]). Treatment with comprehensive disease-modifying pharmacological therapy was estimated to afford 2·7 additional years (for an 80-year-old) to 8·3 additional years (for a 55-year-old) free from cardiovascular death or first hospital admission for heart failure and 1·4 additional years (for an 80-year-old) to 6·3 additional years (for a 55-year-old) of survival compared with conventional therapy. INTERPRETATION Among patients with HFrEF, the anticipated aggregate treatment effects of early comprehensive disease-modifying pharmacological therapy are substantial and support the combination use of an ARNI, β blocker, MRA, and SGLT2 inhibitor as a new therapeutic standard. FUNDING None.",2020,HRs were also favourable for cardiovascular death alone (HR 0·50 [,"['patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional therapy consisting of', '2·7 additional years (for an 80-year-old) to 8·3 additional years (for a 55-year-old) free from cardiovascular death or first hospital admission for heart failure and 1·4 additional years (for an 80-year-old) to 6·3 additional years (for a 55-year-old) of survival compared with conventional therapy', 'patients with HFrEF', 'patients with heart failure with reduced ejection fraction', 'patients with chronic HFrEF.\nMETHODS', 'patients with chronic HFrEF by making indirect comparisons of three pivotal trials, EMPHASIS-HF (n=2737), PARADIGM-HF (n=8399), and DAPA-HF (n=4744']","['comprehensive disease-modifying pharmacological therapy', 'angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and β blockers', 'comprehensive disease-modifying pharmacological therapies', 'comprehensive therapy versus conventional therapy', 'comprehensive disease-modifying pharmacological therapy (ARNI, β blocker, MRA, and SGLT2 inhibitor) versus conventional therapy (ACE inhibitor or ARB and β blocker']","['cardiovascular death or hospital admission for heart failure', 'hospital admission for heart failure alone (0·32', 'hazard ratio (HR', 'composite of cardiovascular death or first hospital admission for heart failure', 'cardiovascular death alone (HR 0·50 ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C4280934', 'cui_str': 'Reduced ejection fraction co-occurrent and due to chronic heart failure'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0022709', 'cui_str': 'Dipeptidyl carboxypeptidase I'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0243032', 'cui_str': 'Magnetic resonance imaging (MRI) of vessels'}, {'cui': 'C3273807', 'cui_str': 'SGLT2 Inhibitors'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205199', 'cui_str': 'Composite'}]",,0.181843,HRs were also favourable for cardiovascular death alone (HR 0·50 [,"[{'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Pardeep S', 'Initials': 'PS', 'LastName': 'Jhund', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Cunningham', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Pedro Ferreira', 'Affiliation': ""Université de Lorraine INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France; Department of Physiology and Cardiothoracic Surgery, University of Porto, Porto, Portugal.""}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""Université de Lorraine INSERM, Centre d'Investigations Cliniques Plurithématique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.""}, {'ForeName': 'Milton', 'Initials': 'M', 'LastName': 'Packer', 'Affiliation': 'Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA; Imperial College, London, UK.'}, {'ForeName': 'Gregg C', 'Initials': 'GC', 'LastName': 'Fonarow', 'Affiliation': 'Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ssolomon@bwh.harvard.edu.""}]","Lancet (London, England)",['10.1016/S0140-6736(20)30748-0'] 1652,32447474,Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.,"BACKGROUND The ALTER 0303 study showed that anlotinib can significantly improve overall survival (OS) compared with the placebo in advanced non-small-cell lung cancer (NSCLC). Hand-foot syndrome (HFS) is a common anlotinib-related adverse event. The aim of this study was to assess the association of HFS with clinical benefit. METHODS A subgroup analysis of patients treated with anlotinib from the ALTER 0303 study was performed. Our analysis assessed if the appearance of anlotinib-related HFS in the first 42 days (second-cycle HFS) and at any time could produce better clinical benefits. RESULTS In this study, 294 patients were treated with anlotinib. Of which, 129 patients had HFS at any time, and 76 patients developed HFS in the first 2 cycles. Patients who received anlotinib and developed HFS had significantly prolonged OS, progression-free survival (PFS) compared to those who did not develop HFS in the first 2 cycles (13.5 vs 8.7 months, p = 0.001; adjusted hazard ratio (HR) 0.63 (95% confidence interval [CI] 0.44-0.89), p = 0.009; 5.8 vs 4.5 months, p = 0.001; adjusted HR, 0.59 [0.43-0.81], p = 0.001). The significant OS and PFS benefits for patients with HFS versus without were seen at any time (14.5 vs 7.3 months, p = 0.000; adjusted HR, 0.50 [0.36-0.67], p = 0.000; 5.8 vs 4.2 months, p = 0.000; adjusted HR, 0.49 [0.37-0.65], p = 0.000). In addition, the grade of severity of HFS was strongly correlated with OS (p = 0.000). CONCLUSION Presence of HFS may be a potential clinical marker for the treatment of NSCLC with anlotinib.",2020,"Patients who received anlotinib and developed HFS had significantly prolonged OS, progression-free survival (PFS) compared to those who did not develop HFS in the first 2 cycles (13.5 vs 8.7 months, p = 0.001; adjusted hazard ratio (HR) 0.63","['patients with advanced non-small-cell lung cancer receiving', '129 patients had HFS at any time, and 76 patients developed', '294 patients were treated with anlotinib']","['anlotinib', 'HFS', 'placebo']","['grade of severity of HFS', 'overall survival (OS', 'HFS', 'prolonged OS, progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4519250', 'cui_str': 'anlotinib'}]","[{'cui': 'C4519250', 'cui_str': 'anlotinib'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",294.0,0.273917,"Patients who received anlotinib and developed HFS had significantly prolonged OS, progression-free survival (PFS) compared to those who did not develop HFS in the first 2 cycles (13.5 vs 8.7 months, p = 0.001; adjusted hazard ratio (HR) 0.63","[{'ForeName': 'Xueli', 'Initials': 'X', 'LastName': 'Nan', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Xie', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.'}, {'ForeName': 'Qingqing', 'Initials': 'Q', 'LastName': 'Zhu', 'Affiliation': 'Department of Oncology, Shandong Cancer Hospital and Institute, Shandong, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Fu', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Han', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China.'}, {'ForeName': 'Qiujing', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Department of Oncology, Shandong Cancer Hospital and Institute, Shandong, China.'}, {'ForeName': 'Baohui', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong, China. lj691012@126.com.'}]",International journal of clinical oncology,['10.1007/s10147-020-01683-0'] 1653,32455486,Dermoscopy comparative approach for early diagnosis in familial melanoma: influence of MC1R genotype.,"BACKGROUND MC1R polymorphisms interact with CDKN2A mutations modulating melanoma risk and contribute to a less suspicious clinical and dermoscopic appearance of melanomas. Different strategies, including dermoscopic comparative approach and digital monitoring, are used for the melanoma diagnosis in this context. OBJECTIVE To analyse the diagnostic accuracy of the morphologic approach and comparative approach in dermoscopy, and to detect melanoma in familial melanoma (FamMM) patients according to different genetic backgrounds. METHODS Two independent readers evaluated 415 lesions belonging to 25 FamMM: 26 melanomas (62% in situ, 36% early invasive) and 389 naevi, blinded for dermoscopic and histopathologic diagnosis, following two different steps. First step-Randomized: all lesions were randomly located in one single folder. Second step-Comparative approach: the lesions were clustered by patient. Sensitivity, specificity and number needed to excise (NNE) for melanoma diagnosis were calculated for both diagnostic strategies. Sensitivity and specificity were also assessed regarding the genetic background. RESULTS The comparative approach showed lower sensitivity compared to the morphologic approach (69.2 and 73.1 vs. 76.9 both readers) but better specificity (95.9 and 95.1 vs. 84.3 and 90.2, respectively). NNE was better in the comparative approach. The readers had more difficulties diagnosing lesions from CDKN2A mutation carriers with red hair colour (RHC) MC1R variants. CONCLUSION The comparative approach can be useful in high-risk patients to decrease the NNE. Early melanomas in CDKN2A carriers with RHC polymorphisms are more difficult to diagnose even with the comparative approach and benefit from the detection of changes during digital dermoscopy monitoring for early diagnosis.",2020,Early melanomas in CDKN2A carriers with RHC polymorphisms are more difficult to diagnose even with the comparative approach and benefit from the detection of changes during digital dermoscopy monitoring for early diagnosis.,"['Two independent readers evaluated 415 lesions belonging to 25 FamMM', 'familial melanoma (FamMM) patients according to different genetic backgrounds', 'Early melanomas in CDKN2A carriers with RHC polymorphisms', 'early diagnosis in familial melanoma', '26 melanomas (62% in situ, 36% early invasive) and 389 nevi, blinded for dermoscopic and histopathologic diagnosis']",[],"['lower sensitivity', 'Sensitivity, specificity, and number needed to excise (NNE) for melanoma diagnosis', 'Sensitivity and specificity']","[{'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0151779', 'cui_str': 'Malignant melanoma of skin'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4042916', 'cui_str': 'Genetic Background'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0384826', 'cui_str': 'p14ARF Protein'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0239803', 'cui_str': 'Red hair'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0596473', 'cui_str': 'Early Diagnosis'}, {'cui': 'C0444498', 'cui_str': 'In situ'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C4517752', 'cui_str': '389'}, {'cui': 'C0027960', 'cui_str': 'Nevi'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C0677043', 'cui_str': 'Histopathology'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0036668', 'cui_str': 'Sensitivity and Specificity'}]",,0.0603168,Early melanomas in CDKN2A carriers with RHC polymorphisms are more difficult to diagnose even with the comparative approach and benefit from the detection of changes during digital dermoscopy monitoring for early diagnosis.,"[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Longo', 'Affiliation': 'Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Barquet', 'Affiliation': 'Dermatology Department, Hospital de Clínicas, Montevideo, Uruguay.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Hernandez', 'Affiliation': ""Dermatology Department, Hospital Universitary Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.""}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Marghoob', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Potrony', 'Affiliation': 'Dermatology Department, Melanoma Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Carrera', 'Affiliation': 'Dermatology Department, Melanoma Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Aguilera', 'Affiliation': 'Dermatology Department, Melanoma Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Badenas', 'Affiliation': ""Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Malvehy', 'Affiliation': 'Dermatology Department, Melanoma Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Puig', 'Affiliation': 'Dermatology Department, Melanoma Unit, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.'}]",Journal of the European Academy of Dermatology and Venereology : JEADV,['10.1111/jdv.16679'] 1654,30250241,"The effect of brisk walking in the fasted versus fed state on metabolic responses, gastrointestinal function, and appetite in healthy men.","OBJECTIVE To investigate the effect of brisk walking in the fasted versus fed state on gastric emptying rate (GER), metabolic responses and appetite hormone responses. SUBJECTS/METHODS Twelve healthy men completed two 45 min treadmill walks, fasted (FASTED) and followed consumption of a standardised breakfast (FED). GER of a standardised lunch was subsequently measured for 2 h using the 13 C-breath test method. Blood samples were collected at baseline, post-breakfast period, pre-exercise, immediately post exercise, pre-lunch then every 30 min following lunch for 2 h. Circulating concentrations of acylated ghrelin (GHR), glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and cholesterol were measured. Subjective feelings of appetite were assessed at 15 min intervals throughout. Substrate utilisation was measured every 30 min, and continuously throughout exercise by indirect calorimetry. RESULTS No differences were observed for GER T ½ (FASTED 89 ± 22 vs. FED 89 ± 24 min, P = 0.868) nor T lag (FASTED 55 ± 15 vs. FED 54 ± 14 min, P = 0.704). NEFA concentrations were higher in FASTED at pre-exercise, post exercise and 30 min post exercise (pre-lunch) (all P < 0.05) but no differences were observed for glucose, cholesterol or triglycerides. Carbohydrate oxidation was greater at all time-points during FED exercise (all P < 0.05). Minimal changes in appetite were observed post lunch ingestion with no differences in PYY or GHR observed between trials. GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch. A greater concentration of PP was observed in FED from pre-exercise to 30 min post lunch consumption (all P < 0.05). Insulin concentrations were higher in FED pre-exercise but higher in FASTED 1.5 h post lunch (P < 0.05). CONCLUSION These findings suggest that gastrointestinal function, hunger and appetite regulatory hormones are not sensitive to low-intensity bouts of physical activity and holds positive implications for weight management practices.",2019,"GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch.","['Twelve healthy men completed two', 'healthy men']","['brisk walking', '45\u2009min treadmill walks, fasted (FASTED) and followed consumption of a standardised breakfast (FED', 'glucagon-like peptide-1 ']","['GLP-1), peptide tyrosine tyrosine (PYY), pancreatic polypeptide (PP), glucose, insulin, triglycerides, non-esterified fatty acids (NEFA) and cholesterol', 'glucose, cholesterol or triglycerides', 'Carbohydrate oxidation', 'concentration of PP', 'Substrate utilisation', 'Insulin concentrations', 'Subjective feelings of appetite', 'metabolic responses, gastrointestinal function, and appetite', 'appetite', 'gastric emptying rate (GER), metabolic responses and appetite hormone responses', 'GLP-1 concentrations', 'NEFA concentrations']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0077599', 'cui_str': 'tyrosyltyrosine'}, {'cui': 'C0030298', 'cui_str': 'Pancreatic peptide'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}]",12.0,0.0837764,"GLP-1 concentrations were greater in FED post-breakfast and pre-exercise (P < 0.05), though no differences were observed after lunch.","[{'ForeName': 'Victoria J', 'Initials': 'VJ', 'LastName': 'McIver', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Mattin', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Gethin H', 'Initials': 'GH', 'LastName': 'Evans', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK.'}, {'ForeName': 'Adora M W', 'Initials': 'AMW', 'LastName': 'Yau', 'Affiliation': 'School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK. a.yau@mmu.ac.uk.'}]",International journal of obesity (2005),['10.1038/s41366-018-0215-x'] 1655,30538278,"Associations between reliable changes in depression and changes in BMI, total body fatness and visceral adiposity during a 12-month weight loss trial.","We investigated associations between changes in depression and body composition over a 12-month weight loss trial. Of the 298 adults (BMI > 27 m/kg 2 ), 219 with complete depression and body composition data were included. A 10-item Center for Epidemiologic Studies Depression Scale measured depression; dual-energy X-ray absorptiometry measured body composition. Multinomial logistic regression predicted reliable changes in depression by BMI, body fat (BF) and visceral adiposity (VAT). Multiplicative interaction terms tested modification by sex and ethnicity. Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18). Sex and ethnicity interaction terms were not significant. However, the relationship was only significant among females, among non-Latinos for BMI and BF, and among Latinos for VAT. Our study supports the association between depression and obesity and highlights the need for longitudinal studies investigating VAT and depression in diverse ethnic groups.",2019,"Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18).","['298 adults (BMI\u2009>\u200927\u2009m/kg 2 ), 219 with complete depression and body composition data were included']",[],"['depression and changes in BMI, total body fatness and visceral adiposity', 'body composition', 'depression by BMI, body fat (BF) and visceral adiposity (VAT']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517648', 'cui_str': '219'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",[],"[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0442045', 'cui_str': 'Visceral'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}]",298.0,0.0200185,"Participants with increases in body composition were less likely to experience improvements in depression (BMI: RRR = 0.79 (0.68-0.91), p < 0.01; BF: RRR = 0.97 (0.94 - 0.99), p = 0.01; VAT: RRR = 0.99 (0.98-1.00), p = 0.02), but not worsening of depression (BMI: RRR = 1.29 (0.96-1.73), p = 0.10; BF: RRR = 1.04 (0.99-1.09), p = 0.15; VAT: RRR = 1.01 (1.00-1.03), p = 0.18).","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Cameron', 'Affiliation': 'University of California San Diego School of Medicine, 9500 Gilman Drive, La Jolla, CA, 92093, USA. ncameron1002@gmail.com.'}, {'ForeName': 'Job G', 'Initials': 'JG', 'LastName': 'Godino', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Skipper', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Dillon', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Waalen', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hill', 'Affiliation': 'Center for Wireless and Population Health Systems, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Patrick', 'Affiliation': 'Department of Family Medicine and Public Health UC San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA.'}]",International journal of obesity (2005),['10.1038/s41366-018-0272-1'] 1656,32459597,Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.,"PURPOSE Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC). We present safety and patient-reported outcomes (PROs) to provide additional information on the relative impact of adding atezolizumab to chemotherapy with and without bevacizumab in nonsquamous NSCLC. METHODS Patients were randomly assigned to receive atezolizumab, carboplatin, and paclitaxel (ACP), ABCP, or BCP. Coprimary end points were overall survival and investigator-assessed progression-free survival. The incidence, nature, and severity of adverse events (AEs) were assessed. PROs, a secondary end point, were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-Lung Cancer 13. RESULTS Overall, 400 (ACP), 393 (ABCP), and 394 (BCP) patients were safety evaluable (ie, intention-to-treat population that received one or more doses of any study treatment). More patients had grade 3/4 treatment-related AEs during the induction versus maintenance phase (ACP, 40.5% v 8.2%; ABCP, 48.6% v 21.2%; BCP, 44.7% v 11.1%). During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively. During maintenance, SAE incidences were 20.0%, 26.3%, and 13.0%, respectively. Completion rates of the PRO questionnaires were > 88% at baseline and remained ≥ 70% throughout most study visits. Across arms, patients on average reported no clinically meaningful worsening of global health status or physical functioning scores through cycle 13. Patients across arms rated common symptoms with chemotherapy and immunotherapy similarly. CONCLUSION ABCP seems tolerable and manageable versus ACP and BCP in first-line nonsquamous NSCLC. Treatment tolerability differed between induction and maintenance phases across treatment arms. PROs reflect a minimal treatment burden (eg, health-related quality of life, symptoms) with each regimen.",2020,"During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively.","['Non-Small-Cell Lung Cancer', 'chemotherapy-naïve nonsquamous non-small-cell lung cancer (NSCLC', 'Patients']","['Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy', 'Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP', 'atezolizumab to chemotherapy with and without bevacizumab', 'ABCP', 'bevacizumab, carboplatin, and paclitaxel (BCP', 'atezolizumab, carboplatin, and paclitaxel (ACP), ABCP, or BCP']","['incidence of serious AEs (SAEs', 'Completion rates of the PRO questionnaires', 'European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core 30 and EORTC QLQ-Lung Cancer 13', 'global health status or physical functioning scores', 'incidence, nature, and severity of adverse events (AEs', 'overall survival and investigator-assessed progression-free survival', 'Treatment tolerability']","[{'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4055433', 'cui_str': 'atezolizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451149', 'cui_str': 'EORTC - Quality of life questionnaire'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.253518,"During induction, the incidence of serious AEs (SAEs) was 28.3%, 28.5%, and 26.4% in the ACP, ABCP, and BCP arms, respectively.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Reck', 'Affiliation': 'Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Wehler', 'Affiliation': 'Evangelisches Krankenhaus Hamm gGmbH, Hamm, Germany.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Orlandi', 'Affiliation': 'Instituto Nacional del Tórax, Santiago, Chile.'}, {'ForeName': 'Naoyuki', 'Initials': 'N', 'LastName': 'Nogami', 'Affiliation': 'National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Barone', 'Affiliation': 'Università Cattolica del Sacro Cuore, Rome, Italy.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Moro-Sibilot', 'Affiliation': 'Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Mikhail', 'Initials': 'M', 'LastName': 'Shtivelband', 'Affiliation': 'Ironwood Cancer & Research Center, Chandler, AZ.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'González Larriba', 'Affiliation': 'Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Rothenstein', 'Affiliation': 'Durham Regional Cancer Center, Lakeridge Health, Oshawa, Ontario, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Früh', 'Affiliation': 'Cantonal Hospital of St Gallen, St Gallen, Switzerland.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Yu', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Shelley', 'Initials': 'S', 'LastName': 'Coleman', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Geetha', 'Initials': 'G', 'LastName': 'Shankar', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Hina', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Kelsch', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Piault', 'Affiliation': 'Genentech, South San Francisco, CA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Socinski', 'Affiliation': 'AdventHealth Cancer Institute, Orlando, FL.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03158'] 1657,32459776,Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up.,"BACKGROUND This study compared the effectiveness of injectable collagenase clostridium histolyticum and percutaneous needle fasciotomy in the treatment of Dupuytren's contracture. METHODS Patients with a total passive extension deficit of 30 degrees or more in a single digital ray were enrolled and assigned randomly to receive either collagenase clostridium histolyticum injections or percutaneous needle fasciotomy. Preoperative severity of proximal interphalangeal joint contracture for Dupuytren's disease was classified according to the British Society for Surgery of the Hand as less than 30 degrees (stage I) or 30 degrees or more (stage II). RESULTS Of the 70 patients enrolled, 36 patients with 46 joints received collagenase clostridium histolyticum injections and 34 patients with 48 joints received percutaneous needle fasciotomy. At day 30, successful corrections were obtained in only 50 percent of the injection group and 67 percent of the fasciotomy group for stage II proximal interphalangeal joints. Recurrences were frequent among patients with stage II joint contractures. The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively). In the injection group, adverse events were reported for all patients. In the fasciotomy group, complications were reported for 15 percent of patients. CONCLUSIONS The collagenase clostridium histolyticum and percutaneous needle fasciotomy groups had similar outcomes for Dupuytren's contracture with 3 years' follow-up. Recurrences were frequent among patients with stage II proximal interphalangeal joint contractures. The Unité Rhumatologique des Affections de la Main scale and Quick Disabilities of the Arm, Shoulder and Hand questionnaire score decreased significantly for both groups at final follow-up. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2020,"The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively).","['36 patients with 46 joints received', 'and 34 patients with 48 joints received', 'Patients with a total passive extension deficit of 30 degrees or more in a single digital ray', ""Dupuytren's Contracture"", 'patients with stage II proximal interphalangeal joint contractures', 'patients with stage II joint contractures', '70 patients enrolled', ""Dupuytren's contracture""]","['percutaneous needle fasciotomy', 'collagenase clostridium histolyticum injections', 'collagenase clostridium histolyticum injections or percutaneous needle fasciotomy', 'injectable collagenase clostridium histolyticum and percutaneous needle fasciotomy', 'Collagenase Injection and Percutaneous Needle Fasciotomy']","['mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score', 'Unité Rhumatologique des Affections de la Main scale and Quick Disabilities of the Arm, Shoulder and Hand questionnaire score', 'complications', 'adverse events', 'Recurrences']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0086894', 'cui_str': 'Rajiformes'}, {'cui': 'C0013312', 'cui_str': ""Dupuytren's contracture""}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C1563055', 'cui_str': 'Interphalangeal joint structure'}, {'cui': 'C0009917', 'cui_str': 'Contracture'}, {'cui': 'C0009918', 'cui_str': 'Contracture of joint'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0185188', 'cui_str': 'Division of fascia'}, {'cui': 'C4301823', 'cui_str': 'collagenase Clostridium histolyticum Injection'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0009053', 'cui_str': 'collagenase Clostridium histolyticum'}, {'cui': 'C0162745', 'cui_str': 'COLLAGENASE'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011702', 'cui_str': '4-(4-Amino-4-Carboxybutyl)-1-(5-Amino-5-Carboxypentyl)-3,5-bis(3-Amino-3-Carboxypropyl)pyridinium'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",70.0,0.038712,"The mean Quick Disabilities of the Arm, Shoulder and Hand questionnaire score at day 30 was significantly higher in the injection group compared with the fasciotomy group (7.5 versus 4.2, respectively).","[{'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Abe', 'Affiliation': 'Ichihara City, Japan From the Department of Orthopedic Surgery, Chiba Rosai Hospital.'}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006828'] 1658,32460459,Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.,"BACKGROUND/AIMS Several treatment options are currently available for patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment. We aimed to compare the effectiveness of regorafenib and nivolumab in these patients. METHODS Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included. Primary endpoint was overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events. Inverse probability of treatment weighting (IPTW) using the propensity score was conducted to reduce treatment selection bias. RESULTS Among 150 study patients, 102 patients received regorafenib and 48 patients received nivolumab. Median OS was 6.9 (95% confidence interval [CI], 3.0-10.8) months for regorafenib and 5.9 (95% CI, 3.7-8.1) months for nivolumab (P=0.77 by log-rank test). In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30-0.96; P=0.04). Time to progression was not significantly different between groups (nivolumab vs. regorafenib: aHR, 0.82; 95% CI, 0.51-1.30; P=0.48). HRs were maintained after IPTW. Objective response rates were 5.9% and 16.7% in patients treated with regorafenib and nivolumab, respectively (P=0.04). CONCLUSION After sorafenib failure, the use of nivolumab may be associated with improved OS and better objective response rate as compared to using regorafenib.",2020,"In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30-0.96; P=0.04).","['150 study patients', 'Consecutive HCC patients who received regorafenib or nivolumab after failure of sorafenib treatment were included', 'patients with hepatocellular carcinoma (HCC) failing previous sorafenib treatment', '102 patients received', 'hepatocellular carcinoma patients who failed sorafenib treatment']","['nivolumab versus regorafenib', 'regorafenib', 'nivolumab', 'regorafenib and nivolumab']","['overall survival (OS) and secondary endpoints were time to progression, tumor response rate, and adverse events', 'Median OS', 'Objective response rates', 'Time to progression', 'OS and better objective response rate']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205156', 'cui_str': 'Previous'}]","[{'cui': 'C3657270', 'cui_str': 'nivolumab'}, {'cui': 'C2980094', 'cui_str': 'regorafenib'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]",150.0,0.318331,"In multivariable analysis, nivolumab was associated with prolonged OS (vs. regorafenib: adjusted hazard ratio [aHR], 0.54; 95% CI, 0.30-0.96; P=0.04).","[{'ForeName': 'Cheol-Hyung', 'Initials': 'CH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Yun Bin', 'Initials': 'YB', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Minseok Albert', 'Initials': 'MA', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Heejoon', 'Initials': 'H', 'LastName': 'Jang', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyunwoo', 'Initials': 'H', 'LastName': 'Oh', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sun Woong', 'Initials': 'SW', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Eun Ju', 'Initials': 'EJ', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Kyung-Hun', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Jeong-Hoon', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Su Jong', 'Initials': 'SJ', 'LastName': 'Yu', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jung-Hwan', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Tae-You', 'Initials': 'TY', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Yoon Jun', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.'}]",Clinical and molecular hepatology,['10.3350/cmh.2019.0049n'] 1659,32460460,Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.,"BACKGROUND/AIMS Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. METHODS This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. RESULTS Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log10 IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETV-associated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. CONCLUSION ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934).",2020,Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response.,"['patients with LAM-resistant hepatitis B virus (HBV) infections', '91 patients whose', 'chronic hepatitis B patients with prior suboptimal response', 'Patients with baseline ADV resistance were excluded']","['lamivudine or telbivudine plus adefovir (LAM/LdT+ADV', 'Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir', 'LAM/LdT+ADV', 'entecavir plus tenofovir (ETV+TDF', 'ETV+TDF', 'new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV']","['rate of virologic response', 'high baseline HBV DNA level', 'rates of adverse events', 'virologic response', 'serum HBV DNA level', 'serum HBV DNA levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0524909', 'cui_str': 'Chronic type B viral hepatitis'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001483', 'cui_str': 'Adenoviridae'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0209738', 'cui_str': 'Lamivudine'}, {'cui': 'C1453933', 'cui_str': 'telbivudine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0050175', 'cui_str': 'adefovir'}, {'cui': 'C0065041', 'cui_str': 'lipoarabinomannan'}, {'cui': 'C0971023', 'cui_str': 'entecavir'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0369332', 'cui_str': 'Hepatitis B virus DNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019163', 'cui_str': 'Type B viral hepatitis'}, {'cui': 'C0019378', 'cui_str': 'Cercopithecine herpesvirus 1'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}]",91.0,0.051612,Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response.,"[{'ForeName': 'Hyun Young', 'Initials': 'HY', 'LastName': 'Woo', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea.'}, {'ForeName': 'Jun Yong', 'Initials': 'JY', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Si Hyun', 'Initials': 'SH', 'LastName': 'Bae', 'Affiliation': 'Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.'}, {'ForeName': 'Chang Wook', 'Initials': 'CW', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.'}, {'ForeName': 'Jae Young', 'Initials': 'JY', 'LastName': 'Jang', 'Affiliation': 'Department of Internal Medicine, Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Won Young', 'Initials': 'WY', 'LastName': 'Tak', 'Affiliation': 'Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.'}, {'ForeName': 'Dong Joon', 'Initials': 'DJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea.'}, {'ForeName': 'In Hee', 'Initials': 'IH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Chonbuk National University Hospital, Chonbuk National University College of Medicine, Chonju, Korea.'}, {'ForeName': 'Jeong', 'Initials': 'J', 'LastName': 'Heo', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Pusan National University, Busan, Korea.'}, {'ForeName': 'Sang Hoon', 'Initials': 'SH', 'LastName': 'Ahn', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}]",Clinical and molecular hepatology,['10.3350/cmh.2019.0044n'] 1660,32460928,Impact of an automated hand hygiene monitoring system combined with a performance improvement intervention on hospital-acquired infections.,"OBJECTIVE Hand hygiene adherence has been associated with reductions in nosocomial infection. We assessed the effect of improvements in electronically measured hand hygiene adherence on the incidence of hospital-acquired infections. METHODS This quasi-experimental study was conducted in a 555-bed urban safety-net level I trauma center. The preintervention period was January 2015 through June 2016. Baseline electronic hand hygiene data collection took place from April through June 2016. The intervention period was July 2016 through December 2017. An electronic hand hygiene system was installed in 4 locations in our hospital. Performance improvement strategies were implemented that included education, troubleshooting, data dissemination, and feedback. Adherence rates were tracked over time. Rates of hospital-acquired infections were evaluated in the intervention units and in control units selected for comparison. The intervention period was subdivided into the initial and subsequent 9-month periods and were compared to the baseline period. RESULTS Electronically measured hand hygiene rates improved significantly from baseline to intervention, from 47% 77% adherence. Rates >70% continued to be measured 18 months after the intervention. Interrupted time series analysis indicated a significant effect of hand hygiene on healthcare facility-onset Clostridioides difficile infection rates during the first 9 months of the intervention. This trend continued during the final 9 months of the intervention but was nonsignificant. No effects were observed for other hospital-acquired infection rates. CONCLUSIONS Implementation of electronic hand hygiene monitoring and performance improvement interventions resulted in reductions in hospital-onset Clostridioides difficile infection rates.",2020,Interrupted time series analysis indicated a significant effect of hand hygiene on healthcare facility-onset Clostridioides difficile infection rates during the first 9 months of the intervention.,['555-bed urban safety-net level I trauma center'],['automated hand hygiene monitoring system combined with a performance improvement intervention'],"['Adherence rates', 'hospital-acquired infections', 'healthcare facility-onset Clostridioides difficile infection rates', 'Rates of hospital-acquired infections', 'hospital-acquired infection rates', 'hygiene rates', 'hospital-onset Clostridioides difficile infection rates']","[{'cui': 'C4517810', 'cui_str': '555'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0441925', 'cui_str': 'Level I'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0205721', 'cui_str': 'Nosocomial infection'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0343386', 'cui_str': 'Clostridioides difficile infection'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]",,0.07351,Interrupted time series analysis indicated a significant effect of hand hygiene on healthcare facility-onset Clostridioides difficile infection rates during the first 9 months of the intervention.,"[{'ForeName': 'Bryan C', 'Initials': 'BC', 'LastName': 'Knepper', 'Affiliation': 'Department of Patient Safety and Quality, Denver Health Medical Center, Denver, Colorado.'}, {'ForeName': 'Amber M', 'Initials': 'AM', 'LastName': 'Miller', 'Affiliation': 'Department of Patient Safety and Quality, Denver Health Medical Center, Denver, Colorado.'}, {'ForeName': 'Heather L', 'Initials': 'HL', 'LastName': 'Young', 'Affiliation': 'Department of Patient Safety and Quality, Denver Health Medical Center, Denver, Colorado.'}]",Infection control and hospital epidemiology,['10.1017/ice.2020.182'] 1661,31810753,Efficacy of the presence of an emergency physician in prehospital major trauma care: Randomised control trial results are needed!,,2020,,['prehospital major trauma care'],['emergency physician'],[],"[{'cui': 'C0332677', 'cui_str': 'Major injury'}]","[{'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]",[],,0.0446977,,"[{'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Jouffroy', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie Réanimation, Hôpital Universitaire Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, and Université Paris Descartes - Paris 5, Paris, France. Electronic address: romain.jouffroy@aphp.fr.""}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Vivien', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie Réanimation, Hôpital Universitaire Necker - Enfants Malades, Assistance Publique - Hôpitaux de Paris, and Université Paris Descartes - Paris 5, Paris, France.""}]",The American journal of emergency medicine,['10.1016/j.ajem.2019.11.033'] 1662,32585223,Syringe or mask? Loop electrosurgical excision procedure under local or general anesthesia: a randomized trial.,"BACKGROUND Loop electrosurgical excision procedure may be performed under local anesthesia or general anesthesia, and practice patterns differ worldwide. No randomized head-to-head comparison has been published to confirm or refute either practice. OBJECTIVE This study aimed to compare loop electrosurgical excision procedure under local anesthesia vs general anesthesia regarding patient satisfaction and procedure-related outcomes such as rates of involved margins, complications, pain, and blood loss. STUDY DESIGN Consecutive women referred to our colposcopy unit were recruited. Loop electrosurgical excision procedure was performed under local anesthesia with 4 intracervical injections of bupivacaine hydrochloride 0.5% or under general anesthesia with fentanyl, propofol, and a laryngeal mask with sevoflurane maintenance. The primary endpoint was patient satisfaction assessed on the day of surgery and 14 days thereafter using a Likert scale (score 0-100) and a questionnaire. Secondary endpoints included rates of involved margins, procedure-related complications, pain, blood loss, and surgeon preference. Results were compared using nonparametric and chi-square tests. RESULTS Between July 2018 and February 2020, we randomized 208 women, 108 in the local anesthesia arm and 100 in the general anesthesia arm. In the intention-to-treat analysis, patient satisfaction did not differ between the study groups directly after surgery (Likert scale 100 [90-100] vs 100 [90-100]; P=.077) and 14 days thereafter (Likert scale 100 [80-100] vs 100 [90-100]; P=.079). In the per-protocol analysis, women in the local anesthesia arm had significantly smaller cone volumes (1.11 cm 3 [0.70-1.83] vs 1.58 cm 3 [1.08-2.69], respectively; P<.001), less intraoperative blood loss (Δhemoglobin, 0.2 g/dL [-0.1 to 0.4] vs 0.5 g/dL [0.2-0.9]; P<.001), and higher satisfaction after 14 days (100 [90-100] vs 100 [80-100]; P=.026), whereas surgeon preference favored general anesthesia (90 [79-100] vs 100 [90-100], respectively; P=.001). All other secondary outcomes did not differ between groups (resection margin status R1, 6.6% vs 2.1% [P=.26]; cone fragmentation, 12.1% vs 6.3% [P=.27]; procedure duration, 151.5 seconds [120-219.5] vs 180 seconds [117-241.5] [P=.34]; time to complete hemostasis, 60 seconds [34-97] vs 70 seconds [48.25-122.25] [P=.08]; complication rate, 3.3% vs 1.1% [P=.59]). In a multivariate analysis, parity (P=.03), type of transformation zone (P=.03), and cone volume (P=.02) and not study group assignment, age, body mass index, and degree of dysplasia independently influenced the primary endpoint. CONCLUSION Loop electrosurgical excision procedure under local anesthesia is equally well tolerated and offers patient-reported and procedure-related benefits over general anesthesia, supporting the preferred practice in some institutions and refuting the preferred practice in others.",2020,"LEEP under LA is equally well tolerated and offers patient-reported as well as procedure-related benefits over GA, supporting the preferred practice in some institutions and refuting the preferred practice in others.","['Consecutive women referred to our colposcopy unit were recruited', '208 women, 108 in the LA arm and 100 in the GA arm', 'Between July 2018 and February 2020']","['LEEP under LA versus GA', 'electrosurgical excision procedure (LEEP', 'electrosurgical excision procedure under local or general anesthesia', 'LEEP', 'bupivacaine hydrochloride 0.5% or under GA with fentanyl, propofol', 'LEEP under LA']","['time to complete hemostasis', 'patient satisfaction assessed on the day of surgery and 14 days thereafter using a Likert scale', 'intraoperative blood loss', 'smaller cone volumes', 'rates of involved margins, procedure-related complications, pain, blood loss, and surgeon preference', 'rates of involved margins, complications, pain, and blood loss', 'higher satisfaction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0184930', 'cui_str': 'Loop electrosurgical excision procedure'}, {'cui': 'C1720162', 'cui_str': 'Under local anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0887621', 'cui_str': 'Bupivacaine hydrochloride'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0206428', 'cui_str': 'Cone of retina'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",208.0,0.325585,"LEEP under LA is equally well tolerated and offers patient-reported as well as procedure-related benefits over GA, supporting the preferred practice in some institutions and refuting the preferred practice in others.","[{'ForeName': 'Günther A', 'Initials': 'GA', 'LastName': 'Rezniczek', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany. Electronic address: guenther.rezniczek@rub.de.'}, {'ForeName': 'Julia M', 'Initials': 'JM', 'LastName': 'Hecken', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Sadia', 'Initials': 'S', 'LastName': 'Rehman', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Askin', 'Initials': 'A', 'LastName': 'Dogan', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Clemens B', 'Initials': 'CB', 'LastName': 'Tempfer', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany.'}, {'ForeName': 'Ziad', 'Initials': 'Z', 'LastName': 'Hilal', 'Affiliation': 'Department of Obstetrics and Gynecology, Ruhr-Universität Bochum, Bochum, Germany.'}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.06.041'] 1663,32585581,"Zataria multiflora affects clinical symptoms, oxidative stress and cytokines in asthmatic patient: A randomized, double blind, placebo-controlled, phase II clinical trial.","BACKGROUND Z. multiflora effect on clinical symptoms, pulmonary function tests (PFT), oxidative stress and cytokine levels in asthmatic patients were evaluated. METHODS 36 asthmatic patients were divided to; placebo group (P), two groups treated with Z. multiflora extract (5 and 10 mg/kg/day, as Z5 and Z10, respectively), (n = 12 in each group). Medications were administered three times a day for two months and several parameters were evaluated before treatment (step 0), one (step 1) and two months (step 2) after treatment. RESULTS Clinical symptoms and PFTs were significantly improved in Z5 and Z10 groups in steps 1 and 2 compared to step 0 (p < 0.05 to p < 0.001). Improvement of oxidative stress, cytokines levels and their gene expression after treatment with both doses of extract were observed in step 2 compared to step 0 (p < 0.05 to p < 0.001). CONCLUSION These results indicated therapeutic value of Z. multiflora for the management of asthma.",2020,"Improvement of oxidative stress, cytokines levels and their gene expression after treatment with both doses of extract were observed in step 2 compared to step 0 (p < 0.05 to p < 0.001). ","['36 asthmatic patients', 'asthmatic patient', 'asthmatic patients were evaluated']","['Zataria multiflora', 'Z. multiflora extract', 'placebo']","['oxidative stress, cytokines levels and their gene expression', 'Clinical symptoms and PFTs', 'clinical symptoms, pulmonary function tests (PFT), oxidative stress and cytokine levels']","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}]",36.0,0.141139,"Improvement of oxidative stress, cytokines levels and their gene expression after treatment with both doses of extract were observed in step 2 compared to step 0 (p < 0.05 to p < 0.001). ","[{'ForeName': 'Azam', 'Initials': 'A', 'LastName': 'Alavinezhad', 'Affiliation': 'Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Vahideh', 'Initials': 'V', 'LastName': 'Ghorani', 'Affiliation': 'Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Omid', 'Initials': 'O', 'LastName': 'Rajabi', 'Affiliation': 'Department of Drug and Food Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hossein', 'Initials': 'MH', 'LastName': 'Boskabady', 'Affiliation': 'Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Physiology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: boskabadymh@mums.ac.ir.'}]",Cytokine,['10.1016/j.cyto.2020.155169'] 1664,32585668,Intensive Blood Pressure Lowering in Patients with Moderate to Severe Grade Acute Cerebral Hemorrhage: Post Hoc Analysis of Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-2 Trial.,"OBJECTIVE To study the effect of intensive blood pressure reduction in patients with moderate to severe intracerebral hemorrhage (ICH) within the subjects recruited in Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 trial. DESIGN Randomized, multicenter, 2 group, open-label clinical trial. SETTING A total of 110 sites in the USA, Japan, China, Taiwan, South Korea, and Germany. PATIENTS A total of 1,000 patients underwent randomization from May 2011 till September 2015. INTERVENTIONS We analyzed the effect of intensive (goal 110-139 mm Hg) over standard (goal 140-179 mm Hg) systolic blood pressure (SBP) reduction using intravenous nicardipine within 4.5 h of symptom onset in moderate to severe grade subjects with ICH in a non-prespecified analysis. Moderate to severe grade was defined by Glasgow Coma Scale score <13 or baseline National Institutes of Health Stroke Scale score ≥10 or baseline intraparenchymal hemorrhage volume ≥30 mL or presence of intraventricular hemorrhage. The primary outcome was death or disability (score 4-6 on the modified Rankin scale) at 3 months after randomization ascertained by a blinded investigator. MEASUREMENTS AND MAIN RESULTS Of a total of 682 subjects who met the definition of moderate to severe grade (mean age 61.9 ± 13.1 years, 62.5% men) with a mean baseline SBP of 174.7 ± 24.8 mm Hg, the frequency of hematoma expansion was significantly lower among subjects randomized to intensive SBP reduction than among subjects randomized to standard SBP reduction (20.4 vs. 27.9%, relative risk [RR]: 0.7; 95% confidence interval [CI]: 0.55-0.96). The primary endpoint of death or disability was observed in 52.5% (170/324) of subjects receiving intensive SBP reduction and 48.9% (163/333) of subjects receiving standard SBP reduction (RR: 1.1; 95% CI: 0.9-1.2). CONCLUSIONS Intensive SBP lowering reduced the frequency of hematoma expansion but did not reduce the rate of death or disability in patients with moderate to severe grade ICH.",2020,"The primary outcome was death or disability (score 4-6 on the modified Rankin scale) at 3 months after randomization ascertained by a blinded investigator. ","['patients with moderate to severe grade ICH', 'patients with moderate to severe intracerebral hemorrhage (ICH) within the subjects recruited in Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 trial', 'A total of 110 sites in the USA, Japan, China, Taiwan, South Korea, and Germany', 'Patients with Moderate to Severe Grade Acute Cerebral Hemorrhage', 'A total of 1,000 patients underwent randomization from May 2011 till September 2015', 'moderate to severe grade subjects with ICH in a non-prespecified analysis']","['intensive blood pressure reduction', 'nicardipine']","['frequency of hematoma expansion', 'Glasgow Coma Scale score', 'systolic blood pressure (SBP) reduction', 'rate of death or disability', 'standard SBP reduction', 'intensive SBP reduction', 'death or disability (score 4-6 on the modified Rankin scale', 'death or disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0028005', 'cui_str': 'Nicardipine'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]",1000.0,0.292665,"The primary outcome was death or disability (score 4-6 on the modified Rankin scale) at 3 months after randomization ascertained by a blinded investigator. ","[{'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenet Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, Missouri, USA, qureshai@gmail.com.'}, {'ForeName': 'Lydia D', 'Initials': 'LD', 'LastName': 'Foster', 'Affiliation': 'Division of Biostatistics and Epidemiology, Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.'}, {'ForeName': 'Iryna', 'Initials': 'I', 'LastName': 'Lobanova', 'Affiliation': 'Zeenet Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, Missouri, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Huang', 'Affiliation': 'Zeenet Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, Missouri, USA.'}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Suarez', 'Affiliation': 'Neurosciences Critical Care, Departments of Anesthesiology and Critical Care Medicine, Neurology, and Neurosurgery, Johns Hopkins University School of Medicine Baltimore, Baltimore, Maryland, USA.'}]","Cerebrovascular diseases (Basel, Switzerland)",['10.1159/000506358'] 1665,32586639,Phonation With a Variably Occluded Facemask: Effects of Task Duration.,"OBJECTIVE Semioccluded vocal tract (SOVT) exercises are routinely included in many voice therapy programs because they have been shown to improve acoustic, aerodynamic, and patient-reported voice outcomes. One limitation of the traditional SOVT exercise is that the nature of phonation through straws or semioccluded oral postures allows only for single phoneme production. A variably occluded facemask (VOFM) allows for use of articulated connected speech beyond the production of single phonemes, while still providing occlusion and, presumably, the vocal efficiency benefits that arise from it. This study reports on the effect of time duration of phonation with a variably occluded facemask on voice outcomes in patients with voice disorders. DESIGN Prospective, randomized cohort study. METHODS Fifteen patients with voice disorders phonated for 5 minutes through a VOFM with diameter openings of 3.2, 6.4, and 9.6 mm. Acoustic and aerodynamic voice measures were collected before and after each occlusion trial. These results were compared to a historical patient group that received the same phonation training for 2 minutes. RESULTS Positive effect sizes were found for acoustic and aerodynamic improvements for all patients for at least one occlusion diameter. Effect sizes for aerodynamic outcomes were greater in the 5-minute conditions for both the 9.6- and 6.4-mm occlusions than the 2-minute condition. Effect sizes for acoustic outcomes were greater in the 5 minute than 2-minute trial for the 9.6- and 6.4-mm occlusion diameter, but greater in the 2 minute than 5-minute trial for 3.2-mm diameter. DISCUSSION This study provides evidence that all three occlusion sizes may elicit beneficial changes for different patients; however, 5 minutes of phonation into a facemask with end occlusion of 6.4-mm diameter results in improved acoustic and aerodynamic voice outcomes for many patients with voice disorders. Future studies should further explore phonatory physiologic changes of the VOFM in a larger sample of patients and translate effects into clinical treatment for patients with voice disorders.",2020,"Effect sizes for acoustic outcomes were greater in the 5 minute than 2-minute trial for the 9.6- and 6.4-mm occlusion diameter, but greater in the 2 minute than 5-minute trial for 3.2-mm diameter. ","['patients with voice disorders', 'many patients with voice disorders', 'Fifteen patients with voice disorders phonated for 5 minutes through a VOFM with diameter openings of 3.2, 6.4, and 9.6 mm']","['Semioccluded vocal tract (SOVT) exercises', 'phonation with a variably occluded facemask', 'occluded facemask (VOFM', 'traditional SOVT exercise', 'same phonation training']","['acoustic and aerodynamic improvements', 'acoustic outcomes', 'aerodynamic outcomes', 'Acoustic and aerodynamic voice measures', 'acoustic and aerodynamic voice outcomes', 'voice outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042940', 'cui_str': 'Voice Disorders'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C4517822', 'cui_str': '6.4'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031577', 'cui_str': 'Laryngeal voice function'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",15.0,0.0482391,"Effect sizes for acoustic outcomes were greater in the 5 minute than 2-minute trial for the 9.6- and 6.4-mm occlusion diameter, but greater in the 2 minute than 5-minute trial for 3.2-mm diameter. ","[{'ForeName': 'Amanda I', 'Initials': 'AI', 'LastName': 'Gillespie', 'Affiliation': 'Emory University School of Medicine, Emory Voice Center, Atlanta, Georgia. Electronic address: Amanda.i.gillespie@emory.edu.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Fanucchi', 'Affiliation': 'Oncology Rehab, Centennial, Colorado.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Gartner-Schmidt', 'Affiliation': 'University of Pittsburgh School of Medicine, University of Pittsburgh Voice Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Belsky', 'Affiliation': 'University of Pittsburgh School of Medicine, University of Pittsburgh Voice Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Shaheen', 'Initials': 'S', 'LastName': 'Awan', 'Affiliation': 'Bloomsburg University, Bloomsburg, Pennsylvania.'}]",Journal of voice : official journal of the Voice Foundation,['10.1016/j.jvoice.2020.05.011'] 1666,32588030,The Sustained Impact of a Medical School-Based Physical Activity Module on Interns' Perceived Competence in Advising Older Adults about Exercise.,"The study aimed to examine the sustained impact of a 1.5-hour medical school-based physical activity (PA) module on interns' perceived competence and importance in advising older adults about exercise. The modified Exercise and Physical Activity Competence Questionnaire (EPACQ) was administered in 2017 (CG: control group) and 2018 (IG: intervention group) two years post-course. The perceived competence of both, CG (n=23) and IG (n=18), decreased significantly over two years (p≤0.05) with no difference between the groups (p>0.05). However, 72.2% (n=13) of the interns who attended the PA module still felt competent in advising older adults about exercise (4.21±0.66) compared to 47.8% (n=11) of the CG (3.89±0.67). The perceived importance decreased significantly in both groups (p≤0.05) with no difference between the groups (p>0.05). However, both groups still perceived exercise for older people as important (CG:4.55±0.61; IG:4.83±0.47). Subsequently, continued professional development is likely to be a key requirement for ensuring sustainability over time.",2020,The perceived importance decreased significantly in both groups (p≤0.05) with no difference between the groups (p>0.05).,['advising older adults about exercise'],"['1.5-hour medical school-based physical activity (PA) module', 'Medical School-Based Physical Activity Module', 'modified Exercise and Physical Activity Competence Questionnaire (EPACQ']",[],"[{'cui': 'C1828381', 'cui_str': 'Recommendation - action'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",[],,0.0142389,The perceived importance decreased significantly in both groups (p≤0.05) with no difference between the groups (p>0.05).,"[{'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Jadczak', 'Affiliation': 'Agathe Daria Jadczak PhD, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital DX 465701, 28 Woodville Road, Woodville South, SA 5011, Australia, Phone: +61 8 8133 4012 Email: agathedaria.jadczak@adelaide.edu.au.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Visvanathan', 'Affiliation': ''}]",The Journal of frailty & aging,['10.14283/jfa.2019.39'] 1667,32588034,Effects of High-Speed Power Training on Neuromuscular and Gait Functions in Frail Elderly with Mild Cognitive Impairment Despite Blunted Executive Functions: A Randomized Controlled Trial.,"BACKGROUND Physical frailty and impaired executive function of the brain show similar pathophysiology. Both of these factors lead to dysfunction of neuromuscular and abilities in elderly. High-speed power training (HSPT) has been determined to have positive effects on neuromuscular function and gait performance, as well as executive function in the elderly. OBJECTIVES The purpose of this study was to investigate the effects of 8-week HSPT on neuromuscular, gait and executive functions in frail elderly with mild cognitive impairment (MCI). DESIGN, SETTING AND PARTICIPANTS We performed a randomized controlled trial of frail elderly from community and medical center in republic of Korea. Forty-two physically frail elderly with MCI were randomly allocated to control (n=22, age=74.22±4.46) and intervention groups (n=18, age=73.77±4.64). The intervention group was subjected to HSPT, 3 times weekly for 8 weeks. MEASUREMENTS Isometric contraction of knee extension and flexion with electromyography (EMG) was measured to determine the neuromuscular function such as knee extensor strength, rate of torque development, movement time, pre-motor time, motor time, rate of EMG rise, and hamstrings antagonist co-activation. Additionally, the 4.44-meter gait and timed up-and-go (TUG) test were administered to assess gait performance. A frontal assessment battery was measured in this study. RESULTS The 8-week HSPT regimen improved the knee extensor strength from 1.13±0.08 to 1.25±0.07 (p<0.05), the 200-ms RTD from 3.01±0.3 to 3.55±0.24 (p<0.05) and the rate of EMG rise from 166.48±13.31 to 197.94±11.51 (p<0.05), whereas the movement time and motor time were statistically decreased from 921.69±40.10 to 799.51±72.84, and 271.40±19.29 to 181.15±38.08 (p<0.05), respectively. The 4.44-m gait speed and TUG significantly decreased from 6.39±0.25 to 5.5±0.24, and 11.05±0.53 to 9.17±0.43 respectively (p<0.05). CONCLUSION The findings of this study suggest the favorable effects of 8-week HSPT on the neuromuscular function and the gait performance in the frail elderly with MCI without increase in the executive function.",2020,"The 4.44-m gait speed and TUG significantly decreased from 6.39±0.25 to 5.5±0.24, and 11.05±0.53 to 9.17±0.43 respectively (p<0.05). ","['Forty-two physically frail elderly with MCI', 'frail elderly from community and medical center in republic of Korea', 'frail elderly with mild cognitive impairment (MCI', 'elderly', 'Frail Elderly with Mild Cognitive Impairment']","['High-Speed Power Training', 'HSPT', 'High-speed power training (HSPT']","['neuromuscular function such as knee extensor strength, rate of torque development, movement time, pre-motor time, motor time, rate of EMG rise, and hamstrings antagonist co-activation', 'neuromuscular, gait and executive functions', 'gait performance', 'knee extensor strength', 'executive function', 'Neuromuscular and Gait Functions', 'Isometric contraction of knee extension and flexion with electromyography (EMG', '4.44-m gait speed and TUG', 'movement time and motor time', 'rate of EMG rise', 'neuromuscular function and the gait performance']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0079377', 'cui_str': 'Frail elderly'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}]",42.0,0.0422568,"The 4.44-m gait speed and TUG significantly decreased from 6.39±0.25 to 5.5±0.24, and 11.05±0.53 to 9.17±0.43 respectively (p<0.05). ","[{'ForeName': 'D W', 'Initials': 'DW', 'LastName': 'Lee', 'Affiliation': 'Prof. Wook Song, Ph.D., Health and Exercise Science Laboratory, Institute of Sports Science, Seoul National University, 1 Gwanangno, Gwanak-Gu, Seoul 08826, Korea, -mail: songw3@snu.ac.kr, Telephone: 82-2-880-7791, Fax: 82-2-872-2867.'}, {'ForeName': 'D H', 'Initials': 'DH', 'LastName': 'Yoon', 'Affiliation': ''}, {'ForeName': 'J-Y', 'Initials': 'JY', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'S B', 'Initials': 'SB', 'LastName': 'Panday', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Song', 'Affiliation': ''}]",The Journal of frailty & aging,['10.14283/jfa.2020.23'] 1668,32589613,Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.,"More than half of community-dwelling individuals sixty years and older express concern about declining cognitive abilities. The current study's aim was to evaluate hyperbaric oxygen therapy (HBOT) effect on cognitive functions in healthy aging adults.A randomized controlled clinical trial randomized 63 healthy adults (>64) either to HBOT(n=33) or control arms(n=30) for three months. Primary endpoint included the general cognitive function measured post intervention/control. Cerebral blood flow (CBF) was evaluated by perfusion magnetic resonance imaging.There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017). The most striking improvements were in attention (net effect size=0.745) and information processing speed (net effect size=0.788).Voxel-based analysis showed significant cerebral blood flow increases in the HBOT group compared to the control group in the right superior medial frontal gyrus (BA10), right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8) and the right superior parietal gyrus (BA7).In this study, HBOT was shown to induce cognitive enhancements in healthy aging adults via mechanisms involving regional changes in CBF. The main improvements include attention, information processing speed and executive functions, which normally decline with aging.",2020,There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017).,"['63 healthy adults (>64) either to HBOT(n=33) or control arms(n=30) for three months', 'healthy older adults', 'healthy aging adults']","['hyperbaric oxygen', 'hyperbaric oxygen therapy (HBOT']","['global cognitive function post-HBOT', 'attention, information processing speed and executive functions, which normally decline with aging', 'Cerebral blood flow (CBF', 'right and left supplementary motor area (BA6), right middle frontal gyrus (BA6), left middle frontal gyrus (BA9), left superior frontal gyrus (BA8', 'cognitive functions', 'general cognitive function measured post intervention/control', 'cerebral blood flow increases']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4082119', 'cui_str': 'Three months'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0020431', 'cui_str': 'Hyperbaric oxygen therapy'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0152297', 'cui_str': 'Structure of middle frontal gyrus'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0152296', 'cui_str': 'Structure of superior frontal gyrus'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",63.0,0.0790879,There was a significant group-by-time interaction in global cognitive function post-HBOT compared to control (p=0.0017).,"[{'ForeName': 'Hadanny', 'Initials': 'H', 'LastName': 'Amir', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Daniel-Kotovsky', 'Initials': 'DK', 'LastName': 'Malka', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Suzin', 'Initials': 'S', 'LastName': 'Gil', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Boussi-Gross', 'Initials': 'BG', 'LastName': 'Rahav', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Catalogna', 'Initials': 'C', 'LastName': 'Merav', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Dagan', 'Initials': 'D', 'LastName': 'Kobi', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Hachmo', 'Initials': 'H', 'LastName': 'Yafit', 'Affiliation': 'Research and Development Unit, Shamir Medical Center, Zerifin, Israel.'}, {'ForeName': 'Abu Hamed', 'Initials': 'AH', 'LastName': 'Ramzia', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Sasson', 'Initials': 'S', 'LastName': 'Efrat', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Fishlev', 'Initials': 'F', 'LastName': 'Gregory', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Lang', 'Initials': 'L', 'LastName': 'Erez', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Polak', 'Initials': 'P', 'LastName': 'Nir', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Doenyas', 'Initials': 'D', 'LastName': 'Keren', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Friedman', 'Initials': 'F', 'LastName': 'Mony', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Sigal', 'Affiliation': 'Radiology Department, Shamir Medical Center, Zerifin, Israel.'}, {'ForeName': 'Zemel', 'Initials': 'Z', 'LastName': 'Yonatan', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Bechor', 'Initials': 'B', 'LastName': 'Yair', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}, {'ForeName': 'Efrati', 'Initials': 'E', 'LastName': 'Shai', 'Affiliation': 'The Sagol Center for Hyperbaric Medicine and Research, Shamir (Assaf-Harofeh) Medical Center, Zerifin, Israel.'}]",Aging,['10.18632/aging.103571'] 1669,32590049,"Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.","Romosozumab (EVENITY™ [romosozumab-aqqg in the US]) is a humanized monoclonal antibody that inhibits sclerostin and has been approved in several countries for the treatment of osteoporosis in postmenopausal women at high risk of fracture. Sclerostin is expressed in bone and aortic vascular smooth muscle (AVSM). Its function in AVSM is unclear but it has been proposed to inhibit vascular calcification, atheroprogression, and inflammation. An increased incidence of positively adjudicated serious cardiovascular adverse events driven by an increase in myocardial infarction and stroke was observed in romosozumab-treated subjects in a clinical trial comparing alendronate with romosozumab (ARCH; NCT01631214) but not in a placebo-controlled trial (FRAME; NCT01575834). To investigate the effects of sclerostin inhibition with sclerostin antibody on the cardiovascular system, a comprehensive nonclinical toxicology package with additional cardiovascular studies was conducted. Although pharmacodynamic effects were observed in the bone, there were no functional, morphological, or transcriptional effects on the cardiovascular system in animal models in the presence or absence of atherosclerosis. These nonclinical studies did not identify evidence that proves the association between sclerostin inhibition and adverse cardiovascular function, increased cardiovascular calcification, and atheroprogression.",2020,"Although pharmacodynamic effects were observed in the bone, there were no functional, morphological, or transcriptional effects on the cardiovascular system in animal models in the presence or absence of atherosclerosis.",['postmenopausal women at high risk of fracture'],"['sclerostin inhibition with sclerostin antibody', 'romosozumab, an inhibitor of sclerostin', 'alendronate', 'Sclerostin', 'Romosozumab (EVENITY™ [romosozumab-aqqg']",['myocardial infarction and stroke'],"[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C3661283', 'cui_str': 'romosozumab'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C4765894', 'cui_str': 'Evenity'}, {'cui': 'C4765888', 'cui_str': 'romosozumab-aqqg'}]","[{'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",,0.0719188,"Although pharmacodynamic effects were observed in the bone, there were no functional, morphological, or transcriptional effects on the cardiovascular system in animal models in the presence or absence of atherosclerosis.","[{'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Turk', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA. Electronic address: jturk@amgen.com.'}, {'ForeName': 'Aimee M', 'Initials': 'AM', 'LastName': 'Deaton', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Yin', 'Affiliation': 'Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Stolina', 'Affiliation': 'Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Felx', 'Affiliation': 'Charles River Laboratories Montreal ULC, Senneville, QC, Canada.'}, {'ForeName': 'Gabrielle', 'Initials': 'G', 'LastName': 'Boyd', 'Affiliation': 'Charles River Laboratories Montreal ULC, Senneville, QC, Canada.'}, {'ForeName': 'Jean-Guy', 'Initials': 'JG', 'LastName': 'Bienvenu', 'Affiliation': 'Charles River Laboratories Montreal ULC, Senneville, QC, Canada.'}, {'ForeName': 'Aurore', 'Initials': 'A', 'LastName': 'Varela', 'Affiliation': 'Charles River Laboratories Montreal ULC, Senneville, QC, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Guillot', 'Affiliation': 'Charles River Laboratories Montreal ULC, Senneville, QC, Canada.'}, {'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Holdsworth', 'Affiliation': 'UCB Pharma, Slough, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Wolfreys', 'Affiliation': 'UCB Pharma, Slough, UK.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Dwyer', 'Affiliation': 'Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.'}, {'ForeName': 'Sheetal V', 'Initials': 'SV', 'LastName': 'Kumar', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.'}, {'ForeName': 'Emily M', 'Initials': 'EM', 'LastName': 'de Koning', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.'}, {'ForeName': 'Yusheng', 'Initials': 'Y', 'LastName': 'Qu', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Engwall', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Locher', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, South San Francisco, CA, USA.'}, {'ForeName': 'Lucas D', 'Initials': 'LD', 'LastName': 'Ward', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Cambridge, MA, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Glaus', 'Affiliation': 'Cardiometabolic Disorders Research, Amgen Research, Thousand Oaks, CA, USA.'}, {'ForeName': 'Yudong D', 'Initials': 'YD', 'LastName': 'He', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA; Genome Analysis Unit, Amgen Research, South San Francisco, CA, USA.'}, {'ForeName': 'Rogely Waite', 'Initials': 'RW', 'LastName': 'Boyce', 'Affiliation': 'Translational Safety and Bioanalytical Sciences, Amgen Research, Thousand Oaks, CA, USA.'}]",Regulatory toxicology and pharmacology : RTP,['10.1016/j.yrtph.2020.104697'] 1670,32446880,Changes in parental feeding practices and preschoolers' food intake following a randomized controlled childhood obesity trial.,"Childhood obesity treatment involving parents is most effective during the preschool age. However, the mechanisms of change are not known. The present study reports on secondary outcomes (changes in parental feeding practices and child food intake) of early obesity treatment. The More and Less study is a randomized controlled trial conducted in Stockholm County, Sweden. Children with obesity (n = 174, mean BMI SDS 3.0, mean age 5 years, 56% girls) and their parents (60% with foreign background, 40% with a university degree) were randomized to: 1) standard treatment focusing on lifestyle recommendations (ST), 2) a parent support program with boosters (PGB), and 3) a parent support program without boosters (PGNB). The Child Feeding Questionnaire (CFQ) was used to measure parental feeding practices. Child food intake was assessed with a Food Frequency Questionnaire (FFQ). We calculated the monthly changes in CFQ practices and FFQ items based on four measurements. We did not find any significant between-group differences in parental feeding practices and child food intake over time. However, general linear models showed that changes in certain feeding practices predicted changes in child food intake. When ST was compared to the parent support groups, some associations moved in opposite directions. For example, increasing maternal restriction predicted increased consumption of cookies/buns in PGNB (b = 2.3, p < 0.05) and decreased consumption of cookies/buns in ST (b = -2.1, p < 0.05). This is among the few studies to examine the effect of parental feeding practices on child food intake and weight status after obesity treatment among preschoolers. We found no evidence that changes in feeding practices or changes in child food intake mediated child weight loss. Future studies should consider other intermediary processes related to general parenting practices and parent-child interactions.",2020,We did not find any significant between-group differences in parental feeding practices and child food habits over time.,"['Children with obesity (n\u202f=\u202f174, mean BMI SDS 3.0, mean age 5 years, 56% girls) and their parents (60% with foreign background, 40% with a university degree', 'child food habits and weight status after obesity treatment among preschoolers', 'Stockholm County, Sweden']","['standard treatment focusing on lifestyle recommendations (ST), 2) a parent support program with boosters (PGB), and 3) a parent support program without boosters (PGNB', 'parental feeding practices']","['Food Frequency Questionnaire (FFQ', 'parental feeding practices and child food habits) of early obesity treatment', 'consumption of cookies/buns in ST', 'Child Feeding Questionnaire (CFQ']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C4706528', 'cui_str': 'Obesity care'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0020975', 'cui_str': 'Booster vaccination'}]","[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C4706528', 'cui_str': 'Obesity care'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C3853210', 'cui_str': 'Cookie'}, {'cui': 'C0005845', 'cui_str': 'Blood urea nitrogen measurement'}]",,0.0264302,We did not find any significant between-group differences in parental feeding practices and child food habits over time.,"[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Somaraki', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden. Electronic address: maria.somaraki@ikv.uu.se.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Eli', 'Affiliation': 'Unit for Biocultural Variation and Obesity, School of Anthropology and Museum Ethnography, University of Oxford, Oxford, UK; Social Science and Systems in Health, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. Electronic address: karin.eli@anthro.ox.ac.uk.'}, {'ForeName': 'Kimmo', 'Initials': 'K', 'LastName': 'Sorjonen', 'Affiliation': 'Division of Psychology, Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden. Electronic address: kimmo.sorjonen@ki.se.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ek', 'Affiliation': 'Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. Electronic address: anna.ek@ki.se.'}, {'ForeName': 'Pernilla', 'Initials': 'P', 'LastName': 'Sandvik', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden. Electronic address: pernilla.sandvik@ikv.uu.se.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Nowicka', 'Affiliation': 'Department of Food Studies, Nutrition and Dietetics, Uppsala University, Uppsala, Sweden; Division of Pediatrics, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden. Electronic address: paulina.nowicka@ikv.uu.se.'}]",Appetite,['10.1016/j.appet.2020.104746'] 1671,32452344,Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.,"OBJECTIVES This study evaluated the efficacy and safety of baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) therapy. METHODS In this phase 3, double-blind, 52-week, placebo-controlled study, 290 patients with moderately to severely active RA and inadequate response to MTX were randomly assigned 1:1 to placebo or baricitinib 4-mg once daily, stratified by country (China, Brazil, Argentina) and presence of joint erosions. Primary endpoint measures included American College of Rheumatology 20% response (ACR20) at week 12. Secondary endpoints included changes in Health Assessment Questionnaire-Disability Index (HAQ-DI) and Disease Activity Score for 28-joint counts (DAS28)-high-sensitivity C-reactive protein (hsCRP), Simplified Disease Activity Index (SDAI) score ≤3.3, mean duration of morning joint stiffness, severity of morning joint stiffness numeric rating scale (NRS 0-10), worst tiredness NRS, and worst joint pain NRS at week 12. RESULTS Most patients (approximately 80%) were from China. More patients achieved ACR20 response at week 12 with baricitinib than with placebo (58.6% vs. 28.3%; p<0.001). Statistically significant improvements were also seen in HAQ-DI, DAS28-hsCRP, morning joint stiffness, worst tiredness, and worst joint pain in the baricitinib group compared to placebo at week 12. Through week 24, rates of treatment-emergent adverse events, including infections, were higher for baricitinib compared to placebo, while serious adverse event rates were similar between baricitinib and placebo. CONCLUSIONS In patients with RA who had an inadequate response to MTX, baricitinib was associated with significant clinical improvements as compared with placebo.",2020,"Statistically significant improvements were also seen in HAQ-DI, DAS28-hsCRP, morning joint stiffness, worst tiredness, and worst joint pain in the baricitinib group compared to placebo at week 12.","['290 patients with moderately to severely active RA and inadequate response to MTX', 'patients with rheumatoid arthritis with inadequate response to', 'patients with moderately to severely active rheumatoid arthritis (RA']","['methotrexate (MTX) therapy', 'baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor', 'placebo or baricitinib', 'methotrexate', 'placebo']","['changes in Health Assessment Questionnaire-Disability Index (HAQ-DI) and Disease Activity Score for 28-joint counts (DAS28)-high-sensitivity C-reactive protein (hsCRP), Simplified Disease Activity Index (SDAI) score ≤3.3, mean duration of morning joint stiffness, severity of morning joint stiffness numeric rating scale (NRS 0-10), worst tiredness NRS, and worst joint pain NRS', 'HAQ-DI, DAS28-hsCRP, morning joint stiffness, worst tiredness, and worst joint pain', 'serious adverse event rates', 'American College of Rheumatology 20% response (ACR20', 'rates of treatment-emergent adverse events, including infections', 'ACR20 response']","[{'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4044947', 'cui_str': 'baricitinib'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0597721', 'cui_str': 'JAK Kinases'}, {'cui': 'C0266700', 'cui_str': 'Janiceps'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0162298', 'cui_str': 'Joint stiffness'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",290.0,0.435619,"Statistically significant improvements were also seen in HAQ-DI, DAS28-hsCRP, morning joint stiffness, worst tiredness, and worst joint pain in the baricitinib group compared to placebo at week 12.","[{'ForeName': 'Zhanguo', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': ""Peking University People's Hospital, Beijing, China. li99@bjmu.edu.cn.""}, {'ForeName': 'Jiankang', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': ""Jiangxi Pingxiang People's Hospital, Pingxiang, China.""}, {'ForeName': 'Chunde', 'Initials': 'C', 'LastName': 'Bao', 'Affiliation': 'Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Xingfu', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Xiangpei', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Anhui Provincial Hospital, Hefei, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'The First Affiliated Hospital of Anhui Medical University, Hefei, China.'}, {'ForeName': 'Alberto J', 'Initials': 'AJ', 'LastName': 'Spindler', 'Affiliation': 'Centro Medico Privado de Reumatologia, San Miguel de Tucuman, Argentina.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Guangdong General Hospital, Guangzhou, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'First Affiliated Hospital of Kunming Medical University, Kunming, China.'}, {'ForeName': 'Dongyi', 'Initials': 'D', 'LastName': 'He', 'Affiliation': 'GuangHua Hospital, Shanghai, China.'}, {'ForeName': 'Zhijun', 'Initials': 'Z', 'LastName': 'Li', 'Affiliation': 'Affiliated Hospital of Bengbu Medical College, Bengbu, China.'}, {'ForeName': 'Guochun', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': ""Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Hanjun', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Eli Lilly and Company, Shanghai, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Ji', 'Affiliation': 'Eli Lilly and Company, Shanghai, China.'}, {'ForeName': 'Haoxun', 'Initials': 'H', 'LastName': 'Tao', 'Affiliation': 'Eli Lilly and Company, Shanghai, China.'}, {'ForeName': 'Lujing', 'Initials': 'L', 'LastName': 'Zhan', 'Affiliation': 'Eli Lilly and Company, Shanghai, China.'}, {'ForeName': 'Fan', 'Initials': 'F', 'LastName': 'Bai', 'Affiliation': 'Eli Lilly and Company, Shanghai, China.'}, {'ForeName': 'Terence P', 'Initials': 'TP', 'LastName': 'Rooney', 'Affiliation': 'Eli Lilly and Company, Indianapolis, USA.'}, {'ForeName': 'Cristiano A F', 'Initials': 'CAF', 'LastName': 'Zerbini', 'Affiliation': 'CEPIC - Centro Paulista de Investigação Clinica e Serviços Médicos, Ipiranga São Paulo, Brazil.'}]",Clinical and experimental rheumatology,[] 1672,32457373,Participatory practices at work change attitudes and behavior toward societal authority and justice.,"Generalized attitudes toward authority and justice are often conceptualized as individual differences that are resistant to enduring change. However, across two field experiments with Chinese factory workers and American university staff, small adjustments to people's experience of participation in the workplace shifted these attitudes one month later. Both experiments randomly assigned work groups to a 20-minute participatory meeting once per week for six weeks, in which the supervisor stepped aside and workers discussed problems, ideas, and goals regarding their work (vs. a status quo meeting). Across 97 work groups and 1,924 workers, participatory meetings led workers to be less authoritarian and more critical about societal authority and justice, and to be more willing to participate in political, social, and familial decision-making. These findings provide rare experimental evidence of the theoretical predictions regarding participatory democracy: that local participatory experiences can influence broader democratic attitudes and empowerment.",2020,"Across 97 work groups and 1,924 workers, participatory meetings led workers to be less authoritarian and more critical about societal authority and justice, and to be more willing to participate in political, social, and familial decision-making.",[],[],[],[],[],[],,0.0149299,"Across 97 work groups and 1,924 workers, participatory meetings led workers to be less authoritarian and more critical about societal authority and justice, and to be more willing to participate in political, social, and familial decision-making.","[{'ForeName': 'Sherry Jueyu', 'Initials': 'SJ', 'LastName': 'Wu', 'Affiliation': 'Collins Center A-415, Anderson School of Management, University of California Los Angeles, Los Angeles, CA, 90095, USA. sherry.wu@anderson.ucla.edu.'}, {'ForeName': 'Elizabeth Levy', 'Initials': 'EL', 'LastName': 'Paluck', 'Affiliation': '420 Peretsman Scully Hall, Department of Psychology, Princeton University, Princeton, NJ, 08544, USA.'}]",Nature communications,['10.1038/s41467-020-16383-6'] 1673,32462483,Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial.,"Preterm neonates with respiratory distress syndrome (RDS) are commonly treated with surfactant by intubate surfactant extubate (InSurE) technique. Mode of surfactant administration has evolved towards less invasive technique in the last few years. We randomised 58 preterm infants of 28-34 weeks of gestation with RDS within 6 h of birth to receive surfactant by InSurE or minimally invasive surfactant therapy (MIST). Non-invasive positive pressure ventilation (NIPPV) was used as primary respiratory support. The main objective was to compare the need of invasive mechanical ventilation (IMV) in first 72 h of life and secondarily hemodynamically significant patent ductus arteriosus (hsPDA), intraventricular haemorrhage (IVH) (> grade 2), bronchopulmonary dysplasia (BPD) and composite outcome of BPD/mortality. We did not find any difference in need of IMV in first 72 h between MIST and InSurE (relative risk with MIST, 0.62; 95% confidence interval, 0.22 to 1.32). No difference was observed in terms of hs PDA, IVH (> grade 2), BPD and composite outcome of BPD/mortality.Conclusion: There is no difference between MIST and InSurE in preterm neonates with RDS with NIPPV as a primary mode of respiratory support. Larger multicentre studies are needed to further explore differences in treatment failure and other secondary outcomes.Trial registration: www.ctri.nic.in id CTRI/2019/03/017992, registration date March 8, 2019. What is Known • InSurE is commonly used for many years for treatment of RDS in preterm neonates. • MIST has been introduced as a newer tool. What is New • MIST with feeding tube is comparable with InSurE in preterm infants with RDS in developing countries. •NIPPV can be used as primary respiratory support for MIST.",2020,"We did not find any difference in need of IMV in first 72 h between MIST and InSurE (relative risk with MIST, 0.62; 95% confidence interval, 0.22 to 1.32).","['Preterm neonates with respiratory distress syndrome (RDS', 'preterm infants with RDS', 'preterm neonates with RDS with', '58 preterm infants of 28-34 weeks of gestation with RDS within 6 h of birth to receive', 'preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation']","['surfactant by intubate surfactant extubate (InSurE) technique', 'Minimally invasive surfactant therapy', 'invasive positive pressure ventilation (NIPPV', 'surfactant by InSurE or minimally invasive surfactant therapy (MIST', 'NIPPV']","['need of IMV', 'hs PDA, IVH (> grade 2), BPD and composite outcome of BPD/mortality', 'need of invasive mechanical ventilation (IMV', 'life and secondarily hemodynamically significant patent ductus arteriosus (hsPDA), intraventricular haemorrhage (IVH) (> grade 2), bronchopulmonary dysplasia (BPD) and composite outcome of BPD/mortality']","[{'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}]","[{'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0021778', 'cui_str': 'Intermittent positive pressure ventilation'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}]","[{'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0013274', 'cui_str': 'Patent ductus arteriosus'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]",58.0,0.200468,"We did not find any difference in need of IMV in first 72 h between MIST and InSurE (relative risk with MIST, 0.62; 95% confidence interval, 0.22 to 1.32).","[{'ForeName': 'Bhupendra Kumar', 'Initials': 'BK', 'LastName': 'Gupta', 'Affiliation': 'Department of Neonatology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, 244, A J C Bose Road, Kolkata, 700020, India.'}, {'ForeName': 'Anindya Kumar', 'Initials': 'AK', 'LastName': 'Saha', 'Affiliation': 'Department of Neonatology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, 244, A J C Bose Road, Kolkata, 700020, India.'}, {'ForeName': 'Suchandra', 'Initials': 'S', 'LastName': 'Mukherjee', 'Affiliation': 'Department of Neonatology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, 244, A J C Bose Road, Kolkata, 700020, India.'}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Saha', 'Affiliation': 'Department of Neonatology, Institute of Post Graduate Medical Education & Research and SSKM Hospital, 244, A J C Bose Road, Kolkata, 700020, India. bijansaha18@gmail.com.'}]",European journal of pediatrics,['10.1007/s00431-020-03682-9'] 1674,32459643,Adherence to Blended or Face-to-Face Smoking Cessation Treatment and Predictors of Adherence: Randomized Controlled Trial.,"BACKGROUND Blended face-to-face and web-based treatment is a promising way to deliver smoking cessation treatment. Since adherence has been shown to be an indicator of treatment acceptability and a determinant for effectiveness, we explored and compared adherence and predictors of adherence to blended and face-to-face alone smoking cessation treatments with similar content and intensity. OBJECTIVE The objectives of this study were (1) to compare adherence to a blended smoking cessation treatment with adherence to a face-to-face treatment; (2) to compare adherence within the blended treatment to its face-to-face mode and web mode; and (3) to determine baseline predictors of adherence to both treatments as well as (4) the predictors to both modes of the blended treatment. METHODS We calculated the total duration of treatment exposure for patients (N=292) of a Dutch outpatient smoking cessation clinic who were randomly assigned either to the blended smoking cessation treatment (n=130) or to a face-to-face treatment with identical components (n=162). For both treatments (blended and face-to-face) and for the two modes of delivery within the blended treatment (face-to-face vs web mode), adherence levels (ie, treatment time) were compared and the predictors of adherence were identified within 33 demographic, smoking-related, and health-related patient characteristics. RESULTS We found no significant difference in adherence between the blended and the face-to-face treatments. Participants in the blended treatment group spent an average of 246 minutes in treatment (median 106.7% of intended treatment time, IQR 150%-355%) and participants in the face-to-face group spent 238 minutes (median 103.3% of intended treatment time, IQR 150%-330%). Within the blended group, adherence to the face-to-face mode was twice as high as that to the web mode. Participants in the blended group spent an average of 198 minutes (SD 120) in face-to-face mode (152% of the intended treatment time) and 75 minutes (SD 53) in web mode (75% of the intended treatment time). Higher age was the only characteristic consistently found to uniquely predict higher adherence in both the blended and face-to-face groups. For the face-to-face group, more social support for smoking cessation was also predictive of higher adherence. The variability in adherence explained by these predictors was rather low (blended R 2 =0.049; face-to-face R 2 =0.076). Within the blended group, living without children predicted higher adherence to the face-to-face mode (R 2 =0.034), independent of age. Higher adherence to the web mode of the blended treatment was predicted by a combination of an extrinsic motivation to quit, a less negative attitude toward quitting, and less health complaints (R 2 =0.164). CONCLUSIONS This study represents one of the first attempts to thoroughly compare adherence and predictors of adherence of a blended smoking cessation treatment to an equivalent face-to-face treatment. Interestingly, although the overall adherence to both treatments appeared to be high, adherence within the blended treatment was much higher for the face-to-face mode than for the web mode. This supports the idea that in blended treatment, one mode of delivery can compensate for the weaknesses of the other. Higher age was found to be a common predictor of adherence to the treatments. The low variance in adherence predicted by the characteristics examined in this study suggests that other variables such as provider-related health system factors and time-varying patient characteristics should be explored in future research. TRIAL REGISTRATION Netherlands Trial Register NTR5113; http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=5113.",2020,"Within BSCT, adherence to the face-to-face mode was twice as high as to the web-mode.",['patients (N=292) of a Dutch outpatient smoking cessation clinic'],"['blended smoking cessation treatment (BSCT, N=162) or to a face-to-face treatment with identical ingredients', 'Blended Treatment with Face-To-Face Treatment', 'BSCT', 'blended smoking cessation treatment (BSCT) with adherence to a face-to-face treatment (F2F']","['adherence', 'adherence levels', 'negative attitude toward quitting and less health complaints']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}]","[{'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1262620', 'cui_str': 'Negative attitude'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}]",,0.0203694,"Within BSCT, adherence to the face-to-face mode was twice as high as to the web-mode.","[{'ForeName': 'Lutz', 'Initials': 'L', 'LastName': 'Siemer', 'Affiliation': 'Technology, Health & Care Research Group, Saxion University of Applied Sciences, Enschede, Netherlands.'}, {'ForeName': 'Marjolein G J', 'Initials': 'MGJ', 'LastName': 'Brusse-Keizer', 'Affiliation': 'Medical School Twente, Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Marloes G', 'Initials': 'MG', 'LastName': 'Postel', 'Affiliation': 'Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands.'}, {'ForeName': 'Somaya', 'Initials': 'S', 'LastName': 'Ben Allouch', 'Affiliation': 'Digital Life Research Group, Amsterdam University of Applied Science, Amsterdam, Netherlands.'}, {'ForeName': 'Robbert', 'Initials': 'R', 'LastName': 'Sanderman', 'Affiliation': 'Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands.'}, {'ForeName': 'Marcel E', 'Initials': 'ME', 'LastName': 'Pieterse', 'Affiliation': 'Centre for eHealth and Well-being Research, University of Twente, Enschede, Netherlands.'}]",Journal of medical Internet research,['10.2196/17207'] 1675,32460523,"A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.","Objective: To evaluate the efficacy and long-term safety of vilazodone in children and adolescent outpatients with major depressive disorder (MDD). Methods: Children and adolescents aged 7-17 years of age with MDD were randomized 2:2:1 to 8 weeks of double-blind placebo, vilazodone 15 or 30 mg/day or fluoxetine 20 mg/day, respectively. The primary and secondary efficacy outcomes, respectively, were change from baseline to week 8 in Children's Depression Rating Scale-Revised (CDRS-R) score total score and Clinical Global Impressions-Severity (CGI-S) score analyzed using a mixed model for repeated measurement approach. Patients who completed the 8-week randomized controlled trial (RCT), as well as new ( de novo ) patients, could participate in a 26-week, vilazodone-only, open-label extension (OLE) study. Results: The RCT enrolled 473 patients (60% female) with an average age of 13 years. Change in CDRS-R and CGI-S scores from baseline to week 8 did not differ between patients who received vilazodone and those randomized to placebo. The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40). For fluoxetine, the LSMD versus placebo was -2.3 ( p  = 0.14). The OLE enrolled 330 patients (60% female) with an average age of 13-14 years. Overall, no new safety concerns were identified compared to what is known in adults. Conclusions: Similar improvements in depressive symptoms were observed in all arms. This study does not support the efficacy of vilazodone 15 or 30 mg/day for pediatric patients with MDD. No new or unexpected safety concerns were detected during the RCT or OLE studies.",2020,"The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40).","['pediatric patients with MDD', 'enrolled 330 patients (60% female) with an average age of 13-14 years', 'Children and adolescents aged 7-17 years of age with MDD', 'enrolled 473 patients (60% female) with an average age of 13 years', 'Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up', 'children and adolescent outpatients with major depressive disorder (MDD']","['Vilazodone', 'Placebo', 'OLE', 'RCT', 'placebo', 'fluoxetine', 'placebo, vilazodone 15 or 30\u2009mg/day or fluoxetine', 'vilazodone-only, open-label extension (OLE) study', 'vilazodone']","['Change in CDRS-R and CGI-S scores', ""Children's Depression Rating Scale-Revised (CDRS-R) score total score and Clinical Global Impressions-Severity (CGI-S) score"", 'CDRS-R scores', 'depressive symptoms']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1269683', 'cui_str': 'Major depressive disorder'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}]","[{'cui': 'C1530072', 'cui_str': 'vilazodone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",473.0,0.134338,"The least-squares mean change from baseline in CDRS-R scores was similar for vilazodone and placebo (-20.7 vs. -20.3, p  = 0.77; least-squares mean difference [LSMD] = -0.40).","[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Findling', 'Affiliation': 'Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'McCusker', 'Affiliation': 'CNS, AbbVie, Irvine, California, USA.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Strawn', 'Affiliation': 'Anxiety Disorders Research Program, University of Cincinnati, Cincinnati, Ohio, USA.'}]",Journal of child and adolescent psychopharmacology,['10.1089/cap.2019.0176'] 1676,32466854,Preoperative Vitamin D Supplementation in Patients With Vitamin D Deficiency Undergoing Total Thyroidectomy.,"BACKGROUND Transient hypocalcemia due to parathyroid gland or vessel manipulation is a common complication following thyroidectomy. Considering the role of 25-hydroxyvitamin D (25(OH)D) in calcium hemostasis, this study aimed to evaluate the effect of preoperative vitamin D supplementation on hypocalcemia incidence in thyroidectomy patients. METHODS In this randomized clinical trial, 100 patients scheduled for total thyroidectomy and suffering from preoperative moderate or severe vitamin D deficiency were enrolled. Patients were randomly allocated to either study or control groups using the sealed envelope method. Patients in the study group received vitamin D3 50,000-unit pearl weekly for 4 weeks prior to the operation. The control group received placebo. Total and ionized serum calcium levels were checked before surgery, the day after surgery, and 2 weeks postoperatively. RESULTS No significant difference was observed in terms of demographic data. During serial total calcium checks (5 episodes), total calcium levels changed significantly in patients who had received vitamin D supplements compared to the control group (P = 0.043). Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D) (P = 0.04). Also, the requirement for intravenous calcium administration in order to treat the hypocalcemia symptoms was significantly lower in the study in comparison to the control group (P = 0.03). CONCLUSIONS Vitamin D supplementation in patients with vitamin D deficiency might lead to a lower incidence of early-onset symptomatic hypocalcemia; hence, requiring less calcium supplementation for the management of hypocalcemia.",2020,Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D),"['100 patients scheduled for total thyroidectomy and suffering from preoperative moderate or severe vitamin D deficiency were enrolled', 'thyroidectomy patients', 'Patients With Vitamin D Deficiency Undergoing Total Thyroidectomy', 'patients with vitamin D deficiency']","['vitamin D supplements', 'preoperative vitamin D supplementation', 'Vitamin D supplementation', '25-hydroxyvitamin D (25(OH)D', 'Preoperative Vitamin D Supplementation', 'vitamin D3', 'placebo']","['Total and ionized serum calcium levels', 'demographic data', 'Symptomatic hypocalcemia incidence', 'total calcium levels', 'hypocalcemia symptoms', 'hypocalcemia incidence']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0193788', 'cui_str': 'Total thyroidectomy'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0040145', 'cui_str': 'Thyroidectomy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0728876', 'cui_str': 'Serum calcium measurement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020598', 'cui_str': 'Hypocalcemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0201925', 'cui_str': 'Calcium measurement'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",100.0,0.0588547,Symptomatic hypocalcemia incidence was significantly lower in patients supplemented with 25-hydroxyvitamin D (25(OH)D),"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ramouz', 'Affiliation': 'Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Mahdie', 'Initials': 'M', 'LastName': 'Hosseini', 'Affiliation': 'Department of Cardiothoracic Surgery, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Cardiothoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Seyedeh Shaghayegh', 'Initials': 'SS', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Seyed Ziaeddin', 'Initials': 'SZ', 'LastName': 'Rasihashemi', 'Affiliation': 'Department of Cardiothoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: zia.hashemi@yahoo.com.'}]",The American journal of the medical sciences,['10.1016/j.amjms.2020.04.036'] 1677,32470022,Peripheral endothelial function can be improved by daily consumption of water containing over 7 ppm of dissolved hydrogen: A randomized controlled trial.,"BACKGROUND Measurement of the reactive hyperemia index (RHI) using peripheral arterial tonometry (PAT) has shown benefits in the evaluation of vascular endothelial function and prediction of cardiovascular disease prognosis. Thus, it is important to examine the factors that promote the RHI. In this study, we aimed to investigate the effect of molecular hydrogen (H2) on reactive hyperemia-PAT of the small arteries of fingers in healthy people. METHODS To determine the efficacy of H2 for improving peripheral vascular endothelial function, water containing high H2 concentrations was administered to participants, and the Ln_RHI was measured in the finger vasculature. Sixty-eight volunteers were randomly divided into two groups: a placebo group (n = 34) that drank molecular nitrogen (N2)-containing water and a high H2 group (n = 34) that drank high H2 water (containing 7 ppm of H2: 3.5 mg H2 in 500-mL water). The Ln_RHI was measured before ingesting the placebo or high H2 water, 1 h and 24 h after the first ingestion, and 14 days after daily ingestion of high H2 water or the placebo. The mixed effects model for repeated measures was used in data analysis. RESULTS The high H2 group had a significantly greater improvement in Ln_RHI than the placebo group. Ln_RHI improved by 22.2% (p<0.05) at 24 h after the first ingestion of high H2 water and by 25.4% (p<0.05) after the daily consumption of high H2 water for 2 weeks. CONCLUSIONS Daily consumption of high H2 water improved the endothelial function of the arteries or arterioles assessed by the PAT test. The results suggest that the continuous consumption of high H2 water contributes to improved cardiovascular health.",2020,"Ln_RHI improved by 22.2% (p<0.05) at 24 h after the first ingestion of high H2 water and by 25.4% (p<0.05) after the daily consumption of high H2 water for 2 weeks. ","['Sixty-eight volunteers', 'healthy people']","['molecular hydrogen (H2', 'peripheral arterial tonometry (PAT', 'drank molecular nitrogen (N2)-containing water and a high H2 group (n = 34) that drank high H2 water (containing 7 ppm of H2: 3.5 mg H2 in 500-mL water', 'placebo']","['endothelial function', 'Ln_RHI', 'cardiovascular health', 'peripheral vascular endothelial function, water containing high H2 concentrations', 'Peripheral endothelial function']","[{'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0040420', 'cui_str': 'Tonometry'}, {'cui': 'C0028158', 'cui_str': 'Nitrogen'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C3844010', 'cui_str': '3.5'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",68.0,0.102059,"Ln_RHI improved by 22.2% (p<0.05) at 24 h after the first ingestion of high H2 water and by 25.4% (p<0.05) after the daily consumption of high H2 water for 2 weeks. ","[{'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Ishibashi', 'Affiliation': 'Anicom Speciality Medical Institute, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Kosuke', 'Initials': 'K', 'LastName': 'Kawamoto', 'Affiliation': 'Anicom Speciality Medical Institute, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Kasumi', 'Initials': 'K', 'LastName': 'Matsuno', 'Affiliation': 'Anicom Speciality Medical Institute, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Genki', 'Initials': 'G', 'LastName': 'Ishihara', 'Affiliation': 'Anicom Speciality Medical Institute, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Takamichi', 'Initials': 'T', 'LastName': 'Baba', 'Affiliation': 'Department of Rheumatology, Orthopaedic Surgery and Health Care, Huis Ten Bosch Satellite H2 Clinic Hakata, Hakata-ku, Fukuoka, Japan.'}, {'ForeName': 'Nobuaki', 'Initials': 'N', 'LastName': 'Komori', 'Affiliation': 'Anicom Speciality Medical Institute, Shinjuku-ku, Tokyo, Japan.'}]",PloS one,['10.1371/journal.pone.0233484'] 1678,32470370,Effect of Diclofenac Potassium Premedication on Postendodontic Pain in Mandibular Molars with Symptomatic Irreversible Pulpitis: A Randomized Placebo-Controlled Double-Blind Trial.,"INTRODUCTION The aim of this prospective, randomized, double-blind clinical trial was to evaluate the effect of a preoperative, single, oral dose of diclofenac potassium (DFK) on postoperative pain and rescue analgesic intake in patients with symptomatic irreversible pulpitis in mandibular molars treated in 1 visit. METHODS Seventy emergency patients with moderate to severe preoperative pain randomly received either 50 mg DFK or placebo tablets 1 hour before starting endodontic treatment (n = 35 per group). Patients recorded their pain level 6, 12, 24, and 48 hours after treatment on a 170-mm Heft-Parker visual analog scale. The incidence of rescue analgesic intake was also recorded. Outcome data were statistically analyzed using Mann-Whitney U, Friedman, Wilcoxon signed rank, and chi-square tests. Binary logistic regression assessed the association of predisposing factors with postoperative pain. The significance level (α) was set at 0.05. RESULTS Of the 70 patients, 68 were analyzed (n = 34 per group). Both groups had similar baseline characteristics (P > .05). DFK showed significantly less pain incidence and intensity than the placebo at 48 hours only (P < .05). A significant decrease occurred from 24 to 48 hours with DFK (P < .05), which was not recorded with the placebo (P > .05). No difference in the incidence of rescue analgesic intake was reported between groups (P > .05). Food intake timing, sex, and rescue analgesic intake were associated with postoperative pain (P < .05). CONCLUSIONS Premedication by a single, oral dose of 50 mg DFK could be effective in reducing postendodontic pain at 48 hours after 1-visit endodontic treatment in mandibular molars with symptomatic irreversible pulpitis.",2020,"Food-intake timing, gender, and rescue-analgesic intake were associated with postoperative pain (p<0.05). ","['70 patients', 'Mandibular Molars with Symptomatic Irreversible Pulpitis', 'patients with symptomatic irreversible pulpitis (SIP) in mandibular molars treated in one visit', 'Seventy emergency patients with moderate-to-severe preoperative pain randomly received either']","['Placebo', '50mg DFK or placebo tablets (PLC', 'diclofenac potassium', 'DFK', 'diclofenac potassium (DFK', 'Diclofenac Potassium Premedication']","['Postendodontic Pain', 'pain level', 'postoperative pain and rescue-analgesic intake', 'pain incidence and intensity', 'postendodontic pain', 'incidence of rescue-analgesic intake', '170-mm Heft-Parker visual analogue scale']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0282131', 'cui_str': 'Diclofenac potassium'}, {'cui': 'C0033045', 'cui_str': 'Premedication'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",70.0,0.553297,"Food-intake timing, gender, and rescue-analgesic intake were associated with postoperative pain (p<0.05). ","[{'ForeName': 'Amatallah Hussein', 'Initials': 'AH', 'LastName': 'Al-Rawhani', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Shaimaa Ismail', 'Initials': 'SI', 'LastName': 'Gawdat', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Suzan Abdul', 'Initials': 'SA', 'LastName': 'Wanees Amin', 'Affiliation': 'Department of Endodontics, Faculty of Dentistry, Cairo University, Cairo, Egypt. Electronic address: suzan.wanis@dentistry.cu.edu.eg.'}]",Journal of endodontics,['10.1016/j.joen.2020.05.008'] 1679,32473797,Prior Application of 10% Potassium Nitrate to Reduce Postbleaching Sensitivity: A Randomized Triple-Blind Clinical Trial.,"OBJECTIVE To evaluate if the topical application of 10% potassium nitrate applied before in-office bleaching is effective to reduce the risk and intensity of tooth sensitivity (TS), as well as to evaluate if its application can jeopardize color change. MATERIALS AND METHODS A randomized, split-mouth triple-blind clinical trial was conducted on 43 young patients with incisors A2 or darker. Half of the patient's upper arch received either the application of a 10% potassium nitrate or placebo gel for 10 min in a university setting. In-office bleaching was performed in three 15-min applications in two clinical sessions (1-week interval) using 35% hydrogen peroxide. Risk and intensity of TS was recorded with a 0-4 Numeric Rating Scale and a 0-10 Visual Analogue Scale during bleaching, 1 hour, 24 hours, and 48 hours after bleaching. Color was evaluated before and 1 month after bleaching with shade guides (Vita Classical and Vita Bleachedguide) and a spectrophotometer. The risk of TS (McNemar's test) and intensity of TS (Wilcoxon signed-rank for Numeric Rating Scale and paired t-test for Visual Analogue Scale) were statistically evaluated. Color change was compared using paired t-test. Significant level was set at 5%. RESULTS No significant difference was observed in the absolute risks of TS between groups (RR = 1.11; 95% CI 0.97 to 1.27; P = .12), which exceeded 87% for both groups. Similarly, no difference in TS intensities was detected (P > .05). Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). CONCLUSION The topical application of 10% potassium nitrate, before in-office bleaching, did not reduce the risk and intensity of TS and did not jeopardize color change.",2020,"Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). ",['43 young patients with incisors A2 or darker'],"['hydrogen peroxide', 'potassium nitrate or placebo gel', 'Potassium Nitrate', '10% potassium nitrate']","[""risk of TS (McNemar's test) and intensity of TS (Wilcoxon signed-rank for Numeric Rating Scale and paired t-test for Visual Analogue Scale"", 'risk and intensity of tooth sensitivity (TS', 'absolute risks of TS', 'risk and intensity of TS', 'Postbleaching Sensitivity', 'Risk and intensity of TS', 'TS intensities']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021156', 'cui_str': 'Structure of incisor tooth'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}]","[{'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0071772', 'cui_str': 'potassium nitrate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0017243', 'cui_str': 'Gel'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011432', 'cui_str': 'Sensitive dentin'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0667477', 'cui_str': 'TNFRSF11A protein, human'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",43.0,0.123407,"Significant whitening was observed with all color measurement instruments with no difference between groups (P > .05). ","[{'ForeName': 'Márcia', 'Initials': 'M', 'LastName': 'Rezende', 'Affiliation': 'School of Dentistry, Paulo Picanço School of Dentistry, Fortaleza, Ceará, Brazil.'}, {'ForeName': 'Karine Leticia', 'Initials': 'KL', 'LastName': 'da Silva', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Thais Caroline', 'Initials': 'TC', 'LastName': 'Miguel', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Paulo Vitor', 'Initials': 'PV', 'LastName': 'Farago', 'Affiliation': 'School of Pharmacy, State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Alessandro Dourado', 'Initials': 'AD', 'LastName': 'Loguercio', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Luciana Dorochenko', 'Initials': 'LD', 'LastName': 'Martins', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Reis', 'Affiliation': 'State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil. Electronic address: reis_ale@hotmail.com.'}]",The journal of evidence-based dental practice,['10.1016/j.jebdp.2020.101406'] 1680,32483147,"Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula.","Mother's milk is the best choice for infants nutrition, however when it is not available or insufficient to satisfy the needs of the infant, formula is proposed as an effective substitute. Here, we report the results of a randomized controlled clinical trial (NCT03637894) designed to evaluate the effects of two different dietary regimens (standard formula and Lactobacillus paracasei CBA L74-fermented formula) versus breastfeeding (reference group) on immune defense mechanisms (primary endpoint: secretory IgA, antimicrobial peptides), the microbiota and its metabolome (secondary outcomes), in healthy full term infants according to the type of delivery (n = 13/group). We show that the fermented formula, safe and well tolerated, induces an increase in secretory IgA (but not in antimicrobial peptides) and reduces the diversity of the microbiota, similarly, but not as much as, breastmilk. Metabolome analysis allowed us to distinguish subjects based on their dietary regimen and mode of delivery. Together, these results suggest that a fermented formula favors the maturation of the immune system, microbiota and metabolome.",2020,"We show that the fermented formula, safe and well tolerated, induces an increase in secretory IgA (but not in antimicrobial peptides) and reduces the diversity of the microbiota, similarly, but not as much as, breastmilk.",['healthy full term infants according to the type of delivery (n\u2009=\u200913/group'],"['Lactobacillus paracasei CBA', 'dietary regimens (standard formula and Lactobacillus paracasei CBA L74-fermented formula']","['secretory IgA', 'safe and well tolerated']","[{'cui': 'C4551581', 'cui_str': 'Term baby'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C1080735', 'cui_str': 'Lactobacillus paracasei'}, {'cui': 'C0025922', 'cui_str': 'Mouse, Inbred CBA'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}]","[{'cui': 'C0020838', 'cui_str': 'Immunoglobulin A secretory'}]",,0.03072,"We show that the fermented formula, safe and well tolerated, induces an increase in secretory IgA (but not in antimicrobial peptides) and reduces the diversity of the microbiota, similarly, but not as much as, breastmilk.","[{'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Roggero', 'Affiliation': ""Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy. paola.roggero@unimi.it.""}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Liotto', 'Affiliation': ""Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy.""}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Pozzi', 'Affiliation': 'Humanitas Clinical and Research Center-IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Braga', 'Affiliation': 'Humanitas Clinical and Research Center-IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.'}, {'ForeName': 'Jacopo', 'Initials': 'J', 'LastName': 'Troisi', 'Affiliation': 'Theoreo Srl, Via degli Ulivi 3, 84090, Montecorvino Pugliano, SA, Italy.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Menis', 'Affiliation': ""Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy.""}, {'ForeName': 'Maria Lorella', 'Initials': 'ML', 'LastName': 'Giannì', 'Affiliation': ""Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy.""}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Berni Canani', 'Affiliation': 'Department of Translational Medical Science, University Federico II, Naples, Italy.'}, {'ForeName': 'Lorella', 'Initials': 'L', 'LastName': 'Paparo', 'Affiliation': 'Department of Translational Medical Science, University Federico II, Naples, Italy.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Nocerino', 'Affiliation': 'Department of Translational Medical Science, University Federico II, Naples, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Budelli', 'Affiliation': 'School of Engineering, Niccoló Cusano University, Rome, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Mosca', 'Affiliation': ""Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IRCCS), Milan, Italy.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Rescigno', 'Affiliation': 'Humanitas Clinical and Research Center-IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy. maria.rescigno@hunimed.eu.'}]",Nature communications,['10.1038/s41467-020-16582-1'] 1681,32480319,Effectiveness of an app-based cognitive behavioral therapy program for postpartum depression in primary care: A randomized controlled trial.,"OBJECTIVE The objective of this study was to examine the effect of mobile phone applications (App) based cognitive behavioral therapy (CBT) on postpartum depression. METHOD A non-blinded parallel-group randomized controlled trial was conducted. The study population consisted of women attended to three health care centers in Kerman, Iran. Participants were recruited between September and November 2018, and randomized 1:1 to either the intervention group (mobile application access) or control group (no mobile application access). All participants completed the Edinburgh Postnatal Depression Scale (EPDS) at the baseline and 2 months after baseline. Data were analyzed using inferential statistics including chi-square, independent sample t-test, paired t-test and linear regression. RESULTS A total of 75 women with an average age of 27 years participated in this study. Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001). However, in the intervention group, the average EPDS score after intervention was 8.18 and in the control group was 15.05, which was statistically significant (p < 0.001). CONCLUSION These findings provide proof that providing a CBT program using a mobile application can lead to clinically important improvements in outcomes for mothers who suffer from postpartum depression.",2020,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","['Participants were recruited between September and November 2018', 'postpartum depression in primary care', 'women attended to three health care centers in Kerman, Iran', 'mothers who suffer from postpartum depression', '75 women with an average age of 27 years participated in this study']","['intervention group (mobile application access) or control group (no mobile application access', 'app-based cognitive behavioral therapy program', 'mobile phone applications (App) based cognitive behavioral therapy (CBT']","['Edinburgh Postnatal Depression Scale (EPDS', 'average EPDS score', 'EPDS score']","[{'cui': 'C0221074', 'cui_str': 'Postpartum depression'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0185125', 'cui_str': 'Application'}]","[{'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score'}]",75.0,0.174326,"Before the intervention, there was no statistically significant difference between the EPDS score between the two groups (p > 0.001).","[{'ForeName': 'Nazanin', 'Initials': 'N', 'LastName': 'Jannati', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Mazhari', 'Affiliation': 'Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Ahmadian', 'Affiliation': 'Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: ahmadianle@yahoo.com.'}, {'ForeName': 'Moghaddameh', 'Initials': 'M', 'LastName': 'Mirzaee', 'Affiliation': 'Epidemiology and Biostatistics, Kerman University of Medical Sciences, Kerman, Iran.'}]",International journal of medical informatics,['10.1016/j.ijmedinf.2020.104145'] 1682,32482361,[Comparison of channelled videolaryngoscope and intubating laryngeal mask airway for tracheal intubation in obese patients: a randomised clinical trial].,"BACKGROUND Obesity causes various difficulties in intubation and ventilation, which are confronted due to increased fat tissue in the upper airway and diminished compliance in the chest wall. Videolaryngoscopes and Intubating Laryngeal Mask Airway (ILMA) are good options as recommended by the American Society of Anesthesologists (ASA) difficult airway guidelines. We aimed to compare ILMA and Airtraq (a channeled videolaryngoscope) in obese patients. METHODS Eighty patients with ASA physical status I-III, aged between 18 and 65 years and with a body mass index greater than 35 kg.m -2 , who were undergoing elective surgery requiring orotracheal intubation, were included in the study. Patients were intubated with one of the devices cited. RESULTS There was no difference between the number of intubation attempts, insertion times and need for optimisation manoeuvres of Airtraq and ILMA. The intubation with Airtraq was accomplished in a shorter period of time than in that in the ILMA group (29.9±22.1s vs. 50.7±21.2s; p<0.001). A significant difference was found when the times of total intubation were compared (29.9±22.1s vs. 97.4±42.7s; p<0.001). The mean arterial pressure statistically increased after device insertion in the ILMA group (p<0.05). CONCLUSIONS Airtraq appears to be superior to ILMA in obese patients, with a total of time intubation of less than 60 seconds and with low mean arterial pressure changes. However, ILMA is still a useful tool that provides both ventilation and intubation throughout the whole intubation process.",2020,"There was no difference between the number of intubation attempts, insertion times and need for optimisation manoeuvres of Airtraq and ILMA.","['obese patients', 'Eighty patients with ASA physical status I-III, aged between 18 and 65 years and with a body mass index greater than 35 kg.m -2 , who were undergoing elective surgery requiring orotracheal intubation, were included in the study']","['channelled videolaryngoscope and intubating laryngeal mask airway for tracheal intubation', 'Videolaryngoscopes and Intubating Laryngeal Mask Airway (ILMA', 'ILMA and Airtraq (a channeled videolaryngoscope', 'ILMA']","['mean arterial pressure', 'number of intubation attempts, insertion times and need for optimisation manoeuvres of Airtraq and ILMA', 'times of total intubation']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0396621', 'cui_str': 'Orotracheal intubation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0439799', 'cui_str': 'Channel'}, {'cui': 'C3164607', 'cui_str': 'Videolaryngoscope'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0162645', 'cui_str': 'Laryngeal mask'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",80.0,0.137797,"There was no difference between the number of intubation attempts, insertion times and need for optimisation manoeuvres of Airtraq and ILMA.","[{'ForeName': 'Canan Kamile', 'Initials': 'CK', 'LastName': 'Turna', 'Affiliation': 'Kocaeli University Medical Faculty, Anesthesiology and Reanimation, Kocaeli, Turkey.'}, {'ForeName': 'Zehra Ipek', 'Initials': 'ZI', 'LastName': 'Arslan', 'Affiliation': 'Kocaeli University Medical Faculty, Anesthesiology and Reanimation, Kocaeli, Turkey. Electronic address: zehraipek48@gmail.com.'}, {'ForeName': 'Volkan', 'Initials': 'V', 'LastName': 'Alparslan', 'Affiliation': 'Kocaeli University Medical Faculty, Anesthesiology and Reanimation, Kocaeli, Turkey.'}, {'ForeName': 'Kamil', 'Initials': 'K', 'LastName': 'Okyay', 'Affiliation': 'Kocaeli University Medical Faculty, Anesthesiology and Reanimation, Kocaeli, Turkey.'}, {'ForeName': 'Mine', 'Initials': 'M', 'LastName': 'Solak', 'Affiliation': 'Kocaeli University Medical Faculty, Anesthesiology and Reanimation, Kocaeli, Turkey.'}]",Revista brasileira de anestesiologia,['10.1016/j.bjan.2020.01.008'] 1683,32482392,Early Cardiac and Cerebral Hemodynamics with Umbilical Cord Milking Compared with Delayed Cord Clamping in Infants Born Preterm.,"OBJECTIVE To evaluate changes in cerebral oxygenation, peripheral arterial oxygenation, respiratory status, and administered fraction of inspired oxygen during the first 10 minutes of life in premature infants receiving umbilical cord milking compared with delayed cord clamping (DCC). STUDY DESIGN Premature infants born at 23 0/7 to 27 6/7  weeks of gestation were randomized to umbilical cord milking or DCC. A near infrared spectroscopy sensor, pulse oximeter, and electrocardiogram electrodes were placed. Pulse rate, cerebral tissue oxygenation, peripheral oxygen saturation, airway pressure, and fraction of inspired oxygen were collected for 10 minutes in the delivery room. Longitudinal models were used to compare effects of umbilical cord milking and DCC. RESULTS Fifty-six infants had cerebral oximetry and advanced monitoring at birth. There was an increased incidence of severe intraventricular hemorrhage in infants who received umbilical cord milking compared with DCC (P = .0211). Longitudinal models suggested that peripheral oxygen saturation was higher in the umbilical cord milking group in the first 4 minutes (P = .0221) and that mean airway pressures were lower in the umbilical cord milking group after the first 7 minutes (P = .0072). No statistical differences were observed for fraction of inspired oxygen, cerebral tissue oxygenation, or heart rates. CONCLUSIONS The data suggest that the rapid transfer of blood during umbilical cord milking may facilitate lung expansion with improved pulmonary blood flow, but may also increase cerebral blood flow, resulting in severe intraventricular hemorrhage. TRIAL REGISTRATION ClinicalTrials.gov: NCT03145142.",2020,There was an increased incidence of severe intraventricular hemorrhage in infants who received umbilical cord milking compared with DCC (P = .0211).,"['Infants Born Preterm', 'Fifty-six infants had cerebral oximetry and advanced monitoring at birth', 'premature infants receiving umbilical cord milking compared with delayed cord clamping (DCC', 'Premature infants born at 23 0/7 to 27 6/7 \xa0weeks of gestation']","['umbilical cord milking or DCC', 'Umbilical Cord Milking Compared with Delayed Cord Clamping']","['fraction of inspired oxygen, cerebral tissue oxygenation, or heart rates', 'mean airway pressures', 'cerebral oxygenation, peripheral arterial oxygenation, respiratory status, and administered fraction of inspired oxygen', 'peripheral oxygen saturation', 'cerebral blood flow', 'severe intraventricular hemorrhage', 'Pulse rate, cerebral tissue oxygenation, peripheral oxygen saturation, airway pressure, and fraction of inspired oxygen']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C1744681', 'cui_str': 'Congenital'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}]","[{'cui': 'C0428167', 'cui_str': 'Fraction of inspired oxygen'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0240059', 'cui_str': 'Ventricular hemorrhage'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}]",56.0,0.151184,There was an increased incidence of severe intraventricular hemorrhage in infants who received umbilical cord milking compared with DCC (P = .0211).,"[{'ForeName': 'Anup C', 'Initials': 'AC', 'LastName': 'Katheria', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA. Electronic address: anup.katheria@sharp.com.'}, {'ForeName': 'Jeff M', 'Initials': 'JM', 'LastName': 'Szychowski', 'Affiliation': 'Department of Biostatistics at the UAB School of Public Health, Birmingham, AL.'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Essers', 'Affiliation': 'Department of Pediatrics University of Ulm, Ulm, Germany.'}, {'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Mendler', 'Affiliation': 'Department of Pediatrics University of Ulm, Ulm, Germany.'}, {'ForeName': 'Eugene M', 'Initials': 'EM', 'LastName': 'Dempsey', 'Affiliation': 'Department of Pediatrics and INFANT Centre, University College Cork, Ireland.'}, {'ForeName': 'Georg M', 'Initials': 'GM', 'LastName': 'Schmölzer', 'Affiliation': 'Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Arnell', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA.'}, {'ForeName': 'Wade D', 'Initials': 'WD', 'LastName': 'Rich', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA.'}, {'ForeName': 'Kasim', 'Initials': 'K', 'LastName': 'Hassen', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Allman', 'Affiliation': 'Department of Biostatistics at the UAB School of Public Health, Birmingham, AL.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Varner', 'Affiliation': 'Department of Obstetrics and Gynecology, Salt Lake City, UT.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Cutter', 'Affiliation': 'Department of Biostatistics at the UAB School of Public Health, Birmingham, AL.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Finer', 'Affiliation': 'Neonatal Research Institute, Sharp Mary Birch Hospital for Women & Newborns, San Diego, CA.'}]",The Journal of pediatrics,['10.1016/j.jpeds.2020.04.010'] 1684,32489264,A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.,"Introduction Improving health-related quality of life (hrqol) is a key goal of systemic therapy in advanced lung cancer, although routine assessment remains challenging. We analyzed the impact of a real-time electronic hrqol tool, the electronic Lung Cancer Symptom Scale (elcss-ql), on palliative care (pc) referral rates, patterns of chemotherapy treatment, and use of other supportive interventions in patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemotherapy. Methods Patients with advanced nsclc starting first-line chemotherapy were randomized to their oncologist receiving or not receiving their elcss-ql data before each clinic visit. Patients completed the elcss-ql at baseline, before each chemotherapy cycle, and at subsequent follow-up visits until disease progression. Prospective data about the pc referral rate, hrqol, and use of other supportive interventions were collected. Results For the 95 patients with advanced nsclc who participated, oncologists received real-time elcss-ql data for 44 (elcss-ql arm) and standard clinical assessment alone for 51 (standard arm). The primary endpoint, the pc referral rate, was numerically higher, but statistically similar, for patients in the elcss-ql and standard arms. The hrqol scores over time were not significantly different between the two study arms. Conclusions The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer.",2020,"The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study.","['Patients with advanced nsclc starting first-line chemotherapy', '95 patients with advanced nsclc who participated, oncologists received real-time elcss-ql data for 44 (elcss-ql arm) and standard clinical assessment alone for 51 (standard arm', 'patients with advanced non-small-cell lung cancer', 'advanced lung cancer', 'patients with advanced non-small-cell lung cancer (nsclc) receiving first-line chemotherapy', 'patients with advanced lung cancer']",['electronic Lung Cancer Symptom Scale'],"['pc referral rate', 'hrqol scores over time', 'electronic Lung Cancer Symptom Scale (elcss-ql']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C4524268', 'cui_str': 'Advanced lung cancer'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]","[{'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",95.0,0.106901,"The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study.","[{'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Kuo', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'D M', 'Initials': 'DM', 'LastName': 'Graham', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Salvarrey', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Kassam', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'L W', 'Initials': 'LW', 'LastName': 'Le', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Shepherd', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Burkes', 'Affiliation': 'Division of Medical Oncology, Mount Sinai Hospital, Toronto, ON.'}, {'ForeName': 'P J', 'Initials': 'PJ', 'LastName': 'Hollen', 'Affiliation': 'School of Nursing, University of Virginia, Charlottesville, VA, U.S.A.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Gralla', 'Affiliation': 'Albert Einstein College of Medicine, New York, NY, U.S.A.'}, {'ForeName': 'N B', 'Initials': 'NB', 'LastName': 'Leighl', 'Affiliation': 'Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON.'}]","Current oncology (Toronto, Ont.)",['10.3747/co.27.5651'] 1685,32593123,Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials.,,2020,,['patients with schizophrenia'],['yoga therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}]",[],,0.0595902,,"[{'ForeName': 'Saeko', 'Initials': 'S', 'LastName': 'Ikai-Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Faculty of Kinesiology & Physical Education, University of Toronto, 55 Harbord Street, M5S 2W6, Toronto, ON, Canada. Electronic address: sako0609@gmail.com.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Tani', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Kimel Family Translational Imaging-Genetics Laboratory, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}, {'ForeName': 'Saki', 'Initials': 'S', 'LastName': 'Kamiyama', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Mimura', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Uchida', 'Affiliation': 'Department of Neuropsychiatry, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582 Tokyo, Japan; Geriatric Mental Health Program, Centre for Addiction and Mental Health, 1001 Queen St W, M6J 1H4, Toronto, ON, Canada.'}]",Asian journal of psychiatry,['10.1016/j.ajp.2020.102250'] 1686,32593750,Effect of acute caffeine intake on hit accuracy and reaction time in professional e-sports players.,"Caffeine is considered a cognitive enhancer at low to moderate doses because it improves alertness, vigilance, attention, and reaction time. However, no previous investigation has assessed the effect of acute caffeine intake on e-sports-specific performance. The aim of this investigation was to determine the effect of the ingestion of 3 mg per kg of body mass on simple reaction time in a color test and on hit accuracy and reaction time during a first-person shooting game. Fifteen professional e-gamers (age= 22 ± 3 years) participated in a double-blind, cross-over, randomized experimental trial. In two trials 3 days apart, participants either ingested a placebo (cellulose) or 3 mg/kg of caffeine in an opaque and unidentifiable capsule. After a 45-min wait for substance absorption, participants performed 5 attempts at a simple reaction time test and completed a first-person shooting game that included 3 attempts at a 2-min game with 60 fixed targets (180 targets in total). Reaction times (in both tests) and accuracy in hitting the targets (only in the shooting game) were measured. In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01). In summary, the acute ingestion of 3 mg/kg of caffeine reduced the time taken to react to a simple stimulus, decreased the time taken to hit a fixed target and improved accuracy in hitting the target in a first-person shooting game in professional e-gamers. Thus, the caffeine ingestion (3 mg/kg) might be considered as an ergogenic aid for e-sports gamers based on its effect to enhance hit accuracy and time.",2020,"In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01).","['Fifteen professional e-gamers (age= 22 ± 3 years) participated in a double-blind, cross-over, randomized experimental trial', 'professional e-sports players']","['acute caffeine intake', 'caffeine ingestion', 'caffeine', 'placebo (cellulose) or 3 mg/kg of caffeine', 'Caffeine', 'placebo, caffeine']","['enhanced hit accuracy', 'time taken to hit a fixed target and improved accuracy', 'alertness, vigilance, attention, and reaction time', 'simple reaction time', 'Reaction times', 'hit accuracy and reaction time', 'mean time taken to hit the targets']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0038039', 'cui_str': 'Sport'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}]","[{'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0043012', 'cui_str': 'Wakefulness'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0879569,"In comparison to the placebo, caffeine decreased simple reaction time (0.20 ± 0.01 vs. 0.19 ± 0.01 s, P < 0.01), the mean time taken to hit the targets (0.92 ± 0.07 vs. 0.88 ± 0.07 s, P < 0.01) and enhanced hit accuracy (98.8 ± 0.92 vs. 99.8 ± 0.35% of targets hit, P < 0.01).","[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Sainz', 'Affiliation': 'Team Queso, e-Gamers Club. Madrid, Spain. Electronic address: nachosainz10@gmail.com.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Collado-Mateo', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Madrid, Spain. Electronic address: daniel.collado@urjc.es.'}, {'ForeName': 'Juan Del', 'Initials': 'JD', 'LastName': 'Coso', 'Affiliation': 'Centre for Sport Studies, Rey Juan Carlos University, Fuenlabrada, Madrid, Spain. Electronic address: juan.delcoso@urjc.es.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113031'] 1687,32595176,Efficacy and Safety of Left Atrial Appendage Closure With WATCHMAN in Japanese Nonvalvular Atrial Fibrillation Patients　- Final 2-Year Follow-up Outcome Data From the SALUTE Trial.,"BACKGROUND The SALUTE trial was a prospective, multicenter, single-arm trial to confirm the safety and efficacy of the WATCHMAN left atrial appendage closure (LAAC) device for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in Japan.Methods and Results:A total of 54 subjects (including 12 roll-in subjects) with a WATCHMAN implant procedure were followed in 10 investigational centers. Follow-up visits were performed up to 2 years post-implant. The baseline CHA 2 DS 2 -VASc score was 3.6±1.6 and the baseline HAS-BLED score was 3.0±1.1. All 42 subjects in the intention to treat (ITT) cohort underwent successful implantation of the LAAC device without any serious complications, achieving the prespecified performance goal. The effective LAAC rate was maintained at 100% from 45 days to 12 months post-implant, achieving the prespecified performance goal. During follow-up, 1 subject died of heart failure, and 3 had ischemic strokes, but there were no cases of hemorrhagic stroke or systemic embolism. All events were adjudicated as unrelated to the WATCHMAN device/procedure by the independent Clinical Events Committee. All 3 ischemic strokes were classified as nondisabling based on no change in the modified Rankin scale score. CONCLUSIONS Final results of the SALUTE trial demonstrated that the WATCHMAN LAAC device is an effective and safe alternative nonpharmacological therapy for stroke risk reduction in Japanese NVAF patients who are not optimal candidates for lifelong anticoagulation. (Trial Registration: clinicaltrials.gov Identifier NCT03033134).",2020,"All 42 subjects in the intention to treat (ITT) cohort underwent successful implantation of the LAAC device without any serious complications, achieving the prespecified performance goal.","['Japanese NVAF patients who are not optimal candidates for lifelong anticoagulation', 'Japanese Nonvalvular Atrial Fibrillation Patients', 'patients with nonvalvular atrial fibrillation (NVAF) in Japan', '54 subjects (including 12 roll-in subjects) with a WATCHMAN implant procedure were followed in 10 investigational centers', 'All 42 subjects in the intention to treat (ITT) cohort underwent']","['Left Atrial Appendage Closure', 'left atrial appendage closure (LAAC) device', 'successful implantation of the LAAC device']","['Efficacy and Safety', 'baseline CHA 2 DS 2 -VASc score', 'hemorrhagic stroke or systemic embolism', 'safety and efficacy', 'modified Rankin scale score', 'effective LAAC rate']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4274169', 'cui_str': 'Lifelong'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0335390', 'cui_str': 'Watchman'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}]","[{'cui': 'C4759306', 'cui_str': 'Left atrial appendage closure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C4523927', 'cui_str': 'Atrial appendage closure'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0574369', 'cui_str': 'Chamorro language'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0553692', 'cui_str': 'Haemorrhagic stroke'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C4523927', 'cui_str': 'Atrial appendage closure'}]",54.0,0.0923228,"All 42 subjects in the intention to treat (ITT) cohort underwent successful implantation of the LAAC device without any serious complications, achieving the prespecified performance goal.","[{'ForeName': 'Kazutaka', 'Initials': 'K', 'LastName': 'Aonuma', 'Affiliation': 'Cardiovascular Division, University of Tsukuba Hospital.'}, {'ForeName': 'Hiro', 'Initials': 'H', 'LastName': 'Yamasaki', 'Affiliation': 'Cardiovascular Division, University of Tsukuba Hospital.'}, {'ForeName': 'Masato', 'Initials': 'M', 'LastName': 'Nakamura', 'Affiliation': 'Division of Cardiovascular Medicine, Toho University Ohashi Medical Center.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Matsumoto', 'Affiliation': 'Department of Cardiology, Sendai Kousei Hospital.'}, {'ForeName': 'Morimasa', 'Initials': 'M', 'LastName': 'Takayama', 'Affiliation': 'Department of Cardiology, Sakakibara Heart Institute.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Ando', 'Affiliation': 'Division of Cardiology, Kokura Memorial Hospital.'}, {'ForeName': 'Kenzo', 'Initials': 'K', 'LastName': 'Hirao', 'Affiliation': 'Department of Cardiology, AOI Universal Hospital.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Goya', 'Affiliation': 'Department of Cardiovascular Medicine, Tokyo Medical and Dental University.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Morino', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Iwate Medical University.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Hayashida', 'Affiliation': 'Department of Cardiology, Keio University School of Medicine.'}, {'ForeName': 'Kengo', 'Initials': 'K', 'LastName': 'Kusano', 'Affiliation': 'Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center.'}, {'ForeName': 'Yutaka', 'Initials': 'Y', 'LastName': 'Gomi', 'Affiliation': 'Boston Scientific Japan K.K.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Main', 'Affiliation': ""Saint Luke's Mid America Heart Institute.""}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Uchida', 'Affiliation': ""Department of Cardiology, Tokyo Women's Medical University.""}, {'ForeName': 'Shigeru', 'Initials': 'S', 'LastName': 'Saito', 'Affiliation': 'Division of Cardiology & Catheterization Laboratories, Shonan Kamakura General Hospital.'}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-20-0196'] 1688,32463593,Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects.,"Sildenafil citrate is approved to treat erectile dysfunction. An orally disintegrating tablet (ODT) of sildenafil citrate that does not require swallowing or administration with fluids has been developed. The bioequivalence and bioavailability of sildenafil citrate ODT (50 mg) without and with water were compared with conventional sildenafil citrate tablets (50 mg) in an open-label, randomized crossover study. Healthy Chinese male subjects (n = 36) were allocated to 1 of 6 sildenafil citrate treatment sequences under fasted conditions, and plasma samples for determination of sildenafil concentrations were collected predose through 14 hours postdose. Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil AUC last , C max , and AUC inf (ratio, 101.41%; 90%CI, 95.49%-107.70%; ratio, 93.55%; 90%CI, 84.15%-104.00%; and ratio, 101.03%; 90%CI, 94.80%-107.66%; respectively) were wholly contained within the bioequivalence acceptance range of 80% to 125%, indicating bioequivalence criteria were met. Relative bioavailability of sildenafil citrate ODT administered with water to the sildenafil citrate tablet (50 mg) administered with water was 97.10%, 91.43%, and 97.09% with respect to sildenafil AUC last , C max , and AUC inf , respectively (90%CI, 91.43%-03.12%, 82.25%-101.65%, and 90.90%-103.71%, respectively). Both sildenafil citrate formulations were generally well tolerated in healthy Chinese men. Sildenafil citrate ODT administered without or with water was bioequivalent to or met bioequivalence criteria compared with conventional sildenafil citrate tablets administered with water under fasted conditions in healthy Chinese men, thus offering a convenient alternative method of oral administration.",2020,Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil,"['Healthy Chinese male subjects (n = 36', 'healthy Chinese men', 'Healthy Chinese Male Subjects']","['sildenafil citrate tablet', 'sildenafil citrate ODT', 'Sildenafil citrate ODT', 'conventional sildenafil citrate tablets', 'sildenafil AUC', 'sildenafil citrate ODT (50 mg) without and with water were compared with conventional sildenafil citrate tablets', 'sildenafil citrate formulations', 'Sildenafil citrate', 'sildenafil citrate', 'Sildenafil Citrate', 'sildenafil']","['Relative bioavailability', 'AUC last , C max , and AUC inf', 'Bioequivalence and Bioavailability', 'last , C max , and AUC inf']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0724693', 'cui_str': 'Sildenafil citrate'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C2960508', 'cui_str': 'Orodispersible tablet'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0529793', 'cui_str': 'sildenafil'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0039789', 'cui_str': 'Equivalencies, Therapeutic'}]",36.0,0.0744477,Bioequivalence was demonstrated for sildenafil citrate ODT administered without water relative to the sildenafil citrate tablet administered with water; 90%CIs for the ratios of adjusted geometric means for sildenafil,"[{'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Lv', 'Affiliation': 'Peking University First Hospital, Institute of Clinical Pharmacology, Beijing, China.'}, {'ForeName': 'Bin-Yu', 'Initials': 'BY', 'LastName': 'Luo', 'Affiliation': 'Pfizer Inc, Shanghai, China.'}, {'ForeName': 'Robert R', 'Initials': 'RR', 'LastName': 'LaBadie', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Hua', 'Initials': 'H', 'LastName': 'Zhu', 'Affiliation': 'Pfizer Inc, Shanghai, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Feng', 'Affiliation': 'Pfizer Inc, Beijing, China.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Ernst', 'Affiliation': 'ExecuPharm, King of Prussia, Pennsylvania, USA.'}, {'ForeName': 'Penelope H', 'Initials': 'PH', 'LastName': 'Crownover', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Yali', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}, {'ForeName': 'Qinying', 'Initials': 'Q', 'LastName': 'Zhao', 'Affiliation': 'Pfizer Inc, Groton, Connecticut, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.806'] 1689,32459738,"Effects of Exercise on Body Posture, Functional Movement, and Physical Fitness in Children With Overweight/Obesity.","Molina-Garcia, P, Mora-Gonzalez, J, Migueles, JH, Rodriguez-Ayllon, M, Esteban-Cornejo, I, Cadenas-Sanchez, C, Plaza-Florido, A, Gil-Cosano, JJ, Pelaez-Perez, MA, Garcia-Delgado, G, Vanrenterghem, J, and Ortega, FB. Effects of exercise on body posture, functional movement, and physical fitness in children with overweight/obesity. J Strength Cond Res 34(8): 2146-2155, 2020-This study aims to analyze whether a 13-week exercise program based on ""movement quality"" and ""multi-games"" can lead to simultaneous benefits to body posture, fundamental movements, and physical fitness of children with overweight/obesity. A total of 64 children (10.9 ± 1.3 years, 25.9 ± 3.8 kg·m, 38 girls and 26 boys) with overweight/obesity were assigned either to a 13-week exercise-based intervention group (IG) (n = 33) or to a control group (CG) (n = 31). Subjects underwent assessments of basic anthropometry (body mass and height), body posture (2-dimensional photogrammetry), fundamental movements (Functional Movement Screen), and physical fitness (1 repetition maximum [1RM] arm and leg press, and ALPHA test battery). After the exercise program, the IG reduced lower limb angle (high effect size: -0.82 SDs; p = 0.001) and plumb-tragus distance (low effect: -0.43 SDs; p = 0.002) in the sagittal plane and increased lower limb angle in the frontal plane (high effect: 0.82 SDs; p = 0.003) compared with the CG. The IG improved their performance in deep squat (p = 0.004), active straight leg raise (p < 0.001), 1RM arm (low effect: 0.46 SDs; p = 0.002), handgrip strength (medium effect: 0.53 SDs; p < 0.001), and standing long jump (medium effect: 0.59 SDs; p = 0.003), all compared with the CG. In conclusion, children with overweight/obesity who participated in our 13-week exercise program developed a better alignment of the head and lower limb, improved their performance in fundamental movements, and experienced global muscular strength gains compared with the peers who continued with their usual lives. Among other potential implications, these improvements could contribute to the prevention of musculoskeletal disorders associated with childhood obesity and could increase adherence by positioning these children in a better physical status to keep practicing exercise.",2020,"The IG improved their performance in deep squat (p = 0.004), active straight leg raise (p < 0.001), 1RM arm (low effect: 0.46 SDs; p = 0.002), handgrip strength (medium effect: 0.53 SDs; p < 0.001), and standing long jump (medium effect: 0.59 SDs; p = 0.003), all compared with the CG.","['64 children (10.9 ± 1.3 years, 25.9 ± 3.8 kg·m, 38 girls and 26 boys) with overweight/obesity', 'Children With Overweight/Obesity', 'children with overweight/obesity who participated in our 13-week', 'children with overweight/obesity']","['control group (CG', 'J Strength Cond Res XX(X', 'exercise', '13-week exercise program based on ""movement quality"" and ""multi-games', 'exercise program', 'Exercise', '13-week exercise-based intervention group (IG']","['active straight leg raise', 'basic anthropometry (body mass and height), body posture (2-dimensional photogrammetry), fundamental movements (Functional Movement Screen), and physical fitness (1 repetition maximum [1RM] arm and leg press, and ALPHA test battery', 'body posture, functional movement, and physical fitness', 'Body Posture, Functional Movement, and Physical Fitness', 'lower limb angle', 'handgrip strength', 'performance in fundamental movements, and experienced global muscular strength gains', 'deep squat']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517499', 'cui_str': '1.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0422926', 'cui_str': 'Straight leg raise test response'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C1262869', 'cui_str': 'Body position'}, {'cui': 'C0031747', 'cui_str': 'Photogrammetry'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}]",64.0,0.0264643,"The IG improved their performance in deep squat (p = 0.004), active straight leg raise (p < 0.001), 1RM arm (low effect: 0.46 SDs; p = 0.002), handgrip strength (medium effect: 0.53 SDs; p < 0.001), and standing long jump (medium effect: 0.59 SDs; p = 0.003), all compared with the CG.","[{'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Molina-Garcia', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Mora-Gonzalez', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Jairo H', 'Initials': 'JH', 'LastName': 'Migueles', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Rodriguez-Ayllon', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Esteban-Cornejo', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cadenas-Sanchez', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Abel', 'Initials': 'A', 'LastName': 'Plaza-Florido', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Jose J', 'Initials': 'JJ', 'LastName': 'Gil-Cosano', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Manuel A', 'Initials': 'MA', 'LastName': 'Pelaez-Perez', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Garcia-Delgado', 'Affiliation': 'Research Group CTS-545 ERGOLAB ""Sport Physical Activity and Ergonomy to Life Quality,"" Department of Physical and Sports Education, Faculty of Sports Science, University of Granada, Granada, Spain.'}, {'ForeName': 'Jos', 'Initials': 'J', 'LastName': 'Vanrenterghem', 'Affiliation': 'Department of Rehabilitation Sciences, KU Leuven-University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Francisco B', 'Initials': 'FB', 'LastName': 'Ortega', 'Affiliation': 'PROFITH ""PROmoting FITness and Health Through Physical Activity"" Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003655'] 1690,32460697,"The effect of oral care intervention on pneumonia hospitalization, Staphylococcus aureus distribution, and salivary bacterial concentration in Taiwan nursing home residents: a pilot study.","BACKGROUND Elevated Staphylococcus aureus and oral bacterial concentrations are known to correlate with pneumonia hospitalization in nursing home residents. However, the effects of a professional oral care intervention on these factors remain unclear. The aims of this quasi-experimental study were to compare bacterial concentrations in saliva and sputum, oral health status, distribution of Staphylococcus aureus, and pneumonia status before and after a professional oral care intervention. METHODS A purposive sample of residents from two nursing homes was divided into an intervention group that received a weekly professional oral care intervention and a control group. Oral bacterial concentration was determined by real-time polymerase chain reaction. The Staphylococcus aureus distribution was determined by bacterial culture and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. After data collection, a statistical analysis was performed to evaluate the effect of the intervention. RESULTS Most residents were unconscious (80%), and most had a history of pneumonia (76%). Baseline demographic data did not significantly differ between the two groups. After the intervention, the intervention group had significant improvements in plaque index (1.66 ± 0.78 vs. 0.94 ± 0.64, p <  0.01), gingival index (2.36 ± 0.76 vs. 1.65 ± 0.83, p <  0.01), tongue coating index (0.96 ± 1.10 vs. 0.16 ± 0.47, p <  0.01), distribution of Staphylococcus aureus in salivary samples (11.11 ± 14.47% vs. 1.74 ± 3.75%, p = 0.02), and salivary bacterial concentration ([4.27 ± 3.65] × 10 5 vs. [0.75 ± 1.20] × 10 5 , p <  0.01). Sputum bacterial concentration did not significantly differ. The intervention group also had a significantly lower annual prevalence of pneumonia hospitalization (1.24 ± 1.51 vs. 0.48 ± 0.59, p = 0.01), especially in residents whose salivary bacterial concentration exceeded the median. However, the duration of pneumonia hospitalization did not significantly differ between the two groups. CONCLUSION A professional oral care intervention in nursing home residents can improve oral health, reduce levels of salivary bacteria and Staphylococcus aureus, and decrease the annual prevalence of pneumonia hospitalization. TRIAL REGISTRATION Trial registration: ClinicalTrials.gov, NCT03874962. Registered 12 March 2019 - Retrospectively registered.",2020,"A professional oral care intervention in nursing home residents can improve oral health, reduce levels of salivary bacteria and Staphylococcus aureus, and decrease the annual prevalence of pneumonia hospitalization. ","['nursing home residents', 'A purposive sample of residents from two nursing homes', 'Taiwan nursing home residents']","['professional oral care intervention', 'professional oral care intervention and a control group', 'oral care intervention']","['distribution of Staphylococcus aureus in salivary samples', 'Sputum bacterial concentration', 'annual prevalence of pneumonia hospitalization', 'salivary bacterial concentration', 'bacterial concentrations in saliva and sputum, oral health status, distribution of Staphylococcus aureus, and pneumonia status', 'pneumonia hospitalization, Staphylococcus aureus distribution, and salivary bacterial concentration', 'oral health, reduce levels of salivary bacteria and Staphylococcus aureus', 'tongue coating index', 'Oral bacterial concentration', 'history of pneumonia', 'duration of pneumonia hospitalization', 'gingival index', 'Baseline demographic data', 'plaque index']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0009144', 'cui_str': 'Furred tongue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0455542', 'cui_str': 'H/O: pneumonia'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0017569', 'cui_str': 'Gingival Indexes'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}]",,0.0851238,"A professional oral care intervention in nursing home residents can improve oral health, reduce levels of salivary bacteria and Staphylococcus aureus, and decrease the annual prevalence of pneumonia hospitalization. ","[{'ForeName': 'Tien-Cheng', 'Initials': 'TC', 'LastName': 'Chiang', 'Affiliation': 'School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, No.100, Shiquan 1st Rd., Sanmin Dist., Kaohsiung City, 807, Taiwan.'}, {'ForeName': 'Ming-Shyan', 'Initials': 'MS', 'LastName': 'Huang', 'Affiliation': 'Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, E-DA Cancer Hospital, No. 21, Yida Rd., Yanchao Dist., Kaohsiung City, 824, Taiwan.'}, {'ForeName': 'Po-Liang', 'Initials': 'PL', 'LastName': 'Lu', 'Affiliation': 'Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Rd., Sanmin Dist., Kaohsiung City, 807, Taiwan.'}, {'ForeName': 'Shun-Te', 'Initials': 'ST', 'LastName': 'Huang', 'Affiliation': 'Division of Special Care Dentistry, Department of Dentistry, Kaohsiung Medical University Hospital, No.100, Tzyou 1st Rd., Sanmin Dist., Kaohsiung City, 807, Taiwan. shuntehuang@gmail.com.'}, {'ForeName': 'Ying-Chu', 'Initials': 'YC', 'LastName': 'Lin', 'Affiliation': 'School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, No.100, Shiquan 1st Rd., Sanmin Dist., Kaohsiung City, 807, Taiwan. chulin@kmu.edu.tw.'}]",BMC infectious diseases,['10.1186/s12879-020-05061-z'] 1691,32460712,Efficacy of a single dose versus a multiple dose regimen of Mebendazole against hookworm infections among school children: a randomized open-label trial.,"BACKGROUND Despite the existence of a population-based control program using single dose albendazole or mebendazole as a preventive chemotherapy, hookworm transmission remains high. It causes a negative impact on the growth and school performance of children. In connection to this preventive chemotherapy, different studies produced conflicting results. This study aimed at evaluating the efficacy of single (500 mg) versus multiple doses (100 mg twice a day during three consecutive days) of mebendazole against hookworm infections among school-aged children. METHODS This randomized open-label clinical trial took place among school-aged children (6-14 years old) in Burie and Debre Elias towns, Northwest Ethiopia. Using simple randomization, eligible hookworm-positive children were allocated (1:1) to either a single or multiple dose treatment arms. Stool samples were collected and processed using McMaster method at baseline and follow-up period (14-21 days after treatment). Only laboratory technicians were blinded. The cure and egg reduction rates were the primary and secondary therapeutic outcome measures against hookworm infections, respectively. An independent t-test was used to compare group means, and logistic regression was used to calculate odds ratio (OR). P-value < 0.05 at 95% CI was considered statistically significant. RESULT One hundred eight children, 54 in each treatment arm had completed baseline data and received allocated treatment. One hundred three children had completed follow-up data records and included for the final efficacy analysis. Cure rate against hookworm was significantly higher in the multiple dose (96.1%) than in the single dose (30.8%) with OR = 55.125; 95% CI: 11.92-254.9; P < 0.001. The egg reduction rate in the multiple dose treatment arm (99.5%) was also significantly higher than in the single dose arm (68.9%) with difference t (101) =5.38; 95% CI 230.95-505.36; P < 0.001. CONCLUSION The single dose regimen of mebendazole for the treatment of hookworm infections showed poor cure and egg reduction rates, while the multiple doses revealed satisfactory. Although multiple dose regimen administration is a bit more complex than the single dose, we strongly encourage replacing it with multiple dose regimen during deworming programs in hookworm endemic areas. TRIAL REGISTRATION This trial is retrospectively registered in www.pactr.org, number PACTR201911466695052 on November 26, 2019.",2020,Cure rate against hookworm was significantly higher in the multiple dose (96.1%) than in the single dose (30.8%) with OR = 55.125; 95% CI: 11.92-254.9; P < 0.001.,"['eligible hookworm-positive children', 'school-aged children', 'One hundred eight children, 54 in each treatment arm had completed baseline data and received allocated treatment', 'school children', 'school-aged children (6-14\u2009years old) in Burie and Debre Elias towns, Northwest Ethiopia', 'One hundred three children had completed follow-up data records and included for the final efficacy analysis']","['Mebendazole', 'albendazole or mebendazole', 'mebendazole']","['poor cure and egg reduction rates', 'cure and egg reduction rates', 'Cure rate against hookworm', 'egg reduction rate']","[{'cui': 'C0002830', 'cui_str': 'Superfamily ancylostomatoidea'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0025023', 'cui_str': 'Mebendazole'}, {'cui': 'C0001911', 'cui_str': 'Albendazole'}]","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0013710', 'cui_str': 'Eggs (edible)'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0002830', 'cui_str': 'Superfamily ancylostomatoidea'}]",108.0,0.16424,Cure rate against hookworm was significantly higher in the multiple dose (96.1%) than in the single dose (30.8%) with OR = 55.125; 95% CI: 11.92-254.9; P < 0.001.,"[{'ForeName': 'Tegegne', 'Initials': 'T', 'LastName': 'Eshetu', 'Affiliation': 'Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O.Box: 196, Gondar, Ethiopia. tegegneeshetu5@gmail.com.'}, {'ForeName': 'Mulugeta', 'Initials': 'M', 'LastName': 'Aemero', 'Affiliation': 'Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O.Box: 196, Gondar, Ethiopia.'}, {'ForeName': 'Ayalew Jejaw', 'Initials': 'AJ', 'LastName': 'Zeleke', 'Affiliation': 'Department of Medical Parasitology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O.Box: 196, Gondar, Ethiopia.'}]",BMC infectious diseases,['10.1186/s12879-020-05097-1'] 1692,32461554,Colchicine's effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial.,"OBJECTIVE Recent clinical trials have demonstrated that colchicine may have metabolic and cardiovascular and benefits in at-risk patients; however, the mechanisms through which colchicine may improve outcomes are still unclear. We sought to examine colchicine's effects on circulating inflammatory and metabolic molecules in adults with obesity and metabolic syndrome (MetS). METHODS Blood samples were collected pre- and post-intervention during a double-blind randomized controlled trial in which 40 adults with obesity and MetS were randomized to colchicine 0.6 mg or placebo twice-daily for 3 months. Serum samples were analyzed for 1305 circulating factors using the SomaScan Platform. The Benjamini-Hochberg procedure was used to adjust the false discovery rate (FDR) for multiple testing. RESULTS At baseline, age (48.0 ± 13.8 vs. 44.7 ± 10.3 years) and BMI (39.8 ± 6.4 vs. 41.8 ± 8.2 kg/m 2 ) were not different between groups. After controlling for the FDR, 34 molecules were significantly changed by colchicine. Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A). Conversely, relative to placebo, colchicine significantly increased concentrations of eight molecules including secreted factors associated with metabolism and anti-thrombosis. CONCLUSIONS In adults with obesity, colchicine significantly affected concentrations of proteins involved in the innate immune system, endothelial function and atherosclerosis, uncovering new mechanisms behind its cardiometabolic effects. Further research is warranted to investigate whether colchicine's IL-6 suppressive effects may be beneficial in COVID-19.",2020,"Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A).","['adults with obesity and metabolic syndrome', '40 adults with obesity and MetS', 'adults with obesity and metabolic syndrome (MetS', 'At baseline, age (48.0\u2009±\u200913.8 vs. 44.7\u2009±\u200910.3 years) and BMI (39.8\u2009±\u20096.4 vs. 41.8\u2009±\u20098.2\u2009kg/m 2 ']","['placebo, colchicine', 'Colchicine', 'colchicine', ""Colchicine's"", 'colchicine 0.6\u2009mg or placebo']","['concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin', 'metabolic and inflammatory molecules', 'circulating inflammatory and metabolic molecules', 'false discovery rate (FDR']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517561', 'cui_str': '13.8'}, {'cui': 'C4517519', 'cui_str': '10.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517822', 'cui_str': '6.4'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009262', 'cui_str': 'Colchicine'}, {'cui': 'C0985108', 'cui_str': 'Colchicine 0.6 MG'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0567416', 'cui_str': 'Molecule'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0963992', 'cui_str': 'Resistin'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0205557', 'cui_str': 'False positive'}]",40.0,0.602228,"Colchicine decreased concentrations of multiple inflammatory molecules, including C-reactive protein, interleukin 6, and resistin, in addition to vascular-related proteins (e.g., oxidized low-density lipoprotein receptor, phosphodiesterase 5A).","[{'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Demidowich', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA. ademido1@jh.edu.'}, {'ForeName': 'Jordan A', 'Initials': 'JA', 'LastName': 'Levine', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Apps', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Foo K', 'Initials': 'FK', 'LastName': 'Cheung', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Jinguo', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Fantoni', 'Affiliation': 'Center for Human Immunology (CHI), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, 20892, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Tushar P', 'Initials': 'TP', 'LastName': 'Patel', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}, {'ForeName': 'Jack A', 'Initials': 'JA', 'LastName': 'Yanovski', 'Affiliation': 'Section on Growth and Obesity, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892-1103, USA.'}]",International journal of obesity (2005),['10.1038/s41366-020-0598-3'] 1693,32580914,Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal: A Proof of Concept Study.,"BACKGROUND Hypersexuality and hyposexuality occur frequently, often in a variety of psychiatric disorders, and are difficult to treat. While there is meta-analytic evidence for the significant effect of non-invasive brain stimulation on drug and food craving, no study has investigated the potential of this technique to modulate sexual behavior. AIM Here, we tested the hypothesis that a single session of high-frequency repetitive transcranial magnetic stimulation (rTMS) over the dorsolateral prefrontal cortex (DLPFC) would reduce sexual arousal. METHODS We employed a randomized, double-blind, sham-controlled crossover study design. 19 healthy male participants received high-frequency rTMS over the left DLPFC, high-frequency rTMS over the right DLPFC, and sham rTMS (each 10 Hz; 110% resting motor threshold; 60 trains with 50 pulses) in randomized and counterbalanced order with a 1-week interval between stimulation sessions to avoid carryover effects. Participants were exposed to neutral and sexual cues before and after each intervention and rated their sexual arousal after each block of cue presentation. MAIN OUTCOME MEASURE Efficacy of the respective intervention was operationalized by the change of subjective sexual arousal according to a rating scale. RESULTS rTMS of the right DLPFC significantly reduced subjective sexual arousal (t 18  = 2.282, P = .035). In contrast, neither sham rTMS nor rTMS of the left DLPFC affected sexual arousal (P > .389). Greater rTMS-induced reduction of subjective sexual arousal was observed in participants with higher trait-based dyadic sexual desire within the last 12 months (r = -0.417, P = .038). CLINICAL IMPLICATION Non-invasive brain stimulation might hold potential for influencing hypersexual behavior. STRENGTH & LIMITATION This was a randomized, double-blind, sham-controlled crossover study with subjective but no physiological measures of sexual arousal. CONCLUSION The results indicate that 1 session of high-frequency rTMS (10 Hz) of the right DLPFC could significantly reduce subjective sexual arousal induced by visual stimuli in healthy subjects. On this basis, future studies with larger sample sizes and more stimulation sessions are needed to explore the therapeutic potential of rTMS in hypersexual behavior. Schecklmann M, Sakreida K, Oblinger B, et al. Repetitive Transcranial Magnetic Stimulation as a Potential Tool to Reduce Sexual Arousal: A Roof of Concept Study. J Sex Med 2020;17:1553-1559.",2020,"Greater rTMS-induced reduction of subjective sexual arousal was observed in participants with higher trait-based dyadic sexual desire within the last 12 months (r = -0.417, P = .038). ","['19 healthy male participants received', 'healthy subjects']","['high-frequency repetitive transcranial magnetic stimulation (rTMS', 'high-frequency rTMS over the left DLPFC, high-frequency rTMS over the right DLPFC, and sham rTMS', 'Repetitive Transcranial Magnetic Stimulation']","['Schecklmann M, Sakreida K, Oblinger B, et', 'subjective sexual arousal', 'Sexual Arousal', 'sexual arousal', 'dyadic sexual desire']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0233972', 'cui_str': 'Sexual excitation'}, {'cui': 'C0023618', 'cui_str': 'Libido'}]",19.0,0.181717,"Greater rTMS-induced reduction of subjective sexual arousal was observed in participants with higher trait-based dyadic sexual desire within the last 12 months (r = -0.417, P = .038). ","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schecklmann', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Sakreida', 'Affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Oblinger', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Berthold', 'Initials': 'B', 'LastName': 'Langguth', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany.'}, {'ForeName': 'Timm B', 'Initials': 'TB', 'LastName': 'Poeppl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, Germany; Department of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. Electronic address: timm.poeppl@rwth-aachen.de.'}]",The journal of sexual medicine,['10.1016/j.jsxm.2020.05.002'] 1694,30421537,Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.,"Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibrosis progression and hepatocellular carcinoma. Data were pooled from five phase 2 or 3 trials that evaluated 8-, 12- and 16-week G/P in patients with chronic HCV GT3 infection. Patients without cirrhosis or with compensated cirrhosis were either treatment-naïve or experienced with interferon- or sofosbuvir-based regimens. Safety and sustained virologic response 12 weeks post-treatment (SVR12) were assessed. The analysis included 693 patients with GT3 infection. SVR12 was achieved by 95% of treatment-naïve patients without cirrhosis receiving 8-week (198/208) and 12-week (280/294) G/P. Treatment-naïve patients with cirrhosis had a 97% (67/69) SVR12 rate with 12-week G/P. Treatment-experienced, noncirrhotic patients had SVR12 rates of 90% (44/49) and 95% (21/22) with 12- and 16-week G/P, respectively; 94% (48/51) of treatment-experienced patients with cirrhosis treated for 16 weeks achieved SVR12. No serious adverse events (AEs) were attributed to G/P; AEs leading to study drug discontinuation were rare (<1%). G/P was well-tolerated and efficacious for patients with chronic HCV GT3 infection, regardless of cirrhosis status or prior treatment experience. Eight- and 12-week durations were efficacious for treatment-naïve patients without cirrhosis and with compensated cirrhosis, respectively; 16-week G/P was efficacious in patients with prior treatment experience irrespective of cirrhosis status.",2019,"SVR12 was achieved by 95% of treatment-naïve patients without cirrhosis receiving 8-week (198/208) and 12-week (280/294) G/P. Treatment-naïve patients with cirrhosis had a 97% (67/69) SVR12 rate with 12-week G/P. Treatment-experienced, noncirrhotic patients had SVR12 rates of 90% (44/49) and 95% (21/22) with 12- and 16-week G/P, respectively; 94% (48/51) of treatment-experienced patients with cirrhosis treated for 16 weeks achieved SVR12.","['Patients without cirrhosis or with compensated cirrhosis', 'patients with chronic HCV genotype', 'patients with chronic HCV GT3 infection', '693 patients with GT3 infection']","['interferon- or sofosbuvir-based regimens', 'Glecaprevir/Pibrentasvir', 'Glecaprevir coformulated with pibrentasvir (G/P']","['SVR12', 'SVR12 rate', 'SVR12 rates', 'Safety and sustained virologic response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023890', 'cui_str': 'Cirrhosis of liver'}, {'cui': 'C1608426', 'cui_str': 'Compensated cirrhosis'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4519575', 'cui_str': 'glecaprevir and pibrentasvir'}, {'cui': 'C4519536', 'cui_str': 'glecaprevir'}, {'cui': 'C4519537', 'cui_str': 'pibrentasvir'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}]",693.0,0.0164474,"SVR12 was achieved by 95% of treatment-naïve patients without cirrhosis receiving 8-week (198/208) and 12-week (280/294) G/P. Treatment-naïve patients with cirrhosis had a 97% (67/69) SVR12 rate with 12-week G/P. Treatment-experienced, noncirrhotic patients had SVR12 rates of 90% (44/49) and 95% (21/22) with 12- and 16-week G/P, respectively; 94% (48/51) of treatment-experienced patients with cirrhosis treated for 16 weeks achieved SVR12.","[{'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Flamm', 'Affiliation': 'Northwestern Feinberg School of Medicine, Chicago, Illinois.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mutimer', 'Affiliation': 'Queen Elizabeth Hospital and NIHR Liver Biomedical Research Unit, Birmingham, UK.'}, {'ForeName': 'Armen', 'Initials': 'A', 'LastName': 'Asatryan', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Rockstroh', 'Affiliation': 'Universitätsklinikum Bonn, Bonn, Germany.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Horsmans', 'Affiliation': 'Cliniques Universitaires Saint-Luc, UCL, Brussels, Belgium.'}, {'ForeName': 'Paul Y', 'Initials': 'PY', 'LastName': 'Kwo', 'Affiliation': 'Division of Gastroenterology and Hepatology, Stanford University, Palo Alto, California.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Weiland', 'Affiliation': 'Karolinska University Hospital Huddinge at Karolinska Institute, Stockholm, Sweden.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Villa', 'Affiliation': 'University of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'Jeong', 'Initials': 'J', 'LastName': 'Heo', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Gane', 'Affiliation': 'Liver Unit, Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Ryder', 'Affiliation': 'NIHR Nottingham Biomedical Research Centre and Nottingham University Hospitals NHS Trust, Nottingham, UK.'}, {'ForeName': 'Tania M', 'Initials': 'TM', 'LastName': 'Welzel', 'Affiliation': 'JW Goethe University Hospital, Frankfurt, Germany.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Ruane', 'Affiliation': 'Ruane Medical & Liver Health Institute, Los Angeles, California.'}, {'ForeName': 'Kosh', 'Initials': 'K', 'LastName': 'Agarwal', 'Affiliation': 'Institute of Liver Studies, Kings College Hospital, London, UK.'}, {'ForeName': 'Teresa I', 'Initials': 'TI', 'LastName': 'Ng', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Zhenyi', 'Initials': 'Z', 'LastName': 'Xue', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Sandra S', 'Initials': 'SS', 'LastName': 'Lovell', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Preethi', 'Initials': 'P', 'LastName': 'Krishnan', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Kopecky-Bromberg', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Trinh', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'Federico J', 'Initials': 'FJ', 'LastName': 'Mensa', 'Affiliation': 'AbbVie Inc, North Chicago, Illinois.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Wyles', 'Affiliation': 'Denver Health Medical Center, Denver, Colorado.'}]",Journal of viral hepatitis,['10.1111/jvh.13038'] 1695,32469625,A case series of suprascapular nerve block (with an historical comparator) for shoulder pain in motor neurone disease.,"BACKGROUND Shoulder pain is a distressing but under-reported and poorly managed symptom in people with motor neurone disease. OBJECTIVES This study aimed to assess the efficacy of suprascapular nerve block for the management of shoulder pain in patients with motor neurone disease. METHODS A total of 27 patients with motor neurone disease and shoulder pain were offered a suprascapular nerve block. Ten of these patients had bilateral shoulder pain and both were injected, making a total of 37 shoulders. The patients were followed up for a total of 3 months, or until death. Shoulder pain was measured using the pain scale (out of 100) of the shoulder pain and disability index and compared with baseline scores and a placebo control group from an earlier study using the same methodology (ACTRN12619000353190). RESULTS Following the nerve block there was a significant improvement of pain scores from baseline (58.4) at week 1 (20.8, p  < 0.000), week 6 (17.6, p  < 0.000) and week 12 (30.4, p  = 0.001) and a significant improvement compared with the control group across each time interval. CONCLUSION Suprascapular nerve block is a safe, effective therapy for patients with chronic shoulder pain.",2020,"Following the nerve block there was a significant improvement of pain scores from baseline (58.4) at week 1 (20.8, p  < 0.000), week 6 (17.6, p  < 0.000) and week 12 (30.4, p  = 0.001) and a significant improvement compared with the control group across each time interval. ","['shoulder pain in motor neurone disease', 'patients with motor neurone disease', 'patients with chronic shoulder pain', 'people with motor neurone disease', '27 patients with motor neurone disease and shoulder pain']","['Suprascapular nerve block', 'suprascapular nerve block (with an historical comparator', 'suprascapular nerve block']","['pain scores', 'shoulder pain and disability index', 'Shoulder pain', 'bilateral shoulder pain', 'pain scale']","[{'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0085084', 'cui_str': 'Motor neuron disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0394703', 'cui_str': 'Injection of anesthetic agent into suprascapular nerve'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}]",27.0,0.133856,"Following the nerve block there was a significant improvement of pain scores from baseline (58.4) at week 1 (20.8, p  < 0.000), week 6 (17.6, p  < 0.000) and week 12 (30.4, p  = 0.001) and a significant improvement compared with the control group across each time interval. ","[{'ForeName': 'E Michael', 'Initials': 'EM', 'LastName': 'Shanahan', 'Affiliation': 'Department of Rheumatology, Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Glaezter', 'Affiliation': 'Department of Rheumatology, Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Tiffany', 'Initials': 'T', 'LastName': 'Gill', 'Affiliation': 'Discipline of Medicine, The University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Hill', 'Affiliation': 'Discipline of Medicine, The University of Adelaide, Adelaide, SA, Australia.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Graf', 'Affiliation': 'Department of Rheumatology, Flinders University and Flinders Medical Centre, Adelaide, SA, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Allcroft', 'Affiliation': 'Southern Adelaide Local Health Network, Adelaide, SA, Australia.'}]",Palliative medicine,['10.1177/0269216320929553'] 1696,32469893,Acceptability and tolerability of repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine among healthy African participants in a phase 1 randomized controlled trial.,"INTRODUCTION Intramuscular electroporation (IM/EP) is a vaccine delivery technique that improves the immunogenicity of DNA vaccines. We evaluated the acceptability and tolerability of electroporation among healthy African study participants. METHODS Forty-five participants were administered a DNA vaccine (HIV-MAG) or placebo by electroporation at three visits occurring at four week-intervals. At the end of each visit, participants were asked to rate pain at four times: (1) when the device was placed on the skin and vaccine injected, before the electrical stimulation, (2) at the time of electrical stimulation and muscle contraction, and (3) at 10 minutes and (4) 30 minutes after the procedure was completed. For analyses, pain level was dichotomized as either ""acceptable"" (none/slight/uncomfortable) or ""too much"" (Intense, severe, and very severe) and examined over time using repeated measures models. Optional brief comments made by participants were summarized anecdotally. RESULTS All 45 participants completed all three vaccination visits; none withdrew from the study due to the electroporation procedure. Most (76%) reported pain levels as acceptable at every time point across all vaccination visits. The majority of ""unacceptable"" pain was reported at the time of electrical stimulation. The majority of the participants (97%) commented that they preferred electroporation to standard injection. CONCLUSION Repeated intramuscular electroporation for vaccine delivery was found to be acceptable and feasible among healthy African HIV vaccine trial participants. The majority of participants reported an acceptable pain level at all vaccination time points. Further investigation may be warranted into the value of EP to improve immunization outcomes. ClinicalTrials.gov NCT01496989.",2020,The majority of participants reported an acceptable pain level at all vaccination time points.,"['All 45 participants completed all three vaccination visits; none withdrew from the study due to the electroporation procedure', 'Forty-five participants', 'healthy African participants', 'healthy African study participants', 'healthy African HIV vaccine trial participants']","['DNA vaccine (HIV-MAG) or placebo', 'repeated intramuscular electroporation of Multi-antigenic HIV (HIVMAG) DNA vaccine', 'Intramuscular electroporation (IM/EP']","['Acceptability and tolerability', 'acceptability and tolerability of electroporation', 'pain level', 'rate pain', 'pain levels', 'acceptable pain level']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0424092', 'cui_str': 'Withdrawn'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0376613', 'cui_str': 'DNA Vaccines'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0129439', 'cui_str': 'Myelin associate glycoprotein'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0486959', 'cui_str': 'Human immunodeficiency virus DNA'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0206691', 'cui_str': 'Electropermeabilisation'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}]",45.0,0.16596,The majority of participants reported an acceptable pain level at all vaccination time points.,"[{'ForeName': 'Juliet', 'Initials': 'J', 'LastName': 'Mpendo', 'Affiliation': 'Uganda Virus Research Institute-International AIDS Vaccine Initiative, HIV Vaccine Program, Entebbe, Uganda.'}, {'ForeName': 'Gaudensia', 'Initials': 'G', 'LastName': 'Mutua', 'Affiliation': 'Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Annet', 'Initials': 'A', 'LastName': 'Nanvubya', 'Affiliation': 'Uganda Virus Research Institute-International AIDS Vaccine Initiative, HIV Vaccine Program, Entebbe, Uganda.'}, {'ForeName': 'Omu', 'Initials': 'O', 'LastName': 'Anzala', 'Affiliation': 'Kenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Nyombayire', 'Affiliation': 'Project San Francisco (PSF), Kigali, Rwanda.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Karita', 'Affiliation': 'Project San Francisco (PSF), Kigali, Rwanda.'}, {'ForeName': 'Len', 'Initials': 'L', 'LastName': 'Dally', 'Affiliation': 'EMMES Corporation, Rockville, Maryland, United States of America.'}, {'ForeName': 'Drew', 'Initials': 'D', 'LastName': 'Hannaman', 'Affiliation': 'Ichor Medical Systems, Inc., San Diego, California, United States of America.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Price', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Patricia E', 'Initials': 'PE', 'LastName': 'Fast', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Priddy', 'Affiliation': 'International AIDS Vaccine Initiative (IAVI), New York, NY, United States of America.'}, {'ForeName': 'Huub C', 'Initials': 'HC', 'LastName': 'Gelderblom', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.'}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Hills', 'Affiliation': 'University of California at San Francisco, San Francisco, California, United States of America.'}]",PloS one,['10.1371/journal.pone.0233151'] 1697,32469906,"Training intervention to improve hygiene practices in Islamic boarding school in Yogyakarta, Indonesia: A mixed-method study.","BACKGROUND The primary objective of this study was to determine the effect of a training intervention in overall improvement in students' (santris) knowledge, behavior, and outcome. METHODS A mixed-methods exploratory sequential design was applied. First, qualitative data were collected from three focus group discussions with 20 supervisors and one in-depth interview with school principal to explore current hygiene practices. The information was then used to develop training intervention using either video, poster, and leaflet. To measure the effect, a stepped wedge cluster design with pre- and post-test analyses was conducted. A total of 452 junior high school santris in one Islamic boarding school were non-randomly allocated to either three intervention groups. Outcome measures were knowledge, personal behavior, and room hygiene. Codes and categories were produced in the qualitative analysis, while paired t-tests and Wilcoxon rank tests test were used in the quantitative analysis. RESULTS The qualitative study identified poor practices on personal and room hygiene among the santris and proposed a training intervention. Overall, there was a significant increase in knowledge and personal behavior after the intervention (7.22 ± 1.34 pre-intervention to 7.70 ± 0.74 post-intervention and 9.75 ± 2.98 pre-intervention to 12.16 ± 2.12 post-intervention, respectively, p < 0.001). Room hygiene was significantly improved among boys and those who received leaflets. CONCLUSION Having developed a specific training materials, school-based hygiene training intervention improved knowledge and personal behavior. Its effect on room hygiene particularly for female santris needs further strengthening of the intervention in this Islamic boarding school setting.",2020,"Overall, there was a significant increase in knowledge and personal behavior after the intervention (7.22 ± 1.34 pre-intervention to 7.70 ± 0.74 post-intervention and 9.75 ± 2.98 pre-intervention to 12.16 ± 2.12 post-intervention, respectively, p < 0.001).","['Islamic boarding school in Yogyakarta, Indonesia', '452 junior high school santris in one Islamic boarding school']","['training intervention', 'Training intervention']","[""overall improvement in students' (santris) knowledge, behavior, and outcome"", 'knowledge and personal behavior', 'Room hygiene', 'knowledge, personal behavior, and room hygiene']","[{'cui': 'C0022126', 'cui_str': 'Islam'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0021247', 'cui_str': 'Indonesia'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]",452.0,0.0218919,"Overall, there was a significant increase in knowledge and personal behavior after the intervention (7.22 ± 1.34 pre-intervention to 7.70 ± 0.74 post-intervention and 9.75 ± 2.98 pre-intervention to 12.16 ± 2.12 post-intervention, respectively, p < 0.001).","[{'ForeName': 'Vita', 'Initials': 'V', 'LastName': 'Widyasari', 'Affiliation': 'International Health, Public Health Graduate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Yayi Suryo', 'Initials': 'YS', 'LastName': 'Prabandari', 'Affiliation': 'Department of Health Behavior, Environment, and Social Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Utarini', 'Affiliation': 'Department of Health Policy and Management, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.'}]",PloS one,['10.1371/journal.pone.0233267'] 1698,32473365,Central nervous system activities of extract Mangifera indica L.,"ETHNOBOTANICAL RELEVANCE Leaves of Mangifera indica L. have folk-uses in tropical regions of the world as health teas, as a remedy for exhaustion and fatigue, as a vegetable, and as a medicine. Mangifera indica leaf extract (MLE) had previously been demonstrated to alter brain electrical activity in-vivo. The aim of the present series of studies was to investigate whether mangiferin, a major compound in leaves and in MLE, is responsible for the neurocognitive activity of MLE, and if the CNS activities of MLE have translational potential. MATERIALS AND METHODS MLE, tradename Zynamite, is produced by Nektium Pharma, Spain. Isolated mangiferin was tested in-vitro in radioligand binding and enzyme inhibition studies against 106 CNS targets. Changes in the electroencephalograms (EEG's) of MLE and mangiferin were recorded in-vivo from four brain regions. Two double blind randomized placebo-controlled crossover clinical trials were conducted, each with 16 subjects. At 90 min and at 60 min respectively, after oral intake of 500 mg MLE, EEG recordings, psychometric tests, mood state, and tolerability were studied. RESULTS Isolated mangiferin is a selective inhibitor of catechol-O-methyltransferase (COMT) with an IC50 of 1.1 μM, with no activity on the CNS targets of caffeine. Both mangiferin and MLE induce similar changes in long-term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo. In both translational clinical trials MLE was well tolerated, with no cardiovascular side-effects. In both studies MLE caused significant spectral changes in brain electrical activity in cortical regions during cognitive challenges, different to the attenuated spectral changes induced by caffeine. There were no significant changes in the psychometric tests other than reaction time for all groups. In the second study there was a trend to faster reaction time within group for MLE (p = 0.066) and the percentage improvement in reaction time for MLE compared to placebo was significant (p = 0.049). In the first study MLE improved all scores for Profile of Mood States (POMS), with the score for ""fatigue"" significantly improved (p = 0.015); in the second study the POMS score for ""dejection"" was improved in the caffeine group, p = 0.05. CONCLUSIONS Mangiferin is a COMT inhibitor of moderate potency and is the major CNS-active compound in MLE. Both mangiferin and MLE increase hippocampal LTP in-vitro, and induce a similar pattern of changes in brain electrical activity in-vivo. While the translational clinical trials of MLE are limited by being single dose studies in a small number of subjects, they provide the first clinical evidence that the extract is well tolerated with no cardiovascular side-effects, can induce changes in brain electrical activity, may give a faster reaction time, and decrease fatigue. These CNS activities support the reported folk-uses use of mango leaf tea as a substitute for tea and as a traditional remedy for fatigue and exhaustion. Extract Mangifera indica L., Zynamite, has nootropic potential, and larger clinical studies are needed to realise this potential.",2020,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.",['16 subjects'],"['Mangifera indica leaf extract (MLE', 'caffeine', 'mangiferin and MLE', 'MLE', 'extract Mangifera indica L', 'placebo']","['fatigue', 'POMS score for ""dejection', 'Profile of Mood States (POMS', 'brain electrical activity', 'psychometric tests, mood state, and tolerability', 'reaction time for MLE', 'faster reaction time']",[],"[{'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0065654', 'cui_str': 'mangiferin'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0330955', 'cui_str': 'Mangifera indica'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0234388', 'cui_str': 'Electrical activity of brain'}, {'cui': 'C0033920', 'cui_str': 'Psychometric testing'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]",,0.0364453,"Both mangiferin and MLE induce similar changes in long term potentiation (LTP) in the hippocampus in-vitro, and induce a similar pattern of EEG changes in-vivo.","[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'López-Ríos', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: llopez@nektium.com.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'Wiebe', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: jwiebe@nektium.com.'}, {'ForeName': 'Tanausú', 'Initials': 'T', 'LastName': 'Vega-Morales', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain. Electronic address: tvega@nektium.com.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Gericke', 'Affiliation': 'Department of Research, Development and Innovation, Nektium Pharma SL, 35118, Las Palmas de Gran Canaria, Spain; Department of Botany and Plant Biotechnology, University of Johannesburg, Auckland Park, 2006, Johannesburg, South Africa. Electronic address: ngericke@nektium.com.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.112996'] 1699,32473403,Testing a self-directed lifestyle intervention among veterans: The D-ELITE pragmatic clinical trial.,"Nearly half of Veterans have obesity, fueling chronic diseases. The Department of Veterans Affairs (VA) offers an evidence-based behavioral weight management intervention called MOVE!, mostly delivered through in-person group sessions. Few eligible Veterans participate due to factors like distance and preferences, mirroring barriers in the general population. Practical alternatives to standard in-person programs are needed to improve access and engagement. A self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious in a general primary care population, may provide such an alternative. This pragmatic clinical trial will evaluate whether D-ELITE improves weight and general health status among Veterans with obesity, relative to VA usual care. The yearlong intervention includes one orientation by phone, supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions over 3 months, and continued self-directed weight management for months 4-12. Participants use MyFitnessPal.com or paper booklets for self-monitoring weight, diet, and physical activity. Follow-up assessments at 12 and 24 months are administered by mail or phone. The study hypothesis is that compared with usual care, D-ELITE will lead to greater improvements in 12-month weight loss, per VA electronic health records, and general physical health status, assessed using the self-reported SF-12 physical composite score. We will also explore D-ELITE's effects on secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact. If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.",2020,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","['veterans', 'Veterans with obesity, relative to VA usual care']","['supplemental lifestyle coaching primarily via technology-based messages, 12 DVD or online streaming sessions', 'self-directed lifestyle intervention', 'self-directed lifestyle intervention called D-ELITE-delivered through pre-recorded videos by DVD or online streaming-previously efficacious']","['secondary biometric (e.g., HbA1c) and intermediate (e.g., diet) outcomes, reach, and budget impact', 'weight and general health status']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0006347', 'cui_str': 'Budgets'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",,0.02449,"If effective, D-ELITE will offer a potentially scalable, low-cost alternative to VA's existing weight loss interventions by mitigating barriers presented by distance and technology.","[{'ForeName': 'Katherine D', 'Initials': 'KD', 'LastName': 'Hoerster', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; VA Puget Sound Healthcare System, Seattle Division, Mental Health Service, 1660 South Columbian Way (S-116), Seattle, WA 98108, United States; University of Washington, Department of Psychiatry and Behavioral Sciences, 1100 NE 45(th) Street, Suite 300, Seattle, WA 98105, United States. Electronic address: Katherine.Hoerster@va.gov.'}, {'ForeName': 'Margaret P', 'Initials': 'MP', 'LastName': 'Collins', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Margaret.Collins@va.gov.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Au', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: David.Au@va.gov.'}, {'ForeName': 'Amber', 'Initials': 'A', 'LastName': 'Lane', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Amber.Lane2@va.gov.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Epler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Eric.Epler@va.gov.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'McDowell', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Jennifer.McDowell@va.gov.'}, {'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Barón', 'Affiliation': 'Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 13001 E. 17(th) Place, Aurora, CO 80045, United States. Electronic address: Anna.Baron@cuanschutz.edu.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rise', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Peter.Rise@va.gov.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Plumley', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Robert.Plumley@va.gov.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Nguyen', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Tanya.Nguyen@va.gov.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Schooler', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States. Electronic address: Mary.Schooler@va.gov.'}, {'ForeName': 'Linnaea', 'Initials': 'L', 'LastName': 'Schuttner', 'Affiliation': 'VA Puget Sound Healthcare System, Seattle Division, Health Services Research and Development, 1660 South Columbian Way (S-152), Seattle, WA 98108, United States; University of Washington, Department of Medicine, 1959 NE Pacific St, Seattle, WA 98195, United States. Electronic address: Linnaea.Schuttner@va.gov.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': 'University of Illinois at Chicago, Department of Medicine, 1747 W. Roosevelt Rd, Room 586 (MC 275), Chicago, IL 60608, United States. Electronic address: maj2015@uic.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106045'] 1700,32475085,The Weight Optimization Revamping Lifestyle using the Dietary Guidelines (WORLD) Study: Sustained Weight Loss Over 12 Months.,"OBJECTIVE This study aimed to compare two energy-restricted, nutrient-dense diets at the upper or lower ends of the dietary fat recommendation range (lower fat [20% energy from fat] versus moderate fat [35%]) on weight loss using behavioral theory-based nutrition education. METHODS A total of 101 premenopausal women with overweight or obesity were randomized to an energy-restricted lower-fat or moderate-fat diet for 1 year. Interventions included 28 behavioral theory-based nutrition education sessions plus weekly exercise sessions. RESULTS Both treatment groups experienced weight loss (-5.0 kg for lower fat and -4.3 kg for moderate fat; P < 0.0001), but there was no difference in weight loss or fat intake between groups. Total and low-density lipoprotein cholesterol decreased (-3. 4 mg/dL and -3.8 mg/dL; P < 0.05), and high-density lipoprotein cholesterol increased (1.9 mg/dL; P < 0.05) in both groups at 12 months. Diet quality, assessed by the Healthy Eating Index, increased significantly at 4 months versus baseline (70.8 [0.9] vs. 77.8 [1.0]) and was maintained through 12 months. Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). CONCLUSIONS In the context of a well-resourced, free-living weight-loss intervention, total fat intake did not change; however, theory-based nutrition education underpinned by food-based recommendations resulted in caloric deficits, improvements in diet quality, and weight loss that was sustained for 1 year.",2020,"Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). ",['101 premenopausal women with overweight or obesity'],"['28 behavioral theory-based nutrition education sessions plus weekly exercise sessions', 'energy-restricted lower-fat or moderate-fat diet for 1 year']","['Weight Loss', 'Diet quality', 'diet quality, and weight loss', 'high-density lipoprotein cholesterol', 'weight loss', 'Healthy Eating Index', 'weight loss or fat intake', 'Higher Healthy Eating Index scores', 'Total and low-density lipoprotein cholesterol']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0242970', 'cui_str': 'Low fat diet'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0301585', 'cui_str': 'Fat diet'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C4280021', 'cui_str': 'Healthy Eating Index'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",101.0,0.0236992,"Higher Healthy Eating Index scores were associated with greater weight loss at 4 months (r = -0.2; P < 0.05). ","[{'ForeName': 'Tricia L', 'Initials': 'TL', 'LastName': 'Psota', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Tindall', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Lohse', 'Affiliation': 'Wegmans School of Health and Nutrition, Rochester Institute of Technology, Rochester, New York, USA.'}, {'ForeName': 'Paige E', 'Initials': 'PE', 'LastName': 'Miller', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Kristina S', 'Initials': 'KS', 'LastName': 'Petersen', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}, {'ForeName': 'Penny M', 'Initials': 'PM', 'LastName': 'Kris-Etherton', 'Affiliation': 'Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22824'] 1701,32602803,Participant Satisfaction and Acceptability of a Culturally Adapted Brief Intervention to Reduce Unhealthy Alcohol Use Among Latino Immigrant Men.,"Latino immigrant men are at increased risk for unhealthy alcohol use, yet few interventions have been designed to meet their unique needs. The current study assessed participant satisfaction and acceptability of a culturally adapted brief intervention to reduce unhealthy alcohol use in this population. Adaptations to the brief intervention included delivering it in Spanish by promotores in a community setting. The mixed methods approach included surveys ( N = 73) and in-depth interviews ( N = 20) with participants in a pilot randomized controlled trial. The study drew on Sekhon's theoretical framework of acceptability to asses affective attitude, burden, and perceived effectiveness of the intervention, along with satisfaction with the content, setting, and promotor . Participants' survey responses indicated that they were highly satisfied with the content, setting, and delivery of the brief intervention. In interviews participants noted that the brief intervention helped them reflect on their drinking behaviors, that they perceived promotores to be a trusted source of health information, and that they liked receiving personalized feedback via tablets. Some participants found the feedback did not match their own perceptions of their alcohol use and wanted clearer advice on how to reduce their drinking. Men felt they would benefit from more contact with promotores . These findings suggest that Latino immigrant men in this study were receptive to the culturally adapted brief intervention. Future interventions may be more effective if they include multiple contacts with promotores and more directive guidance on strategies to reduce drinking.",2020,The current study assessed participant satisfaction and acceptability of a culturally adapted brief intervention to reduce unhealthy alcohol use in this population.,"['Latino Immigrant Men', 'Latino immigrant men']",['Culturally Adapted Brief Intervention to Reduce Unhealthy Alcohol Use'],[],"[{'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0282163', 'cui_str': 'Immigrant'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",[],,0.0241914,The current study assessed participant satisfaction and acceptability of a culturally adapted brief intervention to reduce unhealthy alcohol use in this population.,"[{'ForeName': 'Vanessa N', 'Initials': 'VN', 'LastName': 'Torres', 'Affiliation': 'Department of Health Services, University of Washington, Seattle, USA.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Williams', 'Affiliation': 'Department of Health Services, University of Washington, Seattle, USA.'}, {'ForeName': 'Rachel M', 'Initials': 'RM', 'LastName': 'Ceballos', 'Affiliation': 'Department of Health Services, University of Washington, Seattle, USA.'}, {'ForeName': 'Dennis M', 'Initials': 'DM', 'LastName': 'Donovan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA.'}, {'ForeName': 'India J', 'Initials': 'IJ', 'LastName': 'Ornelas', 'Affiliation': 'Department of Health Services, University of Washington, Seattle, USA.'}]",American journal of men's health,['10.1177/1557988320925652'] 1702,32599815,"Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial.","OBJECTIVES To analyze the use and prognostic impact of active mechanical circulatory support (MCS) devices in a large prospective contemporary cohort of patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). BACKGROUND Although increasingly used in clinical practice, data on the efficacy and safety of active MCS devices in patients with CS complicating AMI are limited. METHODS This is a predefined subanalysis of the CULPRIT-SHOCK randomized trial and prospective registry. Patients with CS, AMI and multivessel coronary artery disease were categorized in two groups: (1) use of at least one active MCS device vs. (2) no active MCS or use of intra-aortic balloon pump (IABP) only. The primary endpoint was a composite of all-cause death or renal replacement therapy at 30 days. RESULTS Two hundred of 1055 (19%) patients received at least one active MCS device ( n = 112 Impella ® ; n = 95 extracorporeal membrane oxygenation (ECMO); n = 6 other devices). The primary endpoint occurred significantly more often in patients treated with active MCS devices compared with those without active MCS devices (142 of 197, 72% vs. 374 of 827, 45%; p < 0.001). All-cause mortality and bleeding rates were significantly higher in the active MCS group (all p < 0.001). After multivariable adjustment, the use of active MCS was significantly associated with the primary endpoint (odds ratio (OR) 4.0, 95% confidence interval (CI) 2.7-5.9; p < 0.001). CONCLUSIONS In the CULPRIT-SHOCK trial, active MCS devices were used in approximately one fifth of patients. Patients treated with active MCS devices showed worse outcome at 30 days and 1 year.",2020,All-cause mortality and bleeding rates were significantly higher in the active MCS group (,"['patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI', 'Patients with CS, AMI and multivessel coronary artery disease', 'patients with CS complicating AMI', 'Cardiogenic Shock Complicating Acute Myocardial Infarction', 'Two hundred of 1055 (19%) patients received at least one active MCS device ( n = 112 Impella ® ; n = 95']","['active MCS devices', 'active mechanical circulatory support (MCS) devices', 'active MCS', 'active MCS device vs. (2) no active MCS or use of intra-aortic balloon pump (IABP', 'Active Mechanical Circulatory Support', 'extracorporeal membrane oxygenation (ECMO); n = 6 other devices']","['mortality and bleeding rates', 'composite of all-cause death or renal replacement therapy at 30 days']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036980', 'cui_str': 'Cardiogenic shock'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C4319548', 'cui_str': '112'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0021860', 'cui_str': 'Cardioassist by aortic balloon pump'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",,0.380042,All-cause mortality and bleeding rates were significantly higher in the active MCS group (,"[{'ForeName': 'Hans-Josef', 'Initials': 'HJ', 'LastName': 'Feistritzer', 'Affiliation': 'Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, 04289 Leipzig, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Desch', 'Affiliation': 'Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, 04289 Leipzig, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Freund', 'Affiliation': 'Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, 04289 Leipzig, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Poess', 'Affiliation': 'Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, 04289 Leipzig, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Zeymer', 'Affiliation': 'Institut für Herzinfarktforschung GmbH, IHF, 67063 Ludwigshafen, Germany.'}, {'ForeName': 'Taoufik', 'Initials': 'T', 'LastName': 'Ouarrak', 'Affiliation': 'Institut für Herzinfarktforschung GmbH, IHF, 67063 Ludwigshafen, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Schneider', 'Affiliation': 'Institut für Herzinfarktforschung GmbH, IHF, 67063 Ludwigshafen, Germany.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'de Waha-Thiele', 'Affiliation': 'Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, University Hospital Schleswig-Holstein, 23538 Lübeck, Germany.'}, {'ForeName': 'Georg', 'Initials': 'G', 'LastName': 'Fuernau', 'Affiliation': 'Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, University Hospital Schleswig-Holstein, 23538 Lübeck, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Eitel', 'Affiliation': 'Department of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lübeck, University Hospital Schleswig-Holstein, 23538 Lübeck, Germany.'}, {'ForeName': 'Marko', 'Initials': 'M', 'LastName': 'Noc', 'Affiliation': 'University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.'}, {'ForeName': 'Janina', 'Initials': 'J', 'LastName': 'Stepinska', 'Affiliation': 'Institute of Cardiology, 04-628 Warsaw, Poland.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': 'Department of Cardiology, Wilhelminenspital and Sigmund Freud University, Medical School, 1160 Vienna, Austria.'}, {'ForeName': 'Holger', 'Initials': 'H', 'LastName': 'Thiele', 'Affiliation': 'Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig and Leipzig Heart Institute, 04289 Leipzig, Germany.'}]",Journal of clinical medicine,['10.3390/jcm9061976'] 1703,32608166,Safety and efficacy of platelet-rich plasma vs carboxytherapy in the treatment of atrophic scars: A comparative clinical and histopathological study.,"Atrophic scars that occur after surgical procedure or trauma are considered as a cosmetic problem for patients. Atrophic scarring results usually during wound healing with inadequate production of collagen and connective tissue. Factors that precipitate to the formation of depressed scars include: individual variations in wound healing, wound tension, tissue apposition, and scar contraction. To evaluate the safety and efficacy of PRP vs carboxytherapy in treatment of atrophic scars. This study included 40 patients with atrophic scars divided into two groups; group A including 20 patients received PRP injection, group B including 20 patients received CO 2 injection. They received the treatment every 4 weeks for four sessions and had follow up for 6 months after the end of treatment. Skin biopsies were taken before and after treatment to evaluate clinical results. There was statistically significant difference between both groups in treating atrophic scars, regarding clinical improvement and patients' satisfaction with better results in group B. Histopathological examination showed significant expression of MMP-1 in group B more than group A. Both methods were safe and effective with minimal side effects with better improvement in patients treated with carboxytherapy than those treated with PRP.",2020,"There was statistically significant difference between both groups in treating atrophic scars, regarding clinical improvement and patients' satisfaction with better results in group B. Histopathological examination showed significant expression of MMP-1 in group B more than group A. CONCLUSIONS ","['Atrophic Scars', '40 patients with atrophic scars divided into 2 groups; group A including 20 patients received']","['Platelet Rich Plasma Versus Carboxytherapy', 'PRP', 'carboxytherapy', 'CO2 injection', 'PRP injection', 'PRP versus carboxytherapy']","['safety and efficacy', 'wound healing, wound tension, tissue apposition, and scar contraction', 'treating atrophic scars', 'expression of MMP-1']","[{'cui': 'C0162154', 'cui_str': 'Atrophic scar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0032027', 'cui_str': 'Pityriasis rubra pilaris'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0162154', 'cui_str': 'Atrophic scar'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C2001899', 'cui_str': 'MMP1 protein, human'}]",40.0,0.0223083,"There was statistically significant difference between both groups in treating atrophic scars, regarding clinical improvement and patients' satisfaction with better results in group B. Histopathological examination showed significant expression of MMP-1 in group B more than group A. CONCLUSIONS ","[{'ForeName': 'Samia O', 'Initials': 'SO', 'LastName': 'Nassar', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Rania A R', 'Initials': 'RAR', 'LastName': 'Eltatawy', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}, {'ForeName': 'Ghada F R', 'Initials': 'GFR', 'LastName': 'Hassan', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Tanta University, Tanta, Egypt.'}]",Dermatologic therapy,['10.1111/dth.13942'] 1704,32471973,The neuropeptide substance P regulates aldosterone secretion in human adrenals.,"Aldosterone, produced by the adrenals and under the control of plasma angiotensin and potassium levels, regulates hydromineral homeostasis and blood pressure. Here we report that the neuropeptide substance P (SP) released by intraadrenal nerve fibres, stimulates aldosterone secretion via binding to neurokinin type 1 receptors (NK1R) expressed by aldosterone-producing adrenocortical cells. The action of SP is mediated by the extracellular signal-regulated kinase pathway and involves upregulation of steroidogenic enzymes. We also conducted a prospective proof-of-concept, double blind, placebo-controlled clinical trial aimed to investigate the impact of the NK1R antagonist aprepitant on aldosterone secretion in healthy male volunteers (EudraCT: 2008-003367-40, ClinicalTrial.gov: NCT00977223). Participants received during two 7-day treatment periods aprepitant (125 mg on the 1 st day and 80 mg during the following days) or placebo in a random order at a 2-week interval. The primary endpoint was plasma aldosterone levels during posture test. Secondary endpoints included basal aldosterone alterations, plasma aldosterone variation during metoclopramide and hypoglycaemia tests, and basal and stimulated alterations of renin, cortisol and ACTH during the three different stimulatory tests. The safety of the treatment was assessed on the basis of serum transaminase measurements on days 4 and 7. All pre-specified endpoints were achieved. Aprepitant decreases aldosterone production by around 30% but does not influence the aldosterone response to upright posture. These results indicate that the autonomic nervous system exerts a direct stimulatory tone on mineralocorticoid synthesis through SP, and thus plays a role in the maintenance of hydromineral homeostasis. This regulatory mechanism may be involved in aldosterone excess syndromes.",2020,Aprepitant decreases aldosterone production by around 30% but does not influence the aldosterone response to upright posture.,"['healthy male volunteers (EudraCT', 'human adrenals']","['NK1R antagonist aprepitant', 'Aldosterone', 'neuropeptide substance P (SP', 'placebo']","['plasma aldosterone levels', 'aldosterone secretion', 'aldosterone production', 'plasma angiotensin and potassium levels, regulates hydromineral homeostasis and blood pressure', 'basal aldosterone alterations, plasma aldosterone variation during metoclopramide and hypoglycaemia tests, and basal and stimulated alterations of renin, cortisol and ACTH']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0001625', 'cui_str': 'Adrenal structure'}]","[{'cui': 'C0038581', 'cui_str': 'Neurokinin alpha'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C4543207', 'cui_str': 'Receptor antagonist'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C0002006', 'cui_str': 'Aldosterone'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C0038585', 'cui_str': 'Substance P'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1272143', 'cui_str': 'Plasma aldosterone level'}, {'cui': 'C0002006', 'cui_str': 'Aldosterone'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003018', 'cui_str': 'Angiotensin'}, {'cui': 'C0202194', 'cui_str': 'Potassium measurement'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0857639', 'cui_str': 'Plasma aldosterone'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0025853', 'cui_str': 'Metoclopramide'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0001655', 'cui_str': 'Corticotropin'}]",,0.0620632,Aprepitant decreases aldosterone production by around 30% but does not influence the aldosterone response to upright posture.,"[{'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Wils', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Duparc', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Anne-Françoise', 'Initials': 'AF', 'LastName': 'Cailleux', 'Affiliation': 'Rouen University Hospital, Department of Endocrinology, Diabetes and Metabolic Diseases, 76000, Rouen, France.'}, {'ForeName': 'Antoine-Guy', 'Initials': 'AG', 'LastName': 'Lopez', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Guiheneuf', 'Affiliation': 'Rouen University Hospital, Department of Endocrinology, Diabetes and Metabolic Diseases, 76000, Rouen, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Boutelet', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Hadrien-Gaël', 'Initials': 'HG', 'LastName': 'Boyer', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Dubessy', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Saloua', 'Initials': 'S', 'LastName': 'Cherifi', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Cauliez', 'Affiliation': 'Rouen University Hospital, Department of Biochemistry, 76000, Rouen, France.'}, {'ForeName': 'Françoise', 'Initials': 'F', 'LastName': 'Gobet', 'Affiliation': 'Rouen University Hospital, Department of Pathology, 76000, Rouen, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Defortescu', 'Affiliation': 'Rouen University Hospital, Department of Urology, 76000, Rouen, France.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Ménard', 'Affiliation': 'Rouen University Hospital, Department of Biostatistics, 76000, Rouen, France.'}, {'ForeName': 'Estelle', 'Initials': 'E', 'LastName': 'Louiset', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France.'}, {'ForeName': 'Hervé', 'Initials': 'H', 'LastName': 'Lefebvre', 'Affiliation': 'Normandie Univ, UNIROUEN, INSERM, DC2N, 76000, Rouen, France. herve.lefebvre@chu-rouen.fr.'}]",Nature communications,['10.1038/s41467-020-16470-8'] 1705,32469870,"Effect of a nutrient-rich, food-based supplement given to rural Vietnamese mothers prior to and/or during pregnancy on birth outcomes: A randomized controlled trial.","Obtaining a nutrient-rich diet during pregnancy is a challenge for pregnant women living in low-income countries. This randomized, controlled trial was designed to determine if a freshly prepared food supplement from local animal-source foods and dark-green leafy vegetables given prior to and/or during pregnancy improved birth outcomes in rural Vietnamese women. Primiparous women, 18 to 30 years of age, who participated in the study were assigned to one of three groups: PC-T women received the supplement from pre-conception to term, MG-T women received the supplement from mid-gestation to term, and the RPC women received routine prenatal care. Supplement intake was observed and quantified. Infant anthropometry was measured at birth and/or within seven days of delivery. The effect of the intervention on maternal and birth outcomes was determined using linear regression modeling. Of the 460 women enrolled in the study, 317 women completed the study. Those not completing the study had either moved from the area, did not conceive within 12 months of study enrollment, or miscarried. The food-based supplement increased protein, iron, zinc, folate, vitamin A and B12 intakes in the PC-T and the MG-T groups. However, it failed to alter infant anthropometric measurements at birth. In the entire cohort, maternal gestational weight gain was greater in women with a low pre-pregnancy BMI (<18.5) and in women with a higher educational attainment. Working as a farmer reduced gestational weight gain but it did not affect birth weight or length. In summary, a nutrient-rich, food-based supplement given to rural Vietnamese women from pre-conception to term or mid-gestation to term did not affect maternal or infant outcomes. The low weight gains, possibly due to demanding farm work done throughout the reproductive cycle, may have obviated any effects of the low energy, nutrient-rich food supplement on birth outcomes. Trial registration : Registered Clinical Trials.gov: NCT01235767.",2020,"The food-based supplement increased protein, iron, zinc, folate, vitamin A and B12 intakes in the PC-T and the MG-T groups.","['rural Vietnamese women', 'pregnant women living in low-income countries', 'Primiparous women, 18 to 30 years of age, who participated in the study', 'rural Vietnamese mothers prior to and/or during pregnancy on birth outcomes', '460 women enrolled in the study, 317 women completed the study']","['freshly prepared food supplement from local animal-source foods and dark-green leafy vegetables', 'nutrient-rich, food-based supplement', 'nutrient-rich diet', 'PC-T women received the supplement from pre-conception to term, MG-T women received the supplement from mid-gestation to term, and the RPC women received routine prenatal care']","['protein, iron, zinc, folate, vitamin A and B12 intakes', 'maternal gestational weight gain', 'low weight gains', 'gestational weight gain', 'maternal and birth outcomes', 'birth weight or length']","[{'cui': 'C0042660', 'cui_str': 'Vietnamese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0033150', 'cui_str': 'Para 1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0003062', 'cui_str': 'Kingdom Animalia'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}, {'cui': 'C2348897', 'cui_str': 'Green leafy vegetable'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0009637', 'cui_str': 'Conception'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}, {'cui': 'C0231246', 'cui_str': 'Failure to gain weight'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",317.0,0.162934,"The food-based supplement increased protein, iron, zinc, folate, vitamin A and B12 intakes in the PC-T and the MG-T groups.","[{'ForeName': 'Hoang T', 'Initials': 'HT', 'LastName': 'Nga', 'Affiliation': 'National Institute of Nutrition, Hanoi, Vietnam.'}, {'ForeName': 'Phi N', 'Initials': 'PN', 'LastName': 'Quyen', 'Affiliation': 'National Institute of Nutrition, Hanoi, Vietnam.'}, {'ForeName': 'Benjamin W', 'Initials': 'BW', 'LastName': 'Chaffee', 'Affiliation': 'University of California San Francisco, San Francisco, CA, United States of America.'}, {'ForeName': 'Nguyen T', 'Initials': 'NT', 'LastName': 'Diep Anh', 'Affiliation': 'National Institute of Nutrition, Hanoi, Vietnam.'}, {'ForeName': 'Tu', 'Initials': 'T', 'LastName': 'Ngu', 'Affiliation': 'National Institute of Nutrition, Hanoi, Vietnam.'}, {'ForeName': 'Janet C', 'Initials': 'JC', 'LastName': 'King', 'Affiliation': ""Children's Hospital Oakland Research Institute, Oakland, CA, United States of America.""}]",PloS one,['10.1371/journal.pone.0232197'] 1706,32469881,"Two casting methods compared in patients with Colles' fracture: A pragmatic, randomized controlled trial.","BACKGROUND Distal radius fractures are common fractures and the cornerstone of treatment remains immobilization of the wrist in a cast. At present, there is a scarcity of studies that compare different cast immobilization methods. The objective of the study was therefore to compare volar-flexion and ulnar deviation cast to functional cast position in the treatment of dorsally displaced distal radius fracture among elderly patients. METHODS AND FINDINGS We performed a pragmatic, randomized, controlled trial in three emergency centers in Finland. After closed reduction of the fracture, the wrist was placed in either volar-flexion and ulnar deviation cast or functional cast position. The follow-up was 12 months. The primary outcome was patient-rated wrist evaluation (PRWE) score at 12 months. The secondary outcomes were Quick-DASH score, grip strength, health-related quality of life (15D), and pain catastrophizing scale. The number of complications was also recorded. In total, 105 participants were included in the study. Of these, 88% were female and the mean age was 73.5 (range 65-94) years. In the primary analysis, the mean difference in patient-rated wrist evaluation measure between groups was -4.9 (95% CI: -13.1.- 3.4., p = .24) in favor of the functional cast position. Operative treatment due to loss of reduction of fracture was performed for four patients (8%) in the FC group and for seven patients (13%) in the volar-flexion and ulnar deviation cast group (OR: 0.63, 95% CI: 0.16-2.1). CONCLUSION In this study, the data were consistent with a wide range of treatment effects when comparing two different cast positions in the treatment of distal radius fracture among elderly patients at 12-month follow-up. However, the functional cast is more likely to be superior when compared to volar-flexion and ulnar deviation cast. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02894983 Accessible: https://clinicaltrials.gov/ct2/show/NCT02894983.",2020,"In the primary analysis, the mean difference in patient-rated wrist evaluation measure between groups was -4.9","['88% were female and the mean age was 73.5 (range 65-94) years', 'dorsally displaced distal radius fracture among elderly patients', '105 participants were included in the study', ""patients with Colles' fracture"", 'three emergency centers in Finland']",['volar-flexion and ulnar deviation cast to functional cast position'],"['Quick-DASH score, grip strength, health-related quality of life (15D), and pain catastrophizing scale', 'patient-rated wrist evaluation (PRWE) score', 'patient-rated wrist evaluation measure', 'number of complications', 'reduction of fracture', 'distal radius fracture']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0009353', 'cui_str': ""Colles' fracture""}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0016132', 'cui_str': 'Finland'}]","[{'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0449752', 'cui_str': 'Ulnar deviation'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0733755', 'cui_str': 'Position'}]","[{'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1112432', 'cui_str': 'Reduction of fracture'}, {'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]",105.0,0.170183,"In the primary analysis, the mean difference in patient-rated wrist evaluation measure between groups was -4.9","[{'ForeName': 'Lauri', 'Initials': 'L', 'LastName': 'Raittio', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Antti P', 'Initials': 'AP', 'LastName': 'Launonen', 'Affiliation': 'Department of Orthopaedics, Unit of Musculoskeletal Surgery, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Teemu', 'Initials': 'T', 'LastName': 'Hevonkorpi', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Luokkala', 'Affiliation': 'Central Finland Central Hospital, Jyväskylä, Finland.'}, {'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Kukkonen', 'Affiliation': 'Satakunta Central Hospital, Pori, Finland.'}, {'ForeName': 'Aleksi', 'Initials': 'A', 'LastName': 'Reito', 'Affiliation': 'Department of Orthopaedics, Unit of Musculoskeletal Surgery, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Minna K', 'Initials': 'MK', 'LastName': 'Laitinen', 'Affiliation': 'Division of Orthopaedics and Traumatology, Unit of Musculoskeletal Surgery, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Ville M', 'Initials': 'VM', 'LastName': 'Mattila', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}]",PloS one,['10.1371/journal.pone.0232153'] 1707,32474156,Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis.,"BACKGROUND Comorbid perennial allergic rhinitis (PAR) or year-round aeroallergen sensitivity substantially contributes to disease burden in patients with asthma. Dupilumab blocks the shared receptor for interleukin (IL) 4 and IL-13, key drivers of type 2 inflammation that play important roles in asthma and PAR. In the LIBERTY ASTHMA QUEST trial (NCT02414854), dupilumab reduced severe asthma exacerbations and improved forced expiratory volume in 1 second (FEV 1 ) in patients with uncontrolled, moderate-to-severe asthma, with greater efficacy observed in patients with elevated type 2 inflammatory biomarkers at baseline (blood eosinophils and fractional exhaled nitric oxide). OBJECTIVE To assess dupilumab efficacy in LIBERTY ASTHMA QUEST patients with comorbid PAR. METHODS Severe asthma exacerbation rates, FEV 1 , asthma control (5-item Asthma Control Questionnaire), rhinoconjunctivitis-specific health-related quality of life (Standardized Rhinoconjunctivitis Quality of Life Questionnaire +12 scores), and type 2 inflammatory biomarkers during the 52-week treatment period were assessed. RESULTS A total of 814 of the 1902 patients (42.8%) had comorbid PAR (defined as an allergic rhinitis history and ≥1 perennial aeroallergen specific immunoglobulin E (IgE) level ≥0.35 kU/L at baseline). Dupilumab, 200 and 300 mg every 2 weeks, vs placebo reduced severe exacerbations rates by 32.2% and 34.6% (P < .05 for both) and improved FEV 1 at week 12 by 0.14 L and 0.18 L (P < .01 for both); greater efficacy was observed in patients with elevated baseline blood eosinophil counts (≥300 cells/μL) and fractional exhaled nitric oxide. Dupilumab treatment also numerically improved the 5-item Asthma Control Questionnaire and Standardized Rhinoconjunctivitis Quality of Life Questionnaire +12 scores and suppressed type 2 inflammatory biomarkers. CONCLUSION Dupilumab improved key asthma-related outcomes, asthma control, and rhinoconjunctivitis-specific health-related quality of life while suppressing type 2 inflammatory biomarkers and perennial allergen-specific IgE in patients with moderate-to-severe asthma and comorbid PAR, highlighting its dual inhibitory effects on IL-4 and IL-13 and its role in managing asthma and PAR.",2020,"Dupilumab 200 and 300 mg q2w versus placebo reduced severe exacerbations rates by 32.2% and 34.6% (both P<.05), and improved FEV1 at Week 12 by 0.14 L and 0.18 L (both P<.01); greater efficacy was observed in patients with elevated baseline blood eosinophils (≥300 cells/μL) and FeNO.","['asthma patients', 'patients with asthma and perennial allergic rhinitis', 'patients with moderate-to-severe asthma and comorbid PAR', 'patients had comorbid PAR', 'QUEST patients with comorbid PAR (allergic rhinitis history and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline']","['Dupilumab', 'placebo']","['Severe asthma exacerbation rates, FEV1, asthma control (ACQ-5), rhinoconjunctivitis-specific health-related quality of life (HRQoL) (RQLQ[S]+12), and type 2 inflammatory biomarkers', 'forced expiratory volume', 'ACQ-5 and RQLQ(s)+12 scores, and suppressed type 2 inflammatory biomarkers', 'severe exacerbations rates', 'FEV1', 'dupilumab efficacy', 'efficacy']","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035457', 'cui_str': 'Perennial allergic rhinitis'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C0001697', 'cui_str': 'Aeroallergen'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0439340', 'cui_str': 'kU/L'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]","[{'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1260953', 'cui_str': 'Suppressed'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C3660996', 'cui_str': 'dupilumab'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0837837,"Dupilumab 200 and 300 mg q2w versus placebo reduced severe exacerbations rates by 32.2% and 34.6% (both P<.05), and improved FEV1 at Week 12 by 0.14 L and 0.18 L (both P<.01); greater efficacy was observed in patients with elevated baseline blood eosinophils (≥300 cells/μL) and FeNO.","[{'ForeName': 'William W', 'Initials': 'WW', 'LastName': 'Busse', 'Affiliation': 'Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin. Electronic address: wwb@medicine.wisc.edu.'}, {'ForeName': 'Jorge F', 'Initials': 'JF', 'LastName': 'Maspero', 'Affiliation': 'Fundación CIDEA, Buenos Aires, Argentina.'}, {'ForeName': 'Yufang', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Corren', 'Affiliation': 'David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California.'}, {'ForeName': 'Nicola A', 'Initials': 'NA', 'LastName': 'Hanania', 'Affiliation': 'Baylor College of Medicine, Texas Medical Center, Houston, Texas.'}, {'ForeName': 'Bradley E', 'Initials': 'BE', 'LastName': 'Chipps', 'Affiliation': 'Capital Allergy and Respiratory Disease Center, Sacramento, California.'}, {'ForeName': 'Constance H', 'Initials': 'CH', 'LastName': 'Katelaris', 'Affiliation': 'Campbelltown Hospital and Western Sydney University, Campbelltown, Australia.'}, {'ForeName': 'J Mark', 'Initials': 'JM', 'LastName': 'FitzGerald', 'Affiliation': 'The University of British Columbia, Vancouver, British Columbia.'}, {'ForeName': 'Santiago', 'Initials': 'S', 'LastName': 'Quirce', 'Affiliation': 'Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.'}, {'ForeName': 'Linda B', 'Initials': 'LB', 'LastName': 'Ford', 'Affiliation': 'Asthma and Allergy Center, Bellevue, Nebraska.'}, {'ForeName': 'Megan S', 'Initials': 'MS', 'LastName': 'Rice', 'Affiliation': 'Sanofi, Cambridge, Massachusetts.'}, {'ForeName': 'Siddhesh', 'Initials': 'S', 'LastName': 'Kamat', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Asif H', 'Initials': 'AH', 'LastName': 'Khan', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Jagerschmidt', 'Affiliation': 'Sanofi, Chilly-Mazarin, France.'}, {'ForeName': 'Sivan', 'Initials': 'S', 'LastName': 'Harel', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Rowe', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Pirozzi', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Nikhil', 'Initials': 'N', 'LastName': 'Amin', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Marcella', 'Initials': 'M', 'LastName': 'Ruddy', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Neil M H', 'Initials': 'NMH', 'LastName': 'Graham', 'Affiliation': 'Regeneron Pharmaceuticals, Inc, Tarrytown, New York.'}, {'ForeName': 'Ariel', 'Initials': 'A', 'LastName': 'Teper', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}]","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",['10.1016/j.anai.2020.05.026'] 1708,32476255,"Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.","AIM To determine the glucose-independent effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin versus the sulphonylurea glimepiride on systemic haemodynamics in the fasting and postprandial state in patients with type 2 diabetes (T2D). MATERIALS AND METHODS In this prespecified secondary analysis of a phase IV, double-blind trial, 46 metformin-treated, overweight patients with T2D were included and randomly assigned (1:1) to once-daily linagliptin (5 mg) or glimepiride (1 mg) for 8 weeks. In a sub-study involving 26 patients, systemic haemodynamics were also assessed following a standardized liquid meal (Nutridrink Yoghurt style). Systemic haemodynamics (oscillometric device and finger photoplethysmography), arterial stiffness (applanation tonometry) and cardiac sympathovagal balance (heart rate variability [HRV]) were measured in the fasting state and repetitively following the meal. Ewing tests were performed in the fasting state. RESULTS From baseline to week 8, linagliptin compared with glimepiride did not affect systemic haemodynamics, arterial stiffness or HRV in the fasting state. Linagliptin increased parasympathetic nervous activity, as measured by the Valsalva manoeuvre (P = .021) and deep breathing test (P = .027) compared with glimepiride. Postprandially, systolic blood pressure (SBP) dropped an average of 7.6 ± 1.6 mmHg. Linagliptin reduced this decrease to 0.7 ± 2.3 mmHg, which was significant to glimepiride (P = .010). CONCLUSIONS When compared with glimepiride, linagliptin does not affect fasting blood pressure. However, linagliptin blunted the postprandial drop in SBP, which could benefit patients with postprandial hypotension.",2020,"RESULTS From baseline to Week-8, linagliptin compared to glimepiride did not affect systemic hemodynamics, arterial stiffness or HRV in the fasting state.","['46 metformin-treated, overweight T2DM patients', 'overweight patient with type 2 diabetes', 'patients with type 2 diabetes mellitus (T2DM']","['Linagliptin', 'glimepiride, linagliptin', 'sulfonylurea glimepiride', 'dipeptidyl peptidase (DPP)-4 inhibitor linagliptin', 'glimepiride', 'DPP-4 inhibitor linagliptin', 'linagliptin']","['systemic hemodynamics, arterial stiffness or HRV', 'systemic hemodynamics', 'fasting blood pressure', 'parasympathetic nervous activity', 'Systemic haemodynamic (oscillometric device and finger photoplethysmography), arterial stiffness (applanation tonometry), and cardiac sympathovagal balance (heart rate variability; HRV', 'Valsalva-manoeuvre', 'systemic haemodynamics']","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C2746078', 'cui_str': 'Linagliptin'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}, {'cui': 'C0012515', 'cui_str': 'Dipeptidylpeptide hydrolase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl peptidase IV inhibitor'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0162599', 'cui_str': 'Photoplethysmography'}, {'cui': 'C0430862', 'cui_str': 'Applanation tonometry'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0042293', 'cui_str': 'Valsalva maneuver'}]",26.0,0.102531,"RESULTS From baseline to Week-8, linagliptin compared to glimepiride did not affect systemic hemodynamics, arterial stiffness or HRV in the fasting state.","[{'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Kraaijenhof', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Marcel H A', 'Initials': 'MHA', 'LastName': 'Muskiet', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Lennart', 'Initials': 'L', 'LastName': 'Tonneijck', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'D Margriet', 'Initials': 'DM', 'LastName': 'Ouwens', 'Affiliation': 'German Diabetes Center (DDZ), Leibniz Center for Diabetes Research, Heinrich Heine University, Medical Faculty, Düsseldorf, Germany.'}, {'ForeName': 'Mark H H', 'Initials': 'MHH', 'LastName': 'Kramer', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Daniël H', 'Initials': 'DH', 'LastName': 'van Raalte', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}, {'ForeName': 'Mark M', 'Initials': 'MM', 'LastName': 'Smits', 'Affiliation': 'Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, location VUmc, Amsterdam, The Netherlands.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14107'] 1709,32483957,The preemptive effect of tramadol and metamizole on the intensity of postoperative pain.,"Aim To demonstrate the analgesic effect of preemptively administered tramadol and metamizole on the postoperative pain severity, after an elective operative hysterectomy with adnexectomy. Methods There were three groups with 30 patients in each group. Patients included in the study were between 45 to 67 years old. They were all in the ASA group II. Randomization was performed in random order according to the regular elective operating program. Patients in Group I received i. m. tramadol 1mg/kg, and in Group II 30mg/kg of metamizole, five minutes before anaesthesia induction. Patients did not receive preemptive analgesia in Group III (control). All patients underwent the same induction anaesthesiology procedure with propofol, fentanyl, tracrium, supplemented with O2, N2O, and sevoflurane at an appropriate dose until MAC 1 was reached. Surgeries lasted for 80-120 minutes. Every patient performed a resting pain assessment 30 minutes after an extubation by Numerical Pain Scale (NPS). Results We found out that tramadol had a better effect in preemptive analgesia and that the average pain score for Group I was 6.10 (p=0.043). In Group II, it was 7.93 (p=0.022). There is significant difference in pain intensity between patients in the control group, (pain intensity was 9.16), and those who received tramadol and metamizole. There was no significant difference in the intensity of pain when using these two analgesics (p=0.733). Conclusion The effect of preemptively administered tramadol prior to the introduction of general anaesthesia in postoperative pain is significantly more favourable than the effect of metamizole.",2020,There was no significant difference in the intensity of pain when using these two analgesics (p=0.733).,"['Patients included in the study were between 45 to 67 years old', 'elective operative hysterectomy with adnexectomy']","['tramadol and metamizole', 'propofol, fentanyl, tracrium, supplemented with O2, N2O, and sevoflurane', 'preemptive analgesia', 'tramadol']","['pain intensity', 'analgesic effect', 'postoperative pain severity', 'preemptive analgesia', 'intensity of postoperative pain', 'intensity of pain', 'average pain score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0036132', 'cui_str': 'Salpingo-oophorectomy'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0012586', 'cui_str': 'Dipyrone'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0592193', 'cui_str': 'Tracrium'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0028215', 'cui_str': 'Nitrous Oxide'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0948482', 'cui_str': 'Analgesic effect'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",,0.0268795,There was no significant difference in the intensity of pain when using these two analgesics (p=0.733).,"[{'ForeName': 'Ismet', 'Initials': 'I', 'LastName': 'Suljević', 'Affiliation': 'Clinic for Anaesthesia and Resuscitation, Clinical Centre of University of Sarajevo, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Muamer', 'Initials': 'M', 'LastName': 'Hadžiavdić', 'Affiliation': 'Clinic for Bone Surgery, Clinical Centre of University of Sarajevo, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Ismana', 'Initials': 'I', 'LastName': 'Šurković', 'Affiliation': 'Department for Endocrinology, Diabetes, and Diseases of Metabolism, Clinical Centre of University of Sarajevo, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Omer', 'Initials': 'O', 'LastName': 'Suljević', 'Affiliation': 'Sarajevo Health Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Maida', 'Initials': 'M', 'LastName': 'Turan', 'Affiliation': 'Healthcare Group Acibadem, Representative Office in Sarajevo, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Ehlimana', 'Initials': 'E', 'LastName': 'Mušija', 'Affiliation': 'Clinic for Heart Diseases and Rheumatism, Clinical Centre of University of Sarajevo, Sarajevo, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1118-20'] 1710,32490976,Baerveldt implant versus trabeculectomy as the first filtering surgery for uncontrolled primary congenital glaucoma: a randomized clinical trial.,"PURPOSE Our initial goal was to compare the efficacy and safety of a glaucoma drainage device and trabeculectomy for children with primary congenital glaucoma after angular surgery failure. However, we discontinued the study due to the rate of complications and wrote this report to describe the results obtained with the two techniques in this particular group. METHODS This was a parallel, non-masked, controlled trial that included patients aged 0-13 years who had undergone previous trabeculotomy or goniotomy and presented inadequately controlled glaucoma with an intraocular pressure ≥21 mmHg on maximum tolerated medical therapy. We randomized the patients to undergo either placement of a 250-mm2 Baerveldt glaucoma implant or mitomycin-augmented trabeculectomy. The main outcome measure was intraocular pressure control. We calculated complete success (without hypotensive ocular medication) and qualified success (with medication) rates. We defined failure as uncontrolled intraocular pressure, presence of serious complications, abnormal increase in ocular dimensions, or confirmed visual acuity decrease. RESULTS We studied 13 eyes of 13 children (five in the glaucoma drainage device group; eight in the trabeculectomy group). Both surgical procedures produced a significant intraocular pressure reduction 12 months after intervention from the baseline (tube group, 22.8 ± 5.9 mmHg to 12.20 ± 4.14 mmHg, p=0.0113; trabeculectomy group, 23.7 ± 7.3 mmHg to 15.6 ± 5.9 mmHg, p=0.0297). None of the patients in the tube group and 37.5% of those in the trabeculectomy group achieved complete success in intraocular pressure control after 12 months of follow-up (p=0.928, Chi-square test). Two patients (40%) had serious complications at the time of tube aperture (implant extrusion, retinal detachment). CONCLUSIONS Both the tube and trabeculectomy groups presented similar intraocular pressure controls, but complete success was more frequent in the trabeculectomy group. Non-valved glaucoma drainage devices caused potentially blinding complications during tube opening. Because of the small sample size, we could not draw conclusions as to the safety data of the studied technique.",2020,"Both surgical procedures produced a significant intraocular pressure reduction 12 months after intervention from the baseline (tube group, 22.8 ± 5.9 mmHg to 12.20 ± 4.14 mmHg, p=0.0113; trabeculectomy group, 23.7 ± 7.3 mmHg to 15.6 ± 5.9 mmHg, p=0.0297).","['children with primary congenital glaucoma after angular surgery failure', '13 eyes of 13 children (five in the glaucoma drainage device group; eight in the trabeculectomy group', 'uncontrolled primary congenital glaucoma', 'patients aged 0-13 years who had undergone previous trabeculotomy or goniotomy and presented inadequately controlled glaucoma with an intraocular pressure ≥21 mmHg on maximum tolerated medical therapy']","['Baerveldt implant versus trabeculectomy', 'trabeculectomy', '250-mm2 Baerveldt glaucoma implant or mitomycin-augmented trabeculectomy', 'glaucoma drainage device and trabeculectomy']","['serious complications', 'intraocular pressure controls', 'complete success in intraocular pressure control', 'intraocular pressure reduction', 'efficacy and safety', 'complete success', 'ocular dimensions, or confirmed visual acuity decrease', 'intraocular pressure control']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1533041', 'cui_str': 'Primary congenital glaucoma'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0040576', 'cui_str': 'Trabeculotomy'}, {'cui': 'C0018072', 'cui_str': 'Goniotomy'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}]","[{'cui': 'C0600545', 'cui_str': 'Baerveldt Implants'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0456786', 'cui_str': 'sq. mm'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0234632', 'cui_str': 'Reduced visual acuity'}]",13.0,0.099004,"Both surgical procedures produced a significant intraocular pressure reduction 12 months after intervention from the baseline (tube group, 22.8 ± 5.9 mmHg to 12.20 ± 4.14 mmHg, p=0.0113; trabeculectomy group, 23.7 ± 7.3 mmHg to 15.6 ± 5.9 mmHg, p=0.0297).","[{'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Rolim-de-Moura', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Bruno L B', 'Initials': 'BLB', 'LastName': 'Esporcatte', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'F Netto', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Paranhos', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.'}]",Arquivos brasileiros de oftalmologia,['10.5935/0004-2749.20200060'] 1711,31820289,"Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.","Methamphetamine (MA) triggers neuroinflammation and medications that counteract MA-induced neuroinflammation may reduce MA-induced neurodegeneration and improve neurocognition and treatment outcomes in MA use disorder. We performed a randomized, placebo-controlled trial to determine the safety and efficacy of ibudilast (IBUD), a phosphodiesterase inhibitor that reduces neuroinflammation, for the treatment of MA use disorder. Treatment-seeking volunteers with MA use disorder were randomly assigned to receive 12 weeks of IBUD 50 mg twice daily (N = 64) or placebo (N = 61) with medication management counseling. Participants visited the outpatient research clinic twice weekly to provide urine specimens for drug screens and undergo study assessments. The primary outcome was end of treatment MA-abstinence (EOTA) during weeks 11 and 12 of treatment. Serum IBUID levels were measured for IBUD participants during week 3 of treatment. There was no difference in EOTA for IBUD (14%) versus placebo (16%, p > 0.05). There was no correlation between serum IBUD levels and MA use during treatment and mean IBUD levels for participants with (mean = 51.3, SD = 20.3) and without (mean = 54.7, SD = 33.0, p = 0.70) EOTA. IBUD was well tolerated. IBUD did not facilitate MA abstinence in this outpatient trial. Whether targeting neuroinflammation, either with IBUD in other subgroups of MA users or clinical trial designs, or with other anti-inflammatory medications, is an effective strategy for treating MA use disorder is not clear. Graphical Abstract The proportion of urine drug screens negative for methamphetamine (MA) during the two week lead-in period (weeks -2 and - 1) and the 12 week medication treatment period (weeks 1-12) for ibudilast versus placebo.",2020,"There was no difference in EOTA for IBUD (14%) versus placebo (16%, p > 0.05).","['Treatment-seeking volunteers with MA use disorder', 'Participants visited the outpatient research clinic twice weekly to provide urine specimens for drug screens and undergo study assessments']","['Placebo', 'Graphical Abstract', 'Methamphetamine (MA', 'medication management counseling', 'ibudilast (IBUD', 'IBUD 50', 'placebo']","['EOTA for IBUD', 'tolerated', 'Serum IBUID levels', 'serum IBUD levels and MA use during treatment and mean IBUD levels', 'proportion of urine drug screens negative for methamphetamine (MA', 'treatment MA-abstinence (EOTA']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0038577', 'cui_str': 'Drug of abuse screen'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0000857', 'cui_str': 'Abstracting as Topic'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0123047', 'cui_str': 'ibudilast'}]","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0123047', 'cui_str': 'ibudilast'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0920168', 'cui_str': 'Urine drug screen negative'}]",,0.282391,"There was no difference in EOTA for IBUD (14%) versus placebo (16%, p > 0.05).","[{'ForeName': 'Keith G', 'Initials': 'KG', 'LastName': 'Heinzerling', 'Affiliation': 'Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. kheinzerling@mednet.ucla.edu.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Briones', 'Affiliation': 'Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'April D', 'Initials': 'AD', 'LastName': 'Thames', 'Affiliation': 'Department of Psychology, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Charles H', 'Initials': 'CH', 'LastName': 'Hinkin', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Tianle', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': 'Department of Statistics, UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Ying Nian', 'Initials': 'YN', 'LastName': 'Wu', 'Affiliation': 'Department of Statistics, UCLA, Los Angeles, CA, USA.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Shoptaw', 'Affiliation': 'Department of Family Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.'}]",Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,['10.1007/s11481-019-09883-w'] 1712,32583907,Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.,"BACKGROUND Agonists of 5-hydroxytryptamine 4 receptor are potential agents for irritable bowel syndrome with predominant constipation (IBS-C). However, only tegaserod has been approved for a very limited population in the US. AIM To evaluate the efficacy and safety of minesapride in patients with Rome IV defined IBS-C. METHODS A double-blind, placebo-controlled, dose-finding study was performed. Overall, 411 patients were randomised to receive minesapride at 10, 20 or 40 mg/d, or placebo for 12 weeks. The primary endpoint was Food and Drug Administration (FDA) composite endpoint (responder: a patient who reported an increase in one or more complete spontaneous bowel movements from baseline and improvement of ≥30% from baseline in weekly average of worst abdominal pain score, both in the same week for ≥6/12 weeks). RESULTS The FDA composite responder rate was 13.6% (14/103) in the placebo group, 13.6% (14/103) in the 10 mg group, 19.2% (20/104) in the 20 mg group and 14.9% (15/101) in the 40 mg group, and no dose-response relationship was found. A greater percentage of minesapride 40 mg-treated patients than placebo-treated patients met both responder requirements for ≥9/12 weeks as the stricter composite evaluation (P < 0.05). Furthermore, minesapride 40 mg significantly increased SBM frequency compared with placebo (adjusted P < 0.001 at Week 12). The most common adverse event was mild diarrhoea. CONCLUSIONS Minesapride was safe and well-tolerated. Although the primary endpoint was negative, minesapride 40 mg is likely to improve the stricter composite endpoint and SBM frequency. Japan Pharmaceutical Information Center Number: Japic CTI-163459.",2020,"Furthermore, minesapride 40 mg significantly increased SBM frequency compared with placebo (adjusted P < 0.001 at Week 12).","['irritable bowel syndrome with predominant constipation (IBS-C', 'patients with Rome IV defined IBS-C', 'irritable bowel syndrome with predominant constipation', '411 patients']","['5-hydroxytryptamine', 'minesapride vs placebo', 'minesapride', 'placebo']","['stricter composite endpoint and SBM frequency', 'SBM frequency', 'Food and Drug Administration (FDA) composite endpoint (responder: a patient who reported an increase in one or more complete spontaneous bowel movements', 'efficacy and safety', 'safe and well-tolerated', 'worst abdominal pain score', 'FDA composite responder rate']","[{'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C3539106', 'cui_str': 'Defined'}]","[{'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",411.0,0.467554,"Furthermore, minesapride 40 mg significantly increased SBM frequency compared with placebo (adjusted P < 0.001 at Week 12).","[{'ForeName': 'Tatsuto', 'Initials': 'T', 'LastName': 'Hamatani', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Fukudo', 'Affiliation': 'Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Nakada', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Inada', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Kiyoyasu', 'Initials': 'K', 'LastName': 'Kazumori', 'Affiliation': 'Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Miwa', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.'}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15907'] 1713,32585185,"Effectiveness of a brief lay counsellor-delivered, problem-solving intervention for adolescent mental health problems in urban, low-income schools in India: a randomised controlled trial.","BACKGROUND Mental health problems are a leading cause of disability in adolescents worldwide. Problem solving is a well-tested mental health intervention in many populations. We aimed to investigate the effectiveness of a brief, transdiagnostic problem-solving intervention for common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India. METHODS This randomised trial was done in six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities. We recruited participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment. Clinical eligibility criteria were assessed by research assistants using the Hindi-language version of the Strengths and Difficulties Questionnaire (SDQ), with reference to locally validated borderline cutoff scores of 19 or greater for boys and 20 or greater for girls on the SDQ Total Difficulties scale, an abnormal score of 2 or more on the SDQ Impact scale, and persistence of more than 1 month on the SDQ Chronicity index. Participants were randomly allocated (1:1) to problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group). Primary outcomes were adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP]) at 6 weeks. Primary analyses were done on an intention-to-treat basis at the 6-week endpoint. The trial is registered with ClinicalTrials.gov, NCT03630471. FINDINGS Participants were enrolled between Aug 20, and Dec 4, 2018. 283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys). 125 participants were allocated to each group (after accounting for one participant in the intervention group who withdrew consent after randomisation). Primary outcome data were available for 245 (98%) participants. At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61; p=0·0015). The mean SDQ Total Difficulties scores were 17·48 (5·45) in the intervention group and 18·33 (5·45) in the control group (-0·86, -2·14 to 0·41; 0·16, -0·09 to 0·41; p=0·18). We observed no adverse events. INTERPRETATION A brief lay counsellor-delivered problem-solving intervention combined with printed booklets seemed to have a modest effect on psychosocial outcomes among adolescents with diverse mental health problems compared with problem-solving booklets alone. This counsellor-delivered intervention might be a suitable first-line intervention in a stepped care approach, which is being evaluated in ongoing studies. FUNDING Wellcome Trust.",2020,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","['125 participants', 'adolescent mental health problems in urban, low-income schools in India', 'common adolescent mental health problems when delivered by non-specialist school counsellors in New Delhi, India', '283 eligible adolescents were referred to the trial, and 251 (89%) of these were enrolled (mean age 15·61 years; 174 [69%] boys', 'adolescents with diverse mental health problems', 'participants from grades 9 to 12 (ages 12-20 years) by selecting students with persistently elevated mental health symptoms accompanied by distress or functional impairment', 'six government-run schools (three all-boys schools, two all-girls schools, and one co-educational school) that serve low-income communities', 'Participants were enrolled between Aug 20, and Dec 4, 2018']","['problem solving delivered through a brief (2-3 week) counsellor-led intervention with supporting printed materials (intervention group), or problem solving delivered via printed booklets alone (control group', 'lay counsellor-delivered problem-solving intervention combined with printed booklets', 'brief lay counsellor-delivered, problem-solving intervention', 'transdiagnostic problem-solving intervention']","['SDQ Total Difficulties scale', 'SDQ Chronicity index', 'psychosocial outcomes', 'mean YTP scores', 'mean SDQ Total Difficulties scores', 'adolescent-reported mental health symptoms (SDQ Total Difficulties scale) and idiographic psychosocial problems (Youth Top Problems [YTP']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0557802', 'cui_str': 'Specialist school'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0086541', 'cui_str': 'Dry form of cutaneous leishmaniasis'}, {'cui': 'C4708786', 'cui_str': '283'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0761050', 'cui_str': '(GVGVP)251'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018104', 'cui_str': 'Government'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0033211', 'cui_str': 'Problem solving'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0034036', 'cui_str': 'Printed material'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023668', 'cui_str': 'Liechtenstein'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0547045', 'cui_str': 'Chronicity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}]",125.0,0.178681,"At 6 weeks, the mean YTP scores were 3·52 (SD 2·66) in the intervention group and 4·60 (2·75) in the control group (adjusted mean difference -1·01, 95% CI -1·63 to -0·38; adjusted effect size 0·36, 95% CI 0·11 to 0·61;","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Michelson', 'Affiliation': 'School of Psychology, University of Sussex, Brighton, UK.'}, {'ForeName': 'Kanika', 'Initials': 'K', 'LastName': 'Malik', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rachana', 'Initials': 'R', 'LastName': 'Parikh', 'Affiliation': 'Sagath, New Delhi, India; Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Helen A', 'Initials': 'HA', 'LastName': 'Weiss', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Aoife M', 'Initials': 'AM', 'LastName': 'Doyle', 'Affiliation': 'Medical Research Council Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Bhargav', 'Initials': 'B', 'LastName': 'Bhat', 'Affiliation': 'Sangath, Goa, India.'}, {'ForeName': 'Rooplata', 'Initials': 'R', 'LastName': 'Sahu', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Bhagwant', 'Initials': 'B', 'LastName': 'Chilhate', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Sonal', 'Initials': 'S', 'LastName': 'Mathur', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Madhuri', 'Initials': 'M', 'LastName': 'Krishna', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Rhea', 'Initials': 'R', 'LastName': 'Sharma', 'Affiliation': 'Sagath, New Delhi, India.'}, {'ForeName': 'Paulomi', 'Initials': 'P', 'LastName': 'Sudhir', 'Affiliation': 'Department of Clinical Psychology, National Institute of Mental Health and Neuro Sciences, Bengaluru, India.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'King', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, University College London, London, UK.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Cuijpers', 'Affiliation': 'Department of Clinical Psychology, Vrije Universiteit, Amsterdam, Netherlands.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Chorpita', 'Affiliation': 'Department of Psychology, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Fairburn', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Vikram', 'Initials': 'V', 'LastName': 'Patel', 'Affiliation': 'Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA; Harvard TH Chan School of Public Health, Boston, MA, USA. Electronic address: vikram_patel@hms.harvard.edu.'}]",The Lancet. Child & adolescent health,['10.1016/S2352-4642(20)30173-5'] 1714,32588685,Study of the Functional Brain Connectivity and Lower-Limb Motor Imagery Performance After Transcranial Direct Current Stimulation.,"The use of transcranial direct current stimulation (tDCS) has been related to the improvement of motor and learning tasks. The current research studies the effects of an asymmetric tDCS setup over brain connectivity, when the subject is performing a motor imagery (MI) task during five consecutive days. A brain-computer interface (BCI) based on electroencephalography is simulated in offline analysis to study the effect that tDCS has over different electrode configurations for the BCI. This way, the BCI performance is used as a validation index of the effect of the tDCS setup by the analysis of the classifier accuracy of the experimental sessions. In addition, the relationship between the brain connectivity and the BCI accuracy performance is analyzed. Results indicate that tDCS group, in comparison to the placebo sham group, shows a higher significant number of connectivity interactions in the motor electrodes during MI tasks and an increasing BCI accuracy over the days. However, the asymmetric tDCS setup does not improve the BCI performance of the electrodes in the intended hemisphere.",2020,"Results indicate that tDCS group, in comparison to the placebo sham group, shows a higher significant number of connectivity interactions in the motor electrodes during MI tasks and an increasing BCI accuracy over the days.",[],"['transcranial direct current stimulation (tDCS', 'tDCS', 'placebo']","['Functional Brain Connectivity and Lower-Limb Motor Imagery Performance', 'brain connectivity and the BCI accuracy performance', 'BCI accuracy', 'BCI performance', 'connectivity interactions']",[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C3494288', 'cui_str': 'Brain-Computer Interface'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}]",,0.0405879,"Results indicate that tDCS group, in comparison to the placebo sham group, shows a higher significant number of connectivity interactions in the motor electrodes during MI tasks and an increasing BCI accuracy over the days.","[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Ortiz', 'Affiliation': 'Brain-Machine Interface Systems Lab, Miguel Hernández University of Elche, Avenida Universidad sn. Ed. Innova, Elche, Alicante 03202, Spain.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Iáñez', 'Affiliation': 'Brain-Machine Interface Systems Lab, Miguel Hernández University of Elche, Avenida Universidad sn. Ed. Innova, Elche, Alicante 03202, Spain.'}, {'ForeName': 'Jorge A', 'Initials': 'JA', 'LastName': 'Gaxiola-Tirado', 'Affiliation': ""Center for Research and Advanced Studies (Cinvestav), Monterrey's Unit, Vía del Conocimiento 201 PIIT, 66600, Apodaca NL 66600, Mexico.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gutiérrez', 'Affiliation': ""Center for Research and Advanced Studies (Cinvestav), Monterrey's Unit, Vía del Conocimiento 201 PIIT, 66600, Apodaca NL 66600, Mexico.""}, {'ForeName': 'José M', 'Initials': 'JM', 'LastName': 'Azorín', 'Affiliation': 'Systems Engineering and Automation Department, Miguel Hernández University of Elche, Avenida Universidad sn. Ed. Innova, Elche, Alicante 03202, Spain.'}]",International journal of neural systems,['10.1142/S0129065720500380'] 1715,32589630,Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial.,"BACKGROUND Patients with unprovoked (i.e., without the presence of apparent transient risk factors such as recent surgery) venous thromboembolism (VTE) are at risk of recurrence if anticoagulants are stopped after 3-6 months, yet their risk remains heterogeneous. Thus, prolonging anticoagulant treatment should be considered in high-risk patients, whereas stopping is likely preferred in those with a low predicted risk. The Vienna Prediction Model (VPM) could aid clinicians in estimating this risk, yet its clinical effects and external validity are currently unknown. The aim of this study was to investigate the clinical impact of this model on reducing recurrence risk in patients with unprovoked VTE, compared to usual care. METHODS AND FINDINGS In a randomized controlled trial, the decision to prolong or stop anticoagulant treatment was guided by predicted recurrence risk using the VPM (n = 441), which was compared with usual care (n = 442). Patients with unprovoked VTE were recruited from local thrombosis services in the Netherlands (in Utrecht, Harderwijk, Ede, Amersfoort, Zwolle, Hilversum, Rotterdam, Deventer, and Enschede) between 22 July 2011 and 30 November 2015, with 24-month follow-up complete for all patients by early 2018. The primary outcome was recurrent VTE during 24 months of follow-up. Secondary outcomes included major bleeding and clinically relevant non-major (CRNM) bleeding. In the total study population of 883 patients, mean age was 55 years, and 507 (57.4%) were men. A total of 96 recurrent VTE events (10.9%) were observed, 46 in the intervention arm and 50 in the control arm (risk ratio 0.92, 95% CI 0.63-1.35, p = 0.67). Major bleeding occurred in 4 patients, 2 in each treatment arm, whereas CRNM bleeding occurred in 20 patients (12 in intervention arm versus 8 in control arm). The VPM showed good discriminative power (c-statistic 0.76, 95% CI 0.69-0.83) and moderate to good calibration, notably at the lower spectrum of predicted risk. For instance, in 284 patients with a predicted risk of >2% to 4%, the observed rate of recurrence was 2.5% (95% CI 0.7% to 4.3%). The main limitation of this study is that it did not enroll the preplanned number of 750 patients in each study arm due to declining recruitment rate. CONCLUSIONS Our results show that application of the VPM in all patients with unprovoked VTE is unlikely to reduce overall recurrence risk. Yet, in those with a low predicted risk of recurrence, the observed rate was also low, suggesting that it might be safe to stop anticoagulant treatment in these patients. TRIAL REGISTRATION Netherlands Trial Register NTR2680.",2020,"The VPM showed good discriminative power (c-statistic 0.76, 95% CI 0.69-0.83) and moderate to good calibration, notably at the lower spectrum of predicted risk.","['284 patients', '883 patients, mean age was 55 years, and 507 (57.4%) were men', 'patients with venous thromboembolism compared to usual care', 'Patients with unprovoked VTE were recruited from local thrombosis services in the Netherlands (in Utrecht, Harderwijk, Ede, Amersfoort, Zwolle, Hilversum, Rotterdam, Deventer, and Enschede) between 22 July 2011 and 30 November 2015, with 24-month follow-up complete for all patients by early 2018', 'patients with unprovoked VTE, compared to usual care']",[],"['CRNM bleeding', 'recurrence risk', 'recurrent VTE', 'major bleeding and clinically relevant non-major (CRNM) bleeding', 'overall recurrence risk', 'Major bleeding', 'rate of recurrence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0450381', 'cui_str': '507'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1279919', 'cui_str': 'Early'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",284.0,0.138641,"The VPM showed good discriminative power (c-statistic 0.76, 95% CI 0.69-0.83) and moderate to good calibration, notably at the lower spectrum of predicted risk.","[{'ForeName': 'Geert-Jan', 'Initials': 'GJ', 'LastName': 'Geersing', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Janneke M T', 'Initials': 'JMT', 'LastName': 'Hendriksen', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Nicolaas P A', 'Initials': 'NPA', 'LastName': 'Zuithoff', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Kit C', 'Initials': 'KC', 'LastName': 'Roes', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Ruud', 'Initials': 'R', 'LastName': 'Oudega', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Toshihiko', 'Initials': 'T', 'LastName': 'Takada', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Roger E G', 'Initials': 'REG', 'LastName': 'Schutgens', 'Affiliation': 'Van Creveld Clinic, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Karel G M', 'Initials': 'KGM', 'LastName': 'Moons', 'Affiliation': 'Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.'}]",PLoS medicine,['10.1371/journal.pmed.1003142'] 1716,32589632,"A randomized controlled trial comparing the effectiveness of individual versus household treatment for Scabies in Lambaréné, Gabon.","BACKGROUND It is unclear whether individual treatment of scabies is similarly effective compared to household treatment. This study compared these two treatment strategies with topical benzyl benzoate for treating scabies in Lambaréné, Gabon. METHODS Participants presenting with uncomplicated scabies were randomized into either the Individual Treatment group, where only the affected participants received treatment, or the Household Treatment group, where all family members were treated in parallel to the affected participants regardless of signs and symptoms. The primary endpoint was clinical cure after 28 days; the secondary endpoint was the proportion of affected household members per household after 28 days. RESULTS After 28 days, from a total of 79 participants assessed, 67% (n = 53) were clinically cured; 59% (20/34) in the Individual Treatment group and 73% (33/45) in the Household Treatment group. Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17). For the secondary outcome, an effect of similar size was observed. CONCLUSIONS Our findings show that treating close contacts of persons affected by scabies may be beneficial to patients and contacts, however, the benefit was less pronounced than anticipated and further research is needed to definitively answer this question.",2020,"Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17).",['Participants presenting with uncomplicated scabies'],['topical benzyl benzoate'],['clinical cure'],"[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0036262', 'cui_str': 'Infestation by Sarcoptes scabiei var hominis'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0053289', 'cui_str': 'benzyl benzoate'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}]",53.0,0.160026,"Participants in the Household Treatment group had about twice the odds of being cured (odds ratio 1.9, 95% confidence interval: 0.8-4.9; p = 0.17).","[{'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Matthewman', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Rella Zoleko', 'Initials': 'RZ', 'LastName': 'Manego', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Lia Betty', 'Initials': 'LB', 'LastName': 'Dimessa Mbadinga', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Hana', 'Initials': 'H', 'LastName': 'Šinkovec', 'Affiliation': 'Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Clinical Biometrics, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Völker', 'Affiliation': 'Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, & I Dep. of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Malik', 'Initials': 'M', 'LastName': 'Akinosho', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Haedrich', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': ""Tardif d'Hamonville"", 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Lell', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Ayola Akim', 'Initials': 'AA', 'LastName': 'Adegnika', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ramharter', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}, {'ForeName': 'Ghyslain', 'Initials': 'G', 'LastName': 'Mombo-Ngoma', 'Affiliation': 'Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon.'}]",PLoS neglected tropical diseases,['10.1371/journal.pntd.0008423'] 1717,32593960,Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.,"BACKGROUND Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on hemostasis of exercise and rehabilitation strategies have been extensively investigated, relationships between MS rehabilitation strategies and hemostasis have not been previously reported. OBJECTIVES To investigate in MS patients the association between outcomes of rehabilitative exercise and plasma levels of selected hemostasis inhibitors. METHODS Sixty-one severely disabled progressive-MS (P-MS) patients were randomized in the RAGTIME trial to receive 12 walking session of robot-assisted gait training (RAGT) or conventional overground therapy (CT). Outcome parameters were: timed 25-foot walk test (T25FWT) speed, 6-minute walking test (6MWT), Berg Balance Scale (BBS), and MS impact scale-29 (MSIS-29). Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3). Descriptive analysis, trend analysis, Spearman's rank and Pearson's correlations, and multiple regression models were used. RESULTS Rehabilitative exercises moderately modified plasma protein concentrations. A significant trend to increase was observed for PS (p=0.015) and TFPI (p=0.047) in the whole population, and for PS (p=0.011) in the CT group. Correlation between TFPI and sTM levels was detectable at all time points in the whole P-MS patients and in RAGT group. The correlation between TFPI and PS, present at T0, was lost during the rehabilitation, and recovered at T3 in the whole population and CT group. During rehabilitation, positive variations of TFPI were inversely related with changes in 6MWT in the whole population (r=-0.309, p=0.021), and in the RAGT group (r=-0.51, p=0.004). In all P-MS, PS T0 levels were associated (r=0.379, p=0.004) with increased gait speed, which in the RAGT group was associated both with PS T0 (r=0.378, p=0.040), and sTM T0 (r=0.453, p=0.012). Accordingly, in the regression model including age, sex and EDSS and the stepwise enter of PS T0, higher PS T0 levels predicted increased gait speed in all P-MS (F=3.4, p=0.016) The regression model in the RAGT group indicated that higher PS and sTM T0 levels were both predictors of increased gait speed (F=5.7, p=0.001). CONCLUSIONS Plasma levels of coagulation inhibitors were related to variations of outcome measurements after high-intensity walking rehabilitation programs. Patients with decreased TFPI levels from T0 to T2 displayed the most significant functional recovery following rehabilitation, and particularly after RAGT. Higher baseline total PS levels were associated with favorable outcomes of rehabilitation therapies in MS. These novel findings, which suggest that plasma levels of hemostasis inhibitors might have implication for rehabilitative therapy options in MS, warrant further investigation.",2020,"Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3).","['Sixty-one severely disabled progressive-MS (P-MS) patients', 'multiple sclerosis patients undergoing rehabilitation programs', 'multiple sclerosis (MS']",['12 walking session of robot-assisted gait training (RAGT) or conventional overground therapy (CT'],"['PS T0 levels', 'TFPI levels', 'Higher baseline total PS levels', 'gait speed', 'Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI', 'timed 25-foot walk test (T25FWT) speed, 6-minute walking test (6MWT), Berg Balance Scale (BBS), and MS impact scale-29 (MSIS-29', 'plasma protein concentrations', 'PS', 'TFPI', 'PS and sTM T0 levels', 'TFPI and sTM levels', 'multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1095979', 'cui_str': 'Progressive multiple sclerosis'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}]","[{'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0072393', 'cui_str': 'Protein S'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0164707', 'cui_str': 'Tissue factor pathway inhibitor'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1168441', 'cui_str': 'Protein S total'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032120', 'cui_str': 'Plasma protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",61.0,0.0295241,"Plasma levels of coagulation inhibitors protein S (PS), soluble thrombomodulin (sTM), and tissue factor pathway inhibitor (TFPI) were assayed by multiplex assay and ELISA at 4-time points: baseline (T0), intermediate (T1), end of rehabilitation (T2), 3-month follow-up (T3).","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Ziliotto', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara; School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Lamberti', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Manfredini', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy; Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Straudi', 'Affiliation': 'Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Baroni', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Tisato', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Carantoni', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Secchiero', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Nino', 'Initials': 'N', 'LastName': 'Basaglia', 'Affiliation': 'Department of Neurosciences/Rehabilitation, Unit of Physical and Rehabilitation Medicine, University Hospital of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Marchetti', 'Affiliation': 'Department of Biomedical and Surgical Specialties Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bernardi', 'Affiliation': 'Department of Life Sciences and Biotechnology, University of Ferrara. Electronic address: ber@unife.it.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102319'] 1718,32594135,Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids.,"CONTEXT Glucocorticoids (GCs) are commonly prescribed, but their use is associated with adverse metabolic effects. 5α-reductase inhibitors (5α-RI) are also frequently prescribed, mainly to inhibit testosterone conversion to dihydrotestosterone. However, they also prevent the inactivation of GCs. OBJECTIVE We hypothesized that 5α-RI may worsen the adverse effects of GCs. DESIGN Prospective, randomized study. PATIENTS A total of 19 healthy male volunteers (age 45 ± 2 years; body mass index 27.1 ± 0.7kg/m2). INTERVENTIONS Participants underwent metabolic assessments; 2-step hyperinsulinemic, euglycemic clamp incorporating stable isotopes, adipose tissue microdialysis, and biopsy. Participants were then randomized to either prednisolone (10 mg daily) or prednisolone (10 mg daily) plus a 5α-RI (finasteride 5 mg daily or dutasteride 0.5 mg daily) for 7 days; metabolic assessments were then repeated. MAIN OUTCOME MEASURES Ra glucose, glucose utilization (M-value), glucose oxidation, and nonesterified fatty acids (NEFA) levels. RESULTS Co-administration of prednisolone with a 5α-RI increased circulating prednisolone levels (482 ± 96 vs 761 ± 57 nmol/L, P = 0.029). Prednisolone alone did not alter Ra glucose (2.55 ± 0.34 vs 2.62 ± 0.19 mg/kg/minute, P = 0.86), M-value (3.2 ± 0.5 vs 2.7 ± 0.7 mg/kg/minute, P = 0.37), or glucose oxidation (0.042 ± 0.007 vs 0.040 ± 0.004 mmol/hr/kg/minute, P = 0.79). However, co-administration with a 5α-RI increased Ra glucose (2.67 ± 0.16 vs 3.05 ± 0.18 mg/kg/minute, P < 0.05) and decreased M-value (4.0 ± 0.5 vs 2.6 ± 0.4 mg/kg/minute, P < 0.05), and oxidation (0.043 ± 0.003 vs 0.036 ± 0.002 mmol/hr/kg, P < 0.01). Similarly, prednisolone did not impair insulin-mediated suppression of circulating NEFA (43.1 ± 28.9 vs 36.8 ± 14.3 μmol/L, P = 0.81), unless co-administered with a 5α-RI (49.8 ± 8.6 vs 88.5 ± 13.5 μmol/L, P < 0.01). CONCLUSIONS We have demonstrated that 5α-RIs exacerbate the adverse effects of prednisolone. This study has significant translational implications, including the need to consider GC dose adjustments, but also the necessity for increased vigilance for the development of adverse effects.",2020,"Similarly, prednisolone did not impair insulin-mediated suppression of circulating NEFA (43.1±28.9 vs. 36.8±14.3μmol/L, p=0.81), unless co-administered with a 5aRI (49.8±8.6 vs. 88.5±13.5μmol/L, p<0.01). ","['19 healthy male volunteers (age; 45±2 years, BMI; 27.1±0.7kg/m2']","['5α-reductase inhibitors', '5aRI (finasteride 5mg daily or dutasteride', 'hyperinsulinemic, euglycemic clamp incorporating stable-isotopes, adipose tissue microdialysis and biopsy', 'Prednisolone', 'prednisolone']","['adverse metabolic effects', 'M-value', 'Ra glucose', 'Ra glucose, glucose utilization (M-value), glucose oxidation, non-esterified fatty acids (NEFA) levels', 'circulating prednisolone levels', 'glucose oxidation', 'insulin-mediated suppression of circulating NEFA']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0030016', 'cui_str': 'Oxidoreductase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0986066', 'cui_str': 'Finasteride 5 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0754659', 'cui_str': 'Dutasteride'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0302918', 'cui_str': 'Stable isotope'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0206056', 'cui_str': 'Microdialysis'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}]","[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0369212', 'cui_str': 'Esterified fatty acid'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}]",19.0,0.0933746,"Similarly, prednisolone did not impair insulin-mediated suppression of circulating NEFA (43.1±28.9 vs. 36.8±14.3μmol/L, p=0.81), unless co-administered with a 5aRI (49.8±8.6 vs. 88.5±13.5μmol/L, p<0.01). ","[{'ForeName': 'Nantia', 'Initials': 'N', 'LastName': 'Othonos', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Marjot', 'Affiliation': 'Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, University of Oxford, John Radcliffe Hospital, Oxford, UK.'}, {'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Woods', 'Affiliation': 'Department of Endocrinology, Naas General Hospital, Kildare and Tallaght Hospital, Dublin, Ireland.'}, {'ForeName': 'Jonathan M', 'Initials': 'JM', 'LastName': 'Hazlehurst', 'Affiliation': 'Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK.'}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Nikolaou', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Pofi', 'Affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'White', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Bonaventura', 'Affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Webster', 'Affiliation': 'Department of Pathology, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Duffy', 'Affiliation': 'Department of Pathology, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Cornfield', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Moolla', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Isidori', 'Affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Rome, 00161, Italy.'}, {'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Hodson', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}, {'ForeName': 'Jeremy W', 'Initials': 'JW', 'LastName': 'Tomlinson', 'Affiliation': 'Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford, UK.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa408'] 1719,31427720,The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.,,2020,,['patients with relapsed chronic lymphocytic leukemia treated with'],"['idelalisib plus rituximab', 'complex karyotype']",['overall survival'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0023434', 'cui_str': 'Chronic lymphocytic leukemia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C2698692', 'cui_str': 'idelalisib'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0022526', 'cui_str': 'Karyotype determination'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0533494,,"[{'ForeName': 'Karl-Anton', 'Initials': 'KA', 'LastName': 'Kreuzer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany. karl-anton.kreuzer@uni-koeln.de.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Furman', 'Affiliation': 'Weill Cornell Medical College, New York, NY, USA.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department III of Internal Medicine, Ulm University Medical Center, Ulm, Germany.'}, {'ForeName': 'Ronald L', 'Initials': 'RL', 'LastName': 'Dubowy', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Yeonhee', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Veerendra', 'Initials': 'V', 'LastName': 'Munugalavadla', 'Affiliation': 'Gilead Sciences, Inc., Foster City, CA, USA.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Lilienweiss', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Hans Christian', 'Initials': 'HC', 'LastName': 'Reinhardt', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cramer', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hillmen', 'Affiliation': ""St. James's University Hospital, Leeds, UK.""}, {'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': ""O'Brien"", 'Affiliation': 'University of California-Irvine, Irvine Chao Family Comprehensive Cancer Center, Orange, CA, USA.'}, {'ForeName': 'Andrew R', 'Initials': 'AR', 'LastName': 'Pettitt', 'Affiliation': 'University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine, University of Cologne, Cologne, Germany.'}]",Leukemia,['10.1038/s41375-019-0533-6'] 1720,32615473,Acceptance and commitment therapy combined with vestibular rehabilitation for persistent postural-perceptual dizziness: A pilot study.,"PURPOSE This study investigated the feasibility of acceptance and commitment therapy for persistent postural-perceptual dizziness and preliminarily verified the long-term effectiveness of the therapy. MATERIALS AND METHODS This study implemented the within-group pre-post comparison design. We enrolled 27 adult patients who met the criteria of persistent postural-perceptual dizziness. They underwent a treatment program including acceptance and commitment therapy combined with vestibular rehabilitation once a week for a total of six sessions. The primary outcome was changes in the Dizziness Handicap Inventory score 6 months posttreatment. RESULTS All 27 patients completed the acceptance and commitment therapy + vestibular rehabilitation program, and 25 patients (92.6%) could be followed for 6 months posttreatment. For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42). At 6 months posttreatment, 11 patients (40.7%) achieved remission (the score ≤ 14), 16 (59.3%) achieved treatment response (reduction in the score ≥ 18), and 20 (74.1%) achieved remission and/or treatment response. CONCLUSIONS Acceptance and commitment therapy is feasible for persistent postural-perceptual dizziness and might have long-term effectiveness. However, a randomized controlled trial is warranted.",2020,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","['persistent postural-perceptual dizziness', '27 adult patients who met the criteria of persistent postural-perceptual dizziness']","['Acceptance and commitment therapy combined with vestibular rehabilitation', 'acceptance and commitment therapy', 'acceptance and commitment therapy combined with vestibular rehabilitation']","['Dizziness Handicap Inventory effect size', 'remission', 'Dizziness Handicap Inventory score 6\xa0months posttreatment', 'remission and/or treatment response']","[{'cui': 'C0522360', 'cui_str': 'Persistent postural perceptual dizziness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0200324', 'cui_str': 'Vestibular rehabilitation'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C4304791', 'cui_str': 'Dizziness Handicap Inventory score'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",27.0,0.176719,"For 27 participants, the scores from pretreatment to 6 months posttreatment significantly declined (P < .001), and the Dizziness Handicap Inventory effect size was 1.11 (95% confidence interval = 0.80-1.42).","[{'ForeName': 'Junya', 'Initials': 'J', 'LastName': 'Kuwabara', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: jurry7777@hotmail.co.jp.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Kondo', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kondo-masaki@umin.ac.jp.'}, {'ForeName': 'Kayoko', 'Initials': 'K', 'LastName': 'Kabaya', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: kabaya@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Wakako', 'Initials': 'W', 'LastName': 'Watanabe', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Kikuchi Mental Clinic, Ushikubo-cho, Toyokawa 442-0826, Japan. Electronic address: wakakoigarashi@gmail.com.'}, {'ForeName': 'Nao', 'Initials': 'N', 'LastName': 'Shiraishi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: fecitanno@gmail.com.'}, {'ForeName': 'Mie', 'Initials': 'M', 'LastName': 'Sakai', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: mie.sakai.38@gmail.com.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Toshishige', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: yuu0323uchi@yahoo.co.jp.'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Ino', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: miniture_flute@hotmail.com.'}, {'ForeName': 'Meiho', 'Initials': 'M', 'LastName': 'Nakayama', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; Good Sleep Center, Nagoya City University Hospital, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: nakayama@med.nagoya-cu.ac.jp.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Iwasaki', 'Affiliation': 'Department of Otolaryngology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: iwashin-tky@umin.ac.jp.'}, {'ForeName': 'Tatsuo', 'Initials': 'T', 'LastName': 'Akechi', 'Affiliation': 'Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Electronic address: takechi@med.nagoya-cu.ac.jp.'}]",American journal of otolaryngology,['10.1016/j.amjoto.2020.102609'] 1721,31833413,Impact of Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography on Heart Team Treatment Decision-Making in Patients With Multivessel Coronary Artery Disease: Insights From the SYNTAX III REVOLUTION Trial.,"BACKGROUND Fractional flow reserve (FFR) is a reliable tool for the functional assessment of coronary stenoses. FFR computed tomography (CT) derived (FFR CT ) has shown to be accurate, but its clinical usefulness in patients with complex coronary artery disease remains to be investigated. The present study sought to determine the impact of FFR CT on heart team's treatment decision-making and selection of vessels for revascularization in patients with 3-vessel coronary artery disease. METHODS The trial was an international, multicenter study randomizing 2 heart teams to make a treatment decision between percutaneous coronary interventions and coronary artery bypass grafting using either coronary computed tomography angiography or conventional angiography. The heart teams received the FFR CT and had to make a treatment decision and planning integrating the functional component of the stenoses. Each heart team calculated the anatomic SYNTAX score, the noninvasive functional SYNTAX score and subsequently integrated the clinical information to compute the SYNTAX score III providing a treatment recommendation, that is, coronary artery bypass grafting, percutaneous coronary intervention, or equipoise coronary artery bypass grafting-percutaneous coronary intervention. The primary objective was to determine the proportion of patients in whom FFR CT changed the treatment decision and planning. RESULTS Overall, 223 patients were included. Coronary computed tomography angiography assessment was feasible in 99% of the patients and FFR CT analysis in 88%. FFR CT was available for 1030 lesions (mean FFR CT value 0.64±13). A treatment recommendation of coronary artery bypass grafting was made in 24% of the patients with coronary computed tomography angiography with FFR CT . The addition of FFR CT changed the treatment decision in 7% of the patients and modified selection of vessels for revascularization in 12%. With conventional angiography as reference, FFR CT assessment resulted in reclassification of 14% of patients from intermediate and high to low SYNTAX score tertile. CONCLUSIONS In patients with 3-vessel coronary artery disease, a noninvasive physiology assessment using FFR CT changed heart team's treatment decision-making and procedural planning in one-fifth of the patients. CLINICAL TRIAL REGISTRATION URL: https://www.clinicaltrials.gov. Unique identifier: NCT02813473.",2019,The addition of FFR CT changed the treatment decision in 7% of the patients and modified selection of vessels for revascularization in 12%.,"['Patients With Multivessel Coronary Artery Disease', '223 patients were included', 'patients with complex coronary artery disease', 'patients with 3-vessel coronary artery disease']","['Fractional flow reserve (FFR', 'Coronary computed tomography angiography assessment', 'FFR CT', 'Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography', 'coronary computed tomography angiography with FFR CT ', 'conventional angiography', 'FFR computed tomography (CT) derived (FFR CT ', 'coronary artery bypass grafting, percutaneous coronary intervention, or equipoise coronary artery bypass grafting-percutaneous coronary intervention', 'coronary artery bypass grafting', 'percutaneous coronary interventions and coronary artery bypass grafting using either coronary computed tomography angiography or conventional angiography']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0010075', 'cui_str': 'Coronary Vessels'}, {'cui': 'C0852949', 'cui_str': 'Disorder of artery'}]","[{'cui': 'C1299469', 'cui_str': 'Fractional flow reserve'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0002978', 'cui_str': 'Angiography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0442842', 'cui_str': 'Conventional angiography'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0702057', 'cui_str': 'Equipoise'}]",[],223.0,0.0295032,The addition of FFR CT changed the treatment decision in 7% of the patients and modified selection of vessels for revascularization in 12%.,"[{'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Andreini', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Modolo', 'Affiliation': 'Department of Cardiology, Amsterdam University Medical Center, the Netherlands (R.M., Y.K.).'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Katagiri', 'Affiliation': 'Department of Cardiology, Amsterdam University Medical Center, the Netherlands (R.M., Y.K.).'}, {'ForeName': 'Saima', 'Initials': 'S', 'LastName': 'Mushtaq', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Sonck', 'Affiliation': 'Cardiovascular Center Aalst, OLV Hospital, Belgium (J.S., C.C.).'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Collet', 'Affiliation': 'Cardiovascular Center Aalst, OLV Hospital, Belgium (J.S., C.C.).'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'De Martini', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Roberto', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Kaoru', 'Initials': 'K', 'LastName': 'Tanaka', 'Affiliation': 'Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium (K.T., J.C., D.S.).'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Miyazaki', 'Affiliation': 'Thoraxcenter, Erasmus MC, the Netherlands (Y.M., Y.O.).'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Czapla', 'Affiliation': 'Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium (K.T., J.C., D.S.).'}, {'ForeName': 'Danny', 'Initials': 'D', 'LastName': 'Schoors', 'Affiliation': 'Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Belgium (K.T., J.C., D.S.).'}, {'ForeName': 'Andre', 'Initials': 'A', 'LastName': 'Plass', 'Affiliation': 'University of Zurich, Switzerland (A.P., F.M., P.K.).'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Maisano', 'Affiliation': 'University of Zurich, Switzerland (A.P., F.M., P.K.).'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Kaufmann', 'Affiliation': 'University of Zurich, Switzerland (A.P., F.M., P.K.).'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Orry', 'Affiliation': 'CHRU Nancy and Universite de Lorraine, Nancy, France (X.O., P.-A.M., T.F.).'}, {'ForeName': 'Pierre-Adrien', 'Initials': 'PA', 'LastName': 'Metzdorf', 'Affiliation': 'CHRU Nancy and Universite de Lorraine, Nancy, France (X.O., P.-A.M., T.F.).'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Folliguet', 'Affiliation': 'CHRU Nancy and Universite de Lorraine, Nancy, France (X.O., P.-A.M., T.F.).'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Färber', 'Affiliation': 'Jena University Hospital, Friedrich Schiller University of Jena, Germany (G.F., I.D.).'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Diamantis', 'Affiliation': 'Jena University Hospital, Friedrich Schiller University of Jena, Germany (G.F., I.D.).'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Schönweiß', 'Affiliation': 'Heinrich Braun Klinikum, Zwickau, Germany (M.S.).'}, {'ForeName': 'Giorgia', 'Initials': 'G', 'LastName': 'Bonalumi', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Guglielmo', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Ferrari', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Olivares', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cavallotti', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Leal', 'Affiliation': 'Cardialysis BV, Rotterdam, the Netherlands (I.L., W.L.).'}, {'ForeName': 'Wietze', 'Initials': 'W', 'LastName': 'Lindeboom', 'Affiliation': 'Cardialysis BV, Rotterdam, the Netherlands (I.L., W.L.).'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Onuma', 'Affiliation': 'Thoraxcenter, Erasmus MC, the Netherlands (Y.M., Y.O.).'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Department of Cardiology, Royal Brompton and Harefield Hospitals, Imperial College London, United Kingdom (P.W.S.).'}, {'ForeName': 'Antonio L', 'Initials': 'AL', 'LastName': 'Bartorelli', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy (D.A., S.M., S.d.M., M.R., G.B., M.G., C.F., P.O., L.C., A.L.B.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.118.007607'] 1722,32490650,The effect of sacrospinous ligament fixation during vaginal hysterectomy on postoperative de-novo stress incontinence occurrence: A prospective study with two-year follow up.,"BACKGROUND/AIM To investigate the risk of de novo stress urinary incontinence (SUI) occurrence in women who were treated for pelvic organ prolapse (POP) with sacrospinous ligament fixation (SSLF) in addition to vaginal hysterectomy (VAH) and antero-posterior colporrhaphy (CAP) over a 24 month follow up period. MATERIALS AND METHODS A prospective randomized study was designed. Women without occult or obvious SUI were randomized into either one of the study groups: Group1: VAH+CAP, and Group2: VAH+CAP+SSLF. Postoperatively, the patients were re-evaluated for de novo SUI occurrence. RESULTS A total of 150 women were analyzed [G1=VAH+CAP (n:77) and G2= VAH+CAP+SSLF (n:73)]. Mean age, parity, body mass index, menopausal status, and preoperative POP degree, grade 1 and grade 2-3 cystocele and rectocele frequencies were similar between the two groups. During follow-up period, de novo SUI developed in 7 patients (9.1%) of Group1, and in 6 patients (8.2%) of Group2 (p>0.05). In Groups 1 and 2, POP recurrence occurred in 5(6.4%) vs 1(1.3%) cases,respectively (p<0.05). CONCLUSION In patients undergoing surgery for POP, the addition of SSLF did not result in an increased rate of de novo SUI. Careful patient selection, and informing the patients about the risks and benefits of the planned surgical procedure are essential steps in each case of POP.",2020,"In patients undergoing surgery for POP, the addition of SSLF did not result in an increased rate of de novo SUI.","['Women without occult or obvious SUI', 'A total of 150 women were analyzed [G1=VAH+CAP (n:77) and G2= VAH+CAP+SSLF (n:73', 'women who were treated for pelvic organ prolapse (POP) with', 'patients undergoing surgery for POP']","['Group1: VAH+CAP, and Group2: VAH+CAP+SSLF', 'sacrospinous ligament fixation (SSLF', 'vaginal hysterectomy (VAH) and antero-posterior colporrhaphy (CAP', 'sacrospinous ligament fixation', 'vaginal hysterectomy']","['POP recurrence', 'Mean age, parity, body mass index, menopausal status, and preoperative POP degree, grade 1 and grade 2-3 cystocele and rectocele frequencies', 'postoperative de-novo stress incontinence occurrence', 'rate of de novo SUI']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028794', 'cui_str': 'Occultism'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}]","[{'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0225049', 'cui_str': 'Structure of sacrospinous ligament'}, {'cui': 'C0020700', 'cui_str': 'Vaginal hysterectomy'}, {'cui': 'C0195230', 'cui_str': 'Posterior repair of vagina'}, {'cui': 'C0009416', 'cui_str': 'Suture of vagina'}]","[{'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0010695', 'cui_str': 'Cystocele'}, {'cui': 'C0149771', 'cui_str': 'Herniation of rectum into vagina'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",150.0,0.0426981,"In patients undergoing surgery for POP, the addition of SSLF did not result in an increased rate of de novo SUI.","[{'ForeName': 'Eralp', 'Initials': 'E', 'LastName': 'Başer', 'Affiliation': ''}, {'ForeName': 'Kerem Doğa', 'Initials': 'KD', 'LastName': 'Seçkin', 'Affiliation': ''}, {'ForeName': 'Pinar', 'Initials': 'P', 'LastName': 'Kadiroğullari', 'Affiliation': ''}, {'ForeName': 'Hüseyin', 'Initials': 'H', 'LastName': 'Kiyak', 'Affiliation': ''}]",Turkish journal of medical sciences,['10.3906/sag-2005-117'] 1723,32485734,Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial.,"CONTEXT Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. OBJECTIVE To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects the CV benefits of empagliflozin, a sodium-glucose cotransporter-2 inhibitor. DESIGN Post hoc analysis. SETTING Randomized CV outcome trial (EMPA-REG OUTCOME). PARTICIPANTS Type 2 diabetes patients with established CV disease. INTERVENTION Empagliflozin or placebo. MAIN OUTCOME MEASURES Risk of CV outcomes-including the treatment effect of empagliflozin-by achieving 7 goals for CV risk factor control at baseline: (1) glycated hemoglobin <7.5%, (2) low-density lipoprotein cholesterol <100 mg/dL or statin use, (3) systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, (4) pharmacological renin-angiotensin-aldosterone system blockade, (5) normoalbuminuria, (6) aspirin use, (7) nonsmoking. RESULTS In the placebo group, the hazard ratio (HR) for CV death was 4.00 (95% CI, 2.26-7.11) and 2.48 (95% CI, 1.52-4.06) for patients achieving only 0-3 or 4-5 risk factor goals at baseline, respectively, compared with those achieving 6-7 goals. Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]). Empagliflozin significantly reduced these outcomes across all risk factor control categories (P > 0.05 for treatment-by-subgroup interactions). CONCLUSIONS Cardiovascular risk in EMPA-REG OUTCOME was inversely associated with baseline CV risk factor control. Empagliflozin's cardioprotective effect was consistent regardless of multiple baseline risk factor control.",2020,"Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]).",['individuals with type 2 diabetes (T2D'],"['empagliflozin', 'Empagliflozin or placebo', 'Empagliflozin', 'EMPA', 'placebo']","['hazard ratio (HR) for CV death', 'risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke', 'risk factor control categories', 'baseline CV risk factor control', '3-point major adverse CV events', 'Risk of CV outcomes - including treatment effect of empagliflozin - by achievement of seven goals for CV risk factor control at baseline: glycated hemoglobin <7.5%, low-density lipoprotein cholesterol <100 mg/dL or statin use, systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg, pharmacological renin-angiotensin-aldosterone system blockade, normoalbuminuria, aspirin use, non-smoking.\nRESULTS']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]",,0.196854,"Participants achieving 0-3 or 4-5 goals also had increased risk for the composite outcome of hospitalization for heart failure or CV death (excluding fatal stroke) (HR 2.89 [1.82-4.57] and 1.90 [1.31-2.78], respectively) and 3-point major adverse CV events (HR 2.21 [1.53-3.19] and 1.42 [1.06-1.89]).","[{'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Section of Endocrinology, Yale School of Medicine, New Haven, Connecticut.'}, {'ForeName': 'Kamlesh', 'Initials': 'K', 'LastName': 'Khunti', 'Affiliation': 'Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Fitchett', 'Affiliation': ""Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Division of Nephrology, Würzburg University Clinic, Würzburg, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Mattheus', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Anne Pernille', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Boehringer Ingelheim Norway KS, Asker, Norway.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa321'] 1724,32580666,Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease.,"BACKGROUND AND AIMS Physical activity is beneficial in several chronic disorders including Crohn's disease, but the preferred type of exercise is unknown. Our study aimed to examine and compare the safety, feasibility and potential beneficial effects of individual moderate endurance and moderate muscle training in patients with Crohn's disease. METHODS Quiescent or mildly active (Crohn's disease activity index <220) patients with Crohn's disease were randomly allocated to either a control, endurance, or muscle training group. Participants exercised individually for 3 months three times per week. Endpoints included dropout rate, disease activity, inflammatory parameters including faecal calprotectin, anthropometric data, quality of life, physical activity and strength. RESULTS A total of 45 patients with Crohn's disease were randomly allocated. In the endurance group ( n  = 17), the dropout rate was significantly higher (47% vs. 13%) compared with the muscle group ( n  = 15). In both groups the maximal and average strength in the upper and lower extremities increased significantly (all P  < 0.04). In the endurance group emotional function was significantly improved ( P  = 0.03). Statistically significant changes of disease activity and other outcome parameters were not observed in this pilot cohort. CONCLUSION Both individual moderate endurance and muscle training can be safely performed in patients with mild or quiescent Crohn's disease. Muscle training appears more feasible and may be favoured. Both forms of exercise have beneficial effects on strength. Quality of life increased in both intervention groups, although statistical significance was only reached in one subgroup.",2020,In both groups the maximal and average strength in the upper and lower extremities increased significantly (all P  < 0.04).,"[""patients with Crohn's disease"", ""45 patients with Crohn's disease"", ""Quiescent or mildly active (Crohn's disease activity index"", ""220) patients with Crohn's disease"", ""patients with mild or quiescent Crohn's disease"", ""patients with quiescent or mildly active Crohn's disease""]","['individual moderate endurance and muscle training', 'individual moderate endurance and moderate muscle training', 'Muscle training', 'control, endurance, or muscle training group', 'Moderate endurance and muscle training']","['dropout rate', 'emotional function', 'disease activity', 'dropout rate, disease activity, inflammatory parameters including faecal calprotectin, anthropometric data, quality of life, physical activity and strength', 'Quality of life', 'maximal and average strength in the upper and lower extremities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0451071', 'cui_str': ""Crohn's disease activity index""}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1964053', 'cui_str': 'Faecal calprotectin'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]",45.0,0.0320355,In both groups the maximal and average strength in the upper and lower extremities increased significantly (all P  < 0.04).,"[{'ForeName': 'Wolfgang Alexander', 'Initials': 'WA', 'LastName': 'Seeger', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}, {'ForeName': 'Juliane', 'Initials': 'J', 'LastName': 'Thieringer', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Esters', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Allmendinger', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Stein', 'Affiliation': 'Department of Gastroenterology and Clinical Nutrition, Interdisziplinäres Crohn Colitis Centrum, Frankfurt, Germany.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Schulze', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Dignass', 'Affiliation': 'Department of Medicine I, Agaplesion Markus Hospital, Frankfurt, Germany.'}]",United European gastroenterology journal,['10.1177/2050640620936383'] 1725,32585354,The benefits and costs of changing treatment technique in electroconvulsive therapy due to insufficient improvement of a major depressive episode.,"BACKGROUND Electroconvulsive therapy (ECT) technique is often changed after insufficient improvement, yet there has been little research on switching strategies. OBJECTIVE To document clinical outcome in ECT nonresponders who were received a second course using high dose, brief pulse, bifrontotemporal (HD BP BL) ECT, and compare relapse rates and cognitive effects relative to patients who received only one ECT course and as a function of the type of ECT first received. METHODS Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University. Nonresponders received HD BP BL ECT. In a separate multi-site trial, Optimization of ECT, patients were randomized to right unilateral or BL ECT and nonresponders also received further treatment with HD BP BL ECT. RESULTS Remission rates with a second course of HD BP BL ECT were high in ECT nonresponders, approximately 60% and 40% in the Columbia University and Optimization of ECT studies, respectively. Clinical outcome was independent of the type of ECT first received. A second course with HD BP BL ECT resulted in greater retrograde amnesia immediately, two months, and six months following ECT. CONCLUSIONS In the largest samples of ECT nonresponders studied to date, a second course of ECT had marked antidepressant effects. Since the therapeutic effects were independent of the technique first administered, it is possible that many patients may benefit simply from longer courses of ECT. Randomized trials are needed to determine whether, when, and how to change treatment technique in ECT.",2020,Clinical outcome was independent of the type of ECT first received.,"['Patients were classified as receiving Weak, Strong, or HD BP BL ECT during three randomized trials at Columbia University', 'patients who received only one ECT course and as a function of the type of ECT first received']","['Electroconvulsive therapy (ECT) technique', 'right unilateral or BL ECT', 'Electroconvulsive Therapy', 'HD BP BL ECT']","['retrograde amnesia', 'HD BP BL ECT']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C1762617', 'cui_str': 'Weak'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}]","[{'cui': 'C0002624', 'cui_str': 'Retrograde amnesia'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}]",,0.0665526,Clinical outcome was independent of the type of ECT first received.,"[{'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; Department of Radiology, Columbia University, NY, USA. Electronic address: has1@columbia.edu.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Prudic', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA.'}, {'ForeName': 'D P', 'Initials': 'DP', 'LastName': 'Devanand', 'Affiliation': 'Department of Psychiatry, Columbia University, NY, USA; New York State Psychiatric Institute, NY, USA; Department of Neurology, Columbia University, NY, USA.'}, {'ForeName': 'Mitchell S', 'Initials': 'MS', 'LastName': 'Nobler', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, New York Medical College, NY, USA.'}, {'ForeName': 'Roger F', 'Initials': 'RF', 'LastName': 'Haskett', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.'}, {'ForeName': 'Benoit H', 'Initials': 'BH', 'LastName': 'Mulsant', 'Affiliation': 'Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Rosenquist', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'McCall', 'Affiliation': 'Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Augusta, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.06.016'] 1726,32585438,Effect of in-bed cycling on acute muscle wasting in critically ill adults: A randomised clinical trial.,"PURPOSE To examine whether in-bed cycling assists critically ill adults to reduce acute muscle wasting, improve function and improve quality of life following a period of critical illness. MATERIALS AND METHODS A single-centre, two-group, randomised controlled trial with blinded assessment of the primary outcome was conducted in a tertiary ICU. Critically ill patients expected to be mechanically ventilated for at least 48 h were randomised to 30 min daily in-bed cycling in addition to usual-care physiotherapy (n = 37) or usual-care physiotherapy (n = 37). The primary outcome was muscle atrophy of rectus femoris cross-sectional area (RF CSA ) measured by ultrasound at Day 10 following study enrolment. Secondary outcomes included manual muscle strength, handgrip strength, ICU mobility score, six-minute walk test distance and health-related quality of life up to six-months following hospital admission. RESULTS Analysis included the 72 participants (mean age, 56-years; male, 68%) who completed the study. There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). CONCLUSIONS AND RELEVANCE In-bed cycling did not reduce muscle wasting in critically ill adults, but this study provides useful effect estimates for large-scale clinical trials. TRIAL REGISTRATION anzctr.org.au Identifier: ACTRN12616000948493.",2020,"There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). ","['72 participants (mean age, 56-years; male, 68%) who completed the study', 'critically ill adults', 'Critically ill patients expected to be mechanically ventilated for at least 48\xa0h']","['anzctr.org.au Identifier', '30\xa0min daily in-bed cycling in addition to usual-care physiotherapy (n\xa0=\xa037) or usual-care physiotherapy', 'bed cycling']","['quality of life', 'manual muscle strength, handgrip strength, ICU mobility score, six-minute walk test distance and health-related quality of life up to six-months following hospital admission', 'muscle atrophy of rectus femoris cross-sectional area (RF CSA ', 'muscle atrophy of RF CSA']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}]","[{'cui': 'C0600091', 'cui_str': 'Identifier'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0584894', 'cui_str': 'Rectus femoris muscle structure'}]",,0.450536,"There were no significant between-group differences in muscle atrophy of RF CSA at Day 10 (mean difference 3.4, 95% CI -6.9% to 13.6%; p = .52), or for secondary outcomes (p-values ranged p = .11 to p = .95). ","[{'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Nickels', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia; Centre for Functioning and Health Research, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: marc.nickels@health.qld.gov.au.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Aitken', 'Affiliation': 'School of Health Sciences, City, University of London, London, United Kingdom; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia. Electronic address: leanne.aitken.1@city.ac.uk.'}, {'ForeName': 'Adrian G', 'Initials': 'AG', 'LastName': 'Barnett', 'Affiliation': 'Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia. Electronic address: a.barnett@qut.edu.au.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Walsham', 'Affiliation': 'Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; School of Medicine, University of Queensland, Brisbane, Queensland, Australia. Electronic address: james.walsham@health.qld.gov.au.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'King', 'Affiliation': 'Department of Radiology, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: scott.king@health.qld.gov.au.'}, {'ForeName': 'Nicolette E', 'Initials': 'NE', 'LastName': 'Gale', 'Affiliation': 'Department of Radiology, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: nicolette.gale@health.qld.gov.au.'}, {'ForeName': 'Alicia C', 'Initials': 'AC', 'LastName': 'Bowen', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: alicia.bowen@health.qld.gov.au.'}, {'ForeName': 'Brent M', 'Initials': 'BM', 'LastName': 'Peel', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: brent.peel@health.qld.gov.au.'}, {'ForeName': 'Samuel L', 'Initials': 'SL', 'LastName': 'Donaldson', 'Affiliation': 'Physiotherapy Department, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia; Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: samuel.donaldson2@health.qld.gov.au.'}, {'ForeName': 'Stewart T J', 'Initials': 'STJ', 'LastName': 'Mealing', 'Affiliation': 'Intensive Care Unit, Princess Alexandra Hospital, Metro South Health, Brisbane, Queensland, Australia. Electronic address: stewart.mealing@health.qld.gov.au.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'McPhail', 'Affiliation': 'Australian Centre for Health Services Innovation for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology, Brisbane, Queensland, Australia; Centre for Functioning and Health Research, Metro South Health, Brisbane, Queensland, Australia; Clinical Informatics, Metro South Health, Brisbane, Australia. Electronic address: steven.mcphail@qut.edu.au.'}]",Journal of critical care,['10.1016/j.jcrc.2020.05.008'] 1727,32586429,Effectiveness of an mHealth Intervention for Infant Sleep Disturbances.,"Bedtime problems and night wakings are highly prevalent in infants. This study assessed the real-world effectiveness of an mHealth behavioral sleep intervention (Customized Sleep Profile; CSP). Caregivers (83.9% mothers) of 404 infants (age 6 to 11.9 m, M = 8.32 m, 51.2% male) used the CSP (free and publicly available behavioral sleep intervention delivered via smartphone application, Johnson's® Bedtime® Baby Sleep App). Caregivers completed the Brief Infant Sleep Questionnaire-Revised (BISQ-R) at baseline and again 4 to 28 days later. Changes in sleep patterns were analyzed, based on sleep problem status (problem versus no problem sleepers; PS; NPS). Sleep onset latency improved in both groups. Earlier bedtimes, longer continuous stretches of sleep, as well as decreased number and duration of night wakings, were evident in the PS group only. The BISQ-R Total score, total nighttime sleep, and total 24-hour sleep time improved for both groups, with a greater change for the PS group. Further, caregivers of infants in the PS group decreased feeding (bedtime and overnight) and picking up overnight, and perceived better sleep. Bedtime routine regularity, bedtime difficulty, sleep onset difficulty, and caregiver confidence improved for both groups, with the PS group showing a greater magnitude of change. Thus, a real-world, publicly available, mHealth behavioral sleep intervention was associated with improved outcomes for older infants. Intervention recommendations resulted in changes in caregivers' behavior and improvements in caregiver-reported sleep outcomes in infants, in as few as 4 days.",2020,"The BISQ-R Total score, total nighttime sleep, and total 24-hour sleep time improved for both groups, with a greater change for the PS group.","['Caregivers (83.9% mothers) of 404 infants (age 6 to 11.9 m', 'Infant Sleep Disturbances', 'older infants']","['mHealth behavioral sleep intervention (Customized Sleep Profile; CSP', ""CSP (free and publicly available behavioral sleep intervention delivered via smartphone application, Johnson's® Bedtime® Baby Sleep App"", 'mHealth Intervention']","[""caregivers' behavior and improvements in caregiver-reported sleep outcomes"", 'Bedtime routine regularity, bedtime difficulty, sleep onset difficulty, and caregiver confidence', 'BISQ-R Total score, total nighttime sleep, and total 24-hour sleep time', 'feeding (bedtime and overnight) and picking up overnight, and perceived better sleep', 'number and duration of night wakings', 'Bedtime problems and night wakings', 'Brief Infant Sleep Questionnaire-Revised (BISQ-R', 'Sleep onset latency']","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010701', 'cui_str': 'Phyllodes tumour'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C4505222', 'cui_str': 'Sleep Onset Latency'}]",404.0,0.0378914,"The BISQ-R Total score, total nighttime sleep, and total 24-hour sleep time improved for both groups, with a greater change for the PS group.","[{'ForeName': 'Erin S', 'Initials': 'ES', 'LastName': 'Leichman', 'Affiliation': ""Saint Joseph's University. Electronic address: erin.leichman@sju.edu.""}, {'ForeName': 'Russell A', 'Initials': 'RA', 'LastName': 'Gould', 'Affiliation': 'Johnson & Johnson Consumer Inc.'}, {'ForeName': 'Ariel A', 'Initials': 'AA', 'LastName': 'Williamson', 'Affiliation': ""Children's Hospital of Philadelphia.""}, {'ForeName': 'Russel M', 'Initials': 'RM', 'LastName': 'Walters', 'Affiliation': 'Johnson & Johnson Consumer Inc.'}, {'ForeName': 'Jodi A', 'Initials': 'JA', 'LastName': 'Mindell', 'Affiliation': ""Saint Joseph's University; Children's Hospital of Philadelphia.""}]",Behavior therapy,['10.1016/j.beth.2019.12.011'] 1728,32589148,Web-Based Health Coaching for Spinal Cord Injury: Results From a Mixed Methods Feasibility Evaluation.,"BACKGROUND Individuals with spinal cord injury (SCI) are at high risk of experiencing secondary conditions like pressure injuries. Self-management programs may reduce the risk of complications, but traditional programs have proven to be insufficiently tailored to the needs of people with SCI. To overcome barriers to self-management support, a web-based, self-management program was developed for Canadians with SCI called SCI & U. OBJECTIVE This study aims to evaluate the feasibility and potential impact of the SCI & U program in the context of a mixed methods pilot study. METHODS The study followed an explanatory, sequential mixed methods design. Participants (N=11) were Canadians with SCI who had been living in the community for more than 1 year. Each took part in a self-paced, six-session self-management program guided by a trained peer health coach. During sessions, participants could discuss a health topic with their coach from a predefined list (eg, skin or bowel management). Quantitative data were gathered before and after program participation to assess program feasibility and impact. Feasibility measures included attrition rates, frequency of topics selected, and recorded goals, whereas impact measures included measures of self-efficacy (University of Washington Self-Efficacy Scale [UW-SES]), mood (Personal Health Questionnaire Depression Scale [PHQ-8]), secondary conditions (Spinal Cord Injury Secondary Conditions Scale [SCI-SCS]), and resilience (Spinal Cord Injury Quality of Life Resilience Scale [SCI-QOL-R]). Qualitative measures were based on postintervention interviews; these were designed to confirm and expand on quantitative. RESULTS Of the 11 participants, 10 completed pre- and postassessments, and 6 coaching sessions. Sessions lasted between 31 and 81 min (average 55, SD 13), and the duration of the program ranged from 35 to 88 days (average 56, SD 23). Diet and exercise were selected as topics 40% (20/50 sessions with topics) of the time, whereas topics such as mental health, bladder management, pain, and bowel management were chosen less frequently. Results gathered before and after the pilot study demonstrated improvements with moderate effect sizes on the UW-SES and the electronic health literacy scale (ie, Hedges g>0.5). Effect sizes for measures of resilience (SCI-QOL-R), depression (PHQ-8), and secondary conditions (SCI-SCS) were small (ie, Hedges g>0.3). Qualitative results confirmed a common focus on diet and exercise, and defined coaches as sources of accountability, information, reassurance and affirmation, and emotional and technical support. CONCLUSIONS Results demonstrated that a web-based self-management program is feasible and acceptable by Canadians with SCI. Results also indicated a web-based, peer-led self-management program may impact resilience, self-efficacy, mood, and secondary complications. Finally, results illuminated the role of the coach in facilitating behavior change. Future work seeks to validate results in the context of a randomized controlled trial.",2020,Pre- and post results demonstrated improvements with moderate effect sizes on the UW-SES and eHEALS,"['Spinal Cord Injury', 'Individuals with spinal cord injury (SCI', 'Participants (N=11) were Canadians with SCI who had been living in the community for more than 1 year']","['Online Health Coaching', 'SCI&U"" program']","['resilience (SCI-QOL-R), depression (PHQ-8) and secondary conditions (SCI-SCS', 'impact resilience, self-efficacy, mood and secondary complications', 'attrition rates, frequency of health topics selected and recorded goals, while impact measures included measures of self-efficacy (UW-SES), mood (PHQ-8), secondary conditions (SCI-SCS) and resilience (SCI-QOL-R', 'UW-SES and eHEALS']","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0037925', 'cui_str': 'Spinal cord structure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1879301', 'cui_str': 'PHQ Patient Health Questionnaire'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0175699', 'cui_str': 'Saethre-Chotzen syndrome'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332257', 'cui_str': 'Including'}]",11.0,0.0375081,Pre- and post results demonstrated improvements with moderate effect sizes on the UW-SES and eHEALS,"[{'ForeName': 'Sonya', 'Initials': 'S', 'LastName': 'Allin', 'Affiliation': 'Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Shepherd', 'Affiliation': 'Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Teri', 'Initials': 'T', 'LastName': 'Thorson', 'Affiliation': 'Spinal Cord Injury BC, Vancouver, BC, Canada.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Tomasone', 'Affiliation': 'School of Kinesiology and Health Studies, Queens University, Kingston, ON, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Munce', 'Affiliation': 'Toronto Rehabilitation Institute, Toronto, ON, Canada.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Linassi', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'McBride', 'Affiliation': 'Spinal Cord Injury BC, Vancouver, BC, Canada.'}, {'ForeName': 'Tizneem', 'Initials': 'T', 'LastName': 'Jiancaro', 'Affiliation': 'Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Jaglal', 'Affiliation': 'Department of Physical Therapy, University of Toronto, Toronto, ON, Canada.'}]",JMIR rehabilitation and assistive technologies,['10.2196/16351'] 1729,32590214,Perceived social support and posttraumatic stress symptoms in children and youth in therapy: A parallel process latent growth curve model.,"Many studies show that perceived social support protects against the development of posttraumatic stress symptoms (PTSS) in the aftermath of trauma, but less is known about support in relation to PTSS in trauma therapy. This study examined associations between perceived social support and PTSS in children and adolescents during trauma therapy. Parallel process latent growth curve modeling was used to examine trajectories of perceived social support and PTSS over five measurement waves in a sample of 156 patients, aged between 10 and 18 years (M age = 15.1, SD = 2.2, 79.5% girls), randomized to receive trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU). Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy. Most of the change occurred during therapy and was maintained after therapy. Higher levels of PTSS prior to therapy were associated with lower levels of perceived social support prior to therapy, and a decrease in PTSS was associated with increase in perceived social support. This co-development may have been directed by a third underlying factor or short-term temporal effects. Studies investigating within-person associations over shorter time intervals will benefit our understanding of possible temporal effects.",2020,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"['children and adolescents during trauma therapy', '156 patients, aged between 10 and 18 years (M age\xa0=\xa015.1, SD\xa0=\xa02.2, 79.5% girls', 'children and youth in therapy']",['trauma-focused cognitive behavior therapy (TF-CBT) or therapy-as-usual (TAU'],"['Perceived social support and posttraumatic stress symptoms', 'PTSS', 'perceived social support']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1320387', 'cui_str': 'Trauma therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",156.0,0.02545,Across all participants there was an average decline in PTSS and increase of perceived social support from pre-therapy to 18 months after therapy.,"[{'ForeName': 'Marianne S', 'Initials': 'MS', 'LastName': 'Birkeland', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway. Electronic address: Marianne.s.birkeland@gmail.com.'}, {'ForeName': 'Tonje', 'Initials': 'T', 'LastName': 'Holt', 'Affiliation': 'Division of Mental & Physical Health, Norwegian Institute of Public Health, Norway.'}, {'ForeName': 'Silje M', 'Initials': 'SM', 'LastName': 'Ormhaug', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway.'}, {'ForeName': 'Tine K', 'Initials': 'TK', 'LastName': 'Jensen', 'Affiliation': 'Norwegian Centre for Violence and Traumatic Stress Studies, Norway; Department of Psychology, University of Oslo, Norway.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103655'] 1730,32592995,Proactive Integrated Consultation-Liaison Psychiatry: A new service model for the psychiatric care of general hospital inpatients.,"OBJECTIVE To describe a new service model for the psychiatric care of general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK). METHOD The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients. Its design was informed by the published literature and the clinical experience of C-L psychiatrists. It was operationalized by a process of iterative piloting. RESULTS The rationale for the new model and the principles underpinning it are outlined. Details of how to implement it, including a service manual and associated workbook, are provided. The training of clinicians to deliver it is described. The effectiveness and cost-effectiveness of this new service model is being evaluated. Whilst we have found it feasible to deliver and well-accepted by ward teams, potential challenges to its wider implementation are discussed. CONCLUSION Proactive Integrated Consultation-Liaison Psychiatry (PICLP) is a fusion of proactive consultation and integrated care, operationalized in a field-tested service manual. Initial experience indicates that it is feasible to deliver. Its effectiveness and cost effectiveness for older patients on acute medical wards is currently being evaluated in a large multicentre randomized controlled trial (The HOME Study).",2020,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","['general hospital inpatient populations with multimorbidity, such as older medical inpatients', ""general hospital inpatients, called Proactive Integrated Consultation-Liaison Psychiatry ('Proactive Integrated Psychological Medicine' in the UK"", 'general hospital inpatients', 'older patients on acute medical wards']","['Proactive Integrated Consultation-Liaison Psychiatry (PICLP', 'Proactive Integrated Consultation-Liaison Psychiatry']",['effectiveness and cost-effectiveness'],"[{'cui': 'C0020008', 'cui_str': 'Hospitals, General'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1535889', 'cui_str': 'Multimorbidity'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1305702', 'cui_str': 'Ward'}]","[{'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0145088,"The new service model was developed especially for general hospital inpatient populations with multimorbidity, such as older medical inpatients.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sharpe', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK. Electronic address: michael.sharpe@psych.ox.ac.uk.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Toynbee', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Walker', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Psychological Medicine Research, University of Oxford Department of Psychiatry, Warneford Hospital, Oxford, UK.'}]",General hospital psychiatry,['10.1016/j.genhosppsych.2020.06.005'] 1731,32594600,Comparative evaluation of therapeutic efficacy and safety of intralesional triamcinolone acetonide injection vs intralesional radiofrequency with intralesional triamcinolone acetonide in treatment of keloids.,"Management of keloid is difficult, so there is always a need for adequate and effective therapy. In this study, we explored and compared the efficacy and synergistic effect of combined intralesional radiofrequency (RF) and intralesional triamcinolone acetonide (TAC) with intralesional triamcinolone acetonide alone in the treatment of keloids. Sixty patients with keloid were divided in two groups of 30 patients each. In both groups total six sittings every 3 weeks and post treatment follow-up every 6 weeks was done. In group A, intralesional TAC was given. In group B, intralesional radiofrequency followed by triamcinolone was injected. In this study, there were 29 males and 31 females. In groups A and B, 73.4% and 80% of the patients, respectively, achieved grade 4 improvement at the end of 33 weeks, but there was greater mean POSAS score decline in group B in comparison with group A at each visit compared to baseline. Six patients in group A while three in group B showed recurrence. Side effects were equal in number in both groups Thus both the studied modalities of treatment produced equal efficacy and safety but with less recurrence in group B.",2020,Side effects were equal in number in both groups CONCLUSION:,"['Sixty patients with keloid were divided in two groups of 30 patients each', '29 males and 31 females']","['intralesional TAC', 'intralesional triamcinolone acetonide injection', 'combined intralesional radiofrequency (RF) and intralesional triamcinolone acetonide[TAC', 'intralesional radiofrequency followed by triamcinolone', 'triamcinolone acetonide']","['efficacy and synergistic effect', 'Side effects', 'efficacy and safety', 'recurrence', 'mean POSAS score decline']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C3489891', 'cui_str': 'TAC Alternate'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0271219,Side effects were equal in number in both groups CONCLUSION:,"[{'ForeName': 'Vishw', 'Initials': 'V', 'LastName': 'Kaushal', 'Affiliation': 'Guru gobind Singh Medical College and Hospital, Faridkot, Punjab, India.'}, {'ForeName': 'Sumir', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Guru gobind Singh Medical College and Hospital, Faridkot, Punjab, India.'}, {'ForeName': 'Balwinder Kaur', 'Initials': 'BK', 'LastName': 'Brar', 'Affiliation': 'Guru gobind Singh Medical College and Hospital, Faridkot, Punjab, India.'}, {'ForeName': 'Amarbir', 'Initials': 'A', 'LastName': 'Singh', 'Affiliation': 'Guru gobind Singh Medical College and Hospital, Faridkot, Punjab, India.'}]",Dermatologic therapy,['10.1111/dth.13919'] 1732,32683997,Managing Cancer and Living Meaningfully (CALM) Intervention on Chemotherapy-Related Cognitive Impairment in Breast Cancer Survivors.,"Objective: To evaluate the effectiveness and feasibility of Managing Cancer and Living Meaningfully (CALM), which is used to reduce chemotherapy-related cognitive impairment (CRCI), relieve psychological distress, and improve quality of life (QOL) in Chinese breast cancer survivors (BCs). Methods: Seventy-four BCs were enrolled in this study. All patients were randomly assigned to either the CALM group or the care as usual (CAU) group. All patients were evaluated by the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy-Breast (FACT-B) before and after CALM or CAU application to BCs with CRCI. We compared the differences in all these scores between the CALM group and the control group and analyzed the correlation between cognitive function and QOL. Results: Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909, -5.180, -32.421, P = .000, .000, .000, respectively). Finally, there was a positive correlation between cognitive function and QOL in breast cancer patients before ( r = 0.579, P = .000) and after ( r = 0.797, P = .000) treatment. Conclusions: The present results indicated that CALM has salutary effects on the improvement of cognitive impairment and QOL and relieves psychological distress in breast cancer patients, which may be due to a positive correlation between psychological distress and cognitive function or QOL.",2020,"Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909,","['Breast Cancer Survivors', 'breast cancer patients', 'Methods: Seventy-four BCs were enrolled in this study', 'Chinese breast cancer survivors (BCs']","['CALM', 'Managing Cancer and Living Meaningfully (CALM', 'Managing Cancer and Living Meaningfully (CALM) Intervention', 'CAU', 'CALM group or the care as usual (CAU']","['quality of life (QOL', 'cognitive impairment and QOL and relieves psychological distress', 'cognitive function and QOL', 'Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), Distress Thermometer (DT), and the Functional Assessment of Cancer Therapy-Breast']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0917927', 'cui_str': 'Breast conserving surgery'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0150157', 'cui_str': 'Calming'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0444892', 'cui_str': 'CAU'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0332303', 'cui_str': 'Relieved by'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0009738', 'cui_str': 'Congo'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0039818', 'cui_str': 'Thermometer'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}]",74.0,0.0371166,"Compared with the CAU group, the performance of the CALM group on the FACT-Cog, DT, and FACT-B showed significant differences before and after CALM ( t = -18.909,","[{'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Ding', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Xiuqing', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'He', 'Initials': 'H', 'LastName': 'Zuo', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Ziran', 'Initials': 'Z', 'LastName': 'Bi', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}, {'ForeName': 'Huaidong', 'Initials': 'H', 'LastName': 'Cheng', 'Affiliation': 'The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.'}]",Integrative cancer therapies,['10.1177/1534735420938450'] 1733,32602301,Endovascular or open surgical treatment of high-risk patients with infrainguinal peripheral arterial disease and critical limb ischemia.,"Aim To determine preferable type of treatment in our clinical circumstances by following two groups of patients with critical limb ischemia (CLI), who were treated endovascularly and surgically. Methods Research was carried out in the form of a prospective study of 80 patients with CLI and Trans-Atlantic Inter-Society Consensus (TASC) C or D type of arterial disease, with American Society of Anesthesiology (ASA) class III risk, who were randomly divided in two groups as per the treatment they received, surgical and endovascular. Patients were followed during 28 months using clinical examination and Duplex Ultrasound (DUS) in accordance with prescheduled control visits. Results There was a statistical difference between surgical and endovascular group in two years patency (82.5% vs. 55%; p=0.022) but it did not result in the difference in amputation free survival (AFS) (95% vs. 85%; p=0.171) or two-year freedom from major adverse limb events (MALE) (87.5 vs. 77.5; p=0.254). Also, there was no difference in the overall survival of patients (100% vs. 97.5%; p=0.317). Conclusion Initial endovascular treatment is a preferred form of the treatment for selected patient population.",2020,There was a statistical difference between surgical and endovascular group in two years patency (82.5% vs. 55%; p=0.022) but it did not result in the difference in amputation free survival (AFS) (95% vs. 85%; p=0.171) or two-year freedom from major adverse limb events (MALE) (87.5 vs. 77.5; p=0.254).,"['80 patients with CLI and Trans-Atlantic Inter-Society Consensus (TASC) C or D type of arterial disease, with American Society of Anesthesiology (ASA) class III risk', 'patients with critical limb ischemia (CLI), who were treated endovascularly and surgically', 'selected patient population', 'high-risk patients with infrainguinal peripheral arterial disease and critical limb ischemia']","['Endovascular or open surgical treatment', 'surgical and endovascular']","['amputation free survival (AFS', 'overall survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0852949', 'cui_str': 'Disorder of artery'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0085096', 'cui_str': 'Peripheral vascular disease'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]","[{'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",80.0,0.0316282,There was a statistical difference between surgical and endovascular group in two years patency (82.5% vs. 55%; p=0.022) but it did not result in the difference in amputation free survival (AFS) (95% vs. 85%; p=0.171) or two-year freedom from major adverse limb events (MALE) (87.5 vs. 77.5; p=0.254).,"[{'ForeName': 'Dragan', 'Initials': 'D', 'LastName': 'Totić', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Ðurović Sarajlić', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Haris', 'Initials': 'H', 'LastName': 'Vranić', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Amel', 'Initials': 'A', 'LastName': 'Hadžimehmedagić', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Nedžad', 'Initials': 'N', 'LastName': 'Rustempašić', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Muhamed', 'Initials': 'M', 'LastName': 'Djedović', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Haris', 'Initials': 'H', 'LastName': 'Vukas', 'Affiliation': 'Department of Surgery, Cantonal Hospital, Zenica, Bosnia and Herzegovina.'}, {'ForeName': 'Alen', 'Initials': 'A', 'LastName': 'Ahmetašević', 'Affiliation': 'Clinic for Cardiovascular Surgery, University Clinical Centre, Sarajevo, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1143-20'] 1734,32598752,"[Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β].","AIM To evaluate an association of genetic polymorphisms CYP2C19, MDR1, and IL-1β on the eradication rate by 10-day modified therapy in patients with H. pylori - associated diseases. MATERIALS AND METHODS In this study was conducted a prospective, randomized trial, included 89 patients with H. pylori - associated diseases. They were divided into 2 groups depending on therapy: clarithromycin 500 mg, b.i.d., amoxicillin 1000 mg, b.i.d., bismuth subcitrate 240 mg, b.i.d. rabeprazole 20 mg or 40 mg, b.i.d. for 10 days. All subjects underwent pharmacogenetic testing of CYP2C19, MDR1, and IL-1β. RESULTS AND DISCUSSION Per - protocol (PP) eradication rates in group with rabeprazole 40 mg were 97.6% (41/42; 95% CI 87.7-99.6), in group with rabeprazole 20 mg were 82.1% (32/39; 95% CI 67.3-91.0). Intention - to - treat analysis in group with rabeprazole 40 mg eradication rates were 89.1% (41/46; 95% CI 77.0-95.3), in group with standard dose rabeprazole - 74.4% (32/43; 95% CI 59.8-85.1). No significant differences in eradication rates between the groups of ultrarapid, rapid, normal and intermediate CYP2C19 metabolizers (PP: 93.5%/90.3%/84.6% respectively; χ2=0.87, p=0.65). Eradication rates in group with IL-1β CC genotype there was no difference among the IL-1β CT and TT genotype groups (PP: 92.9%/85.7%/94.7% respectively; χ2=1.34; p=0.51). The cure rate among MDR1 TT genotype was significantly lower than among subjects in the MDR1 CC/CT genotype groups (PP: 76.2% vs 96.3%: χ2=5.04; p=0.025; OR=8.13). CONCLUSION Ten - day modified triple therapy with high dose rabeprazole significantly high eradication rates in patients with H. pylori - associated diseases. Independent factor for treatment failure is MDR1 CC/CT genotype status.",2019,"No significant differences in eradication rates between the groups of ultrarapid, rapid, normal and intermediate CYP2C19 metabolizers (PP: 93.5%/90.3%/84.6% respectively; χ2=0.87, p=0.65).","['patients with H. pylori - associated diseases', '89 patients with H. pylori - associated diseases']","['amoxicillin', 'therapy: clarithromycin', 'bismuth subcitrate', 'rabeprazole']","['eradication rate', 'eradication rates', 'cure rate among MDR1 TT genotype', 'Eradication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0243083', 'cui_str': 'associated disease'}]","[{'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0106556', 'cui_str': 'bismuth subcitrate'}, {'cui': 'C0378482', 'cui_str': 'rabeprazole'}]","[{'cui': 'C0017431', 'cui_str': 'Genotype'}]",89.0,0.0359192,"No significant differences in eradication rates between the groups of ultrarapid, rapid, normal and intermediate CYP2C19 metabolizers (PP: 93.5%/90.3%/84.6% respectively; χ2=0.87, p=0.65).","[{'ForeName': 'N V', 'Initials': 'NV', 'LastName': 'Bakulina', 'Affiliation': 'Mechnikov North-Western State Medical University.'}, {'ForeName': 'I V', 'Initials': 'IV', 'LastName': 'Maev', 'Affiliation': 'Yevdokimov Moscow State University of Medicine and Dentistry.'}, {'ForeName': 'I V', 'Initials': 'IV', 'LastName': 'Savilova', 'Affiliation': 'Mechnikov North-Western State Medical University.'}, {'ForeName': 'I G', 'Initials': 'IG', 'LastName': 'Bakulin', 'Affiliation': 'Mechnikov North-Western State Medical University.'}, {'ForeName': 'T A', 'Initials': 'TA', 'LastName': ""Il'chishina"", 'Affiliation': 'SM-clinic.'}, {'ForeName': 'K A', 'Initials': 'KA', 'LastName': 'Zagorodnikova', 'Affiliation': 'Mechnikov North-Western State Medical University.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Murzina', 'Affiliation': 'Mechnikov North-Western State Medical University.'}, {'ForeName': 'D N', 'Initials': 'DN', 'LastName': 'Andreev', 'Affiliation': 'Yevdokimov Moscow State University of Medicine and Dentistry.'}]",Terapevticheskii arkhiv,['10.26442/00403660.2019.08.000380'] 1735,32619050,Super-mini percutaneous nephrolithotomy (PCNL) vs standard PCNL for the management of renal calculi of <2 cm: a randomised controlled study.,"OBJECTIVE To compare the effectiveness and safety of standard percutaneous nephrolithotomy (sPCNL) and super-mini PCNL (SMP). PATIENTS AND METHODS A total of 150 patients presenting with renal calculi of <2 cm were randomised to either sPCNL (Group 1) or SMP (Group 2). Randomisation was based on centralised computer-generated numbers. Variables studied included: stone-free rates (SFRs), operative time, intra- and postoperative complications, postoperative pain score, analgesic requirement, and hospital stay. Statistical analysis was performed using a t-test or Mann-Whitney U-test for continuous variables and chi-squared test or Fisher's exact test for categorical variables. RESULTS Between September 2018 and April 2019, 75 patients were included in each group. The SFRs of the groups were similar (97.33 vs 98.66%, P = 0.56). The mean (sd) operative time was significantly longer in Group 2, at 36.40 (14.07) vs 23.12 (11.96) min (P < 0.001). The mean (sd) decrease in haemoglobin was significantly less in Group 2, at 3.0 (4.9) vs 7.5 (6.5) g/L (P < 0.001). The mean (sd) pain score at 24 h was significantly lower in Group 2, at 0.3 (0.46) vs 0.75 (0.53) (P < 0.001). The mean (sd) analgesic requirement was significantly less in Group 2, at 67 (22.49) vs 91.5 (30.56) mg tramadol (P < 0.001). The mean (sd) hospital stay was significantly less in Group 2, at 28.38 (3.6) vs 39.84 (3.7) h (P < 0.001). CONCLUSIONS SMP is equally as effective as sPCNL for managing renal calculi of <2 cm, with improved safety. Although SMP is associated with a longer operative time, it has a significantly lower incidence of bleeding and postoperative pain, and a shorter hospital stay.",2020,"The stone free rates in both groups were similar (97.33 vs 98.66%, p = 0.56).","['75 patients were included in each group', 'Between September 2018 and April 2019', 'renal calculi < 2 cm', '150 patients presenting with renal calculi < 2 cm']","['Super-mini Percutaneous Nephrolithotomy (SMP) vs Standard Percutaneous Nephrolithotomy (sPNL', 'SMP', 'standard and super-mini PNL (SMP']","['stone free rates, operating time, intra-operative and postoperative complications, postoperative pain score, analgesic requirement and hospital stay', 'stone free rates', 'efficacy and safety', 'Mean [SD] decrease in hemoglobin', 'Mean [SD] pain score', 'bleeding, postoperative pain score and lesser hospital stay', 'Mean [SD] operating time (minutes', 'Mean [SD] hospital stay (hours', 'Mean [SD] analgesic requirement (mg tramadol']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0150312', 'cui_str': 'Present'}]","[{'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}]",75.0,0.0697676,"The stone free rates in both groups were similar (97.33 vs 98.66%, p = 0.56).","[{'ForeName': 'Raja Sekhar', 'Initials': 'RS', 'LastName': 'Guddeti', 'Affiliation': 'Department of Urology, Kasturba Hospital, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.'}, {'ForeName': 'Padmaraj', 'Initials': 'P', 'LastName': 'Hegde', 'Affiliation': 'Department of Urology, Kasturba Hospital, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Chawla', 'Affiliation': 'Department of Urology, Kasturba Hospital, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.'}, {'ForeName': 'Jean J M C H', 'Initials': 'JJMCH', 'LastName': 'de la Rosette', 'Affiliation': 'Department of Urology, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Maria Pilar', 'Initials': 'MP', 'LastName': 'Laguna Pes', 'Affiliation': 'Department of Urology, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Aseem', 'Initials': 'A', 'LastName': 'Kapadia', 'Affiliation': 'Department of Urology, Kasturba Hospital, Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India.'}]",BJU international,['10.1111/bju.15144'] 1736,32621374,Impact of Point-of-care Testing on Length of Stay of Patients in the Emergency Department: A Cluster-randomized Controlled Study.,"OBJECTIVES Crowding is a frequent concern in the emergency department (ED). Laboratory point-of-care testing (POCT) has been proposed to decrease patients' length of stay (LOS). Our objective was to determine whether an extended panel of POCT solutions could reduce LOS. METHODS This was a single-center, prospective, open-label, controlled cluster-randomized study. Blood test processing was randomized into 1-week inclusion periods: interventional arm (laboratory analyses performed on POCT analyzers implemented in the ED) or control arm (central laboratory). The primary endpoint was LOS of patients in the ED. Secondary endpoints were time to result (TTR), ED crowding surrogates, and average total cost of an ED visit in each arm. RESULTS A total of 23,231 patients were included and 20,923 were analyzed for the main outcome measure. Mean ± SD age was 46 ± 20 years, and 7,905 (36%) underwent blood sampling. Mean ± SD LOSs were 203 ± 161 and 210 ± 168 minutes in the POCT and control arms, respectively. LOS reduction for the entire ED population was -9 minutes (95% confidence interval [CI] = -22 to 5, p = 0.22) compared to the control arm and -17 minutes (95% CI = -34.0 to 0.6, p = 0.06) for patients undergoing blood sampling. The mean ± SD TTRs were 28 ± 31 and 79 ± 34 minutes in the POCT and control arms, respectively (TTR reduction = -51 minutes, 95% CI = -54 to -48 minutes, p < 0.001). CONCLUSIONS The implementation of an extended panel of POCT solutions in an ED did not significantly reduce the LOS, but reduced the TTR.",2020,"Mean LOS was 203 ± 161 and 210 ± 168 minutes (min) in the POCT arm and control arm, respectively.","['Mean age was 46 ± 20 years, and 7,905 (36%) underwent blood sampling', 'of patients in the emergency department', 'A total of 23,231 patients']","['care testing (POCT', 'care testing']","['LOS reduction', 'LOS', 'length of stay', ""patients' length of stay (LOS"", 'time to result (TTR), ED crowding surrogates, and average total cost of an ED visit in each arm', 'TTR reduction']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C1319069', 'cui_str': 'Point of care testing'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]",23231.0,0.138528,"Mean LOS was 203 ± 161 and 210 ± 168 minutes (min) in the POCT arm and control arm, respectively.","[{'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Hausfater', 'Affiliation': 'From the, Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Paris, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hajage', 'Affiliation': 'the, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), Sorbonne Université, APHP, Paris, France.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Bulsei', 'Affiliation': ""the, AP-HP URC Eco Ile de France Hôpital de l'Hôtel Dieu, Paris, France.""}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Canavaggio', 'Affiliation': 'From the, Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Paris, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Lafourcade', 'Affiliation': 'the, Unité de Recherche Clinique Salpêtrière-Charles Foix, APHP, Paris, France.'}, {'ForeName': 'Anne Laure', 'Initials': 'AL', 'LastName': 'Paquet', 'Affiliation': 'From the, Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Paris, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Arock', 'Affiliation': 'the, Sorbonne Université, Paris, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Durand-Zaleski', 'Affiliation': ""the, AP-HP URC Eco Ile de France Hôpital de l'Hôtel Dieu, Paris, France.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Riou', 'Affiliation': 'From the, Emergency Department, Hôpital Pitié-Salpêtrière, APHP, Paris, France.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Oueidat', 'Affiliation': 'and the, Biochemisty and Emergency Biology Department, Hôpital Pitié-Salpêtrière, APHP, Paris, France.'}]",Academic emergency medicine : official journal of the Society for Academic Emergency Medicine,['10.1111/acem.14072'] 1737,32621918,Dexmedetomidine pretreatment attenuates myocardial ischemia reperfusion induced acute kidney injury and endoplasmic reticulum stress in human and rat.,"BACKGROUND Patients undergoing cardiopulmonary bypass (CPB) often develop acute kidney injury (AKI) caused by myocardial ischemia reperfusion (MI/R), and this renal injury can be resolved notably by dexmedetomidine. Endoplasmic reticulum (ER) stress was reported to get involved in organ injury including AKI. OBJECTIVES The current study aimed to address the correlation between MI/R induced AKI with ER stress and to assess the effects of dexmedetomidine pretreatment on AKI protection. METHOD Patients selected for heart valve replacement surgery were randomly assigned to NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine). Rat MI/R model was induced by occluding coronary artery for 30 min followed by 48-hour reperfusion. Rats were randomized into Sham (0.9% NaCl), I/R (MI/R + 0.9% NaCl) and I/R + DEX (MI/R + dexmedetomidine). Organ function and ER stress condition were evaluated by blood chemistry, pathology, and molecular test. RESULTS Clinical data indicated dexmedetomidine pretreatment attenuated AKI and oxidative stress as well as postischemic myocardial injury in patients. Accordingly animal results suggested dexmedetomidine reduced cellular injury and improved postischemic myocardial and renal function. Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. CONCLUSIONS These results suggested that dexmedetomidine pretreatment attenuates MI/R injury-induced AKI by relieving the ER stress.",2020,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","['Patients undergoing', 'Patients selected for heart valve replacement surgery', 'human and rat']","['cardiopulmonary bypass (CPB', 'NS group (pre-anesthesia with 0.9% NaCl) and DEX group (pre-anesthesia with dexmedetomidine', 'Dexmedetomidine', '\u202fDEX (MI/R\u202f+\u202fdexmedetomidine', 'dexmedetomidine']","['MI/R injury-induced AKI', 'Endoplasmic reticulum (ER) stress', 'AKI and oxidative stress', 'myocardial and renal cells apoptosis and down-regulated ER stress', 'cellular injury and improved postischemic myocardial and renal function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0190173', 'cui_str': 'Heart valve replacement'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035124', 'cui_str': 'Reperfusion'}]","[{'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0035126', 'cui_str': 'Ischemia-reperfusion injury'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0014239', 'cui_str': 'Endoplasmic reticulum'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0162638', 'cui_str': 'Apoptosis'}, {'cui': 'C0851285', 'cui_str': 'Regulation'}, {'cui': 'C3178870', 'cui_str': 'Stress, Endoplasmic Reticulum'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}]",,0.0396497,"Dexmedetomidine also reduced myocardial and renal cells apoptosis and down-regulated ER stress. ","[{'ForeName': 'Chaoliang', 'Initials': 'C', 'LastName': 'Tang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: chaolt@ustc.edu.cn.'}, {'ForeName': 'Yida', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesia, Critical Care & Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02144, USA.'}, {'ForeName': 'Jiazhen', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': 'Department of Emergency, Huashan Hospital North, Fudan University, Shanghai, 201907, China.'}, {'ForeName': 'Si', 'Initials': 'S', 'LastName': 'Shi', 'Affiliation': 'Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China.'}, {'ForeName': 'Jiawu', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Qingtian', 'Initials': 'Q', 'LastName': 'Geng', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China.'}, {'ForeName': 'Xinghan', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': 'Department of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230000, Anhui, China.'}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'Chai', 'Affiliation': 'Department of Anesthesiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China. Electronic address: xiaoqingchai@163.com.'}]",Life sciences,['10.1016/j.lfs.2020.118004'] 1738,32622871,Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.,"Efficient therapies are available for the treatment of osteoporosis. Bisphosphonates and denosumab are the most commonly used antiresorptive therapies. Despite differences in the increase in bone mineral density seen with these drugs, the reductions in fracture risk are similar; 50-70%, 20%, and 40% for vertebral, non-vertebral and hip fractures, respectively. The bone-forming treatments; teriparatide and abaloparatide increase bone mineral density more than the antiresorptives and the reductions in fracture risk are 85% and 40-50% for vertebral and non-vertebral fractures, respectively, compared to placebo. The VERO study demonstrated a >50% reduction in vertebral and clinical fractures in women treated with teriparatide compared to risedronate. The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years. The evidence for combination therapy targeting both resorption and formation is limited as only short-term studies with BMD as the endpoint have been performed. All bone-forming and dual-action treatments increase BMD and reduce the fracture risk, however, the effect wears off with time and treatment is therefore only temporary and should be followed by antiresorptive treatment with a bisphosphonate or denosumab. The sequence of treatment matters as the BMD response to teriparatide is reduced in patients previously treated with bisphosphonates; however, based on the findings of the VERO trial, the anti-fracture efficacy of bone-forming treatment in comparison with risedronate seems to be preserved after bisphosphonate therapy. The DATA study suggested that transitioning from denosumab to teriparatide is problematic due to the increase in bone resorption occurring after stopping denosumab. Studies have shown further improvements in BMD when transitioning from oral bisphosphonates to zoledronic acid or denosumab. Management of osteoporosis will in many patients include a long-term treatment plan. This will often include sequential therapy which in severe cases preferably should start with bone-forming followed by antiresorptive treatment. The severity of osteoporosis, reaching a treatment goal, and responding to treatment failure are important factors determining the treatment sequence in the individual patient.",2020,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","['patients previously treated with', 'postmenopausal osteoporosis with bone-forming and antiresorptive treatments']","['teriparatide', 'zoledronic acid or denosumab', 'Bisphosphonates and denosumab', 'bisphosphonates', 'alendronate', 'bisphosphonate or denosumab', 'risedronate', 'placebo']","['bone mineral density', 'vertebral and clinical fractures', 'risk of vertebral, non-vertebral and hip fractures', 'BMD', 'risk of vertebral and clinical fractures', 'fracture risk', 'BMD response', 'bone resorption']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0029458', 'cui_str': 'Postmenopausal osteoporosis'}, {'cui': 'C1286272', 'cui_str': 'Form of bone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0070093', 'cui_str': 'Teriparatide'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0012544', 'cui_str': 'Bisphosphonate'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0246719', 'cui_str': 'Risedronate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0549207', 'cui_str': 'Bone structure of spine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}]",,0.0195905,"The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.","[{'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Langdahl', 'Affiliation': 'Aarhus University Hospital, Endocrinology and Internal Medicine, Palle Juul Jensen Boulevard 115, DK8200 Aarhus N, Denmark. Electronic address: bente.langdahl@aarhus.rm.dk.'}]",Bone,['10.1016/j.bone.2020.115516'] 1739,32622918,Abdominal Ice after Laparoscopic Hysterectomy: A Randomized Controlled Trial.,"STUDY OBJECTIVE To assess the impact of abdominal ice packs on opioid use and pain control after laparoscopic hysterectomy DESIGN: Randomized controlled trial. SETTING Academic tertiary care medical center. PATIENTS Total of 142 adult women undergoing laparoscopic (either conventional or robotic) hysterectomy were randomized to control (n = 69) or intervention (n = 73). Exclusion criteria included preoperative opioid use, planned intensive care unit admission or same-day discharge, an incision ≥4 cm, and regional anesthesia use. INTERVENTIONS Subjects in the intervention group had a large ice pack placed directly on the lower abdomen before leaving the operating room. The ice pack was maintained continuously for 12 hours postoperation, as desired thereafter until discharge, and continued use encouraged after discharge for up to 48 hours. MEASUREMENTS AND MAIN RESULTS Total opioids administered postoperatively, while inpatient and after dismissal, were assessed in morphine milligram equivalents. Postoperative pain, as well as analgesia acceptability and side effects, were assessed using validated measures: Brief Pain Inventory and Overall Benefit of Analgesia Score. Median morphine milligram equivalent was lower in the intervention group than the controls from inpatient stay on the floor to completion of opioid use as an outpatient (22.5 vs 26.2) but was not statistically significant (p = .79). There was no significant difference between the groups in Brief Pain Inventory assessment of postoperative pain severity (p = .80) or pain interference (p = .36) or Overall Benefit of Analgesia Score total score (p = .88). Most patients in the intervention group were very satisfied with ice pack use (n = 51, 79.7%) and very likely to recommend it to friends or family (n = 54, 83.1%). There were no adverse events related to ice pack use. CONCLUSION There was no significant difference in postoperative opioid use or pain assessment with ice pack use after laparoscopic hysterectomy. However, most of the subjects expressed high satisfaction specific to ice pack use and would recommend its use to others, suggesting potential desirability as adjunct therapy in postoperative pain control.",2020,There was no significant difference between groups in BPI assessment of postoperative pain severity (p=.80) or pain interference (p=.36) or OBAS total score (p=.88).,"['One-hundred-forty-two adult women undergoing', 'Exclusion criteria included preoperative opioid use, planned ICU admission or same-day discharge, an incision ≥4 cm, and regional anesthesia use']","['laparoscopic hysterectomy', 'large ice pack placed directly on the lower abdomen prior to leaving the operating room', 'laparoscopic (either conventional or robotic) hysterectomy', 'abdominal ice packs']","['Brief Pain Inventory (BPI) and Overall Benefit of Analgesia Score (OBAS', 'OBAS total score', 'analgesia acceptability and side effects', 'postoperative opioid use or pain assessment', 'BPI assessment of postoperative pain severity', 'pain interference', 'Median MME', 'morphine milligram equivalents (MME', 'Postoperative pain']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}]","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0181264', 'cui_str': 'Ice bag'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0607422', 'cui_str': 'Abdoman (drug)'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030198', 'cui_str': 'Pain assessment'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439210', 'cui_str': 'mg'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]",142.0,0.0867692,There was no significant difference between groups in BPI assessment of postoperative pain severity (p=.80) or pain interference (p=.36) or OBAS total score (p=.88).,"[{'ForeName': 'Adela G', 'Initials': 'AG', 'LastName': 'Cope', 'Affiliation': 'Department of Obstetrics and Gynecology (Drs. Cope, Wetzstein, Laughlin-Tommaso, and Burnett).'}, {'ForeName': 'Marnie M', 'Initials': 'MM', 'LastName': 'Wetzstein', 'Affiliation': 'Department of Obstetrics and Gynecology (Drs. Cope, Wetzstein, Laughlin-Tommaso, and Burnett).'}, {'ForeName': 'Kristin C', 'Initials': 'KC', 'LastName': 'Mara', 'Affiliation': 'Division of Biomedical Statistics and Informatics (Dr. Mara).'}, {'ForeName': 'Shannon K', 'Initials': 'SK', 'LastName': 'Laughlin-Tommaso', 'Affiliation': 'Department of Obstetrics and Gynecology (Drs. Cope, Wetzstein, Laughlin-Tommaso, and Burnett).'}, {'ForeName': 'Nafisseh S', 'Initials': 'NS', 'LastName': 'Warner', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine (Dr. Warner); Kern Center for the Science of Health Care Delivery (Dr. Warner), Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Tatnai L', 'Initials': 'TL', 'LastName': 'Burnett', 'Affiliation': 'Department of Obstetrics and Gynecology (Drs. Cope, Wetzstein, Laughlin-Tommaso, and Burnett). Electronic address: burnett.tatnai@mayo.edu.'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2020.06.027'] 1740,32623230,"Supplemental income program design: A cluster-randomized controlled trial to examine the health and wellbeing effects on older adults by gender, duration, and payment frequency.","BACKGROUND We documented results from a cluster-randomized controlled trial we designed to supplement incomes in poor towns among adults 70 or older. We analyzed effects on health by gender, persistence over time, and variation by payment frequency. METHODS We compared supplemental income effects over an 18-month period for two towns in Yucatan, Mexico: Valladolid, where eligible individuals received a monthly income supplement over the entire analysis period, and Motul, a demographically matched control town, where eligible individuals received a bimonthly income supplement over the last 12 months of the analysis period. While differing in frequency of payment, supplements provided similar levels of income. We conducted three surveys of recipients: (1) at baseline, (2) six months after baseline, and (3) 18 months after baseline. RESULTS The primary outcomes we examined were peak expiratory flow, hemoglobin level, and verbal recall. The secondary outcomes were health care use and food availability. We found health benefits persisted for at least eighteen months for the monthly income supplement, with both males and females benefiting. Bimonthly income supplements had smaller health benefits. CONCLUSIONS Older people in the developing world who lack social security benefits and health care may benefit most from monthly income programs. The greater payment frequency of monthly programs may influence how household resources are allocated. Supplemental income programs are common in low- and middle-income countries; hence, our results have implications for program design in many nations.",2020,"We found health benefits persisted for at least eighteen months for the monthly income supplement, with both males and females benefiting.","['supplement incomes in poor towns among adults 70 or older', 'older adults by gender, duration, and payment frequency']",[],"['health care use and food availability', 'peak expiratory flow, hemoglobin level, and verbal recall', 'smaller health benefits']","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0220808', 'cui_str': 'Compensation'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",[],"[{'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0086387', 'cui_str': 'Health Benefits'}]",,0.190785,"We found health benefits persisted for at least eighteen months for the monthly income supplement, with both males and females benefiting.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Aguila', 'Affiliation': 'Sol Price School of Public Policy, USC, 650 Childs Way, RGL Hall, Room 226, Los Angeles, CA, 90089, USA. Electronic address: eaguilav@usc.edu.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Smith', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA, 90401, USA.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2020.113139'] 1741,32623343,"""Sushi roll"" technique for precise total tongue functional reconstruction using a pre-sutured femoral anterolateral myocutaneous flap.","OBJECTIVES Reconstruction of the total tongue after cancer resection remains one of the challenges in head and neck surgery. Inadequate reconstruction after subtotal or total glossectomy defects leads to poor quality of life. The aim of this study was to explore an economical, practical and effective flap design for functional tongue reconstruction. MATERIAL AND METHODS Sixty patients were randomly divided into two groups, namely, a ""Sushi roll"" technique group (30 patients) and a conventional surgery group (30 patients). Then, the patients underwent total or subtotal tongue reconstruction. Swallowing function, speech intelligibility, cosmetic results, and quality of life were assessed with the appropriate scales. Outcomes were analysed, and a p-value <0.05 was considered significant. RESULTS The perioperative recovery of the ""Sushi roll"" group was superior to that of the conventional group. Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). CONCLUSION The innovative ""Sushi roll"" anterolateral thigh myocutaneous flap approach for total tongue reconstruction creates a free neotongue tip with adequate volume and protuberance and causes minimal damage to the donor site, producing acceptable swallowing function and speech intelligibility.",2020,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","['head and neck surgery', 'Sixty patients']","['Sushi roll"" technique group', 'conventional surgery', 'Sushi roll"" technique', 'subtotal tongue reconstruction']","['speech intelligibility', 'swallowing function', 'Swallowing function, speech intelligibility, cosmetic results, and quality of life', 'perioperative recovery', 'cosmetic results']","[{'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0399188', 'cui_str': 'Tongue reconstruction'}]","[{'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",60.0,0.0201308,"Relative to patients in the conventional group, patients in the ""Sushi roll"" group showed significantly improved speech intelligibility (p = 0.025), cosmetic results (p < 0.001) and swallowing function (p < 0.001). ","[{'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China. Electronic address: drzhouxi0504@csu.edu.cn.'}, {'ForeName': 'Zhi-Jing', 'Initials': 'ZJ', 'LastName': 'He', 'Affiliation': 'Lecturer, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.'}, {'ForeName': 'Yu-Xiong', 'Initials': 'YX', 'LastName': 'Su', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, Faculty of Dentistry, the University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Zhang', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Zhao Jian', 'Initials': 'ZJ', 'LastName': 'Gong', 'Affiliation': 'Associate Professor, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}, {'ForeName': 'Han Jiang', 'Initials': 'HJ', 'LastName': 'Wu', 'Affiliation': 'Professor and Chief, Discipline of Oral & Maxillofacial Surgery, The Second Xiangya hospital, Central South University, Changsha, China.'}]",Oral oncology,['10.1016/j.oraloncology.2020.104866'] 1742,32590084,Blood transfusion and ischaemic outcomes according to anemia and bleeding in patients with non-ST-segment elevation acute coronary syndromes: Insights from the TAO randomized clinical trial.,"BACKGROUND The benefits and risks of blood transfusion in patients with acute myocardial infarction who are anemic or who experience bleeding are debated. We sought to study the association between blood transfusion and ischemic outcomes according to haemoglobin nadir and bleeding status in patients with NST-elevation myocardial infarction (NSTEMI). METHODS The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to heparin plus eptifibatide versus otamixaban. After exclusion of patients who underwent coronary artery bypass surgery, patients were categorized according to transfusion status considering transfusion as a time-varying covariate. The primary ischemic outcome was the composite of all-cause death or MI within 180 days of randomization. Subgroup analyses were performed according to pre-transfusion hemoglobin nadir and bleeding status. RESULTS 12,547 patients were enrolled. Among these, blood transfusion was used in 489 (3.9%) patients. Patients who received transfusion had a higher rate of death or MI (29.9% vs. 8.1%, p<0.01). This excess risk persisted after adjustment on GRACE score and nadir of hemoglobin (HR 3.36 95%CI 2.63-4.29 p<0.01). Subgroup analyses showed that blood transfusion was associated with a higher risk in patients without overt bleeding (adjusted HR 6.25 vs. 2.85; p-interaction 0.001) as well as in those with hemoglobin nadir > 9.0 g/dl (HR 4.01; p-interaction<0.0001). CONCLUSION In patients with NSTEMI, blood transfusion was associated with an overall increased risk of ischaemic events. However, this was mainly driven by patients without overt bleeding and those hemoglobin nadir > 9.0g/dl. This suggests possible harm of transfusion in those groups.",2020,Subgroup analyses showed that blood transfusion was associated with a higher risk in patients without overt bleeding (adjusted HR 6.25 vs. 2.85; p-interaction 0.001) as well as in those with hemoglobin nadir >,"['patients with NST-elevation myocardial infarction (NSTEMI', 'The TAO trial randomized patients with NSTEMI and coronary angiogram scheduled within 72h to', 'patients with acute myocardial infarction who are anemic or who experience bleeding are debated', 'patients with non-ST-segment elevation acute coronary syndromes', '12,547 patients were enrolled']","['blood transfusion', 'coronary artery bypass surgery', 'heparin plus eptifibatide versus otamixaban']","['anemia and bleeding', 'GRACE score and nadir of hemoglobin', 'risk of ischaemic events', 'composite of all-cause death or MI', 'Blood transfusion and ischaemic outcomes', 'rate of death or MI', 'blood transfusion', 'haemoglobin nadir and bleeding status']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0040021', 'cui_str': 'Thromboangiitis obliterans'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C3160886', 'cui_str': 'Non ST segment elevation acute coronary syndrome'}]","[{'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0253563', 'cui_str': 'eptifibatide'}, {'cui': 'C1097497', 'cui_str': 'otamixaban'}]","[{'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",12547.0,0.115362,Subgroup analyses showed that blood transfusion was associated with a higher risk in patients without overt bleeding (adjusted HR 6.25 vs. 2.85; p-interaction 0.001) as well as in those with hemoglobin nadir >,"[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Deharo', 'Affiliation': 'Département de Cardiologie, CHU Timone, Marseille F-13385, France; Aix Marseille Univ, Inserm, Inra, C2VN, Marseille, France; Aix-Marseille Université, Faculté de Médecine, F-13385 Marseille, France.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Ducrocq', 'Affiliation': 'Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris-Diderot, Département Hospitalo-Universitaire FIRE, Sorbonne-Paris Cité, Paris, France; FACT (French Alliance for Cardiovascular clinical Trials), an F-CRIN network,l: NHLI, Royal Brompton Hospital, Imperial College, London, United Kingdom.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Bode', 'Affiliation': 'Heart Center Freiburg University, Cardiology and Angiology I, Faculty of Medicine, Freiburg, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Cohen', 'Affiliation': 'Newark Beth Israel Medical Centre, Newark NJ and Rutgers-New Jersey Medical School, Newark, New Jersey, USA.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Cuisset', 'Affiliation': 'Département de Cardiologie, CHU Timone, Marseille F-13385, France.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Mehta', 'Affiliation': 'McMaster University and the Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'ForeName': 'C V', 'Initials': 'CV', 'LastName': 'Pollack', 'Affiliation': 'Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'S D', 'Initials': 'SD', 'LastName': 'Wiviott', 'Affiliation': ""TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'Rao', 'Affiliation': 'Department of Cardiology, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'J W', 'Initials': 'JW', 'LastName': 'Jukema', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; The Netherlands Heart Institute, Utrecht, the Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Erglis', 'Affiliation': 'University of Latvia, Pauls Stradins Clinical University Hospita, Riga, Latvia.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Moccetti', 'Affiliation': 'Electrophysiology Unit, Department of Cardiology, Fondazione Cardiocentro Ticino, via Tesserete 48, 6900 Lugano, Switzerland.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Elbez', 'Affiliation': 'Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris-Diderot, Département Hospitalo-Universitaire FIRE, Sorbonne-Paris Cité, Paris, France; FACT (French Alliance for Cardiovascular clinical Trials), an F-CRIN network,l: NHLI, Royal Brompton Hospital, Imperial College, London, United Kingdom.'}, {'ForeName': 'P G', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'French Alliance for Cardiovascular Trials, Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale, Paris, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, UK. Electronic address: gabriel.steg@aphp.fr.'}]",International journal of cardiology,['10.1016/j.ijcard.2020.06.020'] 1743,32593791,Differential effects of modafinil on performance of low-performing and high-performing individuals during total sleep deprivation.,"BACKGROUND Individual responses to the effects of inadequate sleep have been well documented; some people are more vulnerable to the effects of sleep loss than others. Fatigue-vulnerable individuals generally require access to effective fatigue countermeasures; however, the question arises as to whether these fatigue-vulnerable individuals receive the same benefits shown in group efficacy data. The present study administered modafinil to individuals to determine its differential effects on performance of best and worst performers during sleep deprivation. METHODS A sample of 22 men, age 21-40 yrs., was tested on 2 separate occasions during which they were kept awake for 36 h. During one period they received 200 mg modafinil; during the other they received placebo. Participants were tested on a variety of tasks while rested and at 5-hr intervals across the continuous wakefulness period. Performance for each cognitive task and subjective measure of fatigue from the placebo period was used to group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task. RESULTS Results indicated that on the MTS task, the HP group performed the same throughout the testing period, regardless of whether they received modafinil or not. However, the LP group significantly improved after receiving modafinil compared to placebo. Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo. Performance on the RDM showed no difference between groups, regardless of drug condition. Groups did not differ after receiving modafinil on subjective fatigue measured by the POMS. CONCLUSIONS Depending on the task, HP individuals did not benefit substantially when administered modafinil compared to placebo. However, the LP individuals improved after receiving modafinil compared to placebo.",2020,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","['low-performing and high-performing individuals during total sleep deprivation', 'group individuals into high (HP) or low performance (LP) groups to indicate fatigue vulnerability for each task', 'A sample of 22 men, age 21-40\u202fyrs., was tested on 2 separate occasions during which they were kept awake for 36\u202fh']","['modafinil', '200\u202fmg modafinil', 'placebo']","['subjective fatigue', 'lapses', 'number of lapses']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0521125', 'cui_str': 'For'}]","[{'cui': 'C0066677', 'cui_str': 'modafinil'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.090569,"Performance on the PVT showed the HP group had a small decrease in the number of lapses after receiving modafinil compared to placebo, whereas the LP group had a large decrease in lapses after receiving modafinil compared to placebo.","[{'ForeName': 'J Lynn', 'Initials': 'JL', 'LastName': 'Caldwell', 'Affiliation': 'Naval Medical Research Unit Dayton, United States of America. Electronic address: jo.caldwell@us.af.mil.'}, {'ForeName': 'Valarie M', 'Initials': 'VM', 'LastName': 'Schroeder', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Christina L', 'Initials': 'CL', 'LastName': 'Kunkle', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}, {'ForeName': 'Henry G', 'Initials': 'HG', 'LastName': 'Stephenson', 'Affiliation': 'The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States of America.'}]","Pharmacology, biochemistry, and behavior",['10.1016/j.pbb.2020.172968'] 1744,32593895,Effect of administration of β-hydroxy-β-methyl butyrate-enriched formula after liver transplantation: A pilot randomized controlled trial.,"OBJECTIVE Most patients undergoing liver transplantation (LT) have decreased skeletal muscle mass, malnutrition, and decreased physical activity levels. These comorbidities may prevent early recovery after surgery. The aim of this study was to examine the effects of oral nutritional formula-enriched β-hydroxy-β-methyl-butyrate (HMB), a leucine metabolite that promotes muscle synthesis and suppresses proteolysis, on postoperative sarcopenia and other outcomes after adult-to-adult living donor LT (LDLT). METHODS Thirty-three consecutive patients who underwent adult LDLT between March 2017 and October 2018 and who met inclusion criteria were randomly assigned in a 1:1 ratio to the HMB or control group. Patients in the HMB group received two packs of HMB-rich nutrients per day, which contained calcium-HMB (1500 mg), l-arginine (7000 mg), and l -glutamine (7000 mg) per pack orally or enterally from postoperative day 1 to 30 with postoperative rehabilitation. The primary endpoint was grip strength (GS) at 2 mo after LDLT. Secondary endpoints included GS at 1 mo after LDLT, skeletal muscle mass index (SMI) at 1 and 2 mo after LDLT, laboratory findings, incidence of postoperative bacteremia, and postoperative hospital length of stay (LOS). RESULTS Twelve patients in the HMB group and 11 in the control group were included in the final analysis. GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04). In the HMB group, white blood cell count 3 wk after LDLT was significantly lower (P = 0.005), and postoperative hospital LOS was significantly shorter (P = 0.028) compared with the control group. The incidence of postoperative bacteremia was lower in the HMB group. CONCLUSIONS Postoperative administration of HMB-enriched formula with rehabilitation significantly increased GS at 1 and 2 mo and SMI at 2 mo and shortened postoperative hospital LOS after LDLT.",2020,"GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04).","['patients undergoing liver transplantation (LT', 'after liver transplantation', 'adult-to-adult living donor LT (LDLT', 'Thirty-three consecutive patients who underwent adult LDLT between March 2017 and October 2018 and who met inclusion criteria', 'Twelve patients in the HMB group and 11 in the control group were included in the final analysis']","['HMB', 'oral nutritional formula-enriched β-hydroxy-β-methyl-butyrate (HMB), a leucine metabolite', 'HMB or control group', 'HMB-rich nutrients per day, which contained calcium-HMB (1500 mg), l-arginine (7000 mg), and l -glutamine', 'β-hydroxy-β-methyl butyrate-enriched formula']","['SMI values', 'grip strength (GS', 'white blood cell count', 'incidence of postoperative bacteremia', 'postoperative hospital LOS', 'GS at 1 mo after LDLT, skeletal muscle mass index (SMI) at 1 and 2 mo after LDLT, laboratory findings, incidence of postoperative bacteremia, and postoperative hospital length of stay (LOS', 'GS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023911', 'cui_str': 'Transplantation of liver'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0450358', 'cui_str': '33'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0066231', 'cui_str': 'Methyl butyrate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0066231', 'cui_str': 'Methyl butyrate'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0439505', 'cui_str': '/day'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C4708914', 'cui_str': '7000'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}]","[{'cui': 'C0915075', 'cui_str': 'samarium diiodide'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0348050', 'cui_str': 'Live donor'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0587081', 'cui_str': 'Laboratory test finding'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",33.0,0.0731392,"GS at 1 and 2 mo and SMI values at 2 mo were significantly higher in the HMB group than in the control group (GS: both P < 0.001, SMI: P = 0.04).","[{'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Kamo', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Toshimi', 'Initials': 'T', 'LastName': 'Kaido', 'Affiliation': ""Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Gastroenterological and General Surgery, St Luke's International University and Hospital, Tokyo, Japan. Electronic address: kaido@kuhp.kyoto-u.ac.jp.""}, {'ForeName': 'Ryuji', 'Initials': 'R', 'LastName': 'Uozumi', 'Affiliation': 'Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ito', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Shintaro', 'Initials': 'S', 'LastName': 'Yagi', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Koichiro', 'Initials': 'K', 'LastName': 'Hata', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Kojiro', 'Initials': 'K', 'LastName': 'Taura', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Uemoto', 'Affiliation': 'Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110871'] 1745,32593936,Endometrial scratch injury with office hysteroscopy before IVF/ICSI: A randomised controlled trial.,"OBJECTIVE Endometrial scratch injury (ESI) has been proposed to improve endometrial receptivity and thereby increase implantation rates in assisted reproductive technology (ART) treatment. ESI has been widely incorporated into clinical practice despite inconclusive evidence of its effect on reproductive outcomes. We aimed to assess pregnancy and live birth rates in subfertile women receiving ESI before IVF treatment in comparison to controls. STUDY DESIGN This was a randomised controlled trial (RCT) with no blinding of participants, investigators or health care personnel. Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group). In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis. The primary outcome was positive serum hCG (s-hCG). Secondary outcomes were ongoing pregnancy and live birth rate. Only per-protocol analyses were performed as all patients included at one centre had to be excluded. The trial is registered at ClinicalTrials.gov, NCT01743391. RESULTS Our results showed a non-significant increase in positive s-hCG (OR 1.23, 95 % CI (0.65-2.33)), ongoing pregnancy (OR 1.52, 95 % CI (0.73-3.17)), and live birth rates (OR 1.69, 95 % CI (0.78-3.64)) per randomised woman between the ESI and the control group. CONCLUSION We observed no significant differences in positive s-hCG or other reproductive outcomes in the ESI vs. the control group. While the crude estimates of positive reproductive outcomes were higher in the ESI group, statistical significance was not reached, and the study was not powered to show smaller differences. However, data from this study will be re-evaluated in the context of an individual participant data meta-analysis (IPD-MA) of RCTs on ESI.",2020,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"['In total 184 women in IVF/ICSI treatment with minimum one previous failed IVF/ICSI cycle, were included in the final analysis', 'Endometrial scratch injury with office hysteroscopy before IVF/ICSI', 'subfertile women receiving ESI before IVF treatment in comparison to controls', 'Women in ART treatment', 'participants, investigators or health care personnel']","['office hysteroscopy with ESI (ESI group) or no intervention (control group', 'ESI']","['positive reproductive outcomes', 'live birth rates', 'ongoing pregnancy and live birth rate', 'ongoing pregnancy', 'positive s-hCG', 'pregnancy and live birth rates', 'positive serum hCG (s-hCG']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0035157', 'cui_str': 'Reproductive Technologies'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}]","[{'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0311213', 'cui_str': 'Dermatitis verrucosa'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1141639', 'cui_str': 'Human chorionic gonadotropin'}]",184.0,0.498981,Women in ART treatment were allocated to either office hysteroscopy with ESI (ESI group) or no intervention (control group).,"[{'ForeName': 'Sine', 'Initials': 'S', 'LastName': 'Berntsen', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark. Electronic address: sine.berntsen.01@regionh.dk.'}, {'ForeName': 'Kristine Juul', 'Initials': 'KJ', 'LastName': 'Hare', 'Affiliation': 'Department of Obstetrics and Gynaecology, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Løssl', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Bogstad', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Palmø', 'Affiliation': 'Department of Obstetrics and Gynaecology, Holbaek Hospital, Smedelundsgade 60, 4300 Holbaek, Denmark.'}, {'ForeName': 'Lisbeth', 'Initials': 'L', 'LastName': 'Prætorius', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Zedeler', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Pinborg', 'Affiliation': 'The Fertility Clinic, Hvidovre Hospital, Copenhagen University Hospital, Kettegaard Allé 30, 2650, Hvidovre, Denmark; The Fertility Clinic, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.034'] 1746,32602177,A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial.,,2020,,['patients with iron deficiency anemia'],['ferric derisomaltose'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}]","[{'cui': 'C3848561', 'cui_str': 'ferric cation'}]",[],,0.0746263,,"[{'ForeName': 'Maureen M', 'Initials': 'MM', 'LastName': 'Achebe', 'Affiliation': ""Divison of Hematology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Glaspy', 'Affiliation': 'Department of Medicine, Division of Hematology Oncology, UCLA School of Medicine, Los Angeles, California, USA.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Kalra', 'Affiliation': 'Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Auerbach', 'Affiliation': 'Department of Medicine, Georgetown University School of Medicine, Washington, District of Columbia, USA.'}, {'ForeName': 'Lars L', 'Initials': 'LL', 'LastName': 'Thomsen', 'Affiliation': 'Department of Clinical and Non-Clinical Research, Pharmacosmos A/S, Holbaek, Denmark.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Bhandari', 'Affiliation': 'Department of Renal Medicine, Hull University Teaching Hospitals NHS Trust, Kingston upon Hull, UK.'}]",American journal of hematology,['10.1002/ajh.25920'] 1747,32601011,The effect of Yakson and Gentle Human Touch methods on pain and physiological parameters in preterm infants during heel lancing.,"BACKGROUND Various non-pharmacologic methods are used to alleviate pain in preterm infants who spend their first days in neonatal intensive care units (NICU) because they are exposed to numerous painful interventions. OBJECTIVE To determine the effects of Yakson and Gentle Human Touch (GHT) methods on pain and physiologic parameters during heel lancing procedures in preterm infants. DESIGN AND METHODS This was a randomised controlled trial. The study was conducted in a NICU between June 2018 and June 2019. A total of 90 preterm infants were divided into three groups: 30 infants in the Yakson group, 30 infants in the GHT group, and 30 infants in the control group. All preterm infants were randomly divided into groups. Pain responses were evaluated using the Neonatal Infant Pain Scale. RESULTS It was found that pain scores and heart rates were significantly lower during and after heel lancing in preterm infants in the Yakson and GHT groups than in the control group, the difference was statistically significant (p < .001). PRACTICAL IMPLICATIONS Yakson and GHT applied to preterm infants during heel lancing has positive effects on pain and physiologic parameters.",2020,"It was found that pain scores and heart rates were significantly lower during and after heel lancing in preterm infants in the Yakson and GHT groups than in the control group, the difference was statistically significant (p < .001). ","['NICU between June 2018 and June 2019', 'All preterm infants', '90 preterm infants were divided into three groups: 30 infants in the Yakson group, 30 infants in the GHT group, and 30 infants in the control group', 'preterm infants during heel lancing', 'preterm infants', 'preterm infants who spend their first days in neonatal intensive care units (NICU']","['Yakson and Gentle Human Touch (GHT) methods', 'Yakson and Gentle Human Touch methods']","['Neonatal Infant Pain Scale', 'pain scores and heart rates', 'pain and physiological parameters', 'pain and physiologic parameters', 'Pain responses']","[{'cui': 'C0021709', 'cui_str': 'Neonatal intensive care unit'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018870', 'cui_str': 'Heel structure'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0424543', 'cui_str': 'Response to pain'}]",90.0,0.0465262,"It was found that pain scores and heart rates were significantly lower during and after heel lancing in preterm infants in the Yakson and GHT groups than in the control group, the difference was statistically significant (p < .001). ","[{'ForeName': 'Şadiye', 'Initials': 'Ş', 'LastName': 'Dur', 'Affiliation': 'Nursing Department, Faculty of Health Sciences, Bahçeşehir University, Istanbul, Turkey.'}, {'ForeName': 'Seda', 'Initials': 'S', 'LastName': 'Çağlar', 'Affiliation': 'Pediatric Nursing Department, Florence Nightingale Faculty of Nursing, Istanbul University-Cerrahpaşa, Istanbul, Turkey. Electronic address: sedac@istanbul.edu.tr.'}, {'ForeName': 'Nagehan Ustabaş', 'Initials': 'NU', 'LastName': 'Yıldız', 'Affiliation': 'Health Sciences University Bursa Higher Specialization Training and Research Hospital, Neonatology Department, Bursa, Turkey.'}, {'ForeName': 'Pelin', 'Initials': 'P', 'LastName': 'Doğan', 'Affiliation': 'Health Sciences University Bursa Higher Specialization Training and Research Hospital, Neonatology Department, Bursa, Turkey.'}, {'ForeName': 'İpek', 'Initials': 'İ', 'LastName': 'Güney Varal', 'Affiliation': 'Health Sciences University Bursa Higher Specialization Training and Research Hospital, Neonatology Department, Bursa, Turkey.'}]",Intensive & critical care nursing,['10.1016/j.iccn.2020.102886'] 1748,32598941,Unskilled shooters improve both accuracy and grouping shot having as reference skilled shooters cortical area: An EEG and tDCS study.,"Transcranial direct current stimulation (tDCS) has been used as a non-invasive method for enhanced motor and cognitive abilities. However, no previous study has investigated if the tDCS application in unskilled shooters on cortical sites, selected based on the cortical activity of skilled shooters, improves the accuracy and shot grouping. Sixty participants were selected, which included 10 skilled shooters and 50 unskilled shooters. After we identified the right dorsolateral prefrontal cortex (DLPFC) as the area with the highest activity in skilled shooters, we applied anodal tDCS over the right DLPFC in the unskilled shooters under two conditions: sham-tDCS (placebo) and real-tDCS (anodal tDCS). We also analyzed electroencephalography. Our results indicated that anodal tDCS application enhanced the shot accuracy (p = 0.001). Furthermore, the beta power in the EEG recording was higher in the left DLPFC, left and right parietal cortex (p = 0,001) after applying anodal tDCS, while the low-gamma power was higher in the right DLPFC in sham-tDCS (p = 0.001) and right parietal cortex after anodal-tDCS (p = 0.001). Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC. Furthermore, beta and low-gamma bands are influenced by anodal tDCS over the right DLPFC, which may be predictive of skill improvement.",2020,Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC.,"['Sixty participants were selected, which included 10 skilled shooters and 50 unskilled shooters']","['tDCS (placebo) and real-tDCS (anodal tDCS', 'Transcranial direct current stimulation (tDCS', 'anodal tDCS']",['beta power in the EEG recording'],"[{'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]",60.0,0.0141525,Our findings indicate that anodal tDCS can improve accuracy and shot grouping when applied over the unskilled shooters' right DLPFC.,"[{'ForeName': 'Kaline', 'Initials': 'K', 'LastName': 'Rocha', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil. Electronic address: kalinemrocha@gmail.com.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Marinho', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Magalhães', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Valécia', 'Initials': 'V', 'LastName': 'Carvalho', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Thayaná', 'Initials': 'T', 'LastName': 'Fernandes', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Ayres', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Crespo', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Bruna', 'Initials': 'B', 'LastName': 'Velasques', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Ribeiro', 'Affiliation': 'Brain Mapping and Sensory Motor Integration Laboratory, Institute of Psychiatry of Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Mauricio', 'Initials': 'M', 'LastName': 'Cagy', 'Affiliation': 'Biomedical Engineering Program, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Victor Hugo', 'Initials': 'VH', 'LastName': 'Bastos', 'Affiliation': 'The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil; Brain Mapping and Functionality Laboratory, Federal University of Delta do Parnaíba, Parnaíba, Brazil.'}, {'ForeName': 'Daya S', 'Initials': 'DS', 'LastName': 'Gupta', 'Affiliation': 'Department of Biology, Camden County College, Blackwood, NJ, United States.'}, {'ForeName': 'Silmar', 'Initials': 'S', 'LastName': 'Teixeira', 'Affiliation': 'Neuro-innovation Technology & Brain Mapping Laboratory, Federal University of Delta of Parnaíba, Parnaíba, Brazil; The Northeast Biotechnology Network, Federal University of Piauí, Teresina, Brazil.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113036'] 1749,32599496,Randomized controlled three-arm study of NADA acupuncture for alcohol addiction.,"INTRODUCTION Alcohol addiction compromises cardiovascular health, possibly due to impaired control of the heart and vasculature by the autonomic nervous system. We aimed to assess the effects of National Acupuncture Detoxification Association (NADA) acupuncture on cardiovascular autonomic functions, psychiatric comorbidities and abstinence in patients addicted to alcohol. MATERIAL AND METHODS A randomized sham controlled three-arm study was undertaken in 72 patients (nine females, aged 43.7 ± 9.2 years, mean ± SD) undergoing in-patient rehabilitation for alcohol addiction. Patients were randomly allocated (1:1:1) to receive twenty 30-minute NADA or sham acupuncture sessions within six weeks or no intervention. They were evaluated for craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response). Testing was performed at baseline, immediately post intervention (sham intervention or control period, respectively) and another four weeks later. Abstinence was assessed one year after study completion. RESULTS Patients in the NADA arm displayed increased HRV immediately post-intervention compared to baseline (SDNN: 72.8 ms ± 34.2 ms vs. 57.9 ms ± 31.2 ms, p = 0.001). This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015). HRV remained unaltered following sham or no acupuncture (p = n.s.). Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence did not differ between study arms. CONCLUSIONS NADA acupuncture may improve autonomic cardiac function. However, this improvement appears not to translate into alleviation of psychiatric comorbidities or sustained abstinence.",2020,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","['patients addicted to alcohol', '72 patients (nine females, aged 43.7\xa0±\xa09.2\xa0years, mean\xa0±\xa0SD) undergoing in-patient rehabilitation for alcohol addiction', '34.2']","['NADA or sham acupuncture sessions within six weeks or no intervention', 'National Acupuncture Detoxification Association (NADA) acupuncture', 'sham or no acupuncture', 'NADA acupuncture']","['HRV', 'Autonomic function of vasculature and sweat glands, psychiatric comorbidities and one-year abstinence', 'craving, depression, anxiety and autonomic control of the heart (heart rate variability, HRV), vasculature (laser Doppler flowmetry) and sweat glands (sympathetic skin response', 'autonomic cardiac function', 'cardiovascular autonomic functions, psychiatric comorbidities and abstinence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191219', 'cui_str': '9.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C5191359', 'cui_str': '34.2'}]","[{'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0010343', 'cui_str': 'Croatia'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0005839', 'cui_str': 'blood supply'}, {'cui': 'C0038989', 'cui_str': 'Sweat gland structure'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0162520', 'cui_str': 'Laser doppler flowmetry'}, {'cui': 'C0312646', 'cui_str': 'Finding related to response to skin test'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",72.0,0.09429,"This increase was sustained four weeks later (66.2 ms ± 32.4 ms, p = 0.015).","[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Krause', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Ana Isabel', 'Initials': 'AI', 'LastName': 'Penzlin', 'Affiliation': 'Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Ritschel', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Barlinn', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Heinz', 'Initials': 'H', 'LastName': 'Reichmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Weidner', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Siepmann', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Siepmann', 'Affiliation': 'Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address: timo.siepmann@ukdd.de.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106488'] 1750,32608505,Psychological therapies for women who experience intimate partner violence.,"BACKGROUND Intimate partner violence (IPV) against women is prevalent and strongly associated with mental health problems. Women experiencing IPV attend health services frequently for mental health problems. The World Health Organization recommends that women who have experienced IPV and have a mental health diagnosis should receive evidence-based mental health treatments. However, it is not known if psychological therapies work for women in the context of IPV and whether they cause harm. OBJECTIVES To assess the effectiveness of psychological therapies for women who experience IPV on the primary outcomes of depression, self-efficacy and an indicator of harm (dropouts) at six- to 12-months' follow-up, and on secondary outcomes of other mental health symptoms, anxiety, quality of life, re-exposure to IPV, safety planning and behaviours, use of healthcare and IPV services, and social support. SEARCH METHODS We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR), CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, and three other databases, to the end of October 2019. We also searched international trials registries to identify unpublished or ongoing trials and handsearched selected journals, reference lists of included trials and grey literature. SELECTION CRITERIA We included randomised controlled trials (RCTs), quasi-RCTs, cluster-RCTs and cross-over trials of psychological therapies with women aged 16 years and older who self-reported recent or lifetime experience of IPV. We included trials if women also experienced co-existing mental health diagnoses or substance abuse issues, or both. Psychological therapies included a wide range of interventions that targeted cognition, motivation and behaviour compared with usual care, no treatment, delayed or minimal interventions. We classified psychological therapies according to Cochrane Common Mental Disorders's psychological therapies list. DATA COLLECTION AND ANALYSIS Two review authors extracted data and undertook 'Risk of Bias' assessment. Treatment effects were compared between experimental and comparator interventions at short-term (up to six months post-baseline), medium-term (six to under 12 months, primary outcome time point), and long-term follow-up (12 months and above). We used standardised mean difference (SMD) for continuous and odds ratio (OR) for dichotomous outcomes, and used random-effects meta-analysis, due to high heterogeneity across trials. MAIN RESULTS We included 33 psychological trials involving 5517 women randomly assigned to experimental (2798 women, 51%) and comparator interventions (2719 women, 49%). Psychological therapies included 11 integrative therapies, nine humanistic therapies, six cognitive behavioural therapy, four third-wave cognitive behavioural therapies and three other psychologically-orientated interventions. There were no trials classified as psychodynamic therapies. Most trials were from high-income countries (19 in USA, three in Iran, two each in Australia and Greece, and one trial each in China, India, Kenya, Nigeria, Pakistan, Spain and UK), among women recruited from healthcare, community, shelter or refuge settings, or a combination of any or all of these. Psychological therapies were mostly delivered face-to-face (28 trials), but varied by length of treatment (two to 50 sessions) and staff delivering therapies (social workers, nurses, psychologists, community health workers, family doctors, researchers). The average sample size was 82 women (14 to 479), aged 37 years on average, and 66% were unemployed. Half of the women were married or living with a partner and just over half of the participants had experienced IPV in the last 12 months (17 trials), 6% in the past two years (two trials) and 42% during their lifetime (14 trials). Whilst 20 trials (61%) described reliable low-risk random-sampling strategies, only 12 trials (36%) described reliable procedures to conceal the allocation of participant status. While 19 trials measured women's depression, only four trials measured depression as a continuous outcome at medium-term follow-up. These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence). However, for self-efficacy, there may be no evidence of a difference between groups (SMD -0.12, 95% CI -0.33 to 0.09; one trial with medium-term follow-up data, 346 women; low-certainty evidence). Further, there may be no difference between the number of women who dropped out from the experimental or comparator intervention groups, an indicator of no harm (OR 1.04, 95% CI 0.75 to 1.44; five trials with medium-term follow-up data, 840 women; low-certainty evidence). Although no trials reported adverse events from psychological therapies or participation in the trial, only one trial measured harm outcomes using a validated scale. For secondary outcomes, trials measured anxiety only at short-term follow-up, showing that psychological therapies may reduce anxiety symptoms (SMD -0.96, 95% CI -1.29 to -0.63; four trials, 158 women; low-certainty evidence). However, within medium-term follow-up, low-certainty evidence revealed that there may be no evidence between groups for the outcomes safety planning (SMD 0.04, 95% CI -0.18 to 0.25; one trial, 337 women), post-traumatic stress disorder (SMD -0.24, 95% CI -0.54 to 0.06; four trials, 484 women) or re-exposure to any form of IPV (SMD 0.03, 95% CI -0.14 to 0.2; two trials, 547 women). AUTHORS' CONCLUSIONS There is evidence that for women who experience IPV, psychological therapies probably reduce depression and may reduce anxiety. However, we are uncertain whether psychological therapies improve other outcomes (self-efficacy, post-traumatic stress disorder, re-exposure to IPV, safety planning) and there are limited data on harm. Thus, while psychological therapies probably improve emotional health, it is unclear if women's ongoing needs for safety, support and holistic healing from complex trauma are addressed by this approach. There is a need for more interventions focused on trauma approaches and more rigorous trials (with consistent outcomes at similar follow-up time points), as we were unable to synthesise much of the research.",2020,"These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence).","['women who experience intimate partner violence', 'women also experienced co-existing mental health diagnoses or substance abuse issues, or both', '82 women (14 to 479), aged 37 years on average, and 66% were unemployed', 'Intimate partner violence (IPV) against women', 'women who have experienced IPV and have a mental health diagnosis', '33 psychological trials involving 5517 women randomly assigned to experimental (2798 women, 51%) and comparator interventions (2719 women, 49', 'Most trials were from high-income countries (19 in USA, three in Iran, two each in Australia and Greece, and one trial each in China, India, Kenya, Nigeria, Pakistan, Spain and UK), among women recruited from healthcare, community, shelter or refuge settings, or a combination of any or all of these', 'Women experiencing IPV attend health services frequently for mental health problems', 'women aged 16 years and older who self-reported recent or lifetime experience of IPV']","['Psychological therapies included 11 integrative therapies, nine humanistic therapies, six cognitive behavioural therapy, four third-wave cognitive behavioural therapies and three other psychologically-orientated interventions', 'psychological therapies', 'Psychological therapies']","['anxiety symptoms', 'post-traumatic stress disorder', 'emotional health', 'mental health symptoms, anxiety, quality of life, re-exposure to IPV, safety planning and behaviours, use of healthcare and IPV services, and social support', 'IPV']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0740858', 'cui_str': 'Substance abuse'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0041674', 'cui_str': 'Unemployed'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0948433', 'cui_str': 'High income'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0018226', 'cui_str': 'Greece'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0028075', 'cui_str': 'Nigeria'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C1446377', 'cui_str': 'Mental health problem'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0332185', 'cui_str': 'Recent'}]","[{'cui': 'C0841584', 'cui_str': 'Psychological therapies'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",5517.0,0.386411,"These showed a probable beneficial effect of psychological therapies in reducing depression (SMD -0.24, 95% CI -0.47 to -0.01; four trials, 600 women; moderate-certainty evidence).","[{'ForeName': 'Mohajer', 'Initials': 'M', 'LastName': 'Hameed', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': ""O'Doherty"", 'Affiliation': 'Faculty of Health and Life Sciences, Coventry University, Coventry, UK.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Gilchrist', 'Affiliation': ""National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Tirado-Muñoz', 'Affiliation': ""Addiction Research Group, IMIM-Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.""}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Taft', 'Affiliation': 'The Judith Lumley Centre, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Patty', 'Initials': 'P', 'LastName': 'Chondros', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Feder', 'Affiliation': 'Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Tan', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Kelsey', 'Initials': 'K', 'LastName': 'Hegarty', 'Affiliation': 'Department of General Practice, The University of Melbourne, Melbourne, Australia.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013017.pub2'] 1751,32605697,Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis.,"Background: The effect of prolonged allergen immunotherapy is still insufficiently known, especially in elderly patients. Objective: The effect after a 3-year course of injected allergen-specific immunotherapy (AIT) for grass pollen allergy in elderly patients with allergic rhinitis was observed. Methods: Thirty-eight elderly patients (mean ± standard deviation, 66.2 ± 2.7 years old) who received preseasonal injected AIT or placebo for grass pollen allergy were monitored for 3 years and compared with a placebo group. The combined symptom medication score (CSMS), serum level of immunoglobulin G4 (IgG4) to phleum pratense 5 (Phl p5) and quality of life were assessed immediately after AIT and 3 years later. Results: After AIT, the CSMS was significantly decreased from 2.15 (range, 1.27-3.00) to 1.13 (range, 0.79-1.36) (p = 0.03) and remained lower (1.41 ± 0.72 versus 2.41 ± 1.11) than that in the placebo group during the 3 years after AIT. Serum-specific IgG4 against increased during the course of AIT and remained at a high level during further observation. Quality of life, based on the Rhinoconjunctivitis Quality of Life Questionnaire, was significantly decreased in the patients who received AIT from 1.51 (95% confidence interval [CI], 1.21-1.84) to 1.01 (95% CI, 0.93-1.87) (p < 0.05) and was decreased to 0.97-1.26 (95% CI, 0.88-1.82) during the 3 years after discontinuation of AIT. Conclusion: A prolonged positive effect after AIT for grass pollen allergy was observed in elderly patients with allergic rhinitis. Further trials are needed to confirm this effect.Clinical trial MC56871/12, www.clinicaltrials.gov.",2020,"Quality of life, based on the Rhinoconjunctivitis Quality of Life Questionnaire, was significantly decreased in the patients who received AIT from 1.51 (95% confidence interval [CI], 1.21-1.84) to 1.01 (95% CI, 0.93-1.87) (p < 0.05) and was decreased to 0.97-1.26 (95% CI, 0.88-1.82) during the 3 years after discontinuation of AIT. ","['elderly patients with allergic rhinitis', 'Thirty-eight elderly patients (mean ± standard deviation, 66.2 ± 2.7 years old) who received', 'elderly patients']","['injected allergen-specific immunotherapy (AIT', 'preseasonal injected AIT or placebo', 'href=""http://www.clinicaltrials.gov"">www.clinicaltrials.gov 0.05). At the 2-month follow-ups, the SFR was higher in the TRU than the SWL group ( p  = 0.002), and the RCOR was lower in the TRU than the SWL group ( p  = 0.005). Postoperative hospitalization was also shorter for the TRU group. No significant difference was noted in the operative time, blood loss, change in serum creatinine, or perioperative complications ( p  > 0.05). Conclusion: Contemporaneous TRU is more effective and equally safe compared to postoperative SWL in the management of residual or migrated stones during laparoscopic pyelolithotomy and ureterolithotomy in kidneys with either intrinsic or extrinsic abnormalities.",2020,"At the two-month follow ups, the SFR was higher in the TRU than the SWL group (P = 0.002), and the RCOR was lower in the TRU than the SWL group (P = 0.005).","['patients all had either urinary tract obstruction distal to the stone or concomitant ipsilateral intrinsic or extrinsic pathology requiring laparoscopic intervention', 'Methods From February 2016 to December 2019, 45 patients with migrated or residual stones following laparoscopic pyelolithotomy and ureterolithotomy', '23 patients underwent', 'migrated or residual stones during laparoscopic pyelolithotomy and ureterolithotomy in kidneys with either intrinsic or extrinsic abnormalities']","['postoperative SWL', 'contemporaneous TRU', 'laparoscopic pyelolithotomy and ureterolithotomy', 'contemporaneous transabdominal rigid ureteroscopy (TRU) with postoperative shock wave lithotripsy (SWL']","['RCOR', 'gender, age, body mass index, location, or stone burden', 'blood loss, operative time, change in serum creatinine, complications per Clavien-Dindo grading system, renal colic occurrence rate (RCOR), and postoperative hospitalization', 'Postoperative hospitalization', 'operative time, blood loss, change in serum creatinine, or perioperative complications', 'final stone free rate (SFR', 'SFR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178879', 'cui_str': 'Urinary tract obstruction'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C2959846', 'cui_str': 'Laparoscopic pyelolithotomy'}, {'cui': 'C0194229', 'cui_str': 'Ureterolithotomy'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}]","[{'cui': 'C0032792', 'cui_str': 'Postoperative shock'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0023878', 'cui_str': 'Lithotripsy'}, {'cui': 'C0205496', 'cui_str': 'Abdominal approach'}, {'cui': 'C0026837', 'cui_str': 'Muscle rigidity'}, {'cui': 'C0194261', 'cui_str': 'Ureteroscopy'}, {'cui': 'C2959846', 'cui_str': 'Laparoscopic pyelolithotomy'}, {'cui': 'C0194229', 'cui_str': 'Ureterolithotomy'}, {'cui': 'C0036974', 'cui_str': 'Shock'}]","[{'cui': 'C0152169', 'cui_str': 'Renal colic'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0450429', 'cui_str': 'Location'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1273712', 'cui_str': 'Grading system used'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C4545429', 'cui_str': 'Perioperative complication'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",45.0,0.0492596,"At the two-month follow ups, the SFR was higher in the TRU than the SWL group (P = 0.002), and the RCOR was lower in the TRU than the SWL group (P = 0.005).","[{'ForeName': 'Wenfeng', 'Initials': 'W', 'LastName': 'Guan', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Shubo', 'Initials': 'S', 'LastName': 'Fan', 'Affiliation': 'Department of Urology, National Urological Cancer Center, Peking University First Hospital, The Institute of Urology, Peking University, Beijing, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Liang', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Nengzhuo', 'Initials': 'N', 'LastName': 'Feng', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Qiyan', 'Initials': 'Q', 'LastName': 'Liang', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Yixin', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Wenchao', 'Initials': 'W', 'LastName': 'Qin', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Jingwei', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Kunlin', 'Initials': 'K', 'LastName': 'Yang', 'Affiliation': 'Department of Urology, National Urological Cancer Center, Peking University First Hospital, The Institute of Urology, Peking University, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': ""Department of Urology, People's Hospital of Yangjiang, Yangjiang, China.""}, {'ForeName': 'Xuesong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Urology, National Urological Cancer Center, Peking University First Hospital, The Institute of Urology, Peking University, Beijing, China.'}]",Journal of endourology,['10.1089/end.2020.0296'] 1767,32609532,Cardiovascular and metabolic responses to passive hypoxic conditioning in overweight and mildly obese individuals.,"Although severe intermittent hypoxia (IH) is well known to induce deleterious cardiometabolic consequences, moderate IH may induce positive effects in obese individuals. The present study aimed to evaluate the effect of two hypoxic conditioning programs on cardiovascular and metabolic health status of overweight or obese individuals. In this randomized single-blind controlled study, 35 subjects (54 ± 9.3 yr, 31.7 ± 3.5 kg/m 2 ) were randomized into three 8-wk interventions (three 1-h sessions per week): sustained hypoxia (SH), arterial oxygen saturation ([Formula: see text]) = 75%; IH, 5 min [Formula: see text] = 75% - 3 min normoxia; normoxia. Ventilation, heart rate, blood pressure, and tissue oxygenation were measured during the first and last hypoxic conditioning sessions. Vascular function, blood glucose and insulin, lipid profile, nitric oxide metabolites, and oxidative stress were evaluated before and after the interventions. Both SH and IH increased ventilation in hypoxia (+1.8 ± 2.1 and +2.3 ± 3.6 L/min, respectively; P < 0.05) and reduced normoxic diastolic blood pressure (-12 ± 15 and -13 ± 10 mmHg, respectively; P < 0.05), whereas changes in normoxic systolic blood pressure were not significant (+3 ± 9 and -6 ± 13 mmHg, respectively; P > 0.05). IH only reduced heart rate variability (e.g., root-mean-square difference of successive normal R-R intervals in normoxia -21 ± 35%; P < 0.05). Both SH and IH induced no significant change in body mass index, vascular function, blood glucose, insulin and lipid profile, nitric oxide metabolites, or oxidative stress, except for an increase in superoxide dismutase activity following SH. This study indicates that passive hypoxic conditioning in obese individuals induces some positive cardiovascular and respiratory improvements despite no change in anthropometric data and even a reduction in heart rate variability during IH exposure.",2020,"Both SH and IH induced no significant change in body mass index, vascular function, blood glucose, insulin and lipid profile, nitric oxide metabolites and oxidative stress, except an increase in superoxide dismutase activity following SH. ","['overweight and mildly obese individuals', 'overweight or obese individuals', 'obese individuals', '35 subjects (54±9.3yr, 31.7±3.5kg·m -2 ']","['hypoxic conditioning programs', 'sustained hypoxia (SH), arterial oxygen saturation (SpO 2 ) =75%; IH, 5min SpO 2 =75% - 3min normoxia; normoxia', 'passive hypoxic conditioning']","['Cardiovascular and metabolic responses', 'normoxic systolic blood pressure', 'body mass index, vascular function, blood glucose, insulin and lipid profile, nitric oxide metabolites and oxidative stress', 'Ventilation, heart rate, blood pressure and tissue oxygenation', 'normoxic diastolic blood pressure', 'ventilation in hypoxia', 'cardiovascular and metabolic health status', 'superoxide dismutase activity', 'heart rate variability', 'Vascular function, blood glucose and insulin, lipid profile, nitric oxide metabolites and oxidative stress']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C2945599', 'cui_str': 'Mild'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0428175', 'cui_str': 'Oxygen saturation measurement, arterial'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",35.0,0.0345242,"Both SH and IH induced no significant change in body mass index, vascular function, blood glucose, insulin and lipid profile, nitric oxide metabolites and oxidative stress, except an increase in superoxide dismutase activity following SH. ","[{'ForeName': 'Samarmar', 'Initials': 'S', 'LastName': 'Chacaroun', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Borowik', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Doutreleau', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Belaidi', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Wuyam', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Tamisier', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Jean-Louis', 'Initials': 'JL', 'LastName': 'Pépin', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Patrice', 'Initials': 'P', 'LastName': 'Flore', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Verges', 'Affiliation': 'HP2 laboratory, Univiversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, Grenoble, France.'}]","American journal of physiology. Regulatory, integrative and comparative physiology",['10.1152/ajpregu.00311.2019'] 1768,32611284,Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data.,"BACKGROUND/PURPOSE Expert guidelines specify no upper age limit for alteplase for thrombolysis of acute ischemic stroke (AIS) but, until recently, European regulatory criteria restricted its use to patients aged 18 to 80 years. We performed pooled analyses of randomized controlled trial (RCT) and registry data to evaluate the benefit-risk profile of alteplase for AIS among patients aged >80 years to support a regulatory application to lift the upper age restriction. METHODS Individual patient data were evaluated from 7 randomized trials of alteplase (0.9 mg/kg) versus placebo or open control for AIS, and the European SITS-UTMOST registry database. Clinical outcomes, including good functional outcome (score 0-1, modified Rankin Scale day 90 or Oxford Handicap Score day 180), were evaluated in the full RCT and registry populations, and specified age-based subgroups (≤80 or >80 years) who met existing European regulatory criteria for alteplase, excluding upper age restriction. RESULTS Regardless of treatment allocation, 90-day mortality was lower among RCT patients aged ≤80 versus >80 years who otherwise met existing European regulatory criteria (246/2405 [10.2%] versus 307/1028 [29.9%], respectively). Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382). The odds of a good stroke outcome following alteplase allocation in the full RCT population were independent of age ( P =0.7383). Good stroke outcome was reported for almost half (4821/11 169 [43.2%]) of the patients who received alteplase in routine practice. Outcomes in routine practice supported those achieved in RCTs. CONCLUSIONS Alteplase for AIS has a positive benefit-risk profile among patients aged >80 years when administered according to other regulatory criteria. Alteplase for AIS should be evaluated on an individual benefit-risk basis.",2020,"Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382).","['Individual patient data', 'patients aged >80 years', 'patients aged 18 to 80 years', 'Patients Aged']","['Alteplase', 'alteplase', 'placebo']","['good functional outcome', 'good stroke outcome (modified Rankin Scale score', '90-day mortality', 'Good stroke outcome']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.126515,"Among patients aged >80 years, alteplase versus placebo was associated with a higher proportion of good stroke outcome (modified Rankin Scale score 0-1; 99/518 [19.1%] versus 67/510 [13.1%]; P =0.0109) and similar 90-day mortality (153/518 [29.5%] versus 154/510 [30.2%]; P =0.8382).","[{'ForeName': 'Erich', 'Initials': 'E', 'LastName': 'Bluhmki', 'Affiliation': 'ADB Building, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany and Hochschule Biberach, University of Applied Sciences, Germany (E.B.).'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Danays', 'Affiliation': 'The Medical Department, Boehringer Ingelheim France SAS, Reims (T.D.).'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Biegert', 'Affiliation': 'The Biostatistics and Data Sciences Corp, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (G.B.).'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Hacke', 'Affiliation': 'The Department of Neurology, University of Heidelberg, Germany (W.H.).'}, {'ForeName': 'Kennedy R', 'Initials': 'KR', 'LastName': 'Lees', 'Affiliation': 'The School of Medicine, Dentistry & Nursing, University of Glasgow, United Kingdom (K.R.L.).'}]",Stroke,['10.1161/STROKEAHA.119.028396'] 1769,32615237,Influence of different clinical criteria on the decision to replace restorations in primary teeth.,"OBJECTIVES This cross-sectional study is nested in a randomized clinical trial. It was designed to evaluate the influence of using two different clinical criteria to assess caries lesion around restorations on the decision to replace restorations in primary posterior teeth. Variables that might influence this decision were also considered. METHODS One trained and calibrated examiner assessed 550 restorations of 160 children (3-10 years old). Children were randomized to have their restorations evaluated and subsequently treated according to World Dental Federation (FDI) or Caries Associated with Restorations and Sealants (CARS) criteria. After reaching the treatment decision, the same examiner performed another evaluation using the other criteria. Spearman's correlation coefficients and 95 % confidence intervals (95 %CI) between the scores obtained with both criteria and respective treatment decisions were calculated. Poisson multilevel regression analysis were performed between the exploratory variables related to children, restored tooth and restoration assessment; the outcome variables were decisions related to restoration replacement, any operative intervention and presence of secondary caries. RESULTS The strongest correlation observed between the methods was for recurrence of caries. A total of 94 restorations (17.1 %) were indicated for replacement with FDI criteria and 30 (5.5 %) were indicated for replacement with CARS. Besides the diagnostic method used, number of decayed teeth and restorations with two and three restored surfaces were associated with the decision of replacement and presence of recurrent caries lesions. CONCLUSIONS The decision to replace posterior restorations in primary teeth is influenced by the criteria used for the restorations assessment and also by the children's caries experience and multisurface restorations. The restoration material did not influence the decision of restorations replacement. CLINICAL SIGNIFICANCE The decision to replace posterior restoration in primary teeth is strongly related to the evaluation method and not only by patients' risk factors.",2020,"Besides the diagnostic method used, number of decayed teeth and restorations with two and three restored surfaces were associated with the decision of replacement and presence of recurrent caries lesions. ","['One trained and calibrated examiner assessed 550 restorations of 160 children (3-10 years old', 'Children were randomized to have their restorations evaluated and subsequently treated according to World Dental Federation (FDI) or Caries Associated with Restorations and Sealants (CARS) criteria', 'primary posterior teeth', 'primary teeth']",[],"['operative intervention and presence of secondary caries', 'recurrence of caries']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C3844103', 'cui_str': '550'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C3266841', 'cui_str': 'All deciduous teeth'}]",[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1882989', 'cui_str': 'Secondary caries'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}]",160.0,0.0402393,"Besides the diagnostic method used, number of decayed teeth and restorations with two and three restored surfaces were associated with the decision of replacement and presence of recurrent caries lesions. ","[{'ForeName': 'Bruna Lorena Pereira', 'Initials': 'BLP', 'LastName': 'Moro', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: bruna.moro@usp.br.'}, {'ForeName': 'Raiza Dias', 'Initials': 'RD', 'LastName': 'Freitas', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: raizafreitas@usp.br.'}, {'ForeName': 'Laura Regina Antunes', 'Initials': 'LRA', 'LastName': 'Pontes', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: laura.pontes@usp.br.'}, {'ForeName': 'Ana Laura', 'Initials': 'AL', 'LastName': 'Pássaro', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: ana.passaro@usp.br.'}, {'ForeName': 'Tathiane Larissa', 'Initials': 'TL', 'LastName': 'Lenzi', 'Affiliation': 'School of Dentistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: tathiane.lenzi@ufrgs.br.'}, {'ForeName': 'Tamara Kerber', 'Initials': 'TK', 'LastName': 'Tedesco', 'Affiliation': 'Graduation Program in Dentistry, Ibirapuera University, São Paulo, Brazil. Electronic address: tamarakt@usp.br.'}, {'ForeName': 'Kim Rud', 'Initials': 'KR', 'LastName': 'Ekstrand', 'Affiliation': 'Section of Cariology and Endodontics, University of Copenhagen, Copenhagen, Denmark. Electronic address: kek@sund.ku.dk.'}, {'ForeName': 'Mariana Minatel', 'Initials': 'MM', 'LastName': 'Braga', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: mmbraga@usp.br.'}, {'ForeName': 'Daniela Prócida', 'Initials': 'DP', 'LastName': 'Raggio', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: danielar@usp.br.'}, {'ForeName': 'Maximiliano Sérgio', 'Initials': 'MS', 'LastName': 'Cenci', 'Affiliation': 'Federal University of Pelotas, Graduate Program in Dentistry, Pelotas, Rio Grande do Sul, Brazil. Electronic address: maximiliano.cenci@ufpel.edu.br.'}, {'ForeName': 'Fausto Medeiros', 'Initials': 'FM', 'LastName': 'Mendes', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, University of São Paulo, São Paulo, Brazil. Electronic address: fmmendes@usp.br.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103421'] 1770,32615727,"Effect of Lactobacillus sakei, a Probiotic Derived from Kimchi, on Body Fat in Koreans with Obesity: A Randomized Controlled Study.","BACKGROUND The increased prevalence of obesity has led to increases in the prevalence of chronic diseases worldwide. There is interest whether probiotics have an effect on obesity, but the effectiveness and safety of only a few probiotics for the treatment of obesity have been reported. The purpose of this study was to investigate whether ingestion of Lactobacillus sakei (CJLS03) derived from kimchi causes weight loss in people with obesity. METHODS This randomized, double-blind, placebo-controlled, clinical trial involved 114 adults with a body mass index (BMI) ≥25 kg/m2 who were assigned randomly to a CJLS03 or placebo group. The groups received two allocations of either 5×109 colony-forming units of CJLS03/allocation or the equivalent vehicle for 12 weeks. Demographic and biochemical parameters, and body composition including fat and muscle mass were measured at baseline and after 12 weeks. Changes in body fat, weight, and waist circumference were compared between the two treatment groups. Adverse events were monitored during study period. RESULTS Body fat mass decreased by 0.2 kg in the CJLS03 group and increased by 0.6 kg in the placebo group (0.8 kg difference, P=0.018). After the 12 weeks, waist circumference was 0.8 cm smaller in the CJLS03 group than in the placebo group (P=0.013). BMI and body weight did not change after the 12 weeks. Adverse events were mild and did not differ between the two groups. CONCLUSION These data suggest that L. sakei (CJLS03) might help people with obesity reduce body fat mass without serious side effects (ClinicalTrials.gov: NCT03248414).",2020,"After the 12 weeks, waist circumference was 0.8 cm smaller in the CJLS03 group than in the placebo group (P=0.013).","['114 adults with a body mass index (BMI) ≥25 kg/m2 who', 'people with obesity', 'Koreans with Obesity']","['L. sakei (CJLS03', 'Lactobacillus sakei, a Probiotic Derived from Kimchi', 'Lactobacillus sakei (CJLS03', '5×109 colony-forming units of CJLS03/allocation', 'CJLS03', 'CJLS03 or placebo', 'placebo']","['Body fat mass', 'body fat, weight, and waist circumference', 'waist circumference', 'Adverse events', 'BMI and body weight', 'Demographic and biochemical parameters, and body composition including fat and muscle mass']","[{'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}]","[{'cui': 'C0317639', 'cui_str': 'Lactobacillus sakei'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0439158', 'cui_str': 'colonies'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle'}]",114.0,0.462224,"After the 12 weeks, waist circumference was 0.8 cm smaller in the CJLS03 group than in the placebo group (P=0.013).","[{'ForeName': 'Soo', 'Initials': 'S', 'LastName': 'Lim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Ji Hye', 'Initials': 'JH', 'LastName': 'Moon', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Chol Min', 'Initials': 'CM', 'LastName': 'Shin', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Dahye', 'Initials': 'D', 'LastName': 'Jeong', 'Affiliation': 'CJ Foods R&D, CJ CheilJedang Corporation, Suwon, Korea.'}, {'ForeName': 'Bongjoon', 'Initials': 'B', 'LastName': 'Kim', 'Affiliation': 'CJ CheilJedang Corporation, Suwon, Korea.'}]","Endocrinology and metabolism (Seoul, Korea)",['10.3803/EnM.2020.35.2.425'] 1771,32618032,The role of novelty and fat and sugar concentration in food selection by captive tufted capuchins (Sapajus apella).,"Capuchins, like other primates, use feedback from sensory cues and digestion to make decisions about which foods to consume and which to avoid. However, little is known about how capuchins make consumption decisions when simultaneously presented with novel and familiar foods, or how food familiarity and macronutrient concentration together influence food choice, topics with potential implications for developmental and health research. In this study, we evaluated the role of familiarity, as well as fat and sugar concentration, in the food selections of captive tufted capuchins (Sapajus apella). In the first experiment, over 10 sessions, subjects were assigned to either a group that chose between one familiar and one novel food item both high in fat or sugar (high condition), or to a group that chose between one familiar and one novel food item both low in fat or sugar (low condition). In the second experiment, subjects were divided into three groups, familiarized with food over five feeding sessions, and then offered the familiarized food and a novel food that varied in fat or sugar for 10 sessions. When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat. These trends were generally not observed in response to foods with sugar. When presented with options that varied in macronutrient concentration, subjects showed an initial interest in the novel food irrespective of whether it was high in fat or sugar, yet formed a final preference for the higher-concentration item. Findings suggest that the concentration of fat or sugar in novel foods may be an important mediator of exploratory behavior and that capuchins rely on immediate feedback from taste and other sensory cues to make consumption decisions.",2020,"When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat.",[],"['familiarized with food over five feeding sessions, and then offered the familiarized food and a novel food that varied in fat or sugar for 10 sessions', 'one familiar and one novel food item both high in fat or sugar (high condition), or to a group that chose between one familiar and one novel food item both low in fat or sugar (low condition']",[],[],"[{'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",[],,0.0156631,"When offered foods high in fat, capuchins showed no clear signs of neophobia, forming an initial preference for the novel food, rejecting foods less frequently, and selecting foods faster than when offered foods low in fat.","[{'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Heuberger', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Paukner', 'Affiliation': 'School of Social Sciences, Nottingham Trent University, Nottingham, Nottingham, UK.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'Wooddell', 'Affiliation': 'Laboratory of Comparative Ethology, National Institute of Child Health and Human Development, Poolesville, Maryland.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Kasman', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}, {'ForeName': 'Ross A', 'Initials': 'RA', 'LastName': 'Hammond', 'Affiliation': 'Center on Social Dynamics and Policy, The Brookings Institution, Washington, District of Columbia.'}]",American journal of primatology,['10.1002/ajp.23165'] 1772,32618048,"Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.","Chronic spontaneous urticaria (CSU) is a debilitating condition, adversely affecting the patient's quality of life. Bilastine is a recently introduced, non-sedative H1-antihistamine for its treatment. We wanted to compare the effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg in moderate-to-severe CSU. We conducted a double-blind, randomized controlled trial with two groups: bilastine 20 mg (n = 31) and levocetirizine 5 mg (n = 27), once daily for 42 days. We included patients (18-65 years), with moderate-to-severe CSU. UAS7, VAS, and DLQI were used to assess severity of urticaria, global urticaria-induced discomfort and quality of life, respectively. DLQI was assessed at baseline (D0) and end-of-treatment (D42), while UAS7 and VAS were noted at baseline and all follow-up visits. Assessment of UAS7 alteration was our primary objective, while changes in DLQI and VAS were the secondary outcomes. Safety was assessed by recording drug-related adverse events, biochemical investigations, and electrocardiogram, along with tolerability and compliance. Both drugs significantly improved UAS7, DLQI, and VAS at end-of-treatment (D42) compared with baseline (intra-group). At the end-of-treatment, all parameters showed greater improvement with bilastine, but only UAS7 reduction was significant (bilastine > levocetirizine, P = .03). In both the groups, UAS7 and VAS improved significantly D14 onwards, and was maintained throughout the study. Sedation was significantly less with bilastine (P = .04), while neither drug showed any serious adverse-effect. Tolerability of both drugs was similar. Therefore, bilastine was found to be a more effective and less-sedative novel therapy for CSU compared to levocetirizine, with similar effect on quality of life.",2020,,['chronic spontaneous urticaria'],['Bilastine 20\u2009mg vs Levocetirizine'],"['Effectiveness, safety and tolerability']","[{'cui': 'C0578870', 'cui_str': 'Chronic idiopathic urticaria'}]","[{'cui': 'C1101148', 'cui_str': 'bilastine'}, {'cui': 'C1174893', 'cui_str': 'levocetirizine'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.259027,,"[{'ForeName': 'Indrashis', 'Initials': 'I', 'LastName': 'Podder', 'Affiliation': 'Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kamarhati, West Bengal, India.'}, {'ForeName': 'Anupam', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India.'}, {'ForeName': 'Shouvik', 'Initials': 'S', 'LastName': 'Ghosh', 'Affiliation': 'Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India.'}, {'ForeName': 'Debalina', 'Initials': 'D', 'LastName': 'Biswas', 'Affiliation': 'Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India.'}, {'ForeName': 'Sujata', 'Initials': 'S', 'LastName': 'Sengupta', 'Affiliation': 'Department of Dermatology, KPC Medical College and Hospital, Kolkata, West Bengal, India.'}, {'ForeName': 'Satyendra Nath', 'Initials': 'SN', 'LastName': 'Chowdhury', 'Affiliation': 'Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kamarhati, West Bengal, India.'}]",Dermatologic therapy,['10.1111/dth.13946'] 1773,32619619,"A commentary on ""Efficacy of single layered intestinal anastomosis over double layered intestinal anastomosis-an open labeled, randomized controlled trial"".",,2020,,[],['single layered intestinal anastomosis'],[],[],"[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0192711', 'cui_str': 'Anastomosis of intestine'}]",[],,0.130852,,"[{'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Colorectal Surgery, Changhai Hospital, Second Military Medical University, 200433, Shanghai, China.'}, {'ForeName': 'Zubing', 'Initials': 'Z', 'LastName': 'Mei', 'Affiliation': 'Department of Anorectal Surgery, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 201203, Shanghai, China; Anorectal Disease Institute of Shuguang Hospital, 201203, Shanghai, China. Electronic address: herrmayor@126.com.'}, {'ForeName': 'Guixin', 'Initials': 'G', 'LastName': 'Shen', 'Affiliation': 'Department of General Surgery, The Second Affiliated Hospital of Jiaxing University, 314000, Jiaxing, Zhejiang Province, China. Electronic address: jxeysgx1191@163.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.06.036'] 1774,32619739,Transvenous phrenic nerve stimulation for central sleep apnea is safe and effective in patients with concomitant cardiac devices.,"BACKGROUND Central sleep apnea is common in heart failure patients. Transvenous phrenic nerve stimulation (TPNS) requires placing a lead to stimulate the phrenic nerve and activate the diaphragm. Data are lacking concerning the safety and efficacy of TPNS in patients with concomitant cardiovascular implantable electronic devices (CIEDs). OBJECTIVE To report the safety and efficacy of TPNS in patients with concomitant CIEDs. METHODS In the remedē System Pivotal Trial, 151 patients underwent TPNS device implant. This analysis compared patients with concomitant CIEDs to those without with respect to safety, implant metrics, and efficacy of TPNS. Safety was assessed using incidence of adverse events and device-device interactions. A detailed interaction protocol was followed. Implant metrics included overall TPNS implantation success. Efficacy endpoints included changes in the apnea-hypopnea index (AHI) and quality of life. RESULTS Of 151 patients, 64 (42%) had a concomitant CIED. There were no significant differences between the groups with respect to safety. There were 4 CIED oversensing events in 3 patients leading to 1 inappropriate defibrillator shock and delivery of antitachycardia pacing. There was no difference in efficacy between the CIED and non-CIED subgroups receiving TPNS, with both having similar percentages of patients who achieved ≥50% reduction in AHI and quality-of-life improvement. CONCLUSION Concomitant CIED and TPNS therapy is safe. The presence of a concomitant CIED did not seem to impact implant metrics, implantation success, and TPNS efficacy. A detailed interaction protocol should be followed to minimize the incidence of device-device interaction.",2020,There were no significant differences between the groups with respect to safety.,"['patients with concomitant CIEDs', 'heart failure patients', 'patients with concomitant cardiovascular implantable electronic devices (CIEDs', '151 patients underwent TPNS device implant', 'Of 151 patients, 64 (42%) had a concomitant CIED', 'Patients with Concomitant Cardiac Devices']","['Transvenous Phrenic Nerve Stimulation', 'Transvenous phrenic nerve stimulation (TPNS', 'Concomitant CIED and TPNS therapy', 'TPNS']","['apnea-hypopnea index (AHI) and quality of life', 'overall TPNS implantation success', 'efficacy', 'AHI and quality of life improvement', 'adverse events and device-device interactions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0522521', 'cui_str': 'Transvenous approach'}, {'cui': 'C0031774', 'cui_str': 'Structure of phrenic nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}]","[{'cui': 'C0522521', 'cui_str': 'Transvenous approach'}, {'cui': 'C0031774', 'cui_str': 'Structure of phrenic nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0522521', 'cui_str': 'Transvenous approach'}, {'cui': 'C0031774', 'cui_str': 'Structure of phrenic nerve'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0853893', 'cui_str': 'Device interaction'}]",151.0,0.0557761,There were no significant differences between the groups with respect to safety.,"[{'ForeName': 'Hemal M', 'Initials': 'HM', 'LastName': 'Nayak', 'Affiliation': 'Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois. Electronic address: hnayak@uchicago.edu.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'McKane', 'Affiliation': 'Respicardia, Inc, Minnetonka, Minnesota.'}, {'ForeName': 'Kristofer J', 'Initials': 'KJ', 'LastName': 'James', 'Affiliation': 'Respicardia, Inc, Minnetonka, Minnesota.'}, {'ForeName': 'Timothy E', 'Initials': 'TE', 'LastName': 'Meyer', 'Affiliation': 'Respicardia, Inc, Minnetonka, Minnesota.'}, {'ForeName': 'Robin E', 'Initials': 'RE', 'LastName': 'Germany', 'Affiliation': 'Respicardia, Inc, Minnetonka, Minnesota.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Stellbrink', 'Affiliation': 'Bielefeld Medical Center, Bielefeld, Germany.'}, {'ForeName': 'Maria Rosa', 'Initials': 'MR', 'LastName': 'Costanzo', 'Affiliation': 'Advocate Heart Institute, Naperville, Illinois.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Augostini', 'Affiliation': 'The Ohio State University Wexner Medical Center, Columbus, Ohio.'}]",Heart rhythm,['10.1016/j.hrthm.2020.06.023'] 1775,32619792,Human urine 1 H NMR metabolomics reveals alterations of the protein and carbohydrate metabolism when comparing habitual Average Danish diet vs. healthy New Nordic diet.,"OBJECTIVES The aim of this study was to investigate the alteration of the human urine metabolome by means of diet and to compare the metabolic effects of the nutritionally healthy New Nordic Diet (NND) with an Average Danish Diet (ADD). The NND was designed a decade ago by scientists and chefs, based on local and sustainable foods, including fish, shellfish, vegetables, roots, fruit, and berries. The NND has been proven to lower blood pressure, reduce glycemia, and lead to weight loss. METHODS The human urine metabolome was measured by untargeted proton nuclear magnetic resonance spectroscopy in samples from 142 centrally obese Danes (20-66 years old), randomized to consume the ADD or the NND. The resulting metabolomics data was processed and analyzed using advanced multivariate data analysis methods to reveal effects related to the design factors, including diet, season, sex, and changes in body weight. RESULTS Exploration of the nuclear magnetic resonance profiles revealed unique metabolite markers reflecting changes in protein and carbohydrate metabolism between the two diets. Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased. Propylene glycol had a strong association with the homeostatic model assessment for insulin resistance in the NND group. The food intake biomarkers found in this study confirm the importance of these as tools for nutritional research. CONCLUSIONS Findings from this study provided new insights into the effects of a healthy diet on glycemia, reduction of inflammation, and weight loss among obese individuals, and alteration of the gut microbiota metabolism.",2020,"Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased.",['in samples from 142 centrally obese Danes (20-66 years old'],"['nutritionally healthy New Nordic Diet (NND) with an Average Danish Diet (ADD', 'Propylene glycol', 'untargeted proton nuclear magnetic resonance spectroscopy']","['relative concentrations of tartrate, dimethyl sulfone, and propylene glycol', 'glycemia, reduction of inflammation, and weight loss', 'Glycine betaine, glucose, trimethylamine N-oxide and creatinine']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0337800', 'cui_str': 'Danes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010969', 'cui_str': 'Danish language'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0033727', 'cui_str': 'Proton'}, {'cui': 'C0877853', 'cui_str': 'Spectroscopy, NMR'}]","[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0039328', 'cui_str': 'Tartrates'}, {'cui': 'C0058231', 'cui_str': 'methylsulfonylmethane'}, {'cui': 'C0033437', 'cui_str': 'Propanediols'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005304', 'cui_str': 'Betaine'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}]",142.0,0.027383,"Glycine betaine, glucose, trimethylamine N-oxide and creatinine were increased in urine of the individuals following the NND compared with the ADD population, whereas relative concentrations of tartrate, dimethyl sulfone, and propylene glycol were decreased.","[{'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Trimigno', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Bekzod', 'Initials': 'B', 'LastName': 'Khakimov', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Savorani', 'Affiliation': 'Department of Applied Science and Technology, Polytechnic of Turin, Turin, Italy.'}, {'ForeName': 'Sanne Kellebjerg', 'Initials': 'SK', 'LastName': 'Poulsen', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Astrup', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lars O', 'Initials': 'LO', 'LastName': 'Dragsted', 'Affiliation': 'Department of Nutrition Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Søren Balling', 'Initials': 'SB', 'LastName': 'Engelsen', 'Affiliation': 'Department of Food Science, Faculty of Science, University of Copenhagen, Copenhagen, Denmark. Electronic address: se@food.ku.dk.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110867'] 1776,32619832,Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction.,"BACKGROUND Chemoradiotherapy is standard treatment for localized oesophageal cancer unsuitable for surgery. We aimed to evaluate the efficacy of cetuximab in combination with chemoradiotherapy. METHODS This non-randomised multicentre phase II trial recruited patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery. Chemotherapy was three 21-day cycles of fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg/m 2, cycle 2-3:85 mg/m 2). Radiotherapy was 50Gy in 2Gy/fraction, 5 days a week, concurrent with cycle 2 and 3 and weekly cetuximab. The primary objective was loco-regional control at one year. RESULTS 52 patients were included. 51 were eligible for toxicity and survival analysis and 46 for recurrence analysis. Full radiotherapy dose was delivered to 80%, 75% received all three cycles of chemotherapy and 75% received four or more doses of cetuximab. The most common related grade III-IV adverse events were gastro-intestinal(16), hypersensitivity(6) and infection(5). There were two drug-related deaths. Within six months from the end of treatment, six patients died from complications from fistulas. The loco-regional control rate at one year was 47.3%(95%CI 30.9%-62.1%). Overall survival at three years was 29.1%(95% CI 17.4-41.9%). CONCLUSIONS Oxaliplatin and fluorouracil given concurrent with radiotherapy and cetuximab had an acceptable safety profile and showed a clinical response in patients with locoregionally advanced oesophageal cancer unsuitable for surgery. However, the primary end-point was not met, and the addition of cetuximab to definitive chemoradiotherapy cannot be recommended.",2020,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","['localized oesophageal cancer unsuitable for surgery', 'cancer in the oesophagus or gastro-oesophageal junction', 'patients with locoregionally advanced oesophageal cancer unsuitable for surgery', 'patients aged 18-75 with WHO performance status 0-2 having squamous cell carcinoma or adenocarcinoma in the oesophagus or gastro-oesophageal junction, T2-4, N0-3, M0 not suitable for surgery', '52 patients were included']","['radiotherapy and cetuximab', 'Chemotherapy', 'Definitive chemoradiotherapy plus cetuximab', 'Oxaliplatin and fluorouracil', 'Full radiotherapy', 'cetuximab', 'Chemoradiotherapy', 'fluorouracil 750 mg/m2 D1-5 and oxaliplatin D1 (cycle 1:130mg', 'Radiotherapy']","['toxicity and survival analysis', 'Overall survival', 'loco-regional control at one year', 'loco-regional control rate']","[{'cui': 'C0392752', 'cui_str': 'Localized'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0014876', 'cui_str': 'Esophageal structure'}, {'cui': 'C0014871', 'cui_str': 'Cardioesophageal junction structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0443196', 'cui_str': 'Definitive'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C4517868', 'cui_str': '750'}, {'cui': 'C1319266', 'cui_str': 'mg/sq.m'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",52.0,0.16028,"Overall survival at three years was 29.1%(95% CI 17.4-41.9%). ","[{'ForeName': 'Gabriella Alexandersson', 'Initials': 'GA', 'LastName': 'von Döbeln', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden. Electronic address: gabriella.alexandersson-vondobeln@sll.se.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Wagenius', 'Affiliation': 'Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Holtved', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Anne-Birgitte', 'Initials': 'AB', 'LastName': 'Jacobsen', 'Affiliation': 'Department of Oncology, Oslo University hospital, Oslo, Norway.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Department of Clinical Sciences Intervention and Technology Karolinska Institutet Division of Upper Abdominal Cancer, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Jingru', 'Initials': 'J', 'LastName': 'Yu', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Lene', 'Initials': 'L', 'LastName': 'Baeksgaard', 'Affiliation': 'Department of Oncology, Rigshospitalet, Copenhagen, Denmark.'}]",Cancer treatment and research communications,['10.1016/j.ctarc.2020.100187'] 1777,32610254,"Antioxidant cocktail following a high-sodium meal does not affect vascular function in young, healthy adult humans: a randomized controlled crossover trial.","Chronic high sodium intake is a risk factor for cardiovascular disease as it impairs vascular function through an increase in oxidative stress. The objective of this study was to investigate the acute effects of a high-sodium meal (HSM) and antioxidant (AO) cocktail on vascular function. We hypothesized that a HSM would impair endothelial function, and increase arterial stiffness and wave reflection, while ingestion of the AO cocktail would mitigate this response. Healthy adults ingested either an AO cocktail (vitamin C, E, alpha-lipoic acid) or placebo (PLA) followed by a HSM (1500 mg) in a randomized crossover blinded design. Blood pressure (BP), endothelial function (flow-mediated dilation; FMD) and measures of arterial stiffness (pulse wave velocity; PWV) and wave reflection (augmentation index; AIx) were made at baseline and 30, 60, 90, and 120 min after meal consumption. Forty-one participants (20M/21W; 24 ± 1 years; BMI 23.4 ± 0.4 kg/m 2 ) completed the study. Mean BP increased at 120 min relative to 60 min (60 min: 79 ± 1; 120 min: 81 ± 1 mmHg; time effect P = .01) but was not different between treatments (treatment × time interaction P = .32). AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31). PWV (treatment × time interaction, P = .91) and FMD (treatment × time interaction P = .65) were also not different between treatments. In conclusion, a HSM does not acutely impair vascular function suggesting young healthy adults can withstand the acute impact of sodium on the vasculature and therefore, the AO cocktail is not necessary to mitigate the response.",2020,AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31).,"['young healthy adults', 'young, healthy adult humans', 'Healthy adults ingested either an', 'Forty-one participants (20M/21W; 24 ± 1 years; BMI 23.4 ± 0.4 kg/m 2 ) completed the study']","['Antioxidant cocktail following a high-sodium meal', 'HSM', 'AO cocktail (vitamin C, E, alpha-lipoic acid) or placebo (PLA) followed by a HSM', 'high-sodium meal (HSM) and antioxidant (AO) cocktail']","['endothelial function', 'Mean BP', 'FMD', 'Blood pressure (BP), endothelial function (flow-mediated dilation; FMD) and measures of arterial stiffness (pulse wave velocity; PWV) and wave reflection (augmentation index; AIx', 'vascular function', 'PWV']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517655', 'cui_str': '23.4'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0678420', 'cui_str': 'Cocktail'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0595879', 'cui_str': 'Sodium high'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0999177', 'cui_str': 'Aix'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}]",,0.120549,AIx decreased from baseline (time effect P < .001) but was not different between treatments (treatment × time interaction P = .31).,"[{'ForeName': 'Katarina', 'Initials': 'K', 'LastName': 'Smiljanec', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: ksmilja@udel.edu.'}, {'ForeName': 'Alexis U', 'Initials': 'AU', 'LastName': 'Mbakwe', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: ambakwe@udel.edu.'}, {'ForeName': 'Macarena', 'Initials': 'M', 'LastName': 'Ramos-Gonzalez', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: macramos@udel.edu.'}, {'ForeName': 'Ryan T', 'Initials': 'RT', 'LastName': 'Pohlig', 'Affiliation': 'Biostatistics Core Facility, University of Delaware, STAR, Newark, DE. Electronic address: rpohlig@udel.edu.'}, {'ForeName': 'Shannon L', 'Initials': 'SL', 'LastName': 'Lennon', 'Affiliation': 'Department of Kinesiology and Applied Physiology, University of Delaware, Newark, DE. Electronic address: slennon@udel.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.011'] 1778,32610257,Oral vitamin C treatment increases polymorphonuclear cell functions in type 2 diabetes mellitus patients with poor glycemic control.,"This study investigated the effect of vitamin C on polymorphonuclear (PMN) cell functions in type 2 diabetes mellitus patients with poor glycemic control. We hypothesized that oral vitamin C treatment improves PMN cell functions. Patients (14) received either a vitamin C (1000 mg/d) or placebo (anhydrous calcium hydrogen phosphate) tablet for 6 weeks and were subjected to a 6-week washout period followed by a 6-week treatment crossover period. Blood samples were collected at pretreatment and posttreatment for PMN cell functions (by flow cytometry) and plasma vitamin C concentration. Phagocytosis was examined by incubating whole blood samples with fluorescein isothiocyanate-labeled Staphylococcus aureus, and oxidative burst was simultaneously evaluated by adding hydroethidine. In comparison with placebo, vitamin C increased both PMN cell phagocytosis (pretreatment: placebo, 17.8% ± 1.6% and vitamin C, 19.0% ± 3.4%, P = .70; posttreatment: placebo, 16.6% ± 1.7% and vitamin C, 27.1% ± 2.9%, P = .005) and oxidative burst (pretreatment: placebo, 6.4% ± 0.8% and vitamin C, 7.1% ± 1.2%, P = .60; posttreatment: placebo, 6.9% ± 1.3% and vitamin C, 12.1% ± 1.6%, P = .02). The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01). Plasma vitamin C concentration and PMN cell functions were not significantly different before both treatments. We conclude that the 6-week 1000-mg/d vitamin C increased PMN phagocytosis and oxidative burst in type 2 diabetes mellitus patients with poor glycemic control.",2020,The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01).,['type 2 diabetes mellitus patients with poor glycemic control'],"['Oral vitamin C treatment', 'placebo, vitamin C', 'oral vitamin C', 'vitamin C', 'placebo (anhydrous calcium hydrogen phosphate) tablet', 'placebo']","['PMN cell functions', 'polymorphonuclear (PMN) cell functions', 'Plasma vitamin C concentration and PMN cell functions', 'Blood samples', 'PMN cell phagocytosis', 'oxidative burst', 'plasma vitamin C concentration', 'polymorphonuclear cell functions', 'PMN phagocytosis and oxidative burst']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0342299', 'cui_str': 'Poor glycemic control'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0108134', 'cui_str': 'Calcium phosphate dibasic'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}]","[{'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C0085416', 'cui_str': 'Oxidative Burst'}]",,0.155192,The plasma vitamin C concentration was elevated after vitamin C treatment as compared with that before treatment (P < .001) and was higher than that observed in the placebo treatment group (P < .01).,"[{'ForeName': 'Nisa', 'Initials': 'N', 'LastName': 'Chuangchot', 'Affiliation': 'Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand; The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: nisachuang@kku.ac.th.'}, {'ForeName': 'Chongchira', 'Initials': 'C', 'LastName': 'Boonthongkaew', 'Affiliation': 'Biomedical Sciences Program, Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand; Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: chongchira@kkumail.com.'}, {'ForeName': 'Wisitsak', 'Initials': 'W', 'LastName': 'Phoksawat', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Graduate School, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: wisitsakphok@kkumail.com.'}, {'ForeName': 'Amonrat', 'Initials': 'A', 'LastName': 'Jumnainsong', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: amonrat@kku.ac.th.'}, {'ForeName': 'Chanvit', 'Initials': 'C', 'LastName': 'Leelayuwat', 'Affiliation': 'The Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Clinical Immunology and Transfusion Sciences, Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: chanvit@kku.ac.th.'}, {'ForeName': 'Naruemon', 'Initials': 'N', 'LastName': 'Leelayuwat', 'Affiliation': 'Exercise and Sport Sciences Development and Research Group, Khon Kaen University, Khon Kaen 40002, Thailand; Department of Physiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand. Electronic address: naruemon@kku.ac.th.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.010'] 1779,32615392,The effects of 6 mo of supplementation with probiotics and synbiotics on gut microbiota in the adults with prediabetes: A double blind randomized clinical trial.,"OBJECTIVES The evidence of 16S rRNA genes in the gut microbiota distinguished a higher Firmicutes-to-Bacteroidetes ratio in individuals who were obese and had diabetes than in a healthy cohort. So, it seems that the modulation of intestinal microbial ecology by pro-/pre-/synbiotics may contribute to the progression and prevention of metabolic diseases. The aim of this study was to assess the effects of probiotics and synbiotic supplementation on the modification of the intestinal microbiome in adults with prediabetes. METHODS In a randomized, double-blinded, placebo-controlled clinical trial, 120 patients with prediabetes were randomly assigned to consume 6 g/d of either a placebo containing maltodextrin (control) or multispecies probiotic or inulin-based synbiotic for 6 mo. Fecal samples were obtained at baseline and after 6 mo of supplementation. Dietary intake was assessed throughout the study (at baseline and after 3 and 6 mo). Total energy, macronutrients, and dietary fiber were calculated using a dietary program Nutritionist 4. DNA was extracted from fecal samples and the numbers of Clostridium perfringens (the represent of phylum Firmicutes), Bacteroides fragilis (the representative of Bacteroidetes) and Escherichia coli (as universal bacteria) were determined by quantitative real-time polymerase chain reactions (qPCR). The changes in the relative abundance of the two fecal bacteria before and after supplementation were analyzed and compared within and between groups. RESULTS There were no significant changes in dietary intake during the study. Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02). Synbiotic had no significant effect on the changes in the bacteria. There were no significant differences between the three groups. CONCLUSION The results of this study suggest that manipulation of the human gut microbiome by using probiotics could provide a potential therapeutic approach in the prevention and management of obesity and metabolic disorders such as diabetes.",2020,"Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02).","['120 patients with prediabetes', 'adults with prediabetes']","['dietary program', 'probiotics and synbiotic supplementation', 'placebo containing maltodextrin (control) or multispecies probiotic or inulin-based synbiotic', 'Synbiotic', 'supplementation with probiotics and synbiotics', 'placebo']","['dietary intake', 'gut microbiota', 'bacteria', 'Total energy, macronutrients, and dietary fiber', 'abundance of the B. fragilis-to-E.coli ratio', 'Dietary intake', 'Fecal samples']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271650', 'cui_str': 'Impaired glucose tolerance'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C2936470', 'cui_str': 'Synbiotics'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]",120.0,0.249584,"Six mo of supplementation with probiotics resulted in a statistically significant increase in the abundance of the B. fragilis-to-E.coli ratio (mean difference [MD] ± SE 0.47 ± 0.37, P = 0.04) and decrease of the relative proportion of Firmicutes-to-Bacteroidetes representatives (MD ± SE -118.8 ± 114.6, P = 0.02).","[{'ForeName': 'Nazila', 'Initials': 'N', 'LastName': 'Kassaian', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: nkassaian@gmal.com.'}, {'ForeName': 'Awat', 'Initials': 'A', 'LastName': 'Feizi', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center and Department of Biostatistics and Epidemiology, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: awat_feiz@hlth.mui.ac.ir.'}, {'ForeName': 'Soodabeh', 'Initials': 'S', 'LastName': 'Rostami', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: srostami1876@gmail.com.'}, {'ForeName': 'Ashraf', 'Initials': 'A', 'LastName': 'Aminorroaya', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: aminorroaya@med.mui.ac.ir.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Yaran', 'Affiliation': 'Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: yaranmajid@yahoo.com.'}, {'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Amini', 'Affiliation': 'Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: M_amini@med.mui.ac.ir.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110854'] 1780,32619458,"Acute psychological stress, autonomic function, and arterial stiffness among women.","This study aimed to investigate the effect of acute psychological stress on autonomic function and arterial stiffness, and to test a mediating role of changes in autonomic function between acute stress and arterial stiffness. Eighty-five healthy female adults were randomized into either an experimental or control group. The Trier Social Stress Test (TSST) was used to induce acute psychological stress. Autonomic function (measured by pre-ejection period [PEP] from cardiac impedance and high frequency [HF] of heart rate variability [HRV]) and arterial stiffness (measured by carotid and femoral pulse wave velocity [cfPWV] and augmentation index [AIx]) were assessed before and after the TSST. The mean age of the participants was 28.78 (±9.84) years old. Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure. However, no significant group differences were observed in changes in PEP (p = .181) and HF (p = .058). Changes in PEP and HF were neither associated with changes in cfPWV (p = .975 and p = .654, respectively), nor in AIx (p = .376 and p = .323, respectively). The results suggest that even a brief period of mild to moderate stress, which does not cause sustainable changes in autonomic function, may still exert significant adverse effects on arterial stiffness. The changes in arterial stiffness were not related to changes in autonomic function. Future experimental studies with several measurement points are recommended to identify distinct effects of stress on autonomic function and arterial stiffness.",2020,"Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure.","['The mean age of the participants was 28.78 (±9.84) years old', 'Eighty-five healthy female adults', 'women']",['Trier Social Stress Test (TSST'],"['heart rate variability [HRV]) and arterial stiffness (measured by carotid and femoral pulse wave velocity [cfPWV] and augmentation index [AIx', 'cfPWV', 'Autonomic function', 'Acute psychological stress, autonomic function, and arterial stiffness', 'arterial stiffness', 'autonomic function and arterial stiffness', 'systolic blood pressure', 'autonomic function', 'changes in PEP']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0686752', 'cui_str': 'Well female adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0999177', 'cui_str': 'Aix'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031642', 'cui_str': 'Phosphoenolpyruvate'}]",85.0,0.0168326,"Experimental group participants had a significant increase in cfPWV (p = .025) and AIx (p = .017) following the stressor, compared with those in the control group, after controlling for age, body mass index, and systolic blood pressure.","[{'ForeName': 'Jeongok G', 'Initials': 'JG', 'LastName': 'Logan', 'Affiliation': 'University of Virginia, School of Nursing, McLeod Hall 4011, 225 Jeanette Lancaster Way, Charlottesville, VA 22903, United States. Electronic address: jl3zj@virginia.edu.'}, {'ForeName': 'Bethany A', 'Initials': 'BA', 'LastName': 'Teachman', 'Affiliation': 'University of Virginia, Department of Psychology, 207 Gilmer Hall, Charlottesville, VA 22903, United States. Electronic address: bat5x@virginia.edu.'}, {'ForeName': 'Xiaoyue', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'University of Virginia, School of Nursing, McLeod Hall 4034, 225 Jeanette Lancaster Way, Charlottesville, VA 22903, United States. Electronic address: xl5tb@virginia.edu.'}, {'ForeName': 'Charles R', 'Initials': 'CR', 'LastName': 'Farber', 'Affiliation': 'University of Virginia, Public Health Sciences, OMS 3817B, Charlottesville, VA 22908, United States. Electronic address: crf2s@virginia.edu.'}, {'ForeName': 'Zhenqi', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'University of Virginia, School of Medicine, Suite 2100, 450 Ray C. Hunt Drive, Charlottesville, VA 22903, United States. Electronic address: zl3e@virginia.edu.'}, {'ForeName': 'Brian H', 'Initials': 'BH', 'LastName': 'Annex', 'Affiliation': 'Augusta University, Medical College of Georgia, 1120 15th St. Augusta, GA 30912, United States. Electronic address: bannex@augusta.edu.'}]",International journal of psychophysiology : official journal of the International Organization of Psychophysiology,['10.1016/j.ijpsycho.2020.06.015'] 1781,32619868,Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults.,"Few studies examine the effectiveness of treatments for opioid use disorder (OUD) among Black individuals despite recent evidence suggesting opioid overdose death rates are, in some cases, highest and increasing at a faster rate among Black people compared to other racial/ethnic groups. This secondary analysis study investigated treatment preference, retention, and relapse rates amongst a subgroup of 73 Black participants with OUD (81% male, mean age 39.05, SD = 11.80) participating in a 24-week multisite randomized clinical trial (""X:BOT"") comparing the effectiveness of extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX) between 2014 and 2017. Chi-square analyses were used to investigate treatment preference assessed at baseline, and logistic regression analyses were used to investigate differences in the odds of retention and relapse assessed over the 24-week course of treatment between treatment groups. Our findings suggest no differences in preference for XR-NTX versus BUP-NX. However, similar to the parent trial, there was an induction hurdle such that only 59.5% of those randomized to XR-NTX successfully initiated medication compared to 91.6% of those randomized to BUP-NX (OR = 0.13, 95% CI = 0.04, 0.52). No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol [i.e., those who initiated medication]: OR = 0.60, 95% CI = 0.20, 1.82) or relapse rates between treatment groups (intention-to-treat: OR = 1.53, 95% CI = 0.57, 4.13; per-protocol: OR = 0.69, 95% CI = 0.23, 2.06). Although there is a significant initiation hurdle with XR-NTX, once inducted, both medications appear similar in effectiveness, but as in the main study, dropout rates were high. Future research is needed on how to improve adherence.",2020,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","['black adults', '73 Black participants with OUD (81% male, mean age 39.05, SD\xa0=\xa011.80) participating']","['extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX', 'naltrexone', 'buprenorphine-naloxone']",['relapse rates'],"[{'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0027360', 'cui_str': 'Naltrexone'}, {'cui': 'C0285526', 'cui_str': 'N-telopeptide'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine- and naloxone-containing product'}]","[{'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",73.0,0.101327,"No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol","[{'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Haeny', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 34 Park St., New Haven, CT 06511, United States. Electronic address: angela.haeny@yale.edu.'}, {'ForeName': 'LaTrice', 'Initials': 'L', 'LastName': 'Montgomery', 'Affiliation': 'University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience, 3131 Harvey Avenue., Cincinnati, OH 45229, United States.'}, {'ForeName': 'A Kathleen', 'Initials': 'AK', 'LastName': 'Burlew', 'Affiliation': 'University of Cincinnati, Department of Psychology, 2600 Clifton Ave., Cincinnati, OH 45221, United States.'}, {'ForeName': 'Aimee N C', 'Initials': 'ANC', 'LastName': 'Campbell', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Scodes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Pavlicova', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Rotrosen', 'Affiliation': 'New York University Grossman School of Medicine, One Park Ave., New York, NY 10016, United States.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Nunes', 'Affiliation': 'Columbia University Irving Medical Center, Department of Psychiatry and New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106514'] 1782,32621083,Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.,"INTRODUCTION Gastrointestinal (GI) events are a common side effect of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) class. This post hoc analysis assessed the characteristics of GI adverse events in Chinese patients with type 2 diabetes (T2D) who were treated with once-weekly dulaglutide from two randomized clinical trials. METHODS Chinese patients with T2D, treated with once-weekly dulaglutide (1.5 mg and 0.75 mg) from two phase III multicenter trials (AWARD-CHN1 and AWARD-CHN2) were included. Descriptive statistics were used to present the data. The characteristics (incidence, severity, onset, duration, and time of occurrence) of GI adverse events reported through 26 weeks in a Chinese subpopulation from the two trials were investigated. RESULTS A total of 787 Chinese patients with T2D were included in this analysis. Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE). The most frequently reported GI TEAEs were diarrhea (13.1%), nausea (6.6%), abdominal distension (6.4%), and vomiting (3.0%), with most being categorized as mild to moderate in severity in proportions of 92%, 88%, 94%, and 83%, respectively. A total of 12 patients (1.5%) discontinued the dulaglutide treatment as a result of GI TEAEs. The median duration of the first reported GI TEAEs was 4.0, 5.0, 12.5, and 4.0 days for diarrhea, nausea, abdominal distension, and vomiting, respectively. The incidence of GI TEAEs was more frequent during the first 2 weeks of dulaglutide treatment; however, the incidence declined rapidly after 2 weeks and remained low until week 26. CONCLUSIONS Most of the GI TEAEs associated with once-weekly dulaglutide (1.5 mg and 0.75 mg) were mild to moderate in severity. The incidence of GI TEAEs was more pronounced during the first 2 weeks of dulaglutide treatment but declined rapidly as treatment continued, and was low at week 26, indicating that dulaglutide was well tolerated in Chinese patients with T2D. TRIAL REGISTRATION NCT01648582 and NCT01644500.",2020,"Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE).","['Chinese patients with T2D, treated with once-weekly dulaglutide (1.5\xa0mg and 0.75\xa0mg) from two phase\xa0III multicenter trials (AWARD-CHN1 and AWARD-CHN2) were included', 'Chinese patients with type\xa02 diabetes (T2D) who were treated with once-weekly dulaglutide from two randomized clinical trials', '787 Chinese patients with T2D', 'Chinese Patients with Type']",[],"['diarrhea', 'incidence of GI TEAEs', 'abdominal distension', 'median duration', 'characteristics (incidence, severity, onset, duration, and time of occurrence) of GI adverse events', 'vomiting', 'nausea', 'diarrhea, nausea, abdominal distension, and vomiting']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0558293', 'cui_str': 'Once a week'}, {'cui': 'C3179549', 'cui_str': 'dulaglutide'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0206012', 'cui_str': 'Multicentre Trials'}, {'cui': 'C0004446', 'cui_str': 'Awards'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0000731', 'cui_str': 'Swollen abdomen'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",787.0,0.0832677,"Up to week 26, 225 patients (28.6%) reported at least one GI treatment-emergent adverse event (TEAE).","[{'ForeName': 'Lixin', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Department of Endocrinology, Beijing Hospital, National Center of Gerontology, No.1, Dahua Road, Dongcheng District, Beijing, 100730, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co., Ltd, 19F, Tower 1 HKRI, Taikoo Hui, No. 288, Shi Men No. 1 Rd, Shanghai, 200041, China.'}, {'ForeName': 'Jianing', 'Initials': 'J', 'LastName': 'Hou', 'Affiliation': 'Lilly Suzhou Pharmaceutical Co., Ltd, 19F, Tower 1 HKRI, Taikoo Hui, No. 288, Shi Men No. 1 Rd, Shanghai, 200041, China. hou_jia_ning@lilly.com.'}, {'ForeName': 'Zhiguang', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, 139 Renmin Road, Changsha, 410011, Hunan, China. zhouzhiguang@csu.edu.cn.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00869-z'] 1783,32621657,Effects of hyaluronic acid injected using the mesogun injector with stamp-type microneedle on skin hydration.,"The elasticity of the skin and its capacity to hold water decrease with aging because of the loss of hyaluronic acid (HA) in the skin. Therefore, there is an increasing interest in the use of HA fillers in skin rejuvenation beyond its conventional use which is supplementing decreased dermis volume and filling deep wrinkles. We investigated the efficacy and safety of a novel device (Dermashine balance) that injects HA into the dermis using a stamp-type microneedle for maintenance of hydration and elasticity of the skin. A single-center randomized double-blinded parallel-group clinical study was conducted, and 60 participants enrolled in this study. The subjects were randomized to receive HA injections or a placebo three times across the face using an automatic intradermal injector. At 4, 8, and 12 weeks after the treatment, skin hydration was measured using a corneometer. The patients who received HA showed significantly greater skin hydration than those who received the placebo. However, a significant difference was not noted in skin elasticity between the groups. No severe adverse event was reported. Intradermal supplementation of HA using mesogun multineedle injector may be a safe and effective treatment for improving skin hydration.",2020,The elasticity of the skin and its capacity to hold water decrease with aging because of the loss of hyaluronic acid (HA) in the skin.,['60 participants enrolled in this study'],"['novel device (Dermashine® balance', 'hyaluronic acid', 'HA injections', 'placebo']","['severe adverse event', 'efficacy and safety', 'skin hydration', 'skin elasticity']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0423761', 'cui_str': 'Skin elasticity'}]",60.0,0.072965,The elasticity of the skin and its capacity to hold water decrease with aging because of the loss of hyaluronic acid (HA) in the skin.,"[{'ForeName': 'Sun Young', 'Initials': 'SY', 'LastName': 'Choi', 'Affiliation': 'Department of Dermatology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Eun Jung', 'Initials': 'EJ', 'LastName': 'Ko', 'Affiliation': 'Department of Dermatology, National Police Hospital, Seoul, South Korea.'}, {'ForeName': 'Kwang Ho', 'Initials': 'KH', 'LastName': 'Yoo', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hye Sung', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Beom Joon', 'Initials': 'BJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Chung-Ang University College of Medicine, Seoul, South Korea.'}]",Dermatologic therapy,['10.1111/dth.13963'] 1784,32621663,A comparative study of topical tacrolimus and topical triamcinolone acetonide in nodular scabies.,"The aim of this study was to compare the efficacy and safety of 0.1% triamcinolone acetonide and 0.03% tacrolimus ointment for the treatment of nodular lesions of scabies. In this double-blind randomized controlled trial, 50 Indian men with postscabeitic persistent nodular lesions (labelled to have nodular scabies (NS)/postscabies prurigo (PSP)) over the external genitalia, were enrolled. They were randomized into two groups to receive either a mid-potency topical corticosteroid (TCS); triamcinolone acetonide 0.1% ointment twice daily, or topical calcineurin inhibitor (CNI); tacrolimus ointment 0.03% twice daily over the nodular lesions for 2 weeks. All patients were followed up on three visits: 1, 2, and 6 weeks, for assessment. Efficacy was evaluated by 5-point range investigator-assessed VAS, and a 4-point severity of pruritus scale (SPS) score. The mean VAS score was higher in triamcinolone group compared to tacrolimus group at both follow-ups, although statistically significant only at 2nd week visit. The fall in mean SPS at both follow-ups was also higher in the steroid group, but the difference was not statistically significant. While, the overall tolerance to either ointment was excellent, mild hypopigmentation, and epidermal atrophy were detected on dermoscopic evaluation of the treated areas at the 2nd week visit in a small subset of patients in the triamcinolone group. The frequency of relapse of lesions and/or pruritus after four weeks of the 2-week therapy was high in both the groups (higher in tarolimus group). Conclusively, although both treatment options provided safe and satisfactory short term improvement, the results from this study suggest an overall higher efficacy of a mid-potency TCS like triamcinolone 0.1% over topical CNI like tacrolimus 0.03%, in the short-term treatment of nodular lesions of NS/PSP. Topical CNIs may be considered for maintenance of effect, if prolonged therapy is warranted.",2020,"The mean VAS score was higher in triamcinolone group compared to tacrolimus group at both follow ups, although statistically significant only at 2 nd week visit.","['nodular scabies', 'such nodular lesions of scabies', 'fifty Indian men with postscabeitic persistent nodular lesions over the external genitalia, were enrolled']","['triamcinolone acetonide 0.1% ointment twice daily, or tacrolimus ointment', 'triamcinolone', 'triamcinolone ointment', 'topical tacrolimus and topical triamcinolone acetonide', 'Topical CNIs', 'triamcinolone acetonide and 0.1% tacrolimus ointment', 'tacrolimus']","['efficacy and safety', 'Efficacy', '5-point range investigator-assessed VAS, and a 4-point severity of pruritus scale (SPS) score', 'mean VAS score', 'mean SPS']","[{'cui': 'C0344064', 'cui_str': 'Post-scabetic nodules'}, {'cui': 'C0205297', 'cui_str': 'Nodular'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0036262', 'cui_str': 'Infestation by Sarcoptes scabiei var hominis'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0042993', 'cui_str': 'Vulval structure'}]","[{'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1253468', 'cui_str': 'Tacrolimus Topical Ointment'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0939241', 'cui_str': 'Tacrolimus-containing product in cutaneous dose form'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",50.0,0.0529841,"The mean VAS score was higher in triamcinolone group compared to tacrolimus group at both follow ups, although statistically significant only at 2 nd week visit.","[{'ForeName': 'Mukesh', 'Initials': 'M', 'LastName': 'Manjhi', 'Affiliation': 'Department of Dermatology, Hamdard Institute of Medical Sciences and Research and HAH Centenary Hospital, New Delhi, India.'}, {'ForeName': 'Pravesh', 'Initials': 'P', 'LastName': 'Yadav', 'Affiliation': 'Department of Dermatology, Lady Hardinge Medical College and Associated Hospital, New Delhi, India.'}, {'ForeName': 'Sneha', 'Initials': 'S', 'LastName': 'Mohan', 'Affiliation': 'Department of Microbiology, School of Medical Sciences and Research and Sharda Hospital, Greater Noida, Uttar Pradesh, India.'}, {'ForeName': 'Sidharth', 'Initials': 'S', 'LastName': 'Sonthalia', 'Affiliation': 'Department of Dermatology and Dermatosurgery, Skinnocence: The Skin Clinic and Research Center, Gurugram, Haryana, India.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ramesh', 'Affiliation': 'Department of Dermatology, Hamdard Institute of Medical Sciences and Research and HAH Centenary Hospital, New Delhi, India.'}, {'ForeName': 'Varun', 'Initials': 'V', 'LastName': 'Kashyap', 'Affiliation': 'Department of Community Medicine, Hamdard Institute of Medical Sciences and Research and HAH Centenary Hospital, New Delhi, India.'}]",Dermatologic therapy,['10.1111/dth.13954'] 1785,32684500,Impact of a decision-aid tool on influenza vaccine coverage among HCW in two French hospitals: A cluster-randomized trial.,"INTRODUCTION Nosocomial outbreaks of seasonal influenza are frequent, and vaccination is largely recommended for healthcare workers (HCWs). Vaccine coverage in French HCWs does not exceed 20%. Decision-aids (DA) are potential useful interventions to increase vaccine coverage (VC). Our aim was to evaluate the impact of a DA on HCWs influenza vaccine coverage. MATERIAL AND METHODS Prospective cluster-randomized trial conducted in 83 departments in two public hospitals (a teaching and a non-teaching hospital) during the 2018-2019 flu season. Distribution of the DA and of questionnaire about decisional conflict and knowledge in the departments randomized in the intervention group. RESULTS A total number of 3 547 HCWs were concerned by the study (1 953 in the intervention group, 1 594 in the control group). Global VC was 35.6% during the 2018-2019 season, instead of 23.6% in the 2017-2018 season (p < 0.005). During the 2018-2019 season, VC was 31% (95% CI 28.7-33.3) in the control group and 38.7% (95% CI 36.5-40.9) in the intervention group (p < 0.005). Among the 158 HCWs exposed to the DA who answered the survey, 51.3% had no decisional conflict. HCWs without decisional conflict were more prone to get vaccinated before flu season. CONCLUSION The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza. This modest increase remained far from the WHO 75% target, but may have reduced the number of nosocomial. Multi-component interventions are needed to increase VC in HCWs.",2020,The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza.,"['HCW in two French hospitals', '83 departments in two public hospitals (a teaching and a non-teaching hospital) during the 2018-2019 flu season']","['Decision-aids (DA', 'decision-aid tool']","['total number of 3 547 HCWs', 'Global VC']","[{'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0020022', 'cui_str': 'Public Hospitals'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}]","[{'cui': 'C0086104', 'cui_str': 'Decision Aids'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",3547.0,0.0318562,The use of the DA was associated with a 25% relative increase in VC among HCWs against seasonal influenza.,"[{'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Saunier', 'Affiliation': 'Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Berthelot', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France.""}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Mottet-Auselo', 'Affiliation': 'Infection Control Unit, Hospital of Roanne, France.'}, {'ForeName': 'Carole', 'Initials': 'C', 'LastName': 'Pelissier', 'Affiliation': 'Department of occupational medicine, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Fontana', 'Affiliation': 'Department of occupational medicine, University Hospital of Saint-Etienne, France.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Botelho-Nevers', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France.""}, {'ForeName': 'Amandine', 'Initials': 'A', 'LastName': 'Gagneux-Brunon', 'Affiliation': ""Department of Infectious Diseases, and Infection Control Unit, University Hospital of Saint-Etienne, France; Groupe Immunité des Muqueuses et Agents Pathogènes, Centre International de Recherche en Infectiologie, Université Jean Monnet, Université de Lyon, Saint-Etienne, France; Institut de Recherche PRESAGE, Chaire vaccination, Prévention et Contrôle de l'Infection, Université de Lyon Saint-Etienne, France. Electronic address: amandine.gagneux-brunon@chu-st-etienne.fr.""}]",Vaccine,['10.1016/j.vaccine.2020.07.011'] 1786,32628293,Behavioural activation therapy for depression in adults.,"BACKGROUND Behavioural activation is a brief psychotherapeutic approach that seeks to change the way a person interacts with their environment. Behavioural activation is increasingly receiving attention as a potentially cost-effective intervention for depression, which may require less resources and may be easier to deliver and implement than other types of psychotherapy. OBJECTIVES To examine the effects of behavioural activation compared with other psychological therapies for depression in adults. To examine the effects of behavioural activation compared with medication for depression in adults. To examine the effects of behavioural activation compared with treatment as usual/waiting list/placebo no treatment for depression in adults. SEARCH METHODS We searched CCMD-CTR (all available years), CENTRAL (current issue), Ovid MEDLINE (1946 onwards), Ovid EMBASE (1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020 to identify randomised controlled trials (RCTs) of 'behavioural activation', or the main elements of behavioural activation for depression in participants with clinically diagnosed depression or subthreshold depression. We did not apply any restrictions on date, language or publication status to the searches. We searched international trials registries via the World Health Organization's trials portal (ICTRP) and ClinicalTrials.gov to identify unpublished or ongoing trials. SELECTION CRITERIA We included randomised controlled trials (RCTs) of behavioural activation for the treatment of depression or symptoms of depression in adults aged 18 or over. We excluded RCTs conducted in inpatient settings and with trial participants selected because of a physical comorbidity. Studies were included regardless of reported outcomes. DATA COLLECTION AND ANALYSIS Two review authors independently screened all titles/abstracts and full-text manuscripts for inclusion. Data extraction and 'Risk of bias' assessments were also performed by two review authors in duplicate. Where necessary, we contacted study authors for more information. MAIN RESULTS Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs. We found moderate-certainty evidence that behavioural activation had greater short-term efficacy than treatment as usual (risk ratio (RR) 1.40, 95% confidence interval (CI) 1.10 to 1.78; 7 RCTs, 1533 participants), although this difference was no longer evident in sensitivity analyses using a worst-case or intention-to-treat scenario. Compared with waiting list, behavioural activation may be more effective, but there were fewer data in this comparison and evidence was of low certainty (RR 2.14, 95% CI 0.90 to 5.09; 1 RCT, 26 participants). No evidence on treatment efficacy was available for behavioural activation versus placebo and behavioural activation versus no treatment. We found moderate-certainty evidence suggesting no evidence of a difference in short-term treatment efficacy between behavioural activation and CBT (RR 0.99, 95% CI 0.92 to 1.07; 5 RCTs, 601 participants). Fewer data were available for other comparators. No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty). Behavioural activation was more effective than humanistic therapy (RR 1.84, 95% CI 1.15 to 2.95; 2 RCTs, 46 participants; low certainty) and medication (RR 1.77, 95% CI 1.14 to 2.76; 1 RCT; 141 participants; moderate certainty), but both of these results were based on a small number of trials and participants. No evidence on treatment efficacy was available for comparisons between behavioural activation versus interpersonal, cognitive analytic, and integrative therapies. There was moderate-certainty evidence that behavioural activation might have lower treatment acceptability (based on dropout rate) than treatment as usual in the short term, although the data did not confirm a difference and results lacked precision (RR 1.64, 95% CI 0.81 to 3.31; 14 RCTs, 2518 participants). Moderate-certainty evidence did not suggest any difference in short-term acceptability between behavioural activation and waiting list (RR 1.17, 95% CI 0.70 to 1.93; 8 RCTs. 359 participants), no treatment (RR 0.97, 95% CI 0.45 to 2.09; 3 RCTs, 187 participants), medication (RR 0.52, 95% CI 0.23 to 1.16; 2 RCTs, 243 participants), or placebo (RR 0.72, 95% CI 0.31 to 1.67; 1 RCT; 96 participants; low-certainty evidence). No evidence on treatment acceptability was available comparing behavioural activation versus psychodynamic therapy. Low-certainty evidence did not show a difference in short-term treatment acceptability (dropout rate) between behavioural activation and CBT (RR 1.03, 95% CI 0.85 to 1.25; 12 RCTs, 1195 participants), third-wave CBT (RR 0.84, 95% CI 0.33 to 2.10; 3 RCTs, 147 participants); humanistic therapy (RR 1.06, 95% CI 0.20 to 5.55; 2 RCTs, 96 participants) (very low certainty), and interpersonal, cognitive analytic, and integrative therapy (RR 0.84, 95% CI 0.32 to 2.20; 4 RCTs, 123 participants). Results from medium- and long-term primary outcomes, secondary outcomes, subgroup analyses, and sensitivity analyses are summarised in the text. AUTHORS' CONCLUSIONS This systematic review suggests that behavioural activation may be more effective than humanistic therapy, medication, and treatment as usual, and that it may be no less effective than CBT, psychodynamic therapy, or being placed on a waiting list. However, our confidence in these findings is limited due to concerns about the certainty of the evidence. We found no evidence of a difference in short-term treatment acceptability (based on dropouts) between behavioural activation and most comparison groups (CBT, humanistic therapy, waiting list, placebo, medication, no treatment or treatment as usual). Again, our confidence in all these findings is limited due to concerns about the certainty of the evidence. No data were available about the efficacy of behaioural activation compared with placebo, or about treatment acceptability comparing behavioural activation and psychodynamic therapy, interpersonal, cognitive analytic and integrative therapies. The evidence could be strengthened by better reporting and better quality RCTs of behavioural activation and by assessing working mechanisms of behavioural activation.",2020,"No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty).","['participants with clinically diagnosed depression or subthreshold depression', '1980 onwards), and Ovid PsycINFO (1806 onwards) on the 17 January 2020', 'Fifty-three studies with 5495 participants were included; 51 parallel group RCTs and two cluster-RCTs', 'adults', 'depression in adults', 'depression or symptoms of depression in adults aged 18 or over']","['Behavioural activation therapy', 'behavioural activation', 'Ovid EMBASE ', 'placebo']","['usual (risk ratio (RR', 'behavioural activation and waiting list', 'short term-efficacy', 'Behavioural activation']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C2733064', 'cui_str': 'Behavioral activation therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",5495.0,0.306503,"No evidence of a difference in short term-efficacy was found between behavioural activation and third-wave CBT (RR 1.10, 95% CI 0.91 to 1.33; 2 RCTs, 98 participants; low certainty), and psychodynamic therapy (RR 1.21, 95% CI 0.74 to 1.99; 1 RCT,60 participants; very low certainty).","[{'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Uphoff', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ekers', 'Affiliation': 'Lanchester Road Hospital, Tees, Esk and Wear Valleys NHS Foundation Trust, Durham, UK.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Robertson', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dawson', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Sanger', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'South', 'Affiliation': 'Centre for Reviews and Dissemination, University of York, York, UK.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Samaan', 'Affiliation': 'Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Canada.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Richards', 'Affiliation': 'School of Psychology, University of Exeter, Exeter, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Meader', 'Affiliation': 'Centre for Reviews and Dissemination, University of York, York, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Churchill', 'Affiliation': 'Cochrane Common Mental Disorders, University of York, York, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013305.pub2'] 1787,32623059,Applying an immersive tutorial in virtual reality to learning a new technique.,"OBJECTIVE The medical world is continuously evolving, with techniques being created or improved almost daily. Immersive virtual reality (VR) is a technology that could be harnessed to develop tools that meet the educational challenges of this changing environment. We previously described the immersive tutorial, a 3D video (filmed from the first-person point of view), displayed on a VR application. This tool offers access to supplementary educational data in addition to the video. Here we attempt to assess improvement in learning a technique using this new educational format. MATERIAL AND METHODS We selected a single neurosurgical technique for the study: external ventricular drainage. We wrote a technical note describing this procedure and produced the corresponding immersive tutorial. We conducted a prospective randomized comparative study with students. All participants read the technical note, and one group used the immersive tutorial as a teaching supplement. The students completed a multiple-choice questionnaire immediately after the training and again at six months. RESULTS One hundred seventy-six fourth-year medical students participated in the study; 173 were included in assessing the immediate learning outcomes and 72 were included at the six-month follow-up. The VR group demonstrated significantly better short-term results than the control group (P=0.01). The same trend was seen at six months. CONCLUSION To our knowledge, this study presents one of the largest cohorts for VR. The use of the immersive tutorial could enable a large number of healthcare professionals to be trained without the need for expensive equipment.",2020,The VR group demonstrated significantly better short-term results than the control group (p = 0.01).,"['students', 'One hundred seventy-six fourth-year medical students participated in the study; 173 were included in assessing the immediate learning outcomes and 72 were included at the six-month follow-up']",['Immersive virtual reality (VR'],[],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]",[],,0.021312,The VR group demonstrated significantly better short-term results than the control group (p = 0.01).,"[{'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ros', 'Affiliation': 'Education sciences school - LIRDEF, Montpellier university 3, 2, place Marcel-Godechot, 34000 Montpellier, France. Electronic address: maximeros@gmail.com.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Debien', 'Affiliation': ""Medical simulation training center, 641, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France; Montpellier medical school, 2, rue de l'École de Médecine, 34090 Montpellier, France.""}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cyteval', 'Affiliation': ""Radiology department, Lapeyronie hospital, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France; Montpellier medical school, 2, rue de l'École de Médecine, 34090 Montpellier, France.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Molinari', 'Affiliation': ""IT medical department, Lapeyronie hospital, 371, avenue du Doyen Gaston-Giraud, 34090 Montpellier, France; Montpellier medical school, 2, rue de l'École de Médecine, 34090 Montpellier, France.""}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Gatto', 'Affiliation': 'Education sciences school - LIRDEF, Montpellier university 3, 2, place Marcel-Godechot, 34000 Montpellier, France.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Lonjon', 'Affiliation': ""Neurosurgery department, Gui de Chauliac hospital, 80, avenue Augustin-Fliche, 34295 Montpellier, France; Montpellier medical school, 2, rue de l'École de Médecine, 34090 Montpellier, France.""}]",Neuro-Chirurgie,['10.1016/j.neuchi.2020.05.006'] 1788,32623140,Emotion self-regulation training in major depressive disorder using simultaneous real-time fMRI and EEG neurofeedback.,"Simultaneous real-time fMRI and EEG neurofeedback (rtfMRI-EEG-nf) is an emerging neuromodulation approach, that enables simultaneous volitional regulation of both hemodynamic (BOLD fMRI) and electrophysiological (EEG) brain activities. Here we report the first application of rtfMRI-EEG-nf for emotion self-regulation training in patients with major depressive disorder (MDD). In this proof-of-concept study, MDD patients in the experimental group (n = 16) used rtfMRI-EEG-nf during a happy emotion induction task to simultaneously upregulate two fMRI and two EEG activity measures relevant to MDD. The target measures included BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz). MDD patients in the control group (n = 8) were provided with sham feedback signals. An advanced procedure for improved real-time EEG-fMRI artifact correction was implemented. The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC. Average individual FAA changes during the rtfMRI-EEG-nf task positively correlated with depression and anhedonia severities, and negatively correlated with after-vs-before changes in depressed mood ratings. Temporal correlations between the FAA and FBA time courses and the LA BOLD activity were significantly enhanced during the rtfMRI-EEG-nf task. The experimental group participants reported significant mood improvements after the training. Our results suggest that the rtfMRI-EEG-nf may have potential for treatment of MDD.",2020,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.",['patients with major depressive disorder (MDD'],"['Emotion self-regulation training', 'rtfMRI-EEG-nf for emotion self-regulation training']","['BOLD activities of the left amygdala (LA) and left rostral anterior cingulate cortex (rACC), and frontal EEG asymmetries in the alpha band (FAA, [7.5-12.5] Hz) and high-beta band (FBA, [21-30] Hz', 'Average individual FAA changes', 'depression and anhedonia severities', 'LA BOLD activity', 'fMRI connectivity', 'LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C3163631', 'cui_str': 'Rostral'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0060441', 'cui_str': 'flavone acetic acid'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0178417', 'cui_str': 'Anhedonia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]",,0.014664,"The experimental group participants demonstrated significant upregulation of the LA BOLD activity, FAA, and FBA during the rtfMRI-EEG-nf task, as well as significant enhancement in fMRI connectivity between the LA and left rACC.","[{'ForeName': 'Vadim', 'Initials': 'V', 'LastName': 'Zotev', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA. Electronic address: vzotev@laureateinstitute.org.'}, {'ForeName': 'Ahmad', 'Initials': 'A', 'LastName': 'Mayeli', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Electrical and Computer Engineering, University of Oklahoma, Tulsa, OK, USA.'}, {'ForeName': 'Masaya', 'Initials': 'M', 'LastName': 'Misaki', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA.'}, {'ForeName': 'Jerzy', 'Initials': 'J', 'LastName': 'Bodurka', 'Affiliation': 'Laureate Institute for Brain Research, Tulsa, OK, USA; Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, USA. Electronic address: jbodurka@laureateinstitute.org.'}]",NeuroImage. Clinical,['10.1016/j.nicl.2020.102331'] 1789,32623182,"Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).","BACKGROUND Chemotherapy is effective in metastatic pancreatic adenocarcinoma (mPA), but new approaches are still needed to improve patients' survival and quality of life. We have previously published good efficacy and tolerability results on a sequential treatment strategy of gemcitabine followed by an intensified FOLFIRI (5FU+irinotecan) regimen. In the present study, we evaluated the same sequence but replaced gemcitabine by the new gemcitabine + nab-paclitaxel standard first-line combination. PATIENTS AND METHODS We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status 0-2 to alternately receive gemcitabine + nab-paclitaxel for 2 months then FOLFIRI.3 for 2 months in arm A, or gemcitabine + nab-paclitaxel alone until progression in arm B. The primary objective was to increase the 6-month progression-free survival (PFS) rate from 40% (H 0 ) to 60% (H 1 ); using the binomial exact method, 124 patients were required. Analyses were carried out in preplanned modified intention-to-treat (mITT) and per-protocol (PP) populations. RESULTS Between November 2015 and November 2016, 127 patients were enrolled. Main grade III-IV toxicities (% in arm A/B) were: diarrhoea (12.5/1.7), neutropenia (46.9/31, including febrile neutropenia: 1.6/0), skin toxicity (6.3/13.8), and peripheral neuropathy (6.3/8.6). No toxic deaths occurred. The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm B. The primary end-point (6-month PFS rate) was 45.2% [one-sided 95% CI: 34.3-56.4] in arm A and 23.3% in arm B [one-sided 95% CI: 14.3-32.3] in the mITT population. In the PP population, median PFS and OS were 7.6 months and 6 months and 14.5 months and 12.2 months in arm A and B, respectively. CONCLUSIONS The FIRGEMAX strategy with gemcitabine + nab-paclitaxel alternating with FOLFIRI.3 every 2 months, appears feasible and effective, with manageable toxicities, in patients able to reach >2mo of treatment. TRIAL REGISTRATION INFORMATION EudraCT: 2014-004449-28: NCT: 0282701.",2020,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"['We randomised chemotherapy-naive patients with proven mPA, bilirubin levels ≤1.5 upper limit of normal values and performance status\xa00-2 to alternately receive', 'metastatic pancreatic adenocarcinoma (mPA', 'patients with metastatic pancreatic adenocarcinoma', 'Between November 2015 and November 2016', '127 patients were enrolled']","['gemcitabine\xa0+\xa0nab-paclitaxel', 'Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3', 'gemcitabine\xa0+\xa0nab-paclitaxel standard first-line combination', 'gemcitabine\xa0+\xa0nab-paclitaxel alone until progression in arm B', 'gemcitabine', 'gemcitabine\xa0+\xa0nab-paclitaxel alternating with FOLFIRI.3']","['peripheral neuropathy', 'toxic deaths', 'neutropenia', 'diarrhoea', 'Main grade III-IV toxicities', 'median PFS and OS', 'skin toxicity', 'objective response rate', '6-month progression-free survival (PFS) rate']","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0861727', 'cui_str': 'Pancreatic adenocarcinoma metastatic'}, {'cui': 'C0344395', 'cui_str': 'Bilirubin measurement'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0449438', 'cui_str': 'Status'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]",127.0,0.0595149,The objective response rate was 40.3% (95% confidence interval [CI]: 28.1-53.6) in arm A and 26.7% (95% CI: 16.1-39.7) in arm,"[{'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Rinaldi', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Anne-Laure', 'Initials': 'AL', 'LastName': 'Pointet', 'Affiliation': 'Department of Hepato-gastroenterology, Georges Pompidou European Hospital, Paris, France.'}, {'ForeName': 'Faiza', 'Initials': 'F', 'LastName': 'Khemissa Akouz', 'Affiliation': 'Department of Hepato-gastroenterology, Saint Jean Hospital, Perpignan, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Le Malicot', 'Affiliation': 'Biostatistics Department, Francophone Federation of Digestive Cancerology, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Bidaut', 'Initials': 'B', 'LastName': 'Wahiba', 'Affiliation': 'Department of Hepato-gastroenterology, European Hospital, Marseille, France.'}, {'ForeName': 'Samy', 'Initials': 'S', 'LastName': 'Louafi', 'Affiliation': 'Department of Oncology, Sud Francilien Hospital Center, Corbeil-Essonnes, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Gratet', 'Affiliation': 'Oncology and Hematology ONCOSUD Unit, Clinic Pasteur, Toulouse, France.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Miglianico', 'Affiliation': 'Department of Radiotherapy, Private Hospital Center, Saint-Grégoire, France.'}, {'ForeName': 'Hortense', 'Initials': 'H', 'LastName': 'Laharie', 'Affiliation': 'Department of Oncology and Radiotherapy, Clinic Tivoli, Bordeaux, France.'}, {'ForeName': 'Karine', 'Initials': 'K', 'LastName': 'Bouhier Leporrier', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital, Caen, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Thirot Bidault', 'Affiliation': 'Department of Hepato-gastroenterology, Private Hospital, Antony, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Texereau', 'Affiliation': 'Department of Hepato-gastroenterology, Layne Hospital, Mont-De-Marsan, France.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Coriat', 'Affiliation': 'Department of Hepato-gastroenterology, Cochin Hospital, APHP, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Terrebonne', 'Affiliation': 'Department of Hepato-gastroenterology, Haut Lévêque Hospital, Pessac, France.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Gouttebel', 'Affiliation': 'Department of Oncology, Drôme Nord Hospital, Romans Sur Isère, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Malka', 'Affiliation': 'Department of Hepato-gastroenterology, Gustave Roussy Cancer Campus, Villejuif, France.'}, {'ForeName': 'Jean-Baptiste', 'Initials': 'JB', 'LastName': 'Bachet', 'Affiliation': 'Department of Hepato-gastroenterology, Pitié-Salpêtrière Hospital, Paris, France.'}, {'ForeName': 'Côme', 'Initials': 'C', 'LastName': 'Lepage', 'Affiliation': 'Department of Hepato-gastroenterology, University Hospital of Dijon, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taieb', 'Affiliation': 'Department of Hepato-gastroenterology, Sorbonne Paris City, Paris Descartes University, Georges Pompidou European Hospital, Paris, France. Electronic address: jtaieb75@gmail.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.018'] 1790,32623977,Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2.,"BACKGROUND AND PURPOSE Evidence regarding sex differences in clinical outcomes and treatment effect following intracerebral hemorrhage is limited. Using the ATACH-2 trial (Antihypertensive Treatment in Intracerebral Hemorrhage-2) data, we explored whether sex disparities exist in outcomes and response to intensive blood pressure (BP)-lowering therapy. METHODS Eligible intracerebral hemorrhage subjects were randomly assigned to intensive (target systolic BP, 110-139 mm Hg) or standard (140-179 mm Hg) BP-lowering therapy within 4.5 hours after onset. Relative risk of death or disability corresponding to the modified Rankin Scale score of 4 to 6 was calculated, and interaction between sex and treatment was explored. RESULTS In total, 380 women and 620 men were included. Women were older, more prescribed antihypertensive drugs before onset, and had more lobar intracerebral hemorrhage than men. Hematoma expansion was observed less in women. After multivariable adjustment, the relative risk of death or disability in women was 1.19 (95% CI, 1.02-1.37, P =0.023). The relative risk of death or disability between intensive versus standard BP-lowering therapy was 0.91 (95% CI, 0.74-1.13) in women versus 1.13 (95% CI, 0.92-1.39) in men ( P for interaction=0.11), with inconclusive Gail-Simmon test ( P =0.16). CONCLUSIONS Women had a higher risk of death or disability following intracerebral hemorrhage. The benefit of intensive BP-lowering therapy in women is inconclusive, consistent with the overall results of ATACH-2. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01176565.",2020,"The relative risk of death or disability between intensive versus standard BP-lowering therapy was 0.91 (95% CI, 0.74-1.13) in women versus 1.13 (95% CI, 0.92-1.39) in men (","['Eligible intracerebral hemorrhage subjects', '380 women and 620 men were included', 'Women were older, more prescribed antihypertensive drugs before onset, and had more lobar intracerebral hemorrhage than men']","['intensive BP-lowering therapy', 'Hg) BP-lowering therapy']","['Hematoma expansion', 'risk of death or disability', 'relative risk of death or disability', 'Relative risk of death or disability corresponding to the modified Rankin Scale score']","[{'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}, {'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4708788', 'cui_str': '620'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]","[{'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0018944', 'cui_str': 'Hematoma'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",380.0,0.38882,"The relative risk of death or disability between intensive versus standard BP-lowering therapy was 0.91 (95% CI, 0.74-1.13) in women versus 1.13 (95% CI, 0.92-1.39) in men (","[{'ForeName': 'Mayumi', 'Initials': 'M', 'LastName': 'Fukuda-Doi', 'Affiliation': 'Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Haruko', 'Initials': 'H', 'LastName': 'Yamamoto', 'Affiliation': 'Center for Advancing Clinical and Translational Sciences (M.F.-D., H.Y.), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Koga', 'Affiliation': 'Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Yuko Y', 'Initials': 'YY', 'LastName': 'Palesch', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., V.L.D.-M.).'}, {'ForeName': 'Valerie L', 'Initials': 'VL', 'LastName': 'Durkalski-Mauldin', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina, Charleston (Y.Y.P., V.L.D.-M.).'}, {'ForeName': 'Adnan I', 'Initials': 'AI', 'LastName': 'Qureshi', 'Affiliation': 'Zeenat Qureshi Stroke Institute, St. Cloud, MN (A.I.Q.).'}, {'ForeName': 'Sohei', 'Initials': 'S', 'LastName': 'Yoshimura', 'Affiliation': 'Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Shuhei', 'Initials': 'S', 'LastName': 'Okazaki', 'Affiliation': 'Department of Neurology (S. Okazaki), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Miwa', 'Affiliation': 'Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Okada', 'Affiliation': 'Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Center Clinical Research Institute, Fukuoka, Japan (Y.O.).'}, {'ForeName': 'Toshihiro', 'Initials': 'T', 'LastName': 'Ueda', 'Affiliation': 'Department of Strokology, Stroke Center, St. Marianna University Toyoko Hospital, Kawasaki, Japan (T.U.).'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Okuda', 'Affiliation': 'Department of Neurology, National Hospital Organization Nagoya Medical Center, Japan (S. Okuda).'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Nakahara', 'Affiliation': 'Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).'}, {'ForeName': 'Norihiro', 'Initials': 'N', 'LastName': 'Suzuki', 'Affiliation': 'Department of Neurology, Keio University School of Medicine, Tokyo, Japan (M.F.-D., J.N., N.S., K.T.).'}, {'ForeName': 'Kazunori', 'Initials': 'K', 'LastName': 'Toyoda', 'Affiliation': 'Department of Cerebrovascular Medicine (M.F.-D., M.K., S.Y., K.M., K.T.), National Cerebral and Cardiovascular Center, Suita, Japan.'}]",Stroke,['10.1161/STROKEAHA.120.029770'] 1791,32648924,Association of Adherence to Weight Telemonitoring With Health Care Use and Death: A Secondary Analysis of a Randomized Clinical Trial.,"Importance Adherence to telemonitoring may be associated with heart failure exacerbation but is not included in telemonitoring algorithms. Objective To assess whether telemonitoring adherence is associated with a patient's risk of hospitalization, emergency department visit, or death. Design, Setting, and Participants This post hoc secondary analysis of the Better Effectiveness After Transition-Heart Failure randomized clinical trial included patients from 6 academic medical centers in California who were eligible if they were hospitalized for decompensated heart failure and excluded if they were discharged to a skilled nursing facility, were expected to improve because of a medical procedure, or did not have the cognitive or physical ability to participate. The trial compared a telemonitoring intervention with usual care for patients with heart failure after hospital discharge from October 12, 2011, to September 30, 2013. Data analysis was performed from November 8, 2016, to May 10, 2019. Interventions The intervention group (n = 722) received heart failure education, telephone check-ins, and a wireless telemonitoring system that allowed the patient to transmit weight, blood pressure, heart rate, and selected symptoms. The control group (n = 715) received usual care. Patients were followed up for 180 days after discharge. Main Outcomes and Measures The main outcome was within-person risk of hospitalization, emergency department visit, or death by week during the study period. Poisson regression was used to determine the within-person association of adherence to daily weighing with the risk of experiencing these events in the following week. Results Among the 538 participants (mean [SD] age, 70.9 [14.1] years; 287 [53.8%] male; 269 [50.7%] white) in the present analysis, adherence was lowest during the first week after enrollment but steadily increased, peaking between days 26 and 60 at 69%, or 371 transmissions. Adherence to weight telemonitoring was associated with events in the following week; an increase in adherence by 1 day was associated with a 19% decrease in the rate of death in the following week (incidence rate ratio, 0.81; 95% CI, 0.73-0.90) and an 11% decrease in the rate of hospitalization (incidence rate ratio, 0.89; 95% CI, 0.86-0.91). Adherence in the previous week was not associated with reduced rates of emergency department visits (incidence rate ratio, 0.95; 95% CI, 0.90-1.02). Conclusions and Relevance In this study, lower adherence to weight telemonitoring in a given week was associated with an increased risk of subsequent hospitalization or death in the following week. It is unlikely that this is a result of the telemonitoring intervention; rather, adherence may be an important factor associated with a patient's health status.",2020,"Adherence in the previous week was not associated with reduced rates of emergency department visits (incidence rate ratio, 0.95; 95% CI, 0.90-1.02). ","['patients with heart failure after hospital discharge from October 12, 2011, to September 30, 2013', 'patients from 6 academic medical centers in California who were eligible if they were hospitalized for decompensated heart failure and excluded if they were discharged to a skilled nursing facility, were expected to improve because of a medical procedure, or did not have the cognitive or physical ability to participate', '538 participants (mean [SD] age, 70.9 [14.1] years; 287 [53.8%] male; 269 [50.7%] white', 'Death']","['telemonitoring intervention with usual care', 'heart failure education, telephone check-ins, and a wireless telemonitoring system', 'usual care']","['adherence', 'person risk of hospitalization, emergency department visit, or death', 'rate of death', 'risk of subsequent hospitalization or death', 'rate of hospitalization', 'Adherence to weight telemonitoring', 'rates of emergency department visits']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0006754', 'cui_str': 'California'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0037265', 'cui_str': 'Skilled nursing facility'}, {'cui': 'C1272747', 'cui_str': 'Expected to improve'}, {'cui': 'C0199171', 'cui_str': 'Medical procedure'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517682', 'cui_str': '287'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0011065', 'cui_str': 'Death'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1828111', 'cui_str': 'Heart failure education'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",,0.230963,"Adherence in the previous week was not associated with reduced rates of emergency department visits (incidence rate ratio, 0.95; 95% CI, 0.90-1.02). ","[{'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Haynes', 'Affiliation': 'Center for Health and Technology, Department of Pediatrics, University of California, Davis, Sacramento.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Tancredi', 'Affiliation': 'Center for Healthcare Policy and Research, Department of Pediatrics, University of California, Davis, Sacramento.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Tong', 'Affiliation': 'Adventist Heart and Vascular Institute, St Helena, California.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Hoch', 'Affiliation': 'Center for Healthcare Policy and Research, Department of Public Health Sciences, University of California, Davis, Sacramento.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Ong', 'Affiliation': 'Division of General Internal Medicine and Health Services Research, University of California, Los Angeles.'}, {'ForeName': 'Theodore G', 'Initials': 'TG', 'LastName': 'Ganiats', 'Affiliation': 'Department of Family Medicine and Public Health, University of California, San Diego School of Medicine, La Jolla.'}, {'ForeName': 'Lorraine S', 'Initials': 'LS', 'LastName': 'Evangelista', 'Affiliation': 'Sue and Bill Gross School of Nursing, University of California, Irvine.'}, {'ForeName': 'Jeanne T', 'Initials': 'JT', 'LastName': 'Black', 'Affiliation': 'Department of Orthopaedics, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Auerbach', 'Affiliation': 'Department of Medicine, University of California, San Francisco School of Medicine, San Francisco.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Romano', 'Affiliation': 'Center for Healthcare Policy and Research, Division of General Medicine, University of California, Davis, Sacramento.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA network open,['10.1001/jamanetworkopen.2020.10174'] 1792,32645213,Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.,"OBJECTIVE This post hoc analysis evaluated long-term efficacy and safety in patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies to receive long-term adjunctive perampanel. METHODS Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.",2020,"Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts.","['patients (aged 12\xa0years and older) with FBTCS or GTCS', 'patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies', 'tonic-clonic seizures', 'Patients aged 12\xa0years and older who completed phase II or III randomized']","['GTCS', 'perampanel', 'FBTCS', 'adjunctive perampanel', 'placebo']","['efficacious and well tolerated', 'Retention rates', 'seizure frequency', 'Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs', 'seizure-freedom rates', 'Efficacy', 'Mean (standard deviation) cumulative duration of perampanel exposure', 'TEAE incidence', 'dizziness and somnolence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}]",720.0,0.190572,"Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts.","[{'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Rektor', 'Affiliation': 'Brno Epilepsy Center and Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.'}, {'ForeName': 'Gregory L', 'Initials': 'GL', 'LastName': 'Krauss', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.'}, {'ForeName': 'Yushi', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.'}, {'ForeName': 'Sunao', 'Initials': 'S', 'LastName': 'Kaneko', 'Affiliation': 'North Tohoku Epilepsy Center, Minato Hospital, Hachinohe, Japan.'}, {'ForeName': 'Betsy', 'Initials': 'B', 'LastName': 'Williams', 'Affiliation': 'Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd., Hatfield, UK.'}, {'ForeName': 'Manoj', 'Initials': 'M', 'LastName': 'Malhotra', 'Affiliation': 'Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Laurenza', 'Affiliation': 'Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Wechsler', 'Affiliation': 'Idaho Comprehensive Epilepsy Center, Boise, Idaho, USA.'}]",Epilepsia,['10.1111/epi.16573'] 1793,32645683,Eye tracking of smoking-related stimuli in tobacco use disorder: A proof-of-concept study combining attention bias modification with alpha-transcranial alternating current stimulation.,"BACKGROUND Tobacco use disorder (TUD) is characterized by the presence of an attentional bias (AB) towards smoking-related stimuli. We investigated whether combining an AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS) applied over the dorsolateral prefrontal cortex (DLPFC) reduces the AB towards smoking-related stimuli, as well as craving level and impulsive choices. METHODS In a sham-controlled, crossover preliminary study, 19 subjects with TUD received two stimulation arms: 1) active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM, in a randomized order, separated by one week. AB towards smoking cues during passive observation of smoking and neutral cues was assessed with an eye-tracking device and reactions times at a visual-probe task. Craving level was measured with the Questionnaire of Smoking Urges. Impulsive choices were assessed with the delay discounting task. RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM. No significant effects were reported on other craving dimensions and on AB based on reaction times. CONCLUSIONS These preliminary findings suggest that combining tACS with ABM may help smokers who wish to quit by reducing the desire to smoke, attention to smoking-cues, and impulsive decision-making.",2020,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","['19 subjects with TUD received two stimulation arms: 1', 'tobacco use disorder']","['tACS with ABM', 'alpha-transcranial alternating current stimulation', 'active tACS (10 Hz, 2 mA, 30 min) combined with ABM and 2) sham tACS combined with ABM', 'AB modification paradigm (ABM) with transcranial alternating current stimulation (tACS']","['Impulsive choices', 'increase of self-reported desire to smoke', 'delay discounting task', 'proportion of impulsive choices', 'craving dimensions and on AB based on reaction times', 'Craving level', 'time spent looking at smoking-related pictures']","[{'cui': 'C0040336', 'cui_str': 'Tobacco abuse'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}]","[{'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C3850035', 'cui_str': 'Intertemporal Preferences'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}]",19.0,0.0484381,"RESULTS Active tACS combined with ABM reduced the amount of time spent looking at smoking-related pictures (p = 0.03), prevented the increase of self-reported desire to smoke (p = 0.026), and reduced the proportion of impulsive choices (p = 0.049), compared to sham tACS combined with ABM.","[{'ForeName': 'Marine', 'Initials': 'M', 'LastName': 'Mondino', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lenglos', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Cinti', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Renauld', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada.""}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': 'Fecteau', 'Affiliation': ""Department of Psychiatry and Neurosciences, Medical School, Université Laval, CERVO Brain Research Center, Centre intégré universitaire en santé et services sociaux de la Capitale-Nationale, 2325 rue de l'Université, Quebec City, QC, G1V 0A6, Canada. Electronic address: shirley.fecteau@fmed.ulaval.ca.""}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108152'] 1794,32646275,A Pilot Evaluation of an Intervention to Improve Social Reactions to Sexual and Partner Violence Disclosures.,"The purpose of this study was to evaluate an intervention ( Supporting Survivors and Self [SSS]) created to increase positive social reactions and decrease negative social reactions to sexual assault and partner violence disclosures among informal support disclosure recipients. Participants were 1,268 college students from a medium-sized New England university who completed an online baseline survey and were assigned to either the treatment or control condition. The SSS intervention trained potential informal supports on what to say and not to say to disclosure recipients. Six months after the SSS intervention, participants in both conditions completed the follow-up survey online. Although intentions to provide positive social reactions significantly increased among participants in the treatment group compared with the control group and there were marginally significant effects in the anticipated directions for alcohol-specific intended social reactions, no overall difference was observed across conditions in actual social reactions provided. Moderation analyses suggested that, in general, the SSS intervention was more effective on various outcomes for students who were younger, male, non-White, sexual minorities, and/or non-victims. Moderation analyses also suggested that the intervention varied in efficacy depending on the circumstances of the disclosure. Despite the mixed outcomes of the SSS intervention, these data suggest that the SSS intervention was effective in improving social reactions for some students and under some circumstances. Future research is needed to further refine the SSS intervention to bolster its effectiveness in reducing negative social reactions and increasing positive social reactions for all students.",2020,"Although intentions to provide positive social reactions significantly increased among participants in the treatment group compared with the control group and there were marginally significant effects in the anticipated directions for alcohol-specific intended social reactions, no overall difference was observed across conditions in actual social reactions provided.","['informal support disclosure recipients', 'students who were younger, male, non-White, sexual minorities, and/or non-victims', 'Participants were 1,268 college students from a medium-sized New England university who completed an online baseline survey']","['SSS intervention', 'intervention ( Supporting Survivors and Self [SSS']","['social reactions', 'positive social reactions', 'Social Reactions to Sexual and Partner Violence Disclosures']","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4277573', 'cui_str': 'Lesbigay Persons'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0027965', 'cui_str': 'Northeastern United States'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}]","[{'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0012625', 'cui_str': 'Information Disclosure'}]",1268.0,0.0189298,"Although intentions to provide positive social reactions significantly increased among participants in the treatment group compared with the control group and there were marginally significant effects in the anticipated directions for alcohol-specific intended social reactions, no overall difference was observed across conditions in actual social reactions provided.","[{'ForeName': 'Katie M', 'Initials': 'KM', 'LastName': 'Edwards', 'Affiliation': 'University of Nebraska-Lincoln, USA.'}, {'ForeName': 'Emily A', 'Initials': 'EA', 'LastName': 'Waterman', 'Affiliation': 'University of Nebraska-Lincoln, USA.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Ullman', 'Affiliation': 'University of Illinois at Chicago, USA.'}, {'ForeName': 'Lindsey M', 'Initials': 'LM', 'LastName': 'Rodriguez', 'Affiliation': 'University of South Florida, Tampa, USA.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Dardis', 'Affiliation': 'Towson University, MD, USA.'}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Dworkin', 'Affiliation': 'University of Washington, Seattle, USA.'}]",Journal of interpersonal violence,['10.1177/0886260520934437'] 1795,32646282,"Effects of judo training upon body composition, autonomic function, and cardiorespiratory fitness in overweight or obese children aged 8- to 13 years.","Physical training is recommended for obese paediatric populations. We investigated the effects of recreational judo training (JT) upon body composition and distribution, cardiorespiratory fitness, and heart rate variability (HRV) in overweight or obese children. A controlled trial (RBR-9d94td) was conducted with 35 children (8-13 years) assigned into groups according to their body mass index (BMI): eutrophic (EU; n = 15; z-BMI ≤ +l and ≥ -2) and overweight or obese (OB; n = 20; z-BMI > +1 and ≤ +3). The 12-week JT included 60-min sessions performed 2 times/week at 65-75% maximal heart rate (HR). BMI, waist circumference, blood pressure, HRV, peak oxygen uptake (VO 2peak ), gas exchange threshold (GET), and body fractioning were assessed. Significant reductions in OB (P < 0.05) occurred for whole body and trunk fat (~3%), trunk/limb fat-ratio (~4%), resting HR (~3%), and sympathovagal balance (log LF:HF, ~85%). Increases (P < 0.05) occurred in lean mass (~8%), parasympathetic modulation (log HF, ~4%), VO 2peak (~5-10%), and VO 2 (~15%), speed (~10%) and slope (~13%) at GET. Markers of cardiorespiratory fitness (relative VO 2 , slope and speed at GET) in OB approached EU after JT. In conclusion, a relatively short JT intervention to improved body composition, autonomic modulation, and physical fitness in obese children.",2020,"Significant reductions in OB (P < 0.05) occurred for whole body and trunk fat (~3%), trunk/limb fat-ratio (~4%), resting HR (~3%), and sympathovagal balance (log LF:HF, ~85%).","['obese children', '35 children (8-13\xa0years) assigned into groups according to their', '2) and overweight or obese (OB; n =\xa020; z-BMI > +1 and ≤ +3', 'overweight or obese children aged 8- to 13 years', 'obese paediatric populations', 'overweight or obese children']","['recreational judo training (JT', 'Physical training', 'judo training', 'JT intervention', 'body mass index (BMI): eutrophic (EU; n =\xa015; z-BMI ≤ +l and ≥']","['body composition and distribution, cardiorespiratory fitness, and heart rate variability (HRV', 'BMI, waist circumference, blood pressure, HRV, peak oxygen uptake (VO 2peak ), gas exchange threshold (GET), and body fractioning', 'lean mass', 'body composition, autonomic function, and cardiorespiratory fitness', 'cardiorespiratory fitness (relative VO 2 , slope and speed at GET', 'sympathovagal balance', 'OB', 'parasympathetic modulation', 'body composition, autonomic modulation, and physical fitness']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0079650', 'cui_str': 'Judo'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0004388', 'cui_str': 'Autonomic nervous system structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}]",35.0,0.0188821,"Significant reductions in OB (P < 0.05) occurred for whole body and trunk fat (~3%), trunk/limb fat-ratio (~4%), resting HR (~3%), and sympathovagal balance (log LF:HF, ~85%).","[{'ForeName': 'Iedda', 'Initials': 'I', 'LastName': 'Brasil', 'Affiliation': 'Laboratory of Physical Activity and Health Promotion, University of Rio de Janeiro State , Rio de Janeiro, Brazil.'}, {'ForeName': 'Walace', 'Initials': 'W', 'LastName': 'Monteiro', 'Affiliation': 'Laboratory of Physical Activity and Health Promotion, University of Rio de Janeiro State , Rio de Janeiro, Brazil.'}, {'ForeName': 'Tainah', 'Initials': 'T', 'LastName': 'Lima', 'Affiliation': 'Laboratory of Physical Activity and Health Promotion, University of Rio de Janeiro State , Rio de Janeiro, Brazil.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Seabra', 'Affiliation': 'Research Centre in Physical Activity, Health and Leisure, Faculty of Sport, University of Porto , Porto, Portugal.'}, {'ForeName': 'Paulo', 'Initials': 'P', 'LastName': 'Farinatti', 'Affiliation': 'Laboratory of Physical Activity and Health Promotion, University of Rio de Janeiro State , Rio de Janeiro, Brazil.'}]",Journal of sports sciences,['10.1080/02640414.2020.1792189'] 1796,32646850,Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.,"The PRECISION trial was a multicentre randomised study that demonstrated that multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy is superior to standard transrectal ultrasound-guided biopsy for the detection of prostate cancer. The outcomes of studies reporting mpMRI-targeted biopsies are dependent on the quality of the mpMRI but there are currently no scoring systems available for evaluating this. We introduced a novel scoring system, the Prostate Imaging Quality (PI-QUAL) score, to assess the quality of scans in the PRECISION trial. PI-QUAL is a score on a Likert scale from 1 to 5, where 1 means that no mpMRI sequences are of diagnostic quality and 5 implies that each sequence is independently of optimal diagnostic quality. Fifty-eight out of 252 (23%) mpMRI scans chosen at random from each of the 22 centres in this trial were evaluated by two experienced radiologists from the coordinating trial centre, in consensus, blinded to pathology results. Overall, the mpMRI quality in the centres participating in PRECISION was good. MpMRI quality was of sufficient diagnostic quality (PI-QUAL ≥3) for 55 scans (95%) and of good or optimal diagnostic quality (PI-QUAL ≥4) for 35 scans (60%). Fifty-five out of 58 (95%) scans were of diagnostic quality for T2WI, followed by DWI (46/58 scans; 79%), and DCE (38/58 scans; 66%). Further validation of this scoring system is warranted. PATIENT SUMMARY: In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection. We used scans from 22 centres that participated in the PRECISION trial. Although there was room for improvement in images that used intravenous contrast, we found that mpMRI in the PRECISION trial was of sufficient diagnostic quality (PI-QUAL score ≥3) for 95% of the scans.",2020,In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection.,"['prostate cancer detection', 'Fifty-eight out of 252 (23']","['multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy', 'standard transrectal ultrasound-guided biopsy', 'Prostate Imaging Quality (PI-QUAL', 'multiparametric magnetic resonance imaging (mpMRI']","['diagnostic quality', 'MpMRI quality', 'mpMRI quality', 'Prostate Imaging Quality (PI-QUAL) score']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C3898221', 'cui_str': 'Multiparametric magnetic resonance elastography'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C3898221', 'cui_str': 'Multiparametric magnetic resonance elastography'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",252.0,0.0461845,In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection.,"[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Giganti', 'Affiliation': 'Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK; Division of Surgery & Interventional Science, University College London, London, UK. Electronic address: f.giganti@ucl.ac.uk.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Allen', 'Affiliation': 'Department of Radiology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Emberton', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Moore', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Veeru', 'Initials': 'V', 'LastName': 'Kasivisvanathan', 'Affiliation': 'Division of Surgery & Interventional Science, University College London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European urology oncology,['10.1016/j.euo.2020.06.007'] 1797,32619274,The impact of two root canal treatment protocols on the oral health-related quality of life: a randomized controlled pragmatic clinical trial.,"AIM To assess the impact of two root canal treatment protocols on the oral health-related quality of life (OHRQoL) of patients in need of root canal treatment on their anterior teeth. METHODOLOGY The sample consisted of 120 participants (mean age: 34 years) enrolled in a pragmatic randomized clinical trial evaluating two root canal treatment protocols. Anterior teeth with nonvital pulps were allocated for root canal preparation with either hand files and filled with lateral compaction of gutta-percha (manual protocol) or canal preparation with a single file in a reciprocating movement and filled with a single cone technique (Reciproc protocol). OHRQoL data were assessed using the Oral Health Impact Profile instrument (OHIP-14), which was administered before the root canal intervention (baseline), and 6 and 12 months after treatment. Demographic and clinical characteristics of participants were collected at baseline. Data were analysed using bivariate analyses, Poisson univariate and multiple regression (α = 0.05). RESULTS The drop-out rate from baseline was 27% and 28% at 6 and 12 months after treatment, respectively. Both root canal protocols significantly enhanced patients' OHRQoL, regardless of the follow-up time (P < 0.001). After 6 months, patients treated with the Reciproc protocol had significantly lower OHIP-14 overall scores (P = 0.030), as well as significantly lower scores for psychological discomfort (P = 0.031) and social disability (P = 0.013). After 12 months, no significant difference was observed between the two root canal protocols for OHIP-14 overall scores (P = 0.174). Either large or moderate effect sizes were observed for all domains and overall scores at both evaluation times, irrespective of the protocol. Low-income persons (RR = 2.03) and the Reciproc protocol (RR = 1.52) had a higher likelihood of a positive impact on OHRQoL 12 months after root canal treatment. CONCLUSIONS The two root canal protocols improved the OHRQoL and differences in scores were observed only after 6 months with poorer OHRQoL for the manual protocol. After 12 months, patients with low-income status and treated with Reciproc were associated with a greater improvement in OHRQoL scores.",2020,"Either large or moderate effect sizes were observed for all domains and overall scores at both evaluation times, irrespective of the protocol.","['120 participants (mean age: 34 years old', 'patients in need of root canal treatment on their anterior teeth', 'Anterior teeth with nonvital pulps']",['root canal preparation with either hand files and filled with lateral compaction of gutta-percha (manual protocol) or canal preparation with a single file in a reciprocating movement and filled with a single cone technique (Reciproc protocol'],"['social disability', 'OHRQoL data', 'OHIP-14 overall scores', 'OHRQoL and differences in scores', 'psychological discomfort', 'oral health-related quality of life', 'oral health-related quality of life (OHRQoL', 'OHRQoL scores']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0011399', 'cui_str': 'Structure of pulp of tooth'}]","[{'cui': 'C0282543', 'cui_str': 'Root canal preparation'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0016094', 'cui_str': 'Filing'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0018407', 'cui_str': 'Gutta percha'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0206428', 'cui_str': 'Cone of retina'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}]",120.0,0.0932869,"Either large or moderate effect sizes were observed for all domains and overall scores at both evaluation times, irrespective of the protocol.","[{'ForeName': 'F E', 'Initials': 'FE', 'LastName': 'Diniz-de-Figueiredo', 'Affiliation': 'Graduate Program in Health Sciences, Federal University of Sergipe, Aracaju, SE, Brazil.'}, {'ForeName': 'L F', 'Initials': 'LF', 'LastName': 'Lima', 'Affiliation': 'Private clinic, Aracaju, SE, Brazil.'}, {'ForeName': 'L S', 'Initials': 'LS', 'LastName': 'Oliveira', 'Affiliation': 'Graduate Program in Health Sciences, Federal University of Sergipe, Aracaju, SE, Brazil.'}, {'ForeName': 'I M', 'Initials': 'IM', 'LastName': 'Bernardino', 'Affiliation': 'Department of Dentistry, State University of Paraíba, Campina Grande, PB, Brazil.'}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Paiva', 'Affiliation': 'Department of Pediatric Dentistry, School of Dentistry, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Faria-E-Silva', 'Affiliation': 'Department of Dentistry, Federal University of Sergipe, Aracaju, SE, Brazil.'}]",International endodontic journal,['10.1111/iej.13356'] 1798,32621557,Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.,"AIMS Whether glycaemic control is associated with cardiovascular outcomes in patients with type 2 diabetes (T2D) is unclear. Consequently, we assessed the relationship between glycated haemoglobin (HbA 1c ) and cardiovascular outcomes in a placebo-controlled randomized trial which demonstrated no cardiovascular effect of sitagliptin in patients with T2D and atherosclerotic vascular disease. METHODS AND RESULTS Secondary analysis of 14 656 TECOS participants with time to event analyses using multivariable Cox proportional hazard models. During a median 3.0 (interquartile range 2.3-3.8) year follow-up, 456 (3.1% of 14 656) patients had first hospitalization for heart failure (HF), 1084 (11.5%) died, 1406 (9.6%) died or were hospitalized for HF, and 1689 (11.5%) had a non-HF cardiovascular event (cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, or hospitalization for unstable angina). Associations between baseline or time-varying HbA 1c and cardiovascular outcomes were U-shaped, with the lowest risk when HbA 1c was around 7%. Each one-unit increase in the time-varying HbA 1c above 7% was associated with an adjusted hazard ratio (HR) of 1.21 [95% confidence interval (CI) 1.11-1.33] for first HF hospitalization, 1.11 (1.03-1.21) for all-cause death, 1.18 (1.09-1.26) for death or HF hospitalization, and 1.10 (1.02-1.17) for non-HF cardiovascular events. Each one-unit decrease in the time-varying HbA 1c below 7% was associated with an adjusted HR of 1.35 (95% CI 1.12-1.64) for first HF hospitalization, 1.37 (1.16-1.61) for death, 1.42 (1.23-1.64) for death or HF hospitalization, and 1.22 (1.06-1.41) for non-HF cardiovascular events. CONCLUSION Glycated haemogobin exhibits a U-shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00790205.",2020,"HbA 1c exhibits a U-shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.","['patients with T2D and atherosclerotic vascular disease', 'patients with type 2 diabetes (T2D', 'Patients With Type 2 Diabetes and Cardiovascular Disease', 'Secondary analysis of 14,656 TECOS participants with time to event analyses using multivariable Cox proportional hazard models', 'patients with T2D and atherosclerotic vascular disease, with nadir around 7']",['sitagliptin'],"['time-varying HbA 1c and cardiovascular outcomes', 'first hospitalization for heart failure (HF', 'glycated hemoglobin (HbA 1c ) and cardiovascular outcomes', 'Cardiovascular Outcomes', 'death or HF hospitalization', 'non-HF cardiovascular event (cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, or hospitalization for unstable angina', 'time-varying HbA 1c']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332311', 'cui_str': 'With time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0010235', 'cui_str': 'Cox Proportional Hazards Models'}]","[{'cui': 'C1565750', 'cui_str': 'sitagliptin'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}]",14656.0,0.0828028,"HbA 1c exhibits a U-shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.","[{'ForeName': 'Finlay A', 'Initials': 'FA', 'LastName': 'McAlister', 'Affiliation': 'Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Yinggan', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Westerhout', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Eberhard', 'Initials': 'E', 'LastName': 'Standl', 'Affiliation': 'Diabetes Research Group, Munich Helmholtz Center, Munich, Germany.'}, {'ForeName': 'Darren K', 'Initials': 'DK', 'LastName': 'McGuire', 'Affiliation': 'Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Frans', 'Initials': 'F', 'LastName': 'Van de Werf', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Green', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Paul W', 'Initials': 'PW', 'LastName': 'Armstrong', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada.'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of heart failure,['10.1002/ejhf.1958'] 1799,32622294,The effects of yoga on functionality appreciation and additional facets of positive body image.,"This study investigated the effects of yoga on functionality appreciation, and the potential mechanisms that could explain the impact of yoga on additional facets of positive body image. Young adult women (N = 114; M age  = 22.19) were randomised to a 10-week Hatha yoga programme or waitlist control group. Participants completed measures of functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up. Follow-up data could not be analysed due to high levels of attrition. The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time. Further, all participants experienced improvements in body appreciation, body compassion, and appearance evaluation over time, regardless of their assigned group. Lower self-objectification contributed to improvements in body appreciation and body compassion. In addition, greater embodiment contributed to improvements in body appreciation, body compassion, and appearance evaluation. Contrary to our expectations, yoga did not lead to increased functionality appreciation, nor was functionality appreciation a mediator of the impact of yoga on positive body image. Instead, lower self-objectification, and greater embodiment, drove improvements in positive body image.",2020,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.",['Young adult women (N\u202f=\u202f114; M age \u202f=\u202f22.19'],['Hatha yoga programme or waitlist control group'],"['body appreciation and body compassion', 'functionality appreciation, body appreciation, body compassion, appearance evaluation, self-objectification, and embodiment at Pretest, Midtest, Posttest, and 1-month Follow-Up', 'body appreciation, body compassion, and appearance evaluation']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",,0.0268438,"The remaining data showed that, compared to the control group, women in the yoga programme experienced lower self-objectification at Midtest and greater embodiment over time.","[{'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Alleva', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands. Electronic address: Jessica.Alleva@maastrichtuniversity.nl.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Tylka', 'Affiliation': 'Department of Psychology, The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'van Oorsouw', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Montanaro', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Perey', 'Affiliation': 'Chair of Sport and Health Management, Technical University of Munich, Germany.'}, {'ForeName': 'Cheyenne', 'Initials': 'C', 'LastName': 'Bolle', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jantine', 'Initials': 'J', 'LastName': 'Boselie', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Madelon', 'Initials': 'M', 'LastName': 'Peters', 'Affiliation': 'Department of Clinical Psychological Science, Maastricht University, Maastricht, the Netherlands.'}, {'ForeName': 'Jennifer B', 'Initials': 'JB', 'LastName': 'Webb', 'Affiliation': 'Department of Psychology, The University of North Carolina at Charlotte, Charlotte, NC, United States.'}]",Body image,['10.1016/j.bodyim.2020.06.003'] 1800,32622394,"Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial.","BACKGROUND Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed to describe the duration of hospitalisation and safety of ambulatory management compared with standard care. METHODS In this open-label, randomised controlled trial, adults (aged 16-55 years) with symptomatic primary spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years. Patients were randomly assigned (1:1) to treatment with either an ambulatory device or standard guideline-based management (aspiration, standard chest tube insertion, or both). The primary outcome was total length of hospital stay including re-admission up to 30 days after randomisation. Patients with available data were included in the primary analysis and all assigned patients were included in the safety analysis. The trial was prospectively registered with the International Standard Randomised Clinical Trials Number, ISRCTN79151659. FINDINGS Of 776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to ambulatory care (n=117) and standard care (n=119). At day 30, the median hospitalisation was significantly shorter in the 114 patients with available data who received ambulatory treatment (0 days [IQR 0-3]) than in the 113 with available data who received standard care (4 days [IQR 0-8]; p<0·0001; median difference 2 days [95% CI 1-3]). 110 (47%) of 236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in the standard care arm. All 14 serious adverse events occurred in patients who received ambulatory care, eight (57%) of which were related to the intervention, including an enlarging pneumothorax, asymptomatic pulmonary oedema, and the device malfunctioning, leaking, or dislodging. INTERPRETATION Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events. This data suggests that primary spontaneous pneumothorax can be managed for outpatients, using ambulatory devices in those who require intervention. FUNDING UK National Institute for Health Research.",2020,"INTERPRETATION Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events.","['Patients with available data were included in the primary analysis and all assigned patients were included in the safety analysis', '110 (47%) of 236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in the standard care arm', '776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to ambulatory care (n=117) and standard care (n=119', 'primary spontaneous pneumothorax', 'adults (aged 16-55 years) with symptomatic primary spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years', 'otherwise healthy young patients']","['ambulatory device or standard guideline-based management (aspiration, standard chest tube insertion, or both', 'ambulatory management compared with standard care']","['duration of hospitalisation including re-admissions', 'total length of hospital stay including re-admission', 'adverse events', 'median hospitalisation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C1868193', 'cui_str': 'Primary spontaneous pneumothorax'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0189476', 'cui_str': 'Insertion of pleural tube drain'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.148264,"INTERPRETATION Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events.","[{'ForeName': 'Rob J', 'Initials': 'RJ', 'LastName': 'Hallifax', 'Affiliation': 'Oxford Centre for Respiratory Medicine, University of Oxford, Oxford, UK. Electronic address: robert.hallifax@ndm.ox.ac.uk.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'McKeown', 'Affiliation': 'Royal Berkshire National Health Service (NHS) Foundation Trust, Reading, UK.'}, {'ForeName': 'Parthipan', 'Initials': 'P', 'LastName': 'Sivakumar', 'Affiliation': ""Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Fairbairn', 'Affiliation': 'Queen Margaret Hospital, NHS Fife, Dunfermline, UK.'}, {'ForeName': 'Christy', 'Initials': 'C', 'LastName': 'Peter', 'Affiliation': 'Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Leitch', 'Affiliation': 'Western General Hospital, NHS Lothian, Edinburgh, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Knight', 'Affiliation': 'West Hertfordshire Hospitals NHS Trust, Watford, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Stanton', 'Affiliation': 'Great Western Hospital NHS Foundation Trust, Swindon, UK.'}, {'ForeName': 'Asim', 'Initials': 'A', 'LastName': 'Ijaz', 'Affiliation': 'University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, UK.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Marciniak', 'Affiliation': 'Department of Medicine, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Cameron', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Amrithraj', 'Initials': 'A', 'LastName': 'Bhatta', 'Affiliation': 'Blackpool Fylde and Wyre Hospitals NHS Foundation Trust, Blackpool, UK.'}, {'ForeName': 'Kevin G', 'Initials': 'KG', 'LastName': 'Blyth', 'Affiliation': 'Queen Elizabeth University Hospital, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Raja', 'Initials': 'R', 'LastName': 'Reddy', 'Affiliation': 'Kettering General Hospital, Kettering, UK.'}, {'ForeName': 'Marie-Clare', 'Initials': 'MC', 'LastName': 'Harris', 'Affiliation': 'Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.'}, {'ForeName': 'Nadeem', 'Initials': 'N', 'LastName': 'Maddekar', 'Affiliation': 'University Hospitals of North Midlands, Stoke-on-Trent, UK.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Walker', 'Affiliation': 'Academic Respiratory Unit, University of Bristol, Bristol, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'West', 'Affiliation': ""Guy's and St Thomas' NHS Foundation Trust, London, UK.""}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Laskawiec-Szkonter', 'Affiliation': 'Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Corcoran', 'Affiliation': 'University Hospitals Plymouth NHS Trust, Plymouth, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Gerry', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Corran', 'Initials': 'C', 'LastName': 'Roberts', 'Affiliation': 'Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Harvey', 'Affiliation': 'North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Maskell', 'Affiliation': 'Academic Respiratory Unit, University of Bristol, Bristol, UK.'}, {'ForeName': 'Robert F', 'Initials': 'RF', 'LastName': 'Miller', 'Affiliation': 'Institute for Global Health, University College London, London, UK.'}, {'ForeName': 'Najib M', 'Initials': 'NM', 'LastName': 'Rahman', 'Affiliation': 'Oxford Respiratory Trials Unit, University of Oxford, Oxford, UK.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)31043-6'] 1801,32622397,Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial.,"BACKGROUND Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium laser transurethral vaporesection of the prostate (ThuVARP) is a technique with suggested advantages over TURP, including reduced complications and hospital stay. We aimed to investigate TURP versus ThuVARP in men with lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction. METHODS In this randomised, blinded, parallel-group, pragmatic equivalence trial, men in seven UK hospitals with bothersome lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction were randomly assigned (1:1) at the point of surgery to receive ThuVARP or TURP. Patients were masked until follow-up completion. Centres used their usual TURP procedure (monopolar or bipolar). All trial surgeons underwent training on the ThuVARP technique. Co-primary outcomes were maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS) at 12-months post-surgery. Equivalence was defined as a difference of 2·5 points or less for IPSS and 4 mL per s or less for Qmax. Analysis was done according to the intention-to-treat principle. The trial is registered with the ISRCTN Registry, ISRCTN00788389. FINDINGS Between July 23, 2014, and Dec 30, 2016, 410 men were randomly assigned to ThuVARP or TURP, 205 per study group. TURP was superior for Qmax (mean 23·2 mL per s for TURP and 20·2 mL per s for ThuVARP; adjusted difference in means -3·12, 95% CI -5·79 to -0·45). Equivalence was shown for IPSS (mean 6·3 for TURP and 6·4 for ThuVARP; adjusted difference in means 0·28, -0·92 to 1·49). Mean hospital stay was 48 h in both study groups. 91 (45%) of 204 patients in the TURP group and 96 (47%) of 203 patients in the ThuVARP group had at least one complication. INTERPRETATION TURP and ThuVARP were equivalent for urinary symptom improvement (IPSS) 12-months post-surgery, and TURP was superior for Qmax. Anticipated laser benefits for ThuVARP of reduced hospital stay and complications were not observed. FUNDING UK National Institute for Health Research Health Technology Assessment Programme.",2020,"INTERPRETATION TURP and ThuVARP were equivalent for urinary symptom improvement (IPSS) 12-months post-surgery, and TURP was superior for Qmax.","['men in seven UK hospitals with bothersome lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction', 'Between July 23, 2014, and Dec 30, 2016, 410 men', 'men with lower urinary tract symptoms or urinary retention (UNBLOCS', 'men with lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction']","['TURP', 'ThuVARP technique', 'ThuVARP', 'Thulium laser transurethral vaporesection of the prostate versus transurethral resection', 'ThuVARP or TURP', 'TURP versus ThuVARP', 'Transurethral resection of the prostate (TURP', 'usual TURP procedure (monopolar or bipolar', 'Thulium laser transurethral vaporesection of the prostate (ThuVARP']","['maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS', 'Mean hospital stay', 'hospital stay and complications']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0268889', 'cui_str': 'Prostatic obstruction'}]","[{'cui': 'C0040771', 'cui_str': 'Transurethral prostatectomy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040066', 'cui_str': 'Thulium'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0429783', 'cui_str': 'Urinary flow rate'}, {'cui': 'C1998280', 'cui_str': 'International prostate symptom score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",410.0,0.20003,"INTERPRETATION TURP and ThuVARP were equivalent for urinary symptom improvement (IPSS) 12-months post-surgery, and TURP was superior for Qmax.","[{'ForeName': 'Hashim', 'Initials': 'H', 'LastName': 'Hashim', 'Affiliation': 'Bristol Urological Institute, Southmead Hospital, North Bristol NHS Trust, Bristol, UK. Electronic address: h.hashim@gmail.com.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Worthington', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Abrams', 'Affiliation': 'Bristol Urological Institute, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Young', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': 'Hilary', 'Initials': 'H', 'LastName': 'Taylor', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': 'Sian M', 'Initials': 'SM', 'LastName': 'Noble', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': 'Sara T', 'Initials': 'ST', 'LastName': 'Brookes', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': 'Nikki', 'Initials': 'N', 'LastName': 'Cotterill', 'Affiliation': 'Bristol Urological Institute, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Page', 'Affiliation': 'Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'ForeName': 'K Satchi', 'Initials': 'KS', 'LastName': 'Swami', 'Affiliation': 'Urology Department, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.'}, {'ForeName': 'J Athene', 'Initials': 'JA', 'LastName': 'Lane', 'Affiliation': 'Bristol Randomised Trials Collaboration, Bristol Trials Centre, University of Bristol, Bristol, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30537-7'] 1802,32629226,Occurrence of c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in DHCR7 gene in population of polish women with recurrent miscarriage.,"INTRODUCTION Recurrent miscarriage is a serious clinical problem that affects 1-5 % of all couples trying to conceive. Although the incidence of Smith-Lemli-Opitz Syndrome (SLOS, OMIM #270400), an autosomal recessive condition caused by variants in the DHCR7 gene, is very low, (1:83 000), the observed carrier frequency of DHCR7 gene variants in the Polish population is high, ranging from 1:24 to 1:31. It is possible that this carriage may be responsible for early pregnancy loss. OBJECTIVES The aim of the study is to determine the carrier frequency of the p c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in the DHCR7 gene in patients experiencing recurrent miscarriage. METHODS The study group included 480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage. The variants were identified by genotyping: c.976 G>T (p.Val326Leu) by the TaqMan® SNP Genotyping Assay system, and c.452 G>A (p.Trp151Ter) using the BfaI restriction enzyme. Statistical analysis was performed using R software. RESULTS No examples of c.976 G>T (p.Val326Leu) were found in either group. c.452 G>A (p.Trp151Ter) was found in 22 participants from the study group and 4 from the control group; however, this difference was not significant (Chi2 test p = 0.61). CONCLUSIONS Being a carrier of the c.976 G>T (p.Val326Leu) and c.452 G>A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.",2020,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"['population of polish women with recurrent miscarriage', 'patients experiencing recurrent miscarriage', '480 patients: a study group of 380 with at least 2 miscarriages before the 20th week of pregnancy, and a control group of 100 who had not experienced miscarriage']","['Val326Leu) and c.452 G', 'G']",[],"[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0032376', 'cui_str': 'Polish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0000809', 'cui_str': 'Recurrent miscarriage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319693', 'cui_str': '380'}, {'cui': 'C0000786', 'cui_str': 'Miscarriage'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1704407', 'cui_str': '100'}]",[],[],,0.0226355,A (p.Trp151Ter) variants in theDHCR7 gene is not a risk factor for recurrent miscarriage in the Polish population.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Chrzanowska-Steglińska', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland. Electronic address: marta.chrzanowska85@interia.pl.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Moczulska', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland; Clinical Genetics Clinic, Central Clinical Hospital of the Medical University of Lodz, Poland.'}, {'ForeName': 'Beata', 'Initials': 'B', 'LastName': 'Skoczylas', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Pietrusiński', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Antosik', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Jakiel', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Kacprzak', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}, {'ForeName': 'Maciej', 'Initials': 'M', 'LastName': 'Borowiec', 'Affiliation': 'Department of Clinical and Laboratory Genetics, the Medical University of Lodz, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Sieroszewski', 'Affiliation': 'Department of Fetal Medicine and Gynaecology, the Medical University of Lodz, Poland.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.05.063'] 1803,32629291,A randomised double-blind trial of cognitive training for the prevention of psychopathology in at-risk youth.,"BACKGROUND The aim of this study was to evaluate the effectiveness of online cognitive training as a means of reducing psychopathology in at-risk youth. METHODS In a double-blind randomised controlled trial, 228 youths (mean age = 18.6, 74.6% female) were randomly allocated to either an intervention group (n = 114; online cognitive training focused on executive functioning) and a control group (n = 114; online cognitive training focused on other cognitive abilities). Participants were assessed online at baseline, post-training, 3-, 6- and 12-month follow-up. The primary outcome of the study was overall psychopathology as measured by the Strengths and Difficulties Questionnaire. Secondary outcomes were executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking. RESULTS Mixed model intention-to-treat analyses indicated that psychopathology increased and day-to-day functioning decreased, regardless of intervention group. Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons. There were no statistically significant effects on risky drinking, or the trail-making and Stroop tasks. CONCLUSION This study failed to provide evidence for the efficacy of cognitive training as a stand-alone intervention for psychopathology.",2020,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","['psychopathology in at-risk youth', '228 youths (mean age\xa0=\xa018.6, 74.6% female']","['cognitive training', 'intervention group (n\xa0=\xa0114; online cognitive training focused on executive functioning) and a control group (n\xa0=\xa0114; online cognitive training focused on other cognitive abilities', 'online cognitive training']","['psychopathology increased and day-to-day functioning', 'executive functioning ability (assessed using the n-back, trail-making and Stroop tasks), day-to-day functioning and risky drinking', 'risky drinking, or the trail-making and Stroop tasks', 'overall psychopathology as measured by the Strengths and Difficulties Questionnaire']","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}]","[{'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}]",228.0,0.191026,"Those in the intervention group improved more than those in the control group in terms of the n-back task, but this was not statistically significant after adjusting for multiple comparisons.","[{'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Mewton', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia. Electronic address: louisem@unsw.edu.au.'}, {'ForeName': 'Antoinette', 'Initials': 'A', 'LastName': 'Hodge', 'Affiliation': ""Child Development Unit, The Children's Hospital, Westmead, Australia.""}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Gates', 'Affiliation': 'Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Visontay', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Briana', 'Initials': 'B', 'LastName': 'Lees', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}, {'ForeName': 'Maree', 'Initials': 'M', 'LastName': 'Teesson', 'Affiliation': 'The Matilda Centre for Research in Mental Health and Substance Use, University of Sydney, Sydney, Australia.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103672'] 1804,32631074,"Utility of Neuromuscular Electrical Stimulation to Preserve Quadriceps Muscle Fiber Size and Contractility After Anterior Cruciate Ligament Injuries and Reconstruction: A Randomized, Sham-Controlled, Blinded Trial.","BACKGROUND Anterior cruciate ligament (ACL) injuries and reconstruction (ACLR) promote quadriceps muscle atrophy and weakness that can persist for years, suggesting the need for more effective rehabilitation programs. Whether neuromuscular electrical stimulation (NMES) can be used to prevent maladaptations in skeletal muscle size and function is unclear. PURPOSE To examine whether early NMES use, started soon after an injury and maintained through 3 weeks after surgery, can preserve quadriceps muscle size and contractile function at the cellular (ie, fiber) level in the injured versus noninjured leg of patients undergoing ACLR. STUDY DESIGN Randomized controlled trial; Level of evidence, 1. METHODS Patients (n = 25; 12 men/13 women) with an acute, first-time ACL rupture were randomized to NMES (5 d/wk) or sham (simulated microcurrent electrical nerve stimulation; 5 d/wk) treatment to the quadriceps muscles of their injured leg. Bilateral biopsies of the vastus lateralis were performed 3 weeks after surgery to measure skeletal muscle fiber size and contractility. Quadriceps muscle size and strength were assessed 6 months after surgery. RESULTS A total of 21 patients (9 men/12 women) completed the trial. ACLR reduced single muscle fiber size and contractility across all fiber types ( P < .01 to P < .001) in the injured compared with noninjured leg 3 weeks after surgery. NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001). NMES preserved contractility in slow-twitch MHC I fibers ( P < .01 to P < .001), increasing maximal contractile velocity ( P < .01) and preserving power output ( P < .01), but not in MHC II fibers. Differences in whole muscle strength between groups were not discerned 6 months after surgery. CONCLUSION Early NMES use reduced skeletal muscle fiber atrophy in MHC II fibers and preserved contractility in MHC I fibers. These results provide seminal, cellular-level data demonstrating the utility of the early use of NMES to beneficially modify skeletal muscle maladaptations to ACLR. CLINICAL RELEVANCE Our results provide the first comprehensive, cellular-level evidence to show that the early use of NMES mitigates early skeletal muscle maladaptations to ACLR. REGISTRATION NCT02945553 (ClinicalTrials.gov identifier).",2020,NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001).,"['Patients (n = 25; 12 men/13 women) with an acute, first-time ACL rupture', '21 patients (9 men/12 women) completed the trial', 'After Anterior Cruciate Ligament Injuries and Reconstruction']","['Anterior cruciate ligament (ACL) injuries and reconstruction (ACLR', 'neuromuscular electrical stimulation (NMES', 'Neuromuscular Electrical Stimulation', 'NMES (5 d/wk) or sham (simulated microcurrent electrical nerve stimulation; 5 d/wk) treatment to the quadriceps muscles of their injured leg']","['maximal contractile velocity', 'preserving power output', 'Quadriceps Muscle Fiber Size and Contractility', 'ACLR reduced single muscle fiber size and contractility', 'Quadriceps muscle size and strength', 'fast-twitch myosin heavy chain (MHC) II fibers', 'contractility in slow-twitch MHC', 'muscle fiber atrophy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0409312', 'cui_str': 'Rupture of anterior cruciate ligament'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1456574', 'cui_str': 'Injury of anterior cruciate ligament'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}]","[{'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0026820', 'cui_str': 'Muscle contraction'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0027100', 'cui_str': 'Myosin Heavy Chain'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0024518', 'cui_str': 'Major histocompatibility complex'}, {'cui': 'C0333751', 'cui_str': 'Muscle fiber atrophy'}]",21.0,0.154142,NMES reduced muscle fiber atrophy ( P < .01) through effects on fast-twitch myosin heavy chain (MHC) II fibers ( P < .01 to P < .001).,"[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Toth', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Timothy W', 'Initials': 'TW', 'LastName': 'Tourville', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Thomas B', 'Initials': 'TB', 'LastName': 'Voigt', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Rebecca H', 'Initials': 'RH', 'LastName': 'Choquette', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Bradley M', 'Initials': 'BM', 'LastName': 'Anair', 'Affiliation': 'Department of Medicine, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Falcone', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Mathew J', 'Initials': 'MJ', 'LastName': 'Failla', 'Affiliation': 'Department of Rehabilitation and Movement Science, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Stevens-Lapslaey', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, University of Colorado, Denver, Colorado, USA.'}, {'ForeName': 'Nathan K', 'Initials': 'NK', 'LastName': 'Endres', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'James R', 'Initials': 'JR', 'LastName': 'Slauterbeck', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Beynnon', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Vermont, Burlington, Vermont, USA.'}]",The American journal of sports medicine,['10.1177/0363546520933622'] 1805,32634745,"Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers.","Adverse childhood experiences (ACE) are associated with greater neuroendocrine responses to social stress in substance users. The neuropeptide oxytocin might attenuate this relationship. Given sex differences in ACE exposure and neuroendocrine stress reactivity, it is unknown whether this association is similar for males and females. Therefore, this secondary analysis evaluated the interactive effect of sex, ACE, and acute oxytocin administration on neuroendocrine stress responses in adult cigarette smokers (N = 144). Participants completed the Adverse Childhood Experiences Questionnaire at screening and were randomized to receive intranasal oxytocin or placebo before undergoing the Trier Social Stress Task (TSST). Cortisol levels were assessed at pre- and post-medication administration and at 20 and 40 min following the TSST. Generalized linear mixed models were developed to predict post-TSST cortisol levels. Predictors included treatment assignment (placebo vs. oxytocin), sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration. The hypothesized three-way interaction between sex, oxytocin, and ACE scores was significant. Linear associations between ACE scores and cortisol reactivity indicated higher ACE scores were associated with attenuated cortisol response in females, regardless of treatment condition. For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin. Results indicate that the association between ACE and neuroendocrine reactivity to social stress, as well as the attenuating effect of oxytocin, is differentially impacted by sex. Males with greater childhood adversity may be more likely to benefit from oxytocin's anxiolytic properties.",2020,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","['adult cigarette smokers (N\u2009=\u2009144', 'smokers', 'Participants completed the Adverse Childhood Experiences Questionnaire at screening']","['oxytocin', 'treatment assignment (placebo vs. oxytocin', 'neuropeptide oxytocin', 'intranasal oxytocin or placebo', 'oxytocin administration']","['sex (male vs. female), ACE (0-10 total score), pre-medication cortisol levels, and minutes since medication administration', 'cortisol response', 'ACE scores', 'Cortisol levels', 'ACE scores and cortisol reactivity indicated higher ACE scores']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4284014', 'cui_str': 'Adverse Childhood Experience questionnaire'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0027895', 'cui_str': 'Neuropeptide'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4296616', 'cui_str': 'Adverse Childhood Experiences'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C3469597', 'cui_str': 'Administration of medication'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0291417,"For males, higher ACE scores were associated with heightened cortisol response, an effect that was attenuated by oxytocin.","[{'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, College of Arts & Sciences, University of Kentucky, United States. Electronic address: caitlyn.hood@uky.edu.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Breanna M', 'Initials': 'BM', 'LastName': 'Tuck', 'Affiliation': 'Steve Hicks School of Social Work, University of Texas at Austin, United States.'}, {'ForeName': 'Julianne C', 'Initials': 'JC', 'LastName': 'Flanagan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Ralph H. Johnson VA Medical Center, United States.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Saladin', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States; Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, United States.'}, {'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, United States.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104752'] 1806,32634760,Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.,"BACKGROUND Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. METHODS Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) ≥ 20%; luminal B-like cohort as having a Ki67 ≥ 20% and/or a PgR < 20%. RESULTS Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). CONCLUSIONS No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule.",2020,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","['2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer', 'Patients with node-positive early breast cancer', 'hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype']","['DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel', 'progesterone receptor (PgR', 'dose-dense adjuvant chemotherapy']","['overall survival (OS', 'disease-free survival (DFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0699493', 'cui_str': 'Luminal'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}]","[{'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0439794', 'cui_str': 'Dense'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0034833', 'cui_str': 'Progesterone receptor'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}]",2003.0,0.206045,"We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively).","[{'ForeName': 'Benedetta', 'Initials': 'B', 'LastName': 'Conte', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Carrer de Rosselló, 149, 08036, Barcelona, Spain.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Bruzzone', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Lambertini', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Poggio', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Bighin', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Blondeaux', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Michelino', 'Initials': 'M', 'LastName': 'De Laurentiis', 'Affiliation': 'Breast Unit, Istituto Nazionale Tumori-Fondazione ""G. Pascale"", Via Mariano Semmola, 53, 80131, Naples, NA, Italy.'}, {'ForeName': 'Enrichetta', 'Initials': 'E', 'LastName': 'Valle', 'Affiliation': 'Department of Medical Oncology, Ospedale Businco, Via Edward Jenner, 1, 09121, Cagliari, CA, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cognetti', 'Affiliation': 'Department of Clinical and Molecolar Medicine, La Sapienza University, Viale Regina Elena, 324, 00161, Rome, RM, Italy.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nisticò', 'Affiliation': 'Department of Medical Oncology 1, Istituto Nazionale Tumori ""Regina Elena"", Via Elio Chianesi, 53, 00128, Rome, RM, Italy.'}, {'ForeName': 'Sabino', 'Initials': 'S', 'LastName': 'De Placido', 'Affiliation': 'Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131, Naples, NA, Italy.'}, {'ForeName': 'Ornella', 'Initials': 'O', 'LastName': 'Garrone', 'Affiliation': 'Breast Unit, Department of Oncology, Azienda Ospedaliera Santa Croce e Carle, Via Michele Coppino, 26, 12100, Cuneo, CN, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Gamucci', 'Affiliation': 'Department of Medical Oncology, Ospedale Sandro Pertini, Via dei Monti Tiburtini, 385/389, 00157, Rome, RM, Italy; Department of Medical Oncology, Ospedale SS Trinità, Località San Marciano, 03039, Sora, FR, Italy.'}, {'ForeName': 'Filippo', 'Initials': 'F', 'LastName': 'Montemurro', 'Affiliation': 'Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale, 142, 10060, Turin, TO, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Puglisi', 'Affiliation': 'Department of Medicine, University of Udine, Piazzale Massimiliano Kolbe, 4, 33100, Udine, Italy; Department of Medical Oncology, IRCCS Centro di Riferimento Oncologico Aviano - National Cancer Institute, Via Franco Gallini, 2, 33081, Aviano, PN, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Cardinali', 'Affiliation': 'Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Fregatti', 'Affiliation': 'Department of Surgical Sciences and Integrated Diagnostic (DISC), University of Genova, Viale Benedetto XV, 6, 1612, Genoa, GE, Italy; Department of Surgery, IRCCS Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy.'}, {'ForeName': 'Loredana', 'Initials': 'L', 'LastName': 'Miglietta', 'Affiliation': 'Medical Oncology Unit 2, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Boccardo', 'Affiliation': 'Medical Oncology Department, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 1632, Genoa, GE, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Marcello', 'Initials': 'M', 'LastName': 'Ceppi', 'Affiliation': 'Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Del Mastro', 'Affiliation': 'Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Viale Benedetto XV, 10, 16132, Genoa, GE, Italy; Breast Unit, IRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, 16132, Genoa, GE, Italy. Electronic address: lucia.delmastro@hsanmartino.it.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.007'] 1807,32640411,"The experience of trial participation, treatment approaches and perceptions of change among participants with dissociative seizures within the CODES randomized controlled trial: A qualitative study.","BACKGROUND Nested within a large, multicenter randomized controlled trial (RCT) for people with dissociative seizures (DS), the study used purposive sampling to explore participants' experience of participating in an RCT, their experience of DS-specific cognitive behavioral therapy (CBT) and another component of the RCT, Standardized Medical Care (SMC) and their perceptions of and reflections on seizure management and change. METHODS A qualitative study using semistructured interviews was conducted with 30 participants in an RCT (the COgnitive behavioral therapy vs standardized medical care for adults with Dissociative non-Epileptic Seizures (CODES) Trial) investigating the effectiveness of two treatments for DS. Key themes and subthemes were identified using thematic framework analysis (TFA). RESULTS Analysis yielded three overarching themes: taking part in a treatment trial - ""the only thing out there"", the experience of treatment techniques that were perceived to help with seizure management, and reflections on an ""unpredictable recovery"". CONCLUSIONS People with DS are amenable to participating in a psychotherapy RCT and described a largely positive experience. They also described the applicability of aspects of DS-specific CBT and SMC in the management of their DS, received within the confines of the CODES trial. Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.",2020,"Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.","['participants with dissociative seizures', 'adults with Dissociative non-Epileptic Seizures (CODES) Trial', '30 participants in an', 'people with dissociative seizures (DS']","['DS-specific cognitive behavioral therapy (CBT) and another component of the RCT, Standardized Medical Care (SMC', 'RCT (the COgnitive behavioral therapy vs standardized medical care']",[],"[{'cui': 'C0349245', 'cui_str': 'Dissociative convulsions'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0349245', 'cui_str': 'Dissociative convulsions'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0496675', 'cui_str': 'Medical care'}]",[],30.0,0.0596229,"Factors that appeared to account for the variability in response to treatment delivery included individual preferences for the nature of sessions, the nature of therapeutic relationships, readiness to discuss trauma, other aspects of emotional avoidance, and whether therapy provided something new.","[{'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Read', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Jordan', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Iain', 'Initials': 'I', 'LastName': 'Perdue', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Purnell', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Murray', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Trudie', 'Initials': 'T', 'LastName': 'Chalder', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK.""}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Reuber', 'Affiliation': 'Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Stone', 'Affiliation': 'Department of Clinical Neuroscience, Centre for Clinical Brain Sciences, University of Edinburgh, UK.'}, {'ForeName': 'Laura H', 'Initials': 'LH', 'LastName': 'Goldstein', 'Affiliation': ""King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK. Electronic address: laura.goldstein@kcl.ac.uk.""}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107230'] 1808,32640945,High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source.,"BACKGROUND AND PURPOSE Optimal secondary prevention for patients with embolic stroke of undetermined source (ESUS) remains unknown. We aimed to assess whether high-sensitivity cardiac troponin T (hs-cTnT) levels are associated with major vascular events and whether hs-cTnT may identify patients who benefit from anticoagulation following ESUS. METHODS Data were obtained from the biomarker substudy of the NAVIGATE ESUS trial, a randomized controlled trial testing the efficacy of rivaroxaban versus aspirin for secondary stroke prevention in ESUS. Patients were dichotomized at the hs-cTnT upper reference limit (14 ng/L, Gen V, Roche Diagnostics). Cox proportional hazard models were computed to explore the association between hs-cTnT, the combined cardiovascular end point (recurrent stroke, myocardial infarction, systemic embolism, cardiovascular death), and recurrent ischemic stroke. RESULTS Among 1337 patients enrolled at 111 participating centers in 18 countries (mean age 67±9 years, 61% male), hs-cTnT was detectable in 95% and at/above the upper reference limit in 21%. During a median follow-up of 11 months, the combined cardiovascular end point occurred in 68 patients (5.0%/y, rivaroxaban 28 events, aspirin 40 events; hazard ratio, 0.67 [95% CI, 0.41-1.1]), and recurrent ischemic stroke occurred in 50 patients (4.0%/y, rivaroxaban 16 events, aspirin 34 events, hazard ratio 0.45 [95% CI, 0.25-0.81]). Annualized combined cardiovascular end point rates were 8.2% (9.5% rivaroxaban, 7.0% aspirin) for those above hs-cTnT upper reference limit and 4.8% (3.1% rivaroxaban, 6.6% aspirin) below with a significant treatment modification ( P =0.04). Annualized ischemic stroke rates were 4.7% above hs-cTnT upper reference limit and 3.9% below, with no suggestion of an interaction between hs-cTnT and treatment ( P =0.3). CONCLUSIONS In patients with ESUS, hs-cTnT was associated with increased cardiovascular event rates. While fewer recurrent strokes occurred in patients receiving rivaroxaban, outcomes were not stratified by hs-cTn results. Our findings support using hs-cTnT for cardiovascular risk stratification but not for decision-making regarding anticoagulation therapy in patients with ESUS. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02313909.",2020,"In patients with ESUS, hs-cTnT was associated with increased cardiovascular event rates.","['secondary stroke prevention in ESUS', '1337 patients enrolled at 111 participating centers in 18 countries (mean age 67±9 years, 61% male), hs-cTnT was detectable in 95% and at/above the upper reference limit in 21', 'patients with ESUS', 'patients with embolic stroke of undetermined source (ESUS', 'patients who benefit from anticoagulation following ESUS', 'Patients With Embolic Stroke of Undetermined Source']","['rivaroxaban', 'High-Sensitivity Cardiac Troponin T', 'rivaroxaban versus aspirin']","['combined cardiovascular end point (recurrent stroke, myocardial infarction, systemic embolism, cardiovascular death), and recurrent ischemic stroke', 'cardiovascular event rates', 'Annualized combined cardiovascular end point rates', 'recurrent strokes', 'recurrent ischemic stroke', 'Annualized ischemic stroke rates']","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1277289', 'cui_str': 'Stroke prevention'}, {'cui': 'C3888970', 'cui_str': 'Embolic stroke of undetermined source'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1836785', 'cui_str': 'Recurrent stroke'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013922', 'cui_str': 'Embolism'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",1337.0,0.250989,"In patients with ESUS, hs-cTnT was associated with increased cardiovascular event rates.","[{'ForeName': 'Jan F', 'Initials': 'JF', 'LastName': 'Scheitz', 'Affiliation': 'Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Germany (J.F.S., C.H.N., M.E.).'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Pare', 'Affiliation': 'Population Health Research Institute, McMaster University, Hamilton, ON, Canada (G.P.).'}, {'ForeName': 'Lesly A', 'Initials': 'LA', 'LastName': 'Pearce', 'Affiliation': 'Biostatistics Consultant, Minot, ND (L.A.P.).'}, {'ForeName': 'Hardi', 'Initials': 'H', 'LastName': 'Mundl', 'Affiliation': 'Bayer AG, Wuppertal, Germany (H.M., T.K.).'}, {'ForeName': 'W Frank', 'Initials': 'WF', 'LastName': 'Peacock', 'Affiliation': 'Baylor College of Medicine, Houston, TX (W.F.P.).'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Czlonkowska', 'Affiliation': '2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland (A.C.).'}, {'ForeName': 'Mukul', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'Department of Medicine (Neurology), Population Health Research Institute, McMaster University, Hamilton Health Sciences, Canada (M.S., A.S.).'}, {'ForeName': 'Christian H', 'Initials': 'CH', 'LastName': 'Nolte', 'Affiliation': 'Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Germany (J.F.S., C.H.N., M.E.).'}, {'ForeName': 'Ashkan', 'Initials': 'A', 'LastName': 'Shoamanesh', 'Affiliation': 'Department of Medicine (Neurology), Population Health Research Institute, McMaster University, Hamilton Health Sciences, Canada (M.S., A.S.).'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Berkowitz', 'Affiliation': 'Research & Development, Pharmaceuticals, Bayer U.S., LLC, Whippany (S.D.B.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Krahn', 'Affiliation': 'Bayer AG, Wuppertal, Germany (H.M., T.K.).'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Endres', 'Affiliation': 'Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Germany (J.F.S., C.H.N., M.E.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Stroke,['10.1161/STROKEAHA.120.029628'] 1809,32651582,Injuries on the Youth Soccer (Football) Field: Do Additional Referees Reduce Risk? Randomized Crossover Trial.,"OBJECTIVE Youth soccer injury can be prevented through various means, but few studies consider the role of referees. Following previous research suggesting children take fewer risks when supervised intensely, this randomized crossover trial evaluated whether risky play and injuries decrease under supervision from three referees instead of one referee. METHODS Youth soccer clubs serving a metropolitan U.S. area participated. Boys' and girls' clubs at under age 10 (U10) and under age 11 (U11) levels were randomly assigned such that when the same clubs played each other twice in the same season, they played once with one referee and once with three referees. A total of 98 games were videotaped and subsequently coded to obtain four outcomes: collisions between players, aggressive fouls (involving physical player-to-player contact) called by the referee(s) on the field, aggressive fouls judged by trained coders, and injuries requiring adult attention or play stoppage. RESULTS Poisson mixed model results suggest players in the 98 games committed fewer aggressive fouls, as identified independently by referees (rate ratio [RR] 0.58; 95% confidence interval [CI] 0.35-0.96) and by researchers (RR 0.67; 95% CI 0.50-0.90), when there were three referees versus one referee. Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. CONCLUSION When the same youth soccer clubs played with three referees rather than one, they committed fewer aggressive fouls. More intense supervision created better rule adherence. Injury rates were unchanged with increased supervision. Results raise questions concerning whether financial investment in additional referees on youth soccer fields yields safety benefits.",2020,"Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. ","['Youth soccer clubs serving a metropolitan U.S. area participated', ""Boys' and girls' clubs at under age 10 (U10) and under age 11 (U11) levels""]","['videotaped and subsequently coded to obtain four outcomes: collisions between players, aggressive fouls (involving physical player-to-player contact) called by the referee(s) on the field, aggressive fouls judged by trained coders, and injuries requiring adult attention or play stoppage']","['injury rates', 'Injury rates', 'aggressive fouls']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0149651', 'cui_str': 'Clubbing'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0007465', 'cui_str': 'Cause of death'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0221191', 'cui_str': 'Judge'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032214', 'cui_str': 'Play'}]","[{'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]",98.0,0.150697,"Collisions (RR 0.98; 95% CI 0.86-1.12) and injury rates (RR 1.15; 95% CI 0.60-2.19) were similar across conditions. ","[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Schwebel', 'Affiliation': 'Department of Psychology, University of Alabama at Birmingham.'}, {'ForeName': 'D Leann', 'Initials': 'DL', 'LastName': 'Long', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham.'}, {'ForeName': 'Leslie A', 'Initials': 'LA', 'LastName': 'McClure', 'Affiliation': 'Department of Epidemiology and Biostatistics, Drexel University.'}]",Journal of pediatric psychology,['10.1093/jpepsy/jsaa050'] 1810,32652462,Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder.,"BACKGROUND Medication adherence is crucial for improving clinical outcomes in the treatment of patients. We evaluate the effect of short message service (SMS) reminder on medication adherence and serum hormones in patients with breast cancer on aromatase inhibitors. METHODS An open-label, multi-centre, prospective randomised controlled trial of SMS versus Standard Care was conducted. Medication adherence was assessed via self-report using the Simplified Medication Adherence Questionnaire at baseline, 6 month, and 1 year. Androstenedione, estradiol, and estrone were measured at baseline and 1 year. The χ 2 test and mixed effects logistic regression was performed to compare medication adherence between groups. Difference in androstenedione and estrone levels were assessed using analysis of covariance, whereas χ 2 test and logistic regression was used for estradiol. Analysis was based on intention-to-treat. RESULTS A total of 244 patients were randomised to receive weekly SMS reminder (n = 123) or Standard Care (n = 121) between May 2015 and December 2018. The odds of adherence was higher at 6-month in SMS (OR = 1.78, 95% CI 1.04-3.05, p = 0.034), and not significantly different at 1-year (OR = 1.15, 95% CI: 0.67-1.96 p = 0.617). Mixed effects logistic regression analysis showed higher odds of adherence in SMS over the 1-year period (OR = 2.35, 95% CI: 1.01-5.49, p = 0.048). There was no difference in serum hormone levels between groups. CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term. Future studies could investigate the use of tailored SMS intervention according to patient preference to improve its sustainability.",2020,"CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term.","['patients with breast cancer on aromatase inhibitors', 'patients', '244 patients', 'women with breast cancer']","['short message service (SMS) reminder', 'SMS', 'adjuvant aromatase inhibitor', 'SMS intervention', 'SMS reminder (n\xa0=\xa0123) or Standard Care']","['Medication adherence', 'Androstenedione, estradiol, and estrone', 'medication adherence and serum hormones', 'odds of adherence', 'serum hormones levels', 'androstenedione and estrone levels', 'serum hormone levels', 'medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0593802', 'cui_str': 'Aromatase inhibitor'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0002860', 'cui_str': 'Androstenedione'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0014942', 'cui_str': 'Estrone'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}, {'cui': 'C0236379', 'cui_str': 'Estrone measurement'}]",244.0,0.22356,"CONCLUSION SMS reminder improved medication adherence in the short-term but had no effect on serum hormones levels in the longer term.","[{'ForeName': 'Eng Hooi', 'Initials': 'EH', 'LastName': 'Tan', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-03F, 117549, Singapore.'}, {'ForeName': 'Andrea Li Ann', 'Initials': 'ALA', 'LastName': 'Wong', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Chuan Chien', 'Initials': 'CC', 'LastName': 'Tan', 'Affiliation': 'Department of General Surgery, Ng Teng Fong General Hospital, 1 Jurong East Street 21, 609606, Singapore.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Wong', 'Affiliation': 'Division of Oncology Pharmacy, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Sing Huang', 'Initials': 'SH', 'LastName': 'Tan', 'Affiliation': 'OncoCare Cancer Centre, 6 Napier Road, #02-17/18/19, Gleneagles Medical Centr, 258499, Singapore.'}, {'ForeName': 'Li En Yvonne', 'Initials': 'LEY', 'LastName': 'Ang', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Siew Eng', 'Initials': 'SE', 'LastName': 'Lim', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Wan Qin', 'Initials': 'WQ', 'LastName': 'Chong', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Jingshan', 'Initials': 'J', 'LastName': 'Ho', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Soo Chin', 'Initials': 'SC', 'LastName': 'Lee', 'Affiliation': 'Department of Haematology-Oncology, National University Cancer Institute, NUHS Tower Block Level 7, 1E Kent Ridge Road, 119228, Singapore.'}, {'ForeName': 'Bee Choo', 'Initials': 'BC', 'LastName': 'Tai', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, 12 Science Drive 2, #10-03F, 117549, Singapore; Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, 1E Kent Ridge Road, 119228, Singapore. Electronic address: ephtbc@nus.edu.sg.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.06.012'] 1811,32652516,Protein and calorie restriction may improve outcomes in living kidney donors and kidney transplant recipients.,"Previously, we and others showed that dietary restriction protects against renal ischemia-reperfusion injury in animals. However, clinical translation of preoperative diets is scarce, and in the setting of kidney transplantation these data are lacking. In this pilot study, we investigated the effects of five days of a preoperative protein and caloric dietary restriction (PCR) diet in living kidney donors on the perioperative effects in donors, recipients and transplanted kidneys. Thirty-five kidney donors were randomized into either the PCR, 30% calorie and 80% protein reduction, or control group without restrictions. Adherence to the diet and kidney function in donors and their kidney recipients were analyzed. Perioperative kidney biopsies were taken in a selected group of transplanted kidneys for gene expression analysis. All donors adhered to the diet. From postoperative day 2 up until month 1, kidney function of donors was significantly better in the PCR-group. PCR-donor kidney recipients showed significantly improved kidney function and lower incidence of slow graft function and acute rejection. PCR inhibited cellular immune response pathways and activated stress-resistance signaling. These observations are the first to show that preoperative dietary restriction induces postoperative recovery benefits in humans and may be beneficial in clinical settings involving ischemia-reperfusion injury.",2020,"From postoperative day 2 up until month 1, kidney function of donors was significantly better in the PCR-group.","['living kidney donors and kidney transplant recipients', 'donors and their kidney recipients', 'Thirty-five kidney donors', 'living kidney donors', 'donors, recipients and transplanted kidneys']","['PCR, 30% calorie and 80% protein reduction, or control group without restrictions', 'Protein and calorie restriction', 'preoperative protein and caloric dietary restriction (PCR) diet']","['kidney function of donors', 'Perioperative kidney biopsies', 'kidney function and lower incidence of slow graft function and acute rejection']","[{'cui': 'C4305252', 'cui_str': 'Live donor of kidney'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0260788', 'cui_str': 'Donor of kidney for transplant'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]","[{'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0194073', 'cui_str': 'Kidney biopsy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}]",,0.0125707,"From postoperative day 2 up until month 1, kidney function of donors was significantly better in the PCR-group.","[{'ForeName': 'Franny', 'Initials': 'F', 'LastName': 'Jongbloed', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Ron W F', 'Initials': 'RWF', 'LastName': 'de Bruin', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Harry Van', 'Initials': 'HV', 'LastName': 'Steeg', 'Affiliation': 'Laboratory of Health Protection Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Piet', 'Initials': 'P', 'LastName': 'Beekhof', 'Affiliation': 'Laboratory of Health Protection Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Wackers', 'Affiliation': 'Laboratory of Health Protection Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Dennis A', 'Initials': 'DA', 'LastName': 'Hesselink', 'Affiliation': 'Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Jan H J', 'Initials': 'JHJ', 'LastName': 'Hoeijmakers', 'Affiliation': 'Department of Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}, {'ForeName': 'Martijn E T', 'Initials': 'MET', 'LastName': 'Dollé', 'Affiliation': 'Laboratory of Health Protection Research, National Institute of Public Health and the Environment, Bilthoven, The Netherlands.'}, {'ForeName': 'Jan N M', 'Initials': 'JNM', 'LastName': 'IJzermans', 'Affiliation': 'Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.'}]",Aging,['10.18632/aging.103619'] 1812,32657704,Predischarge transcutaneous bilirubin screening reduces readmission rate for hyperbilirubinaemia in diverse South African newborns: A randomised controlled trial.,"BACKGROUND In South Africa (SA), healthy term newborns are usually discharged ˂72 hours after delivery. Discharged babies remain at risk for severe hyperbilirubinaemia if it is not identified early. Hyperbilirubinaemia is an important cause of readmission, and also leads to neonatal mortality and morbidity. Use of transcutaneous bilirubin (TcB) screening before hospital discharge has been controversial. OBJECTIVES To test the clinical benefits of TcB screening of healthy newborns before discharge for the outcomes of readmission for jaundice and severe hyperbilirubinaemia in a randomised controlled trial (RCT). METHODS This was a RCT. We compared predischarge TcB screening with visual assessment (alone) for jaundice in apparently healthy newborns at a public tertiary hospital in Cape Town, SA. Patients or study participants were not involved in the study design and implementation. RESULTS Of the 1 858 infants, 63% were black, 35% of mixed race and 1% white. There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. CONCLUSIONS Predischarge TcB screening is superior in identifying newborns at risk of severe hyperbilirubinaemia compared with visual inspection. We recommend that every newborn, regardless of skin pigmentation, should receive objective bilirubin screening before hospital discharge. Universal bilirubin screening in newborns could potentially reduce hyperbilirubinaemia-related morbidity and mortality.",2020,"There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. ","['Of the 1 858 infants, 63% were black, 35% of mixed race and 1% white', 'hyperbilirubinaemia in diverse South African newborns', 'apparently healthy newborns at a public tertiary hospital in Cape Town, SA', 'healthy newborns']","['TcB screening', 'transcutaneous bilirubin (TcB) screening', 'Predischarge transcutaneous bilirubin screening', 'predischarge TcB screening with visual assessment (alone']","['incidence of severe hyperbilirubinaemia', 'rate of readmission for jaundice']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0027567', 'cui_str': 'African race'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0578757', 'cui_str': 'Good neonatal condition at birth'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0054434', 'cui_str': 'caffeic acid phenethyl ester'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0037712', 'cui_str': 'South Africa'}]","[{'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020433', 'cui_str': 'Hyperbilirubinemia'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0022346', 'cui_str': 'Jaundice'}]",63.0,0.285629,"There was a significant reduction in the rate of readmission for jaundice (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.14 - 0.46; p<0.0001) and in the incidence of severe hyperbilirubinaemia (RR 0.27; 95% CI 0.08 - 0.97; p=0.05) with the use of TcB screening compared with visual inspection. ","[{'ForeName': 'C', 'Initials': 'C', 'LastName': 'Okwundu', 'Affiliation': 'Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. charlesokwundu@gmail.com.'}, {'ForeName': 'V K', 'Initials': 'VK', 'LastName': 'Bhutani', 'Affiliation': ''}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Smith', 'Affiliation': ''}, {'ForeName': 'T M', 'Initials': 'TM', 'LastName': 'Esterhuizen', 'Affiliation': ''}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Wiysonge', 'Affiliation': ''}]",South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,['10.7196/SAMJ.2020.v110i3.14186'] 1813,32629091,Early-onset pneumonia following bag-mask ventilation versus endotracheal intubation during cardiopulmonary resuscitation: A substudy of the CAAM trial.,"AIM Early-onset pneumonia (EOP) is a common in-hospital complication in survivors of out-of-hospital cardiac arrest. In this substudy of the CAAM trial, we aimed to compare whether bag mask ventilation (BMV) compared to endotracheal intubation (ETI) performed during cardiopulmonary resuscitation increases the risk of developing EOP. METHODS Adult patients from the CAAM trial that survived beyond 12 h of hospitalization were included. Information about in-hospital management and outcome of study subjects was systematically collected. Our primary aim was to compare the incidence of EOP in the BMV and ETI group using a series of bivariate analysis adjusting for one variable at a time and a logistic regression controlled for survival beyond 96 h, age, gender, catecholamine administration, no flow time, and initial shockable rhythm. RESULTS Of 627 patients from the CAAM trial that survived to hospital admission, 409 patients were hospitalized beyond 12 h and thus included (202 randomized to BMV and 20 7 randomized to ETI). Patients in the BMV group had a significantly longer period of unsecured airway during prehospital cardiopulmonary resuscitation (BMV (median): 33 min; ETI (median): 17 min, p < 0.0001). No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7-1.5], p = 1.0). We found no difference in the development of EOP according to airway management in the series of bivariate analyses or in the multivariable regression analysis either. CONCLUSION In this substudy of the CAAM trial, development of early-onset pneumonia in out-of-hospital cardiac arrest survivors did not depend on airway management technique during CPR.",2020,"No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7 - 1.5], p = 1.0).","['cardiopulmonary resuscitation', 'Adult patients from the CAAM trial that survived beyond 12\u2009hours of hospitalization were included', '627 patients from the CAAM trial that survived to hospital admission', '409 patients were hospitalized beyond 12\u2009hours and thus included (202 randomized to BMV and 20 7 randomized to ETI']","['endotracheal intubation (ETI', 'bag-mask ventilation versus endotracheal intubation', 'bag mask ventilation (BMV']","['development of EOP according to airway management', 'risk of developing EOP', 'incidence of EOP']","[{'cui': 'C0007203', 'cui_str': 'Cardiopulmonary resuscitation'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1292430', 'cui_str': '12 hours'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0179196', 'cui_str': 'Bag'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}]","[{'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",627.0,0.0603892,"No significant difference in the development of EOP according to airway management was identified on univariate analysis (BMV: 53%, ETI: 53%, Odds Ratio 1.0 [0.7 - 1.5], p = 1.0).","[{'ForeName': 'Josefine S', 'Initials': 'JS', 'LastName': 'Baekgaard', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark; Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France. Electronic address: josefine.stokholm.baekgaard.01@regionh.dk.'}, {'ForeName': 'Mohamed N', 'Initials': 'MN', 'LastName': 'Triba', 'Affiliation': ""Sorbonne Paris Cité, Equipe Nanomédecine Biomarqueurs Détection, Laboratoire de Chimie, Structures et Propriétés de Biomateriaux et d'Agents Therapeutiques, UMR CNRS 7244, University Paris 13 Bobigny, France.""}, {'ForeName': 'Morgane', 'Initials': 'M', 'LastName': 'Brandeis', 'Affiliation': 'Service des Urgences, Hopital Ballanger, 93600 Aulnays, France.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Steinmetz', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Cohen', 'Affiliation': 'Intensive Care Unit, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Gorlicki', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Lars S', 'Initials': 'LS', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Anesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Denmark.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Deltour', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Lapostolle', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Adnet', 'Affiliation': 'Urgences et Samu 93, AP-HP, Hôpital Avicenne, Inserm U942, 93000 Bobigny, France.'}]",Resuscitation,['10.1016/j.resuscitation.2020.06.011'] 1814,32629662,Exploratory study on the safety and effectiveness of Yizhi Qingxin Decoction (capsules) in the treatment of hypertension in the elderly with mild cognitive impairment (deficiency of kidney essence syndrome).,"BACKGROUND Hypertension in the elderly with cognitive impairment has been one of the global health issues. Mild cognitive impairment (MCI) is the state of transition between the normal aging process and cognitive changes of unformed dementia. Diagnosis and treatment of MCI are the keys to prevent dementia, and hypertension is one of the important influencing factors of MCI. Our preclinical experiment found that Yizhi Qingxin Decoction (YQD) could effectively reduce the blood pressure of spontaneously hypertensive rats (SHR), improve their spatial learning and memory abilities in Morris water maze, and play a neuroprotective role. The objective is to estimate the safety and efficacy of YQD (capsules) in the treatment of hypertension in the elderly with MCI (deficiency of kidney essence syndrome) through this study. METHODS According to the random number generated by the block random method, 100 participants will be randomly and equally divided into the treatment group (YQD) or the control group (Ginkgo biloba extract tablets). The conversion rate of dementia will be used as the main evaluating indicator by the CDR scale. The MoCA scale, MMSE scale, ADCS-MCI-ADL-24 scale, CGIC-KDS scale, and 24-h ambulatory blood pressure will be used as the secondary evaluating indicator. Safety will be evaluated based on specific manifestations of adverse reactions and the incidence of adverse events. OBJECTIVE The objective is to estimate the curative effect of YQD (capsules) on hypertension in the elderly with MCI (deficiency of kidney essence syndrome), and to evaluate the safety of its clinical application. TRIAL REGISTRATION Chinese Clinical Trial Registry (ICTRP member): ChiCTR2000030292.",2020,"Our preclinical experiment found that Yizhi Qingxin Decoction (YQD) could effectively reduce the blood pressure of spontaneously hypertensive rats (SHR), improve their spatial learning and memory abilities in Morris water maze, and play a neuroprotective role.","['hypertension in the elderly with mild cognitive impairment (deficiency of kidney essence syndrome', 'hypertension in the elderly with MCI (deficiency of kidney essence syndrome', 'elderly with cognitive impairment', 'spontaneously hypertensive rats (SHR', 'elderly with MCI (deficiency of kidney essence syndrome']","['Yizhi Qingxin Decoction (YQD', 'Yizhi Qingxin Decoction (capsules', 'YQD (capsules', 'control group (Ginkgo biloba extract tablets', 'MCI']","['safety and effectiveness', 'Mild cognitive impairment (MCI', 'blood pressure', 'MoCA scale, MMSE scale, ADCS-MCI-ADL-24 scale, CGIC-KDS scale, and 24-h ambulatory blood pressure']","[{'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0011155', 'cui_str': 'Deficiency'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0028910', 'cui_str': 'Volatile oil'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0034705', 'cui_str': 'Spontaneously hypertensive rat'}]","[{'cui': 'C1869287', 'cui_str': 'yi-zhi'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0772125', 'cui_str': 'Ginkgo biloba extract'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1270972', 'cui_str': 'Mild cognitive disorder'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0025750', 'cui_str': ""3,3'-Dichloro-4,4'-Diaminodiphenylmethane""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}]",100.0,0.0229678,"Our preclinical experiment found that Yizhi Qingxin Decoction (YQD) could effectively reduce the blood pressure of spontaneously hypertensive rats (SHR), improve their spatial learning and memory abilities in Morris water maze, and play a neuroprotective role.","[{'ForeName': 'Bi-Qing', 'Initials': 'BQ', 'LastName': 'Wang', 'Affiliation': 'Clinical College, Beijing University of Chinese Medicine.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Mei', 'Affiliation': 'Institute of Geriatrics.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Liu', 'Affiliation': 'Clinical College, Beijing University of Chinese Medicine.'}, {'ForeName': 'Chun-Xiao', 'Initials': 'CX', 'LastName': 'Ju', 'Affiliation': 'Clinical College, Beijing University of Chinese Medicine.'}, {'ForeName': 'Jun-Nan', 'Initials': 'JN', 'LastName': 'Zhao', 'Affiliation': 'Institute of Geriatrics.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'Institute of Geriatrics.'}, {'ForeName': 'Feng-Qin', 'Initials': 'FQ', 'LastName': 'Xu', 'Affiliation': 'Institute of Geriatrics.'}, {'ForeName': 'Ke-Ji', 'Initials': 'KJ', 'LastName': 'Chen', 'Affiliation': 'Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.'}]",Medicine,['10.1097/MD.0000000000020789'] 1815,32629668,"Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial.","INTRODUCTION Glucocorticoids (GCs), especially low-dose GCs, are commonly prescribed for rheumatoid arthritis (RA), although the risk/benefit ratio is controversial. A randomized, double-blind clinical trial was performed to evaluate the efficacy and safety of low-dose oral GCs combined with methotrexate (MTX) and hydroxychloroquine (HCQ) in early RA (ERA). METHODS Eighty untreated ERA patients were randomized into the trial (GCs + MTX + HCQ) and control (placebo + MTX + HCQ) groups, for 1-year treatment. Therapeutic evaluation indices were American College of Rheumatology (ACR) 20 of ACR, disease activity score (DAS) 28- erythrocyte sedimentation rate (ESR), visual analog scale scores, joint function, health assessment questionnaire-disability index score, morning stiffness duration, C-reaction protein and ESR. The clinical indicators were evaluated pre-treatment and at 1st, 3th, 6th and 12th month of treatment. The MRI data of single joint (ie, the most swollen joint) for each patient were acquired with a revised OMERACT RAMRIS Scoring System before and after treatment. The correlation analysis was adopted to confirm whether the efficacy of GC treatment is related to the time of RA onset. The side effects (eg, gastrointestinal reactions, liver dysfunction, upper respiratory tract infection, leukocyte reduction) were also monitored. RESULTS At 1st month, 55% and 20% cases in the experimental and control groups achieved ACR20 response, respectively, indicating a significant difference (χ = 16.157, P < .001). This trend continued until 6th month. At 12th month, the number of patients achieved ACR20 response was similar in both groups. At 1st to 6th month, DAS28- ESR scores in the experimental group were significantly lower than control values (all p < .05). The experimental group showed improved inflammation, quality of life and radiological symptoms. Bone erosion remained unchanged in the experimental group, while worsening in control group. Correlation coefficients between RA duration and DAS28-ESR score were 0.496, 0.464, 0.509, and 0.550 at 1st, 3th, 6th, and 12th month, respectively. No differences were found in adverse events between the 2 groups. CONCLUSIONS Low-dose GCs combined with MTX and HCQ significantly achieves disease remission indexed by ACR20 and DAS28-ESR, and improves clinical and radiological outcomes in ERA patients at the early stage, with superiority over placebo + MTX + HCQ, without enhancing adverse reactions.",2020,"At 1st to 6th month, DAS28- ESR scores in the experimental group were significantly lower than control values (all p < .05).","['Eighty untreated ERA patients', 'early rheumatoid arthritis']","['low-dose glucocorticoids combined with methotrexate and hydroxychloroquine', 'placebo + MTX + HCQ', 'MTX and HCQ', 'low-dose oral GCs combined with methotrexate (MTX) and hydroxychloroquine (HCQ', 'trial (GCs + MTX + HCQ) and control (placebo + MTX + HCQ', 'Glucocorticoids (GCs']","['American College of Rheumatology (ACR) 20 of ACR, disease activity score (DAS', 'side effects (eg, gastrointestinal reactions, liver dysfunction, upper respiratory tract infection, leukocyte reduction', 'Efficacy and safety', 'inflammation, quality of life and radiological symptoms', 'disease remission', '28- erythrocyte sedimentation rate (ESR), visual analog scale scores, joint function, health assessment questionnaire-disability index score, morning stiffness duration, C-reaction protein and ESR', 'efficacy and safety', 'DAS28- ESR scores', 'Bone erosion', 'adverse events', 'RA duration and DAS28-ESR score', 'ACR20 response', 'clinical and radiological outcomes']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0035452', 'cui_str': 'Rheumatology'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}, {'cui': 'C0041912', 'cui_str': 'Upper respiratory infection'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0542330', 'cui_str': 'Joint mobilization'}, {'cui': 'C0451208', 'cui_str': 'Health assessment questionnaire'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0457086', 'cui_str': 'Morning stiffness - joint'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C0587240', 'cui_str': 'Bone erosion'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",80.0,0.115868,"At 1st to 6th month, DAS28- ESR scores in the experimental group were significantly lower than control values (all p < .05).","[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Hua', 'Affiliation': 'Department of Rheumatology.'}, {'ForeName': 'Hongwei', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'Department of Rheumatology.'}, {'ForeName': 'Mingliang', 'Initials': 'M', 'LastName': 'Ying', 'Affiliation': 'Department of Radiology, Jinhua Municipal Central Hospital, Jinhua Zhejiang, China.'}, {'ForeName': 'Honghua', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Rheumatology.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Fan', 'Affiliation': 'Department of Rheumatology.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'Department of Rheumatology.'}]",Medicine,['10.1097/MD.0000000000020824'] 1816,32629682,Enhanced recovery after surgery (ERAS) protocols in patients undergoing radical cystectomy with ileal urinary diversions: A randomized controlled trial.,"BACKGROUND Enhanced Recovery After Surgery (ERAS) protocols were introduced in clinical practice to reduce complication rates and hospital stay. We performed a randomized controlled single center study to evaluate perioperative benefits of an adapted ERAS protocol in patients with bladder cancer who underwent radical cystectomy (RC) and ileal urinary diversions (IUD). MATERIALS AND METHODS Forty five from 90 consecutive randomized patients were enrolled in an adapted ERAS protocol. Length of stay, diet issues, return of bowel function, readmission rates and complications were examined. RESULTS Among patients following ERAS protocol, we found a significant reduction in time to first flatus (1 vs 5 days, P < .001), time to first stool (2 vs 5 days, P < .001), time to normal diet (5 vs 6 days, P < .001) and length of stay (16 vs 18 days, P < .001). Also, postoperative ileus at less than 4 days was lower than in non-ERAS patients (15.6% vs 24.4%), but with a marginal trend toward significance (P = .05). Readmission rate was lower in the ERAS group, but the difference did not reach statistical significance. We also found a lower readmission and complication rate in patients with ERAS protocol (6.6% vs 11.1%, P = .23 and 46.6% vs 57.5%, P = .29, respectively). CONCLUSIONS Implementation of ERAS protocol for patients undergoing RC in our center was associated with a significant reduction in the time to the first flatus, time to the first stool, time to a normal diet, length of hospital stay.",2020,"Readmission rate was lower in the ERAS group, but the difference did not reach statistical significance.","['Forty five from 90 consecutive randomized patients were enrolled in an adapted ERAS protocol', 'patients undergoing radical cystectomy with ileal urinary diversions', 'patients with bladder cancer who underwent radical cystectomy (RC) and ileal urinary diversions (IUD']","['surgery (ERAS) protocols', 'adapted ERAS protocol']","['time to first flatus', 'time to first stool', 'lower readmission and complication rate', 'postoperative ileus', 'length of stay', 'Readmission rate', 'Length of stay, diet issues, return of bowel function, readmission rates and complications', 'time to normal diet', 'complication rates and hospital stay']","[{'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C5197734', 'cui_str': 'Enhanced Postsurgical Recovery'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0194401', 'cui_str': 'Complete cystectomy'}, {'cui': 'C0020885', 'cui_str': 'Ileal structure'}, {'cui': 'C0042020', 'cui_str': 'Urinary diversion procedure'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C5197734', 'cui_str': 'Enhanced Postsurgical Recovery'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0400877', 'cui_str': 'Postoperative ileus'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",90.0,0.0619973,"Readmission rate was lower in the ERAS group, but the difference did not reach statistical significance.","[{'ForeName': 'Olaru', 'Initials': 'O', 'LastName': 'Vlad', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}, {'ForeName': 'Baston', 'Initials': 'B', 'LastName': 'Catalin', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}, {'ForeName': 'Harza', 'Initials': 'H', 'LastName': 'Mihai', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}, {'ForeName': 'Preda', 'Initials': 'P', 'LastName': 'Adrian', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}, {'ForeName': 'Olaru', 'Initials': 'O', 'LastName': 'Manuela', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Gener', 'Affiliation': 'University of Medicine and Pharmacy ""Carol Davila"" Bucharest.'}, {'ForeName': 'Sinescu', 'Initials': 'S', 'LastName': 'Ioanel', 'Affiliation': 'Fundeni Clinical Institute, Center of Uronephrology and Renal Transplant.'}]",Medicine,['10.1097/MD.0000000000020902'] 1817,32629685,The efficacy of acupuncture for the treatment and the fertility improvement in child-bearing period female with Hashimoto Disease: A randomized controlled study.,"BACKGROUND Hashimoto thyroiditis (HT) is highly prevalent among reproductive-aged women and has a substantial negative impact on fertility. Currently, there is no specific treatment for Hashimoto thyroiditis. We hypothesize that acupuncture can halt or delay the progression of HT and improve fertility in child-bearing period female. We therefore designed a randomized controlled trial to test this hypothesis by comparing the therapeutic effect of acupuncture vs sham acupuncture in patients with Hashimoto thyroiditis. METHODS In this randomized controlled study, a total of 284 eligible patients will be assigned to acupuncture group (n = 142) or sham acupuncture group (n = 142) in a 1:1 ratio. All patients will receive 36 sessions in total for 12 consecutive weeks with the same acupoint prescription (RN23, ST9, RN17, RN4, RN6, ST36, SP6, KI6). The primary assessment is the titers of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb). Secondary outcomes include the thyroid function, ovarian function, the rate of primary ovarian insufficiency, and pregnancy outcome. The thyroid function and thyroid antibodies tests will be measured at weeks 0, 4, 8, and 12 after randomization. The ovarian function will be examined on the 2nd to 4th day of the menstrual period in the 1st month, 2nd month and 3rd month compared with baseline. Both the pregnancy outcome and the rate of primary ovarian insufficiency will be evaluated 1 year after treatment. DISCUSSION This will be the first large-scale trial specifically evaluating acupuncture therapy in child-bearing period female with Hashimoto thyroiditis. If the study confirms the effectiveness of acupuncture treatment, more consistent acupuncture therapy can be set up for clinical practice. TRIAL REGISTRATION Chinese Clinical Trials Register identifier, ChiCTR2000031320, registered on 27 March 2020.",2020,The primary assessment is the titers of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb).,"['reproductive-aged women', 'child-bearing period female with Hashimoto thyroiditis', 'patients with Hashimoto thyroiditis', 'child-bearing period female with Hashimoto Disease', '284 eligible patients', 'group (n\u200a=\u200a142) or']","['acupuncture', 'acupuncture vs sham acupuncture', 'Hashimoto thyroiditis (HT', 'acupuncture therapy', 'sham acupuncture']","['fertility improvement', 'thyroid function, ovarian function, the rate of primary ovarian insufficiency, and pregnancy outcome', 'thyroid function and thyroid antibodies tests', 'rate of primary ovarian insufficiency', 'titers of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb', 'ovarian function']","[{'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0677607', 'cui_str': 'Hashimoto thyroiditis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0677607', 'cui_str': 'Hashimoto thyroiditis'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture'}]","[{'cui': 'C0015895', 'cui_str': 'Ability to conceive'}, {'cui': 'C0040132', 'cui_str': 'Thyroid structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0025322', 'cui_str': 'Premature menopause'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0700384', 'cui_str': 'Thyroid antibody'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0076635', 'cui_str': 'Thyroid microsomal antibody'}, {'cui': 'C0201512', 'cui_str': 'Thyroglobulin antibody measurement'}]",284.0,0.195251,The primary assessment is the titers of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TGAb).,"[{'ForeName': 'Fangyuan', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Zhang', 'Initials': 'Z', 'LastName': 'Qi', 'Affiliation': 'College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Hua', 'Affiliation': 'College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.'}, {'ForeName': 'Xinxin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'College of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu.'}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Ling', 'Affiliation': 'Maternal and Child Reproductive Hospital affiliated to Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, PR China.'}, {'ForeName': 'Du', 'Initials': 'D', 'LastName': 'Juan', 'Affiliation': 'Maternal and Child Reproductive Hospital affiliated to Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, PR China.'}]",Medicine,['10.1097/MD.0000000000020909'] 1818,32639649,Trial of restarting and tolerating metformin (TreatMet).,"This randomized, double-blind, placebo-controlled, n-of-1 crossover study assessed whether metformin's side effects are reproducible in patients with a history of metformin intolerance. Participants completed up to four cycles of 2 weeks of metformin exposure and 2 weeks of placebo exposure. Participants completed surveys based on the Gastrointestinal Symptom Rating Scale and the Treatment Satisfaction Questionnaire for Medication. The primary hypotheses were that treatment satisfaction would be equal for placebo and metformin and that more than 30% of the study enrollees would be able to adhere to a higher dose of metformin 6 months after participation. Thirteen patients (all women, mean age 52.4 years) enrolled, three of whom were lost to follow-up or were non-adherent to study protocol. Metformin was associated with significantly lower global treatment satisfaction scores compared with placebo (39.58 vs. 53.75, P < .05 ) but participants could not distinguish metformin from placebo and did not report higher rates of gastrointestinal side effects on metformin. Two out of 10 participants adhered to a higher dose of metformin after trial completion. Metformin appears to have barriers to use beyond its classic gastrointestinal side effects.",2020,,[],['Restarting and Tolerating Metformin (TreatMet'],[],[],"[{'cui': 'C0025598', 'cui_str': 'Metformin'}]",[],,0.0175862,,"[{'ForeName': 'Jeremy N', 'Initials': 'JN', 'LastName': 'Orloff', 'Affiliation': 'Weill Cornell Medicine, Population Health Sciences, New York, New York, USA.'}, {'ForeName': 'Samir H', 'Initials': 'SH', 'LastName': 'Touhamy', 'Affiliation': 'Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Truong', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Casper', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Alpana P', 'Initials': 'AP', 'LastName': 'Shukla', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Leon I', 'Initials': 'LI', 'LastName': 'Igel', 'Affiliation': 'Division of Endocrinology, Diabetes and Metabolism Comprehensive Weight Control Center, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'James H', 'Initials': 'JH', 'LastName': 'Flory', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York, USA.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14137'] 1819,32635784,Effect of warm environment on the skin blood flow response to food intake.,"BACKGROUND AND OBJECTIVE Warm exposure places high demands on thermoregulation mechanisms, which depend on the effectiveness of the microvascular function. The associations between the microcirculation and metabolism in warm environments have received little attention. The purpose of this study was to explore skin blood flow (SkBF) in response to food intake in a warm environment compared to control. METHODS Thirty-two healthy, acclimated-to-warm-environment and physically active participants were recruited (20 females and 12 males). They participated in two sessions (warm environment: 31 °C and control: 20 °C, presented in randomized order). SkBF was measured before and after standardized food intake through the acquisition of perfusion signals by laser Doppler flowmetry (Periflux System 5000), following a local heating protocol. RESULTS SkBF was affected by the environmental temperature, showing an increase in the warm environment compared to control (all p  < .001). SkBF was significantly affected by food intake (all p  < .007), being reduced after meals. In the men's group, SkBF was reduced in both environmental temperatures after meals. In women, meals affected SkBF at 20 °C but not in the warm environment. CONCLUSION These results may indicate a competition between thermo- and glyco-regulation in a warm environment to the detriment of glucose homeostasis in women.",2020,"RESULTS SkBF was affected by the environmental temperature, showing an increase in the warm environment compared to control (all p  < .001).","['Thirty-two healthy, acclimated-to-warm-environment and physically active participants were recruited (20 females and 12 males', 'women']",[],"['skin blood flow response', 'skin blood flow (SkBF', 'SkBF']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0563030', 'cui_str': 'Warm environment'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}]",[],"[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}]",32.0,0.0342166,"RESULTS SkBF was affected by the environmental temperature, showing an increase in the warm environment compared to control (all p  < .001).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reminy', 'Affiliation': 'Laboratoire ACTES (Adaptation Climat Tropical Exercice Santé, EA3596), Université des Antilles, Pointe-à-Pitre, Guadeloupe, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Hue', 'Affiliation': 'Laboratoire ACTES (Adaptation Climat Tropical Exercice Santé, EA3596), Université des Antilles, Pointe-à-Pitre, Guadeloupe, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Antoine-Jonville', 'Affiliation': 'Laboratoire ACTES (Adaptation Climat Tropical Exercice Santé, EA3596), Université des Antilles, Pointe-à-Pitre, Guadeloupe, France.'}]","International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group",['10.1080/02656736.2020.1788174'] 1820,32640112,Combined strategies following surgical drainage for perianal fistulizing Crohn's disease: failure rates and prognostic factors.,"AIM The medico-surgical strategy for the treatment of perianal fistulizing Crohn's disease (CD) following surgical drainage remains challenging and debated. Our aims were to describe the failure rate of therapeutic interventions after drainage of the fistula tract and determine the factors associated with failure to optimize medico-surgical strategies. METHOD All consecutive patients with perianal fistulizing CD who underwent surgical drainage with at least a 12-week follow-up were included. Failure was defined as the occurrence of at least one of the following items: abscess recurrence, purulent discharge from the tract, visible external opening and further drainage procedure(s). RESULTS One hundred and sixty-nine patients were included. The median follow-up was 4.0 years. The cumulative failure rates were 20%, 30% and 36% at 1, 3 and 5 years, respectively. The cumulative failure rates in patients who had sphincter-sparing surgeries or seton removal were significantly higher than in those who had a fistulotomy. Anterior fistula [hazard ratio (HR) = 2.52 (1.13-5.61), P = 0.024], supralevator extension [HR = 20.78 (3.38-127.80), P = 0.001] and the absence or discontinuation of immunosuppressants after anal drainage [HR = 3.74 (1.11-12.5), P = 0.032] were significantly associated with failure in the multivariate analysis model. CONCLUSION Combined strategies for perianal fistulizing CD lead to a failure rate of 36% at 5 years. Where advisable, fistulotomy may be preferred because it has a lower rate of recurrence. The benefits of immunosuppressants require a dedicated prospective randomized trial.",2020,"Anterior fistula (HR = 2.52 [1.13-5.61], p=0.024), supralevator extension (HR = 20.78 [3.38-127.80], p=0.001) and the absence or discontinuation of immunosuppressants after anal drainage (HR = 3.74 [1.11-12.5], p=0.032) were significantly associated with failure in the multivariate analysis model. ","['One hundred sixty-nine patients were included', 'All consecutive patients with perianal fistulising CD who underwent surgical drainage with at least a 12-week follow-up were included']",[],"['supralevator extension', 'failure rate', 'cumulative failure rates', 'absence or discontinuation of immunosuppressants after anal drainage']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0442158', 'cui_str': 'Perianal'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]",[],"[{'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0003461', 'cui_str': 'Anal structure'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]",169.0,0.0718637,"Anterior fistula (HR = 2.52 [1.13-5.61], p=0.024), supralevator extension (HR = 20.78 [3.38-127.80], p=0.001) and the absence or discontinuation of immunosuppressants after anal drainage (HR = 3.74 [1.11-12.5], p=0.032) were significantly associated with failure in the multivariate analysis model. ","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Herissay', 'Affiliation': 'CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Siproudhis', 'Affiliation': 'INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': ""Le Balc'h"", 'Affiliation': 'CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': ""Merlini L'Heritier"", 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dewitte', 'Affiliation': 'CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Wallenhorst', 'Affiliation': 'CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bouguen', 'Affiliation': 'INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), CHU Rennes, Universitaire Rennes, Rennes, France.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Brochard', 'Affiliation': 'INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), CHU Rennes, Universitaire Rennes, Rennes, France.'}]",Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland,['10.1111/codi.15241'] 1821,32640124,Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts.,"BACKGROUND Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear. METHODS We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed. RESULTS A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out. CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.).",2020,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","['A total of 752 household contacts of 545 index patients', 'household contacts of index patients with confirmed influenza during the 2018-2019 season in Japan', 'Household Contacts', 'household contacts of patients with influenza']","['Baloxavir', 'baloxavir', 'Baloxavir Marboxil', 'Baloxavir marboxil (baloxavir', 'baloxavir or placebo', 'placebo']","['postexposure prophylactic efficacy', 'clinical influenza, as confirmed by reverse-transcriptase-polymerase-chain-reaction testing', 'clinical influenza', 'viral PA substitutions I38T/M or E23K', 'incidence of adverse events']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C4517809', 'cui_str': '545'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C4734224', 'cui_str': 'baloxavir'}, {'cui': 'C4688747', 'cui_str': 'Baloxavir marboxil'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0021400', 'cui_str': 'Influenza'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0599161', 'cui_str': 'Polymerase Chain Reaction, Reverse Transcriptase'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.380895,"CONCLUSIONS Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza.","[{'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Ikematsu', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Frederick G', 'Initials': 'FG', 'LastName': 'Hayden', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Keiko', 'Initials': 'K', 'LastName': 'Kawaguchi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Kinoshita', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Menno D', 'Initials': 'MD', 'LastName': 'de Jong', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Lee', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Takashima', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Noshi', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tsuchiya', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}, {'ForeName': 'Takeki', 'Initials': 'T', 'LastName': 'Uehara', 'Affiliation': 'From Ricerca Clinica, Fukuoka (H.I.), and Shionogi, Osaka (K.K., M.K., S.T., T.N., K.T., T.U.) - both in Japan; the Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia School of Medicine, Charlottesville (F.G.H.); the Department of Medical Microbiology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam (M.D.J.); and the Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Canada (N.L.).'}]",The New England journal of medicine,['10.1056/NEJMoa1915341'] 1822,32640130,Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.,"BACKGROUND Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations. METHODS We conducted a phase 1-2 ascending-dose trial evaluating tofersen in adults with ALS due to SOD1 mutations. In each dose cohort (20, 40, 60, or 100 mg), participants were randomly assigned in a 3:1 ratio to receive five doses of tofersen or placebo, administered intrathecally for 12 weeks. The primary outcomes were safety and pharmacokinetics. The secondary outcome was the change from baseline in the cerebrospinal fluid (CSF) SOD1 concentration at day 85. Clinical function and vital capacity were measured. RESULTS A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture-related adverse events were observed in most participants. Elevations in CSF white-cell count and protein were reported as adverse events in 4 and 5 participants, respectively, who received tofersen. Among participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the placebo group died from respiratory failure on day 52. The difference at day 85 in the change from baseline in the CSF SOD1 concentration between the tofersen groups and the placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose, -25 percentage points (95% CI, -40 to -5) for the 40-mg dose, -19 percentage points (95% CI, -35 to 2) for the 60-mg dose, and -33 percentage points (95% CI, -47 to -16) for the 100-mg dose. CONCLUSIONS In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture-related adverse events were observed in most participants. (Funded by Biogen; ClinicalTrials.gov number, NCT02623699; EudraCT number, 2015-004098-33.).",2020,"In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.","['50 participants underwent randomization and were included in the analyses; 48 participants', 'participants who received tofersen, one died from pulmonary embolus on day 137, and one from respiratory failure on day 152; one participant in the', 'adults with ALS due to SOD1 mutations']","['tofersen or placebo', 'placebo']","['Clinical function and vital capacity', 'safety and pharmacokinetics', 'cerebrospinal fluid (CSF) SOD1 concentration', 'CSF pleocytosis', 'Lumbar puncture-related adverse events', 'CSF SOD1 concentrations', 'CSF SOD1 concentration']","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002736', 'cui_str': 'Amyotrophic lateral sclerosis'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0669516', 'cui_str': 'Superoxide Dismutase 1'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0422813', 'cui_str': 'Clinical function'}, {'cui': 'C0042834', 'cui_str': 'Vital capacity'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0669516', 'cui_str': 'Superoxide Dismutase 1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0151857', 'cui_str': 'Pleocytosis'}, {'cui': 'C0037943', 'cui_str': 'Lumbar puncture'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",50.0,0.595845,"In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks.","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Miller', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Merit', 'Initials': 'M', 'LastName': 'Cudkowicz', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Shaw', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'Andersen', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Nazem', 'Initials': 'N', 'LastName': 'Atassi', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Bucelli', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Genge', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Glass', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Shafeeq', 'Initials': 'S', 'LastName': 'Ladha', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Albert L', 'Initials': 'AL', 'LastName': 'Ludolph', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Maragakis', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'McDermott', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Pestronk', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ravits', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Salachas', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Randall', 'Initials': 'R', 'LastName': 'Trudell', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Van Damme', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Lorne', 'Initials': 'L', 'LastName': 'Zinman', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'C Frank', 'Initials': 'CF', 'LastName': 'Bennett', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Lane', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Alfred', 'Initials': 'A', 'LastName': 'Sandrock', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Runz', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Graham', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Hani', 'Initials': 'H', 'LastName': 'Houshyar', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'McCampbell', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Nestorov', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Ih', 'Initials': 'I', 'LastName': 'Chang', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Manjit', 'Initials': 'M', 'LastName': 'McNeill', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Fanning', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Fradette', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}, {'ForeName': 'Toby A', 'Initials': 'TA', 'LastName': 'Ferguson', 'Affiliation': 'From the Washington University School of Medicine, St. Louis (T.M., R.C.B., A.P.); the Healey Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston (M.C., N.A.), and Biogen, Cambridge (A.S., H.R., D.G., H.H., A.M., I.N., I.C., L.F., S.F., T.A.F.) - both in Massachusetts; the Sheffield Institute for Translational Neuroscience, University of Sheffield, and NIHR Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield (P.J.S., C.J.M.), and Biogen, Maidenhead (M.M.) - both in the United Kingdom; the Department of Clinical Science, Neurosciences, Umeå University, Umea, Sweden (P.M.A.); Montreal Neurological Institute and Hospital, Montreal (A.G.), and Sunnybrook Research Institute, Toronto (L.Z.); Emory University, Atlanta (J.G.); Barrow Neurological Institute, Phoenix, AZ (S.L.); the University of Ulm, Ulm, Germany (A.L.L.); Johns Hopkins University School of Medicine, Baltimore (N.J.M.); the University of California San Diego, La Jolla (J.R.), and Ionis Pharmaceuticals, Carlsbad (C.F.B., R.L.) - both in California; Paris ALS Centre, Hôpital de la Salpêtrière, Paris (F.S.); the University of Tennessee Medical Center, Knoxville (R.T.); and KU Leuven, VIB Center for Brain and Disease Research, University Hospitals Leuven, Leuven, Belgium (P.V.D.).'}]",The New England journal of medicine,['10.1056/NEJMoa2003715'] 1823,32658830,The feasibility of acupuncture as an adjunct intervention for antenatal depression: a pragmatic randomised controlled trial.,"BACKGROUND Antenatal depression is common and associated with adverse consequences for mothers, babies, and future generations. Limitations with conventional approaches has resulted in additional therapies being considered. This study examined the feasibility and effectiveness of acupuncture for improving mental health. METHODS Fifty-seven pregnant women with depressive symptomologies were randomised to acupuncture (n=19) plus treatment as usual (TAU), progressive muscle relaxation (PMR, n=19) plus TAU or TAU (n=19). Treatments were conducted from 24 to 31 weeks gestation. Clinical assessments were performed throughout the intervention, as well as at a six-week postnatal follow-up. The primary outcome measure was depression. Secondary outcome measurements were stress, anxiety, psychological distress, quality of life and adjustment to mothering. Intention to treat (ITT), Linear Mixed Model (LMM) repeated measures and per protocol (PP) analyses were conducted. RESULTS At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD) -5.84 (95% CI -9.10 to -2.58); MD -3.42 (95% CI -6.64 to -0.20)]. LMM repeated measures analysis (including postnatal follow-up) also demonstrated significantly lowered acupuncture group scores for stress (p=0.006) and psychological distress (p<0.001) when compared to PMR and TAU. Between group differences were not significant at six-weeks postnatal. No adverse events were reported. LIMITATIONS Main limitations are small sample size and the use of self-reported outcome measures. CONCLUSION Prenatal acupuncture reduced depression, stress and distress, whilst also being well-tolerated and free from adverse events. Further research is warranted.",2020,"At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD)","['Fifty-seven pregnant women with depressive symptomologies', 'antenatal depression']","['acupuncture', 'acupuncture (n=19) plus treatment as usual (TAU), progressive muscle relaxation (PMR, n=19) plus TAU or TAU']","['mean difference (MD', 'depression scores', 'depression', 'adverse events', 'depression, stress and distress, whilst also being well-tolerated and free from adverse events', 'psychological distress', 'stress, anxiety, psychological distress, quality of life and adjustment to mothering']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0454043', 'cui_str': 'Jacobson technique'}, {'cui': 'C0032533', 'cui_str': 'Polymyalgia rheumatica'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0376209', 'cui_str': 'Adjustment'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]",57.0,0.185105,"At end-of-intervention there were significantly lower depression scores in the acupuncture group versus TAU and PMR respectively [ITT p<0.001, mean difference (MD)","[{'ForeName': 'Simone M', 'Initials': 'SM', 'LastName': 'Ormsby', 'Affiliation': 'Adjunct Fellow, NICM Health Research Institute, Level 1, Building J, Western Sydney University, Westmead Campus, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: simone.ormsby@westernsydney.edu.au.'}, {'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Smith', 'Affiliation': 'Professor of Clinical Research, NICM Health Research Institute, Level 1, Building J, Western Sydney University, Westmead Campus, Locked Bag 1797, Penrith, NSW, 2751, Australia. Electronic address: caroline.smith@westernsydney.edu.au.edu.au.'}, {'ForeName': 'Hannah G', 'Initials': 'HG', 'LastName': 'Dahlen', 'Affiliation': 'Professor of Midwifery, Associate Dean Research and HDR, Midwifery Discipline, Building EB, UWS Parramatta Campus, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: H.Dahlen@westernsydney.edu.au.'}, {'ForeName': 'Phillipa J', 'Initials': 'PJ', 'LastName': 'Hay', 'Affiliation': 'Professor of Mental Health, Translational Health Research Institute, School of Medicine Western Sydney University and Camden and Campbelltown Hospitals SWSLHD, Locked Bag 1797, Penrith, NSW 2751, Australia. Electronic address: P.Hay@westernsydney.edu.au.'}]",Journal of affective disorders,['10.1016/j.jad.2020.05.089'] 1824,32658939,Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.,"Uncertainty about the importance of influenza transmission by airborne droplet nuclei generates controversy for infection control. Human challenge-transmission studies have been supported as the most promising approach to fill this knowledge gap. Healthy, seronegative volunteer 'Donors' (n = 52) were randomly selected for intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). 'Recipients' randomized to Intervention (IR, n = 40) or Control (CR, n = 35) groups were exposed to Donors for four days. IRs wore face shields and hand sanitized frequently to limit large droplet and contact transmission. One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure. The main difference between these studies was mechanical building ventilation in the follow-on study, suggesting a possible role for aerosols.",2020,"One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure.","[""Healthy, seronegative volunteer 'Donors' (n = 52""]",['intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2). '],[],"[{'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1615607', 'cui_str': 'Influenza A virus subtype H1N1'}]",[],52.0,0.0134321,"One transmitted infection was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among CR, 0% in IR (p = 0.47 for group difference), and 1.3% overall, significantly less than 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and considering that there were twice as many Donors and days of exposure.","[{'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Nguyen-Van-Tam', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Killingley', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Enstone', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hewitt', 'Affiliation': 'Health Protection and Influenza Research Group, Division of Epidemiology and Public Heath, University of Nottingham School of Medicine, Nottingham, United Kingdom.'}, {'ForeName': 'Jovan', 'Initials': 'J', 'LastName': 'Pantelic', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Grantham', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'P Jacob', 'Initials': 'PJ', 'LastName': 'Bueno de Mesquita', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lambkin-Williams', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gilbert', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Mann', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Forni', 'Affiliation': 'hVIVO London, United Kingdom.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Noakes', 'Affiliation': 'University of Leeds School of Civil Engineering, Leeds, United Kingdom.'}, {'ForeName': 'Min Z', 'Initials': 'MZ', 'LastName': 'Levine', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'LaShondra', 'Initials': 'L', 'LastName': 'Berman', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Lindstrom', 'Affiliation': 'Centers for Disease Control and Prevention, Influenza Division, Atlanta, Georgia, United States of America.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cauchemez', 'Affiliation': 'Imperial College London, MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, London, United Kingdom.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Bischoff', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.'}, {'ForeName': 'Raymond', 'Initials': 'R', 'LastName': 'Tellier', 'Affiliation': 'McGill University, Dept of Medicine, Montreal, Canada.'}, {'ForeName': 'Donald K', 'Initials': 'DK', 'LastName': 'Milton', 'Affiliation': 'University of Maryland School of Public Health, Maryland Institute for Applied Environmental Health, College Park, Maryland, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",PLoS pathogens,['10.1371/journal.ppat.1008704'] 1825,32659032,Impact of end-expiratory pressure fluctuation on tidal volume in the trilevel positive airway pressure mode.,"INTRODUCTION In noninvasive positive-pressure ventilation (NPPV), the changes in the expiratory positive airway pressure (EPAP) directly affect the magnitude of the tidal volume. OBJECTIVES This experimental study aims to verify the precise effects of end-expiratory fluctuation on the body tidal volume to better assist NPPV in clinical practice. METHODS We selected the TestChest-simulated lung simulation of different populations, including healthy subjects (normal group), patients with chronic obstructive pulmonary disease (COPD) with emphysema as their primary phenotype (COPD1 group), and patients with COPD with bronchitis as their primary phenotype (COPD2 group). RESULTS Regarding the tidal volume curves of the three groups under various conditions, sixfold charts revealed that the tidal volume changed with the end-expiratory pressure fluctuations. In addition, regression coefficients for end-expiratory pressure fluctuations, (IPAP-EPAP) and (IPAP-EEPAP) exhibited a significant contribution to the tidal volume. The two coefficients in the normal, COPD1 and COPD2 groups were 52.294 and 10.414, 46.192 and -8.816, and 11.922 and 17.947, respectively. The circuit simulation results showed that the simulation curve fitted the experimental curve better by changing the coefficient of the descending edge of the expiratory phase. CONCLUSIONS The study results suggest that the end-expiratory pressure fluctuation affects the body tidal volume. Compared with the bilevel positive airway pressure (PAP), the trilevel PAP provides additional respiratory support to the body during a respiratory difference in initial respiration and descent.",2020,"The two coefficients in the normal, COPD1, and COPD2 groups were 52.294 and 10.414, 46.192 and -8.816, and 11.922 and 17.947, respectively.","['healthy subjects (normal group), patients with chronic obstructive pulmonary disease (COPD) with emphysema as their primary phenotype (COPD1 group), and patients with COPD with bronchitis as their primary phenotype (COPD2 group']","['end-expiratory pressure fluctuation', 'noninvasive positive-pressure ventilation (NPPV', 'bilevel positive airway pressure (PAP']","['body tidal volume', 'expiratory positive airway pressure (EPAP']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0013990', 'cui_str': 'Emphysema'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0428720', 'cui_str': 'End-expiratory pressure'}, {'cui': 'C0231239', 'cui_str': 'Fluctuation'}, {'cui': 'C3164735', 'cui_str': 'Noninvasive positive pressure ventilation'}, {'cui': 'C1611149', 'cui_str': 'Bilevel positive airway pressure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0428719', 'cui_str': 'Airway pressure'}]","[{'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C3697361', 'cui_str': 'Expiratory positive airway pressure'}]",,0.0255494,"The two coefficients in the normal, COPD1, and COPD2 groups were 52.294 and 10.414, 46.192 and -8.816, and 11.922 and 17.947, respectively.","[{'ForeName': 'Zhi-Xiang', 'Initials': 'ZX', 'LastName': 'Ma', 'Affiliation': 'Biomedical Engineering Institute, School of Control Science and Engineering, Shandong University, Jinan, China.'}, {'ForeName': 'Tian-Ran', 'Initials': 'TR', 'LastName': 'Zhou', 'Affiliation': 'Biomedical Engineering Institute, School of Control Science and Engineering, Shandong University, Jinan, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Biomedical Engineering Institute, School of Control Science and Engineering, Shandong University, Jinan, China.'}, {'ForeName': 'De-Dong', 'Initials': 'DD', 'LastName': 'Ma', 'Affiliation': 'Department of Respiratory Medicine, Qilu Hospital, Shandong University, Jinan, China.'}]",The clinical respiratory journal,['10.1111/crj.13233'] 1826,32659854,Comparing two airway management strategies for moderately sedated patients undergoing awake craniotomy: A single-blinded randomized controlled trial.,"BACKGROUND In the monitored anesthesia care (MAC) setting for awake craniotomy (AC), maintaining airway patency in sedated patients remains challenging. This randomized controlled trial aimed to compare the validity of the below-epiglottis transnasal tube insertion (the tip of the tube placed between the epiglottis and vocal cords) and the nasopharyngeal airway (simulated by the above-epiglottis transnasal tube with the tip of the tube placed between the epiglottis and the free edge of the soft palate) with respect to maintaining upper airway patency for moderately sedated patients undergoing AC. METHODS Sixty patients scheduled for elective AC were randomized to receive below-epiglottis (n = 30) or above-epiglottis (n = 30) transnasal tube insertion before surgery. Moderate sedation was maintained in the pre- and post-awake phases. The primary outcome was the upper airway obstruction (UAO) remission rate (relieved obstructions after tube insertion/the total number of obstructions before tube insertion). RESULTS The UAO remission rate was higher in the below-epiglottis group [100% (12/12) vs 45% (5/11); P = .005]. The tidal volume values monitored through the tube were greater in the below-epiglottis group during the pre-awake phase (P < .001). End-tidal carbon dioxide (EtCO 2 ) monitored through the tube was higher in the below-epiglottis group at bone flap removal (P < .001). During the awake phase, patients' ability to speak was not impeded. No patient had serious complications related to the tube. CONCLUSION The below-epiglottis tube insertion is a more effective method to maintain upper airway patency than the nasopharyngeal airway for moderately sedated patients undergoing AC.",2020,The UAO remission rate was higher in the below-epiglottis group [100% (12/12) vs 45% (5/11); P = .005].,"['Sixty patients scheduled for elective AC', 'moderately sedated patients undergoing awake craniotomy', 'moderately sedated patients undergoing AC', 'sedated patients']","['nasopharyngeal airway (simulated by the above-epiglottis transnasal tube with the tip of the tube placed between the epiglottis and the free edge of the soft palate) with respect to maintaining upper airway patency', 'below-epiglottis transnasal tube insertion', 'below-epiglottis (n = 30) or above-epiglottis (n = 30) transnasal tube insertion before surgery']","['serious complications', 'End-tidal carbon dioxide monitored through the tube', 'Moderate sedation', 'upper airway obstruction (UAO) remission rate (relieved obstructions after tube insertion/the total number of obstructions before tube insertion', 'tidal volume values', 'UAO remission rate']","[{'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0010280', 'cui_str': 'Craniotomy'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0150683', 'cui_str': 'Nasopharyngeal airway device'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0014540', 'cui_str': 'Epiglottis structure'}, {'cui': 'C0521131', 'cui_str': 'Transnasal approach'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0339897', 'cui_str': 'Transjugular intrahepatic portosystemic shunt'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0030219', 'cui_str': 'Soft palate structure'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0225377', 'cui_str': 'Structure of upper respiratory tract cavity'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0542276', 'cui_str': 'Respired carbon dioxide monitoring'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0079159', 'cui_str': 'Conscious sedation'}, {'cui': 'C0740852', 'cui_str': 'Upper airway obstruction'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",60.0,0.0557128,The UAO remission rate was higher in the below-epiglottis group [100% (12/12) vs 45% (5/11); P = .005].,"[{'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Deng', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Meng-Yun', 'Initials': 'MY', 'LastName': 'Tu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Yi-Heng', 'Initials': 'YH', 'LastName': 'Liu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Xiao-Bing', 'Initials': 'XB', 'LastName': 'Hu', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Jin-Song', 'Initials': 'JS', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, Huashan Hospital of Fudan University, Shanghai, China.'}, {'ForeName': 'Ying-Wei', 'Initials': 'YW', 'LastName': 'Wang', 'Affiliation': 'Department of Anesthesiology, Huashan Hospital of Fudan University, Shanghai, China.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13667'] 1827,32661682,"Within-group comparisons led to unsubstantiated conclusions in ""Low-phytate wholegrain bread instead of high-phytate wholegrain bread in a total diet context did not improve iron status of healthy Swedish females: a 12-week, randomized, parallel-design intervention Study"".",,2020,,['healthy Swedish females'],[],[],"[{'cui': 'C0038996', 'cui_str': 'Swedish language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],,0.027488,,"[{'ForeName': 'Colby J', 'Initials': 'CJ', 'LastName': 'Vorland', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA. cvorland@iu.edu.'}, {'ForeName': 'Luis M', 'Initials': 'LM', 'LastName': 'Mestre', 'Affiliation': 'Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA.'}, {'ForeName': 'Sachintha S', 'Initials': 'SS', 'LastName': 'Mendis', 'Affiliation': 'Department of Agricultural and Resource Economics, Colorado State University, Fort Collins, CO, USA.'}, {'ForeName': 'Andrew W', 'Initials': 'AW', 'LastName': 'Brown', 'Affiliation': 'Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA. awb1@iu.edu.'}]",European journal of nutrition,['10.1007/s00394-020-02287-0'] 1828,32662309,The value of a first MRI and targeted biopsies after several years of active surveillance for low-risk prostate cancer - results from the SAMS trial.,"OBJECTIVE To assess the value of a first MRI examination and image-fusion-guided biopsies in men with low-risk prostate cancer who have been on active surveillance (AS) for several years with no signs of progression. PATIENTS AND METHODS All 45 participants from two centers who had not previously had an MRI were included. They had been on AS for T1c Gleason score 6 prostate cancer for 2.6 to 6.7 years and had 2 to 5 sets of systematic biopsies with a total of 1640 cores. All underwent a bi-parametric MRI, PI-RADS ≥ 3 lesions were targeted with image-fusion-guided biopsies. Primary outcome measure: detection of Gleason score ≥7 cancer. RESULTS Twenty-five of the 45 men (56%) had a total of 30 suspicious MRI lesions. The lesion with the highest score was a PI-RADS 3 in 18, a PI-RADS 4 in 5 and PI-RADS 5 in 3 men. Targeted biopsies from the 30 lesions detected Gleason score 7 cancer in 6 men. Of these six cancers, four were located in the apical and one in the anterior/apical part of the prostate. A Gleason score 7 cancer was detected in 3 of 5 men with PSA density >0.15 ng/ml/cm 3 . CONCLUSIONS Even after several years of AS with stable PSA values and many sets of systematic biopsies, a first MRI and targeted biopsies lead to the detection of Gleason score 7 (ISUP 2 and ISUP 3) cancer in a significant proportion of men, particularly among those with a high PSA density.",2020,"A Gleason score 7 cancer was detected in 3 of 5 men with PSA density >0.15 ng/ml/cm 3 . ","['men with low-risk prostate cancer who have been on active surveillance (AS) for several years with no signs of progression', 'Twenty-five of the 45 men (56%) had a total of 30 suspicious MRI lesions', 'All 45 participants from two centers who had not previously had an MRI were included']",['MRI examination and image-fusion-guided biopsies'],['detection of Gleason score ≥7 cancer'],"[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0700325', 'cui_str': 'Patient status observation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0332326', 'cui_str': 'Gleason grading system for prostatic cancer'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",5.0,0.079837,"A Gleason score 7 cancer was detected in 3 of 5 men with PSA density >0.15 ng/ml/cm 3 . ","[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Carlsson', 'Affiliation': 'Urology Department, Karolinska University Hospital, Solna, Sweden.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Bratt', 'Affiliation': 'Department of Urology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Dushanka', 'Initials': 'D', 'LastName': 'Kristiansson', 'Affiliation': 'Farsta Urology Clinic, Stockholm, Sweden.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Jäderling', 'Affiliation': 'Department of Molecular Medicine and Surgery (MMKa), Karolinska Institute, Stockholm, Sweden.'}]",Scandinavian journal of urology,['10.1080/21681805.2020.1788634'] 1829,32445440,Remdesivir for the Treatment of Covid-19 - Preliminary Report.,"BACKGROUND Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious. METHODS We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. The primary outcome was the time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only. RESULTS A total of 1063 patients underwent randomization. The data and safety monitoring board recommended early unblinding of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%). CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 ClinicalTrials.gov number, NCT04280705.).",2020,"CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.","['1059 patients (538 assigned to remdesivir and 521 to', 'adults hospitalized with Covid-19 and evidence of lower respiratory tract infection', '1063 patients underwent randomization', 'adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement']","['remdesivir', 'intravenous remdesivir', 'placebo']","['median recovery time', 'time to recovery, defined by either discharge from the hospital or hospitalization for infection-control purposes only', 'Serious adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4726677', 'cui_str': 'remdesivir'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0458579', 'cui_str': 'Lower respiratory tract structure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}]","[{'cui': 'C4726677', 'cui_str': 'remdesivir'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0085557', 'cui_str': 'Infection control procedure'}, {'cui': 'C1285529', 'cui_str': 'Purpose'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1063.0,0.687871,"CONCLUSIONS Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.","[{'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Beigel', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Tomashek', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Lori E', 'Initials': 'LE', 'LastName': 'Dodd', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Aneesh K', 'Initials': 'AK', 'LastName': 'Mehta', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Barry S', 'Initials': 'BS', 'LastName': 'Zingman', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Andre C', 'Initials': 'AC', 'LastName': 'Kalil', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Hohmann', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Helen Y', 'Initials': 'HY', 'LastName': 'Chu', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Luetkemeyer', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Kline', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Lopez de Castilla', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Finberg', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Kerry', 'Initials': 'K', 'LastName': 'Dierberg', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Tapson', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Lanny', 'Initials': 'L', 'LastName': 'Hsieh', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Thomas F', 'Initials': 'TF', 'LastName': 'Patterson', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Paredes', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Sweeney', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Short', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Giota', 'Initials': 'G', 'LastName': 'Touloumi', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'David Chien', 'Initials': 'DC', 'LastName': 'Lye', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Ohmagari', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Myoung-Don', 'Initials': 'MD', 'LastName': 'Oh', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Guillermo M', 'Initials': 'GM', 'LastName': 'Ruiz-Palacios', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Benfield', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fätkenheuer', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Kortepeter', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Atmar', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'C Buddy', 'Initials': 'CB', 'LastName': 'Creech', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lundgren', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Abdel G', 'Initials': 'AG', 'LastName': 'Babiker', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Pett', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Neaton', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Timothy H', 'Initials': 'TH', 'LastName': 'Burgess', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Bonnett', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Green', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Mat', 'Initials': 'M', 'LastName': 'Makowski', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Osinusi', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Nayak', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': 'H Clifford', 'Initials': 'HC', 'LastName': 'Lane', 'Affiliation': 'From the National Institute of Allergy and Infectious Diseases, National Institutes of Health (J.H.B., K.M.T., L.E.D., S.N., H.C.L.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, the Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick (T. Bonnett), and Emmes, Rockville (M.G., M.M.) - all in Maryland; Emory University, Atlanta (A.K.M.); Montefiore Medical Center-Albert Einstein College of Medicine (B.S.Z.) and NYU Langone Health and NYC Health + Hospitals- Bellevue (K.D.), New York; University of Nebraska Medical Center, Omaha (A.C.K., M.G.K.); Massachusetts General Hospital, Boston (E.H.), and University of Massachusetts Medical School, Worcester (R.W.F.); University of Washington, Seattle (H.Y.C.), and Evergreen Health Medical Center, Kirkland (D.L.C.) - both in Washington; University of California, San Francisco, San Francisco (A.L.), Cedars Sinai Medical Center, Los Angeles (V.T.), University of California, Irvine, Irvine (L.H.), University of California, San Diego, La Jolla (D.A.S.), and Gilead Sciences, Foster City (A.O.) - all in California; University of Minnesota (S.K.) and University of Minnesota, School of Public Health and INSIGHT (J.D.N.), Minneapolis; University of Texas Health San Antonio, University Health System, and the South Texas Veterans Health Care System, San Antonio (T.F.P.), and Baylor College of Medicine, Houston (R.L.A.); Hospital Germans Trias i Pujol & irsiCaixa AIDS Research Institute, Badalona, Spain (R.P.); University of Pennsylvania, Philadelphia (W.R.S.); Medical School, National and Kapodistrian University of Athens, Athens (G.T.); National Center for Infectious Diseases-Tan Tock Seng Hospital-Lee Kong Chian School of Medicine-Yong Loo Lin School of Medicine, Singapore, Singapore (D.C.L.); the National Center for Global Health and Medicine Hospital, Tokyo (N.O.); Seoul National University Hospital, Seoul, South Korea (M.O.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (G.M.R.-P.); the Department of Infectious Diseases, Amager Hvidovre Hospital-University of Copenhagen, Hvidovre (T. Benfield), and Rigshospitalet, Department of Infectious Diseases (CHIP) and INSIGHT, Copenhagen (J.L.) - both in Denmark; University Hospital of Cologne, Cologne, Germany (G.F.); Vanderbilt University Medical Center, Nashville (C.B.C.); and University College London, MRC Clinical Trials Unit at UCL and INSIGHT, London (A.G.B., S.P.).'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2007764'] 1830,32628781,The systemic inflammatory response following hand instrumentation versus ultrasonic instrumentation-A randomized controlled trial.,"OBJECTIVE This study sought to investigate whether the immediate systemic inflammatory response following full-mouth debridement differs following use of hand compared with ultrasonic instruments. METHODS Thirty-nine periodontitis patients were randomized to treatment with full-mouth debridement using either hand or ultrasonic instrumentation completed within 24 hr. Serum and periodontal clinical parameters were collected at baseline, day 1, day 7 and day 90 post-treatment. Differences in systemic inflammatory markers were assessed using general linear models at each timepoint, corrected for age, gender, smoking status, body mass index and baseline levels of each marker. RESULTS Across all patients, serum C-reactive protein increased at day 1, with no differences between hand and ultrasonic groups (p(adjusted) = .22). There was no difference between groups in interleukin-6 (p(adjusted) = .29) or tumour necrosis factor α (p(adjusted) = .53) at day 1. Inflammatory markers returned to baseline levels by day 7. Treatment resulted in equal and marked improvements in clinical parameters in both groups; however, total treatment time was on average shorter for ultrasonic instruments (p(adjusted) = .002). CONCLUSIONS Ultrasonic instrumentation resulted in shorter treatment time with comparable clinical outcomes. Levels of serum C-reactive protein at day 1 were similar following debridement with hand or ultrasonic instruments.",2020,There was no difference between groups in interleukin-6 (p(adjusted)=0.29) or tumour necrosis factor α,['Thirty-nine periodontitis patients'],['full-mouth debridement using either hand or ultrasonic instrumentation'],"['Serum and periodontal clinical parameters', 'Inflammatory markers', 'interleukin-6 (p(adjusted)=0.29) or tumour necrosis factor α', 'total treatment time', 'clinical parameters', 'serum C-reactive protein', 'Levels of serum C-reactive protein', 'Systemic Inflammatory Response', 'systemic inflammatory markers']","[{'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0031099', 'cui_str': 'Periodontitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0021632', 'cui_str': 'instrumentation'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]",39.0,0.23062,There was no difference between groups in interleukin-6 (p(adjusted)=0.29) or tumour necrosis factor α,"[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Johnston', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Paterson', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Krystyna', 'Initials': 'K', 'LastName': 'Piela', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Davison', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Annabel', 'Initials': 'A', 'LastName': 'Simpson', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Goulding', 'Affiliation': 'Global Clinical Affairs, Dentsply Sirona, York, PA, USA.'}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Ramage', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Sherriff', 'Affiliation': 'Community Oral Health, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Shauna', 'Initials': 'S', 'LastName': 'Culshaw', 'Affiliation': 'Oral Sciences, Glasgow Dental Hospital and School, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}]",Journal of clinical periodontology,['10.1111/jcpe.13342'] 1831,32631152,Intradetrusor OnabotulinumtoxinA Injections Ameliorate Autonomic Dysreflexia while Improving Lower Urinary Tract Function and Urinary Incontinence-Related Quality of Life in Individuals with Cervical and Upper Thoracic Spinal Cord Injury.,"Pilot data of our phase IV clinical trial (pre/post study design) highlighted a beneficial effect of intradetrusor onabotulinumtoxinA (200 IU) injections to reduce autonomic dysreflexia (AD) in individuals with chronic spinal cord injury (SCI) at T6 or above. After trial completion, we assessed whether our primary expectation (i.e., decrease of AD severity in 50% of participants during urodynamics [UDS]) was met. Secondary outcome measures were reduction of spontaneous AD in daily life as well as amelioration of AD-related and urinary incontinence-related quality of life (QoL). In addition, we conducted injury-level-dependent analysis-i.e., cervical and upper thoracic-to explore group-specific treatment efficacy. Post-treatment, AD severity decreased in 82% (28/34) of all participants during UDS and in 74% (25/34) in daily life assessed with 24-h ambulatory blood pressure monitoring. In addition, urinary incontinence-related QoL was improved, cystometric capacity was increased, and maximum detrusor pressure during storage was reduced (all p  < 0.001). Further, the treatment was well tolerated, with only minor complications (grade I [ n  = 7] and II [ n  = 7]) in accordance with the Clavien-Dindo classification recorded in 11 individuals (cervical n  = 9, upper thoracic n  = 2). Injury-level-dependent analysis revealed lower incidence (cervical n  = 15/23, upper thoracic n  = 6/11) and lesser severity (cervical p  = 0.009; upper thoracic p  = 0.06 [Pearson r  = -0.6, i.e., large effect size]) of AD during UDS. Further, reduced AD severity in daily life, improved urinary incontinence-related QoL, greater cystometric capacity, and lower maximum detrusor pressure during storage (all p  < 0.05) were found in both groups post-treatment. Intradetrusor onabotulinumtoxinA injections are an effective and safe second-line treatment option that ameliorates AD while improving lower urinary tract function and urinary incontinence-related QoL in individuals with cervical and upper thoracic SCI.",2020,"Additionally, urinary incontinence-related QoL was improved (all p<0.001), cystometric capacity was increased and maximum storage detrusor pressure (both p<0.001) was reduced.","['individuals with cervical and upper thoracic SCI', 'individuals with cervical and upper thoracic spinal cord injury', 'individuals with chronic spinal cord injury (SCI) at T6 or above']",['intradetrusor onabotulinumtoxinA (200 IU) injections'],"['AD severity', 'daily life assessed with 24-hour ambulatory blood pressure monitoring', 'autonomic dysreflexia (AD', 'cystometric capacity', 'reduced AD severity in daily life, improved urinary incontinence-related QoL, greater cystometric capacity, and lower maximum storage detrusor pressure', 'urinary tract function and urinary incontinence-related quality of life', 'urinary incontinence-related QoL', 'maximum storage detrusor pressure', 'spontaneous AD in daily life, amelioration of AD and urinary incontinence-related quality of life (QoL']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0228625', 'cui_str': 'Structure of upper thoracic spinal cord'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}]","[{'cui': 'C2719767', 'cui_str': 'OnabotulinumtoxinA'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0238015', 'cui_str': 'Autonomic dysreflexia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0429766', 'cui_str': 'Detrusor pressure'}, {'cui': 'C0042031', 'cui_str': 'Urinary tract function'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}]",,0.20053,"Additionally, urinary incontinence-related QoL was improved (all p<0.001), cystometric capacity was increased and maximum storage detrusor pressure (both p<0.001) was reduced.","[{'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Walter', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Stephanie L', 'Initials': 'SL', 'LastName': 'Kran', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Ramirez', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Rapoport', 'Affiliation': 'Department of Urologic Sciences, and Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Mark K', 'Initials': 'MK', 'LastName': 'Nigro', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Stothers', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Kavanagh', 'Affiliation': 'Department of Urologic Sciences, and Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Andrei V', 'Initials': 'AV', 'LastName': 'Krassioukov', 'Affiliation': 'International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.'}]",Journal of neurotrauma,['10.1089/neu.2020.7115'] 1832,32634551,Effects of resistance training on hepcidin levels and iron bioavailability in older individuals with end-stage renal disease: A randomized controlled trial.,"Anemia is an inherent complication of older individuals with end-stage renal disease (ESRD) that is associated with inflammation which in turn is an important factor in the activation of hepcidin that contributes to the decrease in serum iron. Athough resistance training (RT) seems to reduce inflammation in ESRD, its influence on hepcidin and iron availability in hemodialysis patients is unclear. Therefore, the aim of this study was to exemine the effects of RT in on inflammatory profile, hepcidin, and iron status in older individuals with ESRD. End-stage renal disease patients (N: 157, age: 66.8 ± 3.6; body mass: 73 ± 15 body mass index:27 ± 3), were assigned to control (CTL n: 76) and exercise groups (RT n: 81). RT consisted of 24 weeks/3 days per week of a moderate intensity. There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile. These novel findings show that RT is a potential coadjuvant to reduce iron deficiency by decreasing the levels of hepcidin and pro-inflammatory markers in older patients undergoing hemodialysis.",2020,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","['N: 157, age: 66.8\u202f±\u202f3.6; body mass: 73\u202f±\u202f15 body mass index:27\u202f±\u202f3', 'older individuals with ESRD', 'older individuals with end-stage renal disease', 'older individuals with end-stage renal disease (ESRD', 'older patients undergoing hemodialysis', 'hemodialysis patients', 'End-stage renal disease patients']","['Athough resistance training (RT', 'RT', 'resistance training']","['inflammatory profile, hepcidin, and iron status', 'hepcidin levels and iron bioavailability', 'hepcidin levels', 'bioavailability of iron']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517844', 'cui_str': '66.8'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}]",157.0,0.0490397,"There was an increase in the bioavailability of iron (ΔRT: 22.2; ΔCTL: -1 μg/dL, p < 0.0001), a decrease in hepcidin levels (ΔRT: -7.9; ΔCTL: 0.2 ng/mL, p < 0.0001),and an improvement of the inflammatory profile.","[{'ForeName': 'Sting Ray Gouveia', 'Initials': 'SRG', 'LastName': 'Moura', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Hugo Luca', 'Initials': 'HL', 'LastName': 'Corrêa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil. Electronic address: hugo.efucb@gmail.com.'}, {'ForeName': 'Rodrigo Vanerson Passos', 'Initials': 'RVP', 'LastName': 'Neves', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Cláudio Avelino Rodrigues', 'Initials': 'CAR', 'LastName': 'Santos', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Luiz Sinésio Silva', 'Initials': 'LSS', 'LastName': 'Neto', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Victor Lopes', 'Initials': 'VL', 'LastName': 'Silva', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Michel Kendy', 'Initials': 'MK', 'LastName': 'Souza', 'Affiliation': 'Federal University of Tocantins, Medicine Department, Tocantins, Brazil.'}, {'ForeName': 'Lysleine Alves', 'Initials': 'LA', 'LastName': 'Deus', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Andrea Lucena', 'Initials': 'AL', 'LastName': 'Reis', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Herbert Gustavo', 'Initials': 'HG', 'LastName': 'Simões', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Fabiani Lage Rodrigues', 'Initials': 'FLR', 'LastName': 'Beal', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Milton Rocha', 'Initials': 'MR', 'LastName': 'Moraes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Navalta', 'Affiliation': 'University of Nevada, Las Vegas, Department of Kinesiology and Nutrition Sciences, Las Vegas, NV, USA.'}, {'ForeName': 'Jonato', 'Initials': 'J', 'LastName': 'Prestes', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'André Bonadias', 'Initials': 'AB', 'LastName': 'Gadelha', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil; Federal Institute of Education, Science and Technology Goiano, Goiás, Brazil.'}, {'ForeName': 'Thiago Dos Santos', 'Initials': 'TDS', 'LastName': 'Rosa', 'Affiliation': 'Catholic University of Brasilia, Federal District, Brazil.'}]",Experimental gerontology,['10.1016/j.exger.2020.111017'] 1833,32636319,Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.,"PURPOSE The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes by baseline alpha-fetoprotein (AFP) and on-treatment AFP changes. PATIENTS AND METHODS Serum AFP was measured every 8 weeks by blinded, centralized testing. Outcomes were analyzed by baseline AFP bifurcated at 400 ng/mL and by on-treatment AFP response (≥20% decrease from baseline at Week 8). The optimal cutoff for change in AFP at Week 8 was evaluated using maximally selected rank statistics. RESULTS Median OS for cabozantinib versus placebo was 13.9 versus 10.3 months [HR, 0.81; 95% confidence interval (CI), 0.62-1.04] for patients with baseline AFP <400 ng/mL, and 8.5 versus 5.2 months (HR, 0.71; 95% CI, 0.54-0.94) for patients with baseline AFP ≥400 ng/mL. Week 8 AFP response rate was 50% for cabozantinib versus 13% for placebo. In the cabozantinib arm, median OS for patients with and without AFP response was 16.1 versus 9.1 months (HR, 0.61; 95% CI, 0.45-0.84). AFP response was independently associated with longer OS. The optimal cutoff for association with OS in the cabozantinib arm was ≤0% change in AFP at Week 8 [AFP control; HR 0.50 (95% CI, 0.35-0.71)]. HRs for PFS were consistent with those for OS. CONCLUSIONS Cabozantinib improved outcomes versus placebo across a range of baseline AFP levels. On-treatment AFP response and control rates were higher with cabozantinib than placebo, and were associated with longer OS and PFS with cabozantinib.",2020,ng/mL. Week 8 AFP response rate was 50% for cabozantinib versus 13% for placebo.,"['patients with previously treated, advanced hepatocellular carcinoma (HCC', '≥400', 'patients with advanced hepatocellular carcinoma']","['cabozantinib versus placebo', 'placebo']","['Median OS', 'median OS', 'AFP response rate', 'AFP response and control rates', 'AFP response', 'overall survival (OS) and progression-free survival (PFS', 'Serum alpha-fetoprotein levels and clinical outcome']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}]","[{'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0002210', 'cui_str': 'Alpha fetoprotein'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C1287375', 'cui_str': 'Serum alpha-fetoprotein level - finding'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.249652,ng/mL. Week 8 AFP response rate was 50% for cabozantinib versus 13% for placebo.,"[{'ForeName': 'Robin Kate', 'Initials': 'RK', 'LastName': 'Kelley', 'Affiliation': 'UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. katie.kelley@ucsf.edu.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Meyer', 'Affiliation': 'Royal Free Hospital and UCL Cancer Institute, London, United Kingdom.'}, {'ForeName': 'Lorenza', 'Initials': 'L', 'LastName': 'Rimassa', 'Affiliation': 'Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Merle', 'Affiliation': 'Groupement Hospitalier Lyon Nord, Lyon, France.'}, {'ForeName': 'Joong-Won', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'National Cancer Center, Goyang, Republic of Korea.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Yau', 'Affiliation': 'Queen Mary Hospital, Hong Kong, China.'}, {'ForeName': 'Stephen L', 'Initials': 'SL', 'LastName': 'Chan', 'Affiliation': 'The Chinese University of Hong Kong, Shatin, Hong Kong, China.'}, {'ForeName': 'Jean-Frederic', 'Initials': 'JF', 'LastName': 'Blanc', 'Affiliation': 'Hôpital Haut-Lévêque, CHU Bordeaux, Bordeaux, France.'}, {'ForeName': 'Vincent C', 'Initials': 'VC', 'LastName': 'Tam', 'Affiliation': 'Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Tran', 'Affiliation': ""Groupe Hospitalier L'Archet, Nice, France.""}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Dadduzio', 'Affiliation': 'Medical Oncology Unit 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Markby', 'Affiliation': 'Exelixis, Inc., Alameda, California.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Kaldate', 'Affiliation': 'Exelixis, Inc., Alameda, California.'}, {'ForeName': 'Ann-Lii', 'Initials': 'AL', 'LastName': 'Cheng', 'Affiliation': 'National Taiwan University Cancer Center, Taipei, Taiwan.'}, {'ForeName': 'Anthony B', 'Initials': 'AB', 'LastName': 'El-Khoueiry', 'Affiliation': 'USC Norris Comprehensive Cancer Center, Los Angeles, California.'}, {'ForeName': 'Ghassan K', 'Initials': 'GK', 'LastName': 'Abou-Alfa', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, New York.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-19-3884'] 1834,32639946,A validated survival nomogram for early-onset diffuse gastric cancer.,"This study aimed to establish and independently validate a prognostic nomogram for individual risk prediction in patients with early-onset diffuse gastric cancer (EODGC). Data for 794 patients with EODGC from the SEER database were randomly assigned to training (N=558) and internal validation (N=236) sets, and data for 82 patients from the Renmin Hospital of Wuhan University (RMHWHU) were used as an independent validation cohort. Our LASSO regression analyses of the training set yielded five clinicopathological features (race, AJCC stage, surgery for primary site, chemotherapy and tumor size), which were used to create a survival nomogram. Our survival nomogram achieved better predictive performance than the AJCC staging system, the current standard. Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values. Indeed, our nomogram, which estimates individualized survival probabilities for patients with EODGC, shows good predictive accuracy and calibration ability for both the SEER and RMHWHU cohorts. These results suggest that a survival nomogram may be better at predicting OS for EODGC patients than the AJCC staging system.",2020,"Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values.","['82 patients from the Renmin Hospital of Wuhan University (RMHWHU) were used as an independent validation cohort', '794 patients with EODGC from the SEER database', 'early-onset diffuse gastric cancer', 'patients with early-onset diffuse gastric cancer (EODGC']",[],"['survival probabilities', 'individualized survival probabilities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0242638', 'cui_str': 'Surveillance, Epidemiology, and End Results Program'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}]",[],"[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}]",794.0,0.0291444,"Additionally, the calibration curves of the prognostic nomogram revealed good agreement between the predicted survival probabilities and the ground truth values.","[{'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Liao', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Xufeng', 'Initials': 'X', 'LastName': 'Guo', 'Affiliation': 'Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Xiaohong', 'Initials': 'X', 'LastName': 'Lu', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}, {'ForeName': 'Weiguo', 'Initials': 'W', 'LastName': 'Dong', 'Affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430061, Hubei Province, China.'}]",Aging,['10.18632/aging.103406'] 1835,32640940,Impact of Goal-Directed Therapy on Delayed Ischemia After Aneurysmal Subarachnoid Hemorrhage: Randomized Controlled Trial.,"BACKGROUND AND PURPOSE Delayed cerebral ischemia (DCI) is the most important cause for a poor clinical outcome after a subarachnoid hemorrhage. The aim of this study was to assess whether goal-directed hemodynamic therapy (GDHT), as compared to standard clinical care, reduces the rate of DCI after subarachnoid hemorrhage. METHODS We conducted a prospective randomized controlled trial. Patients >18 years of age with an aneurysmal subarachnoid hemorrhage were enrolled and randomly assigned to standard therapy or GDHT. Advanced hemodynamic monitoring and predefined GDHT algorithms were applied in the GDHT group. The primary end point was the occurrence of DCI. Functional outcome was assessed using the Glasgow Outcome Scale (GOS) 3 months after discharge. RESULTS In total, 108 patients were randomized to the control (n=54) or GDHT group (n=54). The primary outcome (DCI) occurred in 13% of the GDHT group and in 32% of the control group patients (odds ratio, 0.324 [95% CI, 0.11-0.86]; P =0.021). Even after adjustment for confounding parameters, GDHT was found to be superior to standard therapy (hazard ratio, 2.84 [95% CI, 1.18-6.86]; P =0.02). The GOS was assessed 3 months after discharge in 107 patients; it showed more patients with a low disability (GOS 5, minor or no deficits) than patients with higher deficits (GOS 1-4) in the GDHT group compared with the control group (GOS 5, 66% versus 44%; GOS 1-4, 34% versus 56%; P =0.025). There was no significant difference in mortality between the groups. CONCLUSIONS GDHT reduced the rate of DCI after subarachnoid hemorrhage with a better functional outcome (GOS=5) 3 months after discharge. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01832389.",2020,"Even after adjustment for confounding parameters, GDHT was found to be superior to standard therapy (hazard ratio, 2.84 [95% CI, 1.18-6.86]; P =0.02).","['108 patients', 'After Aneurysmal Subarachnoid Hemorrhage', 'Patients >18 years of age with an aneurysmal subarachnoid hemorrhage']","['standard therapy or GDHT', 'GDHT', 'goal-directed hemodynamic therapy (GDHT', 'Goal-Directed Therapy']","['rate of DCI after subarachnoid hemorrhage', 'GOS', 'Glasgow Outcome Scale (GOS', 'occurrence of DCI', 'mortality', 'Delayed Ischemia']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751530', 'cui_str': 'Subarachnoid Hemorrhage, Aneurysmal'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1271494', 'cui_str': 'Goal directed therapy'}]","[{'cui': 'C4761225', 'cui_str': 'Delayed cerebral ischaemia'}, {'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}, {'cui': 'C0701887', 'cui_str': 'Glasgow outcome scale'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}]",108.0,0.182296,"Even after adjustment for confounding parameters, GDHT was found to be superior to standard therapy (hazard ratio, 2.84 [95% CI, 1.18-6.86]; P =0.02).","[{'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Anetsberger', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Gempt', 'Affiliation': 'Department of Neurosurgery (J.G., F.R., B.M., Y.-M.R., M.W.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Manfred', 'Initials': 'M', 'LastName': 'Blobner', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Ringel', 'Affiliation': 'Department of Neurosurgery (J.G., F.R., B.M., Y.-M.R., M.W.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Bogdanski', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Heim', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Schneider', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Meyer', 'Affiliation': 'Department of Neurosurgery (J.G., F.R., B.M., Y.-M.R., M.W.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Schmid', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Yu-Mi', 'Initials': 'YM', 'LastName': 'Ryang', 'Affiliation': 'Department of Neurosurgery (J.G., F.R., B.M., Y.-M.R., M.W.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Wostrack', 'Affiliation': 'Department of Neurosurgery (J.G., F.R., B.M., Y.-M.R., M.W.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Martin', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Ehrhardt', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Jungwirth', 'Affiliation': 'Department of Anesthesiology (A.A., M.B., R.B., M.H., G.S., S.S., J.S., J.M., M.E., B.J.), Klinikum rechts der Isar, Technical University Munich, Germany.'}]",Stroke,['10.1161/STROKEAHA.120.029279'] 1836,32643454,Efficacy of intradermal minoxidil 5% injections for treatment of patchy non-severe alopecia areata.,"BACKGROUND Intradermal minoxidil is used as an off-label treatment for patchy non-severe alopecia areata (AA) either alone or in combination with steroids; however, studies estimating its efficacy are still lacking. OBJECTIVES To assess the efficacy of intradermal delivery of minoxidil 5% alone and in combination with intralesional triamcinolone acetonide for treatment of patchy non-severe AA. PATIENTS AND METHODS One hundred patches in twenty patients with patchy non-severe AA, five patches for each patient, were included in this prospective intra-patient comparative controlled clinical study. Four comparative patches per each patient were randomly assigned to receive 4 sessions, at a 4-week interval, of one of the following treatments: intralesional triamcinolone acetonide, intralesional minoxidil 5%, combination treatment, or micro-needling. The fifth patch was observed as the negative control. Treatment outcomes were assessed at baseline, and 1 month after treatment ends. RESULTS Minoxidil intradermal injection was nearly comparable to the micro-needling effect and its combination to steroids had no additive effect. Hair regrowth in response to minoxidil occurred earlier than the spontaneous recovery. CONCLUSION Monotherapy of intralesional minoxidil is of limited efficacy in treating non-severe patchy AA, but it speeds the recovery.",2020,Minoxidil intradermal injection was nearly comparable to the micro-needling effect and its combination to steroids had no additive effect.,"['patchy non-severe alopecia areata (AA', 'One hundred patches in twenty patients with patchy non-severe AA, five patches for each patient', 'patchy non-severe alopecia areata', 'patchy non-severe AA', 'Patients and Methods ']","['minoxidil', 'intralesional triamcinolone acetonide, intralesional minoxidil 5%, combination treatment, or micro-needling', 'Minoxidil intradermal injection', 'intralesional minoxidil', 'intradermal minoxidil', 'intralesional triamcinolone acetonide']",[],"[{'cui': 'C0205413', 'cui_str': 'Patchy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002170', 'cui_str': 'Alopecia'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0026196', 'cui_str': 'Minoxidil'}, {'cui': 'C1512955', 'cui_str': 'Intralesional route'}, {'cui': 'C0040866', 'cui_str': 'Triamcinolone acetonide'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0021489', 'cui_str': 'Intradermal injection'}, {'cui': 'C1522475', 'cui_str': 'Intradermal route'}]",[],20.0,0.0286038,Minoxidil intradermal injection was nearly comparable to the micro-needling effect and its combination to steroids had no additive effect.,"[{'ForeName': 'Mahmoud Abd El-Rahim', 'Initials': 'MAE', 'LastName': 'Abdallah', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Rasha', 'Initials': 'R', 'LastName': 'Shareef', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Marwa Y', 'Initials': 'MY', 'LastName': 'Soltan', 'Affiliation': 'Faculty of Medicine, Department of Dermatology and Venereology, Ain Shams University, Cairo, Egypt.'}]",The Journal of dermatological treatment,['10.1080/09546634.2020.1793893'] 1837,32648108,Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.,"INTRODUCTION This post hoc exploratory analysis examined the effects of ertugliflozin on liver enzymes in patients with type 2 diabetes mellitus (T2DM). METHODS Data were pooled from seven randomized, double-blind VERTIS phase 3 trials that evaluated ertugliflozin (5 mg and 15 mg) versus non-ertugliflozin (placebo, glimepiride, or sitagliptin) treatment in patients with T2DM. Change from baseline at week 52 of treatment in alanine and aspartate aminotransferase (ALT and AST, respectively) serum levels (overall and categorized into tertiles by baseline ALT and AST), Fibrosis-4 Index (FIB-4), glycated hemoglobin (HbA1c), and body weight were evaluated, along with the association between changes in ALT and AST and changes in HbA1c and body weight by treatment. RESULTS Baseline characteristics were balanced across treatment groups (ertugliflozin 5 mg, n = 1716; ertugliflozin 15 mg, n = 1693; non-ertugliflozin, n = 1450). At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group. The comparator-adjusted mean (95% confidence interval [CI]) difference in change from baseline at week 52 for ALT was - 3.35 (- 4.40, - 2.31) IU/L for ertugliflozin 5 mg and - 4.08 (- 5.13, - 3.03) IU/L for ertugliflozin 15 mg; for AST, the respective values were - 1.81 (- 2.50, - 1.11) IU/L and - 2.12 (- 2.82, - 1.42) IU/L. The effects of ertugliflozin were detected across all baseline ALT and AST tertiles, with the highest tertile showing the greatest treatment differences. No meaningful differences were observed between treatment groups for FIB-4. Changes in ALT and AST showed a weak but statistically significant association with changes in HbA1c and body weight in all treatment groups. CONCLUSIONS Treatment with ertugliflozin resulted in a reduction in the levels of hepatic transaminases compared with the non-ertugliflozin group after 52 weeks of treatment. Changes in body weight and HbA1c contributed at least in part to the effects of ertugliflozin on liver enzymes. TRIAL REGISTRATION Clinicaltrials.gov registry numbers: NCT02033889, NCT01958671, NCT02036515, NCT01986855, NCT02099110, NCT02226003, NCT01999218.",2020,"At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group.","['patients with T2DM', 'patients with type 2 diabetes mellitus (T2DM', 'Patients with Type 2 Diabetes']","['ertugliflozin', 'ertugliflozin (5 mg and 15\xa0mg) versus non-ertugliflozin (placebo, glimepiride, or sitagliptin', 'Ertugliflozin', 'IU/L']","['serum levels of ALT and AST', 'alanine and aspartate aminotransferase (ALT and AST, respectively) serum levels (overall and categorized into tertiles by baseline ALT and AST), Fibrosis-4 Index (FIB-4), glycated hemoglobin (HbA1c), and body weight', 'Liver Enzymes', 'levels of hepatic transaminases', 'liver enzymes', 'HbA1c and body weight', 'body weight and HbA1c']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}]","[{'cui': 'C4079805', 'cui_str': 'ertugliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0061323', 'cui_str': 'glimepiride'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0439457', 'cui_str': 'mIU/mL'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4304377', 'cui_str': 'Fibrosis-4 index'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferase'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.085715,"At week 52 of treatment, serum levels of ALT and AST were reduced in patients in the ertugliflozin treatment groups (5 and 15 mg, respectively) compared with those in the non-ertugliflozin group.","[{'ForeName': 'Silvina', 'Initials': 'S', 'LastName': 'Gallo', 'Affiliation': 'Pfizer Pharma GmbH, Berlin, Germany.'}, {'ForeName': 'Roberto A', 'Initials': 'RA', 'LastName': 'Calle', 'Affiliation': 'Pfizer Inc., Cambridge, MA, USA.'}, {'ForeName': 'Steven G', 'Initials': 'SG', 'LastName': 'Terra', 'Affiliation': 'Pfizer Inc., Andover, MA, USA.'}, {'ForeName': 'Annpey', 'Initials': 'A', 'LastName': 'Pong', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Tarasenko', 'Affiliation': 'Pfizer Inc., New York, NY, USA.'}, {'ForeName': 'Annaswamy', 'Initials': 'A', 'LastName': 'Raji', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA. annaswamy.raji@merck.com.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00867-1'] 1838,32666008,Effects of Dietary Carbohydrate Content on Circulating Metabolic Fuel Availability in the Postprandial State.,"Context According to the carbohydrate-insulin model of obesity, an elevated insulin-to-glucagon ratio in response to a high-carbohydrate diet directs metabolic fuels toward storage, resulting in lower circulating energy. Objective To determine differences in total circulating energy post-meal related to dietary carbohydrate. Design Ancillary study within the Framingham State Food Study. Setting University community. Participants 29 adults (aged 20 to 65 years) with overweight or obesity (body mass index ≥25 kg/m 2 ). Intervention After achieving 10% to 14% weight loss on a run-in diet, participants were randomized to weight-loss-maintenance test diets varying in carbohydrate content (high-carbohydrate, 60% of total energy, n = 11; moderate-carbohydrate, 40%, n = 8; low-carbohydrate, 20%, n = 10) and controlled for protein (20%). During 24-hour metabolic ward admissions between 10 and 15 weeks on the test diets, metabolic fuels and hormones were measured. Main Outcome Measure Energy availability (EA) based on energy content of blood glucose, beta-hydroxybutyrate, and free fatty acids, in the late postprandial period (180 to 300 minutes). Insulin at 30 minutes into the test meal (Meal Insulin-30) was measured as an effect modifier. Results Insulin-to-glucagon ratio was 7-fold higher in participants on the high- vs low-carbohydrate diet (2.5 and 0.36, respectively). Late postprandial EA was 0.58 kcal/L lower on the high- vs low-carbohydrate diet ( P < 0.0001), primarily related to suppression of free fatty acids. Early postprandial EA (30 to 180 minutes) declined fastest in the high-carbohydrate group, and Meal Insulin-30 modified this diet effect. Conclusions During weight-loss maintenance on a high-carbohydrate diet, late postprandial EA is reduced, consistent with the carbohydrate-insulin model.",2020,"Results Insulin-to-glucagon ratio was 7-fold higher in participants on the high- vs low-carbohydrate diet (2.5 and 0.36, respectively).","['Setting\n\n\nUniversity community', 'Participants\n\n\n29 adults (aged 20 to 65 years) with overweight or obesity (body mass index ≥25 kg/m 2 ']",['Dietary Carbohydrate Content'],"['Late postprandial EA', 'Results\n\n\nInsulin-to-glucagon ratio', 'Circulating Metabolic Fuel Availability', 'Energy availability (EA) based on energy content of blood glucose, beta-hydroxybutyrate, and free fatty acids, in the late postprandial period']","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0012170', 'cui_str': 'Carbohydrates, Dietary'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0556991', 'cui_str': 'Fuel'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0106006', 'cui_str': '3-hydroxybutyrate'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}]",29.0,0.0165793,"Results Insulin-to-glucagon ratio was 7-fold higher in participants on the high- vs low-carbohydrate diet (2.5 and 0.36, respectively).","[{'ForeName': 'Kim J', 'Initials': 'KJ', 'LastName': 'Shimy', 'Affiliation': ""New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Henry A', 'Initials': 'HA', 'LastName': 'Feldman', 'Affiliation': ""Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Gloria L', 'Initials': 'GL', 'LastName': 'Klein', 'Affiliation': ""New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Bielak', 'Affiliation': ""New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Cara B', 'Initials': 'CB', 'LastName': 'Ebbeling', 'Affiliation': ""New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, Massachusetts.""}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Ludwig', 'Affiliation': ""New Balance Foundation Obesity Prevention Center, Boston Children's Hospital, Boston, Massachusetts.""}]",Journal of the Endocrine Society,['10.1210/jendso/bvaa062'] 1839,32663638,"Better off at home? Effects of nursing home eligibility on costs, hospitalizations and survival.","Encouraging and helping elderly to postpone a nursing home admission appears to be a win-win that keeps long-term care spending in check and is in line with the target population's preferences, but there is little evidence about its effects. We study the causal impact of nursing home admission eligibility using Dutch administrative data and exploiting variation between randomly assigned assessors in their tendency to grant eligibility for a nursing home admission. We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected. This suggests that postponing an admission may not always be a win-win after all.",2020,"We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected.",[],[],"['costs, hospitalizations and survival']",[],[],"[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0493303,"We find a drop in medical care use when eligibility is granted, especially in hospital admissions, while total healthcare spending is unaffected.","[{'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Bakx', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands. Electronic address: bakx@eshpm.eur.nl.'}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Wouterse', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands.'}, {'ForeName': 'Eddy', 'Initials': 'E', 'LastName': 'van Doorslaer', 'Affiliation': 'Erasmus School of Health Policy and Management, the Netherlands; Network for Studies on Pensions, Ageing and Retirement, the Netherlands; Erasmus School of Economics, Erasmus University Rotterdam, the Netherlands; Tinbergen Institute, the Netherlands.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Network for Studies on Pensions, Ageing and Retirement, the Netherlands; RIVM National Institute for Public Health and the Environment, the Netherlands.'}]",Journal of health economics,['10.1016/j.jhealeco.2020.102354'] 1840,32663640,"A commentary on ""Effects of edaravone on postoperative cognitive function in elderly patients undergoing hip joint replacement surgery: A randomized controlled trial"" (Int J Surg 2020;80:13-18).",,2020,,['Elderly Patients undergoing Hip Joint Replacement Surgery'],['Edaravone'],['Postoperative Cognitive Function'],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019558', 'cui_str': 'Hip joint structure'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0070694', 'cui_str': 'edaravone'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",,0.104829,,"[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Woo', 'Affiliation': 'School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom. Electronic address: wootk@cardiff.ac.uk.'}, {'ForeName': 'Sashiananthan', 'Initials': 'S', 'LastName': 'Ganesananthan', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, United Kingdom.'}, {'ForeName': 'ChunHei', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Surgery and Cancer, Imperial College London, United Kingdom.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.001'] 1841,32663660,"Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.","BACKGROUND Current guidelines recommend anticoagulation therapy during primary percutaneous coronary intervention (pPCI) for ST-segment elevation myocardial infarction (STEMI). However, whether anticoagulation should be continued after pPCI has not been well investigated. METHODS/DESIGN The RIGHT trial is a prospective, multicenter, randomized, double-blind, placebo-controlled trial in STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure. Patients are randomized in a 1:1 fashion to receive either prolonged anticoagulant or matching placebo (no anticoagulation) for at least 48 hours after the procedure. When randomized to anticoagulation prolongation, the patient is assigned to intravenous unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin (same drug and same regimen at each center). The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days. The primary safety endpoint is major bleeding (BARC 3-5) at 30 days. Based on a superiority design and assuming a 35% relative risk reduction (from 7% to 4.5%), 2856 patients will be enrolled, accounting for a 5% drop-out rate (α = 0.05 and power = 80%). CONCLUSION The RIGHT trial tests the hypothesis that post-procedural anticoagulation is superior to no anticoagulation in reducing ischemic events in STEMI patients undergoing pPCI.",2020,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","['STEMI patients undergoing pPCI', 'STEMI patients treated with pPCI evaluating the prolongation of anticoagulation after the procedure', 'after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction']","['prolonged anticoagulant or matching placebo (no anticoagulation', 'unfractionated heparin (UFH) or subcutaneous enoxaparin or intravenous bivalirudin', 'anticoagulation prolongation versus no anticoagulation', 'placebo']","['composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel', 'major bleeding (BARC 3-5', 'ischemic events']","[{'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0206460', 'cui_str': 'Enoxaparin'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0168273', 'cui_str': 'bivalirudin'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0442758', 'cui_str': '3/5'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",2856.0,0.600901,"The primary efficacy endpoint is the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel) at 30 days.","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: eva3321@sina.com.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spaceeye123@126.com.'}, {'ForeName': 'Jincheng', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Beijing Luhe Hospital, Capital Medical University, Beijing, China. Electronic address: guojcmd@126.com.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'The Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: lyjbs2009@yeah.net.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Ai', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: aihui0814@126.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gong', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: tjmusky@126.com.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Que', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: quebin@sohu.com.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Zhen', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: 13439546840@yeah.net.'}, {'ForeName': 'Jiapeng', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: jiapeng.lu@fwoxford.org.'}, {'ForeName': 'Changsheng', 'Initials': 'C', 'LastName': 'Ma', 'Affiliation': 'Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Electronic address: chshma@vip.sina.com.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Montalescot', 'Affiliation': 'Sorbonne University, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.'}, {'ForeName': 'Shaoping', 'Initials': 'S', 'LastName': 'Nie', 'Affiliation': 'Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China. Electronic address: spnie@ccmu.edu.cn.'}]",American heart journal,['10.1016/j.ahj.2020.06.005'] 1842,32664094,Effect of phenylephrine infusion on hypotension induced by the beach chair position: A prospective randomized trial.,"BACKGROUND The beach chair position (BCP), used during shoulder surgery, is associated with hypotension, bradycardia, and risk of cerebral hypoperfusion. Phenylephrine is commonly used as a first treatment of choice of intraoperative hypotension during surgery. We evaluated the hemodynamic effects of 2 doses of intravenous phenylephrine infusion administered before being placed in BCP for arthroscopic shoulder surgery. The primary endpoint was the incidence of hypotension after positional change. METHODS Sixty-six patients were randomized to receive either intravenous normal saline (group NS) or intravenous phenylephrine infusion (0.5 μg/kg/min, group LP or 1.0 μg/kg/min, group HP) for 5 minutes before being placed in the BCP. Mean arterial pressure(MAP), heart rate, stroke volume variation, and cardiac index were measured before and after positional change. RESULTS The total incidence of hypotension after the BCP was 93.65%, but was not significantly different among the 3 groups. However, there was a significant difference in trends between the groups for MAP for 5 minutes after BCP (P = .028). Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). CONCLUSION Infusion of 0.5 and 1.0 μg/kg/min of phenylephrine for 5 minutes before the BCP has no preventive effect for incidence of hypotension. However, this study showed that 1.0 μg/kg/min of phenylephrine infusion for 5 minutes can attenuate the severity of hypotension.",2020,"Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). ","['Sixty-six patients', 'arthroscopic shoulder surgery']","['phenylephrine', 'phenylephrine infusion', 'intravenous normal saline', 'Phenylephrine', 'intravenous phenylephrine infusion']","['Mean arterial pressure(MAP), heart rate, stroke volume variation, and cardiac index', 'incidence of hypotension after positional change', 'total incidence of hypotension', 'hemodynamic effects', 'hypotension', 'severity of hypotension']","[{'cui': 'C4517841', 'cui_str': '66'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0186321', 'cui_str': 'Operative procedure on shoulder'}]","[{'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0232108', 'cui_str': 'Arterial pulse pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C4518814', 'cui_str': 'Stroke volume variation'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",66.0,0.324466,"Comparison of changes in MAP at 1 minute compared to post-induction MAP was significantly different between group HP and group NS (P = .014). ","[{'ForeName': 'Myoung Jin', 'Initials': 'MJ', 'LastName': 'Ko', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Hyojoong', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Hyun-Seong', 'Initials': 'HS', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Soo Jee', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Yei Heum', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}, {'ForeName': 'Jin-Young', 'Initials': 'JY', 'LastName': 'Bang', 'Affiliation': 'Department of Orthopedic Surgery, Haeundae Paik Hospital of Inje University, Busan, Republic of Korea.'}, {'ForeName': 'Ki Hwa', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Anesthesiology and Pain Medicine.'}]",Medicine,['10.1097/MD.0000000000020946'] 1843,32664101,Randomized trial protocol of interscalene nerve block vs liposomal bupivacaine injection after total shoulder arthroplasty.,"BACKGROUND The possibility of local infiltration analgesia (LIA) replacing interscalene blockade (ISB) as an integral component of a multimodal clinical pathway for total shoulder arthroplasty (TSA) needs to be further investigated. We thus further designed a randomized controlled study to compare LIA with ISB in the treatment of TSA. METHODS This blinded and randomised study was performed after approval of the institutional review board in the first affiliated hospital of Jinan University. The included patients were all aged over 18 years and underwent shoulder arthroplasty because of osteoarthritis of the shoulder. Subjects were randomized into 2 groups as follows: LIA or ISB. The primary outcome of this noninferiority study is opioid consumption within the first 24 hours following surgery. Secondary outcomes included pain scores, length of hospital stay, complication, and satisfaction score. P value < .05 was considered statistically significant. RESULTS For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. TRIAL REGISTRATION This study protocol was registered in Research Registry (researchregistry5640).",2020,"For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. ","['total shoulder arthroplasty (TSA', 'The included patients were all aged over 18 years and underwent shoulder arthroplasty because of osteoarthritis of the shoulder', 'institutional review board in the first affiliated hospital of Jinan University', 'total shoulder arthroplasty']","['local infiltration analgesia (LIA) replacing interscalene blockade (ISB', 'LIA with ISB', 'LIA or ISB', 'interscalene nerve block vs liposomal bupivacaine injection']","['opioid consumption within the first 24\u200ahours following surgery', 'pain scores, length of hospital stay, complication, and satisfaction score', 'pain score levels']","[{'cui': 'C0186657', 'cui_str': 'Total shoulder replacement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0186662', 'cui_str': 'Arthroplasty of shoulder'}, {'cui': 'C0409939', 'cui_str': 'Osteoarthritis of glenohumeral joint'}, {'cui': 'C0086911', 'cui_str': 'Ethics Committee, Research'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0589495', 'cui_str': 'Interscalene approach'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0027741', 'cui_str': 'Nerve block'}, {'cui': 'C0023828', 'cui_str': 'Liposomes'}, {'cui': 'C4060211', 'cui_str': 'Bupivacaine Injection [Sensorcaine]'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.275289,"For the present trial, we hypothesized that there would be no difference in pain score levels and opioid medication use throughout admission. ","[{'ForeName': 'Jianbin', 'Initials': 'J', 'LastName': 'He', 'Affiliation': ""Department of Anesthesiology, The Second Clinical Medical College, Jinan University/Shenzhen People's Hospital.""}, {'ForeName': 'Yalan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, The first affiliated hospital of Jinan University, Guangdong Province, China.'}]",Medicine,['10.1097/MD.0000000000020968'] 1844,32664105,Feasibility of customizing titanium implant with three-dimensional CT imaging of low dose in skull.,"OBJECT To explore the feasibility and practicability of making virtual three-dimensional model of skull defect and customizing titanium implant by skull three-dimensional CT examination of low dose. METHODS Sixty patients with skull defects who underwent skull three-dimensional CT before cranioplasty were randomly divided into 4 groups: group A (conventional dose 120 peak Kilovoltage (kVp), 150 tube current time product (mAs)), low dose group B (120 kVp, 50 mAs), low dose group C (100 kVp, 50 mAs), low dose group D (100 kVp, 30 mAs). After the scanning, we compared radiation doses and image quality among the groups. The CT data were sent to the reconstruction company to produce accurate titanium implants, and neurosurgeons performed cranioplasty. After the operation, patients immediately underwent head CT scans to confirm the accuracy of the implantation position, and a series of clinical functions were evaluated. RESULTS There were significant differences in dose length product (DLP) and effective dose (ED) among the 4 groups (P < .001). The volume CT dose index (CDTIvol), DLP, and ED in group D were, respectively, 87.1%, 86.9%, and 87.3% lower than those in group A (P < .001). All images quality were at or above the general level, and there was no statistical difference (P > .05). Titanium implants were successfully manufactured, every cranioplasty was carried out smoothly, and the clinical function of patients recovered well. CONCLUSION Customizing titanium implant with three-dimensional CT imaging of low dose in skull not only met the clinical requirements, but also significantly reduced the radiation dose and hazard.",2020,"All images quality were at or above the general level, and there was no statistical difference (P > .05).",['Sixty patients with skull defects who underwent skull three-dimensional CT before cranioplasty'],"['customizing titanium implant', 'group A (conventional dose 120 peak Kilovoltage (kVp), 150 tube current time product (mAs', 'head CT scans']","['volume CT dose index (CDTIvol), DLP, and ED', 'dose length product (DLP) and effective dose (ED']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0196112', 'cui_str': 'Cranioplasty'}]","[{'cui': 'C0040302', 'cui_str': 'Titanium'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0025048', 'cui_str': 'Meconium aspiration syndrome'}, {'cui': 'C0202691', 'cui_str': 'CT of head'}]","[{'cui': 'C1956110', 'cui_str': 'Cone beam CT'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",60.0,0.0148684,"All images quality were at or above the general level, and there was no statistical difference (P > .05).","[{'ForeName': 'Min-Xia', 'Initials': 'MX', 'LastName': 'Yang', 'Affiliation': ""Department of Radiology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang Province, China.""}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Ya-Ping', 'Initials': 'YP', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Zhen-Hua', 'Initials': 'ZH', 'LastName': 'Zhao', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000021009'] 1845,32669708,The National Lung Matrix Trial of personalized therapy in lung cancer.,"The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke 1-3 . As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents. Here we report the current outcomes of 19 drug-biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC. We use next-generation sequencing to match patients to appropriate targeted therapies on the basis of their tumour genotype. The Bayesian trial design enables outcome data from open cohorts that are still recruiting to be reported alongside data from closed cohorts. Of the 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 that re-registered to the trial for a sequential trial drug. Despite pre-clinical data supporting the drug-biomarker combinations, current evidence shows that a limited number of combinations demonstrate clinically relevant benefits, which remain concentrated in patients with lung cancers that are associated with minimal exposure to tobacco smoke.",2020,Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents.,"['lung cancer', '19 drug-biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC', 'patients with light exposure to tobacco smoke 1-3 ', 'patients with lung cancers', '5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 that re-registered\xa0to the trial for a sequential trial drug']",['personalized therapy'],[],"[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C4761125', 'cui_str': 'Exposure to tobacco'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],5467.0,0.0938514,Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents.,"[{'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Middleton', 'Affiliation': 'Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK. g.middleton@bham.ac.uk.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fletcher', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Popat', 'Affiliation': 'The Royal Marsden Hospital, London, UK.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Savage', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Summers', 'Affiliation': 'The Christie, Manchester, UK.'}, {'ForeName': 'Alastair', 'Initials': 'A', 'LastName': 'Greystoke', 'Affiliation': 'Newcastle University, Newcastle, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Gilligan', 'Affiliation': ""Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Cave', 'Affiliation': 'Southampton University Hospitals NHS Trust, Southampton, UK.'}, {'ForeName': 'Noelle', 'Initials': 'N', 'LastName': ""O'Rourke"", 'Affiliation': 'Beatson West of Scotland Cancer Centre, Glasgow, UK.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Brewster', 'Affiliation': 'Velindre Cancer Centre, Cardiff, UK.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Toy', 'Affiliation': 'Royal Devon and Exeter Foundation NHS Trust, Exeter, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Spicer', 'Affiliation': ""King's College London, Guy's Hospital, London, UK.""}, {'ForeName': 'Pooja', 'Initials': 'P', 'LastName': 'Jain', 'Affiliation': ""St James's University Hospital, Leeds, UK.""}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Dangoor', 'Affiliation': 'Bristol Haematology and Oncology Centre, Bristol, UK.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Mackean', 'Affiliation': 'Western General Hospital, Edinburgh, UK.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Forster', 'Affiliation': 'University College Hospital, London, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Farley', 'Affiliation': 'Institute of Applied Health Research, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Dee', 'Initials': 'D', 'LastName': 'Wherton', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Manita', 'Initials': 'M', 'LastName': 'Mehmi', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Rowena', 'Initials': 'R', 'LastName': 'Sharpe', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Tara C', 'Initials': 'TC', 'LastName': 'Mills', 'Affiliation': 'Cancer Research UK, London, UK.'}, {'ForeName': 'Maria Antonietta', 'Initials': 'MA', 'LastName': 'Cerone', 'Affiliation': 'Cancer Research UK, London, UK.'}, {'ForeName': 'Timothy A', 'Initials': 'TA', 'LastName': 'Yap', 'Affiliation': 'The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Thomas B K', 'Initials': 'TBK', 'LastName': 'Watkins', 'Affiliation': 'The Francis Crick Institute, London, UK.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Lim', 'Affiliation': 'The Francis Crick Institute, London, UK.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Swanton', 'Affiliation': 'The Francis Crick Institute, London, UK.'}, {'ForeName': 'Lucinda', 'Initials': 'L', 'LastName': 'Billingham', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.'}]",Nature,['10.1038/s41586-020-2481-8'] 1846,32649063,Efficacy of home-use light-emitting diode device at 637 and 854-nm for facial rejuvenation: A split-face pilot study.,"BACKGROUND The use of light-emitting diode (LED) in combination wavelength for facial rejuvenation has been previously reported. Nowadays, there has been a growing market for home-use cosmetic devices because of its low cost and convenience. AIMS To evaluate the efficacy and safety of home-use LED device on facial rejuvenation. METHODS This was a prospective split-face clinical trial with a total of 24 subjects, who presented with photo aging skin. All subjects were treated with the home-use LED device on the left side of their face, twice a week for 8 weeks. Primary outcomes measured in the study were the changes in the biophysical properties of the skin assessed with the following parameters: skin elasticity, skin hydration, texture, and wrinkles. Evaluations were done at baseline, 2-, 4-, 6-, and 8-week follow-up. Subjects' self-improvement scores and adverse reactions were also recorded. RESULTS All 24 subjects completed the study and attended all follow-up. Skin elasticity was significantly higher in the LED group compared to the control during the 6- and 8-week follow-up (P < .05). In the LED group, an image of the treated skin captured using Visioscan ® showed improvement of the skin texture at 8-week follow-up. Majority of the subjects in the LED group scored good improvement on all follow-ups (37.5%, 41.7%, 58.3%, and 62.5%) when compared to the baseline. No adverse reactions or pain were recorded in the study. CONCLUSION The home-use LED device, with a combination wavelength of 637 and 854 nm, is safe and can be used as an adjunctive treatment for self-administered facial rejuvenation.",2020,"In the LED group, an image of the treated skin captured using Visioscan® showed improvement of the skin texture at 8-week follow-up.","['24 subjects, who presented with photo aging skin', 'All 24 subjects completed the study and attended all follow-up']","['home-use LED device', 'Home-Use Light-Emitting Diode Device', 'light-emitting diode (LED']","[""Subjects' self-improvement scores and adverse reactions"", 'Skin elasticity', 'biophysical properties of the skin assessed with the following parameters: skin elasticity, skin hydration, texture and wrinkles', 'efficacy and safety', 'adverse reactions or pain', 'skin texture']","[{'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037271', 'cui_str': 'Skin aging'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0423761', 'cui_str': 'Skin elasticity'}, {'cui': 'C0005553', 'cui_str': 'Biophysics'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0449582', 'cui_str': 'With texture'}, {'cui': 'C0037301', 'cui_str': 'Wrinkled skin'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0423752', 'cui_str': 'Finding of skin texture'}]",24.0,0.0396583,"In the LED group, an image of the treated skin captured using Visioscan® showed improvement of the skin texture at 8-week follow-up.","[{'ForeName': 'Janice Natasha C', 'Initials': 'JNC', 'LastName': 'Ng', 'Affiliation': 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Rungsima', 'Initials': 'R', 'LastName': 'Wanitphakdeedecha', 'Affiliation': 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chadakan', 'Initials': 'C', 'LastName': 'Yan', 'Affiliation': 'Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13613'] 1847,32645251,"Topical odorant application of the specific olfactory receptor OR2AT4 agonist, Sandalore ® , improves telogen effluvium-associated parameters.","BACKGROUND Human hair follicles (HFs) express the olfactory receptor (OR)2AT4, which is selectively stimulated by the synthetic sandalwood-like odorant, Sandalore ® . In organ-cultured, human scalp HFs, Sandalore ® prolongs anagen and suppresses apoptosis by up-regulating intrafollicular IGF-1 mediated signaling. AIMS The objective of this study is to demonstrate whether effects of Sandalore ® observed ex vivo translate into a clinically relevant effect in patients with telogen effluvium. PATIENTS/METHODS In a randomized, double-blinded, placebo-controlled, clinical trial, 60 female volunteers (18-65 years) affected by telogen effluvium received over a period of 24 weeks treatment with either 1% Sandalore ® solution (n = 30) or placebo (identically smelling, but non-OR2AT4 activating sandalwood oil n = 30). The study read-out parameters were the degree of hair shedding, hair volume, terminal/vellus hair ratio, anagen/catagen-telogen ratio, and patient self-assessment. RESULTS Sandalore ® 1% ameliorated clinical signs of telogen effluvium, namely it reduced hair shedding, and increased hair volume and the percentage of anagen HFs, the latter two parameters significantly more than placebo when changes were calculated to baseline. Sandalore ® also increased the ratio of terminal/vellus hairs at week 8. Most of the anti-hair shedding effects were seen after 8 weeks and maintained at week 24. Patient questionnaire showed that verum group patients were more satisfied than the placebo group in regard to the overall results. CONCLUSION This clinical trial supports previous findings of anagen-prolonging effects of Sandalore ® ex vivo with similar results now reproduced in clinical practice. It also provides proof-of-principle that a topically applied cosmetic odorant acting through HF olfactory receptors can be a therapeutic alternative to treat hair loss disorders characterized by excessive hair shedding such as telogen effluvium.",2020,"RESULTS Sandalore ® 1% ameliorated clinical signs of telogen effluvium, namely it reduced hair shedding, and increased hair volume and the percentage of anagen HFs, the latter two parameters significantly more than placebo, when changes were calculated to baseline.","['patients with telogen effluvium', '60 female volunteers (18-65 years) affected by telogen effluvium received over a period of 24 weeks treatment with either']","['1% Sandalore ® solution', 'placebo']","['hair volume and the percentage of anagen HFs', 'degree of hair shedding, hair volume, terminal/vellus hair ratio, anagen/catagen-telogen ratio, and patient self-assessment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0263518', 'cui_str': 'Telogen effluvium'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C4742605', 'cui_str': 'Sandalore'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0221976', 'cui_str': 'Anagen hair'}, {'cui': 'C0018120', 'cui_str': 'Ovarian follicle structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0221959', 'cui_str': 'Structure of vellus hair'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}]",60.0,0.203102,"RESULTS Sandalore ® 1% ameliorated clinical signs of telogen effluvium, namely it reduced hair shedding, and increased hair volume and the percentage of anagen HFs, the latter two parameters significantly more than placebo, when changes were calculated to baseline.","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Jimenez', 'Affiliation': 'Mediteknia Clinic and Monasterium Clinical Hair Trial Unit, Gran Canaria, Spain.'}, {'ForeName': 'Esmeralda', 'Initials': 'E', 'LastName': 'López', 'Affiliation': 'Mediteknia Clinic and Monasterium Clinical Hair Trial Unit, Gran Canaria, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Bertolini', 'Affiliation': 'Monasterium Laboratory, Skin and Hair Research Solutions GmbH, Muenster, Germany.'}, {'ForeName': 'Majid', 'Initials': 'M', 'LastName': 'Alam', 'Affiliation': 'Universidad Fernando Pessoa Canarias, Gran Canaria, Spain.'}, {'ForeName': 'Jérémy', 'Initials': 'J', 'LastName': 'Chéret', 'Affiliation': 'Monasterium Laboratory, Skin and Hair Research Solutions GmbH, Muenster, Germany.'}, {'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Westgate', 'Affiliation': 'Gill Westgate Consultancy Ltd, Stevington, UK.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Rinaldi', 'Affiliation': 'Giuliani Pharma S.p.A, Milan, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Marzani', 'Affiliation': 'Giuliani Pharma S.p.A, Milan, Italy.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Paus', 'Affiliation': 'Monasterium Laboratory, Skin and Hair Research Solutions GmbH, Muenster, Germany.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13608'] 1848,32649493,Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: A Randomized Controlled Trial.,"OBJECTIVE To evaluate whether a short course of tamoxifen decreases bothersome bleeding in etonogestrel contraceptive implant users. METHODS In a 90-day, double-blind randomized control trial, we enrolled etonogestrel implant users with frequent or prolonged bleeding or spotting. A sample size of 40 per group (N=80) was planned to compare 10 mg tamoxifen or placebo twice daily for 7 days after 3 consecutive days of bleeding or spotting no more than once per 30 days (maximum three treatments). Participants then entered a 90-day open-label study where all received tamoxifen if needed every 30 days (maximum three treatments). Participants used text messages to record daily bleeding patterns. Our primary outcome was the total number of consecutive amenorrhea days after the first treatment. Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. RESULTS From January 2017 to November 2018, 112 women enrolled in the study; 88 (79%) completed 90 days, and 79 (71%) completed 180 days. Participant characteristics did not differ between groups; mean age 24, majority identified as white not Hispanic with at least some college education. After the first treatment, the tamoxifen group reported an average of 9.8 (95% CI 4.6-15.0) more consecutive days of amenorrhea and more total days of no bleeding (amenorrhea or spotting) in the first 90 days (median 73.5 [range 24-89] vs 68 [range 11-81], P=.001). The placebo group showed a similar treatment benefit after first active use of tamoxifen in the open-label phase. At the end of the randomized study (first 90 days), women who received tamoxifen reported higher satisfaction (median 62 mm [range 16-100]) than those treated with placebo (46 mm [range 0-100]; P=.023). CONCLUSION A short course of tamoxifen reduces problematic bleeding and improves satisfaction in users of etonogestrel implants. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02903121.",2020,"Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. ","['From January 2017 to November 2018, 112 women enrolled in the study; 88 (79%) completed 90 days, and 79 (71%) completed 180 days', 'enrolled etonogestrel implant users with frequent or prolonged bleeding or spotting', 'users of etonogestrel implants', 'etonogestrel contraceptive implant users', 'Contraceptive Implant Users']","['placebo', 'tamoxifen', 'tamoxifen or placebo']","['total number of consecutive amenorrhea days', 'consecutive days of amenorrhea and more total days of no bleeding (amenorrhea or spotting', 'time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction', 'bothersome bleeding', 'higher satisfaction']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C1306383', 'cui_str': 'Etonogestrel Drug Implant'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0047683', 'cui_str': 'Etonogestrel'}, {'cui': 'C1657106', 'cui_str': 'Contraceptive implant'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039286', 'cui_str': 'Tamoxifen'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002453', 'cui_str': 'Amenorrhea'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0205250', 'cui_str': 'High'}]",112.0,0.624149,"Secondary outcomes included time to bleeding or spotting cessation and restart after first treatment, overall bleeding patterns, and satisfaction. ","[{'ForeName': 'Alison B', 'Initials': 'AB', 'LastName': 'Edelman', 'Affiliation': 'Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon; the Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, Hawaii; and the Department of Obstetrics & Gynecology, the Permanente Medical Group, San Leandro, California.'}, {'ForeName': 'Bliss', 'Initials': 'B', 'LastName': 'Kaneshiro', 'Affiliation': ''}, {'ForeName': 'Katharine B', 'Initials': 'KB', 'LastName': 'Simmons', 'Affiliation': ''}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Hauschildt', 'Affiliation': ''}, {'ForeName': 'Kise', 'Initials': 'K', 'LastName': 'Bond', 'Affiliation': ''}, {'ForeName': 'Emily R', 'Initials': 'ER', 'LastName': 'Boniface', 'Affiliation': ''}, {'ForeName': 'Jeffrey T', 'Initials': 'JT', 'LastName': 'Jensen', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003896'] 1849,32649494,Permanent Compared With Absorbable Suture for Vaginal Mesh Fixation During Total Hysterectomy and Sacrocolpopexy: A Randomized Controlled Trial.,"OBJECTIVE To compare mesh and permanent suture exposure rates in the first year after minimally invasive total hysterectomy and sacrocolpopexy with a light-weight polypropylene mesh using permanent or delayed absorbable sutures. METHODS Across five centers in the United States, women were randomized to permanent or delayed absorbable suture for vaginal attachment of a Y-mesh during hysterectomy and sacrocolpopexy for stage II prolapse and worse. The primary outcome was mesh or permanent suture exposure in the first year after surgery. The secondary outcome was to compare a composite measure for success defined as leading edge of prolapse not beyond the hymen and apex not descended more than one third vaginal length, and no subjective bulge and no prolapse retreatment. Patients completed a pelvic examination including the pelvic organ prolapse quantification system and questionnaires at baseline, 6 weeks and 1 year postsurgery. A sample size of 80 per group was planned to compare the rate of mesh or permanent suture exposure in the permanent compared with delayed absorbable groups. RESULTS From April 2015 to May 2019, 204 patients (n=102 permanent; n=102 delayed absorbable) were randomized. One hundred ninety-eight women had follow-up data, with 182 (93%) completing 1-year follow-up: 95 of 99 (96%) permanent, 87 of 101 (86%) delayed absorbable. The total rate of mesh or permanent suture exposure was 12 of 198 (6.1%): 5.1% for permanent compared with 7.0% for delayed absorbable (risk ratio 0.73, 95% CI 0.24-2.22). The majority (9/12) were asymptomatic. Composite success was 93% for permanent compared with 95% for delayed absorbable suture, P=.43). Six (3.0%) women had a serious adverse event. CONCLUSION Suture type used for vaginal graft attachment did not influence mesh or permanent suture exposure rates. FUNDING SOURCE Boston Scientific Corporation. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02277925.",2020,"Composite success was 93% for permanent compared with 95% for delayed absorbable suture, P=.43).","['From April 2015 to May 2019, 204 patients (n=102 permanent; n=102 delayed absorbable', 'One hundred ninety-eight women had follow-up data, with 182 (93%) completing 1-year follow-up: 95 of 99 (96%) permanent, 87 of 101 (86%) delayed absorbable']","['sacrocolpopexy with a light-weight polypropylene mesh', 'Absorbable Suture for Vaginal Mesh Fixation', 'delayed absorbable groups', 'permanent or delayed absorbable suture for vaginal attachment of a Y-mesh during hysterectomy and sacrocolpopexy', 'Total Hysterectomy and Sacrocolpopexy']","['rate of mesh or permanent suture exposure', 'Composite success', 'composite measure for success defined as leading edge of prolapse not beyond the hymen and apex not descended more than one third vaginal length, and no subjective bulge and no prolapse retreatment', 'serious adverse event', 'mesh or permanent suture exposure in the first year after surgery', 'total rate of mesh or permanent suture exposure']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319627', 'cui_str': '98'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0554325', 'cui_str': 'Sacrocolpopexy'}, {'cui': 'C0332264', 'cui_str': 'Light (weight)'}, {'cui': 'C1321585', 'cui_str': 'Polypropylene mesh'}, {'cui': 'C0461643', 'cui_str': 'Absorbable suture'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0677962', 'cui_str': 'Total hysterectomy'}]","[{'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}, {'cui': 'C0205386', 'cui_str': 'Descending'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0376495', 'cui_str': 'Retreatments'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",198.0,0.368163,"Composite success was 93% for permanent compared with 95% for delayed absorbable suture, P=.43).","[{'ForeName': 'Catherine A', 'Initials': 'CA', 'LastName': 'Matthews', 'Affiliation': 'Department of Urology, Wake Forest Baptist Health, Winston Salem, and the Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Augusta University, Augusta, Georgia; Northwestern Feinberg School of Medicine, Chicago, Illinois; and Atrium Health, Charlotte, North Carolina.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': 'Geller', 'Affiliation': ''}, {'ForeName': 'Barbara R', 'Initials': 'BR', 'LastName': 'Henley', 'Affiliation': ''}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Kenton', 'Affiliation': ''}, {'ForeName': 'Erinn M', 'Initials': 'EM', 'LastName': 'Myers', 'Affiliation': ''}, {'ForeName': 'Alexis A', 'Initials': 'AA', 'LastName': 'Dieter', 'Affiliation': ''}, {'ForeName': 'Brent', 'Initials': 'B', 'LastName': 'Parnell', 'Affiliation': ''}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Lewicky-Gaupp', 'Affiliation': ''}, {'ForeName': 'Margaret G', 'Initials': 'MG', 'LastName': 'Mueller', 'Affiliation': ''}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Wu', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003884'] 1850,32649498,Candy Cane Compared With Boot Stirrups in Vaginal Surgery: A Randomized Controlled Trial.,"OBJECTIVE To evaluate differences in physical function at 6 weeks after vaginal surgery among women positioned in candy cane and boot stirrups. METHODS We conducted a single-masked, randomized controlled trial of women undergoing vaginal surgery with either candy cane or boot stirrup use. The primary outcome was a change in the PROMIS (Patient-Reported Outcomes Measurement Information System) physical function short form-20a from baseline to 6 weeks after surgery. To achieve 80% power to detect a moderate Cohen effect (d=0.5), we required 64 participants in each group. RESULTS From March 2018 to October 2019, 141 women were randomized, and 138 women (72 in the candy cane group and 66 in the boot stirrup group) were included in the final analysis. There were no baseline differences in participant characteristics including age, body mass index, comorbidities, or preoperative history of joint replacements. There were no between-group differences in surgery type, duration of surgery, estimated blood loss, or adverse events at 6 weeks postoperation. Participants in the candy cane group demonstrated worse physical function at 6 weeks compares with the improvement seen in those in the boot stirrup group; this was significantly different between groups (-1.9±7.9 candy cane vs 1.9±7.0 boot, P<.01). CONCLUSION Women undergoing vaginal surgery positioned in boot stirrups have significantly better physical function at 6 weeks after surgery when compared with women positioned in candy cane stirrups. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT03446950.",2020,"There were no between-group differences in surgery type, duration of surgery, estimated blood loss, or adverse events at 6 weeks postoperation.","['women positioned in candy cane and boot stirrups', '64 participants in each group', 'From March 2018 to October 2019, 141 women were randomized, and 138 women (72 in the candy cane group and 66 in the boot stirrup group) were included in the final analysis', 'Women undergoing', 'Vaginal Surgery', 'women undergoing vaginal surgery with either']","['vaginal surgery positioned in boot stirrups', 'candy cane', 'Candy Cane', 'candy cane or boot stirrup use']","['surgery type, duration of surgery, estimated blood loss, or adverse events', 'worse physical function', 'physical function', 'change in the PROMIS (Patient-Reported Outcomes Measurement Information System) physical function short form-20a']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0006855', 'cui_str': 'Candy'}, {'cui': 'C0006856', 'cui_str': 'Cane'}, {'cui': 'C0331794', 'cui_str': 'Boots'}, {'cui': 'C0038152', 'cui_str': 'Stapes structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0195117', 'cui_str': 'Operation on vagina'}]","[{'cui': 'C0195117', 'cui_str': 'Operation on vagina'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0331794', 'cui_str': 'Boots'}, {'cui': 'C0038152', 'cui_str': 'Stapes structure'}, {'cui': 'C0006855', 'cui_str': 'Candy'}, {'cui': 'C0006856', 'cui_str': 'Cane'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]",141.0,0.329057,"There were no between-group differences in surgery type, duration of surgery, estimated blood loss, or adverse events at 6 weeks postoperation.","[{'ForeName': 'Ankita', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics & Gynecology, and the Department of Obstetrics & Gynecology, University of Louisville School of Medicine, and the Department of Bioinformatics & Biostatistics, School of Public Health and Information Sciences, University of Louisville, Louisville, Kentucky; the Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, University of New Mexico, Albuquerque, New Mexico; and the Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, Michigan.'}, {'ForeName': 'Kate', 'Initials': 'K', 'LastName': 'Meriwether', 'Affiliation': ''}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Tuller', 'Affiliation': ''}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sekula', 'Affiliation': ''}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Gaskins', 'Affiliation': ''}, {'ForeName': 'J Ryan', 'Initials': 'JR', 'LastName': 'Stewart', 'Affiliation': ''}, {'ForeName': 'Deslyn', 'Initials': 'D', 'LastName': 'Hobson', 'Affiliation': ''}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Cardenas-Trowers', 'Affiliation': ''}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Francis', 'Affiliation': ''}]",Obstetrics and gynecology,['10.1097/AOG.0000000000003954'] 1851,32652133,Smartphone-based financial incentives to promote smoking cessation during pregnancy: A pilot study.,"Cigarette smoking during pregnancy increases risk for pregnancy complications, growth restriction, and other adverse health outcomes. The most effective intervention for reducing smoking during pregnancy is financial incentives contingent on biochemically-verified smoking abstinence. The present study examined the efficacy of a smartphone-based intervention whereby smoking monitoring and incentive delivery occurred remotely using a mobile app. If efficacious, this remote intervention would allow pregnant women residing in geographically remote areas to benefit from incentives-based cessation interventions. Sixty U.S. pregnant smokers were recruited between May 2018 to May 2019 via obstetrical clinics, Women, Infants, and Children (WIC) offices, and Facebook. Participants were assigned sequentially to one of two treatments: best practices alone (N = 30) or best practices plus financial incentives (N = 30). Outcomes were analyzed using repeated measures analysis based on generalized estimating equations (GEE). Seven-day point prevalence abstinence rates were greater in the incentives versus best practices arms early- (46.7% vs 20.0%, OR = 3.50, 95%CI = 1.11,11.02) and late-antepartum (36.7% vs 13.3%, OR = 3.76, 95%CI = 1.04,13.65), and four- (36.7% vs 10.0%, OR = 5.21, 95%CI = 1.28,21.24) and eight-weeks postpartum (40.0% vs 6.7%, OR = 9.33, 95%CI = 1.87,46.68), although not at the 12- (23.3% vs 10.0%, OR = 2.74, 95%CI = 0.63,11.82) or 24-week (20.0% vs 6.7%, OR = 3.50, 95%CI = 0.65,18.98) postpartum assessments likely due to this pilot study being underpowered for discerning differences at the later assessments, especially 24-weeks postpartum which was three months after treatment completion. These results support the efficacy of this remote, incentives-based intervention for pregnant smokers. Further research evaluating its efficacy and cost-effectiveness in a well-powered, randomized controlled trial appears warranted.",2020,"24-week (20.0% vs 6.7%, OR = 3.50, 95%CI = 0.65,18.98) postpartum assessments likely due to this pilot study being underpowered for discerning differences at the later assessments, especially 24-weeks postpartum which was three months after treatment completion.","['pregnant smokers', 'Sixty U.S. pregnant smokers were recruited between May 2018 to May 2019 via obstetrical clinics, Women, Infants, and Children (WIC) offices, and Facebook']","['practices alone (N\u202f=\u202f30) or best practices plus financial incentives', 'smartphone-based intervention whereby smoking monitoring and incentive delivery occurred remotely using a mobile app', 'Smartphone-based financial incentives']","['Cigarette smoking', 'efficacy and cost-effectiveness', 'prevalence abstinence rates', 'late-antepartum']","[{'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0442603', 'cui_str': 'Office'}]","[{'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C0239059', 'cui_str': 'Cigarette smoke'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0456336', 'cui_str': 'Antepartum'}]",60.0,0.125537,"24-week (20.0% vs 6.7%, OR = 3.50, 95%CI = 0.65,18.98) postpartum assessments likely due to this pilot study being underpowered for discerning differences at the later assessments, especially 24-weeks postpartum which was three months after treatment completion.","[{'ForeName': 'Allison N', 'Initials': 'AN', 'LastName': 'Kurti', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA; Psychological Science, University of Vermont, Burlington, VT, USA. Electronic address: akurti@uvm.edu.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Tang', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Hypatia A', 'Initials': 'HA', 'LastName': 'Bolivar', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Evemy', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA; Psychological Science, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Norman', 'Initials': 'N', 'LastName': 'Medina', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'Skelly', 'Affiliation': 'Medical Biostatistics, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Nighbor', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Higgins', 'Affiliation': 'Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, USA; Departments of Psychiatry, University of Vermont, Burlington, VT, USA; Psychological Science, University of Vermont, Burlington, VT, USA.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106201'] 1852,32656738,Dynamic Eye Tracking as a Predictor and Outcome Measure of Social Skills Intervention in Adolescents and Adults with Autism Spectrum Disorder.,"To evaluate an eye tracking task as a predictor and outcome measure of treatment response for autism spectrum disorder (ASD) social skills interventions, adolescents and young adults with ASD completed the eye tracking task before, immediately after, and two months after completing Social Cognition and Interaction Training for Autism (SCIT-A). The study compared SCIT-A participants (n = 20) to participants with ASD who received treatment as usual (TAU; n = 21). Overall, increased visual attention to faces and background objects and decreased attention to hands playing with toys at baseline were associated with improved social functioning immediately following intervention, suggesting this eye tracking task may reliably predict ASD social intervention outcomes.",2020,"Overall, increased visual attention to faces and background objects and decreased attention to hands playing with toys at baseline were associated with improved social functioning immediately following intervention, suggesting this eye tracking task may reliably predict ASD social intervention outcomes.","['Adolescents and Adults with Autism Spectrum Disorder', 'autism spectrum disorder (ASD) social skills interventions, adolescents and young adults with ASD']",['Social Skills Intervention'],"['visual attention to faces and background objects and decreased attention to hands playing with toys', 'social functioning']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0679005', 'cui_str': 'Social Abilities'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0589102', 'cui_str': 'Visual attention'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0040565', 'cui_str': 'Toy'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}]",,0.0620067,"Overall, increased visual attention to faces and background objects and decreased attention to hands playing with toys at baseline were associated with improved social functioning immediately following intervention, suggesting this eye tracking task may reliably predict ASD social intervention outcomes.","[{'ForeName': 'Rachel K', 'Initials': 'RK', 'LastName': 'Greene', 'Affiliation': 'Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Parish-Morris', 'Affiliation': ""Center for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Sullivan', 'Affiliation': 'Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Kinard', 'Affiliation': 'Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Maya G', 'Initials': 'MG', 'LastName': 'Mosner', 'Affiliation': 'Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Lauren M', 'Initials': 'LM', 'LastName': 'Turner-Brown', 'Affiliation': 'TEACCH Autism Program, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Penn', 'Affiliation': 'Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Wiesen', 'Affiliation': 'The Odum Institute, The University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ashley A', 'Initials': 'AA', 'LastName': 'Pallathra', 'Affiliation': 'Center for Neurobiology and Behavior, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Brodkin', 'Affiliation': 'Center for Neurobiology and Behavior, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Robert T', 'Initials': 'RT', 'LastName': 'Schultz', 'Affiliation': ""Center for Autism Research, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.""}, {'ForeName': 'Gabriel S', 'Initials': 'GS', 'LastName': 'Dichter', 'Affiliation': 'Carolina Institute for Developmental Disabilities, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. dichter@med.unc.edu.'}]",Journal of autism and developmental disorders,['10.1007/s10803-020-04594-1'] 1853,32653539,The management of diabetes in everyday life study: Design and methods for a pragmatic randomized controlled trial comparing the effectiveness of text messaging versus health coaching.,"Background African American patients with uncontrolled diabetes living in medically underserved areas need effective clinic-based interventions to improve self-care behaviors. Text messaging (TM) and health coaching (HC) are among the most promising low-cost population-based approaches, but little is known about their comparative effectiveness in real-world clinical settings. Objective Use a pragmatic randomized controlled trial design to determine the comparative effectiveness of TM and HC with enhanced usual care (EC) in African American adults with uncontrolled diabetes and multiple chronic health conditions. Methods/design The Management of Diabetes in Everyday Life (MODEL) study is randomizing 646 patients (n = 581with anticipated 90% retention) to 3 intervention arms: TM, HC, and EC. Participants are African American adults living in medically underserved areas of the Mid-South, age ≥ 18, with uncontrolled diabetes (A1c ≥ 8), one or more additional chronic conditions, and who have a phone with texting and voicemail capability. Primary outcome measures: the general diet, exercise, and medication adherence subscales of the revised Summary of Diabetes Self-Care Activities questionnaire assessed at one year. Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c). The study will also assess heterogeneity of treatment effects by six key baseline participant characteristics. Conclusions We describe the design and methods of the MODEL study along with design revisions required during implementation in a pragmatic setting. This trial, upon its conclusion, will allow us to compare the effectiveness of two promising low-cost primary care-based strategies for supporting self-care behaviors among African Americans individuals with uncontrolled diabetes. ClinicalTrials.gov registration number: NCT02957513.",2020,"Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c).","['African American adults with uncontrolled diabetes and multiple chronic health conditions', ' African American patients with uncontrolled diabetes living in medically underserved areas', 'Participants are African American adults living in medically underserved areas of the Mid-South, age ≥ 18, with uncontrolled diabetes (A1c ≥ 8), one or more additional chronic conditions, and who have a phone with texting and voicemail capability', '646 patients (n\u202f=\u202f581with anticipated 90% retention) to 3 intervention arms: TM, HC, and EC', 'African Americans individuals with uncontrolled diabetes']","['Text messaging (TM) and health coaching (HC', 'text messaging versus health coaching', 'TM and HC with enhanced usual care (EC']","['diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c', 'general diet, exercise, and medication adherence subscales of the revised Summary of Diabetes Self-Care Activities questionnaire assessed at one year']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C3266262', 'cui_str': 'Multiple chronic diseases'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0025112', 'cui_str': 'Area, Medically Underserved'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0301563', 'cui_str': 'General diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4082117', 'cui_str': 'One year'}]",646.0,0.105121,"Secondary outcomes: diabetes-specific quality of life, primary care engagement, and average blood sugar (A1c).","[{'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Bailey', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of General Internal Medicine, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America. Electronic address: jeb@uthsc.edu.'}, {'ForeName': 'Satya', 'Initials': 'S', 'LastName': 'Surbhi', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of General Internal Medicine, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Gatwood', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Butterworth', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Q-consult, LLC, St. Petersburg, FL, United States of America.'}, {'ForeName': 'Mace', 'Initials': 'M', 'LastName': 'Coday', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Sohul A', 'Initials': 'SA', 'LastName': 'Shuvo', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Institute for Health Outcomes and Policy, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Ankur A', 'Initials': 'AA', 'LastName': 'Dashputre', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Institute for Health Outcomes and Policy, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Brooks', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Surgery, Anne Arundel Medical Center, Annapolis, MD, United States of America.'}, {'ForeName': 'Bonnie L', 'Initials': 'BL', 'LastName': 'Binkley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Carrie Jo', 'Initials': 'CJ', 'LastName': 'Riordan', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Helmut O', 'Initials': 'HO', 'LastName': 'Steinberg', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Division of Endocrinology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Mary Lou', 'Initials': 'ML', 'LastName': 'Gutierrez', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Haley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Cardella L', 'Initials': 'CL', 'LastName': 'Leak', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Tolley', 'Affiliation': 'Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, TN, United States of America; Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106080'] 1854,32654022,Two different therapies for the middle turbinate during endoscopic sinus surgery for chronic rhinosinusitis.,"BACKGROUND The population of patients with chronic rhinosinusitis (CRS) has greatly increased. When medical treatment fails, endoscopic sinus surgery (ESS) is considered. In the present study, the value of two different therapies for the middle turbinate to optimize surgical outcomes was observed. Our objective was to determine a better management approach for the middle turbinate to effectively preserve the middle turbinate mucosa and function and avoid complications following ESS, such as nasal adhesions on the operative side. METHODS Thirty patients [group A; treated prior to 2015 (primary surgery)] undergoing resection of the middle turbinate bone during complete ESS for CRS and 30 patients [group B; treated after 2015 (later surgery)] undergoing middle turbinate preservation and multiapproach therapy during complete ESS for CRS were observed. Nasal cavities were compared using perioperative sinus endoscopy (POSE) and Lund-Kennedy (LKES) scores preoperatively and at 15 days, 2 months and 1 year after ESS. RESULTS Preoperatively, the POSE (8.83 ± 3.81 vs 9.15 ± 3.85, p = 0.45, for groups A and B, respectively) and LKES (4.23 ± 0.74 vs 4.13 ± 0.70, p = 0.34) scores were similar between groups. In group A, anterior adhesions were reported on six sides of the middle turbinate, severe adhesions were observed on two sides, mild adhesions were observed on one side, and adhesions occurred on two sides during follow-up. After retreatment, adhesions were still observed on two sides at 1 year. In group B, only mild anterior adhesions were observed on two sides. There was no difference between group A and group B at 15 days, and the POSE (4.31 ± 1.19 vs 4.07 ± 1.42, p = 0.11, for groups A and B, respectively) and LKES (3.35 ± 0.82 vs 3.33 ± 0.90, p = 0.91) scores were similar between groups. There was no significant difference in LKES (0.22 ± 0.49 vs 0.10 ± 0.35, p = 0.15) scores at 1 year between the two groups. There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). CONCLUSIONS Our results show that middle turbinate preservation and combined therapy was a better ESS method for CRS. Multiapproach middle conchoplasty, which is predominately a submucoperiosteal surgery, can preserve more of the mucosa and functions of the middle turbinate. Unlike the single-approach middle conchoplasty described in previous research, multiapproach middle conchoplasty is achieved by combining a three-step surgical procedure (""surgery, packing and removal"") with ""cocktail-style"" postoperative packing and removal.",2020,"There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). ","['patients with chronic rhinosinusitis (CRS', 'chronic rhinosinusitis', 'Thirty patients [group A']","['endoscopic sinus surgery', 'treated prior to 2015 (primary surgery)] undergoing resection of the middle turbinate bone during complete ESS for CRS and 30 patients [group B; treated after 2015 (later surgery)] undergoing middle turbinate preservation and multiapproach therapy', 'endoscopic sinus surgery (ESS']","['nasal cavities', 'endoscopic appearance', 'LKES', 'LKES scores', 'severe adhesions', 'mild anterior adhesions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0225435', 'cui_str': 'Middle nasal turbinate structure'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0027423', 'cui_str': 'Nasal cavity structure'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}]",,0.0319759,"There was a significant difference in the nasal cavities between group A and group B at 2 months and 1 year, where group B showed a better endoscopic appearance than group A at 2 months and 1 year (with POSE scores of 3.48 ± 0.83 vs 2.43 ± 1.38 (p = 0.00) and LKES scores of 1.35 ± 0.86 vs 1.15 ± 0.90 (p = 0.02) at 2 months for groups A and B, respectively, and POSE scores of 1.00 ± 0.96 vs 0.62 ± 0.87 (p = 0.001) at 1 year for groups A and B, respectively). ","[{'ForeName': 'Meichan', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China. zhumeichan@126.com.""}, {'ForeName': 'Yongyi', 'Initials': 'Y', 'LastName': 'Yan', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China. yungyi@188.com.""}, {'ForeName': 'Huicheng', 'Initials': 'H', 'LastName': 'Gong', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}, {'ForeName': 'Yunwen', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}, {'ForeName': 'Guojie', 'Initials': 'G', 'LastName': 'Tan', 'Affiliation': ""Department of Otorhinolaryngology, Guangzhou Twelfth People's Hospital (Guangzhou Otolarynology-Head and Neck Surgery Hospital), Tianhe District, No 1. Tianqiang Road, Guangzhou, 510620, Guangdong, China.""}]",European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery,['10.1007/s00405-020-06184-4'] 1855,32659247,Children overcoming picky eating (COPE) - A cluster randomised controlled trial.,"OBJECTIVES Food neophobia limits dietary variety in children and adults. Interventions to alleviate the impact of neophobia on children's dietary variety have had varying success. The potential effectiveness of mindfulness, a process of bringing awareness to the present moment, has received little attention. This trial aimed to explore the effectiveness of two mindfulness exercises on novel food acceptance for children. METHODS A cluster-randomised controlled trial with three trial arms compared the impact of two mindfulness exercises (mindful breathing and mindful raisin-eating) and a non-mindful control task on anticipated liking and intake of a novel fruit. Seventy-one children aged 10-12 years engaged in one of the three tasks at school over five days and were offered a novel fruit at the end of the intervention. Children self-reported mindfulness, food neophobia and anxiety at baseline and follow-up. RESULTS Two mixed-effects models showed that, controlling for school effects and covariates (including mindfulness, food neophobia and anxiety), children in the mindful raisin-eating arm reported greater anticipated liking of a novel fruit and children in both mindfulness arms consumed greater amounts of a novel fruit than children in the control arm. Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. CONCLUSIONS The results provide promising evidence for the potential effectiveness of mindfulness interventions in encouraging children to try new foods. The mechanisms underlying effectiveness remain unclear and further research, exploring long-term effects and the possibility to generalise these findings to other food groups such as vegetables, is needed.",2020,"Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. ","['children and adults', 'Children overcoming picky eating (COPE) ', 'Seventy-one children aged 10-12 years engaged in one of the three tasks at school over five days and were offered a novel fruit at the end of the intervention', 'children']","['mindfulness exercises (mindful breathing and mindful raisin-eating) and a non-mindful control task', 'mindfulness exercises']","['school effects and covariates (including mindfulness, food neophobia and anxiety', 'mindfulness, food neophobia and anxiety', 'Children self-reported mindfulness, food neophobia and anxiety']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0450389', 'cui_str': '71'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0453310', 'cui_str': 'Raisins'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C3840121', 'cui_str': 'Avoidant restrictive food intake disorder'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",71.0,0.0797824,"Mixed-design ANOVAs indicated that mindfulness, food neophobia and anxiety did not change over time in each trial arm. ","[{'ForeName': 'Carmel', 'Initials': 'C', 'LastName': 'Bennett', 'Affiliation': 'Birmingham and Solihull Mental Health NHS Foundation Trust, UK. Electronic address: carmelbennett@nhs.net.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Copello', 'Affiliation': 'Birmingham and Solihull Mental Health NHS Foundation Trust, UK; School of Psychology, University of Birmingham, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'School of Psychology, University of Birmingham, UK.'}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Blissett', 'Affiliation': 'Department of Psychology, School of Life and Health Sciences, Aston University, UK.'}]",Appetite,['10.1016/j.appet.2020.104791'] 1856,32659480,Effectiveness of a physiologic voice therapy program based on different semioccluded vocal tract exercises in subjects with behavioral dysphonia: A randomized controlled trial.,"PURPOSE The present study aimed to assess the effectiveness of a physiologic voice therapy program based on different semioccluded vocal tract exercises in subjects with behavioral dysphonia. METHODS Thirty-four participants with behavioral dysphonia were randomly assigned to one of two treatment groups: 1) voice treatment with physiologic voice therapy plus vocal hygiene program (n=20), and 2) vocal hygiene program only (n=14). Laryngoscopic assessment was performed in all subjects. Before and after voice therapy, participants underwent aerodynamic, electroglottographic, and acoustic assessment. The Voice Handicap Index (VHI), Voice symptom scale (VoiSs), Vocal tract discomfort scale (VTDS), and self-assessment of resonant voice quality were also performed. The treatment included eight voice therapy sessions. For the experimental group, the exercises consisted of a sequence of seven phonatory tasks performed with four different semioccluded vocal tract exercises (SOVTE). Comparison for all variables were performed between experimental group and control group. RESULTS Wilcoxon test showed significant improvements for experimental group for VHI, VoiSs, VTDS (decrease), and self-perception of resonant voice quality (increase). Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. CONCLUSION Physiologic voice therapy based on semioccluded vocal tract exercises seems to be an effective tool to improve voice in subjects diagnosed with behavioral dysphonia. Apparently, most changes should be expected in variables related to physical and functional aspects compared to objective variables. Subglottic pressure and phonation threshold pressure seem to be the most change-sensitive parameters and they may reflect a reduction in phonatory effort reported by patients after voice therapy.",2020,"Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. ","['subjects diagnosed with behavioral dysphonia', 'Thirty-four participants with behavioral dysphonia', 'subjects with behavioral dysphonia']","['physiologic voice therapy program', 'phonatory tasks performed with four different semioccluded vocal tract exercises (SOVTE', 'voice treatment with physiologic voice therapy plus vocal hygiene program (n=20), and 2) vocal hygiene program', 'Physiologic voice therapy']","['VHI, VoiSs, VTDS (decrease), and self-perception of resonant voice quality (increase', 'Subglottic pressure and phonation threshold pressure', 'Laryngoscopic assessment', 'Voice Handicap Index (VHI), Voice symptom scale (VoiSs), Vocal tract discomfort scale (VTDS), and self-assessment of resonant voice quality', 'subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0019825', 'cui_str': 'Hoarse'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C2202690', 'cui_str': 'Voice therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020405', 'cui_str': 'Hygiene'}]","[{'cui': 'C2985106', 'cui_str': 'Voice handicap index'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0577554', 'cui_str': 'Resonant'}, {'cui': 'C0042943', 'cui_str': 'Vocal quality'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0234833', 'cui_str': 'Subglottic pressure'}, {'cui': 'C0031577', 'cui_str': 'Laryngeal voice function'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042939', 'cui_str': 'Voice'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0231999', 'cui_str': 'Airflow'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]",34.0,0.0112718,"Significant decrease for experimental groups was observed on subglottic pressure, phonation threshold pressure, and glottal airflow across the implemented tasks. ","[{'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Guzman', 'Affiliation': 'Department of Communication Sciences and Disorders, Universidad de los Andes, Chile; Department of Otolaryngology, Las Condes Clinic, Santiago, Chile. Electronic address: guzmann.marcoa@gmail.com.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Bertucci', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: terebertucci@gmail.com.'}, {'ForeName': 'Constanza', 'Initials': 'C', 'LastName': 'Pacheco', 'Affiliation': 'Department of Otolaryngology, Las Condes Clinic, Av. Estoril 850, Santiago, Chile. Electronic address: cpachecob@clinicalascondes.cl.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Leiva', 'Affiliation': 'Department of Communication Sciences and Disorders, Universidad Pedro de Valdivia, Vicuña Mackena 44, Santiago, Chile. Electronic address: fernando.leiva.solari@gmail.com.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Quintana', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: quintana.b.felipe@gmail.com.'}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Ansaldi', 'Affiliation': 'Facultad de Ciencias de la Salud, Universidad de las Américas, Santiago, Chile. Electronic address: romina.ansaldi@gmail.com.'}, {'ForeName': 'Camilo', 'Initials': 'C', 'LastName': 'Quezada', 'Affiliation': 'Department of Communication Sciences and Disorders, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: cequezad@uc.cl.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Muñoz', 'Affiliation': 'Department of Otolaryngology, University of Chile, Av. Independencia 1027, Santiago, Chile. Electronic address: daniel.uchile@gmail.com.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106023'] 1857,32659699,A web-based daily care training to improve the quality of life of mothers of children with cerebral palsy: A randomized controlled trial.,"BACKGROUND Mothers of moderately to severely affected children with cerebral palsy (CP) have to spend a long time to take care of their children. This time-consuming responsibility affects their physical and psychosocial health. Therefore, mothers as caregivers are required to receive special training to take care of their children. AIMS The aim of this study was to evaluate the effectiveness of a developed web-based intervention for daily care training of children with CP on their mothers' quality of life (QOL), anxiety, depression, stress, and their musculoskeletal pain. METHODS AND PROCEDURES This study was a single blind randomized controlled trial. 91 mothers of children with CP with Gross Motor Function Classification System (GMFCS) levels III, IѴ, and Ѵ, who aged from 4 to 12 years were assigned to the intervention and control groups using block randomization. Mothers in the control group received their routine face to face occupational therapy intervention and mothers in the intervention group received 12 weeks web-based intervention. QOL, depression, anxiety, stress, and pain were measured before and after the intervention in both groups. OUTCOMES AND RESULTS The results of analysis of covariance showed that after controlling the mean score of pretest of pain, the mean score of post-tests in the intervention and control groups was significantly different (P < 0.05). The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. CONCLUSIONS AND IMPLICATIONS Designed web-based intervention affects the caregivers' QOL and pain significantly. This intervention can be used to provide daily care training for mothers of children with CP.",2020,"The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. ","['91 mothers of children with CP with Gross Motor Function Classification System (GMFCS) levels III, IѴ, and Ѵ, who aged from 4 to 12 years', 'mothers of children with cerebral palsy', 'Mothers of moderately to severely affected children with cerebral palsy (CP', 'mothers of children with CP', 'children with CP on their mothers']","['special training', 'A web-based daily care training', 'routine face to face occupational therapy intervention and mothers in the intervention group received 12 weeks web-based intervention']","['quality of life', 'QOL, depression, anxiety, stress, and pain', 'mean score of pretest of pain', 'quality of life (QOL), anxiety, depression, stress, and their musculoskeletal pain', 'mean scores of physical health and total QOL scores of post-tests']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441927', 'cui_str': 'Level III'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1318464', 'cui_str': 'Occupational therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",91.0,0.0560542,"The mean scores of physical health and total QOL scores of post-tests in the intervention group were significantly higher than the control group with controlling pretest scores. ","[{'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Nobakht', 'Affiliation': 'Pediatric Neurorehabilitation Research Center and Occupational Therapy Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Rassafiani', 'Affiliation': 'Occupational Therapy Department, Faculty of Allied Health Sciences, Kuwait University, Kuwait. Pediatric Neurorehabilitation Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Electronic address: mrassafiani@yahoo.com.'}, {'ForeName': 'S A', 'Initials': 'SA', 'LastName': 'Hosseini', 'Affiliation': 'Social Determinants of Health Research Center and Occupational Therapy Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Hosseinzadeh', 'Affiliation': 'Biosatistics Department, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.'}]",Research in developmental disabilities,['10.1016/j.ridd.2020.103731'] 1858,32659755,Prophylactic Ligature of AV Fistula Prevents High Output Heart Failure after Kidney Transplantation.,"BACKGROUND Arteriovenous (AV) fistulas are considered the gold standard for ensuring safe and long-term vascular access in patients with haemodialysis-dependent end-stage renal disease. However, previous studies demonstrated that high-flow AV fistulas might add additional cardiovascular burden in the post-transplant setting, leading to frequent fistula closure in this population. Currently, there is no consensus regarding management of high-flow fistulas in post-transplant patients with stable kidney function. The present randomized controlled trial examines the effect of prophylactic AV fistula closure on high-output heart failure. METHODS Twenty-eight kidney transplant patients with stable graft function, absence of pre-existing severe cardiac failure, and brachial arterial flow rate of at least 1,500 mL/min were recruited and randomized in a 1:1 ratio to an intervention and control group, respectively. The intervention group was subject to immediate fistula ligature. Patients within the control group were referred to fistula ligature only if the main study endpoint high-output heart failure was reached. The latter was defined by the presence of at least 1 clinical sign (i.e., worsening NYHA score) and at least 2 of the following echocardiographic parameters: diameter of right atrium (major) >53 mm, right atrium (minor) >44 mm, inferior vena cava ≥21 mm, right pulmonary artery >20 mm, TAPSE <16 mm, systolic pulmonal artery pressure >40 mm Hg, and/or left ventricular eccentricity index <1. During a 24-month follow-up period, quarterly measurements of kidney function, NT-proBNP, and lactate dehydrogenase as well as a biannual echocardiographic check-up were performed. RESULTS High-output heart failure attributable to high-flow fistula was reported in 5 of 13 control patients (38.5%), whereas no patient in the intervention group presented with clinical and echocardiographic signs of high-output heart failure during the follow-up period. Thus, prophylactic ligature of high-flow fistulas avoided high-output heart failure in our patient population (p = 0.013). Three patients in the control group, however, had to undergo fistula ligature due to aneurysm formation (n = 2) and steal phenomenon (n = 1). Median NT-proBNP levels decreased from 317 ng/L pre-ligature to 223 ng/L post-ligature (p = 0.003). Serum creatinine levels did not significantly differ before and after AV fistula ligature (1.69 vs. 1.60 mg/dL, respectively, p = 0.059). Improvement of echocardiographic findings (e.g., a decrease in systolic pulmonary arterial pressure) was found in 7 of 8 ligature patients but did not reach statistical significance. CONCLUSION Prophylactic ligature of high-flow AV fistulas after kidney transplantation can avoid high-output heart failure, and a more liberal approach to close AV fistulas might be justified.",2020,"Serum creatinine levels did not significantly differ before and after AV fistula ligature (1.69 vs. 1.60 mg/dL, respectively, p = 0.059).","['patients with haemodialysis-dependent end-stage renal disease', 'Twenty-eight kidney transplant patients with stable graft function, absence of pre-existing severe cardiac failure, and brachial arterial flow rate of at least 1,500 mL/min', 'Kidney Transplantation', 'post-transplant patients with stable kidney function']","['prophylactic AV fistula closure', 'Prophylactic Ligature of AV Fistula']","['clinical and echocardiographic signs of high-output heart failure', 'Serum creatinine levels', 'systolic pulmonary arterial pressure', 'systolic pulmonal artery pressure', 'Median NT-proBNP levels', 'kidney function, NT-proBNP, and lactate dehydrogenase']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0429856', 'cui_str': 'Arterial flow'}, {'cui': 'C0439445', 'cui_str': 'mL/min'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0023692', 'cui_str': 'Ligature'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0221045', 'cui_str': 'High output heart failure'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1168098', 'cui_str': 'Pulmonary arterial pressure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0022917', 'cui_str': 'Lactate dehydrogenase'}]",28.0,0.0372347,"Serum creatinine levels did not significantly differ before and after AV fistula ligature (1.69 vs. 1.60 mg/dL, respectively, p = 0.059).","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Hetz', 'Affiliation': 'Department of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Pirklbauer', 'Affiliation': 'Department of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Müller', 'Affiliation': 'Department of Internal Medicine III - Cardiology and Angiology, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Posch', 'Affiliation': 'Department for Surgery, University Hospital for Vascular Surgery, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gummerer', 'Affiliation': 'Department for Surgery, University Hospital for Vascular Surgery, Medical University Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Tiefenthaler', 'Affiliation': 'Department of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria, martin.tiefenthaler@i-med.ac.at.'}]",American journal of nephrology,['10.1159/000508957'] 1859,32660604,Effects of virtual reality associated with serious games for upper limb rehabilitation inpatients with multiple sclerosis: randomized controlled trial.,"BACKGROUND Dexterity and activities of daily living limitations on the upper limb (UL) represent one of the most common problems in patients with multiple sclerosis (MS). The aim of this study was to evaluate the effectiveness of the specially developed Serious Games that make use of the Leap Motion Controller (LMC) as main user interface for improving UL grip muscle strength, dexterity, fatigue, quality of life, satisfaction and compliance. METHODS A single-blinded randomized controlled trial was conducted. The sample was randomized into two groups: an experimental group who received treatment based on serious games designed by the research team using the developed LMC based Serious Games for the UL plus conventional rehabilitation, and a control group who received the same conventional rehabilitation for the UL. Both groups received two 60 min sessions per week over a ten-week period. Grip muscle strength, coordination, speed of movements, fine and gross UL dexterity, fatigue, quality of life, satisfaction and compliance were assessed in both groups pre-treatment, post-treatment and in a follow-up period of 1 month without receiving any treatment. RESULTS In the experimental group compared to the control group, significant improvements were observed in the post-treatment assessment for coordination, speed of movements, fine and gross UL dexterity. Also, significant results were found in the follow-up in coordination, speed of movements, fine and gross for the more affected side. CONCLUSIONS An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. TRIAL REGISTRATION This randomized controlled trial has been registered at ClinicalTrials.gov Identifier: NCT04171908 , Nov 2019.",2020,"An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. ","['upper limb rehabilitation inpatients with multiple sclerosis', 'patients with multiple sclerosis (MS']","['virtual reality associated with serious games', 'serious games designed by the research team using the developed LMC based Serious Games for the UL plus conventional rehabilitation, and a control group who received the same conventional rehabilitation for the UL', 'LMC based Serious Games designed for UL rehabilitation', 'Leap Motion Controller (LMC']","['unilateral gross manual dexterity, fine manual dexterity, and coordination', 'post-treatment assessment for coordination, speed of movements, fine and gross UL dexterity', 'Grip muscle strength, coordination, speed of movements, fine and gross UL dexterity, fatigue, quality of life, satisfaction and compliance', 'follow-up in coordination, speed of movements, fine and gross for the more affected side', 'UL grip muscle strength, dexterity, fatigue, quality of life, satisfaction and compliance']","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0565699', 'cui_str': 'Ability to perform general manipulative activities'}, {'cui': 'C0205232', 'cui_str': 'Fine'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}]",,0.0783139,"An experimental protocol using an LMC based Serious Games designed for UL rehabilitation showed improvements for unilateral gross manual dexterity, fine manual dexterity, and coordination in MS patients with high satisfaction and excellent compliance. ","[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Cuesta-Gómez', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Sánchez-Herrera-Baeza', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain. patricia.sanchezherrera@urjc.es.'}, {'ForeName': 'Edwin Daniel', 'Initials': 'ED', 'LastName': 'Oña-Simbaña', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Martínez-Medina', 'Affiliation': 'Asociación de Esclerosis Múltiple de Toledo (ADEMTO), Toledo, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Ortiz-Comino', 'Affiliation': 'Asociación de Esclerosis Múltiple de Toledo (ADEMTO), Toledo, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Balaguer-Bernaldo-de-Quirós', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Jardón-Huete', 'Affiliation': 'Robotics Lab. University Carlos III of Madrid, Leganés, Madrid, Spain.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cano-de-la-Cuerda', 'Affiliation': 'Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Faculty of Health Sciences, Rey Juan Carlos University, Avenida de Atenas s/n 28922 Alcorcón, Madrid, Spain.'}]",Journal of neuroengineering and rehabilitation,['10.1186/s12984-020-00718-x'] 1860,32668111,Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.,"BACKGROUND Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not better than aspirin in preventing vascular events or death after stroke or TIA. The effect of the combination of ticagrelor and aspirin on prevention of stroke has not been well studied. METHODS We conducted a randomized, placebo-controlled, double-blind trial involving patients who had had a mild-to-moderate acute noncardioembolic ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 5 or less (range, 0 to 42, with higher scores indicating more severe stroke), or TIA and who were not undergoing thrombolysis or thrombectomy. The patients were assigned within 24 hours after symptom onset, in a 1:1 ratio, to receive a 30-day regimen of either ticagrelor (180-mg loading dose followed by 90 mg twice daily) plus aspirin (300 to 325 mg on the first day followed by 75 to 100 mg daily) or matching placebo plus aspirin. The primary outcome was a composite of stroke or death within 30 days. Secondary outcomes were first subsequent ischemic stroke and the incidence of disability within 30 days. The primary safety outcome was severe bleeding. RESULTS A total of 11,016 patients underwent randomization (5523 in the ticagrelor-aspirin group and 5493 in the aspirin group). A primary-outcome event occurred in 303 patients (5.5%) in the ticagrelor-aspirin group and in 362 patients (6.6%) in the aspirin group (hazard ratio, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P = 0.02). Ischemic stroke occurred in 276 patients (5.0%) in the ticagrelor-aspirin group and in 345 patients (6.3%) in the aspirin group (hazard ratio, 0.79; 95% CI, 0.68 to 0.93; P = 0.004). The incidence of disability did not differ significantly between the two groups. Severe bleeding occurred in 28 patients (0.5%) in the ticagrelor-aspirin group and in 7 patients (0.1%) in the aspirin group (P = 0.001). CONCLUSIONS Among patients with a mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score ≤5) or TIA who were not undergoing intravenous or endovascular thrombolysis, the risk of the composite of stroke or death within 30 days was lower with ticagrelor-aspirin than with aspirin alone, but the incidence of disability did not differ significantly between the two groups. Severe bleeding was more frequent with ticagrelor. (Funded by AstraZeneca; THALES ClinicalTrial.gov number, NCT03354429.).",2020,The incidence of disability did not differ significantly between the two groups.,"['patients who had had a mild-to-moderate acute noncardioembolic ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 5 or less (range, 0 to 42, with higher scores indicating more severe stroke), or TIA and who were not undergoing thrombolysis or thrombectomy', 'group and 5493 in the aspirin group', '11,016 patients underwent randomization (5523 in the', 'Acute Ischemic Stroke or TIA', 'patients with a mild-to-moderate acute noncardioembolic ischemic stroke (NIHSS score ≤5) or TIA who were not undergoing intravenous or']","['placebo', 'ticagrelor-aspirin', 'endovascular thrombolysis', 'Ticagrelor and Aspirin or Aspirin Alone', 'aspirin', 'placebo plus aspirin', 'clopidogrel and aspirin', 'ticagrelor and aspirin', 'ticagrelor']","['incidence of disability', 'severe bleeding', 'Severe bleeding', 'risk of the composite of stroke or death', 'subsequent ischemic stroke and the incidence of disability', 'composite of stroke or death within 30 days', 'Ischemic stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C3472496', 'cui_str': 'National Institutes of Health stroke scale'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0162578', 'cui_str': 'Removal of thrombus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",11016.0,0.444595,The incidence of disability did not differ significantly between the two groups.,"[{'ForeName': 'S Claiborne', 'Initials': 'SC', 'LastName': 'Johnston', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Amarenco', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Denison', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Scott R', 'Initials': 'SR', 'LastName': 'Evans', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Himmelmann', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'James', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Mikael', 'Initials': 'M', 'LastName': 'Knutsson', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Ladenvall', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Molina', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': ""From the Dean's Office, Dell Medical School, University of Texas at Austin, Austin (S.C.J.); the Department of Neurology and Stroke Center, Bichat-Claude Bernard Hospital, University of Paris, Paris (P.A.); Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg (H.D., A.H., M.K., P.L.), and the Department of Medical Sciences, Uppsala University, Uppsala (S.J.) - both in Sweden; the Biostatistics Center, George Washington University, Washington, DC (S.R.E.); the Stroke Unit, Vall d'Hebron Hospital, Barcelona (C.A.M.); and the Department of Neurology, Tiantan Hospital, Capital Medical University, Beijing (Y.W.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1916870'] 1861,32651161,"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.","BACKGROUND Low-dose interleukin-2 (ld-IL-2) enhances regulatory T-cell (Treg) function in auto-inflammatory conditions. Neuroinflammation being a pathogenic feature of amyotrophic lateral sclerosis (ALS), we evaluated the pharmacodynamics and safety of ld-IL-2 in ALS subjects. METHODS We performed a single centre, parallel three-arm, randomised, double-blind, placebo-controlled study. Eligibility criteria included age < 75 years, disease duration < 5 years, riluzole treatment > 3 months, and a slow vital capacity ≥ 70% of normal. Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or placebo once daily for 5 days every 4 weeks for 3 cycles. Primary outcome was change from baseline in Treg percentage of CD4 + T cells (%Tregs) following a first cycle. Secondary laboratory outcomes included: %Treg and Treg number following repeated cycles, and plasma CCL2 and neurofilament light chain protein (NFL) concentrations as surrogate markers of efficacy. Safety outcomes included motor-function (ALSFRS-R), slow vital capacity (SVC), and adverse event reports. This trial is registered with ClinicalTrials.gov, NCT02059759. FINDINGS All randomised patients (12 per group), recruited from October 2015 to December 2015, were alive at the end of follow-up and included in the intent-to-treat (ITT) analysis. No drug-related serious adverse event was observed. Non-serious adverse events occurred more frequently with the 1 and 2 MIU IL-2 doses compared to placebo, including injection site reactions and flu-like symptoms. Primary outcome analysis showed a significant increase (p < 0·0001) in %Tregs in the 2 MIU and 1 MIU arms (mean [SD]: 2 MIU: +6·2% [2·2]; 1 MIU: +3·9% [1·2]) as compared to placebo (mean [SD]: -0·49% [1·3]). Effect sizes (ES) were large in treated groups: 2 MIU ES=3·7 (IC95%: 2·3-4·9) and 1 MIU ES=3·5 (IC95%: 2·1-4·6). Secondary outcomes showed a significant increase in %Tregs following repeated cycles (p < 0·0001) as compared to placebo, and a dose-dependent decrease in plasma CCL2 (p = 0·0049). There were no significant differences amongst the three groups on plasma NFL levels. INTERPRETATION Ld-IL-2 is well tolerated and immunologically effective in subjects with ALS. These results warrant further investigation into their eventual therapeutic impact on slowing ALS disease progression. FUNDING The French Health Ministry (PHRC-I-14-056), EU H2020 (grant #633413), and the Association pour la Recherche sur la SLA (ARSLA).",2020,"Non-serious adverse events occurred more frequently with the 1 and 2 MIU IL-2 doses compared to placebo, including injection site reactions and flu-like symptoms.","['Eligibility criteria included age', 'amyotrophic lateral sclerosis (IMODALS', 'subjects with ALS', 'ALS subjects', 'All randomised patients (12 per group), recruited from October 2015 to December 2015, were alive at the end of follow-up and included in the intent-to-treat (ITT) analysis']","['riluzole treatment', 'aldesleukin 2 MIU, 1 MIU, or placebo', 'placebo']","['motor-function (ALSFRS-R), slow vital capacity (SVC), and adverse event reports', 'injection site reactions and flu-like symptoms', 'change from baseline in Treg percentage of CD4 + T cells', 'disease duration', 'plasma NFL levels', 'plasma CCL2 and neurofilament light chain protein (NFL) concentrations', 'plasma CCL2']","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0002736', 'cui_str': 'Amyotrophic lateral sclerosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2584946', 'cui_str': 'Alive'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0073379', 'cui_str': 'Riluzole'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0218986', 'cui_str': 'Aldesleukin'}, {'cui': 'C0439455', 'cui_str': 'mIU'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0231957', 'cui_str': 'Slow vital capacity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0392171', 'cui_str': 'Influenza-like symptoms'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1449159', 'cui_str': 'CCL2 protein, human'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0427716', 'cui_str': 'Protein concentration, test strip measurement'}]",,0.755312,"Non-serious adverse events occurred more frequently with the 1 and 2 MIU IL-2 doses compared to placebo, including injection site reactions and flu-like symptoms.","[{'ForeName': 'William', 'Initials': 'W', 'LastName': 'Camu', 'Affiliation': 'Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Marius', 'Initials': 'M', 'LastName': 'Mickunas', 'Affiliation': ""Department Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.""}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Veyrune', 'Affiliation': 'Department of Cell and Tisue Engineering, University of Montpellier, CHU Montpellier, Montpellier France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Payan', 'Affiliation': ""Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), Nîmes University Hospital, Nîmes, France; Department of Pharmacology, AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 47, Bd de l'Hôpital, F-75013 Paris, France.""}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Garlanda', 'Affiliation': 'IRCCS Humanitas Clinical & Research Institute, Milan, Italy; Humanitas University, Pieve Emanuele, Milan, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Locati', 'Affiliation': 'IRCCS Humanitas Clinical & Research Institute, Milan, Italy; Department of Medical Biotechnologies and Translational Medicine, University Milan, Milan Italy.'}, {'ForeName': 'Raul', 'Initials': 'R', 'LastName': 'Juntas-Morales', 'Affiliation': 'Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Pageot', 'Affiliation': 'Clinique du Motoneurone, CHU Gui de Chauliac, University of Montpellier, Montpellier, France.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Malaspina', 'Affiliation': 'Neuroscience and Trauma Centre, Institute of Cell and Molecular Medicine, Department of Neuroimmunology, Barts and the London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Andreasson', 'Affiliation': 'Department of Psychiatry & Neurochemistry, University of Gothenburg, Mölndal, Sweden.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Kirby', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Carey', 'Initials': 'C', 'LastName': 'Suehs', 'Affiliation': 'Departments of Medical Information and Respiratory Diseases, University of Montpellier, CHU Montpellier, Montpellier, France.'}, {'ForeName': 'Safa', 'Initials': 'S', 'LastName': 'Saker', 'Affiliation': 'DNA and Cell Bank, Genethon, Evry, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Masseguin', 'Affiliation': 'Delegation for Clinical Research and Innovation, Nîmes University Hospital, Nîmes, France.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'De Vos', 'Affiliation': 'Department of Cell and Tisue Engineering, University of Montpellier, CHU Montpellier, Montpellier France.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Zetterberg', 'Affiliation': 'Department of Psychiatry & Neurochemistry, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; UK Dementia Research Institute at UCL, London, UK.'}, {'ForeName': 'Pamela J', 'Initials': 'PJ', 'LastName': 'Shaw', 'Affiliation': 'Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Ammar', 'Initials': 'A', 'LastName': 'Al-Chalabi', 'Affiliation': ""Institute of Psychiatry Psychology and Neuroscience, Department of Basic and Clinical Neuroscience, King's College London, London, UK; Department of Neurology, King's College Hospital, London, UK.""}, {'ForeName': 'P Nigel', 'Initials': 'PN', 'LastName': 'Leigh', 'Affiliation': 'The Trafford Centre for Biomedical Research, Brighton and Sussex Medical School, Falmer, Brighton BN1 9RY, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Tree', 'Affiliation': ""Department Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, UK; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK. Electronic address: timothy.tree@kcl.ac.uk.""}, {'ForeName': 'Gilbert', 'Initials': 'G', 'LastName': 'Bensimon', 'Affiliation': ""Department of Biostatistics, Clinical Epidemiology, Public Health and Innovation in Methodology (BESPIM), Nîmes University Hospital, Nîmes, France; Department of Pharmacology, AP-HP.Sorbonne Université, Pitié-Salpêtrière Hospital, 47, Bd de l'Hôpital, F-75013 Paris, France; Department of Pharmacology, Sorbonne Université Médecine, F-75013 Paris, France. Electronic address: gbensimon.psl@gmail.com.""}]",EBioMedicine,['10.1016/j.ebiom.2020.102844'] 1862,32650033,Effect of clinical inertia and trial participation in younger and older adults with diabetes having comorbidities and progressive complications.,"AIM Clinical inertia is a multifactorial phenomenon, with contributing factors from people with diabetes and their healthcare team. It is widely cited that clinical inertia is minimised by participation in clinical trials. We assessed whether trial participation per se improves metabolic parameters in people with diabetes, or a specific focus on glycaemia is required. METHODS We compared improvement in glycaemic control in a pooled set of people assigned to the ""placebo"" arm from 25 glycaemia-focused trials with a pooled group of people with diabetes allocated to sham or non-pharmacological intervention for the treatment of diabetic retinal disease. Mean change in HbA1c (ANCOVA) was evaluated. RESULTS The overall placebo effect in studies focused on glucose control (N = 3081) was comparable between strata groups with and without complications. Adjusted least square mean change in HbA1c at 24 weeks was between -0.23% (-2.50 mmol/mol) and -0.32% (-3.50 mmol/mol). In studies focused on retinal disease (N = 288), the change from baseline in HbA1c was +0.10% (1.10 mmol/mol) and fasting plasma glucose was +0.50 mmol/L showing no improvement in metabolic parameters at 12 months. CONCLUSIONS Clinical trial participation alone does not seem to improve metabolic parameters in people living with diabetes. The benefits observed in glycaemia-focused studies were independent of age and comorbidities.",2020,The overall placebo effect in studies focused on glucose control (N=3081) was comparable between strata groups with and without complications.,"['people with diabetes and their healthcare team', 'people with diabetes', 'younger and older adults with diabetes having comorbidities and progressive complications', 'people living with diabetes']","['sham or non-pharmacological intervention', 'placebo']","['metabolic parameters', 'fasting plasma glucose', 'Mean change in HbA1c (ANCOVA']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086390', 'cui_str': 'Health Care Team'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}]","[{'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",,0.202893,The overall placebo effect in studies focused on glucose control (N=3081) was comparable between strata groups with and without complications.,"[{'ForeName': 'William David', 'Initials': 'WD', 'LastName': 'Strain', 'Affiliation': 'University of Exeter Medical School, Exeter, United Kingdom; Academic Department of Healthcare for the Elderly, Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom. Electronic address: d.strain@exeter.ac.uk.'}, {'ForeName': 'Päivi Maria', 'Initials': 'PM', 'LastName': 'Paldánius', 'Affiliation': ""Children's Hospital, Helsinki University Hospital, Helsinki, Finland; Program for Clinical and Molecular Metabolism, Helsinki University, Helsinki, Finland.""}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108310'] 1863,32650223,Skin carotenoids are inversely associated with adiposity in breast cancer survivors.,"Carotenoids are antioxidants which may mitigate some of the adverse effects of obesity, a condition associated with poor outcomes in breast cancer patients. We hypothesized that baseline skin carotenoids would be inversely associated with adiposity in breast cancer survivors and would increase with weight loss. Skin carotenoid score (SCS) was assessed by resonance Raman spectroscopy in breast cancer survivors (body mass index ≥25 kg/m 2 ) enrolled in a 6-month randomized controlled weight loss trial (n = 47). Measurements included total body fat using dual-energy X-ray absorptiometry, height, weight, waist and hip circumference, dietary intake, and serum biomarkers. Associations between SCS, adiposity measures, and serum biomarkers were assessed at baseline, as was the change in SCS from baseline to 6 months, in the intervention and usual care groups. At baseline, SCS was inversely correlated with all adiposity measures (P ≤ .05). In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20). Baseline SCS was significantly inversely associated with log C-reactive protein levels (regression coefficient β ± SE: -0.051± 0.019; P = .011) and log leptin (β ± SE: -0.019± 0.009; P = .046), but the associations were no longer significant after adjustment for adiposity. Over the 6-month study, the intervention group had a 17.6% increase in SCS compared to a 1.5% decrease in the usual care group (P = .28). In our study of overweight and obese breast cancer survivors, dual-energy X-ray absorptiometry-measured body fat explained a large portion of the variation in skin carotenoids at baseline, suggesting a stronger association than that previously seen in studies using less accurate measures of adiposity.",2020,"In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20).","['breast cancer patients', 'breast cancer survivors', 'overweight and obese breast cancer survivors', 'breast cancer survivors (body mass index ≥25\u202fkg/m 2 ) enrolled in a 6-month randomized controlled weight loss trial (n\u202f=\u202f47']",[],"['Skin carotenoid score (SCS', 'log C-reactive protein levels', 'SCS', 'SCS, adiposity measures, and serum biomarkers', 'weight loss', 'adiposity measures', 'total body fat using dual-energy X-ray absorptiometry, height, weight, waist and hip circumference, dietary intake, and serum biomarkers']","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]",[],"[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0424677', 'cui_str': 'Total body fat'}, {'cui': 'C1510486', 'cui_str': 'Dual energy X-ray absorptiometry'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}, {'cui': 'C0562350', 'cui_str': 'Hip circumference'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}]",,0.0209892,"In multivariate analyses, baseline percent body fat had the strongest association with baseline SCS (partial R 2 = 0.20).","[{'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Cartmel', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: brenda.cartmel@yale.edu.'}, {'ForeName': 'Chelsea', 'Initials': 'C', 'LastName': 'Anderson', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: chelsea.anderson@cancer.org.'}, {'ForeName': 'Melinda L', 'Initials': 'ML', 'LastName': 'Irwin', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: melinda.irwin@yale.edu.'}, {'ForeName': 'Maura', 'Initials': 'M', 'LastName': 'Harrigan', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: maura.harrigan@yale.edu.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Sanft', 'Affiliation': 'Yale Cancer Center, PO Box 208028, New Haven, CT 06519; Yale School of Medicine, 333 Cedar St, New Haven, CT 06511. Electronic address: tara.sanft@yale.edu.'}, {'ForeName': 'Fangyong', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511. Electronic address: fangyong.li@yale.edu.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Gellermann', 'Affiliation': 'Longevity Link Corporation, 391 Chipeta Way, Suite E, Salt Lake City, UT 84108. Electronic address: werner@longevitylinkcorporation.com.'}, {'ForeName': 'Igor V', 'Initials': 'IV', 'LastName': 'Ermakov', 'Affiliation': 'Longevity Link Corporation, 391 Chipeta Way, Suite E, Salt Lake City, UT 84108. Electronic address: igor@longevitylinkcorporation.com.'}, {'ForeName': 'Leah M', 'Initials': 'LM', 'LastName': 'Ferrucci', 'Affiliation': 'Yale School of Public Health, 60 College St, New Haven, CT 06511; Yale Cancer Center, PO Box 208028, New Haven, CT 06519. Electronic address: leah.ferrucci@yale.edu.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2020.05.012'] 1864,32650231,Race and cultural factors in an RCT of prolonged exposure and sertraline for PTSD.,"The efficacy of treatments for posttraumatic stress disorder (PTSD) among African Americans is less clear given underrepresentation in clinical research. Additionally, intervention research examining race has typically not considered within-group heterogeneity, such as acculturation, ethnic identity, and cultural attitudes. In a randomized controlled trial, African American (n = 43) and Caucasian (n = 130) individuals received prolonged exposure (PE) or sertraline for PTSD, comparing: treatment response, retention, and treatment beliefs and preferences. Indirect effects of cultural variables were also examined. African Americans reported stronger ethnic identity (d = 0.71), less positive attitudes toward other groups (d = 0.36), and less acculturation (d = 0.51) than Caucasians. Noninferiority analyses indicated clinically equivalent PTSD outcomes for African Americans and Caucasians in both treatments. Groups showed comparable improvements in depression and functioning, and similar treatment preferences and beliefs. African Americans attended fewer sessions in PE (d = 0.87) and sertraline (d = 0.53) than Caucasians. Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention. Despite no differential effectiveness, findings may highlight the need to target retention among African Americans. Within-group cultural aspects of race may be an informative complement to basic, categorical conceptualizations.",2020,Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention.,"['African Americans', 'posttraumatic stress disorder (PTSD) among African Americans', 'African American (n\xa0=\xa043) and Caucasian (n\xa0=\xa0130) individuals received']","['prolonged exposure (PE) or sertraline', 'sertraline']","['depression and functioning, and similar treatment preferences and beliefs', 'positive attitudes', 'positive cultural attitudes']","[{'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",130.0,0.0210524,Indirect effects analyses indicated positive cultural attitudes toward other ethnoracial groups were consistently associated with better treatment outcome and retention.,"[{'ForeName': 'Alexander C', 'Initials': 'AC', 'LastName': 'Kline', 'Affiliation': 'PTSD Treatment and Research Program, Case Western Reserve University, Department of Psychological Sciences, 11220 Bellflower Road, Cleveland, OH, 44106-7123, USA. Electronic address: alexander.kline@va.gov.'}, {'ForeName': 'Norah C', 'Initials': 'NC', 'LastName': 'Feeny', 'Affiliation': 'PTSD Treatment and Research Program, Case Western Reserve University, Department of Psychological Sciences, 11220 Bellflower Road, Cleveland, OH, 44106-7123, USA.'}, {'ForeName': 'Lori A', 'Initials': 'LA', 'LastName': 'Zoellner', 'Affiliation': 'Center for Anxiety and Traumatic Stress, University of Washington, Department of Psychology, Guthrie Hall, Box 351525, Seattle, WA, 98195-1525, USA.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103690'] 1865,32650261,Efficacy and safety of systemic tranexamic acid administration in total knee arthroplasty: A case series.,"INTRODUCTION Total knee arthroplasty (TKA) are associated with significant postoperative blood loss. Tranexamic acid (TXA) is a potent agent with antifibrinolytic activity, that can be administered via the intravenous (IV) and/or topical (intra-articular, IA) route, which can possibly interrupt the cascade of events due to hemostatic irregularities close to the source of bleeding. However, the literature contains scarce scientific evidence related to IV only TXA usage in TKA. The current study aims to compare the outcome between patients who were administered IV TXA and a control group in terms of blood loss, transfusion rate, and incidence of deep vein thrombosis (DVT) and thromboembolism (TE). METHODS 110 patients, who underwent TKA were placed into two groups: 1) 34 patients who received IV TXA; and 2) 76 patients in the control group. In the TXA group, patients received an IV TXA dose of 1 g, 30 min before incision. Two drains were placed. RESULTS Usage of IV TXA showed better results when compared to the control group in terms of mean blood transfusion (0.5 less transfusion during hospital stay), hemoglobin drop (10%). No cases of DVT or TE were noted among the two study groups. CONCLUSION Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA. Moreover, TXA use is safe in terms of incidence of symptomatic DVT and TE.",2020,Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA.,"['total knee arthroplasty', '110 patients, who underwent TKA were placed into two groups: 1) 34 patients who received']","['IV TXA', 'TXA', 'systemic tranexamic acid', 'Tranexamic acid (TXA', 'Total knee arthroplasty (TKA']","['mean blood transfusion', 'DVT or TE', 'Efficacy and safety', 'blood loss, transfusion rate, and incidence of deep vein thrombosis (DVT) and thromboembolism (TE']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",110.0,0.0314014,Use of IV TXA provided significantly better results compared to no TXA use with respect to all variables related to postoperative blood loss in TKA.,"[{'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Maalouly', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Josephmaalouly2@gmail.com.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'El Assaad', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Donna.elassaad@lau.edu.'}, {'ForeName': 'Rami', 'Initials': 'R', 'LastName': 'Ayoubi', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: rami.ayoubi1@gmail.com.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Tawk', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Antoniostawk@gmail.com.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Darwish', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Mohammaddarwish2@gmail.com.'}, {'ForeName': 'Dany', 'Initials': 'D', 'LastName': 'Aouad', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Dany_aouad@hotmail.com.'}, {'ForeName': 'Georgio', 'Initials': 'G', 'LastName': 'Lati', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Georgio.lati@gmail.com.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Darwish', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: Mohammaddarwish2@gmail.com.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'El Rassi', 'Affiliation': 'Department of Orthopedic Surgery and Traumatology Saint Georges University Medical Center, Balamand University, P.O. Box 166378, Achrafieh, Beirut, 1100 2807, Lebanon. Electronic address: gselrassi@gmail.com.'}]",International journal of surgery case reports,['10.1016/j.ijscr.2020.06.077'] 1866,32652388,"Buying despite negative consequences: Interaction of craving, implicit cognitive processes, and inhibitory control in the context of buying-shopping disorder.","BACKGROUND Buying-shopping disorder (BSD) is a severe mental disorder in which individuals lose control over their buying/shopping behavior. It is debated whether BSD shares characteristics with other behavioral addictions. The current study aimed at investigating addiction-related concepts, i.e. cue-reactivity/craving, implicit cognitions, and inhibitory control mechanisms, in the context of BSD. METHODS An analog sample of 277 participants completed a cue-reactivity paradigm with shopping-related pictures. To assess implicit cognitions (attentional bias and implicit associations) and inhibitory control, a visual dot probe paradigm, an implicit association test, and an affective shifting task, all with shopping-related and control pictures, were administered. The sequence of the three tasks was randomized across participants. Craving was measured prior and after the cue-reactivity paradigm and after completion of the experimental procedure. BSD severity was assessed using the Pathological Buying Screener (PBS). RESULTS Increases in craving during the cue-reactivity paradigm, but decreases after the experimental procedure were observed. Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control. However, we found moderating effects of attentional bias and inhibitory control as well as implicit associations and inhibitory control on the relationship between craving and BSD severity. DISCUSSION/CONCLUSION Results emphasize the role of cue-reactivity/craving, implicit cognitions and inhibitory control in the context of BSD. In line with models for behavioral addictions (I-PACE; Brand et al., 2019), the interaction of affective and cognitive biases towards shopping cues and dysfunctional inhibitory control mechanisms seems to explain the pathological engagement in buying/shopping despite negative consequences.",2020,"Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control.",['An analog sample of 277 participants completed a cue-reactivity paradigm with shopping-related pictures'],[],"['Craving', 'BSD severity', 'Craving, attentional bias and implicit cognitions', 'Pathological Buying Screener (PBS', 'implicit cognitions (attentional bias and implicit associations']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}]",[],"[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0150768', 'cui_str': 'Shopping'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C4277667', 'cui_str': 'Attentional Biases'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0004083', 'cui_str': 'Association'}]",277.0,0.020093,"Craving, attentional bias and implicit cognitions were related to BSD severity-but not to inhibitory control.","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Trotzke', 'Affiliation': 'Department of General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), University of Duisburg-Essen, Duisburg, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany. Electronic address: patrick.trotzke@uni-due.de.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Müller', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Brand', 'Affiliation': 'Department of General Psychology: Cognition and Center for Behavioral Addiction Research (CeBAR), University of Duisburg-Essen, Duisburg, Germany; Erwin L. Hahn Institute for Magnetic Resonance Imaging, Essen, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Starcke', 'Affiliation': 'SRH Berlin School of Popular Arts, Berlin, Germany.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Steins-Loeber', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.'}]",Addictive behaviors,['10.1016/j.addbeh.2020.106523'] 1867,32652799,High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels.,"BACKGROUND AND AIMS Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent and nutrition intervention remains the most important therapeutic approach for NAFLD. Our aim was to investigate whether low- (LP) or high-protein (HP) diets are more effective in reducing liver fat and reversing NAFLD and which mechanisms are involved. METHODS 19 participants with morbid obesity undergoing bariatric surgery were randomized into two hypocaloric (1500-1600 kcal/day) diet groups, a low protein (10E% protein) and a high protein (30E% protein), for three weeks prior to surgery. Intrahepatic lipid levels (IHL) and serum fibroblast growth factor 21 (FGF21) were measured before and after the dietary intervention. Autophagy flux, histology, mitochondrial activity and gene expression analyses were performed in liver samples collected during surgery. RESULTS IHL levels decreased by 42.6% in the HP group, but were not significantly changed in the LP group despite similar weight loss. Hepatic autophagy flux and serum FGF21 increased by 66.7% and 42.2%, respectively, after 3 weeks in the LP group only. Expression levels of fat uptake and lipid biosynthesis genes were lower in the HP group compared with those in the LP group. RNA-seq analysis revealed lower activity of inflammatory pathways upon HP diet. Hepatic mitochondrial activity and expression of β-oxidation genes did not increase in the HP group. CONCLUSIONS HP diet more effectively reduces hepatic fat than LP diet despite of lower autophagy and FGF21. Our data suggest that liver fat reduction upon HP diets result primarily from suppression of fat uptake and lipid biosynthesis.",2020,"Hepatic autophagy flux and serum FGF21 increased by 66.7% and 42.2%, respectively, after 3 weeks in the LP group only.",['19 participants with morbid obesity undergoing bariatric surgery'],"['HP diet', 'low', 'High-protein diet', 'low protein (10E% protein) and a high protein (30E% protein', 'LP) or high-protein (HP) diets', 'hypocaloric']","['Hepatic autophagy flux and serum FGF21', 'Expression levels of fat uptake and lipid biosynthesis genes', 'IHL levels', 'Autophagy flux, histology, mitochondrial activity, and gene expression analyses', 'Hepatic mitochondrial activity and expression of β-oxidation genes', 'fat uptake and lipid biosynthesis', 'hepatic fat', 'Intrahepatic lipid levels (IHL) and serum fibroblast growth factor 21 (FGF21']","[{'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0425403', 'cui_str': 'Increased protein diet'}, {'cui': 'C0242972', 'cui_str': 'Low protein diet'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0004391', 'cui_str': 'Autophagocytosis'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0972232', 'cui_str': 'fibroblast growth factor 21'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C1563744', 'cui_str': 'Lipogenesis'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0428460', 'cui_str': 'Lipid level - finding'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0026237', 'cui_str': 'Mitochondrion'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",19.0,0.0165321,"Hepatic autophagy flux and serum FGF21 increased by 66.7% and 42.2%, respectively, after 3 weeks in the LP group only.","[{'ForeName': 'Chenchen', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Mariya', 'Initials': 'M', 'LastName': 'Markova', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Seebeck', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Loft', 'Affiliation': 'German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Hornemann', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Gantert', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kabisch', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Herz', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Loske', 'Affiliation': 'Research Group Molecular Nutritional Medicine, Department of Molecular Toxicology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Ost', 'Affiliation': 'Department of Physiology of Energy Metabolism, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'Coleman', 'Affiliation': 'Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Klauschen', 'Affiliation': 'Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Rosenthal', 'Affiliation': 'Clinic for Nutritional Medicine, Berlin, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Lange', 'Affiliation': 'Centre for Obesity and Metabolic Surgery, Vivantes Hospital, Berlin, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Machann', 'Affiliation': 'German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Klaus', 'Affiliation': 'Institute of Nutritional Science, University of Potsdam, Nuthetal, Germany.'}, {'ForeName': 'Tilman', 'Initials': 'T', 'LastName': 'Grune', 'Affiliation': 'German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Herzig', 'Affiliation': 'German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Pivovarova-Ramich', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}, {'ForeName': 'Andreas F H', 'Initials': 'AFH', 'LastName': 'Pfeiffer', 'Affiliation': 'Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE), Nuthetal, Germany.'}]",Liver international : official journal of the International Association for the Study of the Liver,['10.1111/liv.14596'] 1868,32653055,"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.","BACKGROUND Vitiligo is a chronic autoimmune disease resulting in skin depigmentation and reduced quality of life. There is no approved treatment for vitiligo repigmentation and current off-label therapies have limited efficacy, emphasising the need for improved treatment options. We investigated the therapeutic potential of ruxolitinib cream in patients with vitiligo and report the efficacy and safety results up to 52 weeks of double-blind treatment. METHODS We did a multicentre, randomised, double-blind, phase 2 study for adult patients with vitiligo in 26 US hospitals and medical centres in 18 states. Patients with depigmentation of 0·5% or more of their facial body surface area (BSA) and 3% or more of their non-facial BSA were randomly assigned (1:1:1:1:1) by use of an interactive response technology system to receive ruxolitinib cream (1·5% twice daily, 1·5% once daily, 0·5% once daily, or 0·15% once daily) or vehicle (control group) twice daily on lesions constituting 20% or less of their total BSA for 24 weeks. Patients in the control group in addition to patients in the 0·15% once daily group who did not show a 25% or higher improvement from baseline in facial Vitiligo Area Scoring Index (F-VASI) at week 24 were re-randomised to one of three higher ruxolitinib cream doses (0·5% once daily, 1·5% once daily, 1·5% twice daily). Patients in the 0·5% once daily, 1·5% once daily, or 1·5% twice daily groups remained at their original dose up to week 52. Patients, investigators, and the study sponsor (except members of the interim analysis and primary endpoint analysis data monitoring teams) remained masked to treatment assignment throughout the study. The primary endpoint was the proportion of patients achieving a 50% or higher improvement from baseline in F-VASI (F-VASI50) at week 24, assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03099304. FINDINGS Between June 7, 2017, and March 21, 2018, 205 patients were screened for eligibility, 48 were excluded and 157 patients (mean age, 48·3 years [SD 12·9]; 73 [46%] male and 84 [54%] female) were randomly assigned to either an intervention group or the control group. 32 (20%) of 157 were assigned to the control group, 31 (20%) to the 0·15% once daily group, 31 (20%) to the 0·5% once daily group, 30 (19%) to the 1·5% once daily group, and 33 (21%) to the 1·5% twice daily group. F-VASI50 at week 24 was reached by significantly more patients given ruxolitinib cream at 1·5% twice daily (15 [45%] of 33) and 1·5% once daily (15 [50%] of 30) than were treated with vehicle (one [3%] of 32). Four patients had serious treatment-emergent adverse events (one patient in the 1·5% twice daily group developed subdural haematoma; one patient in the 1·5% once daily group had a seizure; one patient in the 0·5% once daily group had coronary artery occlusion; and one patient in the 0·5% once daily group had oesophageal achalasia), all of which were unrelated to study treatment. Application site pruritus was the most common treatment-related adverse event among patients given ruxolitinib cream (one [3%] of 33 in the 1·5% twice daily group; three [10%] of 30 in the 1·5% once daily group; three [10%] of 31 in the 0·5% once daily group; and six [19%] of 31 in the 0·15% once daily group)with three [9%] of 32 patients showing application site pruritis in the control group. Acne was noted as a treatment-related adverse event in 13 (10%) of 125 patients who received ruxolitinib cream and one (3%) of 32 patients who received vehicle cream. All treatment-related adverse events were mild or moderate in severity and similar across treatment groups. INTERPRETATION Treatment with ruxolitinib cream was associated with substantial repigmentation of vitiligo lesions up to 52 weeks of treatment, and all doses were well tolerated. These data suggest that ruxolitinib cream might be an effective treatment option for patients with vitiligo. FUNDING Incyte.",2020,Application site pruritus was the most common treatment-related adverse event among patients given ruxolitinib cream (one [3%] of 33 in the 1·5% twice daily group; three [10%] of 30 in the 1·5% once daily group; three [10%] of 31 in the 0·5% once daily group; and six [19%] of 31 in the 0·15% once daily group)with three [9%] of 32 patients showing application site pruritis in the control group.,"['vitiligo', 'patients with vitiligo', 'adult patients with vitiligo in 26 US hospitals and medical centres in 18 states', '205 patients were screened for eligibility, 48 were excluded and 157 patients (mean age, 48·3 years [SD 12·9]; 73 [46%] male and 84 [54%] female', 'Between June 7, 2017, and March 21, 2018', 'Patients with depigmentation of 0·5% or more of their facial body surface area (BSA) and 3% or more of their non-facial BSA']","['interactive response technology system to receive ruxolitinib cream (1·5% twice daily, 1·5% once daily, 0·5% once daily, or 0·15% once daily) or vehicle (control group) twice daily on lesions constituting 20% or less of their total BSA', 'ruxolitinib cream', 'Ruxolitinib cream', 'vehicle cream']","['substantial repigmentation of vitiligo lesions', 'tolerated', 'F-VASI50', 'oesophageal achalasia', 'serious treatment-emergent adverse events', 'facial Vitiligo Area Scoring Index', 'subdural haematoma', 'proportion of patients achieving a 50% or higher improvement from baseline in F-VASI (F-VASI50', 'coronary artery occlusion']","[{'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0162835', 'cui_str': 'Hypopigmentation'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C2931926', 'cui_str': 'ruxolitinib'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0229978', 'cui_str': '90 percent of body surface or more'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0014848', 'cui_str': 'Achalasia of esophagus'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0018946', 'cui_str': 'Subdural hematoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0151814', 'cui_str': 'Coronary occlusion'}]",205.0,0.162939,Application site pruritus was the most common treatment-related adverse event among patients given ruxolitinib cream (one [3%] of 33 in the 1·5% twice daily group; three [10%] of 30 in the 1·5% once daily group; three [10%] of 31 in the 0·5% once daily group; and six [19%] of 31 in the 0·15% once daily group)with three [9%] of 32 patients showing application site pruritis in the control group.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rosmarin', 'Affiliation': 'Tufts Medical Center, Boston, MA, USA. Electronic address: drosmarin@tuftsmedicalcenter.org.'}, {'ForeName': 'Amit G', 'Initials': 'AG', 'LastName': 'Pandya', 'Affiliation': 'Palo Alto Foundation Medical Group, Mountain View, CA, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Lebwohl', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Pearl', 'Initials': 'P', 'LastName': 'Grimes', 'Affiliation': 'The Vitiligo and Pigmentation Institute of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Iltefat', 'Initials': 'I', 'LastName': 'Hamzavi', 'Affiliation': 'Henry Ford Medical Center, Detroit, MI, USA.'}, {'ForeName': 'Alice B', 'Initials': 'AB', 'LastName': 'Gottlieb', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Butler', 'Affiliation': 'Incyte Corporation, Wilmington, DE, USA.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Kuo', 'Affiliation': 'Incyte Corporation, Wilmington, DE, USA.'}, {'ForeName': 'Kang', 'Initials': 'K', 'LastName': 'Sun', 'Affiliation': 'Incyte Corporation, Wilmington, DE, USA.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Ji', 'Affiliation': 'Incyte Corporation, Wilmington, DE, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Howell', 'Affiliation': 'Incyte Corporation, Wilmington, DE, USA.'}, {'ForeName': 'John E', 'Initials': 'JE', 'LastName': 'Harris', 'Affiliation': 'University of Massachusetts Medical School, Worcester, MA, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)30609-7'] 1869,32653604,"Impact of bupivacaine injection to trocar sites on postoperative pain following laparoscopic hysterectomy: Results from a prospective, multicentre, double-blind randomized controlled trial.","OBJECTIVES Laparoscopic surgery has numerous advantages over open surgery in view of postoperative pain. In this context, to elevate its benefits and patient satisfaction, different pain management interventions have been used so far. This study aimed to evaluate the effect of bupivacaine injection to trocar sites following laparoscopic hysterectomy for the management of postoperative pain. STUDY DESIGN In this study, patients were randomized into two groups (56 cases; 52 controls). A single injection of bupivacaine (0.5 %, 5 mg/mL) was introduced to trocar sites under subcutaneous tissue at a dose of 4 ml for the umbilicus and 2 ml for each 5-mm ancillary trocar site in the study group. No bupivacaine was administered to the control group. The primary aim was to measure differences in 2 -h postoperative numerical rating scale (NRS) pain scores between the two groups. The secondary aims were to evaluate differences between 1-, 4-, 6-, 24- and 48 -h postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption. RESULTS The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01). The 1-, 4-, 6-, 24- and 48-hour postoperative NRS pain scores were also found to be lower in the study group compared to the control group (p < 0.01 at each follow-up). The mean duration of surgery and uterus removal, as well as the estimated blood loss, were not significantly different between the two groups. CONCLUSIONS The present study suggests that bupivacaine injection to trocar sites is an effective and safe method for reducing pain following laparoscopic hysterectomy.",2020,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,['laparoscopic hysterectomy'],"['laparoscopic hysterectomy', 'Laparoscopic surgery', 'bupivacaine injection to trocar sites', 'bupivacaine']","['48-hour postoperative NRS pain scores', '2 -h postoperative numerical rating scale (NRS) pain scores', 'mean duration of surgery and uterus removal', 'postoperative pain', 'postoperative NRS pain scores, surgical complications, estimated blood loss, duration of operation and analgesic consumption', 'estimated blood loss', 'pain', 'number of postoperative rescue doses of analgesics']","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C4060211', 'cui_str': 'Bupivacaine Injection [Sensorcaine]'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]","[{'cui': 'C0439586', 'cui_str': '48 hours'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.144145,The number of postoperative rescue doses of analgesics was found to be lower in the study group compared to the control group (median of 2 vs. 4; p < 0.01).,"[{'ForeName': 'Ismet', 'Initials': 'I', 'LastName': 'Hortu', 'Affiliation': 'Department of Obstetrics and Gynaecology, Ege University School of Medicine, Izmir, Turkey; Department of Stem Cell, Ege University Institute of Health Sciences, Izmir, Turkey. Electronic address: ismethortu@yahoo.com.'}, {'ForeName': 'Unal', 'Initials': 'U', 'LastName': 'Turkay', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Terzi', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Kale', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Yılmaz', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Canan', 'Initials': 'C', 'LastName': 'Balcı', 'Affiliation': 'Department of Anaesthesiology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Umit', 'Initials': 'U', 'LastName': 'Aydın', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Health Sciences Derince Education and Research Hospital, Kocaeli, Turkey.'}, {'ForeName': 'Antonio Simone', 'Initials': 'AS', 'LastName': 'Laganà', 'Affiliation': 'Department of Obstetrics and Gynaecology, ""Filippo Del Ponte"" Hospital, University of Insubria, Varese, Italy.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.07.007'] 1870,32653606,Effects of the levonorgestrel intrauterine system on the endometrium after long-term exposure to mifepristone: Secondary outcomes of a randomized controlled trial.,"OBJECTIVE Long-term treatment with progesterone receptor modulators (PRM) is associated with a distinct histological entity termed progesterone receptor modulator associated endometrial changes (PAEC). While accumulating evidence implies that these changes are benign and reversible after cessation of treatment, there are currently no data underpinning their development. Consequently, as a precaution, endometrial shedding is recommended after long-term PRM intake. Avoiding endometrial shedding after treatment with a PRM and prior to the start of a progestin treatment would be beneficial for women in reproductive age to avoid pregnancy and bleeding. However, the endometrial morphology with such a treatment regimen is unknown. The aim of this study was to delineate the endometrial morphology following continuous long-term treatment with the PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS) without prior shedding of the endometrium. STUDY DESIGN This study reports the secondary outcome from a double-blinded randomized controlled trial conducted at Karolinska University Hospital, Sweden, November 2009 to January 2015. Healthy women aged 18-43 years with regular menstrual cycles were included. Eligible women were randomized to receive either 50 mg of mifepristone (n = 29) or a comparator (n = 29), every other day for two months followed by insertion of an LNG-IUS 52 mg. Endometrial biopsies were obtained at baseline and three months after placement of the device. The samples were histologically assessed. The main outcome measure of this sub-study was the endometrial morphology including presence of PAEC three months after LNG-IUS insertion. RESULTS Nine and eight paired biopsies from the mifepristone and comparator group, respectively, were included in the histological analysis. There were no differences in baseline characteristics between the groups and all baseline endometrial biopsies were physiological. Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator. A progestin effect on the endometrium was seen in all samples. CONCLUSIONS Placement of an LNG-IUS immediately following two months' treatment with the PRM mifepristone, without any prior shedding of the endometrium, may represent a feasible approach in terms of endometrial safety. However, larger studies are needed to confirm our results.",2020,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"['Karolinska University Hospital, Sweden, November 2009 to January 2015', 'Eligible women', 'Healthy women aged 18-43 years with regular menstrual cycles']","['progesterone receptor modulators (PRM', 'mifepristone', 'PRM mifepristone', 'levonorgestrel intrauterine system', 'progestin treatment', 'PRM mifepristone and subsequent placement of a levonorgestrel intrauterine system (LNG-IUS']",['Endometrial biopsies'],"[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0025329', 'cui_str': 'Normal menstrual cycle'}]","[{'cui': 'C3653463', 'cui_str': 'Progesterone receptor modulators'}, {'cui': 'C0026088', 'cui_str': 'Mifepristone'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0404066', 'cui_str': 'Endometrial scraping'}]",,0.419988,Three months after LNG-IUS placement the endometrial morphology was still benign without PAEC in all samples treated with either mifepristone or comparator.,"[{'ForeName': 'Kiriaki', 'Initials': 'K', 'LastName': 'Papaikonomou', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden. Electronic address: kiriaki.papaikonomou@ki.se.""}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Frisendahl', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}, {'ForeName': 'Alistair R W', 'Initials': 'ARW', 'LastName': 'Williams', 'Affiliation': 'Division of Pathology, The Royal Infirmary of Edinburgh, The University of Edinburgh, Edinburgh, United Kingdom.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Gemzell-Danielsson', 'Affiliation': ""Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.""}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.056'] 1871,32653721,Leveraging immersive technology to expand access to opioid overdose reversal training in community settings: Results from a randomized controlled equivalence trial.,"BACKGROUND Immersive video (e.g. virtual reality) poses a promising and engaging alternative to standard in-person trainings and can potentially increase access to evidence-based opioid overdose prevention programs (OOPPs). Therefore, the objective of this equivalence study was to test whether the immersive video OOPP was equivalent to a standard in-person OOPP for changes in opioid overdose knowledge and attitudes. METHODS A team of nurses and communication researchers developed a 9-minute immersive video OOPP. To test whether this immersive video OOPP (treatment) demonstrated equivalent gains in opioid overdose response knowledge and attitudes as in-person OOPPs (standard of care control), researchers deployed a two-day field experiment in Philadelphia, Pennsylvania, USA. In this equivalence trial, 9 libraries were randomly assigned to offer treatment or control OOPP to community members attending naloxone giveaway events. In this equivalence design, a difference between treatment and control groups pre- to post-training scores within -1.0 to 1.0 supports equivalence between the trainings. RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP. However, these minor differences in knowledge and attitudes were within the equivalence interval indicating that the immersive video OOPP remained equivalently effective for community members. CONCLUSIONS Community partnerships, like those between public health departments and libraries, can provide opportunities for deploying novel immersive video OOPP that, alongside standard offerings, can strengthen community response to the opioid crisis.",2020,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.",['community settings'],"['immersive video OOPP (treatment', 'immersive video OOPP', 'control OOPP']","['posttest knowledge', 'favorable attitudes about responding to an opioid overdose']","[{'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0029944', 'cui_str': 'Drug overdose'}]",9.0,0.046718,"RESULTS Results demonstrate participants (N = 94) exposed to the immersive video OOPP had equivalent improvements on posttest knowledge (β=-0.18, p = .61) and more favorable attitudes about responding to an opioid overdose (β=0.26, p = .02) than those exposed to the standard OOPP.","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Herbert', 'Affiliation': 'Woods Institute for the Environment, Stanford University, 473 Via Ortega, Stanford, CA, USA.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Axson', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Leeann', 'Initials': 'L', 'LastName': 'Siegel', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Cassidy', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, 620 Walnut Street, Philadelphia, PA, USA.'}, {'ForeName': 'Ann Marie', 'Initials': 'AM', 'LastName': 'Hoyt-Brennan', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Whitney', 'Affiliation': 'School of Nursing, University of Pennsylvania, 418 Curie Boulevard, Philadelphia, PA, USA.'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Herens', 'Affiliation': 'Division of Substance Use Prevention and Harm Reduction, Philadelphia Department of Public Health, 1101 Market Street, 13th Floor, Suite 1320, Philadelphia PA, USA.'}, {'ForeName': 'Nicholas A', 'Initials': 'NA', 'LastName': 'Giordano', 'Affiliation': 'Nell Hodgson Woodruff School of Nursing, Emory University, 1520 Clifton Road, Atlanta, GA, USA. Electronic address: ngiorda@emory.edu.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108160'] 1872,32655245,A Comparative Study to Assess the Efficacy of Fractional Carbon Dioxide Laser and Combination of Fractional Carbon Dioxide Laser with Topical Autologous Platelet-rich Plasma in Post-acne Atrophic Scars.,"Context Acne vulgaris is a chronic inflammatory disorder of the pilosebaceous unit prevalent in adolescent population. Atrophic acne scarring negatively affects the quality of life. Although challenging to treat, the introduction of fractional carbon dioxide (CO 2 ) laser and platelet-rich plasma (PRP) therapy for atrophic scars has opened up new avenues. Aim The aim of this study was to evaluate and compare the efficacy of fractional CO 2 laser alone and in combination with topical PRP in treating post-acne atrophic scars. Subjects and Methods A hospital-based prospective, double-blinded, randomized, and comparative study was conducted. A total of 33 cases with post-acne atrophic scars of moderate to severe grade were randomly allotted into Group A and Group B who were treated for three monthly sessions of fractional CO 2 laser followed by topical PRP and fractional CO 2 laser monotherapy, respectively. Evaluation at baseline and every visit was carried out and compared at the end of 12 weeks. Results Of the 33 patients, 25 completed the study. The mean change in score was higher in subjects of Group A. The mean scar score significantly reduced in both groups. The mean visual analog scale was higher in Group A. The reduction in scar score was significantly higher in patients with rolling scars and boxcar scars and least in ice pick scars. Erythema, edema, pain, and hyperpigmentation were higher in Group B. Conclusion Combination therapy with PRP is more efficacious in reducing post-acne atrophic scars and reducing adverse effects of laser therapy as compared to fractional CO 2 laser monotherapy.",2019,The reduction in scar score was significantly higher in patients with rolling scars and boxcar scars and least in ice pick scars.,"['33 patients', '33 cases with post-acne atrophic scars of moderate to severe grade', 'Subjects and Methods\n\n\nA hospital-based prospective', 'Post-acne Atrophic Scars']","['PRP', 'fractional carbon dioxide (CO 2 ) laser and platelet-rich plasma (PRP) therapy', 'fractional CO 2 laser followed by topical PRP and fractional CO 2 laser monotherapy', 'Fractional Carbon Dioxide Laser and Combination of Fractional Carbon Dioxide Laser with Topical Autologous Platelet-rich Plasma', 'fractional CO 2 laser alone and in combination with topical PRP']","['quality of life', 'mean visual analog scale', 'mean scar score', 'scar score', 'Erythema, edema, pain, and hyperpigmentation', 'mean change in score', 'adverse effects', 'Atrophic acne scarring']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0162154', 'cui_str': 'Atrophic scar'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0392251', 'cui_str': 'Carbon dioxide laser device'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}]",33.0,0.0307602,The reduction in scar score was significantly higher in patients with rolling scars and boxcar scars and least in ice pick scars.,"[{'ForeName': 'Nazneen Z', 'Initials': 'NZ', 'LastName': 'Arsiwala', 'Affiliation': 'Department of Dermatology, Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Bijapur, Karnataka, India.'}, {'ForeName': 'Arun C', 'Initials': 'AC', 'LastName': 'Inamadar', 'Affiliation': 'Department of Dermatology, Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Bijapur, Karnataka, India.'}, {'ForeName': 'Keshavmurthy A', 'Initials': 'KA', 'LastName': 'Adya', 'Affiliation': 'Department of Dermatology, Shri B. M. Patil Medical College, Hospital and Research Centre, BLDE (Deemed to be University), Bijapur, Karnataka, India.'}]",Journal of cutaneous and aesthetic surgery,['10.4103/JCAS.JCAS_142_19'] 1873,32658765,Assessment of stress markers in restrained individuals following physical stress with and without sham CED activation.,"INTRODUCTION Law enforcement and pre-hospital care personnel often confront individuals who must be physically restrained. Many are under the influence of illicit substances, and law enforcement officers may need to use a controlled electrical device (CED) to gain control of the individual and they are often placed into the prone maximum restraint (PMR) position. These techniques have previously been evaluated for their physiologic effects. The purpose of this study was to investigate the psychological effects of anticipating and experiencing a sham CED activation in healthy human subjects who were exercised and restrained compared with no sham activation by assessing the differences in a panel of several known biomarkers of stress. METHODS We performed a randomized, crossover controlled human subject trial to study the stress associated with exercise, physical exhaustion, and restraint with and without an added psychological stress simulating the field use of a CED. Twenty five total subjects; each subject performed two different trials each consisting of a brief period of intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress. Blood samples were collected for analysis pre and post exercise, as well as 10 min after completion of the exercise. A panel of hormones and stress markers were measured. RESULTS We found no significant differences in any of the stress biomarkers measured between the two study groups. A trend towards higher levels of copeptin was measured in the sham CED activation arm. CONCLUSION During a brief period of intense exercise followed by the psychological stress of anticipated CED application, there did not appear to be statistically significant changes in the stress panel of biomarkers measured, only a trend towards significance for higher copeptin levels in the patients exposed to the psychological stress.",2020,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"['healthy human subjects', 'Twenty five total subjects']",['intense exercise on a treadmill to exhaustion followed by placement in the PMR with and without induced psychological stress'],"['stress biomarkers', 'levels of copeptin']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0033422', 'cui_str': 'Prone body position'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0035260', 'cui_str': 'Physical restraint'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0038443', 'cui_str': 'Psychological Stress'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0056279', 'cui_str': 'copeptins'}]",25.0,0.0515782,We found no significant differences in any of the stress biomarkers measured between the two study groups.,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Sloane', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA. Electronic address: csloane@ucsd.edu.'}, {'ForeName': 'Deborah C', 'Initials': 'DC', 'LastName': 'Mash', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Theodore C', 'Initials': 'TC', 'LastName': 'Chan', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Kolkhorst', 'Affiliation': 'School of Exercise and Nutritional Sciences, San Diego State University San Diego, CA, USA.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Neuman', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Edward M', 'Initials': 'EM', 'LastName': 'Castillo', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Lasoff', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Wardi', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA; Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, San Diego, San Diego, CA, USA.'}, {'ForeName': 'Xiaobin', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'Department of Neurology, Molecular and Cellular Pharmacology, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Gary M', 'Initials': 'GM', 'LastName': 'Vilke', 'Affiliation': 'Department of Emergency Medicine, University of California, San Diego, CA, USA.'}]",Journal of forensic and legal medicine,['10.1016/j.jflm.2020.101982'] 1874,32658797,Addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia improves analgesic efficacy after tonsillectomy and adenoidectomy: A randomized controlled trial.,"OBJECTIVES The aim of this study was to determine whether the addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia was more effective than ropivacaine alone in attenuating pain after tonsillectomy and adenoidectomy. METHODS This was a double-blind randomized clinical trial. One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia were randomized into the dexmedetomidine plus ropivacaine group (DR) and ropivacaine group (R). The children were locally infiltrated with 1 μg kg -1 dexmedetomidine and 0.25% ropivacaine in the DR group or 0.25% ropivacaine alone in the R group. In both groups, local infiltration anaesthesia was performed using 5 ml of solution. The pain scores were recorded at the 1st, 4th, 8th, 12th, 16th, 20th, and 24th hours after surgery using the Face Legs Activity Cry Consolability (FLACC) scale. When the pain score exceeded 4, paracetamol syrup (15 mg kg -1 ) was administered as a rescue analgesic. Time to the first administration of analgesic was recorded. RESULTS 8th, 16th, 20th, and 24th hours after surgery, the children in the DR group had lower pain scores than those in the R group (P<0.05). The time to the first administration of analgesic was significantly longer in the DR group (mean: 10.4 h, range: 9.4-11.4 h) than in the R group (mean: 8.1 h, range: 7.3-8.8 h) (P < 0.001). CONCLUSION The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.",2020,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,['One hundred and twenty children scheduled for tonsillectomy and adenoidectomy using a combination of general anaesthesia and local infiltration anaesthesia'],"['dexmedetomidine plus ropivacaine', 'tonsillectomy and adenoidectomy', 'ropivacaine', 'paracetamol syrup', 'dexmedetomidine']","['pain scores', 'Face Legs Activity Cry Consolability (FLACC) scale', 'efficacy of analgesia and extended the duration of analgesia', 'time to the first administration of analgesic', 'analgesic efficacy', 'pain', 'pain score', 'lower pain scores']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0198813', 'cui_str': 'Local anesthesia, by infiltration'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0193959', 'cui_str': 'Tonsillectomy and adenoidectomy'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0010399', 'cui_str': 'Crying'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0262176', 'cui_str': 'Administration of analgesic'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",120.0,0.171204,The addition of dexmedetomidine to ropivacaine for local infiltration anaesthesia effectively improved the efficacy of analgesia and extended the duration of analgesia after tonsillectomy and adenoidectomy.,"[{'ForeName': 'Jianhong', 'Initials': 'J', 'LastName': 'Hao', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zanqing', 'Initials': 'Z', 'LastName': 'Wu', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Zhenguo', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China.""}, {'ForeName': 'Buhuai', 'Initials': 'B', 'LastName': 'Dong', 'Affiliation': ""Department of Anesthesiology, HongHui Hospital, Xi'an JiaoTong University, Xi'an, China. Electronic address: dongbuhai@sina.com.""}]",International journal of pediatric otorhinolaryngology,['10.1016/j.ijporl.2020.110168'] 1875,32658817,Effects of family-focused therapy on suicidal ideation and behavior in youth at high risk for bipolar disorder.,"BACKGROUND Youth who are at clinical and familial risk for bipolar disorder (BD) often have significant suicidal ideation (SI). In a randomized trial, we examined whether family-focused therapy (FFT) is associated with reductions in SI and suicidal behaviors in high-risk youth. METHODS Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II. Participants were randomly allocated to 12 sessions in 4 months of FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC), with pharmacotherapy as needed. Clinician- and child-rated assessments of mood, suicidal thoughts and behaviors, and family conflict were obtained at baseline and 4-6 month intervals over 1-4 years. RESULTS Participants (N=127; mean 13.2±2.6 yrs., 82 female) were followed over an average of 105.9±64.0 weeks. Youth with high baseline levels of SI who received FFT had lower levels of (and fewer weeks with) SI at follow-up compared to youth with high baseline SI who received EC. Participants in FFT had longer intervals without suicidal behaviors than participants in EC. Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. LIMITATIONS Family conflict was based on questionnaires rather than observer ratings of family interactions. CONCLUSIONS Family psychoeducation with skill training can be an effective deterrent to suicidal thoughts and behaviors in youth at high risk for BD. Reducing parent/offspring conflict should be a central objective of psychosocial interventions for high-risk youth with SI.",2020,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","['Youth who are at clinical and familial risk for bipolar disorder (BD', 'youth at high risk for bipolar disorder', 'Participants (N=127; mean 13.2±2.6 yrs., 82 female', 'high-risk youth with SI', 'Participants (ages 9-17 years) met diagnostic criteria for unspecified BD or major depressive disorder with active mood symptoms and had at least one relative with BD type I or II', 'Youth with high baseline levels of SI who received']","['FFT or 6 sessions in 4 months of psychoeducation (enhanced care, EC', 'family-focused therapy', 'FFT', 'skill training', 'family-focused therapy (FFT']","['longer intervals without suicidal behaviors', 'SI and suicidal behaviors', 'mood, suicidal thoughts and behaviors, and family conflict', 'suicidal ideation and behavior']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C1760428', 'cui_str': 'Suicidal behavior'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0233542', 'cui_str': 'Family conflict'}]",127.0,0.111281,"Youths' ratings of family conflict significantly mediated the effects of treatment on SI at follow-up. ","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Miklowitz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA. Electronic address: dmiklowitz@mednet.ucla.edu.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Merranko', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Weintraub', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Patricia D', 'Initials': 'PD', 'LastName': 'Walshaw', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Los Angeles (UCLA) School of Medicine, University of California, 760 Westwood Plaza Rm A8-256, Los Angeles, 90024-1759 CA, USA.'}, {'ForeName': 'Manpreet K', 'Initials': 'MK', 'LastName': 'Singh', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Kiki D', 'Initials': 'KD', 'LastName': 'Chang', 'Affiliation': 'Private Practice, Menlo Park, CA, USA.'}, {'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Schneck', 'Affiliation': 'Department of Psychiatry, University of Colorado Anschutz Medical Campus, Denver, CO, USA.'}]",Journal of affective disorders,['10.1016/j.jad.2020.06.015'] 1876,32658822,Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study.,"BACKGROUND This report seeks to evaluate improvements in symptoms of irritability with sertraline (a selective serotonin reuptake inhibitor antidepressant) versus placebo. METHODS Participants of Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study who were randomized to 8 weeks of treatment with either sertraline or placebo and completed 5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR) at baseline were included (n = 292). Repeated measures mixed model analysis with CAST-IRR as the outcome variable and treatment arm-by-time interaction as the independent variable of interest evaluated whether changes in irritability with treatment differed between sertraline and placebo arms. A separate analysis controlled for levels of overall depression severity (17-item Hamilton Depression Rating Scale). Covariates included age, sex, race, ethnicity, and site. RESULTS There was a significant treatment arm-by-time interaction (F = 6.96, df = 6, 1418, p <0.0001) suggesting that changes in irritability with sertraline differed from placebo. The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56). After controlling for levels of overall depression severity at each visit, reduction in irritability with time continued to be significant with sertraline but not with placebo. LIMITATIONS Secondary analysis, limited generalizability, lack of non-serotonergic antidepressants. DISCUSSION There is greater improvement in irritability with sertraline than with placebo. Improvement in irritability with sertraline was independent of its effects on overall depression severity. CLINICALTRIALS. GOV IDENTIFIER NCT01407094.",2020,The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56).,['Participants of Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study who'],"['sertraline or placebo', 'sertraline', 'placebo']","['5-item irritability domain of Concise Associated Symptom Tracking scale (CAST-IRR', 'reduction in irritability', 'overall depression severity', 'irritability', 'overall depression severity (17-item Hamilton Depression Rating Scale']","[{'cui': 'C0443211', 'cui_str': 'Established'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0521989', 'cui_str': 'Associated symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0083017', 'cui_str': 'insulin receptor-related receptor'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}]",,0.370511,The magnitude of reduction in irritability from baseline to week-8 was greater with sertraline than with placebo (Cohen's d effect size = 0.56).,"[{'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Jha', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States.'}, {'ForeName': 'Abu', 'Initials': 'A', 'LastName': 'Minhajuddin', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States.'}, {'ForeName': 'Cherise', 'Initials': 'C', 'LastName': 'Chin Fatt', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States.'}, {'ForeName': 'Madhukar H', 'Initials': 'MH', 'LastName': 'Trivedi', 'Affiliation': 'Center for Depression Research and Clinical Care, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9119, United States. Electronic address: madhukar.trivedi@utsouthwestern.edu.'}]",Journal of affective disorders,['10.1016/j.jad.2020.06.021'] 1877,32677876,Intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells in patients with symptomatic bilateral knee osteoarthritis: a Phase I pilot study.,"Aim: This study investigated the safety and clinical outcomes of expanded allogeneic human adipose-derived mesenchymal progenitor cells injected into patients with symptomatic, bilateral knee osteoarthritis. Design: In this single-site, randomized, double-blind, dose-ranging, Phase I study, patients were randomized to three treatment groups (low dose, 1 × 10 7 cells; medium dose, 2 × 10 7 cells; high dose, 5 × 10 7 cells). All patients received two bilateral intra-articular injections: week 0 (baseline) and week 3. The primary end point was adverse events within 48 weeks. Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48. Quantitative MRI measurements of cartilage volume were compared from baseline and week 48. Results:  A total of 22 subjects were enrolled of which 19 (86%) completed the study. Adverse events were transient, including mild to moderate pain and swelling of injection site. Improvements from baseline were measured in the secondary end points. MRI assessments showed slight improvements in the low-dose group. Conclusion: Safety and improvements in pain and function after intra-articular injections of allogeneic human adipose-derived mesenchymal progenitor cells into arthritic patients was demonstrated.",2020,"Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48.","['arthritic patients', 'A total of\xa022 subjects were enrolled of which\xa019 (86%) completed the study', 'patients with symptomatic, bilateral knee osteoarthritis', 'patients with symptomatic bilateral knee osteoarthritis']","['allogeneic human adipose-derived mesenchymal progenitor cells', 'expanded allogeneic human adipose-derived mesenchymal progenitor cells']","['Quantitative MRI measurements of cartilage volume', 'pain and function', 'adverse events', 'Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C3535670', 'cui_str': 'human adipose preparation'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}]","[{'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C3472647', 'cui_str': 'Western Ontario and McMaster Universities osteoarthritis index'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}]",22.0,0.457349,"Secondary end points were measured with Western Ontario and McMaster Universities Osteoarthritis index, visual analog scale, short form-36 at weeks 12, 24 and 48.","[{'ForeName': 'Liangjing', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Chengxiang', 'Initials': 'C', 'LastName': 'Dai', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Du', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Suke', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Ye', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Xiaoying', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Cellular Biomedicine Group, 333 Guiping Road, Bldg 1, 6th FI, Shanghai 200233, PR China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Togashi', 'Affiliation': 'Department of Orthopaedic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, CA 90033, USA.'}, {'ForeName': 'C Thomas', 'Initials': 'CT', 'LastName': 'Vangsness', 'Affiliation': 'Department of Orthopaedic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, CA 90033, USA.'}, {'ForeName': 'Chunde', 'Initials': 'C', 'LastName': 'Bao', 'Affiliation': 'Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai 200001, PR\xa0China.'}]",Regenerative medicine,['10.2217/rme-2019-0106'] 1878,32653532,Quantitative Assessment of the Efficacy of Two Different Single-file Systems in Reducing the Bacterial load in Oval-Shaped Canals: A Clinical Study.,"INTRODUCTION This randomized clinical study compared the in vivo antibacterial efficacy of Reciproc Blue (RB), XP-endo Shaper (XP-S), and XP-endo Shaper associated with XP-endo Finisher (XP-F) systems in infected oval-shaped root canals with primary apical periodontitis. METHODS In this study, 28 human teeth with a single root and a single canal were randomly assigned to 2 groups according to the instrumentation technique: group 1, RB (n = 14) and group 2, XP-endo (XP-S and XP-F, n = 14). The single-rooted teeth were prepared by reciprocating and rotary nickel-titanium instruments with 5.25% sodium hypochlorite irrigation. Samples were collected from the canal at the baseline (S1), after chemomechanical preparation (S2), and after XP-F instrumentation (S3). The DNA extracts were subjected to quantitative analysis for total bacterial counts by quantitative real-time polymerase chain reaction. The data were analyzed using the analysis of variance test, and the level of significance was set at 5%. RESULTS All samples tested positive for the presence of bacteria at baseline, and the bacterial counts substantially reduced after treatment procedures (P < .01). The results showed no statistical difference between RB and XP-S instrumentation with respect to the bacterial reduction (P > .05). A marked bacterial reduction was observed after the use of the XP-F instrument (P < .01). CONCLUSIONS The XP-S and RB systems sharply reduced the bacterial load in oval-shaped root canals with primary apical periodontitis. XP-F used as a supplementary instrument to chemomechanical preparation promoted a significantly higher bacterial reduction.",2020,The results showed no statistical difference between RB and XP-S instrumentation with respect to the bacterial reduction (P ˃ 0.05).,"['Oval- Shaped Canals', '28 human teeth with a single root and a single canal', 'infected oval-shaped root canals with primary apical periodontitis']","['reciprocating and rotary nickel-titanium (NiTi) instruments with 5.25% sodium hypochlorite irrigation', 'Reciproc Blue (RB), XP-endo Shaper (XP-S),XP-endo Shaper associated with XP-endo Finisher (XP-F) systems']","['bacterial counts', 'bacterial reduction']","[{'cui': 'C0332479', 'cui_str': 'Shape finding'}, {'cui': 'C0086881', 'cui_str': 'Pulp canal'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0031030', 'cui_str': 'Apical periodontitis'}]","[{'cui': 'C0068790', 'cui_str': 'nitinol'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0037518', 'cui_str': 'sodium hypochlorite'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C1260957', 'cui_str': 'Blue color'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}]","[{'cui': 'C0004618', 'cui_str': 'Bacterial count'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",28.0,0.0301852,The results showed no statistical difference between RB and XP-S instrumentation with respect to the bacterial reduction (P ˃ 0.05).,"[{'ForeName': 'Rodrigo Rodrigues', 'Initials': 'RR', 'LastName': 'Amaral', 'Affiliation': 'School of Dentistry and Oral Health Griffith University, Gold Coast, Queensland, Australia; Department of Dentistry, Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. Electronic address: dr.rodrigoamaral@gmail.com.'}, {'ForeName': 'Anna Gabriella', 'Initials': 'AG', 'LastName': 'Guimarães Oliveira', 'Affiliation': 'Laboratory of Oral Microbiology and Anaerobes, Department of Microbiology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Tiago', 'Initials': 'T', 'LastName': 'Braga', 'Affiliation': 'School of Dentistry and Oral Health Griffith University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reher', 'Affiliation': 'School of Dentistry and Oral Health Griffith University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Luiz', 'Initials': 'L', 'LastName': 'de Macêdo Farias', 'Affiliation': 'Laboratory of Oral Microbiology and Anaerobes, Department of Microbiology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Paula Prazeres', 'Initials': 'PP', 'LastName': 'Magalhães', 'Affiliation': 'Laboratory of Oral Microbiology and Anaerobes, Department of Microbiology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Pedro Gonçalves', 'Initials': 'PG', 'LastName': 'Ferreira', 'Affiliation': 'Department of Dentistry, Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Ilma de Souza Côrtes', 'Affiliation': 'Department of Dentistry, Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.'}]",Journal of endodontics,['10.1016/j.joen.2020.06.007'] 1879,31818048,Comparison of Effectiveness between Abdominal Vibration Stimulation and Walking Exercise for Bowel Cleansing before Therapeutic Colonoscopy.,"Background/Aims Adequate bowel preparation is important for successful colonoscopy. We aimed to evaluate the clinical feasibility and effectiveness of abdominal vibration stimulation in bowel preparation before therapeutic colonoscopy. Methods A single center, prospective, randomized, investigator-blinded study was performed between January 2016 and December 2016. Patients for therapeutic colonoscopy were prospectively enrolled and assigned to either the vibrator group or walking group. Patients who refused to participate in this study as part of the experimental group consented to register in the control group instead. During the preparation period, patients assigned to the walking group walked ≥3,000 steps, whereas those assigned to the vibrator group received abdominal vibrator stimulation and restricted walking. All patients received the same colon cleansing regimen: 4-L split-dose polyethylene glycol (PEG) solution. Results Three hundred patients who received PEG solution for therapeutic colonoscopy were finally enrolled in this study (n=100 per group). Bowel cleansing with abdominal vibration stimulation showed almost similar results to that with walking exercise (Boston Bowel Preparation Scale score for the entire colon: vibrator vs walking vs control, 7.38±1.55 vs 7.39±1.55 vs 6.17±1.15, p<0.001). There were no significant differences between the vibrator group and walking group regarding instances of diarrhea after taking PEG, time to first diarrhea after taking PEG, total procedure time, and patient satisfaction. Conclusions This study indicates that, compared with conventional walking exercise, abdominal vibration stimulation achieved similar rates of bowel cleansing adequacy and colonoscopy success without compromising safety or patient satisfaction.",2020,"There were no significant differences between the vibrator group and walking group regarding instances of diarrhea after taking PEG, time to first diarrhea after taking PEG, total procedure time, and patient satisfaction. ","['January 2016 and December 2016', 'Patients who refused to participate in this study as part of the experimental group consented to register in the control group instead', 'Patients for therapeutic colonoscopy', 'Three hundred patients who received']","['PEG solution', 'vibrator group or walking group', 'Abdominal Vibration Stimulation and Walking Exercise', 'conventional walking exercise, abdominal vibration stimulation', 'vibrator group received abdominal vibrator stimulation and restricted walking', 'same colon cleansing regimen: 4-L split-dose polyethylene glycol (PEG) solution', 'abdominal vibration stimulation']","['walking exercise (Boston Bowel Preparation Scale score', 'diarrhea after taking PEG, time to first diarrhea after taking PEG, total procedure time, and patient satisfaction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1136454', 'cui_str': 'Refusal to Participate'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0554063', 'cui_str': 'Therapeutic colonoscopy'}, {'cui': 'C4319604', 'cui_str': '300'}]","[{'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0184304', 'cui_str': 'Vibrator'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4302285', 'cui_str': 'BBPS - Boston bowel preparation scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0032483', 'cui_str': 'Polyethylene Glycols'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}]",300.0,0.0410102,"There were no significant differences between the vibrator group and walking group regarding instances of diarrhea after taking PEG, time to first diarrhea after taking PEG, total procedure time, and patient satisfaction. ","[{'ForeName': 'Choong-Kyun', 'Initials': 'CK', 'LastName': 'Noh', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'In Sung', 'Initials': 'IS', 'LastName': 'Kim', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Gil Ho', 'Initials': 'GH', 'LastName': 'Lee', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Jin Woong', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Eunyoung', 'Initials': 'E', 'LastName': 'Lee', 'Affiliation': 'Departments of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Bumhee', 'Initials': 'B', 'LastName': 'Park', 'Affiliation': 'Departments of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Hye Jeon', 'Initials': 'HJ', 'LastName': 'Hong', 'Affiliation': 'General Ward Nursing Unit, Ajou University Medical Center, Suwon, Korea.'}, {'ForeName': 'Sun Gyo', 'Initials': 'SG', 'LastName': 'Lim', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Sung Jae', 'Initials': 'SJ', 'LastName': 'Shin', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Jin Hong', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}, {'ForeName': 'Kee Myung', 'Initials': 'KM', 'LastName': 'Lee', 'Affiliation': 'Departments of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.'}]",Gut and liver,['10.5009/gnl19999'] 1880,32659483,Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts.,"BACKGROUND Traumatic stress can have lasting effects on neurobiology and result in psychiatric conditions such as posttraumatic stress disorder (PTSD). We hypothesize that non-invasive cervical vagal nerve stimulation (nVNS) may alleviate trauma symptoms by reducing stress sympathetic reactivity. This study examined how nVNS alters neural responses to personalized traumatic scripts. METHODS Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study. In three sequential time blocks, personalized traumatic scripts were presented to participants immediately followed by either sham stimulation (n = 8; 0-14 V, 0.2 Hz, pulse width = 5s) or active nVNS (n = 11; 0-30 V, 25 Hz, pulse width = 40 ms). Brain activity during traumatic scripts was assessed using High Resolution Positron Emission Tomography (HR-PET) with radiolabeled water to measure brain blood flow. RESULTS Traumatic scripts resulted in significant activations within the bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen. Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate. During the first exposure to the trauma scripts, greater activations were found in the motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations were more predominant with later script presentations for those subjects receiving sham stimulation. CONCLUSION nVNS decreases neural reactivity to an emotional stressor in limbic and other brain areas involved in stress, with changes over repeated exposures suggesting a shift from scene appraisal to cognitively processing the emotional event.",2020,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.",['Nineteen participants who had experienced trauma but did not have the diagnosis of PTSD completed this double-blind sham-controlled study'],"['invasive cervical vagal nerve stimulation (nVNS', 'active nVNS', 'nVNS']","['bilateral medial and orbital prefrontal cortex, premotor cortex, anterior cingulate, thalamus, insula, hippocampus, right amygdala, and right putamen', 'motor cortices and ventral visual stream whereas prefrontal cortex and anterior cingulate activations', 'Greater activation', 'Brain activity']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0205177', 'cui_str': 'Active'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0699036', 'cui_str': 'Orbital'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0228202', 'cui_str': 'Premotor cortex'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0039729', 'cui_str': 'Thalamic structure'}, {'cui': 'C0021640', 'cui_str': 'Insular structure'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0026607', 'cui_str': 'Motor cortex'}, {'cui': 'C1704448', 'cui_str': 'Ventral'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0442540', 'cui_str': 'Stream'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0443158', 'cui_str': 'Brain activity'}]",19.0,0.0708328,"Greater activation was observed during sham stimulation compared to nVNS within the bilateral prefrontal and orbitofrontal cortex, premotor cortex, temporal lobe, parahippocampal gyrus, insula, and left anterior cingulate.","[{'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Wittbrodt', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA. Electronic address: mattwittbrodt@emory.edu.'}, {'ForeName': 'Nil Z', 'Initials': 'NZ', 'LastName': 'Gurel', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Jonathon A', 'Initials': 'JA', 'LastName': 'Nye', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Ladd', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Md Mobashir H', 'Initials': 'MMH', 'LastName': 'Shandhi', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'Minxuan', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Amit J', 'Initials': 'AJ', 'LastName': 'Shah', 'Affiliation': 'Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}, {'ForeName': 'Bradley D', 'Initials': 'BD', 'LastName': 'Pearce', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Zuhayr S', 'Initials': 'ZS', 'LastName': 'Alam', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Rapaport', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Murrah', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Yi-An', 'Initials': 'YA', 'LastName': 'Ko', 'Affiliation': 'Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Ammer A', 'Initials': 'AA', 'LastName': 'Haffer', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Lucy H', 'Initials': 'LH', 'LastName': 'Shallenberger', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Vaccarino', 'Affiliation': 'Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Department of Medicine (Cardiology), Emory University School of Medicine, Atlanta, GA, USA.'}, {'ForeName': 'Omer T', 'Initials': 'OT', 'LastName': 'Inan', 'Affiliation': 'Department of Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.'}, {'ForeName': 'J Douglas', 'Initials': 'JD', 'LastName': 'Bremner', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA; Department of Radiology, Emory University School of Medicine, Atlanta, GA, USA; Atlanta VA Medical Center, Decatur, GA, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.07.002'] 1881,32659637,Cost and cost-effectiveness of three strategies for implementing motivational interviewing for substance misuse on medical inpatient units.,"BACKGROUND This study conducted cost and cost-effectiveness analyses of three strategies for implementing motivational interviewing for substance misuse on general medical inpatient units: workshop, apprenticeship, and consult. METHODS The economic analyses were conducted prospectively alongside a type 3 hybrid effectiveness-implementation randomized trial comprising 38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts. The trial took place in a university affiliated teaching hospital in New Haven, CT, USA. After completing a 1-day workshop on motivational interviewing, providers were randomized to conditions. The primary outcome measure was the number of study-eligible patients who received a motivational interview. The economic analyses included the costs of both start-up and on-going activities in each condition. Incremental cost-effectiveness ratios were used to determine cost effectiveness. Results are presented from the healthcare provider (i.e., hospital) perspective in 2018 US dollars. RESULTS The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively. Workshop and apprenticeship were extended dominated by the combination of consult and doing nothing. Doing nothing is cost effective when the willingness-to-pay for an additional patient receiving a motivational interview is less than $185.65, and consult is cost-effective when the willingness-to-pay for an additional patient receiving a motivational interview is greater than $185.65. CONCLUSIONS Given that typical reimbursements for brief intervention services for substance misuse are $35-$65, none of the three implementation strategies is likely to be economically viable from the healthcare provider perspective.",2020,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","['substance misuse on medical inpatient units', '38 medical providers, 1173 inpatients, and four consultation-liaison motivational interviewing experts', 'university affiliated teaching hospital in New Haven, CT, USA']",['implementing motivational interviewing'],"['Cost and cost-effectiveness', 'Incremental cost-effectiveness ratios', 'total cost per patient receiving a motivational interview']","[{'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]",38.0,0.0294972,"The total cost per patient receiving a motivational interview averaged $804.53, $606.52, and $185.65 for workshop, apprenticeship, and consult, respectively.","[{'ForeName': 'Todd A', 'Initials': 'TA', 'LastName': 'Olmstead', 'Affiliation': 'The University of Texas at Austin, Lyndon B. Johnson School of Public Affairs, Sid Richardson Hall, Unit 3, Austin, TX, 78712, USA. Electronic address: tolmstead@austin.utexas.edu.'}, {'ForeName': 'Kimberly A', 'Initials': 'KA', 'LastName': 'Yonkers', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; Yale School of Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, 333 Cedar Street, New Haven, CT, 06510, USA; Yale School of Epidemiology and Public Health Division of Chronic Disease, 60 College Street, New Haven, CT, 06520, USA.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Forray', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Zimbrean', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Gilstad-Hayden', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Martino', 'Affiliation': 'Yale School of Medicine, Department of Psychiatry, 300 George Street, Suite 901, New Haven, CT, 06520, USA; VA Connecticut Healthcare System, Psychology Service, 950 Campbell Avenue (116B), West Haven, CT, 06516, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108156'] 1882,32659641,A comparative study of autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure in treatment of women with urodynamic stress urinary incontinence.,"OBJECTIVE To compare short term results of autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure in treatment of female stress urinary incontinence (SUI) STUDY DESIGN: It was a comparative study on 30 women between 25-65 years of age with urodynamic proven SUI who were randomly allocated to autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure (Group II) (15 women). Preoperative and postoperative ICIQ (International Consultation on Incontinence Questionnaire) score, urodynamic study and serum CRP and IL-6 were done in all cases. RESULTS The baseline characteristics in terms of age, body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels were similar in two groups. Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II. Mean hospital stay of 7.1 ± 1.2 vs 1.2 ± 0.4 days, mean duration of catheterization 5.8 vs 1.2 day (<0.01) and postoperative urinary retention requiring recathterization were all significantly higher in group I than II. Wound infection was more in group I than in group II (p = 0.01) while groin pain was significantly more in group II (p = 0.01). One patient developed vesicovaginal fistula, while one patient required cutting of tape in group I. Pdet at Q max (Detrusor pressure at peak urine flow) increased significantly in both the groups after surgery. ICIQ score was zero in both the groups indicating 100 % success. Surgical trauma was more in group I as shown by significantly higher CRP levels. CONCLUSION The success rate of the two groups was similar but, autologous rectus fascia sling surgery took longer, had more complications and urinary retention as compared to transobturator vaginal tape procedure.",2020,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","['Group II) (15 women', 'women with urodynamic stress urinary incontinence', '30 women between 25-65 years of age with urodynamic proven SUI', 'female stress urinary incontinence']","['autologous rectus fascia pubovaginal sling surgery (Group I)(15 women) and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery and synthetic transobturator vaginal tape procedure', 'autologous rectus fascia pubovaginal sling surgery with synthetic transobturator vaginal tape procedure']","['Preoperative and postoperative ICIQ ', 'Mean operative time', 'Mean hospital stay', 'ICIQ score', 'Surgical trauma', 'CRP and IL-6', 'Wound infection', 'postoperative urinary retention requiring recathterization', 'CRP levels', 'complications and urinary retention', 'groin pain', 'vesicovaginal fistula', 'mean duration of catheterization', 'success rate', 'body mass index (BMI), parity, mean ICIQ score and mean preoperative CRP and IL-6 levels', 'Incontinence Questionnaire) score, urodynamic study and serum']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0456369', 'cui_str': 'Proven'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0225234', 'cui_str': 'Structure of fascia of rectus abdominis muscle'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0239783', 'cui_str': 'Inguinal pain'}, {'cui': 'C0042582', 'cui_str': 'Vesicovaginal fistula'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0030563', 'cui_str': 'Parity'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042059', 'cui_str': 'Urodynamics'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",30.0,0.0224989,"Mean operative time was significantly longer (55.60 ± 5.77 vs 25.27 ± 4.32 minutes, p = 0.001) in group I than group II.","[{'ForeName': 'J B', 'Initials': 'JB', 'LastName': 'Sharma', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India. Electronic address: jbsharma@aiims.ac.in.'}, {'ForeName': 'Manasi Kamalakar', 'Initials': 'MK', 'LastName': 'Deoghare', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Neerja', 'Initials': 'N', 'LastName': 'Bhatla', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Garima', 'Initials': 'G', 'LastName': 'Kachhawa', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Reeta', 'Initials': 'R', 'LastName': 'Mahey', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Kumari', 'Affiliation': 'Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Amlesh', 'Initials': 'A', 'LastName': 'Seth', 'Affiliation': 'Department of Urology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Alpana', 'Initials': 'A', 'LastName': 'Sharma', 'Affiliation': 'Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.'}]","European journal of obstetrics, gynecology, and reproductive biology",['10.1016/j.ejogrb.2020.06.062'] 1883,32660299,Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study.,"OBJECTIVE Low-dose testosterone has been shown to improve depression symptom severity, fatigue, and sexual function in small studies in women not formally diagnosed with major depressive disorder. The authors sought to determine whether adjunctive low-dose transdermal testosterone improves depression symptom severity, fatigue, and sexual function in women with antidepressant-resistant major depression. A functional MRI (fMRI) substudy examined effects on activity in the anterior cingulate cortex (ACC), a brain region important in mood regulation. METHODS The authors conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone cream in 101 women, ages 21-70, with antidepressant-resistant major depression. The primary outcome measure was depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS). Secondary endpoints included fatigue, sexual function, and safety measures. The primary outcome of the fMRI substudy (N=20) was change in ACC activity. RESULTS The participants' mean age was 47 years (SD=14) and their mean baseline MADRS score was 26.6 (SD=5.9). Eighty-seven (86%) participants completed 8 weeks of treatment. MADRS scores decreased in both study arms from baseline to week 8 (testosterone arm: from 26.8 [SD=6.3] to 15.3 [SD=9.6]; placebo arm: from 26.3 [SD=5.4] to 14.4 [SD=9.3]), with no significant difference between groups. Improvement in fatigue and sexual function did not differ between groups, nor did side effects. fMRI results showed a relationship between ACC activation and androgen levels before treatment but no difference in ACC activation with testosterone compared with placebo. CONCLUSIONS Adjunctive transdermal testosterone, although well tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction. Imaging in a subset of participants demonstrated that testosterone did not result in greater activation of the ACC.",2020,"CONCLUSIONS Adjunctive transdermal testosterone, although well tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction.","['women with antidepressant-resistant major depression', 'women not formally diagnosed with major depressive disorder', '101 women, ages 21-70, with antidepressant-resistant major depression', 'Antidepressant-Resistant Major Depressive Disorder in Women']","['Placebo', 'testosterone', 'adjunctive testosterone cream', 'Low-Dose Testosterone Augmentation', 'adjunctive low-dose transdermal testosterone', 'placebo']","['fatigue and sexual function', 'ACC activation and androgen levels', 'ACC activation', 'ACC activity', 'depression symptom severity, fatigue, and sexual function', 'MADRS scores', 'mean baseline MADRS score', 'depression symptom severity as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS', 'fatigue, sexual function, and safety measures', 'symptoms of depression, fatigue, or sexual dysfunction']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0278092', 'cui_str': 'Sexual function'}, {'cui': 'C0175190', 'cui_str': 'Anterior Cingulate Gyrus'}, {'cui': 'C0919646', 'cui_str': 'Androgen level'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}]",101.0,0.641546,"CONCLUSIONS Adjunctive transdermal testosterone, although well tolerated, was not more effective than placebo in improving symptoms of depression, fatigue, or sexual dysfunction.","[{'ForeName': 'Laura E', 'Initials': 'LE', 'LastName': 'Dichtel', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Linda L', 'Initials': 'LL', 'LastName': 'Carpenter', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'Nyer', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mischoulon', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'Kimball', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Thilo', 'Initials': 'T', 'LastName': 'Deckersbach', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Darin D', 'Initials': 'DD', 'LastName': 'Dougherty', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Schoenfeld', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Fisher', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Cusin', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Dording', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Nhi-Ha', 'Initials': 'NH', 'LastName': 'Trinh', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Pedrelli', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Yeung', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Farabaugh', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'George I', 'Initials': 'GI', 'LastName': 'Papakostas', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Trina', 'Initials': 'T', 'LastName': 'Chang', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Benjamin G', 'Initials': 'BG', 'LastName': 'Shapero', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Cassano', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Emily M', 'Initials': 'EM', 'LastName': 'Hahn', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Rao', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Roscoe O', 'Initials': 'RO', 'LastName': 'Brady', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Ravinder J', 'Initials': 'RJ', 'LastName': 'Singh', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Audrey R', 'Initials': 'AR', 'LastName': 'Tyrka', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Lawrence H', 'Initials': 'LH', 'LastName': 'Price', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}, {'ForeName': 'Karen K', 'Initials': 'KK', 'LastName': 'Miller', 'Affiliation': 'Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Dichtel, Kimball, Miller); Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Nyer, Mischoulon, Deckersbach, Dougherty, Yeung, Cassano, Hahn, Farabaugh, Pedrelli, Trinh, Dording, Cusin, Papakostas, Chang, Fisher, Shapero, Chen, Fava); Department of Psychiatry, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston (Brady); Biostatistics Center, Massachusetts General Hospital, Boston (Schoenfeld); Butler Hospital and Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Medicine, Brown University, Providence, R.I. (Carpenter, Tyrka, Price); Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston (Rao); Mayo Clinic Endocrine Laboratory, Rochester, Minn. (Singh).'}]",The American journal of psychiatry,['10.1176/appi.ajp.2020.19080844'] 1884,32665367,Oral immunotherapy for treatment of peanut allergy.,"The US Food and Drug Administration's approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy. While food allergy prevalence has been increasing, this product is the first approved therapy for food allergy. Oral immunotherapy has many similarities to subcutaneous immunotherapy and drug desensitization protocols, but does not lead to sustained unresponsiveness. The studies leading to approval of the Palforzia product demonstrated increase in the amount of peanut protein able to be consumed, with 67% of subjects randomized to the treatment arm able to consume 600 mg of peanut protein in double-blind placebo-controlled food challenge at study exit. However, side effects are an important consideration, and dropout rates in studies of Palforzia ranged from 11% to 21%. Postmarketing surveillance of this product will be critical in assessing its long-term risks and benefits.",2020,The US Food and Drug Administration's approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy.,['peanut allergy'],['Oral immunotherapy'],[],"[{'cui': 'C0559470', 'cui_str': 'Allergy to peanut'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]",[],,0.033605,The US Food and Drug Administration's approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy.,"[{'ForeName': 'Joan H', 'Initials': 'JH', 'LastName': 'Dunlop', 'Affiliation': 'Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA jdunlop7@jhmi.edu.'}]",Journal of investigative medicine : the official publication of the American Federation for Clinical Research,['10.1136/jim-2020-001422'] 1885,32663820,Design and Baseline Characteristics of the Chlorthalidone in Chronic Kidney Disease (CLICK) Trial.,"BACKGROUND Hypertension often accompanies chronic kidney disease (CKD), and diuretics are widely prescribed to reduce blood pressure (BP). Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in treating hypertension in individuals with advanced CKD. METHODS Chlorthalidone in Chronic Kidney Disease (CLICK) is a phase II, single-institution, multicenter, double-blind randomized control trial to test the hypothesis that CTD improves BP, through reduction of extracellular fluid volume, and results in target organ protection in patients with stage 4 CKD and poorly controlled hypertension. After a single-blind placebo run-in for 2 weeks and confirmation of hypertension by 24-h ambulatory blood pressure (ABP), patients are randomized to either placebo or CTD 12.5 mg once daily (QD) followed by dose escalation. Randomization is stratified by prior loop diuretic use, and the double-blind phase lasts 12 weeks. With a total of 160 patients, the study will have ≥80% power to detect a 6 mm Hg difference in systolic 24-h ABP between the 2 treatment groups. RESULTS Between June 2016 and October 2019, 131 patients have been randomized. The baseline characteristics are as follows: average age 65.8 years, 79% men, 36% Black, 79% with diabetes, mean eGFR 23.2 mL/min/1.73 m2, median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. CONCLUSION Among patients with stage 4 CKD and uncontrolled hypertension, CLICK should answer the question whether CTD is safe and effective.",2020,"median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. ","['patients with stage 4 CKD and poorly controlled hypertension', '160 patients', 'individuals with advanced CKD', 'patients with stage 4 CKD and uncontrolled hypertension', 'Chronic Kidney Disease (CLICK) Trial', 'Between June 2016 and October 2019, 131 patients have been randomized', 'follows: average age 65.8 years, 79% men, 36% Black, 79% with diabetes, mean eGFR 23.2 mL/min/1.73 m2', 'Chronic Kidney Disease (CLICK']","['Chlorthalidone (CTD', 'CTD', 'placebo or CTD', 'Chlorthalidone', 'placebo']","['blood pressure (BP', 'systolic 24-h ABP', 'median urine albumin/creatinine ratio 923 mg/g, average number of BP medications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2317473', 'cui_str': 'Chronic kidney disease stage 4'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}]","[{'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0455271', 'cui_str': 'Urine albumin/creatinine ratio measurement'}, {'cui': 'C1300563', 'cui_str': 'g/kg'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",160.0,0.405279,"median urine albumin/creatinine ratio 923 mg/g, average number of BP medications 3.4, 60% on loop diuretics, and 24-h ABP averaged 141.7/73.8 mm Hg. ","[{'ForeName': 'Rajiv', 'Initials': 'R', 'LastName': 'Agarwal', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA, ragarwal@iu.edu.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Cramer', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Balmes-Fenwick', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Arjun D', 'Initials': 'AD', 'LastName': 'Sinha', 'Affiliation': 'Division of Nephrology, Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.'}, {'ForeName': 'Fangqian', 'Initials': 'F', 'LastName': 'Ouyang', 'Affiliation': 'Department of Biostatistics, Richard M. Fairbanks School of Public Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Wanzhu', 'Initials': 'W', 'LastName': 'Tu', 'Affiliation': 'Department of Biostatistics, Richard M. Fairbanks School of Public Health, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}]",American journal of nephrology,['10.1159/000508700'] 1886,32673766,Making sense of cross-trial comparisons for the frontline treatment of advanced-stage Hodgkin lymphoma.,,2020,,['advanced-stage Hodgkin lymphoma'],[],[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0019829', 'cui_str': 'Hodgkin lymphoma'}]",[],[],,0.0468669,,"[{'ForeName': 'Deepesh P', 'Initials': 'DP', 'LastName': 'Lad', 'Affiliation': 'Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India. Electronic address: deepesh.lad12@gmail.com.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.05.012'] 1887,32673830,Accelerated treatment of endocarditis-The POET II trial: Rationale and design of a randomized controlled trial.,"BACKGROUND The optimal antibiotic treatment length for infective endocarditis (IE) is uncertain. International guidelines recommend treatment duration of up to 6 weeks for patients with left-sided IE but are primarily based on historical data and expert opinion. Efficacies of modern therapies, fast recovery seen in many patients with IE, and complications to long hospital stays challenge the rationale for fixed treatment durations in all patients. OBJECTIVE The objective was to conduct a noninferiority randomized controlled trial (acronym POET II) investigating the safety of accelerated (shortened) antibiotic therapy as compared to standard duration in patients with left-sided IE. METHODS The POET II trial is a multicenter, multinational, open-label, noninferiority randomized controlled trial. Patients with definite left-sided IE due to Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis will be eligible for enrolment. Each patient will be randomized to accelerated antibiotic treatment or standard-length treatment (1:1) following clinical stabilization as defined by clinical parameters, laboratory values, and transesophageal echocardiography findings. Accelerated treatment will be between 2 and 4 weeks, whereas standard-length treatment will be between 4 and 6 weeks, depending on microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis. The primary outcome is a composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6 months of randomization. CONCLUSIONS The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis. The results of the POET II trial will improve the evidence base of treatment recommendations, and clinical practice may be altered.",2020,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","['patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis', 'patients with left-sided IE']","['accelerated (shortened) antibiotic therapy', 'accelerated antibiotic therapy']","['microbiologic etiology, complications, need for valve surgery, and prosthetic versus native valve endocarditis', 'composite of all-cause mortality, unplanned cardiac surgery, relapse of bacteremia, or embolization within 6\u202fmonths of randomization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1827151', 'cui_str': 'Left sided infective endocarditis'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0085494', 'cui_str': 'Genus Enterococcus'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}]","[{'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1142550', 'cui_str': 'Native valve endocarditis'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]",,0.224308,"The POET II trial will investigate the safety of accelerated antibiotic therapy for patients with left-sided IE caused by Streptococcus spp, Staphylococcus aureus, or Enterococcus faecalis.","[{'ForeName': 'Lauge', 'Initials': 'L', 'LastName': 'Østergaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Mia Marie', 'Initials': 'MM', 'LastName': 'Pries-Heje', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Rasmus Bo', 'Initials': 'RB', 'LastName': 'Hasselbalch', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Åkesson', 'Affiliation': 'Department of Infectious Diseases, Skåne University Hospital, Lund, Sweden.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Horvath', 'Affiliation': 'Department of Infectious Diseases, The Prince Charles Hospital, Brisbane, Australia.'}, {'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Povlsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Gill', 'Affiliation': 'Department of Cardiology, Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Niels Eske', 'Initials': 'NE', 'LastName': 'Bruun', 'Affiliation': 'Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Katrine', 'Initials': 'K', 'LastName': 'Müllertz', 'Affiliation': 'Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.'}, {'ForeName': 'Christian Ditlev', 'Initials': 'CD', 'LastName': 'Tuxen', 'Affiliation': 'Department of Cardiology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Nikolaj', 'Initials': 'N', 'LastName': 'Ihlemann', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Jannik', 'Initials': 'J', 'LastName': 'Helweg-Larsen', 'Affiliation': 'Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Moser', 'Affiliation': 'Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Emil Loldrup', 'Initials': 'EL', 'LastName': 'Fosbøl', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Bundgaard', 'Affiliation': 'The Heart Center, Rigshospitalet, Copenhagen, Denmark. Electronic address: Henning.Bundgaard@regionh.dk.'}, {'ForeName': 'Kasper', 'Initials': 'K', 'LastName': 'Iversen', 'Affiliation': 'Department of Cardiology, Herlev-Gentofte Hospital, Copenhagen, Denmark.'}]",American heart journal,['10.1016/j.ahj.2020.05.012'] 1888,32673060,Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial.,"BACKGROUND No effective oral therapy exists for early coronavirus disease 2019 (COVID-19). OBJECTIVE To investigate whether hydroxychloroquine could reduce COVID-19 severity in adult outpatients. DESIGN Randomized, double-blind, placebo-controlled trial conducted from 22 March through 20 May 2020. (ClinicalTrials.gov: NCT04308668). SETTING Internet-based trial across the United States and Canada (40 states and 3 provinces). PARTICIPANTS Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset. INTERVENTION Oral hydroxychloroquine (800 mg once, followed by 600 mg in 6 to 8 hours, then 600 mg daily for 4 more days) or masked placebo. Measures : Symptoms and severity at baseline and then at days 3, 5, 10, and 14 using a 10-point visual analogue scale. The primary end point was change in overall symptom severity over 14 days. RESULTS Of 491 patients randomly assigned to a group, 423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, -0.27 points [95% CI, -0.61 to 0.07 points]; P  = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo ( P  = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo ( P  < 0.001). With placebo, 10 hospitalizations occurred (2 non-COVID-19-related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). LIMITATIONS Only 58% of participants received SARS-CoV-2 testing because of severe U.S. testing shortages. CONCLUSION Hydroxychloroquine did not substantially reduce symptom severity in outpatients with early, mild COVID-19. PRIMARY FUNDING SOURCE Private donors.",2020,"With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). ","['outpatients with early, mild COVID-19', 'Nonhospitalized Adults', '22 March through 20 May 2020', '341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting', 'Internet-based trial across the United States and Canada', 'Symptomatic, nonhospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 and high-risk exposure within 4 days of symptom onset', 'adult outpatients', '491 patients randomly assigned to a group, 423 contributed primary end point data']","['hydroxychloroquine', 'Hydroxychloroquine', 'Early COVID-19', 'Oral hydroxychloroquine', 'placebo']","['ongoing symptoms', 'overall symptom severity', '10-point visual analogue scale', 'Medication adverse effects', 'symptom severity', 'hospitalized death', 'Change in symptom severity', 'COVID-19 severity']","[{'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",423.0,0.761778,"With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death ( P  = 0.29). ","[{'ForeName': 'Caleb P', 'Initials': 'CP', 'LastName': 'Skipper', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Katelyn A', 'Initials': 'KA', 'LastName': 'Pastick', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Nicole W', 'Initials': 'NW', 'LastName': 'Engen', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Ananta S', 'Initials': 'AS', 'LastName': 'Bangdiwala', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Abassi', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Lofgren', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Darlisha A', 'Initials': 'DA', 'LastName': 'Williams', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Elizabeth C', 'Initials': 'EC', 'LastName': 'Okafor', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Pullen', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Melanie R', 'Initials': 'MR', 'LastName': 'Nicol', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Alanna A', 'Initials': 'AA', 'LastName': 'Nascene', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Kathy H', 'Initials': 'KH', 'LastName': 'Hullsiek', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Cheng', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Darlette', 'Initials': 'D', 'LastName': 'Luke', 'Affiliation': 'M Health Fairview Investigational Drug Service Pharmacy, Minneapolis, Minnesota (D.L.).'}, {'ForeName': 'Sylvain A', 'Initials': 'SA', 'LastName': 'Lother', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'MacKenzie', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Drobot', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Kelly', 'Affiliation': 'George & Fay Yee Centre for Healthcare Innovation, Winnipeg, Manitoba, Canada (L.E.K.).'}, {'ForeName': 'Ilan S', 'Initials': 'IS', 'LastName': 'Schwartz', 'Affiliation': 'University of Alberta, Edmonton, Alberta, Canada (I.S.S.).'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Zarychanski', 'Affiliation': 'University of Manitoba, Winnipeg, Manitoba, Canada (S.A.L., L.J.M., G.D., R.Z.).'}, {'ForeName': 'Emily G', 'Initials': 'EG', 'LastName': 'McDonald', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Lee', 'Affiliation': 'Research Institute of the McGill University Health Centre and McGill University, Montréal, Quebec, Canada (M.P.C., E.G.M., T.C.L.).'}, {'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Rajasingham', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Boulware', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota (C.P.S., K.A.P., N.W.E., A.S.B., M.A., S.M.L., D.A.W., E.C.O., M.F.P., M.R.N., A.A.N., K.H.H., R.R., D.R.B.).'}]",Annals of internal medicine,['10.7326/M20-4207'] 1889,32673496,The Arousal Threshold as a Drug-Target to Improve CPAP Adherence: Secondary Analysis of a Randomized Trial.,,2020,,[],[],['CPAP Adherence'],[],[],"[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",,0.20808,,"[{'ForeName': 'Christopher N', 'Initials': 'CN', 'LastName': 'Schmickl', 'Affiliation': 'University of California San Diego, 8784, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States; cschmickl@health.ucsd.edu.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lettieri', 'Affiliation': 'Uniformed Services University of the Health Sciences, 1685, Pulmonary, Critical Care and Sleep Medicine, Bethesda, Maryland, United States.'}, {'ForeName': 'Jeremy E', 'Initials': 'JE', 'LastName': 'Orr', 'Affiliation': 'University of California San Diego, 8784, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'DeYoung', 'Affiliation': 'University of California San Diego, 8784, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States.'}, {'ForeName': 'Bradley A', 'Initials': 'BA', 'LastName': 'Edwards', 'Affiliation': 'Monash University, 2541, Sleep and Circadian Medicine Laboratory, Department of Physiology, School of Biomedical Sciences and Biomedical Discovery Institute, Clayton, Victoria, Australia.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Owens', 'Affiliation': 'University of California San Diego, 8784, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States.'}, {'ForeName': 'Atul', 'Initials': 'A', 'LastName': 'Malhotra', 'Affiliation': 'University of California San Diego, 8784, Division of Pulmonary, Critical Care and Sleep Medicine, La Jolla, California, United States.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.202003-0502LE'] 1890,31203233,Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.,"APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs; based on qualitative apolipoprotein complement) have been associated with dyslipidemia and CVD. Our main objective was to define associations of serum apolipoproteins and ADLSs with ""any CVD"" and ""major atherosclerotic cardiovascular events"" (MACEs) in a prospective study of T1D. Serum apolipoproteins and ADLSs (14 biomarkers in total) were measured in sera (obtained between 1997 and 2000) from a subset ( n = 465) of the Epidemiology of Diabetes Interventions and Complications cohort. Prospective associations of ""any CVD"" (myocardial infarction, stroke, confirmed angina, silent myocardial infarction, revascularization, or congestive heart failure) and MACEs (fatal or nonfatal myocardial infarction or stroke), over 5,943 and 6,180 patient-years follow-up, respectively, were investigated using Cox proportional hazards models that were unadjusted and adjusted for risk factors. During 15 years of follow-up, 50 ""any CVD"" events and 24 MACEs occurred. Nominally significant positive univariate associations with ""any CVD"" were APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B. In adjusted analyses, APOC3-HS remained nominally significant. Nominally significant positive univariate associations with MACEs were APOC3 and its subfractions and Lp-B:C; those with total APOC3 and APOC3-HS persisted in adjusted analyses. However, these associations did not reach significance after adjusting for multiple testing. There were no significant associations of APOA1, APOA2, APOE, or other ADLSs with either ""any CVD"" or MACEs. These hypothesis-generating data suggest that total serum APOC3 and APOC3 in HDL are potentially important predictive biomarkers for any CVD and MACEs in adults with T1D.",2019,"Nominally significant positive univariate associations with ""any CVD"" were APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B.","['T1D. Serum apolipoproteins and ADLSs (14 biomarkers in total) were measured in sera (obtained between 1997 and 2000) from a subset ( n = 465) of the Epidemiology of Diabetes Interventions and Complications cohort', 'adults with T1D']",[],"['any CVD"" (myocardial infarction, stroke, confirmed angina, silent myocardial infarction, revascularization, or congestive heart failure) and MACEs (fatal or nonfatal myocardial infarction or stroke', 'APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B', 'Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses', 'APOA1, APOA2, APOE, or other ADLSs with either ""any CVD"" or MACEs', 'APOB, APOC3, and APOE and apolipoprotein-defined lipoprotein subclasses (ADLSs']","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003591', 'cui_str': 'Apolipoprotein'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0445604', 'cui_str': 'Subclass'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0730225', 'cui_str': '1997'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0014507', 'cui_str': 'Epidemiology'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]",[],"[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0340324', 'cui_str': 'Silent myocardial infarction'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0003593', 'cui_str': 'Apolipoprotein B'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003591', 'cui_str': 'Apolipoprotein'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C0445604', 'cui_str': 'Subclass'}, {'cui': 'C1677784', 'cui_str': 'APOA1 protein, human'}, {'cui': 'C0855605', 'cui_str': 'Measurement of apolipoprotein A-II'}, {'cui': 'C0003595', 'cui_str': 'Apolipoprotein E'}]",,0.025063,"Nominally significant positive univariate associations with ""any CVD"" were APOB, APOC3 and its subfractions [heparin precipitate, heparin-soluble (HS)], and ADLS-defined Lp-B.","[{'ForeName': 'Arpita', 'Initials': 'A', 'LastName': 'Basu', 'Affiliation': 'Department of Kinesiology and Nutrition Sciences, University of Nevada, Las Vegas, Las Vegas, NV.'}, {'ForeName': 'Ionut', 'Initials': 'I', 'LastName': 'Bebu', 'Affiliation': 'The Biostatistics Center Milken Institute School of Public Health, The George Washington University, Rockville, MD.'}, {'ForeName': 'Alicia J', 'Initials': 'AJ', 'LastName': 'Jenkins', 'Affiliation': 'NHMRC Clinical Trials Centre University of Sydney, Camperdown, Sydney, Australia.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Stoner', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Klein', 'Affiliation': 'Division of Endocrinology Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'Maria F', 'Initials': 'MF', 'LastName': 'Lopes-Virella', 'Affiliation': 'Division of Endocrinology Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'W Timothy', 'Initials': 'WT', 'LastName': 'Garvey', 'Affiliation': 'Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham Veterans Affairs Medical Center, Birmingham, AL.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Budoff', 'Affiliation': 'Division of Cardiology Los Angeles Biomedical Research Institute, Torrance, CA.'}, {'ForeName': 'Petar', 'Initials': 'P', 'LastName': 'Alaupovic', 'Affiliation': 'Oklahoma Medical Research Foundation Oklahoma City, OK.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Lyons', 'Affiliation': 'Division of Endocrinology Medical University of South Carolina, Charleston, SC lyonstj@musc.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of lipid research,['10.1194/jlr.P090647'] 1891,32678725,"A randomized blinded retrospective study: the combined use of micro-needling technique, low-level laser therapy and autologous non-activated platelet-rich plasma improves hair re-growth in patients with androgenic alopecia.","INTRODUCTION Mini-invasive therapies based on autologous non-activated Platelet-Rich Plasma (ANA-PRP), Low-Level Laser Therapy (LLL-T), and Micro-Needling Technique (MN-T) used in combining for hair re-growth need to be standardized. OBJECTIVES The work aims to show in vivo outcomes resulted from retrospective case-series study in which ANA-PRP + MN-T + LLL-T were used in combined in patients affected by Androgenic alopecia. METHODS 23 patients were treated, of which 13 males were classified in stage I-V by the Norwood-Hamilton scale, and 10 females were classified in stage I-III by the Ludwig scale. Assessment of hair re-growth was evaluated with photography, physician's and patient's global assessment scale, and standardized phototrichograms during a follow-up: T0 - baseline, T1 - 12 weeks, T2 - 23 weeks, T3 - 44 weeks, T4 - 58 weeks. RESULTS Interesting outcomes represented by a hair density increase of 81 ± 5 hairs/cm 2 and 57 ± 7 hairs/cm 2 respectively at T1 and T2 compared with baseline (173 ± 5 hairs/cm 2 at T1 and 149 ± 9 hairs/cm 2 at T2 versus 92 ± 2 hairs/cm 2 at baseline) were observed using computerized trichograms. EXPERT OPINION The main limitation in the autologous regenerative therapies and biotechnologies in hair-regrowth is the extreme variability of PRP products used, in the absence of standardized protocols and widely shared. Appropriate PRP preparations have to be pick after carefully thinking about their bio-molecular specifications and intended indications for use in patients. This approach will aid in matching the optimal PRP product to specific patient factors, leading to improved outcomes and the elucidation of the cost-effectiveness of this treatment. The combined use of biotechnologies as the association of PRP with micro-needling and low-level laser therapy may improve the results in terms of hair count and hair density compared with those obtained by alone PRP. All the procedures must be performed in the full respect of international and local rules. CONCLUSIONS The effect of the combined use of MN-T, LLL-T, and ANA-PRP has been demonstrated.",2020,"Interesting outcomes represented by a hair density increase of 81 ± 5 hairs/cm 2 and 57 ± 7 hairs/cm 2 respectively at T1 and T2 compared with baseline (173 ± 5 hairs/cm 2 at T1 and 149 ± 9 hairs/cm 2 at T2 versus 92 ± 2 hairs/cm 2 at baseline) were observed using computerized trichograms. ","['patients with Androgenic Alopecia', '23 patients were treated, of which 13 males were classified in stage I - V by the Norwood-Hamilton scale, and 10 females were classified in stage I - III by the Ludwig scale']","['Micro-needling Technique, Low-Level Laser Therapy and Autologous Non-Activated Platelet-Rich Plasma', 'ANA-PRP + MN-T + LLL-T', 'MN-T, LLL-T, and ANA-PRP', 'Mini-invasive therapies based on autologous non-activated Platelet-Rich Plasma (ANA-PRP), Low-Level Laser Therapy (LLL-T), and Micro-Needling Technique (MN-T']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0024081', 'cui_str': ""Ludwig's angina""}]","[{'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",[],13.0,0.0364,"Interesting outcomes represented by a hair density increase of 81 ± 5 hairs/cm 2 and 57 ± 7 hairs/cm 2 respectively at T1 and T2 compared with baseline (173 ± 5 hairs/cm 2 at T1 and 149 ± 9 hairs/cm 2 at T2 versus 92 ± 2 hairs/cm 2 at baseline) were observed using computerized trichograms. ","[{'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Gentile', 'Affiliation': 'Department of Surgical Sciences, Plastic and Reconstructive Surgery, University of Rome ""Tor Vergata"" School of Medicine , Rome, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Dionisi', 'Affiliation': 'Dionisi Law Firm , Rome, Italy.'}, {'ForeName': 'Jacopo', 'Initials': 'J', 'LastName': 'Pizzicannella', 'Affiliation': 'ASL02 Lanciano-Vasto Chieti, Ss. Annunziata Hospital , Chieti, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'de Angelis', 'Affiliation': 'Department of Surgical Sciences, Plastic and Reconstructive Surgery, University of Rome ""Tor Vergata"" School of Medicine , Rome, Italy.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'de Fazio', 'Affiliation': 'Institute of Plastic Surgery, Galeazzi Hospital , Milan, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Garcovich', 'Affiliation': 'Institute of Dermatology, F. Policlinico Gemelli IRCSS, Università Cattolica del Sacro Cuore , Rome, Italy.'}]",Expert opinion on biological therapy,['10.1080/14712598.2020.1797676'] 1892,32679537,Blood pressure postpartum (BP 2 ) RCT protocol: Follow-up and lifestyle behaviour change strategies in the first 12 months after hypertensive pregnancy.,"OBJECTIVES Women who had hypertensive disorders of pregnancy (HDP) are twice as likely to experience maternal cardiovascular disease later in life. The primary aim of this study (BP 2 ) is to compare outcomes of 3 different management strategies, including lifestyle behaviour change (LBC), in the first 12 months postpartum in women who had HDP in their preceding pregnancy. Secondary aims include assessing the effects on other cardiometabolic parameters. STUDY DESIGN Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480. Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2) Brief intervention: information package as per group 1, plus assessment and brief LBC counselling at a specialised clinic with an obstetric physician and dietitian 6 months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6 month telephone-based LBC program from 6 to 12 months postpartum. All women have an outcome assessment at 12 months. MAIN OUTCOME MEASURES Primary outcomes: (a) BP change or (b) weight change and/or waist circumference change. SECONDARY OUTCOMES maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios. The study is powered to detect a 4 mmHg difference in systolic BP between groups, or a 4 kg weight loss difference/2cm waist circumference change. CONCLUSIONS BP 2 will provide evidence regarding the feasibility and effectiveness of postpartum LBC interventions and structured clinical follow-up in improving cardiovascular health markers after HDP.",2020,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"['women who had HDP in their preceding pregnancy', 'Three-arm multicentre randomised trial in metropolitan Australian hospitals, (registration: ACTRN12618002004246) target sample size 480', 'Women who had hypertensive disorders of pregnancy (HDP']","['LBC counselling at a specialised clinic with an obstetric physician and dietitian 6\xa0months postpartum 3) Extended intervention: as per group 2 plus enrolment into a 6\xa0month telephone-based LBC program', 'Optimised usual care: information package and family doctor follow-up 6\xa0months postpartum 2']","['Blood pressure postpartum (BP 2 ', 'BP change or (b) weight change and/or waist circumference change', 'maternal health-related quality of life, engagement and retention in LBC program, biochemical markers, vascular function testing, infant weight trajectory, incremental cost-effectiveness ratios', 'systolic BP', 'lifestyle behaviour change (LBC']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0852260', 'cui_str': 'Hypertension associated disorders of pregnancy'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C4319609', 'cui_str': '480'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C1704221', 'cui_str': 'Family medicine specialist'}, {'cui': 'C0589124', 'cui_str': 'Follow-up 6 months'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0024921', 'cui_str': 'Maternal Health'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C4704805', 'cui_str': 'Weight Trajectory'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",480.0,0.118249,Participants are randomised to one of three groups: 1) Optimised usual care: information package and family doctor follow-up 6 months postpartum 2),"[{'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Henry', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; The George Institute for Global Health, Sydney, Australia. Electronic address: Amanda.Henry@unsw.edu.au.""}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Arnott', 'Affiliation': 'The George Institute for Global Health, Sydney, Australia; Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Makris', 'Affiliation': 'Faculty of Medicine, University of New South Wales, Sydney, Australia; School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Davis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Hennessy', 'Affiliation': 'School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Beech', 'Affiliation': 'Royal Hospital for Women, Randwick, New South Wales, Australia.'}, {'ForeName': 'Franziska', 'Initials': 'F', 'LastName': 'Pettit', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Se Homer', 'Affiliation': 'Burnet Institute, Melbourne, Victoria, Australia; Faculty of Health, University of Technology, Sydney, New South Wales, Australia.'}, {'ForeName': 'Maria E', 'Initials': 'ME', 'LastName': 'Craig', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Roberts', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.""}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Hyett', 'Affiliation': 'Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Sydney Medical School, University of Sydney, Australia.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Chambers', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Oisin', 'Initials': 'O', 'LastName': 'Fitzgerald', 'Affiliation': ""National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health and Centre for Big Data Research in Health, University of New South Wales, Sydney, NSW, Australia.""}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Gow', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Mann', 'Affiliation': 'General Practitioner, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Challis', 'Affiliation': ""School of Women's and Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia; Royal Hospital for Women, Randwick, New South Wales, Australia.""}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Gale', 'Affiliation': 'New South Wales Ministry of Health, North Sydney, New South Wales, Australia.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Ruhotas', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Emilee', 'Initials': 'E', 'LastName': 'Kirwin', 'Affiliation': ""Women's and Children's Health, St George Hospital, Kogarah, New South Wales, Australia.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Denney-Wilson', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia; St George and Sutherland Clinical School, UNSW Medicine, University of New South Wales, Sydney, Australia.'}]",Pregnancy hypertension,['10.1016/j.preghy.2020.07.001'] 1893,31175052,Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.,"BACKGROUND Anthracycline agents can cause cardiotoxicity. We used multivariable risk prediction models to identify a subset of patients with breast cancer at high risk of cardiotoxicity, for whom the harms of anthracycline chemotherapy may balance or exceed the benefits. PATIENTS AND METHODS A clinical prediction model for anthracycline cardiotoxicity was created in 967 patients with human epidermal growth factor receptor-negative breast cancer treated with doxorubicin in the ECOG-ACRIN study E5103. Cardiotoxicity was defined as left ventricular ejection fraction (LVEF) decline of ≥ 10% to < 50% and/or a centrally adjudicated clinical heart failure diagnosis. Patient-specific incremental absolute benefit of anthracyclines (compared with non-anthracycline taxane chemotherapy) was estimated using the PREDICT model to assess breast cancer mortality risk. RESULTS Of the 967 women who initiated therapy, 51 (5.3%) developed cardiotoxicity (12 with clinical heart failure). In a multivariate model, increasing age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.01-1.08), higher body mass index (OR, 1.06; 95% CI, 1.02-1.10), and lower baseline LVEF (OR, 0.93; 95% CI, 0.89-0.98) at baseline were significantly associated with cardiotoxicity. The concordance statistic of the risk model was 0.70 (95% CI, 0.63-0.77). In patients with low anticipated treatment benefit (n = 176) from the addition of anthracycline (< 2% absolute risk difference of breast cancer mortality at 10 years), 16 (9%) of 176 had a > 10% risk of cardiotoxicity and 61 (35%) of 176 had a 5% to 10% risk of cardiotoxicity at 1 year. CONCLUSION Older age, higher body mass index, and lower baseline LVEF were associated with increased risk of cardiotoxicity. We identified a subgroup with low predicted absolute benefit of anthracyclines but with high predicted risk of cardiotoxicity. Additional studies are needed incorporating long-term cardiac outcomes and cardiotoxicity model external validation prior to implementation in routine clinical practice.",2019,"The concordance statistic of the risk model was 0.70 (95% CI, 0.63-0.77).","['967 women who initiated therapy, 51 (5.3%) developed cardiotoxicity (12 with clinical heart failure', 'Early Stage Breast Cancer', '967 patients with human epidermal growth factor receptor-negative breast cancer treated with', 'patients with breast cancer at high risk of cardiotoxicity, for whom the harms of']","['anthracycline chemotherapy', 'anthracyclines (compared with non-anthracycline taxane chemotherapy', 'doxorubicin', 'anthracycline']","['breast cancer mortality', 'cardiotoxicity', 'Cardiotoxicity', 'left ventricular ejection fraction (LVEF) decline', 'risk of cardiotoxicity', 'higher body mass index']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4087185', 'cui_str': 'Human epidermal growth factor receptor negative'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}]","[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",967.0,0.0610911,"The concordance statistic of the risk model was 0.70 (95% CI, 0.63-0.77).","[{'ForeName': 'Jenica N', 'Initials': 'JN', 'LastName': 'Upshaw', 'Affiliation': 'Division of Cardiology, Tufts Medical Center, Boston, MA; The Predictive Analytics and Comparative Effectiveness Center Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA. Electronic address: jupshaw@tuftsmedicalcenter.org.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Ruthazer', 'Affiliation': 'The Predictive Analytics and Comparative Effectiveness Center Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.'}, {'ForeName': 'Kathy D', 'Initials': 'KD', 'LastName': 'Miller', 'Affiliation': 'Indiana University Simon Cancer Center, Indianapolis, IN.'}, {'ForeName': 'Susan K', 'Initials': 'SK', 'LastName': 'Parsons', 'Affiliation': 'The Predictive Analytics and Comparative Effectiveness Center Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA; Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.'}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Erban', 'Affiliation': 'Division of Hematology/Oncology, Tufts Medical Center, Boston, MA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': ""O'Neill"", 'Affiliation': 'Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA.'}, {'ForeName': 'Biniyam', 'Initials': 'B', 'LastName': 'Demissei', 'Affiliation': 'Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Sledge', 'Affiliation': 'Stanford University Medical Center, Palo Alto, CA.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Wagner', 'Affiliation': 'Wake Forest University Health Services, Winston-Salem, NC.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Ky', 'Affiliation': 'Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Kent', 'Affiliation': 'The Predictive Analytics and Comparative Effectiveness Center Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.'}]",Clinical breast cancer,['10.1016/j.clbc.2019.04.012'] 1894,32663119,Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.,"PURPOSE Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented. METHODS Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy. The primary end point was change in photographic breast appearance at 2 and 5 years; secondary end points were physician assessments of NTE and local tumor control. Odds ratios (ORs) from longitudinal analyses compared regimens. RESULTS A total of 915 women were recruited from 18 UK centers (2004-2007). Five-year photographs were available for 615/862 (71%) eligible patients. ORs for change in photographic breast appearance were 1.64 (95% CI, 1.08 to 2.49; P = .019) for 30 Gy and 1.10 (95% CI, 0.70 to 1.71; P = .686) for 28.5 Gy versus 50 Gy. α/β estimate for photographic end point was 2.7 Gy (95% CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95% CI, 26 to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr. ORs for any moderate/marked physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95% CI, 1.55 to 2.89; P < .001) for 30 Gy and 1.22 (95% CI, 0.87 to 1.72; P = .248) for 28.5 Gy versus 50 Gy. With 9.9 years median follow-up, 11 ipsilateral breast cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred. CONCLUSION At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr. Results confirm the published 3-year findings that a once-weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiobiologically comparable for NTE to a conventionally fractionated regimen.",2020,"At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr.","['Early Breast Cancer', 'A total of 915 women were recruited from 18 UK centers (2004-2007', 'Women ≥ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0']","['5-Fraction Whole-Breast Radiotherapy', 'FAST', 'hypofractionated adjuvant whole-breast radiotherapy']","['NTE rates', 'normal tissue effects (NTE) and disease outcomes', 'moderate/marked physician-assessed breast NTE (shrinkage, induration, telangiectasia, edema', 'photographic breast appearance', 'physician assessments of NTE and local tumor control', 'Odds ratios (ORs']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0853879', 'cui_str': 'Invasive carcinoma of breast'}, {'cui': 'C0332391', 'cui_str': 'pT1 category'}, {'cui': 'C0332396', 'cui_str': 'pN0 category'}]","[{'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0457102', 'cui_str': 'Whole breast'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}]","[{'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0332513', 'cui_str': 'Shrinkage'}, {'cui': 'C0332534', 'cui_str': 'Induration'}, {'cui': 'C0039446', 'cui_str': 'Telangiectasis'}, {'cui': 'C0013604', 'cui_str': 'Edema'}, {'cui': 'C1286082', 'cui_str': 'Appearance of breast'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",915.0,0.119608,"At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with 50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr.","[{'ForeName': 'Adrian Murray', 'Initials': 'AM', 'LastName': 'Brunt', 'Affiliation': 'Cancer Centre, University Hospitals of North Midlands NHS Trust and Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.'}, {'ForeName': 'Joanne S', 'Initials': 'JS', 'LastName': 'Haviland', 'Affiliation': 'Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, London, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Sydenham', 'Affiliation': 'Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, London, United Kingdom.'}, {'ForeName': 'Rajiv K', 'Initials': 'RK', 'LastName': 'Agrawal', 'Affiliation': 'Oncology Centre, Lingen Davies Centre, Royal Shrewsbury Hospital, Shrewsbury, Shropshire, United Kingdom.'}, {'ForeName': 'Hafiz', 'Initials': 'H', 'LastName': 'Algurafi', 'Affiliation': 'Oncology Department, Southend University Hospital, Southend, Essex, United Kingdom.'}, {'ForeName': 'Abdulla', 'Initials': 'A', 'LastName': 'Alhasso', 'Affiliation': 'Radiotherapy, Beatson West of Scotland Cancer Centre, Glasgow, Scotland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Barrett-Lee', 'Affiliation': 'Velindre Cancer Centre, Velindre Hospital, Cardiff, Wales.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bliss', 'Affiliation': 'Oncology, Torbay Hospital, Torquay, Devon, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Bloomfield', 'Affiliation': 'Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, Sussex, United Kingdom.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Bowen', 'Affiliation': 'Oncology Centre, Cheltenham General Hospital, Cheltenham, Gloucestershire, United Kingdom.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Donovan', 'Affiliation': 'Centre for Vision, Speech, and Signal Processing, University of Surrey, Guildford, Surrey, United Kingdom.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Goodman', 'Affiliation': 'Exeter Oncology Centre, Royal Devon and Exeter Hospital, Exeter, Devon, United Kingdom.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Harnett', 'Affiliation': 'Oncology and Haematology Department, Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Hogg', 'Affiliation': 'The Cancer Centre, Royal Preston Hospital, Preston, Lancashire, United Kingdom.'}, {'ForeName': 'Sri', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': ""Leeds Cancer Centre, St James's University Hospital, Leeds, Yorkshire, United Kingdom.""}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Passant', 'Affiliation': 'Velindre Cancer Centre, Velindre Hospital, Cardiff, Wales.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Quigley', 'Affiliation': ""Oncology Department, Queen's Hospital, Romford, Essex, United Kingdom.""}, {'ForeName': 'Liz', 'Initials': 'L', 'LastName': 'Sherwin', 'Affiliation': 'Department of Oncology and Haematology, Ipswich Hospital, Ipswich, Suffolk, United Kingdom.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Stewart', 'Affiliation': 'Radiotherapy Department, The Christie Hospital, Manchester, Lancashire, United Kingdom.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Syndikus', 'Affiliation': 'The Clatterbridge Cancer Centre, Clatterbridge Hospital, Bebington, Wirral, Cheshire, United Kingdom.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Tremlett', 'Affiliation': 'Sussex Cancer Centre, Royal Sussex County Hospital, Brighton, Sussex, United Kingdom.'}, {'ForeName': 'Yat', 'Initials': 'Y', 'LastName': 'Tsang', 'Affiliation': 'RTTQA, Mount Vernon Hospital, Rickmansworth, Middlesex, United Kingdom.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Venables', 'Affiliation': 'RTTQA, Mount Vernon Hospital, Rickmansworth, Middlesex, United Kingdom.'}, {'ForeName': 'Duncan', 'Initials': 'D', 'LastName': 'Wheatley', 'Affiliation': 'The Sunrise Centre, Royal Cornwall Hospital, Truro, Cornwall, United Kingdom.'}, {'ForeName': 'Judith M', 'Initials': 'JM', 'LastName': 'Bliss', 'Affiliation': 'Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, London, United Kingdom.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Yarnold', 'Affiliation': 'Institute of Cancer Research and Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02750'] 1895,32664074,Promoting breastfeeding in Chinese women undergoing cesarean section based on the health belief model: A randomized controlled trial.,"BACKGROUND The high rate of cesarean section is an important factor affecting breastfeeding in China. To improve the nation's current situation of breastfeeding, promoting breastfeeding in women undergoing cesarean section is essential. OBJECTIVE To explore the effects of health belief model-based interventions on breastfeeding knowledge, breastfeeding behaviors, and breastfeeding satisfaction of Chinese cesarean women. METHODS A total of 346 cesarean section women were enrolled in the randomized controlled trial conducted at a center in Chengdu, China, between July 1, 2018 and August 31, 2018. While the control group (n = 173) received conventional breastfeeding guidance only, the intervention group (n = 173) received additional interventions based on the health belief model. Questionnaires were distributed to assess breastfeeding knowledge, breastfeeding behavior, and breastfeeding satisfaction at discharge, 42 days postpartum, and 4 months postpartum, respectively. RESULTS At discharge from hospital, the breastfeeding knowledge score of the intervention group was higher than that of the control group (Z = -11.753, P < .001). The exclusive breastfeeding rates in the intervention group at the time of discharge, 42 days postpartum, and 4 months postpartum were 67.3%, 60.7%, and 52.9%, respectively, while those of the control group were 41.2%, 41.6%, and 40.4%, respectively. The differences were statistically significant (χ = 23.353, P < .001; χ = 11.853, P < .001; χ = 4.805, P = .03). The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (t = 4.955, P < .001; t = 3.051, P = .002; Z = -3.801, P < .001). CONCLUSION The health belief model-based interventions can effectively increase breastfeeding knowledge for Chinese cesarean women and improve their breastfeeding behaviors and breastfeeding satisfaction within 4 months after delivery. CLINICAL TRIAL REGISTRATION ChiCTR1900026006 .",2020,"The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (","['A total of 346 cesarean section women were enrolled in the randomized controlled trial conducted at a center in Chengdu, China, between July 1, 2018 and August 31, 2018', 'Chinese women undergoing cesarean section based on the health belief model', 'women undergoing cesarean section', 'Chinese cesarean women']","['health belief model-based interventions', 'additional interventions based on the health belief model', 'conventional breastfeeding guidance']","['breastfeeding satisfaction', 'breastfeeding knowledge score', 'breastfeeding behaviors and breastfeeding satisfaction', 'breastfeeding knowledge, breastfeeding behavior, and breastfeeding satisfaction', 'breastfeeding knowledge', 'exclusive breastfeeding rates', 'breastfeeding knowledge, breastfeeding behaviors, and breastfeeding satisfaction']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C3714363', 'cui_str': 'Health belief model'}]","[{'cui': 'C3714363', 'cui_str': 'Health belief model'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}]","[{'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0517671', 'cui_str': 'Knowledge level: breastfeeding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1319304', 'cui_str': 'Breastfeeding performance'}]",346.0,0.0719075,"The breastfeeding satisfaction of the intervention group was also higher than the control group at the time of discharge, 42 days postpartum and 4 months postpartum (","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Hu', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}, {'ForeName': 'Tingting', 'Initials': 'T', 'LastName': 'Ding', 'Affiliation': ""Department of Intensive Care Unit, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}, {'ForeName': 'Biru', 'Initials': 'B', 'LastName': 'Luo', 'Affiliation': 'Department of Nursing, West China Second University Hospital, Sichuan University.'}]",Medicine,['10.1097/MD.0000000000020815'] 1896,32664084,"A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild osteoarthritis.","BACKGROUND The increasing prevalence of osteoarthritis among the old population worldwide is a great concern. Two of the biggest complaints of OA patients are joint pain and inflammation. Currently, people are relying on non-steroidal anti-inflammatory drugs (NSAIDs) and steroids to control pain and inflammation. However, long-term use of these pharmaceutical drugs has negative health consequences in the elderly, including gastro-intestinal, respiratory, and renal diseases. Natural products are receiving more attention than ever as alternative treatments against OA for their efficacies and safety. The root of Paeonia lactiflora Pal and the gum resin of Commiphora myrrha have been used as analgesics and anti-inflammatory agents since ancient time. A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA. We design this study to investigate the safety and the efficacy of HT083 to prevent OA in patients with mild OA. METHODS This is a randomized, double-blind, and placebo-controlled study. A total of 100 eligible participants will be divided into two groups and will be given HT083 and a placebo for 12 weeks in 1:1 ratio. Treatment results will be assessed using a visual analog scale (VAS), Korean-Short Form health survey-36 score (SF-36), personal evaluation, and laboratory analysis. DISCUSSION This trial is expected to provide clinical evidence on the effectiveness and the safety of HT083 as a natural treatment for mild OA. TRIAL REGISTRATION Korean Clinical Research Information Service (CRIS) number KCT0004925 Registered on 2020.04.16.",2020,"A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA.","['100 eligible participants', 'patients with mild OA', 'mild OA']",['placebo'],"['visual analog scale (VAS), Korean-Short Form health survey-36 score (SF-36), personal evaluation, and laboratory analysis', 'mild osteoarthritis', 'joint pain and inflammation']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",100.0,0.275995,"A new herbal formula composed of P. lactiflora root and C. myrrha gum resin extracts, known as HT083, has shown promising antinociceptive and anti-inflammatory effects in a rodent model of OA.","[{'ForeName': 'Donghun', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Department of Herbal Pharmacology, College of Korean Medicine, Gachon University, Seongnam.'}, {'ForeName': 'Seok Jung', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Orthopedic Surgery, College of Medicine, The Catholic University of Korea.'}, {'ForeName': 'Hocheol', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Herbal Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.'}]",Medicine,['10.1097/MD.0000000000020907'] 1897,32664090,The myocardial protective effect of monosodium phosphate cardioplegia in cardiopulmonary bypass in infants with an atrial septal defect.,"This study aimed to investigate the myocardial protective effect of liquid sodium phosphocreatine cardiac arrest in extracorporeal circulation surgery treating infants with atrial septal defects.Eighty-four infants with atrial septal defects who required extracorporeal circulation surgery treatment at our hospital from January 2016 to June 2018 were divided into an observation group and a control group through a digitally randomized method, with 42 cases in each group. The control group adopted the conventional modified St Thomas II high potassium cold liquid crystal cardiac arrest, while the observation group adopted the liquid sodium phosphocreatine cardiac arrest.The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid sodium phosphocreatine cardiac arrest used in extracorporeal circulation surgery treating infants with atrial septal defects can reduce myocardial ischemia-reperfusion injury, maintain energy supply during ischemia, strengthen the St Thomas II effect, and aid postoperative cardiac function recovery of high potassium cold liquid crystal cardiac arrest used in infants with atrial septal defects and treated with extracorporeal circulation surgery.",2020,"The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid","['infants with an atrial septal defect', 'extracorporeal circulation surgery treating infants with atrial septal defects', 'Eighty-four infants with atrial septal defects who required extracorporeal circulation surgery treatment at our hospital from January 2016 to June 2018', 'infants with atrial septal defects']","['extracorporeal circulation surgery', 'monosodium phosphate cardioplegia', 'liquid sodium phosphocreatine cardiac arrest']","['myocardial enzyme indexes', 'adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels', 'myocardial protective effect']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018817', 'cui_str': 'Atrial septal defect'}, {'cui': 'C0015354', 'cui_str': 'Extracorporeal circulation procedure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0015354', 'cui_str': 'Extracorporeal circulation procedure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0031603', 'cui_str': 'Phosphate'}, {'cui': 'C0018791', 'cui_str': 'Induced cardioplegia'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0031634', 'cui_str': 'fosfocreatine'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}]","[{'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0001459', 'cui_str': 'Adenosine diphosphate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0127664,"The myocardial enzyme indexes of the 2 groups 3, 6, 12, and 24 hours postoperatively were higher than before establishing the cardiopulmonary bypass and the enzyme indexes of the control group at the same time were higher than that of the observation group; adenosine triphosphate, adenosine diphosphate, and other energy levels and the postoperative recovery rate energy levels of the observation group were higher than those in the control group, the difference was statistically significant (P < .05).Liquid","[{'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ''}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Zhai', 'Affiliation': ''}]",Medicine,['10.1097/MD.0000000000020934'] 1898,32664177,Effects of Kinect exergames on balance training among community older adults: A randomized controlled trial.,"BACKGROUND Recent years have witnessed wide applications of exergames to balance training among the older adults. However, research concerning balance training with the use of Kinect for Xbox has remained scarce. While previous studies have shown the positive effects of exergames on improving balance and preventing falling among the older adults, there has been a paucity of empirical evidence supporting the superiority of Kinect exercise to conventional exercise over balance training among the older adults. Therefore, this study aimed to compare the feasibility, safety, and effectiveness of Kinect exercise against conventional exercise over balance training among the community older adults. METHOD A total of 20 participants were randomly assigned to the Kinect Exercise Group (N = 10) or the Conventional Exercise Group (N = 10) for a 5-week balance training (45 minutes a time, 2 times a week). Assessor blinding was employed to assess the participants' performance before and after the treatment, including 30-Second Chair Stand Test (30-sec CST), Timed Up and Go (TUG), Functional Reach Test (FRT), and One-Leg Stance Test (OLST) respectively with eyes open and closed. Subjective feeling of the intensity of pain and side effects were recorded throughout the investigation period. Nonparametric statistics was used for data analysis. RESULTS Within-group comparison between the pre-test and post-test indicated that significant differences existed in all of the 5 tests (30-sec CST, TUG, FRT, OLST with eyes open, and OLST with eyes closed) in the Kinect exercise group. To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open. With regard to between-group comparison, significant differences were only found in FRT. CONCLUSION Such results indicated that both treatments were helpful in improving the participants' balance performance, that Kinect exercise was more effective in terms of overall balance ability, and that Kinect exercise was particularly beneficial to functional reach enhancement in comparison with traditional exercise. Kinect exercise could be a feasible, safe, and effective alternative for dynamic balance training among older adults.",2020,"To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open.","['older adults', 'community older adults', 'A total of 20 participants']","['Kinect exergames', 'Kinect exercise to conventional exercise over balance training', 'Kinect Exercise Group (N\u200a=\u200a10) or the Conventional Exercise Group (N\u200a=\u200a10) for a 5-week balance training', 'Kinect exercise', 'Kinect exercise against conventional exercise over balance training']","['Subjective feeling of the intensity of pain and side effects', '30-Second Chair Stand Test (30-sec CST), Timed Up and Go (TUG), Functional Reach Test (FRT), and One-Leg Stance Test (OLST', 'balance training', 'FRT']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C1998271', 'cui_str': 'Functional reach test'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]",20.0,0.0207085,"To the Conventional exercise group, however, significant differences were only observed in 30-sec CST, FRT and OLST with eyes open.","[{'ForeName': 'Chi-Min', 'Initials': 'CM', 'LastName': 'Yang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Chi-Mei Medical Center.'}, {'ForeName': 'Jun Scott', 'Initials': 'JS', 'LastName': 'Chen Hsieh', 'Affiliation': 'Department of Foreign Languages and Literature, Asia University, Taichung.'}, {'ForeName': 'Yi-Chen', 'Initials': 'YC', 'LastName': 'Chen', 'Affiliation': 'Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan, ROC.'}, {'ForeName': 'Shu-Yu', 'Initials': 'SY', 'LastName': 'Yang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Chi-Mei Medical Center.'}, {'ForeName': 'Hao-Chiang Koong', 'Initials': 'HK', 'LastName': 'Lin', 'Affiliation': 'Department of Information and Learning Technology, National University of Tainan, Tainan.'}]",Medicine,['10.1097/MD.0000000000021228'] 1899,32687741,Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes: Results From a Randomized Trial.,"BACKGROUND The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS) are unknown. OBJECTIVE To investigate the effect of an age- and weight-adapted dose of prasugrel versus a standard dose of ticagrelor in patients with ACS. (ClinicalTrials.gov: NCT01944800). DESIGN Prespecified analysis of the multicenter, randomized ISAR-REACT 5 trial. SETTING 23 centers in Germany and Italy. PATIENTS 3997 patients with ACS planned for invasive management. INTERVENTION Participants were randomly assigned to receive a standard dose of ticagrelor or prasugrel (reduced dose in the elderly or low-weight group and standard dose in the neither elderly nor low-weight group). MEASUREMENTS The efficacy end point was a composite of death, myocardial infarction, or stroke, and the safety end point was bleeding, both at 12 months. RESULTS In the elderly or low-weight group, the efficacy end point occurred in 12.7% of patients assigned to receive prasugrel and 14.6% of those assigned to receive ticagrelor (hazard ratio [HR], 0.82 [95% CI, 0.60 to 1.14]); in the neither elderly nor low-weight group, the efficacy end point occurred in 4.8% of patients assigned to receive prasugrel and 7.3% of those assigned to receive ticagrelor (HR, 0.65 [CI, 0.48 to 0.88]; P for interaction > 0.2). In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). LIMITATION The study is a subgroup analysis. CONCLUSION In elderly or low-weight patients with ACS, a reduced dose of prasugrel compared with the standard dose of ticagrelor is associated with maintained anti-ischemic efficacy while protecting these patients against the excess risk for bleeding. PRIMARY FUNDING SOURCE German Center for Cardiovascular Research and Deutsches Herzzentrum München.",2020,"In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). ","['23 centers in Germany and Italy', 'Patients With Acute Coronary Syndromes', 'elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS', 'patients with ACS', '3997 patients with ACS planned for invasive management', 'In elderly or low-weight patients with ACS']","['Prasugrel Versus Standard Dose of Ticagrelor', 'prasugrel', 'ticagrelor or prasugrel (reduced dose in the elderly or low-weight group and standard dose in the neither elderly nor low-weight group', 'ticagrelor']","['efficacy end point', 'composite of death, myocardial infarction, or stroke, and the safety end point was bleeding']","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C1620287', 'cui_str': 'prasugrel'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",3997.0,0.113308,"In the elderly or low-weight group, Bleeding Academic Research Consortium type 3 to 5 bleeding occurred in 8.1% of patients assigned to receive prasugrel and 10.6% of those assigned to receive ticagrelor (HR, 0.72 [0.46 to 1.12]), and in 3.7% and 3.8%, respectively, of patients in the neither elderly nor low-weight group (HR, 0.98 [CI, 0.65 to 1.47]; P for interaction > 0.2). ","[{'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Menichelli', 'Affiliation': 'Ospedale Fabrizio Spaziani, Cardiology, Frosinone, Italy (M.M.).'}, {'ForeName': 'Franz-Josef', 'Initials': 'FJ', 'LastName': 'Neumann', 'Affiliation': 'University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany (F.N., D.T.).'}, {'ForeName': 'Gjin', 'Initials': 'G', 'LastName': 'Ndrepepa', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Mayer', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Jochen', 'Initials': 'J', 'LastName': 'Wöhrle', 'Affiliation': 'Medical Campus Lake Constance, Friedrichshafen, Germany (J.W.).'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Bernlochner', 'Affiliation': 'Medizinische Klinik und Poliklinik Innere Medizin I (Kardiologie, Angiologie, Pneumologie), Klinikum rechts der Isar, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (I.B.).'}, {'ForeName': 'Gert', 'Initials': 'G', 'LastName': 'Richardt', 'Affiliation': 'Heart Center Bad Segeberg, Bad Segeberg, Germany (G.R.).'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Witzenbichler', 'Affiliation': 'Helios Amper-Klinikum Dachau, Dachau, Germany (B.W.).'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Sibbing', 'Affiliation': 'Klinik der Universität München, Ludwig-Maximilians-Universität, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (D.S.).'}, {'ForeName': 'Senta', 'Initials': 'S', 'LastName': 'Gewalt', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Dominick J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'University of Florida College of Medicine, Jacksonville, Florida (D.J.A.).'}, {'ForeName': 'Shqipdona', 'Initials': 'S', 'LastName': 'Lahu', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany (G.N., K.M., S.G., S.L.).'}, {'ForeName': 'Christian W', 'Initials': 'CW', 'LastName': 'Hamm', 'Affiliation': 'Heart Center, Campus Kerckhoff of Justus-Liebig-University, Giessen, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Germany (C.W.H.).'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hapfelmeier', 'Affiliation': 'Technical University of Munich, School of Medicine, Institute of Medical Informatics, Statistics and Epidemiology, Munich, Germany (A.H.).'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Trenk', 'Affiliation': 'University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany (F.N., D.T.).'}, {'ForeName': 'Karl-Ludwig', 'Initials': 'KL', 'LastName': 'Laugwitz', 'Affiliation': 'Medizinische Klinik und Poliklinik Innere Medizin I, Klinikum rechts der Isar, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (K.L.).'}, {'ForeName': 'Heribert', 'Initials': 'H', 'LastName': 'Schunkert', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Schüpke', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}, {'ForeName': 'Adnan', 'Initials': 'A', 'LastName': 'Kastrati', 'Affiliation': 'Deutsches Herzzentrum München and Technische Universität München, Munich, Germany, and German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (H.S., S.S., A.K.).'}]",Annals of internal medicine,['10.7326/M20-1806'] 1900,32687788,Self-Management Training in Chronic Obstructive Lung Disease Improves the Quality of Life.,"OBJECTIVES Management of chronic obstructive pulmonary disease (COPD) includes interventions such as improving skills in coping with the disease. We aimed to examine the effect of self-management training on the quality of life and functional parameters in patients with moderate to severe COPD. MATERIALS AND METHODS Sixty-one consecutive patients with COPD were recruited in the study prospectively. The patients were randomized into two groups: self-management training (n=31) and standard care (n=30). Each patient was evaluated by spirometry, COPD assessment test (CAT), St George's respiratory questionnaire (SGRQ), hospital anxiety and depression scale (HADS), modified British Medical Research Council (mMRC) dyspnea scale, and short form-36 (SF-36). A team of physiotherapists, psychologists, pulmonary disease specialists, and dietitians provided self-management training and biweekly counseling via phone. At the end of three months, both the groups were re-evaluated using the same assessment parameters. RESULTS We found no significant difference between the baseline demographic characteristics of the self-management training and standard care groups. We observed a reduction in CAT (p<0.001), SGRQ impact (p=0.013), activity subscales (p<0.001) and the total scores (p=0.020), and HADS anxiety (p=0.012) and depression (p=0.014) scores in the self-management training group after the education session. A significant increase in SF-36 physical function score was also observed (p=0.008). No significant improvement in the functional parameters was observed in either group; however, the change in FEV1 was more pronounced in the self-management training group than in the control group (p=0.017). The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). CONCLUSION Our results suggest that the self-management training of the patients with COPD improves the quality of life and reduces the symptoms of depression and anxiety. Therefore, at the least, self-management training should be done as the first step of pulmonary rehabilitation in patients with COPD who cannot access pulmonary rehabilitation facilities.",2020,"The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). ","['patients with COPD who cannot access pulmonary rehabilitation facilities', 'patients with moderate to severe COPD', 'Sixty-one consecutive patients with COPD were recruited in the study prospectively', 'chronic obstructive pulmonary disease (COPD']","['self-management training', 'self-management training (n=31) and standard care', 'Self-Management Training']","['quality of life', 'hospital readmissions and 1-year survival rates', 'Quality of Life', 'quality of life and functional parameters', 'functional parameters', 'activity subscales', 'reduction in CAT (p<0.001), SGRQ impact', 'SF-36 physical function score', 'symptoms of depression and anxiety', ""spirometry, COPD assessment test (CAT), St George's respiratory questionnaire (SGRQ), hospital anxiety and depression scale (HADS), modified British Medical Research Council (mMRC) dyspnea scale, and short form-36 (SF-36"", 'change in FEV1', 'total scores (p=0.020), and HADS anxiety', 'depression']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C4284282', 'cui_str': 'COPD assessment test'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]",61.0,0.0197593,"The hospital readmissions and 1-year survival rates were similar for both the groups after receiving education (p>0.05). ","[{'ForeName': 'Betül Özdel', 'Initials': 'BÖ', 'LastName': 'Öztürk', 'Affiliation': 'Clinic of Pulmonary Diseases, İzzet Baysal State Hospital, Bolu, Turkey.'}, {'ForeName': 'Aylin Özgen', 'Initials': 'AÖ', 'LastName': 'Alpaydın', 'Affiliation': 'Department of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}, {'ForeName': 'Sevgi', 'Initials': 'S', 'LastName': 'Özalevli', 'Affiliation': 'Department of Pulmonary Rehabilitation, Dokuz Eylül University, Izmir, Turkey.'}, {'ForeName': 'Nurcan', 'Initials': 'N', 'LastName': 'Güler', 'Affiliation': 'Department of Pulmonary Diseases, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Cimilli', 'Affiliation': 'Department of Psychiatry, Dokuz Eylül University School of Medicine, İzmir, Turkey.'}]",Turkish thoracic journal,['10.5152/TurkThoracJ.2019.19015'] 1901,32671719,Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives.,"Cabozantinib (Cabometyx ® ) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the ""anexelekto"" (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since November 2018) and in the USA (since January 2019). The approval of cabozantinib was based on results of the randomized, placebo-controlled, phase 3 CELESTIAL trial in patients with unresectable HCC, who received one or two prior lines of treatment including sorafenib. At the second planned interim analysis, the trial was stopped, because the primary end point overall survival was clearly in favor for cabozantinib. Additionally, median progression-free survival was superior to placebo. The most common ≥ grade 3 relevant adverse events in patients with HCC treated with cabozantinib were palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea. In this review, current data on cabozantinib for the treatment of patients with advanced HCC, with a focus on the management of common adverse events and ongoing clinical trials, are discussed.",2020,"Additionally, median progression-free survival was superior to placebo.","['patients with advanced HCC', 'Advanced Hepatocellular Carcinoma', 'patients with unresectable HCC, who received one or two prior lines of treatment including', 'advanced hepatocellular carcinoma (HCC) after failure of sorafenib in Europe (since\xa0November 2018) and in the USA (since January 2019']","['Cabozantinib (Cabometyx ® ', 'sorafenib', 'Cabozantinib', 'placebo']","['palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea', 'overall survival', 'median progression-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C1112459', 'cui_str': 'Liver cell carcinoma non-resectable'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C3181682', 'cui_str': 'cabozantinib'}, {'cui': 'C4237933', 'cui_str': 'Cabometyx'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.065429,"Additionally, median progression-free survival was superior to placebo.","[{'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Trojan', 'Affiliation': 'Universitätsklinikum Frankfurt, Medizinische Klinik 1, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. trojan@em.uni-frankfurt.de.'}]",Drugs,['10.1007/s40265-020-01361-5'] 1902,32672570,Outcomes of the Shunt Tube Exposure Prevention Study: A Randomized Clinical Trial.,"PURPOSE To compare the long-term safety and efficacy of amniotic membrane-umbilical cord (AM-UC) and pericardium patch grafts in reducing glaucoma shunt tube exposure. DESIGN Multicenter, prospective, randomized clinical trial. PARTICIPANTS Adults with uncontrolled glaucoma undergoing glaucoma drainage device (GDD) implantation. METHODS Patients were randomized to receive GDD with either AM-UC or pericardium patch grafts to cover GDD tubes. Patients were followed up clinically with anterior segment (AS) OCT to assess patch graft stability and host-tissue integration prospectively. MAIN OUTCOME MEASURES Tube exposure, graft thinning, and graft-related complications. RESULTS A total of 81 eyes of 81 patients (50 women, 31 men) with a mean age of 67±13 years underwent GGD implantation using Baerveldt (n = 72) or Ahmed valve (n = 9). Tubes were inserted in the anterior chamber (n = 71), sulcus (n = 6), or pars plana (n = 4). Tube ligation was performed with Baerveldt GDD along with fenestration (n = 51) or orphan trabeculectomy (n = 21). Tubes were covered with AM-UC (n = 41) or pericardium (n = 40). The mean follow-up time was 29±8 months (range, 13-40 months). Tube exposure occurred in 1 eye (2%) in the AM-UC group at 3 months and in 2 eyes (5%) in the pericardium group at 2 and 6 months (P = 0.54). Sequential AS OCT showed better host-tissue integration and significantly less graft thinning in the AM-UC group. Early graft thinning (≤3 months) occurred in 5 eyes (12%) in the AM-UC group and in 17 eyes (43%) in the pericardium group (P = 0.002). Late thinning occurred in 2 eyes (5%) and 11 eyes (28%) in the AM-UC and pericardium groups, respectively (P = 0.007). Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft. No evidence of graft rejection or infection was associated with the patch grafts in either group. CONCLUSIONS Amniotic membrane-umbilical cord grafts are well tolerated and offer an alternative to pericardium for safe and stable tube shunt coverage. Its high-tensile strength, low immunogenicity, and excellent host-tissue integration significantly reduced graft thinning.",2019,Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft.,"['Adults with uncontrolled glaucoma undergoing glaucoma drainage device (GDD) implantation', 'Patients', 'A total of 81 eyes of 81 patients (50 women, 31 men) with a mean age of 67±13 years underwent GGD implantation using Baerveldt (n\xa0= 72) or Ahmed valve (n']","['amniotic membrane-umbilical cord (AM-UC) and pericardium patch grafts', 'AM-UC', 'Tube ligation was performed with Baerveldt GDD along with fenestration (n\xa0= 51) or orphan trabeculectomy', 'GDD with either AM-UC or pericardium patch grafts to cover GDD tubes']","['graft rejection or infection', 'Tube exposure, graft thinning, and graft-related complications', 'graft thinning', 'Tube exposure', 'Early graft thinning', 'host-tissue integration', 'Late thinning', 'Graft translucency and cosmetic appearance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}]","[{'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C0031050', 'cui_str': 'Pericardial sac structure'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0181041', 'cui_str': 'Glaucoma drainage device'}, {'cui': 'C0015825', 'cui_str': 'Inner ear fenestration'}, {'cui': 'C0242299', 'cui_str': 'Orphan'}, {'cui': 'C0040574', 'cui_str': 'Trabeculoplasty'}, {'cui': 'C0439844', 'cui_str': 'Covered'}]","[{'cui': 'C0018129', 'cui_str': 'Graft rejection'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0522503', 'cui_str': 'Translucent'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}]",81.0,0.0452362,Graft translucency and cosmetic appearance of the AM-UC graft were superior to those of the pericardium graft.,"[{'ForeName': 'Hosam', 'Initials': 'H', 'LastName': 'Sheha', 'Affiliation': 'Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, New York, New York; Hofstra Northwell Zucker School of Medicine, Hempstead, New York; Herbert Wertheim College of Medicine, Florida International University, Miami, Florida. Electronic address: hsheha@northwell.edu.'}, {'ForeName': 'Celso', 'Initials': 'C', 'LastName': 'Tello', 'Affiliation': 'Department of Ophthalmology, Manhattan Eye, Ear & Throat Hospital, New York, New York; Hofstra Northwell Zucker School of Medicine, Hempstead, New York.'}, {'ForeName': 'Lama A', 'Initials': 'LA', 'LastName': 'Al-Aswad', 'Affiliation': 'Harkness Eye Institute, Columbia University, New York, New York.'}, {'ForeName': 'Mohamed S', 'Initials': 'MS', 'LastName': 'Sayed', 'Affiliation': 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Richard K', 'Initials': 'RK', 'LastName': 'Lee', 'Affiliation': 'Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida. Electronic address: rlee@med.miami.edu.'}]",Ophthalmology. Glaucoma,['10.1016/j.ogla.2019.08.003'] 1903,32667956,Improved balance in middle-aged adults after 8 weeks of a modified version of Otago Exercise Program: A randomized controlled trial.,"OBJECTIVE The objective of this randomized controlled trial was to examine dynamic balance changes (reach distance) in middle-aged adults using the Y Balance Test (YBT) following 8 weeks of home-based exercise program adapted from the Otago Exercise Program (OEP). METHODS Fifty-two healthy middle-aged adults with mean age of 54.4±5.4 years and body mass index of 27.7±5.7 kg/m2 were randomly assigned into either the exercise group (a modification of the Otago Exercise Program, that consisted of home-based balance and strength exercises) or the non-exercise group (continuation of usual lifestyle) by having the participants select a paper from a sealed envelope. The YBT was used to measure participants' dynamic balance in the right and left anterior (RA, LA), posteromedial (RPM, LPM), and posterolateral (RPL, LPL) directions. RESULTS The outcome in this trial was reach distance (cm). There was a significant group by time interaction in terms of reach distance for all directions (p<0.05, η2 ranged from 0.06 to 0.20). In the exercise group, results of the repeated measures analysis of variance (ANOVA) showed significant improvements in the reach distance in all the directions (p<0.001). In contrast, the non-exercise group had significant difference only in the left posterolateral direction (p = 0.009). Participants in the exercise group achieved significantly greater reach distance (cm) (95% confidence interval (CI)) for RA[(2.8, 0.4 to 5.2), p = 0.023]; LA[(3.2, 0.9 to 5.6), p = 0.008]; RPM[(4.0, 1.0 to 7.9), p = 0.046]; LPM[(5.8,1.3 to 10.3), p = 0.013]; RPL[(7.6, 2.6 to 12.6), p = 0.003]; and LPL[(4.2, 0.3 to 8.2), p = 0.035]. CONCLUSION The modified version of OEP appears to be effective in improving parameters of dynamic balance in the middle-aged adult population. The improvements in YBT reach distance in the exercise group are indicative of the significance of performing balance and strength exercises regularly for this population.",2020,The modified version of OEP appears to be effective in improving parameters of dynamic balance in the middle-aged adult population.,"['middle-aged adult population', 'middle-aged adults', 'middle-aged adults using the Y Balance Test (YBT) following 8 weeks of', 'Fifty-two healthy middle-aged adults with mean age of 54.4±5.4 years and body mass index of 27.7±5.7 kg/m2']","['exercise group (a modification of the Otago Exercise Program, that consisted of home-based balance and strength exercises) or the non-exercise group (continuation of usual lifestyle) by having the participants select a paper from a sealed envelope', 'home-based exercise program adapted from the Otago Exercise Program (OEP', 'YBT']","['reach distance (cm', 'left posterolateral direction', 'YBT reach distance', 'greater reach distance (cm', 'dynamic balance changes (reach distance']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0332195', 'cui_str': 'Posterolateral'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",52.0,0.0643444,The modified version of OEP appears to be effective in improving parameters of dynamic balance in the middle-aged adult population.,"[{'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Almarzouki', 'Affiliation': 'Department of Physical Therapy, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}, {'ForeName': 'Gurinder', 'Initials': 'G', 'LastName': 'Bains', 'Affiliation': 'Department of Allied Health Studies, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}, {'ForeName': 'Everett', 'Initials': 'E', 'LastName': 'Lohman', 'Affiliation': 'Department of Physical Therapy, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Bradley', 'Affiliation': 'Department of Physical Therapy, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Nelson', 'Affiliation': 'Department of Physical Therapy, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}, {'ForeName': 'Samiah', 'Initials': 'S', 'LastName': 'Alqabbani', 'Affiliation': 'Department of Rehabilitation Sciences, School of Health and Rehabilitation Sciences, Princess Nourah bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia.'}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Alonazi', 'Affiliation': 'Department of Physical Therapy, School of Applied Medical Sciences, Majmaah University, Riyadh, Kingdom of Saudi Arabia.'}, {'ForeName': 'Noha', 'Initials': 'N', 'LastName': 'Daher', 'Affiliation': 'Department of Allied Health Studies, School of Allied Health Professions, Loma Linda University, Loma Linda, California, United States of America.'}]",PloS one,['10.1371/journal.pone.0235734'] 1904,32668487,"Acupuncture for pain, mandibular function and oral health-related quality of life in patients with masticatory myofascial pain: A randomised controlled trial.","BACKGROUND Masticatory myofascial pain is the most prevalent muscular temporomandibular disorders (TMD). It primarily affects masseter and temporal muscles. Several treatments, including acupuncture, have been recommended. However, systematic reviews have highlighted gaps in studies and absence of conclusive results. OBJECTIVES We performed a randomised controlled clinical trial to evaluate the effectiveness of acupuncture in improving pain, mandibular function and oral health-related quality of life in women with masticatory myofascial pain. METHODS Thirty-six patients diagnosed with masticatory myofascial pain according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) were divided into the following two groups: acupuncture and control (non-penetrating acupuncture).Treatment was performed weekly for 5 weeks, and pain, mandibular function and oral health-related quality of life were evaluated one week before treatment, one week after treatment and one month after treatment. Non-parametric and parametric tests were used for comparisons between times and treatment groups (significance level of P ≤ .05). RESULTS The acupuncture group showed a significant reduction in pain (P ≤ .01), which was not observed in the control group. Pain intensity was reduced by 61% and 84% at 1 week and 1 month after treatment, respectively. Both groups showed significant improvements in mandibular function and oral health-related quality of life over time (P ≤ .01). Statistical analysis did not show a significant difference between the groups for any other evaluated outcome (P > .05). CONCLUSION Although acupuncture was effective in pain reduction, non-specific factors may have influenced mandibular function and oral health-related quality of life improvements in both groups, and this needs to be further addressed.",2020,"Statistical analysis did not show a significant difference between the groups for any other evaluated outcome (p>0.05). ","['patients with masticatory myofascial pain', 'Thirty-six patients diagnosed with masticatory myofascial pain according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD', 'women with masticatory myofascial pain']","['acupuncture', 'acupuncture or control (non-penetrating acupuncture).Treatment', 'Acupuncture']","['mandibular function and oral health-related quality of life over time (p≤0.01', 'pain, mandibular function and oral health-related quality of life', 'Pain intensity', 'pain, mandibular function, and oral health-related quality of life', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0207800', 'cui_str': 'monorden'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}]","[{'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",36.0,0.175874,"Statistical analysis did not show a significant difference between the groups for any other evaluated outcome (p>0.05). ","[{'ForeName': 'Franklin Teixeira', 'Initials': 'FT', 'LastName': 'de Salles-Neto', 'Affiliation': 'Pathology Postgraduate Program, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Janice Simpson', 'Initials': 'JS', 'LastName': 'de Paula', 'Affiliation': 'Department of Social and Preventive Dentistry, Faculty of Dentistry, UFMG, Belo Horizonte, Brazil.'}, {'ForeName': 'João Gabriel de Azevedo José', 'Initials': 'JGAJ', 'LastName': 'Romero', 'Affiliation': 'Pathology Postgraduate Program, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.'}, {'ForeName': 'Camila Megale', 'Initials': 'CM', 'LastName': 'Almeida-Leite', 'Affiliation': 'Department of Morphology, Biological Sciences Institute, UFMG, Belo Horizonte, Brazil.'}]",Journal of oral rehabilitation,['10.1111/joor.13055'] 1905,32668499,"Effect of botulinum toxin type A for treating hypertrophic scars: A split-scar, double-blind randomized controlled trial.","BACKGROUND Hypertrophic scars (HS) are a challenging disorder that mostly develops during wound-healing process following skin injuries. METHODS A split-scar, double-blind randomized controlled trial was held to assess the safety and efficacy of botulinum toxin type A (BTA) injection in hypertrophic scars (HS). Thirty patients with old scars (range: 1-15 years) were treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline once monthly for three consecutive months. Scars were assessed using the Vancouver scar scale (VSS) along with digital photograph standardization. RESULTS Twenty-one subjects completed the study. The mean VSS score for the BTA-treated half of the scars decreased from 7.29 ± 2.327 before injection to 5.33 ± 2.41 following injection which was highly significant (P = .01). For the control half, the mean VSS decreased insignificantly from 7.29 ± 2.327 before injection to 7.10 ± 2.234 following injection (P = .104). CONCLUSION Clinical and cosmetic improvement was demonstrated significantly among the BTA-treated group. BTA can be an additional and useful tool for improving scar outcomes.",2020,"For the control half, the mean VSS decreased insignificantly from 7.29±2.327 before injection to 7.10±2.234 following injection (p = 0.104). ","['hypertrophic scars (HS', 'Thirty patients with old scars (range 1-15years', ' Twenty one subjects completed the study', 'hypertrophic scars']","['botulinum toxin type A (BTA) injection', 'BTA', 'BTA or 0.9% normal saline', 'Botulium toxin type A']","['safety and efficacy', 'mean VSS score', 'Vancouver scar scale (VSS', 'mean VSS']","[{'cui': 'C0162810', 'cui_str': 'Hypertrophic scar'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0439166', 'cui_str': '% normal'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0445349', 'cui_str': 'Toxin typing'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",30.0,0.351475,"For the control half, the mean VSS decreased insignificantly from 7.29±2.327 before injection to 7.10±2.234 following injection (p = 0.104). ","[{'ForeName': 'Ahmad R', 'Initials': 'AR', 'LastName': 'Elshahed', 'Affiliation': 'Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Al Azhar University, Cairo, Egypt.'}, {'ForeName': 'Khaled S', 'Initials': 'KS', 'LastName': 'Elmanzalawy', 'Affiliation': 'Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Al Azhar University, Cairo, Egypt.'}, {'ForeName': 'Hany', 'Initials': 'H', 'LastName': 'Shehata', 'Affiliation': 'Department of Dermatology and Venereology, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Mohamed L', 'Initials': 'ML', 'LastName': 'ElSaie', 'Affiliation': 'Department of Dermatology and Venereology, National Research Centre, Giza, Egypt.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13627'] 1906,32669121,A Combined Randomised and Observational Study of Surgery for Fractures In the distal Radius in the Elderly (CROSSFIRE): a statistical analyses plan.,"BACKGROUND We are performing a combined randomised and observational study comparing internal fixation to non-surgical management for common wrist fractures in older patients. This paper describes the statistical analysis plan. METHODS/DESIGN A Combined Randomised and Observational Study of Surgery for Fractures In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation. The primary aim of this comparative-effectiveness study is to determine whether surgery is superior to non-surgical treatment with respect to patient-reported wrist function at 12 months post treatment. The secondary outcomes include radiographic outcomes, complication rates and patient-reported outcomes including quality of life, pain, treatment success and cosmesis. Primary analysis will use a two-sample t test and an intention-to-treat analysis using the randomised arm of the study. Statistical analyses will be two-tailed and significance will be determined by p < 0.05. Sensitivity analyses will be conducted to assess for differences in intention-to-treat, per-protocol and as-treated analyses. Sensitivity analyses will also be conducted to assess selection bias by evaluating differences in participants between the randomised and observational study arms, and for bias relating to any missing data. An economic analysis will be conducted separately if surgery is shown to provide superior outcomes to a level of clinical significance. DISCUSSION This statistical analysis plan describes the analysis of the CROSSFIRE study which aims to provide evidence to aid clinical decision-making in the treatment of distal radius fractures in older patients. TRIAL REGISTRATION CROSSFIRE was approved by The Hunter New England Human Research Ethics Committee (HNEHREC Reference No: 16/02/17/3.04). Registered on 22 July 2016 with The Australian and New Zealand Clinical Trials Registry (ANZCTR Number; ACTRN12616000969460 ). This manuscript is based on v.11 of the statistical analysis plan. A copy of v.11, signed by the chief investigator and the senior statistician is kept at the administering institution.",2020,"In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation.","['older patients', 'Surgery for Fractures']","['surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation', 'internal fixation to non-surgical management']","['radiographic outcomes, complication rates and patient-reported outcomes including quality of life, pain, treatment success and cosmesis']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C2363849', 'cui_str': 'Non-surgical treatment'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0460977', 'cui_str': 'Plasters'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.126119,"In the distal Radius in the Elderly (CROSSFIRE) is a randomised controlled trial comparing two types of usual care for treating wrist fractures in older patients, surgical fixation using volar locking plates and non-surgical treatment using closed reduction and plaster immobilisation.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Lawson', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia. aalawson@tpg.com.au.'}, {'ForeName': 'Justine', 'Initials': 'J', 'LastName': 'Naylor', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Rachelle', 'Initials': 'R', 'LastName': 'Buchbinder', 'Affiliation': 'Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Ivers', 'Affiliation': 'School of Public Health and Community Medicine, UNSW Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Zsolt', 'Initials': 'Z', 'LastName': 'Balogh', 'Affiliation': 'John Hunter Hospital, Newcastle, NSW, Australia.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Smith', 'Affiliation': 'Canberra Hospital, Canberra, ACT, Australia.'}, {'ForeName': 'Rajat', 'Initials': 'R', 'LastName': 'Mittal', 'Affiliation': 'South Western Sydney Clinical School, UNSW, Sydney, NSW, Australia.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xuan', 'Affiliation': 'Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Howard', 'Affiliation': 'Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Arezoo', 'Initials': 'A', 'LastName': 'Vafa', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Piers', 'Initials': 'P', 'LastName': 'Yates', 'Affiliation': 'Fiona Stanley Hospital, Perth, WA, Australia.'}, {'ForeName': 'Bertram', 'Initials': 'B', 'LastName': 'Rieger', 'Affiliation': 'Fiona Stanley Hospital, Perth, WA, Australia.'}, {'ForeName': 'Geoff', 'Initials': 'G', 'LastName': 'Smith', 'Affiliation': 'St George and Sutherland Hospitals, Sydney, NSW, Australia.'}, {'ForeName': 'Ilia', 'Initials': 'I', 'LastName': 'Elkinson', 'Affiliation': 'Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Woosung', 'Initials': 'W', 'LastName': 'Kim', 'Affiliation': 'Wellington Hospital, Wellington, New Zealand.'}, {'ForeName': 'Jai', 'Initials': 'J', 'LastName': 'Sungaran', 'Affiliation': 'Concord Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Latendresse', 'Affiliation': 'Nambour Hospital and Sunshine Coast University Hospital, Nambour, QLD, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Wong', 'Affiliation': 'Westmead Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Viswanathan', 'Affiliation': 'Campbelltown Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Landale', 'Affiliation': 'Campbelltown Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Herwig', 'Initials': 'H', 'LastName': 'Drobetz', 'Affiliation': 'Mackay Base Hospital, Mackay, QLD, Australia.'}, {'ForeName': 'Phong', 'Initials': 'P', 'LastName': 'Tran', 'Affiliation': 'Western Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Page', 'Affiliation': 'University Hospital Geelong, Barwon Health, Geelong, NSW, Australia.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Hau', 'Affiliation': 'Northern Health, Melbourne, VIC, Australia.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Mulford', 'Affiliation': 'Launceston Hospital, Launceston, TAS, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Incoll', 'Affiliation': 'Gosford and Wyong Hospitals, Gosford, NSW, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kale', 'Affiliation': 'Gosford and Wyong Hospitals, Gosford, NSW, Australia.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Schick', 'Affiliation': 'Prince of Wales Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Higgs', 'Affiliation': ""St Vincent's Hospital, Sydney, NSW, Australia.""}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Oppy', 'Affiliation': 'Royal Melbourne Hospital, Melbourne, VIC, Australia.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Perriman', 'Affiliation': 'Canberra Hospital, Canberra, ACT, Australia.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Harris', 'Affiliation': 'Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.'}]",Trials,['10.1186/s13063-020-4228-0'] 1907,32682049,"Employee perseverance in a ""no phone use while driving"" organizational road-safety intervention.","INTRODUCTION This interdisciplinary study explores factors that contribute to the perseverance of participants in an organizational ""no phone use while driving"" road-safety intervention. METHOD The study sample comprised 200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel. Subjects completed a 4-month organizational intervention using a smartphone application that monitored smartphone use, operationalized as taps per minute, where each tap represents a single instance of contact with the screen (e.g., touching, tapping or swiping). The app also silenced notifications during the intervention stage. Changes over time in tapping-while-driving behavior were examined through self-report questionnaires and objectively through the application's monitoring function. Validated measures were used to examine factors associated with perseverance in the program. RESULTS Organizational safety climate and gender (male) were positively related to perseverance in the intervention. Contrary to our hypothesis, safety motivation was not found to influence perseverance. CONCLUSIONS The present intervention is most effective for employees with high safety climate perceptions and for male employees. PRACTICAL APPLICATIONS The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving. Our findings show that people will download and use an app that actively reduces their incentive to use their phones at the wheel by silencing incoming notifications. The findings support calls to harness the positive potential of information and communications technologies for organizational interventions.",2020,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","['employees with high safety climate perceptions and for male employees', '200 employees (mean age 43 years; 104 females [52 %], 96 males [48 %]) from 8 organizations in Israel']",[],['safety motivation'],"[{'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0008946', 'cui_str': 'Climate'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0022271', 'cui_str': 'Israel'}]",[],"[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}]",200.0,0.0146053,"The organizational intervention presented in the current study was shown to be effective in reducing smartphone use (touching, tapping or swiping) while driving.","[{'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Rispler', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: clararispler5510@gmail.com.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Luria', 'Affiliation': 'Faculty of Welfare and Health Sciences, Department of Human Services, University of Haifa, Mount Carmel, Haifa, 31905, Israel. Electronic address: gluria@univ.haifa.ac.il.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105689'] 1908,32682074,Pulmonary deposition of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler formulated using co-suspension delivery technology in healthy male subjects.,"This gamma scintigraphy imaging study assessed pulmonary, extrathoracic and regional lung deposition patterns of a radiolabelled inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β 2 -agonist triple fixed-dose combination budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF 320/14.4/10 μg), delivered by pressurised metered dose inhaler (pMDI) using innovative co-suspension delivery technology (Aerosphere™). In this Phase I, randomised, single-centre, single-dose, two-period, crossover study (NCT03740373), 10 healthy male adults received two actuations of BGF MDI (160/7.2/4.8 μg per actuation) radiolabelled with 99m Tc, not exceeding 5 MBq per actuation. Immediately following each inhalation, subjects performed a 10- or 3-second breath-hold, then exhaled into an exhalation filter. The primary objective was to assess the pulmonary deposition of BGF MDI following the 10-second breath-hold. The secondary objectives were to assess deposition after the 3-second breath-hold and lung regional and extrathoracic deposition after each breath-hold length. Imaging of the lungs, stomach, head and neck was recorded by gamma scintigraphy immediately after exhalation. The mean BGF MDI emitted dose deposited in the lungs was 37.7% for the 10-second breath-hold and 34.5% for the 3-second breath-hold. Emitted dose detected in the exhalation filter was ≤0.4% for both breath-hold lengths. The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively. There were no new or unexpected safety findings. In conclusion, BGF MDI was efficiently deposited in the central and the peripheral regions of the lungs, with similar regional deposition patterns following a 10- and 3-second breath-hold.",2020,"The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively.","['10 healthy male adults received', 'healthy male subjects']","['two actuations of BGF MDI', 'budesonide/glycopyrronium/formoterol fumarate dihydrate']","['exhalation filter', 'deposition after the 3-second breath-hold and lung regional and extrathoracic deposition after each breath-hold length', 'mean BGF MDI', 'pulmonary deposition of BGF MDI', 'mean normalised peripheral/central ratio', 'BGF MDI']","[{'cui': 'C0686751', 'cui_str': 'Well male adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4319628', 'cui_str': 'Actuation'}, {'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C3814772', 'cui_str': 'glycopyrronium'}, {'cui': 'C1579393', 'cui_str': 'Formoterol fumarate dihydrate'}]","[{'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0180860', 'cui_str': 'Filter'}, {'cui': 'C0333562', 'cui_str': 'Deposition'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0235744', 'cui_str': 'Interrupted breathing'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",10.0,0.0611695,"The mean normalised peripheral/central ratio was 0.65 and 0.75 for the 10- and 3-second breath-holds, respectively, while the standardised central/peripheral ratios were 1.79 and 1.40, respectively.","[{'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Israel', 'Affiliation': 'Simbec Research Ltd, Merthyr Tydfil, South Wales, CF48 4DR, UK.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Kelly Services Global LLC, Suite 401A, 999W. Big Beaver Rd., Troy, MI, 48084, USA.'}, {'ForeName': 'Kiernan', 'Initials': 'K', 'LastName': 'DeAngelis', 'Affiliation': 'Formerly of AstraZeneca, 4222 Emperor Blvd, Suite 560, Durham, NC, 27703, USA.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Aurivillius', 'Affiliation': 'AstraZeneca Gothenburg, Pepparedsleden 1, SE-431 50, Mölndal, Sweden.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dorinsky', 'Affiliation': 'AstraZeneca, 4222 Emperor Blvd, Suite 560, Durham, NC, 27703, USA. Electronic address: paul.dorinsky1@astrazeneca.com.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Roche', 'Affiliation': 'Respiratory Medicine, Hôpital Cochin (AP-HP), University Paris Descartes, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France.'}, {'ForeName': 'Omar S', 'Initials': 'OS', 'LastName': 'Usmani', 'Affiliation': 'National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital, Guy Scadding Building, Dovehouse St, Chelsea, London SW3 6LY, UK.'}]",European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,['10.1016/j.ejps.2020.105472'] 1909,32682174,The renin secretion profile under the influence of sleep deprivation and the neuropeptides CRH and GHRH.,"It is already known that during normal sleep plasma renin activity (PRA) shows oscillations with decreases during rapid-eye-movement (REM) sleep and increases during non-REM (NREM) sleep. We also know that renin correlates positively with slow-wave sleep (SWS). Sleep deprivation is known to enhance significantly SWS and slow wave activity (SWA, known as δ power). Based on these findings we addressed the question whether and to which extent sleep deprivation may affect the synchronization found between PRA and REM sleep during normal sleep and whether this synchronization is affected by other sleep regulating factors. To investigate these questions we compared sleep EEG and sleep-related free renin levels in 48 normal women and men 19-69 years old between nights before and after 40 h of sleep deprivation. During the recovery night, four bolus injections of either GHRH, CRH or placebo were injected via long catheter around sleep onset. When compared to baseline after each of the treatments SWS, SWA and renin levels increased. The characteristical oscillation profiles of renin during normal sleep were also preserved after sleep deprivation. Similar to normal sleep our data support also a distinct link between nocturnal renin secretion and SWS after sleep deprivation and that independent of the applied treatments.",2020,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.",['48 normal women and men 19-69 years old between nights before and after 40\u2009h of sleep deprivation'],"['GHRH, CRH or placebo']","['renin correlates positively with slow-wave sleep (SWS', 'SWA and renin levels', 'sleep EEG and sleep-related free renin levels']","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}]","[{'cui': 'C0037668', 'cui_str': 'Somatotropin releasing factor'}, {'cui': 'C0010132', 'cui_str': 'Corticotropin-Releasing Hormone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035094', 'cui_str': 'Renin'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0038977', 'cui_str': 'Swahili language'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0200101', 'cui_str': 'Sleep electroencephalogram'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",48.0,0.0236425,"When compared to baseline after each of the treatments SWS, SWA and renin levels increased.","[{'ForeName': 'H', 'Initials': 'H', 'LastName': 'Künzel', 'Affiliation': 'Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Germany; Max-Planck-Institut für Psychiatrie München, Germany. Electronic address: Heike.Kuenzel@med.uni-muenchen.de.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Schüssler', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Regensburg, Klinik und Poliklinik für Psychiatrie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Yassouridis', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Uhr', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kluge', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany; Universität Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Germany.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Steiger', 'Affiliation': 'Max-Planck-Institut für Psychiatrie München, Germany.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104799'] 1910,32682277,Effects of repeated exposure to fearful and disgusting stimuli on fear renewal in blood-injection-injury phobia.,"Although exposure is effective for blood-injection-injury (BII) phobia, fear often returns after treatment. While disgust has been implicated in BII phobia, its effects on fear renewal are unclear. To address this knowledge gap, the present study examined the effect of repeated video exposure to fearful and disgusting stimuli in multiple contexts on fear renewal in BII phobia. Individuals with BII phobia (N = 57) were randomized to Disgust-Specific Exposure (DSE) which included exposure to disgusting but threat-irrelevant stimuli (i.e., vomit), Fear-Specific Exposure (FSE) which included exposure to threat-relevant stimuli (i.e., injections), or General Negative Exposure (GNE) which included exposure designed to elicit negative affect (i.e., tornado) without being disgusting or threat-relevant. During session one, participants watched a pre- and post-exposure assessment injection video (""pre/post assessment""), and a novel injection video after exposure to assess renewal effects (""novel 1""). Participants came in one week later to rate the same videos, and a new injection video (""novel 2""). For week one outcomes, comparisons of covariate adjusted means indicated the fear-specific group reported significantly lower levels of anxiety than the general-negative group to the post-exposure and novel 1 stimulus. When presented with the post-exposure stimuli during week two, the disgust-specific and fear-specific groups reported significantly lower levels of anxiety than the general negative group. The fear-specific group also reported significantly lower levels of anxiety than the disgust-specific and general-negative groups when presented with novel 1 and novel 2 stimuli at week two. These findings suggest that repeated exposure to threat-relevant cues in multiple contexts does reduce the return of anxiety. However, repeated exposure to disgusting but threat irrelevant stimuli may also produce some therapeutic effects. The implications of the integration of disgust-relevant processes into exposure-based treatment of BII phobia are discussed.",2020,The fear-specific group also reported significantly lower levels of anxiety than the disgust-specific and general-negative groups when presented with novel 1 and novel 2 stimuli at week two.,"['Individuals with BII phobia (N = 57', 'blood-injection-injury phobia', 'multiple contexts on fear renewal in BII phobia']","['Disgust-Specific Exposure (DSE) which included exposure to disgusting but threat-irrelevant stimuli (i.e., vomit), Fear-Specific Exposure (FSE) which included exposure to threat-relevant stimuli (i.e., injections), or General Negative Exposure', 'repeated exposure to fearful and disgusting stimuli', 'pre- and post-exposure assessment injection video (""pre/post assessment']","['return of anxiety', 'levels of anxiety']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0349231', 'cui_str': 'Phobia'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449255', 'cui_str': 'Context'}, {'cui': 'C0015726', 'cui_str': 'Fear'}]","[{'cui': 'C0683283', 'cui_str': 'Disgust'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}]",57.0,0.00929875,The fear-specific group also reported significantly lower levels of anxiety than the disgust-specific and general-negative groups when presented with novel 1 and novel 2 stimuli at week two.,"[{'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Jessup', 'Affiliation': 'Vanderbilt University, United States.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Tomarken', 'Affiliation': 'Vanderbilt University, United States.'}, {'ForeName': 'Megan A', 'Initials': 'MA', 'LastName': 'Viar-Paxton', 'Affiliation': 'Vanderbilt University, United States.'}, {'ForeName': 'Bunmi O', 'Initials': 'BO', 'LastName': 'Olatunji', 'Affiliation': 'Vanderbilt University, United States. Electronic address: olubunmi.o.olatunji@vanderbilt.edu.'}]",Journal of anxiety disorders,['10.1016/j.janxdis.2020.102272'] 1911,32682554,Evaluation of an enhanced pulse oximeter auditory display: a simulator study.,"BACKGROUND We compared anaesthetists' ability to identify haemoglobin oxygen saturation (SpO 2 ) levels using two auditory displays: one based on a standard pulse oximeter display (varying pitch plus alarm) and the other enhanced with additional sound properties (varying pitch plus tremolo and acoustic brightness) to differentiate SpO 2 ranges. METHODS In a counter-balanced crossover study in a simulator, 20 experienced anaesthetists supervised a junior colleague (an actor) managing two airway surgery scenarios: once while using the enhanced auditory display and once while using a standard auditory display. Participants were distracted with other tasks such as paperwork and workplace interruptions, but were required to identify when SpO 2 transitioned between pre-set ranges (target, low, critical) and when other vital signs transitioned out of a target range. They also identified the range once a transition had occurred. Visual displays were available for all monitored vital signs, but the numerical value for SpO 2 was excluded. RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively). They were also more accurate at identifying the SpO 2 range once a transition had occurred when using the enhanced display (100.0%) than when using the standard display plus alarm (57.1%; P<0.001). CONCLUSIONS The enhanced auditory display helps anaesthetists judge SpO 2 levels more effectively than current auditory displays and may facilitate 'eyes-free' monitoring.",2020,"RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively).",[],['anaesthetists supervised a junior colleague (an actor) managing two airway surgery scenarios'],['haemoglobin oxygen saturation (SpO 2 ) levels'],[],"[{'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0335083', 'cui_str': 'Actor'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0651879,"RESULTS Participants were more accurate and faster at detecting transitions to and from the target SpO 2 range when using the enhanced display (100.0%, 3.3 s) than when using the standard display plus alarm (73.2%, 27.4 s) (P<0.001 and P=0.004, respectively).","[{'ForeName': 'Estrella', 'Initials': 'E', 'LastName': 'Paterson', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia. Electronic address: estrella.paterson@uqconnect.edu.au.'}, {'ForeName': 'Penelope M', 'Initials': 'PM', 'LastName': 'Sanderson', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia; School of Information Technology and Electrical Engineering, The University of Queensland, St Lucia, Queensland, Australia; School of Clinical Medicine, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Isaac S', 'Initials': 'IS', 'LastName': 'Salisbury', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Felicity P', 'Initials': 'FP', 'LastName': 'Burgmann', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Mohamed', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Loeb', 'Affiliation': 'School of Psychology, The University of Queensland, St Lucia, Queensland, Australia; Department of Anesthesiology, University of Florida College of Medicine, Gainesville, FL, USA.'}, {'ForeName': 'Neil A B', 'Initials': 'NAB', 'LastName': 'Paterson', 'Affiliation': ""School of Clinical Medicine, The University of Queensland, St Lucia, Queensland, Australia; Anaesthesia and Pain Management Services, Queensland Children's Hospital, South Brisbane, Queensland, Australia.""}]",British journal of anaesthesia,['10.1016/j.bja.2020.05.038'] 1912,32672329,Aiding shared decision making in lung cancer screening: two decision tools.,"BACKGROUND Shared decision making (SDM) preceding lung cancer screening is important for populations that are underrepresented in lung cancer screening trials. Current evidence-based guidelines; however, do not address personal risk and outcomes in underrepresented populations. This study compared two SDM decision aids (Option Grids and Shouldiscreen.com) for SDM efficacy, decision regret and knowledge. METHODS We conducted a prospective trial of lung cancer screening patients (N = 237) randomized to SDM with Option Grids or Shouldiscreen.com. To evaluate the SDM process after lung cancer screening, patients answered two questionnaires: CollaboRATE and Decision Regret. Patients also completed a questionnaire to test their knowledge of lung cancer screening. RESULTS Patients were predominantly African American (61.6%), though multiple races, varying education levels and equal genders were represented. Patients in both Option Grids and Shouldiscreen.com groups reported favorable SDM experiences (P = 0.60) and equivalent knowledge about lung cancer screening (P = 0.43). Patients using Shouldiscreen.com had less knowledge regarding the potential complications of subsequent testing (P = 0.02). Shouldiscreen.com patients had increased regret regarding their decision to pursue screening (P = 0.02). CONCLUSIONS Option Grids and Shouldiscreen.com both facilitated a meaningful SDM process. However, Option Grids patients experienced decreased decision regret and enhanced knowledge of the potential complications of screening.",2020,Patients using Shouldiscreen.com had less knowledge regarding the potential complications of subsequent testing (P = 0.02).,"['lung cancer screening patients (N\xa0=\xa0237', 'lung cancer screening']","['SDM with Option Grids or Shouldiscreen.com', 'SDM decision aids (Option Grids and Shouldiscreen.com']","['SDM efficacy, decision regret and knowledge', 'equivalent knowledge about lung cancer screening', 'regret regarding their decision to pursue screening', 'decision regret', 'favorable SDM experiences']","[{'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0080101', 'cui_str': 'Regret'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0281477', 'cui_str': 'Screening for malignant neoplasm of lung'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",237.0,0.0257629,Patients using Shouldiscreen.com had less knowledge regarding the potential complications of subsequent testing (P = 0.02).,"[{'ForeName': 'Shelby R', 'Initials': 'SR', 'LastName': 'Sferra', 'Affiliation': 'Lewis Katz School of Medicine at Temple University, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Joyce S', 'Initials': 'JS', 'LastName': 'Cheng', 'Affiliation': 'Medical Students, Lewis Katz School of Medicine, Temple University, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Boynton', 'Affiliation': 'Medical Students, Lewis Katz School of Medicine, Temple University, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Verdi', 'Initials': 'V', 'LastName': 'DiSesa', 'Affiliation': 'Temple University Health System, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Larry R', 'Initials': 'LR', 'LastName': 'Kaiser', 'Affiliation': 'Department of Thoracic Medicine and Surgery; Temple University Health System, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Grace X', 'Initials': 'GX', 'LastName': 'Ma', 'Affiliation': 'Department of Clinical Sciences, Lewis Katz School of Medicine Temple University, Philadelphia 19140, PA, USA.'}, {'ForeName': 'Cherie P', 'Initials': 'CP', 'LastName': 'Erkmen', 'Affiliation': 'Department of Thoracic Medicine and Surgery; Temple University Health System, Philadelphia 19140, PA, USA.'}]","Journal of public health (Oxford, England)",['10.1093/pubmed/fdaa063'] 1913,32668036,When to install the endodontic post? First visit with root canal filling versus a separate second visit for post-restoration: A randomized controlled trial.,"BACKGROUND The vibrations created by post-space preparation during the first visit for endodontic treatment could have a significant effect on the intensity of post-operative pain than that association with post-space preparation at the second appointment. OBJECTIVE The aim of this study was to evaluate the effect of vibrations generated during post-installation, on post-operative pain in endodontically treated teeth. METHODS One hundred patients with asymptomatic teeth requiring primary root canal treatment and post-installation were enrolled in this study. Fifty patients underwent endodontic treatment with post-installation at the first visit (group 1), while the remaining 50 patients underwent post-installation at the second visit (group 2). The intensity of post-operative pain in both groups was evaluated 1, 2, 3 days and 1 week after the first visit using the visual analogue scale. The time required to achieve complete pain relief for each patient was also recorded. The patients' age, sex, tooth type, size of the periapical lesion and time required for complete post-operative pain relief for each tooth were recorded. RESULTS The pain intensity score was significantly higher in group 1 than group 2 (P < .05). No significant differences were observed in parameters such as sex, tooth type, jaw and size of the periapical lesion (P > .05), whereas age had a significant effect on the post-operative pain scores (P < .05). CONCLUSION Vibrations occurring during post-installation on the same visit as that of root canal filling may increase the post-operative pain.",2020,The pain intensity score was significantly higher in group 1 than group 2 (P < .05).,"['One hundred patients with asymptomatic teeth requiring primary root canal treatment and post installation were enrolled in this study', 'Fifty patients underwent']",['endodontic treatment'],"['parameters such as sex, tooth type, jaw, and size of the periapical lesion', 'postoperative pain scores', 'postoperative pain', 'intensity of postoperative pain', 'pain intensity score', 'time required to achieve complete pain relief']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0700632', 'cui_str': 'Endodontic procedure'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0729269', 'cui_str': 'Periapical'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}]",100.0,0.0630033,The pain intensity score was significantly higher in group 1 than group 2 (P < .05).,"[{'ForeName': 'Tan Firat', 'Initials': 'TF', 'LastName': 'Eyuboglu', 'Affiliation': 'Department of Endodontics, School of Dentistry, Istanbul Medipol University, Istanbul, Turkey.'}, {'ForeName': 'Hyeon-Cheol', 'Initials': 'HC', 'LastName': 'Kim', 'Affiliation': 'Department of Conservative Dentistry, School of Dentistry, Dental Research Institute, Pusan National University, Yangsan, Korea.'}]",Journal of oral rehabilitation,['10.1111/joor.13056'] 1914,32668087,Associations between resting-state functional connectivity and treatment response in a randomized clinical trial for posttraumatic stress disorder.,"BACKGROUND Alterations in resting-state functional connectivity (rsFC) have been reported in posttraumatic stress disorder (PTSD). Here, we examined pre- and post-treatment rsFC during a randomized clinical trial to characterize alterations and examine predictors of treatment response. METHODS Sixty-four combat veterans with PTSD were randomly assigned to prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline. Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans occurred before and after treatment. Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake. Seed-based and region of interest (ROI)-to-ROI connectivities, as well as an exploratory connectome-based approach were used to analyze rsFC patterns. Based on previously reported findings, analyses focused on Salience Network (SN) and Default-Mode Network (DMN). RESULTS At intake, patients with PTSD showed greater DMN-dorsal attention network (DAN) connectivity (between ventromedial prefrontal cortex and superior parietal lobule; family-wise error corrected p = .011), greater SN-DAN connectivity (between insula and middle frontal gyrus; corrected p = .003), and a negative correlation between re-experiencing symptoms and within-DMN connectivity (between posterior cingulate cortex (PCC) and middle temporal gyrus; corrected p < .001). We also found preliminary evidence for associations between rsFC and treatment response. Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). CONCLUSIONS Our findings suggest neural abnormalities in PTSD and may inform future research examining neural biomarkers of PTSD treatment response.",2020,"Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). ","['Twenty-nine trauma-exposed combat veterans without PTSD served as a control group at intake', 'Sixty-four combat veterans with PTSD', 'posttraumatic stress disorder']","['prolonged exposure (PE) plus placebo, sertraline plus enhanced medication management, or PE plus sertraline']","['greater DMN-dorsal attention network (DAN) connectivity', 'Symptom assessment and resting-state functional magnetic resonance imaging (fMRI) scans', 'greater SN-DAN connectivity', 'SN-DMN segregation', 'Salience Network (SN) and Default-Mode Network (DMN']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C4517839', 'cui_str': '64'}]","[{'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0074393', 'cui_str': 'Sertraline'}, {'cui': 'C0150270', 'cui_str': 'Management of drug regimen'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}]","[{'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0080141', 'cui_str': 'Racial Segregation'}]",,0.0394609,"Specifically, high responders (≥50% PTSD symptom improvement), compared with low responders, had greater SN-DMN segregation (i.e., less pre-treatment amygdala-PCC connectivity; p = .011) and lower pre-treatment global centrality (p = .042). ","[{'ForeName': 'Jony', 'Initials': 'J', 'LastName': 'Sheynin', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Duval', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Anthony P', 'Initials': 'AP', 'LastName': 'King', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Angstadt', 'Affiliation': 'Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'K Luan', 'Initials': 'KL', 'LastName': 'Phan', 'Affiliation': 'Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Naomi M', 'Initials': 'NM', 'LastName': 'Simon', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Sheila A M', 'Initials': 'SAM', 'LastName': 'Rauch', 'Affiliation': 'Mental Health Service Line, Atlanta VA Healthcare System, Decatur, Georgia.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Liberzon', 'Affiliation': 'Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.'}]",Depression and anxiety,['10.1002/da.23075'] 1915,32668113,Trial of Roflumilast Cream for Chronic Plaque Psoriasis.,"BACKGROUND Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis. METHODS In this phase 2b, double-blind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream, or vehicle (placebo) cream once daily for 12 weeks. The primary efficacy outcome was the investigator's global assessment (IGA) of a status of clear or almost clear at week 6 (assessed on a 5-point scale of plaque thickening, scaling, and erythema; a score of 0 indicates clear, 1 almost clear, and 4 severe). Secondary outcomes included an IGA score indicating clear or almost clear plus a 2-grade improvement in the IGA score for the intertriginous area and the change in the Psoriasis Area and Severity Index (PASI) score (range, 0 to 72, with higher scores indicating worse disease). Safety was also assessed. RESULTS Among 331 patients who underwent randomization, 109 were assigned to roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle cream. An IGA score indicating clear or almost clear at week 6 was observed in 28% of the patients in the roflumilast 0.3% group, in 23% in the roflumilast 0.15% group, and in 8% in the vehicle group (P<0.001 and P = 0.004 vs. vehicle for roflumilast 0.3% and 0.15%, respectively). Among the approximately 15% of patients overall who had baseline intertriginous psoriasis of at least mild severity, an IGA score at week 6 indicating clear or almost clear plus a 2-grade improvement in the intertriginous-area IGA score occurred in 73% of the patients in the roflumilast 0.3% group, 44% of those in the roflumilast 0.15% group, and 29% of those in the vehicle group. The mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline at week 6 was -50.0%, -49.0%, and -17.8%, respectively. Application-site reactions occurred with similar frequency in the roflumilast groups and the vehicle group. CONCLUSIONS Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. (Funded by Arcutis Biotherapeutics; ARQ-151 201 ClinicalTrials.gov number, NCT03638258.).",2020,"CONCLUSIONS Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks.","['Chronic Plaque Psoriasis', 'adults with plaque psoriasis in a 1:1:1 ratio to use', '331 patients who underwent randomization']","['Roflumilast Cream', 'Roflumilast cream', 'roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle cream', 'roflumilast 0.3% cream, roflumilast 0.15% cream, or vehicle (placebo) cream']","['intertriginous-area IGA score', 'Safety', 'IGA score', ""investigator's global assessment (IGA) of a status of clear or almost clear at week 6 (assessed on a 5-point scale of plaque thickening, scaling, and erythema; a score of 0 indicates clear, 1 almost clear, and 4 severe"", 'IGA score indicating clear or almost clear plus a 2-grade improvement in the IGA score for the intertriginous area and the change in the Psoriasis Area and Severity Index (PASI) score', 'Application-site reactions', 'mean baseline PASI scores', 'durability and safety']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0406317', 'cui_str': 'Chronic small plaque psoriasis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]","[{'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C0700385', 'cui_str': 'Cream'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C4068886', 'cui_str': '0.15'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}]","[{'cui': 'C0205268', 'cui_str': 'Intertriginous'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0205400', 'cui_str': 'Thickened'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0151505', 'cui_str': 'Application site reaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",331.0,0.233761,"CONCLUSIONS Roflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks.","[{'ForeName': 'Mark G', 'Initials': 'MG', 'LastName': 'Lebwohl', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Papp', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Stein Gold', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Melinda J', 'Initials': 'MJ', 'LastName': 'Gooderham', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Leon H', 'Initials': 'LH', 'LastName': 'Kircik', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Zoe D', 'Initials': 'ZD', 'LastName': 'Draelos', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Kempers', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Mathew', 'Initials': 'M', 'LastName': 'Zirwas', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Smith', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Osborne', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Marie-Louise', 'Initials': 'ML', 'LastName': 'Trotman', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Navale', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Merritt', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Berk', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Welgus', 'Affiliation': ""From the Icahn School of Medicine at Mount Sinai, New York (M.G.L., L.H.K.); Probity Medical Research and K. Papp Clinical Research, Waterloo (K.A.P.), and the SkiN Centre for Dermatology, Probity Medical Research and Queen's University, Peterborough (M.J.G.) - both in Ontario, Canada; Henry Ford Medical Center, Detroit (L.S.G.); Indiana Medical Center, Indianapolis (L.H.K.); Physicians Skin Care and DermResearch, Louisville, KY (L.H.K.); Dermatology Consulting Services, High Point, NC (Z.D.D.); Minnesota Clinical Study Center, Fridley (S.E.K.); Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley (M.Z.); and Arcutis Biotherapeutics, Westlake Village (K.S., D.W.O., L.N., C.M., D.R.B., H.W.), and ML Trotman Consulting, Newbury Park (M.-L.T.) - both in California.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2000073'] 1916,32669026,Arthroscopic confirmation of femoral button deployment avoids post-operative X-ray in ACL reconstruction.,"BACKGROUND Anterior cruciate ligament reconstruction (ACLR) with cortical fixation adjustable-loop devices are associated with high potential risk of button malpositioning or interposition of the soft tissue between lateral femoral cortex and the button. Surgeons usually use X-rays to check and avoid button malposition and soft tissue interposition. Arthroscopic visualization of button position through the lateral gutter has been described. With this technique, it is possible for identification and correction of femoral button malalignment in the setting of soft tissue interposition and it could avoid the use of post-operative X-ray. METHODS A total of 193 ACLR were included and patients were randomized into two groups. The first series (Group A) of 112 patients who sustained an ACLR with post-operative X-ray to assess the position of the femoral button and the second series (Group B) of 81 patients who sustained an ACLR with an arthroscopic exploration of the button followed by post-operative X-ray. RESULTS On the post-operative radiographs, tissue interposition between the button and femoral cortex was found in nine cases of 112 in Group A (8%) and in zero case of 81 in Group B (0%). In six cases (7,4%) in Group B, there was a soft tissue interposition between the button and femoral cortex as visualized by arthroscopic confirmation and before post-operative X-ray; in all these cases, the soft tissue was removed, and the button was in contact with the bone in all X-ray made in the Group B. CONCLUSIONS This technique allows for identification and correction of femoral button malalignment in the setting of soft tissue interposition and reduces the use of post-operative X-ray.",2020,"In 6 cases (7,4%) in the Group B there was a soft tissue interposition between the button and femoral cortex as visualized by arthroscopic confirmation and before post operative X-ray; in all these cases the soft tissue was removed, and the button was in contact with the bone in all X-ray made in the group B. Conclusions: This technique could allows identification and correction of femoral button malalignment in the setting of soft tissue interposition and could reduce the use of postoperative x-ray.","['A total of 193 ACLR', '112 patients who sustained an ACLR with post operative X-ray to assess the position of the femoral button and the second series (Group B) of 81 patients who sustained an ACLR with an arthroscopic exploration of the button followed by post operative X-ray']","['Arthroscopic Confirmation of Femoral Button Deployment Avoids Post Operative X-ray in ACL Reconstruction', 'Anterior cruciate ligament reconstruction (ACLR) with cortical fixation adjustable-loop devices']",['soft tissue interposition'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0453985', 'cui_str': 'Button'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205549', 'cui_str': 'Series'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0453985', 'cui_str': 'Button'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0162596', 'cui_str': 'Cardiolipin antibody'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0225317', 'cui_str': 'Soft tissue'}]",193.0,0.0175416,"In 6 cases (7,4%) in the Group B there was a soft tissue interposition between the button and femoral cortex as visualized by arthroscopic confirmation and before post operative X-ray; in all these cases the soft tissue was removed, and the button was in contact with the bone in all X-ray made in the group B. Conclusions: This technique could allows identification and correction of femoral button malalignment in the setting of soft tissue interposition and could reduce the use of postoperative x-ray.","[{'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Matassi', 'Affiliation': 'Orthopaedic Clinic, University of Florence, AOU Careggi , Florence, Italy.'}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Sani', 'Affiliation': 'Orthopaedic Clinic, University of Florence, AOU Careggi , Florence, Italy.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Innocenti', 'Affiliation': 'Orthopaedic Clinic, University of Florence, AOU Careggi , Florence, Italy.'}, {'ForeName': 'Niccolò', 'Initials': 'N', 'LastName': 'Giabbani', 'Affiliation': 'Orthopaedic Clinic, University of Florence, AOU Careggi , Florence, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Civinini', 'Affiliation': 'Orthopaedic Clinic, University of Florence, AOU Careggi , Florence, Italy.'}]",The Physician and sportsmedicine,['10.1080/00913847.2020.1796469'] 1917,32674714,A Prescription for Wellness: Exercise Referrals at a Federally Qualified Health Center.,"Introduction/Objectives: Physical activity (PA) improves quality of life and prevents chronic disease, but many adults are inactive. Planning with a health care provider in the form of an exercise ""prescription"" or referral may increase PA, but determinants of referral utilization are not well understood among underserved populations. This study examined sociodemographic and theory-based psychosocial determinants of exercise referral program utilization. Methods: Patients at a large, federally qualified health center with an on-site exercise facility (ie, ""Wellness Center"") referral were eligible to exercise with a personal fitness advisor. Self-reported PA behavior, self-efficacy, and self-regulation strategies were measured via survey and merged with electronic health records and attendance data. Negative binomial regression was used to estimate the rate of Wellness Center utilization. Results: Patients with exercise referrals (n = 1136) were, on average, 45.6 ± 14.6 years, 78.8% female, and 78.0% Hispanic/Latino or non-Hispanic Black. Approximately half (593/1136; 52.2%) initiated exercise at the Wellness Center; initiators completed 8.8 ± 12.4 visits during follow-up. Older age was associated with higher utilization ( P < .001) and patients meeting PA recommendations had lower utilization than patients not meeting recommendations (incident rate ratio = 0.72, 95% CI 0.53-0.97; P = .03). Baseline self-efficacy ( P < .001) and self-regulation strategies ( P = .03) were significantly associated with follow-up PA, even after adjusting for baseline PA. Conclusions: In this racially/ethnically diverse patient population, older and less active patients at baseline had higher program utilization. Patients with higher self-efficacy and self-regulation strategies reported higher PA over time. Community health centers have a unique opportunity to support PA through exercise referral programs to public health priority populations.",2020,"Older age was associated with higher utilization ( P < .001) and patients meeting PA recommendations had lower utilization than patients not meeting recommendations (incident rate ratio = 0.72, 95% CI 0.53-0.97; P = .03).","['were, on average, 45.6 ± 14.6 years, 78.8% female, and 78.0% Hispanic/Latino or non-Hispanic Black', 'Results: Patients with exercise referrals (n = 1136', 'Methods: Patients at a large, federally qualified health center with an on-site exercise facility (ie, ""Wellness Center', 'Wellness: Exercise Referrals at a Federally Qualified Health Center']",['Physical activity (PA'],"['quality of life and prevents chronic disease', 'Self-reported PA behavior, self-efficacy, and self-regulation strategies', 'Baseline self-efficacy', 'self-regulation strategies']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C5191065', 'cui_str': '1136'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0600622', 'cui_str': 'Wellness Centers'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",1136.0,0.0233475,"Older age was associated with higher utilization ( P < .001) and patients meeting PA recommendations had lower utilization than patients not meeting recommendations (incident rate ratio = 0.72, 95% CI 0.53-0.97; P = .03).","[{'ForeName': 'Kelly R', 'Initials': 'KR', 'LastName': 'Ylitalo', 'Affiliation': 'Baylor University, Waco, TX, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Cox', 'Affiliation': 'Heart of Texas Community Health Center, Waco, TX, USA.'}, {'ForeName': 'Mariela', 'Initials': 'M', 'LastName': 'Gutierrez', 'Affiliation': 'Baylor University, Waco, TX, USA.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Benavidez', 'Affiliation': 'Baylor University, Waco, TX, USA.'}, {'ForeName': 'M Renée', 'Initials': 'MR', 'LastName': 'Umstattd Meyer', 'Affiliation': 'Baylor University, Waco, TX, USA.'}, {'ForeName': 'Brock', 'Initials': 'B', 'LastName': 'Niceler', 'Affiliation': 'Heart of Texas Community Health Center, Waco, TX, USA.'}, {'ForeName': 'Jackson O', 'Initials': 'JO', 'LastName': 'Griggs', 'Affiliation': 'Heart of Texas Community Health Center, Waco, TX, USA.'}]",Journal of primary care & community health,['10.1177/2150132720942396'] 1918,32675074,BCI training to move a virtual hand reduces phantom limb pain: A randomized crossover trial.,"OBJECTIVE To determine whether training with a brain-computer interface (BCI) to control an image of a phantom hand, which moves based on cortical currents estimated from magnetoencephalographic signals, reduces phantom limb pain. METHODS Twelve patients with chronic phantom limb pain of the upper limb due to amputation or brachial plexus root avulsion participated in a randomized single-blinded crossover trial. Patients were trained to move the virtual hand image controlled by the BCI with a real decoder, which was constructed to classify intact hand movements from motor cortical currents, by moving their phantom hands for 3 days (""real training""). Pain was evaluated using a visual analogue scale (VAS) before and after training, and at follow-up for an additional 16 days. As a control, patients engaged in the training with the same hand image controlled by randomly changing values (""random training""). The 2 trainings were randomly assigned to the patients. This trial is registered at UMIN-CTR (UMIN000013608). RESULTS VAS at day 4 was significantly reduced from the baseline after real training (mean [SD], 45.3 [24.2]-30.9 [20.6], 1/100 mm; p = 0.009 < 0.025), but not after random training ( p = 0.047 > 0.025). Compared to VAS at day 1, VAS at days 4 and 8 was significantly reduced by 32% and 36%, respectively, after real training and was significantly lower than VAS after random training ( p < 0.01). CONCLUSION Three-day training to move the hand images controlled by BCI significantly reduced pain for 1 week. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that BCI reduces phantom limb pain.",2020,"Compared to VAS at day 1, VAS at days 4 and 8 was significantly reduced by 32% and 36%, respectively, after real training and was significantly lower than VAS after random training ( p < 0.01). ",['Twelve patients with chronic phantom limb pain of the upper limb due to amputation or brachial plexus root avulsion participated'],"['VAS', 'training with a brain-computer interface (BCI', 'BCI', 'BCI training']","['phantom limb pain', 'visual analogue scale (VAS', 'Pain', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0031315', 'cui_str': 'Phantom limb'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0457886', 'cui_str': 'Root of brachial plexus'}, {'cui': 'C0185044', 'cui_str': 'Surgical avulsion'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C3494288', 'cui_str': 'Brain-Computer Interface'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0031315', 'cui_str': 'Phantom limb'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",12.0,0.0973384,"Compared to VAS at day 1, VAS at days 4 and 8 was significantly reduced by 32% and 36%, respectively, after real training and was significantly lower than VAS after random training ( p < 0.01). ","[{'ForeName': 'Takufumi', 'Initials': 'T', 'LastName': 'Yanagisawa', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan. tyanagisawa@nsurg.med.osaka-u.ac.jp.'}, {'ForeName': 'Ryohei', 'Initials': 'R', 'LastName': 'Fukuma', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Seymour', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Masataka', 'Initials': 'M', 'LastName': 'Tanaka', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Koichi', 'Initials': 'K', 'LastName': 'Hosomi', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Okito', 'Initials': 'O', 'LastName': 'Yamashita', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Haruhiko', 'Initials': 'H', 'LastName': 'Kishima', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Yukiyasu', 'Initials': 'Y', 'LastName': 'Kamitani', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}, {'ForeName': 'Youichi', 'Initials': 'Y', 'LastName': 'Saitoh', 'Affiliation': 'From the Institute for Advanced Co-Creation Studies (T.Y.), Osaka University; Departments of Neurosurgery (T.Y., R.F., M.T., K.H., H.K., Y.S.) and Neuromodulation and Neurosurgery (K.H., Y.S.), Osaka University Graduate School of Medicine; Department of Neuroinformatics (T.Y., R.F., Y.K.), ATR Computational Neuroscience Laboratories, Kyoto, Japan; Computational and Biological Learning Laboratory, Department of Engineering (B.S.), University of Cambridge, UK; Center for Information and Neural Networks (B.S.), National Institute for Information and Communications Technology, Osaka; RIKEN Center for Advanced Intelligence Project (O.Y.), Tokyo; Department of Computational Brain Imaging (O.Y.), ATR Neural Information Analysis Laboratories, Kyoto; and Graduate School of Informatics (Y.K.), Kyoto University, Japan.'}]",Neurology,['10.1212/WNL.0000000000009858'] 1919,32676977,"A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.","BACKGROUND The delta opioid receptor (DOR) has been identified as a therapeutic target for migraine, with DOR agonists exhibiting low abuse potential compared with conventional µ-opioid agonists. TRV250 is a novel small molecule agonist of the DOR that is preferentially selective for G-protein signaling, with relatively little activation of the β-arrestin2 post-receptor signaling pathway. This selectivity provides reduced susceptibility to proconvulsant activity seen with non-selective DOR agonists. TRV250 significantly reduced nitroglycerin-evoked hyperalgesia in rodents, indicating a potential utility in acute migraine without the risk of seizure activity or abuse potential. OBJECTIVE This trial evaluated the safety, tolerability, and pharmacokinetics of ascending dose levels of TRV250 administered subcutaneously (SC) and the relative bioavailability of TRV250 administered orally compared with SC administration. METHODS This was a two-part, single ascending dose study. Part A included four cohorts of healthy adults (N = 38). Each cohort was dosed on three occasions (placebo and two different dose levels of TRV250, allocated in randomized order and administered by SC route). In Part B, a single cohort of nine subjects received an oral dose of either TRV250 (n = 7) or placebo (n = 2) in a fed or fasted state. Serial blood samples were obtained for pharmacokinetic determination across a 24-h post-dose period. Safety assessments included clinical laboratory measures, vital signs, 12-lead electrocardiogram (ECG), and electroencephalogram (EEG) pre- and post-dosing. RESULTS TRV250 was well tolerated. There were no serious adverse events (SAEs), and all AEs were mild in severity. Injection-site reactions and headache were the most common AEs. One subject was withdrawn from the study due to a TRV250-related AE of postural orthostatic tachycardia. There were no clinically relevant changes in physical examination, hematology, clinical chemistry, urinalysis, suicidal ideation, or vital signs, with the exception of orthostatic changes in some subjects. No subject experienced abnormalities in EEGs or experienced a change from baseline in heart-rate-corrected QT interval (QTcF) > 60 ms, or an absolute QTcF interval > 480 ms at any post-dosing observation. Peak and total plasma exposure to TRV250 increased in a dose-proportional manner following 0.1-30 mg SC doses, with the mean half-life ranging from 2.39 to 3.76 h. Oral bioavailability of TRV250 ranged from 14% (fasting) to 19% (fed) relative to SC dosing, while administration with food increased the AUC but decreased the rate of absorption as reflected by a modest delay in median time to maximum concentration and a slight reduction in maximum concentration. CONCLUSION The findings from the first-in-human study support further evaluation of TRV250, a G-protein selective DOR agonist, in the treatment of acute migraine.",2020,"There were no clinically relevant changes in physical examination, hematology, clinical chemistry, urinalysis, suicidal ideation, or vital signs, with the exception of orthostatic changes in some subjects.","['Part A included four cohorts of healthy adults (N\u2009=\u200938', 'Healthy Subjects']","['occasions (placebo', 'Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist', 'TRV250 administered subcutaneously (SC', 'TRV250', 'placebo']","['clinical laboratory measures, vital signs, 12-lead electrocardiogram (ECG), and electroencephalogram (EEG) pre- and post-dosing', 'absolute QTcF interval\u2009', 'tolerated', 'rate of absorption', 'safety, tolerability, and pharmacokinetics', 'Peak and total plasma exposure to TRV250', 'physical examination, hematology, clinical chemistry, urinalysis, suicidal ideation, or vital signs', 'serious adverse events (SAEs', 'nitroglycerin-evoked hyperalgesia', 'heart-rate-corrected QT interval (QTcF)\u2009']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0086376', 'cui_str': 'G protein'}, {'cui': 'C0140057', 'cui_str': 'delta Opioid Receptor'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C1533734', 'cui_str': 'Administration'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0430456', 'cui_str': '12 lead ECG'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0008000', 'cui_str': 'Clinical Chemistry'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0017887', 'cui_str': 'Nitroglycerin'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0020429', 'cui_str': 'Hyperalgesia'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}]",,0.101361,"There were no clinically relevant changes in physical examination, hematology, clinical chemistry, urinalysis, suicidal ideation, or vital signs, with the exception of orthostatic changes in some subjects.","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Fossler', 'Affiliation': 'Clinical Development and Quantitative Sciences, Trevena, Inc., 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, USA. mfossler@trevena.com.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Schmith', 'Affiliation': 'Nuventra Pharma Sciences, Durham, NC, USA.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Greene', 'Affiliation': 'Nuventra Pharma Sciences, Durham, NC, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Lohmer', 'Affiliation': 'Nuventra Pharma Sciences, Durham, NC, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Kramer', 'Affiliation': 'Scientific Operations and Alliance Management, Trevena Inc, 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, USA.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Arscott', 'Affiliation': 'Clinical Operations and Medical Affairs Department, Trevena Inc, 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, USA.'}, {'ForeName': 'Ian E', 'Initials': 'IE', 'LastName': 'James', 'Affiliation': 'Clinical Operations and Medical Affairs Department, Trevena Inc, 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, USA.'}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Demitrack', 'Affiliation': 'Clinical Operations and Medical Affairs Department, Trevena Inc, 955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, 19087, USA.'}]",CNS drugs,['10.1007/s40263-020-00738-0'] 1920,32677716,Can prophylactic argon plasma coagulation reduce delayed post-papillectomy bleeding? A prospective multicenter trial.,"BACKGROUND AND AIM Endoscopic post-papillectomy bleeding occurs in 3% to 20% of the cases, and delayed bleeding is also problematic. However, there is no consensus on how to reduce delayed post-papillectomy bleeding. The aim of this study was to evaluate the efficacy of prophylactic argon plasma coagulation (APC) to minimize delayed bleeding and reduce the persistence of residual tumors after endoscopic papillectomy. METHODS In a prospective pilot study of patients with benign ampullary tumors, the prophylactic APC group underwent APC at the resection margin following a conventional snaring papillectomy. Then, 24 h later after the papillectomy, all patients underwent a follow-up duodenoscopy to identify post-papillectomy bleeding and were followed up until 12 months. The main outcomes were the delayed (≥24 h) post-papillectomy bleeding rate and the tumor persistence rate. RESULTS The delayed post-papillectomy bleeding rate was 30.8% (8/26) in the prophylactic APC group and 21.4% (6/28) in the non-APC group (P = 0.434). The post-procedure pancreatitis rates were 23.1% (6/26) and 35.7% (10/28), respectively (P = 0.310). The rate of tumor persistence did not differ between the two groups at 1 month (12.5% vs 7.4%, P = 0.656), 3 months (4.2% vs 3.7%, P = 1.00), 6 months (8.3% vs 3.7%, P = 0.595), and 12 months (0% vs 3.7%, P = 1.00). There were no procedure-related mortalities or serious complications. CONCLUSION Prophylactic APC may not be effective in reducing delayed post-papillectomy bleeding or remnant tumor ablation immediately after conventional papillectomy (Clinical trial registration-cris.nih.go.kr; KCT0001955).",2020,Prophylactic APC may not be effective in reducing delayed post-papillectomy bleeding or remnant tumor ablation immediately after conventional papillectomy (Clinical trial registration - cris.nih.go.kr; KCT0001955).,"['patients with benign ampullary tumors, the prophylactic APC group underwent APC at the resection margin following a conventional snaring papillectomy']","['prophylactic APC', 'prophylactic argon plasma coagulation (APC', 'Prophylactic APC']","['post-procedure pancreatitis rates', 'delayed (≥ 24 h) post-papillectomy bleeding rate and the tumor persistence rate', 'delayed post-papillectomy bleeding rate', 'rate of tumor persistence', 'procedure-related mortalities or serious complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0345916', 'cui_str': 'Neoplasm of ampulla of Vater'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C1879736', 'cui_str': 'Argon plasma coagulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0229985', 'cui_str': 'Surgical margins'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C1879736', 'cui_str': 'Argon plasma coagulation'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0546816', 'cui_str': 'Persistence'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",,0.0330276,Prophylactic APC may not be effective in reducing delayed post-papillectomy bleeding or remnant tumor ablation immediately after conventional papillectomy (Clinical trial registration - cris.nih.go.kr; KCT0001955).,"[{'ForeName': 'Jae Kook', 'Initials': 'JK', 'LastName': 'Yang', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.'}, {'ForeName': 'Jong Jin', 'Initials': 'JJ', 'LastName': 'Hyun', 'Affiliation': 'Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.'}, {'ForeName': 'Tae Hoon', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.'}, {'ForeName': 'Jun-Ho', 'Initials': 'JH', 'LastName': 'Choi', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Dankook University, Cheonan, Republic of Korea.'}, {'ForeName': 'Yun Nah', 'Initials': 'YN', 'LastName': 'Lee', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.'}, {'ForeName': 'Jung Wan', 'Initials': 'JW', 'LastName': 'Choe', 'Affiliation': 'Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Republic of Korea.'}, {'ForeName': 'Jin-Seok', 'Initials': 'JS', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Chang-Il', 'Initials': 'CI', 'LastName': 'Kwon', 'Affiliation': 'Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.'}, {'ForeName': 'Seok', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Department of Internal Medicine, Inha University School of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Hong Ja', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, College of Medicine, Dankook University, Cheonan, Republic of Korea.'}, {'ForeName': 'Jong Ho', 'Initials': 'JH', 'LastName': 'Moon', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.'}, {'ForeName': 'Sang-Heum', 'Initials': 'SH', 'LastName': 'Park', 'Affiliation': 'Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.'}]",Journal of gastroenterology and hepatology,['10.1111/jgh.15186'] 1921,32678376,Weighted Blankets: Anxiety Reduction in Adult Patients Receiving Chemotherapy.,"BACKGROUND Weighted blankets have been used as a deep touch pressure (DTP) tool to alleviate anxiety in many patient populations. Patients with cancer can experience anxiety related to diagnosis and treatments, such as chemotherapy infusions. Research on the effectiveness of weighted blankets as a DTP tool to alleviate anxiety in patients receiving chemotherapy is limited. OBJECTIVES This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. METHODS A randomized controlled trial with a crossover design was performed with new patients in the outpatient chemotherapy infusion center. Patients were randomized to one of two study arms (given the weighted blanket during their first infusion or given the weighted blanket during their second infusion). Anxiety was measured using an anxiety inventory and a visual analog scale. FINDINGS Anxiety was reduced among patients receiving chemotherapy when the weighted blanket was used. Based on the results, a standard-weight, medical-grade therapeutic weighted blanket can be safely used to reduce anxiety in patients of various weights, and a visual analog scale can be a reliable indicator of patients' state anxiety.",2020,"This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. ","['new patients in the outpatient chemotherapy infusion center', 'patients receiving chemotherapy is limited', 'patients receiving their first and second chemotherapy infusions at an outpatient infusion center', 'Patients with cancer', 'Adult Patients Receiving Chemotherapy']","['medical-grade therapeutic weighted blanket', 'weighted blankets']","['Anxiety', 'anxiety inventory and a visual analog scale']","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0179330', 'cui_str': 'Blanket'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0336687,"This study assessed the effectiveness of a medical-grade therapeutic weighted blanket on anxiety in patients receiving their first and second chemotherapy infusions at an outpatient infusion center. ","[{'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Vinson', 'Affiliation': 'Parkview Health System.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Powers', 'Affiliation': 'Parkview Health System.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Mosesso', 'Affiliation': 'Indiana University.'}]",Clinical journal of oncology nursing,['10.1188/20.CJON.360-368'] 1922,32673969,A systematic review and indirect treatment comparison of perampanel versus brivaracetam as adjunctive therapy in patients with focal-onset seizures with or without secondary generalization.,"PURPOSE To date, there has not been a single randomized controlled trial (RCT) conducted to directly compare the efficacy and safety of perampanel to brivaracetam in the adjunctive treatment of focal-onset seizures. This study makes these comparisons through the use of indirect treatment comparison (ITC) methods. METHODS A systematic review was conducted to identify RCTs that evaluated either one of perampanel or brivaracetam in the treatment of patients with focal-onset seizures. The Bucher ITC method was then used to compare efficacy and safety outcomes between perampanel and brivaracetam. Additional subgroup analyses, by levetiracetam usage (prior or concomitant), were conducted. RESULTS Eight RCTs (four comparing perampanel to placebo, four comparing brivaracetam to placebo) were included in the ITC. For patients taking concomitant levetiracetam, perampanel showed a significantly better responder rate compared to brivaracetam [relative risk (RR) and 95 % confidence interval (CI): 2.62 (1.15, 5.99)]. For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate. In the overall population, both perampanel and brivaracetam were more effective than placebo in terms of responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate; however, for these outcomes, no evidence of a difference between perampanel and brivaracetam was found. Patients taking brivaracetam showed significantly less dizziness compared to patients taking perampanel. No differences for any other safety outcome were found. CONCLUSION Perampanel and brivaracetam are effective for the adjunctive treatment of focal-onset seizures and display similar adverse event profiles. Perampanel demonstrated an improved focal-onset seizure responder rate compared to brivaracetam in patients taking concomitant levetiracetam. This may be due to the similarity in the mechanism of action between brivaracetam and levetiracetam.",2020,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","['focal-onset seizures', 'patients with focal-onset seizures with or without secondary generalization', 'patients with focal-onset seizures']","['perampanel', 'perampanel versus brivaracetam', 'perampanel or brivaracetam', 'levetiracetam, perampanel', 'Perampanel', 'placebo']","['efficacy and safety outcomes', 'dizziness', 'responder rate', 'responder rate, seizure freedom, and secondarily generalized tonic-clonic seizure responder rate', 'efficacy and safety', 'focal-onset seizure responder rate']","[{'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0017324', 'cui_str': 'Generalization (Psychology)'}]","[{'cui': 'C2698764', 'cui_str': 'perampanel'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0494475', 'cui_str': 'Tonic-clonic seizure'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}]",,0.188512,"For patients who had previously, or never, taken levetiracetam, there was no difference in the responder rate.","[{'ForeName': 'Eugen', 'Initials': 'E', 'LastName': 'Trinka', 'Affiliation': 'FRCP Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University, Harrerstrasse 79, A-5020, Salzburg, Austria. Electronic address: eugen@trinka.at.'}, {'ForeName': 'Wan', 'Initials': 'W', 'LastName': 'Tsong', 'Affiliation': 'Formerly Eisai Inc, 100 Tice Blvd, Woodcliff Lake, NJ, 07677, United States. Electronic address: wtsong.esi@gmail.com.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Toupin', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: sydney.toupin@outlook.com.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Patten', 'Affiliation': 'Eisai Ltd. European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, United Kingdom. Electronic address: Anna_Patten@eisai.net.'}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Wilson', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: katy.wilson@york.ac.uk.'}, {'ForeName': 'Jaana', 'Initials': 'J', 'LastName': 'Isojarvi', 'Affiliation': 'York Health Economics Consortium, Enterprise House, Innovation Way, University of York, York, YO10 5NQ, United Kingdom. Electronic address: jaana.isojarvi@york.ac.uk.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'James', 'Affiliation': 'Quantics Biostatistics, Exchange Tower, 19 Canning Street Fourth Floor, Edinburgh, EH3 8EG, United Kingdom. Electronic address: Daniel.James@quantics.co.uk.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106403'] 1923,32673128,A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology.,"AIMS To construct and compare a partitioned-survival analysis (PartSA) and a semi-Markov multi-state model (MSM) to investigate differences in estimated cost effectiveness of a novel cancer treatment from a UK perspective. MATERIALS AND METHODS Data from a cohort of late-stage cancer patients ( N  > 700) enrolled within a randomized, controlled trial were used to populate both modelling approaches. The statistical software R was used to fit parametric survival models to overall survival (OS) and progression-free survival (PFS) data to inform the PartSA (package ""flexsurv""). The package ""mstate"" was used to estimate the MSM transitions (permitted transitions: (T1) ""progression-free"" to ""dead"", (T2) ""post-progression"" to ""death"", and (T3) ""pre-progression"" to ""post-progression""). Key costs included were treatment-related (initial, subsequent, and concomitant), adverse events, hospitalizations and monitoring. Utilities were stratified by progression. Outcomes were discounted at 3.5% per annum over a 15-year time horizon. RESULTS The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively. Scenario analyses exploring alternative parametric forms provided incremental discounted life-year estimates that ranged from +0.15 to +0.33 for the PartSA approach, compared with -0.13 to +0.23 for the MSM approach. This variation was reflected in the range of ICERs. The PartSA produced ICERs between £234,829 and £522,963, whereas MSM results were more variable and included instances where the intervention was dominated and ICERs above £7 million (caused by very small incremental QALYs). LIMITATIONS AND CONCLUSIONS Structural uncertainty in economic modelling is rarely explored due to time and resource limitations. This comparison of structural approaches indicates that the choice of structure may have a profound impact on cost-effectiveness results. This highlights the importance of carefully considered model conceptualization, and the need for further research to ascertain when it may be most appropriate to use each approach.",2020,"The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively.",['cohort of late-stage cancer patients (N\u2009>\u2009700'],['partitioned-survival analysis (PartSA) and a semi-Markov multi-state model (MSM'],"['adverse events, hospitalizations and monitoring', 'incremental cost-effectiveness ratios (ICERs', 'overall survival (OS) and progression-free survival (PFS) data']","[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C1279941', 'cui_str': 'Late stage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517862', 'cui_str': '700'}]","[{'cui': 'C0038953', 'cui_str': 'Analysis, Survival'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0058231', 'cui_str': 'methylsulfonylmethane'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.046322,"The PartSA and MSM approaches estimated incremental cost-effectiveness ratios (ICERs) of £342,474 and £411,574, respectively.","[{'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Cranmer', 'Affiliation': 'Takeda Pharmaceuticals International Co., London, UK.'}, {'ForeName': 'Gemma E', 'Initials': 'GE', 'LastName': 'Shields', 'Affiliation': 'Faculty of Biology, Medicine, and Health, Division of Population Health, Health Services Research, and Primary Care, School of Health Sciences, Manchester Centre for Health Economics, University of Manchester, Manchester, UK.'}, {'ForeName': 'Ash', 'Initials': 'A', 'LastName': 'Bullement', 'Affiliation': 'Delta Hat Limited, Nottingham, UK.'}]",Journal of medical economics,['10.1080/13696998.2020.1796360'] 1924,32687890,The value of ultrasound guidance during IUD insertion in women with RVF uterus: A randomized controlled trial.,"OBJECTIVE The study objective is to evaluate the benefits of using ultrasound guidance during insertion of Intrauterine device IUD in women with retroverted flexed RVF uteri. STUDY DESIGN A randomized controlled trial conducted on 400 women with RVF uteri eligible for IUD insertion. They were randomly divided into 2 groups. Group 1 underwent IUD insertion under ultrasound guidance while in group 2 no ultrasound guidance was used. The primary outcome measure was the(Visual Analogue Scale) VAS pain score reported by the women during insertion. Other outcome included easiness of insertion, the procedure time and occurrence of complications as nausea, vomiting, abdominal cramps, failure of insertion, uterine perforation and bleeding. RESULTS The VAS pain score was significantly lower (2.36 ± 1.77 vs. 4.74 ± 2.35, p < 0.001), the insertion was much easier (score 4.0 ± 0.9 vs. 2.5 ± 1.27, p < 0.001) and the time needed for the procedure was significantly shorter (5.82 ± 2.56 vs. 9.4 ± 4.99 min, p < 0.001) in women within the ultrasound guided group when compared to control group. The total rate of complications was significantly lower (6 vs. 16 %, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28 %, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. CONCLUSION Insertion of Intrauterine device IUD under ultrasound guidance in women with Retroverted flexed RVF uterus easier and less painful than the blind standard technique.",2020,"The total rate of complications was significantly lower (6 vs. 16%, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28%, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. ","['women with RVF uterus', '400 women with RVF uteri eligible for IUD insertion', 'women with retroverted flexed RVF uteri']","['IUD insertion under ultrasound guidance while in group 2 no ultrasound guidance', 'ultrasound guidance', 'Insertion of Intrauterine device IUD under ultrasound guidance', 'Intrauterine device IUD', 'ultrasound guidance during IUD insertion']","['easiness of insertion, the procedure time and occurrence of complications as nausea, vomiting, abdominal cramps, failure of insertion, uterine perforation and bleeding', 'the(Visual Analogue Scale) VAS pain score', 'VAS pain score', 'bleeding', 'time needed for the procedure', 'failure of the procedure', 'abdominal cramps', 'total rate of complications']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035613', 'cui_str': 'Rift valley fever'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0812450', 'cui_str': 'Insertion of intrauterine contraceptive device'}]","[{'cui': 'C0812450', 'cui_str': 'Insertion of intrauterine contraceptive device'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0015927', 'cui_str': 'Fetal death'}, {'cui': 'C0021900', 'cui_str': 'Intrauterine contraceptive device'}]","[{'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0000729', 'cui_str': 'Abdominal Cramps'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0042139', 'cui_str': 'Perforation of uterus'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",400.0,0.274029,"The total rate of complications was significantly lower (6 vs. 16%, p 0.001) especially bleeding (2 vs. 9%, p = 0.002), abdominal cramps (10.5 vs. 28%, p 0.012) and failure of the procedure (0 vs. 3%, p = 005) in ultrasound guided group women when compared to control. ","[{'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Maged', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: ahmedmaged@gmail.com.'}, {'ForeName': 'Adel M', 'Initials': 'AM', 'LastName': 'Nada', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: adel.nada29@gmail.com.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Abdelwahab', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: halaabdelwahab@gmail.com.'}, {'ForeName': 'Emad', 'Initials': 'E', 'LastName': 'Salah', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: emadsalah148@gmail.com.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Soliman', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: dr_mahmoudsoliman@yahoo.com.'}, {'ForeName': 'Eman A', 'Initials': 'EA', 'LastName': 'Hussein', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: emanalyhussein@yahoo.com.'}, {'ForeName': 'Aimy', 'Initials': 'A', 'LastName': 'Essam', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: aimyessam@hotmail.com.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Nabil', 'Affiliation': 'Obstetrics and Gynecology Department Cairo University, Egypt. Electronic address: Fawzy.Jana@yahoo.com.'}]",Journal of gynecology obstetrics and human reproduction,['10.1016/j.jogoh.2020.101875'] 1925,32687924,"Intake of Lactiplantibacillus plantarum HEAL9 reduces the inflammatory markers soluble fractalkine and CD163 during acute stress: A randomized, double blind, placebo-controlled study.","The intestine and the brain are connected via the brain-gut axis and the intestinal microbiota influences the immune activation and signaling molecules that are involved in the stress response. The aim of the study was to investigate if intake of the probiotic strain Lactiplantibacillus plantarum HEAL9 (LPHEAL9) for four weeks could counteract elevated cortisol and inflammation levels in subjects with chronic stress that are exposed to an acute stress test (Trier Social Stress Test, TSST). Seventy participants were included, and 63 participants completed the study (LPHEAL9, n = 32; placebo, n  =  31). Cardiovascular reactivity and cortisol levels were affected by the TSST, but no differences between the groups were observed. Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo. In conclusion, intake of LPHEAL9 for four weeks may reduce inflammatory markers coupled to acute stress in chronically stressed individuals.",2020,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","['acute stress', 'subjects with chronic stress', 'chronically stressed individuals', 'Seventy participants were included, and 63 participants completed the study (LPHEAL9, n=32; placebo, n=31']","['probiotic strain Lactobacillus plantarum HEAL9 (LPHEAL9', 'Lactobacillus plantarum HEAL9', 'placebo']","['elevated cortisol and inflammation levels', 'plasma levels', 'Cardiovascular reactivity and cortisol levels']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0317608', 'cui_str': 'Lactobacillus plantarum'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",70.0,0.191303,"Intake of LPHEAL9 did, however, result in significantly decreased plasma levels of two inflammatory markers (soluble fractalkine and CD163) compared to placebo.","[{'ForeName': 'Gunilla', 'Initials': 'G', 'LastName': 'Önning', 'Affiliation': 'Biomedical Nutrition, Pure and Applied Biochemistry, Lund University, Lund, Sweden; Probi AB, Lund, Sweden. Electronic address: gunilla.onning@probi.com.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Hillman', 'Affiliation': 'Department of Clinical Sciences Lund, Diabetes Research Laboratory, Lund University, Lund, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hedin', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Montelius', 'Affiliation': 'Probi AB, Lund, Sweden.'}, {'ForeName': 'Joakim', 'Initials': 'J', 'LastName': 'Eriksson', 'Affiliation': 'Ergonomics and Aerosol Technology, Department of Design Studies, Lund University, Lund, Sweden.'}, {'ForeName': 'Siv', 'Initials': 'S', 'LastName': 'Ahrné', 'Affiliation': 'Department of Food Technology, Engineering and Nutrition, Lund University, Lund, Sweden.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Jönsson', 'Affiliation': 'Department of Psychology, Faculty of Education, Kristianstad University, Kristianstad, Sweden.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113083'] 1926,32679281,"China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.","Acute ST-segment elevation myocardial infarction (STEMI) remains a serious life-threatening event. Despite coronary revascularization, patients might still suffer from poor outcomes caused by myocardial no-reflow and ischemic/reperfusion injury. Tongxinluo (TXL), a traditional Chinese medicine, has been preliminarily demonstrated to reduce myocardial no-reflow and ischemic/reperfusion injury. We further hypothesize that TXL treatment is also effective in reducing clinical end points for the patients with STEMI. METHODS AND RESULTS: The CTS-AMI trial is a prospective, randomized, double-blind, placebo-controlled, multicenter clinical study in China. An estimated 3,796 eligible patients with STEMI from about 120 centers are randomized 1:1 ratio to TXL or placebo groups. All enrolled patients are orally administrated a loading dose of 8 capsules of TXL or placebo together with dual antiplatelet agents on admission followed by 4 capsules 3 times a day until 12 months. The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke. Secondary end points include each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters. CONCLUSIONS: Results of CTS-AMI trial will determine the clinical efficacy and safety of traditional Chinese medicine TXL capsule in the treatment of STEMI patients in the reperfusion era.",2020,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","['patients with Acute Myocardial Infarction (CTS-AMI', '3,796 eligible patients with STEMI from about 120 centers']","['Tongxinluo (TXL', 'TXL', 'TXL or placebo', 'placebo']","['each component of the primary end point, 1-year major adverse cardiovascular and cerebrovascular events, and other efficacy and safety parameters', '30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C1742872', 'cui_str': 'tongxinluo'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0948369', 'cui_str': 'Myocardial reinfarction'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",3796.0,0.355531,"The primary end point is 30-day major adverse cardiovascular and cerebrovascular events, a composite of cardiac death, myocardial reinfarction, emergency coronary revascularization, and stroke.","[{'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiangdong', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Kefei', 'Initials': 'K', 'LastName': 'Dou', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Yan', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Shijie', 'Initials': 'S', 'LastName': 'You', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lianjun', 'Initials': 'L', 'LastName': 'Xu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Xiaojin', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Qiuting', 'Initials': 'Q', 'LastName': 'Dong', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Wenjia', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guangyuan', 'Initials': 'G', 'LastName': 'Song', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Guihao', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Ruijie', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Jingang', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yao', 'Affiliation': 'Peking University Clinical Research Institute, Peking University, Beijing, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Xian', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Peterson', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA.'}, {'ForeName': 'Runlin', 'Initials': 'R', 'LastName': 'Gao', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.'}, {'ForeName': 'Yuejin', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Fuwai Hospital, National Center of Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: yangyjfw@126.com.'}]",American heart journal,['10.1016/j.ahj.2020.06.011'] 1927,32679370,Early application of caffeine improves white matter development in very preterm infants.,"The aim of this study was to evaluate the effect of early prophylactic caffeine treatment on white matter development in very preterm infants using cerebral magnetic resonance imaging. A total of 194 preterm infants (≤32 weeks gestational age) were randomly assigned to the caffeine (n = 96) or placebo (n = 93) treatment group and administered with either caffeine or placebo within 72 h after birth. Cerebral magnetic resonance imaging, including diffuse tensor imaging examination, was performed at 34-36 weeks of corrected gestational age, and the fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values were measured. In total, 160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group. There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0.05). Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group. ADC values in the above white matter areas were significantly reduced in the caffeine group. However, there were no significant differences regarding the FA and ADC in the gray matter between the two groups. These results demonstrate that early administration of caffeine improves white matter micro-structural development in preterm infants, but with no significant effect on short-term complications related to prematurity.",2020,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","['very preterm infants', 'very preterm infants using cerebral magnetic resonance imaging', 'preterm infants', '194 preterm infants (≤32 weeks gestational age', '160 infants were included in the final analysis, including 80 cases in the placebo group and 80 cases in the caffeine group']","['placebo', 'caffeine', 'caffeine or placebo', 'prophylactic caffeine']","['white matter micro-structural development', 'apnea of prematurity and shorter assisted ventilation times', 'FA values', 'fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values', 'FA and ADC', 'ADC values']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0475715', 'cui_str': 'Apnea of prematurity'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0554804', 'cui_str': 'Assisted breathing'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085406', 'cui_str': 'Anisotropy'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}]",194.0,0.144528,"Infants in the caffeine group had significantly higher FA values in white matter, including the posterior limb of the internal capsule, the corpus callosum, the frontal, occipital, and parietal white matter, the cerebellum, and the cerebral peduncle, compared to infants in the placebo group.","[{'ForeName': 'Shasha', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoli', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Yanchao', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiao', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Ruili', 'Initials': 'R', 'LastName': 'Zhang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Brain Imaging, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Xiaoyang', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Perinatal Medicine and Health, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden.'}, {'ForeName': 'Falin', 'Initials': 'F', 'LastName': 'Xu', 'Affiliation': 'Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China.'}, {'ForeName': 'Changlian', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': ""Henan Key Laboratory of Child Brain Injury, Third Affiliated Hospital and Institute of Neuroscience, Zhengzhou University, Zhengzhou 450052, China; Center for Brain Repair and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg 40530, Sweden; Department of Women's and Children's Health, Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: changlian.zhu@neuro.gu.se.""}]",Respiratory physiology & neurobiology,['10.1016/j.resp.2020.103495'] 1928,32679400,Determinants of healthcare use by homeless people with schizophrenia or bipolar disorder: results from the French Housing First Study.,"OBJECTIVES There is limited evidence available on the health-seeking behaviours of individuals in relation to determinants of healthcare use. This study aimed to analyse the determinants of healthcare use (including both hospital and outpatient services) among homeless people with severe mental health illnesses. STUDY DESIGN The study used data from a multicentre, randomised, controlled trial conducted in four large French cities (the French Housing First Study). METHODS Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014. Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons. Data collection was performed during face-to-face interviews. Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period. The data were analysed with zero-inflated (ZI) two-part models. RESULTS In total, 61.1% of participants had at least one hospitalisation stay over the previous 6 months, with a mean of 25 (+/- 39.2) hospital days, and the majority (51%) had visited the ED (either for regular or mental health issues) during the same time period. The results confirmed the role of financial barriers (resources and health insurance) in seeking hospital care (P < 0.05). The main predictors for hospital use in the study population were a better social functioning score (odds ratio [OR]: 1.03; P < 0.001) and having schizophrenia (OR: 1.39; P < 0.01). Higher mental health scores (assessed by the Medical Outcomes Study 36-item Short Form Health Survey) (OR: 1.03, P < 0.01) and alcohol dependence (OR: 2.13; P < 0.01) were associated with not using ED healthcare services. Being 'absolutely homeless' predicted an increased use of the ED and a zero use of outpatient services. Inversely, no association with factors related to the homelessness trajectory was found in hospital ZI negative binomial models. CONCLUSION This study is important because a comprehensive understanding of the determinants of healthcare use enables healthcare systems to adapt and develop. The efficiency of medicosocial interventions targeting the homeless population with mental health illnesses must also be assessed. CLINICAL TRIAL NUMBER NCT01570712.",2020,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","['homeless people with schizophrenia or bipolar disorder', 'Mobile mental health outreach teams recruited homeless individuals with severe mental health illnesses who were living on the street or in emergency shelters, hospitals or prisons', 'Data were drawn from 671 homeless people enrolled in the study between August 2011 and April 2014', 'four large French cities (the French Housing First Study', 'homeless people with severe mental health illnesses', 'homeless population with mental health illnesses']",['medicosocial interventions'],"['hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits', 'alcohol dependence ', 'social functioning score', 'hospitalisation stay', 'financial barriers (resources and health insurance', 'Higher mental health scores']","[{'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0005586', 'cui_str': 'Bipolar disorder'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0425242', 'cui_str': 'Homeless single person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C3178959', 'cui_str': 'Evacuation Shelter'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0020056', 'cui_str': 'Housed'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0001973', 'cui_str': 'Alcohol dependence'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}, {'cui': 'C0205250', 'cui_str': 'High'}]",,0.0642052,"Healthcare service use included hospitalisations, mental health and regular emergency department (ED) visits and outpatient visits to healthcare facilities or physicians' offices over a 6-month follow-up period.","[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Loubière', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France. Electronic address: sandrine.loubiere@univ-amu.fr.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tinland', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Psychiatry, Sainte-Marguerite University Hospital, Marseille, 13009, France.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Taylor', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Loundou', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Girard', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boyer', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Auquier', 'Affiliation': 'Aix Marseille University, School of Medicine - La Timone Medical Campus, EA 3279: CEReSS - Health Service Research and Quality of Life Center, Marseille, 13005, France; Department of Research and Innovation, Support Unit for Clinical Research and Economic Evaluation, Assistance Publique - Hôpitaux de Marseille, Marseille, 13385, France.'}]",Public health,['10.1016/j.puhe.2020.05.019'] 1929,32679403,"Commentary on Liu, K. et al. (2018). Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis in patients with solid cancers: A randomized controlled trial.",,2020,,['patients with solid cancers'],['Handgrip exercise reduces peripherally-inserted central catheter-related venous thrombosis'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0179740', 'cui_str': 'Peripherally inserted central catheter'}, {'cui': 'C0042487', 'cui_str': 'Venous thrombosis'}]",[],,0.162369,,"[{'ForeName': 'Cui', 'Initials': 'C', 'LastName': 'Wen', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Ying', 'Affiliation': 'Department of Nursing, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China. Electronic address: yanpingying0116@126.com.'}, {'ForeName': 'Jianpeng', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021 Nanning, Guangxi, China.'}]",International journal of nursing studies,['10.1016/j.ijnurstu.2020.103691'] 1930,32679405,A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311.,"PURPOSE Understanding the role of transoral surgery in oropharyngeal cancer (OPC) requires prospective, randomized multi-institutional data. Meticulous evaluation of surgeon expertise and surgical quality assurance (QA) will be critical to the validity of such trials. We describe a novel surgeon credentialing and QA process developed to support the ECOG-ACRIN Cancer Research Group E3311 (E3311) and report outcomes related to QA. PATIENTS AND METHODS E3311 was a phase II randomized clinical trial of transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy with stage III-IVa (AJCC 7th edition) HPV-associated OPC. In order to be credentialed to accrue to this trial, surgeons were required to demonstrate active hospital credentials and technique-specific surgical expertise with ≥20 cases of transoral resection for OPC. In addition, 10 paired operative and surgical pathology reports from the preceding 24 months were reviewed by an expert panel. Ongoing QA required <10% rate of positive margins, low oropharyngeal bleeding rates, and accrual of at least one patient per 12 months. Otherwise surgeons were placed on hold and not permitted to accrue until re-credentialed using a new series of transoral resections. RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers. During QA on E3311, positive final pathologic margins were reported in 19 (3.8%) patients. Grade III/IV and grade V oropharyngeal bleeding was reported in 29 (5.9%) and 1 (0.2%) of patients. CONCLUSIONS We provide proof of concept that a comprehensive credentialing process can support multicenter transoral head and neck surgical oncology trials, with low incidence of positive margins and *grade III/V oropharyngeal bleeding.",2020,"RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers.","['120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers', 'oropharyngeal cancer (OPC']","['surgeon expertise and surgical quality assurance (QA', 'transoral surgery', 'transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy with stage III-IVa (AJCC 7th edition) HPV-associated OPC']","['positive final pathologic margins', 'positive margins, low oropharyngeal bleeding rates', 'Grade III/IV and grade V oropharyngeal bleeding']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0282624', 'cui_str': 'Procedures, Minimally Invasive Surgical'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0010298', 'cui_str': 'Credentialing'}, {'cui': 'C0030768', 'cui_str': 'Peer review'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}]","[{'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0268575', 'cui_str': 'Isovaleryl-CoA dehydrogenase deficiency'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0441792', 'cui_str': 'Editions'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C1709603', 'cui_str': 'Positive Surgical Margins'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0441800', 'cui_str': 'Grade'}]",120.0,0.0606723,"RESULTS 120 surgeons trained in transoral minimally invasive surgery applied for credentialing for E3311 and after peer-review, 87 (73%) were approved from 59 centers.","[{'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Ferris', 'Affiliation': 'UPMC Hillman Cancer Center, Pittsburgh, PA, United States. Electronic address: Ferrisrl@upmc.edu.'}, {'ForeName': 'Yael', 'Initials': 'Y', 'LastName': 'Flamand', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, United States.'}, {'ForeName': 'F Christopher', 'Initials': 'FC', 'LastName': 'Holsinger', 'Affiliation': 'Stanford University, Palo Alto, CA, United States.'}, {'ForeName': 'Gregory S', 'Initials': 'GS', 'LastName': 'Weinstein', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Quon', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'Ranee', 'Initials': 'R', 'LastName': 'Mehra', 'Affiliation': 'University of Maryland, Baltimore, MD, United States.'}, {'ForeName': 'Joaquin J', 'Initials': 'JJ', 'LastName': 'Garcia', 'Affiliation': 'Mayo Clinic, Rochester, MN, United States.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Hinni', 'Affiliation': 'Mayo Clinic in Arizona, Phoenix, AZ, United States.'}, {'ForeName': 'Neil D', 'Initials': 'ND', 'LastName': 'Gross', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Erich M', 'Initials': 'EM', 'LastName': 'Sturgis', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Umamaheswar', 'Initials': 'U', 'LastName': 'Duvvuri', 'Affiliation': 'UPMC Hillman Cancer Center, Pittsburgh, PA, United States.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Méndez', 'Affiliation': 'University of Washington, Seattle, WA, United States.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Ridge', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA, United States.'}, {'ForeName': 'J Scott', 'Initials': 'JS', 'LastName': 'Magnuson', 'Affiliation': 'Florida Hospital Orlando, Celebration, FL, United States.'}, {'ForeName': 'Kerry A', 'Initials': 'KA', 'LastName': 'Higgins', 'Affiliation': 'ECOG-ACRIN Cancer Research Group, Boston, MA, United States.'}, {'ForeName': 'Mihir R', 'Initials': 'MR', 'LastName': 'Patel', 'Affiliation': 'Winship Cancer Institute at Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Russel B', 'Initials': 'RB', 'LastName': 'Smith', 'Affiliation': 'University of Nebraska, Omaha, NE, United States.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Karakla', 'Affiliation': 'Sentara Norfolk General Hospital, Norfolk, VA, United States.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Kupferman', 'Affiliation': 'The University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Malone', 'Affiliation': 'UPMC Pinnacle Cancer Center, Harrisburg, PA, United States.'}, {'ForeName': 'Benjamin L', 'Initials': 'BL', 'LastName': 'Judson', 'Affiliation': 'Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Richmon', 'Affiliation': 'Massachusetts Eye and Ear, Harvard University, Boston, MA, United States.'}, {'ForeName': 'Jay O', 'Initials': 'JO', 'LastName': 'Boyle', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, United States.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Bayon', 'Affiliation': 'University of Iowa, Iowa City, IA, United States.'}, {'ForeName': 'Bert W', 'Initials': 'BW', 'LastName': ""O'Malley"", 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Enver', 'Initials': 'E', 'LastName': 'Ozer', 'Affiliation': 'The Ohio State University, Columbus, OH, United States.'}, {'ForeName': 'Giovana R', 'Initials': 'GR', 'LastName': 'Thomas', 'Affiliation': 'University of Miami Leonard Miller School of Medicine, Miami, FL, United States.'}, {'ForeName': 'Wayne M', 'Initials': 'WM', 'LastName': 'Koch', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, United States.'}, {'ForeName': 'R Bryan', 'Initials': 'RB', 'LastName': 'Bell', 'Affiliation': 'Providence Cancer Institute, Portland, OR, United States.'}, {'ForeName': 'Nabil F', 'Initials': 'NF', 'LastName': 'Saba', 'Affiliation': 'Winship Cancer Institute at Emory University, Atlanta, GA, United States.'}, {'ForeName': 'Shuli', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA, United States.'}, {'ForeName': 'Elin R', 'Initials': 'ER', 'LastName': 'Sigurdson', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA, United States.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Burtness', 'Affiliation': 'Yale School of Medicine and Yale Cancer Center, New Haven, CT, United States.'}]",Oral oncology,['10.1016/j.oraloncology.2020.104797'] 1931,32680773,Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine.,"BACKGROUND Vaccine-induced mucosal immune responses may be critical for protection against HIV infection, but may also result in short or long-term changes that enhance susceptibility to infection in some individuals, such as those with baseline seroreactivity to vaccine vector antigens. We examined cellular immune responses in blood and gut mucosal tissue roughly two years following vaccination with placebo or the Step study vaccine MRKAd5/HIV-1. METHODS Participants vaccinated with either placebo or MRKAd5/HIV-1 during participation in HVTN 071, and HVTN 502/Merck 023 underwent phlebotomy and colonic mucosal biopsies via flexible sigmoidoscopy at two timepoints roughly six months apart. After isolation of mononuclear cells, we compared cellular phenotypes and intracellular cytokine responses in vaccine and placebo recipients with and without baseline serological reactivity to Ad5. RESULTS Surface expression of activation and gut-homing markers were elevated on CD4 + and CD8 + gut mucosal mononuclear cells (GMMC) in comparison with PBMC (p < 0.01), but were not significantly affected by baseline Ad5 serostatus or receipt of MRKAd5/HIV-1. ICS responses to stimulation with vaccine antigens were of low frequency and magnitude. Ad5 vector responses were seen in vaccinees and baseline seropositive individuals. CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). CONCLUSION Vaccination with the Ad5 vectored candidate HIV vaccine MRKAd5/HIV-1 does not lead to long-term changes in the activation state of mucosal CD4 + or CD8 + T lymphocytes regardless of baseline Ad5 serostatus. The findings of this study do not reveal a basis for enhanced susceptibility to HIV infection two years post vaccination.",2020,"CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). ","['Participants vaccinated with either', 'recipients of an Ad5-vectored HIV vaccine', 'during participation in HVTN 071, and HVTN 502/Merck 023 underwent']","['phlebotomy and colonic mucosal biopsies via flexible sigmoidoscopy', 'placebo or MRKAd5/HIV-1', 'placebo']","['CD4\xa0+\xa0and CD8\xa0+\xa0gut mucosal mononuclear cells (GMMC', 'cellular phenotypes and intracellular cytokine responses', 'Ad5 vector responses']","[{'cui': 'C0528480', 'cui_str': 'Presenilin 2'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0190979', 'cui_str': 'Phlebotomy'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C0852695', 'cui_str': 'Mucosal biopsy'}, {'cui': 'C0016234', 'cui_str': 'Flexible fiberoptic sigmoidoscopy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0175996', 'cui_str': 'Protoplasm'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0528480', 'cui_str': 'Presenilin 2'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}]",,0.146174,"CD4 + responses to vector antigens were more common in GMMC than PBMC (p < 0.01) and CD8 + responses to HIV gag insert antigens were more frequent in Ad5 seropositive than Ad5 seronegative individuals (p = 0.03). ","[{'ForeName': 'Marcel E', 'Initials': 'ME', 'LastName': 'Curlin', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. Electronic address: curlin@ohsu.edu.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Shao', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Diaz', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Edlefsen', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Novak', 'Affiliation': 'Division of Infectious Diseases, University of Illinois, Chicago, USA.'}, {'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Mayer', 'Affiliation': 'Fenway Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Allen', 'Affiliation': 'Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Morgan', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Maenza', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Buchbinder', 'Affiliation': 'Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Keefer', 'Affiliation': 'Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY, USA.'}, {'ForeName': 'Stephen C De', 'Initials': 'SC', 'LastName': 'Rosa', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Corey', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Duerr', 'Affiliation': 'Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Vaccine,['10.1016/j.vaccine.2020.06.043'] 1932,32687974,Design and rationale for a randomized trial of a theory- and technology- enhanced physical activity intervention for Latinas: The Seamos Activas II study.,"INTRODUCTION Latina women report disproportionately high rates of physical inactivity and related chronic health conditions. Physical activity (PA) efforts to date have shown modest success in this at-risk population; thus, more effective interventions are necessary to help Latinas reach national PA guidelines and reduce related health disparities. This paper describes the design, rationale, and baseline findings from the Seamos Activas II intervention. METHODS/DESIGN The ongoing RCT will test the efficacy of the Seamos Saludables PA print intervention vs. a theory-and technology-enhanced version (Seamos Activas II). The purpose of the study is to increase the percentage of Latinas meeting the national PA guidelines compared to the prior trial, improve biomarkers related to disease, and extend generalizability to a broader and more representative population of Latinas (i.e. Mexican/Mexican-Americans). Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies. The primary outcome is change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers at 6- and 12-months. Secondary PA outcomes assessed by the 7-Day PA Recall will be used to corroborate findings. RESULTS Participants (N = 199) are Latinas 18-65 years (mean = 43.8) of predominantly Mexican origin (89%). At baseline, objectively measured MVPA was 39.51 min/week (SD = 71.20, median = 10) and self-reported MVPA was 12.47 min/week (SD = 22.54, median = 0).Participants reported generally low self-efficacy and higher cognitive vs. behavioral processes of change. CONCLUSION Addressing interactivity and accountability through text messaging, and more rigorously targeting theoretical constructs may be key to helping Latinas achieve nationally recommended PA levels and thereby reducing health disparities.",2020,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","['representative population of Latinas (i.e. Mexican/Mexican-Americans', 'Latina women report disproportionately high rates of physical inactivity and related chronic health conditions', 'Participants (N\u202f=\u202f199) are Latinas 18-65\u202fyears (mean\u202f=\u202f43.8) of predominantly Mexican origin (89', 'Latinas']","['Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies', 'theory- and technology- enhanced physical activity intervention']","['low self-efficacy and higher cognitive vs. behavioral processes of change', 'change in minutes per week of MVPA measured by ActiGraph GT3X+ accelerometers']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0949335', 'cui_str': 'Latinas'}, {'cui': 'C0025884', 'cui_str': 'Chicanos'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2712043', 'cui_str': 'Lacking belief in own ability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0702093', 'cui_str': '/minute'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",,0.0266557,"Intervention refinements included further targeting key constructs of Social Cognitive Theory, and incorporating interactive text message-based self-monitoring strategies.","[{'ForeName': 'Tanya J', 'Initials': 'TJ', 'LastName': 'Benitez', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America.'}, {'ForeName': 'Shira I', 'Initials': 'SI', 'LastName': 'Dunsiger', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America.'}, {'ForeName': 'Dori J', 'Initials': 'DJ', 'LastName': 'Pekmezi', 'Affiliation': 'Department of Health Behavior, School of Public Health at University of Alabama at Birmingham, Birmingham, AL, United States of America.'}, {'ForeName': 'Britta A', 'Initials': 'BA', 'LastName': 'Larsen', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Andrea S', 'Initials': 'AS', 'LastName': 'Mendoza-Vasconez', 'Affiliation': 'School of Medicine, Stanford University, Stanford, CA, United States of America.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Linke', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Beth C', 'Initials': 'BC', 'LastName': 'Bock', 'Affiliation': 'Department of Psychiatry & Human Behavior, Alpert Medical School, Brown University, Providence, RI, United States of America.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Gans', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America; Department of Human Development and Family Studies, University of Connecticut, Storrs, CT, United States of America.'}, {'ForeName': 'Sheri J', 'Initials': 'SJ', 'LastName': 'Hartman', 'Affiliation': 'Department of Family Medicine & Public Health, University of California San Diego, La Jolla, CA, United States of America.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, RI, United States of America. Electronic address: bess_marcus@brown.edu.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106081'] 1933,32688045,"Effects of attention training technique on brain function in high- and low-cognitive-attentional syndrome individuals: Regional dynamics before, during, and after a single session of ATT.","OBJECTIVE Attention Training Technique (ATT) is a key therapeutic tool in metacognitive therapy. There are numerous studies on the behavioral effects of ATT, however the neural mechanisms at work in the training are yet to be uncovered. To date there have been no controlled fMRI studies of ATT. METHOD We conducted a randomized double-blind controlled study of two groups with varying levels of cognitive-attentional syndrome (CAS). Groups with high (n = 43) and low (n = 46) levels of CAS underwent a single session of ATT or a control condition (CON) in an MRI scanner. Participants underwent resting state functional MRI (rsfMRI) sessions and rumination induction sessions both pre- and post-intervention Functional connectivity analyses and inter-subject correlations analyses were computed. We also collected data on emotion and attention functioning pre- and post-intervention. RESULTS We did not observe any behavioral effects of ATT. However, direct comparison between ATT and CON sessions revealed greater inter-subject correlations in almost all hubs belonging to the studied functional networks. Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively. Furthermore, some of the observed effects in functional connectivity and inter-subject correlations were specific to different levels of CAS. CONCLUSIONS Our results may support a proposed neural mechanism for ATT: disengagement of attention from CAS-type processing in either low- or high-CAS individuals. It is also possible that some neural effects of ATT are specific to individuals with different levels of CAS.",2020,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","['two groups with varying levels of cognitive-attentional syndrome (CAS', 'high- and low-cognitive-attentional syndrome individuals']","['Attention Training Technique (ATT', 'attention training technique', 'resting state functional MRI (rsfMRI) sessions and rumination induction sessions']",['brain function'],"[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0556509', 'cui_str': 'Attention training'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0498982,"Moreover, subjects who received ATT showed diminished connectivity in the fronto-parietal network during ruminations and diminished connectivity of the precuneus with lateral occipital cortices and the intraparietal sulcus in abstract thinking and rsfMRI, respectively.","[{'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Kowalski', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland; Institute of Psychology, Polish Academy of Sciences, Stefana Jaracza 1, 00-378, Warsaw, Poland. Electronic address: joachim.kowalski@psych.uw.edu.pl.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Wierzba', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Wypych', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Artur', 'Initials': 'A', 'LastName': 'Marchewka', 'Affiliation': 'Laboratory of Brain Imaging, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Pasteur Street 3, 02-093, Warsaw, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Dragan', 'Affiliation': 'Faculty of Psychology, University of Warsaw, Stawki 5/7, 00-183, Warsaw, Poland.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103693'] 1934,32688046,Effectiveness of a transdiagnostic group intervention to enhance emotion regulation in young Afghan refugees: A pilot randomized controlled study.,"There are several challenges to providing mental health care for refugees, including high comorbidity and structural barriers. Targeting transdiagnostic processes in a low-threshold group intervention appears particularly promising to meet these challenges. This study examined the feasibility, acceptability and effectiveness of a new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC), focusing on conveying strategies to improve emotional clarity and to regulate emotions. A parallel-group (STARC vs. waitlist) randomized-controlled study with 44 young male Afghan refugees was conducted in a routine clinical setting (NCT03162679). In intention-to-treat analyses, participants of STARC significantly improved in self-reported difficulties in emotion regulation (Δd STARC-Waitlist  = 1.22), transdiagnostic symptom severity (Δd STARC-Waitlist  = 1.69), posttraumatic stress symptoms (Δd STARC-Waitlist  = 1.19), and caregiver-reported emotional competence (Δd STARC-Waitlist  = -0.90), but not anger reactions (Δd STARC-Waitlist  = 0.50) compared to waitlist. Effects were maintained over 3 months. STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees. If replicated in large-scale studies with active control groups, it might be promising as an initial low-threshold intervention offered in a phased-based and/or stepped care approach.",2020,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"['young Afghan refugees', '44 young male Afghan refugees']","['STARC', 'transdiagnostic group intervention', 'new transdiagnostic intervention, Skills-Training of Affect Regulation-A Culture-sensitive Approach (STARC']","['self-reported difficulties in emotion regulation', 'emotion regulation', 'transdiagnostic symptom severity', 'caregiver-reported emotional competence', 'posttraumatic stress symptoms']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0559197', 'cui_str': 'Skills training'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C2370884', 'cui_str': 'Emotion Self-Regulation'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]",44.0,0.0299985,STARC is a feasible transdiagnostic intervention in a routine clinical setting and effective for young Afghan refugees.,"[{'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Koch', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany. Electronic address: Theresa.koch@refugio-muenchen.de.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Ehring', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Liedl', 'Affiliation': 'LMU Munich, Department of Psychology, Clinical Psychology and Psychotherapy, Germany; Refugio Munich, Germany.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103689'] 1935,32688047,Power posing for paranoia: A double-blind randomised controlled experimental test using virtual reality.,"Paranoia is theorised to build upon feelings of inferior social rank. Power posing has been shown to increase feelings of power, and hence could reduce paranoia. One hundred participants with current paranoia and 50 individuals without paranoia were recruited. Using a double-blind randomised controlled experimental design, participants twice held powerful or neutral postures before entering neutral virtual reality social environments. In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = -0.23, C.I. = -1.17; 0.72; p = 0.634). In the non-paranoid sample, there was a small significant increase in powerful feelings by the end of testing in the powerful group (group difference = 1.13, C.I. = 0.23; 2.02; p = 0.013), but no significant decrease in paranoia (group difference = -0.71, C.I. = -2.16; 0.74; p = 0.338). Paranoia status was not a modifier on the relationship between condition and feelings of power. We conclude that power posing results in only very small changes in self-reported feelings of power and has no subsequent effect on paranoia.",2020,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","['One hundred participants with current paranoia and 50 individuals without paranoia were recruited', 'participants twice held powerful or neutral postures before entering neutral virtual reality social environments']",[],"['paranoia', 'powerful feelings', 'feelings of power']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0037414', 'cui_str': 'Social context'}]",[],"[{'cui': 'C1456784', 'cui_str': 'Paranoid disorder'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}]",100.0,0.16838,"In the paranoid sample, those who held a powerful pose did not significantly increase in feelings of power by the end of testing in comparison to controls (group difference = 0.67, C.I. = -1.12; 1.46; p = 0.098), or decrease in paranoia (group difference = ","[{'ForeName': 'Poppy', 'Initials': 'P', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK. Electronic address: poppy.brown@psych.ox.ac.uk.'}, {'ForeName': 'Felicity', 'Initials': 'F', 'LastName': 'Waite', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Aitor', 'Initials': 'A', 'LastName': 'Rovira', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Freeman', 'Affiliation': 'Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK; Oxford Health NHS Foundation Trust, UK.'}]",Behaviour research and therapy,['10.1016/j.brat.2020.103691'] 1936,32681734,"Muscle structural, energetic and functional benefits of endurance exercise training in sickle cell disease.","Sickle cell disease (SCD) patients display skeletal muscle hypotrophy, altered oxidative capacity, exercise intolerance and poor quality of life. We previously demonstrated that moderate-intensity endurance training is beneficial for improving muscle function and quality of life of patients. The present study evaluated the effects of this moderate-intensity endurance training program on skeletal muscle structural and metabolic properties. Of the 40 randomized SCD patients, complete data sets were obtained from 33. The training group (n = 15) followed a personalized moderate-intensity endurance training program, while the non-training (n = 18) group maintained a normal lifestyle. Biopsies of the vastus lateralis muscle and submaximal incremental cycling tests were performed before and after the training program. Endurance training increased type I muscle fiber surface area (P = .038), oxidative enzyme activity [citrate synthase, P < .001; β-hydroxyacyl-CoA dehydrogenase, P = .009; type-I fiber cytochrome c oxidase, P = .042; respiratory chain complex IV, P = .017] and contents of respiratory chain complexes I (P = .049), III (P = .005), IV (P = .003) and V (P = .002). Respiratory frequency, respiratory exchange ratio, blood lactate concentration and rating of perceived exertion were all lower at a given submaximal power output after training vs non-training group (all P < .05). The muscle content of proteins involved in glucose transport and pH regulation were unchanged in the training group relative to the non-training group. The moderate-intensity endurance exercise program improved exercise capacity and muscle structural and oxidative properties. This trial was registered at www.clinicaltrials.gov as #NCT02571088.",2020,The muscle content of proteins involved in glucose transport and pH regulation were unchanged in the training group relative to the non-training group.,['sickle cell disease'],"['endurance exercise training', 'personalized moderate-intensity endurance training program, while the non-training (n=18) group maintained a normal lifestyle', 'moderate-intensity endurance training', 'Endurance training', 'type-I fiber cytochrome', 'moderate-intensity endurance training program']","['Respiratory frequency, respiratory exchange ratio, blood lactate concentration and rating of perceived exertion', 'exercise capacity and muscle structural and oxidative properties', 'type I muscle fiber surface area ', 'Sickle cell disease (SCD) patients display skeletal muscle hypotrophy, altered oxidative capacity, exercise intolerance and poor quality of life', 'oxidative enzyme activity [citrate synthase, p<0.001', 'muscle content of proteins involved in glucose transport and pH regulation', 'skeletal muscle structural and metabolic properties']","[{'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}]","[{'cui': 'C0419120', 'cui_str': 'Muscular endurance development exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0010798', 'cui_str': 'Cytochrome'}]","[{'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0242874', 'cui_str': 'Skeletal muscle fiber, type I'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0424551', 'cui_str': 'Impaired exercise tolerance'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0243102', 'cui_str': 'enzyme activity'}, {'cui': 'C0008855', 'cui_str': 'Citrate(si)-synthase'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0005528', 'cui_str': 'Biological transport'}, {'cui': 'C0220905', 'cui_str': 'regulations'}]",40.0,0.0227297,The muscle content of proteins involved in glucose transport and pH regulation were unchanged in the training group relative to the non-training group.,"[{'ForeName': 'Angèle N', 'Initials': 'AN', 'LastName': 'Merlet', 'Affiliation': 'Laboratoire Interuniversitaire de Biologie de la Motricité, Université de Lyon, Université Jean Monnet, Saint-Etienne, France.'}, {'ForeName': 'Léonard', 'Initials': 'L', 'LastName': 'Féasson', 'Affiliation': 'Laboratoire Interuniversitaire de Biologie de la Motricité, Université de Lyon, Université Jean Monnet, Saint-Etienne, France.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Bartolucci', 'Affiliation': 'Service de Médecine Interne, Hôpital Henri-Mondor (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Hourdé', 'Affiliation': 'Laboratoire Interuniversitaire de Biologie de la Motricité, Université Savoie Mont Blanc, Chambéry, France.'}, {'ForeName': 'Céline', 'Initials': 'C', 'LastName': 'Schwalm', 'Affiliation': 'Institute of Neuroscience, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Barnabas', 'Initials': 'B', 'LastName': 'Gellen', 'Affiliation': 'Service de Réhabilitation Cardiaque, Hôpital Henri-Mondor (Assistance Publique-Hôpitaux de Paris [APHP]), Créteil, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Galactéros', 'Affiliation': 'Service de Santé Publique, Hôpital Henri-Mondor (AP-HP), Université Paris-Est Créteil, Créteil, France.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Deldicque', 'Affiliation': 'Institute of Neuroscience, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Francaux', 'Affiliation': 'Institute of Neuroscience, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Laurent A', 'Initials': 'LA', 'LastName': 'Messonnier', 'Affiliation': 'Laboratoire Interuniversitaire de Biologie de la Motricité, Université Savoie Mont Blanc, Chambéry, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of hematology,['10.1002/ajh.25936'] 1937,32688143,"The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington's disease.","BACKGROUND Huntington's disease (HD) is a chronic, progressive neurodegenerative condition for which there are currently no proven disease-modifying therapies. Lifestyle factors have been shown to impact on the age of disease onset and progression of disease features. We therefore investigated the effects of a nine-month multidisciplinary rehabilitation intervention on neuroimaging, biological and clinical disease outcomes in individuals with premanifest HD. METHODS 31 individuals with premanifest HD participated in the study. Eighteen participants underwent a nine-month multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance. The remaining 13 participants were allocated to a standard care control group. Neuroimaging, biological, cognitive, motor and cardiorespiratory fitness data was collected. RESULTS Participants displayed good adherence (87%) and compliance (85%) to the intervention. Maintenance of the shape of the right putamen was observed in the intervention group when compared to the control group. The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group. Performance on the mini-social cognition and emotional assessment (mini-SEA) was maintained in the intervention group, but decreased in the control group. No changes were observed in serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness. CONCLUSION This study adds to the accumulating body of literature to suggest that multidisciplinary rehabilitation is of clinical benefit for individuals with HD. Large randomised controlled trials are necessary to determine the extent to which benefits occur across the spectrum of the disease.",2020,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","['individuals with HD', 'individuals with premanifest HD', '31 individuals with premanifest HD participated in the study', ""individuals with premanifest Huntington's disease"", 'Eighteen participants underwent a nine-month']","['nine-month multidisciplinary rehabilitation intervention', 'multidisciplinary rehabilitation', 'multidisciplinary rehabilitation intervention comprising aerobic and resistance exercise, computerised cognitive training, dual-task training and sleep hygiene and nutritional guidance', 'standard care control group']","['serum neurofilament light protein levels, postural stability outcomes or cardiorespiratory fitness', 'mini-social cognition and emotional assessment (mini-SEA', 'good adherence', 'neuroimaging, biological, cognitive and motor outcomes', 'verbal learning and memory, attention, cognitive flexibility and processing speed']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020179', 'cui_str': ""Huntington's chorea""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4277672', 'cui_str': 'Good Sleep Habits'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0027834', 'cui_str': 'Neurofilaments'}, {'cui': 'C0670902', 'cui_str': 'LIGHT Protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0042531', 'cui_str': 'Verbal learning'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0582591', 'cui_str': 'Processing speed'}]",18.0,0.0225136,"The intervention group displayed significant improvements in verbal learning and memory, attention, cognitive flexibility and processing speed following the intervention when compared to the control group.","[{'ForeName': 'Danielle M', 'Initials': 'DM', 'LastName': 'Bartlett', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Govus', 'Affiliation': 'School of Allied Health, Human Services & Sport, Department of Dietetics, Nutrition and Sport, La Trobe University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Rankin', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Centre for Sleep Science, School of Human Sciences, Faculty of Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Lampit', 'Affiliation': 'Department of Psychiatry, University of Melbourne, Victoria, Australia; Department of Neurology, Charité - Universitätsmedizin Berlin, Germany.'}, {'ForeName': 'Kirk', 'Initials': 'K', 'LastName': 'Feindel', 'Affiliation': 'Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Australia.'}, {'ForeName': 'Govinda', 'Initials': 'G', 'LastName': 'Poudel', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.'}, {'ForeName': 'Wei-Peng', 'Initials': 'WP', 'LastName': 'Teo', 'Affiliation': 'National Institute of Education, Nanyang Technological University, Singapore.'}, {'ForeName': 'Johnny', 'Initials': 'J', 'LastName': 'Lo', 'Affiliation': 'School of Science, Edith Cowan University, Joondalup, Western Australia, Australia.'}, {'ForeName': 'Nellie', 'Initials': 'N', 'LastName': 'Georgiou-Karistianis', 'Affiliation': 'School of Psychological Sciences, The Turner Institute of Brain and Mental Health, Monash University, Clayton, Victoria, Australia.'}, {'ForeName': 'Mel R', 'Initials': 'MR', 'LastName': 'Ziman', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; School of Biomedical Science, University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Travis M', 'Initials': 'TM', 'LastName': 'Cruickshank', 'Affiliation': 'School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Exercise Medicine Research Institute, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Perron Institute for Neurological and Translational Science, Perth, Western Australia, Australia. Electronic address: t.cruickshank@ecu.edu.au.'}]",Journal of the neurological sciences,['10.1016/j.jns.2020.117022'] 1938,32688208,PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.,"BACKGROUND Enhanced recovery after surgery (ERAS) programs include multiple perioperative elements designed to achieve early recovery after surgery and a shorter length of stay (LOS) in hospital. The PROFAST trial aimed to expand the evidence base for implementing ERAS in advanced gynaecologic oncology surgery. METHODS This prospective, interventional randomised clinical trial enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an ERAS protocol or conventional management (CM) protocol. All enrolled women who underwent cytoreductive surgery were included in the primary analysis. The primary outcome was reduction in LOS, and secondary outcomes were incidence and type of intraoperative and postoperative complications, rate of readmission and mortality within a 30-d follow-up period. This trial is registered at ClinicalTrials.gov, number NCT02172638. FINDINGS From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded. The ERAS group comprised 50 patients, and the CM group, 49 patients. Both groups were comparable with respect to baseline characteristics and complexity of the cytoreductive surgery, with an overall medium/high Aletti surgical complexity score of 7.4. Overall compliance to the ERAS protocol was 92%. As compared with the patients in the CM group, patients in the ERAS group had a decreased median of LOS of two days (7 versus 9 days; p = 0.0099) and a decreased rate of readmission (6% versus 20%, p = 0.0334). No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. INTERPRETATION Patients with advanced ovarian cancer in the ERAS program had a decreased LOS and decreased rate of readmission as compared with those in CM, with no increased morbidity or mortality. This study provides important evidence for the benefits of ERAS management even for gynaecologic surgeries of medium/high complexity and suggests that ERAS should be a standard practice for cytoreductive surgeries for peritoneal carcinomatosis.",2020,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","['Patients with advanced ovarian cancer', 'enrolled women undergoing surgery for either suspected or diagnosed advanced ovarian cancer, at a reference hospital in gynaecologic oncology in Barcelona (Spain) and who were treated after either an', 'All enrolled women who underwent cytoreductive surgery were included in the primary analysis', 'From June 2014 to March 2018, 110 women were recruited, of which eleven were excluded', 'advanced gynaecologic oncology surgery', 'highcomplexity advanced ovarian cancer surgery']","['PROFAST', 'ERAS', 'ERAS protocol or conventional management (CM) protocol']","['incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality', 'incidence and type of intraoperative and postoperative complications, rate of readmission\xa0and mortality within a 30-d\xa0follow-up period', 'rate of readmission', 'morbidity or mortality', 'median of LOS', 'reduction in LOS', 'Overall compliance']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205480', 'cui_str': 'Gynecologic'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0381011', 'cui_str': 'ProFast'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}]",110.0,0.308005,"No further significant differences were detected with respect to incidence of intraoperative or postoperative complications, severe (Clavien-Dindo grade IIIB-IV) complications, Comprehensive Complication Index, reoperation during primary stay, or mortality. ","[{'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Sánchez-Iglesias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jlsanig@yahoo.es.""}, {'ForeName': 'Melchor', 'Initials': 'M', 'LastName': 'Carbonell-Socias', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Assumpció', 'Initials': 'MA', 'LastName': 'Pérez-Benavente', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Monreal Clua', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Manrique-Muñoz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'García Gorriz', 'Affiliation': ""Unit of Anesthesiology and Resuscitation, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Burgos-Peláez', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Hegoi', 'Initials': 'H', 'LastName': 'Segurola Gurrutxaga', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Mónica', 'Initials': 'M', 'LastName': 'Pamies Serrano', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Del', 'Initials': 'MD', 'LastName': 'Pilar Gutiérrez-Barceló', 'Affiliation': ""Nutritional Support Unit, Endocrinology and Nutrition Service, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Serrano-Castro', 'Affiliation': ""Nursing Unit for Gynecologic Oncology and Breast Diseases, Vall d'Hebron Hospital, Barcelona, Spain.""}, {'ForeName': 'Ma Teresa', 'Initials': 'MT', 'LastName': 'Balcells-Farré', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Pérez-Barragán', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Axelle', 'Initials': 'A', 'LastName': 'Scaillet-Houberechts', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Yolima', 'Initials': 'Y', 'LastName': 'Cossio-Gil', 'Affiliation': ""Data and Innovation Department, Vall d'Hebron Hospital, Barcelona, Spain; Research Group of Healthcare System Management, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Gil-Moreno', 'Affiliation': ""Gynecological Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Biomedical Research Group in Gynecology, Vall d'Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, CIBERONC, Barcelona, Spain. Electronic address: antonioimma@yahoo.es.""}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2020.06.011'] 1939,32682482,Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment in predicted severe acute gallstone pancreatitis (APEC): a multicentre randomised controlled trial.,"BACKGROUND It remains unclear whether urgent endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy improves the outcome of patients with gallstone pancreatitis without concomitant cholangitis. We did a randomised trial to compare urgent ERCP with sphincterotomy versus conservative treatment in patients with predicted severe acute gallstone pancreatitis. METHODS In this multicentre, parallel-group, assessor-masked, randomised controlled superiority trial, patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands. Patients were randomly assigned (1:1) by a web-based randomisation module with randomly varying block sizes to urgent ERCP with sphincterotomy (within 24 h after hospital presentation) or conservative treatment. The primary endpoint was a composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency) within 6 months of randomisation. Analysis was by intention to treat. This trial is registered with the ISRCTN registry, ISRCTN97372133. FINDINGS Between Feb 28, 2013, and March 1, 2017, 232 patients were randomly assigned to urgent ERCP with sphincterotomy (n=118) or conservative treatment (n=114). One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission. The primary endpoint occurred in 45 (38%) of 117 patients in the urgent ERCP group and in 50 (44%) of 113 patients in the conservative treatment group (risk ratio [RR] 0·87, 95% CI 0·64-1·18; p=0·37). No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010). Adverse events were reported in 87 (74%) of 118 patients in the urgent ERCP group versus 91 (80%) of 114 patients in the conservative treatment group. INTERPRETATION In patients with predicted severe gallstone pancreatitis but without cholangitis, urgent ERCP with sphincterotomy did not reduce the composite endpoint of major complications or mortality, compared with conservative treatment. Our findings support a conservative strategy in patients with predicted severe acute gallstone pancreatitis with an ERCP indicated only in patients with cholangitis or persistent cholestasis. FUNDING The Netherlands Organization for Health Research and Development, Fonds NutsOhra, and the Dutch Patient Organization for Pancreatic Diseases.",2020,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","['predicted severe acute gallstone pancreatitis (APEC', 'patients with predicted severe acute gallstone pancreatitis', 'patients with predicted severe (Acute Physiology and Chronic Health Evaluation II score ≥8, Imrie score ≥3, or C-reactive protein concentration >150 mg/L) gallstone pancreatitis without cholangitis were assessed for eligibility in 26 hospitals in the Netherlands', 'Between Feb 28, 2013, and March 1, 2017', '232 patients', 'patients with cholangitis or persistent cholestasis', 'patients with gallstone pancreatitis without concomitant cholangitis', 'One patient from each group was excluded from the final analysis because of cholangitis (urgent ERCP group) and chronic pancreatitis (conservative treatment group) at admission', 'patients with predicted severe acute gallstone pancreatitis with an']","['ERCP', 'Urgent endoscopic retrograde cholangiopancreatography with sphincterotomy versus conservative treatment', 'ERCP with sphincterotomy versus conservative treatment', 'endoscopic retrograde cholangiopancreatography (ERCP) with biliary sphincterotomy', 'conservative treatment', 'ERCP with sphincterotomy']","['Adverse events', 'composite endpoint of major complications or mortality', 'composite of mortality or major complications (new-onset persistent organ failure, cholangitis, bacteraemia, pneumonia, pancreatic necrosis, or pancreatic insufficiency', 'severe gallstone pancreatitis', 'occurrence of cholangitis']","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4758051', 'cui_str': 'APACHE II (Acute Physiology and Chronic Health Evaluation II) score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0027778', 'cui_str': 'Netherlands'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0008370', 'cui_str': 'Cholestasis'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0149521', 'cui_str': 'Chronic pancreatitis'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0177047', 'cui_str': 'Sphincterotomy (bladder)'}, {'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0948386', 'cui_str': 'Biliary sphincterotomy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0267941', 'cui_str': 'Acute necrotizing pancreatitis'}, {'cui': 'C0030293', 'cui_str': 'Pancreatic insufficiency'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}]",232.0,0.207888,"No relevant differences in the individual components of the primary endpoint were recorded between groups, apart from the occurrence of cholangitis (two [2%] of 117 in the urgent ERCP group vs 11 [10%] of 113 in the conservative treatment group; RR 0·18, 95% CI 0·04-0·78; p=0·010).","[{'ForeName': 'Nicolien J', 'Initials': 'NJ', 'LastName': 'Schepers', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands. Electronic address: n.schepers@antoniusziekenhuis.nl.'}, {'ForeName': 'Nora D L', 'Initials': 'NDL', 'LastName': 'Hallensleben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marc G', 'Initials': 'MG', 'LastName': 'Besselink', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Marie-Paule G F', 'Initials': 'MGF', 'LastName': 'Anten', 'Affiliation': 'Department of Gastroenterology and Hepatology, Franciscus and Vlietland Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Bollen', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'da Costa', 'Affiliation': 'Department of Radiology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Foke', 'Initials': 'F', 'LastName': 'van Delft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Sven M', 'Initials': 'SM', 'LastName': 'van Dijk', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Hendrik M', 'Initials': 'HM', 'LastName': 'van Dullemen', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Casper H J', 'Initials': 'CHJ', 'LastName': 'van Eijck', 'Affiliation': 'Department of Surgery, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'G Willemien', 'Initials': 'GW', 'LastName': 'Erkelens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Gelre Hospital, Apeldoorn, Netherlands.'}, {'ForeName': 'Nicole S', 'Initials': 'NS', 'LastName': 'Erler', 'Affiliation': 'Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Erwin J M', 'Initials': 'EJM', 'LastName': 'van Geenen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'Janneke', 'Initials': 'J', 'LastName': 'van Grinsven', 'Affiliation': 'Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Robbert A', 'Initials': 'RA', 'LastName': 'Hollemans', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Jeanin E', 'Initials': 'JE', 'LastName': 'van Hooft', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Netherlands.'}, {'ForeName': 'Rene W M', 'Initials': 'RWM', 'LastName': 'van der Hulst', 'Affiliation': 'Department of Gastroenterology and Hepatology, Spaarne Hospital, Haarlem, Netherlands.'}, {'ForeName': 'Jeroen M', 'Initials': 'JM', 'LastName': 'Jansen', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Frank J G M', 'Initials': 'FJGM', 'LastName': 'Kubben', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maasstad Hospital, Rotterdam, Netherlands.'}, {'ForeName': 'Sjoerd D', 'Initials': 'SD', 'LastName': 'Kuiken', 'Affiliation': 'Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.'}, {'ForeName': 'Robert J F', 'Initials': 'RJF', 'LastName': 'Laheij', 'Affiliation': 'Department of Gastroenterology and Hepatology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.'}, {'ForeName': 'Rutger', 'Initials': 'R', 'LastName': 'Quispel', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Rogier J J', 'Initials': 'RJJ', 'LastName': 'de Ridder', 'Affiliation': 'Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, Netherlands.'}, {'ForeName': 'Marno C M', 'Initials': 'MCM', 'LastName': 'Rijk', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, Netherlands.'}, {'ForeName': 'Tessa E H', 'Initials': 'TEH', 'LastName': 'Römkens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, Den Bosch, Netherlands.'}, {'ForeName': 'Carola H M', 'Initials': 'CHM', 'LastName': 'Ruigrok', 'Affiliation': 'Department of Gastroenterology and Hepatology, Reinier de Graaf Group, Delft, Netherlands.'}, {'ForeName': 'Erik J', 'Initials': 'EJ', 'LastName': 'Schoon', 'Affiliation': 'Department of Gastroenterology and Hepatology, Catharina Hospital, Eindhoven, Netherlands.'}, {'ForeName': 'Matthijs P', 'Initials': 'MP', 'LastName': 'Schwartz', 'Affiliation': 'Department of Gastroenterology and Hepatology, Meander Medical Center, Amersfoort, Netherlands.'}, {'ForeName': 'Xavier J N M', 'Initials': 'XJNM', 'LastName': 'Smeets', 'Affiliation': 'Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.'}, {'ForeName': 'B W Marcel', 'Initials': 'BWM', 'LastName': 'Spanier', 'Affiliation': 'Department of Gastroenterology and Hepatology, Rijnstate Hospital, Arnhem, Netherlands.'}, {'ForeName': 'Adriaan C I T L', 'Initials': 'ACITL', 'LastName': 'Tan', 'Affiliation': 'Department of Gastroenterology and Hepatology, Canisius Wilhelmina Hospital, Nijmegen, Netherlands.'}, {'ForeName': 'Willem J', 'Initials': 'WJ', 'LastName': 'Thijs', 'Affiliation': 'Department of Gastroenterology and Hepatology, Martini Hospital, Groningen, Netherlands.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Timmer', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Niels G', 'Initials': 'NG', 'LastName': 'Venneman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Medisch Spectrum Twente, Enschede, Netherlands.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Verdonk', 'Affiliation': 'Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Frank P', 'Initials': 'FP', 'LastName': 'Vleggaar', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van de Vrie', 'Affiliation': 'Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, Netherlands.'}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Witteman', 'Affiliation': 'Department of Gastroenterology and Hepatology, Hospital Gelderse Vallei, Ede, Netherlands.'}, {'ForeName': 'Hjalmar C', 'Initials': 'HC', 'LastName': 'van Santvoort', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands; Department of Surgery, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Olaf J', 'Initials': 'OJ', 'LastName': 'Bakker', 'Affiliation': 'Department of Surgery, St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'Marco J', 'Initials': 'MJ', 'LastName': 'Bruno', 'Affiliation': 'Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30539-0'] 1940,32682483,Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial.,"BACKGROUND Atrial fibrillation and delirium are common consequences of cardiac surgery. Dexmedetomidine has unique properties as sedative agent and might reduce the risk of each complication. This study coprimarily aimed to establish whether dexmedetomidine reduces the incidence of new-onset atrial fibrillation and the incidence of delirium. METHODS A randomised, placebo-controlled trial was done at six academic hospitals in the USA. Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled. Patients were randomly assigned 1:1, stratified by site, to dexmedetomidine or normal saline placebo. Randomisation was computer generated with random permuted block size 2 and 4, and allocation was concealed by a web-based system. Patients, caregivers, and evaluators were all masked to treatment. The study drug was prepared by the pharmacy or an otherwise uninvolved research associate so that investigators and clinicians were fully masked to allocation. Participants were given either dexmedetomidine infusion or saline placebo started before the surgical incision at a rate of 0·1 μg/kg per h then increased to 0·2 μg/kg per h at the end of bypass, and postoperatively increased to 0·4 μg/kg per h, which was maintained until 24 h. The coprimary outcomes were atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge. All analyses were intention-to-treat. The trial is registered with ClinicalTrials.gov, NCT02004613 and is closed. FINDINGS 798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018. The trial was stopped per protocol after the last designated interim analysis. Among 798 patients randomly assigned, 794 were analysed, with 400 assigned to dexmedetomidine and 398 assigned to placebo. The incidence of atrial fibrillation was 121 (30%) in 397 patients given dexmedetomidine and 134 (34%) in 395 patients given placebo, a difference that was not significant: relative risk 0·90 (97·8% CI 0·72, 1·15; p=0·34). The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23). Safety outcomes were clinically important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death. 21 (5%) of 394 patients given dexmedetomidine and 8 (2%) of 396 patients given placebo, had a serious adverse event as determined by clinicians. 1 (<1%) of 391 patients given dexmedetomidine and 1 (<1%) of 387 patients given placebo died. INTERPRETATION Dexmedetomidine infusion, initiated at anaesthetic induction and continued for 24 h, did not decrease postoperative atrial arrhythmias or delirium in patients recovering from cardiac surgery. Dexmedetomidine should not be infused to reduce atrial fibrillation or delirium in patients having cardiac surgery. FUNDING Hospira Pharmaceuticals.",2020,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"['six academic hospitals in the USA', '798 patients of 3357 screened were enrolled from April 17, 2013, to Dec 6, 2018', '391 patients given', 'patients recovering from cardiac surgery', '394 patients given', 'patients having cardiac surgery', '798 patients randomly assigned, 794 were analysed, with 400 assigned to', 'atrial fibrillation and delirium after cardiac surgery (DECADE', 'Patients who had had cardiac surgery with cardiopulmonary bypass were enrolled']","['dexmedetomidine infusion or saline placebo', 'dexmedetomidine or normal saline placebo', 'Dexmedetomidine', 'dexmedetomidine', 'placebo']","['incidence of atrial fibrillation', 'relative risk 0·90', 'postoperative atrial arrhythmias or delirium', 'atrial fibrillation and delirium occurring between intensive care unit admission and the earlier of postoperative day 5 or hospital discharge', 'serious adverse event', 'incidence of delirium', 'atrial fibrillation or delirium', 'important bradycardia (requiring treatment) and hypotension, myocardial infarction, stroke, surgical site infection, pulmonary embolism, deep venous thrombosis, and death', 'incidence of new-onset atrial fibrillation']","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0521108', 'cui_str': 'Recovering from'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085611', 'cui_str': 'Atrial arrhythmia'}, {'cui': 'C0011206', 'cui_str': 'Delirium'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]",3357.0,0.797581,The incidence of delirium was non-significantly increased from 12% in patients given placebo to 17% in those given dexmedetomidine: 1·48 (97·8% CI 0·99-2·23).,"[{'ForeName': 'Alparslan', 'Initials': 'A', 'LastName': 'Turan', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: turana@ccf.org.'}, {'ForeName': 'Andra', 'Initials': 'A', 'LastName': 'Duncan', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Leung', 'Affiliation': 'Department of Radiology, Metrohealth Hospital, Cleveland, OH, USA.'}, {'ForeName': 'Nika', 'Initials': 'N', 'LastName': 'Karimi', 'Affiliation': 'Department of Anesthesiology, University of Rochester, Rochester, NY, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Fang', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Guangmei', 'Initials': 'G', 'LastName': 'Mao', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hargrave', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Gillinov', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Trombetta', 'Affiliation': 'Department of Cardiovascular Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Sabry', 'Initials': 'S', 'LastName': 'Ayad', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Manal', 'Initials': 'M', 'LastName': 'Hassan', 'Affiliation': 'Department of Regional Practice, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Feider', 'Affiliation': 'Department of Anesthesia, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Howard-Quijano', 'Affiliation': 'Department of Anesthesiology and Perioperative Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA, USA.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA; Department of General Anesthesiology, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': 'Daniel I', 'Initials': 'DI', 'LastName': 'Sessler', 'Affiliation': 'Department of Outcomes Research, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30631-0'] 1941,32682484,"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.","BACKGROUND Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. METHODS In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m 2 (20 mg/m 2 ; days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients ≥75 years old starting on the second week). The primary endpoint was progression-free survival assessed by intention to treat. Adverse events were assessed in the safety population. This trial (NCT03158688) is registered with ClinicalTrials.gov, and is active but not recruiting. FINDINGS Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled. After median follow-up of approximately 17 months, median progression-free survival was not reached in the KdD group versus 15·8 months in the Kd group (hazard ratio 0·63; 95% CI 0·46-0·85; p=0·0027). Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks). Grade 3 or higher adverse events were reported in 253 (82%) patients in the KdD group and 113 (74%) patients in the Kd group. The frequency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]). INTERPRETATION KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile. FUNDING Amgen.",2020,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"['patients with relapsed or refractory multiple myeloma', '466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma', 'Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled', 'patients with relapsed or refractory multiple myeloma (CANDOR']","['dexamethasone', 'carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd', 'carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone', 'Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone']","['frequency of adverse events leading to treatment discontinuation', 'median progression-free survival', 'Adverse events', 'progression-free survival', 'Median treatment duration', 'efficacy and safety', 'Grade 3 or higher adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0003980', 'cui_str': 'Asia'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C2001856', 'cui_str': 'carfilzomib'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}]",466.0,0.106024,Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks).,"[{'ForeName': 'Meletios', 'Initials': 'M', 'LastName': 'Dimopoulos', 'Affiliation': 'National and Kapodistrian University Athens School of Medicine, Athens, Greece.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Quach', 'Affiliation': ""University of Melbourne, St Vincent's Hospital, Fitzroy, VIC, Australia.""}, {'ForeName': 'Maria-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'Cancer Research Center, University Hospital Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.'}, {'ForeName': 'Ola', 'Initials': 'O', 'LastName': 'Landgren', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Leleu', 'Affiliation': 'Department of Hematology, CHU la Miletrie and Inserm CIC 1402, Poitiers, France.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Siegel', 'Affiliation': 'John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Weisel', 'Affiliation': 'University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Zandra', 'Initials': 'Z', 'LastName': 'Klippel', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Zahlten-Kumeli', 'Affiliation': 'Amgen, Thousand Oaks, CA, USA.'}, {'ForeName': 'Saad Z', 'Initials': 'SZ', 'LastName': 'Usmani', 'Affiliation': 'Atrium Health, Charlotte, NC, USA. Electronic address: usmani@atriumhealth.org.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)30734-0'] 1942,32690063,"Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial.","BACKGROUND In the past two decades, the massive scale-up of long-lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) has led to significant reductions in malaria mortality and morbidity. Nonetheless, the malaria burden remains high, and a dozen countries in Africa show a trend of increasing malaria incidence over the past several years. This underscores the need to improve the effectiveness of interventions by optimizing first-line intervention tools and integrating newly approved products into control programs. Because transmission settings and vector ecologies vary from place to place, malaria interventions should be adapted and readapted over time in response to evolving malaria risks. An adaptive approach based on local malaria epidemiology and vector ecology may lead to significant reductions in malaria incidence and transmission risk. METHODS/DESIGN This study will use a longitudinal block-cluster sequential multiple assignment randomized trial (SMART) design with longitudinal outcome measures for a period of 3 years to develop an adaptive intervention for malaria control in western Kenya, the first adaptive trial for malaria control. The primary outcome is clinical malaria incidence rate. This will be a two-stage trial with 36 clusters for the initial trial. At the beginning of stage 1, all clusters will be randomized with equal probability to either LLIN, piperonyl butoxide-treated LLIN (PBO Nets), or LLIN + IRS by block randomization based on their respective malaria risks. Intervention effectiveness will be evaluated with 12 months of follow-up monitoring. At the end of the 12-month follow-up, clusters will be assessed for ""response"" versus ""non-response"" to PBO Nets or LLIN + IRS based on the change in clinical malaria incidence rate and a pre-defined threshold value of cost-effectiveness set by the Ministry of Health. At the beginning of stage 2, if an intervention was effective in stage 1, then the intervention will be continued. Non-responders to stage 1 PBO Net treatment will be randomized equally to either PBO Nets + LSM (larval source management) or an intervention determined by an enhanced reinforcement learning method. Similarly, non-responders to stage 1 LLIN + IRS treatment will be randomized equally to either LLIN + IRS + LSM or PBO Nets + IRS. There will be an 18-month evaluation follow-up period for stage 2 interventions. We will monitor indoor and outdoor vector abundance using light traps. Clinical malaria will be monitored through active case surveillance. Cost-effectiveness of the interventions will be assessed using Q-learning. DISCUSSION This novel adaptive intervention strategy will optimize existing malaria vector control tools while allowing for the integration of new control products and approaches in the future to find the most cost-effective malaria control strategies in different settings. Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. TRIAL REGISTRATION US National Institutes of Health, study ID NCT04182126 . Registered on 26 November 2019.",2020,"Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. ","['malaria control in western Kenya, the first adaptive trial for malaria control']","['LLIN, piperonyl butoxide-treated LLIN (PBO Nets), or LLIN + IRS', 'LLIN + IRS + LSM or PBO Nets + IRS', 'Adaptive interventions', 'PBO Nets + LSM (larval source management) or an intervention determined by an enhanced reinforcement learning method']","['malaria mortality and morbidity', 'Intervention effectiveness', 'Cost-effectiveness', 'clinical malaria incidence rate']","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0031962', 'cui_str': 'Piperonyl Butoxide'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0449416', 'cui_str': 'Source'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0035007', 'cui_str': 'Psychological Reinforcement'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0024530', 'cui_str': 'Malaria'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C4543807', 'cui_str': 'Clinical malaria'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",,0.093538,"Given the urgent global need for optimization of malaria control tools, this study can have far-reaching implications for malaria control and elimination. ","[{'ForeName': 'Guofa', 'Initials': 'G', 'LastName': 'Zhou', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA.'}, {'ForeName': 'Ming-Chieh', 'Initials': 'MC', 'LastName': 'Lee', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA.'}, {'ForeName': 'Harrysone E', 'Initials': 'HE', 'LastName': 'Atieli', 'Affiliation': 'Department of Public Health, Maseno University, Kisumu, Kenya.'}, {'ForeName': 'John I', 'Initials': 'JI', 'LastName': 'Githure', 'Affiliation': 'Department of Public Health, Maseno University, Kisumu, Kenya.'}, {'ForeName': 'Andrew K', 'Initials': 'AK', 'LastName': 'Githeko', 'Affiliation': 'Kenya Medical Research Institute, Kisumu, Kenya.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Kazura', 'Affiliation': 'Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Guiyun', 'Initials': 'G', 'LastName': 'Yan', 'Affiliation': 'Program in Public Health, University of California, Irvine, CA, USA. guiyuny@uci.edu.'}]",Trials,['10.1186/s13063-020-04573-y'] 1943,32696820,"An intensive education program for caregivers ameliorates anxiety, depression, and quality of life in patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis who underwent cortico-amygdalohippocampectomy.","This study aimed to investigate the effect of a caregiver intensive education program (CIEP) on anxiety, depression, and quality of life (QOL) in patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis (TLE-MTS) who underwent cortico-amygdalohippocampectomy (CAH). Ninety patients with drug-resistant TLE-MTS who underwent CAH and their caregivers were recruited and randomly allocated to the CIEP group or control group as 1:1 ratio. Caregivers received the CIEP program or routine guidance/education (control group). Anxiety/depression and QOL in patients at month (M)0, M1, M3, and M6 were assessed by the Hospital Anxiety and Depression Scale (HADS) scale and the QOL in Epilepsy Inventory-31 (QOLIE-31), respectively. Treatment efficacy at M6 was assessed by Engel classification. The HADS-anxiety score at M3 (P=0.049) and M6 (P=0.028), HADS-anxiety score change (M6-M0) (P=0.001), percentage of anxiety patients at M6 (P=0.025), and anxiety severity at M6 (P=0.011) were all decreased in the CIEP group compared with the control group. The HADS-depression score at M6 (P=0.033) and HADS-depression score change (M6-M0) (P=0.022) were reduced, while percentage of depression patients at M6 (P=0.099) and depression severity at M6 (P=0.553) showed no difference in the CIEP group compared with the control group. The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group. In conclusion, CIEP for caregivers contributed to the recovery of anxiety and depression as well as the improvement of QOL in patients with drug-resistant TLE-MTS who underwent CAH.",2020,The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group.,"['patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis who underwent cortico-amygdalohippocampectomy', 'patients with drug-resistant temporal lobe epilepsy and mesial temporal sclerosis (TLE-MTS) who underwent cortico-amygdalohippocampectomy (CAH', 'Ninety patients with drug-resistant TLE-MTS who underwent CAH and their caregivers']","['CIEP program or routine guidance/education (control group', 'caregiver intensive education program (CIEP', 'CIEP', 'intensive education program']","['QOLIE-31 score at M6', 'HADS-anxiety score change (M6-M0', 'percentage of anxiety patients at M6', 'HADS-depression score change (M6-M0', 'recovery of anxiety and depression', 'Anxiety/depression and QOL', 'HADS-depression score', 'anxiety severity at M6', 'QOLIE-31 score change (M6-M0', 'Hospital Anxiety and Depression Scale (HADS) scale and the QOL in Epilepsy Inventory-31 (QOLIE-31', 'HADS-anxiety score at M3', 'anxiety, depression, and quality of life (QOL', 'depression severity', 'anxiety, depression, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0014556', 'cui_str': 'Temporal lobe epilepsy'}, {'cui': 'C2062593', 'cui_str': 'Mesial temporal sclerosis'}, {'cui': 'C2921031', 'cui_str': 'Amygdalohippocampectomy'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}]","[{'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",90.0,0.0319824,The QOLIE-31 score at M6 (P=0.043) and QOLIE-31 score change (M6-M0) (P=0.010) were both elevated in the CIEP group compared with the control group.,"[{'ForeName': 'Yuena', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Dongyu', 'Initials': 'D', 'LastName': 'Hou', 'Affiliation': 'Department of Orthopedics, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Xiaohua', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Qiu', 'Affiliation': 'Department of Endocrinology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Jianxia', 'Initials': 'J', 'LastName': 'Xin', 'Affiliation': 'Department of Neurosurgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Zhirong', 'Initials': 'Z', 'LastName': 'Yan', 'Affiliation': 'Department of Orthopedics, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Sun', 'Affiliation': 'Department of Nursing, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.'}]",Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,['10.1590/1414-431x20209000'] 1944,32692747,"Polygenic risk score for obesity and the quality, quantity, and timing of workplace food purchases: A secondary analysis from the ChooseWell 365 randomized trial.","BACKGROUND The influence of genetic risk for obesity on food choice behaviors is unknown and may be in the causal pathway between genetic risk and weight gain. The aim of this study was to examine associations between genetic risk for obesity and food choice behaviors using objectively assessed workplace food purchases. METHODS AND FINDINGS This study is a secondary analysis of baseline data collected prior to the start of the ""ChooseWell 365"" health-promotion intervention randomized control trial. Participants were employees of a large hospital in Boston, MA, who enrolled in the study between September 2016 and February 2018. Cafeteria sales data, collected retrospectively for 3 months prior to enrollment, were used to track the quantity (number of items per 3 months) and timing (median time of day) of purchases, and participant surveys provided self-reported behaviors, including skipping meals and preparing meals at home. A previously validated Healthy Purchasing Score was calculated using the cafeteria traffic-light labeling system (i.e., green = healthy, yellow = less healthy, red = unhealthy) to estimate the healthfulness (quality) of employees' purchases (range, 0%-100% healthy). DNA was extracted and genotyped from blood samples. A body mass index (BMI) genome-wide polygenic score (BMIGPS) was generated by summing BMI-increasing risk alleles across the genome. Additionally, 3 polygenic risk scores (PRSs) were generated with 97 BMI variants previously identified at the genome-wide significance level (P < 5 × 10-8): (1) BMI97 (97 loci), (2) BMICNS (54 loci near genes related to central nervous system [CNS]), and (3) BMInon-CNS (43 loci not related to CNS). Multivariable linear and logistic regression tested associations of genetic risk score quartiles with workplace purchases, adjusted for age, sex, seasonality, and population structure. Associations were considered significant at P < 0.05. In 397 participants, mean age was 44.9 years, and 80.9% were female. Higher genetic risk scores were associated with higher BMI. The highest quartile of BMIGPS was associated with lower Healthy Purchasing Score (-4.8 percentage points [95% CI -8.6 to -1.0]; P = 0.02), higher quantity of food purchases (14.4 more items [95% CI -0.1 to 29.0]; P = 0.03), later time of breakfast purchases (15.0 minutes later [95% CI 1.5-28.5]; P = 0.03), and lower likelihood of preparing dinner at home (Q4 odds ratio [OR] = 0.3 [95% CI 0.1-0.9]; P = 0.03) relative to the lowest BMIGPS quartile. Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home. A limitation of this study is our data come from a relatively small sample of healthy working adults of European ancestry who volunteered to enroll in a health-promotion study, which may limit generalizability. CONCLUSIONS In this study, genetic risk for obesity was associated with the quality, quantity, and timing of objectively measured workplace food purchases. These findings suggest that genetic risk for obesity may influence eating behaviors that contribute to weight and could be targeted in personalized workplace wellness programs in the future. TRIAL REGISTRATION Clinicaltrials.gov NCT02660086.",2020,"Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home.","['healthy working adults of European ancestry who volunteered to enroll in a health-promotion study', 'Participants were employees of a large hospital in Boston, MA, who enrolled in the study between September 2016 and February 2018', '397 participants, mean age was 44.9 years, and 80.9% were female']",[],"['higher quantity of food purchases', 'skipping breakfast', 'A body mass index (BMI) genome-wide polygenic score (BMIGPS', 'highest BMInon-CNS quartile', 'Polygenic risk score for obesity and the quality, quantity, and timing of workplace food purchases', '3 polygenic risk scores (PRSs', 'Higher genetic risk scores', 'later time of breakfast purchases', 'Healthy Purchasing Score']","[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0560435', 'cui_str': 'Does skip'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",,0.112173,"Compared with the lowest quartile, the highest BMICNS quartile was associated with fewer items purchased (P = 0.04), and the highest BMInon-CNS quartile was associated with purchasing breakfast at a later time (P = 0.01), skipping breakfast (P = 0.03), and not preparing breakfast (P = 0.04) or lunch (P = 0.01) at home.","[{'ForeName': 'Hassan S', 'Initials': 'HS', 'LastName': 'Dashti', 'Affiliation': 'Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Marie-France', 'Initials': 'MF', 'LastName': 'Hivert', 'Affiliation': 'Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Douglas E', 'Initials': 'DE', 'LastName': 'Levy', 'Affiliation': 'Mongan Institute Health Policy Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'McCurley', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Richa', 'Initials': 'R', 'LastName': 'Saxena', 'Affiliation': 'Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Thorndike', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.'}]",PLoS medicine,['10.1371/journal.pmed.1003219'] 1945,32692751,Effect of supplemental nutrition in pregnancy on offspring's risk of cardiovascular disease in young adulthood: Long-term follow-up of a cluster trial from India.,"BACKGROUND Undernutrition during intrauterine life and early childhood is hypothesised to increase the risk of cardiovascular disease (Developmental Origins of Health and Disease Hypothesis), but experimental evidence from humans is limited. This hypothesis has major implications for control of the cardiovascular disease epidemic in South Asia (home to a quarter of world's population), where a quarter of newborns have low birth weight. We investigated whether, in an area with prevalent undernutrition, supplemental nutrition offered to pregnant women and their offspring below the age of 6 years was associated with a lower risk of cardiovascular disease in the offspring when they were young adults. METHODS AND FINDINGS The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990). Protein-calorie food supplement was offered daily to pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years in the 15 intervention villages, but not in the 14 control villages. A total of 1,826 participants (949 from the intervention villages and 877 from the control villages, representing 70% of the cohort) at a mean age of 21.6 years (62% males) were examined between 2009 and 2012. The mean body mass index (BMI) of the participants was 20 kg/m2 and the mean systolic blood pressure was 115 mm Hg. The age, sex, socioeconomic position, and urbanisation-adjusted effects of intervention (beta coefficients and 95% confidence intervals) on outcomes were as follows: carotid intima-media thickness, 0.01 mm (-0.01 to 0.03), p = 0.36; arterial stiffness (augmentation index), -1.1% (-2.5 to 0.3), p = 0.097; systolic blood pressure, 0.5 mm Hg (-0.6 to 1.6), p = 0.36; BMI, -0.13 kg/m2 (-0.75 to 0.09), p = 0.093; low-density lipoprotein (LDL) cholesterol, 0.06 mmol/L (-0.07 to 0.2), p = 0.37; and fasting insulin (log), -0.06 mU/L (-0.19 to 0.07), p = 0.43. The limitations of this study include nonrandomised allocation of intervention and lack of data on compliance, and potential for selection bias due to incomplete follow-up. CONCLUSIONS Our results showed that in an area with prevalent undernutrition, protein-calorie food supplements offered to pregnant women and their offspring below the age of 6 years were not associated with lower levels of cardiovascular risk factors among offspring when they were young adults. Our findings, coupled with evidence from other intervention studies to date, suggest that policy makers should attach limited value to cardiovascular health benefits of maternal and child protein-calorie food supplementation programmes.",2020,"The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990).","['pregnant women and their offspring below the age of 6 years was associated with a lower risk of cardiovascular disease in the offspring when they were young adults', 'young adulthood', '1,826 participants (949 from the intervention villages and 877 from the control villages, representing 70% of the cohort) at a mean age of 21.6 years (62% males) were examined between 2009 and 2012', 'pregnant and lactating women (2.09 MJ energy and 20-25 g protein) and their offspring (1.25 MJ energy and 8-10 g protein) until the age of six years in the 15 intervention villages, but not in the 14 control villages', '29 villages near Hyderabad, India (1987-1990']","['supplemental nutrition', 'Protein-calorie food supplement']","['mean systolic blood pressure', 'mean body mass index (BMI', 'cardiovascular risk factors', 'arterial stiffness (augmentation index', 'fasting insulin', 'systolic blood pressure', 'low-density lipoprotein (LDL) cholesterol']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C1720477', 'cui_str': 'When'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0456638', 'cui_str': '25G'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C4517497', 'cui_str': '1.25'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C1720302', 'cui_str': 'Until'}, {'cui': 'C0233535', 'cui_str': 'Butting'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0456591', 'cui_str': '1987'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439259', 'cui_str': 'kcal'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}]",1826.0,0.0584498,"The Hyderabad Nutrition Trial was a community-based nonrandomised controlled intervention trial conducted in 29 villages near Hyderabad, India (1987-1990).","[{'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Kinra', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gregson', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Poornima', 'Initials': 'P', 'LastName': 'Prabhakaran', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Vipin', 'Initials': 'V', 'LastName': 'Gupta', 'Affiliation': 'Department of Anthropology, University of Delhi, Delhi, India.'}, {'ForeName': 'Gagandeep Kaur', 'Initials': 'GK', 'LastName': 'Walia', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Santhi', 'Initials': 'S', 'LastName': 'Bhogadi', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Aastha', 'Initials': 'A', 'LastName': 'Aggarwal', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'Poppy Alice Carson', 'Initials': 'PAC', 'LastName': 'Mallinson', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Bharati', 'Initials': 'B', 'LastName': 'Kulkarni', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Dorairaj', 'Initials': 'D', 'LastName': 'Prabhakaran', 'Affiliation': 'Public Health Foundation of India, Delhi, India.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Davey Smith', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.'}, {'ForeName': 'K V', 'Initials': 'KV', 'LastName': 'Radha Krishna', 'Affiliation': 'National Institute of Nutrition, Hyderabad, India.'}, {'ForeName': 'Shah', 'Initials': 'S', 'LastName': 'Ebrahim', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Kuper', 'Affiliation': 'Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Yoav', 'Initials': 'Y', 'LastName': 'Ben-Shlomo', 'Affiliation': 'Population Health Sciences, University of Bristol, Bristol, United Kingdom.'}]",PLoS medicine,['10.1371/journal.pmed.1003183'] 1946,32698151,The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome.,"Arginine vasopressin (AVP) was suggested to contribute to cardiovascular risk and type 2 diabetes in patients with metabolic syndrome. The proinflammatory cytokine interleukin (IL)-1 is able to induce AVP secretion and plays a causal role in cardiovascular mortality and type 2 diabetes. We investigated in two studies whether copeptin levels - the surrogate marker for AVP - are regulated by IL-1-mediated chronic inflammation in patients with metabolic syndrome. Study A was a prospective, interventional, single-arm study (2014-2016). Study B was a randomized, placebo-controlled, double-blind study (2016-2017). n = 73 (Study A) and n = 66 (Study B) adult patients with metabolic syndrome were treated with 100 mg anakinra or placebo (only in study B) twice daily for 1 day (study A) and 28 days (study B). Fasting blood samples were drawn at day 1, 7, and 28 of treatment for measurement of serum copeptin. Patients with chronic low-grade inflammation (C-reactive protein levels ≥2 mg/L) and BMI >35 kg/m2 had higher baseline copeptin levels (7.7 (IQR 4.9-11.9) vs 5.8 (IQR 3.9-9.3) pmol/L, Pinflamm = 0.009; 7.8 (IQR 5.4-11.7) vs 4.9 (IQR 3.7-9.8) pmol/L, PBMI = 0.008). Copeptin levels did not change either in the anakinra or in the placebo group and remained stable throughout the treatment (P = 0.44). Subgroup analyses did not reveal effect modifications. Therefore, we conclude that, although IL-1-mediated inflammation is associated with increased circulating copeptin levels, antagonizing IL-1 does not significantly alter copeptin levels in patients with metabolic syndrome.",2020,Copeptin levels did not change neither in the anakinra nor in the placebo group and remained stable throughout the treatment (p=0.44).,"['patients with metabolic syndrome', 'n=73 (Study A) and', 'Patients with chronic low-grade inflammation (C-reactive protein levels ≥2', 'n=66 (Study B) adult patients with metabolic syndrome']","['Arginine vasopressin (AVP', '100 mg anakinra or placebo', 'placebo']","['Copeptin levels', 'Fasting blood samples', 'baseline copeptin levels', 'copeptin levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0003779', 'cui_str': 'Argipressin'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0245109', 'cui_str': 'anakinra'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0056279', 'cui_str': 'copeptins'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",,0.131798,Copeptin levels did not change neither in the anakinra nor in the placebo group and remained stable throughout the treatment (p=0.44).,"[{'ForeName': 'Milica', 'Initials': 'M', 'LastName': 'Popovic', 'Affiliation': 'Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Fahim', 'Initials': 'F', 'LastName': 'Ebrahimi', 'Affiliation': 'Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Sandrine Andrea', 'Initials': 'SA', 'LastName': 'Urwyler', 'Affiliation': 'Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Marc Yves', 'Initials': 'MY', 'LastName': 'Donath', 'Affiliation': 'Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Christ-Crain', 'Affiliation': 'Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.'}]",Endocrine connections,['10.1530/EC-20-0197'] 1947,32698159,"Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.","OBJECTIVE Combining conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA) is a novel orally-administered menopausal therapy. We investigated the effect of CE/BZA on insulin sensitivity, energy metabolism, and serum metabolome in postmenopausal women with obesity. DESIGN Randomized, double-blind, crossover pilot trial with washout was conducted at Pennington Biomedical Research Center. Eight postmenopausal women (age 50-60 y, BMI 30-40 kg/m2) were randomized to 8 weeks CE/BZA or placebo. Primary outcome was insulin sensitivity (hyperinsulinemic-euglycemic clamp). Secondary outcomes included body composition (DXA); resting metabolic rate (RMR); substrate oxidation (indirect calorimetry); ectopic lipids (1H-MRS); fat cell size, adipose and skeletal muscle gene expression (biopsies); serum inflammatory markers; and serum metabolome (LC/MS). RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo. CE/BZA increased serum high-density lipoprotein (HDL)-cholesterol. CE/BZA also increased serum diacylglycerol (DAG) and triacylglycerol (TAG) species containing long-chain saturated, mono- and polyunsaturated fatty acids (FAs), and decreased long-chain acylcarnitines, possibly reflecting increased hepatic de novo FA synthesis and esterification into TAGs for export into very low-density lipoproteins, as well as decreased FA oxidation, respectively (p<0.05). CE/BZA increased serum phosphatidylcholines, phosphatidylethanolamines, ceramides, and sphingomyelins, possibly reflecting the increase in serum lipoproteins (p<0.05). CONCLUSIONS A short treatment of obese postmenopausal women with CE/BZA does not alter insulin action or ectopic fat but increases serum markers of hepatic de novo lipogenesis and TAG production.",2020,"RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo.","['obese postmenopausal women', 'postmenopausal women with obesity', 'Eight postmenopausal women (age 50-60 y, BMI 30-40 kg/m2', 'obese postmenopausal women with']","['CE/BZA or placebo', 'conjugated estrogens (CE) with the selective estrogen receptor modulator bazedoxifene (BZA', 'CE/BZA', 'conjugated estrogens and bazedoxifene', 'placebo']","['serum phosphatidylcholines, phosphatidylethanolamines, ceramides, and sphingomyelins, possibly reflecting the increase in serum lipoproteins (p<0.05', 'RMR', 'glucose, energy and lipid metabolism', 'body composition (DXA); resting metabolic rate (RMR); substrate oxidation (indirect calorimetry); ectopic lipids (1H-MRS); fat cell size, adipose and skeletal muscle gene expression (biopsies); serum inflammatory markers; and serum metabolome (LC/MS', 'insulin sensitivity (hyperinsulinemic-euglycemic clamp', 'insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation', 'serum high-density lipoprotein (HDL)-cholesterol', 'insulin sensitivity, energy metabolism, and serum metabolome', 'serum diacylglycerol (DAG) and triacylglycerol']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0014938', 'cui_str': 'Estrogens, Conjugated (USP)'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0732611', 'cui_str': 'Selective estrogen receptor modulator'}, {'cui': 'C2346970', 'cui_str': 'bazedoxifene'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C1959616', 'cui_str': 'Lecithin'}, {'cui': 'C0031618', 'cui_str': 'Phosphatidylethanolamines'}, {'cui': 'C0007745', 'cui_str': 'Ceramides'}, {'cui': 'C0037906', 'cui_str': 'Sphingomyelin'}, {'cui': 'C2362652', 'cui_str': 'Possible diagnosis'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0023820', 'cui_str': 'Lipoprotein'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0006781', 'cui_str': 'Indirect calorimetry'}, {'cui': 'C0340464', 'cui_str': 'Ectopic beats'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C3850002', 'cui_str': '1H-MRS'}, {'cui': 'C0206131', 'cui_str': 'Adipocyte'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C2350399', 'cui_str': 'Metabolome'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0079318', 'cui_str': 'Euglycaemic Clamp'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0012262', 'cui_str': 'Diacylglycerols'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",,0.199062,"RESULTS CE/BZA treatment produced no detectable effect on insulin sensitivity, body composition, ectopic fat, fat cell size, or substrate oxidation, but resulted in a non-significant increase in RMR (basal: p=0.06; high-dose clamp: p=0.08) compared to placebo.","[{'ForeName': 'Kara L', 'Initials': 'KL', 'LastName': 'Marlatt', 'Affiliation': 'K Marlatt, Clinical Science, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Lovre', 'Affiliation': 'D Lovre, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'R Beyl, Biostatistics, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Chandra R', 'Initials': 'CR', 'LastName': 'Tate', 'Affiliation': 'C Tate, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}, {'ForeName': 'Evelyn K', 'Initials': 'EK', 'LastName': 'Hayes', 'Affiliation': 'E Hayes, Baton Rouge General Hospital, Baton Rouge General, Baton Rouge, United States.'}, {'ForeName': 'Charles F', 'Initials': 'CF', 'LastName': 'Burant', 'Affiliation': 'C Burant, Molecular and Integrative Physiology, University of Michigan, Ann Arbor, United States.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ravussin', 'Affiliation': 'E Ravussin, Clinical Science, Pennington Biomedical Research Center, Baton Rouge, United States.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Mauvais-Jarvis', 'Affiliation': 'F Mauvais-Jarvis, Endocrinology, Tulane University Health Sciences Center, New Orleans, United States.'}]",European journal of endocrinology,['10.1530/EJE-20-0619'] 1948,32700191,"Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.","BACKGROUND Felbinac trometamol, an anti-inflammatory and analgesic drug, has been used to treat immediate postoperative pain. OBJECTIVE The aim of this study was to evaluate the safety, tolerability, and pharmacokinetics of single or multiple intravenous infusions of felbinac trometamol in healthy Chinese volunteers. METHODS A total of 56 healthy subjects were enrolled in a single-ascending dose study (11.78-377.00 mg), meanwhile 36 subjects were enrolled in a multiple-ascending dose study (47.13-188.50 mg). Safety endpoints included treatment-emergent adverse events, vital signs, electrocardiograms, and laboratory parameters. Pharmacokinetic endpoints included exposure of subjects to felblinac and metabolites of the drug in plasma, urine, and feces. RESULTS Felblinac time to maximum plasma concentration was obtained at 0.5 h, corresponding to the end of the infusion. Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses. After intravenous infusions of multiple doses three times (30 min each time) per day, the accumulation ratio of felblinac and its metabolite based on the area under the curve had a range of 1.34-1.45 and 1.60-1.87, respectively, across cohorts. After administration of the fourth dose, the plasma concentration of both felblinac and its metabolites was maintained at a steady state. Felbinac trometamol was well tolerated. Neither treatment-emergent adverse event frequency nor severity increased with increasing felbinac trometamol dose. CONCLUSIONS Felbinac trometamol was well tolerated in our study. Based on the dose range in this study, 94.25 mg is the recommended target dose for a phase II study. CLINICAL TRIAL REGISTRATION CTR20170496 and CTR20180896. The dates of registration are 2017-06-19 and 2018-07-02 ( https://www.chinadrugtrials.org.cn/ ).",2020,"Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses.","['56 healthy subjects were enrolled in a single-ascending dose study (11.78-377.00\xa0mg), meanwhile 36 subjects were enrolled in a multiple-ascending dose study (47.13-188.50\xa0mg', 'healthy Chinese volunteers', 'Healthy Chinese Volunteers']","['Felbinac trometamol', 'Placebo', 'Intravenous Felbinac Trometamol', 'felbinac trometamol']","['tolerated', 'treatment-emergent adverse events, vital signs, electrocardiograms, and laboratory parameters', 'safety, tolerability, and pharmacokinetics', 'Maximum plasma concentration and area under the curve', 'Felblinac time to maximum plasma concentration', 'exposure of subjects to felblinac and metabolites of the drug in plasma, urine, and feces', 'plasma concentration of both felblinac and its metabolites', 'accumulation ratio of felblinac and its metabolite', 'Pharmacokinetics, Safety, and Tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0877860', 'cui_str': 'Felbinac'}, {'cui': 'C0041175', 'cui_str': 'Tromethamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",56.0,0.0956679,"Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses.","[{'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Cuiyun', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Jixuan', 'Initials': 'J', 'LastName': 'Sun', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xiaoxue', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xiaojiao', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China.'}, {'ForeName': 'Xuedong', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, 050035, Hebei, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Shijiazhuang Yiling Pharmaceutical Co., Ltd, Shijiazhuang, 050035, Hebei, China.'}, {'ForeName': 'Yanhua', 'Initials': 'Y', 'LastName': 'Ding', 'Affiliation': 'Department of Phase I Clinical Trial Unit, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. dingyanhua2003@126.com.'}]",CNS drugs,['10.1007/s40263-020-00739-z'] 1949,32701129,Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.,"Importance The role of locoregional radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma (mNPC) is unclear. Objective To investigate the efficacy and safety of locoregional radiotherapy in de novo mNPC. Design, Setting, and Participants Patients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of cisplatin and fluorouracil chemotherapy, were enrolled. Eligible patients were randomly assigned (1:1) to receive either chemotherapy plus radiotherapy or chemotherapy alone. Overall, 126 of 173 patients screened were eligible to the study, and randomized to chemotherapy plus radiotherapy (n = 63) or chemotherapy alone (n = 63). Median (IQR) follow-up duration was 26.7 (17.2-33.5) months. Interventions The chemotherapy regimens were fluorouracil continuous intravenous infusion at 5 g/m2 over 120 hours and 100 mg/m2 intravenous cisplatin on day 1, administered every 3 weeks for 6 cycles. Patients assigned to the chemotherapy plus radiotherapy group received intensity-modulated radiotherapy (IMRT) after chemotherapy. Main Outcomes and Measures The primary end point of the study was overall survival (OS). The secondary end point was progression-free survival (PFS) and safety. Results Overall, 126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years). The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group. The study met its primary end point of improved OS (stratified hazard ratio [HR], 0.42; 95% CI, 0.23-0.77; P = .004) in favor of chemotherapy plus radiotherapy. Progression-free survival was also improved in the chemotherapy plus radiotherapy group compared with the chemotherapy-alone group (stratified HR, 0.36; 95% CI, 0.23-0.57). No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms. The frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia was 8.1%, 33.9%, and 6.5%, respectively, in the chemotherapy plus radiotherapy group. The frequency of late severe grade 3 or higher hearing loss and trismus was 5.2% and 3.4%, respectively, in the chemotherapy plus radiotherapy group. Conclusions and Relevance In this randomized clinical trial, radiotherapy added to chemotherapy significantly improved OS in chemotherapy-sensitive patients with mNPC. Trial Registration ClinicalTrials.gov Identifier: NCT02111460.",2020,"The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group.","['De Novo Metastatic Nasopharyngeal Carcinoma', '126 patients were enrolled (105 men [83.3%] and 21 women [16.7%]; median [IQR] age, 46 [39-52] years', 'Participants\n\n\nPatients with biopsy-proven mNPC, who demonstrated complete or partial response (RECIST v1.1) following 3 cycles of', 'chemotherapy-sensitive patients with mNPC', '126 of 173 patients screened were eligible to the study, and randomized to', 'patients with de novo metastatic nasopharyngeal carcinoma (mNPC', 'Eligible patients']","['locoregional radiotherapy', 'chemotherapy plus radiotherapy', 'chemotherapy plus radiotherapy or chemotherapy alone', 'radiotherapy', 'Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone', 'cisplatin', 'cisplatin and fluorouracil chemotherapy', 'chemotherapy alone', 'intensity-modulated radiotherapy (IMRT) after chemotherapy', 'chemotherapy']","['progression-free survival (PFS) and safety', 'Efficacy and Safety', '24-month OS', 'OS', 'frequency of acute grade 3 or higher dermatitis, mucositis, and xerostomia', 'Median (IQR) follow-up duration', 'frequency of late severe grade 3 or higher hearing loss and trismus', 'overall survival (OS', 'Progression-free survival', 'acute hematological or gastrointestinal toxic effects']","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517590', 'cui_str': '16.7'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011603', 'cui_str': 'Dermatitis'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0041105', 'cui_str': 'Trismus'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}]",126.0,0.264303,"The 24-month OS was 76.4% (95% CI, 64.4%-88.4%) in the chemotherapy plus radiotherapy group, compared with 54.5% (95% CI, 41.0%-68.0%) in the chemotherapy-alone group.","[{'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'You', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'You-Ping', 'Initials': 'YP', 'LastName': 'Liu', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Pei-Yu', 'Initials': 'PY', 'LastName': 'Huang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Xiong', 'Initials': 'X', 'LastName': 'Zou', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Sun', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yu-Xiang', 'Initials': 'YX', 'LastName': 'He', 'Affiliation': 'Department of Radiation Oncology, Xiangya Hospital of Central South University, Changsha, China.'}, {'ForeName': 'Yi-Shan', 'Initials': 'YS', 'LastName': 'Wu', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Guo-Ping', 'Initials': 'GP', 'LastName': 'Shen', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Hong-Dan', 'Initials': 'HD', 'LastName': 'Zhang', 'Affiliation': ""Department of Radiation Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Science, Guangzhou 510080, China.""}, {'ForeName': 'Chong-Yang', 'Initials': 'CY', 'LastName': 'Duan', 'Affiliation': 'Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, 510515, China.'}, {'ForeName': 'Sze Huey', 'Initials': 'SH', 'LastName': 'Tan', 'Affiliation': 'Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore.'}, {'ForeName': 'Jing-Yu', 'Initials': 'JY', 'LastName': 'Cao', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ji-Bin', 'Initials': 'JB', 'LastName': 'Li', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Yu-Long', 'Initials': 'YL', 'LastName': 'Xie', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yi-Nuan', 'Initials': 'YN', 'LastName': 'Zhang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Zhi-Qiang', 'Initials': 'ZQ', 'LastName': 'Wang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Yang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Lin', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Rou', 'Initials': 'R', 'LastName': 'Jiang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Meng-Xia', 'Initials': 'MX', 'LastName': 'Zhang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yi-Jun', 'Initials': 'YJ', 'LastName': 'Hua', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Lin-Quan', 'Initials': 'LQ', 'LastName': 'Tang', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ai-Hua', 'Initials': 'AH', 'LastName': 'Zhuang', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Qiu-Yan', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Hao-Yuan', 'Initials': 'HY', 'LastName': 'Mo', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Hai-Qiang', 'Initials': 'HQ', 'LastName': 'Mai', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ling', 'Affiliation': 'Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China.'}, {'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': 'Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.'}, {'ForeName': 'Melvin Lee Kiang', 'Initials': 'MLK', 'LastName': 'Chua', 'Affiliation': 'Division of Radiation Oncology and Medical Sciences, National Cancer Centre Singapore, 169610, Singapore.'}, {'ForeName': 'Ming-Yuan', 'Initials': 'MY', 'LastName': 'Chen', 'Affiliation': 'Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.'}]",JAMA oncology,['10.1001/jamaoncol.2020.1808'] 1950,32697957,"Effects of long-term concurrent training to failure or not in muscle power output, muscle quality and cardiometabolic risk factors in older men: A secondary analysis of a randomized clinical trial.","This study investigated the effects of concurrent training performed either with repetitions to failure or not to failure in muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat in older men. This is an ancillary analysis of a randomized controlled trial. 36 older men (mean age ± SD; 67.1 ± 5.1 years) were randomized into three groups: one performing repetitions to failure (RFG, n = 13), another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n = 12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n = 11). The training was performed twice a week for 20 weeks at intensities ranging from 65 to 80% of maximal strength. In each session, the individuals started with strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill. The primary endpoint was change from baseline to post-20 wk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill. All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001). In addition, all groups significantly decreased visceral fat thickness (ranging from -11 to -21%) (P < .001), and significantly increased VO 2peak (ranging from 4 to 8%) (P < .01), with no differences between groups. No changes were observed in the MQ outcomes. Concurrent training performed using repetitions to failure or not to failure promoted similar gains in the muscle power output, aerobic capacity, and visceral fat in healthy older men.",2020,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"['36 older men (mean age\u202f±\u202fSD; 67.1\u202f±\u202f5.1\u202fyears', 'healthy older men', 'older men']","['another performing repetitions not to failure and 50% of the repetitions of the RFG (NFG, n\u202f=\u202f12), and third performing repetitions not to failure with equal training volume of the RFG (ENFG, n', 'strengthening exercises and then performed aerobic exercise (i.e., walking) on a treadmill']","['VO 2peak', 'visceral fat thickness', 'MQ outcomes', 'muscle power output, muscle quality and cardiometabolic risk factors', 'change from baseline to post-20\u202fwk of absolute and relative muscle power output during squat and countermovement jump, ultrasound measurements for MQ using quadriceps echo intensity, and visceral fat thickness, as well as their VO 2peak through a maximal incremental test on a treadmill', 'jump height', 'muscle power, muscle quality (MQ), peak oxygen uptake (VO 2peak ), and visceral fat']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332273', 'cui_str': 'Through'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",36.0,0.0273081,All training groups improved similarly and significantly jump height (ranging from 9 to 16%) and all their muscle power outcomes (mean change ranging from 2 to 7%) (P < .001).,"[{'ForeName': 'Juliana L', 'Initials': 'JL', 'LastName': 'Teodoro', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Larissa X N', 'Initials': 'LXN', 'LastName': 'da Silva', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Bruno M', 'Initials': 'BM', 'LastName': 'Baroni', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Grazioli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Lopez', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Carolina G', 'Initials': 'CG', 'LastName': 'Fritsch', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Régis', 'Initials': 'R', 'LastName': 'Radaelli', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Mikel L', 'Initials': 'ML', 'LastName': 'Saez de Asteasu', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; Navarrabiomed, Complejo Hospitalario de Navarra (CHN)-Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.'}, {'ForeName': 'Martim', 'Initials': 'M', 'LastName': 'Bottaro', 'Affiliation': 'College of Physical Education, University of Brasilia, Brasília, DF, Brazil.'}, {'ForeName': 'Juliano', 'Initials': 'J', 'LastName': 'Farinha', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Ronei S', 'Initials': 'RS', 'LastName': 'Pinto', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.'}, {'ForeName': 'Eduardo L', 'Initials': 'EL', 'LastName': 'Cadore', 'Affiliation': 'School of Physical Education, Physiotherapy and Dance, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. Electronic address: edu.cadore@ufrgs.br.'}]",Experimental gerontology,['10.1016/j.exger.2020.111023'] 1951,32690730,Identifying significant contributors for smoking cessation among male prisoners in Australia: results from a randomised clinical trial.,"INTRODUCTION In Australia, an estimated 90% of those entering prison are current tobacco smokers and three-quarters of current prisoners are tobacco smokers. AIMS To identify factors and their relative contributions to smoking cessation among male prisoners. METHODS A total of 425 male tobacco smokers with a median age of 32 years in Australian prisons. The primary outcome was continuous abstinence at 3, 6 and 12 months. We measured various sociodemographic characteristics, drug use, psychological distress and the mental and physical health status of the participants. Multivariate logistic regression models and population attributable risks (PAR%) were used to identify the significant factors and their contributions to smoking cessation rates. RESULTS The median age of participants was 32 years (IQR 25-41 years). High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). CONCLUSION Our study suggests that not using drugs and being in good mental/physical health are the important contributors to continuous abstinence among prisoners. Thus, effective smoking cessation programmes require a multicomponent approach that includes addressing drug problems and mental health functioning. TRIAL REGISTRATION NUMBER 12606000229572.",2020,"High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). ","['425 male tobacco smokers with a median age of 32 years in Australian prisons', 'male prisoners', 'male prisoners in Australia']",[],"['psychological distress, good mental health scores and better physical health', 'continuous abstinence', 'High smoking cessation rates', 'various sociodemographic characteristics, drug use, psychological distress and the mental and physical health status']","[{'cui': 'C3844105', 'cui_str': '425'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033168', 'cui_str': 'Prisons'}, {'cui': 'C0033167', 'cui_str': 'Prisoners'}, {'cui': 'C0004340', 'cui_str': 'Australia'}]",[],"[{'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0018759', 'cui_str': 'Health status'}]",425.0,0.0559297,"High smoking cessation rates were collectively associated with not using drugs, lower psychological distress, good mental health scores and better physical health (PAR%: 93%, 98% and 88% at 3, 6 and 12 months). ","[{'ForeName': 'Handan', 'Initials': 'H', 'LastName': 'Wand', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Richmond', 'Affiliation': 'School of Public Health and Community Medicine, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Armita', 'Initials': 'A', 'LastName': 'Adily', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Le', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kay', 'Initials': 'K', 'LastName': 'Wilhelm', 'Affiliation': 'School of Psychiatry, University of New South Wales, Sydney, Australila.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Butler', 'Affiliation': 'Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia tbutler@kirby.unsw.edu.au.'}]",BMJ open,['10.1136/bmjopen-2019-034046'] 1952,32692386,Effect of Levothyroxine on Left Ventricular Ejection Fraction in Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction: A Randomized Clinical Trial.,"Importance Thyroid hormones play a key role in modulating myocardial contractility. Subclinical hypothyroidism in patients with acute myocardial infarction is associated with poor prognosis. Objective To evaluate the effect of levothyroxine treatment on left ventricular function in patients with acute myocardial infarction and subclinical hypothyroidism. Design, Setting, and Participants A double-blind, randomized clinical trial conducted in 6 hospitals in the United Kingdom. Patients with acute myocardial infarction including ST-segment elevation and non-ST-segment elevation were recruited between February 2015 and December 2016, with the last participant being followed up in December 2017. Interventions Levothyroxine treatment (n = 46) commencing at 25 µg titrated to aim for serum thyrotropin levels between 0.4 and 2.5 mU/L or identical placebo (n = 49), both provided in capsule form, once daily for 52 weeks. Main Outcomes and Measures The primary outcome measure was left ventricular ejection fraction at 52 weeks, assessed by magnetic resonance imaging, adjusted for age, sex, type of acute myocardial infarction, affected coronary artery territory, and baseline left ventricular ejection fraction. Secondary measures were left ventricular volumes, infarct size (assessed in a subgroup [n = 60]), adverse events, and patient-reported outcome measures of health status, health-related quality of life, and depression. Results Among the 95 participants randomized, the mean (SD) age was 63.5 (9.5) years, 72 (76.6%) were men, and 65 (69.1%) had ST-segment elevation myocardial infarction. The median serum thyrotropin level was 5.7 mU/L (interquartile range, 4.8-7.3 mU/L) and the mean (SD) free thyroxine level was 1.14 (0.16) ng/dL. The primary outcome measurements at 52 weeks were available in 85 patients (89.5%). The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%]; P = .37). None of the 6 secondary outcomes showed a significant difference between the levothyroxine and placebo treatment groups. There were 15 (33.3%) and 18 (36.7%) cardiovascular adverse events in the levothyroxine and placebo groups, respectively. Conclusions and Relevance In this preliminary study involving patients with subclinical hypothyroidism and acute myocardial infarction, treatment with levothyroxine, compared with placebo, did not significantly improve left ventricular ejection fraction after 52 weeks. These findings do not support treatment of subclinical hypothyroidism in patients with acute myocardial infarction. Trial Registration isrctn.org Identifier: http://www.isrctn.com/ISRCTN52505169.",2020,"The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%];","['patients with acute myocardial infarction', '95 participants randomized, the mean (SD) age was 63.5 (9.5) years, 72 (76.6%) were men, and 65 (69.1%) had ST-segment elevation myocardial infarction', '6 hospitals in the United Kingdom', 'Patients with acute myocardial infarction including ST-segment elevation and non-ST-segment elevation were recruited between February 2015 and December 2016, with the last participant being followed up in December 2017', 'patients with acute myocardial infarction and subclinical hypothyroidism', 'patients with subclinical hypothyroidism and acute myocardial infarction, treatment with', 'Patients With Subclinical Hypothyroidism and Acute Myocardial Infarction']","['Levothyroxine', 'L or identical placebo', 'levothyroxine', 'placebo']","['left ventricular volumes, infarct size (assessed in a subgroup [n\u2009=\u200960]), adverse events, and patient-reported outcome measures of health status, health-related quality of life, and depression', 'median serum thyrotropin level', 'Left Ventricular Ejection Fraction', 'left ventricular function', 'Subclinical hypothyroidism', 'serum thyrotropin levels', 'mean (SD) free thyroxine level', 'mean left ventricular ejection fraction', 'cardiovascular adverse events', 'left ventricular ejection fraction', 'left ventricular ejection fraction at 52 weeks, assessed by magnetic resonance imaging, adjusted for age, sex, type of acute myocardial infarction, affected coronary artery territory, and baseline left ventricular ejection fraction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0040165', 'cui_str': 'levothyroxine'}, {'cui': 'C0205280', 'cui_str': 'Identical'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0021308', 'cui_str': 'Infarct'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0271790', 'cui_str': 'Subclinical hypothyroidism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0202225', 'cui_str': 'T4 free measurement'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205042', 'cui_str': 'Coronary artery structure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",95.0,0.618371,"The mean left ventricular ejection fraction at baseline and at 52 weeks was 51.3% and 53.8%, respectively, in the levothyroxine group compared with 54.0% and 56.1%, respectively, in the placebo group (adjusted difference in groups, 0.76% [95% CI, -0.93% to 2.46%];","[{'ForeName': 'Avais', 'Initials': 'A', 'LastName': 'Jabbar', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Lorna', 'Initials': 'L', 'LastName': 'Ingoe', 'Affiliation': 'Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Junejo', 'Affiliation': 'Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Carey', 'Affiliation': 'Department of Endocrinology and Cardiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Addison', 'Affiliation': 'Department of Endocrinology, Gateshead Health NHS Foundation Trust, Gateshead, United Kingdom.'}, {'ForeName': 'Honey', 'Initials': 'H', 'LastName': 'Thomas', 'Affiliation': 'Department of Cardiology, Northumbria Healthcare NHS Foundation Trust, Cramlington, United Kingdom.'}, {'ForeName': 'Jehill D', 'Initials': 'JD', 'LastName': 'Parikh', 'Affiliation': 'Newcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Austin', 'Affiliation': 'Department of Cardiology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom.'}, {'ForeName': 'Kieren G', 'Initials': 'KG', 'LastName': 'Hollingsworth', 'Affiliation': 'Newcastle Magnetic Resonance Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Deborah D', 'Initials': 'DD', 'LastName': 'Stocken', 'Affiliation': 'Leeds Institute of Clinical Trials Research, University of Leeds, United Kingdom.'}, {'ForeName': 'Simon H S', 'Initials': 'SHS', 'LastName': 'Pearce', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Greenwood', 'Affiliation': 'Leeds University and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.'}, {'ForeName': 'Azfar', 'Initials': 'A', 'LastName': 'Zaman', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}, {'ForeName': 'Salman', 'Initials': 'S', 'LastName': 'Razvi', 'Affiliation': 'Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.'}]",JAMA,['10.1001/jama.2020.9389'] 1953,32692425,Adolescent cannabis and tobacco use are associated with opioid use in young adulthood-12-year longitudinal study in an urban cohort.,"BACKGROUND AND AIMS Cannabis, tobacco and alcohol use are prevalent among youth in the United States and may be risk factors for opioid use. The current study aimed at investigating associations between developmental trajectories of cannabis, tobacco and alcohol use in adolescence and opioid use in young adulthood in an urban cohort over the span of 12 years. DESIGN Cohort study of adolescents originally recruited for a randomized prevention trial with yearly assessments into young adulthood. SETTING Nine urban elementary schools in Baltimore, MD in the United States. PARTICIPANTS Participants (n = 583, 86.8% African American, 54.7% male) were originally recruited as first grade students. MEASUREMENTS Cannabis, tobacco and alcohol use were assessed annually from ages 14-18 years and opioid use from ages 19-26. Socio-demographics were assessed at age 6. Intervention status was also randomly assigned at age 6. Gender, race, free/reduced-priced lunch and intervention status were included as covariates in individual and sequential growth models. FINDINGS There were significant positive associations between the cannabis use intercept at age 14 and the opioid use intercept at age 19 (beta = 1.43; P = 0.028), the tobacco use intercept at age 14 and the opioid use intercept at age 19 (beta = 0.82; P = 0.042). Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. CONCLUSIONS Cannabis and tobacco use in early adolescence may be risk factors for opioid use in young adulthood among African Americans living in urban areas.",2020,"Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. ","['young adulthood in an urban cohort over the span of 12\xa0years', 'young adulthood-12-year longitudinal study in an urban cohort', 'Nine urban elementary schools in Baltimore, MD in the United States', 'African Americans living in urban areas', 'Participants (n\xa0=\xa0583, 86.8% African American, 54.7% male) were originally recruited as first grade students', 'Cohort study of adolescents originally recruited for a randomized prevention trial with yearly assessments into young adulthood']",[],"['Socio-demographics', 'Cannabis, tobacco and alcohol use']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C5191355', 'cui_str': '583'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",[],"[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]",,0.0279499,"Specifically, more frequent use of cannabis or tobacco at age 14 was associated with more frequent use of opioids at age 19. ","[{'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Thrul', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Jill A', 'Initials': 'JA', 'LastName': 'Rabinowitz', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Beth A', 'Initials': 'BA', 'LastName': 'Reboussin', 'Affiliation': 'Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC,, USA.'}, {'ForeName': 'Brion S', 'Initials': 'BS', 'LastName': 'Maher', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Nicholas S', 'Initials': 'NS', 'LastName': 'Ialongo', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.15183'] 1954,32696695,Impact of Self-Monitoring of Blood Pressure on Processes of Hypertension Care and Long-Term Blood Pressure Control.,"Background Self-monitoring of blood pressure (SMBP) improves blood pressure (BP) outcomes at 12-months, but information is lacking on how SMBP affects hypertension care processes and longer-term BP outcomes. Methods and Results We pooled individual participant data from 4 randomized clinical trials of SMBP in the United Kingdom (combined n=2590) with varying intensities of support. Multivariable random effects regression was used to estimate the probability of antihypertensive intensification at 12 months for usual care versus SMBP. Using these data, we simulated 5-year BP control rates using a validated mathematical model. Trial participants were mostly older adults (mean age 66.6 years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0 mm Hg. Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2). Over 5 years, we estimated 33.4% BP control (<140/90 mm Hg) with usual care (95% uncertainty interval 27.7%-39.4%). One year of SMBP with feedback to patient or provider alone achieved 33.9% (28.3%-40.3%) BP control and SMBP with telemonitoring or self-management 39.0% (33.1%-45.2%) over 5 years. If SMBP interventions and associated BP control processes were extended to 5 years, BP control increased to 52.4% (45.4%-59.8 %) and 72.1% (66.5%-77.6%), respectively. Conclusions One year of SMBP plus telemonitoring or self-management increases the likelihood of antihypertensive intensification and could improve BP control rates at 5 years; continuing SMBP for 5 years could further improve BP control.",2020,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","['Trial participants were mostly older adults (mean age 66.6\xa0years, SD 9.5), male (53.9%), and predominantly white (95.6%); mean baseline BP was 151.8/85.0\xa0mm\xa0Hg']","[' Self-monitoring of blood pressure (SMBP', 'SMBP', 'Self-Monitoring of Blood Pressure']","['5-year BP control rates', 'BP control processes', 'BP control rates', 'BP control', 'blood pressure (BP) outcomes']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517899', 'cui_str': '9.5'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.0699419,"Compared with usual care, the likelihood of antihypertensive intensification increased with both SMBP with feedback to patient or provider alone (odds ratio 1.8, 95% CI 1.2-2.6) and with telemonitoring or self-management (3.3, 2.5-4.2).","[{'ForeName': 'Kelsey B', 'Initials': 'KB', 'LastName': 'Bryant', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Sheppard', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Ruiz-Negrón', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Kronish', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Valy', 'Initials': 'V', 'LastName': 'Fontil', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Jordan B', 'Initials': 'JB', 'LastName': 'King', 'Affiliation': 'University of Utah Salt Lake City UT.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Pletcher', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Bibbins-Domingo', 'Affiliation': 'University of California at San Francisco CA.'}, {'ForeName': 'Andrew E', 'Initials': 'AE', 'LastName': 'Moran', 'Affiliation': 'Columbia University New York NY.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McManus', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences University of Oxford United Kingdom.'}, {'ForeName': 'Brandon K', 'Initials': 'BK', 'LastName': 'Bellows', 'Affiliation': 'Columbia University New York NY.'}]",Journal of the American Heart Association,['10.1161/JAHA.120.016174'] 1955,32693177,Enhancing employer coverage of smoking cessation treatment: A randomized trial of the Partners in Helping You Quit (PiHQ) program.,"The workplace is a key channel for delivering tobacco cessation treatment to a population. Employers can provide workplace-based programs and/or financial incentives such as health insurance benefits that cover the cost of treatment accessed outside the workplace. Little is known about the effect of combining these strategies. We tested the benefit of adding a workplace cessation program, Partners in Helping You Quit (PiHQ), to comprehensive health insurance coverage of smoking cessation medications by Partners HealthCare, a large Boston-based healthcare delivery system. PiHQ offers biweekly telephone-based behavioral support, additional automated calls, and medication care coordination for 3 months then monthly telephone monitoring for 9 months. In a pragmatic randomized trial, employees who smoked were informed about the insurance benefit, then randomly assigned (2:1) to PiHQ or to active referral to a free 3-month phone-based community program, Massachusetts Quitline (QL). Outcomes were assessed at 3, 6, and 12 months. During 2015-2018, 106 smokers (n = 73 PiHQ, n = 33 QL) enrolled (64% female; 75% white, 21% black; mean age 46 years, mean cigarettes/day = 13). More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95% CI, 1.05-10.60). Among participants using behavioral support, PiHQ participants completed more scheduled calls and rated counseling helpfulness higher than did QL participants. These results suggest that employers can enhance the impact of providing comprehensive health insurance coverage of smoking cessation medication by adding a phone-based worksite cessation program.",2020,"More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95%CI, 1.05-10.60).","['During 2015-2018, 106 smokers (n\u202f=\u202f73 PiHQ, n\u202f=\u202f33 QL) enrolled (64% female; 75% white, 21% black; mean age 46\u202fyears, mean cigarettes/day\u202f=\u202f13']","['PiHQ or to active referral to a free 3-month phone-based community program, Massachusetts Quitline (QL', 'workplace cessation program, Partners in Helping You Quit (PiHQ']","['scheduled calls and rated counseling helpfulness', '7-day cigarette abstinence']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0024874', 'cui_str': 'Massachusetts'}, {'cui': 'C0162579', 'cui_str': 'Work environment'}]","[{'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}]",,0.052749,"More PiHQ than QL participants made a quit attempt by 3 months (82 vs. 61%, p < .02) and achieved the primary outcome, verified past 7-day cigarette abstinence at 6 months (31 vs. 12%, odds ratio 3.34, 95%CI, 1.05-10.60).","[{'ForeName': 'Nancy A', 'Initials': 'NA', 'LastName': 'Rigotti', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America. Electronic address: Rigotti.Nancy@mgh.harvard.edu.'}, {'ForeName': 'Jennifer H K', 'Initials': 'JHK', 'LastName': 'Kelley', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Regan', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Inman', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Kalkhoran', 'Affiliation': 'Tobacco Research and Treatment Center, Division of General Internal Medicine and Mongan Institute, Massachusetts General Hospital, Boston, MA, United States of America; Department of Medicine, Harvard Medical School, Boston, MA, United States of America.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Flaster', 'Affiliation': ""Department of Medicine, Harvard Medical School, Boston, MA, United States of America; Population Health, Partners HealthCare, Inc., Boston, MA, United States of America; Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, United States of America.""}, {'ForeName': 'Sreekanth K', 'Initials': 'SK', 'LastName': 'Chaguturu', 'Affiliation': 'Department of Medicine, Harvard Medical School, Boston, MA, United States of America; Population Health, Partners HealthCare, Inc., Boston, MA, United States of America.'}]",Preventive medicine,['10.1016/j.ypmed.2020.106216'] 1956,32693197,"Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.","Vitamin K antagonists are the only approved oral anticoagulants for long-term prophylaxis against valve thrombosis and thromboembolism in patients with a mechanical heart valve. Despite the proven efficacy and safety of anticoagulation with the oral direct factor Xa inhibitor apixaban compared with warfarin in high-risk populations including subjects with atrial fibrillation or with venous thromboembolism, it remains unknown whether patients with a mechanical heart valve can be safely managed with apixaban. The On-X Aortic Heart Valve and On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft may have lower rates of valve thrombosis and thromboembolism than conventional bileaflet and tilting disc valves due its unique pyrolytic carbon composition and flared inlet design. DESIGN: PROACT Xa is a randomized, multicenter, open-label, active-controlled trial comparing apixaban with warfarin in patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft. The study will randomize approximately 1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3 months prior. Patients will be randomized 1:1 to receiving apixaban 5 mg twice daily or warfarin with a target international normalized ratio of 2.0-3.0. The last randomized participant will be followed for at least 2 years. The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding. Assuming the primary outcome occurs in warfarin-anticoagulated patients at a rate of 1.75%/patient-year, the study has more than 90% power to assess noninferiority of apixaban treatment with an absolute noninferiority margin of 1.75%/patient-year. A second co-primary analysis is to compare the hazard rate for the apixaban arm to twice the objective performance criterion for thromboembolism and valve thrombosis, that is, 3.4%/patient-year. SUMMARY: PROACT Xa will determine whether patients with an On-X Aortic Heart Valve can be anticoagulated with apixaban as an alternative to warfarin.",2020,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","['patients with an On-X Aortic Heart Valve or On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft', 'subjects with atrial fibrillation or with venous thromboembolism', '1,000 patients from approximately 60 sites in North America who underwent aortic valve replacement at least 3\u202fmonths prior', 'patients with a mechanical heart valve', 'patients with a mechanical On-X Aortic Heart Valve']","['PROACT Xa', 'apixaban 5\u202fmg twice daily or warfarin', 'apixaban versus warfarin', 'apixaban', 'warfarin', 'Vitamin K antagonists', 'apixaban with warfarin']","['efficacy and safety', 'composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding', 'hazard rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0018825', 'cui_str': 'Cardiac valve prosthesis'}, {'cui': 'C0205385', 'cui_str': 'Ascending'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0018829', 'cui_str': 'Prosthetic heart'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}]","[{'cui': 'C3530472', 'cui_str': 'apixaban 5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",,0.0697264,"The primary efficacy outcome is the composite of valve thrombosis and valve-related thromboembolism, and the primary safety outcome is major bleeding.","[{'ForeName': 'Oliver K', 'Initials': 'OK', 'LastName': 'Jawitz', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC; Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address: oliver.jawitz@duke.edu.'}, {'ForeName': 'Tracy Y', 'Initials': 'TY', 'LastName': 'Wang', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Alma', 'Initials': 'A', 'LastName': 'Chavez', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Brittanny', 'Initials': 'B', 'LastName': 'Boyer', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'Hwasoon', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Anstrom', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Richard C', 'Initials': 'RC', 'LastName': 'Becker', 'Affiliation': 'Division of Cardiovascular Health and Diseases, University of Cincinnati Heart, Lung & Vascular Institute, Cincinnati, OH.'}, {'ForeName': 'Eugene', 'Initials': 'E', 'LastName': 'Blackstone', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ruel', 'Affiliation': 'Division of Cardiac Surgery, University of Ottawa, Ottawa, Ontario, Canada.'}, {'ForeName': 'Vinod H', 'Initials': 'VH', 'LastName': 'Thourani', 'Affiliation': 'Piedmont Heart Institute, Atlanta, GA.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Puskas', 'Affiliation': ""Department of Cardiovascular Surgery, Mount Sinai St. Luke's, New York, NY.""}, {'ForeName': 'Marc W', 'Initials': 'MW', 'LastName': 'Gerdisch', 'Affiliation': 'Department of Cardiothoracic Surgery, Franciscan Hospital, Indianapolis, IN.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Johnston', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Capps', 'Affiliation': 'CryoLife, Inc., Kennesaw, GA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Alexander', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Lars G', 'Initials': 'LG', 'LastName': 'Svensson', 'Affiliation': 'Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH.'}]",American heart journal,['10.1016/j.ahj.2020.06.014'] 1957,32699126,Barriers and facilitators to uptake and retention of inner-city ethnically diverse women in a postnatal weight management intervention: a mixed-methods process evaluation within a feasibility trial in England.,"OBJECTIVES To understand the barriers and facilitators to uptake and retention of postnatal women randomised to a commercial group weight management intervention using the COM-B (capability, opportunity, motivation and behaviour) behaviour change model. DESIGN Concurrent mixed-methods (qualitative dominant) process evaluation nested within a feasibility randomised controlled trial, comprising questionnaires and interviews at 6 and 12 months postbirth. SETTING One National Health Service maternity unit in an inner city area in the south of England. PARTICIPANTS 98 postnatal women with body mass indices>25 kg/m 2 (overweight/obese) at pregnancy commencement. INTERVENTION Twelve-week Slimming World (SW) commercial group weight management programme, commencing anytime from 8 to 16 weeks postnatally. PRIMARY AND SECONDARY OUTCOME MEASURES Data regarding uptake and retention from questionnaires and interviews conducted 6 and 12 months postbirth analysed thematically and mapped to the COM-B model. RESULTS Barriers to SW uptake mostly concerned opportunity issues (eg, lack of time or childcare support) though some women also lacked motivation, not feeling that weight reduction was a priority, and a few cited capability issues such as lacking confidence. Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle. In addition, barriers relating to beliefs and expectations about the SW programme were identified, including concerns regarding compatibility with breastfeeding and importance of exercise. Women's understanding of the SW approach, and capability to implement into their lifestyles, appeared related to level of attendance (dose-response effect). CONCLUSIONS Uptake and retention in commercial weight management programmes may be enhanced by applying behaviour change techniques to address the barriers impacting on women's perceived capability, motivation and opportunity to participate. TRIAL REGISTRATION NUMBER ISRCTN39186148.",2020,"Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle.","['One National Health Service maternity unit in an inner city area in the south of England', '98 postnatal women with body mass indices>25 kg/m 2 (overweight/obese) at pregnancy commencement']","['postnatal weight management intervention', 'commercial group weight management intervention']","['COM-B (capability, opportunity, motivation and behaviour) behaviour change model']","[{'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0557849', 'cui_str': 'Inner city'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0920298', 'cui_str': 'Weight maintenance regimen'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009490', 'cui_str': 'Comoros islands'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]",98.0,0.0765417,"Weight loss aspirations were also a key factor explaining retention, as were social opportunity issues, particularly in relation to factors such as the extent of group identity and relationship with the group consultant; and physical opportunity such as perceived support from and fit with family lifestyle.","[{'ForeName': 'Cath', 'Initials': 'C', 'LastName': 'Taylor', 'Affiliation': 'School of Health Sciences, University of Surrey, Guildford, UK cath.taylor@surrey.ac.uk.'}, {'ForeName': 'Vanita', 'Initials': 'V', 'LastName': 'Bhavnani', 'Affiliation': 'National Childbirth Trust, London, UK.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Zasada', 'Affiliation': 'School of Health Sciences, University of Surrey, Guildford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ussher', 'Affiliation': ""Population Health Research Institute, St George's University of London, London, UK.""}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Bick', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, West Midlands, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-034747'] 1958,32699128,Early Parenting Intervention - Biobehavioral Outcomes in infants with Neurodevelopmental Disabilities (EPI-BOND): study protocol for an Italian multicentre randomised controlled trial.,"INTRODUCTION Neurodevelopmental disability (ND) represents an adverse condition for infants' socio-emotional and behavioural development as well as for caregiving (eg, parental sensitivity) and mother-infant interaction. Adverse exposures are associated with altered neuroendocrine hormones concentrations (eg, oxytocin and cortisol) and epigenetic regulation (eg, methylation of stress-related genes), which in turn may contribute to less-than-optimal mother-infant interaction. Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children. The present multi-centric and longitudinal randomised controlled trial aims to assess if and to which extent early VFI could benefit both infants and mothers in terms of behavioural outcomes as well as neuroendocrine and epigenetic regulation. METHODS AND ANALYSIS Dyads will be randomly assigned to the video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls). Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy. A multi-layer approach to intervention effects will include videotapes of mother-infant interaction, maternal reports as well as saliva samples for hormones concentrations and target-gene methylation analysis (eg, BDNF , NR3C1 , OXTR and SCL6A4 ) that will be obtained at each of the four assessment sessions: T 0 , baseline; T 1 , post-intervention; T 2 , short-term follow-up (3 month); T 3 , long-term follow-up (6 month). Primary effectiveness measures will be infant socio-emotional behaviour and maternal sensitivity. Neuroendocrine hormones concentrations and DNA methylation status of target genes will be secondary outcomes. Feasibility, moderation and confounding variables will be measured and controlled between the two groups. ETHICS AND DISSEMINATION Ethics approval has been obtained in all three participating units. Results of the main trial and each of the secondary endpoints will be submitted for publication in peer-reviewed journals and international conferences. TRIAL REGISTRATION NUMBER NCT03853564; Pre-results.",2020,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","['children', 'Infants with ND aged 3 to 18 months will be recruited from three major child neuropsychiatric units in northern Italy', 'infants with Neurodevelopmental Disabilities (EPI-BOND']","[""video-feedback Intervention Group or Control Group ('dummy' intervention: telephone calls""]",['infant socio-emotional behaviour and maternal sensitivity'],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",,0.22658,"Parental sensitivity is a protective factor for childrens' development and early parental interventions (eg, video-feedback intervention) can promote parental caregiving and better developmental outcomes in children.","[{'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Montirosso', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy rosario.montirosso@lanostrafamiglia.it.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Rosa', 'Affiliation': '0-3 Center for the at-Risk Infant, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Giorda', 'Affiliation': 'Biology Lab, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Fazzi', 'Affiliation': 'Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Orcesi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cavallini', 'Affiliation': 'Neuropsychiatry and Neurorehabilitation Unit, Scientific Institute IRCCS E. Medea, Bosisio Parini, Lecco, Italy.'}, {'ForeName': 'Livio', 'Initials': 'L', 'LastName': 'Provenzi', 'Affiliation': 'Child Neurology and Psychiatry Unit, IRCCS Mondino Foundation, Pavia, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-035249'] 1959,32699167,Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.,"INTRODUCTION There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiveness. Advances in biosensor technologies made it possible to continuously monitor physiological parameters using wearable biosensors with a variety of form factors. OBJECTIVE To explore the potential of using wearable biosensors to continuously monitor multidimensional physiological parameters for early detection of COVID-19 clinical progression. METHOD This randomised controlled open-labelled trial will involve 200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong. Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period. In addition to fever and symptom surveillance in the control group, subjects in the intervention group will wear wearable biosensors on their arms to continuously monitor skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities. These physiological parameters will be transferred in real time to a smartphone application called Biovitals Sentinel. These data will then be processed using a cloud-based multivariate physiology analytics engine called Biovitals to detect subtle physiological changes. The results will be displayed on a web-based dashboard for clinicians' review. The primary outcome is the time to diagnosis of COVID-19. ETHICS AND DISSEMINATION Ethical approval has been obtained from institutional review boards at the study sites. Results will be published in peer-reviewed journals.",2020,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"['200-1000 asymptomatic subjects with close COVID-19 contact under mandatory quarantine at designated facilities in Hong Kong', 'quarantine subjects']","['Artificial intelligence mobile health platform', 'remote monitoring strategy (intervention group) or standard strategy (control group']","['skin temperature, respiratory rate, blood pressure, pulse rate, blood oxygen saturation and daily activities', 'time to diagnosis of COVID-19', 'fever and symptom surveillance']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0003916', 'cui_str': 'Computer Reasoning'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}]",1000.0,0.0878264,Subjects will be randomised to receive a remote monitoring strategy (intervention group) or standard strategy (control group) in a 1:1 ratio during the 14 day-quarantine period.,"[{'ForeName': 'Chun Ka', 'Initials': 'CK', 'LastName': 'Wong', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Deborah Tip Yin', 'Initials': 'DTY', 'LastName': 'Ho', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Anthony Raymond', 'Initials': 'AR', 'LastName': 'Tam', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Mi', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Yuk Ming', 'Initials': 'YM', 'LastName': 'Lau', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Milky Oi Yan', 'Initials': 'MOY', 'LastName': 'Tang', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}, {'ForeName': 'Raymond Cheuk Fung', 'Initials': 'RCF', 'LastName': 'Tong', 'Affiliation': 'Harmony Medical Inc, Hong Kong, Hong Kong.'}, {'ForeName': 'Kuldeep Singh', 'Initials': 'KS', 'LastName': 'Rajput', 'Affiliation': 'Biofourmis, Singapore.'}, {'ForeName': 'Gengbo', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Soon Chee', 'Initials': 'SC', 'LastName': 'Chan', 'Affiliation': 'Research and Development, Biofourmis, Singapore.'}, {'ForeName': 'Chung Wah', 'Initials': 'CW', 'LastName': 'Siu', 'Affiliation': 'Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong cwdsiu@hku.hk.'}, {'ForeName': 'Ivan Fan Ngai', 'Initials': 'IFN', 'LastName': 'Hung', 'Affiliation': 'Division of Infectious Diseases, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.'}]",BMJ open,['10.1136/bmjopen-2020-038555'] 1960,32701140,Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.,"Importance Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective To evaluate the association of pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS) in subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents. Design, Setting, and Participants Multicenter platform trial of women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger. Women with tumors that were ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score were excluded. Participants were adaptively randomized to one of several different investigational regimens or control therapy within molecular subtypes from March 2010 through 2016. The analysis included participants with follow-up data available as of February 26, 2019. Interventions Standard-of-care neoadjuvant therapy consisting of taxane treatment with or without (as control) one of several investigational agents or combinations followed by doxorubicin and cyclophosphamide. Main Outcomes and Measures Pathologic complete response and 3-year EFS and DRFS. Results Of the 950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR. Three-year EFS and DRFS for patients who achieved pCR were both 95%. Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. Conclusions and Relevance The 3-year outcomes from the I-SPY2 trial show that, regardless of subtype and/or treatment regimen, including 9 novel therapeutic combinations, achieving pCR after neoadjuvant therapy implies approximately an 80% reduction in recurrence rate. The goal of the I-SPY2 trial is to rapidly identify investigational therapies that may improve pCR when validated in a phase 3 confirmatory trial. Whether pCR is a validated surrogate in the sense that a therapy that improves pCR rate can be assumed to also improve long-term outcome requires further study. Trial Registration ClinicalTrials.gov Identifier: NCT01042379.",2020,"Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. ","['participants with follow-up data available as of February 26, 2019', 'Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer', 'women with operable clinical stage 2 or 3 breast cancer with no prior surgery or systemic therapy for breast cancer; primary tumors were 2.5 cm or larger', 'subpopulations of women with high-risk operable breast cancer treated with standard therapy or one of several novel agents', '950 participants (median [range] age, 49 [23-77] years), 330 (34.7%) achieved pCR']","['taxane', 'pCR', 'doxorubicin and cyclophosphamide', 'control therapy']","['Hazard ratios', 'ERBB2 negative/hormone receptor (HR) positive with low 70-gene assay score', 'pCR with event-free survival (EFS) and pCR with distant recurrence-free survival (DRFS', 'pCR rate', 'Measures\n\n\nPathologic complete response and 3-year EFS and DRFS', 'recurrence rate']","[{'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205188', 'cui_str': 'Operable'}, {'cui': 'C0205563', 'cui_str': 'Clinical stage finding'}, {'cui': 'C0455610', 'cui_str': 'H/O: surgery'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1257890', 'cui_str': 'Group'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C4708800', 'cui_str': '950'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517719', 'cui_str': '330'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}]","[{'cui': 'C0215136', 'cui_str': 'taxane'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",,0.184284,"Hazard ratios for pCR vs non-pCR were 0.19 for EFS (95% CI, 0.12-0.31) and 0.21 for DRFS (95% CI, 0.13-0.34) and were similar across molecular subtypes, varying from 0.14 to 0.18 for EFS and 0.10 to 0.20 for DRFS. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Yee', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, Minneapolis.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'DeMichele', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Yau', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Claudine', 'Initials': 'C', 'LastName': 'Isaacs', 'Affiliation': 'Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.'}, {'ForeName': 'W Fraser', 'Initials': 'WF', 'LastName': 'Symmans', 'Affiliation': 'Department of Pathology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Kathy S', 'Initials': 'KS', 'LastName': 'Albain', 'Affiliation': 'Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Yunn-Yi', 'Initials': 'YY', 'LastName': 'Chen', 'Affiliation': 'Department of Pathology, University of California, San Francisco.'}, {'ForeName': 'Gregor', 'Initials': 'G', 'LastName': 'Krings', 'Affiliation': 'Department of Pathology, University of California, San Francisco.'}, {'ForeName': 'Shi', 'Initials': 'S', 'LastName': 'Wei', 'Affiliation': 'Department of Pathology, University of Alabama Birmingham.'}, {'ForeName': 'Shuko', 'Initials': 'S', 'LastName': 'Harada', 'Affiliation': 'Department of Pathology, University of Alabama Birmingham.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Datnow', 'Affiliation': 'Department of Pathology, University of California, San Diego.'}, {'ForeName': 'Oluwole', 'Initials': 'O', 'LastName': 'Fadare', 'Affiliation': 'Department of Pathology, University of California, San Diego.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Klein', 'Affiliation': 'Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Pambuccian', 'Affiliation': 'Department of Pathology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Beiyun', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Kathi', 'Initials': 'K', 'LastName': 'Adamson', 'Affiliation': 'Department of Pathology, Swedish Cancer Institute, Seattle, Washington.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Sams', 'Affiliation': 'Department of Pathology, University of Colorado, Denver.'}, {'ForeName': 'Paulette', 'Initials': 'P', 'LastName': 'Mhawech-Fauceglia', 'Affiliation': 'Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Magliocco', 'Affiliation': 'Department of Pathology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Feldman', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Rendi', 'Affiliation': 'Department of Anatomic Pathology, University of Washington, Seattle.'}, {'ForeName': 'Husain', 'Initials': 'H', 'LastName': 'Sattar', 'Affiliation': 'Department of Pathology, University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Zeck', 'Affiliation': 'Department of Pathology, Georgetown University, Washington, DC.'}, {'ForeName': 'Idris T', 'Initials': 'IT', 'LastName': 'Ocal', 'Affiliation': 'Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Scottsdale, Arizona.'}, {'ForeName': 'Ossama', 'Initials': 'O', 'LastName': 'Tawfik', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of Kansas, Lawrence.'}, {'ForeName': 'Lauren Grasso', 'Initials': 'LG', 'LastName': 'LeBeau', 'Affiliation': 'Department of Pathology, University of Arizona, Tucson.'}, {'ForeName': 'Sunati', 'Initials': 'S', 'LastName': 'Sahoo', 'Affiliation': 'Department of Pathology, University of Texas Southwestern, Dallas.'}, {'ForeName': 'Tuyethoa', 'Initials': 'T', 'LastName': 'Vinh', 'Affiliation': 'Inova Pathology Institute, Inova Health System, Falls Church, Virginia.'}, {'ForeName': 'A Jo', 'Initials': 'AJ', 'LastName': 'Chien', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Forero-Torres', 'Affiliation': 'Division of Hematology and Oncology, University of Alabama Birmingham.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Stringer-Reasor', 'Affiliation': 'Division of Hematology and Oncology, University of Alabama Birmingham.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Wallace', 'Affiliation': 'Department of Surgery, University of California, San Diego.'}, {'ForeName': 'Lajos', 'Initials': 'L', 'LastName': 'Pusztai', 'Affiliation': 'Medical Oncology, Yale Cancer Center, New Haven, Connecticut.'}, {'ForeName': 'Judy C', 'Initials': 'JC', 'LastName': 'Boughey', 'Affiliation': 'Department of Surgery, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Erin D', 'Initials': 'ED', 'LastName': 'Ellis', 'Affiliation': 'Medical Oncology, Swedish Cancer Institute, Seattle, Washington.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Elias', 'Affiliation': 'Department of Medicine, University of Colorado, Denver.'}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Lu', 'Affiliation': 'Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Lang', 'Affiliation': 'Surgery, Keck School of Medicine, University of Southern California, Los Angeles.'}, {'ForeName': 'Hyo S', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Medical Oncology, Moffitt Cancer Center, Tampa, Florida.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Clark', 'Affiliation': 'Perelman School of Medicine, University of Pennsylvania, Philadelphia.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Nanda', 'Affiliation': 'Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Donald W', 'Initials': 'DW', 'LastName': 'Northfelt', 'Affiliation': 'Medical Oncology, Mayo Clinic Scottsdale, Scottsdale, Arizona.'}, {'ForeName': 'Qamar J', 'Initials': 'QJ', 'LastName': 'Khan', 'Affiliation': 'Medical Oncology, University of Kansas Medical Center, Lawrence.'}, {'ForeName': 'Rebecca K', 'Initials': 'RK', 'LastName': 'Viscusi', 'Affiliation': 'Hematology/Oncology, University of Arizona, Tucson.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Euhus', 'Affiliation': 'Department of Surgery, Johns Hopkins Medicine, Baltimore, Maryland.'}, {'ForeName': 'Kirsten K', 'Initials': 'KK', 'LastName': 'Edmiston', 'Affiliation': 'Inova Schar Cancer Institute, Fairfax, Virginia.'}, {'ForeName': 'Stephen Y', 'Initials': 'SY', 'LastName': 'Chui', 'Affiliation': 'Genentech, South San Francisco, California.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Kemmer', 'Affiliation': 'Knight Cancer Institute, Oregon Health & Science University, Portland.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Minetta C', 'Initials': 'MC', 'LastName': 'Liu', 'Affiliation': 'Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota.'}, {'ForeName': 'Olufunmilayo', 'Initials': 'O', 'LastName': 'Olopade', 'Affiliation': 'Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Leyland-Jones', 'Affiliation': 'Avera Cancer Institute, Sioux Falls, South Dakota.'}, {'ForeName': 'Debasish', 'Initials': 'D', 'LastName': 'Tripathy', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Stacy L', 'Initials': 'SL', 'LastName': 'Moulder', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Schwab', 'Affiliation': 'Medical Oncology, University of California, San Diego.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Lo', 'Affiliation': 'Medical Oncology, Loyola University Chicago Stritch School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Helsten', 'Affiliation': 'Medical Oncology, University of California, San Diego.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Beckwith', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, Minneapolis.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Haugen', 'Affiliation': 'National Breast Cancer Coalition, Washington, DC.'}, {'ForeName': 'Nola M', 'Initials': 'NM', 'LastName': 'Hylton', 'Affiliation': 'Department of Radiology and Biomedical Imaging, University of California, San Francisco.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': ""Van't Veer"", 'Affiliation': 'Department of Laboratory Medicine, University of California, San Francisco.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Perlmutter', 'Affiliation': 'Gemini Group, Ann Arbor, Michigan.'}, {'ForeName': 'Michelle E', 'Initials': 'ME', 'LastName': 'Melisko', 'Affiliation': 'Division of Hematology and Oncology, University of California, San Francisco.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Wilson', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Garry', 'Initials': 'G', 'LastName': 'Peterson', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Adam L', 'Initials': 'AL', 'LastName': 'Asare', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Meredith B', 'Initials': 'MB', 'LastName': 'Buxton', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Paoloni', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Julia L', 'Initials': 'JL', 'LastName': 'Clennell', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Gillian L', 'Initials': 'GL', 'LastName': 'Hirst', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': 'Singhrao', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Steeg', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Jeffrey B', 'Initials': 'JB', 'LastName': 'Matthews', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Smita M', 'Initials': 'SM', 'LastName': 'Asare', 'Affiliation': 'Quantum Leap Healthcare Collaborative, San Francisco, California.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Sanil', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Scott M', 'Initials': 'SM', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Esserman', 'Affiliation': 'Department of Surgery, University of California, San Francisco.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Berry', 'Affiliation': 'Berry Consultants, LLC, Austin, Texas.'}]",JAMA oncology,['10.1001/jamaoncol.2020.2535'] 1961,32697889,Improving self-management in adolescents with sickle cell disease.,"BACKGROUND Sickle cell disease (SCD) is associated with significant medical challenges that often worsen in adolescence when caregivers are beginning to transfer responsibility for disease management. Behavioral activation (BA) is an important precedent to improvements in self-management and ultimately health outcomes; however, few interventions targeting BA have been developed for the SCD population. The goal of the present study was to evaluate a technology-enhanced self-management intervention for adolescents and young adults (AYA) with SCD targeting BA domains (ie, disease knowledge, self-efficacy, motivation, and self-management skills). DESIGN/METHODS Participants were randomized to one of two study arms. SCThrive participants (N = 26) completed six weekly group sessions, an in-person booster session, and used a companion app (iManage) to record symptoms, progress on goals, and connect with other group members. Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics. All AYA completed questionnaires assessing BA at baseline and posttreatment. RESULTS Separate mixed ANOVA analyses to assess for the effects of group (SCThrive/SCHealthEd), time (baseline/posttreatment), and group × time interaction indicated that there was a clinically meaningful improvement (8-point change) in self-efficacy, with a medium effect size, P = .09, η 2  = .06, and there was statistically significant improvement in one self-management skill (tracking health), P = .001, d = .71, among SCThrive participants. CONCLUSIONS The results support the potential for a self-management intervention to improve self-efficacy in AYA with SCD. Health care providers are encouraged to target BA skills to support self-management of AYA with SCD.",2020,Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics.,"['adolescents and young adults (AYA', 'Participants', 'adolescents with sickle cell disease', 'Sickle cell disease (SCD']","['six weekly phone calls on SCD-related and general health education topics', 'technology-enhanced self-management intervention']","['Behavioral activation (BA', 'one self-management skill (tracking health', 'self-efficacy']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0002895', 'cui_str': 'Sickling disorder due to hemoglobin S'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.045265,Each SCHealthEd participant (N = 27) received six weekly phone calls on SCD-related and general health education topics.,"[{'ForeName': 'Lori E', 'Initials': 'LE', 'LastName': 'Crosby', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hood', 'Affiliation': 'Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Kidwell', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Nwankwo', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Peugh', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Strong', 'Affiliation': ""Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Quinn', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Maria T', 'Initials': 'MT', 'LastName': 'Britto', 'Affiliation': 'Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}]",Pediatric blood & cancer,['10.1002/pbc.28492'] 1962,32703200,Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.,"BACKGROUND First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects. AXEPT, an Asian phase III study, showed that modified CAPIRI+BEV [capecitabine (CAP: 1600 mg/m 2 ), irinotecan (IRI: 200 mg/m 2 ), and BEV (7.5 mg/m 2 )] was non-inferior to FOLFIRI+BEV as a second-line therapy for mCRC patients and was associated with a lower incidence of hematologic toxicities. Thus, a reduced dose of the CAP and IRI regimen in combination with oxaliplatin (OX) and BEV (CAPOXIRI+BEV) may be more feasible than FOLFOXIRI+BEV, without compromising efficacy. METHODS QUATTRO-II is an open-label, multicenter, randomized phase II study. In Step 1, the recommended doses of OX and IRI will be investigated as a safety lead-in. In Step 2, patients will be randomized to the recommended dose of either CAPOXIRI+BEV or FOLFOXIRI+BEV. Induction triplet chemotherapy plus BEV treatments will be administered for up to 4 months followed by fluoropyrimidine plus BEV maintenance. The primary endpoint is progression-free survival (PFS). The similarity in PFS between the two arms will be evaluated by observing whether the point estimate of hazard ratio (HR) for PFS falls between 0.80 and 1.25. Ensuring a 70% probability that the observed HR will be ""0.8 < HR < 1.25"" under the assumption of the true HR of 1.0, and 100 patients will be evaluated during the 3-year study period. Secondary endpoints include overall survival, overall response rate, safety, and patient reported outcome (PRO) (FACT/GOG-Ntx4). DISCUSSION Considering the lower incidence of hematologic toxicities with modified CAPIRI+BEV than with FOLFIRI+BEV, CAPOXIRI+BEV may be a promising treatment option if sufficient efficacy and lower hematologic toxicities are indicated in this study. Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. TRIAL REGISTRATION Clinicaltrials.gov NCT04097444 . Registered September 20, 2019, https://clinicaltrials.gov/ct2/show/study/NCT04097444 / Japan Registry of Clinical Trials jRCTs041190072. Registered October 9, 2019.",2020,"Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. ","['patients with metastatic colorectal cancer (mCRC', 'patients with metastatic colorectal cancer']","['CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab', 'oxaliplatin (OX) and BEV (CAPOXIRI+BEV', 'modified CAPIRI+BEV [capecitabine (CAP', 'CAPOXIRI+BEV or FOLFOXIRI+BEV', 'irinotecan', 'FOLFOXIRI plus bevacizumab (BEV']","['hematologic toxicities', 'overall survival, overall response rate, safety, and patient reported outcome (PRO', 'hazard ratio (HR) for PFS falls', 'peripheral sensory neuropathy (PSN', 'progression-free survival (PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}]","[{'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0151313', 'cui_str': 'Sensory neuropathy'}]",,0.0966627,"Additionally, a lower incidence of peripheral sensory neuropathy (PSN) reported following CAPEOX treatment compared to that after FOLFOX in ACHIEVE, an adjuvant phase III trial, suggest that CAPOXIRI+BEV can mitigate OX-induced PSN. ","[{'ForeName': 'Masaaki', 'Initials': 'M', 'LastName': 'Miyo', 'Affiliation': 'Department of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kato', 'Affiliation': 'Department of Surgery, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka, 540-0006, Japan. ken-kato@momo.so-net.ne.jp.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Yoshino', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.'}, {'ForeName': 'Takeharu', 'Initials': 'T', 'LastName': 'Yamanaka', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Bando', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Hironaga', 'Initials': 'H', 'LastName': 'Satake', 'Affiliation': 'Cancer Treatment Center, Kansai Medical University Hospital, Hirakata City, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.'}, {'ForeName': 'Hiroya', 'Initials': 'H', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa City, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Oki', 'Affiliation': 'Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Kotaka', 'Affiliation': 'Gastrointestinal cancer center, Sano Hospital, Kobe, Japan.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Oba', 'Affiliation': 'Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Yoshinori', 'Initials': 'Y', 'LastName': 'Miyata', 'Affiliation': 'Saku Central Hospital Advanced Care Center, Saku City, Japan.'}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Komatsu', 'Affiliation': 'Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan.'}, {'ForeName': 'Hideo', 'Initials': 'H', 'LastName': 'Baba', 'Affiliation': 'Department of Gastroenterological Surgery Graduate School of Medical Sciences Kumamoto University, Kumamoto, Japan.'}, {'ForeName': 'Akihito', 'Initials': 'A', 'LastName': 'Tsuji', 'Affiliation': 'Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan.'}]",BMC cancer,['10.1186/s12885-020-07186-5'] 1963,32703201,"Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study.","BACKGROUND Two antifibrotic drugs, nintedanib and pirfenidone, are available for treatment of idiopathic pulmonary fibrosis (IPF). Although efficacy and adverse events have been well studied, little is known about patient experiences with these drugs. We aimed to systematically and quantitatively evaluate patient expectations, experiences, and satisfaction with nintedanib and pirfenidone. Furthermore, we assessed which factors were associated with overall patient satisfaction with medication. METHODS Outpatients with IPF prospectively completed the Patient Experiences and Satisfaction with Medication (PESaM) questionnaire before start, and after three and 6 months of antifibrotic treatment, as part of a randomized eHealth trial (NCT03420235). The PESaM questionnaire consists of an expectation module, a validated generic module evaluating patient experiences and satisfaction concerning the effectiveness, side-effects, and ease of use of a medication, and a disease-specific module about IPF. Satisfaction was scored on a scale from - 5 (very dissatisfied) to + 5 (very satisfied). RESULTS In total, 90 patients were included, of whom 43% used nintedanib and 57% pirfenidone. After 6 months, the mean overall score for satisfaction with medication was 2.1 (SD 1.9). No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone. Perceived effectiveness of medication was rated as significantly more important than side-effects and ease of use (p = 0.001). Expectations of patients regarding effectiveness were higher than experiences after 6 months. Self-reported experience with effectiveness was the main factor associated with overall medication satisfaction. CONCLUSIONS Patient experiences and satisfaction with antifibrotic treatment were fairly positive, and similar for nintedanib and pirfenidone. Systematic evaluation of patient expectations, experiences, and satisfaction with medication could enhance shared-decision making and guide drug treatment decisions in the future. TRIAL REGISTRATION NCT03420235 .",2020,"No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone.","['90 patients were included, of whom 43% used nintedanib and 57% pirfenidone', 'idiopathic pulmonary fibrosis (IPF', 'idiopathic pulmonary fibrosis', 'Outpatients with IPF prospectively completed the Patient Experiences and Satisfaction with Medication (PESaM) questionnaire before start, and after three and 6 months of antifibrotic treatment']",['nintedanib and pirfenidone'],"['Satisfaction', 'number and severity of side-effects', 'mean overall score for satisfaction with medication']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0298067', 'cui_str': 'pirfenidone'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]",90.0,0.0265175,"No differences were found in experiences and satisfaction with medication, and the number and severity of side-effects between nintedanib and pirfenidone.","[{'ForeName': 'C C', 'Initials': 'CC', 'LastName': 'Moor', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.'}, {'ForeName': 'R L M', 'Initials': 'RLM', 'LastName': 'Mostard', 'Affiliation': 'Department of Respiratory Medicine, Zuyderland Medical, Heerlen, the Netherlands.'}, {'ForeName': 'J C', 'Initials': 'JC', 'LastName': 'Grutters', 'Affiliation': 'Interstitial Lung Diseases Centre of Excellence, Department of Pulmonology, St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bresser', 'Affiliation': 'Department of Respiratory Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.'}, {'ForeName': 'J G J V', 'Initials': 'JGJV', 'LastName': 'Aerts', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands.'}, {'ForeName': 'C D', 'Initials': 'CD', 'LastName': 'Dirksen', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Kimman', 'Affiliation': 'Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Wijsenbeek', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands. m.wijsenbeek-lourens@erasmusmc.nl.'}]",Respiratory research,['10.1186/s12931-020-01458-1'] 1964,32703216,"Acute supplementation with an amino acid mixture suppressed the exercise-induced cortisol response in recreationally active healthy volunteers: a randomized, double-blinded, placebo-controlled crossover study.","BACKGROUND Few studies have demonstrated the suppressive effects of amino acids (AAs) on the level of cortisol during exercise in humans. We hypothesized that an AA mixture containing arginine, which promotes lipid metabolism, valine, which effectively decreases the level of glucocorticoid, and serine, a substrate in the production of phosphatidylserine that is reported to blunt increases in cortisol, would suppress the exercise-induced cortisol response by combining the positive effects of the AAs synergistically. METHODS A randomized, double-blinded, placebo-controlled crossover trial was conducted. Twenty healthy recreationally active males ingested either an AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine or a placebo. Thirty minutes after ingestion, subjects performed an exercise trial on a cycle ergometer for 80 min at 50% maximal oxygen consumption. Plasma cortisol and other blood parameters immediately before and after the exercise were evaluated. RESULTS Plasma cortisol concentrations after exercise were significantly higher than those before exercise in the placebo condition (9.51 ± 0.85 vs 14.39 ± 2.15, p < 0.05), while there was no significant difference in the AA condition (9.71 ± 0.93 vs 9.99 ± 1.23, p = 0.846). In addition, the increase in plasma cortisol before and after exercise was significantly lower in the AA condition than in the placebo condition (0.28 [- 2.75, 3.31] vs 4.87 [0.89, 8.86], p < 0.05). For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057). Blood glucose, plasma lactate, plasma ammonia, serum creatine phosphokinase, serum total ketone body, and serum free fatty acid were also significantly changed by the exercise load in both conditions, but no significant differences were observed between the two conditions. CONCLUSIONS The present study demonstrated that the AA mixture suppressed the cortisol response during exercise without affecting exercise-related biological parameters such as glucose or lipid metabolism. TRIAL REGISTRATION UMIN Clinical Trials Registry, UMIN000023587 . Registered 19 August 2016.",2020,"For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057).","['recreationally active healthy volunteers', 'Twenty healthy recreationally active males ingested either an', 'humans']","['AA mixture containing 1.8\u2009g of arginine, 1.1\u2009g of valine, and 0.1\u2009g of serine or a placebo', 'amino acid mixture', 'placebo']","['Plasma cortisol concentrations', 'Blood glucose, plasma lactate, plasma ammonia, serum creatine phosphokinase, serum total ketone body, and serum free fatty acid', 'cortisol response', 'Plasma cortisol and other blood parameters', 'plasma cortisol']","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0003765', 'cui_str': 'Arginine'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0042285', 'cui_str': 'Valine'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C0036720', 'cui_str': 'Serine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}]","[{'cui': 'C1281899', 'cui_str': 'Plasma cortisol measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C1278131', 'cui_str': 'Plasma ammonia measurement'}, {'cui': 'C0750860', 'cui_str': 'Serum creatine phosphokinase'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022631', 'cui_str': 'Ketone body'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",20.0,0.344236,"For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057).","[{'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Tsuda', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan. yuuichi.tsuda@meiji.com.'}, {'ForeName': 'Rika', 'Initials': 'R', 'LastName': 'Murakami', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Yamaguchi', 'Affiliation': 'R&D Division, Meiji Co., Ltd., 1-29-1 Nanakuni, Hachiouji, Tokyo, 192-0919, Japan.'}, {'ForeName': 'Taiichiro', 'Initials': 'T', 'LastName': 'Seki', 'Affiliation': 'College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, Kanagawa, 252-0880, Japan.'}]",Journal of the International Society of Sports Nutrition,['10.1186/s12970-020-00369-2'] 1965,32705417,High-dose rocuronium-induced paralysis of the adductor pollicis muscle facilitates detection of the timing for tracheal intubation in elderly patients: a randomized double-blind study.,"PURPOSE To prevent coughing related to tracheal intubation and the resultant exposure of intubating staff to the patients' expiratory aerosols, the timing of tracheal intubation needs to be precisely predicted. The aim of this study was to evaluate the hypothesis that the timing for safe tracheal intubation in elderly patients can be determined by acceleromyographically monitoring paralysis of the adductor pollicis muscle when high-dose rocuronium, given to block the respiratory muscles, is administered. METHODS Forty elderly (65-92 years) patients were enrolled in this study and randomly assigned to two groups, to receive rocuronium 0.6 mg/kg or 1 mg/kg. After induction of anesthesia and observing acceleromyographic train-of-four (TOF) responses of the adductor pollicis muscle to ulnar nerve stimulation, the patients randomly received either dose of rocuronium. The onset times from rocuronium administration to TOF counts of 0 were measured. Soon thereafter, a single anesthesiologist who was blinded to the allocated dose of rocuronium performed laryngoscopy and tracheal intubation, and assessed intubating conditions. Data were analyzed by the unpaired t-test and Chi-squared test. RESULTS The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8 [37.5] s, p < 0.001). Patients who received 0.6 mg/kg rocuronium variously showed either poor (n = 9) or good (n = 11) intubating conditions. However, all patients who received 1 mg/kg rocuronium had excellent intubating conditions. CONCLUSIONS If 1 mg/kg rocuronium is administered, a TOF count of 0 acceleromyographically observed at the adductor pollicis muscle can reveal the adequate timing for tracheal intubation.",2020,The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8,"['Forty elderly (65-92\xa0years', 'elderly patients']","['rocuronium', 'anesthesia and observing acceleromyographic train-of-four (TOF', 'rocuronium 0.6\xa0mg/kg or 1\xa0mg/kg', 'rocuronium performed laryngoscopy and tracheal intubation, and assessed intubating conditions']","['averaged [SD] onset time of neuromuscular blockade', 'excellent intubating conditions']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C4068883', 'cui_str': '0.6'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0234119', 'cui_str': 'Neuromuscular blockade'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",40.0,0.550908,The averaged [SD] onset time of neuromuscular blockade was significantly shorter with 1 mg/kg than 0.6 mg/kg rocuronium (104.3 [30.1] s vs. 186.8,"[{'ForeName': 'Shunichi', 'Initials': 'S', 'LastName': 'Takagi', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Nami', 'Initials': 'N', 'LastName': 'Sugaya', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Kiuchi', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Iwasa', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Masumi', 'Initials': 'M', 'LastName': 'Itagaki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Aya', 'Initials': 'A', 'LastName': 'Seki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Department of Anesthesiology, Nihon University School of Medicine, 30-1, Oyaguchi-Kamicho, Itabashi-Ku, Tokyo, 173-8610, Japan. suzuki.takahiro@nihon-u.ac.jp.'}]",Journal of anesthesia,['10.1007/s00540-020-02831-6'] 1966,32701836,"Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.","Propranolol is a nonselective beta-adrenergic receptor antagonist. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2b trial enrolled participants aged 18 to 65 years with temporomandibular disorder myalgia to evaluate efficacy and safety of propranolol compared with placebo in reducing facial pain. Participants were randomized 1:1 to either extended-release propranolol hydrochloride (60 mg, BID) or placebo. The primary endpoint was change in facial pain index (FPI = facial pain intensity multiplied by facial pain duration, divided by 100). Efficacy was analyzed as a mean change in FPI from randomization to week 9 and as the proportion of participants with ≥30% or ≥50% reductions in FPI at week 9. Regression models tested for treatment-group differences adjusting for study site, sex, race, and FPI at randomization. Of 299 participants screened, 200 were randomized; 199 had at least one postrandomization FPI measurement and were included in intention-to-treat analysis. At week 9, model-adjusted reductions in mean FPI did not differ significantly between treatment groups (-1.8, 95% CL: -6.2, 2.6; P = 0.41). However, the proportion with a ≥30% reduction in FPI was significantly greater for propranolol (69.0%) than placebo (52.6%), and the associated number-needed-to-treat was 6.1 (P = 0.03). Propranolol was likewise efficacious for a ≥50% reduction in FPI (number-needed-to-treat = 6.1, P = 0.03). Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group. Propranolol was not different from placebo in reducing mean FPI but was efficacious in achieving ≥30% and ≥50% FPI reductions after 9 weeks of treatment among temporomandibular disorder participants.",2020,"Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group.","['temporomandibular disorder pain', '299 participants screened, 200 were randomized; 199 had at least one postrandomization FPI measurement and were included in intention-to-treat analysis', 'participants aged 18 to 65 years with temporomandibular disorder myalgia', 'temporomandibular disorder participants']","['Propranolol', 'extended-release propranolol hydrochloride', 'propranolol', 'placebo']","['frequent fatigue, dizziness, and sleep disorder', 'FPI', 'facial pain index (FPI = facial pain intensity multiplied by facial pain duration, divided by 100', 'Efficacy and safety', 'Adverse event rates', 'Efficacy', 'mean change in FPI', 'mean FPI', 'facial pain']","[{'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}]","[{'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0282321', 'cui_str': 'Propranolol hydrochloride'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C1719797', 'cui_str': 'Multiply'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",200.0,0.579533,"Adverse event rates were similar between treatment groups, except for more frequent fatigue, dizziness, and sleep disorder in the propranolol group.","[{'ForeName': 'Inna E', 'Initials': 'IE', 'LastName': 'Tchivileva', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Hadgraft', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Pei Feng', 'Initials': 'PF', 'LastName': 'Lim', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Massimiliano', 'Initials': 'M', 'LastName': 'Di Giosia', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}, {'ForeName': 'Margarete', 'Initials': 'M', 'LastName': 'Ribeiro-Dasilva', 'Affiliation': 'Department of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Campbell', 'Affiliation': 'Departments of Oral and Maxillofacial Surgery and.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Willis', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'James', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Herman-Giddens', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Department of Community Dentistry & Behavioral Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ohrbach', 'Affiliation': 'Oral Diagnostic Sciences, University at Buffalo, State University of New York, Buffalo, NY, United States.'}, {'ForeName': 'Samuel J', 'Initials': 'SJ', 'LastName': 'Arbes', 'Affiliation': 'Rho Inc, Durham, NC, United States.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Slade', 'Affiliation': 'Center for Pain Research and Innovation, Adams School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.'}]",Pain,['10.1097/j.pain.0000000000001882'] 1967,32701843,Enhanced mindfulness-based stress reduction in episodic migraine: a randomized clinical trial with magnetic resonance imaging outcomes.,"We aimed to evaluate the efficacy of an enhanced mindfulness-based stress reduction (MBSR+) vs stress management for headache (SMH). We performed a randomized, assessor-blind, clinical trial of 98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n = 50) with SMH (n = 48). MBSR+ and SMH were delivered weekly by group for 8 weeks, then biweekly for another 8 weeks. The primary clinical outcome was reduction in headache days from baseline to 20 weeks. Magnetic resonance imaging (MRI) outcomes included activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula to DLPFC and cognitive task network, and gray matter volume of DLPFC, dorsal anterior insula, and anterior midcingulate. Secondary outcomes were headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses. Reduction in headache days from baseline to 20 weeks was greater for MBSR+ (7.8 [95% CI, 6.9-8.8] to 4.6 [95% CI, 3.7-5.6]) than for SMH (7.7 [95% CI 6.7-8.7] to 6.0 [95% CI, 4.9-7.0]) (P = 0.04). Fifty-two percent of the MBSR+ group showed a response to treatment (50% reduction in headache days) compared with 23% in the SMH group (P = 0.004). Reduction in headache-related disability was greater for MBSR+ (59.6 [95% CI, 57.9-61.3] to 54.6 [95% CI, 52.9-56.4]) than SMH (59.6 [95% CI, 57.7-61.5] to 57.5 [95% CI, 55.5-59.4]) (P = 0.02). There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed. Enhanced mindfulness-based stress reduction is an effective treatment option for episodic migraine.",2020,"There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed.","['headache (SMH', '98 adults with episodic migraine recruited at a single academic center comparing MBSR+ (n = 50) with SMH (n = 48', 'episodic migraine']","['Magnetic resonance imaging (MRI', 'enhanced mindfulness-based stress reduction (MBSR', 'MBSR+ and SMH', 'SMH', 'MBSR']","['headache days', 'reduction in headache days', 'headache-related disability', 'headache-related disability, pain severity, response to treatment, migraine days, and MRI whole-brain analyses', 'MBSR', 'activity of left dorsolateral prefrontal cortex (DLPFC) and cognitive task network during cognitive challenge, resting state connectivity of right dorsal anterior insula to DLPFC and cognitive task network, and gray matter volume of DLPFC, dorsal anterior insula, and anterior midcingulate']","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C0018681', 'cui_str': 'Headache'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0228259', 'cui_str': 'Anterior insula'}, {'cui': 'C0018220', 'cui_str': 'Grey Matter'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}]",98.0,0.12879,"There were no differences in clinical outcomes at 52 weeks or MRI outcomes at 20 weeks, although changes related to cognitive networks with MBSR+ were observed.","[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Seminowicz', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Shana A B', 'Initials': 'SAB', 'LastName': 'Burrowes', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Kearson', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Samuel R', 'Initials': 'SR', 'LastName': 'Krimmel', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Luma', 'Initials': 'L', 'LastName': 'Samawi', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Furman', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Keaser', 'Affiliation': 'Department of Neural and Pain Sciences, School of Dentistry, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Neda F', 'Initials': 'NF', 'LastName': 'Gould', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Trish', 'Initials': 'T', 'LastName': 'Magyari', 'Affiliation': 'Private Mindfulness-based Psychotherapy Practice, Baltimore, MD, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'White', 'Affiliation': 'Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Goloubeva', 'Affiliation': 'University of Maryland Greenebaum Comprehensive Cancer Center, University of Maryland Baltimore, Baltimore, MD, United States.'}, {'ForeName': 'Madhav', 'Initials': 'M', 'LastName': 'Goyal', 'Affiliation': 'Department of Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}, {'ForeName': 'B Lee', 'Initials': 'BL', 'LastName': 'Peterlin', 'Affiliation': 'Neuroscience Institute, Penn Medicine Lancaster General Health, Lancaster, PA, United States.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Haythornthwaite', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States.'}]",Pain,['10.1097/j.pain.0000000000001860'] 1968,32702216,A Neurofeedback Protocol for Executive Function to Reduce Depression and Rumination: A Controlled Study.,"Objective Rumination is a maladaptive emotional-regulation strategy that is strongly associated with depression. Impaired executive function can lead to difficulties in disengaging from rumination, thus exacerbating depression. In this study, we inspect an electroencephalograph neurofeedback protocol that enhance the target peak alpha frequency (PAF) activation in the prefrontal region. We examine the protocol's effects on depression and rumination. Methods We randomly assigned 30 dysphoric participants into either the neurofeedback training group or the control group. We then evaluated their depression, rumination, and executive function at pre- and posttraining so as to examine the effects of the neurofeedback. Results The results show that this neurofeedback protocol can specifically enhance participants' target PAF. The participants' executive function performances significantly improved after undergoing 20 neurofeedback sessions. Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination. Moreover, as target PAF and executive function improved, depression and rumination both declined. Conclusion Our data are in line with those of previous studies that indicated a relationship between upper-band alpha activity and executive function. This PAF neurofeedback can effectively enhance participants' executive function, which can reduce rumination and ameliorate depression. This neurofeedback training is based on basic cognitive neuroscience, so it sheds light on depression's pathological factors and etiology.",2020,"Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination.",[],['neurofeedback training group or the control group'],"['target PAF and executive function improved, depression and rumination both declined', 'rumination', 'depression and rumination', 'peak alpha frequency (PAF) activation', 'depression, rumination, and executive function', 'executive function performances', 'Depression and Rumination', 'depressive symptoms']",[],"[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0154575', 'cui_str': 'Rumination disorder'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",30.0,0.043171,"Compared with those in the control group, those in the neurofeedback group had significantly fewer depressive symptoms and significantly reduced rumination.","[{'ForeName': 'Sheng-Hsiang', 'Initials': 'SH', 'LastName': 'Yu', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}, {'ForeName': 'Chao-Yuan', 'Initials': 'CY', 'LastName': 'Tseng', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}, {'ForeName': 'Wei-Lun', 'Initials': 'WL', 'LastName': 'Lin', 'Affiliation': 'Department of Psychology, Fo Guang University, Jiaosi, Yilan County, Taiwan.'}]",Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology,['10.9758/cpn.2020.18.3.375'] 1969,32708637,Virtual Reality Aggression Prevention Therapy (VRAPT) versus Waiting List Control for Forensic Psychiatric Inpatients: A Multicenter Randomized Controlled Trial.,"Many forensic psychiatric inpatients have difficulties regulating aggressive behavior. Evidence of effective aggression treatments is limited. We designed and investigated the effectiveness of a transdiagnostic application of a virtual reality aggression prevention training (VRAPT). In this randomized controlled trial at four Dutch forensic psychiatric centers, 128 inpatients with aggressive behavior were randomly assigned to VRAPT ( N = 64) or waiting list control group ( N = 64). VRAPT consisted of 16 one-hour individual treatment sessions twice a week. Assessments were done at baseline, post-treatment and at 3-month follow-up. Primary outcome measures were aggressive behavior observed by staff and self-reported aggressive behavior. Analysis was by intention to treat. This trial was registered in the Dutch Trial Register (NTR, TC = 6340). Participants were included between 1 March 2017, and 31 December 2018. Compared to waiting list, VRAPT did not significantly decrease in self-reported or observed aggressive behavior (primary outcomes). Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment. Improvements were not maintained at 3-month follow-up. Results suggest that VRAPT does not decrease aggressive behavior in forensic inpatients. However, there are indications that VRAPT temporarily influences anger control skills, impulsivity and hostility.",2020,"Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment.","['forensic inpatients', 'Participants were included between 1 March 2017, and 31 December 2018', 'Forensic Psychiatric Inpatients', 'four Dutch forensic psychiatric centers, 128 inpatients with aggressive behavior']","['virtual reality aggression prevention training (VRAPT', 'waiting list control', 'Virtual Reality Aggression Prevention Therapy (VRAPT', 'VRAPT']","['anger control skills, impulsivity and hostility', 'Hostility, anger control, and non-planning impulsiveness', 'aggressive behavior', 'aggressive behavior observed by staff and self-reported aggressive behavior']","[{'cui': 'C0016557', 'cui_str': 'Medicine, Forensic'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric in-patient'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0020039', 'cui_str': 'Hostile behavior'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]",128.0,0.149137,"Hostility, anger control, and non-planning impulsiveness improved significantly in the VRAPT group compared to the control group at post-treatment.","[{'ForeName': 'Stéphanie', 'Initials': 'S', 'LastName': 'Klein Tuente', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bogaerts', 'Affiliation': 'Department of Developmental Psychology, Tilburg University, Prof Cobbenhagenlaan 225, P.O. Box 90153, 5000 LE Tilburg, The Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Bulten', 'Affiliation': 'Division Diagnostics Research and Education, Forensic Psychiatric Hospital Pompefoundation, Weg door Jonkerbos 55, 6532 CN Nijmegen, The Netherlands.'}, {'ForeName': 'Marije', 'Initials': 'M', 'LastName': 'Keulen-de Vos', 'Affiliation': 'Forensic Psychiatric Center (FPC) de Rooyse Wissel, P.O. Box 433, 5800AK Venray, The Netherlands.'}, {'ForeName': 'Maarten', 'Initials': 'M', 'LastName': 'Vos', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Hein', 'Initials': 'H', 'LastName': 'Bokern', 'Affiliation': 'Forensic Psychiatric Center (FPC) Dr. S. van Mesdag, Helperlinie 2, 9722 AZ Groningen, The Netherlands.'}, {'ForeName': 'Sarah van', 'Initials': 'SV', 'LastName': 'IJzendoorn', 'Affiliation': 'Fivoor, Fivoor Science & Treatment Innovation, Kijvelandsekade 1, 3172 AB Poortugaal, The Netherlands.'}, {'ForeName': 'Chris N W', 'Initials': 'CNW', 'LastName': 'Geraets', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Veling', 'Affiliation': 'Department of Psychiatry, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.'}]",Journal of clinical medicine,['10.3390/jcm9072258'] 1970,32708657,Changes in Circulating Extracellular Vesicles in Patients with ST-Elevation Myocardial Infarction and Potential Effects of Remote Ischemic Conditioning-A Randomized Controlled Trial.,"(1) Background: Extracellular vesicles (EVs) have been recognized as a cellular communication tool with cardioprotective properties; however, it is unknown whether cardioprotection by remote ischemic conditioning (RIC) involves EVs. (2) Methods: We randomized patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) to additionally receive a protocol of RIC or a sham-intervention. Blood was taken before and immediately, 24 h, four days and one month after PCI. Additionally, we investigated EVs from healthy volunteers undergoing RIC. EVs were characterized by a high-sensitive flow cytometer (Beckman Coulter Cytoflex S, Krefeld, Germany). (3) Results: We analyzed 32 patients (16 RIC, 16 control) and five healthy volunteers. We investigated platelet-, endothelial-, leukocyte-, monocyte- and granulocyte-derived EVs and their pro-thrombotic sub-populations expressing superficial phosphatidylserine (PS + ). We did not observe a significant effect of RIC on the numbers of circulating EVs, although granulocyte-derived EVs were significantly higher in the RIC group. In line, RIC had not impact on EVs in healthy volunteers. Additionally, we observed changes of PS + /PEV, EEVs and PS + /CD15 + EVs irrespective of RIC with time following STEMI. 4) Conclusion: We provide further insights into the course of different circulating EVs during the acute and sub-acute phases of STEMI. With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.",2020,"With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.","['patients with ST-elevation myocardial infarction (STEMI) undergoing primary', 'healthy volunteers', 'Patients with ST-Elevation Myocardial Infarction', '32 patients (16 RIC, 16 control) and five healthy volunteers', 'healthy volunteers undergoing RIC']","['platelet-, endothelial-, leukocyte-, monocyte- and granulocyte-derived EVs and their pro-thrombotic sub-populations expressing superficial phosphatidylserine (PS + ', 'percutaneous coronary intervention (PCI) to additionally receive a protocol of RIC or a sham-intervention']","['PS + /PEV, EEVs and PS + /CD15 + EVs irrespective of RIC', 'numbers of circulating EVs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0018183', 'cui_str': 'Granulocyte'}, {'cui': 'C0560135', 'cui_str': 'eV'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0031623', 'cui_str': 'Phosphatidylserine'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0560135', 'cui_str': 'eV'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}]",32.0,0.0477398,"With respect to the investigated EV populations, RIC seems to have no effect, with only minor differences found for granulocyte EVs.","[{'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Haller', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Jäger', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Edita', 'Initials': 'E', 'LastName': 'Piackova', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Sztulman', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Wegberger', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Wojta', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Mariann', 'Initials': 'M', 'LastName': 'Gyöngyösi', 'Affiliation': 'Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Attila', 'Initials': 'A', 'LastName': 'Kiss', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Bruno K', 'Initials': 'BK', 'LastName': 'Podesser', 'Affiliation': 'Ludwig Boltzmann Institute for Cardiovascular Research, 1160 Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Spittler', 'Affiliation': 'Core Facility, Medical University of Vienna, 1090 Vienna, Austria.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Huber', 'Affiliation': '3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, 1160 Vienna, Austria.'}]",Biomedicines,['10.3390/biomedicines8070218'] 1971,32708699,A Randomized Controlled Trial of Thermo-Sensitive Sol-Gel Anti-Adhesion Agent after Gynecologic Surgery.,"Postoperative abdominal adhesions can lead to several adverse consequences such as pelvic pain, bowel obstruction, and infertility. We aimed to explore the anti-adhesion efficacy and safety of a thermo-sensitive sol-gel agent in patients who receive abdominopelvic surgery for benign gynecologic disease. This study was a randomized, controlled, single-blind clinical trial of women undergoing benign gynecologic surgery between January 2017 and December 2017. The patients were randomly assigned to three groups with a 1:1:1 ratio: experimental group (received the thermo-sensitive sol-gel agent), control group (untreated), and comparator group (received 4% icodextrin). Patients were followed for 4 weeks postoperatively, and efficacy was evaluated by performing the visceral slide test to identify adhesion formation. In total, 183 patients were enrolled in the study, and 178 (97.3%) completed the trial. The incidence rate of abdominal adhesion formation was significantly lower in the experimental group than in the control group (7.9% vs. 21.1%, p = 0.040); however, it was similar between the experimental and comparator groups (7.9% vs. 13.8%. p = 0.299). At 4 weeks, no differences in adhesion-related symptoms were observed between the experimental and control groups. Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375). In conclusion, use of a thermo-sensitive sol-gel agent was safe and effective to prevent abdominal adhesions after benign gynecologic surgeries.",2020,Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375).,"['patients who receive abdominopelvic surgery for benign gynecologic disease', 'after Gynecologic Surgery', '183 patients were enrolled in the study, and 178 (97.3%) completed the trial', 'women undergoing benign gynecologic surgery between January 2017 and December 2017']","['thermo-sensitive sol-gel agent', 'Thermo-Sensitive Sol-Gel Anti-Adhesion Agent', 'thermo-sensitive sol-gel agent), control group (untreated), and comparator group (received 4% icodextrin']","['adhesion-related symptoms', 'abdominal adhesions', 'Adverse events', 'incidence rate of abdominal adhesion formation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0017411', 'cui_str': 'Disorder of female genital organs'}, {'cui': 'C0038902', 'cui_str': 'Operation on female genital organs'}, {'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205208', 'cui_str': 'Solid'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0538727', 'cui_str': 'icodextrin'}]","[{'cui': 'C0001511', 'cui_str': 'Adhesion'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0549357', 'cui_str': 'Abdominal adhesions'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0220781', 'cui_str': 'Anabolism'}]",183.0,0.0586886,Adverse events were mostly mild and did not differ significantly among the three groups ( p = 0.375).,"[{'ForeName': 'Young Im', 'Initials': 'YI', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul 03080, Korea.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Se Ik', 'Initials': 'SI', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Aeran', 'Initials': 'A', 'LastName': 'Seol', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Eun Ji', 'Initials': 'EJ', 'LastName': 'Lee', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Hee Seung', 'Initials': 'HS', 'LastName': 'Kim', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}, {'ForeName': 'Yong Sang', 'Initials': 'YS', 'LastName': 'Song', 'Affiliation': 'Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul 03080, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9072261'] 1972,32708705,Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.,"The metabolic requirements of metastatic non-small cell lung (mNSCLC) tumors from patients receiving first-line platinum-doublet chemotherapy are hypothesized to imprint a blood signature suitable for survival prediction. Pre-treatment samples prospectively collected at baseline from a randomized phase III trial were assayed using nuclear magnetic resonance (NMR) spectroscopy ( n = 341) and ultra-high performance liquid chromatography - mass spectrometry (UPLC-MS) ( n = 297). Distributions of time to event outcomes were estimated by Kaplan-Meier analysis, and baseline characteristics adjusted Cox regression modeling was used to correlate markers' levels to time to event outcomes. Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025). Formate, 2-hydroxybutyrate, glycine and myo -inositol were selected for a multivariate model. The median OS was 6.6 months in the high-risk group compared to 11.4 months in the low risk group HR (Hazard Ratio) = 1.99, 95% C.I. (Confidence Interval) 1.45-2.68; p < 0.0001). Modeling of lipids by class (sphingolipids, acylcarnitines and lysophosphatidylcholines) revealed a median OS = 5.7 months vs. 11. 9 months for the high vs. low risk group. (HR: 2.23, 95% C.I. 1.55-3.20; p < 0.0001). These results demonstrate that metabolic profiles from pre-treatment samples may be useful to stratify clinical outcomes for mNSCLC patients receiving chemotherapy. Genomic and longitudinal measurements pre- and post-treatment may yield addition information to personalize treatment decisions further.",2020,Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025).,"['Metastatic Non-Small Cell Lung Cancer', 'metastatic non-small cell lung (mNSCLC) tumors from patients receiving first-line platinum-doublet chemotherapy', 'mNSCLC patients receiving chemotherapy']","['nuclear magnetic resonance (NMR) spectroscopy ( n = 341) and ultra-high performance liquid chromatography - mass spectrometry (UPLC-MS', 'First-Line Platinum-Doublet Chemotherapy']","['median OS', 'overall survival (OS']","[{'cui': 'C0278987', 'cui_str': 'Metastatic non-small cell lung cancer'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0445128', 'cui_str': 'Non-small cell'}, {'cui': 'C0024121', 'cui_str': 'Neoplasm of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0877853', 'cui_str': 'Spectroscopy, NMR'}, {'cui': 'C0008562', 'cui_str': 'High pressure liquid chromatography'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.0689696,Sixteen polar metabolites were significantly correlated with overall survival (OS) by univariate analysis ( p < 0.025).,"[{'ForeName': 'Desirée', 'Initials': 'D', 'LastName': 'Hao', 'Affiliation': 'Department of Medical Oncology, Tom Baker Cancer Centre and Cummings School of Medicine, University of Calgary, 1331-29th Street N.W., Calgary, AB T2N 4N2, Canada.'}, {'ForeName': 'Arjun', 'Initials': 'A', 'LastName': 'Sengupta', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Keyue', 'Initials': 'K', 'LastName': 'Ding', 'Affiliation': ""Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.""}, {'ForeName': 'E R', 'Initials': 'ER', 'LastName': 'Ubeydullah', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Saikumari', 'Initials': 'S', 'LastName': 'Krishnaiah', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}, {'ForeName': 'Natasha B', 'Initials': 'NB', 'LastName': 'Leighl', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.'}, {'ForeName': 'Frances A', 'Initials': 'FA', 'LastName': 'Shepherd', 'Affiliation': 'University Health Network, Princess Margaret Cancer Centre, 700 University Avenue, Toronto, ON M5G 1Z5, Canada.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Seymour', 'Affiliation': ""Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada.""}, {'ForeName': 'Aalim', 'Initials': 'A', 'LastName': 'Weljie', 'Affiliation': 'Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.'}]",Cancers,['10.3390/cancers12071926'] 1973,32708741,Locally Applied Slow-Release of Minocycline Microspheres in the Treatment of Peri-Implant Mucositis: An Experimental In Vivo Study.,"BACKGROUND The objective of this is preclinical investigation was to evaluate the differential drug sustainability and pharmacodynamic properties of two local minocycline microsphere carriers: chitosan-coated alginate (CA) and poly(meth)acrylate-glycerin (PG). METHODS Four dental implants were placed unilaterally in the edentulous mandible of six beagle dogs. Each implant was randomly assigned to receive one of the following four treatments: (i) CA (CA-based minocycline), (ii) placebo (CA substrate without minocycline), (iii) PG (PG-based minocycline) and (iv) control (mechanical debridement only). After inducing peri-implant mucositis, the randomly assigned treatments were administered into the gingival sulcus twice at a 4-week interval using a plastic-tipped syringe. Drug sustainability and pharmacodynamic (clinical, radiographical and cell marker intensity) evaluations were performed after each administration. RESULTS The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days). The efficacy of the applied therapies based on clinical, radiographical and histological analyses were comparable across all treatment groups. CONCLUSIONS CA microspheres showed longer carrier and bacteriostatic effect sustainability when compared to PG microspheres, however, longer drug sustainability did not lead to improved treatment outcomes.",2020,The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days).,"['Peri-Implant Mucositis', 'Four dental implants were placed unilaterally in the edentulous mandible of six beagle dogs']","['Minocycline Microspheres', 'CA microspheres', 'CA (CA-based minocycline), (ii) placebo (CA substrate without minocycline), (iii) PG (PG-based minocycline) and (iv) control (mechanical debridement only', 'minocycline microsphere carriers: chitosan-coated alginate (CA) and poly(meth)acrylate-glycerin (PG']","['longer carrier and bacteriostatic effect sustainability', 'bacteriostatic effect', 'Drug sustainability and pharmacodynamic (clinical, radiographical and cell marker intensity) evaluations', 'CA microspheres']","[{'cui': 'C3698407', 'cui_str': 'Peri-implant mucositis'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C3853359', 'cui_str': 'Edentulous mandible'}, {'cui': 'C0324306', 'cui_str': 'Beagle'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}]","[{'cui': 'C0026187', 'cui_str': 'Minocycline'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0002040', 'cui_str': 'Alginates'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0597265', 'cui_str': 'polyacrylate'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C0162969', 'cui_str': 'Chitosan'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0007294', 'cui_str': 'Genetic disorder carrier'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1611701', 'cui_str': 'Cell marker'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0453946', 'cui_str': 'Coat'}, {'cui': 'C0002040', 'cui_str': 'Alginates'}, {'cui': 'C0026032', 'cui_str': 'Microbeads'}]",,0.0567987,The CA microspheres remained longer around the healing abutment compared to the PG microspheres at both administrations and a longer bacteriostatic effect was observed from CA (7.0 ± 5.7 days) compared to PG (1.2 ± 2.6 days).,"[{'ForeName': 'Sung-Wook', 'Initials': 'SW', 'LastName': 'Yoon', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Myong-Ji', 'Initials': 'MJ', 'LastName': 'Kim', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Kyeong-Won', 'Initials': 'KW', 'LastName': 'Paeng', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Kyeong Ae', 'Initials': 'KA', 'LastName': 'Yu', 'Affiliation': 'College of Pharmacy, Chungbuk National University, Cheongju 28165, Korea.'}, {'ForeName': 'Chong-Kil', 'Initials': 'CK', 'LastName': 'Lee', 'Affiliation': 'College of Pharmacy, Chungbuk National University, Cheongju 28165, Korea.'}, {'ForeName': 'Young Woo', 'Initials': 'YW', 'LastName': 'Song', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Jae-Kook', 'Initials': 'JK', 'LastName': 'Cha', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Sanz', 'Affiliation': 'Section of Graduate Periodontology, Faculty of Odontology, Complutense University of Madrid, 28040 Madrid, Spain.'}, {'ForeName': 'Ui-Won', 'Initials': 'UW', 'LastName': 'Jung', 'Affiliation': 'Department of Periodontology, Research Institute for Periodontal Regeneration, Yonsei University College of Dentistry, Seoul 03772, Korea.'}]",Pharmaceutics,['10.3390/pharmaceutics12070668'] 1974,32708743,Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study.,"AIMS The gut microbiota exerts a critical influence in the immune system. The gut microbiota of human virus immunodeficiency (HIV)-infected children remains barely explored. We aimed to characterize the fecal microbiota in vertically HIV-infected children and to explore the effects of its modulation with a symbiotic nutritional intervention. METHODS a pilot, double blind, randomized placebo-controlled study including HIV-infected children who were randomized to receive a nutritional supplementation including prebiotics and probiotics or placebo for four weeks. HIV-uninfected siblings were recruited as controls. The V3-V4 region of the 16S rRNA gene was sequenced in fecal samples. RESULTS 22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period. Mean age was 11.4 ± 3.4 years, eight (32%) were male. Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level (Adonis p = 0.042). Patients showed decreased abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia. The nutritional intervention shaped the microbiota towards the control group, without a clear directionality. CONCLUSIONS Vertical HIV infection is characterized by changes in gut microbiota structure, distinct at the compositional level from the findings reported in adults. A short nutritional intervention attenuated bacterial dysbiosis, without clear changes at the community level. SUMMARY In a group of 24 vertically HIV-infected children, in comparison to 11 uninfected controls, intestinal dysbiosis was observed despite effective ART. Although not fully effective to restore the microbiota, a short intervention with pre/probiotics attenuated bacterial dysbiosis.",2020,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"['HIV-infected children', 'Vertically HIV-Infected Children', '22 HIV-infected children on antiretroviral therapy (ART) and with viral load (VL) <50/mL completed the follow-up period', 'vertically HIV-infected children', 'HIV-uninfected siblings', 'Mean age was 11.4 ± 3.4 years, eight (32%) were male']","['nutritional supplementation including prebiotics and probiotics or placebo', 'Nutritional Intervention', 'symbiotic nutritional intervention', 'placebo']","['abundance of commensals Faecalibacterium and an increase in Prevotella, Akkermansia and Escherichia', 'fecal microbiota', 'alpha diversity']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0037047', 'cui_str': 'Sibling'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C2717875', 'cui_str': 'Prebiotics'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0542329', 'cui_str': 'Commensal parasite'}, {'cui': 'C1229075', 'cui_str': 'Faecalibacterium'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0242946', 'cui_str': 'Prevotella'}, {'cui': 'C1490589', 'cui_str': 'Akkermansia'}, {'cui': 'C0014833', 'cui_str': 'Escherichia'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}]",,0.0511436,Their microbiota showed reduced alpha diversity compared to controls and distinct beta diversity at the genus level,"[{'ForeName': 'Talía', 'Initials': 'T', 'LastName': 'Sainz', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Gosalbes', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Talavera', 'Affiliation': 'Bioinformatics Unit, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Jimenez-Hernandez', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Prieto', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Escosa', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Guillén', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'José Tomás', 'Initials': 'JT', 'LastName': 'Ramos', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María Ángeles', 'Initials': 'MÁ', 'LastName': 'Muñoz-Fernández', 'Affiliation': 'Laboratorio InmunoBiología Molecular, Sección Inmunología, Hospital General Universitario Gregorio Marañón and Spanish HIV HGM BioBank, Madrid Spain, Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 28007 Madrid, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Moya', 'Affiliation': 'Área Genómica y Salud, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), 46010 Valencia, Spain.'}, {'ForeName': 'Maria Luisa', 'Initials': 'ML', 'LastName': 'Navarro', 'Affiliation': 'Red de Investigación CoRISpe integrada en la Red en Infectología Pediátrica (RITIP), 28046 Madrid, Spain.'}, {'ForeName': 'María José', 'Initials': 'MJ', 'LastName': 'Mellado', 'Affiliation': 'Servicio de Pediatría, Hospital Universitario La Paz and IdiPAZ, 28046 Madrid, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Serrano-Villar', 'Affiliation': 'Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal and IRYCIS, 28034 Madrid, Spain.'}]",Nutrients,['10.3390/nu12072112'] 1975,32708831,Effect of a Single Nutritional Intervention Previous to a Critical Period of Fat Gain in University Students with Overweight and Obesity: A Randomized Controlled Trial.,"BACKGROUND the present study aimed to investigate the effects of a single nutritional preventive session previous to a critical period linked to fat gain in university students with overweightness and obesity, emulating a nutritional session of a public health system. METHODS In this single-blind randomized controlled trial, 23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women) who were divided into two groups: intervention group (IG) and control group (CG). Fat mass (FM) by dual-energy X-ray absorptiometry (DXA), physical activity by accelerometry, feeding evaluation through three questionnaires, and a set of healthy lifestyle recommendations were evaluated before and after the national holidays (NH). RESULTS Our findings showed that FM increased significantly in the CG, but not in the IG (CG = 428.1 g; IG = 321.9 g; Δ = 106.2 g; p = 0.654 [95% CI = -379.57, 591.92]). However, no differences were found during the NH between them (Hedges' g effect size = 0.19; p = 0.654). In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. CONCLUSION a single preventive session before a critical period, using a similar counselling approach as used in the public health system, might not be enough to promote changes in eating and physical activity patterns and preventing fat gain in overweight/obese university students. Long-term interventions are a must.",2020,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","['university students with overweightness and obesity, emulating a nutritional session of a public health system', 'University Students with Overweight and Obesity', 'overweight/obese university students', '23 students met all the criteria to be included (20.91 ± 2.52-year-old; 52.2% women']","['Single Nutritional Intervention', 'single nutritional preventive session', 'intervention group (IG) and control group (CG']","['FM', 'Fat mass (FM']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517632', 'cui_str': '2.52'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517801', 'cui_str': '52.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",23.0,0.0394414,"In addition, no statistical differences were observed between groups in feeding evaluations, the set of recommendations performed, and physical activity. ","[{'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Hernández-Jaña', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Huber-Pérez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Ximena', 'Initials': 'X', 'LastName': 'Palma-Leal', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Guerrero-Ibacache', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Campos-Nuñez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Juan Pablo', 'Initials': 'JP', 'LastName': 'Zavala-Crichton', 'Affiliation': 'Faculty of Education and Social Sciences, Universidad Andres Bello, 2531015 Viña del Mar, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Jorquera-Aguilera', 'Affiliation': 'School of Nutrition and Dietetics, Faculty of Science, Universidad Mayor, 8580000 Santiago, Chile.'}, {'ForeName': 'Kabir P', 'Initials': 'KP', 'LastName': 'Sadarangani', 'Affiliation': 'Department of Kinesiology, Universidad Autónoma de Chile, 7500912 Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Rodríguez-Rodríguez', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Cristi-Montero', 'Affiliation': 'IRyS Research Group, School of Physical Education, Pontificia Universidad Católica de Valparaíso, 2374631 Valparaíso, Chile.'}]",International journal of environmental research and public health,['10.3390/ijerph17145149'] 1976,32708859,Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir.,"Proton-pump inhibitors (PPIs), frequently prescribed to lower gastric acid secretion, often exert an effect on the absorption of co-medicated drug products. A previous study showed decreased plasma levels of the lipophilic drug ritonavir after co-administration with the PPI Nexium (40 mg esomeprazole), even though duodenal concentrations were not affected. The present study explored if a PPI-induced decrease in gastrointestinal (GI) fluid volume might contribute to the reduced absorption of ritonavir. In an exploratory cross-over study, five volunteers were given a Norvir tablet (100 mg ritonavir) orally, once without PPI pre-treatment and once after a three-day pre-treatment with the PPI esomeprazole. Blood samples were collected for eight hours to assess ritonavir absorption and magnetic resonance imaging (MRI) was used to determine the gastric and duodenal fluid volumes during the first three hours after administration of the tablet. The results confirmed that PPI intake reduced ritonavir plasma concentrations by 40%. The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%. These data suggest that the PPI esomeprazole lowers the available fluid volume for dissolution, which may limit the amount of ritonavir that can be absorbed. Although additional factors may play a role, the effect of PPI intake on the GI fluid volume should be considered when simulating the absorption of poorly soluble drugs like ritonavir in real-life conditions.",2020,"The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%.",[],"['Norvir tablet (100 mg ritonavir', 'PPI esomeprazole', 'esomeprazole', 'Proton-pump inhibitors (PPIs', 'Esomeprazole', 'ritonavir absorption and magnetic resonance imaging (MRI']","['duodenal concentrations', 'Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir', 'duodenal fluid volume', 'plasma levels', 'gastric residual volume and gastric fluid volume', 'ritonavir plasma concentrations']",[],"[{'cui': 'C0678152', 'cui_str': 'Norvir'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0937846', 'cui_str': 'Esomeprazole'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}]","[{'cui': 'C0013303', 'cui_str': 'Duodenal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0227306', 'cui_str': 'Duodenal juice'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3665864', 'cui_str': 'Gastric residual assessment'}, {'cui': 'C0449971', 'cui_str': 'Volume of fluid used'}]",5.0,0.0522133,"The gastric residual volume and gastric fluid volume decreased by 41% and 44% respectively, while the duodenal fluid volume was reduced by 33%.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'de Waal', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Rubbens', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Grimm', 'Affiliation': 'Center of Drug Absorption and Transport, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Vandecaveye', 'Affiliation': 'Radiology Department, University Hospitals Leuven, 3000 Leuven, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Tack', 'Affiliation': 'Translational Research Center for Gastrointestinal Disorders, TARGID, KU Leuven, 3000 Leuven, Belgium.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Weitschies', 'Affiliation': 'Center of Drug Absorption and Transport, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Brouwers', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Augustijns', 'Affiliation': 'Drug Delivery and Disposition, KU Leuven, Gasthuisberg O&N II, Herestraat 49-Box 921, 3000 Leuven, Belgium.'}]",Pharmaceutics,['10.3390/pharmaceutics12070670'] 1977,32708860,We Don't Talk about It: Cancer Pain and American Indian Survivors.,"Pain is a common symptom among cancer survivors, yet is rarely talked about by American Indians. Understanding the reasons for reduced communication by American Indian cancer survivors is important for healthcare providers, family members, and others providing treatment and support for cancer symptoms. Thirteen focus groups with Southwest American Indian adult cancer survivors were audiotaped and transcribed as part of a randomized intervention to remove barriers to cancer symptom management. Constant comparative methods were employed in the data analysis, topic categories were grouped for comparison, and final assessment followed Grounded Theory methods. Findings were categorized into two major groupings: communication with family members and communication with health care providers. Within these two groupings, three themes emerged to describe cancer pain experiences and communication barriers: (1) We don't talk about it, (2) Respect for healthcare providers; and (3) Culturally prohibitive topics on death and pain experiences. Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare. Findings have implications for educational interventions and quality of life improvement for American Indian and other underrepresented communities.",2020,"Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare.","['Thirteen focus groups with Southwest American Indian adult cancer survivors', 'American Indian and other underrepresented communities', 'American Indian cancer survivors']",[],['death and pain experiences'],"[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0016400', 'cui_str': 'Focus Groups'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",[],"[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",,0.0190248,"Not talking about their cancer diagnosis and cancer-related pain leaves many American Indian cancer survivors without much-needed social support, contributing to reduced treatment compliance and access to healthcare.","[{'ForeName': 'Felicia Schanche', 'Initials': 'FS', 'LastName': 'Hodge', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Tracy Line', 'Initials': 'TL', 'LastName': 'Itty', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Samuel-Nakamura', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Cadogan', 'Affiliation': 'School of Nursing, University of California, 700 Tiverton Avenue, Room 5-934A Factor Building, Los Angeles, CA 90095-1702, USA.'}]",Cancers,['10.3390/cancers12071932'] 1978,32708864,Effects of a Multidisciplinary Residential Nutritional Rehabilitation Program in Head and Neck Cancer Survivors-Results from the NUTRI-HAB Randomized Controlled Trial.,"Head and neck cancer survivors frequently experience nutritional challenges, and proper rehabilitation should be offered. The trial objective was to test the effect of a multidisciplinary residential nutritional rehabilitation programme addressing physical, psychological, and social aspects of eating problems after treatment. In a randomized controlled trial, 71 head and neck cancer survivors recruited through a nationwide survey were randomized to the program or a wait-list control group. Inclusion was based on self-reported interest in participation. The primary outcome was change in body weight. Secondary outcomes included physical function, quality of life, and symptoms of anxiety and depression. Differences between groups at the 3-month follow-up were tested. No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": p = 0.040; ""Pain"": p = 0.048) in the intervention group. To conclude, a multidisciplinary residential nutritional rehabilitation program had no effect on body weight in head and neck cancer survivors with self-reported interest in participation, but it may have effect on physical function and quality of life. Further research on relevant outcomes, inclusion criteria, and the program's effect in different subgroups is needed.",2020,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","['Head and Neck Cancer Survivors', 'head and neck cancer survivors', '71 head and neck cancer survivors recruited through a nationwide survey', 'Head and neck cancer survivors']","['Multidisciplinary Residential Nutritional Rehabilitation Program', 'multidisciplinary residential nutritional rehabilitation programme', 'wait-list control group', 'multidisciplinary residential nutritional rehabilitation program']","['quality of life', 'physical function', 'physical function, quality of life, and symptoms of anxiety and depression', 'body weight', 'change in body weight', 'physical function and quality of life', 'body weight change']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}]",71.0,0.117048,"No significant differences were seen in body weight change, but there were overall trends towards greater improvements in physical function (hand grip strength: p = 0.042; maximal mouth opening: p = 0.072) and quality of life (""Role functioning"": p = 0.041; ""Speech problems"": ","[{'ForeName': 'Marianne Boll', 'Initials': 'MB', 'LastName': 'Kristensen', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Wessel', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.'}, {'ForeName': 'Anne Marie', 'Initials': 'AM', 'LastName': 'Beck', 'Affiliation': 'Department of Nursing and Nutrition, University College Copenhagen, Sigurdsgade 26, 2200 Copenhagen N, Denmark.'}, {'ForeName': 'Karin B', 'Initials': 'KB', 'LastName': 'Dieperink', 'Affiliation': 'Research Unit of Oncology, Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, 5000 Odense C, Denmark.'}, {'ForeName': 'Tina Broby', 'Initials': 'TB', 'LastName': 'Mikkelsen', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Jens-Jakob Kjer', 'Initials': 'JK', 'LastName': 'Møller', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}, {'ForeName': 'Ann-Dorthe', 'Initials': 'AD', 'LastName': 'Zwisler', 'Affiliation': 'REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care, Odense University Hospital, and Department of Clinical Research, University of Southern Denmark, Vestergade 17, 5800 Nyborg, Denmark.'}]",Nutrients,['10.3390/nu12072117'] 1979,32640131,A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries.,"BACKGROUND Injuries from falls are major contributors to complications and death in older adults. Despite evidence from efficacy trials that many falls can be prevented, rates of falls resulting in injury have not declined. METHODS We conducted a pragmatic, cluster-randomized trial to evaluate the effectiveness of a multifactorial intervention that included risk assessment and individualized plans, administered by specially trained nurses, to prevent fall injuries. A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each). The participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries. The primary outcome, assessed in a time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data. We hypothesized that the event rate would be lower by 20% in the intervention group than in the control group. RESULTS The demographic and baseline characteristics of the participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women. The rate of a first adjudicated serious fall injury did not differ significantly between the groups, as assessed in a time-to-first-event analysis (events per 100 person-years of follow-up, 4.9 in the intervention group and 5.3 in the control group; hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P = 0.25). The rate of a first participant-reported fall injury was 25.6 events per 100 person-years of follow-up in the intervention group and 28.6 events per 100 person-years of follow-up in the control group (hazard ratio, 0.90; 95% CI, 0.83 to 0.99; P = 0.004). The rates of hospitalization or death were similar in the two groups. CONCLUSIONS A multifactorial intervention, administered by nurses, did not result in a significantly lower rate of a first adjudicated serious fall injury than enhanced usual care. (Funded by the Patient-Centered Outcomes Research Institute and others; STRIDE ClinicalTrials.gov number, NCT02475850.).",2020,A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each).,"['participants were similar in the intervention group (2802 participants) and the control group (2649 participants); the mean age was 80 years, and 62.0% of the participants were women', '86 primary care practices across 10 health care systems', 'older adults', 'participants were community-dwelling adults, 70 years of age or older, who were at increased risk for fall injuries']","['multifactorial intervention', 'intervention or to enhanced usual care (the control']","['time-to-event analysis, was the first serious fall injury, adjudicated with the use of participant report, electronic health records, and claims data', 'rate of a first adjudicated serious fall injury', 'rate of a first participant-reported fall injury', 'rates of hospitalization or death']","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0051533', 'cui_str': 'Am 80'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0018696', 'cui_str': 'Healthcare Systems'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1268740', 'cui_str': 'At risk for falls'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0085639', 'cui_str': 'Falls'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",2802.0,0.136147,A total of 86 primary care practices across 10 health care systems were randomly assigned to the intervention or to enhanced usual care (the control) (43 practices each).,"[{'ForeName': 'Shalender', 'Initials': 'S', 'LastName': 'Bhasin', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Gill', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Reuben', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Nancy K', 'Initials': 'NK', 'LastName': 'Latham', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Ganz', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Erich J', 'Initials': 'EJ', 'LastName': 'Greene', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Shehzad', 'Initials': 'S', 'LastName': 'Basaria', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jerry H', 'Initials': 'JH', 'LastName': 'Gurwitz', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Patricia C', 'Initials': 'PC', 'LastName': 'Dykes', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'McMahon', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Storer', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Priscilla', 'Initials': 'P', 'LastName': 'Gazarian', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Miller', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Travison', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Esserman', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Martha B', 'Initials': 'MB', 'LastName': 'Carnie', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Goehring', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Fagan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Greenspan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Alexander', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jocelyn', 'Initials': 'J', 'LastName': 'Wiggins', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Ko', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Albert L', 'Initials': 'AL', 'LastName': 'Siu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Volpi', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Albert W', 'Initials': 'AW', 'LastName': 'Wu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Rich', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Waring', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Wallace', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Carri', 'Initials': 'C', 'LastName': 'Casteel', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Neil M', 'Initials': 'NM', 'LastName': 'Resnick', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Magaziner', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Charpentier', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Lu', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Katy', 'Initials': 'K', 'LastName': 'Araujo', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Haseena', 'Initials': 'H', 'LastName': 'Rajeevan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Can', 'Initials': 'C', 'LastName': 'Meng', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Allore', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Brooke F', 'Initials': 'BF', 'LastName': 'Brawley', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Rich', 'Initials': 'R', 'LastName': 'Eder', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'McGloin', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Eleni A', 'Initials': 'EA', 'LastName': 'Skokos', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Pamela W', 'Initials': 'PW', 'LastName': 'Duncan', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Baker', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Chad', 'Initials': 'C', 'LastName': 'Boult', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Rosaly', 'Initials': 'R', 'LastName': 'Correa-de-Araujo', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Peduzzi', 'Affiliation': ""From the Boston Claude D. Pepper Older Americans Independence Center, Research Program in Men's Health: Aging and Metabolism (S. Bhasin, N.K.L., S. Basaria, T.W.S., T.G.T., L.G., B.F.B., R.E.), Brigham and Women's Hospital (S. Bhasin, N.K.L., S. Basaria, P.C.D., T.W.S., T.G.T., P.G., M.B.C., L.G., B.F.B., R.E.), Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School (T.G.T.), and the University of Massachusetts Boston (P.G.), Boston, and Meyers Primary Care Institute (joint endeavor of Reliant Medical Group, Fallon Health, and University of Massachusetts Medical School), Worcester (J.H.G.); the Yale Claude D. Pepper Older Americans Independence Center (T.M.G., P.C., K.A., J.M.M., E.A.S., D.B.), the Yale Center for Analytical Sciences (E.J.G., J.D., D.E., C.L., H.R., C.M., H.A., P.P.), and the Section of Geriatrics, Department of Internal Medicine, Yale School of Medicine (T.M.G., H.A.), Yale University, New Haven, CT; the Multicampus Program in Geriatric Medicine and Gerontology, David Geffen School of Medicine at UCLA (D.B.R., D.A.G.), the Geriatric Research, Education and Clinical Center, Veterans Affairs Greater Los Angeles Healthcare System (D.A.G.), and the UCLA Claude D. Pepper Older Americans Independence Center (D.B.R, D.A.G.), Los Angeles, and HealthCare Partners, El Segundo (J.R.) - all in California; the School of Nursing, University of Minnesota, Minneapolis (S.M.M.), and Essentia Health, Duluth (S.C.W.) - both in Minnesota; Wake Forest University, School of Medicine, Winston-Salem, NC (M.E.M., P.W.D.); the University of Miami Health System, Miami (M.F.); the Pittsburgh Claude D. Pepper Older Americans Independence Center, Division of Geriatrics and Gerontology, University of Pittsburgh, Pittsburgh (S.L.G., N.M.R.); the University of Michigan, Ann Arbor (N.A., J.W.); Icahn School of Medicine at Mount Sinai, New York (F.K., A.L.S.); the UTMB Claude D. Pepper Older Americans Independence Center, Sealy Center on Aging, University of Texas Medical Branch, Galveston (E.V.); Johns Hopkins University (A.W.W., C.B.) and the University of Maryland School of Medicine (J.M.), Baltimore, and the National Institute on Aging, Bethesda (R.C.-A.) - all in Maryland; and the University of Iowa, Iowa City (R.B.W., C.C.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa2002183'] 1980,32690738,Risk assessment and antibiotic prescribing decisions in children presenting to UK primary care with cough: a vignette study.,"OBJECTIVES The validated 'STARWAVe' (Short illness duration, Temperature, Age, Recession, Wheeze, Asthma, Vomiting) clinical prediction rule (CPR) uses seven variables to guide risk assessment and antimicrobial stewardship in children presenting with cough. We aimed to compare general practitioners' (GPs) risk assessments and prescribing decisions to those of STARWAVe and assess the influence of the CPR's clinical variables. SETTING Primary care. PARTICIPANTS 252 GPs, currently practising in the UK. DESIGN GPs were randomly assigned to view four (of a possible eight) clinical vignettes online. Each vignette depicted a child presenting with cough, who was described in terms of the seven STARWAVe variables. Systematically, we manipulated patient age (20 months vs 5 years), illness duration (3 vs 6 days), vomiting (present vs absent) and wheeze (present vs absent), holding the remaining STARWAVe variables constant. OUTCOME MEASURES Per vignette, GPs assessed risk of hospitalisation and indicated whether they would prescribe antibiotics or not. RESULTS GPs overestimated risk of hospitalisation in 9% of vignette presentations (88/1008) and underestimated it in 46% (459/1008). Despite underestimating risk, they overprescribed: 78% of prescriptions were unnecessary relative to GPs' own risk assessments (121/156), while 83% were unnecessary relative to STARWAVe risk assessments (130/156). All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). CONCLUSIONS Relative to STARWAVe, GPs underestimated risk of hospitalisation, overprescribed and appeared to misinterpret illness duration (prescribing for longer rather than shorter illnesses). It is important to ascertain discrepancies between CPRs and current clinical practice. This has implications for the integration of CPRs into the electronic health record and the provision of intelligible explanations to decision-makers.",2020,"All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). ","['children presenting with cough', '252 GPs, currently practising in the UK', 'children presenting to UK primary care with cough']",[],"['illness duration', 'vomiting', 'risk of hospitalisation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]",[],"[{'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",252.0,0.0689741,"All four of the manipulated variables influenced risk assessments, but only three influenced prescribing decisions: a shorter illness duration reduced prescribing odds (OR 0.14, 95% CI 0.08 to 0.27, p<0.001), while vomiting and wheeze increased them (OR vomit 2.17, 95% CI 1.32 to 3.57, p=0.002; OR wheeze 8.98, 95% CI 4.99 to 16.15, p<0.001). ","[{'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Nurek', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK m.nurek@imperial.ac.uk.'}, {'ForeName': 'Brendan C', 'Initials': 'BC', 'LastName': 'Delaney', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Kostopoulou', 'Affiliation': 'Surgery and Cancer, Imperial College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035761'] 1981,32690739,Study protocol for the POPART study-Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial.,"INTRODUCTION Many preterm infants develop respiratory distress syndrome (RDS), a condition characterised by a relative lack of surfactant. Endotracheal surfactant therapy revolutionised the care of preterm infants in the 1990s. However, supporting newborns with RDS with continuous positive airway pressure (CPAP) and reserving endotracheal surfactant for those who develop respiratory failure despite CPAP yield better results than intubating all infants for surfactant. Half of preterm infants born before 29 weeks gestation initially managed with CPAP are intubated for surfactant. Intubation is difficult to learn and associated with adverse effects. Surfactant administration into the oropharynx has been reported in preterm animals and humans and may be effective. We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. METHODS AND ANALYSIS Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial (POPART, Eudract No. 2016-004198-41) is an investigator-led, unblinded, multicentre, randomised, parallel group, controlled trial. Infants are eligible if born at a participating centre before 29 weeks gestational age (GA) and there is a plan to offer intensive care. Infants are excluded if they have major congenital anomalies. Infants are randomised at birth to treatment with oropharyngeal surfactant (120 mg vial <26 weeks GA stratum; 240 mg vial 26-28 +6 weeks GA stratum) in addition to CPAP or CPAP alone. The primary outcome is intubation within 120 hours of birth, for bradycardia and/or apnoea despite respiratory support in the delivery room or respiratory failure in the intensive care unit. Secondary outcomes include incidence of mechanical ventilation, endotracheal surfactant use, chronic lung disease and death before hospital discharge. ETHICS AND DISSEMINATION Approval for the study has been granted by the Research Ethics Committees at the National Maternity Hospital, Dublin, Ireland (EC31.2016) and at each participating site. The trial is being conducted at nine centres in six European countries. The study results will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER 2016-004198-41; Pre-results.",2020,"We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. ","['Many preterm infants develop respiratory distress syndrome (RDS', 'newborns with RDS with continuous positive airway pressure (CPAP', 'Infants are eligible if born at a participating centre before 29 weeks gestational age (GA) and there is a plan to offer intensive care', 'nine centres in six European countries', 'preterm infants in the 1990s', 'Preterm infants', 'preterm infants born before 29 weeks gestation initially managed with', 'preterm infants within 120\u2009hours of birth']","['Endotracheal surfactant therapy', 'oropharyngeal surfactant', 'CPAP', 'Prophylactic Oropharyngeal surfactant', 'CPAP or CPAP alone']","['intubation within 120\u2009hours of birth, for bradycardia and/or apnoea despite respiratory support in the delivery room or respiratory failure in the intensive care unit', 'incidence of mechanical ventilation, endotracheal surfactant use, chronic lung disease and death before hospital discharge']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C0454713', 'cui_str': 'European country'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]","[{'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0009653', 'cui_str': 'Condom'}]","[{'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0011212', 'cui_str': 'Delivery suite'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C1522653', 'cui_str': 'Intratracheal route'}, {'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0746102', 'cui_str': 'Chronic lung disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}]",,0.44978,"We wished to determine whether giving oropharyngeal surfactant at birth reduces the rate of endotracheal intubation for respiratory failure in preterm infants within 120 hours of birth. ","[{'ForeName': 'Madeleine Claire', 'Initials': 'MC', 'LastName': 'Murphy', 'Affiliation': 'Department of Neonatology, National Maternity Hospital, Dublin, Ireland.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Galligan', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Molloy', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Hussain', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Doran', 'Affiliation': 'UCD Clinical Research Centre, School of Medicine, University College Dublin, Dublin, Ireland.'}, {'ForeName': 'Colm', 'Initials': 'C', 'LastName': ""O'Donnell"", 'Affiliation': 'Department of Neonatology, National Maternity Hospital, Dublin, Ireland codonnell@nmh.ie.'}]",BMJ open,['10.1136/bmjopen-2019-035994'] 1982,32690743,Wool-derived keratin dressings versus usual care dressings for treatment of slow healing venous leg ulceration: a randomised controlled trial (Keratin4VLU).,"OBJECTIVE To determine the effect of a keratin dressing for treating slow-to-heal venous leg ulcers (VLU) on VLU healing. DESIGN Pragmatic parallel group randomised controlled trial. SETTING Community-dwelling participants. PARTICIPANTS People aged 18 or more years with VLU (either present for more than 26 weeks or ulcer area larger than 5 cm 2 or both). INTERVENTION Wool-derived keratin dressing or usual care formulary of non-medicated dressings, on a background treatment with compression. PRIMARY AND SECONDARY OUTCOME MEASURES Healing at 24 weeks based on blinded assessment of ulcer photographs. Other outcomes included time to complete healing, change in ulcer area to 24 weeks, change in health-related quality of life and incidence of adverse events. RESULTS We screened 1068 patients with VLU and randomised 143 participants (51.1% of target recruitment), 71 to the keratin dressing group and 72 to the usual care group.The mean age was 66.1 years (SD 15.9) and 53 participants (37.1%) were women. There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses. However, the direction of effect on the primary outcome was reversed in a per protocol analysis specified a priori (risk difference 6.2%, 95% CI -12.4% to 24.9%). CONCLUSION The effect of adding a keratin dressing to the treatment regimen for prognostically slow-to-heal VLU remains unclear. TRIAL REGISTRATION NUMBER NCT02896725.",2020,"There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses.","['slow healing venous leg ulceration', 'People aged 18 or more years with VLU (either present for more than 26 weeks or ulcer area larger than 5 cm 2 or both', 'The mean age was 66.1 years (SD 15.9) and 53 participants (37.1%) were women', 'Community-dwelling participants', '1068 patients with VLU and randomised 143 participants (51.1% of target recruitment), 71 to the keratin dressing group and 72 to the usual care group']","['Wool-derived keratin dressings versus usual care dressings', 'Wool-derived keratin dressing', 'keratin dressing']","['change in ulcer area', 'time to complete healing, change in ulcer area to 24 weeks, change in health-related quality of life and incidence of adverse events', 'incidence of adverse events', 'time to complete healing']","[{'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042344', 'cui_str': 'Stasis ulcer'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C3876144', 'cui_str': 'Keratin dressing'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0043220', 'cui_str': 'Wool'}, {'cui': 'C3876144', 'cui_str': 'Keratin dressing'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1068.0,0.218728,"There were no significant differences between the groups on the primary outcome (risk difference -6.4%, 95% CI -22.5% to 9.7%), change in ulcer area (-1.9 cm 2 , 95% CI -16.5 to 12.8 cm 2 ), time to complete healing (HR 0.80, 95% CI 0.52 to 1.23) or the incidence of adverse events (incidence rate ratio 1.19, 95% CI 0.89 to 1.59) in the intention-to-treat analyses.","[{'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Jull', 'Affiliation': 'School of Nursing, University of Auckland, Auckland, Auckland, New Zealand a.jull@auckland.ac.nz.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Wadham', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Bullen', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'Parag', 'Affiliation': 'National Institute for Health Innovation, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Weller', 'Affiliation': 'School of Nursing and Midwifery, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Waters', 'Affiliation': 'Hope Foundation for Research on Ageing, Auckland, New Zealand.'}]",BMJ open,['10.1136/bmjopen-2019-036476'] 1983,32690749,Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol.,"INTRODUCTION The radial artery has become the standard access site for percutaneous coronary intervention (PCI) in stable coronary artery disease and acute coronary syndrome, because of less access site related bleeding complications. Patients with complex coronary lesions are under-represented in randomised trials comparing radial with femoral access with regard to safety and efficacy. The femoral artery is currently the most applied access site in patients with complex coronary lesions, especially when large bore guiding catheters are required. With slender technology, transradial PCI may be increasingly applied in patients with complex coronary lesions when large bore guiding catheters are mandatory and might be a safer alternative as compared with the transfemoral approach. METHODS AND ANALYSIS A total of 388 patients undergoing complex PCI will be randomised to radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator. The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention. Procedural success and major adverse cardiovascular events up to 1 month will also be compared between both groups. ETHICS AND DISSEMINATION Ethical approval for the study was granted by the local Ethics Committee at each recruiting center ('Medisch Ethische Toetsing Commissie Isala Zwolle', 'Commissie voor medische ethiek ZNA', 'Comité Medische Ethiek Ziekenhuis Oost-Limburg', 'Comité d'éthique CHU-Charleroi-ISPPC', 'Commission cantonale d'éthique de la recherche CCER-Republique et Canton de Geneve', 'Ethik Kommission de Ärztekammer Nordrhein' and 'Riverside Research Ethics Committee'). The trial outcomes will be published in peer-reviewed journals of the concerned literature. TRIAL REGISTRATION NUMBER NCT03846752.",2020,The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention.,"['388 patients undergoing', 'Patients with complex coronary lesions', 'patients with complex coronary lesions']","['radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator', 'percutaneous coronary intervention (PCI', 'Complex Large-Bore Radial percutaneous coronary intervention', 'complex PCI']","['safety and efficacy', 'incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention', 'Procedural success and major adverse cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C2945608', 'cui_str': 'Bore'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",388.0,0.369498,The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention.,"[{'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Meijers', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Adel', 'Initials': 'A', 'LastName': 'Aminian', 'Affiliation': 'Cardiology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Wallonie, Belgium.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Teeuwen', 'Affiliation': 'Cardiology, Catharina Hospital, Eindhoven, Noord Brabant, The Netherlands.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'van Wely', 'Affiliation': 'Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Schmitz', 'Affiliation': 'Cardiology, Elisabeth-Krankenhaus-Essen GmbH, Essen, Nordrhein-Westfalen, Germany.'}, {'ForeName': 'Maurits T', 'Initials': 'MT', 'LastName': 'Dirksen', 'Affiliation': 'Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, Noord-Holland, The Netherlands.'}, {'ForeName': 'Rene J', 'Initials': 'RJ', 'LastName': 'van der Schaaf', 'Affiliation': 'Cardiology, OLVG, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Iglesias', 'Affiliation': 'Cardiology, Geneva University Hospitals, Geneve, Genève, Switzerland.'}, {'ForeName': 'Pierfrancesco', 'Initials': 'P', 'LastName': 'Agostoni', 'Affiliation': 'Cardiology, ZNA, Antwerpen, Belgium.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Dens', 'Affiliation': 'Cardiology, Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Knaapen', 'Affiliation': 'Cardiology, Amsterdam UMC - Locatie VUMC, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Sudhir', 'Initials': 'S', 'LastName': 'Rathore', 'Affiliation': 'Cardiology, Frimley Health NHS Foundation Trust, Frimley, Surrey, UK.'}, {'ForeName': 'Jan Paul', 'Initials': 'JP', 'LastName': 'Ottervanger', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Jan-Henk E', 'Initials': 'JE', 'LastName': 'Dambrink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Roolvink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'A T Marcel', 'Initials': 'ATM', 'LastName': 'Gosselink', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Renicus S', 'Initials': 'RS', 'LastName': 'Hermanides', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'van Royen', 'Affiliation': 'Cardiology, Radboudumc, Nijmegen, Gelderland, The Netherlands.'}, {'ForeName': 'Maarten A H', 'Initials': 'MAH', 'LastName': 'van Leeuwen', 'Affiliation': 'Cardiology, Isala Hospitals, Zwolle, The Netherlands m.a.h.van.leeuwen@isala.nl.'}]",BMJ open,['10.1136/bmjopen-2020-038042'] 1984,32697335,A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.,"BACKGROUND In a randomized study, glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC) significantly prolonged survival in comparison with LDAC in patients with acute myeloid leukemia (AML). A quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) approach was used to evaluate comparative quality-adjusted survival. METHODS Overall survival was partitioned into the following: time with any treatment-emergent grade 3 or higher adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL). Q-TWiST was calculated by multiplying the restricted mean time in each state by respective utilities and then summing up the utility-adjusted time. RESULTS At 20 months of follow-up, the survival probabilities for the glasdegib-LDAC arm and the LDAC arm were 28.2% and 7.9%, respectively. Glasdegib-LDAC patients (n = 78), in comparison with LDAC patients (n = 38), had significantly longer mean TWiST (+3.4 months; 95% confidence interval [CI], 1.8-5.2 months) and TOX (+0.8 months; 95% CI, 0.1-1.6 months) and longer but nonsignificant REL (+0.3 months; 95% CI, -1.9 to 2.3 months). Q-TWiST was 4.0 months (95% CI, 2.1-5.8 months) longer with glasdegib plus LDAC, and this translated into a 75% relative improvement in quality-adjusted survival with respect to LDAC. Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. CONCLUSIONS These results suggest that most of the survival benefit from glasdegib plus LDAC versus LDAC alone is TWiST, and this represents added time in relatively ""good"" health. These results support the clinical value of glasdegib plus LDAC as initial therapy for AML in patients for whom intensive chemotherapy is not an option.",2020,"Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. ","['acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy', 'patients with acute myeloid leukemia (AML']","['cytarabine', 'glasdegib (a hedgehog inhibitor) plus low-dose cytarabine (LDAC', 'LDAC', 'glasdegib plus low-dose cytarabine']","['comparative quality-adjusted survival', 'survival probabilities', 'adverse events (TOX); time without symptoms of disease progression or toxicity (TWiST); and time after treatment discontinuation due to insufficient clinical response, relapse, or death time after progression (REL', 'TOX', 'quality-adjusted survival', 'longer mean TWiST']","[{'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C4519273', 'cui_str': 'glasdegib'}, {'cui': 'C0018866', 'cui_str': 'Erinaceidae'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C1301931', 'cui_str': 'Time of death'}, {'cui': 'C0040541', 'cui_str': 'Toxicology'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.107607,"Results were robust to the length of follow-up (6-24 months) and remained significant when all adverse events, regardless of grade, were included. ","[{'ForeName': 'Caitlyn T', 'Initials': 'CT', 'LastName': 'Solem', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'Bell', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Youngmin', 'Initials': 'Y', 'LastName': 'Kwon', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Cappelleri', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Bhattacharyya', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Caroline J', 'Initials': 'CJ', 'LastName': 'Hoang', 'Affiliation': 'Pfizer, Inc, New York, New York.'}, {'ForeName': 'Jorge E', 'Initials': 'JE', 'LastName': 'Cortes', 'Affiliation': 'Pharmerit - an OPEN Health Company, Bethesda.'}]",Cancer,['10.1002/cncr.33072'] 1985,32693198,Short term effects of the REAL media e-learning media literacy substance prevention curriculum: An RCT of adolescents disseminated through a community organization.,"BACKGROUND The primary aim of this study was to evaluate the short-term effects of testing an e-learning program to reduce adolescent substance use and abuse. Early initiation of substance use is linked to a variety of negative outcomes, thus effective intervention programs are needed. One approach is to use media literacy to capitalize on adolescents' immersion with media in a variety of forms. We developed, implemented, and tested an engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H). METHODS 639 middle adolescents from nine U.S. states participated in an RCT of REAL media. Participants completed a series of online surveys and were randomized to use an online substance prevention program (REAL media) or serve as control (delayed program use). Self-report surveys were administered at three points in time. This short-term evaluation uses data from the pretest (Time 1) and short-term posttest three-month surveys, which measured demographics, self-efficacy to counterargue, and injunctive and descriptive substance use norms. RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program. No significant differences were observed for descriptive norms. CONCLUSIONS We found support for the REAL media program in changing key predictors of youth substance use demonstrating (1) the efficacy of media literacy interventions targeting adolescents and (2) that e-learning substance use prevention efforts can be adapted for and implemented through community organizations.",2020,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.",['639 middle adolescents from nine U.S. states participated in an RCT of REAL media'],"['e-learning program', 'engaging substance use prevention program by collaborating with a youth-oriented community partner (4-H', 'REAL media e-learning media literacy substance prevention curriculum', 'online substance prevention program (REAL media) or serve as control (delayed program use']",['self-efficacy to counterargue and decreased positive injunctive norms'],"[{'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}]","[{'cui': 'C0086858', 'cui_str': 'Programmed Learning'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0150358', 'cui_str': 'Substance use prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0023864', 'cui_str': 'Literacy'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}]",639.0,0.0245006,"RESULTS Participants who completed the REAL media program reported increased self-efficacy to counterargue and decreased positive injunctive norms compared to control participants who did not complete the program.","[{'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Greene', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA. Electronic address: klgreene@rutgers.edu.'}, {'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Ray', 'Affiliation': 'Department of Health, Behavior & Society, University of Kentucky, 343 Bowman Hall, Lexington, KY, 40536, USA.'}, {'ForeName': 'Hye Jeong', 'Initials': 'HJ', 'LastName': 'Choi', 'Affiliation': 'Department of Health Sciences, University of Missouri, 501 Clark Hall, Columbia, MO, 65211, USA.'}, {'ForeName': 'Shannon D', 'Initials': 'SD', 'LastName': 'Glenn', 'Affiliation': 'Department of Communication, Rutgers, the State University of New Jersey, 4 Huntington St., New Brunswick, NJ, 08901, USA; REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Lyons', 'Affiliation': 'Department of 4-H Youth Development, Rutgers, the State University of New Jersey, 88 Lipman Drive, New Brunswick, NJ, 08901, USA.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Hecht', 'Affiliation': 'REAL Prevention, LLC, 130 Pearl Brook Drive, Clifton, NJ, 07013, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108170'] 1986,32693310,The influence of type of feedback during tablet-based delivery of intensive treatment for childhood apraxia of speech.,"PURPOSE One of the key principles of motor learning supports using knowledge of results feedback (KR, i.e., whether a response was correct / incorrect only) during high intensity motor practice, rather than knowledge of performance (KP, i.e., whether and how a response was correct/incorrect). In the future, mobile technology equipped with automatic speech recognition (ASR) could provide KR feedback, enabling this practice to move outside the clinic, supplementing speech pathology sessions and reducing burden on already stretched speech-language pathology resources. Here, we employ a randomized controlled trial design to test the impact of KR vs KP feedback on children's response to the Nuffield Dyspraxia Programme 3, delivered through an android tablet. At the time of testing, ASR was not feasible and so correctness of responses was decided by the treating clinician. METHOD Fourteen children with CAS, aged 4-10 years, participated in a parallel group design, matched for age and severity of CAS. Both groups attended a university clinic for 1-hr therapy sessions 4 days a week for 3 weeks. One group received high frequency feedback comprised of both KR and KP, in the style of traditional, face-to-face intensive intervention on all days. The other group received high frequency KR + KP feedback on 1 day per week and high frequency KR feedback on the other 3 days per week, simulating the service delivery model of one clinic session per week supported by tablet-based home practice. RESULTS Both groups had significantly improved speech outcomes at 4-months post-treatment. Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment. Heterogeneity in response to intervention within the groups suggests that other factors, not measured here, may be having a substantive influence on response to intervention and feedback type. CONCLUSION Mobile technology has the potential to increase motivation and engagement with therapy and to mitigate barriers associated with distance and access to speech pathology services. Further research is needed to explore the influence of type and frequency of feedback on motor learning, optimal timing for transitioning from KP to KR feedback, and how these parameters interact with task, child and context-related factors.",2020,Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment.,"['childhood apraxia of speech', 'Fourteen children with CAS, aged 4-10 years, participated in a parallel group design, matched for age and severity of CAS']","['KR vs KP feedback', 'mobile technology equipped with automatic speech recognition (ASR', 'high frequency KR + KP feedback', 'high frequency feedback comprised of both KR and KP']",['speech outcomes'],"[{'cui': 'C0750927', 'cui_str': 'Developmental verbal dyspraxia'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}]","[{'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",14.0,0.0201653,Post-hoc comparisons suggested that only the KP group showed a significant change from pre- to immediately post-treatment but the group difference had dissipated by 1-month post-treatment.,"[{'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'McKechnie', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia; Faculty of Health, University of Canberra, Bruce, ACT, Australia. Electronic address: Jacqui.McKechnie@canberra.edu.au.'}, {'ForeName': 'Beena', 'Initials': 'B', 'LastName': 'Ahmed', 'Affiliation': 'Texas A&M University at Qatar, Doha, Qatar; Faculty of Engineering, University of New South Wales, Sydney, NSW, Australia.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Gutierrez-Osuna', 'Affiliation': 'Texas A & M University, College Station, TX, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Murray', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'McCabe', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}, {'ForeName': 'Kirrie J', 'Initials': 'KJ', 'LastName': 'Ballard', 'Affiliation': 'Faculty of Health Sciences, The University of Sydney, Lidcombe, NSW, Australia.'}]",Journal of communication disorders,['10.1016/j.jcomdis.2020.106026'] 1987,32693322,"Effects of messaging on public support for drug consumption rooms in scotland, UK.","BACKGROUND There is evidence to suggest that medically supervised drug consumption rooms (DCRs) may form part of responses to reduce drug-related harm. Although DCRs have been established globally, they are perceived by some to be a controversial approach in the UK, and Government has repeatedly rejected proposals to establish one in Glasgow, Scotland. As public support is an important component of policy development and enactment, we sought to investigate the effects of different types of message framing on public support for DCR. METHODS We undertook a cross-sectional online study with a randomised design, conducted with a nationally representative sample. Participants were randomised to one of six message conditions comprising combinations of four components. All conditions included i) a basic description of a DCR, and conditions included combinations of ii) factual information; iii) pre-emptive refutation of common public concerns about DCR; and/or iv) a sympathetic narrative describing a mother whose son died from a heroin overdose. After reading each message, participants completed a bespoke measure assessing support for DCR. Data were analysed using ANCOVA. RESULTS Complete data were obtained from 1591 participants (50.3% Female; mean age 44.9 ± 16.1 years). Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001); sympathetic + factual (p < .05); and sympathetic + factual + refutation (p < .001) message conditions. Presenting factual or sympathetic messages alone were not associated with increased support. CONCLUSION Our findings suggest that public support for DCRs is not improved through communication of factual statements outlining potential benefits of the intervention alone. Advocates seeking to foster public support, and thus influence policy making, should also consider communication campaigns that address common concerns that the public might have about DCRs, and present the intervention in relation to potential benefits that they hold for people indirectly affected by drug-related harm.",2020,"Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001);",['1591 participants (50.3% Female; mean age 44.9\xa0±\xa016.1 years'],[],[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}]",[],[],1591.0,0.119354,"Compared to reading a basic description of DCR alone, there was greater support for DCR in participants receiving the refutation (p < .001);","[{'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Sumnall', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK. Electronic address: h.sumnall@ljmu.ac.uk.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Atkinson', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK.'}, {'ForeName': 'K M A', 'Initials': 'KMA', 'LastName': 'Trayner', 'Affiliation': 'School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Gage', 'Affiliation': 'Psychological Sciences, University of Liverpool, UK.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'McAuley', 'Affiliation': 'Public Health Institute, Liverpool John Moores University, Liverpool, UK; Health Protection Scotland, Glasgow, UK.'}]",The International journal on drug policy,['10.1016/j.drugpo.2020.102855'] 1988,32699176,"Effects of food supplementation on cognitive function, cerebral blood flow, and nutritional status in young children at risk of undernutrition: randomized controlled trial.","OBJECTIVE To assess the effects of food supplementation on improving working memory and additional measures including cerebral blood flow in children at risk of undernutrition. DESIGN Randomized controlled trial. SETTING 10 villages in Guinea-Bissau. PARTICIPANTS 1059 children aged 15 months to 7 years; children younger than 4 were the primary population. INTERVENTIONS Supervised isocaloric servings (≈1300 kJ, five mornings each week, 23 weeks) of a new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast). MAIN OUTCOME MEASUREMENTS The primary outcome was working memory, a core executive function predicting long term academic achievement. Additional outcomes were hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ). In addition to an intention-to-treat analysis, a predefined per protocol analysis was conducted in children who consumed at least 75% of the supplement (820/925, 89%). The primary outcome was assessed by a multivariable Poisson model; other outcomes were assessed by multivariable linear mixed models. RESULTS Among children younger than 4, randomization to NEWSUP increased working memory compared with the control meal (rate ratio 1.20, 95% confidence interval 1.02 to 1.41, P=0.03), with a larger effect in the per protocol population (1.25, 1.06 to 1.47, P=0.009). NEWSUP also increased hemoglobin concentration among children with anemia (adjusted mean difference 0.65 g/dL, 95% confidence interval 0.23 to 1.07, P=0.003) compared with the control meal, decreased body mass index z score gain (-0.23, -0.43 to -0.02, P=0.03), and increased lean tissue accretion (2.98 cm 2 , 0.04 to 5.92, P=0.046) with less fat (-5.82 cm 2 , -11.28 to -0.36, P=0.04) compared with FBF. Additionally, NEWSUP increased CBF i compared with the control meal and FBF in both age groups combined (1.14 mm 2 /s×10 -8 , 0.10 to 2.23, P=0.04 for both comparisons). Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). CONCLUSIONS Childhood undernutrition is associated with long term impairment in cognition. Contrary to current understanding, supplementary feeding for 23 weeks could improve executive function, brain health, and nutritional status in vulnerable young children living in low income countries. Further research is needed to optimize nutritional prescriptions for regenerative improvements in cognitive function, and to test effectiveness in other vulnerable groups. TRIAL REGISTRATION ClinicalTrials.gov NCT03017209.",2020,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","['10 villages in Guinea-Bissau', 'young children at risk of undernutrition', 'children at risk of undernutrition', '1059 children aged 15 months to 7 years; children younger than 4 were the primary population']","['NEWSUP', 'food supplementation', 'Supervised isocaloric servings', 'new food supplement (NEWSUP, high in plant polyphenols and omega 3 fatty acids, within a wide variety and high fortification of micronutrients, and a high protein content), or a fortified blended food (FBF) used in nutrition programs, or a control meal (traditional rice breakfast']","['working memory, a core executive function predicting long term academic achievement', 'hemoglobin concentration', 'lean tissue accretion', 'working memory', 'hemoglobin concentration, growth, body composition, and index of cerebral blood flow (CBF i ', 'cerebral blood flow', 'body mass index z score gain', 'CBF', 'executive function, brain health, and nutritional status', 'lean tissue', 'cognitive function, cerebral blood flow, and nutritional status', 'working memory or anemia']","[{'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0018387', 'cui_str': 'Guinea-Bissau'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C0425119', 'cui_str': 'Child at risk'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032098', 'cui_str': 'Kingdom Viridiplantae'}, {'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0332464', 'cui_str': 'Widening'}, {'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0453850', 'cui_str': 'Liquidized food'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0035567', 'cui_str': 'Rice'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}]","[{'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C1318517', 'cui_str': 'Hemoglobin concentration, dipstick - finding'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0333038', 'cui_str': 'Accretion'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]",1059.0,0.234524,"Among children aged 4 and older, NEWSUP had no significant effect on working memory or anemia, but increased lean tissue compared with FBF (4.31 cm 2 , 0.34 to 8.28, P=0.03). ","[{'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Roberts', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA susan.roberts@tufts.edu.'}, {'ForeName': 'Maria A', 'Initials': 'MA', 'LastName': 'Franceschini', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Rachel E', 'Initials': 'RE', 'LastName': 'Silver', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Salima F', 'Initials': 'SF', 'LastName': 'Taylor', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Augusto Braima', 'Initials': 'AB', 'LastName': 'de Sa', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Raimundo', 'Initials': 'R', 'LastName': 'Có', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Aliu', 'Initials': 'A', 'LastName': 'Sonco', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Krauss', 'Affiliation': 'Peeled Snacks, Cumberland, RI, USA.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Taetzsch', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Webb', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Sai Krupa', 'Initials': 'SK', 'LastName': 'Das', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'C-Y', 'Initials': 'CY', 'LastName': 'Chen', 'Affiliation': 'Biofortis, Mérieux NutriSciences, Addison, IL, USA.'}, {'ForeName': 'Beatrice L', 'Initials': 'BL', 'LastName': 'Rogers', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Saltzman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'Pei-Yi', 'Initials': 'PY', 'LastName': 'Lin', 'Affiliation': 'Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, USA.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Schlossman', 'Affiliation': 'Gerald J and Dorothy R Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pruzensky', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Carlito', 'Initials': 'C', 'LastName': 'Balé', 'Affiliation': 'International Partnership for Human Development, Leesburg, VA, USA and Bissau, Guinea Bissau.'}, {'ForeName': 'Kenneth Kwan Ho', 'Initials': 'KKH', 'LastName': 'Chui', 'Affiliation': 'Department of Public Health and Community Medicine, Tufts School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Muentener', 'Affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}]",BMJ (Clinical research ed.),['10.1136/bmj.m2397'] 1989,32700409,The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial.,"AIMS Patients with heart failure (HF) have impaired quality of life (QoL). The randomized controlled trial PHARM-CHF investigated whether an interdisciplinary intervention consisting of regular contacts with the community pharmacy and weekly dosing aids improves medication adherence in patients with HF. It is unknown how an intervention involving frequent structured pharmacy visits affects QoL. Our aim was to explore adherence to the intervention and effects on QoL. METHODS AND RESULTS Among 237 patients, n = 110 were randomized to pharmacy care and n = 127 to usual care. The pharmacy care group received a medication review followed by (bi-)weekly dose dispensing and counselling. The median follow-up was 2.0 years [inter-quartile range (IQR) 1.2-2.7]. Median interval between pharmacy visits was 8.4 days (IQR 8.0-10.3) and the visits lasted in median 14 min (IQR 10-15). Median adherence to the intervention was 96% (IQR 84-100). QoL at 365 days was predefined as a main secondary and at 730 days as another secondary endpoint in PHARM-CHF. QoL was measured by the Minnesota Living with Heart Failure Questionnaire; and for 111 patients (n = 47 in the pharmacy care group and n = 64 in the usual care group), data were available at baseline, and after 365 and 730 days (mean age 74 years; 41% female). Improvement in QoL was numerically higher in the pharmacy care group after 365 days and was significantly better after 730 days (difference in total scores -7.7 points [-14.5 to -1.0]; P = 0.026) compared to the usual care group. In all subgroups examined, this treatment effect was preserved. Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [-6.9 to -1.2]; P = 0.006, and -1.9 points [-3.7 to -0.1]; P = 0.039, respectively. CONCLUSIONS A pharmacy-based interdisciplinary intervention was well received by the patients and suggests clinically important improvements in QoL.",2020,Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [,"['patients with HF', '111 patients (n\xa0=\xa047 in the pharmacy care group and n\xa0=\xa064 in the usual care group), data were available at baseline, and after 365 and 730\xa0days (mean age 74\xa0years; 41% female', 'Patients with heart failure (HF', 'heart failure patients', '237 patients, n\xa0=\xa0110 were randomized to pharmacy care and n\xa0=\xa0127 to usual care']",['pharmacist/physician care'],"['quality of life', 'Improvement in QoL', 'quality of life (QoL', 'QoL', 'physical and emotional dimensions', 'Median interval between pharmacy visits', 'Median adherence', 'medication adherence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517536', 'cui_str': '110'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0031831', 'cui_str': 'Physician'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",110.0,0.0898566,Improvements in the physical and emotional dimensions were numerically higher in the pharmacy care group after 365 days and were significantly better after 730 days: -4.0 points [,"[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schulz', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Griese-Mammen', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Pia M', 'Initials': 'PM', 'LastName': 'Schumacher', 'Affiliation': 'Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Berlin, Germany.'}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Division of Cardiology and Metabolism, Department of Cardiology (CVK) and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Friedrich', 'Initials': 'F', 'LastName': 'Koehler', 'Affiliation': 'Centre for Cardiovascular Telemedicine, Department of Cardiology and Angiology, Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ruckes', 'Affiliation': 'Interdisciplinary Centre for Clinical Trials, University Medical Centre Mainz, Mainz, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Rettig-Ewen', 'Affiliation': 'Schwemlinger Gemeinschaftspraxis, Merzig, Germany.'}, {'ForeName': 'Rolf', 'Initials': 'R', 'LastName': 'Wachter', 'Affiliation': 'Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Trenk', 'Affiliation': 'Department of Clinical Pharmacology, University Heart Centre Freiburg-Bad Krozingen, Bad Krozingen, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Department of Internal Medicine III - Cardiology, Angiology and Intensive Care Medicine, University Hospital of Saarland, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Laufs', 'Affiliation': 'Department of Cardiology, University Hospital, Leipzig University, Leipzig, Germany.'}]",ESC heart failure,['10.1002/ehf2.12904'] 1990,32708906,The Contrasting Effects of an Action Video Game on Visuo-Spatial Processing and Proactive Cognitive Control.,"First person shooter or action video games represent one of the most popular genres within the gaming industry. Studies reveal that action gaming experience leads to enhancements of visuo-spatial processing. In contrast, some correlational evidence reveals that experience with action video games may be associated with reduced proactive cognitive control. The two primary goals of the current study were to test the causal nature of the effect of action gaming on proactive cognitive control and to examine whether an increase in visuo-spatial processing and a decrease in proactive cognitive control arise from the same amount of experience playing an action video game. Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group. The data revealed the typical increase in visuo-spatial processing and a decrease in proactive, but not reactive, cognitive control following action game training. The sizes of these two training effects were similar in magnitude, but interpretation of the effects was constrained by baseline differences between the four groups of subjects. The possibility of a causal effect of action gaming on proactive cognitive control is interesting within the context of correlational evidence linking greater action gaming experience to reduced cognitive control, poor decision making, and increased impulsivity.",2020,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,[],"['tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group', 'action gaming', 'Action Video Game']","['visuo-spatial processing', 'proactive cognitive control', 'Visuo-Spatial Processing and Proactive Cognitive Control']",[],"[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0441472', 'cui_str': 'Action'}]","[{'cui': 'C3850026', 'cui_str': 'Auditory Spatial Processing'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0152109,Participants completed tasks measuring visuo-spatial processing and cognitive control before and after 10 practice sessions involving one of three video games or were assigned to a no gaming experience control group.,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Psychology and Neuroscience, DePauw University, Greencastle, IN 46135, USA.'}, {'ForeName': 'Edward L', 'Initials': 'EL', 'LastName': 'Swing', 'Affiliation': ""Phoenix Children's Hospital, Phoenix, AZ 85016, USA.""}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Anderson', 'Affiliation': 'Department of Psychology, Iowa State University, Ames, IA 50010, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Prot', 'Affiliation': 'School of Psychological, Social, and Behavioral Sciences, Coventry University, Coventry CV1 5FB, UK.'}]",International journal of environmental research and public health,['10.3390/ijerph17145160'] 1991,32708930,The Effects of Loaded Plyometric Exercise during Warm-Up on Subsequent Sprint Performance in Collegiate Track Athletes: A Randomized Trial.,"Prior evidence demonstrates the efficacy by which plyometric activities during warm-up conditions augment the subsequent performance in power-centric exercise. We investigated the acute effects of loaded jump squats incorporated into a standard sprinters' warm-up protocol on subsequent sprint performance in collegiate track athletes. Sprint times of 22 male and female collegiate track athletes were measured in 10-m intervals during a 30-m sprint trial following a standard sprinters' warm-up routine with or without plyometric exercise. Subjects were tested on two separate occasions, once with loaded jump squats as the experimental treatment (two sets of eight jumps, load = 13% bodyweight) (PLYO) and once with time-equated rest as the control treatment (CON). Treatments were implemented following a standard sprinters' warm-up routine familiar to the subjects. A dependent T-test was used for comparison of sprint interval times between conditions with a significant effect indicated by a p -value < 0.05. Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals. There was no interaction between treatment and sex, sex-specific ranking (above vs. below sex-specific mean), or sprint event (short vs. short-long vs. long) for 10 m, 20 m, or 30-m interval sprint times. At least within the limits of the current investigation, no evidence was provided to suggest that jump squats loaded at 13% bodyweight are an effective means to acutely potentiate sprint performance in collegiate track athletes. However, a further examination of responders indicates that the present loaded jump squat protocol may preferentially potentiate sprint performance in faster male athletes.",2020,"Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals.","['22 male and female collegiate track athletes', 'Collegiate Track Athletes', 'faster male athletes', 'collegiate track athletes']","[""standard sprinters' warm-up routine with or without plyometric exercise"", 'Loaded Plyometric Exercise']","['sprint performance', 'Sprint time']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C2350169', 'cui_str': 'Warming-Up Exercise'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}]",22.0,0.0364633,"Sprint time did not differ between CON vs. PLYO at the 10 m (PLYO = 1.90 ± 0.12 s vs. CON = 1.90 ± 0.11 s, p = 0.66), 20 m (PLYO = 3.16 ± 0.21 s vs. CON = 3.15 ± 0.19 s, p = 0.53), and 30 m (PLYO = 4.32 ± 0.32 s vs. CON = 4.31 ± 0.28 s, p = 0.61) intervals.","[{'ForeName': 'Kalin A', 'Initials': 'KA', 'LastName': 'Tomlinson', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Hansen', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Helzer', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Zakkoyya H', 'Initials': 'ZH', 'LastName': 'Lewis', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Whitney D', 'Initials': 'WD', 'LastName': 'Leyva', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'McCauley', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Pritchard', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Silvestri', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Quila', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Yi', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Jo', 'Affiliation': 'Human Performance Research Laboratory, Department of Kinesiology and Health Promotion, California State Polytechnic University, Pomona, CA 91768, USA.'}]","Sports (Basel, Switzerland)",['10.3390/sports8070101'] 1992,32708938,"Effectiveness of 6-Week Nordic Walking Training on Functional Performance, Gait Quality, and Quality of Life in Parkinson's Disease.","Background and objectives: Motor rehabilitation improves physical mobility and quality of life in Parkinson's disease (PD). As specialized rehabilitation is expensive and resource-consuming, there is a need for simpler, cost-effective methods. The purpose of the study was to determine whether Nordic Walking (NW) training may support the management of motor disability in PD. Materials and Methods: Forty patients (median age 64.0 years, range 50-75 years) with idiopathic PD, Hoehn and Yahr stages II-III, were randomly assigned to NW or standard rehabilitation (SR) programs, comprising twelve rehabilitation sessions conducted bi-weekly throughout the 6-week study period. Results: Median Unified Parkinson's Disease Rating Scale part III scores were significantly reduced with NW, by 8.5, and with SR, by 6.0 points (both p < 0.001), with significantly greater improvement with NW than with SR ( p = 0.047). Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064). Quality of life, assessed using the Parkinson's Disease Questionnaire (PDQ-39), improved with NW by a median of 15 and with SR by 12 points, p = 0.001 and p = 0.008, respectively. Conclusions: The 6-week Nordic Walking program improves functional performance, quality of gait, and quality of life in patients with PD and has comparable effectiveness to standard rehabilitation.",2020,"Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064).","['patients with PD', ""Parkinson's Disease"", ""Parkinson's disease (PD"", 'Forty patients (median age 64.0 years, range 50-75 years) with idiopathic PD, Hoehn and Yahr stages II-III']","['Nordic Walking program', 'Motor rehabilitation', 'NW or standard rehabilitation (SR) programs', '6-Week Nordic Walking Training', 'Nordic Walking (NW) training']","[""Quality of life, assessed using the Parkinson's Disease Questionnaire (PDQ-39"", ""Unified Parkinson's Disease Rating Scale part III scores"", 'Functional Performance, Gait Quality, and Quality of Life', 'Dynamic Gait Index', 'physical mobility and quality of life', 'Gait quality and balance control', 'functional performance, quality of gait, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C2919794', 'cui_str': 'Dynamic gait index'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0206053,"Gait quality and balance control, measured using the Dynamic Gait Index, improved with NW by a median of 8.0 and with SR by 5.5 points (both p < 0.001), with slightly greater improvement with NW, compared to the SR group ( p = 0.064).","[{'ForeName': 'Justyna', 'Initials': 'J', 'LastName': 'Szefler-Derela', 'Affiliation': 'Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'Arkuszewski', 'Affiliation': 'Institute for Innovative Medicine, 15-082 Białystok, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Knapik', 'Affiliation': 'Department of Adapted Physical Activity and Sport, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Dagmara', 'Initials': 'D', 'LastName': 'Wasiuk-Zowada', 'Affiliation': 'Department of Physiotherapy, School of Health Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Gorzkowska', 'Affiliation': 'Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Krzystanek', 'Affiliation': 'Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56070356'] 1993,32708973,Efficacy of a High-Iron Dietary Intervention in Women with Celiac Disease and Iron Deficiency without Anemia: A Clinical Trial.,"BACKGROUND AND AIM Iron deficiency without anemia (IDWA) is a common finding in celiac disease (CD) and can also persist in case of good compliance and clinical response to a strict gluten-free diet (GFD). This scenario usually presents in CD women of child-bearing age in whom the imbalance between menstrual iron loss and inadequate iron intake from their diet plays the major role. A recommended approach to this condition is yet to be established. This study aimed to compare, in this subset of patients, the efficacy of a dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy. MATERIAL AND METHODS Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled. After the completion of a 7-day weighed food intake recording to assess the usual iron dietary intake, the patients were randomized in two arms to receive a 12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS) (105 mg/day). Blood tests and dietary assessments were repeated at the end of treatment. The degree of compliance and tolerability to the treatments were assessed every month by means of specific questionnaires and symptoms evaluation. RESULTS A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years). The food intake records demonstrated an inadequate daily intake of iron in all the enrolled subjects. At the end of the treatments, ferritin levels were higher in the FS group (8.5 (5) versus 34 (30.8), p = 0.002). Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). CONCLUSIONS These findings did not support any equivalent efficacy of an iron-rich diet compared to a FS supplementation in non-anemic iron-deficient women affected by CD. However, the diet appeared a well-tolerated approach, and adequate dietary instructions could effectively increase the daily iron consumption, suggesting a role in the long-term management of IDWA, especially in patients who do not tolerate pharmacological supplementation.",2020,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","['Between February and December 2016, consecutive CD female patients of child-bearing age as referred to our outpatient center with evidence of IDWA (ferritin <15 ng/mL or 15-20 ng/L with transferrin saturation <15%) were enrolled', 'Women with Celiac Disease and Iron Deficiency without Anemia', 'A total of 22 women were enrolled and divided in the diet group ( n = 10, age 37 ± 8 years) and in the FS group ( n = 12, age 38 ± 10 years']","['12-week iron-rich diet (iron intake >20 mg/die) versus oral iron supplementation with ferrous sulfate (FS', 'High-Iron Dietary Intervention', 'dietary approach consisting of an iron-rich diet against the traditional pharmacological oral-replacement therapy', 'FS supplementation']","['Compliance and tolerability', 'daily iron consumption', 'degree of compliance and tolerability', 'Blood tests and dietary assessments', 'ferritin levels']","[{'cui': 'C0007570', 'cui_str': 'Celiac disease'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0340950', 'cui_str': 'Iron deficiency without anemia'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0439297', 'cui_str': 'ng/L'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0518043', 'cui_str': 'Iron intake'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0060282', 'cui_str': 'ferrous sulfate'}, {'cui': 'C0860976', 'cui_str': 'Iron increased'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0031330', 'cui_str': 'Pharmacology'}, {'cui': 'C0279033', 'cui_str': 'Replacement therapy'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0373607', 'cui_str': 'Ferritin measurement'}]",22.0,0.0323893,"Compliance and tolerability were similar in both treatment groups (89% versus 87%, p = ns). ","[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Scricciolo', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Elli', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'Doneda', 'Affiliation': 'Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy.'}, {'ForeName': 'Karla A', 'Initials': 'KA', 'LastName': 'Bascunan', 'Affiliation': 'Department of Nutrition, School of Medicine, University of Chile, 8380453 Santiago, Chile.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Branchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Ferretti', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Vecchi', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}, {'ForeName': 'Leda', 'Initials': 'L', 'LastName': 'Roncoroni', 'Affiliation': ""Center for Prevention and Diagnosis of Coeliac Disease-Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milan, Italy.""}]",Nutrients,['10.3390/nu12072122'] 1994,32708991,"Effect of High versus Low Dairy Consumption on the Gut Microbiome: Results of a Randomized, Cross-Over Study.","The influence of dairy on the gut microbiome has not been studied extensively. We performed a randomized cross-over study to analyze the effect of high dairy intake on the gut microbiome. Subjects were randomly assigned to a high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD) (≤1 dairy portion per day) for 6 weeks with a washout period of 4 weeks in between both diets. The gut microbiome was assessed using 16S rRNA gene sequencing. Compositionality and functionality of the gut microbiome was assessed using Quantitative Insights Into Microbial Ecology (QIIME) and Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Stool consistency was evaluated using the Bristol stool chart. In total, 46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods. During the HDD, there was a significantly higher abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides ( p FDR < 0.10). Furthermore, during the HDD, there was a significantly lower abundance of the genera Faecalibacterium and Bilophila , and the species Faecalibacterium prausnitzii , Clostridium aldenense , Acetivibrio ethanolgignens , Bilophila wadsworthia and Lactococcus lactis ( p FDR < 0.10). There were eight subjects who became constipated during the HDD and these subjects all had a lower abundance of F. prausnitzii . This is the first cross-over study in which the effect of an HDD compared to an LDD on the gut microbiome has been studied. An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus . Constipation was observed in several subjects during the HDD. Predicted metabolic pathways were not significantly altered due to an HDD.",2020,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","['46 healthy overweight subjects (BMI range 25-30 kg/m 2 ) completed both intervention periods', 'Gut Microbiome']","['High versus Low Dairy Consumption', 'high-dairy diet (HDD) (5-6 dairy portions per day) and a low-dairy diet (LDD']","['abundance of the genera Streptococcus , Leuconostoc , and Lactococcus , and the species Streptococcus thermophilus , Erysipelatoclostridium ramosum and Leuconostoc mesenteroides', 'Stool consistency', 'Predicted metabolic pathways', 'Constipation']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0442749', 'cui_str': '6/5'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0023411', 'cui_str': 'Leuconostoc'}, {'cui': 'C0085549', 'cui_str': 'Lactococcus'}, {'cui': 'C0318180', 'cui_str': 'Streptococcus salivarius subsp. thermophilus'}, {'cui': 'C0315111', 'cui_str': 'Clostridium ramosum'}, {'cui': 'C0317708', 'cui_str': 'Leuconostoc mesenteroides'}, {'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C1291081', 'cui_str': 'Metabolic pathway'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",46.0,0.0185083,"An HDD led to a significantly different composition of the gut microbiome, with a particularly lower abundance of F. prausnitzii and a higher abundance of S. thermophilus .","[{'ForeName': 'J Casper', 'Initials': 'JC', 'LastName': 'Swarte', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Coby', 'Initials': 'C', 'LastName': 'Eelderink', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Rianne M', 'Initials': 'RM', 'LastName': 'Douwes', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'M Yusof', 'Initials': 'MY', 'LastName': 'Said', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Shixian', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Post', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Ralf', 'Initials': 'R', 'LastName': 'Westerhuis', 'Affiliation': 'Dialyses Center Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Stephan J L', 'Initials': 'SJL', 'LastName': 'Bakker', 'Affiliation': 'Department of Nephrology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}, {'ForeName': 'Hermie J M', 'Initials': 'HJM', 'LastName': 'Harmsen', 'Affiliation': 'Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.'}]",Nutrients,['10.3390/nu12072129'] 1995,32709779,Evaluation of skills transfer in short-term phacoemulsification surgery training program by International Council of Ophthalmology -Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR) and assessment of efficacy of ICO-OSCAR for objective evaluation of skills transfer.,"Purpose To evaluate skills transfer in short-term phacoemulsification surgery training program by International Council of Ophthalmology -Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR) and assessment of efficacy of ICO-OSCAR for objective evaluation of skills transfer. Methods Prospective analysis of total 1300 phacoemulsification surgeries performed by 52 phacoemulsification trainees divided into three groups based on the previous cataract surgical experience. The pretraining and posttraining average mean scores, independent completion rates (ICR), and complication rates among the groups were calculated and statistically analyzed. Results Mean age of trainees (N = 52) was found to be 30.98 ± 2.44 years. Mean pretraining scores in the three groups were 42.8 ± 0.2, 46.6 ± 0.2, and 50.1 ± 0.1, respectively, and posttraining mean scores of the groups were 88.4 ± 0.2, 92.3 ± 0.2, and 94.3 ± 0.2, respectively, out of 100. Pretraining independent completion rates (%) were 22.1 ± 2.5, 52.1 ± 2.5, and 62 ± 3.7, respectively, and posttraining independent completion rates (%) were 74.8 ± 3, 79.7 ± 3, and 90.6 ± 3.5, respectively. Learning curves of all groups were noted to be steep. Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases). OSCAR scores correlate significantly (P = 0.0004) with ICR. Conclusion Steep learning curve for phacoemulsification can be made easy by the use of standardized rubrics, proper techniques, expert guidance, and adequate surgical volume. The previous SICS experience provides smoother learning curve. ICO-OSCAR is indicator of proficiency and provides constructive feedback and objective evaluation immediately after surgery as well as at the end of training. Short-term (1 Month) training program is an effective, efficient, and safe approach to progressively master phacoemulsification skills for trainees with SICS experience.",2020,"Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases).","['total 1300 phacoemulsification surgeries performed by 52 phacoemulsification trainees divided into three groups based on the previous cataract surgical experience', 'short-term phacoemulsification surgery training program by International Council of Ophthalmology', 'Mean age of trainees (N = 52) was found to be 30.98 ± 2.44 years', 'trainees with SICS experience']",['ICO-OSCAR'],"['completion rates (ICR), and complication rates', 'overall complication rate', 'OSCAR scores', 'Learning curves', 'Rate of complications', 'Mean pretraining scores', 'Ophthalmology Surgical Competency Assessment Rubrics (ICO-OSCAR']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0282545', 'cui_str': 'Phacoemulsification'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0329207', 'cui_str': 'Astronotus ocellatus'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1299583', 'cui_str': 'Independent'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0329207', 'cui_str': 'Astronotus ocellatus'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0029087', 'cui_str': 'Ophthalmology'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0086035', 'cui_str': 'Competence'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",1300.0,0.0188267,"Rate of complications was within acceptable range, overall complication rate being 12.30% (160 out of 1300 cases).","[{'ForeName': 'Khurshed M', 'Initials': 'KM', 'LastName': 'Bharucha', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Vivek G', 'Initials': 'VG', 'LastName': 'Adwe', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Atul M', 'Initials': 'AM', 'LastName': 'Hegade', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Rahul D', 'Initials': 'RD', 'LastName': 'Deshpande', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'Madan D', 'Initials': 'MD', 'LastName': 'Deshpande', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}, {'ForeName': 'V K S', 'Initials': 'VKS', 'LastName': 'Kalyani', 'Affiliation': ""PBMA's H V Desai Eye Hospital, Hadapsar, Pune, Maharashtra, India.""}]",Indian journal of ophthalmology,['10.4103/ijo.IJO_2058_19'] 1996,32709786,Short-term outcome of botulinum neurotoxin A injection with or without sodium hyaluronate in the treatment of infantile esotropia-a prospective interventional study.,"Purpose To compare the short-term outcome of botulinum neurotoxin A (BoNT-A) with or without sodium hyaluronate in the treatment of infantile esotropia (IE). Methods In this tertiary care hospital-based prospective, interventional, non-randomized study on infants with IE below one year of age, 25 cases were enrolled in the sodium hyaluronate (SH) group to receive 2.5 U BoNT-A injection combined with SH in each medial rectus muscle (MR). Thirty patients were enrolled in the control group to receive 2.5 U BoNT-A injection with normal saline in each MR. The change in mean primary ocular deviation (POD) and complications were assessed at 2 weeks, 1 month, 3 months, and 6 months post injection. Mann-Whitney U test was used for non-parametric unpaired data. Chi-square test and Fisher's exact test were used to test for the strength of the association between the two categorical variables. Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80). While the change in mean POD was comparable (29.2 prism diopters [PD] vs 29.3 PD; P value = 0.65), the complication rates were significantly lesser in SH (16% vs 33.3%; P value = 0.14). Conclusion BoNT-A combined with SH is equally effective with lesser complications as compared to botulinum toxin alone in the treatment of IE.",2020,"Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80).","['Thirty patients were enrolled in the control group to', 'infants with IE below one year of age, 25 cases were enrolled in the', 'infantile esotropia (IE']","['botulinum neurotoxin', 'A injection with or without sodium hyaluronate', 'SH', 'botulinum toxin', 'sodium hyaluronate (SH) group to receive 2.5 U BoNT-A injection combined with SH', 'receive 2.5 U BoNT-A injection with normal saline', 'botulinum neurotoxin A (BoNT-A) with or without sodium hyaluronate']","['complication rates', 'mean primary ocular deviation (POD) and complications', 'Satisfactory ocular alignment', 'mean POD', 'SH']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0014877', 'cui_str': 'Esotropia'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0868928', 'cui_str': 'Case'}]","[{'cui': 'C1295507', 'cui_str': 'Bontoxilysin'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}, {'cui': 'C0006055', 'cui_str': 'botulinum toxin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1112602', 'cui_str': 'Ocular deviation'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0729280', 'cui_str': 'Ocular muscle balance'}, {'cui': 'C0087000', 'cui_str': 'Hyaluronate sodium'}]",30.0,0.0204661,"Results Satisfactory ocular alignment was achieved in 76% in SH group and 73% in the control group (P value = 0.80).","[{'ForeName': 'Nitika', 'Initials': 'N', 'LastName': 'Pandey', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Siddharth', 'Initials': 'S', 'LastName': 'Agrawal', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Rajat M', 'Initials': 'RM', 'LastName': 'Srivastava', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}, {'ForeName': 'Vinita', 'Initials': 'V', 'LastName': 'Singh', 'Affiliation': ""Department of Ophthalmology, King George's Medical University, Lucknow, Uttar Pradesh, India.""}]",Indian journal of ophthalmology,['10.4103/ijo.IJO_1552_19'] 1997,32709851,"Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.",,2020,,['pediatric patients with relapsed/refractory acute lymphoblastic leukemia'],['Blinatumomab'],[],"[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}]","[{'cui': 'C3853839', 'cui_str': 'blinatumomab'}]",[],,0.0367656,,"[{'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Locatelli', 'Affiliation': ""Department of Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza, University of Rome, Rome, Italy.""}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Zugmaier', 'Affiliation': 'Amgen Research (Munich) GmbH, Munich, Germany. gerhardz@amgen.com.'}, {'ForeName': 'Noemi', 'Initials': 'N', 'LastName': 'Mergen', 'Affiliation': 'Amgen Research (Munich) GmbH, Munich, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bader', 'Affiliation': 'Department for Children and Adolescents, University Hospital Frankfurt, Frankfurt, Germany.'}, {'ForeName': 'Sima', 'Initials': 'S', 'LastName': 'Jeha', 'Affiliation': ""St Jude Children's Research Hospital, Memphis, TN, USA.""}, {'ForeName': 'Paul-Gerhardt', 'Initials': 'PG', 'LastName': 'Schlegel', 'Affiliation': ""University Children's Hospital Wuerzburg, Wuerzburg, Germany.""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Bourquin', 'Affiliation': ""Department of Pediatric Oncology, Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland.""}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Handgretinger', 'Affiliation': ""Department of Hematology/Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.""}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Brethon', 'Affiliation': 'Pediatric Hematology and Immunology Department, Robert Debre Hospital, APHP, Paris, France.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Rossig', 'Affiliation': ""Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.""}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Chen-Santel', 'Affiliation': 'Department of Pediatrics, Division of Oncology and Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",Blood cancer journal,['10.1038/s41408-020-00342-x'] 1998,32709890,Impact of an active lifestyle on heart rate variability and oxidative stress markers in offspring of hypertensives.,"Familial history of hypertension is associated with autonomic dysfunction and increase in blood pressure (BP). However, an active lifestyle has been found to improve a number of health outcomes and reduce all-cause mortality. The aim of the present study was to investigate the effects of an active lifestyle on hemodynamics, heart rate variability (HRV) and oxidative stress markers in offspring of hypertensive parents. One hundred twenty-seven subjects were assigned into four groups: sedentary offspring of normotensives (S-ON) or hypertensives (S-OH); and physically active offspring of normotensives (A-ON) or hypertensives (A-OH). Diastolic BP and heart rate were reduced in the physically active groups when compared to S-OH group. A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± 241 ms 2 ). Cardiac sympato-vagal balance (LF/HF), systemic hydrogen peroxide and superoxide anion were markedly increased in S-OH group when compared to all other studied groups. Additionally, important correlations were observed between LF/HF with diastolic BP (r = 0.30) and hydrogen peroxide (r = 0.41). Thus, our findings seem to confirm an early autonomic dysfunction in offspring of hypertensive parents, which was associated with a systemic increase in reactive oxygen species and blood pressure. However, our most important finding lies in the attenuation of such disorders in offspring of physically active hypertensives, thus emphasizing the importance of a physically active lifestyle in the prevention of early disorders that may be associated with onset of hypertension.",2020,"A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± ","['offspring of hypertensives', 'One hundred twenty-seven subjects', 'offspring of hypertensive parents']","['active lifestyle', 'sedentary offspring of normotensives (S-ON) or hypertensives (S-OH); and physically active offspring of normotensives (A-ON) or hypertensives (A-OH']","['LF/HF with diastolic BP', 'heart rate variability and oxidative stress markers', 'hydrogen peroxide', 'blood pressure (BP', 'values of RR total variance', 'reactive oxygen species and blood pressure', 'hemodynamics, heart rate variability (HRV) and oxidative stress markers', 'Diastolic BP and heart rate', 'Cardiac sympato-vagal balance (LF/HF), systemic hydrogen peroxide and superoxide anion']","[{'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}]","[{'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0162772', 'cui_str': 'Oxygen Species, Reactive'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0038836', 'cui_str': 'Superoxide'}]",127.0,0.0258121,"A-ON and A-OH groups presented increased values of RR total variance when compared to the sedentary ones (A-ON: 4,912 ± 538 vs. S-ON: 2,354 ± 159; A-OH: 3,112 ± 236 vs. S-OH: 2,232 ± ","[{'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Santa-Rosa', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'G L', 'Initials': 'GL', 'LastName': 'Shimojo', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'D S', 'Initials': 'DS', 'LastName': 'Dias', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Viana', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'F C', 'Initials': 'FC', 'LastName': 'Lanza', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Irigoyen', 'Affiliation': 'Heart Institute (InCor), Medical School, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'De Angelis', 'Affiliation': 'Laboratory of Translational Physiology, Universidade Nove de Julho (UNINOVE), São Paulo, Brazil. prof.kangelis@yahoo.com.br.'}]",Scientific reports,['10.1038/s41598-020-69104-w'] 1999,32709912,Exercise as a protective mechanism against the negative effects of oxidative stress in first-episode psychosis: a biomarker-led study.,"First-episode psychosis (FEP) is a psychiatric disorder, characterised by positive and negative symptoms, usually emerging during adolescence and early adulthood. FEP represents an early intervention opportunity for intervention in psychosis. Redox disturbance and subsequent oxidative stress have been linked to the pathophysiology of FEP. Exercise training can perturb oxidative stress and rebalance the antioxidant system and thus represents an intervention with the potential to interact with a mechanism of disease. The aim of this study was to assess the effect of exercise on markers of redox status in FEP. Twenty-two young men were recruited from Birmingham Early Intervention services and randomised to either a 12-week exercise programme or treatment as usual (control). Measures of blood and brain glutathione (GSH), markers of oxidative damage, inflammation, neuronal health, symptomology and habitual physical activity were assessed. Exercise training was protective against changes related to continued psychosis. Symptomatically, those in the exercise group showed reductions in positive and general psychopathology, and stable negative symptoms (compared to increased negative symptoms in the control group). Peripheral GSH was increased by 5.6% in the exercise group, compared to a significant decrease (24.4%) (p = 0.04) in the control group. Exercise attenuated negative changes in markers of neuronal function (brain-derived neurotrophic factor), lipid damage (thiobarbituric acid-reactive substances) and total antioxidant capacity. C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged. Moderate-intensity exercise training has the ability to elicit changes in markers of oxidative stress and antioxidant concentration, with subsequent improvements in symptoms of psychosis.",2020,"C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged.","['Twenty-two young men', 'first-episode psychosis']","['Exercise training', 'Moderate-intensity exercise training', 'FEP', 'exercise programme or treatment as usual (control']","['Peripheral GSH', 'protein and DNA oxidation', 'blood and brain glutathione (GSH), markers of oxidative damage, inflammation, neuronal health, symptomology and habitual physical activity', 'positive and general psychopathology, and stable negative symptoms', 'C-reactive protein and tumour necrosis factor-α', 'neuronal function (brain-derived neurotrophic factor), lipid damage (thiobarbituric acid-reactive substances) and total antioxidant capacity']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0907533', 'cui_str': 'NOS1 protein, human'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1456820', 'cui_str': 'Tumor necrosis factor alpha'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",22.0,0.0277852,"C-reactive protein and tumour necrosis factor-α also decreased in the exercise group, although protein and DNA oxidation were unchanged.","[{'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fisher', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Wood', 'Affiliation': 'Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, Melbourne, VIC, 3052, Australia.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'Elsworthy', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Upthegrove', 'Affiliation': 'Institute for Mental Health, University of Birmingham, Edgbaston, B15 2TT, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Aldred', 'Affiliation': 'School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, B15 2TT, UK. s.aldred.1@bham.ac.uk.'}]",Translational psychiatry,['10.1038/s41398-020-00927-x'] 2000,32710204,PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy.,"Intraperitoneal chemoperfusion (IPEC) of cisplatin is a popular treatment for advanced ovarian cancer, typically under hyperthermia (HIPEC). The use of cisplatin under (H)IPEC is off-label, and the role of hyperthermia is unknown. The aim of this study was to characterize the pharmacokinetic/pharmacodynamic (PKPD) properties of cisplatin under (H)IPEC and to predict the optimal treatment regimen. Using a randomized design, data on intact cisplatin perfusate and plasma concentrations, leukocyte counts-a hematotoxicity marker-and serum creatinine-a nephrotoxicity marker-were collected from 50 patients treated with a combination of cytoreductive surgery (CRS) and either normothermic or hyperthermic IPEC of cisplatin dosed at 75, 100, and 120 mg/m 2 . The non-linear mixed effects modeling technique was used to construct the PKPD models. The PK of intact cisplatin was characterized by a two-compartment model. A semi-physiological myelosuppression model for the leukopenia was modified to account for the CRS-induced leukocytosis and the residual myelosuppression effect of neoadjuvant chemotherapy. The incidence and severity of nephrotoxicity were described by a discrete-time Markov model. Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia. Leukopenia was not severe, but nephrotoxicity can become severe or life-threatening and was affected by the dose and IPEC duration. The model predicted that nephrotoxicity is minimal at a cisplatin dose of 75 mg/m 2 with an IPEC duration of 1-2 h and an 1-h duration is favored for doses between 100 and 120 mg/m 2 . Graphical abstract.",2020,Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia.,"['advanced ovarian cancer, typically under hyperthermia (HIPEC', '50 patients treated with a combination of cytoreductive surgery (CRS) and either', 'Advanced Ovarian Cancer Patients Treated with']","['Intraperitoneal chemoperfusion (IPEC) of cisplatin', 'cisplatin under (H)IPEC', 'normothermic or hyperthermic IPEC of cisplatin', 'Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy']","['incidence and severity of nephrotoxicity', 'toxicities', 'Leukopenia', 'plasma concentrations, leukocyte counts-a hematotoxicity marker-and serum creatinine-a nephrotoxicity marker', 'absorption rate of cisplatin']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive surgery'}]","[{'cui': 'C0442120', 'cui_str': 'Intraperitoneal'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0445103', 'cui_str': 'Normothermia'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0595916', 'cui_str': 'Toxic nephropathy'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C0920103', 'cui_str': 'Haematotoxicity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}]",,0.0393438,Hyperthermia increased the absorption rate of cisplatin by 16.3% but did not show a clinically relevant impact on the investigated toxicities compared with normothermia.,"[{'ForeName': 'Feifan', 'Initials': 'F', 'LastName': 'Xie', 'Affiliation': 'Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Tongzipo Road 172, Changsha, 410013, China. feifan.xie@csu.edu.cn.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Van Bocxlaer', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Colin', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Carlier', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Van Kerschaver', 'Affiliation': 'Department of Surgery, St. Lucas Andreas Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Weerts', 'Affiliation': 'Department of Surgery, CHC, Liège, Belgium.'}, {'ForeName': 'Hannelore', 'Initials': 'H', 'LastName': 'Denys', 'Affiliation': 'Cancer Research Institute Ghent (CRIG), 9000, Ghent, Belgium.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Tummers', 'Affiliation': 'Department of Gynecology, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'Willaert', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'Ceelen', 'Affiliation': 'Department of GI Surgery, Ghent University Hospital, 9000, Ghent, Belgium.'}, {'ForeName': 'An', 'Initials': 'A', 'LastName': 'Vermeulen', 'Affiliation': 'Laboratory of Medical Biochemistry and Clinical Analysis, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.'}]",The AAPS journal,['10.1208/s12248-020-00489-2'] 2001,32710304,Early surfactant replacement guided by lung ultrasound in preterm newborns with RDS: the ULTRASURF randomised controlled trial.,"This study aimed to investigate whether using lung ultrasound (LUS) scores in premature newborns with respiratory distress syndrome (RDS) allows for earlier surfactant therapy (within the first 3 h of life) than using FiO 2 criteria. This was a randomised, non-blinded clinical trial conducted in a neonatal intensive care unit. The inclusion criteria were newborns with a gestational age of ≤ 32 weeks and RDS. Patients meeting the inclusion criteria were randomly assigned to two groups: the ultrasound group, administered surfactant based on LUS score and/or FiO 2 threshold, and the control group, guided by FiO 2 only. Fifty-six patients were included. The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011). After surfactant treatment, newborns in the ultrasound group presented a greater SpO 2 (p = 0.001) and SpO 2 /FiO 2 ratio (p = 0.012).Conclusions: LUS score allowed an earlier surfactant therapy, reduced oxygen exposure early in life and a better oxygenation after the treatment. This early surfactant replacement may lead to reduced oxygen exposure. What is Known: • Lung ultrasound scores predict the need for surfactant therapy in premature newborns. What is New: • This study shows that using lung ultrasound scores improves the timeliness of surfactant replacement compared with using FiO 2 alone.",2020,"The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011).","['premature newborns', 'preterm newborns with RDS', 'Patients meeting the inclusion criteria', 'newborns with a gestational age of ≤ 32 weeks and RDS', 'premature newborns with respiratory distress syndrome (RDS', 'Fifty-six patients were included']","['surfactant replacement guided by lung ultrasound', 'surfactant therapy', 'lung ultrasound (LUS) scores', 'ultrasound group, administered surfactant based on LUS score and/or FiO 2 threshold, and the control group, guided by FiO 2 only']",['oxygen exposure early in life and a better oxygenation'],"[{'cui': 'C0233315', 'cui_str': 'Premature birth of newborn'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0035220', 'cui_str': 'Respiratory distress syndrome in the newborn'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0034085', 'cui_str': 'Lung surfactant'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}]",56.0,0.110221,"The ultrasound group received surfactant earlier (1 h of life vs. 6 h, p < 0.001), with lower FiO 2 (25% vs. 30%, p = 0.016) and lower CO 2 (48 vs. 54, p = 0.011).","[{'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Rodriguez-Fanjul', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. javier.rodriguez.fanjul@gmail.com.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Jordan', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Balaguer', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Batista-Muñoz', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ramon', 'Affiliation': 'Neonatal Intensive Care Unit, Paediatrics Department, Hospital Joan XXIII, Tarragona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bobillo-Perez', 'Affiliation': 'Paediatric Intensive Care Unit, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain.'}]",European journal of pediatrics,['10.1007/s00431-020-03744-y'] 2002,32706640,"Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.","PURPOSE NRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802. METHODS IDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates. RESULTS Of the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH- wild type, 43 (41%) were IDH- mutant/non-codeleted, and 37(35%) were IDH- mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH- mutant/non-codeleted and IDH- mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. CONCLUSION This study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH -mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.",2020,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","['patients with WHO low-grade glioma (LGG, grade II', 'NRG Oncology/RTOG 9802', 'High-Risk Low-Grade Glioma']","['NRG', 'Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine', 'postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine', 'adjuvant chemoradiotherapy over radiotherapy']","['PFS', 'PFS or OS', 'Progression-free survival (PFS) and overall survival (OS', 'Hazard ratios (HRs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1997217', 'cui_str': 'Low grade glioma'}, {'cui': 'C1629836', 'cui_str': 'Lactobacillus rhamnosus GG'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0033223', 'cui_str': 'Procarbazine'}, {'cui': 'C0023972', 'cui_str': 'Lomustine'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C3178761', 'cui_str': 'Adjuvant Chemoradiotherapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439227', 'cui_str': 'hour'}]",,0.0972708,"In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH- wild-type subgroup. ","[{'ForeName': 'Erica H', 'Initials': 'EH', 'LastName': 'Bell', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Peixin', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Edward G', 'Initials': 'EG', 'LastName': 'Shaw', 'Affiliation': 'Wake Forest School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Buckner', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Geoffrey R', 'Initials': 'GR', 'LastName': 'Barger', 'Affiliation': 'Wayne State University, Detroit, MI.'}, {'ForeName': 'Dennis E', 'Initials': 'DE', 'LastName': 'Bullard', 'Affiliation': 'Triangle Neurosurgery, Raleigh, NC.'}, {'ForeName': 'Minesh P', 'Initials': 'MP', 'LastName': 'Mehta', 'Affiliation': 'Baptist Hospital of Miami, Miami, FL.'}, {'ForeName': 'Mark R', 'Initials': 'MR', 'LastName': 'Gilbert', 'Affiliation': 'National Institutes of Health, Bethesda, MD.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Brown', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'Keith J', 'Initials': 'KJ', 'LastName': 'Stelzer', 'Affiliation': 'Mid-Columbia Medical Center, The Dalles, OR.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McElroy', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Fleming', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Cynthia D', 'Initials': 'CD', 'LastName': 'Timmers', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Aline P', 'Initials': 'AP', 'LastName': 'Becker', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Salavaggione', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Ziyan', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': 'The Ohio State University, Columbus, OH.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Aldape', 'Affiliation': 'Princess Margaret Cancer Centre, Toronto, Ontario, Canada.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Brachman', 'Affiliation': 'Arizona Oncology Services Foundation, Phoenix, AZ.'}, {'ForeName': 'Stanley Z', 'Initials': 'SZ', 'LastName': 'Gertler', 'Affiliation': 'The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada.'}, {'ForeName': 'Albert D', 'Initials': 'AD', 'LastName': 'Murtha', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Schultz', 'Affiliation': 'Froedtert and the Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Johnson', 'Affiliation': 'Wichita NCORP, Wichita, KS.'}, {'ForeName': 'Nadia N', 'Initials': 'NN', 'LastName': 'Laack', 'Affiliation': 'Rochester Methodist Hospital, Rochester, MN.'}, {'ForeName': 'Grant K', 'Initials': 'GK', 'LastName': 'Hunter', 'Affiliation': 'Intermountain Medical Center, Murray, UT.'}, {'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Crocker', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Minhee', 'Initials': 'M', 'LastName': 'Won', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, PA.'}, {'ForeName': 'Arnab', 'Initials': 'A', 'LastName': 'Chakravarti', 'Affiliation': 'The Ohio State University, Columbus, OH.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.02983'] 2003,32706652,Changes in Patient-Reported Outcome Measures With a Technology-Supported Behavioral Lifestyle Intervention Among Patients With Type 2 Diabetes: Pilot Randomized Controlled Clinical Trial.,"BACKGROUND In the United States, more than one-third of the adult population is obese, and approximately 25.2% of those aged ≥65 years have type 2 diabetes (T2D), which is the seventh leading cause of death. It is important to measure patient-reported outcomes and monitor progress or challenges over time when managing T2D to understand patients' perception of health and quantify the impact of disease processes or intervention effects. The evaluation of patient-reported outcome measures (PROMs) is especially important among patients with multiple chronic conditions in which clinical measures do not provide a complete picture of health. OBJECTIVE This study examined the feasibility of collecting Patient-Reported Outcome Measurement Information System (PROMIS) measures, and preliminarily evaluated changes in PROMIS scores and compared the scores with standard scores of the general US population. The parent study is a pilot randomized controlled clinical trial testing three different modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention among overweight or obese patients with T2D. METHODS Patients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program. Participants were randomized to the following three groups: mHealth, paper diary, and control (standard of care) groups. Paper diary and mHealth experimental groups received additional behavioral lifestyle intervention education sessions, as well as tools to self-monitor weight, physical activity, diet, and blood glucose. All participants completed PROMIS-57 and PROMIS-Global Health (GH) version 1.0 questionnaires during visits at baseline, 3 months, and 6 months. The PROMIS-57 includes the following seven domains: anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance. The PROMIS-GH is composed of the following two domains: global mental health and global physical health. RESULTS A total of 26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis. The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m 2 . All patients completed the PROMIS-57 and PROMIS-GH questionnaires, and we compared the mean scores of the three groups to investigate potential differences. No relevant differences were noted across the groups. However, positive trends were noted in both intervention (mHealth and paper diary) groups in the middle (month 3) and end (month 6) of the study. CONCLUSIONS Our pilot study provides evidence for the feasibility of using PROMIS questionnaires to record important components of T2D-related symptoms among overweight or obese individuals. The results from our study support the use of PROMIS questionnaires to provide clinicians and researchers with a benchmark for assessing the overall need for symptom management and determining the success or challenges of an intervention. TRIAL REGISTRATION ClinicalTrials.gov NCT02858648; https://clinicaltrials.gov/ct2/show/NCT02858648.",2020,No relevant differences were noted across the groups.,"['overweight or obese patients with T2D.\nMETHODS\n\n\nPatients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program', 'The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m 2 ', 'overweight or obese individuals', '26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis', 'Patients With Type']","['additional behavioral lifestyle intervention education sessions', 'Technology-Supported Behavioral Lifestyle Intervention', 'modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention']","['anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517742', 'cui_str': '37.5'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0037317', 'cui_str': 'Disturbance in sleep behavior'}]",6.0,0.0698373,No relevant differences were noted across the groups.,"[{'ForeName': 'Rozmin', 'Initials': 'R', 'LastName': 'Jiwani', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Berndt', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Padmavathy', 'Initials': 'P', 'LastName': 'Ramaswamy', 'Affiliation': 'Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.'}, {'ForeName': 'Nitha', 'Initials': 'N', 'LastName': 'Mathew Joseph', 'Affiliation': 'Cizik School of Nursing, The University of Texas Health Science Center at Houston, Houston, TX, United States.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Du', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Jisook', 'Initials': 'J', 'LastName': 'Ko', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Espinoza', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.'}]",JMIR diabetes,['10.2196/19268'] 2004,32706658,Scheduled Telephone Support for Internet Cognitive Behavioral Therapy for Depression in Patients at Risk for Dropout: Pragmatic Randomized Controlled Trial.,"BACKGROUND Therapist-supported, internet-delivered cognitive behavioral therapy (iCBT) is efficient in the treatment of depression. However, the optimal mode and intensity of therapist support remain to be identified. Scheduled telephone support (STS) may improve adherence and outcomes but, as it is time- and resource-consuming, should be reserved for patients for whom the usual support may be insufficient. OBJECTIVE This paper aims to reveal whether add-on STS for patients at risk of dropping out improves treatment adherence and symptoms in iCBT for depression. METHODS Among patients participating in an ongoing large observational routine clinical practice study of iCBT for depression delivered nationwide by Helsinki University Hospital (HUS-iCBT), those demonstrating a ≥14-day delay in initiation of treatment received invitations to this subsidiary STS study. A total of 100 consenting patients were randomly allocated to either HUS-iCBT as usual (control group, n=50) or HUS-iCBT plus add-on STS (intervention group, n=50). Proportions of those reaching midtreatment and treatment end point served as the primary outcome; secondary outcomes were change in Beck Depression Inventory (BDI)-measured depressive symptoms and time spent in treatment. RESULTS Add-on STS raised the proportion of patients reaching midtreatment compared with HUS-iCBT as usual (29/50, 58% vs 18/50, 36%; P=.045) and treatment end point (12/50, 24% vs 3/50, 6%; P=.02). Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. CONCLUSIONS Add-on STS enhances adherence and symptom improvement of patients at risk of dropping out of iCBT for depression in routine clinical practice. TRIAL REGISTRATION International Standard Randomised Controlled Trial Number (ISRCTN) 55123131; http://www.isrctn.com/ISRCTN55123131.",2020,"Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. ","['patients participating in an ongoing large observational routine clinical practice study of iCBT for depression delivered nationwide by Helsinki University Hospital (HUS-iCBT', '100 consenting patients']","['Scheduled Telephone Support for Internet Cognitive Behavioral Therapy', 'HUS-iCBT as usual (control group, n=50) or HUS-iCBT plus add-on STS (intervention', 'Scheduled telephone support (STS', 'Therapist-supported, internet-delivered cognitive behavioral therapy (iCBT']","['Change in BDI score', 'change in Beck Depression Inventory (BDI)-measured depressive symptoms and time spent in treatment']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0019061', 'cui_str': 'Hemolytic uremic syndrome'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C2711213', 'cui_str': 'Consented'}]","[{'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0019061', 'cui_str': 'Hemolytic uremic syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",100.0,0.220979,"Change in BDI score also favored add-on STS (3.63 points vs 1.1 points; P=.049), whereas duration of treatment did not differ. ","[{'ForeName': 'Satu', 'Initials': 'S', 'LastName': 'Pihlaja', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Jari', 'Initials': 'J', 'LastName': 'Lahti', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Jari Olavi', 'Initials': 'JO', 'LastName': 'Lipsanen', 'Affiliation': 'Department of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Ritola', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Eero-Matti', 'Initials': 'EM', 'LastName': 'Gummerus', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Jan-Henry', 'Initials': 'JH', 'LastName': 'Stenberg', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}, {'ForeName': 'Grigori', 'Initials': 'G', 'LastName': 'Joffe', 'Affiliation': 'Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.'}]",Journal of medical Internet research,['10.2196/15732'] 2005,32689849,Assessment of two prophylactic fluid strategies in aneurysmal subarachnoid hemorrhage: A randomized trial.,"OBJECTIVE To compare the effect of two prophylactic euvolemic fluid strategy regimens on the incidence of cerebral vasospasm and clinical outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). METHODS Ninety-six patients with a basal intravenous intake of 15 mL/kg/day of Ringer's lactate solution were included, and an additional 15 to 50 mL/kg/day Ringer's lactate (RL-group) or hydroxyethyl starch 130/0.4 solution (HES-group) was administered to maintain the targeted mean arterial pressure. The primary end point was the occurrence of cerebral vasospasm during the first 14 days. The secondary end points were case fatality, Barthel's index, and Glasgow Outcome Scores (GOS) at 30 days after SAH. RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe. The vasospasm rate among the RL- and HES-based groups was 25/48 and 17/48, respectively. For the secondary endpoint, four patients (4%) died by the end of follow-up (two in each group). Unfavorable outcome cases were not different in the RL and HES groups (9 vs. 14, respectively). There was no difference between the Barthel's scores at 30 days between the two groups. CONCLUSIONS Using starches in a prophylactic treatment strategy in aneurysmal SAH in not supported by the study.The trial was registered at Clinicaltrials.gov under the number NCT02064075.",2020,"RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe.","['aneurysmal subarachnoid hemorrhage', ""Ninety-six patients with a basal intravenous intake of 15 mL/kg/day of Ringer's lactate solution"", 'patients with aneurysmal subarachnoid hemorrhage (SAH']","['prophylactic euvolemic fluid strategy regimens', ""Ringer's lactate (RL-group) or hydroxyethyl starch 130/0.4 solution (HES-group) was administered to maintain the targeted mean arterial pressure""]","[""Barthel's scores"", 'cerebral vasospasm and clinical outcomes', 'vasospasm rate', 'Cerebral vasospasm', 'occurrence of cerebral vasospasm', ""case fatality, Barthel's index, and Glasgow Outcome Scores (GOS""]","[{'cui': 'C0751530', 'cui_str': 'Subarachnoid Hemorrhage, Aneurysmal'}, {'cui': 'C4319625', 'cui_str': '96'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1532579', 'cui_str': 'mL/kg/day'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0038525', 'cui_str': 'Subarachnoid hemorrhage'}]","[{'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C3495434', 'cui_str': 'hydroxyethyl starch 130-0.4'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0265110', 'cui_str': 'Spasm of cerebral arteries'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0042396', 'cui_str': 'Vascular constriction'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}]",96.0,0.232831,"RESULTS Cerebral vasospasm developed in 42 patients (43.7%), and nine of these events were severe.","[{'ForeName': 'Judit', 'Initials': 'J', 'LastName': 'Gál', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Béla', 'Initials': 'B', 'LastName': 'Fülesdi', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Dávid', 'Initials': 'D', 'LastName': 'Varga', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Babett', 'Initials': 'B', 'LastName': 'Fodor', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Varga', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Péter', 'Initials': 'P', 'LastName': 'Siró', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Dániel', 'Initials': 'D', 'LastName': 'Bereczki', 'Affiliation': 'Department of Neurology Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Sándor', 'Initials': 'S', 'LastName': 'Szabó', 'Affiliation': 'Department of Neurosurgery, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}, {'ForeName': 'Csilla', 'Initials': 'C', 'LastName': 'Molnár', 'Affiliation': 'Department of Anesthesiology and Intensive Care, University of Debrecen, Faculty of Medicine, Debrecen, Hungary.'}]",The Journal of international medical research,['10.1177/0300060520927526'] 2006,32696598,High-flow nasal cannula vs standard respiratory care in pediatric procedural sedation: A randomized controlled pilot trial.,"INTRODUCTION Respiratory instability is frequently observed during pediatric procedural sedation. The aim of this trial was to estimate the impact of high-flow nasal cannula (HFNC) therapy on respiratory stability during sedation for upper gastrointestinal tract endoscopy in children. METHODS Prospective randomized controlled non-blinded single-center pilot trial. Children were randomly allocated to receive either HFNC (2 L/kg/min) or low-flow nasal oxygen cannula (LFNC, standard care). FiO 2 was titrated to maintain SpO 2 94% to 98% in both groups. Primary outcome was the number of events of respiratory instability defined by prespecified criteria (hypoxia, hypercapnia, apnea). Secondary outcomes included type and duration of events, number of interventions to regain respiratory stability and cumulative doses of medication. RESULTS Fifty children (mean age, 12.3 ± 3.1 years) were enrolled and treated with HFNC (n = 25) or LFNC (n = 25). Patient and intervention characteristics were not different in the two study groups, including total oxygen flow rate. Mean (SD) number of respiratory events in the HFNC group was 2.0 ± 1.9 events compared to 2.0 ± 1.4 events in the LFNC group (P = .65; 95% CI of difference, -1.0 to 1.0). There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. CONCLUSIONS HFNC did not increase respiratory stability in sedated children undergoing upper gastrointestinal tract endoscopy compared to LFNC.",2020,"There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. ","['upper gastrointestinal tract endoscopy in children', 'sedated children undergoing upper gastrointestinal tract endoscopy', 'Fifty children (mean', 'age 12.3±3.1 years) were enrolled and treated with', 'pediatric procedural sedation']","['HFNC (2 L/kg/min) or low-flow nasal oxygen cannula (LFNC, standard care', 'High-flow nasal cannula versus standard respiratory care', 'LFNC', 'nasal high-flow nasal cannula (HFNC) therapy', 'HFNC']","['total oxygen flow rate', 'Mean (SD) number of respiratory events', 'respiratory stability', 'type and duration of events, number of interventions to regain respiratory stability and cumulative doses of medication', 'number of respiratory events or airway management maneuvers', 'number of events of respiratory instability defined by prespecified criteria (hypoxia, hypercapnia, apnea']","[{'cui': 'C0079304', 'cui_str': 'Esophagogastroduodenoscopy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C1637390', 'cui_str': 'mL/g'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0520453', 'cui_str': 'Cannula'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0035239', 'cui_str': 'Respiratory therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1320717', 'cui_str': 'Respiratory event'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0150126', 'cui_str': 'Airway management'}, {'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}]",50.0,0.190034,"There was no difference for any secondary outcome criteria, percentage of patients for any outcome criteria and no difference in the number of respiratory events or airway management maneuvers per patient between treatment groups. ","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Klotz', 'Affiliation': 'Division of Neonatology and Pediatric Intensive Care Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Seifert', 'Affiliation': 'Division of Neonatology and Pediatric Intensive Care Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Baumgartner', 'Affiliation': 'Division of Neonatology and Pediatric Intensive Care Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Teufel', 'Affiliation': 'Department of Gastroenterology, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Fuchs', 'Affiliation': 'Division of Neonatology and Pediatric Intensive Care Medicine, Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.'}]",Pediatric pulmonology,['10.1002/ppul.24975'] 2007,32692952,Posterior Rotational and Translational Stability in Acromioclavicular Ligament Complex Reconstruction: A Comparative Biomechanical Analysis in Cadaveric Specimens.,"BACKGROUND Persistent posterior instability of the acromioclavicular (AC) joint is a reported complication after isolated coracoclavicular (CC) reconstruction. Thus, multiple techniques have been proposed attempting to restore biomechanics of the AC ligament complex (ACLC). PURPOSE/HYPOTHESIS The purpose was to evaluate the posterior translational and rotational stability of an ACLC reconstruction with a dermal allograft (ACLC patch) as compared with 3 suture brace constructs. It was hypothesized that the ACLC patch would better restore AC joint posterior stability. STUDY DESIGN Controlled laboratory study. METHODS A total of 28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years) were randomly assigned to 1 of 4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace. The force and torque to achieve 10 mm of posterior translation and 20° of posterior rotation of the AC joint were recorded in the following conditions: intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair. RESULTS For posterior translation, transection of the ACLC reduced resistance to 16.7% of the native. With the native CC ligaments intact, the ACLC patch (59.1%), oblique brace (54.1%), and anterior brace (60.7%) provided significantly greater stability than the x-frame brace (33.2%; P < .001, P = .008, P < .001, respectively). ACLC patch, oblique brace, and anterior brace continued to have significantly higher posterior translational resistance than the x-frame (35.1%; P < .001, P = .003, P < .001) after transection and subsequent CC ligament repair. For posterior rotation, transection of the ACLC decreased the resistance to 5.4% of the intact state. With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001). CC ligament transection and subsequent repair demonstrated the ACLC patch (41.0%) to have improved stability when compared with the oblique (16.0%), anterior (14.0%), and x-frame (12.7%) repairs ( P = .006, P = .003, P = .002). CONCLUSION ACLC reconstruction with a dermal allograft better restored native posterior rotational stability than other brace constructs, with translational stability similar to the oblique and anterior brace technique at the time of surgery. CLINICAL RELEVANCE Horizontal stability of the AC joint is primarily controlled by the ACLC. Inability to restore AC joint biomechanics can result in persistent posterior instability and lead to functional impairment.",2020,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","['Cadaveric Specimens', 'Acromioclavicular Ligament Complex Reconstruction', '28 cadaveric shoulders (mean ± SD age, 57.6 ± 8.3 years']","['ACLC reconstruction with a dermal allograft (ACLC patch', '4 surgical techniques: ACLC patch, oblique brace, anterior brace, and x-frame brace', 'ACLC patch', 'intact, transected ACLC, ACLC patch/brace repair, ACLC patch/brace repair with dissected CC ligaments, and ACLC patch/brace repair with CC ligament repair']","['posterior translational and rotational stability', 'restore AC joint posterior stability', 'anterior brace', 'oblique brace', 'posterior rotational stability', 'posterior translational resistance']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0225039', 'cui_str': 'Structure of acromioclavicular ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0205239', 'cui_str': 'Dissecting'}, {'cui': 'C0225040', 'cui_str': 'Coracoclavicular ligament structure'}]","[{'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0001208', 'cui_str': 'Acromioclavicular joint structure'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}]",28.0,0.0329299,"With the CC ligaments intact, the ACLC patch (77.1%) better restored posterior rotational stability than the oblique (35.3%), anterior (48.5%), and x-frame (23.0%) brace repairs ( P < .001, P = .002, P < .001).","[{'ForeName': 'Daichi', 'Initials': 'D', 'LastName': 'Morikawa', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Joel B', 'Initials': 'JB', 'LastName': 'Huleatt', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Lukas N', 'Initials': 'LN', 'LastName': 'Muench', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Cameron', 'Initials': 'C', 'LastName': 'Kia', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Daniel P', 'Initials': 'DP', 'LastName': 'Berthold', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Mark P', 'Initials': 'MP', 'LastName': 'Cote', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Elifho', 'Initials': 'E', 'LastName': 'Obopilwe', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Kelolli', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Bastian', 'Initials': 'B', 'LastName': 'Scheiderer', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}, {'ForeName': 'Augustus D', 'Initials': 'AD', 'LastName': 'Mazzocca', 'Affiliation': 'Department of Orthopaedic Surgery, University of Connecticut, Farmington, Connecticut, USA.'}]",The American journal of sports medicine,['10.1177/0363546520939882'] 2008,32693009,Physical exercise interventions have no effect on serum BDNF concentration in older adults living in long-term nursing homes.,"Physical exercise protects against age-related cognitive decline. Brain-derived neurotrophic factor (BDNF) may mediate some of the cognitive benefits of physical exercise, but the effect of physical exercise on serum BDNF is unclear. Indeed, differential findings have been reported depending on the characteristics of the participants and the intensity, duration, and type of exercise. The aim of this study was to determine whether three different physical exercise interventions alter serum BDNF levels in older adults living in long-term nursing homes (LTNHs) and whether changes in physical, cognitive, and dual-task performance are related to changes in serum BDNF. LTNH study participants (n = 126) were randomly assigned to multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA. We also assessed physical, cognitive, and dual-task parameters. Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs. Changes in BDNF during the interventions were not significantly associated with modifications in physical, cognitive or dual-task performance parameters. Our results provide new evidence clarifying the relationship between physical and cognitive exercise and BDNF.",2020,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","['older adults living in long-term nursing homes (LTNHs', 'older adults living in LTNHs', 'LTNH study participants (n\u202f=\u202f126', 'older adults living in long-term nursing homes']","['physical exercise interventions', 'multicomponent or dual-task training or a walking program and serum BDNF levels were analyzed by ELISA', 'Physical exercise', 'multicomponent, dual-task, nor walking exercise programs', 'Physical exercise interventions']","['physical, cognitive, and dual-task parameters', 'physical, cognitive or dual-task performance parameters', 'serum BDNF levels', 'serum BDNF concentration']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0470256', 'cui_str': '126'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",126.0,0.0209679,"Neither the multicomponent, dual-task, nor walking exercise programs caused changes in serum BDNF concentration in older adults living in LTNHs.","[{'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Rezola-Pardo', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: chloe.rezola@ehu.eus.'}, {'ForeName': 'Gotzone', 'Initials': 'G', 'LastName': 'Hervás', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: gotzone.hervas@ehu.eus.'}, {'ForeName': 'Haritz', 'Initials': 'H', 'LastName': 'Arrieta', 'Affiliation': 'Department of Nursing II, Faculty of Medicine and Nursery, University of the Basque Country (UPV/EHU), Paseo Dr. J. Beguiristain, 105, Donostia/San Sebastian 20014, Gipuzkoa, Spain; Onkologikoa Foundation, Paseo Doctor Beguiristain, 121, Donostia/San Sebastián 20014, Gipuzkoa, Spain. Electronic address: haritz.arrieta@ehu.eus.'}, {'ForeName': 'Alejandra', 'Initials': 'A', 'LastName': 'Hernández-de Diego', 'Affiliation': 'Zorroaga Foundation, Alto Zorroaga, 1, Donostia/San Sebastian 20014, Gipuzkoa, Spain. Electronic address: s.hernandez@zorroaga.eus.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Ruiz-Litago', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: fatima.ruiz@ehu.eus.'}, {'ForeName': 'Susana Maria', 'Initials': 'SM', 'LastName': 'Gil', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: susana.gil@ehu.eus.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Rodriguez-Larrad', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: ana.rodriguez@ehu.eus.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Irazusta', 'Affiliation': 'Department of Physiology, Faculty of Medicine and Nursery, University of the Basque Country, Bo Sarriena s/n, Leioa 48940, Bizkaia, Spain. Electronic address: jon.irazusta@ehu.eus.'}]",Experimental gerontology,['10.1016/j.exger.2020.111024'] 2009,32700955,A randomized controlled trial of central executive training (CET) versus inhibitory control training (ICT) for ADHD.,"OBJECTIVE Executive function deficits are well-established in ADHD. Unfortunately, replicated evidence indicates that executive function training for ADHD has been largely unsuccessful. We hypothesized that this may reflect insufficient targeting, such that extant protocols do not sufficiently and specifically target the neurocognitive systems associated with phenotypic ADHD behaviors/impairments. METHOD Children with ADHD ages 8-12 (M = 10.41, SD = 1.46; 12 girls; 74% Caucasian/Non-Hispanic) were randomized with allocation concealment to either central executive training (CET; n = 25) or newly developed inhibitory control training (ICT; n = 29). Detailed data analytic plans were preregistered. RESULTS Both treatments were feasible/acceptable based on training duration, child-reported ease of use, and parent-reported high satisfaction. CET was superior to ICT for improving its primary intervention targets: phonological and visuospatial working memory (d = 0.70-0.84). CET was also superior to ICT for improving go/no-go (d = 0.84) but not stop-signal inhibition. Mechanisms of change analyses indicated that CET-related working memory improvements produced significant reductions in the primary clinical endpoints (objectively assessed hyperactivity) during working memory and inhibition testing (indirect effects: β ≥ -.11; 95% CIs exclude 0.0). CET was also superior to ICT on 3 of 4 secondary clinical endpoints (blinded teacher-rated ADHD symptoms; d = 0.46-0.70 vs. 0.16-0.42) and 2 of 4 feasibility/acceptability clinical endpoints (parent-reported ADHD symptoms; d = 0.96-1.42 vs. 0.45-0.65). CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. CONCLUSIONS Results support the use of CET for treating executive function deficits and targeting ADHD behavioral symptoms in children with ADHD. Findings for ICT were mixed at best and indicate the need for continued development/study. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. ","['children with ADHD', 'Children with ADHD ages 8-12 (M = 10.41, SD = 1.46; 12 girls; 74% Caucasian/Non-Hispanic']","['central executive training (CET; n = 25) or newly developed inhibitory control training (ICT', 'central executive training (CET) versus inhibitory control training (ICT', 'ICT', 'CET']",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C5191363', 'cui_str': '1.46'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],,0.087537,"CET-related gains were maintained at 2-4 month follow-up; ICT-related gains were maintained for attention problems but not hyperactivity/impulsivity per parent report. ","[{'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Kofler', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Erica L', 'Initials': 'EL', 'LastName': 'Wells', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Leah J', 'Initials': 'LJ', 'LastName': 'Singh', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Elia F', 'Initials': 'EF', 'LastName': 'Soto', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Lauren N', 'Initials': 'LN', 'LastName': 'Irwin', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Nicole B', 'Initials': 'NB', 'LastName': 'Groves', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Elizabeth S M', 'Initials': 'ESM', 'LastName': 'Chan', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Caroline E', 'Initials': 'CE', 'LastName': 'Miller', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Kijana P', 'Initials': 'KP', 'LastName': 'Richmond', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Schatschneider', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lonigan', 'Affiliation': 'Department of Psychology.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000550'] 2010,32700956,Applying experimental therapeutics to examine cognitive and chronological vulnerabilities as mediators of acute outcomes in cognitive-behavioral therapy and light therapy for winter depression.,"OBJECTIVE We applied the experimental therapeutics approach to test whether acute treatment outcomes for winter seasonal affective disorder (SAD) are mediated by a cognitive mechanism in cognitive-behavioral therapy (CBT-SAD) versus a chronobiologic mechanism in light therapy (LT). METHOD Currently depressed adults with major depression, recurrent with seasonal pattern (N = 177; 83.6% female, 92.1% non-Hispanic White, M age = 45.6) were randomized to 6 weeks of LT or group CBT-SAD. SAD symptoms were assessed weekly on the Structured Clinical Interview for the Hamilton Rating Scale for Depression-SAD Version. At pre-, mid-, and posttreatment, participants completed measures of general depressogenic cognitions (Dysfunctional Attitudes Scale; DAS); SAD-specific negative cognitions (Seasonal Beliefs Questionnaire; SBQ); chronotype (Morningness-Eveningness Questionnaire; MEQ); and depressive symptoms (Beck Depression Inventory-Second Edition). RESULTS Parallel-process growth models showed evidence for hypothesized mechanisms. For SAD-specific negative cognitions (SBQ), both symptom measures showed (1) an effect of treatment group on the slope of the mediator, with CBT-SAD demonstrating greater decreases, and (2) an effect of the slope of the mediator on the slope of the outcome. These effects held for the SBQ but not the broader measure of depressogenic cognitions (DAS). For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. CONCLUSIONS CBT-SAD promoted decreases in SAD-specific negative cognitions, and these changes were related to decreases in symptoms. Consistent with the theory that LT corrects misaligned circadian rhythms, LT reduced eveningness, but this did not correspond to symptom improvement. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. ","['winter depression', 'Currently depressed adults with major depression, recurrent with seasonal pattern (N = 177; 83.6% female, 92.1% non-Hispanic White, M age = 45.6', 'winter seasonal affective disorder (SAD']","['cognitive-behavioral therapy (CBT-SAD', 'cognitive-behavioral therapy and light therapy', 'CBT-SAD', 'LT or group CBT-SAD']","['general depressogenic cognitions (Dysfunctional Attitudes Scale; DAS); SAD-specific negative cognitions (Seasonal Beliefs Questionnaire; SBQ); chronotype (Morningness-Eveningness Questionnaire; MEQ); and depressive symptoms (Beck Depression Inventory-Second Edition', 'depressogenic cognitions (DAS', 'SAD symptoms', 'SAD-specific negative cognitions', 'Structured Clinical Interview for the Hamilton Rating Scale for Depression-SAD Version', 'For SAD-specific negative cognitions (SBQ']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0031765', 'cui_str': 'Light therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0051767', 'cui_str': 'amsonic acid'}, {'cui': 'C0085159', 'cui_str': 'Seasonal affective disorder'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439601', 'cui_str': 'Seasonal course'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439152', 'cui_str': 'mEq'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0441795', 'cui_str': 'Second edition'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0199182', 'cui_str': 'History taking'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C2607870', 'cui_str': 'Version'}]",,0.0343493,"For the chronotype measure (MEQ), treatment assignment affected change, whereby LT was associated with reduced ""eveningness,"" but this was unrelated to change in symptoms. ","[{'ForeName': 'Kelly J', 'Initials': 'KJ', 'LastName': 'Rohan', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Keith B', 'Initials': 'KB', 'LastName': 'Burt', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Camuso', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Perez', 'Affiliation': 'Department of Psychological Science.'}, {'ForeName': 'Jonah', 'Initials': 'J', 'LastName': 'Meyerhoff', 'Affiliation': 'Department of Psychological Science.'}]",Journal of consulting and clinical psychology,['10.1037/ccp0000499'] 2011,32697479,Financial Toxicity After Acute Respiratory Distress Syndrome: A National Qualitative Cohort Study.,"OBJECTIVES The financial burdens and subsequent related distress of medical care, referred to as financial toxicity, may limit access to beneficial treatments. However, financial toxicity after acute care is less described-and may be an important but underexplored mechanism preventing full recovery after critical illnesses such as acute respiratory distress syndrome. We sought to identify the mechanisms by which financial toxicity manifested in patients with acute respiratory distress syndrome, protective factors against such toxicity, and the consequences of financial toxicity to survivors' lives following acute respiratory distress syndrome. DESIGN We conducted semistructured interviews following patients' hospitalization and during recovery as an ancillary study to a multicenter randomized clinical trial in acute respiratory distress syndrome. Patients were 9-16 months post randomization at the time of interview. SETTING AND PARTICIPANTS The Reevaluation Of Systemic Early Neuromuscular Blockade trial examined the use of early neuromuscular blockade in mechanically ventilated patients with moderate/severe acute respiratory distress syndrome. We recruited consecutive surviving patients who were English speaking, consented to follow-up, and were randomized between December 11, 2017, and May 4, 2018 (n = 79) from 29 U.S. sites. MEASUREMENTS AND MAIN RESULTS We asked about patients' perceptions of financial burden(s) that they associated with their acute respiratory distress syndrome hospitalization. Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participated (from 22 sites); their median age was 56 (interquartile range 47-62). Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact. Financial toxicity manifested via medical bills, changes in insurance coverage, and loss of employment income. Respondents reported not working prior to acute respiratory distress syndrome, using Medicaid or Medicare, or, conversely, generous work benefits as factors which may have limited financial burdens. Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. CONCLUSIONS Financial toxicity related to critical illness is common and may limit patients' emotional, physical, and social recovery after acute respiratory distress syndrome hospitalization for at least a year.",2020,"Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. ","['patients with acute respiratory distress syndrome', 'acute respiratory distress syndrome', 'consecutive surviving patients who were English speaking, consented to follow-up, and were randomized between December 11, 2017, and May 4, 2018 (n = 79) from 29 U.S. sites', 'Forty-six of 79 eligible acute respiratory distress syndrome survivors (58%) participated (from 22 sites); their median age was 56 (interquartile range 47-62', 'mechanically ventilated patients with moderate/severe acute respiratory distress syndrome', 'Thirty-one of 46 reported at least one acute respiratory distress syndrome-related financial impact', 'After Acute Respiratory Distress Syndrome']",[],"['Financial toxicity manifested via medical bills, changes in insurance coverage, and loss of employment income', 'acute respiratory distress syndrome hospitalization', 'financial toxicity', 'Financial Toxicity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0234856', 'cui_str': 'Speaking'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1299448', 'cui_str': 'Patient ventilated'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",[],"[{'cui': 'C0376243', 'cui_str': 'finances'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0004895', 'cui_str': 'Beak'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0376629', 'cui_str': 'Insurance Status'}, {'cui': 'C0425083', 'cui_str': 'Loss of job'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0035222', 'cui_str': 'Acute respiratory distress syndrome'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.13736,"Patients reported multiple consequences of acute respiratory distress syndrome-related financial toxicity, including harms to their mental and physical health, increased reliance on others, and specific material hardships. ","[{'ForeName': 'Katrina E', 'Initials': 'KE', 'LastName': 'Hauschildt', 'Affiliation': '1Department of Sociology, College of Literature, Science, and Arts, University of Michigan, Ann Arbor, MI. 2Institute for Social Research, University of Michigan, Ann Arbor, MI. 3Veterans Affairs Center for Clinical Management Research, HSR&D Center of Innovation, Ann Arbor, MI. 4Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, WA. 5Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO. 6NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, United Kingdom. 7University of Glasgow, School of Medicine, Dentistry and Nursing, Glasgow, United Kingdom. 8Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Seigworth', 'Affiliation': ''}, {'ForeName': 'Lee A', 'Initials': 'LA', 'LastName': 'Kamphuis', 'Affiliation': ''}, {'ForeName': 'Catherine L', 'Initials': 'CL', 'LastName': 'Hough', 'Affiliation': ''}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Moss', 'Affiliation': ''}, {'ForeName': 'Joanne M', 'Initials': 'JM', 'LastName': 'McPeake', 'Affiliation': ''}, {'ForeName': 'Theodore J', 'Initials': 'TJ', 'LastName': 'Iwashyna', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Critical care medicine,['10.1097/CCM.0000000000004378'] 2012,32700772,GLP-1 receptor agonists for Parkinson's disease.,"BACKGROUND Parkinson's disease (PD) is a progressive disorder characterised by both motor and non-motor problems. Glucagon-like peptide-1 (GLP-1) receptor agonists, licensed for treatment of type 2 diabetes, work by stimulating GLP-1 receptors in the pancreas, which triggers the release of insulin. GLP-1 receptors have been found in the brain. Insulin signalling in the brain plays a key role in neuronal metabolism and repair and in synaptic efficacy, but insulin signalling is desensitised in the brain of people with PD. Researchers are exploring the neuroprotective effects of GLP-1 receptor agonists in neurodegenerative disorders such as PD. OBJECTIVES To evaluate the effectiveness and safety of GLP-1 receptor agonists for Parkinson's disease. SEARCH METHODS We searched the Cochrane Movement Disorders Group trials register; the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library; and Ovid MEDLINE and Embase. We also searched clinical trials registries, and we handsearched conference abstracts. The most recent search was run on 25 June 2020. SELECTION CRITERIA We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment. DATA COLLECTION AND ANALYSIS Two review authors independently assessed studies for inclusion, extracted data, and assessed risk of bias. We rated the quality of evidence using GRADE. We resolved discrepancies between the two data extractors by consultation with a third review author. MAIN RESULTS Through our searches, we retrieved 99 unique records, of which two met our inclusion criteria. One double-blind study of exenatide versus placebo randomised 62 participants, who self-administered exenatide or placebo for 48 weeks and were followed up at 60 weeks after a 12-week washout. One single-blind study of exenatide versus no additional treatment randomised 45 participants; participants in the intervention group self-administered exenatide for 12 months, and all participants were followed up at 14 months and 24 months following absence of exenatide for 2 months and 12 months, respectively. These trials had low risk of bias, except risk of performance bias was high for Aviles-Olmos 2013. Exenatide versus placebo Primary outcomes We found low-certainty evidence suggesting that exenatide improves motor impairment as assessed by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III in the off-medication state (mean difference (MD) -3.10, 95% confidence interval (CI) -6.11 to -0.09). The difference in scores was slightly greater when scores were adjusted for baseline severity of the condition (as reported by study authors) (MD -3.5, 95% CI -6.7 to -0.3), exceeding the minimum clinically important difference (MCID). We found low-certainty evidence suggesting that exenatide has little or no effect on health-related quality of life (HRQoL) as assessed by the Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI) (MD -1.80, 95% CI -6.95 to 3.35), the EuroQol scale measuring health status in five dimensions (EQ5D) (MD 0.07, 95% CI -0.03 to 0.16), or the EQ5D visual analogue scale (VAS) (MD 5.00, 95% CI -3.42 to 13.42). Eight serious adverse events (SAEs) were recorded, but all were considered unrelated to the intervention. Low-certainty evidence suggests that exenatide has little or no effect on weight loss (risk ratio (RR) 1.25, 95% CI 0.89 to 1.76). Exenatide versus no treatment Primary outcomes at 14 months We found very low-certainty evidence suggesting that exenatide improves motor impairment as assessed by MDS-UPDRS Part III off medication (MD -4.50, 95% CI -8.64 to -0.36), exceeding the MCID. We are uncertain whether exenatide improves HRQoL as assessed by the PDQ-39 SI (MD 3.50, 95% CI -2.75 to 9.75; very low-quality evidence). We found very low-certainty evidence suggesting that exenatide has little or no effect on the number of SAEs (RR 1.60, 95% 0.40 to 6.32). We found very low-certainty evidence suggesting that exenatide may lead to weight loss (MD -2.40 kg, 95% CI -4.56 to -0.24). Primary outcomes at 24 months We found evidence as reported by study authors to suggest that exenatide improves motor impairment as measured by MDS-UPDRS Part III off medication (MD 5.6 points, 95% CI 2.2 to 9.0). Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). AUTHORS' CONCLUSIONS Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The difference in motor impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide may have a disease-modifying effect. SAEs were unlikely to be related to treatment. The effectiveness of exenatide for improving HRQoL, non-motor outcomes, ADLs, and psychological outcomes is unclear. Ongoing studies are assessing other GLP-1 receptor agonists.",2020,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[""Parkinson's disease"", 'adults with PD that compared', 'randomised 62 participants, who self-administered', 'people with PD', '45 participants']","['exenatide', 'Glucagon-like peptide-1', 'Exenatide', 'exenatide or placebo', 'GLP-1 receptor agonists', 'GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment', 'placebo']","['motor impairment', 'health-related quality of life (HRQoL', 'HRQoL', 'weight loss', ""Parkinson's Disease Questionnaire (PDQ)-39 Summary Index (SI"", ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS"", 'Eight serious adverse events (SAEs', 'EuroQol scale measuring health status', 'number of SAEs', 'MDS-UPDRS Part III off medication', 'EQ5D visual analogue scale (VAS']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1562104', 'cui_str': 'Glucagon-like peptide 1 receptor agonist-containing product'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026650', 'cui_str': 'Movement disorder'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.369049,"Exenatide may not improve HRQoL as assessed by the PDQ-39 SI (P = 0.682) and may not result in weight loss (MD 0.1 kg, 95% CI 3.0 to 2.8). ","[{'ForeName': 'Caroline A', 'Initials': 'CA', 'LastName': 'Mulvaney', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Gonçalo S', 'Initials': 'GS', 'LastName': 'Duarte', 'Affiliation': 'Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Handley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'David Jw', 'Initials': 'DJ', 'LastName': 'Evans', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}, {'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Menon', 'Affiliation': 'Department of Medicine, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': ""The Cure Parkinson's Trust, London, UK.""}, {'ForeName': 'Hedley Ca', 'Initials': 'HC', 'LastName': 'Emsley', 'Affiliation': 'Lancaster Medical School, Lancaster University, Lancaster, UK.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD012990.pub2'] 2013,32702468,Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).,"AIMS Predicting likely durability of glucose-lowering therapies for people with type 2 diabetes (T2D) could help inform individualised therapeutic choices. METHODS We used data from UKPDS patients with newly-diagnosed T2D randomised to first-line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin. In 2339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c  ≥ 7.5% or requiring second-line therapy). Model validation was performed using bootstrap sampling. RESULTS Follow-up was median (IQR) 11.0 (8.0-14.0) years. Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA 1c and BMI values-with other risk factors varying by type of monotherapy-with predictions to within ±2.5 years for 55%-60%-56% and 57% of the chlorpropamide-glibenclamide-basal insulin and metformin monotherapy cohorts respectively. CONCLUSIONS Post one-year glycaemic durability can be predicted robustly in individuals with newly-diagnosed T2D who achieve HbA 1c values  < 7.5% one year after commencing traditional monotherapies. Such information could be used to help guide glycaemic management for individual patients.",2020,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"['2,339 participants who achieved one-year HbA 1c values <7.5% (<59 mmol/mol)-we assessed relationships between one-year characteristics and time to monotherapy-failure (HbA 1c ≥7.5% or requiring second-line therapy', 'people with type 2 diabetes ', 'Patients with Newly-diagnosed Type 2 Diabetes Mellitus', 'UKPDS patients with newly-diagnosed T2D randomised to first']","['chlorpropamide-glibenclamide-basal insulin or metformin', 'line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin', 'glucose-lowering therapies', 'Glucose-lowering Monotherapies']","['Monotherapy-failure', 'Time-to-monotherapy-failure']","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C1710038', 'cui_str': 'Second line treatment'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}]","[{'cui': 'C0008287', 'cui_str': 'Chlorpropamide'}, {'cui': 'C0017628', 'cui_str': 'Glyburide'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",2339.0,0.0533422,Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years.,"[{'ForeName': 'Olorunsola F', 'Initials': 'OF', 'LastName': 'Agbaje', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK. Electronic address: olorunsola.agbaje@dtu.ox.ac.uk.'}, {'ForeName': 'Ruth L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Hattersley', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Angus G', 'Initials': 'AG', 'LastName': 'Jones', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Ewan R', 'Initials': 'ER', 'LastName': 'Pearson', 'Affiliation': 'Medical Research Institute, University of Dundee, Dundee, UK.'}, {'ForeName': 'Beverley M', 'Initials': 'BM', 'LastName': 'Shields', 'Affiliation': 'Institute of Biomedical & Clinical Science-University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Rury R', 'Initials': 'RR', 'LastName': 'Holman', 'Affiliation': 'Diabetes Trials Unit, University of Oxford, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Diabetes research and clinical practice,['10.1016/j.diabres.2020.108333'] 2014,32702522,Impact of couple conflict and mediation on how romantic partners are seen: An fMRI study.,"Previous studies on romantic love have reported increased neural activity in the brain's reward circuitry such as the striatum. To date, the extent to which this activity is modulated by couple conflict in general and mediated couple conflict in particular, is unknown. The present study seeks to fill this gap by randomly assigning 36 romantic heterosexual couples to a mediated or non-mediated conflict discussion. Before and after the conflict discussion, self-reports and functional neuroimaging data in response to a picture of the romantic partner versus an unknown person were acquired. Self-reports indicate that mediation increases conflict resolution, satisfaction about the contents and process of the discussion and decreases levels of remaining disagreement. Pre-conflict neuroimaging results replicate previous studies on romantic love, showing activations in the striatum, insula, anterior and posterior cingulate gyrus, orbitofrontal cortex, hippocampus, temporal and occipital poles and amygdala when viewing the romantic partner versus an unknown person. The general effect of conflict on neural activations in response to the romantic partner across both conditions consisted of deactivations in the striatum, insula, thalamus, precuneus and ventral tegmental area. Small volume correction analyses revealed that participants in the mediated condition trended towards having greater activation in the nucleus accumbens than participants in the non-mediated condition when looking at the romantic partner versus the unknown after the conflict discussion. Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution. Our results illustrate that mediation improves conflict resolution and is associated with increased activity in the nucleus accumbens, a key region in the brain's reward circuitry.",2020,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,['36 romantic heterosexual couples to a mediated or non-mediated conflict discussion'],[],"['neural activity', 'conflict resolution']","[{'cui': 'C0019421', 'cui_str': 'Heterosexuality'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}]",[],"[{'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0150526', 'cui_str': 'Conflict Resolution'}]",36.0,0.0299096,Parametric modulation analyses also revealed greater activity in the nucleus accumbens when viewing the romantic partner versus the unknown for participants who felt more satisfied after the conflict resolution.,"[{'ForeName': 'Halima', 'Initials': 'H', 'LastName': 'Rafi', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Department of Psychology, University of Geneva, Geneva, Switzerland. Electronic address: Halima.Rafi@unige.ch.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Bogacz', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Computer Vision and Multimedia Laboratory, University of Geneva, Battelle Campus, Carouge, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Sander', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Klimecki', 'Affiliation': 'Swiss Center for Affective Sciences, University of Geneva, Geneva, Switzerland; Laboratory for the Study of Emotion Elicitation and Expression, Department of Psychology, University of Geneva, Geneva, Switzerland; Laboratory for Behavioral Neurology and Imaging of Cognition, Department of Neuroscience, Medical School, University of Geneva, Geneva, Switzerland. Electronic address: Olga.Klimecki@unige.ch.'}]",Cortex; a journal devoted to the study of the nervous system and behavior,['10.1016/j.cortex.2020.04.036'] 2015,32702651,Evaluation of the efficiency of the web-based epilepsy education program (WEEP) for youth with epilepsy and parents: A randomized controlled trial.,"BACKGROUND When youth with epilepsy and their parents have insufficient information about the disease, they are known to have more problems with disease management, and they show poor compliance. Providing accurate, reliable, and accessible information with no time and space limitations is extremely important for individuals with epilepsy as well as for their caregivers. AIM In this study, we aimed to evaluate the content, quality, usability, and efficacy of our web-based epilepsy education program (WEEP) that we developed for youth with epilepsy and their parents. METHODS The sample of this randomized controlled trail was composed of youth with epilepsy who were between the ages of 9 and 18 years and their parents who had applied to the Pediatric Neurology Unit of a tertiary healthcare hospital in Turkey between November 2017 and April 2018. This study was conducted in two stages: (1) the preparation phase, during which we developed a WEEP for epilepsy, and tested its content, quality, and usability; and (2) the implementation phase, during which we evaluated the efficacy of the website by assessing users' knowledge of epilepsy, seizure self-efficacy, attitudes, and e-health literacy. Before the implementation phase, data collection tools were used to test the prior knowledge of epilepsy of the participants and control groups. Next, the youth and their parents were asked to use the WEEP for 12 weeks, while a control group was not provided with additional education tools. Written consent was obtained from the participants prior to the study in addition to obtaining approval from the ethics committee and permission from the institution where the research was conducted. The data were finally analyzed using SAS 9.4 software. RESULTS During the preparation phase, the website was developed and tested for content, quality, and usability. The WEEP was graded 72.7 ± 3.4 points by experts, 92.4 ± 1.63 by youth with epilepsy, and 92.31 ± 1.94 by the parents. During the implementation phase, the efficacy of the web site was evaluated through the assessment of participants' scores. We found that the mean knowledge, seizure self-efficacy, attitude, and e-health literacy scores of youth with epilepsy in the experimental group had significantly increased after the WEEP (p < 0.05). An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). CONCLUSION The content, quality, and usability of the WEEP were adequate and effective in improving knowledge, self-efficacy, attitudes, and e-health literacy of youth with epilepsy as well as those of their parents.",2020,"An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). ","['youth with epilepsy who were between the ages of 9 and 18\u202fyears and their parents who had applied to the Pediatric Neurology Unit of a tertiary healthcare hospital in Turkey between November 2017 and April 2018', 'youth with epilepsy and parents', 'youth with epilepsy and their parents']",['web-based epilepsy education program (WEEP'],"['content, quality, and usability of the WEEP were adequate and effective in improving knowledge, self-efficacy, attitudes, and e-health literacy of youth with epilepsy', 'content, quality, usability, and efficacy', ""efficacy of the website by assessing users' knowledge of epilepsy, seizure self-efficacy, attitudes, and e-health literacy"", 'scores of knowledge, anxiety, self-management, and e-health literacy scale', 'mean knowledge, seizure self-efficacy, attitude, and e-health literacy scores of youth with epilepsy']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0279167', 'cui_str': 'Pediatric neurology'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0299077,"An increase in the scores of knowledge, anxiety, self-management, and e-health literacy scale was also found among the parents in the intervention group (p < 0.05). ","[{'ForeName': 'Şerife', 'Initials': 'Ş', 'LastName': 'Tutar Güven', 'Affiliation': 'Department of Pediatric Nursing, Faculty of Health Sciences, Süleyman Demirel University, Isparta, Turkey. Electronic address: serifeguven@sdu.edu.tr.'}, {'ForeName': 'Ayşegül', 'Initials': 'A', 'LastName': 'İşler Dalgiç', 'Affiliation': 'Department of Pediatric Nursing, Faculty of Nursing, Akdeniz University, Antalya, Turkey. Electronic address: aisler@akdeniz.edu.tr.'}, {'ForeName': 'Özgür', 'Initials': 'Ö', 'LastName': 'Duman', 'Affiliation': 'Department of Pediatric Neurology, Faculty of Medicine, Akdeniz University, Antalya, Turkey. Electronic address: oduman@akdeniz.edu.tr.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2020.107142'] 2016,32703293,Communities for Healthy Living (CHL) A Community-based Intervention to Prevent Obesity in Low-Income Preschool Children: Process Evaluation Protocol.,"BACKGROUND Process evaluation can illuminate barriers and facilitators to intervention implementation as well as the drivers of intervention outcomes. However, few obesity intervention studies have documented process evaluation methods and results. Community-based participatory research (CBPR) requires that process evaluation methods be developed to (a) prioritize community members' power to adapt the program to local needs over strict adherence to intervention protocols, (b) share process evaluation data with implementers to maximize benefit to participants, and (c) ensure partner organizations are not overburdened. Co-designed with low-income parents using CBPR, Communities for Healthy Living (CHL) is a family-centered intervention implemented within Head Start to prevent childhood obesity and promote family well-being. We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area. In this protocol paper, we outline an embedded process evaluation designed to monitor intervention adherence and adaptation, support ongoing quality improvement, and examine contextual factors that may moderate intervention implementation and/or effectiveness. METHODS This mixed methods process evaluation was developed using the Pérez et al. framework for evaluating adaptive interventions and is reported following guidelines outlined by Grant et al. Trained research assistants will conduct structured observations of intervention sessions. Intervention facilitators and recipients, along with Head Start staff, will complete surveys and semi-structured interviews. De-identified data for all eligible children and families will be extracted from Head Start administrative records. Qualitative data will be analyzed thematically. Quantitative and qualitative data will be integrated using triangulation methods to assess intervention adherence, monitor adaptations, and identify moderators of intervention implementation and effectiveness. DISCUSSION A diverse set of quantitative and qualitative data sources are employed to fully characterize CHL implementation. Simultaneously, CHL's process evaluation will provide a case study on strategies to address the challenges of process evaluation for CBPR interventions. Results from this process evaluation will help to explain variation in intervention implementation and outcomes across Head Start programs, support CHL sustainability and future scale-up, and provide guidance for future complex interventions developed using CBPR. TRIAL REGISTRATION ClinicalTrials.gov, NCT03334669 . Registered on October 10, 2017.",2020,We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area.,"['Healthy Living (CHL', '23 Head Start centers in the greater Boston area', 'Low-Income Preschool Children', 'Communities for Healthy Living (CHL']","['Community-based participatory research (CBPR', 'Community-based Intervention', 'CHL']",[],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}]","[{'cui': 'C2350575', 'cui_str': 'Community-Based Participatory Research'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.062973,We are currently undertaking a randomized controlled trial to test the effectiveness of CHL in 23 Head Start centers in the greater Boston area.,"[{'ForeName': 'Jacob P', 'Initials': 'JP', 'LastName': 'Beckerman-Hsu', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.'}, {'ForeName': 'Alyssa', 'Initials': 'A', 'LastName': 'Aftosmes-Tobio', 'Affiliation': 'Boston College School of Social Work, McGuinn Hall Room 115, 140 Commonwealth Ave, Chestnut Hill, MA, 02467, USA.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Gavarkovs', 'Affiliation': 'Institute of Health Policy, Management and Evaluation & Wilson Centre, Faculty of Medicine, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Kitos', 'Affiliation': 'Massachusetts Department of Public Health, Boston, MA, 02115, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Figueroa', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, 244 Garden Ave, Ithaca, NY, 14853, USA.'}, {'ForeName': 'Z Begum', 'Initials': 'ZB', 'LastName': 'Kalyoncu', 'Affiliation': 'Nutrition and Dietetics Department, Atilim University, Kizilcasar Mahallesi, Incek Golbasi, 06830, Ankara, Turkey.'}, {'ForeName': 'Kindra', 'Initials': 'K', 'LastName': 'Lansburg', 'Affiliation': 'Action for Boston Community Development, 178 Tremont Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Xinting', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Departments of Medicine, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.""}, {'ForeName': 'Crystal', 'Initials': 'C', 'LastName': 'Kazik', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Vigilante', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Jessie', 'Initials': 'J', 'LastName': 'Leonard', 'Affiliation': 'Community Action Agency of Somerville, 66 Union Square, Somerville, MA, 02143, USA.'}, {'ForeName': 'Merieka', 'Initials': 'M', 'LastName': 'Torrico', 'Affiliation': 'Action for Boston Community Development, 178 Tremont Street, Boston, MA, 02111, USA.'}, {'ForeName': 'Janine M', 'Initials': 'JM', 'LastName': 'Jurkowski', 'Affiliation': 'Department of Health Policy, Management & Behavior, University at Albany School of Public Health, 1 University Place, Rensselaer, NY, 12144, USA.'}, {'ForeName': 'Kirsten K', 'Initials': 'KK', 'LastName': 'Davison', 'Affiliation': 'Boston College School of Social Work, McGuinn Hall Room 115, 140 Commonwealth Ave, Chestnut Hill, MA, 02467, USA. kirsten.davison@bc.edu.'}]",Trials,['10.1186/s13063-020-04571-0'] 2017,32703316,"Efficacy of brief dynamic interpersonal therapy in patients with major depressive disorder: a prospective, multicenter randomized controlled trial protocol.","BACKGROUND In China, psychodynamic psychotherapies are widely used as a treatment for depression. However, very few efficacy studies of psychodynamic therapies have been conducted with the Chinese population. This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). METHODS Recruitment is planned in five hospitals. Two hundred forty patients with MDD will be randomly allocated on a 1:1:1 basis to either medication plus DIT, medication plus an active control psychotherapy, or medication alone. Patients will be assessed at baseline and at weeks 2, 4, 8, 12, and 16 during the acute treatment phase and 1, 3, 6, and 12 months posttreatment. The primary outcome is change from baseline in the 17-item Hamilton Depression Rating Scale, administered by independent raters who are blind to treatment allocation. The Hamilton Anxiety Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder 7-item scale, response, remission and relapse rates, self-assessment of overall efficacy and satisfaction of patients, and side effect profiles are secondary measures. DISCUSSION This will be the first multicentered RCT in China to assess the efficacy of a brief psychodynamic intervention for MDD. The study has the potential to inform clinical treatment guidelines for the treatment of depression in China. TRIAL REGISTRATION ChiCTR, ChiCTR1800016970 . Registered on July 5, 2018.",2020,"This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). ","['Recruitment is planned in five hospitals', 'Chinese adults with major depressive disorder (MDD', 'patients with major depressive disorder', 'Two hundred forty patients with MDD']","['dynamic interpersonal psychotherapy (DIT', 'medication plus DIT, medication plus an active control psychotherapy, or medication alone', 'brief dynamic interpersonal therapy']","['Hamilton Anxiety Rating Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder 7-item scale, response, remission and relapse rates, self-assessment of overall efficacy and satisfaction of patients, and side effect profiles are secondary measures', '17-item Hamilton Depression Rating Scale']","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0871787', 'cui_str': 'Interpersonal psychotherapy'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}]",240.0,0.10072,"This paper describes a study protocol of a multicenter randomized controlled trial of dynamic interpersonal psychotherapy (DIT), a brief manualized depression-focused intervention, in Chinese adults with major depressive disorder (MDD). ","[{'ForeName': 'Lanlan', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Wang', 'Affiliation': 'Beijing Anding Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Wenhui', 'Initials': 'W', 'LastName': 'Jiang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tong', 'Affiliation': 'Wuhan Mental Health Center, Wuhan, Hubei Province, China.'}, {'ForeName': 'Xiaosi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Anhui Mental Health Center, Hefei, Anhui Province, China.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Fang', 'Affiliation': 'Shanghai Hongkou District Mental Health Center, Shanghai, China.'}, {'ForeName': 'Hongyan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Zhao', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Koszycki', 'Affiliation': 'University of Ottawa and Insitut du Savoir Montfort, Ottawa, Ontario, Canada. dkoszyck@uottawa.ca.'}, {'ForeName': 'Jianyin', 'Initials': 'J', 'LastName': 'Qiu', 'Affiliation': 'Shanghai Mental Health Center, Shanghai Jiaotong University Medical School, Shanghai, China. jianyin_qiu@163.com.'}]",Trials,['10.1186/s13063-020-04569-8'] 2018,32701865,Use of the Fundamentals of Arthroscopic Surgical Training Workstation for Immediate Objective Feedback During Training Improves Hand-Tied Surgical Knot Proficiency: A Randomized Controlled Study.,"INTRODUCTION In a prior study, we validated the FAST workstation as an objective evaluator of hand-tied surgical knots. The goal of this study was to determine whether guided practice with the FAST workstation could lead to objective improvement in hand-tied surgical knot performance. METHODS Sixty participants were randomized into 1 of 2 groups: a control group, with access to only the knot-tying station, and a test group, with access to the knot-tying station plus the knot testing station. The study was divided into 3 phases: prepractice, practice, and postpractice. Using the FAST workstation, participants hand-tied 5 knots, 15 knots, and 5 knots using 0 Vicryl suture in the prepractice, practice, and postpractice phases, respectively. Knots for each participant from the prepractice and postpractice phases were collected, tested, and compared. RESULTS Within the control group, the average number of prepractice knot successes was 2.63, and the average number of postpractice knot successes was 3.40, which resulted in an improvement of average knot successes of 0.77 (P < 0.01). Within the test group, the average number of prepractice knot successes was 2.40, and the average number of postpractice knot successes was 4.10, which resulted in an improvement of average knot successes of 1.70 (P < 0.01). The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). DISCUSSION A knot-tying trainer that provides objective feedback on knot performance may better improve hand-tied surgical knot proficiency compared with one without objective feedback.",2020,"The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). ",['Sixty participants'],"['FAST workstation', 'Arthroscopic Surgical Training Workstation', 'control group, with access to only the knot-tying station, and a test group, with access to the knot-tying station plus the knot testing station', 'knot-tying trainer']","['average number of prepractice knot successes', 'average knot successes', 'average improvement of knot-tying successes', 'average number of postpractice knot successes']",[],"[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1736830', 'cui_str': 'Workstation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0453920', 'cui_str': 'Tie'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0453962', 'cui_str': 'Trainers'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0560032', 'cui_str': 'knot'}, {'cui': 'C0453920', 'cui_str': 'Tie'}]",60.0,0.0219455,"The difference in average improvement of knot-tying successes (0.93 knots) between the 2 groups was statistically significant (P < 0.01). ","[{'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Schneider', 'Affiliation': 'From the Department of Orthopaedic Surgery and Rehabilitation (A.M.S., W.D., D.W., D.A.E.), Loyola University Medical Center, Maywood, IL; and Department of Orthopaedic Surgery (R.A.P.), University of California Los Angeles, Los Angeles, CA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Davis', 'Affiliation': ''}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Walsh', 'Affiliation': ''}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Pedowitz', 'Affiliation': ''}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Evans', 'Affiliation': ''}]",Simulation in healthcare : journal of the Society for Simulation in Healthcare,['10.1097/SIH.0000000000000494'] 2019,32706698,A Dietary Mobile App for Patients Undergoing Hemodialysis: Prospective Pilot Study to Improve Dietary Intakes.,"BACKGROUND Mobile technology has an impact on the health care sector, also within dietetics. Mobile health (mHealth) apps may be used for dietary assessment and self-monitoring, allowing for real-time reporting of food intakes. Changing eating behaviors is quite challenging, and patients undergoing hemodialysis, particularly, struggle to meet the target intakes set by dietary guidelines. Usage of mobile apps that are developed in a person-centered approach and in line with recommendations may support both patients and health care practitioners. OBJECTIVE This study is a pilot that aims at estimating the potential efficacy of a dietary intervention using a theory-based, person-centered smartphone app. Results will be used to improve both the app and a planned large-scale trial intended to assess app efficacy thoroughly. METHODS A prospective pilot study was performed at the hemodialysis unit of Al Qassimi Hospital (The Emirate of Sharjah). All patients that fulfilled the study inclusion criteria were considered eligible to be enrolled in the pilot study. Upon successful installation of the app, users met with a dietitian once a week. Outcomes were measured at baseline (T0) and 2 weeks post app usage (T1). This pilot is reported as per guidelines for nonrandomized pilot and feasibility studies and in line with the CONSORT 2010 checklist for reporting pilot or feasibility trials. RESULTS A total of 23 patients completed the pilot intervention. Mean energy intakes increased from 24.4 kcal/kg/day (SD 8.0) to 29.1 kcal/kg/day (SD 7.8) with a medium effect size (d=0.6, 95% CI 0.0-1.2). Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7). Dietary intakes of minerals did not change, apart from sodium which decreased from a mean intake of 2218.8 mg/day (SD 631.6) to 1895.3 mg/day (SD 581.0) with a medium effect size (d=0.5, 95% CI 0.1-1.1). Mean serum phosphorus, potassium, and albumin levels did not change relevantly. Mean serum iron increased from 7.9 mg/dL (SD 2.8) to 11.5 mg/dL (SD 7.9) postintervention with a medium effect size (d=0.6, 95% CI 0.0-1.2). CONCLUSIONS This pilot study showed that the KELA.AE app has the potential to improve dietary intakes. Processes related to procedure, resources, tools, and app improvement for a future trial were assessed. A more extended intervention using a randomized controlled trial is required to estimate parameters concerning app efficacy accurately.",2020,"Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7).","['All patients that fulfilled the study inclusion criteria were considered eligible to be enrolled in the pilot study', 'Patients Undergoing Hemodialysis', 'hemodialysis unit of Al Qassimi Hospital', '23 patients completed the pilot intervention']","['KELA.AE', 'dietary intervention']","['Mean protein intakes', 'Mean serum iron', 'mean intake of high biological value', 'Mean serum phosphorus, potassium, and albumin levels', 'Mean energy intakes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0019005', 'cui_str': 'Hemodialysis machine'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0032821', 'cui_str': 'Potassium'}, {'cui': 'C0201838', 'cui_str': 'Albumin measurement'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",23.0,0.105351,"Mean protein intakes increased from 0.9 g/kg/day (SD 0.3) to 1.3 g/kg/day (SD 0.5) with a large effect size (d=1.0, 95% CI 0.4-1.6); mean intake of high biological value (%HBV) proteins also increased from 58.6% (SD 10.1) to 70.1% (SD 10.7) with a large effect size (d=1.1, 95% CI 0.5-1.7).","[{'ForeName': 'Cosette', 'Initials': 'C', 'LastName': 'Fakih El Khoury', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Rik', 'Initials': 'R', 'LastName': 'Crutzen', 'Affiliation': 'Department of Health Promotion, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Jos M G A', 'Initials': 'JMGA', 'LastName': 'Schols', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Ruud J G', 'Initials': 'RJG', 'LastName': 'Halfens', 'Affiliation': 'Department of Health Services Research, Care and Public Health Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Mirey', 'Initials': 'M', 'LastName': 'Karavetian', 'Affiliation': 'Department of Health Sciences, Zayed University, Dubai, United Arab Emirates.'}]",Journal of medical Internet research,['10.2196/17817'] 2020,32706704,Features of a Patient Portal for Blood Test Results and Patient Health Engagement: Web-Based Pre-Post Experiment.,"BACKGROUND The use of patient portals for presenting health-related patient data, such as blood test results, is becoming increasingly important in health practices. Patient portals have the potential to enhance patient health engagement, but content might be misinterpreted. OBJECTIVE This study aimed to discover whether the way of presenting blood test outcomes in an electronic patient portal is associated with patient health engagement and whether this varies across different blood test outcomes. METHODS A 2x3 between-subjects experiment was conducted among members of the Nivel Dutch Health Care Consumer Panel. All participants read a scenario in which they were asked to imagine themselves receiving blood test results. These results differed in terms of the presented blood values (ie, normal vs partially abnormal vs all abnormal) as well as in terms of whether the results were accompanied with explanatory text and visualization. Patient health engagement was measured both before (T0) and after (T1) participants were exposed to their fictive blood test results. RESULTS A total 487 of 900 invited members responded (response rate 54%), of whom 50.3% (245/487) were female. The average age of the participants was 52.82 years (SD 15.41 years). Patient health engagement saw either a significant decrease or a nonsignificant difference in the experimental groups after viewing the blood test results. The mean difference was smaller in the groups that received blood test results with additional text and visualization (mean T0 5.33, SE 0.08; mean T1 5.14, SE 0.09; mean difference 0.19, SE 0.08, P=.02) compared with groups that received blood test results without explanatory text and visualization (mean T0 5.19, SE 0.08; mean T1 4.55, SE 0.09; mean difference 0.64, SE 0.08, P<.001). Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). CONCLUSIONS Adding text and visualization features can attenuate the decrease in patient health engagement in participants who receive outcomes of a blood test via a patient portal, particularly when blood test results are (partly) normal. This suggests that explanatory text and visualization can be reassuring. Future research is warranted to determine whether these results can be generalized to a patient population who receive their actual blood test results.",2020,"Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). ","['participants who received normal results or mixed results (ie, combination of normal and abnormal results', 'The average age of the participants was 52.82 years (SD 15.41 years', 'A total 487 of 900 invited members responded (response rate 54%), of whom 50.3% (245/487) were female', 'A 2x3 between-subjects experiment was conducted among members of the Nivel Dutch Health Care Consumer Panel']",[],"['blood values', 'Patient health engagement', 'patient health engagement']","[{'cui': 'C0459422', 'cui_str': 'Normal result'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0459424', 'cui_str': 'Abnormal result'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0665509', 'cui_str': 'OF 900'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0441833', 'cui_str': 'Groups'}]",[],"[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]",900.0,0.0704985,"Adding text and visualization, in particular, reduced the decline in patient health engagement in participants who received normal results or mixed results (ie, combination of normal and abnormal results). ","[{'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Struikman', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Bol', 'Affiliation': 'Department of Communication and Cognition, Tilburg School of Humanities and Digital Sciences, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Annelijn', 'Initials': 'A', 'LastName': 'Goedhart', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Julia C M', 'Initials': 'JCM', 'LastName': 'van Weert', 'Affiliation': 'Department of Communication Science, Amsterdam School of Communication Research, University of Amsterdam, Amsterdam, Netherlands.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Talboom-Kamp', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'van Delft', 'Affiliation': 'Saltro, Diagnostics Center for Health Care, Utrecht, Netherlands.'}, {'ForeName': 'Anne E M', 'Initials': 'AEM', 'LastName': 'Brabers', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}, {'ForeName': 'Liset', 'Initials': 'L', 'LastName': 'van Dijk', 'Affiliation': 'Nivel (Netherlands Institute for Health Services Research), Utrecht, Netherlands.'}]",Journal of medical Internet research,['10.2196/15798'] 2021,32706708,Evaluation of a Web-Based Self-Management Program for Patients With Cardiovascular Disease: Explorative Randomized Controlled Trial.,"BACKGROUND Web-based self-management programs have the potential to support patients with cardiovascular disease (CVD) in their self-management (eg, by focusing on behavior change and improving physical activity). The intervention mapping framework was used to develop a web-based program called Vascular View. The Vascular View program contained 6 modules (coping with CVD, setting boundaries, lifestyle, healthy nutrition, being physically active, interaction with health professionals) aiming to increase self-management behavior by tailoring to the perceived problems and (support) needs of patients after CVD. OBJECTIVE The aim was to test the effectiveness of Vascular View before embarking on a full-scale randomized clinical trial (RCT) by evaluating the potential effectiveness and effect sizes of the Vascular View program and identifying outcome measures most likely to capture the potential benefits. METHODS An explorative RCT was performed. Both control and intervention groups received care as usual and, in addition, the intervention group received 12 months of access to a web-based self-management program. Assessment occurred at baseline, 6 months, and 12 months. Outcome measures included general patient-reported outcome measurements: Illness Perception Questionnaire (IPQ), Rand-36, Patient Activation Measure, and patient self-efficacy. Module-specific patient-reported outcome measurements were Beliefs about Medicines Questionnaire, International Physical Activity Questionnaire, Dutch Healthy Diet Index, Fagerström Test for Nicotine Dependence (FTND), Alcohol Use Disorders Identification Test, and Perceived Efficacy in Patient-Physician Interaction. Linear mixed models for repeated measures using intention-to-treat and per-protocol analysis were applied to study differences between the patients in the intervention and control groups. Floor and ceiling effects were explored to give insight into the outcome measures most likely to capture the potential benefits. RESULTS A total of 105 patients in the control group and 103 patients in the intervention group participated in the study. A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND). Floor and ceiling effects were seen in the IPQ, Rand-36, and the self-efficacy questionnaire. CONCLUSIONS No conclusion for the efficacy of the Vascular View program or selection of outcome measurements can be taken yet. A process evaluation will be conducted to gain thorough insight into the working elements of the program, patient needs in eHealth, and the use of the program by patients. This can determine for whom web-based self-management programs will work and help to adapt the program. TRIAL REGISTRATION Dutch Trial Register NTR5412; https://www.trialregister.nl/trial/5303. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/resprot.6352.",2020,"A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND).","['Patients With Cardiovascular Disease', '105 patients in the control group and 103 patients in the intervention group participated in the study', 'patients with cardiovascular disease (CVD']","['Web-Based Self-Management Program', 'care as usual and, in addition, the intervention group received 12 months of access to a web-based self-management program', 'NTR5412']","['self-efficacy questionnaire', 'Beliefs about Medicines Questionnaire, International Physical Activity Questionnaire, Dutch Healthy Diet Index, Fagerström Test for Nicotine Dependence (FTND), Alcohol Use Disorders Identification Test, and Perceived Efficacy in Patient-Physician Interaction', 'significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND', 'general patient-reported outcome measurements: Illness Perception Questionnaire (IPQ), Rand-36, Patient Activation Measure, and patient self-efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0028043', 'cui_str': 'Nicotine dependence'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0450985', 'cui_str': 'Alcohol use disorders identification test'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0031830', 'cui_str': 'Physician Patient Relations'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0020964', 'cui_str': 'Immune status'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C4075707', 'cui_str': 'Patient Activation Measure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",105.0,0.0846981,"A positive direction of change between baseline and 12 months was shown for most outcome measurements in favor of the intervention group, of which 2 out of 10 outcomes showed a significant effect: attribution of cause of the disease to risk factors and immunity factors (IPQ) and dependency of nicotine (FTND).","[{'ForeName': 'Marscha M', 'Initials': 'MM', 'LastName': 'Engelen', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'van Dulmen', 'Affiliation': 'Department of Primary and Community Care, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Puijk-Hekman', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Hester', 'Initials': 'H', 'LastName': 'Vermeulen', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Maria Wg', 'Initials': 'MW', 'LastName': 'Nijhuis-van der Sanden', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Sebastian Jh', 'Initials': 'SJ', 'LastName': 'Bredie', 'Affiliation': 'Department of Internal Medicine, Radboud university medical center, Nijmegen, Netherlands.'}, {'ForeName': 'Betsie Gi', 'Initials': 'BG', 'LastName': 'van Gaal', 'Affiliation': 'IQ Healthcare, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, Netherlands.'}]",Journal of medical Internet research,['10.2196/17422'] 2022,32706716,Efficacy of a Smartphone App Intervention for Reducing Caregiver Stress: Randomized Controlled Trial.,"BACKGROUND Caregivers play a pivotal role in maintaining an economically viable health care system, yet they are characterized by low levels of psychological well-being and consistently report unmet needs for psychological support. Mobile app-based (mobile health [mHealth]) interventions present a novel approach to both reducing stress and improving well-being. OBJECTIVE This study aims to evaluate the effectiveness of a self-guided mobile app-based psychological intervention for people providing care to family or friends with a physical or mental disability. METHODS In a randomized, single-blind, controlled trial, 183 caregivers recruited through the web were randomly allocated to either an intervention (n=73) or active control (n=110) condition. The intervention app contained treatment modules combining daily self-monitoring with third-wave (mindfulness-based) cognitive-behavioral therapies, whereas the active control app contained only self-monitoring features. Both programs were completed over a 5-week period. It was hypothesized that intervention app exposure would be associated with decreases in depression, anxiety, and stress, and increases in well-being, self-esteem, optimism, primary and secondary control, and social support. Outcomes were assessed at baseline, postintervention, and 3-4 months postintervention. App quality was also assessed. RESULTS In total, 25% (18/73) of the intervention participants were lost to follow-up at 3 months, and 30.9% (34/110) of the participants from the wait-list control group dropped out before the postintervention survey. The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention. These changes were further enhanced from postintervention to follow-up, with the intervention group continuing to report lower levels of depression (b=-1.82; P=.03) and higher levels of emotional well-being (b=6.13; P<.001), optimism (b=0.78; P=.007), self-esteem (b=-0.84; P=.005), support from family (b=2.15; P=.001), support from significant others (b=2.66; P<.001), and subjective well-being (b=4.82; P<.001). On average, participants completed 2.5 (SD 1.05) out of 5 treatment modules. The overall quality of the app was also rated highly, with a mean score of 3.94 out of a maximum score of 5 (SD 0.58). CONCLUSIONS This study demonstrates that mHealth psychological interventions are an effective treatment option for caregivers experiencing high levels of stress. Recommendations for improving mHealth interventions for caregivers include offering flexibility and customization in the treatment design. TRIAL REGISTRATION Australian New Zealand Clinical Trial Registry ACTRN12616000996460; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371170.",2020,The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention.,"['183 caregivers recruited through the web were randomly allocated to either an intervention (n=73) or active control (n=110) condition', 'people providing care to family or friends with a physical or mental disability', 'caregivers experiencing high levels of stress']","['self-guided mobile app-based psychological intervention', 'mHealth psychological interventions', 'Smartphone App Intervention', 'Mobile app-based (mobile health [mHealth]) interventions', 'intervention app contained treatment modules combining daily self-monitoring with third-wave (mindfulness-based) cognitive-behavioral therapies, whereas the active control app contained only self-monitoring features']","['levels of depression', 'overall quality', 'depression, anxiety, and stress, and increases in well-being, self-esteem, optimism, primary and secondary control, and social support', 'self-esteem', 'reductions in stress', 'depressive symptoms']","[{'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0079382', 'cui_str': 'Friend'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1306341', 'cui_str': 'Mental handicap'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]","[{'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",183.0,0.198433,The intervention group experienced reductions in stress (b=-2.07; P=.04) and depressive symptoms (b=-1.36; P=.05) from baseline to postintervention.,"[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Fuller-Tyszkiewicz', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Richardson', 'Affiliation': 'Nous Group, Melbourne, Australia.'}, {'ForeName': 'Keriann', 'Initials': 'K', 'LastName': 'Little', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Teague', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Hartley-Clark', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Capic', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Khor', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Cummins', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Olsson', 'Affiliation': 'Deakin University, Geelong, Australia.'}, {'ForeName': 'Delyse', 'Initials': 'D', 'LastName': 'Hutchinson', 'Affiliation': 'Deakin University, Geelong, Australia.'}]",JMIR mental health,['10.2196/17541'] 2023,32706738,User Engagement Among Diverse Adults in a 12-Month Text Message-Delivered Diabetes Support Intervention: Results from a Randomized Controlled Trial.,"BACKGROUND Text message-delivered interventions are a feasible and scalable approach for improving chronic disease self-care and reducing health disparities; however, information on long-term user engagement with these interventions is limited. OBJECTIVE The aim of this study is to examine user engagement in a 12-month text message-delivered intervention supporting diabetes self-care, called REACH (Rapid Education/Encouragement And Communications for Health), among racially and socioeconomically diverse patients with type 2 diabetes (T2D). We explored time trends in engagement, associations between patient characteristics and engagement, and whether the addition of a human component or allowing patients to change their text frequency affected engagement. Qualitative data informed patients' subjective experience of their engagement. METHODS We recruited patients with T2D for a randomized trial evaluating mobile phone support relative to enhanced treatment as usual. This analysis was limited to participants assigned to the intervention. Participants completed a survey and hemoglobin A1c (HbA1c) test and received REACH text messages, including self-care promotion texts, interactive texts asking about medication adherence, and adherence feedback texts. For the first 6 months, texts were sent daily, and half of the participants also received monthly phone coaching. After 6 months, coaching stopped, and participants had the option to receive fewer texts for the subsequent 6 months. We defined engagement via responses to the interactive texts and responses to a follow-up interview. We used regression models to analyze associations with response rate and thematic and structural analysis to understand participants' reasons for responding to the texts and their preferred text frequency. RESULTS The participants were, on average, aged 55.8 (SD 9.8) years, 55.2% (137/248) female, and 52.0% (129/248) non-White; 40.7% (101/248) had ≤ a high school education, and 40.7% (101/248) had an annual household income 0.10). However, there was the suggestion of a greater decrease in sedentary activity in the LI group compared to the HW group (β = -3.56, p = 0.09). CONCLUSIONS In this randomized trial among high-risk Hispanic women, both groups benefitted from participation in a postpartum intervention.",2020,"Compared to baseline levels, both groups had significant increases in moderate-to-vigorous PA at 6 months and one year postpartum (i.e., LI: mean change =","['Hispanic women who screened positive for gestational diabetes mellitus', 'at-risk hispanic women', 'high-risk Hispanic women', 'Western Massachusetts from 2013-17', 'Hispanic women']","['Lifestyle Intervention (LI, n = 100) or to a comparison Health and Wellness (HW, n = 104) group during late pregnancy', 'lifestyle intervention', 'culturally modified, motivationally targeted, individually-tailored intervention']","['moderate-to-vigorous PA', 'Pregnancy Physical Activity Questionnaire (PPAQ) and the Self-Efficacy for Physical Activity Questionnaire', 'vigorous PA', 'PA intensity and type over time', 'sedentary activity', 'postpartum physical activity', 'postpartum physical activity (PA) and PA self-efficacy']","[{'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]",,0.0849279,"Compared to baseline levels, both groups had significant increases in moderate-to-vigorous PA at 6 months and one year postpartum (i.e., LI: mean change =","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Burkart', 'Affiliation': 'Department of Kinesiology, School of Public Health & Health Sciences, University of Massachusetts, Amherst, Massachusetts, United States of America.'}, {'ForeName': 'Bess H', 'Initials': 'BH', 'LastName': 'Marcus', 'Affiliation': 'Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island, United States of America.'}, {'ForeName': 'Penelope', 'Initials': 'P', 'LastName': 'Pekow', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America.'}, {'ForeName': 'Milagros C', 'Initials': 'MC', 'LastName': 'Rosal', 'Affiliation': 'Division of Preventive and Behavioral Medicine, Department of Population & Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.""}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Braun', 'Affiliation': 'Department of Health and Exercise Science, College of Health and Human Sciences, Colorado State University, Fort Collins, Colorado, United States of America.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Chasan-Taber', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Public Health & Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, United States of America.'}]",PloS one,['10.1371/journal.pone.0236408'] 2027,32707289,Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial.,"OBJECTIVES To test the effect of a structured abdominal hypopressive technique (AHT) programme on pelvic floor muscle (PFM) tone and urinary incontinence (UI) in women. DESIGN Crossover trial with random assignment of women to one of two groups: Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT). SETTING Two cultural centres in Madrid, Spain. PARTICIPANTS Women aged 20-65 years. INTERVENTIONS Two months of supervised AHT exercises compared with 2 months of rest. MAIN OUTCOME MEASURES Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF)]. RESULTS Forty-two women were randomised to two groups (both n=21). No sequence or period effect was noted. The mean difference in PFM tone after the 2-month AHT programme was 59g/cm² [95% confidence interval (CI) 37 to 82]; the between-group difference was 83g/cm² (95% CI 50 to 116; P<0.001). After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001). The majority of participants reported improved body image and sense of well-being. CONCLUSIONS A structured 2-month AHT programme for women showed short-term benefits in PFM tone and UI. In addition, study participants reported improved body image and sense of well-being, and programme satisfaction, as demonstrated by questionnaire at the end of the intervention period. Further research is needed to test the long-term effects and effectiveness of AHT compared with other PFM exercises. ClinicalTrials.gov Identifier NCT0221241.",2020,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","['women', 'women to one of two groups', 'Forty-two women', 'Two cultural centres in Madrid, Spain', 'Women aged 20-65 years']","['Group 1 (AHT followed by rest) and Group 2 (rest followed by AHT', 'structured abdominal hypopressive technique (AHT) programme', 'supervised AHT exercises', 'AHT', 'abdominal hypopressive technique programme']","['pelvic floor muscle tone and urinary incontinence', 'ICIQ-SF score', 'PFM tone', 'pelvic floor muscle (PFM) tone and urinary incontinence (UI', 'body image and sense of well-being, and programme satisfaction', 'Variation in PFM tone and score on the International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF', 'body image and sense of well-being']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026841', 'cui_str': 'Muscle Tension'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}]",42.0,0.187985,"After 2 months, the between-group difference in the ICIQ-SF score was 3.3 points (P<0.001).","[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Soriano', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'González-Millán', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain.'}, {'ForeName': 'M M', 'Initials': 'MM', 'LastName': 'Álvarez Sáez', 'Affiliation': 'Maio Medical Centre, Vigo, Spain.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Curbelo', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Carmona', 'Affiliation': 'Universidad Camilo José Cela, Madrid, Spain; Instituto de Salud Musculoesquelética, Madrid, Spain. Electronic address: loreto.carmona@inmusc.eu.'}]",Physiotherapy,['10.1016/j.physio.2020.02.004'] 2028,32707294,Effects of stress on 6- and 7-year-old children's emotional memory differs by gender.,"Understanding effects of emotional valence and stress on children's memory is important for educational and legal contexts. This study disentangled the effects of emotional content of to-be-remembered information (i.e., items differing in emotional valence and arousal), stress exposure, and associated cortisol secretion on children's memory. We also examined whether girls' memory is more affected by stress induction. A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40). At 25 min after stressor onset, children incidentally encoded 75 objects varying in emotional valence (crossed with arousal) together with neutral scene backgrounds. We found that response bias corrected memory was worse for low-arousing negative items than for neutral and positive items, with the latter two categories not being different from each other. Whereas boys' memory was largely unaffected by stress, girls in the stress condition showed worse memory for negative items, especially the low-arousing ones, than girls in the control condition. Girls, compared with boys, reported higher subjective stress increases following stress exposure and had higher cortisol stress responses. Whereas a higher cortisol stress response was associated with better emotional memory in girls in the stress condition, boys' memory was not associated with their cortisol secretion. Taken together, our study suggests that 6- and 7-year-old children, more so girls, show memory suppression for negative information. Girls' memory for negative information, compared with that of boys, is also more strongly modulated by stress experience and the associated cortisol response.",2020,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[""6- and 7-year-old children's emotional memory differs by gender"", 'A total of 143 6- and 7-year-old children', ""children's memory""]",['Trier Social Stress Test for Children (n\xa0=\xa0103) or a control condition'],"['cortisol response', 'cortisol stress responses', 'cortisol stress response']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517573', 'cui_str': '143'}]","[{'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",143.0,0.0372713,A total of 143 6- and 7-year-old children were randomly allocated to the Trier Social Stress Test for Children (n = 103) or a control condition (n = 40).,"[{'ForeName': 'Laurel', 'Initials': 'L', 'LastName': 'Raffington', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Department of Psychology, University of Texas at Austin, Austin, TX 78712, USA.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Falck', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Heim', 'Affiliation': 'Institute of Medical Psychology, Charité - Universitäts medizin Berlin, 10117 Berlin, Germany; Department of Biobehavioral Health, Pennsylvania State University, University Park, PA 16802, USA.'}, {'ForeName': 'Mara', 'Initials': 'M', 'LastName': 'Mather', 'Affiliation': 'Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA.'}, {'ForeName': 'Yee Lee', 'Initials': 'YL', 'LastName': 'Shing', 'Affiliation': 'Center for Lifespan Psychology, Max Planck Institute for Human Development, 14195 Berlin, Germany; Institute of Psychology, Goethe-Universität Frankfurt, 60323 Frankfurt am Main, Germany. Electronic address: shing@psych.uni-frankfurt.de.'}]",Journal of experimental child psychology,['10.1016/j.jecp.2020.104924'] 2029,32707332,An invited commentary: The efficacy of transversus abdominis plane block with or without dexmedetomidine for postoperative analgesia in renal transplantation. A randomized controlled trial.,,2020,,['renal transplantation'],['transversus abdominis plane block with or without dexmedetomidine'],[],"[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}]","[{'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}]",[],,0.168804,,"[{'ForeName': 'Yuhang', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China. Electronic address: yulang5301@sina.com.'}, {'ForeName': 'Taowu', 'Initials': 'T', 'LastName': 'Gong', 'Affiliation': 'Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, Guizhou, 563000, China. Electronic address: chenmingaini1232@sina.com.'}]","International journal of surgery (London, England)",['10.1016/j.ijsu.2020.07.008'] 2030,32693660,Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up.,"Aim: To evaluate the long-term efficacy of sublingual immunotherapy (SLIT) in treating mite-sensitized allergic rhinitis (AR). Materials & methods:  150 AR children were randomly divided into SLIT and pharmacotherapy (PT) groups, receiving a 3-year course of SLIT along with PT or PT only. Results: The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group. No significant differences were observed between 3- and 6-year follow-up in SLIT group. Conclusion: 3-year SLIT along with PT appeared more effective compared with PT only for mite-induced AR in children, and the treatment was effective for at least 3 consecutive years even after SLIT ceased.",2020,"The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group.","['150\xa0AR children', 'treating mite-sensitized allergic rhinitis (AR', 'mite-induced allergic rhinitis with a 3-year follow-up']","['sublingual immunotherapy', 'sublingual immunotherapy (SLIT', 'SLIT', 'SLIT and pharmacotherapy (PT)\xa0groups, receiving a 3-year course of SLIT along with PT or PT only']",['symptom and medication scores'],"[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026231', 'cui_str': 'Mite'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C3658366', 'cui_str': 'Sublingual Immunotherapy'}, {'cui': 'C0184904', 'cui_str': 'Slitting'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0113851,"The symptom and medication scores at the 3- and 6-year follow-up were significantly lower compared with the baseline levels in both groups, while the values were significantly lower in SLIT group than in PT group.","[{'ForeName': 'Wen-Bo', 'Initials': 'WB', 'LastName': 'Chen', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Xiao-Fei', 'Initials': 'XF', 'LastName': 'Shen', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': ""Department of Otorhinolaryngology, Children's Hospital of Nanjing Medical University, 72 Guangzhou Road, Nanjing 210008, China.""}, {'ForeName': 'Wen-Cheng', 'Initials': 'WC', 'LastName': 'Zhou', 'Affiliation': 'Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Cheng', 'Affiliation': 'Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.'}]",Immunotherapy,['10.2217/imt-2020-0006'] 2031,32700217,"A Telehealth-supported, Integrated care with CHWs, and MEdication-access (TIME) Program for Diabetes Improves HbA1c: a Randomized Clinical Trial.","BACKGROUND Many individuals with diabetes live in low- or middle-income settings. Glycemic control is challenging, particularly in resource-limited areas that face numerous healthcare barriers. OBJECTIVE To compare HbA1c outcomes for individuals randomized to TIME, a Telehealth-supported, Integrated care with CHWs (Community Health Workers), and MEdication-access program (intervention) versus usual care (wait-list control). DESIGN Randomized clinical trial. PARTICIPANTS Low-income Latino(a) adults with type 2 diabetes. INTERVENTIONS TIME consisted of (1) CHW-participant telehealth communication via mobile health (mHealth) for 12 months, (2) CHW-led monthly group visits for 6 months, and (3) weekly CHW-physician diabetes training and support via telehealth (video conferencing). MAIN MEASURES Investigators compared TIME versus control participant baseline to month 6 changes of HbA1c (primary outcome), blood pressure, body mass index (BMI), weight, and adherence to seven American Diabetes Association (ADA) standards of care. CHW assistance in identifying barriers to healthcare in the intervention group were measured at the end of mHealth communication (12 months). KEY RESULTS A total of 89 individuals participated. TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6. At month 6, more TIME than control participants achieved > 0.50% HbA1c reductions (88.57% vs. 43.75%, p < 0.001). BMI and weight changes were not significant between groups. Many (54.6%) TIME participants experienced > 1 barrier to care, of whom 91.7% had medication issues. CHWs identified the majority (87.5%) of barriers. CONCLUSIONS TIME participants resulted in improved outcomes including HbA1c. CHWs are uniquely positioned to identify barriers to care particularly related to medications that may have gone unrecognized otherwise. Larger trials are needed to determine the scalability and sustainability of the intervention. CLINICAL TRIAL NCT03394456, accessed at https://clinicaltrials.gov/ct2/show/NCT03394456.",2020,"TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6.","['Diabetes Improves HbA1c', 'individuals with diabetes live in low- or middle-income settings', 'Low-income Latino(a) adults with type 2 diabetes', '89 individuals participated']","['Integrated care with CHWs, and MEdication-access (TIME', 'MEdication-access program (intervention) versus usual care (wait-list control', 'TIME consisted of (1) CHW-participant telehealth communication via mobile health (mHealth) for 12\xa0months, (2) CHW-led monthly group visits for 6\xa0months, and (3) weekly CHW-physician diabetes training and support via telehealth (video conferencing']","['blood pressure, body mass index (BMI), weight, and adherence to seven American Diabetes Association (ADA) standards of care', 'blood pressure changes', 'BMI and weight changes', 'outcomes including HbA1c', 'ADA guideline adherence']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0021162', 'cui_str': 'Income'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0042655', 'cui_str': 'Video'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0525059', 'cui_str': 'Guideline Adherence'}]",89.0,0.135301,"TIME individuals compared to control participants had significant HbA1c decreases (9.02 to 7.59% (- 1.43%) vs. 8.71 to 8.26% (- 0.45%), respectively, p = 0.002), blood pressure changes (systolic: - 6.89 mmHg vs. 0.03 mmHg, p = 0.023; diastolic: - 3.36 mmHg vs. 0.2 mmHg, respectively, p = 0.046), and ADA guideline adherence (p < 0.001) from baseline to month 6.","[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Vaughan', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA. elizabeth.vaughan@bcm.edu.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Hyman', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Aanand D', 'Initials': 'AD', 'LastName': 'Naik', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Susan L', 'Initials': 'SL', 'LastName': 'Samson', 'Affiliation': 'Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, USA.'}, {'ForeName': 'Javad', 'Initials': 'J', 'LastName': 'Razjouyan', 'Affiliation': 'Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E DeBakey VA Medical Center, Houston, TX, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Foreyt', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine , Baylor College of Medicine, Houston, TX, USA.'}]",Journal of general internal medicine,['10.1007/s11606-020-06017-4'] 2032,32697707,Antidepressant effects of ketamine and ECT: A pilot comparison.,"BACKGROUND To compare the antidepressant effects and cognitive adverse effects of intravenous ketamine infusion and Electro-convulsive therapy (ECT) in persons with severe depressive episodes. METHODS This assessor-blinded randomized control trial included 25 patients (either sex; 18-65 years) meeting ICD-10 criteria for severe depression (bipolar or unipolar). Patients received either ECT (n = 13) or intravenous infusions of ketamine hydrochloride (0.5 mg/kg over 45 min; n = 12) for six alternate day sessions over a period of two weeks. Severity of depression was assessed at baseline and on every alternate day of intervention using the Hamilton Depression Rating Scale (HDRS) and self-reported Beck Depression Inventory (BDI). RESULTS Baseline socio-demographic and clinical variables including HDRS (ECT: 25.15±6.58; Ketamine: 23.33±4.05, p = 0.418) and BDI (ECT: 37.07±6.58; Ketamine: 33.33±9.29; p = 0.254) were comparable. Repeated-measures analysis of variance revealed that ECT patients showed significantly greater reduction in HDRS (group*time interaction effect; F = 4.79; p<0.001) and BDI scores (group*time interaction effect; F = 3.83; p<0.01). ECT patients had higher response rate than ketamine patients [HDRS: ECT- 13/13(100%) vs ketamine- 8/12 (66.70%); p = 0.04]. This was true for remission as well [ECT- 12/13(92.30%) vs ketamine- 6/12(50%), p = 0.030; both HDRS and BDI]. Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). LIMITATIONS Relatively small sample size; higher proportion of dropouts in the Ketamine arm. CONCLUSION This study favoured ECT over ketamine for a better efficacy over six treatment sessions in severe depression. The results need to be replicated in larger studies. TRIAL REGISTRATION CTRI/2019/09/021184.",2020,"Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). ","['25 patients (either sex; 18-65 years) meeting ICD-10 criteria for severe depression (bipolar or unipolar', 'persons with severe depressive episodes', 'severe depression']","['ECT', 'ketamine', 'Ketamine', 'ketamine infusion and Electro-convulsive therapy (ECT', 'ketamine and ECT', 'ketamine hydrochloride']","['Severity of depression', 'Hamilton Depression Rating Scale (HDRS) and self-reported Beck Depression Inventory (BDI', 'HDRS', 'Cognitive Deficits scale', 'Performance on Digit Symbol Substitution Test', 'response rate', 'BDI scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C1137110', 'cui_str': 'ICD-10'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0588008', 'cui_str': 'Severe depression'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0443340', 'cui_str': 'Unipolar'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode, unspecified'}]","[{'cui': 'C0009953', 'cui_str': 'Convulsive therapy'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0700541', 'cui_str': 'Ketamine hydrochloride'}]","[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0009241', 'cui_str': 'Cognitive disorder'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C2960571', 'cui_str': 'Beck depression inventory score'}]",25.0,0.172461,"Performance on Digit Symbol Substitution Test (as part of the Battery for ECT-Related Cognitive Deficits scale) significantly improved in ketamine patients (p = 0.02) while that in ECT patients worsened non significantly (p = 0.30). ","[{'ForeName': 'Ravi K', 'Initials': 'RK', 'LastName': 'Sharma', 'Affiliation': 'Department of Psychiatry, Trivanta Medical and Neuro-psychiatry Hospital and Research Center, Udaipur, Rajasthan 313001, India. Electronic address: drravisharma1984@gmail.com.'}, {'ForeName': 'Gajanan', 'Initials': 'G', 'LastName': 'Kulkarni', 'Affiliation': 'Department of Psychiatry, Magna Centers for Obesity, Diabetes and Endocrinology, Bangalore, Karnataka 560076, India. Electronic address: gajanan.kulkarni.97@gmail.com.'}, {'ForeName': 'Channaveerachari Naveen', 'Initials': 'CN', 'LastName': 'Kumar', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: cnkumar1974@gmail.com.'}, {'ForeName': 'Shyam Sundar', 'Initials': 'SS', 'LastName': 'Arumugham', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: a.shyamsundar@gmail.com.'}, {'ForeName': 'Venkataramaiah', 'Initials': 'V', 'LastName': 'Sudhir', 'Affiliation': 'Department of Neuro-anaesthesia, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 560029, India. Electronic address: vsudhir77@gmail.com.'}, {'ForeName': 'Urvakhsh M', 'Initials': 'UM', 'LastName': 'Mehta', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: urvakhsh@gmail.com.'}, {'ForeName': 'Sayantanava', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': 'Queensland Health and Faculty of Medicine, University of Queensland Rural Medical\xa0School, Rockhampton, Queensland 4700, Australia. Electronic address: sayantanava@gmail.com.'}, {'ForeName': 'Milind Vijay', 'Initials': 'MV', 'LastName': 'Thanki', 'Affiliation': 'Hertfordshire Partnership University, NHS Foundation Trust, Hatfeild, Hertfordshire, AL108YE England United Kingdom. Electronic address: milind_thanki@yahoo.com.'}, {'ForeName': 'Jagadisha', 'Initials': 'J', 'LastName': 'Thirthalli', 'Affiliation': 'Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka 60029, India. Electronic address: jagatth@yahoo.com.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.066'] 2033,32703245,"Community Tele-pal: A community-developed, culturally based palliative care tele-consult randomized controlled trial for African American and White Rural southern elders with a life-limiting illness.","BACKGROUND Patients living in rural areas experience a variety of unmet needs that result in healthcare disparities. The triple threat of rural geography, racial inequities, and older age hinders access to high-quality palliative care (PC) for a significant proportion of Americans. Rural patients with life-limiting illness are at risk of not receiving appropriate palliative care due to a limited specialty workforce, long distances to treatment centers, and limited PC clinical expertise. Although culture strongly influences people's response to diagnosis, illness, and treatment preferences, culturally based care models are not currently available for most seriously ill rural patients and their family caregivers. The purpose of this randomized clinical trial (RCT) is to compare a culturally based tele-consult program (that was developed by and for the rural southern African American (AA) and White (W) population) to usual hospital care to determine the impact on symptom burden (primary outcome) and patient and care partner quality of life (QOL), care partner burden, and resource use post-discharge (secondary outcomes) in hospitalized AA and White older adults with a life-limiting illness. METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner. Half of the participants (n = 176) and a care partner (n = 176) will be randomized to receive the culturally based palliative care consult. The other half of the patient participants (n = 176) and care partners (n = 176) will receive usual hospital care appropriate to their illness. DISCUSSION This is the first community-developed, culturally based PC tele-consult program for rural southern AA and W populations. If effective, the tele-consult palliative program and methods will serve as a model for future culturally based PC programs that can reduce patients' symptoms and care partner burden. TRIAL REGISTRATION ClinicalTrials.gov NCT03767517 . Registered on 27 December 2018.",2020,"METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner.","['Rural patients with life-limiting illness', 'rural southern African American (AA) and White (W) population', 'Community Tele-pal', 'hospitalized AA and White older adults with a life-limiting illness', 'Half of the participants (n\u2009=\u2009176) and a care partner (n\u2009=\u2009176', 'patient participants (n\u2009=\u2009176) and care partners (n\u2009=\u2009176) will receive usual hospital care appropriate to their illness', 'for hospitalized rural AA and W older adults with life-limiting illnesses (n\u2009=\u2009352) and a care partner', 'African American and White Rural southern elders with a life-limiting illness']","['culturally based palliative care consult', 'community-developed, culturally based PC tele-consult program']","['patient and care partner quality of life (QOL), care partner burden, and resource use post-discharge']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0030360', 'cui_str': 'Papillon-Lefèvre syndrome'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0331055', 'cui_str': 'Genus Sambucus'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1515258', 'cui_str': 'Telephone number (property)'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]",,0.11513,"METHODS Community Tele-pal is a three-site RCT that will test the efficacy of a community-developed, culturally based PC tele-consult program for hospitalized rural AA and W older adults with life-limiting illnesses (n = 352) and a care partner.","[{'ForeName': 'Kristen Allen', 'Initials': 'KA', 'LastName': 'Watts', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Shena', 'Initials': 'S', 'LastName': 'Gazaway', 'Affiliation': 'College of Nursing, Augusta University, Augusta, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Malone', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Ronit', 'Initials': 'R', 'LastName': 'Elk', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Tucker', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'McCammon', 'Affiliation': 'Center for Palliative and Supportive Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Goldhagen', 'Affiliation': 'Russell Medical Center, Alexander City, USA.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Graham', 'Affiliation': 'Forrest General Hospital, Hattiesburg, USA.'}, {'ForeName': 'Veronica', 'Initials': 'V', 'LastName': 'Tassin', 'Affiliation': 'Highland Community Hospital, Picayune, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Hauser', 'Affiliation': 'Department of Medical Education at Northwestern University, Chicago, USA.'}, {'ForeName': 'Sidney', 'Initials': 'S', 'LastName': 'Rhoades', 'Affiliation': 'Aiken Regional Medical Center, Aiken, USA.'}, {'ForeName': 'Marjorie', 'Initials': 'M', 'LastName': 'Kagawa-Singer', 'Affiliation': 'Fielding School of Public Health, Department of Community Health Sciences, University of California Los Angeles, Los Angeles, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Wallace', 'Affiliation': 'Department of Medicine, Division of Nephrology, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'McElligott', 'Affiliation': 'College of Medicine, The Medical University of South Carolina, Charleston, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Kennedy', 'Affiliation': 'School of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, USA.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Bakitas', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham, USA. mbakitas@uab.edu.'}]",Trials,['10.1186/s13063-020-04567-w'] 2034,32703246,Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: statistical analysis plan for a randomised controlled trial (UPGRADE trial).,"BACKGROUND Approximately 8-15% of patients undergoing bariatric surgery develop symptomatic gallstone disease within 24 months after surgery. Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery. The aim of the UPGRADE trial is to provide evidence on the prophylactic use of UDCA in preventing symptomatic gallstone disease postoperatively. METHODS The UPGRADE trial is designed as a randomised, placebo-controlled, double-blind multicentre trial in patients with morbid obesity undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Patients are randomly assigned to either UDCA 900 mg daily for 6 months or placebo treatment. This paper details the statistical analysis plan (SAP) of this trial and was submitted before outcome data were available. RESULTS The primary endpoint of this trial is symptomatic gallstone disease within 24 months after bariatric surgery, defined as admission or hospital visit for symptomatic gallstone disease. Secondary outcomes consist of the development of gallstones/sludge on ultrasound at 24 months in the gallstone-negative group at baseline, presence of gallstones/sludge on ultrasound at 24 months, number of cholecystectomies, side effects of UDCA, therapy compliance, quality of life, costs and revenues. Analyses will be completed according to this pre-specified SAP. The main analysis will be performed as a standard ITT analysis using the chi-squared test. DISCUSSION The UPGRADE trial will show if prophylactic use of UDCA reduces the incidence of symptomatic gallstone disease after bariatric surgery. Unforeseen deviations from the SAP at the time of analysis will be motivated and discussed. TRIAL REGISTRATION The Netherlands Trial Register NL5954 . Registered on 21 November 2016.",2020,Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery.,"['patients undergoing bariatric surgery develop symptomatic gallstone disease within 24\u2009months after surgery', 'symptomatic gallstone disease after bariatric surgery', 'patients with morbid obesity undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG']","['Ursodeoxycholic acid', 'UDCA 900\u2009mg daily for 6 months or placebo', 'Ursodeoxycholic acid (UDCA', 'UDCA', 'placebo']","['admission or hospital visit for symptomatic gallstone disease', 'symptomatic gallstone disease', 'development of gallstones/sludge on ultrasound at 24\u2009months in the gallstone-negative group at baseline, presence of gallstones/sludge on ultrasound at 24\u2009months, number of cholecystectomies, side effects of UDCA, therapy compliance, quality of life, costs and revenues']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0028756', 'cui_str': 'Morbid obesity'}, {'cui': 'C0399839', 'cui_str': 'Bypass gastrojejunostomy'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C4517900', 'cui_str': '900'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1704447', 'cui_str': 'Patient visit for'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0008350', 'cui_str': 'Biliary calculus'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0282346', 'cui_str': 'Sludge'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C1321605', 'cui_str': 'Compliance behavior'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.41657,Ursodeoxycholic acid (UDCA) seems to effectively prevent the formation of gallstones detectable by ultrasound after bariatric surgery.,"[{'ForeName': 'Sylke', 'Initials': 'S', 'LastName': 'Haal', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. s.haal@amsterdamumc.nl.'}, {'ForeName': 'Maimoena S S', 'Initials': 'MSS', 'LastName': 'Guman', 'Affiliation': 'Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'L Maurits', 'Initials': 'LM', 'LastName': 'de Brauw', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'Ruben N', 'Initials': 'RN', 'LastName': 'van Veen', 'Affiliation': 'Department of Surgery, OLVG, Amsterdam, the Netherlands.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Schouten', 'Affiliation': 'Department of Surgery, Flevoziekenhuis, Almere, the Netherlands.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fockens', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Victor E A', 'Initials': 'VEA', 'LastName': 'Gerdes', 'Affiliation': 'Department of Internal Medicine, Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'Marcel G W', 'Initials': 'MGW', 'LastName': 'Dijkgraaf', 'Affiliation': 'Department of Epidemiology and Data Science, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Rogier P', 'Initials': 'RP', 'LastName': 'Voermans', 'Affiliation': 'Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}]",Trials,['10.1186/s13063-020-04605-7'] 2035,32703257,The effect of knowledge brokering on nurses' empathy with patients receiving cardiac care: a study protocol.,"BACKGROUND Hospitalization could be an unpleasant experience for patients with cardiovascular disease leading to some negative emotional reactions. These emotions can be managed by nursing empathy. There are different methods for improving empathy, but some evidence indicates a dramatic drop in nurses' empathy. In this study, we aim to provide a protocol for investigating the effect of knowledge brokering on nurses' empathy with patients receiving cardiac care. METHODS This study protocol is developed based on SPIRIT checklist with an experimental design. The study population are nurses working in cardiac wards of three educational hospitals in western Iran, Khorramabad. The quota sampling method is used. The sample size is 100 individuals. The samples will be assigned to two intervention and comparison groups using stratified random allocation method. Permuted block randomization is used in each stratum. To prevent contamination between participants; firstly, the measurements of the comparison group is done. Knowledge brokering intervention is performed in 7 stages based on Dobbins' knowledge translation framework 2009. Monica's Empathy Construct Self-Rating Scale is used for measuring empathy. Statistical analyses are performed using SPSS (SPPS Inc. Chicago, Il, version 21). P value below 0.05 is considered as statistically significant. DISCUSSION To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge. It helps nurses to improve their empathy in caring relationships.",2020,"To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge.","['cardiac wards of three educational hospitals in western Iran, Khorramabad', ""nurses' empathy with patients receiving cardiac care"", 'patients with cardiovascular disease leading to some negative emotional reactions']",['knowledge brokering'],"[""Monica's Empathy Construct Self-Rating Scale""]","[{'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150158', 'cui_str': 'Cardiac care'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0221736', 'cui_str': 'Reaction emotional'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}]","[{'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0349054,"To our knowledge, there is no similar study using an experimental design to examine the efficacy of a knowledge brokering method to improve humanistic knowledge.","[{'ForeName': 'Atefeh', 'Initials': 'A', 'LastName': 'Galehdarifard', 'Affiliation': 'Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Moloud', 'Initials': 'M', 'LastName': 'Radfar', 'Affiliation': 'Faculty of Nursing and Midwifery, Urmia University of Medical Sciences, Urmia, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Gholami', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Khademi', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. khademi.m@lums.ac.ir.'}, {'ForeName': 'Farzad', 'Initials': 'F', 'LastName': 'Ebrahimzadeh', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}, {'ForeName': 'Mohammad-Hasan', 'Initials': 'MH', 'LastName': 'Imani-Nasab', 'Affiliation': 'Social Determinants of Health Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.'}]",BMC health services research,['10.1186/s12913-020-05377-1'] 2036,32706534,Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.,"BACKGROUND Vitamin D metabolites support innate immune responses to Mycobacterium tuberculosis . Data from phase 3, randomized, controlled trials of vitamin D supplementation to prevent tuberculosis infection are lacking. METHODS We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT) to receive a weekly oral dose of either 14,000 IU of vitamin D 3 or placebo for 3 years. The primary outcome was a positive QFT result at the 3-year follow-up, expressed as a proportion of children. Secondary outcomes included the serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events. RESULTS A total of 8851 children underwent randomization: 4418 were assigned to the vitamin D group, and 4433 to the placebo group; 95.6% of children had a baseline serum 25(OH)D level of less than 20 ng per milliliter. Among children with a valid QFT result at the end of the trial, the percentage with a positive result was 3.6% (147 of 4074 children) in the vitamin D group and 3.3% (134 of 4043) in the placebo group (adjusted risk ratio, 1.10; 95% confidence interval [CI], 0.87 to 1.38; P = 0.42). The mean 25(OH)D level at the end of the trial was 31.0 ng per milliliter in the vitamin D group and 10.7 ng per milliliter in the placebo group (mean between-group difference, 20.3 ng per milliliter; 95% CI, 19.9 to 20.6). Tuberculosis disease was diagnosed in 21 children in the vitamin D group and in 25 children in the placebo group (adjusted risk ratio, 0.87; 95% CI, 0.49 to 1.55). A total of 29 children in the vitamin D group and 34 in the placebo group were hospitalized for treatment of acute respiratory infection (adjusted risk ratio, 0.86; 95% CI, 0.52 to 1.40). The incidence of adverse events did not differ significantly between the two groups. CONCLUSIONS Vitamin D supplementation did not result in a lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection than placebo among vitamin D-deficient schoolchildren in Mongolia. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT02276755.).",2020,"The incidence of adverse events did not differ significantly between the two groups. ","['8851 children underwent randomization: 4418', 'We randomly assigned children who had negative results for M. tuberculosis infection according to the QuantiFERON-TB Gold In-Tube assay (QFT', '29 children in the']","['Vitamin D metabolites', 'vitamin D 3 or placebo', 'Vitamin D supplementation', 'Vitamin D Supplements', 'vitamin D', 'vitamin D supplementation', 'placebo']","['Tuberculosis disease', 'lower risk of tuberculosis infection, tuberculosis disease, or acute respiratory infection', 'positive QFT result at the 3-year follow-up, expressed as a proportion of children', 'acute respiratory infection', 'serum 25-hydroxyvitamin D (25[OH]D) level at the end of the trial and the incidence of tuberculosis disease, acute respiratory infection, and adverse events', 'incidence of adverse events', 'mean 25(OH)D level']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C4704700', 'cui_str': 'Null Results'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0026926', 'cui_str': 'Mycobacterium tuberculosis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}]","[{'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0238990', 'cui_str': 'Acute lower respiratory tract infection'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",8851.0,0.752656,"The incidence of adverse events did not differ significantly between the two groups. ","[{'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Ganmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Buyanjargal', 'Initials': 'B', 'LastName': 'Uyanga', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Garmaa', 'Initials': 'G', 'LastName': 'Gantsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Baigali', 'Initials': 'B', 'LastName': 'Delgerekh', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Davaasambuu', 'Initials': 'D', 'LastName': 'Enkhmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Dorjnamjil', 'Initials': 'D', 'LastName': 'Khulan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Saranjav', 'Initials': 'S', 'LastName': 'Ariunzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Erdenebaatar', 'Initials': 'E', 'LastName': 'Sumiya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Batbileg', 'Initials': 'B', 'LastName': 'Bolortuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jutmaan', 'Initials': 'J', 'LastName': 'Yanjmaa', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Tserenkhuu', 'Initials': 'T', 'LastName': 'Enkhtsetseg', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ankhbat', 'Initials': 'A', 'LastName': 'Munkhzaya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Murneren', 'Initials': 'M', 'LastName': 'Tunsag', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Polyna', 'Initials': 'P', 'LastName': 'Khudyakov', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Seddon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ben J', 'Initials': 'BJ', 'LastName': 'Marais', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ochirbat', 'Initials': 'O', 'LastName': 'Batbayar', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Ganbaatar', 'Initials': 'G', 'LastName': 'Erdenetuya', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Bazarsaikhan', 'Initials': 'B', 'LastName': 'Amarsaikhan', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Spiegelman', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Jadambaa', 'Initials': 'J', 'LastName': 'Tsolmon', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}, {'ForeName': 'Adrian R', 'Initials': 'AR', 'LastName': 'Martineau', 'Affiliation': ""From the Harvard T.H. Chan School of Public Health (D.G., P.K., D.S.) and the Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School (D.G.) - all in Boston; the Mongolian Health Initiative (D.G., B.U., G.G., D.E., D.K., S.A., E.S., B.B., J.Y., T.E., O.B.) and Global Laboratory (B.D., A.M.), Royal Plaza, Bayanzurkh District, the National Center for Communicable Diseases (M.T.), and the Mongolian National University of Medical Sciences (G.E., B.A., J.T.) - all in Ulaanbaatar, Mongolia; Yale School of Public Health, New Haven, CT (X.Z., D.S.); the Faculty of Medicine, Imperial College (J.A.S.), and the Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (A.R.M.) - all in London; the Desmond Tutu Tuberculosis Centre, Department of Pediatrics and Child Health, Stellenbosch University, Cape Town, South Africa (J.A.S.); and the Faculty of Medicine and Health, University of Sydney, Sydney (B.J.M.).""}]",The New England journal of medicine,['10.1056/NEJMoa1915176'] 2037,32706546,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Ajeet', 'Initials': 'A', 'LastName': 'Gajra', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}, {'ForeName': 'Marjorie E', 'Initials': 'ME', 'LastName': 'Zettler', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}, {'ForeName': 'Bruce A', 'Initials': 'BA', 'LastName': 'Feinberg', 'Affiliation': 'Cardinal Health Specialty Solutions, Dublin, OH ajeet.gajra@cardinalhealth.com.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2038,32706547,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Aguirre Dávila', 'Affiliation': 'Paul-Ehrlich-Institut, Langen, Germany aguirredavila.lukas@gmx.de.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Koch', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Lasch', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2039,32706548,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Dal-Ré', 'Affiliation': ', Madrid, Spain rafael.dalre@quironsalud.es.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Mentz', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC.'}, {'ForeName': 'Frits R', 'Initials': 'FR', 'LastName': 'Rosendaal', 'Affiliation': 'Leiden University Medical Center, Leiden, the Netherlands.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2040,32706549,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Almut G', 'Initials': 'AG', 'LastName': 'Winterstein', 'Affiliation': 'University of Florida, Gainesville, FL almut@ufl.edu.'}, {'ForeName': 'Cynthia J', 'Initials': 'CJ', 'LastName': 'Girman', 'Affiliation': 'CERobs Consulting, Chapel Hill, NC.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Pottegård', 'Affiliation': 'Syddansk Universitet, Odense, Denmark.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2041,32706550,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Shrier', 'Affiliation': 'McGill University, Montreal, QC, Canada ian.shrier@mcgill.ca.'}, {'ForeName': 'Steven D', 'Initials': 'SD', 'LastName': 'Stovitz', 'Affiliation': 'University of Minnesota, Minneapolis, MN.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2042,32706551,Randomization versus Real-World Evidence.,,2020,,[],[],[],[],[],[],,0.0783911,,"[{'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Balzer', 'Affiliation': 'University of Massachusetts-Amherst, Amherst, MA lbalzer@umass.edu.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Dominici', 'Affiliation': 'Harvard T.H. Chan School of Public Health, Boston, MA.'}]",The New England journal of medicine,['10.1056/NEJMc2020020'] 2043,32708511,Lactobacillus paracasei KW3110 Suppresses Inflammatory Stress-Induced Premature Cellular Senescence of Human Retinal Pigment Epithelium Cells and Reduces Ocular Disorders in Healthy Humans.,"Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure. We investigated whether KW3110 suppresses chronic inflammatory stress-induced RPE cell damage by modulating immune cell activity and whether it improves ocular disorders in healthy humans. First, we showed that KW3110 treatment of mouse macrophages (J774A.1) produced significantly higher levels of interleukin-10 as compared with other lactic acid bacterium strains (all p < 0.01). Transferring supernatant from KW3110- and E. coli 0111:B4 strain and adenosine 5'-triphosphate (LPS/ATP)-stimulated J774A.1 cells to human retinal pigment epithelium (ARPE-19) cells suppressed senescence-associated phenotypes, including proliferation arrest, abnormal appearance, cell cycle arrest, and upregulation of cytokines, and also suppressed expression of tight junction molecule claudin-1. A randomized, double-blind, placebo-controlled parallel-group study of healthy subjects ( n = 88; 35 to below 50 years) ingesting placebo or KW3110-containing supplements for 8 weeks showed that changes in critical flicker frequency, an indicator of eye fatigue, from the week-0 value were significantly larger in the KW3110 group at weeks 4 ( p = 0.040) and 8 ( p = 0.036). These results suggest that KW3110 protects ARPE-19 cells against premature senescence and aberrant expression of tight junction molecules caused by chronic inflammatory stress, and may improve chronic eye disorders including eye fatigue.",2020,Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure.,"['Healthy Humans', 'healthy humans', 'healthy subjects ( n = 88; 35 to below 50 years) ingesting']","['placebo or KW3110-containing supplements', 'Lactobacillus paracasei KW3110 (KW3110', 'KW3110', 'Lactobacillus paracasei KW3110', 'placebo']","['critical flicker frequency, an indicator of eye fatigue']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C1080735', 'cui_str': 'Lactobacillus paracasei'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0004095', 'cui_str': 'Accommodative asthenopia'}]",,0.0862613,Lactobacillus paracasei KW3110 (KW3110) has anti-inflammatory effects and mitigates retinal pigment epithelium (RPE) cell damage caused by blue-light exposure.,"[{'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Yamazaki', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Sayuri', 'Initials': 'S', 'LastName': 'Yamada', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Konomi', 'Initials': 'K', 'LastName': 'Ohshio', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Sugamata', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}, {'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Yamada', 'Affiliation': 'Ario Nishi-Arai Eye Clinic, Tokyo 123-0843, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Morita', 'Affiliation': 'KIRIN Central Research Institute, Kirin Holdings Co., Ltd., Kanagawa 236-0004, Japan.'}]",International journal of molecular sciences,['10.3390/ijms21145091'] 2044,32708517,Concurrent Validity of Digital Vascular Auscultation for the Assessment of Blood Flow Obliteration on the Radial Artery in Healthy Subjects.,"This study aimed to determine the validity of digital vascular auscultation for the assessment of changes in the radial pulse in healthy subjects, using Doppler sonography as a validated test referent. Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years) were assigned and evaluated under one of the following conditions: In condition 1, blood flow of the radial artery was not modified; for condition 2, blood flow of the radial artery was modified using a pressure sleeve around the humerus. The radial pulse was then measured three times with each diagnostic tool by three different blinded evaluators. Both instruments demonstrated a high association between the identification of blood flow modifications or not and the assigned condition ( p < 0.001). A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001). Stethoscope sensitivity was 95%, and specificity was 99%. In conclusion, digital vascular auscultation seems to be a valid technique to examine blood flow changes of the radial artery in non-symptomatic subjects, and it could be useful for physical therapists when combined with provocative tests for the screening of possible thoracic outlet syndrome in patients.",2020,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","['Sixty-one non-symptomatic subjects (mean age of 52.5 ± 16.1 years', 'healthy subjects', 'Healthy Subjects']","['digital vascular auscultation', 'Digital Vascular Auscultation']","['changes"" or ""no changes"" in blood flow', 'Stethoscope sensitivity', 'Blood Flow Obliteration', 'radial pulse']","[{'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517802', 'cui_str': '52.5'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0004339', 'cui_str': 'Auscultation'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0442739', 'cui_str': 'No status change'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0183559', 'cui_str': 'Stethoscope'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0332465', 'cui_str': 'Obliteration'}, {'cui': 'C0232142', 'cui_str': 'Radial pulse'}]",,0.0586544,"A strong concordance between the two devices when detecting the ""changes"" or ""no changes"" in blood flow was demonstrated ( k = 0.936, p < 0.001).","[{'ForeName': 'María-Dolores', 'Initials': 'MD', 'LastName': 'Cortés-Vega', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María Jesús', 'Initials': 'MJ', 'LastName': 'Casuso-Holgado', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Oliva-Pascual-Vaca', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'María-Isabel', 'Initials': 'MI', 'LastName': 'García-Bernal', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'González-García', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}, {'ForeName': 'Cleofás', 'Initials': 'C', 'LastName': 'Rodríguez-Blanco', 'Affiliation': 'Department of Physiotherapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Seville, C/Avicena s/n, 41009 Seville, Spain.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics10070494'] 2045,32708555,"Caffeine Supplementation for 4 Days Does Not Induce Tolerance to the Ergogenic Effects Promoted by Acute Intake on Physiological, Metabolic, and Performance Parameters of Cyclists: A Randomized, Double-Blind, Crossover, Placebo-Controlled Study.","The present study investigated whether the caffeine supplementation for four days would induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters of cyclists. A double-blind placebo-controlled cross-over design was employed, involving four experimental trials; placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo (acute)/CP. Fourteen male recreationally-trained cyclists ingested capsules containing either placebo or caffeine (6 mg∙kg -1 ) for 4 days. On day 5 (acute), capsules containing placebo or caffeine (6 mg∙kg -1 ) were ingested 60 min before completing a 16 km time-trial (TT). CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively. These effects were accompanied by increased heart rate (2.63%, ES = 0.47; 1.99%, ES = 0.34), minute volume (13.11%, ES = 0.61; 16.32%, ES = 0.75), expired O 2 fraction (3.29%, ES = 0.96; 2.87, ES = 0.72), lactate blood concentration (immediately after, 29.51% ES = 0.78; 28.21% ES = 0.73 recovery (10 min), 36.01% ES = 0.84; 31.22% ES = 0.81), and reduction in expired CO 2 fraction (7.64%, ES = 0.64; 7.75%, ES = 0.56). In conclusion, these results indicate that caffeine, when ingested by cyclists in a dose of 6 mg∙kg -1 for 4 days, does not induce tolerance to the ergogenic effects promoted by acute intake on physiological, metabolic, and performance parameters.",2020,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.",['Fourteen male recreationally-trained cyclists ingested capsules containing either'],"['Placebo', 'Caffeine Supplementation', 'placebo or caffeine', 'caffeine supplementation', 'caffeine', 'placebo (4-day)-placebo (acute)/PP, placebo (4-day)-caffeine (acute)/PC, caffeine (4-day)-caffeine (acute)/CC and caffeine (4-day)-placebo', 'placebo']","['acute intake on physiological, metabolic, and performance parameters', 'lactate blood concentration', 'output power', 'heart rate', 'minute volume']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0427728', 'cui_str': 'Blood concentration, dipstick - finding'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0428679', 'cui_str': 'Minute volume'}]",,0.335508,"CC and PC showed improvements in time (3.54%, ES = 0.72; 2.53%, ES = 0.51) and in output power (2.85%, ES = 0.25; 2.53%, ES = 0.20) ( p < 0.05) compared to CP and PP conditions, respectively.","[{'ForeName': 'Anderson Pontes', 'Initials': 'AP', 'LastName': 'Morales', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Sampaio-Jorge', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Barth', 'Affiliation': 'Postgraduate Program in Bioactive Products and Biosciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}, {'ForeName': 'Anna Paola Trindade Rocha', 'Initials': 'APTR', 'LastName': 'Pierucci', 'Affiliation': 'Postgraduate Program in Nutrition, Josué de Castro Nutrition Institute, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 21941-590, Brazil.'}, {'ForeName': 'Beatriz Gonçalves', 'Initials': 'BG', 'LastName': 'Ribeiro', 'Affiliation': 'Laboratory Research and Innovation in Sports Sciences, Federal University of Rio de Janeiro (UFRJ), Macaé, RJ 27930-560, Brazil.'}]",Nutrients,['10.3390/nu12072101'] 2046,32708600,Impact of Exercises and Chair Massage on Musculoskeletal Pain of Young Musicians.,"Due to the occurrence among musicians of musculoskeletal problems associated with playing a musical instrument, it is necessary to use prophylaxis. The aim of the study was to compare the effectiveness of two physioprophylaxis methods: chair massage and an original set of exercises. The study lasted four weeks and consisted of eight 15-min meetings (chair massage/exercises). The study was conducted on 44 music students assigned to three groups (chair massage/exercise program/control group). The algometric measurements and questionnaire were conducted. Health problems associated with playing an instrument was reported by 86.4% of the participants. The largest changes in pain threshold concerned the trigger points of the muscles with the highest pain sensitivity, i.e., upper part of trapezius ones, and reached 25-34% in relation to the initial values. For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%. Raising the pain threshold was observed both after each session and meeting by meeting, and these differences were most visible in the massage group. This effect was particularly visible from the fourth treatment. Chair massage and exercise should be used regularly, and significant results can be obtained after two weeks.",2020,"For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%.","['44 music students assigned to three groups ', 'Musculoskeletal Pain of Young Musicians']","['Exercises and Chair Massage', 'physioprophylaxis methods: chair massage', 'Chair massage and exercise', 'chair massage/exercise program/control group']",['pain threshold'],"[{'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026858', 'cui_str': 'Musculoskeletal pain'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}]",44.0,0.0195533,"For the trigger points of the levator scapulae and lower part of trapezius, the increase in the pain threshold was between 20 and 28%.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Cygańska', 'Affiliation': 'Faculty of Rehabilitation, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Truszczyńska-Baszak', 'Affiliation': 'Faculty of Rehabilitation, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}, {'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Tomaszewski', 'Affiliation': 'Faculty of Physical Education, Józef Piłsudski University of Physical Education in Warsaw, Poland, Marymoncka 34, 00-968 Warsaw, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145128'] 2047,32708292,The Impact of Novel Anticoagulants on the Upper Gastrointestinal Tract Mucosa.,"Background and objectives: Although treatment with novel oral non-vitamin K antagonist 3anticoagulants (NOACs) is associated with an overall decrease in hemorrhagic complications compared to warfarin, the incidence of gastrointestinal bleeding remains contradictory. Materials and Methods: After the exclusion of patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years) was randomly divided into four equivalent groups, treated with dabigatran, rivaroxaban, apixaban, or warfarin. Patients were prospectively followed up for three months of treatment, with a focus on anamnestic and endoscopic signs of bleeding. In addition, bleeding risk factors were evaluated. Results: In none of the patients treated with warfarin or NOACs was any serious or clinically significant bleeding recorded within the follow-up period. The incidence of clinical bleeding and endoscopically detected bleeding in the upper GT after three months of treatment was not statistically different among groups (χ 2 = 2.8458; p = 0.41608). The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205). We did not record any post-biopsy continued bleeding. Conclusions: No significant GIT bleeding was found in any of the treatment groups, so we consider it beneficial to perform routine EGD before the initiation of any anticoagulant therapy in patients with an increased risk of upper GIT bleeding. Detection and eradication of HP as well as preventive PPI treatment may mitigate the occurrence of endoscopic bleeding. Endoscopic biopsy during the NOAC treatment is safe.",2020,"The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205).","['patients with pre-existing pathological lesions in the upper gastrointestinal tract (GIT) on esophageal-gastroduodenoscopy (EGD) at entry, a cohort of 80 patients (mean age of 74.8 ± 2.0 years']","['novel oral non-vitamin K antagonist 3anticoagulants (NOACs', 'dabigatran, rivaroxaban, apixaban, or warfarin', 'warfarin or NOACs', 'Novel Anticoagulants', 'Endoscopic biopsy']","['bleeding risk factors', 'GIT bleeding', 'hemorrhagic complications', 'presence of Helicobacter pylori (HP', 'risk of upper GIT bleeding', 'anamnestic and endoscopic signs of bleeding', 'incidence of clinical bleeding and endoscopically detected bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C3203348', 'cui_str': 'Upper gastrointestinal tract structure'}, {'cui': 'C0192657', 'cui_str': 'Gastroduodenoscopy'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}, {'cui': 'C0642228', 'cui_str': 'N(4)-oleylcytosine arabinoside'}, {'cui': 'C2348066', 'cui_str': 'dabigatran'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0184980', 'cui_str': 'Endoscopic biopsy'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0442726', 'cui_str': 'Detected'}]",80.0,0.0200152,"The presence of Helicobacter pylori (HP) was a risk factor for upper GIT bleeding ( p < 0.05), while the use of proton pump inhibitors (PPIs) was a protective factor ( p = 0.206; Spearman's correlation coefficient = 0.205).","[{'ForeName': 'Lubomir', 'Initials': 'L', 'LastName': 'Mihalkanin', 'Affiliation': 'Gastroenterology Department, Gastro-LM, 080 01 Presov, Slovakia.'}, {'ForeName': 'Branislav', 'Initials': 'B', 'LastName': 'Stancak', 'Affiliation': 'Cardiology Department, East Slovakia Institute for Cardiovascular Diseases, 040 11 Kosice, Slovakia.'}]","Medicina (Kaunas, Lithuania)",['10.3390/medicina56070363'] 2048,32708368,Effect of Sechium edule var. nigrum spinosum (Chayote) on Telomerase Levels and Antioxidant Capacity in Older Adults with Metabolic Syndrome.,"Patients with metabolic syndrome (MetS) have a redox imbalance, due to a decay in antioxidant capacity. Oxidative stress (OxS) is considered an important modulator of telomere shortening and telomerase activity. One of the fruits that has been associated with an antioxidant effect is Sechium edule and although its properties are well established, there is only one exploratory study evaluating its effectiveness in patients with MetS. The present investigation is a much more robust and controlled study, including a placebo group. Hence, we determined the effect of consumption of the dried fruit powder (500 mg, three times per day) for three months. We measured effects on telomerase levels, antioxidant capacity, and markers for OxS. The study was performed in a sample of 75 older adults: placebo group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III (NCEP/ATP III) criteria. All markers were measured before and after three months of treatment. There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule . Our findings suggest that consumption of this fruit has a hypoglycemic, hypotensive, and antioxidant effect, without altering telomerase levels, which could suggest better protection against telomere shortening.",2020,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","['75 older adults', 'Patients with metabolic syndrome (MetS', 'patients with MetS', 'Older Adults with Metabolic Syndrome', 'group ( n = 30) and experimental group ( n = 45) with the diagnosis of MetS according to the National Adult Treatment Panel of the National Cholesterol Program III']","['placebo', 'dried fruit powder', 'Sechium edule var', 'nigrum spinosum (Chayote']","['lipoperoxides and protein carbonylation', 'Oxidative stress (OxS', 'telomerase levels, antioxidant capacity, and markers for OxS', 'superoxide dismutase (SOD', 'Telomerase Levels and Antioxidant Capacity']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0453296', 'cui_str': 'Dried fruit'}, {'cui': 'C0032861', 'cui_str': 'Powder'}]","[{'cui': 'C0023776', 'cui_str': 'Fatty Acid Hydroperoxides'}, {'cui': 'C1563721', 'cui_str': 'Carbonylation, Protein'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0087071', 'cui_str': 'Telomerase Reverse Transcriptase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}]",75.0,0.0375362,"There was a statistically significant decrease in lipoperoxides and protein carbonylation with an increased superoxide dismutase (SOD), as well as sustained levels of telomerase in patients who consumed Sechium edule .","[{'ForeName': 'Graciela', 'Initials': 'G', 'LastName': 'Gavia-García', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Juana', 'Initials': 'J', 'LastName': 'Rosado-Pérez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Itzen', 'Initials': 'I', 'LastName': 'Aguiñiga-Sánchez', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Edelmiro', 'Initials': 'E', 'LastName': 'Santiago-Osorio', 'Affiliation': 'Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}, {'ForeName': 'Víctor Manuel', 'Initials': 'VM', 'LastName': 'Mendoza-Núñez', 'Affiliation': 'Research Unit on Gerontology, FES Zaragoza, National Autonomous University of Mexico, Mexico City 09230, Mexico.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9070634'] 2049,32710888,Effects of Ramadan intermittent fasting on inflammatory and biochemical biomarkers in males with obesity.,"BACKGROUND To determine the effects of Ramadan intermittent fasting (RIF) on inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine) in males with obesity. MATERIALS AND METHODS Twenty-eight males with obesity were randomly allocated to an experimental group (EG, n = 14) or a control group (CG, n = 14). The EG group completed their fasting rituals for the entire month of Ramadan (30 days) whereas the CG group continued with their normal daily habits. Blood samples were collected 24 h before the start of Ramadan (T0), on the 15th day of Ramadan (T1), the day after the end of Ramadan (T2), and 21 days after the end of Ramadan (T3). Resting plasma volume variation between pre and post-RIF (ΔPV) was calculated. RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d = 0.1) in the EG compared to CG group. There were no changes (P > 0.05) in ΔPV recorded after RIF for either EG (-0.035 ± 0.02%) and CG (0.055 ± 0.06%). CONCLUSION This study demonstrates that RIF improves systemic inflammation biomarkers in males with obesity. Moreover, RIF did not negatively affect biomarkers of liver and renal function.",2020,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","['males with obesity', 'Twenty-eight males with obesity']","['Ramadan intermittent fasting', 'Ramadan intermittent fasting (RIF', 'RIF']","['systemic inflammation biomarkers', 'inflammatory (C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)) and biochemical markers of liver-renal function (aspartate aminotransferase (AST), alanine amino transferase (ALT), bilirubin, lactate dehydrogenase (LDH), urea and creatinine', 'Blood samples', 'biomarkers of liver and renal function', 'inflammatory and biochemical biomarkers', 'tumor necrosis factor-alpha']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C4704881', 'cui_str': 'Intermittent Fasting'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0022662', 'cui_str': 'Renal function study'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0057041', 'cui_str': 'D-amino-acid transaminase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0041942', 'cui_str': 'Urea'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",28.0,0.0245917,"RESULTS Decreases were noted for interleukin-6 (p = 0.02, d = 1.4) and tumor necrosis factor-alpha (p = 0.01, d = 0.7), with no changes for C-reactive protein (p = 0.3; d=0.1) in the EG compared to CG group.","[{'ForeName': 'Hassane', 'Initials': 'H', 'LastName': 'Zouhal', 'Affiliation': 'Univ Rennes, M2S (Laboratoire Mouvement, Sport, Santé) - EA 1274, F-35000 Rennes, France. Electronic address: hassane.zouhal@univ-rennes2.fr.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Bagheri', 'Affiliation': 'Department of Exercise Physiology, University of Isfahan, Isfahan, Iran.'}, {'ForeName': 'Damoon', 'Initials': 'D', 'LastName': 'Ashtary-Larky', 'Affiliation': 'Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Alexei', 'Initials': 'A', 'LastName': 'Wong', 'Affiliation': 'Department of Health and Human Performance, Marymount University, Arlington, USA.'}, {'ForeName': 'Raoua', 'Initials': 'R', 'LastName': 'Triki', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}, {'ForeName': 'Anthony C', 'Initials': 'AC', 'LastName': 'Hackney', 'Affiliation': 'Department of Exercise & Sport Science, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ismail', 'Initials': 'I', 'LastName': 'Laher', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, The University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Abderraouf Ben', 'Initials': 'AB', 'LastName': 'Abderrahman', 'Affiliation': 'ISSEP Ksar Said, University of Manouba, Tunis, Tunisia.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113090'] 2050,32711031,Developing and Evaluating ASTHMAXcel Adventures: A Novel Gamified Mobile App for Pediatric Patients with Asthma.,"BACKGROUND The ASTHMAXcel mobile application has been linked to favorable outcomes among adult asthma patients. OBJECTIVE We assessed the impact of ASTHMAXcel Adventures, a gamified, guideline-based, pediatric version on asthma control, knowledge, healthcare utilization, and patient satisfaction. METHODS Pediatric asthma patients received the ASTHMAXcel Adventures mobile intervention on-site only at baseline (Visit 1), 4 months (Visit 2) and 6 months (Visit 3). The Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8) were used to assess asthma control, knowledge, and patient satisfaction. Patients reported the number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use. RESULTS 39 patients completed the study. The proportion of controlled asthma increased from Visit 1 to Visits 2 and 3 (30.8% vs. 53.9%, p=0.04; 30.8% vs. 59.0%, p=0.02), and largely seen in males. Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001). PAIS scores improved from baseline to Visits 2 and 3 (43.33 vs 34.08, p=0.0006; 43.33 vs. 31.74, p=0.0001). ED visits and prednisone use significantly decreased from baseline to Visits 2 and 3 (ED: 0.46 vs 0.13, p=0.03; 0.46 vs. 0.02, p=0.02; Prednisone: 0.49 vs 0.13, p=0.02; 0.49 vs. 0.03, p=0.003. Satisfaction was high with mean CSQ ∼30 (out of 32) at all visits. CONCLUSION ASTHMAXcel Adventures improved asthma control, knowledge, and quality of life, and reduced ED visits and prednisone use with high satisfaction scores.",2020,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","['adult asthma patients', 'Pediatric asthma patients', '39 patients completed the study', 'Pediatric Patients with Asthma']","['Prednisone', 'ASTHMAXcel Adventures mobile intervention']","['number of asthma-related emergency department (ED) visits, hospitalizations, and oral prednisone use', 'asthma control, knowledge, and patient satisfaction', 'asthma control, knowledge, healthcare utilization, and patient satisfaction', 'proportion of controlled asthma', 'Asthma Control Test (ACT), Asthma Illness Representation Scale-Self Administered (AIRS-SR), Pediatric Asthma Impact Survey (PAIS), and Client Satisfaction Questionnaire (CSQ-8', 'Mean AIRS-SR scores', 'PAIS scores', 'asthma control, knowledge, and quality of life, and reduced ED visits', 'Satisfaction']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",39.0,0.059259,"Mean AIRS-SR scores increased from baseline pre to post-intervention, with sustained improvements at Visits 2 and 3 (3.55 vs. 3.76, p=0.0006; 3.55 vs. 3.80, p=0.001; 3.55 vs. 3.99, p=0.0001).","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hsia', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Anjani K', 'Initials': 'AK', 'LastName': 'Singh', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Obumneme', 'Initials': 'O', 'LastName': 'Njeze', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Cosar', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Wenzhu B', 'Initials': 'WB', 'LastName': 'Mowrey', 'Affiliation': 'Division of Biostatistics, Department of Epidemiology and Population Health, Albert Einstein College of Medicine. Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Feldman', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY; Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY.""}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Reznik', 'Affiliation': ""Department of Pediatrics, Division of Academic General Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY.""}, {'ForeName': 'Sunit P', 'Initials': 'SP', 'LastName': 'Jariwala', 'Affiliation': 'Division of Allergy/Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY. Electronic address: sjariwal@montefiore.org.'}]","Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",['10.1016/j.anai.2020.07.018'] 2051,32714547,Immunomodulation by ketamine as an adjunct to total intravenous anesthesia in patients undergoing minimally invasive radical prostatectomy: A randomized pilot trial.,"Post-surgery immunomodulation, including reduced natural killer cell cytotoxicity (NKCC), is recognized as a predictor of poor outcomes in patients following cancer surgery. The present study investigated direct immunomodulation via ketamine as an anesthetic adjuvant in patients undergoing cancer surgery. The present non-double blinded randomized trial was conducted at Hirosaki University Hospital with 60 patients who underwent minimally invasive robotic radical prostatectomy to minimize the immunomodulation due to surgical stress. Patients received total intravenous anesthesia using propofol and remifentanil, with ketamine as an anesthetic adjuvant (the ketamine group) or without ketamine (the control group). The primary outcome was the difference in NKCC between these groups. The secondary outcomes were the differences in neutrophil-lymphocyte ratio (NLR) and levels of interleukin (IL)-6, IL-1β, IL-10 and tumor necrosis factor-alpha (TNF-α). NKCC and cytokines were measured before anesthesia (baseline) and at 6 and 24 h after baseline measurements were recorded. NLR was determined on the last day before admission and at 48 h post-baseline. NKCC values were similar in each group at 6 h when compared with respective baseline results (baseline control, 36.9±15.6%; 6 h control, 38.3±13.4%; baseline ketamine, 36.1±17.0%; 6 h ketamine, 36.6±16.4%) but significantly decreased at 24 h (control, 26.5±12.2%; ketamine, 24.1±12.7%; P<0.001). There were no significant differences in NKCC between the ketamine and control groups (P=0.64) at any of the assessed time points. NLR, IL-1β, IL-10 and TNF-α levels were also similar between two groups. In contrast, IL-6 at 24 h was significantly lower in the ketamine group compared with the control group (mean difference, -7.3 pg ml -1 ; 95% confidence interval, -14.4 to -0.2; P=0.04). Ketamine as an anesthetic adjuvant did not provide direct immunomodulation in patients who underwent cancer surgery.",2020,There were no significant differences in NKCC between the ketamine and control groups (P=0.64) at any of the assessed time points.,"['patients who underwent cancer surgery', 'patients undergoing minimally invasive radical prostatectomy', 'patients undergoing cancer surgery', 'patients following cancer surgery', 'Hirosaki University Hospital with 60 patients who underwent minimally invasive robotic radical prostatectomy to minimize the immunomodulation due to surgical stress']","['ketamine', 'Ketamine', 'ketamine group) or without ketamine', 'total intravenous anesthesia using propofol and remifentanil, with ketamine']","['reduced natural killer cell cytotoxicity (NKCC', 'neutrophil-lymphocyte ratio (NLR) and levels of interleukin (IL)-6, IL-1β, IL-10 and tumor necrosis factor-alpha (TNF-α', 'NKCC and cytokines', 'NLR', 'NKCC', 'NLR, IL-1β, IL-10 and TNF-α levels', 'NKCC values']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0194810', 'cui_str': 'Radical prostatectomy'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C1963758', 'cui_str': 'Immunomodulatory therapy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0473965', 'cui_str': 'Total intravenous anesthesia'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0024264', 'cui_str': 'Lymphocyte'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",,0.236335,There were no significant differences in NKCC between the ketamine and control groups (P=0.64) at any of the assessed time points.,"[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Kawaguchi', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Hospital, Hirosaki, Aomori 036-8563, Japan.'}, {'ForeName': 'Daichi', 'Initials': 'D', 'LastName': 'Ota', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Hospital, Hirosaki, Aomori 036-8563, Japan.'}, {'ForeName': 'Hidetomo', 'Initials': 'H', 'LastName': 'Niwa', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Hospital, Hirosaki, Aomori 036-8563, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Sugo', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Hospital, Hirosaki, Aomori 036-8563, Japan.'}, {'ForeName': 'Tetsuya', 'Initials': 'T', 'LastName': 'Kushikata', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.'}, {'ForeName': 'Kazuyoshi', 'Initials': 'K', 'LastName': 'Hirota', 'Affiliation': 'Department of Anesthesiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan.'}]",Molecular and clinical oncology,['10.3892/mco.2020.2060'] 2052,32714561,Engagement intervention versus treatment as usual for young adults with serious mental illness: a randomized pilot trial.,"Background Young adults have elevated rates of mental health disorders, yet they often do not receive consistent care. The challenge of continuing to engage young adults has been pervasive worldwide. Few engagement interventions have been designed for young adults with serious mental illness. Just Do You is a theoretically guided engagement intervention. It uses innovative modalities (i.e., technology, expressive arts activities, narrative expression, mentoring) to engage participants in conversations about services and how they work, while simultaneously orienting them to treatment. Methods/design This pilot and feasibility study utilizes a hybrid research design, examining feasibility, acceptability, and preliminary impact, alongside implementation. The study combines qualitative methods, a small pilot randomized trial, and a small cost-benefit analysis. Respondents are clinic staff and young adults who have made initial contact with the Personalized Recovery Oriented Services (PROS) program. Quantitative survey data are collected at baseline, 2 weeks (post-intervention), 1 month, and 3 months. The assessments focus on measuring feasibility, acceptability, engagement, and mental health outcomes. Medical record extraction will be used to triangulate self-report data. We will conduct single degree of freedom contrasts to examine whether Just Do You leads to improved outcomes relative to Treatment-As-Usual using robust regression for each outcome measure. We will examine whether changes in the proposed mediating variables occur across groups using a similar contrast strategy. In addition, we will use structural equation modeling to examine the contribution of mediators to ultimate outcomes. Finally, we will use constant comparison coding techniques for qualitative analyses. Discussion The aim of this study is to examine the feasibility of a young adult engagement meta-intervention through an intensive preliminary pilot trial, learning through collaboration with stakeholders. Just Do You has the potential to fill a gap in the service system for young adults with serious mental illnesses, improving the seemingly intractable problem of disengagement. The program uses culturally responsive strategies, is recovery-oriented, and builds upon the best evidence to date. Our efforts align with local and national health care reform efforts embedding people with lived experience. Trial registration This trial was registered with ClinicalTrials.gov (Identifier: NCT03423212) on April 18, 2018, as Protocol Record R34 MH111861-01, New York University, as the Just Do You Program for Young Adults with Serious Mental Illness.",2020,"Just Do You has the potential to fill a gap in the service system for young adults with serious mental illnesses, improving the seemingly intractable problem of disengagement.","['Young Adults with Serious Mental Illness', 'young adults with serious mental illnesses', 'young adults with serious mental illness', 'Respondents are clinic staff and young adults who have made initial contact with the Personalized Recovery Oriented Services (PROS) program']",['Engagement intervention'],"['feasibility, acceptability, engagement, and mental health outcomes']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C1704322', 'cui_str': 'Spatial orientation'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.144967,"Just Do You has the potential to fill a gap in the service system for young adults with serious mental illnesses, improving the seemingly intractable problem of disengagement.","[{'ForeName': 'Michelle R', 'Initials': 'MR', 'LastName': 'Munson', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'James J', 'Initials': 'JJ', 'LastName': 'Jaccard', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Lionel D', 'Initials': 'LD', 'LastName': 'Scott', 'Affiliation': 'School of Social Work, Georgia State University, Atlanta, Georgia 30302 USA.'}, {'ForeName': 'Sarah C', 'Initials': 'SC', 'LastName': 'Narendorf', 'Affiliation': 'Graduate College of Social Work, University of Houston, 3511 Cullen Blvd, Houston, TX 77204 USA.'}, {'ForeName': 'Kiara L', 'Initials': 'KL', 'LastName': 'Moore', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Jenefsky', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Cole', 'Affiliation': 'New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032 USA.'}, {'ForeName': 'Maryann', 'Initials': 'M', 'LastName': 'Davis', 'Affiliation': 'Medical School, Psychiatry, University of Massachusetts, 55 Lake Avenue North, Worcester, MA 01655 USA.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Gilmer', 'Affiliation': 'Department of Family Medicine and Public Health, University of California San Diego, San Diego, CA 92093 USA.'}, {'ForeName': 'Rei', 'Initials': 'R', 'LastName': 'Shimizu', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Kristin', 'Initials': 'K', 'LastName': 'Pleines', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Kamilyah', 'Initials': 'K', 'LastName': 'Cooper', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Aaron H', 'Initials': 'AH', 'LastName': 'Rodwin', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Hylek', 'Affiliation': 'Silver School of Social Work, New York University, 1 Washington Square North, New York, NY 10003 USA.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Amaro', 'Affiliation': 'School of Social Work, Columbia University, 1255 Amsterdam Ave, New York, NY 10027 USA.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00650-w'] 2053,32714565,Comparison of hydroxyapatite and fluoride oral care gels for remineralization of initial caries: a pH-cycling study.,"Objective The present in vitro study investigated if simulated daily use of hydroxyapatite-based gel (15% HAP) remineralizes early caries lesions as effective as weekly use of high fluoride (12,500 ppm) concentration gel, comparing them with artificial saliva alone. Materials and methods Three tooth blocks were produced from each of 20 bovine teeth. Caries-like lesion was created on each block by 4-day demineralization in acidified gel. The blocks were randomized into three remineralization groups (20 blocks/group); Hydroxyapatite-based gel (Karex gelée, 15% HAP, fluoride-free), fluoride-based gel (Elmex gelée, 12,500 ppm F - ), and artificial saliva (AS). Remineralization was conducted using pH-cycling model for 28 days with storage in AS. The pH cycling model consisted of 2 h demineralization once daily for all groups, and 3 min HAP gel application once daily, 3 min fluoride gel application once weekly, or remain in AS only respectively. Baseline and post-test mineral loss were quantified using microradiography. Results Paired t-tests (baseline vs. post-Test) indicated significant ( p  < 0.0001) remineralization in all groups. When compared against each other using Games-Howell's multiple comparison test, no significant difference in remineralization was observed between the two gels, but both gels exhibited significantly ( p  < 0.001) higher percentage mineral gain (HAP:39 ± 7%; fluoride:41 ± 11%) than AS alone (6 ± 2%). Conclusion Hydroxyapatite-based gel (15% HAP) was as effective as fluoride-based gel (12,500 ppm F - ) in remineralizing initial caries lesion.",2020,"When compared against each other using Games-Howell's multiple comparison test, no significant difference in remineralization was observed between the two gels, but both gels exhibited significantly ( p  < 0.001) higher percentage mineral gain (HAP:39 ± 7%; fluoride:41 ± 11%) than AS alone (6 ± 2%). ",['initial caries'],"['hydroxyapatite and fluoride oral care', 'Hydroxyapatite-based gel (15% HAP', 'hydroxyapatite-based gel', 'Hydroxyapatite-based gel (Karex gelée, 15% HAP, fluoride-free), fluoride-based gel (Elmex gelée, 12,500\u2009ppm F - ), and artificial saliva (AS']","['percentage mineral gain', 'remineralization']","[{'cui': 'C0266858', 'cui_str': 'Incipient enamel caries'}]","[{'cui': 'C0020326', 'cui_str': 'Hydroxyapatite Derivatives'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0059034', 'cui_str': 'Elmex'}, {'cui': 'C0439187', 'cui_str': 'ppm'}, {'cui': 'C0036088', 'cui_str': 'Artificial saliva'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}]",,0.0504058,"When compared against each other using Games-Howell's multiple comparison test, no significant difference in remineralization was observed between the two gels, but both gels exhibited significantly ( p  < 0.001) higher percentage mineral gain (HAP:39 ± 7%; fluoride:41 ± 11%) than AS alone (6 ± 2%). ","[{'ForeName': 'Bennett T', 'Initials': 'BT', 'LastName': 'Amaechi', 'Affiliation': 'Department of Comprehensive Dentistry, School of Dentistry, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900 USA.'}, {'ForeName': 'Parveez Ahamed', 'Initials': 'PA', 'LastName': 'AbdulAzees', 'Affiliation': 'Department of Comprehensive Dentistry, School of Dentistry, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900 USA.'}, {'ForeName': 'Linda O', 'Initials': 'LO', 'LastName': 'Okoye', 'Affiliation': 'Department of Restorative Dentistry, Faculty of Dentistry, College of Medicine, University of Nigeria, Enugu, Nigeria.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Meyer', 'Affiliation': 'Dr. Kurt Wolff GmbH & Co. KG, Research Department, Johanneswerkstr. 34-36, 33611 Bielefeld, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Enax', 'Affiliation': 'Dr. Kurt Wolff GmbH & Co. KG, Research Department, Johanneswerkstr. 34-36, 33611 Bielefeld, Germany.'}]",BDJ open,['10.1038/s41405-020-0037-5'] 2054,32714774,Workplace-based opportunities to support child care workers' health and safety.,"Child care workers earn among the lowest wages in the United States and they struggle with many health issues. The purpose of this study was to describe workplace supports for nutrition, physical activity, other health behaviors (e.g., smoking cessation, stress management), and occupational health and safety available to child care workers, and thereby inform the development of future workplace-based interventions to improve worker well-being. Between 2015 and 2016, 74 North Carolina child care centers (and directors), participating in a larger randomized controlled trial, completed a Workplace Health and Safety Assessment (interview and observation) measuring four domains: Infrastructure, Organizational Policies and Procedures, Programs and Promotions, and Internal Physical Environment. This study used baseline data to report means and standard deviations. Participating child care centers employed, on average, 12.7 ± 8.4 employees. Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety. More specifically, centers scored on average 9.5 ± 3.9 on Infrastructure (35% of potential points), 11.1 ± 3.9 on Organizational Policies and Procedures (32% of potential), 7.6 ± 5.4 on Programs and Promotions (12% of potential), and 13.1 ± 2.2 on Internal Physical Environment (49% of potential). The most frequent supports available were for occupational health and safety issues, while fewer supports were available for physical activity and other health behaviors. Child care workers could benefit greatly from more comprehensive workplace health and safety interventions; however, strategies must overcome centers' limited capacity and resources.",2020,"Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety.","['Participating child care centers employed, on average, 12.7\xa0±\xa08.4 employees', 'Between 2015 and 2016, 74 North Carolina child care centers (and directors']","['Workplace Health and Safety Assessment (interview and observation) measuring four domains: Infrastructure, Organizational Policies and Procedures, Programs and Promotions, and Internal Physical Environment']",['Total scores'],"[{'cui': 'C0008070', 'cui_str': 'Child day care center'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C4517546', 'cui_str': '12.7'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C0028407', 'cui_str': 'North Carolina'}]","[{'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0079945', 'cui_str': 'Organizational Policies'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0557720', 'cui_str': 'Physical environment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0152136,"Total scores from the Workplace Health and Safety Assessment averaged 41.3 ± 12.6 out of a possible 154, demonstrating many missed opportunities for supporting health/safety.","[{'ForeName': 'Amber E', 'Initials': 'AE', 'LastName': 'Vaughn', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Erik A', 'Initials': 'EA', 'LastName': 'Willis', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Dianne S', 'Initials': 'DS', 'LastName': 'Ward', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Falon', 'Initials': 'F', 'LastName': 'Smith', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Grummon', 'Affiliation': 'Center for Health Promotion and Disease Prevention, The University of North Carolina at Chapel Hill, 1700 Martin L. King Jr. Blvd., CB 7426, Chapel Hill, NC 27599-7426, USA.'}, {'ForeName': 'Laura A', 'Initials': 'LA', 'LastName': 'Linnan', 'Affiliation': 'Department of Health Behavior, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, 307 Rosenau Hall, CB 7440, Chapel Hill, NC 27599-7440, USA.'}]",Preventive medicine reports,['10.1016/j.pmedr.2020.101154'] 2055,32715116,Caries arrest and lesion appearance using two different silver fluoride therapies with and without potassium iodide: 6-month results.,"Objectives to compare arrest rates and colour change in carious lesions in primary teeth using two different silver fluoride solutions with and without potassium iodide (KI). Methods The study was a four-armed, parallel-design randomised controlled trial and investigated four protocols for caries arrest at 6m. Children in Group 1 and Group 2 received Rivastar Silver Diammine Fluoride (SDF), and Children in Group 3 and Group 4 received an aqueous silver fluoride solution (AgF). Children in Group 2 and Group 4 received a two-step procedure where application of the AgF or SDF solution was followed by KI. Results At the six-month follow-up 446 (82.2%) children were re-examined. The arrest rate across the full sample was 51.4% and there were no significant differences in arrest rate by type of silver fluoride therapy. The lesion size, tooth type, surface type, presence of plaque on the carious lesion and caries increment all had an influence on caries arrest. Once clustering effects were accounted for, the use of KI was associated with a higher chance of arrest (OR 1.23; P-value 0.008) and a lower chance of the lesion darkening (OR 0.73; P-value <0.001). Conclusions The combination of AgF & KI was associated with the most favourable clinical outcomes in terms of caries arrest and lesion colour. Clinical significance The major draw-back of arrest of caries treatment with silver fluoride solutions is that it can create an appearance which may be aesthetically unacceptable. This study explores ways in which the base colour of lesions could be improved and as such provide the opportunity for better aesthetic outcomes for children afflicted with a severe burden of dental caries in their primary dentition, and in whom conventional treatment is not being provided.",2020,"The combination of AgF & KI was associated with the most favourable clinical outcomes in terms of caries arrest and lesion colour. ","['caries arrest at 6m', 'carious lesions in primary teeth', 'children afflicted with a severe burden of dental caries in their primary dentition']","['silver fluoride solutions', 'Rivastar Silver Diammine Fluoride (SDF), and Children in Group 3 and Group 4 received an aqueous silver fluoride solution (AgF', 'AgF or SDF solution was followed by KI', 'silver fluoride solutions with and without potassium iodide (KI']","['Caries arrest and lesion appearance', 'arrest rate']","[{'cui': 'C0266848', 'cui_str': 'Arrested dental caries'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C3266841', 'cui_str': 'All deciduous teeth'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0303296', 'cui_str': 'silver fluoride'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0074538', 'cui_str': 'Silver diamine fluoride'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0312818', 'cui_str': 'Angiogenesis growth factor'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0032831', 'cui_str': 'Potassium Iodide'}]","[{'cui': 'C0266848', 'cui_str': 'Arrested dental caries'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}]",,0.078207,"The combination of AgF & KI was associated with the most favourable clinical outcomes in terms of caries arrest and lesion colour. ","[{'ForeName': 'Bathsheba', 'Initials': 'B', 'LastName': 'Turton', 'Affiliation': 'University of Puthisastra, Cambodia.'}, {'ForeName': 'Rithvitou', 'Initials': 'R', 'LastName': 'Horn', 'Affiliation': 'University of Puthisastra, Cambodia.'}, {'ForeName': 'Callum', 'Initials': 'C', 'LastName': 'Durward', 'Affiliation': 'University of Puthisastra, Cambodia.'}]",Heliyon,['10.1016/j.heliyon.2020.e04287'] 2056,32715148,Effect of electrical stimulation of receptive fields in people with lower limb amputation on variables of gait.,"People with amputation may perceive phantom limb sensations or pain in the amputated body part when ipsilateral body-regions are stimulated. These body-regions are called receptive fields. This study assessed whether receptive fields change in size and position over the course of one month in people with trans-tibial amputation and whether electrical stimulation of these fields in synchrony with walking affects phantom sensations and variables of gait. Thirty-one subjects participated in this study. Receptive fields were mapped seven times over a one month period. Thereafter, the effect of electrical stimulation in synchrony with walking was compared to placebo stimulation in an acute setting with a randomized, single-blind gait analysis in 18 participants. Results showed that receptive field size and position presented an adequate degree of consistency (difference in point of first response position of 4.9 ± 4.8 cm and overlap of total receptive field area of 54.3 ± 35.0 %) for future use of electrical stimulation. Gait parameters for everyday activities (speed, gait width, % stance and swing phase) as well as perception of phantom pain were not altered to a clinically relevant degree by electrical stimulation and no negative effects were reported. In conclusion: Location and size of receptive fields are consistent enough for daily electrical stimulation without laborious daily assessment. If applied acutely, no significant effect on gait or pain could be detected. However, results are promising enough to test chronic application of electrical stimulation during gait in a long-term setting.",2020,"Gait parameters for everyday activities (speed, gait width, % stance and swing phase) as well as perception of phantom pain were not altered to a clinically relevant degree by electrical stimulation and no negative effects were reported.","['people with lower limb amputation on variables of gait', 'Thirty-one subjects participated in this study', '18 participants', 'people with trans-tibial amputation']",['electrical stimulation of receptive fields'],"['perception of phantom pain', 'Gait parameters for everyday activities (speed, gait width, % stance and swing phase', 'gait or pain']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0337308', 'cui_str': 'Amputation of lower limb'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0234686', 'cui_str': 'Receptive field'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0031315', 'cui_str': 'Phantom limb'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0487742', 'cui_str': 'Width'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",31.0,0.0587551,"Gait parameters for everyday activities (speed, gait width, % stance and swing phase) as well as perception of phantom pain were not altered to a clinically relevant degree by electrical stimulation and no negative effects were reported.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pleus', 'Affiliation': 'Sports Medicine and Rehabilitation, Rehaklinik Bellikon, Bellikon, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Koller', 'Affiliation': 'Orthopedic and Hand Surgery Rehabilitation, Rehaklinik Bellikon, Bellikon, Switzerland.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Tschui', 'Affiliation': 'Orthopedic and Hand Surgery Rehabilitation, Rehaklinik Bellikon, Bellikon, Switzerland.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Grögli', 'Affiliation': 'Sports Medicine and Rehabilitation, Rehaklinik Bellikon, Bellikon, Switzerland.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Spengler', 'Affiliation': 'Exercise Physiology Lab, Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland.'}]",IBRO reports,['10.1016/j.ibror.2020.06.008'] 2057,32715149,Sample size planning in the design and analysis of cluster randomized trials using the symbolic two-step method.,"Introduction Evidence that can be used to improve clinical practice patterns and processes is frequently generated through standard, parallel-arms cluster randomized trial (CRT) designs that test interventions implemented at the center-level. Although the primary endpoint of these trials is often a center-level outcome, patient-level factors may vary between centers and, consequently, may influence the center-level outcome. Furthermore, there may be important factors that predict the variation in the center-level outcome and this knowledge can help contextualize the trial results and inform practice patterns. Methods Our symbolic two-step method that applies symbolic data analysis to account for patient-level factors when estimating and testing a center-level effect on both the average center-level outcome and its variation was developed for such settings. Herein, we sought to extend the method to prospectively size a CRT so that the application of our method in data analysis is consistent with the design. Results Our formulaic approach to sample size planning incorporated predictive factors of the within-center variation and accounted for patient-level characteristics. The sample size approximation performed well in many different pragmatic settings. Conclusions Our symbolic two-step method provides an alternate approach in the design and analysis of CRTs evaluating novel improvement processes within care delivery research.",2020,Our symbolic two-step method provides an alternate approach in the design and analysis of CRTs evaluating novel improvement processes within care delivery research.,[],[],[],[],[],[],,0.156058,Our symbolic two-step method provides an alternate approach in the design and analysis of CRTs evaluating novel improvement processes within care delivery research.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Zahrieh', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Le-Rademacher', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100609'] 2058,32715151,Assessing the impact of Social Networking Site use on older people's loneliness and social isolation. A randomized controlled trial: The Aging in a Networked Society-Social Experiment Study (ANS-SE).,"Introduction An ageing society poses unprecedented challenges to societies. Information and Communication Technologies (ICTs), including Social Networking Sites (SNSs), may contribute to contrast loneliness and social isolation in old age. Despite of the potentialities of SNSs, there is only a handful of studies assessing the causal relationship of SNS use and older people's well-being. This paper aims to provide further evidence on the design of randomised controlled trials exploring the causal impact of SNS use on loneliness and social isolation in old age. Methods and analysis The Aging in a Networked Society-Social Experiment Study (ANS-SE) is a randomised controlled trial conducted on people aged 75 and over residing in a town located in the Milan area (Italy) aiming to assess the impact of SNS use on loneliness and social isolation (i.e. the primary outcomes of this study). The study is constituted of two stages, i.e. the baseline and the follow up. The experiment is structured into one treatment group and two control groups; the interventions are the attendance to a course on SNS use (T1) and lifestyle education and brain functioning (C1). The inactive control group (C) is constituted of a waiting list. We will perform bivariate and regression analysis. Ethics and dissemination The study has been approved by the Ethic Committee of the University of Milano Bicocca (prot. 431/2019) and was registered at Clinical Trials.gov (NCT04242628). Written consent was obtained from all respondents. Results from the study will be discussed with the local community and stakeholders, presented in national and international conferences and published in leading peer-review journals. The consent forms, the anonymised dataset, and the relevant statistical codes will be deposited with the Italian Unidata archive, also in charge of releasing the data to the public, upon a short embargo period.",2020,The experiment is structured into one treatment group and two control groups; the interventions are the attendance to a course on SNS use (T1) and lifestyle education and brain functioning (C1).,"['people aged 75 and over residing in a town located in the Milan area (Italy', ""older people's loneliness and social isolation""]",['SNS'],[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0557750', 'cui_str': 'Town environment'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0023974', 'cui_str': 'Feeling lonely'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}]","[{'cui': 'C0039044', 'cui_str': 'Sympathetic nervous system structure'}]",[],,0.0397034,The experiment is structured into one treatment group and two control groups; the interventions are the attendance to a course on SNS use (T1) and lifestyle education and brain functioning (C1).,"[{'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Zaccaria', 'Affiliation': 'University of Applied Sciences and Arts of Southern Switzerland, Department of Business Economics, Health and Social Care, Centre of Competence on Ageing, Manno, Switzerland.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Guaita', 'Affiliation': 'Golgi Cenci Foundation, Abbiategrasso, Italy.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Vaccaro', 'Affiliation': 'Golgi Cenci Foundation, Abbiategrasso, Italy.'}, {'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Casanova', 'Affiliation': 'IRCCS-INRCA-National Institute of Health & Science on Ageing, Centre for Socio-Economic Research on Ageing, Ancona, Italy.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Abbondanza', 'Affiliation': 'Golgi Cenci Foundation, Abbiategrasso, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Pettinato', 'Affiliation': 'University of Milan Bicocca, Department of Sociology and Social Research, Milan, Italy.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Cerati', 'Affiliation': 'Golgi Cenci Foundation, Abbiategrasso, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Rolandi', 'Affiliation': 'Golgi Cenci Foundation, Abbiategrasso, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Sala', 'Affiliation': 'University of Milan Bicocca, Department of Sociology and Social Research, Milan, Italy.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100615'] 2059,32715152,A prospective controlled randomized multicenter study to evaluate the severity of compensatory sweating after one-stage bilateral thoracic sympathectomy versus unilateral thoracic sympathectomy in the dominant side.,"Objective To evaluate the contribution that unilateral thoracic sympathectomy in dominant side or two-stage bilateral thoracic sympathectomy can have as strategies to reduce the incidence of compensatory sweating after sympathectomy for palmar hyperhidrosis. Methods This is a prospective, controlled, randomized multicenter trial of 200 participants with palmar hyperhidrosis, which will be randomized into two arms: (a) one-stage bilateral thoracic sympathectomy (control arm); or (b) unilateral thoracic sympathectomy in dominant side (intervention arm). At six months the participants submitted to unilateral procedure can make the contralateral surgery if they wanted it, creating a third group called two-stage bilateral sympathectomy. Participants will be evaluated for the degree of sweating by the Hyperhidrosis Disease Severity Scale (HDSS) and of quality of life questionnaires. Results 96 participants out of the 200 proposed have been included so far, with 48 participants randomized to each arm. From the sample 61 (63.5%) are female, with a mean age of 24 (20-32) years. There were exclusive palmar hiperhydrosis in 14 cases (14.5%), palmar and plantar hyperhidrosis in 36 (37.5%) cases, palmar and axillar hyperhidrosis in 12 (12,5%) cases and palmar-axillary-plantar hyperhidrosis in 34 (35,4%) cases. The age at the beginning of the disease was childhood (78%), with mean of time of disease 15 (11-22) years. Conclusions If one or both hypothesis: (a) unilateral sympathectomy in dominant hand is a satisfactory treatment; b) two-stage bilateral sympathectomy causes less compensatory sweating than in one stage are confirmed there is a chance that surgical therapy for palmar hyperhidrosis can be changed for better.",2020,"Participants will be evaluated for the degree of sweating by the Hyperhidrosis Disease Severity Scale (HDSS) and of quality of life questionnaires. ","['200 participants with palmar hyperhidrosis', 'From the sample 61 (63.5%) are female, with a mean age of 24 (20-32) years', '96 participants out of the 200 proposed have been included so far, with 48 participants randomized to each arm']","['unilateral thoracic sympathectomy', 'stage bilateral thoracic sympathectomy (control arm); or (b) unilateral thoracic sympathectomy in dominant side (intervention arm']","['degree of sweating by the Hyperhidrosis Disease Severity Scale (HDSS) and of quality of life questionnaires', 'compensatory sweating', 'palmar and axillar hyperhidrosis', 'palmar and plantar hyperhidrosis', 'exclusive palmar hiperhydrosis']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0039038', 'cui_str': 'Sympathectomy'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0445480', 'cui_str': 'Dominant side'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1735334', 'cui_str': 'Compensatory sweating'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}, {'cui': 'C1735625', 'cui_str': 'Plantar hyperhidrosis'}]",200.0,0.0799491,"Participants will be evaluated for the degree of sweating by the Hyperhidrosis Disease Severity Scale (HDSS) and of quality of life questionnaires. ","[{'ForeName': 'Niura Noro', 'Initials': 'NN', 'LastName': 'Hamilton', 'Affiliation': 'Heart Institute (InCor) Hospital das Clinicas, University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-900, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Miguel Lia', 'Initials': 'ML', 'LastName': 'Tedde', 'Affiliation': 'Heart Institute (InCor) Hospital das Clinicas, University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-900, Sao Paulo, SP, Brazil.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Wolosker', 'Affiliation': 'Hospital das Clinicas, University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 255, 05403-000, São Paulo, SP, Brazil.'}, {'ForeName': 'Wolfgang William Schmidt', 'Initials': 'WWS', 'LastName': 'Aguiar', 'Affiliation': 'Hospital Universitário Oswaldo Cruz, R. Arnóbio Marquês, 310, 50100-130, Recife, PE, Brazil.'}, {'ForeName': 'Hylas Paiva da Costa', 'Initials': 'HPDC', 'LastName': 'Ferreira', 'Affiliation': 'Hospital Liga Norte Riograndense Contra o Cancer, Av. Miguel Castro, 1355, 59075-740, Natal, RN, Brazil.'}, {'ForeName': 'Humberto Alves de', 'Initials': 'HA', 'LastName': 'Oliveira', 'Affiliation': 'Hospital de Base, SMHS, Área Especial, Q. 101, 70330-150, Brasília, DF, Brazil.'}, {'ForeName': 'Alexandre Marcelo Rodrigues', 'Initials': 'AMR', 'LastName': 'Lima', 'Affiliation': 'Hospital Geral Dr. Cesar Cals, Av. Imperador, 545, 60015-152, Fortaleza, CE, Brazil.'}, {'ForeName': 'Fernando Luiz', 'Initials': 'FL', 'LastName': 'Westphal', 'Affiliation': 'Hospital da Universidade Federal do Amazonas, Av. Gen. Rodrigo Octávio, 6200, 69080-900, Manaus, AM, Brazil.'}, {'ForeName': 'Marina Varela Braga de', 'Initials': 'MVB', 'LastName': 'Oliveira', 'Affiliation': 'Hospital das Clinicas da Universidade Federal de Minas Gerais, Av. Prof. Alfredo Balena, 110, 30130-100, Belo Horizonte, MG, Brazil.'}, {'ForeName': 'Fabio de Oliveira', 'Initials': 'FO', 'LastName': 'Riuto', 'Affiliation': 'Hospital da Universidade Federal da Grande Dourados, R. Ivo Alves da Rocha, 558, 79823-501, Dourados, MS, Brazil.'}, {'ForeName': 'Sergio Tadeu Lima F', 'Initials': 'STLF', 'LastName': 'Pereira', 'Affiliation': 'Hospital Santa Isabel, Praça Conselheiro Almeida Couto, 500, 40050-410, Salvador, BA, Brazil.'}, {'ForeName': 'Guilherme Cançado', 'Initials': 'GC', 'LastName': 'Rezende', 'Affiliation': 'Hospital Universitário de Brasília, Setor de Grandes Áreas Norte, 605, 70840-040, Brasília, DF, Brazil.'}, {'ForeName': 'Caroline Elizabeth Brero', 'Initials': 'CEB', 'LastName': 'Valero', 'Affiliation': 'Empresa Brasileira de Serviços Hospitalares, SCS, Quadra 9, Ed Parque Cidade Corporate, 70308-200, Brasília, DF, Brazil.'}, {'ForeName': 'Paulo M', 'Initials': 'PM', 'LastName': 'Pego-Fernandes', 'Affiliation': 'Heart Institute (InCor) Hospital das Clinicas, University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-900, Sao Paulo, SP, Brazil.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100618'] 2060,32715449,The Obturator Nerve Reflex after Thulium Laser vs. Monopolar Transurethral Resection of Bladder Tumors: A Randomized Clinical trial.,"BACKGROUND Obturator nerve reflex is the surgery treatment side effect in patients with bladder cancers. This study is run to determine the obturator Nerve reflex by Thulium laser versus monopolar Transurethral Resection of Bladder Tumors (TURBT). MATERIALS AND METHODS After clinical trial approval code receiving IRCT20190624043991N4, one hundred and eighty-nine patients with bladder tumors from 2010 to 2016 were assessed and among them, 35 patients were randomly assigned into two groups in a blinded manner; the first group (16 patients) received thulium laser and the second group (19 patients) were patients undergoing monopolar transurethral resection of bladder tumor after spinal analgesia. Clinical data, including different variables such as; age, tumor characteristics, gender, operation duration, types of leg jerking, and some intraoperative complications, were recorded. The site of the obturator nerve was determined by nerve stimulation, anatomical landmarks, and ultrasonography. Leg jerking was compared in both groups. RESULTS Of the 35 patients, 28 cases were male and 7 cases were female. The mean age was 62.0±6.9 (40-75) years in the Thulium laser group and 64.0±7.1 (41-77) years in the monopolar TURBT group. The mean operation time was no different between the two groups significantly (P > 0.05). Leg jerking was reported in 25% and 63.1% of the patients in Thulium laser and monopolar TURBT groups, respectively (P<0.05). CONCLUSION Thulium laser is a more feasible and effective method to prevent leg jerking in patients with bladder cancer; so, it is recommended more than monopolar Transurethral.",2020,The mean operation time was no different between the two groups significantly (P > 0.05).,"['patients with bladder cancer', 'Bladder Tumors', '35 patients', 'one hundred and eighty-nine patients with bladder tumors from 2010 to 2016 were assessed and among them, 35 patients', 'The mean age was 62.0±6.9 (40-75) years in the Thulium laser group and 64.0±7.1 (41-77) years in the monopolar TURBT group', '28 cases were male and 7 cases were female', 'patients with bladder cancers']","['Thulium Laser vs. Monopolar Transurethral Resection', 'Thulium laser versus monopolar Transurethral Resection', 'Thulium laser', 'thulium laser and the second group', 'monopolar transurethral resection of bladder tumor after spinal analgesia']","['Leg jerking', 'mean operation time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005684', 'cui_str': 'Malignant tumor of urinary bladder'}, {'cui': 'C0005695', 'cui_str': 'Neoplasm of bladder'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040066', 'cui_str': 'Thulium'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0040066', 'cui_str': 'Thulium'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C1963862', 'cui_str': 'Spinal analgesia'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",189.0,0.0349748,The mean operation time was no different between the two groups significantly (P > 0.05).,"[{'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Abedi Yarandi', 'Affiliation': 'Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Khatami', 'Affiliation': 'Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Seyed Mohammad Kazem', 'Initials': 'SMK', 'LastName': 'Aghamir', 'Affiliation': 'Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mkaghamir@tums.ac.ir.'}]",Urology journal,['10.22037/uj.v0i0.5599'] 2061,32715455,Minimally Invasive Percutaneous Nephrolithotomy with a Novel Vacuum-assisted Access Sheath for obstructive calculous pyonephrosis ：A Randomized Study.,"PURPOSE To investigate the safety and efficacy of Minimally Invasive Percutaneous Nephrolithotomy (MPCNL) combined with Vacuum-assisted Access Sheath in the treatment of obstructive calculous pyonephrosis. MATERIALS AND METHODS Seventy-six patients with obstructive calculous pyonephrosis, who were planned to receive MPCNL, were randomly divided into two groups. Group A was treated with Amplatz sheath combined with Cyberwand double probe ultrasound lithotripsy, and group B was treated with Vacuum-assisted Access Sheath (VAAS, ClearPetra, Well lead Medical) combined with holmium laser lithotripsy. The primary outcome was the operation successful rate. Other perioperative, and postoperative data such as operation time, stone free rate and complications were compared between groups. RESULTS Single 20F access sheath was established in all cases. All patients underwent one-stage procedure. Compared with group A, group B had a higher initial stone-free rate (84.2% vs 63.1%, P= .037). The operation time of group B was 56.3 ± 19.83 min, significantly shorter than that of group A at 70.4 ± 14.83 min. The complication rate of B group was 15.8%, which was lower than that of group A (P= .035 ). Five patients (15.8 %) of group B had a postoperative fever (>38.5 ºC) (Clavien grade 2) that required additional antibiotics; whereas 8 patients (21.1 %) of group A (P= .361). There was no blood transfusion in group A, and one case in group B required transfusion. CONCLUSION One-stage MPCNL combined with Vacuum-assisted Access Sheath and holmium laser lithotripsy is a simple, safe, effective, and ergonomically practical method for selected patients with obstructive calculous pyonephrosis.",2020,"The operation time of group B was 56.3 ± 19.83 min, significantly shorter than that of group A at 70.4 ± 14.83 min.","['Seventy-six patients with obstructive calculous pyonephrosis, who were planned to receive', 'obstructive calculous pyonephrosis', 'selected patients with obstructive calculous pyonephrosis']","['MPCNL', 'Minimally Invasive Percutaneous Nephrolithotomy with a Novel Vacuum-assisted Access Sheath', 'Minimally Invasive Percutaneous Nephrolithotomy (MPCNL)\xa0combined with Vacuum-assisted Access Sheath', 'Vacuum-assisted Access Sheath and holmium laser lithotripsy', 'Amplatz sheath combined with Cyberwand double probe ultrasound lithotripsy, and group B was treated with Vacuum-assisted Access Sheath (VAAS, ClearPetra, Well lead Medical) combined with holmium laser lithotripsy']","['postoperative fever', 'initial stone-free rate', 'operation successful rate', 'complication rate', 'operation time, stone free rate and complications', 'blood transfusion']","[{'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034216', 'cui_str': 'Pyonephrosis'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0042221', 'cui_str': 'Vacuum'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0441085', 'cui_str': 'Holmium:YAG laser device'}, {'cui': 'C0023878', 'cui_str': 'Lithotripsy'}, {'cui': 'C0441087', 'cui_str': 'Double probe'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}]","[{'cui': 'C0424786', 'cui_str': 'Postoperative fever'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}]",76.0,0.0757774,"The operation time of group B was 56.3 ± 19.83 min, significantly shorter than that of group A at 70.4 ± 14.83 min.","[{'ForeName': 'Dehui', 'Initials': 'D', 'LastName': 'Lai', 'Affiliation': 'Urology, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. dehuilai@hotmail.com.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': 'Urology, Jinshazhou Hospital of Guangzhou Chinese Medicine University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Meiling', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': 'Urology, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Yongzhong', 'Initials': 'Y', 'LastName': 'He', 'Affiliation': 'Urology, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xun', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Urology, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Sheng', 'Affiliation': 'Urology, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.'}, {'ForeName': 'Xingrong', 'Initials': 'X', 'LastName': 'Zeng', 'Affiliation': 'College of Materials Science and Engineering, Key Lab of Guangdong Province for High Property and Functional Polymer Materials, South China University of Technology, Guangzhou, China.'}]",Urology journal,['10.22037/uj.v16i7.5577'] 2062,32715482,"Effect of novel short-arm human centrifugation induced gravitational gradients upon cardiovascular responses, cerebral perfusion and g-tolerance.","KEY POINTS Aim of this study was to determine the effect of rotational axis position (RAP and thus g-gradient) during short-arm human centrifugation (SAHC) upon cardiovascular responses, cerebral perfusion and g-tolerance. In 10 male and 10 female participants, 10-min passive SAHC runs were performed with the RAP above (P1), or at the apex of the head (P2), or at heart-level (P3), with foot-level Gz at 1.0 g, 1.7 g and 2.4 g. We hypothesized that movement of the RAP from (the conventional position) above the head towards the heart may reduce central hypovolemia, limit cardiovascular responses, aid cerebral perfusion, and thus promote g-tolerance. Moving the RAP footward towards the heart decreased the cerebral tissue saturation index, calf circumference and heart rate responses to SAHC, thereby promoting g-tolerance. Our results also suggest that RAP, and thus g-gradient warrants further investigation as it may support use as a holistic spaceflight countermeasure. ABSTRACT Artificial gravity (AG) through short-arm human centrifugation (SAHC) has been proposed as a holistic spaceflight countermeasure. Movement of the rotational axis position (RAP) from above the head towards the heart may reduce central hypovolemia, aid cerebral perfusion, and thus promote g-tolerance. This study determined the effect of RAP upon cardiovascular responses, peripheral blood displacement (i.e. central hypovolemia), cerebral perfusion and g-tolerance, and their inter-relationships. Twenty (10 male) healthy participants (26.2 ± 4.0 yr) underwent nine (following a familiarisation run) randomised 10-minute passive SAHC runs with RAP set above the head (P1), at the apex of the head (P2), or at heart-level (P3) with foot-level Gz at 1.0 g, 1.7 g and 2.4 g. Cerebral tissue saturation index (cTSI, cerebral perfusion surrogate), calf circumference (CC, central hypovolemia), heart rate (HR) and digital heart-level mean arterial blood pressure (MAP) were continuously recorded, in addition to incidence of pre-syncopal symptoms (PSS). ΔCC and ΔHR increases were attenuated from P1 to P3 (ΔCC: 5.46 ± 0.54 mm to 2.23 ± 0.42 mm; ΔHR: 50 ± 4 bpm to 8 ± 2 bpm, P < 0.05). In addition, ΔcTSI decrements were also attenuated (ΔcTSI: -2.85 ± 0.48% to -0.95 ± 0.34%, P < 0.05) and PSS incidence lower in P3 vs. P1 (P < 0.05). A positive linear relationship was observed between ΔCC and ΔHR with increasing +Gz, and a negative relationship between ΔCC and ΔcTSI, both independent of RAP. Our data suggests that movement of RAP towards the heart (reduced g-gradient), independent of foot-level Gz, leads to improved g-tolerance. Further investigations are required to assess effect of differential baroreceptor feedback (i.e. aortic - carotid g-gradient). This article is protected by copyright. All rights reserved.",2020,"Moving the RAP footward towards the heart decreased the cerebral tissue saturation index, calf circumference and heart rate responses to SAHC, thereby promoting g-tolerance.","['10 male and 10 female participants, 10-min passive SAHC runs were performed with the RAP above (P1), or at the apex of the head (P2), or at heart-level (P3), with foot-level Gz at 1.0\xa0g, 1.7\xa0g and 2.4\xa0g', 'Twenty (10 male) healthy participants (26.2\xa0±\xa04.0\xa0yr) underwent nine (following a familiarisation run) randomised']","['novel short-arm human centrifugation induced gravitational gradients', 'rotational axis position (RAP', 'short-arm human centrifugation (SAHC', 'RAP', '10-minute passive SAHC runs with RAP set above the head (P1), at the apex of the head (P2), or at heart-level (P3) with foot-level Gz at 1.0\xa0g, 1.7\xa0g and 2.4\xa0g', 'rotational axis position (RAP and thus g-gradient) during short-arm human centrifugation (SAHC']","['incidence of pre-syncopal symptoms (PSS', 'ΔcTSI decrements', 'cerebral tissue saturation index, calf circumference and heart rate responses to SAHC, thereby promoting g-tolerance', 'ΔCC and ΔHR increases', 'cardiovascular responses, peripheral blood displacement (i.e. central hypovolemia), cerebral perfusion and g-tolerance, and their inter-relationships', 'cardiovascular responses, cerebral perfusion and g-tolerance', 'PSS incidence', 'Cerebral tissue saturation index (cTSI, cerebral perfusion surrogate), calf circumference (CC, central hypovolemia), heart rate (HR) and digital heart-level mean arterial blood pressure (MAP']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0426857', 'cui_str': 'Short arm'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007703', 'cui_str': 'Centrifugation'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0426857', 'cui_str': 'Short arm'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007703', 'cui_str': 'Centrifugation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0004457', 'cui_str': 'Bone structure of axis'}, {'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0140145', 'cui_str': 'APEX1 protein, human'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C4517631', 'cui_str': '2.4'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C1997754', 'cui_str': 'Heart rate response'}, {'cui': 'C0426857', 'cui_str': 'Short arm'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007703', 'cui_str': 'Centrifugation'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0546884', 'cui_str': 'Hypovolemia'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}]",10.0,0.0415868,"Moving the RAP footward towards the heart decreased the cerebral tissue saturation index, calf circumference and heart rate responses to SAHC, thereby promoting g-tolerance.","[{'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Laing', 'Affiliation': 'Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Green', 'Affiliation': ""King's College London, Centre for Human and Applied Physiological Sciences (CHAPS), London, UK.""}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'Mulder', 'Affiliation': 'Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany.'}, {'ForeName': 'Helmut', 'Initials': 'H', 'LastName': 'Hinghofer-Szalkay', 'Affiliation': 'Gravitational Physiology and Medicine Research Unit, Division of Physiology, Medical University of Graz, Austria.'}, {'ForeName': 'Andrew P', 'Initials': 'AP', 'LastName': 'Blaber', 'Affiliation': 'Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.'}, {'ForeName': 'Joern', 'Initials': 'J', 'LastName': 'Rittweger', 'Affiliation': 'Institute of Aerospace Medicine, German Aerospace Center (DLR), Cologne, Germany.'}, {'ForeName': 'Nandu', 'Initials': 'N', 'LastName': 'Goswami', 'Affiliation': 'Gravitational Physiology and Medicine Research Unit, Division of Physiology, Medical University of Graz, Austria.'}]",The Journal of physiology,['10.1113/JP273615'] 2063,32715513,Acceptance and Commitment Therapy for perinatal mood and anxiety disorders: A feasibility and proof of concept study.,"OBJECTIVES The aim of the current study was to assess the feasibility, safety, and effectiveness of a newly developed Acceptance and Commitment Therapy (ACT) intervention developed specifically to address the unique context of pregnancy and parenthood. The intervention was delivered to women accessing a specialist Perinatal Community Mental Health Service (PCMHS). DESIGN An open-label pilot study was conducted of an 8-week, group-delivered ACT intervention targeting women with moderate-to-severe mood and/or anxiety disorders during pregnancy and/or postpartum. METHODS Outcomes included session attendance rates, dropout rates, crisis/inpatient service use, and standardized symptom scales. Participant's responses to open-ended questions contained in an end of therapy questionnaire were analysed using thematic analysis. RESULTS Seventy-four women were referred to the intervention with 65 (88%) completing treatment. The median number of sessions attended was 7. No women required input from crisis/inpatient services. All reported finding the intervention helpful. The implementation of ACT in daily life, therapist support, and group processes were cited as helpful aspects of the intervention. At post-treatment, there was a significant reduction in global distress (d = 0.99) and depressive symptoms (d = 1.05), and an increase in psychological flexibility (d = 0.93). On the secondary outcome of global distress, 38% of women were classified as recovered, 31% had reliably improved, 27% remained the same, and 4% had reliably deteriorated. CONCLUSIONS The delivery of ACT in a routine practice setting is feasible, safe, and effective. A randomized control trial (RCT) is needed to establish the efficacy and cost-effectiveness of this group-delivered ACT intervention. PRACTITIONER POINTS Group-delivered Acceptance and Commitment Therapy (ACT) is acceptable for women with moderate-to-severe perinatal mood and/or anxiety disorders and can be feasibly delivered in a routine practice setting. The trans-diagnostic nature of ACT enables the concurrent treatment of depressive and anxiety symptoms within the same intervention which is particularly helpful in the perinatal context given the comorbidity of mood and anxiety disorders. With training and supervision, mental health practitioners without extensive education in the delivery of psychological therapies can facilitate the ACT group programme. As this was a feasibility study, there was no control group, adherence to the manual was not assessed, and the absence of a follow-up period limits our knowledge of the longer-term benefits of the ACT group programme.",2020,"At post-treatment, there was a significant reduction in global distress (d = 0.99) and depressive symptoms (d = 1.05), and an increase in psychological flexibility","['Seventy-four women were referred to the intervention with 65 (88%) completing treatment', 'women with moderate-to-severe perinatal mood and/or anxiety disorders', 'perinatal mood and anxiety disorders', 'targeting women with moderate-to-severe mood and/or anxiety disorders during pregnancy and/or postpartum']","['newly developed Acceptance and Commitment Therapy (ACT) intervention', 'Acceptance and Commitment Therapy (ACT', 'Acceptance and Commitment Therapy', 'women accessing a specialist Perinatal Community Mental Health Service (PCMHS', 'ACT intervention']","['feasibility, safety, and effectiveness', 'efficacy and cost-effectiveness', 'session attendance rates, dropout rates, crisis/inpatient service use, and standardized symptom scales', 'global distress', 'psychological flexibility', 'depressive symptoms']","[{'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0009475', 'cui_str': 'Mental Health Services, Community'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0231224', 'cui_str': 'Crisis'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",74.0,0.0679024,"At post-treatment, there was a significant reduction in global distress (d = 0.99) and depressive symptoms (d = 1.05), and an increase in psychological flexibility","[{'ForeName': 'Cerith S', 'Initials': 'CS', 'LastName': 'Waters', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Annear', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Gillean', 'Initials': 'G', 'LastName': 'Flockhart', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Jones', 'Affiliation': 'Division of Psychological Medicine and Clinical Neurosciences, National Centre for Mental Health, Cardiff University, Wales, UK.'}, {'ForeName': 'Jessica R', 'Initials': 'JR', 'LastName': 'Simmonds', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Traylor', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}, {'ForeName': 'Jessica F', 'Initials': 'JF', 'LastName': 'Williams', 'Affiliation': 'Cardiff and Vale University Health Board, Perinatal Community Mental Health Service, Wales, UK.'}]",The British journal of clinical psychology,['10.1111/bjc.12261'] 2064,32715556,Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double-blind controlled trial.,"AIM To evaluate the efficacy and safety of 25 μg of estradiol gel on postmenopausal vaginal tissue. METHODS This randomized double-blind controlled trial included postmenopausal women with vaginal atrophy who attended our menopause clinic during July 2017-January 2018. Women were randomly assigned to the estradiol gel group or control group (K-Y® Jelly). Treatment consisted of 2 mL of product applied intravaginally daily for 2 weeks, and two doses per week for the next 6 weeks. The most bothersome symptom (MBS), vaginal health index (VHI), vaginal pH, vaginal maturation index, vaginal maturation value (VMV), female sexual function index (FSFI), serum estradiol level and endometrial thickness were evaluated at baseline, 4 and 8 weeks. RESULTS Seventy-five of 80 women completed the trial. After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group. The MBS was decreased in both groups with no significant difference between groups. Serum estradiol level and endometrial thickness were not significantly different between groups at baseline or at week 8. CONCLUSION Estradiol vaginal gel demonstrated an ability to reverse vaginal atrophy with a high safety profile and low systemic absorption of estradiol.",2020,"After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group.","['Seventy-five of 80 women completed the trial', 'postmenopausal women with vaginal atrophy who attended our menopause clinic during July 2017-January 2018', 'postmenopausal women', 'postmenopausal vaginal tissue']","['estradiol vaginal gel', 'estradiol gel', 'Estradiol vaginal gel', 'estradiol gel group or control group (K-Y® Jelly']","['vaginal atrophy', 'bothersome symptom (MBS), vaginal health index (VHI), vaginal pH, vaginal maturation index, vaginal maturation value (VMV), female sexual function index (FSFI), serum estradiol level and endometrial thickness', 'efficacy and safety', 'MBS', 'Serum estradiol level and endometrial thickness', 'VMV, VHI, vaginal pH and FSFI']","[{'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0347984', 'cui_str': 'During'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]","[{'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0042257', 'cui_str': 'Vaginal gel'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0241616', 'cui_str': 'Atrophy of vagina'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0429263', 'cui_str': 'Vaginal pH'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0278098', 'cui_str': 'Female sexual function'}, {'cui': 'C0474672', 'cui_str': 'Serum estradiol measurement'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.326198,"After 8 weeks of treatment, VMV, VHI, vaginal pH and FSFI improved significantly in the estradiol group, with no observed change in the control group.","[{'ForeName': 'Prasong', 'Initials': 'P', 'LastName': 'Tanmahasamut', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Titima', 'Initials': 'T', 'LastName': 'Jirasawas', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Vachira Hospital, Navamindradhiraj University, Bangkok, Thailand.'}, {'ForeName': 'Somsak', 'Initials': 'S', 'LastName': 'Laiwejpithaya', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chatchai', 'Initials': 'C', 'LastName': 'Areeswate', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Chongdee', 'Initials': 'C', 'LastName': 'Dangrat', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kittayaporn', 'Initials': 'K', 'LastName': 'Silprasit', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.'}]",The journal of obstetrics and gynaecology research,['10.1111/jog.14336'] 2065,32715609,Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.,"INTRODUCTION Brain bioenergetics are defective in Alzheimer's disease (AD). Preclinical studies find oxaloacetate (OAA) enhances bioenergetics, but human safety and target engagement data are lacking. METHODS We orally administered 500 or 1000 mg OAA, twice daily for 1 month, to AD participants (n = 15 each group) and monitored safety and tolerability. To assess brain metabolism engagement, we performed fluorodeoxyglucose positron emission tomography (FDG PET) and magnetic resonance spectroscopy before and after the intervention. We also assessed pharmacokinetics and cognitive performance. RESULTS Both doses were safe and tolerated. Compared to the lower dose, the higher dose benefited FDG PET glucose uptake across multiple brain regions (P < .05), and the higher dose increased parietal and frontoparietal glutathione (P < .05). We did not demonstrate consistent blood level changes and cognitive scores did not improve. CONCLUSIONS 1000 mg OAA, taken twice daily for 1 month, is safe in AD patients and engages brain energy metabolism.",2020,"Compared to the lower dose, the higher dose benefited FDG PET glucose uptake across multiple brain regions (P < .05), and the higher dose increased parietal and frontoparietal glutathione (P < .05).","[""Alzheimer's patients""]","['fluorodeoxyglucose positron emission tomography (FDG PET) and magnetic resonance spectroscopy', 'oxaloacetate (OAA']","['blood level changes and cognitive scores', 'parietal and frontoparietal glutathione', 'safety and tolerability', 'pharmacokinetics and cognitive performance', 'safe and tolerated', 'FDG PET glucose uptake across multiple brain regions']","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0024487', 'cui_str': 'Magnetic resonance spectroscopy'}, {'cui': 'C0029989', 'cui_str': 'Ketosuccinates'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1273723', 'cui_str': 'Brain region'}]",,0.104164,"Compared to the lower dose, the higher dose benefited FDG PET glucose uptake across multiple brain regions (P < .05), and the higher dose increased parietal and frontoparietal glutathione (P < .05).","[{'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Vidoni', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'In-Young', 'Initials': 'IY', 'LastName': 'Choi', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Lee', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Reed', 'Affiliation': 'Department of Pharmacology and Toxicology, Kansas University Medical Center, Kansas City, Kansas, USA.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Department of Pharmacology and Toxicology, Kansas University Medical Center, Kansas City, Kansas, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Pleen', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Jonathan D', 'Initials': 'JD', 'LastName': 'Mahnken', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Clutton', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Becker', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Sherry', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Bothwell', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Anderson', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Harris', 'Affiliation': 'Biochemistry and Molecular Biology, Kansas University Medical Center, Kansas City, Kansas, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Brooks', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Heather M', 'Initials': 'HM', 'LastName': 'Wilkins', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Mosconi', 'Affiliation': 'Department of Neurology, Weill Cornell Medical College, New York, New York, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Burns', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}, {'ForeName': 'Russell H', 'Initials': 'RH', 'LastName': 'Swerdlow', 'Affiliation': ""University of Kansas Alzheimer's Center, Fairway, Kansas, USA.""}]",Alzheimer's & dementia : the journal of the Alzheimer's Association,['10.1002/alz.12156'] 2066,32715623,"A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.","INTRODUCTION This phase 2b/3 trial examined the effects of plasma exchange (PE) in patients with mild-to-moderate Alzheimer's disease (AD). METHODS Three hundred forty-seven patients (496 screened) were randomized (1:1:1:1) into three PE treatment arms with different doses of albumin and intravenous immunoglobulin replacement (6-week period of weekly conventional PE followed by a 12-month period of monthly low-volume PE), and placebo (sham). RESULTS PE-treated patients performed significantly better than placebo for the co-primary endpoints: change from baseline of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL; P = .03; 52% less decline) with a trend for Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog; P = .06; 66% less decline) scores at month 14. Moderate-AD patients (baseline Mini-Mental State Examination [MMSE] 18-21) scored better on ADCS-ADL (P = .002) and ADAS-Cog (P = .05), 61% less decline both. There were no changes in mild-AD patients (MMSE 22-26). PE-treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR-sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (P < .0001; 100% less decline) scales. DISCUSSION This trial suggests that PE with albumin replacement could slow cognitive and functional decline in AD, although further studies are warranted.",2020,PE-treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR-sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (P ,"[""patients with mild-to-moderate Alzheimer's disease (AD"", 'Three hundred forty-seven patients (496 screened', ""Alzheimer's disease""]","['albumin and intravenous immunoglobulin replacement', 'plasma exchange (PE', 'plasma exchange with albumin replacement', 'PE with albumin replacement', 'placebo (sham', 'placebo']","['ADCS-ADL', 'Clinical Dementia Rating Sum of Boxes (CDR-sb', ""baseline of Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL"", ""Alzheimer's Disease Assessment Scale-Cognitive Subscale"", ""Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC""]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0085297', 'cui_str': 'Intravenous Immunoglobulins'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0032113', 'cui_str': 'Plasma exchange'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0451074', 'cui_str': 'Clinical dementia rating scale'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",,0.637549,PE-treated patients scored better on the Clinical Dementia Rating Sum of Boxes (CDR-sb) (P = .002; 71% less decline) and Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) (P ,"[{'ForeName': 'Mercè', 'Initials': 'M', 'LastName': 'Boada', 'Affiliation': 'Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades - Universitat Internacional de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Oscar L', 'Initials': 'OL', 'LastName': 'López', 'Affiliation': 'Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Olazarán', 'Affiliation': 'Neurology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Núñez', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Pfeffer', 'Affiliation': 'Medical Services, Allied Biomedical Research Institute, Inc., Miami, Florida, USA.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Paricio', 'Affiliation': 'Center for Prevention of Alzheimer´s Disease, Miami Dade Medical Research Institute, Miami, Florida, USA.'}, {'ForeName': 'Jesús', 'Initials': 'J', 'LastName': 'Lorites', 'Affiliation': 'Medical Services, L&L Research Choices, Inc., Miami, Florida, USA.'}, {'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'Piñol-Ripoll', 'Affiliation': 'Seizure Disorders Unit, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain.'}, {'ForeName': 'José E', 'Initials': 'JE', 'LastName': 'Gámez', 'Affiliation': 'Psychiatry Department, Galiz Research, Hialeah, Florida, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Anaya', 'Affiliation': 'Nephrology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.'}, {'ForeName': 'Dobri', 'Initials': 'D', 'LastName': 'Kiprov', 'Affiliation': 'Apheresis Care Group and Fresenius Medical Care, San Francisco, California, USA.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Lima', 'Affiliation': 'American Red Cross Southern Blood Services Region, Atlanta, Georgia, USA.'}, {'ForeName': 'Carlota', 'Initials': 'C', 'LastName': 'Grifols', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Torres', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Costa', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Bozzo', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}, {'ForeName': 'Zbigniew M', 'Initials': 'ZM', 'LastName': 'Szczepiorkowski', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Hendrix', 'Affiliation': 'Pentara Corporation, Salt Lake City, Utah, USA.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Páez', 'Affiliation': ""Alzheimer's Research Group, Grifols, Barcelona, Spain.""}]",Alzheimer's & dementia : the journal of the Alzheimer's Association,['10.1002/alz.12137'] 2067,32715653,"A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial.","The attainment of target hemoglobin levels in hemodialysis patients is low. Several factors play a role, such as hyporesponsiveness to erythropoiesis-stimulating agents (ESA), but also suboptimal prescribing of ESA and iron. The goal of this study was to investigate if a pharmacist-managed dosing algorithm for darbepoetin alfa (DA) and iron sucrose improves the attainment of target hemoglobin levels. In this randomized controlled trial, 200 hemodialysis patients from a Dutch teaching hospital were included. In the intervention group (n = 100), a pharmacist monthly provided dose recommendations for DA and iron sucrose based on dosing algorithms. The control group (n = 100) received usual care. In the intervention group, the percentage per patient within the target range (PTR) for hemoglobin (target range 6.8-7.4 mmol/L) and iron status was higher than in the control group (for hemoglobin median 38.5% vs 23.1%, P = .001 and for iron status median 21.1% vs 8.3%, P = .003). The percentage of high hemoglobin levels (>8.1 mmol/L) was lower in the intervention group (median 0.0% vs 7.7%, P = .034). The weekly dose of DA was lower in the intervention group (median 34.0 vs 46.9 mcg, P = .020), whereas iron dose was higher (median 75 vs 0 mg). No difference was found for the percentage of hemoglobin levels below the target range. In conclusion, a pharmacist-managed dosing algorithm for DA and iron sucrose increased the attainment of target levels for hemoglobin and iron status, reduced the percentage of high hemoglobin levels, and was associated with a lower DA and a higher iron sucrose dose.",2020,"The percentage of high hemoglobin levels (>8.1 mmol/L) was lower in the intervention group (median 0.0% vs 7.7%, P = .034).","['200 hemodialysis patients from a Dutch teaching hospital were included', 'hemodialysis patients']","['pharmacist monthly provided dose recommendations for DA and iron sucrose based on dosing algorithms', 'usual care', 'darbepoetin alfa and iron sucrose', 'darbepoetin alfa (DA) and iron sucrose']","['attainment of target hemoglobin levels', 'iron status', 'hemoglobin levels', 'percentage per patient within the target range (PTR) for hemoglobin', 'percentage of high hemoglobin levels']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}, {'cui': 'C0060241', 'cui_str': 'iron sucrose'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0549448', 'cui_str': 'Increased hemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",200.0,0.0682988,"The percentage of high hemoglobin levels (>8.1 mmol/L) was lower in the intervention group (median 0.0% vs 7.7%, P = .034).","[{'ForeName': 'Francisca Johanna', 'Initials': 'FJ', 'LastName': 'van den Oever', 'Affiliation': 'Department of Clinical Pharmacy, Franciscus Gasthuis, Rotterdam, the Netherlands.'}, {'ForeName': 'Carolien F M', 'Initials': 'CFM', 'LastName': 'Heetman-Meijer', 'Affiliation': 'Department of Clinical Pharmacy, Franciscus Gasthuis, Rotterdam, the Netherlands.'}, {'ForeName': 'Erwin', 'Initials': 'E', 'LastName': 'Birnie', 'Affiliation': 'Department of Genetics, University Medical Centre Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Erwin C', 'Initials': 'EC', 'LastName': 'Vasbinder', 'Affiliation': 'Department of Clinical Pharmacy, Franciscus Gasthuis, Rotterdam, the Netherlands.'}, {'ForeName': 'Eleonora L', 'Initials': 'EL', 'LastName': 'Swart', 'Affiliation': 'Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Centers, Amsterdam, the Netherlands.'}, {'ForeName': 'Yvonne C', 'Initials': 'YC', 'LastName': 'Schrama', 'Affiliation': 'Department of Internal Medicine, Franciscus Gasthuis, Rotterdam, the Netherlands.'}]",Pharmacology research & perspectives,['10.1002/prp2.628'] 2068,32715744,"The effectiveness of pulsed ultrasound treatment on pain, function, synovial sac thickness and femoral cartilage thickness in patients with knee osteoarthritis: a randomized, double-blind clinical, controlled study.","OBJECTIVE This study aims to investigate the efficacy of therapeutic pulsed ultrasound on pain, function, synovial sac and femoral cartilage in knee osteoarthritis. DESIGN Randomized, double-blind, controlled study. SETTING Dokuz Eylul University, Department of Physical Medicine and Rehabilitation. SUBJECTS A total of 96 patients with knee osteoarthritis. INTERVENTIONS Participants were randomized into two groups; Group I ( n = 48, pulsed ultrasound) and Group II ( n = 48, sham ultrasound). The sessions were held three times a week for 8 weeks. The study continued for 12 weeks (with 4 weeks follow-up). All participants performed exercises at home for 12 weeks. MAIN MEASURES Knee pain (at rest and ADLs) was assessed using the visual analog scale (VAS). Functionality was assessed using the Timed Up and Go test and Western Ontario and McMaster Universities Osteoarthritis (WOMAC) questionnaire. Femoral cartilage and synovial sac thickness was measured using ultrasonography. All evaluations were performed at the baseline, at the 8 and 12 weeks after baseline. RESULTS The study was completed with a total of 75 patients ( n = 39 in group I and n = 36 in group II). The mean (SD) pain at ADLs score at baseline and week 12 was 7.2 (2.1), with 3.6 (2.9) in the group I, and 6.7 (2.0) and 4.3 (2.2) in the group II, respectively. Both groups presented significant improvements in terms of pain and function ( P < 0.001). There was no difference between groups for any parameters. CONCLUSION Treatment of pulsed ultrasound has no positive effect on knee pain, function, femoral cartilage and synovial sac thickness in knee osteoarthritis.",2020,"Treatment of pulsed ultrasound has no positive effect on knee pain, function, femoral cartilage and synovial sac thickness in knee osteoarthritis.","['96 patients with knee osteoarthritis', '75 patients ( n = 39 in group I and n = 36 in group II', 'knee osteoarthritis', 'Dokuz Eylul University, Department of Physical Medicine and Rehabilitation', 'patients with knee osteoarthritis']","['pulsed ultrasound', 'therapeutic pulsed ultrasound', 'pulsed ultrasound treatment']","['pain, function, synovial sac and femoral cartilage', 'mean (SD) pain at ADLs score', 'visual analog scale (VAS', 'Femoral cartilage and synovial sac thickness', 'knee pain, function, femoral cartilage and synovial sac thickness', 'pain and function', 'pain, function, synovial sac thickness and femoral cartilage thickness', 'Timed Up and Go test and Western Ontario and McMaster Universities Osteoarthritis (WOMAC) questionnaire', 'Knee pain (at rest and ADLs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0031813', 'cui_str': 'Physical Medicine and Rehabilitation'}]","[{'cui': 'C2143225', 'cui_str': 'Pulsed Ultrasound'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0007301', 'cui_str': 'Cartilage tissue'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0443144', 'cui_str': 'At rest'}]",96.0,0.0768472,"Treatment of pulsed ultrasound has no positive effect on knee pain, function, femoral cartilage and synovial sac thickness in knee osteoarthritis.","[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Karakaş', 'Affiliation': 'Department of Rheumatology, Physical Medicine and Rehabilitation, Dokuz Eylül University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Dilek', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dokuz Eylül University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'M Abdulkerim', 'Initials': 'MA', 'LastName': 'Şahin', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dokuz Eylül University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Hülya', 'Initials': 'H', 'LastName': 'Ellidokuz', 'Affiliation': 'Department of Preventive Oncology, Institute of Oncology, Dokuz Eylül University School of Medicine, Izmir, Turkey.'}, {'ForeName': 'Özlem', 'Initials': 'Ö', 'LastName': 'Şenocak', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Dokuz Eylül University School of Medicine, Izmir, Turkey.'}]",Clinical rehabilitation,['10.1177/0269215520942953'] 2069,32715754,Fidaxomicin for the treatment of Clostridioides difficile in children.,"Fidaxomicin is an oral narrow-spectrum novel 18-membered macrocyclic antibiotic that was initially approved in 2011 by the US FDA for the treatment of Clostridioides difficile infections (CDI) in adults. In February 2020, the FDA approved fidaxomicin for the treatment of CDI in children age >6 months. In adults, fidaxomicin is as efficacious as vancomycin in treating CDI and reduces the risk of recurrent CDI. An investigator-blinded, randomized, multicenter, multinational clinical trial comparing the efficacy and safety of fidaxomicin with vancomycin in children was recently published confirming similar findings as previously reported in adults. Fidaxomicin is the first FDA-approved treatment for CDI in children and offers a promising option for reducing recurrent CDI in this population.",2020,"In adults, fidaxomicin is as efficacious as vancomycin in treating CDI and reduces the risk of recurrent CDI.",['Clostridioides difficile in children'],"['fidaxomicin', 'Fidaxomicin', 'vancomycin', 'fidaxomicin with vancomycin']",[],"[{'cui': 'C0079134', 'cui_str': 'Clostridium difficile (bacteria)'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0065023', 'cui_str': 'fidaxomicin'}, {'cui': 'C0042313', 'cui_str': 'Vancomycin'}]",[],,0.0536865,"In adults, fidaxomicin is as efficacious as vancomycin in treating CDI and reduces the risk of recurrent CDI.","[{'ForeName': 'Andrew M', 'Initials': 'AM', 'LastName': 'Skinner', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, Loyola University Medical Center, Maywood, IL, USA.'}, {'ForeName': 'Tonya', 'Initials': 'T', 'LastName': 'Scardina', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.""}, {'ForeName': 'Larry K', 'Initials': 'LK', 'LastName': 'Kociolek', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.""}]",Future microbiology,['10.2217/fmb-2020-0104'] 2070,32715828,Five-Year Outcomes Prospective Study of Two First-Generation Trabecular Micro-Bypass Stents (iStent®) in Open-Angle Glaucoma.,"PURPOSE To assess 5-year effectiveness and safety of 2 iStent® trabecular micro-bypass stents in eyes with open-angle glaucoma (OAG) not controlled on 1 medication. MATERIALS AND METHODS This prospective, interventional, single-arm, multi-surgeon study (NCT #1252862, clinicaltrials.gov) enrolled eyes with OAG, preoperative intraocular pressure (IOP) of 18-30 mmHg on 1 ocular hypotensive medication, and 22-38 mmHg after medication washout. Eyes underwent standalone implantation of 2 iStent devices and were followed through 60 months postoperatively. Efficacy was quantified by mean diurnal IOP and medication usage. Efficacy endpoints included the proportion of eyes with ≥20% IOP reduction versus baseline unmedicated IOP (primary efficacy), and the proportion of eyes with IOP ≤18 mmHg (secondary efficacy) without medication or secondary glaucoma surgery. Safety parameters included visual acuity, cup-to-disc ratio, visual field, and complications and adverse events. RESULTS Preoperative mean IOP on 1 medication was 20.6 ± 2.0 mmHg and post-washout unmedicated IOP was 24.1 ± 1.4 mmHg (n = 39). At 5 years postoperative, medication-free mean diurnal IOP reduced to 14.5 ± 2.2 mmHg, constituting a 40% decrease versus preoperative washed-out IOP ( p < .0001). In addition, this 5-year medication-free IOP constituted a 30% decrease versus preoperative IOP on 1 medication ( p < .0001). At Month 60, 89.7% (26/29) of eyes achieved the primary efficacy endpoint of ≥20% IOP reduction versus baseline unmedicated IOP, and 86.2% (25/29) of eyes achieved the secondary efficacy endpoint of IOP ≤18 mmHg, without medication or secondary glaucoma surgery. Throughout follow-up, 89.7-91.3% of eyes were on no medications. Favorable safety included no secondary glaucoma surgeries, minimal adverse events, and stable visual acuity, cup-to-disc ratio, and visual fields through 5 years postoperative. CONCLUSIONS This prospective interventional study demonstrates persistent 5-year reductions in IOP and freedom from medications, together with favorable safety, following implantation of 2 first-generation trabecular micro-bypass stents in eyes with OAG on 1 preoperative medication.",2020,"At 5 years postoperative, medication-free mean diurnal IOP reduced to 14.5 ± 2.2 mmHg, constituting a 40% decrease versus preoperative washed-out IOP ( p < .0001).","['eyes with OAG on 1 preoperative medication', 'eyes with open-angle glaucoma (OAG', 'multi-surgeon study (NCT #1252862, clinicaltrials.gov) enrolled eyes with OAG, preoperative intraocular pressure (IOP) of 18-30\xa0mmHg on 1 ocular hypotensive medication, and 22-38\xa0mmHg after medication washout']","['2 iStent® trabecular micro-bypass stents', 'Two First-Generation Trabecular Micro-Bypass Stents (iStent®', 'implantation of 2 first-generation trabecular micro-bypass stents', 'standalone implantation of 2 iStent devices']","['5-year medication-free IOP', 'visual acuity, cup-to-disc ratio, visual field, and complications and adverse events', 'proportion of eyes with ≥20% IOP reduction versus baseline unmedicated IOP (primary efficacy', 'Efficacy', 'secondary glaucoma surgeries, minimal adverse events, and stable visual acuity, cup-to-disc ratio, and visual fields through 5\xa0years postoperative', 'medication-free mean diurnal IOP', '5-year effectiveness and safety', 'proportion of eyes with IOP ≤18\xa0mmHg (secondary efficacy) without medication or secondary glaucoma surgery']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0017612', 'cui_str': 'Open-angle glaucoma'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}]","[{'cui': 'C0085672', 'cui_str': 'Microbiology procedure'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0423471', 'cui_str': 'Optic cup/disc ratio'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0149893', 'cui_str': 'Secondary glaucoma'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",,0.0665154,"At 5 years postoperative, medication-free mean diurnal IOP reduced to 14.5 ± 2.2 mmHg, constituting a 40% decrease versus preoperative washed-out IOP ( p < .0001).","[{'ForeName': 'Hady', 'Initials': 'H', 'LastName': 'Saheb', 'Affiliation': 'Department of Ophthalmology, McGill University , Montreal, Quebec, Canada.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Donnenfeld', 'Affiliation': 'Ophthalmic Consultants of Long Island , Rockville Centre, New York, USA.'}, {'ForeName': 'Kerry D', 'Initials': 'KD', 'LastName': 'Solomon', 'Affiliation': 'Carolina Eyecare Physicians , Mt Pleasant, South Carolina, USA.'}, {'ForeName': 'Lilit', 'Initials': 'L', 'LastName': 'Voskanyan', 'Affiliation': 'S.V. Malayan Ophthalmology Center , Yerevan, Armenia.'}, {'ForeName': 'David F', 'Initials': 'DF', 'LastName': 'Chang', 'Affiliation': 'Altos Eye Physicians , Los Altos, California, USA.'}, {'ForeName': 'Thomas W', 'Initials': 'TW', 'LastName': 'Samuelson', 'Affiliation': 'Minnesota Eye Consultants , Minneapolis, Minnesota, USA.'}, {'ForeName': 'Iqbal Ike K', 'Initials': 'IIK', 'LastName': 'Ahmed', 'Affiliation': 'Department of Ophthalmology, University of Toronto , Toronto, Ontario, Canada.'}, {'ForeName': 'L Jay', 'Initials': 'LJ', 'LastName': 'Katz', 'Affiliation': 'Department of Ophthalmology, Wills Eye Hospital, Jefferson Medical College , Philadelphia, Pennsylvania, USA.'}]",Current eye research,['10.1080/02713683.2020.1795881'] 2071,32715915,"Re: Evaluating the Safety and Potential Activity of URO-902 (hMaxi-K) Gene Transfer by Intravesical Instillation or Direct Injection into the Bladder Wall in Female Participants with Idiopathic (Non-Neurogenic) Overactive Bladder Syndrome and Detrusor Overactivity from Two Double-Blind, Imbalanced, Placebo-Controlled Randomized Phase 1 Trials.",,2020,,['Female Participants with Idiopathic (Non-Neurogenic) Overactive Bladder Syndrome and Detrusor Overactivity'],"['URO-902', 'hMaxi-K) Gene Transfer by Intravesical Instillation or Direct Injection']",[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0268849', 'cui_str': 'Detrusor overactivity'}]","[{'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0021917', 'cui_str': 'Instillation of bladder'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",[],,0.212251,,"[{'ForeName': 'Alan J', 'Initials': 'AJ', 'LastName': 'Wein', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001223.02'] 2072,32715946,Validation of equations to estimate the peak oxygen uptake in adolescents from 20 metres shuttle run test.,"This study aimed to develop new prediction models from directly determined peak of oxygen uptake (VO 2peak ) in adolescents using 20-metre shuttle run test (20 m-SR) and to compare the new models with previously published equations. This study included 148 adolescents (43% girls), aged 13.37 ± 1.84 years old. Adolescents were randomly assigned to validation (n = 91) and cross-validation (n = 57) groups. VO 2peak was measured using a gas analyser in both maximal exercise tests in the laboratory as well as by 20 m-SR. The multiple linear regression method was applied to develop the models using BMI, BMI-z score and body fat percentage (%FM). The proposed models presented better predictive performance (R2 = 75.6% to 78.9%) and a lower absolute percentage error (%error = 10.51 to 11.78%) than the previously published equations (R2 = 38.8% to 69.1%; %error = 13.13% to 21.54%). The Model with BMI-z was the best fit equation in girls, and the model with BMI-z and %FM in boys. Therefore, it is recommended that the equations developed in the present study be used in future research and projects in the school environment to estimate VO 2peak in adolescents by the 20 m-SR test.",2020,The proposed models presented better predictive performance (R2 = 75.6% to 78.9%) and a lower absolute percentage error (%error = 10.51 to 11.78%) than the previously published equations (R2 = 38.8% to 69.1%; %error = 13.13% to 21.54%).,"['adolescents using 20-metre shuttle run test (20 m-SR', 'Adolescents', '148 adolescents (43% girls), aged 13.37\xa0±\xa01.84\xa0years old', 'adolescents from 20 metres shuttle run test']",[],"['VO 2peak', 'peak oxygen uptake', 'oxygen uptake (VO 2peak ']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0475209', 'cui_str': 'meter'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}]",148.0,0.015017,The proposed models presented better predictive performance (R2 = 75.6% to 78.9%) and a lower absolute percentage error (%error = 10.51 to 11.78%) than the previously published equations (R2 = 38.8% to 69.1%; %error = 13.13% to 21.54%).,"[{'ForeName': 'Francisco José de', 'Initials': 'FJ', 'LastName': 'Menezes-Junior', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Íncare Correa de', 'Initials': 'ÍC', 'LastName': 'Jesus', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Mota', 'Affiliation': 'Department of Centro de Investigação em Actividade Fìsica, Saúde e Lazer (CIAFEL), University of Porto , Porto, Portugal.'}, {'ForeName': 'Maria de Fatima Aguiar', 'Initials': 'MFA', 'LastName': 'Lopes', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Patricia Ribeiro Paes', 'Initials': 'PRP', 'LastName': 'Corazza', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Maiara Cristina', 'Initials': 'MC', 'LastName': 'Tadiotto', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Tatiana Aparecida Affornali', 'Initials': 'TAA', 'LastName': 'Tozo', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}, {'ForeName': 'Kátia Sheylla Malta', 'Initials': 'KSM', 'LastName': 'Purim', 'Affiliation': 'Area of Teaching, Positive University , Curitiba, Brazil.'}, {'ForeName': 'Enio Ricardo Vaz', 'Initials': 'ERV', 'LastName': 'Ronque', 'Affiliation': 'Department of Physical Education, State University of Londrina , Londrina, Brazil.'}, {'ForeName': 'Neiva', 'Initials': 'N', 'LastName': 'Leite', 'Affiliation': 'Department of Physical Education, Federal University of Paraná , Curitiba, Brazil.'}]",Journal of sports sciences,['10.1080/02640414.2020.1794255'] 2073,32715972,The effectiveness of a non-tourniquet procedure on peripheral intravenous catheterization in older patients: A pilot study.,"Background: In an older population, insertion of peripheral intravenous catheterizations (PIVCs) are more difficult because of specific problems, such as physiological changes (particularly in veins and subcutaneous tissue), age-related diseases, malnutrition, or insufficient hydration. For older patients, it has been determined that best practices are to use a small gauge needle, avoid using a tourniquet, insert the needle almost flat to the skin (at a 10 to 20-degree angle), stabilize the vein, and monitor the patient's signs and symptoms in order to reduce risk (e.g., pain, bruising, or infiltration). Aim: This pilot study aimed to determine the initial efficacy of non-tourniquet procedure during insertion of PIVC in older patients. Design/ Methods: This quasi-experimental study was conducted in one internal medicine clinic in Yozagat, Turkey in which 78 older patients were assigned to either a tourniquet procedure group (experimental) (n = 38) or a control group (n =40). The initial efficacy of non-tourniquet procedure was tested during insertion of PIVC, such as local pain intensity, PIVC first-attempt success, PIVC dwell time, and phlebitis grade. Results: This study showed that similar pain intensity scores immediately after inserting the PIVC (p>0.05). In addition, the first-attempt success and dwell time in non-tourniquet procedure older patients were be higher/longer and phlebitis scores were lower than the control group (p<0.05). Conclusions: To increase the success of PIVC first-attempt, a longer dwell time, and lower phlebitis scores in older patients, nurses should insert PIVCs at an almost flat degree and stabilize the vein without a tourniquet. Impact statement: This non-tourniquet procedure will lead to the long dwell time and using safely of PIVC in older patients. It is our belief that these results will be a guide for clinical nurses.",2020,"In addition, the first-attempt success and dwell time in non-tourniquet procedure older patients were be higher/longer and phlebitis scores were lower than the control group (p<0.05). ","['For older patients', 'one internal medicine clinic in Yozagat, Turkey in which 78 older patients', 'older patients']","['tourniquet procedure', 'non-tourniquet procedure']","['local pain intensity, PIVC first-attempt success, PIVC dwell time, and phlebitis grade', 'peripheral intravenous catheterization', 'phlebitis scores', 'pain intensity scores']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3838887', 'cui_str': 'Internal medicine clinic'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}]","[{'cui': 'C0412797', 'cui_str': 'Tourniquet procedure'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0429659', 'cui_str': 'Dwell time'}, {'cui': 'C0031542', 'cui_str': 'Phlebitis'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",78.0,0.0210696,"In addition, the first-attempt success and dwell time in non-tourniquet procedure older patients were be higher/longer and phlebitis scores were lower than the control group (p<0.05). ","[{'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Büyükyılmaz', 'Affiliation': 'PhD. BSN. RN. Associate Professor, Florence Nightingale Faculty of Nursing, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}, {'ForeName': 'Merdiye', 'Initials': 'M', 'LastName': 'Şendir', 'Affiliation': 'PhD. BSN. RN. Professor, University of Health Sciences, Hamidiye Faculty of Nursing, Istanbul, Turkey.'}, {'ForeName': 'Betül', 'Initials': 'B', 'LastName': 'Kuş', 'Affiliation': 'PhD. BSN. RN. Assistant Professor, Health Sciences Faculty, Yozgat Bozok University, Yozgat, Turkey.'}, {'ForeName': 'Hacer', 'Initials': 'H', 'LastName': 'Yaman', 'Affiliation': 'RN. Education and Research Hospital, Yozgat Bozok University, Yozgat, Turkey.'}]",Contemporary nurse,['10.1080/10376178.2020.1801351'] 2074,32715995,Clinical Outcomes of TAVI or SAVR in Men and Women with Aortic Stenosis at Intermediate Operative Risk: a post hoc analysis of the randomized SURTAVI trial.,"AIMS In patients with aortic stenosis randomized to transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR), sex-specific differences in complication rates are unclear in intermediate-risk patients. METHODS AND RESULTS 1,660 intermediate-risk patients underwent TAVI with a supra-annular, self-expanding bioprosthesis or SAVR. The population was stratified by sex and treatment modality (female TAVI=366, male TAVI=498, female SAVR=358, male SAVR=438). The primary endpoint was a composite of all-cause mortality or disabling stroke at two years. Compared to males, females had a smaller body surface area, a higher Society of Thoracic Surgeons score (4.7±1.6% vs. 4.3±1.6%, p<0.01) and more frailty. Men required more concomitant revascularization (23% vs. 16%). All-cause mortality or disabling stroke at two years was similar between TAVI and SAVR for females (10.2% vs. 10.5%, p=0.90) and males (14.5% vs. 14.4%, p=0.99); the difference between females and males was 10.2% vs. 14.5%, for TAVI (p=0.08) and 10.5% vs. 14.4%, SAVR (p=0.13). Functional status improvement was more pronounced after TAVI for females than males. CONCLUSIONS Aortic valve replacement, either by surgical or transcatheter approach, appears similarly effective and safe for males and females at intermediate surgical risk. Functional status appears to improve most in females after TAVI.",2020,"All-cause mortality or disabling stroke at two years was similar between TAVI and SAVR for females (10.2% vs. 10.5%, p=0.90) and males (14.5% vs. 14.4%, p=0.99); the difference between females and males was 10.2% vs. 14.5%, for TAVI (p=0.08) and 10.5% vs. 14.4%, SAVR (p=0.13).","['Men and Women with Aortic Stenosis at Intermediate Operative Risk', 'males and females at intermediate surgical risk', 'patients with aortic stenosis', '1,660 intermediate-risk patients underwent TAVI with a supra-annular, self-expanding bioprosthesis or SAVR']","['transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR', 'TAVI or SAVR']","['Thoracic Surgeons score', 'composite of all-cause mortality or disabling stroke', 'mortality or disabling stroke', 'Functional status improvement', 'concomitant revascularization']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C0005557', 'cui_str': 'Bioprosthesis'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}]","[{'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}]","[{'cui': 'C0278626', 'cui_str': 'Thoracic surgeon'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]",1660.0,0.0296006,"All-cause mortality or disabling stroke at two years was similar between TAVI and SAVR for females (10.2% vs. 10.5%, p=0.90) and males (14.5% vs. 14.4%, p=0.99); the difference between females and males was 10.2% vs. 14.5%, for TAVI (p=0.08) and 10.5% vs. 14.4%, SAVR (p=0.13).","[{'ForeName': 'Nicolas M', 'Initials': 'NM', 'LastName': 'Van Mieghem', 'Affiliation': 'Department of Interventional Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Reardon', 'Affiliation': ''}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Yakubov', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Heiser', 'Affiliation': ''}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Merhi', 'Affiliation': ''}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': ''}, {'ForeName': 'Raj R', 'Initials': 'RR', 'LastName': 'Makkar', 'Affiliation': ''}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Cheng', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Robbins', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fail', 'Affiliation': ''}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Feinberg', 'Affiliation': ''}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Stoler', 'Affiliation': ''}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Hebeler', 'Affiliation': ''}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': ''}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Popma', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00303'] 2075,32715996,Ticagrelor versus Clopidogrel in patients with STEMI treated with thrombolysis: the MIRTOS trial.,"AIMS We aimed to demonstrate whether coronary microvascular function is improved after ticagrelor administration compared to clopidogrel administration in STEMI subjects undergoing thrombolysis. METHODS AND RESULTS MIRTOS is a multicenter study of ticagrelor versus clopidogrel in STEMI subjects treated with fibrinolysis. We enrolled 335 patients <75 years old with STEMI eligible for thrombolysis, of which 167 were randomized to receive clopidogrel and 168 to receive ticagrelor together with thrombolysis. Primary outcome was the difference in post-PCI corrected TIMI frame count (CTFC). All clinical events were recorded in a 3-month follow-up period. From the 335 patients that were randomized, 259 underwent PCI (129 clopidogrel and 130 ticagrelor) and 154 angiographies were analyzable for study primary endpoint. No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10). No significant differences were observed in MACE and major bleeding events between randomization groups (OR 2.0, 95% CI 0.18-22.2, p=0.99). CONCLUSIONS Thrombolysis with ticagrelor in patients <75 years old was not able to demonstrate superiority compared to clopidogrel in terms of microvascular injury, while there was no difference between the 2 groups in MACE and major bleeding events.",2020,"No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10).","['patients with STEMI treated with thrombolysis', 'STEMI subjects treated with fibrinolysis', '335 patients <75 years old with STEMI eligible for thrombolysis, of which 167 were randomized to receive', '335 patients that were randomized, 259 underwent', 'STEMI subjects undergoing thrombolysis']","['Ticagrelor', 'ticagrelor together with thrombolysis', 'Clopidogrel', 'PCI (129 clopidogrel and 130 ticagrelor', 'clopidogrel', 'ticagrelor']","['post-PCI corrected TIMI frame count (CTFC', 'MACE and major bleeding events', 'coronary microvascular function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1536220', 'cui_str': 'ST Segment Elevation Myocardial Infarction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0016017', 'cui_str': 'Fibrinolysis'}, {'cui': 'C4709307', 'cui_str': '335'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4517595', 'cui_str': '167'}]","[{'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}, {'cui': 'C4319552', 'cui_str': '130'}]","[{'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0080089', 'cui_str': 'Reading Frames'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",335.0,0.0628197,"No significant difference was found between the clopidogrel (n=85) and ticagrelor (n=69) groups for CTFC (24.33±17.35 vs 28.33±17.59, p=0.10).","[{'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Hamilos', 'Affiliation': 'Cardiology Department, University Hospital of Heraklion, Greece.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kanakakis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Anastasiou', 'Affiliation': ''}, {'ForeName': 'Charalambos', 'Initials': 'C', 'LastName': 'Karvounis', 'Affiliation': ''}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Vasilikos', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Goudevenos', 'Affiliation': ''}, {'ForeName': 'Lampros', 'Initials': 'L', 'LastName': 'Michalis', 'Affiliation': ''}, {'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Koutouzis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Tsiafoutis', 'Affiliation': ''}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Raisakis', 'Affiliation': ''}, {'ForeName': 'Dimitrios', 'Initials': 'D', 'LastName': 'Stakos', 'Affiliation': ''}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Hahalis', 'Affiliation': ''}, {'ForeName': 'Panos', 'Initials': 'P', 'LastName': 'Vardas', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Mantas', 'Affiliation': ''}, {'ForeName': 'Emmanouil', 'Initials': 'E', 'LastName': 'Foukarakis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Kanonidis', 'Affiliation': ''}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Ziakas', 'Affiliation': ''}, {'ForeName': 'Stergios', 'Initials': 'S', 'LastName': 'Tzikas', 'Affiliation': ''}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Papaioannou', 'Affiliation': ''}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Draganigos', 'Affiliation': ''}, {'ForeName': 'Grigorios', 'Initials': 'G', 'LastName': 'Ikonomou', 'Affiliation': ''}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Damelou', 'Affiliation': ''}, {'ForeName': 'Ilias', 'Initials': 'I', 'LastName': 'Samiotis', 'Affiliation': ''}, {'ForeName': 'Nikolaos', 'Initials': 'N', 'LastName': 'Kampouridis', 'Affiliation': ''}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Tsounos', 'Affiliation': ''}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Chlouverakis', 'Affiliation': ''}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Kochiadakis', 'Affiliation': ''}, {'ForeName': 'Stylianos', 'Initials': 'S', 'LastName': 'Petousis', 'Affiliation': ''}, {'ForeName': 'Emmanouil', 'Initials': 'E', 'LastName': 'Skalidis', 'Affiliation': ''}, {'ForeName': 'Evangelos', 'Initials': 'E', 'LastName': 'Zacharis', 'Affiliation': ''}, {'ForeName': 'Fragkiskos', 'Initials': 'F', 'LastName': 'Parthenakis', 'Affiliation': ''}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Nikolaou', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00268'] 2076,32716001,Effects of pony-assisted therapy on the behavior of older people with neurocognitive disorders living in nursing homes.,"CONTEXT Experienced in psychomotricity in two nursing homes, pony-assisted therapy shows first positive effects on psycho-behavioral symptoms. Recognized in the field of disability and psychiatry, this form of therapy is not developed in gerontology. OBJECTIVES To measure the effects of this therapy on the behavior of elderly people with neurocognitive disorders living in long-term care and especially on the involvement in this activity. Anxiety and apathy were chosen as the measurement criteria. METHODS An intervention study with an experimental cross-study design was conducted over two months for 23 subjects. An intervention group was studied during a period with TAP and a period without TAP. Another group without intervention was also studied. All participants were assessed before and after intervention with the NPI-R scale. The engagement during two TAP sessions and one animation time was also evaluated with the ECPAI scale. RESULTS In the crossover study, positive engagement is more important in participant/pony interaction than in participant/facilitator interaction (p<0.01). The ECPAI score reflecting apathetic behavior was significantly decreased during interaction with the animal than in the interaction with the facilitator in patients undergoing therapy (p<0.01). The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01). There is no significant change in the scores for the anxiety and apathy items on the NPI-R scale. CONCLUSION TAP participates in the positive engagement of the elderly people in the interaction with the animal. These results are consistent with the conclusions of the studies on animal mediation and confirm the clinical observations collected. TAP could work by improving self-esteem and valuing all of the person's preserved abilities.",2020,The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01).,"['older people with neurocognitive disorders living in nursing homes', '23 subjects', 'elderly people with neurocognitive disorders living in long-term care']","['pony-assisted therapy', 'TAP', 'TAP and a period without TAP']","['psycho-behavioral symptoms', 'ECPAI score reflecting apathetic behavior', 'self-esteem', 'NPI-R scale']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4041080', 'cui_str': 'Neurocognitive disorder'}, {'cui': 'C0425205', 'cui_str': 'Lives in a nursing home'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0324180', 'cui_str': 'Pony'}, {'cui': 'C0557035', 'cui_str': 'Assisting with therapy'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}]","[{'cui': 'C0004941', 'cui_str': 'Behavioral Symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0085632', 'cui_str': 'Indifference'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",23.0,0.0238065,The ECPAI score reflecting engagement is greater in pony interaction for participants in therapy than in the control group in facilitator interaction (p<0.01).,"[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Carillon', 'Affiliation': 'Sorbonne Université, Paris, France, Pôle médical, Ehpad Arpavie Sainte-Lucie, Issy-les-Moulineaux, France, Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Witold', 'Initials': 'W', 'LastName': 'Jarzebowski', 'Affiliation': 'Court Séjour Gériatrique, Centre Hospitalier de Bastia, France.'}, {'ForeName': 'Bénédicte', 'Initials': 'B', 'LastName': 'Fulpin', 'Affiliation': 'Pôle médical, Ehpad Arpavie Sainte-Lucie, Issy-les-Moulineaux, France.'}, {'ForeName': 'Adélaïde', 'Initials': 'A', 'LastName': 'Miliotis', 'Affiliation': 'Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bernadac', 'Affiliation': 'Pôle médical, Ehpad Korian Hauts de Jardy, Vaucresson, France.'}, {'ForeName': 'Yann', 'Initials': 'Y', 'LastName': 'Saint-Georges Chaumet', 'Affiliation': 'Bioredac, Chambourcy, France.'}, {'ForeName': 'Joël', 'Initials': 'J', 'LastName': 'Belmin', 'Affiliation': 'Sorbonne Université, Paris, France, Service de gériatrie, Hôpital Charles-Foix, AP-HP, Ivry-sur-Seine, France.'}]",Geriatrie et psychologie neuropsychiatrie du vieillissement,['10.1684/pnv.2020.0854'] 2077,30877053,Hoarding Symptoms in Children and Adolescents With Obsessive-Compulsive Disorder: Clinical Features and Response to Cognitive-Behavioral Therapy.,"OBJECTIVE Although adult hoarding disorder is relatively common and often debilitating, few studies have examined the phenomenology of pediatric hoarding. We examined the clinical phenomenology and response to cognitive-behavioral therapy (CBT) treatment in youths with a diagnosis of obsessive-compulsive disorder (OCD) with and without hoarding symptoms. Age was tested as a moderator across analyses, given prior findings that the impact of hoarding symptoms may not become apparent until adolescence. METHOD Youths (N = 215; aged 7-17 years) with OCD pursuing evaluation and/or treatment at a university-based specialty clinic participated in the current study. Presence of hoarding symptoms was assessed as part of a larger battery. Data from a subset of youths (n = 134) who received CBT were included in treatment response analyses. RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment. Youths with hoarding met criteria for more concurrent diagnoses, including greater rates of internalizing and both internalizing/externalizing, but not externalizing-only, disorders. Youths with and without hoarding symptoms did not significantly differ in rate of response to CBT. Age did not moderate any of these relationships, suggesting that the presence of hoarding symptoms was not associated with greater impairments across the clinical presentation of OCD or its response to treatment by age. CONCLUSION We found no evidence that hoarding is associated with greater OCD severity or poorer treatment response in affected youth. Theoretical and clinical implications of these findings, including future directions for research on testing developmental models of hoarding across the lifespan, are discussed.",2019,"RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment.","['Children and Adolescents With Obsessive-Compulsive Disorder', 'Youths (N\xa0= 215; aged 7-17 years) with OCD pursuing evaluation and/or treatment at a university-based specialty clinic participated in the current study', 'youths with a diagnosis of obsessive-compulsive disorder (OCD) with and without hoarding symptoms', 'Data from a subset of youths (n\xa0= 134) who received']","['CBT', 'cognitive-behavioral therapy (CBT']","['OCD severity', 'overall OCD symptom severity and impairment', 'rate of response to CBT']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4709308', 'cui_str': '215'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0037778', 'cui_str': 'Medical specialty'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0424337', 'cui_str': 'Hoarding'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C4517565', 'cui_str': '134'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]",215.0,0.0266047,"RESULTS Youths with hoarding symptoms did not differ from those without hoarding symptoms with respect to overall OCD symptom severity and impairment.","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Rozenman', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA; University of Denver, CO. Electronic address: mrozenman@mednet.ucla.edu.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'McGuire', 'Affiliation': 'Johns Hopkins University, Baltimore, MD.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Wu', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Ricketts', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Peris', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': ""O'Neill"", 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'R Lindsey', 'Initials': 'RL', 'LastName': 'Bergman', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Chang', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Piacentini', 'Affiliation': 'UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2019.01.017'] 2078,32703182,Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection for rectal cancer: study protocol of a randomised controlled multicentre trial (BIOPEX-2 study).,"BACKGROUND Abdominoperineal resection (APR) for rectal cancer is associated with high morbidity of the perineal wound, and controversy exists about the optimal closure technique. Primary perineal wound closure is still the standard of care in the Netherlands. Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study). It is suggested, based on meta-analysis of cohort studies, that filling of the perineal defect with well-vascularised tissue improves perineal wound healing. A gluteal turnover flap seems to be a promising method for this purpose, and with the advantage of not having a donor site scar. The aim of this study is to investigate whether a gluteal turnover flap improves the uncomplicated perineal wound healing after APR for rectal cancer. METHODS Patients with primary or recurrent rectal cancer who are planned for APR will be considered eligible in this multicentre randomised controlled trial. Exclusion criteria are total exenteration, sacral resection above S4/S5, intersphincteric APR, biological mesh closure of the pelvic floor, collagen disorders, and severe systemic diseases. A total of 160 patients will be randomised between gluteal turnover flap (experimental arm) and primary closure (control arm). The total follow-up duration is 12 months, and outcome assessors and patients will be blinded for type of perineal wound closure. The primary outcome is the percentage of uncomplicated perineal wound healing on day 30, defined as a Southampton wound score of less than two. Secondary outcomes include time to perineal wound closure, incidence of perineal hernia, the number, duration and nature of the complications, re-interventions, quality of life and urogenital function. DISCUSSION The uncomplicated perineal wound healing rate is expected to increase from 65 to 85% by using the gluteal turnover flap. With proven effectiveness, a quick implementation of this relatively simple surgical technique is expected to take place. TRIAL REGISTRATION The trial was retrospectively registered at Clinicaltrials.gov NCT04004650 on July 2, 2019.",2020,Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study).,"['Patients with primary or recurrent rectal cancer who are planned for', 'rectal cancer', '160 patients']","['Perineal wound closure using gluteal turnover flap or primary closure after abdominoperineal resection', 'Abdominoperineal resection (APR', 'Biological mesh closure', 'gluteal turnover flap (experimental arm) and primary closure (control arm', 'gluteal turnover flap', 'APR']","['uncomplicated perineal wound healing rate', 'time to perineal wound closure, incidence of perineal hernia, the number, duration and nature of the complications, re-interventions, quality of life and urogenital function', 'wound healing', 'percentage of uncomplicated perineal wound healing on day 30, defined as a Southampton wound score of less']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0278554', 'cui_str': 'Rectal cancer recurrent'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C4319554', 'cui_str': '160'}]","[{'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C2004459', 'cui_str': 'Abdominoperineal resection'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0181805', 'cui_str': 'Mesh'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0450015', 'cui_str': 'Method of wound closure'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0019305', 'cui_str': 'Perineal hernia'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0349590', 'cui_str': 'Nature'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0579062', 'cui_str': 'Urogenital function'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",160.0,0.151325,Biological mesh closure did not improve wound healing in our previous randomised controlled trial (BIOPEX-study).,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Sharabiany', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. s.sharabiany@amsterdamumc.nl.'}, {'ForeName': 'Robin D', 'Initials': 'RD', 'LastName': 'Blok', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Oren', 'Initials': 'O', 'LastName': 'Lapid', 'Affiliation': 'Department of Plastic Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Roel', 'Initials': 'R', 'LastName': 'Hompes', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Wilhelmus A', 'Initials': 'WA', 'LastName': 'Bemelman', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Victor P', 'Initials': 'VP', 'LastName': 'Alberts', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'Lamme', 'Affiliation': 'Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Jan H', 'Initials': 'JH', 'LastName': 'Wijsman', 'Affiliation': 'Department of Surgery, Amphia Hospital, Breda, The Netherlands.'}, {'ForeName': 'Jurriaan B', 'Initials': 'JB', 'LastName': 'Tuynman', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, Free University, Amsterdam, The Netherlands.'}, {'ForeName': 'Arend G J', 'Initials': 'AGJ', 'LastName': 'Aalbers', 'Affiliation': 'Department of Surgery, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Geerard L', 'Initials': 'GL', 'LastName': 'Beets', 'Affiliation': 'Department of Surgery, Antoni van Leeuwenhoek Hospital-Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Hans F J', 'Initials': 'HFJ', 'LastName': 'Fabry', 'Affiliation': 'Department of Surgery, Bravis Hospital, Roosendaal, The Netherlands.'}, {'ForeName': 'Ivan M', 'Initials': 'IM', 'LastName': 'Cherepanin', 'Affiliation': 'Department of Surgery, Bravis Hospital, Roosendaal, The Netherlands.'}, {'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Polat', 'Affiliation': 'Department of Surgery, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands.'}, {'ForeName': 'Jacobus W A', 'Initials': 'JWA', 'LastName': 'Burger', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'Harm J T', 'Initials': 'HJT', 'LastName': 'Rutten', 'Affiliation': 'Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.'}, {'ForeName': 'Robert J I', 'Initials': 'RJI', 'LastName': 'Bosker', 'Affiliation': 'Department of Surgery, Deventer Hospital, Deventer, The Netherlands.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'Talsma', 'Affiliation': 'Department of Surgery, Deventer Hospital, Deventer, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Rothbarth', 'Affiliation': 'Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Cees', 'Initials': 'C', 'LastName': 'Verhoef', 'Affiliation': 'Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.'}, {'ForeName': 'Anthony W H', 'Initials': 'AWH', 'LastName': 'van de Ven', 'Affiliation': 'Department of Surgery, Flevo Hospital, Almere, The Netherlands.'}, {'ForeName': 'Jarmila D W', 'Initials': 'JDW', 'LastName': 'van der Bilt', 'Affiliation': 'Department of Surgery, Flevo Hospital, Almere, The Netherlands.'}, {'ForeName': 'Eelco J R', 'Initials': 'EJR', 'LastName': 'de Graaf', 'Affiliation': 'Department of Surgery, IJsselland Hospital, Capelle aan den Ijssel, The Netherlands.'}, {'ForeName': 'Pascal G', 'Initials': 'PG', 'LastName': 'Doornebosch', 'Affiliation': 'Department of Surgery, IJsselland Hospital, Capelle aan den Ijssel, The Netherlands.'}, {'ForeName': 'Jeroen W A', 'Initials': 'JWA', 'LastName': 'Leijtens', 'Affiliation': 'Department of Surgery, Laurentius Hospital, Roermond, The Netherlands.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'Heemskerk', 'Affiliation': 'Department of Surgery, Laurentius Hospital, Roermond, The Netherlands.'}, {'ForeName': 'Baljit', 'Initials': 'B', 'LastName': 'Singh', 'Affiliation': 'Department of Surgery, Leicester Hospital, Leicester, UK.'}, {'ForeName': 'Sanjay', 'Initials': 'S', 'LastName': 'Chaudhri', 'Affiliation': 'Department of Surgery, Leicester Hospital, Leicester, UK.'}, {'ForeName': 'Michael F', 'Initials': 'MF', 'LastName': 'Gerhards', 'Affiliation': 'Department of Surgery, OLVG Hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Tom M', 'Initials': 'TM', 'LastName': 'Karsten', 'Affiliation': 'Department of Surgery, OLVG Hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Johannes H W', 'Initials': 'JHW', 'LastName': 'de Wilt', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Andre J A', 'Initials': 'AJA', 'LastName': 'Bremers', 'Affiliation': 'Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands.'}, {'ForeName': 'Ronald J C L M', 'Initials': 'RJCLM', 'LastName': 'Vuylsteke', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'Gijsbert', 'Initials': 'G', 'LastName': 'Heuff', 'Affiliation': 'Department of Surgery, Spaarne Gasthuis, Haarlem, The Netherlands.'}, {'ForeName': 'Anna A W', 'Initials': 'AAW', 'LastName': 'van Geloven', 'Affiliation': 'Department of Surgery, Tergooi Hospital, Hilversum, The Netherlands.'}, {'ForeName': 'Pieter J', 'Initials': 'PJ', 'LastName': 'Tanis', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Gijsbert D', 'Initials': 'GD', 'LastName': 'Musters', 'Affiliation': 'Department of Surgery, Amsterdam UMC, Cancer Centre Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.'}]",BMC surgery,['10.1186/s12893-020-00823-7'] 2079,32703188,Scent dog identification of samples from COVID-19 patients - a pilot study.,"BACKGROUND As the COVID-19 pandemic continues to spread, early, ideally real-time, identification of SARS-CoV-2 infected individuals is pivotal in interrupting infection chains. Volatile organic compounds produced during respiratory infections can cause specific scent imprints, which can be detected by trained dogs with a high rate of precision. METHODS Eight detection dogs were trained for 1 week to detect saliva or tracheobronchial secretions of SARS-CoV-2 infected patients in a randomised, double-blinded and controlled study. RESULTS The dogs were able to discriminate between samples of infected (positive) and non-infected (negative) individuals with average diagnostic sensitivity of 82.63% (95% confidence interval [CI]: 82.02-83.24%) and specificity of 96.35% (95% CI: 96.31-96.39%). During the presentation of 1012 randomised samples, the dogs achieved an overall average detection rate of 94% (±3.4%) with 157 correct indications of positive, 792 correct rejections of negative, 33 incorrect indications of negative or incorrect rejections of 30 positive sample presentations. CONCLUSIONS These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls. This data may form the basis for the reliable screening method of SARS-CoV-2 infected people.",2020,These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls.,['Eight detection dogs'],[],['overall average detection rate'],"[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0012984', 'cui_str': 'Canis lupus familiaris'}]",[],"[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.105029,These preliminary findings indicate that trained detection dogs can identify respiratory secretion samples from hospitalised and clinically diseased SARS-CoV-2 infected individuals by discriminating between samples from SARS-CoV-2 infected patients and negative controls.,"[{'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Jendrny', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Schulz', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Twele', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Meller', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Maren', 'Initials': 'M', 'LastName': 'von Köckritz-Blickwede', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Albertus Dominicus Marcellinus Erasmus', 'Initials': 'ADME', 'LastName': 'Osterhaus', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Janek', 'Initials': 'J', 'LastName': 'Ebbers', 'Affiliation': ', Hörstel, Germany.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Pilchová', 'Affiliation': 'Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.'}, {'ForeName': 'Isabell', 'Initials': 'I', 'LastName': 'Pink', 'Affiliation': 'Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Welte', 'Affiliation': 'Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael Peter', 'Initials': 'MP', 'LastName': 'Manns', 'Affiliation': 'Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Fathi', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Christiane', 'Initials': 'C', 'LastName': 'Ernst', 'Affiliation': 'Central Institute of Medical Service, German Armed Forces, Koblenz, Germany.'}, {'ForeName': 'Marylyn Martina', 'Initials': 'MM', 'LastName': 'Addo', 'Affiliation': 'Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Schalke', 'Affiliation': 'Bundeswehr School of Dog handling, German Armed Forces, Ulmen, Germany.'}, {'ForeName': 'Holger Andreas', 'Initials': 'HA', 'LastName': 'Volk', 'Affiliation': 'Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Hannover, Germany. holger.volk@tiho-hannover.de.'}]",BMC infectious diseases,['10.1186/s12879-020-05281-3'] 2080,32703194,Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial.,"BACKGROUND Patients suffering from fibrotic interstitial lung diseases (fILD) have a poor prognosis and a high symptom burden. Palliative treatment includes relief of symptoms such as breathlessness. There is no evidence-based treatment for chronic breathlessness but opioids are often used despite concerns due to the hypothetical risk of respiratory depression. This study investigated the effect of oral morphine drops in patients with fILD on chronic breathlessness and safety. METHODS In a double-blinded placebo-controlled study, 36 patients with fILD were randomised to either four daily doses of 5 mg of oral morphine drops or placebo for 1 week. Endpoints and safety parameters were obtained at baseline, at follow-up after 1 h and 1 week. RESULTS The primary endpoint, the visual analogue score (VAS) of dyspnea was reduced by 1.1 ± 0.33 cm in the morphine group at follow-up compared to baseline (P < 0.01), whereas the reduction was 0.35 ± 0.47 cm in the placebo group. However, the difference between the two groups was not statistically significant (p = 0.2). Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test. More patients treated with morphine reported constipation, nausea and confusion. CONCLUSION Oral administration of morphine drops, 20 mg a day, in patients with fILD did not significantly reduce dyspnea VAS score during 1 week compared to placebo. Oral morphine did not induce respiratory depression, but was related to an increased risk of constipation, nausea and confusion. TRIAL REGISTRATION The trial is registered in clinicaltrials.gov (Identifier: NCT02622022 ). Registered 4 December 2015.",2020,"Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test.","['Patients suffering from fibrotic interstitial lung diseases (fILD', '36 patients with fILD', 'patients with fILD on chronic breathlessness and safety', 'patients with fibrotic interstitial lung disease - a randomised']","['oral morphine drops or placebo', 'morphine', 'oral morphine', 'Oral morphine', 'placebo']","['dyspnea VAS score', 'constipation, nausea and confusion', 'risk of constipation, nausea and confusion', 'respiratory depression', 'relief of symptoms such as breathlessness', 'respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test', 'visual analogue score (VAS) of dyspnea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0360457', 'cui_str': 'Morphine-containing product in oral dose form'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0009676', 'cui_str': 'Confusional state'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0235063', 'cui_str': 'Decreased respiratory function'}, {'cui': 'C0564405', 'cui_str': 'Feeling relief'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",36.0,0.451365,"Oral morphine drops did not affect respiratory frequency, pulse rate, blood pressure, peripheral saturation or the 6-min walk test.","[{'ForeName': 'Sissel', 'Initials': 'S', 'LastName': 'Kronborg-White', 'Affiliation': 'Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200, Aarhus N, Denmark. siskro@rm.dk.'}, {'ForeName': 'Charlotte Uggerhøj', 'Initials': 'CU', 'LastName': 'Andersen', 'Affiliation': 'Department of Pharmacology, Aarhus University Hospital, 8200, Aarhus N, Denmark.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Kohberg', 'Affiliation': 'Department of Oncology, Odense University Hospital, Odense, 5000, Denmark.'}, {'ForeName': 'Ole', 'Initials': 'O', 'LastName': 'Hilberg', 'Affiliation': 'Department of Internal Medicine, Lillebaelt Hospital, 7100, Vejle, Denmark.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Bendstrup', 'Affiliation': 'Department of Respiratory Diseases and Allergy, Aarhus University Hospital, 8200, Aarhus N, Denmark.'}]",Respiratory research,['10.1186/s12931-020-01452-7'] 2081,32703974,"Functional high-intensity exercise is more effective in acutely increasing working memory than aerobic walking: an exploratory randomized, controlled trial.","Aerobic and resistance exercise acutely increase cognitive performance (CP). High-intensity functional training (HIFT) combines the characteristics of both regimes but its effect on CP is unclear. Thirty-five healthy individuals (26.7 ± 3.6 years, 18 females) were randomly allocated to three groups. The first (HIFT) performed a functional whole-body workout at maximal effort and in circuit format, while a second walked at 60% of the heart rate reserve (WALK). The third group remained physically inactive reading a book (CON). Before and after the 15-min intervention period, CP was assessed with the Stroop Test, Trail Making Test and Digit Span Test. Repeated-measures ANOVAs and post-hoc 95% confidence intervals (95% CI) were used to detect time/group differences. A significant group*time interaction was found for the backwards condition of the Digit Span Test (p = 0.04) and according to the 95% CI, HIFT was superior to WALK and CON. Analysis of the sum score of the Digit Span Test and the incongruent condition of the Stroop Test, furthermore, revealed main effects for time (p < 0.05) with HIFT being the only intervention improving CP. No differences were found for the Trail Making Test (p > 0.05). In conclusion, HIFT represents an appropriate method to acutely improve working memory, potentially being superior to moderate aerobic-type exercise.",2020,No differences were found for the Trail Making Test (p > 0.05).,"['Thirty-five healthy individuals (26.7\u2009±\u20093.6\xa0years, 18 females']","['Aerobic and resistance exercise', 'HIFT', 'Functional high-intensity exercise', 'High-intensity functional training (HIFT']","['cognitive performance (CP', 'Stroop Test, Trail Making Test and Digit Span Test', 'physically inactive reading a book (CON']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C4517694', 'cui_str': '3.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]","[{'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C0385242', 'cui_str': 'Apo-2 Ligand'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0006002', 'cui_str': 'Book'}]",35.0,0.0307978,No differences were found for the Trail Making Test (p > 0.05).,"[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Wilke', 'Affiliation': 'Department of Sports Medicine, Goethe University Frankfurt am Main, Ginnheimer Landstraße 39, 60487, Frankfurt am Main, Germany. wilke@sport.uni-frankfurt.de.'}]",Scientific reports,['10.1038/s41598-020-69139-z'] 2082,32704023,"Soluble Klotho, a biomarker and therapeutic strategy to reduce bronchopulmonary dysplasia and pulmonary hypertension in preterm infants.","Preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH) have accelerated lung aging and poor long-term outcomes. Klotho is an antiaging protein that modulates oxidative stress, angiogenesis and fibrosis. Here we test the hypothesis that decreased cord Klotho levels in preterm infants predict increased BPD-PH risk and early Klotho supplementation prevents BPD-like phenotype and PH in rodents exposed to neonatal hyperoxia. In experiment 1, Klotho levels were measured in cord blood of preterm infants who were enrolled in a longitudinal cohort study. In experiment 2, using an experimental BPD-PH model, rat pups exposed to room air or hyperoxia (85% O 2 ) were randomly assigned to receive every other day injections of recombinant Klotho or placebo. The effect of Klotho on lung structure, PH and cardiac function was assessed. As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels. Early Klotho supplementation in neonatal hyperoxia-exposed rodents preserved lung alveolar and vascular structure, attenuated PH, reduced pulmonary vascular remodeling and improved cardiac function. Together, these findings have important implications as they suggest that perinatal Klotho deficiency contributes to BPD-PH risk and strategies that preserve Klotho levels, may improve long-term cardiopulmonary outcomes in preterm infants.",2020,"As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels.","['Preterm infants with bronchopulmonary dysplasia (BPD) and pulmonary hypertension (PH', 'rat pups exposed to room air or hyperoxia (85% O 2 ', 'preterm infants']","['Klotho', 'recombinant Klotho or placebo']","['bronchopulmonary dysplasia and pulmonary hypertension', 'lung structure, PH and cardiac function', 'cord Klotho levels', 'Klotho levels', 'neonatal hyperoxia-exposed rodents preserved lung alveolar and vascular structure, attenuated PH, reduced pulmonary vascular remodeling and improved cardiac function']","[{'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0020542', 'cui_str': 'Pulmonary hypertension'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}]","[{'cui': 'C1144173', 'cui_str': 'KL protein, human'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0006287', 'cui_str': 'Bronchopulmonary dysplasia of newborn'}, {'cui': 'C0020542', 'cui_str': 'Pulmonary hypertension'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C1144173', 'cui_str': 'KL protein, human'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0242706', 'cui_str': 'Hyperoxia'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0035804', 'cui_str': 'Order Rodentia'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C3850148', 'cui_str': 'Vascular Remodeling'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0610072,"As compared to controls, preterm infants with BPD or BPD-PH had decreased cord Klotho levels.","[{'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Batlahally', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Franklin', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.""}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Damianos', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Chen', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Mayank', 'Initials': 'M', 'LastName': 'Sharma', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Duara', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Keerthy', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Zambrano', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Lina A', 'Initials': 'LA', 'LastName': 'Shehadeh', 'Affiliation': 'The Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Eliana C', 'Initials': 'EC', 'LastName': 'Martinez', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Marissa J', 'Initials': 'MJ', 'LastName': 'DeFreitas', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Shathiyah', 'Initials': 'S', 'LastName': 'Kulandavelu', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Carolyn L', 'Initials': 'CL', 'LastName': 'Abitbol', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Freundlich', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Rosemeire M', 'Initials': 'RM', 'LastName': 'Kanashiro-Takeuchi', 'Affiliation': 'The Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Schmidt', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Merline', 'Initials': 'M', 'LastName': 'Benny', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Wu', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Karen K', 'Initials': 'KK', 'LastName': 'Mestan', 'Affiliation': ""Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.""}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Young', 'Affiliation': 'Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL, USA. Kyoung3@med.miami.edu.'}]",Scientific reports,['10.1038/s41598-020-69296-1'] 2083,32704082,Green-banana biomass consumption by diabetic patients improves plasma low-density lipoprotein particle functionality.,"The aim of this study was to investigate the effects of 6-months consumption of green-banana biomass on the LDL particle functionality in subjects with type 2 diabetes. Subjects (n = 39, mean age 65 years old) of both sexes with diabetes (HbA1c ≥ 6·5%) were randomized to receive nutritional support plus green-banana biomass (40 g) (n = 21) or diet alone (n = 18) for 6-months. Non-linear optical responses of LDL solutions from these participants were studied by Z-scan technique. UV-visible spectrophotometer was used to measure the absorbance of the LDL samples. Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution. The Lipoprint test was used to determine the LDL sub-fractions in terms of distribution and size. Consumption of green-banana biomass, reduced total- (p = 0.010), non-HDL-cholesterol (p = 0.043), glucose (p = 0.028) and HbA1c (p = 0.0007), and also improved the protection of the LDL particle against oxidation, by the increase in carotenoids content in the particles (p = 0.007). This higher protection against modifications may decrease the risk of developing cardiovascular disease. These benefits of the green-banana biomass encourage the use of resistant starches with potential clinical applications in individuals with pre-diabetes and diabetes.",2020,Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution.,"['individuals with pre-diabetes and diabetes', 'subjects with type 2 diabetes', 'Subjects (n\u2009=\u200939, mean age 65\xa0years old) of both sexes with diabetes (HbA1c\u2009≥\u20096·5']","['6-months consumption of green-banana biomass', 'nutritional support plus green-banana biomass (40\xa0g) (n\u2009=\u200921) or diet alone']","['LDL particle functionality', 'Consumption of green-banana biomass, reduced total- ', 'plasma low-density lipoprotein particle functionality', 'non-HDL-cholesterol', 'carotenoids content', 'protection of the LDL particle against oxidation']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0004722', 'cui_str': 'Banana'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0332583', 'cui_str': 'Green color'}, {'cui': 'C0004722', 'cui_str': 'Banana'}, {'cui': 'C0005535', 'cui_str': 'Biomass'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0007271', 'cui_str': 'Carotinoid'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}]",,0.0222308,Small Angle X-ray Scattering and Dynamic Light Scattering experiments were used to look for any structural changes in LDL samples and to determine their size distribution.,"[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Lotfollahi', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil.'}, {'ForeName': 'Ana Paula de Queiroz', 'Initials': 'APQ', 'LastName': 'Mello', 'Affiliation': 'University Center São Camilo, São Paulo, Brazil.'}, {'ForeName': 'Edna S', 'Initials': 'ES', 'LastName': 'Costa', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Cristiano L P', 'Initials': 'CLP', 'LastName': 'Oliveira', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil.'}, {'ForeName': 'Nagila R T', 'Initials': 'NRT', 'LastName': 'Damasceno', 'Affiliation': 'Faculty of Public Health, University of São Paulo (USP), São Paulo, Brazil.'}, {'ForeName': 'Maria Cristina', 'Initials': 'MC', 'LastName': 'Izar', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Antonio Martins Figueiredo', 'Initials': 'AMF', 'LastName': 'Neto', 'Affiliation': 'Complex Fluids Group, Instituto de Física, Universidade de São Paulo, Rua Do Matão, 1371, Butantã, São Paulo, SP, CEP: 05508-090, Brazil. afigueiredo@if.usp.br.'}]",Scientific reports,['10.1038/s41598-020-69288-1'] 2084,32704155,Effects of movement representation techniques on motor learning of thumb-opposition tasks.,"The present work is the first study that assess long run change after motor learning. The study's main objective was to evaluate the short to medium-term impact of motor imagery (MI) and action observation (AO) on motor learning of a sequence of thumb-opposition tasks of increasing complexity. We randomly assigned 45 participants to an AO, MI, or placebo observation (PO) group. A sequence of 12 thumb-opposition tasks was taught for 3 consecutive days (4 per day). The primary outcome was accuracy. The secondary outcomes were required time and perfect positioning. The outcomes were assessed immediately after the intervention and at 1 week, 1 month and 4 months postintervention. Regarding the primary outcome, AO group had significantly higher accuracy than the MI or PO group until at least 4 months (p < 0.01, d > 0.80). However, in the bimanual positions, AO was not superior to MI at 1 week postintervention. Regarding secondary outcomes, AO group required less time than the MI group to remember and perform the left-hand and both-hand gestures, with a large effect size (p < 0.01, d > 0.80). In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29). AO training resulted in greater and longer term motor learning than MI and placebo intervention. If the goal is to learn some motor skills for whatever reason (e.g., following surgery or immobilization.), AO training should be considered clinically.",2020,"In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29).",[],"['AO, MI, or placebo observation (PO', 'AO training', 'movement representation techniques', 'motor imagery (MI) and action observation (AO']","['required time and perfect positioning', 'longer term motor learning', 'motor learning of thumb-opposition tasks']",[],"[{'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0427082', 'cui_str': 'Opposition of thumb'}]",45.0,0.0563366,"In terms of percentage of perfect positions, AO group achieved significantly better results than the MI group until at least 4 months after the intervention in the unimanual gestures (p < 0.01, d > 0.80) and up to 1 month postintervention in the bimanual gestures (p = 0.012, d = 1.29).","[{'ForeName': 'Ferran', 'Initials': 'F', 'LastName': 'Cuenca-Martínez', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Suso-Martí', 'Affiliation': 'Motion in Brains Research Group, Institute of Neuroscience and Sciences of the Movement (INCIMOV), Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Jose Vicente', 'Initials': 'JV', 'LastName': 'León-Hernández', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'ForeName': 'Roy', 'Initials': 'R', 'LastName': 'La Touche', 'Affiliation': 'Departmento de Fisioterapia, Centro Superior de Estudios Universitarios CSEU La Salle, Universidad Autónoma de Madrid, Madrid, Spain. roylatouche@yahoo.es.'}]",Scientific reports,['10.1038/s41598-020-67905-7'] 2085,32706442,Effects of eccentric training at long-muscle length on architectural and functional characteristics of the hamstrings.,"Hamstring strain injuries during sprinting or stretching frequently occur at long-muscle length. Yet, previous research has mainly focused on studying the effectiveness of eccentric hamstring strengthening at shorter muscle length on hamstring performance, morphology, and hamstring strain injury risk factors. Here, we evaluated the effects of 6-week eccentric hamstring training at long-muscle length on functional and architectural characteristics of the hamstrings. Healthy and injury-free participants (n = 40; age 23.7 ± 2.5 years) were randomly assigned to control or intervention group. Training intervention consisted of 12 sessions with two eccentric hamstring exercises in a lengthened position. Outcome measures included isokinetic and isometric knee flexion peak torque, Nordic hamstring exercise peak torque, voluntary activation level, and countermovement jump performance. Ultrasonography was used to determine muscle thickness, pennation angle, and fascicle length of biceps femoris long head (BFlh). A significant time × group interaction effect was observed for all measured parameters except countermovement jump performance and muscle thickness. The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d = 0.55-0.62, P = .02 and .03) and concentric peak torque at 180°/s (d = 0.99, P = .001), increased isometric knee flexion peak torque (d = 0.73, P = .008) and Nordic hamstring exercise peak torque (d = 1.19, P < .001), increased voluntary activation level (d = 1.29, P < .001), decreased pennation angle (d = 1.31, P < .001), and increased fascicle length (d = 1.12, P < .001) of BFlh. These results provide evidence that short-term eccentric hamstring strengthening at long-muscle length can have significant favorable effects on various architectural and functional characteristics of the hamstrings.",2020,"The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d=0.55-0.62, p=0.02 and 0.03) and concentric peak torque at 180°/s",['Healthy and injury-free participants (n=40; age 23.7±2.5 years'],"['eccentric training', 'eccentric hamstring training', 'eccentric hamstring exercises', 'Ultrasonography']","['fascicle length', 'isokinetic and isometric knee flexion peak torque, Nordic hamstring exercise peak torque, voluntary activation level, and countermovement jump performance', 'muscle thickness, pennation angle and fascicle length of biceps femoris long head (BFlh', 'decreased pennation angle', 'concentric peak torque', 'isometric knee flexion peak torque', 'Nordic hamstring exercise peak torque', 'countermovement jump performance and muscle thickness', 'Hamstring strain injuries', 'voluntary activation level', 'concentric and eccentric knee flexion peak torque']","[{'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0584895', 'cui_str': 'Posterior muscle of thigh structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0224449', 'cui_str': 'Biceps femoris muscle structure'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}]",,0.034489,"The training intervention resulted in increased concentric and eccentric knee flexion peak torque at 60°/s (d=0.55-0.62, p=0.02 and 0.03) and concentric peak torque at 180°/s","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Marušič', 'Affiliation': 'Faculty of Health Sciences, University of Primorska, Izola, Slovenia.'}, {'ForeName': 'Rok', 'Initials': 'R', 'LastName': 'Vatovec', 'Affiliation': 'Faculty of Health Sciences, University of Primorska, Izola, Slovenia.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Marković', 'Affiliation': 'Faculty of Kinesiology, University of Zagreb, Zagreb, Croatia.'}, {'ForeName': 'Nejc', 'Initials': 'N', 'LastName': 'Šarabon', 'Affiliation': 'Faculty of Health Sciences, University of Primorska, Izola, Slovenia.'}]",Scandinavian journal of medicine & science in sports,['10.1111/sms.13770'] 2086,32701984,Acupuncture in persons with an increased stress level-Results from a randomized-controlled pilot trial.,"BACKGROUND In today's Western societies a high percentage of people experience increased or chronic stress. Acupuncture could serve as treatment for persons affected adversely by the increased stress. METHODS The AkuRest study was a two-centre randomized controlled pilot study in adult persons with increased stress levels. Participants were randomly allocated to one of three groups: verum acupuncture treatment, sham acupuncture, and a waiting control group. The feasibility of the study was assessed. In addition, effects on stress level (measured by the Perceived Stress Questionnaire (PSQ-20)) and other variables were assessed at the end of treatment and a 3-month follow-up. RESULTS Altogether, N = 70 persons were included in the study. At the end of the treatment 15.7% were lost to follow-up. The adherence to the protocol was good: 82.9% of the participants completed 100% of their treatment. The stress level of the participants was high at baseline (mean PSQ-20 score 75.5, SD = 8.2). Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) = -1.39, 95%-CI = [-2.11; -0.67]: ES (sham) = -1.12, CI = [-1.78;-0.44]). At follow-up, effect sizes were in favour of the verum group (as compared to sham). However, confidence intervals and t-tests showed that these differences were not significant. CONCLUSION The pilot study demonstrated the feasibility of the acupuncture RCT in persons with increased stress levels. Estimated parameters can be used to design a larger RCT to prove the-here indicated-efficacy of verum acupuncture to decrease stress. TRIAL REGISTRATION NUMBER ISRCTN15259166.",2020,Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) =,"['persons with increased stress levels', 'persons with an increased stress level', 'Altogether, N = 70 persons were included in the study', 'adult persons with increased stress levels']","['acupuncture RCT', 'verum and sham acupuncture', 'Acupuncture', 'verum acupuncture', 'verum acupuncture treatment, sham acupuncture, and a waiting control group']","['Perceived Stress Questionnaire (PSQ-20', 'stress level']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1319127', 'cui_str': 'Level of stress'}]",70.0,0.0786007,Effect sizes (ES) at T1 showed that verum and sham acupuncture were superior to the waiting condition in reducing stress (ES (verum) =,"[{'ForeName': 'Beate', 'Initials': 'B', 'LastName': 'Wild', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Brenner', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Joos', 'Affiliation': 'Institute for General Practice and Interprofessional Care, Medical University Hospital Tübingen, Tübingen, Germany.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Samstag', 'Affiliation': 'Institute of Immunology, Section Molecular Immunology, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Buckert', 'Affiliation': 'Department of General Internal Medicine and Psychosomatics, Medical University Hospital Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Valentini', 'Affiliation': 'Institute for General Practice and Interprofessional Care, Medical University Hospital Tübingen, Tübingen, Germany.'}]",PloS one,['10.1371/journal.pone.0236004'] 2087,32708396,Effects of Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation on Body Composition and Metabolic Markers-A Pilot Study.,"Aging is accompanied by a progressive decline in muscle mass and an increase in fat mass, which are detrimental changes associated with the development of health conditions such as type-2 diabetes mellitus or chronic low-grade inflammation. Although both exercise as well as nutritional interventions are known to be beneficial in counteracting those age-related changes, data to which extent untrained elderly people may benefit is still sparse. Therefore, a randomized, controlled, 12-week interventional trial was conducted in which 134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ) were allocated to one of four study groups: (1) control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO). Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids, were analyzed at the beginning and the end of the study. The highest decreases in body fat were observed within the EXCO group (-1.70 ± 2.45 kg, p < 0.001), and the EXDC (-1.41 ± 2.13 kg, p = 0.008) group. Markers of glucose metabolism and blood lipids remained unchanged in all groups. Taken together results of this pilot study suggest that a combination of moderate exercise and intake of oil from Calanus finmarchicus or a healthy diet may promote fat loss in elderly untrained overweight participants.",2020,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"['elderly untrained overweight participants', '134 healthy untrained participants (96 women and 38 men, age 59.4 ± 5.6 years, body mass index (BMI) 28.4 ± 5.8 kg/m 2 ']","['Exercise Combined with a Healthy Diet or Calanus finmarchicus Oil Supplementation', 'control group with no intervention (CON); (2) 2×/week aerobic and resistance training only (EX); (3) exercise routine combined with dietary counseling in accordance with the guidelines of the German Nutrition Society (EXDC); (4) exercise routine combined with intake of 2 g/day oil from Calanus finmarchicus (EXCO']","['Markers of glucose metabolism and blood lipids', 'Body composition (bioelectrical impedance analysis), as well as markers of glucose metabolism and blood lipids', 'body fat', 'Body Composition and Metabolic Markers']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517796', 'cui_str': '5.8'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0162536', 'cui_str': 'Biolectric Impedance'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C1513159', 'cui_str': 'Metabolic marker'}]",134.0,0.0438269,Markers of glucose metabolism and blood lipids remained unchanged in all groups.,"[{'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Wasserfurth', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Josefine', 'Initials': 'J', 'LastName': 'Nebl', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Jan Philipp', 'Initials': 'JP', 'LastName': 'Schuchardt', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Mattea', 'Initials': 'M', 'LastName': 'Müller', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}, {'ForeName': 'Tim Konstantin', 'Initials': 'TK', 'LastName': 'Boßlau', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Karsten', 'Initials': 'K', 'LastName': 'Krüger', 'Affiliation': 'Department of Exercise Physiology and Sports Therapy, Institute of Sports Science, Justus-Liebig-University Giessen, 35394 Giessen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hahn', 'Affiliation': 'Faculty of Natural Sciences, Institute of Food Science and Human Nutrition, Leibniz University Hannover, 30167 Hannover, Germany.'}]",Nutrients,['10.3390/nu12072139'] 2088,32708428,Randomised Controlled Trial: Partial Hydrolysation of Casein Protein in Milk Decreases Gastrointestinal Symptoms in Subjects with Functional Gastrointestinal Disorders.,"Unspecific gastrointestinal symptoms associated with milk consumption are common. In addition to lactose, also other components of milk may be involved. We studied whether the partial hydrolysation of milk proteins would affect gastrointestinal symptoms in subjects with functional gastrointestinal disorders. In a randomised, placebo-controlled crossover intervention, subjects ( n = 41) were given ordinary or hydrolysed high-protein, lactose-free milkshakes (500 mL, 50 g protein) to be consumed daily for ten days. After a washout period of ten days, the other product was consumed for another ten days. Gastrointestinal symptoms were recorded daily during the study periods, and a validated irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire was completed at the beginning of the study and at the end of both study periods. Blood and urine samples were analysed for markers of inflammation, intestinal permeability and immune activation. Both the IBS-SSS score ( p = 0.001) and total symptom score reported daily ( p = 0.002) were significantly reduced when participants consumed the hydrolysed product. Less bloating was reported during both study periods when compared with the baseline ( p < 0.01 for both groups). Flatulence ( p = 0.01) and heartburn ( p = 0.03) decreased when consuming the hydrolysed product but not when drinking the control product. No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods. The results suggest that the partial hydrolysation of milk proteins (mainly casein) reduces subjective symptoms to some extent in subjects with functional gastrointestinal disorders. The mechanism remains to be resolved.",2020,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","['subjects ( n = 41', 'Subjects with Functional Gastrointestinal Disorders', 'subjects with functional gastrointestinal disorders']","['ordinary or hydrolysed high-protein, lactose-free milkshakes', 'milk proteins (mainly casein', 'partial hydrolysation of milk proteins', 'Partial Hydrolysation of Casein Protein', 'placebo']","['total symptom score', 'IBS-SSS score', 'subjective symptoms', 'levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine', 'Flatulence', 'irritable bowel syndrome-symptom severity scale (IBS-SSS) questionnaire', 'Less bloating', 'gastrointestinal symptoms', 'heartburn', 'Gastrointestinal symptoms']","[{'cui': 'C0559031', 'cui_str': 'Functional disorder of gastrointestinal tract'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0022949', 'cui_str': 'Lactose'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0026138', 'cui_str': 'Milk protein'}, {'cui': 'C0007332', 'cui_str': 'Caseins'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0037052', 'cui_str': 'Sick sinus syndrome'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C1173118', 'cui_str': 'FABP2 protein, human'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0076065', 'cui_str': 'tele-methylhistamine'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0018834', 'cui_str': 'Heartburn'}]",41.0,0.0657328,"No significant differences in the levels of inflammatory markers (tumor necrosis factor alpha, TNF-α and interleukin 6, IL-6), intestinal permeability (fatty acid binding protein 2, FABP2) or immune activation (1-methylhistamine) were detected between the treatment periods.","[{'ForeName': 'Reijo', 'Initials': 'R', 'LastName': 'Laatikainen', 'Affiliation': 'Booston Oy Ltd., Viikinkaari 6, FI-00790 Helsinki, Finland.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Salmenkari', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Sibakov', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}, {'ForeName': 'Heikki', 'Initials': 'H', 'LastName': 'Vapaatalo', 'Affiliation': 'Pharmacology, Medical Faculty, University of Helsinki, P.O. Box 63, FI-00014 Helsinki, Finland.'}, {'ForeName': 'Anu', 'Initials': 'A', 'LastName': 'Turpeinen', 'Affiliation': 'Valio Ltd., R&D, P.O. Box 30, FI-00039 Valio, Finland.'}]",Nutrients,['10.3390/nu12072140'] 2089,32708446,Effects on Gastroesophageal Reflux of Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier in Preterm Newborns: Additional Data from the FortiLat Study.,"BACKGROUND Feeding intolerance is a frequent diagnosis in very preterm infants. As seen in the FortiLat trial, human milk fortification with the new donkey milk-derived human milk fortifier (DF) seems to improve feeding tolerance in these infants. The aim of this study was to evaluate the effects of using the DF compared with bovine milk-derived fortifier (BF) on gastroesophageal reflux (GER) in very low birth weight (VLBW) infants. METHODS Over a total of 156 preterm infants were enrolled into the FortiLat trial (GA <32 weeks and birth weight <1500 g) and randomized into the BF arm or DF arm, and we selected all infants with clinical signs of GER and cardiorespiratory (CR) symptoms. All the infants underwent CR and multichannel intraluminal impedance and pH (MII/pH) monitoring associated with gastric ultrasound to evaluate GER and gastric emptying time. RESULTS 10 infants were enrolled, and 5 were in the DF arm. At MII/pH, infants enrolled into the DF arm showed a lower GER frequency than BF arm infants ( p = 0.036). Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). CONCLUSION The use of donkey-derived human milk fortifier reduced the GER frequency and consequently should be recommended in infants with feeding intolerance.",2020,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","['very preterm infants', 'infants with feeding intolerance', 'very low birth weight (VLBW) infants', '156 preterm infants were enrolled into the FortiLat trial (GA', 'Preterm Newborns', '10 infants were enrolled, and 5 were in the DF arm']","['bovine milk-derived fortifier (BF', 'Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier']","['feeding tolerance', 'gastroesophageal reflux (GER', 'GER frequency', 'lower GER frequency', 'Half gastric emptying time']","[{'cui': 'C3897192', 'cui_str': 'Very preterm infant'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1820738', 'cui_str': 'Feeding intolerance'}, {'cui': 'C0282666', 'cui_str': 'Very Low Birth Weight'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0026140', 'cui_str': 'Breast milk'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0324145', 'cui_str': 'Equus asinus'}, {'cui': 'C3853188', 'cui_str': 'Human milk fortifier'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0017168', 'cui_str': 'Gastroesophageal reflux disease'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0040223', 'cui_str': 'Time'}]",156.0,0.0357146,"Half gastric emptying time was similar in DF and BF arm infants ( p = 0.744). ","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cresi', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Maggiora', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Pirra', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Paola', 'Initials': 'P', 'LastName': 'Tonetto', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Carlotta', 'Initials': 'C', 'LastName': 'Rubino', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Cavallarin', 'Affiliation': 'Institute of Sciences of Food Production, Italian National Research Council, 10126 Turin, Italy.'}, {'ForeName': 'Marzia', 'Initials': 'M', 'LastName': 'Giribaldi', 'Affiliation': 'Research Centre for Engineering and Agro-Food Processing, Council for Agricultural Research and Economics (CREA), 10100 Turin, Italy.'}, {'ForeName': 'Guido E', 'Initials': 'GE', 'LastName': 'Moro', 'Affiliation': 'Italian Association of Human Milk Banks, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Peila', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Coscia', 'Affiliation': ""Neonatal Care Unit, Sant'Anna Hospital, Città della Salute e della Scienza, Università degli Studi di Torino, 10126 Turin, Italy.""}]",Nutrients,['10.3390/nu12072142'] 2090,32708456,Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy.,"We previously performed a randomized controlled trial (RCT) comparing targeted and random biopsy in neoplasia detection in patients with ulcerative colitis (UC), which showed the short-term effectiveness of targeted biopsy with one-time colonoscopy. In this retrospective cohort study, we investigated the long-term effectiveness of targeted biopsy in tertiary care hospitals, using the follow-up data from patients with UC for ≥ 8 years who had enrolled in the initial RCT. The primary outcome was death from colorectal cancer (CRC). Secondary outcomes were advanced neoplasia (CRC or high-grade dysplasia) and colectomy due to neoplasia after the RCT. We compared these outcomes between target and random groups. Data on 195 of the 221 patients (88.2%) enrolled in the previous RCT were collected from 28 institutions between 2008 and 2019. No patients died of CRC in either group, with a median 8.8-year follow-up demonstrating a robustness for targeted biopsy in terms of CRC death prevention. Advanced neoplasia was detected in four and three patients in the target and random groups, respectively. Colectomy was required due to neoplasia in three patients in each group. The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population. Conversely, patients found with low-grade dysplasia at initial RCT have 10-fold higher risk of progression to high-grade dysplasia and/or CRC. Ten extracolonic malignancies were observed during the follow-up, resulting in four deaths. Panchromoendoscopy was used only in 4.6% and targeted biopsy was only performed in 59.1% of colonoscopies. We recommend targeted biopsy rather than > 33 random biopsies in real-world settings under adequate observation by specialists.",2020,"The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population.","['patients with ulcerative colitis (UC', 'patients with UC for ≥ 8 years who had enrolled in the initial RCT', 'Ulcerative Colitis Surveillance Colonoscopy', 'Data on 195 of the 221 patients (88.2%) enrolled in the previous RCT were collected from 28 institutions between 2008 and 2019']","['random biopsy', 'Panchromoendoscopy']","['Advanced neoplasia', 'advanced neoplasia (CRC or high-grade dysplasia) and colectomy due to neoplasia after the RCT', 'died of CRC', 'death from colorectal cancer (CRC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]","[{'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0009274', 'cui_str': 'Excision of colon'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",28.0,0.0353662,"The chance of developing CRC in patients with a negative colonoscopy was low, and the targeted biopsy appeared effective in this population.","[{'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Hata', 'Affiliation': 'Department of Surgical Oncology, The University Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.'}, {'ForeName': 'Soichiro', 'Initials': 'S', 'LastName': 'Ishihara', 'Affiliation': 'Department of Surgical Oncology, The University Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.'}, {'ForeName': 'Yoichi', 'Initials': 'Y', 'LastName': 'Ajioka', 'Affiliation': 'Division of Molecular and Diagnostic Pathology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan.'}, {'ForeName': 'Keiichi', 'Initials': 'K', 'LastName': 'Mitsuyama', 'Affiliation': 'Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Watanabe', 'Affiliation': 'Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Hanai', 'Affiliation': 'Center for Gastroenterology & IBD Research Hamamatsu South Hospital, 26 Shirowa-cho, Minami-ku, Hamamatsu 430-0846, Japan.'}, {'ForeName': 'Reiko', 'Initials': 'R', 'LastName': 'Kunisaki', 'Affiliation': 'Inflammatory Bowel Disease Center, Yokohama City University Medical Center, 4-57 Urafune, Minami-ku, Yokohama 232-0024, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nakase', 'Affiliation': 'Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo 060-8543 Japan.'}, {'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Matsuda', 'Affiliation': 'Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo 117-0033, Japan.'}, {'ForeName': 'Ryuichi', 'Initials': 'R', 'LastName': 'Iwakiri', 'Affiliation': 'Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga 849-8501, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Hida', 'Affiliation': 'Center for Inflammatory Bowel Disease, Division of Internal Medicine, Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Endoscopy, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.'}, {'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Takeuchi', 'Affiliation': 'Department of Medicine, Division of Gastroenterology, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Shinozaki', 'Affiliation': 'Department of Surgery, the Institute of Medical Science, the University of Tokyo, Tokyo 108-8639, Japan.'}, {'ForeName': 'Noriyuki', 'Initials': 'N', 'LastName': 'Ogata', 'Affiliation': 'Digestive Disease Center, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tsuzuki Yokohama 224-8503, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Moriichi', 'Affiliation': 'Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.'}, {'ForeName': 'Fumihito', 'Initials': 'F', 'LastName': 'Hirai', 'Affiliation': 'Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, 7-45-1 Nakanuma, Jonan-ku, Fukuoka 814-0180, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Sugihara', 'Affiliation': 'Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.'}, {'ForeName': 'Tadakazu', 'Initials': 'T', 'LastName': 'Hisamatsu', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo 181-8611, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Inflammatory Bowel Disease Center, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 285-8741, Japan.'}, {'ForeName': 'Mamoru', 'Initials': 'M', 'LastName': 'Watanabe', 'Affiliation': 'Department of Gastroenterology and Hepatology, Advanced Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, 5-9-1 Shirokanedai, Minato-ku, Tokyo 108-8642, Japan.'}]",Journal of clinical medicine,['10.3390/jcm9072286'] 2091,32716280,Cardiac rehabilitation in the paediatric Fontan population: development of a home-based high-intensity interval training programme.,"INTRODUCTION We evaluated the safety and feasibility of high-intensity interval training via a novel telemedicine ergometer (MedBIKE™) in children with Fontan physiology. METHODS The MedBIKE™ is a custom telemedicine ergometer, incorporating a video game platform and live feed of patient video/audio, electrocardiography, pulse oximetry, and power output, for remote medical supervision and modulation of work. There were three study phases: (I) exercise workload comparison between the MedBIKE™ and a standard cardiopulmonary exercise ergometer in 10 healthy adults. (II) In-hospital safety, feasibility, and user experience (via questionnaire) assessment of a MedBIKE™ high-intensity interval training protocol in children with Fontan physiology. (III) Eight-week home-based high-intensity interval trial programme in two participants with Fontan physiology. RESULTS There was good agreement in oxygen consumption during graded exercise at matched work rates between the cardiopulmonary exercise ergometer and MedBIKE™ (1.1 ± 0.5 L/minute versus 1.1 ± 0.5 L/minute, p = 0.44). Ten youth with Fontan physiology (11.5 ± 1.8 years old) completed a MedBIKE™ high-intensity interval training session with no adverse events. The participants found the MedBIKE™ to be enjoyable and easy to navigate. In two participants, the 8-week home-based protocol was tolerated well with completion of 23/24 (96%) and 24/24 (100%) of sessions, respectively, and no adverse events across the 47 sessions in total. CONCLUSION The MedBIKE™ resulted in similar physiological responses as compared to a cardiopulmonary exercise test ergometer and the high-intensity interval training protocol was safe, feasible, and enjoyable in youth with Fontan physiology. A randomised-controlled trial of a home-based high-intensity interval training exercise intervention using the MedBIKE™ will next be undertaken.",2020,"The MedBIKE™ resulted in similar physiological responses as compared to a cardiopulmonary exercise test ergometer and the high-intensity interval training protocol was safe, feasible, and enjoyable in youth with Fontan physiology.","['two participants with Fontan physiology', '10 healthy adults', 'Ten youth with Fontan physiology (11.5 ± 1.8 years old) completed a MedBIKE™ high-intensity interval training session with no adverse events', 'children with Fontan physiology', 'paediatric Fontan population']","['high-intensity interval training via a novel telemedicine ergometer (MedBIKE™', 'exercise workload comparison between the MedBIKE™ and a standard cardiopulmonary exercise ergometer', 'home-based high-intensity interval training exercise intervention', 'Cardiac rehabilitation', 'MedBIKE™ high-intensity interval training protocol']",['oxygen consumption'],"[{'cui': 'C0031842', 'cui_str': 'Physiology'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C4517534', 'cui_str': '11.5'}, {'cui': 'C4068742', 'cui_str': '1.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C1963761', 'cui_str': 'No adverse event'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}]",2.0,0.0310135,"The MedBIKE™ resulted in similar physiological responses as compared to a cardiopulmonary exercise test ergometer and the high-intensity interval training protocol was safe, feasible, and enjoyable in youth with Fontan physiology.","[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Khoury', 'Affiliation': ""Division of Pediatric Cardiology, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.""}, {'ForeName': 'Devin B', 'Initials': 'DB', 'LastName': 'Phillips', 'Affiliation': 'Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Wood', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Mott', 'Affiliation': 'Department of Computing Science, Faculty of Science, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Stickland', 'Affiliation': 'Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Boulanger', 'Affiliation': 'Department of Computing Science, Faculty of Science, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Gwen R', 'Initials': 'GR', 'LastName': 'Rempel', 'Affiliation': 'Faculty of Health Disciplines, Athabasca University, Alberta, Canada.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Conway', 'Affiliation': ""Division of Pediatric Cardiology, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.""}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Mackie', 'Affiliation': ""Division of Pediatric Cardiology, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.""}, {'ForeName': 'Nee S', 'Initials': 'NS', 'LastName': 'Khoo', 'Affiliation': ""Division of Pediatric Cardiology, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.""}]",Cardiology in the young,['10.1017/S1047951120002097'] 2092,32716291,A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence
.,"OBJECTIVES To establish the relative bioavailability between a newly developed oral gel and a marketed oral lyophilisate-containing rizatriptan benzoate. MATERIALS AND METHODS A total of 47 out of 48 healthy subjects, aged 34 ± 10 (SD) years and body mass index 24.7 ± 3.3 (SD) kg/m2 completed this single-center, open-label, randomized, 2-period cross-over trial with single-dose fasted administrations. Intake of both investigational products was separated by a washout period of at least 6 days. For pharmacokinetic evaluation, blood samples were withdrawn until 24 hours post dose. A validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was applied for the determination of rizatriptan in plasma. The lower limit of quantitation (LLOQ) was 0.100 ng/mL. Adverse events (AEs) were descriptively analyzed in the study population. Palatability of the new product was investigated based on a questionnaire. RESULTS The geometric means of the parameters related with the extent of total exposure, i.e., AUC 0-tlast and AUC 0-∞ , were 60.285 ng × h/mL and 60.865 ng × h/mL for test and 62.729 ng × h/mL and 63.312 ng × h/mL for reference, respectively. The geometric means of the peak exposure, i.e., C max , were 21.262 ng/mL for test and 21.447 ng/mL for reference. The point estimates (PEs) of the test/reference (T/R) adjusted geometric mean ratios of AUC 0-tlast , C max , and AUC 0-∞ (secondary parameter) were 96.11%, 99.12%, and 96.15%, respectively, and all of them showed 90% confidence intervals (CIs) within the range of 80.00 - 125.00% as suggested by regulatory requirements for bioequivalence assessment. In total, 13 subjects experienced 20 AEs during the trial; the most frequently reported AEs were headache (5 cases) and dizziness (3 cases). No AEs of severe intensity were reported. Palatability assessment of the new product provided sufficient data to discuss its acceptability. CONCLUSION Bioequivalence was demonstrated in terms of rate and extent of absorption after administration of test and reference products. Concerning the safety evaluation, no negative implications on the possible use of the test formulation could be determined. Based on ratings by the subjects no relevant problem concerning acceptability of the new formulation in particular regarding taste and smell is to be expected.",2020,Based on ratings by the subjects no relevant problem concerning acceptability of the new formulation in particular regarding taste and smell is to be expected.,"['A total of 47 out of 48 healthy subjects, aged 34 ± 10 (SD) years and body mass index 24.7 ± 3.3 (SD) kg/m2 completed this single-center, open-label, randomized, 2-period cross-over trial with single-dose fasted administrations']",['rizatriptan'],"['headache', 'dizziness', 'lower limit of quantitation (LLOQ', 'severe intensity', 'relative bioavailability', 'geometric mean ratios of AUC 0-tlast , C max , and AUC 0-∞']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0297635', 'cui_str': 'rizatriptan'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",48.0,0.078419,Based on ratings by the subjects no relevant problem concerning acceptability of the new formulation in particular regarding taste and smell is to be expected.,"[{'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Tellone', 'Affiliation': ''}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Dragone', 'Affiliation': ''}, {'ForeName': 'Rossella', 'Initials': 'R', 'LastName': 'Picollo', 'Affiliation': ''}, {'ForeName': 'Maria Teresa', 'Initials': 'MT', 'LastName': 'Rosignoli', 'Affiliation': ''}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Garofolo', 'Affiliation': ''}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Del Vecchio', 'Affiliation': ''}, {'ForeName': 'Fabrizio', 'Initials': 'F', 'LastName': 'Calisti', 'Affiliation': ''}, {'ForeName': 'Alessandro', 'Initials': 'A', 'LastName': 'Comandini', 'Affiliation': ''}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Donath', 'Affiliation': ''}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Schug', 'Affiliation': ''}, {'ForeName': 'Ralph-Steven', 'Initials': 'RS', 'LastName': 'Wedemeyer', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203652'] 2093,32716299,An mHealth Intervention (ReZone) to Help Young People Self-Manage Overwhelming Feelings: Cluster-Randomized Controlled Trial.,"BACKGROUND Mental health difficulties in young people are increasing, and there is a need for evidence on the effectiveness of digital interventions to increase opportunities for supporting mental health in young people. Such studies are complicated due to issues of implementation and adoption, outcome measurement, and appropriate study designs. OBJECTIVE The objective of this study was to examine the effectiveness of an mHealth intervention (ReZone) in reducing mental health difficulties in young people. METHODS The cluster-randomized controlled trial enrolled 409 participants aged 10-15 years, and classes were allocated to ReZone or management as usual. Self-reported questionnaires were completed at baseline and 3-month follow-up. RESULTS There were no significant differences between the ReZone condition and management as usual in the self-reported outcome measures. However, there were 3467 usage sessions, which corresponds to 16.9 times per student (total of 205 students) in classes allocated to ReZone. CONCLUSIONS It is essential to publish studies that do not show significant differences, as these findings can still contribute to the literature, help in learning, and inform the direction of future work. The results reported in this paper could be due to a range of reasons, including whether ReZone has the scope to impact change or limitations related to the setting, context, and appropriateness of an RCT. The findings of this study suggest that ReZone was implemented and adopted. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) RR2-10.2196/resprot.7019.",2020,There were no significant differences between the ReZone condition and management as usual in the self-reported outcome measures.,"['Young People', 'young people', '409 participants aged 10-15 years, and classes']","['mHealth Intervention (ReZone', 'mHealth intervention (ReZone']",['mental health difficulties'],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}]",409.0,0.0945038,There were no significant differences between the ReZone condition and management as usual in the self-reported outcome measures.,"[{'ForeName': 'Chloe', 'Initials': 'C', 'LastName': 'Edridge', 'Affiliation': 'Clinical, Educational and Health Psychology, University College London, London, United Kingdom.'}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Wolpert', 'Affiliation': 'Clinical, Educational and Health Psychology, University College London, London, United Kingdom.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Deighton', 'Affiliation': 'Clinical, Educational and Health Psychology, University College London, London, United Kingdom.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Edbrooke-Childs', 'Affiliation': 'Clinical, Educational and Health Psychology, University College London, London, United Kingdom.'}]",Journal of medical Internet research,['10.2196/14223'] 2094,32716303,Evaluating the Effects of a Mobile Health App on Reducing Patient Care Needs and Improving Quality of Life After Oral Cancer Surgery: Quasiexperimental Study.,"BACKGROUND Intervention with a mobile Health (mHealth) app can improve the efficacy of early detection of oral cancer and the outcomes for patients taking oral anticancer medications. The quality of life of oral cancer patients is significantly reduced within three months after surgery; also, their needs for nursing care and health information increase, mainly due to side effects and associated psychological problems. OBJECTIVE This study aimed to evaluate changes in the care needs and quality of life of patients with oral cancer after receiving the intervention of a newly developed mHealth app. METHODS After surgery, oral cancer patients were divided into an experimental group (n=50) who received the mHealth app intervention and a control group (n=50) who received routine health care and instruction. After 3 months of intervention, survey questionnaires were used to assess the patients' quality of life, nursing care needs, and acceptance of the mHealth app. RESULTS The physiological care needs were significantly decreased in the experimental group compared with the control group (P<.05). Although the differences were not statistically significant, the psychological needs, communication needs, and care support needs all improved after the mHealth app intervention. The overall improvement in quality of life was higher in the experimental group than in the control group (-7.24 vs -4.36). In terms of intention to use, perceived usefulness, and perceived ease of use, the acceptability scores of the mHealth app were significantly increased after 3 months of intervention (P<.05). CONCLUSIONS Compared with routine health care and instruction, for patients after surgery, the education/information intervention using the mHealth app significantly reduced their nursing care needs, improved their quality of life, and increased their acceptance of using an mHealth app on a mobile device. These findings can provide a theoretical basis for future health care app design and improvement. This study suggests that an mHealth app should be incorporated into the routine care of oral cancer patients to provide medical information quickly and improve their self-management abilities, thereby reducing the patients' need for physiological care and improving their quality of life. TRIAL REGISTRATION ClinicalTrials.gov NCT04049968; https://www.clinicaltrials.gov/ct2/show/NCT04049968.",2020,The overall improvement in quality of life was higher in the experimental group than in the control group (-7.24 vs -4.36).,"['After surgery, oral cancer patients', 'patients with oral cancer after receiving the intervention of a newly developed mHealth app', 'patients taking oral anticancer medications', 'oral cancer patients']","['Mobile Health App', 'mHealth app intervention and a control group (n=50) who received routine health care and instruction']","['quality of life', 'acceptability scores of the mHealth app', ""patients' quality of life, nursing care needs, and acceptance of the mHealth app"", 'psychological needs, communication needs, and care support needs', 'quality of life of oral cancer patients', 'Patient Care Needs and Improving Quality of Life']","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0153381', 'cui_str': 'Malignant tumor of oral cavity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0153381', 'cui_str': 'Malignant tumor of oral cavity'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0657756,The overall improvement in quality of life was higher in the experimental group than in the control group (-7.24 vs -4.36).,"[{'ForeName': 'Tze-Fang', 'Initials': 'TF', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, National Yang-Ming University, Taipei City, Taiwan.'}, {'ForeName': 'Rou-Chen', 'Initials': 'RC', 'LastName': 'Huang', 'Affiliation': 'School of Nursing, National Yang-Ming University, Taipei City, Taiwan.'}, {'ForeName': 'Su-Chen', 'Initials': 'SC', 'LastName': 'Yang', 'Affiliation': 'Department of Nursing, Far Eastern Memorial Hospital, New Taipei City, Taiwan.'}, {'ForeName': 'Chyuan', 'Initials': 'C', 'LastName': 'Chou', 'Affiliation': 'Excellent Dental Center, Taipei City, Taiwan.'}, {'ForeName': 'Lee-Chen', 'Initials': 'LC', 'LastName': 'Chen', 'Affiliation': 'Department of Nursing, Far Eastern Memorial Hospital, New Taipei City, Taiwan.'}]",JMIR mHealth and uHealth,['10.2196/18132'] 2095,32716540,Efficacy of Cleaning Methods for Ophthalmic Microscopic Instruments: A Comparison Study.,"The combination of silicone oil and blood is difficult to remove from ophthalmic surgical instruments during cleaning and decontamination processes. We sought to establish the most efficient cleaning procedure for this type of contaminated instrument. We uniformly contaminated microscopic instruments made of titanium alloy and stainless steel with either blood alone or blood and silicone oil. We randomly assigned each instrument to one of four types of cleaning procedures that involved combinations of water, a multi-enzyme detergent, or an alkaline detergent. After completing the designated cleaning procedure, a sterile processing technician used an adenosine triphosphate cleaning verification test to evaluate the cleaning efficacy. When cleaning blood- and silicone oil-contaminated titanium-alloy and stainless-steel instruments, the alkaline detergent immersion followed by a multi-enzyme detergent ultrasonic cleaning yielded the highest cleaning effectiveness score (92.5%), which indicates this was the most effective of the four cleaning procedures that we tested.",2020,"We randomly assigned each instrument to one of four types of cleaning procedures that involved combinations of water, a multi-enzyme detergent, or an alkaline detergent.",[],"['Cleaning Methods', 'silicone oil and blood', 'titanium alloy and stainless steel with either blood alone or blood and silicone oil', 'cleaning procedures that involved combinations of water, a multi-enzyme detergent, or an alkaline detergent']",['cleaning effectiveness score'],[],"[{'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0037111', 'cui_str': 'Silicone oil'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0076732', 'cui_str': 'titanium alloy (TiAl6V4)'}, {'cui': 'C0038126', 'cui_str': 'Stainless steel material'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0014442', 'cui_str': 'Enzyme'}, {'cui': 'C0011740', 'cui_str': 'Detergent'}]","[{'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0463481,"We randomly assigned each instrument to one of four types of cleaning procedures that involved combinations of water, a multi-enzyme detergent, or an alkaline detergent.","[{'ForeName': 'Wenzhe', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': ''}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Ye', 'Affiliation': ''}, {'ForeName': 'Xiaoqiong', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Peihua', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Senguo', 'Initials': 'S', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Qin', 'Affiliation': ''}, {'ForeName': 'Yanyan', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': ''}]",AORN journal,['10.1002/aorn.13105'] 2096,32716589,Platform switching in two-implant bar-retained mandibular overdentures: 1-year results from a split-mouth randomized controlled clinical trial.,"OBJECTIVES The concept of platform switching is widely applied in current implant dentistry, however, the influence on peri-implant bone level alterations (ΔIBL), especially in the field of implant overdentures (IODs), remains inconclusive. Therefore, the present study aimed to test the alternative hypothesis that there is an equivalent ΔIBL at platform-switching and platform-matching implant abutments in 2-implant bar-retained IODs. MATERIALS AND METHODS Two interforaminal implants were placed in 32 subjects, who were randomly assigned to either an immediate- or a 3-month post-placement loading group. Furthermore, one implant in each subject was randomly assigned to receive a platform-switched (test), and one a platform-matching abutment (control). The implants were splinted with prefabricated, chairside customized bars. ΔIBL was recorded by using customized radiograph holders at implant placement, implant loading, 3 months, 6 months, and 12 months after loading. RESULTS After one year, equivalent ΔIBL could be identified (test: -0.51 mm +/- 0.49 vs. control: -0.56 mm +/- 0.52; p<0.001). ΔIBL increased over time and was more pronounced in the delayed-loaded (-0.87 mm +/- 0.61) relative to the immediately loaded implants (-0.35 mm +/- 0.43; p = 0.022). CONCLUSIONS The prosthetic concept of platform switching does not necessarily lead to reduced bone loss. Immediate loading of implants, primarily splinted with a bar, might be beneficial regarding peri-implant bone-level changes over a short-term period.",2020,"Immediate loading of implants, primarily splinted with a bar, might be beneficial regarding peri-implant bone-level changes over a short-term period.",['Two interforaminal implants were placed in 32 subjects'],[],"['ΔIBL', 'bone loss']","[{'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0442504', 'cui_str': 'Place'}]",[],"[{'cui': 'C0029453', 'cui_str': 'Osteopenia'}]",32.0,0.0683944,"Immediate loading of implants, primarily splinted with a bar, might be beneficial regarding peri-implant bone-level changes over a short-term period.","[{'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Abou-Ayash', 'Affiliation': 'Department of Reconstructive Dentistry and Gerodontology, University of Bern, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schimmel', 'Affiliation': 'Department of Reconstructive Dentistry and Gerodontology, University of Bern, Switzerland.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Kraus', 'Affiliation': 'Department of Prosthodontics, Preclinical Education and Dental Material Science, University of Bonn, Germany.'}, {'ForeName': 'Regina', 'Initials': 'R', 'LastName': 'Mericske-Stern', 'Affiliation': 'School of Dental Medicine, University of Bern, Switzerland.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': 'Albrecht', 'Affiliation': 'Private Practice, St. Gallen, Switzerland.'}, {'ForeName': 'Norbert', 'Initials': 'N', 'LastName': 'Enkling', 'Affiliation': 'Department of Reconstructive Dentistry and Gerodontology, University of Bern, Switzerland.'}]",Clinical oral implants research,['10.1111/clr.13640'] 2097,32716603,The effect of adjuvant oral irrigation on self-administered oral care in the management of peri-implant mucositis. A randomized controlled clinical trial.,"OBJECTIVES This single blinded randomized clinical trial evaluated the effect of adjuvant oral irrigation in addition to self-administered oral care on prevalence and severity of peri-implant mucositis. MATERIAL & METHODS After randomization, patients suffering from peri-implant mucositis were assigned to the following: Group 1 (control) received oral hygiene instruction following a standardized protocol, including a sub- and supramucosal mechanical debridement. Group 2 and 3 additionally were instructed to use an oral irrigator with either water or 0.06% CHX solution. One implant per patient was considered for examination. Clinical examinations included probing depth (PD), bleeding on probing (BOP-positive sites), modified plaque and gingiva-index (mPI, mGI). A surrogate variable (mucositis-severity-score) was applied measuring severity of disease. Statistical analysis included linear regression models and sensitivity analysis. RESULTS 60 periodontally healthy patients were examined for presence and severity of peri-implant mucositis. 70% of all patients reached complete resolution of disease after 12-weeks. The prevalence of peri-implant mucositis after 12 weeks was 50% in group 1, 35% in group 2, and 5% in group 3. Average BOP-positive sites were reduced in all groups after 12 weeks (mean change from baseline: group 1: -1.5; group 2: -1.8; group 3: -2.3). CONCLUSION Within the limits of the study, adjuvant use of an oral irrigator with 0.06% CHX in addition to mechanical biofilm removal and oral hygiene instruction can reduce the presence and severity of peri-implant mucositis after 12-weeks.",2020,"The prevalence of peri-implant mucositis after 12 weeks was 50% in group 1, 35% in group 2, and 5% in group 3.","['peri-implant mucositis', 'patients suffering from peri-implant mucositis', '60', 'periodontally healthy patients']","['oral hygiene instruction following a standardized protocol, including a sub- and supramucosal mechanical debridement', 'adjuvant oral irrigation', 'oral irrigator with either water or 0.06% CHX solution']","['prevalence of peri-implant mucositis', 'presence and severity of peri-implant mucositis', 'probing depth (PD), bleeding on probing (BOP-positive sites), modified plaque and gingiva-index (mPI, mGI', 'Average BOP-positive sites', 'complete resolution of disease']","[{'cui': 'C3698407', 'cui_str': 'Peri-implant mucositis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0204131', 'cui_str': 'Oral hygiene education'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0399271', 'cui_str': 'Oral irrigation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0335463', 'cui_str': 'Irrigator'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C3698407', 'cui_str': 'Peri-implant mucositis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0663932', 'cui_str': 'SLPI protein, human'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",60.0,0.0604381,"The prevalence of peri-implant mucositis after 12 weeks was 50% in group 1, 35% in group 2, and 5% in group 3.","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bunk', 'Affiliation': 'Clinic of Prosthetic Dentistry and Biomedical Materials Science, Hannover Medical School, Hanover, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Eisenburger', 'Affiliation': 'Clinic of Prosthetic Dentistry and Biomedical Materials Science, Hannover Medical School, Hanover, Germany.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Häckl', 'Affiliation': 'Institute for Biostatistics, Hannover Medical School, Hanover, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Eberhard', 'Affiliation': 'The University of Sydney, School of Dentistry and the Charles Perkins Centre, Faculty of Health and Medicine, The University of Sydney, Sydney, Australia.'}, {'ForeName': 'Meike', 'Initials': 'M', 'LastName': 'Stiesch', 'Affiliation': 'Clinic of Prosthetic Dentistry and Biomedical Materials Science, Hannover Medical School, Hanover, Germany.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Grischke', 'Affiliation': 'Clinic of Prosthetic Dentistry and Biomedical Materials Science, Hannover Medical School, Hanover, Germany.'}]",Clinical oral implants research,['10.1111/clr.13638'] 2098,32711414,Incremental Benefits of Multiple Tobacco Control Interventions: A Factorial Randomized Control Trial.,"Tobacco control requires a comprehensive approach. The present study aims to examine the incremental effectiveness of health systems intervention when combined with other interventions in enhancing knowledge and practices of physicians in tobacco cessation. METHODS A randomized control trial was conducted among 437 physicians in 12 districts of two states of India in 2011-13. The interventions consisted of Health Systems (H), Community (C) and Youth intervention (Y). Administrative Blocks /Mandals were randomly assigned to one of the three interventions (HC /HCY/HY) and control units. The health system intervention consisted of training physicians and developing a system of patient support and supervision for tobacco cessation. The primary outcome was change in knowledge and practices of physicians in tobacco cessation. Logistic regression model was applied to assess the impact of single and combination of interventions. RESULTS An increase in knowledge was observed on effects of tobacco on adverse birth outcomes, advice on NRT and, information provided on chronic disease management among physicians in HC, HY and HCY intervention units compared to control units from pre-intervention to post-intervention. Statistically significant change was observed in knowledge of physicians on effects of tobacco on adverse birth outcomes in HC (OR- 4.75, p-0.02) and HCY (OR- 5.08, p-0.04) intervention units. CONCLUSIONS HCY intervention was most effective in enhancing knowledge and practices of physicians in tobacco cessation. Our study suggests that individual tobacco control interventions when combined together has an incremental effect and increases the likelihood of provision of tobacco cessation services in primary care. 
.",2020,"An increase in knowledge was observed on effects of tobacco on adverse birth outcomes, advice on NRT and, information provided on chronic disease management among physicians in HC, HY and HCY intervention units compared to control units from pre-intervention to post-intervention.","['437 physicians in 12 districts of two states of India in 2011-13', 'Administrative Blocks /Mandals']","['Health Systems (H), Community (C) and Youth intervention (Y', 'health systems intervention', 'HCY intervention', 'Multiple Tobacco Control Interventions']","['change in knowledge and practices of physicians in tobacco cessation', 'adverse birth outcomes']","[{'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0040329', 'cui_str': 'Tobacco'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0600549', 'cui_str': 'Tobacco Cessation'}, {'cui': 'C1286282', 'cui_str': 'Birth outcome'}]",,0.0620255,"An increase in knowledge was observed on effects of tobacco on adverse birth outcomes, advice on NRT and, information provided on chronic disease management among physicians in HC, HY and HCY intervention units compared to control units from pre-intervention to post-intervention.","[{'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Persai', 'Affiliation': 'Indian Institute of Public Health, Public Health Foundation of India, Delhi NCR, India.'}, {'ForeName': 'Anup', 'Initials': 'A', 'LastName': 'Karan', 'Affiliation': 'Indian Institute of Public Health, Public Health Foundation of India, Delhi NCR, India.'}, {'ForeName': 'Rajmohan', 'Initials': 'R', 'LastName': 'Panda', 'Affiliation': 'Indian Institute of Public Health, Public Health Foundation of India, Delhi NCR, India.'}]",Asian Pacific journal of cancer prevention : APJCP,['10.31557/APJCP.2020.21.7.1905'] 2099,32711435,"The Outcome of a Self-Efficacy Enhancement Program for Cervical Cancer Screening among Women in Phrasaeng District, Suratthani Province, Thailand.","OBJECTIVE The purpose of this research was to examine the effect of a self-efficacy enhancement program on perceived self-efficacy and cervical cancer screening among women. METHODS This research was quasi-experimental research, using the subjects consisted of 130 samples; each of the experimental and control group consisted of 65 samples. The experimental group received a self-efficacy enhancement program. The control group received knowledge and usual care by health personnel in the health promoting hospital. The duration of the research was 8 weeks. The self-efficacy was testing the reliability equal to 0.90. Data were analyzed using descriptive statistics, Chi-square, and t-test. RESULTS The mean scores of perceived self-efficacy between the experimental and control group before using the program (M=2.18, S.D.=0.40; M=2.22, S.D.=0.39), there was no significantly different (p> 0.05). The mean scores of perceived self-efficacy between the experimental and control group after using the program (M=4.11, S.D.=0.44; M=2.28, S.D.=0.42), there was a significantly different (p< 0.001). The mean scores of perceived self-efficacy of the experimental group before and after using the program were higher, (M=2.18, S.D.=0.40; M=4.11, S.D.=0.44), there was a significantly different (p< 0.001). The experimental group came to screening 64 people (98.5 %), and the control group came to screening eight people (12.3 %), calculated ratio as 8:1 and compared the cervical cancer screening in the experimental and control group had differences significantly (p< 0.001). CONCLUSION The self-efficacy enhancement program, resulting in increased screening rates and screened after the first week by having most screening tests in the community. Therefore, the program should be applied, and proactive services should be provided for women to have access in community and a health service place.
.",2020,"The mean scores of perceived self-efficacy of the experimental group before and after using the program were higher, (M=2.18, S.D.=0.40; M=4.11, S.D.=0.44), there was a significantly different (p< 0.001).","['Cervical Cancer Screening among Women in Phrasaeng District, Suratthani Province, Thailand', 'women']","['knowledge and usual care by health personnel in the health promoting hospital', 'self-efficacy enhancement program']","['cervical cancer screening', 'mean scores of perceived self-efficacy', 'self-efficacy and cervical cancer screening']","[{'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4075891', 'cui_str': 'Enhancement of self-efficacy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",,0.0170426,"The mean scores of perceived self-efficacy of the experimental group before and after using the program were higher, (M=2.18, S.D.=0.40; M=4.11, S.D.=0.44), there was a significantly different (p< 0.001).","[{'ForeName': 'Ornuma', 'Initials': 'O', 'LastName': 'Bunkarn', 'Affiliation': 'School of Nursing, Walailak University, Thasala, Nakhon Si Thammarat, Thailand.'}, {'ForeName': 'Kiatkamjorn', 'Initials': 'K', 'LastName': 'Kusol', 'Affiliation': 'School of Nursing, Walailak University, Thasala, Nakhon Si Thammarat, Thailand.'}, {'ForeName': 'Thidarat', 'Initials': 'T', 'LastName': 'Eksirinimit', 'Affiliation': 'School of Nursing, Walailak University, Thasala, Nakhon Si Thammarat, Thailand.'}]",Asian Pacific journal of cancer prevention : APJCP,['10.31557/APJCP.2020.21.7.2075'] 2100,32711440,Efficacy Oral Glutamine to Prevent Oral Mucositis and Reduce Hospital Costs During Chemotherapy in Children with Acute Lymphoblastic Leukemia.,"OBJECTIVE To investigate the use of glutamine administered orally during Methotrexate chemotherapy to prevent oral mucositis and reduce hospital costs in children with acute lymphoblastic leukemia (ALL). METHODS Twenty-four children received oral glutamine (400 mg/kg body weight per day) and twenty four received placebo on days of chemotherapy administration and for at least 14 additional days. Oral mucositis  was graded daily at each day of treatment till completion of therapy. The study groups were compared for the oral mucositis development using the WHO scale. RESULTS Oral mucositis occurred in 4.2 % of the glutamine group and 62.5% in the placebo group. The use of glutamine was directly associated with prevention of oral mucositis than placebo (OR 0,026; 95% CI: 0,003-0,228). The duration of length hospital stay was lower in the glutamine group than in the placebo group ((8 vs 12 days); p = 0,005). Hospital cost per day for glutamine group was 40 USD per day while placebo group was 48 USD per day. CONCLUSIONS There was significant difference in the prevention of oral mucositis by oral glutamine vs placebo. The hospital cost for glutamine supplementation was lower than control group.",2020,"The use of glutamine was directly associated with prevention of oral mucositis than placebo (OR 0,026; 95% CI: 0,003-0,228).","['Children with Acute Lymphoblastic Leukemia', 'Twenty-four children received', 'children with acute lymphoblastic leukemia (ALL']","['oral glutamine', 'Glutamine', 'glutamine', 'Methotrexate chemotherapy', 'placebo']","['prevention of oral mucositis', 'Oral mucositis', 'Oral Mucositis and Reduce Hospital Costs', 'hospital cost for glutamine supplementation', 'oral mucositis and reduce hospital costs', 'duration of length hospital stay', 'oral mucositis', 'Hospital cost']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C3715070', 'cui_str': '24'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0206174', 'cui_str': 'Cost, Hospital'}, {'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}]",24.0,0.099924,"The use of glutamine was directly associated with prevention of oral mucositis than placebo (OR 0,026; 95% CI: 0,003-0,228).","[{'ForeName': 'Nur Aisiyah', 'Initials': 'NA', 'LastName': 'Widjaja', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.'}, {'ForeName': 'Ardha', 'Initials': 'A', 'LastName': 'Pratama', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.'}, {'ForeName': 'Rendi', 'Initials': 'R', 'LastName': 'Prihaningtyas', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.'}, {'ForeName': 'Roedi', 'Initials': 'R', 'LastName': 'Irawan', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.'}, {'ForeName': 'Idg', 'Initials': 'I', 'LastName': 'Ugrasena', 'Affiliation': 'Department of Child Health, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.'}]",Asian Pacific journal of cancer prevention : APJCP,['10.31557/APJCP.2020.21.7.2117'] 2101,32711493,Correction to: On-site multi-component intervention to improve productivity and reduce the economic and personal burden of neck pain in Swiss office-workers (NEXpro): protocol for a cluster-randomized controlled trial.,An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,['Swiss office-workers (NEXpro'],[],[],"[{'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C1306056', 'cui_str': 'Worker'}]",[],[],,0.101378,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Aegerter', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland. andrea.aegerter@zhaw.ch.'}, {'ForeName': 'Manja', 'Initials': 'M', 'LastName': 'Deforth', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Venerina', 'Initials': 'V', 'LastName': 'Johnston', 'Affiliation': 'The University of Queensland, School of Health and Rehabilitation Sciences, Brisbane, Queensland, Australia.'}, {'ForeName': 'Markus J', 'Initials': 'MJ', 'LastName': 'Ernst', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Volken', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Hannu', 'Initials': 'H', 'LastName': 'Luomajoki', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Brunner', 'Affiliation': 'ZHAW School of Management and Law, Winterthur Institute of Health Economics, Gertrudstrasse 15, 8401, Winterthur, Switzerland.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Dratva', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': 'Gisela', 'Initials': 'G', 'LastName': 'Sjøgaard', 'Affiliation': 'Department of Sport Sciences and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Achim', 'Initials': 'A', 'LastName': 'Elfering', 'Affiliation': 'University of Bern, Institute of Psychology, Fabrikstrasse 8, 3012, Bern, Switzerland.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Melloh', 'Affiliation': 'ZHAW School of Health Professions, Technikumstrasse 71, 8400, Winterthur, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03507-8'] 2102,32711519,Avenanthramide supplementation reduces eccentric exercise-induced inflammation in young men and women.,"BACKGROUND Avenanthramides (AVA) are a group of di-phenolic acids found only in oats and have shown antioxidant and anti-inflammatory effects in vitro and in vivo. Eccentric muscle contraction is intimately involved in rigorous exercise that activates systemic and local inflammatory responses. The objective of the study is to evaluate whether chronic AVA supplementation could attenuate peripheral inflammatory and immunological markers in human subjects in response to an acute bout of downhill running (DR). METHODS Eleven male and thirteen female subjects voluntarily participated in this double-blinded, randomized controlled study and were randomly divided into AVA-supplemented (AVA) or control (C) groups. All subjects conducted a DR protocol at - 10% grade with an intensity equivalent to 75% of their maximal heart rate. Blood samples were collected at rest and various time points (0-72 h) after DR (PRE). After an 8-week washout period, participants received two cookies daily containing either 206 mg/kg (AVA) or 0 mg/kg (C) AVA for 8 weeks. Following the oat supplementation regimen, the DR and blood sampling protocols were repeated (POST). Plasma inflammatory and immunological markers were measured using Multiplex immunoassay and muscle soreness was evaluated with pain rating scale. RESULTS DR increased plasma creatine kinase (CK) activity (P < 0.01) during PRE, but the response was reduced at 24 and 48 h during POST vs. PRE regardless of AVA status (P < 0.05). Neutrophil respiratory burst (NRB) levels were elevated at 4 and 24 h (P < 0.05) during PRE but were significantly decreased at 0-48 h during POST vs. PRE (P < 0.05 or 0.01). Granulocyte-colony stimulating factor (G-CSF), the neutrophil stimulating cytokine, was also increased in response to DR but showed lower levels in AVA compared to C during POST vs. PRE (P < 0.05). Plasma interleukin-6 (IL-6) content showed an increase at 0 and 4 h during PRE and 0 h during POST (P < 0.01), whereas during POST there was a trend toward a lower IL-6 level in AVA vs. C (P = 0.082). Plasma levels of anti-inflammatory agent interleukin-1 receptor antagonist (IL-1Ra) showed an increase at 4 h during PRE, and was significantly elevated in AVA vs. C during POST. Both soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) contents increased at 0 and 24 h post DR during PRE as well as POST sessions, however, sVCAM-1 content was lower in AVA vs. C during POST (P < 0.05) and MCP-1 levels were below resting level at 24, 48 and 72 h during POST (P < 0.05). DR increased muscle pain at all post-DR time points (P < 0.01), but the pain level was alleviated by oat supplementation at 48 and 72 h during POST regardless of AVA treatment (P < 0.05). CONCLUSIONS Oat AVA supplementation reduced circulatory inflammatory cytokines and inhibited expression of chemokines and cell adhesion molecules induced by DR. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02584946 . Registered 23 October 2015.",2020,"Both soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) contents increased at 0 and 24 h post DR during PRE as well as POST sessions, however, sVCAM-1 content was lower in AVA vs. C during POST (P < 0.05) and MCP-1 levels were below resting level at 24, 48 and 72 h during POST (P < 0.05).","['young men and women', 'human subjects in response to an acute bout of downhill running (DR', 'Eleven male and thirteen female subjects voluntarily participated']","['chronic AVA supplementation', 'Avenanthramide supplementation', 'AVA-supplemented (AVA) or control (C', 'cookies daily containing either 206\u2009mg/kg (AVA) or 0\u2009mg/kg (C) AVA', 'Oat AVA supplementation']","['pain level', 'Neutrophil respiratory burst (NRB) levels', 'MCP-1 levels', 'Plasma levels of anti-inflammatory agent interleukin-1 receptor antagonist (IL-1Ra', 'Blood samples', 'pain rating scale', 'circulatory inflammatory cytokines and inhibited expression of chemokines and cell adhesion molecules', 'Plasma inflammatory and immunological markers', 'DR increased muscle pain', 'eccentric exercise-induced inflammation', 'soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) contents', 'peripheral inflammatory and immunological markers', 'sVCAM-1 content', 'Plasma interleukin-6 (IL-6) content', 'plasma creatine kinase (CK) activity', 'IL-6 level']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0035953', 'cui_str': 'Running'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C3715149', 'cui_str': '13'}]","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0083355', 'cui_str': 'MAZE protocol'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1956476', 'cui_str': 'avenanthramide'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3853210', 'cui_str': 'Cookie'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0028753', 'cui_str': 'Oats'}]","[{'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0085416', 'cui_str': 'Oxidative Burst'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0128897', 'cui_str': 'Monocyte Chemoattractant Protein-1'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C1704264', 'cui_str': 'Interleukin 1 Inhibitor, Urine'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0282554', 'cui_str': 'Cytokines, Chemotactic'}, {'cui': 'C0007578', 'cui_str': 'Cell Adhesion Molecules'}, {'cui': 'C0205470', 'cui_str': 'Immunologic'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0078056', 'cui_str': 'Lymphocyte antigen CD106'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0858114', 'cui_str': 'Plasma creatine'}, {'cui': 'C0031727', 'cui_str': 'Kinase'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",11.0,0.12927,"Both soluble vascular cell adhesion molecule-1 (sVCAM-1) and monocyte chemoattractant protein-1 (MCP-1) contents increased at 0 and 24 h post DR during PRE as well as POST sessions, however, sVCAM-1 content was lower in AVA vs. C during POST (P < 0.05) and MCP-1 levels were below resting level at 24, 48 and 72 h during POST (P < 0.05).","[{'ForeName': 'Tianou', 'Initials': 'T', 'LastName': 'Zhang', 'Affiliation': 'Laboratory of Exercise and Sports Nutrition (LESN), Department of Kinesiology, The University of Texas at San Antonio, San Antonio, TX, 78249, USA.'}, {'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Zhao', 'Affiliation': 'Laboratory of Physiological Hygiene and Exercise Science (LPHES), School of Kinesiology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Yuzi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Laboratory of Physiological Hygiene and Exercise Science (LPHES), School of Kinesiology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Liu', 'Affiliation': 'Laboratory of Physiological Hygiene and Exercise Science (LPHES), School of Kinesiology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Gagnon', 'Affiliation': 'Ceapro Inc., Edmonton, AB, T6E 6W2, Canada.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Ebrahim', 'Affiliation': 'Ceapro Inc., Edmonton, AB, T6E 6W2, Canada.'}, {'ForeName': 'Jodee', 'Initials': 'J', 'LastName': 'Johnson', 'Affiliation': 'PepsiCo R&D Nutrition, Barrington, IL, 60010, USA.'}, {'ForeName': 'Yi-Fang', 'Initials': 'YF', 'LastName': 'Chu', 'Affiliation': 'PepsiCo R&D Nutrition, Barrington, IL, 60010, USA.'}, {'ForeName': 'Li Li', 'Initials': 'LL', 'LastName': 'Ji', 'Affiliation': 'Laboratory of Physiological Hygiene and Exercise Science (LPHES), School of Kinesiology, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA. llji@umn.edu.'}]",Journal of the International Society of Sports Nutrition,['10.1186/s12970-020-00368-3'] 2103,32711523,Long-term outcomes (2 and 3.5 years post-intervention) of the INFANT early childhood intervention to improve health behaviors and reduce obesity: cluster randomised controlled trial follow-up.,"BACKGROUND The few health behavior interventions commencing in infancy have shown promising effects. Greater insight into their longer-term benefits is required. This study aimed to assess post-intervention effects of the Melbourne INFANT Program to child age 5y on diet, movement and adiposity. METHODS Two and 3.5y post-intervention follow-up (2011-13; analyses completed 2019) of participants retained in the Melbourne INFANT Program at its conclusion (child age ~ 19 m; 2008-10) was conducted. The Melbourne INFANT Program is a 15-month, six session program delivered within first-time parent groups in Melbourne, Australia, between child age 4-19 m. It involves strategies to help parents promote healthy diet, physical activity and reduced sedentary behavior in their infants. No intervention was delivered during the follow-up period reported in this paper. At all time points height, weight and waist circumference were measured by researchers, children wore Actigraph and activPAL accelerometers for 8-days, mothers reported children's television viewing and use of health services. Children's dietary intake was reported by mothers in three unscheduled telephone-administered 24-h recalls. RESULTS Of those retained at program conclusion (child age 18 m, n = 480; 89%), 361 families (75% retention) participated in the first follow-up (2y post-intervention; age 3.6y) and 337 (70% retention) in the second follow-up (3.5y post-intervention; age 5y). At 3.6y children in the intervention group had higher fruit (adjusted mean difference [MD] = 25.34 g; CI 95 :1.68,48.99), vegetable (MD = 19.41; CI 95 :3.15,35.67) and water intake (MD = 113.33; CI 95 :40.42,186.25), than controls. At 5y they consumed less non-core drinks (MD = -27.60; CI 95 :-54.58,-0.62). Sweet snack intake was lower for intervention children at both 3.6y (MD = -5.70; CI 95 :-9.75,-1.65) and 5y (MD = -6.84; CI 95 :-12.47,-1.21). Intervention group children viewed approximately 10 min/day less television than controls at both follow-ups, although the confidence intervals spanned zero (MD = -9.63; CI 95 :-30.79,11.53; MD = -11.34; CI 95 :-25.02,2.34, respectively). There was no evidence for effect on zBMI, waist circumference z-score or physical activity. CONCLUSIONS The impact of this low-dose intervention delivered during infancy was still evident up to school commencement age for several targeted health behaviors but not adiposity. Some of these effects were only observed after the conclusion of the intervention, demonstrating the importance of long-term follow-up of interventions delivered during early childhood. TRIAL REGISTRATION ISRCTN Register ISRCTN81847050 , registered 7th November 2007.",2020,"At 5y they consumed less non-core drinks (MD = -27.60; CI 95 :-54.58,-0.62).","['child age 18\u2009m, n\u2009', '480; 89%), 361 families (75% retention) participated in the first follow-up (2y post-intervention; age 3.6y) and 337 (70% retention) in the second follow-up (3.5y post-intervention; age 5y']","['Melbourne INFANT Program', 'INFANT early childhood intervention']","[""children's television viewing and use of health services"", 'Sweet snack intake', ""Children's dietary intake"", 'health behaviors and reduce obesity', 'zBMI, waist circumference z-score or physical activity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205436', 'cui_str': 'Second'}]","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0039461', 'cui_str': 'Television'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}, {'cui': 'C0085077', 'cui_str': 'Acute febrile neutrophilic dermatosis'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.173757,"At 5y they consumed less non-core drinks (MD = -27.60; CI 95 :-54.58,-0.62).","[{'ForeName': 'Kylie D', 'Initials': 'KD', 'LastName': 'Hesketh', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia. kylieh@deakin.edu.au.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Salmon', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'McNaughton', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Crawford', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Abbott', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}, {'ForeName': 'Adrian J', 'Initials': 'AJ', 'LastName': 'Cameron', 'Affiliation': 'Global Obesity Centre (GLOBE), Institute for Health Transformation, School of Health and Social Development, Deakin University, Geelong, Australia.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Lioret', 'Affiliation': 'Université de Paris, Research Center in Epidemiology and Biostatistics (CRESS), INSERM, INRA, Paris, France.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Gold', 'Affiliation': 'School of Health and Social Development, Deakin University, Geelong, Australia.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Downing', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Campbell', 'Affiliation': 'School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition, Deakin University, Geelong, Australia.'}]",The international journal of behavioral nutrition and physical activity,['10.1186/s12966-020-00994-9'] 2104,32711565,"Proposal for a new therapeutic high dosage of Pidotimod in children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: a randomized controlled study.","BACKGROUND Despite to PFAPA syndrome is considered a benign and self-limited condition in childhood its impact on patients and families can be remarkable in many cases. Currently, the therapeutic options for managing are non-specific and no consensus exists about the best treatment to use. Pidotimod has been suggested as a new potential treatment in PFAPA syndrome for its immunodulatory effects. We conducted a preliminary, prospective, controlled, open, cross-over trial to assess the efficacy and the safety of Pidotimod in the treatment of children with PFAPA syndrome. METHODS 22 children with PFAPA syndrome were randomly allocated to treatment with pidotimod (with 2 vials of 400 mg daily) in combination with betamethasone 0.5-1 mg on need, based on parents/caregivers' decision (group A) or betamethasone 0.5-1 mg on need, based on parents/caregivers' decision (group B). Each treatment period was for 3 months (Phase 1), after that patients were switched to the other arm for other 3 months (Phase 2). Efficacy was expressed in terms of number of episodes of fever, pharyngitis, or aphthous stomatitis, as well as the additional use of betamethasone on need. Safety and tolerability of the Pidotimod were evaluated on the basis of the number and type of adverse events (AEs) recorded during the treatment. RESULTS Patients receiving Pidotimod and use betametasone showed a significant decrease in frequency of fevers (p = 0.002); number of episodes of pharyngitis (p = 0.049); aphthous stomatitis (p = 0.036) as well as the betamethasone use on need (p = 0.007). Overall, 19/22 (86.4%) showed benefits from Pidotimod administration. The safety profile of Pidotimod was excellent as no serious adverse events have been reported in the treated groups. CONCLUSIONS We firstly showed that high dosage of Pidotimod could be an effective and safe to reduce the PFAPA attacks in children.",2020,"RESULTS Patients receiving Pidotimod and use betametasone showed a significant decrease in frequency of fevers (p = 0.002); number of episodes of pharyngitis (p = 0.049); aphthous stomatitis (p = 0.036) as well as the betamethasone use on need (p = 0.007).","['22 children with PFAPA syndrome', 'children with PFAPA syndrome', 'children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome', 'children']","['betamethasone', ""pidotimod (with 2 vials of 400\u2009mg daily) in combination with betamethasone 0.5-1\u2009mg on need, based on parents/caregivers' decision (group A) or betamethasone 0.5-1\u2009mg on need, based on parents/caregivers' decision"", 'Pidotimod']","['aphthous stomatitis', 'Safety and tolerability', 'number of episodes of pharyngitis', 'Efficacy', 'frequency of fevers', 'number of episodes of fever, pharyngitis, or aphthous stomatitis']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4082167', 'cui_str': 'PFAPA syndrome'}, {'cui': 'C0015974', 'cui_str': 'Periodic fever'}, {'cui': 'C0038363', 'cui_str': 'Aphtha'}, {'cui': 'C0001344', 'cui_str': 'Acute pharyngitis'}, {'cui': 'C0001416', 'cui_str': 'Adenitis'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}]","[{'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0081002', 'cui_str': 'pidotimod'}, {'cui': 'C1706398', 'cui_str': 'Vial - unit of product usage'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0038363', 'cui_str': 'Aphtha'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0001344', 'cui_str': 'Acute pharyngitis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",22.0,0.0251606,"RESULTS Patients receiving Pidotimod and use betametasone showed a significant decrease in frequency of fevers (p = 0.002); number of episodes of pharyngitis (p = 0.049); aphthous stomatitis (p = 0.036) as well as the betamethasone use on need (p = 0.007).","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Manti', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Filosco', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Giuseppe Fabio', 'Initials': 'GF', 'LastName': 'Parisi', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy. gf.parisi@policlinico.unict.it.'}, {'ForeName': 'Giuseppe Germano', 'Initials': 'GG', 'LastName': 'Finocchiaro', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Papale', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Giugno', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Barone', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Leonardi', 'Affiliation': 'Pediatric Respiratory Unit - San Marco Hospital, Department of Clinical and Experimental Medicine, University of Catania, Viale Carlo Azeglio Ciampi, 95121, Catania, Italy.'}]",Italian journal of pediatrics,['10.1186/s13052-020-00871-y'] 2105,32711568,Conducting clinical trials in sub-Saharan Africa: challenges and lessons learned from the Malawi Cryptosporidium study.,"BACKGROUND An effective drug to treat cryptosporidial diarrhea in HIV-infected individuals is a global health priority. Promising drugs need to be evaluated in endemic areas which may be challenged by both lack of resources and experience to conduct International Committee of Harmonisation-Good Clinical Practice (ICH-GCP)-compliant clinical trials. METHODS We present the challenges and lessons learned in implementing a phase 2A, randomized, double-blind, placebo-controlled trial of clofazimine, in treatment of cryptosporidiosis among HIV-infected adults at a single site in Malawi. RESULTS Primary challenges are grouped under study initiation, study population, study implementation, and cultural issues. The lessons learned primarily deal with regulatory system and operational barriers, and recommendations can be applied to other human experimental trials in low- and middle-income countries, specifically in sub-Saharan Africa. CONCLUSION This study demonstrated that initiating and implementing human experimental trials in sub-Saharan Africa can be challenging. However, solutions exist and successful execution requires careful planning, ongoing evaluation, responsiveness to new developments, and oversight of all trial operations.",2020,"The lessons learned primarily deal with regulatory system and operational barriers, and recommendations can be applied to other human experimental trials in low- and middle-income countries, specifically in sub-Saharan Africa. ",['cryptosporidiosis among HIV-infected adults at a single site in Malawi'],"['clofazimine', 'placebo']",[],"[{'cui': 'C0010418', 'cui_str': 'Cryptosporidiosis'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0024548', 'cui_str': 'Malawi'}]","[{'cui': 'C0008996', 'cui_str': 'Clofazimine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.362216,"The lessons learned primarily deal with regulatory system and operational barriers, and recommendations can be applied to other human experimental trials in low- and middle-income countries, specifically in sub-Saharan Africa. ","[{'ForeName': 'Neema', 'Initials': 'N', 'LastName': 'Toto', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Douglas', 'Affiliation': 'Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Gmeiner', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Lynn K', 'Initials': 'LK', 'LastName': 'Barrett', 'Affiliation': 'Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Lindblad', 'Affiliation': 'Emmes, Rockville, MD, USA.'}, {'ForeName': 'Lumbani', 'Initials': 'L', 'LastName': 'Makhaza', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Wilfred', 'Initials': 'W', 'LastName': 'Nedi', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Phulusa', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Gerald V', 'Initials': 'GV', 'LastName': 'Quinnan', 'Affiliation': 'Emmes, Rockville, MD, USA.'}, {'ForeName': 'Leigh A', 'Initials': 'LA', 'LastName': 'Sawyer', 'Affiliation': 'Emmes, Rockville, MD, USA.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Thole', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi.'}, {'ForeName': 'Wesley C', 'Initials': 'WC', 'LastName': 'Van Voorhis', 'Affiliation': 'Center for Emerging and Re-emerging Infectious Diseases (CERID), University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Pui-Ying', 'Initials': 'PY', 'LastName': 'Iroh Tam', 'Affiliation': 'Malawi-Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi. irohtam@mlw.mw.'}]",Trials,['10.1186/s13063-020-04620-8'] 2106,32711599,Benefits of a Nanosilver Nasal Spray for Postoperative Care of Patients with Chronic Rhinosinusitis.,"To explore tending to patients with chronic rhinosinusitis using a nanosilver compound. From February 2014 to August 2016, 112 surgical patients with chronic rhinosinusitis were randomly divided into an observation group and a control group. Patients in the observation group were given antibiotics, care to retain hemostasis, and other treatment after surgery. Patients in the observation group were administered treatment with bonbijing nano antibacterial water spray post-surgery. The progress of both groups recorded. Nanosilver is metallic silver of nanometer size. Nanosilver particles in the spray are approximately 25 nm in diameter, strongly inhibit growth of or kill dozens of pathogenic microorganisms, e.g., Escherichia coli . Postoperative pain in patients in the observation group was less than pain in the control group patients ( p < 0.05). Symptom and sign scores in observation group patients were lower than scores in control group patients ( p < 0.05). Incidence of adverse reactions and complications was also lower in observation group patients ( p <0.05). Use of nanosilver for tending to patients with chronic rhinosinusitis after surgery can significantly improve clinical symptoms and signs, and reduce adverse reactions and complications.",2020,Postoperative pain in patients in the observation group was less than pain in the control group patients ( p < 0.05).,"['patients with chronic rhinosinusitis using a nanosilver compound', 'From February 2014 to August 2016, 112 surgical patients with chronic rhinosinusitis', 'patients with chronic rhinosinusitis after surgery', 'Patients with Chronic Rhinosinusitis']","['Nanosilver Nasal Spray', 'bonbijing nano antibacterial water spray post-surgery']","['Symptom and sign scores', 'Postoperative pain', 'Incidence of adverse reactions and complications', 'pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0772313', 'cui_str': 'colloidal silver'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]","[{'cui': 'C0772313', 'cui_str': 'colloidal silver'}, {'cui': 'C0461725', 'cui_str': 'Nasal spray'}, {'cui': 'C0279516', 'cui_str': 'Antibacterial'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0037088', 'cui_str': 'Clinical finding'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",112.0,0.0241786,Postoperative pain in patients in the observation group was less than pain in the control group patients ( p < 0.05).,"[{'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': 'Department of Nursing Weifang Yidu Central Hospital, Weifang 262500, Shandong, PR China.'}, {'ForeName': 'Chenghua', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': 'Department of Nursing Weifang Yidu Central Hospital, Weifang 262500, Shandong, PR China.'}, {'ForeName': 'Xiaoning', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Nursing Weifang Yidu Central Hospital, Weifang 262500, Shandong, PR China.'}, {'ForeName': 'Liqun', 'Initials': 'L', 'LastName': 'Xing', 'Affiliation': 'Department of Nursing Jinan Infectious Diseases Hospital, Jinan 250013, Shandong, PR China.'}]",Journal of nanoscience and nanotechnology,['10.1166/jnn.2020.18891'] 2107,32711612,Study on the Effect of Nano Albumin Paclitaxel Combined with Carboplatin in the Treatment of Lung Squamous Cell Carcinoma.,"This study aims to compare the efficacy and side effects of albumin-binding paclitaxel plus carboplatin (NAB PC) and paclitaxel plus carboplatin (PC) in the first-line treatment of advanced non-small cell lung cancer (NSCLC). A total of 60 patients with advanced NSCLC diagnosed by histopathology or cytology were randomly divided into nab PC group (albumin-binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1) and PC group (paclitaxel 175 mg/mL, D1; carboplatin AUC = 6, D1), one cycle every three weeks. RECIST 1.1 standard was used to evaluate the short-term objective efficacy, and who acute and subacute toxicity classification standard was used to evaluate the toxicity. The total effective rate (RR) and disease control rate (DCR) of NAB PC group were 40.0% and 80.0%, respectively, which were higher than 23.3% and 60.0% of the PC group, respectively. This difference was statistically significant ( p < 0.05). In squamous cell carcinoma, the RR of NAB PC group and PC group were 57.1% (8/14) and 23.1% (3/13) respectively, with a statistically significant difference ( p < 0.05); in non-squamous cell carcinoma, the RR of the two groups were 25.0% (4/16) and 23.3% (4/17) without statistical significance ( p > 0.05). The median progression free survival time of the NAB PC group and PC group was 6.5 and 5.9 months, respectively, with no significant difference ( p >0.05). No significant difference arose in the incidence of grade III-IV toxicity between the two groups ( p > 0.05). The incidence of neutropenia in the NAB PC group was higher than that in the PC group ( p < 0.05). The therapeutic effect of paclitaxel combined with carboplatin in the treatment of advanced NSCLC is better, the effect of paclitaxel combined with carboplatin is better, and the side effects can be tolerated, which is worthy of clinical application. Patients are more satisfied with their care.",2020,No significant difference arose in the incidence of grade III-IV toxicity between the two groups ( p > 0.05).,"['advanced non-small cell lung cancer (NSCLC', 'Lung Squamous Cell Carcinoma', '60 patients with advanced NSCLC diagnosed by histopathology or cytology']","['nab PC group (albumin-binding paclitaxel 130 mg/mL, D1, D; carboplatin AUC = 6, D1) and PC group (paclitaxel 175 mg/mL, D1; carboplatin AUC', 'albumin-binding paclitaxel plus carboplatin (NAB PC) and paclitaxel plus carboplatin (PC', 'Nano Albumin Paclitaxel Combined with Carboplatin', 'paclitaxel combined with carboplatin']","['incidence of neutropenia', 'incidence of grade III-IV toxicity', 'toxicity', 'median progression free survival time', 'total effective rate (RR) and disease control rate (DCR']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0149782', 'cui_str': 'Squamous cell carcinoma of lung'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243140', 'cui_str': 'histopathology'}, {'cui': 'C0010818', 'cui_str': 'Cytology'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C4319552', 'cui_str': '130'}, {'cui': 'C0439294', 'cui_str': 'g/L'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0205617', 'cui_str': 'Poorly differentiated'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",60.0,0.0428994,No significant difference arose in the incidence of grade III-IV toxicity between the two groups ( p > 0.05).,"[{'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'School of Nursing, Chongqing Medical University, Chongqing 400016, PR China.'}, {'ForeName': 'Shaoyu', 'Initials': 'S', 'LastName': 'Mou', 'Affiliation': 'School of Nursing, Chongqing Medical University, Chongqing 400016, PR China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Tu', 'Affiliation': 'Department of Respiratory Medicine, Wuhan 4th Hospital, Wuhan 430034, Hubei, PR China.'}]",Journal of nanoscience and nanotechnology,['10.1166/jnn.2020.18880'] 2108,32711658,Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction.,"To assess the efficacy of intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis on clinical outcomes and risk of death in patients with acute cerebral infarction. Patients ( n = 258) with acute cerebral infarction, treated within 4-5 h of the episode, were grouped according to whether intravenous thrombolysis was performed using rt-PA or not. Both groups received routine treatment for cerebral infarction, but the former received rt-PA intravenously at a dosage of 0.9 mg/kg. The National Institutes of Health Stroke Scale (NIHSS) score, clinical efficacy, and risk of bleeding and death were compared between the two groups. The NIHSS score and clinical effects for the rt-PA group were more favorable than those of its counterpart ( P < 0.05), though there was no significant difference in risk of an intracranial hemorrhage. The mortality rate for the rt-PA group was lower than that of the control group ( P < 0.05). Administration of intravenous rt-PA thrombolysis within 4.5 h of an acute cerebral infarction had a significant impact and did not increase risk of intracranial hemorrhage or death.",2020,The mortality rate for the rt-PA group was lower than that of the control group ( P < 0.05).,"['patients with acute cerebral infarction', 'Patients ( n = 258) with acute cerebral infarction, treated within 4-5 h of the episode']","['Recombinant Tissue Plasminogen Activator', 'intravenous rt-PA thrombolysis', 'intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis']","['Health Stroke Scale (NIHSS) score, clinical efficacy, and risk of bleeding and death', 'NIHSS score and clinical effects', 'intracranial hemorrhage or death', 'Acute Cerebral Infarction', 'risk of an intracranial hemorrhage', 'mortality rate', 'clinical outcomes and risk of death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}]","[{'cui': 'C0032143', 'cui_str': 'alteplase'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0520997', 'cui_str': 'Thrombolysis'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1697238', 'cui_str': 'NIH stroke scale'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0151699', 'cui_str': 'Intracranial hemorrhage'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",258.0,0.0172602,The mortality rate for the rt-PA group was lower than that of the control group ( P < 0.05).,"[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology, Linyi Central Hospital, Linyi 276400, Shandong, PR China.'}, {'ForeName': 'Peiling', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Infectious Disease, Linyi Central Hospital, Linyi 276400, Shandong, PR China.'}, {'ForeName': 'Deke', 'Initials': 'D', 'LastName': 'Sun', 'Affiliation': 'Department of Neurology, Linyi Central Hospital, Linyi 276400, Shandong, PR China.'}]",Journal of nanoscience and nanotechnology,['10.1166/jnn.2020.18875'] 2109,32711663,Multimedia intervention for specific phobias: A clinical and experimental study.,"BACKGROUND Exposure is the treatment of choice for specific phobias. We present an experimental and clinical study on the efficacy of the progressive multimedia exposure procedure for specific phobias. METHOD The sample size consisted of 36 individuals, 7 men and 29 women (mean age: 29 years old), with different types of specific phobias. A combined between-groups (3x4) with repeated measures design was used, including several follow-ups up to 3 years. Participants were assigned to different groups: Experimental (10), Waiting List (12), and Control (14). As an evaluation method, a Behavioural Avoidance Test (BAT) with subjective anxiety and heart rate was used for images and videos, plus general and specific anxiety questionnaires for each phobia. The intervention was carried out in four phases of multimedia exposure: photographs, videos, simulated stimuli, and real stimulation. RESULTS Anxiety and avoidance were significantly reduced in the experimental group, with a very large effect size (between d = 1.37 and 5.37). There were no significant changes in either the Control Group or the Waiting List Group. CONCLUSIONS The treatment had a clinically significant impact on the daily life of the participants. This multimedia procedure was shown to be effective and to use few resources, thus allowing it to always be adapted to the individual characteristics of the participants.",2020,"RESULTS Anxiety and avoidance were significantly reduced in the experimental group, with a very large effect size (between d = 1.37 and 5.37).","['36 individuals, 7 men and 29 women (mean age: 29 years old), with different types of specific phobias']","['progressive multimedia exposure procedure', 'Multimedia intervention']","['Behavioural Avoidance Test (BAT) with subjective anxiety and heart rate', 'Anxiety and avoidance', 'daily life']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0236801', 'cui_str': 'Simple phobia'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",36.0,0.0227913,"RESULTS Anxiety and avoidance were significantly reduced in the experimental group, with a very large effect size (between d = 1.37 and 5.37).","[{'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Ruiz-García', 'Affiliation': 'Universidad de Málaga.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Valero-Aguayo', 'Affiliation': ''}]",Psicothema,['10.7334/psicothema2020.87'] 2110,32711671,A nutrition education intervention in adolescents who play soccer: The IDEHA-F project.,"BACKGROUND Diet and physical activity are prioritised in behavioural interventions given their influence on major child health issues. The objective of this study was to assess the feasibility of an educational intervention, based on the Behaviour Change Wheel model, on adherence to healthy eating habits in adolescent soccer players in Asturias, Spain. METHOD This pilot study involved 319 soccer players (mean age=14.19 years; SD=1.089), who were distributed into a control group (CG) and an intervention group (IG). The response variables were: the usage rate of, adherence to, and acquisition of knowledge of the Mediterranean diet. The intervention included posters, a web-app, and practical activities. RESULTS The mean score on the knowledge questionnaire was 2.53 for the CG and 3.42 for the IG (p <.001). A weak direct correlation was observed between diet knowledge and KIDMED scores (r =.222, p =.013). The total pre-test KIDMED (p <.001) and diet knowledge ( p =.05) scores explained approximately 33% of the total post-test KIDMED score. CONCLUSIONS The combined use of posters and a web app as intervention tools have been shown to be feasible in order to provide information on healthy eating habits to adolescents who play soccer and to help them maintain those eating habits.",2020,"The total pre-test KIDMED (p <.001) and diet knowledge ( p =.05) scores explained approximately 33% of the total post-test KIDMED score. ","['adolescents who play soccer', 'healthy eating habits to adolescents who play soccer', '319 soccer players (mean age=14.19 years; SD=1.089), who were distributed into a control group (CG) and an intervention group (IG', 'healthy eating habits in adolescent soccer players in Asturias, Spain']","['educational intervention', 'nutrition education intervention']","['diet knowledge', 'diet knowledge and KIDMED scores', 'usage rate of, adherence to, and acquisition of knowledge of the Mediterranean diet', 'mean score on the knowledge questionnaire']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0016468', 'cui_str': 'Eating Habits'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C1138412', 'cui_str': 'Mediterranean Diet'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",319.0,0.0237194,"The total pre-test KIDMED (p <.001) and diet knowledge ( p =.05) scores explained approximately 33% of the total post-test KIDMED score. ","[{'ForeName': 'María M', 'Initials': 'MM', 'LastName': 'Fernández-Álvarez', 'Affiliation': 'Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Martín-Payo', 'Affiliation': ''}, {'ForeName': 'Rebeca', 'Initials': 'R', 'LastName': 'García-García', 'Affiliation': ''}, {'ForeName': 'Marcelino', 'Initials': 'M', 'LastName': 'Cuesta', 'Affiliation': ''}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Carrasco-Santos', 'Affiliation': ''}]",Psicothema,['10.7334/psicothema2019.394'] 2111,32711724,Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial.,"BACKGROUND Despite several clinical trials on haemodynamic therapy, the optimal intraoperative haemodynamic management for high-risk patients undergoing major abdominal surgery remains unclear. We tested the hypothesis that personalised haemodynamic management targeting each individual's baseline cardiac index at rest reduces postoperative morbidity. METHODS In this single-centre trial, 188 high-risk patients undergoing major abdominal surgery were randomised to either routine management or personalised haemodynamic management requiring clinicians to maintain personal baseline cardiac index (determined at rest preoperatively) using an algorithm that guided intraoperative i.v. fluid and/or dobutamine administration. The primary outcome was a composite of major complications (European Perioperative Clinical Outcome definitions) or death within 30 days of surgery. Secondary outcomes included postoperative morbidity (assessed by a postoperative morbidity survey), hospital length of stay, mortality within 90 days of surgery, and neurocognitive function assessed after postoperative Day 3. RESULTS The primary outcome occurred in 29.8% (28/94) of patients in the personalised management group, compared with 55.3% (52/94) of patients in the routine management group (relative risk: 0.54, 95% confidence interval [CI]: 0.38 to 0.77; absolute risk reduction: -25.5%, 95% CI: -39.2% to -11.9%; P<0.001). One patient assigned to the personalised management group, compared with five assigned to the routine management group, died within 30 days after surgery (P=0.097). There were no clinically relevant differences between the two groups for secondary outcomes. CONCLUSIONS In high-risk patients undergoing major abdominal surgery, personalised haemodynamic management reduces a composite outcome of major postoperative complications or death within 30 days after surgery compared with routine care. CLINICAL TRIAL REGISTRATION NCT02834377.",2020,"In high-risk patients undergoing major abdominal surgery, personalised haemodynamic management reduces a composite outcome of major postoperative complications or death within 30 days after surgery compared with routine care. ","['188 high-risk patients undergoing major abdominal surgery', 'high-risk patients undergoing major abdominal surgery']","['Personalised haemodynamic management', 'routine management or personalised haemodynamic management requiring clinicians to maintain personal baseline cardiac index (determined at rest preoperatively) using an algorithm that guided intraoperative i.v']","['postoperative morbidity (assessed by a postoperative morbidity survey), hospital length of stay, mortality within 90 days of surgery, and neurocognitive function assessed after postoperative Day 3', 'composite of major complications (European Perioperative Clinical Outcome definitions) or death within 30 days of surgery', 'major postoperative complications or death']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}]","[{'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3539107', 'cui_str': 'Definition'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C3887296', 'cui_str': 'Within thirty days of surgery'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}]",188.0,0.326373,"In high-risk patients undergoing major abdominal surgery, personalised haemodynamic management reduces a composite outcome of major postoperative complications or death within 30 days after surgery compared with routine care. ","[{'ForeName': 'Julia Y', 'Initials': 'JY', 'LastName': 'Nicklas', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine. Electronic address: j.nicklas@uke.de.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Diener', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine.'}, {'ForeName': 'Maximilian', 'Initials': 'M', 'LastName': 'Leistenschneider', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Sellhorn', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Schön', 'Affiliation': 'Department of Medical Biometry and Epidemiology.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Winkler', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine.'}, {'ForeName': 'Guenter', 'Initials': 'G', 'LastName': 'Daum', 'Affiliation': 'Clinic and Polyclinic for Vascular Medicine, University Heart Center.'}, {'ForeName': 'Edzard', 'Initials': 'E', 'LastName': 'Schwedhelm', 'Affiliation': 'Institute of Clinical Pharmacology and Toxicology.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Schröder', 'Affiliation': 'Department of Neurology.'}, {'ForeName': 'Margit', 'Initials': 'M', 'LastName': 'Fisch', 'Affiliation': 'Department of Urology.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Schmalfeldt', 'Affiliation': 'Department of Gynecology and Gynecologic Oncology.'}, {'ForeName': 'Jakob R', 'Initials': 'JR', 'LastName': 'Izbicki', 'Affiliation': 'General-, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Bauer', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine.'}, {'ForeName': 'Sina M', 'Initials': 'SM', 'LastName': 'Coldewey', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine; Septomics Research Center, Center for Sepsis Control and Care, Jena University Hospital, Jena, Germany.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Reuter', 'Affiliation': 'Department of Anesthesiology, Rostock University Medical Center, University of Rostock, Rostock, Germany.'}, {'ForeName': 'Bernd', 'Initials': 'B', 'LastName': 'Saugel', 'Affiliation': 'Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine; Outcomes Research Consortium, Cleveland, OH, USA.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.04.094'] 2112,32711800,"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.","BACKGROUND Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention. METHODS This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial done at 94 community, public health, and hospital-associated clinics located in regions of Europe and North America, where there is a high incidence of HIV or prevalence of people living with HIV, or both. We enrolled adult cisgender men who have sex with men and transgender women who have sex with men, both with a high risk of acquiring HIV on the basis of their self-reported sexual behaviour in the past 12 weeks or their recent history (within 24 weeks of enrolment) of bacterial sexually transmitted infections. Participants with current or previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded. We used a computer-generated random allocation sequence to randomly assign (1:1) participants to receive either emtricitabine (200 mg) and tenofovir alafenamide (25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). As such, all participants were given two tablets. The trial sponsor, investigators, participants, and the study staff who provided the study drugs, assessed the outcomes, and collected the data were masked to group assignment. The primary efficacy outcome was incident HIV infection, which was assessed when all participants had completed 48 weeks of follow-up and half of all participants had completed 96 weeks of follow-up. This full analysis set included all randomly assigned participants who had received at least one dose of the assigned study drug and had at least one post-baseline HIV test. Non-inferiority of emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upper bound of the 95·003% CI of the HIV incidence rate ratio (IRR) was less than the prespecified non-inferiority margin of 1·62. We prespecified six secondary bone mineral density and renal biomarker safety endpoints to evaluate using the safety analysis set. This analysis set included all randomly assigned participants who had received at least one dose of the assigned study drug. This trial is registered with ClinicalTrials.gov, NCT02842086, and is no longer recruiting. FINDINGS Between Sept 13, 2016, and June 30, 2017, 5387 (92%) of 5857 participants were randomly assigned and received emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693). At the time of the primary efficacy analysis (ie, when all participants had completed 48 weeks and 50% had completed 96 weeks) emtricitabine and tenofovir alafenamide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the upper limit of the 95% CI of the IRR, was less than the prespecified non-inferiority margin of 1·62 (IRR 0·47 [95% CI 0·19-1·15]). After 8756 person-years of follow-up, 22 participants were diagnosed with HIV, seven participants in the emtricitabine and tenofovir alafenamide group (0·16 infections per 100 person-years [95% CI 0·06-0·33]), and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0·34 infections per 100 person-years [0·19-0·56]). Both regimens were well tolerated, with a low number of participants reporting adverse events that led to discontinuation of the study drug (36 [1%] of 2694 participants in the emtricitabine and tenofovir alafenamide group vs 49 [2%] of 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group). Emtricitabine and tenofovir alafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoints. INTERPRETATION Daily emtricitabine and tenofovir alafenamide shows non-inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and the number of adverse events for both regimens was low. Emtricitabine and tenofovir alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than emtricitabine and tenofovir disoproxil fumarate. FUNDING Gilead Sciences.",2020,"Emtricitabine and tenofovir alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than emtricitabine and tenofovir disoproxil fumarate. ","['group (0·34 infections per 100 person-years [0·19-0·56', 'Between Sept 13, 2016, and June 30, 2017, 5387 (92%) of 5857 participants', 'enrolled adult cisgender men who have sex with men and transgender women who have sex with men, both with a high risk of acquiring HIV on the basis of their self-reported sexual behaviour in the past 12 weeks or their recent history (within 24 weeks of enrolment) of bacterial sexually transmitted infections', 'After 8756 person-years of follow-up, 22 participants were diagnosed with HIV, seven participants in the', '94 community, public health, and hospital-associated clinics located in regions of Europe and North America', '15 participants in the', 'Participants with current or previous use of PrEP with', 'HIV pre-exposure prophylaxis (DISCOVER', 'group (0·16 infections per 100 person-years']","['Tenofovir alafenamide', 'tenofovir alafenamide', 'emtricitabine', 'emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate', 'emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate', 'emtricitabine and tenofovir alafenamide', 'placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate', 'Emtricitabine and tenofovir alafenamide', 'placebo tablets (emtricitabine and tenofovir disoproxil fumarate group', 'Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate', 'tenofovir disoproxil fumarate', 'pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate', 'emtricitabine and tenofovir disoproxil fumarate']","['bone mineral density and biomarkers of renal safety', 'incident HIV infection', 'antiviral efficacy and improved renal and bone safety', 'efficacy and safety', 'bone mineral density and renal biomarker safety endpoints', 'HIV incidence rate ratio (IRR']","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C1319927', 'cui_str': 'Male-to-female transsexual'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0028405', 'cui_str': 'North America'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C1096319', 'cui_str': 'Prophylaxis against HIV infection'}]","[{'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C4059167', 'cui_str': 'emtricitabine and tenofovir alafenamide'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}]","[{'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0019693', 'cui_str': 'Human immunodeficiency virus infection'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",22.0,0.592697,"Emtricitabine and tenofovir alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than emtricitabine and tenofovir disoproxil fumarate. ","[{'ForeName': 'Kenneth H', 'Initials': 'KH', 'LastName': 'Mayer', 'Affiliation': 'The Fenway Institute, Fenway Health, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Molina', 'Affiliation': 'Infectious Diseases Department, Hopitaux Saint-Louis Lariboisière, University of Paris and INSERM U944, Paris, France.'}, {'ForeName': 'Melanie A', 'Initials': 'MA', 'LastName': 'Thompson', 'Affiliation': 'AIDS Research Consortium of Atlanta, Atlanta, GA, USA.'}, {'ForeName': 'Peter L', 'Initials': 'PL', 'LastName': 'Anderson', 'Affiliation': 'Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.'}, {'ForeName': 'Karam C', 'Initials': 'KC', 'LastName': 'Mounzer', 'Affiliation': 'Philadelphia FIGHT, Philadelphia, PA, USA.'}, {'ForeName': 'Joss J', 'Initials': 'JJ', 'LastName': 'De Wet', 'Affiliation': 'Spectrum Health, Vancouver, BC, Canada.'}, {'ForeName': 'Edwin', 'Initials': 'E', 'LastName': 'DeJesus', 'Affiliation': 'Orlando Immunology Center, Orlando, FL, USA.'}, {'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Jessen', 'Affiliation': 'Praxis Jessen(2)\u2008+\u2008Kollegen, Berlin, Germany.'}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'Grant', 'Affiliation': 'San Francisco AIDS Foundation, and University of California, San Francisco, CA, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Ruane', 'Affiliation': 'Ruane Medical and Liver Health Institute, Los Angeles, CA, USA.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Wong', 'Affiliation': 'Department of Biometrics, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Ebrahimi', 'Affiliation': 'Department of Biometrics, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Lijie', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Department of Biometrics, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Mathias', 'Affiliation': 'Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Callebaut', 'Affiliation': 'Department of Virology, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Sean E', 'Initials': 'SE', 'LastName': 'Collins', 'Affiliation': 'Department of HIV and Emerging Viral Infections Clinical Research, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Moupali', 'Initials': 'M', 'LastName': 'Das', 'Affiliation': 'Department of HIV and Emerging Viral Infections Clinical Research, Gilead Sciences, Foster City, CA, USA. Electronic address: moupali.as@gilead.com.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'McCallister', 'Affiliation': 'Department of HIV and Emerging Viral Infections Clinical Research, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Diana M', 'Initials': 'DM', 'LastName': 'Brainard', 'Affiliation': 'Department of HIV and Emerging Viral Infections Clinical Research, Gilead Sciences, Foster City, CA, USA.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Brinson', 'Affiliation': 'Central Texas Clinical Research, Austin, TX, USA.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Clarke', 'Affiliation': 'Royal Sussex County Hospital, Brighton and Sussex University Hospitals National Health Service (NHS) Trust, Brighton, UK.'}, {'ForeName': 'Pep', 'Initials': 'P', 'LastName': 'Coll', 'Affiliation': 'BCN Checkpoint and IrsiCaixa-AIDS Research Institute, Barcelona, Spain.'}, {'ForeName': 'Frank A', 'Initials': 'FA', 'LastName': 'Post', 'Affiliation': ""King's College Hospital NHS Foundation Trust, King's College Hospital, London, UK.""}, {'ForeName': 'C Bradley', 'Initials': 'CB', 'LastName': 'Hare', 'Affiliation': 'Department of Adult and Family Medicine, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)31065-5'] 2113,32711801,"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.","BACKGROUND Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis. METHODS In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged ≥12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score ≥3, Eczema Area and Severity Index [EASI] score ≥16, percentage of body surface area affected ≥10%, and Peak Pruritus Numerical Rating Scale score ≥4) with a bodyweight of 40 kg or more, were enrolled at 69 sites in Australia, Canada, Europe, and the USA. Patients were randomly assigned (2:2:1) to oral abrocitinib 100 mg, abrocitinib 200 mg, or placebo once daily for 12 weeks. Randomisation was done using an interactive response technology system, stratified by baseline disease severity and age. Patients, investigators, and the funder of the study were masked to study treatment. The coprimary endpoints were the proportion of patients who had achieved an Investigator Global Assessment response (score of 0 [clear] or 1 [almost clear] with a ≥2-grade improvement from baseline), and the proportion of patients who achieved at least a 75% improvement in EASI score from baseline (EASI-75) score, both assessed at week 12. Efficacy was assessed in the full analysis set, which included all randomised patients who received at least one dose of study medication. Safety was assessed in all randomised patients. This study is registered with ClinicalTrials.gov, NCT03349060. FINDINGS Between Dec 7, 2017, and March 26, 2019, 387 patients were enrolled: 156 were assigned to abrocitinib 100 mg, 154 to abrocitinib 200 mg, and 77 to placebo. All enrolled patients received at least one dose of study treatment and thus were evaluable for 12-week efficacy. Of the patients with available data for the coprimary endpoints at week 12, the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocitinib 100 mg group than in the placebo group (37 [24%] of 156 patients vs six [8%] of 76 patients; p=0·0037) and in the abrocitinib 200 mg group compared with the placebo group (67 [44%] of 153 patients vs six [8%] of 76 patients; p<0·0001). Of the patients with available data for the coprimary endpoints at week 12, compared with the placebo group, the proportion of patients who had achieved an EASI-75 response was significantly higher in the abrocitinib 100 mg group (62 [40%] of 156 patients vs nine [12%] of 76 patients; p<0·0001) and abrocitinib 200 mg group (96 [63%] of 153 patients vs nine [12%] of 76 patients; p<0·0001). Adverse events were reported in 108 (69%) of 156 patients in the abrocitinib 100 mg group, 120 (78%) of 154 patients in the abrocitinib 200 mg group, and 44 (57%) of 77 patients in the placebo group. Serious adverse events were reported in five (3%) of 156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) of 77 patients in the placebo group. No treatment-related deaths were reported. INTERPRETATION Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis. FUNDING Pfizer.",2020,"Serious adverse events were reported in five (3%) of 156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) of 77 patients in the placebo group.","['adolescents and adults with moderate-to-severe atopic dermatitis', 'patients (aged ≥12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score ≥3, Eczema Area and Severity Index [EASI] score ≥16, percentage of body surface area affected ≥10%, and Peak Pruritus Numerical Rating Scale score ≥4) with a bodyweight of 40 kg or more, were enrolled at 69 sites in Australia, Canada, Europe, and the USA', '387 patients were enrolled: 156', 'adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1', 'adults with moderate-to-severe atopic dermatitis', 'Between Dec 7, 2017, and March 26, 2019']","['abrocitinib 100 mg, 154 to abrocitinib 200 mg, and 77 to placebo', 'abrocitinib monotherapy', 'oral abrocitinib 100 mg, abrocitinib 200 mg, or placebo', 'abrocitinib', 'placebo']","['Safety', 'proportion of patients who had achieved an Investigator Global Assessment response', 'Investigator Global Assessment response', 'Adverse events', 'Efficacy and safety', 'efficacy and safety', 'Efficacy', 'EASI-75 response', 'EASI score', 'Serious adverse events']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011615', 'cui_str': 'Atopic dermatitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0013595', 'cui_str': 'Eczema'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0021345', 'cui_str': 'Infectious mononucleosis'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",387.0,0.611278,"Serious adverse events were reported in five (3%) of 156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) of 77 patients in the placebo group.","[{'ForeName': 'Eric L', 'Initials': 'EL', 'LastName': 'Simpson', 'Affiliation': 'Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.'}, {'ForeName': 'Rodney', 'Initials': 'R', 'LastName': 'Sinclair', 'Affiliation': 'Sinclair Dermatology, Melbourne, VIC, Australia.'}, {'ForeName': 'Seth', 'Initials': 'S', 'LastName': 'Forman', 'Affiliation': 'ForCare Clinical Research, Tampa, FL, USA.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Wollenberg', 'Affiliation': 'Department of Dermatology, Ludwig Maximilian University of Munich, Munich, Germany.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Aschoff', 'Affiliation': 'University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Cork', 'Affiliation': ""Sheffield Dermatology Research, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield Children's Hospital, Sheffield Teaching Hospitals, Sheffield, UK.""}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bieber', 'Affiliation': 'Department of Dermatology and Allergy, University Hospital, University of Bonn, Bonn, Germany.'}, {'ForeName': 'Jacob P', 'Initials': 'JP', 'LastName': 'Thyssen', 'Affiliation': 'Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Yosipovitch', 'Affiliation': 'Miami Itch Center, Miller School of Medicine, University of Miami, Miami, FL, USA.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Flohr', 'Affiliation': ""Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.""}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Magnolo', 'Affiliation': 'University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Maari', 'Affiliation': 'Innovaderm Research, Montréal, QC, Canada; University of Montreal Hospital Center, Montréal, QC, Canada.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Feeney', 'Affiliation': 'Pfizer UK, Surrey, UK.'}, {'ForeName': 'Pinaki', 'Initials': 'P', 'LastName': 'Biswas', 'Affiliation': 'Pfizer, New York, NY, USA.'}, {'ForeName': 'Svitlana', 'Initials': 'S', 'LastName': 'Tatulych', 'Affiliation': 'Pfizer, Groton, CT, USA.'}, {'ForeName': 'Hernan', 'Initials': 'H', 'LastName': 'Valdez', 'Affiliation': 'Pfizer, New York, NY, USA.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Rojo', 'Affiliation': 'Pfizer, Groton, CT, USA. Electronic address: ricardo.rojo@pfizer.com.'}]","Lancet (London, England)",['10.1016/S0140-6736(20)30732-7'] 2114,32711802,"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.","BACKGROUND Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis. METHODS The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS28-ESR) of 3·2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS28-ESR change from baseline to week 24, with a difference of more than 0·6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov, NCT02573012. FINDINGS Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08 (-0·27 to 0·12) with continued prednisone (difference 0·61 [0·35-0·88]; p<0·0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0·83; 95% CI 0·71-0·97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency. INTERPRETATION In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose. FUNDING F Hoffmann-La Roche.",2020,"In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08","['Adult patients with rheumatoid arthritis receiving', 'Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77', '0·35-0·88', 'patients with rheumatoid arthritis', '23%] men) were recruited onto the trial', '39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia', 'women and 59']","['prednisone', 'Continuing versus tapering glucocorticoids', 'tocilizumab', 'continue masked prednisone', 'tapered prednisone and -0·08', 'glucocorticoids', 'tocilizumab and glucocorticoids', 'glucocorticoid', 'continuing low-dose oral glucocorticoids']","['symptomatic adrenal insufficiency', 'mean DAS28-ESR change', 'Steroid EliMination', 'disease activity control', 'Serious adverse events']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0454664', 'cui_str': 'Country'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0035970', 'cui_str': 'Russian federation - Europe'}, {'cui': 'C0036708', 'cui_str': 'Republic of Serbia'}, {'cui': 'C0041388', 'cui_str': 'Tunisia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0441640', 'cui_str': 'Tapering - action'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0001623', 'cui_str': 'Hypoadrenalism'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4706353', 'cui_str': 'DAS - Disease Activity Score'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",421.0,0.383193,"In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS28-ESR from baseline to week 24 was 0·54 (95% CI 0·35-0·73) with tapered prednisone and -0·08","[{'ForeName': 'Gerd R', 'Initials': 'GR', 'LastName': 'Burmester', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany. Electronic address: gerd.burmester@charite.de.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Buttgereit', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany.'}, {'ForeName': 'Corrado', 'Initials': 'C', 'LastName': 'Bernasconi', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Álvaro-Gracia', 'Affiliation': 'Hospital General Universitario Gregorio Marañon, Universidad Complutense de Madrid, Spain.'}, {'ForeName': 'Nidia', 'Initials': 'N', 'LastName': 'Castro', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Dougados', 'Affiliation': 'Rheumatology Service, Université Paris-Descartes, Paris, France.'}, {'ForeName': 'Cem', 'Initials': 'C', 'LastName': 'Gabay', 'Affiliation': 'Department of Rheumatology, Hôpital Cochin, Geneva University Hospitals and Geneva School of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Jacob M', 'Initials': 'JM', 'LastName': 'van Laar', 'Affiliation': 'University Medical Centre Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Jan Michael', 'Initials': 'JM', 'LastName': 'Nebesky', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Attila', 'Initials': 'A', 'LastName': 'Pethoe-Schramm', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Salvarani', 'Affiliation': 'Department of Rheumatology and Clinical Immunology, Università di Modena e Reggio Emilia and Azienda unità sanitaria locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.'}, {'ForeName': 'Marc Y', 'Initials': 'MY', 'LastName': 'Donath', 'Affiliation': 'Department of Rheumatology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Markus R', 'Initials': 'MR', 'LastName': 'John', 'Affiliation': 'Pharmaceuticals Division, F Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30636-X'] 2115,32711853,Sucralose Consumption over 2 Weeks in Healthy Subjects Does Not Modify Fasting Plasma Concentrations of Appetite-Regulating Hormones: A Randomized Clinical Trial.,"BACKGROUND The effect of nonnutritive sweeteners on appetite is controversial. Some studies have found changes in certain appetite control hormones with sucralose intake that may be through interaction with sweet taste receptors located in the intestine. OBJECTIVE The aim of this study was to evaluate whether sucralose consumption could produce changes in fasting plasma concentrations of appetite-regulating hormones, including glucagon-like peptide 1, ghrelin, peptide tyrosine tyrosine, and leptin, and secondarily in insulin resistance. DESIGN A 2-week parallel randomized clinical trial with an additional visit conducted 1 week after dosing termination. PARTICIPANTS/SETTING Sixty healthy, normal-weight individuals, without habitual consumption of nonnutritive sweeteners were recruited from July 2015 to March 2017 in Mexico City. INTERVENTION Daily sucralose consumption at 15% of the acceptable daily intake by using commercial sachets added to food. The control group followed the same protocol without an intervention. MAIN OUTCOMES MEASURED Fasting concentrations of appetite regulating hormones before and after the intervention. Fasting glucose and insulin concentrations were measured to assess insulin resistance as a secondary outcome. STATISTICAL ANALYSIS PERFORMED Basal and final concentrations were compared using Wilcoxon matched-pairs test and Mann-Whitney U test for analysis between groups. Repeated measures analysis of variance was used to evaluate changes in the homeostasis model assessment of insulin resistance. RESULTS Sucralose was not associated with changes in any of the hormones measured. One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group. CONCLUSIONS Sucralose intake is not associated with changes in fasting concentrations of glucagon-like peptide 1, ghrelin, peptide tyrosine tyrosine, or leptin. An increase in the homeostasis model assessment of insulin resistance observed only at 1 week postdosing is of unknown clinical significance, if any.",2020,"One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group. ","['Sixty healthy, normal-weight individuals, without habitual consumption of nonnutritive sweeteners were recruited from July 2015 to March 2017 in Mexico City', 'Healthy Subjects']","['sucralose consumption', 'Sucralose Consumption']","['Fasting concentrations of appetite regulating hormones', 'homeostasis model assessment of insulin resistance', 'Daily sucralose consumption', 'Basal and final concentrations', 'fasting plasma concentrations of appetite-regulating hormones, including glucagon-like peptide 1, ghrelin, peptide tyrosine tyrosine, and leptin, and secondarily in insulin resistance', 'Fasting glucose and insulin concentrations']","[{'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0038998', 'cui_str': 'Sweeteners'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0025885', 'cui_str': 'Mexico'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0077046', 'cui_str': 'sucralose'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C1829779', 'cui_str': 'Homeostasis model assessment'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0077046', 'cui_str': 'sucralose'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin'}, {'cui': 'C0077599', 'cui_str': 'tyrosyltyrosine'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]",,0.122383,"One week postintervention, an incremental change (P=0.04) in the homeostasis model assessment of insulin resistance was found in the intervention group. ","[{'ForeName': 'Alonso', 'Initials': 'A', 'LastName': 'Romo-Romo', 'Affiliation': ''}, {'ForeName': 'Carlos A', 'Initials': 'CA', 'LastName': 'Aguilar-Salinas', 'Affiliation': ''}, {'ForeName': 'M Guadalupe', 'Initials': 'MG', 'LastName': 'López-Carrasco', 'Affiliation': ''}, {'ForeName': 'Luz E', 'Initials': 'LE', 'LastName': 'Guillén-Pineda', 'Affiliation': ''}, {'ForeName': 'Griselda X', 'Initials': 'GX', 'LastName': 'Brito-Córdova', 'Affiliation': ''}, {'ForeName': 'Rita A', 'Initials': 'RA', 'LastName': 'Gómez-Díaz', 'Affiliation': ''}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Gómez-Pérez', 'Affiliation': ''}, {'ForeName': 'Paloma', 'Initials': 'P', 'LastName': 'Almeda-Valdes', 'Affiliation': ''}]",Journal of the Academy of Nutrition and Dietetics,['10.1016/j.jand.2020.03.018'] 2116,32711855,"Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.","BACKGROUND Low-calorie sweetened beverages (LCSBs) are commonly used as a lower-calorie alternative to sugar-sweetened beverages (SSBs) by individuals with type 2 diabetes. However, little is known about how intake of LCSBs is related to dietary intake and cardiometabolic health, particularly among youth. OBJECTIVE To test the hypothesis that having higher baseline LCSB intake and increasing LCSB intake over 2 years of follow-up are associated with poorer dietary intake and higher cardiometabolic risk factors among youth enrolled in the Treatment Option for Type 2 Diabetes in Adolescents and Youth (TODAY) study. DESIGN Secondary, exploratory, analysis of baseline and longitudinal data from the TODAY study, which was a randomized, multisite trial conducted from 2004 to 2012, to compare effects of 3 interventions (metformin alone, metformin + rosiglitazone, and metformin + intensive lifestyle intervention) on glycemic control in youth with type 2 diabetes. PARTICIPANTS/SETTING The study included 476 children and adolescents (10-17 years, mean body mass index 34.9 ± 7.8 kg/m 2 ), who were participants in the multicenter (n = 15) TODAY study. MAIN OUTCOME MEASURES Diet was assessed using a food frequency questionnaire. Differences in energy intake, macronutrients, food group intakes, and cardiometabolic biomarkers were evaluated in 3 groups of LCSB consumers at baseline (low [1-4 servings/wk], medium [5-11 servings/wk], and high [≥12 servings/wk]), each compared with nonconsumers, and between 4 groups of change in LCSB intake (nonconsumption at start of study and nonconsumption after 2 years, increase in consumption after 2 years, decrease in consumption after 2 years, and high consumption at start of study and high consumption after 2 years). STATISTICAL ANALYSES PERFORMED Multivariable linear regression was performed at baseline and longitudinally over 2 years of follow-up. RESULTS Energy (kilocalories), fiber, carbohydrate, total fat, saturated fat, and protein intake (grams) were higher among high LCSB consumers compared with nonconsumers at baseline. No associations were observed between LCSB consumption and cardiometabolic risk factors at baseline. Change in LCSB intake between baseline and follow-up was not associated with change in energy intake or cardiometabolic risk factors. Participants who decreased LCSB consumption reported greater increases in sugar intake (18.4 ± 4.8 g) compared with those who increased LCSB consumption (5.7 ± 4.9 g) or remained high LCSB consumers (5.9 ± 7.4 g), but this trend was not statistically significant after a correction for multiple testing. CONCLUSIONS LCSB consumption was associated with higher energy intake in youth with type 2 diabetes, with the highest energy intakes reported in high LCSB consumers. Those who reduced LCSB consumption tended to report greater increases in sugar intake during follow-up, but further studies are needed to better understand this trend.",2020,Change in LCSB intake between baseline and follow-up was not associated with change in energy intake or cardiometabolic risk factors.,"['Youth With Type 2 Diabetes', '476 children and adolescents (10-17 years, mean body mass index 34.9 ± 7.8 kg/m 2 ), who were participants in the multicenter (n\xa0= 15) TODAY study', 'youth with type 2 diabetes', 'individuals with type 2 diabetes']","['Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health', '3 interventions (metformin alone, metformin\xa0+ rosiglitazone, and metformin\xa0+ intensive lifestyle intervention', 'Low-calorie sweetened beverages (LCSBs']","['LCSB consumption', 'Energy (kilocalories), fiber, carbohydrate, total fat, saturated fat, and protein intake (grams', 'energy intake, macronutrients, food group intakes, and cardiometabolic biomarkers', 'LCSB intake', 'sugar intake', 'LCSB consumption and cardiometabolic risk factors', 'energy intake or cardiometabolic risk factors', 'glycemic control', 'cardiometabolic risk factors']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0310367', 'cui_str': 'Today'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0038998', 'cui_str': 'Sweeteners'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0289313', 'cui_str': 'rosiglitazone'}, {'cui': 'C0023676', 'cui_str': 'Life style'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0556234', 'cui_str': 'Sugar intake'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",476.0,0.0517615,Change in LCSB intake between baseline and follow-up was not associated with change in energy intake or cardiometabolic risk factors.,"[{'ForeName': 'Allison C', 'Initials': 'AC', 'LastName': 'Sylvetsky', 'Affiliation': ''}, {'ForeName': 'Avinash', 'Initials': 'A', 'LastName': 'Chandran', 'Affiliation': ''}, {'ForeName': 'Sameera A', 'Initials': 'SA', 'LastName': 'Talegawkar', 'Affiliation': ''}, {'ForeName': 'Jean A', 'Initials': 'JA', 'LastName': 'Welsh', 'Affiliation': ''}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Drews', 'Affiliation': ''}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'El Ghormli', 'Affiliation': ''}]",Journal of the Academy of Nutrition and Dietetics,['10.1016/j.jand.2020.04.005'] 2117,32711878,Mid-term CT assessment of bone healing after nanohydroxyapatite augmentation in open-wedge high tibial osteotomy.,"BACKGROUND The aim of the present study was to confirm the effectiveness of adding nanohydroxyapatite (NHA) to a heterologous bone graft in open-wedge high tibial osteotomy (OWHTO) by measuring the bone density via multislice computed tomography (CT) of the tibial osteotomy gap in a mid-term follow-up (five years). METHODS Twenty-six patients undergoing OWHTO were randomly assigned to two groups: a pure graft group (Group A), in which the osteotomy gap was filled with only heterologous bone graft, and an NHA group (Group B), in which the osteotomy gap was filled with heterologous bone graft and NHA. CT was performed within one week of the operation, after two months, after 12 months and after five years. CT volume acquired in Hounsfield units (HU) was measured on three planes. RESULTS The normal bone density was 110.2 ± 11.7 HU. The value of mean density at five years in Group A was 296.8 ± 81.8 HU, while in Group B, it was 202.2 ± 45.1 HU, showing a density more similar to normal bone and greater bone uniformity inside the osteotomy. The difference between the two groups was statistically significant (p < 0.05). Furthermore, both groups showed excellent mid-term clinical outcomes without significant differences. CONCLUSIONS This study revealed that absorbability and bone formation at the osteotomy site in the NHA group was significantly higher as compared with the pure graft group at five years postoperatively.",2020,"Furthermore, both groups showed excellent mid-term clinical outcomes without significant differences. ",['Twenty-six patients undergoing OWHTO'],"['CT', 'multislice computed tomography (CT', 'nanohydroxyapatite augmentation', 'nanohydroxyapatite (NHA', 'pure graft group', 'osteotomy gap was filled with only heterologous bone graft, and an NHA group (Group B), in which the osteotomy gap was filled with heterologous bone graft and NHA']","['absorbability and bone formation', 'normal bone density', 'CT volume acquired in Hounsfield units (HU', 'bone healing']","[{'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445153', 'cui_str': 'Opening wedge'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}]","[{'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C3179130', 'cui_str': 'Multidetector-Row Computed Tomography'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0029468', 'cui_str': 'Osteotomy'}, {'cui': 'C0061928', 'cui_str': 'GTPase-Activating Protein'}, {'cui': 'C0439860', 'cui_str': 'Heterologous'}, {'cui': 'C0005976', 'cui_str': 'Bone graft'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}]",26.0,0.0265569,"Furthermore, both groups showed excellent mid-term clinical outcomes without significant differences. ","[{'ForeName': 'Piergiorgio', 'Initials': 'P', 'LastName': 'Drogo', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Valerio', 'Initials': 'V', 'LastName': 'Andreozzi', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy. Electronic address: valerioandreozzi1@gmail.com.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Rossini', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Ludovico', 'Initials': 'L', 'LastName': 'Caperna', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Iorio', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Mazza', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Ferretti', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Conteduca', 'Affiliation': ""Department of Orthopaedic Surgery, University of Rome La Sapienza, Sant'Andrea Hospital, via di Grottarossa, 1035, 00189 Rome, Italy.""}]",The Knee,['10.1016/j.knee.2020.05.011'] 2118,32711916,Understanding randomized trial design in vascular surgery.,,2020,,[],[],[],[],[],[],,0.145349,,"[{'ForeName': 'Graham R', 'Initials': 'GR', 'LastName': 'McClure', 'Affiliation': 'Division of Vascular Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'McIntyre', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Richard P', 'Initials': 'RP', 'LastName': 'Whitlock', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada; Division of Cardiac Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada.'}, {'ForeName': 'Emilie P', 'Initials': 'EP', 'LastName': 'Belley-Cote', 'Affiliation': 'Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Population Health Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, Université de Sherbrooke, Québec, Canada.'}]",Journal of vascular surgery,['10.1016/j.jvs.2020.04.013'] 2119,32711920,Skin Toxicity in Early Breast Cancer Patients Treated with Field-In-Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy: Results of a Phase III Randomised Controlled Trial.,"AIMS Skin toxicity is a common adverse effect of breast radiotherapy. We investigated whether inverse-planned intensity-modulated radiotherapy (IMRT) would reduce the incidence of skin toxicity compared with forward field-in-field breast IMRT (FiF-IMRT) in early stage breast cancer. MATERIALS AND METHODS This phase III randomised controlled trial compared whole-breast irradiation with either FiF-IMRT or helical tomotherapy IMRT (HT-IMRT), with skin toxicity as the primary end point. Patients received 50 Gy in 25 fractions and were assessed to compare skin toxicity between treatment arms. RESULTS In total, 177 patients were available for assessment and the median follow-up was 73.1 months. Inverse IMRT achieved more homogeneous coverage than FiF-IMRT; erythema and moist desquamation were higher with FiF-IMRT compared with HT-IMRT (61% versus 34%; P < 0.001; 33% versus 11%; P < 0.001, respectively). Multivariate analysis showed large breast volume, FiF-IMRT and chemotherapy were independent factors associated with worse acute toxicity. There was no difference between treatment arms in the incidence of late toxicities. The 5-year recurrence-free survival was 96.3% for both FiF-IMRT and HT-IMRT and the 5-year overall survival was 96.3% for FiF-IMRT and 97.4% for HT-IMRT. CONCLUSIONS Our study showed significant reduction in acute skin toxicity using HT-IMRT compared with FiF-IMRT, without significant reduction in late skin toxicities. On the basis of these findings, inverse-planned IMRT could be used in routine practice for whole-breast irradiation with careful plan optimisation to achieve the required dose constraints for organs at risk.",2020,"Inverse IMRT achieved more homogeneous coverage than FiF-IMRT; erythema and moist desquamation were higher with FiF-IMRT compared with HT-IMRT (61% versus 34%; P < 0.001; 33% versus 11%; P < 0.001, respectively).","['177 patients were available for assessment and the median follow-up was 73.1 months', 'Early Breast Cancer Patients Treated with Field']","['FiF-IMRT or helical tomotherapy IMRT (HT-IMRT', 'Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy', 'breast radiotherapy', 'FiF-IMRT', 'inverse-planned intensity-modulated radiotherapy (IMRT']","['acute toxicity', 'moist desquamation', 'incidence of late toxicities', '5-year recurrence-free survival', 'Skin Toxicity', '5-year overall survival', 'acute skin toxicity', 'skin toxicity', 'late skin toxicities']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}]","[{'cui': 'C1851124', 'cui_str': 'Desmoid disease, hereditary'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C1831735', 'cui_str': 'Helical Tomotherapies'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0439850', 'cui_str': 'Inverse'}, {'cui': 'C0852216', 'cui_str': 'Breast radiotherapies'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C1167791', 'cui_str': 'Skin toxicity'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",177.0,0.125783,"Inverse IMRT achieved more homogeneous coverage than FiF-IMRT; erythema and moist desquamation were higher with FiF-IMRT compared with HT-IMRT (61% versus 34%; P < 0.001; 33% versus 11%; P < 0.001, respectively).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Joseph', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'L J', 'Initials': 'LJ', 'LastName': 'Vos', 'Affiliation': 'Alberta Cancer Clinical Trials, Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Z', 'Initials': 'Z', 'LastName': 'Gabos', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pervez', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Chafe', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Tankel', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Warkentin', 'Affiliation': 'Division of Medical Physics, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Ghosh', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Amanie', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Powell', 'Affiliation': 'Division of Medical Physics, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'L-A', 'Initials': 'LA', 'LastName': 'Polkosnik', 'Affiliation': 'Division of Medical Physics, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Horsman', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'MacKenzie', 'Affiliation': 'Division of Medical Physics, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sabri', 'Affiliation': 'Division of Experimental Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'Parliament', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Mackey', 'Affiliation': 'Division of Medical Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Abdulkarim', 'Affiliation': 'Division of Radiation Oncology, Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Alberta, Canada. Electronic address: bassam.abdulkarim@mcgill.ca.'}]",Clinical oncology (Royal College of Radiologists (Great Britain)),['10.1016/j.clon.2020.07.005'] 2120,32711943,Quality of life outcomes after minimally invasive repair of pectus excavatum utilizing a new set of metallic bars and stabilizers.,"BACKGROUND/PURPOSE The aim of the study was to evaluate the postoperative quality of life (QoL) of patients who underwent minimally invasive repair of pectus excavatum (MIRPE) with a newly designed bar and bar stabilizers. METHODS We conducted a prospective randomized study in which patients were operated either with standard perpendicular stabilizers (control group) or with the newly designed oblique stabilizers (intervention group). All patients were evaluated 6 months after the operation with the Pectus Excavatum Evaluation Questionnaire (PEEQ). RESULTS There were 16 patients in the control group and 14 in the intervention group. Mean age was 17 (SD: 3.3, range 14-27) years. There were no demographic differences between groups. Two patients in the control group and one in the intervention group were repaired with two bars instead of one. There was one reoperation in each group. There was a significant difference between the pre- and postoperative scores, in both groups, in the patient body image domain (control group: 9.5 to 3; p < 0.01; intervention group 10 to 3; p < 0.01), as well as in the psychosocial domain (control group: 13.5 to 24, p < 0.01; intervention group: 15 to 24, p < 0.01). With regards to the patients' perception of physical difficulties before and after MIRPE, the difference between pre- and postoperative scores was greater in the intervention group (8 to 12, p < 0.01) than in the control group (10 to 11, p = 0.04). The mean length of stay was 4.5 and 5 days in the intervention group and the control group, respectively. CONCLUSION Our study showed that patients who underwent MIRPE with the newly designed bars and stabilizers had non-inferior outcomes than patients reported in the literature who underwent MIRPE with standard bars and stabilizers. We found slightly better outcomes in patients in the intervention group compared to the control group, but larger studies will be needed to confirm if those differences are statistically significant. LEVEL OF EVIDENCE II.",2020,"There was a significant difference between the pre- and postoperative scores, in both groups, in the patient body image domain (control group: 9.5 to 3; p < 0.01; intervention group 10 to 3; p < 0.01), as well as in the psychosocial domain (control group: 13.5 to 24, p < 0.01; intervention group: 15 to 24, p < 0.01).","['patients who underwent minimally invasive repair of pectus excavatum (MIRPE) with a newly designed bar and bar stabilizers', 'Mean age was 17 (SD: 3.3, range 14-27) years', '16 patients in the control group and 14 in the intervention group']",['standard perpendicular stabilizers (control group) or with the newly designed oblique stabilizers (intervention group'],"['postoperative quality of life (QoL', 'Pectus Excavatum Evaluation Questionnaire (PEEQ', 'pre- and postoperative scores', 'mean length of stay', 'Quality of life outcomes']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0405934', 'cui_str': 'Reconstructive repair of pectus excavatum'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0001643', 'cui_str': 'Beta-2 adrenergic receptor'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517688', 'cui_str': '3.3'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1295725', 'cui_str': 'Perpendicular axis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0016842', 'cui_str': 'Congenital pectus excavatum'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",,0.02836,"There was a significant difference between the pre- and postoperative scores, in both groups, in the patient body image domain (control group: 9.5 to 3; p < 0.01; intervention group 10 to 3; p < 0.01), as well as in the psychosocial domain (control group: 13.5 to 24, p < 0.01; intervention group: 15 to 24, p < 0.01).","[{'ForeName': 'Rafael Lucas Costa', 'Initials': 'RLC', 'LastName': 'de Carvalho', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Miguel Lia', 'Initials': 'ML', 'LastName': 'Tedde', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil; Hospital Alemão Oswaldo Cruz, R Treze de Maio, 1815, 01327-001, Sao Paulo, Brazil. Electronic address: tedde@usp.br.'}, {'ForeName': 'Jose Ribas Milanese', 'Initials': 'JRM', 'LastName': 'de Campos', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Niura Noro', 'Initials': 'NN', 'LastName': 'Hamilton', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil; Hospital Alemão Oswaldo Cruz, R Treze de Maio, 1815, 01327-001, Sao Paulo, Brazil.'}, {'ForeName': 'Gustavo Falavigna', 'Initials': 'GF', 'LastName': 'Guilherme', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Vanessa Moreira', 'Initials': 'VM', 'LastName': 'Sousa', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Vitor Floriano Salomao', 'Initials': 'VFS', 'LastName': 'Junior', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Flavio Henrique', 'Initials': 'FH', 'LastName': 'Savazzi', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}, {'ForeName': 'Paulo Manuel', 'Initials': 'PM', 'LastName': 'Pego-Fernandes', 'Affiliation': 'Heart Institute (InCor), University of Sao Paulo, R. Dr. Eneas de Carvalho Aguiar, 44, 05403-000, Sao Paulo, Brazil.'}]",Journal of pediatric surgery,['10.1016/j.jpedsurg.2020.06.036'] 2121,32711948,Active and Passive Distraction Interventions in a Pediatric Emergency Department to Reduce the Pain and Anxiety During Venous Blood Sampling: A Randomized Clinical Trial.,"INTRODUCTION Distraction is a method that is easy to use in emergency rooms and effective in relieving procedural pain and anxiety. This study aimed to determine the effect of 2 new distraction methods-1 active distraction (rotatable wooden toy) and 1 passive distraction (toy wristband)-on procedural pain, fear, and anxiety in children during venous blood sampling. METHODS This study was a randomized controlled experimental study. The sample consisted of 216 children aged 6 years to 12 years. They were divided into 3 groups using the block randomization procedure: active distraction group (n = 72); passive distraction group (n = 72); and control group (n = 72). The levels of pain and anxiety in the children were measured before and during the blood sampling by the children themselves, their parents, and the researcher using the Visual Analog Scale, the Wong-Baker FACES Pain Rating Scale, and the Children's Fear Scale. RESULTS The children and their parents included in the control and experimental groups had similar sociodemographic characteristics. The active distraction group had lower levels of procedural pain, fear, and anxiety than the other groups (children's visual analog scale score, F = 134.220; P < 0.05; Wong-Baker FACES Pain Rating Scale score, F = 137.538; P < 0.001; and Children's Fear Scale score, F = 92.436; P < 0.001). DISCUSSION Both the toy wristband and rotatable wooden toy interventions can be used to reduce procedural pain, fear, and anxiety in children during blood sampling in emergency departments.",2020,"The active distraction group had lower levels of procedural pain, fear, and anxiety than the other groups (children's visual analog scale score, F = 134.220; P < 0.05; Wong-Baker FACES Pain Rating Scale score, F = 137.538; P < 0.001; and Children's Fear Scale score, F = 92.436; P < 0.001). ","['216 children aged 6 years to 12 years', 'children during blood sampling in emergency departments', 'children during venous blood sampling']","['Active and Passive Distraction Interventions', '2 new distraction methods-1 active distraction (rotatable wooden toy) and 1 passive distraction', 'passive distraction group']","['Baker FACES Pain Rating Scale score', 'Pain and Anxiety', 'visual analog scale score', 'procedural pain, fear, and anxiety', 'levels of pain and anxiety', ""Children's Fear Scale score"", ""Visual Analog Scale, the Wong-Baker FACES Pain Rating Scale, and the Children's Fear Scale""]","[{'cui': 'C4708905', 'cui_str': '216'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0190979', 'cui_str': 'Phlebotomy'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0557859', 'cui_str': 'Wooden'}, {'cui': 'C0040565', 'cui_str': 'Toy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0238749', 'cui_str': 'Baker, general'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1619712', 'cui_str': 'Procedural pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",216.0,0.0429442,"The active distraction group had lower levels of procedural pain, fear, and anxiety than the other groups (children's visual analog scale score, F = 134.220; P < 0.05; Wong-Baker FACES Pain Rating Scale score, F = 137.538; P < 0.001; and Children's Fear Scale score, F = 92.436; P < 0.001). ","[{'ForeName': 'Aylin', 'Initials': 'A', 'LastName': 'Arıkan', 'Affiliation': ''}, {'ForeName': 'Figen Işık', 'Initials': 'FI', 'LastName': 'Esenay', 'Affiliation': ''}]",Journal of emergency nursing,['10.1016/j.jen.2020.05.004'] 2122,32711957,Thermoregulatory responses to ice slurry ingestion during low and moderate intensity exercises with restrictive heat loss.,"OBJECTIVES We investigated the thermoregulatory responses to ice slurry ingestion during low- and moderate-intensity exercises with restrictive heat loss. DESIGN Randomised, counterbalanced, cross-over design. METHODS Following a familiarisation trial, ten physically active males exercised on a motorised treadmill at low-intensity (L; 40% VO 2max ) or moderate-intensity (M; 70% VO 2max ) for 75-min, in four randomised, counterbalanced trials. Throughout the exercise bout, participants donned a raincoat to restrict heat loss. Participants ingested 2gkg -1 body mass of ambient water (L+AMB and M+AMB trials) or ice slurry (L+ICE and M+ICE trials) at 15-min intervals during exercise in environmental conditions of T db, 25.1±0.6°C and RH, 63±5%. Heart rate (HR), gastrointestinal temperature (T gi ), mean weighted skin temperature (T sk ), estimated sweat loss, ratings of perceived exertion (RPE) and thermal sensation (RTS) were recorded. RESULTS Compared to L+AMB, participants completed L+ICE trials with lower ΔT gi (0.8±0.3°C vs 0.6±0.2°C; p=0.03), mean RPE (10±1 vs 9±1; p=0.03) and estimated sweat loss (0.91±0.2L vs 0.78±0.27L; p=0.04). Contrastingly, T gi (p=0.22), T sk (p=0.37), HR (p=0.31), RPE (p=0.38) and sweat loss (p=0.17) were similar between M+AMB and M+ICE trials. RTS was similar during both low-intensity (4.9±0.5 vs 4.7±0.3; p=0.10) and moderate-intensity exercise (5.3±0.47 vs 5.0±0.4; p=0.09). CONCLUSIONS Per-cooling using ice slurry ingestion marginally reduced thermal strain during low-intensity but not during moderate-intensity exercise. Ice slurry may be an effective and practical heat mitigation strategy during low-intensity exercise such as in occupational and military settings, but a greater volume should be considered to ensure its efficacy.",2020,"Ice slurry may be an effective and practical heat mitigation strategy during low-intensity exercise such as in occupational and military settings, but a greater volume should be considered to ensure its efficacy.","['Following a familiarisation trial, ten physically active males exercised on a']",['motorised treadmill at low-intensity (L; 40% VO 2max ) or moderate-intensity (M; 70% VO 2max '],"['mean RPE', 'estimated sweat loss', 'RTS', 'moderate-intensity exercise', 'thermal strain', 'Heart rate (HR), gastrointestinal temperature (T gi ), mean weighted skin temperature (T sk ), estimated sweat loss, ratings of perceived exertion (RPE) and thermal sensation (RTS', 'sweat loss', 'RPE']","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0038984', 'cui_str': 'Sweat'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0039478', 'cui_str': 'Thermal sensation, function'}]",10.0,0.135853,"Ice slurry may be an effective and practical heat mitigation strategy during low-intensity exercise such as in occupational and military settings, but a greater volume should be considered to ensure its efficacy.","[{'ForeName': 'Sharifah B', 'Initials': 'SB', 'LastName': 'Alhadad', 'Affiliation': 'NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.'}, {'ForeName': 'Ivan C C', 'Initials': 'ICC', 'LastName': 'Low', 'Affiliation': 'Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.'}, {'ForeName': 'Jason K W', 'Initials': 'JKW', 'LastName': 'Lee', 'Affiliation': 'Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Global Asia Institute, National University of Singapore, Singapore; N.1 Institute for Health, National University of Singapore, Singapore. Electronic address: phsjlkw@nus.edu.sg.'}]",Journal of science and medicine in sport,['10.1016/j.jsams.2020.07.002'] 2123,32712009,The Effect of Position Support During Orthopedic Surgery on Postoperative Pain: A Randomized Controlled Trial.,"BACKGROUND Positional pain affect the patient's healing process after the operation. Anti-pressure positioning pads are medical products used to support the patient positioning during surgical procedures. AIMS The aim of the study was to examine pain related to positioning when anti-pressure gel pads and current visoelastic sponge support options are used during orthopedic surgical cases. DESIGN The randomized controlled experimental study. SETTINGS The operating room of an educational research hospital. PARTICIPANTS/SUBJECTS The study consisted of 100 patients (50 control group and 50 study group) undergoing surgery in a supine position. METHODS Information form, McGill Melzack Pain Questionnaire, and Visual Analogue Scale were used for data collection. Routine institutional policy was applied to the control group. Study group patients were additionally supported with antipressure position gel pads on the operating table. RESULTS The rate of pain presence in areas other than the operative area was significantly lower in the patients in the study group (p = .001). The patients in the control group reported that preoperative pain in the waist area increased to unbearable levels during operation. In addition, it was noted that the ""addition of the anti-pressure gel pads"" resulted in study group patients being mobilized significantly early (p = .001). CONCLUSIONS The conclusion of this study demonstrated that postoperative pain related to positioning, not the surgical procedure itself, was decreased when antipressure gel pads and viscoelastic sponge support were used together. An unanticipated benefit discovered during the study was earlier mobilization of the study group compared to the control group.",2020,An unanticipated benefit discovered during the study was earlier mobilization of the study group compared to the control group.,['100 patients (50 control group and 50 study group) undergoing surgery in a supine position'],"['Position Support', 'antipressure position gel pads on the operating table', 'Orthopedic Surgery']","['McGill Melzack Pain Questionnaire, and Visual Analogue Scale', 'rate of pain presence', 'unbearable levels', 'Postoperative Pain', 'preoperative pain']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0038846', 'cui_str': 'Supine body position'}]","[{'cui': 'C0733755', 'cui_str': 'Position'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0017243', 'cui_str': 'Gel'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0039224', 'cui_str': 'Table'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]",100.0,0.0517208,An unanticipated benefit discovered during the study was earlier mobilization of the study group compared to the control group.,"[{'ForeName': 'Döndü Soyer', 'Initials': 'DS', 'LastName': 'Erdemir', 'Affiliation': 'Baltalimanı Metin Sabancı Bone and Joint Diseases Education and Research Hospital, İstanbul, Turkey.'}, {'ForeName': 'Leman', 'Initials': 'L', 'LastName': 'Şenturan', 'Affiliation': 'Baltalimanı Metin Sabancı Bone and Joint Diseases Education and Research Hospital, İstanbul, Turkey; Nursing Department, Biruni University, Istanbul, Turkey. Electronic address: lsenturan@biruni.edu.tr.'}]",Pain management nursing : official journal of the American Society of Pain Management Nurses,['10.1016/j.pmn.2020.06.003'] 2124,32708893,Timing of Nutrient Ingestion after Mild to Moderate Cycling Exercise Does Not Affect Gastric Emptying Rate in Humans.,"This study examined the effect of carbohydrate drink ingestion timing on gastrointestinal tract blood flow and motility after mild cycling exercise. Eight healthy participants were randomly assigned to ingest a liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise according to target heart rate (approximately 120 beats/min). As the control trial (Con), participants ingested the same liquid solution without exercise. Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate were assessed by ultrasonography before and for 60 min after ingesting the glucose solution. Blood lactate, glucose, and plasma insulin were also measured at baseline and for 60 min after ingesting the glucose solution. Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial. After ingesting the glucose solution, changes in celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin were not significantly different among the three trials. The timing of nutrient ingestion after mild exercise does not seem to impact the subsequent gastrointestinal motility, blood flow, and glycemic responses.",2020,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","['Eight healthy participants', 'Humans', 'after mild cycling exercise']","['carbohydrate drink ingestion', 'liquid solution with 75 g glucose at either 5 min (PE-5) or 30 min (PE-30) after a single bout of leg cycling exercise']","['Gastric Emptying Rate', 'Celiac artery blood flow (BF), superior mesenteric artery BF, and gastric emptying rate', 'celiac artery BF, superior mesenteric artery BF, % gastric emptying rate, blood lactate, blood glucose, and plasma insulin', 'gastrointestinal motility, blood flow, and glycemic responses', 'Celiac artery BF', 'gastrointestinal tract blood flow and motility', 'Blood lactate, glucose, and plasma insulin']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0007569', 'cui_str': 'Structure of celiac artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0162861', 'cui_str': 'Superior mesenteric artery structure'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0857690', 'cui_str': 'Plasma insulin'}, {'cui': 'C0017184', 'cui_str': 'Gastrointestinal Motility'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0007608', 'cui_str': 'Motility, Cell'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",8.0,0.0331816,"Celiac artery BF significantly decreased from resting baseline immediately after exercise in both the PE-5 and PE-30 trials, and then returned to resting baseline just before the ingestion of glucose solution in the PE-30 trial.","[{'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Kashima', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Kamimura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Ayumi', 'Initials': 'A', 'LastName': 'Honma', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Masako Yamaoka', 'Initials': 'MY', 'LastName': 'Endo', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Miura', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Department of Health Promotion and Development, Graduate School of Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima 734-8551, Japan.'}, {'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Fukuba', 'Affiliation': 'Department of Exercise Science and Physiology, School of Health Sciences, Prefectural University of Hiroshima, 1-1-71 Ujina-higashi, Minami-ku, Hiroshima 734-8558, Japan.'}]",Nutrients,['10.3390/nu12072118'] 2125,32708894,"Effects of Ibuprofen Intake in Muscle Damage, Body Temperature and Muscle Power in Paralympic Powerlifting Athletes.","The aim of this study is to evaluate the effect of ingesting ibuprofen on post-workout recovery of muscle damage, body temperature and muscle power indicators in Paralympic powerlifting athletes. The study was carried out with eight Paralympic powerlifting athletes (aged 27.0 ± 5.3 years and 79.9 ± 25.5 kg of body mass) competing at the national level, with a minimum training experience of 12 months, who all submitted to two experimental conditions: Ibuprofen (2 × 00 mg) and control. The maximal isometric force of the upper limbs and rate of force development, thermography, and serum biochemical analyzes of creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase were measured before, after, 24 h after and 48 h after the intervention. Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected. After the exercise, the rate of force development decreased significantly for both conditions and did not exceed baseline levels again after 48 h. Muscle temperature decreased significantly at 48-h post-exercise in the placebo condition, when compared with the previous day of measurement; and deltoid muscle temperature at 48-h post-exercise was higher with the ibuprofen condition. Although the results indicate some positive effects of ibuprofen use, they do not enable a clear statement regarding its positive effects on muscle function and muscle damage. Ibuprofen seems to have caused a delay in the anti-inflammatory response following exercise.",2020,"Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected.","['Paralympic powerlifting athletes', 'eight Paralympic powerlifting athletes (aged 27.0 ± 5.3 years and 79.9 ± 25.5 kg of body mass) competing at the national level, with a minimum training experience of 12 months, who all submitted to two experimental conditions', 'Paralympic Powerlifting Athletes']","['ingesting ibuprofen', 'Ibuprofen (2 × 00 mg) and control', 'ibuprofen', 'Ibuprofen']","['deltoid muscle temperature', 'Muscle temperature', 'Muscle Damage, Body Temperature and Muscle Power', 'Maximal isometric force', 'rate of force development', 'maximal isometric force of the upper limbs and rate of force development, thermography, and serum biochemical analyzes of creatine kinase, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4708663', 'cui_str': '5.3'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517663', 'cui_str': '25.5'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0039810', 'cui_str': 'Thermography'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0202113', 'cui_str': 'Lactate dehydrogenase measurement'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}]",,0.0728658,"Maximal isometric force only decreased in the placebo condition, which increased back to baseline levels, while no substantial decline in baseline force was seen in the ibuprofen condition, although no effect for exercise condition was detected.","[{'ForeName': 'Guacira S', 'Initials': 'GS', 'LastName': 'Fraga', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Felipe J', 'Initials': 'FJ', 'LastName': 'Aidar', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Dihogo G', 'Initials': 'DG', 'LastName': 'Matos', 'Affiliation': 'Group of Studies and Research of Performance, Sport, Health and Paralympic Sports (GEPEPS), Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Anderson C', 'Initials': 'AC', 'LastName': 'Marçal', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Jymmys L', 'Initials': 'JL', 'LastName': 'Santos', 'Affiliation': 'Northeast Network in Biotechnology (RENORBIO), Federal University of Sergipe, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Raphael F', 'Initials': 'RF', 'LastName': 'Souza', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'André L', 'Initials': 'AL', 'LastName': 'Carneiro', 'Affiliation': 'Department of Physical Education, State University of Montes Claros, Minas Gerais 30000-000, Brazil.'}, {'ForeName': 'Alan B', 'Initials': 'AB', 'LastName': 'Vasconcelos', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Marzo E', 'Initials': 'ME', 'LastName': 'Da Silva-Grigoletto', 'Affiliation': 'Department of Physical Education, Federal University of Sergipe (UFS), São Cristovão, Sergipe 49100-000, Brazil.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'van den Tillaar', 'Affiliation': 'Department of Sport Sciences and Physical Education, Nord University, 7600 Levanger, Norway.'}, {'ForeName': 'Breno T', 'Initials': 'BT', 'LastName': 'Cabral', 'Affiliation': 'Department of Physical Education, Federal University of Rio Grande do Norte, Natal 59072970, Brazil.'}, {'ForeName': 'Victor M', 'Initials': 'VM', 'LastName': 'Reis', 'Affiliation': 'Research Center in Sports Sciences, Health Sciences and Human Development (CIDESD), University of Trás-os-Montes and Alto Douro, 5000-412 Vila Real, Portugal.'}]",International journal of environmental research and public health,['10.3390/ijerph17145157'] 2126,32708898,Sex Differences in Maintaining the Requested Handgrip Force Enhanced by Auditory or Visual Feedback.,"Thus far, the differences in effect of auditory or visual feedback in motor learning have presented results derived from mixed groups and sex differences have not been considered. However, perception and processing of auditory stimuli and performance of visual motor tasks appear to be sex-related. The purpose of this study was to investigate the learning of the simple motor task of maintaining a requested handgrip force in separate male and female groups. A total of 31 volunteers (15 males, 16 females) were randomly assigned to one of four experimental groups with defined sex and training conditions (audio or visual feedback). Participants performed training sessions over a period of six days, for which auditory or visual feedback was provided, and the effectiveness of both types of signals was compared. The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05). On the other hand, the main effect of feedback conditions was found to be significant among females, beneficially in the case of auditory displays ( p < 0.05). The results lead to the conclusion that an equal number of males and females in mixed experimental groups may be supportive to obtain reliable results. Moreover, in motor-learning studies conducted on females only, a design including auditory feedback would be more suitable.",2020,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","['31 volunteers (15 males, 16 females', 'separate male and female groups']",['defined sex and training conditions (audio or visual feedback'],"['evident learning effect', 'perception and processing of auditory stimuli and performance of visual motor tasks']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0178490', 'cui_str': 'Auditory stimulus'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",31.0,0.0238798,"The evident learning effect was found in all groups, and the main effect of sex was significant among visual groups in favor of the males ( p < 0.05).","[{'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Tarnas', 'Affiliation': 'Department of Physical Education and Lifelong Sports, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Stemplewski', 'Affiliation': 'Department of Physical Activity Sciences and Health Promotion, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Krutki', 'Affiliation': 'Department of Neurobiology, Poznan University of Physical Education, Królowej Jadwigi 27/39, 61-871 Poznań, Poland.'}]",International journal of environmental research and public health,['10.3390/ijerph17145158'] 2127,32709005,Importance of Self-Efficacy in Eating Behavior and Physical Activity Change of Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me: A Lifestyle Intervention with Mobile Technology.,"Very little is known about how multicomponent interventions directed to entire populations work in selected groups of adolescents. The aim was to evaluate the effectiveness of the Healthy Me one-year program on changes in healthy eating and physical activity among overweight and non-overweight female students. Randomization involved the allocation of full, partial or null intervention. The randomized field trial was implemented in 48 secondary schools (clusters) all over Poland among 1198 15-year-old girls. In this study, a sample of N = 1111 girls who participated in each evaluation study was analyzed. Using multimedia technologies, efforts were made to improve health behaviors and increase self-efficacy. The main outcome was a health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity. HBI was analyzed before and immediately after intervention and at three months' follow-up, and the HBI change was modeled. Statistical analysis included nonparametric tests and generalized linear models with two-way interactions. Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened. After adjusting for other factors, a significant interaction between body weight status and level of self-efficacy as predictors of HBI changes was confirmed. The program turned out to be more beneficial for overweight girls.",2020,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","['sample of N = 1111 girls who participated in each evaluation study was analyzed', 'Overweight and Non-Overweight Adolescent Girls Participating in Healthy Me', 'healthy eating and physical activity among overweight and non-overweight female students', '48 secondary schools (clusters) all over Poland among 1198 15-year-old girls']",['Healthy Me one-year program'],"['health behavior index (HBI), built on the basis of six nutritional indicators and one related to physical activity', 'HBI index', 'body weight status and level of self-efficacy', 'HBI', 'health behaviors and increase self-efficacy']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015196', 'cui_str': 'Evaluation Studies'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0032356', 'cui_str': 'Poland'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",1111.0,0.0178854,"Comparing the first and third surveys, in the overweight girls, the HBI index improved by 0.348 (SD = 3.17), while in the non-overweight girls it had worsened.","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Dzielska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Mazur', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Nałęcz', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Oblacińska', 'Affiliation': 'Department of Child and Adolescent Health, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Fijałkowska', 'Affiliation': 'Department of Cardiology, Institute of Mother and Child, 17a Kasprzaka St., 01-211 Warsaw, Poland.'}]",Nutrients,['10.3390/nu12072128'] 2128,32709051,The Effect of Dietary Inorganic Nitrate Supplementation on Cardiac Function during Submaximal Exercise in Men with Heart Failure with Reduced Ejection Fraction (HFrEF): A Pilot Study.,"Heart failure with reduced ejection fraction (HFrEF) is a common end point for patients with coronary artery disease and it is characterized by exercise intolerance due, in part, to a reduction in cardiac output. Nitric oxide (NO) plays a vital role in cardiac function and patients with HFrEF have been identified as having reduced vascular NO. This pilot study aimed to investigate if nitrate supplementation could improve cardiac measures during acute, submaximal exercise. Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study. All participants supplemented with inorganic nitrate (beetroot juice) or a nitrate-depleted placebo for ~13 days prior to testing. Participants completed a three-stage submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography for calculation of cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR). Heart rate and blood pressure were measured at rest and during each stage. Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation. There were no differences between interventions at rest, but the percent change in SV and Q from rest to stage two and stage three of exercise was higher following nitrate supplementation (all p > 0.05, ES > 0.8). Both interventions showed decreases in TPR during exercise, but the percent reduction TPR in stages two and three was greater following nitrate supplementation ( p = 0.09, ES = 0.98 and p = 0.14, ES = 0.82, respectively). There were clinically relevant increases in cardiac function during exercise following supplementation with nitrate. The findings from this pilot study warrant further investigation in larger clinical trials.",2020,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","['Five male participants (61 ± 3 years) with HFrEF (EF 32 ± 2.2%) completed this pilot study', 'Men with Heart Failure with Reduced Ejection Fraction (HFrEF', 'patients with coronary artery disease']","['Nitric oxide (NO', 'Dietary Inorganic Nitrate Supplementation', 'nitrate supplementation', 'inorganic nitrate (beetroot juice) or a nitrate-depleted placebo', 'submaximal exercise protocol on a recumbent cycle ergometer with simultaneous echocardiography', 'reduced ejection fraction (HFrEF']","['percent reduction TPR', 'Heart rate and blood pressure', 'Cardiac Function', 'TPR during exercise', 'cardiac measures', 'cardiac function', 'cardiac output (Q), stroke volume (SV), and total peripheral resistance (TPR', 'plasma nitrate']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}, {'cui': 'C4517629', 'cui_str': '2.2'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0444334', 'cui_str': 'Recumbent body position'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0013516', 'cui_str': 'Echocardiography'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C3839346', 'cui_str': 'Heart failure with reduced ejection fraction'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1258192', 'cui_str': 'Systemic vascular resistance'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0588131', 'cui_str': 'Cardiac measure'}, {'cui': 'C0007165', 'cui_str': 'Cardiac output'}, {'cui': 'C0038455', 'cui_str': 'Stroke volume'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}]",5.0,0.203872,"Both plasma nitrate (mean = ~1028%, p = 0.004) and nitrite (mean = ~109%, p = 0.01) increased following supplementation.","[{'ForeName': 'Mary N', 'Initials': 'MN', 'LastName': 'Woessner', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Itamar', 'Initials': 'I', 'LastName': 'Levinger', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Jason D', 'Initials': 'JD', 'LastName': 'Allen', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Luke C', 'Initials': 'LC', 'LastName': 'McIlvenna', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Neil', 'Affiliation': 'Institute for Health and Sport (IHES), Victoria University, Melbourne, VIC 3011, Australia.'}]",Nutrients,['10.3390/nu12072132'] 2129,32709172,Bilateral Ultrasound-Guided Erector Spinae Plane Block Versus Transversus Abdominis Plane Block on Postoperative Analgesia after Total Abdominal Hysterectomy.,"BACKGROUND Transversus abdominis plane (TAP) blocks provide postoperative pain relief after various abdominal surgeries. Recently, erector spinae plane (ESP) block has obtained vast attention due to its simplicity and usage in truncal procedures. OBJECTIVES This study aims to compare the ultrasound-guided bilateral ESP block versus bilateral TAP block on postoperative analgesia after open total abdominal hysterectomy. STUDY DESIGN A prospective, double-blinded, randomized, controlled, clinical trial. SETTING Zagazig University Hospitals. METHODS After ending of surgical procedure and before reversing of the muscle relaxant, 48 women were randomly allocated into 2 equal groups: erector spinae (ES) group received bilateral ultrasound-guided ESP block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000) in each side at the level of T9, and transversus abdominis (TA) group received bilateral ultrasound-guided TAP block with the same volume of bupivacaine plus adrenaline. RESULTS Visual Analog Scale scores at 30 minutes, 2, 4, 6, 8, 12, 16, 20, and 24 hours were statistically significantly lower in the ES group compared with the TA group. The time for requirement of first morphine was highly statistically significantly prolonged in the ES group (14.81 ± 3.52 hours) compared with the TA group (10.58 ± 2.35 hours). The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01. Incidence of postoperative nausea and vomiting was higher but statistically insignificant in the TA group than the ES group. There were statistically significant numbers of unsatisfied patients (4) in the TA group compared with the ES group (no patient). LIMITATIONS Sensorial evaluation of patients was not performed because both blocks had been done under general anesthesia but did not affect outcome. Therefore we recommend further studies comparing between both blocks. CONCLUSIONS Bilateral ultrasound-guided ESP block provides more potent and longer postoperative analgesia with less morphine consumption than TAP block after open total abdominal hysterectomy. KEY WORDS Abdominal hysterectomy, transversus abdominis plane block, erector spinae plane block, postoperative analgesia.",2020,The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01.,"['Zagazig University Hospitals', 'Postoperative Analgesia after Total Abdominal Hysterectomy', '48 women']","['Bilateral Ultrasound-Guided Erector Spinae Plane Block Versus Transversus Abdominis Plane Block', 'Abdominal hysterectomy, transversus abdominis plane block, erector spinae plane block, postoperative analgesia', 'Transversus abdominis plane (TAP) blocks', 'bupivacaine plus adrenaline', 'ultrasound-guided bilateral ESP block versus bilateral TAP block', 'erector spinae (ES) group received bilateral ultrasound-guided ESP block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000) in each side at the level of T9, and transversus abdominis (TA) group received bilateral ultrasound-guided TAP block']","['Incidence of postoperative nausea and vomiting', 'total amount of morphine consumption', 'time for requirement of first morphine', 'postoperative analgesia', 'Visual Analog Scale scores']","[{'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0404079', 'cui_str': 'Total abdominal hysterectomy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0404077', 'cui_str': 'Abdominal hysterectomy'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517455', 'cui_str': '0.375'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0520909', 'cui_str': 'Postoperative nausea and vomiting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",48.0,0.14806,The total amount of morphine consumption in 24 hours postoperatively was statistically significantly decreased in the ES group; P = 0.01.,"[{'ForeName': 'Alshaimaa Abdel Fattah', 'Initials': 'AAF', 'LastName': 'Kamel', 'Affiliation': 'Anaesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}, {'ForeName': 'Olfat Abdelmoniem Ibrahem', 'Initials': 'OAI', 'LastName': 'Amin', 'Affiliation': 'Anaesthesia and Surgical Intensive Care Department, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}, {'ForeName': 'Mohamed Abdel Moniem', 'Initials': 'MAM', 'LastName': 'Ibrahem', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, Alsharkia, Egypt.'}]",Pain physician,[] 2130,32709173,Contrast Medium Volume Needed to Reach Anterior Epidural Space via the Kambin Triangle or Subpedicular Approach for Transforaminal Epidural Injection.,"BACKGROUND Transforaminal (TF) lumbar injection is a commonly used minimally invasive intervention for management of chronic low back pain. TF injection can be performed using various approaches to inject the drug to the anterior epidural space (AES). OBJECTIVES To identify the volumes of contrast medium needed to reach the AES and other landmarks in the Kambin triangle (KB) and subpedicular (SP) approach of TF injection in patients with lumbosacral radicular pain. STUDY DESIGN Randomized controlled trial. SETTING Pain clinic and operating room of a tertiary care hospital. METHODS Seventy-five eligible patients were randomized to receive TF epidural injection either by SP (SP group; n = 38) or the KB (KB group; n = 37) approach under fluoroscopic guidance. After confirming the appropriate needle position, contrast medium was injected at 0.5 mL increments up to 2 mL under intermittent fluoroscopy. Contrast medium volumes needed to reach specific landmarks, that is, AES, medial to superior pedicle, medial to inferior pedicle, medial aspect of both the superior, and neural spread, were recorded. Following this, 4 mL of the drug (0.5% lidocaine 1 mL + methylprednisolone 80 mg + 1 mL normal saline solution) was injected. Patients were evaluated for Visual Analog Scale (VAS) and modified Oswestry Disability Questionnaire (MODQ) scores after epidural injections at 2 weeks, 1 month, and 2 months. RESULTS Average volume of contrast medium needed to reach AES was 1.10 ± 0.46 mL in the KB approach and 1.10 ± 0.38 mL in the SP approach. Contrast medium volume needed to reach other landmarks showed comparable results in both groups. AES was seen in 27.02% (10/37) patients in the KB group and 23.6% (9/38) patients in the SP group with 0.5 mL of contrast medium. This increased to 56.76% (21/37) and 77.7% (28/38) with 1 mL of contrast medium (P = 0.03, chi-square test). No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group. Neural spread was seen in 100% of patients in the KB group after 0.5 mL of contrast medium, but in 34 (89.4%) patients in the SP group (P = 0.03, chi-square test). We did not note any contralateral spread. Short-term effectiveness in pain relief in terms of VAS for back pain and functional improvement in terms of MODQ score over time showed similar results in both groups. Intravascular needle puncture and needle paresthesia was comparable in both groups. LIMITATIONS Small follow-up duration is one the limitations of this study. Future studies will be needed to assess any long-term differences in outcome between approach methods. Also, use of intermittent fluoroscopy might have limited detection of intravascular injections of the contrast medium in comparison to the continuous fluoroscopy. CONCLUSIONS To conclude, our study revealed that average volume of contrast medium needed to reach AES and other landmarks were comparable with both approaches of TF injection. KEY WORDS Transforaminal injection, subpedicular approach, Kambin triangle approach, contrast medium spread, anterior epidural spread.",2020,No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group.,"['patients with lumbosacral radicular pain', 'Seventy-five eligible patients', 'Pain clinic and operating room of a tertiary care hospital']","['KB (KB group; n = 37) approach under fluoroscopic guidance', 'TF injection', 'Transforaminal (TF) lumbar injection', 'TF epidural injection either by SP', 'lidocaine 1 mL + methylprednisolone 80 mg + 1 mL normal saline solution']","['pain relief', 'Neural spread', 'Visual Analog Scale (VAS) and modified Oswestry Disability Questionnaire (MODQ) scores', 'MODQ score', 'Intravascular needle puncture and needle paresthesia', 'AES']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450206', 'cui_str': 'Lumbosacral'}, {'cui': 'C0278147', 'cui_str': 'Radicular pain'}, {'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0242936', 'cui_str': 'Pain clinic'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital'}]","[{'cui': 'C0205119', 'cui_str': 'Triangular'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0560563', 'cui_str': 'Fluoroscopic guidance'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0021486', 'cui_str': 'Injections, Peridural'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0332261', 'cui_str': 'Spreading'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0442123', 'cui_str': 'Intravascular'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0014537', 'cui_str': 'Structure of epidural space'}]",75.0,0.0565945,No anterior spread was seen even after 2 mL of contrast medium in 4 patients in the KB group and 2 patients in the SP group.,"[{'ForeName': 'Babita', 'Initials': 'B', 'LastName': 'Ghai', 'Affiliation': 'Department of Anaesthesia, Post Graduate Institute of Medical Education and Research, Chandigarh.'}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Gupta', 'Affiliation': 'Departments of Orthopaedic Surgery, Anesthesia, and Intensive Care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Jeetinder Kaur', 'Initials': 'JK', 'LastName': 'Makkar', 'Affiliation': 'Department of Anesthesia and Intensive care, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Sarvdeep Singh', 'Initials': 'SS', 'LastName': 'Dhatt', 'Affiliation': 'Department of Orthopedics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.'}]",Pain physician,[] 2131,32709189,"Re: Comparisons of Monopolar Lesion Volumes with Hypertonic Saline Solution in Radiofrequency Ablation: A Randomized, Double-Blind, Ex Vivo Study.",,2020,,['Radiofrequency Ablation'],['Hypertonic Saline Solution'],[],"[{'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}]","[{'cui': 'C0036085', 'cui_str': 'sodium chloride, hypertonic'}]",[],,0.71595,,"[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Provenzano', 'Affiliation': 'Pain Diagnostics and Interventional Care, Sewickley, Pennsylvania.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Cosman', 'Affiliation': 'Cambridge Interventional, Burlington, MA.'}, {'ForeName': 'Jared', 'Initials': 'J', 'LastName': 'Wilsey', 'Affiliation': 'Smith-Nephew, Memphis, TN.'}]",Pain physician,[] 2132,32709230,Real-time monitoring and just-in-time intervention for adherence to pre-exposure prophylaxis among men who have sex with men in China: a multicentre RCT study protocol.,"BACKGROUND Pre-exposure prophylaxis (PrEP) is an effective biomedical strategy to prevent transmission of HIV infection, although medication adherence remains a challenge. We present the protocol for a multicentre randomised controlled trial to measure the effectiveness of a real-time monitoring and just-in-time intervention on medication adherence among PrEP users in China. METHODS Study participants will include 1000 men who have sex with men (MSM) from four cites in China (Shenyang, Beijing, Chongqing and Shenzhen) attending a tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP project as part of a real-world, prospective multicentre cohort study (CROPrEP). Participants will be randomised into the intervention and control arms in a 1:1 ratio. Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time SMS medication reminders to clinicians half an hour when there is no supplement after the second just-in-time SMS reminder to PrEP users. Clinicians will initiate individualised telephone intervention as soon as possible upon receipt of the just-in-time SMS missed dose alert. Those in the control arm will only receive generic weekly SMS reminders. The study will last 6 months. Participants will be seen at follow-up visits at three and 6 months. Trial outcomes to be measured include self-reported adherence assessed via questionnaire and pill counts, as well as drug concentration test results. DISCUSSION Medication adherence is critical to achieve optimal benefits from PrEP. This study will be the first individualised behaviour intervention using real-time technology to increase adherence among MSM PrEP users globally. If found effective, a real-time monitoring and just-in-time intervention system may be utilized for improving adherence and thus effectiveness of global PrEP application. TRIAL REGISTRATION This study registered at ClinicalTrials.gov ( ChiCTR1900025604 ) on September 2, 2019.",2020,"Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time","['Study participants will include 1000 men who have sex with men (MSM) from four cites in China (Shenyang, Beijing, Chongqing and Shenzhen) attending a', 'men who have sex with men in China', 'PrEP users in China']","['remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP', 'Real-time monitoring and just-in-time intervention', 'Pre-exposure prophylaxis (PrEP', 'tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) PrEP project', 'real-time monitoring and just-in-time intervention']","['self-reported adherence assessed via questionnaire and pill counts, as well as drug concentration test results', 'medication adherence']","[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}]","[{'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0456984', 'cui_str': 'Test finding'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",1000.0,0.0827213,"Participants in the intervention arm will be provided with remote real-time monitoring equipment that triggers twice just-in-time SMS (Short Messaging Service) medication reminders to PrEP users every half an hour when a scheduled dosage is missed, and followed with just-in-time","[{'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Jin', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hongyi', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hang', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Zhenxing', 'Initials': 'Z', 'LastName': 'Chu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Qinghai', 'Initials': 'Q', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Lv', 'Affiliation': 'Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.'}, {'ForeName': 'Xiaojie', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.'}, {'ForeName': 'Yaokai', 'Initials': 'Y', 'LastName': 'Chen', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, 400036, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': ""Shenzhen Third People's Hospital, Shenzhen, 518000, Guangdong, China.""}, {'ForeName': 'Xiaoqing', 'Initials': 'X', 'LastName': 'He', 'Affiliation': 'Chongqing Public Health Medical Center, Chongqing, 400036, China.'}, {'ForeName': 'Lukun', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': ""Shenzhen Third People's Hospital, Shenzhen, 518000, Guangdong, China.""}, {'ForeName': 'Zhili', 'Initials': 'Z', 'LastName': 'Hu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Rantong', 'Initials': 'R', 'LastName': 'Bao', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Shangcao', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Wenqing', 'Initials': 'W', 'LastName': 'Geng', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Yongjun', 'Initials': 'Y', 'LastName': 'Jiang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Shang', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. hongshang100@hotmail.com.'}, {'ForeName': 'Junjie', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'NHC Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China. xjjcmu@163.com.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMC public health,['10.1186/s12889-020-08709-2'] 2133,32709274,Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology.,"There is excitement in the air for patients with vitiligo. For the first time in decades, we have early case studies showing that targeted therapies can repigment vitiliginous skin, and well-powered clinical trials are underway. However, at the time of this writing, there is no Food and Drug Administration-approved drug for vitiligo. In a randomized clinical trial by Khemis et al. report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo. The results of this trial are a reminder that clinical management of vitiligo is challenging at best, even when combining anti-inflammatory and/or immunomodulating agents with repigmenting agents. However, these negative trials are critical in improving our understanding of this complex and disfiguring disease.",2020,"report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo.","['Vitiligo', 'patients with vitiligo', 'patients with nonsegmental vitiligo']","['phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B']",[],"[{'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C2936609', 'cui_str': 'Phosphodiesterase 4 inhibitor'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.131962,"report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo.","[{'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Ezzedine', 'Affiliation': 'Department of Dermatology, Henri Mondor University Hospital, Créteil, France; EpidermE, Université Paris-Est Créteil, UPEC, Créteil, France. Electronic address: khaled.ezzedine@aphp.fr.'}, {'ForeName': 'Terrence M', 'Initials': 'TM', 'LastName': 'Vance', 'Affiliation': 'Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.'}, {'ForeName': 'Iltefat H', 'Initials': 'IH', 'LastName': 'Hamzavi', 'Affiliation': 'Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, USA.'}, {'ForeName': 'Abrar A', 'Initials': 'AA', 'LastName': 'Qureshi', 'Affiliation': 'Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.'}]",The Journal of investigative dermatology,['10.1016/j.jid.2020.01.033'] 2134,32709643,Is a definitive trial of prehospital continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure indicated? The ACUTE pilot randomised controlled trial.,"OBJECTIVES To determine the feasibility of a large-scale definitive multicentre trial of prehospital continuous positive airway pressure (CPAP) in acute respiratory failure. DESIGN A single-centre, open-label, individual patient randomised, controlled, external pilot trial. SETTING A single UK Ambulance Service, between August 2017 and July 2018. PARTICIPANTS Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment. INTERVENTIONS Patients were randomised to prehospital CPAP (O-Two system) versus standard oxygen therapy in a 1:1 ratio using simple randomisation. PRIMARY AND SECONDARY OUTCOME MEASURES Feasibility outcomes comprised recruitment rate, adherence to allocated treatment, retention and data completeness. The primary clinical outcome was 30-day mortality. RESULTS 77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful. CPAP was fully delivered in 74% (target 75%). There were no major protocol violations. Full data were available for all key outcomes (targets ≥90%). Overall 30-day mortality was 27.3%. Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care. CONCLUSIONS Recruitment rate was below target and feasibility was not demonstrated. Limited compliance with CPAP, and difficulty in identifying patients who could benefit from CPAP, indicate that prehospital CPAP is unlikely to materially reduce mortality. A definitive effectiveness trial of CPAP is therefore not recommended. TRIAL REGISTRATION NUMBER ISRCTN12048261; Post-results.",2020,There were no major protocol violations.,"['77 patients were enrolled (target 120), including 7 cases with a diagnosis where CPAP could be ineffective or harmful', 'Adults with respiratory distress and peripheral oxygen saturations below British Thoracic Society target levels despite controlled oxygen treatment', 'A single UK Ambulance Service, between August 2017 and July 2018', 'Of these deceased patients, 14/21 (68%) either did not have a respiratory condition or had ceiling of treatment decisions implemented excluding hospital non-invasive ventilation and critical care']","['prehospital CPAP (O-Two system) versus standard oxygen therapy', 'CPAP', 'prehospital continuous positive airway pressure versus standard oxygen therapy', 'prehospital continuous positive airway pressure (CPAP']","['30-day mortality', 'recruitment rate, adherence to allocated treatment, retention and data completeness', 'CPAP', 'Overall 30-day mortality']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0476273', 'cui_str': 'Respiratory distress'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",77.0,0.313875,There were no major protocol violations.,"[{'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Fuller', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK g.fuller@sheffield.ac.uk.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Keating', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Steve', 'Initials': 'S', 'LastName': 'Goodacre', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Herbert', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Perkins', 'Affiliation': 'Clinical Trials Unit, University of Warwick, Coventry, UK.'}, {'ForeName': 'Andy', 'Initials': 'A', 'LastName': 'Rosser', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Imogen', 'Initials': 'I', 'LastName': 'Gunson', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Josh', 'Initials': 'J', 'LastName': 'Miller', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ward', 'Affiliation': 'West Midlands Ambulance Service NHS Foundation Trust, Brierley Hill, West Midlands, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Bradburn', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Thokala', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Harris', 'Affiliation': 'School of Medicine and Dentistry, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK.'}, {'ForeName': 'Maggie', 'Initials': 'M', 'LastName': 'Marsh', 'Affiliation': 'Sheffield Emergency Care Forum, Sheffield, UK.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Scott', 'Affiliation': 'School of Health and Related Research, The University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035915'] 2135,32709645,Infant formula composition and educational performance: a protocol to extend follow-up for a set of randomised controlled trials using linked administrative education records.,"INTRODUCTION The effect of infant nutrition on long-term cognition is important for parents and policy makers. However, most clinical trials typically have short follow-up periods, when measures of cognition are poorly predictive of later function. The few trials with longer-term follow-up have high levels of attrition, which can lead to selection bias, and in turn to erroneous interpretation of long-term harms and benefits of infant nutrition. We address the need for unbiased, long-term follow-up, by linking measures of educational performance from administrative education records. Educational performance is a meaningful marker of cognitive function in children and it is strongly correlated with IQ. We aim to evaluate educational performance for children who, as infants, were part of a series of trials that randomised participants to either nutritionally modified infant formula or standard formula. Most trialists anticipated positive effects of these interventions on later cognitive function. METHODS AND ANALYSIS Using data from 1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD), this study will provide new insights into the effect of nutrient intake in infancy on school achievement. Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16. Secondary outcomes will be z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11. We will also evaluate intervention effects on the likelihood of receiving special educational needs (SEN) support. All analyses will be performed separately by trial. ETHICS AND DISSEMINATION Research ethics approval, and approval from the Health Research Authority Confidentiality Advisory Group, has been obtained for this study. The results of this study will be disseminated to scientific, practitioner, and lay audiences, submitted for publication in peer-reviewed journals, and will contribute towards a PhD dissertation.",2020,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"['1923 participants of seven randomised infant formula trials linked to the English National Pupil Database (NPD', 'children who, as infants']",['nutritionally modified infant formula or standard formula'],"['z-scores for a compulsory English exam at age 16 and z-scores for compulsory Mathematics and English exams at age 11', 'z-scores', 'educational performance']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0034121', 'cui_str': 'Pupil structure'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0150589', 'cui_str': 'Infant formula'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}]","[{'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0024934', 'cui_str': 'Mathematics'}, {'cui': 'C0036373', 'cui_str': 'Academic Test Performance'}]",1923.0,0.167281,Our primary outcome will be the mean differences in z-scores between intervention and control groups for a compulsory Mathematics exam sat at age 16.,"[{'ForeName': 'Maximiliane', 'Initials': 'M', 'LastName': 'Verfürden', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK m.verfuerden@ucl.ac.uk.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Harron', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Jerrim', 'Affiliation': 'Institute of Education, University College London, London, UK.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Fewtrell', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Gilbert', 'Affiliation': 'Great Ormond Street Institute of Child Health, University College London, London, UK.'}]",BMJ open,['10.1136/bmjopen-2019-035968'] 2136,32709656,"Efficacy, cost-utility and physiological effects of Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment for Depression (BATD) in patients with chronic low back pain and depression: study protocol of a randomised, controlled trial including mobile-technology-based ecological momentary assessment (IMPACT study).","INTRODUCTION The IMPACT study focuses on chronic low back pain (CLBP) and depression symptoms, a prevalent and complex problem that represents a challenge for health professionals. Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively. The objectives of this 12 month, multicentre, randomised, controlled trial (RCT) are (i) to examine the efficacy and cost-utility of adding a group-based form of ACT or BATD to treatment-as-usual (TAU) for patients with CLBP and moderate to severe levels of depressive symptoms; (ii) identify pre-post differences in levels of some physiological variables and (iii) analyse the role of polymorphisms in the FKBP5 gene, psychological process measures and physiological variables as mediators or moderators of long-term clinical changes. METHODS AND ANALYSIS Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain), randomly allocated to one of the three study arms: TAU vs TAU+ACT versus TAU+BATD. A comprehensive assessment to collect clinical variables and costs will be conducted pretreatment, post-treatment and at 12 months follow-up, being pain interference the primary outcome measure. The following physiological variables will be considered at pretreatment and post-treatment assessments in 50% of the sample: immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms in the FKBP5 gene (rs3800373, rs9296158, rs1360780, rs9470080 and rs4713916) will be analysed at baseline assessment. Moreover, we will include mobile-technology-based ecological momentary assessment, through the Pain Monitor app, to track ongoing clinical status during ACT and BATD treatments. Linear mixed-effects models using restricted maximum likelihood, and a full economic evaluation applying bootstrapping techniques, acceptability curves and sensitivity analyses will be computed. ETHICS AND DISSEMINATION This study has been approved by the Ethics Committee of the Fundació Sant Joan de Déu and Hospital del Mar. The results will be actively disseminated through peer-reviewed journals, conference presentations, social media and various community engagement activities. TRIAL REGISTRATION NUMBER NCT04140838.",2020,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","['patients with chronic low back pain and depression', 'patients with CLBP and moderate to severe levels of depressive symptoms', 'patients with persistent pain and depression, respectively', 'Participants will be 225 patients with CLBP and moderate to severe depression symptoms recruited at Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat, Spain) and Hospital del Mar (Barcelona, Spain']","['Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment', 'Acceptance and Commitment Therapy (ACT) and Behavioural Activation Treatment', 'ACT or BATD to treatment-as-usual (TAU', 'TAU vs TAU+ACT\u2009versus TAU+BATD']","['chronic low back pain (CLBP) and depression symptoms', 'immune-inflammatory markers, hair cortisol and cortisone, serum cortisol, corticosteroid-binding globulin and vitamin D. Polymorphisms', 'efficacy and cost-utility', 'Efficacy, cost-utility and physiological effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4517652', 'cui_str': '225'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008628', 'cui_str': 'Chromosomal deletion'}, {'cui': 'C0024782', 'cui_str': 'Marathi language'}]","[{'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011570', 'cui_str': 'Depression'}]","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0018494', 'cui_str': 'Hair structure'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0010137', 'cui_str': 'Cortisone'}, {'cui': 'C0236396', 'cui_str': 'Serum cortisol measurement'}, {'cui': 'C0040643', 'cui_str': 'Corticotropin binding globulin'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",225.0,0.185291,"Acceptance and Commitment Therapy (ACT) and Brief Behavioural Activation Treatment for Depression (BATD) are effective treatments for patients with persistent pain and depression, respectively.","[{'ForeName': 'Juan P', 'Initials': 'JP', 'LastName': 'Sanabria-Mazo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Carlos G', 'Initials': 'CG', 'LastName': 'Forero', 'Affiliation': 'Department of Medicine, International University of Catalunya, Barcelona, Spain.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Cristobal-Narváez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Suso-Ribera', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Azucena', 'Initials': 'A', 'LastName': 'García-Palacios', 'Affiliation': 'Department of Basic and Clinical Psychology and Psychobiology, Universitat Jaume I, Castelló de la Plana, Spain.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Colomer-Carbonell', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Adrián', 'Initials': 'A', 'LastName': 'Pérez-Aranda', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Andrés-Rodríguez', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lance M', 'Initials': 'LM', 'LastName': 'McCracken', 'Affiliation': 'Psychology Department, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': ""D'Amico"", 'Affiliation': 'Personal Social Services Research Unit, London School of Economics and Political Science, London, UK.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Estivill-Rodríguez', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Bernat', 'Initials': 'B', 'LastName': 'Carreras-Marcos', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Montes-Pérez', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Comps-Vicente', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Montserrat', 'Initials': 'M', 'LastName': 'Esteve', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Grasa', 'Affiliation': 'Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Araceli', 'Initials': 'A', 'LastName': 'Rosa', 'Affiliation': 'Network Centre for Biomedical Research in Mental Health (CIBERSAM), Institute of Health Carlos III, Madrid, Spain.'}, {'ForeName': 'Antonio I', 'Initials': 'AI', 'LastName': 'Cuesta-Vargas', 'Affiliation': 'Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Maes', 'Affiliation': 'Department of Psychiatry, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Borràs', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Edo', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Sanz', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Feliu-Soler', 'Affiliation': 'Department of Basic, Developmental and Educational Psychology, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Juan R', 'Initials': 'JR', 'LastName': 'Castaño-Asins', 'Affiliation': 'Consorci Parc de Salut MAR de Barcelona, Barcelona, Catalunya, Spain.'}, {'ForeName': 'Juan V', 'Initials': 'JV', 'LastName': 'Luciano', 'Affiliation': 'Parc Sanitari Sant Joan de Deu, Sant Boi de Llobregat, Catalunya, Spain jvluciano@pssjd.org.'}]",BMJ open,['10.1136/bmjopen-2020-038107'] 2137,32709657,Bridging the gap between physical and mental illness in community pharmacy ( PharMIbridge ): protocol for an Australian cluster randomised controlled trial.,"INTRODUCTION There is a significant life expectancy gap attributable to physical comorbidities for people living with severe and persistent mental illness (SPMI) compared with the general population. Medications are a major treatment for SPMI management and physical illnesses, hence pharmacists are well positioned to support mental healthcare and comorbidities. The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck). METHODS AND ANALYSIS: PharMIbridge is a cluster RCT, whereby community pharmacies in four Australian regions will be randomised (1:1 ratio), to either Intervention Group (IG) or Comparator Group (CG). All IG and CG pharmacy staff will receive Blended-Mental Health First Aid training. Additionally, IG pharmacists will receive further training on medication adherence, goal setting, motivational interviewing, managing physical health concerns and complex issues relating to psychotropic medication. CG pharmacists will not receive additional training, and will provide standard care (MedsCheck). The primary outcome will be change in participants medication adherence for psychotropic medication over 6-months. Using mixed-effects logistic regression model and a cluster size of 48 pharmacies, a total of 190 participants will need to be recruited to each arm to find a statistically significant difference in medication adherence. Secondary outcomes will be changes in factors associated with cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation. A within RCT-based economic evaluation comparing the intervention with standard care will be undertaken. ETHICS AND DISSEMINATION The protocol and pharmacist training programme received Griffith University Human Research Ethics Committee approval (HREC/2019/473 and HREC/2019/493 respectively). Results will be published in peer-reviewed journals and available at the Sixth Community Pharmacy Agreement website (http://6cpa.com.au/about-6cpa/). TRIAL REGISTRATION NUMBER ANZCTR12620000577910.",2020,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","['people living with severe and persistent mental illness (SPMI', '48 pharmacies, a total of 190 participants']",['Blended-Mental Health First Aid training'],"['cardiometabolic risk and quality of life, emphasising physical and psychological well-being; medication-related problems; adherence to other prescribed medication; pharmacists knowledge, confidence and ability to support people experiencing SPMI; and effects on healthcare utilisation', 'participants medication adherence for psychotropic medication', 'medication adherence']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C0031321', 'cui_str': 'Pharmacy service'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517622', 'cui_str': '190'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1276379', 'cui_str': 'First aid education'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424578', 'cui_str': 'Well in self'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0031323', 'cui_str': 'Pharmacist'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0870281', 'cui_str': 'Chronic mental disorder'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0033978', 'cui_str': 'Psychotherapeutic agent'}]",190.0,0.139524,"The randomised controlled trial (RCT) aim is to evaluate effectiveness of an individualised, pharmacist led, support service for people experiencing SPMI focusing on medication adherence and physical comorbidity management, compared with standard care (a medication-management service; MedsCheck).","[{'ForeName': 'Amanda J', 'Initials': 'AJ', 'LastName': 'Wheeler', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia a.wheeler@griffith.edu.au.'}, {'ForeName': 'Claire L', 'Initials': 'CL', 'LastName': ""O'Reilly"", 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Sarira', 'Initials': 'S', 'LastName': 'El-Den', 'Affiliation': 'Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Byrnes', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Ware', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Sara S', 'Initials': 'SS', 'LastName': 'McMillan', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-039983'] 2138,32709710,Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial.,"BACKGROUND Regional anesthesia improves short-term blood flow through arteriovenous fistulas (AVFs). We previously demonstrated that, compared with local anesthesia, regional anesthesia improves primary AVF patency at 3 months. METHODS To study the effects of regional versus local anesthesia on longer-term AVF patency, we performed an observer-blinded randomized controlled trial at three university hospitals in Glasgow, United Kingdom. We randomly assigned 126 patients undergoing primary radiocephalic or brachiocephalic AVF creation to receive regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine) or local anesthesia (0.5% L-bupivacaine and 1% lidocaine). This report includes findings on primary, functional, and secondary patency at 12 months; reinterventions; and additional access procedures (primary outcome measures were previously reported). We analyzed data by intention to treat, and also performed cost-effectiveness analyses. RESULTS At 12 months, we found higher primary patency among patients receiving regional versus local anesthesia (50 of 63 [79%] versus 37 of 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P =0.02) as well as higher functional patency (43 of 63 [68%] versus 31 of 63 [49%] patients; OR, 2.1; 95% CI, 1.5 to 2.7; P =0.008). In 12 months, 21 revisional procedures, 53 new AVFs, and 50 temporary dialysis catheters were required. Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon. Results were robust after extensive sensitivity and scenario analyses. CONCLUSIONS Compared with local anesthesia, regional anesthesia significantly improved both primary and functional AVF patency at 1 year and is cost-effective. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.",2020,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","['126 patients undergoing', 'three university hospitals in Glasgow, United Kingdom']","['primary radiocephalic or brachiocephalic', 'regional versus local anesthesia', 'regional anesthesia (brachial plexus block; 0.5% L-bupivacaine and 1.5% lidocaine with epinephrine', 'Arteriovenous Fistula Creation under Regional Anesthesia', 'local anesthesia, regional anesthesia', 'local anesthesia (0.5% L-bupivacaine and 1% lidocaine']","['functional patency', 'primary patency', 'primary AVF patency', 'incremental cost-effectiveness ratio', 'net savings', 'cost-effective', 'functional AVF patency']","[{'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0002911', 'cui_str': 'Regional anesthesia'}, {'cui': 'C0394697', 'cui_str': 'Injection of anesthetic agent into brachial plexus'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0398221', 'cui_str': 'Arteriovenous fistulization'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449215', 'cui_str': 'aVF'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0036245', 'cui_str': 'Savings'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",126.0,0.356984,"Regional anesthesia resulted in net savings of £195.10 (US$237.36) per patient at 1 year, and an incremental cost-effectiveness ratio of approximately £12,900 (US$15,694.20) per quality-adjusted life years over a 5-year time horizon.","[{'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Aitken', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom emmaaitken@nhs.net.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kearns', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Lucian', 'Initials': 'L', 'LastName': 'Gaianu', 'Affiliation': 'Scottish Health Technologies Group, Healthcare Improvement Scotland, Edinburgh, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Jackson', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Steven', 'Affiliation': 'Department of Anaesthesia, Golden Jubilee National Hospital, Clydebank, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Kinsella', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Clancy', 'Affiliation': 'Department of Renal Surgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Macfarlane', 'Affiliation': 'Department of Anaesthesia, Critical Care and Pain Medicine, University of Glasgow, Glasgow, United Kingdom.'}]",Journal of the American Society of Nephrology : JASN,['10.1681/ASN.2019111209'] 2139,32712307,A 24-month randomized controlled trial on the success rates of restoring untreated and SDF-treated dentine caries lesions in primary teeth with the ART approach.,"OBJECTIVE To compare the success rates of restoring untreated and SDF-treated dentine caries lesions in primary teeth with atraumatic restorative treatment (ART) approach. METHOD Cavitated dentine caries lesions in preschool children were randomly allocated to two groups to be applied with either 38% silver diamine fluoride (SDF) solution or tonic water (control) ten weeks before being restored with the ART approach. Status of the restorations were assessed every six months by a blinded independent examiner. Multilevel logistic regression and multilevel survival analyses were conducted to assess the restoration success rates. RESULTS A total of 194 children (SDF group, 101; control group, 93) were included, with 260 and 249 ART restorations placed in the SDF and the control groups, respectively. At 24-month follow-up, 88 (87 %) and 84 (90 %) children remained in the SDF and the control groups, respectively. There was no significant difference between the ART restoration success rates of the two study groups (p > 0.05). The success rate of ART restorations was associated with the class of restorations. Class I restorations had the highest success rate (∼50 %), followed by Class V (∼35 %), Class II (∼15 %) and Class III (<10 %). Besides, the mean time used to place an ART restoration in a SDF-treated caries lesion was shorter than that in untreated lesion (4.8 vs. 5.1 min, p = 0.006). CONCLUSION Prior SDF application does not significantly affect the success rate of ART restorations placed in primary teeth. Besides, it is faster to place ART restorations in caries lesions that have been previously treated with SDF. CLINICAL SIGNIFICANCE Prior application of silver diamine fluoride solution on cavitated dentine caries lesions in primary teeth can shorten the average time required to place an ART restoration while not jeopardizing the success rate of the restorations.",2020,There was no significant difference between the ART restoration success rates of the two study groups (p > 0.05).,"['Cavitated dentine caries lesions in preschool children', 'primary teeth with atraumatic restorative treatment (ART) approach', '194 children (SDF group, 101; control group, 93) were included, with 260 and 249 ART restorations placed in the SDF and the control groups, respectively', 'cavitated dentine caries lesions in primary teeth', 'primary teeth with the ART approach']","['38% silver diamine fluoride (SDF) solution or tonic water (control) ten weeks before being restored with the ART approach', 'restoring untreated and SDF-treated dentine caries lesions', 'silver diamine fluoride solution']","['ART restoration success rates', 'highest success rate', 'success rates', 'mean time used to place an ART restoration in a SDF-treated caries lesion', 'success rate of ART restorations', 'success rate']","[{'cui': 'C0266846', 'cui_str': 'Dental caries extending into dentin'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C3266841', 'cui_str': 'All deciduous teeth'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0074538', 'cui_str': 'Silver diamine fluoride'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517669', 'cui_str': '260'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0442504', 'cui_str': 'Place'}]","[{'cui': 'C0074538', 'cui_str': 'Silver diamine fluoride'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0452449', 'cui_str': 'Tonic water'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0266846', 'cui_str': 'Dental caries extending into dentin'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0074538', 'cui_str': 'Silver diamine fluoride'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]",194.0,0.0638187,There was no significant difference between the ART restoration success rates of the two study groups (p > 0.05).,"[{'ForeName': 'Jiang', 'Initials': 'J', 'LastName': 'Meng', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'May Chun Mei', 'Initials': 'MCM', 'LastName': 'Wong', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Chu Chun', 'Initials': 'CC', 'LastName': 'Hung', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Linlu', 'Initials': 'L', 'LastName': 'Dai', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Edward Chin Man', 'Initials': 'ECM', 'LastName': 'Lo', 'Affiliation': 'Faculty of Dentistry, The University of Hong Kong, Hong Kong, China. Electronic address: edward-lo@hku.hk.'}]",Journal of dentistry,['10.1016/j.jdent.2020.103435'] 2140,32712322,Postoperative urinary retention rates after autofill versus backfill void trial following total laparoscopic hysterectomy: a randomized controlled trial.,"STUDY OBJECTIVE To compare the rate of postoperative urinary retention (POUR) after total laparoscopic hysterectomy (TLH) using the autofill versus the backfill void trial. Secondary objectives were to compare the time to discharge from the recovery room, rate of postoperative urinary tract infection (UTI), perceived bladder condition, bladder function impact on life, and patient satisfaction. DESIGN Randomized controlled trial. SETTING Single academic medical center. PATIENTS Women who underwent TLH by conventional laparoscopy or robotic-assisted laparoscopy for benign non-urogynecologic indications. INTERVENTIONS After TLH, participants were randomized to have an autofill void trial (group A) or a backfill void trial once able to ambulate (group B). Failure rate, time to discharge, and UTI rate were assessed. Participants completed the patient perception of bladder condition (PPBC) and the incontinence impact questionnaire-short form (IIQ-7) questionnaires. Patient satisfaction was assessed. Multiple regression analysis was performed to determine predictors of POUR. MEASUREMENTS AND MAIN RESULTS 82 participants completed the study after randomization: 42 in group A and 40 in group B. There were no statistically significant differences in demographic or perioperative outcomes. Seven participants had POUR in group A (16.7%) and 11 in group B (27.5%) (p = .36). The median time to discharge was 176 minutes for group A [160.5, 255.5] and 218 minutes for group B [180, 265] (p = 0.01). There were no statistically significant differences in rate of postoperative UTI (p = 1.00), PPBC scores (p = 0.24), IIQ-7 scores (p = 0.23), and patient satisfaction scores (p = 0.26). A stepwise logistic regression analysis did not demonstrate any predictors of POUR. CONCLUSION Backfill void trial once the participant was able to ambulate was not superior to the autofill void trial with respect to the rate of POUR.. The autofill void trial resulted in faster same-day discharge.",2020,"There were no statistically significant differences in rate of postoperative UTI (p = 1.00), PPBC scores (p = 0.24), IIQ-7 scores (p = 0.23), and patient satisfaction scores (p = 0.26).","['Single academic medical center', 'Women who underwent', 'for benign non-urogynecologic indications']","['total laparoscopic hysterectomy', 'TLH by conventional laparoscopy or robotic-assisted laparoscopy', 'total laparoscopic hysterectomy (TLH']","['Patient satisfaction', 'IIQ-7 scores', 'patient perception of bladder condition (PPBC) and the incontinence impact questionnaire-short form (IIQ-7) questionnaires', 'Postoperative urinary retention rates', 'PPBC scores', 'time to discharge from the recovery room, rate of postoperative urinary tract infection (UTI), perceived bladder condition, bladder function impact on life, and patient satisfaction', 'rate of postoperative UTI', 'rate of postoperative urinary retention (POUR', 'Failure rate, time to discharge, and UTI rate', 'patient satisfaction scores', 'median time to discharge']","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0034871', 'cui_str': 'Postoperative anesthesia care unit'}, {'cui': 'C0403709', 'cui_str': 'Postoperative urinary tract infection'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0232840', 'cui_str': 'Bladder function'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0451370', 'cui_str': 'Patient satisfaction score'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",82.0,0.319498,"There were no statistically significant differences in rate of postoperative UTI (p = 1.00), PPBC scores (p = 0.24), IIQ-7 scores (p = 0.23), and patient satisfaction scores (p = 0.26).","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Farag', 'Affiliation': 'Division of Gynecology, Cleveland Clinic Florida, Weston, FL. Electronic address: faragsara@gmail.com.'}, {'ForeName': 'Pamela Frazzini', 'Initials': 'PF', 'LastName': 'Padilla', 'Affiliation': 'Division of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Katherine A', 'Initials': 'KA', 'LastName': 'Smith', 'Affiliation': 'Division of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Zimberg', 'Affiliation': 'Division of Gynecology, Cleveland Clinic Florida, Weston, FL.'}, {'ForeName': 'Michael L', 'Initials': 'ML', 'LastName': 'Sprague', 'Affiliation': 'Division of Gynecology, Cleveland Clinic Florida, Weston, FL.'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2020.07.013'] 2141,32712347,Impact of myoglobin oxygenation state prior to frozen storage on color stability of thawed beef steaks through retail display.,"Consumers consider beef color to be an indicator of freshness and therefore it is a major factor when purchasing beef. The ideal conditions for maintaining color throughout retail display following frozen storage have yet to be well established. Therefore, the objective of this study was to determine the effects of myoglobin oxygenation levels (especially high oxygenation) during freezing on color stability of thawed steaks during retail display (RD) and to determine the impact that frozen storage duration, aging, and packaging films have on meat color after thawing under RD conditions. USDA Choice strip loins (n = 36) were aged for 4 or 20 d. Steaks were randomly assigned to a myoglobin oxygenation level [deoxymyoglobin (DeOxy; packaged within 3 min), oxygenation (Oxy; oxygenated in air for 30 min), or high oxygenation (HiOxy; packaged for 24 h in 80% O 2 )]. Steaks were then vacuum packaged in oxygen permeable or impermeable film and immediately frozen (-10 °C). Following either 0, 2, 4, or 6 months of frozen storage at -5 °C, steaks were removed from the packaging and immediately placed under simulated RD conditions for 7 d. During RD, instrumental color and subjective color were measured every day after the initial 24 h thaw period. Steaks were analyzed for instrumental color (L*, a*, b*), a*:b* ratio, percentage oxymyoglobin, metmyoglobin, and deoxymyoglobin, delta E, redness ratio, subjective discoloration, and lipid oxidation. For all days of RD, steaks that were frozen for 0 months had higher a* values (greater redness) than steaks frozen for 6 months which typically had the lowest a* values (P < .0001). HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P < .05). The HiOxy steaks frozen for 4 and 6 months had higher percentage metmyoglobin than DeOxy and Oxy, regardless of packaging (P < .05). Delta E, discoloration, and lipid oxidation were greatest for HiOxy steaks compared to Oxy and DeOxy (P < .05). Extended storage brought about detrimental color effects for all differing levels of myoglobin oxygenation. The HiOxy steaks through the first few days of RD and frozen for under 6 months provided had bright cherry red color, similar to that of DeOxy and Oxy. However, with extended frozen storage and RD, HiOxy steaks had worse color characteristics (more discoloration) than the other myoglobin oxygenation levels.",2020,HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P ,['n\xa0=\xa036) were aged for 4 or 20\xa0d. Steaks'],"['myoglobin oxygenation state prior to frozen storage', 'USDA Choice strip loins', 'myoglobin oxygenation level [deoxymyoglobin (DeOxy; packaged within 3\xa0min), oxygenation (Oxy; oxygenated in air for 30\xa0min), or high oxygenation (HiOxy']","['myoglobin oxygenation levels', 'percentage oxymyoglobin, metmyoglobin, and deoxymyoglobin, delta E, redness ratio, subjective discoloration, and lipid oxidation', 'Delta E, discoloration, and lipid oxidation', 'color stability']","[{'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0085410', 'cui_str': 'Department of Agriculture (U.S.)'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0185047', 'cui_str': 'Stripping'}, {'cui': 'C0446502', 'cui_str': 'Loin (surface region)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0057444', 'cui_str': 'deoxymyoglobin'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0205250', 'cui_str': 'High'}]","[{'cui': 'C0027078', 'cui_str': 'Myoglobin'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0069830', 'cui_str': 'oxymyoglobin'}, {'cui': 'C0025852', 'cui_str': 'Metmyoglobin'}, {'cui': 'C0057444', 'cui_str': 'deoxymyoglobin'}, {'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0332572', 'cui_str': 'Abnormal color'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",36.0,0.0389964,HiOxy steaks frozen for 6 months had the lowest amounts of percentage oxymyoglobin than all other frozen storage periods and myoglobin oxygenation levels on days 4-7 of RD (P ,"[{'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Henriott', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'N J', 'Initials': 'NJ', 'LastName': 'Herrera', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'F A', 'Initials': 'FA', 'LastName': 'Ribeiro', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'K B', 'Initials': 'KB', 'LastName': 'Hart', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Bland', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Eskridge', 'Affiliation': 'Department of Statistics, University of Nebraska, Lincoln 68583-0908, USA.'}, {'ForeName': 'C R', 'Initials': 'CR', 'LastName': 'Calkins', 'Affiliation': 'Department of Animal Science, University of Nebraska, Lincoln 68583-0908, USA. Electronic address: ccalkins1@unl.edu.'}]",Meat science,['10.1016/j.meatsci.2020.108232'] 2142,32712583,Effect of Sequential Noninvasive Ventilation on Early Extubation After Acute Type A Aortic Dissection.,"BACKGROUND Acute type A aortic dissection (aTAAD) is associated with a high incidence of prolonged postoperative invasive mechanical ventilation. We aimed to assess whether sequential noninvasive ventilation (NIV) could facilitate early extubation postoperatively after a spontaneous breathing trial (SBT) failure among aTAAD patients. METHODS Beginning in December 2016, we transitioned our weaning strategy from repeated SBT until success (phase 1) to extubation concomitant with sequential NIV (phase 2) for subjects who failed their first SBT. The primary outcomes were re-intubation rate, duration of invasive ventilation, and total duration of ventilation. RESULTS During the study period, 78 subjects with aTAAD failed their first postoperative SBT (38 subjects in phase 1 and 40 subjects in phase 2). Subjects extubated with sequential NIV had shorter median (interquartile range [IQR]) duration of invasive ventilation of 39.5 (30.8-57.8) h vs 89.5 (64-112) h ( P < .001) and median (IQR) length of ICU stay of 6 (4.0-7.8) d vs 7.5 (5.8-9.0) d ( P = .030). There were no significant differences between the 2 phases with regard to rates of re-intubation (7.5% vs 7.89%, P = .95), tracheostomy (2.5% vs 5.26%, P = .53), and in-hospital mortality (2.5% vs 2.63%, P = .97). CONCLUSIONS Early extubation followed by sequential NIV significantly reduced duration of invasive ventilation and length of ICU stay without increasing re-intubation rate in postoperative subjects with aTAAD who failed their first SBT.",2020,"There were no significant differences between the 2 phases with regard to rates of re-intubation (7.5% vs 7.89%, P = .95), tracheostomy (2.5% vs 5.26%, P = .53), and in-hospital mortality (2.5% vs 2.63%, P = .97). ","['Acute type A aortic dissection (aTAAD', 'Beginning in December 2016', '78 subjects with aTAAD failed their first postoperative SBT (38 subjects in phase 1 and 40 subjects in phase 2', 'aTAAD patients']","['Sequential Noninvasive Ventilation', 'sequential noninvasive ventilation (NIV']","['median (IQR) length of ICU stay', 'rates of re-intubation', 'shorter median (interquartile range [IQR]) duration of invasive ventilation', 'tracheostomy', 'duration of invasive ventilation and length of ICU stay', 'Early Extubation', 're-intubation rate, duration of invasive ventilation, and total duration of ventilation', 'hospital mortality']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0578575', 'cui_str': 'Dissection of proximal aorta'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C1828139', 'cui_str': 'Trial for spontaneous breathing'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0282460', 'cui_str': 'Clinical Trials, Phase II as Topic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0040590', 'cui_str': 'Tracheostomy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}]",78.0,0.0726045,"There were no significant differences between the 2 phases with regard to rates of re-intubation (7.5% vs 7.89%, P = .95), tracheostomy (2.5% vs 5.26%, P = .53), and in-hospital mortality (2.5% vs 2.63%, P = .97). ","[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Liu', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guang-Wei', 'Initials': 'GW', 'LastName': 'Hao', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Ji-Li', 'Initials': 'JL', 'LastName': 'Zheng', 'Affiliation': 'Department of Nursing, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jing-Chao', 'Initials': 'JC', 'LastName': 'Luo', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Su', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jun-Yi', 'Initials': 'JY', 'LastName': 'Hou', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Guo-Guang', 'Initials': 'GG', 'LastName': 'Ma', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Shen-Ji', 'Initials': 'SJ', 'LastName': 'Yu', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': 'Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yong-Xin', 'Initials': 'YX', 'LastName': 'Sun', 'Affiliation': 'Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Lai', 'Affiliation': 'Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Chun-Sheng', 'Initials': 'CS', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Luo', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. luo.zhe@zs-hospital.sh.cn tu.guowei@zs-hospital.sh.cn.'}, {'ForeName': 'Guo-Wei', 'Initials': 'GW', 'LastName': 'Tu', 'Affiliation': 'Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.'}]",Respiratory care,['10.4187/respcare.07522'] 2143,32712591,"Effect of lumbar stabilization exercises and thoracic mobilization with strengthening exercises on pain level, thoracic kyphosis, and functional disability in chronic low back pain.","Objectives The purpose of this study was to compare the effect of lumbar stabilization exercise and thoracic mobilization with strengthening exercise on pain level, thoracic kyphosis, and functional disability in patients with Chronic Low Back Pain (CLBP). Methods Thirty patients with CLBP were recruited based on inclusion and exclusion criteria. They were randomly allocated into two groups i. e., Group A (n = 15) and B (n = 15). Group A has received lumbar stabilization exercise and thoracic mobilization with strengthening exercises and Group B received only lumbar stabilization exercises, three sessions per week for 4 weeks both the groups. The conventional moist hot pack and interferential therapy was given to both the groups before the administration of exercise. Pre- and post-treatment pain level, Thoracic kyphosis, and functional disability were taken and statistical analysis was done. Results The result of this study showed significant improvement from pre-intervention to post-intervention on pain level, thoracic kyphosis, and functional disability for both the groups i. e., Group A and group B but Group A showed greater changes in Numerical pain rating scale (NPRS), Kyphotic index, and Oswestry disability index (ODI), than Group B. Conclusions The 4 week of therapeutic intervention including lumbar stabilization exercise with thoracic mobilization and strengthening exercise showed significantly reduction of the thoracic kyphosis, pain level and functional disability in patients with Chronic Low Back Pain.",2020,"The 4 week of therapeutic intervention including lumbar stabilization exercise with thoracic mobilization and strengthening exercise showed significantly reduction of the thoracic kyphosis, pain level and functional disability in patients with Chronic Low Back Pain.","['chronic low back pain', 'patients with Chronic Low Back Pain', 'patients with Chronic Low Back Pain (CLBP', 'Thirty patients with CLBP were recruited based on inclusion and exclusion criteria']","['lumbar stabilization exercise and thoracic mobilization with strengthening exercise', 'lumbar stabilization exercises and thoracic mobilization with strengthening exercises', 'lumbar stabilization exercise with thoracic mobilization and strengthening exercise', 'conventional moist hot pack and interferential therapy', 'lumbar stabilization exercise and thoracic mobilization with strengthening exercises and Group B received only lumbar stabilization exercises']","['thoracic kyphosis, pain level and functional disability', 'pain level, thoracic kyphosis, and functional disability', 'Thoracic kyphosis, and functional disability', 'Numerical pain rating scale (NPRS), Kyphotic index, and Oswestry disability index (ODI']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0452260', 'cui_str': 'Muscular strength development exercise'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0556898', 'cui_str': 'Interferential therapy'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0022821', 'cui_str': 'Kyphosis deformity of spine'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}]",30.0,0.0321456,"The 4 week of therapeutic intervention including lumbar stabilization exercise with thoracic mobilization and strengthening exercise showed significantly reduction of the thoracic kyphosis, pain level and functional disability in patients with Chronic Low Back Pain.","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences Jamia Millia Islamia, A Central University, Delhi, India.'}, {'ForeName': 'Adila', 'Initials': 'A', 'LastName': 'Parveen', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences Jamia Millia Islamia, A Central University, Delhi, India.'}, {'ForeName': 'Shibili', 'Initials': 'S', 'LastName': 'Nuhmani', 'Affiliation': 'Department of Physical Therapy, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.'}, {'ForeName': 'Mohammed', 'Initials': 'M', 'LastName': 'Ejaz Hussain', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences Jamia Millia Islamia, A Central University, Delhi, India.'}, {'ForeName': 'Moazzam', 'Initials': 'M', 'LastName': 'Hussain Khan', 'Affiliation': 'Centre for Physiotherapy and Rehabilitation Sciences Jamia Millia Islamia, A Central University, Delhi, India.'}]",Journal of complementary & integrative medicine,['10.1515/jcim-2019-0327'] 2144,32712606,Acupuncture as Complementary Treatment for Acute Tinnitus: A Randomized Controlled Pilot Study.,"BACKGROUND Up to now, tinnitus has been an almost non-treatable symptom affecting more than 18% of the population in industrialized countries. So far, there are only a few studies evaluating the effectiveness of acupuncture in tinnitus treatment, none of which include acute tinnitus (<3 months). The aim of this pilot study was to explore the feasibility of recruitment and adherence to acupuncture conducted according to the principles of traditional Chinese medicine in patients with acute idiopathic tinnitus and to assess effect sizes on subjective and objective outcomes within a randomized controlled design. PATIENTS AND METHODS After randomization patients of the control group received usual care (n = 23), and patients of the intervention group (n = 25) received 4 additional acupuncture treatments in a 4- to 6-week period. Tinnitus severity was assessed by means of a visual analogue scale as well as standardized and validated tinnitus questionnaires (Tinnitus Functional Index and 12-item Mini Tinnitus Questionnaire) at baseline and 6 weeks after. These subjective parameters were completed by tone audiometry. Comparisons of the groups were carried out using the Wilcoxon-Mann-Whitney test. RESULTS Both groups were comparable without significant differences in baseline values. All outcomes, except for the overall well-being, showed better improvements in the intervention group with clinically significant differences from baseline to end point. However, among the outcomes only the subjective change in tinnitus severity showed a significant group difference. No serious side effects were observed. CONCLUSION The design of our pilot study was feasible in terms of recruitment, although patient adherence to treatment remained challenging. However, considering the small intergroup differences, procedures regarding the numbers of acupuncture sessions and the total period of the acupuncture treatment should be reconsidered. The results of this pilot study provide a good basis for future confirmatory trials.",2020,"All outcomes, except for the overall well-being, showed better improvements in the intervention group with clinically significant differences from baseline to end point.","['Acute Tinnitus', 'patients with acute idiopathic tinnitus']","['acupuncture', 'usual care', '4 additional acupuncture treatments', 'Acupuncture', 'traditional Chinese medicine']","['serious side effects', 'visual analogue scale as well as standardized and validated tinnitus questionnaires (Tinnitus Functional Index and 12-item Mini Tinnitus Questionnaire', 'Tinnitus severity', 'subjective change in tinnitus severity']","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture'}, {'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0040264', 'cui_str': 'Tinnitus'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",,0.144456,"All outcomes, except for the overall well-being, showed better improvements in the intervention group with clinically significant differences from baseline to end point.","[{'ForeName': 'Enikö Julia', 'Initials': 'EJ', 'LastName': 'Manz', 'Affiliation': 'Institute for General Practice and Interprofessional Care, University Hospital, Tübingen, Germany, eni-manz@gmx.de.'}, {'ForeName': 'Serkan', 'Initials': 'S', 'LastName': 'Sertel', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Szecsenyi', 'Affiliation': 'Department of General Practice and Health Service Research, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Peter-Karl', 'Initials': 'PK', 'LastName': 'Plinkert', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Stefanie', 'Initials': 'S', 'LastName': 'Joos', 'Affiliation': 'Institute for General Practice and Interprofessional Care, University Hospital, Tübingen, Germany.'}]",Complementary medicine research,['10.1159/000508630'] 2145,32712663,Cost effectiveness of preemptive therapy versus prophylaxis in a randomized clinical trial for the prevention of CMV disease in seronegative liver transplant recipients with seropositive donors.,"BACKGROUND The relative costs of preemptive therapy (PET) or prophylaxis for the prevention of CMV disease in high-risk donor CMV seropositive/recipient seronegative. METHODS A decision tree model was constructed based on the probability of outcomes in a randomized controlled trial that compared valganciclovir as PET or prophylaxis for 100 days in 205 D+R- liver transplant recipients. Itemized costs for each site were obtained from a federal cost transparency database. Total costs included costs of implementation of the strategy and CMV disease treatment-related costs. Net cost per patient was estimated from the decision tree for each strategy. RESULTS PET was associated with a 10% lower absolute rate of CMV disease (9% vs 19%). The cost of treating a case of CMV disease in our patients was $88,190. Considering cost of implementation of strategy and treatment-related cost for CMV disease, net cost-savings per patient associated with PET was $8,707 compared to prophylaxis. PET remained cost-effective across a range of assumptions (varying costs of monitoring and treatment, and rates of disease). CONCLUSION PET is the dominant CMV prevention strategy in that it was associated with lower rates of CMV disease and lower overall costs compared to prophylaxis in D+R- liver transplant recipients. Costs were driven primarily by more hospitalizations and higher CMV disease-associated costs due to delayed onset post-prophylaxis disease in the prophylaxis group.",2020,Costs were driven primarily by more hospitalizations and higher CMV disease-associated costs due to delayed onset post-prophylaxis disease in the prophylaxis group.,"['D+R- liver transplant recipients', '205 D+R- liver transplant recipients', 'seronegative liver transplant recipients with seropositive donors']","['preemptive therapy (PET', 'valganciclovir', 'preemptive therapy versus prophylaxis']","['absolute rate of CMV disease', 'Cost effectiveness', 'Total costs included costs of implementation of the strategy and CMV disease treatment-related costs']","[{'cui': 'C0455647', 'cui_str': 'H/O: liver recipient'}, {'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0521143', 'cui_str': 'Seropositive'}, {'cui': 'C0013018', 'cui_str': 'Donors'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0909381', 'cui_str': 'valganciclovir'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]",,0.0318992,Costs were driven primarily by more hospitalizations and higher CMV disease-associated costs due to delayed onset post-prophylaxis disease in the prophylaxis group.,"[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'University of Pittsburgh, and VA Pittsburgh Healthcare System, Pittsburgh, PA.'}, {'ForeName': 'Drew J', 'Initials': 'DJ', 'LastName': 'Winston', 'Affiliation': 'University of California Los Angeles Medical Center, Los Angeles, CA.'}, {'ForeName': 'Raymund R', 'Initials': 'RR', 'LastName': 'Razonable', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'G Marshall', 'Initials': 'GM', 'LastName': 'Lyon', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Fernanda P', 'Initials': 'FP', 'LastName': 'Silveira', 'Affiliation': 'University of Pittsburgh and UPMC, Pittsburgh PA.'}, {'ForeName': 'Marilyn M', 'Initials': 'MM', 'LastName': 'Wagener', 'Affiliation': 'University of Pittsburgh, and VA Pittsburgh Healthcare System, Pittsburgh, PA.'}, {'ForeName': 'Ajit P', 'Initials': 'AP', 'LastName': 'Limaye', 'Affiliation': 'University of Washington, Seattle, WA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1051'] 2146,32712805,Correction to: Influence of Postoperative Posture on Macular Slippage after Macula-Off Retinal Detachment: A Randomized Controlled Trial.,The original article can be found online.,2020,The original article can be found online.,['Macular Slippage after Macula-Off Retinal Detachment'],['Postoperative Posture'],[],"[{'cui': 'C0227662', 'cui_str': 'Structure of macula densa'}, {'cui': 'C0035305', 'cui_str': 'Retinal detachment'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}]",[],,0.0996259,The original article can be found online.,"[{'ForeName': 'Megir', 'Initials': 'M', 'LastName': 'Schawkat', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Valmaggia', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Lang', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Hendrik P N', 'Initials': 'HPN', 'LastName': 'Scholl', 'Affiliation': 'Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Harsum', 'Affiliation': 'Epsom and St Helier University Hospitals, NHS Trust, London, UK.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Guber', 'Affiliation': 'Department of Ophthalmology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Guber', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland. josef.guber@kssg.ch.'}]",Ophthalmology and therapy,['10.1007/s40123-020-00284-4'] 2147,32712806,"Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.","INTRODUCTION Patients with relapsed or refractory multiple myeloma (RRMM) represent an unmet clinical need. Belantamab mafodotin (belamaf; GSK2857916) is a first-in-class antibody-drug conjugate (ADC; or immunoconjugate) that delivers a cytotoxic payload, monomethyl auristatin F (MMAF), to myeloma cells. In the phase II DREAMM-2 study (NCT03525678), single-agent belamaf (2.5 mg/kg) demonstrated clinically meaningful anti-myeloma activity (overall response rate 32%) in patients with heavily pretreated disease. Microcyst-like epithelial changes (MECs) were common, consistent with reports from other MMAF-containing ADCs. METHODS Corneal examination findings from patients in DREAMM-2 were reviewed, and the clinical descriptions and accompanying images (slit lamp microscopy and in vivo confocal microscopy [IVCM]) of representative events were selected. A literature review on corneal events reported with other ADCs was performed. RESULTS In most patients receiving single-agent belamaf (72%; 68/95), MECs were observed by slit lamp microscopy early in treatment (69% had their first event by dose 4). However, IVCM revealed hyperreflective material. Blurred vision (25%) and dry eye (15%) were commonly reported symptoms. Management of MECs included dose delays (47%)/reductions (25%), with few patients discontinuing due to MECs (1%). The first event resolved in most patients (grade ≥2 MECs and visual acuity [each 77%], blurred vision [67%], and dry eye [86%]), with no reports of permanent vision loss to date. A literature review confirmed that similar MECs were reported with other ADCs; however, event management strategies varied. The pathophysiology of MECs is unclear, though the ADC cytotoxic payload may contribute to on- or off-target effects on corneal epithelial cells. CONCLUSION Single-agent belamaf represents a new treatment option for patients with RRMM. As with other ADCs, MECs were observed and additional research is warranted to determine their pathophysiology. A multidisciplinary approach, involving close collaboration between eye care professionals and hematologist/oncologists, is needed to determine appropriate diagnosis and management of these patients. TRIAL REGISTRATION ClinicalTrials.gov Identifier, NCT03525678.",2020,"The first event resolved in most patients (grade ≥2 MECs and visual acuity [each 77%], blurred vision [67%], and dry eye [86%]), with no reports of permanent vision loss to date.","['patients with heavily pretreated disease', 'patients with RRMM', 'Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin', 'Corneal examination findings from patients in DREAMM-2 were reviewed, and the clinical descriptions and accompanying images (slit lamp microscopy and in vivo confocal microscopy [IVCM]) of representative events were selected', 'Patients with relapsed or refractory multiple myeloma (RRMM']",[],"['visual acuity', 'Blurred vision', 'clinically meaningful anti-myeloma activity', 'blurred vision', 'Microcyst-like epithelial changes (MECs', 'MECs', 'permanent vision loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C4551538', 'cui_str': 'Plasma cell myeloma refractory'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4704928', 'cui_str': 'Antibody-Drug Conjugates'}, {'cui': 'C0438105', 'cui_str': 'Examination finding'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0419360', 'cui_str': 'Ocular slit lamp examination'}, {'cui': 'C0242842', 'cui_str': 'Confocal Microscopy'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]",[],"[{'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0344232', 'cui_str': 'Hazy vision'}, {'cui': 'C0026764', 'cui_str': 'Multiple myeloma'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205355', 'cui_str': 'Permanent'}, {'cui': 'C3665346', 'cui_str': 'Unspecified visual loss'}]",,0.0423515,"The first event resolved in most patients (grade ≥2 MECs and visual acuity [each 77%], blurred vision [67%], and dry eye [86%]), with no reports of permanent vision loss to date.","[{'ForeName': 'Asim V', 'Initials': 'AV', 'LastName': 'Farooq', 'Affiliation': 'University of Chicago Medical Center, Chicago, IL, USA. afarooq@bsd.uchicago.edu.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Degli Esposti', 'Affiliation': 'NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology, London, UK.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Popat', 'Affiliation': 'University College London Hospitals, NHS Foundation Trust, London, UK.'}, {'ForeName': 'Praneetha', 'Initials': 'P', 'LastName': 'Thulasi', 'Affiliation': 'Emory Eye Center, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Sagar', 'Initials': 'S', 'LastName': 'Lonial', 'Affiliation': 'Emory University, Winship Cancer Institute, Atlanta, GA, USA.'}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Nooka', 'Affiliation': 'Emory University, Winship Cancer Institute, Atlanta, GA, USA.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Jakubowiak', 'Affiliation': 'University of Chicago Medical Center, Chicago, IL, USA.'}, {'ForeName': 'Douglas', 'Initials': 'D', 'LastName': 'Sborov', 'Affiliation': 'Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Brian E', 'Initials': 'BE', 'LastName': 'Zaugg', 'Affiliation': 'Moran Eye Center, University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Ashraf Z', 'Initials': 'AZ', 'LastName': 'Badros', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Bennie H', 'Initials': 'BH', 'LastName': 'Jeng', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.'}, {'ForeName': 'Natalie S', 'Initials': 'NS', 'LastName': 'Callander', 'Affiliation': 'University of Wisconsin, Carbone Cancer Center, Madison, WI, USA.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Opalinska', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'January', 'Initials': 'J', 'LastName': 'Baron', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Piontek', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Byrne', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Gupta', 'Affiliation': 'GlaxoSmithKline, Upper Providence, PA, USA.'}, {'ForeName': 'Kathryn', 'Initials': 'K', 'LastName': 'Colby', 'Affiliation': 'University of Chicago Medical Center, Chicago, IL, USA.'}]",Ophthalmology and therapy,['10.1007/s40123-020-00280-8'] 2148,32712847,Spectrophotometric insights: calcium hydroxide influences tooth discolorations induced by short-term application of antibiotic/corticosteroid pastes.,"OBJECTIVES This in vitro study aimed to assess the influence of a calcium hydroxide dressing regarding the relative color change (ΔE) of enamel-dentin specimens previously exposed to antibiotic/corticosteroid pastes. MATERIALS AND METHODS Eighty bovine enamel-dentin specimens with a cylindrical central cavity were randomly allocated to four groups: NEG (empty), POS (blood), LED (Ledermix), and ODO (Odontopaste) (n = 20 each). The materials were applied and sealed with self-adhesive resin luting material. After 3 weeks, the materials were removed and a calcium hydroxide (Ca(OH) 2 ) dressing was placed in all cavities. After a further 3-week storage period, the cavities were restored with resin-based composite. Spectrophotometric color measurements were taken over 6 months, and ΔE values were calculated. A Tukey's multiple comparison test was performed to assess significant differences within the treatment groups (p < 0.05). RESULTS Tooth discolorations were present after 3 weeks in LED (ΔE 29.14 ± 6.55) and POS (ΔE 18.05 ± 7.03); NEG and ODO remained color stable (ΔE 3.2 ± 1.36 and ΔE 2.3 ± 1.16). The 3-week Ca(OH) 2 dressing decreased discolorations of POS (ΔE 15.93 ± 6.63; p = 0.37), whereas LED showed a further significant increase (ΔE 39.55; p < 0.0001). Between the end of the Ca(OH) 2 dressing and the final restoration no significant color changes were observed in any group (p > 0.9). CONCLUSIONS Discolorations induced by LED progressed during the Ca(OH) 2 dressing despite careful removal of all residues. CLINICAL RELEVANCE Calcium hydroxide might negatively affect the discoloring potential of Ledermix. This highlights the need for direct intracanal application methods of Ledermix ensuring a material-free access cavity or alternative antibiotic/corticosteroid pastes such as Odontopaste should be used.",2020,"Between the end of the Ca(OH) 2 dressing and the final restoration no significant color changes were observed in any group (p > 0.9). ",['Eighty bovine enamel-dentin specimens with a cylindrical central cavity'],"['NEG (empty), POS (blood), LED (Ledermix), and ODO (Odontopaste', 'calcium hydroxide dressing']","['discolorations of POS', 'Spectrophotometric color measurements']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0007452', 'cui_str': 'Cattle'}, {'cui': 'C0011350', 'cui_str': 'Enamel structure'}, {'cui': 'C1292488', 'cui_str': 'Dentin specimen'}, {'cui': 'C0205114', 'cui_str': 'Cylindrical'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}]","[{'cui': 'C1262869', 'cui_str': 'Body position'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0006701', 'cui_str': 'calcium hydroxide'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}]","[{'cui': 'C0332572', 'cui_str': 'Abnormal color'}, {'cui': 'C1262869', 'cui_str': 'Body position'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}]",80.0,0.0193277,"Between the end of the Ca(OH) 2 dressing and the final restoration no significant color changes were observed in any group (p > 0.9). ","[{'ForeName': 'Florin', 'Initials': 'F', 'LastName': 'Eggmann', 'Affiliation': 'Department of Periodontology, Endodontology and Cariology, University Center for Dental Medicine Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Rihs', 'Affiliation': 'Department of Periodontology, Endodontology and Cariology, University Center for Dental Medicine Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Lenherr', 'Affiliation': 'Department of Reconstructive Dentistry, University Center for Dental Medicine Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Weiger', 'Affiliation': 'Department of Periodontology, Endodontology and Cariology, University Center for Dental Medicine Basel, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Krastl', 'Affiliation': 'Department of Operative Dentistry and Periodontology and Center of Dental Traumatology, University Hospital of Würzburg, Würzburg, Germany.'}, {'ForeName': 'Lucia K', 'Initials': 'LK', 'LastName': 'Zaugg', 'Affiliation': 'Department of Reconstructive Dentistry, University Center for Dental Medicine Basel, University of Basel, Basel, Switzerland. lucia.zaugg@unibas.ch.'}]",Clinical oral investigations,['10.1007/s00784-020-03414-1'] 2149,32706659,Predictors of Self-Determined Module Choice in a Web-Based Computer-Tailored Diet and Physical Activity Intervention: Secondary Analysis of Data From a Randomized Controlled Trial.,"BACKGROUND Tailoring an online intervention to participant preferences (eg, by giving participants a choice which modules to follow) may increase engagement in the intervention, motivation for behavioral change, and possibly intervention effects. So far, little is known about what characteristics predict these module choices. Filling this knowledge gap is useful for optimizing program engagement. OBJECTIVE We investigated participant choice for a dietary and/or physical activity (PA) promotion module in our web-based computer-tailored intervention based on self-determination theory (SDT) and motivational interviewing (MI). Furthermore, we investigated which demographic characteristics, current behavior, psychosocial constructs and constructs from SDT and MI, and program-related variables such as advice on which module to follow were associated with these choices. METHODS Observational data were used from the randomized controlled trial MyLifestyleCoach of participants who were randomized into the intervention condition, completed the baseline questionnaire, and made a module choice in the opening session of the intervention. Here, they received advice on their own dietary and PA behavior. At the session's end, they chose which lifestyle modules they would like to follow (both, diet, PA, or no module). Measurements included demographic information; self-reported diet and PA; and several psychosocial, SDT, and MI constructs. In total, data from 619 Dutch adults (59.6% women; mean age was 51.9 [SD 13.5] years) were analyzed. A stepwise multinomial logistic regression analysis was conducted to investigate which characteristics are related to module choice; the diet module served as reference category as almost everyone was advised to follow this module. RESULTS Of this sample, 54.8% (339/619) chose to do both the diet and PA module, 25.4% (157/619) chose to follow the diet module, 17.8% (110/619) preferred to follow no module, and 2.1% (13/619) chose to do the PA module only. Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module. People who had more motivation to change their current PA and those who received strong advice compared with slight advice to follow the diet module were more likely to choose both modules compared with the diet module only. CONCLUSIONS The results show that more than half of the sample was interested in following both the diet and PA module in this online lifestyle intervention. Several characteristics were found to be related to module choice. A future challenge is to examine how this knowledge can be used to improve future interventions, such as tailoring (messages or content) on specific groups or examining where and how MI could be used to motivate people to make a certain module choice. TRIAL REGISTRATION Netherlands Trial Register NL7333; https://www.trialregister.nl/trial/7333.",2020,"Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module.","['619 Dutch adults (59.6% women; mean age was 51.9 [SD 13.5] years) were analyzed', 'People who had more motivation to change their current PA and those who received']","['Self-Determined Module Choice in a Web-Based Computer-Tailored Diet and Physical Activity Intervention', 'dietary and/or physical activity (PA) promotion module', 'strong advice', 'self-determination theory (SDT) and motivational interviewing (MI']","['demographic information; self-reported diet and PA; and several psychosocial, SDT, and MI constructs']","[{'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0036595', 'cui_str': 'Self Determination'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}]","[{'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036595', 'cui_str': 'Self Determination'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0012931', 'cui_str': 'Recombinant DNA'}]",619.0,0.0446689,"Furthermore, it was found that older people, those who consumed more fruit, and those who scored lower on importance to change their current diet were more likely to choose no module compared to the diet module.","[{'ForeName': 'Juul M J', 'Initials': 'JMJ', 'LastName': 'Coumans', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}, {'ForeName': 'Catherine A W', 'Initials': 'CAW', 'LastName': 'Bolman', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Oenema', 'Affiliation': 'Department of Health Promotion, Caphri, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Lilian', 'Initials': 'L', 'LastName': 'Lechner', 'Affiliation': 'Department of Health Psychology, Faculty of Psychology, Open University of the Netherlands, Heerlen, Netherlands.'}]",Journal of medical Internet research,['10.2196/15024'] 2150,32706660,Combination of 3-Dimensional Virtual Reality and Hands-On Aromatherapy in Improving Institutionalized Older Adults' Psychological Health: Quasi-Experimental Study.,"BACKGROUND In Taiwan, which has one of the most rapidly aging populations in the world, it is becoming increasingly critical to promote successful aging strategies that are effective, easily usable, and acceptable to institutionalized older adults. Although many practitioners and professionals have explored aromatherapy and identified its psychological benefits, the effectiveness of combining 3-dimensional (3D) virtual reality and hands-on aromatherapy remains unknown. OBJECTIVE A quasi-experimental trial was designed to evaluate the effectiveness of this combination in lowering perceived stress and promoting happiness, sleep quality, meditation experience, and life satisfaction among institutionalized older adults in Taiwan. METHODS A total of 60 institutionalized elderly participants either received the combined intervention or were in a control group. Weekly 2-hour sessions were implemented over 9 weeks. The outcome variables were happiness, perceived stress, sleep quality, meditation experience, and life satisfaction, which were assessed at baseline and after the intervention. RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001). Another GEE analysis showed that the significant improvements in the 5 outcome variables persisted in participants aged 80 years and older (n=35; all P<.001). CONCLUSIONS This is the first trial to explore the effectiveness of a combination of 3D virtual reality and hands-on aromatherapy in improving older adults' psychological health. The results are promising for the promotion of psychological health in institutionalized older adults. TRIAL REGISTRATION ClinicalTrials.gov NCT04324216; https://clinicaltrials.gov/ct2/show/NCT04324216.",2020,"RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001).","['institutionalized older adults in Taiwan', '60 institutionalized elderly participants', ""older adults' psychological health"", 'participants aged 80 years and older (n=35; all P<.001', 'institutionalized older adults', ""Institutionalized Older Adults' Psychological Health""]","['3-Dimensional Virtual Reality and Hands', 'Aromatherapy', '3D virtual reality and hands-on aromatherapy', 'combined intervention']","['scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction', 'lowering perceived stress and promoting happiness, sleep quality, meditation experience, and life satisfaction', 'happiness, perceived stress, sleep quality, meditation experience, and life satisfaction']","[{'cui': 'C0562359', 'cui_str': 'Institutionalized'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0376547', 'cui_str': 'Aromatherapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}]",60.0,0.0374316,"RESULTS Generalized estimating equation (GEE) analyses indicated that the experimental group showed significant post-intervention improvements in terms of scores for happiness, perceived stress, sleep quality, meditation experience, and life satisfaction (n=48; all P<.001).","[{'ForeName': 'Vivian Ya-Wen', 'Initials': 'VY', 'LastName': 'Cheng', 'Affiliation': 'PureAroma Healing Academy, Taipei, Taiwan.'}, {'ForeName': 'Chiu-Mieh', 'Initials': 'CM', 'LastName': 'Huang', 'Affiliation': 'Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Jung-Yu', 'Initials': 'JY', 'LastName': 'Liao', 'Affiliation': 'Institute of Population Health sciences, National Health Research Institutes, Miaoli, Taiwan.'}, {'ForeName': 'Hsiao-Pei', 'Initials': 'HP', 'LastName': 'Hsu', 'Affiliation': 'Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Shih-Wen', 'Initials': 'SW', 'LastName': 'Wang', 'Affiliation': 'Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, Taipei, Taiwan.'}, {'ForeName': 'Su-Fei', 'Initials': 'SF', 'LastName': 'Huang', 'Affiliation': 'Department of Senior Citizen Service, Mackay Junior College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Jong-Long', 'Initials': 'JL', 'LastName': 'Guo', 'Affiliation': 'Department of Health Promotion and Health Education, College of Education, National Taiwan Normal University, Taipei, Taiwan.'}]",Journal of medical Internet research,['10.2196/17096'] 2151,32706667,"An Internet-Based Psychological Intervention With a Serious Game to Improve Vitality, Psychological and Physical Condition, and Immune Function in Healthy Male Adults: Randomized Controlled Trial.","BACKGROUND Recently, internet-based cognitive behavioral therapy (ICBT) and serious gaming interventions have been suggested to enhance accessibility to interventions and engagement in psychological interventions that aim to promote health outcomes. Few studies, however, have investigated their effectiveness in the context of simulated real-life challenges. OBJECTIVE We aimed to examine the effectivity of a guided ICBT combined with a serious gaming intervention in improving self-reported psychophysiological and immunological health endpoints in response to psychophysiological and immune-related challenges. METHODS Sixty-nine healthy men were randomly assigned to the intervention condition, receiving ICBT combined with serious gaming for 6 weeks, or the control condition, receiving no intervention. Self-reported vitality was the primary endpoint. Other self-reported psychophysiological and immunological endpoints were assessed following various challenges, including a bacillus Calmette-Guérin vaccination evoking pro-inflammatory responses, 1 and 4 weeks after the intervention period. RESULTS Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls. Furthermore, wellbeing (P=.024) was higher in the intervention group after the psychophysiological challenges. Although no significant group differences were found for the psychophysiological and immunological endpoints, the data provided preliminary support for increased immunoglobulin antibody responses at the follow-up time points (P<.05). Differential chemokine endpoints between conditions were observed at the end of the test day. CONCLUSIONS The present study provides some support for improving health endpoints with an innovative ICBT intervention. Future research should replicate and further extend the present findings by consistently including challenges and a wide range of immune parameters into the study design. TRIAL REGISTRATION Nederlands Trial Register NTR5610; https://www.trialregister.nl/trial/5466.",2020,"Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls.","['Sixty-nine healthy men', 'Healthy Male Adults']","['ICBT combined with serious gaming for 6 weeks, or the control condition, receiving no intervention', 'guided ICBT combined with a serious gaming intervention', 'internet-based cognitive behavioral therapy (ICBT', 'Internet-Based Psychological Intervention With a Serious Game']","['vitality-associated parameters, self-reported sleep problems', 'immunoglobulin antibody responses', 'bodily sensations']","[{'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0686751', 'cui_str': 'Well male adult'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}]","[{'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnia'}, {'cui': 'C0021027', 'cui_str': 'Immunoglobulin'}, {'cui': 'C0003261', 'cui_str': 'Antibody Production'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",69.0,0.0729687,"Although the intervention did not affect vitality-associated parameters, self-reported sleep problems (P=.027) and bodily sensations (P=.042) were lower directly after the intervention compared with controls.","[{'ForeName': 'Lemmy', 'Initials': 'L', 'LastName': 'Schakel', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Dieuwke S', 'Initials': 'DS', 'LastName': 'Veldhuijzen', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Henriët', 'Initials': 'H', 'LastName': 'van Middendorp', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Corine', 'Initials': 'C', 'LastName': 'Prins', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Anne M H F', 'Initials': 'AMHF', 'LastName': 'Drittij', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Vrieling', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Leo G', 'Initials': 'LG', 'LastName': 'Visser', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Tom H M', 'Initials': 'THM', 'LastName': 'Ottenhoff', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Simone A', 'Initials': 'SA', 'LastName': 'Joosten', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Andrea W M', 'Initials': 'AWM', 'LastName': 'Evers', 'Affiliation': 'Health, Medical and Neuropsychology Unit, Institute of Psychology, Leiden University, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/14861'] 2152,32706674,Novel Stepped Care Approach to Provide Education and Exercise Therapy for Patellofemoral Pain: Feasibility Study.,"BACKGROUND Patellofemoral pain (PFP) impairs joint- and health-related quality of life and may be associated with knee osteoarthritis. We developed a novel, 2-phase, stepped-care approach for PFP, combining (1) self-directed web-based education and exercise therapy with (2) physiotherapist-supported education and exercise therapy. Physiotherapy sessions can be provided using 2 different modalities: face-to-face and telerehabilitation. OBJECTIVE This study aims to (1) determine the feasibility of our stepped-care approach, (2) explore patient-reported outcomes following self-directed web-based education and exercise therapy in people with PFP (phase 1), and (3) estimate the differences in treatment effects between face-to-face and telerehabilitation to support further education and exercise therapy (phase 2) in those who had not completely recovered following self-directed care. METHODS Phase 1 involved 6 weeks of self-directed web-based education and exercise therapy. Phase 2 involved random allocation to a further 12 weeks of physiotherapist-led (up to 8 sessions) education and exercise therapy delivered face-to-face or via telerehabilitation to participants who did not rate themselves as completely recovered following phase 1. Feasibility indicators of process, adherence, and participant retention were collected as primary outcomes alongside patient-reported outcomes on Global Rating of Change and knee pain, disability, knee-related quality of life, pain catastrophism, kinesiophobia, and knee self-efficacy. All participants were assessed at baseline, 6 weeks, and 18 weeks. RESULTS A total of 71 participants were screened to identify 35 participants with PFP to enter the study. Overall, 100% (35/35) and 88% (31/35) of the participants were followed up with at 6 and 18 weeks, respectively. In phase 1 of the study, participants accessed the My Knee Cap website for an average of 6 (7.5) days and performed the exercises for an average of 2.5 (3.6) times per week. A total of 20% (7/35) of the participants reported that they had completely recovered at 6 weeks. Furthermore, 93% (26/28) of the participants who were followed up and had not completely recovered at 6 weeks agreed to be enrolled in phase 2. No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome. The novel stepped-care approach was associated with marked improvement or complete recovery in 40% (14/35) of the participants following phase 1 and 71% (25/35) of the participants following phase 2. CONCLUSIONS Self-directed web-based education and exercise therapy for people with PFP is feasible, as noted by the high rate of participant retention and home exercise adherence achieved in this study. Furthermore, 20% (7/35) of people reported complete recovery at 6 weeks. Both face-to-face and telerehabilitation physiotherapy should be considered for those continuing to seek care, as there is no difference in outcomes between these delivery modes. Determining the efficacy of the stepped-care model may help guide more efficient health care for PFP.",2020,No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome.,"['people with PFP (phase 1', '71 participants were screened to identify 35 participants with PFP to enter the study']","['Physiotherapy sessions', 'physiotherapist-led (up to 8 sessions) education and exercise therapy delivered face-to-face or via telerehabilitation', 'Novel Stepped Care Approach to Provide Education and Exercise Therapy', 'self-directed web-based education and exercise therapy', 'Self-directed web-based education and exercise therapy', 'PFP, combining (1) self-directed web-based education and exercise therapy with (2) physiotherapist-supported education and exercise therapy']","['Global Rating of Change and knee pain, disability, knee-related quality of life, pain catastrophism, kinesiophobia, and knee self-efficacy', 'Feasibility indicators of process, adherence, and participant retention', 'My Knee Cap website']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439559', 'cui_str': 'Phase 1'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C2362565', 'cui_str': 'Physiotherapist'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C4042802', 'cui_str': 'Remote Rehabilitation'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0231749', 'cui_str': 'Knee pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0030647', 'cui_str': 'Bone structure of patella'}]",71.0,0.133706,No statistically significant differences were found between the face-to-face and telerehabilitation groups for any outcome.,"[{'ForeName': 'Danilo', 'Initials': 'D', 'LastName': 'De Oliveira Silva', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Marcella F', 'Initials': 'MF', 'LastName': 'Pazzinatto', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Kay M', 'Initials': 'KM', 'LastName': 'Crossley', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}, {'ForeName': 'Fabio M', 'Initials': 'FM', 'LastName': 'Azevedo', 'Affiliation': 'Laboratory of Biomechanics and Motor Control, Sao Paulo State University, Presidente Prudente, Brazil.'}, {'ForeName': 'Christian J', 'Initials': 'CJ', 'LastName': 'Barton', 'Affiliation': 'La Trobe Sport and Exercise Medicine Research Centre, School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Australia.'}]",Journal of medical Internet research,['10.2196/18584'] 2153,32706681,Recruiting and Retaining Youth and Young Adults in the Policy and Communication Evaluation (PACE) Vermont Study: Randomized Controlled Trial of Participant Compensation.,"BACKGROUND The standard approach for evaluating the effects of population-level substance use prevention efforts on youth and young adult perceptions and behaviors has been to compare outcomes across states using national surveillance data. Novel surveillance methods that follow individuals over shorter time intervals and capture awareness of substance use prevention policy and communication efforts may provide a stronger basis for their evaluation than annual cross-sectional studies. OBJECTIVE This study aimed to identify a combination of strategies to recruit a sample of youth and young adults sufficiently representative of the Vermont population and determine how best to retain a web-based panel of youth and young adults over a 6-month period. METHODS Eligible participants were Vermont residents aged 12 to 25 years who were willing to complete three 10 to 15-minute web-based surveys over a 6-month period. Recruitment was conducted via the following three main mechanisms: (1) web-based recruitment (paid and unpaid), (2) community-based recruitment through partners, and (3) participant referrals via a personalized link. Upon completion of the baseline survey, participants were randomly assigned to one of the following three retention incentive conditions: (1) guaranteed incentive (US $10), (2) lottery incentive (US $50 weekly lottery drawing), and (3) preferred method (guaranteed or lottery). Analyses examined cost per survey start by recruitment source, distribution of demographic characteristics across incentive conditions, and retention by study condition at 3-month and 6-month follow-ups. RESULTS Over a 10-week period in 2019, we recruited 480 eligible youth (aged 12-17 years) and 1037 eligible young adults (aged 18-25 years) to the Policy and Communication Evaluation (PACE) Vermont Study. Facebook and Instagram advertising produced the greatest number of survey starts (n=2013), followed by posts to a state-wide web-based neighborhood forum (n=822) and Google advertisements (n=749). Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months. Retention was equivalent across all incentive study conditions at both waves, despite a strong stated preference among study participants for the guaranteed payment at baseline. Youth had greater retention than young adults at both waves (wave 2: 395/480, 82.3% vs 790/1037, 76.18%; wave 3: 366/480, 76.3% vs 729/1037, 70.30%). Substance use prevalence in this cohort was similar to national and state-level surveillance estimates for young adults, but was lower than state-level surveillance estimates for youth. Most participants retained at wave 3 provided positive qualitative feedback on their experience. CONCLUSIONS Our study supports the feasibility of recruiting a web-based cohort of youth and young adults with representation across an entire state to evaluate substance use prevention efforts. Findings suggest that a guaranteed payment immediately upon survey completion coupled with a bonus for completing all survey waves and weekly survey reminders may facilitate retention in a cohort of youth and young adults.",2020,Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months.,"['Eligible participants were Vermont residents aged 12 to 25 years who were willing to complete three 10 to 15-minute web-based surveys over a 6-month period', '480 eligible youth (aged 12-17 years) and 1037 eligible young adults (aged 18-25 years) to the Policy and Communication Evaluation (PACE) Vermont Study']","['retention incentive conditions: (1) guaranteed incentive (US $10), (2) lottery incentive (US $50 weekly lottery drawing), and (3) preferred method (guaranteed or lottery']",['Retention'],"[{'cui': 'C0042537', 'cui_str': 'Vermont'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0600109', 'cui_str': 'Willing'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C4319609', 'cui_str': '480'}, {'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0242456', 'cui_str': 'Policy'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0013113', 'cui_str': 'Drawings'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}]",,0.157918,Retention was 78.11% (1185/1517) at 3 months and 72.18% (1095/1517) at 6 months.,"[{'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Villanti', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Christie P', 'Initials': 'CP', 'LastName': 'Vallencourt', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'West', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Peasley-Miklus', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'S Elisha', 'Initials': 'SE', 'LastName': 'LePine', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'McCluskey', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Klemperer', 'Affiliation': 'Department of Psychiatry, Vermont Center on Behavior and Health, University of Vermont Larner College of Medicine, Burlington, VT, United States.'}, {'ForeName': 'Jeffrey S', 'Initials': 'JS', 'LastName': 'Priest', 'Affiliation': 'Biomedical Statistics Research Core, University of Vermont, Burlington, VT, United States.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Logan', 'Affiliation': 'Hark Inc, Burlington, VT, United States.'}, {'ForeName': 'Bill', 'Initials': 'B', 'LastName': 'Patton', 'Affiliation': 'Hark Inc, Burlington, VT, United States.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Erickson', 'Affiliation': 'Communication, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hicks', 'Affiliation': 'Health Surveillance, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': 'Horton', 'Affiliation': 'Communication, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Shayla', 'Initials': 'S', 'LastName': 'Livingston', 'Affiliation': 'Public Health Policy, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Roemhildt', 'Affiliation': 'Health Surveillance, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Singer', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Trutor', 'Affiliation': 'Alcohol & Drug Abuse Programs, Vermont Department of Health, Burlington, VT, United States.'}, {'ForeName': 'Rhonda', 'Initials': 'R', 'LastName': 'Williams', 'Affiliation': 'Health Promotion & Disease Prevention, Vermont Department of Health, Burlington, VT, United States.'}]",Journal of medical Internet research,['10.2196/18446'] 2154,32706692,Internet-Based Self-Management Support After High-Altitude Climate Treatment for Severe Asthma: Randomized Controlled Trial.,"BACKGROUND In patients with severe asthma, high-altitude climate treatment has been shown to improve asthma control. However, asthma symptoms and limitations may increase after finishing inpatient rehabilitation programs and returning to sea level. OBJECTIVE We assessed the effectiveness of a patient-tailored, internet-based, self-management strategy in addition to usual care after finishing high-altitude climate treatment. METHODS We performed a randomized controlled trial with a 1-year follow-up in patients from a high-altitude asthma center in Davos, Switzerland. At the end of a 12-week multidisciplinary rehabilitation program, 62 adults with asthma were randomized to receive either internet-based self-management support in addition to usual care (n=33) or usual care only after discharge (n=29). The endpoints were changes in asthma-related quality of life according to the Asthma Quality of Life Questionnaire (AQLQ) (a higher score is better) and asthma control according to the Asthma Control Questionnaire (ACQ) (a lower score is better), with a minimally important difference of 0.5 points for both. RESULTS Asthma-related quality of life and asthma control declined over time in the usual care strategy group, whereas there was a slower decline in the internet-based strategy group. For both endpoints, mixed-model analysis showed a significant positive effect in favor of internet-based self-management during follow-up (mean AQLQ score difference 0.39, 95% CI 0.092-0.69; P=.01 and ACQ score difference -0.50, 95% CI -0.86 to -0.15; P=.006), which was prominent among patients with uncontrolled asthma at discharge (AQLQ score difference 0.59, 95% CI 0.19-0.99; P=.003 and ACQ score difference -0.73, 95% CI -1.18 to -0.28; P=.002). CONCLUSIONS Internet-based self-management support was associated with a smaller decline in quality of life and asthma control as compared with usual care, especially in patients with lower asthma control, after completion of high-altitude climate treatment. Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. TRIAL REGISTRATION The trial is registered in the Netherlands Trial Register (NTR1995).",2020,"Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. ","['patients from a high-altitude asthma center in Davos, Switzerland', 'Severe Asthma', 'adults with severe asthma', '62 adults with asthma', 'patients with severe asthma']","['internet-based self-management support in addition to usual care (n=33) or usual care only after discharge', 'Internet-Based Self-Management Support', 'Internet-based self-management support']","['quality of life and asthma control', 'Asthma-related quality of life and asthma control', 'changes in asthma-related quality of life according to the Asthma Quality of Life Questionnaire (AQLQ) (a higher score is better) and asthma control according to the Asthma Control Questionnaire (ACQ']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0238617', 'cui_str': 'High altitude'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}]",62.0,0.119011,"Internet-based self-management support in adults with severe asthma seems feasible and effective to maintain quality of life and asthma control. ","[{'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Beerthuizen', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Lucia H', 'Initials': 'LH', 'LastName': 'Rijssenbeek-Nouwens', 'Affiliation': 'Dutch Asthma Centre Davos, Davos, Switzerland.'}, {'ForeName': 'Sophia M', 'Initials': 'SM', 'LastName': 'van Koppen', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Rishi J', 'Initials': 'RJ', 'LastName': 'Khusial', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Jiska B', 'Initials': 'JB', 'LastName': 'Snoeck-Stroband', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Jacob K', 'Initials': 'JK', 'LastName': 'Sont', 'Affiliation': 'Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/13145'] 2155,32706719,A Novel Educational Control Group Mobile App for Meditation Interventions: Single-Group Feasibility Trial.,"BACKGROUND Smartphone ownership is becoming ubiquitous among US adults, making the delivery of health interventions via a mobile app (ie, mobile health [mHealth]) attractive to many researchers and clinicians. Meditation interventions have become popular and have been delivered to study participants via mobile apps to improve a range of health outcomes in both healthy adults and those with chronic diseases. However, these meditation mHealth interventions have been limited by a lack of high-quality control groups. More specifically, these studies have lacked consistency in their use of active, time-matched, and attention-matched control groups. OBJECTIVE The purpose of this study is to beta test a novel health education podcast control condition delivered via a smartphone app that would be a strong comparator to be used in future studies of app-based meditation interventions. METHODS Patients with myeloproliferative neoplasm (MPN) cancer were recruited nationally. Upon enrollment, participants were informed to download the investigator-developed health education podcast app onto their mobile phone and listen to ~60 min/week of cancer-related educational podcasts for 12 weeks. The benchmarks for feasibility included ≥70% of participants completing ≥70% of the prescribed 60 min/week of podcasts, ≥70% of participants reporting that they were satisfied with the intervention, and ≥70% of participants reporting that they enjoyed the health education podcasts. RESULTS A total of 96 patients with MPN were enrolled in the study; however, 19 never began the intervention. Of the 77 patients who participated in the intervention, 39 completed the entire study (ie, sustained participation through the follow-up period). Participation averaged 103.2 (SD 29.5) min/week. For 83.3% (10/12) of the weeks, at least 70% of participants completed at least 70% of their total prescribed use. Almost half of participants reported that they enjoyed the health education podcasts (19/39, 48.7%) and were satisfied with the intervention (17/39, 43.6%). There were no significant changes in cancer-related outcomes from baseline to postintervention. CONCLUSIONS A 12-week, health education podcast mobile app was demanded but not accepted in a sample of patients with cancer. Using the mobile app was not associated with significant changes in cancer-related symptoms. Based on findings from this study, a health education podcast mobile app may be a feasible option as a time- and attention-matched control group for efficacy trials with more extensive formative research for the content of the podcasts and its acceptability by the specific population. TRIAL REGISTRATION ClinicalTrials.gov NCT03907774; https://clinicaltrials.gov/ct2/show/NCT03907774.",2020,"There were no significant changes in cancer-related outcomes from baseline to postintervention. ","['77 patients who participated in the intervention, 39 completed the entire study (ie, sustained participation through the follow-up period', 'healthy adults and those with chronic diseases', 'patients with cancer', 'Patients with myeloproliferative neoplasm (MPN) cancer were recruited nationally', '96 patients with MPN were enrolled in the study; however, 19 never began the intervention']","['Educational Control Group Mobile App for Meditation Interventions', 'Meditation interventions']","['health education podcasts', 'cancer-related symptoms']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0027022', 'cui_str': 'Myeloproliferative disorder'}, {'cui': 'C0439659', 'cui_str': 'Origins'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2718063', 'cui_str': 'Podcasts'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",96.0,0.183313,"There were no significant changes in cancer-related outcomes from baseline to postintervention. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Huberty', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Eckert', 'Affiliation': 'Mays Cancer Center, University of Texas Health San Antonio MD Anderson, San Antonio, TX, United States.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Puzia', 'Affiliation': 'Behavioral Research and Analytics, LLC, Salt Lake City, UT, United States.'}, {'ForeName': 'Breanne', 'Initials': 'B', 'LastName': 'Laird', 'Affiliation': 'College of Health Solutions, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Larkey', 'Affiliation': 'Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, United States.'}, {'ForeName': 'Ruben', 'Initials': 'R', 'LastName': 'Mesa', 'Affiliation': 'Mays Cancer Center, University of Texas Health San Antonio MD Anderson, San Antonio, TX, United States.'}]",JMIR formative research,['10.2196/19364'] 2156,32706720,An Internet-Based Cognitive Behavioral Program for Adolescents With Anxiety: Pilot Randomized Controlled Trial.,"BACKGROUND Internet-based cognitive behavioral therapy (ICBT) is a treatment approach recently developed and studied to provide frontline treatment to adolescents with anxiety disorders. OBJECTIVE This study aimed to pilot procedures and obtain data on methodological processes and intervention satisfaction to determine the feasibility of a definitive randomized controlled trial (RCT) to test the effectiveness of a self-managed ICBT program, Breathe (Being Real, Easing Anxiety: Tools Helping Electronically), for adolescents with anxiety concerns. METHODS This study employed a two-arm, multisite, pilot RCT. Adolescents aged 13 to 17 years with a self-identified anxiety concern were recruited online from health care settings and school-based mental health care services across Canada between April 2014 and May 2016. We compared 8 weeks of ICBT with ad hoc telephone and email support (Breathe experimental group) to access to a static webpage listing anxiety resources (control group). The primary outcome was the change in self-reported anxiety from baseline to 8 weeks (posttreatment), which was used to determine the sample size for a definitive RCT. Secondary outcomes were recruitment and retention rates, a minimal clinically important difference (MCID) for the primary outcome, intervention acceptability and satisfaction, use of cointerventions, and health care resource use, including a cost-consequence analysis. RESULTS Of the 588 adolescents screened, 94 were eligible and enrolled in the study (49 adolescents were allocated to Breathe and 45 were allocated to the control group). Analysis was based on 74% (70/94) of adolescents who completed baseline measures and progressed through the study. Enrolled adolescents were, on average, 15.3 years old (SD 1.2) and female (63/70, 90%). Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group). Overall, 39% (14/36) of adolescents provided feedback on completion of the Breathe program. Adolescents' scores on a satisfaction survey indicated a moderate level of satisfaction. All but one adolescent indicated that Breathe was easy to use and they understood all the material presented. The most frequent barrier identified for program completion was difficulty in completing exposure activities. The power analysis indicated that 177 adolescents per group would be needed to detect a medium effect size (d=0.3) between groups in a definitive trial. Data for calculating an MCID or conducting a cost-consequence analysis were insufficient due to a low response rate at 8 weeks. CONCLUSIONS Adolescents were moderately satisfied with Breathe. However, program adjustments will be needed to address attrition and reduce perceived barriers to completing key aspects of the program. A definitive RCT to evaluate the effectiveness of the program is feasible if protocol adjustments are made to improve recruitment and retention to ensure timely study completion and increase the completeness of the data at each outcome measurement time point. TRIAL REGISTRATION ClinicalTrials.gov NCT02059226; http://clinicaltrials.gov/ct2/show/NCT02059226.",2020,Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group).,"['adolescents with anxiety concerns', '94 were eligible and enrolled in the study (49 adolescents', 'Adolescents aged 13 to 17 years with a self-identified anxiety concern were recruited online from health care settings and school-based mental health care services across Canada between April 2014 and May 2016', 'Adolescents With Anxiety', 'Enrolled adolescents were, on average, 15.3 years old (SD 1.2) and female (63/70, 90', '588 adolescents screened', 'adolescents with anxiety disorders', ' Easing Anxiety', '177 adolescents per group']","['ICBT with ad hoc telephone and email support (Breathe experimental group) to access to a static webpage listing anxiety resources (control group', 'Internet-Based Cognitive Behavioral Program', 'self-managed ICBT program, Breathe (Being Real', 'Internet-based cognitive behavioral therapy (ICBT']","['moderate level of satisfaction', 'Retention rates', 'recruitment and retention rates, a minimal clinically important difference (MCID) for the primary outcome, intervention acceptability and satisfaction, use of cointerventions, and health care resource use, including a cost-consequence analysis', 'change in self-reported anxiety']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184643', 'cui_str': 'Mental health care'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C4517578', 'cui_str': '15.3'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4068880', 'cui_str': '1.2'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C4277733', 'cui_str': 'Minimal Clinically Important Difference'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",49.0,0.139181,Retention rates at 8 weeks were 28% (13/46; Breathe group) and 58% (24/43; control group).,"[{'ForeName': 'Kathleen', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': 'Glenrose Rehabilitation Hospital, Edmonton, AB, Canada.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Bagnell', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'McGrath', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Wozney', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Radomski', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Rhonda J', 'Initials': 'RJ', 'LastName': 'Rosychuk', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Curtis', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Mona', 'Initials': 'M', 'LastName': 'Jabbour', 'Affiliation': 'Department of Neurosurgery, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Eleanor', 'Initials': 'E', 'LastName': 'Fitzpatrick', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Johnson', 'Affiliation': 'University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Arto', 'Initials': 'A', 'LastName': 'Ohinmaa', 'Affiliation': 'School of Public Health, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Joyce', 'Affiliation': 'University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Newton', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB, Canada.'}]",JMIR mental health,['10.2196/13356'] 2157,32706731,Validation of a Mobile Version of the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form: An Observational Randomized Crossover Trial.,"BACKGROUND The American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) questionnaire is an effective tool for evaluating shoulder joint function. The development and usage of a mobile version of the ASES questionnaire has the potential to save time, money, and effort. OBJECTIVE The aim of this study is to assess the equivalence between the paper and mobile versions of the ASES questionnaire and their acceptability among patients. METHODS The paper and mobile versions of the ASES questionnaire were used to evaluate the shoulder joint function of 50 patients with shoulder pain. This study included patients from the shoulder clinic of Sun Yat-sen Memorial Hospital. The intraclass correlation coefficient (ICC) and Bland-Altman method were used to evaluate the agreement (reliability) of the scores obtained by the two methods (paper versus mobile). RESULTS Of the 50 patients recruited from March 2018 to May 2019, 46 (92%) completed the study. There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001). The mean difference between the scores of the mobile and paper versions was 1.0, and only 1/46 (2%) had a difference greater than the minimal clinically important difference of 12 points. About 75% of patients preferred the mobile version to the paper version. CONCLUSIONS Our study shows that the mobile version of the ASES questionnaire is comparable to the paper version, and has a higher patient preference. This could prove to be a useful tool for epidemiological studies and patient follow-up over longer periods of time.",2020,"There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001).","['American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form', '50 patients recruited from March 2018 to May 2019, 46 (92%) completed the study', '50 patients with shoulder pain', 'patients', 'patients from the shoulder clinic of Sun Yat-sen Memorial Hospital']",['Elbow Surgeons Standardized Shoulder Assessment Form (ASES) questionnaire'],[],"[{'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0037011', 'cui_str': 'Shoulder pain'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036644', 'cui_str': 'Senegal'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",[],50.0,0.0611349,"There was a high agreement between the paper and mobile versions of the ASES questionnaire (ICC=0.979, 95% CI 0.943-0.987; P<.001).","[{'ForeName': 'Jingyi', 'Initials': 'J', 'LastName': 'Hou', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Qingyue', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Menglei', 'Initials': 'M', 'LastName': 'Yu', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Fangqi', 'Initials': 'F', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yiyong', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Long', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yamuhanmode', 'Initials': 'Y', 'LastName': 'Alike', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yuanhao', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Maslah Idiris', 'Initials': 'MI', 'LastName': 'Ali', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Congda', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Li', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': 'Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.'}]",JMIR mHealth and uHealth,['10.2196/16758'] 2158,32706734,Acceptability of an Embodied Conversational Agent for Type 2 Diabetes Self-Management Education and Support via a Smartphone App: Mixed Methods Study.,"BACKGROUND Embodied conversational agents (ECAs) are increasingly used in health care apps; however, their acceptability in type 2 diabetes (T2D) self-management apps has not yet been investigated. OBJECTIVE This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. METHODS A sequential mixed methods design was applied. Adults with T2D allocated to the intervention arm of the MDC trial used the MDC app over a period of 12 months. At 6 months, they completed questions assessing their interaction with, and attitudes toward, the ECA. In-depth qualitative interviews were conducted with a subsample of the participants from the intervention arm to explore their experiences of using the ECA. The interview questions included the participants' perceptions of Laura, including their initial impression of her (and how this changed over time), her personality, and human character. The quantitative and qualitative data were interpreted using integrated synthesis. RESULTS Of the 93 intervention participants, 44 (47%) were women; the mean (SD) age of the participants was 55 (SD 10) years and the baseline glycated hemoglobin A1c level was 7.3% (SD 1.5%). Overall, 66 of the 93 participants (71%) provided survey responses. Of these, most described Laura as being helpful (57/66, 86%), friendly (57/66, 86%), competent (56/66, 85%), trustworthy (48/66, 73%), and likable (40/66, 61%). Some described Laura as not real (18/66, 27%), boring (26/66, 39%), and annoying (20/66, 30%). Participants reported that interacting with Laura made them feel more motivated (29/66, 44%), comfortable (24/66, 36%), confident (14/66, 21%), happy (11/66, 17%), and hopeful (8/66, 12%). Furthermore, 20% (13/66) of the participants were frustrated by their interaction with Laura, and 17% (11/66) of the participants reported that interacting with Laura made them feel guilty. A total of 4 themes emerged from the qualitative data (N=19): (1) perceived role: a friendly coach rather than a health professional; (2) perceived support: emotional and motivational support; (3) embodiment preference acceptability of a human-like character; and (4) room for improvement: need for greater congruence between Laura's words and actions. CONCLUSIONS These findings suggest that an ECA is an acceptable means to deliver T2D self-management education and support. A human-like character providing ongoing, friendly, nonjudgmental, emotional, and motivational support is well received. Nevertheless, the ECA can be improved by increasing congruence between its verbal and nonverbal communication and accommodating user preferences. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry CTRN12614001229662; https://tinyurl.com/yxshn6pd.",2020,"This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. ","['Adults with T2D', ""participants' perceptions of Laura, including their initial impression of her (and how this changed over time), her personality, and human character""]","['Embodied Conversational Agent', 'Embodied conversational agents (ECAs', 'ECA (Laura', ""friendly coach rather than a health professional; (2) perceived support: emotional and motivational support; (3) embodiment preference acceptability of a human-like character; and (4) room for improvement: need for greater congruence between Laura's words and actions"", 'ECA']","['survey responses', 'baseline glycated hemoglobin A1c level']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007952', 'cui_str': 'Character'}]","[{'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007952', 'cui_str': 'Character'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C0441472', 'cui_str': 'Action'}]","[{'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}]",93.0,0.0433844,"This study aimed to evaluate the acceptability of the ECA (Laura) used to deliver diabetes self-management education and support in the My Diabetes Coach (MDC) app. ","[{'ForeName': 'Shaira', 'Initials': 'S', 'LastName': 'Baptista', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Wadley', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Bird', 'Affiliation': 'The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Speight', 'Affiliation': 'The University of Melbourne, Melbourne, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ""see Authors' Contributions, .""}]",JMIR mHealth and uHealth,['10.2196/17038'] 2159,32707101,The Family Check-Up 4 Health: Study protocol of a randomized type II hybrid effectiveness-implementation trial in integrated primary care (the healthy communities 4 healthy students study).,"BACKGROUND Parenting interventions like the Family Check-Up have demonstrated effects on child physical and behavioral health outcomes. However, access to these programs is limited, particularly for populations experiencing health disparities. Primary care settings have become recognized as a potential delivery system in which these programs may be implemented at scale. The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. METHODS We will conduct a hybrid type 2 effectiveness-implementation trial in partnership with a primary care clinic in a low-income, majority Latino community. Families with 2- to 5-year-old children will be eligible to participate. Families will be randomized to receive the intervention (n = 130) or services as usual (n = 70) and will be assessed annually over three years. Outcomes are informed by the RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance). Effectiveness outcomes include child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting). Early stage implementation outcomes are also included (e.g., cost, acceptability, appropriateness, and feasibility). Effectiveness outcomes will be assessed via intent-to-treat (ITT) analyses. Implementation outcomes will be primarily descriptive with comparisons to prior trials of FCU4Health and the original FCU. PROJECTED OUTCOMES This trial will provide evidence related to the potential of integrated primary care settings to deliver evidence-based preventive interventions with a dual focus on behavioral and physical health.",2020,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","['partnership with a primary care clinic in a low-income, majority Latino community', 'Families with 2- to 5-year-old children', 'integrated primary care (the healthy communities 4 healthy students study']",['Family Check-Up 4 Health (FCU4Health) program'],"['RE-AIM framework (i.e., reach, effectiveness, adoption, implementation, and maintenance', 'cost, acceptability, appropriateness, and feasibility', 'child health behaviors (e.g., Dietary Screener Questionnaire), behavioral health (e.g., Strengths and Difficulties Questionnaire), and parenting (e.g., Proactive Parenting']","[{'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0420160', 'cui_str': 'History and physical examination, school'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}]",,0.0514529,"The purpose of this trial is to test the effectiveness of the Family Check-Up 4 Health (FCU4Health) program, an adaptation of the FCU for primary care, and assess program implementation in an integrated primary care setting. ","[{'ForeName': 'Cady', 'Initials': 'C', 'LastName': 'Berkel', 'Affiliation': ""REACH Institute, Arizona State University, Tempe, AZ, USA; Phoenix Children's Hospital, Phoenix, AZ, USA. Electronic address: Cady.Berkel@asu.edu.""}, {'ForeName': 'Justin D', 'Initials': 'JD', 'LastName': 'Smith', 'Affiliation': 'Center for Prevention Implementation Methodology (Ce-PIM), Department of Psychiatry and Behavioral Sciences, Department of Preventive Medicine, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Meg M', 'Initials': 'MM', 'LastName': 'Bruening', 'Affiliation': 'Department of Nutrition, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Jordan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Fu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Mauricio', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kevin J', 'Initials': 'KJ', 'LastName': 'Grimm', 'Affiliation': 'Department of Psychology, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Winslow', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}, {'ForeName': 'Kristen', 'Initials': 'K', 'LastName': 'Ray', 'Affiliation': 'Bayless Integrated Healthcare, Phoenix, AZ, USA.'}, {'ForeName': 'Annette', 'Initials': 'A', 'LastName': 'Bourne', 'Affiliation': 'Southwest Maricopa Regional Council, First Things First, Peoria, AZ, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Dishion', 'Affiliation': 'REACH Institute, Arizona State University, Tempe, AZ, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106088'] 2160,32707159,Obesity blunts cephalic-phase microvascular responses to food.,"Neurally mediated anticipatory responses, also named cephalic-phase responses, and microcirculatory regulation are two important mechanisms to maintain metabolic homeostasis. Altered cephalic-phase responses in obesity and its metabolic consequences have been proposed. There is, however, a lack of studies focusing on in vivo assessment of the microcirculation during this phase in patients with obesity. In this randomized controlled trial, we selected patients with obesity and healthy subjects after clinical and laboratory assessments. Those with obesity were randomized into two groups: experimental (cephalic-phase microvascular response stimulation - CP group, n = 13) and controls (n = 14). Healthy subjects (n = 17) were also included to form a CP control group. Skin microvascular assessment was used as a model of systemic microcirculation. Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH) were measured by dorsal finger videocapillaroscopy and expressed mainly capillary recruitment capacity. Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ) were assessed by dynamic nailfold videocapillaroscopy and expressed the microhemodynamics. Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p = 0.221 and p = 0.307, respectively) depicting lack of capillary recruitment. In contrast, healthy subjects presented an increase in this microvascular outcome (p = 0.004). Changes in all variables of microhemodynamics occurred in both CP groups (healthy and those with obesity). During CP, we originally demonstrated an absence of capillary recruitment in subjects with obesity. These findings might contribute to the literature of microvascular impairment and metabolic conditions.",2020,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","['healthy subjects', 'Patients with obesity (with or without stimulus', 'group, n=13) and controls (n=14', 'patients with obesity', 'Healthy subjects (n=17) were also included to form a CP control group', 'subjects with obesity', 'patients with obesity and healthy subjects after clinical and laboratory assessments']",['experimental (cephalic-phase microvascular response stimulation - CP'],"['Resting red blood cell velocity (RBCV), peak RBCV during PORH (RBCV max ), and time taken to reach RBCV max (TRBCV max ', 'microvascular outcome', 'Skin microvascular assessment', 'FCD during PORH post-stimulus', 'Resting functional capillary density (FCD) and peak FCD during post-occlusive reactive hyperemia (PORH']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205096', 'cui_str': 'Cephalic'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1562113', 'cui_str': 'Fleck corneal dystrophy'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0006901', 'cui_str': 'Structure of capillary blood vessel (organ)'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0178824', 'cui_str': 'Reactive Hyperemia'}]",17.0,0.0160267,"Patients with obesity (with or without stimulus) failed to show an increase on FCD during PORH post-stimulus (p=0.221 and p=0.307, respectively) depicting lack of capillary recruitment.","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Buss', 'Affiliation': 'Department of Nutrition Federal University of Health Sciences of Porto Alegre (UFCSPA), RS, Brazil; Graduate Program in Health Sciences, UFCSPA, RS, Brazil. Electronic address: carolinebuss@ufcspa.edu.br.'}, {'ForeName': 'Priscila A', 'Initials': 'PA', 'LastName': 'Maranhão', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Faculty of Medicine, Center for Research in Health Technologies and Information Systems (CINTESIS), University of Porto, Porto, Portugal.'}, {'ForeName': 'Maria das Graças C', 'Initials': 'MDGC', 'LastName': 'de Souza', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Eliete', 'Initials': 'E', 'LastName': 'Bouskela', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Luiz Guilherme', 'Initials': 'LG', 'LastName': 'Kraemer-Aguiar', 'Affiliation': 'Clinical and Experimental Research Laboratory on Vascular Biology (BioVasc) Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil; Department of Internal Medicine Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113087'] 2161,32707403,"Changes to stance limb peak, cumulative, and regional plantar foot forces among normal walking and three mobility aids in healthy older adults.","BACKGROUND Mobility aids are commonly prescribed to offload an injured lower extremity. Device selection may impact stance foot loading patterns and foot health in clinical populations at risk of foot ulceration. RESEARCH QUESTIONS Two questions motivated this study: How does device selection influence peak plantar and regional (rearfoot, mid foot and forefoot) foot forces on the stance foot? Does device selection influence peak, cumulative, and regional plantar forces within a 200 m walking trial? METHODS Twenty-one older adults walked 200 m at self-selected pace in four randomized conditions for this prospective crossover study. Participants used a walker, crutches, wheeled knee walker (WKW), and no assistive device (control condition). Plantar forces were measured using a wireless in-shoe system (Loadsol, Novel Inc., St. Paul, MN). Repeated measures analyses of variance were used to determine differences in peak and cumulative total and regional forces among walking conditions. Paired sample t-tests compared forces during first and last 30 s epochs of each condition to determine device influence over time. RESULTS The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions. Crutch use had similar peak forces as control. There were no differences in the number of steps taken within devices comparing first and last epochs. Crutches had a 0.04 and 0.07 BW increase in peak net and forefoot forces during the last epoch. Walker use had 66.44 BW lower cumulative forefoot forces in the last epoch. SIGNIFICANCE Crutches had similar stance foot loading as normal walking while a walker lowered forefoot forces at the expense of increased steps. A WKW may be the best choice to 'protect' tissues in the stance foot from exposure to peak and cumulative forces in the forefoot region.",2020,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"['healthy older adults', 'Twenty-one older adults walked 200 m at self-selected pace']",['normal walking and three mobility aids'],"['device selection influence peak, cumulative, and regional plantar forces', 'peak net forces', 'Plantar forces', 'peak net and forefoot forces', 'stance limb peak, cumulative, and regional plantar foot forces', 'peak and cumulative total and regional forces among walking conditions', 'cumulative forefoot forces']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}]","[{'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C3495449', 'cui_str': 'Mobility aid'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0031222', 'cui_str': 'Personnel Selection'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C1510667', 'cui_str': 'Forefoot region of foot'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",21.0,0.0456241,The WKW reduced peak net forces by 0.29 and 0.35 bodyweight (BW) when compared to the walker or control condition with similar trends in all foot regions.,"[{'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Kingston', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada. Electronic address: david.kingston@usask.ca.'}, {'ForeName': 'A Gary', 'Initials': 'AG', 'LastName': 'Linassi', 'Affiliation': 'College of Medicine, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada; School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: anl931@mail.usask.ca.'}, {'ForeName': 'Audrey R', 'Initials': 'AR', 'LastName': 'Zucker-Levin', 'Affiliation': 'School of Rehabilitation Science, University of Saskatchewan, Suite 3400, 3rd Floor, 104 Clinic Pl, Saskatoon, SK, S7N 2Z4, Canada. Electronic address: audrey.zuckerlevin@usask.ca.'}]",Gait & posture,['10.1016/j.gaitpost.2020.07.015'] 2162,32707476,Sales to apparently alcohol-intoxicated customers and online responsible vendor training in recreational cannabis stores in a randomized trial.,"BACKGROUND In some U.S. states, laws prohibit sales of recreational marijuana to intoxicated customers to prevent associated harms. In alcohol markets, training in responsible sales practices is one intervention to help reduce such sales to intoxicated customers. Similar training may be beneficial in the recreational cannabis market. METHODS An online responsible marijuana vendor (RMV) training was developed. Among its five modules, learning elements taught store personnel to recognize signs of alcohol impairment and intoxication, refuse sales, and understand the risks of driving under the influence of cannabis. A sample of n = 150 recreational cannabis stores in Colorado, Oregon, and Washington State, USA were enrolled in a randomized controlled trial, half of which were randomly assigned to use the RMV training. Stores were posttested using a pseudo-customer protocol in which confederate buyers feigned obvious signs of alcohol intoxication. RESULTS Deterrence of sales to intoxicated customers does not seem to exist, regardless of whether the states' laws prohibit it. Only 16 of 146 stores (11.0%; 4 Oregon stores were eliminated that were not in business) refused sales. There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401 [1-tailed]) or between stores that used the RMV training (6.3% [4.0%]) or not (12.0% [5.7%], F = 0.91, p = 0.343 [2-tailed]). In 11 visits, store personnel commented on the buyers' behavior, or expressed concern/suspicion about buyers, but sold to them anyway. CONCLUSIONS Training in responsible sales practices alone did not appear to reduce sales to apparently alcohol-intoxicated customers. Legal deterrence from making these sales may be insufficient or nonexistent for store management to support adherence to this responsible sales practice. Regulatory and policy actions may be needed to increase perceived risk with such sales (i.e., clear policy and swift, severe, and certain penalties) to achieve training's benefits.",2020,"There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401","['A sample of n\xa0=\xa0150 recreational cannabis stores in Colorado, Oregon, and Washington State, USA']","['RMV training', 'alcohol-intoxicated customers and online responsible vendor training']","['control stores', 'refusal rates']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0029195', 'cui_str': 'Oregon'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}]","[{'cui': 'C1273518', 'cui_str': 'Responsible to'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0042462', 'cui_str': 'Vendors'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1698986', 'cui_str': 'Storage'}, {'cui': 'C0040809', 'cui_str': 'Refusal of treatment by patient'}]",150.0,0.027768,"There was no difference in refusal rates between intervention (11.6% [3.9%]) and control stores (7.6% [3.1%], F = 0.71, p = 0.401","[{'ForeName': 'David B', 'Initials': 'DB', 'LastName': 'Buller', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: dbuller@kleinbuendel.com.'}, {'ForeName': 'W Gill', 'Initials': 'WG', 'LastName': 'Woodall', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: gwoodall@kleinbuendel.com.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Saltz', 'Affiliation': 'Prevention Research Center, 2150 Shattuck, Avenue, Suite 601, Berkeley, CA 94704, USA. Electronic address: saltz@prc.org.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Grayson', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: agrayson@kleinbuendel.com.'}, {'ForeName': 'Sierra', 'Initials': 'S', 'LastName': 'Svendsen', 'Affiliation': 'Klein Buendel, Inc., 1667 Cole Boulevard, Suite 225, Golden, CO 80401, USA. Electronic address: ssvendsen@kleinbuendel.com.'}, {'ForeName': 'Gary R', 'Initials': 'GR', 'LastName': 'Cutter', 'Affiliation': 'Department of Biostatistics, School of Public Health, University of Alabama, 403b Ryals Public Health Building 1665 University Boulevard, Birmingham, AL 35294, USA. Electronic address: cutterg@uab.edu.'}]",The International journal on drug policy,['10.1016/j.drugpo.2020.102860'] 2163,32713109,Low-dose and long-term azithromycin significantly decreases Staphylococcus aureus in the microbiome of refractory CRS patients.,"BACKGROUND The sinonasal microbiome is believed to play an important role in the pathophysiology of refractory chronic rhinosinusitis (CRS). We evaluated changes in the microbiome following a 4-month course of low-dose azithromycin. Assessing microbiome alterations following such a treatment may help identify underlying mechanisms of this drug. METHODS A total of 48 adults with refractory CRS were enrolled in a double-blind, randomized, placebo-controlled trial. Patients were randomized to 250 mg of azithromycin or placebo 3 times weekly for 4 months. During this time, daily budesonide saline irrigations were continued. Sinonasal swabs were collected by endoscopically-assisted method prior to treatment initiation and at the end of it, and sent for 16S ribosomal RNA gene sequencing. High-resolution ANCHOR pipeline was used to infer and annotate putative species. The 2 patient groups were compared using DESeq2 differential abundance analysis. RESULTS From initiation to the end of azithromycin treatment, patients showed a significant difference in beta diversity analysis (p = 0.0004) along with a significant decrease in 71 different operational taxonomic units (OTUs) of Staphylococcus aureus (false discovery rate [FDR] < 0.05) obtained from the differential abundance analysis. This was not observed in placebo-treated patients. By the end of treatments, azithromycin-treated patients had a significant decrease in 29 different OTUs of S. aureus (FDR < 0.05) when compared to placebo. CONCLUSION A 4-month course of 250 mg of azithromycin 3 times weekly in patients with refractory CRS significantly decreases S. aureus abundance in the sinonasal microbiome. Considering the pathogenic role of S. aureus in the refractory CRS population, azithromycin may constitute an additional therapeutic option to help control this disease.",2020,"From initiation to the end of azithromycin treatment, patients showed a significant difference in beta diversity analysis (p = 0.0004) along with a significant decrease in 71 different operational taxonomic units (OTUs) of Staphylococcus aureus (false discovery rate [FDR] < 0.05) obtained from the differential abundance analysis.","['48 adults with refractory CRS', 'refractory CRS patients']","['azithromycin', 'azithromycin or placebo', 'placebo']","['beta diversity analysis', 'operational taxonomic units (OTUs) of Staphylococcus aureus (false discovery rate [FDR', 'Staphylococcus aureus']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0008903', 'cui_str': 'classification'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0038172', 'cui_str': 'Staphylococcus aureus'}, {'cui': 'C0205557', 'cui_str': 'False positive'}]",48.0,0.399879,"From initiation to the end of azithromycin treatment, patients showed a significant difference in beta diversity analysis (p = 0.0004) along with a significant decrease in 71 different operational taxonomic units (OTUs) of Staphylococcus aureus (false discovery rate [FDR] < 0.05) obtained from the differential abundance analysis.","[{'ForeName': 'Axel E', 'Initials': 'AE', 'LastName': 'Renteria', 'Affiliation': ""Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.""}, {'ForeName': 'Anastasios', 'Initials': 'A', 'LastName': 'Maniakas', 'Affiliation': ""Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.""}, {'ForeName': 'Leandra Endam', 'Initials': 'LE', 'LastName': 'Mfuna', 'Affiliation': ""Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.""}, {'ForeName': 'Marc-Henri', 'Initials': 'MH', 'LastName': 'Asmar', 'Affiliation': ""Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.""}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Gonzalez', 'Affiliation': 'Canadian Centre for Computational Genomics (C3G), Department of Human Genetics, McGill University, Montréal, QC, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Desrosiers', 'Affiliation': ""Centre de Recherche du Centre Hospitalier, de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.""}]",International forum of allergy & rhinology,['10.1002/alr.22653'] 2164,32713115,A Multicenter Prospective Randomized Controlled Trial for Preoperative Biliary Drainage with Uncovered Metal versus Plastic Stents for Resectable Periampullary Cancer.,"BACKGROUND AND STUDY AIMS Although routine preoperative biliary drainage (PBD) in patients with distal malignant biliary obstruction is generally not recommended, there are still various situations where it may be necessary. The current study aims to compare between the uncovered self-expandable metal stent (uSEMS) and plastic stent (PS), where PBD may be necessary. PATIENTS AND METHODS In this multicenter prospective randomized study, patients with resectable periampullary cancer with cholangitis, deep jaundice, or expected long waiting time for surgery were included. PBD was performed endoscopically, but percutaneous drainage was allowed if the initial endoscopic drainage was not feasible. The primary outcome was the reintervention rate; the secondary outcomes were the complication rates, rate of decrease of total bilirubin, waiting time for surgery, and postoperative hospital stay. RESULTS Of the 60 enrolled patients, 53 were included for analysis (26 PS and 27 uSEMS). Common bile duct cancer was the most common (27, 50.9%), followed by pancreatic head cancer (20, 37.7%). Regarding PBD indication, 36 (67.9%) had cholangitis and 21 (39.6%) had a total bilirubin level of more than 10mg/dL at randomization; 10 (18.9%) were included due to delayed surgery by more than seven days. Fifty (94.3%) patients received pancreaticoduodenectomy, and one (1.9%) patient received palliative hepaticojejunostomy. The median waiting time for surgery was 11.0 days. There was no difference in the reintervention rate (3.8% and 3.8% in PS and uSEMS, P > 0.999), PBD-related complication rate (23.1% and 22.2%, P > 0.999), PBD- or surgery-related complication rate (57.7% and 48.1%, P = 0.674), and the rate of decrease of total bilirubin (P=0.541). The median hospital stay after surgery was 13.0 days without significant difference. CONCLUSION For patients who received surgery within the first two weeks from receiving PBD, there was no superiority of uSEMS to PS. According to the expected waiting time for surgery, selective approach for stent choice should be considered.",2020,"There was no difference in the reintervention rate (3.8% and 3.8% in PS and uSEMS, P > 0.999), PBD-related complication rate (23.1% and 22.2%, P > 0.999), PBD- or surgery-related complication rate (57.7% and 48.1%, P = 0.674), and the rate of decrease of total bilirubin (P=0.541).","['60 enrolled patients, 53 were included for analysis (26 PS and 27 uSEMS', 'patients with distal malignant biliary obstruction', 'patients with resectable periampullary cancer with cholangitis, deep jaundice, or expected long waiting time for surgery were included', 'Resectable Periampullary Cancer']","['Preoperative Biliary Drainage with Uncovered Metal versus Plastic Stents', 'pancreaticoduodenectomy', 'self-expandable metal stent (uSEMS) and plastic stent (PS', 'routine preoperative biliary drainage (PBD', 'palliative hepaticojejunostomy', 'PBD']","['rate of decrease of total bilirubin', 'complication rates, rate of decrease of total bilirubin, waiting time for surgery, and postoperative hospital stay', 'median waiting time', 'PBD-related complication rate', 'median hospital stay', 'reintervention rate', 'PBD- or surgery-related complication rate', 'total bilirubin level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0441289', 'cui_str': 'Plastic stent'}, {'cui': 'C0439845', 'cui_str': 'Uncovered'}, {'cui': 'C4042807', 'cui_str': 'Self Expandable Metallic Stent'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C3898473', 'cui_str': 'Malignant biliary obstruction'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0008311', 'cui_str': 'Cholangitis'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0022346', 'cui_str': 'Jaundice'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0400745', 'cui_str': 'Biliary drainage'}, {'cui': 'C0025552', 'cui_str': 'Metal'}, {'cui': 'C0441289', 'cui_str': 'Plastic stent'}, {'cui': 'C0085162', 'cui_str': 'Pancreaticoduodenectomy'}, {'cui': 'C4042807', 'cui_str': 'Self Expandable Metallic Stent'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0587605', 'cui_str': 'Palliative care service'}, {'cui': 'C0193425', 'cui_str': 'Hepatojejunostomy'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0400745', 'cui_str': 'Biliary drainage'}, {'cui': 'C0201913', 'cui_str': 'Bilirubin, total measurement'}]",60.0,0.309048,"There was no difference in the reintervention rate (3.8% and 3.8% in PS and uSEMS, P > 0.999), PBD-related complication rate (23.1% and 22.2%, P > 0.999), PBD- or surgery-related complication rate (57.7% and 48.1%, P = 0.674), and the rate of decrease of total bilirubin (P=0.541).","[{'ForeName': 'Jaeae Hee', 'Initials': 'JH', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'YooSeok', 'Initials': 'Y', 'LastName': 'Yoon', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'EuiJoo', 'Initials': 'E', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Yeon Suk', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Jai Young', 'Initials': 'JY', 'LastName': 'Cho', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Ho-Seong', 'Initials': 'HS', 'LastName': 'Han', 'Affiliation': 'Department of Surgery, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Yeon Ho', 'Initials': 'YH', 'LastName': 'Park', 'Affiliation': 'Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Dong Woo', 'Initials': 'DW', 'LastName': 'Shin', 'Affiliation': 'Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea.'}, {'ForeName': 'Jong-Chan', 'Initials': 'JC', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Jin-Hyeok', 'Initials': 'JH', 'LastName': 'Hwang', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}, {'ForeName': 'Jaihwan', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hosptial, Seoul National University College of Medicine, Seongnam, Korea.'}]",Journal of hepato-biliary-pancreatic sciences,['10.1002/jhbp.811'] 2165,32713171,"Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients.",,2020,,['ulcerative colitis patients'],['mesalazine'],[],"[{'cui': 'C0009324', 'cui_str': 'Ulcerative colitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0127615', 'cui_str': 'mesalamine'}]",[],,0.0275622,,"[{'ForeName': 'Keiji', 'Initials': 'K', 'LastName': 'Yagisawa', 'Affiliation': 'Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Taku', 'Initials': 'T', 'LastName': 'Kobayashi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Ozaki', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Okabayashi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Takahiko', 'Initials': 'T', 'LastName': 'Toyonaga', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Miki', 'Initials': 'M', 'LastName': 'Miura', 'Affiliation': 'The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Mari', 'Initials': 'M', 'LastName': 'Hayashida', 'Affiliation': 'The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Eiko', 'Initials': 'E', 'LastName': 'Saito', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Masaru', 'Initials': 'M', 'LastName': 'Nakano', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Hajime', 'Initials': 'H', 'LastName': 'Matsubara', 'Affiliation': 'Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}, {'ForeName': 'Tadakazu', 'Initials': 'T', 'LastName': 'Hisamatsu', 'Affiliation': 'The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Toshifumi', 'Initials': 'T', 'LastName': 'Hibi', 'Affiliation': 'Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.'}]",Intestinal research,['10.5217/ir.2018.00078-c1'] 2166,32713213,What Motivates Engagement in a Community-Based Behavior Change Strategy for Overweight Children?,"Introduction . The success of family-based community programs for childhood obesity may be increased by promoting social-cognitive factors that influence motivation and participant engagement. Incentivizing behavior can potentially enhance engagement and encourage behavior change. This research investigated motivators to engagement with a multicomponent incentive-based strategy to improve attendance and health-related behavior change in a family community-based weight management program for overweight and obese children. Method . Qualitative analysis combining; demographic data ( n = 512), survey of parents ( n = 273), and stakeholder ( n = 10) and family interviews ( n = 24). Participants were selected from program providers and families participating in an Australian community weight management program during a randomized controlled trial ( n = 512 children). Maximum variation sampling (demographics and group characteristics) and inductive thematic analysis were used. Results/Conclusion . Four factors influencing engagement were (1) personal value, (2) achievement, (3) support, and (4) overwhelm. These themes corroborated with social-cognitive factors, fostered by a combination of behavior change components in the program that increased participant accountability and intrinsic motivation. Focusing on autonomous goal planning with parental involvement, tracking of goals, and reviewing of goals may complement existing strategies in child-focused treatment programs. Low-value noncash incentives linked to goal setting for encouraging healthy eating and physical activity were well accepted and may enhance family engagement and attendance.",2020,The success of family-based community programs for childhood obesity may be increased by promoting social-cognitive factors that influence motivation and participant engagement.,"['Participants were selected from program providers and families participating in an Australian community weight management program during a randomized controlled trial ( n = 512 children', 'overweight and obese children', ' n = 512), survey of parents ( n = 273), and stakeholder ( n = 10) and family interviews ( n = 24']","['multicomponent incentive-based strategy', 'Qualitative analysis combining; demographic data']",[],"[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}]",[],512.0,0.0186529,The success of family-based community programs for childhood obesity may be increased by promoting social-cognitive factors that influence motivation and participant engagement.,"[{'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Enright', 'Affiliation': 'University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Gyani', 'Affiliation': 'NSW Department of Premier and Cabinet, Sydney, New South Wales Australia.'}, {'ForeName': 'Karice', 'Initials': 'K', 'LastName': 'Hyun', 'Affiliation': 'University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Allman-Farinelli', 'Affiliation': 'University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Innes-Hughes', 'Affiliation': 'NSW Office of Preventive Health, Sydney, New South Wales, Australia.'}, {'ForeName': 'Lily', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Redfern', 'Affiliation': 'University of Sydney, Sydney, New South Wales, Australia.'}]",Health promotion practice,['10.1177/1524839920944859'] 2167,32713290,Assessing the user experience and usability of the PRECIOUS system: a randomized controlled trial in obese patients.,"Objective To assess users' usability, satisfaction, acceptance and effectiveness of the PRECIOUS system to promote behavior change toward healthier lifestyles. Design : Thirty-one adult patients with BMI>30 (M = 44.23, SD = 5.91) were recruited and randomized into three conditions for a longitudinal study (3 months length): 1) Control group (TAU + biofeedback + follow-ups); 2) PRECIOUS only (app + biofeedback + follow-ups); 3) PRECIOUS + MI (app + biofeedback + motivational interviewing follow-ups). Main Outcome Measures : Usability, satisfaction, acceptance and effectiveness of PRECIOUS, and stages of change (S-Weight questionnaire). Results : The system was described as easy to use, flexible, fairly satisfying and good as a preventive health system. Participants rated biofeedback and the Physical Activity module as the most satisfying features. However, participants were unsatisfied with the Diet module. All additional features received acceptable scores in terms of satisfaction. Despite this, the PRECIOUS only group reported that they would probably recommend the system to others because it meets its purposes quite well. Conclusion : PRECIOUS was found a usable and acceptable solution, although improving several features in the Diet module in successive versions of the app would promote sustained use and satisfaction among users, possibly increasing its effectiveness in promoting healthier lifestyles. Abbreviations: ADA American Diabetes Association; BG2 : BodyGuard2; BMI : Body Mass Index; CBT : Cognitive-behavioral therapy; EMA : Ecological Momentary Assessment; eHealth : Electronic health; mHealth : Mobile health; MI : Motivational interviewing; NCD : Non-communicable diseases; PA : Physical activity; PRECIOUS : PREventive Care Infrastructure based On Ubiquitous Sensing.",2020,"Objective To assess users' usability, satisfaction, acceptance and effectiveness of the PRECIOUS system to promote behavior change toward healthier lifestyles. ","['obese patients', 'Abbreviations', 'Thirty-one adult patients with BMI>30 (M\xa0=\xa044.23, SD\xa0=\xa05.91']","['Control group (TAU + biofeedback ', ' MI (app + biofeedback + motivational interviewing follow-ups']","['Usability, satisfaction, acceptance and effectiveness of PRECIOUS, and stages of change (S-Weight questionnaire', ""users' usability, satisfaction, acceptance and effectiveness""]","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0000723', 'cui_str': 'Abbreviation'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",31.0,0.0343451,"Objective To assess users' usability, satisfaction, acceptance and effectiveness of the PRECIOUS system to promote behavior change toward healthier lifestyles. ","[{'ForeName': 'Carmina', 'Initials': 'C', 'LastName': 'Castellano-Tejedor', 'Affiliation': ""Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Moreno', 'Affiliation': ""Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}, {'ForeName': 'Keegan', 'Initials': 'K', 'LastName': 'Knittle', 'Affiliation': 'Department of Social Research, University of Helsinki , Helsinki, Finland, Europe.'}, {'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Nurmi', 'Affiliation': 'Department of Social Research, University of Helsinki , Helsinki, Finland, Europe.'}, {'ForeName': 'Todor', 'Initials': 'T', 'LastName': 'Ginchev', 'Affiliation': 'Department of Communications and Networking, Aalto University School of Electrical Engineering , Aalto, Espoo, Finland, Europe.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Parramón', 'Affiliation': ""Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}, {'ForeName': 'Andreea', 'Initials': 'A', 'LastName': 'Ciudin', 'Affiliation': ""Department of Endocrinology, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}, {'ForeName': 'Jose Antonio', 'Initials': 'JA', 'LastName': 'Ramos-Quiroga', 'Affiliation': ""Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Lusilla-Palacios', 'Affiliation': ""Department of Psychiatry, University Hospital Vall d'Hebron, CIBERSAM, Autonomous University of Barcelona , Barcelona, Spain.""}]",Informatics for health & social care,['10.1080/17538157.2020.1776292'] 2168,32713405,Targeting binge eating in bulimia nervosa and binge eating disorder using inhibitory control training and implementation intentions: a feasibility trial.,"BACKGROUND This trial examined the feasibility, acceptability, and effect sizes of clinical outcomes of an intervention that combines inhibitory control training (ICT) and implementation intentions (if-then planning) to target binge eating and eating disorder psychopathology. METHODS Seventy-eight adult participants with bulimia nervosa or binge eating disorder were randomly allocated to receive food-specific, or general, ICT and if-then planning for 4 weeks. RESULTS Recruitment and retention rates at 4 weeks (97.5% and 79.5%, respectively) met the pre-set cut-offs. The pre-set adherence to the intervention was met for the ICT sessions (84.6%), but not for if-then planning (53.4%). Binge eating frequency and eating disorder psychopathology decreased in both intervention groups at post-intervention (4 weeks) and follow-up (8 weeks), with moderate to large effect sizes. There was a tendency for greater reductions in binge eating frequency and eating disorders psychopathology (i.e. larger effect sizes) in the food-specific intervention group. Across both groups, ICT and if-then planning were associated with small-to-moderate reductions in high energy-dense food valuation (post-intervention), food approach (post-intervention and follow-up), anxiety (follow-up), and depression (follow-up). Participants indicated that both interventions were acceptable. CONCLUSIONS The study findings reveal that combined ICT and if-then planning is associated with reductions in binge eating frequency and eating disorder psychopathology and that the feasibility of ICT is promising, while improvements to if-then planning condition may be needed.",2020,"Binge eating frequency and eating disorder psychopathology decreased in both intervention groups at post-intervention (4 weeks) and follow-up (8 weeks), with moderate to large effect sizes.","['bulimia nervosa and binge eating disorder', 'Seventy-eight adult participants with bulimia nervosa or binge eating disorder']","['inhibitory control training and implementation intentions', 'food-specific, or general, ICT and if-then planning for 4 weeks', 'inhibitory control training (ICT) and implementation intentions (if-then planning']","['Recruitment and retention rates', 'Binge eating frequency and eating disorder psychopathology', 'binge eating frequency and eating disorders psychopathology', 'binge eating frequency and eating disorder psychopathology']","[{'cui': 'C2267227', 'cui_str': 'Bulimia nervosa'}, {'cui': 'C0596170', 'cui_str': 'Binge eating disorder'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0006370', 'cui_str': 'Binge Eating'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",78.0,0.0880878,"Binge eating frequency and eating disorder psychopathology decreased in both intervention groups at post-intervention (4 weeks) and follow-up (8 weeks), with moderate to large effect sizes.","[{'ForeName': 'Rayane', 'Initials': 'R', 'LastName': 'Chami', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Cardi', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Lawrence', 'Affiliation': 'School of Psychology, University of Exeter, Exeter, UK.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'MacDonald', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Rowlands', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Hodsoll', 'Affiliation': ""Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Treasure', 'Affiliation': ""Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}]",Psychological medicine,['10.1017/S0033291720002494'] 2169,32713418,[Treatment of external snapping hip with targeted resistance training intervention].,"This case report describes an 18-year-old woman, who had symptomatic bilateral external and internal snapping hip and completed 28 of 30 training sessions during a 12-week resistance training intervention. The intervention proved to be feasible and improved maximal strength in hip abduction and extension measured with Isokinetic Dynamometry. Improvements were also seen in The Copenhagen Hip and Groin Outcome Score, and The Forgotten Joint Score. Furthermore, visual analog scale pain markedly decreased after the intervention.",2019,The intervention proved to be feasible and improved maximal strength in hip abduction and extension measured with Isokinetic Dynamometry.,"['18-year-old woman, who had symptomatic bilateral external and internal snapping hip and completed 28 of 30 training sessions during a 12-week']","['external snapping hip with targeted resistance training intervention', 'resistance training intervention']","['maximal strength in hip abduction and extension measured with Isokinetic Dynamometry', 'Furthermore, visual analog scale pain', 'Copenhagen Hip and Groin Outcome Score, and The Forgotten Joint Score']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C1177045', 'cui_str': 'Snap'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0263843', 'cui_str': 'Snapping hip'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0018246', 'cui_str': 'Inguinal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4759288', 'cui_str': 'Forgotten Joint Score'}]",,0.0204797,The intervention proved to be feasible and improved maximal strength in hip abduction and extension measured with Isokinetic Dynamometry.,"[{'ForeName': 'Troels', 'Initials': 'T', 'LastName': 'Kjeldsen', 'Affiliation': 'Troels.kjeldsen@post.au.dk.'}, {'ForeName': 'Ulrik', 'Initials': 'U', 'LastName': 'Dalgas', 'Affiliation': ''}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Lamm', 'Affiliation': ''}, {'ForeName': 'Lisa Cecilie Urup', 'Initials': 'LCU', 'LastName': 'Reimer', 'Affiliation': ''}, {'ForeName': 'Inger', 'Initials': 'I', 'LastName': 'Mechlenburg', 'Affiliation': ''}]",Ugeskrift for laeger,[] 2170,32713421,CPAP titration failure is not equivalent to long-term CPAP treatment failure in patients with obesity hypoventilation syndrome: a case series.,"STUDY OBJECTIVES Medium and long-term trials comparing CPAP with noninvasive ventilation in patients with obesity hypoventilation syndrome (OHS) have shown no differences in outcomes. However, it remains unclear whether CPAP therapy should be prescribed if significant hypoxemia persists during CPAP titration, despite optimization of upper airway obstructive events or if maximum CPAP pressure is reached. We aimed to examine the effects of 6 weeks of home CPAP therapy on gas exchange in patients with OHS who failed CPAP titration due to persistent hypoxemia. METHODS This case series is a substudy of a randomized-controlled trial evaluating efficacy of three different PAP modalities in OHS. Patients randomized to CPAP who failed titration and were prescribed CPAP are included. CPAP failure was defined as spending more than 20% of total sleep time with oxygen saturation below 90% despite adequate resolution of apneas and hypopneas. Follow-up data included in-laboratory PSG on prescribed CPAP after 6 weeks of home CPAP therapy. RESULTS Three out of seven participants (43%) randomized to CPAP failed CPAP titration. All were morbidly obese, had severe OSA (AHI >90/h) and severe sleep hypoxemia (percentage of total sleep time with oxygen saturation <90% [T90] = 60-89%). Hypoxemia (T90: 43-67%, T80: 0-31% and T70: 0-11%) and hypercapnia (transcutaneous pCO₂ levels >50mmHg) persisted during CPAP titration PSG. The final PSG after 6 weeks of adherent home CPAP therapy showed effective control of OSA. Hypoventilation and hypoxemia severity decreased significantly in all three participants. CONCLUSIONS Our data suggests that CPAP titration failure does not equal CPAP treatment failure. CLINICAL TRIAL REGISTRATION Registry: ClinicalTrials.gov, Title: AVAPS-AE Efficacy Study, URL: https://clinicaltrials.gov/ct2/show/NCT01368614, Identifier: NCT01368614.",2020,"Hypoventilation and hypoxemia severity decreased significantly in all three participants. ","['patients with OHS who failed CPAP titration due to persistent hypoxemia', 'All were morbidly obese, had severe OSA (AHI >90/h) and severe sleep hypoxemia (percentage of total sleep time with oxygen saturation <90% [T90] = 60-89', 'patients with obesity hypoventilation syndrome (OHS', 'patients with obesity hypoventilation syndrome']","['CPAP with noninvasive ventilation', 'CPAP', 'hypercapnia ', 'home CPAP therapy']","['CPAP failure', 'transcutaneous pCO₂ levels ', 'Hypoventilation and hypoxemia severity', 'Hypoxemia', 'effective control of OSA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031880', 'cui_str': 'Extreme obesity with alveolar hypoventilation'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0439087', 'cui_str': '<90'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0020440', 'cui_str': 'Hypercapnia'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3203358', 'cui_str': 'Hypoventilation'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}]",7.0,0.113595,"Hypoventilation and hypoxemia severity decreased significantly in all three participants. ","[{'ForeName': 'Alejandra C', 'Initials': 'AC', 'LastName': 'Lastra', 'Affiliation': 'Division of Pulmonary, Critical Care and Sleep Medicine, Rush University Medical Center, Chicago, Illinois.'}, {'ForeName': 'Juan F', 'Initials': 'JF', 'LastName': 'Masa', 'Affiliation': 'Respiratory Department, San Pedro de Alcántara Hospital, Cáceres, Spain.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Mokhlesi', 'Affiliation': 'Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago, Chicago, Illinois.'}]",Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine,['10.5664/jcsm.8712'] 2171,32713463,Randomized trial for the treatment of post-traumatic elbow stiffness: surgical release vs. rehabilitation.,"BACKGROUND There are no previous randomized trials comparing surgical to conservative treatment for post-traumatic elbow stiffness. The aim of our study was to compare elbow range of motion (ROM) and clinical outcomes among patients undergoing surgical treatment or a standardized rehabilitation for post-traumatic elbow stiffness. METHODS Randomized clinical trial of patients with post-traumatic elbow stiffness for more than 6 months who failed conventional physical therapy for 4 months. Patients were randomized into 2 treatment groups. The conservative group underwent the rehabilitation protocol associated with the use of orthoses (static progressive for extension and dynamic for flexion) and continuous passive motion. The surgical group underwent surgical release by a posterior approach without triceps detachment, followed by a rehabilitation protocol similar to the conservative group. The primary outcome of the study was flexion-extension ROM at 6 months of follow-up. Secondary outcomes included the visual analog scale for pain, the Mayo Elbow Performance Score, the Disabilities of the Arm, Shoulder, and Hand score, absolute and relative increase in flexion-extension ROM, and complication rates. RESULTS Thirty patients were analyzed in the study, 15 in each group. The mean elbow flexion-extension ROM at the end of 6 months of follow-up was 108° in the surgical group and 88° in the conservative group (P = .002). The mean absolute and the relative increase of elbow flexion-extension at 6 months were, respectively, 17° and 27% in the conservative group and 41° and 59% in the surgical group (P < .001). CONCLUSION Surgical elbow release associated with the rehabilitation protocol resulted in a greater flexion-extension ROM, as well as a greater absolute and relative increase compared with rehabilitation alone at 6 months of follow-up. The groups did not differ regarding clinical scores and complication rates.",2020,The groups did not differ regarding clinical scores and complication rates.,"['patients undergoing surgical treatment or a standardized rehabilitation for post-traumatic elbow stiffness', 'Thirty patients were analyzed in the study, 15 in each group', 'patients with post-traumatic elbow stiffness for more than 6 months who failed conventional physical therapy for 4 months']","['surgical release by a posterior approach without triceps detachment, followed by a rehabilitation protocol similar to the conservative group', 'rehabilitation protocol associated with the use of orthoses (static progressive for extension and dynamic for flexion) and continuous passive motion']","['clinical scores and complication rates', 'mean elbow flexion-extension ROM', 'elbow range of motion (ROM', 'flexion-extension ROM', 'visual analog scale for pain, the Mayo Elbow Performance Score, the Disabilities of the Arm, Shoulder, and Hand\xa0score, absolute and relative increase in flexion-extension ROM, and complication rates', 'elbow flexion-extension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0239272', 'cui_str': 'Elbow stiff'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439093', 'cui_str': '>'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0205512', 'cui_str': 'Posterior approach'}, {'cui': 'C0541879', 'cui_str': 'Detachment psychological'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0079991', 'cui_str': 'Passive movement'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0444509', 'cui_str': 'Flexion/extension'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0575649', 'cui_str': 'Elbow joint - range of movement'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0454788', 'cui_str': 'Mayo'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",30.0,0.0594835,The groups did not differ regarding clinical scores and complication rates.,"[{'ForeName': 'César L B', 'Initials': 'CLB', 'LastName': 'Guglielmetti', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Mauro E C', 'Initials': 'MEC', 'LastName': 'Gracitelli', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. Electronic address: mgracitelli@gmail.com.'}, {'ForeName': 'Jorge H', 'Initials': 'JH', 'LastName': 'Assunção', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Fernando B', 'Initials': 'FB', 'LastName': 'Andrade-Silva', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Mariana M Nicolosi', 'Initials': 'MMN', 'LastName': 'Pessa', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Maria Candida', 'Initials': 'MC', 'LastName': 'Luzo', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Arnaldo A', 'Initials': 'AA', 'LastName': 'Ferreira Neto', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Eduardo A', 'Initials': 'EA', 'LastName': 'Malavolta', 'Affiliation': 'Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.'}]",Journal of shoulder and elbow surgery,['10.1016/j.jse.2020.03.023'] 2172,32713578,Project DiabEHT: An approach to improve self-care management of diabetes.,"OBJECTIVES To determine whether the project DiabEHT (Diabetic Electronic Health Tool) has significantly improved self-care management of participants with diabetes along with the aspects of general diet, physical activities, blood glucose monitoring, and foot-care; and their blood glucose level 6 weeks after the project implementation. METHODS Pre-experimental, one group pretest-posttest research study was conducted among 30 participants medically diagnosed with Diabetes Mellitus regardless of type. The project which included weekly support group activities and lecture series on diabetes, installation and use of the DiabEHT mobile app, and diabooth in the health center was implemented for 6 weeks. Participants' blood glucose levels were obtained before the start of each weekly session for 6 weeks. A modified version of the ""Summary of Diabetes Self-Care Activities (SDSCA)"" measure was used to evaluate participants' self-care management before and after the intervention. RESULTS After 6 weeks of project implementation, the participants have showed significant improvement on the following diabetes self-care activities: general diet (P=0.000), physical activities (P=0.007), blood glucose monitoring (P=0.000), and foot-care (P=0.000). Their blood glucose levels had also significantly reduced (P=0.005). CONCLUSION Indeed, the project had improved the diabetic participants' self-care management and compliance, and glycemic control. Nursescan take advantage of this innovation and consider integration into patient care. However, further studies are recommended to ensure sustainable incorporation and application into various settings.",2020,"After 6 weeks of project implementation, the participants have showed significant improvement on the following diabetes self-care activities: general diet (P=0.000), physical activities (P=0.007), blood glucose monitoring (P=0.000), and foot-care (P=0.000).","['30 participants medically diagnosed with Diabetes Mellitus regardless of type', 'diabetes', 'participants with diabetes']","['project DiabEHT (Diabetic Electronic Health Tool', 'Project DiabEHT']","['blood glucose monitoring (P=0.000), and foot-care', 'physical activities', ""diabetic participants' self-care management and compliance, and glycemic control"", 'blood glucose levels', 'diabetes self-care activities: general diet']","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0150240', 'cui_str': 'Foot care'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C2004436', 'cui_str': 'Activity therapy'}, {'cui': 'C0301563', 'cui_str': 'General diet'}]",30.0,0.0119748,"After 6 weeks of project implementation, the participants have showed significant improvement on the following diabetes self-care activities: general diet (P=0.000), physical activities (P=0.007), blood glucose monitoring (P=0.000), and foot-care (P=0.000).","[{'ForeName': 'Geraldine S', 'Initials': 'GS', 'LastName': 'Ridad', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines. Electronic address: geraldineridad@gmail.com.'}, {'ForeName': 'Val Clinton S', 'Initials': 'VCS', 'LastName': 'Maybituin', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines.'}, {'ForeName': 'Carlito Y', 'Initials': 'CY', 'LastName': 'Bella', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines.'}, {'ForeName': 'Karla Mae R', 'Initials': 'KMR', 'LastName': 'Cañete', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines.'}, {'ForeName': 'Omar Khayyam M', 'Initials': 'OKM', 'LastName': 'Usman', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines.'}, {'ForeName': 'Erik Louwe R', 'Initials': 'ELR', 'LastName': 'Sala', 'Affiliation': 'MSU-Iligan Institute of Technology, Andres Bonifacio Ave. Tibanga, Iligan City, 9200 Lanao del Norte, Philippines.'}]",Enfermeria clinica,['10.1016/j.enfcli.2020.04.004'] 2173,32707771,Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults.,"Brain-derived neurotrophic factor (BDNF) is key for the maintenance of normal neuronal function and energy homeostasis and has been suggested to improve cognitive function, including learning and memory. Iron and the antioxidant curcumin have been shown to influence BDNF homeostasis. This 6-week, double blind, randomized, placebo-controlled study examined the effects of oral iron supplementation at low (18 mg) and high (65 mg) ferrous (FS) iron dosages, compared to a combination of these iron doses with a bioavailable formulated form of curcumin (HydroCurc TM ; 500 mg) on BDNF levels in a healthy adult cohort of 155 male (26.42 years ± 0.55) and female (25.82 years ± 0.54) participants. Participants were randomly allocated to five different treatment groups: both iron and curcumin placebo (FS0+Plac), low dose iron and curcumin placebo (FS18+Plac), low dose iron and curcumin (FS18+Curc), high dose iron and curcumin placebo (FS65+Plac) and high dose iron and curcumin (FS65+Curc). Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF. The addition of curcumin to iron supplementation may therefore provide a novel approach to further enhance the benefits associated with increased BDNF levels.",2020,"Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF.","['Healthy Adults', 'healthy adult cohort of 155 male (26.42 years ± 0.55) and female (25.82 years ± 0.54) participants']","['iron and curcumin placebo (FS0+Plac), low dose iron and curcumin placebo (FS18+Plac), low dose iron and curcumin (FS18+Curc), high dose iron and curcumin placebo (FS65+Plac) and high dose iron and curcumin (FS65+Curc', 'Brain-derived neurotrophic factor (BDNF', 'FS18+Curc', 'oral iron supplementation at low (18 mg) and high (65 mg) ferrous (FS) iron dosages, compared to a combination of these iron doses with a bioavailable formulated form of curcumin (HydroCurc TM ', 'Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases', 'placebo']","['BDNF over time', 'serum BDNF', 'BDNF levels', 'Serum BDNF Levels']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517462', 'cui_str': '0.55'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3537005', 'cui_str': 'Iron supplement therapy'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0935763', 'cui_str': 'Bioavailable'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]","[{'cui': 'C0107103', 'cui_str': 'Brain-Derived Neurotrophic Factor'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.187068,"Results showed a significant increase in BDNF over time (26%) in the FS18+Curc group ( p = 0.024), and at end-point between FS18+Curc and FS18+Plac groups (35%, p = 0.042), demonstrating for the first time that the combination with curcumin, rather than iron supplementation alone, results in increased serum BDNF.","[{'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Tiekou Lorinczova', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Owen', 'Initials': 'O', 'LastName': 'Fitzsimons', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Mursaleen', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Renshaw', 'Affiliation': 'Centre for Sport, Exercise and Life Sciences, Faculty of Health and Life Sciences, Coventry University, Priory St, Coventry CV1 5FB, UK.'}, {'ForeName': 'Gulshanara', 'Initials': 'G', 'LastName': 'Begum', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}, {'ForeName': 'Mohammed Gulrez', 'Initials': 'MG', 'LastName': 'Zariwala', 'Affiliation': 'School of Life Sciences, University of Westminster, 115 New Cavendish Street, London W1W 6UW, UK.'}]","Antioxidants (Basel, Switzerland)",['10.3390/antiox9080645'] 2174,32707877,Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study.,"Short Physical Performance Battery (SPPB) assessment is a widely used measure of lower extremity function, strength, and balance. In the Lifestyles Interventions and Independence for Elders (LIFE) Study, baseline SPPB and changes throughout the trial were strongly associated with major mobility disability (MMD). This study further investigated this association by identifying trajectories of SPPB and evaluating the predictive validity of SPPB trajectories for future MMD. Participants ( n = 1635) aged 70-89 years were randomized to a physical activity or health education intervention and assessed every 6 months for MMD. We used group-based trajectory models (GBTMs) to identify trajectories of a binary outcome for a decrease from baseline SPPB of ≥1. Multinomial logistic regression explored baseline factors associated with group membership. Survival analyses evaluated the association between trajectories with MMD. The GBTM identified a 3-group model which included a ""No Decline"" group (46.0%), ""Late Decline"" group (27.7%), and an ""Early Decline"" group (26.3%). Adjusting for all other baseline characteristics, group assignment during the previous follow-up visit was strongly associated with MMD at the subsequent period. Comparisons between groups showed a 2-to-3-fold increase in MMD comparing the ""Late"" to ""No"" decline group and a 4-to-5-fold increase in MMD comparing the ""Early"" to ""No"" decline group. Group membership and impact on MMD was not different between intervention arms. Group-based trajectories of SPPB scores identified distinct subgroups in LIFE Study participants. Using these group assignments in outcome models were highly associated with MMD. GBTMs have potential to identify and improve prediction of aging-related decline to better design and identify patients for interventions.",2020,Group membership and impact on MMD was not different between intervention arms.,['Participants ( n = 1635) aged 70-89 years'],"['physical activity or health education intervention and assessed every 6 months for MMD', 'Short Physical Performance Battery (SPPB) assessment']","['MMD', 'major mobility disability (MMD']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0585339', 'cui_str': 'Every six months'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C4075461', 'cui_str': 'Short Physical Performance Battery'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",1635.0,0.024193,Group membership and impact on MMD was not different between intervention arms.,"[{'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Brown', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Wei-Hsuan', 'Initials': 'WH', 'LastName': 'Lo-Ciganic', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Shao', 'Affiliation': 'Center for Drug Evaluation & Safety, Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Pahor', 'Affiliation': 'Institute on Aging, Department of Aging and Geriatric Research, University of Florida College of Medicine, Gainesville, FL 32610, USA.'}, {'ForeName': 'Todd M', 'Initials': 'TM', 'LastName': 'Manini', 'Affiliation': 'Institute on Aging, Department of Aging and Geriatric Research, University of Florida College of Medicine, Gainesville, FL 32610, USA.'}]",Journal of clinical medicine,['10.3390/jcm9082332'] 2175,32707905,Noodles Made from High Amylose Wheat Flour Attenuate Postprandial Glycaemia in Healthy Adults.,"Previous research has not considered the effect of high amylose wheat noodles on postprandial glycaemia. The aim of the study is to investigate the effect of consumption of high amylose noodles on postprandial glycaemia over 2-h periods by monitoring changes in blood glucose concentration and calculating the total area under the blood glucose concentration curve. Twelve healthy young adults were recruited to a repeated measure randomised, single-blinded crossover trial to compare the effect of consuming noodles (180 g) containing 15%, 20% and 45% amylose on postprandial glycaemia. Fasting blood glucose concentrations were taken via finger-prick blood samples. Postprandial blood glucose concentrations were taken at 15, 30, 45, 60, 90 and 120 min. Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L). The total area under the blood glucose concentration curve after consumption of high amylose noodles with 45% amylose was 640.4 ± 9.49 mmol/L/min, 3.4% lower than consumption of low amylose noodles with 15% amylose (662.9 ± 9.49 mmol/L/min), p = 0.021. Noodles made from high amylose wheat flour attenuate postprandial glycaemia in healthy young adults, as characterised by the significantly lower blood glucose concentration and a 3.4% reduction in glycaemic response.",2020,"Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L).","['Twelve healthy young adults', 'Healthy Adults', 'healthy young adults']",['High Amylose Wheat Flour'],"['Postprandial blood glucose concentrations', 'blood glucose concentration and calculating the total area under the blood glucose concentration curve', 'glycaemic response', 'postprandial glycaemia', 'Fasting blood glucose concentrations', 'blood glucose concentration', 'Postprandial Glycaemia', 'total area under the blood glucose concentration curve']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0002732', 'cui_str': 'Amylose'}, {'cui': 'C0458980', 'cui_str': 'Wheat flour'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",12.0,0.0154981,"Subjects consuming high amylose noodles made with flour containing 45% amylose had significantly lower blood glucose concentration at 15, 30 and 45 min (5.5 ± 0.11, 6.1 ± 0.11 and 5.6 ± 0.11 mmol/L; p = 0.01) compared to subjects consuming low amylose noodles with 15% amylose (5.8 ± 0.12, 6.6 ± 0.12 and 5.9 ± 0.12 mmol/L).","[{'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Ang', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Bourgy', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Haelee', 'Initials': 'H', 'LastName': 'Fenton', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Regina', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation, Agriculture and Food, Canberra 2601, ACT, Australia.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Newberry', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation, Agriculture and Food, Canberra 2601, ACT, Australia.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Diepeveen', 'Affiliation': 'Department of Primary Industries and Regional Development, South Perth 6151, Western Australia; Australia.'}, {'ForeName': 'Domenico', 'Initials': 'D', 'LastName': 'Lafiandra', 'Affiliation': 'Department Agricultural and Forestry Sciences, University of Tuscia, 01100 Viterbo, Italy.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Grafenauer', 'Affiliation': 'Grains and Legumes Nutrition Council, North Ryde 2113, Australia.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Hunt', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Solah', 'Affiliation': 'School Public Health, Curtin University, Perth 6845, Western Australia, Australia.'}]",Nutrients,['10.3390/nu12082171'] 2176,32707917,Extending the Overnight Fast: Sex Differences in Acute Metabolic Responses to Breakfast.,"Fasting for over 24 h is associated with worsening glucose tolerance, but the effect of extending the overnight fast period (a form of time-restricted feeding) on acute metabolic responses and insulin sensitivity is unclear. The aim of this pilot study was to determine the acute impact of an increased fasting period on postprandial glycaemia, insulinemia, and acute insulin sensitivity responses to a standard meal. Twenty-four lean, young, healthy adults (12 males, 12 females) consumed a standard breakfast after an overnight fast of 12, 14, and 16 h. Each fast duration was repeated on three separate occasions (3 × 3) in random order. Postprandial glucose and insulin responses were measured at regular intervals over 2 h and quantified as incremental area under the curve (iAUC). Insulin sensitivity was determined by homeostatic modelling assessment (HOMA). After 2 h, ad libitum food intake at a buffet meal was recorded. In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002). Overall, males showed no differences in glucose or insulin homeostasis. Both sexes consumed more energy (+28%) at the subsequent meal (16 h vs. 12 h). Delaying the first meal of the day by 4 h by extending the fasting period may have adverse metabolic effects in young, healthy, adult females, but not males.",2020,"In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002).","['Twenty-four lean, young, healthy adults (12 males, 12 females']",[],"['adverse metabolic effects', 'postprandial glycaemia, insulinemia, and acute insulin sensitivity responses', 'postprandial glycaemia', 'glucose or insulin homeostasis', 'Postprandial glucose and insulin responses', 'insulin sensitivity', 'Insulin sensitivity']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}]",,0.0341348,"In females, but not males, insulin sensitivity improved (HOMA%S +35%, p = 0.016, marginally significant) with longer fast duration (16 h vs. 12 h), but paradoxically, postprandial glycaemia was higher (glucose iAUC +37%, p = 0.002).","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'S Atkinson', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'A Heruc', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Verena', 'Initials': 'V', 'LastName': 'M H Tan', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Petocz', 'Affiliation': 'Department of Mathematics and Statistics, Macquarie University, Sydney 2109, Australia.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'C Brand-Miller', 'Affiliation': 'Charles Perkins Centre and School of Life and Environmental Sciences, The University of Sydney, Sydney 2006, Australia.'}]",Nutrients,['10.3390/nu12082173'] 2177,32708055,The Effect of Inquiry-Based Stress Reduction on Teacher Burnout: A Controlled Trial.,"Burnout is a well-known phenomenon with significant social, biological and economic costs. In particular, teacher burnout is associated with unfavorable mental health outcomes and economic costs due to reduced hours and teacher turnover. This study investigated the effect of an Inquiry-Based Stress Reduction (IBSR) cognitive-reframing program on teacher burnout using a quasi-experimental design. Fifty-three teachers participated in a prospective intervention with a passive control group. The intervention group completed a 12-week IBSR program with 4.5 h of weekly engagement. Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04). Significant correlations were found between change in emotional exhaustion and negative affect (positive correlation; r = 0.32; p = 0.034) and between personal accomplishment and perceived stress (negative correlation; r = -0.451; p = 0.002). This study demonstrates the potential of IBSR to improve teacher well-being. Future randomized studies are needed to evaluate the causality of IBSR in reducing burnout among teachers and other high-stress workplaces.",2020,"Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04).",['Fifty-three teachers participated in a prospective intervention with a passive control group'],"['Inquiry-Based Stress Reduction (IBSR) cognitive-reframing program', 'IBSR program with 4.5 h of weekly engagement', 'Inquiry-Based Stress Reduction']","['personal accomplishment', 'emotional exhaustion', 'personal accomplishment and perceived stress']","[{'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3844009', 'cui_str': '4.5'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]",53.0,0.0193901,"Relative to control, teachers in the intervention group showed greater improvements in emotional exhaustion (18.8 ± 5.2 to 15.9 ± 5.7 vs. 16.0 ± 4.8 to 17.4 ± 4.8; p = 0.01) and personal accomplishment (21.8 ± 5.0 to 24.6 ± 4.3 vs. 21.9 ± 4.5 to 22.8 ± 4.3; p = 0.04).","[{'ForeName': 'Lia', 'Initials': 'L', 'LastName': 'Schnaider-Levi', 'Affiliation': 'Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.'}, {'ForeName': 'Ariel B', 'Initials': 'AB', 'LastName': 'Ganz', 'Affiliation': 'Department of Genetics, Stanford University, Stanford, CA 94305, USA.'}, {'ForeName': 'Keren', 'Initials': 'K', 'LastName': 'Zafrani', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Zehavit', 'Initials': 'Z', 'LastName': 'Goldman', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Mitnik', 'Affiliation': ""Begin High School, John Kennedy Street 8, Rosh Ha'Ayin 4852028, Israel.""}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Rolnik', 'Affiliation': 'Department of Genetics, Stanford University, Stanford, CA 94305, USA.'}, {'ForeName': 'Shahar', 'Initials': 'S', 'LastName': 'Lev-Ari', 'Affiliation': 'Department of Health Promotion, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.'}]",Brain sciences,['10.3390/brainsci10070468'] 2178,32708119,Neurophysiological Correlates of a Single Session of Prefrontal tDCS in Patients with Prolonged Disorders of Consciousness: A Pilot Double-Blind Randomized Controlled Study.,"Background. Transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex (lDLPFC) was reported to promote the recovery of signs of consciousness in some patients in a minimally conscious state (MCS), but its electrophysiological effects on brain activity remain poorly understood. Objective. We aimed to assess behavioral (using the Coma Recovery Scale-Revised; CRS-R) and neurophysiological effects (using high density electroencephalography; hdEEG) of lDLPFC-tDCS in patients with prolonged disorders of consciousness (DOC). Methods. In a double-blind, sham-controlled, crossover design, one active and one sham tDCS (2 mA, 20 min) were delivered in a randomized order. Directly before and after tDCS, 10 min of hdEEG were recorded and the CRS-R was administered. Results. Thirteen patients with severe brain injury were enrolled in the study. We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results). Higher weighted symbolic mutual information (wSMI) connectivity was found between left and right parietal regions, and higher fronto-parietal weighted phase lag index (wPLI) connectivity was found, both in the alpha band (uncorrected results). At the group level, no significant treatment effect was observed. Three patients showed behavioral improvement after the active session and one patient improved after the sham. Conclusion. We provide preliminary indications that neurophysiological changes can be observed after a single session of tDCS in patients with prolonged DOC, although they are not necessarily paralleled with significant behavioral improvements.",2020,We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results).,"['patients with prolonged disorders of consciousness (DOC', 'Patients with Prolonged Disorders of Consciousness', 'Thirteen patients with severe brain injury']","['Transcranial direct current stimulation (tDCS', 'lDLPFC-tDCS', 'Prefrontal tDCS']","['higher fronto-parietal weighted phase lag index (wPLI) connectivity', 'Higher weighted symbolic mutual information (wSMI) connectivity', 'behavioral improvement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009792', 'cui_str': 'Consciousness Disorders'}, {'cui': 'C0011710', 'cui_str': 'desoxycorticosterone'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0442030', 'cui_str': 'Parietal'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0948775', 'cui_str': 'High weight'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",13.0,0.240879,We found higher relative power at the group level after the active tDCS session in the alpha band in central regions and in the theta band over the frontal and posterior regions (uncorrected results).,"[{'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Carrière', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Sepehr', 'Initials': 'S', 'LastName': 'Mortaheb', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Raimondo', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Jitka', 'Initials': 'J', 'LastName': 'Annen', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Barra', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Binda Fossati', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Chatelle', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Hermann', 'Affiliation': 'Institut du Cerveau et de la Moelle épinière, ICM, PICNIC Lab, F-75013 Paris, France.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'Martens', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Di Perri', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Laureys', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}, {'ForeName': 'Aurore', 'Initials': 'A', 'LastName': 'Thibaut', 'Affiliation': 'Brain2 Clinic, Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, 4000 Liège, Belgium.'}]",Brain sciences,['10.3390/brainsci10070469'] 2179,31819995,"Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.","OBJECTIVE Data from two double-blind, randomized, Phase III studies were analysed to investigate the ability of Routine Assessment of Patient Index Data 3, DAS28 (CRP), modified (M)-DAS28 (CRP) and Simplified or Clinical Disease Activity Indices to predict structural damage progression in RA. METHODS This post hoc analysis included data from the 2-year Abatacept vs adaliMumab comParison in bioLogic-naïvE RA subjects with background MTX (AMPLE) trial in biologic-naïve patients with active RA (<5 years) and an inadequate response to MTX, and the 12-month treatment period of the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial in MTX-naïve patients with early RA (⩽2 years) and poor prognostic indicators. Adjusted logistic regression analysis assessed the relationship between baseline disease activity and structural damage progression (defined as change from baseline greater than the smallest detectable change) at 12 and 24 months in AMPLE and 6 and 12 months in AVERT. Areas under the receiver operating characteristic curves for the impact of baseline disease activity on structural damage progression were calculated. RESULTS Adjusted logistic regression analyses included all randomized and treated patients in AMPLE (N = 646) and those who received abatacept plus MTX or MTX monotherapy in AVERT (N = 235). Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. CONCLUSION In this post hoc analysis of two patient populations with RA, Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) were good at predicting structural damage. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov: NCT00929864 (AMPLE); NCT01142726 (AVERT).",2020,"Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. ",['comParison in bioLogic-naïvE RA subjects with background MTX (AMPLE) trial in biologic-naïve patients with active RA (<5 years'],"['adaliMumab', 'abatacept plus MTX or MTX monotherapy']","['Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores', 'Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP', 'Disease activity measures', 'ability of Routine Assessment of Patient Index Data 3, DAS28 (CRP), modified (M)-DAS28 (CRP) and Simplified or Clinical Disease Activity Indices', 'baseline disease activity and structural damage progression']","[{'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C1619966', 'cui_str': 'abatacept'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0010957', 'cui_str': 'Damage'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}]",646.0,0.149377,"Baseline Routine Assessment of Patient Index Data 3, DAS28 (CRP) and M-DAS28 (CRP) scores significantly predicted structural progression at months 12 and 24 in AMPLE (P < 0.05) and months 6 and 12 in AVERT (P < 0.01), and were stronger predictors than Simplified or Clinical Disease Activity Indices. ","[{'ForeName': 'Edward C', 'Initials': 'EC', 'LastName': 'Keystone', 'Affiliation': 'Department of Rheumatology, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Harris A', 'Initials': 'HA', 'LastName': 'Ahmad', 'Affiliation': 'Rheumatology, Bristol-Myers Squibb, Princeton, NJ.'}, {'ForeName': 'Yusuf', 'Initials': 'Y', 'LastName': 'Yazici', 'Affiliation': 'Department of Internal Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Bergman', 'Affiliation': 'Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/kez455'] 2180,32710862,Effect of a quality improvement package for intrapartum and immediate newborn care on fresh stillbirth and neonatal mortality among preterm and low-birthweight babies in Kenya and Uganda: a cluster-randomised facility-based trial.,"BACKGROUND Although gains in newborn survival have been achieved in many low-income and middle-income countries, reductions in stillbirth and neonatal mortality have been slow. Prematurity complications are a major driver of stillbirth and neonatal mortality. We aimed to assess the effect of a quality improvement package for intrapartum and immediate newborn care on stillbirth and preterm neonatal survival in Kenya and Uganda, where evidence-based practices are often underutilised. METHODS This unblinded cluster-randomised controlled trial was done in western Kenya and eastern Uganda at facilities that provide 24-h maternity care with at least 200 births per year. The study assessed outcomes of low-birthweight and preterm babies. Eligible facilities were pair-matched and randomly assigned (1:1) into either the intervention group or the control group. All facilities received maternity register data strengthening and a modified WHO Safe Childbirth Checklist; facilities in the intervention group additionally received provider mentoring using PRONTO simulation and team training as well as quality improvement collaboratives. Liveborn or fresh stillborn babies who weighed between 1000 g and 2500 g, or less than 3000 g with a recorded gestational age of less than 37 weeks, were included in the analysis. We abstracted data from maternity registers for maternal and birth outcomes. Follow-up was done by phone or in person to identify the status of the infant at 28 days. The primary outcome was fresh stillbirth and 28-day neonatal mortality. This trial is registered with ClinicalTrials.gov, NCT03112018. FINDINGS Between Oct 1, 2016, and April 30, 2019, 20 facilities were randomly assigned to either the intervention group (n=10) or the control group (n=10). Among 5343 eligible babies in these facilities, we assessed outcomes of 2938 newborn and fresh stillborn babies (1447 in the intervention and 1491 in the control group). 347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81). No harm or adverse effects were found. INTERPRETATION Fresh stillbirth and neonatal mortality among low-birthweight and preterm babies can be decreased using a package of interventions that reinforces evidence-based practices and invests in health system strengthening. FUNDING Bill & Melinda Gates Foundation.",2020,"347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81).","['Liveborn or fresh stillborn babies who weighed between 1000 g and 2500 g, or less than 3000 g with a recorded gestational age of less than 37 weeks, were included in the analysis', 'Between Oct 1, 2016, and April 30, 2019', 'western Kenya and eastern Uganda at facilities that provide 24-h maternity care with at least 200 births per year', ' 20 facilities', '5343 eligible babies in these facilities, we assessed outcomes of 2938 newborn and fresh stillborn babies (1447 in the intervention and 1491 in the control group', 'preterm and low-birthweight babies in Kenya and Uganda']","['provider mentoring using PRONTO simulation and team training', 'quality improvement package for intrapartum and immediate newborn care']","['fresh stillbirth and 28-day neonatal mortality', 'low-birthweight and preterm babies', 'fresh stillbirth and neonatal mortality', 'stillborn or died', 'harm or adverse effects', 'stillbirth and preterm neonatal survival']","[{'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C4319601', 'cui_str': '2500'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0470279', 'cui_str': '3000'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C1442824', 'cui_str': 'POU2F1 protein, human'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0439508', 'cui_str': '/year'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}]","[{'cui': 'C1260720', 'cui_str': 'Pronto'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C2936612', 'cui_str': 'Quality Improvement'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}, {'cui': 'C0456337', 'cui_str': 'Intrapartum'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0204792', 'cui_str': 'Routine care of newborn'}]","[{'cui': 'C0405334', 'cui_str': 'Fresh stillbirth'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0024032', 'cui_str': 'Low Birth Weights'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infants'}, {'cui': 'C0595939', 'cui_str': 'Stillbirth'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",,0.207075,"347 (23%) of 1491 infants in the control group were stillborn or died in the neonatal period compared with 221 (15%) of 1447 infants in the intervention group at 28 days (odds ratio 0·66, 95% CI 0·54-0·81).","[{'ForeName': 'Dilys', 'Initials': 'D', 'LastName': 'Walker', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA. Electronic address: dilys.walker@ucsf.edu.'}, {'ForeName': 'Phelgona', 'Initials': 'P', 'LastName': 'Otieno', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Butrick', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Gertrude', 'Initials': 'G', 'LastName': 'Namazzi', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Achola', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Rikita', 'Initials': 'R', 'LastName': 'Merai', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Otare', 'Affiliation': 'Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Mubiri', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Rakesh', 'Initials': 'R', 'LastName': 'Ghosh', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Santos', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Miller', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Nancy L', 'Initials': 'NL', 'LastName': 'Sloan', 'Affiliation': 'Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Waiswa', 'Affiliation': 'Maternal, Newborn and Child Health Centre of Excellence, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda; Global Health Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Global health,['10.1016/S2214-109X(20)30232-1'] 2181,32714831,Neurofeedback self-regulating training in patients with Post traumatic stress disorder: A randomized controlled trial study protocol.,"Background Post-traumatic stress disorder (PTSD) has become an important public health problem. However, the conventional therapeutic strategy, including pharmacotherapy and cognitive behavioral therapy, has limitations. Neurofeedback is a technique that utilizes electroencephalography (EEG) signaling to monitor human physiological functions and is widely used to treat patients with PTSD. The purpose of our study is to assess the efficacy and safety level of neurofeedback treatment in patients with PTSD using quantitative EEG. Methods This is a randomized, waitlist-controlled, assessor-blinded, clinical trial. Forty-six patients with PTSD will be randomly assigned at a 1:1 ratio into two groups. The participants in the treatment group will receive neurofeedback treatment for 50 min, twice a week, for 8 weeks (16 sessions). Quantitative EEG will be utilized to monitor the physiological functions and brain waves of the participants. A four-week follow-up period is planned. The participants in the control group will wait for 12 weeks. The primary outcome is the Korean version of PTSD Checklist-5 (PCL-5-K) score. The PCL-5-K scores on week 8 will be compared between the two groups. Anxiety, depression, insomnia, emotions, EEG, quality-of-life, and safety level will be assessed as secondary outcomes. Discussion This trial will describe a clinical research methodology for neurofeedback in patients with PTSD. The numerous subjective and objective secondary outcomes add to the value of this trial's results. It will also suggest a therapeutic strategy for utilizing quantitative EEG in patients with PTSD. Our trial will provide basic evidence for the management of PTSD via an integrative treatment. Trial registration Clinical Research Information Service (CRIS): KCT0003271.",2020,The PCL-5-K scores on week 8 will be compared between the two groups.,"['patients with PTSD', 'Forty-six patients with PTSD', '\n\n\nPost-traumatic stress disorder (PTSD', 'patients with Post traumatic stress disorder', 'patients with PTSD using quantitative EEG']","['Neurofeedback self-regulating training', 'neurofeedback treatment']","['PCL-5-K scores', 'Anxiety, depression, insomnia, emotions, EEG, quality-of-life, and safety level', 'Korean version of PTSD Checklist-5 (PCL-5-K) score', 'efficacy and safety level']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}]","[{'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C1704423', 'cui_str': 'Hereditary lymphedema'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",46.0,0.0624636,The PCL-5-K scores on week 8 will be compared between the two groups.,"[{'ForeName': 'Jungtae', 'Initials': 'J', 'LastName': 'Leem', 'Affiliation': 'Research and Development Institute, CY Pharma Co., Seoul, South Korea.'}, {'ForeName': 'Moon Joo', 'Initials': 'MJ', 'LastName': 'Cheong', 'Affiliation': 'College of Education, Hanyang University, Seoul, South Korea.'}, {'ForeName': 'Sang-Hoon', 'Initials': 'SH', 'LastName': 'Yoon', 'Affiliation': 'Chung-Yeon Central Institute, Gwangju, South Korea.'}, {'ForeName': 'Hyunho', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Chung-Yeon Central Institute, Gwangju, South Korea.'}, {'ForeName': 'Hee-Geun', 'Initials': 'HG', 'LastName': 'Jo', 'Affiliation': 'Chung-Yeon Central Institute, Gwangju, South Korea.'}, {'ForeName': 'Hyeryun', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Department of Korean Neuropsychiatry Medicine, Wonkwang University, Iksan, South Korea.'}, {'ForeName': 'Jeesu', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Korean Neuropsychiatry Medicine, Wonkwang University, Iksan, South Korea.'}, {'ForeName': 'Hyang Yi', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': ""Department of Nursing, Kyung-In Women's University, Incheon, South Korea.""}, {'ForeName': 'Geun-Woo', 'Initials': 'GW', 'LastName': 'Kim', 'Affiliation': 'Department of Neuropsychiatry, Dongguk University Bundang Oriental Hospital, Seongnam, South Korea.'}, {'ForeName': 'Hyung Won', 'Initials': 'HW', 'LastName': 'Kang', 'Affiliation': 'Department of Korean Neuropsychiatry Medicine, Wonkwang University, Iksan, South Korea.'}]",Integrative medicine research,['10.1016/j.imr.2020.100464'] 2182,32714891,Feasibility and Acceptability of a Culturally- and Linguistically-Adapted Smoking Cessation Text Messaging Intervention for Latino Smokers.,"Objective: Assess the feasibility and acceptability of a culturally- and linguistically-adapted smoking cessation text messaging intervention for Latino smokers. Methods: Using a community-based strategy, 50 Latino smokers were recruited to participate in a smoking cessation pilot study. Participants received a 12-week text messaging intervention and were offered Nicotine Replacement Therapy (NRT) at no cost. We assessed biochemically verified abstinence at 12 weeks, text messaging interactivity with the program, NRT utilization, self-efficacy, therapeutic alliance, and satisfaction. Results: Participants were 44.8 years old on average (SD 9.80), and they were primarily male (66%) and had no health insurance (78%). Most of the participants were born in Mexico (82%) and were light smokers (1-10 CPD) (68%). All participants requested the first order of NRT, and 66% requested a refill. Participants sent an average of 39.7 text messages during the 12-week intervention (SD 82.70). At 12 weeks, 30% of participants were biochemically verified abstinent (88% follow-up rate) and working alliance mean value was 79.2 (SD 9.04). Self-efficacy mean score increased from 33.98 (SD 10.36) at baseline to 40.05 (SD 17.65) at follow-up ( p = 0.04). The majority of participants (90.9%, 40/44) reported being very or extremely satisfied with the program. Conclusion: A culturally- and linguistically-adapted smoking cessation text messaging intervention for Latinos offers a promising strategy to increase the use of NRT, generated high satisfaction and frequent interactivity, significantly increased self-efficacy, produced high therapeutic alliance, and resulted in noteworthy cessation rates at the end of treatment. Additional testing as a formal randomized clinical trial is warranted.",2020,"The majority of participants (90.9%, 40/44) reported being very or extremely satisfied with the program. ","['50 Latino smokers were recruited to participate in a smoking cessation pilot study', 'Participants were 44.8 years old on average (SD 9.80), and they were primarily male (66%) and had no health insurance (78', 'Latino smokers', 'Latinos', 'Latino Smokers']","['culturally- and linguistically-adapted smoking cessation text messaging intervention', '12-week text messaging intervention and were offered Nicotine Replacement Therapy (NRT', 'Culturally- and Linguistically-Adapted Smoking Cessation Text Messaging Intervention']","['NRT utilization, self-efficacy, therapeutic alliance, and satisfaction', 'Self-efficacy mean score', 'feasibility and acceptability', 'noteworthy cessation rates', 'self-efficacy', 'Feasibility and Acceptability']","[{'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0021682', 'cui_str': 'Health Insurance'}]","[{'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C1444648', 'cui_str': 'Offered'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}]","[{'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}]",,0.0494245,"The majority of participants (90.9%, 40/44) reported being very or extremely satisfied with the program. ","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Cartujano-Barrera', 'Affiliation': 'Department of Cancer Prevention and Control, Hackensack University Medical Center, Hackensack, NJ, United States.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Sanderson Cox', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, KS, United States.'}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Arana-Chicas', 'Affiliation': 'Department of Cancer Prevention and Control, Hackensack University Medical Center, Hackensack, NJ, United States.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Ramírez', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, KS, United States.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Perales-Puchalt', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, KS, United States.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Valera', 'Affiliation': 'Department of Urban-Global Public Health, Rutgers University, Newark, NJ, United States.'}, {'ForeName': 'Francisco J', 'Initials': 'FJ', 'LastName': 'Díaz', 'Affiliation': 'Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, United States.'}, {'ForeName': 'Delwyn', 'Initials': 'D', 'LastName': 'Catley', 'Affiliation': ""Center for Children's Healthy Lifestyles & Nutrition, Children's Mercy Kansas City, Kansas City, MO, United States.""}, {'ForeName': 'Edward F', 'Initials': 'EF', 'LastName': 'Ellerbeck', 'Affiliation': 'Department of Population Health, University of Kansas Medical Center, Kansas City, KS, United States.'}, {'ForeName': 'Ana Paula', 'Initials': 'AP', 'LastName': 'Cupertino', 'Affiliation': 'James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States.'}]",Frontiers in public health,['10.3389/fpubh.2020.00269'] 2183,32714972,The Effect of Selected Exercise Programs on the Quality of Life in Women with Grade 1 Stress Urinary Incontinence and Its Relationship with Various Body Mass Indices: A Randomized Trial.,"Aims The aim of the study was to analyze the influence gymnastics has on the quality of life (QOL) in women with grade 1 stress urinary incontinence (SUI) and to determine the relationship between the outcome and selected body weight indices: body mass index (BMI) and waist-to-hip ratio (WHR). Methods A randomized study of 140 women (45-60 years) with grade 1 SUI. The subjects were randomly assigned to a 3-month training for pelvic floor muscles and a transverse abdominal muscle (PFM + TrA, n = 70) or PFM alone ( n = 70). The QOL was determined with the questionnaire International Consultation on Incontinence Modular Questionnaire-Lower Urinary Tract Symptoms Quality of Life (ICIQ LUTS QOL), before and after the program. Results Women with BMI < 30 kg/m 2 benefited more from the PFM + TrA program with respect to physical limitations and embarrassment domains, whereas patients with a gynoid body type (WHR < 0.8) benefited more in terms of physical and social limitations, SUI-evoked emotions, severity measures, and embarrassment domains. Conclusions After the PFM + TrA training, women with WHR < 0.8 had a better QOL than those with WHR > 0.8.",2020,"kg/m 2 benefited more from the PFM + TrA program with respect to physical limitations and embarrassment domains, whereas patients with a gynoid body type (WHR < 0.8) benefited more in terms of physical and social limitations, SUI-evoked emotions, severity measures, and embarrassment domains. ","['140 women (45-60 years) with grade 1 SUI', 'Women with BMI < 30', 'women with grade 1 stress urinary incontinence (SUI', 'Women with Grade 1 Stress Urinary Incontinence and Its Relationship with Various Body Mass Indices']","['3-month training for pelvic floor muscles and a transverse abdominal muscle (PFM\u2009+\u2009TrA, n = 70) or PFM alone', 'Selected Exercise Programs']","['Quality of Life', 'Incontinence Modular Questionnaire-Lower Urinary Tract Symptoms Quality of Life (ICIQ LUTS QOL', 'quality of life (QOL', 'mass index (BMI) and waist-to-hip ratio (WHR', 'physical and social limitations, SUI-evoked emotions, severity measures, and embarrassment domains']","[{'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0224378', 'cui_str': 'Structure of transversus abdominis muscle'}, {'cui': 'C1868598', 'cui_str': 'Enlarged parietal foramina'}, {'cui': 'C0040845', 'cui_str': 'Tretinoin'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0574785', 'cui_str': 'Lower urinary tract symptoms'}, {'cui': 'C0043328', 'cui_str': 'Lutein'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0679112', 'cui_str': 'Embarrassment'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}]",140.0,0.0601173,"kg/m 2 benefited more from the PFM + TrA program with respect to physical limitations and embarrassment domains, whereas patients with a gynoid body type (WHR < 0.8) benefited more in terms of physical and social limitations, SUI-evoked emotions, severity measures, and embarrassment domains. ","[{'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Ptak', 'Affiliation': 'Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University in Szczecin, Poland.'}, {'ForeName': 'Sylwester', 'Initials': 'S', 'LastName': 'Ciećwież', 'Affiliation': 'Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University in Szczecin, Poland.'}, {'ForeName': 'Agnieszka', 'Initials': 'A', 'LastName': 'Brodowska', 'Affiliation': 'Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University in Szczecin, Poland.'}, {'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Szylińska', 'Affiliation': 'Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University in Szczecin, Poland.'}, {'ForeName': 'Andrzej', 'Initials': 'A', 'LastName': 'Starczewski', 'Affiliation': 'Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University in Szczecin, Poland.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Rotter', 'Affiliation': 'Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University in Szczecin, Poland.'}]",BioMed research international,['10.1155/2020/1205281'] 2184,32714989,The Impact of 12-Week Jaques-Dalcroze Eurhythmics Programme on the Dynamic Agility in Single-Dual-Task Conditions in Older Women: A Randomized Controlled Trial.,"Background Progressive degenerative changes in the body of elderly people lead to a decrease in physical and mental fitness. Seniors have a problem with performing tasks that involve both physical and mental health at the same time. The risk of falls increases, the consequences of which in old age may be particularly dangerous. It was decided to investigate the impact of performing exercises involving both physical and mental spheres on the dynamic agility in older women. Methods 73 women (69.9 ± 3.2) were divided into two groups: intervention (IG, n = 34) and control (CG, n = 39). Individuals with IG participated in the Jaques-Dalcroze Eurhythmics exercise programme for 12 weeks, twice a week for 45 minutes each. Dynamic agility was determined by the Timed Up and Go test, which was conducted both in single-task (TUG_ST) and dual-task (TUG_DT) conditions, where the participant was simultaneously counting down from 60 every 3. The percentage difference between the results of both tests (dual-task cost, DTC) was also determined. Both groups had two measurement sessions: one week before the start of the exercise programme and one week after the end of exercise programme. Results After 12 weeks of exercise, IG participants obtained significantly better results in TUG_DT ( p < 0.001) and DTC ( p = 0.003) tests. During this time, CG participants had significantly worse results in TUG_DT ( p < 0.001) and DTC ( p < 0.001) tests. In the TUG_ST test, neither IG nor CG achieved a significant change in the result. In each test, a significant interaction between the group assignment and the measurement session was observed: TUG_ST: F = 11.523, η 2 P = 0.139, p = 0.001; TUG_DT: F = 60.227, η 2 P = 0.458, p < 0.001; DTC: F = 32.382, η 2 P = 0.313, p < 0.001. Conclusion JDE exercises with a frequency of twice a week, for about 12 weeks, have a significant impact on the improvement of the dynamic agility control in women over 65 years of age.",2020,"During this time, CG participants had significantly worse results in TUG_DT ( p < 0.001) and DTC ( p < 0.001) tests.","['older women', 'women over 65 years of age', 'Older Women', '73 women (69.9 ± 3.2']","['Jaques-Dalcroze Eurhythmics exercise programme', '12-Week Jaques-Dalcroze Eurhythmics Programme']","['dynamic agility control', 'Dynamic Agility', 'Dynamic agility', 'physical and mental fitness']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517687', 'cui_str': '3.2'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",73.0,0.0442287,"During this time, CG participants had significantly worse results in TUG_DT ( p < 0.001) and DTC ( p < 0.001) tests.","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Adamczyk', 'Affiliation': 'Department of Dance and Gymnastics, Faculty of Sport Sciences, Poznań University of Physical Education, 61-871 Poznań, Poland.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Celka', 'Affiliation': 'Department of Dance and Gymnastics, Faculty of Sport Sciences, Poznań University of Physical Education, 61-871 Poznań, Poland.'}, {'ForeName': 'Rafał', 'Initials': 'R', 'LastName': 'Stemplewski', 'Affiliation': 'Department of Physical Activity Sciences and Health Promotion, Faculty of Sport Sciences, Poznań University of Physical Education, 61-871 Poznań, Poland.'}, {'ForeName': 'Kinga', 'Initials': 'K', 'LastName': 'Ceynowa', 'Affiliation': 'Faculty of Compositions, Conducting, Theory of Music and Eurhythmics, Academy of Music in Poznań, 61-808 Poznań, Poland.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Kamińska', 'Affiliation': 'Graduate School for Sports Sciences, Poznań University of Physical Education, 61-871 Poznań, Poland.'}, {'ForeName': 'Janusz', 'Initials': 'J', 'LastName': 'Maciaszek', 'Affiliation': 'Department of Physical Activity Sciences and Health Promotion, Faculty of Sport Sciences, Poznań University of Physical Education, 61-871 Poznań, Poland.'}]",BioMed research international,['10.1155/2020/9080697'] 2185,32715153,A community-based positive psychology group intervention to promote physical activity among people with metabolic syndrome: Proof of concept results to inform a pilot randomized controlled trial protocol.,"Background Community-based physical activity interventions can offset the burden of developing chronic diseases. Positive psychology (PP) interventions may improve health behaviors, but little is known about their effectiveness in community-based prevention settings. A multilevel PP-based intervention has never been studied in people at risk for chronic diseases. Purpose The aim of the trial is to demonstrate feasibility, acceptability, and improve physical activity. The purpose is to describe the theory, design, and rationale of the randomized controlled trial (RCT) phase of an iteratively developed physical activity intervention for metabolic syndrome. The feasibility results of the proof-of-concept phase are presented. Methods Participants are adult primary care patients at community health centers with metabolic syndrome and low physical activity (target n = 64). The 8-week group intervention consists of weekly physical activity goal-setting and self-monitoring, positive psychology activities, and neighborhood walks. Participants rate feasibility and acceptability of sessions. Pre-post-intervention, and 24 weeks later, participants complete accelerometers, questionnaires, and biometrics. Feasibility results Eight participants enrolled and seven completed. The median number of group sessions attended was 7 out of 8. Average ease and usefulness of sessions were rated as 7.0 (±0.5)/10 and 8.1 (±1.0)/10, respectively, indicating feasibility and acceptability. Average pre-post physical activity increased by 2152 steps and 29.25 min of MVPA/week. Discussion This proof-of-concept trial demonstrated high feasibility and acceptability, with increased physical activity. These positive findings suggest that the RCT phase will show high feasibility, acceptability, and initial impact on physical activity.",2020,"Average pre-post physical activity increased by 2152 steps and 29.25 min of MVPA/week. ","['Methods\n\n\nParticipants are adult primary care patients at community health centers with metabolic syndrome and low physical activity (target n\xa0=\xa064', 'Eight participants enrolled and seven completed', 'people with metabolic syndrome', 'metabolic syndrome']","['physical activity intervention', 'Positive psychology (PP) interventions', 'community-based positive psychology group intervention', '\n\n\nCommunity-based physical activity interventions', 'weekly physical activity goal-setting and self-monitoring, positive psychology activities, and neighborhood walks']","['feasibility and acceptability', 'Average pre-post physical activity', 'health behaviors']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1510628', 'cui_str': 'Positive Psychology'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0150598', 'cui_str': 'Goal setting'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",8.0,0.0614831,"Average pre-post physical activity increased by 2152 steps and 29.25 min of MVPA/week. ","[{'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'Millstein', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, United States.'}, {'ForeName': 'Anne N', 'Initials': 'AN', 'LastName': 'Thorndike', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, United States.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, United States.'}, {'ForeName': 'Elyse R', 'Initials': 'ER', 'LastName': 'Park', 'Affiliation': 'Department of Medicine, Massachusetts General Hospital, United States.'}, {'ForeName': 'Jeff C', 'Initials': 'JC', 'LastName': 'Huffman', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, United States.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100626'] 2186,32715381,Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels.,"INTRODUCTION The studies described here were conducted to investigate the central nervous system (CNS) transfer of ASP3652, a peripherally acting inhibitor of fatty acid amide hydrolase, after multiple doses at around the anticipated therapeutic dose and the safety, tolerability, and pharmacokinetics after single doses at corresponding supratherapeutic doses in healthy subjects. METHODS Study 1 was an open-label multiple dose study in which ASP3652 (300 mg bid) or matching placebo was administered in multiple doses to healthy subjects. Study 2 was a placebo-controlled, randomized 4 × 4 crossover study in which ASP3652 was given as three single ascending doses of ASP3652 (600-1800 mg) or matching placebo to healthy subjects. Levels of ASP3652 and endocannabinoids (eCBs) in plasma, cerebrospinal fluid (CSF) (study 1 only), and safety were evaluated. RESULTS In study 1, ASP3652 was readily absorbed to reach C max at 1 h after dosing. AUC tau and C max of ASP3652 in CSF were approximately 0.2% and 0.06% of the AUC tau and C max in plasma after multiple doses of ASP3652 300 mg bid. At steady state the area under the response-time curve (AURC) from 0 to 12 h and the maximum response for anandamide in plasma were approximately 550-fold and 230-fold higher than those in CSF. In study 2, the C max and AUC of ASP3652 increased higher than dose proportionally in subjects receiving 600-1800 mg ASP3652. For eCBs, although the AURC increased less than dose proportionally, maximum plasma levels were comparable across all treatment groups. The incidence of adverse events (AEs) was similar across all treatment groups including the placebo group. There was no evidence of CNS-related side effects. CONCLUSIONS ASP3652 showed low CNS penetration at the anticipated therapeutic dose and was well tolerable without any CNS-related AEs at supratherapeutic doses, supporting that the drug can be safely tested at the anticipated therapeutic dose. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT02034734 for study 1, NCT01815684 for study 2.",2020,"Levels of ASP3652 and endocannabinoids (eCBs) in plasma, cerebrospinal fluid (CSF)","['to healthy subjects', 'healthy subjects']","['placebo', 'ASP3652', 'matching placebo', 'ASP3652 (300\xa0mg bid) or matching placebo']","['response-time curve (AURC', 'AUC tau and C max of ASP3652 in CSF', 'maximum plasma levels', 'low CNS penetration', 'Cerebrospinal Fluid Transfer', 'C max and AUC of ASP3652', 'incidence of adverse events (AEs', 'maximum response for anandamide in plasma', 'Levels of ASP3652 and endocannabinoids (eCBs) in plasma, cerebrospinal fluid (CSF']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}]","[{'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C3540014', 'cui_str': 'CENTRAL NERVOUS SYSTEM'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0211726', 'cui_str': 'anandamide'}, {'cui': 'C1172779', 'cui_str': 'Endocannabinoid'}]",,0.105325,"Levels of ASP3652 and endocannabinoids (eCBs) in plasma, cerebrospinal fluid (CSF)","[{'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Takizawa', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan. masaomi.takizawa@astellas.com.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Cerneus', 'Affiliation': 'Astellas Pharma Europe B. V., Leiden, The Netherlands.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Michon', 'Affiliation': 'Astellas Pharma Europe B. V., Leiden, The Netherlands.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'Rijnders', 'Affiliation': 'Astellas Pharma Europe B. V., Leiden, The Netherlands.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Meijer', 'Affiliation': 'Astellas Pharma Europe B. V., Leiden, The Netherlands.'}, {'ForeName': 'Akiyoshi', 'Initials': 'A', 'LastName': 'Someya', 'Affiliation': 'Astellas Pharma Inc, Tokyo, Japan.'}, {'ForeName': 'Yuichiro', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'Astellas Pharma Inc, Ibaraki, Japan.'}]",Advances in therapy,['10.1007/s12325-020-01451-6'] 2187,32715401,Tranexamic acid is beneficial for blood management of high tibial osteotomy: a randomized controlled study.,"INTRODUCTION The purpose of this study was to investigate whether TXA can effectively reduce blood loss after HTO and related complications and to evaluate its safety. MATERIALS AND METHODS From March 2016 to March 2018, 100 patients who underwent medial opening wedge HTO in the Department of Orthopedics, the second affiliated hospital of xi'an jiaotong university, with an average age of 52.8 ± 3.2 years, were randomly divided into the TXA group (using intravenous TXA) and the control group (using the same amount of normal saline), with 50 patients in each group. The postoperative wound drainage volume, decrease in hemoglobin and hematocrit value, total blood loss, wound healing, blood transfusion, deep venous thrombosis (DVT) and pulmonary embolism (PE) were compared between the two groups. RESULTS The drainage volume on the first postoperative day and the total drainage volume of the TXA group were significantly lower compared with those of the control group (145.7 vs 264.5 ml, 282.3 vs 413.2 ml, P < 0.05). The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 g, P < 0.05; 3.3 vs 5.5, 5.0 vs 9.1, 3.8 vs 7.2%, P < 0.05), and the mean total blood loss was also lower in the TXA group than that in the control group (477.9 vs 834.6 ml, P < 0.05). In the control group, 1 patient had wound hematoma requiring additional paracentesis and pressure dressing, 1 patient had superficial wound infection requiring additional debridement, and 1 patient had postoperative blood transfusion compared to none in the TXA group (P > 0.05). There was no symptomatic DVT or PE in either of the groups. CONCLUSION Intravenous TXA can effectively and safely reduce blood loss and bleeding-related complications after HTO and was beneficial for the blood management of HTO.",2020,"The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 ","[""100 patients who underwent medial opening wedge HTO in the Department of Orthopedics, the second affiliated hospital of xi'an jiaotong university, with an average age of 52.8\u2009±\u20093.2\xa0years"", 'high tibial osteotomy']","['TXA group (using intravenous TXA', 'Intravenous TXA', 'TXA', 'Tranexamic acid']","['wound hematoma requiring additional paracentesis and pressure dressing', 'symptomatic DVT or PE', 'postoperative wound drainage volume, decrease in hemoglobin and hematocrit value, total blood loss, wound healing, blood transfusion, deep venous thrombosis (DVT) and pulmonary embolism (PE', 'postoperative blood transfusion', 'hemoglobin and hematocrit values', 'superficial wound infection requiring additional debridement', 'total drainage volume', 'mean total blood loss', 'blood loss']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0439639', 'cui_str': 'Wedge'}, {'cui': 'C0029355', 'cui_str': 'Orthopedics'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0187826', 'cui_str': 'Osteotomy of tibia'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0281860', 'cui_str': 'Wound hematoma'}, {'cui': 'C0034115', 'cui_str': 'Centesis'}, {'cui': 'C1289828', 'cui_str': 'Pressure dressing'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0406834', 'cui_str': 'Wound discharge finding'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0332804', 'cui_str': 'Superficial wound'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",,0.0336011,"The decreases in the hemoglobin and hematocrit values on the postoperative first, second and fifth days were lower in the TXA group than those in the control group (1.4 VS 3.5, 2.6 vs 3.3, 1.9 vs 2.9 ","[{'ForeName': 'Jianlong', 'Initials': 'J', 'LastName': 'Ni', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Xiaoqian', 'Initials': 'X', 'LastName': 'Dang', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China.""}, {'ForeName': 'Zhibin', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': ""Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, Shaanxi, China. shizb1001@163.com.""}]",Archives of orthopaedic and trauma surgery,['10.1007/s00402-020-03558-5'] 2188,32715442,"Variation in the UGT2B17 genotype, exemestane metabolism and menopause-related toxicities in the CCTG MAP.3 trial.","PURPOSE To examine associations between the UGT2B17 gene deletion and exemestane metabolites, and commonly reported side effects (fatigue, hot flashes, and joint pain) among postmenopausal women participating in the MAP.3 chemoprevention trial. METHODS The analytical samples for the UGT2B17 analysis comprised 1752 women on exemestane and 1721 women on placebo; the exemestane metabolite analysis included 1360 women on exemestane with one-year serum samples. Both the UGT2B17 gene deletion and metabolites were measured in blood. The metabolites were conceptualized as a ratio (17-DHE-Gluc:17-DHE). Symptoms were assessed using the CTCAE v4.0 at approximately 1-year intervals. Log-binomial regression was used to examine the associations between UGT2B17 deletion, exemestane metabolites and each side effect at 1 and up to 5-year follow-up, adjusting for potential confounders. RESULTS Among individuals on exemestane with the UGT2B17 gene deletion (i.e., lower detoxification), a higher risk of severe fatigue (RR = 2.59 95% CI: 1.14-5.89) was observed at up to 5-year follow-up. Among individuals on placebo, those with the UGT2B17 gene deletion had a higher risk of any fatigue (RR = 1.39, 95% CI: 1.02-1.89) at year 1. A lower metabolite ratio (poor detoxification) was associated with a higher risk of any fatigue, hot flashes and joint pain at year 1 (fatigue: RR = 1.89, 95% CI: 1.16-3.09; hot flashes: RR = 1.77, 95% CI: 1.40-2.24; joint pain: RR = 2.05, 95% CI: 1.35-3.12); similar associations were observed at 5-year follow-up. CONCLUSION Variation in the metabolism of exemestane through the UGT2B17-mediated pathway is associated with subsequent risk of commonly reported symptoms in MAP.3.",2020,"A lower metabolite ratio (poor detoxification) was associated with a higher risk of any fatigue, hot flashes and joint pain at year 1 (fatigue: RR = 1.89, 95% CI: 1.16-3.09; hot flashes: RR = 1.77, 95% CI: 1.40-2.24; joint pain: RR = 2.05, 95% CI: 1.35-3.12); similar associations were observed at 5-year follow-up. ","['analysis included 1360 women on exemestane with one-year serum samples', '1752 women on exemestane and 1721 women on', 'postmenopausal women participating in the MAP.3 chemoprevention trial']","['exemestane', 'exemestane metabolite', 'placebo']","['higher risk of any fatigue, hot flashes and joint pain', 'severe fatigue', 'higher risk of any fatigue', 'side effects (fatigue, hot flashes, and joint pain', 'metabolite ratio (poor detoxification']","[{'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C1550100', 'cui_str': 'Serum specimen'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0282515', 'cui_str': 'Prophylactic chemotherapy'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0851344', 'cui_str': 'exemestane'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0025516', 'cui_str': 'Detoxication, Drug, Metabolic'}]",1752.0,0.292134,"A lower metabolite ratio (poor detoxification) was associated with a higher risk of any fatigue, hot flashes and joint pain at year 1 (fatigue: RR = 1.89, 95% CI: 1.16-3.09; hot flashes: RR = 1.77, 95% CI: 1.40-2.24; joint pain: RR = 2.05, 95% CI: 1.35-3.12); similar associations were observed at 5-year follow-up. ","[{'ForeName': 'Vikki', 'Initials': 'V', 'LastName': 'Ho', 'Affiliation': 'Department of Social and Preventive Medicine, University of Montreal, 850 rue Saint-Denis, Tour Saint-Antoine, 3rd Floor, S03.412, Montréal, QC, H2X0A9, Canada.'}, {'ForeName': 'Romain', 'Initials': 'R', 'LastName': 'Pasquet', 'Affiliation': 'Department of Social and Preventive Medicine, University of Montreal, 850 rue Saint-Denis, Tour Saint-Antoine, 3rd Floor, S03.412, Montréal, QC, H2X0A9, Canada.'}, {'ForeName': 'Shaman', 'Initials': 'S', 'LastName': 'Luo', 'Affiliation': 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., PBS 431, Spokane, WA, 99202-2131, USA.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Chen', 'Affiliation': 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., PBS 431, Spokane, WA, 99202-2131, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Goss', 'Affiliation': 'Harvard Medical School, MGH Cancer Center, Massachusetts General Hospital, 55 Fruit St, Boston, MA, 02114, USA.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Tu', 'Affiliation': ""Division Canadian Cancer Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada.""}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Lazarus', 'Affiliation': 'Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Blvd., PBS 431, Spokane, WA, 99202-2131, USA.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Richardson', 'Affiliation': ""Divisions of Canadian Cancer Trials Group and Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, 10 Stuart Street, Room 220, Kingston, ON, K7L 3N6, Canada. hrichardson@ctg.queensu.ca.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Breast cancer research and treatment,['10.1007/s10549-020-05812-1'] 2189,32714133,Rhythmic Auditory Stimulation as an Adjuvant Therapy Improved Post-stroke Motor Functions of the Upper Extremity: A Randomized Controlled Pilot Study.,"Objectives To explore whether rhythmic auditory stimulation (RAS) could improve motor functions of post-stroke hemiparetic upper extremity. Design A prospective, randomized controlled, assessor-blinded pilot study. Methods Thirty stroke patients were randomly distributed into the RAS group ( n = 15) and the control group ( n = 15). Both groups received regular therapies. The RAS group received additional 30 min of RAS training, while the control group received additional 30 min of regular therapies for 5 days per week for 4 weeks. The Fugl-Meyer Assessment-Upper Extremity (FMA-UE), Wolf Motor Function Test (WMFT), and Barthel Index (BI) were used. The co-activation interval and co-contraction index were calculated from surface electromyography (sEMG) recordings on the affected biceps and triceps during elbow flexion and extension. Assessments were performed before and after the treatments. Results Significant improvements in motor functions were observed within both groups ( p < 0.05 in the FMA-UE, WMFT, and BI, respectively), as well as between groups after the treatments (higher scores in the RAS group, all p < 0.05 except for p = 0.052 in the FMA-UE; group × time interaction, all p < 0.05). Statistical significance was found in the co-activation interval between groups after the treatments (lower in the RAS group; p = 0.022 during elbow extension; p = 0.001 during elbow flexion; group × time interaction, p < 0.05 only during elbow extension). No statistical significance was found in the co-contraction index between groups; an inversed pattern of changes was observed between groups supported by relatively higher increments in the triceps recruitments to the biceps. Conclusion Using RAS in task-oriented exercises was effective in moderating co-contraction, facilitating task-oriented movements of the hemiparetic upper extremity, and improving ADLs among those who had emerging isolated joint movements. The effects were evident on sEMG possibly by adjusting the balance of recruitments between the agonist and the antagonist. Clinical Trial Registration The study was registered at the Chinese Clinical Trial Registry (No. 1900026665).",2020,"Results Significant improvements in motor functions were observed within both groups ( p < 0.05 in the FMA-UE, WMFT, and BI, respectively), as well as between groups after the treatments (higher scores in the RAS group, all p < 0.05 except for p = 0.052 in the FMA-UE; group × time interaction, all p < 0.05).","['Methods\n\n\nThirty stroke patients', 'Upper Extremity']","['Rhythmic Auditory Stimulation', 'rhythmic auditory stimulation (RAS']","['Fugl-Meyer Assessment-Upper Extremity (FMA-UE), Wolf Motor Function Test (WMFT), and Barthel Index (BI', 'co-activation interval and co-contraction index', 'co-contraction index', 'co-activation interval', 'motor functions']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}]","[{'cui': 'C0001164', 'cui_str': 'Stimulation, Acoustic'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0325001', 'cui_str': 'Wolf'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0711873,"Results Significant improvements in motor functions were observed within both groups ( p < 0.05 in the FMA-UE, WMFT, and BI, respectively), as well as between groups after the treatments (higher scores in the RAS group, all p < 0.05 except for p = 0.052 in the FMA-UE; group × time interaction, all p < 0.05).","[{'ForeName': 'Rujin', 'Initials': 'R', 'LastName': 'Tian', 'Affiliation': 'Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}, {'ForeName': 'Yulian', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Rehabilitation Medicine, Huashan Hospital, Fudan University, Shanghai, China.'}]",Frontiers in neuroscience,['10.3389/fnins.2020.00649'] 2190,32714162,Effects of Caffeine on Event-Related Potentials and Neuropsychological Indices After Sleep Deprivation.,"Objective : Caffeine is a central nervous system stimulant that can effectively alleviate brain fatigue and low cognitive efficiency induced by total sleep deprivation (TSD). Recent studies have demonstrated that caffeine can improve subjective attention and objective behavioral metrics, such as arousal level, reaction time, and memory efficiency. However, only a few studies have examined the electrophysiological changes caused by the caffeine in humans following sleep disturbance. In this study, an event-related potential (ERP) technique was employed to measure the behavioral, cognitive, and electrophysiological changes produced by caffeine administration after TSD. Methods : Sixteen healthy subjects within-subject design performed a visual Go/No-Go task with simultaneous electroencephalogram recording. Behavioral and ERP data were evaluated after 36 h of TSD, and the effects of ingestion of either 400 mg of caffeine or placebo were compared in a double-blind randomized design. Results : Compared with placebo administration, the Go hit rates were significantly enhanced in the caffeine condition. A simple effect analysis revealed that, compared with baseline, the Go-P2 amplitude was significantly enhanced after TSD in the caffeine consumption condition. A significant main effect of the drug was found on No-Go-P2, No-Go-N2 amplitude, and Go-P2 latency before and after TSD. Conclusion : Our findings indicate that caffeine administration has acute effects on improving the efficiency of individual automatic reactions and early cognitive processes. Caffeine was related to the preservation of an individual's arousal level and accelerated response-related decisions, while subjects' higher-level recognition had limited improvement with prolonged awareness.",2020,"A simple effect analysis revealed that, compared with baseline, the Go-P2 amplitude was significantly enhanced after TSD in the caffeine consumption condition.",['Sixteen healthy subjects within-subject design performed a'],"['caffeine', 'Caffeine', 'visual Go/No-Go task with simultaneous electroencephalogram recording', 'caffeine or placebo', 'placebo']","['efficiency of individual automatic reactions and early cognitive processes', 'Go-P2 amplitude', 'No-Go-P2, No-Go-N2 amplitude, and Go-P2 latency', 'subjective attention and objective behavioral metrics, such as arousal level, reaction time, and memory efficiency', 'Event-Related Potentials and Neuropsychological Indices', 'Behavioral and ERP data', 'Go hit rates']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0025361', 'cui_str': 'Form of thinking'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0282171', 'cui_str': 'Event-related potentials'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}]",16.0,0.0391193,"A simple effect analysis revealed that, compared with baseline, the Go-P2 amplitude was significantly enhanced after TSD in the caffeine consumption condition.","[{'ForeName': 'Xuewei', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}, {'ForeName': 'Liwei', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Key Laboratory of Behavioral Science, Institute of Psychology, Chinese Academy of Sciences (CAS), Beijing, China.'}, {'ForeName': 'Danfeng', 'Initials': 'D', 'LastName': 'Yang', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}, {'ForeName': 'Gaihong', 'Initials': 'G', 'LastName': 'An', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}, {'ForeName': 'Yongcong', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': 'School of Psychology, Beijing Sport University, Beijing, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Fan', 'Affiliation': 'Central Laboratory, Xi Qing Hospital, Tianjin, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Ma', 'Affiliation': 'Department of Operational Medicine, Tianjin Institute of Environmental and Operational Medicine, Tianjin, China.'}]",Frontiers in behavioral neuroscience,['10.3389/fnbeh.2020.00108'] 2191,32714170,Different Effects of 2 mA and 4 mA Transcranial Direct Current Stimulation on Muscle Activity and Torque in a Maximal Isokinetic Fatigue Task.,"Studies investigating the effects of transcranial direct current stimulation (tDCS) on fatigue and muscle activity have elicited measurable improvements using stimulation intensities ≤2 mA and submaximal effort tasks. The purpose of this study was to determine the effects of 2 mA and 4 mA anodal tDCS over the primary motor cortex (M1) on performance fatigability and electromyographic (EMG) activity of the leg muscles during a maximal isokinetic task in healthy young adults. A double-blind, randomized, sham-controlled crossover study design was applied. Twenty-seven active young adults completed four sessions, each spaced by 5-8 days. During session 1, dominance was verified with isokinetic strength testing, and subjects were familiarized with the fatigue task (FT). The FT protocol included 40 continuous maximum isokinetic contractions of the knee extensors and flexors (120°/s, concentric/concentric). During Sessions 2-4, tDCS was applied for 20 min with one of three randomly assigned intensities (sham, 2 mA or 4 mA) and the FT was repeated. The anode and cathode of the tDCS device were placed over C3 and the contralateral supraorbital area, respectively. A wireless EMG system collected muscle activity during the FT. The 2 mA tDCS condition had significantly less torque (65.9 ± 32.7 Nm) during the FT than both the sham (68.4 ± 33.9 Nm, p < 0.001) and 4 mA conditions (68.4 ± 33.9 Nm, p = 0.001). Furthermore, the 2 mA condition (33.8 ± 11.7%) had significantly less EMG activity during the FT than both the sham (39.7 ± 10.6%, p < 0.001) and 4 mA conditions (40.5 ± 13.4%, p = 0.001). Contrary to previous submaximal isometric fatigue investigations, the 2 mA tDCS condition significantly reduced torque production and EMG activity of the leg extensors during a maximal isokinetic FT compared with the sham and 4 mA conditions. Also, torque production and EMG activity in the 4 mA condition were not significantly different from sham. Thus, the effects of tDCS, and the underlying mechanisms, might not be the same for different tasks and warrants more investigation.",2020,"Contrary to previous submaximal isometric fatigue investigations, the 2 mA tDCS condition significantly reduced torque production and EMG activity of the leg extensors during a maximal isokinetic FT compared with the sham and 4 mA conditions.","['Twenty-seven active young adults', 'healthy young adults']","['transcranial direct current stimulation (tDCS', '2 mA and 4 mA Transcranial Direct Current Stimulation', '2 mA and 4 mA anodal tDCS']","['fatigue and muscle activity', 'torque production and EMG activity of the leg extensors', 'Muscle Activity and Torque in a Maximal Isokinetic Fatigue Task', 'torque production and EMG activity', 'EMG activity', 'performance fatigability and electromyographic (EMG) activity']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0231230', 'cui_str': 'Fatigability'}]",27.0,0.038553,"Contrary to previous submaximal isometric fatigue investigations, the 2 mA tDCS condition significantly reduced torque production and EMG activity of the leg extensors during a maximal isokinetic FT compared with the sham and 4 mA conditions.","[{'ForeName': 'Craig David', 'Initials': 'CD', 'LastName': 'Workman', 'Affiliation': 'Department of Health and Human Physiology, College of Liberal Arts and Sciences, University of Iowa, Iowa City, IA, United States.'}, {'ForeName': 'Alexandra C', 'Initials': 'AC', 'LastName': 'Fietsam', 'Affiliation': 'Department of Health and Human Physiology, College of Liberal Arts and Sciences, University of Iowa, Iowa City, IA, United States.'}, {'ForeName': 'Thorsten', 'Initials': 'T', 'LastName': 'Rudroff', 'Affiliation': 'Department of Health and Human Physiology, College of Liberal Arts and Sciences, University of Iowa, Iowa City, IA, United States.'}]",Frontiers in human neuroscience,['10.3389/fnhum.2020.00240'] 2192,32714172,Aerobic Exercise Induces Functional and Structural Reorganization of CNS Networks in Multiple Sclerosis: A Randomized Controlled Trial.,"Objectives : Evidence from animal studies suggests that aerobic exercise may promote neuroplasticity and could, therefore, provide therapeutic benefits for neurological diseases such as multiple sclerosis (MS). However, the effects of exercise in human CNS disorders on the topology of brain networks, which might serve as an outcome at the interface between biology and clinical performance, remain poorly understood. Methods : We investigated functional and structural networks in patients with relapsing-remitting MS in a clinical trial of standardized aerobic exercise. Fifty-seven patients were randomly assigned to moderate-intensity exercise for 3 months or a non-exercise control group. We reconstructed functional networks based on resting-state functional magnetic resonance imaging (MRI) and used probabilistic tractography on diffusion-weighted imaging data for structural networks. Results : At baseline, compared to 30 healthy controls, patients exhibited decreased structural connectivity that was most pronounced in hub regions of the brain. Vice versa, functional connectivity was increased in hubs. After 3 months, we observed hub independent increased functional connectivity in the exercise group while the control group presented a loss of functional hub connectivity. On a structural level, the control group remained unchanged, while the exercise group had also increased connectivity. Increased clustering of hubs indicates a better structural integration and internal connectivity at the top of the network hierarchy. Conclusion : Increased functional connectivity of hubs contrasts a loss of structural connectivity in relapsing-remitting MS. Under an exercise condition, a further hub independent increase of functional connectivity seems to translate in higher structural connectivity of the whole brain.",2020,"At baseline, compared to 30 healthy controls, patients exhibited decreased structural connectivity that was most pronounced in hub regions of the brain.","['Fifty-seven patients', 'patients with relapsing-remitting MS in a clinical trial of', 'human CNS disorders', 'Multiple Sclerosis']","['moderate-intensity exercise for 3 months or a non-exercise control group', 'Aerobic Exercise', 'standardized aerobic exercise', 'resting-state functional magnetic resonance imaging (MRI) and used probabilistic tractography', 'aerobic exercise']","['connectivity', 'structural connectivity', 'Vice versa, functional connectivity', 'functional connectivity']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0007682', 'cui_str': 'Disorder of the central nervous system'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}]",57.0,0.0690538,"At baseline, compared to 30 healthy controls, patients exhibited decreased structural connectivity that was most pronounced in hub regions of the brain.","[{'ForeName': 'Jan-Patrick', 'Initials': 'JP', 'LastName': 'Stellmann', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Adil', 'Initials': 'A', 'LastName': 'Maarouf', 'Affiliation': 'APHM, Hopital de la Timone, CEMEREM, Marseille, France.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Schulz', 'Affiliation': 'Institut und Poliklinik für Medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Baquet', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Jana', 'Initials': 'J', 'LastName': 'Pöttgen', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Patra', 'Affiliation': 'Institut und Poliklinik für Medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Iris-Katharina', 'Initials': 'IK', 'LastName': 'Penner', 'Affiliation': 'Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Gellißen', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Gesche', 'Initials': 'G', 'LastName': 'Ketels', 'Affiliation': 'Department of Physiotherapy, University Medical Center Hamburg Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Besson', 'Affiliation': 'APHM, Hopital de la Timone, CEMEREM, Marseille, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Ranjeva', 'Affiliation': 'APHM, Hopital de la Timone, CEMEREM, Marseille, France.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Guye', 'Affiliation': 'APHM, Hopital de la Timone, CEMEREM, Marseille, France.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Nolte', 'Affiliation': 'Department of Neurophysiology and Pathophysiology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Andreas K', 'Initials': 'AK', 'LastName': 'Engel', 'Affiliation': 'Department of Neurophysiology and Pathophysiology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Audoin', 'Affiliation': 'APHM, Hopital de la Timone, CEMEREM, Marseille, France.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Heesen', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}, {'ForeName': 'Stefan M', 'Initials': 'SM', 'LastName': 'Gold', 'Affiliation': 'Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.'}]",Frontiers in human neuroscience,['10.3389/fnhum.2020.00255'] 2193,32716040,Feasibility of a social media-based weight loss intervention designed for low-SES adults.,"Low-socioeconomic status (SES) individuals have higher rates of obesity. Social media platforms are used frequently by low-SES individuals and facilitate important weight loss program components including social support. Very few social media-based weight loss interventions, however, have enrolled or been tailored to low-SES participants. The purpose of this article is to examine the feasibility of a social media-based weight loss intervention among low-SES adults. We conducted a one-group pretest post-test pilot intervention study with two groups (group 1, n = 39, group 2, n = 16) of low-SES overweight/obese adults who were enrolled in a 12-week social media-based weight loss intervention including self-monitoring via Fitbits and participation in a private Facebook group. A moderator provided educational content and encouraged social support via Facebook. Descriptive statistics were used to assess intervention acceptability and engagement. Exploratory analyses were conducted to examine changes in study outcomes and engagement patterns. The study had good retention (86%). Among 55 total participants enrolled, there were 9,175 participant interactions within the Facebook group. Among completers (n = 47), 96% indicated they would recommend the intervention to a friend. Mean weight loss was 1.07 kg (SD = 3.96, p = .0498), and participants reported increases in positive dietary social support (mean = 2.47, SD = 5.09, p = .0007). Engagement in this social media-based pilot intervention was high and exceeded results from previous studies using similar formats. Participants evaluated the intervention favorably. Changes in weight loss and several theoretical mediators were in the desired direction. Overall, our results indicate social media groups as a platform for weight loss intervention delivery among low-SES adults are feasible and should be studied in larger randomized trials.",2020,"Mean weight loss was 1.07 kg (SD = 3.96, p = .0498), and participants reported increases in positive dietary social support (mean = 2.47, SD = 5.09, p = .0007).","['55 total participants enrolled, there were 9,175 participant interactions within the Facebook group', 'low-SES adults', 'two groups (group 1, n = 39, group 2, n = 16) of low-SES overweight/obese adults who were enrolled in a 12-week']","['social media-based weight loss intervention including self-monitoring via Fitbits and participation in a private Facebook group', 'social media-based weight loss intervention']","['Mean weight loss', 'positive dietary social support', 'weight loss and several theoretical mediators']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C3179065', 'cui_str': 'Social Medium'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0037438', 'cui_str': 'Social support'}]",,0.0165,"Mean weight loss was 1.07 kg (SD = 3.96, p = .0498), and participants reported increases in positive dietary social support (mean = 2.47, SD = 5.09, p = .0007).","[{'ForeName': 'David N', 'Initials': 'DN', 'LastName': 'Cavallo', 'Affiliation': 'Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Rogelio', 'Initials': 'R', 'LastName': 'Martinez', 'Affiliation': 'University of the Incarnate Word School of Osteopathic Medicine, San Antonio, TX, USA.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Webb Hooper', 'Affiliation': 'Office of Cancer Disparities Research, Case Comprehensive Cancer Center, Cleveland, OH, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Flocke', 'Affiliation': 'Department of Family Medicine, Oregon Health and Science University, Portland, OR, USA.'}]",Translational behavioral medicine,['10.1093/tbm/ibaa070'] 2194,32716061,Impact of different surgical protocols on dimensional changes of free soft tissue autografts. A randomized controlled trial.,"BACKGROUND To determine if there is a difference in the amount of shrinkage during healing of free soft tissue autografts (FSTA) using different surgical techniques-suturing the vestibular flap margin apically to the base of the recipient bed versus leaving the flap margin free and unsutured. METHODS Twenty-eight patients with mucogingival defects requiring FSTAs were recruited and enrolled in the study. Patients were randomized into test and control groups (14 per group) and received one or more FSTAs on non-molar mandibular teeth. In the test group the mucosal flap margin was sutured apically to the periosteum at the base of the graft; whereas, the mucosal flap margin in the control group was left free. Graft dimensional measurements were taken at time of surgery, then at 1, 3, and 6 months post-surgery. RESULTS Thirty-five grafts were performed (15 test, 20 control). All FSTAs experienced vertical shrinkage after 6 months, but there was no significant difference (P = 0.51) in the mean amount of shrinkage after 6 months between the test (23.20 ± 20.88%) and control (21.10 ± 21.88%) groups. There was significantly greater horizontal shrinkage in the test (loss of 7.59 ± 10.20%) compared to the control (small gain of 0.32 ± 4.20%) group (P = 0.01). CONCLUSIONS The findings suggest that there is similar vertical shrinkage when performing FSTA surgery when the mucosal flap margin is left free and unsutured when compared to leaving the flap margin free. This article is protected by copyright. All rights reserved.",2020,"All FSTAs experienced vertical shrinkage after 6 months, but there was no significant difference (P = 0.51) in the mean amount of shrinkage after 6 months between the test (23.20 ± 20.88%) and control (21.10 ± 21.88%) groups.",['Twenty-eight patients with mucogingival defects requiring FSTAs were recruited and enrolled in the study'],['one or more FSTAs on non-molar mandibular teeth'],"['dimensional changes of free soft tissue autografts', 'mean amount of shrinkage', 'vertical shrinkage', 'mucosal flap margin', 'horizontal shrinkage']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0026367', 'cui_str': 'Structure of molar tooth'}, {'cui': 'C0227029', 'cui_str': 'Structure of mandibular teeth'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332513', 'cui_str': 'Shrinkage'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0729268', 'cui_str': 'Mucosal flap'}, {'cui': 'C0205284', 'cui_str': 'Marginal'}, {'cui': 'C0205126', 'cui_str': 'Horizontal'}]",35.0,0.0387735,"All FSTAs experienced vertical shrinkage after 6 months, but there was no significant difference (P = 0.51) in the mean amount of shrinkage after 6 months between the test (23.20 ± 20.88%) and control (21.10 ± 21.88%) groups.","[{'ForeName': 'Akemi', 'Initials': 'A', 'LastName': 'Arzouman', 'Affiliation': 'Department of Periodontics, UT Health San Antonio School of Dentistry, San Antonio, TX, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Deas', 'Affiliation': 'Department of Periodontics, UT Health San Antonio School of Dentistry, San Antonio, TX, USA.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Mills', 'Affiliation': 'Department of Periodontics, UT Health San Antonio School of Dentistry, San Antonio, TX, USA.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Huynh-Ba', 'Affiliation': 'Department of Periodontics, UT Health San Antonio School of Dentistry, San Antonio, TX, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Prihoda', 'Affiliation': 'Department of Pathology, UT Health San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Mealey', 'Affiliation': 'Department of Periodontics, UT Health San Antonio School of Dentistry, San Antonio, TX, USA.'}]",Journal of periodontology,['10.1002/JPER.20-0033'] 2195,32716114,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 of Tivantinib in Japanese Patients with MET-high Hepatocellular Carcinoma.","A previous randomized phase 2 study of hepatocellular carcinoma revealed that the c-Met inhibitor tivantinib as second-line treatment significantly prolonged progression-free survival in a subpopulation whose tumor samples highly expressed c-Met (MET-high). Accordingly, this phase 3 study was conducted to evaluate the efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. This randomized, double-blind, placebo-controlled study was conducted at 60 centers in Japan. Hepatocellular carcinoma patients with one prior sorafenib treatment and those with MET-high tumor samples were eligible for inclusion. Registered patients were randomly assigned to either the tivantinib or placebo group at a 2:1 ratio and were treated with twice-a-day oral tivantinib (120 mg bid) or placebo until the discontinuation criteria were met. The primary endpoint was progression-free survival while the secondary endpoints included overall survival and safety. Between January 2014 and June 2016, 386 patients provided consent, and 195 patients were randomized to the tivantinib (n=134) or placebo (n=61) group. Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) months in the tivantinib and placebo groups, respectively (hazard ratio=0.74, 95% confidence interval: 0.52-1.04, p=0.082). Median overall survival was 10.3 (95% confidence interval: 8.1-11.6) and 8.5 (6.2-11.4) months in the tivantinib and placebo group, respectively (hazard ratio=0.82, 95% confidence interval: 0.58-1.15). The most common tivantinib-related grade ≥3 adverse events were neutropenia (31.6%), leukocytopenia (24.8%), and anemia (12.0%). This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma.",2020,"Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) months in the tivantinib and placebo groups, respectively (hazard ratio=0.74, 95% confidence interval: 0.52-1.04, p=0.082).","['Between January 2014 and June 2016, 386 patients provided consent, and 195 patients', '60 centers in Japan', 'Japanese patients with MET-high hepatocellular carcinoma', 'Japanese Patients with MET-high Hepatocellular Carcinoma', 'Hepatocellular carcinoma patients with one prior sorafenib treatment and those with MET-high tumor samples were eligible for inclusion']","['tivantinib', 'Placebo', 'tivantinib or placebo', 'placebo']","['Median overall survival', 'neutropenia', 'Median progression-free survival', 'leukocytopenia', 'progression-free survival', 'anemia', 'overall survival and safety']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0475358', 'cui_str': 'Tumor tissue sample'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.681592,"Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) months in the tivantinib and placebo groups, respectively (hazard ratio=0.74, 95% confidence interval: 0.52-1.04, p=0.082).","[{'ForeName': 'Masatoshi', 'Initials': 'M', 'LastName': 'Kudo', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Morimoto', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Kanagawa, Japan.'}, {'ForeName': 'Michihisa', 'Initials': 'M', 'LastName': 'Moriguchi', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.'}, {'ForeName': 'Namiki', 'Initials': 'N', 'LastName': 'Izumi', 'Affiliation': 'Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Takayama', 'Affiliation': 'Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Yoshiji', 'Affiliation': 'Department of Gastroenterology, Nara Medical University, Nara, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Hino', 'Affiliation': 'Department of Hepatology and Pancreatology, Kawasaki Medical School, Okayama, Japan.'}, {'ForeName': 'Takayoshi', 'Initials': 'T', 'LastName': 'Oikawa', 'Affiliation': 'Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Iwate, Japan.'}, {'ForeName': 'Tetsuhiro', 'Initials': 'T', 'LastName': 'Chiba', 'Affiliation': 'Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Motomura', 'Affiliation': 'Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Kato', 'Affiliation': 'Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Kentaro', 'Initials': 'K', 'LastName': 'Yasuchika', 'Affiliation': 'Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.'}, {'ForeName': 'Akio', 'Initials': 'A', 'LastName': 'Ido', 'Affiliation': 'Department of Gastroenterology, Kagoshima University Medical and Dental Hospital, Kagoshima, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Nakashima', 'Affiliation': 'R&D Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.'}, {'ForeName': 'Kazuomi', 'Initials': 'K', 'LastName': 'Ueshima', 'Affiliation': 'Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.'}, {'ForeName': 'Masafumi', 'Initials': 'M', 'LastName': 'Ikeda', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': 'Takuji', 'Initials': 'T', 'LastName': 'Okusaka', 'Affiliation': 'Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Tamura', 'Affiliation': 'General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.'}, {'ForeName': 'Junji', 'Initials': 'J', 'LastName': 'Furuse', 'Affiliation': 'Department of Medical Oncology, Kyorin University, Faculty of Medicine, Tokyo, Japan.'}]",Cancer science,['10.1111/cas.14582'] 2196,32716115,"Synergistic effects of using novel home-use 660- and 850-nm light-emitting diode mask in combination with hyaluronic acid ampoule on photoaged Asian skin: A prospective, controlled study.","BACKGROUND Recently, light-emitting diode (LED) devices are among those mostly preferred for esthetic application because they improve the appearance of photoaged skin characterized by wrinkles, sagginess, pigmented lesions, and others. In addition, the use of hyaluronic acid (HA) for skin rejuvenation is already well proven. AIMS This study aims to evaluate the synergistic effects of using home-use LED mask device with HA ampoule. METHODS The total number of recruited subjects was 48:24 in Group A treated with both home-use LED mask device and HA ampoule and 24 in Group B treated with HA ampoule only, for 4 weeks. To assess the efficacy of the treatment, the following were used: Antera 3D CS, EOS 800D with Image-Pro Plus, DUB-USB, VisioFace Quick, and Visioscan VC98. RESULTS After treatment, the volume measurement (mm 3 ) for prejowl sulci and nasolabial fold flattening as well as the area measurement (pixel) for lower chin firmness improvement was significantly reduced, and the number of pores (ea) for enlarged pores as well as the desquamation index (%) for the amount of corneocytes significantly decreased in both Group A and Group B. Moreover, the percentage of skin density significantly improved. Furthermore, Group A showed a significantly faster and higher rate of improvement than Group B. CONCLUSION The use of 660- and 850-nm home-use LED mask device can generate synergistic effects on home-use topical applications like HA on photoaged face, and such device can be safely and efficiently used daily in personal environments.",2020,"Furthermore, Group A showed a significantly faster and higher rate of improvement than Group B. CONCLUSION ",['photoaged Asian skin'],"['hyaluronic acid ampoule', 'hyaluronic acid (HA', 'LED mask device and HA ampoule and 24 in Group B treated with HA ampoule', 'novel home-use 660- and 850-nm light-emitting diode mask', 'EOS 800D with Image-Pro']","['percentage of skin density', 'desquamation index', 'prejowl sulci and nasolabial fold flattening as well as the area measurement (pixel) for lower chin firmness improvement', 'number of pores (ea) for enlarged pores']","[{'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0020196', 'cui_str': 'hyaluronic acid'}, {'cui': 'C0179031', 'cui_str': 'Ampule'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0162676', 'cui_str': 'Enzyme-multiplied immunoassay technique'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C4517845', 'cui_str': '660'}, {'cui': 'C3840657', 'cui_str': '850'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0317562', 'cui_str': 'Eubacterium sulci'}, {'cui': 'C0221328', 'cui_str': 'Nasolabial sulcus structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0008114', 'cui_str': 'Chin structure'}, {'cui': 'C0237753', 'cui_str': 'Number'}]",,0.0379939,"Furthermore, Group A showed a significantly faster and higher rate of improvement than Group B. CONCLUSION ","[{'ForeName': 'Dae Sung', 'Initials': 'DS', 'LastName': 'Kim', 'Affiliation': 'Research Development Center, CELLRETURN, Incheon, South Korea.'}, {'ForeName': 'Ki Uk', 'Initials': 'KU', 'LastName': 'Song', 'Affiliation': 'Clinical Research Consultant, Brighlans, Inc., Manila, Philippines.'}, {'ForeName': 'Hae Kwang', 'Initials': 'HK', 'LastName': 'Lee', 'Affiliation': 'P&K Skin Research Center, Seoul, South Korea.'}, {'ForeName': 'Jong Ho', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'P&K Skin Research Center, Seoul, South Korea.'}, {'ForeName': 'Beom Joon', 'Initials': 'BJ', 'LastName': 'Kim', 'Affiliation': 'Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Kwang Ho', 'Initials': 'KH', 'LastName': 'Yoo', 'Affiliation': 'Department of Dermatology, Chung-Ang University Hospital, Chung-Ang University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jin Hee', 'Initials': 'JH', 'LastName': 'Shin', 'Affiliation': 'P&K Skin Research Center, Seoul, South Korea.'}]",Journal of cosmetic dermatology,['10.1111/jocd.13599'] 2197,32716149,Exploring the concept of vigor and dys-vigor in men of 50-65 years: effects of Robuvit®.,"BACKGROUND The aim of this registry study was to evaluate the effects of Robuvit® (extract from oak wood), in otherwise healthy subjects (aged 50 to 65 years) who complained of decreased general vigor. Robuvit® has been shown to be effective in convalescence, chronic fatigue syndrome and post-traumatic stress disorder. METHODS The standard management (SM) for this condition included diet, regular daily routines and regular exercise. All subjects had increased oxidative stress (>350 Carr Units) at inclusion. Two groups, SM and SM+Robuvit® supplementation, were formed. Robuvit® was supplemented at a dose of 300 mg/day for 4 weeks. A visual analogue scale line or vigor visual analogue line score of the most common problems associated with a decrease in vigor was used by all included subjects. RESULTS Forty subjects were included in the study. 20 in the SM group and 20 in the SM + Robuvit® supplement group. All subjects completed the 4-week study; both groups improved with the health program and under SM. No drop-outs and no side effects were recorded; a very good tolerability for the supplement was reported. At 4 weeks, the scores in Robuvit®-supplemented subjects, were significantly higher for all vigor-related items in comparison with the scores of subjects managed with the SM only (P<0.05). In parallel, oxidative stress (plasma free radicals expressed in Carr units) was statistically lower (P<0.05) in Robuvit®-supplemented subjects than in SM only after 4 weeks. CONCLUSIONS The concept of vigor, partially associated with premature aging, decreased level of activity and exercise, a sedentary lifestyle, appears to be a quantifiable entity. Robuvit® supplementation - previously shown to be effective in chronic fatigue syndrome, convalescence, post-mononucleosis, PTSD or in liver failure - improves vigor; further evaluations need to be planned according to the concept of this pilot registry.",2020,"In parallel, oxidative stress (plasma free radicals expressed in Carr units) was statistically lower (P<0.05) in Robuvit®-supplemented subjects than in SM only after 4 weeks. ","['Forty subjects were included in the study', 'otherwise healthy subjects (aged 50 to 65 years) who complained of decreased general vigor', 'men of 50-65 years']","['Robuvit® (extract from oak wood', 'Robuvit®', 'health program and under SM']","['oxidative stress (plasma free radicals expressed in Carr units', 'visual analogue scale line or vigor visual analogue line score', 'oxidative stress', 'drop-outs and no side effects']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C3850290', 'cui_str': 'Robuvit'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0330302', 'cui_str': 'Genus Quercus'}, {'cui': 'C0043217', 'cui_str': 'Wood'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0016693', 'cui_str': 'Free radical'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0439787', 'cui_str': 'Out'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",40.0,0.0252686,"In parallel, oxidative stress (plasma free radicals expressed in Carr units) was statistically lower (P<0.05) in Robuvit®-supplemented subjects than in SM only after 4 weeks. ","[{'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Ledda', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Morio', 'Initials': 'M', 'LastName': 'Hosoi', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Maria R', 'Initials': 'MR', 'LastName': 'Cesarone', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Dugall', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Hu', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Gianni', 'Initials': 'G', 'LastName': 'Belcaro', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy - cardres@abol.it.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Maione', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cotellese', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Beatrice', 'Initials': 'B', 'LastName': 'Feragalli', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Scipione', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Scipione', 'Affiliation': 'IRVINE3 Labs, Department of Medical Oral and Biotechnological Sciences, Chieti-Pescara University, IAPSS, Pescara, Italy.'}]",Panminerva medica,['10.23736/S0031-0808.19.03795-9'] 2198,32716206,Effects on Suxiao Jiuxin Pills in the Treatment of Patients with Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention: A Multicenter Randomized Double-Blind Placebo-Controlled Trial.,"Objectives: Acute coronary syndrome (ACS) is an acute disease with high mortality. Although early percutaneous coronary intervention (PCI) is proved to be the practical approach in treating ACS, the incidence of cardiovascular events is still far from satisfactory. The combination of Suxiao Jiuxin Pill (SJP) and Western medicine is one conventional approach in the treatment of ACS. Many elementary and clinical trials have proved the efficacy and safety in the improvement of cardiocerebral vascular conditions. The aim of this project is to evaluate the safety and efficacy of SJP on ACS with early PCI patients. Trial Design: This is a multicenter randomized, double-blind placebo-controlled trial. Trial registration: ChiCTR-TRC-13003053. Settings: Hospitals. Subjects: A total of 200 ACS with early PCI patients were randomly divided into SJP group ( n  = 100) and placebo group ( n  = 100). Interventions: The SJP group was treated with routine treatment and SJP (taking eight SJP pills orally each time, three times per day). The placebo group was treated with routine treatment along with equal amounts of SJP placebo. The course of treatment was 6 months and a follow-up visit at 12 months. Outcome Measures: Assessments of major adverse cardiovascular events (MACE), safety assessments, adverse events, left ventricular systolic function (LVEF), Seattle angina questionnaire (SAQ), troponin C (cTNI), C-reactive protein (CRP), fibrinogen (Fib), and cystatin C (cysC). Results: The SJP group had a relatively low incidence of MACE than the placebo ( p  < 0.05, odds ratio: 1.916, 95% confidence interval [0.999-3.674]). LVEF was significantly higher in the SJP group than the placebo group on the 360-day follow-up ( p  < 0.01). SJP had a significant increase score in the SAQ subscale of physical limitation, angina frequency, and treatment satisfaction ( p  < 0.05). There is no significant difference in the cTNI and CRP level between the two groups. The serum concentration of Fib and cysC in the SJP was significantly decreased compared with the placebo ( p  < 0.05). The numbers of adverse events between the two groups were not statistically different ( p  > 0.05). Conclusions: SJP is associated with a reduction in MACE, and an improvement of heart function and quality of life in ACS patients with early PCI, and is probably safe to use.",2020,The serum concentration of Fib and cysC in the SJP was significantly decreased compared with the placebo ( p  < 0.05).,"['Undergoing Early Percutaneous Coronary Intervention', 'Patients with Acute Coronary Syndrome', 'ACS patients with early PCI', 'early PCI patients', 'Subjects: A total of 200 ACS with early PCI patients']","['Suxiao Jiuxin Pill (SJP) and Western medicine', 'percutaneous coronary intervention (PCI', 'Suxiao Jiuxin Pills', 'Placebo', 'routine treatment and SJP', 'SJP', 'SJP placebo', 'placebo']","['LVEF', 'cTNI and CRP level', 'SAQ subscale of physical limitation, angina frequency, and treatment satisfaction', 'numbers of adverse events', 'heart function and quality of life', 'safety and efficacy', 'serum concentration of Fib and cysC in the SJP', 'Outcome Measures: Assessments of major adverse cardiovascular events (MACE), safety assessments, adverse events, left ventricular systolic function (LVEF), Seattle angina questionnaire (SAQ), troponin C (cTNI), C-reactive protein (CRP), fibrinogen (Fib), and cystatin C (cysC']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0002455', 'cui_str': 'American Cancer Society'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0050133', 'cui_str': '9,10-anthraquinone'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C3695257', 'cui_str': 'Frequency of angina'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0077400', 'cui_str': 'Troponin C'}, {'cui': 'C0016006', 'cui_str': 'Fibrinogen'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}]",200.0,0.258197,The serum concentration of Fib and cysC in the SJP was significantly decreased compared with the placebo ( p  < 0.05).,"[{'ForeName': 'Zhijie', 'Initials': 'Z', 'LastName': 'Shen', 'Affiliation': 'Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Tiejun', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Deng', 'Affiliation': 'Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Fan', 'Affiliation': 'Department of Cardiology, Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}, {'ForeName': 'Junyi', 'Initials': 'J', 'LastName': 'Hua', 'Affiliation': 'Department of Cardiology, Zhejiang Province Hospital of Traditional Chinese Medicine, Zhejiang, China.'}, {'ForeName': 'Minzhou', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Cardiology, Guangdong Province Hospital of Traditional Chinese Medicine, Guangdong, China.'}, {'ForeName': 'Xiaolong', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.'}]","Journal of alternative and complementary medicine (New York, N.Y.)",['10.1089/acm.2020.0014'] 2199,32716241,"Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.",,2020,,['Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA'],['Re: Prostate-Specific Membrane Antigen PET-CT'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1283828', 'cui_str': 'Has intent'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0067685', 'cui_str': 'Glutamate carboxypeptidase II'}, {'cui': 'C1699633', 'cui_str': 'Positron emission tomography with computed tomography'}]",[],,0.0402414,,"[{'ForeName': 'Samir S', 'Initials': 'SS', 'LastName': 'Taneja', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001220.01'] 2200,32716270,Re: Prospective Randomized Trial Comparing the Safety and Clarity of Water versus Saline Irrigant in Ureteroscopy.,,2020,,[],['Water versus Saline Irrigant'],[],[],"[{'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0593225', 'cui_str': 'Solution for irrigation'}]",[],,0.0542995,,"[{'ForeName': 'Dean G', 'Initials': 'DG', 'LastName': 'Assimos', 'Affiliation': ''}]",The Journal of urology,['10.1097/JU.0000000000001217.04'] 2201,32716320,Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.,"BACKGROUND Parkinson's disease psychosis (PDP) is a common nonmotor symptom that affects up to 60% of patients. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is approved for treating hallucinations and delusions associated with PDP. OBJECTIVE Evaluate the efficacy and tolerability of pimavanserin in an open-label extension (OLE) study. METHODS Patients completing a pivotal 6-week placebo-controlled trial (Core Study) could enroll in the OLE. All patients pimavanserin 34 mg once daily, blinded to previous treatment allocation. Prespecified blinded assessments at Week 4 were the Scale for the Assessment of Positive Symptoms (SAPS) PD version and SAPS H + D scales, Caregiver Burden Scale (CBS), and Clinical Global Impression (CGI) Improvement and Severity scales. RESULTS Of 171 who entered the OLE, 148 (87%) completed Week 4. Among patients who received placebo in the Core Study, mean (SD) change from OLE baseline to OLE Week 4 for the SAPS-PD was - 3.4 (6.3); p < 0.0001. Mean change from Core Study baseline to OLE Week 4 for SAPS-PD was similar among prior pimavanserin- and placebo-treated patients (-6.9 vs. -6.3). Improvement was similar with CGI-I, CGI-S, CBS, and SAPS-H + D in patients previously treated with placebo. Adverse events occurred in 92 (53.8%) patients during the 4-week OLE. CONCLUSION Improvements at OLE Week 4 from pretreatment baseline were similar with placebo and pimavanserin in the Core Study. The beneficial effects observed with pimavanserin in the 6-week Core Study were maintained for 4 weeks in the blinded OLE, supporting the durability of response with pimavanserin 34 mg for PDP over 10 weeks.",2020,Mean change from Core Study baseline to OLE Week 4 for SAPS-PD was similar among prior pimavanserin- and placebo-treated patients (-6.9 vs. -6.3).,"[""Parkinson's Disease Psychosis"", 'Of 171 who entered the OLE, 148 (87%) completed Week 4', ""Parkinson's disease psychosis (PDP"", 'Patients completing a pivotal 6-week']","['pimavanserin- and placebo', 'SAPS-PD Assessment', 'pimavanserin', 'Pimavanserin', 'placebo']","['Adverse events', 'Positive Symptoms (SAPS', 'PD version and SAPS H\u200a+\u200aD scales, Caregiver Burden Scale (CBS), and Clinical Global Impression (CGI) Improvement and Severity scales', 'efficacy and tolerability']","[{'cui': 'C3805119', 'cui_str': ""Parkinson's disease psychosis""}, {'cui': 'C1522196', 'cui_str': 'Enteral route'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1722267', 'cui_str': 'pimavanserin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.183307,Mean change from Core Study baseline to OLE Week 4 for SAPS-PD was similar among prior pimavanserin- and placebo-treated patients (-6.9 vs. -6.3).,"[{'ForeName': 'Stuart H', 'Initials': 'SH', 'LastName': 'Isaacson', 'Affiliation': ""Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.""}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Coate', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Norton', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'Srdjan', 'Initials': 'S', 'LastName': 'Stankovic', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}]",Journal of Parkinson's disease,['10.3233/JPD-202047'] 2202,32716326,Effect of lidocaine iontophoresis combined with exercise intervention on gait and spasticity in children with spastic hemiplegic cerebral palsy: A randomized controlled trial.,"BACKGROUND Spasticity is a common impairment seen in children with cerebral palsy (CP) and may interfere with functional performance and effective walking pattern. Lidocaine iontophoresis is effective for reducing muscle spasticity in adults. PURPOSE To investigate the effect of lidocaine epinephrine iontophoresis combined with exercises on gait and spasticity in children with spastic hemiplegic cerebral palsy (HCP). METHODS Thirty children with spastic HCP aged 4-6 (5.20±0.32) years were randomly assigned to the experimental group (n = 15) and control group (n = 15). Children in both groups received one hour of exercises, three times a week for three months. Children in the experimental group received 2% lidocaine iontophoresis immediately before the exercises. The lidocaine iontophoresis was delivered for 20 minutes (1mA/min). Spatio-temporal gait parameters were assessed within one week before and after the intervention using 3D motion analysis. Surface electromyography was used to assess muscle tone using H/M ratio of the soleus muscle. RESULTS There was no difference between groups at baseline. Post-intervention, the experimental group showed significant improvements when compared to the control group for gait speed (p = 0.03), stride length (p = 0.04), cadence (p = 0.0001), cycle time (p = 0.0001), and H/M ratio (p = 0.02). CONCLUSION Lidocaine iontophoresis combined with exercises was effective in improving gait spatiotemporal parameters and reducing spasticity in children with CP.",2020,Lidocaine iontophoresis combined with exercises was effective in improving gait spatiotemporal parameters and reducing spasticity in children with CP.,"['Thirty children with spastic HCP aged 4-6 (5.20±0.32) years', 'children with cerebral palsy (CP', 'children with spastic hemiplegic cerebral palsy (HCP', 'children with spastic hemiplegic cerebral palsy', 'adults', 'children with CP']","['lidocaine epinephrine iontophoresis combined with exercises', 'Lidocaine iontophoresis combined with exercises', 'lidocaine iontophoresis combined with exercise intervention', 'lidocaine iontophoresis', 'Lidocaine iontophoresis']","['gait spatiotemporal parameters', 'gait speed', 'cycle time', 'gait and spasticity', 'stride length ', 'Spatio-temporal gait parameters', 'gait and\xa0spasticity']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0270805', 'cui_str': 'Hemiplegic cerebral palsy'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0359949', 'cui_str': 'Epinephrine- and lidocaine-containing product'}, {'cui': 'C0022024', 'cui_str': 'Iontophoresis procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}]",30.0,0.0481527,Lidocaine iontophoresis combined with exercises was effective in improving gait spatiotemporal parameters and reducing spasticity in children with CP.,"[{'ForeName': 'Fatma A', 'Initials': 'FA', 'LastName': 'Hegazy', 'Affiliation': 'Department of Physiotherapy, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.'}, {'ForeName': 'Emad A', 'Initials': 'EA', 'LastName': 'Aboelnasr', 'Affiliation': 'Cairo University, Faculty of Physical Therapy, Cairo, Egypt.'}, {'ForeName': 'Yasser T', 'Initials': 'YT', 'LastName': 'Salem', 'Affiliation': 'University of North Texas Health Science Center, Texas, USA.'}]",NeuroRehabilitation,['10.3233/NRE-203152'] 2203,32716479,Continuous vs Routine Electroencephalogram in Critically Ill Adults With Altered Consciousness and No Recent Seizure: A Multicenter Randomized Clinical Trial.,"Importance In critically ill patients with altered consciousness, continuous electroencephalogram (cEEG) improves seizure detection, but is resource-consuming compared with routine EEG (rEEG). It is also uncertain whether cEEG has an effect on outcome. Objective To assess whether cEEG is associated with reduced mortality compared with rEEG. Design, Setting, and Participants The pragmatic multicenter Continuous EEG Randomized Trial in Adults (CERTA) was conducted between 2017 and 2018, with follow-up of 6 months. Outcomes were assessed by interviewers blinded to interventions.The study took place at 4 tertiary hospitals in Switzerland (intensive and intermediate care units). Depending on investigators' availability, we pragmatically recruited critically ill adults having Glasgow Coma Scale scores of 11 or less or Full Outline of Responsiveness score of 12 or less, without recent seizures or status epilepticus. They had cerebral (eg, brain trauma, cardiac arrest, hemorrhage, or stroke) or noncerebral conditions (eg, toxic-metabolic or unknown etiology), and EEG was requested as part of standard care. An independent physician provided emergency informed consent. Interventions Participants were randomized 1:1 to cEEG for 30 to 48 hours vs 2 rEEGs (20 minutes each), interpreted according to standardized American Clinical Neurophysiology Society guidelines. Main Outcomes and Measures Mortality at 6 months represented the primary outcome. Secondary outcomes included interictal and ictal features detection and change in therapy. Results We analyzed 364 patients (33% women; mean [SD] age, 63 [15] years). At 6 months, mortality was 89 of 182 in those with cEEG and 88 of 182 in those with rEEG (adjusted relative risk [RR], 1.02; 95% CI, 0.83-1.26; P = .85). Exploratory comparisons within subgroups stratifying patients according to age, premorbid disability, comorbidities on admission, deeper consciousness reduction, and underlying diagnoses revealed no significant effect modification. Continuous EEG was associated with increased detection of interictal features and seizures (adjusted RR, 1.26; 95% CI, 1.08-1.15; P = .004 and 3.37; 95% CI, 1.63-7.00; P = .001, respectively) and more frequent adaptations in antiseizure therapy (RR, 1.84; 95% CI, 1.12-3.00; P = .01). Conclusions and Relevance This pragmatic trial shows that in critically ill adults with impaired consciousness and no recent seizure, cEEG leads to increased seizure detection and modification of antiseizure treatment but is not related to improved outcome compared with repeated rEEG. Pending larger studies, rEEG may represent a valid alternative to cEEG in centers with limited resources. Trial Registration ClinicalTrials.gov Identifier: NCT03129438.",2020,"At 6 months, mortality was 89 of 182 in those with cEEG and 88 of 182 in those with rEEG (adjusted relative risk [RR], 1.02; 95% CI, 0.83-1.26; P = .85).","['critically ill patients with altered consciousness', '4 tertiary hospitals in Switzerland (intensive and intermediate care units', 'critically ill adults with impaired consciousness', '364 patients (33% women; mean [SD] age, 63 [15] years', 'Critically Ill Adults With Altered Consciousness and No Recent Seizure', 'critically ill adults having Glasgow Coma Scale scores of 11 or less or Full Outline of Responsiveness score of 12 or less, without recent seizures or status epilepticus']","['cEEG', 'continuous electroencephalogram (cEEG', 'Continuous vs Routine Electroencephalogram']","['detection of interictal features and seizures', 'mortality', 'interictal and ictal features detection and change in therapy', 'cerebral (eg, brain trauma, cardiac arrest, hemorrhage, or stroke) or noncerebral conditions (eg, toxic-metabolic or unknown etiology']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0234428', 'cui_str': 'Disturbance of consciousness'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0600661', 'cui_str': 'Outlines'}, {'cui': 'C0038220', 'cui_str': 'Status epilepticus'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0332240', 'cui_str': 'Unknown (origin)'}, {'cui': 'C0015127', 'cui_str': 'etiology'}]",,0.282436,"At 6 months, mortality was 89 of 182 in those with cEEG and 88 of 182 in those with rEEG (adjusted relative risk [RR], 1.02; 95% CI, 0.83-1.26; P = .85).","[{'ForeName': 'Andrea O', 'Initials': 'AO', 'LastName': 'Rossetti', 'Affiliation': 'Department of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Kaspar', 'Initials': 'K', 'LastName': 'Schindler', 'Affiliation': 'Sleep-Wake-Epilepsy-Center, Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Sutter', 'Affiliation': 'Clinic for Intensive Care Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Rüegg', 'Affiliation': 'Department of Neurology, University Hospital Basel and University of Basel, Basel, Switzerland.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Zubler', 'Affiliation': 'Sleep-Wake-Epilepsy-Center, Department of Neurology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Novy', 'Affiliation': 'Department of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Oddo', 'Affiliation': 'Department of Intensive Care Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Loane', 'Initials': 'L', 'LastName': 'Warpelin-Decrausaz', 'Affiliation': 'Clinical Trial Unit, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Alvarez', 'Affiliation': 'Department of Neurology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.'}]",JAMA neurology,['10.1001/jamaneurol.2020.2264'] 2204,32716500,"Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.","BACKGROUND Pneumococcal conjugate vaccines (PCVs) have significantly decreased pneumococcal disease worldwide; however, expanding serotype coverage may further reduce disease burden. A 20-valent PCV (PCV20) containing capsular polysaccharide conjugates of serotypes present in the 13-valent PCV (PCV13) and 7 new serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) is currently in development. This phase 2 study evaluated safety, tolerability, and immunogenicity of PCV20 in adults without prior pneumococcal vaccination. METHODS In this randomized, active-controlled, double-blinded trial, 444 adults 60 through 64 years of age were randomized to receive either a single dose of PCV20 followed 1 month later by saline placebo or a single dose of PCV13 followed 1 month later by 23-valent polysaccharide vaccine. Local injection site reactions, select systemic symptoms, and adverse events (AEs) were recorded. Immunogenicity was assessed by measuring serotype-specific opsonophagocytic activity (OPA) titers before and approximately 1 month after each vaccination. RESULTS Local reaction and systemic event rates were similar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported. In the PCV20 group, functional immune responses as measured by OPA were robust for all 20 serotypes included in the vaccine, with geometric mean fold rises from baseline ranging from 6.0 to 113.4. CONCLUSIONS PCV20 was well tolerated in adults 60 to 64 years of age, with a safety profile consistent with historical experience of PCVs in this age group. Substantial OPA responses were elicited against all serotypes. Results demonstrate the potential for PCV20 to expand pneumococcal disease protection.",2020,"RESULTS Local reaction and systemic event rates were similar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported.","['444 adults 60 through 64 years of age', 'adults without prior pneumococcal vaccination', 'Adults 60 to 64 Years of Age', 'adults 60 to 64 years of age']","['PCV20 followed 1 month later by saline placebo', 'PCV20', 'polysaccharide vaccine', '20-Valent Pneumococcal Conjugate Vaccine (PCV20']","['functional immune responses', 'Substantial OPA responses', 'serotype-specific opsonophagocytic activity (OPA) titers', 'Local reaction and systemic event rates', 'safety, tolerability, and immunogenicity of PCV20', 'Safety, Tolerability, and Immunogenicity', 'Immunogenicity', 'Local injection site reactions, select systemic symptoms, and adverse events (AEs']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0419707', 'cui_str': 'Pneumococcal vaccination'}]","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0032594', 'cui_str': 'Polysaccharide'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1579319', 'cui_str': 'Pneumococcal conjugate vaccine'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0036759', 'cui_str': 'Serotyping'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0853813', 'cui_str': 'Local reaction'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",444.0,0.424414,"RESULTS Local reaction and systemic event rates were similar after vaccination with PCV20 or PCV13; no serious vaccine-related AEs were reported.","[{'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Hurley', 'Affiliation': 'Medical Research South, LLC, Charleston, SC, USA.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Griffin', 'Affiliation': 'Lynn Health Science Institute, Oklahoma City, OK, USA.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Young', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Daniel A', 'Initials': 'DA', 'LastName': 'Scott', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Pride', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.'}, {'ForeName': 'Ingrid L', 'Initials': 'IL', 'LastName': 'Scully', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ginis', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Severs', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.'}, {'ForeName': 'Kathrin U', 'Initials': 'KU', 'LastName': 'Jansen', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Gruber', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Pearl River, NY, USA.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Watson', 'Affiliation': 'Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1045'] 2205,32711541,Beta alanine supplementation effects on metabolic contribution and swimming performance.,"BACKGROUND Investigations of β-alanine supplementation shows effects on metabolic (aerobic and anaerobic) participation and performance on swimming by a possible blood acidosis buffering. Considering this background, the objective of the present study was to analyze the effects of β-alanine supplementation on metabolic contribution and performance during 400-m swim. METHODS Thirteen competitive swimmers underwent a 6-week, double-blind placebo-controlled study, ingesting 4.8 g.day - 1 of β-alanine or placebo. Before and after the supplementation period, the total anaerobic contribution (TAn) and 30-s all-out tethered swimming effort (30TS) were assessed. Anaerobic alactic (AnAl) and lactic energy (AnLa) was assumed as the fast component of excess post-exercise oxygen consumption and net blood lactate accumulation during exercise (∆[La - ]), respectively. Aerobic contribution (Aer) was determined by the difference between total energy demand and TAn. In addition to conventional statistical analysis (Repeated measures ANOVA; p > 0.05), a Bayesian repeated measures ANOVA was used to evidence the effect probability (BF incl ). RESULTS No differences and effects were found between groups, indicating no supplementation effects. Repeated measures ANOVA, with confirmation of effect, was indicate reduce in ∆Lactate (p: 0.001; BF incl : 25.02); absolute AnLa (p: 0.002; BF incl : 12.61), fatigue index (p > 0.001; BF incl : 63.25) and total anaerobic participation (p: 0.008; BF incl : 4.89). CONCLUSIONS Thus, the results demonstrated that all changes presented were evidenced as a result of exposure to the training period and β-alanine supplementation doesn't affect metabolic contribution and performance during 400-m freestyle.",2020,"Repeated measures ANOVA, with confirmation of effect, was indicate reduce in ∆Lactate (p: 0.001; BF incl : 25.02); absolute AnLa (p: 0.002; BF incl : 12.61), fatigue index (p > 0.001; BF incl : 63.25) and total anaerobic participation (p: 0.008; BF incl : 4.89). ",['Thirteen competitive swimmers'],"['Beta alanine supplementation', 'β-alanine or placebo', 'β-alanine supplementation', 'placebo']","['metabolic contribution and swimming performance', 'total anaerobic contribution (TAn) and 30-s all-out tethered swimming effort (30TS', 'fatigue index', 'total anaerobic participation', 'metabolic contribution and performance', 'Anaerobic alactic (AnAl) and lactic energy (AnLa', 'total energy demand and TAn']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0450068', 'cui_str': 'Swimmer'}]","[{'cui': 'C0000392', 'cui_str': 'beta-Alanine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0577538', 'cui_str': 'Tethered'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0040854', 'cui_str': 'Triacetoneamine-N-Oxyl'}]",13.0,0.124956,"Repeated measures ANOVA, with confirmation of effect, was indicate reduce in ∆Lactate (p: 0.001; BF incl : 25.02); absolute AnLa (p: 0.002; BF incl : 12.61), fatigue index (p > 0.001; BF incl : 63.25) and total anaerobic participation (p: 0.008; BF incl : 4.89). ","[{'ForeName': 'Matheus Silva', 'Initials': 'MS', 'LastName': 'Norberto', 'Affiliation': 'University of São Paulo, Medicine University of Ribeirão Preto (FMRP-USP), Ribeirão Preto, São Paulo, Brazil. matheus.norberto@usp.br.'}, {'ForeName': 'Ricardo Augusto', 'Initials': 'RA', 'LastName': 'Barbieri', 'Affiliation': 'University of São Paulo, School of Physical Education and sport of Ribeirão Preto (EEFERP-USP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Danilo Rodrigues', 'Initials': 'DR', 'LastName': 'Bertucci', 'Affiliation': 'Department of Physical Education, State São Paulo University, (UNESP), Rio Claro, São Paulo, Brazil.'}, {'ForeName': 'Ronaldo Bucken', 'Initials': 'RB', 'LastName': 'Gobbi', 'Affiliation': 'University of São Paulo, School of Physical Education and sport of Ribeirão Preto (EEFERP-USP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Eduardo Zapaterra', 'Initials': 'EZ', 'LastName': 'Campos', 'Affiliation': 'Department of Physical Education, Federal University of Pernambuco, (UFPE), Recife, Pernambuco, Brazil.'}, {'ForeName': 'Alessandrou Moura', 'Initials': 'AM', 'LastName': 'Zagatto', 'Affiliation': 'Department of Physical Education, State São Paulo University, (UNESP), Bauru, São Paulo, Brazil.'}, {'ForeName': 'Ellen Cristini', 'Initials': 'EC', 'LastName': 'De Freitas', 'Affiliation': 'University of São Paulo, School of Physical Education and sport of Ribeirão Preto (EEFERP-USP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Papoti', 'Affiliation': 'University of São Paulo, Medicine University of Ribeirão Preto (FMRP-USP), Ribeirão Preto, São Paulo, Brazil.'}]",Journal of the International Society of Sports Nutrition,['10.1186/s12970-020-00365-6'] 2206,32711546,Two different troponin isoforms for detecting early myocardial injury after curative resection of oesophageal cancer.,"BACKGROUND The objective of this study was to explore the consistency and correlation of two troponin (cTn) subtypes, troponin I (cTnI) and high-sensitivity troponin T (hs-cTnT), which can be used to judge early myocardial injury after curative resection of oesophageal cancer. METHODS This study is a secondary analysis of data obtained from a previous randomized controlled trial on postoperative myocardial injury in 70 patients undergoing elective curative resection of oesophageal cancer who were randomly assigned to undergo aggressive body temperature management (nasopharyngeal temperature 36.61 ± 0.18 °C) or standard body temperature management (35.80 ± 0.18 °C, n = 35 in each arm). The serum cTnI and hs-cTnT levels were measured in each patient at the 4 time points: before the operation and 6 h ~ 12 h, 24 h and 48 h after the operation. The diagnostic criteria of myocardial injury followed the third edition ESC/ACCF definition of myocardial infarction. The primary outcomes included the following: (1) the incidence of myocardial injury and the relationship between hs-cTnT and cTn and (2) the consistency and correlation of the two cTn subtypes. RESULTS A total of 280 pairs of cTn samples were tested. The incidence of postoperative day 2 myocardial injury was 8.6% (3/35) among patients receiving aggressive body temperature management and 31.4% (11/35) among patients receiving standard body temperature management (P < 0.05). Among 3 patients who experienced myocardial injury in the aggressive body temperature management group, 2 met the diagnostic criteria for cTnI and hs-cTnT and only 1 met the diagnostic criteria for hs-cTnT. Among the 11 patients who experienced myocardial injury in the standard body temperature management group, 7 met the diagnostic criteria for cTnI and hs-cTnT and only 3 met the diagnostic criteria for hs-cTnT; only 1 met the diagnostic criteria for cTnI. The bias of cTnI and hs-cTnT was - 8.82 ± 31.91 ng/L. The consistency limit was - 71.37 ~ 53.73 ng/L. The proportion within the scope of the consistency of its corresponding boundary was 98.57%. The correlation coefficient of cTnI and hs-cTnT was 0.845 (P < 0.05). CONCLUSIONS In the evaluation of postoperative myocardial injury in patients undergoing curative resection of oesophageal cancer, cTnI and hs-cTnT exhibit high consistency and a good correlation. The combination of cTnI and hs-cTnT can improve the detection rate of myocardial injury, thus providing a better reference than a single measure alone for reducing the risk of perioperative myocardial injury in patients. TRIAL REGISTRATION ChiCTR-INR-17011621 . Registered June 10, 2017.",2020,The incidence of postoperative day 2 myocardial injury was 8.6% (3/35) among patients receiving aggressive body temperature management and 31.4% (11/35) among patients receiving standard body temperature management (P < 0.05).,"['11 patients who experienced myocardial injury in the standard body temperature management group, 7 met the diagnostic criteria for cTnI and hs-cTnT and only 3 met the diagnostic criteria for hs-cTnT; only 1 met the diagnostic criteria for cTnI', 'patients undergoing curative resection of oesophageal cancer', '70 patients undergoing elective curative resection of oesophageal cancer', 'A total of 280 pairs of cTn samples were tested', 'early myocardial injury after curative resection of oesophageal cancer', '3 patients who experienced myocardial injury in the aggressive body temperature management group, 2 met the diagnostic criteria for cTnI and hs-cTnT and only 1 met the diagnostic criteria for hs-cTnT']",['aggressive body temperature management (nasopharyngeal temperature 36.61\u2009±\u20090.18\u2009°C) or standard body temperature management'],"['incidence of postoperative day 2 myocardial injury', 'incidence of myocardial injury and the relationship between hs-cTnT and cTn and (2) the consistency and correlation of the two cTn subtypes', 'serum cTnI and hs-cTnT levels', 'consistency limit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C3538889', 'cui_str': 'Cardiac troponin T'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0546837', 'cui_str': 'Malignant tumor of esophagus'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]","[{'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C3697005', 'cui_str': 'Nasopharyngeal temperature'}, {'cui': 'C4517433', 'cui_str': '0.18'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C3538889', 'cui_str': 'Cardiac troponin T'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0883409', 'cui_str': 'Cardiac troponin I'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]",70.0,0.0974198,The incidence of postoperative day 2 myocardial injury was 8.6% (3/35) among patients receiving aggressive body temperature management and 31.4% (11/35) among patients receiving standard body temperature management (P < 0.05).,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Gu', 'Affiliation': 'Department of Anaesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241 Huaihai Rd. West, Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Tang', 'Affiliation': 'Department of Anaesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241 Huaihai Rd. West, Shanghai, China.'}, {'ForeName': 'Zuojing', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Anaesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241 Huaihai Rd. West, Shanghai, China.'}, {'ForeName': 'Meiying', 'Initials': 'M', 'LastName': 'Xu', 'Affiliation': 'Department of Anaesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241 Huaihai Rd. West, Shanghai, China.'}, {'ForeName': 'Jingxiang', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': 'Department of Anaesthesiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241 Huaihai Rd. West, Shanghai, China. Wu_jingxiang@shchest.org.'}]",Journal of cardiothoracic surgery,['10.1186/s13019-020-01225-9'] 2207,32711551,Accuracy of time to treatment estimates in the CRASH-3 clinical trial: impact on the trial results.,"BACKGROUND Early treatment with tranexamic acid may reduce deaths after traumatic brain injury (TBI). In mild and moderate TBI, there is a time to treatment interaction, with early treatment being most beneficial. Time to treatment was recorded by clinicians and is subject to error. Using monitoring data from the CRASH-3 trial, we examine the impact of errors in time to treatment on estimated treatment effects. METHODS The CRASH-3 trial was a randomised trial of the effect of tranexamic acid on death and vascular occlusive events in 12,737 TBI patients. This analysis includes the 8107 patients with a Glasgow coma scale score of 9 to 15 since previous analyses showed that these patients benefit most from early treatment. Clinician-recorded time to treatment was checked against ambulance and hospital records for 1368/12,737 (11%) patients. Patients who died were preferentially selected for monitoring and we monitored 36% of head injury deaths. We describe measurement errors using Bland-Altman graphs. We model the effect of tranexamic acid on head injury death using logistic regression with a time-treatment interaction term. We use regression calibration, multiple imputation and Bayesian analysis to estimate the impact of time to treatment errors. RESULTS Clinicians rounded times to the nearest half or full hour in 66% of cases. Monitored times were also rounded and were identical to clinician times in 63% of patients. Times were underestimated by an average of 9 min (95% CI - 85, 66). There was more variability between clinician-recorded and monitored times in low- and middle-income countries than in high-income countries. The treatment effect estimate at 1 h was greater for monitored times OR = 0.61 (95% CI 0.47, 0.81) than for clinician-recorded times OR = 0.63 (95% CI 0.48, 0.83). All three adjustment methods gave similar time to treatment interactions. For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78). Using monitored times increased the time-treatment interaction term from 1.15 (95% CI 1.03, 1.27) to 1.16 (95% CI 1.05, 1.28). CONCLUSIONS Accurate estimation of time from injury to treatment is challenging, particularly in low resource settings. Adjustment for known errors in time to treatment had minimal impact on the trial results. TRIAL REGISTRATION ClinicalTrials.gov NCT01402882 . Registered on 25 July 2011.",2020,"For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78).","['Patients who died were preferentially selected for monitoring and we monitored 36% of head injury deaths', '8107 patients with a', '12,737 TBI patients']",['tranexamic acid'],"['Glasgow coma scale score', 'death and vascular occlusive events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0018674', 'cui_str': 'Injury of head'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0017594', 'cui_str': 'Glasgow coma scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C1947917', 'cui_str': 'Occluded'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",12737.0,0.182158,"For Bayesian methods, the treatment effect at 1 h was OR = 0.58 (95% CI 0.43, 0.78).","[{'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Mansukhani', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK. raoul.mansukhani@lshtm.ac.uk.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Frimley', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Haleema', 'Initials': 'H', 'LastName': 'Shakur-Still', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Sharples', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Roberts', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.'}]",Trials,['10.1186/s13063-020-04623-5'] 2208,32711554,BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.,"BACKGROUND We previously showed that BRCA-like profiles can be used to preselect individuals with the highest risk of carrying BRCA mutations but could also indicate which patients would benefit from double-strand break inducing chemotherapy. A simple, robust, and reliable assay for clinical use that utilizes limited amounts of formalin-fixed, paraffin-embedded tumor tissue to assess BRCAness status in both ER-positive and ER-negative breast cancer (BC) is currently lacking. METHODS A digital multiplex ligation-dependent probe amplification (digitalMLPA) assay was designed to detect copy number alterations required for the classification of BRCA1-like and BRCA2-like BC. The BRCA1-like classifier was trained on 71 tumors, enriched for triple-negative BC; the BRCA2-like classifier was trained on 55 tumors, enriched for luminal-type BC. A shrunken centroid-based classifier was developed and applied on an independent validation cohort. A total of 114 cases of a randomized controlled trial were analyzed, and the association of the classifier result with intensified platinum-based chemotherapy response was assessed. RESULTS The digitalMLPA BRCA1-like classifier correctly classified 91% of the BRCA1-like samples and 82% of the BRCA2-like samples. Patients with a BRCA-like tumor derived significant benefit of high-dose chemotherapy (adjusted hazard ratio (HR) 0.12, 95% CI 0.04-0.44) which was not observed in non-BRCA-like patients (HR 0.9, 95% CI 0.37-2.18) (p = 0.01). Analysis stratified for ER status showed borderline significance. CONCLUSIONS The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.",2020,The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.,[],"['digital multiplex ligation-dependent probe amplification', 'digitalMLPA', 'intensified platinum-based chemotherapy']",[],[],"[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C3494189', 'cui_str': 'Multiplex Ligation-Dependent Probe Amplification'}, {'cui': 'C3536920', 'cui_str': 'Platinum compounds'}]",[],114.0,0.164868,The digitalMLPA is a reliable method to detect a BRCA1- and BRCA2-like pattern on clinical samples and predicts platinum-based chemotherapy benefit in both triple-negative and luminal-type BC.,"[{'ForeName': 'Esther H', 'Initials': 'EH', 'LastName': 'Lips', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. e.lips@nki.nl.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Benard-Slagter', 'Affiliation': 'Department of Oncogenetics, MRC Holland, Amsterdam, The Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Opdam', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Caroline E', 'Initials': 'CE', 'LastName': 'Scheerman', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Jelle', 'Initials': 'J', 'LastName': 'Wesseling', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Frans B L', 'Initials': 'FBL', 'LastName': 'Hogervorst', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Sabine C', 'Initials': 'SC', 'LastName': 'Linn', 'Affiliation': 'Department of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.'}, {'ForeName': 'Suvi', 'Initials': 'S', 'LastName': 'Savola', 'Affiliation': 'Department of Oncogenetics, MRC Holland, Amsterdam, The Netherlands.'}, {'ForeName': 'Petra M', 'Initials': 'PM', 'LastName': 'Nederlof', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.'}]",Breast cancer research : BCR,['10.1186/s13058-020-01313-7'] 2209,32711555,Efficacy of acupuncture for treatment of intermittent claudication in patients with degenerative lumbar spinal stenosis: protocol for a randomized controlled trial.,"BACKGROUND Degenerative lumbar spinal stenosis (DLSS) is a common condition secondary to degenerative changes. Acupuncture may be effective for treating DLSS. However, there is a lack of sufficient evidence showing the efficacy of acupuncture. The aim of this study is to assess the efficacy and safety of acupuncture for relieving neurogenic claudication in patients with DLSS. METHODS A total of 196 patients will be randomly assigned to an acupuncture group or a sham acupuncture group at a ratio of 1:1. Patients will receive 18 sessions of treatment for 6 continuous weeks. The primary outcome will be the change in the Modified Roland-Morris Disability Questionnaire score from baseline to week 6. The secondary outcomes will include the change in the scores from baseline for the Numerical Rating Scale, Swiss Spinal Stenosis Questionnaire, and Anxiety and Depression Scale. Additionally, the expectancy of acupuncture, blinding, and safety will also be assessed. All analysis will be performed based on intention-to-treat. DISCUSSION The aim of this study is to evaluate the efficacy and safety of acupuncture for the treatment of neurogenic claudication in patients with DLSS. A limitation of this study is that acupuncturists cannot be blinded according to the characteristics of acupuncture, which may introduce some bias. TRIAL REGISTRATION ClinicalTrials.gov NCT03784729 and protocol ID 2018-161-KY. Registered on 18 December 2018.",2020,"The secondary outcomes will include the change in the scores from baseline for the Numerical Rating Scale, Swiss Spinal Stenosis Questionnaire, and Anxiety and Depression Scale.","['Degenerative lumbar spinal stenosis (DLSS', '196 patients', 'patients with DLSS', 'patients with degenerative lumbar spinal stenosis']","['acupuncture', 'acupuncture group or a sham acupuncture', 'Acupuncture']","['change in the Modified Roland-Morris Disability Questionnaire score', 'efficacy and safety', 'Numerical Rating Scale, Swiss Spinal Stenosis Questionnaire, and Anxiety and Depression Scale', 'expectancy of acupuncture, blinding, and safety']","[{'cui': 'C0410636', 'cui_str': 'Degenerative lumbar spinal stenosis'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0037944', 'cui_str': 'Spinal stenosis'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}]",196.0,0.289104,"The secondary outcomes will include the change in the scores from baseline for the Numerical Rating Scale, Swiss Spinal Stenosis Questionnaire, and Anxiety and Depression Scale.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing, 100053, China.""}, {'ForeName': 'Sixing', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Guiyang University of Chinese Medicine, Dongqing St., Huaxi District, Guiyang, China.'}, {'ForeName': 'Yuanjie', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing, 100053, China.""}, {'ForeName': 'Weiming', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing, 100053, China.""}, {'ForeName': 'Zhishun', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing, 100053, China. zhishunjournal@163.com.""}]",Trials,['10.1186/s13063-020-04612-8'] 2210,32716862,Effect of prefabricated thermoformable foot orthoses on plantar surface temperature after running: A gender comparison.,"There is a lack of evidence about the effect of different type of foot orthoses on plantar surface temperature. Moreover, that effect could be different depending on gender due to anatomical and physiological differences between men and women. The aim of the study was to analyze the effect of a prefabricated thermoformable foot orthosis on plantar surface temperature after running and taking gender differences into account. Thirty recreational runners (15 males, mean (standard deviation): 28 (7) years, 69.7 (6.5) kg, 1.74 (0.05) cm and 22.9 (1.7) kg/m 2 ; and 15 females: 35 (7) years, 55.2 (6.9) kg, 1.63 (0.06) cm and 20.6 (1.9) kg/m 2 ) carried out a maximum incremental test as pre-test, and two running tests on a treadmill at the laboratory wearing previously randomized different foot orthoses (thermoformable and prefabricated generic). The plantar surface temperature of the dominant foot sole in ten regions of interest was assessed before and immediately after 30-min running at 75% of VO 2max . The use of thermoformable foot orthoses produced lower temperatures only in men after the run in medial heel (P = 0.033, ES = 0.7), which then disappeared in temperature variation (after - before) (P = 0.910). Regarding gender, women showed lower temperatures before the run in both orthosis conditions (P < 0.039, ES > 0.8), but no differences in temperatures after the run (P = 0.910) in comparison with men. Moreover, absolute temperatures after running were always greater than before the run (P < 0.001, ES > 5.0). In conclusion, the thermoformable foot orthoses do not modify plantar surface temperature after running in healthy runners of either gender, compared to prefabricated generic foot orthoses. Although women present lower baseline plantar temperatures than men, these differences disappear after exercise.",2020,"Regarding gender, women showed lower temperatures before the run in both orthosis conditions (P < 0.039, ES > 0.8), but no differences in temperatures after the run (P = 0.910) in comparison with men.","['Thirty recreational runners (15 males, mean (standard deviation): 28 (7) years, 69.7 (6.5) kg, 1.74 (0.05) cm and 22.9 (1.7) kg/m 2 ; and 15 females: 35 (7) years, 55.2 (6.9) kg, 1.63 (0.06) cm and 20.6 (1.9) kg/m 2 ', 'healthy runners']","['prefabricated thermoformable foot orthosis', 'prefabricated thermoformable foot orthoses', 'foot orthoses (thermoformable and prefabricated generic']","['absolute temperatures', 'plantar surface temperature']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517826', 'cui_str': '6.9'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C4517517', 'cui_str': '1.9'}]","[{'cui': 'C1283250', 'cui_str': 'Foot orthosis'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0085155', 'cui_str': 'Generic Drugs'}]","[{'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0230463', 'cui_str': 'Structure of sole of foot'}, {'cui': 'C0205148', 'cui_str': 'Surface'}]",,0.0825587,"Regarding gender, women showed lower temperatures before the run in both orthosis conditions (P < 0.039, ES > 0.8), but no differences in temperatures after the run (P = 0.910) in comparison with men.","[{'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Jimenez-Perez', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, St: Gascó Oliag, 3, 46010, Valencia, Spain; Research Group in Medical Physics (GIFIME), Department of Physiology, University of Valencia, Ave: Blasco Ibáñez, 15, 46010, Valencia, Spain.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Gil-Calvo', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, St: Gascó Oliag, 3, 46010, Valencia, Spain.'}, {'ForeName': 'Jose Ignacio', 'Initials': 'JI', 'LastName': 'Priego-Quesada', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, St: Gascó Oliag, 3, 46010, Valencia, Spain; Research Group in Medical Physics (GIFIME), Department of Physiology, University of Valencia, Ave: Blasco Ibáñez, 15, 46010, Valencia, Spain.'}, {'ForeName': 'Inmaculada', 'Initials': 'I', 'LastName': 'Aparicio', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, St: Gascó Oliag, 3, 46010, Valencia, Spain; Textile Research Institute (AITEX), Sq: Emilio Sala, 1, 03801, Alcoy, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Pérez-Soriano', 'Affiliation': 'Research Group in Sports Biomechanics (GIBD), Department of Physical Education and Sports, University of Valencia, St: Gascó Oliag, 3, 46010, Valencia, Spain. Electronic address: pedro.perez-soriano@uv.es.'}, {'ForeName': 'Rosa Ma Cibrián', 'Initials': 'RMC', 'LastName': 'Ortiz de Anda', 'Affiliation': 'Research Group in Medical Physics (GIFIME), Department of Physiology, University of Valencia, Ave: Blasco Ibáñez, 15, 46010, Valencia, Spain.'}]",Journal of thermal biology,['10.1016/j.jtherbio.2020.102612'] 2211,32716876,Experimental study on the effectiveness of the PCM cooling vest in persons with paraplegia of varying levels.,"Persons with paraplegia (PA) from thoracic spinal cord injury (T1-T12) are prone to thermal stress during exercise due to impaired thermoregulation. This study evaluates the effectiveness of phase change material (PCM) cooling vests on persons with PA of different levels of injury during exercise in hot exposure. Sixteen participants were recruited and divided to three groups based on injury level; high-thoracic T1-T3, mid-thoracic T4-T8, and low thoracic T9-T12 to perform a 30-min arm-crank exercise at a 30 °C room condition. Two types of PCM vests at melting temperature of 20 °C were tested: i) V1 with PCM covering the trunk of 3.4 kg overall vest mass and ii) V2 with PCM covering chest and upper back of 2.17 kg overall vest mass. High thoracic and low-thoracic groups performed NV and V1 tests; whereas, mid-thoracic group performed NV, V1, and V2 tests. Heart rate, core, and skin temperatures were monitored during 15-min preconditioning, 30-min exercise, and 15-min recovery. In addition, thermal comfort, sensation, skin wettedness, and perceived exertion were recorded during exercise only. The main findings were that the effectiveness of the cooling vest was dependent on injury level and portion of sensate skin of trunk covered by the PCM packets. Rise in core temperature (ΔT cr ) was reduced significantly for the low-thoracic group during exercise and recovery (ΔT cr =0.41°C, 0.26°C for NV and V1; respectively, p<0.05). For the mid-thoracic group, both V1 (p = 0.001) and V2 (p = 0.008) were effective in reducing ΔT cr compared to the NV test at the end of the recovery period (0.74°C,0.42°C,0.56°C, for NV, V1 and V2; respectively). For the high-thoracic group, V1 was not effective in reducing core temperature (p>0.05). For the mid-thoracic group, V2 at 36% lower mass significantly improved thermal comfort (p = 0.0004) compared to the NV test and was as effective compared to V1 in reducing core temperature.",2020,"For the high-thoracic group, V1 was not effective in reducing core temperature (p>0.05).","['persons with paraplegia of varying levels', 'Sixteen participants were recruited and divided to three groups based on injury level; high', 'Persons with paraplegia (PA) from thoracic spinal cord injury (T1-T12', 'persons with PA of different levels of injury during exercise in hot exposure']","['High thoracic and low-thoracic', 'PCM cooling vest', 'cooling vest', 'phase change material (PCM) cooling vests', 'thoracic T1-T3, mid-thoracic T4-T8, and low thoracic T9-T12 to perform a 30-min arm-crank exercise at a 30\xa0°C room condition']","['thermal comfort', 'thermal comfort, sensation, skin wettedness, and perceived exertion', 'Heart rate, core, and skin temperatures']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030486', 'cui_str': 'Paraplegia'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0840477', 'cui_str': 'Injury of thoracic spinal cord'}, {'cui': 'C0054967', 'cui_str': 'Lymphocyte antigen CD6'}, {'cui': 'C0587107', 'cui_str': 'During exercise'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0033677', 'cui_str': 'Deficiency of macronutrients'}, {'cui': 'C0453884', 'cui_str': 'Vest'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0444598', 'cui_str': 'Mid'}, {'cui': 'C0054967', 'cui_str': 'Lymphocyte antigen CD6'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0037294', 'cui_str': 'Temperature of skin'}]",16.0,0.0431619,"For the high-thoracic group, V1 was not effective in reducing core temperature (p>0.05).","[{'ForeName': 'Farah', 'Initials': 'F', 'LastName': 'Mneimneh', 'Affiliation': 'Mechanical Engineering Department, American University of Beirut, P.O. Box 11-0236, Beirut, 1107-2020, Lebanon.'}, {'ForeName': 'Charbel', 'Initials': 'C', 'LastName': 'Moussalem', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El Solh Beirut, 1107 2020, Beirut, Lebanon.'}, {'ForeName': 'Nesreen', 'Initials': 'N', 'LastName': 'Ghaddar', 'Affiliation': 'Mechanical Engineering Department, American University of Beirut, P.O. Box 11-0236, Beirut, 1107-2020, Lebanon. Electronic address: farah@aub.edu.lb.'}, {'ForeName': 'Kamel', 'Initials': 'K', 'LastName': 'Ghali', 'Affiliation': 'Mechanical Engineering Department, American University of Beirut, P.O. Box 11-0236, Beirut, 1107-2020, Lebanon.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Omeis', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, American University of Beirut Medical Center, P.O. Box: 11-0236, Riad El Solh Beirut, 1107 2020, Beirut, Lebanon.'}]",Journal of thermal biology,['10.1016/j.jtherbio.2020.102634'] 2212,32717033,Brain-Responsive Neurostimulation for Loss of Control Eating: Early Feasibility Study.,"BACKGROUND Loss of control (LOC) is a pervasive feature of binge eating, which contributes significantly to the growing epidemic of obesity; approximately 80 million US adults are obese. Brain-responsive neurostimulation guided by the delta band was previously found to block binge-eating behavior in mice. Following novel preclinical work and a human case study demonstrating an association between the delta band and reward anticipation, the US Food and Drug Administration approved an Investigational Device Exemption for a first-in-human study. OBJECTIVE To assess feasibility, safety, and nonfutility of brain-responsive neurostimulation for LOC eating in treatment-refractory obesity. METHODS This is a single-site, early feasibility study with a randomized, single-blinded, staggered-onset design. Six subjects will undergo bilateral brain-responsive neurostimulation of the nucleus accumbens for LOC eating using the RNS® System (NeuroPace Inc). Eligible participants must have treatment-refractory obesity with body mass index ≥ 45 kg/m2. Electrophysiological signals of LOC will be characterized using real-time recording capabilities coupled with synchronized video monitoring. Effects on other eating disorder pathology, mood, neuropsychological profile, metabolic syndrome, and nutrition will also be assessed. EXPECTED OUTCOMES Safety/feasibility of brain-responsive neurostimulation of the nucleus accumbens will be examined. The primary success criterion is a decrease of ≥1 LOC eating episode/week based on a 28-d average in ≥50% of subjects after 6 mo of responsive neurostimulation. DISCUSSION This study is the first to use brain-responsive neurostimulation for obesity; this approach represents a paradigm shift for intractable mental health disorders.",2020,Six subjects will undergo bilateral brain-responsive neurostimulation of the nucleus accumbens for LOC eating using the RNS® System (NeuroPace Inc).,"['Six subjects will undergo bilateral brain-responsive neurostimulation of the nucleus accumbens for LOC eating using the RNS® System (NeuroPace Inc', 'Eligible participants must have treatment-refractory obesity with body mass index\xa0≥\xa045\xa0kg/m2']",['Brain-Responsive Neurostimulation'],"['decrease of\xa0≥1 LOC eating episode/week based on a 28-d average', 'eating disorder pathology, mood, neuropsychological profile, metabolic syndrome, and nutrition']","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0521307', 'cui_str': 'Neurostimulation procedure'}, {'cui': 'C0007610', 'cui_str': 'Nucleus'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0521307', 'cui_str': 'Neurostimulation procedure'}]","[{'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}]",6.0,0.0397596,Six subjects will undergo bilateral brain-responsive neurostimulation of the nucleus accumbens for LOC eating using the RNS® System (NeuroPace Inc).,"[{'ForeName': 'Hemmings', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Adler', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Dan E', 'Initials': 'DE', 'LastName': 'Azagury', 'Affiliation': 'Department of Surgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Bohon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Debra L', 'Initials': 'DL', 'LastName': 'Safer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Daniel A N', 'Initials': 'DAN', 'LastName': 'Barbosa', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Mahendra T', 'Initials': 'MT', 'LastName': 'Bhati', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Nolan R', 'Initials': 'NR', 'LastName': 'Williams', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Laura B', 'Initials': 'LB', 'LastName': 'Dunn', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Tass', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Brian D', 'Initials': 'BD', 'LastName': 'Knutson', 'Affiliation': 'Department of Psychology, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Yutsis', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Ayesha', 'Initials': 'A', 'LastName': 'Fraser', 'Affiliation': 'Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Cunningham', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Kara', 'Initials': 'K', 'LastName': 'Richardson', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Tara L', 'Initials': 'TL', 'LastName': 'Skarpaas', 'Affiliation': 'NeuroPace Inc, 455\xa0N Bernardo Avenue, Mountain View, California.'}, {'ForeName': 'Thomas K', 'Initials': 'TK', 'LastName': 'Tcheng', 'Affiliation': 'NeuroPace Inc, 455\xa0N Bernardo Avenue, Mountain View, California.'}, {'ForeName': 'Martha J', 'Initials': 'MJ', 'LastName': 'Morrell', 'Affiliation': 'NeuroPace Inc, 455\xa0N Bernardo Avenue, Mountain View, California.'}, {'ForeName': 'Laura Weiss', 'Initials': 'LW', 'LastName': 'Roberts', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Malenka', 'Affiliation': 'Nancy Pritzker Laboratory, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Lock', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Casey H', 'Initials': 'CH', 'LastName': 'Halpern', 'Affiliation': 'Department of Neurosurgery, Stanford University School of Medicine, Stanford, California.'}]",Neurosurgery,['10.1093/neuros/nyaa300'] 2213,32717350,A sequential multiple assignment randomized trial (SMART) protocol for empirically developing an adaptive preventive intervention for college student drinking reduction.,"College student alcohol use and associated negative consequences are clear public health problems with consequences including damage to self, others, and institutions. This paper describes the protocol of a research study designed to answer a number of important questions in the development of an adaptive preventive intervention (API) to reduce high-risk drinking among first-year college students. The API is designed to educate students and to motivate heavy-drinking college students to engage in existing resources to support reducing high-risk alcohol use, by leveraging technology-based intervention modalities. The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization. Adaptive preventive interventions have the potential to reduce the acute and long-term negative health consequences of young adult alcohol use.",2020,"The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization.","['college student drinking reduction', 'first-year college students']",['adaptive preventive intervention (API'],"['reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization']","[{'cui': 'C4042862', 'cui_str': 'Alcohol Drinking, College Students'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0199176', 'cui_str': 'Preventive procedure'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0556346', 'cui_str': 'Drinking binge'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0030672', 'cui_str': 'Health Care Utilization'}]",,0.0187936,"The primary outcome is a reduction in binge drinking, with secondary outcomes of reducing negative alcohol-related consequences and increasing health services utilization.","[{'ForeName': 'Megan E', 'Initials': 'ME', 'LastName': 'Patrick', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA. Electronic address: mpatrick@umn.edu.""}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Boatman', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Morrell', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA.""}, {'ForeName': 'Anna C', 'Initials': 'AC', 'LastName': 'Wagner', 'Affiliation': ""Institute for Translational Research in Children's Mental Health, University of Minnesota, 1100 Washington Avenue South, Suite 101, Minneapolis, MN 55415, USA.""}, {'ForeName': 'Grace R', 'Initials': 'GR', 'LastName': 'Lyden', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Inbal', 'Initials': 'I', 'LastName': 'Nahum-Shani', 'Affiliation': 'Institute for Social Research, University of Michigan, P.O. Box 1248, 426 Thompson Street, Ann Arbor, MI 48106, USA.'}, {'ForeName': 'Cheryl A', 'Initials': 'CA', 'LastName': 'King', 'Affiliation': 'Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Room 2129, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Bonar', 'Affiliation': 'Department of Psychiatry, University of Michigan, 4250 Plymouth Road, Room 2129, Ann Arbor, MI 48109, USA; Injury Prevention Center, University of Michigan, 2800 Plymouth Road, NCRC Building 10, Ann Arbor, MI 48109, USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Lee', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington, 1100 Northeast 45(th) Street, Suite 300, Seattle, WA 98105, USA.'}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Larimer', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Center for the Study of Health and Risk Behaviors, University of Washington, 1100 Northeast 45(th) Street, Suite 300, Seattle, WA 98105, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Vock', 'Affiliation': 'Division of Biostatistics, University of Minnesota, 420 Delaware Street Southeast, MMC 303 Mayo, Minneapolis, MN 55455, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Almirall', 'Affiliation': 'Institute for Social Research, University of Michigan, P.O. Box 1248, 426 Thompson Street, Ann Arbor, MI 48106, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106089'] 2214,32717448,"Analgesic efficacy of ultrasound guided bilateral transversus thoracis muscle plane block in pediatric cardiac surgery: a randomized, double-blind, controlled study.","STUDY OBJECTIVE Adequate perioperative pain control in children undergoing cardiac surgery is mandatory. Intravenous opioids and neuraxial anesthetic techniques have been used but didn't gained any popularity. The aim of the current study was to evaluate the analgesic efficacy of transversus thoracis plane (TTP) block in pediatric cardiac surgery. DESIGN Superiority, randomized, double-blind, controlled study. SETTING Intraoperative and postoperative in intensive care unit (ICU), Mansoura university children hospital, Egypt. PATIENTS Eighty pediatric patients aged 2-12 years, undergoing cardiac surgery via median sternotomy, were randomly allocated into 2 equal groups, the control group and TTP block group. INTERVENTIONS Controlled group received only fentanyl for perioperative analgesia, while TTP block was performed in the intervention group (TTP group). MEASUREMENTS The primary outcome measure was the total dose of fentanyl in the first postoperative 24 h after extubation, while the secondary outcome measures were postoperative pain score, intraoperative fentanyl consumption, time to extubation and ICU length of stay. MAIN RESULTS During the first postoperative 24 h, total fentanyl consumption was significantly lower (P < 0.05) in the TTP block group (9.892 ± 3.397 μg/kg) than the control group (18.500 ± 3.401 μg/kg) and modified objective pain score was significantly (P < 0.05) lower in TTP block group than the control group all over the time. Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). CONCLUSION The use of TTP block decreased perioperative fentanyl consumption and reduced postoperative pain intensity.",2020,"Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). ","['children undergoing cardiac surgery', 'Intraoperative and postoperative in intensive care unit (ICU), Mansoura university children hospital, Egypt', 'Eighty pediatric patients aged 2-12\xa0years, undergoing cardiac surgery via median sternotomy', 'pediatric cardiac surgery']","['TTP block', 'transversus thoracis plane (TTP) block', 'fentanyl for perioperative analgesia, while TTP block was performed in the intervention group (TTP group', 'control group and TTP block group', 'ultrasound guided bilateral transversus thoracis muscle plane block']","['postoperative pain intensity', 'modified objective pain score', 'perioperative fentanyl consumption', 'Analgesic efficacy', 'analgesic efficacy', 'total fentanyl consumption', 'Total intraoperative fentanyl requirement', 'postoperative pain score, intraoperative fentanyl consumption, time to extubation and ICU length of stay', 'total dose of fentanyl in the first postoperative 24\xa0h after extubation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1282959', 'cui_str': 'Median sternotomy'}]","[{'cui': 'C1744608', 'cui_str': 'Structure of transverse thoracis muscle'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C1096288', 'cui_str': 'Perioperative analgesia'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0553891', 'cui_str': 'Extubation of trachea'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}]",80.0,0.408484,"Total intraoperative fentanyl requirement was significantly (P < 0.05) lower in TTP block group (8.27 ± 1.170 μg/kg) than the control group (13.72 ± 1.186 μg/kg). ","[{'ForeName': 'Ibrahim I', 'Initials': 'II', 'LastName': 'Abdelbaser', 'Affiliation': 'Department of Anesthesiology and Surgical Intensive Care, Faculty of Medicine, Mansoura University, 2 El-Gomhouria St, Mansoura 35516, Egypt. Electronic address: ibraheem2005@mans.edu.eg.'}, {'ForeName': 'Nabil A', 'Initials': 'NA', 'LastName': 'Mageed', 'Affiliation': 'Department of Anesthesiology and Surgical Intensive Care, Faculty of Medicine, Mansoura University, 2 El-Gomhouria St, Mansoura 35516, Egypt.'}]",Journal of clinical anesthesia,['10.1016/j.jclinane.2020.110002'] 2215,32717627,Does a Facebook-enhanced Mindful Self-Compassion intervention improve body image? An evaluation study.,"This study evaluates a brief intervention aimed at improving body image. The intervention comprised a Mindful Self-Compassion workshop complemented by a group discussion on Facebook. Young women (M age = 18.31), screened for body concerns, were allocated by university campus to a 50-minute workshop intervention (n = 42) or a waitlist control (n = 34). Following the workshop, participants in the intervention group utilized self-compassion techniques when experiencing appearance distress and posted about their experiences on a private Facebook group three times per week for two weeks. Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up. All effects, except those for body dissatisfaction, were held at 3-month follow-up. Additionally, common humanity predicted gains in body appreciation from pretest to posttest. The Mindful Self-Compassion intervention involving a Facebook group may have resonated with young women as it allowed them to share moments of self-compassionate body image experiences in a private and supportive environment.",2020,"Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up.","['Young women (M age = 18.31), screened for body concerns, were allocated by university campus to a']","['Facebook-enhanced Mindful Self-Compassion intervention', 'Mindful Self-Compassion workshop complemented by a group discussion on Facebook', '50-minute workshop intervention', 'waitlist control']","['lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0009498', 'cui_str': 'Complement'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1282911', 'cui_str': 'Upward'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C2732632', 'cui_str': 'Dissatisfaction with body image'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0039870', 'cui_str': 'Thin build'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}]",,0.0146737,"Findings showed that, relative to control, the intervention group experienced lower upward appearance comparison, social appearance anxiety, body dissatisfaction, and drive for thinness, and higher body appreciation and self-compassion, at posttest and 1-month follow-up.","[{'ForeName': 'Veya', 'Initials': 'V', 'LastName': 'Seekis', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: v.seekis@griffith.edu.au.'}, {'ForeName': 'Graham L', 'Initials': 'GL', 'LastName': 'Bradley', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: g.bradley@griffith.edu.au.'}, {'ForeName': 'Amanda L', 'Initials': 'AL', 'LastName': 'Duffy', 'Affiliation': 'School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia. Electronic address: a.duffy@griffith.edu.au.'}]",Body image,['10.1016/j.bodyim.2020.07.006'] 2216,32717684,"Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes ✰ .","BACKGROUND Injectable disease-modifying therapies (iDMTs) are often used as first-line treatments for relapsing multiple sclerosis. Fingolimod is frequently used following treatment with iDMTs. Whether prior iDMT treatment impacts the effectiveness of subsequent fingolimod therapy is unclear. Here, we assessed switching from iDMTs to fingolimod, and the impact of treatment history on fingolimod escalation using data from the 12-month 'Prospective, Randomized, active-controlled, open-label study to Evaluate patient retention on Fingolimod versus approved first-line disease-modifying thErapies in adults with Relapsing-remitting Multiple Sclerosis' (PREFERMS). The study design and results at the end of randomized treatment (EoRT) in PREFERMS have been published. METHODS Both treatment-naïve patients and those who had previously received an iDMT were eligible for enrolment in PREFERMS, and one treatment switch was permitted on study. Pre-specified exploratory analyses compared outcomes in those randomized to fingolimod or to an iDMT at end of study (EoS), which included time spent on randomized and on switch treatment. Post hoc exploratory analyses (unadjusted for multiplicity owing to the large number of comparisons) among patients randomized to an iDMT who switched to fingolimod, compared outcomes longitudinally before (EoRT) and after (EoS) switching, and compared outcomes at EoRT and EoS among subgroups stratified by iDMT-treatment history. Outcomes included brain volume, various measures of gadolinium-enhancing [Gd+] lesion counts, annualized relapse rate (ARR), Symbol Digit Modalities Test (SDMT) score, patient-reported treatment satisfaction using the Medication Satisfaction Questionnaire (MSQ) and adverse event (AE) rates. RESULTS At EoS, 255 of 439 patients randomized to an iDMT had switched to fingolimod and 27 of 436 patients randomized to fingolimod had switched to an iDMT. By EoS, 44.2% of total treatment exposure in the iDMT group was to fingolimod and the mean time spent on fingolimod in this group was 220 days (approximately 7 months). Outcomes in the fingolimod group at EoS (brain volume, changes in Gd+ lesion counts, ARR, oral SDMT score and MSQ score) were similar to those seen at EoRT, but in the iDMT group these outcomes were more favorable at EoS than at EoRT and were similar to rates seen in the fingolimod group. Among patients who switched from iDMT to fingolimod, there were longitudinal improvements in ARR (EoRT, 0.3 [95% confidence interval (CI), 0.2-0.4]; EoS, 0.2 [0.1-0.3]; odds ratio, 0.5 [0.3-0.9]) and in treatment satisfaction (proportion of patients with MSQ > 5; EoRT, 67.4%; EoS, 90.4%; odds ratio, 5.7 [95% CI, 3.4-9.4]) after fingolimod treatment, and changes in brain volume, Gd+ lesion count, and AEs or AEs causing discontinuation were also more favorable at EoS than at EoRT. In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. CONCLUSION These analyses indicate that patients in PREFERMS had improved outcomes within months of switching to fingolimod from an iDMT and that improvements occurred irrespective of the number of iDMTs previously administered. These data provide a unique opportunity to explore clinical, radiological and safety outcomes associated with a range of clinically relevant treatment pathways.",2020,"In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. ","['At EoS, 255 of 439 patients randomized to an iDMT had switched to fingolimod and 27 of 436 patients randomized to', 'Both treatment-naïve patients and those who had previously received an iDMT were eligible for enrolment in PREFERMS, and one treatment switch was permitted on study', ""adults with Relapsing-remitting Multiple Sclerosis' (PREFERMS""]","['fingolimod had switched to an iDMT', 'Fingolimod versus approved first-line disease-modifying thErapies']","['EoS (brain volume, changes in Gd+ lesion counts, ARR, oral SDMT score and MSQ score', 'mean time spent on fingolimod', 'brain volume, various measures of gadolinium-enhancing [Gd+] lesion counts, annualized relapse rate (ARR), Symbol Digit Modalities Test (SDMT) score, patient-reported treatment satisfaction using the Medication Satisfaction Questionnaire (MSQ) and adverse event (AE) rates', 'longitudinal improvements in ARR', 'brain volume, Gd+ lesion count, and AEs or AEs causing discontinuation']","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023636', 'cui_str': 'Licenses'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751967', 'cui_str': 'Relapsing remitting multiple sclerosis'}]","[{'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0016911', 'cui_str': 'Gadolinium'}, {'cui': 'C0451522', 'cui_str': 'Symbol digit modalities test'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",439.0,0.0609136,"In all patient groups stratified by iDMT-treatment history, differences in outcomes narrowed or disappeared after fingolimod treatment. ","[{'ForeName': 'Samuel F', 'Initials': 'SF', 'LastName': 'Hunter', 'Affiliation': 'Advanced Neurosciences Institute, 101 Forrest Crossing Blvd. Suite 103, Franklin, TN 37064, United States. Electronic address: sfhunter@neurosci.us.'}, {'ForeName': 'Florian P', 'Initials': 'FP', 'LastName': 'Thomas', 'Affiliation': 'Hackensack Meridian School of Medicine at Seton Hall University, South Orange, and Hackensack University Medical Center, Hackensack, NJ, United States. Electronic address: florian.thomas@hackensackmeridian.org.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Cascione', 'Affiliation': 'Tampa Neurology Associates, Tampa, FL, United States. Electronic address: me@markcascione.com.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Williams', 'Affiliation': 'Oxford PharmaGenesis, Oxford, United Kingdom. Electronic address: ian.williams@pharmagenesis.com.'}, {'ForeName': 'Xiangyi', 'Initials': 'X', 'LastName': 'Meng', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: xiangyi.meng@novartis.com.'}, {'ForeName': 'Lesley', 'Initials': 'L', 'LastName': 'Schofield', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: lesley.schofield@novartis.com.'}, {'ForeName': 'Jamie L', 'Initials': 'JL', 'LastName': 'Weiss', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: jamie.weiss@novartis.com.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Tenenbaum', 'Affiliation': 'Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. Electronic address: nadia.tenebaum@novartis.com.'}, {'ForeName': 'Bruce A C', 'Initials': 'BAC', 'LastName': 'Cree', 'Affiliation': 'UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States. Electronic address: bruce.cree@ucsf.edu.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102346'] 2217,32717941,Feasibility of Using the Epidural Space Detecting Device (EPI-Detection TM ) for Interlaminar Cervical Epidural Injection.,"Cervical epidural injection (CEI), which is widely used for the treatment of cervical radiculopathy, sometimes has been associated with post-operative complications. Recently, EPI-Detection TM , which detects the negative pressure of the epidural space and notifies the proceduralist by flashing a light and producing a beeping sound, was introduced. We assumed that the newly developed device could be as safe and efficient as the conventional loss of resistance (LOR) method. Therefore, we aimed to evaluate the effectiveness of the EPI-Detection TM and compare it to that of the conventional LOR method. We randomly assigned 57 patients to the LOR and EPI-Detection groups (29 and 28 patients, respectively). Subjects were treated with interlaminar CEI (ILCEI) using one of two methods. The measured parameters, i.e., operation time and radiation dose were lower in the EPI-Detection TM group (4.6 ± 1.2 min vs. 6.9 ± 2.1 min; and 223.2 ± 206.7 mGy·cm 2 vs. 380.3 ± 340.9 mGy·cm 2 , respectively; all p < 0.05) than in the LOR group. There were no complications noted in either group. Both the EPI-Detection TM and LOR methods were safe and effective in detecting the epidural space, but the former was superior to the latter in terms of operation time and radiation exposure. The EPI-Detection TM may help perform ILCEI safely.",2020,"The measured parameters, i.e., operation time and radiation dose were lower in the EPI-Detection TM group (4.6 ± 1.2 min vs. 6.9 ± 2.1 min; and 223.2 ± 206.7 mGy·cm 2 vs. 380.3 ± 340.9 mGy·cm 2 , respectively; all p < 0.05) than in the LOR group.",[],"['LOR and EPI-Detection', 'interlaminar CEI (ILCEI', 'Cervical epidural injection (CEI', 'Epidural Space Detecting Device (EPI-Detection TM ']",['operation time and radiation dose'],[],"[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0021486', 'cui_str': 'Injections, Peridural'}, {'cui': 'C0014537', 'cui_str': 'Structure of epidural space'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",57.0,0.0438403,"The measured parameters, i.e., operation time and radiation dose were lower in the EPI-Detection TM group (4.6 ± 1.2 min vs. 6.9 ± 2.1 min; and 223.2 ± 206.7 mGy·cm 2 vs. 380.3 ± 340.9 mGy·cm 2 , respectively; all p < 0.05) than in the LOR group.","[{'ForeName': 'Jiin', 'Initials': 'J', 'LastName': 'Kang', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Sam Sun', 'Initials': 'SS', 'LastName': 'Park', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Chul Hwan', 'Initials': 'CH', 'LastName': 'Kim', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Eui Chul', 'Initials': 'EC', 'LastName': 'Kim', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Hyung Cheol', 'Initials': 'HC', 'LastName': 'Kim', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Hyungseok', 'Initials': 'H', 'LastName': 'Jeon', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}, {'ForeName': 'Kyung Hyun', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Department of Neurosurgery, Gangnam Severance Hospital, Spine and Spinal Cord Institute, Yonsei University College of Medicine, 211, Eonju-ro, Gangnam-gu, Seoul 06273, Korea.'}, {'ForeName': 'Dong Ah', 'Initials': 'DA', 'LastName': 'Shin', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea.'}]",Journal of clinical medicine,['10.3390/jcm9082355'] 2218,32717956,Impact of Trunk Resistance and Stretching Exercise on Fall-Related Factors in Patients with Parkinson's Disease: A Randomized Controlled Pilot Study.,"BACKGROUND This study aimed to examine the effect of a 12-week progressive trunk resistance and stretching exercise program on fall-related factors in patients with Parkinson's disease (PD). METHODS A randomized study assessed a progressive trunk resistance and stretching exercise program over a 12-week period. A total of 17 patients with PD participated and wererandomly allocated into an exercise group ( n = 10) or a control group ( n = 7). Participants in the exercise group completed the exercise program in 60- to 90-min sessions for three days per week. Primary and secondary outcome measures included the trunk mobility scale, functional fitness test, standing balance, and sit-to-walk test. RESULTS The exercise group showed improvements in functional fitness, trunk mobility, standing balance, and dynamic stability compared with the control group (all p < 0.05). The 2.44 m timed up and go test (odds ratio (OR): 0.125) and the 2 min step test (OR: 10.584) of the functional fitness test, and the first-step length (OR: 3.558) and first-toe clearance height (OR: 4.777) of the sit-to-walk test, were different between the groups following the exercise program. CONCLUSION This 12-week exercise program improved fall-related factors in patients with PD and may lead to prevention of fall-related injuries.",2020,"The exercise group showed improvements in functional fitness, trunk mobility, standing balance, and dynamic stability compared with the control group (all p < 0.05).","[""patients with Parkinson's disease (PD"", ""Patients with Parkinson's Disease"", '17 patients with PD', 'patients with PD and may lead to prevention of fall-related injuries']","['exercise program', 'progressive trunk resistance and stretching exercise program', 'Trunk Resistance and Stretching Exercise']","['functional fitness, trunk mobility, standing balance, and dynamic stability', 'trunk mobility scale, functional fitness test, standing balance, and sit-to-walk test']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}]",17.0,0.0209581,"The exercise group showed improvements in functional fitness, trunk mobility, standing balance, and dynamic stability compared with the control group (all p < 0.05).","[{'ForeName': 'Changhong', 'Initials': 'C', 'LastName': 'Youm', 'Affiliation': 'Department of Health Care and Science, College of Health Sciences, Dong-A University, Saha-gu, Busan 49315, Korea.'}, {'ForeName': 'Youkyung', 'Initials': 'Y', 'LastName': 'Kim', 'Affiliation': 'Biomechanics Laboratory, College of Health Sciences, Dong-A University, Saha-gu, Busan 49315, Korea.'}, {'ForeName': 'Byungjoo', 'Initials': 'B', 'LastName': 'Noh', 'Affiliation': 'Department of Health Care and Science, College of Health Sciences, Dong-A University, Saha-gu, Busan 49315, Korea.'}, {'ForeName': 'Myeounggon', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Biomechanics Laboratory, College of Health Sciences, Dong-A University, Saha-gu, Busan 49315, Korea.'}, {'ForeName': 'Jinhee', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Biomechanics Laboratory, College of Health Sciences, Dong-A University, Saha-gu, Busan 49315, Korea.'}, {'ForeName': 'Sang-Myung', 'Initials': 'SM', 'LastName': 'Cheon', 'Affiliation': 'Department of Neurology, School of Medicine, Dong-A University, Dongdaesin-dong 3-ga, Seo-gu, Busan 49201, Korea.'}]","Sensors (Basel, Switzerland)",['10.3390/s20154106'] 2219,32717995,Randomized Trial on the Clinical Utility of a Novel Biomarker Panel to Identify Treatable Determinants of Chronic Pain.,"Millions suffer daily from chronic pain diagnosed anatomically and treated with opioids. Research shows that underlying nutritional, metabolic and oxidative stressors, which drive the development or worsening of chronic pain, are not diagnosed despite the fact that treatment of these primary pain pathways relieves pain and increases function. One of the main reasons for this gap in care is the lack of a simple diagnostic assay to help clinicians make these diagnoses. We examined the clinical utility of a urine-based pain biomarker panel. Primary care physicians were randomized into the test group and compared to controls. We measured their ability to make the diagnosis and treat a total of nine standardized patients, with common but challenging cases of chronic pain, over two rounds of data collection in a pre-post design using a fixed-effects model. Intervention doctors received educational materials on a novel pain biomarker panel after the baseline round and had access to biomarker test results. Provider responses were measured against evidence-based criteria. The two study arms at baseline provided similar, poor care for three different primary pain pathways: nutritional deficiencies (5.0% control versus 9.2% intervention treated, p = 0.208), metabolic abnormalities (1.0% control versus 0% for intervention treated, p = 0.314), and oxidative stress (1.2% control versus 0% intervention treated, p = 0.152). After the introduction of the Foundation Pain Index (FPI) biomarker test, physicians in the intervention group were 41.5% more likely to make the diagnosis of a micronutrient deficiency, 29.4% more likely to identify a treatable metabolic abnormality and 26.1% more likely to identify an oxidative stressor. These diagnostic and treatment improvements were seen across all three case types, ranging from a relative +54% ( p = 0.004) for chronic neuropathic pain to +35% ( p = 0.007) in chronic pain from other causes to +38% ( p = 0.002) in chronic pain with associated mental health issues. Intervention doctors were also 75.1% more likely to provide a non-opioid treatment to patients on chronic opioids (O.R. 1.8, 95% C.I. 0.8-3.7), 62% less likely to order unnecessary imaging for their patients with low back pain (O.R. 0.38, 95% C.I. 0.15-0.97) and 66% less likely to order an unnecessary pain referral (O.R. 0.34, 95% C.I. 0.13-0.90). This experimental study showed significant clinical utility of a validated pain biomarker panel that determines nutritional deficiencies, metabolic abnormalities and oxidative stressors that drive underlying treatable causes of pain. When integrated into routine primary care practice, this testing approach could considerably improve diagnostic accuracy and provide more targeted, non-opioid treatments for patients suffering from chronic pain.",2020,"Intervention doctors were also 75.1% more likely to provide a non-opioid treatment to patients on chronic opioids (O.R. 1.8, 95% C.I. 0.8-3.7), 62% less likely to order unnecessary imaging for their patients with low back pain (O.R. 0.38, 95% C.I. 0.15-0.97) and 66% less likely to order an unnecessary pain referral (O.R. 0.34, 95% C.I. 0.13-0.90).","['patients suffering from chronic pain', 'Primary care physicians']","['opioids', 'educational materials']","['unnecessary pain referral', 'oxidative stress', 'chronic pain', 'metabolic abnormalities', 'diagnostic accuracy', 'chronic neuropathic pain', 'Provider responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}]","[{'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0520510', 'cui_str': 'Material'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0034927', 'cui_str': 'Patient referral'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C4544057', 'cui_str': 'Chronic neuropathic pain'}]",9.0,0.0718495,"Intervention doctors were also 75.1% more likely to provide a non-opioid treatment to patients on chronic opioids (O.R. 1.8, 95% C.I. 0.8-3.7), 62% less likely to order unnecessary imaging for their patients with low back pain (O.R. 0.38, 95% C.I. 0.15-0.97) and 66% less likely to order an unnecessary pain referral (O.R. 0.34, 95% C.I. 0.13-0.90).","[{'ForeName': 'John', 'Initials': 'J', 'LastName': 'Peabody', 'Affiliation': 'College of Medicine, University of California, San Francisco, CA 94158, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Paculdo', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Tamondong-Lachica', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Ian Theodore', 'Initials': 'IT', 'LastName': 'Cabaluna', 'Affiliation': 'QURE Healthcare, San Francisco, CA 94133, USA.'}, {'ForeName': 'Joshua', 'Initials': 'J', 'LastName': 'Gunn', 'Affiliation': 'Ethos Laboratories, Newport, KY 41071, USA.'}]","Diagnostics (Basel, Switzerland)",['10.3390/diagnostics10080513'] 2220,32717999,"Acute Effects of a Polyphenol-Rich Leaf Extract of Mangifera indica L. (Zynamite) on Cognitive Function in Healthy Adults: A Double-Blind, Placebo-Controlled Crossover Study.","Extracts made from the leaves of the mango food plant ( Mangifera indica L., Anacardiaceae ) have a long history of medicinal usage, most likely due to particularly high levels of the polyphenol mangiferin. In rodent models, oral mangiferin protects cognitive function and brain tissue from a number of challenges and modulates cerebro-electrical activity. Recent evidence has confirmed the latter effect in healthy humans following a mangiferin-rich mango leaf extract using quantitative electroencephalography (EEG). The current study therefore investigated the effects of a single dose of mango leaf extract, standardised to contain >60% mangiferin (Zynamite ® ), on cognitive function and mood. This study adopted a double-blind, placebo-controlled cross-over design in which 70 healthy young adults (18 to 45 years) received 300 mg mango leaf extract and a matched placebo, on separate occasions, separated by at least 7 days. On each occasion, cognitive/mood assessments were undertaken pre-dose and at 30 min, 3 h and 5 h post-dose using the Computerised Mental Performance Assessment System (COMPASS) assessment battery and the Profile of Mood States (POMS). The results showed that a single dose of 300 mg mango leaf extract significantly improved performance accuracy across the tasks in the battery, with domain-specific effects seen in terms of enhanced performance on an 'Accuracy of Attention' factor and an 'Episodic Memory' factor. Performance was also improved across all three tasks (Rapid Visual Information Processing, Serial 3s and Serial 7s subtraction tasks) that make up the Cognitive Demand Battery sub-section of the assessment. All of these cognitive benefits were seen across the post-dose assessments (30 min, 3 h, 5 h). There were no interpretable treatment related effects on mood. These results provide the first demonstration of cognition enhancement following consumption of mango leaf extract and add to previous research showing that polyphenols and polyphenol rich extracts can improve brain function.",2020,"All of these cognitive benefits were seen across the post-dose assessments (30 min, 3 h, 5 h).","['healthy humans', 'Healthy Adults', '70 healthy young adults (18 to 45 years']","['Polyphenol-Rich Leaf Extract of', 'Placebo', 'mango leaf extract, standardised to contain >60% mangiferin (Zynamite ® ', '300 mg mango leaf extract and a matched placebo', 'polyphenols and polyphenol rich extracts', 'Mangifera indica L. (Zynamite', 'placebo']","['Computerised Mental Performance Assessment System (COMPASS) assessment battery and the Profile of Mood States (POMS', 'brain function', ""Accuracy of Attention' factor and an 'Episodic Memory' factor"", 'performance accuracy', 'Cognitive Function']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0071649', 'cui_str': 'Polyphenol'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0242724', 'cui_str': 'Leaves'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4081111', 'cui_str': 'mango leaf extract'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0065654', 'cui_str': 'mangiferin'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0330955', 'cui_str': 'Mangifera indica'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}]",70.0,0.145388,"All of these cognitive benefits were seen across the post-dose assessments (30 min, 3 h, 5 h).","[{'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Wightman', 'Affiliation': 'NUTRAN, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Philippa A', 'Initials': 'PA', 'LastName': 'Jackson', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Forster', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Khan', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}, {'ForeName': 'Julia C', 'Initials': 'JC', 'LastName': 'Wiebe', 'Affiliation': 'Nektium Pharma, Agüimes, 35118 Las Palmas de Gran Canaria, Spain.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Gericke', 'Affiliation': 'Nektium Pharma, Agüimes, 35118 Las Palmas de Gran Canaria, Spain.'}, {'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Kennedy', 'Affiliation': 'Brain, Performance and Nutrition Research Centre, Northumbria University, Newcastle-upon-Tyne NE1 8ST, UK.'}]",Nutrients,['10.3390/nu12082194'] 2221,32718044,The Effectiveness of Laser-Activated Irrigation on the Apical Microleakage Qualities of MTA Repair HP and NeoMTA Plus in Simulated Immature Teeth: A Comparative Study.,"There are limited data regarding the potential effect of erbium, chromium: yttrium-scandium-gallium-garnet (Er,Cr:YSGG) laser-activated irrigation (LAI) on the microleakage qualities of calcium silicate-based cements. The objective of the present study was to assess the effect of LAI on the microleakage qualities of MTA Repair HP (MTA-HP) and NeoMTA Plus (Neo) used in root-end filling and to compare the antimicrobial effectiveness of MTA- HP. Two experimental sets were conducted: antimicrobial activity (agar diffusion test/at 24, 48 h) and microleakage (glucose leakage model/at 1st, 10th, 20th days). Antimicrobial activities of MTA-HP, Neo, Biodentine, ProRoot and MTA Angelus were evaluated, and inhibition zones were observed not only against a range of Gram-positive and Gram-negative bacteria but also against yeast at 48h. For microleakage evaluation, fifty teeth were prepared to simulate the clinical situation where the root-tips (apex) are open, and randomly divided into two experimental groups (n = 20/group) according to the cement type ( MTA-HP and Neo ), and two control (n = 5/group) groups. Each experimental group was further divided into two subgroups (n = 10/group) with respect to LAI: MTA-HP , L-HP , Neo , L-Neo . A statistical difference was only detected between Neo and L-HP groups on day 1. Subsequently, MTA-HP exhibited superior microleakage quality compared to Neo in the short-term. Er,Cr:YSGG laser-activated irrigation could be used as a reliable technique without creating adverse effects on the sealing abilities of MTA Repair HP and NeoMTA Plus.",2020,"Er,Cr:YSGG laser-activated irrigation could be used as a reliable technique without creating adverse effects on the sealing abilities of MTA Repair HP and NeoMTA",['Simulated Immature Teeth'],"['Er,Cr:YSGG) laser-activated irrigation (LAI', 'Laser-Activated Irrigation', 'erbium, chromium: yttrium-scandium-gallium-garnet', 'MTA Repair HP (MTA-HP) and NeoMTA Plus (Neo', 'MTA- HP']","['microleakage quality', 'antimicrobial activity']","[{'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}]","[{'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C0008574', 'cui_str': 'Chromium'}, {'cui': 'C0043432', 'cui_str': 'Yttrium'}, {'cui': 'C0036274', 'cui_str': 'Scandium'}, {'cui': 'C0016980', 'cui_str': 'Gallium'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0210657', 'cui_str': 'pemetrexed'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C1271650', 'cui_str': 'Antimicrobial activity'}]",50.0,0.0163903,"Er,Cr:YSGG laser-activated irrigation could be used as a reliable technique without creating adverse effects on the sealing abilities of MTA Repair HP and NeoMTA","[{'ForeName': 'Serenad', 'Initials': 'S', 'LastName': 'Çırakoğlu', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry Near East University, 99138 Nicosia, North Cyprus.'}, {'ForeName': 'Buket', 'Initials': 'B', 'LastName': 'Baddal', 'Affiliation': 'Department of Medical Microbiology and Clinical Microbiology, Faculty of Medicine, Near East University, 99138 Nicosia, North Cyprus.'}, {'ForeName': 'Aylin', 'Initials': 'A', 'LastName': 'İslam', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry Near East University, 99138 Nicosia, North Cyprus.'}]","Materials (Basel, Switzerland)",['10.3390/ma13153287'] 2222,32718220,Safety and efficacy study of the wound care 360° SiteSeal® vascular closure device in percutaneous cardiac catheterization procedures.,"OBJECTIVES Vascular access site complications after percutaneous transfemoral cardiovascular procedures remain a common cause of morbidity and mortality. We evaluated the SiteSeal® VCD for achieving hemostasis following diagnostic cardiac catheterization. METHODS We conducted a prospective case control single center study to assess the safety and efficacy of SiteSeal® VCD compared to standard manual compression following diagnostic cardiac catheterization. Forty patients were enrolled in study to receive either SiteSeal® device or manual compression (20 in each group). RESULTS Patients in the SiteSeal® group achieved hemostasis in a significantly shorter time (4 ± 2.4 vs. 19 ± 2.4 min, P  < 0.001), had shorter time from hemostasis to ambulation (95 ± 44 vs. 388 ± 63 min, P  < 0.001) and significantly earlier device deployment to discharge time compared to the manual compression group (4.7 ± 1.1 vs. 8.9 ± 4.8 h, P  = 0.001). There was one non-major bleeding event in the SiteSeal® group which occurred >24 h after discharge from the hospital and was managed conservatively. In the remaining device patients, there was no clinical or Doppler ultrasound evidence of major or minor vascular complication with good overall patient comfort at discharge, 7 days and 30 days follow-up. CONCLUSIONS In this first clinical experience, the SiteSeal® VCD achieved safe and efficient hemostasis, allowed for earlier ambulation and faster discharge compared to manual compression.",2020,There was one non-major bleeding event in the SiteSeal® group which occurred >24 h after discharge from the hospital and was managed conservatively.,"['percutaneous cardiac catheterization procedures', 'Forty patients were enrolled in study to receive either']","['SiteSeal® device or manual compression', 'wound care 360° SiteSeal® vascular closure device', 'SiteSeal® VCD']","['shorter time from hemostasis to ambulation', 'earlier device deployment to discharge time', 'hemostasis', 'major bleeding event', 'safety and efficacy', 'clinical or Doppler ultrasound evidence of major or minor vascular complication']","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0018795', 'cui_str': 'Cardiac catheterization'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0886052', 'cui_str': 'Wound care'}, {'cui': 'C4319607', 'cui_str': '360'}, {'cui': 'C3504161', 'cui_str': 'Vascular Closure Devices'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0162481', 'cui_str': 'Doppler ultrasound'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",40.0,0.19645,There was one non-major bleeding event in the SiteSeal® group which occurred >24 h after discharge from the hospital and was managed conservatively.,"[{'ForeName': 'Suresh', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Department of Cardiovascular medicine, University of Kansas Medical Center and Hospital, Kansas City, USA.'}, {'ForeName': 'Nilay', 'Initials': 'N', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiovascular medicine, University of Kansas Medical Center and Hospital, Kansas City, USA.'}, {'ForeName': 'Vinodh', 'Initials': 'V', 'LastName': 'Jeevanantham', 'Affiliation': 'Department of Cardiovascular medicine, University of Kansas Medical Center and Hospital, Kansas City, USA.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Gupta', 'Affiliation': 'Department of Cardiovascular medicine, University of Kansas Medical Center and Hospital, Kansas City, USA.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Earnest', 'Affiliation': 'Department of Cardiovascular medicine, University of Kansas Medical Center and Hospital, Kansas City, USA.'}]",Vascular,['10.1177/1708538120934573'] 2223,32718237,"Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.","AIMS Statins are pivotal to the secondary prevention of major adverse cardiovascular events, but some patients are statin-intolerant. We examined the effects of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab on the risk of major adverse cardiovascular events according to the intensity of background statin treatment. METHODS AND RESULTS The ODYSSEY OUTCOMES trial compared alirocumab with placebo in 18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented). The primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina. Median follow-up was 2.8 years. Baseline statin treatment was high-intensity (88.8%), low/moderate-intensity (8.7%) or none (2.4%). Median baseline low-density lipoprotein cholesterol was 86, 89 and 139 mg/dL ( P  < 0.001) in these statin treatment categories, respectively. Alirocumab produced similar relative reductions in low-density lipoprotein cholesterol from baseline across statin treatment subgroups, but the mean absolute reductions differed (52.9, 56.7 and 86.1 mg/dL, respectively; P  < 0.001). With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively). Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80-0.96; 0.68, 0.49-0.94; and 0.65, 0.44-0.97, respectively; P interaction  = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34-2.16; 3.16%, 0.38-5.94; 7.97%, 0.42-15.51; P interaction  = 0.106). CONCLUSIONS PCSK9 inhibition with alirocumab reduces the relative risk of major adverse cardiovascular events after acute coronary syndrome irrespective of background statin treatment. However, patients on no statin are at high absolute risk for recurrent major adverse cardiovascular events; alirocumab substantially reduces that risk. PCSK9 inhibition may be an important therapeutic strategy for statin-intolerant patients with acute coronary syndrome.",2020,"Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80-0.96; 0.68, 0.49-0.94; and 0.65, 0.44-0.97, respectively; P interaction  = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34-2.16; 3.16%, 0.38-5.94; 7.97%, 0.42-15.51; P interaction  = 0.106). ","['statin-intolerant patients with acute coronary syndrome', '18,924 patients with acute coronary syndrome and dyslipidaemia despite intensive or maximum-tolerated statin treatment (including no statin if intolerance was documented']","['alirocumab', 'Alirocumab', 'proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab', 'alirocumab with placebo', 'placebo']","['low-density lipoprotein cholesterol', 'relative risk of major adverse cardiovascular events', 'primary outcome (major adverse cardiovascular events) comprised coronary heart disease death, non-fatal myocardial infarction, ischaemic stroke, or unstable angina', 'incidence of major adverse cardiovascular events', 'Median baseline low-density lipoprotein cholesterol', 'major adverse cardiovascular events']","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemia'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C1301725', 'cui_str': 'Documented'}]","[{'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C1174937', 'cui_str': 'PCSK9 protein, human'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",18924.0,0.262183,"Alirocumab reduced major adverse cardiovascular events in each statin subgroup (hazard ratio 0.88, 95% confidence interval (CI) 0.80-0.96; 0.68, 0.49-0.94; and 0.65, 0.44-0.97, respectively; P interaction  = 0.14) with a gradient of absolute risk reduction: 1.25%, 95% CI 0.34-2.16; 3.16%, 0.38-5.94; 7.97%, 0.42-15.51; P interaction  = 0.106). ","[{'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Argentina.'}, {'ForeName': 'Qian H', 'Initials': 'QH', 'LastName': 'Li', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, USA.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, USA.""}, {'ForeName': 'Vera A', 'Initials': 'VA', 'LastName': 'Bittner', 'Affiliation': 'Division of Cardiovascular Disease, University of Alabama at Birmingham, USA.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Baccara-Dinet', 'Affiliation': 'Sanofi R&D, Montpellier, France.'}, {'ForeName': 'Shaun G', 'Initials': 'SG', 'LastName': 'Goodman', 'Affiliation': 'Canadian VIGOUR Centre, University of Alberta, Canada.'}, {'ForeName': 'J Wouter', 'Initials': 'JW', 'LastName': 'Jukema', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, The Netherlands.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Kimura', 'Affiliation': 'Kyoto University, Graduate School of Medicine, Japan.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Parkhomenko', 'Affiliation': 'MD Strazhesko Institute of Cardiology, AMS of Ukraine, Ukraine.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, USA.'}, {'ForeName': 'Željko', 'Initials': 'Ž', 'LastName': 'Reiner', 'Affiliation': 'University Hospital Center Zagreb, University of Zagreb, Croatia.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Roe', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Szarek', 'Affiliation': 'State University of New York, Downstate School of Public Health, USA.'}, {'ForeName': 'Hung-Fat', 'Initials': 'HF', 'LastName': 'Tse', 'Affiliation': ""Queen Mary Hospital, Hong Kong, Special Administrative Region of the People's Republic of China.""}, {'ForeName': 'Harvey D', 'Initials': 'HD', 'LastName': 'White', 'Affiliation': 'Green Lane Cardiovascular Services, Auckland City Hospital, New Zealand.'}, {'ForeName': 'Doron', 'Initials': 'D', 'LastName': 'Zahger', 'Affiliation': 'Soroka University Medical Center, Ben Gurion University of the Negev, Israel.'}, {'ForeName': 'Andreas M', 'Initials': 'AM', 'LastName': 'Zeiher', 'Affiliation': 'Department of Medicine III, Goethe University, Germany.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, USA.'}, {'ForeName': 'Ph Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Université de Paris, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of preventive cardiology,['10.1177/2047487320941987'] 2224,32718248,"Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial.",,2020,,[],"['Evolocumab', 'Placebo']",['Atherogenic Lipoproteins'],[],"[{'cui': 'C3529352', 'cui_str': 'evolocumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023820', 'cui_str': 'Lipoprotein'}]",,0.111008,,"[{'ForeName': 'Thorsten M', 'Initials': 'TM', 'LastName': 'Leucker', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Blaha', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Jones', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Vavuranakis', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Marlene S', 'Initials': 'MS', 'LastName': 'Williams', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Lai', 'Affiliation': 'Department of Radiology, Johns Hopkins University School of Medicine (H.L.), Baltimore, Maryland.'}, {'ForeName': 'Thomas H', 'Initials': 'TH', 'LastName': 'Schindler', 'Affiliation': 'Mallinckrodt Institute of Radiology, Division of Nuclear Medicine, Washington University School of Medicine, Washington University in St. Louis, MO (T.H.S.).'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Latina', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Schulman', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Gerstenblith', 'Affiliation': 'Division of Cardiology, Department of Medicine (T.M.L., M.J.B., S.R.J., M.A.V., M.S.W., J.L., S.P.S., G.G.), Baltimore, Maryland.'}]",Circulation,['10.1161/CIRCULATIONAHA.120.046320'] 2225,32718308,"Recruitment, experience, and retention among women with HIV and hazardous drinking participating in a clinical trial.","BACKGROUND Despite efforts by the NIH to enhance the participation of women and minorities in clinical research, women with HIV continue to remain underrepresented in alcohol intervention research. The purpose of this study is to better understand the reasons why women with HIV and hazardous drinking participated in the WHAT-IF? study and to discuss their experience (positive or negative) in the study. The WHAT-IF? study was a randomized clinical trial that evaluated pharmacotherapy for a reduction in drinking among women with HIV. METHODS Convenience and theoretical sampling were used to recruit women with HIV and hazardous drinking to complete qualitative interviews. These women had previously completed a clinical alcohol intervention trial and had consented to be contacted in the future for study-related purposes. The biopsychosocial model was used to frame the interview questions that assessed multiple determinants of drinking behavior and helped explain linkages to broader health constructs. RESULTS A total of 20 women with HIV and hazardous drinking completed the qualitative interview. Several factors were identified by the women as influential in their decision to participate in the WHAT-IF? study, such as the ability to quit or reduce their drinking to nonhazardous levels (biological), the ability to gain knowledge or a greater understanding of the negative effects of hazardous drinking on HIV disease progression (psychological), and peer pressure and monetary compensation (social). Also, the women identified factors (positive or negative) associated with their clinical trial experience, such as the effects of the study medication on the woman's body (biological), thoughts and feelings toward study procedures (i.e. medication, lab work, study assessments) and the length of the study (psychological), and the interactions with the WHAT-IF? study staff (social). CONCLUSION Recruiting and retaining women with HIV in alcohol intervention research remains a challenge. Findings from this study suggest that women with HIV who are hazardous drinkers may benefit from participating in research studies that could help them to reduce or quit their drinking, increase their knowledge about specific behavior changes, and earn monetary compensation. Also, positive staff interactions may be instrumental in retaining minority women in alcohol intervention research.",2020,Several factors were identified by the women as influential in their decision to participate in the WHAT-IF?,"['women had previously completed a clinical alcohol intervention trial and had consented to be contacted in the future for study-related purposes', 'women with HIV and hazardous drinking participated in the WHAT-IF', 'women with HIV and hazardous drinking participating in a clinical trial', 'women with HIV', '20 women with HIV and hazardous drinking completed the qualitative interview', 'women with HIV who are hazardous drinkers', 'women with HIV and hazardous drinking to complete qualitative interviews']",['pharmacotherapy'],"['HIV disease progression (psychological), and peer pressure and monetary compensation (social']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0016884', 'cui_str': 'Future'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C1285529', 'cui_str': 'Purpose'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0205556', 'cui_str': 'Qualitative'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1141957', 'cui_str': 'HIV disease progression'}, {'cui': 'C0562366', 'cui_str': 'Pressured by peers'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}]",20.0,0.0342862,Several factors were identified by the women as influential in their decision to participate in the WHAT-IF?,"[{'ForeName': 'Shantrel S', 'Initials': 'SS', 'LastName': 'Canidate', 'Affiliation': 'University of Florida, College of Public Health and Health Professions, 2004 Mowry Road PO Box 100231, Gainesville, FL, 32610-0182, USA. ssc1987@phhp.ufl.edu.'}, {'ForeName': 'Christa L', 'Initials': 'CL', 'LastName': 'Cook', 'Affiliation': 'College of Nursing, University of Central Florida, Orlando, FL, 32816, USA.'}, {'ForeName': 'Deepthi', 'Initials': 'D', 'LastName': 'Varma', 'Affiliation': 'University of Florida, College of Public Health and Health Professions, 2004 Mowry Road PO Box 100231, Gainesville, FL, 32610-0182, USA.'}, {'ForeName': 'Giselle D', 'Initials': 'GD', 'LastName': 'Carnaby', 'Affiliation': 'College of Health Professions and Sciences, University of Central Florida, Orlando, FL, 32816, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Ennis', 'Affiliation': 'College of Medicine, Florida State University, Tallahassee, FL, 32304, USA.'}, {'ForeName': 'Nichole E', 'Initials': 'NE', 'LastName': 'Stetten', 'Affiliation': 'University of Florida, College of Public Health and Health Professions, 2004 Mowry Road PO Box 100231, Gainesville, FL, 32610-0182, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Cook', 'Affiliation': 'University of Florida, College of Public Health and Health Professions, 2004 Mowry Road PO Box 100231, Gainesville, FL, 32610-0182, USA.'}]",BMC public health,['10.1186/s12889-020-09233-z'] 2226,32718426,Use of Computer-Assisted Instrument Guidance Technology by Student Registered Nurse Anesthetists for Simulated Invasive Procedures.,"This study was conducted to determine if computer-assisted instrument guidance (CAIG, Clear Guide Medical), with an optical tracking mechanism, enhances simulated transversus abdominis plane (TAP) block performance in a porcine model by novice student registered nurse anesthetists (SRNAs) compared with standalone ultrasonography (US). In a crossover design, 26 students were randomly assigned into 2 groups: US only and CAIG. Performance was assessed using a task-specific checklist survey tool and a global rating scale to assess performance. Time to hydrodissection and number of insertion attempts were recorded. A pre-procedure and postprocedure survey obtained participants' demographics and measured overall experience. Results revealed higher mean scores for all items in the global rating scale and overall performance (P = .010). The checklist survey results indicated no significant between-group differences. The CAIG group was observed to have significantly lower simulated block performance times (P = .037) and number of attempts (P = .002). The postprocedure survey results showed most participants (88%) reported an enhanced experience using the CAIG. Use of the CAIG showed favorable results in novice SRNAs performing the simulated block. Procedure performance, number of attempts, and time to complete were significantly lower, with a strong preference for the CAIG system.",2020,Results revealed higher mean scores for all items in the global rating scale and overall performance (P = .010).,['26 students'],"['computer-assisted instrument guidance (CAIG, Clear Guide Medical', 'US only and CAIG', 'standalone ultrasonography (US']","['global rating scale and overall performance', 'simulated block performance times', 'Procedure performance, number of attempts, and time to complete', 'Time to hydrodissection and number of insertion attempts']","[{'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]",26.0,0.0170887,Results revealed higher mean scores for all items in the global rating scale and overall performance (P = .010).,"[{'ForeName': 'Shayne D', 'Initials': 'SD', 'LastName': 'Hauglum', 'Affiliation': 'is an assistant professor of clinical at the University of Miami School of Nursing and Health Studies, Coral Gables, Florida. Email: s.hauglum@umiami.edu.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Vera', 'Affiliation': 'is a full-time Doctor of Philosophy student at Vanderbilt University School of Nursing in Nashville, Tennessee, with a research focus on safe, high-quality patient care in nonhospital settings. She is a practicing nurse anesthetist in hospital, office-based, and ambulatory settings throughout South Florida.'}, {'ForeName': 'Steve L', 'Initials': 'SL', 'LastName': 'Alves', 'Affiliation': 'serves as an associate professor of anesthesiology at Barry University College of Nursing and Health Sciences, Miami Shores, Florida. Email: stevelalves@gmail.com.'}, {'ForeName': 'Connie', 'Initials': 'C', 'LastName': 'Tran', 'Affiliation': 'is a recent graduate of the Nurse Anesthesia Program at the University of Miami School of Nursing and Health Studies. Email: cxt401@miami.edu.'}]",AANA journal,[] 2227,32718515,Promotion of Preconception Care Among Adolescents and Young Adults by Conversational Agent.,"PURPOSE Preconception care is important for all women to improve infant and maternal health outcomes and may be especially important for adolescents and young adults. This study assesses the acceptance, usability, and use of an automated intervention to screen women on 108 preconception care risks and address them over the course of a year via a Web-based virtual animated health counselor and compares these measures for the adolescent and young adult users aged 18-25 years with those of users aged 26-34 years. We hypothesize that the younger cohort will have significantly greater use of and satisfaction with the online intervention. METHODS A randomized controlled trial involving a national sample of 528 women was conducted. We present a secondary data analysis on the system use and self-reported usability and satisfaction of the 79 women aged 18-25 years randomized to the intervention group, compared with the 183 women aged 26-34 years in the intervention group. Participants were required to self-identify as female, black or African American, aged 18-34 years, not pregnant, and English-speaking and were recruited through a variety of advertisements and outreach activities. RESULTS Of the adolescent and young adult participants (aged 18-25 years) enrolled and randomized to the intervention, 20.25% of participants accessed the system 0 times; 29.11%, 1-3 times; and 50.63%, >3 times over the course of a year. At the end of the year, almost all (96.4%) indicated they had either acted on recommendations made by the agent or planned to. Most (75.0%) said they would recommend the system to someone they knew. There were no significant differences between the two age groups on intervention use or satisfaction. CONCLUSIONS Web-based conversational agents are a viable medium for delivering longitudinal preconception care counseling to adolescents and young adults.",2020,"There were no significant differences between the two age groups on intervention use or satisfaction. ","['Participants were required to self-identify as female, black or African American, aged 18-34 years, not pregnant, and English-speaking and were recruited through a variety of advertisements and outreach activities', 'adolescents and young adults', 'Of the adolescent and young adult participants (aged 18-25 years', 'screen women on 108 preconception care risks and address them over the course of a year via a Web-based virtual animated health counselor and compares these measures for the adolescent and young adult users aged 18-25 years with those of users aged 26-34 years', '79 women aged 18-25 years randomized to the intervention group, compared with the 183 women aged 26-34 years in the intervention group', 'national sample of 528 women was conducted', 'Adolescents and Young Adults by Conversational Agent']",['Preconception Care'],['intervention use or satisfaction'],"[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0232973', 'cui_str': 'Not pregnant'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0949214', 'cui_str': 'Advertisements'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0085284', 'cui_str': 'Preconception care'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1571885', 'cui_str': 'Professional counselor'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0039828', 'cui_str': 'Theses'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C0085284', 'cui_str': 'Preconception care'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",528.0,0.06694,"There were no significant differences between the two age groups on intervention use or satisfaction. ","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Bickmore', 'Affiliation': 'Khoury College of Computer Sciences, Northeastern University, Boston, Massachusetts. Electronic address: bickmore@ccs.neu.edu.'}, {'ForeName': 'Zhe', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Khoury College of Computer Sciences, Northeastern University, Boston, Massachusetts.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Reichert', 'Affiliation': 'Department of Government, Harvard University, Cambridge, Massachusetts.'}, {'ForeName': 'Clevanne', 'Initials': 'C', 'LastName': 'Julce', 'Affiliation': 'Department of Family Medicine, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Jack', 'Affiliation': 'Department of Family Medicine, Boston Medical Center/Boston University School of Medicine, Boston, Massachusetts.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2019.09.006'] 2228,32718528,"Aprepitant in the Treatment of Subacute Sclerosing Panencephalitis: A Randomized, Double-Blind, Placebo-Controlled Study.","BACKGROUND Aprepitant is a neurokinin-1 receptor antagonist approved for the treatment of chemotherapy-induced nausea. We aimed to investigate the safety and efficacy of aprepitant in patients with subacute sclerosing panencephalitis. METHODS A randomized, double-blind, placebo-controlled study was conducted in patients with subacute sclerosing panencephalitis assigned to receive two courses of aprepitant 250 mg/day orally or placebo for 15 days with an interval of two months between courses. Primary end points were safety and tolerability, and secondary end point was clinical improvement or stabilization assessed by subacute sclerosing panencephalitis scoring system. Electroencephalography (EEG), brain magnetic resonance imaging, and cerebrospinal fluid measles-specific immunoglobulin G index were evaluated before and after treatment. RESULTS Sixty-two patients with subacute sclerosing panencephalitis were allocated to aprepitant (n = 31, median age 18 years) or placebo (n = 31, median age 22 years) group. Fifteen patients left the study within the first six months and 12 patients left between six and 12 months. Aprepitant was well tolerated and treatment-associated adverse events were similar to those described in the treatment of nausea. Clinical status at six and 12 months' follow-up did not differ between aprepitant and placebo groups. Post-treatment EEG scores at 12 months were better in the aprepitant group (P = 0.015). Cerebral atrophy on magnetic resonance imaging increased in both groups, whereas measles-specific immunoglobulin G index decreased in the placebo group. CONCLUSIONS In this first clinical trial of aprepitant treatment in patients with subacute sclerosing panencephalitis, the drug was safe and well tolerated. No clinical effect was observed. A modest improvement in EEG findings might justify trials for longer periods because EEG changes can precede clinical findings in subacute sclerosing panencephalitis.",2020,Post-treatment EEG scores at 12 months were better in the aprepitant group (P = 0.015).,"['Sixty-two patients with subacute sclerosing panencephalitis', 'patients with subacute sclerosing panencephalitis', 'Subacute Sclerosing Panencephalitis', 'Fifteen patients left the study within the first six\xa0months and 12 patients left between six and 12\xa0months']","['Placebo', 'aprepitant 250\xa0mg/day orally or placebo', 'placebo']","['Cerebral atrophy on magnetic resonance imaging', 'safety and efficacy', 'safety and tolerability, and secondary end point was clinical improvement or stabilization assessed by subacute sclerosing panencephalitis scoring system', 'measles-specific immunoglobulin G index', 'tolerated and treatment-associated adverse events', 'Electroencephalography (EEG), brain magnetic resonance imaging, and cerebrospinal fluid measles-specific immunoglobulin G index', 'nausea', 'safe and well tolerated']","[{'cui': 'C4517835', 'cui_str': '62'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038522', 'cui_str': 'Subacute sclerosing panencephalitis'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1176306', 'cui_str': 'aprepitant'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0235946', 'cui_str': 'Cerebral atrophy'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0038522', 'cui_str': 'Subacute sclerosing panencephalitis'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0358334', 'cui_str': 'Specific immunoglobulins'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0025007', 'cui_str': 'Measles'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",62.0,0.342205,Post-treatment EEG scores at 12 months were better in the aprepitant group (P = 0.015).,"[{'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Oncel', 'Affiliation': 'Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey. Electronic address: dribrahimoncel@gmail.com.'}, {'ForeName': 'Mesut', 'Initials': 'M', 'LastName': 'Sancar', 'Affiliation': 'Faculty of Pharmacy, Marmara University, Istanbul, Turkey.'}, {'ForeName': 'Bahadir', 'Initials': 'B', 'LastName': 'Konuskan', 'Affiliation': 'Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey; Pediatric Neurology Clinic, Ministry of Health Mardin Public Hospital, Mardin, Turkey.'}, {'ForeName': 'Filiz', 'Initials': 'F', 'LastName': 'Arioz', 'Affiliation': 'Analytic Chemistry, Istanbul, Turkey.'}, {'ForeName': 'Songul', 'Initials': 'S', 'LastName': 'Tezcan', 'Affiliation': 'Faculty of Pharmacy, Marmara University, Istanbul, Turkey.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Arman-Kandirmaz', 'Affiliation': 'School of Applied Disciplines, Marmara University, Istanbul, Turkey.'}, {'ForeName': 'Safak', 'Initials': 'S', 'LastName': 'Parlak', 'Affiliation': 'Department of Radiology, Hacettepe University, Ankara, Turkey.'}, {'ForeName': 'Ekim', 'Initials': 'E', 'LastName': 'Gumeler', 'Affiliation': 'Department of Radiology, Hacettepe University, Ankara, Turkey.'}, {'ForeName': 'Banu', 'Initials': 'B', 'LastName': 'Anlar', 'Affiliation': 'Department of Pediatric Neurology, Hacettepe University, Ankara, Turkey.'}]",Pediatric neurology,['10.1016/j.pediatrneurol.2020.05.009'] 2229,32718555,Incidence and Prognostic Impact of Incomplete Revascularization Documented by Coronary Angiography 1 Year After Coronary Artery Bypass Grafting.,"Complete revascularization (CR) at the time of coronary artery bypass graft (CABG) surgery improves long-term cardiac outcomes. No studies have previously reported angiographically confirmed CR rates post-CABG. This study's aim was to assess the impact upon long-term outcomes of CR versus incomplete revascularization (IR), confirmed by coronary angiography 1 year after CABG. Randomized On/Off Bypass Study patients who returned for protocol-specified 1-year post-CABG coronary angiograms were included. Patients with a widely patent graft supplying the major diseased artery within each diseased coronary territory were considered to have CR. Outcomes were all-cause mortality and major adverse cardiovascular events (MACE; all-cause mortality, nonfatal myocardial infarction, repeat revascularization) over the 4 years after angiography. Of the 1,276 patients, 756 (59%) had CR and 520 (41%) had IR. MACE was 13% CR versus 26% IR, p <0.001. This difference was driven by fewer repeat revascularizations (5% CR vs 18% IR; p <0.001). There were no differences in mortality (7.1% CR vs 8.1% IR, p = 0.13) or myocardial infarction (4% in both). Adjusted multivariable models confirmed CR was associated with reduced MACE (odds ratio 0.44, 95% confidence interval 0.33 to 0.58, p <0.01), but had no impact on mortality. In conclusion, CR confirmed by post-CABG angiography was associated with improved MACE but not mortality. Repeat revascularization of patients with IR, driven by knowledge of the research angiography results, may have ameliorated potential mortality differences.",2020,"Adjusted multivariable models confirmed CR was associated with reduced MACE (odds ratio 0.44, 95% confidence interval 0.33 to 0.58, p <0.01), but had no impact on mortality.","['Bypass Study patients who returned for protocol-specified 1-year post-CABG coronary angiograms were included', 'Patients with a widely patent graft supplying the major diseased artery within each diseased coronary territory', 'After Coronary Artery Bypass Grafting']","['CR versus incomplete revascularization (IR', 'Coronary Angiography 1 Year', 'Complete revascularization (CR', 'coronary artery bypass graft (CABG) surgery', 'MACE']","['repeat revascularizations', 'cause mortality and major adverse cardiovascular events (MACE; all-cause mortality, nonfatal myocardial infarction, repeat revascularization', 'mortality', 'myocardial infarction']","[{'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332156', 'cui_str': 'Return to'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030650', 'cui_str': 'Patents'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]",1276.0,0.137461,"Adjusted multivariable models confirmed CR was associated with reduced MACE (odds ratio 0.44, 95% confidence interval 0.33 to 0.58, p <0.01), but had no impact on mortality.","[{'ForeName': 'Brack', 'Initials': 'B', 'LastName': 'Hattler', 'Affiliation': 'Department of Medicine, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO; Department of Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: brack.hattler@va.gov.'}, {'ForeName': 'Frederick L', 'Initials': 'FL', 'LastName': 'Grover', 'Affiliation': 'Department of Surgery, University of Colorado School of Medicine, Aurora, CO; Department of Surgery, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO.'}, {'ForeName': 'Todd', 'Initials': 'T', 'LastName': 'Wagner', 'Affiliation': 'Department of Veterans Affairs Palo Alto Health Economics Resource Center, Palo Alto, CA; Department of Surgery, Stanford University, Stanford, CA.'}, {'ForeName': 'Robert B', 'Initials': 'RB', 'LastName': 'Hawkins', 'Affiliation': 'Department of Surgery, University of Virginia, Charlottesville, VA.'}, {'ForeName': 'Jacquelyn A', 'Initials': 'JA', 'LastName': 'Quin', 'Affiliation': 'Department of Surgery, Veterans Affairs Boston Healthcare System, West Roxbury, MA.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Collins', 'Affiliation': 'Cooperative Studies Program Coordinating Center, Perry Point Veterans Affairs Medical Center, Perry Point, MD.'}, {'ForeName': 'Muath', 'Initials': 'M', 'LastName': 'Bishawi', 'Affiliation': 'Research and Development Office, Northport Veterans Affairs Medical Center, Northport, NY; Department of Surgery, Duke University, Durham, NC.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Almassi', 'Affiliation': 'Department of Surgery, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, WI; Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.'}, {'ForeName': 'Annie Laurie', 'Initials': 'AL', 'LastName': 'Shroyer', 'Affiliation': 'Research and Development Office, Northport Veterans Affairs Medical Center, Northport, NY.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The American journal of cardiology,['10.1016/j.amjcard.2020.06.047'] 2230,32718692,Exercise and Testosterone Countermeasures to Mitigate Metabolic Changes during Bed Rest.,"BACKGROUND/OBJECTIVES Exercise is a front-line countermeasure used to maintain astronaut health during long-duration spaceflight; however, reductions in metabolic health still occur. Accordingly, we evaluated serial changes in metabolic parameters in a spaceflight analog and evaluated the efficacy of exercise with or without the addition of low-dose testosterone treatment on mitigating adverse metabolic changes. SUBJECTS/METHODS Healthy young (<55 years) men were randomly assigned to one of three groups during 70-days of strict, diet controlled, 6° head-down bed rest: Control (CON, n=9), exercise plus testosterone countermeasure (TEX, n=8), or exercise countermeasure plus placebo (PEX, n=9). Basal metabolic rate (BMR), glucose tolerance, and insulin sensitivity were measured before, during, and after bed rest. Exercise energy expenditure and excess post-exercise oxygen consumption were measured in TEX and PEX subjects during bed rest. RESULTS Leptin decreased during bed rest (Pre to BR+0 changed from 6.9 ± 5.1, 5.8 ± 4.2, and 4.7 ± 4.1 to 7.9 ±3.6, 6.5 ± 4.6, and 4.1 ±3.0 ug• L -1 for CON, PEX, and TEX respectively). Bed rest induced a decrease in BMR (Pre to BR57 changed from 1655 ± 212, 1629 ± 108, and 1706 ± 146 to 1476 ± 166, 1668 ± 142, and 1603 ± 132 kcal • day -1 ± 95%CI for CON, PEX, and TEX respectively). Similarly, bed rest negatively affected glucose metabolism assessed by 2hr OGTT glucose (Pre to BR66 changed from 6.29 ± 0.72, 5.13 ± 0.72, and 5.87 ± 0.73 to 6.62 ± 0.72, 5.83 ± 0.72, and 7.08 ± 0.72 mmol • L -1 ± 95%CI). Reambulation following bed rest positively affected glucose tolerance in CON (2hr OGTT glucose at BR+12: 5.3 ± 0.72, 6.42 ± 0.73, and 6.04 ± 0.73 mmol • L -1 ± 95%CI). Testosterone protected against bed rest induced insulin resistance (HOMA-IR from Pre to BR+66 changed from 1.74 ± 0.54, 1.18 ± 0.55, and 1.45 ± 0.56 to 2.24 ± 0.56, 1.47 ± 0.54, and 1.07 ± 0.54). CONCLUSION This study confirmed that inactivity during 70 days of head-down bed rest adversely affects metabolic health. The daily exercise countermeasures were beneficial but not completely protective of bed rest induced decrements in metabolic health. Supplementary countermeasures such as testosterone may provide additional benefits not provided by exercise alone.",2020,"Testosterone protected against bed rest induced insulin resistance (HOMA-IR from Pre to BR+66 changed from 1.74 ± 0.54, 1.18 ± 0.55, and 1.45 ± 0.56 to 2.24 ± 0.56, 1.47 ± 0.54, and 1.07 ± 0.54). ",['Healthy young (<55 years'],"['Exercise and Testosterone Countermeasures', 'diet controlled, 6° head-down bed rest: Control (CON, n=9), exercise plus testosterone countermeasure (TEX, n=8), or exercise countermeasure plus placebo (PEX, n=9', 'testosterone', 'Testosterone']","['glucose tolerance', 'Basal metabolic rate (BMR), glucose tolerance, and insulin sensitivity', 'Leptin', 'metabolic health', 'Exercise energy expenditure and excess post-exercise oxygen consumption', 'BMR', 'insulin resistance (HOMA-IR', 'glucose metabolism']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0743195', 'cui_str': 'Dietary control'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0004910', 'cui_str': 'Bedrest'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0542499', 'cui_str': 'Measurement of basal metabolic rate'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C1979962', 'cui_str': 'After exercise'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",,0.254929,"Testosterone protected against bed rest induced insulin resistance (HOMA-IR from Pre to BR+66 changed from 1.74 ± 0.54, 1.18 ± 0.55, and 1.45 ± 0.56 to 2.24 ± 0.56, 1.47 ± 0.54, and 1.07 ± 0.54). ","[{'ForeName': 'Meghan E', 'Initials': 'ME', 'LastName': 'Downs', 'Affiliation': 'National Aeronautics and Space Administration, Houston, TX.'}, {'ForeName': 'Jessica M', 'Initials': 'JM', 'LastName': 'Scott', 'Affiliation': 'Memorial Sloan Kettering Cancer Center, New York, NY.'}, {'ForeName': 'Lori L', 'Initials': 'LL', 'LastName': 'Ploutz-Snyder', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ploutz-Snyder', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Goetchius', 'Affiliation': 'University of Houston, Houston, TX.'}, {'ForeName': 'Roxanne E', 'Initials': 'RE', 'LastName': 'Buxton', 'Affiliation': 'University of Houston, Houston, TX.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Danesi', 'Affiliation': 'University of Texas Medical Branch, Galveston, TX.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Randolph', 'Affiliation': 'University of Texas Medical Branch, Galveston, TX; Texas A&M University, College Station, TX.'}, {'ForeName': 'Randall J', 'Initials': 'RJ', 'LastName': 'Urban', 'Affiliation': 'University of Texas Medical Branch, Galveston, TX.'}, {'ForeName': 'Melinda', 'Initials': 'M', 'LastName': 'Sheffield-Moore', 'Affiliation': 'University of Texas Medical Branch, Galveston, TX; Texas A&M University, College Station, TX.'}, {'ForeName': 'E Lichar', 'Initials': 'EL', 'LastName': 'Dillon', 'Affiliation': 'University of Texas Medical Branch, Galveston, TX. Electronic address: edgar.l.dillon@nasa.gov.'}]",Life sciences in space research,['10.1016/j.lssr.2020.03.008'] 2231,32718702,Nitric oxide delivery during cardiopulmonary bypass reduces acute kidney injury: A randomized trial.,"OBJECTIVE Acute kidney injury (AKI) is a serious complication of cardiac surgery with cardiopulmonary bypass (CPB). The aim of this study was to evaluate the effects of nitric oxide (NO) supplementation to the CPB circuit on the development of cardiac surgery-associated AKI. METHODS This prospective randomized controlled study included 96 patients with moderate risk of renal complications who underwent elective cardiac surgery with CPB. The study protocol was registered at ClinicalTrials.gov (identifier NCT03527381). Patients were randomly allocated to either NO supplementation to the CPB bypass circuit (NO treatment group; n = 48) or usual care (control group; n = 48). In the NO treatment group, 40-ppm NO was administered during the entire CPB period. The primary outcome was the incidence of AKI. RESULTS NO treatment was associated with a significant decrease in AKI incidence (10 cases [20.8%] vs 20 cases [41.6%] in the control group; relative risk, 0.5; 95% confidence interval, 0.26-0.95; P = .023) and a higher median urine output during CPB (2.6 mL/kg/h [interquartile range (IQR), 2.1-5.08 mL/kg/h] vs 1.7 mL/kg/h [IQR, 0.80-2.50 mL/kg/h]; P = .0002). The median urinary neutrophil gelatinase-associated lipocalin level at 4 hours after surgery was significantly lower in the NO treatment group (1.12 ng/mL [IQR, 0.75-5.8 ng/mL] vs 4.62 ng/mL [IQR, 2.02-34.55 ng/mL]; P = .005). In the NO treatment group, concentrations of NO metabolites were significantly increased at 5 minutes postclamping, at 5 minutes after declamping, and at the end of the operation. Concentrations of proinflammatory and anti-inflammatory mediators and free plasma hemoglobin did not differ significantly between the 2 groups. CONCLUSIONS NO administration in patients at moderate risk of renal complications undergoing elective cardiac surgery with CPB was associated with a lower incidence of AKI.",2020,"The median urinary neutrophil gelatinase-associated lipocalin level at 4 hours after surgery was significantly lower in the NO treatment group (1.12 ng/mL [IQR, 0.75-5.8 ng/mL] vs 4.62 ng/mL","['patients at moderate risk of renal complications undergoing elective cardiac surgery with', '96 patients with moderate risk of renal complications who underwent elective cardiac surgery with\xa0CPB']","['cardiopulmonary bypass (CPB', 'Nitric oxide delivery', 'nitric oxide (NO) supplementation', 'cardiopulmonary bypass', 'NO supplementation to the CPB bypass circuit (NO treatment group; n\xa0=\xa048) or usual care (control group; n\xa0=\xa048', 'CPB']","['median urinary neutrophil gelatinase-associated lipocalin level', 'median urine output', 'concentrations of NO metabolites', 'Concentrations of proinflammatory and anti-inflammatory mediators and free plasma hemoglobin', 'incidence of AKI', 'AKI incidence']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332166', 'cui_str': 'Moderate risk of'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C0948712', 'cui_str': 'Free plasma haemoglobin'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}]",96.0,0.219173,"The median urinary neutrophil gelatinase-associated lipocalin level at 4 hours after surgery was significantly lower in the NO treatment group (1.12 ng/mL [IQR, 0.75-5.8 ng/mL] vs 4.62 ng/mL","[{'ForeName': 'Nikolay O', 'Initials': 'NO', 'LastName': 'Kamenshchikov', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia. Electronic address: Nikolajkamenof@mail.ru.'}, {'ForeName': 'Yana J', 'Initials': 'YJ', 'LastName': 'Anfinogenova', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.'}, {'ForeName': 'Boris N', 'Initials': 'BN', 'LastName': 'Kozlov', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; Department of Cardiovascular Surgery, Siberian State Medical University, Tomsk, Russia.'}, {'ForeName': 'Yulia S', 'Initials': 'YS', 'LastName': 'Svirko', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; Department of Cardiovascular Surgery, Siberian State Medical University, Tomsk, Russia.'}, {'ForeName': 'Stanislav E', 'Initials': 'SE', 'LastName': 'Pekarskiy', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.'}, {'ForeName': 'Vladimir V', 'Initials': 'VV', 'LastName': 'Evtushenko', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.'}, {'ForeName': 'Vladimir A', 'Initials': 'VA', 'LastName': 'Lugovsky', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.'}, {'ForeName': 'Vladimir M', 'Initials': 'VM', 'LastName': 'Shipulin', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; Department of Cardiovascular Surgery, Siberian State Medical University, Tomsk, Russia.'}, {'ForeName': 'Vladimir V', 'Initials': 'VV', 'LastName': 'Lomivorotov', 'Affiliation': 'Department of Anesthesiology and Critical Care, Meshalkin National Medical Research Center, Novosibirsk, Russia.'}, {'ForeName': 'Yuriy K', 'Initials': 'YK', 'LastName': 'Podoksenov', 'Affiliation': 'Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; Department of Cardiovascular Surgery, Siberian State Medical University, Tomsk, Russia.'}]",The Journal of thoracic and cardiovascular surgery,['10.1016/j.jtcvs.2020.03.182'] 2232,32718724,Effects of dobutamine and phenylephrine on cerebral perfusion in patients undergoing cerebral bypass surgery: a randomised crossover trial.,"BACKGROUND Patients undergoing cerebral bypass surgery are prone to cerebral hypoperfusion. Currently, arterial blood pressure is often increased with vasopressors to prevent cerebral ischaemia. However, this might cause vasoconstriction of the graft and cerebral vasculature and decrease perfusion. We hypothesised that cardiac output, rather than arterial blood pressure, is essential for adequate perfusion and aimed to determine whether dobutamine administration resulted in greater graft perfusion than phenylephrine administration. METHODS This randomised crossover study included 10 adult patients undergoing cerebral bypass surgery. Intraoperatively, patients randomly and sequentially received dobutamine to increase cardiac index or phenylephrine to increase mean arterial pressure (MAP). An increase of >10% in cardiac index or >10% in MAP was targeted, respectively. Before both interventions, a reference phase was implemented. The primary outcome was the absolute difference in graft flow between the reference and intervention phase. We compared the absolute flow difference between each intervention and constructed a random-effect linear regression model to explore treatment and carry-over effects. RESULTS Graft flow increased with a median of 4.1 (inter-quartile range [IQR], 1.7-12.0] ml min -1 ) after dobutamine administration and 3.6 [IQR, 1.3-7.8] ml min -1 after phenylephrine administration (difference -0.6 ml min -1 ; 95% confidence interval [CI], -14.5 to 5.3; P=0.441). There was no treatment effect (0.9 ml min -1 ; 95% CI, 0.0-20.1; P=0.944) and no carry-over effect. CONCLUSIONS Both dobutamine and phenylephrine increased graft flow during cerebral bypass surgery, without a preference for one method over the other. CLINICAL TRIAL REGISTRATION Netherlands Trial Register, NL7077 (https://www.trialregister.nl/trial/7077).",2020,"There was no treatment effect (0.9 ml min -1 ; 95% CI, 0.0-20.1; P=0.944) and no carry-over effect. ","['Patients undergoing', '10 adult patients undergoing cerebral bypass surgery', 'patients undergoing cerebral bypass surgery']","['cerebral bypass surgery', 'phenylephrine', 'dobutamine', 'dobutamine and phenylephrine']","['mean arterial pressure (MAP', 'graft perfusion', 'arterial blood pressure', 'graft flow', 'cerebral perfusion', 'Graft flow', 'absolute difference in graft flow']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C1536078', 'cui_str': 'Bypass surgery'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C1536078', 'cui_str': 'Bypass surgery'}, {'cui': 'C0031469', 'cui_str': 'Phenylephrine'}, {'cui': 'C0012963', 'cui_str': 'Dobutamine'}]","[{'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C1272641', 'cui_str': 'Systemic arterial pressure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}]",10.0,0.476268,"There was no treatment effect (0.9 ml min -1 ; 95% CI, 0.0-20.1; P=0.944) and no carry-over effect. ","[{'ForeName': 'Annemarie', 'Initials': 'A', 'LastName': 'Akkermans', 'Affiliation': 'Department of Anaesthesiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: a.akkermans@umcutrecht.nl.'}, {'ForeName': 'Judith A R', 'Initials': 'JAR', 'LastName': 'van Waes', 'Affiliation': 'Department of Anaesthesiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Tristan P C', 'Initials': 'TPC', 'LastName': 'van Doormaal', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Centre, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Neurosurgery, University Hospital Zürich, Zurich, Switzerland.'}, {'ForeName': 'Eric E C', 'Initials': 'EEC', 'LastName': 'de Waal', 'Affiliation': 'Department of Anaesthesiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Gabriël J E', 'Initials': 'GJE', 'LastName': 'Rinkel', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Centre, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'van der Zwan', 'Affiliation': 'Department of Neurology and Neurosurgery, Brain Centre, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Cor J', 'Initials': 'CJ', 'LastName': 'Kalkman', 'Affiliation': 'Department of Anaesthesiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}, {'ForeName': 'Wilton A', 'Initials': 'WA', 'LastName': 'van Klei', 'Affiliation': 'Department of Anaesthesiology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.'}]",British journal of anaesthesia,['10.1016/j.bja.2020.05.040'] 2233,32718746,"Electromyographic biofeedback improves upper extremity function: a randomized, single-blinded, controlled trial.","OBJECTIVE To examine the effects of a 6-week surface electromyographic biofeedback intervention on the re-learning of upper extremity motor function in subjects with paretic upper extremity after stroke. DESIGN A randomized controlled trial. SETTING State Centre of Attention to Brain Injury, Madrid, Spain. PARTICIPANTS Thirty-eight participants in the sub-acute post-stroke stage were recruited and randomly allocated into either the surface electromyographic biofeedback (sEMG-BFB) or sham biofeedback (BFB) groups. INTERVENTIONS The sEMG-BFB group (n=19) received the intervention focused on re-learning scapulothoracic control during arm-reaching tasks involving shoulder abduction. The sham BFB group (n=19) received a sham intervention. OUTCOME MEASURES Upper extremity motor function assessed using the Fugl-Meyer Assessment-Upper Extremity Scale (66 points), the glenohumeral active range of motion, and the electromyographic amplitude signal of the middle deltoid and upper trapezius muscles were collected at baseline, after the intervention, and at the one-month follow-up. RESULTS Compared with the sham BFB group, the sEMG-BFB group experienced significant increases in upper extremity motor function after the intervention. The mean differences between groups were as follows: 4.79 points (95% CI 2.92 to 6.66) after the intervention; 6.55 points (95% CI 3.75 to 9.34) at the one-month follow-up; improved active range of motion 15.75 points (95% CI 6 to 30) after the intervention and electromyographic activity in the upper trapezius muscle changed in favour of the sEMG-BFB. CONCLUSIONS In the short term, a 6-week sEMG-BFB intervention effectively improved paretic upper limb motor function. Future research is needed to determine if the sEMG-BFB intervention has any long-term effects. Clinical trial number registration: NCT02974465 (ClinicalTrials.gov).",2020,"In the short term, a 6-week sEMG-BFB intervention effectively improved paretic upper limb motor function.","['Thirty-eight participants in the sub-acute post-stroke stage', 'subjects with paretic upper extremity after stroke', 'State Centre of Attention to Brain Injury, Madrid, Spain']","['sEMG-BFB intervention', 'sEMG-BFB', 'intervention focused on re-learning scapulothoracic control during arm-reaching tasks involving shoulder abduction', 'surface electromyographic biofeedback intervention', 'Electromyographic biofeedback', 'sham BFB', 'surface electromyographic biofeedback (sEMG-BFB) or sham biofeedback (BFB) groups', 'sham intervention']","['Fugl-Meyer Assessment-Upper Extremity Scale', 'paretic upper limb motor function', 'glenohumeral active range of motion, and the electromyographic amplitude signal of the middle deltoid and upper trapezius muscles', 'upper extremity function', 'upper extremity motor function']","[{'cui': 'C0450361', 'cui_str': '38'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0270611', 'cui_str': 'Brain injury'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0204624', 'cui_str': 'Electromyographic biofeedback'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",,0.0995422,"In the short term, a 6-week sEMG-BFB intervention effectively improved paretic upper limb motor function.","[{'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Lirio-Romero', 'Affiliation': 'Faculty of Physiotherapy and Nursing, University of Castilla-La Mancha, Toledo, Spain; State Center of Attention to Brain Injury, Madrid, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Torres-Lacomba', 'Affiliation': ""Physiotherapy in Women's Health (FPSM) Research Group, University of Alcalá, Madrid, Spain. Electronic address: maria.torres@uah.es.""}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Gómez-Blanco', 'Affiliation': 'State Center of Attention to Brain Injury, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Acero-Cortés', 'Affiliation': 'State Center of Attention to Brain Injury, Madrid, Spain.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Retana-Garrido', 'Affiliation': 'State Center of Attention to Brain Injury, Madrid, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'de la Villa-Polo', 'Affiliation': ""Physiotherapy in Women's Health (FPSM) Research Group, University of Alcalá, Madrid, Spain.""}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Sánchez-Sánchez', 'Affiliation': ""Physiotherapy in Women's Health (FPSM) Research Group, University of Alcalá, Madrid, Spain.""}]",Physiotherapy,['10.1016/j.physio.2020.02.002'] 2234,32718783,Effect of a Peer-led Lifestyle Intervention on Individuals With Normal Weight Obesity: Insights From the Kerala Diabetes Prevention Program.,"PURPOSE Normal weight obesity (NWO) is a unique phenotype of obesity associated with high cardiovascular mortality. There is limited literature on assessing the effect of therapeutic interventions on the cardiometabolic health of these individuals. We studied the effect of a peer-led lifestyle intervention on key cardiometabolic parameters (blood glucose, blood pressure, and plasma lipids) in individuals with NWO. METHODS This study is a secondary data analysis of the Kerala Diabetes Prevention Program, a cluster-randomized controlled study that involves a peer-led, real-life lifestyle intervention for individuals from the community between the ages of 30 and 60 years with a high diabetes risk. Participants underwent a rigorous cardiometabolic evaluation at baseline and at 2-year follow-up. FINDINGS A total of 292 recruited individuals with NWO were randomized into the intervention (n = 159) and control (n = 133) arms. At 2 years of follow-up, there was minimal but statistically significant improvement in systolic blood pressure and serum HDL level in the intervention arm, but no statistical difference was seen in other lipid and glycemic parameters. IMPLICATIONS This study provides early evidence of the effect of a lifestyle intervention in a cohort of individuals with NWO. Only systolic blood pressure and serum HDL level had a mild favorable change in the intervention arm when compared with the control arm.",2020,Only systolic blood pressure and serum HDL level had a mild favorable change in the intervention arm when compared with the control arm.,"['cohort of individuals with NWO', 'A total of 292 recruited individuals with NWO', 'Individuals With Normal Weight Obesity', 'individuals with NWO', 'individuals from the community between the ages of 30 and 60 years with a high diabetes risk']","['Peer-led Lifestyle Intervention', 'lifestyle intervention', 'peer-led, real-life lifestyle intervention', 'peer-led lifestyle intervention']","['cardiometabolic parameters (blood glucose, blood pressure, and plasma lipids', 'systolic blood pressure and serum HDL level', 'lipid and glycemic parameters']","[{'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0376558', 'cui_str': 'Life'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1278073', 'cui_str': 'Plasma lipid measurement'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}]",292.0,0.0298572,Only systolic blood pressure and serum HDL level had a mild favorable change in the intervention arm when compared with the control arm.,"[{'ForeName': 'Nitin', 'Initials': 'N', 'LastName': 'Kapoor', 'Affiliation': 'Department of Endocrinology, Diabetes, and Metabolism, Christian Medical College & Hospital, Vellore, Tamil Nadu, India; Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, Australia. Electronic address: nitin.kapoor@cmcvellore.ac.in.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Lotfaliany', 'Affiliation': 'Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Thirunavukkarasu', 'Initials': 'T', 'LastName': 'Sathish', 'Affiliation': 'Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, Australia; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; Centre for Population Health Sciences, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.'}, {'ForeName': 'Kavumpurathu R', 'Initials': 'KR', 'LastName': 'Thankappan', 'Affiliation': 'Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Trivandrum, Kerala, India; Department of Public Health and Community Medicine, Central University, Kasaragod, Kerala, India.'}, {'ForeName': 'Robyn J', 'Initials': 'RJ', 'LastName': 'Tapp', 'Affiliation': 'Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, Australia; The School of Biomedical Engineering and Imaging Sciences, Kings College London, London, United Kingdom; Centre for Intelligent Healthcare, Faculty of Health and Life Sciences, Coventry University, United Kingdom.'}, {'ForeName': 'Nihal', 'Initials': 'N', 'LastName': 'Thomas', 'Affiliation': 'Department of Endocrinology, Diabetes, and Metabolism, Christian Medical College & Hospital, Vellore, Tamil Nadu, India.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Furler', 'Affiliation': 'Department of General Practice, Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Melbourne, Australia.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Oldenburg', 'Affiliation': 'Melbourne School of Population and Global Health, Faculty of Medicine, Dentistry, and Health Science, The University of Melbourne, Melbourne, Australia.'}]",Clinical therapeutics,['10.1016/j.clinthera.2020.06.007'] 2235,32718787,A Prospective Randomized Trial Comparing the Functional Results of Buddy Taping Versus Closed Reduction and Cast Immobilization in Patients With Fifth Metacarpal Neck Fractures.,"PURPOSE Although fifth metacarpal neck fractures are typically treated nonsurgically, most often with closed reduction and orthosis immobilization, cast immobilization may not improve outcomes compared with buddy taping without reduction. The aim of this study was to compare functional outcomes of buddy taping versus reduction and cast immobilization in patients with fifth metacarpal neck fractures. METHODS Adult patients with acute fifth metacarpal neck fractures with less than 70º volar angulation and without rotational deformity were randomly assigned to be treated either with buddy taping or a cast after closed reduction. The primary outcome was the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire score at 9 weeks. Secondary outcomes included the DASH score at 3 weeks and 1 year, range of motion of the metacarpophalangeal joint, pain, grip strength, return to work, radiographic angulation, and complication rate. RESULTS We recruited 72 patients between August 2016 and January 2018. After 3 weeks, the DASH score was significantly lower for patients treated with buddy taping (19.7 ± 19.7) compared with cast immobilization (44.6 ± 15.0). At 9 weeks, clinical outcomes in the buddy taping group were better in terms of range of motion and DASH score, with a mean difference of 6.3 points, which did not exceed the minimally clinically important difference. There were more complications in the cast immobilization group. Fracture angulation after reduction was followed by a loss of reduction at 3 weeks' follow-up and equivalent residual radiographic volar angulation was observed at 3 and 9 weeks after injury in both groups. Duration of time off from work was 28 days shorter with buddy taping compared with cast treatment. CONCLUSIONS There is no benefit to reduction and orthosis immobilization of fifth metacarpal neck fractures with an initial angulation less than 70°. Use of buddy taping and early mobilization had good clinical results as well as significant improvement in time lost from work. TYPE OF STUDY/LEVEL OF EVIDENCE Therapeutic I.",2020,"At 9 weeks, clinical outcomes in the buddy taping group were better in terms of range of motion and DASH score, with a mean difference of 6.3 points, which did not exceed the minimally clinically important difference.","['Patients With Fifth Metacarpal Neck Fractures', 'Adult patients with acute fifth metacarpal neck fractures with less than 70º volar angulation and without rotational deformity', 'patients with fifth metacarpal neck fractures', '72 patients between August 2016 and January 2018']","['buddy taping or a cast after closed reduction', 'buddy taping', 'buddy\xa0taping versus reduction and cast immobilization', 'Buddy Taping Versus Closed Reduction and Cast Immobilization']","['Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire score', 'range of motion and DASH score', 'DASH score at 3 weeks and 1 year, range of motion of the metacarpophalangeal joint, pain, grip strength, return to work, radiographic angulation, and complication rate', 'Fracture angulation', 'residual radiographic volar angulation', 'DASH score', 'Duration of time off from work']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0730166', 'cui_str': 'Fifth metacarpal bone structure'}, {'cui': 'C0262414', 'cui_str': 'Fracture of cervical spine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0445237', 'cui_str': 'Rotational'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}]","[{'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025525', 'cui_str': 'Metacarpophalangeal joint structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0333179', 'cui_str': 'Angulated'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0443349', 'cui_str': 'Volar'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0043227', 'cui_str': 'Working'}]",72.0,0.0843819,"At 9 weeks, clinical outcomes in the buddy taping group were better in terms of range of motion and DASH score, with a mean difference of 6.3 points, which did not exceed the minimally clinically important difference.","[{'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Martínez-Catalán', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Hospital Universitario Fundación Jiménez Diaz, FJD Health Research Institute, Madrid, Spain. Electronic address: natalia.martinezcat@gmail.com.'}, {'ForeName': 'Samuel', 'Initials': 'S', 'LastName': 'Pajares', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Hospital Universitario Fundación Jiménez Diaz, FJD Health Research Institute, Madrid, Spain.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Llanos', 'Affiliation': 'Clinical Research Unit, Hospital Universitario Fundación Jiménez Diaz, FJD Health Research Institute, Madrid, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Mahillo', 'Affiliation': 'Department of Statistics, Hospital Universitario Fundación Jiménez Diaz, FJD Health Research Institute, Madrid, Spain.'}, {'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Calvo', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Hospital Universitario Fundación Jiménez Diaz, FJD Health Research Institute, Madrid, Spain.'}]",The Journal of hand surgery,['10.1016/j.jhsa.2020.05.013'] 2236,32718800,Enhanced Antenatal Care: Combining one-to-one and group Antenatal Care models to increase childbirth education and address childbirth fear.,"BACKGROUND We designed and implemented a new model of care, Enhanced Antenatal Care (EAC), which offers a combined approach to midwifery-led care with six one-to-one visits and four group sessions. AIM To assess EAC in terms of women's satisfaction with care, autonomy in decision-making, and its effectiveness in lowering childbirth fear. METHODS This was a quasi-experimental controlled trial comparing 32 nulliparous women who received EAC (n=32) and usual antenatal care (n=60). We compared women's satisfaction with care and autonomy in decision-making post-intervention using chi-square test. We administered a Fear of Birth Scale pre- and post-intervention and assessed change in fear of birth in each group using the Cohen's d for effect size. To isolate the effect of EAC, we then restricted this analysis to women who did not attend classes alongside maternal care (n=13 in EAC and n=13 in usual care). FINDINGS Women's satisfaction with care in terms of monitoring their/their baby's health was similar in both groups. Women receiving EAC were more likely than those in usual care to report having received enough information about the postpartum period (75% vs 30%) and parenting (91% vs 55%). Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). CONCLUSION This study is the first to report findings on EAC and suggests that this novel model may be beneficial in terms of providing education and support, as well as lowering childbirth fear.",2020,"Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). ","['Enhanced Antenatal Care', '32 nulliparous women who received EAC (n=32) and usual antenatal care (n=60', 'women who did not attend classes alongside maternal care (n=13 in EAC and n=13 in usual care']","['EAC', 'Fear of Birth Scale pre- and post-intervention']",['fear of birth'],"[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0559294', 'cui_str': 'Did not attend'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0005615', 'cui_str': 'Birth'}]",32.0,0.0446806,"Overall, EAC was more effective than usual care in reducing fear of birth (Cohen's d=-0.21), especially among women not attending classes alongside antenatal care (Cohen's d=-0.83). ","[{'ForeName': 'Emma Marie', 'Initials': 'EM', 'LastName': 'Swift', 'Affiliation': 'Faculty of Nursing/Department of Midwifery, University of Iceland, Eirberg við Eiríksgötu, 101 Reykjavík, Iceland. Electronic address: emmas@hi.is.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Zoega', 'Affiliation': 'Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Sturlugata 8, 101 Reykjavík, Iceland; Centre for Big Data Research in Health, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Stoll', 'Affiliation': 'Division of Midwifery, University of British Columbia, Vancouver, Canada.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Avery', 'Affiliation': 'University of Minnesota, School of Nursing, Minneapolis, MN, USA.'}, {'ForeName': 'Helga', 'Initials': 'H', 'LastName': 'Gottfreðsdóttir', 'Affiliation': ""Faculty of Nursing/Department of Midwifery, University of Iceland, Eirberg við Eiríksgötu, 101 Reykjavík, Iceland; Women's Clinic, Landspitali University Hospital, 101 Reykjavik, Iceland.""}]",Women and birth : journal of the Australian College of Midwives,['10.1016/j.wombi.2020.06.008'] 2237,32718816,"First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial.","BACKGROUND Human respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in early infancy and in elderly. A pediatric vaccine against RSV would not only prevent morbidity and mortality amongst infants and young children but could also reduce transmission to elderly. The RSVΔG vaccine consists of a live-attenuated RSV that lacks the G attachment protein. RSVΔG is severely impaired in binding to host cells and exhibits reduced infectivity in preclinical studies. Intranasal immunization of cotton rats with RSVΔG vaccine protected against replication of wildtype RSV, without inducing enhanced disease. METHODS We performed a first-in-human trial with primary objective to evaluate safety and shedding of RSVΔG (6.5 log 10 CCID 50 ) after intranasal administration. Healthy adults aged between 18 and 50, with RSV neutralizing serum titers below 9.6 log 2 , received a single dose of either vaccine or placebo (n = 48, ratio 3:1). In addition to safety and tolerability, nasal viral load, and systemic and humoral immune responses were assessed at selected time points until 4 weeks after immunization. RESULTS Intranasal administration of RSVΔG was well tolerated with no findings of clinical concern. No infectious virus was detected in nasal wash samples. Similar to other live-attenuated RSV vaccines, neutralizing antibody response following inoculation was limited in seropositive adults. CONCLUSIONS A single dose of 6.5 log 10 CCID 50 of RSVΔG was safe and well-tolerated in seropositive healthy adults. RSVΔG was sufficiently attenuated but there were no signs of induction of antibodies. Safety and immunogenicity can now be explored in children and eventually in seronegative infants. Clinical trial register: NTR7173/EudraCT number 2016-002437-30.",2020,"In addition to safety and tolerability, nasal viral load, and systemic and humoral immune responses were assessed at selected time points until 4 weeks after immunization. ","['seropositive healthy adults', 'early infancy and in elderly', 'infants and young children', 'children and eventually in seronegative infants', 'number 2016-002437-30', 'Healthy adults aged between 18 and 50, with RSV neutralizing serum titers below 9.6 log 2 , received a single dose of either', 'cotton rats with']","['RSVΔG', 'RSVΔG vaccine', 'vaccine or placebo', 'NTR7173/EudraCT']","['morbidity and mortality', 'safety, tolerability, shedding and immunogenicity', 'Safety and immunogenicity', 'safety and tolerability, nasal viral load, and systemic and humoral immune responses']","[{'cui': 'C0521143', 'cui_str': 'Seropositive'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0231330', 'cui_str': 'Infancy'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0034695', 'cui_str': 'Rats, Cotton'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0376705', 'cui_str': 'Viral Burden'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0020967', 'cui_str': 'Humoral Immunity'}]",,0.293366,"In addition to safety and tolerability, nasal viral load, and systemic and humoral immune responses were assessed at selected time points until 4 weeks after immunization. ","[{'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Verdijk', 'Affiliation': 'Institute for Translational Vaccinology (Intravacc), Bilthoven, The Netherlands.'}, {'ForeName': 'Johan L', 'Initials': 'JL', 'LastName': 'van der Plas', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Emilie M J', 'Initials': 'EMJ', 'LastName': 'van Brummelen', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Rienk E', 'Initials': 'RE', 'LastName': 'Jeeninga', 'Affiliation': 'Viroclinics Biosciences B.V., Rotterdam, The Netherlands.'}, {'ForeName': 'Cornelis A M', 'Initials': 'CAM', 'LastName': 'de Haan', 'Affiliation': 'Virology Division, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Meta', 'Initials': 'M', 'LastName': 'Roestenberg', 'Affiliation': 'Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands; Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Jacobus', 'Initials': 'J', 'LastName': 'Burggraaf', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands; Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'Ingrid M C', 'Initials': 'IMC', 'LastName': 'Kamerling', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands; Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: IdVisser@chdr.nl.'}]",Vaccine,['10.1016/j.vaccine.2020.07.029'] 2238,32718898,Edge-to-Edge Repair Versus Secondary Cord Cutting During Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy: A Pilot Randomised Study.,"BACKGROUND To evaluate whether the Alfieri technique improves clinical and haemodynamic results and compare it with transaortic mitral valve secondary cord cutting in patients scheduled for septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy. METHODS Forty-eight (48) patients with moderate-to-severe systolic anterior motion (SAM)-mediated mitral regurgitation were randomly assigned to the Alfieri or Cutting groups in addition to septal myectomy. The primary endpoint was postoperative mean transmitral pressure gradient (TPG). The secondary endpoints were residual left ventricular outflow tract (LVOT) gradient after procedure, residual mitral regurgitation (MR), postoperative SAM, repeating bypass, and survival. RESULTS There were no 30-day mortality and ventricular septal defects. The postoperative LVOT gradient was 15.4±7.6 mmHg and 11.1±4.9 mmHg (p=0.078) in the Alfieri and Cutting groups, respectively. The Alfieri technique was associated with higher peak (7.8±3.3 vs 4.7±2.8 mmHg; p=0.014) and mean (3.9±1.7 vs 2.1±1.6 mmHg; p=0.013) TPG. The Cutting group was associated with higher mild MR rate at discharge (six vs no patients; p=0.009). One (1) patient (4.2%) in the Alfieri group required pacemaker implantation owing to conduction disturbances (p=0.312). Two-year (2-year) freedom from late mortality and sudden cardiac death rates were 95.5%±4.4% and 100% for the Alfieri and Cutting groups, respectively (log rank, p=0.317). No patients had New York Heart Association functional class III or IV or moderate or severe MR. The maximum LVOT gradient was 20.4±15.2 mmHg and 16.7±10.4 mmHg, respectively (p=0.330). There were no reoperations during follow-up. CONCLUSIONS Both techniques with septal myectomy effectively eliminated SAM-induced MR and LVOT obstructions in hypertrophic cardiomyopathy patients.",2020,The Cutting group was associated with higher mild MR rate at discharge (six vs no patients; p=0.009).,"['hypertrophic cardiomyopathy patients', 'patients scheduled for septal myectomy for severely symptomatic hypertrophic obstructive cardiomyopathy', 'Patients With Hypertrophic Obstructive Cardiomyopathy', 'No patients had New York Heart Association functional class III or IV or moderate or severe MR', 'Forty-eight (48) patients with moderate-to-severe systolic anterior motion (SAM)-mediated mitral regurgitation']","['transaortic mitral valve secondary cord cutting', 'Alfieri technique', 'Edge-to-Edge Repair Versus Secondary Cord Cutting During Septal Myectomy', 'Alfieri or Cutting groups in addition to septal myectomy']","['mild MR rate', 'maximum LVOT gradient', 'SAM-induced MR and LVOT obstructions', 'postoperative mean transmitral pressure gradient (TPG', 'postoperative LVOT gradient', 'residual left ventricular outflow tract (LVOT) gradient after procedure, residual mitral regurgitation (MR), postoperative SAM, repeating bypass, and survival', '30-day mortality and ventricular septal defects', 'late mortality and sudden cardiac death rates']","[{'cui': 'C0007194', 'cui_str': 'Hypertrophic cardiomyopathy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C3888847', 'cui_str': 'Septal myectomy'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C4551472', 'cui_str': 'Hypertrophic obstructive cardiomyopathy'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]","[{'cui': 'C0442339', 'cui_str': 'Transaortic approach'}, {'cui': 'C0026264', 'cui_str': 'Mitral valve structure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C3489532', 'cui_str': 'Cone-Rod Dystrophy 2'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205154', 'cui_str': 'Along edge'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C3888847', 'cui_str': 'Septal myectomy'}, {'cui': 'C0000925', 'cui_str': 'Incised wound'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0344917', 'cui_str': 'Left ventricular outflow tract obstruction'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0225912', 'cui_str': 'Structure of outflow tract of left ventricle'}, {'cui': 'C0543419', 'cui_str': 'Sequela of disorder'}, {'cui': 'C0580203', 'cui_str': 'Postprocedural period'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0741847', 'cui_str': 'Bypass'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0085298', 'cui_str': 'Sudden cardiac death'}]",,0.0568618,The Cutting group was associated with higher mild MR rate at discharge (six vs no patients; p=0.009).,"[{'ForeName': 'Alexander V', 'Initials': 'AV', 'LastName': 'Afanasyev', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation. Electronic address: av.afanasyev@icloud.com.'}, {'ForeName': 'Alexander V', 'Initials': 'AV', 'LastName': 'Bogachev-Prokophiev', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Sergei I', 'Initials': 'SI', 'LastName': 'Zheleznev', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Ravil M', 'Initials': 'RM', 'LastName': 'Sharifulin', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Anton S', 'Initials': 'AS', 'LastName': 'Zalesov', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}, {'ForeName': 'Sergei A', 'Initials': 'SA', 'LastName': 'Budagaev', 'Affiliation': 'Heart Valves Surgery Department, Meshalkin National Medical Research Center, Novosibirsk, Russian Federation.'}]","Heart, lung & circulation",['10.1016/j.hlc.2020.05.106'] 2239,32718911,Transcatheter Reshaping of the Mitral Annulus in Patients with Functional Mitral Regurgitation: One-year Outcomes of the MAVERIC Trial.,"AIMS To assess the one-year safety and efficacy of the transcatheter ARTO™ system in the treatment of functional mitral regurgitation (FMR). METHODS AND RESULTS MAVERIC is a multicenter, prospective, non-randomized pre-commercial study. Eligible patients were on guideline-recommended therapy for NYHA class II-IV systolic heart failure and had an FMR grade≥2+. ARTO™ system was implanted in forty-five (100%) patients. Primary safety composite endpoint (death, stroke, myocardial infarction, device related surgery, cardiac tamponade, renal failure) at 30-days and one-year was 4.4% [95%CI 1.5-16.6] and 17.8% [95%CI 9.3-32.4]. Periprocedural complications occurred in seven patients (15.5% [95%CI 6.5-29.5]) and five patients (11.1% [95%CI 4.9-24.0]) died during one-year follow-up. Paired results for 36 patients demonstrated 24 (66.7%) had Grade 3+/4+ mitral regurgitation at baseline however, only 5 (13.9%) and 3 (8.3%) patients remained at Grade 3+/4+ 30-days and one-year post-procedure (p<0.0001). Echocardiographic parameters such as antero-posterior annulus diameter decreased from 41.4mm (baseline) to 36.0 and 35.3mm at 30-days and one-year respectively (p<0.0001). Twenty-five patients (69.4%) had baseline NYHA Class III/IV symptoms decreasing significantly to 9 (25.0%) at 30-days and 8 (22.2%) at one-year post-procedure (p<0.0001). CONCLUSION The ARTO™ transcatheter mitral valve repair system is both safe and effective in decreasing FMR up to one-year post-procedure.",2020,The ARTO™ transcatheter mitral valve repair system is both safe and effective in decreasing FMR up to one-year post-procedure.,"['Eligible patients were on guideline-recommended therapy for NYHA class II-IV systolic heart failure and had an FMR grade≥2', 'Patients with Functional Mitral Regurgitation', 'functional mitral regurgitation (FMR']",['Transcatheter Reshaping'],"['Primary safety composite endpoint (death, stroke, myocardial infarction, device related surgery, cardiac tamponade, renal failure) at 30-days and one-year', 'Echocardiographic parameters such as antero-posterior annulus diameter', 'Grade 3+/4+ mitral regurgitation', 'baseline NYHA Class III/IV symptoms', 'Periprocedural complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0441886', 'cui_str': 'Class 2'}, {'cui': 'C1135191', 'cui_str': 'Systolic heart failure'}, {'cui': 'C0340369', 'cui_str': 'Functional mitral regurgitation'}]","[{'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0007177', 'cui_str': 'Cardiac tamponade'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0026266', 'cui_str': 'Mitral valve regurgitation'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1141861', 'cui_str': 'Procedural complication'}]",,0.0944125,The ARTO™ transcatheter mitral valve repair system is both safe and effective in decreasing FMR up to one-year post-procedure.,"[{'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Worthley', 'Affiliation': 'St Andrews Hospital, Adelaide, SA, Australia. GenesisCare, The Mill, 41-43 Bourke Road, Alexandria, NSW, Australia.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Redwood', 'Affiliation': ''}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Hildick-Smith', 'Affiliation': ''}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Rafter', 'Affiliation': ''}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Whelan', 'Affiliation': ''}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'De Marco', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Horrigan', 'Affiliation': ''}, {'ForeName': 'Sinny', 'Initials': 'S', 'LastName': 'Delacroix', 'Affiliation': ''}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gregson', 'Affiliation': ''}, {'ForeName': 'Andrejs', 'Initials': 'A', 'LastName': 'Erglis', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00484'] 2240,32718912,"A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs. Ticagrelor in Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention: rationale and design of the TALOS-AMI trial.","AIMS In patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI), the risk of ischemic complications is highest in early phase (during the first 30days), while most bleeding events predominantly occur during maintenance phase of treatment (after the first 30days). Data on the de-escalating dual antiplatelet therapy of switching from ticagrelor to clopidogrel in stabilized AMI patients are limited. METHODS AND RESULTS The TALOS-AMI is a, multicenter, randomized, open-label study enrolling 2590 AMI patients with no adverse events during the first month after the index PCI. One month after the index PCI, eligible patients are randomly assigned either to the 1) aspirin 100 mg plus clopidogrel 75mg daily or 2) aspirin 100 mg plus ticagrelor 90 mg twice daily in a 1:1 ratio. The primary endpoint is a composite of cardiovascular death, MI, stroke, and bleeding type 2, 3 or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months after the index PCI. CONCLUSIONS The TALOS-AMI trial is the first large-scale, multicenter, randomized study exploring the efficacy and safety of the de-escalating antiplatelet therapy that switches ticagrelor to clopidogrel in stabilized AMI patients undergoing PCI.",2020,"The primary endpoint is a composite of cardiovascular death, MI, stroke, and bleeding type 2, 3 or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months after the index PCI. ","['Stabilized Patients with Acute Myocardial Infarction after Percutan eous Coronary Intervention', '2590 AMI patients with no adverse events during the first month after the index PCI', 'stabilized AMI patients undergoing PCI', 'stabilized AMI patients', 'patients undergoing']","['Clopidogrel vs. Ticagrelor', 'aspirin 100 mg plus clopidogrel 75mg daily or 2) aspirin 100 mg plus ticagrelor', 'percutaneous coronary intervention (PCI']","['efficacy and safety', 'composite of cardiovascular death, MI, stroke, and bleeding type 2, 3 or 5 according to Bleeding Academic Research Consortium (BARC) criteria']","[{'cui': 'C0184512', 'cui_str': 'Stabilized'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1963761', 'cui_str': 'No adverse event'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C1124475', 'cui_str': 'Aspirin 100 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1124675', 'cui_str': 'clopidogrel 75 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]",2590.0,0.0391861,"The primary endpoint is a composite of cardiovascular death, MI, stroke, and bleeding type 2, 3 or 5 according to Bleeding Academic Research Consortium (BARC) criteria from 1 to 12 months after the index PCI. ","[{'ForeName': 'Mahn-Won', 'Initials': 'MW', 'LastName': 'Park', 'Affiliation': ""Department of Cardiology, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.""}, {'ForeName': 'Chan Joon', 'Initials': 'CJ', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Min-Chul', 'Initials': 'MC', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Eun-Ho', 'Initials': 'EH', 'LastName': 'Choo', 'Affiliation': ''}, {'ForeName': 'Byung-Hee', 'Initials': 'BH', 'LastName': 'Hwang', 'Affiliation': ''}, {'ForeName': 'Chul-Soo', 'Initials': 'CS', 'LastName': 'Park', 'Affiliation': ''}, {'ForeName': 'Hee-Yeol', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': ''}, {'ForeName': 'Ki-Dong', 'Initials': 'KD', 'LastName': 'Yoo', 'Affiliation': ''}, {'ForeName': 'Doo-Soo', 'Initials': 'DS', 'LastName': 'Jeon', 'Affiliation': ''}, {'ForeName': 'Myung Ho', 'Initials': 'MH', 'LastName': 'Jeong', 'Affiliation': ''}, {'ForeName': 'Ki-Bae', 'Initials': 'KB', 'LastName': 'Seung', 'Affiliation': ''}, {'ForeName': 'Youngkeun', 'Initials': 'Y', 'LastName': 'Ahn', 'Affiliation': ''}, {'ForeName': 'Kiyuk', 'Initials': 'K', 'LastName': 'Chang', 'Affiliation': ''}]",EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,['10.4244/EIJ-D-20-00187'] 2241,32718922,"PROMISE (Program Refinements to Optimize Model Impact and Scalability based on Evidence): a cluster-randomised, stepped-wedge trial assessing effectiveness of the revised versus original Ryan White Part A HIV Care Coordination Programme for patients with barriers to treatment in the USA.","INTRODUCTION Growing evidence supports combining social, behavioural and biomedical strategies to strengthen the HIV care continuum. However, combination interventions can be resource-intensive and challenging to scale up. Research is needed to identify intervention components and delivery models that maximise uptake, engagement and effectiveness. In New York City (NYC), a multicomponent Ryan White Part A-funded medical case management intervention called the Care Coordination Programme (CCP) was launched at 28 agencies in 2009 in order to address barriers to care and treatment. Effectiveness estimates based on >7000 clients enrolled by April 2013 and their controls indicated modest CCP benefits over 'usual care' for short-term and long-term viral suppression, with substantial room for improvement. METHODS AND ANALYSIS Integrating evaluation findings and CCP service-provider and community-stakeholder input on modifications, the NYC Health Department packaged a Care Coordination Redesign (CCR) in a 2017 request for proposals. Following competitive re-solicitation, 17 of the original CCP-implementing agencies secured contracts. These agencies were randomised within matched pairs to immediate or delayed CCR implementation. Data from three 9-month periods (pre-implementation, partial implementation and full implementation) will be examined to compare CCR versus CCP effects on timely viral suppression (TVS, within 4 months of enrolment) among individuals with unsuppressed HIV viral load newly enrolling in the CCR/CCP. Based on current enrolment (n=933) and the pre-implementation outcome probability (TVS=0.54), the detectable effect size with 80% power is an OR of 2.75 (relative risk: 1.41). ETHICS AND DISSEMINATION This study was approved by the NYC Department of Health and Mental Hygiene Institutional Review Board (IRB, Protocol 18-009) and the City University of New York Integrated IRB (Protocol 018-0057) with a waiver of informed consent. Findings will be disseminated via publications, conferences, stakeholder meetings, and Advisory Board meetings with implementing agency representatives. TRIAL REGISTRATION NUMBER Registered with ClinicalTrials.gov under identifier: NCT03628287, V.2, 25 September 2019; pre-results.",2020,"Effectiveness estimates based on >7000 clients enrolled by April 2013 and their controls indicated modest CCP benefits over 'usual care' for short-term and long-term viral suppression, with substantial room for improvement. ","['patients with barriers to treatment in the USA', 'individuals with unsuppressed HIV viral load newly enrolling in the CCR/CCP', 'NYC Department of Health and Mental Hygiene Institutional Review Board (IRB, Protocol 18-009) and the City University of New York Integrated IRB', ""7000 clients enrolled by April 2013 and their controls indicated modest CCP benefits over 'usual care' for short-term and long-term viral suppression, with substantial room for improvement""]",['CCP service-provider and community-stakeholder input on modifications'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1168369', 'cui_str': 'HIV viral load'}, {'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0086911', 'cui_str': 'Ethics Committee, Research'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C4708914', 'cui_str': '7000'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205136', 'cui_str': 'Over'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0242414', 'cui_str': 'Coordination'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",[],7000.0,0.0888393,"Effectiveness estimates based on >7000 clients enrolled by April 2013 and their controls indicated modest CCP benefits over 'usual care' for short-term and long-term viral suppression, with substantial room for improvement. ","[{'ForeName': 'Mary K', 'Initials': 'MK', 'LastName': 'Irvine', 'Affiliation': 'Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New York, USA mirvine@health.nyc.gov.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Levin', 'Affiliation': 'Department of Biostatistics, Mailman School of Public Health (MSPH), Columbia University, New York, New York, USA.'}, {'ForeName': 'McKaylee M', 'Initials': 'MM', 'LastName': 'Robertson', 'Affiliation': 'Institute for Implementation Science in Population Health, Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA.'}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Penrose', 'Affiliation': 'Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New York, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Carmona', 'Affiliation': 'Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New York, USA.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Harriman', 'Affiliation': 'Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New York, USA.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Braunstein', 'Affiliation': 'Bureau of HIV, New York City Department of Health and Mental Hygiene, Queens, New York, USA.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Nash', 'Affiliation': 'Institute for Implementation Science in Population Health, Graduate School of Public Health and Health Policy, City University of New York, New York, New York, USA.'}]",BMJ open,['10.1136/bmjopen-2019-034624'] 2242,32718924,Implementation of blood glucose self-monitoring among insulin-dependent patients with type 2 diabetes in three rural districts in Rwanda: 6 months open randomised controlled trial.,"INTRODUCTION Most patients diagnosed with diabetes in sub-Saharan Africa (SSA) present with poorly controlled blood glucose, which is associated with increased risks of complications and greater financial burden on both the patients and health systems. Insulin-dependent patients with diabetes in SSA lack appropriate home-based monitoring technology to inform themselves and clinicians of the daily fluctuations in blood glucose. Without sufficient home-based data, insulin adjustments are not data driven and adopting individual behavioural change for glucose control in SSA does not have a systematic path towards improvement. METHODS AND ANALYSIS This study explores the feasibility and impact of implementing self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes in rural Rwandan districts. This is an open randomised controlled trial comprising of two arms: (1) Intervention group-participants will receive a glucose metre, blood test strips, logbook, waste management box and training on how to conduct SMBG in additional to usual care and (2) Control group-participants will receive usual care, comprising of clinical consultations and routine monthly follow-up. We will conduct qualitative interviews at enrolment and at the end of the study to assess knowledge of diabetes. At the end of the study period, we will interview clinicians and participants to assess the perceived usefulness, facilitators and barriers of SMBG. The primary outcomes are change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness and adverse effects resulting from SMBG. Secondary outcomes include reliability and acceptability of SMBG and change in the quality of life of the participants. ETHICS AND DISSEMINATION This study has been approved by the Rwanda National Ethics Committee (Kigali, Rwanda No.102/RNEC/2018). We will disseminate the findings of this study through presentations within our study settings, scientific conferences and publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER PACTR201905538846394; pre-results.",2020,"The primary outcomes are change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness and adverse effects resulting from SMBG.","['dependent patients with type 2 diabetes in three rural districts in Rwanda', 'patients diagnosed with diabetes in sub-Saharan Africa (SSA', 'patients with type 2 diabetes in rural Rwandan districts']","['Intervention group-participants will receive a glucose metre, blood test strips, logbook, waste management box and training on how to conduct SMBG in additional to usual care and (2) Control group-participants will receive usual care, comprising of clinical consultations and routine monthly follow-up', 'blood glucose self-monitoring among insulin', 'implementing self-monitoring of blood glucose (SMBG']","['change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness and adverse effects resulting from SMBG', 'reliability and acceptability of SMBG and change in the quality of life of the participants']","[{'cui': 'C0581116', 'cui_str': 'Dependent patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0035978', 'cui_str': 'Rwanda'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0001738', 'cui_str': 'Sub-Saharan Africa'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0475209', 'cui_str': 'meter'}, {'cui': 'C0462899', 'cui_str': 'Blood testing strips'}, {'cui': 'C0242716', 'cui_str': 'Waste Management'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C4520547', 'cui_str': 'Implemented'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.0961424,"The primary outcomes are change in haemoglobin A1c, fidelity to SMBG protocol by patients, appropriateness and adverse effects resulting from SMBG.","[{'ForeName': 'Loise', 'Initials': 'L', 'LastName': ""Ng'ang'a"", 'Affiliation': 'Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda loisehaks@gmail.com.'}, {'ForeName': 'Gedeon', 'Initials': 'G', 'LastName': 'Ngoga', 'Affiliation': 'Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.'}, {'ForeName': 'Symaque', 'Initials': 'S', 'LastName': 'Dusabeyezu', 'Affiliation': 'Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.'}, {'ForeName': 'Bethany L', 'Initials': 'BL', 'LastName': 'Hedt-Gauthier', 'Affiliation': 'Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Patient', 'Initials': 'P', 'LastName': 'Ngamije', 'Affiliation': 'Kirehe District Hospital, Ministry of Health, Kigali, Rwanda.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Habiyaremye', 'Affiliation': 'Rwinkwavu District Hospital, Ministry of Health, Kigali, Rwanda.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Harerimana', 'Affiliation': 'Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Ndayisaba', 'Affiliation': 'Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Rusangwa', 'Affiliation': 'Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.'}, {'ForeName': 'Simon Pierre', 'Initials': 'SP', 'LastName': 'Niyonsenga', 'Affiliation': 'Non-Communicable Diseases Division, Rwanda Biomedical Center, Kigali, Rwanda.'}, {'ForeName': 'Charlotte M', 'Initials': 'CM', 'LastName': 'Bavuma', 'Affiliation': 'Internal Medicine, University of Rwanda College of Medicine and Health Sciences, Kigali, Rwanda.'}, {'ForeName': 'Gene', 'Initials': 'G', 'LastName': 'Bukhman', 'Affiliation': 'NCD Synergies, Partners in Health, Boston, Massachusetts, United States.'}, {'ForeName': 'Alma J', 'Initials': 'AJ', 'LastName': 'Adler', 'Affiliation': 'Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'Fredrick', 'Initials': 'F', 'LastName': 'Kateera', 'Affiliation': 'Research, Inshuti Mu Buzima, Partners In Health-Rwanda, Rwinkwavu, Rwanda.'}, {'ForeName': 'Paul H', 'Initials': 'PH', 'LastName': 'Park', 'Affiliation': 'NCD Synergies, Partners in Health, Boston, Massachusetts, United States.'}]",BMJ open,['10.1136/bmjopen-2019-036202'] 2243,32718927,Are prolonged sitting and sleep restriction a dual curse for the modern workforce? a randomised controlled trial protocol.,"INTRODUCTION Prolonged sitting and inadequate sleep are a growing concern in society and are associated with impairments to cardiometabolic health and cognitive performance. However, the combined effect of prolonged sitting and inadequate sleep on measures of health and cognitive performance are unknown. In addition, the circadian disruption caused by shiftwork may further impact workers' cardiometabolic health and cognitive performance. This protocol paper outlines the methodology for exploring the impact of simultaneous exposure to prolonged sitting, sleep restriction and circadian disruption on cardiometabolic and cognitive performance outcomes. METHODS AND ANALYSIS This between-subjects study will recruit 208 males and females to complete a 7-day in-laboratory experimental protocol (1 Adaptation Day, 5 Experimental Days and 1 Recovery Day). Participants will be allocated to one of eight conditions that include all possible combinations of the following: dayshift or nightshift, sitting or breaking up sitting and 5 hour or 9 hour sleep opportunity. On arrival to the laboratory, participants will be provided with a 9 hour baseline sleep opportunity (22:00 to 07:00) and complete five simulated work shifts (09:00 to 17:30 in the dayshift condition and 22:00 to 06:30 in the nightshift condition) followed by a 9 hour recovery sleep opportunity (22:00 to 07:00). During the work shifts participants in the sitting condition will remain seated, while participants in the breaking up sitting condition will complete 3-min bouts of light-intensity walking every 30 mins on a motorised treadmill. Sleep opportunities will be 9 hour or 5 hour. Primary outcome measures include continuously measured interstitial blood glucose, heart rate and blood pressure, and a cognitive performance and self-perceived capacity testing battery completed five times per shift. Analyses will be conducted using linear mixed models. ETHICS AND DISSEMINATION The CQUniversity Human Ethics Committee has approved this study (0000021914). All participants who have already completed the protocol have provided informed consent. Study findings will be disseminated via scientific publications and conference presentations. TRIAL REGISTRATION DETAILS This study has been registered on Australian New Zealand Clinical Trials Registry (12619001516178) and is currently in the pre-results stage.",2020,"Participants will be allocated to one of eight conditions that include all possible combinations of the following: dayshift or nightshift, sitting or breaking up sitting and 5 hour or 9 hour sleep opportunity.","['208 males and females to complete a 7-day in-laboratory experimental protocol (1 Adaptation Day, 5 Experimental Days and 1 Recovery Day', 'All participants who have already completed the protocol have provided informed consent']","['dayshift or nightshift, sitting or breaking up sitting and 5\u2009hour or 9\u2009hour sleep opportunity']","['continuously measured interstitial blood glucose, heart rate and blood pressure, and a cognitive performance and self-perceived capacity testing battery completed five times per shift']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0163299', 'cui_str': 'A 7'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0000934', 'cui_str': 'Acclimation'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}]","[{'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C1442467', 'cui_str': '5 hours'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C1522203', 'cui_str': 'Interstitial route'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0333051', 'cui_str': 'Shift'}]",208.0,0.0567258,"Participants will be allocated to one of eight conditions that include all possible combinations of the following: dayshift or nightshift, sitting or breaking up sitting and 5 hour or 9 hour sleep opportunity.","[{'ForeName': 'Grace E', 'Initials': 'GE', 'LastName': 'Vincent', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia g.vincent@cqu.edu.au.'}, {'ForeName': 'Charlotte C', 'Initials': 'CC', 'LastName': 'Gupta', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia.'}, {'ForeName': 'Madeline', 'Initials': 'M', 'LastName': 'Sprajcer', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia.'}, {'ForeName': 'Corneel', 'Initials': 'C', 'LastName': 'Vandelanotte', 'Affiliation': 'School of Health Medical and Applied Sciences, Central Queensland University, Rockhampton, Queensland, Australia.'}, {'ForeName': 'Mitch J', 'Initials': 'MJ', 'LastName': 'Duncan', 'Affiliation': 'School of Medicine & Public Health, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia.'}, {'ForeName': 'Phil', 'Initials': 'P', 'LastName': 'Tucker', 'Affiliation': 'Psychology Department, Swansea University, Swansea, United Kingdom.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Lastella', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia.'}, {'ForeName': 'Georgia A', 'Initials': 'GA', 'LastName': 'Tuckwell', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia.'}, {'ForeName': 'Sally A', 'Initials': 'SA', 'LastName': 'Ferguson', 'Affiliation': 'Appleton Institute, Central Queensland University - Adelaide Campus, Wayville, South Australia, Australia.'}]",BMJ open,['10.1136/bmjopen-2020-040613'] 2244,32718934,Use of a diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack improves glycemic responses assessed by continuous glucose monitoring in people with type 2 diabetes: a randomized clinical pilot study.,"INTRODUCTION This pilot study evaluated the impact of a diabetes-specific nutritional shake (DSNS) used twice daily by people with type 2 diabetes (T2D) on glycemic response assessed by continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS Adults (n=81) with T2D managed by oral medications were studied in a randomized, open-label, three-group parallel study design. The study was conducted in two phases over 14 days: Baseline (days 1-6), during which study participants consumed their habitual self-selected diets (SSD), followed by the Intervention (days 7-14), during which participants were randomized as follows: (1) SSD group received no study product (n=32); (2) DSNS breakfast/afternoon snack (Bkfst/AS) group consumed one DSNS as a breakfast meal replacement and a second to replace their mid-afternoon snack (n=24); (3) DSNS breakfast/prebed snack (Bkfst/PBS) group consumed one DSNS as a breakfast meal replacement and added a second as a prebed snack (n=25). Glucose was assessed by CGM throughout the study. Additionally, participants were asked about snacking behaviors, cravings, and other questions related to the use of DSNS as meal replacements and snacks. RESULTS All groups reduced their postprandial glycemic response (positive area under the curve (pAUC, mg/min*dL -1 )) and adjusted peak value (mg/dL) when compared with the baseline phase. Participants consuming DSNS in place of their usual breakfast showed greater reductions in pAUC compared with the SSD group (p=0.008) for the DSNS Bkfst/AS group with a trend (p=0.069) for the DSNS Bkfst/PBS group. Adjusted peak value showed greater reductions in both DSNS groups as compared with the SSD group (p=0.002 for DSNS Bkfst/AS and p=0.010 for DSNS Bkfst/PBS). Nocturnal glucose variability was significantly decreased during the intervention phase compared with baseline phase in the DSNS Bkfst/AS group (p=0.020), with no significant differences between groups. After intervention, the DSNS Bkfst/AS group had a significantly lower percentage of participants (17%) reporting cravings for starchy meals/sides compared with before the study (33%) (p=0.046). This group also reported a significant increase in confidence in choosing foods to control their diabetes (from 58.3% to 91.7%, preintervention vs postintervention, respectively, p=0.005). CONCLUSIONS Use of DSNS to replace breakfast and as an afternoon snack improves both glycemic control and behavioral factors related to dietary management of diabetes. TRAIL REGISTRATION NUMBER NCT04230889.",2020,AS group had a significantly lower percentage of participants (17%) reporting cravings for starchy meals/sides compared with before the study (33%) (p=0.046).,"['people with type 2 diabetes (T2D', 'Adults (n=81) with T2D managed by oral medications', 'people with type 2 diabetes']","['continuous glucose monitoring (CGM', 'habitual self-selected diets (SSD', 'diabetes-specific nutritional shake to replace a daily breakfast and afternoon snack', 'diabetes-specific nutritional shake (DSNS', 'DSNS breakfast/afternoon snack (Bkfst/AS) group consumed one DSNS as a breakfast meal replacement and a second to replace their mid-afternoon snack (n=24); (3) DSNS breakfast/prebed snack (Bkfst/PBS) group consumed one DSNS as a breakfast meal replacement and added a second as a prebed snack', 'SSD']","['Glucose', 'pAUC', 'Nocturnal glucose variability', 'glycemic responses', 'postprandial glycemic response (positive area under the curve (pAUC, mg/min*dL -1 )) and adjusted peak value', 'reporting cravings for starchy meals/sides', 'confidence in choosing foods to control their diabetes']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}, {'cui': 'C0559956', 'cui_str': 'Replacement - action'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0439550', 'cui_str': 'Afternoon'}, {'cui': 'C0453863', 'cui_str': 'Snack food'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205447', 'cui_str': '1'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0441987', 'cui_str': 'Side'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",81.0,0.0241566,AS group had a significantly lower percentage of participants (17%) reporting cravings for starchy meals/sides compared with before the study (33%) (p=0.046).,"[{'ForeName': 'Vikkie A', 'Initials': 'VA', 'LastName': 'Mustad', 'Affiliation': 'Research and Development Department, Abbott Nutrition, Columbus, Ohio, USA.'}, {'ForeName': 'Refaat A', 'Initials': 'RA', 'LastName': 'Hegazi', 'Affiliation': 'Research and Development Department, Abbott Nutrition, Columbus, Ohio, USA Refaat.Hegazi@abbott.com.'}, {'ForeName': 'Deborah S', 'Initials': 'DS', 'LastName': 'Hustead', 'Affiliation': 'Research and Development Department, Abbott Nutrition, Columbus, Ohio, USA.'}, {'ForeName': 'Erwin S', 'Initials': 'ES', 'LastName': 'Budiman', 'Affiliation': 'Research and Development Department, Abbott Diabetes Care, Alameda, California, USA.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Rueda', 'Affiliation': 'Research and Development Department, Abbott Nutrition, Granada, Spain.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Maki', 'Affiliation': 'President and Chief Scientist, MB Clinical Research, Boca Raton, Florida, USA.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': 'Powers', 'Affiliation': 'International Diabetes Center at Park Nicollet, St. Louis Park, Minnesota, USA.'}, {'ForeName': 'Jeffrey I', 'Initials': 'JI', 'LastName': 'Mechanick', 'Affiliation': 'Professor of Medicine and Medical Director, Kravis Center for Cardiovascular Health at Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Richard M', 'Initials': 'RM', 'LastName': 'Bergenstal', 'Affiliation': 'International Diabetes Center at Park Nicollet, St. Louis Park, Minnesota, USA.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Hamdy', 'Affiliation': 'Obesity Clinical Program, Director of Inpatient Diabetes Program, Joslin Diabetes Center, Boston, Massachusetts, USA.'}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2020-001258'] 2245,32718943,Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: a Randomized Clinical Trial.,"Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer (CRC) in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those most likely to benefit. The major urinary metabolite of PGE2, 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), is a biomarker for CRC risk, but it is unknown if PGE-M is modifiable by aspirin in individuals at risk for CRC. Adults (N=180) who recently underwent adenoma resection and did not regularly use aspirin or non-steroidal anti-inflammatory drugs were recruited to a double-blind, placebo-controlled, randomized trial of aspirin at 81 or 325 mg/day for 8-12 weeks. The primary outcome was post-intervention change in urinary PGE-M as measured by liquid-chromatography mass spectrometry. 169 participants provided paired urine samples for analysis. Baseline PGE-M excretion was 15.9±14.6 (mean±S.D. ng/mg creatinine). Aspirin significantly reduced PGE-M excretion (-4.7±14.8) compared to no decrease (0.8±11.8) in the placebo group (p=0.015) (mean duration of treatment = 68.9 days). Aspirin significantly reduced PGE-M levels in participants receiving either 81 (-15%; p=0.018) or 325 mg/day (-28%; p<0.0001) compared to placebo. In 40% and 50% of the individuals randomized to 81 or 325 mg/day aspirin, respectively, PGE-M reduction reached a threshold expected to prevent recurrence in 10% of individuals. These results support that aspirin significantly reduces elevated levels of PGE-M in those at increased CRC risk to levels consistent with lower risk for recurrent neoplasia and underscore the potential utility of PGE-M as a precision chemoprevention biomarker. The ASPIRED trial is registered as NCT02394769.",2020,Aspirin significantly reduced PGE-M levels in participants receiving either 81 (-15%; p=0.018) or 325 mg/day (-28%; p<0.0001) compared to placebo.,"['Individuals with Colorectal Adenomas', 'Adults (N=180) who recently underwent adenoma resection and did not regularly use aspirin or non-steroidal anti-inflammatory drugs', 'individuals at risk for CRC', '169 participants provided paired urine samples for analysis']","['placebo', 'Aspirin', 'Low-dose and Standard-dose Aspirin', 'aspirin']","['Baseline PGE-M excretion', 'recurrence', 'PGE-M excretion', 'PGE-M levels', 'post-intervention change in urinary PGE-M as measured by liquid-chromatography mass spectrometry', 'PGE2 Biosynthesis']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1302401', 'cui_str': 'Adenoma of large intestine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0001430', 'cui_str': 'Adenoma'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0003211', 'cui_str': 'Non-steroidal anti-inflammatory agent'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C1610733', 'cui_str': 'Urine specimen'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0049896', 'cui_str': 'prostaglandin M'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0008565', 'cui_str': 'Liquid chromatography measurement'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0005572', 'cui_str': 'bioformation'}]",169.0,0.217073,Aspirin significantly reduced PGE-M levels in participants receiving either 81 (-15%; p=0.018) or 325 mg/day (-28%; p<0.0001) compared to placebo.,"[{'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Drew', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Madeline M', 'Initials': 'MM', 'LastName': 'Schuck', 'Affiliation': 'Clinical & Translational Epidemiology Unit, Massachusetts General Hospital.'}, {'ForeName': 'Marina V', 'Initials': 'MV', 'LastName': 'Magicheva-Gupta', 'Affiliation': 'Massachusetts General Hospital.'}, {'ForeName': 'Katheleen O', 'Initials': 'KO', 'LastName': 'Stewart', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Katherine K', 'Initials': 'KK', 'LastName': 'Gilpin', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Miller', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Melanie P', 'Initials': 'MP', 'LastName': 'Parziale', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Emily N', 'Initials': 'EN', 'LastName': 'Pond', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Takacsi-Nagy', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Dylan C', 'Initials': 'DC', 'LastName': 'Zerjav', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Samantha M', 'Initials': 'SM', 'LastName': 'Chin', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Mackinnon Krems', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Meixell', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Amit D', 'Initials': 'AD', 'LastName': 'Joshi', 'Affiliation': 'Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School.'}, {'ForeName': 'Wenjie', 'Initials': 'W', 'LastName': 'Ma', 'Affiliation': 'Massachusetts General Hospital.'}, {'ForeName': 'Francis P', 'Initials': 'FP', 'LastName': 'Colizzo', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Carolan', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Norman S', 'Initials': 'NS', 'LastName': 'Nishioka', 'Affiliation': 'Harvard Medical School.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Staller', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Richter', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Khalili', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Manish K', 'Initials': 'MK', 'LastName': 'Gala', 'Affiliation': 'Gastroenterology, Massachusetts General Hospital, Harvard Medical School.'}, {'ForeName': 'John J', 'Initials': 'JJ', 'LastName': 'Garber', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Chung', 'Affiliation': 'GI Unit, Massachusetts General Hospital.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Yarze', 'Affiliation': 'Division of Gastroenterology, Massachusetts General Hospital.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Zukerberg', 'Affiliation': 'Department of Pathology, Massachusetts General Hospital.'}, {'ForeName': 'Giovanna', 'Initials': 'G', 'LastName': 'Petrucci', 'Affiliation': 'Institute of Pharmacology.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Rocca', 'Affiliation': 'Section on Pharmacology, Catholic University School of Medicine.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Patrono', 'Affiliation': ''}, {'ForeName': 'Ginger L', 'Initials': 'GL', 'LastName': 'Milne', 'Affiliation': 'Division of Clinical Pharmacology, Vanderbilt University School of Medicine.'}, {'ForeName': 'Molin', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': 'Harvard School of Public Health.'}, {'ForeName': 'Andrew T', 'Initials': 'AT', 'LastName': 'Chan', 'Affiliation': 'Massachusetts General Hospital achan@mgh.harvard.edu.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-20-0216'] 2246,32718986,"Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.","PURPOSE This randomized, double-blind, placebo-controlled, parallel-group, phase II trial assessed the efficacy and safety of adagloxad simolenin (OBI-822; a Globo H epitope covalently linked to keyhole limpet hemocyanin (KLH)) with adjuvant OBI-821 in metastatic breast cancer (MBC). METHODS At 40 sites in Taiwan, USA, Korea, India, and Hong Kong, patients with MBC of any molecular subtype and ≤2 prior progressive disease events with stable/responding disease after the last anticancer regimen were randomized (2:1) to adagloxad simolenin (AS/OBI-821) or placebo, subcutaneously for nine doses with low-dose cyclophosphamide. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, correlation of clinical outcome with humoral immune response and Globo H expression, and safety. RESULTS Of 349 patients randomized, 348 received study drug. Patients with the following breast cancer subtypes were included: hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (70.4%), triple negative (12.9%), and HER2+ (16.7%), similarly distributed between treatment arms. Median PFS was 7.6 months (95% CI: 6.5-10.9) with AS/OBI-821 (n=224) and 9.2 months (95% CI: 7.3-11.3) with placebo (n=124) (HR=0.96; 95% CI: 0.74-1.25; p=0.77), with no difference by breast cancer subtype. AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03). Anti-KLH immune responses were similar at week 40 between AS/OBI-821 recipients with anti-Globo IgG titer ≥1:160 and those with anti-Globo IgG titer <1:160. The most common adverse events with AS/OBI-821 were grade 1 or 2 injection site reactions (56.7%; placebo, 8.9%) and fever (20.1%; placebo, 6.5%). CONCLUSION AS/OBI-821 did not improve PFS in patients with previously treated MBC. However, humoral immune response to Globo H correlated with improved PFS in AS/OBI-821 recipients, leading the way to further marker-driven studies. Treatment was well tolerated.NCT01516307.",2020,AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03).,"['patients with metastatic breast cancer', 'metastatic breast cancer (MBC', 'patients with previously treated MBC', '349 patients randomized, 348 received study drug', 'Patients with the following breast cancer subtypes were included']","['OBI-822)/OBI-821', 'Globo H-KLH vaccine adagloxad simolenin ', 'adagloxad simolenin ', 'adagloxad simolenin (AS/OBI-821) or placebo, subcutaneously for nine doses with low-dose cyclophosphamide', 'placebo']","['Anti-KLH immune responses', 'Median PFS', 'PFS', 'tolerated', 'overall survival, correlation of clinical outcome with humoral immune response and Globo H expression, and safety', 'efficacy and safety', 'median PFS', 'progression-free survival (PFS', 'fever', 'hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C4517733', 'cui_str': '348'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0449560', 'cui_str': 'Subtype'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C1175421', 'cui_str': 'Globo-H'}, {'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}]","[{'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C0301872', 'cui_str': 'Immune response'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0010101', 'cui_str': 'Correlation Studies'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0020967', 'cui_str': 'Humoral Immunity'}, {'cui': 'C1175421', 'cui_str': 'Globo-H'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}]",349.0,0.523881,AS/OBI-821 recipients with anti-Globo H IgG titer ≥1:160 had significantly longer median PFS (11.1 months (95% CI: 9.3-17.6)) versus those with titers <1:160 (5.5 months (95% CI: 3.7-5.6); HR=0.52; p<0.0001) and placebo recipients (HR=0.71; p=0.03).,"[{'ForeName': 'Chiun-Sheng', 'Initials': 'CS', 'LastName': 'Huang', 'Affiliation': 'Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Alice L', 'Initials': 'AL', 'LastName': 'Yu', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital & Chang Gung University, Linkou, Taiwan.'}, {'ForeName': 'Ling-Ming', 'Initials': 'LM', 'LastName': 'Tseng', 'Affiliation': 'Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Louis W C', 'Initials': 'LWC', 'LastName': 'Chow', 'Affiliation': 'UNIMED Medical Institute, Hong Kong, China.'}, {'ForeName': 'Ming-Feng', 'Initials': 'MF', 'LastName': 'Hou', 'Affiliation': 'Division of Breast Surgery, Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Sara A', 'Initials': 'SA', 'LastName': 'Hurvitz', 'Affiliation': 'Jonsson Comprehensive Cancer Center, Department of Hematology/Oncology, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Schwab', 'Affiliation': 'Moores Cancer Center, University of California San Diego, San Diego, California, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'L Murray', 'Affiliation': 'Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.'}, {'ForeName': 'Hsien-Kun', 'Initials': 'HK', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, Division of Hematology-Oncology, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Hong-Tai', 'Initials': 'HT', 'LastName': 'Chang', 'Affiliation': 'Department of Surgery, Kaohsiung Municipal United Hospital, Kaohsiung, Taiwan.'}, {'ForeName': 'Shin-Cheh', 'Initials': 'SC', 'LastName': 'Chen', 'Affiliation': 'Department of General Surgery, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Sung-Bae', 'Initials': 'SB', 'LastName': 'Kim', 'Affiliation': 'Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, The Republic of Korea.'}, {'ForeName': 'Jung-Tung', 'Initials': 'JT', 'LastName': 'Hung', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Shir-Hwa', 'Initials': 'SH', 'LastName': 'Ueng', 'Affiliation': 'Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Linkou, Taiwan.'}, {'ForeName': 'Su-Hua', 'Initials': 'SH', 'LastName': 'Lee', 'Affiliation': 'Department of Statistics and Biometrics, OBI Pharma Inc, Taipei, Taiwan.'}, {'ForeName': 'Chwen-Cheng', 'Initials': 'CC', 'LastName': 'Chen', 'Affiliation': 'Institute of Biotechnology and Pharmaceutical Research, National Health Research Institute, Taipei, Taiwan.'}, {'ForeName': 'Hope S', 'Initials': 'HS', 'LastName': 'Rugo', 'Affiliation': 'Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA hope.rugo@ucsf.edu.'}]",Journal for immunotherapy of cancer,['10.1136/jitc-2019-000342'] 2247,32719000,"Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma.","Despite standard of care for glioblastoma (GBM), including gross total resection, high dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this diagnosis compared to more common solid tumors in clinical trials commits new GBM therapies to testing in small, underpowered, non-randomized settings. Among ~200 registered GBM trials identified between 2005 and 2015, nearly half were single-arm studies with sample sizes not exceeding 50 patients. These constraints have made demonstrating efficacy for novel therapies difficult in GBM and other rare and aggressive cancers. Novel immunotherapies for GBM such as vaccination with dendritic cells (DCs) have yielded mixed results in clinical trials. To address limited numbers, we sequentially conducted three separate clinical trials utilizing Cytomegalovirus (CMV) specific DC vaccines in patients with newly diagnosed GBM whereby each follow-up study had nearly doubled in sample size. Follow-up data from the first blinded, randomized phase II clinical trial (NCT00639639) revealed that nearly one-third of this cohort is without tumor recurrence at five years from diagnosis. A second clinical trial (NCT00639639) resulted in a 36% survival rate at five years from diagnosis. Results of the first two-arm trial (NCT00639639) showed increased migration of the DC vaccine to draining lymph nodes, and this increased migration has been recapitulated in our larger confirmatory clinical study (NCT02366728). We have now observed that nearly one-third of the GBM study patient population receiving CMV-specific DC vaccines results in exceptional long-term survivors.",2020,A second clinical trial (NCT00639639) resulted in a 36% survival rate at five years from diagnosis.,"['200 registered GBM trials identified between 2005 and 2015, nearly half were single-arm studies with sample sizes not exceeding 50 patients', 'patients with newly diagnosed GBM whereby each follow-up study had nearly doubled in sample size']","['CMV-specific DC vaccines', 'Cytomegalovirus (CMV) specific DC vaccines']",['survival rate'],"[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0016441', 'cui_str': 'Followup Studies'}, {'cui': 'C0205173', 'cui_str': 'Double'}]","[{'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]","[{'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",,0.387828,A second clinical trial (NCT00639639) resulted in a 36% survival rate at five years from diagnosis.,"[{'ForeName': 'Kristen A', 'Initials': 'KA', 'LastName': 'Batich', 'Affiliation': 'Oncology, Duke University.'}, {'ForeName': 'Duane A', 'Initials': 'DA', 'LastName': 'Mitchell', 'Affiliation': 'Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Healy', 'Affiliation': 'Divisions of Medical Oncology and Urology, Duke University, Duke Cancer Institute.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Herndon', 'Affiliation': 'Biostatistics, Duke Medical Center.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Sampson', 'Affiliation': 'Neurosurgery, Duke Medical Center john.sampson@duke.edu.'}]",Clinical cancer research : an official journal of the American Association for Cancer Research,['10.1158/1078-0432.CCR-20-1082'] 2248,32719011,Effects on time to lapse of switching menthol smokers to non-menthol cigarettes prior to a cessation attempt: a pilot study.,"INTRODUCTION Menthol smokers (particularly African-Americans) have lower cessation success rates than non-menthol smokers. With bans being considered on characterising menthol flavour in cigarettes, data are needed regarding how switching to non-menthol cigarettes impacts cessation measures. METHODS In this randomised pilot study, African-American menthol cigarette smokers interested in quitting smoking either continued smoking menthol cigarettes (n=60) or switched to non-menthol cigarettes (n=62) for a 1-month period prior to a cessation attempt. The primary endpoint was time to smoking lapse (ie, time from quitting until any smoking). Additional endpoints included time to smoking relapse (ie, number of days from quitting until the first of seven consecutive smoking days) and difference between groups in subjective measures. RESULTS After attempting to quit, the non-menthol cigarette group had indications of delayed time to lapse (HR 0.82; 95% CI 0.55 to 1.22; p=0.33) and time to relapse (HR 0.67; 95% CI 0.42 to 1.06; p=0.09), although these were not statistically significant. Post hoc analyses suggest that observed differences were largely due to a smaller proportion of participants in the non-menthol group relapsing within the first day of quitting (21% vs 40%; p=0.05). Values of other measures assessed postcessation were largely similar between groups. CONCLUSIONS These data suggest that among African-American smokers, a menthol cigarette ban would not undermine short-term cessation measures and may result in some benefits. Future research is needed to assess longer term cessation rates and to identify interventions to maximise cessation success in the event of a menthol ban. TRIAL REGISTRATION NUMBER NCT02342327.",2020,Post hoc analyses suggest that observed differences were largely due to a smaller proportion of participants in the non-menthol group relapsing within the first day of quitting (21% vs 40%; p=0.05).,"['Menthol smokers (particularly African-Americans', 'African-American smokers', 'African-American menthol cigarette smokers interested in quitting smoking either continued smoking menthol cigarettes (n=60) or']",['switched to non-menthol cigarettes'],"['time to relapse', 'time to smoking relapse (ie, number of days from quitting until the first of seven consecutive smoking days) and difference between groups in subjective measures', 'indications of delayed time to lapse', 'time to smoking lapse (ie, time from quitting until any smoking']","[{'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker'}, {'cui': 'C0543488', 'cui_str': 'Interested'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0522486', 'cui_str': 'Delay time'}]",,0.0205715,Post hoc analyses suggest that observed differences were largely due to a smaller proportion of participants in the non-menthol group relapsing within the first day of quitting (21% vs 40%; p=0.05).,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kotlyar', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA kotly001@umn.edu.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Shanley', 'Affiliation': 'Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Sheena R', 'Initials': 'SR', 'LastName': 'Dufresne', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Gretchen A', 'Initials': 'GA', 'LastName': 'Corcoran', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Kolawole S', 'Initials': 'KS', 'LastName': 'Okuyemi', 'Affiliation': 'Department of Family and Preventive Medicine, University of Utah Health, Salt Lake City, Utah, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Mills', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Dorothy K', 'Initials': 'DK', 'LastName': 'Hatsukami', 'Affiliation': 'Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2020-055689'] 2249,32719050,Online supplementation for teaching evidence-based medicine: feasibility of a randomised-controlled trial.,"BACKGROUND AND OBJECTIVES As teaching technologyadvances, medical education is increasingly using digital mediums and exploringinstructional models such as the flipped classroom and blended learningcourses, where the in-class taught sessions are more groups on contentdelivered before class. Early evidence suggestslectures and foundational material can be equally provided onlinebut we have low-quality research to be convinced. We aim to test anddevelop an online evidence-based teaching resource that seeks to improve theavailability and scalability of evidence-based medicine (EBM) learning tools. Weevaluate the feasibility of a study design that could test for changes inacademic performance in EBM skills using an online supplement. METHODS Mixed-methods feasibility study of a randomised controlled trial (RCT) in an undergraduate medical student cohort. RESULTS Of a small cohort (n=34), eightparticipants agreed to randomisation and completed the studyNo studyparticipant completed the EBM supplementary course in full. Students reporttime- management as a significant barrier in participation, and all aspects ofthe study and communications should be delivered with efficiency a keyconsideration. CONCLUSION andomising students to an onlineEBM supplement within a medical school programme presents challenges ofrecruitment and student motivation, but the studydesign is potentially feasible.",2020,We aim to test anddevelop an online evidence-based teaching resource that seeks to improve theavailability and scalability of evidence-based medicine (EBM) learning tools.,"['undergraduate medical student cohort', 'Of a small cohort (n=34']",['Online supplementation'],[],"[{'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}]","[{'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]",[],,0.153404,We aim to test anddevelop an online evidence-based teaching resource that seeks to improve theavailability and scalability of evidence-based medicine (EBM) learning tools.,"[{'ForeName': 'Marcy C', 'Initials': 'MC', 'LastName': 'McCall', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK marcy.mccall@phc.ox.ac.uk.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Fanshawe', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'McCartney', 'Affiliation': 'Medical Sciences Division, Oxford University, Oxford, Oxfordshire, UK.'}, {'ForeName': 'Damion', 'Initials': 'D', 'LastName': 'Young', 'Affiliation': 'Medical Sciences Division, Oxford University, Oxford, Oxfordshire, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nunan', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Heneghan', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, Oxford University, Oxford, UK.'}]",BMJ evidence-based medicine,['10.1136/bmjebm-2020-111372'] 2250,32719055,What matters most to patients when choosing treatment for mild-moderate asthma? Results from a discrete choice experiment.,"BACKGROUND An as-needed combination preventer and reliever regimen was recently introduced as an alternative to conventional daily preventer treatment for mild asthma. In a subgroup analysis of the PRACTICAL study, a pragmatic randomised controlled trial of budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild asthma, we recently reported that about two-thirds preferred as-needed combination preventer and reliever therapy. The aim of this study was to determine the relative importance of attributes associated with these two asthma therapies in this subgroup of participants who indicated their preferred treatment in the PRACTICAL study. METHODS At their final study visit, a subgroup of participants indicated their preferred treatment and completed a discrete choice experiment using the Potentially All Pairwise RanKings of all possible Alternatives method and 1000minds software. Treatment attributes and their levels were selected from measurable study outcomes, and included: treatment regimen, shortness of breath, steroid dose and likelihood of asthma flare-up. RESULTS The final analysis dataset included 288 participants, 64% of whom preferred as-needed combination preventer and reliever. Of the attributes, no shortness of breath and lowest risk of asthma flare-up were ranked highest and second highest, respectively. However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment. CONCLUSIONS Knowledge of patient preferences for treatment attributes together with regimen characteristics can be used in shared decision-making regarding choice of treatment for patients with mild-moderate asthma. TRIAL REGISTRATION NUMBER ACTRN12616000377437.",2020,"However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment. ","['288 participants, 64% of whom preferred as-needed combination preventer and reliever', 'adults with mild asthma', 'mild asthma', 'patients with mild-moderate asthma']","['budesonide-formoterol reliever therapy', 'budesonide plus terbutaline reliever therapy']","['shortness of breath, steroid dose and likelihood of asthma flare-up']","[{'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0581124', 'cui_str': 'Mild asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}]","[{'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039542', 'cui_str': 'Terbutaline'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}]",288.0,0.0755572,"However, the relative importance of the other two attributes varied by preferred therapy: treatment regimen was ranked higher by participants who preferred as-needed treatment than by participants who preferred maintenance treatment. ","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Baggott', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand christina.baggott@mrinz.ac.nz.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Hansen', 'Affiliation': 'Economics, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Hancox', 'Affiliation': 'Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.'}, {'ForeName': 'Jo Katherine', 'Initials': 'JK', 'LastName': 'Hardy', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Sparks', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Holliday', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Weatherall', 'Affiliation': 'Medicine, University of Otago Wellington, Wellington, New Zealand.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Beasley', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': 'Helen K', 'Initials': 'HK', 'LastName': 'Reddel', 'Affiliation': 'Woolcock Institute of Medical Research, University of Sydney, Glebe, New South Wales, Australia.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Fingleton', 'Affiliation': 'Asthma Programme, Medical Research Institute of New Zealand, Wellington, New Zealand.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Thorax,['10.1136/thoraxjnl-2019-214343'] 2251,32719073,Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an invasive versus conservative strategy: angiographic and procedural results from the After Eighty study.,"OBJECTIVES We aimed to report the angiographic and procedural results of the After Eighty study (ClinicalTrials.gov, NCT01255540), and to identify independent predictors of revascularisation. METHODS Patients of ≥80 years old with non-ST-elevation myocardial infarction and unstable angina pectoris were randomised to an invasive or conservative strategy. Angiographic and procedural results were recorded. Univariate and multivariate analyses were performed to explore variables predicting revascularisation. RESULTS Among 229 patients in the invasive group, 220 underwent immediate coronary angiography (90% performed via the radial artery). Of these patients, 48% had three-vessel disease or left main stenosis, 18% two-vessel disease, 16% one-vessel disease, 17% minor coronary vessel wall changes and two patients had normal coronary arteries. Six patients (3%) underwent coronary artery bypass graft. Percutaneous coronary intervention (PCI) was performed in 107 patients (49%), with 57% treated with bare metal stents, 37% drug-eluting stents and 6% balloon angioplasty. On average, 1.7 lesions were treated and 2 stents delivered per patient. Complications included 1 major PCI-related bleeding (successfully treated), 2 minor access site-related bleedings, 3 side branch occlusions during PCI and 11 periprocedural myocardial infarctions (considered end points). Sex, bundle branch block and smoking were independent predictors of revascularisation. CONCLUSIONS PCI was performed in approximately half of the patients, similar to findings in younger populations. Procedural success was high, with few complications. TRIAL REGISTRATION NUMBER NCT01255540.",2020,"Procedural success was high, with few complications. ","['Patients of ≥80 years old with non-ST-elevation myocardial infarction and unstable angina pectoris', '107 patients (49%), with 57% treated with', 'Patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris randomised to an', '229 patients in the invasive group']","['invasive versus conservative strategy: angiographic', 'bare metal stents, 37% drug-eluting stents and 6% balloon angioplasty', 'invasive or conservative strategy', 'Percutaneous coronary intervention (PCI', 'coronary artery bypass graft', 'immediate coronary angiography']","['major PCI-related bleeding (successfully treated), 2 minor access site-related bleedings, 3 side branch occlusions during PCI and 11 periprocedural myocardial infarctions', 'vessel disease or left main stenosis', 'normal coronary arteries', 'Procedural success']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1276061', 'cui_str': 'Acute non-ST segment elevation myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0085532', 'cui_str': 'Coronary angiography'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0026193', 'cui_str': 'Minor'}, {'cui': 'C0589360', 'cui_str': 'Site of access'}, {'cui': 'C0205384', 'cui_str': 'Branching'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C4324584', 'cui_str': 'Periprocedural myocardial infarction'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}, {'cui': 'C1299335', 'cui_str': 'Normal coronary arteries'}]",229.0,0.141913,"Procedural success was high, with few complications. ","[{'ForeName': 'Nicolai', 'Initials': 'N', 'LastName': 'Tegn', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Eek', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Abdelnoor', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Aaberge', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Endresen', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Skårdal', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Erlend Sturle', 'Initials': 'ES', 'LastName': 'Berg', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Gullestad', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.'}, {'ForeName': 'Bjørn', 'Initials': 'B', 'LastName': 'Bendz', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway bbendz@ous-hf.no.'}]",Open heart,['10.1136/openhrt-2020-001256'] 2252,32719096,Effect of random deferral of percutaneous coronary intervention in patients with diabetes and stable ischaemic heart disease.,"BACKGROUND In stable ischaemic heart disease (SIHD), measurement of fractional flow reserve (FFR) to guide selection of lesions for percutaneous coronary intervention (PCI) reduces death and myocardial infarction (MI) compared with angiographic guidance. However, it is unknown if the improved outcomes are due to avoidance of stenting of physiologically insignificant lesions or are a by-product of placing fewer stents. METHODS We developed a Monte Carlo simulation using the PCI strata of the Bypass Angioplasty Revascularization Investigation 2 Diabetes study to investigate how random deferral of PCI impacts outcomes. To simulate deferral, a randomly selected group of patients randomised to PCI were removed and replaced by an equal number of randomly selected patients randomised to intensive medical therapy (IMT) using a random number generator in Python's NumPy module. The primary endpoint was the rate of death or non-fatal MI at 1 year. RESULTS Death/MI at 1 year occurred in 8.3% of 798 patients in the PCI group and 5.1% of 807 patients in the IMT control group (p=0.02). Following 10 000 iterations of random replacement of 10%, 20%, 30% or 40% of PCI patients with randomly selected IMT patients, the rate of death/MI at 1 year progressively declined from 8.3% to 8.0%, 7.6%, 7.3% and 7.0%, respectively. CONCLUSIONS In this simulation model, random deferral of PCI procedures in SIHD progressively reduced death/MI as the percentage of procedures deferred increases. FFR-guided deferral of PCI may improve outcomes as a result of placing fewer stents and be unrelated to the haemodynamic severity of lesions.",2020,"RESULTS Death/MI at 1 year occurred in 8.3% of 798 patients in the PCI group and 5.1% of 807 patients in the IMT control group (p=0.02).",['patients with diabetes and stable ischaemic heart disease'],"['percutaneous coronary intervention (PCI', ""intensive medical therapy (IMT) using a random number generator in Python's NumPy module"", 'percutaneous coronary intervention', 'PCI']","['rate of death or non-fatal MI', 'death and myocardial infarction (MI', 'Death/MI', 'rate of death/MI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0237638', 'cui_str': 'Generator'}, {'cui': 'C0206304', 'cui_str': 'Genus Python'}, {'cui': 'C3542953', 'cui_str': 'Module'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]",,0.0477253,"RESULTS Death/MI at 1 year occurred in 8.3% of 798 patients in the PCI group and 5.1% of 807 patients in the IMT control group (p=0.02).","[{'ForeName': 'Conor', 'Initials': 'C', 'LastName': 'Williams', 'Affiliation': 'Department of Medicine, Washington University in St Louis, St Louis, Missouri, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Brown', 'Affiliation': 'Cardiovascular Division, Washington University in St Louis, St Louis, Missouri, USA d.brown@wustl.edu.'}]",Heart (British Cardiac Society),['10.1136/heartjnl-2019-316432'] 2253,32719097,"A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina.","BACKGROUND Reduction of the coronary sinus was shown to improve angina in patients unsuitable for revascularisation. We assessed whether a percutaneous device that reduces the diameter of the coronary sinus improved outcomes across multiple endpoints in a phase II trial. METHODS We conducted a novel analysis performed as a post hoc efficacy analysis of the COSIRA ( Co ronary Si nus R educer for Treatment of Refractory A ngina) trial, which enrolled patients with Canadian Cardiovascular Society (CCS) class 3-4 refractory angina. We used four domains: symptoms (CCS Angina Scale), functionality (total exercise duration), ischaemia (imaging) and health-related quality of life. For all domains, we specified a meaningful threshold for change. The primary endpoint was defined as a probability of ≥80% that the reducer exceeded the meaningful threshold on two or more domains (group-level analysis) or that the average efficacy score in the reducer group exceeded the sham control group by at least two points (patient-level analysis). RESULTS We randomised 104 participants to either a device that narrows to coronary sinus (n=52) or a sham implantation (n=52). The reducer group met the prespecified criteria for concordance at the group level and demonstrated improvement in symptoms (0.59 CCS grade, 95% credible interval (CrI)=0.22 to 0.95), total exercise duration (+27.9%, 95% CrI=2.8% to 59.8%) and quality of life (stability +11.2 points, 95% CrI=3.3 to 19.1; perception +11.0, 95% CrI=3.3 to 18.7). CONCLUSIONS The reducer concordantly improved symptoms, functionality and quality of life compared with a sham intervention in patients with angina unsuitable for coronary revascularisation. Concordant analysis such as this one can help interpret early phase trials and guide the decision to pursue a clinical programme into a larger confirmatory trial. TRAIL REGISTRATION NUMBER ClinicalTrials.gov identifier: NCT01205893.",2020,"The reducer concordantly improved symptoms, functionality and quality of life compared with a sham intervention in patients with angina unsuitable for coronary revascularisation.","['patients unsuitable for revascularisation', 'enrolled patients with Canadian Cardiovascular Society (CCS) class 3-4 refractory angina', 'patients with angina unsuitable for coronary revascularisation', '104 participants to either a device that narrows to coronary sinus (n=52) or a sham implantation (n=52']","['COSIRA ', 'percutaneous device', 'Co ronary']","['quality of life', 'Si nus', 'average efficacy score', 'symptoms', 'symptoms, functionality and quality of life', 'symptoms, functional status and quality of life', 'total exercise duration', 'symptoms (CCS Angina Scale), functionality (total exercise duration), ischaemia (imaging) and health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0741032', 'cui_str': 'Refractory angina'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0877341', 'cui_str': 'Coronary revascularisation'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C0456944', 'cui_str': 'Coronary sinus structure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0002962', 'cui_str': 'Angina pectoris'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",104.0,0.150174,"The reducer concordantly improved symptoms, functionality and quality of life compared with a sham intervention in patients with angina unsuitable for coronary revascularisation.","[{'ForeName': 'E Marc', 'Initials': 'EM', 'LastName': 'Jolicoeur', 'Affiliation': 'Department of Medicine, Interventional Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada marc.jolicoeur@icm-mhi.org.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Verheye', 'Affiliation': 'Antwerp Cardiovascular Institute, ZNA Middelheim Hospital, Antwerpen, Belgium.'}, {'ForeName': 'Timothy D', 'Initials': 'TD', 'LastName': 'Henry', 'Affiliation': 'The Carl and Edyth Lindner Center for Research and Education, The Christ Hospital, Cincinnati, Ohio, United States.'}, {'ForeName': 'Lawrence', 'Initials': 'L', 'LastName': 'Joseph', 'Affiliation': 'Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Doucet', 'Affiliation': 'Department of Medicine, Interventional Cardiology, Montreal Heart Institute, Montreal, Quebec, Canada.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'White', 'Affiliation': 'The John Ochsner Heart & Vascular Institute, Ochsner Clinical School, University of Queensland, New Orleans, Louisiana, USA.'}, {'ForeName': 'Elazer', 'Initials': 'E', 'LastName': 'Edelman', 'Affiliation': 'Institute for Medical Engineering and Science, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Banai', 'Affiliation': 'The Tel Aviv Medical Center, The Tel Aviv University Medical School, Tel Aviv, Israel.'}]",Heart (British Cardiac Society),['10.1136/heartjnl-2020-316644'] 2254,32719129,Randomized trial shows healthcare payment reform has equal-sized spillover effects on patients not targeted by reform.,"Changes in the way health insurers pay healthcare providers may not only directly affect the insurer's patients but may also affect patients covered by other insurers. We provide evidence of such spillovers in the context of a nationwide Medicare bundled payment reform that was implemented in some areas of the country but not in others, via random assignment. We estimate that the payment reform-which targeted traditional Medicare patients-had effects of similar magnitude on the healthcare experience of nontargeted, privately insured Medicare Advantage patients. We discuss the implications of these findings for estimates of the impact of healthcare payment reforms and more generally for the design of healthcare policy.",2020,"We estimate that the payment reform-which targeted traditional Medicare patients-had effects of similar magnitude on the healthcare experience of nontargeted, privately insured Medicare Advantage patients.",[],[],[],[],[],[],,0.0338305,"We estimate that the payment reform-which targeted traditional Medicare patients-had effects of similar magnitude on the healthcare experience of nontargeted, privately insured Medicare Advantage patients.","[{'ForeName': 'Liran', 'Initials': 'L', 'LastName': 'Einav', 'Affiliation': 'Department of Economics, Stanford University, Stanford, CA 94305.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Finkelstein', 'Affiliation': 'National Bureau of Economic Research, Cambridge, MA 02138; afink@mit.edu.'}, {'ForeName': 'Yunan', 'Initials': 'Y', 'LastName': 'Ji', 'Affiliation': 'Graduate School of Arts and Sciences, Harvard University, Cambridge, MA 02138.'}, {'ForeName': 'Neale', 'Initials': 'N', 'LastName': 'Mahoney', 'Affiliation': 'Department of Economics, Stanford University, Stanford, CA 94305.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2004759117'] 2255,32719133,Objecting to experiments even while approving of the policies or treatments they compare.,"We resolve a controversy over two competing hypotheses about why people object to randomized experiments: 1) People unsurprisingly object to experiments only when they object to a policy or treatment the experiment contains, or 2) people can paradoxically object to experiments even when they approve of implementing either condition for everyone. Using multiple measures of preference and test criteria in five preregistered within-subjects studies with 1,955 participants, we find that people often disapprove of experiments involving randomization despite approving of the policies or treatments to be tested.",2020,"Using multiple measures of preference and test criteria in five preregistered within-subjects studies with 1,955 participants, we find that people often disapprove of experiments involving randomization despite approving of the policies or treatments to be tested.","['five preregistered within-subjects studies with 1,955 participants']",[],[],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],[],,0.0207082,"Using multiple measures of preference and test criteria in five preregistered within-subjects studies with 1,955 participants, we find that people often disapprove of experiments involving randomization despite approving of the policies or treatments to be tested.","[{'ForeName': 'Patrick R', 'Initials': 'PR', 'LastName': 'Heck', 'Affiliation': 'Center for Translational Bioethics and Health Care Policy, Geisinger Health System, Danville, PA 17822; pheck1000@gmail.com.'}, {'ForeName': 'Christopher F', 'Initials': 'CF', 'LastName': 'Chabris', 'Affiliation': 'Autism and Developmental Medicine Institute, Geisinger Health System, Lewisburg, PA 17837.'}, {'ForeName': 'Duncan J', 'Initials': 'DJ', 'LastName': 'Watts', 'Affiliation': 'Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA 19104.'}, {'ForeName': 'Michelle N', 'Initials': 'MN', 'LastName': 'Meyer', 'Affiliation': 'Center for Translational Bioethics and Health Care Policy, Geisinger Health System, Danville, PA 17822.'}]",Proceedings of the National Academy of Sciences of the United States of America,['10.1073/pnas.2009030117'] 2256,32719151,'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?',"Total hip and total knee arthroplasty) remain important interventions to treat symptomatic knee and hip damage in patients with rheumatoid arthritis, with little change in utilisation rates despite the increasingly widespread use of potent conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and targeted DMARDs including Janus kinase inhibitors and biologics. The majority of patients are receiving these immunosuppressing medications and glucocorticoids at the time they present for arthroplasty. There is minimal randomised controlled trial data addressing the use of DMARDs in the perioperative period, yet patients and their physicians face these decisions daily. This paper reviews what is known regarding perioperative management of targeted and csDMARDs and glucocorticoids.",2020,"Total hip and total knee arthroplasty) remain important interventions to treat symptomatic knee and hip damage in patients with rheumatoid arthritis, with little change in utilisation rates despite the increasingly widespread use of potent conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and targeted DMARDs including Janus kinase inhibitors and biologics.","['patients with rheumatoid arthritis', 'patients with inflammatory rheumatic diseases', 'Total hip and total knee arthroplasty']",['conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0009326', 'cui_str': 'Collagen disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0242708', 'cui_str': 'Disease-Modifying Antirheumatic Drugs'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]",[],,0.0359957,"Total hip and total knee arthroplasty) remain important interventions to treat symptomatic knee and hip damage in patients with rheumatoid arthritis, with little change in utilisation rates despite the increasingly widespread use of potent conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and targeted DMARDs including Janus kinase inhibitors and biologics.","[{'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'Goodman', 'Affiliation': 'Department of Medicine, Hospital for Special Surgery, Weill Cornell Medicine, New York, USA Goodmans@hss.edu.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'George', 'Affiliation': 'Department of Biostatistics, Epidemiology and Informatics, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}]",RMD open,['10.1136/rmdopen-2020-001214'] 2257,32719231,Comparison of efficacy of potassium titanyl phosphate laser & diode laser in the management of inferior turbinate hypertrophy: A randomized controlled trial.,"Background & objectives Inferior turbinate hypertrophy (ITH) is a common condition causing nasal obstruction. This study was undertaken to compare the efficacy of potassium titanyl phosphate (KTP) laser and diode laser in the reduction of the turbinate size. Methods This randomized controlled trial included 209 patients with ITH. Pre-operative symptoms were assessed based on the Nasal Obstruction Symptom Evaluation (NOSE) score. Diagnostic nasal endoscopy was done to rule out other nasal sinuses. Nasal mucociliary clearance was measured by saccharin transit time (STT). Postoperatively, the NOSE score, STT and complications were assessed at days one and two, at one week, one month and three months. Results Of the 209 patients analyzed at day one, the median NOSE score was 50 in the diode group and 40 in the KTP group, and at three months, 15 in the diode group and five in the KTP group. KTP laser showed a 93 per cent improvement in the NOSE score as compared to 77 per cent improvement shown by diode laser group. Among the intra-operative complications, of the 104 patients in the diode group, 6.73 per cent had burning sensation and 91.43 per cent had bleeding, and of 105 patients in the KTP group, 54.29 per cent had burning sensation and 36.54 per cent had bleeding. Among the post-operative complications in the KTP group, 32 and 34 per cent had bloody nasal discharge on days one and two, compared to 12 and 14 per cent in diode group. Crusting was present in 61 and 49 per cent on days one and two in KTP group as compared to 9 and 15 per cent in diode group, respectively. In the KTP group 30 per cent had synechiae as compared to 10 per cent in diode group. Interpretation & conclusions KTP laser was more efficacious than diode laser in improving the NOSE scores but with slightly increased rate of complications in early post-operative period. Both the lasers impaired the mucociliary clearance mechanism of the nose till three months of post-operative follow up.",2020,Both the lasers impaired the mucociliary clearance mechanism of the nose till three months of post-operative follow up.,"['209 patients with ITH. Pre-operative symptoms', '209 patients analyzed at day one', 'inferior turbinate hypertrophy']","['Diagnostic nasal endoscopy', 'potassium titanyl phosphate laser & diode laser', 'potassium titanyl phosphate (KTP) laser and diode laser', 'diode laser', 'KTP laser', 'KTP']","['Nasal mucociliary clearance', 'NOSE score', 'saccharin transit time (STT', 'burning sensation', 'NOSE scores', 'bloody nasal discharge', 'Crusting', 'mucociliary clearance mechanism', 'bleeding', 'Nasal Obstruction Symptom Evaluation (NOSE) score', 'median NOSE score', 'rate of complications', 'NOSE score, STT and complications']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0225434', 'cui_str': 'Inferior nasal turbinate bone structure'}, {'cui': 'C0020564', 'cui_str': 'Hypertrophy'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0189024', 'cui_str': 'Endoscopy of nose'}, {'cui': 'C0392222', 'cui_str': 'Potassium titanyl phosphate laser device'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}]","[{'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary clearance'}, {'cui': 'C0027429', 'cui_str': 'Nasal obstruction'}, {'cui': 'C3494438', 'cui_str': 'Symptom Evaluation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0036023', 'cui_str': 'Saccharin'}, {'cui': 'C1301827', 'cui_str': 'In transit'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0085624', 'cui_str': 'Burning sensation'}, {'cui': 'C0333275', 'cui_str': 'Hemorrhagic'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0205204', 'cui_str': 'Crust'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",209.0,0.070627,Both the lasers impaired the mucociliary clearance mechanism of the nose till three months of post-operative follow up.,"[{'ForeName': 'Subhashini Puducherry', 'Initials': 'SP', 'LastName': 'Ravichandran', 'Affiliation': 'Department of Otorhinolarngology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.'}, {'ForeName': 'Karthikeyan', 'Initials': 'K', 'LastName': 'Ramasamy', 'Affiliation': 'Department of Otorhinolarngology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.'}, {'ForeName': 'Pradipta Kumar', 'Initials': 'PK', 'LastName': 'Parida', 'Affiliation': 'Department of Otorhinolarngology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Alexander', 'Affiliation': 'Department of Otorhinolarngology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.'}, {'ForeName': 'Sivaraman', 'Initials': 'S', 'LastName': 'Ganesan', 'Affiliation': 'Department of Otorhinolarngology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.'}, {'ForeName': 'Sunil Kumar', 'Initials': 'SK', 'LastName': 'Saxena', 'Affiliation': 'Department of Otorhinolarngology, Jawaharlal Institute of Postgraduate Medical Education & Research, Puducherry, India.'}]",The Indian journal of medical research,['10.4103/ijmr.IJMR_424_18'] 2258,32719239,Evaluation of the safety and efficacy of minimal endoscopic sphincterotomy followed by papillary balloon dilation for the removal of common bile duct stones.,"Background/Aim A sufficiently open papilla is needed to remove common bile duct stones (CBDS) but endoscopic sphincterotomy (EST) requires a high level of skill and is difficult with endoscopic papillary balloon dilation (EPBD). The main adverse event of EST is bleeding and perforation and that of EPBD is post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. To reduce these adverse events we employed minimal EST followed by papillary dilation (ESBD), and retrospectively evaluated its efficacy and safety compared with EST. Patients and Methods CBDS patients who underwent EST (n = 114) or ESBD (n = 321) at Juntendo University Hospital from January 2009 to December 2018 were consecutively enrolled, retrospectively. The exclusion criteria were large-balloon dilation (≥ 12 mm), large CBDS (>12 mm), and previous EST/EPBD. We compared the overall stone removal rate, incidence of adverse event, procedure time, number of ERCP procedures, and rate of mechanical lithotripsy (ML) between the two groups. Results Complete stone removal was successful in both ESBD and EST group. However, the rate of multiple ERCP sessions was significantly lower (35.1% vs. 12.8%, P < 0.001), procedure time was shorter (31.6 vs. 25.8 min, P = 0.01), and rate of ML was lower (16.7% vs. 7.8%, P = 0.01) in ESBD group. Bleeding was significantly more frequent in the EST group (9.6% vs. 1.2%, P < 0.001), particularly acute bleeding (7.9% vs. 0.9%, P < 0.001). Conclusions ESBD is more efficient and safer in the management of CBD stones than EST. A prospective randomized study comparing ESBD with EST is needed to establish this combination technique.",2020,"Bleeding was significantly more frequent in the EST group (9.6% vs. 1.2%, P < 0.001), particularly acute bleeding (7.9% vs. 0.9%, P < 0.001). ","['Patients and Methods\n\n\nCBDS patients who underwent EST (n = 114) or ESBD (n = 321) at Juntendo University Hospital from January 2009 to December 2018 were consecutively enrolled, retrospectively']","['ESBD with EST', 'endoscopic sphincterotomy (EST', 'minimal endoscopic sphincterotomy followed by papillary balloon dilation', 'EST']","['procedure time', 'acute bleeding', 'Bleeding', 'efficacy and safety', 'safety and efficacy', 'overall stone removal rate, incidence of adverse event, procedure time, number of ERCP procedures, and rate of mechanical lithotripsy (ML', 'rate of ML', 'rate of multiple ERCP sessions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0009438', 'cui_str': 'Common bile duct calculus'}, {'cui': 'C0085263', 'cui_str': 'Endoscopic Sphincterotomy'}, {'cui': 'C4708785', 'cui_str': '114'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205312', 'cui_str': 'Papillary'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0085263', 'cui_str': 'Endoscopic Sphincterotomy'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}]","[{'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0333276', 'cui_str': 'Acute hemorrhage'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0008310', 'cui_str': 'Endoscopic retrograde cholangiopancreatography'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0023878', 'cui_str': 'Lithotripsy'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]",,0.085548,"Bleeding was significantly more frequent in the EST group (9.6% vs. 1.2%, P < 0.001), particularly acute bleeding (7.9% vs. 0.9%, P < 0.001). ","[{'ForeName': 'Shigeto', 'Initials': 'S', 'LastName': 'Ishii', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Fujisawa', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Mako', 'Initials': 'M', 'LastName': 'Ushio', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Sho', 'Initials': 'S', 'LastName': 'Takahashi', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Wataru', 'Initials': 'W', 'LastName': 'Yamagata', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Takasaki', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Akinori', 'Initials': 'A', 'LastName': 'Suzuki', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Yoshihiro', 'Initials': 'Y', 'LastName': 'Okawa', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Kazushige', 'Initials': 'K', 'LastName': 'Ochiai', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Ko', 'Initials': 'K', 'LastName': 'Tomishima', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Ryo', 'Initials': 'R', 'LastName': 'Kanazawa', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Hiroaki', 'Initials': 'H', 'LastName': 'Saito', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Shuichiro', 'Initials': 'S', 'LastName': 'Shiina', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Isayama', 'Affiliation': 'Department of Gastroenterology, Juntendo University Graduate School of Medicine, Hongo, Bunkyo-ku, Tokyo, Japan.'}]",Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association,['10.4103/sjg.SJG_162_20'] 2259,32719251,The efficacy of an ayurvedic preparation of yashtimadhu ( Glycyrrhiza glabra ) on radiation-induced mucositis in head-and-neck cancer patients: A pilot study.,"Background Oral mucositis is a common and debilitating painful side effect of many forms of chemotherapy and radiation therapy. Mucositis may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy (RT) and often affects patients' quality of life. Aim The objective of the study was to assess the efficacy of the ayurvedic preparation in decreasing the severity of mucositis in head-and-neck cancer patients receiving concomitant chemoradiotherapy. Materials and Methods In this prospective randomized study, the patients were divided into three groups. Group 1 patients received conventional mucositis treatment, whereas Group 2 patients received ayurvedic preparation Yashtimadhu in addition to conventional treatment. Group 3 patients received honey for local application in oral cavity as well as one tea spoon of honey twice daily orally in addition to routine conventional treatment. All the patients were assessed for mucositis at the end of every week during the RT for a period of 6 weeks. Results A significant difference was observed between the groups at each time point. Nearly 42.85% of patients in conventional treatment arm developed Grade 3 mucositis, 20% of patients developed Grade 3 mucositis in group where honey was given, and only 15.5% of patients developed Grade 3 mucositis in Yastimadhu group. Unplanned treatment breaks and hospitalization of patients were reduced with the use of yashtimadhu as compared to other two groups. Conclusion Yashtimadhu was observed to be effective and delayed the development of severe form of mucositis. The drug appeared to be more efficient in the management of radiation-induced mucositis.",2020,"Unplanned treatment breaks and hospitalization of patients were reduced with the use of yashtimadhu as compared to other two groups. ","['head-and-neck cancer patients receiving concomitant chemoradiotherapy', 'head-and-neck cancer patients']","['conventional mucositis treatment', 'honey for local application in oral cavity as well as one tea spoon of honey twice daily orally in addition to routine conventional treatment', 'ayurvedic preparation', 'ayurvedic preparation of yashtimadhu ( Glycyrrhiza glabra ', 'chemotherapy', 'ayurvedic preparation Yashtimadhu in addition to conventional treatment', 'and/or radiotherapy (RT']","['Grade 3 mucositis', 'mucositis', 'Mucositis', 'severity of mucositis']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019906', 'cui_str': 'Honey'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0039400', 'cui_str': 'Tea'}, {'cui': 'C0581226', 'cui_str': 'Spoon'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0697105', 'cui_str': 'Glycyrrhiza glabra'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]","[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.0160937,"Unplanned treatment breaks and hospitalization of patients were reduced with the use of yashtimadhu as compared to other two groups. ","[{'ForeName': 'Ravindra Kumar', 'Initials': 'RK', 'LastName': 'Mamgain', 'Affiliation': 'Department of Ayurvedic Medicine, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Meenu', 'Initials': 'M', 'LastName': 'Gupta', 'Affiliation': 'Department of Radiation Oncology, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Pratibha', 'Initials': 'P', 'LastName': 'Mamgain', 'Affiliation': 'Department of Ayurvedic Medicine, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Sanjeev Kumar', 'Initials': 'SK', 'LastName': 'Verma', 'Affiliation': 'Department of Medicine, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Deep Shankar', 'Initials': 'DS', 'LastName': 'Pruthi', 'Affiliation': 'Department of Radiation Oncology, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Abhishek', 'Initials': 'A', 'LastName': 'Kandwal', 'Affiliation': 'Department of Dental Surgery, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Saini', 'Affiliation': 'Department of Surgery, Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_831_16'] 2260,32719253,Effect of probiotic bacteria on oral Candida in head- and neck-radiotherapy patients: A randomized clinical trial.,"Objective The aim of the study is to assess the effect of probiotic bacteria on oral Candida counts in cancer patients who are undergoing head- and neck-radiotherapy in a tertiary care center. Study Design The study was a randomized clinical trial including 90 patients who just completed head- and neck-radiotherapy. Materials and Methods Participants were randomly allocated into three equal sized groups, i.e., probiotics group, candid group, and combination groups. Oral rinse samples of the patients were collected before and after the intervention for the identification of Candida. The samples were incubated on Sabouraud's Dextrose Agar with Chloramphenicol at 37°C for 48 h, to assess the counts of colony-forming units/milliliter (CFU/ml) of Candida in saliva, and further on chrome agar plates to identify the Candida spp. Data were analyzed using mixed ANOVA to compare mean CFU/ml of Candida among three groups before and after the intervention. Results A total of 86 patients were included in the final analysis and there was a statistically significant reduction in mean Candida spp. Counts (CFU/ml) after intervention in all the three groups (P = 0.000) and significant reductions identified in both probiotic and combination therapy groups. Apart from reduction in Candida albicans, significant decrease in Candida glabrata and Candida tropicalis was observed after probiotics usage compared to other groups. Conclusions The present study suggests that probiotic bacteria were effective in reducing oral Candida spp which can be recommended alone or in combination with traditional antifungal agents for effective reduction in oral Candida in head- and neck-radiotherapy patients.",2020,Counts (CFU/ml) after intervention in all the three groups (P = 0.000) and significant reductions identified in both probiotic and combination therapy groups.,"['head- and neck-radiotherapy patients', '86 patients', 'cancer patients who are undergoing head- and neck-radiotherapy in a tertiary care center', '90 patients who just completed head- and neck-radiotherapy']","['probiotics group, candid group, and combination groups', 'probiotic bacteria', 'Chloramphenicol']","['oral Candida counts', 'Candida albicans', 'mean Candida spp', 'Candida glabrata and Candida tropicalis']","[{'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0008168', 'cui_str': 'Chloramphenicol'}]","[{'cui': 'C0006849', 'cui_str': 'Candidiasis of mouth'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0006837', 'cui_str': 'Candida albicans'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0006836', 'cui_str': 'Candida'}, {'cui': 'C0074992', 'cui_str': 'sphingosine 1-phosphate'}, {'cui': 'C0319899', 'cui_str': 'Candida glabrata'}, {'cui': 'C0319882', 'cui_str': 'Candida tropicalis'}]",90.0,0.0590852,Counts (CFU/ml) after intervention in all the three groups (P = 0.000) and significant reductions identified in both probiotic and combination therapy groups.,"[{'ForeName': 'Radhika', 'Initials': 'R', 'LastName': 'Doppalapudi', 'Affiliation': 'Department of Oral Radiology, College of Dentistry, Aljouf University, Sakaka, Kingdom of Saudi Arabia.'}, {'ForeName': 'Sudhakar', 'Initials': 'S', 'LastName': 'Vundavalli', 'Affiliation': 'Department of Preventive Dentistry, College of Dentistry, Aljouf University, Sakaka, Kingdom of Saudi Arabia.'}, {'ForeName': 'M P', 'Initials': 'MP', 'LastName': 'Prabhat', 'Affiliation': 'Department of Oral Medicine and Radiology, Drs. S and NR Siddhartha Institute of Dental Sciences, Gannavaram, Andhra Pradesh, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_334_18'] 2261,32719254,A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer.,"Context As the number of head-and-neck cancer (HNC) patients are high in our subcontinent, the study was designed to reduce the treatment time and increase efficacy. Aims Comparative evaluation of the efficacy, toxicity, local control, and survival of concomitant boost radiotherapy (CBRT), CBRT with concurrent chemoradiation (CBRT + CCT) and conventionally fractionated radiotherapy with concomitant chemotherapy (CFRT + CCT) in locally advanced HNC (LAHNC). Materials and Methods Patients with LAHNC were randomly assigned to 3-groups of 30-patients each. Group I (CBRT) received, 45 Gy/25#/5-weeks and 18 Gy/10# concomitant boost in the last 2-week of treatment, receiving a total dose of 63 Gy. Group II (CBRT + CCT) received CBRT with concomitant cisplatin 75 mg/m 2 on day 1, 17, and 34. Group III (CFRT + CCT) received 64 Gy/32#/6.2 weeks, concurrent with injection cisplatin 75 mg/m 2 on day 1, 22, and 42. Statistical Analysis Used Stata 9.0 SPSS and Chi-square test were used for analysis and disease-free survival (DFS) rates were calculated using the Kaplan-Meier method. Results The median follow-up period was 8.2 months. At last follow-up, locoregional control was 36%, 57%, and 40% and DFS was seen in 33%, 53%, and 40% of patients in Group I, II, and III, respectively. Grade-3 cutaneous reactions were significantly higher in Group-II as compared to that of Group-III (P = 0.033) and Group-I (P = 0.715). Conclusion All three groups have similar response rates and DFS with manageable toxicity.",2020,"Grade-3 cutaneous reactions were significantly higher in Group-II as compared to that of Group-III (P = 0.033) and Group-I (P = 0.715). ","['Patients with LAHNC', 'locally advanced HNC (LAHNC', 'locally advanced head-and-neck cancer']","['injection cisplatin', 'concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation', 'concomitant boost radiotherapy (CBRT), CBRT with concurrent chemoradiation (CBRT + CCT) and conventionally fractionated radiotherapy with concomitant chemotherapy (CFRT + CCT', 'Group III (CFRT + CCT', 'CBRT with concomitant cisplatin']","['efficacy, toxicity, local control, and survival', 'DFS', 'Grade-3 cutaneous reactions', 'DFS) rates', 'response rates and DFS with manageable toxicity', 'locoregional control', 'analysis and disease-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1721358', 'cui_str': 'MMP8 protein, human'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}]","[{'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C2919491', 'cui_str': 'Boost radiation therapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0524811', 'cui_str': 'Dose Fractionation, Radiotherapy'}, {'cui': 'C4049005', 'cui_str': 'Cataract, total congenital with posterior sutural opacities in Heterozygotes'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]",,0.0191286,"Grade-3 cutaneous reactions were significantly higher in Group-II as compared to that of Group-III (P = 0.033) and Group-I (P = 0.715). ","[{'ForeName': 'Parul', 'Initials': 'P', 'LastName': 'Gupta', 'Affiliation': 'Department of Radiation Oncology, Regional Cancer Centre, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.'}, {'ForeName': 'Anil Kumar', 'Initials': 'AK', 'LastName': 'Dhull', 'Affiliation': 'Department of Radiation Oncology, Regional Cancer Centre, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.'}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Kaushal', 'Affiliation': 'Department of Radiation Oncology, Regional Cancer Centre, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_475_18'] 2262,32719258,A radiobiological and dosimetrical comparison between simultaneous integrated and sequential boost intensity-modulated arc treatment of locally advanced head-and-neck cancer.,"Purpose The study aimed to compare the radiobiological and dosimetric parameters between sequential boost (SEQB) and simultaneous integrated boost (SIB) treatment regimen using intensity-modulated arc therapy technique in locally advanced head-and-neck cancer (LAHNC) patients. Materials and Methods A total of 24 previously untreated LAHNC patients were randomized into SIB (n= 11) and SEQB (n = 13) arms. The planning computed tomography data set was transferred to the treatment planning system. All the target volumes and organ at risk volumes were delineated. Single plan for SIB group and three plans (three phases) were generated for SEQB group of patients. Radiobiological and dosimetric parameters were compared. Results The BED 10 (planned) value for high-risk (HR) planning target volume (PTV) was same in both groups, whereas for intermediate-risk (IR) PTV and low-risk (LR) PTV, the values were higher in SEQB arm than SIB arm. The V 95 values were 100% for all the target volumes in both arms of patients. The average D 100 value for gross target volume, HR PTV, and IR PTV was higher in SEQB arm than that in the SIB arm. The average D 100 value for LR PTV was higher in the SIB arm compared to that of the SEQB arm. The BED 10 (achieved) was calculated using D 100 values of target volumes. The difference of BED 10 (achieved) values between SEQB arm and SIB arm further increased than the BED 10 (planned) values for all target volumes. The maximum doses for spinal cord, spinal cord planning risk volume, and brain stem were within the tolerance dose in both groups of patients. The left and right parotid glands sparing was comparable in both groups of patients. Average integral dose was higher in the SIB group than SEQB group. The average total monitor unit per fraction was higher in the SEQB arm than that in the SIB arm. Conclusion SIB regimen may be considered as more logical and efficient over SEQB regimen in the treatment of LAHNC with comparable radiobiological and dosimetric parameters.",2020,The average D 100 value for LR PTV was higher in the SIB arm compared to that of the SEQB arm.,"['locally advanced head-and-neck cancer', 'locally advanced head-and-neck cancer (LAHNC) patients', 'A total of 24 previously untreated LAHNC patients']","['SEQB', 'sequential boost (SEQB) and simultaneous integrated boost (SIB) treatment regimen using intensity-modulated arc therapy technique']","['average D 100 value for gross target volume, HR PTV, and IR PTV', 'average total monitor unit per fraction', 'intermediate-risk (IR) PTV and low-risk (LR) PTV', 'Average integral dose', 'average D 100 value for LR PTV', 'BED 10 (achieved) values between SEQB arm and SIB arm further increased than the BED 10 (planned) values', 'BED 10 (planned) value for high-risk (HR) planning target volume (PTV']","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C3489631', 'cui_str': 'Intensity-Modulated Arc Therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0454199', 'cui_str': 'Planning target volume'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0443238', 'cui_str': 'Integral'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0004914', 'cui_str': 'Bedding'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",24.0,0.022098,The average D 100 value for LR PTV was higher in the SIB arm compared to that of the SEQB arm.,"[{'ForeName': 'Abhijit', 'Initials': 'A', 'LastName': 'Mandal', 'Affiliation': 'Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Choudhary', 'Affiliation': 'Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.'}, {'ForeName': 'Nilesh', 'Initials': 'N', 'LastName': 'Mani', 'Affiliation': 'Department of Radiotherapy and Radiation Medicine, Institute of Medical Sciences, Varanasi, Uttar Pradesh, India.'}, {'ForeName': 'Sushil Kumar', 'Initials': 'SK', 'LastName': 'Aggarwal', 'Affiliation': 'Department of Otorhinolaryngology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_211_19'] 2263,32719263,Comparison of extraoral and intraoral routes of glossopharyngeal nerve block for pain relief in patient with carcinoma tongue: A prospective randomized study.,"Background and Objective Glossopharyngeal nerve block (GNB) technique has been used as alternative of treatment of cancer and noncancer pain of the oral cavity. The objective of the study is to compare the two approaches (extraoral and intraoral) of GNB in patients of carcinoma of the tongue in terms of efficacy, duration, and complications. Materials and Methods This was a prospective comparative randomized study over a period of 1 year. Fifty patients of either sex of ASA physical status and 2, between 21 and 70 years of age, suffering from carcinoma of the tongue, were selected. The patients were randomly divided into two groups. Group I received 4 mL of 0.5% bupivacaine combined with 40 mg, of triamcinolonacetonide by extraoral approach of GNB, and Group II received the same amount of drug by intraoral approach of GNB. Hemodynamic parameters, degree of pain relief using visual analog scale (VAS), number of attempts, effect on quality of life (QOL), and complication were noted during the performance of GNB. Results Demographic profile in both groups was comparable. Rate of complication and number of attempts to complete intervention were higher in Group I, which was found to be statistically significant. However, mean VAS scores in Group I were significantly higher as compared to those in Group II during most of the study period starting from the 1 st follow-up at 30 min to the 2 nd month postintervention (P < 0.05). No statistically significant difference in mean QOL scores of two groups was observed for the entire study period except at 1 week when mean scores in Group I were higher as compared to those in Group II (P = 0.011). Conclusion The intraoral approach of GNB was better with respect to pain control and improvement in QOL whereas the rate of complication and number of attempts was lower in extraoral approach of GNB.",2020,"Rate of complication and number of attempts to complete intervention were higher in Group I, which was found to be statistically significant.","['patient with carcinoma tongue', 'Fifty patients of either sex of ASA physical status and 2, between 21 and 70 years of age, suffering from carcinoma of the tongue, were selected', 'patients of carcinoma of the tongue in terms of']","['extraoral and intraoral routes of glossopharyngeal nerve block', 'GNB', '4 mL of 0.5% bupivacaine combined with 40 mg, of triamcinolonacetonide by extraoral approach of GNB', 'Glossopharyngeal nerve block (GNB) technique']","['pain relief', 'Hemodynamic parameters, degree of pain relief using visual analog scale (VAS), number of attempts, effect on quality of life (QOL), and complication', 'QOL', 'mean VAS scores', 'efficacy, duration, and complications', 'mean QOL scores', 'Rate of complication and number of attempts to complete intervention']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0558353', 'cui_str': 'Tongue carcinoma'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]","[{'cui': 'C0442089', 'cui_str': 'Extraoral approach'}, {'cui': 'C0442119', 'cui_str': 'Intraoral approach'}, {'cui': 'C0013153', 'cui_str': 'Route of administration'}, {'cui': 'C0394814', 'cui_str': 'Local anesthetic glossopharyngeal nerve block'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0025664', 'cui_str': 'methods'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",,0.032264,"Rate of complication and number of attempts to complete intervention were higher in Group I, which was found to be statistically significant.","[{'ForeName': 'Neetu', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'Department of Anaesthesiology, King George Medical University, Lucknow, Uttar Pradesh, India.'}, {'ForeName': 'Sarita', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Anaesthesiology, King George Medical University, Lucknow, Uttar Pradesh, India.'}, {'ForeName': 'Neel Kamal', 'Initials': 'NK', 'LastName': 'Mishra', 'Affiliation': 'Department of Anaesthesiology, King George Medical University, Lucknow, Uttar Pradesh, India.'}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Department of Surgical Oncology, King George Medical University, Lucknow, Uttar Pradesh, India.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': 'Department of Anaesthesiology, King George Medical University, Lucknow, Uttar Pradesh, India.'}, {'ForeName': 'Shefali', 'Initials': 'S', 'LastName': 'Gautam', 'Affiliation': 'Department of Anaesthesiology, King George Medical University, Lucknow, Uttar Pradesh, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_309_18'] 2264,32719274,Clinical and dosimetric impact of adaptive intensity-modulated radiotherapy in locally advanced head-and-neck cancer.,"Background Radiotherapy in head-and-neck cancer (HNC) is a challenging task, and the anatomical alterations occurring during the course of intensity-modulated radiotherapy (IMRT) can be compensated by adaptive radiotherapy (ART) which utilizes repeat computed tomography (CT) scans during the treatment course for replanning. In this study, the clinical and dosimetric benefits of ART were compared with the conventional IMRT. Materials and Methods Sixty patients with locally advanced HNC were randomized into two arms to receive IMRT up to a curative dose of 70 Gy with concurrent weekly chemotherapy and were prospectively analyzed between March 2018 and March 2019. Repeat CT scan was acquired after the 3 rd week of radiation. Patients in the study arm underwent replanning, whereas those in the control arm continued with the first IMRT plan. Assessment was done weekly till the end of treatment and at 1, 3, and 6 months post IMRT for disease response and toxicities. Tumor volume reduction rate (TVRR) and dose reduction to organs at risk were also recorded. Results Complete response was observed in 90% and 96.7% patients in the control and study arms, respectively, at the end of 6 months. Insignificant differences were found between the two arms in terms of toxicities. Xerostomia was statistically significantly higher in the control arm at 6 months (P = 0.01). TVRR was found to be 31.85%. Dose to spinal cord, ipsilateral, and contralateral parotid reduced by 4.3%, 6%, and 2.2%, respectively, with ART. Conclusion Mid-treatment adaptive replanning can help in better target coverage and minimize toxicities in HNC patients.",2020,Xerostomia was statistically significantly higher in the control arm at 6 months (P = 0.01).,"['head-and-neck cancer (HNC', 'HNC patients', 'locally advanced head-and-neck cancer', 'Sixty patients with locally advanced HNC']","['adaptive radiotherapy (ART) which utilizes repeat computed tomography (CT) scans', 'IMRT up to a curative dose of 70 Gy with concurrent weekly chemotherapy', 'adaptive intensity-modulated radiotherapy', '\n\n\nRadiotherapy', 'intensity-modulated radiotherapy (IMRT']","['target coverage and minimize toxicities', 'Complete response', 'toxicities', 'TVRR', 'disease response and toxicities', 'Repeat CT scan', 'Tumor volume reduction rate (TVRR) and dose reduction to organs at risk', 'Xerostomia']","[{'cui': 'C0278996', 'cui_str': 'Malignant tumor of head and neck'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C2936599', 'cui_str': 'Organs at Risk'}, {'cui': 'C0043352', 'cui_str': 'Xerostomia'}]",60.0,0.0304342,Xerostomia was statistically significantly higher in the control arm at 6 months (P = 0.01).,"[{'ForeName': 'Guncha', 'Initials': 'G', 'LastName': 'Maheshwari', 'Affiliation': 'Department of Radiation Oncology, Sardar Patel Medical College, Bikaner, Rajasthan, India.'}, {'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Dhanawat', 'Affiliation': 'Department of Internal Medicine, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India.'}, {'ForeName': 'Harvindra S', 'Initials': 'HS', 'LastName': 'Kumar', 'Affiliation': 'Department of Radiation Oncology, Sardar Patel Medical College, Bikaner, Rajasthan, India.'}, {'ForeName': 'Neeti', 'Initials': 'N', 'LastName': 'Sharma', 'Affiliation': 'Department of Radiation Oncology, Sardar Patel Medical College, Bikaner, Rajasthan, India.'}, {'ForeName': 'Shankar Lal', 'Initials': 'SL', 'LastName': 'Jakhar', 'Affiliation': 'Department of Radiation Oncology, Sardar Patel Medical College, Bikaner, Rajasthan, India.'}]",Journal of cancer research and therapeutics,['10.4103/jcrt.JCRT_928_19'] 2265,32719307,Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.,"BACKGROUND A previous phase 3 clinical trial in de novo adult kidney transplant recipients (NCT01187953) compared the efficacy and safety of once-daily LCP-tacrolimus (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). However, whether the rate of tacrolimus metabolism affects outcomes between LCPT and IR-Tac was not examined. MATERIAL AND METHODS Patients were initiated on 0.17 mg/kg/day LCPT or 0.1 mg/kg/day IR-Tac, with doses adjusted over time to maintain target therapeutic trough concentrations. This post hoc analysis examined dosing trends, relative efficacy, and safety of LCPT (n=247) and IR-Tac (n=249) in slow, intermediate, and rapid metabolizers as defined by concentration/dose ratios at day 30. RESULTS For all metabolizer subgroups, minimum target tacrolimus trough concentrations were obtained more rapidly with LCPT than with IR-Tac. Slow metabolizers were more likely to exceed target trough concentrations with LCPT, while rapid metabolizers were more likely to fall below target trough concentrations with IR-Tac. Regardless of metabolizer status, significant differences were not detected between LCPT and IR-Tac for treatment failure, death, graft failure, biopsy-proven acute rejection, estimated glomerular filtration rate, or other clinical outcomes. CONCLUSIONS Although within metabolizer subgroups, attainment of target trough concentrations in the first week differed between LCPT and IR-Tac, these results suggest that, regardless of metabolizer phenotype, clinical outcomes do not differ between these formulations when dose adjustments are made.",2020,"Regardless of metabolizer status, significant differences were not detected between LCPT and IR-Tac for treatment failure, death, graft failure, biopsy-proven acute rejection, estimated glomerular filtration rate, or other clinical outcomes.","['De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release', 'Patients were initiated on 0.17 mg/kg/day']","['LCPT', 'Tacrolimus', 'LCP-tacrolimus (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac']","['attainment of target trough concentrations', 'LCPT and IR-Tac for treatment failure, death, graft failure, biopsy-proven acute rejection, estimated glomerular filtration rate', 'minimum target tacrolimus trough concentrations']","[{'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0023234', 'cui_str': 'Coxa plana'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517432', 'cui_str': '0.17'}, {'cui': 'C3665414', 'cui_str': 'mg/kg/day'}]","[{'cui': 'C0023234', 'cui_str': 'Coxa plana'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]","[{'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023234', 'cui_str': 'Coxa plana'}, {'cui': 'C0085149', 'cui_str': 'Tacrolimus'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0521983', 'cui_str': 'Absence of therapeutic response'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1262018', 'cui_str': 'Transplant failure'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0035015', 'cui_str': 'Rejection (Psychology)'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]",,0.0370611,"Regardless of metabolizer status, significant differences were not detected between LCPT and IR-Tac for treatment failure, death, graft failure, biopsy-proven acute rejection, estimated glomerular filtration rate, or other clinical outcomes.","[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Suwelack', 'Affiliation': 'Department of Internal Medicine, Transplant Nephrology, University Hospital Münster, Westfalian Wilhelms University, Münster, Germany.'}, {'ForeName': 'Suphamai', 'Initials': 'S', 'LastName': 'Bunnapradist', 'Affiliation': 'Division of Nephrology, University of California Los Angeles (UCLA) Medical Center, Los Angeles, CA, USA.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Meier-Kriesche', 'Affiliation': 'Veloxis Pharmaceuticals Inc., Cary, NC, USA.'}, {'ForeName': 'Daniel R', 'Initials': 'DR', 'LastName': 'Stevens', 'Affiliation': 'Veloxis Pharmaceuticals Inc., Cary, NC, USA.'}, {'ForeName': 'Claudio', 'Initials': 'C', 'LastName': 'Procaccianti', 'Affiliation': 'Chiesi Farmaceutici S.p.A., Parma, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Morganti', 'Affiliation': 'Chiesi Farmaceutici S.p.A., Parma, Italy.'}, {'ForeName': 'Klemens', 'Initials': 'K', 'LastName': 'Budde', 'Affiliation': 'Department of Nephrology and Medical Intensive Care, Charité - University Medicine Berlin, Berlin, Germany.'}]",Annals of transplantation,['10.12659/AOT.923278'] 2266,32719354,Effects of high-intensity interval training compared with resistance training in prostate cancer patients undergoing radiotherapy: a randomized controlled trial.,"BACKGROUND Exercise training has shown beneficial effects in the management of radiotherapy-related side effects in prostate cancer (PCa) patients undergoing radiation therapy (RT). However, the optimal modality of the exercise programs have not been yet determined. The aim of this randomized controlled trial was to investigate the effects of high-intensity interval training (HIIT) and resistance training (RES) compared to usual care (UC) on cancer-treatment-related fatigue (CTRF) (primary outcome), quality of life, depression, daytime sleepiness, insomnia, sleep quality, functional exercise capacity and executive function in PCa patients during RT. METHODS PCa patients undergoing RT with or without ADT were randomized in HIIT, RES or UC. Both exercise programs included three sessions per week during 5-8 weeks. HIIT consisted of 8-15 × 60 s intervals (≥85% maximal heart rate). RES was performed with 1-3 sets of 8-12 repetitions for each large muscle groups. The primary outcome was changed in CTRF measured with the Functional Assessment of Chronic Illness Therapy-Fatigue. RESULTS Seventy-two subjects (69.1 ± 8.2 years) completed the study. No exercise-related adverse events occurred. HIIT (p = 0.012) and RES (p = 0.039) training attenuated increases in CTRF compared to UC. Functional exercise capacity, evaluated by the 6-min walk test, increased after HIIT (p = 0 = 0.43) and RES (p = 0.041) compared to UC (+0.1%). No other secondary variables were different between groups. CONCLUSIONS Both intervention groups displayed beneficial effects on CTRF and functional exercise capacity in PCa patients undergoing RT. In addition, HIIT and RES are both safe with an excellent attendance rate to the exercise sessions.",2020,"Functional exercise capacity, evaluated by the 6-min walk test, increased after HIIT (p = 0 = 0.43) and RES (p = 0.041) compared to UC (+0.1%).","['PCa patients undergoing RT', 'Seventy-two subjects (69.1\u2009±\u20098.2 years) completed the study', 'PCa patients undergoing RT with or without ADT were randomized in HIIT, RES or UC', 'prostate cancer patients undergoing', 'prostate cancer (PCa) patients undergoing radiation therapy (RT']","['high-intensity interval training', 'radiotherapy', 'high-intensity interval training (HIIT) and resistance training (RES', 'HIIT and RES', 'Exercise training', 'resistance training', 'usual care (UC']","['Functional exercise capacity', 'CTRF and functional exercise capacity', 'cancer-treatment-related fatigue (CTRF) (primary outcome), quality of life, depression, daytime sleepiness, insomnia, sleep quality, functional exercise capacity and executive function', 'RES', 'CTRF measured with the Functional Assessment of Chronic Illness Therapy-Fatigue', 'CTRF']","[{'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}]","[{'cui': 'C0454284', 'cui_str': 'Functional exercises'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0541854', 'cui_str': 'Daytime sleepiness'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",72.0,0.0811396,"Functional exercise capacity, evaluated by the 6-min walk test, increased after HIIT (p = 0 = 0.43) and RES (p = 0.041) compared to UC (+0.1%).","[{'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Piraux', 'Affiliation': 'Pôle de Neuro Musculo Skeletal Lab, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium. elise.piraux@uclouvain.be.'}, {'ForeName': 'Gilles', 'Initials': 'G', 'LastName': 'Caty', 'Affiliation': 'Pôle de Neuro Musculo Skeletal Lab, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Laurette', 'Initials': 'L', 'LastName': 'Renard', 'Affiliation': 'Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Vancraeynest', 'Affiliation': 'Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Tombal', 'Affiliation': ""Service d'urologie, Cliniques universitaires Saint-Luc, Brussels, Belgium.""}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Geets', 'Affiliation': 'Department of Radiation Oncology, Cliniques universitaires Saint-Luc, Brussels, Belgium.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Reychler', 'Affiliation': 'Pôle de Pneumologie, ORL & Dermatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-020-0259-6'] 2267,32719355,Preferential inhibition of adaptive immune system dynamics by glucocorticoids in patients after acute surgical trauma.,"Glucocorticoids (GC) are a controversial yet commonly used intervention in the clinical management of acute inflammatory conditions, including sepsis or traumatic injury. In the context of major trauma such as surgery, concerns have been raised regarding adverse effects from GC, thereby necessitating a better understanding of how GCs modulate the immune response. Here we report the results of a randomized controlled trial (NCT02542592) in which we employ a high-dimensional mass cytometry approach to characterize innate and adaptive cell signaling dynamics after a major surgery (primary outcome) in patients treated with placebo or methylprednisolone (MP). A robust, unsupervised bootstrap clustering of immune cell subsets coupled with random forest analysis shows profound (AUC = 0.92, p-value = 3.16E-8) MP-induced alterations of immune cell signaling trajectories, particularly in the adaptive compartments. By contrast, key innate signaling responses previously associated with pain and functional recovery after surgery, including STAT3 and CREB phosphorylation, are not affected by MP. These results imply cell-specific and pathway-specific effects of GCs, and also prompt future studies to examine GCs' effects on clinical outcomes likely dependent on functional adaptive immune responses.",2020,"A robust, unsupervised bootstrap clustering of immune cell subsets coupled with random forest analysis shows profound (AUC = 0.92, p-value = 3.16E-8) MP-induced alterations of immune cell signaling trajectories, particularly in the adaptive compartments.","['patients treated with', 'patients after acute surgical trauma']","['Glucocorticoids (GC', 'placebo or methylprednisolone (MP', 'glucocorticoids']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}]","[{'cui': 'C0017710', 'cui_str': 'Glucocorticoid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0025815', 'cui_str': 'Methylprednisolone'}]",[],,0.170748,"A robust, unsupervised bootstrap clustering of immune cell subsets coupled with random forest analysis shows profound (AUC = 0.92, p-value = 3.16E-8) MP-induced alterations of immune cell signaling trajectories, particularly in the adaptive compartments.","[{'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': 'Ganio', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Stanley', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Viktoria', 'Initials': 'V', 'LastName': 'Lindberg-Larsen', 'Affiliation': 'The Lundbeck Foundation Center for Fast-track Hip and Knee replacement, Copenhagen, Denmark.'}, {'ForeName': 'Jakob', 'Initials': 'J', 'LastName': 'Einhaus', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Amy S', 'Initials': 'AS', 'LastName': 'Tsai', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Verdonk', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Culos', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Sajjad', 'Initials': 'S', 'LastName': 'Gahemi', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Kristen K', 'Initials': 'KK', 'LastName': 'Rumer', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Ina A', 'Initials': 'IA', 'LastName': 'Stelzer', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Dyani', 'Initials': 'D', 'LastName': 'Gaudilliere', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Department of Surgery, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': 'Tsai', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Ramin', 'Initials': 'R', 'LastName': 'Fallahzadeh', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Choisy', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Kehlet', 'Affiliation': 'Section of Surgical Pathophysiology 7621, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark.'}, {'ForeName': 'Nima', 'Initials': 'N', 'LastName': 'Aghaeepour', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Martin S', 'Initials': 'MS', 'LastName': 'Angst', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Brice', 'Initials': 'B', 'LastName': 'Gaudilliere', 'Affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, School of Medicine, Stanford University, Stanford, CA, USA. gbrice@stanford.edu.'}]",Nature communications,['10.1038/s41467-020-17565-y'] 2268,32719399,Controlling technical variation amongst 6693 patient microarrays of the randomized MINDACT trial.,"Gene expression data obtained in large studies hold great promises for discovering disease signatures or subtypes through data analysis. It is also prone to technical variation, whose removal is essential to avoid spurious discoveries. Because this variation is not always known and can be confounded with biological signals, its removal is a challenging task. Here we provide a step-wise procedure and comprehensive analysis of the MINDACT microarray dataset. The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction. The study also yielded a full-transcriptome microarray for each tumor. We show for the first time in such a large dataset how technical variation can be removed while retaining expected biological signals. Because of its unprecedented size, we hope the resulting adjusted dataset will be an invaluable tool to discover or test gene expression signatures and to advance our understanding of breast cancer.",2020,The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction.,"['6693 breast cancer patients', '6693 patient microarrays']",[],[],"[{'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],[],6693.0,0.0324953,The MINDACT trial enrolled 6693 breast cancer patients and prospectively validated the gene expression signature MammaPrint for outcome prediction.,"[{'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Jacob', 'Affiliation': 'Université de Lyon, Université Lyon 1, CNRS, Laboratoire de Biométrie et Biologie Évolutive UMR 5558, Villeurbanne, France.'}, {'ForeName': 'Anke', 'Initials': 'A', 'LastName': 'Witteveen', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Inès', 'Initials': 'I', 'LastName': 'Beumer', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Delahaye', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Diederik', 'Initials': 'D', 'LastName': 'Wehkamp', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'van den Akker', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Mireille', 'Initials': 'M', 'LastName': 'Snel', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Bob', 'Initials': 'B', 'LastName': 'Chan', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Arno', 'Initials': 'A', 'LastName': 'Floore', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Bakx', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Brink', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands.'}, {'ForeName': 'Coralie', 'Initials': 'C', 'LastName': 'Poncet', 'Affiliation': 'EORTC, Brussels, Belgium.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Bogaerts', 'Affiliation': 'EORTC, Brussels, Belgium.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Delorenzi', 'Affiliation': 'University Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Piccart', 'Affiliation': 'Institute Jules Bordet, Brussels, Belgium.'}, {'ForeName': 'Emiel', 'Initials': 'E', 'LastName': 'Rutgers', 'Affiliation': 'Netherlands Cancer Institute, Amsterdam, The Netherlands.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Cardoso', 'Affiliation': 'Champalimaud, Lisbon, Portugal.'}, {'ForeName': 'Terence', 'Initials': 'T', 'LastName': 'Speed', 'Affiliation': 'Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': ""van 't Veer"", 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands. Laura.Vantveer@ucsf.edu.'}, {'ForeName': 'Annuska', 'Initials': 'A', 'LastName': 'Glas', 'Affiliation': 'Agendia NV/Agendia Inc, Amsterdam, The Netherlands. annuska.glas@agendia.com.'}]",Communications biology,['10.1038/s42003-020-1111-1'] 2269,32719420,Neuroplastic effects of end-effector robotic gait training for hemiparetic stroke: a randomised controlled trial.,"Detecting neuroplastic changes during locomotor neurorehabilitation is crucial for independent primal motor behaviours. However, long-term locomotor training-related neuroplasticity remains unexplored. We compared the effects of end-effector robot-assisted gait training (E-RAGT) and bodyweight-supported treadmill training (BWST) on cortical activation in individuals with hemiparetic stroke. Twenty-three men and five women aged 53.2 ± 11.2 years were recruited and randomly assigned to participate in E-RAGT (n = 14) or BWST (n = 14) for 30 min/day, 5 days/week, for 4 weeks. Cortical activity, lower limb motor function, and gait speed were evaluated before and after training. Activation of the primary sensorimotor cortex, supplementary motor area, and premotor cortex in the affected hemisphere significantly increased only in the E-RAGT group, although there were no significant between-group differences. Clinical outcomes, including the Fugl-Meyer assessment (FMA), timed up and go test, and 10-m walk test scores, improved after training in both groups, with significantly better FMA scores in the E-RAGT group than in the BWST group. These findings suggest that E-RAGT effectively improves neuroplastic outcomes in hemiparetic stroke, although its superiority over conventional training remains unclear. This may have clinical implications and provides insight for clinicians interested in locomotor neurorehabilitation after hemiparetic stroke.Trial Registration: ClinicalTrials.gov Identifier NCT04054739 (12/08/2019).",2020,"Activation of the primary sensorimotor cortex, supplementary motor area, and premotor cortex in the affected hemisphere significantly increased only in the E-RAGT group, although there were no significant between-group differences.","['Twenty-three men and five women aged 53.2\u2009±\u200911.2\xa0years', 'hemiparetic stroke', 'individuals with hemiparetic stroke']","['BWST', 'end-effector robotic gait training', 'E-RAGT', 'end-effector robot-assisted gait training (E-RAGT) and bodyweight-supported treadmill training (BWST']","['Fugl-Meyer assessment (FMA), timed up and go test, and 10-m walk test scores', 'FMA scores', 'neuroplastic outcomes', 'supplementary motor area, and premotor cortex', 'cortical activation', 'Cortical activity, lower limb motor function, and gait speed']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517531', 'cui_str': '11.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C4543203', 'cui_str': 'Effector'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0085673', 'cui_str': 'Gait training procedure'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C3496174', 'cui_str': 'Supplementary Motor Area'}, {'cui': 'C0228202', 'cui_str': 'Premotor cortex'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}]",,0.117378,"Activation of the primary sensorimotor cortex, supplementary motor area, and premotor cortex in the affected hemisphere significantly increased only in the E-RAGT group, although there were no significant between-group differences.","[{'ForeName': 'Hayeon', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Translational Research Center for Rehabilitation Robots, National Rehabilitation Center, Seoul, Republic of Korea.'}, {'ForeName': 'Gyulee', 'Initials': 'G', 'LastName': 'Park', 'Affiliation': 'Translational Research Center for Rehabilitation Robots, National Rehabilitation Center, Seoul, Republic of Korea.'}, {'ForeName': 'Joon-Ho', 'Initials': 'JH', 'LastName': 'Shin', 'Affiliation': 'Translational Research Center for Rehabilitation Robots, National Rehabilitation Center, Seoul, Republic of Korea. asfreelyas@gmail.com.'}, {'ForeName': 'Joshua H', 'Initials': 'JH', 'LastName': 'You', 'Affiliation': 'Department of Physical Therapy, Dynamic Movement Institute and Technology, College of Health Science, Sports Movement Artificial-Intelligence Robotics Technology (SMART) Institute, ""Yonsei GOODWELLNESS Center"" for Sports, Wellness, and Fitness Across Life Span Disabilities, Yonsei University, 1 Yonseidae-gil, Wonju, Gangwon-do, 26493, Republic of Korea. neurorehab@yonsei.ac.kr.'}]",Scientific reports,['10.1038/s41598-020-69367-3'] 2270,32719455,Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.,"Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalTrials.gov identifier: NCT03805399), a phase Ib/II subtyping-based and genomic biomarker-guided umbrella trial, to evaluate the efficacy of these targets. Patients with refractory metastatic TNBC were enrolled and stratified by TNBC subtypes and genomic biomarkers, and assigned to one of these seven arms: (A) pyrotinib with capecitabine, (B) androgen receptor inhibitor with CDK4/6 inhibitor, (C) anti PD-1 with nab-paclitaxel, (D) PARP inhibitor included, (E) and (F) anti-VEGFR included, or (G) mTOR inhibitor with nab-paclitaxel. The primary end point was the objective response rate (ORR). We enrolled 69 refractory metastatic TNBC patients with a median of three previous lines of therapy (range, 1-8). Objective response was achieved in 20 (29.0%, 95% confidence interval (CI): 18.7%-41.2%) of the 69 intention-to-treat (ITT) patients. Our results showed that immunotherapy (arm C), in particular, achieved the highest ORR (52.6%, 95% CI: 28.9%-75.6%) in the ITT population. Arm E demonstrated favorable ORR (26.1%, 95% CI: 10.2%-48.4% in the ITT population) but with more high grade (≥ 3) adverse events. Somatic mutations of TOP2A and CD8 immunohistochemical score may have the potential to predict immunotherapy response in the immunomodulatory subtype of TNBC. In conclusion, the phase Ib/II FUTURE trial suggested a new concept for TNBC treatment, demonstrating the clinical benefit of subtyping-based targeted therapy for refractory metastatic TNBC.",2020,"Objective response was achieved in 20 (29.0%, 95% confidence interval (CI): 18.7%-41.2%) of the 69 intention-to-treat (ITT) patients.","['69 refractory metastatic TNBC patients with a median of three previous lines of therapy (range, 1-8', 'Patients with refractory metastatic TNBC', 'refractory metastatic triple-negative breast cancer']","['Molecular subtyping and genomic profiling expand precision medicine', 'pyrotinib with capecitabine, (B) androgen receptor inhibitor with CDK4/6 inhibitor, (C) anti PD-1 with nab-paclitaxel, (D', 'Triple-negative breast cancer (TNBC']","['highest ORR', 'Objective response', 'objective response rate (ORR', 'favorable ORR']","[{'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C3539878', 'cui_str': 'Triple-negative breast cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]","[{'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C2718059', 'cui_str': 'P Health'}, {'cui': 'C3828434', 'cui_str': 'pyrotinib'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0034786', 'cui_str': 'Androgen receptor'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C1527223', 'cui_str': '130-nm albumin-bound paclitaxel'}, {'cui': 'C3539878', 'cui_str': 'Triple-negative breast cancer'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0018017', 'cui_str': 'Goal'}]",69.0,0.114049,"Objective response was achieved in 20 (29.0%, 95% confidence interval (CI): 18.7%-41.2%) of the 69 intention-to-treat (ITT) patients.","[{'ForeName': 'Yi-Zhou', 'Initials': 'YZ', 'LastName': 'Jiang', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Yin', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Jiang', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Wen-Jia', 'Initials': 'WJ', 'LastName': 'Zuo', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Ding', 'Initials': 'D', 'LastName': 'Ma', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Jiahan', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China.'}, {'ForeName': 'Xiaoyu', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Jiangsu Hengrui Medicine Co Ltd, Lianyungang, Jiangsu, 222002, China.'}, {'ForeName': 'Jianjun', 'Initials': 'J', 'LastName': 'Zou', 'Affiliation': 'Jiangsu Hengrui Medicine Co Ltd, Lianyungang, Jiangsu, 222002, China.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Verschraegen', 'Affiliation': 'Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH, 43210, USA.'}, {'ForeName': 'Daniel G', 'Initials': 'DG', 'LastName': 'Stover', 'Affiliation': 'The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Kaklamani', 'Affiliation': 'Division of Hematology/Oncology, University of Texas Health Science Center San Antonio, San Antonio, TX, 78284, USA.'}, {'ForeName': 'Zhong-Hua', 'Initials': 'ZH', 'LastName': 'Wang', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China. zhonghuawang95@hotmail.com.'}, {'ForeName': 'Zhi-Ming', 'Initials': 'ZM', 'LastName': 'Shao', 'Affiliation': 'Department of Breast Surgery, Fudan University Shanghai Cancer Center; Key Laboratory of Breast Cancer in Shanghai, Shanghai, 200032, China. zhimingshao@yahoo.com.'}]",Cell research,['10.1038/s41422-020-0375-9'] 2271,32719487,Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin.,"We asked whether pharmacological stimulation of endogenous neural precursor cells (NPCs) may promote cognitive recovery and brain repair, focusing on the drug metformin, in parallel rodent and human studies of radiation injury. In the rodent cranial radiation model, we found that metformin enhanced the recovery of NPCs in the dentate gyrus, with sex-dependent effects on neurogenesis and cognition. A pilot double-blind, placebo-controlled crossover trial was conducted (ClinicalTrials.gov, NCT02040376) in survivors of pediatric brain tumors who had been treated with cranial radiation. Safety, feasibility, cognitive tests and MRI measures of white matter and the hippocampus were evaluated as endpoints. Twenty-four participants consented and were randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either an AB or BA sequence with a 10-week washout period at crossover. Blood draws were conducted to monitor safety. Feasibility was assessed as recruitment rate, medication adherence and procedural adherence. Linear mixed modeling was used to examine cognitive and MRI outcomes as a function of cycle, sequence and treatment. We found no clinically relevant safety concerns and no serious adverse events associated with metformin. Sequence effects were observed for all cognitive outcomes in our linear mixed models. For the subset of participants with complete data in cycle 1, metformin was associated with better performance than placebo on tests of declarative and working memory. We present evidence that a clinical trial examining the effects of metformin on cognition and brain structure is feasible in long-term survivors of pediatric brain tumors and that metformin is safe to use and tolerable in this population. This pilot trial was not intended to test the efficacy of metformin for cognitive recovery and brain growth, but the preliminary results are encouraging and warrant further investigation in a large multicenter phase 3 trial.",2020,"For the subset of participants with complete data in cycle 1, metformin was associated with better performance than placebo on tests of declarative and working memory.","['Twenty-four participants consented', 'survivors of pediatric brain tumors', 'survivors of pediatric brain tumors who had been treated with cranial radiation']","['metformin (A) and placebo (B', 'pharmacological stimulation of endogenous neural precursor cells (NPCs', 'metformin', 'placebo']","['Safety, feasibility, cognitive tests and MRI measures of white matter and the hippocampus', 'declarative and working memory', 'recruitment rate, medication adherence and procedural adherence', 'recovery of NPCs']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0006118', 'cui_str': 'Neoplasm of brain'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0037303', 'cui_str': 'Bone structure of cranium'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0441694', 'cui_str': 'Pharmacological stimulation'}, {'cui': 'C0205227', 'cui_str': 'Endogenous'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0019564', 'cui_str': 'Hippocampal structure'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0018956', 'cui_str': 'Hematopoietic stem cell'}]",24.0,0.0743775,"For the subset of participants with complete data in cycle 1, metformin was associated with better performance than placebo on tests of declarative and working memory.","[{'ForeName': 'Ramy', 'Initials': 'R', 'LastName': 'Ayoub', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Rebecca M', 'Initials': 'RM', 'LastName': 'Ruddy', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Cox', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Adeoye', 'Initials': 'A', 'LastName': 'Oyefiade', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Derkach', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Laughlin', 'Affiliation': 'Diagnostic Imaging, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Ades-Aron', 'Affiliation': 'Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Shirzadi', 'Affiliation': 'Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Els', 'Initials': 'E', 'LastName': 'Fieremans', 'Affiliation': 'Center for Biomedical Imaging, Department of Radiology, New York University Grossman School of Medicine, New York, NY, USA.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'MacIntosh', 'Affiliation': 'Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Cynthia B', 'Initials': 'CB', 'LastName': 'de Medeiros', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Jovanka', 'Initials': 'J', 'LastName': 'Skocic', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Bouffet', 'Affiliation': 'Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Freda D', 'Initials': 'FD', 'LastName': 'Miller', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'ForeName': 'Cindi M', 'Initials': 'CM', 'LastName': 'Morshead', 'Affiliation': 'Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. cindi.morshead@utoronto.ca.'}, {'ForeName': 'Donald J', 'Initials': 'DJ', 'LastName': 'Mabbott', 'Affiliation': 'Neurosciences and Mental Health Program, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada. donald.mabbott@sickkids.ca.'}]",Nature medicine,['10.1038/s41591-020-0985-2'] 2272,32719525,A randomized masked pilot clinical trial to compare the efficacy of topical 1% voriconazole ophthalmic solution as monotherapy with combination therapy of topical 0.02% polyhexamethylene biguanide and 0.02% chlorhexidine in the treatment of Acanthamoeba keratitis.,"PURPOSE To compare the efficacy of topical voriconazole 1% and the combination therapy of 0.02% polyhexamethylene biguanide (PHMB) and 0.02% chlorhexidine for the treatment of Acanthamoeba keratitis (AK). METHODS This is a prospective, pilot, double-masked randomized comparative study. Twenty-three eyes of 23 patients with microbiologically (smear and/or growth on culture) confirmed AK were randomized to group BG (PHMB 0.02% and chlorhexidine 0.02%) or group VZ (voriconazole 1%). Primary outcome measure was change in geometric mean (GM) of the corneal ulcer size at final visit. Secondary outcome measures were change in visual acuity. RESULTS Out of 71 patients with confirmed AK seen during study period, 23 patients were recruited and 18 patients completed minimum 2 weeks of treatment and further analyzed. Ten patients received BG, whereas eight received VZ. Median ulcer size measured as GM of infiltrate decreased from 5.7 mm (IQR, 5.3-6.5 mm) (p = 0.02) to 1 mm (IQR, 0-4.3 mm) in group BG and from 4.5 mm (IQR, 1.8-5.1 mm) (p < 0.05) to 0.7 mm (IQR, 0-1.6 mm) in VZ group. Median visual acuity improved from 1.79 (IQR, 1.48-2.78) to 1.10 (IQR, 0.48-1.79) in BG group (p = 0.02) and from 1.60 (IQR, 1.00-2.78) to 0.80 (IQR, 0.48-1.30) in VZ group (p = 0.18). CONCLUSION These outcomes suggest that topical VZ as a monotherapy in AK treatment is effective and comparable to BG combination therapy but needs trials with larger sample size and longer follow-up to provide conclusive evidence.",2020,"Median ulcer size measured as GM of infiltrate decreased from 5.7 mm (IQR, 5.3-6.5 mm) (p = 0.02) to 1 mm (IQR, 0-4.3 mm) in group BG and from 4.5 mm (IQR, 1.8-5.1 mm) (p < 0.05) to 0.7 mm (IQR, 0-1.6 mm) in VZ group.","['71 patients with confirmed AK seen during study period, 23 patients were recruited and 18 patients completed minimum 2 weeks of treatment and further analyzed', 'Acanthamoeba keratitis', 'Twenty-three eyes of 23 patients with microbiologically (smear and/or growth on culture) confirmed AK', 'Acanthamoeba keratitis (AK']","['chlorhexidine 0.02%) or group VZ (voriconazole', 'VZ', 'polyhexamethylene biguanide (PHMB) and 0.02% chlorhexidine', 'topical voriconazole', 'chlorhexidine', 'topical 1% voriconazole ophthalmic solution']","['Median visual acuity', 'change in visual acuity', 'Median ulcer size measured as GM of infiltrate', 'change in geometric mean (GM) of the corneal ulcer size at final visit']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0000880', 'cui_str': 'Acanthamoeba keratitis'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0444186', 'cui_str': 'Smear test'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C4517398', 'cui_str': '0.02'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0393080', 'cui_str': 'voriconazole'}, {'cui': 'C0376892', 'cui_str': 'polihexanide'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0015399', 'cui_str': 'Eye drops'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0010043', 'cui_str': 'Corneal ulcer'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]",71.0,0.333436,"Median ulcer size measured as GM of infiltrate decreased from 5.7 mm (IQR, 5.3-6.5 mm) (p = 0.02) to 1 mm (IQR, 0-4.3 mm) in group BG and from 4.5 mm (IQR, 1.8-5.1 mm) (p < 0.05) to 0.7 mm (IQR, 0-1.6 mm) in VZ group.","[{'ForeName': 'Bhupesh', 'Initials': 'B', 'LastName': 'Bagga', 'Affiliation': 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, India. bhupesh@lvpei.org.'}, {'ForeName': 'Savitri', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'Jhaveri Microbiology Centre, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Ruchi Pratap Singh', 'Initials': 'RPS', 'LastName': 'Gour', 'Affiliation': 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Ashik', 'Initials': 'A', 'LastName': 'Mohamed', 'Affiliation': 'Ophthalmic Biophysics, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Joveeta', 'Initials': 'J', 'LastName': 'Joseph', 'Affiliation': 'Jhaveri Microbiology Centre, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Varsha', 'Initials': 'V', 'LastName': 'M Rathi', 'Affiliation': 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, India.'}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'Garg', 'Affiliation': 'The Cornea Institute, L V Prasad Eye Institute, Hyderabad, India.'}]","Eye (London, England)",['10.1038/s41433-020-1109-4'] 2273,32719581,Long-Term Reduction of Short-Wavelength Light Affects Sustained Attention and Visuospatial Working Memory With No Evidence for a Change in Circadian Rhythmicity.,"The short wavelength, i.e., blue light, is crucial for non-image forming effects such as entrainment of the circadian system in humans. Moreover, many studies showed that blue light enhances alertness and performance in cognitive tasks. However, most scientific reports in this topic are based on experiments using short exposure to blue or blue-enriched light, and only a few focused on the effects of its reduced transmittance, especially in longer periods. The latter could potentially give insight into understanding if age-related sleep problems and cognitive decline are related to less amount of blue light reaching the retina, as the eyes' lenses yellow with age. In this study, we investigated the effects of prolonged blocking of blue light on cognitive functioning, in particular-sustained attention and visuospatial working memory, as well as on sleep, and melatonin and cortisol levels. A group of young, healthy participants was randomly allocated to either blue light blocking or control group. Depending on the group, participants wore amber contact lenses, reducing the transmittance of blue light by ∼90% or regular contact lenses for a period of 4 weeks. No changes were observed for measurements related to sleep and sleep-wake rhythm. Dim light melatonin onset, evening levels of melatonin, and morning cortisol answer did not show any significant alterations during blue light (BL) blockade. The significant effects were revealed both for sustained attention and visuospatial memory, i.e., the longer blocking the blue light lasted, the greater decrease in performance observed. Additionally, the follow-up session conducted ∼1 week after taking off the blue-blocking lenses revealed that in case of sustained attention, this detrimental effect of blocking BL is fully reversible. Our findings provide evidence that prolonged reduction of BL exposure directly affects human cognitive functioning regardless of circadian rhythmicity.",2020,"Dim light melatonin onset, evening levels of melatonin, and morning cortisol answer did not show any significant alterations during blue light (BL) blockade.","['A group of young, healthy participants']","['prolonged blocking of blue light', 'amber contact lenses, reducing the transmittance of blue light by ∼90% or regular contact lenses', 'blue light blocking or control group']","['Visuospatial Working Memory', 'sleep and sleep-wake rhythm', 'blue light enhances alertness and performance in cognitive tasks', 'Dim light melatonin onset, evening levels of melatonin, and morning cortisol', 'sustained attention and visuospatial memory', 'sleep, and melatonin and cortisol levels']","[{'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C0242864', 'cui_str': 'Amber'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C0114346', 'cui_str': 'dimesna'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement'}]",,0.0183072,"Dim light melatonin onset, evening levels of melatonin, and morning cortisol answer did not show any significant alterations during blue light (BL) blockade.","[{'ForeName': 'Aleksandra', 'Initials': 'A', 'LastName': 'Domagalik', 'Affiliation': 'Brain Imaging Core Facility, Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Halszka', 'Initials': 'H', 'LastName': 'Oginska', 'Affiliation': 'Brain Imaging Core Facility, Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Beldzik', 'Affiliation': 'Brain Imaging Core Facility, Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Fafrowicz', 'Affiliation': 'Brain Imaging Core Facility, Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.'}, {'ForeName': 'Malgorzata', 'Initials': 'M', 'LastName': 'Pokrywka', 'Affiliation': 'Department of Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Chaniecki', 'Affiliation': 'Ophthalmology Private Practice, Kraków, Poland.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Rekas', 'Affiliation': 'Ophthalmology Department, Military Institute of Medicine, Warsaw, Poland.'}, {'ForeName': 'Tadeusz', 'Initials': 'T', 'LastName': 'Marek', 'Affiliation': 'Brain Imaging Core Facility, Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.'}]",Frontiers in neuroscience,['10.3389/fnins.2020.00654'] 2274,32719592,Role of Single Low Pulse Intensity of Transcranial Magnetic Stimulation Over the Frontal Cortex for Cognitive Function.,"Background : The principal aim of this study was to measure the effect of online single-pulse transcranial magnetic stimulation (TMS) over the right dorsolateral prefrontal cortex (DLPFC) on cognition via the Cambridge Neuropsychological Test Automated Battery (CANTAB) in healthy individuals. Methods : In a single-blind, sham-controlled study, we assessed both 50% and 60% of the resting motor threshold (RMT) over the right DLPFC in healthy right-handed ( n = 42) adults using cognitive function, such as attention and memory, as a measure via CANTAB. Results : We observed an improvement in the cognitive function level during the use of online low intensities of 50% and 60% RMT active stimulation of the DLPFC compared to the sham stimulation. Conclusions : The results showed that low-intensity TMS can indeed effectively modulate cognitive function in DLPFC. Future research is, however, necessary to investigate the potential effects of low-intensity TMS on different brain areas to increase confidence in the observed results.",2020,We observed an improvement in the cognitive function level during the use of online low intensities of 50% and 60% RMT active stimulation of the DLPFC compared to the sham stimulation. ,"['healthy right-handed ( n = 42) adults using cognitive function, such as attention and memory, as a measure via CANTAB', 'healthy individuals']","['Transcranial Magnetic Stimulation', 'online single-pulse transcranial magnetic stimulation (TMS']","['cognitive function level', 'cognitive function']","[{'cui': 'C0230370', 'cui_str': 'Structure of right hand'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C4505411', 'cui_str': 'CANTAB'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C1564622', 'cui_str': 'Transcranial Magnetic Stimulation, Single Pulse'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.0557822,We observed an improvement in the cognitive function level during the use of online low intensities of 50% and 60% RMT active stimulation of the DLPFC compared to the sham stimulation. ,"[{'ForeName': 'Shahid', 'Initials': 'S', 'LastName': 'Bashir', 'Affiliation': 'Department of Neurophysiology, Neuroscience Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia.'}, {'ForeName': 'Fawaz', 'Initials': 'F', 'LastName': 'Al-Hussain', 'Affiliation': 'Department of Neurology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Hamza', 'Affiliation': 'Department of Electrical Engineering, National University of Computer and Emerging Sciences, Lahore, Pakistan.'}, {'ForeName': 'Ghadah Faisal', 'Initials': 'GF', 'LastName': 'Shareefi', 'Affiliation': 'Department of Neurophysiology, Neuroscience Center, King Fahad Specialist Hospital, Dammam, Saudi Arabia.'}, {'ForeName': 'Turki', 'Initials': 'T', 'LastName': 'Abualait', 'Affiliation': 'College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.'}, {'ForeName': 'Woo-Kyoung', 'Initials': 'WK', 'LastName': 'Yoo', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Division of Neuroscience Center, Hallym University Sacred Heart Hospital, Anyang, South Korea.'}]",Frontiers in human neuroscience,['10.3389/fnhum.2020.00205'] 2275,32719630,Dimensions of Leader Anger Expression Unveiled: How Anger Intensity and Gender of Leader and Observer Affect Perceptions of Leadership Effectiveness and Status Conferral.,"While significant organizational research evaluates effective leadership traits and decades of psychological research have investigated emotion, there is a lack of consensus in organizational behavior research related to whether emotion expressed by a leader elicits positive or negative outcomes. We seek to augment existing research by exploring the effect of three dimensions, namely, the intensity of anger expressed, the gender of the leader, and the gender of the observer on perceptions of leadership effectiveness and future status conferral. In Study 1, we recruited 40 participants from a well-known U.S. university to select appropriate terms attributable to intense, moderate, and neutral levels of anger expression. In Study 2, we recruited a diverse pool of 296 participants and employed a quasi-experimental method by randomly assigning participants into one of the six conditions created by three levels of anger expression intensity and the leader gender. Participants were asked to read a vignette in which a male or a female leader responds to an anger-provoking situation with different levels of anger expression and evaluate the leader on perceived leadership effectiveness and future status conferral. Our study findings demonstrated that a leader demonstrating no anger was perceived higher in leadership effectiveness than a leader showing either moderate or intense anger. Juxtaposed to these results, for future status conferral, a leader expressing no anger was perceived as higher in future status than a leader expressing moderate anger without significant difference found between no anger and intense anger. We also found a significant main effect of observer gender with female participants giving lower ratings for leadership effectiveness and status conferral than male participants. Possible explanations and practical implications regarding gender-specific findings are discussed.",2020,We also found a significant main effect of observer gender with female participants giving lower ratings for leadership effectiveness and status conferral than male participants.,"['male participants', '296 participants and employed a quasi-experimental method by randomly assigning participants into one of the six conditions created by three levels of anger expression intensity and the leader gender', '40 participants from a well-known U.S. university to select appropriate terms attributable to intense, moderate, and neutral levels of anger expression']",[],"['leadership effectiveness', 'Anger Intensity and Gender of Leader and Observer Affect Perceptions of Leadership Effectiveness and Status Conferral']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}]",[],"[{'cui': 'C0023181', 'cui_str': 'Leadership'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002957', 'cui_str': 'Feeling angry'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",296.0,0.0313816,We also found a significant main effect of observer gender with female participants giving lower ratings for leadership effectiveness and status conferral than male participants.,"[{'ForeName': 'Dongwon', 'Initials': 'D', 'LastName': 'Yun', 'Affiliation': 'School of Business, Konkuk University, Seoul, South Korea.'}, {'ForeName': 'Heajung', 'Initials': 'H', 'LastName': 'Jung', 'Affiliation': 'School of Business, Konkuk University, Seoul, South Korea.'}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Ashihara', 'Affiliation': 'School of Business, Konkuk University, Seoul, South Korea.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01237'] 2276,32719633,Verbal Cuing Is Not the Path to Enlightenment. Psychological Effects of a 10-Session Hatha Yoga Practice.,"Verbal instructions provided during yoga classes can differ substantially. Yoga instructors might choose to focus on the physical aspects of yoga (e.g., by emphasizing the characteristics of the poses), or they might take a more spiritual approach (e.g., by mentioning energy flow and chakras). The present study investigated the effects of verbal cues during yoga practice on various psychological measures. Eighty-four female students (22.0 ± 3.80 years) participated in the study. Two groups attended a beginner level hatha yoga course in which physically identical exercise was accompanied by different verbal cues. The so-called ""Sport group"" ( N = 27) received instructions referring primarily to the physical aspects of yoga practice, while the ""Spiritual group"" ( N = 23) was additionally provided with philosophical and spiritual information. A control group ( N = 34) did not receive any intervention. Mindfulness, body awareness, spirituality, and affect were assessed 1 week before and after the training. 2 × 3 mixed (time × intervention) ANOVAs did not show an interaction effect for any of the variables. However, when the two yoga groups were merged and compared to the control group, we found that spirituality increased, and negative affect decreased among yoga participants. In conclusion, yoga practice might influence psychological functioning through its physical components, independent of the style of verbal instructions provided.",2020,ANOVAs did not show an interaction effect for any of the variables.,['Eighty-four female students (22.0 ± 3.80 years) participated in the study'],"['instructions referring primarily to the physical aspects of yoga practice, while the ""Spiritual group"" ( N = 23) was additionally provided with philosophical and spiritual information', '10-Session Hatha Yoga Practice']","['Mindfulness, body awareness, spirituality, and affect', 'Verbal Cuing']","[{'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0237104', 'cui_str': 'Spirituality'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}]",84.0,0.0142357,ANOVAs did not show an interaction effect for any of the variables.,"[{'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Csala', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Ferentzi', 'Affiliation': 'Institute of Health Promotion and Sport Sciences, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Benedek T', 'Initials': 'BT', 'LastName': 'Tihanyi', 'Affiliation': 'Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Raechel', 'Initials': 'R', 'LastName': 'Drew', 'Affiliation': 'Institute of Health Promotion and Sport Sciences, ELTE Eötvös Loránd University, Budapest, Hungary.'}, {'ForeName': 'Ferenc', 'Initials': 'F', 'LastName': 'Köteles', 'Affiliation': 'Institute of Health Promotion and Sport Sciences, ELTE Eötvös Loránd University, Budapest, Hungary.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01375'] 2277,32719636,"Active Learning Norwegian Preschool(er)s (ACTNOW) - Design of a Cluster Randomized Controlled Trial of Staff Professional Development to Promote Physical Activity, Motor Skills, and Cognition in Preschoolers.","Introduction There is a dearth of high-quality evidence on effective, sustainable, and scalable interventions to increase physical activity (PA) and concomitant outcomes in preschoolers. Specifically, there is a need to better understand how the preschool context can be used to increase various types of physically active play to promote holistic child development. The implementation of such interventions requires highly competent preschool staffs, however, the competence in promoting PA is often low. The main aim of the ACTNOW study is therefore to investigate the effects of professional development for preschool staffs on child PA and developmental outcomes. Methods The study will be conducted in Norway 2019-2022 and is designed as a two-arm (intervention, control) cluster randomized controlled trial (RCT) with 7- and 18-months follow-ups. We aim to recruit 60 preschools and 1,200 3- to 5-years-old children to provide sufficient power to detect effect sizes (ESs) between 0.20 and 0.30. The intervention is nested within two levels: the preschool and the child. Central to the ACTNOW intervention are opportunities for children to engage in a variety of ""enriched,"" meaningful, and enjoyable physically active play that supports the development of the whole child. To this end, the main intervention is a 7-month professional development/education module for preschool staff, aimed to provide them with the necessary capacity to deliver four core PA components to the children (moderate-to-vigorous PA, motor-challenging PA, cognitively engaging play, and physically active learning). We will include a range of child-level outcomes, including PA, physical fitness, adiposity, motor skills, socioemotional health, self-regulation, executive function, and learning. At the preschool level, we will describe implementation and adaptation processes using quantitative and qualitative data. Discussion Professional development of staff and a whole-child approach that integrates PA with cognitively engaging play and learning activities in the preschool setting may provide a feasible vehicle to enhance both physical and cognitive development in young children. ACTNOW is designed to test this hypothesis to provide a sustainable way to build human capital and provide an early solution to lifelong public health and developmental challenges. Clinical Trial Registration www.ClinicalTrials.gov identifier NCT04048967.",2020,"Central to the ACTNOW intervention are opportunities for children to engage in a variety of ""enriched,"" meaningful, and enjoyable physically active play that supports the development of the whole child.","['young children', 'preschoolers', '60 preschools and 1,200 3- to 5-years-old children', 'preschool staffs on child PA and developmental outcomes', 'Norway 2019-2022', 'Preschoolers']",['Active Learning Norwegian Preschool(er)s'],"['physical activity (PA', 'PA, physical fitness, adiposity, motor skills, socioemotional health, self-regulation, executive function, and learning']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0028423', 'cui_str': 'Norway'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0684274', 'cui_str': 'Self-control'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",,0.0584507,"Central to the ACTNOW intervention are opportunities for children to engage in a variety of ""enriched,"" meaningful, and enjoyable physically active play that supports the development of the whole child.","[{'ForeName': 'Eivind', 'Initials': 'E', 'LastName': 'Aadland', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Hege Eikeland', 'Initials': 'HE', 'LastName': 'Tjomsland', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Kjersti', 'Initials': 'K', 'LastName': 'Johannessen', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Ada Kristine Ofrim', 'Initials': 'AKO', 'LastName': 'Nilsen', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Geir Kåre', 'Initials': 'GK', 'LastName': 'Resaland', 'Affiliation': 'Center for Physically Active Learning, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Øyvind', 'Initials': 'Ø', 'LastName': 'Glosvik', 'Affiliation': 'Department of Pedagogy, Religion and Social Studies, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Osvald', 'Initials': 'O', 'LastName': 'Lykkebø', 'Affiliation': 'Department of Strategic Initiatives, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Rasmus', 'Initials': 'R', 'LastName': 'Stokke', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Lars Bo', 'Initials': 'LB', 'LastName': 'Andersen', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Sigmund Alfred', 'Initials': 'SA', 'LastName': 'Anderssen', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}, {'ForeName': 'Karin Allor', 'Initials': 'KA', 'LastName': 'Pfeiffer', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing, MI, United States.'}, {'ForeName': 'Phillip D', 'Initials': 'PD', 'LastName': 'Tomporowski', 'Affiliation': 'Department of Kinesiology, University of Georgia, Athens, GA, United States.'}, {'ForeName': 'Ingunn', 'Initials': 'I', 'LastName': 'Størksen', 'Affiliation': 'Norwegian Centre for Learning Environment and Behavioural Research in Education, University of Stavanger, Stavanger, Norway.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Bartholomew', 'Affiliation': 'Department of Kinesiology and Health Education, The University of Texas at Austin, Austin, TX, United States.'}, {'ForeName': 'Yngvar', 'Initials': 'Y', 'LastName': 'Ommundsen', 'Affiliation': 'Department of Coaching and Psychology, Norwegian School of Sport Sciences, Oslo, Norway.'}, {'ForeName': 'Steven James', 'Initials': 'SJ', 'LastName': 'Howard', 'Affiliation': 'Early Start and School of Education, University of Wollongong, Wollongong, NSW, Australia.'}, {'ForeName': 'Anthony D', 'Initials': 'AD', 'LastName': 'Okely', 'Affiliation': 'Early Start and School of Education, University of Wollongong, Wollongong, NSW, Australia.'}, {'ForeName': 'Katrine Nyvoll', 'Initials': 'KN', 'LastName': 'Aadland', 'Affiliation': 'Department of Sport, Food and Natural Sciences, Faculty of Education, Arts and Sports, Western Norway University of Applied Sciences, Sogndal, Norway.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01382'] 2278,32664175,Cervus and cucumis peptides combined umbilical cord mesenchymal stem cells therapy for rheumatoid arthritis.,"Cervus and cucumis peptides (Lugua polypeptides, LG) are traditional Chinese medicine, which are active components of polypeptide extracted from Sika deer bone and melon seed, and they contain bone induced polypeptide biological factors. Umbilical cord mesenchymal stem cell, (UC-MSC) have tissue repair multiple effects, anti-inflammatory, and immune regulation function, which become a very promising start in rheumatoid arthritis (RA) treatment. Hence, LG combined UC-MSC can significantly enhance the UC-MSC treatment of rheumatoid arthritis (RA).To explore the clinical curative effect and therapeutic mechanism of LG combined UC-MSC for treating RA.119 patients were divided into control and treatment groups, and both groups were treated with methotrexate tablets, leflunomide, and UC-MSC. But, LG were added to the treatment group. In vitro, the effects of LG on UC-MSC cell secretion of anti-inflammatory factors were also performed.The Health Assessment Questionnaire; the 28 joint disease activity score; C reactive protein; the erythrocyte sedimentation rate; rheumatoid factor; and anti-cyclic citrullinated peptide antibody were significantly reduced in treatment group 1 year after treatment (P < .05). In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (P < .05).LG combined UC-MSCs can significantly improve the curative effect of RA patients, while LG may reduce inflammatory cytokines, regulate immunity, improve microcirculation, and are conducive to UC-MSCs migration and the repair of damaged tissue.",2020,"In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (",['rheumatoid arthritis'],"['umbilical cord mesenchymal stem cells therapy', 'P\u200a<\u200a.05).LG', 'combined UC-MSCs', 'methotrexate tablets, leflunomide, and UC-MSC']","['UC-MSC cell secretion of anti-inflammatory factors', 'erythrocyte sedimentation rate; rheumatoid factor; and anti-cyclic citrullinated peptide antibody', 'number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6', 'curative effect']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0074299', 'cui_str': 'selenomethylselenocysteine'}, {'cui': 'C1246896', 'cui_str': 'Methotrexate Oral Tablet'}, {'cui': 'C0063041', 'cui_str': 'leflunomide'}]","[{'cui': 'C0041633', 'cui_str': 'Umbilical cord structure'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatory agent'}, {'cui': 'C1176468', 'cui_str': 'Erythrocyte sedimentation rate measurement'}, {'cui': 'C0035448', 'cui_str': 'Rheumatoid factor'}, {'cui': 'C0439596', 'cui_str': 'Cyclic'}, {'cui': 'C0030956', 'cui_str': 'Peptide'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0062534', 'cui_str': 'Scatter Factor'}, {'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",,0.0240053,"In vitro, compared with the control group, the number of hepatocyte growth factor (HGF), the secretion of prostaglandin E2 (PGE2) and tumor necrosis factor-inducible gene 6 protein (TSG6) increased significantly (","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Qi', 'Affiliation': ""Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.""}, {'ForeName': 'Hongxiang', 'Initials': 'H', 'LastName': 'Gao', 'Affiliation': ""Department of Radiotherapy Oncology, Chang An Hospital, Xi'an, Shaan Xi.""}, {'ForeName': 'Yazheng', 'Initials': 'Y', 'LastName': 'Dang', 'Affiliation': ""Department of Radiation Oncology, 986 Hospital of People's Liberation Army Air Force.""}, {'ForeName': 'Shigao', 'Initials': 'S', 'LastName': 'Huang', 'Affiliation': 'Cancer Centre.'}, {'ForeName': 'Minfei', 'Initials': 'M', 'LastName': 'Peng', 'Affiliation': 'Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Linhai, Zhejiang Province, China.'}]",Medicine,['10.1097/MD.0000000000021222'] 2279,31604088,Development and initial validation of the Asthma Severity Scoring System (ASSESS).,"BACKGROUND Tools for quantification of asthma severity are limited. OBJECTIVE We sought to develop a continuous measure of asthma severity, the Asthma Severity Scoring System (ASSESS), for adolescents and adults, incorporating domains of asthma control, lung function, medications, and exacerbations. METHODS Baseline and 36-month longitudinal data from participants in phase 3 of the Severe Asthma Research Program (NCT01606826) were used. Scale properties, responsiveness, and a minimally important difference were determined. External replication was performed in participants enrolled in the Severe Asthma Research Program phase 1/2. The utility of ASSESS for detecting treatment response was explored in participants undergoing corticosteroid responsiveness testing with intramuscular triamcinolone and participants receiving biologics. RESULTS ASSESS scores ranged from 0 to 20 (8.78 ± 3.9; greater scores reflect worse severity) and differed among 5 phenotypic groups. Measurement properties were acceptable. ASSESS was responsive to changes in quality of life with a minimally important difference of 2, with good specificity for outcomes of asthma improvement and worsening but poor sensitivity. Replication analyses yielded similar results, with a 2-point decrease (improvement) associated with improvements in quality of life. Participants with a 2-point or greater decrease (improvement) in ASSESS scores also had greater improvement in lung function and asthma control after triamcinolone, but these differences were limited to phenotypic clusters 3, 4, and 5. Participants treated with biologics also had a 2-point or greater decrease (improvement) in ASSESS scores overall. CONCLUSIONS The ASSESS tool is an objective measure that might be useful in epidemiologic and clinical research studies for quantification of treatment response in individual patients and phenotypic groups. However, validation studies are warranted.",2020,"Participants with a 2-point or greater decrease (improvement) in ASSESS scores also had greater improvement in lung function and asthma control after triamcinolone, but these differences were limited to phenotypic clusters 3, 4, and 5.","['Baseline and 36-month longitudinal data from participants in phase 3 of the Severe Asthma Research Program (NCT01606826) were used', 'adolescents and adults, incorporating domains of asthma control, lung function, medications, and exacerbations', 'participants undergoing corticosteroid responsiveness testing with intramuscular triamcinolone and participants receiving biologics', 'participants enrolled in the Severe Asthma Research Program phase 1/2']",['triamcinolone'],"['quality of life', 'lung function and asthma control']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0442117', 'cui_str': 'Intramuscular'}, {'cui': 'C0040864', 'cui_str': 'Triamcinolone'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0580272', 'cui_str': '1/2'}]","[{'cui': 'C0040864', 'cui_str': 'Triamcinolone'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0024119', 'cui_str': 'Pulmonary function test'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",,0.0707634,"Participants with a 2-point or greater decrease (improvement) in ASSESS scores also had greater improvement in lung function and asthma control after triamcinolone, but these differences were limited to phenotypic clusters 3, 4, and 5.","[{'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Fitzpatrick', 'Affiliation': ""Department of Pediatrics, Emory University, Atlanta, Ga; Children's Healthcare of Atlanta, Atlanta, Ga. Electronic address: anne.fitzpatrick@emory.edu.""}, {'ForeName': 'Stanley J', 'Initials': 'SJ', 'LastName': 'Szefler', 'Affiliation': ""Children's Hospital Colorado, Aurora, Colo; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colo.""}, {'ForeName': 'David T', 'Initials': 'DT', 'LastName': 'Mauger', 'Affiliation': 'Department of Public Health Sciences, Pennsylvania State University, Hershey, Pa.'}, {'ForeName': 'Brenda R', 'Initials': 'BR', 'LastName': 'Phillips', 'Affiliation': 'Department of Public Health Sciences, Pennsylvania State University, Hershey, Pa.'}, {'ForeName': 'Loren C', 'Initials': 'LC', 'LastName': 'Denlinger', 'Affiliation': 'Department of Medicine, University of Wisconsin, Madison, Wis.'}, {'ForeName': 'Wendy C', 'Initials': 'WC', 'LastName': 'Moore', 'Affiliation': 'Department of Internal Medicine, Wake Forest University, Winston-Salem, NC.'}, {'ForeName': 'Ronald L', 'Initials': 'RL', 'LastName': 'Sorkness', 'Affiliation': 'Department of Medicine, University of Wisconsin, Madison, Wis.'}, {'ForeName': 'Sally E', 'Initials': 'SE', 'LastName': 'Wenzel', 'Affiliation': 'Department of Medicine, University of Pittsburgh, Pittsburgh, Pa.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Gergen', 'Affiliation': 'National Institute of Allergy and Infectious Diseases, Bethesda, Md.'}, {'ForeName': 'Eugene R', 'Initials': 'ER', 'LastName': 'Bleecker', 'Affiliation': 'College of Medicine, University of Arizona, Tucson, Ariz.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Castro', 'Affiliation': 'Department of Internal Medicine, Washington University, St Louis, Mo.'}, {'ForeName': 'Serpil C', 'Initials': 'SC', 'LastName': 'Erzurum', 'Affiliation': 'Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'John V', 'Initials': 'JV', 'LastName': 'Fahy', 'Affiliation': 'Department of Medicine, San Francisco, Calif.'}, {'ForeName': 'Benjamin M', 'Initials': 'BM', 'LastName': 'Gaston', 'Affiliation': 'Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Elliot', 'Initials': 'E', 'LastName': 'Israel', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Bruce D', 'Initials': 'BD', 'LastName': 'Levy', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.""}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Meyers', 'Affiliation': 'College of Medicine, University of Arizona, Tucson, Ariz.'}, {'ForeName': 'W Gerald', 'Initials': 'WG', 'LastName': 'Teague', 'Affiliation': 'Department of Pediatrics, University of Virginia, Charlottesville, Va.'}, {'ForeName': 'Leonard B', 'Initials': 'LB', 'LastName': 'Bacharier', 'Affiliation': 'Department of Pediatrics, Washington University, St Louis, Mo.'}, {'ForeName': 'Ngoc P', 'Initials': 'NP', 'LastName': 'Ly', 'Affiliation': 'Department of Pediatrics, University of California San Francisco, Cleveland, Ohio.'}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Phipatanakul', 'Affiliation': ""Division of Immunology, Boston Children's Hospital, Boston, Mass.""}, {'ForeName': 'Kristie R', 'Initials': 'KR', 'LastName': 'Ross', 'Affiliation': 'Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Zein', 'Affiliation': 'Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Nizar N', 'Initials': 'NN', 'LastName': 'Jarjour', 'Affiliation': 'Department of Medicine, University of Wisconsin, Madison, Wis.'}]",The Journal of allergy and clinical immunology,['10.1016/j.jaci.2019.09.018'] 2280,31612475,Pilot study investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post-allogeneic transplantation.,"Nutrition support is frequently required post-allogeneic haematopoietic progenitor cell transplantation (HPCT); however, the impact of mode of feeding on the gastrointestinal microbiome has not been explored. This study aimed to determine if there is a difference in the microbiome between patients receiving enteral nutrition (EN) and parenteral nutrition (PN) post-allogeneic HPCT. Twenty-three patients received either early EN or PN when required. Stool samples were collected at 30 days post-transplant and analysed with shotgun metagenomic sequencing. There was no difference in microbial diversity between patients who received predominantly EN (n = 13) vs. PN (n = 10) however patients who received predominantly EN had greater abundance of Faecalibacterium (P < 0·001) and ruminococcus E bromii (P = 0·026). Patients who had minimal oral intake for a longer duration during provision of nutrition support had a different overall microbial profile (P = 0·044), lower microbial diversity (P = 0·004) and lower abundance of faecalibacterium prausnitzii_C (P = 0·030) and Blautia (P = 0·007) compared to patients with greater oral intake. Lower microbial diversity was found in patients who received additional beta lactam antibiotics (P = 0·042) or had a longer length of hospital stay (P = 0·019). Post-HPCT oral intake should be encouraged to maintain microbiota diversity and, if nutrition support is required, EN may promote a more optimal microbiota profile.",2020,Lower microbial diversity was found in patients who received additional beta lactam antibiotics (P = 0·042) or had a longer length of hospital stay (P = 0·019).,"['gastrointestinal microbiome post-allogeneic transplantation', 'patients receiving']","['enteral nutrition (EN) and parenteral nutrition (PN) post-allogeneic HPCT', 'early EN or PN', 'additional beta lactam antibiotics', 'enteral and parenteral nutrition']","['Lower microbial diversity', 'overall microbial profile', 'longer length of hospital stay', 'abundance of Faecalibacterium', 'abundance of faecalibacterium prausnitzii_C', 'microbial diversity']","[{'cui': 'C4018878', 'cui_str': 'Gastrointestinal Microbiota'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0014327', 'cui_str': 'Enteral nutrition'}, {'cui': 'C0030547', 'cui_str': 'Parenteral nutrition'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0018957', 'cui_str': 'Hematopoietic system structure'}, {'cui': 'C0038250', 'cui_str': 'Stem cell'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0026458', 'cui_str': 'Monobactam'}, {'cui': 'C1304890', 'cui_str': 'Enteral'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1229075', 'cui_str': 'Faecalibacterium'}]",,0.0362767,Lower microbial diversity was found in patients who received additional beta lactam antibiotics (P = 0·042) or had a longer length of hospital stay (P = 0·019).,"[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Andersen', 'Affiliation': ""Department of Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Herston, Qld, Australia.""}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Staudacher', 'Affiliation': 'Faculty of Health and Behavioural Sciences, University of Queensland, Brisbane, Qld, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Weber', 'Affiliation': ""Department of Clinical Haematology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.""}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Kennedy', 'Affiliation': ""Department of Clinical Haematology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia.""}, {'ForeName': 'Antiopi', 'Initials': 'A', 'LastName': 'Varelias', 'Affiliation': 'QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.'}, {'ForeName': 'Merrilyn', 'Initials': 'M', 'LastName': 'Banks', 'Affiliation': ""Department of Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Herston, Qld, Australia.""}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Bauer', 'Affiliation': 'School of Human Movement and Nutrition Sciences, University of Queensland, Brisbane, Qld, Australia.'}]",British journal of haematology,['10.1111/bjh.16218'] 2281,31625136,Autoimmune conditions and primary central nervous system lymphoma risk among older adults.,"Primary central nervous system lymphoma (PCNSL) risk is highly increased in immunosuppressed individuals, such as those with human immunodeficiency virus infection and solid organ transplant recipients, but rates are increasing among immunocompetent older adults (age ≥65 years). We utilized data from a large, nationally-representative cohort of older adults in the United States and found that PCNSL is significantly associated with systemic lupus erythematosus, polyarteritis nodusa, autoimmune hepatitis, myasthenia gravis and uveitis. Immunosuppressive drugs given to treat these conditions may increase PCNSL risk, but these associations cannot explain the observed temporal increase in PCNSL rates, given the low prevalence of these conditions.",2020,"Immunosuppressive drugs given to treat these conditions may increase PCNSL risk, but these associations cannot explain the observed temporal increase in PCNSL rates, given the low prevalence of these conditions.","['immunocompetent older adults (age ≥65\xa0years', 'older adults']",['PCNSL'],[],"[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0280803', 'cui_str': 'Primary central nervous system lymphoma'}]",[],,0.0275646,"Immunosuppressive drugs given to treat these conditions may increase PCNSL risk, but these associations cannot explain the observed temporal increase in PCNSL rates, given the low prevalence of these conditions.","[{'ForeName': 'Parag', 'Initials': 'P', 'LastName': 'Mahale', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.'}, {'ForeName': 'Megan M', 'Initials': 'MM', 'LastName': 'Herr', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Engels', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.'}, {'ForeName': 'Ruth M', 'Initials': 'RM', 'LastName': 'Pfeiffer', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.'}, {'ForeName': 'Meredith S', 'Initials': 'MS', 'LastName': 'Shiels', 'Affiliation': 'Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.'}]",British journal of haematology,['10.1111/bjh.16222'] 2282,32712034,Pragmatic Randomized Controlled Pilot Trial on Trigger Point Injections With 1% Lidocaine Versus Conventional Approaches for Myofascial Pain in the Emergency Department.,"BACKGROUND Myofascial neck and back pain is an increasingly common chief symptom in the emergency department. Currently, there are no widely accepted conventional therapies, and there is little evidence on the efficacy of interventions such as trigger point injections (TPIs). OBJECTIVE This study evaluates whether TPIs with 1% lidocaine can improve myofascial back and neck pain compared with conventional therapies. Secondary outcomes include changes in length of stay and number of opioid prescriptions on discharge. METHODS This single-center, prospective, randomized, pragmatic trial was carried out in patients clinically determined to have myofascial back or neck pain. Patients were randomized into the experimental arm (TPI with 1% lidocaine) or the control arm (standard conventional approach). Numeric Rating Scores (NRS) for pain and additional surveys were obtained prior to and 20 min after the intervention. RESULTS The NRS for pain was lower in the TPI group compared with the control group after adjustment for initial pain (median difference -3.01; 95% confidence interval -4.20 to -1.83; p < 0.001). Median length of stay was 2.61 h for the TPI group and 4.63 h for the control group (p < 0.001). More patients in the control group (47.4%) were discharged home with an opioid compared with the TPI group (2.9%) (p < 0.001). CONCLUSIONS TPI is an effective method for managing myofascial pain in the emergency department. This study indicates it may improve pain compared with conventional methods, reduce length of stay in the emergency department, and reduce opioid prescriptions on discharge.",2020,Median length of stay was 2.61 h for the TPI group and 4.63 h for the control group (p < 0.001).,['patients clinically determined to have myofascial back or neck pain'],"['Lidocaine', 'TPIs with 1% lidocaine', 'lidocaine']","['changes in length of stay and number of opioid prescriptions on discharge', 'Numeric Rating Scores (NRS) for pain and additional surveys', 'myofascial pain', 'myofascial back and neck pain', 'NRS for pain', 'pain', 'Myofascial Pain', 'Median length of stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0185340', 'cui_str': 'Injection of trigger points'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0549183', 'cui_str': 'Midline'}]",,0.172924,Median length of stay was 2.61 h for the TPI group and 4.63 h for the control group (p < 0.001).,"[{'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Yanuck', 'Affiliation': 'Department of Emergency Medicine, University of California, Irvine, Orange, California; Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Soheil', 'Initials': 'S', 'LastName': 'Saadat', 'Affiliation': 'Department of Emergency Medicine, University of California, Irvine, Orange, California.'}, {'ForeName': 'Jonathan B', 'Initials': 'JB', 'LastName': 'Lee', 'Affiliation': 'Department of Emergency Medicine, University of California, Irvine, Orange, California.'}, {'ForeName': 'Maxwell', 'Initials': 'M', 'LastName': 'Jen', 'Affiliation': 'Department of Emergency Medicine, University of California, Irvine, Orange, California.'}, {'ForeName': 'Bharath', 'Initials': 'B', 'LastName': 'Chakravarthy', 'Affiliation': 'Department of Emergency Medicine, University of California, Irvine, Orange, California.'}]",The Journal of emergency medicine,['10.1016/j.jemermed.2020.06.015'] 2283,32712083,Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia.,"BACKGROUND Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease. OBJECTIVES To assess the safety profile of two doses of 4CMenB in adolescents. METHODS Cluster randomised controlled trial of senior school students in South Australia (SA) with participating schools randomised to intervention (4CMenB) or control. Vaccine safety was monitored using the South Australian Vaccine Safety Surveillance System (SAVSS), a spontaneous reporting system for adverse events following immunisation (AEFI) with enhanced follow-up of AEFI. RESULTS 58,637 doses of 4CMenB vaccine were administered to 30,522 students (median age 16 years) during 2017-2018. Of 18,348 and 12,174 students vaccinated in 2017 and 2018, 97.3% and 84.3%, respectively, received both scheduled doses (N = 28,115). 193 AEFI in 187 students were reported with a reporting rate of 0.32% (95%CI: 0.28-0.39%). Seventy individuals sought medical review, including nine serious adverse events. 98% (166/169) of those who were contactable for AEFI follow-up (87.6% 169/193) reported resolution of the event. Most common AEFI were injection site reaction (126/193), headache (99/193) and nausea (61/193). AEFI were more frequently reported in females (aOR = 1.409 (95%CI: 1.002, 1.980)), schools with high level of educational advantage (adjusted Odds Ratio (aOR) = 1.515 (95%CI: 1.005, 2.284)), following first dose (aOR = 1.619 (95%CI: 1.168, 2.244)), and in 2017 (aOR = 1.437 (95%CI: 1.001, 2.064)). Reported AEFI declined with increasing age (aOR = 0.771 (95%CI: 0.673, 0.883)). CONCLUSION In this largest post-licensure use of 4CMenB in adolescents, the low AEFI reporting rate provides real-world evidence of 4CMenB safety in this age group. (ClinicalTrials.gov number: NCT03089086).",2020,AEFI were more frequently reported in females (aOR = 1.409,"['Of 18,348 and 12,174 students vaccinated in 2017 and 2018, 97.3% and 84.3%, respectively, received both scheduled doses (N\xa0=\xa028,115', 'senior school students in South Australia (SA) with participating schools randomised to', 'Seventy individuals sought medical review, including nine serious adverse events', 'adolescents in Australia', '193 AEFI in 187 students', '30,522 students (median age 16\xa0years) during 2017-2018', 'adolescents']","['meningococcal B vaccine (4CMenB', 'intervention (4CMenB) or control', '4CMenB vaccine', '4CMenB']","['Vaccine safety', 'injection site reaction (126/193), headache (99/193) and nausea', 'AEFI']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0037715', 'cui_str': 'South Australia'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C2721654', 'cui_str': 'Adverse event following immunisation'}, {'cui': 'C4517618', 'cui_str': '187'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C3859491', 'cui_str': 'meningococcal group B vaccine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3490189', 'cui_str': '4CMenB vaccine'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C2721654', 'cui_str': 'Adverse event following immunisation'}]",187.0,0.386608,AEFI were more frequently reported in females (aOR = 1.409,"[{'ForeName': 'H S', 'Initials': 'HS', 'LastName': 'Marshall', 'Affiliation': ""Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, Australia. Electronic address: helen.marshall@adelaide.edu.au.""}, {'ForeName': 'A P', 'Initials': 'AP', 'LastName': 'Koehler', 'Affiliation': 'Communicable Disease Control Branch, SA Health, Government of South Australia, Adelaide, Australia.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wang', 'Affiliation': ""Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, Australia.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': ""A'Houre"", 'Affiliation': 'Communicable Disease Control Branch, SA Health, Government of South Australia, Adelaide, Australia.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gold', 'Affiliation': 'Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Australia.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Quinn', 'Affiliation': 'National Centre for Immunisation Research and Surveillance (NCIRS), Westmead, Sydney, Australia; Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Crawford', 'Affiliation': ""Murdoch Children's Research Institute (MCRI), Royal Children's Hospital & Department of Paediatrics, The University of Melbourne, Parkville, Australia.""}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pratt', 'Affiliation': 'School of Pharmacy and Medical Services, University of South Australia, Adelaide, Australia.'}, {'ForeName': 'T R', 'Initials': 'TR', 'LastName': 'Sullivan', 'Affiliation': 'SAHMRI Women & Kids, South Australian Health & Medical Research Institute, Adelaide, Australia; School of Public Health, The University of Adelaide, Australia.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Macartney', 'Affiliation': 'National Centre for Immunisation Research and Surveillance (NCIRS), Westmead, Sydney, Australia; Discipline of Child and Adolescent Health, University of Sydney, Sydney, Australia.'}]",Vaccine,['10.1016/j.vaccine.2020.07.009'] 2284,32712103,Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice.,"BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric chronic liver disease. Little is known about outcomes in recognized youth. METHODS We compared paired liver biopsies from 122 of 139 children with NAFLD (74% male; 64% white; 71% Hispanic; mean age, 13±3 years; age range, 8-17 years) who received placebo and standard of care lifestyle advice in 2 double-blind, randomized clinical trials within the nonalcoholic steatohepatitis (NASH) clinical research network from 2005 through 2015. We analyzed histologic changes with respect to baseline and longitudinal change in clinical variables using regression analysis. RESULTS At enrollment, 31% of the children had definite NASH, 34% had borderline zone 1 NASH, 13% had borderline zone 3 NASH, and 21% had fatty liver but not NASH. Over a mean time period of 1.6±0.4 years, borderline or definite NASH resolved in 29% of the children, whereas 18% of the children with fatty liver or borderline NASH developed definite NASH. Fibrosis improved in 34% of the children but worsened in 23%. Any progression to definite NASH or in fibrosis occurred in 36% of the children, and both occurred in 11% of the children. Any improvement in NASH or fibrosis occurred in 52%, and both occurred in 20% of children. Type 2 diabetes developed in 5% of the cohort. Any progression to NASH and/or fibrosis were associated with adolescent age, higher waist circumference, levels of alanine or aspartate aminotransferase, total and low density lipoprotein cholesterol at baseline, increasing level of alanine aminotransferase, hemoglobin A1C (P<.05). Progression to NASH and/or fibrosis were also associated with increasing level of gamma-glutamyl transferase and development of type 2 diabetes (P<.01). Increasing level of gamma-glutamyl transferase also associated with reduced odds of any improvement (P=.003). CONCLUSIONS One-third of children with NAFLD enrolled in placebo groups of clinical trials had histologic features of progression within 2 years, in association with increasing obesity and serum levels of aminotransferases and loss of glucose homeostasis.",2020,"Increasing level of gamma-glutamyl transferase also associated with reduced odds of any improvement (P=.003). ","['We compared paired liver biopsies from 122 of 139 children with NAFLD (74% male; 64% white; 71% Hispanic; mean age, 13±3 years; age range, 8-17 years) who received', 'Children Receiving Standard of Care Lifestyle Advice']","['placebo and standard of care lifestyle advice', 'placebo', 'NASH']","['Increasing level of gamma-glutamyl transferase', 'Fibrosis', 'borderline or definite NASH', 'level of gamma-glutamyl transferase and development of type 2 diabetes', 'obesity and serum levels of aminotransferases and loss of glucose homeostasis', 'NASH or fibrosis', 'waist circumference, levels of alanine or aspartate aminotransferase, total and low density lipoprotein cholesterol at baseline, increasing level of alanine aminotransferase, hemoglobin A1C (P<.05']","[{'cui': 'C0193388', 'cui_str': 'Biopsy of liver'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}]","[{'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C3241937', 'cui_str': 'Nonalcoholic steatohepatitis'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0002594', 'cui_str': 'Aminotransferase'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0019868', 'cui_str': 'Homeostasis'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]",139.0,0.180644,"Increasing level of gamma-glutamyl transferase also associated with reduced odds of any improvement (P=.003). ","[{'ForeName': 'Stavra A', 'Initials': 'SA', 'LastName': 'Xanthakos', 'Affiliation': ""Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.""}, {'ForeName': 'Joel E', 'Initials': 'JE', 'LastName': 'Lavine', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia Vagelos College of Physicians and Surgeons, New York, New York. Electronic address: jl3553@columbia.edu.'}, {'ForeName': 'Katherine P', 'Initials': 'KP', 'LastName': 'Yates', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Jeffrey B', 'Initials': 'JB', 'LastName': 'Schwimmer', 'Affiliation': 'Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California.'}, {'ForeName': 'Jean P', 'Initials': 'JP', 'LastName': 'Molleston', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Indiana University School of Medicine/Riley Hospital for Children, Indianapolis, Indiana.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Rosenthal', 'Affiliation': ""Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, Benioff Children's Hospital, San Francisco, California.""}, {'ForeName': 'Karen F', 'Initials': 'KF', 'LastName': 'Murray', 'Affiliation': ""Pediatrics Institute, Cleveland Clinic Children's, Cleveland, Ohio.""}, {'ForeName': 'Miriam B', 'Initials': 'MB', 'LastName': 'Vos', 'Affiliation': ""Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia.""}, {'ForeName': 'Ajay K', 'Initials': 'AK', 'LastName': 'Jain', 'Affiliation': 'Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, St. Louis University, St. Louis, Missouri.'}, {'ForeName': 'Ann O', 'Initials': 'AO', 'LastName': 'Scheimann', 'Affiliation': 'Johns Hopkins School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Tamir', 'Initials': 'T', 'LastName': 'Miloh', 'Affiliation': 'Miami Transplant Institute, University of Miami Miller School of Medicine, Miami, Florida.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Fishbein', 'Affiliation': 'Department of Pediatrics, Feinberg Medical School of Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Cynthia A', 'Initials': 'CA', 'LastName': 'Behling', 'Affiliation': 'Department of Pathology, Sharp Memorial Hospital; Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California, San Diego, CA.'}, {'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Brunt', 'Affiliation': 'Department of Pathology and Immunology, Washington University, St. Louis, Missouri.'}, {'ForeName': 'Arun J', 'Initials': 'AJ', 'LastName': 'Sanyal', 'Affiliation': 'Department of Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Tonascia', 'Affiliation': 'Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Gastroenterology,['10.1053/j.gastro.2020.07.034'] 2285,32712155,Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).,"OBJECTIVE MicroRNAs (miRNAs) are promising biomarkers in ovarian cancer. Their kinetics during treatment might be useful for monitoring disease burden, and guiding treatments in patients treated with peri-operative chemotherapy and interval debulking surgery (IDS). METHODS Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing first line carboplatin-paclitaxel +/- nintedanib (NCT01583322) and IDS, were investigated to assess the kinetics of 11 relevant miRNAs. Their prognostic/predictive values regarding the likelihood of complete IDS, and the patient survival, were assessed and compared to those of CA125 kinetics. The selection of the miRNAs (miR-15b-5p, miR-16-5p, miR-20a-5p, miR-21-5p, miR-93-5p, miR-122-5p, miR-150-5p, miR-195-5p, miR-200b-3p, miR-148b-5p and miR-34a-5p) was based on the expression levels found with a large explorative panel, and on the literature data. RESULTS 756 serial blood samples from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA125 values. The longitudinal kinetics of the miRNA expressions were highly inconsistent, and were not related to CA125 dynamics. The miRNA changes during neoadjuvant treatment were not found associated with RECIST tumor response or IDS outcomes. Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests. CONCLUSIONS The longitudinal kinetics of miRNA expressions during neoadjuvant treatment in ovarian cancer patients were inconsistent, and were not found to be associated with tumor burden changes. Although some prognostic value could be discussed, no predictive value regarding tumor responses or IDS quality could be identified.",2020,"Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests. ","['756 serial blood samples from 119 patients were analyzed for a total of 8172 miRNA assays, and 1299 CA125 values', 'ovarian cancer patients', 'Serial blood samples of patients enrolled in the randomized phase II CHIVA trial, comparing first', 'patients treated with peri-operative chemotherapy and interval debulking surgery (IDS']",['line carboplatin-paclitaxel '],"['RECIST tumor response or IDS outcomes', 'OS benefits', 'patient survival']","[{'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0006610', 'cui_str': 'Cancer antigen 125'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0919267', 'cui_str': 'Neoplasm of ovary'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",119.0,0.0509418,"Decreases of miR-34a-5p and miR-93-5p were associated with PFS benefit (p = .009) and OS benefits (p < .001), respectively, using univariate tests. ","[{'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Robelin', 'Affiliation': ""EMR3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France, Université de Lyon, Lyon, France; Service d'Oncologie Médicale, CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France, GINECO, Paris, France. Electronic address: patrick.robelin@chu-lyon.fr.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Tod', 'Affiliation': 'EMR3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France, Université de Lyon, Lyon, France; Pharmacie, Hôpital de la Croix Rousse, Hospices civils de Lyon, Lyon, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Colomban', 'Affiliation': 'EMR3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France, Université de Lyon, Lyon, France.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Lachuer', 'Affiliation': 'ProfileXpert, SFR-Est, CNRS UMR-S3453, INSERM US7, Lyon, France.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Ray-Coquard', 'Affiliation': 'Centre Léon Bérard, Cancérologie médicale - 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon Université Claude Bernard Lyon 1, GINECO, Paris, France.'}, {'ForeName': 'Gaëtan De', 'Initials': 'G', 'LastName': 'Rauglaudre', 'Affiliation': 'Institut Sainte-Catherine, Oncologie radiothérapie, 250 Chemin De Baigne Pieds Cs80005, 84918 Avignon, GINECO, Paris, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Joly', 'Affiliation': 'Centre François Baclesse, Oncologie Médicale, 13 Rue du Général Harris 14000 Caen, Université Unicaen, GINECO, Paris, France.'}, {'ForeName': 'Annick', 'Initials': 'A', 'LastName': 'Chevalier-Place', 'Affiliation': 'Centre Oscar Lambret, Cancérologie gynécologique, 3 Frédéric COMBEMALE 59020 Lille, GINECO, Paris, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Combe', 'Affiliation': 'Hôpital Européen Georges Pompidou, Oncologie Médicale, 20 Rue Leblanc, 75015 Paris, GINECO, Paris, France.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Lortholary', 'Affiliation': 'Hôpital Privé du Confluent, Oncologie médicale, 4 rue Eric Tabarly 44200 Nantes, GINECO, Paris, France.'}, {'ForeName': 'Salima', 'Initials': 'S', 'LastName': 'Hamizi', 'Affiliation': 'Centre Hospitalier Lyon Sud, Oncologie médicale, 165 Chemin Du Grand Revoyet (CH LYON SUD), 69310 Pierre Benite, GINECO, Paris, France.'}, {'ForeName': 'Nadia', 'Initials': 'N', 'LastName': 'Raban', 'Affiliation': 'Hôpital de la Milétrie, Centre Hospitalier Universitaire de Poitiers, Oncologie médicale, 2 Rue De La Miletrie 86000 Poitiers, GINECO, Paris, France.'}, {'ForeName': 'Gwénaël', 'Initials': 'G', 'LastName': 'Ferron', 'Affiliation': 'Institut Claudius Regaud, Service de chirurgie oncologique, 1 avenue Irène Joliot-Curie, 31059 Toulouse CEDEX 09, GINECO, Paris, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Meunier', 'Affiliation': ""Centre Hospitalier Régional d'Orléans, Oncologie médicale, 14 Avenue De L'Hôpital, 45100 Orléans, GINECO, Paris, France.""}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Berton-Rigaud', 'Affiliation': 'ICO site René Gauducheau, Oncologie médicale, Boulevard Jacques Monod, 44800 Saint Herblain, GINECO, France.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Alexandre', 'Affiliation': 'Hôpital Cochin, Cancérologie oncologie, 27, Rue du Faubourg Saint Jacques, 75014 Paris, GINECO, Paris, France.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Kaminsky', 'Affiliation': 'Institut de cancérologie de lorraine, Alexis Vautrin, Oncologie médicale, 6 avenue de bourgogne 54500 Vandœuvre-lès-Nancy, GINECO, Paris, France.'}, {'ForeName': 'Coraline', 'Initials': 'C', 'LastName': 'Dubot', 'Affiliation': 'Centre RENE HUGUENIN INSTITUT CURIE, Oncologie médicale, 35 Rue Dailly, 92210 Saint Cloud, GINECO, Paris, France.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Leary', 'Affiliation': 'Institut Gustave Roussy, Département de médecine, 114 rue Edouard Vaillant 94805 VILLEJUIF, GINECO, Paris, France.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Malaurie', 'Affiliation': 'Centre Hospitalier Intercommunal de Créteil, Oncologie Médicale et Radiothérapie, 40 Avenue de Verdun, 94000 Créteil, GINECO, Paris, France.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'You', 'Affiliation': ""EMR3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France, Université de Lyon, Lyon, France; Service d'Oncologie Médicale, CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite, France, GINECO, Paris, France.""}]",Gynecologic oncology,['10.1016/j.ygyno.2020.07.021'] 2286,32712388,Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomised Controlled Trial.,"BACKGROUND A common complication of central venous access devices (CVADs) is catheter-associated bloodstream infection (CA-BSI). We previously demonstrated that insertion of CVADs on the right side was associated with increased risk of CA-BSI, and hypothesized that this related to the predominance of right-handedness in the patient population, resulting in greater movement and bacterial contamination. AIM We performed a prospective randomised controlled, non-blinded study to determine whether the side of CVAD insertion influenced the incidence of CA-BSI. METHODS Adult cancer patients were randomly allocated to either dominant or non-dominant side CVAD insertion. The primary end-point of the study was the number of line days until CA-BSI, determined in a blinded fashion by two assessors. FINDINGS 640 CVADs were randomised to dominant (n=322) or non-dominant (n=318) side of insertion, 60% had hematological malignancies, and 40% solid tumors. CVADs were a peripherally inserted central catheter line (67%), tunnelled CVAD (23%) and non-tunnelled CVAD (10%). 22% of CVADs were complicated by CA-BSI. The rate of CA-BSI per 1000 line days was 3.49 vs 3.66 in the non-dominant vs dominant group (HR 0.91; 95%CI, 0.65-1.28). By multivariable analysis, the rate of CA-BSI was increased by: use of tunnelled CVADs compared to PICC lines (HR 2.05, 95%CI 1.45-2.91); having a haematological malignancy compared to non-gastrointestinal solid tumors (HR 5.55; 95%CI 2.47-12.5); but not dominant compared to non-dominant side of CVAD (HR 0.97, 95%CI 0.69-1.36). CONCLUSION CA-BSI in adult patients with cancer was not impacted by whether CVAD insertion was on the dominant or non-dominant side.",2020,"The rate of CA-BSI per 1000 line days was 3.49 vs 3.66 in the non-dominant vs dominant group (HR 0.91; 95%CI, 0.65-1.28).","['Adult cancer patients', 'Adults with Cancer', '640 CVADs were randomised to dominant (n=322) or non-dominant (n=318) side of insertion, 60% had hematological malignancies, and 40% solid tumors', 'adult patients with cancer']","['dominant or non-dominant side CVAD insertion', 'Catheter-Associated Bloodstream Infections (CA-BSI']","['haematological malignancy', 'rate of CA-BSI', 'tunnelled CVAD', 'number of line days until CA-BSI', 'incidence of CA-BSI', 'risk of CA-BSI']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4708790', 'cui_str': '640'}, {'cui': 'C0444466', 'cui_str': 'Central venous'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0280100', 'cui_str': 'Solid tumour'}]","[{'cui': 'C0445549', 'cui_str': 'Non-dominant side'}, {'cui': 'C0082139', 'cui_str': 'CVAD protocol'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}]","[{'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0082139', 'cui_str': 'CVAD protocol'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",640.0,0.118602,"The rate of CA-BSI per 1000 line days was 3.49 vs 3.66 in the non-dominant vs dominant group (HR 0.91; 95%CI, 0.65-1.28).","[{'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Mollee', 'Affiliation': 'School of Medicine, University of Queensland, Brisbane, Australia; Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia. Electronic address: peter.mollee@health.qld.gov.au.'}, {'ForeName': 'Satomi', 'Initials': 'S', 'LastName': 'Okano', 'Affiliation': 'Statistics Unit, QIMR Berghofer Medical Research Institute, Brisbane, Australia.'}, {'ForeName': 'Emad', 'Initials': 'E', 'LastName': 'Abro', 'Affiliation': 'School of Medicine, University of Queensland, Brisbane, Australia; Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Looke', 'Affiliation': 'School of Medicine, University of Queensland, Brisbane, Australia; Department of Infectious Diseases, Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'Glen', 'Initials': 'G', 'LastName': 'Kennedy', 'Affiliation': ""Department of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Australia; School of Medicine, University of Queensland, St Lucia, Australia.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Harper', 'Affiliation': 'Department of Interventional Radiology, Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Clouston', 'Affiliation': ""Royal Brisbane and Women's Hospital, Brisbane, Australia.""}, {'ForeName': 'Rosita', 'Initials': 'R', 'LastName': 'Van Kuilenburg', 'Affiliation': 'Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'Alanna', 'Initials': 'A', 'LastName': 'Geary', 'Affiliation': ""Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.""}, {'ForeName': 'Warren', 'Initials': 'W', 'LastName': 'Joubert', 'Affiliation': 'Division of Cancer Services, Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Eastgate', 'Affiliation': ""Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Australia.""}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Jones', 'Affiliation': 'School of Public Health, University of Queensland, Brisbane, Australia.'}]",The Journal of hospital infection,['10.1016/j.jhin.2020.07.021'] 2287,32712460,Effect of a newly developed ready-to-use supplementary food on growth indicators in children with mild to moderate malnutrition.,"OBJECTIVES Malnutrition is one of the leading causes of death among children younger than five years. In this study, we aimed to formulate a ready-to-use supplementary food (RUSF), based on local food products, and investigate its efficacy on growth indicators in children with mild to moderate malnutrition. STUDY DESIGN This is a randomized controlled clinical trial. METHODS This study was performed in six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017. One hundred children, aged 24-59 months, with mild to moderate malnutrition (weight-for-height Z-score [WHZ] between -3 and -1) were randomly assigned to two groups to receive either 1-3 sachets of RUSF or normal diet for 8 weeks. All mothers and caregivers received nutrition education. Growth indicators including weight and height, WHZ, and body mass index (BMI), along with clinical outcomes, were assessed. RESULTS Children who received RUSF had a significant increase in weight (1.44 ± 0.38 vs 0.7 ± 0.32 kg, respectively, P < 0.001), and BMI (1.2 ± 0.47 vs 0.35 ± 0.33 kg/m 2 , respectively, P < 0.001) compared with the control group. There was a greater daily weight gain during the first 4 weeks (P < 0.001) and throughout the study (P = 0.013) in the RUSF group. Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027). Children in the RUSF group had more improvement in WHZ (1.18 ± 0.41 vs 0.41 ± 0.31, P < 0.001) after supplementation. Besides, 92% of the RUSF and 12% of the control group reached to WHZ > -1 at the end of the study (P < 0.001). There was lower prevalence of diarrhea (12% vs 28.6%, respectively, P = 0.01) and marginally lower fever (16% vs 36.7%, respectively, P = 0.05) in the intervention than in the control group. CONCLUSIONS A newly developed RUSF improved growth indicators and clinical outcomes in children with mild to moderate malnutrition. CLINICAL TRIAL REGISTRY NUMBER IRCT2017021315536N6 (registered at www.irct.ir).",2020,Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027).,"['children with mild to moderate malnutrition', 'One hundred children, aged 24-59 months, with mild to moderate malnutrition (weight-for-height Z-score [WHZ] between\xa0-3 and\xa0-1', 'six health centers in Shahr-e-Rey, Tehran, Iran, between April and October 2017', 'children younger than five years']","['RUSF or normal diet', 'nutrition education', 'RUSF', 'ready-to-use supplementary food (RUSF']","['diarrhea', 'weight', 'Daily height gain', 'weight and height, WHZ, and body mass index (BMI', 'BMI', 'daily weight gain', 'WHZ', 'fever']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0162429', 'cui_str': 'Undernourished'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0424670', 'cui_str': 'Weight for height'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0184625', 'cui_str': 'Normal diet'}, {'cui': 'C0204932', 'cui_str': 'Diet education'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0015967', 'cui_str': 'Fever'}]",100.0,0.0904359,Daily height gain was considerably higher in the RUSF group during the first 4 weeks (P = 0.027).,"[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Azimi', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Esmaillzadeh', 'Affiliation': 'Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Alipoor', 'Affiliation': 'Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Moslemi', 'Affiliation': 'Food and Drug Laboratories Research Center, Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Yaseri', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'M J', 'Initials': 'MJ', 'LastName': 'Hosseinzadeh-Attar', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran; Cardiac Primary Prevention Research Center (CPPRC), Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: hosseinzadeh.md.phd@gmail.com.'}]",Public health,['10.1016/j.puhe.2020.06.025'] 2288,32712560,Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.,"INTRODUCTION Pimavanserin is a selective 5-HT 2A inverse agonist/antagonist approved for treating hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Results from short-term, placebo-controlled studies demonstrated a positive benefit/risk profile. This multi-year, open-label study assessed long-term safety and tolerability of pimavanserin. METHODS This was an open-label extension (OLE) study in patients previously completing a double-blind, placebo-controlled study or a previous OLE study. Safety was evaluated from adverse events (AEs), clinical laboratory results, motor symptoms, electrocardiograms (ECG), and mortality. Durability of response was assessed from the Clinical Global Impression-Severity (CGI-S) scale and Caregiver Burden Scale (CBS). RESULTS Of 459 participants treated in this OLE study (average age 71.2 years), the median duration of treatment was 454 days. Over the entire study period (approximately 11 years), ≥1 AE occurred in 392 (85.4%) patients; the majority were of mild to moderate intensity, with fall (32.0%), urinary tract infection (19.0%), and hallucination (13.7%) most common. Serious AEs occurred in 188 (41.0%) patients, and an AE leading to study termination or dose discontinuation occurred in 133 (29.0%) patients. Sixty-one patients died, 59 (12.9%) during treatment or within 30 days after the last dose of study drug; the observed mortality rate was 6.45 per 100 patient-years of exposure. Mean scores for the CGI-S scale and CBS generally remained stable for up to 192 weeks (>3.5 years). CONCLUSIONS Long-term treatment with pimavanserin 34 mg once daily demonstrated a favorable benefit/risk profile with no unexpected safety concerns. Mortality rates suggested no increased risk following long-term treatment.",2020,"Mean scores for the CGI-S scale and CBS generally remained stable for up to 192 weeks (>3.5 years). ","[""Parkinson's disease psychosis"", '459 participants treated in this OLE study (average age 71.2 years']","['pimavanserin', 'Pimavanserin', 'placebo']","['adverse events (AEs), clinical laboratory results, motor symptoms, electrocardiograms (ECG), and mortality', 'Mean scores for the CGI-S scale and CBS', 'Clinical Global Impression-Severity (CGI-S) scale and Caregiver Burden Scale (CBS', 'urinary tract infection', 'AE leading to study termination or dose discontinuation', 'Serious AEs', 'Mortality rates', 'observed mortality rate', 'median duration of treatment']","[{'cui': 'C3805119', 'cui_str': ""Parkinson's disease psychosis""}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1722267', 'cui_str': 'pimavanserin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",459.0,0.12366,"Mean scores for the CGI-S scale and CBS generally remained stable for up to 192 weeks (>3.5 years). ","[{'ForeName': 'Clive G', 'Initials': 'CG', 'LastName': 'Ballard', 'Affiliation': 'University of Exeter Medical School, Exeter, UK. Electronic address: c.ballard@exeter.ac.uk.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Kreitzman', 'Affiliation': ""Parkinson's Disease and Movement Disorders Center of Long Island, Commack, NY, USA.""}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Isaacson', 'Affiliation': ""Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.""}, {'ForeName': 'I-Yuan', 'Initials': 'IY', 'LastName': 'Liu', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Norton', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Demos', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'Hubert H', 'Initials': 'HH', 'LastName': 'Fernandez', 'Affiliation': 'Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Tihomir V', 'Initials': 'TV', 'LastName': 'Ilic', 'Affiliation': 'Medical Faculty of Military Medical Academy, Belgrade, Serbia.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Azulay', 'Affiliation': 'Timone Hospital, Marseille, France.'}, {'ForeName': 'Joaquim J', 'Initials': 'JJ', 'LastName': 'Ferreira', 'Affiliation': 'Faculty of Medicine, University of Lisbon, Lisbon, Portugal.'}, {'ForeName': 'Victor', 'Initials': 'V', 'LastName': 'Abler', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': 'Srdjan', 'Initials': 'S', 'LastName': 'Stankovic', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, CA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2020.06.026'] 2289,32712569,"A randomized pilot trial of topiramate for alcohol use disorder in veterans with traumatic brain injury: Effects on alcohol use, cognition, and post-concussive symptoms.","BACKGROUND Topiramate is an effective treatment for alcohol use disorder (AUD) and has also been used in the care of mild traumatic brain injury (mTBI). This pilot study aimed to obtain a preliminary assessment of topiramate's efficacy in reducing alcohol use and post-concussive symptoms, and its potential negative impact on cognitive function in 32 Veterans with co-occurring AUD and mTBI. METHODS This was a prospective 12-week, randomized, double-blind, placebo-controlled pilot study of flexible-dose topiramate or placebo. Primary outcome was reduction of drinking days per week within the topiramate arm. Secondary outcomes included between group comparisons of alcohol use and craving, post-concussive symptoms, and cognitive function. RESULTS Drinking days per week significantly decreased within both the topiramate and placebo arm. There were no significant treatment-by-week interactions on alcohol use/craving, or post-concussive symptoms in intent-to-treat analyses. In per-protocol analyses, topiramate significantly reduced number of drinks per week compared with placebo. Topiramate transiently impaired verbal fluency and working memory. Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. CONCLUSIONS Significant improvement occurred in both the topiramate and placebo groups over 12 weeks of treatment in alcohol use and post-concussive symptoms. Among treatment completers there was greater reduction of alcohol use in the topiramate arm. Topiramate was also associated with negative but transient effects on cognitive function. Results suggest both a possible benefit for topiramate treatment in reducing alcohol use and some potential for negative cognitive effects in Veterans with AUD and mTBI.",2020,"Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. ","['32 Veterans with co-occurring AUD and mTBI', 'Veterans with AUD and mTBI', 'veterans with traumatic brain injury']","['Topiramate', 'flexible-dose topiramate or placebo', 'placebo', 'topiramate']","['reduction of alcohol use', 'alcohol use/craving, or post-concussive symptoms', 'alcohol use and craving, post-concussive symptoms, and cognitive function', 'verbal fluency and working memory', 'cognitive function', 'reduction of drinking days', 'Processing speed, cognitive inhibition, and mental flexibility']","[{'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0006107', 'cui_str': 'Concussion injury of brain'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}]","[{'cui': 'C0076829', 'cui_str': 'topiramate'}, {'cui': 'C0443220', 'cui_str': 'Flexible'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0546983', 'cui_str': 'Postconcussion syndrome'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0556347', 'cui_str': 'Drinking day'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",32.0,0.0870034,"Processing speed, cognitive inhibition, and mental flexibility significantly improved between weeks 1 and 12, regardless of treatment arm. ","[{'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Pennington', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA. Electronic address: david.pennington2@va.gov.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Bielenberg', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Brooke', 'Initials': 'B', 'LastName': 'Lasher', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Herbst', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Abrams', 'Affiliation': 'San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Novakovic-Agopian', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}, {'ForeName': 'Steven L', 'Initials': 'SL', 'LastName': 'Batki', 'Affiliation': 'University of California, San Francisco, Department of Psychiatry, 4150 Clement St., San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System (SFVAHCS), 4150 Clement St., San Francisco, CA, USA; Northern California Institute for Research and Education (NCIRE), 4150 Clement St., San Francisco, CA, USA.'}]",Drug and alcohol dependence,['10.1016/j.drugalcdep.2020.108149'] 2290,32712674,A Randomized Controlled Trial of an Electronic Clinical Decision Support Tool for Inpatient Antimicrobial Stewardship.,"BACKGROUND The weighted incidence syndromic combination antibiogram (WISCA) is an antimicrobial stewardship tool that utilizes electronic medical record data to provide real-time clinical decision support regarding empiric antibiotic prescription in the hospital setting. The aim of this study was to determine the impact of WISCA utilization for empiric antibiotic prescription on hospital length of stay (LOS). METHODS We performed a cross-over randomized controlled trial of the WISCA tool at 4 hospitals. Study participants included adult inpatients receiving empiric antibiotics for urinary tract infection (UTI), abdominal-biliary infection (ABI), pneumonia, or non-purulent cellulitis. Antimicrobial stewardship (ASP) physicians utilized WISCA and clinical guidelines to provide empiric antibiotic recommendations. The primary outcome was LOS. Secondary outcomes included 30-day mortality, 30-day readmission, C. difficile infection, acquisition of multidrug resistant Gram-negative organism (MDRO), and antibiotics costs. RESULTS 6,849 participants enrolled in the study. There were no overall differences in outcomes among the intervention vs. control groups. Participants with cellulitis in the intervention group had significantly shorter mean LOS compared to participants with cellulitis in the control group (coefficient estimate = 0.53 [-0.97, -0.09], p=0.0186). For patients with community acquired pneumonia (CAP), the intervention group had significantly lower odds of 30-day mortality compared to the control group (aOR= 0.58, 95% CI [0.396, 0.854], p=0.02). CONCLUSION Use of WISCA was not associated with improved outcomes for UTI and ABI. Guidelines-based interventions were associated with decreased LOS for cellulitis and decreased mortality for CAP.",2020,Participants with cellulitis in the intervention group had significantly shorter mean LOS compared to participants with cellulitis in the control group (coefficient estimate = 0.53,"['patients with community acquired pneumonia (CAP', 'Study participants included adult inpatients receiving empiric antibiotics for urinary tract infection (UTI), abdominal-biliary infection (ABI), pneumonia, or non-purulent cellulitis', '6,849 participants enrolled in the study', 'tool at 4 hospitals']","['empiric antibiotic prescription', 'syndromic combination antibiogram (WISCA', 'WISCA']","['hospital length of stay (LOS', 'shorter mean LOS', '30-day mortality, 30-day readmission, C. difficile infection, acquisition of multidrug resistant Gram-negative organism (MDRO), and antibiotics costs', 'LOS', '30-day mortality', 'LOS for cellulitis and decreased mortality for CAP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0694549', 'cui_str': 'Community acquired pneumonia'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0439665', 'cui_str': 'Purulent'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C1720786', 'cui_str': 'Antibiogram'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0439208', 'cui_str': 'g'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0029235', 'cui_str': 'Organism'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]",6849.0,0.205696,Participants with cellulitis in the intervention group had significantly shorter mean LOS compared to participants with cellulitis in the control group (coefficient estimate = 0.53,"[{'ForeName': 'Jessica P', 'Initials': 'JP', 'LastName': 'Ridgway', 'Affiliation': 'Department of Medicine, University of Chicago, Chicago, IL, USA.'}, {'ForeName': 'Ari', 'Initials': 'A', 'LastName': 'Robicsek', 'Affiliation': 'Providence St. Joseph Health, Seattle, WA, USA.'}, {'ForeName': 'Nirav', 'Initials': 'N', 'LastName': 'Shah', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Becky A', 'Initials': 'BA', 'LastName': 'Smith', 'Affiliation': 'Department of Medicine, Duke University, Durham, NC, USA.'}, {'ForeName': 'Kamaljit', 'Initials': 'K', 'LastName': 'Singh', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Semel', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Mary Ellen', 'Initials': 'ME', 'LastName': 'Acree', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Grant', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Urmila', 'Initials': 'U', 'LastName': 'Ramichandran', 'Affiliation': 'NorthShore University HealthSystem, Evanston, IL, USA.'}, {'ForeName': 'Lance', 'Initials': 'L', 'LastName': 'Peterson', 'Affiliation': 'Pritzer School of Medicine, University of Chicago, Chicago, IL, USA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1048'] 2291,32712683,Arthroscopic reduction and internal fixation (ARIF) versus open reduction internal fixation (ORIF) to elucidate the difference for tibial side PCL avulsion fixation: a randomized controlled trail (RCT).,"PURPOSE To compare the clinical, radiological outcomes, economic and technical differences for ORIF by cancellous screw fixation versus ARIF by double-tunnel suture fixation for displaced tibial-side PCL avulsion fractures. METHODS Forty patients with displaced tibial-sided PCL avulsions were operated upon after randomizing them into two groups (20 patients each in the open and arthroscopic group) and followed up prospectively. Assessment included duration of surgery, cost involved, pre- and post-operative functional scores, radiological assessment of union, and posterior laxity using stress radiography and complications. RESULTS The mean follow-up period was 33 months (27-42) (open group) and 30 months (26-44) (arthroscopic group). The duration of surgery was significantly larger in the arthroscopic group (47.8 ± 17.9 min) as compared to the open group (33.4 ± 10.1 min). The costs involved were significantly higher in the arthroscopic group (p- 0.01). At final follow-up, knee function in the form of IKDC (International Knee Documentation Committee) evaluation (89.9 ± 4.8-open and 89.3 ± 5.9-arthroscopic) and Lysholm scores (94.2 ± 4.1-open and 94.6 ± 4.1-arthroscopic) had improved significantly with the difference (n.s.) between the two groups. The mean posterior tibial displacement was 5.7 ± 1.8 mm in the open group and 6.3 ± 3.1 mm in the arthroscopic group which was (n.s.). There were two non-unions and one popliteal artery injury in the arthroscopic group. CONCLUSION Both ARIF and ORIF for PCL avulsion fractures yield good clinical and radiological outcomes. However, ORIF was better than ARIF in terms of cost, duration of surgery, and complications like non-union and iatrogenic vascular injury. LEVEL OF EVIDENCE II.",2020,The costs involved were significantly higher in the arthroscopic group (p- 0.01).,['Forty patients with displaced tibial-sided PCL avulsions'],"['cancellous screw fixation versus ARIF by double-tunnel suture fixation', 'Arthroscopic reduction and internal fixation (ARIF) versus open reduction internal fixation (ORIF']","['duration of surgery', 'duration of surgery, cost involved, pre- and post-operative functional scores, radiological assessment of union, and posterior laxity using stress radiography and complications', 'cost, duration of surgery, and complications like non-union and iatrogenic vascular injury', 'mean posterior tibial displacement']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0441987', 'cui_str': 'Side'}, {'cui': 'C1704423', 'cui_str': 'Hereditary lymphedema'}, {'cui': 'C0185044', 'cui_str': 'Surgical avulsion'}]","[{'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0337138', 'cui_str': 'Tunnel'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0016642', 'cui_str': 'Internal fixation of fracture'}, {'cui': 'C1297885', 'cui_str': 'Open reduction with internal fixation'}]","[{'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0332536', 'cui_str': 'Laxity'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0178324', 'cui_str': 'Injury of blood vessel'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}]",40.0,0.0301599,The costs involved were significantly higher in the arthroscopic group (p- 0.01).,"[{'ForeName': 'Silvampatti Ramaswamy', 'Initials': 'SR', 'LastName': 'Sundararajan', 'Affiliation': 'Department of Arthroscopy and Sports Medicine, Ganga Medical Centre and Hospitals Pvt Ltd, 313 Mettupalayam Road, Coimbatore, 641043, India. sundarbone70@hotmail.com.'}, {'ForeName': 'Joseph Babu', 'Initials': 'JB', 'LastName': 'Joseph', 'Affiliation': 'Department of Arthroscopy and Sports Medicine, Ganga Medical Centre and Hospitals Pvt Ltd, 313 Mettupalayam Road, Coimbatore, 641043, India.'}, {'ForeName': 'Rajagopalakrishnan', 'Initials': 'R', 'LastName': 'Ramakanth', 'Affiliation': 'Department of Arthroscopy and Sports Medicine, Ganga Medical Centre and Hospitals Pvt Ltd, 313 Mettupalayam Road, Coimbatore, 641043, India.'}, {'ForeName': 'Amit Kumar', 'Initials': 'AK', 'LastName': 'Jha', 'Affiliation': 'Department of Arthroscopy and Sports Medicine, Ganga Medical Centre and Hospitals Pvt Ltd, 313 Mettupalayam Road, Coimbatore, 641043, India.'}, {'ForeName': 'Shanmuganathan', 'Initials': 'S', 'LastName': 'Rajasekaran', 'Affiliation': 'Department of Orthopaedics and Spine Surgery, Ganga Medical Centre and Hospitals Pvt Ltd, 313 Mettupalayam Road, Coimbatore, 641043, India.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-020-06144-9'] 2292,32712762,The effect of ketamine on depth of hypnosis indices during total intravenous anesthesia-a comparative study using a novel electroencephalography case replay system.,"Ketamine may affect the reliability of electroencephalographic (EEG) depth-of-hypnosis indices as it affects power in high-frequency EEG components. The purpose of this study was to compare the effects of ketamine on three commonly-used depth-of-hypnosis indices by extending our EEG simulator to allow replay of previously-recorded EEG. Secondary analysis of previously-collected data from a randomized controlled trial of intravenous anesthesia with ketamine: Group 0.5 [ketamine, 0.5 mg kg -1 bolus followed by a 10 mcg kg -1  min -1 infusion], Group 0.25 [ketamine, 0.25 mg kg -1  bolus, 5 mcg kg -1  min -1 infusion], and Control [no ketamine]. EEG data were replayed to three monitors: NeuroSENSE (WAV), Bispectral Index (BIS), and Entropy (SE). Differences in depth-of-hypnosis indices during the initial 15 min after induction of anesthesia were compared between monitors, and between groups. Monitor agreement was evaluated using Bland-Altman analysis. Available data included 45.6 h of EEG recordings from 27 cases. Ketamine was associated with higher depth-of-hypnosis index values measured at 10 min (BIS, χ 2  = 8.01, p = 0.018; SE, χ 2  = 11.44, p = 0.003; WAV, χ 2  = 9.19, p = 0.010), and a higher proportion of index values > 60 for both ketamine groups compared to the control group. Significant differences between monitors were not observed, except between BIS and SE in the control group. Ketamine did not change agreement between monitors. The ketamine-induced increase in depth-of-hypnosis indices was observed consistently across the three EEG monitoring algorithms evaluated. The observed increase was likely caused by a power increase in the beta and gamma bands. However, there were no lasting differences in depth-of-hypnosis reported between the three compared indices.",2020,The ketamine-induced increase in depth-of-hypnosis indices was observed consistently across the three EEG monitoring algorithms evaluated.,[],"['intravenous anesthesia with ketamine', 'ketamine, 0.25\xa0mg', 'ketamine', 'Ketamine', 'Control [no ketamine']","['depth-of-hypnosis indices', 'reliability of electroencephalographic (EEG) depth-of-hypnosis indices', 'depth of hypnosis indices', 'higher depth-of-hypnosis index values', 'Bispectral Index (BIS), and Entropy (SE', 'depth-of-hypnosis']",[],"[{'cui': 'C0002920', 'cui_str': 'Intravenous anesthesia'}, {'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C4517443', 'cui_str': '0.25'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0020587', 'cui_str': 'Hypnotherapy'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0376522', 'cui_str': 'Entropy'}]",,0.0564491,The ketamine-induced increase in depth-of-hypnosis indices was observed consistently across the three EEG monitoring algorithms evaluated.,"[{'ForeName': 'Stephanie S', 'Initials': 'SS', 'LastName': 'Schüler', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Christian L', 'Initials': 'CL', 'LastName': 'Petersen', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Nicholas C', 'Initials': 'NC', 'LastName': 'West', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'J Mark', 'Initials': 'JM', 'LastName': 'Ansermino', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Richard N', 'Initials': 'RN', 'LastName': 'Merchant', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Görges', 'Affiliation': 'Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada. mgorges@bcchr.ca.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-020-00565-0'] 2293,32712769,Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial.,"BACKGROUND For patients with locally advanced proximal gastric cancer (LAPGC), the individualized selection of patients with highly suspected splenic hilar (No. 10) lymph node (LN) metastasis to undergo splenic hilar lymphadenectomy, is a clinical dilemma. This study aimed to re-evaluate the feasibility and safety of laparoscopic spleen-preserving splenic hilar lymphadenectomy (LSPSHL) and to identify the population who would benefit from it. METHODS A total of 1068 patients (D2 group = 409; D2 + No. 10 group = 659) who underwent laparoscopic total gastrectomy from four prospective trials between January 2015 and July 2019 were analyzed. RESULTS No significant difference in the incidence (16.9% vs. 16.4%; P = 0.837) of postoperative complications were found between the two groups. The metastasis rate of No. 10 LN among patients in the D2 + No. 10 group was 10.3% (68/659). Based on the decision tree, patients with LAPGC with tumor invading the greater curvature (Gre), patients with non-Gre-invading LAPGC with a tumor size > 5 cm and clinical positive locoregional LNs were defined as the high-priority No. 10 dissection group. The metastasis rate of No. 10 LNs in the high-priority group was 19.4% (41/211). In high-priority group, the 3-year overall survival of the D2 + No. 10 group was better than that of the D2 group (74.4% vs. 42.1%; P = 0.005), and the therapeutic index of No. 10 was higher than the indices of most suprapancreatic stations. CONCLUSIONS LSPSHL for LAPGC is safe and feasible when performed by experienced surgeons. LSPSHL could be recommended for the high-priority group patients even without invasion of the Gre.",2020,No significant difference in the incidence (16.9% vs. 16.4%; P = 0.837) of postoperative complications were found between the two groups.,"['patients with highly suspected splenic hilar (No. 10) lymph node (LN) metastasis to undergo splenic hilar lymphadenectomy', 'proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy', '1068 patients (D2 group\u2009=\u2009409; D2\u2009+\u2009No. 10 group\u2009=\u2009659) who underwent laparoscopic total gastrectomy from four prospective trials between January 2015 and July 2019 were analyzed', 'patients with LAPGC with tumor invading the greater curvature (Gre), patients with non-Gre-invading LAPGC with a tumor size\u2009>\u20095\xa0cm and clinical positive locoregional LNs', 'patients with locally advanced proximal gastric cancer (LAPGC']","['LAPGC', 'laparoscopic spleen-preserving splenic hilar lymphadenectomy (LSPSHL', '10 lymphadenectomy']","['3-year overall survival', 'postoperative complications', 'metastasis rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0205150', 'cui_str': 'Hilar'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C1521863', 'cui_str': 'estrogen receptor alpha, human'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0161899', 'cui_str': 'Total gastrectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4038617', 'cui_str': 'Laparoscopic total gastrectomy'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0227223', 'cui_str': 'Structure of greater curvature of stomach'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0439084', 'cui_str': '>5'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0023374', 'cui_str': 'Lesch-Nyhan syndrome'}]","[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0037993', 'cui_str': 'Splenic structure'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0205150', 'cui_str': 'Hilar'}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]",1068.0,0.0202243,No significant difference in the incidence (16.9% vs. 16.4%; P = 0.837) of postoperative complications were found between the two groups.,"[{'ForeName': 'Qing', 'Initials': 'Q', 'LastName': 'Zhong', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China.'}, {'ForeName': 'Qi-Yue', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China.'}, {'ForeName': 'Yan-Chang', 'Initials': 'YC', 'LastName': 'Xu', 'Affiliation': 'The First Hospital of Putian City, Putian, 351100, China.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Zhao', 'Affiliation': 'Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.'}, {'ForeName': 'Li-Sheng', 'Initials': 'LS', 'LastName': 'Cai', 'Affiliation': 'Department of General Surgery Unit 4, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, Fujian, China.'}, {'ForeName': 'Guo-Xin', 'Initials': 'GX', 'LastName': 'Li', 'Affiliation': 'Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.'}, {'ForeName': 'Ze-Kuan', 'Initials': 'ZK', 'LastName': 'Xu', 'Affiliation': 'Department of General Surgery, Jiangsu Province Hospital, Nanjing Medical University, Nanjing, 210000, China.'}, {'ForeName': 'Su', 'Initials': 'S', 'LastName': 'Yan', 'Affiliation': 'Department of Gastrointestinal Surgery, Affiliated Hospital of Qinghai University, Qinghai Medical University, Xining, 810000, China.'}, {'ForeName': 'Zu-Guang', 'Initials': 'ZG', 'LastName': 'Wu', 'Affiliation': ""Department of General Surgery Unit 2, Meizhou People's Hospital of Guangdong, Meizhou, 514021, China.""}, {'ForeName': 'Fang-Qin', 'Initials': 'FQ', 'LastName': 'Xue', 'Affiliation': 'Department of Gastrointestinal Surgery, Fujian Provincial Hospital, Fuzhou, 350001, China.'}, {'ForeName': 'Yi-Hong', 'Initials': 'YH', 'LastName': 'Sun', 'Affiliation': 'Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.'}, {'ForeName': 'Dong-Po', 'Initials': 'DP', 'LastName': 'Xu', 'Affiliation': 'Department of General Surgery, Longyan First Hospital, Longyan, 364000, China.'}, {'ForeName': 'Wen-Bin', 'Initials': 'WB', 'LastName': 'Zhang', 'Affiliation': 'Department of General Surgery, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Medical University, Wulumuqi, 830001, China.'}, {'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Wan', 'Affiliation': 'Department of General Surgery, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510515, China.'}, {'ForeName': 'Pei-Wu', 'Initials': 'PW', 'LastName': 'Yu', 'Affiliation': 'Department of General Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.'}, {'ForeName': 'Jian-Kun', 'Initials': 'JK', 'LastName': 'Hu', 'Affiliation': 'Department of Gastrointestinal Surgery, West China Hospital of Sichuan University, Sichuan University, Chengdu, 610000, China.'}, {'ForeName': 'Xiang-Qian', 'Initials': 'XQ', 'LastName': 'Su', 'Affiliation': 'Gastrointestinal Cancer Center, Beijing University Cancer Hospital, Beijing, 100142, China.'}, {'ForeName': 'Jia-Fu', 'Initials': 'JF', 'LastName': 'Ji', 'Affiliation': 'Gastrointestinal Cancer Center, Beijing University Cancer Hospital, Beijing, 100142, China.'}, {'ForeName': 'Zi-Yu', 'Initials': 'ZY', 'LastName': 'Li', 'Affiliation': 'Gastrointestinal Cancer Center, Beijing University Cancer Hospital, Beijing, 100142, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'You', 'Affiliation': 'Department of Gastrointestinal Surgery, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, 361000, China.'}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Gastrointestinal Surgery, Guangdong General Hospital, Guangzhou, 510515, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Fan', 'Affiliation': ""Department of General Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.""}, {'ForeName': 'Chao-Hui', 'Initials': 'CH', 'LastName': 'Zheng', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China.'}, {'ForeName': 'Jian-Wei', 'Initials': 'JW', 'LastName': 'Xie', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'Li', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China.'}, {'ForeName': 'Chang-Ming', 'Initials': 'CM', 'LastName': 'Huang', 'Affiliation': 'Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, China. hcmlr2002@163.com.'}]",Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,['10.1007/s10120-020-01110-3'] 2294,32712793,Zygomaticomaxillary fracture fixation: a prospective comparative evaluation of two-point versus three-point fixation.,"PURPOSE Zygomatic bone has a higher risk of sustaining injuries in the maxillofacial skeleton. On fracturing, zygomatic bone separates from the four neighbouring bones at its articulations. Treatment for zygomaticomaxillary fractures has evolved a long way since 3000 BC. With the advent of miniplates for midface fracture, controversies still exist regarding the stability of zygoma following 1, 2, and 3 points for fixation. The study aims to compare and determine the most effective technique for the reduction of zygomaticomaxillary fractures and the ability to retain the fractured zygoma in a stable position. Hence, a study was conducted in our institute to compare 2 and 3-point fixation of zygomaticomaxillary fractures taking into account the clinical and radiographic parameters. METHODS Twenty-four patients were divided into 2 equal groups A and B, receiving 2- and 3-point fixation respectively. Fracture displacement and stability were assessed using coronal and axial CT scan tracings at preoperatively, immediate, and 5-week postoperatively. RESULTS Group B showed a significant reduction in postoperative mean displacement at sphenozygomatic and infraorbital region when compared with group A. Patients in group A had an increase incidence in vertical dystopia and enophthalmos. There was no postoperative displacement at any site in both the groups. CONCLUSION The fractured segment was held in place by both the fixation methods but 3-point fixation gave better stability in maintaining the fractured segment in desired reduced position.",2020,"RESULTS Group B showed a significant reduction in postoperative mean displacement at sphenozygomatic and infraorbital region when compared with group A. Patients in group A had an increase incidence in vertical dystopia and enophthalmos.",['Twenty-four patients'],['Zygomaticomaxillary fracture fixation'],"['postoperative mean displacement at sphenozygomatic and infraorbital region', 'postoperative displacement', 'vertical dystopia and enophthalmos', 'Fracture displacement and stability']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0016641', 'cui_str': 'Fixation of fracture'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012725', 'cui_str': 'Displacement - mental defense mechanism'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0585059', 'cui_str': 'Fracture with displacement'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",24.0,0.013502,"RESULTS Group B showed a significant reduction in postoperative mean displacement at sphenozygomatic and infraorbital region when compared with group A. Patients in group A had an increase incidence in vertical dystopia and enophthalmos.","[{'ForeName': 'Saikrishna', 'Initials': 'S', 'LastName': 'Degala', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, JSS Dental College and Hospital, Mysore, Karnataka, 570015, India.'}, {'ForeName': 'Sathish', 'Initials': 'S', 'LastName': 'Radhakrishna', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, JSS Dental College and Hospital, Mysore, Karnataka, 570015, India. drsathish75@gmail.com.'}, {'ForeName': 'Shweta', 'Initials': 'S', 'LastName': 'Dharmarajan', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, JSS Dental College and Hospital, Mysore, Karnataka, 570015, India.'}]",Oral and maxillofacial surgery,['10.1007/s10006-020-00881-4'] 2295,31895658,"Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence.","Whether marine omega-3 fatty acid (n-3 FA) or vitamin D supplementation can prevent cardiovascular disease (CVD) in general populations at usual risk for this outcome is unknown. A major goal of VITAL (Vitamin D and Omega-3 Trial) was to fill this knowledge gap. In this article, we review the results of VITAL, discuss relevant mechanistic studies regarding n-3 FAs, vitamin D, and vascular disease, and summarize recent meta-analyses of the randomized trial evidence on these agents. VITAL was a nationwide, randomized, placebo-controlled, 2×2 factorial trial of marine n-3 FAs (1 g/d) and vitamin D 3 (2000 IU/d) in the primary prevention of CVD and cancer among 25 871 US men aged ≥50 and women aged ≥55 years, including 5106 blacks. Median treatment duration was 5.3 years. Supplemental n-3 FAs did not significantly reduce the primary cardiovascular end point of major CVD events (composite of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95% CI, 0.80-1.06]) but were associated with significant reductions in total myocardial infarction (HR, 0.72 [95% CI, 0.59-0.90]), percutaneous coronary intervention (HR, 0.78 [95% CI, 0.63-0.95]), and fatal myocardial infarction (HR, 0.50 [95% CI, 0.26-0.97]) but not stroke or other cardiovascular end points. For major CVD events, a treatment benefit was seen in those with dietary fish intake below the cohort median of 1.5 servings/wk (HR, 0.81 [95% CI, 0.67-0.98]) but not in those above ( P interaction=0.045). For myocardial infarction, the greatest risk reductions were in blacks (HR, 0.23 [95% CI, 0.11-0.47]; P interaction by race, 0.001). Vitamin D supplementation did not reduce major CVD events (HR, 0.97 [95% CI, 0.85-1.12]) or other cardiovascular end points. Updated meta-analyses that include VITAL and other recent trials document coronary risk reduction from supplemental marine n-3 FAs but no clear CVD risk reduction from supplemental vitamin D. Additional research is needed to determine which individuals may be most likely to derive net benefit from supplementation. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01169259.",2020,"Supplemental n-3 FAs did not significantly reduce the primary cardiovascular end point of major CVD events (composite of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95% CI, 0.80-1.06]) but were associated with significant reductions in total myocardial infarction (HR, 0.72","['CVD and cancer among 25\u2009871 US men aged ≥50 and women aged ≥55 years, including 5106 blacks']","['marine n-3 FAs (1 g/d) and vitamin D 3', 'marine omega-3 fatty acid (n-3 FA) or vitamin D supplementation', 'Vitamin D supplementation', 'Vitamin D, Marine n-3 Fatty Acids', 'placebo']","['primary cardiovascular end point of major CVD events (composite of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR', 'major CVD events', 'total myocardial infarction', 'fatal myocardial infarction', 'cardiovascular disease (CVD']","[{'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}]","[{'cui': 'C0524645', 'cui_str': 'Marines'}, {'cui': 'C0015683', 'cui_str': 'Fatty-acid synthase'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}]",25871.0,0.659422,"Supplemental n-3 FAs did not significantly reduce the primary cardiovascular end point of major CVD events (composite of myocardial infarction, stroke, and CVD mortality; hazard ratio [HR], 0.92 [95% CI, 0.80-1.06]) but were associated with significant reductions in total myocardial infarction (HR, 0.72","[{'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'Shari S', 'Initials': 'SS', 'LastName': 'Bassuk', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Cook', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'I-Min', 'Initials': 'IM', 'LastName': 'Lee', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'Samia', 'Initials': 'S', 'LastName': 'Mora', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Albert', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': 'Julie E', 'Initials': 'JE', 'LastName': 'Buring', 'Affiliation': ""From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.E.M., S.S.B., N.R.C., I.-M.L., S.M., C.M.A., J.E.B.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Circulation research,['10.1161/CIRCRESAHA.119.314541'] 2296,32087394,"Evaluating the effects of a simulator-based training on knowledge, attitudes and driving profiles of German ambulance drivers.","INTRODUCTION Accident risk is increased for emergency responders driving with warning lights and sirens compared to other road users' driving. Currently no standards for education of ambulance drivers exist. Research shows that high order understanding trainings focusing on insight to avoid critical driving situations might be more helpful than trainings focusing on car handling. The present controlled intervention study evaluates a one-day simulator-based high order training program specifically designed for ambulance drivers. METHODS In a longitudinal design with three measurement times multiple methods were used to evaluate the training holistically targeting the levels of reaction to training, learning, behavior and results of training. Questionnaire, knowledge test and driving profile data were analyzed with repeated measures analysis of variance controlling for age and sex. Data of two intervention groups and one control-waiting group was collected between 2014 and 2017 in two German federal states. RESULTS 183 German paramedics (age: M = 33.1, SD = 9.4, 21.9 % female) participated in the study. 147 participants (80.3 %) completed post-training tests, and 30 participants (16.4 %) completed follow-up measurements six months after training. Participants' reaction to training was positive directly after the training, and dropped slightly over time. Intervention group participants gained traffic-relevant knowledge compared to control group participants. Risk sensitivity of regular driving situations was the only attitude variable positively affected by training. This effect was not sustained six months after training. Training led to a decrease of average and maximum speed in short- as well as long-term measurements but did not affect drivers' acceleration. Although speed was lower in post-tests, emergency response times did not differ. CONCLUSION The simulator-based training for paramedics has small but notable effects on drivers' knowledge, attitudes and real driving behavior. Although only very few measured variables showed positive training effects, no negative training effects were found. Speed was reduced in the long term which underlines the importance of such a training. More research is needed to determine effects on different types of participants and to elicit framework conditions for training integration in formal education.",2020,"The simulator-based training for paramedics has small but notable effects on drivers' knowledge, attitudes and real driving behavior.","['183 German paramedics (age: M\u202f=\u202f33.1, SD\u202f=\u202f9.4, 21.9 % female) participated in the study', '147 participants (80.3 %) completed post-training tests, and 30 participants (16.4 %) completed follow-up measurements six months after training', 'German ambulance drivers']",['simulator-based training'],"['Questionnaire, knowledge test and driving profile data', 'traffic-relevant knowledge', 'Risk sensitivity of regular driving situations', 'emergency response times']","[{'cui': 'C4517615', 'cui_str': '183'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0002422', 'cui_str': 'Ambulance'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}]","[{'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}]",147.0,0.0320528,"The simulator-based training for paramedics has small but notable effects on drivers' knowledge, attitudes and real driving behavior.","[{'ForeName': 'Maria J', 'Initials': 'MJ', 'LastName': 'Prohn', 'Affiliation': 'Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstraße 1, 80336 München, Germany. Electronic address: Maria.Prohn@med.uni-muenchen.de.'}, {'ForeName': 'Britta', 'Initials': 'B', 'LastName': 'Herbig', 'Affiliation': 'Institute and Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Ziemssenstraße 1, 80336 München, Germany. Electronic address: Britta.Herbig@med.uni-muenchen.de.'}]",Accident; analysis and prevention,['10.1016/j.aap.2020.105466'] 2297,32719638,Cognition and Brain Activation in Response to Various Doses of Caffeine: A Near-Infrared Spectroscopy Study.,"Caffeine, which is widely used for enhancing athletic performance, has been suggested to have a positive impact on cognition via stimulating the brain. However, no study published to date has explored the effects of different doses of caffeine ingestion on brain activation via cortical hemodynamics. The purpose of the present crossover, double-blind study was to investigate the effects of low, moderate, and high doses of caffeine ingestion on cognitive performance and brain activation. Ten healthy male subjects ingested placebo or caffeine (3, 6, or 9 mg/kg body mass). The effects of each treatment condition were evaluated by Stroop tasks before and 60 min after the ingestion of caffeine. Reaction time (RT) and accuracy of responses to congruent and incongruent stimuli were assessed. As an index of brain activation with cognition, levels of oxygenated hemoglobin (HbO) were measured via near-infrared spectroscopy. A 4 × 2 mixed ANOVA revealed that there were significant interaction effects for RT in both incongruent and congruent conditions ( P < 0.01, P η 2 = 0.384; P < 0.05, P η 2 = 0.259; and P < 0.05, P η 2 = 0.309). Both 3 and 6 mg/kg of caffeine ingestion significantly decreased RT to incongruent stimuli. The only dose of caffeine to decrease RT in response to congruent stimuli was 3 mg/kg. None of the doses of caffeine administered affected accuracy of responses to incongruent or congruent stimuli. Under the congruent stimulus condition, ingestion of 3 mg/kg of caffeine significantly increased mean HbO in the dorsolateral prefrontal cortex, frontal pole area, ventrolateral prefrontal cortex ( P < 0.01, P η 2 = 0.319; P < 0.05, P η 2 = 0.263; and P < 0.05, P η 2 = 0.259, respectively). None of the doses of caffeine investigated affected HbO under the incongruent stimulus condition. Ingestion of low-dose caffeine has greater effects on cognition and brain activation than moderate and high doses of caffeine, suggesting that low-dose caffeine may be a selective supplement in enhancing executive function and prefrontal activities.",2020,None of the doses of caffeine administered affected accuracy of responses to incongruent or congruent stimuli.,['Ten healthy male subjects ingested'],"['caffeine ingestion', 'placebo or caffeine', 'caffeine', 'Caffeine']","['Cognition and Brain Activation', 'index of brain activation with cognition, levels of oxygenated hemoglobin (HbO', 'RT to incongruent stimuli', 'Reaction time (RT) and accuracy of responses to congruent and incongruent stimuli', 'cognition and brain activation', 'mean HbO in the dorsolateral prefrontal cortex, frontal pole area, ventrolateral prefrontal cortex', 'cognitive performance and brain activation']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030069', 'cui_str': 'Oxyhemoglobin'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C1321310', 'cui_str': 'Incongruous'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0439853', 'cui_str': 'Congruent'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0149546', 'cui_str': 'Structure of frontal pole'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C3266730', 'cui_str': 'Ventrolateral'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}]",10.0,0.0448674,None of the doses of caffeine administered affected accuracy of responses to incongruent or congruent stimuli.,"[{'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Zhang', 'Affiliation': 'Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Xiaochun', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Shanghai University of Sport, Shanghai, China.'}, {'ForeName': 'Yuqin', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'School of Sports Science, Nantong University, Nantong, China.'}, {'ForeName': 'Xinyan', 'Initials': 'X', 'LastName': 'Zheng', 'Affiliation': 'Shanghai University of Sport, Shanghai, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01393'] 2298,32719742,Automated Quality Assurance of OAR Contouring for Lung Cancer Based on Segmentation With Deep Active Learning.,"Purpose: Ensuring high-quality data for clinical trials in radiotherapy requires the generation of contours that comply with protocol definitions. The current workflow includes a manual review of the submitted contours, which is time-consuming and subjective. In this study, we developed an automated quality assurance (QA) system for lung cancer based on a segmentation model trained with deep active learning. Methods: The data included a gold atlas with 36 cases and 110 cases from the ""NRG Oncology/RTOG 1308 Trial"". The first 70 cases enrolled to the RTOG 1308 formed the candidate set, and the remaining 40 cases were randomly assigned to validation and test sets (each with 20 cases). The organs-at-risk included the heart, esophagus, spinal cord, and lungs. A preliminary convolutional neural network segmentation model was trained with the gold standard atlas. To address the deficiency of the limited training data, we selected quality images from the candidate set to be added to the training set for fine-tuning of the model with deep active learning. The trained robust segmentation models were used for QA purposes. The segmentation evaluation metrics derived from the validation set, including the Dice and Hausdorff distance, were used to develop the criteria for QA decision making. The performance of the strategy was assessed using the test set. Results: The QA method achieved promising contouring error detection, with the following metrics for the heart, esophagus, spinal cord, left lung, and right lung: balanced accuracy, 0.96, 0.95, 0.96, 0.97, and 0.97, respectively; sensitivity, 0.95, 0.98, 0.96, 1.0, and 1.0, respectively; specificity, 0.98, 0.92, 0.97, 0.94, and 0.94, respectively; and area under the receiving operator characteristic curve, 0.96, 0.95, 0.96, 0.97, and 0.94, respectively. Conclusions: The proposed system automatically detected contour errors for QA. It could provide consistent and objective evaluations with much reduced investigator intervention in multicenter clinical trials.",2020,"The QA method achieved promising contouring error detection, with the following metrics for the heart, esophagus, spinal cord, left lung, and right lung: balanced accuracy, 0.96, 0.95, 0.96, 0.97, and 0.97, respectively; sensitivity, 0.95, 0.98, 0.96, 1.0, and 1.0, respectively; specificity, 0.98, 0.92, 0.97, 0.94, and 0.94, respectively; and area under the receiving operator characteristic curve, 0.96, 0.95, 0.96, 0.97, and 0.94, respectively. ","['lung cancer based on a segmentation model trained with deep active learning', 'gold atlas with 36 cases and 110 cases from the ""NRG Oncology/RTOG 1308 Trial', '70 cases enrolled to the RTOG 1308 formed the candidate set, and the remaining 40 cases']","['automated quality assurance (QA) system', 'radiotherapy']",[],"[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}]",[],70.0,0.0507785,"The QA method achieved promising contouring error detection, with the following metrics for the heart, esophagus, spinal cord, left lung, and right lung: balanced accuracy, 0.96, 0.95, 0.96, 0.97, and 0.97, respectively; sensitivity, 0.95, 0.98, 0.96, 1.0, and 1.0, respectively; specificity, 0.98, 0.92, 0.97, 0.94, and 0.94, respectively; and area under the receiving operator characteristic curve, 0.96, 0.95, 0.96, 0.97, and 0.94, respectively. ","[{'ForeName': 'Kuo', 'Initials': 'K', 'LastName': 'Men', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Huaizhi', 'Initials': 'H', 'LastName': 'Geng', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Tithi', 'Initials': 'T', 'LastName': 'Biswas', 'Affiliation': 'UH Cleveland Medical Center, Cleveland, OH, United States.'}, {'ForeName': 'Zhongxing', 'Initials': 'Z', 'LastName': 'Liao', 'Affiliation': 'MD Anderson Cancer Center, The University of Texas, Houston, TX, United States.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': 'University of Pennsylvania, Philadelphia, PA, United States.'}]",Frontiers in oncology,['10.3389/fonc.2020.00986'] 2299,32719969,Changes in functional connectivity after theta-burst transcranial magnetic stimulation for post-traumatic stress disorder: a machine-learning study.,"Intermittent theta burst stimulation (iTBS) is a novel treatment approach for post-traumatic stress disorder (PTSD), and recent neuroimaging work indicates that functional connectivity profiles may be able to identify those most likely to respond. However, prior work has relied on functional magnetic resonance imaging, which is expensive and difficult to scale. Alternatively, electroencephalography (EEG) represents a different approach that may be easier to implement in clinical practice. To this end, we acquired an 8-channel resting-state EEG signal on participants before (n = 47) and after (n = 43) randomized controlled trial of iTBS for PTSD (ten sessions, delivered at 80% of motor threshold, 1,800 pulses, to the right dorsolateral prefrontal cortex). We used a cross-validated support vector machine (SVM) to track changes in EEG functional connectivity after verum iTBS stimulation. We found that an SVM classifier was able to successfully separate patients who received active treatment vs. sham treatment, with statistically significant findings in the Delta band (1-4 Hz, p = 0.002). Using Delta coherence, the classifier was 75.0% accurate in detecting sham vs. active iTBS, and observed changes represented an increase in functional connectivity between midline central/occipital and a decrease between frontal and central regions. The primary limitations of this work are the sparse electrode system and a modest sample size. Our findings raise the possibility that EEG and machine learning may be combined to provide a window into mechanisms of action of TMS, with the potential that these approaches can inform the development of individualized treatment methods.",2020,"We found that an SVM classifier was able to successfully separate patients who received active treatment vs. sham treatment, with statistically significant findings in the Delta band (1-4 Hz, p = 0.002).","['post-traumatic stress disorder (PTSD', 'post-traumatic stress disorder', 'participants before (n\u2009=\u200947) and after (n\u2009=\u200943) randomized controlled trial of']","['theta-burst transcranial magnetic stimulation', 'electroencephalography (EEG', 'iTBS for PTSD', 'Intermittent theta burst stimulation (iTBS', 'cross-validated support vector machine (SVM']",['functional connectivity'],"[{'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C2699740', 'cui_str': 'Support Vector Machine'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}]",,0.0253457,"We found that an SVM classifier was able to successfully separate patients who received active treatment vs. sham treatment, with statistically significant findings in the Delta band (1-4 Hz, p = 0.002).","[{'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Zandvakili', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02906, USA. amin_zandvakili@brown.edu.'}, {'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Swearingen', 'Affiliation': 'VA RR&D Center for Neurorestoration and Neurotechnology, Providence VA Medical Center, 830 Chalkstone Ave, Providence, RI, 02908, USA.'}, {'ForeName': 'Noah S', 'Initials': 'NS', 'LastName': 'Philip', 'Affiliation': 'Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, 02906, USA.'}]",European archives of psychiatry and clinical neuroscience,['10.1007/s00406-020-01172-5'] 2300,32719973,Computerized clinical decision system and mobile application with expert support to optimize management of vertigo in primary care: study protocol for a pragmatic cluster-randomized controlled trial.,"Vertigo and dizziness are amongst the most common symptoms in medicine and often have a major impact on activities of daily life. Although many causes of vertigo and dizziness can easily be recognized, patients often receive inappropriate and ineffective treatment. The reasons for this are various. Because vertigo/dizziness is an interdisciplinary symptom and there is a lack of standardised diagnostic tools, it is easy to lose the overview of the possible differential diagnoses. There is evidence though, that the management of patients with vertigo/dizziness can be optimized using standardized care pathways with digital support. The present study (within the framework of ""PoiSe-prevention, online feedback, and interdisciplinary therapy of acute vestibular syndromes by e-health"") aims to evaluate the implementation of a program with several interlocking components. The three main components are a computerized clinical decision system, a mobile application, a counselling and interdisciplinary educational program developed by the German Center for Vertigo and Balance Disorders (DSGZ). The study is a cluster-randomized controlled trial with a parallel-group design, as well as a detailed process evaluation. Clusters comprise of primary care physician practices in Bavaria, Germany. In the scope of the study the effectiveness, acceptability and efficiency of the intervention will be evaluated. It is anticipated that the intervention will improve the quality and efficiency of the management of dizzy patients. A higher diagnostic accuracy, optimized treatment, and disease progression monitoring is expected to improve patient-relevant outcomes and reduce health-care costs.",2020,"There is evidence though, that the management of patients with vertigo/dizziness can be optimized using standardized care pathways with digital support.",['patients with vertigo/dizziness'],[],"['vertigo and dizziness', 'effectiveness, acceptability and efficiency', 'Vertigo and dizziness', 'quality and efficiency']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0042571', 'cui_str': 'Vertigo'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}]",[],"[{'cui': 'C0042571', 'cui_str': 'Vertigo'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0332306', 'cui_str': 'Quality'}]",,0.0723732,"There is evidence though, that the management of patients with vertigo/dizziness can be optimized using standardized care pathways with digital support.","[{'ForeName': 'Filipp M', 'Initials': 'FM', 'LastName': 'Filippopulos', 'Affiliation': 'German Center for Vertigo and Balance Disorders, LMU Klinikum, Ludwig Maximilians Universität, Marchioninistraße 15, 81377, Munich, Germany. Filipp.Filippopulos@med.uni-muenchen.de.'}, {'ForeName': 'Doreen', 'Initials': 'D', 'LastName': 'Huppert', 'Affiliation': 'German Center for Vertigo and Balance Disorders, LMU Klinikum, Ludwig Maximilians Universität, Marchioninistraße 15, 81377, Munich, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Brandt', 'Affiliation': 'German Center for Vertigo and Balance Disorders, LMU Klinikum, Ludwig Maximilians Universität, Marchioninistraße 15, 81377, Munich, Germany.'}, {'ForeName': 'Margit', 'Initials': 'M', 'LastName': 'Hermann', 'Affiliation': 'AOK Bayern, Die Gesundheitskasse, Carl-Wery-Straße 28, 81739, Munich, Germany.'}, {'ForeName': 'Mareike', 'Initials': 'M', 'LastName': 'Franz', 'Affiliation': 'Kassenärztliche Vereinigung Bayerns, Referat Versorgungsinnovationen, Elsenheimerstraße 39, 80687, Munich, Germany.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Fleischer', 'Affiliation': 'Institute for Health and Nursing Sciences, Medical Faculty, Martin Luther University Halle-Wittenberg, Magdeburger Straße 8, 06112, Halle (Saale), Germany.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Grill', 'Affiliation': 'Institute of Medical Informatics, Biometry and Epidemiology, Ludwig Maximilians Universität, Marchioninistraße 15, 81377, Munich, Germany.'}]",Journal of neurology,['10.1007/s00415-020-10078-0'] 2301,32719981,Assessment of eldecalcitol and alendronate effect on postural balance control in aged women with osteoporosis.,"INTRODUCTION Older people aged over 75 are more prone to falls because physical functions become deteriorated along with aging, and also fracture risk is strongly correlated with age. We evaluated the effects of anti-osteoporosis agents, eldecalcitol (ELD) and alendronate (ALN) on physical functions by assessing dynamic and static postural balance in aged patients with osteoporosis. MATERIALS AND METHODS A randomized, open-label, controlled clinical trial has been conducted with 124 female patients aged 65 or over with osteoporosis. Patients were randomly assigned to receive either 0.75 μg of ELD once-a-day or 35 mg of ALN once-a-week for 24 weeks. The primary endpoint was the change in a postural balance index, adjusted composite equilibrium score (CES) of sensory organization test (SOT). The SOT equilibrium scores, leg muscle strength, and other physical functions were also evaluated. RESULTS The Adjusted CES increased from baseline by 6.10% in the ELD group and 6.28% in the ALN group. There was no statistically significant difference between the two groups. The static postural balance at fixed platform were maintained in the ELD group, but declined in the ALN group. The dynamic postural balance at swaying platform and knee extension power increased from baseline in both groups. CONCLUSIONS These results suggest that ELD and ALN treatments may each be beneficial to improve postural balance control in older patients with osteoporosis via different mechanisms of action.",2020,"The dynamic postural balance at swaying platform and knee extension power increased from baseline in both groups. ","['aged women with osteoporosis', 'older patients with osteoporosis', 'Older people aged over 75', 'aged patients with osteoporosis', '124 female patients aged 65 or over with osteoporosis']","['anti-osteoporosis agents, eldecalcitol (ELD) and alendronate (ALN', 'ELD once-a-day or 35\xa0mg of ALN', 'eldecalcitol and alendronate', 'ELD', 'ELD and ALN']","['change in a postural balance index, adjusted composite equilibrium score (CES) of sensory organization test (SOT', 'Adjusted CES', 'dynamic postural balance at swaying platform and knee extension power', 'SOT equilibrium scores, leg muscle strength, and other physical functions', 'static postural balance', 'postural balance control']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517553', 'cui_str': '124'}]","[{'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C2828245', 'cui_str': 'eldecalcitol'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1256755', 'cui_str': 'Postural balance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4720873', 'cui_str': 'Sensory organization test'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0224456', 'cui_str': 'Skeletal muscle structure of lower leg'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",124.0,0.0296625,"The dynamic postural balance at swaying platform and knee extension power increased from baseline in both groups. ","[{'ForeName': 'Takao', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'Institute of Gerontology, J. F. Oberlin University, 3758 Tokiwa-machi, Machida, 194-0294, Tokyo, Japan. anant501@obirin.ac.jp.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Harada', 'Affiliation': 'Department of Orthopedic Surgery, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Shimada', 'Affiliation': 'Department of Preventive Gerontology, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.'}, {'ForeName': 'Takayuki', 'Initials': 'T', 'LastName': 'Hosoi', 'Affiliation': 'Kenkoin Clinic, Tokyo, Japan.'}, {'ForeName': 'Yuichi', 'Initials': 'Y', 'LastName': 'Kawata', 'Affiliation': 'Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.'}, {'ForeName': 'Tomoyuki', 'Initials': 'T', 'LastName': 'Inoue', 'Affiliation': 'Taisho Pharmaceutical Co. Ltd., Tokyo, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Saito', 'Affiliation': 'Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.'}]",Journal of bone and mineral metabolism,['10.1007/s00774-020-01118-w'] 2302,32720085,Losing my loss aversion: The effects of current and past environment on the relative sensitivity to losses and gains.,"It is often assumed that most people are loss averse, placing more weight on losses than commensurate gains; however, some research identifies variability in loss sensitivity that reflects features of the environment. We examined this plasticity in loss sensitivity by manipulating the size and distribution of possible outcomes in a set of mixed gambles, and assessing individual stability in loss sensitivity. In each of two sessions, participants made accept-reject decisions for 64 mixed-outcome gambles. Participants were randomly assigned to conditions defined by the relative range of losses and gains (wider range of losses vs. wider range of gains), and the currency-units at stake ('pennies' vs. 'pounds'). Participants showed modest but non-trivial consistency in their sensitivity to losses; though loss sensitivity also varied substantially with our manipulations. When possible gains had greater range than possible losses, most participants were loss averse; however, when possible losses had the greater range, reverse loss aversion was the norm (i.e., more weight on gains than losses). This is consistent with decision-by-sampling theory, whereby an outcome's rank within a consideration-set determines its value, but can also be explained by the gamble's expected-value rank within the decision-set, or by adapting aspirations to the decision-environment. Loss aversion was also reduced in the second session of decisions when the stakes had been higher in the previous session. This illustrates the influence of prior context on current sensitivity to losses, and suggests a role for idiosyncratic experiences in the development of individual differences in loss sensitivity.",2020,Participants showed modest but non-trivial consistency in their sensitivity to losses; though loss sensitivity also varied substantially with our manipulations.,['Losing my loss aversion'],[],['Loss aversion'],"[{'cui': 'C0233496', 'cui_str': 'Aversion'}]",[],"[{'cui': 'C0233496', 'cui_str': 'Aversion'}]",,0.0406523,Participants showed modest but non-trivial consistency in their sensitivity to losses; though loss sensitivity also varied substantially with our manipulations.,"[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Rakow', 'Affiliation': ""Institute of Psychiatry, Psychology and Neuroscience - Department of Psychology, King's College London, London, UK. tim.rakow@kcl.ac.uk.""}, {'ForeName': 'Nga Yiu', 'Initials': 'NY', 'LastName': 'Cheung', 'Affiliation': ""Institute of Psychiatry, Psychology and Neuroscience - Department of Psychology, King's College London, London, UK.""}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Restelli', 'Affiliation': ""Institute of Psychiatry, Psychology and Neuroscience - Department of Psychology, King's College London, London, UK.""}]",Psychonomic bulletin & review,['10.3758/s13423-020-01775-y'] 2303,32720113,The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.,"PURPOSE Chemotherapy-induced diarrhoea (CID) is a common, but often underreported problem in patients with breast cancer that has a profound effect on quality of life. It is best measured from a patient's perspective, but tools are limited. The aim of this study was to develop and evaluate the Diarrhoea Management Diary (DMD), a self-report measure to assess CID, use of self-management strategies and treatment adherence. METHODS The DMD was constructed using an iterative process of instrument development: concept elicitation (literature review), item generation and reduction (cognitive debriefing), and pilot testing in the target population. After translation into eight languages, the DMD was used in an international randomised trial for women receiving lapatinib and capecitabine for metastatic breast cancer with or without prophylactic octreotide. Patterns of missing data and sensitivity to change were examined. RESULTS The understandability and completeness of the 8-item DMD was confirmed in cognitive interviews and pilot testing. Practicability of the DMD was evaluated in 62 women with metastatic breast cancer (median age 57). Up to 68% reported CID at any given time-point, and 19% had diarrhoea at each time-point. Patients also described efficacy of different strategies for diarrhoea management. Missing data were associated with study discontinuation. DMD missing item response was 0.9%. Sensitivity to change was good at most assessment points. CONCLUSIONS Although further psychometric testing is recommended, initial evaluation of the DMD showed good content validity and practicability in international research with cancer patients.",2020,"Up to 68% reported CID at any given time-point, and 19% had diarrhoea at each time-point.","['patients with metastatic breast cancer', 'patients with breast cancer', '62 women with metastatic breast cancer (median age 57', 'for metastatic breast cancer with or without']","['lapatinib and capecitabine', 'prophylactic octreotide', 'Diarrhoea Management Diary (DMD']","['DMD missing item response', 'diarrhoea', 'understandability and completeness of the 8-item DMD', 'Diarrhoea Management Diary (DMD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C1506770', 'cui_str': 'lapatinib'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0028833', 'cui_str': 'Octreotide'}, {'cui': 'C1171188', 'cui_str': 'Diarrhea care'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}]","[{'cui': 'C1171188', 'cui_str': 'Diarrhea care'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0439812', 'cui_str': 'Completeness'}]",62.0,0.0344362,"Up to 68% reported CID at any given time-point, and 19% had diarrhoea at each time-point.","[{'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Harder', 'Affiliation': 'Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK. h.harder@sussex.ac.uk.'}, {'ForeName': 'Valerie M', 'Initials': 'VM', 'LastName': 'Shilling', 'Affiliation': 'Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK.'}, {'ForeName': 'Shirley F', 'Initials': 'SF', 'LastName': 'May', 'Affiliation': 'Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Cella', 'Affiliation': 'Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Schmid', 'Affiliation': 'Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK.'}, {'ForeName': 'Lesley J', 'Initials': 'LJ', 'LastName': 'Fallowfield', 'Affiliation': 'Sussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK.'}]",Breast cancer research and treatment,['10.1007/s10549-020-05798-w'] 2304,32720131,Focused Training of Community Health Volunteers on Cervical Cancer in Rural Kisumu.,"The cancer disease burden is higher in the low- and middle-income countries like Kenya where uptake of screening services is low. Community health volunteers (CHVs) have been shown to be effective in improving uptake of health services and could also be used in cervical cancer screening. However, they still have inadequate knowledge hindering effective public education. The aim of this study is to determine the effect of focused training of the CHVs on their knowledge on cervical cancer and screening uptake among women of reproductive age. This was a quasi-experimental study in rural sub-counties of Nyando and Nyakach. Nyando was the intervention arm with 186 CHVs and Nyakach the control with 239 CHVs. Participants' knowledge on cervical cancer was assessed using a self-administered questionnaire. CHVs in the intervention arm were trained about cervical cancer and screening. Knowledge was re-assessed following a 6-month public education period. The focused training improved the CHVs' knowledge on cervical cancer to 60.9% compared to 13.4% in the control arm (p = 0.004) at the end-line. The knowledge was dependent on the level of education (χ 2  = 34.41, p = 0.045), religion (χ 2  = 25.85, p = 0.007), and occupation (χ 2  = 95.04, p < 0.0001). Screening uptake was significantly associated with knowledge of risk factors (p = 0.019) and sign and symptoms (p = 0.017). Screening uptake improved in the intervention arm while declined in the control arm. The training significantly improved the CHVs' knowledge on cervical cancer and uptake of screening services in the intervention area, Kisumu County, Kenya, and should be continuous.",2020,"The training significantly improved the CHVs' knowledge on cervical cancer and uptake of screening services in the intervention area, Kisumu County, Kenya, and should be continuous.","['Community Health Volunteers on Cervical Cancer in Rural Kisumu', 'rural sub-counties of Nyando and Nyakach', 'women of reproductive age', 'Community health volunteers (CHVs']",['CHVs'],"[""CHVs' knowledge on cervical cancer"", 'cervical cancer', 'Screening uptake', 'knowledge of risk factors', ""CHVs' knowledge on cervical cancer and uptake of screening services""]","[{'cui': 'C0034019', 'cui_str': 'Community Health'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0001779', 'cui_str': 'Age'}]",[],"[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",,0.0225371,"The training significantly improved the CHVs' knowledge on cervical cancer and uptake of screening services in the intervention area, Kisumu County, Kenya, and should be continuous.","[{'ForeName': 'Edwin Onyango', 'Initials': 'EO', 'LastName': 'Ochomo', 'Affiliation': 'AMPATH Cervical Cancer Program, P.O. Box 4606, Eldoret, Kenya. edochomo@gmail.com.'}, {'ForeName': 'Samson', 'Initials': 'S', 'LastName': 'Ndege', 'Affiliation': 'AMPATH Cervical Cancer Program, P.O. Box 4606, Eldoret, Kenya.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Itsura', 'Affiliation': 'AMPATH Cervical Cancer Program, P.O. Box 4606, Eldoret, Kenya.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-020-01839-6'] 2305,32720362,Outcomes of left ventricular assist device implantation in hypercoagulable patients.,"BACKGROUND The aim of this study was to evaluate outcomes of left ventricular assist devices (LVADs) in patients who tested positive for hypercoagulable hematologic disorders. METHODS Adults undergoing continuous-flow LVAD implantation with preoperative hypercoagulability testing between 2004 and 2018 at a single center were reviewed. Hypercoagulability was defined as testing positive for antiphospholipid antibody, anticardiolipin antibody, lupus anticoagulant, protein C, protein S, factor V Leiden, and/or heparin-induced thrombocytopenia. The primary outcome was survival on the original LVAD. Secondary outcomes included rates of thromboembolic complications and readmission for intravenous heparin treatment. RESULTS A total of 270 LVAD patients with pre-implant hypercoagulability testing were included, and 157 (58%) tested positive for a hypercoagulable disorder. Of those testing positive, 10 (6.4%) had a clinical pre-LVAD history of thromboembolic events. Survival was comparable between hypercoagulable and non-hypercoagulable patients (1 year: 73.3% vs 78.9%, P = .2195, 2-year: 60.7% vs 62.8%, P = .3627). Rates of pump thrombosis (14.0% vs 13.3%, P = .8618), hemolysis (4.5% vs 3.5%, P = .3536), stroke (18.5% vs 14.2%, P = .3483) and readmission for IV heparin therapy (87.3% (n = 137) vs 77.9% (n = 88), P = .7560) were similar. Outcomes were comparable in patients with positive hypercoagulable tests when stratified by pre-implant clinical history of hypercoagulability as well as stratified by recent preoperative exposure to heparin or warfarin. CONCLUSIONS In this series, positive laboratory tests for hypercoagulability were common amongst patients undergoing LVAD implantation although few had positive clinical histories. Survival and freedom from thromboembolic complications were comparable to non-hypercoagulable patients. Hypercoagulability alone should therefore not serve as a contraindication to LVAD implantation.",2020,"Rates of pump thrombosis (14.0% vs 13.3%, P = .8618), hemolysis (4.5% vs 3.5%, P = .3536), stroke (18.5% vs 14.2%, P = .3483) and readmission for IV heparin therapy (87.3% (n = 137) vs 77.9% (n = 88), P = .7560) were similar.","['270 LVAD patients with pre-implant hypercoagulability testing were included, and 157 (58%) tested positive for a hypercoagulable disorder', 'patients who tested positive for hypercoagulable hematologic disorders', 'Adults undergoing continuous-flow LVAD implantation with preoperative hypercoagulability testing between 2004 and 2018 at a single center were reviewed', 'hypercoagulable patients']","['left ventricular assist device implantation', 'heparin or warfarin', 'left ventricular assist devices (LVADs']","['clinical pre-LVAD history of thromboembolic events', 'survival on the original LVAD', 'Survival and freedom from thromboembolic complications', 'Survival', 'stroke', 'rates of thromboembolic complications and readmission for intravenous heparin treatment', 'hemolysis', 'Hypercoagulability', 'Rates of pump thrombosis']","[{'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0398623', 'cui_str': 'Thrombophilia'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0018939', 'cui_str': 'Disorder of hematopoietic system'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0282443', 'cui_str': 'Review'}]","[{'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205313', 'cui_str': 'Original'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0019054', 'cui_str': 'Haemolysis'}, {'cui': 'C0398623', 'cui_str': 'Thrombophilia'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}]",270.0,0.227396,"Rates of pump thrombosis (14.0% vs 13.3%, P = .8618), hemolysis (4.5% vs 3.5%, P = .3536), stroke (18.5% vs 14.2%, P = .3483) and readmission for IV heparin therapy (87.3% (n = 137) vs 77.9% (n = 88), P = .7560) were similar.","[{'ForeName': 'Keith A', 'Initials': 'KA', 'LastName': 'Dufendach', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Seese', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Blaise', 'Initials': 'B', 'LastName': 'Stearns', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Hickey', 'Affiliation': 'Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Mathier', 'Affiliation': 'Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Keebler', 'Affiliation': 'Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Shangzhen', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Christopher M', 'Initials': 'CM', 'LastName': 'Sciortino', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Floyd W', 'Initials': 'FW', 'LastName': 'Thoma', 'Affiliation': 'Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Arman', 'Initials': 'A', 'LastName': 'Kilic', 'Affiliation': 'Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}]",Journal of cardiac surgery,['10.1111/jocs.14710'] 2306,32720367,Comparison of pleural effusion between fenestrated and nonfenestrated extracardiac Fontan: A prospective randomized study.,"BACKGROUND Fenestration of the baffle/conduit is believed to reduce pleural effusion following the Fontan operation. However, equivocal results have been observed with or without fenestration. This study aims to evaluate the efficacy of fenestration on the amount and duration of pleural effusion following the Fontan operation. METHODS About 40 patients undergoing extracardiac Fontan (ECF) were randomized into two groups: one with fenestration (ECF-F; n = 20) or without fenestration (ECF-NF; n = 20). Primary outcome was the amount and duration of pleural effusions. Secondary outcomes were time to removal of the chest tubes, hospital stay, and readmission to the hospital because of recurrent pleural within 30 days of the operation. RESULTS Mean age was 11.5 ± 5.07 (range, 8.7-13.5) years in the ECF-F group and 13.6 ± 0.4 years (range, 10.5-15.5) in the (ECF-NF) group. The total drain output was 7.89 mL/kg/d in ECF-NF compared with 6.9 mL/kg/d in the ECF-group (P = .14). Time for removal of pleural tubes was 14.6 ± 0.95 days in the ECF-NF group compared with 11.6 ± days in the ECF-F group. Total duration of hospital stay was higher but not significant in the ECF-NF group compared with the ECF-F group. Two patients in ECF-NF required readmission to the hospital within 30 days following discharge, while there were no readmissions in the ECF-F group. CONCLUSION Contrary to the literature, the creation of a fenestration in the ECF circuit was not clearly associated with a reduction in the amount and duration of pleural effusion compared with a non-fenestrated Fontan. These findings may be debatable in high risks versus low risk candidates. However in the present study, in a low risk canditates undergoing the Fontan operation, the daily amount of pleural drainage was no different. Larger studies are needed to confirm these findings.",2020,Total duration of hospital stay was higher but not significant in the ECF-NF group compared with the ECF-F group.,"['Mean age was 11.5\u2009±\u20095.07 (range, 8.7-13.5) years in the ECF-F group and 13.6\u2009±\u20090.4 years (range, 10.5-15.5) in the (ECF-NF) group', 'pleural effusion between fenestrated and nonfenestrated extracardiac Fontan', '40 patients undergoing extracardiac Fontan (ECF']",['fenestration (ECF-F; n\u2009=\u200920) or without fenestration (ECF-NF'],"['Time for removal of pleural tubes', 'amount and duration of pleural effusions', 'total drain output', 'time to removal of the chest tubes, hospital stay, and readmission to the hospital because of recurrent pleural within 30 days of the operation', 'Total duration of hospital stay']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517534', 'cui_str': '11.5'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C4517559', 'cui_str': '13.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0441840', 'cui_str': 'Group F'}, {'cui': 'C4517560', 'cui_str': '13.6'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0032227', 'cui_str': 'Pleural effusion'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0015825', 'cui_str': 'Inner ear fenestration'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0032227', 'cui_str': 'Pleural effusion'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}, {'cui': 'C0008034', 'cui_str': 'Chest drain'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",40.0,0.0456897,Total duration of hospital stay was higher but not significant in the ECF-NF group compared with the ECF-F group.,"[{'ForeName': 'Sachin', 'Initials': 'S', 'LastName': 'Talwar', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Adarsh', 'Initials': 'A', 'LastName': 'Paidi', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Vishnubhatla', 'Initials': 'V', 'LastName': 'Sreeniwas', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Dutt Upadhyay', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Sambhunath', 'Initials': 'S', 'LastName': 'Das', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Shiv K', 'Initials': 'SK', 'LastName': 'Choudhary', 'Affiliation': 'Department of Biostatistics, Cardiothoracic Center, All India Institute of Medical Sciences, New Delhi, India.'}]",Journal of cardiac surgery,['10.1111/jocs.14886'] 2307,32720384,Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?,"BACKGROUND The reduction of cardiovascular events with icosapent ethyl-intervention trial (REDUCE-IT) trial revealed robust atherosclerotic cardiovascular risk reduction with a strategy comprising high-dose omega-3 icosapent ethyl vs placebo in statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol (LDL-C). HYPOTHESIS Are the results of the REDUCE-IT trial applicable to the French registry on acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) population? METHODS Data were extracted from the FAST-MI 2010 and 2015 registries. We applied the REDUCE-IT enrolment criteria (triglycerides 150-500 mg/dL and LDL-C 40-100 mg/dL on statins) to the FAST-MI population in patients aged ≥45 years who had detailed lipid values postacute hospitalization, focusing on their clinical profile and cardiovascular prognosis. RESULTS Of the 3789 FAST-MI patients with a full lipid profile (median 11.1 [IQR 7.6-17.4] months after hospitalization for myocardial infarction), 472 (12.5%; 95% CI 11.4-13.5) met the eligibility criteria for REDUCE-IT (REDUCE-IT-like group). The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial. The residual cardiovascular risk related to elevated triglycerides in the REDUCE-IT-like group was similar to the risk in the REDUCE-IT trial. CONCLUSIONS If the results of REDUCE-IT are applied to patients hospitalized for a myocardial infarction in France, 12.5% of these patients could benefit from a strategy of high-dose omega-3 icosapent ethyl on top of contemporary therapy including statins to improve their clinical outcomes.",2020,"The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial.","['patients aged ≥45\u2009years who had detailed lipid values postacute hospitalization, focusing on their clinical profile and cardiovascular prognosis', 'Of the 3789 FAST-MI patients with a', 'statin-treated patients with elevated triglycerides and controlled low-density lipoprotein cholesterol (LDL-C', 'Data were extracted from the FAST-MI 2010 and 2015 registries']","['LDL-C 40-100\u2009mg/dL on statins', 'omega-3 icosapent ethyl vs placebo']","['full lipid profile', 'cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke', '1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0033325', 'cui_str': 'Determination of prognosis'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0520886', 'cui_str': 'ST segment elevation'}, {'cui': 'C1276061', 'cui_str': 'Acute non-ST segment elevation myocardial infarction'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0020557', 'cui_str': 'Hypertriglyceridemia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0058978', 'cui_str': 'icosapent ethyl'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}]",3789.0,0.0901599,"The cardiovascular event rate (all-cause death, nonfatal myocardial infarction, nonfatal stroke) was 36.7 (95% CI 27.8-48.6) per 1000 person-years for the REDUCE-IT-like group, which compares with the 36.9 (95% CI 26.1-51.5) per 1000 person-years (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) reported in the REDUCE-IT trial.","[{'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Ferrières', 'Affiliation': 'Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Bataille', 'Affiliation': 'Department of Cardiology, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Puymirat', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Schiele', 'Affiliation': 'Department of Cardiology, Regional University Hospital Jean Minjoz, Besançon, France.'}, {'ForeName': 'Tabassome', 'Initials': 'T', 'LastName': 'Simon', 'Affiliation': 'Department of Clinical Pharmacology and Unité de Recherche Clinique (URCEST), AP-HP, Hôpital Saint Antoine, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Danchin', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Cardiology, Hôpital Européen Georges Pompidou, Paris, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical cardiology,['10.1002/clc.23437'] 2308,32720457,Examining the interdependence of parent-child dyads: Effects on weight loss and maintenance.,"BACKGROUND This study aimed to further elucidate correlated weight changes in parent-child dyads enrolled in family-based treatment (FBT) by modeling the interdependence of weight changes during treatment. METHODS Parent-child dyads (n = 172) with overweight/obesity (child mean zBMI = 2.16 ± 0.39; parent mean BMI = 37.9 ± 9.4 kg/m 2 ) completed 4 months of FBT and were randomized to one of three 8-month maintenance interventions (Social Facilitation Maintenance [SFM]-high dose, SFM-low dose or control). Weight/height was measured at 0, 4 and 12 months. Structural equation models simultaneously estimated the effect that an individual had on their own (actor effect) and on one another's (partner effect) weight-status across time using the actor-partner interdependence model. RESULTS Actor paths were significant over time for parent and child. Partner paths were significant for child zBMI predicting parent BMI at 4 and 12 months. Maintenance condition moderated actor/partner paths in the model. CONCLUSIONS Child weight change may motivate parents to make environmental and behavioural changes that impact their own weight. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT00759746.",2020,Partner paths were significant for child zBMI predicting parent BMI at 4 and 12 months.,"['Parent-child dyads (n = 172) with overweight/obesity (child mean zBMI = 2.16\u2009±\u20090.39', 'parent-child dyads enrolled in family-based treatment (FBT']","['maintenance interventions (Social Facilitation Maintenance [SFM]-high dose, SFM-low dose or control']","['weight loss and maintenance', 'Weight/height', 'weight changes', 'child zBMI predicting parent BMI']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517627', 'cui_str': '2.16'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0037415', 'cui_str': 'Social Facilitation'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C4552097', 'cui_str': 'Epidermal nevus syndrome'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",172.0,0.0215294,Partner paths were significant for child zBMI predicting parent BMI at 4 and 12 months.,"[{'ForeName': 'Lauren A', 'Initials': 'LA', 'LastName': 'Fowler', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Anne Claire', 'Initials': 'AC', 'LastName': 'Grammer', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Mary Katherine', 'Initials': 'MK', 'LastName': 'Ray', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Katherine N', 'Initials': 'KN', 'LastName': 'Balantekin', 'Affiliation': 'Department of Exercise and Nutrition Sciences, University of Buffalo, Buffalo, New York, USA.'}, {'ForeName': 'Richard I', 'Initials': 'RI', 'LastName': 'Stein', 'Affiliation': 'Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Rachel P', 'Initials': 'RP', 'LastName': 'Kolko Conlon', 'Affiliation': 'Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'R Robinson', 'Initials': 'RR', 'LastName': 'Welch', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Perri', 'Affiliation': 'Department of Clinical & Health Psychology, University of Florida, Gainesville, Florida, USA.'}, {'ForeName': 'Leonard H', 'Initials': 'LH', 'LastName': 'Epstein', 'Affiliation': 'Department of Pediatrics, University at Buffalo, Buffalo, New York, USA.'}, {'ForeName': 'Denise E', 'Initials': 'DE', 'LastName': 'Wilfley', 'Affiliation': 'Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.'}]",Pediatric obesity,['10.1111/ijpo.12697'] 2309,32720602,"Have we learnt all from IMPROVE-IT? Part I. Core results and subanalyses on the effects of ezetimibe added to statin therapy related to age, gender and selected chronic diseases (kidney disease, diabetes mellitus and non-alcoholic fatty liver disease)","IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clini- cal trial (18,144 patients) that evaluated the efficacy of the combination of ezetimibe with simvastatin vs simvastatin mono- therapy in patients with acute coronary syndrome (ACS) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016). Therefore, for very high cardiovascular risk patients ""even lower is even better"" regarding LDL-C, independently of the LDL-C reducing strategy. These findings confirm ezetimibe as an option to treat very-high-risk patients who cannot achieve LDL-C targets with statin monotherapy. Additional analyses of the IMPROVE-IT (both prespecified and post-hoc) include specific very-high-risk subgroups of patients (those with previous acute events and/or coronary revascularization, older than 75 years, as well as patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease). The data from IMPROVE-IT also provide reassurance regarding longer-term safety and efficacy of the intensification of li- pid-lowering therapy in very-high-risk patients resulting in very low LDL-C levels. We comment on the results of several (sub) analyses of IMPROVE-IT.",2020,"After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016).","['18,144 patients', 'of up to 2.6-3.2 mmol/L; 100-120 mg/dL', 'patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease', 'patients with acute coronary syndrome (ACS']","['ezetimibe', 'simvastatin', 'ezetimibe with simvastatin vs simvastatin mono- therapy', 'dL for simvastatin', ' ezetimibe']","['incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization', 'low-density lipoprotein cholesterol (LDL-C) levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C4517633', 'cui_str': '2.6'}, {'cui': 'C4517687', 'cui_str': '3.2'}, {'cui': 'C1532563', 'cui_str': 'mmol/L'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}, {'cui': 'C0002455', 'cui_str': 'American Cancer Society'}]","[{'cui': 'C1142985', 'cui_str': 'ezetimibe'}, {'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0021345', 'cui_str': 'Infectious mononucleosis'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0002965', 'cui_str': 'Impending infarction'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0027686', 'cui_str': 'Neovascularization'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",18144.0,0.0705357,"After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit (composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary re- vascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016).","[{'ForeName': 'Zlatko', 'Initials': 'Z', 'LastName': 'Fras', 'Affiliation': 'Centre for Preventive Cardiology, Department of Vascular Medicine, Division of Medicine, University Medical Centre Ljubljana. Slovenia.'}, {'ForeName': 'Dimitri P', 'Initials': 'DP', 'LastName': 'Mikhailidis', 'Affiliation': 'Department of Clinical Biochemistry, Royal Free Hospital Campus, University College Medical School, University College London, London. United Kingdom.'}]",Current vascular pharmacology,['10.2174/1570161118999200727224946'] 2310,32720608,Levofloxacin versus ceftriaxone for treatment of acute pyelonephritis in Iranian adults.,"INTRODUCTION Acute pyelonephritis is among the most common bacterial infections. Options for initial treatment of pyelonephritis include an extended-spectrum cephalosporin or a fluoroquinolone. In this study, we aimed to compare the clinical outcomes of patients receiving ceftriaxone to those who received levofloxacin for the treatment of acute pyelone-phritis. METHODS In this randomized, open-label trial, hospitalized adults with acute pyelonephritis were treated with ceftriaxone (1g IV every 12 hours) or levofloxacin (750 mg IV daily) for at least 7 days. Clinical and microbiological characteristics were compared among patients treated with ceftriaxone and levofloxacin. RESULTS A total of 59 patients were randomized, 30 to the ceftriaxone group and 29 to the levofloxacin group. The clinical response for 68.0% of patients in the ceftriaxone group and 56.0% of patients in the levofloxacin group were cured. The mi-crobiological response (pathogen eradication rates) was 68.7% in the ceftriaxone group and 21.4% in the levofloxacin group.(P value=0.00028) Escherichia coliwas the most common pathogen (n = 31), followed by Klebsiella pneumoniae(n = 21). High resistance rates were detected for cotrimoxazole (55%), ciprofloxacin (48%), and ceftriaxone (34.4%) in isolat-ed E.coli. Likewise, all K. pneumoniaeisolates were resistant to ciprofloxacin. CONCLUSIONS Our study indicates that ceftriaxone was more effective than levofloxacin in the treatment of acute pyelone-phritis, on the basis of microbiological response, but there were no statistically significant differences between the treatment groups in the rates of clinical cure.The resistance of uropathogens to the most used antibiotics was relatively high. Choosing the treatment regimen based on susceptibility testing results and shortening the duration of the therapy are now recommend-ed to be the most important approaches to decrease the spread of antibiotic resistance worldwide.",2020,"High resistance rates were detected for cotrimoxazole (55%), ciprofloxacin (48%), and ceftriaxone (34.4%) in isolat-ed E.coli.","['hospitalized adults with acute pyelonephritis', 'for the treatment of acute pyelone-phritis', 'acute pyelonephritis in Iranian adults', '59 patients', 'patients receiving']","['Levofloxacin', 'ciprofloxacin', 'cotrimoxazole', 'levofloxacin', 'fluoroquinolone', 'ceftriaxone', 'ceftriaxone and levofloxacin']","['clinical response', 'rates of clinical cure', 'High resistance rates', 'mi-crobiological response (pathogen eradication rates']","[{'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0520575', 'cui_str': 'Acute pyelonephritis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0282386', 'cui_str': 'Levofloxacin'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0041044', 'cui_str': 'sulfamethoxazole and trimethoprim'}, {'cui': 'C0949665', 'cui_str': 'Fluoroquinolones'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0450254', 'cui_str': 'Pathogenic organism'}]",59.0,0.0365724,"High resistance rates were detected for cotrimoxazole (55%), ciprofloxacin (48%), and ceftriaxone (34.4%) in isolat-ed E.coli.","[{'ForeName': 'Shabnam', 'Initials': 'S', 'LastName': 'Tehrani', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Elyasi', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Abolghasemi', 'Affiliation': 'Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}]",Infectious disorders drug targets,['10.2174/1871526520999200727154214'] 2311,32720618,[Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention].,"Aim To evaluate the effect of empagliflozin on glycemia and renal filtration function in patients with stable ischemic heart disease (IHD) and type 2 diabetes mellitus (DM2) who underwent a percutaneous coronary intervention (PCI).Materials and methods This study included 40 patients with stable IHD and DM2 (age, 63 (58; 65) years; DM2 duration, 7 (4; 15) years) who had indications for an elective PCI. At baseline in the total sample, the level of glycated hemoglobin was 7.2 (6.5; 8.3)%; 48.7 % failed to achieve glycemic goals. A decrease in glomerular filtration rate (GFR) to below 60 ml/min/1.73 m2 was observed in 10.3 % of patients. All patients were divided into two group by simple randomization with successively assigned numbers. The main group consisted of 20 patients who received empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy irrespective of their baseline glycemic control. Patients of the comparison group (n=20) continued on their previous hypoglycemic therapy as prescribed by their endocrinologist. The follow-up duration was 6 months. Statistical analysis was performed with the Statistica 10.0 software.Results The empagliflozin treatment improved the glycemic control; in the comparison group, no significant changes in glycemic control were observed. In both groups, GFR significantly decreased during the follow-up period; median decreases in GFR were -6.0 (-16.0; 4.0) and -8.4 (-26.5; 2.5) ml/min / 1.73 m2 in the main and comparison groups, respectively (p = 0.646). No significant changes in 24-h proteinuria were observed for patients taking empagliflozin. In the control group, the 24-h urinary protein excretion significantly progressed (p=0.011) during the follow-up period.Conclusion In patients with DM2 and stable IHD who underwent a PCI, addition of empagliflozin 10 mg/day to their current hypoglycemic therapy was associated with a significant improvement of glycemic control. The decrease in GFR during the empagliflozin treatment did not significantly differ from the value for patient receiving the other hypoglycemic therapy.",2020,"In the control group, the 24-h urinary protein excretion significantly progressed (p=0.011) during the follow-up period.","['40 patients with stable IHD and DM2 (age, 63 (58; 65) years; DM2 duration, 7 (4; 15) years) who had indications for an elective PCI', 'patients with stable ischemic heart disease (IHD) and type 2 diabetes mellitus (DM2) who underwent a', 'patients with DM2 and stable IHD', 'patients with coronary heart disease undergoing percutaneous coronary intervention']","['empagliflozin 10 mg/day in addition to their previous hypoglycemic therapy irrespective of their baseline glycemic control', 'empagliflozin', 'empagliflosin', 'percutaneous coronary intervention']","['GFR', '24-h urinary protein excretion', 'renal filtration', '24-h proteinuria', 'glycemic control', 'glomerular filtration rate (GFR', 'level of glycated hemoglobin', 'glycemia and renal filtration function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C1300562', 'cui_str': 'dm2'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C3848773', 'cui_str': 'empagliflozin 10 MG [Jardiance]'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic agent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0016107', 'cui_str': 'Filtration'}, {'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",40.0,0.0174065,"In the control group, the 24-h urinary protein excretion significantly progressed (p=0.011) during the follow-up period.","[{'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Khorlampenko', 'Affiliation': 'Federal State Budgetary Institution of Higher Professional Education Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russia.'}, {'ForeName': 'V N', 'Initials': 'VN', 'LastName': 'Karetnikova', 'Affiliation': 'Federal State Budgetary Institution of Higher Professional Education Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russia.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Kochergina', 'Affiliation': 'Federal State Budgetary Institution of Higher Professional Education Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russia.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Ignatova', 'Affiliation': 'Federal State Budgetary Institution of Higher Professional Education Kemerovo State Medical University of the Ministry of Healthcare of the Russian Federation, Kemerovo, Russia.'}, {'ForeName': 'J A', 'Initials': 'JA', 'LastName': 'Dyleva', 'Affiliation': 'Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.'}, {'ForeName': 'O V', 'Initials': 'OV', 'LastName': 'Gruzdeva', 'Affiliation': 'Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.'}, {'ForeName': 'O L', 'Initials': 'OL', 'LastName': 'Barbarash', 'Affiliation': 'Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia.'}]",Kardiologiia,['10.18087/cardio.2020.6.n825'] 2312,32720628,Cost-effectiveness of WHO Problem Management Plus for adults with mood and anxiety disorders in a post-conflict area of Pakistan: randomised controlled trial.,"BACKGROUND With the development of evidence-based interventions for treatment of priority mental health conditions in humanitarian settings, it is important to establish the cost-effectiveness of such interventions to enable their scale-up. AIMS To evaluate the cost-effectiveness of the Problem Management Plus (PM+) intervention compared with enhanced usual care (EUC) for common mental disorders in primary healthcare in Peshawar, Pakistan. Trial registration ACTRN12614001235695 (anzctr.org.au). METHOD We randomly allocated 346 participants to either PM+ (n = 172) or EUC (n = 174). Effectiveness was measured using the Hospital Anxiety and Depression Scale (HADS) at 3 months post-intervention. Cost-effectiveness analysis was performed as incremental costs (measured in Pakistani rupees, PKR) per unit change in anxiety, depression and functioning scores. RESULTS The total cost of delivering PM+ per participant was estimated at PKR 16 967 (US$163.14) using an international trainer and supervisor, and PKR 3645 (US$35.04) employing a local trainer. The mean cost per unit score improvement in anxiety and depression symptoms on the HADS was PKR 2957 (95% CI 2262-4029) (US$28) with an international trainer/supervisor and PKR 588 (95% CI 434-820) (US$6) with a local trainer/supervisor. The mean incremental cost-effectiveness ratio (ICER) to successfully treat a case of depression (PHQ-9 ≥ 10) using an international supervisor was PKR 53 770 (95% CI 39 394-77 399) (US$517), compared with PKR 10 705 (95% CI 7731-15 627) (US$102.93) using a local supervisor. CONCLUSIONS The PM+ intervention was more effective but also more costly than EUC in reducing symptoms of anxiety, depression and improving functioning in adults impaired by psychological distress in a post-conflict setting of Pakistan.",2020,"The PM+ intervention was more effective but also more costly than EUC in reducing symptoms of anxiety, depression and improving functioning in adults impaired by psychological distress in a post-conflict setting of Pakistan.","['53', 'common mental disorders in primary healthcare in Peshawar, Pakistan', 'adults with mood and anxiety disorders in a post-conflict area of Pakistan', '346 participants to either']","['WHO Problem Management', 'PM+ intervention', 'enhanced usual care (EUC', 'Problem Management Plus (PM+) intervention', 'PM', 'EUC', 'international supervisor was PKR']","['mean cost per unit score improvement in anxiety and depression symptoms', 'mean incremental cost-effectiveness ratio (ICER', 'incremental costs (measured in Pakistani rupees, PKR) per unit change in anxiety, depression and functioning scores', 'symptoms of anxiety, depression and improving functioning', 'Hospital Anxiety and Depression Scale (HADS', 'cost-effectiveness', 'total cost of delivering PM']","[{'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030211', 'cui_str': 'Pakistan'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0403172', 'cui_str': 'Supervisor'}, {'cui': 'C0058980', 'cui_str': 'Hemin-Controlled Translational Repressor'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0240620', 'cui_str': 'Pakistani'}, {'cui': 'C0058980', 'cui_str': 'Hemin-Controlled Translational Repressor'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",346.0,0.173334,"The PM+ intervention was more effective but also more costly than EUC in reducing symptoms of anxiety, depression and improving functioning in adults impaired by psychological distress in a post-conflict setting of Pakistan.","[{'ForeName': 'Syed Usman', 'Initials': 'SU', 'LastName': 'Hamdani', 'Affiliation': 'Institute of Life and Human Sciences, University of Liverpool, UK; and Human Development Research Foundation, Islamabad, Pakistan.'}, {'ForeName': 'Zill-E-', 'Initials': 'ZE', 'LastName': 'Huma', 'Affiliation': 'Human Development Research Foundation, Islamabad, Pakistan.'}, {'ForeName': 'Atif', 'Initials': 'A', 'LastName': 'Rahman', 'Affiliation': 'Institute of Life and Human Sciences, University of Liverpool, UK.'}, {'ForeName': 'Duolao', 'Initials': 'D', 'LastName': 'Wang', 'Affiliation': 'Liverpool School of Tropical Medicine, UK.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Chen', 'Affiliation': 'Liverpool School of Tropical Medicine, UK.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'van Ommeren', 'Affiliation': 'Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Chisholm', 'Affiliation': 'WHO Regional Office for Europe, Copenhagen, Denmark.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Farooq', 'Affiliation': 'Lady Reading Hospital, Peshawar, Pakistan; and School of Primary, Community and Social Care, Keele University, UK.'}]",The British journal of psychiatry : the journal of mental science,['10.1192/bjp.2020.138'] 2313,32720695,Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV.,"BACKGROUND Pregnancy is accompanied by immune suppression. We hypothesized that M. tuberculosis-specific inflammatory responses used to identify latent tuberculosis infection (LTBI) lose positivity during pregnancy. We also hypothesized that isoniazid preventive therapy (IPT) may revert LTBI diagnoses because of its sterilizing activity. METHODS 944 women with HIV participating in a randomized, double-blind, placebo-controlled study comparing 28 weeks of IPT antepartum versus postpartum, were tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST) at delivery and postpartum. Serial QGIT positivity was assessed by logistic regression using generalized estimating equations. RESULTS From entry to delivery, 68 (24%) of 284 QGIT-positive women (24%) reverted to QGIT-negative or indeterminate. Of these, 42 (62%) recovered QGIT positivity postpartum. The loss of QGIT positivity during pregnancy was explained by decreased IFNγ production in response to TB antigen and/or mitogen. At delivery, QGIT identified 205 and TST 113 women with LTBI. Corresponding numbers postpartum were 229 and 122 women. QGIT and TST kappa agreement coefficients were 0.4 and 0.5, respectively. Among QGIT-positive women antepartum or at delivery, 34 (12%) reverted to QGIT-negative after IPT. There were no differences between women who initiated IPT antepartum or postpartum. CONCLUSIONS Decreased IFNγ responses in pregnancy reduced QGIT positivity, suggesting that this test cannot reliably rule out LTBI during pregnancy. TST was less affected by pregnancy, but had lower positivity compared to QGIT at all time points. IPT was associated with loss of QGIT positivity, the potential clinical consequences of which need to be investigated.",2020,"TST was less affected by pregnancy, but had lower positivity compared to QGIT at all time points.","['Women with HIV', 'Corresponding numbers postpartum were 229 and 122 women', '944 women with HIV participating']","['IPT', 'Pregnancy and Isoniazid Preventive Therapy', 'IPT antepartum versus postpartum, were tested by QuantiFERON-gold-in-tube (QGIT) antepartum and by QGIT and tuberculin skin test (TST', 'isoniazid preventive therapy (IPT', 'placebo']","['Serial QGIT positivity', 'QGIT and TST kappa agreement coefficients', 'IPT antepartum or postpartum', 'QGIT positivity postpartum', 'TST', 'loss of QGIT positivity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]","[{'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0456336', 'cui_str': 'Antepartum'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0041290', 'cui_str': 'Delayed hypersensitivity skin test for tuberculin PPD'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0031082', 'cui_str': 'Periodicals'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0175730', 'cui_str': 'Tube'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439099', 'cui_str': 'Kappa'}, {'cui': 'C0022209', 'cui_str': 'isoniazid'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0456336', 'cui_str': 'Antepartum'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]",944.0,0.21607,"TST was less affected by pregnancy, but had lower positivity compared to QGIT at all time points.","[{'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Weinberg', 'Affiliation': 'Department of Pediatrics, Medicine and Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Aaron', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Boston, USA.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Montepiedra', 'Affiliation': 'Harvard T. H. Chan School of Public Health, Boston, USA.'}, {'ForeName': 'Timothy R', 'Initials': 'TR', 'LastName': 'Sterling', 'Affiliation': 'Vanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Browning', 'Affiliation': 'Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Blandina', 'Initials': 'B', 'LastName': 'Mmbaga', 'Affiliation': 'Kilimanjaro Christian Medical Centre (KCMC) Moshi,\xa0Tanzania.'}, {'ForeName': 'Tichaona', 'Initials': 'T', 'LastName': 'Vhembo', 'Affiliation': 'University of Zimbabwe College of Health Sciences Clinical Trials Research Centre (UZCHS-CTRC), Harare, Zimbabwe.'}, {'ForeName': 'Shilpa', 'Initials': 'S', 'LastName': 'Naik', 'Affiliation': 'Department of Obstetrics and Gynaecology, BJGMC, Pune, India.'}, {'ForeName': 'Enid', 'Initials': 'E', 'LastName': 'Kabugho', 'Affiliation': 'Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Gaerolwe', 'Initials': 'G', 'LastName': 'Masheto', 'Affiliation': 'Botswana Harvard AIDS Institute Partnership and Harvard T.H. Chan School of Public Health.'}, {'ForeName': 'Savita', 'Initials': 'S', 'LastName': 'Pahwa', 'Affiliation': 'Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA.'}, {'ForeName': 'Jyoti S', 'Initials': 'JS', 'LastName': 'Mathad', 'Affiliation': 'Department of Medicine, Center for Global Health, Weill Cornell Medicine, New York, NY, USA.'}, {'ForeName': 'Sylvia M', 'Initials': 'SM', 'LastName': 'LaCourse', 'Affiliation': 'Department of Medicine, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'McCarthy', 'Affiliation': 'FHI 360, Durham, NC, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bradford', 'Affiliation': 'FHI 360, Durham, NC, USA.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Theron', 'Affiliation': 'FAM-CRU CRS, Department of Obstetrics and Gynaecology, Stellenbosch University, Cape Town, South Africa.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Costello', 'Affiliation': 'University of California Los Angeles, Los Angeles CA, USA.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Zimmer', 'Affiliation': 'Frontier Science Foundation, Amherst NY, USA.'}, {'ForeName': 'Marie F', 'Initials': 'MF', 'LastName': 'Pierre', 'Affiliation': 'Les Centres GHESKIO, Port-au-Prince, Haïti.'}, {'ForeName': 'Kamunkhwala', 'Initials': 'K', 'LastName': 'Gausi', 'Affiliation': 'Division of Clinical Pharmacology, University of Cape Town, South Africa.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Denti', 'Affiliation': 'Division of Clinical Pharmacology, University of Cape Town, South Africa.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Haas', 'Affiliation': 'Vanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.'}, {'ForeName': 'Amita', 'Initials': 'A', 'LastName': 'Gupta', 'Affiliation': 'Departments of Medicine and International Health, Johns Hopkins University, Baltimore, MD.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1083'] 2314,32720717,Sample size calculation in three-level cluster randomized trials using generalized estimating equation models.,"Three-level cluster randomized trials (CRTs) are increasingly used in implementation science, where 2fold-nested-correlated data arise. For example, interventions are randomly assigned to practices, and providers within the same practice who provide care to participants are trained with the assigned intervention. Teerenstra et al proposed a nested exchangeable correlation structure that accounts for two levels of clustering within the generalized estimating equations (GEE) approach. In this article, we utilize GEE models to test the treatment effect in a two-group comparison for continuous, binary, or count data in three-level CRTs. Given the nested exchangeable correlation structure, we derive the asymptotic variances of the estimator of the treatment effect for different types of outcomes. When the number of clusters is small, researchers have proposed bias-corrected sandwich estimators to improve performance in two-level CRTs. We extend the variances of two bias-corrected sandwich estimators to three-level CRTs. The equal provider and practice sizes were assumed to calculate number of practices for simplicity. However, they are not guaranteed in practice. Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes. The expressions of REs are obtained from both asymptotic variance estimation and bias-corrected sandwich estimators. Their performances are evaluated for different scenarios of provider and practice size distributions through simulation studies. Finally, a percentage increase in the number of practices is proposed due to efficiency loss from unequal provider and/or practice sizes.",2020,Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes.,[],[],['Relative efficiency (RE'],[],[],"[{'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}]",,0.0599549,Relative efficiency (RE) is defined as the ratio of variance of the estimator of the treatment effect for equal to unequal provider and practice sizes.,"[{'ForeName': 'Jingxia', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': 'Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine (WUSM), St. Louis, Missouri, USA.'}, {'ForeName': 'Graham A', 'Initials': 'GA', 'LastName': 'Colditz', 'Affiliation': 'Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine (WUSM), St. Louis, Missouri, USA.'}]",Statistics in medicine,['10.1002/sim.8670'] 2315,32720779,Assesment of the influence of global and local exercises on core stabilisation mechanisms: randomised control trial.,"BACKGROUND Over the last few years, various concepts of applying core stabilisation mechanisms in the formation of human motor function have come to existence. The objective of the research was to assess the influence of two types of core stability training on deep abdominal muscle thickness and on global trunk mobility. METHODS The study involved 108 individuals divided into 3 groups: LT (local training) -performing the stability training based on locally isolated work of the transversus abdominis muscle, GT (global training) - performing the training based on global movement patterns, and CG (control group) - who did not undergo the training. The workout programmes comprised 4 weeks of the exercise, 4 times a week. The measurement of the observed muscle thickness was carried out by means of ultrasound imaging. Trunk mobility was evaluated based on the toe-touch test, as well as the measurement of lateral flexion ranges. All the measurements were performed before the workout programmes, right after finishing, and 2 weeks after the end of the training cycle. RESULTS Both training concepts have an impact on deep abdominal muscle thickness; however, in the LT group, significant improvement was noted with regard to the transversus abdominis, whereas in the GT group the improvement concerned the external oblique muscle. Both of the training methods also improved trunk mobility in the sagittal and frontal plane. CONCLUSIONS The results we have obtained imply that both concepts of core stability training affect the human body at a structural as well as functional level. The application of the described training methods may not only provide measureable benefits in the field of clinical physiotherapy, for instance in the treatment of spine-related back pain, but also in motor training designed to improve athletes' performance and to minimise the risk of injury.",2020,"Both training concepts have an impact on deep abdominal muscle thickness; however, in the LT group, significant improvement was noted with regard to the transversus abdominis, whereas in the GT group the improvement concerned the external oblique muscle.",['108 individuals divided into 3 groups'],"['LT (local training) -performing', 'global and local exercises', 'core stability training', 'transversus abdominis muscle, GT (global training) - performing the training based on global movement patterns, and CG (control group) - who did not undergo the training']","['Trunk mobility', 'deep abdominal muscle thickness', 'external oblique muscle', 'trunk mobility']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0427096', 'cui_str': 'Patterning of movement'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}]","[{'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0000739', 'cui_str': 'Skeletal muscle structure of abdomen'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0224375', 'cui_str': 'External Oblique Muscle'}]",108.0,0.0188652,"Both training concepts have an impact on deep abdominal muscle thickness; however, in the LT group, significant improvement was noted with regard to the transversus abdominis, whereas in the GT group the improvement concerned the external oblique muscle.","[{'ForeName': 'Paweł', 'Initials': 'P', 'LastName': 'Niewiadomy', 'Affiliation': 'Department of Balneoclimatology and Biological Regeneration, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland.'}, {'ForeName': 'Katarzyna', 'Initials': 'K', 'LastName': 'Szuścik-Niewiadomy', 'Affiliation': 'Department of Adapted Physical Activity and Sport, School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland.'}, {'ForeName': 'Michał T', 'Initials': 'MT', 'LastName': 'Kuszewski', 'Affiliation': 'Institute of Physioterapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland.'}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Kochan', 'Affiliation': 'Institute of Physioterapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland - michalkochan@poczta.fm.'}, {'ForeName': 'Mateusz', 'Initials': 'M', 'LastName': 'Pawlukiewicz', 'Affiliation': 'Institute of Physioterapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland.'}, {'ForeName': 'Mateusz', 'Initials': 'M', 'LastName': 'Rychlik', 'Affiliation': 'School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland.'}, {'ForeName': 'Klaudia', 'Initials': 'K', 'LastName': 'Piątkowska', 'Affiliation': 'School of Health Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11086-7'] 2316,32720780,Caffeine improves performance but not duration of the countermovement jump phases.,"BACKGROUND The countermovement jump (CMJ) test is often employed to assess power generated in the lower limbs and has been related to performance in several sports modalities. The objective of this study was to assess the effects of caffeine supplementation on jump height, average power (AP), peak power (PP), maximum velocity (Vmax), force production and duration of the eccentric, isometric and concentric muscle contraction phases of a CMJ. METHODS Sixteen resistance-trained men (age: 22.69 ± 2.12 years; height: 1.78 ± 0.06 m; weight: 78.09 ± 10.27 kg) performed a CMJ 60 minutes after having taken an oral supplement containing 6 mg·kg-1 of caffeine or placebo (sucrose). The study design was randomized, double-blind crossover. RESULTS Caffeine ingestion improved jump height (+3.86%, p=0.02), Vmax (+1.49%, p=0.023), AP (+4.83%, p=0.006), and PP (+3.49%, p=0.004). CONCLUSIONS Acute caffeine supplementation leads to improved CMJ height, Vmax, AP and PP without significantly affecting the duration of the different test phases. Therefore, caffeine supplementation may be employed as ergogenic aid in sports where CMJ performance has been associated with sport-specific performance enhancements.",2020,"RESULTS Caffeine ingestion improved jump height (+3.86%, p=0.02), Vmax (+1.49%, p=0.023), AP (+4.83%, p=0.006), and PP (+3.49%, p=0.004). ",['Sixteen resistance-trained men (age: 22.69 ± 2.12 years; height: 1.78 ± 0.06 m; weight: 78.09 ± 10.27 kg) performed a'],"['caffeine supplementation', 'Caffeine', 'CMJ 60 minutes after having taken an oral supplement containing 6 mg·kg-1 of caffeine or placebo (sucrose']","['CMJ height, Vmax, AP and PP', 'jump height, average power (AP), peak power (PP), maximum velocity (Vmax), force production and duration of the eccentric, isometric and concentric muscle contraction phases of a CMJ', 'jump height']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C4517412', 'cui_str': '0.06'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0006644', 'cui_str': 'Caffeine'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C1563191', 'cui_str': 'Concentric muscle contraction'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",,0.140098,"RESULTS Caffeine ingestion improved jump height (+3.86%, p=0.02), Vmax (+1.49%, p=0.023), AP (+4.83%, p=0.006), and PP (+3.49%, p=0.004). ","[{'ForeName': 'Ángel', 'Initials': 'Á', 'LastName': 'Lago-Rodríguez', 'Affiliation': 'Faculty of Health Sciences, University Isabel I, Burgos, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Jodra', 'Affiliation': 'Faculty of Education, University of Alcalá, Madrid, Spain - pablo.jodraj@uah.es.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Bailey', 'Affiliation': 'School of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.'}, {'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Domínguez', 'Affiliation': 'Faculty of Health Sciences, University Isabel I, Burgos, Spain.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11099-5'] 2317,32720782,Obesity does not modulate men's eating behavior after a high intensity interval exercise session: an exercise trial.,"BACKGROUND We investigated the impact of obesity on responses to high intensity interval exercise (HIIE) on hunger and energy intake (EI) in young men. METHODS Ten men with obesity (OB) (body mass index [BMI]: 34.6±4.4 kg/m²) and 10 with normal weight (CG) (BMI: 23.1±3.9 kg/m²) participated in a HIIE session. The session consisted of 6 rounds performed at 100% of maximum aerobic velocity (MAV) for 30 seconds, followed by 30 seconds of active recovery at 50% MAV and concluded with 4 minutes of passive recovery. This was repeated three times. EI was estimated at baseline and 24h-post HIIE. Hunger was measured at baseline, 2h- and 24h-post HIIE. RESULTS Carbohydrate (CHO) intake increased in both groups (p<0.01). Hunger feelings [19.5 (0-50) mm at baseline to 50 (9-73) mm Post-2h and 60 (8-92) mm in Post-24h (Group:p=0.71, Time: p<0.01, Group x Time: p=0.06)] and a desire to eat [34 (1-89)±36.0 mm at baseline to 63 (11-86) mm Post-2h and 51 (7-84) mm Post-24h (Group: p=0.65, Time: p<0.01, Group x Time: p=0.29)] increased in both groups. CONCLUSIONS Weight status does not modulate hunger and EI post-HIIE. However, the compensatory increase in CHO intake and hunger feelings is particularly noteworthy for health professionals.",2020,"RESULTS Carbohydrate (CHO) intake increased in both groups (p<0.01).","['Ten men with obesity (OB) (body mass index [BMI]: 34.6±4.4 kg/m²) and 10 with normal weight (CG', 'young men']","['high intensity interval exercise (HIIE', 'maximum aerobic velocity (MAV']","['Hunger feelings', 'Hunger', 'desire to eat', 'Carbohydrate (CHO) intake', 'hunger and energy intake (EI', 'CHO intake and hunger feelings']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]","[{'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}]",10.0,0.292167,"RESULTS Carbohydrate (CHO) intake increased in both groups (p<0.01).","[{'ForeName': 'Caio M', 'Initials': 'CM', 'LastName': 'Terra', 'Affiliation': 'Department of Human Performance, Federal University of São Paolo, Santos, SP, Brazil.'}, {'ForeName': 'Joao P', 'Initials': 'JP', 'LastName': 'Botero', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, CA, USA.'}, {'ForeName': 'Jaddy', 'Initials': 'J', 'LastName': 'Antunes', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, CA, USA.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Haddock', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, CA, USA.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Malik', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, CA, USA - neal.malik@csusb.edu.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Thivel', 'Affiliation': 'Department of Human Kinetics, Université Clermont Auvergne, Clermont-Ferrand, France.'}, {'ForeName': 'Wagner L', 'Initials': 'WL', 'LastName': 'Prado', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, CA, USA.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11181-2'] 2318,32720783,A 4-week diet with exercise intervention had a better effect on blood glucose levels compared to diet only intervention in obese individuals with insulin resistance.,"BACKGROUND The majority of prediabetic people are overweight and weight loss is still the most effective treatment strategy. The aim of this study was to evaluate the effects of short-term exercise and/or diet on weight loss and clinical parameters in subjects with insulin resistance (IR). METHODS A total of 60 subjects (BMI ≥ 25.0 kg/m2) were included in the study. Subjects divided into two groups as follows: diet only (DI, n=27) and diet and exercise (DEI, n=27). DI group received an energy restricted diet program, while DEI group received a diet combined with an exercise program for four weeks. Anthropometric measurements and biochemical parameters were assessed at baseline and at the end. RESULTS Total body weight (BW) loss was 2.3 kg (2.5%) in DI group and 3.0 kg (3.2%) in DEI group at the end of four weeks. Fasting blood glucose (FBG) levels decreased significantly in DEI group (p=0.021). However, the reductions in FBG levels were mild and not statistically significant in DE group (p>0.05). Total cholesterol and LDL-c levels reduced in both groups, while triglyceride levels significantly decreased only in DI group (p<0.05). CONCLUSIONS Short-term lifestyle interventions have beneficial effects on weight loss and clinical parameters associated with glucose control and lipid profile in subjects with IR. Even small changes in BW (loss of <5% of initial BW) have a positive impact on clinical parameters.",2020,"However, the reductions in FBG levels were mild and not statistically significant in DE group (p>0.05).","['subjects with insulin resistance (IR', 'subjects with IR', '60 subjects (BMI ≥ 25.0 kg/m2) were included in the study', 'obese individuals with insulin resistance']","['short-term exercise and/or diet', 'exercise intervention', 'energy restricted diet program, while DEI group received a diet combined with an exercise program']","['Total cholesterol and LDL-c levels', 'triglyceride levels', 'weight loss and clinical parameters', 'Fasting blood glucose (FBG) levels', 'Total body weight (BW) loss', 'weight loss', 'FBG levels', 'blood glucose levels', 'Anthropometric measurements and biochemical parameters']","[{'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}]",60.0,0.0179781,"However, the reductions in FBG levels were mild and not statistically significant in DE group (p>0.05).","[{'ForeName': 'Özlem', 'Initials': 'Ö', 'LastName': 'Tok', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Savaş V', 'Initials': 'SV', 'LastName': 'Kisioglu', 'Affiliation': 'Division of Endocrinology and Metabolism, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Halil Ö', 'Initials': 'HÖ', 'LastName': 'Ersoz', 'Affiliation': 'Division of Endocrinology and Metabolism, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Bahittin', 'Initials': 'B', 'LastName': 'Kahveci', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Health Sciences, Karadeniz Technical University, Trabzon, Turkey.'}, {'ForeName': 'Zeynep', 'Initials': 'Z', 'LastName': 'Goktas', 'Affiliation': 'Department of Nutrition and Dietetics, Faculty of Health Sciences, Hacettepe University, Ankara, Turkey - zeynep.goktas@hacettepe.edu.tr.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.11188-5'] 2319,32720823,Effect of Low-dose ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Low Dose Trial.,"BACKGROUND Studies using 1 mg of colchicine to prevent postoperative atrial fibrillation (POAF) reported conflicting results. Moreover, colchicine was associated with significant gastrointestinal (GI) side effects. This study examined whether low-dose colchicine effectively prevents POAF and whether low-dose therapy is associated with lower rates of colchicine-induced GI side effects. METHODS In this prospective, randomized, double-blind, placebo-controlled study, consecutive adult patients admitted for elective cardiac surgeries randomly received a 1-mg dose of colchicine (n = 81) or placebo (n = 71) orally 12 to 24 hours before surgery followed by a daily dose of 0.5 mg until hospital discharge. The primary efficacy endpoint was the development of at least one episode of POAF of ≥5 minutes. The primary safety endpoint was the development of adverse events, especially diarrhea. RESULTS The in-hospital mortality rate was 3.9%. POAF occurred in 13 patients (16.1%) in the colchicine group and 13 patients (18.3%) in the placebo group (odds ratio 0.85 [95% Confidence Interval = 0.37-1.99]). Diarrhea occurred in two patients in each group and necessitated treatment discontinuation in one patient in each group. CONCLUSION Low-dose colchicine did not prevent POAF in patients undergoing cardiac surgery. These results should be interpreted cautiously because of the small sample size and early study termination. ClinicalTrials.gov Unique Identifier number: NCT03015831.",2020,POAF occurred in 13 patients (16.1%) in the colchicine group and 13 patients (18.3%) in the placebo group (odds ratio 0.85 [95% Confidence Interval = 0.37-1.99]).,"['consecutive adult patients admitted for elective cardiac surgeries', 'Open Heart Surgery Patients', 'patients undergoing cardiac surgery']","['placebo', 'Low-dose ColchiciNe', 'colchicine']","['postoperative atrial fibrillation (POAF', 'significant gastrointestinal (GI) side effects', 'POAF', 'hospital mortality rate', 'InciDence of Atrial Fibrillation', 'development of at least one episode of POAF of ≥5 minutes', 'development of adverse events, especially diarrhea', 'Diarrhea']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0189745', 'cui_str': 'Open heart surgery'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0009262', 'cui_str': 'Colchicine'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.572716,POAF occurred in 13 patients (16.1%) in the colchicine group and 13 patients (18.3%) in the placebo group (odds ratio 0.85 [95% Confidence Interval = 0.37-1.99]).,"[{'ForeName': 'Ramzi A', 'Initials': 'RA', 'LastName': 'Tabbalat', 'Affiliation': 'Abdali Clemenceau Hospital, Amman, Jordan.'}, {'ForeName': 'Imad', 'Initials': 'I', 'LastName': 'Alhaddad', 'Affiliation': 'Jordan Hospital, Amman, Jordan.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Hammoudeh', 'Affiliation': 'Istishari Hospital, Amman, Jordan.'}, {'ForeName': 'Yousef S', 'Initials': 'YS', 'LastName': 'Khader', 'Affiliation': 'Jordan University of Science and Technology, Irbid, Jordan.'}, {'ForeName': 'Hassan Abu', 'Initials': 'HA', 'LastName': 'Khalaf', 'Affiliation': 'Abdali Clemenceau Hospital, Amman, Jordan.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Obaidat', 'Affiliation': 'Abdali Clemenceau Hospital, Amman, Jordan.'}, {'ForeName': 'Jude', 'Initials': 'J', 'LastName': 'Barakat', 'Affiliation': 'Al Khalidi Hospital and Medical Center, Amman, Jordan.'}]",The Journal of international medical research,['10.1177/0300060520939832'] 2320,32720831,"Positive effect of care bundles on patients with central venous catheter insertions at a tertiary hospital in Beijing, China.","OBJECTIVE This study was performed to evaluate the effect of care bundles on the prevention of central venous catheter-related bloodstream infection (CRBSI) and improvement of patients' experience. METHODS In total, 212 patients with central venous catheter insertions were enrolled in this study. All patients were matched by sex, age, Acute Physiology and Chronic Health Evaluation II score, body mass index, department, and catheter insertion site and were randomly divided into case and control groups (n = 106 each). The control group was given conventional care, and the case group was given care bundles including nurse education, hand hygiene, maximal sterile barrier precautions, bedside observation, and evaluation. The anxiety scores, hospitalization days, CRBSI rate, and degree of satisfaction with hospitalization were compared between the two groups. RESULTS The patients' mean self-rating anxiety scale score and self-rating depression scale score after nursing intervention were significantly lower in the case group than in the control group. The mean number of hospitalization days and CRBSI rate were significantly lower and the satisfaction rate was significantly higher in the case group. CONCLUSION Care bundles are essential for preventing CRBSI. They can improve patients' psychological state and hospitalization satisfaction and reduce the hospitalization days.",2020,The patients' mean self-rating anxiety scale score and self-rating depression scale score after nursing intervention were significantly lower in the case group than in the control group.,"['All patients were matched by sex, age, Acute Physiology and Chronic Health Evaluation II score, body mass index, department, and catheter insertion site', ""patients' experience"", 'patients with central venous catheter insertions at a tertiary hospital in Beijing, China', '212 patients with central venous catheter insertions']","['conventional care, and the case group was given care bundles including nurse education, hand hygiene, maximal sterile barrier precautions, bedside observation, and evaluation']","['mean number of hospitalization days and CRBSI rate', 'satisfaction rate', ""patients' psychological state and hospitalization satisfaction"", 'mean self-rating anxiety scale score and self-rating depression scale score', 'anxiety scores, hospitalization days, CRBSI rate, and degree of satisfaction with hospitalization']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4758051', 'cui_str': 'APACHE II (Acute Physiology and Chronic Health Evaluation II) score'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1145640', 'cui_str': 'Central venous catheter'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C3658308', 'cui_str': 'Care Bundles'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2886794', 'cui_str': 'Catheter related bloodstream infection'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",212.0,0.0184669,The patients' mean self-rating anxiety scale score and self-rating depression scale score after nursing intervention were significantly lower in the case group than in the control group.,"[{'ForeName': 'Yuling', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhongying', 'Initials': 'Z', 'LastName': 'Bao', 'Affiliation': 'Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Yuan', 'Affiliation': 'Department of Infectious Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.'}]",The Journal of international medical research,['10.1177/0300060520942113'] 2321,32720832,"A combination of three probiotic strains for treatment of acute diarrhoea in hospitalised children: an open label, randomised controlled trial.","Acute diarrhoea continues to be a leading cause of morbidity, hospitalisation, and mortality worldwide, and probiotics have been proposed as a complementary therapy in the treatment of acute diarrhoea. The goal of this study is to assess the efficacy and safety of three combined probiotic strains, Bifidobacterium lactis Bi-07, Lactobacillus rhamnosus HN001, and Lactobacillus acidophilus NCFM, as an adjunct to rehydration therapy in treatment of acute watery diarrhoea in hospitalised children. Eligible diarrheal children were randomised into intervention group (IG, n=96, conventional treatment for diarrhoea in combination with probiotics) and control group (CG, n=98, conventional treatment for diarrhoea without probiotics). The primary assessments of this study were duration of diarrhoea and hospital stay and improvement in diarrhoea symptoms. Significantly more children in the IG showed improvements in diarrhoea (defined as a decrease of stool frequency to no more than four times per day and an improved stool consistency within 24-48 h after the treatment) than those in the CG (96.9 vs 79.6%, P <0.05). Children supplemented with the mixed strains had a 22.5 h shorter (121.4±13.7 h vs 143.9±19.8 h) mean duration of diarrhoea and 1.2 d shorter hospital stays (5.1±1.2 d vs 6.3±1.4 d) than children only receiving the rehydration therapy ( P <0.05). The prevalence of constipation of children in the IG (3.1%) was markedly lower ( P <0.05) than that of children in the CG (13.3%) after treatment. In conclusion, the mixture of three probiotic strains given to children aged 1-3 years resulted in shorter durations of diarrhoea and hospitalisation and a higher percentage of improved children.",2020,"Significantly more children in the IG showed improvements in diarrhoea (defined as a decrease of stool frequency to no more than four times per day and an improved stool consistency within 24-48 h after the treatment) than those in the CG (96.9 vs 79.6%, P <0.05).","['hospitalised children', 'Eligible diarrheal children']","['probiotic strains', 'conventional treatment for diarrhoea in combination with probiotics) and control group (CG, n=98, conventional treatment for diarrhoea without probiotics']","['stool consistency', 'mean duration of diarrhoea', 'duration of diarrhoea and hospital stay and improvement in diarrhoea symptoms', 'diarrhoea', 'stool frequency', 'efficacy and safety', 'prevalence of constipation of children', 'shorter durations of diarrhoea and hospitalisation', 'hospital stays']","[{'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0426740', 'cui_str': 'Consistency of stool'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.0416913,"Significantly more children in the IG showed improvements in diarrhoea (defined as a decrease of stool frequency to no more than four times per day and an improved stool consistency within 24-48 h after the treatment) than those in the CG (96.9 vs 79.6%, P <0.05).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': ""Department of Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan 6100131, China P.R.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Xin', 'Affiliation': 'Infinitus (China) Company Ltd., Hangzhou, Zhejiang, China P.R.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Zhang', 'Affiliation': ""Department of Pediatric Intensive Care Unit, Chengdu Women's & Children's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China P.R.""}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Xie', 'Affiliation': 'Department of Pediatrics, Dayi Maternal and Child Health Care Hospital, Chengdu, Sichuan, China P.R.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Luo', 'Affiliation': 'Department of Pediatrics, Dayi Maternal and Child Health Care Hospital, Chengdu, Sichuan, China P.R.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Yuan', 'Affiliation': ""Department of Nutrition, Chengdu Women's & Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617, Riyue Avenue, Qingyang District, Chengdu, Sichuan 6100131, China P.R.""}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Bu', 'Affiliation': 'Department of Pediatrics, Dayi Maternal and Child Health Care Hospital, Chengdu, Sichuan, China P.R.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Yang', 'Affiliation': 'Department of Pediatrics, Dayi Maternal and Child Health Care Hospital, Chengdu, Sichuan, China P.R.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Ge', 'Affiliation': 'Infinitus (China) Company Ltd., Hangzhou, Zhejiang, China P.R.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': 'School of Exercise and Nutritional Sciences, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182-7251, USA.'}]",Beneficial microbes,['10.3920/BM2020.0046'] 2322,32712884,Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.,"Background Hepatitis C virus infection is one of the major causes of liver cirrhosis and hepatocellular carcinoma worldwide. IL28B gene polymorphism has a direct relation to the response of interferon-based regimens. However, the effect of IL28B gene polymorphism on efficacy of the new direct acting antivirals used in treatment of chronic hepatitis C Egyptian patients hasn't been studied yet. Objective This study aimed to investigate the frequency of IL28B genotypes and impact of its polymorphism on the efficacy and safety of two direct acting antiviral regimens. Setting Patients were recruited form faculty of Medicine Ain shams research institute, Cairo, Egypt. Methods Easy to treat chronic hepatitis C Egyptian patients were included in this prospective study. Patients were randomized into two groups, group 1 received sofosbuvir plus daclatasvir and group 2 received paritaprevir, ombitasvir and ritonavir plus ribavirin. Both treatment regimens were given for 3 months. Laboratory evaluation and IL28B rs 12979860 genotyping were performed at baseline. Follow ups were performed monthly. Fibrosis was assessed at baseline and after treatment. Main outcome measures The frequency of IL28B genotypes and their correlation with safety and efficacy of direct acting antiviral regimens. Results CT genotype was present in 52.42% of patients while CC and TT genotypes were present in 28.16% and 19.42% of patients, respectively. IL28B genotypes weren't correlated to sustained virologic response in both treatment groups. Baseline fibroscan scores didn't show any significant relations with IL28B genotypes. Aspartate aminotransferase/alanine aminotransferase ratio increased significantly at the end of treatment in group1. CC genotype had shown higher ratio values at the end of treatment in Group 2. Conclusion CT genotype is the predominant genotype in easy to treat HCV Egyptian patients. IL28B genotypes hasn't any predictive value on the efficacy or the safety of direct acting antiviral regimens.",2020,Aspartate aminotransferase/alanine aminotransferase ratio increased significantly at the end of treatment in group1.,"['Setting Patients were recruited form faculty of Medicine Ain shams research institute, Cairo, Egypt', 'chronic hepatitis C Egyptian patients', 'hepatitis C Egyptian patients']","['IL28B gene polymorphism', 'sofosbuvir plus daclatasvir and group 2 received paritaprevir, ombitasvir and ritonavir plus ribavirin']","['ratio values', 'Fibrosis', 'Baseline fibroscan scores', 'Aspartate aminotransferase/alanine aminotransferase ratio', 'efficacy and safety', 'sustained virologic response', 'frequency of IL28B genotypes and their correlation with safety and efficacy of direct acting antiviral regimens']","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0347129', 'cui_str': 'Dysplasia of anus'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0035172', 'cui_str': 'Research Institutes'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C0013717', 'cui_str': 'Egyptian language'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}]","[{'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3252090', 'cui_str': 'daclatasvir'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C3864824', 'cui_str': 'paritaprevir'}, {'cui': 'C3852670', 'cui_str': 'ombitasvir'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C0035525', 'cui_str': 'Ribavirin'}]","[{'cui': 'C1532109', 'cui_str': 'Ratio value'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4050171', 'cui_str': 'Sustained Viral Suppression'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]",,0.0270569,Aspartate aminotransferase/alanine aminotransferase ratio increased significantly at the end of treatment in group1.,"[{'ForeName': 'Abdel-Hameed Ibrahim Mohamed', 'Initials': 'AIM', 'LastName': 'Ebid', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt.'}, {'ForeName': 'Ossama Ashraf', 'Initials': 'OA', 'LastName': 'Ahmed', 'Affiliation': 'Department of Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Sara Hassan', 'Initials': 'SH', 'LastName': 'Agwa', 'Affiliation': 'Department of Clinical and Chemical Pathology at MASRI, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Sara Mohamed', 'Initials': 'SM', 'LastName': 'Abdel-Motaleb', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmacy, Helwan University, Cairo, Egypt.'}, {'ForeName': 'Radwa Samir', 'Initials': 'RS', 'LastName': 'Hagag', 'Affiliation': 'Department of Pharmacy Practice, Faculty of Pharmacy, Egyptian Russian University, Badr City, Egypt. Radwahagag@yahoo.com.'}]",International journal of clinical pharmacy,['10.1007/s11096-020-01085-2'] 2323,32712967,Suggestive seizure induction for inpatients with suspected psychogenic nonepileptic seizures.,"OBJECTIVE To determine the utility of suggestive seizure induction for inpatient work-up of suspected psychogenic nonepileptic seizures (PNES). METHODS Prospective study of epilepsy center inpatient admissions with suspected PNES. Patients were randomized to undergo suggestive induction first (group A) and then, if necessary, long-term video-electroencephalography (EEG) monitoring, or vice versa (group B). Diagnostic pathways were compared. Potential clinical predictors for diagnostic success were evaluated. RESULTS Length of in-hospital stay did not significantly differ between groups. Suspicion of PNES was confirmed in 43 of 77 (56%) patients, evenly distributed between group A (22 of 39) and group B (21 of 38). In nine patients, recorded habitual seizures were epileptic and in 25 cases, no diagnostic event could be recorded. Diagnosis of PNES was ascertained primarily by recording a typical seizure through suggestive induction in 24 patients and through long-term monitoring in 19 patients. In group A (induction first), monitoring was not deemed necessary in 21% of cases. In group B (monitoring first), 13% would have remained inconclusive without suggestive induction. Patients who reported triggers to their habitual seizures were not more likely to have spontaneous or provoked PNES during monitoring or suggestive inducion, respectively. Patients with subjective seizure prodromes (auras) were significantly more likely to have a PNES during suggestive induction than those without (odds ratio [OR] 3.4, 95% confidence interval [CI] 1.1-10.4). There was no significant difference in seizure frequency between patients with spontaneous PNES during long-term monitoring and those with nondiagnostic monitoring sessions. SIGNIFICANCE Our results support the notion that suggestive seizure induction can reduce the number of inconclusive inpatient workups, and can obviate resource-intensive long-term monitoring in one fifth of cases. Patients who are aware of prodromes might have a higher chance of having seizures induced through suggestion.",2020,"There was no significant difference in seizure frequency between patients with spontaneous PNES during long-term monitoring and those with nondiagnostic monitoring sessions. ","['Patients who reported triggers to their habitual seizures', 'Patients with subjective seizure prodromes (auras', 'inpatients with suspected psychogenic nonepileptic seizures', 'inpatient work-up of suspected psychogenic nonepileptic seizures (PNES', 'epilepsy center inpatient admissions with suspected PNES']","['necessary, long-term video-electroencephalography (EEG) monitoring, or vice versa']","['seizure frequency', 'Length of in-hospital stay', 'Suspicion of PNES', 'habitual seizures']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0032930', 'cui_str': 'Precipitating Factors'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0240805', 'cui_str': 'Prodrome'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0458006', 'cui_str': 'Psychogenic'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0149775', 'cui_str': 'Fit frequency'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0242114', 'cui_str': 'Suspicion'}, {'cui': 'C0458006', 'cui_str': 'Psychogenic'}, {'cui': 'C3495874', 'cui_str': 'Non-Epileptic Seizures'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}]",24.0,0.0369929,"There was no significant difference in seizure frequency between patients with spontaneous PNES during long-term monitoring and those with nondiagnostic monitoring sessions. ","[{'ForeName': 'Stoyan', 'Initials': 'S', 'LastName': 'Popkirov', 'Affiliation': 'Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Wenke', 'Initials': 'W', 'LastName': 'Grönheit', 'Affiliation': 'Ruhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Jungilligens', 'Affiliation': 'Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Wehner', 'Affiliation': 'Ruhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Uwe', 'Initials': 'U', 'LastName': 'Schlegel', 'Affiliation': 'Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Wellmer', 'Affiliation': 'Ruhr-Epileptology, Department of Neurology, University Hospital Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Bochum, Germany.'}]",Epilepsia,['10.1111/epi.16629'] 2324,32713006,Glycaemic Response to a Renal-Specific Oral Nutritional Supplement in Patients with Diabetes Undergoing Haemodialysis: a randomised crossover trial.,"BACKGROUND Diabetes and malnutrition are common in patients with end-stage kidney disease (ESKD). We aimed to evaluate the postprandial glucose response to oral nutritional supplement drinks (ONS) in patients with diabetes undergoing haemodialysis treatment. METHODS A randomised, single-blind crossover study was conducted in patients with diabetes and ESKD requiring chronic haemodialysis. Patients consumed either a renal-specific ONS, a macronutrient matched ONS or a standard ONS on three separate study days, during dialysis, following an overnight fast. Blood was collected before, 15, 30, 45, 60, 90, 120, and 180 minutes post ingestion. Mean net incremental area under the curve (iAUC) and peak incremental blood glucose concentration (iBGC) were compared across conditions, using analyses of variance. RESULTS Consumption of the renal-specific ONS resulted in the lowest mean net iAUC (87.9±169.0 mmol/L per 3 hours compared to the macronutrient matched (188.0±127.5 mmol/L per 3 hours) and standard ONS (199.5±169.2 mmol/L per 3 hours), (F (2,30) = 5.115, p = 0.012, partial n 2 = 0.254). Post-hoc pairwise comparisons demonstrated a mean difference of 100.1 mmol/L per 3 hours (95% CI -2.8 to 202.9) in mean iAUC between the renal-specific ONS and the macronutrient matched ONS (p = 0.058). Peak blood glucose concentration, corrected for baseline, was significantly lower after the renal-specific ONS (1.40±1.0 mmol/L) compared to both the macronutrient matched (2.02±0.71 mmol/L, p = 0.036) and standard ONS (2.3±1.06 mmol/L, p = 0.017). CONCLUSION A renal-specific ONS elicits a lower postprandial glucose response than either macronutrient matched ONS or a standard ONS in patients with diabetes and ESKD undergoing haemodialysis. This article is protected by copyright. All rights reserved.",2020,A renal-specific ONS elicits a lower postprandial glucose response than either macronutrient matched ONS or a standard ONS in patients with diabetes and ESKD undergoing haemodialysis.,"['patients with diabetes and ESKD undergoing haemodialysis', 'Patients with Diabetes Undergoing Haemodialysis', 'patients with diabetes and ESKD requiring chronic haemodialysis', 'patients with end-stage kidney disease (ESKD', 'patients with diabetes undergoing haemodialysis treatment']","['oral nutritional supplement drinks (ONS', 'Renal-Specific Oral Nutritional Supplement', 'renal-specific ONS, a macronutrient matched ONS or a standard ONS', 'macronutrient matched ONS or a standard ONS']","['mean net iAUC', 'Mean net incremental area under the curve (iAUC) and peak incremental blood glucose concentration (iBGC', 'Glycaemic Response', 'Peak blood glucose concentration', 'postprandial glucose response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1740835', 'cui_str': 'Chronic haemodialysis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",,0.0467334,A renal-specific ONS elicits a lower postprandial glucose response than either macronutrient matched ONS or a standard ONS in patients with diabetes and ESKD undergoing haemodialysis.,"[{'ForeName': 'Vishal Nainesh', 'Initials': 'VN', 'LastName': 'Patel', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Dijk', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}, {'ForeName': 'Bridget', 'Initials': 'B', 'LastName': 'Malarkey', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}, {'ForeName': 'Jennifer R', 'Initials': 'JR', 'LastName': 'Brooke', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Whelan', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}, {'ForeName': 'Helen L', 'Initials': 'HL', 'LastName': 'MacLaughlin', 'Affiliation': ""Department of Nutritional Sciences, Life Sciences and Medicine, King's College London, Franklin-Wilkins Building, Stamford Street, London, SE1 9NH, UK.""}]",JPEN. Journal of parenteral and enteral nutrition,['10.1002/jpen.1970'] 2325,32713062,Levonorgestrel vs combined oral contraceptive pills in treatment of female acne and hirsutism.,"Combined oral contraception was used in many studies for treatment of acne and hirsutism. However, levonorgestrel (LNG) alone has not been evaluated before. Our objective is to evaluate the efficacy of oral contraceptive (OC) pills containing LNG and ethinyl estradiol (EE) compared with LNG only for the treatment of acne and hirsutism in a randomized, controlled prospective clinical trial. Eighty females (20 with acne, 20 with hirsutism, and 40 healthy females) received LNG + EE or LNG only for 6 months. Assessment of acne by global acne grading system (GAGS) and hirsutism by modified Ferriman-Gallwey scale (MFGS) grading system and serum free testosterone was measured before and 6 months after treatment. Serum free testosterone was significantly higher before treatment in acne and hirsutism patients compared to control group (P < .000). In acne patients, after 6 months of treatment with LNG/EE, serum free testosterone, and (GAGS), were significantly decreased compared to LNG only (P < .000). In hirsutism group, after 6 months of treatment with LNG/EE, serum free testosterone and (MFGS), were nonsignificantly decreased compared to LNG only. OCs containing either LNG/EE or LNG seem to be effective and safe treatment for acne and hirsutism.",2020,Serum free testosterone was significantly higher before treatment in acne and hirsutism patients compared to control group (P < .000).,"['Eighty females (20 with acne, 20 with hirsutism, and 40 healthy females', 'female acne and hirsutism']","['Combined oral contraception', 'LNG', 'LNG/EE or LNG', 'LNG\u2009+\u2009EE or LNG', 'levonorgestrel (LNG', 'Levonorgestrel vs combined oral contraceptive pills', 'oral contraceptive (OC) pills containing LNG and ethinyl estradiol (EE']","['serum free testosterone and (MFGS', 'Assessment of acne by global acne grading system (GAGS) and hirsutism by modified Ferriman-Gallwey scale (MFGS) grading system and serum free testosterone', 'Serum free testosterone', 'LNG/EE, serum free testosterone, and (GAGS']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0019572', 'cui_str': 'Hirsutism'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0029151', 'cui_str': 'Oral contraception'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}, {'cui': 'C0717761', 'cui_str': 'medroxyprogesterone and ethinylestradiol'}, {'cui': 'C0009906', 'cui_str': 'Oral Contraceptives, Combined'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0202228', 'cui_str': 'Testosterone measurement, unbound'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4749813', 'cui_str': 'Ferriman-Gallwey scale'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C1273712', 'cui_str': 'Grading system used'}, {'cui': 'C0019572', 'cui_str': 'Hirsutism'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C0015011', 'cui_str': 'Ethinyl Estradiol'}]",80.0,0.0221176,Serum free testosterone was significantly higher before treatment in acne and hirsutism patients compared to control group (P < .000).,"[{'ForeName': 'Alaa E A', 'Initials': 'AEA', 'LastName': 'Moubasher', 'Affiliation': 'Department of Dermatology, Venerology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Hisham A', 'Initials': 'HA', 'LastName': 'Abdel Basset', 'Affiliation': 'Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}, {'ForeName': 'Asmaa A M', 'Initials': 'AAM', 'LastName': 'Khalil', 'Affiliation': 'General Luxor Hospital, Luxor, Egypt.'}, {'ForeName': 'Eman M K', 'Initials': 'EMK', 'LastName': 'Youssef', 'Affiliation': 'Department of Dermatology, Venerology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.'}]",Dermatologic therapy,['10.1111/dth.13700'] 2326,32713072,Near-infrared heating of skin to delineate non-melanoma skin cancer lesions: A pilot study.,"BACKGROUND Surgical excision is a mainstay of treatment for non-melanoma skin cancer (NMSC); improving margin delineation can reduce the need for further monitoring/treatment. The objective of this pilot study was to determine if near-infrared radiation (NIR) application to skin causes visible changes in normal and NMSC skin, to help delineate margins. MATERIALS/METHODS Eleven biopsy-proven NMSC lesions were included. The skin was then heated under a 175W NIR heating bulb; margins were traced onto acetate film before and after heating. Lesions were then randomly assigned to excision based on pre- or post-heating margins. Composite images were generated by overlaying the heat and no-heat lesion contours. All specimens were sent for histopathology. RESULTS The range of closest margins in the control group was 2.0-3.0 mm with a median of 2.0 mm; the range in the intervention group was 4.0-9.0 mm with a median of 5.0 mm. Composite images showed larger heat contours when the initial lesion was larger. There was a statistically significant difference between the two groups. Overall, NIR light caused visible hyperaemia to skin, and more intense erythema to malignant skin lesions. CONCLUSION Near-infrared light may have use in an outpatient setting for skin cancer delineation, possibly reducing the rate of positive margins.",2020,The range of closest margins in the control group was 2.0-3.0 mm with a median of 2.0 mm; the range in the intervention group was 4.0-9.0 mm with a median of 5.0 mm.,"['non-melanoma skin cancer (NMSC', 'Eleven biopsy-proven NMSC lesions']",['near-infrared radiation (NIR'],['larger heat contours'],"[{'cui': 'C0699893', 'cui_str': 'Skin carcinoma'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}]","[{'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0021431', 'cui_str': 'Infrared radiation'}]","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0018837', 'cui_str': 'Heat'}]",,0.0240568,The range of closest margins in the control group was 2.0-3.0 mm with a median of 2.0 mm; the range in the intervention group was 4.0-9.0 mm with a median of 5.0 mm.,"[{'ForeName': 'Kiersten', 'Initials': 'K', 'LastName': 'Pianosi', 'Affiliation': 'Department of Otolaryngology - Head & Neck Surgery, University of Western Ontario, London, ON, Canada.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Jordan', 'Affiliation': 'Departments of Oncology and Medical Biophysics, University of Western Ontario, London, ON, Canada.'}, {'ForeName': 'Corey C', 'Initials': 'CC', 'LastName': 'Moore', 'Affiliation': 'Department of Otolaryngology - Head & Neck Surgery, University of Western Ontario, London, ON, Canada.'}]",Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI),['10.1111/srt.12936'] 2327,32713085,Ribociclib therapy in peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer: A clinical case with a positive outcome.,"Although metastatic breast cancer can be fatal, a series of randomized double-blind placebo-controlled phase 3 trials (MONALEESA studies) have shown that ribociclib is an effective anticancer drug for the treatment of advanced breast cancer with bones, liver, lungs, and brain as major metastatic sites. Here, we report the clinical case of a woman with peritoneal carcinomatosis secondary to HER2-negative estrogen receptor-positive breast cancer successfully treated with ribociclib and letrozole. After 9-month follow-up, total body computed tomography imaging showed resolution of hypodense areas surrounding the hepatic hilus with concomitant reduction in both bile duct dilatation and peritoneal effusion, and abdominal lymphadenopathy was excluded. Notably, therapy was well tolerated throughout the treatment with no side effects.",2020,"Notably, therapy was well tolerated throughout the treatment with no side effects.","['woman with peritoneal carcinomatosis secondary to HER2-negative estrogen receptor-positive breast cancer successfully treated with', 'peritoneal carcinomatosis secondary to HER2-negative metastatic breast cancer']","['Ribociclib therapy', 'ribociclib and letrozole', 'placebo']",[],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0346990', 'cui_str': 'Carcinomatosis of peritoneal cavity'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C4087376', 'cui_str': 'HER2 negative'}, {'cui': 'C2938924', 'cui_str': 'Oestrogen receptor positive breast cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0278488', 'cui_str': 'Breast cancer stage IV'}]","[{'cui': 'C4045494', 'cui_str': 'ribociclib'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0246421', 'cui_str': 'letrozole'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0384137,"Notably, therapy was well tolerated throughout the treatment with no side effects.","[{'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Guarino', 'Affiliation': 'U.O.C. di Oncologia AV1 ASUR Marche, Ospedale di Urbino, Urbino, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Stocchi', 'Affiliation': 'U.O.C. di Oncologia AV1 ASUR Marche, Ospedale di Urbino, Urbino, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Massaioli', 'Affiliation': 'U.O.C. Diagnostica per immagini AV1 ASUR Marche, Ospedale di Urbino, Urbino, Italy.'}]",The breast journal,['10.1111/tbj.13940'] 2328,32713104,Searching for an optimal therapy for H pylori eradication: High-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days.,"BACKGROUND & AIMS We compared a high-dose dual therapy (HDDT) with rabeprazole and amoxicillin and compared it with a standard triple therapy (STT) with rabeprazole, amoxicillin, and clarithromycin for 2 weeks for H pylori eradication in treatment naïve patients. METHODS H pylori-positive patients were randomly assigned to either a rabeparzole (Pariet) 20 mg b.i.d., amoxicillin (Ospamox) 1 g b.i.d. and clarithromycin (Klacid) 500 mg b.i.d. for 14 days or rabeprazole (Pariet) 20 mg q.i.d., amoxicillin (Ospamox) 1 g q.i.d. also for 14 days. Eradication was tested for by the C 13 -UBT at least 4 weeks after the completion of therapy. RESULTS H pylori was eradicated in 86.2% of patients (81/94) (95% CI: 77.8-91.7) in the STT group compared with 92.8% (90/97) (95% CI: 85.9-96.5) in the HDDT group on ITT analysis. On PP analysis, H pylori was eradicated in 91.0% of patients (81/89) (95% CI: 83.3-95.4) in the STT group compared with 93.8% (90/96) (95% CI: 87.0-97.1) in the HDDT group. Side effects were few although many patients in the STT arm complained of bitter taste. The HDDT arm was well tolerated by patients. CONCLUSIONS The HDDT gave a high eradication rate comparable to the STT for 2 weeks and was a well-tolerated regimen for H pylori eradication.",2020,The HDDT gave a high eradication rate comparable to the STT for 2 weeks and was a well-tolerated regimen for H pylori eradication.,"['H\xa0pylori-positive patients', 'treatment naïve patients']","['rabeparzole (Pariet', 'rabeprazole (Pariet) 20', 'rabeprazole, amoxicillin, and clarithromycin', 'clarithromycin (Klacid', 'amoxicillin vs. standard triple therapy', 'rabeprazole and amoxicillin', 'amoxicillin (Ospamox']","['Side effects', 'eradication rate', 'Eradication', 'bitter taste']","[{'cui': 'C0079488', 'cui_str': 'Helicobacter pylori'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0378482', 'cui_str': 'rabeprazole'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0235290', 'cui_str': 'Taste bitter'}]",,0.0469821,The HDDT gave a high eradication rate comparable to the STT for 2 weeks and was a well-tolerated regimen for H pylori eradication.,"[{'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Hwong-Ruey Leow', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Jo-Ven', 'Initials': 'JV', 'LastName': 'Chang', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Khean-Lee', 'Initials': 'KL', 'LastName': 'Goh', 'Affiliation': 'Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}]",Helicobacter,['10.1111/hel.12723'] 2329,32713326,Prospective randomized appraisal of the best pain relief option after L4/L5 discectomy.,"OBJECTIVES To determine the efficacy of paracetamol and tramadol analgesia via patient controlled pump and intermittent administration using the Short-Form McGill Pain Questionnaire after L4/L5 discectomy in neurosurgical patients. METHODS Fourteen months prospective quantitative study with 200 neurosurgical patients' participation who underwent elective discectomy of the L4/L5 intervertebral disc extrusion. The study was conducted due to a patient-controlled analgesia pump and intermittent analgesia application. Pain was assessed using the Short-Form McGill Pain Questionnaire in the Croatian language during the zero, first, and second postoperative day. RESULTS Perception of pain was reduced in patient controlled analgesia pump groups after the second measurement during the first postoperative day [95% CI: -3.89, -0.76], regardless of administered analgesic ( p < 0.001). After the final measurement, at 7 PM on the second postoperative day, the differences were not significant ( p = 0.070). This study results are registered and allocated in the Australian New Zealand Clinical Trials Registry (ANZCTR). DISCUSSION Analgesia administration via patient-controlled pump contributes to the alleviation of postoperative pain after L4/L5 disc extrusion surgery regardless of administered analgesic.",2020,"After the final measurement, at 7 PM on the second postoperative day, the differences were not significant ( p = 0.070).","['neurosurgical patients', ""200 neurosurgical patients' participation who underwent elective discectomy of the L4/L5 intervertebral disc extrusion""]","['L4/L5 discectomy', 'paracetamol and tramadol analgesia']","['postoperative pain', 'Pain', 'Short-Form McGill Pain Questionnaire', 'Perception of pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0242362', 'cui_str': 'Intervertebral disc prolapse'}]","[{'cui': 'C0206078', 'cui_str': 'Discectomy of spine'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}]","[{'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0457972', 'cui_str': 'Short form McGill pain questionnaire'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",200.0,0.0577158,"After the final measurement, at 7 PM on the second postoperative day, the differences were not significant ( p = 0.070).","[{'ForeName': 'Tomislav', 'Initials': 'T', 'LastName': 'Sajko', 'Affiliation': 'University of Applied Health Sciences , Zagreb, Croatia.'}, {'ForeName': 'Kresimir', 'Initials': 'K', 'LastName': 'Rotim', 'Affiliation': 'University of Applied Health Sciences , Zagreb, Croatia.'}, {'ForeName': 'Biljana', 'Initials': 'B', 'LastName': 'Kurtovic', 'Affiliation': 'University of Applied Health Sciences , Zagreb, Croatia.'}, {'ForeName': 'Cecilija', 'Initials': 'C', 'LastName': 'Rotim', 'Affiliation': 'University of Applied Health Sciences , Zagreb, Croatia.'}, {'ForeName': 'Ante', 'Initials': 'A', 'LastName': 'Rotim', 'Affiliation': 'Department of Neurosurgery, Dubrava University Hospital , Zagreb, Croatia.'}]",Neurological research,['10.1080/01616412.2020.1796383'] 2330,32713349,Effectiveness of the Ready to Reduce Risk (3R) complex intervention for the primary prevention of cardiovascular disease: a pragmatic randomised controlled trial.,"BACKGROUND Cardiovascular disease is responsible for 31% of all global deaths. Primary prevention strategies are needed to improve longer-term adherence to statins and healthy lifestyle behaviours to reduce risk in people at risk of cardiovascular disease. METHODS Pragmatic randomised controlled trial recruited between May 2016 and March 2017 from primary care practices, England. Participants (n = 212) prescribed statins for primary prevention of cardiovascular disease with total cholesterol level ≥ 5 mmol/l were randomised: 105 to the intervention group and 107 to the control group, stratified by age and sex. The 3R intervention involved two facilitated, structured group education sessions focusing on medication adherence to statins, lifestyle behaviours and cardiovascular risk, with 44 weeks of medication reminders and motivational text messages and two supportive, coaching phone calls (at approximately 2 weeks and 6 months). The control group continued with usual clinical care. Both groups received a basic information leaflet. The primary outcome was medication adherence to statins objectively measured by a biochemical urine test. Self-reported adherence and practice prescription data provided additional measures. Secondary outcomes included cholesterol profile, blood pressure, anthropometric data, cardiovascular risk score, and self-reported lifestyle behaviours and psychological measures (health/medication beliefs, quality of life, health status). All outcomes were assessed at 12 months. RESULTS Baseline adherence to statins was 47% (control) and 62% (intervention). No significant difference between the groups found for medication adherence to statins using either the urine test (OR 1.02, 95% CI 0.34 to 3.06, P = 0.968) or other measures. This may have been due to the higher than expected adherence levels at baseline. The adjusted mean difference between the groups (in favour of the intervention group) for diastolic blood pressure (- 4.28 mmHg (95% CI - 0.98 to - 1.58, P = 0.002)) and waist circumference (- 2.55 cm (95% CI - 4.55 to - 0.55, P = 0.012)). The intervention group also showed greater perceived control of treatment and more coherent understanding of the condition. CONCLUSIONS The 3R programme successfully led to longer-term improvements in important clinical lifestyle indicators but no improvement in medication adherence, raising questions about the suitability of such a broad, multiple risk factor approach for improving medication adherence for primary prevention of CVD. TRIAL REGISTRATION International Standard Randomized Controlled Trial Number (ISRCTN16863160), March 11, 2006.",2020,"The 3R programme successfully led to longer-term improvements in important clinical lifestyle indicators but no improvement in medication adherence, raising questions about the suitability of such a broad, multiple risk factor approach for improving medication adherence for primary prevention of CVD. ","['212) prescribed statins for primary prevention of cardiovascular disease with total cholesterol level ≥', 'Pragmatic randomised controlled trial recruited between May 2016 and March 2017 from primary care practices, England', 'Participants (n\xa0', 'cardiovascular disease']","['Ready to Reduce Risk (3R) complex intervention', 'usual clinical care', 'structured group education sessions focusing on medication adherence to statins, lifestyle behaviours and cardiovascular risk, with 44\u2009weeks of medication reminders and motivational text messages and two supportive, coaching phone calls']","['waist circumference', 'medication adherence to statins objectively measured by a biochemical urine test', 'cholesterol profile, blood pressure, anthropometric data, cardiovascular risk score, and self-reported lifestyle behaviours and psychological measures (health/medication beliefs, quality of life, health status', 'Baseline adherence to statins', 'diastolic blood pressure', 'medication adherence']","[{'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C2585889', 'cui_str': 'Primary prevention of cardiovascular disease'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0150375', 'cui_str': 'Group education'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0360714', 'cui_str': 'HMG-CoA reductase inhibitor'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0042014', 'cui_str': 'Urinalysis'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",,0.163159,"The 3R programme successfully led to longer-term improvements in important clinical lifestyle indicators but no improvement in medication adherence, raising questions about the suitability of such a broad, multiple risk factor approach for improving medication adherence for primary prevention of CVD. ","[{'ForeName': 'Jo L', 'Initials': 'JL', 'LastName': 'Byrne', 'Affiliation': 'Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.'}, {'ForeName': 'Helen M', 'Initials': 'HM', 'LastName': 'Dallosso', 'Affiliation': 'Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Rogers', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Laura J', 'Initials': 'LJ', 'LastName': 'Gray', 'Affiliation': 'Department of Health Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Ghazala', 'Initials': 'G', 'LastName': 'Waheed', 'Affiliation': 'Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.'}, {'ForeName': 'Prashanth', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Pankaj', 'Initials': 'P', 'LastName': 'Gupta', 'Affiliation': 'Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Doherty', 'Affiliation': 'Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.'}, {'ForeName': 'Melanie J', 'Initials': 'MJ', 'LastName': 'Davies', 'Affiliation': 'Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.'}, {'ForeName': 'Kamlesh', 'Initials': 'K', 'LastName': 'Khunti', 'Affiliation': 'Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK. kk22@leicester.ac.uk.'}]",BMC medicine,['10.1186/s12916-020-01664-0'] 2331,32713367,"Low frequency rTMS, inhibits the antidepressive effect of ECT. A pilot study.","OBJECTIVE Low frequency rTMS of the prefrontal cortex have been shown to have a statistically and clinically significant antidepressant effect. The present pilot study was carried out to investigate if right prefrontal low frequency rTMS as an add-on to ECT accelerates the antidepressant effect and reduces cognitive side effects. METHODS In this randomized, controlled, double blind study thirty-five patients with major depression were allocated to ECT+placebo or ECT+ low frequency right prefrontal rTMS. The severity of depression was evaluated during the course using the Hamilton scale for depression (the 17-item as well as the 6-item scale) and the Major Depression Inventory. Furthermore, neuropsychological assessment of cognitive function was carried out. RESULTS The study revealed no significant difference between the two groups for any of the outcomes, but with a visible trend to lower scores for MDI after treatment in the placebo group. The negative impact of ECT on neurocognitive functions was short lived and scores on logical memory were significantly improved compared to baseline 4 weeks after last treatment. The ECT-rTMS group revealed generally less impairment of cognitive functions than the ECT-placebo group. CONCLUSION The addition of low frequency rTMS as an add-on to ECT treatment did not result in an accelerated response. On the contrary, the results suggest that low frequency rTMS could inhibit the antidepressant effect of ECT.",2020,The negative impact of ECT on neurocognitive functions was short lived and scores on logical memory were significantly improved compared to baseline 4 weeks after last treatment.,['thirty-five patients with major depression'],"['ECT-placebo', 'ECT', 'ECT+placebo or ECT+ low frequency right prefrontal rTMS', 'placebo']","['MDI', 'severity of depression', 'neurocognitive functions', 'impairment of cognitive functions', 'logical memory']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205213', 'cui_str': 'Low frequency'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0993596', 'cui_str': 'Metered dose inhaler'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",35.0,0.0316993,The negative impact of ECT on neurocognitive functions was short lived and scores on logical memory were significantly improved compared to baseline 4 weeks after last treatment.,"[{'ForeName': 'Poul Erik', 'Initials': 'PE', 'LastName': 'Buchholtz', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Ashkanian', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Hjerrild', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Line Kirstine', 'Initials': 'LK', 'LastName': 'Hauptmann', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Torben', 'Initials': 'T', 'LastName': 'Devantier', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Paulina', 'Initials': 'P', 'LastName': 'Jensen', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Sanne', 'Initials': 'S', 'LastName': 'Wissing', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Mette', 'Initials': 'M', 'LastName': 'Thorgaard', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Speed', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Rene Børge Korsgaard', 'Initials': 'RBK', 'LastName': 'Brund', 'Affiliation': 'Department for Affective Disorders, Aarhus University Hospital, Denmark.'}, {'ForeName': 'Poul', 'Initials': 'P', 'LastName': 'Videbech', 'Affiliation': 'Center for Neuropsychiatric Depression Research, Mental Health Center Glostrup, Denmark.'}]",Acta neuropsychiatrica,['10.1017/neu.2020.28'] 2332,32713395,Nocturnal whey protein ingestion impairs postprandial glucose tolerance at breakfast.,"Poor postprandial glucose control is a risk factor for multiple health conditions. The second-meal effect refers to the progressively improved glycaemic control with repeated feedings, an effect which is achievable with protein ingestion at the initial eating occasion. The most pronounced glycaemic response each day therefore typically occurs following breakfast, so this study investigated whether ingesting protein during the night could improve glucose control at the first meal of the day. In a randomised cross-over design, fifteen adults (7 males, 8 females; age, 22 ± 3 years; BMI, 24.0 ± 2.8 kg·m-2; fasting blood glucose, 4.9 ± 0.5 mmol·L-1) woke at 0400 ± 1 h to ingest 300 ml water with or without 63 g whey protein. Participants then completed a mixed-macronutrient meal tolerance test (1 g carbohydrate·kg body mass-1, 563 ± 104 kcal,) 5 h 39 min following the nocturnal feeding. Nocturnal protein ingestion increased the glycaemic response (incremental area under curve) to breakfast by 43.5 ± 55.5 mmol•120 min•L-1 (p=0.009, d=0.94). Consistent with this effect, individual peak blood glucose concentrations were 0.6 ± 1.0 mmol·L-1 higher following breakfast when protein had been ingested (p=0.049, d=0.50). Immediately prior to breakfast, rates of lipid oxidation were 0.02 ± 0.03 g·min-1 higher (p=0.045) in the protein condition, followed by an elevated postprandial energy expenditure (0.09 ± 0.12 kcal·min-1, p=0.018). Postprandial appetite and energy intake were similar between conditions. This study reveals a paradoxical second-meal phenomenon whereby nocturnal whey protein feeding impaired subsequent glucose tolerance, whilst increasing postprandial energy expenditure.",2020,"Nocturnal protein ingestion increased the glycaemic response (incremental area under curve) to breakfast by 43.5 ± 55.5 mmol•120 min•L-1 (p=0.009, d=0.94).","['fifteen adults (7 males, 8 females; age, 22 ± 3 years; BMI, 24.0 ± 2.8 kg·m-2; fasting blood glucose, 4.9 ± 0.5 mmol·L-1) woke at 0400 ± 1 h to ingest 300 ml water with or without 63 g whey protein']",['Nocturnal whey protein ingestion'],"['elevated postprandial energy expenditure', 'individual peak blood glucose concentrations', 'glycaemic response', 'postprandial glucose tolerance', 'Postprandial appetite and energy intake', 'rates of lipid oxidation', 'postprandial energy expenditure', 'subsequent glucose tolerance']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}]","[{'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C2585282', 'cui_str': 'Blood glucose concentration'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0030011', 'cui_str': 'Oxidation'}, {'cui': 'C0332282', 'cui_str': 'Following'}]",15.0,0.0144562,"Nocturnal protein ingestion increased the glycaemic response (incremental area under curve) to breakfast by 43.5 ± 55.5 mmol•120 min•L-1 (p=0.009, d=0.94).","[{'ForeName': 'Eleanor S', 'Initials': 'ES', 'LastName': 'Smith', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Adama', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'Keeley', 'Initials': 'K', 'LastName': 'Clayton', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Holbrey', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Palubiski', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'Harry A', 'Initials': 'HA', 'LastName': 'Smith', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'Javier T', 'Initials': 'JT', 'LastName': 'Gonzalez', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Betts', 'Affiliation': 'Department for Health, University of Bath, BA2 7AY.'}]",The British journal of nutrition,['10.1017/S0007114520002901'] 2333,32713466,Randomized prospective evaluation of the use of tranexamic acid and effects on blood loss for proximal humeral fracture surgery.,"BACKGROUND Tranexamic acid (TXA) is an antifibrinolytic agent that has been used to reduce blood loss in orthopedic surgery. It has been shown to decrease blood loss in upper- and lower-extremity arthroplasty, as well as lower-extremity fracture surgery. The use of TXA for proximal humeral fracture surgery has yet to be evaluated. The purpose of this study was to examine the effects of TXA on blood loss in patients undergoing open reduction-internal fixation (ORIF) or arthroplasty for the treatment of proximal humeral fractures. MATERIALS AND METHODS A total of 101 patients were randomized to receive either a single preoperative dose of intravenous TXA (53 patients) or a control dose of saline solution (48 patients) at the time of proximal humeral fracture surgery. On the basis of patient age and fracture pattern, ORIF was performed in 57 patients (30 TXA and 27 control patients) and reverse shoulder arthroplasty (RSA) was performed in the other 44 patients (23 TXA and 21 control patients). Intraoperative blood loss plus 24-hour drain output was used to calculate total blood loss for each procedure. The preoperative-to-postoperative change in hemoglobin level was also evaluated for each patient. Further stratification of blood loss and change in hemoglobin level based on procedure (ORIF or RSA) was performed as well. RESULTS Compared with the control group, the TXA group had less average intraoperative blood loss (178 mL vs. 129 mL, P < .0001), less postoperative drain output (103 mL vs. 62 mL, P < .0001), and less total blood loss (280 mL vs. 188 mL, P < .0001). Compared with the control group, the TXA group had a smaller average preoperative-to-postoperative change in hemoglobin level (-2.6 g/dL vs. -1.5 g/dL, P < .0001). Further stratification based on procedure showed that among patients undergoing ORIF and patients undergoing RSA, those receiving TXA had less average total blood loss and a smaller decrease in hemoglobin level than the control group. No identifiable intraoperative or postoperative complications associated with the use of TXA occurred in any patient. CONCLUSION TXA was effective in reducing total blood loss and led to a smaller preoperative-to-postoperative decrease in hemoglobin level compared with control in patients undergoing surgery for proximal humeral fractures. This effect was consistent in patients treated with either ORIF or arthroplasty as the surgical procedure. TXA can be used to decrease blood loss in the surgical treatment of proximal humeral fractures.",2020,TXA was effective in reducing total blood loss and led to a smaller preoperative-to-postoperative decrease in hemoglobin level compared with control in patients undergoing surgery for proximal humeral fractures.,"['patients undergoing surgery for proximal humeral fractures', 'proximal humeral fractures', '101 patients', 'patients undergoing open reduction-internal fixation (ORIF) or arthroplasty for the treatment of proximal humeral fractures', 'proximal humeral fracture surgery', '57 patients (30 TXA and 27 control patients) and reverse shoulder arthroplasty (RSA) was performed in the other 44 patients (23 TXA and 21 control patients']","['ORIF or arthroplasty', 'TXA', 'control dose of saline solution', 'intravenous TXA', 'Tranexamic acid (TXA', 'tranexamic acid']","['total blood loss', 'blood loss and change in hemoglobin level based on procedure (ORIF or RSA', 'intraoperative or postoperative complications', 'average total blood loss', 'smaller average preoperative-to-postoperative change in hemoglobin level', 'postoperative drain output', 'hemoglobin level', 'average intraoperative blood loss', 'blood loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0037006', 'cui_str': 'Fracture of shoulder'}, {'cui': 'C1297885', 'cui_str': 'Open reduction with internal fixation'}, {'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0186662', 'cui_str': 'Arthroplasty of shoulder'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0003893', 'cui_str': 'Arthroplasty'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0232100', 'cui_str': 'Exsanguination'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0186662', 'cui_str': 'Arthroplasty of shoulder'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0013103', 'cui_str': 'Drainage procedure'}, {'cui': 'C3251815', 'cui_str': 'Measurement of fluid output'}]",101.0,0.067363,TXA was effective in reducing total blood loss and led to a smaller preoperative-to-postoperative decrease in hemoglobin level compared with control in patients undergoing surgery for proximal humeral fractures.,"[{'ForeName': 'Derek J', 'Initials': 'DJ', 'LastName': 'Cuff', 'Affiliation': 'Suncoast Orthopaedic Surgery and Sports Medicine, Venice, FL, USA. Electronic address: dcuff001@hotmail.com.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Simon', 'Affiliation': 'Foundation for Orthopaedic Research and Education, Tampa, FL, USA; Department of Medical Engineering, University of South Florida, Tampa, FL, USA.'}, {'ForeName': 'R Allen', 'Initials': 'RA', 'LastName': 'Gorman', 'Affiliation': 'Foundation for Orthopaedic Research and Education, Tampa, FL, USA.'}]",Journal of shoulder and elbow surgery,['10.1016/j.jse.2020.04.016'] 2334,32713467,"Suprascapular nerve decompression in addition to rotator cuff repair: a prospective, randomized observational trial.","BACKGROUND Tear and retraction of the supraspinatus (SS) and infraspinatus (IS) musculotendinous units and/or their repair may be associated with traction damage to the suprascapular nerve, potentially responsible for pain or weakness of the rotator cuff (RC). Arthroscopic release of the transverse scapular ligament at the suprascapular notch has been advocated to prevent or treat suprascapular nerve impairment associated with RC retraction and/or repair. The effect of this procedure on preoperative normal nerve function is, however, not well studied.We hypothesize that (1) decompression of the suprascapular nerve without preoperative pathologic neurophysiological findings will not improve clinical or imaging outcome and (2) suprascapular decompression will not measurably change suprascapular nerve function. METHODS Nineteen consecutive patients with a magnetic resonance arthrography documented RC tear involving SS and IS but normal preoperative electromyography (EMG)/nerve conduction studies of the SS and IS were enrolled in a prospective, controlled trial involving RC repair with or without suprascapular nerve decompression at the suprascapular notch. Nine patients were randomized to undergo, and 10 not to undergo, a decompression of the suprascapular nerve. Patients were assessed clinically (Constant score, mobility, pain, strength, subjective shoulder value), with magnetic resonance imaging and neurophysiology preoperatively and at 3- and 12-month follow-up. RESULTS There was no clinically relevant difference between the release and the non-release group in any clinical parameter at any time point. At magnetic resonance imaging, there was a slightly greater increase of fatty infiltration of the IS in the release group without any other differences between the 2 groups. Electromyographically, there were no pathologic findings in the non-release group at any time point. Conversely, 3 of the 9 patients of the release group showed pathologic EMG findings at 3 months, of whom 2 had recovered fully and 1 only partially at 12 months. CONCLUSION In the presence of normal EMG findings, suprascapular nerve release added to arthroscopic RC repair is not associated with any clinical benefit, but with electromyographically documented, postoperative impairment of nerve function in 1 of 3 cases. Suprascapular nerve release does not therefore seem to be justified as an adjunct to RC repair if preoperative EMG findings document normal suprascapular nerve function. Based on these findings, the ongoing prospective randomized trial was terminated.",2020,There was no clinically relevant difference between the release and the non-release group in any clinical parameter at any time point.,"['rotator cuff repair', 'Nineteen consecutive patients with a\xa0magnetic resonance arthrography documented RC tear involving SS and IS but normal preoperative electromyography (EMG)/nerve conduction studies of the SS and IS']","['RC repair with or without suprascapular nerve decompression at the suprascapular notch', 'Suprascapular nerve decompression']","['pathologic\xa0EMG findings', 'fatty infiltration', 'clinically (Constant score, mobility, pain, strength, subjective shoulder value']","[{'cui': 'C0186666', 'cui_str': 'Repair of musculotendinous cuff of shoulder'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028580', 'cui_str': 'Nuclear Magnetic Resonance'}, {'cui': 'C0003885', 'cui_str': 'Arthrography'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0263912', 'cui_str': 'Rotator cuff syndrome'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0584882', 'cui_str': 'Infraspinatus muscle structure'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0232217', 'cui_str': 'Cardiac conduction'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0186666', 'cui_str': 'Repair of musculotendinous cuff of shoulder'}, {'cui': 'C0228878', 'cui_str': 'Structure of suprascapular nerve'}, {'cui': 'C0011117', 'cui_str': 'Decompression'}, {'cui': 'C0205316', 'cui_str': 'Notched'}]","[{'cui': 'C1521733', 'cui_str': 'Pathologic'}, {'cui': 'C0429339', 'cui_str': 'EMG finding'}, {'cui': 'C0333575', 'cui_str': 'Fatty infiltration'}, {'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",19.0,0.0640583,There was no clinically relevant difference between the release and the non-release group in any clinical parameter at any time point.,"[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Gerber', 'Affiliation': 'Department of Orthopaedics, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Dominik C', 'Initials': 'DC', 'LastName': 'Meyer', 'Affiliation': 'Department of Orthopaedics, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Wieser', 'Affiliation': 'Department of Orthopaedics, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Reto', 'Initials': 'R', 'LastName': 'Sutter', 'Affiliation': 'Department of Radiology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schubert', 'Affiliation': 'Department of Neurology, Balgrist University Hospital, University of Zürich, Zürich, Switzerland.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Kriechling', 'Affiliation': 'Department of Orthopaedics, Balgrist University Hospital, University of Zürich, Zürich, Switzerland. Electronic address: philipp.kriechling@balgrist.ch.'}]",Journal of shoulder and elbow surgery,['10.1016/j.jse.2020.03.051'] 2335,32713494,Year 1955: The first clinical trial into inflammatory diseases: Corticosteroids reduce mortality.,,2020,,[],[],[],[],[],[],,0.0275199,,"[{'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Gomollón', 'Affiliation': 'Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Clínico Universitario Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, España; Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, España; Departamento de Medicina, Universidad de Zaragoza, Zaragoza, España. Electronic address: fgomollon@gmail.com.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Marín-Jiménez', 'Affiliation': 'Unidad de Enfermedad Inflamatoria Intestinal, Servicio de Aparato Digestivo, Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, España.'}]",Gastroenterologia y hepatologia,['10.1016/j.gastrohep.2020.02.002'] 2336,32713518,Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.,"BACKGROUND According to the noninferiority result of chemoradiation with carboplatin in our previous nasopharyngeal carcinoma (NPC) study along with the inconclusive data on the efficacy of adjuvant chemotherapy (AC) following concurrent chemoradiotherapy (CCRT), we designed to assess the role of adjuvant carboplatin/fluorouracil following CCRT with carboplatin in locoregionally advanced NPC. MATERIALS AND METHODS A multicenter randomized trial was conducted at 5 cancer centers in Thailand. We enrolled in stage T2N0M0-T4N2M0 (American Joint Cancer Committee 7th edition) WHO Type 2 NPC patients. N3 or metastatic disease patients were excluded. Participants were randomized into 2 groups: CCRT plus AC group vs the CCRT alone group. Patients in both groups received weekly carboplatin 100 mg/m 2 for 6 cycles concurrently with radiotherapy 69.96-70 Gy. Patients in the AC group subsequently received 3 cycles of carboplatin area under curve-5 plus 1000 mg/m 2 /day of fluorouracil infusion within 96 hours every 3 weeks. We report the 2-year overall survival (OS), disease-free survival (DFS), loco-regional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS). Treatment-related toxicities and compliance were also explored. RESULTS Of 175 patients, 82 (46.9%) were assigned to the AC group, and 93 (53.1%) to the CCRT group. The compliance rate during CCRT was 90% and 86% in the AC and CCRT group, whereas 81.7% during adjuvant treatment in the AC group. With a median follow-up time of 24.4 months (interquartile range 17.9-24.4), the 2-year OS rate was 89.6% in the AC group and 81.8% in the CCRT group (P= 0.167). The 2-year DFS rate was 86.8% in the AC group and 74.6% in the CCRT group (P = 0.042). The 2-year LRFS rate was 91.5% in the AC group and 88.2% in the CCRT group (P = 0.443). The 2-year DMFS rate was 85.4% in the AC group and 79.6% in the CCRT group (P = 0.294). The most frequent serious (grade 3/4) nonhematologic toxicity was acute mucositis, which occurred 5% in the AC group vs 4% in the CCRT group (P = 0.498). For hematologic toxicity, grade 3-4 leukopenia were found 10% and 5% in the adjuvant and CCRT groups, respectively (P = 0.003). Multivariate analyses determined stage N2 disease was an adverse prognostic factor associated with shorter OS, DFS, and DMFS. And the adjuvant treatment was a significant protective factor for only DFS. CONCLUSIONS The addition of adjuvant carboplatin/fluorouracil following CCRT with carboplatin significantly improved 2-year DFS in stage T2N0M0-T4N2M0 NPC albeit there was a nonsignificant trend in favor of a higher 2-year OS, LRFS, and DMFS. Long-term efficacy and late toxicities of AC still require exploration.",2020,The addition of adjuvant carboplatin/fluorouracil following CCRT with carboplatin significantly improved 2-year DFS in stage T2N0M0-T4N2M0 NPC,"['nasopharyngeal cancer', 'N3 or metastatic disease patients', 'stage T2N0M0-T4N2M0 NPC', 'WHO Type 2 NPC patients', '5 cancer centers in Thailand']","['carboplatin 100 mg/m 2 for 6 cycles concurrently with radiotherapy 69.96-70 Gy', 'adjuvant chemotherapy (AC) following concurrent chemoradiotherapy (CCRT', 'carboplatin', 'carboplatin area under curve-5 plus 1000 mg/m 2 /day of fluorouracil infusion', 'adjuvant carboplatin/fluorouracil following CCRT with carboplatin', 'CCRT plus AC', 'concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil', 'carboplatin/fluorouracil following CCRT with carboplatin', 'CCRT']","['2-year OS rate', 'adverse prognostic factor associated with shorter OS, DFS, and DMFS', '2-year LRFS rate', '2-year overall survival (OS), disease-free survival (DFS), loco-regional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS', '2-year OS, LRFS, and DMFS', '2-year DFS', 'compliance rate during CCRT', 'hematologic toxicity, grade 3-4 leukopenia', 'nonhematologic toxicity', '2-year DMFS rate', 'acute mucositis', '2-year DFS rate']","[{'cui': 'C0153392', 'cui_str': 'Malignant tumor of nasopharynx'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039725', 'cui_str': 'Thailand'}]","[{'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1514474', 'cui_str': 'Prognostic Factors'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C1269798', 'cui_str': 'pM category'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C1290073', 'cui_str': 'Acute mucositis'}]",,0.0577889,The addition of adjuvant carboplatin/fluorouracil following CCRT with carboplatin significantly improved 2-year DFS in stage T2N0M0-T4N2M0 NPC,"[{'ForeName': 'Imjai', 'Initials': 'I', 'LastName': 'Chitapanarux', 'Affiliation': 'Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Chiang Mai Cancer Registry, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Electronic address: imjai.chitapanarux@cmu.ac.th.'}, {'ForeName': 'Rungarun', 'Initials': 'R', 'LastName': 'Kittichest', 'Affiliation': 'Division of Radiation Oncology, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand.'}, {'ForeName': 'Tharatorn', 'Initials': 'T', 'LastName': 'Tungkasamit', 'Affiliation': 'Udon Thani Cancer Hospital, Udon Thani, Thailand.'}, {'ForeName': 'Tussawan', 'Initials': 'T', 'LastName': 'Asakit', 'Affiliation': 'Lampang Cancer Hospital, Lampang, Thailand.'}, {'ForeName': 'Kittisak', 'Initials': 'K', 'LastName': 'Chomprasert', 'Affiliation': 'Chonburi Cancer Hospital, Chonburi, Thailand.'}, {'ForeName': 'Somvilai', 'Initials': 'S', 'LastName': 'Chakrabandhu', 'Affiliation': 'Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Wimrak', 'Initials': 'W', 'LastName': 'Onchan', 'Affiliation': 'Division of Radiation Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Northern Thai Research Group of Radiation Oncology (NTRG-RO), Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Patrinee', 'Initials': 'P', 'LastName': 'Traisathit', 'Affiliation': 'Research Center in Bioresources for Agriculture, Industry, and Medicine, Department of Statistics, Faculty of Science, Chiang Mai University, Chiang Mai, Thailand.'}]",Current problems in cancer,['10.1016/j.currproblcancer.2020.100620'] 2337,32713556,The effectiveness pre-operative exercise of muscle strength for early ambulation on lower limb fracture with measurement tool - The Modified Iowa Level of Assistance Scale (MILAS) - in hospital inpatients.,"OBJECTIVE To evaluate the effectiveness of pre-operative exercise of muscle strength before surgery, maintains muscle strength and prepare early postoperative ambulation lower limb fracture. METHOD Design research was a quasi-experiment with control and post-test only (unpaired t-test) with 28 respondents (14 respondents intervention group and 14 respondents control group). The intervention group was given muscle strength exercise before surgery, for ±1 week. Every day patients do strength exercise 3 times a day, for ±5-10min. The post-operative assessment was conducted in both groups with Modified Level of Assistance Scale (MILAS), to find out the difference in the ability to do early ambulation. RESULTS The results of the independent t-test were significant differences of ambulation ability of the intervention group were better than the control group. The difference in average ambulation ability after operation between the intervention group and the control group, the average ambulation ability of respondents in the intervention group was 14.14 with a standard deviation (SD=2.93), while for the control group, the average ambulation ability was 18.50 with the standard deviation (SD=5.56). Statistical test results obtained p-value of 0.017 (α<0.005), meaning that at alpha 5% a significant difference was seen in the average ability of early ambulation between respondents in the intervention group and the control group. CONCLUSION There is evidence to suggest that pre-operative exercise of muscle strength is beneficial to early ambulation postoperative lower limb fracture.",2020,The results of the independent t-test were significant differences of ambulation ability of the intervention group were better than the control group.,"['28 respondents (14 respondents intervention group and 14 respondents control group', 'hospital inpatients']",['muscle strength exercise'],"['average ability of early ambulation', 'ambulation ability', 'average ambulation ability']","[{'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0239966', 'cui_str': 'Hospital patient'}]","[{'cui': 'C0419118', 'cui_str': 'Muscle strength exercise'}]","[{'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0013457', 'cui_str': 'Ambulation, Early'}, {'cui': 'C0559964', 'cui_str': 'Ability to walk'}]",,0.0183389,The results of the independent t-test were significant differences of ambulation ability of the intervention group were better than the control group.,"[{'ForeName': '', 'Initials': '', 'LastName': 'Eldawati', 'Affiliation': 'Department of Medical Surgical Nursing, Kharisma Karawang High School of Health Sciences, Karawang, West Java, Indonesia. Electronic address: elda.arif@gmail.com.'}, {'ForeName': 'Uun', 'Initials': 'U', 'LastName': 'Nurjanah', 'Affiliation': 'Department of Medical Surgical Nursing, Kharisma Karawang High School of Health Sciences, Karawang, West Java, Indonesia.'}]",Enfermeria clinica,['10.1016/j.enfcli.2019.11.043'] 2338,32713850,Self-directed multimedia process for delivering participant informed consent.,"OBJECTIVE Obtaining informed consent is a cornerstone requirement of conducting ethical research. Traditional paper-based consent is often excessively lengthy and may fail to achieve the desired participant understanding of study requirements. Multimedia tools including video and audio may be a useful alternative. This study aimed to determine the efficacy, usability and acceptability of self-directed multimedia delivery of participant consent. DESIGN It is a single-centre, randomised, prospective study to determine the efficacy, usability and acceptability of a self-directed multimedia consent process (intervention) compared with the traditional paper-based approach (control). The intervention was free of research staff, with computer-based finger-signed consent. SETTING Pathology blood collection services in Tasmania, Australia. PARTICIPANTS 298 participants (63±8 years; 51% female individuals) referred from general practice were randomised to intervention (n=146) and control (n=152). OUTCOME MEASURES Efficacy, usability and acceptability of the allocated consent process were assessed by a questionnaire. RESULTS All participants successfully completed the allocated interventions. Efficacy parameters were higher among intervention participants, including a better understanding of study requirements compared with controls (p<0.05 all). Intervention participants were more likely to engage with the study information and spend more time on the consent process (p=<0.001 and p=0.006, respectively). Both groups reported similar levels of acceptability, although more control participants reported that the study information was too long (24% vs 14%; p=0.020). CONCLUSION A self-directed multimedia consent process is effective for achieving participant understanding and obtaining consent free of research staff. Thus, multimedia represents a viable method to reduce the burden on researchers, meet participant needs and achieve informed consent in clinical research.",2020,"Efficacy parameters were higher among intervention participants, including a better understanding of study requirements compared with controls (p<0.05 all).","['Pathology blood collection services in Tasmania, Australia', '298 participants (63±8 years; 51% female individuals) referred from general practice were randomised to intervention (n=146) and control (n=152']","['self-directed multimedia consent process (intervention', 'traditional paper-based approach (control']","['Efficacy, usability and acceptability of the allocated consent process', 'likely to engage with the study information and spend more time on the consent process', 'efficacy, usability and acceptability', 'Efficacy parameters', 'levels of acceptability']","[{'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0600644', 'cui_str': 'Collection'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0039335', 'cui_str': 'Tasmania'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086287', 'cui_str': 'Female'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0015607', 'cui_str': 'Family practice'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0376478', 'cui_str': 'Multimedium'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",298.0,0.0393312,"Efficacy parameters were higher among intervention participants, including a better understanding of study requirements compared with controls (p<0.05 all).","[{'ForeName': 'Niamh', 'Initials': 'N', 'LastName': 'Chapman', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Rebekah', 'Initials': 'R', 'LastName': 'McWhirter', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Matthew K', 'Initials': 'MK', 'LastName': 'Armstrong', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Fonseca', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Campbell', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Nelson', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'Martin G', 'Initials': 'MG', 'LastName': 'Schultz', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Sharman', 'Affiliation': 'Menzies Institute for Medical Research, College of Health and Medicine, University of Tasmania, Hobart, Tasmania, Australia James.Sharman@utas.edu.au.'}]",BMJ open,['10.1136/bmjopen-2020-036977'] 2339,32714001,Evaluation of a Novel Trocar-Site Closure Device in Laparoscopic Surgery.,"Background and Objectives We evaluated the effectiveness and safety of EZ-Close TM compared to those of hand suture for trocar-site closure according to obesity. Methods Fifty-four cases of laparoscopic colorectal surgery were enrolled. For the same patient, the right port site was closed using EZ-Close TM and left port site was closed by hand suture among cases with port-site diameter ≥10 mm. Cases switched to use of a conventional fascial closure device or with closure time 120 s were considered failures. Closure time was analyzed according to body mass index (BMI) and abdominal wall thickness (AWT). Results The mean closure time was significantly shorter with EZ-Close TM than with hand suture (87.9 ± 21.0 vs. 128.0 ± 59.0 s, p < 0.001). The number of failure cases was significantly lower with EZ-Close TM than with hand suture (7 vs. 27, p < 0.001). The closure time of EZ-Close TM was significantly shorter than that of hand suture in patients with BMI ≥ 25 and < 27 kg/m 2 (n = 15, 85.9 ± 19.8 vs. 135.6 ± 67.9 s, p < 0.014) and ≥ 27 kg/m 2 (n = 13, 85.1 ± 18.4 vs. 150.2 ± 70.6 s, p < 0.010). With respect to AWT, the closure time of EZ-Close TM was significantly shorter than that of hand suture in patients with AWT ≥ 20 and < 26 mm (n = 12, 81.1 ± 11.5 vs. 142.3 ± 83.7 s, p = 0.023) and ≥ 26 mm (n = 17, 85.6 ± 22.6 vs. 160.2 ± 55.5, p < 0.001). No infection and herniation were detected in both trocar sites during the follow-up period (median 20.4 months). Conclusion EZ-Close TM could provide time efficiency in trocar-site closure, especially in obese patients.",2020,"No infection and herniation were detected in both trocar sites during the follow-up period (median 20.4 months). ","['obese patients', 'Methods\n\n\nFifty-four cases of laparoscopic colorectal surgery were enrolled', 'Laparoscopic Surgery']","['Novel Trocar-Site Closure Device', 'conventional fascial closure device', 'EZ-Close TM']","['number of failure cases', 'mean closure time', 'closure time of EZ-Close TM', 'No infection and herniation', 'Closure time', 'body mass index (BMI) and abdominal wall thickness (AWT']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0041158', 'cui_str': 'Trocar'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0015641', 'cui_str': 'Fascial'}, {'cui': 'C0587267', 'cui_str': 'Closed'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C2712105', 'cui_str': 'Absence of signs and symptoms of infection'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0836916', 'cui_str': 'Abdominal wall structure'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",,0.0446081,"No infection and herniation were detected in both trocar sites during the follow-up period (median 20.4 months). ","[{'ForeName': 'Youngbae', 'Initials': 'Y', 'LastName': 'Jeon', 'Affiliation': 'Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Soohwa', 'Initials': 'S', 'LastName': 'Song', 'Affiliation': 'Department of Biomedical Engineering, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Kyoung-Won', 'Initials': 'KW', 'LastName': 'Han', 'Affiliation': 'Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Dong-Hyuk', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Biomedical Engineering, Gachon University College of Medicine, Incheon, Republic of Korea.'}, {'ForeName': 'Jeong-Heum', 'Initials': 'JH', 'LastName': 'Baek', 'Affiliation': 'Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.'}]",JSLS : Journal of the Society of Laparoendoscopic Surgeons,['10.4293/JSLS.2020.00033'] 2340,32714073,A Novel Nomogram Predicting Distant Metastasis in T1 and T2 Gallbladder Cancer: A SEER-based Study.,"Background: Gallbladder cancer (GBC) is the most common malignancy of the biliary system. Early T stage GBC patients with distant metastasis are proven to have a worse prognosis. In this study, our aim was to construct and validate a novel nomogram for predicting distant metastasis in T1 and T2 GBC. Methods: Between 2004 and 2014, patients with T1 and T2 GBC were identified in the Surveillance, Epidemiology, and End Results (SEER) database. All of the eligible patients were randomly divided into training and validation cohorts. Univariate and multivariate analyses were used to assess significant predictive factors associated with distant metastasis. A nomogram was developed and validated by a calibration curve and receptor operating characteristic curve (ROC) analysis. Results: According to the inclusion and exclusion criteria, 3013 patients with historically confirmed AJCC stage T1 and T2 GBC were enrolled. Younger age, high pathological grade, nonadenocarcinoma, T1, N1 and larger tumor size correlated positively with the risk of distant metastasis. A novel nomogram was established to predict distant metastasis in early T stage GBC patients. Internal validation with a calibration plot in the training cohort showed that this nomogram was well calibrated. Through ROC curve analysis, the areas under the ROC curves in the training and validation cohorts were 0.723 and 0.679, respectively. Conclusions: Although some limitations exist in this predictive model, the nomogram revealed the relationship between the clinicopathological characteristics of T1 and T2 GBC patients and the risk of distant metastasis. The novel nomogram will assist in patient counseling and guide treatment decision making for T1 and T2 GBC patients.",2020,The novel nomogram will assist in patient counseling and guide treatment decision making for T1 and T2 GBC patients.,"['T1 and T2 Gallbladder Cancer', '3013 patients with historically confirmed AJCC stage T1 and T2 GBC were enrolled', 'early T stage GBC patients', 'Early T stage GBC patients with distant metastasis']",[],[],"[{'cui': 'C0153452', 'cui_str': 'Malignant tumor of gallbladder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0441915', 'cui_str': 'AJCC'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0475455', 'cui_str': 'T - Tumor stage'}, {'cui': 'C1269798', 'cui_str': 'pM category'}]",[],[],3013.0,0.0351243,The novel nomogram will assist in patient counseling and guide treatment decision making for T1 and T2 GBC patients.,"[{'ForeName': 'Yu-Long', 'Initials': 'YL', 'LastName': 'Cai', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}, {'ForeName': 'Yi-Xin', 'Initials': 'YX', 'LastName': 'Lin', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}, {'ForeName': 'Li-Sheng', 'Initials': 'LS', 'LastName': 'Jiang', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Ye', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}, {'ForeName': 'Fu-Yu', 'Initials': 'FY', 'LastName': 'Li', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}, {'ForeName': 'Nan-Sheng', 'Initials': 'NS', 'LastName': 'Cheng', 'Affiliation': 'Department of Biliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.'}]",International journal of medical sciences,['10.7150/ijms.47073'] 2341,32714084,Efficacy of intermittent epidural dexamethasone bolus for zoster-associated pain beyond the acute phase.,"Herpes zoster develops when latent varicella zoster virus is reactivated in the trigeminal or dorsal root ganglions. Zoster-associated pain (ZAP) is neuropathic pain caused by the herpes zoster virus. Histological studies of postherpetic neuralgia patients suggest that inflammation is involved in ZAP. The effectiveness of local anesthetic and steroid epidural injections in ZAP patients has been reported. However, most studies included patients with acute herpes zoster, and the safety and therapeutic effects of different doses of epidural steroids in ZAP patients remain elusive. In this study, we randomly assigned 42 patients with severe ZAP beyond the acute phase, as determined by a numeric rating scale (NRS) score ≥7, to receive continuous epidural infusion of local anesthetics with either a one-time 5-mg dose or intermittent repeated doses (15 mg total) of dexamethasone. We found that intermittent repeated epidural dexamethasone bolus resulted in reduced NRS scores and an increased likelihood of complete remission in ZAP patients without any adverse effects. Thus, our results suggest that intermittent repeated epidural dexamethasone administration is safe and effective for treatment of ZAP beyond the acute phase.",2020,Herpes zoster develops when latent varicella zoster virus is reactivated in the trigeminal or dorsal root ganglions.,"['42 patients with severe ZAP beyond the acute phase, as determined by a numeric rating scale (NRS) score ≥7, to receive', 'postherpetic neuralgia patients', 'zoster-associated pain beyond the acute phase', 'ZAP patients']","['epidural dexamethasone', 'epidural steroids', 'intermittent epidural dexamethasone', 'Zoster-associated pain (ZAP', 'dexamethasone', 'continuous epidural infusion of local anesthetics with either a one-time 5-mg dose or intermittent repeated doses (15 mg total) of dexamethasone', 'local anesthetic and steroid epidural injections']","['likelihood of complete remission', 'NRS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0019360', 'cui_str': 'Herpes zoster'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439557', 'cui_str': 'Acute phase'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032768', 'cui_str': 'Postherpetic neuralgia'}]","[{'cui': 'C0228134', 'cui_str': 'Structure of epidural space of spine'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0038317', 'cui_str': 'Steroid'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0019360', 'cui_str': 'Herpes zoster'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0196394', 'cui_str': 'Epidural steroid injection'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",42.0,0.110377,Herpes zoster develops when latent varicella zoster virus is reactivated in the trigeminal or dorsal root ganglions.,"[{'ForeName': 'Eun Mi', 'Initials': 'EM', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Mi Hwa', 'Initials': 'MH', 'LastName': 'Chung', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Joo Hyun', 'Initials': 'JH', 'LastName': 'Jun', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Eun Hee', 'Initials': 'EH', 'LastName': 'Chun', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'In-Jung', 'Initials': 'IJ', 'LastName': 'Jun', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jong Hee', 'Initials': 'JH', 'LastName': 'Park', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Eun-Ha', 'Initials': 'EH', 'LastName': 'Choi', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Eun', 'Initials': 'JE', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.'}]",International journal of medical sciences,['10.7150/ijms.46038'] 2342,30536797,Single-Dose Pharmacokinetic Properties and Relative Bioavailability of Different Formulations of Posaconazole Oral Suspension in Healthy Volunteers.,"The rate and extent of absorption of drugs belonging to Biopharmaceutics Classification System class II are rate-limited by dissolution and highly dependent on the performance of the formulated product. The purpose of the present study was to investigate the potential impact of a surfactant and the particle size of the active substance on the in vitro drug dissolution profiles and in vivo pharmacokinetics of the poorly soluble drug posaconazole. A comparative physicochemical evaluation was conducted, and 3 formulations of posaconazole oral suspension were tested in various dissolution media compared with the reference product. In addition, a comparative bioavailability study was conducted in healthy volunteers under high-fat fed conditions. Bioequivalence was assessed based on plasma concentrations of the parent drug (posaconazole) measured by a validated high-pressure liquid chromatography-tandem mass spectrometry method. The 90% confidence intervals for C max and AUC 0-72 least-squares mean T/R ratios of all 3 posaconazole formulations were within the bioequivalence acceptance range of 80.00% to 125.00%. The study was useful in the formulation development process and demonstrated that neither surfactant type nor particle size of the active substance within the studied range affected the extent or rate of absorption of posaconazole under the tested fed conditions.",2019,The rate and extent of absorption of drugs belonging to Biopharmaceutics Classification System class II are rate-limited by dissolution and highly dependent on the performance of the formulated product.,"['Healthy Volunteers', 'healthy volunteers under high-fat fed conditions']","['posaconazole oral suspension', 'Posaconazole Oral Suspension']",['plasma concentrations of the parent drug (posaconazole'],"[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C1812974', 'cui_str': 'posaconazole Oral Suspension'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0936148', 'cui_str': 'posaconazole'}]",,0.0284824,The rate and extent of absorption of drugs belonging to Biopharmaceutics Classification System class II are rate-limited by dissolution and highly dependent on the performance of the formulated product.,"[{'ForeName': 'Lucija', 'Initials': 'L', 'LastName': 'Vuletić', 'Affiliation': 'R&D, PLIVA Croatia Ltd, TEVA Group Member, Zagreb, Croatia.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Herceg', 'Affiliation': 'R&D, PLIVA Croatia Ltd, TEVA Group Member, Zagreb, Croatia.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Ferderber', 'Affiliation': 'R&D, PLIVA Croatia Ltd, TEVA Group Member, Zagreb, Croatia.'}, {'ForeName': 'Iva', 'Initials': 'I', 'LastName': 'Tunjić', 'Affiliation': 'R&D, PLIVA Croatia Ltd, TEVA Group Member, Zagreb, Croatia.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Rizea-Savu', 'Affiliation': '3S-Pharmacological Consultation & Research GmbH, Harpstedt, Germany.'}, {'ForeName': 'Simona Nicoleta', 'Initials': 'SN', 'LastName': 'Duna', 'Affiliation': '3S-Pharmacological Consultation & Research GmbH, Harpstedt, Germany.'}, {'ForeName': 'Biserka', 'Initials': 'B', 'LastName': 'Cetina-Čižmek', 'Affiliation': 'R&D, PLIVA Croatia Ltd, TEVA Group Member, Zagreb, Croatia.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Filipović-Grčić', 'Affiliation': 'University of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Technology, Zagreb, Croatia.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.636'] 2343,30570431,Integrated Assessment of the Clinical Performance of GalNAc 3 -Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience.,"Advances in medicinal chemistry have produced new chemical classes of antisense oligonucleotides (ASOs) with enhanced therapeutic properties. Conjugation of the triantennary N-acetylgalactosamine (GalNAc 3 ) moiety to the extensively characterized phosphorothioate (PS)-modified 2'-O-methoxyethyl (2'MOE) ASO exemplifies such an advance. This structure-activity optimized moiety effects receptor-mediated uptake of the ASO prodrug through the asialoglycoprotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available from randomized placebo-controlled dose-ranging studies of this chemical class of ASOs administered systemically to healthy human volunteers. First, we compare the pharmacokinetic and pharmacodynamic profiles of a subset of the GalNAc 3 -conjugated PS-modified 2'MOE ASOs to the parent PS-modified 2'MOE ASOs for which plasma analytes are available. We then evaluate the safety profile of the full set of GalNAc 3 -conjugated PS-modified 2'MOE ASO conjugates by the incidence of signals in standardized laboratory tests and by the mean laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED 50 for the GalNAc 3 -conjugated PS-modified 2'MOE ASO subset ranges from 4 to 10 mg/week, up to 30-fold more potent than the parent PS-modified 2'MOE ASO. No GalNAc 3 -conjugated PS-modified 2'MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens. The increase in potency supports an increase in the safety margin for this new chemical class of ASOs now under broad investigation in the clinic. Although the total exposure is limited in the initial phase 1 trials, ongoing and future investigations in patient populations will support evaluation of the effects of long-term exposure.",2019,No GalNAc 3 -conjugated PS-modified 2'MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens.,"['Human Volunteer Experience', 'healthy human volunteers']","['placebo', 'triantennary N-acetylgalactosamine (GalNAc 3 ', 'GalNAc']",[],"[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0001055', 'cui_str': '2-Acetamido-2-D-galactopyranose'}, {'cui': 'C1612749', 'cui_str': 'phenyl 2-acetamido-2-deoxy-4-O-sulfonatogalactopyranoside'}]",[],,0.0237703,No GalNAc 3 -conjugated PS-modified 2'MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens.,"[{'ForeName': 'Stanley T', 'Initials': 'ST', 'LastName': 'Crooke', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Brenda F', 'Initials': 'BF', 'LastName': 'Baker', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Shuting', 'Initials': 'S', 'LastName': 'Xia', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Rosie Z', 'Initials': 'RZ', 'LastName': 'Yu', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Viney', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Yanfeng', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Sotirios', 'Initials': 'S', 'LastName': 'Tsimikas', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}, {'ForeName': 'Richard S', 'Initials': 'RS', 'LastName': 'Geary', 'Affiliation': 'Ionis Pharmaceuticals, Inc., Carlsbad, California.'}]",Nucleic acid therapeutics,['10.1089/nat.2018.0753'] 2344,30885824,Early blood transcriptomic signature predicts patients' outcome after out-of-hospital cardiac arrest.,"BACKGROUND Early prognostication is a major challenge after out-of-hospital cardiac arrest (OHCA). AIMS We hypothesized that a genome-wide analysis of blood gene expression could offer new prognostic tools and lines of research. METHODS Sixty-nine patients were enrolled from an ancillary study of the clinical trial NCT00999583 that tested the effect of erythropoietin (EPO) after OHCA. Blood samples were collected in comatose survivors of OHCA at hospital admission and 1 and 3 days after resuscitation. Gene expression profiles were analyzed (Illumina HumanHT-12 V4 BeadChip; >34,000 genes). Patients were classified into two categories representing neurological favorable outcome (cerebral performance category [CPC] = 1-2) vs unfavorable outcome (CPC > 2) at Day 60 after OHCA. Differential and functional enrichment analyses were performed to compare transcriptomic profiles between these two categories. RESULTS Among the 69 enrolled patients, 33 and 36 patients were treated or not by EPO, respectively. Among them, 42% had a favorable neurological outcome in both groups. EPO did not affect the transcriptomic response at Day-0 and 1 after OHCA. In contrast, 76 transcripts differed at Day-0 between patients with unfavorable vs favorable neurological outcome. This signature persisted at Day-1 after OHCA. Functional enrichment analysis revealed a down-regulation of adaptive immunity with concomitant up-regulation of innate immunity and inflammation in patients with unfavorable vs favorable neurological outcome. The transcription of many genes of the HLA family was decreased in patients with unfavorable vs favorable neurological outcome. Concomitantly, neutrophil activation and inflammation were observed. Up-stream regulators analysis showed the implication of numerous factors involved in cell cycle and damages. A logistic regression including a set of genes allowed a reliable prediction of the clinical outcomes (specificity = 88%; Hit Rate = 83%). CONCLUSIONS A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA. This deserves confirmation in a larger population.",2019,A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA.,"['Sixty-nine patients', 'Patients were classified into two categories representing neurological favorable outcome (cerebral performance category [CPC]\u2009=\u20091-2) vs unfavorable outcome (CPC\u2009>\u20092) at Day 60 after OHCA', '69 enrolled patients, 33 and 36 patients were treated or not by EPO, respectively', 'patients with unfavorable vs favorable neurological outcome']","['erythropoietin (EPO) after OHCA', 'EPO']","['favorable neurological outcome', 'Gene expression profiles', 'transcriptomic response', 'neutrophil activation and inflammation']","[{'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0056911', 'cui_str': ""cytidylyl-(3'-5')-cytidine""}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}]","[{'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}]","[{'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1449575', 'cui_str': 'Microarray Analysis'}, {'cui': 'C0242599', 'cui_str': 'Neutrophil Activation'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",69.0,0.0361291,A transcriptomic signature involving a counterbalance between adaptive and innate immune responses is able to predict neurological outcome very early after hospital admission after OHCA.,"[{'ForeName': 'Renaud', 'Initials': 'R', 'LastName': 'Tissier', 'Affiliation': ""Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France. Electronic address: renaud.tissier@inserm.fr.""}, {'ForeName': 'Hakim', 'Initials': 'H', 'LastName': 'Hocini', 'Affiliation': 'Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Tchitchek', 'Affiliation': 'Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France; CEA - Université Paris Sud 11 - INSERM U1184, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Infrastructure, F-92265 Fontenay-aux-Roses, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Deye', 'Affiliation': 'Medical ICU, Inserm U942, Lariboisiere Hospital, APHP, F-75010, Paris, France.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Legriel', 'Affiliation': 'Intensive Care Unit, Versailles Hospital, Le Chesnay, F-78150, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Pichon', 'Affiliation': 'Intensive Care Unit, University Hospital Dupuytren, Limoges, F-87042, France.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Daubin', 'Affiliation': 'CHU de Caen, Department of Medical Intensive Care, Caen, F-14000, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Hermine', 'Affiliation': 'Department of Hematology and INSERM U1163 CNRS ERL 8654, Imagine Institute and Necker Hospital, Paris, F-75015, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Carli', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie-Réanimation, Hôpital Universitaire Necker- Enfants Malades, Université Paris Descartes, F-75015, Paris, France.""}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Vivien', 'Affiliation': ""SAMU de Paris, Service d'Anesthésie-Réanimation, Hôpital Universitaire Necker- Enfants Malades, Université Paris Descartes, F-75015, Paris, France.""}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Tréluyer', 'Affiliation': 'Clinical Research Unit, Paris Centre and Paris Descartes University, Paris, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Lefebvre', 'Affiliation': 'Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.'}, {'ForeName': 'Pascaline', 'Initials': 'P', 'LastName': 'Tisserand', 'Affiliation': 'Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.'}, {'ForeName': 'Jean-Luc', 'Initials': 'JL', 'LastName': 'Dubois-Randé', 'Affiliation': ""Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France.""}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Berdeaux', 'Affiliation': ""Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France.""}, {'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Ghaleh', 'Affiliation': ""Inserm, U955, F94000, Créteil, France; Université Paris Est, UMR_S955, UPEC, Ecole Nationale Vétérinaire d'Alfort, F-94000, Créteil, France; APHP, Hôpitaux Universitaires Henri Mondor, Plateforme de Ressources Biologiques, F-94000, Créteil, France.""}, {'ForeName': 'Jean-Daniel', 'Initials': 'JD', 'LastName': 'Lelièvre', 'Affiliation': 'Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France.'}, {'ForeName': 'Yves', 'Initials': 'Y', 'LastName': 'Levy', 'Affiliation': 'Inserm, U955, F94000, Créteil, France; Vaccine Research Institute, Université Paris Est-Créteil, F-94000, Créteil, France. Electronic address: yves.levy@inserm.fr.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Cariou', 'Affiliation': 'Service de Réanimation Médicale, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Paris, France.'}]",Resuscitation,['10.1016/j.resuscitation.2019.03.006'] 2345,31162177,Context Association in Glaucoma Patients Using a Touch Screen.,"PRECIS The results showed that people with glaucoma are able to perform with high accuracy a context-association task on a touch screen. This device could be a new possibility for communication and for clinical assessment. BACKGROUND The present study was designed to investigate the ability of patients with glaucoma to use a touch screen to find and associate pictures with limited text. METHODS Eighty-four volunteers were recruited in 3 groups and tested binocularly or monocularly. Twenty-eight patients with binocular glaucoma (M=68.5 y) were selected with a visual acuity of 0.4 log MAR or better in each eye and visual field defects, with a mean deviation equal to or less than -6 dB in each eye. Twenty-eight age-matched controls (M=68.8 y) and 28 young controls (M=22.1 y) were also recruited (normal acuity; exclusion of ocular disease). The participants had to associate, by moving their index on a 22″ touch screen, a target on the unique scene (between 3 other distractor images) with a consistent background related to the target (eg, to match a fish with the sea). RESULTS The performances of the glaucomatous patients were significantly (P<0.01) impaired in monocular vision compared with binocular vision with regard to the exploration duration (+2 s), accuracy (-3% of correct response), and peak speed (-10 cm/s). However, with binocular vision, representing daily life conditions, exploration duration, deviation, movement duration, peak speed, and accuracy were not affected by glaucoma, as demonstrated by comparison with the age-matched group. CONCLUSIONS People with glaucoma are able to perform with high accuracy a context-association task on a touch screen. Many applications involving touch screen devices should provide new tools with limited text to help patients with visual disabilities.",2019,The results showed that people with glaucoma are able to perform with high accuracy a context-association task on a touch screen.,"['Glaucoma Patients Using a Touch Screen', 'Twenty-eight patients with binocular glaucoma (M=68.5\u2009y) were selected with a visual acuity of 0.4 log MAR or better in each eye and visual field defects, with a mean deviation equal to or less than -6\u2009dB in each eye', 'Eighty-four volunteers were recruited in 3 groups and tested binocularly or monocularly', 'patients with glaucoma', 'People with glaucoma', 'participants had to associate, by moving their index on a 22″ touch screen, a target on the unique scene (between 3 other distractor images) with a consistent background related to the target (eg, to match a fish with the sea', 'Twenty-eight age-matched controls (M=68.8\u2009y) and 28 young controls (M=22.1\u2009y) were also recruited (normal acuity; exclusion of ocular disease', 'patients with visual disabilities']",[],"['peak speed ', 'monocular vision', 'binocular vision, representing daily life conditions, exploration duration, deviation, movement duration, peak speed, and accuracy']","[{'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0152054', 'cui_str': 'Touch'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C2594855', 'cui_str': 'Binoculars'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0024782', 'cui_str': 'Marathi language'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C3887875', 'cui_str': 'Visual field defect'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0578671', 'cui_str': 'Does move'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205394', 'cui_str': 'Other'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0036493', 'cui_str': 'Sea'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0042797', 'cui_str': 'Monocular vision'}, {'cui': 'C0042794', 'cui_str': 'Binocular vision observable'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1280903', 'cui_str': 'Exploration procedure'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012727', 'cui_str': 'Displacement'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",84.0,0.0204908,The results showed that people with glaucoma are able to perform with high accuracy a context-association task on a touch screen.,"[{'ForeName': 'Quentin', 'Initials': 'Q', 'LastName': 'Lenoble', 'Affiliation': 'SCALab, CNRS-UMR 9193, Cognitive & Affective Sciences Laboratory, Université de Lille.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Rouland', 'Affiliation': 'SCALab, CNRS-UMR 9193, Cognitive & Affective Sciences Laboratory, Université de Lille.'}]",Journal of glaucoma,['10.1097/IJG.0000000000001297'] 2346,32713721,"Effects of time-restricted feeding on body weight, body composition and vital signs in low-income women with obesity: A 12-month randomized clinical trial.","BACKGROUND & AIMS Time-restricted feeding (TRF) studies usually are of short-term, involving heterogeneous populations, without a control group with similar energy restriction. Besides, it seldom assess vital signs such as body temperature and heart rate, which may be influenced by the fasting state. In this investigation, we assessed the long-term effects of TRF on body weight, body composition and vital signs of low-income women with obesity undergoing diets with the same energy deficit. METHODS Low-income women with obesity were randomly allocated to a group with a hypoenergetic diet and 12 h of TRF or to a group with only a hypoenergetic diet, for 12 months. Body fat and waist circumference were estimated using a tetrapolar electrical bioimpedance and an inelastic measuring tape, respectively, at baseline and after 4, 6 and 12 months of intervention. Systolic and diastolic blood pressure, heart rate, and axillary temperature were measured at baseline and 12 months of intervention. The energy content of the diets was determined based on the women's resting metabolic rate (by indirect calorimetry) and level of physical activity (by triaxial accelerometers). Effects were analyzed using an intention-to-treat approach. RESULTS Fifty-eight women were randomized and 31 (53.44%) were lost to follow-up at 12 months. Dropout rates were similar between groups. In the intention-to-treat analysis, there were no significant changes in the body weight after 12 months (Differences in changes from baseline between groups: -0.05 95%CI [-2.34; 2.24] Kg; p = 0.96). An increase in axillary temperature (0.40 °C, 95% CI [-0.14; 0.67]°C, p < 0.01), a reduction in the percentage of body fat (-1.64%, 95% CI [-3.08; -0.19]%, p = 0.02) and waist circumference (-2.57 cm, 95% CI [-5.73; 0.58] cm, p = 0.03 in the mixed model involving 4 measurements) were observed in the intervention group, when compared to the control group. CONCLUSIONS TRF showed no effects on weight loss. Nevertheless the findings on waist circumference and body fat, although not clinically meaningful, suggest that this strategy may help in the long-term management of obesity in this population, since it is an easy to apply intervention. Axillary temperature findings warrants further investigation. Registered under www.ensaiosclinicos.gov.br Identifier no. RBR-387v6v. TRIAL REGISTRATION http://www.ensaiosclinicos.gov.br/rg/RBR-387v6v/.",2020,"An increase in axillary temperature (0.40 °C, 95% CI","['low-income women with obesity', 'low-income women with obesity undergoing diets with the same energy deficit', 'Fifty-eight women', 'Low-income women with obesity']","['RBR-387v6v', 'TRF', 'time-restricted feeding', 'hypoenergetic diet and 12\xa0h of TRF or to a group with only a hypoenergetic diet']","['waist circumference', 'axillary temperature', 'body weight', 'Dropout rates', 'weight loss', 'body weight, body composition and vital signs', 'percentage of body fat', 'Body fat and waist circumference', 'Systolic and diastolic blood pressure, heart rate, and axillary temperature']","[{'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C4517817', 'cui_str': '58'}]","[{'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1531924', 'cui_str': 'Axillary temperature'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}]",58.0,0.141779,"An increase in axillary temperature (0.40 °C, 95% CI","[{'ForeName': 'Isabele Rejane', 'Initials': 'IR', 'LastName': 'de Oliveira Maranhão Pureza', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'André Eduardo', 'Initials': 'AE', 'LastName': 'da Silva Junior', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Dafiny Rodrigues', 'Initials': 'DR', 'LastName': 'Silva Praxedes', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Laís Gomes', 'Initials': 'LG', 'LastName': 'Lessa Vasconcelos', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Mateus', 'Initials': 'M', 'LastName': 'de Lima Macena', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Ingrid Sofia', 'Initials': 'IS', 'LastName': 'Vieira de Melo', 'Affiliation': 'Instituto Federal de Alagoas, Rua 17 de agosto, s/n, 57120-000, Satuba-AL, Brazil.'}, {'ForeName': 'Telma Maria', 'Initials': 'TM', 'LastName': 'de Menezes Toledo Florêncio', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil.'}, {'ForeName': 'Nassib Bezerra', 'Initials': 'NB', 'LastName': 'Bueno', 'Affiliation': 'Faculdade de Nutrição (FANUT) - Universidade Federal de Alagoas (UFAL), Campus AC Simões, 57072-900, Cidade Universitária, Maceió-AL, Brazil. Electronic address: nassib.bueno@fanut.ufal.br.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.036'] 2347,32713741,Adolescents' Health Perceptions of Natural American Spirit's On-the-Pack Eco-Friendly Campaign.,"PURPOSE Natural American Spirit (NAS) cigarettes, which have recently grown in popularity, are marketed as eco-friendly and natural. The present study examined whether NAS's on-the-pack messaging influences adolescents' health perceptions of the brand. METHODS In a mixed-factor design, adolescent participants (N = 1,003, ages 13-17, 75% female) were randomized to one of the six exposure conditions. All viewed images of an NAS and a Pall Mall (comparison brand) cigarette pack, but differed in pack color (blue, green, or gold/orange) and brand viewed first. Perceptions of pack logos, addictiveness, harms to the smoker, others, and the environment were assessed directly after viewing pack images for each brand. RESULTS Adolescents who perceived NAS as more pro-environment tended to perceive NAS cigarettes to be less addictive, r = -.19, p < .01. NAS cigarettes also were perceived as less addictive and better for the environment than Pall Mall. Most (90%) participants provided nature-friendly words (e.g., environment, recycle) when asked to describe logos on the NAS packs. In adjusted models, relative to Pall Mall, NAS was perceived as healthier for smokers, healthier for smokers' family and friends, and safer for the environment. Findings did not differ by pack color and ever tobacco use. CONCLUSIONS Adolescents perceived a health advantage for NAS cigarettes with its on-the-pack, eco-friendly and pro-health marketing. The findings are consistent with prior research with adults. Given the accumulating evidence of consumer misperceptions, eco-friendly messaging on cigarettes is a public health concern that warrants further consideration for regulatory intervention.",2020,"RESULTS Adolescents who perceived NAS as more pro-environment tended to perceive NAS cigarettes to be less addictive, r = -.19, p < .01.","[""adolescents' health perceptions of the brand"", 'adolescent participants (N\xa0= 1,003, ages 13-17, 75% female']",[],[],"[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],[],,0.0237241,"RESULTS Adolescents who perceived NAS as more pro-environment tended to perceive NAS cigarettes to be less addictive, r = -.19, p < .01.","[{'ForeName': 'Anna E', 'Initials': 'AE', 'LastName': 'Epperson', 'Affiliation': 'Division of Adolescent Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Wong', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Eric F', 'Initials': 'EF', 'LastName': 'Lambin', 'Affiliation': 'School of Earth, Energy & Environmental Sciences, and Woods Institute for the Environment, Stanford University, Stanford, California; Georges Lemaître Earth and Climate Research Centre, Earth and Life Institute, Université catholique de Louvain, Louvain-la-Neuve, Belgium.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Henriksen', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Baiocchi', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'June A', 'Initials': 'JA', 'LastName': 'Flora', 'Affiliation': 'Solutions Science Lab, Department of Pediatrics, Stanford University, Stanford, California.'}, {'ForeName': 'Judith J', 'Initials': 'JJ', 'LastName': 'Prochaska', 'Affiliation': 'Stanford Prevention Research Center, Department of Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: jpro@stanford.edu.'}]",The Journal of adolescent health : official publication of the Society for Adolescent Medicine,['10.1016/j.jadohealth.2020.06.033'] 2348,32713772,Effects of a Humanoid Companion Robot on Dementia Symptoms and Caregiver Distress for Residents in Long-Term Care.,"OBJECTIVES To test the effects of deploying a humanoid companion robot (Kabochan) in comparison with usual care for long-term care facilities' residents with dementia. DESIGN A 2-arm, randomized controlled trial with ABAB withdrawal design, lasting 32 weeks. After an 8-week baseline period, Kabochan was introduced in a nonfacilitated, individual approach with experimental-group participants (n = 52) for 8 weeks, then removed for 8 weeks, and then reintroduced for another 8 weeks. The control group (n = 51) received the usual standardized care. SETTING AND PARTICIPANTS Seven long-term care facilities in Hong Kong. 103 residents (76% women, 87.2 ± 7.4 years) with a clinical diagnosis of dementia. MEASURES Outcome assessments occurred at 5 time points: baseline (week 1) and the end of each phase (weeks 8, 16, 24, and 32). Primary outcomes were assessed with the Neuropsychiatric Inventory Questionnaire (symptom severity and caregiver distress subscales) and the Geriatric Depression Scale; secondary outcomes were measured by the Hong Kong Montreal Cognitive Assessment 5-minute Protocol, the Modified Barthel Index for Activities of Daily Living, and the Quality of Life-Alzheimer's disease scale. RESULTS A multivariate analysis of variance indicated a statistically significant group × time interaction for neuropsychiatric-related caregiver distress at week 16 (F = 6.72, P = .011), with a moderate effect size (η p 2  = 0.06). When Kabochan was removed in the withdrawal phase (weeks 17-24), the neuropsychiatric symptoms became more severe at week 24 for the intervention group (F = 4.68, P = .003), although the effect size was small to moderate (η p 2  = 0.04). No statistical between-group differences were found in other health outcomes. CONCLUSIONS AND IMPLICATIONS The Kabochan was potentially effective at reducing short-term neuropsychiatric symptoms and relevant caregiver distress for residents with dementia. An individualized care plan with continuous monitoring is required to integrate the humanoid robot into routine dementia care.",2020,The Kabochan was potentially effective at reducing short-term neuropsychiatric symptoms and relevant caregiver distress for residents with dementia.,"['Residents in Long-Term Care', 'residents with dementia', '103 residents (76% women, 87.2\xa0±\xa07.4\xa0years) with a clinical diagnosis of dementia', ""comparison with usual care for long-term care facilities' residents with dementia"", 'Seven long-term care facilities in Hong Kong']","['usual standardized care', 'Humanoid Companion Robot', 'humanoid companion robot (Kabochan', 'Kabochan']","[""Neuropsychiatric Inventory Questionnaire (symptom severity and caregiver distress subscales) and the Geriatric Depression Scale; secondary outcomes were measured by the Hong Kong Montreal Cognitive Assessment 5-minute Protocol, the Modified Barthel Index for Activities of Daily Living, and the Quality of Life-Alzheimer's disease scale"", 'neuropsychiatric symptoms became more severe', 'neuropsychiatric-related caregiver distress', 'Dementia Symptoms and Caregiver Distress']","[{'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517858', 'cui_str': '7.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0336537', 'cui_str': 'Robot'}]","[{'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451019', 'cui_str': 'Barthel index'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4285807', 'cui_str': 'Behavioral and psychological symptoms of dementia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",103.0,0.0940314,The Kabochan was potentially effective at reducing short-term neuropsychiatric symptoms and relevant caregiver distress for residents with dementia.,"[{'ForeName': 'Ke', 'Initials': 'K', 'LastName': 'Chen', 'Affiliation': 'Sau Po Centre on Ageing, the University of Hong Kong, Hong Kong, China.'}, {'ForeName': 'Vivian Wei-Qun', 'Initials': 'VW', 'LastName': 'Lou', 'Affiliation': 'Sau Po Centre on Ageing, the University of Hong Kong, Hong Kong, China; Social Work and Social Administration, the University of Hong Kong, Pok Fu Lam, Hong Kong, China. Electronic address: wlou@hku.hk.'}, {'ForeName': 'Kelvin Cheng-Kian', 'Initials': 'KC', 'LastName': 'Tan', 'Affiliation': 'Social Work and Social Administration, the University of Hong Kong, Pok Fu Lam, Hong Kong, China.'}, {'ForeName': 'Man-Yi', 'Initials': 'MY', 'LastName': 'Wai', 'Affiliation': 'Hong Kong Sheng Kung Hui Welfare Council Ltd, Hong Kong, China.'}, {'ForeName': 'Lai-Lok', 'Initials': 'LL', 'LastName': 'Chan', 'Affiliation': 'Hong Kong Sheng Kung Hui Welfare Council Ltd, Hong Kong, China.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.05.036'] 2349,32713797,The evaluation of a surgery and the short-term benefits of a new active bone conduction hearing implant - the Osia®.,"INTRODUCTION Modern medicine offers a wide spectrum of different hearing devices, and bone conduction implants can be found among them. OBJECTIVE The presentation of the outcomes of the implantation of a new active bone conduction hearing implant - the Osia®, and its comparison with the well-known passive transcutaneous system - the Baha® Attract. MATERIALS AND METHODS Eight adult patients with bilateral mixed hearing loss were randomly divided into two groups. Group 1 was implanted with the Osia®, and group 2 was implanted with the Baha® Attract. The details of the surgery were analyzed, along with the functional and audiological results. RESULTS In all the cases, the surgery was successful, and the healing uneventful. In both groups, it was observed that pure tone audiometry and speech audiometry in free field improved significantly after the implantation (mean gain in pure tone audiometry for the Osia group 42.8 dB SPL and for the Baha group 38.8 dB SPL). In the Osia group, the results after the surgery were much better than with the Baha® 5 Power processor on the Softband. The patients implanted with the Osia® evaluated the quality of their hearing as being superior to those implanted with the Baha® Attract. There was an evident improvement in the abbreviated profile of hearing aid benefit questionnaire and in the speech, spatial and qualities of hearing scale for both systems. In the abbreviated profile of hearing aid benefit, changes were more evident in the Osia group (in global score 49% vs. 37.2%). CONCLUSIONS Implantation of the Osia® is an effective treatment option for the patients with bilateral mixed hearing loss. The surgery is safe but more complex and time-consuming than the Baha® Attract implantation. The preliminary audiological results as well as the overall quality of life indicate that the Osia® is a better solution than the Baha® Attract. However, future studies should be carried out to make further observations in a larger group of patients, and with longer follow-up.",2020,"There was an evident improvement in the abbreviated profile of hearing aid benefit questionnaire and in the speech, spatial and qualities of hearing scale for both systems.","['Eight adult patients with bilateral mixed hearing loss', 'patients with bilateral mixed hearing loss']","['new active bone conduction hearing implant - the Osia®', 'Osia®']","['abbreviated profile of hearing aid benefit questionnaire and in the speech, spatial and qualities of hearing scale', 'quality of their hearing', 'healing uneventful', 'pure tone audiometry and speech audiometry']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0452153', 'cui_str': 'Mixed conductive and sensorineural hearing loss, bilateral'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0005935', 'cui_str': 'Bone conduction'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0018768', 'cui_str': 'Hearing aid'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0004292', 'cui_str': 'Pure tone audiometry'}, {'cui': 'C0004293', 'cui_str': 'Speech audiometry'}]",8.0,0.0162416,"There was an evident improvement in the abbreviated profile of hearing aid benefit questionnaire and in the speech, spatial and qualities of hearing scale for both systems.","[{'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Gawęcki', 'Affiliation': 'Poznań University of Medical Sciences, Department of Otolaryngology and Laryngological Oncology, Poznań, Poland. Electronic address: wojgaw@interia.pl.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Gibasiewicz', 'Affiliation': 'Poznań University of Medical Sciences, Department of Otolaryngology and Laryngological Oncology, Poznań, Poland.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Marszał', 'Affiliation': 'Poznań University of Medical Sciences, Department of Otolaryngology and Laryngological Oncology, Poznań, Poland.'}, {'ForeName': 'Magdalena', 'Initials': 'M', 'LastName': 'Błaszczyk', 'Affiliation': 'Medicus sp. z o.o., Wrocław, Poland; University of Silesia in Katowice, Katowice, Poland.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gawłowska', 'Affiliation': 'Medicus sp. z o.o., Wrocław, Poland.'}, {'ForeName': 'Małgorzata', 'Initials': 'M', 'LastName': 'Wierzbicka', 'Affiliation': 'Poznań University of Medical Sciences, Department of Otolaryngology and Laryngological Oncology, Poznań, Poland.'}]",Brazilian journal of otorhinolaryngology,['10.1016/j.bjorl.2020.05.021'] 2350,32713846,Preferences for different diagnostic modalities to follow up abnormal colorectal cancer screening results: a hypothetical vignette study.,"OBJECTIVES In England, a significant proportion of people who take part in the national bowel cancer screening programme (BCSP) and have a positive faecal occult blood test (FOBt) result, do not attend follow-up colonoscopy (CC). The aim of this study was to investigate differences in intended participation in a follow-up investigation by diagnostic modality offered including CC, CT colonography (CTC) or capsule endoscopy (CE). SETTING We performed a randomised online experiment with individuals who had previously completed an FOBt as part of the English BCSP. METHODS Participants (n=953) were randomly allocated to receive one of three online vignettes asking participants to imagine they had received an abnormal FOBt result, and that they had been invited for a follow-up test. The follow-up test offered was either: CC (n=346), CTC (n=302) or CE (n=305). Participants were then asked how likely they were to have their allocated test or if they refused, either of the other tests. Respondents were also asked to cite possible emotional and practical barriers to follow up testing. Multivariable logistic regression models were used to investigate intentions. RESULTS Intention to have the test was higher in the CTC group (96.7%) compared with the CC group (91.8%; OR 2.64; 95% CI 1.22 to 5.73). CTC was considered less 'off-putting' (OR 0.66, 95% CI 0.47 to 0.94) and less uncomfortable compared with CC (OR 0.51, 95% CI 0.34 to 0.77). For those who did not intend to have the test they were offered, CE (39.7%) or no investigation (34.5%) was preferable to CC (8.6%) or CTC (17.2%). CONCLUSIONS Alternative tests have the potential to increase attendance at diagnostic follow-up appointments.",2020,"RESULTS Intention to have the test was higher in the CTC group (96.7%) compared with the CC group (91.8%; OR 2.64; 95% CI 1.22 to 5.73).","['Participants (n=953', 'individuals who had previously completed an FOBt as part of the English BCSP']","['online vignettes asking participants to imagine they had received an abnormal FOBt result, and that they had been invited for a follow-up test', 'CC, CT colonography (CTC) or capsule endoscopy (CE']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0346627', 'cui_str': 'Malignant tumor of intestine'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0201811', 'cui_str': 'Screening for occult blood in feces'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009378', 'cui_str': 'Colonoscopy'}, {'cui': 'C0935912', 'cui_str': 'Computed Tomographic Colonography'}, {'cui': 'C1721048', 'cui_str': 'Capsule endoscopy'}]",[],953.0,0.0915537,"RESULTS Intention to have the test was higher in the CTC group (96.7%) compared with the CC group (91.8%; OR 2.64; 95% CI 1.22 to 5.73).","[{'ForeName': 'Aradhna', 'Initials': 'A', 'LastName': 'Kaushal', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Sandro Tiziano', 'Initials': 'ST', 'LastName': 'Stoffel', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kerrison', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'von Wagner', 'Affiliation': 'Research Department of Behavioural Science and Health, University College London, London, UK c.wagner@ucl.ac.uk.'}]",BMJ open,['10.1136/bmjopen-2019-035264'] 2351,32713847,Evaluation of the teaching recovery techniques community-based intervention for accompanied refugee children experiencing post-traumatic stress symptoms (Accompanied refugeeS In Sweden Trial; ASsIST): study protocol for a cluster randomised controlled trial.,"BACKGROUND Refugee children have often experienced traumas and are at significant risk of developing mental health problems, such as symptoms of post-traumatic stress disorder (PTSD), depression and anxiety, which can continue for years after resettlement. The Accompanied refugeeS In Sweden Trial (ASsIST) aims to evaluate a community-based intervention, called 'Teaching Recovery Techniques' (TRT), for accompanied refugee minors experiencing PTSD symptoms. METHODS/DESIGN A cluster randomised controlled trial will be conducted in which participants will be randomly allocated to one of the two possible arms: the intervention arm (n=113) will be offered the TRT programme and the waitlist-control arm (n=113) will receive services as usual, followed by the TRT programme around 20 weeks later. Outcome data will be collected at three points: pre-intervention (T1), post-intervention (T2; c.8 weeks after randomisation) and follow-up (T3; c.20 weeks after randomisation). ETHICS AND DISSEMINATION Ethical approval was granted by the Regional Ethical Review Board in Uppsala (Ref. 2018/382) (24 th February 2019). Results will be published in scientific journals. TRIAL REGISTRATION DETAILS ISRCTN17754931. Prospectively registered on 4 th June 2019.",2020,"The Accompanied refugeeS In Sweden Trial (ASsIST) aims to evaluate a community-based intervention, called 'Teaching Recovery Techniques' (TRT), for accompanied refugee minors experiencing PTSD symptoms. ","['accompanied refugee children experiencing post-traumatic stress symptoms (Accompanied refugeeS', '2018/382']","['TRT programme and the waitlist-control arm (n=113) will receive services as usual, followed by the TRT programme', 'teaching recovery techniques community-based intervention']",[],"[{'cui': 'C0034961', 'cui_str': 'Refugee'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}]","[{'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.230725,"The Accompanied refugeeS In Sweden Trial (ASsIST) aims to evaluate a community-based intervention, called 'Teaching Recovery Techniques' (TRT), for accompanied refugee minors experiencing PTSD symptoms. ","[{'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Warner', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden georgina.warner@pubcare.uu.se.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Durbeej', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Raziye', 'Initials': 'R', 'LastName': 'Salari', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Fängström', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Elin', 'Initials': 'E', 'LastName': 'Lampa', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Zaruhi', 'Initials': 'Z', 'LastName': 'Baghdasaryan', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Fatumo', 'Initials': 'F', 'LastName': 'Osman', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Gupta Löfving', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Perez Aronsson', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Inna', 'Initials': 'I', 'LastName': 'Feldman', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Filipa', 'Initials': 'F', 'LastName': 'Sampaio', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Ssegonja', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Bjärtå', 'Affiliation': 'Department of Psychology, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Rondung', 'Affiliation': 'Department of Psychology, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Leiler', 'Affiliation': 'Department of Psychology, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Elisabet', 'Initials': 'E', 'LastName': 'Wasteson', 'Affiliation': 'Department of Psychology, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Calam', 'Affiliation': 'Division of Clinical Psychology, The University of Manchester, Manchester, UK.'}, {'ForeName': 'Brit', 'Initials': 'B', 'LastName': 'Oppedal', 'Affiliation': 'Division of Mental Health, Norwegian Institute of Public Health, Oslo, Norway.'}, {'ForeName': 'Brooks', 'Initials': 'B', 'LastName': 'Keeshin', 'Affiliation': 'Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Sarkadi', 'Affiliation': 'Child Health and Parenting, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.'}]",BMJ open,['10.1136/bmjopen-2019-035459'] 2352,32714220,Effects of Trazodone on Sleep Quality and Cognitive Function in Arteriosclerotic Cerebral Small Vessel Disease Comorbid With Chronic Insomnia.,"Background Chronic insomnia is common in patients with arteriosclerotic cerebral small vessel disease (CSVD) and aggravates the cognitive impairment caused by CSVD. Low-dose trazodone is effective in treating insomnia, but it is unclear whether it can also improve cognitive function in CSVD patients. This study was performed to explore the effects of trazodone on sleep quality and cognitive function in CSVD comorbid with chronic insomnia. Methods This was a randomized, double-blind, placebo-controlled pilot study. Forty patients suffering from arteriosclerotic CSVD and insomnia were recruited from an outpatient clinic. Participants were randomized individually to receive either trazodone (study group) or a placebo (control group) for 4 weeks. The primary outcome was the cognitive score on the Montreal Cognitive Assessment scale (MoCA). Secondary outcomes included sleep parameters measured with polysomnography (PSG) and the Pittsburgh Sleep Quality Index. Results Trazodone caused significantly better improvements in concentration and recall abilities, measured with MoCA, as well as in PSG parameters such as sleep efficiency, N3 sleep ratio, and sleep continuity than the placebo, with no significant differences in the occurrence of side effects. The improvement of sleep quality was correlated with increased concentration and recall abilities. Conclusions A low dose of trazodone seems acceptable and effective in reducing insomnia severity and improving concentration and recall abilities in this pilot study. The improvement of cognition could be achieved by alleviation of insomnia severity. Considering the high incidence of insomnia in CSVD patients, the results of this preliminary study support the use of low-dose trazodone to deal with insomnia and cognitive impairment in CSVD.",2020,"Results Trazodone caused significantly better improvements in concentration and recall abilities, measured with MoCA, as well as in PSG parameters such as sleep efficiency, N3 sleep ratio, and sleep continuity than the placebo, with no significant differences in the occurrence of side effects.","['Forty patients suffering from arteriosclerotic CSVD and insomnia were recruited from an outpatient clinic', 'patients with arteriosclerotic cerebral small vessel disease (CSVD', 'CSVD patients', 'CSVD comorbid with chronic insomnia', 'Arteriosclerotic Cerebral Small Vessel Disease Comorbid With Chronic Insomnia']","['trazodone', 'Trazodone', 'placebo']","['sleep efficiency, N3 sleep ratio, and sleep continuity', 'Sleep Quality and Cognitive Function', 'insomnia severity and improving concentration and recall abilities', 'cognitive function', 'cognitive score on the Montreal Cognitive Assessment scale (MoCA', 'sleep quality and cognitive function', 'sleep parameters measured with polysomnography (PSG) and the Pittsburgh Sleep Quality Index', 'concentration and recall abilities', 'sleep quality', 'occurrence of side effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2733158', 'cui_str': 'Small vessel cerebrovascular disease'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}]","[{'cui': 'C0040805', 'cui_str': 'Trazodone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0234451', 'cui_str': 'Non-rapid eye movement sleep'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0456391', 'cui_str': 'Continuities'}, {'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",40.0,0.0725576,"Results Trazodone caused significantly better improvements in concentration and recall abilities, measured with MoCA, as well as in PSG parameters such as sleep efficiency, N3 sleep ratio, and sleep continuity than the placebo, with no significant differences in the occurrence of side effects.","[{'ForeName': 'Jihui', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Psychiatry, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Sanxin', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Chongbang', 'Initials': 'C', 'LastName': 'Zhao', 'Affiliation': 'Department of Psychiatry, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Hongying', 'Initials': 'H', 'LastName': 'Han', 'Affiliation': 'Department of Psychiatry, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Xiaodong', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jiong', 'Initials': 'J', 'LastName': 'Tao', 'Affiliation': 'Department of Psychiatry, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zhengqi', 'Initials': 'Z', 'LastName': 'Lu', 'Affiliation': 'Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00620'] 2353,32714227,Intervention on Externalizing Problems of Undercontrolled Personality Types in Primary School Students.,"Three personality types (resilient, overcontrolled, and undercontrolled) have been repeatedly verified across different languages and cultures, different personality models, and different stages of development. Undercontrollers are socially maladapted types with high impulsivity and low self-control. Research shows they are at risk for externalizing problems, such as aggressiveness, impulsivity, and antisocial behavior. The aim of this study was to develop an intervention to reduce externalizing problems of undercontrolled personality types in primary school students. Participants were 69 undercontrolled primary school students from two primary schools in North China. The experimental group underwent 14 weeks of systematic experiential mental health activities, while the control group performed typical daily classroom activities. Personality and externalizing problem behaviors were measured before the intervention, at the end of the intervention, and 4 months post-intervention. The results showed that the intervention significantly reduced the level of externalizing problems of undercontrolled primary school students. The effects of the intervention were maintained at the 4-month follow-up. This study provides some reference and suggestions on how to intervene in the externalizing problem behaviors of undercontrolled primary school students.",2020,The results showed that the intervention significantly reduced the level of externalizing problems of undercontrolled primary school students.,"['undercontrolled primary school students', 'Participants were 69 undercontrolled primary school students from two primary schools in North China', 'primary school students', 'Primary School Students']","['systematic experiential mental health activities, while the control group performed typical daily classroom activities']","['Personality and externalizing problem behaviors', 'level of externalizing problems']","[{'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0033213', 'cui_str': 'Problem'}]",69.0,0.0205127,The results showed that the intervention significantly reduced the level of externalizing problems of undercontrolled primary school students.,"[{'ForeName': 'Yongjin', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'School of Philosophy and Sociology, Jilin University, Changchun, China.'}, {'ForeName': 'Lizhu', 'Initials': 'L', 'LastName': 'Yang', 'Affiliation': 'College of Psychology, Liaoning Normal University, Dalian, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'College of Psychology, Liaoning Normal University, Dalian, China.'}, {'ForeName': 'Chenhui', 'Initials': 'C', 'LastName': 'Jin', 'Affiliation': 'Bayi Primary School, Dalian, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Shidao Street Primary School, Dalian, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01233'] 2354,32714269,Exergaming With Integrated Head Turn Tasks Improves Compensatory Saccade Pattern in Some Patients With Chronic Peripheral Unilateral Vestibular Hypofunction.,"Background: This study aimed to determine whether vestibular rehabilitation using active video games (Exergames), including promoted head turns and unsupported locomotion, may facilitate vestibular compensation and gait in subjects with one-sided chronic peripheral vestibular hypofunction (cPVH). Methods: 12 patients with cPVH (mean age of 65 ± 12 years, 8 male) were recruited for this study. The study consisted of a four-week baseline control period T1-T2 followed by a four-week intervention period T2-T3. The intervention included exergames that required physical tasks such as steps, weight shifts or balance control to cognitive challenges, in a virtual environment to play the game. The subjects participated in a total of 176 min of exergaming in eight sessions. Because of the changing projection direction of the game to the wall, the subjects had to turn their heads constantly while playing the game. Dynamic visual acuity (DVA) was assessed. Vestibulo-Ocular reflex (VOR) gain deficit and cumulative overt saccade amplitude (COSA) were measured with the video head-impulse test. Additionally, the functional gait assessment (FGA), Extended Timed Get-Up-and-Go (ETGUG), and the Dizziness handicap inventory (DHI), were assessed. Results: DVA showed no significant group level change ( p = 0.475, z = -0.714, d = 0.295) with a small effect size and improvements in five out of 12 subjects. Ipsilesional VOR gain did not improve ( p = 0.157, z = -1.414, d = 0.481) on group level while there was an intermediate effect size and improvements in six out of 12 subjects. COSA got significant smaller ( p = 0.006, z = -2.746, d = 1.354) with improvements in seven out of 12 subjects. The contralesional sides did not change. The FGA for the group significantly improved with an intermediate effect size ( p < 0.001, z = -3.08, d = 1.617) and five individuals showed clinically relevant improvements. The ETGUG group value improved significantly with a strong effect size ( p < 0.001, z = -2.67, d = 1.030), with seven individuals contributing to this change. The DHI showed no change ( p = 0.172, z = -1.381, d = 0.592) neither on the group nor on the individuals' level. The game scores of the subjects improved during the intervention period of the intervention for every game. Conclusion: The results of this study demonstrate that exergaming with promoted head turns facilitates vestibular compensation in some subjects with cPVH. This is the first study that shows an improvement in cumulative overt saccade amplitude after exergaming in chronic vestibular subjects.",2020,"Ipsilesional VOR gain did not improve ( p = 0.157, z","['subjects with cPVH', 'subjects participated in a total of 176 min of exergaming in eight sessions', 'subjects with one-sided chronic peripheral vestibular hypofunction (cPVH', '12 patients with cPVH (mean age of 65 ± 12 years, 8 male', 'chronic vestibular subjects']","['Integrated Head Turn Tasks', 'physical tasks such as steps, weight shifts or balance control to cognitive challenges, in a virtual environment to play the game', 'vestibular rehabilitation using active video games (Exergames']","['functional gait assessment (FGA), Extended Timed Get-Up-and-Go (ETGUG), and the Dizziness handicap inventory (DHI', 'Ipsilesional VOR gain', 'Dynamic visual acuity (DVA', 'cumulative overt saccade amplitude', 'Vestibulo-Ocular reflex (VOR) gain deficit and cumulative overt saccade amplitude (COSA']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0560902', 'cui_str': 'Does turn head'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0200324', 'cui_str': 'Vestibular rehabilitation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0042649', 'cui_str': 'Video Games'}]","[{'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0231172', 'cui_str': 'Handicap'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034944', 'cui_str': 'Vestibulo-ocular reflex'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0042682', 'cui_str': 'Vindesine'}, {'cui': 'C0036019', 'cui_str': 'Saccadic eye movement'}]",12.0,0.0188566,"Ipsilesional VOR gain did not improve ( p = 0.157, z","[{'ForeName': 'Jaap', 'Initials': 'J', 'LastName': 'Swanenburg', 'Affiliation': 'Physiotherapy and Occupational Therapy Research Center, Directorate of Research and Education, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Fabienne', 'Initials': 'F', 'LastName': 'Büchi', 'Affiliation': 'Physiotherapy and Occupational Therapy Research Center, Directorate of Research and Education, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Dominik', 'Initials': 'D', 'LastName': 'Straumann', 'Affiliation': 'Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Konrad P', 'Initials': 'KP', 'LastName': 'Weber', 'Affiliation': 'Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Eling D', 'Initials': 'ED', 'LastName': 'de Bruin', 'Affiliation': 'Department Health Sciences and Technology, Institute of Human Movement Sciences and Sport, ETH Zurich, Zurich, Switzerland.'}]",Frontiers in neurology,['10.3389/fneur.2020.00601'] 2355,32714385,Increased Accuracy of Emotion Recognition in Individuals with Autism-Like Traits after Five Days of Magnetic Stimulations.,"Individuals with autism-like traits (ALT) belong to a subclinical group with similar social deficits as autism spectrum disorders (ASD). Their main social deficits include atypical eye contact and difficulty in understanding facial expressions, both of which are associated with an abnormality of the right posterior superior temporal sulcus (rpSTS). It is still undetermined whether it is possible to improve the social function of ALT individuals through noninvasive neural modulation. To this end, we randomly assigned ALT individuals into the real ( n = 16) and sham ( n = 16) stimulation groups. All subjects received five consecutive days of intermittent theta burst stimulation (iTBS) on the rpSTS. Eye tracking data and functional magnetic resonance imaging (fMRI) data were acquired on the first and sixth days. The real group showed significant improvement in emotion recognition accuracy after iTBS, but the change was not significantly larger than that in the sham group. Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS. At baseline, rsFC in the left cerebellum was negatively correlated with emotion recognition accuracy. Our findings indicated that iTBS of the rpSTS could improve emotion perception of ALT individuals by modulating associated neural networks. This stimulation protocol could be a vital therapeutic strategy for the treatment of ASD.",2020,Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS.,"['Individuals with Autism', 'Individuals with autism-like traits (ALT) belong to a subclinical group with similar social deficits as autism spectrum disorders (ASD']",['intermittent theta burst stimulation (iTBS'],"['Resting-state functional connectivity (rsFC', 'emotion perception', 'Accuracy of Emotion Recognition', 'emotion recognition accuracy']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0004352', 'cui_str': 'Autistic disorder'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}]","[{'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]",,0.0515315,Resting-state functional connectivity (rsFC) between the rpSTS and the left cerebellum significantly decreased in the real group than the sham group after iTBS.,"[{'ForeName': 'Pingping', 'Initials': 'P', 'LastName': 'Liu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Guixian', 'Initials': 'G', 'LastName': 'Xiao', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Kongliang', 'Initials': 'K', 'LastName': 'He', 'Affiliation': ""The Fourth People's Hospital of Hefei, Hefei 230000, China.""}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Xinqi', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Li', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Chunyan', 'Initials': 'C', 'LastName': 'Zhu', 'Affiliation': 'Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei 230032, China.'}, {'ForeName': 'Yanghua', 'Initials': 'Y', 'LastName': 'Tian', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Panpan', 'Initials': 'P', 'LastName': 'Hu', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Bensheng', 'Initials': 'B', 'LastName': 'Qiu', 'Affiliation': 'Centers for Biomedical Engineering, University of Science and Technology of China, Hefei 230000, China.'}, {'ForeName': 'Gong-Jun', 'Initials': 'GJ', 'LastName': 'Ji', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230000, China.'}]",Neural plasticity,['10.1155/2020/9857987'] 2356,32721104,Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.,"IMPORTANCE Retinal ganglion cells endure significant metabolic stress in glaucoma but maintain capacity to recover function. Nicotinamide, a precursor of NAD + , is low in serum of glaucoma patients and its supplementation provides robust protection of retinal ganglion cells in preclinical models. However, the potential of nicotinamide in human glaucoma is unknown. BACKGROUND To examine the effects of nicotinamide on inner retinal function in glaucoma, in participants receiving concurrent glaucoma therapy. DESIGN Crossover, double-masked, randomized clinical trial. Participants recruited from two tertiary care centres. PARTICIPANTS Fifty-seven participants, diagnosed and treated for glaucoma. METHODS Participants received oral placebo or nicotinamide and reviewed six-weekly. Participants commenced 6 weeks of 1.5 g/day then 6 weeks of 3.0 g/day followed by crossover without washout. Visual function measured using electroretinography and perimetry. MAIN OUTCOME MEASURES Change in inner retinal function, determined by photopic negative response (PhNR) parameters: saturated PhNR amplitude (Vmax), ratio of PhNR/b-wave amplitude (Vmax ratio). RESULTS PhNR Vmax improved beyond 95% coefficient of repeatability in 23% of participants following nicotinamide vs 9% on placebo. Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (P = .02) on nicotinamide and 5.2% [-4.2%, 14.6%], (P = .27) on placebo. Vmax ratio improved by 12.6% [5.0%, 20.2%], (P = .002) following nicotinamide, 3.6% [-3.4%, 10.5%], (P = .30) on placebo. A trend for improved visual field mean deviation was observed with 27% improving ≥1 dB on nicotinamide and fewer deteriorating (4%) compared to placebo (P = .02). CONCLUSIONS Nicotinamide supplementation can improve inner retinal function in glaucoma. Further studies underway to elucidate the effects of long-term nicotinamide supplementation.",2020,"Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (P = .02) on nicotinamide and 5.2% [-4.2%, 14.6%], (P = .27) on placebo.","['Fifty-seven participants, diagnosed and treated for glaucoma', 'Participants recruited from two tertiary care centres', 'participants receiving concurrent glaucoma therapy']","['oral placebo or nicotinamide', 'Nicotinamide supplementation', 'nicotinamide (vitamin B3) supplementation', 'nicotinamide', 'placebo']","['Overall, Vmax', 'Change in inner retinal function, determined by photopic negative response (PhNR) parameters: saturated PhNR amplitude (Vmax), ratio of PhNR/b-wave amplitude (Vmax ratio', 'Vmax ratio', 'visual field mean deviation', 'Visual function', 'PhNR Vmax improved beyond 95% coefficient of repeatability']","[{'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028027', 'cui_str': 'Niacinamide'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0027996', 'cui_str': 'Niacin'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0521095', 'cui_str': 'Determined by'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0042826', 'cui_str': 'Visual field'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",57.0,0.649578,"Overall, Vmax improved by 14.8% [95% CI: 2.8%, 26.9%], (P = .02) on nicotinamide and 5.2% [-4.2%, 14.6%], (P = .27) on placebo.","[{'ForeName': 'Flora', 'Initials': 'F', 'LastName': 'Hui', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Pete A', 'Initials': 'PA', 'LastName': 'Williams', 'Affiliation': 'Department of Clinical Neuroscience, Division of Eye and Vision, St. Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Myra B', 'Initials': 'MB', 'LastName': 'McGuinness', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Hadoux', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Robert J', 'Initials': 'RJ', 'LastName': 'Casson', 'Affiliation': 'Ophthalmic Research Laboratories, Discipline of Ophthalmology and Visual Sciences, University of Adelaide, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Coote', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Trounce', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Keith R', 'Initials': 'KR', 'LastName': 'Martin', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'van Wijngaarden', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}, {'ForeName': 'Jonathan G', 'Initials': 'JG', 'LastName': 'Crowston', 'Affiliation': 'Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13818'] 2357,32716652,Impact of Pelvic Floor Muscles Training Isolated and Associated with Game Therapy on Mixed Urinary Incontinence: A Randomized Controlled Trial.,"Objective: To verify whether pelvic floor muscle training (PFMT) associated with game therapy (GT) can potentiate improvements in PFM pressure, urinary loss, and perception of improvement in women with mixed urinary incontinence (MUI). Materials and Methods: A randomized and blinded trial was conducted with 32 women aged between 45 to 70 years presenting diagnosis of MUI. They were randomly divided into two groups: PFMT group and PFMT+GT group. Interventions occurred twice a week during 8 weeks. Primary outcome was PFM pressure, assessed by manometry, and secondary outcomes were 1-hour pad-test, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and patients global impression of improvement for incontinence (PGI-I). Two-way analysis of variance and post hoc Tukey analysis were performed. Results: Initially, no significant difference between groups was found in variables of age, body mass index, educational level, marital status, gynecological and obstetric variables, life habits, and sexual activity. Besides, at baseline clinical variables also showed similar results between groups for PFM pressure, 1-hour pad-test, and ICIQ-SF. Time-group interaction did not present statistically significant differences for PFM pressure ( P  = 0.56), 1-hour pad-test ( P  = 0.75), and ICIQ-SF ( P  = 0.30) in intergroup analysis. All women reported being ""much better or better,"" considering the comparison of urinary complaints in the beginning and end of treatment. Conclusion: There were no statistically significant differences between groups for PFM pressure, 1-hour pad-test, and ICIQ-SF. However, both treatments proved to be effective for MUI symptoms. Perception of improvement was highly improved, according to women's report.",2020,"There were no statistically significant differences between groups for PFM pressure, 1-hour pad-test, and ICIQ-SF.","['Mixed Urinary Incontinence', '32 women aged between 45 to 70 years presenting diagnosis of MUI', 'women with mixed urinary incontinence (MUI']","['PFMT group and PFMT+GT', 'game therapy (GT', 'pelvic floor muscle training (PFMT', 'Pelvic Floor Muscles Training Isolated and Associated with Game Therapy']","['variables of age, body mass index, educational level, marital status, gynecological and obstetric variables, life habits, and sexual activity', 'PFM pressure', 'PFM pressure, 1-hour pad-test, and ICIQ-SF', 'PFM pressure, assessed by manometry, and secondary outcomes were 1-hour pad-test, International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and patients global impression of improvement for incontinence (PGI-I', 'PFM pressure, urinary loss, and perception of improvement', 'ICIQ-SF']","[{'cui': 'C0869256', 'cui_str': 'Mixed urinary incontinence'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0454421', 'cui_str': 'Games for therapy'}, {'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0013658', 'cui_str': 'Educational achievement'}, {'cui': 'C0024819', 'cui_str': 'Marital status'}, {'cui': 'C0018417', 'cui_str': 'Gynecology'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0018464', 'cui_str': 'Habits'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C1868598', 'cui_str': 'Enlarged parietal foramina'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0332568', 'cui_str': 'Pad'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0024751', 'cui_str': 'Manometry'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C4706333', 'cui_str': 'Patient Global Impression of Improvement'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0523816', 'cui_str': 'Pepsinogen I measurement'}, {'cui': 'C0429778', 'cui_str': 'Urinary loss'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",32.0,0.137854,"There were no statistically significant differences between groups for PFM pressure, 1-hour pad-test, and ICIQ-SF.","[{'ForeName': 'Lívia Oliveira', 'Initials': 'LO', 'LastName': 'Bezerra', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Maria Clara Eugênia', 'Initials': 'MCE', 'LastName': 'de Oliveira', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Edson Meneses', 'Initials': 'EM', 'LastName': 'da Silva Filho', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Halana Karolina', 'Initials': 'HK', 'LastName': 'Vicente da Silva', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Gabriela Ferreira', 'Initials': 'GF', 'LastName': 'Menezes de Oliveira', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Ana Katherine', 'Initials': 'AK', 'LastName': 'da Silveira Gonçalves', 'Affiliation': 'Graduate Program in Health Science, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Pegado', 'Affiliation': 'Graduate Program in Rehabilitation Sciences, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}, {'ForeName': 'Maria Thereza Albuquerque Barbosa Cabral', 'Initials': 'MTABC', 'LastName': 'Micussi', 'Affiliation': 'Graduate Program in Physical Therapy, Federal University of Rio Grande do Norte, Rio Grande do Norte, Brazil.'}]",Games for health journal,['10.1089/g4h.2019.0207'] 2358,32716706,Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis: A Population-Based Cohort Study.,"BACKGROUND Denosumab is effective for osteoporosis, but discontinuation leads to rapid reversal of its therapeutic effect. OBJECTIVE To estimate the risk for fracture among users of denosumab who delayed subsequent doses compared with users who received doses on time. DESIGN Population-based cohort study. SETTING The Health Improvement Network U.K. primary care database, 2010 to 2019. PATIENTS Persons aged 45 years or older who initiated denosumab therapy for osteoporosis. MEASUREMENTS Observational data were used to emulate an analysis of a hypothetical trial with 3 dosing intervals: subsequent denosumab injection given within 4 weeks after the recommended date (""on time""), delay by 4 to 16 weeks (""short delay""), and delay by more than 16 weeks (""long delay""). The primary outcome was a composite of all fracture types at 6 months after the recommended date. Secondary outcomes were major osteoporotic fracture, vertebral fracture, hip fracture, and nonvertebral fracture. RESULTS Investigators identified 2594 patients initiating denosumab therapy. The risk for composite fracture over 6 months was 27.3 in 1000 for on-time dosing, 32.2 in 1000 for short delay, and 42.4 in 1000 for long delay. Compared with on-time injections, short delay had a hazard ratio (HR) for composite fracture of 1.03 (95% CI, 0.63 to 1.69) and long delay an HR of 1.44 (CI, 0.96 to 2.17) ( P for trend = 0.093). For vertebral fractures, short delay had an HR of 1.48 (CI, 0.58 to 3.79) and long delay an HR of 3.91 (CI, 1.62 to 9.45). LIMITATION Dosing schedules were not randomly assigned. CONCLUSION Although delayed administration of subsequent denosumab doses by more than 16 weeks is associated with increased risk for vertebral fracture compared with on-time dosing, evidence is insufficient to conclude that fracture risk is increased at other anatomical sites with long delay. PRIMARY FUNDING SOURCE National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation.",2020,"Compared with on-time injections, short delay had a hazard ratio (HR) for composite fracture of 1.03 (95% CI, 0.63 to 1.69) and long delay an HR of 1.44 (CI, 0.96 to 2.17) ( P for trend = 0.093).","['Population-based cohort study', '2594 patients initiating denosumab therapy', 'The Health Improvement Network U.K. primary care database, 2010 to 2019', 'Patients With Osteoporosis', 'Persons aged 45 years or older who initiated denosumab therapy for osteoporosis']",[],"['major osteoporotic fracture, vertebral fracture, hip fracture, and nonvertebral fracture', 'composite of all fracture types', 'hazard ratio (HR) for composite fracture', 'risk for vertebral fracture', 'Fracture Risk']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3839270', 'cui_str': 'Denosumab therapy'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C0029456', 'cui_str': 'Osteoporosis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]",[],"[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0521170', 'cui_str': 'Osteoporotic fracture'}, {'cui': 'C0080179', 'cui_str': 'Fracture of vertebral column'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0457357', 'cui_str': 'Type of fracture'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",2594.0,0.10165,"Compared with on-time injections, short delay had a hazard ratio (HR) for composite fracture of 1.03 (95% CI, 0.63 to 1.69) and long delay an HR of 1.44 (CI, 0.96 to 2.17) ( P for trend = 0.093).","[{'ForeName': 'Houchen', 'Initials': 'H', 'LastName': 'Lyu', 'Affiliation': ""National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, General Hospital of Chinese PLA, Beijing, China, Xiangya Hospital of Central South University, Changsha, China, and Brigham and Women's Hospital, Boston, Massachusetts (H.L.).""}, {'ForeName': 'Kazuki', 'Initials': 'K', 'LastName': 'Yoshida', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (K.Y., S.K.T.).""}, {'ForeName': 'Sizheng S', 'Initials': 'SS', 'LastName': 'Zhao', 'Affiliation': 'Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom (S.S.Z.).'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': 'Health Management Center, Xiangya Hospital of Central South University, Changsha, China (J.W.).'}, {'ForeName': 'Chao', 'Initials': 'C', 'LastName': 'Zeng', 'Affiliation': 'Xiangya Hospital of Central South University, Changsha, China (C.Z.).'}, {'ForeName': 'Sara K', 'Initials': 'SK', 'LastName': 'Tedeschi', 'Affiliation': ""Brigham and Women's Hospital, Boston, Massachusetts (K.Y., S.K.T.).""}, {'ForeName': 'Benjamin Z', 'Initials': 'BZ', 'LastName': 'Leder', 'Affiliation': 'Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (B.Z.L.).'}, {'ForeName': 'Guanghua', 'Initials': 'G', 'LastName': 'Lei', 'Affiliation': 'National Clinical Research Center for Geriatric Disorders, Xiangya Hospital of Central South University, and Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (G.L.).'}, {'ForeName': 'Peifu', 'Initials': 'P', 'LastName': 'Tang', 'Affiliation': 'National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation, General Hospital of Chinese PLA, Beijing, China (P.T.).'}, {'ForeName': 'Daniel H', 'Initials': 'DH', 'LastName': 'Solomon', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (D.H.S.).""}]",Annals of internal medicine,['10.7326/M20-0882'] 2359,32717289,Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.,"BACKGROUND & AIMS Obeticholic acid (OCA) is an agonist of the nuclear bile acid receptor FXR, which regulates hepatic bile acid metabolism. We tested whether OCA treatment would influence hepatic transport of conjugated bile acids in patients with primary biliary cholangitis (PBC) who responded inadequately to treatment with ursodeoxycholic acid (UDCA). PATIENTS & METHODS Eight UDCA-treated PBC patients with alkaline phosphatase ≥ 1.5 ULN participated in a double-blind, placebo-controlled study. While continuing on UDCA, the patients were randomized to two 3-month crossover treatment periods with placebo and OCA, in random order, separated by one month washout without study treatment. After each of the two treatment periods, we determined rate constants for transport of conjugated bile acids between blood, hepatocytes, biliary canaliculi and bile ducts by positron emission tomography (PET) of the liver using the conjugated bile acid tracer [N-methyl- 11 C]cholylsarcosine ( 11 C-CSar), and the hepatic blood perfusion using indocyanine green. RESULTS Compared to placebo, OCA increased the hepatic blood perfusion by median 11% (p = 0.045), the unidirectional uptake clearance of 11 C-CSar from blood into hepatocytes by median 11% (p = 0.01), and the rate constant for secretion of 11 C-CSar from hepatocytes into biliary canaliculi by median 73% (p = 0.03). This resulted in an OCA-induced decrease in hepatocyte residence time of 11 C-CSar by median 30% (p = 0.01), from group median 11 min to 8 min. CONCLUSIONS This study of UDCA-treated PBC patients showed that, compared to placebo, OCA increased the transport of the conjugated bile acid tracer 11 C-CSar, and thus endogenous conjugated bile acids, from hepatocytes into biliary canaliculi. Thereby OCA reduced the time hepatocytes are exposed to potentially cytotoxic bile acids.",2020,"Compared to placebo, OCA increased the hepatic blood perfusion by median 11% (p = 0.045), the unidirectional uptake clearance of 11 C-CSar from blood into hepatocytes by median 11% (p = 0.01), and the rate constant for secretion of 11 C-CSar from hepatocytes into biliary canaliculi by median 73% (p = 0.03).","['patients with primary biliary cholangitis (PBC) who responded inadequately to treatment with', 'patients with primary biliary cholangitis', 'Eight UDCA-treated PBC patients with alkaline phosphatase ≥ 1.5 ULN participated in a double-blind']","['ursodeoxycholic acid (UDCA', 'Obeticholic acid', 'OCA', 'placebo and OCA', 'placebo, OCA', 'Obeticholic acid (OCA', 'UDCA-treated PBC', 'placebo']","['rate constant for secretion', 'unidirectional uptake clearance', 'hepatocyte residence time', 'hepatic bile acid excretion', 'hepatic blood perfusion', 'rate constants for transport of conjugated bile acids between blood, hepatocytes, biliary canaliculi and bile ducts by positron emission tomography (PET) of the liver using the conjugated bile acid tracer [N-methyl']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C0042105', 'cui_str': 'ursodeoxycholic acid'}, {'cui': 'C1143018', 'cui_str': 'obeticholic acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008312', 'cui_str': 'Primary biliary cholangitis'}]","[{'cui': 'C1720529', 'cui_str': 'Constant'}, {'cui': 'C0036536', 'cui_str': 'secretion'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0227525', 'cui_str': 'Hepatic parenchymal cell'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205054', 'cui_str': 'Portal'}, {'cui': 'C0005390', 'cui_str': 'Bile acid'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0005528', 'cui_str': 'Biological transport'}, {'cui': 'C0443599', 'cui_str': 'Conjugated bile acids'}, {'cui': 'C0005400', 'cui_str': 'Bile duct structure'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}]",,0.0897823,"Compared to placebo, OCA increased the hepatic blood perfusion by median 11% (p = 0.045), the unidirectional uptake clearance of 11 C-CSar from blood into hepatocytes by median 11% (p = 0.01), and the rate constant for secretion of 11 C-CSar from hepatocytes into biliary canaliculi by median 73% (p = 0.03).","[{'ForeName': 'Kristoffer', 'Initials': 'K', 'LastName': 'Kjærgaard', 'Affiliation': 'Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Frisch', 'Affiliation': 'Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sørensen', 'Affiliation': 'Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Ole Lajord', 'Initials': 'OL', 'LastName': 'Munk', 'Affiliation': 'Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Alan Frederick', 'Initials': 'AF', 'LastName': 'Hofmann', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, University of California at San Diego, California.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Horsager', 'Affiliation': 'Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Anna Christina', 'Initials': 'AC', 'LastName': 'Schacht', 'Affiliation': 'Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Erickson', 'Affiliation': 'Intercept Pharmaceuticals, Inc., San Diego, California.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Shapiro', 'Affiliation': 'Intercept Pharmaceuticals, Inc., San Diego, California.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Keiding', 'Affiliation': 'Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark. Electronic address: susakeid@clin.au.dk.'}]",Journal of hepatology,['10.1016/j.jhep.2020.07.028'] 2360,32717294,A novel link between the oxytocin receptor gene and impulsivity.,"Impulsivity includes hasty actions, social intrusiveness or premature decision-making. Neuropeptides like oxytocin alleviate haste and anxiety, and affect fear conditioning. However, no investigations have been done via gene-network based approach with cognitive and interventional genetic association studies to scrutinize the link between impulsive behavior and oxytocin. Here, interactive gene network and pathways associated with impulsivity were reconstructed, and serotonin transporter gene (SLC6A4) and serotoninergic synaptic transmission were identified as the most central gene and pathway related to impulsivity. Young healthy males received intranasal oxytocin or placebo, and impulsivity was evaluated via go/no-go test. Test performance scores then were analyzed based on commission and omission errors, response inhibition and reaction time. Blood DNA was extracted and a 761 bp intronic region in oxytocin receptor (OXTR) gene was amplified and sequenced using PCR-pyrosequencing. Employing Haploview, haplotypes and linkage disequilibrium (LD) pattern among all SNPs in the target sequence were determined based on D' and LOD values, and rs2254298 with the highest LD was indicated as the tag SNP. Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition. This means that oxytocin alleviated impulsive behavior, and subjects with GG genotype had lower rate of impulsivity than those with GA and AA genotypes. rs2254298 may modulate the function or expression of the OXTR gene, implying that G allele may increase the expression of OXTR gene compared to A allele. We suggest that intranasal oxytocin may notably moderate impulsive behavior and tendency to make hasty or premature decisions.",2020,Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition.,['Young healthy males'],"['Oxytocin', 'oxytocin', 'intranasal oxytocin or placebo', 'intranasal oxytocin']","['commission and omission errors, response inhibition and reaction time', 'Impulsivity includes hasty actions, social intrusiveness or premature decision-making', 'Blood DNA', 'rate of impulsivity', 'commission error and increased inhibition']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0021125', 'cui_str': 'Impulsive behaviour'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic acid'}, {'cui': 'C0205217', 'cui_str': 'Increased'}]",,0.034954,Oxytocin group and participants with GG genotype showed a significantly decreased commission error and increased inhibition.,"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Bozorgmehr', 'Affiliation': 'Iran Psychiatric Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: bozorgmehr.a@iums.ac.ir.'}, {'ForeName': 'Razieh', 'Initials': 'R', 'LastName': 'Moayedi', 'Affiliation': 'Department of Mathematics, Payam Noor University of Tehran, Tehran, Iran. Electronic address: R_Moayedi11600@yahoo.com.'}, {'ForeName': 'Bahman', 'Initials': 'B', 'LastName': 'Sadeghi', 'Affiliation': 'Department of Biochemistry, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. Electronic address: bahmans1983@yahoo.com.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ghadirivasfi', 'Affiliation': 'Research Center for Addiction and Risky Behavior (ReCARB), Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: gadirivasfi.m@iums.ac.ir.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Taghi Joghataei', 'Affiliation': 'Cellular and Molecular Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: mt.joghataei@yahoo.com.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Shahbazi', 'Affiliation': 'Department of Neuroscience, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran. Electronic address: shahbazi.a@iums.ac.irshah.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.033'] 2361,32717295,Effects of Nicotine on Task Switching and Distraction in Non-smokers. An fMRI Study.,"Nicotine improves sustained attention and reduces distractor interference, promoting cognitive stability. While stable performance may be beneficial in some situations, others require flexible updating of task demands. Frontoparietal networks, basal ganglia and thalamus contribute to an optimal balance of stable and flexible performance. We aimed to test how the cholinergic agonist nicotine modulates this balance and used an ongoing visual task including switch and distractor trials to gauge cognitive flexibility and stability respectively. Young healthy non-smokers (n = 39) received either a 7 mg transdermal nicotine or placebo patch in a double-blind, within-subject design one hour prior to performing the task in a 3 T MR scanner. Nicotine enhanced response times in all task conditions but did not significantly impact distractor or switch costs. Neurally, there was no significant nicotine induced modulation of distractor- or switch-related activity on group level. However, a brain-behaviour correlation analysis revealed that the nicotine-induced alterations of distractor costs correlated positively with distractor-related neural activity in the right intraparietal sulcus and the right pulvinar nucleus of the thalamus. We suggest that a nicotinic contribution to balancing stability and flexibility is weak in young healthy non-smokers. The brain-behaviour correlations imply that if nicotine reduces distractor interference, the modulation is found in thalamic-parietal networks.",2020,"The brain-behaviour correlations imply that if nicotine reduces distractor interference, the modulation is found in thalamic-parietal networks.","['young healthy non-smokers', 'non-smokers', 'Young healthy non-smokers (n=39']","['Nicotine', 'cholinergic agonist nicotine', 'transdermal nicotine or placebo patch', 'nicotine']","['task switching and distraction', 'distractor costs', 'distractor interference', 'sustained attention and reduces distractor interference, promoting cognitive stability', 'impact distractor or switch costs']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0337672', 'cui_str': 'Non-smoker'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0242894', 'cui_str': 'Cholinergic Agonist'}, {'cui': 'C0040652', 'cui_str': 'Transdermal route'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}]","[{'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0589099', 'cui_str': 'Sustained attention'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0033414', 'cui_str': 'Promotion'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]",,0.0408686,"The brain-behaviour correlations imply that if nicotine reduces distractor interference, the modulation is found in thalamic-parietal networks.","[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Ahrens', 'Affiliation': 'Biological Psychology, Department of Psychology, School of Medicine and Health Sciences, Carl-von-Ossietzky Universität Oldenburg, Oldenburg, Germany.'}, {'ForeName': 'Christiane M', 'Initials': 'CM', 'LastName': 'Thiel', 'Affiliation': 'Biological Psychology, Department of Psychology, School of Medicine and Health Sciences, Carl-von-Ossietzky Universität Oldenburg, Oldenburg, Germany; Cluster of Excellence ""Hearing4all"", Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany; Research Center Neurosensory Science, Carl-von-Ossietzky Universität Oldenburg, Oldenburg, Germany. Electronic address: christiane.thiel@uni-oldenburg.de.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.029'] 2362,32717341,Responsiveness of vision-specific and general quality of life metrics to ocular and systemic events in patients with uveitis.,"OBJECTIVE To evaluate the responsiveness of quality of life (QoL) metrics to ocular and systemic events in patients with non-infectious uveitis. DESIGN Cohort study using randomized controlled trial data. PARTICIPANTS Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter Steroid Treatment (MUST) Trial and Follow-up Study. METHODS Data on the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), EuroQol Questionnaire (EQ-5D), and the Short Form Survey Instrument (SF-36) were evaluated semi-annually during the first 3 years after randomization. The impact of ocular (e.g. changes in visual acuity, activity status, cataract surgery) and systemic events (e.g infections requiring treatment) on the 6-month changes in QoL was assessed for each metric using generalized estimating equations. MAIN OUTCOME MEASURES The primary outcomes were the 6-month changes in vision-related (NEI-VFQ-25) and general health-related (EQ-5D index, SF-36 physical component score) QoL. RESULTS Changes in visual acuity (adjusted change [aΔ]: 2.70 units per 5 letter change, p<0.001), implant placement in at least one eye (aΔ: 5.50,p<0.001) cataract surgery (aΔ: 3.01,p=0.017), quieting of all eyes active at the beginning of the interval (aΔ: 2.20, p<0.010) were associated with improvements in the NEI-VFQ-25. Reductions in visual acuity (aΔ: -0.014 per 5 letter decline, p=0.003), infections requiring a prescription (aΔ: -0.024,p=0.021), and incident uveitis activity in at least one eye (aΔ: -0.023,p=0.031) were associated with declines in the EQ-5D index. Hospitalization (aΔ: - 2.24,p=0.019), infections requiring a prescription (aΔ: -1.00,p=0.024), and vitreous hemorrhage in at least 1 eye (aΔ: -1.92,p=0.21) were associated with declines in the SF-36 physical component score. Declines in visual acuity, initiation in IOP medication, and age were associated with changes in SF-36 physical components scores; however, the magnitude of the change was less than a single point. CONCLUSION The NEI-VFQ-25 was more sensitive to ocular changes than the general QoL metrics but less sensitive to acute systemic events. When performing QoL or cost-effectiveness analyses, it is important to consider the expected outcomes (e.g., ocular versus systemic) to ensure that the selected measurement is sensitive enough to detect clinically important changes in disease status or effects of treatment.",2020,"Reductions in visual acuity (aΔ: -0.014 per 5 letter decline, p=0.003), infections requiring a prescription (aΔ: -0.024,p=0.021), and incident uveitis activity in at least one eye (aΔ: -0.023,p=0.031) were associated with declines in the EQ-5D index.","['Patients with active or recently active intermediate, posterior, or panuveitis enrolled in the Multicenter Steroid Treatment (MUST', 'patients with uveitis', 'patients with non-infectious uveitis']",[],"['visual acuity', 'visual acuity, activity status, cataract surgery) and systemic events', 'SF-36 physical components scores', 'National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), EuroQol Questionnaire (EQ-5D), and the Short Form Survey Instrument (SF-36', 'implant placement', 'vitreous hemorrhage', 'EQ-5D index', 'SF-36 physical component score', 'quality of life (QoL) metrics', 'visual acuity, initiation in IOP medication', 'incident uveitis activity', '6-month changes in vision-related (NEI-VFQ-25) and general health-related (EQ-5D index, SF-36 physical component score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0030343', 'cui_str': 'Panuveitis'}, {'cui': 'C0149783', 'cui_str': 'Administration of steroid'}, {'cui': 'C0042164', 'cui_str': 'Uveitis'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",[],"[{'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1955969', 'cui_str': 'National Eye Institute'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451150', 'cui_str': 'EuroQOL'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0042909', 'cui_str': 'Vitreous hemorrhage'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}, {'cui': 'C0578862', 'cui_str': 'Intraocular pressure finding'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0042164', 'cui_str': 'Uveitis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}]",,0.183554,"Reductions in visual acuity (aΔ: -0.014 per 5 letter decline, p=0.003), infections requiring a prescription (aΔ: -0.024,p=0.021), and incident uveitis activity in at least one eye (aΔ: -0.023,p=0.031) were associated with declines in the EQ-5D index.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Sugar', 'Affiliation': 'Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of the Center for Clinical Trials, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Division of Biostatistics and Bioinformatics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins School of Medicine, Baltimore, MD. Electronic address: esugar2@jhu.edu.'}, {'ForeName': 'Alyce E', 'Initials': 'AE', 'LastName': 'Burke', 'Affiliation': 'Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of the Center for Clinical Trials, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Vidya', 'Initials': 'V', 'LastName': 'Venugopal', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Thorne', 'Affiliation': 'Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Janet T', 'Initials': 'JT', 'LastName': 'Holbrook', 'Affiliation': 'Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of the Center for Clinical Trials, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Ophthalmology,['10.1016/j.ophtha.2020.07.038'] 2363,32724661,Combining cognitive stimulation therapy and fall prevention exercise (CogEx) in older adults with mild to moderate dementia: a feasibility randomised controlled trial.,"Background People living with dementia (PLwD) have a high fall risk as cognitive impairment compromises control of gait and balance. Fall prevention exercises that are effective in healthy older adults may not work for PLwD. Cognitive stimulation therapy (CST) has been shown to improve global cognition in PLwD. A programme which combines cognitive (CST) with physical exercises may reduce falls in PLwD. The aim of this study was to assess the feasibility of undertaking a full scale randomised controlled trial to test the effectiveness of CogEx in decreasing falls in PLwD. Specific objectives included recruitment strategy, data collection, outcome measures, intervention fidelity and facilitator/participant experience. Methods A mixed methods feasibility randomised controlled trial recruited people from residential aged care. Inclusion criteria were ≥ 65 years old, Montreal Cognitive Assessment (MoCA) score of 10 to 26 and able to participate in a group. Participants were randomised to CST or CST combined with strength and balance exercises (CogEx). Both CST and CogEx groups were for an hour twice a week for 7 weeks. Descriptive statistics were used to report pre- and post-intervention outcome measures (MoCA, Geriatric Depression Scale-15, Quality of Life-Alzheimer's Disease, Alzheimer's Disease Assessment Scale-Cognitive 11, Brief Balance Evaluation Systems Test and Short Form Physical Performance Battery) and attendance. Qualitative analysis of participant focus groups and facilitator interviews used a conventional approach. Sessions were video recorded and exercise completion documented. Results Thirty-six residents were screened with 23 participants randomised to intervention (CogEx, n = 10) or control (CST, n = 13). The assessments took 45 min to 1.5 h, and there was repetition between two cognitive measures. Ten facilitators completed training with the manualised programme. Exercises were combined into the hour-long CST session; however, limited balance training occurred with participants exercising predominantly in sitting. The facilitators felt the participants engaged more and were safer in sitting. Conclusions The results demonstrated that while fall prevention exercises could be scheduled into the CST structure, the fidelity of the combined programme was poor. Other components of the study design need further consideration before evaluation using a randomised controlled trial is feasible. Trial registration anzctr.org.au (ACTRN12616000751471) 8 Jun 2016, Australian New Zealand Clinical Trials Registry.",2020,"Thirty-six residents were screened with 23 participants randomised to intervention (CogEx, n = 10) or control (CST, n = 13).","['people from residential aged care', 'Thirty-six residents were screened with 23 participants randomised to', 'Inclusion criteria were ≥ 65 years old, Montreal Cognitive Assessment (MoCA) score of 10 to 26 and able to participate in a group', 'healthy older adults', '\n\n\nPeople living with dementia (PLwD', 'older adults with mild to moderate dementia']","['PLwD. Cognitive stimulation therapy (CST', 'limited balance training', 'CST or CST combined with strength and balance exercises (CogEx', 'Fall prevention exercises', 'intervention (CogEx, n = 10) or control (CST', 'cognitive stimulation therapy and fall prevention exercise (CogEx', 'combines cognitive (CST) with physical exercises']","['global cognition in PLwD', ""MoCA, Geriatric Depression Scale-15, Quality of Life-Alzheimer's Disease, Alzheimer's Disease Assessment Scale-Cognitive 11, Brief Balance Evaluation Systems Test and Short Form Physical Performance Battery) and attendance""]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0419193', 'cui_str': 'Care of aged'}, {'cui': 'C4319606', 'cui_str': '36'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0150174', 'cui_str': 'Cognitive stimulation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0150219', 'cui_str': 'Balance exercises'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0450989', 'cui_str': ""Alzheimer's Disease Assessment Scale""}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}]",36.0,0.102279,"Thirty-six residents were screened with 23 participants randomised to intervention (CogEx, n = 10) or control (CST, n = 13).","[{'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Binns', 'Affiliation': 'Physiotherapy Department, AUT University, Auckland, New Zealand.'}, {'ForeName': 'Ngaire', 'Initials': 'N', 'LastName': 'Kerse', 'Affiliation': 'School of Population Health, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Peri', 'Affiliation': 'School of Nursing, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Cheung', 'Affiliation': 'Department of Psychological Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Taylor', 'Affiliation': 'Health and Rehabilitation Institute, AUT University, Auckland, New Zealand.'}]",Pilot and feasibility studies,['10.1186/s40814-020-00646-6'] 2364,32724763,The Effect of Foot Massage by Mother on the Severity of Attention-Deficit Hyperactivity Disorder Symptoms in Children Aged 6-12.,"Background Various pharmacological and non-pharmacological approaches have been proposed to control the symptoms of Attention-Deficit Hyperactivity Disorder (ADHD). The aim of this study was to investigate the effect of foot massage by a mother on the severity of ADHD symptoms in children. Materials and Methods This study was a randomized controlled trial conducted on 56 children who referred to psychiatric clinics affiliated to Isfahan University of Medical Sciences in Iran, 2018. The subjects were randomly divided into two groups of intervention and control. In the intervention group, after giving massage therapy training to the mother, the mother massaged her child's foot three times a week for 1 month. The data were collected using the ADHD questionnaire. Data were analyzed using inferential and descriptive statistics (independent t -test, paired t -test, Mann-Whitney test, and Chi-square test). Results Comparison of the mean score of ADHD symptoms, after the intervention, showed a significant difference between the two groups in terms of the dimensions of the memory and attention deficit (t 47 = 3.42, p = 0.001), lack of responsibility and organization (t 47 = 7.16, p < 0.001), lack of cooperation with others (t 47 = 5.23, p < 0.001), and the total score of symptom severity (t 47 = 3.78, p < 0.001). Conclusions Massage therapy is affordable and low-cost care that together with pharmacotherapy programs can reduce some symptoms of ADHD.",2020,"Results Comparison of the mean score of ADHD symptoms, after the intervention, showed a significant difference between the two groups in terms of the dimensions of the memory and attention deficit (t 47 = 3.42, p = 0.001), lack of responsibility and organization (t 47 = 7.16, ","['56 children who referred to psychiatric clinics affiliated to Isfahan University of Medical Sciences in Iran, 2018', 'Children Aged 6-12', 'children']","['foot massage', 'Massage therapy', 'Foot Massage by Mother']","['mean score of ADHD symptoms', 'lack of responsibility and organization', 'total score of symptom severity', 'dimensions of the memory and attention deficit']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C3536731', 'cui_str': 'Massage physiotherapy'}, {'cui': 'C0026591', 'cui_str': 'Mother'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332268', 'cui_str': 'Lacking'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0041671', 'cui_str': 'Attention Deficit Disorder'}]",56.0,0.023498,"Results Comparison of the mean score of ADHD symptoms, after the intervention, showed a significant difference between the two groups in terms of the dimensions of the memory and attention deficit (t 47 = 3.42, p = 0.001), lack of responsibility and organization (t 47 = 7.16, ","[{'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Asadi', 'Affiliation': 'MSc of Pediatric Nursing, Nursing and Midwifery Care Research Center, Faculty of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Fereshteh', 'Initials': 'F', 'LastName': 'Shakibaei', 'Affiliation': 'Associated Professor, Child and Adolescent Psychiatrist, Behavioral Sciences Research Center, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Mazaheri', 'Affiliation': 'Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.'}, {'ForeName': 'Soheila', 'Initials': 'S', 'LastName': 'Jafari-Mianaei', 'Affiliation': 'Department of Pediatric and Neonatal Nursing, Nursing and Midwifery Care Research Center, School of Nursing and Midwifery, Isfahan University of Medical Sciences, Isfahan, Iran.'}]",Iranian journal of nursing and midwifery research,['10.4103/ijnmr.IJNMR_78_19'] 2365,32724768,The Effects of a Training Program Based on the Health Promotion Model on Physical Activity in Women with Type 2 Diabetes: A Randomized Controlled Clinical Trial.,"Background Physical activity among women with type 2 Diabetes Mellitus (DM) is an undesirable level. This study aimed to determine the effect of a training program based on the Health Promotion Model (HPM) on physical activity in women with type 2 DM. Materials and Methods This randomized clinical trial was performed on 128 women with type 2 DM, who were randomly assigned to control and intervention groups. Data were collected using the Baecke Physical Activity Questionnaire (BPAQ) and a researcher-made questionnaire designed based on the HPM constructs before and 2 months after the intervention. The training was carried out in four sessions in the intervention group and the control group received regular education at the clinic. Data were analyzed using Chi-square, Fisher's exact test, paired t -test, independent t -test, and Mann-Whitney and Wilcoxon tests in Statistical Package for the Social Sciences (SPSS) software. Results The findings showed that the mean [Standard Deviation (SD)] of physical activity in the intervention and control groups before the intervention was 6.52 (0.86) and 6.56 (1.07), respectively, and there was no significant difference between the groups ( p = 0.95). However, after the intervention, the mean (SD) of physical activity in the intervention and control groups was 8.04 (0.92) and 6.33 (1.60), respectively, which showed a significant difference (t 126 = 9.71, p < 0.001). Conclusions The findings of this study revealed that the training program based on the HPM has a positive effect on improving physical activity in women with type 2 DM.",2020,The findings of this study revealed that the training program based on the HPM has a positive effect on improving physical activity in women with type 2 DM.,"['128 women with type 2 DM', 'women with type 2 DM', 'Women with Type 2 Diabetes', 'women with type 2 Diabetes Mellitus (DM']","['control group received regular education at the clinic', 'Training Program Based on the Health Promotion Model', 'training program based on the Health Promotion Model (HPM']","['mean (SD) of physical activity', 'Baecke Physical Activity Questionnaire (BPAQ', 'mean [Standard Deviation (SD)] of physical activity', 'physical activity']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",128.0,0.0466174,The findings of this study revealed that the training program based on the HPM has a positive effect on improving physical activity in women with type 2 DM.,"[{'ForeName': 'Soghra', 'Initials': 'S', 'LastName': 'Rouholamini', 'Affiliation': 'Department of Nursing, School of Nursing and Midwifery, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Mahin', 'Initials': 'M', 'LastName': 'Gheibizadeh', 'Affiliation': 'Nursing Care Research Center in Chronic Diseases, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Elham', 'Initials': 'E', 'LastName': 'Maraghi', 'Affiliation': 'Department of Biostatistics and Epidemiology, School of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Jahanshahi', 'Affiliation': 'Department of Internal Medicine, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.'}]",Iranian journal of nursing and midwifery research,['10.4103/ijnmr.IJNMR_97_19'] 2366,32724771,The Effect of Prenatal Self-Care Based on Orem's Theory on Preterm Birth Occurrence in Women at Risk for Preterm Birth.,"Background Preterm birth is increasing as a major cause of perinatal complications and mortality in Iran. The present study aimed to investigate the effect of prenatal self-care based on Orem's theory on preterm birth occurrence in women at risk for preterm birth. Materials and Methods The present clinical trial was conducted on 176 pregnant women at 24-26 weeks at risk for preterm birth in Mashhad, Iran, from December 2015 to October 2016. A multistage sampling method was used in this study. The intervention group (88 pregnant women) received individual self-care education but the control group (88 pregnant women) received only common prenatal care. Results There was a statistically significant difference between intervention and control groups in terms of preterm birth occurrence (6.80% vs 20.50%) (χ 2 = 6.90, df = 1,p = 0.008). The incidence of preterm birth in the intervention group was approximately three times higher than that in the control group. Conclusions Given that educational interventions could reduce the incidence of preterm birth, it is suggested that the women at risk for preterm birth are trained for prenatal self-care.",2020,"There was a statistically significant difference between intervention and control groups in terms of preterm birth occurrence (6.80% vs 20.50%) (χ 2 = 6.90, df = 1,p = 0.008).","['Women at Risk for Preterm Birth', 'women at risk for preterm birth', '176 pregnant women at 24-26 weeks at risk for preterm birth in Mashhad, Iran, from December 2015 to October 2016']","['individual self-care education but the control group (88 pregnant women) received only common prenatal care', ""prenatal self-care based on Orem's theory"", 'Prenatal Self-Care', 'educational interventions']","['preterm birth occurrence', 'incidence of preterm birth', 'Preterm Birth Occurrence']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0022065', 'cui_str': 'Iran'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}]",176.0,0.0983392,"There was a statistically significant difference between intervention and control groups in terms of preterm birth occurrence (6.80% vs 20.50%) (χ 2 = 6.90, df = 1,p = 0.008).","[{'ForeName': 'Seyedeh-Mahboobeh', 'Initials': 'SM', 'LastName': 'Rezaeean', 'Affiliation': 'Department of Midwifery, Medical Faculty, North Khorasan University of Medical Sciences, Bojnurd, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Abedian', 'Affiliation': 'Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Robab', 'Initials': 'R', 'LastName': 'Latifnejad-Roudsari', 'Affiliation': 'Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Seyed-Reza', 'Initials': 'SR', 'LastName': 'Mazloum', 'Affiliation': 'Nursing and Midwifery Care Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Abbasi', 'Affiliation': 'Department of Midwifery, Medical Faculty, North Khorasan University of Medical Sciences, Bojnurd, Iran.'}]",Iranian journal of nursing and midwifery research,['10.4103/ijnmr.IJNMR_207_19'] 2367,32668114,Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.,"BACKGROUND Acute kidney injury is common in critically ill patients, many of whom receive renal-replacement therapy. However, the most effective timing for the initiation of such therapy remains uncertain. METHODS We conducted a multinational, randomized, controlled trial involving critically ill patients with severe acute kidney injury. Patients were randomly assigned to receive an accelerated strategy of renal-replacement therapy (in which therapy was initiated within 12 hours after the patient had met eligibility criteria) or a standard strategy (in which renal-replacement therapy was discouraged unless conventional indications developed or acute kidney injury persisted for >72 hours). The primary outcome was death from any cause at 90 days. RESULTS Of the 3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group). Of these patients, renal-replacement therapy was performed in 1418 (96.8%) in the accelerated-strategy group and in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P = 0.92). Among survivors at 90 days, continued dependence on renal-replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group (relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients (16.5%) in the standard-strategy group (P<0.001). CONCLUSIONS Among critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.).",2020,"At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P = 0.92).","['critically ill patients with severe acute kidney injury', 'critically ill patients with acute kidney injury', 'Acute Kidney Injury', 'critically ill patients, many of whom receive renal-replacement therapy', '3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group']","['standard strategy (in which renal-replacement therapy', 'Renal-Replacement Therapy', 'accelerated strategy of renal-replacement therapy']","['Adverse events', 'death', 'death from any cause at 90 days', 'lower risk of death', 'renal-replacement therapy']","[{'cui': 'C0010340', 'cui_str': 'Critical illness'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C2718028', 'cui_str': 'Intention to Treat Analysis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0206074', 'cui_str': 'Renal replacement therapy'}]",3019.0,0.2899,"At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P = 0.92).","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Sean M', 'Initials': 'SM', 'LastName': 'Bagshaw', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Ron', 'Initials': 'R', 'LastName': 'Wald', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Neill K J', 'Initials': 'NKJ', 'LastName': 'Adhikari', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Bruno R', 'Initials': 'BR', 'LastName': 'da Costa', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Didier', 'Initials': 'D', 'LastName': 'Dreyfuss', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Du', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Martin P', 'Initials': 'MP', 'LastName': 'Gallagher', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Gaudry', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Hoste', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Lamontagne', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Joannidis', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Landoni', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Kathleen D', 'Initials': 'KD', 'LastName': 'Liu', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Shay P', 'Initials': 'SP', 'LastName': 'McGuinness', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Javier A', 'Initials': 'JA', 'LastName': 'Neyra', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Alistair D', 'Initials': 'AD', 'LastName': 'Nichol', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Ostermann', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Palevsky', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Pettilä', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Quenot', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Haibo', 'Initials': 'H', 'LastName': 'Qiu', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Bram', 'Initials': 'B', 'LastName': 'Rochwerg', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Antoine G', 'Initials': 'AG', 'LastName': 'Schneider', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Orla M', 'Initials': 'OM', 'LastName': 'Smith', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Thomé', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Kevin E', 'Initials': 'KE', 'LastName': 'Thorpe', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Suvi', 'Initials': 'S', 'LastName': 'Vaara', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Weir', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Amanda Y', 'Initials': 'AY', 'LastName': 'Wang', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Young', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zarbock', 'Affiliation': ""From the Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton (S.M.B.), the Division of Nephrology (R.W.), St. Michael's Hospital and the University of Toronto, Li Ka Shing Knowledge Institute (R.W., B.R.C., O.M.S., K.E.T.), Department of Medicine (R.W., O.M.S.), and Applied Health Research Centre (B.R.C., K.E.T.), St. Michael's Hospital, the Dalla Lana School of Public Health (K.E.T.), the Institute of Health Policy, Management, and Evaluation (R.W., B.R.C.), University of Toronto, and the Department of Critical Care Medicine, Sunnybrook Health Sciences Centre and the University of Toronto (N.K.J.A.), Toronto, the Department of Medicine, Université de Sherbrooke and Centre de Recherche du Centre Hospitalier Universitaire (CHU) de Sherbrooke, Sherbrooke, QC (F.L.), the Division of Critical Care, Juravinski Hospital, McMaster University, Hamilton, ON (B.R.), and the Division of Nephrology, London Health Sciences Centre, London, ON (M.W.) - all in Canada; the Department of Intensive Care, Austin Hospital and Royal Melbourne Hospital, School of Medicine, University of Melbourne, Australian and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University (R.B., A.D.N.), Melbourne, VIC, and the George Institute for Global Health, Concord Clinical School, Faculty of Medicine, University of Sydney, Sydney (M.P.G., A.Y.W.) - both in Australia; the Institute of Primary Health Care, University of Bern, Bern (B.R.C.), and the Department of Critical Care Medicine, CHU Vaudois, Lausanne (A.G.S.) - both in Switzerland; Hôpital Louis Mourier (D.D.) and Université Léonard de Vinci (S.G.), INSERM Unité UMR S1155, Sorbonne Université and Université de Paris, Paris, Hôpital Avicenne, Bobigny (S.G.), and Hôpital Universitaire François Mitterrand, Lipness Team, INSERM Research Center Lipids, Nutrition, Cancer-Unité Mixte de Recherche 1231 and Laboratoire d'Excellence LipSTIC, Centre d'Investigation Clinique-Epidemiologie Clinique, CHU Dijon-Bourgogne, and INSERM Centre d'Investigation Clinique 1432, Université de Bourgogne, Dijon (J.-P.Q.) - all in France; the Department of Critical Care Medicine, Peking Union Medical College Hospital, Beijing (B.D.), and the Department of Critical Care Medicine, Zhongda Hospital Southeast University, Nanjing (H.Q.) - both in China; the Department of Intensive Care, University of Ghent, Ghent, Belgium (E.A.H.); the Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria (M.J.); Vita Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Milan (G.L.); the Divisions of Nephrology and Critical Care Medicine, University of California, San Francisco, San Francisco (K.D.L.); the Wellcome-Wolfson Institute for Experimental Medicine, Queen's University, and the Regional Intensive Care Unit, Royal Victoria Hospital, Belfast (D.F.M.), and King's College London, Guy's and St. Thomas' Hospital, London (M.O.) - both in the United Kingdom; the Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland (S.P.M.), and the Medical Research Institute of New Zealand (S.P.M.) and the Intensive Care Unit, Wellington Regional Hospital and Medical Research Institute of New Zealand (P.Y.), Wellington - both in New Zealand; the Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington (J.A.N.); University College Dublin Clinical Research Centre at St. Vincent's University Hospital, Dublin (A.D.N.); the Division of Nephrology, University of Pittsburgh, and Veterans Affairs Pittsburgh Healthcare System, Pittsburgh (P.M.P.); the Department of Intensive Care, University of Helsinki, and Helsinki University Hospital, Helsinki (V.P., S.V.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (F.T.); and the Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany (A.Z.).""}]",The New England journal of medicine,['10.1056/NEJMoa2000741'] 2368,32668323,A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).,"BACKGROUND Lung ultrasound (LUS) has emerged as a new tool for the evaluation of congestion in heart failure (HF); incorporation of LUS during follow-up may detect congestion earlier and prompt interventions to prevent hospitalizations. The aim of this study was to test the hypothesis that the incorporation of LUS during follow-up of patients with HF may reduce the rate of adverse events compared with usual care. METHODS In this single-blinded, randomized controlled trial, patients were randomized into an LUS-guided arm or control arm. Patients were followed in 4 prespecified visits during a 6-month period. LUS was performed in every patient visit in both groups; however, LUS results were available for the treating physician only in the LUS group. The primary outcome was the composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause. RESULTS One hundred twenty-six patients were randomized to either LUS (n = 63) or control (n = 63) (age 62.5 ± 10 years, median left ventricular ejection fraction 31%). The primary end point occurred in 30 (47.6%) patients in the control group and 20 (31.7%) patients in the LUS group (P = .041). LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001). No significant differences in rehospitalizations for HF or death were found. CONCLUSIONS Incorporation of LUS into clinical follow-up of patients with HF significantly reduced the risk of urgent visits for worsening HF.",2020,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).",['One hundred twenty-six patients'],"['LUS-guided arm or control arm', 'lung ultrasound-guided therapy', 'Lung ultrasound (LUS', 'LUS']","['rate of adverse events', 'urgent HF visits', 'rehospitalizations for HF or death', 'composite of urgent HF visits, rehospitalization for worsening HF, and death from any cause', 'risk of urgent visits']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4286019', 'cui_str': 'Lung ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",126.0,0.114217,"LUS-guided treatment was associated with a 45% risk reduction in the primary end point (hazard ratio 0.55, 95% CI 0.31-0.98, P = .044), mainly driven by a reduction in urgent HF visits (hazard ratio 0.28, 95% CI 0.13-0.62, P = .001).","[{'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Araiza-Garaygordobil', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico. Electronic address: dargaray@gmail.com.'}, {'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Gopar-Nieto', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Martinez-Amezcua', 'Affiliation': 'Johns Hopkins University, Baltimore, MD, USA.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Cabello-López', 'Affiliation': 'Centro Médico Nacional ""Siglo XXI,"" Instituto Mexicano del Seguro Social, Mexico City, Mexico.'}, {'ForeName': 'Gabriela', 'Initials': 'G', 'LastName': 'Alanis-Estrada', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Luna-Herbert', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Héctor', 'Initials': 'H', 'LastName': 'González-Pacheco', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Cynthia Paola', 'Initials': 'CP', 'LastName': 'Paredes-Paucar', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Martinez Daniel', 'Initials': 'MD', 'LastName': 'Sierra-Lara', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Jose Luis', 'Initials': 'JL', 'LastName': 'Briseño-De la Cruz', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Hugo', 'Initials': 'H', 'LastName': 'Rodriguez-Zanella', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Marco Antonio', 'Initials': 'MA', 'LastName': 'Martinez-Rios', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Arias-Mendoza', 'Affiliation': 'Instituto Nacional de Cardiología ""Ignacio Chávez,"", Mexico City, Mexico.'}]",American heart journal,['10.1016/j.ahj.2020.06.003'] 2369,32714176,Drum Communication Program Intervention in Older Adults With Cognitive Impairment and Dementia at Nursing Home: Preliminary Evidence From Pilot Randomized Controlled Trial.,"Introduction : Inactivity and consequent deterioration of cognitive and physical function is a major concern among older adults with the limited walking ability and need a high level of care in nursing homes. We aimed to test whether a drumming communication program (DCP) that uses the rhythmic response function of the elderly with cognitive impairment, dementia, and other debilitating disorders would improve their cognitive and physical function. Methods : We conducted a Randomized Controlled Trial (RCT) to investigate the effects of the DCP in 46 nursing home residents who needed high levels of nursing care. The participants were randomly assigned to an intervention and control group. The intervention group attended 30 min of the DCP thrice a week for 3 months. Cognitive function was measured using the Mini-Mental State Examination-Japanese (MMSE-J) and Frontal Assessment Battery (FAB). Physical function was measured using grip strength and active upper limb range of motion with the dominant hand. Body composition was measured using bioelectrical impedance analysis (BIA). These measures were analyzed before and after the DCP intervention period, and data for the two groups were compared thereafter. Results : Initially, the participants had low scores on the MMSE-J, and 84.78% of them used wheelchairs. Following the DCP intervention, the MMSE-J and FAB scores of the DCP group improved significantly. In terms of motor function, the active range of motion of the wrist palmar and the shoulder flexion improved in the intervention group. Regarding body composition, the skeletal muscle mass index, total body protein, and the dominant hand muscle mass that was adding physical load decreased. Conclusions : The DCP provided the participants with an opportunity to engage in continued exercise for 3 months. The intervention group exhibited improved cognitive function and upper limb motion range, and changes in body composition. The results suggest that DCP can be used as an intervention method to promote exercise and improve various health and cognitive functions. Trial Registration : This trial was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000024714) on 4 November 2016. The URL is available at https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028399.",2020,"In terms of motor function, the active range of motion of the wrist palmar and the shoulder flexion improved in the intervention group.","['46 nursing home residents who needed high levels of nursing care', 'Older Adults With Cognitive Impairment and Dementia at Nursing Home', 'elderly with cognitive impairment, dementia, and other debilitating disorders', 'older adults']","['DCP', 'drumming communication program (DCP', 'Drum Communication Program Intervention']","['cognitive function and upper limb motion range, and changes in body composition', 'Body composition', 'MMSE-J and FAB scores', 'active range of motion of the wrist palmar and the shoulder flexion', 'Cognitive function', 'Physical function', 'Mini-Mental State Examination-Japanese (MMSE-J) and Frontal Assessment Battery (FAB']","[{'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0028678', 'cui_str': 'nursing'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0009457', 'cui_str': 'Communication Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0451306', 'cui_str': 'Mini-mental state examination'}, {'cui': 'C0021031', 'cui_str': 'Immunoglobulin, F(ab) fragment'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C2732353', 'cui_str': 'Frontal assessment battery'}]",,0.0565128,"In terms of motor function, the active range of motion of the wrist palmar and the shoulder flexion improved in the intervention group.","[{'ForeName': 'Atsuko', 'Initials': 'A', 'LastName': 'Miyazaki', 'Affiliation': 'Computational Engineering Applications Unit, Head Office for Information Systems and Cybersecurity, RIKEN, Saitama, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Okuyama', 'Affiliation': 'Department of Physical Therapy, Faculty of Health Sciences, School of Medicine, Kobe University, Kobe, Japan.'}, {'ForeName': 'Hayato', 'Initials': 'H', 'LastName': 'Mori', 'Affiliation': 'Technology and Innovation Hub, Cluster for Science, RIKEN, Saitama, Japan.'}, {'ForeName': 'Kazuhisa', 'Initials': 'K', 'LastName': 'Sato', 'Affiliation': 'Medical Collaboration Division, Care 21 Co., Ltd., Tokyo, Japan.'}, {'ForeName': 'Masahiko', 'Initials': 'M', 'LastName': 'Ichiki', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Nouchi', 'Affiliation': 'Department of Cognitive Health Science, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan.'}]",Frontiers in aging neuroscience,['10.3389/fnagi.2020.00142'] 2370,32714178,Impact of Age on tDCS Effects on Pain Threshold and Working Memory: Results of a Proof of Concept Cross-Over Randomized Controlled Study.,"Background : Age is an important factor that impacts the variability of tDCS effects. Objective/Hypothesis : To compare effects of anodal (a)-tDCS over the left dorsolateral prefrontal cortex (DLPFC), and primary motor cortex (M1) in adolescents, adults, and elderly on heat pain threshold (HPT; primary outcome) and the working memory (WM; secondary outcome). We hypothesized that the effect of tDCS on HPT and WM performance would be the largest in adolescents because their pre-frontal cortex is more prone to neuroplasticity. Methods : We included 30 healthy women within the age ranges of 15-16 (adolescents, n = 10), 30-40 (adults, n = 10), and 60-70 (elderly, n = 10) years. In this crossover single-blinded study, participants received three interventions applied over the DLPF and M1. The active stimulation intensity was two mA for 30 min. From 20 min of stimulation onset, the tDCS session was coupled with an online n-back task. The a-tDCS and sham were applied in a random sequence, with a washout time of a minimum 7 days between each trial. HPT was evaluated before and after stimulation. The WM performance with an n-back task was assessed after the tDCS session. Results : A Generalized Estimating Equation (GEE) model revealed a significant effect of the a-tDCS over the left DLPFC to reduce the HPT in adolescents compared with sham. It increased the pain perception significantly [a large effect size (ES) of 1.09)]. In the adults, a-tDCS over M1 enhanced the HPT significantly (a large ES of 1.25) compared to sham. No significant effect for HPT was found in the elderly. Response time for hits was reduced for a-tDCS over the DLPFC in adolescents, as compared to the other two age groups. Conclusions : These findings suggest that a-tDCS modulates pain perception and WM differentially according to age and target area of stimulation. In adolescents, anodal stimulation over the DLPFC increased the pain perception, while in adults, the stimulation over the M1 increased the pain threshold. Thus, they elucidate the impact of tDCS for different age groups and can help to define what is the appropriate intervention according to age in further clinical trials. Clinical Trial Registration: www.ClinicalTrials.gov, Identifier: NCT04328545.",2020,"Response time for hits was reduced for a-tDCS over the DLPFC in adolescents, as compared to the other two age groups. ","['30 healthy women within the age ranges of 15-16 (adolescents, n = 10), 30-40 (adults, n = 10), and 60-70 (elderly, n = 10) years', 'adolescents, adults, and elderly on heat pain threshold (HPT; primary outcome) and the working memory (WM; secondary outcome']","[' ', 'anodal (a)-tDCS', 'tDCS', 'HPT']","['Pain Threshold and Working Memory', 'Response time for hits', 'pain perception and WM', 'HPT and WM performance', 'active stimulation intensity', 'pain perception', 'HPT']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}]","[{'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0272285', 'cui_str': 'Heparin-induced thrombocytopenia'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",30.0,0.051802,"Response time for hits was reduced for a-tDCS over the DLPFC in adolescents, as compared to the other two age groups. ","[{'ForeName': 'Júlia Schirmer', 'Initials': 'JS', 'LastName': 'Saldanha', 'Affiliation': 'Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}, {'ForeName': 'Maxciel', 'Initials': 'M', 'LastName': 'Zortea', 'Affiliation': 'Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}, {'ForeName': 'Cibely Bavaresco', 'Initials': 'CB', 'LastName': 'Deliberali', 'Affiliation': 'Laboratory of Pain & Neuromodulation, Clinical Research Center, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.'}, {'ForeName': 'Min-Fang', 'Initials': 'MF', 'LastName': 'Kuo', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany.'}, {'ForeName': 'Iraci Lucena da Silva', 'Initials': 'ILDS', 'LastName': 'Torres', 'Affiliation': 'Department of Pharmacology, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': 'Laboratory of Neuromodulation and Center for Clinical Research Learning, Physics and Rehabilitation Department, Spaulding Rehabilitation Hospital, Boston, MA, United States.'}, {'ForeName': 'Wolnei', 'Initials': 'W', 'LastName': 'Caumo', 'Affiliation': 'Graduate Program in Medical Sciences, School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.'}]",Frontiers in aging neuroscience,['10.3389/fnagi.2020.00189'] 2371,32714194,Blood Pressure Increase in Hypertensive Individuals During Resistance Training Protocols With Equated Work to Rest Ratio.,"Introduction: Despite growing evidence regarding the benefits of resistance training in hypertension, the large and abrupt rise of systolic blood pressure (SBP) observed during resistance exercise execution has resulted in concern about its safety. However, the manipulation of the resistance training protocol (RTP) organization, maintaining the work to rest ratio equated between protocols (W:R-equated), may reduce the SBP increase. Purpose: To compare cardiovascular responses during two W:R-equated RTPs (3 × 15:88 s vs. 9 × 5:22 s - sets × reps: rest between sets) performed in exercises for the lower and upper limbs. Methods: Twelve medicated hypertensives (48 ± 8 years) randomly performed two RTPs in the bilateral leg extension (BLE) and unilateral elbow flexion (UEF) exercises at 50% 1RM. Increases (Δ) of SBP, heart rate (HR) and rate pressure product (RPP) during the exercises were measured by photoplethysmography. Results: In both BLE and UEF exercises, Δ SBP was significantly greater during 3 × 15:88 s than 9 × 5:22 s (peak values: BLE = + 84 ± 39 vs. + 67 ± 20 mm Hg, and UEF = + 46 ± 25 vs. + 37 ± 18 mm Hg, respectively, both p < 0.05). ΔHR and ΔRPP were significantly higher in the 3 × 15:88 s than 9 × 5:22 s in BLE (peak values + 45 ± 17 vs. + 30 ± 8 bpm, and + 15,559 ± 5570 vs. + 10,483 ± 2614 mm Hg. bpm). Conclusion: In medicated hypertensives, a RTP combining more sets with less repetitions per set and shorter rest intervals between sets (i.e., 9 × 5:22 s) produced a smaller increase in cardiovascular load (ΔSBP, ΔHR and ΔRPP) during its execution than a protocol with fewer longer sets (i.e., 3 × 15:88 s).",2020,"Increases (Δ) of SBP, heart rate (HR) and rate pressure product (RPP) during the exercises were measured by photoplethysmography. ","['Hypertensive Individuals', 'Twelve medicated hypertensives (48 ± 8 years) randomly performed two']","['RTPs in the bilateral leg extension (BLE) and unilateral elbow flexion (UEF) exercises at 50% 1RM', 'two W:R-equated RTPs']","['cardiovascular responses', 'SBP, heart rate (HR) and rate pressure product (RPP', 'cardiovascular load (ΔSBP, ΔHR and ΔRPP', 'ΔHR and ΔRPP', 'Blood Pressure Increase', 'systolic blood pressure (SBP']","[{'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0497247', 'cui_str': 'Elevated blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",,0.0259233,"Increases (Δ) of SBP, heart rate (HR) and rate pressure product (RPP) during the exercises were measured by photoplethysmography. ","[{'ForeName': 'Anderson Caetano', 'Initials': 'AC', 'LastName': 'Paulo', 'Affiliation': 'Academic Department of Physical Education, Federal Technological University of Paranná, Curitiba, Brazil.'}, {'ForeName': 'Claudia L M', 'Initials': 'CLM', 'LastName': 'Forjaz', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Décio', 'Initials': 'D', 'LastName': 'Mion', 'Affiliation': 'General Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Giovanio V', 'Initials': 'GV', 'LastName': 'Silva', 'Affiliation': 'General Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Silvana', 'Initials': 'S', 'LastName': 'Barros', 'Affiliation': 'General Hospital, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Valmor', 'Initials': 'V', 'LastName': 'Tricoli', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}]",Frontiers in physiology,['10.3389/fphys.2020.00481'] 2372,32714216,Establishing the Feasibility of Group Metacognitive Therapy for Anxiety and Depression in Cardiac Rehabilitation: A Single-Blind Randomized Pilot Study.,"Background Anxiety and depression are common in cardiac rehabilitation (CR) patients. However, CR programs which incorporate psychological techniques achieve modest reductions in emotional distress. More efficacious interventions that can be easily integrated within services are required. A promising alternative to current psychological interventions is metacognitive therapy (MCT). The aim was to evaluate the acceptability and feasibility of delivering Group-MCT to CR patients experiencing symptoms of anxiety and depression. Method and Results Fifty-two CR patients with elevated anxiety and/or depression were recruited to a single-blind randomized feasibility trial across three UK National Health Service Trusts and randomized to usual CR or usual CR plus six weekly sessions of group-MCT. Acceptability and feasibility of adding group-MCT to CR was based on recruitment rates, withdrawal, and drop-out by the primary end-point of 4 months; number of MCT and CR sessions attended; completion of follow-up questionnaires; and ability of the outcome measures to discriminate between patients. The study was also used to re-estimate the required sample size for a full-scale trial. We also examined the extent by which non-specialists adhered to the Group-MCT protocol. Group-MCT was found to be feasible and acceptable for CR patients with anxiety and depression. Recruitment and retention of participants was high, and attendance rates at CR were similar for both groups. Conclusion The results suggest the addition of MCT to CR did not have a negative impact on retention and support a full-scale trial of Group-MCT for cardiac patients.",2020,The results suggest the addition of MCT to CR did not have a negative impact on retention and support a full-scale trial of Group-MCT for cardiac patients.,"['and/or depression were recruited to a single-blind randomized feasibility trial across three UK National Health Service Trusts and randomized to', 'Anxiety and Depression in Cardiac Rehabilitation', 'cardiac rehabilitation (CR) patients', 'CR patients experiencing symptoms of anxiety and depression']","['Group Metacognitive Therapy', 'delivering Group-MCT', 'usual CR or usual CR plus six weekly sessions of group-MCT', 'MCT']","['Acceptability and feasibility', 'elevated anxiety', 'emotional distress', 'acceptability and feasibility']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0027462', 'cui_str': 'National Health Services'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}]",52.0,0.10156,The results suggest the addition of MCT to CR did not have a negative impact on retention and support a full-scale trial of Group-MCT for cardiac patients.,"[{'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Wells', 'Affiliation': 'Faculty of Biology, Medicine and Health, School of Psychological Sciences, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Reeves', 'Affiliation': 'NIHR School for Primary Care Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Calvin', 'Initials': 'C', 'LastName': 'Heal', 'Affiliation': 'NIHR School for Primary Care Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Fisher', 'Affiliation': 'Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Davies', 'Affiliation': 'Centre for Health Economics, Division of Population Health, Health Services Research and Primary Care, Faculty of Biology Medicine and Health, School of Health Sciences, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Heagerty', 'Affiliation': 'Core Technology Facility, The University of Manchester School of Medical Sciences, Manchester, United Kingdom.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Doherty', 'Affiliation': 'Department of Health Sciences, University of York, York, United Kingdom.'}, {'ForeName': 'Lora', 'Initials': 'L', 'LastName': 'Capobianco', 'Affiliation': 'Research and Innovation, Greater Manchester Mental Health NHS Foundation Trust, Manchester, United Kingdom.'}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00582'] 2373,32654286,The effectiveness of ferulic acid and microneedling in reducing signs of photoaging: A split-face comparative study.,"Photoaging is closely related to ultraviolet-induced oxidative stress. Ferulic acid is a plant-based antioxidant with antiaging activity. Combining ferulic acid peel with microneedling enhances its transdermal penetration. This study was designed to evaluate the efficacy of 14% ferulic acid peel combined with microneedling for facial photoaging. Sixteen women aged 45 to 60 years with Fitzpatrick skin types II and III were enrolled in this trial. All patients received eight treatment sessions with a full face application of chemical peeling based on 14% ferulic acid in 1-week intervals. During each session, on the right half of patient's face, peeling application was followed by microneedling. Efficacy was measured using Multi Probe Adapter (Courage + Khazaka electronic). The measurement of hydration, elasticity, melanin index, and erythema index were taken before treatments, after eighth session and 1 month after the last application. The objective evaluation showed statistically significant improvement in all measured skin parameters (P < .05), after ferulic acid peel application, as well as ferulic acid peel followed by microneedling. Combined therapy showed significantly greater improvement especially in skin elasticity, comparing to peeling administered alone. Ferulic acid has a significant bleaching, antiredness, smoothing, and moisturizing activity. When combined with microneedling, the efficiency is increased, in particular regarding skin elasticity.",2020,"The objective evaluation showed statistically significant improvement in all measured skin parameters (P < .05), after ferulic acid peel application, as well as ferulic acid peel followed by microneedling.","['for facial photoaging', 'Sixteen women aged 45 to 60\u2009years with Fitzpatrick skin types II and III']","['ferulic acid and microneedling', 'ferulic acid peel combined with microneedling', 'chemical peeling based on 14% ferulic acid', 'Ferulic acid']","['skin parameters', 'measurement of hydration, elasticity, melanin index, and erythema index', 'signs of photoaging', 'Efficacy', 'skin elasticity']","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0439070', 'cui_str': 'III'}]","[{'cui': 'C0060291', 'cui_str': 'ferulic acid'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0411412', 'cui_str': 'Chemical peeling of skin lesion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C1321013', 'cui_str': 'Hydration status'}, {'cui': 'C0025196', 'cui_str': 'Melanin'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0220912', 'cui_str': 'signs'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0423761', 'cui_str': 'Skin elasticity'}]",16.0,0.0178398,"The objective evaluation showed statistically significant improvement in all measured skin parameters (P < .05), after ferulic acid peel application, as well as ferulic acid peel followed by microneedling.","[{'ForeName': 'Master Zduńska-Pęciak', 'Initials': 'MZ', 'LastName': 'Kamila', 'Affiliation': 'Chair of Cosmetology, Department of Cosmetology and Aesthetic Dermatology, Faculty of Pharmacy, Medical University of Łódź, Łódź, Poland.'}, {'ForeName': 'Rotsztejn', 'Initials': 'R', 'LastName': 'Helena', 'Affiliation': ''}]",Dermatologic therapy,['10.1111/dth.14000'] 2374,32717045,Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.,"Importance Fixed-dose combination (FDC) therapies are being increasingly recommended for initial or early management of patients with hypertension, as they reduce treatment complexity and potentially reduce therapeutic inertia. Objective To investigate the association of antihypertensive triple drug FDC therapy with therapeutic inertia and prescribing patterns compared with usual care. Design, Setting, and Participants A post hoc analysis of the Triple Pill vs Usual Care Management for Patients With Mild-to-Moderate Hypertension (TRIUMPH) study, a randomized clinical trial of 700 patients with hypertension, was conducted. Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017. Data were analyzed from September to November 2019. Interventions Once-daily FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) or usual care. Main Outcomes and Measures Therapeutic inertia, defined as not intensifying therapy in those with blood pressure (BP) above target, was assessed at baseline and during follow-up visits. Prescribing patterns were characterized by BP-lowering drug class and treatment regimen potency. Predictors of therapeutic inertia were assessed with binomial logistic regression. Results Of the 700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years. Among patients who did not reach the BP target, therapeutic inertia was more common in the triple pill group compared with the usual care group at the week 6 visit (92 of 106 [86.8%] vs 124 of 194 [63.9%]; P < .001) and week 12 visit (81 of 90 [90%] vs 116 of 179 [64.8%]; P < .001). At the end of the study, 221 of 318 patients in the triple pill group (69.5%) and 182 of 329 patients in the usual care group (55.3%) reached BP targets. Among those who received treatment intensification, the increase in estimated regimen potency was greater in the triple pill group compared with the usual care group at baseline (predicted mean [SD] increase in regimen potency: triple pill, 15 [6] mm Hg; usual care, 10 [5] mm Hg; P < .001), whereas there were no significant differences at the week 6 or at week 12 visit. Clinic systolic BP level was the only consistent predictor of treatment intensification during follow-up. During follow-up, there were 23 vs 54 unique treatment regimens per 100 treated patients in the triple pill vs usual care groups, respectively (P < .001). Conclusions and Relevance Triple pill FDC therapy was associated with greater rates of therapeutic inertia compared with usual care. Despite this, triple pill FDC therapy substantially simplified prescribing patterns and improved 6-month BP control rates compared with usual care. Further improvements in hypertension control could be achieved by addressing therapeutic inertia among the minority of patients who do not achieve BP control after initial FDC therapy. Trial Registration ANZCTR Identifier: ACTRN12612001120864.",2020,"Despite this, triple pill FDC therapy substantially simplified prescribing patterns and improved 6-month BP control rates compared with usual care.","['700 patients with hypertension', '700 included patients, 403 (57.6%) were female, and the mean (SD) age was 56 (11) years', '318 patients in the triple pill group (69.5%) and 182 of 329 patients in the usual care group (55.3%) reached BP targets', 'Patients With Hypertension', 'patients with hypertension', 'Patients were enrolled from 11 urban hospital clinics in Sri Lanka from February 2016 to May 2017; follow-up ended in October 2017', 'Patients With Mild-to-Moderate Hypertension (TRIUMPH']","['Low-Dose Triple Combination Therapy', 'Triple Pill vs Usual Care Management', 'antihypertensive triple drug FDC therapy', 'FDC antihypertensive pill (telmisartan, 20 mg; amlodipine, 2.5 mg; and chlorthalidone, 12.5 mg) or usual care', 'Importance\n\n\nFixed-dose combination (FDC) therapies']","['6-month BP control rates', 'rates of therapeutic inertia', 'estimated regimen potency', 'blood pressure (BP', 'Clinic systolic BP level', 'BP target, therapeutic inertia']","[{'cui': 'C4517862', 'cui_str': '700'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0020029', 'cui_str': 'Urban Hospitals'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0038088', 'cui_str': 'Sri Lanka'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C3643615', 'cui_str': 'Triumph'}]","[{'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0009905', 'cui_str': 'Oral Contraceptives'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0248719', 'cui_str': 'telmisartan'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0008294', 'cui_str': 'Chlorthalidone'}, {'cui': 'C4517544', 'cui_str': '12.5'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",700.0,0.0588462,"Despite this, triple pill FDC therapy substantially simplified prescribing patterns and improved 6-month BP control rates compared with usual care.","[{'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Wang', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Abdul', 'Initials': 'A', 'LastName': 'Salam', 'Affiliation': 'The George Institute for Global Health, New Delhi, India.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Webster', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Asita', 'Initials': 'A', 'LastName': 'de Silva', 'Affiliation': 'Clinical Trials Unit, Department of Pharmacology, Faculty of Medicine, University of Kelaniya, Kelaniya, Sri Lanka.'}, {'ForeName': 'Rama', 'Initials': 'R', 'LastName': 'Guggilla', 'Affiliation': 'Division of Dentistry, Division of Medical Education in English, Department of Population Medicine and Civilization Diseases Prevention, Faculty of Medicine, Medical University of Bialystok, Bialystok, Poland.'}, {'ForeName': 'Sandrine', 'Initials': 'S', 'LastName': 'Stepien', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Jayanthi', 'Initials': 'J', 'LastName': 'Mysore', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Billot', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Jan', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Pallab K', 'Initials': 'PK', 'LastName': 'Maulik', 'Affiliation': 'The George Institute for Global Health, New Delhi, India.'}, {'ForeName': 'Nitish', 'Initials': 'N', 'LastName': 'Naik', 'Affiliation': 'All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Selak', 'Affiliation': 'Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Thom', 'Affiliation': 'Department of Epidemiology and Biostatistics, The University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Dorairaj', 'Initials': 'D', 'LastName': 'Prabhakaran', 'Affiliation': 'Centre for Chronic Disease Control and Public Health Foundation, New Delhi, India.'}, {'ForeName': 'Anushka', 'Initials': 'A', 'LastName': 'Patel', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Rodgers', 'Affiliation': 'The George Institute for Global Health, The University of New South Wales, Sydney, Australia.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA cardiology,['10.1001/jamacardio.2020.2739'] 2375,32717112,Influence of delayed umbilical cord clamping on pain during suture of perineal tears: A randomized controlled study.,"OBJECTIVE This study investigated whether the delayed umbilical cord clamping can influence the pain during suturing perineal tears. DESIGN This randomized controlled study applied the Consolidated Standards of Reporting Trials statement. METHODS The sample comprised 288 pregnant women who gave birth through vaginal delivery in our hospital from November 2019 to December 2019. They were randomly divided into 2 groups-early umbilical cord clamping (n=147) and delayed umbilical cord clamping (n=141)-without severe pregnancy complications. There was no intrauterine infection, neonatal asphyxia, or premature birth in the 288 newborns. The pain scores of the Numerical Rating Scale, Visual Analogue Scale, Verbal Rating Scale, and Faces Pain Scale-Revised were used as indicators to evaluate the mothers' pain. The Mann-Whitney U test was used, and the statistical significance was set to P＜0.05. RESULT All indicators suggest that perineal suture pain of delayed umbilical cord clamping was lower than that of the control group. For the experience group, the perception of pain for the mothers who received analgesia was less than that for those who did not. For the control group, the Verbal Rating Scale suggests a statistical difference in suturing pain between acceptable and unacceptable labor analgesia. The degree of cooperation of the experience group was higher than that of the control group, but labor analgesia did not affect cooperation degree in both groups. CONCLUSION Delayed umbilical cord clamping can alleviate maternal pain when suturing perineal tears and improve the delivery experience. Labor analgesia can enhance the pain relief effect. Trial registration was performed on www.chictr.org.cn (ChiCTR1900026797). RELEVANCE TO CLINICAL PRACTICE As a part of perinatal nursing, delayed umbilical cord clamping can help alleviate the pain of perineal suture and improve the experience of parturient. The method is simple and can be used as a routine nursing operation.",2020,"For the control group, the Verbal Rating Scale suggests a statistical difference in suturing pain between acceptable and unacceptable labor analgesia.","['288 pregnant women who gave birth through vaginal delivery in our hospital from November 2019 to December 2019', 'pain during suture of perineal tears']","['Delayed umbilical cord clamping', 'Labor analgesia', 'umbilical cord clamping (n=147) and delayed umbilical cord clamping', 'delayed umbilical cord clamping']","['intrauterine infection, neonatal asphyxia, or premature birth', ""pain scores of the Numerical Rating Scale, Visual Analogue Scale, Verbal Rating Scale, and Faces Pain Scale-Revised were used as indicators to evaluate the mothers' pain"", 'suturing pain between acceptable and unacceptable labor analgesia', 'perineal suture pain of delayed umbilical cord clamping', 'labor analgesia', 'maternal pain', 'Verbal Rating Scale', 'pain', 'perception of pain', 'pain relief effect']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0404427', 'cui_str': 'Repair of perineal tear'}]","[{'cui': 'C0405737', 'cui_str': 'Umbilical cord clamping'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}]","[{'cui': 'C1112157', 'cui_str': 'Intrauterine infection'}, {'cui': 'C0004045', 'cui_str': 'Asphyxia, in liveborn infant'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0458261', 'cui_str': 'Verbal rating scale'}, {'cui': 'C0015468', 'cui_str': 'Pain in face'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0009068', 'cui_str': 'Closure by suture'}, {'cui': 'C3539083', 'cui_str': 'Acceptable'}, {'cui': 'C1301740', 'cui_str': 'Analgesia in labor'}, {'cui': 'C0031066', 'cui_str': 'Perineal'}, {'cui': 'C0405737', 'cui_str': 'Umbilical cord clamping'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",288.0,0.0279898,"For the control group, the Verbal Rating Scale suggests a statistical difference in suturing pain between acceptable and unacceptable labor analgesia.","[{'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Zou', 'Affiliation': 'Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Cuicun', 'Initials': 'C', 'LastName': 'Han', 'Affiliation': 'Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Xiaowei', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Jiang', 'Affiliation': 'Department of Obstetrics, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}]",Journal of clinical nursing,['10.1111/jocn.15421'] 2376,32717123,Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention.,"BACKGROUND Lifestyle interventions are the primary treatment for metabolic (dysfunction) associated fatty liver disease (MAFLD). However, the histological and cardiometabolic effects of aerobic exercise in MAFLD remain unclear. AIMS To assess the effects of a 12-week aerobic exercise intervention on histological and cardiometabolic endpoints in MAFLD. METHODS Patients with biopsy-confirmed MAFLD participated in a 12-week aerobic exercise intervention. Liver histology, cardiorespiratory fitness (estimated V̇O 2max ), physical activity, anthropometry and biochemical markers were assessed at baseline, intervention completion, and 12 and 52 weeks after intervention completion. RESULTS Twenty-four patients completed the exercise intervention (exercise group n = 16, control group n = 8). In the exercise group, 12 weeks of aerobic exercise reduced fibrosis and hepatocyte ballooning by one stage in 58% (P = 0.034) and 67% (P = 0.020) of patients, with no changes in steatosis (P = 1.000), lobular inflammation (P = 0.739) or NAFLD activity score (P = 0.172). Estimated V̇O 2max increased by 17% compared to the control group (P = 0.027) but this level of improvement was not maintained at 12 or 52 weeks after the intervention. Patients with fibrosis and ballooning improvement increased estimated V̇O 2max by 25% (P = 0.020) and 26% (P = 0.010), respectively. Anthropometric reductions including body mass (P = 0.038), waist circumference (P = 0.015) and fat mass (P = 0.007) were also observed, but no patient achieved 7%-10% weight loss. CONCLUSION This study highlights the potential benefits of a 12-week aerobic exercise intervention in improving histological endpoints of MAFLD. The development of strategies to ensure continued engagement in aerobic exercise in MAFLD are needed.",2020,"Patients with fibrosis and ballooning improvement increased estimated V̇O 2max by 25% (P = 0.020) and 26% (P = 0.010), respectively.",['Patients with biopsy-confirmed MAFLD participated in a 12-week'],"['aerobic exercise intervention', 'exercise intervention (exercise', 'aerobic exercise']","['waist circumference', 'steatosis', 'fibrosis and hepatocyte ballooning', 'Liver histology, cardiorespiratory fitness (estimated V̇O 2max ), physical activity, anthropometry and biochemical markers', 'Anthropometric reductions including body mass', 'fat mass', 'Estimated V̇O 2max', 'lobular inflammation', 'NAFLD activity score', 'estimated V̇O 2max']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0015695', 'cui_str': 'Fatty Liver'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0152254', 'cui_str': 'Fatty degeneration'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0227525', 'cui_str': 'Hepatic parenchymal cell'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003188', 'cui_str': 'Anthropometry'}, {'cui': 'C0206015', 'cui_str': 'Biochemical Markers'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0205417', 'cui_str': 'Lobular'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0400966', 'cui_str': 'Non-alcoholic fatty liver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0431615,"Patients with fibrosis and ballooning improvement increased estimated V̇O 2max by 25% (P = 0.020) and 26% (P = 0.010), respectively.","[{'ForeName': 'Philip', 'Initials': 'P', 'LastName': ""O'Gorman"", 'Affiliation': 'Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Naimimohasses', 'Affiliation': ""Department of Hepatology, St James's Hospital, Dublin, Ireland.""}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Monaghan', 'Affiliation': 'Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Kennedy', 'Affiliation': 'Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Ashanty M', 'Initials': 'AM', 'LastName': 'Melo', 'Affiliation': 'Department of Immunology, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Deirdre', 'Initials': 'D', 'LastName': 'Ní Fhloinn', 'Affiliation': ""Department of Hepatology, St James's Hospital, Dublin, Ireland.""}, {'ForeName': 'Derek G', 'Initials': 'DG', 'LastName': 'Doherty', 'Affiliation': 'Department of Immunology, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Beddy', 'Affiliation': ""Department of Radiology, St James's Hospital, Dublin, Ireland.""}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Finn', 'Affiliation': ""Department of Histopathology, St James's Hospital and Trinity College Dublin, Dublin, Ireland.""}, {'ForeName': 'J Bernadette', 'Initials': 'JB', 'LastName': 'Moore', 'Affiliation': 'School of Food Science and Nutrition, University of Leeds, Leeds, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Gormley', 'Affiliation': 'Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Norris', 'Affiliation': ""Department of Hepatology, St James's Hospital, Dublin, Ireland.""}]",Alimentary pharmacology & therapeutics,['10.1111/apt.15989'] 2377,32717127,Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.,"LESSONS LEARNED A structured teaching module including intensive prophylactic measures to alleviate HFS during capecitabine therapy is feasible but ineffective at protecting patients from HFS. Pharmacologic therapeutic interventions should be investigated for the management of this complication. BACKGROUND Capecitabine-induced hand-foot syndrome (HFS) has a detrimental effect on quality of life. The effect of a structured teaching module including intensive prophylactic measures was evaluated. METHODS This non-crossover phase III double-blinded clinical trial randomized patients in a 1:1 ratio to either a control group or to a group administered a structured teaching model including intensive prophylactic measures on HFS administered by a trained oncology nurse at regular intervals (case) versus standard information on HFS care administered by treating clinician (control). The primary endpoint was comparison of fraction of patients in both arms developing at least grade 2 HFS. RESULTS Between June 15, 2016 and April 4 2018, 280 patients (140 to case and 140 to control) were enrolled. The median number of capecitabine chemotherapy cycles was eight; 269 patients (96%) were evaluable for HFS, of whom 89 patients (33.08%) developed at least grade 2 HFS [grade 2 HFS - 73 patients (26.1%); grade 3 HFS - 16 patients (5.7%)]. There was no difference in at least grade 2 HFS between evaluable case and control arms of the study [control group - 45/135 (33.3%); case - 44/134 (32.8%); p = .93]. CONCLUSION The use of a structured teaching module including intensive prophylactic measures was feasible, but this did not reduce the incidence and severity of capecitabine-induced HFS.",2020,"There was no difference in at least grade 2 HFS between evaluable case and control arms of the study [control group - 45/135 (33.3%); case - 44/134 (32.8%); p = .93]. ","['Between June 15, 2016 and April 4 2018, 280 patients (140 to case and 140 to control) were enrolled']","['structured teaching module', 'Structured Teaching Module', 'structured teaching model including intensive prophylactic measures on HFS administered by a trained oncology nurse at regular intervals (case) versus standard information on HFS care administered by treating clinician (control', 'capecitabine therapy']","['quality of life', 'median number of capecitabine chemotherapy cycles', 'comparison of fraction of patients in both arms developing at least grade 2 HFS', 'Incidence of Capecitabine-Induced Hand-Foot Syndrome']","[{'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009653', 'cui_str': 'Condom'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0557529', 'cui_str': 'Oncology nurse'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C1302181', 'cui_str': 'Chemotherapy cycle'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0230348', 'cui_str': 'Both upper arms'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",,0.0958387,"There was no difference in at least grade 2 HFS between evaluable case and control arms of the study [control group - 45/135 (33.3%); case - 44/134 (32.8%); p = .93]. ","[{'ForeName': 'Vikas', 'Initials': 'V', 'LastName': 'Ostwal', 'Affiliation': 'Medical Oncology Department, Tata Memorial Centre Mumbai, Mumbai, India.'}, {'ForeName': 'Akhil', 'Initials': 'A', 'LastName': 'Kapoor', 'Affiliation': 'tata Memorial Centre Mumbai, Mumbai, India.'}, {'ForeName': 'Sarika', 'Initials': 'S', 'LastName': 'Mandavkar', 'Affiliation': 'Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Neeta', 'Initials': 'N', 'LastName': 'Chavan', 'Affiliation': 'Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Tarachand', 'Initials': 'T', 'LastName': 'Gupta', 'Affiliation': 'Apex Hospitals, Jaipur, Rajasthan, India.'}, {'ForeName': 'Jimmy', 'Initials': 'J', 'LastName': 'Mirani', 'Affiliation': 'Wochardt Hospitals, Mumbai, India.'}, {'ForeName': 'Avanish', 'Initials': 'A', 'LastName': 'Saklani', 'Affiliation': 'Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Ashwin', 'Initials': 'A', 'LastName': 'Desouza', 'Affiliation': 'Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Kalaivani', 'Initials': 'K', 'LastName': 'Shrinivasan', 'Affiliation': 'Tata Memorial Centre, Parel, Mumbai, India.'}, {'ForeName': 'Chaitali', 'Initials': 'C', 'LastName': 'Nashikkar', 'Affiliation': 'Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Sudeep', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'ACTREC (Advanced Centre for Treatment, Research and Education in Cancer) Navi Mumbai, Maharashtra, India.'}, {'ForeName': 'Anant', 'Initials': 'A', 'LastName': 'Ramaswamy', 'Affiliation': 'tata Memorial Centre Mumbai, Mumbai, India.'}]",The oncologist,['10.1634/theoncologist.2020-0698'] 2378,32717696,Using unfolding case studies to develop critical thinking skills in baccalaureate nursing students: A pilot study.,"BACKGROUND Research has consistently demonstrated that new graduate nurses do not possess sufficient critical thinking skills when they transition to clinical practice. Unfolding case studies encourage students to participate in a number of critical thinking skills including information-seeking, logical reasoning, and analyzing of clinical data. OBJECTIVE The aim of this study was to determine how the use of unfolding case studies as a learning modality affected baccalaureate students' critical thinking skills in their Adult Health Theory course. The researcher compared course examination scores earned by nursing students who were taught using traditional case studies to scores obtained by nursing students who completed unfolding case studies. SETTING The pilot study took place at a moderate-sized comprehensive university in Wisconsin. DESIGN A non-experimental correlational design using course examination scores data was employed to examine how the use of unfolding case studies as a learning modality affected baccalaureate students' critical thinking skills in their Adult Health Theory course. PARTICIPANTS A total of 160 students comprised the intervention group while an additional 142 students represented the control group in the study. METHODS An independent-samples t-test was performed to explore differences in mean scores between the intervention and control groups. RESULTS Results of the t-test indicate that mean examination scores were significantly higher for the intervention group (M = 234.9, SD = 13.1) than for the control group (M = 228.2, SD = 13.3); t(299) =, p < .001. CONCLUSIONS Results of this study suggest that unfolding case studies more effectively develop students' critical thinking skills than do a more traditional, static case study.",2020,"RESULTS Results of the t-test indicate that mean examination scores were significantly higher for the intervention group (M = 234.9, SD = 13.1) than for the control group (M = 228.2, SD = 13.3); t(299) =, p < .001. ","['A total of 160 students comprised the intervention group while an additional 142 students represented the control group in the study', 'baccalaureate nursing students', 'The pilot study took place at a moderate-sized comprehensive university in Wisconsin']",[],"['mean scores', 'mean examination scores']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0031928', 'cui_str': 'Pilot Study'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0043193', 'cui_str': 'Wisconsin'}]",[],"[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",160.0,0.0283034,"RESULTS Results of the t-test indicate that mean examination scores were significantly higher for the intervention group (M = 234.9, SD = 13.1) than for the control group (M = 228.2, SD = 13.3); t(299) =, p < .001. ","[{'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Englund', 'Affiliation': 'University of Wisconsin Oshkosh, College of Nursing, 800 Algoma Blvd, Oshkosh, WI, United States of America. Electronic address: englundh@uwosh.edu.'}]",Nurse education today,['10.1016/j.nedt.2020.104542'] 2379,32717713,"Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.","OBJECTIVE To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV) in adults with focal seizures by the number of lifetime (previous and concomitant) antiepileptic drugs (AEDs). METHODS Post-hoc analysis of data from N01358 (NCT01261325), a randomized, double-blind, placebo (PBO)-controlled Phase III trial evaluating BRV 100 and 200 mg/day in patients ≥16 years of age with uncontrolled focal seizures. Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. RESULTS 764 patients received at least one dose of trial medication (BRV: 503; PBO: 261; Safety Set), of whom 14.3% had 1-2, 20.8% had 3-4, 21.3% had 5-6, and 43.6% had ≥7 lifetime AEDs. In all lifetime AED subgroups, >85% of patients completed the trial. Patients with a higher number of lifetime AEDs had a younger age at epilepsy onset, longer epilepsy duration, and higher baseline seizure frequency. In patients on BRV, 50% responder rates were 49.3%, 44.4%, 47.2% and 27.4% in patients with 1-2 (n = 75), 3-4 (n = 99), 5-6 (n = 108) and ≥7 (n = 219) lifetime AEDs; 75% responder rates were 36.0%, 21.2%, 22.2% and 12.3%. In patients on PBO, 50% responder rates were 35.3%, 25.9%, 20.4% and 15.9% in patients with 1-2 (n = 34), 3-4 (n = 58), 5-6 (n = 54) and ≥7 (n = 113) lifetime AEDs; 75% responder rates were 26.5%, 6.9%, 3.7% and 4.4%. The Kaplan-Meier estimated probability of patients achieving a sustained 50% or 75% response from the first day of treatment was generally higher in patients with a lower number of lifetime AEDs (both in patients on BRV and PBO). In patients on adjunctive BRV, the incidence of drug related treatment-emergent adverse events (TEAEs) was 34.7%, 26.0%, 44.4% and 47.7% in patients with 1-2 (n = 75), 3-4 (n = 100), 5-6 (n = 108) and ≥7 (n = 220) lifetime AEDs; the incidence of discontinuations due to TEAEs was 1.3%, 3.0%, 8.3% and 10.5%. CONCLUSIONS This post-hoc analysis suggests a numerically higher response to adjunctive BRV in patients with fewer lifetime AEDs. The lowest response was observed in patients with ≥7 lifetime AEDs, although these patients could also benefit from adjunctive BRV treatment. Patients with fewer lifetime AEDs had lower discontinuation of BRV due to TEAEs.",2020,"Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. ","['adults with focal seizures by the number of lifetime (previous and concomitant) antiepileptic drugs (AEDs', 'adults with focal seizures', 'subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs', 'patients ≥16 years of age with uncontrolled focal seizures']","['adjunctive brivaracetam (BRV', 'adjunctive brivaracetam', 'placebo']","['Efficacy and tolerability outcomes', 'responder rates', 'incidence of drug related treatment-emergent adverse events (TEAEs', 'efficacy and tolerability']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0003299', 'cui_str': 'ANTIEPILEPTICS'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0442749', 'cui_str': '6/5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}]","[{'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",764.0,0.103758,"Efficacy and tolerability outcomes were assessed for the 12-week Treatment Period in subgroups of patients with 1-2, 3-4, 5-6, or ≥7 lifetime AEDs. ","[{'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Klein', 'Affiliation': 'Mid-Atlantic Epilepsy and Sleep Center, 6410 Rockledge Drive, Suite 610, Bethesda, MD 20817, USA. Electronic address: kleinp@epilepsydc.com.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'McLachlan', 'Affiliation': 'Western University, 339 Windermere Road, London, ON N6A 5A5, Canada. Electronic address: rsmcl@uwo.ca.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Foris', 'Affiliation': 'UCB Pharma, 2060 Winston Park Drive, Suite 401, Oakville, ON L6H 5R7, Canada. Electronic address: kforis@sympatico.ca.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Nondonfaz', 'Affiliation': ""UCB Pharma, Chemin du Foriest, 1420 Braine-l'Alleud, Belgium. Electronic address: xavier.nondonfaz@ucb.com.""}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: sami.elmoufti@ucb.com.'}, {'ForeName': 'Svetlana', 'Initials': 'S', 'LastName': 'Dimova', 'Affiliation': 'UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium. Electronic address: svetlana.dimova@ucb.com.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Brandt', 'Affiliation': 'Bethel Epilepsy Center, Mara Hospital, Maraweg 21, 33617 Bielefeld, Germany. Electronic address: christian.brandt@mara.de.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106369'] 2380,32717720,Different Time Course of Recovery in Achilles Tendon Thickness After Low-Load Resistance Training With and Without Blood Flow Restriction.,"CONTEXT Blood flow restriction research has focused on muscular strength and hypertrophy. Limited data have been reported about the blood flow restriction effect on the tendon. OBJECTIVE To analyze and compare the time course of recovery in Achilles tendon thickness after a single bout of low-intensity resistance training (LI-RT) and low-intensity blood flow restriction training (LI-BFRT). METHODS A total of 56 healthy participants (24.60 [4.0] y; 23.65 [3.4] body mass index) were included. The dominant leg was assigned for LI-BFRT using low load (30% 1-repetition maximum) and 30% of the total occlusion pressure (52.21 [17.89] mm Hg) in plantar-flexion exercise (1 × 30 + 3 × 15 repetitions). The nondominant leg was assumed as a control condition. MAIN OUTCOME MEASURE Sonography images were taken before the intervention, immediately posttraining, and 24 hours after exercise (post-24) for the Achilles tendon thickness. RESULTS Changes in Achilles tendon thickness for LI-BFRT group were significant post- (-14.5%; P < .05) and post-24 (-9.2%; P < .05). In contrast, LI-RT group showed a transient decrease after exercise (-9.67%; P < .05) followed by a recovery of thickness post-24 (-1.06%; P < .05). Thickness post-24 was different between LI-BFRT versus LI-RT (P < .01). Hedge effect size analysis showed a large effect (g = 0.90) in LI-BFRT pre-post condition and a medium effect (g = 0.57) in post- to post-24. The LI-RT obtained a medium effect (g = 0.53) in pre-post condition and a small effect (g = 0.49) in post- to post-24. CONCLUSIONS This study showed a different time course of the acute response in Achilles tendon thickness between LI-BFRT and LI-RT. This may be associated with intratendinous fluid movement in response to LI-BFRT.",2020,Thickness post-24 was different between LI-BFRT versus LI-RT (P < .01).,"['56 healthy participants (24.60 [4.0]\xa0y; 23.65 [3.4] body mass index) were included', 'Achilles']","['low-intensity resistance training (LI-RT) and low-intensity blood flow restriction training (LI-BFRT', 'Low-Load Resistance Training With and Without Blood Flow Restriction', 'plantar-flexion exercise', 'LI-BFRT and LI-RT']","['Achilles tendon thickness', 'Tendon Thickness', 'tendon thickness']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C4517692', 'cui_str': '3.4'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0001074', 'cui_str': 'Structure of Achilles tendon'}]","[{'cui': 'C0596836', 'cui_str': 'Light intensity'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0231784', 'cui_str': 'Plantar flexion'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0001074', 'cui_str': 'Structure of Achilles tendon'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}]",56.0,0.150282,Thickness post-24 was different between LI-BFRT versus LI-RT (P < .01).,"[{'ForeName': 'Iván', 'Initials': 'I', 'LastName': 'Chulvi-Medrano', 'Affiliation': ''}, {'ForeName': 'Moisés', 'Initials': 'M', 'LastName': 'Picón-Martínez', 'Affiliation': ''}, {'ForeName': 'Juan Manuel', 'Initials': 'JM', 'LastName': 'Cortell-Tormo', 'Affiliation': ''}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Tortosa-Martínez', 'Affiliation': ''}, {'ForeName': 'Diego Alexandre', 'Initials': 'DA', 'LastName': 'Alonso-Aubin', 'Affiliation': ''}, {'ForeName': 'Yasser', 'Initials': 'Y', 'LastName': 'Alakhdar', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2019-0403'] 2381,32717773,"Effects of high-frequency, high-intensity transcutaneous electrical nerve stimulation versus intravenous opioids for pain relief after hysteroscopy: a randomized controlled study.","Objective To compare the time spent in the Post-Anesthesia Care Unit (PACU) and the pain-relieving effects of treatment with high-frequency, high-intensity transcutaneous electrical nerve stimulation (TENS) or intravenous (IV) opioids after hysteroscopy. Methods All patients who postoperatively reported a visual analogue scale (VAS) pain score of ≥3 were included in the study. TENS treatment was given with a stimulus intensity between 40 and 60 mA for 1 minute and repeated once if there was insufficient pain relief. In the opioid group, a fractionated dose of 5 mg morphine was administered. If the patient reported insufficient pain relief after the assigned treatment, the patient was reassigned to the other treatment group. Results Seventy-four women were randomized to TENS (n=38) or IV opioids (n=36) for treatment. Both groups reported significant pain relief after discharge from the PACU, with a decrease of VAS scores from 5.6 to 1.4 in the TENS group (P<0.001) and 5.1 to 1.3 in the opioid group (P<0.001). There were no significant differences between the groups. When only the responders in both groups, i.e., patients with VAS scores of <3 on respectively assigned treatments, were compared, the TENS responders (n=22) were found to have spent a significantly shorter time in the PACU (91 vs. 69 minutes, P=0.013) compared to the opioid responders (n=20). Conclusion Using TENS as first line of pain relief may reduce the need for postoperative opioids. In addition, TENS appears preferable as the first line of treatment due to its association with a shorter time spent in the PACU if the patient responds to the treatment. Trial Registration Västra Götalandsregionen Identifier: 211261.",2020,"Both groups reported significant pain relief after discharge from the PACU, with a decrease of VAS scores from 5.6 to 1.4 in the TENS group (P<0.001) and 5.1 to 1.3 in the opioid group (P<0.001).","['pain relief after hysteroscopy', 'Results\n\n\nSeventy-four women', 'All patients who postoperatively reported a visual analogue scale (VAS) pain score of ≥3 were included in the study']","['TENS', 'high-frequency, high-intensity transcutaneous electrical nerve stimulation (TENS) or intravenous (IV) opioids', 'high-frequency, high-intensity transcutaneous electrical nerve stimulation versus intravenous opioids', 'IV opioids', 'morphine']","['pain relief', 'VAS scores']","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0020710', 'cui_str': 'Hysteroscopy'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0040654', 'cui_str': 'Percutaneous electrical nerve stimulation'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",74.0,0.0842403,"Both groups reported significant pain relief after discharge from the PACU, with a decrease of VAS scores from 5.6 to 1.4 in the TENS group (P<0.001) and 5.1 to 1.3 in the opioid group (P<0.001).","[{'ForeName': 'Birgitta', 'Initials': 'B', 'LastName': 'Platon', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.'}, {'ForeName': 'Sven-Egron', 'Initials': 'SE', 'LastName': 'Thörn', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Clas', 'Initials': 'C', 'LastName': 'Mannheimer', 'Affiliation': 'Multidisciplinary Pain Center Kungälv Hospital Kungälv and Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Paulin', 'Initials': 'P', 'LastName': 'Andréll', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Obstetrics & gynecology science,['10.5468/ogs.20063'] 2382,32725398,Ultrasound in augmented reality: a mixed-methods evaluation of head-mounted displays in image-guided interventions.,"PURPOSE Augmented reality (AR) and head-mounted displays (HMD) in medical practice are current research topics. A commonly proposed use case of AR-HMDs is to display data in image-guided interventions. Although technical feasibility has been thoroughly shown, effects of AR-HMDs on interventions are not yet well researched, hampering clinical applicability. Therefore, the goal of this study is to better understand the benefits and limitations of this technology in ultrasound-guided interventions. METHODS We used an AR-HMD system (based on the first-generation Microsoft Hololens) which overlays live ultrasound images spatially correctly at the location of the ultrasound transducer. We chose ultrasound-guided needle placements as a representative task for image-guided interventions. To examine the effects of the AR-HMD, we used mixed methods and conducted two studies in a lab setting: (1) In a randomized crossover study, we asked participants to place needles into a training model and evaluated task duration and accuracy with the AR-HMD as compared to the standard procedure without visual overlay and (2) in a qualitative study, we analyzed the user experience with AR-HMD using think-aloud protocols during ultrasound examinations and semi-structured interviews after the task. RESULTS Participants (n = 20) placed needles more accurately (mean error of 7.4 mm vs. 4.9 mm, p = 0.022) but not significantly faster (mean task duration of 74.4 s vs. 66.4 s, p = 0.211) with the AR-HMD. All participants in the qualitative study (n = 6) reported limitations of and unfamiliarity with the AR-HMD, yet all but one also clearly noted benefits and/or that they would like to test the technology in practice. CONCLUSION We present additional, though still preliminary, evidence that AR-HMDs provide benefits in image-guided procedures. Our data also contribute insights into potential causes underlying the benefits, such as improved spatial perception. Still, more comprehensive studies are needed to ascertain benefits for clinical applications and to clarify mechanisms underlying these benefits.",2020,"RESULTS Participants (n = 20) placed needles more accurately (mean error of 7.4 mm vs. 4.9 mm, p = 0.022) but not significantly faster (mean task duration of 74.4 s vs. 66.4 ",[],"['AR-HMD using think-aloud protocols during ultrasound examinations and semi-structured interviews after the task', 'ultrasound-guided needle placements', 'place needles into a training model and evaluated task duration and accuracy with the AR-HMD as compared to the standard procedure without visual overlay and (2', 'Augmented reality (AR) and head-mounted displays (HMD', 'AR-HMD']",[],[],"[{'cui': 'C5197824', 'cui_str': 'Mixed Reality'}, {'cui': 'C5197728', 'cui_str': 'Head Worn Display'}, {'cui': 'C0039869', 'cui_str': 'Thinking'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0948501', 'cui_str': 'Ultrasound examination'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0444456', 'cui_str': 'Overlay'}]",[],,0.0290659,"RESULTS Participants (n = 20) placed needles more accurately (mean error of 7.4 mm vs. 4.9 mm, p = 0.022) but not significantly faster (mean task duration of 74.4 s vs. 66.4 ","[{'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Rüger', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Experimental Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Markus A', 'Initials': 'MA', 'LastName': 'Feufel', 'Affiliation': 'Division of Ergonomics, Department of Psychology and Ergonomics (IPA), Technische Universität Berlin, Marchstr. 23, MAR 3-2, 10587, Berlin, Germany.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Moosburner', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Experimental Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Özbek', 'Affiliation': 'Scopis GmbH, Heinrich-Heine-Platz 10, 10179, Berlin, Germany.'}, {'ForeName': 'Johann', 'Initials': 'J', 'LastName': 'Pratschke', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Experimental Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany.'}, {'ForeName': 'Igor M', 'Initials': 'IM', 'LastName': 'Sauer', 'Affiliation': 'Department of Surgery, Campus Charité Mitte | Campus Virchow-Klinikum, Experimental Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. igor.sauer@charite.de.'}]",International journal of computer assisted radiology and surgery,['10.1007/s11548-020-02236-6'] 2383,32725411,10-Year Paclitaxel Dose-Related Outcomes of Drug-Eluting Stents Treated Below the Knee in Patients with Chronic Limb-Threatening Ischemia (The PADI Trial).,"PURPOSE Recently, two meta-analyses concluded that there appears to be an increased risk of long-term mortality of paclitaxel-coated balloons and stents in the superficial femoral and popliteal artery, and paclitaxel-coated balloons below the knee. In this post hoc study of the PADI Trial, we investigated the long-term safety of first-generation paclitaxel-coated drug-eluting stents (DES) below the knee and the dose-mortality relationships of paclitaxel in patients with chronic limb-threatening ischemia (CLI). MATERIALS AND METHODS The PADI Trial compared paclitaxel-coated DES with percutaneous transluminal angioplasty with bail-out bare-metal stents (PTA ± BMS) in patients with CLI treated below the knee. Follow-up was extended to 10 years after the first inclusion, and survival analyses were performed. In addition, dose-related mortality and dose per patient weight-related mortality relations were examined. RESULTS A total of 140 limbs in 137 patients were included in the PADI Trial. Ten years after the first inclusion, 109/137 (79.6%) patients had died. There was no significant difference between mortality in the DES group compared with the PTA ± BMS group (Log-rank p value = 0.12). No specific dose-related mortality (HR 1.00, 95% CI 0.99-1.00, p = 0.99) or dose per weight mortality (HR 1.05, 95% CI 0.93-1.18, p = 0.46) relationships were identified in the Cox-proportional Hazard models or by Kaplan-Meier survival analyses. CONCLUSIONS There is a poor 10-year survival in both paclitaxel-coated DES and PTA ± BMS in patients with CLI treated below the knee. No dose-related adverse effects of paclitaxel-coated DES were observed in our study of patients with CLI treated below the knee. LEVEL OF EVIDENCE The PADI Trial: level 1, randomized clinical trial.",2020,There was no significant difference between mortality in the DES group compared with the PTA ± BMS group (Log-rank p value = 0.12).,"['patients with chronic limb-threatening ischemia (CLI', 'A total of 140 limbs in 137 patients were included in the PADI Trial', 'patients with CLI treated below the knee', 'Patients with Chronic Limb-Threatening Ischemia (The PADI Trial']","['paclitaxel-coated DES with percutaneous transluminal angioplasty with bail-out bare-metal stents (PTA\u2009±\u2009BMS', 'first-generation paclitaxel-coated drug-eluting stents (DES', 'paclitaxel', 'paclitaxel-coated DES']","['weight mortality', 'specific dose-related mortality', 'risk of long-term mortality', 'died', 'mortality', '10-year survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0304222', 'cui_str': 'Drug coating'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C2936666', 'cui_str': 'Percutaneous transluminal angioplasty'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent'}, {'cui': 'C0015522', 'cui_str': 'Coagulation factor XI'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C1322815', 'cui_str': 'Drug eluting stent'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",137.0,0.0645289,There was no significant difference between mortality in the DES group compared with the PTA ± BMS group (Log-rank p value = 0.12).,"[{'ForeName': 'Louise C D', 'Initials': 'LCD', 'LastName': 'Konijn', 'Affiliation': 'Department of Radiology, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Thijs', 'Initials': 'T', 'LastName': 'Wakkie', 'Affiliation': 'Department of Radiology, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Marlon I', 'Initials': 'MI', 'LastName': 'Spreen', 'Affiliation': 'Department of Radiology, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Pim A', 'Initials': 'PA', 'LastName': 'de Jong', 'Affiliation': 'Department of Radiology, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Lukas C', 'Initials': 'LC', 'LastName': 'van Dijk', 'Affiliation': 'Department of Radiology, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Jan J', 'Initials': 'JJ', 'LastName': 'Wever', 'Affiliation': 'Department of Vascular Surgery, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Hugo T C', 'Initials': 'HTC', 'LastName': 'Veger', 'Affiliation': 'Department of Vascular Surgery, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Randolph G', 'Initials': 'RG', 'LastName': 'Statius van Eps', 'Affiliation': 'Department of Vascular Surgery, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands.'}, {'ForeName': 'Willem P Th M', 'Initials': 'WPTM', 'LastName': 'Mali', 'Affiliation': 'Department of Radiology, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'van Overhagen', 'Affiliation': 'Department of Radiology, Haga Teaching Hospital, Leyweg 275, 2545CH/PO box 40551, The Hague, The Netherlands. h.voverhagen@hagaziekenhuis.nl.'}]",Cardiovascular and interventional radiology,['10.1007/s00270-020-02602-6'] 2384,32725447,Feedback improves the scapular-focused treatment effects in patients with shoulder impingement syndrome.,"PURPOSE This study aimed to evaluate the effects of scapular-focused treatment with (SFTF) and without (SFT) feedback on pain, function, and scapular kinematics in patients with Shoulder Impingement Syndrome (SIS). METHODS Seventy-five males and females with SIS were randomly assigned into SFTF (n = 25), SFT (n = 25) and control (n = 25) groups. The primary outcome was pain, assessed by Visual Analog Scale (VAS). The secondary outcomes were function and scapular kinematics, assessed by DASH Questionnaire and a 3-D motion capture, respectively. All outcomes were measured at the baseline and after the 8-week interventions. RESULTS A post hoc analysis performed to show significant differences between groups after the 8-week interventions. For pain, there were significant differences between SFTF vs. SFT (ES (95% CI) = - 0.3(- 0.4 to - 0.1); P = 0.04), SFTF vs. control (ES (95% CI) = 1.3(0.7-1.9); P = 0.01). For DASH, also, there were significant differences between SFTF vs. SFT (ES (95% CI) = 1.8(1.1-2.4); P = 0.03), SFTF vs. control (ES (95% CI) = 4.4(3.3-5.4); P = 0.01), and SFT vs. control (ES (95% CI) = 2.6(1.8-3.4); P = 0.01). For scapular internal rotation (the sagittal or scapular planes), scapular upward rotation, and the scapular tilt, however, there were no differences between SFTF vs. SFT. CONCLUSION Based on the study results, a rehabilitation program integrated with verbal feedbacks is effective to relieve pain, and improve function and scapular kinematics in patients with SIS. Adding feedback to an exercise therapy could clinically enhance outcomes in patients with SIS. LEVEL OF EVIDENCE Level II. TRIAL REGISTRATION This study was prospectively registered at UMIN-CTR website, and the unique trail number is UMIN000036399.",2020,"P = 0.03), SFTF vs. control (ES (95% CI) = 4.4(3.3-5.4); P = 0.01), and SFT vs. control (ES (95% CI) = 2.6(1.8-3.4); P = 0.01).","['Seventy-five males and females with SIS', 'patients with shoulder impingement syndrome', 'patients with SIS', 'patients with Shoulder Impingement Syndrome (SIS']","['SFT', 'SFTF', 'scapular-focused treatment with (SFTF) and without (SFT) feedback', 'exercise therapy']","['function and scapular kinematics', 'pain, function, and scapular kinematics', 'pain, assessed by Visual Analog Scale (VAS', 'function and scapular kinematics, assessed by DASH\xa0Questionnaire and a 3-D motion capture, respectively']","[{'cui': 'C4319621', 'cui_str': '75'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0376685', 'cui_str': 'Impingement syndrome of shoulder region'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1266119', 'cui_str': 'Solitary fibrous tumor'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600169', 'cui_str': 'Kinematics'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0450363', 'cui_str': 'Three-dimensional'}, {'cui': 'C0026597', 'cui_str': 'Motion'}]",75.0,0.139815,"P = 0.03), SFTF vs. control (ES (95% CI) = 4.4(3.3-5.4); P = 0.01), and SFT vs. control (ES (95% CI) = 2.6(1.8-3.4); P = 0.01).","[{'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Moslehi', 'Affiliation': 'Department of Physical Education and Sports Sciences, Raja University, Qazvin, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Letafatkar', 'Affiliation': 'Department of Biomechanics and Sports Injuries, Kharazmi University, Tehran, Iran. Letafatkaramir@yahoo.com.'}, {'ForeName': 'Hadi', 'Initials': 'H', 'LastName': 'Miri', 'Affiliation': 'Department of Physical Education and Sports Sciences, Amir Kabir University of Technology, Tehran, Iran.'}]","Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA",['10.1007/s00167-020-06178-z'] 2385,32725500,Effects of different doses of abobotulinumtoxinA for the treatment of anterior gingival smile.,"Botulinum toxin type A (BoNT-A) is an easy and fast treatment for gingival smile (GS). The objective of the study was to compare the reduction of gingival exposure using three different doses of abobotulinumtoxinA (ABO) in patients with different severities of anterior GS, and to assess treatment safety and patients' satisfaction. A prospective, single-center, randomized, double-blind study was conducted. Mild GS (2 to < 3 mm) was treated with 2.5 U of abobotulinumtoxinA (ABO) per side, moderate GS (3 to < 4 mm) with 5 U of ABO per side, and severe GS (4 mm or more) with either 2.5 U, or 5 U or 7.5 U of ABO per side. All the 41 enrolled patients completed the study. The mean gingival exposure reduced significantly 4 and 12 weeks after treatment. The average reduction of gingival exposure with 5 U was significantly larger than that obtained with 2.5 U, (3.46 ± 1.39 vs. 2.05 ± 1.29 mm; p = 0.004). All groups of GS severity presented statistically significant reduction in the gingival exposure 4 and 12 weeks after ABO injections. Twelve weeks after treatment, more than 80% of the patients were satisfied or very satisfied. There were no treatment-related adverse events reported by the patients or noticed by the investigators. Gingival smile can be safely and effectively managed with BoNT-A injections and specifically with ABO injections to target the LLSAN muscle. Further and larger studies may determine the exact influence of each factor on BoNT-A treatments of GS.",2020,"The average reduction of gingival exposure with 5 U was significantly larger than that obtained with 2.5 U, (3.46 ± 1.39 vs. 2.05 ± 1.29 mm; p = 0.004).","['anterior gingival smile', '41 enrolled patients completed the study', 'patients with different severities of anterior GS']","['abobotulinumtoxinA (ABO', 'Botulinum toxin type A (BoNT-A', 'abobotulinumtoxinA']","['average reduction of gingival exposure', 'Mild GS', 'adverse events', 'mean gingival exposure']","[{'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0037363', 'cui_str': 'Smiling'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]","[{'cui': 'C2719424', 'cui_str': 'AbobotulinumtoxinA'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}]","[{'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0037363', 'cui_str': 'Smiling'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",41.0,0.0431136,"The average reduction of gingival exposure with 5 U was significantly larger than that obtained with 2.5 U, (3.46 ± 1.39 vs. 2.05 ± 1.29 mm; p = 0.004).","[{'ForeName': 'Doris', 'Initials': 'D', 'LastName': 'Hexsel', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil. doris@hexsel.com.br.'}, {'ForeName': 'Taciana', 'Initials': 'T', 'LastName': ""Dal'Forno"", 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Camozzato', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}, {'ForeName': 'Indira', 'Initials': 'I', 'LastName': 'Valente', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Soirefmann', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}, {'ForeName': 'Aline Flor', 'Initials': 'AF', 'LastName': 'Silva', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Siega', 'Affiliation': 'Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre, RS, 90550-141, Brazil.'}]",Archives of dermatological research,['10.1007/s00403-020-02096-9'] 2386,32725609,A significant increase in exercise test performance with virtual group motivation: a randomised open-label controlled trial.,"AIMS Exercise stress testing is frequently used for the assessment of coronary artery disease. As the validity of the test result is highly dependent on the patient’s cooperation and motivation, we hypothesised that virtual group motivation would result in a higher exercise capacity and may increase the test’s validity. METHODS 108 patients at a Swiss teaching hospital with an indication for exercise testing were included in a controlled, open-label trial and randomised 1:1 to treadmill exercise testing whilst either watching a video of a walking group (video group, n = 43), or watching a static image of flowers (image group, n = 43). The video showed a group of five amateur runners, giving the patients the impression of running within the group. As primary outcomes, the performance achieved and the perceived level of comfort during the test were analysed. RESULTS The video group achieved significantly higher percentages of their age-predicted METs (149 ± 32% vs 135 ± 29%, p = 0.041) and longer exercise durations (11:12 ± 2:54 min vs 08:54 ± 02:39 min, p <0.001). Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. CONCLUSIONS Patients watching a video of a running group achieved significantly higher maximum exercise levels and longer test durations. This may have implications for the test’s validity. Furthermore, the virtual setting enhanced patient comfort. (This trial was formally registered at clinicaltrials.gov: trial ID NCT03704493.).",2020,"Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. ",['108 patients at a Swiss teaching hospital with an indication for exercise testing'],"['treadmill exercise testing whilst either watching a video of a walking group (video group, n = 43), or watching a static image of flowers (image group']","['performance achieved and the perceived level of comfort', 'closeness to their physical limits', 'exercise test performance', 'maximum exercise levels', 'Levels of comfort', 'longer exercise durations']","[{'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0241315', 'cui_str': 'Swiss'}, {'cui': 'C0000872', 'cui_str': 'Academic medical center'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0330090', 'cui_str': 'Flowers'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",,0.11557,"Levels of comfort (8.4 ± 1.4 vs 7.5 ± 1.7 analogue scale, p = 0.011) and closeness to their physical limits (8.9 ± 0.8 vs 8.1 ± 1.5, p = 0.005) were rated significantly higher by patients in the video group. ","[{'ForeName': 'Verena C', 'Initials': 'VC', 'LastName': 'Wilzeck', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Janik', 'Initials': 'J', 'LastName': 'Hufschmid', 'Affiliation': 'Old Cantonal High School, Aarau, Switzerland.'}, {'ForeName': 'Louis', 'Initials': 'L', 'LastName': 'Bischof', 'Affiliation': 'Old Cantonal High School, Aarau, Switzerland.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Hansi', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Matthias P', 'Initials': 'MP', 'LastName': 'Nägele', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland.'}, {'ForeName': 'Juerg H', 'Initials': 'JH', 'LastName': 'Beer', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland / Centre of Molecular Cardiology, University of Zurich, Switzerland.'}, {'ForeName': 'Urs', 'Initials': 'U', 'LastName': 'Hufschmid', 'Affiliation': 'Department of Medicine, Cantonal Hospital of Baden, Switzerland / 0041564862637 | 00414862636.'}]",Swiss medical weekly,['10.4414/smw.2020.20287'] 2387,32725642,The Minimum Clinically Important Difference on the Sleep Disorders Inventory for People with Dementia.,"OBJECTIVES Sleep disturbances in dementia causes distress to people with dementia and their family carers and are associated with care home admission. The Sleep Disorders Inventory (SDI) is a validated questionnaire of sleep disturbances in dementia often used to measure treatment effectiveness, but the minimum clinically important difference (MCID) is unknown. METHODS We triangulated three investigative methods to determine the MCID of the SDI. Using data on SDI from a randomised controlled trial (RCT) with 62 participants in an intervention for sleep disorders in dementia, we (1) calculated distribution-based values where MCID = 0.33 of a SD (SD) (2) an anchor based approach using quality of life (measured using DEMQOL-Proxy) as an anchor. We also employed a Delphi consensus process asking 12 clinicians, sleep researchers and family carers to rate which changes on vignettes were equivalent to a MCID. RESULTS We found that 0.33 SD in the SDI = 4.86. Reduction in SDI total score was not significantly correlated with improvement in DEMQOL-Proxy (Pearson's correlation = -0.01; P = 0.96) score. The Delphi consensus required two rounds to reach a consensus and concluded that changes equivalent to three points on the SDI equated to the MCID. CONCLUSIONS Taking into account both the distribution-based values and the Delphi process we used a whole number at the midpoint and judged the minimum clinically important difference MCID to be equal to four points. We note the clinicians and carers opinions from the Delphi process determined the MCID to be lower at three points. This article is protected by copyright. All rights reserved.",2020,Reduction in SDI total score was not significantly correlated with improvement in DEMQOL-Proxy (Pearson's correlation = ,"['dementia causes distress to people with dementia and their family carers', 'People with Dementia', '62 participants in an intervention for sleep disorders in dementia, we (1) calculated distribution-based values where MCID\xa0=\xa00.33 of a SD (SD) (2) an anchor based approach using']",[],"['quality of life', 'Sleep Disorders Inventory', 'SDI total score', 'Sleep Disorders Inventory (SDI']","[{'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0037775', 'cui_str': 'Distributions'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C4517449', 'cui_str': '0.33'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",[],"[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0851578', 'cui_str': 'Sleep disorder'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",62.0,0.0608141,Reduction in SDI total score was not significantly correlated with improvement in DEMQOL-Proxy (Pearson's correlation = ,"[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Webster', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, UCL, Maple House, London, UK.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, UCL, Maple House, London, UK.'}, {'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Livingston', 'Affiliation': 'Division of Psychiatry, Faculty of Brain Sciences, UCL, Maple House, London, UK.'}]",International journal of geriatric psychiatry,['10.1002/gps.5384'] 2388,32725666,"A strength and neuromuscular exercise program did not improve body composition, nutrition and psychological status in children with obesity.","Even though a wide range of exercise recommendations exist for various patient groups, there is a lack of programs which are specifically designed for children and adolescents with obesity. This study is a secondary analysis of a trial, which evaluated the effectiveness of a physical-intervention program specifically designed for pediatric patients with obesity from a biomechanical and physical therapy point of view. It presents secondary results to body composition, nutrition, and psychological status.",2020,"This study is a secondary analysis of a trial, which evaluated the effectiveness of a physical-intervention program specifically designed for pediatric patients with obesity from a biomechanical and physical therapy point of view.","['children with obesity', 'children and adolescents with obesity', 'pediatric patients with obesity from a biomechanical and physical therapy point of view']","['strength and neuromuscular exercise program', 'physical-intervention program']","['body composition, nutrition and psychological status']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0449911', 'cui_str': 'View'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0449438', 'cui_str': 'Status'}]",,0.0170002,"This study is a secondary analysis of a trial, which evaluated the effectiveness of a physical-intervention program specifically designed for pediatric patients with obesity from a biomechanical and physical therapy point of view.","[{'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Thajer', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Truschner', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Anselm', 'Initials': 'A', 'LastName': 'Jorda', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Skacel', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Horsak', 'Affiliation': 'St. Pölten University of Applied Sciences, Institute of Health Sciences, St. Pölten, Austria.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Greber-Platzer', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}]","Acta paediatrica (Oslo, Norway : 1992)",['10.1111/apa.15498'] 2389,32725680,Dexamethasone combined metronidazole on mammary duct ectasia and its relationship with serum IL-10 and IL-17.,"AIM To explore the effect of dexamethasone combined with metronidazole in the treatment of mammary duct ectasia (MDE) and its relationship with changes in serum interleukin-10 (IL-10) and IL-17 expression. METHODS One hundred and twenty patients with MDE were divided into two groups randomly, control and observation groups (each n = 60). Another 50 patients with normal physical examination were recruited in the normal group. The expressions of serum IL-10 and IL-17 in three groups before and after treatment were observed. The prediction value of IL-10 and IL-17 in clinical efficacy was evaluated. RESULTS Among three groups, the expression of IL-10 in the normal group was the highest (P < 0.001), but the expression of IL-17 was the lowest (P < 0.001). After treatment, the expression of IL-17 in observation group was lower (P < 0.001), the expression of IL-10 was higher (P < 0.05) than that in the control group. The areas under the IL-10 and IL-17 curve were 0.874 and 0.806, respectively. CONCLUSIONS Dexamethasone combined with metronidazole can effectively improve the clinical efficacy of MDE patient treatment and serum IL-10 and IL-17 can be used as potential predictors of treatment efficacy.",2020,"After treatment, the expression of IL-17 in observation group was lower (P < 0.001), the expression of IL-10 was higher (P < 0.05) than that in the control group.","['Another 50 patients with normal physical examination were recruited in the normal group', 'mammary duct ectasia (MDE', 'One hundred and twenty patients with MDE']","['dexamethasone', 'metronidazole', 'Dexamethasone', 'Dexamethasone combined metronidazole']","['expressions of serum IL-10 and IL-17', 'expression of IL-17', 'serum interleukin-10 (IL-10) and IL-17 expression', 'expression of IL-10', 'IL-10 and IL-17 curve', 'mammary duct ectasia and its relationship with serum IL-10 and IL-17']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0152442', 'cui_str': 'Mammary duct ectasia'}, {'cui': 'C4319550', 'cui_str': '120'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0025872', 'cui_str': 'Metronidazole'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0384648', 'cui_str': 'Interleukin 17'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0152442', 'cui_str': 'Mammary duct ectasia'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]",120.0,0.0244319,"After treatment, the expression of IL-17 in observation group was lower (P < 0.001), the expression of IL-10 was higher (P < 0.05) than that in the control group.","[{'ForeName': 'Yuwen', 'Initials': 'Y', 'LastName': 'Tong', 'Affiliation': 'Department of Breast Surgery, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China.'}, {'ForeName': 'Yuandong', 'Initials': 'Y', 'LastName': 'Hao', 'Affiliation': 'Department of Breast Surgery, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China.'}, {'ForeName': 'Xiangyu', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'Department of Breast Surgery, Zaozhuang Hospital of Zaozhuang Mining Group, Zaozhuang, China.'}, {'ForeName': 'Yanshen', 'Initials': 'Y', 'LastName': 'Sun', 'Affiliation': 'Department of Breast Surgery, Zaozhuang Hospital of Zaozhuang Mining Group, Zaozhuang, China.'}, {'ForeName': 'Wentao', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Department of Breast Surgery, Maternity and Child Health Care of Zaozhuang, Zaozhuang, China.'}]",The journal of obstetrics and gynaecology research,['10.1111/jog.14380'] 2390,32714397,"An Oral Formulation of the Probiotic, Bacillus subtilis HU58, Was Safe and Well Tolerated in a Pilot Study of Patients with Hepatic Encephalopathy.","Background Hepatic encephalopathy often results in high blood ammonia levels because of inefficient ammonia processing by the liver. Lactulose treatment promotes the growth of urease-producing gut bacteria and a reduced colon pH, thus reducing blood ammonia absorption. It is thought that probiotics as an add-on therapy may be beneficial. Patients and Methods . Bacillus subtilis HU58 was tested for safety and tolerability in patients with hepatic encephalopathy taking lactulose in this double-bind, placebo-controlled, 4-week pilot study. Study participants received one dose of B . subtilis HU58 or placebo (orally) for the first five days and two daily doses thereafter. Participants were monitored for safety and blood ammonia levels. Results Forty patients participated (placebo, 11; probiotic, 29). Baseline characteristics were generally comparable; the mean baseline blood ammonia level was somewhat higher in the probiotic group. Mild or moderate treatment-emergent adverse events (TEAEs) were reported in 27.3% and 17.2% of patients in the placebo and probiotic groups, respectively; no severe TEAEs were reported. One patient (9.1%) taking placebo and two (6.9%) taking the probiotic experienced serious TEAEs (SAEs); none resulted in study discontinuation and all were considered to have no/unlikely relationship to the study product. There were no significant differences in the mean percent change (MPC) of blood ammonia levels between groups, though the probiotic group exhibited a trend toward a milder increase. Stratification of the probiotic group by baseline blood ammonia level (>60  μ g/dL and ≤60  μ g/dL) resulted in a significantly reduced MPC in the >60  μ g/dL subgroup (MPC (SD); ≤60  μ g/dL ( n  = 14), 35.3% (73.3); >60  μ g/dL ( n  = 14), -26.5% (24.4); p = 0.0087). Conclusions Daily treatment with oral B . subtilis HU58 was safe and well tolerated over a 4-week period in patients with hepatic encephalopathy, and a significantly reduced MPC of blood ammonia level was observed in patients with a baseline level >60  µ g/dL.",2020,"There were no significant differences in the mean percent change (MPC) of blood ammonia levels between groups, though the probiotic group exhibited a trend toward a milder increase.","['Patients with Hepatic Encephalopathy', 'patients with hepatic encephalopathy taking', 'Forty patients participated (placebo, 11; probiotic, 29']","['placebo', 'lactulose', 'HU58 or placebo', 'Lactulose']","['MPC of blood ammonia level', 'blood ammonia absorption', 'mean baseline blood ammonia level', 'Bacillus subtilis', 'safety and tolerability', 'safety and blood ammonia levels', 'growth of urease-producing gut bacteria and a reduced colon pH', 'Mild or moderate treatment-emergent adverse events (TEAEs', 'MPC', 'safe and well tolerated', 'baseline blood ammonia level', 'mean percent change (MPC) of blood ammonia levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019151', 'cui_str': 'Hepatic encephalopathy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0022957', 'cui_str': 'Lactulose'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0428437', 'cui_str': 'Blood ammonia measurement'}, {'cui': 'C0237442', 'cui_str': 'Physiological Absorption'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0004587', 'cui_str': 'Bacillus'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0041945', 'cui_str': 'Urease'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal tract structure'}, {'cui': 'C0004611', 'cui_str': 'Bacterium'}, {'cui': 'C0009368', 'cui_str': 'Colonic'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",40.0,0.292701,"There were no significant differences in the mean percent change (MPC) of blood ammonia levels between groups, though the probiotic group exhibited a trend toward a milder increase.","[{'ForeName': 'Sayed', 'Initials': 'S', 'LastName': 'Yossef', 'Affiliation': 'Sayed Yossef, Inc., 3304 Stones Throw Ave, Poland, OH 44514, USA.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Clark', 'Affiliation': 'Sayed Yossef, Inc., 3304 Stones Throw Ave, Poland, OH 44514, USA.'}, {'ForeName': 'Sarah S', 'Initials': 'SS', 'LastName': 'Bubeck', 'Affiliation': 'Bubeck Scientific, 194 Rainbow Dr. #9418, Livingston, TX 77399, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Abernethy', 'Affiliation': 'Amk Research, 1026 SW 2 Ave D, Gainesville, FL 32601, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Bayne', 'Affiliation': 'Microbiome Labs, 101 E Town Place, Suite 210, Saint Augustine, FL 32092, USA.'}, {'ForeName': 'Kiran', 'Initials': 'K', 'LastName': 'Krishnan', 'Affiliation': 'Microbiome Labs, 101 E Town Place, Suite 210, Saint Augustine, FL 32092, USA.'}, {'ForeName': 'Aicacia', 'Initials': 'A', 'LastName': 'Young', 'Affiliation': 'Microbiome Labs, 101 E Town Place, Suite 210, Saint Augustine, FL 32092, USA.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/1463108'] 2391,32714423,Effect of Baduanjin Sequential Therapy on the Quality of Life and Cardiac Function in Patients with AMI After PCI: A Randomized Controlled Trial.,"Purpose The purpose of this study was to examine the effects of Baduanjin sequential therapy (BST) on the quality of life and cardiac function in patients with AMI after PCI. Subjects 96 patients with AMI after PCI were randomly assigned as subjects to two groups: BST group who received 24 weeks of BST training and control group who received no training. Methods The methods used in this study included the changes in SF-36 subscales, the measures of left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), the body mass index (BMI), and the abdominal circumference. Results Of the 96 participants, 82 total patients completed the entire study. At 12 weeks, role physical and health transition of SF-36 were significantly different between the two groups, with a difference of 26.12 (95% CI, 11.59 to 40.64) in role physical and a difference of 15.94 (95% CI, 5.60 to 26.28) in health transition ( p < 0.05). However, there were statistically significant differences in all aspects of SF-36 between the two groups at 24 weeks ( p < 0.05). The BST also lowered abdominal circumference and BMI as compared with the control group. In the 24-week follow-up, a significant difference was found in the decline of the LVEF in the control group ( p =0.020), while there was a nonsignificant difference in the BST group ( p =0.552). Compared with the control group, the BST group reduced 50 pg/ml on the NT-pro-BNP at 24 weeks ( p =0.013). The effects of BST exercise were maintained at 24 weeks after the intervention. No serious adverse events were observed. Conclusions The BST appears to improve the quality of life in patients with AMI after PCI, with additional benefits of lowered abdominal circumference and BMI and improved level of cardiac function. This trial is registered with NCT02693795.",2020,"At 12 weeks, role physical and health transition of SF-36 were significantly different between the two groups, with a difference of 26.12 (95% CI, 11.59 to 40.64) in role physical and a difference of 15.94 (95% CI, 5.60 to 26.28) in health transition ( p < 0.05).","['96 participants', 'Patients with AMI', '82 total patients completed the entire study', 'Subjects\n\n\n96 patients with AMI after PCI', 'patients with AMI after PCI']","['Baduanjin sequential therapy (BST', 'BST training and control group who received no training', 'BST exercise', 'Baduanjin Sequential Therapy', 'BST']","['quality of life', 'abdominal circumference and BMI', 'Quality of Life and Cardiac Function', 'quality of life and cardiac function', 'SF-36', 'decline of the LVEF', 'health transition', 'serious adverse events', 'abdominal circumference and BMI and improved level of cardiac function', 'role physical and health transition of SF-36', 'SF-36 subscales, the measures of left ventricular ejection fraction (LVEF), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), the body mass index (BMI), and the abdominal circumference']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439751', 'cui_str': 'Entire'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1300813', 'cui_str': 'Abdominal circumference'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction'}, {'cui': 'C0376627', 'cui_str': 'Health Transition'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}]",96.0,0.0564753,"At 12 weeks, role physical and health transition of SF-36 were significantly different between the two groups, with a difference of 26.12 (95% CI, 11.59 to 40.64) in role physical and a difference of 15.94 (95% CI, 5.60 to 26.28) in health transition ( p < 0.05).","[{'ForeName': 'Ming-Gui', 'Initials': 'MG', 'LastName': 'Chen', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Xuefei', 'Initials': 'X', 'LastName': 'Liang', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Kong', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Fangfang', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Xiyan', 'Initials': 'X', 'LastName': 'Hu', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Jianzhuo', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Rui-Xiang', 'Initials': 'RX', 'LastName': 'Zeng', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Mao', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Liheng', 'Initials': 'L', 'LastName': 'Guo', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Min-Zhou', 'Initials': 'MZ', 'LastName': 'Zhang', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}, {'ForeName': 'Xiaoxuan', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Division of Chest Pain Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou 510120, China.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/8171549'] 2392,32714473,Clinical Evaluation of the Use of Ginger Extract in the Preventive Management of Motion Sickness.,"Background Motion sickness can be triggered in a variety of situations and is characterized primarily by nausea and vomiting. Ginger is widely used in treating conditions including chemotherapy-associated gastrointestinal symptoms, morning sickness, postoperative nausea, and motion sickness. Objectives The primary study objective was to evaluate Zingiber officinale extract in the treatment of motion sickness. Secondary objectives were to evaluate treatment effect on Motion Sickness Assessment Questionnaire (MSAQ) score and subscores before and after treatment, and to evaluate treatment tolerability. Methods Open-label, single-arm study assessing motion sickness outcomes with and without pre-travel oral treatment with Zingiber officinale 160 mg extract (containing 8 mg gingerols). All patients answered the MSAQ on 4 separate occasions following a trip of at least 15 minutes in duration: Trip 1 (pretreatment) and Trips 2, 3, and 4 (after oral treatment with study medication). The primary end point was percentage of patients presenting improvement ≥20 score points on the MSAQ during Trip 2, Trip 3, and Trip 4 in comparison to pretreatment score (Trip 1). Secondary end points included percentage of patients presenting improvement in MSAQ subscores during Trips 2, 3, and 4; percentage of patients presenting treatment-related adverse events; and pre- and posttreatment physician assessment scores. Results One hundred eighty-four patients were included and 174 completed treatment. A reduction of ≥20 points in total MSAQ score points occurred in 26.52%, 29.89%, and 29.31% of patients from Trips 2, 3, and 4, respectively. There was no significant difference at Trips 2, 3, and 4 in number of patients presenting improvement ≥20 score points ( P  = 0.9579). There was a significant reduction in total MSAQ scores from Trips 2, 3, and 4 ( P < 0.0001) compared with Trip 1. Total MSAQ scores did not vary at each trip taken under treatment ( P  = 0.28). There were significant ( P < .001) improvements in all domain subscores from Trips 2, 3, and 4 in relation to scores from Trip 1. There was a significant improvement in physician assessment scores at Visit 2 ( P < .0001). Adverse events were reported among 31 patients, mainly affecting the gastrointestinal system. Twenty-four patients (13.04%) reported 39 adverse events considered related to treatment. No significant change in physical exam was noted at Visit 2 in relation to Visit 1. Conclusions These open label, historically controlled study results suggest the need for randomized, blinded, placebo and active substance controlled clinical trials. ( Curr Ther Res Clin Exp . 2020; 81:XXX-XXX).",2020,"There were significant ( P < .001) improvements in all domain subscores from Trips 2, 3, and 4 in relation to scores from Trip 1.","['Motion Sickness', 'One hundred eighty-four patients were included and 174 completed treatment']","['MSAQ', 'Ginger Extract', 'placebo']","['Adverse events', 'percentage of patients presenting improvement in MSAQ subscores during Trips 2, 3, and 4; percentage of patients presenting treatment-related adverse events; and pre- and posttreatment physician assessment scores', 'total MSAQ scores', 'Total MSAQ scores', 'Motion Sickness Assessment Questionnaire (MSAQ) score and subscores', 'total MSAQ score points', 'physician assessment scores', 'treatment tolerability', 'physical exam', 'percentage of patients presenting improvement ≥20 score points']","[{'cui': 'C0026603', 'cui_str': 'Motion sickness'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319623', 'cui_str': '84'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517604', 'cui_str': '174'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0939895', 'cui_str': 'Ginger extract'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0755397', 'cui_str': 'Thyroid Hormone Receptor Associated Protein 220'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026603', 'cui_str': 'Motion sickness'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",184.0,0.0459984,"There were significant ( P < .001) improvements in all domain subscores from Trips 2, 3, and 4 in relation to scores from Trip 1.","[{'ForeName': 'Carlos Pereira', 'Initials': 'CP', 'LastName': 'Nunes', 'Affiliation': 'Centro Universitário Serra dos Órgãos, Teresópolis, Rio de Janeiro, Brazil.'}, {'ForeName': 'Claudio de Campos', 'Initials': 'CC', 'LastName': 'Rodrigues', 'Affiliation': 'Centro Universitário Serra dos Órgãos, Teresópolis, Rio de Janeiro, Brazil.'}, {'ForeName': 'Carlos Alfredo Franco', 'Initials': 'CAF', 'LastName': 'Cardoso', 'Affiliation': 'Centro Universitário Serra dos Órgãos, Teresópolis, Rio de Janeiro, Brazil.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Cytrynbaum', 'Affiliation': 'Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Renato', 'Initials': 'R', 'LastName': 'Kaufman', 'Affiliation': 'Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Helio', 'Initials': 'H', 'LastName': 'Rzetelna', 'Affiliation': 'Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Gerson', 'Initials': 'G', 'LastName': 'Goldwasser', 'Affiliation': 'Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Santos', 'Affiliation': 'Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Oliveira', 'Affiliation': 'Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Geller', 'Affiliation': 'Centro Universitário Serra dos Órgãos, Teresópolis, Rio de Janeiro, Brazil.'}]","Current therapeutic research, clinical and experimental",['10.1016/j.curtheres.2020.100591'] 2393,32717153,"Validation of the Yale Swallow Protocol in Post-Acute Care: A Prospective, Double-Blind, Multirater Study.","Purpose A systematic approach to the diagnosis and treatment of swallowing disorders relies heavily on valid and reliable screening protocols that provide clinicians with clear and objective information. The Yale Swallow Protocol (YSP) has been shown to be a useful, valid, and reliable screening tool for aspiration risk in the acute care setting. However, the YSP was not validated for use in post-acute care. This study evaluated the clinical utility of the YSP in the post-acute care setting. Method This prospective, double-blind, multirater study included a referred sample of 240 individuals, with varying medical diagnoses, who completed the YSP and an endoscopic evaluation of swallowing. Results Sensitivity for the YSP was 95.4%, specificity was 66.9%, positive predictive value was 77.6%, and negative predictive value was 92.4%. Conclusions The data from this prospective study appear to support the use of the YSP in post-acute care due to the ability to use the protocol on virtually all patients-regardless of diagnosis-and its high sensitivity and negative predictive value.",2020,"Results Sensitivity for the YSP was 95.4%, specificity was 66.9%, positive predictive value was 77.6%, and negative predictive value was 92.4%.","['multirater study included a referred sample of 240 individuals, with varying medical diagnoses, who completed the YSP and an endoscopic evaluation of swallowing', 'Post-Acute Care']","['YSP', 'Yale Swallow Protocol', 'Yale Swallow Protocol (YSP']",['positive predictive value'],"[{'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C4274243', 'cui_str': 'Yale Swallow Protocol'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0376635', 'cui_str': 'Postacute Care'}]","[{'cui': 'C4274243', 'cui_str': 'Yale Swallow Protocol'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",240.0,0.0273079,"Results Sensitivity for the YSP was 95.4%, specificity was 66.9%, positive predictive value was 77.6%, and negative predictive value was 92.4%.","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Ward', 'Affiliation': 'SA Swallowing Services, Nashville, TN.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Skelley-Ashford', 'Affiliation': 'SA Swallowing Services, Nashville, TN.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'SA Swallowing Services, Nashville, TN.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Ashford', 'Affiliation': 'SA Swallowing Services, Nashville, TN.'}, {'ForeName': 'Debra', 'Initials': 'D', 'LastName': 'Suiter', 'Affiliation': 'College of Health Sciences, University of Kentucky, Lexington.'}]",American journal of speech-language pathology,['10.1044/2020_AJSLP-19-00147'] 2394,32717180,"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study.","BACKGROUND Diagnosis and treatment of colorectal peritoneal metastases at an early stage, before the onset of signs, could improve patient survival. We aimed to compare the survival benefit of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), with surveillance, in patients at high risk of developing colorectal peritoneal metastases. METHODS We did an open-label, randomised, phase 3 study in 23 hospitals in France. Eligible patients were aged 18-70 years and had a primary colorectal cancer with synchronous and localised colorectal peritoneal metastases removed during tumour resection, resected ovarian metastases, or a perforated tumour. Patients were randomly assigned (1:1) to surveillance or second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m 2 , or oxaliplatin 300 mg/m 2 plus irinotecan 200 mg/m 2 , plus intravenous fluorouracil 400 mg/m 2 ), or mitomycin-HIPEC (mitomycin 35 mg/m 2 ) alone in case of neuropathy, after 6 months of adjuvant systemic chemotherapy with no signs of disease recurrence. Randomisation was done via a web-based system, with stratification by treatment centre, nodal status, and risk factors for colorectal peritoneal metastases. Second-look surgery consisted of a complete exploration of the abdominal cavity via xyphopubic incision, and resection of all peritoneal implants if resectable. Surveillance after resection of colorectal cancer was done according to the French Guidelines. The primary outcome was 3-year disease-free survival, defined as the time from randomisation to peritoneal or distant disease recurrence, or death from any cause, whichever occurred first, analysed by intention to treat. Surgical complications were assessed in the second-look surgery group only. This study was registered at ClinicalTrials.gov, NCT01226394. FINDINGS Between June 11, 2010, and March 31, 2015, 150 patients were recruited and randomly assigned to a treatment group (75 per group). After a median follow-up of 50·8 months (IQR 47·0-54·8), 3-year disease-free survival was 53% (95% CI 41-64) in the surveillance group versus 44% (33-56) in the second-look surgery group (hazard ratio 0·97, 95% CI 0·61-1·56). No treatment-related deaths were reported. 29 (41%) of 71 patients in the second-look surgery group had grade 3-4 complications. The most common grade 3-4 complications were intra-abdominal adverse events (haemorrhage, digestive leakage) in 12 (23%) of 71 patients and haematological adverse events in 13 (18%) of 71 patients. INTERPRETATION Systematic second-look surgery plus oxaliplatin-HIPEC did not improve disease-free survival compared with standard surveillance. Currently, essential surveillance of patients at high risk of developing colorectal peritoneal metastases appears to be adequate and effective in terms of survival outcomes. FUNDING French National Cancer Institute.",2020,"INTERPRETATION Systematic second-look surgery plus oxaliplatin-HIPEC did not improve disease-free survival compared with standard surveillance.","['Between June 11, 2010, and March 31, 2015, 150 patients', 'Eligible patients were aged 18-70 years and had a primary colorectal cancer with synchronous and localised colorectal peritoneal metastases removed during tumour resection, resected ovarian metastases, or a perforated tumour', 'patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15', 'patients at high risk of developing colorectal peritoneal metastases', '23 hospitals in France']","['oxaliplatin-HIPEC', 'surveillance or second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m 2 , or oxaliplatin 300 mg/m 2 plus irinotecan 200 mg/m 2 , plus intravenous fluorouracil 400 mg/m 2 ), or mitomycin-HIPEC (mitomycin 35 mg/m 2 ) alone in case of neuropathy, after 6 months of adjuvant systemic chemotherapy', 'Second-look surgery plus hyperthermic intraperitoneal chemotherapy', 'systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC']","['grade 3-4 complications', '3-year disease-free survival, defined as the time from randomisation to peritoneal or distant disease recurrence, or death from any cause, whichever occurred first, analysed by intention to treat', 'intra-abdominal adverse events (haemorrhage, digestive leakage', '3-year disease-free survival', 'disease-free survival', 'haematological adverse events', 'Surgical complications']","[{'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0439580', 'cui_str': 'Synchronous'}, {'cui': 'C0555952', 'cui_str': 'Colorectal'}, {'cui': 'C0346989', 'cui_str': 'Secondary malignant neoplasm of peritoneum'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C4761063', 'cui_str': 'Tumor resection'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0022790', 'cui_str': 'Krukenberg tumor'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0016674', 'cui_str': 'France'}]","[{'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C0220920', 'cui_str': 'surveillance'}, {'cui': 'C0949626', 'cui_str': 'Incision and reexploration for second look'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0008902', 'cui_str': 'Classification'}]","[{'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0443203', 'cui_str': 'Distant'}, {'cui': 'C0679254', 'cui_str': 'Disease recurrence'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C1512911', 'cui_str': 'Intraabdominal route'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0012238', 'cui_str': 'Digestive system function'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}]",150.0,0.506933,"INTERPRETATION Systematic second-look surgery plus oxaliplatin-HIPEC did not improve disease-free survival compared with standard surveillance.","[{'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Goéré', 'Affiliation': 'Department of Surgical Oncology, University Hospital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Surgical Oncology, University Hospital Gustave Roussy, Villejuif, France. Electronic address: diane.goere@aphp.fr.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Glehen', 'Affiliation': 'Department of Surgical Oncology, University Hospital Lyon Sud, Pierre Bénite, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Quenet', 'Affiliation': 'Department of Surgical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Guilloit', 'Affiliation': 'Department of Surgical Oncology, Centre François Baclesse, Caen, France.'}, {'ForeName': 'Jean-Marc', 'Initials': 'JM', 'LastName': 'Bereder', 'Affiliation': 'Department of Surgical Oncology, University Hospital de Larchet, Nice, France.'}, {'ForeName': 'Gérard', 'Initials': 'G', 'LastName': 'Lorimier', 'Affiliation': 'Department of Surgical Oncology, Centre Paul Papin, Angers, France.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Thibaudeau', 'Affiliation': ""Department of Surgical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.""}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Ghouti', 'Affiliation': 'Department of Surgical Oncology, University Hospital Purpan, Toulouse, France.'}, {'ForeName': 'Amandine', 'Initials': 'A', 'LastName': 'Pinto', 'Affiliation': 'Department of Surgical Oncology, University Hospital Purpan, Toulouse, France.'}, {'ForeName': 'Jean-Jacques', 'Initials': 'JJ', 'LastName': 'Tuech', 'Affiliation': 'Department of Surgical Oncology, University Hospital Charles Nicolle, Rouen, France.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Kianmanesh', 'Affiliation': 'Department of Surgical Oncology, University Hospital Robert Debré, Reims, France.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Carretier', 'Affiliation': 'Department of Surgical Oncology, University Hospital de Poitiers, Poitiers, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Marchal', 'Affiliation': 'Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Arvieux', 'Affiliation': 'Department of Visceral Surgery, University Hospital, Grenoble, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Brigand', 'Affiliation': 'Department of Surgical Oncology, University Hospital Hautepierre, Strasbourg, France.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Meeus', 'Affiliation': 'Department of Surgical Oncology, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Rat', 'Affiliation': 'Department of Surgical Oncology, University Hospital du Bocage, Dijon, France.'}, {'ForeName': 'Sylvaine', 'Initials': 'S', 'LastName': 'Durand-Fontanier', 'Affiliation': 'Department of Surgical Oncology, University Hospital Dupuytren, Limoges, France.'}, {'ForeName': 'Pascale', 'Initials': 'P', 'LastName': 'Mariani', 'Affiliation': 'Department of Surgical Oncology, Institut Curie, Paris, France.'}, {'ForeName': 'Zaher', 'Initials': 'Z', 'LastName': 'Lakkis', 'Affiliation': 'Department of Surgical Oncology, University Hospital Jean Minjoz, Besançon, France.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Loi', 'Affiliation': 'Department of Surgical Oncology, University Hospital Tenon, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Pirro', 'Affiliation': 'Department of Surgical Oncology, University Hospital La Timone, Marseille, France.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Sabbagh', 'Affiliation': 'Department of Surgical Oncology, University Hospital Amiens-Picardie, Amiens, France.'}, {'ForeName': 'Matthieu', 'Initials': 'M', 'LastName': 'Texier', 'Affiliation': 'Department of Biostatistics, University Hospital Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Elias', 'Affiliation': 'Department of Surgical Oncology, University Hospital Gustave Roussy, Villejuif, France.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Oncology,['10.1016/S1470-2045(20)30322-3'] 2395,32717244,Management of Bladder Bowel Dysfunction in Children by Pelvic Floor Interferential Electrical Stimulation and Muscle Exercises: A Randomized Clinical Trial.,"OBJECTIVES To assess efficacy of combined pelvic floor interferential (IF) electrical stimulation and muscle exercises on bladder bowel dysfunction (BBD) in children. MATERIALS AND METHODS A total of 34 children with BBD (6 boys, 28 girls; mean age 7.4±2.2) were included in this study. Children were evaluated with kidney and bladder ultrasounds, uroflowmetry + electromyography (EMG), and a complete voiding and bowel habit diary before treatment. Exclusion criteria were neuropathic disease, anatomical defects and mental retardation. Participants were randomly allocated into two treatment groups including group A (n=17) who underwent IF electrical stimulation in addition to pelvic floor muscle (PFM) exercises and group B (n=17) who received PFM exercises alone. All children were re-evaluated by kidney and bladder ultrasounds, uroflowmetry + EMG and a voiding and bowel habit diary at the end of treatment sessions and 6 months later. RESULTS Constipation improved in 14/17(82%) and 8/17(47%) children in group A and B respectively at the end of treatment sessions (P=0.03). Daytime incontinence improved in all children in group A and 2/8(25%) children in group B after the treatment (P=0.007). Urinary tract infection improved in 8/10(80%) and 5/13(38.4%) children in group A and B respectively, 6 months after the treatment (P=0.02). No significant difference was observed in uroflowmetry measures between two groups after the treatment. CONCLUSION Combination of IF electrical stimulation and PFM exercises is an effective and safe modality for treatment of BBD in children.",2020,Daytime incontinence improved in all children in group A and 2/8(25%) children in group B after the treatment (P=0.007).,"['34 children with BBD (6 boys, 28 girls; mean age 7.4±2.2', 'children']","['IF electrical stimulation in addition to pelvic floor muscle (PFM) exercises', 'Pelvic Floor Interferential Electrical Stimulation and Muscle Exercises', 'Combination of IF electrical stimulation and PFM exercises', 'PFM exercises alone', 'combined pelvic floor interferential (IF) electrical stimulation and muscle exercises']","['bladder bowel dysfunction (BBD', 'uroflowmetry measures', 'Daytime incontinence', 'Urinary tract infection', 'Constipation', 'kidney and bladder ultrasounds, uroflowmetry\u202f+\u202fEMG and a voiding and bowel habit diary', 'kidney and bladder ultrasounds, uroflowmetry\u202f+\u202felectromyography (EMG), and a complete voiding and bowel habit diary']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0021831', 'cui_str': 'Disorder of intestine'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0021831', 'cui_str': 'Disorder of intestine'}, {'cui': 'C0200008', 'cui_str': 'Uroflowmetry'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332169', 'cui_str': 'Daytime'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0855956', 'cui_str': 'Ultrasound bladder'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",34.0,0.0402003,Daytime incontinence improved in all children in group A and 2/8(25%) children in group B after the treatment (P=0.007).,"[{'ForeName': 'Seyedeh-Sanam', 'Initials': 'SS', 'LastName': 'Ladi-Seyedian', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran (IRI).""}, {'ForeName': 'Lida', 'Initials': 'L', 'LastName': 'Sharifi-Rad', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran (IRI); Department of Physical Therapy, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran (IRI).""}, {'ForeName': 'Abdol-Mohammad', 'Initials': 'AM', 'LastName': 'Kajbafzadeh', 'Affiliation': ""Pediatric Urology and Regenerative Medicine Research Center, Children's Medical Center, Pediatric Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran (IRI). Electronic address: kajbafzd@sina.tums.ac.ir.""}]",Urology,['10.1016/j.urology.2020.07.015'] 2396,32717273,High-velocity and traditional resistance exercise on serum antioxidants and inflammation biomarkers in older women: A randomized crossover trial.,"INTRODUCTION Contrary to the production of oxidant and inflammation biomarkers, antioxidant enzymes decrease with age and the adaptive response to oxidative stress is reduced. The effects of the different resistance exercise protocols to attenuate these conditions are largely unexplored. OBJECTIVE We compared the acute effects of traditional resistance exercise (TRE) and high velocity RE (HVRE) on inflammatory biomarkers and antioxidant activity in elderly women. METHODS Fourteen elderly women (67 ± 7 years) were randomly assigned to TRE or HVRE. Blood samples were collected to measure inflammatory markers and antioxidant enzymes at three time-points (pre-exercise, post-exercise, 30 min post-exercise). RESULTS TRE and HVRE induced acute reductions over time on tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), soluble receptor of IL-6 (sIL-6R), as well in catalase, glutathione (GSH) and superoxide dismutase (SOD) antioxidant levels without differences between groups. In addition, TRE and HVRE groups displayed acute increments in interleukin-10 (IL-10) and IL-10/IL-6 ratio over time, while the HVRE protocol displayed higher IL-10 values post-exercise and 30 min post-exercise time points as compared with TRE. Based on magnitude based inference (MBI), subjects from the HVRE group demonstrated superior responsiveness for IL-6 and IL-10 as compared with the TRE group. All participants from the HVRE group displayed a Minimal Clinical Important Difference (MCID) on IL-10 levels as compared to only two persons from the TRE group. CONCLUSION Both RE protocols were capable of positive changes in inflammatory and antioxidant status in elderly subjects, but HVRE demonstrated a superior response on IL-10. The HVRE may be incorporated to exercise recommendation in this population.",2020,"TRE and HVRE induced acute reductions over time on tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), soluble receptor of IL-6 (sIL-6R), as well in catalase, glutathione (GSH) and superoxide dismutase (SOD) antioxidant levels without differences between groups.","['older women', 'elderly subjects', 'Fourteen elderly women (67\u202f±\u202f7\u202fyears', 'elderly women']","['traditional resistance exercise (TRE) and high velocity RE (HVRE', 'HVRE', 'TRE or HVRE', 'TRE and HVRE', 'High-velocity and traditional resistance exercise']","['superior responsiveness for IL-6 and IL-10', 'inflammatory biomarkers and antioxidant activity', 'Minimal Clinical Important Difference (MCID) on IL-10 levels', 'tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), soluble receptor of IL-6 (sIL-6R), as well in catalase, glutathione (GSH) and superoxide dismutase (SOD) antioxidant levels', 'interleukin-10 (IL-10) and IL-10/IL-6 ratio', 'serum antioxidants and inflammation biomarkers']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0257766', 'cui_str': 'SILV protein, human'}, {'cui': 'C0007367', 'cui_str': 'CATALASE'}, {'cui': 'C0017817', 'cui_str': 'Glutathione'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",14.0,0.134689,"TRE and HVRE induced acute reductions over time on tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), soluble receptor of IL-6 (sIL-6R), as well in catalase, glutathione (GSH) and superoxide dismutase (SOD) antioxidant levels without differences between groups.","[{'ForeName': 'Danilo Leandro Santos', 'Initials': 'DLS', 'LastName': 'de Castro', 'Affiliation': 'Department of Physical Education, Catholic University of Brasilia (UCB), Brasilia, Brazil.'}, {'ForeName': 'Dahan', 'Initials': 'D', 'LastName': 'da Cunha Nascimento', 'Affiliation': 'Department of Physical Education, Catholic University of Brasilia (UCB), Brasilia, Brazil; Department of Physical Education, Center University of Distrito Federal (UDF), Brasilia, Brazil; Department of Gerontology, Catholic University of Brasilia, UCB, Brasilia, DF, Brazil.'}, {'ForeName': 'Vânia Silva Macedo', 'Initials': 'VSM', 'LastName': 'Orsano', 'Affiliation': 'Department of Physical Education, Catholic University of Brasilia (UCB), Brasilia, Brazil.'}, {'ForeName': 'Ivo Vieira', 'Initials': 'IV', 'LastName': 'de Sousa Neto', 'Affiliation': 'Laboratory of Molecular Analysis, Graduate Program of Sciences and Technology of Health, University of Brasilia, Federal District, Brazil.'}, {'ForeName': 'Fabiani Lage Rodrigues', 'Initials': 'FLR', 'LastName': 'Beal', 'Affiliation': 'Department of Nutrition, Health and Medicine School, Catholic University of Brasilia, UCB, Brasilia, DF, Brazil; Department of Gerontology, Catholic University of Brasilia, UCB, Brasilia, DF, Brazil.'}, {'ForeName': 'Whitley', 'Initials': 'W', 'LastName': 'Stone', 'Affiliation': 'Department of School of Kinesiology Recreation and Sport, Western Kentucky University, Bowling Green, USA.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Dos Santos Rosa', 'Affiliation': 'Department of Physical Education, Catholic University of Brasilia (UCB), Brasilia, Brazil.'}, {'ForeName': 'Jonato', 'Initials': 'J', 'LastName': 'Prestes', 'Affiliation': 'Department of Physical Education, Catholic University of Brasilia (UCB), Brasilia, Brazil. Electronic address: jonatop@gmail.com.'}]",Experimental gerontology,['10.1016/j.exger.2020.111026'] 2397,32717827,Day 10 Post-Prescription Audit Optimizes Antibiotic Therapy in Patients with Bloodstream Infections.,"This study aimed to investigate the clinical and organizational impact of an active re-evaluation (on day 10) of patients on antibiotic treatment diagnosed with bloodstream infections (BSIs). A prospective, single center, pre-post quasi-experimental study was performed. Patients were enrolled at the time of microbial BSI confirmation. In the pre-intervention phase (August 2014-August 2015), clinical status and antibiotic regimen were re-evaluated at day 3. In the intervention phase (January 2016-January 2017), clinical status and antibiotic regimen were re-evaluated at day 3 and day 10. Primary outcomes were rate of optimal therapy, duration of antibiotic therapy, length of hospitalization, and 30-day mortality. A total of 632 patients were enrolled (pre-intervention period, n = 303; intervention period, n = 329). Average duration of therapy reduced from 18.1 days (standard deviation (SD), 11.4) in the pre-intervention period to 16.8 days (SD, 12.7) in the intervention period ( p < 0.001). Similarly, average length of hospitalization decreased from 24.1 days (SD, 20.8) to 20.6 days (SD, 17.7) ( p = 0.001). No inter-group difference was found for the rate of 30-day mortality. In patients with BSI, re-evaluation of clinical status and antibiotic regimen at day 3 and 10 after microbiological diagnosis was correlated with a reduction in the duration of antibiotic therapy and hospital stay. The intervention is simple and has a low impact on overall costs.",2020,No inter-group difference was found for the rate of 30-day mortality.,"['Patients with Bloodstream Infections', '632 patients were enrolled (pre-intervention period, n = 303; intervention period, n = 329', 'patients on antibiotic treatment diagnosed with bloodstream infections (BSIs', 'Patients were enrolled at the time of microbial BSI confirmation']",['active re-evaluation'],"['rate of optimal therapy, duration of antibiotic therapy, length of hospitalization, and 30-day mortality', 'rate of 30-day mortality', 'Average duration of therapy', 'average length of hospitalization', 'duration of antibiotic therapy and hospital stay']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2316160', 'cui_str': 'Infection of bloodstream'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",632.0,0.0368389,No inter-group difference was found for the rate of 30-day mortality.,"[{'ForeName': 'Rita', 'Initials': 'R', 'LastName': 'Murri', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Palazzolo', 'Affiliation': 'Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Giovannenze', 'Affiliation': 'Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Taccari', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Camici', 'Affiliation': 'Dipartimento di Sicurezza e Bioetica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Spanu', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}, {'ForeName': 'Brunella', 'Initials': 'B', 'LastName': 'Posteraro', 'Affiliation': 'Dipartimento di Scienze biotecnologiche di base, cliniche intensivologiche e perioperatorie, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Sanguinetti', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Cauda', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Fantoni', 'Affiliation': 'Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.'}]","Antibiotics (Basel, Switzerland)",['10.3390/antibiotics9080437'] 2398,32717846,"The Sustainability and Scalability of Private Sector Sanitation Delivery in Urban Informal Settlement Schools: A Mixed Methods Follow Up of a Randomized Trial in Nairobi, Kenya.","There are considerable challenges to achieving the Sustainable Development Goals' target of universal access to basic sanitation in schools. Schools require safe, clean, and sex-segregated facilities for a large number of students. Robust and affordable solutions are needed to address the economic, spatial, social, institutional, and political factors which contribute to poor sanitary conditions in informal settlements. In 2015, we undertook a randomized controlled trial to assess the feasibility of private sector sanitation delivery (PSSD) in 20 primary schools, in informal settlements of Nairobi, Kenya. Our preliminary evaluation after one year of service delivery suggested that PSSD of urine-diverting dry latrines with routine waste collection and maintenance provided a feasible, lower-cost alternative to the government standard delivery (GSD) of cistern-flush toilets or ventilated improved pit latrines. We conducted a mixed-methods follow-up study to assess sanitation delivery over 3-4 years and investigate prevailing drivers and barriers that may influence the scalability of PSSD. The conditions of newly constructed and rehabilitated GSD facilities diminished quickly, reverting to the conditions of existing facilities, indicating lower sustainability compared to sanitation delivered from the private sector. Barriers in financial aspects related to the ongoing implementation of PSSD emerged, particularly among public schools, and few were able to pay for continued service. Our study demonstrates that the engagement of the private sector may lead to improvements in affordable, safely managed sanitation for schools and their students. Yet, to reach a sustained scale, additional guidance is needed on how to develop these partnerships, streamline procurement and contracting processes, and incorporate appropriate financing mechanisms.",2020,"Our study demonstrates that the engagement of the private sector may lead to improvements in affordable, safely managed sanitation for schools and their students.","['Urban Informal Settlement Schools', '20 primary schools, in informal settlements of Nairobi, Kenya']",['private sector sanitation delivery (PSSD'],[],"[{'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0027345', 'cui_str': 'Nairobi sheep virus disease'}, {'cui': 'C0022558', 'cui_str': 'Kenya'}]","[{'cui': 'C0033176', 'cui_str': 'Private Sector'}, {'cui': 'C0036172', 'cui_str': 'Sanitation'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]",[],,0.0218354,"Our study demonstrates that the engagement of the private sector may lead to improvements in affordable, safely managed sanitation for schools and their students.","[{'ForeName': 'Jedidiah S', 'Initials': 'JS', 'LastName': 'Snyder', 'Affiliation': 'Gangarosa Department of Environmental Health, Emory University, Atlanta, GA 30322, USA.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Prentice-Mott', 'Affiliation': 'Gangarosa Department of Environmental Health, Emory University, Atlanta, GA 30322, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Boera', 'Affiliation': 'Consultant, Nairobi 00100, Kenya.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Mwaki', 'Affiliation': 'Safe Water & AIDS Project, Kisumu 40100, Kenya.'}, {'ForeName': 'Kelly T', 'Initials': 'KT', 'LastName': 'Alexander', 'Affiliation': 'CARE, Atlanta, GA 30307, USA.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Freeman', 'Affiliation': 'Gangarosa Department of Environmental Health, Emory University, Atlanta, GA 30322, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17155298'] 2399,32717868,Assessment of Attitudes Toward Physical Education by the Implementation of an Extracurricular Program for Obese Children.,"The World Health Organization (WHO) identifies the importance of implementing physical activity programs such as physical education (PE) classes in schools. This study identifies the attitudes of obese children toward PE, before and after participation in a vigorous-intensity physical exercise program without the participation of normal-weight peers using a questionnaire on Attitudes toward Physical Education (CAEF). 98 children between 8-11 years of age were randomized in an Experimental Group (GE) ( n = 48) and a Control Group (CG) ( n = 47). They were assessed using a questionnaire on Attitudes toward Physical Education (CAEF). All the study participants exhibited a BMI Z-score ≥ 2. Before the intervention, the only difference between boys and girls was ""empathy to teacher and physical education subject"" ( p = 0.001, d de Cohen = 0.72, r = 0.34). The interaction between gender and training was only present in empathy for the teacher, with a medium effect size ( η 2 = 0.055). The implementation of PE with two hours per week elicits only a few effects over the attitude of obese children, even though with a certain engagement of gender through training in the adjustment of empathy for teachers and the PE class.",2020,"Before the intervention, the only difference between boys and girls was ""empathy to teacher and physical education subject"" ( p = 0.001, d de Cohen =","['Obese Children', '98 children between 8-11 years of age']","['vigorous-intensity physical exercise program', 'Control Group (CG']","['Attitudes toward Physical Education (CAEF', 'empathy to teacher and physical education subject']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}]",98.0,0.017797,"Before the intervention, the only difference between boys and girls was ""empathy to teacher and physical education subject"" ( p = 0.001, d de Cohen =","[{'ForeName': 'Ena Monserrat', 'Initials': 'EM', 'LastName': 'Romero-Pérez', 'Affiliation': 'Division of Biological Sciences and Health, University of Sonora, 83000 Hermosillo, Sonora, Mexico.'}, {'ForeName': 'Oscar', 'Initials': 'O', 'LastName': 'Núñez Enríquez', 'Affiliation': 'Faculty of Physical Culture Sciences, Autonomous University of Chihuahua, 31000 Chihuahua, Chih, Mexico.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Gastélum-Cuadras', 'Affiliation': 'Faculty of Physical Culture Sciences, Autonomous University of Chihuahua, 31000 Chihuahua, Chih, Mexico.'}, {'ForeName': 'Mario Alberto', 'Initials': 'MA', 'LastName': 'Horta-Gim', 'Affiliation': 'Division of Biological Sciences and Health, University of Sonora, 83000 Hermosillo, Sonora, Mexico.'}, {'ForeName': 'Jerónimo J', 'Initials': 'JJ', 'LastName': 'González-Bernal', 'Affiliation': 'Department of Health Sciences, University of Burgos, 09001 Burgos, Spain.'}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'de Paz', 'Affiliation': 'Division of Biological Sciences and Health, University of Sonora, 83000 Hermosillo, Sonora, Mexico.'}]",International journal of environmental research and public health,['10.3390/ijerph17155300'] 2400,32717926,The Effects of Alcohol Consumption on Cardiometabolic Health Outcomes Following Weight Loss in Premenopausal Women with Obesity: A Pilot Randomized Controlled Trial.,"Alcohol (i.e., ethanol) is consumed regularly by much of the adult population; yet, the health effects associated with its use are not well-characterized. Clinical interventions to investigate the effects of moderate alcohol consumption on metabolic outcomes, including adiposity and cardiovascular risk factors, are limited and have yielded conflicting data. In addition, no study has reported the effects of routine alcohol intake during weight loss in a controlled feeding trial. We present the first randomized controlled pilot trial to investigate the effects of moderate alcohol consumption on metabolic outcomes during weight loss in women with obesity. Both groups consumed 30% energy restricted diets and were randomized to either an ethanol-free control (CTL) group or a group (EtOH) that consumed 35 g ethanol daily for eight weeks. Our findings demonstrate that, despite similar weight loss, the decrease in mean arterial pressure was attenuated in the EtOH group, relative to the CTL group ( p = 0.02). In addition, decreases in other outcomes, including visceral adipose tissue ( p = 0.23), circulating lipids (triglycerides ( p = 0.11) and cholesterol ( p = 0.11)), and uric acid ( p = 0.07) tended to be attenuated with alcohol consumption. These pilot data provide potential evidence that moderate alcohol consumption may mitigate the beneficial effects of weight loss and support the need for larger Randomized Controlled Trials (RCTs) to better investigate the metabolic effects of moderate alcohol intake in humans.",2020,"In addition, decreases in other outcomes, including visceral adipose tissue ( p = 0.23), circulating lipids (triglycerides ( p = 0.11) and cholesterol ( p = 0.11)), and uric acid ( p = 0.07) tended to be attenuated with alcohol consumption.","['Premenopausal Women with Obesity', 'women with obesity']","['ethanol-free control (CTL', 'moderate alcohol consumption', 'Alcohol Consumption', 'Alcohol (i.e., ethanol']","['visceral adipose tissue', 'circulating lipids (triglycerides', 'Cardiometabolic Health Outcomes', 'uric acid', 'mean arterial pressure', 'weight loss', 'adiposity and cardiovascular risk factors']","[{'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}]","[{'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0041980', 'cui_str': 'Uric Acid'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}]",,0.0546005,"In addition, decreases in other outcomes, including visceral adipose tissue ( p = 0.23), circulating lipids (triglycerides ( p = 0.11) and cholesterol ( p = 0.11)), and uric acid ( p = 0.07) tended to be attenuated with alcohol consumption.","[{'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Apolzan', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Robbie A', 'Initials': 'RA', 'LastName': 'Beyl', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Frank L', 'Initials': 'FL', 'LastName': 'Greenway', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'White', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17155302'] 2401,32718095,Efficacy of Modified Treat-and-Extend Aflibercept Regimen for Macular Edema Due to Branch Retinal Vein Occlusion: 1-Year Prospective Study.,"PURPOSE To assess the efficacy and safety of a modified treat-and-extend (mTAE) regimen of aflibercept for macular edema (ME) due to branch retinal vein occlusion (BRVO). METHODS This prospective multicentre intervention study evaluated 50 eyes of 50 patients enrolled from October 2016 to September 2017. The patients received intravitreal aflibercept (IVA) injections on an mTAE regimen for a total of 12 months. The main outcome measures were best-corrected visual acuity (BCVA) and central subfield thickness (CST) at 12 months. RESULTS The baseline BCVA and CST were 0.33 (0.27) and 488 (171) µm (mean (standard deviation)), respectively. The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110) µm; both p < 0.0001, paired t -test). The mean number of clinic visits and IVA injections was 6.71 (1.41) and 4.26 (0.71), respectively. The time to first recurrence from the first injection was most frequently 3 months. CONCLUSION The mTAE regimen of IVA injections for ME due to BRVO effectively improved BCVA and reduced CST, and thus might be an effective therapy to reduce the number of injections and visits.",2020,The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110),"['50 eyes of 50 patients enrolled from October 2016 to September 2017', 'macular edema (ME', 'Macular Edema Due to Branch Retinal Vein Occlusion']","['intravitreal aflibercept (IVA) injections', 'modified treat-and-extend (mTAE) regimen of aflibercept', 'Modified Treat-and-Extend Aflibercept Regimen']","['best-corrected visual acuity (BCVA) and central subfield thickness (CST', 'time to first recurrence', 'BRVO effectively improved BCVA and reduced CST', 'efficacy and safety', 'mean number of clinic visits and IVA injections', 'baseline BCVA and CST', 'BCVA and CST']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion'}]","[{'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0339505', 'cui_str': 'Venous retinal branch occlusion'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}, {'cui': 'C4050106', 'cui_str': 'aflibercept Injection'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",50.0,0.0280244,The BCVA and CST were significantly improved at month 12 (0.067 (0.19) LogMAR and 295 (110),"[{'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Arai', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Takahashi', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Satoru', 'Initials': 'S', 'LastName': 'Inoda', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Shinichi', 'Initials': 'S', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Tan', 'Affiliation': 'Japan Community Health Care Organization Tokyo Shinjuku Medical Center, Tokyo 162-8543, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Satoko', 'Initials': 'S', 'LastName': 'Tominaga', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Hidetoshi', 'Initials': 'H', 'LastName': 'Kawashima', 'Affiliation': 'Department of Ophthalmology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0431, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Yanagi', 'Affiliation': 'Department of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8802, Japan.'}]",Journal of clinical medicine,['10.3390/jcm9082360'] 2402,32718147,Evaluating the Effects of Probiotics in Pediatrics with Recurrent Abdominal Pain.,"Background Recurrent Abdominal Pains (RAP) is one of the frequent complaints in general practice, particularly in pediatrics and is among the common cause of referral to gastroenterology clinics. Purpose This study is designed to investigate the effects of probiotics for the treatment of RAP and desired therapeutic outcomes. Methods 125 children with the diagnosis of RAP according to Rome III criteria for IBS, Functional Abdominal Pain (FAP), Functional Dyspepsia (FD) and Abdominal Migraine (AM), were enrolled in this double-blind randomized controlled trial. Results 65 subjects received probiotics, and others received placebo treatment for 4 weeks. Lactobacillus Reuteri was therapeutically effective in 32 patients compared to 8 patients, responding to the placebo treatment. Compared to baseline, all pain-related variables showed a significant reduction for the IBS and FD at the end of the 4th week. However, it did not respond well in FAP and AM groups. Pain-related outcomes such as, frequency of the pain, severity and duration of the pain were decreased following the probiotic treatment. No therapeutic response was seen in AM group after the administration of probiotics. Lactobacillus Reuteri significantly led to pain relief in the overall population, and also in FAP, FD and IBS subgroups. Conclusion Lactobacillus Reuteri probiotics are likely to lead to RAP relief and can be recommended for the treatment of functional gastrointestinal disorders.",2020,"Lactobacillus Reuteri significantly led to pain relief in the overall population, and also in FAP, FD and IBS subgroups. ","['Pediatrics with Recurrent Abdominal Pain', '125 children with the diagnosis of RAP according to Rome III criteria for IBS, Functional Abdominal Pain (FAP), Functional Dyspepsia (FD) and Abdominal Migraine (AM', '65 subjects received']","['Probiotics', 'probiotics, and others received placebo']","['pain relief', 'therapeutic response', 'frequency of the pain, severity and duration of the pain', 'IBS and FD']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C2585575', 'cui_str': 'Recurrent abdominal pain'}, {'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0035831', 'cui_str': 'Rome'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia'}, {'cui': 'C0270858', 'cui_str': 'Abdominal migraine'}]","[{'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0022104', 'cui_str': 'Irritable bowel syndrome'}, {'cui': 'C0267167', 'cui_str': 'Nonulcer dyspepsia'}]",125.0,0.0462978,"Lactobacillus Reuteri significantly led to pain relief in the overall population, and also in FAP, FD and IBS subgroups. ","[{'ForeName': 'Parisa', 'Initials': 'P', 'LastName': 'Rahmani', 'Affiliation': 'Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Azin', 'Initials': 'A', 'LastName': 'Ghouran-Orimi', 'Affiliation': 'Iran university of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Motamed', 'Affiliation': 'Pediatric Gastroenterology and Hepatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Moradzadeh', 'Affiliation': ""Department of Pediatric Gastroenterology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.""}]",Clinical and experimental pediatrics,['10.3345/cep.2019.01613'] 2403,32718158,Evaluating and dismantling an intervention aimed at increasing white people's knowledge and understanding of racial justice issues.,"In this study, we built upon prejudice reduction interventions research (primarily in social psychology) and ally development investigations (primarily in applied psychology). We aimed to develop an intervention to foster knowledge and attitude change identified in both areas as central to reducing prejudice and increasing intentions to promote racial justice. Specifically, we aimed to determine whether online imaginal and psychoeducational interventions could contribute to White people's needed understandings to engage in racial justice work. Additionally, if some interventions were successful, we aimed to determine which components were most effective. We used three intervention components, two of which were created for this study: imaginal contact with a person of color, learning and reflecting about racism and its impact on people of color, and increasing awareness of White privilege and positionality. We randomized participants to different combinations of the intervention components and control components to not only evaluate combined components but also dismantle the intervention, determining whether specific aspects of the intervention were more effective. Participants completed outcome measures about their attitudes and understandings prior to the intervention, immediately postintervention, and 3 weeks after completing the intervention. Findings demonstrated that the intervention and its components positively impacted outcomes of interest, with increasingly complicated learning requiring more comprehensive intervention to change. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"Participants completed outcome measures about their attitudes and understandings prior to the intervention, immediately postintervention, and 3 weeks after completing the intervention.",[],['online imaginal and psychoeducational interventions'],[],[],"[{'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],,0.0390303,"Participants completed outcome measures about their attitudes and understandings prior to the intervention, immediately postintervention, and 3 weeks after completing the intervention.","[{'ForeName': 'Alissa L', 'Initials': 'AL', 'LastName': 'Hochman', 'Affiliation': 'Clinical Psychology Program.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Suyemoto', 'Affiliation': 'Department of Psychology.'}]",The American journal of orthopsychiatry,['10.1037/ort0000506'] 2404,32718191,Effect of consumption of ancient grain bread leavened with sourdough or with baker's yeast on cardio-metabolic risk parameters: a dietary intervention trial.,"The aim of this study was to compare the effect of consumption of ancient grain ""Verna"" bread obtained by two different leavening agents, sourdough (SD) and baker's yeast (BY), on inflammatory parameters and cardiometabolic risk factors. Seventeen clinically healthy subjects were included to consume SD or BY bread for 4 weeks each, and blood analyses were carried out. The consumption of ""Verna"" bread obtained with both leavening agents led to a significant improvement of LDL cholesterol. A reduction of -10.6% and -8.53% was observed after replacement with SD and BY bread, respectively. A significant increase in fasting blood glucose (+6%) was observed only after the intervention with BY bread. A 10.7% decrease of vascular endothelial growth factor was found after the SD bread replacement period. The consumption of ""Verna"" bread resulted significantly associated with an improvement in the cardiometabolic and inflammatory profile. However, only consumption of BY bread determined a significant increase in blood glucose levels.",2020,"A reduction of -10.6% and -8.53% was observed after replacement with SD and BY bread, respectively.",['Seventeen clinically healthy subjects'],"[""consumption of ancient grain bread leavened with sourdough or with baker's yeast""]","['fasting blood glucose', 'cardiometabolic and inflammatory profile', 'LDL cholesterol', 'cardio-metabolic risk parameters', 'vascular endothelial growth factor', 'blood glucose levels']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0006138', 'cui_str': 'Bread'}, {'cui': 'C0036025', 'cui_str': 'Saccharomyces cerevisiae'}]","[{'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}]",17.0,0.0192064,"A reduction of -10.6% and -8.53% was observed after replacement with SD and BY bread, respectively.","[{'ForeName': 'Giuditta', 'Initials': 'G', 'LastName': 'Pagliai', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Venturi', 'Affiliation': 'FoodMicroTeam s.r.l, Florence, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Dinu', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Galli', 'Affiliation': 'Department of Agriculture, Food, Environment and Forestry (DAGRI), University of Florence, Florence, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Colombini', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Giangrandi', 'Affiliation': 'Unit of Clinical Nutrition, Careggi University Hospital, Florence, Italy.'}, {'ForeName': 'Niccolò', 'Initials': 'N', 'LastName': 'Maggini', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Sofi', 'Affiliation': 'Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Granchi', 'Affiliation': 'Department of Agriculture, Food, Environment and Forestry (DAGRI), University of Florence, Florence, Italy.'}]",International journal of food sciences and nutrition,['10.1080/09637486.2020.1799956'] 2405,32718193,Detecting asthma exacerbations using daily home monitoring and machine learning.,"Objective: Acute exacerbations contribute significantly to the morbidity of asthma. Recent studies have shown that early detection and treatment of asthma exacerbations leads to improved outcomes. We aimed to develop a machine learning algorithm to detect severe asthma exacerbations using easily available daily monitoring data. Methods: We analysed daily peak expiratory flow and symptom scores recorded by participants in the SAKURA study (NCT00839800), an international multicentre randomised controlled trial comparing budesonide/formoterol as maintenance and reliever therapy versus budesonide/formoterol maintenance plus terbutaline as reliever, in adults with persistent asthma. The dataset consisted of 728,535 records of daily monitoring data in 2010 patients, with 576 severe exacerbation events. Data post-processing techniques included normalisation, standardisation, calculation of differences or slopes over time and the use of smoothing filters. Principal components analysis was used to reduce the large number of derived variables to a smaller number of linearly independent components. Logistic regression, decision tree, naïve Bayes, and perceptron algorithms were evaluated. Model accuracy was assessed using stratified cross-validation. The primary outcome was the detection of exacerbations on the same day or up to three days in the future. Results: The best model used logistic regression with input variables derived from post-processed data using principal components analysis. This had an area under the receiver operating characteristic curve of 0.85, with a sensitivity of 90% and specificity of 83% for severe asthma exacerbations. Conclusion: Asthma exacerbations may be detected using machine learning algorithms applied to daily self-monitoring of peak expiratory flow and asthma symptoms.",2020,"This had an area under the receiver operating characteristic curve of 0.85, with a sensitivity of 90% and specificity of 83% for severe asthma exacerbations.","['adults with persistent asthma', '2010 patients, with 576 severe exacerbation events']","['budesonide/formoterol maintenance plus terbutaline', 'daily home monitoring and machine learning', 'budesonide/formoterol', 'machine learning algorithm']","['daily peak expiratory flow and symptom scores', 'detection of exacerbations', 'morbidity of asthma', 'peak expiratory flow and asthma symptoms', 'Model accuracy']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3266628', 'cui_str': 'Persistent asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}]","[{'cui': 'C1276807', 'cui_str': 'formoterol and budesonide'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039542', 'cui_str': 'Terbutaline'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0376284', 'cui_str': 'Machine Learning'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.440755,"This had an area under the receiver operating characteristic curve of 0.85, with a sensitivity of 90% and specificity of 83% for severe asthma exacerbations.","[{'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Zhang', 'Affiliation': 'INSA Rennes, Rennes, France.'}, {'ForeName': 'Leandro L', 'Initials': 'LL', 'LastName': 'Minku', 'Affiliation': 'School of Computer Science, University of Birmingham, UK.'}, {'ForeName': 'Sherif', 'Initials': 'S', 'LastName': 'Gonem', 'Affiliation': 'Department of Respiratory Medicine, Nottingham City Hospital, Nottingham, UK.'}]",The Journal of asthma : official journal of the Association for the Care of Asthma,['10.1080/02770903.2020.1802746'] 2406,32725783,First Clinical Study with AP30663 - a K Ca 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation.,"Pharmacological cardioversion of atrial fibrillation (AF) is frequently inefficacious. AP30663, a small conductance Ca 2+ activated K + (K Ca 2) channel blocker, prolonged the atrial effective refractory period in preclinical studies and subsequently converted AF into normal sinus rhythm. This first-in-human study evaluated the safety and tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects were explored. Forty-seven healthy male volunteers (23.7 ± 3.0 years) received AP30663 intravenously in ascending doses. Due to infusion site reactions, changes to the formulation and administration were implemented in the latter 24 volunteers. Extractions from a 24-hour continuous electrocardiogram were used to evaluate the PD effect of AP30663. Data were analyzed with a repeated measure analysis of covariance, noncompartmental analysis, and concentration-effect analysis. In total, 33 of 34 adverse events considered related to AP30663 exposure were related to the infusion site, mild in severity, and temporary in nature, although full recovery took up to 110 days. After formulation and administration changes, the local infusion site reaction remained, but the median duration was shorter despite higher dose levels. AP30663 displayed a less than dose proportional increase in peak plasma concentration (C max ) and a terminal half-life of around 5 hours. In healthy volunteers, no effect of AP30663 was observed on electrocardiographic parameters, other than a concentration-dependent effect on the corrected QT Fridericia's formula interval (+18.8 ± 4.3 ms for the highest dose level compared with time matched placebo). In conclusion, administration of AP30663, a novel K Ca 2 channel inhibitor, was safe and well-tolerated systemically in humans, supporting further development in patients with AF undergoing cardioversion.",2020,"After formulation and administration changes, the local infusion site reaction remained, but the median duration was shorter despite higher dose levels.","['Forty-seven healthy male volunteers (23.7\xa0±\xa03.0\xa0years) received', 'healthy volunteers', 'latter 24 volunteers', 'patients with AF undergoing cardioversion']","['Ca 2+ activated K + ', 'AP30663 - a K', 'Pharmacological cardioversion of atrial fibrillation (AF', 'AP30663']","['local infusion site reaction', 'median duration', 'safety and tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects', 'electrocardiographic parameters', 'peak plasma concentration (C max ']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}]","[{'cui': 'C0596235', 'cui_str': 'Calcium ion'}, {'cui': 'C1963873', 'cui_str': 'Pharmacological cardioversion'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C1096343', 'cui_str': 'Infusion site reaction'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",47.0,0.0178514,"After formulation and administration changes, the local infusion site reaction remained, but the median duration was shorter despite higher dose levels.","[{'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'Gal', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Erica S', 'Initials': 'ES', 'LastName': 'Klaassen', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Kirsten R', 'Initials': 'KR', 'LastName': 'Bergmann', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Saghari', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Jacobus', 'Initials': 'J', 'LastName': 'Burggraaf', 'Affiliation': 'Centre for Human Drug Research, Leiden, The Netherlands.'}, {'ForeName': 'Michiel J B', 'Initials': 'MJB', 'LastName': 'Kemme', 'Affiliation': 'Department of Cardiology, Amsterdam UMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Sylvest', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}, {'ForeName': 'Ulrik', 'Initials': 'U', 'LastName': 'Sørensen', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}, {'ForeName': 'Bo H', 'Initials': 'BH', 'LastName': 'Bentzen', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Grunnet', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}, {'ForeName': 'Jonas G', 'Initials': 'JG', 'LastName': 'Diness', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}, {'ForeName': 'Nils', 'Initials': 'N', 'LastName': 'Edvardsson', 'Affiliation': 'Acesion Pharma ApS, Copenhagen, Denmark.'}]",Clinical and translational science,['10.1111/cts.12835'] 2407,32725791,"Supplemental CO 2 improves oxygen saturation, oxygen tension , and cerebral oxygenation in acutely hypoxic healthy subjects.","Oxygen is viewed in medicine as the sole determinant of tissue oxygenation, though carbon dioxide homeostasis is equally important and clinically often ignored. The aims of this study were as follows: (a) to examine the effects of different acute hypoxic conditions on partial pressure of arterial oxygen ( Pa O 2 ), arterial oxygen saturation of hemoglobin ( Sa O 2 ), and regional cerebral saturation of hemoglobin (rSO 2 ); and (b) to evaluate supplemental CO 2 as a tool to improve oxygenation in acutely hypoxic individuals. We hypothesized that exposure to gas mixtures with added CO 2 would improve oxygenation in hypoxic human subjects. Twenty healthy subjects were exposed to 5-min intervals of two gas mixtures: hypoxic gas mixture containing 8% oxygen, and a CO 2 -enriched mixture containing 8% oxygen plus either 3% or 5% CO 2 . Ten subjects received the 3% CO 2 -enriched mixture, and the remaining 10 subjects received the 5% CO 2 -enriched mixture. The order of exposure was randomized. Blood gases, pulse oximetry, end-tidal CO 2 , and cerebral oximetry were measured. Compared to the purely hypoxic gas group, Pa O 2 was increased in the 3% and 5% CO 2 -enriched groups by 14.9 and 9.5 mmHg, respectively. Compared to pure hypoxia, Sa O 2 was increased in the 3% and 5% CO 2 -enriched groups by 16.8% and 12.9%, respectively. Both CO 2 -enriched gas groups had significantly higher end-exposure rSO 2 and recovered to baseline rSO 2 within 1 min, compared to the pure hypoxic gas group, which returned to baseline in 5 min. These results suggest that in acutely hypoxic subjects, CO 2 supplementation improves blood oxygen saturation and oxygen tension as well as cerebral oxygenation measures.",2020,"Both CO 2 -enriched gas groups had significantly higher end-exposure rSO 2 and recovered to baseline rSO 2 within 1 min, compared to the pure hypoxic gas group, which returned to baseline in 5 min.","['acutely hypoxic individuals', 'hypoxic human subjects', 'Twenty healthy subjects', 'acutely hypoxic healthy subjects']","['pure hypoxia, Sa', 'hypoxic gas mixture containing 8% oxygen, and a CO 2 -enriched mixture containing 8% oxygen plus either 3% or 5% CO 2 ']","['Blood gases, pulse oximetry, end-tidal CO 2 , and cerebral oximetry', 'partial pressure of arterial oxygen ( Pa O 2 ), arterial oxygen saturation of hemoglobin ( Sa O 2 ), and regional cerebral saturation of hemoglobin (rSO 2 ', 'Pa O 2', 'blood oxygen saturation and oxygen tension', 'oxygen saturation, oxygen tension , and cerebral oxygenation', 'cerebral oxygenation measures']","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0068879', 'cui_str': 'nitrox'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0005800', 'cui_str': 'Blood gas analysis'}, {'cui': 'C0034108', 'cui_str': 'Pulse oximetry'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0030604', 'cui_str': 'Partial pressure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0428175', 'cui_str': 'Oxygen saturation measurement, arterial'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",20.0,0.0431829,"Both CO 2 -enriched gas groups had significantly higher end-exposure rSO 2 and recovered to baseline rSO 2 within 1 min, compared to the pure hypoxic gas group, which returned to baseline in 5 min.","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Stepanek', 'Affiliation': 'Mayo Clinic, Aerospace Medicine and Vestibular Research Laboratory (AMVRL), Scottsdale, AZ, USA.'}, {'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'Dunn', 'Affiliation': 'Mayo Clinic Alix School of Medicine, Scottsdale, AZ, USA.'}, {'ForeName': 'Gaurav N', 'Initials': 'GN', 'LastName': 'Pradhan', 'Affiliation': 'Mayo Clinic, Aerospace Medicine and Vestibular Research Laboratory (AMVRL), Scottsdale, AZ, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Cevette', 'Affiliation': 'Mayo Clinic, Aerospace Medicine and Vestibular Research Laboratory (AMVRL), Scottsdale, AZ, USA.'}]",Physiological reports,['10.14814/phy2.14513'] 2408,32725799,Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.,"BACKGROUND AND OBJECTIVE Cardiovascular risk is substantially increased in patients with COPD and can be quantified via arterial stiffness. The PDE-IV inhibitor roflumilast revealed a potential reduction of COPD-related cardiovascular risk. We aimed to investigate the effects of roflumilast on arterial stiffness by quantification of pulse wave velocity (PWV) in stable COPD. METHODS In this randomized placebo-controlled trial, 80 COPD patients received roflumilast or placebo for 24 weeks. The primary outcome was the change in cf-PWV. Secondary outcomes comprised markers of vascular function (e.g. Aix and RHI), systemic inflammation (e.g. IL-6 and TNF-α) and clinical characteristics of COPD (e.g. CAT and 6MWT). RESULTS A total of 33 and 34 patients completed the roflumilast and placebo arm, respectively (age, median (IQR): 64.5 (61-69.5) vs 64.5 (56-72) years; FEV 1 , median (IQR): 34.5 (25.5-48.6) vs 35.3 (27-46.8) % predicted; 6MWT, median (IQR): 428 (340-558) vs 456 (364-570) m). Change from baseline PWV did not show a significant difference between roflumilast and placebo (+5.0 (95% CI: -2.0 to +13.0) vs 0.0 (95% CI: -7.0 to +7.0)%, P = 0.268). Roflumilast did not improve markers of vascular function or systemic inflammation. We observed a significant improvement in change from baseline 6MWT with roflumilast versus placebo (+53.0 (95% CI: +19.1 to +86.9) vs -0.92 (95% CI: -35.1 to +33.3) m, P = 0.026). CONCLUSION Our study revealed no beneficial effects of roflumilast on arterial stiffness. Further studies are needed to test a potential improvement of exercise capacity with roflumilast in COPD.",2020,"Change from baseline PWV did not show a significant difference between roflumilast and placebo (+5.0 (95% CI: -2.0 to +13.0) vs 0.0 (95% CI: -7.0 to +7.0)%, P = 0.268).","['patients with COPD', 'arm, respectively (age, median (IQR): 64.5 (61-69.5) vs 64.5 (56-72) years; FEV 1 , median (IQR): 34.5 (25.5-48.6) vs 35.3 (27-46.8) % predicted; 6MWT, median (IQR): 428 (340-558) vs 456 (364-570) m', '80 COPD patients received', 'COPD (ELASTIC']","['roflumilast and placebo', 'Roflumilast', 'roflumilast', 'roflumilast or placebo', 'placebo']","['arterial stiffness by quantification of pulse wave velocity (PWV', 'markers of vascular function (e.g. Aix and RHI), systemic inflammation (e.g. IL-6 and TNF-α) and clinical characteristics of COPD (e.g. CAT and 6MWT', 'arterial stiffness', 'change in cf-PWV', 'vascular function or systemic inflammation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C4517663', 'cui_str': '25.5'}, {'cui': 'C4517775', 'cui_str': '428'}, {'cui': 'C4517730', 'cui_str': '340'}, {'cui': 'C0221839', 'cui_str': 'Orthodontic band, elastic'}]","[{'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0999177', 'cui_str': 'Aix'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0007366', 'cui_str': 'Catalan language'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",80.0,0.789626,"Change from baseline PWV did not show a significant difference between roflumilast and placebo (+5.0 (95% CI: -2.0 to +13.0) vs 0.0 (95% CI: -7.0 to +7.0)%, P = 0.268).","[{'ForeName': 'Matthias H', 'Initials': 'MH', 'LastName': 'Urban', 'Affiliation': 'Department of Internal and Respiratory Medicine, Krankenhaus Nord - Klinik Floridsdorf and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Vienna, Austria.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Kreibich', 'Affiliation': 'Department of Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Gleiss', 'Affiliation': 'Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Georg-Christian', 'Initials': 'GC', 'LastName': 'Funk', 'Affiliation': 'Department of Internal and Respiratory Medicine, Wilhelminenspital, Vienna, Austria.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Hartl', 'Affiliation': 'Department of Respiratory Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Hospital and Sigmund Freud University, Medical School, Vienna, Austria.'}, {'ForeName': 'Otto C', 'Initials': 'OC', 'LastName': 'Burghuber', 'Affiliation': 'Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Otto-Wagner-Hospital and Sigmund Freud University, Medical School, Vienna, Austria.'}]","Respirology (Carlton, Vic.)",['10.1111/resp.13914'] 2409,32725809,Infant growth during the first year of life following a pregnancy lifestyle intervention in routine care-Findings from the cluster-randomised GeliS trial.,"BACKGROUND Lifestyle interventions in pregnancy may influence postpartum development and obesity risk in offspring. The impact of lifestyle interventions as health system-based approaches is unclear. OBJECTIVE To evaluate the effect of an antenatal lifestyle intervention conducted as public health approach on infant development and feeding practices. METHODS We followed offspring born to women participating in the cluster-randomised GeliS trial who received usual care (CG) or repeated lifestyle counselling (IG). We collected data on offspring development and complementary feeding until the 12 th month postpartum. RESULTS Of the 1998 mother-child pairs, 1783 completed the follow-up. Mean infant weight at 12 months was comparable between groups (IG: 9497.9 ± 1137.0 g; CG: 9433.4 ± 1055.2 g; P = .177). There was no significant evidence of differences in sex- and age-adjusted z-scores or in the odds of offspring being overweight. More infants in the IG received whole-grain products compared to the CG (95.6% vs. 90.8%; P = .003). Despite small differences in the timing of introducing solid foods, there were no further significant differences in the pattern of complementary feeding. CONCLUSIONS The antenatal lifestyle intervention embedded in routine care did not substantially influence infant anthropometrics and is thus unlikely to impact future development.",2020,The antenatal lifestyle intervention embedded in routine care did not substantially influence infant anthropometrics and is thus unlikely to impact future development.,"['Of the 1998 mother-child pairs, 1783 completed the follow-up']","['usual care (CG) or repeated lifestyle counselling (IG', 'antenatal lifestyle intervention', 'pregnancy lifestyle intervention']",['Mean infant weight'],"[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0730543', 'cui_str': 'Lifestyle education'}, {'cui': 'C2828394', 'cui_str': 'Antenatal'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}]",,0.0768098,The antenatal lifestyle intervention embedded in routine care did not substantially influence infant anthropometrics and is thus unlikely to impact future development.,"[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Hoffmann', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Günther', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Lynne', 'Initials': 'L', 'LastName': 'Stecher', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Spies', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Geyer', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Raab', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Meyer', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Kathrin', 'Initials': 'K', 'LastName': 'Rauh', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Hauner', 'Affiliation': 'Else Kröner-Fresenius-Centre for Nutritional Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.'}]",Pediatric obesity,['10.1111/ijpo.12705'] 2410,32725838,Exploring dietary changes in an interdisciplinary intervention trial: Application of a dietary guidelines food composition database.,"BACKGROUND Consumption of food groups aligning with dietary guidelines is advised for obesity management and was used in a recent lifestyle intervention trial, the Health Track study. We have conducted a number of dietary pattern analyses on this trial but, with recent access to the new Australian Dietary Guidelines (ADG) food composition database, we can now assess ADG adherence, with the advantage of categorising mixed dishes. The present study aimed to compare changes over time in consumption of ADG food groups. METHODS Secondary analysis of baseline and three-month diet history data was conducted. Participants received individualised dietary advice (I), individualised dietary advice plus 30 g of walnuts per day (IW) or usual care (C). The ADG database was used to determine food group servings with changes in five food groups used as a measure of dietary quality. RESULTS Fruit and vegetable intakes increased in the IW (+0.4 and +1.1 serves, P < 0.05) and I (+0.5 and +0.4 serves, P > 0.05) arms. Consumption of meat/protein foods increased in the IW arm (+0.3 serves, P > 0.05) but decreased in the I and C arms (both - 0.4 serves, P < 0.05). Consumption of grains and milk/alternatives decreased in all study arms (P < 0.05). Greater improvements in grain and dairy food quality were observed in the intervention arms. CONCLUSIONS The ADG database enabled ADG specific food group analysis, addressed food quality and showed the HealthTrack intervention increased adherence to dietary guidelines compared to usual care.",2020,"Consumption of meat/protein foods increased in the IW arm (+0.3 serves, P > 0.05) but decreased in the I and C arms (both - 0.4 serves, P < 0.05).",[],"['individualised dietary advice (I), individualised dietary advice plus 30\xa0g of walnuts per day (IW) or usual care (C']","['grain and dairy food quality', 'Consumption of meat/protein foods', 'Consumption of grains and milk/alternatives', 'Fruit and vegetable intakes']",[],"[{'cui': 'C0204932', 'cui_str': 'Diet education'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0330971', 'cui_str': 'Juglans'}, {'cui': 'C0439505', 'cui_str': '/day'}]","[{'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C0010947', 'cui_str': 'Dairy foods'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0453858', 'cui_str': 'Protein food'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C1271941', 'cui_str': 'Fruit and vegetable intake'}]",,0.0396388,"Consumption of meat/protein foods increased in the IW arm (+0.3 serves, P > 0.05) but decreased in the I and C arms (both - 0.4 serves, P < 0.05).","[{'ForeName': 'K', 'Initials': 'K', 'LastName': 'Zoszak', 'Affiliation': 'School of Medicine, Science Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Neale', 'Affiliation': 'School of Medicine, Science Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Tapsell', 'Affiliation': 'School of Medicine, Science Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Probst', 'Affiliation': 'School of Medicine, Science Medicine and Health, University of Wollongong, Wollongong, NSW, Australia.'}]",Journal of human nutrition and dietetics : the official journal of the British Dietetic Association,['10.1111/jhn.12790'] 2411,32725954,Ibuprofen does not prevent postbronchoscopy fever in children undergoing broncho-alveolar lavage.,"BACKGROUND Fiber-optic bronchoscopy (FOB) of the lower airways is a routine examination performed for investigating varying respiratory complaints in children. A common side effect is a transient high fever on the day of the FOB. Such episodes are usually unrelated to an infectious process but may cause clinical uncertainty and parental anxiety. We have previously showed that a single dose of systemic dexamethasone significantly reduces the rate of fever post bronchoscopy (FPB). RESEARCH QUESTION To prospectively analyze the effect of a prophylactic dose of ibuprofen upon the FPB. STUDY DESIGN AND METHODS Children presenting for elective FOB and broncho-alveolar lavage (BAL) were randomized, in a double blind fashion, to receive a single dose of ibuprofen syrup 10mg/kg or placebo prior the procedure. Parents were contacted the next day to record the presence or absence of fever. RESULTS Sixty one children were included in the final analysis. Thirty one children were in the treatment group and 30 in the placebo group. FPB occurred in 40 children (65%). There was no difference in in the rate of FPB between placebo (63%) and treatment (67%) groups (p=0.717). Fifty (82%) children had a positive BAL culture. Among them 38 had FPB (76%) compared to only 2 of 11 (18%) of those with negative culture (p= 0.00026, relative risk 4.18). Eighty percent of positive cultures grew H. influenza. There was no significant difference between the number of BALs with a positive culture between the treatment and placebo groups (87% vs. 77%, p = 0.35). CONCLUSION FPB occurs in around two thirds of children when BAL is performed. Fever occurred significantly more frequently when BAL culture is positive. A single standard dose of the non-steroidal anti-inflammatory drug ibuprofen administered before a FOB does not prevent FPB. This article is protected by copyright. All rights reserved.",2020,There was no difference in in the rate of FPB between placebo (63%) and treatment (67%) groups (p=0.717).,"['children undergoing broncho-alveolar lavage', 'children', 'Sixty one children were included in the final analysis', 'Children presenting for elective FOB and broncho-alveolar lavage (BAL', 'Fifty (82%) children had a positive BAL culture']","['systemic dexamethasone', 'Ibuprofen', 'ibuprofen syrup 10mg/kg or placebo', 'ibuprofen', 'Fiber-optic bronchoscopy (FOB', 'placebo']","['FPB', 'rate of fever post bronchoscopy (FPB', 'number of BALs with a positive culture', 'postbronchoscopy fever', 'rate of FPB', 'Fever']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0396473', 'cui_str': 'Bronchoscopy and bronchoalveolar lavage'}, {'cui': 'C4517832', 'cui_str': '61'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0020740', 'cui_str': 'Ibuprofen'}, {'cui': 'C0458173', 'cui_str': 'Syrup'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0189391', 'cui_str': 'Fiberoptic bronchoscopy'}]","[{'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0006290', 'cui_str': 'Bronchoscopy'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0012383', 'cui_str': 'Dimercaprol'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0010453', 'cui_str': 'Culture'}]",61.0,0.633658,There was no difference in in the rate of FPB between placebo (63%) and treatment (67%) groups (p=0.717).,"[{'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Joseph', 'Affiliation': 'Pediatric Pulmonary Unit, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.'}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Goldberg', 'Affiliation': 'Pediatric Pulmonary Unit, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.'}, {'ForeName': 'Shlomi', 'Initials': 'S', 'LastName': 'Cohen', 'Affiliation': 'Pediatric Pulmonary Unit, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.'}, {'ForeName': 'Elie', 'Initials': 'E', 'LastName': 'Picard', 'Affiliation': 'Pediatric Pulmonary Unit, Shaare Zedek Medical Center, affiliated with the Hebrew University School of Medicine, Jerusalem, Israel.'}]",Pediatric pulmonology,['10.1002/ppul.24992'] 2412,31781946,Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients.,"PURPOSE To compare estimates of expected survival time (EST) made by patients with advanced cancer and their oncologists. METHODS At enrolment patients recorded their ""understanding of how long you may have to live"" in best-case, most-likely, and worst-case scenarios. Oncologists estimated survival time for each of their patients as the ""median survival of a group of identical patients"". We hypothesized that oncologists' estimates of EST would be unbiased (~ 50% longer or shorter than the observed survival time [OST]), imprecise (< 33% within 0.67 to 1.33 times OST), associated with OST, and more accurate than patients' estimates of their own survival. RESULTS Twenty-six oncologists estimated EST for 179 patients. The median estimate of EST was 6.0 months, and the median OST was 6.2 months. Oncologists' estimates were unbiased (56% longer than OST), imprecise (27% within 0.67 to 1.33 times OST), and significantly associated with OST (HR 0.88, 95% CI 0.82 to 0.93, p < 0.01). Only 41 patients (23%) provided a numerical estimate of their survival with 107 patients (60%) responding ""I don't know"". The median estimate by patients for their most-likely scenario was 12 months. Patient estimates of their most-likely scenario were less precise (17% within 0.67 to 1.33 times OST) and more likely to overestimate survival (85% longer than OST) than oncologist estimates. CONCLUSION Oncologists' estimates were unbiased and significantly associated with survival. Most patients with advanced cancer did not know their EST or overestimated their survival time compared to their oncologist, highlighting the need for improved prognosis communication training. Trial registration ACTRN1261300128871.",2020,"Oncologists' estimates were unbiased (56% longer than OST), imprecise (27% within 0.67 to 1.33 times OST), and significantly associated with OST (HR 0.88, 95% CI 0.82 to 0.93, p < 0.01).","['patients with advanced cancer', 'advanced cancer', 'patients with advanced cancer and their oncologists']",['EST'],"['survival time', 'median survival', 'survival time (EST', 'survival', 'overestimate survival', 'median estimate of EST']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877373', 'cui_str': 'Advanced cancer'}, {'cui': 'C0259990', 'cui_str': 'Oncologists'}]","[{'cui': 'C2919552', 'cui_str': 'Survival time'}]","[{'cui': 'C2919552', 'cui_str': 'Survival time'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}]",,0.0581922,"Oncologists' estimates were unbiased (56% longer than OST), imprecise (27% within 0.67 to 1.33 times OST), and significantly associated with OST (HR 0.88, 95% CI 0.82 to 0.93, p < 0.01).","[{'ForeName': 'M E S', 'Initials': 'MES', 'LastName': 'Smith-Uffen', 'Affiliation': 'Department of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'S B', 'Initials': 'SB', 'LastName': 'Johnson', 'Affiliation': 'Department of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'A J', 'Initials': 'AJ', 'LastName': 'Martin', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'M H N', 'Initials': 'MHN', 'LastName': 'Tattersall', 'Affiliation': 'Department of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'M R', 'Initials': 'MR', 'LastName': 'Stockler', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'M L', 'Initials': 'ML', 'LastName': 'Bell', 'Affiliation': 'Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Detering', 'Affiliation': 'Advance Care Planning Department, Austin Hospital, Melbourne, Victoria, Australia.'}, {'ForeName': 'J M', 'Initials': 'JM', 'LastName': 'Clayton', 'Affiliation': 'HammondCare Palliative and Supportive Care Service, Greenwich Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Silvester', 'Affiliation': 'University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Clarke', 'Affiliation': 'Kolling Institute of Medical Research, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Vaccaro', 'Affiliation': 'Department of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Beale', 'Affiliation': 'Department of Cancer Medicine, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'B E', 'Initials': 'BE', 'LastName': 'Kiely', 'Affiliation': 'National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia. belinda.kiely@ctc.usyd.edu.au.'}]",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,['10.1007/s00520-019-05158-5'] 2413,31821466,Efficacy of Adjunctive Zinc in Improving the Treatment Outcomes in Hospitalized Children with Pneumonia: A Randomized Controlled Trial.,"BACKGROUND The mortality rate of pneumonia is high, placing a huge burden on developing countries. Healthcare professionals use zinc as an adjunctive treatment for children with pneumonia; however, this contradicts with some published reports. Thus, this study aimed to assess the efficacy of zinc supplementation on the treatment outcomes of pneumonia. METHODS A randomized, double-blind, placebo-controlled trial was conducted on hospitalized children with pneumonia. The children randomly received either zinc bis-glycinate (15 mg elemental zinc) or placebo, twice per day. The primary outcome was the resolution time of pneumonia, and the secondary outcomes were the duration of hospitalization and the recovery times of each clinical symptom. RESULTS Out of the 91 children, 65 (71.4%) were males. The resolution period of clinical pneumonia was significantly shorter in the zinc group than the placebo group (48 and 72 h, respectively; hazard ratio = 0.585, 95% confidence interval 0.377-0.908). Similarly, the hospitalization period and the resolution period of fever were shorter in the zinc group [96 and 144 h (p = 0.008), and 24 and 42 h (p = 0.002), respectively]. Children receiving zinc needed a median of 28 h to reach the normal level of oxygen saturation compared to 48 h required by children under placebo (p = 0.014). CONCLUSION Zinc supplementation enhanced the treatment outcomes of pneumonia, by reducing the resolution period of pneumonia and normalizing oxygen levels and body temperature. The length of hospital stay for children receiving zinc was shorter than those receiving placebo.",2020,"The resolution period of clinical pneumonia was significantly shorter in the zinc group than the placebo group (48 and 72 h, respectively; hazard ratio = 0.585, 95% confidence interval 0.377-0.908).","['children with pneumonia', 'Hospitalized Children with Pneumonia', '91 children, 65 (71.4%) were males', 'hospitalized children with pneumonia']","['Zinc supplementation', 'Adjunctive Zinc', 'zinc supplementation', 'zinc bis-glycinate (15\u2009mg elemental zinc) or placebo', 'placebo']","['resolution period of clinical pneumonia', 'hospitalization period and the resolution period of fever', 'resolution period of pneumonia and normalizing oxygen levels and body temperature', 'duration of hospitalization and the recovery times of each clinical symptom', 'length of hospital stay', 'normal level of oxygen saturation', 'resolution time of pneumonia']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0008098', 'cui_str': 'Children, Hospitalized'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C4524022', 'cui_str': 'Zinc supplementation'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0078777', 'cui_str': 'Bis (dibutyldithiocarbamato) zinc'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}]",91.0,0.583354,"The resolution period of clinical pneumonia was significantly shorter in the zinc group than the placebo group (48 and 72 h, respectively; hazard ratio = 0.585, 95% confidence interval 0.377-0.908).","[{'ForeName': 'Lakkana', 'Initials': 'L', 'LastName': 'Rerksuppaphol', 'Affiliation': 'Department of Preventive Medicine, Srinakharinwirot University, Nakorn Nayok 26120, Thailand.'}, {'ForeName': 'Sanguansak', 'Initials': 'S', 'LastName': 'Rerksuppaphol', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Srinakharinwirot University, Nakorn Nayok 26120, Thailand.'}]",Journal of tropical pediatrics,['10.1093/tropej/fmz082'] 2414,31853942,Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.,,2020,,['acute myeloid leukaemia'],[],['Complete remission'],"[{'cui': 'C0023467', 'cui_str': 'Acute myeloid leukemia'}]",[],"[{'cui': 'C0677874', 'cui_str': 'In full remission'}]",,0.020755,,"[{'ForeName': 'Malin S', 'Initials': 'MS', 'LastName': 'Nilsson', 'Affiliation': 'TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Hallner', 'Affiliation': 'TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Brune', 'Affiliation': 'Department of Haematology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Staffan', 'Initials': 'S', 'LastName': 'Nilsson', 'Affiliation': 'Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Fredrik B', 'Initials': 'FB', 'LastName': 'Thorén', 'Affiliation': 'TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Martner', 'Affiliation': 'TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Kristoffer', 'Initials': 'K', 'LastName': 'Hellstrand', 'Affiliation': 'TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",British journal of haematology,['10.1111/bjh.16320'] 2415,32719748,Nomogram for Predicting the Overall Survival of Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma: A SEER- Based Study.,"Background: The aim of this study was to establish a precise prognostic model, based on significant clinical parameters, for predicting the overall survival (OS) of adult patients with primary gastrointestinal diffuse large B cell lymphoma (GI DLBCL). Materials and Methods: The data of 7,121 GI DLBCL patients, diagnosed between 1997 and 2015, were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomly divided into two sequential cohorts: training ( n = 5,697) set and validation ( n = 1,424) set. ROC methodology and calibration curves were explicitly used to evaluate the predictive performance of nomogram. Results: The median OS in the training cohort was 76 months (1-239 months), and 3, 5, and 10-year OS rates were 60.3, 53.9, and 39.5%, respectively. Age at diagnosis, Ann Arbor stage, and marital status were important clinical predictors of OS. These characteristics were used to build a nomogram. The AUC of the nomogram for predicting 3, 5, and 10-year OS were 0.669, 0.692, and 0.740, respectively. All RUC and calibration curves revealed good accuracy in predicting prognosis of GI DLBCL. Conclusion: In summary, the established nomogram was validated to predict OS for adult patients with GI DLBCL. This predictive model could help clinicians identify high-risk patients to improve their prognosis.",2020,"The AUC of the nomogram for predicting 3, 5, and 10-year OS were 0.669, 0.692, and 0.740, respectively.","['7,121 GI DLBCL patients, diagnosed between 1997 and 2015', 'Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma', 'adult patients with primary gastrointestinal diffuse large B cell lymphoma (GI DLBCL', 'adult patients with GI DLBCL']",[],"['median OS', 'overall survival (OS', 'Overall Survival', '10-year OS rates']","[{'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0730225', 'cui_str': '1997'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]",[],"[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0439234', 'cui_str': 'year'}]",7121.0,0.0385306,"The AUC of the nomogram for predicting 3, 5, and 10-year OS were 0.669, 0.692, and 0.740, respectively.","[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Rongfu', 'Initials': 'R', 'LastName': 'Zhou', 'Affiliation': 'Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Jingyan', 'Initials': 'J', 'LastName': 'Xu', 'Affiliation': 'Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.'}]",Frontiers in oncology,['10.3389/fonc.2020.01093'] 2416,32719760,Prospective Randomized Observational Pilot Trial Evaluating the Effect of Different Durations of Interdisciplinary Early Intervention and Family Support in Parents of Very Low Birth Weight Infants (Early Bird Study).,"Background: Early childhood intervention (ECI) is a holistic approach for infants with or at risk for psychomotor and/or cognitive and/or behavioral impairment. It aims to optimally support them and positively influence their neurodevelopmental outcome. The right dosage of intervention and when the intervention should start are still to be determined. Hypothesis: Parents are more satisfied when the duration of ECI is longer (120 min once a week) than the usual 90-min session. Methods: We developed a parental questionnaire (both mother and father) that evaluated the level of satisfaction of parents with the intervention. We compared 120 with 90 min of ECI per week during the school year 2017/18. Included were parents of very low birth weight infants (<1,500 g) following informed consent. ECI was initiated at the NICU at an infant age of ≥ 2 weeks. Parents were randomized (https://www.randomizer.at/) to a 120- or 90-min duration and had to answer the questionnaire to the approximate time-point of 1, 3, and 6 months. Answers were classified as strongly agree, agree, neither agree nor disagree, disagree, and strongly disagree except for the last question, which directly rated the ECI professional. Results: Eleven fathers (55%) and 19 mothers (95%) of the 10 parents of each group participated in the study. Demographic data did not differ between groups, and the median time-points of questionnaire answers were 77, 137, and 220 days, respectively. Overall, 120-min ECI sessions were not superior to 90-min sessions for both parents regarding parental satisfaction during the study time. We found no differences between fathers and mothers and minimal changes over time. All parents were satisfied with the ECI professionals, irrespective of ECI duration. Conclusion: An ECI duration of 120 min once per week was not superior to a 9- min duration regarding parental satisfaction with ECI professionals and their work.",2020,"Overall, 120-min ECI sessions were not superior to 90-min sessions for both parents regarding parental satisfaction during the study time.","['Included were parents of very low birth weight infants (<1,500 g) following informed consent', 'infants with or at risk for psychomotor and/or cognitive and/or behavioral impairment', 'Parents of Very Low Birth Weight Infants (Early Bird Study', 'Eleven fathers (55%) and 19 mothers (95%) of the 10 parents of each group participated in the study']","['Interdisciplinary Early Intervention and Family Support', ': Early childhood intervention (ECI']",['median time-points of questionnaire answers'],"[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0282667', 'cui_str': 'Very low birth weight infant'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0021430', 'cui_str': 'Informed Consent'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0005595', 'cui_str': 'Class Aves'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0015671', 'cui_str': 'Father'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0242687', 'cui_str': 'Provision of early intervention service for child'}, {'cui': 'C0150232', 'cui_str': 'Family support'}, {'cui': 'C0599196', 'cui_str': 'Early childhood'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0397501,"Overall, 120-min ECI sessions were not superior to 90-min sessions for both parents regarding parental satisfaction during the study time.","[{'ForeName': 'Bernhard', 'Initials': 'B', 'LastName': 'Resch', 'Affiliation': 'University Course for Interdisciplinary Early Intervention and Family Support, Postgraduate School, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Hofbauer-Krug', 'Affiliation': 'University Course for Interdisciplinary Early Intervention and Family Support, Postgraduate School, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Pansy', 'Affiliation': 'Division of Neonatology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Prechtl', 'Affiliation': 'Institute for Social and Orthopedagogic Interventions (SHFI), Graz, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Avian', 'Affiliation': 'Institute for Statistics, Medical University of Graz, Graz, Austria.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Kurz', 'Affiliation': 'University Course for Interdisciplinary Early Intervention and Family Support, Postgraduate School, Medical University of Graz, Graz, Austria.'}]",Frontiers in public health,['10.3389/fpubh.2020.00242'] 2417,32719868,"Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients.","BACKGROUND Vadadustat is an investigational, oral hypoxia-inducible factor prolyl hydroxylase inhibitor in development in Japan for the treatment of chronic kidney disease (CKD)-induced anemia. METHODS Two Phase 2, multicenter, double-blind, placebo-controlled studies randomized Japanese patients with nondialysis-dependent (NDD, n = 51) or dialysis-dependent (DD, n = 60) CKD-induced anemia to once-daily vadadustat (150, 300 or 600 mg) or placebo. A 6-week, fixed-dose primary efficacy period was followed by a 10-week vadadustat dose adjustment/maintenance period. The primary endpoint was the mean change in hemoglobin (Hb) level from pretreatment to Week 6. RESULTS Statistically significant (P < 0.01) dose-dependent increases in mean Hb values were observed at Week 6 in all vadadustat groups versus placebo [placebo and vadadustat 150, 300 and 600 mg: -0.47, 0.43, 1.13 and 1.62 (NDD-CKD) and -1.48, -0.28, 0.08 and 0.41 (DD-CKD), respectively]. By Week 16, 91% (NDD-CKD) and 71% (DD-CKD) of vadadustat-treated participants achieved target Hb levels (10.0-12.0 g/dL) and significant dose-dependent changes in iron utilization and mobilization biomarkers were observed with vadadustat. During the primary efficacy period, the incidence of treatment-emergent adverse events (AEs) with placebo and vadadustat 150, 300 and 600 mg was 36, 33, 58 and 54% (NDD-CKD) and 40, 53, 73 and 40% (DD-CKD), respectively. The most common AEs during the primary efficacy period were nausea and hypertension (NDD-CKD) and diarrhea, nasopharyngitis and shunt stenosis (DD-CKD). Of 23 serious AEs in 18 patients, 1 was deemed related (hepatic function abnormal); no deaths were reported. CONCLUSIONS The efficacy and safety results from these studies support the development of vadadustat for the treatment of anemia in patients with CKD.",2020,"Statistically significant (P < 0.01) dose-dependent increases in mean Hb values were observed at Week 6 in all vadadustat groups versus placebo [placebo and vadadustat 150, 300 and 600 mg:","['patients with CKD', 'anemia of chronic kidney disease', 'Japanese patients with nondialysis-dependent (NDD, n\u2009=\u200951) or dialysis-dependent (DD, n\u2009=\u200960) CKD-induced anemia to once-daily vadadustat (150, 300 or 600\u2009mg) or', 'Japanese patients']","['placebo [placebo', 'oral hypoxia-inducible factor prolyl hydroxylase inhibitor', 'placebo']","['mean Hb values', 'nausea and hypertension (NDD-CKD) and diarrhea, nasopharyngitis and shunt stenosis (DD-CKD', 'mean change in hemoglobin (Hb) level', 'target Hb levels', 'incidence of treatment-emergent adverse events (AEs', 'iron utilization and mobilization biomarkers']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C1561828', 'cui_str': 'Anemia in chronic kidney disease'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C4519730', 'cui_str': 'vadadustat'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3816748', 'cui_str': '600'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C3658210', 'cui_str': 'Proline Hydroxylase Inhibitors'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C1142174', 'cui_str': 'Shunt stenosis'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",,0.0817858,"Statistically significant (P < 0.01) dose-dependent increases in mean Hb values were observed at Week 6 in all vadadustat groups versus placebo [placebo and vadadustat 150, 300 and 600 mg:","[{'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Nangaku', 'Affiliation': 'Graduate School of Medicine, University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Youssef M K', 'Initials': 'YMK', 'LastName': 'Farag', 'Affiliation': 'Clinical Development, Akebia Therapeutics Inc., Cambridge, MA, USA.'}, {'ForeName': 'Emil', 'Initials': 'E', 'LastName': 'deGoma', 'Affiliation': 'Akebia Therapeutics Inc., Cambridge, MA, USA.'}, {'ForeName': 'Wenli', 'Initials': 'W', 'LastName': 'Luo', 'Affiliation': 'Biostatistics, Akebia Therapeutics Inc., Cambridge, MA, USA.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Vargo', 'Affiliation': 'Clinical Development, Akebia Therapeutics Inc., Cambridge, MA, USA.'}, {'ForeName': 'Zeeshan', 'Initials': 'Z', 'LastName': 'Khawaja', 'Affiliation': 'Drug Safety and Pharmacovigilance, Akebia Therapeutics Inc., Cambridge, MA, USA.'}]","Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association",['10.1093/ndt/gfaa060'] 2418,32719871,Demystifying the Placebo Effect.,,2020,,[],[],[],[],[],[],,0.266525,,"[{'ForeName': 'Eleanor J', 'Initials': 'EJ', 'LastName': 'Murray', 'Affiliation': 'Department of Epidemiology, Boston University School of Public Health, Boston MA.'}]",American journal of epidemiology,['10.1093/aje/kwaa162'] 2419,32719875,Training cosmetology students in Arkansas to help dermatologists find skin cancers earlier: results of a cluster-randomized controlled trial.,"BACKGROUND We tested an educational video in cosmetology schools to increase students' knowledge about skin cancer, sun-safety practices, identifying suspicious lesions and recommending clients consult a dermatologist when a suspicious lesion is observed. METHODS We used a cluster-randomized controlled study design to randomize 22 cosmetology schools to receive our educational video or a publicly accessible healthy lifestyle video (control). RESULTS Students who received the intervention were more likely than controls to increase their knowledge of skin cancer, risk factors and how to identify potential skin cancers (risk ratio [RR] and 95% confidence interval = 2.86 [1.58-5.20]). At follow-up, students in the intervention group were more likely than those in the control group to look for suspicious moles on their clients' faces, scalps and necks (RRs = 1.75, 2.16 and 2.90, respectively). Additionally, students in the intervention group were more likely to communicate with clients about sun-safety practices (RR = 1.74 [1.11-2.73]) and consulting a dermatologist about suspicious moles (RR = 1.57 [1.03-2.41]). CONCLUSIONS Our educational video helped cosmetology students recognize potential skin cancers and talk with clients about sun safety and consulting a dermatologist about suspicious moles. Such videos may play a role in the public health surveillance of skin cancers in communities.",2020,"At follow-up, students in the intervention group were more likely than those in the control group to look for suspicious moles on their clients' faces, scalps and necks (RRs = 1.75, 2.16 and 2.90, respectively).",['skin cancers in communities'],['educational video or a publicly accessible healthy lifestyle video (control'],"['consulting a dermatologist about suspicious moles', 'likely to communicate with clients about sun-safety practices', 'knowledge of skin cancer, risk factors and how to identify potential skin cancers']","[{'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0009462', 'cui_str': 'Community'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C4277664', 'cui_str': 'Healthy Lifestyles'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0259831', 'cui_str': 'Dermatologist'}, {'cui': 'C0027960', 'cui_str': 'Nevi'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis'}, {'cui': 'C0205196', 'cui_str': 'Communicating'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0038817', 'cui_str': 'Sunlight'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0007114', 'cui_str': 'Malignant neoplasm of skin'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0205396', 'cui_str': 'Identified'}]",,0.0664871,"At follow-up, students in the intervention group were more likely than those in the control group to look for suspicious moles on their clients' faces, scalps and necks (RRs = 1.75, 2.16 and 2.90, respectively).","[{'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Fischbach', 'Affiliation': 'Department of Epidemiology, University of Arkansas for Medical Sciences, College of Public Health, Little Rock, AR, USA.'}, {'ForeName': 'Mohammed F', 'Initials': 'MF', 'LastName': 'Faramawi', 'Affiliation': 'Department of Epidemiology, University of Arkansas for Medical Sciences, College of Public Health, Little Rock, AR, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Girard', 'Affiliation': 'IMPACT Melanoma, Concord, MA USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Thapa', 'Affiliation': 'Department of Epidemiology, University of Arkansas for Medical Sciences, College of Public Health, Little Rock, AR, USA.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Travers', 'Affiliation': 'Skin Care Physicians of Chestnut Hill,Chestnut Hill,MA, USA.'}]","Journal of public health (Oxford, England)",['10.1093/pubmed/fdaa109'] 2420,32719929,Endoscopic enucleation for prostate larger than 60 mL: comparison between holmium laser enucleation and plasmakinetic enucleation.,"PURPOSE To compare perioperative and functional outcomes of two different energy sources, holmium laser and bipolar current for endoscopic enucleation of prostate larger than 60 mL. METHODS A prospective, monocentric, comparative, non-randomized study was conducted including all patients treated for prostate larger than 60 mL, measured by transrectal ultrasound. Patients were assigned to each group based on the surgeons' practice. Perioperative data were collected (preoperative characteristics, operating, catheterization and hospitalization times, hemoglobin loss, complications) and functional outcomes (IPSS, IPSS Quality of Life (QoL), PSA) at 3 months and 1 year. RESULTS 100 patients were included in each group from October 2015 to March 2018. No differences between HoLEP and plasma groups were observed at baseline, except for mean IPSS score, IPSS QoL score and preoperative PVR that were significantly higher in the HoLEP group. Operating time (142.1 vs 122.4 min; p = 0.01), catheterization time (59.6 vs 44.4 h; p = 0.01) and hospitalization time (2.5 vs 1.8 days; p = 0.02) were significantly shorter in the plasma group. Complication and transfusion rate were no significantly different between HoLEP and plasma. No significant differences were observed concerning functional outcomes at 3 months and 1 year. The urinary incontinence rate was higher 21.1% vs 6.4% (p < 0.01) at 3 months in HoLEP group, but no difference was observed at 1 year. CONCLUSION Holmium and plasma are both safe and effective for endoscopic treatment for prostate larger than 60 mL. Operating, catheterization and hospitalization times were significantly shorter in the plasma group. The complication rate and functional outcomes were not significantly different.",2020,"No differences between HoLEP and plasma groups were observed at baseline, except for mean IPSS score, IPSS QoL score and preoperative PVR that were significantly higher in the HoLEP group.","['all patients treated for prostate larger than 60\xa0mL, measured by transrectal ultrasound', '100 patients were included in each group from October 2015 to March 2018']","['HoLEP', 'holmium laser and bipolar current for endoscopic enucleation of prostate larger than 60\xa0mL', 'Endoscopic enucleation', 'Holmium and plasma', 'holmium laser enucleation and plasmakinetic enucleation']","['mean IPSS score, IPSS QoL score and preoperative PVR', 'catheterization time', 'complication rate and functional outcomes', 'hospitalization time', 'Complication and transfusion rate', 'Perioperative data were collected (preoperative characteristics, operating, catheterization and hospitalization times, hemoglobin loss, complications) and functional outcomes (IPSS, IPSS Quality of Life (QoL), PSA', 'urinary incontinence rate', 'catheterization and hospitalization times', 'functional outcomes', 'Operating time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0033572', 'cui_str': 'Prostatic'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0441085', 'cui_str': 'Holmium:YAG laser device'}, {'cui': 'C0443156', 'cui_str': 'Bipolar'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C1293631', 'cui_str': 'Enucleation of prostate'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0014392', 'cui_str': 'Enucleation'}, {'cui': 'C0019846', 'cui_str': 'Holmium'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0242852', 'cui_str': 'Proliferative vitreoretinopathy'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}]",100.0,0.0387562,"No differences between HoLEP and plasma groups were observed at baseline, except for mean IPSS score, IPSS QoL score and preoperative PVR that were significantly higher in the HoLEP group.","[{'ForeName': 'P- M', 'Initials': 'PM', 'LastName': 'Patard', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France. pm.patard@gmail.com.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Roumiguie', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Sanson', 'Affiliation': 'Department of Urology, Clinique du Pont de Chaume, 330 Avenue Marcel Unal, Montauban, France.'}, {'ForeName': 'J- B', 'Initials': 'JB', 'LastName': 'Beauval', 'Affiliation': 'Department of Urology, Saint Jean Languedoc/La Croix du Sud Hospital, Toulouse, France.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Huyghe', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Soulié', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Malavaud', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Gamé', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Rischmann', 'Affiliation': 'Department of Urology, Andrology and Renal Transplantation, CHU Rangueil, Paul-Sabatier University, 1 Avenue J Poulhès, 31059, Toulouse Cedex, France.'}]",World journal of urology,['10.1007/s00345-020-03382-x'] 2421,32719963,In reply: Letter to the editor: Is it time to abandon episiotomy use? A randomized controlled trial (epitrial).,,2020,,[],[],[],[],[],[],,0.0830738,,"[{'ForeName': 'Lena', 'Initials': 'L', 'LastName': 'Sagi-Dain', 'Affiliation': 'Department of Obstetrics and Gynecology, Carmel Medical Center, 7 Michal St., Haifa, Israel. lena2303@gmail.com.'}, {'ForeName': 'Inna', 'Initials': 'I', 'LastName': 'Kreinin-Bleicher', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Haifa, Israel.'}, {'ForeName': 'Rabia', 'Initials': 'R', 'LastName': 'Bahous', 'Affiliation': 'Department of Obstetrics and Gynecology, Bnai-Zion Medical Center, Haifa, Israel.'}, {'ForeName': 'Shlomi', 'Initials': 'S', 'LastName': 'Sagi', 'Affiliation': 'Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.'}]",International urogynecology journal,['10.1007/s00192-020-04453-8'] 2422,32720188,Changes in Family-Level Attitudes and Norms and Association with Secondary School Completion and Child Marriage Among Adolescent Girls: Results from an Exploratory Study Nested Within a Cluster-Randomised Controlled Trial in India.,"We evaluated the impact of Samata, a 3-year multilayered intervention among scheduled caste/scheduled tribe (SC/ST) adolescent girls in rural northern Karnataka, on family-level (parents or guardian) attitudes and direct and indirect norms related to child marriage and girl's education. Endline data from 1840 family members were used to assess the effect of Samata on attitudes and norms related to schooling and child marriage, while data from 4097 family members (including 2257 family members at baseline) were used to understand the shifts in attitudes and norms over the period 2014-2017. Overall, we found that the programme had little impact on family-level attitudes and norms. However, there were shifts in some attitudes, norms and perceived sanctions between baseline (when girls were aged 13-14 years) and endline (when girls were aged 15-16 years), with some becoming more progressive (e.g. direct norms related to child marriage) and others more restrictive (e.g. norms around girls completing secondary education and norms related to child marriage and educational drop-out, blaming girls for eve teasing and limiting girls' mobility so as to protect family honour). Moreover, non-progressive norms related to marriage and education were strongly associated with child marriage and secondary school non-completion among adolescent girls in this rural setting. Norms hypothesised to be important for marriage and schooling outcomes were indeed associated with these outcomes, but the intervention was not able to significantly shift these norms. In part, this may have been due to the intervention focusing much of its initial efforts on working with girls alone rather than family members, the relevant reference group. Future interventions that seek to affect norms should conduct formative research to clarify the specific norms affecting the outcome(s) of interest; likewise, programme planners should ensure that all activities engage those most influential in enforcing the norm(s) from the beginning. ClinicalTrials.gov registration number: NCT01996241.",2020,"Moreover, non-progressive norms related to marriage and education were strongly associated with child marriage and secondary school non-completion among adolescent girls in this rural setting.","['Adolescent Girls', ""girls were aged 13-14\xa0years) and endline (when girls were aged 15-16\xa0years), with some becoming more progressive (e.g. direct norms related to child marriage) and others more restrictive (e.g. norms around girls completing secondary education and norms related to child marriage and educational drop-out, blaming girls for eve teasing and limiting girls' mobility so as to protect family honour"", '4097 family members (including 2257 family members at baseline', '1840 family members', ""scheduled caste/scheduled tribe (SC/ST) adolescent girls in rural northern Karnataka, on family-level (parents or guardian) attitudes and direct and indirect norms related to child marriage and girl's education""]",[],['Changes in Family-Level Attitudes and Norms and Association with Secondary School Completion and Child Marriage'],"[{'cui': 'C0001588', 'cui_str': 'Adolescents, Female'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0047006', 'cui_str': 'Methylenedioxyethylamphetamine'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0086282', 'cui_str': 'Person in the family'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0007337', 'cui_str': 'Caste'}, {'cui': 'C0040881', 'cui_str': 'Tribes'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0023226', 'cui_str': 'Legal guardian'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0036530', 'cui_str': 'Secondary school'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}]",,0.028237,"Moreover, non-progressive norms related to marriage and education were strongly associated with child marriage and secondary school non-completion among adolescent girls in this rural setting.","[{'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Prakash', 'Affiliation': 'Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, Manitoba, R3E 0T6, Canada. ravi.prakash@ihat.in.'}, {'ForeName': 'Tara S', 'Initials': 'TS', 'LastName': 'Beattie', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Beniamino', 'Initials': 'B', 'LastName': 'Cislaghi', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Parinita', 'Initials': 'P', 'LastName': 'Bhattacharjee', 'Affiliation': 'Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, Manitoba, R3E 0T6, Canada.'}, {'ForeName': 'Prakash', 'Initials': 'P', 'LastName': 'Javalkar', 'Affiliation': 'Karnataka Health Promotion Trust (KHPT), Bangalore, India.'}, {'ForeName': 'Satyanarayana', 'Initials': 'S', 'LastName': 'Ramanaik', 'Affiliation': 'Karnataka Health Promotion Trust (KHPT), Bangalore, India.'}, {'ForeName': 'Raghavendra', 'Initials': 'R', 'LastName': 'Thalinja', 'Affiliation': 'Karnataka Health Promotion Trust (KHPT), Bangalore, India.'}, {'ForeName': 'Calum', 'Initials': 'C', 'LastName': 'Davey', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Mitzy', 'Initials': 'M', 'LastName': 'Gafos', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Watts', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Martine', 'Initials': 'M', 'LastName': 'Collumbien', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Moses', 'Affiliation': 'Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, Manitoba, R3E 0T6, Canada.'}, {'ForeName': 'Shajy', 'Initials': 'S', 'LastName': 'Isac', 'Affiliation': 'Department of Community Health Sciences, Institute for Global Public Health, University of Manitoba, R070 Med Rehab Bldg, 771 McDermot Avenue, Winnipeg, Manitoba, R3E 0T6, Canada.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Heise', 'Affiliation': 'Departments of Global Health and Development and Public Health, Environments and Society, London School of Hygiene & Tropical Medicine (LSHTM), 15-17 Tavistock Place, London, UK.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01143-1'] 2423,32720189,The Effectiveness of a Community-Based Mentoring Program for Children Aged 5-11 Years: Results from a Randomized Controlled Trial.,"The study, a two-arm, randomized controlled, parallel group, superiority trial, aimed to evaluate the implementation and effectiveness of a 12-month one-to-one volunteer mentoring program designed to improve behavioral and emotional outcomes in children aged 5 to 11 years who have teacher- and parent/carer-reported behavioral difficulties. Participants were 246 children (123 intervention, 123 control; mean age 8.4 years; 87% boys) in five sites in London, UK, scoring in the ""abnormal"" range on the teacher-rated Strengths and Difficulties Questionnaire (SDQ) Total Difficulties measure and in the ""borderline"" or abnormal range on the parent-rated SDQ Total Difficulties measure. Randomization on a 1:1 ratio took place using a computer-generated sequence and stratifying by site. Data collectors and statisticians were blind to participant allocation status. Outcome measures focused on parent- and teacher-rated child behavior and emotions, and child-rated self-perception and hope. Intention-to-treat analysis on all 246 randomized participants (using imputed data where necessary) showed that at post-intervention (16 months after randomization), there were no statistically significant effects on the primary outcome-parent-rated SDQ Total Difficulties (adjusted standardized mean difference = - 0.12; 95% CI: -0.38 to 0.13; p = 0.33)-or any secondary outcomes. Results from complier average causal effect (CACE) analysis using the primary outcome indicated the intervention was not effective for children who received the recommended duration of mentoring. Exploratory analyses found no sub-group effects on the primary outcome. The article concludes that the mentoring program had no effect on children's behavior or emotional well-being, and that program content needs revising to satisfactorily address key risk and protective factors.",2020,Exploratory analyses found no sub-group effects on the primary outcome.,"['children aged 5 to 11\xa0years who have teacher- and parent/carer-reported behavioral difficulties', 'Participants were 246 children (123 intervention, 123 control; mean age 8.4\xa0years; 87% boys) in five sites in London, UK, scoring in the ""abnormal"" range on the teacher-rated Strengths and Difficulties Questionnaire (SDQ) Total Difficulties measure and in the ""borderline"" or abnormal range on the parent-rated SDQ Total Difficulties measure', 'Children Aged 5-11\xa0Years']",['Community-Based Mentoring Program'],"['behavioral and emotional outcomes', 'primary outcome-parent-rated SDQ Total Difficulties', 'parent- and teacher-rated child behavior and emotions, and child-rated self-perception and hope']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0023973', 'cui_str': 'London'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C3472494', 'cui_str': 'Strengths and difficulties questionnaire'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0008065', 'cui_str': 'Behavior, Child'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0242498', 'cui_str': 'Self-image'}, {'cui': 'C0392347', 'cui_str': 'Hope'}]",246.0,0.15368,Exploratory analyses found no sub-group effects on the primary outcome.,"[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Axford', 'Affiliation': 'NIHR ARC South West Peninsula (PenARC), University of Plymouth, Plymouth, UK.'}, {'ForeName': 'Gretchen', 'Initials': 'G', 'LastName': 'Bjornstad', 'Affiliation': 'University of Exeter Medical School, Exeter, UK. G.J.Bjornstad@exeter.ac.uk.'}, {'ForeName': 'Justin', 'Initials': 'J', 'LastName': 'Matthews', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Whybra', 'Affiliation': 'Dartington Service Design Lab, Dartington, UK.'}, {'ForeName': 'Vashti', 'Initials': 'V', 'LastName': 'Berry', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK.'}, {'ForeName': 'Obioha C', 'Initials': 'OC', 'LastName': 'Ukoumunne', 'Affiliation': 'PenARC, University of Exeter, Exeter, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Hobbs', 'Affiliation': 'Dartington Service Design Lab, Dartington, UK.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Wrigley', 'Affiliation': 'Cardiff University, Cardiff, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Brook', 'Affiliation': 'Devon Partnership NHS Trust, Exeter, UK.'}, {'ForeName': 'Rod', 'Initials': 'R', 'LastName': 'Taylor', 'Affiliation': 'University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Eames', 'Affiliation': 'University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Angeliki', 'Initials': 'A', 'LastName': 'Kallitsoglou', 'Affiliation': 'University of Roehampton, London, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Blower', 'Affiliation': 'NIHR ARC Yorkshire and Humber, University of York, York, UK.'}, {'ForeName': 'Georgina', 'Initials': 'G', 'LastName': 'Warner', 'Affiliation': 'Uppsala University, Uppsala, Sweden.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01132-4'] 2424,32720190,Effects of Therapeutic Intervention on Parentally Bereaved Children's Emotion Reactivity and Regulation 15 Years Later.,"The Family Bereavement Program (FBP) is a family-based intervention for parentally bereaved children and surviving caregivers. Results are reported of a randomized controlled trial, examining intervention effects on emotional reactivity and regulation of young adults who participated in the program 15 years earlier. Participants (N = 152) completed four emotion challenge tasks: reactivity to negative images, detached reappraisal while viewing negative images, positive reappraisal while viewing negative images, and reengagement with positive images. Outcomes included cardiac interbeat interval (IBI), pre-ejection period (PEP), and respiratory sinus arrhythmia (RSA) as well as self-reported emotional experience and regulation effectiveness. Direct intervention effects and effects mediated through improved parenting were estimated. Several significant effects were observed in primary analyses; however, none remained significant after correction for familywise Type I error. Parenting mediated FBP effects on IBI during negative reactivity (b = 15.04), and on RSA during positive reengagement (b = 0.35); the latter effect was accounted for by changes in breathing. Intervention condition was a direct predictor of self-reported detached reappraisal effectiveness (b = 1.00). Intervention and gender interacted in predicting self-reported negative emotion during the negative reactivity (b = 1.04) and positive reappraisal tasks (b = 1.31) such that intervention-condition men reported more negative emotions during those tasks. Although these findings should be considered preliminary given the limited power of the corrected statistical tests, they suggest long-term effects of family intervention following the death of a parent on offspring's emotional reactivity and regulation ability that should be pursued further in future research.",2020,Intervention condition was a direct predictor of self-reported detached reappraisal effectiveness (b = 1.00).,"['young adults who participated in the program 15\xa0years earlier', 'Participants (N\u2009=\u2009152) completed four', ""Parentally Bereaved Children's Emotion Reactivity and Regulation 15\xa0Years Later""]","['emotion challenge tasks: reactivity to negative images, detached reappraisal while viewing negative images, positive reappraisal while viewing negative images, and reengagement with positive images', 'Family Bereavement Program (FBP', 'Therapeutic Intervention']","['emotional reactivity and regulation', 'cardiac interbeat interval (IBI), pre-ejection period (PEP), and respiratory sinus arrhythmia (RSA) as well as self-reported emotional experience and regulation effectiveness', 'negative emotions', 'positive reappraisal tasks']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0205087', 'cui_str': 'Late'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0860659', 'cui_str': 'Aloof'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0425043', 'cui_str': 'Death of relative'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0336969', 'cui_str': 'Ejection'}, {'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.0281621,Intervention condition was a direct predictor of self-reported detached reappraisal effectiveness (b = 1.00).,"[{'ForeName': 'Alexander F', 'Initials': 'AF', 'LastName': 'Danvers', 'Affiliation': 'Department of Psychology, University of Arizona, Tucson, AZ, 85721, USA.'}, {'ForeName': 'Brandon G', 'Initials': 'BG', 'LastName': 'Scott', 'Affiliation': 'Department of Psychology, Montana State University, Culbertson Hall, 100, Bozeman, MT, 59717, USA.'}, {'ForeName': 'Michelle N', 'Initials': 'MN', 'LastName': 'Shiota', 'Affiliation': 'Department of Psychology, Arizona State University, P.O. Box 871104, Tempe, AZ, 85287-1104, USA. lani.shiota@asu.edu.'}, {'ForeName': 'Jenn-Yun', 'Initials': 'JY', 'LastName': 'Tein', 'Affiliation': 'Department of Psychology, Arizona State University, P.O. Box 871104, Tempe, AZ, 85287-1104, USA.'}, {'ForeName': 'Sharlene A', 'Initials': 'SA', 'LastName': 'Wolchik', 'Affiliation': 'Department of Psychology, Arizona State University, P.O. Box 871104, Tempe, AZ, 85287-1104, USA.'}, {'ForeName': 'Irwin I', 'Initials': 'II', 'LastName': 'Sandler', 'Affiliation': 'Department of Psychology, Arizona State University, P.O. Box 871104, Tempe, AZ, 85287-1104, USA.'}]",Prevention science : the official journal of the Society for Prevention Research,['10.1007/s11121-020-01142-2'] 2425,32720198,Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI.,"BACKGROUND Insulin resistance plays a major role in the pathogenesis of polycystic ovary syndrome (PCOS). Therefore, there is a growing interest in the use of insulin sensitizer drugs in the treatment of PCOS. Research in recent years has shown that sitagliptin has been reported to improve ovarian cycles and ovulation in PCOS patients. AIMS We aimed to compare the effects of metformin and sitagliptin on PCOS individuals undergoing ICSI. METHODS Sixty PCOS patients were divided into 3 groups: metformin, sitagliptin, and placebo group. Treatment was carried out 2 months before the start of the ovulation cycle and continued until the day of oocyte aspiration. The serum levels of total testosterone, estradiol, and fasting insulin along with the total number of retrieved, normal and abnormal MII, and fertilized oocytes, the number of transferred embryos (grades I, II and III), and biochemical and clinical pregnancy rates as well as the ovarian hyperstimulation syndrome (OHSS) were evaluated. RESULTS There was a significant reduction in the serum levels of Insulin and total testosterone in the treated groups compared with the placebo. The number of mature and normal MII oocytes increased significantly in the treated groups compared with the placebo. Moreover, the number of immature oocytes decreased significantly and the number of grade I embryos increases significantly in the sitagliptin group compared with the placebo group. CONCLUSION We conclude that sitagliptin can improve the maturation of oocytes and embryos' quality more effectively than metformin, in PCOS patients undergoing ICSI. TRIAL REGISTRATION Trial registration is NCT04268563 ( https://clinicaltrials.gov ).",2020,There was a significant reduction in the serum levels of Insulin and total testosterone in the treated groups compared with the placebo.,"['Sixty PCOS patients', 'PCOS patients undergoing ICSI', 'classic PCOS patients undergoing ICSI', 'PCOS patients', 'PCOS individuals undergoing ICSI']","['metformin and sitagliptin', 'metformin', 'sitagliptin', 'sitagliptin and metformin', 'metformin, sitagliptin, and placebo', 'placebo']","['number of immature oocytes', ""maturation of oocytes and embryos' quality"", 'number of mature and normal MII oocytes', 'number of grade I embryos', 'serum levels of Insulin and total testosterone', 'oocyte and embryo quality', 'serum levels of total testosterone, estradiol, and fasting insulin along with the total number of retrieved, normal and abnormal MII, and fertilized oocytes, the number of transferred embryos (grades I, II and III), and biochemical and clinical pregnancy rates as well as the ovarian hyperstimulation syndrome (OHSS']","[{'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0455164', 'cui_str': 'IVF - In vitro fertilization with intracytoplasmic sperm injection (ICSI)'}, {'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C1952576', 'cui_str': 'metformin and sitagliptin'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1565750', 'cui_str': 'sitagliptin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205252', 'cui_str': 'Immature'}, {'cui': 'C0029045', 'cui_str': 'Oocyte'}, {'cui': 'C0013935', 'cui_str': 'Embryos'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0205286', 'cui_str': 'Mature'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0202227', 'cui_str': 'Testosterone measurement, total'}, {'cui': 'C0014912', 'cui_str': 'Estradiol'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205161', 'cui_str': 'Abnormal'}, {'cui': 'C0029974', 'cui_str': 'Ovum'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}, {'cui': 'C0085083', 'cui_str': 'Ovarian hyperstimulation syndrome'}]",60.0,0.172264,There was a significant reduction in the serum levels of Insulin and total testosterone in the treated groups compared with the placebo.,"[{'ForeName': 'Delbar', 'Initials': 'D', 'LastName': 'Daneshjou', 'Affiliation': 'Department of Biologyt, Faculty of Science, Arak University, Arak, Iran.'}, {'ForeName': 'Shahrzad', 'Initials': 'S', 'LastName': 'Zadeh Modarres', 'Affiliation': ""Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.""}, {'ForeName': 'Malek', 'Initials': 'M', 'LastName': 'Soleimani Mehranjani', 'Affiliation': 'Department of Biologyt, Faculty of Science, Arak University, Arak, Iran. M-Soleimani@araku.ac.ir.'}, {'ForeName': 'Seyed Mohammad Ali', 'Initials': 'SMA', 'LastName': 'Shariat Zadeh', 'Affiliation': 'Department of Biologyt, Faculty of Science, Arak University, Arak, Iran.'}]",Irish journal of medical science,['10.1007/s11845-020-02320-5'] 2426,32720478,Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.,"AIMS This study aimed to compare the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction. METHODS AND RESULTS Data were obtained from the Chang Gung Research Database. The cohort entry date of the ARB group was assigned as that of the ARNI group to avoid immortal time bias. Additionally, 1:1 propensity score matching based on age, sex, and baseline left ventricular ejection fraction was conducted. The expectation-maximization imputation method with inverse probability of treatment weighting was used to compare outcomes between the two groups. The primary outcome was a composite of cardiovascular death and hospitalization for worsening HF. Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57-0.96). The reduction of hospitalization for worsening HF contributed most to the primary outcome benefits. In addition to the primary outcome, the ARNI group had a significantly lower risk of non-fatal myocardial infarction. The improvement of ejection fraction was not significantly different between the groups. The medication doses of ARNI were lower than in clinical trials. CONCLUSIONS In patients with HF with reduced ejection fraction, sacubitril/valsartan was superior to ARB therapy in reducing the occurrence of the primary outcome endpoint of hospitalization for worsening HF and cardiovascular death.",2020,"Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57-0.96).","['patients with heart failure (HF) with reduced ejection fraction', 'Taiwan', 'heart failure']","['Sacubitril/valsartan vs. angiotensin receptor inhibition', 'ARNI therapy', 'angiotensin receptor-neprilysin inhibitor (ARNI) therapy with angiotensin receptor blocker (ARB) therapy']","['hospitalization for worsening HF and cardiovascular death', 'improvement of ejection fraction', 'composite of cardiovascular death and hospitalization for worsening HF', 'risk of non-fatal myocardial infarction']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}]","[{'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0034787', 'cui_str': 'Angiotensin receptor'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C4760695', 'cui_str': 'Neprilysin inhibitor'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}]",,0.108667,"Patients who received ARNI therapy had a significantly lower risk of the primary composite outcome occurring than patients who received ARBs (hazard ratio, 0.74; 95% confidence interval, 0.57-0.96).","[{'ForeName': 'Po-Cheng', 'Initials': 'PC', 'LastName': 'Chang', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Chun-Li', 'Initials': 'CL', 'LastName': 'Wang', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Fu-Chih', 'Initials': 'FC', 'LastName': 'Hsiao', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Ming-Shien', 'Initials': 'MS', 'LastName': 'Wen', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Chien-Ying', 'Initials': 'CY', 'LastName': 'Huang', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Chung-Chuan', 'Initials': 'CC', 'LastName': 'Chou', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}, {'ForeName': 'Pao-Hsien', 'Initials': 'PH', 'LastName': 'Chu', 'Affiliation': 'Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Medical School, 5 Fu-Xing Street, Guishan District, Taoyuan, 33305, Taiwan.'}]",ESC heart failure,['10.1002/ehf2.12924'] 2427,32720546,Nicotine Facilitation of Conditioned Place Preference to Food Reward in Humans.,"BACKGROUND Nicotine has recently been shown to enhance the motivational value of non-nicotine stimuli in nonhumans. To investigate whether nicotine also enhances reward in humans, we used a virtual translation of the conditioned place preference (CPP) paradigm to examine nicotine's reward-enhancing effects using a low-dose 2 mg nicotine lozenge targeted to a mild use population. Methods: Sixty-eight nicotine-using undergraduates were randomly assigned to receive either a 2 mg nicotine or placebo lozenge prior to conditioning. During each of six, three-minute conditioning sessions, participants were confined to one of two VR rooms. In one room, they received real chocolate M&Ms, whereas no M&Ms were administered in the other room. Following conditioning, a three-minute free-access test session occurred during which participants had unrestricted access to both rooms without reward. Results: Individuals who received nicotine demonstrated a CPP by spending significantly more time in the room previously paired with M&Ms compared to the unrewarded room ( p  = 0.04). Those who received placebo did not demonstrate a CPP ( p  > 0.05). Moreover, we observed no significant differences between treatment groups in terms of the amount of time spent in each virtual room. Conclusion: While nicotine seems to facilitate CPP expression for a virtual environment previously paired with chocolate food rewards, further characterization of the mechanism by which this occurs is needed.",2020,Results: Individuals who received nicotine demonstrated a CPP by spending significantly more time in the room previously paired with M&Ms compared to the unrewarded room ( p  = 0.04).,"['Methods: Sixty-eight nicotine-using undergraduates', 'Humans']","['placebo', 'nicotine or placebo lozenge prior to conditioning', 'nicotine']",['amount of time spent in each virtual room'],"[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450387', 'cui_str': '68'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0991564', 'cui_str': 'Lozenge'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}]",,0.0353641,Results: Individuals who received nicotine demonstrated a CPP by spending significantly more time in the room previously paired with M&Ms compared to the unrewarded room ( p  = 0.04).,"[{'ForeName': 'Alexandra N', 'Initials': 'AN', 'LastName': 'Palmisano', 'Affiliation': 'Department of Psychological Sciences, University of Connecticut, Storrs, Connecticut, USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Astur', 'Affiliation': 'Department of Psychological Sciences, University of Connecticut, Storrs, Connecticut, USA.'}]",Substance use & misuse,['10.1080/10826084.2020.1795682'] 2428,32720550,Neurally adjusted ventilatory assist after surgical treatment of intracerebral hemorrhage: a randomized crossover study.,"OBJECTIVE We assessed the neuromechanical efficiency (NME), neuroventilatory efficiency (NVE), and diaphragmatic function effects between pressure support ventilation (PSV) and neutrally adjusted ventilatory assist (NAVA). METHODS Fifteen patients who had undergone surgical treatment of intracerebral hemorrhage were enrolled in this randomized crossover study. The patients were assigned to PSV for the first 24 hours and then to NAVA for the following 24 hours or vice versa. The monitored ventilatory parameters under the two ventilation models were compared. NME, NVE, and diaphragmatic function were compared between the two ventilation models. RESULTS One patient's illness worsened during the study. The study was stopped for this patient, and intact data were obtained from the other 14 patients and analyzed. The monitored tidal volume was significantly higher with PSV than NAVA (487 [443-615] vs. 440 [400-480] mL, respectively). NME, NVE, diaphragmatic function, and the partial pressures of arterial carbon dioxide and oxygen were not significantly different between the two ventilation models. CONCLUSION The tidal volume was lower with NAVA than PSV; however, the patients' selected respiratory pattern during NAVA did not change the NME, NVE, or diaphragmatic function.Clinical trial registration no. ChiCTR1900022861.",2020,"The monitored tidal volume was significantly higher with PSV than NAVA (487 [443-615] vs. 440 [400-480] mL, respectively).","['Fifteen patients who had undergone surgical treatment of intracerebral hemorrhage', 'intracerebral hemorrhage']","['pressure support ventilation (PSV) and neutrally adjusted ventilatory assist (NAVA', 'NAVA']","['tidal volume', 'NME, NVE, and diaphragmatic function', 'NME, NVE, or diaphragmatic function', 'neuromechanical efficiency (NME), neuroventilatory efficiency (NVE), and diaphragmatic function effects', 'NME, NVE, diaphragmatic function, and the partial pressures of arterial carbon dioxide and oxygen', 'monitored tidal volume']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C2937358', 'cui_str': 'Cerebral hemorrhage'}]","[{'cui': 'C0419008', 'cui_str': 'Pressure support'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0040210', 'cui_str': 'Tidal volume'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030604', 'cui_str': 'Partial pressure'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}]",15.0,0.0392167,"The monitored tidal volume was significantly higher with PSV than NAVA (487 [443-615] vs. 440 [400-480] mL, respectively).","[{'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Rongrong', 'Initials': 'R', 'LastName': 'Wu', 'Affiliation': 'Department of Education, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Yao', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Kui', 'Initials': 'K', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Guiliang', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Fan', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Nianlong', 'Initials': 'N', 'LastName': 'Wu', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}, {'ForeName': 'Xinggen', 'Initials': 'X', 'LastName': 'Fang', 'Affiliation': 'Department of Neurosurgery, Research Center for Functional Maintenance and Reconstruction of Viscera, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, China.'}]",The Journal of international medical research,['10.1177/0300060520939837'] 2429,32720552,Can pelvic organ prolapse in postmenopausal women be treated with laser therapy?,"PURPOSE This study aims to assess the effectiveness of the non-ablative photothermal erbium laser (Er:YAG laser) for managing anterior and/or posterior vaginal compartment prolapse. METHODS A randomized, single-blind, 1:1 trial was performed comparing Er:YAG laser treatment to watchful waiting in postmenopausal women with symptomatic cystocele and/or rectocele stage 2 or 3 who opted to undergo surgery due to bothersome prolapse symptoms. Three Er:YAG laser treatments at monthly intervals were applied for the Er:YAG laser group, while there was no treatment for the watchful-waiting group. The primary outcome was the proportion of patients with stage 0 or 1 following laser treatment, while secondary outcomes included the Pelvic Organ Prolapse Quantification System (POP-Q points), Pelvic Floor Distress Inventory Questionnaire short-form, Pelvic Floor Impact Questionnaire short-form, and Patients Global Impression of Improvement (PGI-I). All outcomes were evaluated at baseline and 4 months post baseline. RESULTS Thirty women (15 vs. 15) were eligible to be included. No participants (0%) in either group had POP-Q stage 0 or 1 at 4 months. Moreover, no change was present in the secondary outcomes. In the PGI-I, 2/15 (14%) and 0/15 (0%) participants declared much better/very much better in the laser and watchful-waiting group, respectively. CONCLUSIONS The findings of this study do not support use of the intravaginal Er:YAG laser for treatment of the anterior/posterior vaginal wall. Clinical trial identification number: NCT03714607.",2020,No participants (0%) in either group had POP-Q stage 0 or 1 at 4 months.,"['postmenopausal women', 'postmenopausal women with symptomatic cystocele and/or rectocele stage 2 or 3 who opted to undergo surgery due to bothersome prolapse symptoms', 'Thirty women (15 vs. 15) were eligible to be included']","['intravaginal Er:YAG laser', 'laser therapy', 'YAG laser treatment', 'ablative photothermal erbium laser (Er:YAG laser']","['proportion of patients with stage 0 or 1 following laser treatment', 'Pelvic Organ Prolapse Quantification System (POP-Q points), Pelvic Floor Distress Inventory Questionnaire short-form, Pelvic Floor Impact Questionnaire short-form, and Patients Global Impression of Improvement (PGI-I']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0010695', 'cui_str': 'Cystocele'}, {'cui': 'C0149771', 'cui_str': 'Herniation of rectum into vagina'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0442122', 'cui_str': 'Intravaginal'}, {'cui': 'C0014688', 'cui_str': 'Erbium'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0587723', 'cui_str': 'YAG - laser'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441763', 'cui_str': 'Stage 0'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877015', 'cui_str': 'Urogenital prolapse'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0439820', 'cui_str': 'Popping sensation quality'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C4706333', 'cui_str': 'Patient Global Impression of Improvement'}]",30.0,0.10674,No participants (0%) in either group had POP-Q stage 0 or 1 at 4 months.,"[{'ForeName': 'S', 'Initials': 'S', 'LastName': 'Athanasiou', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Pitsouni', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Cardozo', 'Affiliation': ""Urogynecology Department, King's College Hospital, London, UK.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Zacharakis', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Petrakis', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Loutradis', 'Affiliation': ""1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Grigoriadis', 'Affiliation': ""Urogynaecology Unit, 1st Department of Obstetrics and Gynecology, 'Alexandra' Hospital, National and Kapodistrian University of Athens, Athens, Greece.""}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2020.1789092'] 2430,31809479,Safety and efficacy of bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention: a report from the Acute Catheterization and Urgent Intervention Triage Strategy trial.,"OBJECTIVES There are limited data on bivalirudin monotherapy in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme). We sought to evaluate the safety and efficacy of bivalirudin monotherapy in patients with positive biomarkers from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. PATIENTS AND METHODS We compared the net adverse clinical events [composite ischemia - (death, myocardial infarction, or unplanned ischemic revascularization) - or noncoronary artery bypass graft surgery (CABG)-related major bleeding] among patients with biomarker-positive NSTE-ACS in the ACUITY trial overall and by antithrombotic strategy. RESULTS Among 13 819 patients with NSTE-ACS enrolled in ACUITY, 4728 patients presented with positive biomarkers and underwent an early invasive strategy. Of those, 1547 were randomized to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI), 1555 to bivalirudin plus GPI, and 1626 to bivalirudin monotherapy. Compared with biomarker-negative patients, biomarker-positive patients had higher 30-day rates of net adverse clinical events (14.0 vs. 12.4%; P = 0.04), all-cause death (1.3 vs. 0.5%; P = 0.001), cardiac death (1.1 vs. 0.5%; P = 0.005), and non-CABG-related major bleeding (6.5 vs. 5.2%, P = 0.03). At 30 days, bivalirudin monotherapy was associated with significantly less non-CABG-related major bleeding (bivalirudin monotherapy 4.1% vs. bivalirudin plus GPI 8.4% vs. heparin plus GPI 7.1%) with comparable rates of composite ischemia (bivalirudin monotherapy 9.2% vs. bivalirudin plus GPI 9.9% vs. heparin plus GPI 8.4%). In a multivariable model, bivalirudin monotherapy was associated with a significant reduction in non-CABG-related major bleeding but was not associated with an increased risk of death, myocardial infarction, unplanned revascularization or stent thrombosis. CONCLUSION Compared with heparin plus GPI or bivalirudin plus GPI, bivalirudin monotherapy provides similar protection from ischemic events with less major bleeding at 30 days among patients with NSTE-ACS and positive biomarkers.",2020,"At 30 days, bivalirudin monotherapy was associated with significantly less non-CABG-related major bleeding (bivalirudin monotherapy 4.1% vs. bivalirudin plus GPI 8.4% vs. heparin plus GPI 7.1%) with comparable rates of composite ischemia (bivalirudin monotherapy 9.2% vs. bivalirudin plus GPI 9.9% vs. heparin plus GPI 8.4%).","['patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) with positive biomarkers of myocardial necrosis (troponin and/or creatine kinase-myocardial band isoenzyme', 'patients with biomarker-positive NSTE-ACS in the ACUITY trial overall and by antithrombotic strategy', 'patients with positive biomarkers from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial', 'patients with non-ST-segment elevation acute coronary syndromes with positive biomarkers undergoing percutaneous coronary intervention', '13 819 patients with NSTE-ACS enrolled in ACUITY, 4728 patients presented with positive biomarkers and underwent an early invasive strategy']","['bivalirudin', 'glycoprotein IIb/IIIa inhibitor', 'bivalirudin monotherapy', 'heparin', 'heparin plus GPI or bivalirudin plus GPI, bivalirudin monotherapy']","['cardiac death', 'risk of death, myocardial infarction, unplanned revascularization or stent thrombosis', '30-day rates of net adverse clinical events', 'cause death', 'safety and efficacy', 'Safety and efficacy', 'net adverse clinical events [composite ischemia - (death, myocardial infarction, or unplanned ischemic revascularization) - or noncoronary artery bypass graft surgery (CABG)-related major bleeding', 'non-CABG-related major bleeding']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3160886', 'cui_str': 'Non ST segment elevation acute coronary syndrome'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0010287', 'cui_str': 'Creatine kinase'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0022173', 'cui_str': 'Isozymes'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0040861', 'cui_str': 'Triage'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}]","[{'cui': 'C0168273', 'cui_str': 'bivalirudin'}, {'cui': 'C0016011', 'cui_str': 'Glycoproteins IIb-IIIa'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0019134', 'cui_str': 'heparin'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0376297', 'cui_str': 'Cardiac death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0022116', 'cui_str': 'Ischemia'}, {'cui': 'C0475224', 'cui_str': 'Ischemic'}, {'cui': 'C0189695', 'cui_str': 'Anastomosis of artery with bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}]",13819.0,0.139584,"At 30 days, bivalirudin monotherapy was associated with significantly less non-CABG-related major bleeding (bivalirudin monotherapy 4.1% vs. bivalirudin plus GPI 8.4% vs. heparin plus GPI 7.1%) with comparable rates of composite ischemia (bivalirudin monotherapy 9.2% vs. bivalirudin plus GPI 9.9% vs. heparin plus GPI 8.4%).","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': ""Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.""}, {'ForeName': 'Shmuel', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Björn', 'Initials': 'B', 'LastName': 'Redfors', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Yiran', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Cristiano F', 'Initials': 'CF', 'LastName': 'Souza', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Bansilal', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai.'}, {'ForeName': 'Ajay J', 'Initials': 'AJ', 'LastName': 'Kirtane', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Sorin J', 'Initials': 'SJ', 'LastName': 'Brener', 'Affiliation': 'NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Feite', 'Affiliation': ''}, {'ForeName': 'George D', 'Initials': 'GD', 'LastName': 'Dangas', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Ori', 'Initials': 'O', 'LastName': 'Ben-Yehuda', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation.'}]",Coronary artery disease,['10.1097/MCA.0000000000000737'] 2431,31977699,Evaluation of Microneedling Therapy in Management of Facial Scars.,"BACKGROUND Appearance and beauty always have been playing a major aspect of human's lives, regardless of the era. The desire for man to look better had led to various treatment modalities. One among them is microneedling therapy, also called as percutaneous collagen induction therapy or dermaroller therapy. Henceforth, the aim of the study was to evaluate the efficacy of microneedling therapy in the management of facial scars. METHODS An observational clinical study was conducted with a total of 14 patients who needed treatment and presented to the out-patient department of Department of Oral and Maxillofacial Surgery. The patients who were cooperative, motivated, and esthetically conscious with facial scars due to trauma, soft-tissue injury following incision and drainage, postsurgical scars, scars following surgery of cleft lip correction, and postacne scars were randomly selected. RESULTS In the present study, a statistically significant difference was observed with pre- and postsurgical patient satisfaction scale (PSS) and observed satisfaction scale (OSS; P = 0.001). Preoperatively there were 64.3% with depressed scars and 35.7% with elevated scars. The clinical response of height of scar postoperatively was 100% flattening with the surrounding skin surface. Results showed that all atrophic and hypertrophic scars showed improvement, and color of the scar which was darker or lighter than the surrounding skin got the same color as the surrounding skin after microneedling therapy. Pain during the procedure was easily tolerable by the patient and no postoperative pain was noted. CONCLUSION Microneedling therapy can be considered as an effective modality of treatment for facial scars in patients with an added advantage of minimal downtime and effective improvement. It is simple and cost-effective technique in the treatment of facial scars.",2020,"Results showed that all atrophic and hypertrophic scars showed improvement, and color of the scar which was darker or lighter than the surrounding skin got the same color as the surrounding skin after microneedling therapy.","['patients who were cooperative, motivated, and esthetically conscious with facial scars due to trauma, soft-tissue injury following incision and drainage, postsurgical scars, scars following surgery of cleft lip correction, and postacne scars were randomly selected', '14 patients who needed treatment and presented to the out-patient department of Department of Oral and Maxillofacial Surgery']","['microneedling therapy', 'Microneedling Therapy']","['pre- and postsurgical patient satisfaction scale (PSS) and observed satisfaction scale', 'postoperative pain', 'Pain']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0234421', 'cui_str': 'Consciousness'}, {'cui': 'C2229249', 'cui_str': 'Scar of face'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0037578', 'cui_str': 'Soft tissue injury'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0152277', 'cui_str': 'Incision AND drainage'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0008924', 'cui_str': 'Cleft lip'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0812928', 'cui_str': 'Oral and maxillofacial surgery'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0030201', 'cui_str': 'Postoperative pain'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",14.0,0.0231792,"Results showed that all atrophic and hypertrophic scars showed improvement, and color of the scar which was darker or lighter than the surrounding skin got the same color as the surrounding skin after microneedling therapy.","[{'ForeName': 'Yenugandula', 'Initials': 'Y', 'LastName': 'Vijaya Lakshmi', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Meghna Institute of Dental Sciences, Nizamabad.'}, {'ForeName': 'Lingaladinne', 'Initials': 'L', 'LastName': 'Swetha Reddy', 'Affiliation': 'Department of Public Health Dentistry, Panineeya Institute of Dental Sciences and Research Center, Hyderabad.'}, {'ForeName': 'Kolli', 'Initials': 'K', 'LastName': 'Naga Neelima Devi', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Sibar Institute of Dental Sciences, Guntur.'}, {'ForeName': 'Kuchimanchi', 'Initials': 'K', 'LastName': 'Phani Kumar', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Sibar Institute of Dental Sciences, Guntur.'}, {'ForeName': 'Gandikota', 'Initials': 'G', 'LastName': 'Guru Karthik', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Narayana Dental College and Hospital, Nellore.'}, {'ForeName': 'Pandi', 'Initials': 'P', 'LastName': 'Srinivas Chakravarthy', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Sibar Institute of Dental Sciences, Guntur.'}, {'ForeName': 'Kondrakunta', 'Initials': 'K', 'LastName': 'Nageswar Rao', 'Affiliation': 'Skine Kare Clinic, Guntur, India.'}]",The Journal of craniofacial surgery,['10.1097/SCS.0000000000006145'] 2432,30500116,Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers.,"There is an urgent need to identify safe and effective combination treatments for multidrug-resistant (MDR) Mycobacterium tuberculosis infection (TB). Bedaquiline, a new diarylquinoline, is approved for the treatment of MDR pulmonary TB in combination with other drugs, which could include rifabutin, which is also used to treat drug-resistant TB. Both rifabutin and bedaquiline are metabolized via cytochrome P450 3A4, and rifabutin is an inducer of this enzyme. Bedaquiline is metabolized into its primary N-monodesmethyl metabolite, M2, and further desmethylated into an N-didesmethyl metabolite, M3. Both metabolites are cytotoxic and induce phospholipidosis. The effect of rifabutin on the generation and disposition of the 2 metabolites was investigated in healthy adult volunteers coadministered bedaquiline and either rifabutin or rifampin. Subjects received single oral doses (400 mg) of bedaquiline on days 1 and 29. Oral rifabutin (300 mg) or rifampin (600 mg) were given daily on days 20-41. In the rifabutin group maximum M2 concentrations (C max ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01). This resulted in significantly (P < .001) increased overall exposure (area under the concentration-time curve [AUC 0-τ ]). Peak concentrations of M3 increased approximately 3-fold with little decline thereafter. In rifampin recipients M2 C max doubled (48.44 to 101.52 ng/mL), but M2 clearance and time to C max significantly (P < .001) increased, and AUC 0-∞ and mean residence time significantly decreased (P < .001). Peak M3 concentrations increased 4-fold and rapidly declined. Although both rifamycins accelerate desmethylation of bedaquiline and M2, differences in clearance resulted in sustained elevations of both metabolites during rifabutin, but not rifampin, treatment.",2019,"In the rifabutin group maximum M2 concentrations (C max ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).","['Healthy Adult Volunteers', 'healthy adult volunteers coadministered bedaquiline and either']","['rifabutin or rifampin', 'Rifamycin Coadministration', 'bedaquiline', 'rifabutin and bedaquiline', 'rifabutin', 'Oral rifabutin', 'rifampin']","['maximum M2 concentrations (C max ', 'AUC 0-∞ and mean residence time', 'overall exposure (area under the concentration-time curve [AUC 0-τ ', 'M2 clearance and time to C max', 'Peak M3 concentrations', 'Peak concentrations of M3']","[{'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1664205', 'cui_str': 'bedaquiline'}]","[{'cui': 'C0140575', 'cui_str': 'Rifabutin'}, {'cui': 'C0035608', 'cui_str': 'Rifampin'}, {'cui': 'C0035609', 'cui_str': 'Rifamycins'}, {'cui': 'C1664205', 'cui_str': 'bedaquiline'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",,0.112159,"In the rifabutin group maximum M2 concentrations (C max ) increased significantly (P < .001) from 47.59 to 79.53 ng/mL, and clearance slowed slightly (P = .01).","[{'ForeName': 'Amanda M', 'Initials': 'AM', 'LastName': 'Healan', 'Affiliation': 'Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Salata', 'Affiliation': 'Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'J McLeod', 'Initials': 'JM', 'LastName': 'Griffiss', 'Affiliation': 'ClinicalRM, Hinckley, OH, USA.'}, {'ForeName': 'Howard M', 'Initials': 'HM', 'LastName': 'Proskin', 'Affiliation': 'Howard M. Proskin and Associates, Inc, Rochester, NY, USA.'}, {'ForeName': 'Mary Ann', 'Initials': 'MA', 'LastName': ""O'Riordan"", 'Affiliation': 'Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA.'}, {'ForeName': 'Wesley A', 'Initials': 'WA', 'LastName': 'Gray', 'Affiliation': 'Department of Pediatrics, University of Toledo College of Medicine, Toledo, OH, USA.'}, {'ForeName': 'Jeffrey L', 'Initials': 'JL', 'LastName': 'Blumer', 'Affiliation': 'Department of Pediatrics, University of Toledo College of Medicine, Toledo, OH, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.639'] 2433,30626253,Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4 .,"The efficacy of asparaginase in acute lymphoblastic leukemia (ALL) is dependent on depletion of asparagine, an essential amino acid for ALL cells. The target level of plasma asparaginase activity to achieve asparagine depletion has been between 0.05 and 0.4 IU/mL. COG AALL07P4 examined the asparaginase activity and plasma and CSF asparagine concentration of pegaspargase when given intravenously in the treatment of NCI high risk ALL. Matched plasma asparaginase/asparagine levels of the clearance of 54 doses of pegaspargase given in induction or consolidation demonstrated that all patients who had a plasma asparaginase level >0.02 IU/mL had undetectable plasma asparagine. No difference was observed in CSF asparagine levels associated with matched plasma asparaginase levels of 0.02-0.049 versus 0.05-0.22 IU/mL ( p  = .25). Our data suggest that a plasma asparaginase activity level of 0.02 IU/mL can effectively deplete plasma asparagine. The data also indicate that the 95% CI for plasma asparagine depletion after a pegaspargase dose is 22-29 days. Clinical trial registration: clinicaltrials.gov identifier NCT00671034.",2019,No difference was observed in CSF asparagine levels associated with matched plasma asparaginase levels of 0.02-0.049 versus 0.05-0.22 IU/mL ( p  = .25).,"[""acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4 "", 'acute lymphoblastic leukemia (ALL']",['asparaginase'],"['plasma asparaginase activity level', 'Plasma asparaginase activity and asparagine depletion', 'plasma asparagine depletion', 'CSF asparagine levels', 'asparaginase activity and plasma and CSF asparagine concentration of pegaspargase']","[{'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0071568', 'cui_str': 'pegaspargase'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003995', 'cui_str': 'Asparagine'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0071568', 'cui_str': 'pegaspargase'}]",,0.0755209,No difference was observed in CSF asparagine levels associated with matched plasma asparaginase levels of 0.02-0.049 versus 0.05-0.22 IU/mL ( p  = .25).,"[{'ForeName': 'Reuven J', 'Initials': 'RJ', 'LastName': 'Schore', 'Affiliation': ""a Children's National Medical Center , Washington , DC , USA.""}, {'ForeName': 'Meenakshi', 'Initials': 'M', 'LastName': 'Devidas', 'Affiliation': 'b Department of Biostatistics, Colleges of Medicine, Public Health & Health Professions , University of Florida , Gainesville , FL , USA.'}, {'ForeName': 'Archie', 'Initials': 'A', 'LastName': 'Bleyer', 'Affiliation': 'c St. Charles Medical Center , Bend , OR , USA.'}, {'ForeName': 'Gregory H', 'Initials': 'GH', 'LastName': 'Reaman', 'Affiliation': ""a Children's National Medical Center , Washington , DC , USA.""}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Winick', 'Affiliation': 'd Department of Pediatric Hematology/Oncology , University of Texas Southwestern Medical Center , Dallas , TX , USA.'}, {'ForeName': 'Mignon L', 'Initials': 'ML', 'LastName': 'Loh', 'Affiliation': ""e Department of Pediatrics , Benioff Children's Hospital , San Francisco , CA , USA.""}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Raetz', 'Affiliation': 'g Department of Pediatrics and Perlmutter Cancer Center , New York University Langone Medical Center , New York , NY , USA.'}, {'ForeName': 'William L', 'Initials': 'WL', 'LastName': 'Carroll', 'Affiliation': 'g Department of Pediatrics and Perlmutter Cancer Center , New York University Langone Medical Center , New York , NY , USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Hunger', 'Affiliation': ""h Department of Pediatrics and the Center for Childhood Cancer Research , The Children's Hospital of Philadelphia , Philadelphia , PA , USA.""}, {'ForeName': 'Anne L', 'Initials': 'AL', 'LastName': 'Angiolillo', 'Affiliation': ""a Children's National Medical Center , Washington , DC , USA.""}]",Leukemia & lymphoma,['10.1080/10428194.2018.1542146'] 2434,32721213,Greater Dynamic and Lower Static Functional Brain Connectivity Prospectively Predict Placebo Response in Pediatric Generalized Anxiety Disorder.,"Objectives: Placebo response is one of the most significant barriers to detecting treatment effects in pediatric (and adult) clinical trials focusing on affective and anxiety disorders. We sought to identify neurofunctional predictors of placebo response in adolescents with generalized anxiety disorder (GAD) by examining dynamic and static functional brain connectivity. Methods: Before randomization to blinded placebo, adolescents, aged 12-17 years, with GAD ( N  = 25) underwent resting state functional magnetic resonance imaging. Whole brain voxelwise correlation analyses were used to determine the relationship between change in anxiety symptoms from baseline to week 8 and seed-based dynamic and static functional connectivity maps of regions in the salience and ventral attention networks (amygdala, dorsal anterior cingulate cortex [dACC], and ventrolateral prefrontal cortex [VLPFC]). Results: Greater dynamic functional connectivity variability in amygdala, dACC, VLPFC, and regions within salience, default mode, and frontoparietal networks was associated with greater placebo response. Lower static functional connectivity between amygdala and dorsolateral prefrontal cortex, amygdala and medial prefrontal cortex, dACC and posterior cingulate cortex and greater static functional connectivity between VLPFC and inferior parietal lobule were associated with greater placebo response. Conclusion: Placebo response is associated with a distinct dynamic and static connectivity fingerprint characterized by ""variable"" dynamic but ""weak"" static connectivity in the salience, default mode, frontoparietal, and ventral attention networks. These data provide granular evidence of how circuit-based biotypes mechanistically relate to placebo response. Finding biosignatures that predict placebo response is critically important in clinical psychopharmacology and to improve our ability to detect medication-placebo differences in clinical trials.",2020,"Lower static functional connectivity between amygdala and dorsolateral prefrontal cortex, amygdala and medial prefrontal cortex, dACC and posterior cingulate cortex and greater static functional connectivity between VLPFC and inferior parietal lobule were associated with greater placebo response. ","['adolescents with generalized anxiety disorder (GAD', ' adolescents, aged 12-17 years, with GAD ( N \u2009=\u200925', 'Pediatric Generalized Anxiety Disorder']","['Placebo', 'resting state functional magnetic resonance imaging', 'placebo']","['dynamic functional connectivity variability in amygdala, dACC, VLPFC, and regions within salience, default mode, and frontoparietal networks', 'Lower static functional connectivity between amygdala and dorsolateral prefrontal cortex, amygdala and medial prefrontal cortex, dACC and posterior cingulate cortex and greater static functional connectivity', 'anxiety symptoms']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0270549', 'cui_str': 'Generalized anxiety disorder'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0679218', 'cui_str': 'Resting state'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0002708', 'cui_str': 'Amygdaloid structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C4019080', 'cui_str': 'Prefrontal Cortex, Dorsolateral'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0175191', 'cui_str': 'Posterior Cingulate Gyri'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}]",25.0,0.190626,"Lower static functional connectivity between amygdala and dorsolateral prefrontal cortex, amygdala and medial prefrontal cortex, dACC and posterior cingulate cortex and greater static functional connectivity between VLPFC and inferior parietal lobule were associated with greater placebo response. ","[{'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Hailong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Jeffrey A', 'Initials': 'JA', 'LastName': 'Mills', 'Affiliation': 'Department of Economics, Lindner College of Business, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Schroeder', 'Affiliation': 'Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Mossman', 'Affiliation': 'Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Sara T', 'Initials': 'ST', 'LastName': 'Varney', 'Affiliation': 'Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Kim M', 'Initials': 'KM', 'LastName': 'Cecil', 'Affiliation': 'Department of Radiology, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'Xiaoqi', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Qiyong', 'Initials': 'Q', 'LastName': 'Gong', 'Affiliation': 'Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Levine', 'Affiliation': 'Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York City, New York, USA.'}, {'ForeName': 'Melissa P', 'Initials': 'MP', 'LastName': 'DelBello', 'Affiliation': 'Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Sweeny', 'Affiliation': 'Department of Radiology, Huaxi MR Research Center (HMRRC), West China Hospital of Sichuan University, Chengdu, China.'}, {'ForeName': 'Jeffrey R', 'Initials': 'JR', 'LastName': 'Strawn', 'Affiliation': 'Department of Psychiatry, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.'}]",Journal of child and adolescent psychopharmacology,['10.1089/cap.2020.0024'] 2435,32721228,Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin Plus Insulin vs. Insulin Alone.,"BACKGROUND Diabetes-related distress is common among persons affected by diabetes and is associated with suboptimal glycemic control and complications, thus constituting a relevant patient-report outcome (PRO). Improving glycemic control may reduce diabetes distress and improve treatment satisfaction. This post hoc analysis evaluated PRO data for a pooled cohort of adults with type 1 diabetes (T1D) receiving sotagliflozin as adjunct to optimized insulin in the inTandem1 and inTandem2 studies. METHODS Clinically meaningful changes in the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and the two-item Diabetes Distress Scale (DDS2) total and individual scores were examined in the pooled data from the first 24 weeks of the studies. RESULTS In the cohort of patients with a baseline DTSQs total score ≤32 (~76% of entire cohort), nearly twice as many patients treated with sotagliflozin 200 (45.9%) or 400 mg (42.3%) experienced a >3-point improvement from baseline vs. those treated with placebo (24%). Treatment with sotagliflozin led to statistically significant (P<0.05) improvements across all DTSQs items. Approximately 42% of all patients were considered to have a high risk of diabetes distress (total DDS2 score ≥6) at baseline, following insulin optimization. More patients shifted from high to low risk with sotagliflozin compared to placebo (~40% vs. 23%; P≤0.0002). The baseline-adjusted difference in DDS2 from placebo was significantly (P<0.001) reduced by -0.5 and -0.6 for sotagliflozin 200 and 400 mg, respectively. CONCLUSIONS Patients with T1D treated with sotagliflozin in addition to optimized insulin therapy reported meaningful improvements in treatment satisfaction and diabetes distress.",2020,Treatment with sotagliflozin led to statistically significant (P<0.05) improvements across all DTSQs items.,"['Adults with Type 1 Diabetes Treated with', 'Patients with T1D treated with', 'adults with type 1 diabetes (T1D) receiving']","['sotagliflozin', 'Sotagliflozin Plus Insulin vs. Insulin Alone', 'placebo']","['treatment satisfaction and diabetes distress', 'Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) and the two-item Diabetes Distress Scale (DDS2) total and individual scores', 'DDS2', 'high risk of diabetes distress (total DDS2 score ≥6', 'diabetes distress']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}]","[{'cui': 'C3502471', 'cui_str': '(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C4545498', 'cui_str': 'Diabetes Treatment Satisfaction Questionnaire status version'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]",,0.123148,Treatment with sotagliflozin led to statistically significant (P<0.05) improvements across all DTSQs items.,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Danne', 'Affiliation': 'Kinderkrankenhaus auf der Bult, Diabetes Centre for Children and Adolescents, Janusz-Korczak Allee 12, Hannover, Germany, 30173; danne@hka.de.'}, {'ForeName': 'Vijay N', 'Initials': 'VN', 'LastName': 'Joish', 'Affiliation': 'Lexicon Pharmaceuticals Inc, 57636, The Woodlands, Texas, United States; vjoish@LexPharma.com.'}, {'ForeName': 'Marion', 'Initials': 'M', 'LastName': 'Afonso', 'Affiliation': 'Sanofi SA, 3663, Paris, Île-de-France, France; Marion.Afonso@sanofi.com.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Banks', 'Affiliation': 'Lexicon Pharmaceuticals Inc, 57636, The Woodlands, Texas, United States; pbanks@lexpharma.com.'}, {'ForeName': 'Sangeeta', 'Initials': 'S', 'LastName': 'Sawhney', 'Affiliation': 'Lexicon Pharmaceuticals Inc, 57636, The Woodlands, Texas, United States; sangeetasawhney98@gmail.com.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Lapuerta', 'Affiliation': 'Lexicon Pharmaceuticals Inc, 57636, The Woodlands, Texas, United States; Plapuerta@lexpharma.com.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Davies', 'Affiliation': 'Lexicon Pharmaceuticals Inc, 57636, The Woodlands, Texas, United States; mdavies@LexPharma.com.'}, {'ForeName': 'John B', 'Initials': 'JB', 'LastName': 'Buse', 'Affiliation': 'University of North Carolina at Chapel Hill School of Medicine, 6797, Chapel Hill, North Carolina, United States; john_buse@med.unc.edu.'}, {'ForeName': 'Dee', 'Initials': 'D', 'LastName': 'Lin', 'Affiliation': 'Sanofi US, 5269, Bridgewater, New Jersey, United States; dee.lin@live.com.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Reaney', 'Affiliation': 'Sanofi UK, 3662, Guildford, United Kingdom of Great Britain and Northern Ireland; matthew.reaney@iqvia.com.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Guillonneau', 'Affiliation': 'Sanofi SA, 3663, Paris, Île-de-France, France; sophie.Guillonneau@sanofi.com.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Snoek', 'Affiliation': 'Amsterdam UMC - VUMC location, 1209, Amsterdam, Noord-Holland, Netherlands; fj.snoek@amsterdamumc.nl.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Bailey', 'Affiliation': 'AMCR Institute, 625 West Citracado Parkway, Suite 112, Escondido, California, United States, 92025; tbailey@amcrinstitute.com.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Polonsky', 'Affiliation': 'Behavioral Diabetes Institute, San Diego, California, United States; whp@behavioraldiabetes.org.'}]",Diabetes technology & therapeutics,['10.1089/dia.2020.0068'] 2436,32721237,Prospective Clinical Trial Comparing Curettage and Cryosurgery to Curettage and Electrodesiccation in the Management of Minimally Invasive Basal and Squamous Cell Carcinomas.,"BACKGROUND Basal and squamous cell carcinomas represent the most common cancers in North America. Their management is an important issue. OBJECTIVES The evaluation of cure rates of minimally invasive cutaneous carcinomas with curettage-cryosurgery compared to curettage-electrodesiccation, as well as the assessment of the aesthetic appearance of scars. METHODS This prospective trial randomized 117 patients 1:1 to treatments of curettage-cryosurgery or curettage-electrodesiccation. They were then followed at 6, 12, 18, and 24 months. RESULTS At 12-month follow-up, only one (1/49) patient had a recurrence of cutaneous carcinoma in the curettage-cryosurgery group and none (0/43) in the curettage-electrodesiccation group. Farrington-Manning analysis with a 5% margin of error showed the non-inferiority of the first method ( P = .04). For the aesthetic appearance of scars after 12 months, better results with curettage-cryosurgery procedure has been observed, but this was not statistically significant ( P = .80 and P = .27 for evaluations of patients and clinicians respectively). LIMITATIONS This study was mainly limited by its small sample size. CONCLUSION We have demonstrated that curettage-cryosurgery compared to curettage-electrodesiccation for the treatment of minimally invasive carcinomas is noninferior (comparable) with regards to cure rates at 12-month follow-up. No significant difference has been demonstrated for the appearance of scars.",2020,Farrington-Manning analysis with a 5% margin of error showed the non-inferiority of the first method ( P = .04).,"['117 patients 1:1 to treatments of', 'Minimally Invasive Basal and Squamous Cell Carcinomas']","['curettage-cryosurgery or curettage-electrodesiccation', 'Curettage and Cryosurgery to Curettage and Electrodesiccation', 'curettage-electrodesiccation']","['cure rates', 'recurrence of cutaneous carcinoma', 'appearance of scars']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}]","[{'cui': 'C0010468', 'cui_str': 'Curettage'}, {'cui': 'C0010408', 'cui_str': 'Cryosurgery'}, {'cui': 'C0185056', 'cui_str': 'Electrodesiccation'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0007097', 'cui_str': 'Carcinoma'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0008767', 'cui_str': 'Scarring'}]",117.0,0.0283465,Farrington-Manning analysis with a 5% margin of error showed the non-inferiority of the first method ( P = .04).,"[{'ForeName': 'Suzel', 'Initials': 'S', 'LastName': 'Fournier', 'Affiliation': 'CHU de Quebec - Centre de Recherche Clinique et Évaluative en Oncologie, Quebec, QC, Canada.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Laroche', 'Affiliation': 'CHU de Quebec - Centre de Recherche Clinique et Évaluative en Oncologie, Quebec, QC, Canada.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Leblanc', 'Affiliation': '10012 Dr Georges-L.-Dumont University Hospital Centre, Moncton, NB, Canada.'}, {'ForeName': 'Emilie', 'Initials': 'E', 'LastName': 'Bourgeault', 'Affiliation': 'Clinique GTB, Gatineau, QC, Canada.'}, {'ForeName': 'Mahukpe Narcisse', 'Initials': 'MN', 'LastName': 'Ulrich Singbo', 'Affiliation': ""91452 CHU de Quebec - Centre Hospitalier de l'Universite Laval, Quebec, QC, Canada.""}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Turcotte', 'Affiliation': '266173689626611 Hôtel-Dieu de Levis, Levis, QC, Canada.'}, {'ForeName': 'Marie-Michèle', 'Initials': 'MM', 'LastName': 'Blouin', 'Affiliation': 'CHU de Quebec - Centre de Recherche Clinique et Évaluative en Oncologie, Quebec, QC, Canada.'}, {'ForeName': 'Jimmy', 'Initials': 'J', 'LastName': 'Alain', 'Affiliation': 'CHU de Quebec - Centre de Recherche Clinique et Évaluative en Oncologie, Quebec, QC, Canada.'}]",Journal of cutaneous medicine and surgery,['10.1177/1203475420943258'] 2437,32721411,School-based soccer practice is an effective strategy to improve cardiovascular and metabolic risk factors in overweight children.,"We examined the effects of a 6-month school-based soccer programme on cardiovascular (CV) and metabolic risk factors in overweight children. Methods: 40 boys [8-12 years; body mass index (BMI) >2 standard deviations of WHO reference values] participated in complementary school-based physical education classes (two sessions per week, 45-90 min each). The participants were divided into a soccer group (SG; n = 20) and a control group (CG; n = 20). The SG intervention involved 3 extra-curricular school-based soccer sessions per week, 60-90 min each. The intervention lasted for 6-months. All measurements were taken at baseline and after 6-months. From baseline to 6-months, the SG significantly improved (p < .05) BMI z-score, waist circumference, waist-to-height ratio, percentage of fat mass, percentage of fat-free mass, diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, but no such improvements were observed for the CG. After the intervention, the prevalence of soccer participants with normal waist-to-height ratio (30 vs. 5%; p = .037), systolic blood pressure (90 vs. 55%; p = .039), total cholesterol (80 vs. 65%; p = .035) and LDL-C (90 vs. 75%; p = .012) were significantly higher than at baseline. The findings suggest that a 6-month school-based soccer intervention program represents an effective strategy to reduce CV and metabolic risk factors in overweight children prepared to take part in a soccer program.",2020,"From baseline to 6-months, the SG significantly improved (p < .05) BMI z-score, waist circumference, waist-to-height ratio, percentage of fat mass, percentage of fat-free mass, diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, but no such improvements were observed for the CG.","['Methods: 40 boys [8-12\u202fyears; body mass index (BMI) >2 standard deviations of WHO reference values] participated in complementary school-based physical education classes (two sessions per week, 45-90\u202fmin each', 'overweight children']",['school-based soccer programme'],"['cardiovascular (CV) and metabolic risk factors', 'cardiovascular and metabolic risk factors', 'BMI z-score, waist circumference, waist-to-height ratio, percentage of fat mass, percentage of fat-free mass, diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol', 'total cholesterol', 'normal waist-to-height ratio', 'systolic blood pressure', 'CV and metabolic risk factors']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0086715', 'cui_str': 'Normal range'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0031805', 'cui_str': 'Education, Physical'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C1821269', 'cui_str': 'Waist to Height Ratio'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",3.0,0.0154865,"From baseline to 6-months, the SG significantly improved (p < .05) BMI z-score, waist circumference, waist-to-height ratio, percentage of fat mass, percentage of fat-free mass, diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, but no such improvements were observed for the CG.","[{'ForeName': 'André', 'Initials': 'A', 'LastName': 'Seabra', 'Affiliation': 'Portugal Football School, Portuguese Football Federation, Portugal; Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Portugal. Electronic address: andre.seabra@fpf.pt.'}, {'ForeName': 'João', 'Initials': 'J', 'LastName': 'Brito', 'Affiliation': 'Portugal Football School, Portuguese Football Federation, Portugal.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Figueiredo', 'Affiliation': 'Portugal Football School, Portuguese Football Federation, Portugal; Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University Institute of Maia, ISMAI, Portugal.'}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Beirão', 'Affiliation': 'Center of Research, Education, Innovation and Intervention in Sport (CIFI2D), Faculty of Sport, University of Porto, Portugal.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Seabra', 'Affiliation': 'Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Portugal.'}, {'ForeName': 'Maria José', 'Initials': 'MJ', 'LastName': 'Carvalho', 'Affiliation': 'Center of Research, Education, Innovation and Intervention in Sport (CIFI2D), Faculty of Sport, University of Porto, Portugal.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Abreu', 'Affiliation': 'Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Portugal.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Vale', 'Affiliation': 'Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sport, University of Porto, Portugal.'}, {'ForeName': 'Augusto', 'Initials': 'A', 'LastName': 'Pedretti', 'Affiliation': 'Projeto Esporte Brasil (PROESP-Br), Faculdade de Educação Física, Fisioterapia e Dança, Universidade Federal do Rio Grande do Sul, Brazil.'}, {'ForeName': 'Henrique', 'Initials': 'H', 'LastName': 'Nascimento', 'Affiliation': 'Biological Sciences Department, Faculty of Pharmacy, University of Porto, Portugal, Institute for Molecular and Cell Biology (IBMC), Portugal.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Belo', 'Affiliation': 'Biological Sciences Department, Faculty of Pharmacy, University of Porto, Portugal, Institute for Molecular and Cell Biology (IBMC), Portugal.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Rêgo', 'Affiliation': 'Center for Research in Health Technologies and Information Systems, Faculty of Medicine, University of Porto, Portugal.'}]",Progress in cardiovascular diseases,['10.1016/j.pcad.2020.07.007'] 2438,32721578,The home air in agriculture pediatric intervention (HAPI) trial: Rationale and methods.,"BACKGROUND Data addressing air quality effects on children with asthma in rural U.S. communities are rare. Our community engaged research partnership previously demonstrated associations between neighborhood NH 3 and ambient PM 2.5 and asthma in the agricultural lower Yakima Valley of Washington. As a next step, the partnership desired an intervention approach to address concerns about pediatric asthma in this largely Latino immigrant, farm worker community. OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. We investigated the effect of this enriched approach on these exposures and asthma health measures. DESIGN We randomized children with poorly controlled asthma to a control arm (current asthma education program) or an intervention arm (current asthma education program + placement of two indoor air cleaners in the family's home). Outcomes included (1) 14-day integrated samples of indoor air contaminants (PM 2.5 and NH 3 ) at baseline and one-year follow-up and (2) child asthma health metrics at baseline, midpoint (4-6 months) and one-year follow-up. These included the Asthma Control Test, symptoms days, clinical utilization, oral corticosteroid use, pulmonary function, fractional exhaled nitric oxide, and urinary leukotriene E 4 concentration. DISCUSSION To our knowledge, this is the first randomized HEPA cleaner intervention designed to assess NH 3 as well as PM 2.5 and to evaluate health outcomes of children with asthma in an agricultural region.",2020,"OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. ","['children with asthma in rural U.S. communities', 'children with asthma in an agricultural region', 'children with poorly controlled asthma to a control arm (current asthma education program) or an']","[""intervention arm (current asthma education program + placement of two indoor air cleaners in the family's home""]","['14-day integrated samples of indoor air contaminants (PM 2.5 and NH 3 ) at baseline and one-year follow-up and (2) child asthma health metrics', 'Asthma Control Test, symptoms days, clinical utilization, oral corticosteroid use, pulmonary function, fractional exhaled nitric oxide, and urinary leukotriene E 4 concentration']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1679754', 'cui_str': 'Asthma education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C1679754', 'cui_str': 'Asthma education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0789995', 'cui_str': 'Air cleaner'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0337099', 'cui_str': 'Air contaminant'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C4704932', 'cui_str': 'Health Metrics'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C4523905', 'cui_str': 'Fractional exhaled nitric oxide'}, {'cui': 'C0125644', 'cui_str': 'LTE4'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.0221442,"OBJECTIVE The Home Air in Agriculture Pediatric Intervention (HAPI) sought to examine the effectiveness of enrichment of an existing asthma education program with portable high-efficiency particulate air (HEPA) cleaners designed to reduce PM 2.5 and NH 3. ","[{'ForeName': 'Erin E', 'Initials': 'EE', 'LastName': 'Masterson', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America. Electronic address: emaster@uw.edu.'}, {'ForeName': 'Lisa B', 'Initials': 'LB', 'LastName': 'Younglove', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Perez', 'Affiliation': ""Yakima Valley Farm Worker's Clinic, Toppenish, WA, United States of America.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Torres', 'Affiliation': 'Northwest Communities Education Center, Radio KDNA, Granger, WA, United States of America.'}, {'ForeName': 'Jennifer E', 'Initials': 'JE', 'LastName': 'Krenz', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Maria I', 'Initials': 'MI', 'LastName': 'Tchong French', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Riederer', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Sampson', 'Affiliation': 'Department of Statistics, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Nervana', 'Initials': 'N', 'LastName': 'Metwali', 'Affiliation': 'Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States of America.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Min', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Karen L', 'Initials': 'KL', 'LastName': 'Jansen', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Gino', 'Initials': 'G', 'LastName': 'Aisenberg', 'Affiliation': 'School of Social Work, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Ryan S', 'Initials': 'RS', 'LastName': 'Babadi', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Stephanie A', 'Initials': 'SA', 'LastName': 'Farquhar', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America; Department of Health Services, University of Washington, Seattle, WA, United States of America.'}, {'ForeName': 'Peter S', 'Initials': 'PS', 'LastName': 'Thorne', 'Affiliation': 'Department of Occupational and Environmental Health, University of Iowa, Iowa City, IA, United States of America.'}, {'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Karr', 'Affiliation': 'Department of Environmental Health Sciences, University of Washington, Seattle, WA, United States of America; Department of Pediatrics, University of Washington, Seattle, WA, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2020.106085'] 2439,32721655,Do ethics classes influence student behavior? Case study: Teaching the ethics of eating meat.,"Do university ethics classes influence students' real-world moral choices? We aimed to conduct the first controlled study of the effects of ordinary philosophical ethics classes on real-world moral choices, using non-self-report, non-laboratory behavior as the dependent measure. We assigned 1332 students in four large philosophy classes to either an experimental group on the ethics of eating meat or a control group on the ethics of charitable giving. Students in each group read a philosophy article on their assigned topic and optionally viewed a related video, then met with teaching assistants for 50-minute group discussion sections. They expressed their opinions about meat ethics and charitable giving in a follow-up questionnaire (1032 respondents after exclusions). We obtained 13,642 food purchase receipts from campus restaurants for 495 of the students, before and after the intervention. Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after). Ethical opinion also differed, with 43% of students in the experimental group agreeing that eating the meat of factory farmed animals is unethical compared to 29% in the control group. We also attempted to measure food choice using vouchers, but voucher redemption rates were low and no effect was statistically detectable. It remains unclear what aspect of instruction influenced behavior.",2020,"Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after).",['1332 students in four large philosophy classes to either an experimental group on the ethics of eating meat or a control group on the ethics of charitable giving'],['ordinary philosophical ethics classes'],['Purchase of meat products'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0031534', 'cui_str': 'Philosophy'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0015000', 'cui_str': 'Ethics'}, {'cui': 'C0004135', 'cui_str': 'Ataxia-telangiectasia syndrome'}, {'cui': 'C0025017', 'cui_str': 'Meat'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015000', 'cui_str': 'Ethics'}, {'cui': 'C0456387', 'cui_str': 'Class'}]","[{'cui': 'C0025018', 'cui_str': 'Meat products'}]",1332.0,0.0290026,"Purchase of meat products declined in the experimental group (52% of purchases of at least $4.99 contained meat before the intervention, compared to 45% after) but remained the same in the control group (52% both before and after).","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Schwitzgebel', 'Affiliation': 'University of California at Riverside, USA. Electronic address: eschwitz@ucr.edu.'}, {'ForeName': 'Bradford', 'Initials': 'B', 'LastName': 'Cokelet', 'Affiliation': 'University of Kansas, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Singer', 'Affiliation': 'Princeton University, USA.'}]",Cognition,['10.1016/j.cognition.2020.104397'] 2440,32721815,Effect of intranasal oxytocin administration on self-other distinction: Modulations by psychological distance and gender.,"Preliminary evidence indicates that intranasal oxytocin (OT) administration modulates one's ability to distinguish oneself from others (i.e., self-other distinction). However, previous findings on this topic are contradictory. The current study addressed this issue by (i) using a novel perceptual matching task examining self-other distinction compared to both close and distant others, and (ii) tentatively exploring potential modulations by gender. In a double-blind, placebo-controlled, randomized OT administration study, 100 participants (50 males and 50 females) were randomized to receive intranasal spray of 24 IU OT or placebo (PL). Afterwards, participants completed a geometry perceptual matching task in which different shapes were paired to the self, a friend, or a stranger. Participants were then asked to judge whether each pair of shapes and labels was correctly matched. The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females. These findings provide insights for debates on the role of OT in self-other distinction by revealing modulations by psychological distance and gender, which have implications for the potential clinical applications of OT.",2020,"The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females.",['100 participants (50 males and 50 females'],"['intranasal spray of 24 IU OT or placebo (PL', 'intranasal oxytocin (OT', 'intranasal oxytocin', 'placebo']",[],"[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C1154182', 'cui_str': 'Spray dose form'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],100.0,0.104773,"The results revealed that compared to PL administration, OT facilitated distinction between the self and a friend in males but not in females.","[{'ForeName': 'Chunliang', 'Initials': 'C', 'LastName': 'Feng', 'Affiliation': 'Key Laboratory of Brain, Cognition and Education Sciences, Ministry of Education, China; School of Psychology, Center for Studies of Psychological Application, and Guangdong Key Laboratory of Mental Health and Cognitive Science, South China Normal University, China. Electronic address: chunliang.feng@m.scnu.edu.cn.'}, {'ForeName': 'Xinmei', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China.'}, {'ForeName': 'Xiangru', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'Institute of Cognition, Brain and Health, Institute of Psychology and Behavior, Henan University, Kaifeng, China.'}, {'ForeName': 'Ruida', 'Initials': 'R', 'LastName': 'Zhu', 'Affiliation': 'State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.'}, {'ForeName': 'Shangfeng', 'Initials': 'S', 'LastName': 'Han', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China.'}, {'ForeName': 'Yue-Jia', 'Initials': 'YJ', 'LastName': 'Luo', 'Affiliation': 'Center of Brain Disorder and Cognitive Sciences, College of Psychology and Sociology, Shenzhen Key Laboratory of Affective and Social Cognitive Science, Shenzhen University, Center for Emotion and Brain, Shenzhen Institute of Neuroscience, Shenzhen, China. Electronic address: luoyj@szu.edu.cn.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2020.104804'] 2441,32721845,Implementation of magnesium sulphate as an adjunct to multimodal analgesic approach for perioperative pain control in lumbar laminectomy surgery: A randomized placebo-controlled clinical trial.,"OBJECTIVE To investigate the effect of systemic intraoperative administration of magnesium sulphate when used in the context of a multimodal pain management plan on analgesics consumption and pain scores, and perioperative outcomes after lumbar laminectomy surgery. METHODS Seventy-four patients undergoing lumbar laminectomy were enrolled in this randomized, double-blind, placebo-controlled trial. Participants were randomly allocated to receive magnesium (20 mg/kg iv given as bolus before anesthesia induction followed by 20 mg/kg/h civ until surgery completion) or saline. Hemodynamic variables and desflurane consumption were noted at predefined time-intervals intraoperatively. Primary outcome was postoperative cumulative analgesic consumption over 24 h, while pain intensity (assessed by Visual Analogue Scale [VAS] at 1, 2, 4, 6 and 24 h), intraoperative hemodynamics and opioid requirements, recovery profile, time to first analgesic request, and adverse effects constituted secondary end-points. RESULTS Demographics, surgery duration, desflurane requirements, and recovery profile were comparable between groups. Magnesium attenuated hemodynamic response during incision and emergence from anesthesia. Postoperative analgesics consumption in morphine iv equivalents (mean difference -9.24 [95 %CI -13.31, -5.17] mg; p = 0.001) and VAS scores at all-time points of assessment were lower in magnesium group; this effect peaked at 4 h (mean difference -2.15 [95 %CI -3.21,-1.09; p = 0.001]. Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01). No notable adverse effects were recorded. CONCLUSION It occurs that magnesium infusion during lumbar laminectomy surgery potentiates perioperative analgesia and reduces analgesic requirements up to 24 h postoperatively. No profound adverse effect on either intraoperative hemodynamics or any other clinically relevant endpoints becomes evident.",2020,Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01).,"['lumbar laminectomy surgery', 'Seventy-four patients undergoing lumbar laminectomy']","['Magnesium', 'placebo', 'magnesium (20\u202fmg/kg iv given as bolus before anesthesia induction followed by 20\u202fmg/kg/h civ until surgery completion) or saline', 'magnesium sulphate', 'magnesium', 'morphine']","['adverse effects', 'time-interval to first rescue analgesia', 'intraoperative remifentanil consumption', 'analgesics consumption and pain scores, and perioperative outcomes', 'postoperative cumulative analgesic consumption over 24\u202fh, while pain intensity (assessed by Visual Analogue Scale [VAS] at 1, 2, 4, 6 and 24\u202fh), intraoperative hemodynamics and opioid requirements, recovery profile, time to first analgesic request, and adverse effects constituted secondary end-points', 'analgesic requirements', 'hemodynamic response', 'Postoperative analgesics consumption', 'Hemodynamic variables and desflurane consumption', 'Demographics, surgery duration, desflurane requirements, and recovery profile', 'VAS scores']","[{'cui': 'C1112614', 'cui_str': 'Lumbar laminectomy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0473960', 'cui_str': 'Induction of general anesthesia'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1320755', 'cui_str': 'mg/kg/hr'}, {'cui': 'C0022326', 'cui_str': 'Ivory Coast'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0024480', 'cui_str': 'Magnesium Sulfate'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0246631', 'cui_str': 'remifentanil'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0420259', 'cui_str': 'Analgesics requested'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",74.0,0.791883,Magnesium reduced intraoperative remifentanil consumption and prolonged the time-interval to first rescue analgesia (p < 0.01).,"[{'ForeName': 'Georgia', 'Initials': 'G', 'LastName': 'Tsaousi', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: tsaousig@otenet.gr.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Nikopoulou', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: anastasian1991@windowslive.com.'}, {'ForeName': 'Ioakeim', 'Initials': 'I', 'LastName': 'Pezikoglou', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: makispez@gmail.com.'}, {'ForeName': 'Vasiliki', 'Initials': 'V', 'LastName': 'Birba', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: bsbvasso@yahoo.gr.'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Grosomanidis', 'Affiliation': 'Department of Anesthesiology and ICU, Aristotle University Thessaloniki, University Campus, 54124, Thessaloniki, Greece. Electronic address: grosoman@otenet.gr.'}]",Clinical neurology and neurosurgery,['10.1016/j.clineuro.2020.106091'] 2442,32721919,Desmopressin acetate decreases blood loss in patients with massive hemorrhage undergoing gastrointestinal surgery.,"BACKGROUND/AIMS Intraoperative blood loss more than 400 mL during gastrointestinal surgery is an independent predictor of mortality. Desmopressin acetate (DDAVP) could reduce perioperative blood loss. Few studies have prompted concerning the effects of DDAVP on gastrointestinal surgery. This study was to investigate whether DDAVP can decrease blood loss in patients with massive hemorrhage undergoing gastrointestinal surgery. MATERIALS AND METHODS A multiple-centers, double-blind clinical trial was conducted, patients who underwent gastrointestinal surgery were recruited from 3 hospitals, randomly assigned to two different groups. Patients in the treatment group received desmopressin 0.3 ug/kg,30 min once a day after surgery, patients in the control group received 50 ml saline for 30 min. The primary outcome was the changes of hemoglobin at 24 hours after the surgery. And the secondary outcomes included coagulation function, urine volume, serum creatinine, and safety. RESULTS There were 59 patients enrolled between 1 June 2015 and 1 June 2017. At 24hr.after surgery, a decrease in hemoglobin in the DDAVP group was significantly lower than that in the NS group (-5.0±6.9 g/L vs. -10.2±9.3g/L, p=0.03). Sonoclot® showed that the platelet function in the DDAVP group was higher than that in NS group at 24 hr. (2.56 ±0.59 vs. 1.91 ±0.72, p<0.05). There was no difference in urine volume and serum creatinine at 24 hr. between two group. CONCLUSION DDAVP could reduce post-operation blood loss in patients with massive hemorrhage undergoing surgery by improving the platelet function. We observed no difference in urine volume and serum creatinine in two groups.",2020,"(2.56 ±0.59 vs. 1.91 ±0.72, p<0.05).","['patients with massive hemorrhage undergoing gastrointestinal surgery', 'patients with massive hemorrhage undergoing surgery', 'patients who underwent gastrointestinal surgery were recruited from 3 hospitals', '59 patients enrolled between 1 June 2015 and 1 June 2017']","['Desmopressin acetate (DDAVP', 'Desmopressin acetate', 'DDAVP', '50 ml saline', 'desmopressin']","['platelet function', 'hemoglobin', 'perioperative blood loss', 'urine volume and serum creatinine', 'coagulation function, urine volume, serum creatinine, and safety', 'changes of hemoglobin', 'blood loss']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0333279', 'cui_str': 'Massive hemorrhage'}, {'cui': 'C0524722', 'cui_str': 'Gastrointestinal surgery'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}]","[{'cui': 'C0086135', 'cui_str': 'Desmopressin acetate'}, {'cui': 'C0701195', 'cui_str': 'Desmospray'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0011701', 'cui_str': 'desmopressin'}]","[{'cui': 'C0920267', 'cui_str': 'Platelet aggregation test'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",59.0,0.131007,"(2.56 ±0.59 vs. 1.91 ±0.72, p<0.05).","[{'ForeName': 'Li-Chun', 'Initials': 'LC', 'LastName': 'Wang', 'Affiliation': 'Department of Intensive Care Unit, the Sixth Affiliated Hospital of Sun Yat-Sen University，Guangzhou, China.'}, {'ForeName': 'Ying-Fang', 'Initials': 'YF', 'LastName': 'Hu', 'Affiliation': 'Department of Intensive Care Unit, Guangdong Second Provincial General Hospital, Guangzhou, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Intensive Care Unit, the Sixth Affiliated Hospital of Sun Yat-Sen University，Guangzhou, China.'}, {'ForeName': 'Rui', 'Initials': 'R', 'LastName': 'Xing', 'Affiliation': 'Department of Intensive Care Unit, Guangdong Second Provincial General Hospital, Guangzhou, China.'}, {'ForeName': 'Xin-Feng', 'Initials': 'XF', 'LastName': 'Lin', 'Affiliation': 'Department of Intensive Care Unit, The fist affiliated hospital of Guangzhou university of Chinese medicine, Guangzhou, China.'}, {'ForeName': 'Qiu-Ye', 'Initials': 'QY', 'LastName': 'Kou', 'Affiliation': 'Department of Intensive Care Unit, the Sixth Affiliated Hospital of Sun Yat-Sen University，Guangzhou, China.'}]",The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology,['10.5152/tjg.2020.19021'] 2443,32721923,Correction: Effectiveness of a Web-Based Tailored Intervention With Virtual Assistants Promoting the Acceptability of HPV Vaccination Among Mothers of Invited Girls: Randomized Controlled Trial.,[This corrects the article DOI: .].,2020,[This corrects the article DOI: .].,['Mothers of Invited Girls'],[],"['Vaccination', 'Acceptability of HPV']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]",[],"[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0021344', 'cui_str': 'Human Papillomavirus'}]",,0.124551,[This corrects the article DOI: .].,"[{'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Pot', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Theo Gwm', 'Initials': 'TG', 'LastName': 'Paulussen', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Robert Ac', 'Initials': 'RA', 'LastName': 'Ruiter', 'Affiliation': 'Department of Work and Social Psychology, Maastricht University, Maastricht, Netherlands.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Eekhout', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}, {'ForeName': 'Hester E', 'Initials': 'HE', 'LastName': 'de Melker', 'Affiliation': 'National Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, Netherlands.'}, {'ForeName': 'Maxine Ea', 'Initials': 'ME', 'LastName': 'Spoelstra', 'Affiliation': 'Department of Psychology, Leiden University, Leiden, Netherlands.'}, {'ForeName': 'Hilde M', 'Initials': 'HM', 'LastName': 'van Keulen', 'Affiliation': 'Netherlands Organization for Applied Scientific Research (TNO), Child Health, Leiden, Netherlands.'}]",Journal of medical Internet research,['10.2196/22565'] 2444,32722128,Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.,"The therapeutic landscape of metastatic castration-resistant prostate cancer (mCRPC) has substantially evolved over the last decade. Nonetheless, a better understanding of bone-targeted agents (BTAs) action in mCRPC remains an unmet need. Theuse of BTAs aims to reduce the incidence of skeletal-related events (SREs) in patients with mCRPC. Less frequent BTA schedules are currently being studied to minimize adverse events. In this study, the impact of metastatic compartment (bone and extraskeletal metastases (BESM) vs. bone-only metastases (BOM)) on bone biomarker kinetics, time to first on-study SRE, and symptomatic skeletal events (SSEs) is evaluated. This is a retrospective analysis of the prospective, randomized, multicenter clinical trial of denosumab vs. zoledronic acid in patients with mCRPC and bone metastases. A total of 1901 patients were included, 1559 (82.0%) with BOM and 342 with BESM (18.0%). Bone metastases burden was balanced between groups. Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase did not differ between groups. However, BESM patients had a higher risk of SREs (adjusted HR 1.21; 95% CI 1.01-1.46; p = 0.043) and SSEs (adjusted HR 1.30; 95% CI 1.06-1.61; p = 0.014). This difference was more pronounced in the first 12 months of BTA treatment.In mCRPC, strategies of BTA schedule de-escalation may take into account presence of extraskeletal metastases.",2020,Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase did not differ between groups.,"['Metastatic Castration-Resistant Prostate Cancer with Bone Metastases', 'metastatic castration-resistant prostate cancer (mCRPC', 'patients with mCRPC and bone metastases', 'patients with mCRPC', 'A total of 1901 patients were included, 1559 (82.0%) with BOM and 342 with BESM (18.0']","['metastatic compartment (bone and extraskeletal metastases (BESM) vs. bone-only metastases (BOM', 'BESM', 'Extraskeletal Metastases', 'denosumab vs. zoledronic acid']","['risk of SREs', 'Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase']","[{'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0153690', 'cui_str': 'Secondary malignant neoplasm of bone'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C5191280', 'cui_str': '342'}]","[{'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0257685', 'cui_str': 'zoledronic acid'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0037253', 'cui_str': 'Skeletal system structure'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0312399', 'cui_str': 'Alkaline phosphatase isoenzyme, bone fraction'}]",1901.0,0.0732807,Baseline levels and normalization rates of corrected urinary N-terminal telopeptide and bone alkaline phosphatase did not differ between groups.,"[{'ForeName': 'Soraia', 'Initials': 'S', 'LastName': 'Lobo-Martins', 'Affiliation': 'Oncology Division, Hospital de Santa Maria, 1649-035 Lisbon, Portugal.'}, {'ForeName': 'Arlindo R', 'Initials': 'AR', 'LastName': 'Ferreira', 'Affiliation': 'Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Mansinho', 'Affiliation': 'Oncology Division, Hospital de Santa Maria, 1649-035 Lisbon, Portugal.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Casimiro', 'Affiliation': 'Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': 'Leitzel', 'Affiliation': 'Division of Hematology/Oncology, Penn State Health Milton S Hershey Medical Center, Hershey, PA17033, USA.'}, {'ForeName': 'Suhail', 'Initials': 'S', 'LastName': 'Ali', 'Affiliation': 'Division of Hematology/Oncology, Penn State Health Milton S Hershey Medical Center, Hershey, PA17033, USA.'}, {'ForeName': 'Allan', 'Initials': 'A', 'LastName': 'Lipton', 'Affiliation': 'Division of Hematology/Oncology, Penn State Health Milton S Hershey Medical Center, Hershey, PA17033, USA.'}, {'ForeName': 'Luís', 'Initials': 'L', 'LastName': 'Costa', 'Affiliation': 'Oncology Division, Hospital de Santa Maria, 1649-035 Lisbon, Portugal.'}]",Cancers,['10.3390/cancers12082034'] 2445,32722216,Autologous Mesenchymal Stem Cell Treatment is Consistently Effective for the Treatment of Knee Osteoarthritis: The Results of a Systematic Review of Treatment and Comparison to a Placebo Group.,"Background: Numerous studies have used autologous mesenchymal stem cell injections (AMSCI) to treat osteoarthritis. We hypothesized that AMSCI is an effective osteoarthritis treatment with increasing efficacy at higher doses. Methods: We conducted a PubMed search for human clinical studies using AMSCI for the treatment of osteoarthritis (OA) and a second search for placebo arms of injectate OA treatment. Inclusion criteria included treatment outcomes ratings both pre-treatment and at least 6 months post-treatment. Results: 45 AMSCI cohorts from 34 studies met criteria. All AMSCI cohorts showed improvement at mean 15.3 months post-treatment. Mean WOMAC and VAS scores improved at 6-months and at final follow-up ( p < 0.0001 for all). Scores > 2 years were also significant (WOMAC p = 0.001/VAS p = 0.004). Results greatly exceeded the minimal clinically important difference (MCID) at each time point. AMSCI improvement also substantially exceeded previously published 6-month placebo-treatment improvement. No dose-response relationship was seen. AMSCI cohorts showed continuing improvement ≥ 6 months, and continued upward at one year. Placebo scores were already trending downward by 6 months. Conclusions: AMSCI is a consistently significantly effective treatment for osteoarthritis. It should no longer be stated that data is insufficient to establish AMSCI efficacy for OA. Given its excellent safety profile, AMSCI should be widely used for the treatment of osteoarthritis.",2020,Scores > 2 years were also significant (WOMAC p = 0.001/VAS ,['Knee Osteoarthritis'],"['Placebo', 'autologous mesenchymal stem cell injections (AMSCI', 'AMSCI', 'Autologous Mesenchymal Stem Cell Treatment', 'placebo']","['Mean WOMAC and VAS scores', 'AMSCI improvement']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0201168,Scores > 2 years were also significant (WOMAC p = 0.001/VAS ,"[{'ForeName': 'Chadwick', 'Initials': 'C', 'LastName': 'Prodromos', 'Affiliation': 'Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Finkle', 'Affiliation': 'Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Rumschlag', 'Affiliation': 'Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Lotus', 'Affiliation': 'Illinois Sportsmedicine and Orthopaedic Center, Glenview, IL 60025, USA.'}]","Medicines (Basel, Switzerland)",['10.3390/medicines7080042'] 2446,32722243,Effects of Neuromuscular Electrical Stimulation (NMES) Plus Upper Cervical Spine Mobilization on Forward Head Posture and Swallowing Function in Stroke Patients with Dysphagia.,"After a stroke, forward head posture occurs, resulting in swallowing dysfunction. Neuromuscular electrical stimulation (NMES) combined with upper cervical spine mobilization has demonstrated enhanced recovery of the swallowing function in stroke patients. This study investigated the therapeutic effects of NMES in conjunction with upper cervical mobilization in stroke patients with dysphagia. Thirty-four stroke patients were recruited (in a randomized controlled clinical trial) and divided into an experimental group ( n = 17; NMES plus upper cervical spine mobilization) and a control group ( n = 17; NMES plus sham mobilization). Forward head posture was measured by craniocervical flexion test (CCFT) and craniovertebral angle (CVA). Swallowing function was measured by variations in video fluoroscopic dysphagia scale (VDS) and penetration-aspiration scale (PAS) scores using the video fluoroscopic swallowing study (VFSS). All measurements were done at baseline and after four weeks of NMES plus mobilization. A significant increase was observed in CCFT, CVA, VDS (total VDS score, oral stage score, pharyngeal stage score), and PAS score in all variations in the experimental group. The CCFT, CVA, pharyngeal stage score, total VDS, and PAS score were significantly higher in the experimental group when compared to the control group. NMES plus upper cervical spine mobilization can be regarded as a promising method to improve swallowing function and forward head posture changes in stroke patients with dysphagia.",2020,"A significant increase was observed in CCFT, CVA, VDS (total VDS score, oral stage score, pharyngeal stage score), and PAS score in all variations in the experimental group.","['stroke patients', 'Stroke Patients with Dysphagia', 'Thirty-four stroke patients', 'stroke patients with dysphagia']","['Neuromuscular electrical stimulation (NMES) combined with upper cervical spine mobilization', 'Neuromuscular Electrical Stimulation (NMES) Plus Upper Cervical Spine Mobilization', 'NMES plus upper cervical spine mobilization) and a control group ( n = 17; NMES plus sham mobilization', 'NMES']","['Swallowing function', 'swallowing function', 'video fluoroscopic dysphagia scale (VDS) and penetration-aspiration scale (PAS) scores', 'CCFT, CVA, pharyngeal stage score, total VDS, and PAS score', 'craniocervical flexion test (CCFT) and craniovertebral angle (CVA', 'CCFT, CVA, VDS (total VDS score, oral stage score, pharyngeal stage score), and PAS score', 'Forward Head Posture and Swallowing Function']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C3816446', 'cui_str': '30'}]","[{'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0031354', 'cui_str': 'Pharyngeal structure'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0030125', 'cui_str': 'aminosalicylic acid'}, {'cui': 'C1627359', 'cui_str': 'Flexion test'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0029170', 'cui_str': 'Oral psychosexual phase'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C1536116', 'cui_str': 'Head posture abnormal'}]",34.0,0.0384387,"A significant increase was observed in CCFT, CVA, VDS (total VDS score, oral stage score, pharyngeal stage score), and PAS score in all variations in the experimental group.","[{'ForeName': 'Yung Hyun', 'Initials': 'YH', 'LastName': 'Jeon', 'Affiliation': 'Department of Physical Therapy, College of Public Health & Welfare, Yongin University, 134, Yongindaehak-ro, Cheoin-gu, Yongin-si, Gyeonggi-do 17092, Korea.'}, {'ForeName': 'Kyun Hee', 'Initials': 'KH', 'LastName': 'Cho', 'Affiliation': 'AVENS Hospital, 307, Gwanpyeong-ro, Dongan-gu, Anyang-si, Gyeonggi-do 13936, Korea.'}, {'ForeName': 'Shin Jun', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Physical Therapy, Gangdong University, 278, Daehak-gil, Gamgok-myeon, Eumseong-gun, Chungcheongbuk-do 27600, Korea.'}]",Brain sciences,['10.3390/brainsci10080478'] 2447,32722250,Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration.,"Bacterial vaginosis and vulvovaginal candidiasis are common causes of impaired health and quality of life for women. Although antimicrobial agents remain the main strategy for the treatment of vaginal infections, their repeated use involves high rates of resistance and recurrence. Alternative approaches such as probiotics are studied. Saccharomyces cerevisiae CNCM I-3856 already demonstrated beneficial effects in experimental models of vaginal infections. This randomized, double-blind, placebo-controlled clinical study was performed to evaluate the recovery of S. cerevisiae CNCM I-3856 in vaginal samples in healthy women after oral consumption. Sixty healthy women were randomized to receive a daily dose of S. cerevisiae CNCM I-3856 or a placebo for 4 weeks. Subcultures and quantitative polymerase chain reaction (qPCR) were used to detect the strain in vaginal and stool samples. A safety assessment was carried out throughout the study. Fifty-seven women completed the study. Over the 4-week supplementation phase, S. cerevisiae CNCM I-3856 has been detected in the vaginal samples of 21% of women ( n = 4/19) in the 500 mg Probiotic group and 16% of women ( n = 3/19) in the 1000 mg Probiotic group. The strain was detected in the faeces of 90% of women consuming the probiotic. This is the first clinical study demonstrating the migration of yeast from intestine to vagina where it may exert its benefits.",2020,Sixty healthy women were randomized to receive a daily dose of S. cerevisiae CNCM I-3856 or a placebo for 4 weeks.,"['Sixty healthy women', 'healthy women after oral consumption', 'Fifty-seven women completed the study', 'Healthy Women after Oral Administration']","['Saccharomyces cerevisiae CNCM I-3856', 'Subcultures and quantitative polymerase chain reaction (qPCR', 'S. cerevisiae CNCM I-3856 or a placebo', 'Saccharomyces cerevisiae', 'placebo']",['Bacterial vaginosis and vulvovaginal candidiasis'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001563', 'cui_str': 'Medication administration: oral'}]","[{'cui': 'C0036025', 'cui_str': 'Saccharomyces cerevisiae'}, {'cui': 'C0200940', 'cui_str': 'Microbial subculture'}, {'cui': 'C0392762', 'cui_str': 'Quantitative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0085166', 'cui_str': 'Bacterial vaginosis'}, {'cui': 'C0700345', 'cui_str': 'Candidal vulvovaginitis'}]",57.0,0.162399,Sixty healthy women were randomized to receive a daily dose of S. cerevisiae CNCM I-3856 or a placebo for 4 weeks.,"[{'ForeName': 'Amelie', 'Initials': 'A', 'LastName': 'Decherf', 'Affiliation': 'Research and Applications Department, Gnosis by Lesaffre, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}, {'ForeName': 'Elodie', 'Initials': 'E', 'LastName': 'Dehay', 'Affiliation': 'Research and Applications Department, Gnosis by Lesaffre, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}, {'ForeName': 'Mickaël', 'Initials': 'M', 'LastName': 'Boyer', 'Affiliation': 'Microbiology Laboratory, Research and Development Department, Lesaffre International, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Clément-Ziza', 'Affiliation': 'Data Science and Bioinformatics Laboratory, Research and Development Department, Lesaffre International, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Rodriguez', 'Affiliation': 'Research and Applications Department, Gnosis by Lesaffre, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Legrain-Raspaud', 'Affiliation': 'Research and Applications Department, Gnosis by Lesaffre, Lesaffre Group, 59700 Marcq-en-Baroeul, France.'}]",Nutrients,['10.3390/nu12082211'] 2448,32722253,Implementation of a Urinary Tract Infection Treatment Protocol to Improve Prescribing Practices in the Long-Term Care Facility of a Veteran's Healthcare System.,"Urinary tract infections (UTIs) are a commonly diagnosed problem in long-term care facilities (LTCFs), but antimicrobial treatment is often incorrectly prescribed. Although bacterial resistance to antimicrobials commonly used for UTIs, such as trimethoprim/sulfamethoxazole and fluoroquinolones, has been dramatically increasing, they are still commonly prescribed. The purpose of this project was to determine if implementation of a standard treatment protocol for UTIs, which emphasized correct UTI diagnosis and use of nitrofurantoin and cefpodoxime/ceftriaxone as empiric therapy per the institutional antibiogram, changed clinician prescribing practices. This quasi-experimental model utilized two years of pre-intervention and two years of post-intervention data. Three hundred patient encounters were included. Antibiotics prescribed in the pre-intervention period included: trimethoprim/sulfamethoxazole (32%), ciprofloxacin (14%), amoxicillin (13%), levofloxacin (9%), cefpodoxime (9%), ceftriaxone (8%), amoxicillin/clavulanate (5%), nitrofurantoin (4%), and other (6%). By contrast, antibiotics prescribed in the post-intervention period included: cefpodoxime (46%), nitrofurantoin (30%), ceftriaxone (10%), trimethoprim/sulfamethoxazole (8%), amoxicillin/clavulanate (1%), and other (5%). These differences in prescribed drug between the pre-intervention and post-intervention encounters were statistically significant ( p < 0.001). Overall, appropriate empiric treatment was prescribed in only 48/217 encounters (22%) during the pre-intervention period, but this increased to 73/83 encounters (88%) in the post-intervention period ( p < 0.001). The results indicate that the treatment protocol was successful in changing prescribing practices and decreasing the use of inappropriate antimicrobials at the LTCF.",2020,The results indicate that the treatment protocol was successful in changing prescribing practices and decreasing the use of inappropriate antimicrobials at the LTCF.,['Three hundred patient encounters were included'],"['nitrofurantoin', 'ciprofloxacin', 'amoxicillin/clavulanate (5%), nitrofurantoin', 'nitrofurantoin and cefpodoxime/ceftriaxone', 'amoxicillin', 'trimethoprim/sulfamethoxazole', 'levofloxacin', 'amoxicillin/clavulanate', 'ceftriaxone']",['Urinary tract infections (UTIs'],"[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0028156', 'cui_str': 'Nitrofurantoin'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C0054066', 'cui_str': 'Amoxicillin and clavulanate'}, {'cui': 'C0055011', 'cui_str': 'cefpodoxime'}, {'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0038689', 'cui_str': 'Sulfamethoxazole'}, {'cui': 'C0282386', 'cui_str': 'Levofloxacin'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}]",,0.0308431,The results indicate that the treatment protocol was successful in changing prescribing practices and decreasing the use of inappropriate antimicrobials at the LTCF.,"[{'ForeName': 'Spencer H', 'Initials': 'SH', 'LastName': 'Durham', 'Affiliation': 'Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849-5341, USA.'}, {'ForeName': 'Natalie S', 'Initials': 'NS', 'LastName': 'Hohmann', 'Affiliation': 'Department of Pharmacy Practice, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849-5341, USA.'}, {'ForeName': 'Addison H', 'Initials': 'AH', 'LastName': 'Ragan', 'Affiliation': 'Department of Pharmacy, Central Alabama Veterans Health Care System, Montgomery, AL 36109, USA.'}]","Pharmacy (Basel, Switzerland)",['10.3390/pharmacy8030129'] 2449,32722424,Effect of Choline Forms and Gut Microbiota Composition on Trimethylamine- N -Oxide Response in Healthy Men.,"BACKGROUND Trimethylamine- N -oxide (TMAO), a choline-derived gut microbiota-dependent metabolite, is a newly recognized risk marker for cardiovascular disease. We sought to determine: (1) TMAO response to meals containing free versus lipid-soluble choline and (2) effects of gut microbiome on TMAO response. METHODS In a randomized, controlled, double-blinded, crossover study, healthy men ( n = 37) were provided meals containing 600 mg choline either as choline bitartrate or phosphatidylcholine, or no choline control. RESULTS Choline bitartrate yielded three-times greater plasma TMAO AUC ( p = 0.01) and 2.5-times greater urinary TMAO change from baseline ( p = 0.01) compared to no choline and phosphatidylcholine. Gut microbiota composition differed (permutational multivariate analysis of variance, PERMANOVA; p = 0.01) between high-TMAO producers (with ≥40% increase in urinary TMAO response to choline bitartrate) and low-TMAO producers (with <40% increase in TMAO response). High-TMAO producers had more abundant lineages of Clostridium from Ruminococcaceae and Lachnospiraceae compared to low-TMAO producers (analysis of composition of microbiomes, ANCOM; p < 0.05). CONCLUSION Given that phosphatidylcholine is the major form of choline in food, the absence of TMAO elevation with phosphatidylcholine counters arguments that phosphatidylcholine should be avoided due to TMAO-producing characteristics. Further, development of individualized dietary recommendations based on the gut microbiome may be effective in reducing disease risk.",2020,"Gut microbiota composition differed (permutational multivariate analysis of variance, PERMANOVA; p = 0.01) between high-TMAO producers (with ≥40% increase in urinary TMAO response to choline bitartrate) and low-TMAO producers (with <40% increase in TMAO response).","['Healthy Men', 'healthy men ( n = 37']","['phosphatidylcholine', 'Trimethylamine', 'meals containing 600 mg choline either as choline bitartrate or phosphatidylcholine, or no choline control', 'Choline bitartrate', 'N -oxide (TMAO', 'Choline']","['plasma TMAO AUC', 'urinary TMAO change', 'Trimethylamine- N -Oxide Response', 'TMAO response', 'Gut microbiota composition', 'urinary TMAO response']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C1959616', 'cui_str': 'Lecithin'}, {'cui': 'C0077172', 'cui_str': 'trimethylamine'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0008405', 'cui_str': 'Choline'}, {'cui': 'C0008408', 'cui_str': 'Choline bitartrate'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030015', 'cui_str': 'Oxides'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}]",37.0,0.0598851,"Gut microbiota composition differed (permutational multivariate analysis of variance, PERMANOVA; p = 0.01) between high-TMAO producers (with ≥40% increase in urinary TMAO response to choline bitartrate) and low-TMAO producers (with <40% increase in TMAO response).","[{'ForeName': 'Clara E', 'Initials': 'CE', 'LastName': 'Cho', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Niklas D J', 'Initials': 'NDJ', 'LastName': 'Aardema', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Madison L', 'Initials': 'ML', 'LastName': 'Bunnell', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Deanna P', 'Initials': 'DP', 'LastName': 'Larson', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Sheryl S', 'Initials': 'SS', 'LastName': 'Aguilar', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Janet R', 'Initials': 'JR', 'LastName': 'Bergeson', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}, {'ForeName': 'Olga V', 'Initials': 'OV', 'LastName': 'Malysheva', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.'}, {'ForeName': 'Marie A', 'Initials': 'MA', 'LastName': 'Caudill', 'Affiliation': 'Division of Nutritional Sciences, Cornell University, Ithaca, NY 14853, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lefevre', 'Affiliation': 'Department of Nutrition, Dietetics and Food Sciences, Utah State University, Logan, UT 84322, USA.'}]",Nutrients,['10.3390/nu12082220'] 2450,32722454,"Ingestion of Carbohydrate Prior to and during Maximal, Sprint Interval Cycling Has No Ergogenic Effect: A Randomized, Double-Blind, Placebo Controlled, Crossover Study.","Carbohydrate (CHO) ingestion may improve intermittent sprint performance in repeated sprint efforts ≤15 s. Yet, evidence for its efficacy on sprint interval durations ~30 s is lacking. The purpose of this study was to investigate the effects of CHO ingestion on maximal sprint interval exercise. Fifteen ( n = 15) recreational athletes (13/2 males/females, age 22 ± 2 years; height 176 ± 11 cm; mass 76.8 ± 11.3 kg) volunteered for this randomised, double-blind, placebo-controlled, crossover design. Participants completed two experimental trials (performed 10-days apart) involving the ingestion of an 8% CHO solution or a flavour and appearance-matched placebo (PLA) solution (5 mL/kg/bw), immediately before exercise, and preceding the second interval of four × 30 s bouts of repeated maximal sprint efforts (separated by 3.5 min of passive recovery). Peak and mean power (W) output progressively decreased during the repeated sprints (main effect of time, p < 0.0001), but there were no differences between CHO and PLA during any of the sprints ( p > 0.05 for condition main effect and condition × time interaction). Physiological responses (blood lactate, heart rate, oxygen consumption, respiratory exchange ratio and RPE) were also unaltered by CHO ingestion. In conclusion, CHO ingestion does not enhance performance or modulate physiological responses during intermittent maximal, sprint cycling.",2020,"Physiological responses (blood lactate, heart rate, oxygen consumption, respiratory exchange ratio and RPE) were also unaltered by CHO ingestion.","['Fifteen ( n = 15) recreational athletes (13/2 males/females, age 22 ± 2 years; height 176 ± 11 cm; mass 76.8 ± 11.3 kg) volunteered']","['Placebo', 'Carbohydrate', 'CHO ingestion', 'Carbohydrate (CHO) ingestion', 'ingestion of an 8% CHO solution or a flavour and appearance-matched placebo (PLA) solution', 'placebo']","['CHO and PLA', 'Physiological responses (blood lactate, heart rate, oxygen consumption, respiratory exchange ratio and RPE', 'Peak and mean power (W) output progressively', 'maximal sprint interval exercise', 'intermittent sprint performance']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0054889', 'cui_str': 'CAV protocol'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0682897', 'cui_str': 'Flavor Enhancers'}, {'cui': 'C0700364', 'cui_str': 'Appearance'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0054889', 'cui_str': 'CAV protocol'}, {'cui': 'C0456170', 'cui_str': 'Left atrial pressure'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}, {'cui': 'C0429702', 'cui_str': 'Respiratory quotient'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}]",,0.309035,"Physiological responses (blood lactate, heart rate, oxygen consumption, respiratory exchange ratio and RPE) were also unaltered by CHO ingestion.","[{'ForeName': 'Gerard', 'Initials': 'G', 'LastName': 'McMahon', 'Affiliation': 'Sport & Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, Belfast BT37 0QB, UK.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Thornbury', 'Affiliation': 'Sport & Exercise Sciences Research Institute, School of Sport, Ulster University, Newtownabbey, Belfast BT37 0QB, UK.'}]",Nutrients,['10.3390/nu12082223'] 2451,32722609,Markers of Bone Health and Impact of Whey Protein Supplementation in Army Initial Entry Training Soldiers: A Double-Blind Placebo-Controlled Study.,"Training civilians to be soldiers is a challenging task often resulting in musculoskeletal injuries, especially bone stress injuries. This study evaluated bone health biomarkers (P1NP/CTX) and whey protein or carbohydrate supplementations before and after Army initial entry training (IET). Ninety male IET soldiers participated in this placebo-controlled, double-blind study assessing carbohydrate and whey protein supplementations. Age and fat mass predicted bone formation when controlling for ethnicity, explaining 44% ( p < 0.01) of bone formation variations. Age was the only significant predictor of bone resorption ( p = 0.02) when controlling for run, fat, and ethnicity, and these factors together explained 32% of the variance in bone resorption during week one ( p < 0.01). Vitamin D increased across training ( p < 0.01). There was no group by time interaction for supplementation and bone formation ( p = 0.75), resorption ( p = 0.73), Vitamin D ( p = 0.36), or calcium ( p = 0.64), indicating no influence of a supplementation on bone biomarkers across training. Age, fitness, fat mass, and ethnicity were important predictors of bone metabolism. The bone resorption/formation ratio suggests IET soldiers are at risk of stress injuries. Male IET soldiers are mildly to moderately deficient in vitamin D and slightly deficient in calcium throughout training. Whey protein or carbohydrate supplementations did not affect the markers of bone metabolism.",2020,"There was no group by time interaction for supplementation and bone formation ( p = 0.75), resorption ( p = 0.73), Vitamin D ( p = 0.36), or calcium ( p = 0.64), indicating no influence of a supplementation on bone biomarkers across training.","['Army Initial Entry Training Soldiers', 'Ninety male IET soldiers participated in this']","['Placebo', 'carbohydrate and whey protein supplementations', 'Whey Protein Supplementation', 'bone health biomarkers (P1NP/CTX) and whey protein or carbohydrate supplementations', 'placebo']","['Vitamin D', 'time interaction for supplementation and bone formation', 'bone resorption', 'resorption', 'markers of bone metabolism']","[{'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0524647', 'cui_str': 'Soldiers'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0078479', 'cui_str': 'Whey Proteins'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0556103', 'cui_str': 'Carbohydrate supplementation'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",90.0,0.0690509,"There was no group by time interaction for supplementation and bone formation ( p = 0.75), resorption ( p = 0.73), Vitamin D ( p = 0.36), or calcium ( p = 0.64), indicating no influence of a supplementation on bone biomarkers across training.","[{'ForeName': 'JoEllen M', 'Initials': 'JM', 'LastName': 'Sefton', 'Affiliation': 'Warrior Research Center, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Kaitlin D', 'Initials': 'KD', 'LastName': 'Lyons', 'Affiliation': 'Warrior Research Center, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Darren T', 'Initials': 'DT', 'LastName': 'Beck', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Cody T', 'Initials': 'CT', 'LastName': 'Haun', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Matthew A', 'Initials': 'MA', 'LastName': 'Romero', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Petey W', 'Initials': 'PW', 'LastName': 'Mumford', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Roberson', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Kaelin C', 'Initials': 'KC', 'LastName': 'Young', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Roberts', 'Affiliation': 'Molecular and Applied Sciences Laboratory, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}, {'ForeName': 'Jeremy S', 'Initials': 'JS', 'LastName': 'McAdam', 'Affiliation': 'Warrior Research Center, School of Kinesiology, 301 Wire Road, Auburn University, Auburn, AL 36849-5323, USA.'}]",Nutrients,['10.3390/nu12082225'] 2452,32722634,Effects of an Unstructured Free Play and Mindfulness Intervention on Wellbeing in Kindergarten Students.,"Play is known as the core occupation of young children as it lays a foundation for their early development and physical, emotional and social wellbeing. Literature suggests that unstructured free play and mindfulness interventions may independently promote wellbeing among preschoolers. However, there is no clear evidence of their combination in supporting wellness in early learning environments. We conducted a quasi-experimental study with 42 children aged four to six years, attending two kindergartens in Hong Kong. The intervention included unstructured play with non-directional loose parts (play materials), conducted outdoors for one hour daily followed by a mindfulness intervention for 10 min per day indoors. The intervention lasted for five consecutive days. We examined happiness and aspects of playfulness before and after the intervention, finding a significant increase in all areas. Given greater freedom in play choice, children showed more disruptive behaviors during unstructured play than the control group engaging in recess as usual. We conclude that unstructured play in addition to mindfulness intervention is effective in promoting students' happiness and playfulness, both of which may help maintain mental health and wellbeing amid stressors such as transition and separation. The increased disruptive behavior requires additional investigation.",2020,"Given greater freedom in play choice, children showed more disruptive behaviors during unstructured play than the control group engaging in recess as usual.","['Kindergarten Students', '42 children aged four to six years, attending two kindergartens in Hong Kong']","['Unstructured Free Play and Mindfulness Intervention', 'unstructured play with non-directional loose parts (play materials), conducted outdoors for one hour daily followed by a mindfulness intervention']",['disruptive behaviors'],"[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0019907', 'cui_str': 'Hong Kong'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205407', 'cui_str': 'Loose'}, {'cui': 'C0449719', 'cui_str': 'Part'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332282', 'cui_str': 'Following'}]","[{'cui': 'C0474416', 'cui_str': 'Disruptive behavior'}]",42.0,0.0184046,"Given greater freedom in play choice, children showed more disruptive behaviors during unstructured play than the control group engaging in recess as usual.","[{'ForeName': 'Regina Lai Tong', 'Initials': 'RLT', 'LastName': 'Lee', 'Affiliation': 'School of Nursing and Midwifery, Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Shelly Jerrine', 'Initials': 'SJ', 'LastName': 'Lane', 'Affiliation': 'College of Health and Human Sciences, Colorado State University, Fort Collins, CO 80526, USA.'}, {'ForeName': 'Anson Chiu Yan', 'Initials': 'ACY', 'LastName': 'Tang', 'Affiliation': 'School of Nursing, Tung Wah College, Hong Kong, China.'}, {'ForeName': 'Cynthia', 'Initials': 'C', 'LastName': 'Leung', 'Affiliation': 'Department of Social Sciences, The Hong Kong Polytechnic University, Hong Kong, China.'}, {'ForeName': 'Lobo Hung Tak', 'Initials': 'LHT', 'LastName': 'Louie', 'Affiliation': 'Department of Physical Education, Hong Kong Baptist University, Hong Kong, China.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Browne', 'Affiliation': 'School of Nursing and Midwifery, Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia.'}, {'ForeName': 'Sally Wai Chi', 'Initials': 'SWC', 'LastName': 'Chan', 'Affiliation': 'University of Newcastle Singapore Pte Limited, Singapore 038986, Singapore.'}]",International journal of environmental research and public health,['10.3390/ijerph17155382'] 2453,32722652,Weight Loss after 12 Weeks of Exercise and/or Nutritional Guidance Is Not Obligatory for Induced Changes in Local Fat/Lean Mass Indexes in Adults with Excess of Adiposity.,"The objectives of this secondary analysis are (1) to investigate the differential effects of exercise training modalities-high-intensity interval training (HIIT), resistance training (RT), combined training (CT = HIIT + RT), and/or nutritional guidance (NG) alone-on local fat/lean mass indexes in adults with excess of adiposity; (2) to identify the individual patterns of response based on either a clinical criterion of weight loss (≥5%) and/or technical error (TE) of measurement of local fat/lean mass indexes; and (3) to assess the individual change for body composition parameters assigned either to HIIT, RT, CT, and/or NG groups utilizing a TE. A 12-week trial was conducted in 55 participants randomized to one of the four interventions. The primary outcome was clinical change in body weight (i.e., weight loss of ≥5%). Secondary outcomes included change in ratio of android and gynoid fat mass, as well as local fat and lean mass indexes (arms, trunk, and legs), before and after intervention. The main findings from the current analysis revealed that (i) after 12 weeks of follow-up, significant decreases in several body composition indexes were found including body weight, arm, trunk, and legs fat mass, and android and gynecoid fat mass were observed in HIIT, RT, and CT groups ( p < 0.05); (ii) a significant proportion of individuals showed a positive response following 12 weeks of training, led by the HIIT group with 44% and followed by RT with 39% in 9 indexes; (iii) the HIIT group showed lowest rates of adverse responders with (6%); and (iv) the individual patterns of response utilizing clinically meaningful weight loss were not necessarily associated with the corresponding individual training-induced changes in body composition indexes in adults with excess of adiposity. Overall, the study suggests that HIIT has an important ability to reduce the prevalence of non-response to improve body composition indexes.",2020,"Secondary outcomes included change in ratio of android and gynoid fat mass, as well as local fat and lean mass indexes (arms, trunk, and legs), before and after intervention.","['adults with excess of adiposity; (2', '55 participants randomized to one of the four interventions', 'Adults with Excess of Adiposity']","['exercise training modalities-high-intensity interval training (HIIT), resistance training (RT), combined training (CT = HIIT + RT), and/or nutritional guidance (NG) alone-on local fat/lean mass indexes', 'Exercise']","['clinical change in body weight (i.e., weight loss of ≥5', 'Weight Loss', 'body composition indexes', 'several body composition indexes', 'change in ratio of android and gynoid fat mass, as well as local fat and lean mass indexes (arms, trunk, and legs', 'body weight, arm, trunk, and legs fat mass, and android and gynecoid fat mass', 'positive response']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",55.0,0.0345327,"Secondary outcomes included change in ratio of android and gynoid fat mass, as well as local fat and lean mass indexes (arms, trunk, and legs), before and after intervention.","[{'ForeName': 'Robinson', 'Initials': 'R', 'LastName': 'Ramírez-Vélez', 'Affiliation': 'Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Navarra, Spain.'}, {'ForeName': 'Mikel', 'Initials': 'M', 'LastName': 'Izquierdo', 'Affiliation': 'Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Navarra, Spain.'}, {'ForeName': 'Karem', 'Initials': 'K', 'LastName': 'Castro-Astudillo', 'Affiliation': 'Centro de Acondicionamiento Físico y Nutrición, KCFIT, Santiago de Cali, Valle 760011, Colombia.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Medrano-Mena', 'Affiliation': 'Facultad de Organización Deportiva, Universidad Autónoma de Nuevo León, Nuevo León 66455, Mexico.'}, {'ForeName': 'Angela Liliana', 'Initials': 'AL', 'LastName': 'Monroy-Díaz', 'Affiliation': 'Programa de Bacteriología y Laboratorio Clínico, Facultad de Ciencias de la Salud-Universidad de Boyacá, Tunja 150003, Boyacá, Colombia.'}, {'ForeName': 'Rocío Del Pilar', 'Initials': 'RDP', 'LastName': 'Castellanos-Vega', 'Affiliation': 'Grupo CORPS, Programa de Fisioterapia, Facultad de Ciencias de la Salud, Universidad de Boyacá, Tunja 150003, Boyacá, Colombia.'}, {'ForeName': 'Héctor Reynaldo', 'Initials': 'HR', 'LastName': 'Triana-Reina', 'Affiliation': 'Grupo GICAEDS, Programa de Cultura Física, Deporte y Recreación, Universidad Santo Tomás, Bogotá 110311, Colombia.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Correa-Rodríguez', 'Affiliation': 'Department of Nursing, University of Granada, 18016 Granada, Spain.'}]",Nutrients,['10.3390/nu12082231'] 2454,32722659,Cognitive and emotional empathy after stimulation of brain mineralocorticoid and NMDA receptors in patients with major depression and healthy controls.,"Mineralocorticoid receptors (MR) are predominantly expressed in the hippocampus and prefrontal cortex. Both brain areas are associated with social cognition, which includes cognitive empathy (ability to understand others' emotions) and emotional empathy (ability to empathize with another person). MR stimulation improves memory and executive functioning in patients with major depressive disorder (MDD) and healthy controls, and leads to glutamate-mediated N-methyl-D-aspartate receptor (NMDA-R) signaling. We examined whether the beneficial effects of MR stimulation can be extended to social cognition (empathy), and whether DCS would have additional beneficial effects. In this double-blind placebo-controlled single-dose study, we randomized 116 unmedicated MDD patients (mean age 34 years, 78% women) and 116 age-, sex-, and education years-matched healthy controls to four conditions: MR stimulation (fludrocortisone (0.4 mg) + placebo), NMDA-R stimulation (placebo + D-cycloserine (250 mg)), MR and NMDA-R stimulation (both drugs), or placebo. Cognitive and emotional empathy were assessed by the Multifaceted Empathy Test. The study was registered on clinicaltrials.gov (NCT03062150). MR stimulation increased cognitive empathy across groups, whereas NMDA-R stimulation decreased cognitive empathy in MDD patients only. Independent of receptor stimulation, cognitive empathy did not differ between groups. Emotional empathy was not affected by MR or NMDA-R stimulation. However, MDD patients showed decreased emotional empathy compared with controls but, according to exploratory analyses, only for positive emotions. We conclude that MR stimulation has beneficial effects on cognitive empathy in MDD patients and healthy controls, whereas NMDA-R stimulation decreased cognitive empathy in MDD patients. It appears that MR rather than NMDA-R are potential treatment targets to modulate cognitive empathy in MDD.",2020,"Independent of receptor stimulation, cognitive empathy did not differ between groups.","['patients with major depression and healthy controls', 'patients with major depressive disorder (MDD) and healthy controls', '116 unmedicated MDD patients (mean age 34 years, 78% women) and 116 age-, sex-, and education years-matched healthy controls to four conditions']","['MR stimulation', 'brain mineralocorticoid and NMDA receptors', 'MR stimulation (fludrocortisone (0.4\u2009mg)\u2009+\u2009placebo), NMDA-R stimulation (placebo\u2009+\u2009D-cycloserine (250\u2009mg)), MR and NMDA-R stimulation (both drugs), or placebo', 'NMDA-R stimulation', 'placebo']","['Cognitive and emotional empathy', 'cognitive empathy', 'emotional empathy', 'Emotional empathy', 'memory and executive functioning']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517541', 'cui_str': '116'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0066563', 'cui_str': 'Mineralocorticoid Receptor'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0026160', 'cui_str': 'Mineralocorticoid hormone'}, {'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}, {'cui': 'C0016280', 'cui_str': 'Fludrocortisone'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0010590', 'cui_str': 'Cycloserine'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]",116.0,0.0509834,"Independent of receptor stimulation, cognitive empathy did not differ between groups.","[{'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Nowacki', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Wingenfeld', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kaczmarczyk', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Woo Ri', 'Initials': 'WR', 'LastName': 'Chae', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Ikram', 'Initials': 'I', 'LastName': 'Abu-Tir', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Christian Eric', 'Initials': 'CE', 'LastName': 'Deuter', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Piber', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Hellmann-Regen', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Otte', 'Affiliation': 'Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany. christian.otte@charite.de.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0777-x'] 2455,32722661,Dose-response effects of d-amphetamine on effort-based decision-making and reinforcement learning.,"Effort-related decision-making and reward learning are both dopamine-dependent, but preclinical research suggests they depend on different dopamine signaling dynamics. Therefore, the same dose of a dopaminergic medication could have differential effects on effort for reward vs. reward learning. However, no study has tested how effort and reward learning respond to the same dopaminergic medication within subjects. The current study aimed to test the effect of therapeutic doses of d-amphetamine on effort for reward and reward learning in the same healthy volunteers. Participants (n = 30) completed the Effort Expenditure for Reward Task (EEfRT) measure of effort-related decision-making, and the Probabilistic Reward Task (PRT) measure of reward learning, under placebo and two doses of d-amphetamine (10 mg, and 20 mg). Secondarily, we examined whether the individual characteristics of baseline working memory and willingness to exert effort for reward moderated the effects of d-amphetamine. d-Amphetamine increased willingness to exert effort, particularly at low to intermediate expected values of reward. Computational modeling analyses suggested this was due to decreased effort discounting rather than probability discounting or decision consistency. Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward. In contrast, d-amphetamine had no significant effect on reward learning. These results have implications for treatment of neuropsychiatric disorders, which may be characterized by multiple underlying reward dysfunctions.",2020,"Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward.",['same healthy volunteers'],"['Effort Expenditure for Reward Task (EEfRT) measure of effort-related decision-making, and the Probabilistic Reward Task (PRT) measure of reward learning, under placebo and two doses of d-amphetamine', 'd-amphetamine', 'Amphetamine', 'amphetamine']","['reward and reward learning', 'reward learning']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0015316', 'cui_str': 'Expenditures'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0011812', 'cui_str': 'Dextroamphetamine'}, {'cui': 'C0002658', 'cui_str': 'Amphetamine'}]","[{'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",,0.0271128,"Both baseline effort and working memory emerged as moderators of this effect, such that d-amphetamine increased effort more in individuals with lower working memory and lower baseline effort, also primarily at low to intermediate expected values of reward.","[{'ForeName': 'Heather E', 'Initials': 'HE', 'LastName': 'Soder', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Jessica A', 'Initials': 'JA', 'LastName': 'Cooper', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Lopez-Gamundi', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Hoots', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Nunez', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA.'}, {'ForeName': 'Victoria M', 'Initials': 'VM', 'LastName': 'Lawlor', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Lane', 'Affiliation': 'Faillace Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Treadway', 'Affiliation': 'Department of Psychology, Emory University, Atlanta, GA, 30322, USA. mtreadway@emory.edu.'}, {'ForeName': 'Margaret C', 'Initials': 'MC', 'LastName': 'Wardle', 'Affiliation': 'Department of Psychology, University of Illinois at Chicago, Chicago, IL, USA. mwardle@uic.edu.'}]",Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,['10.1038/s41386-020-0779-8'] 2456,32722729,"NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder.","BACKGROUND NSI-189 phosphate (NSI-189) is a novel neurogenic molecule with pleiotropic properties, including antidepressant, procognitive, synaptoplastic, and neurotrophic activities demonstrated in preclinical studies. Its antidepressant activity is monoamine-independent. NSI-189 was previously tested in patients with recurrent major depressive disorder in an inpatient setting. METHODS This study involved 220 patients randomized to an NSI-189 40-mg dose, NSI-189 80-mg dose, or placebo daily for 12 weeks. The study utilized the sequential parallel comparison design, in which the drug effect was tested in 2 separate stages of 6 weeks each. Herein, post-hoc analyses of the data are presented. RESULTS NSI-189's antidepressant effect increased when the participants' initial baseline depression severity was dichotomized along a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 30. The NSI-189 80-mg dose showed significant benefit over placebo when utilizing the MADRS-6 (P = .046) in the subgroup of patients who were moderately depressed (MADRS < 30) but was not significant in patients who were severely depressed (MADRS ≥30). More pronounced procognitive effects were also observed in the moderate subgroup relative to the severe subgroup or the whole study group, in which 11/36 (31%), 5/36 (14%), or 7/36 (19%) of CogScreen variables significantly improved, respectively. CONCLUSIONS These results suggest that NSI-189 is effective as a safe adjunctive therapy, with most compelling antidepressant and procognitive benefits noted in patients with moderate depression.",2020,The NSI-189 80-mg dose showed significant benefit over placebo when utilizing the MADRS-6 (P = .046) in the subgroup of patients who were moderately depressed (MADRS < 30) but was not significant in patients who were severely depressed (MADRS ≥30).,"['220 patients randomized to an', 'patients with recurrent major depressive disorder in an inpatient setting', 'patients with moderate depression']","['NSI-189 40-mg dose, NSI-189 80-mg dose, or placebo', 'NSI-189 phosphate (NSI-189', 'NSI-189 phosphate', 'NSI-189', 'placebo']","['Montgomery-Åsberg Depression Rating Scale (MADRS) score', 'procognitive effects', 'initial baseline depression severity']","[{'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0154409', 'cui_str': 'Recurrent major depressive episodes'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0588007', 'cui_str': 'Moderate depression'}]","[{'cui': 'C4507670', 'cui_str': 'NSI-189'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4507671', 'cui_str': 'NSI-189 phosphate'}]","[{'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",220.0,0.0867314,The NSI-189 80-mg dose showed significant benefit over placebo when utilizing the MADRS-6 (P = .046) in the subgroup of patients who were moderately depressed (MADRS < 30) but was not significant in patients who were severely depressed (MADRS ≥30).,"[{'ForeName': 'Karl K', 'Initials': 'KK', 'LastName': 'Johe', 'Affiliation': ''}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Kay', 'Affiliation': ''}, {'ForeName': 'Santosh', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': ''}, {'ForeName': 'Katherine E', 'Initials': 'KE', 'LastName': 'Burdick', 'Affiliation': ''}, {'ForeName': 'Roger S', 'Initials': 'RS', 'LastName': 'McIntyre', 'Affiliation': ''}, {'ForeName': 'George I', 'Initials': 'GI', 'LastName': 'Papakostas', 'Affiliation': ''}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Fava', 'Affiliation': ''}]",Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists,[] 2457,32722776,"Spare Roof Technique Versus Component Dorsal Hump Reduction: A Randomized Prospective Study in 250 Primary Rhinoplasties, Aesthetic and Functional Outcomes.","BACKGROUND The majority of Caucasian aesthetic rhinoplasty patients complains about a noticeable hump in the profile view. Based on the integrity of the middle vault, there are two ways to dehump a nose: the structured technique and the preservation technique. OBJECTIVES We compared the aesthetical and functional outcomes of two techniques utilized for reduction rhinoplasty. METHODS We performed a prospective, randomized, interventional, and longitudinal study on 250 patients randomly divided into two groups: the component dorsal hump reduction group (CDRg) (n = 125) and the spare roof technique group (SRTg) (n = 125). We utilized the Utrecht Questionnaire for Outcome Assessment in Aesthetic Rhinoplasty. Patients answered the questionnaire before the surgery, and at 3 and 12 months after surgery. In addition, we utilized a Visual Analog Scale (VAS) to score nasal patency for each side. RESULTS Analyses of the preoperative and postoperative aesthetical VAS scores showed a significant improvement in both groups, from 3.66 to 7.00 (at 3 months) and to 7.35 (at 12 months) in CDRg, and from 3.81 to 8.14 (at 3 months) and to 8.45 (at 12 months) in SRTg. Analyses of postoperative means of aesthetic VAS scores showed a significant improvement in both groups over time. However, aesthetical improvement was higher in SRTg than CDRg, concerning 3 (P < .001) and 12 months (P < 0.001) postsurgery. Analyses of the mean functional VAS scores showed a significant improvement in both techniques, with a better result for SRTg. CONCLUSIONS The spare roof technique (SRT) is a reliable technique that can help deliver consistently better aesthetical and functional results in reduction rhinoplasty over component dorsal hump reduction CDR in Caucasian patients with dorsal hump.",2020,"However, aesthetical improvement was higher in SRTg than CDRg, concerning 3 (P < .001) and 12 months (P < 0.001) postsurgery.","['Caucasian patients with dorsal hump', '250 patients randomly divided into two groups: the', '250 Primary Rhinoplasties, Aesthetic and Functional Outcomes']","['Spare Roof Technique', 'Component Dorsal Hump Reduction', 'component dorsal hump reduction group (CDRg) (n = 125) and the spare roof technique group (SRTg']","['aesthetical improvement', 'mean functional VAS scores', 'preoperative and postoperative aesthetical VAS scores', 'Visual Analog Scale (VAS) to score nasal patency', 'aesthetic VAS scores']","[{'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0035467', 'cui_str': 'Rhinoplasty'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}]","[{'cui': 'C0557685', 'cui_str': 'Roof'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0014901', 'cui_str': 'Aesthetics'}]",250.0,0.0142415,"However, aesthetical improvement was higher in SRTg than CDRg, concerning 3 (P < .001) and 12 months (P < 0.001) postsurgery.","[{'ForeName': 'Miguel Gonçalves', 'Initials': 'MG', 'LastName': 'Ferreira', 'Affiliation': ''}, {'ForeName': 'Mariline', 'Initials': 'M', 'LastName': 'Santos', 'Affiliation': ''}, {'ForeName': 'Diogo Oliveira E', 'Initials': 'DOE', 'LastName': 'Carmo', 'Affiliation': ''}, {'ForeName': 'Aureliano', 'Initials': 'A', 'LastName': 'Fertuzinhos', 'Affiliation': ''}, {'ForeName': 'Cecília Almeida E', 'Initials': 'CAE', 'LastName': 'Sousa', 'Affiliation': ''}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Santos', 'Affiliation': ''}, {'ForeName': 'Nuno', 'Initials': 'N', 'LastName': 'Dourado', 'Affiliation': ''}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Amarante', 'Affiliation': ''}]",Aesthetic surgery journal,['10.1093/asj/sjaa221'] 2458,32722793,"A Double-Blind, Randomized Clinical Trial to Determine Effects of Increasing Doses and Dose-Response Relationship of IncobotulinumtoxinA in the Treatment of Glabellar Rhytids.","BACKGROUND IncobotulinumtoxinA is an effective neuromodulator for treating glabellar rhytids. The relationship between dose and reduction in rhytid severity is well established. However, effects of escalating doses on the treatment duration response are less understood. OBJECTIVE To assess effects of increasing doses of incobotulinumtoxinA on the treatment duration for glabellar rhytids. METHODS A randomized, double-blind, Phase IV study was conducted at a fully accredited, outpatient surgical facility. Subjects (31 female, 7 male) with moderate-to-severe glabellar rhytids were randomized to one of three incobotulinumtoxinA dose groups: 20, 60, or 100 units. Effect duration was determined by calculating the time to return to baseline for dynamic glabellar lines during maximal contraction. Follow-up was completed through 1 year, and adverse events were monitored. RESULTS The median duration of effect was 120 (95%-CI [90, 180]) days, 180 (95%-CI [180, 210]) days, and 270 (95% CI [240, 330]) days for the 20, 60, and 100 U groups respectively. A Wald chi-square test from the Cox regression on the primary efficacy variable indicated a statistically significant effect of dose group on time to baseline (Chi square = 54.63; df = 2; p < 0.001). Hazard ratios were HR = 0.21 (95%-CI = [0.10; 0.43] for 60 U vs. 20 U group, and HR = 0.06 (95%-CI [0.10; 0.43]) for 100-U vs 20 U group, indicating a statistically longer return to baseline for both 60 and 100 U cohorts. CONCLUSIONS There is a dose-dependent relationship between incobotulinumtoxinA and duration of effect in the glabella.",2020,(Chi square = 54.63; df = 2; p < 0.001).,"['Glabellar Rhytids', 'Subjects (31 female, 7 male) with moderate-to-severe glabellar rhytids']","['IncobotulinumtoxinA', 'incobotulinumtoxinA']","['median duration of effect', 'Hazard ratios']","[{'cui': 'C0442019', 'cui_str': 'Glabellar'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}]","[{'cui': 'C2930113', 'cui_str': 'IncobotulinumtoxinA'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.464909,(Chi square = 54.63; df = 2; p < 0.001).,"[{'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Polacco', 'Affiliation': ''}, {'ForeName': 'Adam E', 'Initials': 'AE', 'LastName': 'Singleton', 'Affiliation': ''}, {'ForeName': 'Christian H', 'Initials': 'CH', 'LastName': 'Barnes', 'Affiliation': ''}, {'ForeName': 'Conner', 'Initials': 'C', 'LastName': 'Maas', 'Affiliation': ''}, {'ForeName': 'Corey S', 'Initials': 'CS', 'LastName': 'Maas', 'Affiliation': ''}]",Aesthetic surgery journal,['10.1093/asj/sjaa220'] 2459,32722799,Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.,"Importance Large amounts of optical coherence tomographic (OCT) data of diabetic macular edema (DME) are acquired, but many morphologic features have yet to be identified and quantified. Objective To examine the volumetric change of intraretinal fluid (IRF) and subretinal fluid (SRF) in DME during anti-vascular endothelial growth factor treatment using deep learning algorithms. Design, Setting, and Participants This post hoc analysis of a randomized clinical trial, the Diabetic Retinopathy Clinical Research Network (protocol T), assessed 6945 spectral-domain OCT volume scans of 570 eyes from 570 study participants with DME. The original trial was performed from August 21, 2012, to October 18, 2018. This analysis was performed from December 7, 2017, to January 15, 2020. Interventions Participants were treated according to a predefined, standardized protocol with aflibercept, ranibizumab, or bevacizumab with or without deferred laser. Main Outcomes and Measures The association of treatment with IRF and SRF volumes and best-corrected visual acuity (BCVA) during 12 months using deep learning algorithms. Results Among the 570 study participants (302 [53%] male; 369 [65%] white; mean [SD] age, 43.4 [12.6] years), the mean fluid volumes in the central 3 mm were 448.6 nL (95% CI, 412.3-485.0 nL) of IRF and 36.9 nL (95% CI, 27.0-46.7 nL) of SRF at baseline and 161.2 nL (95% CI, 135.1-187.4 nL) of IRF and 4.4 nL (95% CI, 1.7-7.1 nL) of SRF at 12 months. The presence of SRF at baseline was associated with a worse baseline BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) score of 63.2 (95% CI, 60.2-66.1) (approximate Snellen equivalent of 20/63 [95% CI, 20/50-20/63]) in eyes with SRF vs 66.9 (95% CI, 65.7-68.1) (approximate Snellen equivalent, 20/50 [95% CI, 20/40-20/50]) without SRF (P < .001) and a greater gain in ETDRS score (0.5; 95% CI, 0.3-0.8) every 4 weeks during follow-up in eyes with SRF at baseline vs 0.4 (95% CI, 0.3-0.5) in eyes without SRF at baseline (P = .02) when adjusted for baseline BCVA. Aflibercept was associated with greater reduction of IRF volume compared with bevacizumab after the first injection (difference, 79.8 nL; 95% CI, 5.3-162.5 nL; P < .001) and every 4 weeks thereafter (difference, 10.4 nL; 95% CI, 0.7-20.0 nL; P = .004). Ranibizumab was associated with a greater reduction of IRF after the first injection compared with bevacizumab (difference, 75.2 nL; 95% CI, 1.4-154.7 nL; P < .001). Conclusions and Relevance Automated segmentation of fluid in DME revealed that the presence of SRF was associated with lower baseline BCVA but with good response to anti-vascular endothelial growth factor therapy. These automated spectral-domain OCT analyses may be used clinically to assess anatomical change during therapy. Trial Registration ClinicalTrials.gov Identifier: NCT01627249.",2020,"Aflibercept was associated with greater reduction of IRF volume compared with bevacizumab after the first injection (difference, 79.8 nL; 95% CI, 5.3-162.5 nL; P < .001) and every 4 weeks thereafter (difference, 10.4 nL; 95% CI, 0.7-20.0 nL; P = .004).","['August 21, 2012, to October 18, 2018', 'diabetic macular edema (DME', '570 study participants (302 [53%] male; 369 [65%] white; mean [SD] age, 43.4 [12.6] years), the mean fluid volumes in the central 3 mm were 448.6 nL (95% CI, 412.3-485.0 nL) of IRF and 36.9 nL (95% CI, 27.0-46.7 nL) of SRF at baseline and 161.2 nL (95% CI, 135.1-187.4 nL) of IRF and 4.4 nL (95% CI, 1.7-7.1 nL) of SRF at 12 months', '570 eyes from 570 study participants with DME', 'December 7, 2017, to January 15, 2020', 'Patients With Diabetic Macular Edema Using Deep Learning']","['Fluid Resolution and Visual Acuity Gain', 'optical coherence tomographic (OCT) data', 'Aflibercept', 'intraretinal fluid (IRF) and subretinal fluid (SRF', 'Ranibizumab', 'BCVA', 'aflibercept, ranibizumab, or bevacizumab with or without deferred laser', 'bevacizumab']","['IRF volume', 'greater gain in ETDRS score', 'association of treatment with IRF and SRF volumes and best-corrected visual acuity ', 'IRF', 'baseline BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) score']","[{'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517545', 'cui_str': '12.6'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449971', 'cui_str': 'Volume of fluid used'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4531067', 'cui_str': 'Intraretinal fluid'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C4517512', 'cui_str': '1.7'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4704761', 'cui_str': 'Hierarchical Learning'}]","[{'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C4531067', 'cui_str': 'Intraretinal fluid'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}]","[{'cui': 'C4531067', 'cui_str': 'Intraretinal fluid'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}]",570.0,0.60231,"Aflibercept was associated with greater reduction of IRF volume compared with bevacizumab after the first injection (difference, 79.8 nL; 95% CI, 5.3-162.5 nL; P < .001) and every 4 weeks thereafter (difference, 10.4 nL; 95% CI, 0.7-20.0 nL; P = .004).","[{'ForeName': 'Philipp K', 'Initials': 'PK', 'LastName': 'Roberts', 'Affiliation': 'Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Wolf-Dieter', 'Initials': 'WD', 'LastName': 'Vogl', 'Affiliation': 'Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Bianca S', 'Initials': 'BS', 'LastName': 'Gerendas', 'Affiliation': 'Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Adam R', 'Initials': 'AR', 'LastName': 'Glassman', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Hrvoje', 'Initials': 'H', 'LastName': 'Bogunovic', 'Affiliation': 'Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Jampol', 'Affiliation': 'Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': 'Ursula M', 'Initials': 'UM', 'LastName': 'Schmidt-Erfurth', 'Affiliation': 'Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.'}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2020.2457'] 2460,32722801,Intensive versus standard blood pressure control and vascular procedures: Insights from the Systolic Blood Pressure Intervention Trial (SPRINT).,,2020,,[],['Intensive versus standard blood pressure control and vascular procedures'],[],[],"[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0025664', 'cui_str': 'methods'}]",[],,0.0251511,,"[{'ForeName': 'Maria Lukács', 'Initials': 'ML', 'LastName': 'Krogager', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Manan', 'Initials': 'M', 'LastName': 'Pareek', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Kristian Hay', 'Initials': 'KH', 'LastName': 'Kragholm', 'Affiliation': 'Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Byrne', 'Affiliation': 'Department of Cardiology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Muthiah', 'Initials': 'M', 'LastName': 'Vaduganathan', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Tor', 'Initials': 'T', 'LastName': 'Biering-Sørensen', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Rujic', 'Affiliation': 'Department of Cardiology, Herlev and Gentofte Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Thomas Bastholm', 'Initials': 'TB', 'LastName': 'Olesen', 'Affiliation': 'Department of Internal Medicine, Hospital of Little Belt, Kolding, Denmark.'}, {'ForeName': 'Michael Hecht', 'Initials': 'MH', 'LastName': 'Olsen', 'Affiliation': 'Holbæk Hospital, Division of Cardiology, Department of Internal Medicine, Holbæk, Denmark.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.""}]",European heart journal. Cardiovascular pharmacotherapy,['10.1093/ehjcvp/pvaa093'] 2461,32722823,Term Labor Induction and Cesarean Delivery Risk among Obese Women with and without Comorbidities.,"OBJECTIVE Findings of the recent ARRIVE (A Randomized Trial of Induction Versus Expectant Management) trial, showing reduced cesarean risk with elective labor induction among low-risk nulliparous women at 39 weeks' gestation, have the potential to change interventional delivery practices but require examination in wider populations. The aim of this study was to identify whether term induction of labor was associated with reduced cesarean delivery risk among women with obesity, evaluating several maternal characteristics associated with obesity, induction, and cesarean risk. STUDY DESIGN We studied administrative records for 66,280 singleton, term births to women with a body mass index ≥30, without a prior cesarean delivery, in New York City from 2008 to 2013. We examined elective inductions in 39 and 40 weeks' gestation and calculated adjusted risk ratios for cesarean delivery risk, stratified by parity and maternal age. We additionally evaluated medically indicated inductions at 37 to 40 weeks among women with obesity and diabetic or hypertensive disorders, comorbidities that are strongly associated with obesity. RESULTS Elective induction of labor was associated with a 25% (95% confidence interval: 19-30%) lower adjusted risk of cesarean delivery as compared with expectant management at 39 weeks of gestation and no change in risk at 40 weeks. Patterns were similar when stratified by parity and maternal age. Risk reductions in week 39 were largest among women with a prior vaginal delivery. Women with comorbidities had reduced cesarean risk with early term induction and in 39 weeks. CONCLUSION Labor induction at 39 weeks was consistently associated with reduced risk of cesarean delivery among women with obesity regardless of parity, age, or comorbidity status. Cesarean delivery findings from induction trials at 39 weeks among low-risk nulliparous women may generalize more broadly across the U.S. obstetric population, with potentially larger benefit among women with a prior vaginal delivery. KEY POINTS · We found reduced cesarean risk with induction at 39 weeks.. · Results were consistent for age and comorbidity subgroups.. · Risk reductions were largest among multiparous women..",2020,"Labor induction at 39 weeks was consistently associated with reduced risk of cesarean delivery among women with obesity regardless of parity, age, or comorbidity status.","['women with a prior vaginal delivery', '66,280 singleton, term births to women with a body mass index ≥30, without a prior cesarean delivery, in New York City from 2008 to 2013', ""low-risk nulliparous women at 39 weeks' gestation"", 'women with obesity, evaluating several maternal characteristics associated with obesity, induction, and cesarean risk', 'low-risk nulliparous women', 'women with obesity and diabetic or hypertensive disorders, comorbidities that are strongly associated with obesity', 'Obese Women with and without Comorbidities']",[],"['reduced risk of cesarean delivery', 'Term Labor Induction and Cesarean Delivery Risk', 'cesarean risk', 'adjusted risk of cesarean delivery', 'Risk reductions']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0566690', 'cui_str': 'Vaginal delivery'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0027977', 'cui_str': 'New York City'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0425979', 'cui_str': 'Nulliparous'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}]",[],"[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0259787', 'cui_str': 'Induction of labor'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}]",,0.190463,"Labor induction at 39 weeks was consistently associated with reduced risk of cesarean delivery among women with obesity regardless of parity, age, or comorbidity status.","[{'ForeName': 'Kimberly B', 'Initials': 'KB', 'LastName': 'Glazer', 'Affiliation': 'Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Valery A', 'Initials': 'VA', 'LastName': 'Danilack', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Alison E', 'Initials': 'AE', 'LastName': 'Field', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'Erika F', 'Initials': 'EF', 'LastName': 'Werner', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Savitz', 'Affiliation': 'Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island.'}]",American journal of perinatology,['10.1055/s-0040-1714422'] 2462,32722919,Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial.,"AIMS To evaluate the effect of linagliptin on left ventricular systolic function beyond glycaemic control in type 2 diabetes mellitus. METHODS AND RESULTS A multicentre, randomised, double-blind, placebo controlled, parallel-group study, was performed (the DYDA 2 trial). Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function were randomly allocated in a 1:1 ratio to receive for 48 weeks either linagliptin 5 mg daily or placebo, in addition to their diabetes therapy. Eligibility criteria were age 40 years and older, haemoglobin A1c 8.0% or less (≤64 mmol/mol), no history of cardiac disease, concentric left ventricular geometry (relative wall thickness ≥0.42), impaired left ventricular systolic function defined as midwall fractional shortening 15% or less at baseline echocardiography. The primary end point was the modification of midwall fractional shortening over time. The main secondary objectives were changes in diastolic and/or in longitudinal left ventricular systolic function as measured by tissue Doppler echocardiography. One hundred and eighty-eight patients were enrolled, predominantly men with typical insulin-resistance comorbidities. At baseline, mean midwall fractional shortening was 13.3%±2.5. At final evaluation, 88 linagliptin patients and 86 placebo patients were compared: midwall fractional shortening increased from 13.29 to 13.82 (+4.1%) in the linagliptin group, from 13.58 to 13.84 in the placebo group (+1.8%, analysis of covariance P  = 0.86), corresponding to a 2.3-fold higher increase in linagliptin than the placebo group, although non-statistically significant. Also, changes in diastolic and longitudinal left ventricular systolic function did not differ between the groups. Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. CONCLUSIONS In the DYDA 2 patients the addition of linagliptin to stable diabetes therapy was safe and provided a modest non-significant increase in left ventricular systolic function measured as midwall fractional shortening. Trial registration number: ClinicalTrial.gov (ID NCT02851745).",2020,"Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. ","['patients with type 2 DiAbetes and concentric left ventricular geometry', 'One hundred and eighty-eight patients were enrolled, predominantly men with typical insulin-resistance comorbidities', 'type 2 diabetes mellitus', 'Eligibility criteria were age 40 years and older, haemoglobin A1c 8.0% or less (≤64 mmol/mol), no history of cardiac disease, concentric left ventricular geometry (relative wall thickness', 'Individuals with type 2 diabetes mellitus and asymptomatic impaired left ventricular systolic function']","['placebo', 'linagliptin 5\u2009mg daily or placebo', 'linagliptin/placebo', 'linagliptin']","['left ventricular DYsfunction', 'changes in diastolic and longitudinal left ventricular systolic function', 'modification of midwall fractional shortening over time', 'mean midwall fractional shortening', 'impaired left ventricular systolic function', 'midwall fractional shortening', 'changes in diastolic and/or in longitudinal left ventricular systolic function as measured by tissue Doppler echocardiography', 'left ventricular systolic function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0449829', 'cui_str': 'Geometry'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0332122', 'cui_str': 'No history of'}, {'cui': 'C0018799', 'cui_str': 'Heart disease'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0031843', 'cui_str': 'PH'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C3153993', 'cui_str': 'Linagliptin 5 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2746078', 'cui_str': 'Linagliptin'}]","[{'cui': 'C0242698', 'cui_str': 'Impaired left ventricular function'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0013520', 'cui_str': 'Doppler Echocardiography'}, {'cui': 'C0205091', 'cui_str': 'Left'}]",188.0,0.184505,"Serious adverse events or linagliptin/placebo permanent discontinuation occurred in very few cases and in the same percentage between the groups. ","[{'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Cioffi', 'Affiliation': 'Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona, Italy.'}, {'ForeName': 'Carlo Bruno', 'Initials': 'CB', 'LastName': 'Giorda', 'Affiliation': 'Metabolism and Diabetes Unit, ASL Torino 5, Italy.'}, {'ForeName': 'Donata', 'Initials': 'D', 'LastName': 'Lucci', 'Affiliation': 'ANMCO Research Center, Heart Care Foundation, Italy.'}, {'ForeName': 'Elisa', 'Initials': 'E', 'LastName': 'Nada', 'Affiliation': 'Metabolism and Diabetes Unit, ASL Torino 5, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Ognibeni', 'Affiliation': 'Division of Rheumatology, University and Azienda Ospedaliera Universitaria Integrata of Verona, Italy.'}, {'ForeName': 'Costantino', 'Initials': 'C', 'LastName': 'Mancusi', 'Affiliation': 'Hypertension Research Center, Federico II University, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Latini', 'Affiliation': 'Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche ""Mario Negri"", Italy.'}, {'ForeName': 'Aldo P', 'Initials': 'AP', 'LastName': 'Maggioni', 'Affiliation': 'ANMCO Research Center, Heart Care Foundation, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of preventive cardiology,['10.1177/2047487320939217'] 2463,32722925,Intradialytic exercise with blood flow restriction is more effective than conventional exercise in improving walking endurance in hemodialysis patients: Response to comments on a randomized control trial.,,2020,,['hemodialysis patients'],"['conventional exercise', 'Intradialytic exercise with blood flow restriction']",['walking endurance'],"[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}]",,0.0179709,,"[{'ForeName': 'Maristela', 'Initials': 'M', 'LastName': 'Bohlke', 'Affiliation': 'Dialysis and Renal Transplantation Unit, São Francisco de Paula University Hospital, Catholic University of Pelotas, Pelotas, Brazil.'}, {'ForeName': 'Rodrigo Kohn', 'Initials': 'RK', 'LastName': 'Cardoso', 'Affiliation': 'Postgraduate Program of Physical Education, Federal University of Pelotas, Pelotas, RS, Brazil.'}, {'ForeName': 'Aline Machado', 'Initials': 'AM', 'LastName': 'Araujo', 'Affiliation': 'Postgraduate Program of Physical Education, Federal University of Pelotas, Pelotas, RS, Brazil.'}, {'ForeName': 'Airton José', 'Initials': 'AJ', 'LastName': 'Rombaldi', 'Affiliation': 'Postgraduate Program of Physical Education, Federal University of Pelotas, Pelotas, RS, Brazil.'}]",Clinical rehabilitation,['10.1177/0269215520945659'] 2464,32722931,"Comparison between Fundus Automated Perimetry and Humphrey Field Analyzer: Performance and usability of the Fundus Automated Perimetry and Humphrey Field Analyzer in healthy, ocular hypertensive, and glaucomatous patients.","PURPOSE We compared the performance and usability of the Fundus Automated Perimetry (FAP) and Humphrey Field Analyzer (HFA) in patients with glaucoma, ocular hypertension, and healthy subjects. MATERIALS AND METHODS A total of 60 participants, divided in three groups of 20, glaucoma (POAG), ocular hypertension (OHT), and controls group, underwent a HFA test 24-2 SITA standard and a FAP test 24-2 ZEST sequence, in randomized order. The mean differences between perimeters of mean deviation (MD), pattern standard deviation (PSD) were correlated using the t -test and the Bland-Altman plot while execution time, Glaucoma Staging System 2 (GSS2), Hodapp-Parrish-Anderson staging system, localization of the defect, false positives (FP), and false negatives (FN) were compared with t -test analysis. Usability was measured through answers of a dedicated questionnaire. RESULTS MD's difference was higher for FAP than HFA: OHT -2.20 ± 1.33 dB ( p  < 0.001), POAG -2.00 ± 1.66 dB ( p  < 0.001), and controls -1.08 ± 1.43 dB ( p  < 0.001). PSD's difference was higher for FAP than HFA: OHT 0.85 ± 1.16 dB ( p  < 0.001), POAG 0.78 ± 2.32 dB ( p  = 0.043), and controls 0.49 ± 1.15 dB ( p  < 0.001). GSS2's difference showed that FAP found more severe defects than HFA. Exams duration was longer for FAP versus HFA: in OHT 363 s versus 301 s, in POAG 494 s versus 362 s, and in controls 360 s versus 277 s. For FN and FP, there were no statistically significant differences. The 77% of all subjects preferred FAP to HFA test. CONCLUSION Considering MD and GSS2 classification, FAP finds more severe defects. Moreover, although FAP duration is longer, this method is preferred by most of the patients.",2020,"Exams duration was longer for FAP versus HFA: in OHT 363 s versus 301 s, in POAG 494 s versus 362 s, and in controls 360 s versus 277 s. For FN and FP, there were no statistically significant differences.","['healthy, ocular hypertensive, and glaucomatous patients', '60 participants, divided in three groups of 20, glaucoma (POAG), ocular hypertension (OHT), and controls group, underwent a', 'patients with glaucoma, ocular hypertension, and healthy subjects']","['Fundus Automated Perimetry and Humphrey Field Analyzer', 'Fundus Automated Perimetry (FAP) and Humphrey Field Analyzer (HFA', 'HFA test 24-2 SITA standard and a FAP test 24-2 ZEST sequence', 'FAP', 'HFA', 'dB ']","['execution time, Glaucoma Staging System 2 (GSS2), Hodapp-Parrish-Anderson staging system, localization of the defect, false positives (FP), and false negatives (FN', 'mean deviation (MD), pattern standard deviation (PSD', 'Usability', 'Exams duration']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0028840', 'cui_str': 'Ocular hypertension'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0016823', 'cui_str': 'Structure of fundus of eye'}, {'cui': 'C4760939', 'cui_str': 'Automated perimetry'}, {'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0179038', 'cui_str': 'Analyzer'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}]","[{'cui': 'C1278561', 'cui_str': 'Judicial execution'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0449394', 'cui_str': 'Staging system'}, {'cui': 'C0037710', 'cui_str': 'Auditory localization'}, {'cui': 'C0243067', 'cui_str': 'defects'}, {'cui': 'C0205557', 'cui_str': 'False positive'}, {'cui': 'C0205558', 'cui_str': 'False negative'}, {'cui': 'C1828170', 'cui_str': 'Mean deviation'}, {'cui': 'C1720055', 'cui_str': 'Pattern standard deviation'}, {'cui': 'C0582103', 'cui_str': 'Medical assessment'}, {'cui': 'C0449238', 'cui_str': 'Duration'}]",60.0,0.0281914,"Exams duration was longer for FAP versus HFA: in OHT 363 s versus 301 s, in POAG 494 s versus 362 s, and in controls 360 s versus 277 s. For FN and FP, there were no statistically significant differences.","[{'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Morbio', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Longo', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}, {'ForeName': 'Antonia Maria Luce', 'Initials': 'AML', 'LastName': 'De Vitto', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Comacchio', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}, {'ForeName': 'Lucia Barbara', 'Initials': 'LB', 'LastName': 'Della Porta', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Marchini', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, Eye Clinic, University of Verona, Verona, Italy.'}]",European journal of ophthalmology,['10.1177/1120672120945052'] 2465,32722930,Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.,"AIM We examined eligibility and preventable cardiovascular disease events in US adults with diabetes mellitus from the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). METHODS We identified adults with diabetes mellitus eligible for EMPA-REG OUTCOME based on trial eligibility criteria available from the National Health and Nutrition Examination Surveys, 2007-2016. We estimated composite cardiovascular disease endpoints, as well as all-cause deaths, death from cardiovascular disease and hospitalizations for heart failure from trial treatment and placebo event rates, the difference indicating the preventable events. RESULTS Among 29,629 US adults aged ⩾18 years (representing 231.9 million), 4672 (27.3 million) had diabetes mellitus, with 342 (1.86 million) meeting eligibility criteria of EMPA-REG OUTCOME. We estimated from trial primary endpoint event rates of 10.5% and 12.1% in the empagliflozin and placebo groups, respectively, that based on the 'treatment' of our 1.86 million estimated EMPA-REG OUTCOME eligible subjects, 12,066 (95% confidence interval: 10,352-13,780) cardiovascular disease events could be prevented annually. Estimated annual preventable deaths from any cause, cardiovascular causes and hospitalizations from heart failure were 17,078 (95% confidence interval: 14,652-19,504), 14,479 (95% confidence interval: 12,422-16,536) and 9467 (95% confidence interval: 8122-10,812), respectively. CONCLUSION Empagliflozin, if provided to EMPA-REG OUTCOME eligible US adults, may prevent many cardiovascular disease events, cardiovascular and total deaths, as well as heart failure hospitalizations.",2020,"We estimated composite cardiovascular disease endpoints, as well as all-cause deaths, death from cardiovascular disease and hospitalizations for heart failure from trial treatment and placebo event rates, the difference indicating the preventable events. ","['adults with diabetes mellitus eligible for EMPA-REG OUTCOME based on trial eligibility criteria available from the National Health and Nutrition Examination Surveys, 2007-2016', 'US adults with diabetes mellitus', 'Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME', '29,629 US adults aged ⩾18\u2009years (representing 231.9\u2009million), 4672 (27.3\u2009million']","['Empagliflozin', 'empagliflozin', 'placebo']","['preventable events', 'cardiovascular disease events', 'deaths, death from cardiovascular disease and hospitalizations for heart failure', 'diabetes mellitus']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0208940', 'cui_str': 'REG1A protein, human'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0376344', 'cui_str': 'NHANES'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1881839', 'cui_str': '1000000'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1547273', 'cui_str': 'Preventable'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]",,0.30169,"We estimated composite cardiovascular disease endpoints, as well as all-cause deaths, death from cardiovascular disease and hospitalizations for heart failure from trial treatment and placebo event rates, the difference indicating the preventable events. ","[{'ForeName': 'Nathan D', 'Initials': 'ND', 'LastName': 'Wong', 'Affiliation': 'Heart Disease Prevention Program, University of California-Irvine, Irvine, CA, USA.'}, {'ForeName': 'Wenjun', 'Initials': 'W', 'LastName': 'Fan', 'Affiliation': 'Heart Disease Prevention Program, University of California-Irvine, Irvine, CA, USA.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Pak', 'Affiliation': 'Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.'}]",Diabetes & vascular disease research,['10.1177/1479164120945674'] 2466,32722939,Efficacy of omega-3 fatty acids and punctal plugs in the prevention of isotretinoin-associated ocular surface disease.,"PURPOSE To investigate the effects of omega-3 fatty acids and punctal plugs on tear film and ocular surface parameters in patients receiving systemic isotretinoin therapy. METHODS This is a prospective randomized study that included 180 eyes of 90 patients who had systemic isotretinoin therapy (120-150 mg/kg for at least 4-6 months). Exclusion criteria: DED according to the diagnostic criteria of TFOS DEWS II. Patients were assigned into three groups; (1) O3FAs/PPs group: A soft preloaded silicone plug was inserted in the inferior punctum of both eyes and received oral O3FAs two capsules twice daily total daily dose of 1040 mg/day for 6 months. (2) PPs group: A soft preloaded silicone plug was inserted in the inferior punctum of both eyes and received oral placebo. (3) Isotretinoin group: No intervention was done. At baseline, 1 week, 1, 3, and 6 months of study, Ocular surface evaluation tests were done in following order: OSDI, tear osmolarity, Schirmer's I test, TBUT, ocular surface staining score, and meibomian gland expression. PRIMARY OUTCOME MEASURES The changes in measurement of ocular surface evaluation tests including ocular surface disease index (OSDI), tear film breakup time (TFBUT), corneal staining, tear osmolarity, and meibomian gland expression at 6 months. RESULTS There are significant changes between all groups at 6 months follow-up. The ocular surface parameters were better for the PPs and O3FAs/PPs groups than the isotretinoin group. The isotretinoin group showed worsening of ocular surface parameters including a significant decrease of FTBUT and an increase of OSDI score, corneal staining score, tear osmolarity, and meibomian expression score. There was no significant difference in ST1 throughout the whole study in all groups. At 6 months follow-up, there were no statistically significant differences between PPs and O3FAs/PPs groups except meibomian expression score which showed a significant increase in PPs group. CONCLUSION Our cohort highlights the beneficial effects of the combination of O3FAs supplementation with PPs in the prevention of isotretinoin-associated OSD in this sample study.",2020,"The isotretinoin group showed worsening of ocular surface parameters including a significant decrease of FTBUT and an increase of OSDI score, corneal staining score, tear osmolarity, and meibomian expression score.","['included 180 eyes of 90 patients who had systemic isotretinoin therapy (120-150\u2009mg/kg for at least 4-6\u2009months', 'patients receiving systemic isotretinoin therapy', 'Isotretinoin group']","['omega-3 fatty acids and punctal plugs', 'O3FAs supplementation with PPs', 'oral placebo', 'O3FAs/PPs group: A soft preloaded silicone plug', 'soft preloaded silicone plug']","['ST1', 'ocular surface parameters', ""OSDI, tear osmolarity, Schirmer's I test, TBUT, ocular surface staining score, and meibomian gland expression"", 'meibomian expression score', 'OSDI score, corneal staining score, tear osmolarity, and meibomian expression score', 'ocular surface disease index (OSDI), tear film breakup time (TFBUT), corneal staining, tear osmolarity, and meibomian gland expression', 'worsening of ocular surface parameters']","[{'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C4510271', 'cui_str': 'Isotretinoin therapy'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0022265', 'cui_str': 'Isotretinoin'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C1533108', 'cui_str': 'Punctal plug'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0265259', 'cui_str': 'Popliteal pterygium syndrome'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0580928', 'cui_str': 'Silicone plug'}]","[{'cui': 'C0450498', 'cui_str': 'ST1'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0205148', 'cui_str': 'Surface'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C0029387', 'cui_str': 'Osmolarity'}, {'cui': 'C1301514', 'cui_str': 'Schirmer I test'}, {'cui': 'C0038128', 'cui_str': 'Stain'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025181', 'cui_str': 'Structure of meibomian gland'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0423232', 'cui_str': 'Corneal epithelial staining pattern'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332271', 'cui_str': 'Worsening'}]",,0.0245574,"The isotretinoin group showed worsening of ocular surface parameters including a significant decrease of FTBUT and an increase of OSDI score, corneal staining score, tear osmolarity, and meibomian expression score.","[{'ForeName': 'Tarek Roshdy', 'Initials': 'TR', 'LastName': 'Elhamaky', 'Affiliation': 'Department of Ophthalmology, Faculty of Medicine, Benha University, Benha, Egypt.'}]",European journal of ophthalmology,['10.1177/1120672120945655'] 2467,32722941,Intradialytic exercise with blood flow restriction is more effective than conventional exercise in improving walking endurance in hemodialysis patients: comments on a randomized control trial.,,2020,,['hemodialysis patients'],"['conventional exercise', 'Intradialytic exercise with blood flow restriction']",['walking endurance'],"[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]","[{'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}]",,0.0184829,,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Clarkson', 'Affiliation': 'Institute of Physical Activity and Nutrition, School of exercise and nutrition sciences, Deakin University, Geelong, Victoria, Australia.'}, {'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Bennett', 'Affiliation': 'Medical & Clinical Affairs, Satellite Healthcare, San Jose, CA, USA.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'Warmington', 'Affiliation': 'Institute of Physical Activity and Nutrition, School of exercise and nutrition sciences, Deakin University, Geelong, Victoria, Australia.'}]",Clinical rehabilitation,['10.1177/0269215520945660'] 2468,32722955,"Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.","Purpose: The purpose of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of diabetic macular edema (DME) in a long-term follow-up. Methods: Participants in this prospective study were 112 treatment naïve patients with DME, who received treatment with either intravitreal ranibizumab (n = 54) or aflibercept (n = 58). The demographic data, the best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at month 1,2,3,6,12 and 18 post treatment, while factors affecting visual outcome were determined using multivariate analysis. Results : At month 18, the mean BCVA of ranibizumab-treated eyes increased 7.9 letters compared to 6.9 letters for eyes receiving aflibercept, with greater number of injections in ranibizumab group (9.2 ± 2.3 vs. 7.6 ± 2.1 injections in the ranibizumab and aflibercept group respectively, p = 0.0002). The difference in letters between the two groups was not statistically significant, nor the difference in central subfield thickness at month 18. Factors associated with poorer BCVA were found to be increasing age, HbA1c ≥7.5%, increasing central retinal thickness and disrupted ellipsoid zone. Conclusions: Ranibizumab and aflibercept presented similar anatomical and functional outcomes in 18-month follow-up in patients with DME. It is important to determine factors, affecting VA, so as to provide individualized treatment.",2020,"The difference in letters between the two groups was not statistically significant, nor the difference in central subfield thickness at month 18.","['were 112 treatment naïve patients with DME', 'diabetic macular edema (DME', 'patients with DME', 'diabetic macular edema']","['aflibercept', 'ranibizumab and aflibercept', 'Ranibizumab', 'ranibizumab versus aflibercept', 'intravitreal ranibizumab', 'Ranibizumab and aflibercept', 'ranibizumab']","['mean BCVA', 'spectral-domain optical coherence tomography (SD-OCT) characteristics', 'central subfield thickness', 'central retinal thickness']","[{'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0058217', 'cui_str': 'dimethyl ether'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}]","[{'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}]",112.0,0.0525292,"The difference in letters between the two groups was not statistically significant, nor the difference in central subfield thickness at month 18.","[{'ForeName': 'Alexandros', 'Initials': 'A', 'LastName': 'Chatzirallis', 'Affiliation': '2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Theodossiadis', 'Affiliation': '2nd Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Konstantinos', 'Initials': 'K', 'LastName': 'Droutsas', 'Affiliation': '1st Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Chryssanthi', 'Initials': 'C', 'LastName': 'Koutsandrea', 'Affiliation': '1st Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Ioannis', 'Initials': 'I', 'LastName': 'Ladas', 'Affiliation': '1st Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Marilita M', 'Initials': 'MM', 'LastName': 'Moschos', 'Affiliation': '1st Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.'}]",Cutaneous and ocular toxicology,['10.1080/15569527.2020.1802741'] 2469,32722956,Anti-inflammatory and antioxidative effects of thiamin supplements in patients with gestational diabetes mellitus.,"OBJECTIVE The aim of this study was to evaluate the effects of thiamin supplementation on biomarkers of inflammation and oxidative stress in patients with gestational diabetes mellitus (GDM). METHODS This randomized, double-blind, placebo-controlled trial was conducted among 60 patients with GDM. Patients were randomly allocated into two groups to receive either 100 mg/day thiamin supplements ( n  = 30) or placebo ( n  = 30) for 6 weeks. RESULTS Thiamin supplementation significantly decreased serum high-sensitivity C-reactive protein (hs-CRP) ( β  - 0.98 mg/L; 95% CI, -1.54, -0.42; p  = .001) and plasma malondialdehyde (MDA) levels ( β  - 0.86 µmol/L; 95% CI, -1.15, -0.57; p  < .001) when compared with the placebo. In addition, thiamin supplementation downregulated gene expression of tumor necrosis factor-alpha (TNF-α) ( p  = .002) in peripheral blood mononuclear cells of patients with GDM. Thiamin supplementation did not affect other biomarkers of inflammation and oxidative stress. CONCLUSION Overall, thiamin supplementation for 6 weeks to patients with GDM significantly reduced hs-CRP and MDA levels, and gene expression of TNF-α, but did not affect other biomarkers of inflammation and oxidative stress. CLINICAL TRIAL REGISTRATION NUMBER Clinical Trials.govIdentifier no. http://www.irct.ir: IRCT20170513033941N58.",2020,"In addition, thiamin supplementation downregulated gene expression of tumor necrosis factor-alpha (TNF-α) ( p  = .002) in peripheral blood mononuclear cells of patients with GDM.","['patients with gestational diabetes mellitus (GDM', '60 patients with GDM', 'patients with gestational diabetes mellitus']","['thiamin supplementation', 'Thiamin supplementation', 'thiamin supplements', '100\u2009mg/day thiamin supplements ( n \u2009=\u200930) or placebo', 'placebo']","['peripheral blood mononuclear cells', 'NUMBER', 'serum high-sensitivity C-reactive protein (hs-CRP', 'biomarkers of inflammation and oxidative stress', 'hs-CRP and MDA levels, and gene expression of TNF-α', 'gene expression of tumor necrosis factor-alpha (TNF-α', 'plasma malondialdehyde (MDA) levels']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0085207', 'cui_str': 'Gestational diabetes mellitus'}]","[{'cui': 'C4524016', 'cui_str': 'Thiamin supplementation'}, {'cui': 'C3661612', 'cui_str': 'Thiamine supplement'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1321301', 'cui_str': 'Peripheral blood mononuclear cell'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0000379', 'cui_str': 'Methylenedioxyamphetamine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C1168005', 'cui_str': 'Alpha tumour necrosis factor'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}]",60.0,0.510482,"In addition, thiamin supplementation downregulated gene expression of tumor necrosis factor-alpha (TNF-α) ( p  = .002) in peripheral blood mononuclear cells of patients with GDM.","[{'ForeName': 'Elaheh', 'Initials': 'E', 'LastName': 'Amirani', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Esmat', 'Initials': 'E', 'LastName': 'Aghadavod', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Rana', 'Initials': 'R', 'LastName': 'Shafabakhsh', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Zatollah', 'Initials': 'Z', 'LastName': 'Asemi', 'Affiliation': 'Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Zohreh', 'Initials': 'Z', 'LastName': 'Tabassi', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Panahandeh', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Naderi', 'Affiliation': 'Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Abed', 'Affiliation': 'Physiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2020.1779212'] 2470,32722985,UK primary care survey of venous leg ulceration management and referral - Post-EVRA trial.,"OBJECTIVE Determine standards of referral and management of patients with venous leg ulceration in primary care after the release of the EVRA (A Randomized Trial of Early Endovenous Ablation in Venous Ulceration) study results. METHODS An online questionnaire was disseminated over four months to professionals working within primary care. RESULTS The survey received 643 responses. Of respondents, 90 (14%) had heard of the EVRA trial and 51 (8%) were familiar with the results. Of those who answered the following questions, 410 (69.1%) stated that referral to a vascular specialist must be made by the General Practitioner and 13 (2.2%) reported that they would always refer patients for secondary care assessment before the publication of EVRA. Considering the EVRA results, 128 (29%) reported that they would change practice regarding referral and would experience no barriers and 198 (45%) reported that they would like to refer earlier but is not their decision. Barriers to changing practice included local referral policies, training and time restrictions, 266 (59%) had heard of the NICE guideline (CG168) and 194 (43%) were aware of the recommendations for referral to a vascular service within two weeks for patients with an open or healed ulcer. CONCLUSION There is a considerable variation in local referral pathways for venous leg ulceration, and despite clinicians wanting to refer promptly, many primary care professionals are unable to. Unfortunately, the EVRA study alone may not change the overall practice, and work is needed to overcome barriers faced by primary care professionals.",2020,"Of respondents, 90 (14%) had heard of the EVRA trial and 51 (8%) were familiar with the results.","['An online questionnaire was disseminated over four months to professionals working within primary care', '266 (59%) had heard of the NICE guideline (CG168) and 194 (43%) were aware of the recommendations for referral to a vascular service within two weeks for patients with an open or healed ulcer', 'patients with venous leg ulceration in primary care after the release of the', 'Of respondents, 90 (14%) had heard of the EVRA trial and 51 (8%) were familiar with the results']",['EVRA'],[],"[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205221', 'cui_str': 'Disseminated'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0018767', 'cui_str': 'Hearing'}, {'cui': 'C0721912', 'cui_str': ""N'ICE""}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C2585021', 'cui_str': 'Referral to'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0333293', 'cui_str': 'Healing ulcer'}, {'cui': 'C0042449', 'cui_str': 'Venous structure'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0041582', 'cui_str': 'Ulcer'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C5200009', 'cui_str': 'Evra'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0678226', 'cui_str': 'Due to'}]","[{'cui': 'C5200009', 'cui_str': 'Evra'}]",[],,0.0331104,"Of respondents, 90 (14%) had heard of the EVRA trial and 51 (8%) were familiar with the results.","[{'ForeName': 'Francine', 'Initials': 'F', 'LastName': 'Heatley', 'Affiliation': 'Imperial Health Care NHS Trust, Imperial College London, London, UK.'}, {'ForeName': 'Layla B', 'Initials': 'LB', 'LastName': 'Saghdaoui', 'Affiliation': 'Imperial Health Care NHS Trust, Imperial College London, London, UK.'}, {'ForeName': 'Safa', 'Initials': 'S', 'LastName': 'Salim', 'Affiliation': 'Imperial Health Care NHS Trust, Imperial College London, London, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Onida', 'Affiliation': 'Imperial Health Care NHS Trust, Imperial College London, London, UK.'}, {'ForeName': 'Manj S', 'Initials': 'MS', 'LastName': 'Gohel', 'Affiliation': 'Addenbrookes Hospital, Imperial College, Cambridge, London, UK.'}, {'ForeName': 'Alun H', 'Initials': 'AH', 'LastName': 'Davies', 'Affiliation': 'Imperial Health Care NHS Trust, Imperial College London, London, UK.'}]",Phlebology,['10.1177/0268355520944102'] 2471,32723033,Increases in speed do not change gait symmetry or variability in world-class race walkers.,"The aim of this study was to analyse changes in gait variability and symmetry with increasing speed in race walkers. Eighteen international athletes race walked on an instrumented treadmill at speeds of 11, 12, 13 and 14 km·h -1 in a randomised order for 3 min each. Spatiotemporal and ground reaction force data were recorded for 30 s at each speed. Gait variability was measured using median absolute deviation and inter-leg symmetry was measured using the symmetry angle. There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency. Most athletes were asymmetrical for at least one variable, but none was asymmetrical for more than half of the variables measured. Therefore, being asymmetrical or having higher variability (<5%) in a few variables is normal. Taking all findings together, practitioners should exercise caution when deciding on the need for corrective interventions and should not be concerned that increasing gait speed could increase injury risk through changes to athletes' asymmetry. Race walking coaches should test at competition speeds to ensure that flight times, and any variability or asymmetry, are measured appropriately.",2020,"There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency.","['Eighteen international athletes race walked on an instrumented treadmill at speeds of 11, 12, 13 and 14 km·h -1']",[],"['speed, step length and step frequency', 'gait variability and symmetry', 'Gait variability']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0348000', 'cui_str': 'Instrument'}, {'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}]",[],"[{'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0427126', 'cui_str': 'Step length'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0332516', 'cui_str': 'Symmetrical'}]",18.0,0.0396385,"There was an overall effect of speed on all absolute values except push-off force, but symmetry and variability (except flight time) did not change with increased speed, step length and step frequency.","[{'ForeName': 'Catherine B', 'Initials': 'CB', 'LastName': 'Tucker', 'Affiliation': 'Carnegie School of Sport, Headingley Campus, Leeds Beckett University , Leeds, UK.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Hanley', 'Affiliation': 'Carnegie School of Sport, Headingley Campus, Leeds Beckett University , Leeds, UK.'}]",Journal of sports sciences,['10.1080/02640414.2020.1798730'] 2472,32723072,Impacts of Post-Hospitalization Accessible Health Technology and Caregiver Support on 90-Day Acute Care Use and Self-Care Assistance: A Randomized Clinical Trial.,"Hospitalized patients often are readmitted soon after discharge, with many hospitalizations being potentially preventable. The authors evaluated a mobile health intervention designed to improve post-hospitalization support for older adults with common chronic conditions. All participants enrolled with an informal caregiver or ""CarePartner"" (CP). Intervention patients received automated assessment and behavior change calls. CPs received automated, structured feedback following each assessment. Clinicians received alerts about serious problems identified during patient calls. Controls had a 65% greater risk of hospitalization within 90 days post discharge than intervention patients ( P = .041). For every 6.8 enrollees, the intervention prevented 1 rehospitalization or emergency department encounter. The intervention improved physical functioning at 90 days ( P = .012). The intervention also improved medication adherence and indicators of the quality of communication with CPs (all P < .01). Automated telephone patient monitoring and self-care advice with feedback to primary care teams and CPs reduces readmission rates over 90 days.",2020,Controls had a 65% greater risk of hospitalization within 90 days post discharge than intervention patients ( P = .041).,"['Self-Care Assistance', 'Hospitalized patients often are readmitted soon after discharge, with many hospitalizations being potentially preventable', 'older adults with common chronic conditions', 'All participants enrolled with an informal caregiver or ""CarePartner"" (CP']",[],"['rehospitalization or emergency department encounter', 'physical functioning', 'readmission rates', 'medication adherence and indicators of the quality of communication with CPs', 'risk of hospitalization']","[{'cui': 'C0509063', 'cui_str': 'Assisting with activity of daily living'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C1547273', 'cui_str': 'Preventable'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}]",[],"[{'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0149958', 'cui_str': 'Partial Seizures, Complex'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",,0.0389093,Controls had a 65% greater risk of hospitalization within 90 days post discharge than intervention patients ( P = .041).,"[{'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Piette', 'Affiliation': 'Ann Arbor Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Striplin', 'Affiliation': 'Ann Arbor Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.'}, {'ForeName': 'James E', 'Initials': 'JE', 'LastName': 'Aikens', 'Affiliation': 'University of Michigan, Ann Arbor, MI.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Lee', 'Affiliation': 'University of Mississippi, Oxford, MS.'}, {'ForeName': 'Nicolle', 'Initials': 'N', 'LastName': 'Marinec', 'Affiliation': 'Ann Arbor Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.'}, {'ForeName': 'Madhura', 'Initials': 'M', 'LastName': 'Mansabdar', 'Affiliation': 'MidMichigan Health Network, Midland, MI.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Ann Arbor Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.'}, {'ForeName': 'Lynn A', 'Initials': 'LA', 'LastName': 'Gregory', 'Affiliation': 'Ann Arbor Department of Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI.'}, {'ForeName': 'Christopher S', 'Initials': 'CS', 'LastName': 'Kim', 'Affiliation': 'University of Washington, Seattle, WA.'}]",American journal of medical quality : the official journal of the American College of Medical Quality,['10.1177/1062860620943673'] 2473,32723088,Comparison of the effects of the Feldenkrais method versus core stability exercise in the management of chronic low back pain: a randomised control trial.,"OBJECTIVE To investigate the effect of the Feldenkrais method versus core stability exercises on pain, disability, quality of life and interoceptive awareness in patients with chronic non-specific low back pain. DESIGN A single-blinded, randomised, controlled trial. SETTING Outpatient, sports medicine clinic of Mazandaran medical university. PARTICIPANTS Sixty patients with chronic non-specific low back pain randomised equally into the Feldenkrais method versus core stability exercises groups. INTERVENTION Intervention group received Feldenkrais method consisting of training theoretical content and supervised exercise therapy two sessions per week for five weeks. Control group received educational programme and home-based core stability exercises for five weeks. OUTCOME MEASURES All patients were examined by World Health Organization's Quality of life Questionnaire, McGill Pain Questionnaire, Oswestry Disability Questionnaire and Multidimensional Assessment of Interoceptive Awareness Questionnaire. All outcomes were measured at baseline and the end of the intervention. RESULTS There were statistically significant differences between groups for quality of life ( P  = 0.006, from 45.51 to 60.49), interoceptive awareness ( P  > 0.001, from 2.74 to 4.06) and disability ( P  = 0.021, from 27.17 to 14.5) in favour of the Feldenkrais method. McGill pain score significantly decreased in both the Feldenkrais (from 15.33 to 3.63) and control groups (from 13.17 to 4.17), but there were no between-groups differences ( P  = 0.16). CONCLUSION Feldenkrais method intervention gave increased benefits in improving quality of life, improving interoceptive awareness and reducing disability index.",2020,"There were statistically significant differences between groups for quality of life ( P  = 0.006, from 45.51 to 60.49), interoceptive awareness ( P  > 0.001, from 2.74 to 4.06) and disability ( P  = 0.021, from 27.17 to 14.5) in favour of the Feldenkrais method.","['chronic low back pain', 'Sixty patients with chronic non-specific low back pain randomised equally into the', 'patients with chronic non-specific low back pain', 'Outpatient, sports medicine clinic of Mazandaran medical university']","['Feldenkrais method versus core stability exercise', 'Feldenkrais method versus core stability exercises', 'educational programme and home-based core stability exercises for five weeks', 'Feldenkrais method versus core stability exercises groups', 'Intervention group received Feldenkrais method consisting of training theoretical content and supervised exercise therapy']","['quality of life', 'disability', 'McGill pain score', ""World Health Organization's Quality of life Questionnaire, McGill Pain Questionnaire, Oswestry Disability Questionnaire and Multidimensional Assessment of Interoceptive Awareness Questionnaire"", 'quality of life, improving interoceptive awareness and reducing disability index', 'interoceptive awareness', 'pain, disability, quality of life and interoceptive awareness']","[{'cui': 'C0457949', 'cui_str': 'Chronic low back pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0038040', 'cui_str': 'Medicine, Sport'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0024985', 'cui_str': 'McGill pain chart questionnaire'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",60.0,0.0914339,"There were statistically significant differences between groups for quality of life ( P  = 0.006, from 45.51 to 60.49), interoceptive awareness ( P  > 0.001, from 2.74 to 4.06) and disability ( P  = 0.021, from 27.17 to 14.5) in favour of the Feldenkrais method.","[{'ForeName': 'Hanieh', 'Initials': 'H', 'LastName': 'Ahmadi', 'Affiliation': 'Department of Sports and Exercise Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Hanieh', 'Initials': 'H', 'LastName': 'Adib', 'Affiliation': 'Department of Sports and Exercise Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Selk-Ghaffari', 'Affiliation': 'Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Misagh', 'Initials': 'M', 'LastName': 'Shafizad', 'Affiliation': 'Orthopedic Research Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Siavash', 'Initials': 'S', 'LastName': 'Moradi', 'Affiliation': 'Education Development Center, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Madani', 'Affiliation': 'Department of Sports and Exercise Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Gholamreza', 'Initials': 'G', 'LastName': 'Partovi', 'Affiliation': 'Department of Sports and Exercise Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Aliakbar', 'Initials': 'A', 'LastName': 'Mahmoodi', 'Affiliation': 'Department of Sports and Exercise Medicine, Mazandaran University of Medical Sciences, Sari, Iran.'}]",Clinical rehabilitation,['10.1177/0269215520947069'] 2474,32723109,User experiences with second-generation 32-gauge x 4 mm vs. thinner comparator pen needles: prospective randomized trial.,"Objective: Two similarly designed studies compared user experiences with a second-generation extra-thin-wall, 5-bevel 32Gx4mm pen needle (PN) with redesigned hub versus four thinner commercially available PNs. Methods: Adults (18-75 years old) with type 1 or type 2 diabetes and ≥3 months of experience with pen injectors qualified for single-visit, single-blinded randomized studies. The investigational 32G PN was compared with three 33-34Gx3.5-4mm PNs in Study 1 and one 34Gx4mm PN in Study 2. Participants completed 12 abdominal injections of 0.3 mL sterile saline using insulin pens in 6 pairs, each comprising one investigational 32G PN and one comparator PN in random order. After each injection pair, participants compared injection pain via relative 150-mm visual analog scale (VAS) and perceived dose delivery force via relative 5-point Likert scale. Adjusted models tested injection pain scores (primary endpoint) for noninferiority and, if met, then for superiority. ClinicalTrials.gov identifiers: NCT03878758 and NCT03878745. Results: The investigational 32G PN met noninferiority as well as superiority criteria for less injection pain vs. each comparator ( p <.01), with adjusted mean relative VAS scores from 9.1-17.6 in Study 1 ( n  = 154) and 7.3 in Study 2 ( n  = 55). The investigational 32G PN was also superior vs. each comparator PN in requiring less relative perceived force to deliver the dose ( p <.01). Conclusions: The investigational 32G PN was associated with less participant-reported injection pain and less perceived dose delivery force compared with four thinner PNs, suggesting no additional pain reduction or force reduction benefit conferred by the thinner PNs.",2020,"The investigational 32G PN was associated with less participant-reported injection pain and less perceived dose delivery force compared with four thinner PNs, suggesting no additional pain reduction or force reduction benefit conferred by the thinner PNs.","['Methods: Adults (18-75 years old) with type 1 or type 2 diabetes and ≥3 months of experience with pen injectors qualified for single-visit, single-blinded randomized studies']","['second-generation extra-thin-wall, 5-bevel 32Gx4mm pen needle (PN) with redesigned hub versus four thinner commercially available PNs']","['injection pain via relative 150-mm visual analog scale (VAS) and perceived dose delivery force via relative 5-point Likert scale', 'injection pain', 'injection pain scores', 'VAS scores']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C4025916', 'cui_str': 'Pen Injector'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0205168', 'cui_str': 'Thin'}, {'cui': 'C0205380', 'cui_str': 'Walled'}, {'cui': 'C0070220', 'cui_str': 'penclomedine'}, {'cui': 'C0007431', 'cui_str': 'Insertion of catheter into artery'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0206417', 'cui_str': 'Peripheral nervous system structure'}]","[{'cui': 'C1096717', 'cui_str': 'Pain during injection'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0451267', 'cui_str': 'Likert scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",2.0,0.394199,"The investigational 32G PN was associated with less participant-reported injection pain and less perceived dose delivery force compared with four thinner PNs, suggesting no additional pain reduction or force reduction benefit conferred by the thinner PNs.","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Gibney', 'Affiliation': 'Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitz-Patrick', 'Affiliation': 'East-West Medical Research Institute, Honolulu, HI, USA.'}, {'ForeName': 'David C', 'Initials': 'DC', 'LastName': 'Klonoff', 'Affiliation': 'Mills-Peninsula Medical Center, San Mateo, CA, USA.'}, {'ForeName': 'Shahista', 'Initials': 'S', 'LastName': 'Whooley', 'Affiliation': 'Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA.'}, {'ForeName': 'Betty', 'Initials': 'B', 'LastName': 'Lu', 'Affiliation': 'Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA.'}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Yue', 'Affiliation': 'Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA.'}, {'ForeName': 'Stanislav', 'Initials': 'S', 'LastName': 'Glezer', 'Affiliation': 'Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA.'}]",Current medical research and opinion,['10.1080/03007995.2020.1803248'] 2475,32723114,Comparative study between Amplatz renal dilator vs visual internal urethrotomy (cold knife) for the treatment of male urethral stricture.,"AIM The study aimed to assess and compare urethral stricture (US) management outcomes, efficiency, and complications, treated by either Amplatz renal dilator or visual internal urethrotomy (VIU). PATIENTS AND METHODS This prospective comparative study was carried out on 88 male patients with stricture urethra. All patients have performed a physical examination, ascending and micturition urethrography, urodynamic, and pelvic ultrasound. The patients were randomized divided into group 1 (Amplatz group) 44 patients treated with Amplatz dilator, and group 2 (VIU group) 44 patients treated with a cold knife. Patients were followed up at 15 days,3,6, and 12 months after the procedure. RESULT The mean age was 41.2 (22-73) years. The mean stricture length in group 1 and group 2 was 1.01 ± 0.40 and 1.04 ± 0.30, respectively ( p  = 0.421). The average IPSS score at baseline for group 1 and group 2 was 21.2 and 21.9 points, respectively. During the 12 months follow-up, IPSS improved, with average scores of 16.1 and 17.3 for group 1 and group 2, respectively ( p  > 0.05). The mean values of (Q max) between group 1 and group 2 at baseline, day 15, day 90 and 180 days showed no significant difference but at 12 months, (Q max) showed a higher significant difference in group 1 than group 2 ( p  = 0.003). The post-void residual (PVR) displayed a significant decline in both groups from baseline. After 1 year, PVR showed that group 2 was a little higher than group 1 (no significance) compared to baseline The procedures were found effective without recurrence in all patients (both groups) during the 12 months (Q max > 15m/s). However, group 2 reported (11.4%) intra-operative bleeding, and (6.8%) extravasations. CONCLUSION The guided urethral dilation and internal urethrotomy are safe, short time procedures, and offer satisfactory results with the advance to VIUD in Qmax at 12 months. No recurrence was documented in both groups after 12 months. VIU reported 18% intraoperative complication.",2020,The procedures were found effective without recurrence in all patients (both groups) during the 12 months (Q max > 15m/s).,"['male urethral stricture', 'The mean age was 41.2 (22-73) years', '88 male patients with stricture urethra']","['Amplatz renal dilator or visual internal urethrotomy (VIU', 'Amplatz dilator, and group 2 (VIU group) 44 patients treated with a cold knife', 'guided urethral dilation and internal urethrotomy', 'Amplatz renal dilator vs visual internal urethrotomy (cold knife']","['mean stricture length', 'PVR', 'No recurrence', 'average IPSS score', 'intra-operative bleeding', 'mean values of (Q max', 'IPSS']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0041974', 'cui_str': 'Urethral stenosis'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4551691', 'cui_str': 'Urethral stricture'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0180431', 'cui_str': 'Dilator'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0565436', 'cui_str': 'Internal urethrotomy'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0181467', 'cui_str': 'Knife'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0041967', 'cui_str': 'Urethral'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0242852', 'cui_str': 'Proliferative vitreoretinopathy'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C1504431', 'cui_str': 'Idiopathic pneumonia syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}]",88.0,0.0244908,The procedures were found effective without recurrence in all patients (both groups) during the 12 months (Q max > 15m/s).,"[{'ForeName': 'Sherif Salah', 'Initials': 'SS', 'LastName': 'Azab', 'Affiliation': 'Urology Department, Faculty of Medicine, October 6 University, Cairo, Egypt.'}]",Scandinavian journal of urology,['10.1080/21681805.2020.1798504'] 2476,32723141,External Loop Recorders: Primary Care Placement Is Noninferior to Hospital-Based Cardiac Unit.,"Introduction: External loop recorders (ELRs) are recommended for the investigation of syncope and palpitations. This study aimed to compare rates of arrhythmia detection between primary care (PC) and hospital-based cardiac unit (HBCU) fitted ELRs. Methods: Data were captured from January to December 2015. Twenty-eight general practitioner practices and 1 hospital took part. Patients were divided into those with ELR fitted in PC or HBCU. All ELR data were analyzed by a cardiac physiologist. Results: A total of 560 ELR recordings were analyzed; 219 (PC) versus 341 (HBCU). There was no difference between the baseline characteristics (all P s > .05). The predominant indication for ELR in each group were palpitations; between-group variation was observed for syncope ( P = .0004). There were no significant between-group differences in the number of recordings per patient; however, PC group wore the ELR for less time (median 7 days vs median 14 days; P < .0001). There were no differences in arrhythmia detection between PC- and HBCU-fitted ELRs (16.2% [n = 39] vs 21.7% [n = 74], respectively; P = .28). PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). Conclusions: This study showed no difference in detection of arrhythmias between PC and HBCU fitted ELRs. This suggests adequate ELR recording can be completed by suitably trained staff in PC. Furthermore, ELRs were fitted for less time in PC without an adverse effect on diagnostic yield. ELR usage increased with increasing distance from the specialist center and rurality suggesting improved local access to arrhythmia detection services.",2020,PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). ,['Twenty-eight general practitioner practices and 1 hospital took part'],"['External Loop Recorders', 'Introduction: External loop recorders (ELRs']","['arrhythmia detection', 'PC placement of ELRs', 'detection of arrhythmias']","[{'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0182913', 'cui_str': 'Recorder'}]","[{'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]",28.0,0.0566794,PC placement of ELRs was highest in very remote rural communities ( P = .005) and correlated with distance from HBCU ( r = 0.39; P = .04). ,"[{'ForeName': 'Kara J', 'Initials': 'KJ', 'LastName': 'Callum', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Hall', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Sharon', 'Initials': 'S', 'LastName': 'Jack', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Farman', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}, {'ForeName': 'Gordon F', 'Initials': 'GF', 'LastName': 'Rushworth', 'Affiliation': 'University of the Highlands and Islands, Centre for Health Science, Inverness, UK.'}, {'ForeName': 'Stephen J', 'Initials': 'SJ', 'LastName': 'Leslie', 'Affiliation': 'NHS Highland, Raigmore Hospital, Inverness, UK.'}]",Journal of primary care & community health,['10.1177/2150132720946147'] 2477,32723187,"Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.","Nivolumab, a programmed cell death-1 inhibitor, has demonstrated prolonged survival benefit in patients with advanced melanoma. Bempegaldesleukin (BEMPEG; NKTR-214), a first-in-class CD122-preferential IL-2 pathway agonist, provides sustained signaling through the IL-2βγ receptor, which activates effector T and natural killer cells. In the Phase I/II PIVOT-02 trial, the combination of bempegaldesleukin plus nivolumab was well-tolerated and demonstrated clinical activity as first-line therapy in metastatic melanoma. Here, we describe the design of and rationale for the Phase III, global, randomized, open-label PIVOT IO 001 trial comparing bempegaldesleukin plus nivolumab with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma. Primary end points include objective response rate, progression-free survival and overall survival. Key secondary end points include further investigation of safety/tolerability, previously assessed in the PIVOT-02 trial. Clinical Trial Registration: NCT03635983 (ClinicalTrials.gov).",2020,"Primary end points include objective response rate, progression-free survival and overall survival.","['patients with advanced melanoma', 'untreated, unresectable or metastatic melanoma', 'patients with previously untreated, unresectable or metastatic melanoma']","['bempegaldesleukin plus nivolumab with nivolumab alone', 'Bempegaldesleukin plus nivolumab']","['objective response rate, progression-free survival and overall survival', 'safety/tolerability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0278883', 'cui_str': 'Metastatic melanoma'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3657270', 'cui_str': 'nivolumab'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.541218,"Primary end points include objective response rate, progression-free survival and overall survival.","[{'ForeName': 'Nikhil I', 'Initials': 'NI', 'LastName': 'Khushalani', 'Affiliation': 'Moffitt Cancer Center, Tampa, FL 33612, USA.'}, {'ForeName': 'Adi', 'Initials': 'A', 'LastName': 'Diab', 'Affiliation': 'Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA.'}, {'ForeName': 'Paolo A', 'Initials': 'PA', 'LastName': 'Ascierto', 'Affiliation': 'Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale IRCCS, Napoli, Italy.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Larkin', 'Affiliation': 'Department of Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Shahneen', 'Initials': 'S', 'LastName': 'Sandhu', 'Affiliation': 'Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Victoria, Australia.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Sznol', 'Affiliation': 'Yale Cancer Center, Yale-New Haven Hospital, New Haven, CT 06511, USA.'}, {'ForeName': 'Henry B', 'Initials': 'HB', 'LastName': 'Koon', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ 08543, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Jarkowski', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ 08543, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ 08543, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Statkevich', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ 08543, USA.'}, {'ForeName': 'William J', 'Initials': 'WJ', 'LastName': 'Geese', 'Affiliation': 'Bristol Myers Squibb, Princeton, NJ 08543, USA.'}, {'ForeName': 'Georgina V', 'Initials': 'GV', 'LastName': 'Long', 'Affiliation': 'Melanoma Institute Australia, The University of Sydney, Royal North Shore & Mater Hospital, St Leonards, NSW, Australia.'}]","Future oncology (London, England)",['10.2217/fon-2020-0351'] 2478,32723193,"The Acute Effects of a Multi-Ingredient Herbal Supplement on Performance Fatigability: A Double-Blind, Randomized, and Placebo-Controlled Trial.","The purpose of the present study was to examine the acute effects of an herbal supplement containing a 70:30 blend of Rhaponticum carthamoides extract and Rhodiola rosea extract, respectively, on performance fatigability and the affective responses prior to and following exercise. Thirty men (age = 22.3 ± 4.1 years) volunteered for this randomized, placebo-controlled, double-blind, cross-over study. Following familiarization, participants visited the laboratory on three separate occasions where they consumed one 350 mg dose, a 175 mg dose of the supplement plus 175 mg of maltodextrin, or a placebo. Participants completed feeling, arousal, and mood surveys at supplement ingestion and following testing. Ninety minutes following ingestion, participants performed five sets of 30 maximal, concentric, leg extension muscle actions at 180°/sec, with one minute of rest between sets. Peak torque, average torque, and total work were calculated for each set, and the rating of perceived exertion (RPE) was assessed after each set. Data were analyzed with a repeated measures analysis of variance and intent-to-treat approach. For the performance variables, there was no interaction ( p  ≥ 0.317) or treatment effect ( p  ≥ 0.660), however, all torque variables decreased across sets and plateaued at sets 4-5, whereas RPE increased across sets ( p  < 0.001). For the affective responses, there was no interaction ( p  ≥ 0.781) or treatment effect ( p  ≥ 0.314); however, participants felt better, had an improved mood, and felt more aroused following testing ( p  < 0.047). This combination of herbal extracts likely does not acutely influence performance fatigability during high-intensity, repeated muscle actions.",2020,"For the performance variables, there was no interaction ( p  ≥ 0.317) or treatment effect ( p  ≥ 0.660), however, all torque variables decreased across sets and plateaued at sets 4-5, whereas RPE increased across sets ( p  < 0.001).",['Thirty men (age = 22.3\u2009±\u20094.1\u2009years) volunteered'],"['Multi-Ingredient Herbal Supplement', 'Placebo', 'supplement plus 175\u2009mg of maltodextrin, or a placebo', 'herbal extracts', 'herbal supplement', 'placebo']","['Performance', 'Peak torque, average torque, and total work', 'rating of perceived exertion (RPE', 'Fatigability']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C1504473', 'cui_str': 'Herbal Supplements'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0231230', 'cui_str': 'Fatigability'}]",,0.578432,"For the performance variables, there was no interaction ( p  ≥ 0.317) or treatment effect ( p  ≥ 0.660), however, all torque variables decreased across sets and plateaued at sets 4-5, whereas RPE increased across sets ( p  < 0.001).","[{'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Ryan', 'Affiliation': 'Neuromuscular Assessment Laboratory, Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Gena R', 'Initials': 'GR', 'LastName': 'Gerstner', 'Affiliation': 'Department of Human Movement Sciences, Old Dominion University, Norfolk, VA, USA.'}, {'ForeName': 'Jacob A', 'Initials': 'JA', 'LastName': 'Mota', 'Affiliation': 'Department of Kinesiology, University of Alabama, Tuscaloosa, AL, USA.'}, {'ForeName': 'Eric T', 'Initials': 'ET', 'LastName': 'Trexler', 'Affiliation': 'Stronger By Science LLC, Chapel Hill, NC, USA.'}, {'ForeName': 'Hayden K', 'Initials': 'HK', 'LastName': 'Giuliani', 'Affiliation': 'Neuromuscular Assessment Laboratory, Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Malia N M', 'Initials': 'MNM', 'LastName': 'Blue', 'Affiliation': 'Human Biomechanics and Physiology Lab, Department of Exercise Science, High Point University, High Point, NC, USA.'}, {'ForeName': 'Katie R', 'Initials': 'KR', 'LastName': 'Hirsch', 'Affiliation': 'Center for Translational Research in Aging and Longevity, University of Arkansas for Medical Sciences, Little Rock, AR, USA.'}, {'ForeName': 'Abbie E', 'Initials': 'AE', 'LastName': 'Smith-Ryan', 'Affiliation': 'Human Movement Science Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}]",Journal of dietary supplements,['10.1080/19390211.2020.1790709'] 2479,32723199,γ-Oryzanol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in Drosophila melanogaster .,"Chronic unpredictable mild stress (CUMS) is a valid model for inducing depression-like symptoms in animal models, causing predictive behavioral, neurochemical, and physiological responses to this condition. This work aims to evaluate the possible antidepressant effect of γ-oryzanol (ORY) in the CUMS-induced depressive model in male Drosophila melanogaster . We will use the CUMS protocol to continue the study previously conducted by our research group, mimicking a depressive state in these insects. Male flies were subjected to various stressors according to a 10-day randomized schedule and concomitantly treated with ORY or fluoxetine (FLX). After the experimental period, in vivo behavioral tests were performed (open field, forced swimming, aggressiveness test, mating test, male virility, sucrose preference index and light/dark test) and ex vivo analyses measuring serotonin (5HT), dopamine (DA), octopamine (OCT) levels and body weight. We report here that ORY-treated flies and concomitant exposure to CUMS did not exhibit obvious behaviors such as prolonged immobility or increased aggressive behavior, reduced male mating and virility behavior, and anxiolytic behavior, in contrast to ORY, not altering sucrose preference and body weight flies exposed to CUMS. ORY effectively prevented 5HT and OCT reduction and partially protected against DA reduction. The data presented here are consistent and provide evidence for the use of ORY as a potential antidepressant compound. Lay Summary Flies treated with ORY and concomitant exposure to CUMS did not exhibit obvious depressive-like behaviors, such as prolonged immobility in the FST or increased aggressive behavior, or reduced mating behavior, male virility, or anxiolytic behavior. ORY did not change the preference for sucrose and body weight of flies, about the levels of monoamines in the heads of flies, ORY was effective in preventing the reduction of 5HT and OCT, and we had partial protection of ORY for reducing the levels of DA.",2020,"ORY did not change the preference for sucrose and body weight of flies, about the levels of monoamines in the heads of flies, ORY was effective in preventing the reduction of 5HT and OCT, and we had partial protection of ORY for reducing the levels of DA.","['male Drosophila melanogaster ', 'Male flies', 'Chronic unpredictable mild stress (CUMS']","['ORY or fluoxetine (FLX', 'γ-Oryzanol', 'γ-oryzanol (ORY']","['forced swimming, aggressiveness test, mating test, male virility, sucrose preference index and light/dark test) and ex vivo analyses measuring serotonin (5HT), dopamine (DA), octopamine (OCT) levels and body weight', 'aggressive behavior, or reduced mating behavior, male virility, or anxiolytic behavior', '5HT and OCT reduction']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0013139', 'cui_str': 'D. melanogaster'}, {'cui': 'C0012578', 'cui_str': 'Order Diptera'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0038435', 'cui_str': 'Stress'}]","[{'cui': 'C0061081', 'cui_str': 'gamma-oryzanol'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}]","[{'cui': 'C0443221', 'cui_str': 'Forced'}, {'cui': 'C0039003', 'cui_str': 'Swimming'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042757', 'cui_str': 'Masculinity'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0036751', 'cui_str': 'Serotonin'}, {'cui': 'C0013030', 'cui_str': 'Dopamine'}, {'cui': 'C0028403', 'cui_str': 'Octopamine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0040616', 'cui_str': 'Anxiolytic agent'}, {'cui': 'C0029279', 'cui_str': 'Ornithine carbamoyltransferase'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0212154,"ORY did not change the preference for sucrose and body weight of flies, about the levels of monoamines in the heads of flies, ORY was effective in preventing the reduction of 5HT and OCT, and we had partial protection of ORY for reducing the levels of DA.","[{'ForeName': 'Stífani Machado', 'Initials': 'SM', 'LastName': 'Araujo', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Vandreza Cardoso', 'Initials': 'VC', 'LastName': 'Bortolotto', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Márcia Rósula', 'Initials': 'MR', 'LastName': 'Poetini', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Mustafa Munir Mustafa', 'Initials': 'MMM', 'LastName': 'Dahleh', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Shanda de Freitas', 'Initials': 'SF', 'LastName': 'Couto', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Franciane Cabral', 'Initials': 'FC', 'LastName': 'Pinheiro', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Luana Barreto', 'Initials': 'LB', 'LastName': 'Meichtry', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Elize Aparecida Santos', 'Initials': 'EAS', 'LastName': 'Musachio', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Bruna Piaia', 'Initials': 'BP', 'LastName': 'Ramborger', 'Affiliation': 'Interdisciplinary Group of Research in Teaching Practice, Federal University of Pampa, Uruguaiana, Brazil.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Roehrs', 'Affiliation': 'Interdisciplinary Group of Research in Teaching Practice, Federal University of Pampa, Uruguaiana, Brazil.'}, {'ForeName': 'Gustavo Petri', 'Initials': 'GP', 'LastName': 'Guerra', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Prigol', 'Affiliation': 'Laboratory of Pharmacological and Toxicological Evaluations Applied to Bioactives Molecules - LaftamBio, Federal University of Pampa, Itaqui, Brazil.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2020.1790519'] 2480,32723201,Increase in cortisol concentration due to standardized bright and blue light exposure on saliva cortisol in the morning following sleep laboratory.,"Research studies on LED light exposure and cortisol are inconsistent and not comparable due to different types of light, exposure times, and sample sizes. Therefore, one hour of standardized exposure LED light at different intensities and the spectral composition during the post-awakening phase at 7:30 were compared. A sample of 23 (Study 1) and 26 (Study 2) healthy males were randomly assigned to: 1) bright white light (414 lux) and 2) dim darkened light (<2 lux) as well as 3) red light (235 lux) and 4) blue light (201 lux) exposure conditions. Results from repeated measures ANOVA confirm that light exposure affects the cortisol concentration. Study 1 revealed an increase in the saliva cortisol concentration after bright light exposure compared to dim light. An increase in the cortisol concentration of blue light compared to red light (Study 2) and dim light was found. This study shows that bright light and blue light affect the cortisol response in contrast to dim light and red light conditions. The HPA axis showed a stimulatory effect by bright versus dim light and different wavelengths of light exposure. Lay summary: The effects of LED light exposure on the stress hormone cortisol were investigated. The light exposure took place during the hours people would start working at the office. The results showed that after one hour of exposure to bright light or blue light the stress hormones increase in contrast to dim light and red light conditions. Thus, stress hormones can be altered by the types of light people are exposed to.",2020,Results from repeated measures ANOVA confirm that light exposure affects the cortisol concentration.,"['healthy males', 'A sample of 23 (Study 1) and 26 (Study 2']","['bright white light (414\u2009lux) and 2) dim darkened light (<2\u2009lux) as well as 3) red light (235\u2009lux) and 4) blue light (201\u2009lux) exposure conditions', 'LED light exposure']","['stress hormone cortisol', 'saliva cortisol', 'cortisol response', 'saliva cortisol concentration', 'cortisol concentration', 'cortisol concentration of blue light']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0563228', 'cui_str': 'White light'}, {'cui': 'C4517771', 'cui_str': '414'}, {'cui': 'C0024176', 'cui_str': 'Luxembourg'}, {'cui': 'C0114346', 'cui_str': 'dimesna'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0297096', 'cui_str': 'arsenotriglutathione'}, {'cui': 'C0563227', 'cui_str': 'Red light'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0303896', 'cui_str': 'Blue light'}]",,0.0154196,Results from repeated measures ANOVA confirm that light exposure affects the cortisol concentration.,"[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Petrowski', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Medical Psychology & Medical Sociology, University Medical Center of the Johannes Gutenberg - University Mainz, Mainz, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Bührer', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, Medical Psychology & Medical Sociology, University Medical Center of the Johannes Gutenberg - University Mainz, Mainz, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Albus', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of University Cologne, Cologne, Germany.'}, {'ForeName': 'Bjarne', 'Initials': 'B', 'LastName': 'Schmalbach', 'Affiliation': 'Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg - University Mainz, Mainz, Germany.'}]","Stress (Amsterdam, Netherlands)",['10.1080/10253890.2020.1803265'] 2481,32723264,The effects of melatonin on the oxidative stress and duration of atrial fibrillation after coronary artery bypass graft surgery: A Randomized Controlled Trial.,"BACKGROUND Atrial Fibrillation (AF) is a common complication following Coronary artery bypass graft (CABG) Surgery, which may be due to oxidative stress, necrosis and inflammation during CABG and can lead to increases the length of hospital stay and the risk of morbidity and mortality. Melatonin is a hormone with anti-oxidant and anti-inflammatory properties in the cardiovascular system. This study assessed the efficacy of sublingual consumption of melatonin in reducing necrosis and inflammation, in patients undergoing CABG with respect to C-reactive protein (hs-CRP), Creatine KinaseMuscle-Brain subunits (CK-MB) and cardiac Troponin T (cTnT) levels. METHODS One hundred and two patients were enrolled and twenty-six patients were excluded during the study process and finally seventy-six patients undergoing CABG surgery randomly assigned to melatonin group (n = 38, 12 mg sublingual melatonin the evening before and 1 hour before surgery, or the control group which did not receive Melatonin, n = 38). Three patients in the melatonin group and three patients in the control group were excluded from the study because of discontinued intervention and lost to follow up. The samples were collected before and 24 hours after surgery. hs-CRP, CKMB, and cTnT levels were measured in all patients with the Elisa method. RESULTS There was no significant difference in influencing variables among the groups at the baseline. The incidence of AF following CABG surgery was not statistically significant between the two groups, (p value = 0.71). However, the duration of AF (p value = 0.01), the levels of hs-CRP (p value = 0.001) and CK-MB (p value = 0.004) measured, 24 hours after surgery were significantly lower in the melatonin group. cTnT levels measured 24 hours post-CABG did not show any significant difference in both groups (p value = 0.52). CONCLUSION Our findings suggest that the administration of melatonin may help modulate oxidative stress, based on the reduction of the levels of hs-CRP, CK-MB, and the duration of AF following CABG surgery.",2020,"levels measured 24 hours post-CABG did not show any significant difference in both groups (p value = 0.52). ","['One hundred and two patients were enrolled and twenty-six patients were excluded during the study process and finally seventy-six patients undergoing CABG surgery randomly assigned to', 'patients undergoing CABG with respect to C-reactive protein (hs-CRP', 'after coronary artery bypass graft surgery']","['sublingual melatonin the evening before and 1 hour before surgery, or the control group which did not receive Melatonin', 'Melatonin', 'Coronary artery bypass graft (CABG', 'cTnT', 'melatonin']","['length of hospital stay and the risk of morbidity and mortality', 'Creatine KinaseMuscle-Brain subunits (CK-MB) and cardiac Troponin T (cTnT) levels', 'levels of hs-CRP', 'CK-MB', 'duration of AF', 'incidence of AF following CABG surgery', 'hs-CRP, CKMB, and cTnT levels', 'oxidative stress and duration of atrial fibrillation']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0450349', 'cui_str': '26'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C4319622', 'cui_str': '76'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}]","[{'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0025219', 'cui_str': 'Melatonin'}, {'cui': 'C0587117', 'cui_str': 'Evening'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0599220', 'cui_str': 'Protein Subunit'}, {'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0010290', 'cui_str': 'Creatine kinase isoenzyme, MB fraction'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}]",102.0,0.124024,"levels measured 24 hours post-CABG did not show any significant difference in both groups (p value = 0.52). ","[{'ForeName': 'Saghar', 'Initials': 'S', 'LastName': 'Barati', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Jahangirifard', 'Affiliation': 'Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Zargham Hossein', 'Initials': 'ZH', 'LastName': 'Ahmadi', 'Affiliation': 'Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Tavakoli-Ardakani', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy and pharmaceutical sciences research center, Shahid Beheshti University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Farzaneh', 'Initials': 'F', 'LastName': 'Dastan', 'Affiliation': 'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran. 0.'}]","Endocrine, metabolic & immune disorders drug targets",['10.2174/1871530320666200728152307'] 2482,32723265,Electrophysiological and Clinical Improvement in Non-Invasive Treatment of Carpal Tunnel Syndrome.,"BACKGROUND AND OBJECTIVE Carpal tunnel syndrome (CTS) is the most common form of nerve entrapment. Clinically, various signs and symptoms compare due to overexposure to mechanical vibrations transmitted to the wrist bones and cartilage, resulting in compression of the sensory and motor nerve fibers of median nerve. Early symptoms include nocturnal paresthesia and electromyography reveals reduced sensory nerve conduction velocity. Aim of this study was to evaluate the efficacy of a dietary integrator composed of acetyl-L-carnitine, α-lipoic acid,quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins in patients with early (minimal) carpal tunnel syndrome. METHODS 36 patients (28 female and 8 male) with early CTS characterized by sensory nerve demyelination and inflammation of the transverse carpal ligament. Patients were divided into two groups, group A (18 patients received physical therapy) and group B (18 patients, received physical therapy and an oral integrator). Clinical (sleep quality questionnaire to measure severity of paresthesia) and neurophysiological assessment (Sensory Nerve Conduction Velocity) performed at baseline, and then at 30 and 60 days after treatment. RESULTS Sleep quality and Sensory Nerve Conduction Velocity data analysis show improvement in both groups at 30 and 60 days, with statistically difference between them in both time of analysis. CONCLUSIONS In the early CTS, with sensory fibers damage, use of dietary integrator, such as Micronil Dol®, composed composed of acetyl-L-carnitine, α-lipoic acid,quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins can be effective in quick recovery of median nerve sensory.",2020,"RESULTS Sleep quality and Sensory Nerve Conduction Velocity data analysis show improvement in both groups at 30 and 60 days, with statistically difference between them in both time of analysis. ","['patients with early (minimal) carpal tunnel syndrome', '36 patients (28 female and 8 male) with early CTS characterized by sensory nerve demyelination and inflammation of the transverse carpal ligament', 'Non-Invasive Treatment of Carpal Tunnel Syndrome', 'Carpal tunnel syndrome (CTS']","['physical therapy and an oral integrator', 'dietary integrator composed of acetyl-L-carnitine, α-lipoic acid,quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins', 'physical therapy']","['Sleep quality and Sensory Nerve Conduction Velocity data analysis', 'Clinical (sleep quality questionnaire to measure severity of paresthesia) and neurophysiological assessment (Sensory Nerve Conduction Velocity', 'sensory nerve conduction velocity']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C3875152', 'cui_str': 'Characterizes'}, {'cui': 'C0445254', 'cui_str': 'Sensory'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0011304', 'cui_str': 'Demyelination'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205106', 'cui_str': 'Transverse plane'}, {'cui': 'C0007285', 'cui_str': 'Bone structure of carpus'}, {'cui': 'C0023685', 'cui_str': 'Structure of ligament'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0031818', 'cui_str': 'Physiotherapy Specialty'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0001040', 'cui_str': 'Acetylcarnitine'}, {'cui': 'C0023791', 'cui_str': 'thioctic acid'}, {'cui': 'C0034392', 'cui_str': 'Quercetin'}, {'cui': 'C0006217', 'cui_str': 'Bromelains'}, {'cui': 'C0030342', 'cui_str': 'Pantothenic Acid'}, {'cui': 'C1261069', 'cui_str': 'Structure of left apicoposterior segmental bronchus'}, {'cui': 'C0042845', 'cui_str': 'Vitamin B 12'}]","[{'cui': 'C0424563', 'cui_str': 'Quality of sleep'}, {'cui': 'C0457378', 'cui_str': 'Sensory nerve conduction velocity'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0030554', 'cui_str': 'Paresthesia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",,0.0296892,"RESULTS Sleep quality and Sensory Nerve Conduction Velocity data analysis show improvement in both groups at 30 and 60 days, with statistically difference between them in both time of analysis. ","[{'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Marvulli', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Ianieri', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Grazia', 'Initials': 'G', 'LastName': 'Devenuto', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Falcicchio', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Giulia A', 'Initials': 'GA', 'LastName': 'Gallo', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Catia', 'Initials': 'C', 'LastName': 'Mennuni', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Maria F', 'Initials': 'MF', 'LastName': 'Gallone', 'Affiliation': 'Local Healthcare Company, Bari-Health District, Bari,. Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Fiore', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Ranieri', 'Initials': 'R', 'LastName': 'Maurizio', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}, {'ForeName': 'Marisa', 'Initials': 'M', 'LastName': 'Megna', 'Affiliation': 'Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari ""Aldo Moro"", Policlinico of Bari, Piazza G. Cesare 11, 70124 Bari. Italy.'}]","Endocrine, metabolic & immune disorders drug targets",['10.2174/1871530320666200728152953'] 2483,32723294,Online hemodiafilteration use in children: a single center experience with a twist.,"BACKGROUND Haemodiafilteration (HDF) is a promising new modality of renal replacement therapy (RRT). It is an improvement in the quality of hemodialysis (HD) and thus in the quality of patients'lives. The main obstacle to using HDF is the cost, especially in developing countries. The purpose of this study was to evaluate the benefits of incorporating HDF with different regimens in the treatment of children with end stage renal disease (ESRD). METHODS Thirty-four children with ESRD on regular HD in Pediatric Dialysis Unit, Children's Hospital, Ain Shams University were followed up in 2 phases: initial phase (all patients: HD thrice weekly for 3 months) and second phase, patients were randomized into 2 groups, HDF group and HD group, the former was subdivided into once and twice weekly HDF subgroups. Evaluation using history, clinical and laboratory parameters at 0, 3, 9 and 18 months was carried out. RESULTS On short term, we found that the HDF group was significantly superior to HD group regarding all clinical and laboratory parameters. Also, twice HDF subgroup was significantly superior to once HDF subgroup. This was confirmed on long term follow up, but the once HDF proved comparable to twice subgroup. CONCLUSIONS Incorporating online hemodiafilteration (OL-HDF) in the RRT of children was beneficial in most of the clinical and laboratory parameters measured. It's not all or non; OL-HDF, even once a week, can improve outcomes of HD without significantly affecting the cost.",2020,"On short term, we found that the HDF group was significantly superior to HD group regarding all clinical and laboratory parameters.","[""Thirty-four children with ESRD on regular HD in Pediatric Dialysis Unit, Children's Hospital, Ain Shams University"", 'children with end stage renal disease (ESRD', 'children']","['HDF group and HD', 'Haemodiafilteration (HDF']",['quality of hemodialysis (HD'],"[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1629858', 'cui_str': 'Dialysis unit'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0347129', 'cui_str': 'Dysplasia of anus'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0041740', 'cui_str': 'University'}]","[{'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]",34.0,0.0158975,"On short term, we found that the HDF group was significantly superior to HD group regarding all clinical and laboratory parameters.","[{'ForeName': 'Magid A A', 'Initials': 'MAA', 'LastName': 'Ibrahim', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ihab Z', 'Initials': 'IZ', 'LastName': 'ElHakim', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Soliman', 'Affiliation': 'Department of Clinical Pathology & Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Muhammad A', 'Initials': 'MA', 'LastName': 'Mubarak', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Ragia M', 'Initials': 'RM', 'LastName': 'Said', 'Affiliation': 'Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ragia_marei@med.asu.edu.eg.'}]",BMC nephrology,['10.1186/s12882-020-01957-9'] 2484,32723318,Study protocol for a randomized controlled trial of the effectiveness of adding motivational interviewing or stratified vocational advice intervention to usual case management on return to work for people with musculoskeletal disorders. The MI-NAV study.,"BACKGROUND Little research exists on the effectiveness of motivational interviewing (MI) on return to work (RTW) in workers on long term sick leave. The objectives of this study protocol is to describe a randomized controlled trial (RCT) with the objectives to compare the effectiveness and cost-effectiveness of usual case management alone with usual case management plus MI or usual case management plus stratified vocational advice intervention (SVAI), on RTW among people on sick leave due to musculoskeletal (MSK) disorders. METHODS A multi-arm RCT with economic evaluation will be conducted in Norway with recruitment of 450 participants aged 18-67 years on 50-100% sick leave for > 7 weeks due to MSK disorders. Participants will be randomized to either usual case management by the Norwegian Labour and Welfare Administration (NAV) alone, usual case management by NAV plus MI, or usual case management by NAV plus SVAI. Trained caseworkers in NAV will give two MI sessions, and physiotherapists will give 1-4 SVAI sessions depending upon risk of long-term sick leave. The primary outcome is the number of sick leave days from randomization to 6 months follow-up. Secondary outcomes are number of sick leave days at 12 months follow-up, time until sustainable RTW (≥4 weeks of at least 50% of their usual working hours) at 12 months, proportions of participants receiving sick leave benefits during 12 months of follow-up, and MSK symptoms influencing health at 12 months. Cost-utility evaluated by the EuroQoL 5D-5L and cost-benefit analyses will be performed. Fidelity of the interventions will be assessed through audio-recordings of approximately 10% of the intervention sessions. DISCUSSION The results from this RCT will inform stakeholders involved in supporting RTW due to MSK disorders such as staff within NAV and primary health care. TRIAL REGISTRATION ClinicalTrials.gov ID: NCT03871712 registered March 12th 2020.",2020,"BACKGROUND Little research exists on the effectiveness of motivational interviewing (MI) on return to work (RTW) in workers on long term sick leave.","['people on sick leave due to musculoskeletal (MSK) disorders', 'people with musculoskeletal disorders', 'Norway with recruitment of 450 participants aged 18-67\u2009years on 50-100% sick leave for >\u20097\u2009weeks due to MSK disorders']","['motivational interviewing or stratified vocational advice intervention', 'motivational interviewing (MI', 'usual case management by the Norwegian Labour and Welfare Administration (NAV) alone, usual case management by NAV plus MI, or usual case management by NAV plus SVAI', 'usual case management alone with usual case management plus MI or usual case management plus stratified vocational advice intervention (SVAI']","['number of sick leave days at 12\u2009months follow-up, time until sustainable RTW', 'effectiveness and cost-effectiveness', 'number of sick leave days from randomization to 6\u2009months follow-up']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0026857', 'cui_str': 'Disorder of musculoskeletal system'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C3844104', 'cui_str': '450'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0085971', 'cui_str': 'Case management'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0037440', 'cui_str': 'Social services'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0574545', 'cui_str': 'Navajo language'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0242807', 'cui_str': 'Sick Leave'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0425105', 'cui_str': 'Returned to work'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}]",450.0,0.136165,"BACKGROUND Little research exists on the effectiveness of motivational interviewing (MI) on return to work (RTW) in workers on long term sick leave.","[{'ForeName': 'Britt Elin', 'Initials': 'BE', 'LastName': 'Øiestad', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway. brielo@oslomet.no.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Aanesen', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}, {'ForeName': 'Ida', 'Initials': 'I', 'LastName': 'Løchting', 'Affiliation': 'Research and Communication Unit for MSK Health (FORMI), Oslo University Hospital and Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Kjersti', 'Initials': 'K', 'LastName': 'Storheim', 'Affiliation': 'Department of Physiotherapy, Research and Communication Unit for MSK Health (FORMI), Oslo University Hospital, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Tingulstad', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}, {'ForeName': 'Tarjei L', 'Initials': 'TL', 'LastName': 'Rysstad', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}, {'ForeName': 'Milada C', 'Initials': 'MC', 'LastName': 'Småstuen', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}, {'ForeName': 'Anne Therese', 'Initials': 'AT', 'LastName': 'Tveter', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Sowden', 'Affiliation': 'School of Primary, Community & Social Care, Keele University, Keele, UK.'}, {'ForeName': 'Gwenllian', 'Initials': 'G', 'LastName': 'Wynne-Jones', 'Affiliation': 'Faculty of Medicine and Health Sciences, School of Primary, Community and Social Care, and School of Nursing and Midwifery, Keele University, Keele, UK.'}, {'ForeName': 'Egil A', 'Initials': 'EA', 'LastName': 'Fors', 'Affiliation': 'General Practice Research Unit, Department of Public Health and Nursing Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.'}, {'ForeName': 'Maurits', 'Initials': 'M', 'LastName': 'van Tulder', 'Affiliation': 'Department Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Rigmor C', 'Initials': 'RC', 'LastName': 'Berg', 'Affiliation': 'Norwegian Institute of Public Health, Oslo, Norway.'}, {'ForeName': 'Nadine E', 'Initials': 'NE', 'LastName': 'Foster', 'Affiliation': 'School of Primary, Community & Social Care, Keele University, Keele, UK.'}, {'ForeName': 'Margreth', 'Initials': 'M', 'LastName': 'Grotle', 'Affiliation': 'Department of Physiotherapy, OsloMet - Oslo Metropolitan University, St. Olavs plass, 0130, Oslo, Norway.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03475-z'] 2485,32723330,Study protocol training for life: a stepped wedge cluster randomized trial about emergency obstetric simulation-based training in a low-income country.,"BACKGROUND Globally perinatal and maternal mortality rates remain unacceptably high. There is increasing evidence that simulation-based training in obstetric emergencies is associated with improvement in clinical outcomes. However, the results are not entirely consistent. The need for continued research in a wide variety of clinical settings to establish what works, where and why was recommended. The aim of this study is to investigate the effectiveness of an emergency obstetric simulation-based training program with medical technical and teamwork skills on maternal and perinatal mortality in a low-income country. METHODS A stepped wedge cluster randomized trial will be conducted at the medium to high-risk labour ward at Mulago Hospital, Kampala, Uganda, with an annual delivery rate of over 23,000. The training will be performed using a train-the-trainers model in which training is cascaded down from master trainers to local facilitators (gynaecologists) to learners (senior house officers). Local facilitators will be trained during a four-day train-the-trainers course with an annual repetition. The senior house officers will be naturally divided in seven clusters and randomized for the moment of training. The training consists of a one-day, monodisciplinary, simulation-based training followed by repetition training sessions. Scenarios are based on the main local causes of maternal and neonatal mortality and focus on both medical technical and crew resource management skills. Kirkpatrick's classification will be used to evaluate the training program. Primary outcome will be the composite of maternal and neonatal mortality ratios. Secondary outcome will comprise course perception, evaluation of the instructional design of the training, knowledge, technical skills, team performance, percentage of ventouse deliveries, percentage of caesarean sections, and a Weighted Adverse Outcome Score. DISCUSSION This stepped wedge cluster randomized trial will investigate the effect of a monodisciplinary simulation-based obstetric training in a low-income country, focusing on both medical technical skills and crew resource management skills, on patient outcome at one of the largest labour wards worldwide. We will use a robust study design which will allow us to better understand the training effects, and difficulties in evaluating training programs in low-income countries. TRIAL REGISTRATION ISRCTN98617255 , retrospectively registered July 23, 2018.",2020,"The training consists of a one-day, monodisciplinary, simulation-based training followed by repetition training sessions.","['medium to high-risk labour ward at Mulago Hospital, Kampala, Uganda, with an annual delivery rate of over 23,000']","['monodisciplinary, simulation-based training followed by repetition training sessions', 'emergency obstetric simulation-based training program with medical technical and teamwork skills', 'monodisciplinary simulation-based obstetric training', 'emergency obstetric simulation-based training']","['composite of maternal and neonatal mortality ratios', 'maternal and perinatal mortality', 'course perception, evaluation of the instructional design of the training, knowledge, technical skills, team performance, percentage of ventouse deliveries, percentage of caesarean sections, and a Weighted Adverse Outcome Score']","[{'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C1305702', 'cui_str': 'Ward'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041573', 'cui_str': 'Uganda'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0449851', 'cui_str': 'Technique'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0027616', 'cui_str': 'Neonatal Mortality'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0031062', 'cui_str': 'Perinatal Mortality'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0042225', 'cui_str': 'Delivery by vacuum extraction'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0821601,"The training consists of a one-day, monodisciplinary, simulation-based training followed by repetition training sessions.","[{'ForeName': 'A A C', 'Initials': 'AAC', 'LastName': 'van Tetering', 'Affiliation': 'Department of Obstetrics and Gynaecology, MUMC+, Maastricht, The Netherlands. anne_van_tetering@hotmail.com.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'van Meurs', 'Affiliation': 'Department of Obstetrics and Gynaecology, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Ntuyo', 'Affiliation': 'Department of Obstetrics and Gynaecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda.'}, {'ForeName': 'M B', 'Initials': 'MB', 'LastName': 'van der Hout-van der Jagt', 'Affiliation': 'Department of Obstetrics and Gynaecology, Máxima Medical Centre, Veldhoven, The Netherlands.'}, {'ForeName': 'L G M', 'Initials': 'LGM', 'LastName': 'Mulders', 'Affiliation': 'Department of Obstetrics and Gynaecology, Máxima Medical Centre, Veldhoven, The Netherlands.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Nolens', 'Affiliation': 'Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Namagambe', 'Affiliation': 'Department of Obstetrics and Gynaecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nakimuli', 'Affiliation': 'Department of Obstetrics and Gynaecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Byamugisha', 'Affiliation': 'Department of Obstetrics and Gynaecology, Makerere University and Mulago National Referral Hospital, Kampala, Uganda.'}, {'ForeName': 'S G', 'Initials': 'SG', 'LastName': 'Oei', 'Affiliation': 'Department of Obstetrics and Gynaecology, Máxima Medical Centre, Veldhoven, The Netherlands.'}]",BMC pregnancy and childbirth,['10.1186/s12884-020-03050-3'] 2486,32723349,Study protocol for a group-based motivational interviewing brief intervention to reduce substance use and sexual risk behavior among young adults experiencing homelessness.,"BACKGROUND Young people experiencing homelessness have alarmingly high rates of alcohol and other drug (AOD) use, which is associated with sexual risk behaviors such as unprotected sex, trading sex, and sex with multiple casual partners. Few risk reduction programs for this population have been developed and rigorously evaluated, particularly those that address both of these interrelated behaviors, use a collaborative and non-judgmental approach, and are feasible to deliver in settings where homeless young people seek services. This paper describes the protocol of a study evaluating a four-session Motivational Interviewing (MI)-based group risk reduction intervention for this population. The protocol has been shown to be efficacious in pilot work over 3 months with 200 homeless young adults [1]. The current study seeks to refine the intervention protocol and evaluate the program on a larger scale. METHODS/DESIGN In a cluster-cross-over randomized controlled trial, 18-25 year olds will receive the AWARE risk reduction program (n = 200) or standard care (n = 200) at one of three drop-in centers serving homeless youth in the Los Angeles area. We will evaluate intervention effects on primary outcomes of AOD use and sexual risk behavior, as well as secondary outcomes of health-related quality of life and social stability, over a 12-month period. DISCUSSION This project has the potential to fill a significant gap in prevention services by demonstrating that a brief intervention, feasible to deliver within settings where young people experiencing homelessness typically seeks services, can significantly reduce the interrelated problems of AOD use and sexual risk behavior. Trial registration ClinicalTrials.gov Identifier: NCT03735784. Registered November 18, 2018, https://clinicaltrials.gov/ct2/show/record/NCT03735784 (retrospectively registered).",2020,"This project has the potential to fill a significant gap in prevention services by demonstrating that a brief intervention, feasible to deliver within settings where young people experiencing homelessness typically seeks services, can significantly reduce the interrelated problems of AOD use and sexual risk behavior.","['Young people experiencing homelessness', 'young adults experiencing homelessness', '200 homeless young adults [1']","['motivational interviewing brief intervention', 'session Motivational Interviewing (MI)-based group risk reduction intervention', 'AWARE risk reduction program (n\u2009=\u2009200) or standard care (n\u2009=\u2009200) at one of three drop-in centers serving homeless youth in the Los Angeles area']","['substance use and sexual risk behavior', 'AOD use and sexual risk behavior', 'health-related quality of life and social stability']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0237154', 'cui_str': 'Homeless'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C4319558', 'cui_str': '200'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0242663', 'cui_str': 'Homeless Children'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]","[{'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205360', 'cui_str': 'Stable'}]",,0.0528739,"This project has the potential to fill a significant gap in prevention services by demonstrating that a brief intervention, feasible to deliver within settings where young people experiencing homelessness typically seeks services, can significantly reduce the interrelated problems of AOD use and sexual risk behavior.","[{'ForeName': 'Joan S', 'Initials': 'JS', 'LastName': 'Tucker', 'Affiliation': 'RAND Corporation, 1776 Main Street, PO Box 2136, Santa Monica, CA, 90407-2138, United States. jtucker@rand.org.'}, {'ForeName': 'Elizabeth J', 'Initials': 'EJ', 'LastName': ""D'Amico"", 'Affiliation': 'RAND Corporation, 1776 Main Street, PO Box 2136, Santa Monica, CA, 90407-2138, United States.'}, {'ForeName': 'Eric R', 'Initials': 'ER', 'LastName': 'Pedersen', 'Affiliation': 'RAND Corporation, 1776 Main Street, PO Box 2136, Santa Monica, CA, 90407-2138, United States.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Rodriguez', 'Affiliation': 'RAND Corporation, 20 Park Plaza, Suite 920, Boston, MA, 02116, United States.'}, {'ForeName': 'Rick', 'Initials': 'R', 'LastName': 'Garvey', 'Affiliation': 'RAND Corporation, 1776 Main Street, PO Box 2136, Santa Monica, CA, 90407-2138, United States.'}]",Addiction science & clinical practice,['10.1186/s13722-020-00201-x'] 2487,32723352,"Evaluation of zinc sulfate mucoadhesive formulation on recurrent aphthous stomatitis: a randomized double-blind, placebo-controlled clinical trial.","BACKGROUND Recurrent aphthous stomatitis (RAS) is a common lesion that affects the oral mucosa. There are several methods to treat RAS, including systemic and topical formulations. This study was conducted to evaluate the anti-inflammatory effect of topical zinc sulfate and its efficacy in the treatment of RAS. METHODS A double-blind randomized clinical trial was conducted on 46 patients with RAS. They were randomly assigned into two groups to receive a zinc sulfate mucoadhesive tablet or placebo for 7 days. The pain severity was measured at baseline and daily while the diameter of the lesion was measured at baseline and on days 3, 5, and 7. The obtained data were analyzed in SPSS V.16. RESULTS There was no significant difference in the mean diameter of lesions and pain at baseline between the two groups (P = 0.643 and P = 0.842, respectively). However, on the third, fifth, and seventh days of the study, the diameter of the lesion significantly reduced in the intervention group (P = 0.001) and the pain intensity became significantly different between groups from the fourth day of the study (P = 0.001). CONCLUSION Zinc sulfate mucoadhesive tablet was effective in recovery and reducing the pain and diameter of the aphthous lesion and could be considered for the treatment of RAS. TRIAL REGISTRATION Evaluation of the effectiveness of zinc sulfate mucoadhesive tablet in the improvement of recurrent aphthous stomatitis (RAS), IRCT20151109024975N9. Registered August 1, 2018, https://en.irct.ir/trial/32423 . This project was registered by the Iranian Registry of Clinical Trials ( http://www.irct.ir ). The IRCT ID was IRCT20151109024975N9.",2020,"There was no significant difference in the mean diameter of lesions and pain at baseline between the two groups (P = 0.643 and P = 0.842, respectively).","['recurrent aphthous stomatitis', '46 patients with RAS']","['zinc', 'topical zinc sulfate', 'zinc sulfate mucoadhesive formulation', 'zinc sulfate mucoadhesive tablet or placebo', 'placebo']","['diameter of the lesion', 'pain intensity', 'recurrent aphthous stomatitis (RAS', 'pain and diameter of the aphthous lesion', 'pain severity', 'mean diameter of lesions and pain']","[{'cui': 'C2931748', 'cui_str': 'Sutton disease 2'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0078794', 'cui_str': 'Zinc Sulfate'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C2931748', 'cui_str': 'Sutton disease 2'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",46.0,0.529027,"There was no significant difference in the mean diameter of lesions and pain at baseline between the two groups (P = 0.643 and P = 0.842, respectively).","[{'ForeName': 'Anahita', 'Initials': 'A', 'LastName': 'Ghorbani', 'Affiliation': 'Department of Oral and Maxillofacial Diseases, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Jafar', 'Initials': 'J', 'LastName': 'Akbari', 'Affiliation': 'Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Boorboor', 'Affiliation': 'Department of Oral and Maxillofacial Diseases, Faculty of Dentistry, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Nekoukar', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.'}, {'ForeName': 'Gohar', 'Initials': 'G', 'LastName': 'Eslami', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran. dr.gohar.eslami@gmail.com.'}]",BMC oral health,['10.1186/s12903-020-01194-4'] 2488,32723374,Mannitol and renal graft injury in patients undergoing deceased donor renal transplantation - a randomized controlled clinical trial.,"BACKGROUND Ischaemia/reperfusion (I/R) injury is associated with renal tissue damage during deceased donor renal transplantation. The effect of mannitol to reduce I/R injury during graft reperfusion in renal transplant recipients is based on weak evidence. We evaluated the effect of mannitol to reduce renal graft injury represented by 16 serum biomarkers, which are indicators for different important pathophysiological pathways. Our primary outcome were differences in biomarker concentrations between the mannitol and the placebo group 24 h after graft reperfusion. Additionally, we performed a linear mixed linear model to account biomarker concentrations before renal transplantation. METHODS Thirty-four patients undergoing deceased donor renal transplantation were randomly assigned to receive either 20% mannitol or 0.9% NaCl placebo solution before, during, and after graft reperfusion. Sixteen serum biomarkers (MMP1, CHI3L1, CCL2, MMP8, HGF, GH, FGF23, Tie2, VCAM1, TNFR1, IGFBP7, IL18, NGAL, Endostatin, CystC, KIM1) were measured preoperatively and 24 h after graft reperfusion using Luminex assays and ELISA. RESULTS Sixteen patients in each group were analysed. Tie2 differed 24 h after graft reperfusion between both groups (p = 0.011). Change of log2 transformed concentration levels over time differed significantly in four biomarkers (VCAM1,Endostatin, KIM1, GH; p = 0.007; p = 0.013; p = 0.004; p = 0.033; respectively) out of 16 between both groups. CONCLUSION This study showed no effect of mannitol on I/R injury in patients undergoing deceased renal transplantation. Thus, we do not support the routinely use of mannitol to attenuate I/R injury. TRIAL REGISTRATION NCT02705573 . Registered on 10th March 2016.",2020,"Sixteen serum biomarkers (MMP1, CHI3L1, CCL2, MMP8, HGF, GH, FGF23, Tie2,","['Thirty-four patients undergoing deceased donor renal transplantation', 'patients undergoing deceased renal transplantation', 'Sixteen patients in each group were analysed', 'renal transplant recipients', 'patients undergoing deceased donor renal transplantation ']","['Mannitol', 'mannitol', '20% mannitol or 0.9% NaCl placebo solution', 'placebo']","['Sixteen serum biomarkers (MMP1, CHI3L1, CCL2, MMP8, HGF, GH, FGF23, Tie2', 'renal graft injury', 'VCAM1, TNFR1, IGFBP7, IL18, NGAL, Endostatin, CystC, KIM1', 'biomarker concentrations']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0730392', 'cui_str': 'Donor renal transplantation'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0024730', 'cui_str': 'Mannitol'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0127082', 'cui_str': 'Interstitial Collagenase'}, {'cui': 'C1449159', 'cui_str': 'CCL2 protein, human'}, {'cui': 'C1721358', 'cui_str': 'MMP8 protein, human'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C3272931', 'cui_str': 'Fibroblast growth factor 23'}, {'cui': 'C0022671', 'cui_str': 'Transplant of kidney'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0255808', 'cui_str': 'Lymphocyte antigen CD120A'}, {'cui': 'C0383327', 'cui_str': 'Interleukin 18'}, {'cui': 'C0215955', 'cui_str': 'LCN2 protein, human'}, {'cui': 'C0534628', 'cui_str': 'Endostatin'}, {'cui': 'C2681921', 'cui_str': 'Kidney injury molecule-1'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",34.0,0.330782,"Sixteen serum biomarkers (MMP1, CHI3L1, CCL2, MMP8, HGF, GH, FGF23, Tie2,","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Reiterer', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Hu', 'Affiliation': 'Clinical Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Sljivic', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Falkner von Sonnenburg', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Fleischmann', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. edith.fleischmann@meduniwien.ac.at.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Kainz', 'Affiliation': 'Clinical Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Kabon', 'Affiliation': 'Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.'}]",BMC nephrology,['10.1186/s12882-020-01961-z'] 2489,32723393,Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin.,"OBJECTIVES Maintenance treatment with macrolide antibiotics has shown to be effective in reducing exacerbations in COPD patients. A major concern with prolonged treatment with antibiotics is the development of bacterial resistance. In this study we determined the effect of azithromycin on the development and acquisition of resistance to macrolides in the nasopharyngeal flora in COPD patients. METHODS This study was part of the COLUMBUS trial, a randomised, double-blind, placebo-controlled trial to measure the effect of maintenance treatment with azithromycin in 92 COPD patients on the exacerbation rates during a 12-month period. In order to determine resistance to macrolides, we used a targeted metagenomic approach to measure the presence and relative abundance of specific macrolide resistance genes ermB, ermF and mefA in throat samples collected at different time-points during this 12-month period. RESULTS There was no increased risk for acquisition of macrolide resistance genes in the azithromycin group compared to the placebo group in COPD patients. However, loss of the macrolide resistance gene ermB was increased overtime in the placebo treated group compared to the azithromycin group (n = 5 for the placebo group versus n = 0 for the azithromycin group at 12 months; p = 0.012). The change in relative abundance of the three macrolide-resistance genes showed that all but one (ermF) increased during treatment with azithromycin. CONCLUSIONS The acquisition rate of macrolide resistance genes in COPD patients treated with azithromycin maintenance therapy was limited, but the relative abundance of macrolide resistance genes increased significantly over time compared to placebo. This study was part of the COLUMBUS trial ( Clinicaltrials.gov , NCT00985244 ).",2020,There was no increased risk for acquisition of macrolide resistance genes in the azithromycin group compared to the placebo group in COPD patients.,"['COPD patients during maintenance treatment with', 'COPD patients treated with', 'COPD patients', '92 COPD patients on the exacerbation rates during a 12-month period']","['macrolide antibiotics', 'azithromycin', 'azithromycin maintenance therapy', 'placebo']","['risk for acquisition of macrolide resistance genes', 'loss of the macrolide resistance gene ermB', 'relative abundance of macrolide resistance genes', 'acquisition rate of macrolide resistance genes']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0620347', 'cui_str': 'compound A 12'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0003240', 'cui_str': 'Macrolide antibiotic product'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0677908', 'cui_str': 'Maintenance therapy'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0003240', 'cui_str': 'Macrolide antibiotic product'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0017337', 'cui_str': 'Gene'}, {'cui': 'C0080103', 'cui_str': 'Relative'}]",92.0,0.237699,There was no increased risk for acquisition of macrolide resistance genes in the azithromycin group compared to the placebo group in COPD patients.,"[{'ForeName': 'Remco S', 'Initials': 'RS', 'LastName': 'Djamin', 'Affiliation': 'Department t of Respiratory Medicine, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands.'}, {'ForeName': 'Sander', 'Initials': 'S', 'LastName': 'Talman', 'Affiliation': 'Department t of Respiratory Medicine, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands. STalman@amphia.nl.'}, {'ForeName': 'Eefje J A', 'Initials': 'EJA', 'LastName': 'Schrauwen', 'Affiliation': 'Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands.'}, {'ForeName': 'Christian J H', 'Initials': 'CJH', 'LastName': 'von Wintersdorff', 'Affiliation': 'Department of Medical Microbiology, Maastricht University Medical Center+, Maastricht, The Netherlands.'}, {'ForeName': 'Petra F', 'Initials': 'PF', 'LastName': 'Wolffs', 'Affiliation': 'Department of Medical Microbiology, Maastricht University Medical Center+, Maastricht, The Netherlands.'}, {'ForeName': 'Paul H M', 'Initials': 'PHM', 'LastName': 'Savelkoul', 'Affiliation': 'Department of Medical Microbiology, Maastricht University Medical Center+, Maastricht, The Netherlands.'}, {'ForeName': 'Sevim', 'Initials': 'S', 'LastName': 'Uzun', 'Affiliation': 'Department t of Respiratory Medicine, Amphia Hospital, Molengracht 21, 4818 CK, Breda, The Netherlands.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Kerstens', 'Affiliation': 'Orion Statistical Consulting BV, Hilvarenbeek, The Netherlands.'}, {'ForeName': 'Menno M', 'Initials': 'MM', 'LastName': 'van der Eerden', 'Affiliation': 'Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Jan A J W', 'Initials': 'JAJW', 'LastName': 'Kluytmans', 'Affiliation': 'Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands.'}]",Antimicrobial resistance and infection control,['10.1186/s13756-020-00783-w'] 2490,32723399,Manual therapy versus therapeutic exercise in non-specific chronic neck pain: a randomized controlled trial.,"BACKGROUND Nonspecific chronic neck pain is a fairly common disorder that causes a great impact, and it is greatly influenced by psychosocial factors. Among a number of treatment modalities described for its management, the most common approach is based on manual therapy and specific therapeutic exercise, which have shown a moderate effect on subjects with chronic non-specific neck pain. However, the effect times of these treatments have not been accurately detailed. Our study aims to break down and compare the effects of two experimental treatments based on manual therapy and therapeutic exercise. METHODS The short-term and mid-term changes produced by different therapies on subjects with non-specific chronic neck pain were studied. The sample was randomized divided into three groups: manual therapy, therapeutic exercise, and placebo. As dependent variables of our research, we studied (a) pain, based on the visual analog scale and the pressure pain threshold, and (b) cervical disability, through the Neck Disability Index (NDI). Outcomes were registered on week 1, week 4, and week 12. The findings were analyzed statistically considering a 5% significance level (P ≤ 0.05). RESULTS No statistically significant differences (P 0.05) were obtained between the experimental groups, if they exist against the control group. Nonetheless, we found that manual therapy improved perceived pain before than therapeutic exercise, while therapeutic exercise reduced cervical disability before than manual therapy. Effect size (R 2 ) shows medium and large effects for both experimental treatments. CONCLUSION There are no differences between groups in short and medium terms. Manual therapy achieves a faster reduction in pain perception than therapeutic exercise. Therapeutic exercise reduces disability faster than manual therapy. Clinical improvement could potentially be influenced by central processes. TRIAL REGISTRATION Brazilian Clinical Trial Registry, RBR-2vj7sw. Registered on 28 November 2018.",2020,"No statistically significant differences (P 0.05) were obtained between the experimental groups, if they exist against the control group.","['subjects with non-specific chronic neck pain', 'subjects with chronic non-specific neck pain', 'non-specific chronic neck pain']","['manual therapy, therapeutic exercise, and placebo', 'Manual therapy versus therapeutic exercise', 'Manual therapy', 'Therapeutic exercise']","['perceived pain', 'cervical disability', 'visual analog scale and the pressure pain threshold, and (b) cervical disability, through the Neck Disability Index (NDI', 'pain perception']","[{'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]","[{'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",,0.079981,"No statistically significant differences (P 0.05) were obtained between the experimental groups, if they exist against the control group.","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Bernal-Utrera', 'Affiliation': 'Doctoral Program in Health Sciences, University of Seville, Seville, Spain. cbernal495@gmail.com.'}, {'ForeName': 'Juan Jose', 'Initials': 'JJ', 'LastName': 'Gonzalez-Gerez', 'Affiliation': 'Fisiosur I+D Research Institute, Garrucha, Almería, Spain.'}, {'ForeName': 'Ernesto', 'Initials': 'E', 'LastName': 'Anarte-Lazo', 'Affiliation': 'Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Cleofas', 'Initials': 'C', 'LastName': 'Rodriguez-Blanco', 'Affiliation': 'Fisiosur I+D Research Institute, Garrucha, Almería, Spain.'}]",Trials,['10.1186/s13063-020-04610-w'] 2491,32720870,Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.,"Background Relevance of antiangiogenic treatment with bevacizumab in patients with glioblastoma is controversial because progression-free survival benefit did not translate into an overall survival (OS) benefit in randomized phase III trials. Purpose To perform longitudinal characterization of intratumoral angiogenesis and oxygenation by using dynamic susceptibility contrast agent-enhanced (DSC) MRI and evaluate its potential for predicting outcome from administration of bevacizumab. Materials and Methods In this secondary analysis of the prospective randomized phase II/III European Organization for Research and Treatment of Cancer 26101 trial conducted between October 2011 and December 2015 in 596 patients with first recurrence of glioblastoma, the subset of patients with availability of anatomic MRI and DSC MRI at baseline and first follow-up was analyzed. Patients were allocated into those administered bevacizumab (hereafter, the BEV group; either bevacizumab monotherapy or bevacizumab with lomustine) and those not administered bevacizumab (hereafter, the non-BEV group with lomustine monotherapy). Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated inversion recovery (FLAIR) signal abnormality volume, Gaussian-normalized relative cerebral blood volume (nrCBV), Gaussian-normalized relative blood flow (nrCBF), and tumor metabolic rate of oxygen (nTMRO 2 ) was quantified. The predictive ability of these imaging parameters was assessed with multivariable Cox regression and formal interaction testing. Results A total of 254 of 596 patients were evaluated (mean age, 57 years ± 11; 155 men; 161 in the BEV group and 93 in non-BEV group). Progression-free survival was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different ( P = .15). The nrCBV decreased for the BEV group (-16.3%; interquartile range [IQR], -39.5% to 12.0%; P = .01), but not for the non-BEV group (1.2%; IQR, -17.9% to 23.3%; P = .19) between baseline and first follow-up. An identical pattern was observed for both nrCBF and nTMRO 2 values. Contrast-enhanced tumor and noncontrast-enhanced T2 FLAIR signal abnormality volumes decreased for the BEV group (-66% [IQR, -83% to -35%] and -33% [IQR, -71% to -5%], respectively; P < .001 for both), whereas they increased for the non-BEV group (30% [IQR, -17% to 98%], P = .001; and 10% [IQR, -13% to 82%], P = .02, respectively) between baseline and first follow-up. None of the assessed MRI parameters were predictive for OS in the BEV group. Conclusion Bevacizumab treatment decreased tumor volumes, angiogenesis, and oxygenation, thereby reflecting its effectiveness for extending progression-free survival; however, these parameters were not predictive of overall survival (OS), which highlighted the challenges of identifying patients that derive an OS benefit from bevacizumab. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Dillon in this issue.",2020,"Progression-free survival was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different ( P = .15).","['A total of 254 of 596 patients were evaluated (mean age, 57 years ± 11; 155 men; 161 in the BEV group and 93 in non-BEV group', 'Cancer 26101 trial conducted between October 2011 and December 2015 in 596 patients with first recurrence of glioblastoma, the subset of patients with availability of anatomic MRI and DSC MRI at baseline and first follow-up was analyzed', 'patients with glioblastoma']","['bevacizumab monotherapy or bevacizumab with lomustine', 'bevacizumab (hereafter, the non-BEV group with lomustine monotherapy', 'bevacizumab', 'Bevacizumab']","['Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated inversion recovery (FLAIR) signal abnormality volume, Gaussian-normalized relative cerebral blood volume (nrCBV), Gaussian-normalized relative blood flow (nrCBF), and tumor metabolic rate of oxygen (nTMRO 2 ', 'tumor volumes, angiogenesis, and oxygenation, thereby reflecting its effectiveness for extending progression-free survival', 'Contrast-enhanced tumor and noncontrast-enhanced T2 FLAIR signal abnormality volumes', 'overall survival (OS', 'Progression-free survival', 'nrCBV']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0017636', 'cui_str': 'Glioblastoma'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0220784', 'cui_str': 'Anatomic'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0012655', 'cui_str': 'Diathesis'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0023972', 'cui_str': 'Lomustine'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0021943', 'cui_str': 'Chromosome inversion'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0028377', 'cui_str': 'Gaussian Distribution'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C4277714', 'cui_str': 'Cerebral Blood Volume'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",596.0,0.0767009,"Progression-free survival was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different ( P = .15).","[{'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Kickingereder', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Brugnara', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Mikkel Bo', 'Initials': 'MB', 'LastName': 'Hansen', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Nowosielski', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Irada', 'Initials': 'I', 'LastName': 'Pflüger', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Schell', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Fabian', 'Initials': 'F', 'LastName': 'Isensee', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Martha', 'Initials': 'M', 'LastName': 'Foltyn', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Neuberger', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Kessler', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sahm', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Antje', 'Initials': 'A', 'LastName': 'Wick', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Heiland', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weller', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Platten', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'von Deimling', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Klaus H', 'Initials': 'KH', 'LastName': 'Maier-Hein', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Leif', 'Initials': 'L', 'LastName': 'Østergaard', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'van den Bent', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Thierry', 'Initials': 'T', 'LastName': 'Gorlia', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Wick', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Bendszus', 'Affiliation': 'From the Department of Neuroradiology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany (P.K., G.B., I.P., M.S., M.F., U.N., S.H., M.B.); Center of Functionally Integrative Neuroscience and MINDLab, Aarhus University Hospital, Aarhus, Denmark (M.B.H., L.Ø.); Neurology Clinic, Heidelberg University Hospital, Heidelberg, Germany (M.N., T.K., A.W., W.W.); Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (M.N.); Medical Image Computing, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.I., K.H.M.H.); Clinical Cooperation Unit Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany (T.K., W.W.); Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany (F.S., A.v.D.); Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany (F.S., A.v.D.); Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland (M.W.); Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany (M.P.); Pattern Analysis and Learning Group, Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany (K.H.M.H.); Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark (L.Ø.); Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, the Netherlands (M.J.v.d.B.); and European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium (T.G.).'}]",Radiology,['10.1148/radiol.2020200978'] 2492,32720906,"Maternal Parenting Electronic Diary in the Context of a Home Visit Intervention for Adolescent Mothers in an Urban Deprived Area of São Paulo, Brazil: Randomized Controlled Trial.","BACKGROUND Pregnancy during adolescence is prevalent in low- and middle-income countries (LMICs), which is associated with various adverse outcomes that can be prevented with home visiting programs. However, testing these interventions in LMICs can be challenging due to limited resources. The use of electronic data collection via smartphones can be an alternative and ideal low-cost method to measure outcomes in an environment with adverse conditions. OBJECTIVE Our study had two objectives: to test the efficacy of a nurse home visiting intervention on maternal parenting and well-being measured by an electronic daily diary (eDiary), and to investigate the compliance rate of the eDiary measurement method. METHODS We conducted a randomized controlled trial to test the efficacy of Primeiros Laços, a nurse home visiting program, for adolescent mothers living in an urban deprived area of São Paulo, Brazil. A total of 169 pregnant adolescents were assessed for eligibility criteria, 80 of whom were included and randomized to the intervention (n=40) and control group (care as usual, n=40). Primeiros Laços is a home visiting intervention delivered by trained nurses tailored to first-time pregnant adolescents and their children, starting during the first 16 weeks of pregnancy until the child reaches 24 months of age. Participants were assessed by blind interviewers at 8-16 weeks of pregnancy (baseline), 30 weeks of pregnancy, and when the child was 3, 6, and 12 months of age. At 18 months, participants were assessed regarding maternal parenting and parental well-being using a 7-consecutive-day eDiary. The smartphone app was programmed to notify participants every day at 9:00 PM over a period of seven days. RESULTS We were able to contact 57/80 (71%) participants (29 from the intervention group and 28 from the control group) when the child was 18 months of age. Forty-eight of the 57 participants (84%) completed at least one day of the eDiary protocol. The daily compliance rate ranged from 49% to 70%. Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, 95% CI [0.06, 0.58], P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds ratio=2.33, 95% CI [1.20, 4.50], P=.01).Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds ratio=2.33, P=.01). CONCLUSIONS The Primeiros Laços intervention improved maternal parenting and parental well-being, demonstrating its promise for low-income adolescent mothers. The compliance rate of the eDiary assessment showed that it was generally accepted by adolescent mothers with limited resources. Future studies can implement ambulatory assessment in LMICs via smartphones to measure mother and child behaviors. TRIAL REGISTRATION ClinicalTrials.gov NCT02807818; https://clinicaltrials.gov/ct2/show/NCT02807818.",2020,"Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, 95% CI [0.06, 0.58], P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds ratio=2.33, 95% CI [1.20, 4.50], P=.01).Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds","['adolescent mothers living in an urban deprived area of São Paulo, Brazil', '169 pregnant adolescents were assessed for eligibility criteria, 80 of whom were included and randomized to the intervention (n=40) and control group (care as usual, n=40', 'Forty-eight of the 57 participants (84%) completed at least one day of the eDiary protocol', 'adolescent mothers with limited resources', 'Adolescent Mothers in an Urban Deprived Area of São Paulo, Brazil']","['Primeiros Laços, a nurse home visiting program', 'nurse home visiting intervention']","['compliance rate of the eDiary assessment', 'maternal parenting behavior of the mother telling a story or singing to the child (odds', 'maternal parenting behavior of the mother telling a story or singing to the child', 'Maternal Parenting Electronic Diary', 'maternal parenting and parental well-being', 'daily compliance rate']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0006137', 'cui_str': 'Brazil'}, {'cui': 'C0549206', 'cui_str': 'Pregnant'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0035201', 'cui_str': 'Resources'}]","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",169.0,0.0833277,"Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, 95% CI [0.06, 0.58], P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds ratio=2.33, 95% CI [1.20, 4.50], P=.01).Our analyses showed a significant effect of the intervention on parental well-being (B=0.32, P=.02) and the maternal parenting behavior of the mother telling a story or singing to the child (odds","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Fatori', 'Affiliation': 'Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Argeu', 'Affiliation': 'Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Brentani', 'Affiliation': 'Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Chiesa', 'Affiliation': 'Collective Health Nursing Department, School of Nursing, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Lislaine', 'Initials': 'L', 'LastName': 'Fracolli', 'Affiliation': 'Collective Health Nursing Department, School of Nursing, University of Sao Paulo, Sao Paulo, Brazil.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Matijasevich', 'Affiliation': 'Department of Preventive Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Euripedes C', 'Initials': 'EC', 'LastName': 'Miguel', 'Affiliation': 'Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Polanczyk', 'Affiliation': 'Department of Psychiatry, University of Sao Paulo Medical School, Sao Paulo, Brazil.'}]",JMIR mHealth and uHealth,['10.2196/13686'] 2493,32720907,Impact of an Electronic Health Service on Child Participation in Pediatric Oncology Care: Quasiexperimental Study.,"BACKGROUND For children 6-12 years old, there is a shortage of electronic Health (eHealth) services that promote their participation in health care. Therefore, a digital communication tool, called Sisom, was developed to give children a voice in their health care. Children with long-term diseases want to be more involved in their health care and have the right to receive information, be listened to, express their opinions, and participate in decision making in health care. However, the outcomes of using Sisom in practice at pediatric oncology clinics have not been investigated. OBJECTIVE The aim of this study was to investigate children's participation during appointments with pediatricians at pediatric oncology clinics, with or without the use of the eHealth service Sisom. METHODS A quasiexperimental design with mixed methods was used. We analyzed 27 filmed appointments with pediatricians for 14 children (8 girls and 6 boys) aged 6-12 years (mean 8.3 years) with a cancer diagnosis. The intervention group consisted of children who used Sisom prior to their appointments with pediatricians at a pediatric oncology clinic, and the control group consisted of children who had appointments with pediatricians at 4 pediatric oncology clinics. Data from observations from the videos were quantitatively and qualitatively analyzed. The quantitative analysis included manual calculations of how many times the pediatricians spoke directly to the children, the proportion of the appointment time that the children were talking, and levels of participation by the children. For the qualitative analysis, we used directed content analysis to analyze the children's levels of participation guided by a framework based on Shier's model of participation. RESULTS Pediatricians directed a greater proportion of their discussion toward the child in the intervention group (731 occasions) than in the control group (624 occasions), but the proportion of the appointment time the children talked was almost the same for both the intervention and control groups (mean 17.0 minutes vs 17.6 minutes). The levels of participation corresponded to the first three levels of Shier's participation model: children were listened to, children were supported to express their views, and children's views were taken into account. The results showed an increased level of participation by the children in the intervention group. Several codes that were found did not fit into any of the existing categories, and a new category was thus formed: children received information. CONCLUSIONS This study shows that the eHealth service Sisom can increase children's participation during appointments with health care professionals. Further studies employing a randomized control design focusing on the effects of eHealth services on children's health outcomes, perceived participation, and cost-effectiveness could make a significant contribution to guiding the implementation of eHealth services in pediatric care.",2020,This study shows that the eHealth service Sisom can increase children's participation during appointments with health care professionals.,"['Children with long-term diseases', ""children's participation during appointments with pediatricians at pediatric oncology clinics, with or without the use of the eHealth service Sisom"", 'Child Participation in Pediatric Oncology Care', 'children 6-12 years old', '27 filmed appointments with pediatricians for 14 children (8 girls and 6 boys) aged 6-12 years (mean 8.3 years) with a cancer diagnosis']","['children who used Sisom prior to their appointments with pediatricians at a pediatric oncology clinic, and the control group consisted of children who had appointments with pediatricians at 4 pediatric oncology clinics', 'Electronic Health Service']","['level of participation', 'proportion of the appointment time the children talked']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0237433', 'cui_str': 'Pediatrician'}, {'cui': 'C3816504', 'cui_str': 'Pediatric oncology clinic'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1328956', 'cui_str': 'eHealth'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C1518931', 'cui_str': 'Pediatric oncology'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C1704608', 'cui_str': 'Film'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3816504', 'cui_str': 'Pediatric oncology clinic'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018747', 'cui_str': 'Services, Health'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037817', 'cui_str': 'Speech'}]",,0.0229075,This study shows that the eHealth service Sisom can increase children's participation during appointments with health care professionals.,"[{'ForeName': 'Britt-Mari', 'Initials': 'BM', 'LastName': 'Gilljam', 'Affiliation': 'School of Health and Welfare, Halmstad University, Halmstad, Sweden.'}, {'ForeName': 'Jens M', 'Initials': 'JM', 'LastName': 'Nygren', 'Affiliation': 'School of Health and Welfare, Halmstad University, Halmstad, Sweden.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Svedberg', 'Affiliation': 'School of Health and Welfare, Halmstad University, Halmstad, Sweden.'}, {'ForeName': 'Susann', 'Initials': 'S', 'LastName': 'Arvidsson', 'Affiliation': 'School of Health and Welfare, Halmstad University, Halmstad, Sweden.'}]",Journal of medical Internet research,['10.2196/17673'] 2494,32720908,Changing the Health Behavior of Patients With Cardiovascular Disease Through an Electronic Health Intervention in Three Different Countries: Cost-Effectiveness Study in the Do Cardiac Health: Advanced New Generation Ecosystem (Do CHANGE) 2 Randomized Controlled Trial.,"BACKGROUND During the last few decades, preventing the development of cardiovascular disease has become a mainstay for reducing cardiovascular morbidity and mortality. It has been suggested that interventions should focus more on committed approaches of self-care, such as electronic health techniques. OBJECTIVE This study aimed to provide evidence to understand the financial consequences of implementing the ""Do Cardiac Health: Advanced New Generation Ecosystem"" (Do CHANGE 2) intervention, which was evaluated in a multisite randomized controlled trial to change the health behavior of patients with cardiovascular disease. METHODS The cost-effectiveness analysis of the Do CHANGE 2 intervention was performed with the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing tool, based on a Markov model of five health states. The following two types of costs were considered for both study groups: (1) health care costs (ie, costs associated with the time spent by health care professionals on service provision, including consultations, and associated unplanned hospitalizations, etc) and (2) societal costs (ie, costs attributed to the time spent by patients and informal caregivers on care activities). RESULTS The Do CHANGE 2 intervention was less costly in Spain (incremental cost was -€2514.90) and more costly in the Netherlands and Taiwan (incremental costs were €1373.59 and €1062.54, respectively). Compared with treatment as usual, the effectiveness of the Do CHANGE 2 program in terms of an increase in quality-adjusted life-year gains was slightly higher in the Netherlands and lower in Spain and Taiwan. CONCLUSIONS In general, we found that the incremental cost-effectiveness ratio strongly varied depending on the country where the intervention was applied. The Do CHANGE 2 intervention showed a positive cost-effectiveness ratio only when implemented in Spain, indicating that it saved financial costs in relation to the effect of the intervention. TRIAL REGISTRATION ClinicalTrials.gov NCT03178305; https://clinicaltrials.gov/ct2/show/NCT03178305.",2020,"The Do CHANGE 2 intervention was less costly in Spain (incremental cost was -€2514.90) and more costly in the Netherlands and Taiwan (incremental costs were €1373.59 and €1062.54, respectively).",['patients with cardiovascular disease'],['Electronic Health Intervention'],"['cardiovascular morbidity and mortality', 'incremental cost-effectiveness ratio', 'health care costs (ie, costs associated with the time spent by health care professionals on service provision, including consultations, and associated unplanned hospitalizations, etc) and (2) societal costs (ie, costs attributed to the time spent by patients and informal caregivers on care activities', 'quality-adjusted life-year gains', 'positive cost-effectiveness ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1301700', 'cui_str': 'Cardiovascular morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0085552', 'cui_str': 'Health Costs'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0449234', 'cui_str': 'Attribute'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.0814669,"The Do CHANGE 2 intervention was less costly in Spain (incremental cost was -€2514.90) and more costly in the Netherlands and Taiwan (incremental costs were €1373.59 and €1062.54, respectively).","[{'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Piera-Jiménez', 'Affiliation': 'Open Evidence Research Group, Universitat Oberta de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'Winters', 'Affiliation': 'Smart Homes, Eindhoven, Netherlands.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Broers', 'Affiliation': 'Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Damià', 'Initials': 'D', 'LastName': 'Valero-Bover', 'Affiliation': 'Department of R&D, Badalona Serveis Assistencials, Badalona, Spain.'}, {'ForeName': 'Mirela', 'Initials': 'M', 'LastName': 'Habibovic', 'Affiliation': 'Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Jos W M G', 'Initials': 'JWMG', 'LastName': 'Widdershoven', 'Affiliation': 'Department of Medical and Clinical Psychology, Tilburg University, Tilburg, Netherlands.'}, {'ForeName': 'Frans', 'Initials': 'F', 'LastName': 'Folkvord', 'Affiliation': 'Open Evidence Research Group, Universitat Oberta de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Lupiáñez-Villanueva', 'Affiliation': 'Open Evidence Research Group, Universitat Oberta de Catalunya, Barcelona, Spain.'}]",Journal of medical Internet research,['10.2196/17351'] 2495,32720911,The Assessment of Supportive Accountability in Adults Seeking Obesity Treatment: Psychometric Validation Study.,"BACKGROUND Technology-mediated obesity treatments are commonly affected by poor long-term adherence. Supportive Accountability Theory suggests that the provision of social support and oversight toward goals may help to maintain adherence in technology-mediated treatments. However, no tool exists to measure the construct of supportive accountability. OBJECTIVE This study aimed to develop and psychometrically validate a supportive accountability measure (SAM) by examining its performance in technology-mediated obesity treatment. METHODS Secondary data analyses were conducted in 2 obesity treatment studies to validate the SAM (20 items). Study 1 examined reliability, criterion validity, and construct validity using an exploratory factor analysis in individuals seeking obesity treatment. Study 2 examined the construct validity of SAM in technology-mediated interventions involving different self-monitoring tools and varying amounts of phone-based interventionist support. Participants received traditional self-monitoring tools (standard, in-home self-monitoring scale [SC group]), newer, technology-based self-monitoring tools (TECH group), or these newer technology tools plus additional phone-based support (TECH+PHONE group). Given that the TECH+PHONE group involves more interventionist support, we hypothesized that this group would have greater supportive accountability than the other 2 arms. RESULTS In Study 1 (n=353), the SAM showed strong reliability (Cronbach α=.92). A factor analysis revealed a 3-factor solution (representing Support for Healthy Eating Habits, Support for Exercise Habits, and Perceptions of Accountability) that explained 69% of the variance. Convergent validity was established using items from the motivation for weight loss scale, specifically the social regulation subscale (r=0.33; P<.001) and social pressure for weight loss subscale (r=0.23; P<.001). In Study 2 (n=80), the TECH+PHONE group reported significantly higher SAM scores at 6 months compared with the SC and TECH groups (r 2 =0.45; P<.001). Higher SAM scores were associated with higher adherence to weight management behaviors, including higher scores on subscales representing healthy dietary choices, the use of self-monitoring strategies, and positive psychological coping with weight management challenges. The association between total SAM scores and percent weight change was in the expected direction but not statistically significant (r=-0.26; P=.06). CONCLUSIONS The SAM has strong reliability and validity across the 2 studies. Future studies may consider using the SAM in technology-mediated weight loss treatment to better understand whether support and accountability are adequately represented and how supportive accountability impacts treatment adherence and outcomes. TRIAL REGISTRATION ClinicalTrials.gov NCT01999244; https://clinicaltrials.gov/ct2/show/NCT01999244.",2020,"Higher SAM scores were associated with higher adherence to weight management behaviors, including higher scores on subscales representing healthy dietary choices, the use of self-monitoring strategies, and positive psychological coping with weight management challenges.","['Adults Seeking Obesity Treatment', 'individuals seeking obesity treatment']","['TECH+PHONE', 'traditional self-monitoring tools (standard, in-home self-monitoring scale [SC group]), newer, technology-based self-monitoring tools (TECH group), or these newer technology tools plus additional phone-based support (TECH+PHONE group']","['total SAM scores and percent weight change', 'Higher SAM scores', 'supportive accountability', 'social regulation subscale', 'SAM scores', 'social pressure for weight loss subscale']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4706528', 'cui_str': 'Obesity care'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0078889', 'cui_str': 'Accountability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]",,0.0390713,"Higher SAM scores were associated with higher adherence to weight management behaviors, including higher scores on subscales representing healthy dietary choices, the use of self-monitoring strategies, and positive psychological coping with weight management challenges.","[{'ForeName': 'Karishma', 'Initials': 'K', 'LastName': 'Chhabria', 'Affiliation': 'The Center for Health Care Data, Department of Management, Policy and Community Health, University of Texas Health Science Center at Houston, Houston, TX, United States.'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Ross', 'Affiliation': 'Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Shane J', 'Initials': 'SJ', 'LastName': 'Sacco', 'Affiliation': 'Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.'}, {'ForeName': 'Tricia M', 'Initials': 'TM', 'LastName': 'Leahey', 'Affiliation': 'Department of Allied Health Sciences, University of Connecticut, Storrs, CT, United States.'}]",Journal of medical Internet research,['10.2196/17967'] 2496,32720916,Improving the Quality of Bowel Preparation: Rewarding Patients for Success or Intensive Patient Education?,"INTRODUCTION AND OBJECTIVES The quality of the bowel preparation is a critical parameter for the outcome of colonoscopies. It is well established that the bowel preparation modality (e.g. split or larger volume preparation) significantly improves the quality of the bowel preparation. Patient compliance is another important factor impacting on the quality of bowel preparations that receives relatively little research attention. We aimed to explore if intensified education or a lottery ticket as reward for good bowel preparation could improve outcomes. METHODS After informed consent, all patients received a standardized printed information booklet. In a randomized fashion patients were offered A) a lottery scratchy ticket with an opportunity to win $25,000 as 'reward' for good bowel preparation, B) an education session delivered over the phone by a trained nurse or C) no additional measure. RESULTS Overall, the quality of the bowel preparation was rated good or very good in 69.1% (95% CI 61.7-75.7%) of patients. Reward intervention did not influence the quality of bowel preparation (OR 0.42, 95% CI 0.09-1.91, p=0.260), however bowel preparation quality decreased in patients randomized to receive the additional education (OR 0.28, 95% CI 0.08-0.96, p=0.042). Neither intervention significantly impacted on polyp detection rates. CONCLUSIONS Contrasting general beliefs, additional interventions (e.g. incentives or phone consultation) did not improve the quality of the bowel preparation. The unexpected result shows that utilizing extra resources must be balanced against real-world outcomes and may not always provide the expected result.  .",2020,"Reward intervention did not influence the quality of bowel preparation (OR 0.42, 95% CI 0.09-1.91, p=0.260), however bowel preparation quality decreased in patients randomized to receive the additional education (OR 0.28, 95% CI 0.08-0.96, p=0.042).",[],"[""lottery scratchy ticket with an opportunity to win $25,000 as 'reward' for good bowel preparation, B) an education session delivered over the phone by a trained nurse or C"", 'standardized printed information booklet']","['quality of the bowel preparation', 'quality of bowel preparation', 'bowel preparation quality', 'polyp detection rates']",[],"[{'cui': 'C3887441', 'cui_str': 'Scratchy sensation'}, {'cui': 'C0035397', 'cui_str': 'Rewards'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0455052', 'cui_str': 'Preparation of bowel for procedure'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.0984486,"Reward intervention did not influence the quality of bowel preparation (OR 0.42, 95% CI 0.09-1.91, p=0.260), however bowel preparation quality decreased in patients randomized to receive the additional education (OR 0.28, 95% CI 0.08-0.96, p=0.042).","[{'ForeName': 'Marguerite J', 'Initials': 'MJ', 'LastName': 'Kutyla', 'Affiliation': ''}, {'ForeName': 'Marcus A', 'Initials': 'MA', 'LastName': 'Gray', 'Affiliation': ''}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'von Hippel', 'Affiliation': ''}, {'ForeName': 'Luke F', 'Initials': 'LF', 'LastName': 'Hourigan', 'Affiliation': ''}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Kendall', 'Affiliation': ''}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Whaley', 'Affiliation': ''}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': ""O'Connor"", 'Affiliation': ''}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Holtmann', 'Affiliation': ''}]","Digestive diseases (Basel, Switzerland)",['10.1159/000510461'] 2497,32721007,Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.,"Importance The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials. Objective To assess the association of prior randomized use of estrogen plus progestin or prior randomized use of estrogen alone with breast cancer incidence and mortality in the Women's Health Initiative clinical trials. Design, Setting, and Participants Long-term follow-up of 2 placebo-controlled randomized clinical trials that involved 27 347 postmenopausal women aged 50 through 79 years with no prior breast cancer and negative baseline screening mammogram. Women were enrolled at 40 US centers from 1993 to 1998 with follow-up through December 31, 2017. Interventions In the trial involving 16 608 women with a uterus, 8506 were randomized to receive 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA) and 8102, placebo. In the trial involving 10 739 women with prior hysterectomy, 5310 were randomized to receive 0.625 mg/d of CEE alone and 5429, placebo. The CEE-plus-MPA trial was stopped in 2002 after 5.6 years' median intervention duration, and the CEE-only trial was stopped in 2004 after 7.2 years' median intervention duration. Main Outcomes and Measures The primary outcome was breast cancer incidence (protocol prespecified primary monitoring outcome for harm) and secondary outcomes were deaths from breast cancer and deaths after breast cancer. Results Among 27 347 postmenopausal women who were randomized in both trials (baseline mean [SD] age, 63.4 years [7.2 years]), after more than 20 years of median cumulative follow-up, mortality information was available for more than 98%. CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast cancer incidence with 238 cases (annualized rate, 0.30%) vs 296 cases (annualized rate, 0.37%; hazard ratio [HR], 0.78; 95% CI, 0.65-0.93; P = .005) and was associated with statistically significantly lower breast cancer mortality with 30 deaths (annualized mortality rate, 0.031%) vs 46 deaths (annualized mortality rate, 0.046%; HR, 0.60; 95% CI, 0.37-0.97; P = .04). In contrast, CEE plus MPA compared with placebo among 16 608 women with a uterus was associated with statistically significantly higher breast cancer incidence with 584 cases (annualized rate, 0.45%) vs 447 cases (annualized rate, 0.36%; HR, 1.28; 95% CI, 1.13-1.45; P < .001) and no significant difference in breast cancer mortality with 71 deaths (annualized mortality rate, 0.045%) vs 53 deaths (annualized mortality rate, 0.035%; HR, 1.35; 95% CI, 0.94-1.95; P= .11). Conclusions and Relevance In this long-term follow-up study of 2 randomized trials, prior randomized use of CEE alone, compared with placebo, among women who had a previous hysterectomy, was significantly associated with lower breast cancer incidence and lower breast cancer mortality, whereas prior randomized use of CEE plus MPA, compared with placebo, among women who had an intact uterus, was significantly associated with a higher breast cancer incidence but no significant difference in breast cancer mortality.",2020,"CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast cancer incidence with 238 cases (annualized rate, 0.30%) vs 296 cases (annualized rate, 0.37%; hazard ratio [HR], 0.78; 95% CI, 0.65-0.93; P = .005) and was associated with statistically significantly lower breast cancer mortality with 30 deaths (annualized mortality rate, 0.031%) vs 46 deaths (annualized mortality rate, 0.046%; HR, 0.60; 95% CI, 0.37-0.97; P = .04).","['10\u202f739 women with prior hysterectomy, 5310', '27\u202f347 postmenopausal women aged 50 through 79 years with no prior breast cancer and negative baseline screening mammogram', 'Women were enrolled at 40 US centers from 1993 to 1998 with follow-up through December 31, 2017', '16\u202f608 women with a uterus, 8506', '27\u202f347 postmenopausal women who were randomized in both trials (baseline mean [SD] age, 63.4 years [7.2 years']","['estrogen alone', 'CEE plus MPA', 'conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA) and 8102, placebo', 'CEE', 'CEE alone and 5429, placebo', 'menopausal hormone therapy', 'Menopausal Hormone Therapy', 'estrogen plus progestin', 'placebo']","['median cumulative follow-up, mortality information', 'breast cancer mortality', 'lower breast cancer incidence and lower breast cancer mortality', 'breast cancer incidence', 'Mortality', 'breast cancer incidence (protocol prespecified primary monitoring outcome for harm) and secondary outcomes were deaths from breast cancer and deaths after breast cancer']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4517857', 'cui_str': '7.2'}]","[{'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0282402', 'cui_str': 'Hormone replacement therapy'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",16608.0,0.242551,"CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast cancer incidence with 238 cases (annualized rate, 0.30%) vs 296 cases (annualized rate, 0.37%; hazard ratio [HR], 0.78; 95% CI, 0.65-0.93; P = .005) and was associated with statistically significantly lower breast cancer mortality with 30 deaths (annualized mortality rate, 0.031%) vs 46 deaths (annualized mortality rate, 0.046%; HR, 0.60; 95% CI, 0.37-0.97; P = .04).","[{'ForeName': 'Rowan T', 'Initials': 'RT', 'LastName': 'Chlebowski', 'Affiliation': 'Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.'}, {'ForeName': 'Garnet L', 'Initials': 'GL', 'LastName': 'Anderson', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.'}, {'ForeName': 'Aaron K', 'Initials': 'AK', 'LastName': 'Aragaki', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.'}, {'ForeName': 'JoAnn E', 'Initials': 'JE', 'LastName': 'Manson', 'Affiliation': ""Division of Public Health Sciences, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Marcia L', 'Initials': 'ML', 'LastName': 'Stefanick', 'Affiliation': 'Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, California.'}, {'ForeName': 'Kathy', 'Initials': 'K', 'LastName': 'Pan', 'Affiliation': 'Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Barrington', 'Affiliation': 'Department of Epidemiology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Lewis H', 'Initials': 'LH', 'LastName': 'Kuller', 'Affiliation': 'Department of Epidemiology, School of Public Health, University of Pittsburgh, Pennsylvania.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Simon', 'Affiliation': 'Department of Oncology, Karmanos Cancer Institute at Wayne State University, Detroit, Michigan.'}, {'ForeName': 'Dorothy', 'Initials': 'D', 'LastName': 'Lane', 'Affiliation': 'Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, New York.'}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Johnson', 'Affiliation': 'Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Rohan', 'Affiliation': 'Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.'}, {'ForeName': 'Margery L S', 'Initials': 'MLS', 'LastName': 'Gass', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Cauley', 'Affiliation': 'Department of Epidemiology, School of Public Health, University of Pittsburgh, Pennsylvania.'}, {'ForeName': 'Electra D', 'Initials': 'ED', 'LastName': 'Paskett', 'Affiliation': 'College of Public Health, The Ohio State University, Columbus.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Sattari', 'Affiliation': 'Division of General Internal Medicine, University of Florida Health Internal Medicine, Gainesville.'}, {'ForeName': 'Ross L', 'Initials': 'RL', 'LastName': 'Prentice', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington.'}]",JAMA,['10.1001/jama.2020.9482'] 2498,32721009,Effect of Intravenous Acetaminophen on Postoperative Hypoxemia After Abdominal Surgery: The FACTOR Randomized Clinical Trial.,"Importance Opioid-induced ventilatory depression and hypoxemia is common, severe, and often unrecognized in postoperative patients. To the extent that nonopioid analgesics reduce opioid consumption, they may decrease postoperative hypoxemia. Objective To test the hypothesis that duration of hypoxemia is less in patients given intravenous acetaminophen than those given placebo. Design, Setting, and Participants Randomized, placebo-controlled, double-blind trial conducted at 2 US academic hospitals among 570 patients who were undergoing abdominal surgery, enrolled from February 2015 through October 2018 and followed up until February 2019. Interventions Participants were randomized to receive either intravenous acetaminophen, 1 g (n = 289), or normal saline placebo (n = 291) starting at the beginning of surgery and repeated every 6 hours until 48 postoperative hours or hospital discharge, whichever occurred first. Main Outcomes and Measures The primary outcome was the total duration of hypoxemia (hemoglobin oxygen saturation [Spo2] <90%) per hour, with oxygen saturation measured continuously for 48 postoperative hours. Secondary outcomes were postoperative opioid consumption, pain (0- 10-point scale; 0: no pain; 10: the most pain imaginable), nausea and vomiting, sedation, minimal alveolar concentration of volatile anesthetic, fatigue, active time, and respiratory function. Results Among 580 patients randomized (mean age, 49 years; 48% women), 570 (98%) completed the trial. The primary outcome, median duration with Spo2 of less than 90%, was 0.7 (interquartile range [IQR], 0.1-5.1) minutes per hour among patients in the acetaminophen group and 1.1 (IQR, 0.1-6.6) minutes per hour among patients in the placebo group (P = .29), with an estimated median difference of -0.04 (95% CI,-0.18 to 0.11) minutes per hour. None of the 8 secondary end points differed significantly between the acetaminophen and placebo groups. Mean pain scores within initial 48 postoperative hours were 4.2 (SD, 1.8) in the acetaminophen group and 4.4 (SD, 1.8) in the placebo group (difference, -0.28; 95% CI, -0.71 to 0.15); median opioid use in morphine equivalents was 50 mg (IQR, 18-122 mg) and 58 mg (IQR, 24-151 mg) , respectively, with a ratio of geometric means of 0.86 (95% CI, 0.61-1.21). Conclusions and Relevance Among patients who underwent abdominal surgery, use of postoperative intravenous acetaminophen, compared with placebo, did not significantly reduce the duration of postoperative hypoxemia over 48 hours. The study findings do not support the use of intravenous acetaminophen for this purpose. Trial Registration ClinicalTrials.gov Identifier: NCT02156154.",2020,"Mean pain scores within initial 48 postoperative hours were 4.2 (SD, 1.8) in the acetaminophen group and 4.4 (SD, 1.8) in the placebo group (difference, -0.28; 95% CI, -0.71 to 0.15); median opioid use in morphine equivalents was 50 mg (IQR, 18-122 mg) and 58 mg (IQR, 24-151 mg) , respectively, with a ratio of geometric means of 0.86 (95% CI, 0.61-1.21). ","['580 patients randomized (mean age, 49 years; 48% women), 570 (98%) completed the trial', 'After Abdominal Surgery', 'patients who underwent abdominal surgery', '570 patients who were undergoing abdominal surgery, enrolled from February 2015 through October 2018 and followed up until February 2019']","['normal saline placebo', 'Intravenous Acetaminophen', 'intravenous acetaminophen', 'acetaminophen', 'placebo']","['postoperative opioid consumption, pain (0- 10-point scale; 0: no pain; 10: the most pain imaginable), nausea and vomiting, sedation, minimal alveolar concentration of volatile anesthetic, fatigue, active time, and respiratory function', 'duration of postoperative hypoxemia', 'median opioid use in morphine equivalents', 'Postoperative Hypoxemia', 'total duration of hypoxemia (hemoglobin oxygen saturation [Spo2] <90%) per hour, with oxygen saturation', 'Mean pain scores', 'median duration with Spo2 of less']","[{'cui': 'C4517818', 'cui_str': '580'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0198482', 'cui_str': 'Operation on abdominal region'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0234225', 'cui_str': 'No pain'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0443769', 'cui_str': 'Volatile agent'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0026549', 'cui_str': 'Morphine'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0428174', 'cui_str': 'Hemoglobin saturation with oxygen'}, {'cui': 'C0439087', 'cui_str': '<90'}, {'cui': 'C0564385', 'cui_str': '/hour'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}]",580.0,0.78845,"Mean pain scores within initial 48 postoperative hours were 4.2 (SD, 1.8) in the acetaminophen group and 4.4 (SD, 1.8) in the placebo group (difference, -0.28; 95% CI, -0.71 to 0.15); median opioid use in morphine equivalents was 50 mg (IQR, 18-122 mg) and 58 mg (IQR, 24-151 mg) , respectively, with a ratio of geometric means of 0.86 (95% CI, 0.61-1.21). ","[{'ForeName': 'Alparslan', 'Initials': 'A', 'LastName': 'Turan', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Hani', 'Initials': 'H', 'LastName': 'Essber', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Saasouh', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Hovsepyan', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Natalya', 'Initials': 'N', 'LastName': 'Makarova', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Sabry', 'Initials': 'S', 'LastName': 'Ayad', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Barak', 'Initials': 'B', 'LastName': 'Cohen', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Kurt', 'Initials': 'K', 'LastName': 'Ruetzler', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Loran Mounir', 'Initials': 'LM', 'LastName': 'Soliman', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Kamal', 'Initials': 'K', 'LastName': 'Maheshwari', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Dongsheng', 'Initials': 'D', 'LastName': 'Yang', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Mascha', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Wael', 'Initials': 'W', 'LastName': 'Ali Sakr Esa', 'Affiliation': 'Department of General Anesthesiology, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Herman', 'Initials': 'H', 'LastName': 'Kessler', 'Affiliation': 'Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Conor P', 'Initials': 'CP', 'LastName': 'Delaney', 'Affiliation': 'Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Daniel I', 'Initials': 'DI', 'LastName': 'Sessler', 'Affiliation': 'Department of Outcomes Research, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2020.10009'] 2499,32723555,Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial).,"The SURTAVI trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) to surgical aortic valve replacement (SAVR) in patients with severe, symptomatic aortic stenosis at intermediate surgical risk. Most TAVI patients received an early generation device which is no longer commercially available. This analysis compares TAVI outcomes in patients that received the Evolut R valve to those of similar patients randomized to SAVR in the SURTAVI trial. The continued access study of SURTAVI (CAS) enrolled 290 patients. Of them, 252 were implanted with the 23, 26, or 29 mm Evolut R device. Propensity-score matching between this group and SURTAVI SAVR patients with annular diameter of 26 mm or less was based on 22 clinical characteristics, resulting in 197 matched pairs for analysis. The primary end point for comparison was the rate of all-cause mortality or disabling stroke at 1-year. The mean age for TAVI and SAVR patients in the propensity-score matched population was 79.1 years and STS-PROM was 4.0 ± 1.5% for TAVI and 3.9% ± 1.3% for SAVR. The rate of all-cause mortality or disabling stroke at 30-days significantly favored TAVI (0.5% vs 5.1%; p = 0.006). At 1-year TAVI was numerically favored (4.1% vs 8.2%; p = 0.082). In conclusion, compared with SAVR, TAVI using Evolut R had a favorable 30-day safety profile, significantly better hemodynamic performance, and a comparable 1-year rate of all-cause mortality or disabling stroke, suggesting this may be a preferred treatment for patients with severe, symptomatic aortic stenosis at intermediate surgical risk.",2020,TAVI was numerically favored (4.1% vs 8.2%; p = 0.082).,"['290 patients', 'SAVR patients with annular diameter of 26 mm or less was based on 22 clinical characteristics, resulting in 197 matched pairs for analysis', 'patients with severe, symptomatic aortic stenosis at intermediate surgical risk']","['surgical aortic valve replacement (SAVR', 'Evolut-R Transcatheter Aortic Valve Implantation With Surgery', 'transcatheter aortic valve implantation (TAVI']","['rate of all-cause mortality or disabling stroke', 'TAVI', 'hemodynamic performance']","[{'cui': 'C5191218', 'cui_str': '290'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0003507', 'cui_str': 'Aortic valve stenosis'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}]",290.0,0.0633674,TAVI was numerically favored (4.1% vs 8.2%; p = 0.082).,"[{'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Yakubov', 'Affiliation': 'Riverside Methodist - Ohio Health, Columbus, Ohio. Electronic address: steven.yakubov@ohiohealth.com.'}, {'ForeName': 'Nicolas M', 'Initials': 'NM', 'LastName': 'Van Mieghem', 'Affiliation': 'Erasmus University Medical Center, Rotterdam, The Netherlands.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Reardon', 'Affiliation': 'Houston-Methodist-Debakey Heart and Vascular Center, Houston, Texas.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'International Centre for Circulatory Health, NHLI, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Hemal', 'Initials': 'H', 'LastName': 'Gada', 'Affiliation': 'University of Pittsburgh Medical Center Pinnacle Heath, Harrisburg, Pennsylvania.'}, {'ForeName': 'Mubashir', 'Initials': 'M', 'LastName': 'Mumtaz', 'Affiliation': 'University of Pittsburgh Medical Center Pinnacle Heath, Harrisburg, Pennsylvania.'}, {'ForeName': 'G Michael', 'Initials': 'GM', 'LastName': 'Deeb', 'Affiliation': 'University of Michigan Hospitals, Ann Arbor, Michigan.'}, {'ForeName': 'Susheel', 'Initials': 'S', 'LastName': 'Kodali', 'Affiliation': 'Structural Heart and Valve Center, Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'George', 'Affiliation': 'Structural Heart and Valve Center, Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'University Hospital Bern, Bern, Switzerland.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Kleiman', 'Affiliation': 'Houston-Methodist-Debakey Heart and Vascular Center, Houston, Texas.'}, {'ForeName': 'Stanley J', 'Initials': 'SJ', 'LastName': 'Chetcuti', 'Affiliation': 'University of Michigan Hospitals, Ann Arbor, Michigan.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Sanchez', 'Affiliation': 'Riverside Methodist - Ohio Health, Columbus, Ohio.'}, {'ForeName': 'Harold L', 'Initials': 'HL', 'LastName': 'Dauerman', 'Affiliation': 'University of Vermont Medical Center, Burlington, Vermont.'}, {'ForeName': 'Shuzhen', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Medtronic, Minneapolis, Minnesota.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Popma', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}]",The American journal of cardiology,['10.1016/j.amjcard.2020.06.051'] 2500,32723572,The Influence of Cost Information on Treatment Choice: A Mixed-Methods Study.,"PURPOSE To test the null hypothesis that exposure to societal cost information does not affect choice of treatment for carpal tunnel syndrome (CTS). METHODS We enrolled 304 participants using the Amazon Mechanical Turk platform to complete a survey in which participants were given the choice between carpal tunnel release (CTR) or a less-expensive option (orthosis wear) in a hypothetical mild CTS scenario. Patients were randomized to receive information about the societal cost of CTR (cost cohort) or no cost information (control). The primary outcome was the probability of choosing CTR measured on a 6-point ordinal scale. We employed qualitative content analysis to evaluate participants' rationale for their choice. We also explored agreement with various attitudes toward health care costs on an ordinal scale. RESULTS Participants in the cost cohort exhibited a greater probability of choosing surgery than those in the control cohort. The relative risk of choosing surgery after exposure to societal cost information was 1.43 (95% confidence interval, 1.11-1.85). Among participants who had not previously been diagnosed with CTS (n = 232), the relative risk of choosing surgery after exposure to societal cost information was 1.55 (95% confidence interval, 1.17-2.06). Lack of personal monetary responsibility frequently emerged as a theme in those in the cost cohort who chose surgery. The majority (94%) of participants expressed at least some agreement that health care cost is a major problem whereas only 58% indicated that they consider the country's health care costs when making treatment decisions. CONCLUSIONS Participants who received societal cost information were more likely to choose the more expensive treatment option (CTR) for mild CTS. CLINICAL RELEVANCE Exposure to societal cost information may influence patient decision making in elective hand surgery. A complete understanding of this influence is required prior to implementing processes toward greater cost transparency for diagnostic/treatment options. Sharing out-of-pocket costs with patients may be a beneficial approach because discussing societal cost information alone will likely not improve value of care.",2020,"The relative risk of choosing surgery after exposure to societal cost information was 1.43 (95% confidence interval, 1.11-1.85).","['304 participants using the Amazon Mechanical Turk platform to complete a survey in which participants were given the choice between carpal tunnel release (CTR) or a less-expensive option (orthosis wear) in a hypothetical mild CTS scenario', 'participants who had not previously been diagnosed with CTS (n\xa0= 232', 'carpal tunnel syndrome (CTS']",['information about the societal cost of CTR (cost cohort) or no cost information (control'],"['probability of choosing CTR measured on a 6-point ordinal scale', 'probability of choosing surgery']","[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0337911', 'cui_str': 'Turks'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0196576', 'cui_str': 'Decompression of median nerve'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006086', 'cui_str': 'Brace'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",304.0,0.0815843,"The relative risk of choosing surgery after exposure to societal cost information was 1.43 (95% confidence interval, 1.11-1.85).","[{'ForeName': 'Thompson', 'Initials': 'T', 'LastName': 'Zhuang', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA.'}, {'ForeName': 'Joost T P', 'Initials': 'JTP', 'LastName': 'Kortlever', 'Affiliation': 'Department of Surgery and Perioperative Care, Dell Medical School-The University of Texas at Austin, Austin, TX.'}, {'ForeName': 'Lauren M', 'Initials': 'LM', 'LastName': 'Shapiro', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Baker', 'Affiliation': 'Department of Health Research and Policy, Stanford University, Redwood City, CA.'}, {'ForeName': 'Alex H S', 'Initials': 'AHS', 'LastName': 'Harris', 'Affiliation': 'Center for Health Care Evaluation, VA Palo Alto Health Care System, Palo Alto, CA.'}, {'ForeName': 'Robin N', 'Initials': 'RN', 'LastName': 'Kamal', 'Affiliation': 'VOICES Health Policy Research Center, Department of Orthopaedic Surgery, Stanford University, Redwood City, CA. Electronic address: rnkamal@stanford.edu.'}]",The Journal of hand surgery,['10.1016/j.jhsa.2020.05.019'] 2501,32723609,Surgical outcomes of a randomized controlled trial compared robotic versus laparoscopic adrenalectomy for pheochromocytoma.,"BACKGROUND Robotic adrenalectomy for pheochromocytoma is increasingly popular because of the advantage that have been proved by some researchers recently. However, prospective randomized clinical trials comparing robotic assisted laparoscopic adrenalectomy (RA) with traditional laparoscopic adrenalectomy (LA) for pheochromocytoma are rare. The aim of this study is to compare perioperative outcomes of RA versus LA for pheochromocytoma prospectively. METHODS From March 2016 to April 2019, all patients with pheochromocytoma suitable for laparoscopic adrenalectomy were assigned randomly to RA or LA. The primary endpoint was the operative (exclude docking time) time. Secondary endpoints were estimated blood loss and postoperative recovery. Demographics and perioperative data were prospectively collected. RESULTS A total of 140 (RA 70, LA 70) patients were enrolled in this prospective research. The following significant differences were identified in favor of RA: shorter median operative (exclude docking time) time (92.5 vs 122.5 min, P = 0.007), however, RA group has higher total hospitalization cost (8869.9 vs 4721.8 $, P < 0.001). Demographics and other perioperative outcomes were similar in both groups. The RA group showed a significant lower blood loss and operative (exclude docking time) time compared with LA group (P < 0.05) for patients with high Nor-Metanephrine (NMN). CONCLUSIONS Both RA and LA for pheochromocytoma are safe and effective. Patients with high NMN can benefit from less blood loss and operative time when a robotic surgery system was used, but RA has a significant higher cost.",2020,"shorter median operative (exclude docking time) time (92.5 vs 122.5 min, P = 0.007), however, RA group has higher total hospitalization cost (8869.9 vs 4721.8 $, P ","['From March 2016 to April 2019, all patients with pheochromocytoma suitable for laparoscopic adrenalectomy', 'A total of 140 (RA 70, LA 70) patients']","['RA versus LA', 'robotic versus laparoscopic adrenalectomy', 'robotic assisted laparoscopic adrenalectomy (RA', 'traditional laparoscopic adrenalectomy (LA', 'LA', 'RA or LA']","['shorter median operative (exclude docking time) time', 'blood loss and operative (exclude docking time) time', 'blood loss and operative time', 'operative (exclude docking time)\xa0time', 'favor of RA', 'blood loss and postoperative recovery', 'total hospitalization cost']","[{'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031511', 'cui_str': 'Chromaffinoma'}, {'cui': 'C0521267', 'cui_str': 'Laparoscopic adrenalectomy'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0521267', 'cui_str': 'Laparoscopic adrenalectomy'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0442632', 'cui_str': 'Dock - marine'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0521267', 'cui_str': 'Laparoscopic adrenalectomy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",70.0,0.103366,"shorter median operative (exclude docking time) time (92.5 vs 122.5 min, P = 0.007), however, RA group has higher total hospitalization cost (8869.9 vs 4721.8 $, P ","[{'ForeName': 'Wenming', 'Initials': 'W', 'LastName': 'Ma', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: ma.wm6@sjtu.edu.cn.'}, {'ForeName': 'Yongxin', 'Initials': 'Y', 'LastName': 'Mao', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: jsntmyx@163.com.'}, {'ForeName': 'Ran', 'Initials': 'R', 'LastName': 'Zhuo', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: 531368637@qq.com.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Dai', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: daijun1980@hotmail.com.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Fang', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: fc5655@163.com.'}, {'ForeName': 'Chenghe', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: wch11971@rjh.com.cn.'}, {'ForeName': 'Juping', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: zjp11317@rjh.com.cn.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'He', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: doctorweihe1977@163.com.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: zy10478@rjh.com.cn.'}, {'ForeName': 'Danfeng', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: xdf12306@rjh.com.cn.'}, {'ForeName': 'Fukang', 'Initials': 'F', 'LastName': 'Sun', 'Affiliation': 'Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. Electronic address: sfk10570@rjh.com.cn.'}]",European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,['10.1016/j.ejso.2020.04.001'] 2502,32723668,"Effects of Corrective Exercises on Posture, Pain, and Muscle Activation of Patients With Chronic Neck Pain Exposed to Anterior-Posterior Perturbation.","OBJECTIVES This study aimed to evaluate the effects of corrective exercises on posture, pain, and muscle activation of patients with chronic neck pain exposed to anterior-posterior perturbation. METHODS A total of 32 women (37.76 ± 3.83 years) with chronic, nonspecific neck pain were randomized into corrective exercise and control groups. The experimental group underwent a corrective exercise program for 8 weeks, 30 min/d, 3 days per week. The control group received active self-exercise instructions. Neck pain, forward head and protracted shoulder posture, and timing of superficial neck muscle activation were evaluated using the visual analog scale, photogrammetry, and electromyogram, respectively, before and then 48 hours after the 8-week program for both the experimental and control groups. All measurements at pretest and posttest were taken by a blinded assessor. RESULTS Significant alterations were observed in cervical angle (P = .003, effect size = 0.329), shoulder angle (P = .008, effect size = 0.457), neck pain and disability (P = .009, effect size = 0.645), movement control (P = .038, effect size = 0.353), activation onset of the upper trapezius (P = .015, effect size = 0.746), the sternocleidomastoid (P = .018, effect size = 0.879) and cervical erector spinae (P = .031, effect size = 0.765), and the root mean square of the upper trapezius (P = .033, effect size = 0.742), the sternocleidomastoid (P = .041, effect size = 0.587), and the cervical erector spinae (P = .024, effect size = 0.832) in the intervention group from pre- to posttest (P < .05). CONCLUSION Positive and significant alterations have been observed in the forward head and protracted shoulder posture, the timing of superficial neck muscle activation, neck pain, and disability in female patients with chronic neck pain exposed to anterior-posterior perturbation after performing an 8-week corrective exercise program.",2020,"RESULTS Significant alterations were observed in cervical angle (P = .003, effect size = 0.329), shoulder angle (P = .008, effect size = 0.457), neck pain and disability (P = .009, effect size = 0.645), movement control (P ","['patients with chronic neck pain exposed to anterior-posterior perturbation', 'Patients', 'female patients with chronic neck pain', '32 women (37.76 ± 3.83 years) with chronic, nonspecific neck pain']","['active self-exercise instructions', 'Corrective Exercises', 'corrective exercise', 'corrective exercises', 'corrective exercise program']","['activation onset of the upper trapezius', 'Posture, Pain, and Muscle Activation', 'cervical erector spinae ', 'root mean square of the upper trapezius', 'Neck pain, forward head and protracted shoulder posture, and timing of superficial neck muscle activation', 'shoulder angle', 'cervical erector spinae', 'cervical angle', 'posture, pain, and muscle activation', 'neck pain and disability']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0332453', 'cui_str': 'Disruption'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}]","[{'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0332162', 'cui_str': 'Onset of'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0224361', 'cui_str': 'Structure of trapezius muscle'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0224301', 'cui_str': 'Structure of erector spinae muscle'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0449243', 'cui_str': 'Timing'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C0027532', 'cui_str': 'Skeletal muscle structure of neck'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0231170', 'cui_str': 'Disability'}]",32.0,0.0646873,"RESULTS Significant alterations were observed in cervical angle (P = .003, effect size = 0.329), shoulder angle (P = .008, effect size = 0.457), neck pain and disability (P = .009, effect size = 0.645), movement control (P ","[{'ForeName': 'Akram', 'Initials': 'A', 'LastName': 'Mehri', 'Affiliation': 'Department of Biomechanics and Sport Injuries, Kharazmi University, Tehran, Iran.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Letafatkar', 'Affiliation': 'Department of Biomechanics and Sport Injuries, Kharazmi University, Tehran, Iran. Electronic address: letafatkaramir@yahoo.com.'}, {'ForeName': 'Zohre', 'Initials': 'Z', 'LastName': 'Khosrokiani', 'Affiliation': 'Department of Biomechanics and Sport Injuries, Kharazmi University, Tehran, Iran.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2018.11.032'] 2503,32723727,A Web-Based Program for Cannabis Use and Psychotic Experiences in Young People (Keep It Real): Protocol for a Randomized Controlled Trial.,"BACKGROUND Young Australians (16-25 years) have the highest rates of past-month cannabis use in the world. Cannabis use increases the risk of alcohol and other drug disorders and depressive disorders, and has a robust dose-response association with psychotic experiences (PEs) and disorders. PEs are subthreshold positive psychotic symptoms, including delusions and hallucinations, which increase the risk of substance use, depressive or anxiety disorders, and psychotic disorders. Access to effective web-based early interventions targeting both cannabis use and PEs could reduce such risk in young people. OBJECTIVE The objective of this study is to determine the efficacy and cost-effectiveness of the Keep it Real web-based program compared to an information-only control website among young cannabis users (16-25 years) with PEs. METHODS Participants are recruited online, and consenting individuals meeting inclusion criteria (aged 16-25 years, who have used cannabis in the past month and experienced PEs in the past 3 months) are automatically randomized to either the Keep it Real web-based program (n=249) or an information-only control website (n=249). Both websites are self-guided (fully automated). The baseline and follow-up assessments at 3, 6, 9, and 12 months are self-completed online. Primary outcome measures are weekly cannabis use, PEs, and the relative cost-effectiveness for quality-adjusted life years. Secondary outcomes include other substance use and related problems, PE-related distress, cannabis intoxication experiences, severity of cannabis dependence, depression/anxiety symptoms, suicidality, and mental well-being and functioning. RESULTS Recruitment commenced in February 2019, and the results are expected to be submitted for publication in mid-2021. CONCLUSIONS This study protocol describes a large randomized controlled trial of a new web-based program for young cannabis users experiencing PEs. If effective, the accessibility and scalability of Keep it Real could help reduce growing public health concerns about the significant social, economic, and health impacts of cannabis use. TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12618001107213; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374800. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/15803.",2020,"Cannabis use increases the risk of alcohol and other drug disorders and depressive disorders, and has a robust dose-response association with psychotic experiences (PEs) and disorders.","['Young Australians (16-25 years', 'Participants are recruited online, and consenting individuals meeting inclusion criteria (aged 16-25 years, who have used cannabis in the past month and experienced PEs in the past 3 months', 'young cannabis users experiencing PEs', 'young people', 'young cannabis users (16-25 years) with PEs', 'Young People']",['Keep it Real web-based program (n=249) or an information-only control website'],"['weekly cannabis use, PEs, and the relative cost-effectiveness for quality-adjusted life years', 'efficacy and cost-effectiveness', 'substance use and related problems, PE-related distress, cannabis intoxication experiences, severity of cannabis dependence, depression/anxiety symptoms, suicidality, and mental well-being and functioning', 'risk of alcohol and other drug disorders and depressive disorders']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0007637', 'cui_str': 'Cellular Inclusions'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205171', 'cui_str': 'Singular'}]","[{'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0231303', 'cui_str': 'Distress'}, {'cui': 'C0006872', 'cui_str': 'Cannabis sativa poisoning'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0006870', 'cui_str': 'Cannabis dependence'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0011581', 'cui_str': 'Depressive disorder'}]",,0.128032,"Cannabis use increases the risk of alcohol and other drug disorders and depressive disorders, and has a robust dose-response association with psychotic experiences (PEs) and disorders.","[{'ForeName': 'Leanne', 'Initials': 'L', 'LastName': 'Hides', 'Affiliation': 'Lives Lived Well Group, National Centre for Youth Substance Use Research, School of Psychology, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Baker', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Norberg', 'Affiliation': 'Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Copeland', 'Affiliation': 'Sunshine Coast Mind and Neuroscience - Thompson Institute, University of the Sunshine Coast, Birtinya, Australia.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Quinn', 'Affiliation': 'Lives Lived Well Group, National Centre for Youth Substance Use Research, School of Psychology, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Zoe', 'Initials': 'Z', 'LastName': 'Walter', 'Affiliation': 'Lives Lived Well Group, National Centre for Youth Substance Use Research, School of Psychology, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Janni', 'Initials': 'J', 'LastName': 'Leung', 'Affiliation': 'Lives Lived Well Group, National Centre for Youth Substance Use Research, School of Psychology, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'Stoyan R', 'Initials': 'SR', 'LastName': 'Stoyanov', 'Affiliation': 'Lives Lived Well Group, National Centre for Youth Substance Use Research, School of Psychology, The University of Queensland, Brisbane, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kavanagh', 'Affiliation': ""Centre for Youth Substance Abuse Research, Centre for Children's Health Research, Queensland University of Technology, Brisbane, Australia.""}]",JMIR research protocols,['10.2196/15803'] 2504,32723728,Teens Taking Charge: A Randomized Controlled Trial of a Web-Based Self-Management Program With Telephone Support for Adolescents With Juvenile Idiopathic Arthritis.,"BACKGROUND Juvenile idiopathic arthritis (JIA) is a serious and potentially debilitating pediatric illness. Improved disease self-management may help to improve health outcomes. OBJECTIVE This study aimed to evaluate the effectiveness of the Teens Taking Charge Web-based self-management intervention in reducing symptoms and improving health-related quality of life (HRQL) in adolescents with JIA compared with a Web-based education control condition. METHODS Adolescents with JIA aged 12 to 18 years were recruited from 11 Canadian pediatric rheumatology centers. Caregivers were invited to participate along with their child. In addition to standard medical care, participants were randomized to receive either (1) the Teens Taking Charge self-management intervention or (2) a Web-based education control condition for a period of 12 weeks. Adolescents in the intervention group completed website modules addressing cognitive behavioral coping skills, stress management, and other self-management topics, while also receiving monthly telephone calls from a trained health coach. Adolescents in the education control group were instructed to view a series of preselected public JIA educational websites and received monthly calls from a coach who asked about their own best efforts at managing JIA. Caregivers in the intervention group completed website modules related to promoting independence and disease self-management in their child. Caregivers in the education control group were instructed to view a series of preselected public JIA educational websites. Outcome assessment occurred at baseline, 12 weeks (posttreatment), and at 6 and 12 months postrandomization. The primary outcomes were pain intensity, pain interference, and HRQL. Secondary outcomes were emotional symptoms, adherence, coping, knowledge, and self-efficacy. RESULTS In total, 333 adolescents and 306 caregivers were enrolled. Significant overall reductions in pain intensity (P=.02) and pain interference (P=.007) were observed for intervention group participants compared with those in the education control group, after adjusting for baseline levels. There was a significant overall improvement in HRQL related to problems with pain (P=.02) and problems with daily activities (P=.01). There was also a significant difference in the intervention group over time (P=.008) for HRQL related to treatment problems, with the intervention group participants demonstrating improved HRQL by 12 months compared with education control group participants. Both groups showed nonsignificant improvements compared with baseline in other primary outcomes. There were no significant differences between the groups in any secondary outcomes or caregiver-reported outcomes. CONCLUSIONS The results of this randomized trial suggest that the Teens Taking Charge Web-based intervention is effective at reducing both pain intensity and pain interference, as well as improving HRQL in adolescents with JIA, compared with education control. These effects are sustained for up to 12 months following program completion. The Teens Taking Charge program is now publicly available at no cost. TRIAL REGISTRATION ClinicalTrials.gov NCT01572896; https://clinicaltrials.gov/ct2/show/NCT01572896.",2020,"Significant overall reductions in pain intensity (P=.02) and pain interference (P=.007) were observed for intervention group participants compared with those in the education control group, after adjusting for baseline levels.","['adolescents with JIA compared with a Web-based education control condition', 'Adolescents with JIA aged 12 to 18 years were recruited from 11 Canadian pediatric rheumatology centers', '333 adolescents and 306 caregivers were enrolled', 'Adolescents With Juvenile Idiopathic Arthritis', 'Teens Taking Charge']","['Web-Based Self-Management Program With Telephone Support', 'website modules addressing cognitive behavioral coping skills, stress management, and other self-management topics, while also receiving monthly telephone calls from a trained health coach', 'Teens Taking Charge Web-based self-management intervention', 'preselected public JIA educational websites and received monthly calls from a coach who asked about their own best efforts at managing JIA', 'Teens Taking Charge self-management intervention or (2) a Web-based education control condition']","['symptoms and improving health-related quality of life (HRQL', 'pain intensity, pain interference, and HRQL', 'pain intensity', 'emotional symptoms, adherence, coping, knowledge, and self-efficacy', 'HRQL', 'pain interference', 'pain intensity and pain interference']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0238884', 'cui_str': 'Canadian'}, {'cui': 'C1621271', 'cui_str': 'Pediatric rheumatology'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4517724', 'cui_str': '333'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0007961', 'cui_str': 'Charges'}]","[{'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0150788', 'cui_str': 'Stress management'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C2317129', 'cui_str': 'Health coach'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0007961', 'cui_str': 'Charges'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3495559', 'cui_str': 'Juvenile chronic arthritis'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C1172410', 'cui_str': 'ASK protein, human'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",333.0,0.115157,"Significant overall reductions in pain intensity (P=.02) and pain interference (P=.007) were observed for intervention group participants compared with those in the education control group, after adjusting for baseline levels.","[{'ForeName': 'Jennifer N', 'Initials': 'JN', 'LastName': 'Stinson', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Chitra', 'Initials': 'C', 'LastName': 'Lalloo', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Amos S', 'Initials': 'AS', 'LastName': 'Hundert', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Campillo', 'Affiliation': ""Montreal Children's Hospital, Montreal, QC, Canada.""}, {'ForeName': 'Tania', 'Initials': 'T', 'LastName': 'Cellucci', 'Affiliation': 'Department of Pediatrics, Division of Rheumatology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dancey', 'Affiliation': ""Department of Pediatrics, Division of Rheumatology, Memorial University of Newfoundland, St. John's, NL, Canada.""}, {'ForeName': 'Ciaran', 'Initials': 'C', 'LastName': 'Duffy', 'Affiliation': 'Department of Pediatrics, Division of Rheumatology, McGill Research Institute, Montreal, QC, Canada.'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Ellsworth', 'Affiliation': 'Department of Pediatrics, Division of Rheumatology, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': 'Feldman', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Huber', 'Affiliation': 'IWK Health Centre, Halifax, NS, Canada.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Johnson', 'Affiliation': ""Alberta Children's Hospital, Calgary, AB, Canada.""}, {'ForeName': ""Geert't"", 'Initials': 'G', 'LastName': 'Jong', 'Affiliation': ""Children's Hospital Research Institute of Manitoba, Winnipeg, MB, Canada.""}, {'ForeName': 'Kiem', 'Initials': 'K', 'LastName': 'Oen', 'Affiliation': 'Pediatrics and Child Health, University of Manitoba, Winnipeg, MB, Canada.'}, {'ForeName': 'Alan M', 'Initials': 'AM', 'LastName': 'Rosenberg', 'Affiliation': 'University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Natalie J', 'Initials': 'NJ', 'LastName': 'Shiff', 'Affiliation': 'Biobehavioral Nursing Science, University of Florida, Gainesville, FL, United States.'}, {'ForeName': 'Lynn', 'Initials': 'L', 'LastName': 'Spiegel', 'Affiliation': 'Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Shirley M L', 'Initials': 'SML', 'LastName': 'Tse', 'Affiliation': 'The Hospital for Sick Children, Toronto, ON, Canada.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Tucker', 'Affiliation': 'Department of Pediatrics, Division of Rheumatology, University of British Columbia, Vancouver, ON, Canada.'}, {'ForeName': 'Joseph Charles', 'Initials': 'JC', 'LastName': 'Victor', 'Affiliation': 'Institute for Clinical Evaluative Sciences, Toronto, ON, Canada.'}]",Journal of medical Internet research,['10.2196/16234'] 2505,32723736,Reducing paediatric overweight and obesity through motivational interviewing: study protocol for a randomised controlled trial in the AAP PROS research network.,"INTRODUCTION Primary care remains an underused venue for prevention and management of paediatric overweight and obesity. A prior trial demonstrated a significant impact of paediatrician/nurse practitioner (Ped/NP)-and registered dietitian (RD)-delivered motivational interviewing (MI) on child body mass index (BMI). The study described here will test the effectiveness of an enhanced version of this primary care-based MI counselling intervention on child BMI. METHODS AND ANALYSIS This cluster randomised effectiveness trial includes 24 Ped/NPs from 18 paediatric primary care practices that belong to the American Academy of Pediatrics (AAP) national Pediatric Research in Office Settings (PROS) practice-based research network. To date, practices have been randomised (nine to intervention and nine to usual care). Intervention Ped/NPs have been trained in MI, behavioural therapy, billing/coding for weight management and study procedures. Usual care Ped/NPs received training in billing/coding and study procedures only. Children 3- 11 years old with BMI > the 85th percentile were identified via electronic health records (EHRs). Parents from intervention practices have been recruited and enrolled. Over about 2 years, these parents are offered approximately 10 MI-based counselling sessions (about four in person sessions with their child's Ped/NP and up to six telephonic sessions with a trained RD). The primary outcome is change in child BMI (defined as per cent from median BMI for age and sex) over the study period. The primary comparison is between eligible children in intervention practices whose parents enrol in the study and all eligible children in usual care practices. Data sources will include EHRs, billing records, surveys and counselling call notes. ETHICS AND DISSEMINATION Institutional Review Board approval was obtained from the AAP. All Ped/NPs provided written informed consent, and intervention group parents provided consent and Health Insurance Portability and Accountability Act (HIPAA) authorisation. Findings will be disseminated through peer-reviewed publications, conference presentations and appropriate AAP channels. TRIAL REGISTRATION NUMBER NCT03177148; Pre-results.",2020,"The study described here will test the effectiveness of an enhanced version of this primary care-based MI counselling intervention on child BMI. ","['3- 11 years old with BMI > the 85th percentile were identified via electronic health records (EHRs', 'eligible children in intervention practices whose parents enrol in the study and all eligible children in usual care practices', 'Children', '24 Ped/NPs from 18 paediatric primary care practices that belong to the American Academy of Pediatrics (AAP) national Pediatric Research in Office Settings']","['paediatrician/nurse practitioner (Ped/NP)-and registered dietitian (RD)-delivered motivational interviewing (MI', 'primary care-based MI counselling intervention']","['child body mass index (BMI', 'change in child BMI']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1264641', 'cui_str': 'Percentile'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027341', 'cui_str': 'Nail-patella syndrome'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0000876', 'cui_str': 'Academies'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0442603', 'cui_str': 'Office'}]","[{'cui': 'C0237433', 'cui_str': 'Pediatrician'}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0334932', 'cui_str': 'Dietitian (general)'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",,0.0786239,"The study described here will test the effectiveness of an enhanced version of this primary care-based MI counselling intervention on child BMI. ","[{'ForeName': 'Margaret E', 'Initials': 'ME', 'LastName': 'Wright', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA mewright@uic.edu.'}, {'ForeName': 'Emerson', 'Initials': 'E', 'LastName': 'Delacroix', 'Affiliation': 'School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Kendrin R', 'Initials': 'KR', 'LastName': 'Sonneville', 'Affiliation': 'School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Shannon', 'Initials': 'S', 'LastName': 'Considine', 'Affiliation': 'School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Proctor', 'Affiliation': ""Physician's Computer Company, Winooski, Vermont, USA.""}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Steffes', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.'}, {'ForeName': 'Donna', 'Initials': 'D', 'LastName': 'Harris', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.'}, {'ForeName': 'Laura P', 'Initials': 'LP', 'LastName': 'Shone', 'Affiliation': 'Primary Care Research, American Academy of Pediatrics, Itasca, Illinois, USA.'}, {'ForeName': 'Heide', 'Initials': 'H', 'LastName': 'Woo', 'Affiliation': 'Department of Paediatrics, University of California Los Angeles, Los Angeles, California, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Vaughan', 'Affiliation': 'Department of Hospital Biostatistics, The Rockefeller University, New york City, New york, USA.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Grundmeier', 'Affiliation': ""Department of Paediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.""}, {'ForeName': 'Alexander G', 'Initials': 'AG', 'LastName': 'Fiks', 'Affiliation': 'Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca, Illinois, USA.'}, {'ForeName': 'Melissa S', 'Initials': 'MS', 'LastName': 'Stockwell', 'Affiliation': 'Pediatric Research in Office Settings, American Academy of Pediatrics, Itasca, Illinois, USA.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Resnicow', 'Affiliation': 'School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.'}]",BMJ open,['10.1136/bmjopen-2019-035720'] 2506,32723752,Correction: Effects of home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring in patients with chronic heart failure: a study protocol for a randomised controlled trial.,,2020,,['patients with chronic heart failure'],['home-based cardiac exercise rehabilitation with remote electrocardiogram monitoring'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]",[],,0.0542666,,[],BMJ open,['10.1136/bmjopen-2018-023923corr1'] 2507,32723753,Correction: Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).,,2020,,['people with schizophrenia and related disorders'],"['gradual antipsychotic reduction and discontinuation', 'Correction']",[],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0439833', 'cui_str': 'Gradual'}, {'cui': 'C0040615', 'cui_str': 'Antipsychotic agent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}]",[],,0.0733776,,[],BMJ open,['10.1136/bmjopen-2019-030912corr1'] 2508,32723925,Clinical Assessment and Thickness Changes of the Oblique and Multifidus Muscles Using a Novel Screening Tool and Exercise Program: A Randomized Controlled Trial.,"CONTEXT Training and assessment of the abdominal and trunk muscles are widely used in the clinical setting. However, it is unknown what types of exercises are most effective in activation of both the global and local stabilizers in these regions. OBJECTIVE The purpose of this study was to establish the reliability of a novel clinical screening tool (sling screen) to assess the muscles of the abdomen and trunk. The second aim was to use the clinical screening tool and musculoskeletal ultrasound to compare the effects of a rotary-based exercise program that targets both the global and local muscles to the effects of a traditional exercise program on the activation of the abdominal and trunk muscles. DESIGN Double-blind, randomized controlled trial. SETTING Sports medicine facility. PARTICIPANTS AND INTERVENTIONS Thirty-one healthy participants were randomly allocated to receive a single-session rotary-based or traditional ""core"" exercise program. MAIN OUTCOME MEASURES The participants were assessed at the baseline and immediately postintervention. The primary outcome measures were muscle thickness examined by musculoskeletal ultrasound and clinical examination of muscle activation using a screening tool. The data were collected by blind assessors. Reliability and validity of a clinical screening tool (sling screen) were also assessed. RESULTS The analysis of the covariance tests showed a significant increase in oblique thickness for the rotary exercise group. All participants displayed a significant increase in multifidus thickness. The Wilcoxon signed-rank tests revealed a significant increase in clinical assessment scores in the rotary exercise group but not the traditional exercise group. Reliability of the sling screen ranged from moderate to good. CONCLUSION This clinical trial provides evidence that a rotary-based exercise program may be more effective in producing increases in oblique muscle thickness than traditional ""core"" exercises in young, healthy adults. The sling screen tool was able to identify these muscle thickness changes. Future studies should investigate how these results correlate to injury risk, other populations, and also how to implement the sling screen into clinical practice.",2020,The Wilcoxon signed-rank tests revealed a significant increase in clinical assessment scores in the rotary exercise group but not the traditional exercise group.,"['young, healthy adults', 'Sports medicine facility', 'Thirty-one healthy participants']","['rotary-based exercise program', 'rotary exercise', 'traditional exercise program', 'single-session rotary-based or traditional ""core"" exercise program', 'clinical screening tool (sling screen', 'novel clinical screening tool (sling screen']","['multifidus thickness', 'muscle thickness examined by musculoskeletal ultrasound and clinical examination of muscle activation using a screening tool', 'oblique thickness', 'oblique muscle thickness', 'clinical assessment scores']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0038040', 'cui_str': 'Medicine, Sport'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0183346', 'cui_str': 'Sling'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0224319', 'cui_str': 'Structure of multifidus muscle'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0205315', 'cui_str': 'Oblique'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C4758616', 'cui_str': 'Assessment score'}]",31.0,0.0329503,The Wilcoxon signed-rank tests revealed a significant increase in clinical assessment scores in the rotary exercise group but not the traditional exercise group.,"[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Catania', 'Affiliation': ''}, {'ForeName': 'Travis', 'Initials': 'T', 'LastName': 'Ross', 'Affiliation': ''}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Sandella', 'Affiliation': ''}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Bley', 'Affiliation': ''}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'DiTrani Lobacz', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2019-0156'] 2509,32723991,Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study.,"OBJECTIVE Three-weekly docetaxel causes a high rate of febrile neutropenia, especially in the Asian population. Two-weekly docetaxel has been shown to reduce rate of febrile neutropenia in castrate-resistant prostate cancer patients. We conducted a preliminary study to investigate the safety of two-weekly docetaxel in advanced breast cancer patients. METHODS We recruited 10 patients with advanced breast cancer with ECOG (Eastern Cooperative Oncology Group) performance status score of zero to two, who needed chemotherapy in the first or second-line setting to receive two-weekly docetaxel for 8 cycles. The primary endpoint was safety and secondary endpoints were response rate and progression free survival. RESULTS The most reported adverse events were haematological (anaemia 100% and neutropenia 90%). The febrile neutropenia rate was 10%. The overall response rate was 20%. The median progression free survival was 5.0 months. CONCLUSION Two-weekly docetaxel may be a reasonable alternative treatment regimen for patients with advanced breast cancer in the first or second-line setting. This regimen is yet to be compared with standard 3-weekly schedule in a phase 3 randomised clinical trial.",2020,The most reported adverse events were haematological (anaemia 100% and neutropenia 90%).,"['10 patients with advanced breast cancer with ECOG (Eastern Cooperative Oncology Group) performance status score of zero to two, who needed chemotherapy in the first or second-line setting to receive two-weekly', 'advanced breast cancer', 'patients with advanced breast cancer in the first or second-line setting', 'castrate-resistant prostate cancer patients', 'advanced breast cancer patients']",['docetaxel'],"['response rate and progression free survival', 'febrile neutropenia', 'median progression free survival', 'overall response rate', 'febrile neutropenia rate', 'rate of febrile neutropenia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3495917', 'cui_str': 'Advanced breast cancer'}, {'cui': 'C0430797', 'cui_str': 'Electrocorticogram'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C1328504', 'cui_str': 'Hormone refractory prostate cancer'}]","[{'cui': 'C0246415', 'cui_str': 'docetaxel'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",10.0,0.0327854,The most reported adverse events were haematological (anaemia 100% and neutropenia 90%).,"[{'ForeName': 'D W', 'Initials': 'DW', 'LastName': 'Lee', 'Affiliation': 'University of Malaya, Faculty of Medicine, Clinical Oncology Unit, Kuala Lumpur, Malaysia. daiwee@ummc.edu.my.'}, {'ForeName': 'I H', 'Initials': 'IH', 'LastName': 'Kang', 'Affiliation': 'Universiti Kebangsaan Malaysia, Faculty of Medicine, Clinical Oncology Department, Kuala Lumpur, Malaysia.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Ismail', 'Affiliation': 'Universiti Kebangsaan Malaysia, Faculty of Medicine, Clinical Oncology Department, Kuala Lumpur, Malaysia.'}]",The Medical journal of Malaysia,[] 2510,32723992,"Selective laser trabeculoplasty vs. topical medications for step-up treatment in primary open angle glaucoma: comparing clinical effectiveness, quality of life and cost-effectiveness.","INTRODUCTION The aim of this study was to investigate the clinical effectiveness, health related quality of life (HRQoL) and cost effectiveness of selective laser trabeculoplasty (SLT) compared to topical anti-glaucoma medications in step-up treatment of patients with primary open angle glaucoma (POAG). METHODS Seventeen POAG patients with suboptimal IOP control despite pre-existing topical medications were subjected to adjunct SLT (50 applications 180 degrees) or second line medical therapy. Current medications were continued, and patients were followed up for 6 months for degree of intraocular pressure (IOP) lowering. HRQoL was assessed using Glaucoma Quality of Life 36-item (GlauQoL-36), Assessment of Quality of Life-7D (AQoL-7D) and Vision related Quality of Life (VisQoL). Costs involved were calculated and compared to the effect (IOP reduction) achieved in each arm. RESULTS Ten patients were in the SLT group and 7 in the topical medication (MED) group. Mean baseline intraocular pressure (IOP) was 18.90±3.48mmHg in SLT group and 15.57±2.23mmHg in MED group. Mean reduction of IOP was 4.30±1.64mmHg in SLT group and 2.71±2.56 mmHg in MED group at 6 months which was not statistically significant (p=0.14) between two groups. All the HRQoL questionnaires did not show significant changes in the groups or between groups when compared baseline with 6-month post treatment (p-values ranging from 0.247 to 0.987). For every 1mmHg reduction in IOP, cost involved in MED group (RM53.61) was 165% of the cost involved in SLT group (RM32.56). DISCUSSION AND CONCLUSION This study has shown that SLT was as effective clinically and tolerable as topical anti glaucoma medications and was possibly more cost effective in the step-up treatment of patients with POAG at 6 months follow- up.",2020,All the HRQoL questionnaires did not show significant changes in the groups or between groups when compared baseline with 6-month post treatment (p-values ranging from 0.247 to 0.987).,"['primary open angle glaucoma', 'patients with primary open angle glaucoma (POAG', 'Ten patients were in the SLT group and 7 in the topical medication (MED) group', 'Seventeen POAG patients with suboptimal IOP control despite pre-existing topical medications were subjected to']","['SLT', 'adjunct SLT (50 applications 180 degrees) or second line medical therapy', 'topical anti-glaucoma medications', 'selective laser trabeculoplasty (SLT', 'Selective laser trabeculoplasty vs. topical medications']","['Mean baseline intraocular pressure (IOP', 'clinical effectiveness, quality of life and cost-effectiveness', 'HRQoL questionnaires', 'Glaucoma Quality of Life 36-item (GlauQoL-36), Assessment of Quality of Life-7D (AQoL-7D) and Vision related Quality of Life (VisQoL', 'clinical effectiveness, health related quality of life (HRQoL) and cost effectiveness', 'Costs', 'Mean reduction of IOP']","[{'cui': 'C0339573', 'cui_str': 'Primary open angle glaucoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1271447', 'cui_str': 'Selective laser trabeculoplasty'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C1271447', 'cui_str': 'Selective laser trabeculoplasty'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0021888', 'cui_str': 'Intraocular pressure'}, {'cui': 'C3850123', 'cui_str': 'Treatment Effectiveness'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0017601', 'cui_str': 'Glaucoma'}, {'cui': 'C0281588', 'cui_str': 'Assessment of quality of life'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",10.0,0.0306101,All the HRQoL questionnaires did not show significant changes in the groups or between groups when compared baseline with 6-month post treatment (p-values ranging from 0.247 to 0.987).,"[{'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Yong', 'Affiliation': 'Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Ophthalmology, Kuala Lumpur, Malaysia.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Che Hamzah', 'Affiliation': 'Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Ophthalmology, Kuala Lumpur, Malaysia. jemaima@ppukm.ukm.edu.my.'}]",The Medical journal of Malaysia,[] 2511,32724156,A comparison of the effectiveness of azelaic and pyruvic acid peels in the treatment of female adult acne: a randomized controlled trial.,"Chemical peels are widely used as therapeutic agents in dermatology and cosmetology. This study aims to explore the differences in the effectiveness of azelaic and pyruvic acid peels in the treatment of acne vulgaris. Eligibility criteria for participants were: female gender, 18-25 years of age, no dermatological treatment within the last 12 months and mild to moderate papulopustular acne. We treated 120 young women (with a mean age of 22 years old) with six peeling sessions at 2-week intervals. In the parallel clinical study design, one randomized group (n = 60, 50%) was treated using azelaic acid (AA), whereas the second group participated in pyruvic acid (PA) sessions. We evaluated the patients clinically twice (before and after treatment), using the Scale of Hellegren-Vincent Severity Symptoms to assess the acne diagnosis, and the Nati Analyzer to estimate the skin properties (oily skin, desquamation, porosity, and moisture). The clinical evaluation of the patients demonstrated a significant reduction of acne severity symptoms in both the AA and PA groups, after the peeling sessions. An effect was also found in terms of decreasing desquamation and the oiliness of the skin. PA showed a more significant reduction of greasy skin than AA. In conclusion, after the six peeling sessions using AA and PA, all patients showed better skin parameters in term of reduced oiliness and desquamation. Both AA and PA peelings are a safe and efficient treatment for mild acne, however, during the selection of one of the two acids, side effects, skin properties, and patients' preferences should be taken into account. This study was registered in the ISRCTN registry (registration number ISRCTN79716614, 17/01/2020).",2020,"The clinical evaluation of the patients demonstrated a significant reduction of acne severity symptoms in both the AA and PA groups, after the peeling sessions.","['Eligibility criteria for participants were: female gender, 18-25\xa0years of age, no dermatological treatment within the last 12\xa0months and mild to moderate papulopustular acne', 'female adult acne', '120 young women (with a mean age of 22\xa0years old) with six peeling sessions at 2-week intervals', 'acne vulgaris']","['azelaic acid (AA), whereas the second group participated in pyruvic acid (PA) sessions', 'azelaic and pyruvic acid peels']","['skin properties (oily skin, desquamation, porosity, and moisture', 'skin parameters', 'acne severity symptoms']","[{'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0086287', 'cui_str': 'Female'}, {'cui': 'C0450335', 'cui_str': '18/25'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011625', 'cui_str': 'DERMATOLOGICALS'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1858506', 'cui_str': 'Acne, Adult'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C0052761', 'cui_str': 'azelaic acid'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0072802', 'cui_str': 'Pyruvic acid'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0234925', 'cui_str': 'Greasy skin'}, {'cui': 'C0237849', 'cui_str': 'Peeling of skin'}, {'cui': 'C0080037', 'cui_str': 'Porosity'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}]",120.0,0.0240227,"The clinical evaluation of the patients demonstrated a significant reduction of acne severity symptoms in both the AA and PA groups, after the peeling sessions.","[{'ForeName': 'Karolina', 'Initials': 'K', 'LastName': 'Chilicka', 'Affiliation': 'Faculty of Health Sciences, University of Opole, 45-060, Opole, Poland.'}, {'ForeName': 'Aleksandra M', 'Initials': 'AM', 'LastName': 'Rogowska', 'Affiliation': 'Institute of Psychology, University of Opole, 45-052, Opole, Poland. arogowska@uni.opole.pl.'}, {'ForeName': 'Renata', 'Initials': 'R', 'LastName': 'Szyguła', 'Affiliation': 'Faculty of Health Sciences, University of Opole, 45-060, Opole, Poland.'}, {'ForeName': 'Iwona', 'Initials': 'I', 'LastName': 'Dzieńdziora-Urbińska', 'Affiliation': 'Faculty of Health Sciences, University of Opole, 45-060, Opole, Poland.'}, {'ForeName': 'Jakub', 'Initials': 'J', 'LastName': 'Taradaj', 'Affiliation': 'Institute of Physiotherapy and Health Sciences, Academy of Physical Education, 40-065, Katowice, Poland.'}]",Scientific reports,['10.1038/s41598-020-69530-w'] 2512,32724244,Effect of intravenous lignocaine infusion on bispectral index during spinal anaesthesia for caesarean section: A prospective randomised double-blind study.,"Background and Aims Systemic lignocaine has been shown to have sedative effects. We designed this randomised-double-blind, placebo-controlled study to evaluate the effect of intravenous lignocaine on the bispectral index (BIS) during caesarean section under spinal anaesthesia. Methods 80 patients scheduled for elective caesarean section under spinal anaesthesia were randomly allocated to 2 study groups. Group L received intravenous 1.5 mg/kg of lignocaine bolus, 15 minutes before spinal anaesthesia followed by an intravenous infusion 1.5 mg/kg/h for 60 minutes intravenously. The patients in the control group (C group) were given 0.9% sodium chloride in a double-blind fashion. Spinal anaesthesia was performed with 10 mg of 0.5% bupivacaine. The changes of Sao2, BIS and hemodynamic variables during caesarean section, Apgar score of neonate and the incidence of adverse effects were recorded. Results BIS values were lower in the L group compared to C group ( P ≤ 0.001). Comparison of mean arterial pressure (MAP) changes during spinal anaesthesia and surgery reveal statistically significant difference between two groups through repeated measure analysis ( P ≤ 0.001), but comparision of heart rate (HR) changes during spinal anaesthesia and surgery failed to reveal any statistically significant difference between two groups. ( P = 0.261). The Apgar scores did not reveal a significant difference between the two groups at first and five minutes after delivery ( P = 0.99). Conclusion Intravenous lignocaine infusion given with spinal anaesthesia in women undergoing elective caesarean delivery providing lower BIS values without respiratory depression, in the absence of foetal compromise.",2020,"The Apgar scores did not reveal a significant difference between the two groups at first and five minutes after delivery ( P = 0.99). ","['women undergoing elective caesarean delivery providing lower BIS values without respiratory depression', 'spinal anaesthesia for caesarean section', 'caesarean section under spinal anaesthesia', '80 patients scheduled for elective caesarean section under spinal anaesthesia']","['sodium chloride', 'bupivacaine', 'spinal anaesthesia', 'lignocaine', 'placebo']","['changes of Sao2, BIS and hemodynamic variables during caesarean section, Apgar score of neonate and the incidence of adverse effects', 'bispectral index', 'bispectral index (BIS', 'comparision of heart rate (HR) changes', 'Apgar scores', 'mean arterial pressure (MAP) changes', 'Results\n\n\nBIS values']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0473296', 'cui_str': 'Elective cesarean section'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0235063', 'cui_str': 'Decreased respiratory function'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}]","[{'cui': 'C0037494', 'cui_str': 'Sodium Chloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1301882', 'cui_str': 'Bispectral index'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0003533', 'cui_str': 'Finding of Apgar score'}, {'cui': 'C0003065', 'cui_str': 'Animals, Neonatal'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0232189', 'cui_str': 'Alteration in heart rate'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",80.0,0.242268,"The Apgar scores did not reveal a significant difference between the two groups at first and five minutes after delivery ( P = 0.99). ","[{'ForeName': 'Marzieh Beigom', 'Initials': 'MB', 'LastName': 'Khezri', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Kosar Hospital Research Center, Qazvin, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Rajabi', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Kosar Hospital Research Center, Qazvin, Iran.'}, {'ForeName': 'Siamak', 'Initials': 'S', 'LastName': 'Yaghoobi', 'Affiliation': 'Department of Anesthesiology, Qazvin University of Medical Sciences, Qazvin, Iran.'}, {'ForeName': 'Ameneh', 'Initials': 'A', 'LastName': 'Barikani', 'Affiliation': 'Department of Community and Preventive Medicine, Faculty of Medicine, Qazvin, Iran.'}]",Indian journal of anaesthesia,['10.4103/ija.IJA_424_19'] 2513,32724246,Comparative effect of desflurane and sevoflurane on liver function tests of patients with impaired hepatic function undergoing cholecystectomy: A randomized clinical study.,"Background and Aim Desflurane and sevoflurane are the most common volatile anesthetics used during laparoscopic and hepatic surgery. The objective of the study was to evaluate the effect of desflurane and sevoflurane in patients with elevated preoperative liver functions undergoing laparoscopic cholecystectomy. Methods The study was a randomized study and included 162 patients classified randomly into two groups: Desflurane group: The patients received desflurane (end-tidal concentration 4%-6%) as an inhalational agent during the whole procedure. Sevoflurane group: The patients received sevoflurane (end-tidal concentration 2%-4%) as an inhalational agent during the whole procedure. The investigations included serum level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), and total bilirubin. The values were serially collected at the following timepoints; T0:at the preoperative period, T1:directly after surgery, T2:1 st postoperative day, T3:2 nd postoperative day, T4:3 rd postoperative day, T5:5 th postoperative day, T6:7 th postoperative day, and T7:10 th postoperative day. The statistics were described in terms of mean ± standard deviation, frequencies, and percentages. Results The preoperative liver enzymes and total bilirubin were higher than the normal range in patients of the two groups. Postoperatively, there was a decrease in the AST and ALT with desflurane more than sevoflurane from T1 to T6( P < 0.05). The ALP, GGT, and bilirubin decreased in patients of the two groups, but the comparison was insignificant ( P > 0.05). Conclusion The desflurane is a safe inhalational volatile for maintenance of anesthesia in patients with impaired liver function undergoing laparoscopic cholecystectomy. It was associated with a decrease in the liver enzymes more than the sevoflurane.",2020,"Postoperatively, there was a decrease in the AST and ALT with desflurane more than sevoflurane from T1 to T6( P < 0.05).","['162 patients classified randomly into two groups: Desflurane group', 'patients with impaired liver function undergoing laparoscopic cholecystectomy', 'group', 'patients with elevated preoperative liver functions undergoing laparoscopic cholecystectomy', 'patients with impaired hepatic function undergoing cholecystectomy']","['Desflurane and sevoflurane', 'desflurane and sevoflurane', 'desflurane', 'sevoflurane', 'Sevoflurane']","['AST and ALT', 'serum level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), and total bilirubin', 'preoperative liver enzymes and total bilirubin', 'ALP, GGT, and bilirubin', 'liver enzymes', 'liver function tests']","[{'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0232741', 'cui_str': 'Liver function'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0008320', 'cui_str': 'Cholecystectomy'}]","[{'cui': 'C0063252', 'cui_str': 'desflurane'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]","[{'cui': 'C0004002', 'cui_str': 'Aspartate aminotransferase'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0002059', 'cui_str': 'Alkaline phosphatase'}, {'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0443764', 'cui_str': 'Liver enzyme'}, {'cui': 'C0023901', 'cui_str': 'Hepatic function panel'}]",162.0,0.0366936,"Postoperatively, there was a decrease in the AST and ALT with desflurane more than sevoflurane from T1 to T6( P < 0.05).","[{'ForeName': 'Rabie', 'Initials': 'R', 'LastName': 'Soliman', 'Affiliation': 'Department of Anesthesia, Aldar Hospital, Almadinah Almonwarah, Saudi Arabia.'}, {'ForeName': 'Abdelbadee', 'Initials': 'A', 'LastName': 'Yacoub', 'Affiliation': 'Department of Anesthesia, Aldar Hospital, Almadinah Almonwarah, Saudi Arabia.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Abdellatif', 'Affiliation': 'Department of Surgery Aldar Hospital, Almadinah Almonwarah, Saudi Arabia.'}]",Indian journal of anaesthesia,['10.4103/ija.IJA_168_20'] 2514,32724248,A prospective comparative study of arterial blood gas parameters in smoker versus non-smoker patients undergoing laparoscopic cholecystectomy.,"Background and Aims Smoking is a risk factor for postoperative pulmonary complications in patients undergoing general anaesthesia. These may get amplified with effects of pneumo-peritoneum and carbon dioxide (CO 2 ) insufflation during laparoscopic surgeries. Our aim was to compare metabolic and blood gas analysis of smokers versus non-smoker patients during laparoscopic surgeries under general anaesthesia. Methods After permission from institutional review board, 60 patients undergoing laparoscopic cholecystectomy were divided into two groups, smokers and non-smokers (30 each). Along with baseline haemo-dynamic parameters, arterial blood gas sampling was done to assess and compare PCO 2 , pH and bicarbonate (HCO 3 ) values at various time intervals with respect to pneumo-peritoneum creation, between smokers and non smokers. Results Baseline systolic blood pressure was higher and oxygen saturation was significantly lower in smoker group. PCO 2 and end-tidal CO 2 were significantly higher in smokers at all intervals ( P < 0.001). pH was significantly lower and HCO 3 higher, in smokers after creation of pneumo-peritoneum. Increase in PCO2 due to pneumo-peritoneum was higher in the smoker group (3.49 ± 8.5) mmHg versus non smoker (0.56 ± 4.86) mmHg, although statistically not significant. Change in pH and HCO 3 was similar between smokers and non-smokers. Conclusion There is a significant difference in baseline arterial blood gas characteristics between smokers and non-smokers. Metabolic effects of CO 2 insufflation and increased intraabdominal pressure appears to be more enhanced in smokers.",2020,PCO 2 and end-tidal CO 2 were significantly higher in smokers at all intervals ( P < 0.001).,"['smoker versus non-smoker patients undergoing laparoscopic cholecystectomy', 'smokers versus non-smoker patients during laparoscopic surgeries under general anaesthesia', '60 patients undergoing', 'patients undergoing general anaesthesia']","['pneumo-peritoneum and carbon dioxide (CO 2 ) insufflation', 'laparoscopic cholecystectomy']","['Baseline systolic blood pressure', 'oxygen saturation', 'PCO 2 and end-tidal CO 2', 'PCO 2 , pH and bicarbonate (HCO 3 ) values', 'baseline arterial blood gas characteristics', 'intraabdominal pressure', 'PCO2 due to pneumo-peritoneum', 'pH']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0337672', 'cui_str': 'Non-smoker'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C1719976', 'cui_str': 'Under general anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0021634', 'cui_str': 'Insufflation'}, {'cui': 'C0162522', 'cui_str': 'Laparoscopic cholecystectomy'}]","[{'cui': 'C4274438', 'cui_str': 'Baseline systolic blood pressure'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0150411', 'cui_str': 'Analysis of arterial blood gases and pH'}, {'cui': 'C0231901', 'cui_str': 'Intraabdominal pressure'}, {'cui': 'C0201931', 'cui_str': 'Carbon dioxide measurement, partial pressure'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0031153', 'cui_str': 'Peritoneum (serous membrane) structure'}]",60.0,0.0232977,PCO 2 and end-tidal CO 2 were significantly higher in smokers at all intervals ( P < 0.001).,"[{'ForeName': 'Amiya K', 'Initials': 'AK', 'LastName': 'Barik', 'Affiliation': 'Department of Anaesthesiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.'}, {'ForeName': 'Ajit', 'Initials': 'A', 'LastName': 'Kumar', 'Affiliation': 'Department of Anaesthesiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.'}, {'ForeName': 'Mridul', 'Initials': 'M', 'LastName': 'Dhar', 'Affiliation': 'Department of Anaesthesiology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.'}, {'ForeName': 'Pushkar', 'Initials': 'P', 'LastName': 'Ranjan', 'Affiliation': 'Department of Anaesthesiology and Critical Care, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.'}]",Indian journal of anaesthesia,['10.4103/ija.IJA_953_19'] 2515,32724250,Preoperative oral zinc tablet decreases incidence of postoperative sore throat.,"Background and Aims Postoperative sore throat (POST) is very frequently reported after endotracheal intubation. Zinc lozenge has been shown to reduce POST. The aim of this study was to evaluate the effect of dispersible zinc tablet on POST. Methods Eighty-eight patients undergoing surgery with endotracheal intubation were randomly allocated into two groups, to either receive dispersible zinc tablet 40 mg (zinc group) or placebo tablet (control group), 30 min preoperatively. Assessment for incidence and severity was performed for POST, on a 4-point scale (0-3) at 0, 30 min, 2, 4, and 24 h postoperatively. The primary outcome was incidence of POST at 4 h postoperatively. Secondary outcome was severity of POST at the 5 evaluation time points postoperatively. Mann-Whitney U test, Fisher's exact, and Chi-square test were used as applicable. Results At 4 h, there was a significantly lower incidence of POST in zinc group (6.8%) than the control group (31.8%) with a P value of 0.003. Three patients in placebo group complained of severe POST compared to none in the zinc group. The severity of POST was significantly lower in Zinc group than Placebo group at 0 min ( P = 0.003), 30 min ( P = 0.002), 2 h ( P < 0.001), and 4 h ( P = 0.001). Conclusion Preoperative administration of 40 mg dispersible zinc tablet effectively reduces the incidence and severity of POST in the immediate postoperative period.",2020,"The severity of POST was significantly lower in Zinc group than Placebo group at 0 min ( P = 0.003), 30 min ( P = 0.002), 2 h ( P < 0.001), and 4 h ( P = 0.001). ",['Methods\n\n\nEighty-eight patients undergoing surgery with endotracheal intubation'],"['Placebo', 'dispersible zinc tablet', 'Preoperative oral zinc tablet', 'dispersible zinc tablet 40 mg (zinc group) or placebo tablet (control group), 30 min preoperatively', 'placebo']","['incidence of POST', 'severe POST', 'severity of POST', 'incidence of POST at 4 h postoperatively', 'incidence and severity of POST', 'postoperative sore throat']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4517898', 'cui_str': '88'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0456693', 'cui_str': '/30 min'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0031350', 'cui_str': 'Pharyngitis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",88.0,0.294422,"The severity of POST was significantly lower in Zinc group than Placebo group at 0 min ( P = 0.003), 30 min ( P = 0.002), 2 h ( P < 0.001), and 4 h ( P = 0.001). ","[{'ForeName': 'Tanmay', 'Initials': 'T', 'LastName': 'Sarkar', 'Affiliation': 'Department of Anaesthesiology, North Bengal Medical College, Darjeeling, West Bengal, India.'}, {'ForeName': 'Tanuka', 'Initials': 'T', 'LastName': 'Mandal', 'Affiliation': 'Department of Anaesthesiology, North Bengal Medical College, Darjeeling, West Bengal, India.'}]",Indian journal of anaesthesia,['10.4103/ija.IJA_959_19'] 2516,32724312,Photoaging Skin Therapy with PRP and ADSC: A Comparative Study.,"Background Stem cells from adipose tissue (ADSCs) and platelet-rich plasma (PRP) are innovative modalities that arise due to their regenerative potential. Objective The aim of this study was to characterize possible histological changes induced by PRP and ADSC therapies in photoaged skin. Methods A prospective randomized study involving 20 healthy individuals, showing skin aging. They underwent two therapeutic protocols (protocol 1: PRP; protocol 2: ADSCs). Biopsies were obtained before and after treatment (4 months). Results PRP protocol showed unwanted changes in the reticular dermis, mainly due to the deposition of a horizontal layer of collagen (fibrosis) and elastic fibers tightly linked. Structural analyses revealed infiltration of mononuclear cells and depot of fibrotic material in the reticular dermis. The ADSC protocol leads to neoelastogenesis with increase of tropoelastin and fibrillin. There was an improvement of solar elastosis inducing an increment of macrophage polarization and matrix proteinases. These last effects are probably related to the increase of elastinolysis and the remodeling of the dermis. Conclusions The PRP promoted an inflammatory process with an increase of reticular dermis thickness with a fibrotic aspect. On the other hand, ADSC therapy is a promising modality with an important antiaging effect on photoaged human skin.",2020,There was an improvement of solar elastosis inducing an increment of macrophage polarization and matrix proteinases.,"['20 healthy individuals, showing skin aging']",['Photoaging Skin Therapy with PRP and ADSC'],"['infiltration of mononuclear cells and depot of fibrotic material', 'macrophage polarization and matrix proteinases', 'solar elastosis']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}]","[{'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}]","[{'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C1294062', 'cui_str': 'Mononuclear cell count'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0024426', 'cui_str': 'Macrophage Activation'}, {'cui': 'C4050026', 'cui_str': 'Matrix'}, {'cui': 'C0030940', 'cui_str': 'Peptide Hydrolases'}, {'cui': 'C0263415', 'cui_str': 'Solar degeneration'}]",20.0,0.0177383,There was an improvement of solar elastosis inducing an increment of macrophage polarization and matrix proteinases.,"[{'ForeName': 'Luiz', 'Initials': 'L', 'LastName': 'Charles-de-Sá', 'Affiliation': 'Postgraduate Program in Surgical Science, Federal University of Rio de Janeiro-CCS-Bloco C, Avenida Carlos Chagas Filho, 373, Ilha do Fundão, Rio de Janeiro, RJ 21941-902, Brazil.'}, {'ForeName': 'Natale', 'Initials': 'N', 'LastName': 'Gontijo-de-Amorim', 'Affiliation': 'Dipartamento di Scienze Neurologiche e del Movimento, Sezione di Anatomia e Istologia della Universitá degli Studi di Verona, Strada Le Grazie 8, Verona 37134, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Sbarbati', 'Affiliation': 'Dipartamento di Scienze Neurologiche e del Movimento, Sezione di Anatomia e Istologia della Universitá degli Studi di Verona, Strada Le Grazie 8, Verona 37134, Italy.'}, {'ForeName': 'Donatella', 'Initials': 'D', 'LastName': 'Benati', 'Affiliation': 'Dipartamento di Scienze Neurologiche e del Movimento, Sezione di Anatomia e Istologia della Universitá degli Studi di Verona, Strada Le Grazie 8, Verona 37134, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Bernardi', 'Affiliation': 'Dipartamento di Scienze Neurologiche e del Movimento, Sezione di Anatomia e Istologia della Universitá degli Studi di Verona, Strada Le Grazie 8, Verona 37134, Italy.'}, {'ForeName': 'Radovan', 'Initials': 'R', 'LastName': 'Borojevic', 'Affiliation': 'Universidade Federal do Rio de Janeiro-UFRJ-CCS and Centro de Biotecnologia-IMETRO, Rio de Janeiro, Brazil.'}, {'ForeName': 'Rosana Bizon Vieira', 'Initials': 'RBV', 'LastName': 'Carias', 'Affiliation': 'Universidade Federal do Rio de Janeiro-UFRJ-CCS and Centro de Biotecnologia-IMETRO, Rio de Janeiro, Brazil.'}, {'ForeName': 'Gino', 'Initials': 'G', 'LastName': 'Rigotti', 'Affiliation': 'Casa di Cura San Francesco-Unità di Chirurgia Rigenerativa, Via Monte Ortigara, 21, Verona, Italy.'}]",Stem cells international,['10.1155/2020/2032359'] 2517,32724321,"Effectiveness and Safety of Panax ginseng Extract on Hepatic Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.","Background The purpose of this study was to evaluate the efficacy and safety of Panax ginseng extract (GS-KG9) in the treatment of hepatic dysfunction. Methods A randomized, double-blind, placebo-controlled clinical trial was conducted from December 2017 to January 2019. The trial included 60 subjects between the ages of 19 and 70 who had higher alanine transaminase (ALT) levels than the normal upper limit. The subjects were randomly divided into two groups: GS-KG9 ( n  = 30) and placebo ( n  = 30). The former was administered three GS-KG9 capsules (3 g/day) and the latter three placebo capsules (3 g/day) twice each day orally after meals in the morning and evening for 12 weeks. The primary goal was to observe the changes in ALT and gamma-glutamyl transferase (GGT) levels. The safety of the treatment was assessed and adverse events (AEs) were recorded. Results Out of 60 subjects, nine were excluded from the efficacy analysis because they met the exclusion criteria. Therefore, a total of 51 subjects were evaluated for the effectiveness of the treatment (26 in the GS-KG9 group and 25 in the placebo group). After 12 weeks of treatment, the ALT levels were significantly reduced in the GS-KG9 group compared to the placebo group ( p =0.009). The GGT level of the GS-KG9 group was significantly lower than that of the placebo group ( p =0.036). Mild AEs, such as diarrhea, occurred during the study. There were no significant differences between the two groups. Conclusion The results of this trial suggest that GS-KG9 might be an effective and safe option for mild hepatic dysfunction. This trial is registered with KCT0004080.",2020,"After 12 weeks of treatment, the ALT levels were significantly reduced in the GS-KG9 group compared to the placebo group ( p =0.009).","['60 subjects', 'December 2017 to January 2019', '60 subjects between the ages of 19 and 70 who had higher alanine transaminase (ALT) levels than the normal upper limit']","['Placebo', 'Panax ginseng extract (GS-KG9', 'Panax ginseng Extract', 'GS-KG9', 'placebo']","['GGT level', 'changes in ALT and gamma-glutamyl transferase (GGT) levels', 'ALT levels', 'efficacy and safety', 'adverse events (AEs', 'Hepatic Dysfunction']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0873137', 'cui_str': 'Korean ginseng preparation'}]","[{'cui': 'C0017040', 'cui_str': 'Gamma-glutamyltransferase'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001899', 'cui_str': 'Alanine aminotransferase'}, {'cui': 'C0202035', 'cui_str': 'Gamma glutamyl transferase measurement'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0086565', 'cui_str': 'Abnormal liver function'}]",60.0,0.423572,"After 12 weeks of treatment, the ALT levels were significantly reduced in the GS-KG9 group compared to the placebo group ( p =0.009).","[{'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Shen', 'Affiliation': 'Department of Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.'}, {'ForeName': 'Si Ra', 'Initials': 'SR', 'LastName': 'Gwak', 'Affiliation': 'Department of Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.'}, {'ForeName': 'Jong Cheon', 'Initials': 'JC', 'LastName': 'Joo', 'Affiliation': 'Department of Constitutional Medicine, College of Korean Medicine, Wonkwang University, Iksan 54538, Republic of Korea.'}, {'ForeName': 'Bong Keun', 'Initials': 'BK', 'LastName': 'Song', 'Affiliation': 'Department of Internal Medicine, College of Korean Medicine, Wonkwang University, Gwangju 51729, Republic of Korea.'}, {'ForeName': 'Seon Woo', 'Initials': 'SW', 'LastName': 'Cha', 'Affiliation': 'International Ginseng and Herb Research Institute, Geumsan 32724, Republic of Korea.'}, {'ForeName': 'Young Uk', 'Initials': 'YU', 'LastName': 'Song', 'Affiliation': 'Daedong Korea Ginseng Co., Ltd., Geumsan 32718, Republic of Korea.'}, {'ForeName': 'Mi Kyung', 'Initials': 'MK', 'LastName': 'Pyo', 'Affiliation': 'International Ginseng and Herb Research Institute, Geumsan 32724, Republic of Korea.'}, {'ForeName': 'Soo Jung', 'Initials': 'SJ', 'LastName': 'Park', 'Affiliation': 'Department of Sasang Constitutional Medicine, College of Korean Medicine, Woosuk University, Jeonju 55338, Republic of Korea.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/2689565'] 2518,31237182,Frontal haemodynamic responses in depression and the effect of electroconvulsive therapy.,"BACKGROUND Reduced frontal cortex metabolism and blood flow in depression may be associated with low mood and cognitive impairment. Further reduction has been reported during a course of electroconvulsive therapy but it is not known if this relates to mood and cognitive changes caused by electroconvulsive therapy. AIMS The purpose of this study was to investigate frontal function while undertaking cognitive tasks in depressed patients compared with healthy controls, and following electroconvulsive therapy in patients. METHODS We measured frontal haemodynamic responses to a category verbal fluency task and a working memory N-back task using portable functional near infra-red spectroscopy (fNIRS) in 51 healthy controls and 18 severely depressed patients, 12 of whom were retested after the fourth treatment of a course of electroconvulsive therapy. Mood was assessed using the Montgomery Åsberg Depression Rating Scale and cognitive function using category Verbal Fluency from the Controlled Oral Word Association Test and Digit Span backwards. RESULTS Compared to healthy controls, depressed patients had bilaterally lower frontal oxyhaemoglobin responses to the cognitive tasks, although this was only significant for the N-Back task where performance correlated inversely with depression severity in patients. After four electroconvulsive therapy treatments oxyhaemoglobin responses were further reduced during the Verbal Fluency task but the changes did not correlate with mood or cognitive changes. DISCUSSION Our results confirmed a now extensive literature showing impaired frontal fNIRS oxyhaemoglobin responses to cognitive tasks in depression, and showed for the first time that these are further reduced during a course of electroconvulsive therapy. Further research is needed to investigate the biology and clinical utility of frontal fNIRS in psychiatric patients.",2019,"After four electroconvulsive therapy treatments oxyhaemoglobin responses were further reduced during the Verbal Fluency task but the changes did not correlate with mood or cognitive changes. ","['51 healthy controls and 18 severely depressed patients, 12 of whom were retested after the fourth treatment of a course of', 'psychiatric patients', 'depressed patients compared with healthy controls, and following electroconvulsive therapy in patients']","['electroconvulsive therapy', 'category verbal fluency task and a working memory N-back task using portable functional near infra-red spectroscopy (fNIRS']","['frontal haemodynamic responses', 'Verbal Fluency task', 'mood or cognitive changes', 'Montgomery Åsberg Depression Rating Scale and cognitive function using category Verbal Fluency from the Controlled Oral Word Association Test and Digit Span backwards']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205438', 'cui_str': 'Fourth'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0748064', 'cui_str': 'Psychiatric in-patient'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C1532326', 'cui_str': 'Infra-red'}, {'cui': 'C0037812', 'cui_str': 'Analysis, Spectrum'}]","[{'cui': 'C0205123', 'cui_str': 'Coronal'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C3827022', 'cui_str': 'Controlled Oral Word Association Test'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0439781', 'cui_str': 'Backward'}]",51.0,0.0175711,"After four electroconvulsive therapy treatments oxyhaemoglobin responses were further reduced during the Verbal Fluency task but the changes did not correlate with mood or cognitive changes. ","[{'ForeName': 'Darragh', 'Initials': 'D', 'LastName': 'Downey', 'Affiliation': '1 Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Brigadoi', 'Affiliation': '2 Biomedical Optics Research Laboratory, University College London, London, UK.'}, {'ForeName': 'Liam', 'Initials': 'L', 'LastName': 'Trevithick', 'Affiliation': '4 School of Psychology, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Elliott', 'Affiliation': '6 Neuroscience and Psychiatry Unit, The University of Manchester, Manchester, UK.'}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Elwell', 'Affiliation': '2 Biomedical Optics Research Laboratory, University College London, London, UK.'}, {'ForeName': 'R Hamish', 'Initials': 'RH', 'LastName': 'McAllister-Williams', 'Affiliation': '4 School of Psychology, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Ian M', 'Initials': 'IM', 'LastName': 'Anderson', 'Affiliation': '7 Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119858313'] 2519,31356678,Quantitative Prediction of CYP3A4- and CYP3A5-Mediated Drug Interactions.,"We verified a physiologically-based pharmacokinetic (PBPK) model to predict cytochrome P450 3A4/5-mediated drug-drug interactions (DDIs). A midazolam (MDZ)-ketoconazole (KTZ) interaction study in 24 subjects selected by CYP3A5 genotype, and liquid chromatography and mass spectroscopy quantification of CYP3A4/5 abundance from independently acquired and genotyped human liver (n = 136) and small intestinal (N = 12) samples, were conducted. The observed CYP3A5 genetic effect on MDZ systemic and oral clearance was successfully replicated by a mechanistic framework incorporating the proteomics-informed CYP3A abundance and optimized small intestinal CYP3A4 abundance based on MDZ intestinal availability (F G ) of 0.44. Furthermore, combined with a modified KTZ PBPK model, this framework recapitulated the observed geometric mean ratio of MDZ area under the curve (AUCR) following 200 or 400 mg KTZ, which was, respectively, 2.7-3.4 and 3.9-4.7-fold in intravenous administration and 11.4-13.4 and 17.0-19.7-fold in oral administration, with AUCR numerically lower (P > 0.05) in CYP3A5 expressers than nonexpressers. In conclusion, the developed mechanistic framework supports dynamic prediction of CYP3A-mediated DDIs in study planning by bridging DDIs between CYP3A5 expressers and nonexpressers.",2020,The observed CYP3A5 genetic effect on MDZ systemic and oral clearance was successfully replicated by a mechanistic framework incorporating the proteomics-informed CYP3A abundance and optimized small intestinal CYP3A4 abundance based on MDZ intestinal availability (F G ) of 0.44.,"['24 subjects selected by CYP3A5 genotype, and liquid chromatography and mass spectroscopy quantification of CYP3A4/5 abundance from independently acquired and genotyped human liver (n\xa0=\xa0136) and small intestinal (N\xa0=\xa012) samples, were conducted']",['midazolam (MDZ)-ketoconazole (KTZ) interaction'],['geometric mean ratio of MDZ area under the curve (AUCR'],"[{'cui': 'C3714750', 'cui_str': 'Cytochrome p450 CYP3A5 enzyme'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0008565', 'cui_str': 'Liquid chromatography measurement'}, {'cui': 'C0037813', 'cui_str': 'Mass spectrometry measurement'}, {'cui': 'C0439661', 'cui_str': 'Acquired'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C4517568', 'cui_str': '136'}, {'cui': 'C0021852', 'cui_str': 'Small intestinal'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0022625', 'cui_str': 'Ketoconazole'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",24.0,0.0916028,The observed CYP3A5 genetic effect on MDZ systemic and oral clearance was successfully replicated by a mechanistic framework incorporating the proteomics-informed CYP3A abundance and optimized small intestinal CYP3A4 abundance based on MDZ intestinal availability (F G ) of 0.44.,"[{'ForeName': 'Yingying', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, Indiana, USA.'}, {'ForeName': 'Aroonrut', 'Initials': 'A', 'LastName': 'Lucksiri', 'Affiliation': 'Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.'}, {'ForeName': 'Gemma L', 'Initials': 'GL', 'LastName': 'Dickinson', 'Affiliation': 'Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, Indiana, USA.'}, {'ForeName': 'Raj K', 'Initials': 'RK', 'LastName': 'Vuppalanchi', 'Affiliation': 'Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.'}, {'ForeName': 'Janna K', 'Initials': 'JK', 'LastName': 'Hilligoss', 'Affiliation': 'Department of Medicine, Indiana University, Indianapolis, Indiana, USA.'}, {'ForeName': 'Stephen D', 'Initials': 'SD', 'LastName': 'Hall', 'Affiliation': 'Drug Disposition, Eli Lilly and Company, Lilly Corporate Center DC0714, Indianapolis, Indiana, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1596'] 2520,31385663,Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.,"BACKGROUND Studies show that low skeletal muscle index (SMI) and low skeletal muscle density (SMD) are negative prognostic factors and associated with more toxicity from systemic therapy in cancer patients. However, muscle depletion can be caused by a range of diseases, and many cancer patients have significant co-morbidity. The aim of this study was to investigate whether there were associations between co-morbidity and muscle measures in patients with advanced non-small cell lung cancer. METHODS Patients in a Phase III trial comparing two chemotherapy regimens in advanced non-small cell lung cancer were analysed (n = 436). Co-morbidity was assessed using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), which rates co-morbidity from 0 to 4 on 14 different organ scales. Severe co-morbidity was defined as having any grades 3 and 4 CIRS-G score. Muscle measures were assessed from baseline computed tomography slides at the L3 level using the SliceOMatic software. RESULTS Complete data were available for 263 patients (60%). Median age was 66, 57.0% were men, 78.7% had performance status 0-1, 25.9% Stage IIIB, 11.4% appetite loss, 92.4% were current/former smokers, 22.8% were underweight, 43.7% had normal weight, 26.6% were overweight, and 6.8% obese. The median total CIRS-G score was 7 (range: 0-16), and 48.2% had severe co-morbidity. Mean SMI was 44.7 cm 2 /m 2 (range: 27-71), and the mean SMD was 37.3 Hounsfield units (HU) (range: 16-60). When comparing patients with and without severe co-morbidity, there were no significant differences in median SMI (44.5 vs. 44.1 cm 2 /m 2 ; 0.70), but patients with severe co-morbidity had a significantly lower median SMD (36 HU vs. 39 HU; 0.001), mainly due to a significant difference in SMD between those with severe heart disease and those without (32.5 vs. 37.9 HU; 0.002). Linear regression analyses confirmed the association between severe co-morbidity and SMD both in the simple analysis (0.001) and the multiple analysis (0.037) adjusting for baseline characteristics. Stage of disease, gender, and body mass index (BMI) were significantly associated with SMI in both the simple and multiple analyses. Age and BMI were significantly associated with SMD in the simple analysis; and age, gender, and BMI were significantly associated in the multiple analysis. CONCLUSIONS There were no significant differences in SMI between patients with and patients without severe co-morbidity, but patients with severe co-morbidity had lower SMD than other patients, mainly due to severe heart disease. Co-morbidity might be a confounder in studies of the clinical role of SMD in cancer patients.",2019,"There were no significant differences in SMI between patients with and patients without severe co-morbidity, but patients with severe co-morbidity had lower SMD than other patients, mainly due to severe heart disease.","['Patients in a Phase III trial comparing two chemotherapy regimens in advanced non-small cell lung cancer were analysed (n = 436', 'cancer patients', 'Median age was 66, 57.0% were men, 78.7% had performance status 0-1, 25.9% Stage IIIB, 11.4% appetite loss, 92.4% were current/former smokers, 22.8% were underweight, 43.7% had normal weight, 26.6% were overweight, and 6.8% obese', 'patients with advanced non-small cell lung cancer', 'advanced non-small cell lung cancer patients']",[],"['Cumulative Illness Rating Scale for Geriatrics (CIRS-G), which rates co-morbidity', 'severe co-morbidity and SMD', 'SMD', 'Mean SMI', 'median SMD', 'Age and BMI', 'SMI', 'Severe co-morbidity', 'median SMI', 'median total CIRS-G score', 'Co-morbidity', 'severe co-morbidity', 'Stage of disease, gender, and body mass index (BMI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}, {'cui': 'C4517533', 'cui_str': '11.4'}, {'cui': 'C0003123', 'cui_str': 'Anorexia'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0337671', 'cui_str': 'Ex-smoker'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]",[],"[{'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0079399', 'cui_str': 'Gender'}]",436.0,0.13341,"There were no significant differences in SMI between patients with and patients without severe co-morbidity, but patients with severe co-morbidity had lower SMD than other patients, mainly due to severe heart disease.","[{'ForeName': 'Bjørn H', 'Initials': 'BH', 'LastName': 'Grønberg', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Christine Damgaard', 'Initials': 'CD', 'LastName': 'Valan', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Tarje', 'Initials': 'T', 'LastName': 'Halvorsen', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Bjørg', 'Initials': 'B', 'LastName': 'Sjøblom', 'Affiliation': 'Department of Oncology, Oslo University Hospital, Oslo, Norway.'}, {'ForeName': 'Marit S', 'Initials': 'MS', 'LastName': 'Jordhøy', 'Affiliation': 'Department of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12469'] 2521,31423755,Concentric strength training at optimal or short muscle length improves strength equally but does not reduce fatigability of hamstring muscles.,"The purpose of this study was to compare the effect of a 6-week period of knee flexion strength training at either optimal or short muscle length, on length-specific muscle strength and fatigue. Twelve healthy volunteers performed dynamic (isokinetic concentric) training with one leg at short and the contralateral leg at optimal muscle length for 6 weeks. Knee flexor muscle strength was assessed before and after training, comprising maximal voluntary isometric and dynamic contractions at short, intermediate and near optimal muscle length and electrically evoked, contractions at near optimal length only. Fatigability was tested by performing 60 maximal concentric contractions at either short or optimal muscle length. Isometric torque at all muscle lengths improved equally by training at short and optimal muscle length, for example, tested at short 18 (17) versus 21 (17) % (CI) and at optimal 14 (8) versus 17 (16) % muscle length, respectively. Likewise, equal improvements were observed for dynamic contractions in both groups. Prior to training, fatigue induced at optimal muscle length tended to be more pronounced than at short muscle length (fatigue-indexes -41 (6) vs. -34 (7) %, respectively, P = 0.05). However, training at either length did not reduce fatigability. Training with maximal concentric contractions at either short or optimal muscle length for 6 weeks improved isometric and dynamic muscle strength in the entire range of motion without inducing any discernible length-specific adaptations. However, strength training at restricted muscle length did not reduce relative fatigue when induced at either short or optimal muscle length.",2019,"Isometric torque at all muscle lengths improved equally by training at short and optimal muscle length, for example, tested at short 18 (17) versus 21 (17) % (CI) and at optimal 14 (8) versus 17 (16) % muscle length, respectively.",['Twelve healthy volunteers performed'],"['dynamic (isokinetic concentric) training with one leg at short and the contralateral leg at optimal muscle length for 6\xa0weeks', 'knee flexion strength training', 'strength training', 'Concentric strength training']","['fatigability of hamstring muscles', 'fatigability', 'dynamic contractions', 'relative fatigue', 'Isometric torque', 'Knee flexor muscle strength', 'length-specific muscle strength and fatigue']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0884358', 'cui_str': 'Performed'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0231230', 'cui_str': 'Fatigability'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205369', 'cui_str': 'Specific'}]",60.0,0.0113085,"Isometric torque at all muscle lengths improved equally by training at short and optimal muscle length, for example, tested at short 18 (17) versus 21 (17) % (CI) and at optimal 14 (8) versus 17 (16) % muscle length, respectively.","[{'ForeName': 'Katja K', 'Initials': 'KK', 'LastName': 'Pedersen', 'Affiliation': 'Department of Public Health, Section of Sport Science, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Martin K', 'Initials': 'MK', 'LastName': 'Madsen', 'Affiliation': 'Department of Public Health, Section of Sport Science, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Lars G', 'Initials': 'LG', 'LastName': 'Hvid', 'Affiliation': 'Department of Public Health, Section of Sport Science, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Kristian', 'Initials': 'K', 'LastName': 'Overgaard', 'Affiliation': 'Department of Public Health, Section of Sport Science, Aarhus University, Aarhus, Denmark.'}]",Physiological reports,['10.14814/phy2.14196'] 2522,30420001,Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder.,"BACKGROUND Patient expectancy is an important source of placebo effects in antidepressant clinical trials, but all prior studies measured expectancy prior to the initiation of medication treatment. Little is known about how expectancy changes during the course of treatment and how such changes influence clinical outcome. Consequently, we undertook the first analysis to date of in-treatment expectancy during antidepressant treatment to identify its clinical and demographic correlates, typical trajectories, and associations with treatment outcome. METHODS Data were combined from two randomized controlled trials of antidepressant medication for major depressive disorder in which baseline and in-treatment expectancy assessments were available. Machine learning methods were used to identify pre-treatment clinical and demographic predictors of expectancy. Multilevel models were implemented to test the effects of expectancy on subsequent treatment outcome, disentangling within- and between-patient effects. RESULTS Random forest analyses demonstrated that whereas more severe depressive symptoms predicted lower pre-treatment expectancy, in-treatment expectancy was unrelated to symptom severity. At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003). The greater the gap between expected treatment outcomes and actual depressive severity, the greater the subsequent symptom reductions were (B = 0.49, t = 2.33, p = 0.02). CONCLUSIONS Greater in-treatment patient expectancy is associated with greater subsequent depressive symptom reduction. These findings suggest that clinicians may benefit from monitoring and optimizing patient expectancy during antidepressant treatment. Expectancy may represent another treatment parameter, similar to medication compliance and side effects, to be regularly monitored during antidepressant clinical management.",2019,"At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003).",['major depressive disorder'],['antidepressant medication'],"['severe depressive symptoms', 'actual depressive severity', 'depressive symptoms', 'subsequent symptom reductions']","[{'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}]","[{'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0297572,"At each measurement point, increased in-treatment patient expectancy significantly predicted decreased depressive symptoms at the following measurement (B = -0.45, t = -3.04, p = 0.003).","[{'ForeName': 'Sigal', 'Initials': 'S', 'LastName': 'Zilcha-Mano', 'Affiliation': 'Department of Psychology, University of Haifa, Mount Carmel, Haifa 31905, Israel.'}, {'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Brown', 'Affiliation': 'Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Steven P', 'Initials': 'SP', 'LastName': 'Roose', 'Affiliation': 'Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Kiley', 'Initials': 'K', 'LastName': 'Cappetta', 'Affiliation': 'Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, USA.'}, {'ForeName': 'Bret R', 'Initials': 'BR', 'LastName': 'Rutherford', 'Affiliation': 'Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, USA.'}]",Psychological medicine,['10.1017/S0033291718003343'] 2523,32724619,Efficacy of an iron-fortified infant cereal to reduce the risk of iron deficiency anemia in young children in East Cameroon.,"Complementary foods in Africa are often poor sources of bioavailable iron. We assessed the efficacy of iron-fortified wheat-based infant cereal (IC) to reduce the risk of iron deficiency anemia in children aged 18-59 months in Cameroon. A 6-month double-blind, cluster-randomized controlled trial was conducted in 2017 among anemic (hemoglobin 7-11 g/dl) but otherwise healthy children. In conjunction with usual diet, children received two 50 g servings/day of a standard, micronutrient-fortified IC (providing 3.75 mg iron/serving; n  = 106) or the same IC without iron fortification ( n  = 99). Anthropometric measurements, blood sampling, and systematic deworming were performed in all children at baseline (pre-intervention), 3, and 6 months. Mean hemoglobin, ferritin adjusted for C-reactive protein (CRP), serum iron, transferrin saturation, prevalence of anemia, iron deficiency, and iron deficiency anemia as well as anthropometrics were compared between the groups at baseline, 3, and 6 months. Compared to the control group, children consuming the iron-fortified IC had significantly higher baseline-adjusted mean hemoglobin (10.0 ± 1.8 vs. 9.7 ± 1.4 g/dl, respectively; p  = .023), ferritin adjusted for CRP (16.1 ± 8.3 vs. 9.5 ± 7.5 μg/L, p  < .001), serum iron (14.5 ± 3.9 vs. 11.2 ± 4.4 μg/dl; p  < .001), and transferrin saturation (19.0 ± 17.4 vs. 10.7 ± 12.5%; p  ˂ .001) at 6 months. The prevalence of anemia, iron deficiency, and iron deficiency anemia at 6 months decreased by a larger extent in the iron-fortified group versus controls (all p  < .01). In addition, at 6 months, children in the iron-fortified group demonstrated higher weight-for-age z -scores ( p  = .016) compared to the control group. Wheat-based IC fortified with 7.5 mg ferrous fumarate administered daily for 6 months improved iron and nutritional status and decreased the prevalence of iron deficiency anemia in children aged 18-59 months in Salapoumbé, Cameroon.",2020,"The prevalence of anemia, iron deficiency, and iron deficiency anemia at 6 months decreased by a larger extent in the iron-fortified group versus controls (all p  < .01).","['children aged 18-59\xa0months in Cameroon', '2017 among anemic (hemoglobin 7-11\xa0g/dl) but otherwise healthy children', 'young children in East Cameroon']","['micronutrient-fortified IC (providing 3.75\xa0mg iron/serving; n \xa0=\xa0106) or the same IC without iron fortification', 'iron-fortified wheat-based infant cereal (IC', 'iron-fortified infant cereal']","['prevalence of anemia, iron deficiency, and iron deficiency anemia', 'risk of iron deficiency anemia', 'higher weight-for-age z -scores', 'Mean hemoglobin, ferritin adjusted for C-reactive protein (CRP), serum iron, transferrin saturation, prevalence of anemia, iron deficiency, and iron deficiency anemia', 'transferrin saturation', 'Anthropometric measurements, blood sampling, and systematic deworming', 'prevalence of iron deficiency anemia', 'iron and nutritional status']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0006802', 'cui_str': 'Cameroon'}, {'cui': 'C0857322', 'cui_str': 'Anemic'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0439267', 'cui_str': 'g/dL'}, {'cui': 'C0686744', 'cui_str': 'Well child'}, {'cui': 'C0337547', 'cui_str': 'Younger child'}]","[{'cui': 'C0040577', 'cui_str': 'Trace element'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0007757', 'cui_str': 'Cereal'}, {'cui': 'C4517697', 'cui_str': '3.75'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0043137', 'cui_str': 'Wheat'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0162316', 'cui_str': 'Iron deficiency anemia'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0948775', 'cui_str': 'High weight'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0015879', 'cui_str': 'Ferritin'}, {'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C1318312', 'cui_str': 'Serum iron measurement'}, {'cui': 'C1277709', 'cui_str': 'Transferrin saturation'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0082568', 'cui_str': 'ferryl iron'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}]",,0.301848,"The prevalence of anemia, iron deficiency, and iron deficiency anemia at 6 months decreased by a larger extent in the iron-fortified group versus controls (all p  < .01).","[{'ForeName': 'Tetanye', 'Initials': 'T', 'LastName': 'Ekoe', 'Affiliation': 'Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon.'}, {'ForeName': 'Ousmaila I', 'Initials': 'OI', 'LastName': 'Bianpambe', 'Affiliation': 'Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon.'}, {'ForeName': 'Felicitee', 'Initials': 'F', 'LastName': 'Nguefack', 'Affiliation': 'Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon.'}, {'ForeName': 'Daniel M', 'Initials': 'DM', 'LastName': 'Pondi', 'Affiliation': 'Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon.'}, {'ForeName': 'Marie M', 'Initials': 'MM', 'LastName': 'Kana-Sop', 'Affiliation': 'Faculty of Sciences University of Douala Douala Cameroon.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Hays', 'Affiliation': 'Nestlé Product Technology Center - Nutrition Vevey Switzerland.'}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Medoua', 'Affiliation': 'Food and Nutrition Research Center Institute for Medical Research and Study of Medicinal Plants Yaoundé Cameroon.'}, {'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Koki', 'Affiliation': 'Faculty of Medicine and Biomedical Sciences University of Yaoundé I Yaoundé Cameroon.'}]",Food science & nutrition,['10.1002/fsn3.1639'] 2524,32724622,"Effects of a low-energy diet with and without oat bran and olive oil supplements on body mass index, blood pressure, and serum lipids in diabetic women: A randomized controlled trial.","Type 2 diabetes is an epidemic public health issue worldwide. It is common among adults and is more severe among overweight and obese subjects. This study was conducted to evaluate the effects of a low-energy diet with and without oat bran and olive oil supplements on body mass index, blood pressure, and serum lipids in women with diabetes. It was conducted for three months among 78 participants after dividing them into six groups. Groups 2 to 6 were received low-energy diet (1,600 kcal/day), with or without oat bran (10 g/day) and olive oil (5 g/day) supplements. Weight, height, blood pressure, and serum lipids were measured. A low-energy diet with and without oat bran and olive oil supplements lowers body mass index in subjects by 0.9%-6.0% on average. It also lowers systolic and diastolic blood pressure by 1.0%-9.0% and 4.8%-12.6%, respectively. Serum triglycerides were declined in groups 2, 3, and 4 by 27.2%, 17.3%, and 1.7%, respectively, but not significantly. Total cholesterol was dropped significantly by 8.3% only when the low-energy diet was used with oat bran supplement among obese subjects, while LDL cholesterol was dropped significantly by 20.0% only when it was used with oat bran and olive oil supplements among subjects with high serum triglycerides. Proper control of type 2 diabetes among overweight and obese adults is needed to control cardiovascular complications. This could be accomplished by following a low-energy diet and incorporating healthy foods such as oat and olive oil into the usual diet.",2020,"Serum triglycerides were declined in groups 2, 3, and 4 by 27.2%, 17.3%, and 1.7%, respectively, but not significantly.","['overweight and obese adults', 'diabetic women', 'overweight and obese subjects', 'subjects with high serum triglycerides', 'women with diabetes', '78 participants after dividing them into six groups']","['oat bran and olive oil supplements', 'low-energy diet', 'low-energy diet with and without oat bran and olive oil supplements', 'oat bran supplement', 'olive oil']","['body mass index', 'Serum triglycerides', 'systolic and diastolic blood pressure', 'LDL cholesterol', 'Weight, height, blood pressure, and serum lipids', 'Total cholesterol', 'body mass index, blood pressure, and serum lipids']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0795649', 'cui_str': 'OAT BRAN'}, {'cui': 'C0069449', 'cui_str': 'olive oil'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C2930544', 'cui_str': 'Calorie restricted diet'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428462', 'cui_str': 'Measurement of serum lipid level'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",78.0,0.024955,"Serum triglycerides were declined in groups 2, 3, and 4 by 27.2%, 17.3%, and 1.7%, respectively, but not significantly.","[{'ForeName': 'Nora A', 'Initials': 'NA', 'LastName': 'AlFaris', 'Affiliation': 'Nutrition and Food Science (PhD) Department of Physical Sport Science Princess Nourah bint Abdulrahman University Riyadh Saudi Arabia.'}, {'ForeName': 'Adnan S', 'Initials': 'AS', 'LastName': 'Ba-Jaber', 'Affiliation': 'Department of Food Science and Nutrition College of Food and Agriculture Sciences King Saud University Riyadh Saudi Arabia.'}]",Food science & nutrition,['10.1002/fsn3.1642'] 2525,32724651,Maternal nutrition intervention focused on the adjustment of salt and sugar intake can improve pregnancy outcomes.,"Due to the increasing age of pregnant women, maternal nutrition management is becoming more important. Since pregnant women are more likely to consume sodium and sugars than nonpregnant women of the same age, we investigated whether maternal nutrition intervention focused on the adjustment of salt and sugar intake can help pregnancy outcome. This randomized controlled trial was performed on 142 pregnant women within 22 weeks of gestational age for at least 16 weeks until childbirth. Subjects were unequally assigned to the intervention group ( n  = 98) and the control group ( n  = 44). Dietary changes based on perceived taste preferences were evaluated by 24-hr dietary recall and food frequency questionnaires (FFQ) at pre- and postintervention. In the intervention group, while the intakes of energy, protein, and vitamins were maintained, the intakes of sodium ( p  < .001) and sugar from processed food ( p  < .05) were significantly reduced after the intervention. The decreases in salt and sugar consumption were more pronounced in the mothers who had a high preference for saltiness and sweetness. The mean neonatal birth weight of the intervention group was significantly greater than the weight of control group, (3,251.5 ± 402.2 g vs. 2,974.5 ± 294.8 g, p < .05). Through this study, nutrition intervention was found to be effective for the formation of healthy eating habits such as reduced salt and sugar intake in pregnant women especially with a high preference for saltiness and sweetness. Also, such specialized maternal nutrition intervention during pregnancy promotes the birth of healthy newborn babies of normal weight.",2020,The decreases in salt and sugar consumption were more pronounced in the mothers who had a high preference for saltiness and sweetness.,"['142 pregnant women within 22\xa0weeks of gestational age for at least 16\xa0weeks until childbirth', 'Since pregnant women', 'healthy newborn babies of normal weight', 'pregnant women especially with a high preference for saltiness and sweetness']","['nutrition intervention', 'specialized maternal nutrition intervention', 'Maternal nutrition intervention']","['24-hr dietary recall and food frequency questionnaires (FFQ', 'pregnancy outcomes', 'mean neonatal birth weight', 'salt and sugar consumption']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0017504', 'cui_str': 'Fetal gestational age'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0578757', 'cui_str': 'Good neonatal condition at birth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C2712185', 'cui_str': 'Normal weight'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}]","[{'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0205555', 'cui_str': 'Special'}, {'cui': 'C1720845', 'cui_str': 'Maternal Nutritional Physiological Phenomenon'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032972', 'cui_str': 'Outcomes, Pregnancy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0005612', 'cui_str': 'Birth weight'}, {'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]",142.0,0.0211928,The decreases in salt and sugar consumption were more pronounced in the mothers who had a high preference for saltiness and sweetness.,"[{'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Seo', 'Affiliation': 'Department of Medical Nutrition Graduate School of East-West Medical Science Kyung Hee University Yongin Korea.'}, {'ForeName': 'Yeon Seon', 'Initials': 'YS', 'LastName': 'Jeong', 'Affiliation': 'Department of Obstetrics and Gynecology Ajou University School of Medicine Suwon Korea.'}, {'ForeName': 'Kyung-A', 'Initials': 'KA', 'LastName': 'Koo', 'Affiliation': 'Department of Obstetrics and Gynecology Ajou University School of Medicine Suwon Korea.'}, {'ForeName': 'Jeong In', 'Initials': 'JI', 'LastName': 'Yang', 'Affiliation': 'Department of Obstetrics and Gynecology Ajou University School of Medicine Suwon Korea.'}, {'ForeName': 'Yoo Kyoung', 'Initials': 'YK', 'LastName': 'Park', 'Affiliation': 'Department of Medical Nutrition Graduate School of East-West Medical Science Kyung Hee University Yongin Korea.'}]",Food science & nutrition,['10.1002/fsn3.1699'] 2526,32724786,"Effects of core balance training on Cobb angle, isokinetic torque, and balance in unilateral handed athletes.","This study aimed to provide fundamental data of core balance training (CBT) on Cobb angle and isokinetic torque and balance in unilateral exercised athletes. Forty-eight subjects were divided by control group (CON; n=16), non-CBT exercised group in unilateral handed athletes (NEG, n=16), and CBT exercised group in unilateral handed athletes (EG, n=16), respectively. Although the group by time interaction in the Cobb angle and in the isokinetic torque were not significantly changed in the EG, the balance of the EG showed significantly improved. As conclusions, these results informed that the 16-week CBT would provide a positive effect on the balance except for the Cobb angle and the isokinetic torque.",2020,"Although the group by time interaction in the Cobb angle and in the isokinetic torque were not significantly changed in the EG, the balance of the EG showed significantly improved.","['unilateral handed athletes', 'Forty-eight subjects', 'unilateral exercised athletes']","['core balance training (CBT', 'core balance training', 'CBT exercised group in unilateral handed athletes (NEG, n=16), and CBT exercised group in unilateral handed athletes']","['Cobb angle and isokinetic torque and balance', 'Cobb angle, isokinetic torque, and balance', 'isokinetic torque']","[{'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C4319608', 'cui_str': '48'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0563192', 'cui_str': 'Cobb angle'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",48.0,0.0121943,"Although the group by time interaction in the Cobb angle and in the isokinetic torque were not significantly changed in the EG, the balance of the EG showed significantly improved.","[{'ForeName': 'Sung-Hwan', 'Initials': 'SH', 'LastName': 'Bang', 'Affiliation': 'Department of Special Warfare Medical Non-Commissioned Officer, Daejeon Health Institute of Technology, Daejeon, Korea.'}, {'ForeName': 'Jang-Gun', 'Initials': 'JG', 'LastName': 'Yoon', 'Affiliation': 'Department of Special Warfare Medical Non-Commissioned Officer, Daejeon Health Institute of Technology, Daejeon, Korea.'}, {'ForeName': 'Jeong-Min', 'Initials': 'JM', 'LastName': 'Park', 'Affiliation': 'Department of Physical Education, Chungnam National University, Daejeon, Korea.'}]",Journal of exercise rehabilitation,['10.12965/jer.2040266.133'] 2527,32724788,Effects of spinal stabilization exercise with real-time ultrasound imaging biofeedback in individuals with chronic nonspecific low back pain: a pilot study.,"The use of real-time ultrasound imaging (RUSI) as biofeedback to enhance the performance of spinal stabilization exercise and recovery from low back pain has been a recent trend in musculoskeletal rehabilitation. The aim of this pilot study was to evaluate whether it would be feasible to conduct a randomized controlled trial investigating the effects of spinal stabilization exercise with RUSI biofeedback in individuals with chronic nonspecific low back pain. This was a single-group pretest-posttest quasi-experimental study. Ten consecutive patients with chronic nonspecific low back pain met the study criteria. They received spinal stabilization exercise with the RUSI biofeedback focusing on lumbar multifidus muscle activation. The intervention was provided twice weekly for 6 weeks. Outcome measures were lumbar multifidus muscle cross-sectional area, pain, disability and quality of life assessed at baseline and after intervention. A paired t -test was applied and effect size (Cohen d ) was computed. The recruitment and retention rates were 75% and 83% respectively. No adverse events were reported during the study. Compared with the baseline, the participants demonstrated statistically significant improvement in lumbar multifidus muscle cross-sectional area ( P <0.05, d =1.03), pain ( P <0.001, d =2.56) and disability ( P <0.05, d =1.43) with large effect size after the intervention. However, no statistically significant differences were observed for physical and mental health ( P >0.05) after the intervention. It was concluded that spinal stabilization exercise with RUSI biofeedback is effective in improving lumbar multifidus muscle cross-sectional area, pain and disability in individuals with chronic nonspecific low back pain. The results demonstrated the feasibility of conducting a future, larger-scale powered randomized controlled trial to confirm these preliminary findings.",2020,"However, no statistically significant differences were observed for physical and mental health ( P >0.05) after the intervention.","['Ten consecutive patients with chronic nonspecific low back pain met the study criteria', 'individuals with chronic nonspecific low back pain']","['real-time ultrasound imaging (RUSI', 'spinal stabilization exercise with the RUSI biofeedback', 'spinal stabilization exercise with RUSI biofeedback', 'spinal stabilization exercise with real-time ultrasound imaging biofeedback']","['disability', 'lumbar multifidus muscle cross-sectional area, pain and disability', 'recruitment and retention rates', 'adverse events', 'lumbar multifidus muscle cross-sectional area, pain, disability and quality of life', 'pain', 'physical and mental health', 'lumbar multifidus muscle cross-sectional area']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005491', 'cui_str': 'Biofeedback procedure'}]","[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0224319', 'cui_str': 'Structure of multifidus muscle'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]",10.0,0.0767299,"However, no statistically significant differences were observed for physical and mental health ( P >0.05) after the intervention.","[{'ForeName': 'Raheem', 'Initials': 'R', 'LastName': 'Sarafadeen', 'Affiliation': 'Department of Physiotherapy, Faculty of Allied Health Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria.'}, {'ForeName': 'Sokunbi O', 'Initials': 'SO', 'LastName': 'Ganiyu', 'Affiliation': 'Department of Physiotherapy, Faculty of Allied Health Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria.'}, {'ForeName': 'Aminu A', 'Initials': 'AA', 'LastName': 'Ibrahim', 'Affiliation': 'Department of Physiotherapy, Faculty of Allied Health Sciences, College of Health Sciences, Bayero University Kano, Kano State, Nigeria.'}]",Journal of exercise rehabilitation,['10.12965/jer.2040380.190'] 2528,32724875,"Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer.","In spite of repeated appeal of the effectiveness of three-field lymphadenectomy (3FL) by Japanese esophageal surgeons, it has not been accepted worldwide as a standard therapeutic measure for thoracic esophageal cancer. In this review, a concise summary of the history of 3FL, its present position, and its future perspective is discussed. Although a lack of randomized controlled trial (RCT) is one of the largest criticisms of 3FL, it seems difficult to make 3FL world-standard even if a RCT with a positive result was made. The essence of 3FL has revealed the fact that bilateral cervical paraesophageal nodes and nodes in the bilateral supraclavicular fossae are regional nodes of thoracic esophageal cancer. To let the world admit this essence should be the real endpoint of ""3FL issue"" without RCT. In the era of new modalities, Japanese surgeons should be free from the idea that 3FL is indispensable though the essence of 3FL should remain.",2020,"In the era of new modalities, Japanese surgeons should be free from the idea that 3FL is indispensable though the essence of 3FL should remain.","['Japanese esophageal surgeons', 'thoracic esophageal cancer']",['three-field lymphadenectomy (3FL'],[],"[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0014859', 'cui_str': 'Neoplasm of esophagus'}]","[{'cui': 'C0440042', 'cui_str': ""Field's stain""}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}]",[],,0.0261636,"In the era of new modalities, Japanese surgeons should be free from the idea that 3FL is indispensable though the essence of 3FL should remain.","[{'ForeName': 'Harushi', 'Initials': 'H', 'LastName': 'Udagawa', 'Affiliation': 'Toranomon Hospital Kajigaya Kawasaki City Japan.'}]",Annals of gastroenterological surgery,['10.1002/ags3.12338'] 2529,32724912,Does concurrent use of clopidogrel and PPIs increase CV risk in patients with ACS?,"No. Adding a proton pump inhibitor (PPI) in patients taking antiplatelet medications such as clopidogrel for acute coronary syndrome (ACS) doesn't increase the composite risk of cardiovascular (CV) events: CV death, myocardial infarction (MI), and cerebrovascular accident (CVA) (strength of recommendation: B, randomized, controlled trial [RCT] and prepon-derance of posthoc analyses of large RCTs).",2020,"Adding a proton pump inhibitor (PPI) in patients taking antiplatelet medications such as clopidogrel for acute coronary syndrome (ACS) doesn't increase the composite risk of cardiovascular (CV) events: CV death, myocardial infarction (MI), and cerebrovascular accident (CVA) (strength of recommendation: B, randomized, controlled trial [RCT] and prepon-derance of posthoc analyses of large RCTs).","['patients taking antiplatelet medications such as clopidogrel for acute coronary syndrome (ACS', 'patients with ACS']","['proton pump inhibitor (PPI', 'clopidogrel and PPIs']","['CV risk', 'composite risk of cardiovascular (CV) events: CV death, myocardial infarction (MI), and cerebrovascular accident (CVA) (strength of recommendation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0948089', 'cui_str': 'Acute coronary syndrome'}]","[{'cui': 'C0358591', 'cui_str': 'H+/K+-exchanging ATPase inhibitor'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]",,0.0371785,"Adding a proton pump inhibitor (PPI) in patients taking antiplatelet medications such as clopidogrel for acute coronary syndrome (ACS) doesn't increase the composite risk of cardiovascular (CV) events: CV death, myocardial infarction (MI), and cerebrovascular accident (CVA) (strength of recommendation: B, randomized, controlled trial [RCT] and prepon-derance of posthoc analyses of large RCTs).","[{'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Shehata', 'Affiliation': 'Valley Medical Center, Renton, WA, USA.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Baker', 'Affiliation': 'Valley Family Medicine Residency, University of Washington at Valley in Renton, USA.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Kelsberg', 'Affiliation': 'Valley Family Medicine Residency, University of Washington at Valley in Renton, USA.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Safranek', 'Affiliation': 'University of Washington Health Sciences Library, Seattle, USA.'}]",The Journal of family practice,[] 2530,32725178,Efficacy of a Psychosocial Pain Management Intervention for Men and Women With Substance Use Disorders and Chronic Pain: A Randomized Clinical Trial.,"Importance Chronic pain is common in those with substance use disorders (SUDs) and predicts poorer addiction treatment outcomes. A critical challenge for addiction treatment is to develop effective methods to improve pain-related and substance use-related outcomes for those in treatment for SUDs. Objective To examine the efficacy of an integrated behavioral pain management intervention (Improving Pain During Addiction Treatment [ImPAT]) for men and women with SUDs to treat pain, functioning, and substance use. Design, Setting, and Participants In this randomized clinical trial, 8 sessions of ImPAT were compared with 8 sessions of a supportive psychoeducational control (SPC) condition for adults with pain treated at a large residential SUD treatment program. Follow-up occurred at 3, 6, and 12 months postbaseline. A total of 1372 adults were screened, including 960 men and 412 women, and 510 adults were randomized, including 264 men and 246 women. The goal was to recruit approximately equal numbers of men and women to examine results separately in men and women. A total of 470 of 510 participants (92.2%) completed at least 1 follow-up assessment. Data were collected from October 3, 2011, to January 14, 2016. Data were analyzed from February 1, 2016, to May 1, 2020. Interventions ImPAT focused on how a psychosocial model of pain was associated with functioning and relapse prevention and provides skills to manage pain. SPC served as the active control condition and involved discussions of topics like nutrition and the course of addiction, which were intended to be relevant to the patient population and to have face validity but be distinct from the content of ImPAT. Main Outcomes and Measurements The primary outcomes were pain intensity, pain-related functioning, and behavioral pain tolerance at 12 months. Secondary outcomes were frequency of alcohol and drug use over 12 months. Results Of the 510 included participants, the mean (SD) age was 34.8 (10.3) years. A total of 133 men and 122 women were assigned to ImPAT, and a total of 131 men and 124 women were assigned to the SPC condition. Over 12 months of follow-up, randomization to the ImPAT intervention was associated with higher tolerance of pain among men, higher by a mean score of 0.11 (95% CI, 0.03 to 0.18; P = .004; Cohen d = 0.40) at 3 months and by 0.07 (95% CI, -0.01 to 0.19; P = .11; Cohen d = 0.25) at 12 months. Women receiving the ImPAT intervention experienced a reduction in pain intensity from 3 to 12 months, while women receiving the SPC condition experienced an increase in pain intensity, resulting in lower pain in the ImPAT condition by a mean score of 0.58 (95% CI, -0.07 to 1.22; P = .08; Cohen d = -0.22) at 12 months. No differences were found between the ImPAT and SPC conditions on alcohol or drug use. Conclusions and Relevance Behavioral pain management is not typically included in addiction treatment, but the present results indicate that this type of intervention was associated with better pain-related outcomes, including pain tolerance in men and pain intensity in women. Improvements in substance use-related outcomes beyond that achieved by treatment as usual were not observed. Treatment programs should consider providing psychosocial pain management services to augment standard addiction treatment. Trial Registration ClinicalTrials.gov Identifier: NCT01372267.",2020,"Over 12 months of follow-up, randomization to the ImPAT intervention was associated with higher tolerance of pain among men, higher by a mean score of 0.11 (95% CI, 0.03 to 0.18; P = .004; Cohen d = 0.40) at 3 months and by 0.07 (95% CI, -0.01 to 0.19; P = .11; Cohen d = 0.25) at 12 months.","['men and women with SUDs to treat pain, functioning, and substance use', 'adults with pain treated at a large residential SUD treatment program', 'men and pain intensity in women', 'A total of 470 of 510 participants (92.2%) completed at least 1 follow-up assessment', 'men and women', '1372 adults were screened, including 960 men and 412 women, and 510 adults were randomized, including 264 men and 246 women', 'A total of 133 men and 122 women were assigned to ImPAT, and a total of 131 men and 124 women', 'Men and Women With Substance Use Disorders and Chronic Pain']","['supportive psychoeducational control (SPC) condition', 'Psychosocial Pain Management Intervention', 'ImPAT intervention', 'integrated behavioral pain management intervention (Improving Pain During Addiction Treatment [ImPAT', 'ImPAT']","['frequency of alcohol and drug use over 12 months', 'ImPAT and SPC conditions on alcohol or drug use', 'pain intensity', 'pain intensity, pain-related functioning, and behavioral pain tolerance', 'lower pain', 'pain tolerance', 'tolerance of pain']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517800', 'cui_str': '510'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C4517908', 'cui_str': '960'}, {'cui': 'C4517563', 'cui_str': '133'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0038586', 'cui_str': 'Substance use disorder'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0085281', 'cui_str': 'Addiction'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]",1372.0,0.146191,"Over 12 months of follow-up, randomization to the ImPAT intervention was associated with higher tolerance of pain among men, higher by a mean score of 0.11 (95% CI, 0.03 to 0.18; P = .004; Cohen d = 0.40) at 3 months and by 0.07 (95% CI, -0.01 to 0.19; P = .11; Cohen d = 0.25) at 12 months.","[{'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Ilgen', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Lara N', 'Initials': 'LN', 'LastName': 'Coughlin', 'Affiliation': 'Department of Psychiatry, University of Michigan Medical School, Ann Arbor.'}, {'ForeName': 'Amy S B', 'Initials': 'ASB', 'LastName': 'Bohnert', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Chermack', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Price', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'H Myra', 'Initials': 'HM', 'LastName': 'Kim', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Jannausch', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}, {'ForeName': 'Frederic C', 'Initials': 'FC', 'LastName': 'Blow', 'Affiliation': 'VA Center for Clinical Management Research (CCMR), Department of Veterans Affairs Healthcare System, Ann Arbor, Michigan.'}]",JAMA psychiatry,['10.1001/jamapsychiatry.2020.2369'] 2531,32725199,"A Comparison Between 12 Versus 20 Weeks of Trimethoprim-Sulfamethoxazole as Oral Eradication Treatment for Melioidosis (12vs20): An Open-label, Pragmatic, Multicenter, Non-inferiority, Randomized Controlled Trial.","BACKGROUND Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral trimethoprim-sulfamethoxazole (TMP-SMX) for 12 to 20 weeks. Twelve weeks of oral TMP-SMX is recommended in Australia, and 20 weeks in Thailand. METHODS For this open-label, pragmatic, multicenter, non-inferiority, randomized controlled trial, we enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis. We randomly assigned patients to stop (12-week regimen) or continue treatment for another eight weeks (20-week regimen). The primary endpoint was culture-confirmed recurrent melioidosis within one year after enrollment. The non-inferiority margin was a hazard ratio (HR) of 2.0. The secondary composite endpoint combining overall recurrent melioidosis and mortality was assessed post-hoc. RESULTS 658 patients were enrolled: 322 to the 12-week regimen and 336 to the 20-week regimen. Five patients (2%) in the 12-week regimen and 2 patients (1%) in the 20-week regimen developed culture-confirmed recurrent melioidosis (HR 2.66; 95% confidence interval [CI] 0.52-13.69). The criterion for non-inferiority of primary event was not met (one-sided P=.37). However, all-cause mortality was significantly lower in the 12-week regimen group than in the 20-week regimen group (1 [0.3%] vs. 11 [3%]; HR 0.10; 95% CI 0.01-0.74). The criterion for non-inferiority of the secondary composite endpoint combining overall recurrent melioidosis and mortality was met (one-sided P=.022). CONCLUSIONS Based on the lower total mortality and non-inferiority of the secondary composite endpoint observed, we recommend the 12-week regimen of TMP-SMX for oral eradication treatment of melioidosis.",2020,The criterion for non-inferiority of primary event was not met (one-sided P=.37).,"['Melioidosis (12vs20', 'enrolled patients with culture-confirmed melioidosis who had received oral eradication treatment for 12 weeks and had no clinical evidence of active melioidosis', '658 patients were enrolled: 322 to the 12-week regimen and 336 to the 20-week regimen']","['oral TMP-SMX', 'TMP-SMX', 'trimethoprim-sulfamethoxazole (TMP-SMX', 'Trimethoprim-Sulfamethoxazole']","['overall recurrent melioidosis and mortality', 'total mortality', 'cause mortality', 'culture-confirmed recurrent melioidosis']","[{'cui': 'C0025229', 'cui_str': 'Melioidosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C4517712', 'cui_str': '322'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0041044', 'cui_str': 'sulfamethoxazole and trimethoprim'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0025229', 'cui_str': 'Melioidosis'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010453', 'cui_str': 'Culture'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]",658.0,0.0816991,The criterion for non-inferiority of primary event was not met (one-sided P=.37).,"[{'ForeName': 'Siriluck', 'Initials': 'S', 'LastName': 'Anunnatsiri', 'Affiliation': 'Faculty of Medicine, Khon Kaen University.'}, {'ForeName': 'Wipada', 'Initials': 'W', 'LastName': 'Chaowagul', 'Affiliation': 'Sunpasitthiprasong Hospital, Ubon Ratchathani.'}, {'ForeName': 'Prapit', 'Initials': 'P', 'LastName': 'Teparrukkul', 'Affiliation': 'Sunpasitthiprasong Hospital, Ubon Ratchathani.'}, {'ForeName': 'Ploenchan', 'Initials': 'P', 'LastName': 'Chetchotisakd', 'Affiliation': 'Faculty of Medicine, Khon Kaen University.'}, {'ForeName': 'Kittisak', 'Initials': 'K', 'LastName': 'Tanwisaid', 'Affiliation': 'Nakhonphanom Hospital, Nakhonphanom.'}, {'ForeName': 'Supphachoke', 'Initials': 'S', 'LastName': 'Khemla', 'Affiliation': 'Nakhonphanom Hospital, Nakhonphanom.'}, {'ForeName': 'Surapong', 'Initials': 'S', 'LastName': 'Narenpitak', 'Affiliation': 'Udon Thani Hospital, Udon Thani.'}, {'ForeName': 'Moragot', 'Initials': 'M', 'LastName': 'Pattarapongsin', 'Affiliation': 'Chaiyaphum Hospital, Chaiyaphum.'}, {'ForeName': 'Wirod', 'Initials': 'W', 'LastName': 'Kongsawasd', 'Affiliation': 'Srisaket Hospital, Srisaket.'}, {'ForeName': 'Pornrith', 'Initials': 'P', 'LastName': 'Pisuttimarn', 'Affiliation': 'Khon Kaen Hospital, Khon Kaen.'}, {'ForeName': 'Wilawan', 'Initials': 'W', 'LastName': 'Thipmontree', 'Affiliation': 'Maharat Nakhonratchasima Hospital, Nakhonratchasima.'}, {'ForeName': 'Piroon', 'Initials': 'P', 'LastName': 'Mootsikapun', 'Affiliation': 'Faculty of Medicine, Khon Kaen University.'}, {'ForeName': 'Seksan', 'Initials': 'S', 'LastName': 'Chaisuksant', 'Affiliation': 'Khon Kaen Hospital, Khon Kaen.'}, {'ForeName': 'Wirongrong', 'Initials': 'W', 'LastName': 'Chierakul', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}, {'ForeName': 'Nicholas P J', 'Initials': 'NPJ', 'LastName': 'Day', 'Affiliation': 'Centre for Tropical Medicine, and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Direk', 'Initials': 'D', 'LastName': 'Limmathurotsakul', 'Affiliation': 'Faculty of Tropical Medicine, Mahidol University, Thailand.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1084'] 2532,32725216,Daptomycin plus Fosfomycin versus Daptomycin Alone for Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. A Randomized Clinical Trial.,"BACKGROUND We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. METHODS A randomized (1:1) phase III superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg of daptomycin intravenously per kilogram daily plus 2 g of fosfomycin intravenously every six hours, or 10 mg of daptomycin intravenously per kilogram daily. Primary endpoint was treatment success six weeks after the end of therapy. RESULTS Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at six weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs. 42.0%; relative risk: 1.29, 95%CI 0.93 to 1.8, p=0.135). At six weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs. 9 patients, p=0.003) and lower complicated bacteremia (16.2% vs. 32.1%; p=0.022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in four of 81 patients (4.9%) receiving daptomycin alone (p=0.018). CONCLUSION Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.",2020,"Treatment success at six weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs. 42.0%; relative risk: 1.29, 95%CI 0.93 to 1.8, p=0.135).","['adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals', '167 patients randomized']","['daptomycin plus fosfomycin', 'daptomycin alone', 'daptomycin intravenously per kilogram daily plus 2 g of fosfomycin intravenously every six hours, or 10 mg of daptomycin', 'Daptomycin plus Fosfomycin versus Daptomycin Alone']","['complicated bacteremia', 'rate of treatment success', 'microbiologic failure', 'microbiological failure and complicated bacteremia']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0343401', 'cui_str': 'Methicillin resistant Staphylococcus aureus infection'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C4517595', 'cui_str': '167'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0057144', 'cui_str': 'Daptomycin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0016610', 'cui_str': 'Fosfomycin'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0585325', 'cui_str': 'Every six hours'}]","[{'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C0004610', 'cui_str': 'Bacteremia'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0025953', 'cui_str': 'microbiology'}]",167.0,0.420876,"Treatment success at six weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs. 42.0%; relative risk: 1.29, 95%CI 0.93 to 1.8, p=0.135).","[{'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Pujol', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'José-María', 'Initials': 'JM', 'LastName': 'Miró', 'Affiliation': ""Department of Infectious Diseases, Hospital Clinic, Institut d'Investigacions Biomèdiques Agust Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.""}, {'ForeName': 'Evelyn', 'Initials': 'E', 'LastName': 'Shaw', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jose-María', 'Initials': 'JM', 'LastName': 'Aguado', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario 12 Octubre, Instituto de Investigación Hospital ""12 de Octubre"", Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'San-Juan', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario 12 Octubre, Instituto de Investigación Hospital ""12 de Octubre"", Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Puig-Asensio', 'Affiliation': ""Department of Infectious Diseases, Hospital Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Carles', 'Initials': 'C', 'LastName': 'Pigrau', 'Affiliation': ""Department of Infectious Diseases, Hospital Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.""}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Calbo', 'Affiliation': 'Infectious Diseases Unit, Hospital Universitari Mútua de Terrassa, Fundació Docència i Recerca Mútua de Terrassa, Universitat Internacional de Catalunya, Barcelona, Spain.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Montejo', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Cruces, Biocruces Bizkaia, Bilbao, Spain.'}, {'ForeName': 'Regino', 'Initials': 'R', 'LastName': 'Rodriguez-Álvarez', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Cruces, Biocruces Bizkaia, Bilbao, Spain.'}, {'ForeName': 'María-Jose', 'Initials': 'MJ', 'LastName': 'Garcia-Pais', 'Affiliation': 'Infectious Diseases Unit, Hospital Lucus Augusti, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Lugo, Spain.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Pintado', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (Irycis), Madrid, Spain.'}, {'ForeName': 'Rosa', 'Initials': 'R', 'LastName': 'Escudero-Sánchez', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Ramon y Cajal, Instituto Ramon y Cajal de Investigación Sanitaria (Irycis), Madrid, Spain.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'Lopez-Contreras', 'Affiliation': ""Department of Infectious Diseases, Hospital Universitari de Sant Pau, Institut d'Investigació Biomèdica de Sant Pau (IIB Sant Pau), Barcelona, Spain.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Morata', 'Affiliation': ""Department of Infectious Diseases, Hospital Clinic, Institut d'Investigacions Biomèdiques Agust Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.""}, {'ForeName': 'Milagros', 'Initials': 'M', 'LastName': 'Montero', 'Affiliation': 'Department of Infectious Diseases, Hospital del Mar, Institut de Recerca Hospital del Mar (IMIM), Barcelona, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Andrés', 'Affiliation': 'Infectious Disease Unit, Consorci Sanitari de Terrassa, Terrassa, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Pasquau', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Sanitaria IBS Granada, Granada, Spain.'}, {'ForeName': 'María-Del-Mar', 'Initials': 'MD', 'LastName': 'Arenas', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Sanitaria IBS Granada, Granada, Spain.'}, {'ForeName': 'Belén', 'Initials': 'B', 'LastName': 'Padilla', 'Affiliation': 'Department of Clinical Microbiology and Infectious Diseases, Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Murillas', 'Affiliation': ""Department of Internal Medicine, Hospital Universitari Son Espases, Fundació Institut d'Investigació Sanitària Illes Balears (IDISBA), Mallorca, Spain.""}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Jover-Sáenz', 'Affiliation': 'Territorial Unit of Nosocomial Infection, Hospital Universitari Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain.'}, {'ForeName': 'Luis-Eduardo', 'Initials': 'LE', 'LastName': 'López-Cortes', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitario Virgen Macarena, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain.'}, {'ForeName': 'Graciano', 'Initials': 'G', 'LastName': 'García-Pardo', 'Affiliation': 'Department of Internal Medicine, Hospital Universitari Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain.'}, {'ForeName': 'Oriol', 'Initials': 'O', 'LastName': 'Gasch', 'Affiliation': ""Department of Infectious Diseases, Consorci Sanitari Hospital Parc Taulí, Fundació Institut d'Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain.""}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Videla', 'Affiliation': 'Department of Clinical Pharmacology, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), Clinical Research and Clinical Trials Unit (UICEC), Plataforma SCReN, Barcelona, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Hereu', 'Affiliation': 'Department of Clinical Pharmacology, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), Clinical Research and Clinical Trials Unit (UICEC), Plataforma SCReN, Barcelona, Spain.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Tebé', 'Affiliation': ""Biostatistics Unit, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), L'Hospitalet Llobregat, Spain.""}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Pallarès', 'Affiliation': ""Biostatistics Unit, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), L'Hospitalet Llobregat, Spain.""}, {'ForeName': 'Mireia', 'Initials': 'M', 'LastName': 'Sanllorente', 'Affiliation': 'Department of Clinical Pharmacology, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), Clinical Research and Clinical Trials Unit (UICEC), Plataforma SCReN, Barcelona, Spain.'}, {'ForeName': 'María-Ángeles', 'Initials': 'MÁ', 'LastName': 'Domínguez', 'Affiliation': 'Department of Microbiology and Parasitology, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Càmara', 'Affiliation': 'Department of Microbiology and Parasitology, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Ferrer', 'Affiliation': 'Department of Pharmacy, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Ariadna', 'Initials': 'A', 'LastName': 'Padullés', 'Affiliation': 'Department of Pharmacy, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Cuervo', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Carratalà', 'Affiliation': 'Department of Infectious Diseases, Hospital Universitari de Bellvitge, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1081'] 2533,32725244,Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.,"Importance A stepwise approach that includes screening and lifestyle modification followed by the addition of metformin for individuals with high risk of diabetes is recommended to delay progression to diabetes; however, there is scant evidence regarding whether this approach is cost-effective. Objective To estimate the cost-effectiveness of a stepwise approach in the Diabetes Community Lifestyle Improvement Program. Design, Setting, and Participants This economic evaluation study included 578 adults with impaired glucose tolerance, impaired fasting glucose, or both. Participants were enrolled in the Diabetes Community Lifestyle Improvement Program, a randomized clinical trial with 3-year follow-up conducted at a diabetes care and research center in Chennai, India. Interventions The intervention group underwent a 6-month lifestyle modification curriculum plus stepwise addition of metformin; the control group received standard lifestyle advice. Main Outcomes and Measures Cost, health benefits, and incremental cost-effectiveness ratios (ICERs) were estimated from multipayer (including direct medical costs) and societal (including direct medical and nonmedical costs) perspectives. Costs and ICERs were reported in 2019 Indian rupees (INR) and purchasing power parity-adjusted international dollars (INT $). Results The mean (SD) age of the 578 participants was 44.4 (9.3) years, and 364 (63.2%) were men. Mean (SD) body mass index was 27.9 (3.7), and the mean (SD) glycated hemoglobin level was 6.0% (0.5). Implementing lifestyle modification and metformin was associated with INR 10 549 (95% CI, INR 10 134-10 964) (INT $803 [95% CI, INT $771-834]) higher direct costs; INR 5194 (95% CI, INR 3187-INR 7201) (INT $395; 95% CI, INT $65-147) higher direct nonmedical costs, an absolute diabetes risk reduction of 10.2% (95% CI, 1.9% to 18.5%), and an incremental gain of 0.099 (95% CI, 0.018 to 0.179) quality-adjusted life-years per participant. From a multipayer perspective (including screening costs), mean ICERs were INR 1912 (INT $145) per 1 percentage point diabetes risk reduction, INR 191 090 (INT $14 539) per diabetes case prevented and/or delayed, and INR 196 960 (INT $14 986) per quality-adjusted life-year gained. In the scenario of a 50% increase or decrease in screening and intervention costs, the mean ICERs varied from INR 855 (INT $65) to INR 2968 (INT $226) per 1 percentage point diabetes risk reduction, from INR 85 495 (INT $6505) to INR 296 681 (INT $22 574) per diabetes case prevented, and from INR 88 121 (INT $6705) to INR 305 798 (INT $23 267) per quality-adjusted life-year gained. Conclusions and Relevance The findings of this study suggest that a stepwise approach for diabetes prevention is likely to be cost-effective, even if screening costs for identifying high-risk individuals are added.",2020,"Implementing lifestyle modification and metformin was associated with INR 10 549 (95% CI, INR 10 134-10 964) (INT $803 [95% CI, INT $771-834]) higher direct costs; INR 5194 (95% CI, INR 3187-INR 7201) (INT $395; 95% CI, INT $65-147) higher direct nonmedical costs, an absolute diabetes risk reduction of 10.2% (95% CI, 1.9% to 18.5%), and an incremental gain of 0.099 (95% CI, 0.018 to 0.179) quality-adjusted life-years per participant.","['The mean (SD) age of the 578 participants was 44.4 (9.3) years, and 364 (63.2%) were men', 'individuals with high risk of diabetes', 'Diabetes Prevention in India', '578 adults with impaired glucose tolerance, impaired fasting glucose, or both', 'Participants were enrolled in the Diabetes Community Lifestyle Improvement Program, a randomized clinical trial with 3-year follow-up conducted at a diabetes care and research center in Chennai, India']","['Stepwise Approach vs Standard Care', 'metformin', '6-month lifestyle modification curriculum plus stepwise addition of metformin; the control group received standard lifestyle advice']","['Cost-effectiveness', 'Costs and ICERs', 'screening and intervention costs', 'absolute diabetes risk reduction', 'mean (SD) glycated hemoglobin level', 'cost-effectiveness', 'mean ICERs', 'Mean (SD) body mass index', 'direct nonmedical costs', 'Measures\n\n\nCost, health benefits, and incremental cost-effectiveness ratios (ICERs) were estimated from multipayer (including direct medical costs) and societal (including direct medical and nonmedical costs) perspectives']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0151671', 'cui_str': 'Glucose tolerance decreased'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206034', 'cui_str': 'Trials, Randomized Clinical'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1137094', 'cui_str': 'Risk Reduction'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0518015', 'cui_str': 'Haemoglobin'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0086387', 'cui_str': 'Health Benefits'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}]",578.0,0.0795921,"Implementing lifestyle modification and metformin was associated with INR 10 549 (95% CI, INR 10 134-10 964) (INT $803 [95% CI, INT $771-834]) higher direct costs; INR 5194 (95% CI, INR 3187-INR 7201) (INT $395; 95% CI, INT $65-147) higher direct nonmedical costs, an absolute diabetes risk reduction of 10.2% (95% CI, 1.9% to 18.5%), and an incremental gain of 0.099 (95% CI, 0.018 to 0.179) quality-adjusted life-years per participant.","[{'ForeName': 'Duygu', 'Initials': 'D', 'LastName': 'Islek', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Weber', 'Affiliation': 'Emory Global Diabetes Research Center, Hubert Department of Global Health, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Anjana', 'Initials': 'A', 'LastName': 'Ranjit Mohan', 'Affiliation': ""Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai, India.""}, {'ForeName': 'Viswanathan', 'Initials': 'V', 'LastName': 'Mohan', 'Affiliation': ""Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai, India.""}, {'ForeName': 'Lisa R', 'Initials': 'LR', 'LastName': 'Staimez', 'Affiliation': 'Emory Global Diabetes Research Center, Hubert Department of Global Health, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Ranjani', 'Initials': 'R', 'LastName': 'Harish', 'Affiliation': ""Madras Diabetes Research Foundation and Dr Mohan's Diabetes Specialities Centre, Chennai, India.""}, {'ForeName': 'K M Venkat', 'Initials': 'KMV', 'LastName': 'Narayan', 'Affiliation': 'Emory Global Diabetes Research Center, Hubert Department of Global Health, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Laxy', 'Affiliation': 'Emory Global Diabetes Research Center, Hubert Department of Global Health, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Mohammed K', 'Initials': 'MK', 'LastName': 'Ali', 'Affiliation': 'Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.'}]",JAMA network open,['10.1001/jamanetworkopen.2020.7539'] 2534,30279573,"Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality.","We analyzed micro-RNAs (miRs) as possible diagnostic biomarkers for relevant comorbidities prior to and prognostic biomarkers for mortality following hematopoietic cell transplantation (HCT). A randomly selected group of patients (n = 36) were divided into low-risk (HCT-comorbidity index [HCT-CI] score of 0 and survived HCT) and high-risk (HCT-CI scores ≥ 4 and deceased after HCT) groups. There were 654 miRs tested and 19 met the pre-specified significance level of p < 0.1. In subsequent models, only eight miRs maintained statistical significance in regression models after adjusting for baseline demographic factors; miRs-374b and -454 were underexpressed, whereas miRs-142-3p, -191, -424, -590-3p, -29c, and -15b were overexpressed among high-risk patients relative to low-risk patients. Areas under the curve for these eight miRs ranged between 0.74 and 0.81, suggesting strong predictive capacity. Consideration of miRs may improve risk assessment of mortality and should be further explored in larger future prospective studies.",2019,"Areas under the curve for these eight miRs ranged between 0.74 and 0.81, suggesting strong predictive capacity.",[],['hematopoietic cell transplantation (HCT'],"['Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality', 'low-risk (HCT-comorbidity index [HCT-CI] score of 0 and survived HCT) and high-risk (HCT-CI scores']",[],"[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C1101610', 'cui_str': 'MicroRNA'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}]",,0.0129149,"Areas under the curve for these eight miRs ranged between 0.74 and 0.81, suggesting strong predictive capacity.","[{'ForeName': 'Mohamed L', 'Initials': 'ML', 'LastName': 'Sorror', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA. msorror@fredhutch.org.'}, {'ForeName': 'Ted A', 'Initials': 'TA', 'LastName': 'Gooley', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Kirsteen H', 'Initials': 'KH', 'LastName': 'Maclean', 'Affiliation': 'NanoString Technologies, Seattle, WA, USA.'}, {'ForeName': 'Jesse', 'Initials': 'J', 'LastName': 'Hubbard', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Mario A', 'Initials': 'MA', 'LastName': 'Marcondes', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Beverly J', 'Initials': 'BJ', 'LastName': 'Torok-Storb', 'Affiliation': 'Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Muneesh', 'Initials': 'M', 'LastName': 'Tewari', 'Affiliation': 'University of Michigan, Ann Arbor, MI, USA.'}]",Bone marrow transplantation,['10.1038/s41409-018-0352-9'] 2535,30325567,"Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.","A fixed-dose combination of tenofovir alafenamide (TAF) and emtricitabine (FTC) is available in 2 tablet strengths in Japan (FTC/TAF 200/10 mg and FTC/TAF 200/25 mg). These are used once daily in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection. The primary objective of this study was to investigate if there is any clinically relevant pharmacokinetic difference for TAF, tenofovir (TFV), and FTC between Japanese and non-Japanese with historical data. Three treatment groups were set in the study; FTC/TAF 200/10 mg in combination with darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg (treatment A) or DRV/cobicistat (COBI) 800/150 mg (treatment B) and FTC/TAF 200/25 mg alone (treatment C). Especially for treatment C, it was designated for another purpose to evaluate the pharmacokinetic boosting effects of RTV and COBI on TAF bioavailability. As a result, the mean exposure of TAF among treatment groups was 125 to 154 ng/mL for C max and 119 to 179 ng·h/mL for AUC inf , which were comparable with the historical data in non-Japanese. The exposures of TFV and FTC were also consistent with the historical data. Therefore, no clinically relevant pharmacokinetic differences for TAF, TFV, and FTC were observed between Japanese and non-Japanese. Boosting effects of RTV and COBI on TAF bioavailability were slightly lower than we expected, less than a 2.5-fold increase, but it was within the range of exposures associated with efficacy and safety in phase 3 studies. Therefore, it was not considered clinically relevant.",2019,"Therefore, no clinically relevant pharmacokinetic differences for TAF, TFV, and FTC were observed between Japanese and non-Japanese.","['Healthy Japanese Subjects', 'human immunodeficiency virus type 1 infection']","['FTC/TAF 200/10\xa0mg in combination with darunavir (DRV) 800', 'DRV/cobicistat (COBI) 800/150\xa0mg (treatment B) and FTC/TAF', 'Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide', 'RTV and COBI', 'mg\xa0+\xa0ritonavir (RTV', 'tenofovir alafenamide (TAF) and emtricitabine (FTC', 'TAF, tenofovir (TFV']","['TAF bioavailability', 'TAF, TFV, and FTC', 'mean exposure of TAF', 'efficacy and safety']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0019704', 'cui_str': 'Human immunodeficiency virus type I'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]","[{'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}, {'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C3844106', 'cui_str': '800'}, {'cui': 'C3871454', 'cui_str': 'darunavir and cobicistat'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C4059167', 'cui_str': 'emtricitabine and tenofovir alafenamide'}, {'cui': 'C0292818', 'cui_str': 'Ritonavir'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}]","[{'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C0005508', 'cui_str': 'Availability, Biological'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C0206682', 'cui_str': 'Follicular thyroid carcinoma'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.0453845,"Therefore, no clinically relevant pharmacokinetic differences for TAF, TFV, and FTC were observed between Japanese and non-Japanese.","[{'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Yamada', 'Affiliation': 'Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.'}, {'ForeName': 'Takuma', 'Initials': 'T', 'LastName': 'Yonemura', 'Affiliation': 'SOUSEIKAI Sumida Hospital, Tokyo, Japan.'}, {'ForeName': 'Takanori', 'Initials': 'T', 'LastName': 'Nemoto', 'Affiliation': 'Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Ninomiya', 'Affiliation': 'Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Irie', 'Affiliation': 'SOUSEIKAI Sumida Hospital, Tokyo, Japan.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.623'] 2536,32728546,The Effectiveness of Budesonide Nasal Irrigation After Endoscopic Sinus Surgery in Chronic Allergic Rhinosinusitis with Polyps.,"Nasal polyposis is one of the most common chronic upper airway diseases. Management of allergic rhinosinusitis with polyps is to control the disease process and the local immune response of the nasal mucosa. This is achieved by surgical removal of polypoid mucosa of all sinuses by functional endoscopic sinus surgery (FESS) followed by suppression of local immune response by using steroids. Budesonide nasal douching was introduced recently for postoperative management of patients with allergic rhinosinusitis. The therapeutic effectiveness and safety of this procedure are becoming accepted by many physicians. Evaluation of the efficacy of budesonide nasal irrigation in the postoperative management of chronic allergic rhinosinusitis with polyps. A total of 60 postoperative chronic allergic rhinosinusitis with polyps patients were randomly divided into two groups. Both groups received routine post-FESS medication as per the institute protocol. One group of patients received budesonide nasal douching in addition to regular care. Both groups were evaluated endoscopically at 1, 2, 6 and 10 weeks after surgery. Pre and postoperative quality of life change, the patient complaints, need for revision surgery were evaluated. Endoscopic Lund-Kennedy scoring (objective measurement) and Sino-Nasal Outcome Test-22 (subjective analysis) were used to compare the two postoperative groups. The average preoperative Sino-Nasal Outcome Test 22 score was 52.2. It was reduced to an average of 29.4 in patients who used the standard postoperative regimen and to 15.8 postoperatively in patients who had budesonide added to their douching solutions. The average endoscopy score was 2.2 for patients who did receive budesonide as compared to 2.9 for patients who did not receive budesonide nasal douching. Budesonide nasal douching can offer a safe and effective tool in managing local inflammatory response in allergic rhinosinusitis. It leads to a significantly better quality of life and has an adequate response on nasal mucosa-leading to less mucosal oedema and lower incidence of polypoidal changes postoperatively.",2020,Budesonide nasal douching can offer a safe and effective tool in managing local inflammatory response in allergic rhinosinusitis.,"['Chronic Allergic Rhinosinusitis with Polyps', '60 postoperative chronic allergic rhinosinusitis with polyps patients', 'chronic allergic rhinosinusitis with polyps', 'allergic rhinosinusitis', 'patients with allergic rhinosinusitis']","['Budesonide Nasal Irrigation', 'functional endoscopic sinus surgery (FESS', 'Endoscopic Sinus Surgery', 'budesonide nasal irrigation', 'Budesonide', 'budesonide', 'routine post-FESS medication', 'budesonide nasal douching in addition to regular care']","['quality of life', 'Pre and postoperative quality of life change, the patient complaints, need for revision surgery', 'Endoscopic Lund-Kennedy scoring (objective measurement) and Sino-Nasal Outcome Test-22 (subjective analysis', 'average endoscopy score']","[{'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0032584', 'cui_str': 'Polyp'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0360546', 'cui_str': 'Budesonide-containing product in nasal dose form'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0442968', 'cui_str': 'Functional endoscopic sinus surgery'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0748725', 'cui_str': 'Sinus operation'}, {'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C2936784', 'cui_str': 'Douching'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205272', 'cui_str': 'Regular'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0277786', 'cui_str': 'Complaint'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0014245', 'cui_str': 'Endoscopy'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C5197690', 'cui_str': 'SNOT-22'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0205284,Budesonide nasal douching can offer a safe and effective tool in managing local inflammatory response in allergic rhinosinusitis.,"[{'ForeName': 'Maheshbabu', 'Initials': 'M', 'LastName': 'Thanneru', 'Affiliation': 'Santhi Ram Medical College and General Hospital, Nandyal, Andhra Pradesh India.'}, {'ForeName': 'Sowmya', 'Initials': 'S', 'LastName': 'Lanke', 'Affiliation': 'Santhi Ram Medical College and General Hospital, Nandyal, Andhra Pradesh India.'}, {'ForeName': 'Shanti', 'Initials': 'S', 'LastName': 'Kolavali', 'Affiliation': 'Santhi Ram Medical College and General Hospital, Nandyal, Andhra Pradesh India.'}]",Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India,['10.1007/s12070-020-01878-x'] 2537,32728584,The influence of monitoring activities on maternal weight gain among pregnant women.,"Background: The relationship between nutritional status in early life and the risk of chronic diseases in the future development of the child is a critical factor that needs to be considered. The basic factors that can help in this case include thrifty phenotype hypothesis, developmental plasticity, fetal programming and weight gain regulation. This study aims to determine the average increase in weight gain before and after mentoring program. Design and methods: The sample was taken randomly from 191 pregnant women. From number of women mentored, 106 that met the inclusion criteria. Wilcoxon Signed Ranks Test then was used in the data analysis. Results: The results show that the average body weight of women increased 18.94%, while the BMI rose by 7.46%. Mentoring program led to an increase in maternal body weight, indicated with a P-value of 0.000. Conclusions: In conclusion, mentoring program influences bodyweight in pregnant women. Therefore, it is vital to maintain a high nutritional status during pregnancy.",2020,"Mentoring program led to an increase in maternal body weight, indicated with a P-value of 0.000. ","['191 pregnant women', 'pregnant women']",[],"['maternal body weight', 'average body weight', 'weight gain', 'BMI', 'maternal weight gain']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}]",[],"[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1398625', 'cui_str': 'Maternal Weight Gain'}]",191.0,0.0276804,"Mentoring program led to an increase in maternal body weight, indicated with a P-value of 0.000. ","[{'ForeName': 'Tri', 'Initials': 'T', 'LastName': 'Widodo', 'Affiliation': 'Doctoral Program of Public Health.'}, {'ForeName': 'Sri', 'Initials': 'S', 'LastName': 'Sumarmi', 'Affiliation': 'Department of Nutrition, Faculty of Public Health, Universitas Airlangga, Mulyorejo, Surabaya, Indonesia.'}]",Journal of public health research,['10.4081/jphr.2020.1845'] 2538,32724772,Impact of Accelerated Recovery Program on Compassion Fatigue among Nurses in South India.,"Background Nurses suffer from Compassion Fatigue (CF) when exposed to chronic stress while caring for patients. Depression and anxiety disorders can develop following CF and intervention at the earliest is essential. The present study aimed to evaluate the effectiveness of the Accelerated Recovery Program (ARP) on CF among nurses. Materials and Methods The present experimental study was carried out with a pretest posttest design and control group among 120 nurses working in Narayana Medical College Hospital, India. The nurses selected through simple random sampling were divided into two groups: intervention and control (every 60 nurses). Data were collected using the Professional Quality of Life Scale: Compassion Satisfaction and Fatigue Version 5 (ProQOL) (Stamm, 2010) which consists of the three subscales of Compassion Satisfaction (CS), Burnout (BO), and Secondary Traumatic Stress (STS). The pretest was conducted at day 1, and posttests I, II, III, IV, and V were conducted at 5 th week, 3 rd month, 6 th month, 9 th month, and 12 th month, respectively using ProQOL. ARP and routine care were implemented for 5 weeks in the intervention group, and routine activities were implemented in the control group. Data were analyzed using descriptive and inferential statistics. Results There was a statistically significant difference in the ProQOL score between the intervention and control groups, which demonstrated a significant difference between the groups in terms of CS (F 1,118 = 120.10, p < 0.001), BO (F 1,118 = 123., p < 0.001), and STS (F 1,118 = 205.18, p < 0.001). Conclusion In conclusion, ARP has a significant impact on ProQOL, resulting in an improvement in CS, and a decrease in BO and STS.",2020,"There was a statistically significant difference in the ProQOL score between the intervention and control groups, which demonstrated a significant difference between the groups in terms of CS (F 1,118 = 120.10, p < 0.001), BO (F 1,118 = 123., p < 0.001), and STS (F 1,118 = 205.18, p < 0.001). ","['120 nurses working in Narayana Medical College Hospital, India', 'Nurses in South India']","['Accelerated Recovery Program', 'Accelerated Recovery Program (ARP', 'ARP']","['Professional Quality of Life Scale: Compassion Satisfaction and Fatigue Version 5', 'Compassion Satisfaction (CS), Burnout (BO), and Secondary Traumatic Stress (STS', 'Compassion Fatigue', 'ProQOL score', 'STS', 'BO', 'Depression and anxiety disorders', 'BO and STS']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0021201', 'cui_str': 'India'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0521110', 'cui_str': 'Accelerated'}]","[{'cui': 'C0451401', 'cui_str': 'Quality of life scale'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C4042834', 'cui_str': 'Vicarious Traumatization'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}]",,0.019159,"There was a statistically significant difference in the ProQOL score between the intervention and control groups, which demonstrated a significant difference between the groups in terms of CS (F 1,118 = 120.10, p < 0.001), BO (F 1,118 = 123., p < 0.001), and STS (F 1,118 = 205.18, p < 0.001). ","[{'ForeName': 'Hemanathan', 'Initials': 'H', 'LastName': 'Rajeswari', 'Affiliation': 'Department of Mental Health Nursing Narayana College of Nursing, Chinthareddypalem, Nellore, Andhrapradesh, India.'}, {'ForeName': 'Bhaskara Kurup', 'Initials': 'BK', 'LastName': 'Sreelekha', 'Affiliation': 'Department of Medical Surgical, Faculty of Nursing, Sri Ramachandra Institute of Higher Education and Research (DU), Porur, Chennai, Tamil Nadu, India.'}, {'ForeName': 'Seran', 'Initials': 'S', 'LastName': 'Nappinai', 'Affiliation': 'Consultant Psychologist, Department of Psychiatry, Meenakshi Medical College Hospital and Research Institute, Enathur, Kanchipuram, Tamil Nadu, India.'}, {'ForeName': 'Udathu', 'Initials': 'U', 'LastName': 'Subrahmanyam', 'Affiliation': 'Department of Statistics, Narayana College of Engineering, Chinthareddypalem, Nellore, Andhrapradesh, India.'}, {'ForeName': 'Vaidyanathan', 'Initials': 'V', 'LastName': 'Rajeswari', 'Affiliation': 'Former Principal, Sree Narayana Nursing College, Chinthareddypalem, Nellore, Andhrapradesh, India.'}]",Iranian journal of nursing and midwifery research,['10.4103/ijnmr.IJNMR_218_19'] 2539,32724782,"Effects of whole-body vibration combined with action observation on gross motor function, balance, and gait in children with spastic cerebral palsy: a preliminary study.","This study evaluated the effects of whole-body vibration (WBV) com-bined with action observation on gross motor function, balance, and gait in children with spastic cerebral palsy. The participants were randomized into the WBV combined with action observation (WBVAO) group (n=7) and the WBV group (n=7). The WBVAO group received WBV combined with action observation training, and the WBV group received WBV training for 4 weeks. Both groups received 30 min of training a day, 3 times a week. All participants completed the 5 times sit to stand (FTSTS) test, Timed Up and Go (TUG) test, pediatric reach test, 10-m walk test, 6-min walk test (6MWT), and timed up and down stair (TUDS) test before and after the training intervention. Moreover, the participant's Gross Motor Function Measure (GMFM) and Pediatric Balance Scale (PBS) scores were assessed. Both the WBVAO and WBV groups demonstrated significant increases in the scores of FTSTS test, GMFM (D and E dimensions), PBS, TUG test, 6MWT, and TUDS test. The WBVAO group improved more significantly compared to the WBV group based on the scores of the FTSTS test, GMFM (D dimension), PBS, 6MWT, and TUDS test. WBV combined with action observation improved lower extremity functional strength, gross motor function, and balance and gait in children with cerebral palsy. These results suggest that WBV combined with action observation is both feasible and suitable for individuals with cerebral palsy.",2020,"The WBVAO group improved more significantly compared to the WBV group based on the scores of the FTSTS test, GMFM (D dimension), PBS, 6MWT, and TUDS test.","['individuals with cerebral palsy', 'children with cerebral palsy', 'children with spastic cerebral palsy']","['WBV combined with action observation training', 'WBV combined with action observation', 'whole-body vibration (WBV) com-bined with action observation', 'WBV training', 'whole-body vibration combined with action observation', 'WBV combined with action observation (WBVAO']","['scores of FTSTS test, GMFM (D and E dimensions), PBS, TUG test, 6MWT, and TUDS test', 'lower extremity functional strength, gross motor function, and balance and gait', '5 times sit to stand (FTSTS) test, Timed Up and Go (TUG) test, pediatric reach test, 10-m walk test, 6-min walk test (6MWT), and timed up and down stair (TUDS) test', 'gross motor function, balance, and gait', 'scores of the FTSTS test, GMFM (D dimension), PBS, 6MWT, and TUDS test', 'Gross Motor Function Measure (GMFM) and Pediatric Balance Scale (PBS) scores']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007789', 'cui_str': 'Cerebral palsy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0338596', 'cui_str': 'Spastic cerebral palsy'}]","[{'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0441472', 'cui_str': 'Action'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009490', 'cui_str': 'Comoros islands'}, {'cui': 'C0574497', 'cui_str': 'Edo language'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439534', 'cui_str': 'Dimensions'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0596012', 'cui_str': 'Does reach'}]",,0.0110046,"The WBVAO group improved more significantly compared to the WBV group based on the scores of the FTSTS test, GMFM (D dimension), PBS, 6MWT, and TUDS test.","[{'ForeName': 'Youngmin', 'Initials': 'Y', 'LastName': 'Jung', 'Affiliation': 'Graduate School of Physical Therapy, Sahmyook University, Seoul, Korea.'}, {'ForeName': 'Eun-Jung', 'Initials': 'EJ', 'LastName': 'Chung', 'Affiliation': 'Department of Physical Therapy, Andong Science College, Andong, Korea.'}, {'ForeName': 'Hye-Lim', 'Initials': 'HL', 'LastName': 'Chun', 'Affiliation': 'Graduate School of Physical Therapy, Sahmyook University, Seoul, Korea.'}, {'ForeName': 'Byoung-Hee', 'Initials': 'BH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, Sahmyook University, Seoul, Korea.'}]",Journal of exercise rehabilitation,['10.12965/jer.2040136.068'] 2540,32724783,Gross motor function and health fitness in adults with autistic spectrum disorder and intellectual disability: single-blind retrospective trial.,"This study aimed at providing an exercise program for each type of disability after analyzing the exercise program performed by adults with intellectual disability (ID) or autistic spectrum disorder (ASD). Twenty-nine male adults voluntarily took part in this study, whose age ranged from 19 to 28 years and with an average body mass index of 23.98± 4.02 kg/m 2 . The sample was divided into two groups as follows: ASD group (ASDG; n=15) and ID group (IDG, n=14). The selected tests used to measure gross motor function (GMF, locomotion and object control skills) and health fitness (body composition, flexibility, strength, muscle endurance, and cardiopulmonary endurance) were also used in previous studies. The GMF and health fitness between ASDG and IDG showed no significant differences. This study indicates that exercise programs could provide similar effects, even with other disorder types having similar symptoms.",2020,The GMF and health fitness between ASDG and IDG showed no significant differences.,"['adults with intellectual disability (ID) or autistic spectrum disorder (ASD', 'adults with autistic spectrum disorder and intellectual disability', 'Twenty-nine male adults voluntarily took part in this study, whose age ranged from 19 to 28 years and with an average body mass index of 23.98± 4.02 kg/m 2 ']",['exercise program'],"['gross motor function (GMF, locomotion and object control skills) and health fitness (body composition, flexibility, strength, muscle endurance, and cardiopulmonary endurance', 'Gross motor function and health fitness']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0677549', 'cui_str': 'Gross motor functions'}, {'cui': 'C0061308', 'cui_str': 'Glial Maturation Factor'}, {'cui': 'C0023946', 'cui_str': 'Locomotor Activity'}, {'cui': 'C0347997', 'cui_str': 'Physical object'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}]",29.0,0.0174316,The GMF and health fitness between ASDG and IDG showed no significant differences.,"[{'ForeName': 'Jun-Youl', 'Initials': 'JY', 'LastName': 'Cha', 'Affiliation': 'Division of Martial Arts∙Guard, Howon University, Gunsan, Korea.'}, {'ForeName': 'Su-Kyung', 'Initials': 'SK', 'LastName': 'Min', 'Affiliation': 'Department of Physical Education, Chungbuk National University, Chungju, Korea.'}, {'ForeName': 'Tae-Hyun', 'Initials': 'TH', 'LastName': 'Yoon', 'Affiliation': 'Research Institute of Sports and Industry Science (RISIS), Hanseo University, Seosan, Korea.'}, {'ForeName': 'Yong-Seok', 'Initials': 'YS', 'LastName': 'Jee', 'Affiliation': 'Research Institute of Sports and Industry Science (RISIS), Hanseo University, Seosan, Korea.'}]",Journal of exercise rehabilitation,['10.12965/jer.2040270.135'] 2541,32724785,Russian current versus high voltage current with isokinetic training on the quadriceps muscle strength and endurance.,"Electrotherapy modalities are one of the increasing ways of muscle strength and endurance. However, it is not clear which electrotherapy modalities are more effective. The purpose of this study is to compare the effect of Russian current (RC) and high voltage pulsed current (HVPC) on the strength and endurance of the quadriceps muscle. The study was performed on 10 volleyball athletes. The participants' extremities were divided into two groups as RC and HVPC. Muscle strength and endurance levels were assessed by an isokinetic device. Isokinetic training and 20-min electrotherapy were given in each treatment session. This training program consisted of a total of 12 sessions, scheduled twice a week for 6 weeks. After training, knee extensor peak torque values and endurance ratios have increased in both groups, but it was determined that this increase was only significant in terms of the endurance ratio ( P <0.05). There was no significant difference between the muscle strength and the endurance ratio of the RC and HVPC groups ( P >0.05). RC or HVPC have no advantages over each other, and therefore it has been determined that both currents can be used in order to strengthen muscles and increase muscular endurance. Additional studies whose longer-term effects will investigate are needed.",2020,There was no significant difference between the muscle strength and the endurance ratio of the RC and HVPC groups ( P >0.05).,"[""participants' extremities"", '10 volleyball athletes']","['Russian current (RC) and high voltage pulsed current (HVPC', 'Isokinetic training and 20-min electrotherapy', 'RC or HVPC', 'Russian current versus high voltage current with isokinetic training']","['quadriceps muscle strength and endurance', 'endurance ratio', 'muscle strength and the endurance ratio', 'Muscle strength and endurance levels', 'knee extensor peak torque values and endurance ratios']","[{'cui': 'C0015385', 'cui_str': 'Limb structure'}, {'cui': 'C1956059', 'cui_str': 'Volleyball'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0035967', 'cui_str': 'Russian language'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0013787', 'cui_str': 'Electrotherapy'}]","[{'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",10.0,0.0134758,There was no significant difference between the muscle strength and the endurance ratio of the RC and HVPC groups ( P >0.05).,"[{'ForeName': 'Bihter', 'Initials': 'B', 'LastName': 'Akınoğlu', 'Affiliation': 'Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Ankara Yıldırım Beyazıt University, Ankara, Turkey.'}, {'ForeName': 'Tuğba', 'Initials': 'T', 'LastName': 'Kocahan', 'Affiliation': 'Center of Athlete Training and Health Research, Department of Health Services, Sports General Directorship, The Ministry of Youth and Sports, Ankara, Turkey.'}]",Journal of exercise rehabilitation,['10.12965/jer.2040260.130'] 2542,32724929,Effect of Different Kinds of Music on Anxiety During Implant Surgery in Turkey: Randomized Controlled Study.,"PURPOSE Dental anxiety causes patients to avoid or delay dental treatments. This delay leads to more serious dental problems, which can then lead to more invasive and expensive treatment with possible emergency situations. The purpose of this study was to determine the most successful and effective kind of music to lessen the anxiety of patients during dental implant surgery. MATERIALS AND METHODS This study was a prospective observational randomized controlled study. Eighty dental implant surgery patients aged between 40 and 70 years were chosen for the study. Patients were divided into four groups: group 1-classic Turkish music group (Saba or Rast Tune); group 2-classical music (Vivaldi); group 3-slow rock music; and group 4-control group. Blood pressures, heart rate, and O 2 saturations of the patients were evaluated along with Corah's Dental Anxiety Survey (CDAS) at admittance. After 5 minutes of music in the room, the same evaluations were recorded, and the survey was repeated. RESULTS All the groups with music treatment had a significant decrease in anxiety levels. It was observed that listening to music had a positive effect on dental anxiety regardless of the kind of music. There were significant differences in CDAS values postoperatively. Turkish music and classical music were much more effective in diminishing dental anxiety compared with soft rock music (P = .000 and .002, respectively). CONCLUSION This study indicated that regardless of the kind of music, listening to music diminishes dental anxiety significantly; Turkish music and classical music were the most effective kinds of music.",2020,"Turkish music and classical music were much more effective in diminishing dental anxiety compared with soft rock music (P = .000 and .002, respectively). ","['Eighty dental implant surgery patients aged between 40 and 70 years were chosen for the study', 'patients during dental implant surgery', 'Turkey', 'Dental anxiety causes patients to avoid or delay dental treatments']","['1-classic Turkish music group (Saba or Rast Tune); group 2-classical music (Vivaldi); group 3-slow rock music; and group 4-control group', 'Different Kinds of Music']","['Anxiety', 'dental anxiety', 'CDAS values postoperatively', 'anxiety levels', 'Blood pressures, heart rate, and O 2 saturations']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0011370', 'cui_str': 'Dental implantation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0041400', 'cui_str': 'Turkey - country'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0011331', 'cui_str': 'Dental care'}]","[{'cui': 'C0439658', 'cui_str': 'Classic'}, {'cui': 'C0041402', 'cui_str': 'Turkish language'}, {'cui': 'C0026867', 'cui_str': 'Music'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0047120', 'cui_str': 'serotonin azidobenzamidine'}, {'cui': 'C0034554', 'cui_str': 'Radioallergosorbent test'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0681251', 'cui_str': 'Classical Music'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0439834', 'cui_str': 'Slow'}, {'cui': 'C0005899', 'cui_str': 'Repetitive rocking movements'}, {'cui': 'C0441876', 'cui_str': 'Group 4'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}]",80.0,0.16342,"Turkish music and classical music were much more effective in diminishing dental anxiety compared with soft rock music (P = .000 and .002, respectively). ","[{'ForeName': 'Yakup', 'Initials': 'Y', 'LastName': 'Gulnahar', 'Affiliation': ''}, {'ForeName': 'Ilke', 'Initials': 'I', 'LastName': 'Kupeli', 'Affiliation': ''}]",The International journal of oral & maxillofacial implants,['10.11607/jomi.8329'] 2543,32725073,Restrictive versus Liberal Fluid Therapy for Post-Cesarean Acute Kidney Injury in Severe Preeclampsia: a Pilot Randomized Clinical Trial.,"OBJECTIVES The aim of this study was to determine whether a restrictive compared to a liberal fluid therapy will increase postoperative acute kidney injury (AKI) in patients with severe preeclampsia. METHODS A total of 46 patients (mean age, 32 years; standard deviation, 6.8 years) with severe preeclampsia were randomized to liberal (1500 ml of lactated Ringer's, n=23) or restrictive (250 ml of lactated Ringer's, n=23) intravenous fluid regimen during cesarean section. The primary outcome was the development of a postoperative renal dysfunction defined by AKI Network stage ≥1. Serum cystatin C and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated at postoperative days 1 and 2. ClinicalTrials.gov: NCT02214186. RESULTS The rate of postoperative AKI was 43.5% in the liberal fluid group and 43.5% in the restrictive fluid group (p=1.0). Intraoperative urine output was higher in the liberal (116 ml/h, IQR 69-191) than in the restrictive fluid group (80 ml/h, IQR 37-110, p<0.05). In both groups, serum cystatin C did not change from postoperative day 1 compared to the preoperative period and significantly decreased on postoperative day 2 compared to postoperative day 1 (p<0.05). In the restrictive fluid group, NGAL levels increased on postoperative day 1 compared to the preoperative period (p<0.05) and decreased on postoperative day 2 compared to postoperative day 1 (p<0.05). CONCLUSION Among patients with severe preeclampsia, a restrictive fluid regimen during cesarean section was not associated with increased postoperative AKI.",2020,"Intraoperative urine output was higher in the liberal (116 ml/h, IQR 69-191) than in the restrictive fluid group (80 ml/h, IQR 37-110, p<0.05).","['patients with severe preeclampsia', 'Post-Cesarean Acute Kidney Injury in Severe Preeclampsia', '46 patients (mean age, 32 years; standard deviation, 6.8 years) with severe preeclampsia']","[""liberal (1500 ml of lactated Ringer's, n=23) or restrictive (250 ml of lactated Ringer's, n=23) intravenous fluid regimen"", 'Restrictive versus Liberal Fluid Therapy', 'liberal fluid therapy']","['Serum cystatin C and neutrophil gelatinase-associated lipocalin (NGAL', 'Intraoperative urine output', 'NGAL levels', 'postoperative AKI', 'serum cystatin C', 'rate of postoperative AKI', 'development of a postoperative renal dysfunction defined by AKI Network stage ≥1', 'postoperative acute kidney injury (AKI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0341950', 'cui_str': 'Severe pre-eclampsia'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}]","[{'cui': 'C4517582', 'cui_str': '1500'}, {'cui': 'C0073385', 'cui_str': ""Lactated Ringer's Solution""}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C1289919', 'cui_str': 'Intravenous fluid'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0016286', 'cui_str': 'Therapy, Fluid'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0206528', 'cui_str': 'Gelatinase'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C1956074', 'cui_str': 'Lipocalin'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0232856', 'cui_str': 'Rate of urine output, function'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C1565489', 'cui_str': 'Renal impairment'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",46.0,0.206813,"Intraoperative urine output was higher in the liberal (116 ml/h, IQR 69-191) than in the restrictive fluid group (80 ml/h, IQR 37-110, p<0.05).","[{'ForeName': 'Wallace Andrino da', 'Initials': 'WAD', 'LastName': 'Silva', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Carlo Victor A', 'Initials': 'CVA', 'LastName': 'Varela', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Aline Macedo', 'Initials': 'AM', 'LastName': 'Pinheiro', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Paula Castro', 'Initials': 'PC', 'LastName': 'Scherer', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Rossana P V', 'Initials': 'RPV', 'LastName': 'Francisco', 'Affiliation': 'Departamento de Obstetricia e Ginecologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Marcelo Luis Abramides', 'Initials': 'MLA', 'LastName': 'Torres', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Maria José C', 'Initials': 'MJC', 'LastName': 'Carmona', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Bliacheriene', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Lúcia C', 'Initials': 'LC', 'LastName': 'Andrade', 'Affiliation': 'Departamento de Nefrologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Pelosi', 'Affiliation': 'Dipartimento di Scienze Chirurgiche e Diagnostiche Integrate (DISC), Universitè degli Studi di Genova, Genoa, Italy.'}, {'ForeName': 'Luiz Marcelo S', 'Initials': 'LMS', 'LastName': 'Malbouisson', 'Affiliation': 'Departamento de Anestesia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1797'] 2544,32725102,N-acetylcysteine as an adjunctive treatment for smoking cessation: a randomized clinical trial.,"OBJECTIVE This randomized controlled trial examined the efficacy and safety of N-acetylcysteine as an adjunctive treatment for smoking cessation. METHODS Heavy smokers were recruited from smoking cessation treatment for this 12- week randomized controlled trial. Eligible tobacco use disorder outpatients (n=34) were randomized to N-acetylcysteine or placebo plus first-line treatment. Abstinence was verified by exhaled carbon monoxide (COexh). The assessment scales included the Fagerström Test for Nicotine Dependence, the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, the Minnesota Nicotine Withdrawal Scale, and the Medication Adherence Rating Scale. We also assessed anthropometrics, blood pressure, lipid profile, and soluble tumor necrosis factor receptor (sTNF-R) levels 1 and 2. RESULTS First-line treatment for smoking cessation plus adjunctive N-acetylcysteine or placebo significantly reduced COexh (p < 0.01). In the N-acetylcysteine group, no significant changes were found in nicotine withdrawal symptoms, depressive and anxiety symptoms, anthropometric measures, blood pressure, or glucose compared to placebo. However, there was a significant reduction in sTNF-R2 levels between baseline and week 12 in the N-acetylcysteine group. CONCLUSIONS These findings highlight the need to associate N-acetylcysteine with first-line treatment for smoking cessation, since combined treatment may affect inflammation and metabolism components. CLINICAL TRIAL REGISTRATION NCT02420418.",2020,"In the N-acetylcysteine group, no significant changes were found in nicotine withdrawal symptoms, depressive and anxiety symptoms, anthropometric measures, blood pressure, or glucose compared to placebo.","['Eligible tobacco use disorder outpatients (n=34', 'Heavy smokers were recruited from smoking cessation treatment for this 12- week randomized controlled trial']","['N-acetylcysteine or placebo plus first-line treatment', 'N-acetylcysteine', 'placebo']","['nicotine withdrawal symptoms, depressive and anxiety symptoms, anthropometric measures, blood pressure, or glucose', 'exhaled carbon monoxide (COexh', 'COexh', 'Fagerström Test for Nicotine Dependence, the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, the Minnesota Nicotine Withdrawal Scale, and the Medication Adherence Rating Scale', 'anthropometrics, blood pressure, lipid profile, and soluble tumor necrosis factor receptor (sTNF-R) levels 1 and 2', 'sTNF-R2 levels']","[{'cui': 'C0040336', 'cui_str': 'Tobacco abuse'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C3494625', 'cui_str': 'Heavy tobacco smoker'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1708063', 'cui_str': 'First line treatment'}]","[{'cui': 'C0028047', 'cui_str': 'Nicotine withdrawal'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0028043', 'cui_str': 'Nicotine dependence'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0077503', 'cui_str': 'Tumor Necrosis Factor Receptor'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",34.0,0.0382141,"In the N-acetylcysteine group, no significant changes were found in nicotine withdrawal symptoms, depressive and anxiety symptoms, anthropometric measures, blood pressure, or glucose compared to placebo.","[{'ForeName': 'Regina C B R', 'Initials': 'RCBR', 'LastName': 'Machado', 'Affiliation': 'Centro de Referência de Abordagem e Tratamento do Tabagismo, Hospital Universitário, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil.'}, {'ForeName': 'Heber O', 'Initials': 'HO', 'LastName': 'Vargas', 'Affiliation': 'Centro de Referência de Abordagem e Tratamento do Tabagismo, Hospital Universitário, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil.'}, {'ForeName': 'Marcela M', 'Initials': 'MM', 'LastName': 'Baracat', 'Affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Centro de Ciências da Saúde (CCS), UEL, Londrina, PR, Brazil.'}, {'ForeName': 'Mariana R', 'Initials': 'MR', 'LastName': 'Urbano', 'Affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Centro de Ciências da Saúde (CCS), UEL, Londrina, PR, Brazil.'}, {'ForeName': 'Waldiceu A', 'Initials': 'WA', 'LastName': 'Verri', 'Affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Centro de Ciências da Saúde (CCS), UEL, Londrina, PR, Brazil.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Porcu', 'Affiliation': 'Centro de Referência de Abordagem e Tratamento do Tabagismo, Hospital Universitário, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil.'}, {'ForeName': 'Sandra O V', 'Initials': 'SOV', 'LastName': 'Nunes', 'Affiliation': 'Centro de Referência de Abordagem e Tratamento do Tabagismo, Hospital Universitário, Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil.'}]","Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)",['10.1590/1516-4446-2019-0753'] 2545,32725107,Predictors of recurrence of atrial fibrillation within the first 3 months after ablation.,"AIMS Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation. METHODS AND RESULTS We retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03). CONCLUSION Half of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF. TRIAL REGISTRATION Clinicaltrials.gov identifier NCT02227550, https://clinicaltrials.gov/ct2/show/NCT02227550?term=NCT02227550.&rank=1.",2020,The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ,"['678 patients undergoing first AF ablation', 'patients with AF recurrence (129\u2009±\u200931']","['apixaban', 'vitamin K antagonists']","['recurrence of atrial fibrillation', 'coronary artery disease', 'Vascular disease and cardioversion', 'history of stroke/transient ischaemic attack', 'first recurrent AF within 90\u2009days']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C1520439', 'cui_str': '129 Strain Mouse'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C1096489', 'cui_str': 'Vitamin K antagonist'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0042373', 'cui_str': 'Vascular disorder'}, {'cui': 'C0013778', 'cui_str': 'Cardioversion'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0741282', 'cui_str': 'Recurrent atrial fibrillation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]",678.0,0.0706953,The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ,"[{'ForeName': 'Matthias Daniel', 'Initials': 'MD', 'LastName': 'Zink', 'Affiliation': 'Department of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany.'}, {'ForeName': 'Winnie', 'Initials': 'W', 'LastName': 'Chua', 'Affiliation': 'Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Stef', 'Initials': 'S', 'LastName': 'Zeemering', 'Affiliation': 'Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'di Biase', 'Affiliation': 'Department of Medicine (Cardiology), Albert Einstein College of Medicine at Montefiore Hospital, Montefiore-Einstein Center for Heart & Vascular Care New York, NY, USA.'}, {'ForeName': 'Bayes de Luna', 'Initials': 'BL', 'LastName': 'Antoni', 'Affiliation': 'Autonomous University of Barcelona and Institut Català Ciències Cardiovasculars (ICCC)-St. Pau Hospital, Barcelona, Spain.'}, {'ForeName': 'Callans', 'Initials': 'C', 'LastName': 'David', 'Affiliation': 'Cardiology Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Hindricks', 'Affiliation': 'University of Leipzig, Heart Center Leipzig, Leipzig, Germany.'}, {'ForeName': 'Karl Georg', 'Initials': 'KG', 'LastName': 'Haeusler', 'Affiliation': 'Department of Neurology, University Hospital Würzburg, Würzburg, Germany.'}, {'ForeName': 'Hussein R', 'Initials': 'HR', 'LastName': 'Al-Khalidi', 'Affiliation': 'Department of Cardiac Electrophysiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Jonathan P', 'Initials': 'JP', 'LastName': 'Piccini', 'Affiliation': 'Department of Cardiac Electrophysiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Mont', 'Affiliation': 'Arrhythmia Section, Universitat de Barcelona, Hospital Clinic, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Jens Cosedis', 'Initials': 'JC', 'LastName': 'Nielsen', 'Affiliation': 'Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Luis Alberto', 'Initials': 'LA', 'LastName': 'Escobar', 'Affiliation': 'Autonomous University of Barcelona and Institut Català Ciències Cardiovasculars (ICCC)-St. Pau Hospital, Barcelona, Spain.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'de Bono', 'Affiliation': 'Department of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Isabelle C', 'Initials': 'IC', 'LastName': 'Van Gelder', 'Affiliation': 'Department of Cardiology and Thorax Surgery, UMCG Thorax Center, University of Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'de Potter', 'Affiliation': 'Department of Cardiology, Electrophysiology section, Cardiovascular Center, OLV Hospital, Aalst, Belgium.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Scherr', 'Affiliation': 'Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.'}, {'ForeName': 'Sakis', 'Initials': 'S', 'LastName': 'Themistoclakis', 'Affiliation': ""Unit of Electrophysiology and Cardiac Pacing, Dell'Angelo Hospital, Mestre-Venice, Italy.""}, {'ForeName': 'Derick', 'Initials': 'D', 'LastName': 'Todd', 'Affiliation': 'Department of EP, Devices and ICC, Liverpool Heart and Chest Hospital, Liverpool, UK.'}, {'ForeName': 'Paulus', 'Initials': 'P', 'LastName': 'Kirchhof', 'Affiliation': 'Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Schotten', 'Affiliation': 'Department of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa132'] 2546,32725293,The influence of fish consumption on serum n-3 polyunsaturated fatty acid (PUFA) concentrations in women of childbearing age: a randomised controlled trial (the iFish Study).,"PURPOSE Long-chain polyunsaturated fatty acids (LCPUFA) can be synthesised endogenously from linoleic acid (LA) and α-linolenic acid (ALA) in a pathway involving the fatty acid desaturase (FADS) genes. Endogenous synthesis is inefficient; therefore, dietary intake of preformed LCPUFA from their richest source of fish is preferred. This study investigated the effect of fish consumption on PUFA concentrations in women of childbearing age while stratifying by FADS genotype. The influence of fish consumption on lipid profile, and markers of inflammation and oxidative stress was also examined. METHODS Healthy women (n = 49) provided a buccal swab which was analysed for FADS2 genotype (rs3834458; T/deletion). Participants were stratified according to genotype and randomised to an intervention group to receive either no fish (n = 18), 1 portion (n = 14) or 2 portions (n = 17) (140 g per portion) of fish per week for a period of 8 weeks. Serum PUFA was analysed at baseline and post-intervention. Lipid profile, and markers of inflammation and oxidative stress were also analysed. RESULTS Participants consuming 2 portions of fish per week had significantly higher concentrations of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total n-3 PUFA, and a lower n-6:n-3 ratio compared to those in the no fish or 1 portion per week group (all p < 0.05). Fish consumption did not have a significant effect on biomarkers of oxidative stress, inflammation and lipid profile in the current study. CONCLUSION Consumption of 2 portions of fish per week has beneficial effects on biological n-3 PUFA concentrations in women of childbearing age; however, no effects on oxidative stress, inflammation or lipid profile were observed. This trial was registered at www.clinicaltrials.gov (NCT03765580), registered December 2018.",2020,"Fish consumption did not have a significant effect on biomarkers of oxidative stress, inflammation and lipid profile in the current study. ","['women of childbearing age while stratifying by FADS genotype', 'women of childbearing age', 'Healthy women (n\u2009=\u200949']","['chain polyunsaturated fatty acids (LCPUFA', 'fish consumption']","['serum n-3 polyunsaturated fatty acid (PUFA) concentrations', 'Lipid profile, and markers of inflammation and oxidative stress', 'PUFA concentrations', 'concentrations of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total n-3 PUFA, and a lower n-6:n-3 ratio', 'biological n-3 PUFA concentrations', 'lipid profile, and markers of inflammation and oxidative stress', 'oxidative stress, inflammation or lipid profile', 'biomarkers of oxidative stress, inflammation and lipid profile', 'Serum PUFA']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C0015680', 'cui_str': 'Fatty Acid Desaturating Enzymes'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}]","[{'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0016163', 'cui_str': 'Fish'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0032615', 'cui_str': 'Polyunsaturated fatty acid'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0005515', 'cui_str': 'Biological agent'}]",,0.158035,"Fish consumption did not have a significant effect on biomarkers of oxidative stress, inflammation and lipid profile in the current study. ","[{'ForeName': 'Marie C', 'Initials': 'MC', 'LastName': 'Conway', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK.'}, {'ForeName': 'Emeir M', 'Initials': 'EM', 'LastName': 'McSorley', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK.'}, {'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Mulhern', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK.'}, {'ForeName': 'Toni', 'Initials': 'T', 'LastName': 'Spence', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK.'}, {'ForeName': 'Edwin van', 'Initials': 'EV', 'LastName': 'Wijngaarden', 'Affiliation': 'School of Medicine and Dentistry, University of Rochester, Rochester, USA.'}, {'ForeName': 'Gene E', 'Initials': 'GE', 'LastName': 'Watson', 'Affiliation': 'School of Medicine and Dentistry, University of Rochester, Rochester, USA.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Wahlberg', 'Affiliation': 'The Laboratory of Medicine, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Pineda', 'Affiliation': 'The Laboratory of Medicine, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Broberg', 'Affiliation': 'The Laboratory of Medicine, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden.'}, {'ForeName': 'Barry W', 'Initials': 'BW', 'LastName': 'Hyland', 'Affiliation': 'Mass Spectrometry Centre, Biomedical Sciences Research Institute (BMSRI), Ulster University, Coleraine, Northern Ireland, UK.'}, {'ForeName': 'Diego F', 'Initials': 'DF', 'LastName': 'Cobice', 'Affiliation': 'Mass Spectrometry Centre, Biomedical Sciences Research Institute (BMSRI), Ulster University, Coleraine, Northern Ireland, UK.'}, {'ForeName': 'J J', 'Initials': 'JJ', 'LastName': 'Strain', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK.'}, {'ForeName': 'Alison J', 'Initials': 'AJ', 'LastName': 'Yeates', 'Affiliation': 'Nutrition Innovation Centre for Food and Health (NICHE), School of Biomedical Sciences, Ulster University, Cromore Road, Coleraine, BT52 1SA, Northern Ireland, UK. a.yeates@ulster.ac.uk.'}]",European journal of nutrition,['10.1007/s00394-020-02326-w'] 2547,32725346,"A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.","PURPOSE The present study evaluated the safety and efficacy of neoadjuvant chemotherapy with modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab in clinical stage III rectal cancer with KRAS wild-type. METHODS We conducted a prospective multicenter phase II trial. KRAS wild-type clinical stage III rectal cancer patients were enrolled. Patients received 6 cycles of mFOLFOX6 with 6 mg/kg panitumumab as neoadjuvant chemotherapy. The primary outcome was the response rate (RR) defined by RECIST. Lateral lymph node dissection (LLDN) was performed when patients had a locally advanced tumor < 9 cm from the anal margin. RESULTS A total of 50 patients were enrolled. Twelve (24.0%) experienced grade 3-4 adverse events during neoadjuvant chemotherapy. The RR was 88.0% (complete response 2.0%, partial response 86.0%), which met the primary outcome. All patients underwent laparoscopic surgery and achieved R0 resection. Seven patients underwent resection of other adjacent organs, and 43 underwent LLND. Twelve patients (24.0%) experienced grade 3-4 postoperative complications, and 4 (8.0%) had pathological complete response (pCR). Thirteen patients (26.0%) had lymph node metastasis. Forty-five patients (90.0%) received postoperative adjuvant chemotherapy. The 3-year relapse-free survival (RFS) and overall survival (OS) rates were 79.0% and 93.7%, respectively. CONCLUSIONS Neoadjuvant chemotherapy of mFOLFOX6 plus panitumumab without radiotherapy resulted in a low pCR rate but a high PR rate, low local recurrence rate, and good long-term outcome, suggesting that this treatment strategy may be a viable option for patients unable or unwilling to receive radiotherapy. The trial was registered with the UMIN Clinical Trials Registry, number 000006039.",2020,"The 3-year relapse-free survival (RFS) and overall survival (OS) rates were 79.0% and 93.7%, respectively. ","['KRAS wild-type clinical stage III rectal cancer patients were enrolled', 'Thirteen patients (26.0%) had lymph node metastasis', 'locally advanced rectal cancer', 'Seven patients underwent resection of other adjacent organs, and 43 underwent LLND', 'clinical stage III rectal cancer with KRAS wild-type', '50 patients were enrolled']","['neoadjuvant chemotherapy with modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab', 'mFOLFOX6 with 6\xa0mg/kg panitumumab as neoadjuvant chemotherapy', 'radiotherapy', 'postoperative adjuvant chemotherapy', 'laparoscopic surgery and achieved R0 resection', 'neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy']","['response rate (RR) defined by RECIST', 'grade 3-4 postoperative complications', 'pathological complete response (pCR', 'safety and efficacy', 'Lateral lymph node dissection (LLDN', 'low pCR rate', 'RR', '3-year relapse-free survival (RFS) and overall survival (OS) rates']","[{'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0205578', 'cui_str': 'Clinical stage III'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0686619', 'cui_str': 'Secondary malignant neoplasm of lymph node'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023413', 'cui_str': 'Leucovorin'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0879427', 'cui_str': 'panitumumab'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1709926', 'cui_str': 'RECIST'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0024203', 'cui_str': 'Excision of lymph node'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",50.0,0.496551,"The 3-year relapse-free survival (RFS) and overall survival (OS) rates were 79.0% and 93.7%, respectively. ","[{'ForeName': 'Kenichiro', 'Initials': 'K', 'LastName': 'Toritani', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Watanabe', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. nabe-jun@comet.ocn.ne.jp.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Suwa', 'Affiliation': 'Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Nakagawa', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Hirokazu', 'Initials': 'H', 'LastName': 'Suwa', 'Affiliation': 'Department of Surgery, Yokosuka Kyosai Hospital, Yokosuka, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Ishibe', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Mitsuyoshi', 'Initials': 'M', 'LastName': 'Ota', 'Affiliation': 'Department of Surgery, Yokohama Minato Red Cross hospital, Yokohama, Japan.'}, {'ForeName': 'Chikara', 'Initials': 'C', 'LastName': 'Kunisaki', 'Affiliation': 'Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.'}, {'ForeName': 'Takeharu', 'Initials': 'T', 'LastName': 'Yamanaka', 'Affiliation': 'Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan.'}, {'ForeName': 'Itaru', 'Initials': 'I', 'LastName': 'Endo', 'Affiliation': 'Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.'}]",International journal of colorectal disease,['10.1007/s00384-020-03693-w'] 2548,32725352,Postoperative analgesic efficacy of modified continuous transversus abdominis plane block in laparoscopic colorectal surgery: a triple-blind randomized controlled trial.,"BACKGROUND The optimal opioid-sparing analgesic regimen following laparoscopic colorectal surgery (LCS) remains uncertain. We sought to determine the efficacy of low-dose bupivacaine infusion via surgeon-inserted modified continuous transversus abdominis plane (mcTAP) catheters after LCS. METHODS A parallel-group, placebo-controlled, randomized single-centre trial was conducted between April 2017 and February 2018. Block-of-four randomization and allocation concealment by sequentially-numbered, opaque sealed envelopes were used. Patients, surgeons and assessors were blinded. Fifty-two patients were randomized to receive either 0.2% bupivacaine or saline through mcTAP catheters. A 5 ml bolus followed by a 72 h infusion at 2 ml/h was started, with patient-controlled fentanyl analgesia and oral paracetamol given on demand. Primary outcomes were fentanyl consumptions in the first 24 h, second 24 h, and third 24 h following surgery. Secondary outcomes were pain numeric rating scores, recovery outcomes and complications. RESULTS Twenty-five patients in the bupivacaine group and 26 in the control group were analysed. Patients in the bupivacaine group required significantly less fentanyl overall (106.1 vs 484.5 mcg, p < 0.001) and at all time points (first 24 h: 61.0 vs 324.3 mcg, p < 0.001; second 24 h: 36.3 vs 119.0 mcg, p = 0.033; third 24 h: 8.8 vs 41.2, p = 0.030) when compared to placebo. Significantly lower pain scores at rest at 6 h (2.32 vs 4.0, p = 0.002), and 12 h (1.80 vs 3.08, p = 0.011) and on coughing at 6 h (4.56 vs 5.84, p = 0.019), 12 h (3.76 vs 4.96, p = 0.009), and 24 h (3.44 vs 4.24, p = 0.049) as well as significantly lower opioid-related complications such as nausea or vomiting (9 (36%) vs 1 (4%), p = 0.005) were observed in the bupivacaine group. There were no major block-related complications, and recovery outcomes were similar in both groups. CONCLUSIONS McTAP block reduces postoperative fentanyl consumption and pain scores after LCS, highlighting its role as a safe and useful opioid-sparing analgesia. REGISTRATION NUMBER TCTR20150831001 (Thai Clinical Trials Registry). Full trial protocol can be assessed at https://www.clinicaltrials.in.th/ .",2020,"Significantly lower pain scores at rest at 6 h (2.32 vs 4.0, p = 0.002), and 12 h (1.80 vs 3.08, p = 0.011) and on coughing at 6 h (4.56 vs 5.84, p = 0.019), 12 h (3.76 vs 4.96, p = 0.009), and 24 h (3.44 vs 4.24, p = 0.049) as well as significantly lower opioid-related complications such as nausea or vomiting (9 (36%) vs 1 (4%), p = 0.005) were observed in the bupivacaine group.","['Fifty-two patients', 'laparoscopic colorectal surgery', 'April 2017 and February 2018']","['modified continuous transversus abdominis plane block', 'bupivacaine', 'bupivacaine infusion via surgeon-inserted modified continuous transversus abdominis plane (mcTAP) catheters', 'paracetamol', 'McTAP block', 'bupivacaine or saline through mcTAP catheters', 'placebo']","['fentanyl consumptions in the first 24\xa0h, second 24\xa0h, and third 24\xa0h following surgery', 'pain scores', 'coughing', 'pain numeric rating scores, recovery outcomes and complications', 'nausea or vomiting', 'Postoperative analgesic efficacy', 'major block-related complications, and recovery outcomes', 'fentanyl overall', 'postoperative fentanyl consumption and pain scores']","[{'cui': 'C4319570', 'cui_str': '52'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0009369', 'cui_str': 'Colorectal surgery'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0444660', 'cui_str': 'Plane'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0582175', 'cui_str': 'Surgeon'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0085590', 'cui_str': 'Catheter'}, {'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015846', 'cui_str': 'Fentanyl'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",52.0,0.543366,"Significantly lower pain scores at rest at 6 h (2.32 vs 4.0, p = 0.002), and 12 h (1.80 vs 3.08, p = 0.011) and on coughing at 6 h (4.56 vs 5.84, p = 0.019), 12 h (3.76 vs 4.96, p = 0.009), and 24 h (3.44 vs 4.24, p = 0.049) as well as significantly lower opioid-related complications such as nausea or vomiting (9 (36%) vs 1 (4%), p = 0.005) were observed in the bupivacaine group.","[{'ForeName': 'P', 'Initials': 'P', 'LastName': 'Haruethaivijitchock', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'J L', 'Initials': 'JL', 'LastName': 'Ng', 'Affiliation': 'Department of Colorectal Surgery, Singapore General Hospital, Singapore, Singapore.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Taksavanitcha', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Theerawatanawong', 'Affiliation': 'Department of Anesthesiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Rattananupong', 'Affiliation': 'Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Lohsoonthorn', 'Affiliation': 'Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Sahakitrungruang', 'Affiliation': 'Colorectal Surgery Division, Department of Surgery, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Pathumwan, Bangkok, 10330, Thailand. chucheep@hotmail.com.'}]",Techniques in coloproctology,['10.1007/s10151-020-02311-9'] 2549,32725393,Effect of a nutritional education intervention on breakfast consumption among preparatory school students in Egypt.,"OBJECTIVES The current study evaluates the effect of nutritional education based on Pender's health promotion model on breakfast consumption behavior among Egyptian school students. METHODS A pre-posttest intervention study through a nutritional education message based on Pender's health promotion model was carried on 244 preparatory school students. Data were collected using questionnaires and measuring weight, height and blood pressure before and after educational intervention was conducted to the intervention group. RESULTS The educational intervention was having a significant positive effect on all components of the model in the intervention group, the mean breakfast consumption, frequency of non-skipping and healthy breakfast per week (p ≤ 0.05). Overweight and obesity and higher blood pressure were significantly present among breakfast skippers. CONCLUSIONS The nutritional educational intervention based on Pender's health promotion model was effective in increasing the frequency of healthy breakfast among the school students. There is a need to develop evidence-based policies, community, family, and school-based interventions to promote healthy lifestyle and nutritional behavior among adolescents for a better quality of life.",2020,The nutritional educational intervention based on Pender's health promotion model was effective in increasing the frequency of healthy breakfast among the school students.,"['244 preparatory school students', 'preparatory school students in Egypt', 'Egyptian school students']","[""nutritional education based on Pender's health promotion model"", ""nutritional education message based on Pender's health promotion model"", ""nutritional educational intervention based on Pender's health promotion model"", 'nutritional education intervention']","['weight, height and blood pressure', 'mean breakfast consumption, frequency of non-skipping and healthy breakfast', 'Overweight and obesity and higher blood pressure', 'breakfast consumption']","[{'cui': 'C4517660', 'cui_str': '244'}, {'cui': 'C0557794', 'cui_str': 'Preparatory school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}, {'cui': 'C0013717', 'cui_str': 'Egyptian language'}, {'cui': 'C0036375', 'cui_str': 'School'}]","[{'cui': 'C0204934', 'cui_str': 'Nutrition education'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018738', 'cui_str': 'Health promotion'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C2698559', 'cui_str': 'Breakfast time'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0560435', 'cui_str': 'Does skip'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",244.0,0.01186,The nutritional educational intervention based on Pender's health promotion model was effective in increasing the frequency of healthy breakfast among the school students.,"[{'ForeName': 'Omnia S', 'Initials': 'OS', 'LastName': 'Elseifi', 'Affiliation': 'Community, Environmental and Occupational Medicine Department, Faculty of Medicine, Zagazig University, Zagazig City, 44519, Egypt. omnia2200@yahoo.com.'}, {'ForeName': 'Doaa M', 'Initials': 'DM', 'LastName': 'Abdelrahman', 'Affiliation': 'Department of Pediatrics, Zagazig University, Zagazig City, 44519, Egypt.'}, {'ForeName': 'Eman M', 'Initials': 'EM', 'LastName': 'Mortada', 'Affiliation': 'Community, Environmental and Occupational Medicine Department, Faculty of Medicine, Zagazig University, Zagazig City, 44519, Egypt.'}]",International journal of public health,['10.1007/s00038-020-01439-7'] 2550,32725529,Early Free Range-of-Motion Upper Limb Exercises After Mastectomy and Immediate Implant-Based Reconstruction Are Safe and Beneficial: A Randomized Trial.,"BACKGROUND This study assessed the impact that free range-of-motion (ROM) upper limb exercises 15 or 30 days after mastectomy and immediate implant-based reconstruction has on surgical complications and kinetic-functional recovery. METHODS This randomized clinical trial included 60 women who had breast cancer treated with mastectomy and immediate implant or tissue expander reconstruction. The patients initiated the exercises with shoulder ROM limited to 90° the day after surgery. After 2 weeks, the patients were randomized into two groups of 30 patients each: the ""free-range group,"" which permitted shoulder range exercises until limited by pain or wound dehiscence, and the ""limited-range group,"" which maintained shoulder movement restriction at 90° until 30 days after surgery, at which time they also were allowed to perform free-range exercises. The patients underwent evaluations preoperatively, then 7, 15, 30, 60, and 90 days after surgery. The primary outcomes were incidence and prevalence of dehiscence and seroma and incidence of infection and necrosis. The secondary outcomes were shoulder ROM, pain, and upper limb function. RESULTS The two groups did not differ in terms of incidence and prevalence of postoperative complications. The patients with free upper limb exercise 15 days after surgery had less pain, greater shoulder amplitude, and better upper limb function than those who had movement restricted to 90° for 30 days. CONCLUSION The postoperative protocol with free shoulder ROM on the 15th day after surgery is safe and beneficial in terms of kinetic-functional recovery and pain control for patients after mastectomy and immediate implant-based reconstruction. CLINICAL TRIALS REGISTER NCT02480842.",2020,"The patients with free upper limb exercise 15 days after surgery had less pain, greater shoulder amplitude, and better upper limb function than those who had movement restricted to 90° for 30 days. ",['60 women who had breast cancer treated with'],"['free-range group,"" which permitted shoulder range exercises until limited by pain or wound dehiscence, and the ""limited-range group,"" which maintained shoulder movement restriction', 'Motion Upper Limb Exercises', 'Mastectomy and Immediate Implant-Based Reconstruction Are Safe and Beneficial', 'mastectomy and immediate implant or tissue expander reconstruction', 'motion (ROM) upper limb exercises 15 or 30\xa0days after mastectomy and immediate implant-based reconstruction']","['incidence and prevalence of postoperative complications', 'incidence and prevalence of dehiscence and seroma and incidence of infection and necrosis', 'shoulder ROM, pain, and upper limb function', 'pain, greater shoulder amplitude, and better upper limb function']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0023636', 'cui_str': 'Licenses'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0259768', 'cui_str': 'Wound dehiscence'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0427048', 'cui_str': 'Movement of shoulder'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C0454320', 'cui_str': 'Upper limb exercises'}, {'cui': 'C0024881', 'cui_str': 'Mastectomy'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C0040289', 'cui_str': 'Tissue expander'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0149663', 'cui_str': 'Dehiscence'}, {'cui': 'C0262627', 'cui_str': 'Seroma'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0027540', 'cui_str': 'Necrosis'}, {'cui': 'C0575545', 'cui_str': 'Shoulder joint - range of movement'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]",60.0,0.0751089,"The patients with free upper limb exercise 15 days after surgery had less pain, greater shoulder amplitude, and better upper limb function than those who had movement restricted to 90° for 30 days. ","[{'ForeName': 'Samantha Karlla Lopes', 'Initials': 'SKL', 'LastName': 'de Almeida Rizzi', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil. samyfisio@gmail.com.'}, {'ForeName': 'Cinira Assad Simão', 'Initials': 'CAS', 'LastName': 'Haddad', 'Affiliation': 'Lusíada University Center (UNILUS), Santos, SP, Brazil.'}, {'ForeName': 'Patrícia Santolia', 'Initials': 'PS', 'LastName': 'Giron', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}, {'ForeName': 'Patrícia Vieira Guedes', 'Initials': 'PVG', 'LastName': 'Figueira', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Estevão', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Elias', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}, {'ForeName': 'Afonso Celso Pinto', 'Initials': 'ACP', 'LastName': 'Nazário', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Facina', 'Affiliation': 'Department of Gynecology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.'}]",Annals of surgical oncology,['10.1245/s10434-020-08882-z'] 2551,32725573,Analgesia and side effects of codeine phosphate associated with paracetamol vs. paracetamol after the extraction of mandibular third molars: a randomized double-blind clinical trial using the split-mouth model.,"PURPOSE To assess the analgesia and side effects of codeine phosphate associated with paracetamol (test medication) as compared to paracetamol (control medication) after the extraction of impacted mandibular third molars. MATERIALS AND METHODS Forty-seven patients removed the right and left impacted mandibular third molars. After one surgery, patients took the test medication and after the other surgery, they took the control medication. Patients with exacerbated pain were prescribed to use the rescue medication instead of the medication initially administered and were included in the rescue group. They were evaluated for 7 days postoperatively, and the mean score of the visual analogue scale (VAS) of pain between test and control medications was assessed by the Poisson distribution. The side effects of these medications were assessed by the patient's complaints. A P value of < .05 was considered to be statistically significant. RESULTS The mean score of the VAS of pain was not statistically different between test and control medications in the non-rescue group, but it was significantly greater in patients previously using paracetamol in the rescue group. The most common side effects reported in both groups, predominantly in patients using the test medication, were drowsiness, dizziness, and nausea. CONCLUSION The use of codeine phosphate associated with paracetamol after the extraction of impacted mandibular third molars is a better choice to control the postoperative pain rather than paracetamol, but with more side effects, which are clinically acceptable.",2020,"The mean score of the VAS of pain was not statistically different between test and control medications in the non-rescue group, but it was significantly greater in patients previously using paracetamol in the rescue group.","['Forty-seven patients removed the right and left impacted mandibular third molars', 'Patients with exacerbated pain', 'mandibular third molars', 'impacted mandibular third molars']","['paracetamol (control medication', 'paracetamol', 'paracetamol vs. paracetamol', 'codeine phosphate', 'paracetamol (test medication']","['mean score of the VAS of pain', 'mean score of the visual analogue scale (VAS) of pain between test and control medications', 'drowsiness, dizziness, and nausea']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1883720', 'cui_str': 'Removes'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0024687', 'cui_str': 'Bone structure of mandible'}, {'cui': 'C0026369', 'cui_str': 'Structure of wisdom tooth'}, {'cui': 'C0436331', 'cui_str': 'Symptom aggravating factors'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0009217', 'cui_str': 'Codeine phosphate'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}]",47.0,0.114144,"The mean score of the VAS of pain was not statistically different between test and control medications in the non-rescue group, but it was significantly greater in patients previously using paracetamol in the rescue group.","[{'ForeName': 'Matheus', 'Initials': 'M', 'LastName': 'Furtado de Carvalho', 'Affiliation': 'Department of Maxillofacial Surgery, Federal University of Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Yuri', 'Initials': 'Y', 'LastName': 'Slusarenko da Silva', 'Affiliation': 'School of Dentistry, UniFG University Center (Faculty of Guanambi), Avenida Pedro Felipe Duarte 4911 São Sebastião, Guanambi, Bahia, 46430-000, Brazil. yu.slu@hotmail.com.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reher', 'Affiliation': 'School of Dentistry and Oral Health, Griffith University, Griffith, Australia.'}, {'ForeName': 'Maria da Graça', 'Initials': 'MDG', 'LastName': 'Naclério-Homem', 'Affiliation': 'Department of Oral & Maxillofacial Surgery, Traumatology and Prosthesis, Faculty of Dentistry, University of São Paulo, Sao Paulo, Brazil.'}]",Oral and maxillofacial surgery,['10.1007/s10006-020-00888-x'] 2552,32725584,"Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.","BACKGROUND In older patients with overactive bladder (OAB), mirabegron, a β 3 -adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk-benefit profile. OBJECTIVES Our objective was to further examine the safety and tolerability of mirabegron versus placebo treatment in patients aged ≥ 65 years with OAB-wet. METHODS We conducted a 12-week, double-blind, randomized, placebo-controlled phase IV study to compare mirabegron with placebo. Community-dwelling patients aged ≥ 65 years with OAB-wet (one or more incontinence episode and three or more urgency episodes, and an average of eight or more micturitions/24 h over a 3-day diary) were randomized to receive placebo or mirabegron 25 mg/day (optional dose escalation to 50 mg/day at week 4 or 8). Safety analyses were performed for adverse events (AEs) and vital signs on all randomized patients who received one or more dose of study drug. RESULTS Treatment-emergent AEs (TEAEs), the majority mild or moderate in severity, were reported in 39.4% of placebo patients and 44.2 and 49.8% of those who received mirabegron 25 mg or 50 mg, respectively. The most common TEAEs in mirabegron-treated patients were urinary tract infection, headache, and diarrhea. The incidence of TEAEs was slightly higher in mirabegron patients aged ≥ 75 years than in those aged < 75 years. There were no clinically meaningful differences in changes in vital signs from baseline to end of treatment for any treatment group, and no differences were observed between mirabegron and placebo treatment groups. TEAEs tended to occur early post exposure and were not dose related. CONCLUSIONS Mirabegron treatment was well-tolerated in older adults with OAB-wet. Safety and tolerability were consistent with the known mirabegron safety profile. TRIAL REGISTRATION This study is registered at ClinicalTrials.gov: NCT02216214.",2020,"There were no clinically meaningful differences in changes in vital signs from baseline to end of treatment for any treatment group, and no differences were observed between mirabegron and placebo treatment groups.","['patients aged\u2009≥', '65\xa0years with OAB-wet (one or more incontinence episode and three or more urgency episodes, and an average of eight or more micturitions/24\xa0h over a 3-day diary', 'older adults with OAB-wet', '65\xa0years with OAB-wet', 'Patients\u2009≥', '65\xa0years with Overactive Bladder-Wet', 'Community-dwelling patients aged\u2009≥', 'older patients with overactive bladder (OAB']","['Placebo', 'placebo']","['vital signs', 'Safety and tolerability', 'safety and tolerability', 'incidence of TEAEs', 'Safety and Tolerability', 'urinary tract infection, headache, and diarrhea']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",,0.543871,"There were no clinically meaningful differences in changes in vital signs from baseline to end of treatment for any treatment group, and no differences were observed between mirabegron and placebo treatment groups.","[{'ForeName': 'Sender', 'Initials': 'S', 'LastName': 'Herschorn', 'Affiliation': 'Department of Surgery/Urology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, MG408, Toronto, Ontario, M4N 3M5, Canada. s.herschorn@utoronto.ca.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Staskin', 'Affiliation': ""Division of Urology, St Elizabeth's Medical Center, 736 Cambridge Street, Brighton, MA, USA.""}, {'ForeName': 'Carol R', 'Initials': 'CR', 'LastName': 'Schermer', 'Affiliation': 'Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.'}, {'ForeName': 'Rita M', 'Initials': 'RM', 'LastName': 'Kristy', 'Affiliation': 'Astellas Pharma Global Development, Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Wagg', 'Affiliation': 'Department of Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83 Avenue, Edmonton, AB, Canada.'}]",Drugs & aging,['10.1007/s40266-020-00783-w'] 2553,32725588,Improvement of anti-Müllerian hormone and oxidative stress through regular exercise in Chinese women with polycystic ovary syndrome.,"PURPOSE Structured exercise is shown to be one of the most effective lifestyle interventions for women with polycystic ovary syndrome (PCOS). Anti-Müllerian hormone (AMH) has been proposed as a marker of ovarian dysfunction, and oxidative stress plays an important role in the development of PCOS. We sought to investigate whether there was any effect of aerobic exercise on AMH levels and oxidative stress in Chinese PCOS women. METHODS Thirty-eight PCOS women were enrolled and divided into two groups. The exercise group carried out a 12-week exercise program, while the control group maintained their normal lifestyle. All women underwent blood tests and cardiopulmonary exercise tests (CPETs) at enrollment and at 12-week follow-up. RESULTS At baseline, there was no statistically significant difference between the two groups in clinical characteristics, AMH, oxidative biomarkers, and CPET parameters. After 12 weeks, body mass index (BMI) and cardiovascular fitness indexes of the exercise group were improved. We also found a decrease in AMH (P = 0.021) and malondialdehyde (MDA) (P = 0.002) and an increase in superoxide dismutase (SOD) (P = 0.009) and total antioxidant capacity (TAC) (P = 0.012) in the exercise group, while there was no change in the control group. Moreover, the change of AMH was positively associated with the change of MDA (r = 0.23, P = 0.003) in the exercise group. CONCLUSIONS Our findings demonstrated that 12 weeks of aerobic exercise produced beneficial effects on BMI, cardiovascular fitness, AMH, and oxidative stress in PCOS women. Favorable modification of oxidative stress might thus be an effective method for improvement of AMH in these women, which deserves further exploration in the future.",2020,We also found a decrease in AMH (P = 0.021) and malondialdehyde (MDA),"['PCOS women', 'Chinese women with polycystic ovary syndrome', 'women with polycystic ovary syndrome (PCOS', 'Thirty-eight PCOS women', 'Chinese PCOS women']","['blood tests and cardiopulmonary exercise tests (CPETs', 'Anti-Müllerian hormone (AMH', 'exercise program, while the control group maintained their normal lifestyle', 'regular exercise', 'aerobic exercise']","['AMH', 'malondialdehyde (MDA', 'total antioxidant capacity (TAC', 'AMH levels and oxidative stress', 'change of AMH', 'clinical characteristics, AMH, oxidative biomarkers, and CPET parameters', 'superoxide dismutase (SOD', 'change of MDA', 'BMI, cardiovascular fitness, AMH, and oxidative stress', 'body mass index (BMI) and cardiovascular fitness indexes']","[{'cui': 'C0032460', 'cui_str': 'Polycystic ovary syndrome'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0450361', 'cui_str': '38'}]","[{'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0582191', 'cui_str': 'Regular exercise'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}]","[{'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0024643', 'cui_str': 'Malondialdehyde'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}, {'cui': 'C1287355', 'cui_str': 'Hormone level - finding'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0055954', 'cui_str': 'Clostridium perfringens epsilon toxin'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0038838', 'cui_str': 'Superoxide Dismutase'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",38.0,0.0274535,We also found a decrease in AMH (P = 0.021) and malondialdehyde (MDA),"[{'ForeName': 'Xia', 'Initials': 'X', 'LastName': 'Wu', 'Affiliation': ""Department of Endocrinology, Jing'an District Centre Hospital of Shanghai (Huashan Hospital Fudan University Jing'an Branch), Shanghai, China.""}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Wu', 'Affiliation': 'Department of Psychosomatic Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.'}, {'ForeName': 'Wenjiang', 'Initials': 'W', 'LastName': 'Sun', 'Affiliation': 'Department of Rehabilitation, Shanghai General Hospital, Jiaotong University, Shanghai, China.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': 'Department of General Medicine, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China. wangchen09443@163.com.'}]","Hormones (Athens, Greece)",['10.1007/s42000-020-00233-7'] 2554,32728820,Exercise training improves vascular function in patients with Alzheimer's disease.,"PURPOSE Vascular dysfunction has been demonstrated in patients with Alzheimer's disease (AD). Exercise is known to positively affect vascular function. Thus, the aim of our study was to investigate exercise-induced effects on vascular function in AD. METHODS Thirty-nine patients with AD (79 ± 8 years) were recruited and randomly assigned to exercise training (EX, n = 20) or control group (CTRL, n = 19). All subjects performed 72 treatment sessions (90 min, 3 t/w). EX included moderate-high-intensity aerobic and strength training. CTRL included cognitive stimuli (visual, verbal, auditive). Before and after the 6-month treatment, the vascular function was measured by passive-leg movement test (PLM, calculating the variation in blood flow: ∆peak; and area under the curve: AUC) tests, and flow-mediated dilation (FMD, %). A blood sample was analyzed for vascular endothelial growth factor (VEGF). Arterial blood flow (BF) and shear rate (SR) were measured during EX and CTRL during a typical treatment session. RESULTS EX group has increased FMD% (+ 3.725%, p < 0.001), PLM ∆peak (+ 99.056 ml/min, p = 0.004), AUC (+ 37.359AU, p = 0.037) and VEGF (+ 8.825 pg/ml, p = 0.004). In the CTRL group, no difference between pre- and post-treatment was found for any variable. Increase in BF and SR was demonstrated during EX (BF + 123%, p < 0.05; SR + 134%, p < 0.05), but not during CTRL treatment. CONCLUSION Exercise training improves peripheral vascular function in AD. These ameliorations may be due to the repetitive increase in SR during exercise which triggers NO and VEGF upregulation. This approach might be included in standard AD clinical practice as an effective strategy to treat vascular dysfunction in this population.",2020,"RESULTS EX group has increased FMD% (+ 3.725%, p < 0.001), PLM ∆peak (+ ","[""patients with Alzheimer's disease"", ""patients with Alzheimer's disease (AD"", 'Thirty-nine patients with AD (79\u2009±\u20098\xa0years']","['exercise training (EX, n\u2009=\u200920) or control group (CTRL', 'Exercise training']","['Arterial blood flow (BF) and shear rate (SR', 'CTRL included cognitive stimuli (visual, verbal, auditive', 'vascular endothelial growth factor (VEGF', 'passive-leg movement\xa0test (PLM, calculating the variation in blood flow: ∆peak; and area under the curve: AUC) tests, and flow-mediated dilation (FMD, ', 'FMD', 'PLM ∆peak ', 'moderate-high-intensity aerobic and strength training', 'peripheral vascular function', 'vascular function', 'BF and SR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C3816447', 'cui_str': '39'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0229665', 'cui_str': 'Arterial blood'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0175735', 'cui_str': 'Scissors'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0012359', 'cui_str': 'Dilatation'}, {'cui': 'C0016052', 'cui_str': 'Fibromuscular dysplasia'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}]",39.0,0.064598,"RESULTS EX group has increased FMD% (+ 3.725%, p < 0.001), PLM ∆peak (+ ","[{'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pedrinolla', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Venturelli', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy. massimo.venturelli@univr.it.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Fonte', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Tamburin', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Di Baldassarre', 'Affiliation': ""Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti-Pescara, Chieti, Italy.""}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Naro', 'Affiliation': 'Department of Anatomical, Histological, Forensic Medicine and Orthopedic Science, Rome, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Varalta', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Gaia', 'Initials': 'G', 'LastName': 'Giuriato', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Ghinassi', 'Affiliation': ""Department of Medicine and Aging Sciences, University G. D'Annunzio, Chieti-Pescara, Chieti, Italy.""}, {'ForeName': 'Ettore', 'Initials': 'E', 'LastName': 'Muti', 'Affiliation': 'Mons. A. Mazzali Foundation, Mantua, Italy.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Smania', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Schena', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati 43, 37131, Verona, Italy.'}]",European journal of applied physiology,['10.1007/s00421-020-04447-w'] 2555,32728832,Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog ® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis.,"INTRODUCTION We evaluated the efficacy and safety of ultra-rapid lispro (URLi) in comparison to lispro in a subgroup analysis of Japanese adults with type 1 diabetes mellitus from the phase 3 PRONTO-T1D trial. METHODS After an 8-week lead-in to optimize basal insulin treatment, patients were randomized to 52-week double-blind mealtime URLi or lispro, or 26-week open-label postmeal URLi. The primary endpoint was change in hemoglobin A1c (HbA1c) from baseline (week 0) to week 26 between mealtime URLi and lispro. The multiplicity adjusted objectives were 1- and 2-h postprandial glucose (PPG) excursions after a meal test between mealtime URLi and lispro, and change in HbA1c from baseline to week 26 between postmeal URLi and mealtime lispro. RESULTS This manuscript presents pre-specified exploratory analyses of 26-week data from Japanese patients randomized to double-blind URLi (n = 62) or lispro (n = 59), or open-label URLi (n = 46). Mean baseline HbA1c levels were 7.52% for mealtime URLi, 7.44% for lispro, and 7.51% for postmeal URLi at randomization. At week 26, the least squares mean (LSM) difference compared to lispro was 0.04% (95% confidence interval [CI] - 0.14 to 0.22) for mealtime URLi, and 0.16% (95% CI - 0.04 to 0.35) for postmeal URLi. In comparison to lispro, mealtime URLi resulted in statistically significantly lower 1- and 2-h PPG excursions during the mixed-meal tolerance test. LSM differences were - 40.5 mg/dL, 95% CI - 59.5 to 21.4 (- 2.25 mmol/L, 95% CI - 3.3 to - 1.2) for 1-h PPG excursions and - 51.7 mg/dL, 95% CI - 81.7 to - 21.8 (- 2.87 mmol/L, 95% CI - 4.5 to - 1.2) for 2-h PPG excursions at week 26. There were no significant treatment differences in rates of severe/overall hypoglycemia, or incidence of treatment-emergent adverse events. CONCLUSIONS Mealtime and postmeal URLi provide effective and comparable glycemic control in Japanese patients. Mealtime URLi demonstrated more effective PPG control compared to lispro. TRIAL REGISTRATION ClinicalTrials.gov, NCT03214367.",2020,"In comparison to lispro, mealtime URLi resulted in statistically significantly lower 1- and 2-h PPG excursions during the mixed-meal tolerance test.","['Japanese patients', 'Japanese adults with type\xa01 diabetes mellitus from the phase\xa03 PRONTO-T1D trial', 'Japanese patients randomized to', 'Japanese Patients with Type\xa01 Diabetes']","['double-blind mealtime URLi or lispro, or 26-week open-label postmeal URLi', 'ultra-rapid lispro (URLi', 'lispro (n\u2009=\u200959), or open-label URLi', 'double-blind URLi']","['change in hemoglobin A1c (HbA1c', '2-h postprandial glucose (PPG) excursions', 'rates of severe/overall hypoglycemia, or incidence of treatment-emergent adverse events', 'Mean baseline HbA1c levels', 'LSM differences', 'Ultra-Rapid Lispro Efficacy and Safety', '1- and 2-h PPG excursions']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0282461', 'cui_str': 'Clinical Trials, Phase 3 as Topic'}, {'cui': 'C1260720', 'cui_str': 'Pronto'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0587119', 'cui_str': 'Mealtimes'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0049716', 'cui_str': ""6-thioguanosine 5'-diphosphate""}]",,0.14673,"In comparison to lispro, mealtime URLi resulted in statistically significantly lower 1- and 2-h PPG excursions during the mixed-meal tolerance test.","[{'ForeName': 'Junnosuke', 'Initials': 'J', 'LastName': 'Miura', 'Affiliation': ""Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.""}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Imori', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan. imori_makoto@lilly.com.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nishiyama', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Imaoka', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00892-0'] 2556,32725682,The efficacy of medical treatment for adenomyosis after adenomyomectomy.,"AIMS To compare the efficacy of gonadotropin-releasing hormone agonist (GnRH-a) and GnRH-a + levonorgestrel-releasing intrauterine system (LNG-IUS) after adenomyomectomy for improved adenomyosis-associated symptoms. METHODS Overall, 193 patients with adenomyosis included in this study were categorized into three groups: adenomyomectomy (n = 57, group 1), adenomyomectomy + GnRH-a (n = 83, group 2) and adenomyomectomy + GnRH-a + LNG-IUS (n = 53, group 3). Visual Analog Scale (VAS) scores and uterine volumes were determined to evaluate the severity of adenomyosis. Dysmenorrhea improvement and uterine volume were the main outcomes. RESULTS The VAS scores of all patients reduced from 7.3 (6.0, 8.5) to 0 (0, 0.6) at the 6 months after surgery, which were significantly higher in group 1 compared to other groups (P < 0.05). In groups 1, 2 and 3, there were 14, 7 and 4 patients, respectively, who suffered dysmenorrhea recurrence. The mean recurrent-free-survival (RFS) was 51.6 ± 2.4, 58.0 ± 1.2 and 58.3 ± 1.0 months, respectively, which was significantly shorter in group 1 (P < 0.05). The dysmenorrhea recurrences were 26.3%, 6.1%, 5.9% in groups 1, 2 and 3, respectively, at the 36 months, which was significantly higher in group 1 (P < 0.01). Significantly decreased uterine volumes were observed in all patients from 222.2 (147.6, 350.4) to 77.0 (65.9, 94.1) mL (P < 0.05) at the 6 month after surgery. CONCLUSION Treatment GnRH-a and LNG-IUS after surgery could significantly reduce the recurrence and prolong the RFS. It seemed that the use of LNG-IUS was beneficial for a lower recurrence in long-term follow-up.",2020,It seemed that the use of LNG-IUS was beneficial for a lower recurrence in long-term follow-up.,['193 patients with adenomyosis'],"['adenomyomectomy\u2009+\u2009GnRH-a', 'gonadotropin-releasing hormone agonist (GnRH-a) and GnRH-a\u2009+\u2009levonorgestrel-releasing intrauterine system (LNG-IUS', 'LNG-IUS', 'adenomyomectomy\u2009+\u2009GnRH', 'adenomyomectomy']","['recurrence and prolong the RFS', 'suffered dysmenorrhea recurrence', 'Dysmenorrhea improvement and uterine volume', 'mean recurrent-free-survival (RFS', 'dysmenorrhea recurrences', 'uterine volumes', 'Visual Analog Scale (VAS) scores and uterine volumes', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0341858', 'cui_str': 'Endometriosis of uterus'}]","[{'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0023566', 'cui_str': 'Levonorgestrel'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C4293370', 'cui_str': 'Intrauterine System'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0013390', 'cui_str': 'Dysmenorrhea'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}]",193.0,0.0551487,It seemed that the use of LNG-IUS was beneficial for a lower recurrence in long-term follow-up.,"[{'ForeName': 'Qiuju', 'Initials': 'Q', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Yuan', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Ni', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Qianwei', 'Initials': 'Q', 'LastName': 'Zhen', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Chang', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}, {'ForeName': 'Guoyun', 'Initials': 'G', 'LastName': 'Wang', 'Affiliation': 'Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, China.'}]",The journal of obstetrics and gynaecology research,['10.1111/jog.14376'] 2557,32725695,Effects of blood flow restriction on muscle size and gene expression in muscle during immobilization: A pilot study.,"PURPOSE Muscle mass is known to rapidly decrease with muscle disuse. Previous reports suggest that repetitive blood flow restriction (BFR) mitigates the reduction of muscle mass with disuse. However, the effects of BFR on muscle atrophy and gene expression levels in muscle during cast immobilization have not been clarified. METHODS To investigate the effect of BFR on muscle atrophy and gene expression levels during cast immobilization in humans, we recruited 10 healthy males who were randomly divided into the control and BFR treatment groups. All subjects were immobilized with a cast for 14 days. BFR treatment was conducted only in the BFR group. We evaluated cross sectional area (CSA) of thigh muscles by magnetic resonance imaging before and 14 days after cast immobilization. A percutaneous biopsy of the vastus lateralis muscle (VL) was performed before and 1, 7, and 14 days after cast immobilization. Expression of genes related to muscle atrophy and synthesis were evaluated using real-time PCR. RESULTS The CSA of the VL and the thigh flexor muscles were significantly decreased in both groups; however, percent decrease in CSA was significantly smaller in the BFR group compared with the control group. In two-way repeated ANOVA analysis, the time × treatment interaction in gene expression of the muscle-specific ubiquitin ligases muscle ring finger 1 (MuRF1) was significant, and elevated MURF1 expression level by cast immobilization was seemed to be suppressed by the BFR treatment. CONCLUSION BFR treatment may prevent reduced VL and thigh flexor muscles and increased MuRF1 expression level during cast immobilization. Further study is required to confirm these results.",2020,"The CSA of the VL and the thigh flexor muscles were significantly decreased in both groups; however, percent decrease in CSA was significantly smaller in the BFR group compared with the control group.","['humans, we recruited 10 healthy males who were randomly divided into the control and BFR treatment groups', 'muscle during immobilization']","['blood flow restriction', 'BFR', 'repetitive blood flow restriction (BFR']","['reduced VL and thigh flexor muscles and increased MuRF1 expression level', 'muscle size and gene expression', 'CSA of the VL and the thigh flexor muscles', 'elevated MURF1 expression level', 'CSA', 'muscle atrophy and gene expression levels']","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043237', 'cui_str': 'Organization, World Health'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0332286', 'cui_str': 'Into'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]","[{'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0039866', 'cui_str': 'Thigh structure'}, {'cui': 'C0521164', 'cui_str': 'Annular shape'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0010362', 'cui_str': 'Cross Sectional Analysis'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0026846', 'cui_str': 'Muscle atrophy'}]",10.0,0.0159256,"The CSA of the VL and the thigh flexor muscles were significantly decreased in both groups; however, percent decrease in CSA was significantly smaller in the BFR group compared with the control group.","[{'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Kakehi', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Yoshifumi', 'Initials': 'Y', 'LastName': 'Tamura', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Kubota', 'Affiliation': 'Department of Sports Medicine, Juntendo University Graduate School of Health and Sports Science, Chiba, Japan.'}, {'ForeName': 'Kageumi', 'Initials': 'K', 'LastName': 'Takeno', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Minako', 'Initials': 'M', 'LastName': 'Kawaguchi', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Keishoku', 'Initials': 'K', 'LastName': 'Sakuraba', 'Affiliation': 'Department of Sports Medicine, Juntendo University Graduate School of Health and Sports Science, Chiba, Japan.'}, {'ForeName': 'Ryuzo', 'Initials': 'R', 'LastName': 'Kawamori', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Watada', 'Affiliation': 'Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan.'}]",Physiological reports,['10.14814/phy2.14516'] 2558,32725758,Innovations in Practice: A randomised controlled feasibility trial of Behavioural Activation as a treatment for young people with depression.,"BACKGROUND Behavioural Activation (BA) treatment effectively reduces symptoms of depression in adults and is more cost-effective than more complex therapies. Two recent systematic reviews of BA for depression in young people highlighted the need for more studies in this area. METHODS In order to evaluate the acceptability of BA treatment for adolescents with depression and the feasibility of conducting a trial of this intervention in Child and Adolescent Mental Health Services (CAMHS), 22 patients from across three sites were randomised to BA or usual CAMHS care. Existing CAMHS staff were trained to deliver the manualised intervention via a brief course. Following treatment, young people and their parents/carers were asked to complete a feedback survey. Symptoms and functioning were assessed at 3- and 6-month follow-up. The trial was registered with the ISRCTN Registry (ref: ISRCTN52147450; https://www.isrctn.com/). RESULTS Recruitment targets were achieved through screening large numbers of CAMHS service users. Intervention adherence by the participating adolescents was high (median number of completed BA sessions was seven out of a total of eight). There were tentative suggestions of improvements following treatment; a large change in a positive direction for the BA group, but not for usual care, was observed by visual comparisons of mean scores on measures of depression, self-esteem and functioning. No adverse events were reported. CONCLUSIONS The findings suggest that BA in this setting is acceptable and warrants evaluation via a fully powered randomised controlled trial.",2020,"No adverse events were reported. ","['adolescents with depression', 'Practice', 'young people with depression', 'young people and their parents/carers', 'Child and Adolescent Mental Health Services (CAMHS), 22 patients from across three sites were randomised to BA or usual CAMHS care']","['Behavioural Activation', 'Behavioural Activation (BA']","['adverse events', 'depression, self-esteem and functioning']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0025355', 'cui_str': 'Mental health service'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205145', 'cui_str': 'Site'}]",[],"[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",22.0,0.226135,"No adverse events were reported. ","[{'ForeName': 'Charlotte E W', 'Initials': 'CEW', 'LastName': 'Kitchen', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Tiffin', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Lewis', 'Affiliation': 'School of Social and Political Science, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Gega', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Ekers', 'Affiliation': 'Department of Health Sciences, University of York, York, UK.'}]",Child and adolescent mental health,['10.1111/camh.12415'] 2559,32725772,"Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer.","BACKGROUND Standard treatment for patients with limited stage small cell lung cancer (LS SCLC) is concurrent platinum-etoposide chemotherapy and thoracic radiotherapy (TRT). Up to 30% of patients are cured, but severe toxicity is common, and we are not able to identify those who are cured or those who experience severe toxicity before chemoradiotherapy commences. Studies of other cancer patients show that low muscle mass and muscle radiodensity are associated with inferior survival and that a high drug dose per kilogram lean body mass (LBM) is associated with more toxicity, but this has not been investigated in LS SCLC. We analysed patients from a randomized trial comparing two schedules of TRT (n = 157) to investigate the prognostic and predictive role of these muscle measures in LS SCLC. METHODS Patients from a trial comparing once daily hypofractionated with twice daily hyperfractionated TRT were analysed. The skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), and LBM were assessed from baseline computed tomography scans at the L3 level using the SliceOMatic software. RESULTS Images at the L3 level were available for 122 patients (77.7%). Median age was 64 years, 18% had performance status 2, and 38% had stage III. Grade 3-4 toxicity was observed in 89%, and 5% died from treatment-related side effects. Overall, the median overall survival was 23 months, and the 5 year survival was 25%. Median LBM was 45.2 (range: 16-65) kg, the median SMI 44.8 (range: 29-77) cm 2 /m 2 , and the median SMD 39.3 (range 16-62) HU. There were no significant associations between survival and any of the muscle measures in the univariable analyses (SMI: P = 0.906, SMD: P = 0.829) or in multivariable analyses adjusting for baseline characteristics (SMI: P = 0.836, SMD: P = 0.260). A higher cisplatin dose per kilogram LBM in the first course significantly increased the risk of grade 3-4 haematological toxicity (P = 0.011) and neutropenic infections (P = 0.012). CONCLUSIONS Patients who received a high dose of cisplatin per kilogram LBM had more haematological toxicity and neutropenic infections than other patients. None of the muscle measures were independent prognostic factors for survival in our cohort of LS SCLC patients who underwent standard chemoradiotherapy.",2020,"There were no significant associations between survival and any of the muscle measures in the univariable analyses (SMI: P = 0.906, SMD: P = 0.829) or in multivariable analyses adjusting for baseline characteristics (SMI: P = 0.836, SMD: P = 0.260).","['Patients from a trial comparing once', 'patients with limited stage small cell lung cancer (LS SCLC', 'Median age was 64\xa0years, 18% had performance status 2, and 38% had stage III', 'patients with limited stage small cell lung cancer']","['TRT', 'cisplatin per kilogram LBM', 'platinum-etoposide chemotherapy and thoracic radiotherapy (TRT', 'cisplatin', 'standard chemoradiotherapy', 'daily hypofractionated with twice daily hyperfractionated TRT']","['skeletal muscle index (SMI), skeletal muscle radiodensity (SMD), and LBM', 'severe toxicity', 'survival', 'survival, and toxicity', 'median overall survival', 'haematological toxicity and neutropenic infections', 'Median LBM', 'Grade 3-4 toxicity', 'risk of grade 3-4 haematological toxicity', 'neutropenic infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0278725', 'cui_str': 'Small cell lung cancer limited stage'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0149925', 'cui_str': 'Small cell carcinoma of lung'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}]","[{'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0439209', 'cui_str': 'kg'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1167779', 'cui_str': 'Neutropenic infection'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.376505,"There were no significant associations between survival and any of the muscle measures in the univariable analyses (SMI: P = 0.906, SMD: P = 0.829) or in multivariable analyses adjusting for baseline characteristics (SMI: P = 0.836, SMD: P = 0.260).","[{'ForeName': 'Tarje Onsøien', 'Initials': 'TO', 'LastName': 'Halvorsen', 'Affiliation': 'Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, 7491, Norway.'}, {'ForeName': 'Christine Damgaard', 'Initials': 'CD', 'LastName': 'Valan', 'Affiliation': 'Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, 7491, Norway.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Slaaen', 'Affiliation': 'Department of Internal Medicine, Innlandet Hospital Trust, Hamar, Norway.'}, {'ForeName': 'Bjørn Henning', 'Initials': 'BH', 'LastName': 'Grønberg', 'Affiliation': 'Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, 7491, Norway.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12583'] 2560,32725848,Efficacy of digital cognitive behavioral therapy for moderate-to-severe symptoms of generalized anxiety disorder: A randomized controlled trial.,"BACKGROUND Cognitive behavioral therapy (CBT) is an efficacious intervention for generalized anxiety disorder (GAD). Digital CBT may provide a scalable means of delivering CBT at a population level. We investigated the efficacy of a novel digital CBT program in those with GAD for outcomes of anxiety, worry, depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. METHODS This online, two-arm parallel-group superiority randomized controlled trial compared digital CBT with waitlist control in 256 participants with moderate-to-severe symptoms of GAD. Digital CBT (Daylight), was delivered using participants' own smartphones. Online assessments took place at baseline (Week 0; immediately preceding randomization), mid-intervention (Week 3; from randomization), post-intervention (Week 6; primary endpoint), and follow-up (Week 10). RESULTS Overall, 256 participants were randomized and intention-to-treat analysis found Daylight reduced symptoms of anxiety compared with waitlist control at post-intervention, reflecting a large effect size (adjusted difference [95% CI]: 3.22 [2.14, 4.31], d = 1.08). Significant improvements were found for measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. CONCLUSION Digital CBT (Daylight) appears to be safe and efficacious for symptoms of anxiety, worry, and further measures of mental health compared with waitlist control in individuals with GAD.",2020,"Significant improvements were found for measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. ","['moderate-to-severe symptoms of generalized anxiety disorder', '256 participants', '256 participants with moderate-to-severe symptoms of GAD', 'individuals with GAD']","['Digital CBT (Daylight', 'digital cognitive behavioral therapy', 'digital CBT with waitlist control', 'novel digital CBT program', 'Cognitive behavioral therapy (CBT']","['anxiety, worry, depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life', 'symptoms of anxiety', 'measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life']","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0003469', 'cui_str': 'Anxiety disorder'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0233481', 'cui_str': 'Worried'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",256.0,0.101366,"Significant improvements were found for measures of worry; depressive symptoms, sleep difficulty, wellbeing, and participant-specific quality of life. ","[{'ForeName': 'Jenna R', 'Initials': 'JR', 'LastName': 'Carl', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Christopher B', 'Initials': 'CB', 'LastName': 'Miller', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Alasdair L', 'Initials': 'AL', 'LastName': 'Henry', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Davis', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Stott', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Jasper A J', 'Initials': 'JAJ', 'LastName': 'Smits', 'Affiliation': 'Department of Psychology, The University of Texas at Austin, Austin, Texas.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Emsley', 'Affiliation': ""Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Gu', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Shin', 'Affiliation': 'Big Health Inc., San Francisco, California.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Otto', 'Affiliation': 'Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.'}, {'ForeName': 'Michelle G', 'Initials': 'MG', 'LastName': 'Craske', 'Affiliation': 'Anxiety and Depression Research Centre (ADRC), University of California, Los Angeles, California.'}, {'ForeName': 'Kate E A', 'Initials': 'KEA', 'LastName': 'Saunders', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Guy M', 'Initials': 'GM', 'LastName': 'Goodwin', 'Affiliation': 'Department of Psychiatry, University of Oxford, Oxford, UK.'}, {'ForeName': 'Colin A', 'Initials': 'CA', 'LastName': 'Espie', 'Affiliation': 'Big Health Inc., San Francisco, California.'}]",Depression and anxiety,['10.1002/da.23079'] 2561,32725861,Randomized controlled trial comparing Parent Led Therapist Supervised Articulation Therapy (PLAT) with routine intervention for children with speech disorders associated with cleft palate.,"BACKGROUND A total of 68% of pre-school children with cleft palate have speech problems requiring speech therapy. There is a lack of access to regular targeted therapy. Parent training leads to positive outcomes in early communication skills in cleft palate and non-cleft speech disorders. Connected health has been used to address inadequate access to therapy, providing intervention to those who would not otherwise receive therapy. AIMS To evaluate the speech, activity and participation outcomes of Parent Led, Therapist Supervised, Articulation Therapy (PLAT) compared with routine speech therapy intervention in parent-child dyads. METHODS & PROCEDURES A total of 44 children, aged 2.9-7.5 years, were included in a two-centre, two-phase randomized controlled trial. Informed consent and assent were obtained. Participants and speech and language therapists (SLTs) were unblinded to the groups. Parents, in the parent-trained group (n = 23), attended 2 days' training, received a detailed speech therapy programme, and undertook intervention over 12 weeks supported by the cleft specialist SLT using FaceTime and one face-to-face session. In the control arm (n = 21), parent-child dyads received six therapy sessions over 12 weeks with a research SLT, comparable with usual care. Speech recordings were undertaken pre- and post-intervention. Percent consonant correct (PCC) was analysed by external SLTs blinded to the time and group. Activity and participation were measured using the Intelligibility in Context Scale (ICS) and Focus on Outcomes for Children Under Six (FOCUS) questionnaire. OUTCOMES & RESULTS There was no evidence of an interaction between Time and Group or an overall statistical difference between groups for PCC scores. There was a statistically significant difference over time for both groups (words: p < 0.002; confidence interval (CI) = 9.38-16.27; d = 0.57; sentences: p < 0.002; CI = 16.04-25.97; d = 0.23). Effect sizes were medium for words and small for sentences. For intelligibility and participation, there was no evidence of an interaction between Time and Group or an overall statistical difference between groups. A statistically significant difference over time was found for intelligibility (F = 29.97, d.f. = 1, 42, p < 0.001, 95 % CI = 1.45-3.15 d = 0.46) and for participation (F = 14.19, d.f. = 1, 41, p < 0.001 95% CI = 7.63-25.03; d = 0.36) with FOCUS results indicating clinically meaningful (parent-led group) and significant (control group) change in participation. CONCLUSIONS & IMPLICATIONS PLAT can be as effective as routine care in changing speech, activity and participation outcomes for children with cleft palate, when supported by a specialist cleft SLT using connected health. What this paper adds What is already known on this subject Over 50% of children with cleft palate require speech therapy. However, there is a lack of timely, accessible speech therapy services in the UK and Ireland. Previous studies have shown that parents can deliver therapy effectively, and that connected health can support the delivery of speech therapy. This study aims to provide evidence that parent-led therapy with the supervision of a specialist cleft therapist using FaceTime is effective. What this paper adds to existing knowledge This randomized controlled trial indicates that parents can be trained to deliver therapy for children with cleft palate speech disorders, under the supervision of an SLT. This approach results in improved speech, activity and participation outcomes similar to routine care. What are the potential or actual clinical implications of this work? This study indicates that both parent-led articulation therapy and routine care showed meaningful gains in speech, activity and participation, and that parent-led articulation therapy when supported by a cleft SLT using connected health could be an additional service delivery model for children with cleft palate speech disorders.",2020,There was a statistically significant difference over time for both groups (words: p < 0.002; confidence interval (CI) = 9.38-16.27; d = 0.57; sentences: p < 0.002; CI = 16.04-25.97; d = 0.23).,"['children with speech disorders associated with cleft palate', 'children with cleft palate speech disorders, under the supervision of an SLT', 'cleft palate and non-cleft speech disorders', 'Participants and speech and language therapists (SLTs', 'children with cleft palate require speech therapy', 'children with cleft palate speech disorders', 'Children', 'A total of 68% of pre-school children with cleft palate have speech problems requiring speech therapy', 'children with cleft palate', '44 children, aged 2.9-7.5 years', 'parent-child dyads']","['Parent Led, Therapist Supervised, Articulation Therapy (PLAT', 'detailed speech therapy programme, and undertook intervention over 12 weeks supported by the cleft specialist SLT using FaceTime and one face-to-face session', 'routine speech therapy intervention', 'Parent Led Therapist Supervised Articulation Therapy (PLAT) with routine intervention']","['intelligibility', 'Percent consonant correct (PCC', 'Intelligibility in Context Scale (ICS', 'Activity and participation']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037822', 'cui_str': 'Speech disorder'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0008925', 'cui_str': 'Cleft palate'}, {'cui': 'C0038842', 'cui_str': 'Supervision'}, {'cui': 'C0205242', 'cui_str': 'Cleaved'}, {'cui': 'C0402015', 'cui_str': 'Speech and language therapist'}, {'cui': 'C0009460', 'cui_str': 'Communication disorder'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008100', 'cui_str': 'Preschool child'}, {'cui': 'C0395016', 'cui_str': 'Speech problem'}, {'cui': 'C4517641', 'cui_str': '2.9'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009460', 'cui_str': 'Communication disorder'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205242', 'cui_str': 'Cleaved'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0205547', 'cui_str': 'Routine'}]","[{'cui': 'C0589416', 'cui_str': 'Intelligibility'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}, {'cui': 'C4273753', 'cui_str': 'Intelligibility in Context Scale'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",44.0,0.0894954,There was a statistically significant difference over time for both groups (words: p < 0.002; confidence interval (CI) = 9.38-16.27; d = 0.57; sentences: p < 0.002; CI = 16.04-25.97; d = 0.23).,"[{'ForeName': 'Triona', 'Initials': 'T', 'LastName': 'Sweeney', 'Affiliation': 'Speech at Home, Dublin, Ireland.'}, {'ForeName': 'Fran', 'Initials': 'F', 'LastName': 'Hegarty', 'Affiliation': ""Children's Health Ireland.""}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Powell', 'Affiliation': 'South Thames Cleft Service, London, UK.'}, {'ForeName': 'Liane', 'Initials': 'L', 'LastName': 'Deasy', 'Affiliation': 'formerly Loughlinstown Health Centre, Dublin, Ireland (RIP).'}, {'ForeName': ""Myra O'"", 'Initials': 'MO', 'LastName': 'Regan', 'Affiliation': 'Trinity College, Dublin, Ireland.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Sell', 'Affiliation': 'Centre for Outcomes and Experience Research in Health, Impairment and Disability (ORCHID), Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.'}]",International journal of language & communication disorders,['10.1111/1460-6984.12542'] 2562,32725873,"Antihypertensive efficacy and safety of a standardized herbal medicinal product of Hibiscus sabdariffa and Olea europaea extracts (NW Roselle): A phase-II, randomized, double-blind, captopril-controlled clinical trial.","Hypertension is a public health concern that needs immediate attention upon diagnosis. The demand for natural alternatives is on the rise; Hibiscus sabdariffa and Olea europaea are traditionally used for hypertension management in Egypt. In this study, we aimed to investigate the antihypertensive efficacy and safety of two doses of an herbal product of Hibiscus sabdariffa calyxes and Olea europaea leaves (NW Roselle) in Egyptian patients with grade 1 essential hypertension. We equally randomized 134 patients to receive captopril 25 mg, low-dose NW Roselle, or high-dose NW Roselle BID for 8 weeks. No significant decrease was found in systolic blood pressure or diastolic blood pressure when we compared low-dose NW Roselle and high-dose NW Roselle to captopril (p > .05). In all groups, mean reduction in BP at 8 weeks was significant; 16.4/9.9 mmHg (p < .0001), 15.4/9.6 mmHg (p < .0001), and 14.9/9.4 mmHg (p < .0001) with captopril, low-dose NW Roselle, and high-dose NW Roselle respectively. In addition, low-dose NW Roselle induced a significant reduction in the mean level of triglycerides (17.56 mg/dL; p = .038). In conclusion, NW Roselle had comparable antihypertensive efficacy and safety to captopril in Egyptian patients with grade 1 essential hypertension.",2020,No significant decrease was found in systolic blood pressure or diastolic blood pressure when we compared low-dose NW Roselle and high-dose NW Roselle to captopril (p > .05).,"['Egyptian patients with grade 1 essential hypertension', '134 patients to receive']","['herbal product of Hibiscus sabdariffa calyxes and Olea europaea leaves (NW Roselle', 'captopril', 'standardized herbal medicinal product of Hibiscus sabdariffa and Olea europaea extracts (NW Roselle', 'captopril 25\u2009mg, low-dose NW Roselle, or high-dose NW Roselle BID']","['mean level of triglycerides', 'Antihypertensive efficacy and safety', 'antihypertensive efficacy and safety', 'systolic blood pressure or diastolic blood pressure', 'mean reduction in BP']","[{'cui': 'C0013717', 'cui_str': 'Egyptian language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0085580', 'cui_str': 'Essential hypertension'}, {'cui': 'C4517565', 'cui_str': '134'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C3255680', 'cui_str': 'Hibiscus sabdariffa calyx extract'}, {'cui': 'C3255786', 'cui_str': 'Olea europaea leaf extract'}, {'cui': 'C1207898', 'cui_str': 'Roselle'}, {'cui': 'C0006938', 'cui_str': 'Captopril'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1122969', 'cui_str': 'Common Olive Tree'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0984502', 'cui_str': 'Captopril 25 MG'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0048106', 'cui_str': ""4-benzamido-4'-isothiocyanostilbene-2,2'-disulfonate""}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0003364', 'cui_str': 'Hypotensive agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",134.0,0.0542563,No significant decrease was found in systolic blood pressure or diastolic blood pressure when we compared low-dose NW Roselle and high-dose NW Roselle to captopril (p > .05).,"[{'ForeName': 'Nabil', 'Initials': 'N', 'LastName': 'Elkafrawy', 'Affiliation': 'Internal Medicine and Diabetology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Younes', 'Affiliation': 'Internal Medicine Department, Medical Division, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Naguib', 'Affiliation': 'Faculty of Medicine, Cardiology and Angiology, Alexandria University, Alexandria, Egypt.'}, {'ForeName': 'Hytham', 'Initials': 'H', 'LastName': 'Badr', 'Affiliation': 'Faculty of Medicine, Internal Medicine, Diabetes and Endocrinology, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Shimaa', 'Initials': 'S', 'LastName': 'Kamal Zewain', 'Affiliation': 'Faculty of Medicine, Internal Medicine, Diabetes and Endocrinology, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Mai', 'Initials': 'M', 'LastName': 'Kamel', 'Affiliation': 'Faculty of Medicine, Internal Medicine, Diabetes and Endocrinology, Menoufia University, Menoufia, Egypt.'}, {'ForeName': 'Gehan Fawzy Abdel', 'Initials': 'GFA', 'LastName': 'Raoof', 'Affiliation': 'Pharmacognosy Department, Pharmaceutical and Drug Research Industries Division, National Research Centre, Giza, Egypt.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'M El-Desoky', 'Affiliation': 'Molecular Biology, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Sadat City, Egypt.'}, {'ForeName': 'Shanaz', 'Initials': 'S', 'LastName': 'Mohamed', 'Affiliation': 'School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Malaysia.'}]",Phytotherapy research : PTR,['10.1002/ptr.6792'] 2563,32725875,Randomized controlled and double-blinded study of Caphosol versus saline oral rinses in pediatric patients with cancer.,"BACKGROUND Oral mucositis (OM) is a significant side effect of cancer treatment. The purpose of this study was to compare topically administered Caphosol to saline rinses in the prevention of mucositis in pediatric cancer patients. PROCEDURE A controlled, double-blinded, and randomized clinical crossover study recruited patients between 2 to 17.99 years of age who were diagnosed with a malignancy and were receiving either high-dose methotrexate (≥1 g/m 2 ), anthracycline, or cisplatin chemotherapy (NCT0280733). All patients received two 7-day cycles of the mouth rinses; that is, one cycle of Caphosol and one cycle of saline in a randomized order. Oral changes and symptoms were evaluated using the World Health Organisation (WHO) toxicity scale and the Children's International Mucositis Evaluation Scale (ChIMES). The primary endpoint was the frequency and severity of OM and oral symptoms. RESULTS A total of 56 patients were recruited to the study, of whom 45 were randomized with a median age of 6.5 years (range 2.1-17.1 years). No cases of severe OM were observed. Grade ≥ 3 oral symptoms were present at least once in six (13%) patients during the Caphosol cycle and 13 (29%) patients during the saline cycle (P = .12). The peak of symptom scores was evident at around day 4-7 after administration of the chemotherapy with no marked differences between the rinse solutions. Multivariable regression analysis did not indicate a benefit of using Caphosol over the saline solution. CONCLUSIONS No difference in prevention of oral mucositis was observed between the use of Caphosol or saline rinses.",2020,The peak of symptom scores was evident at around day 4-7 after administration of the chemotherapy with no marked differences between the rinse solutions.,"['patients between 2 to 17.99\xa0years of age who were diagnosed with a malignancy and were receiving either high-dose methotrexate (≥1\xa0g/m 2 ', 'A total of 56 patients were recruited to the study, of whom 45 were randomized with a median age of 6.5\xa0years (range 2.1-17.1\xa0years', 'pediatric cancer patients', 'pediatric patients with cancer']","['anthracycline, or cisplatin chemotherapy', 'Caphosol versus saline oral rinses', 'Caphosol']","['Grade\xa0≥', 'frequency and severity of OM and oral symptoms', 'prevention of oral mucositis', 'peak of symptom scores', ""World Health Organisation (WHO) toxicity scale and the Children's International Mucositis Evaluation Scale (ChIMES"", 'severe OM']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C4068876', 'cui_str': '2.1'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}]","[{'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}]","[{'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0038362', 'cui_str': 'Stomatitis'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0043236', 'cui_str': 'Worldwide Health'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0333355', 'cui_str': 'Inflammatory disease of mucous membrane'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C1848392', 'cui_str': 'Coloboma, congenital heart disease, ichthyosiform dermatosis, intellectual disability ear anomaly syndrome'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",56.0,0.23572,The peak of symptom scores was evident at around day 4-7 after administration of the chemotherapy with no marked differences between the rinse solutions.,"[{'ForeName': 'Egle', 'Initials': 'E', 'LastName': 'Immonen', 'Affiliation': 'Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Liisa', 'Initials': 'L', 'LastName': 'Aine', 'Affiliation': 'Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Atte', 'Initials': 'A', 'LastName': 'Nikkilä', 'Affiliation': 'Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Mataleena', 'Initials': 'M', 'LastName': 'Parikka', 'Affiliation': 'Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Grönroos', 'Affiliation': 'Department of Pediatrics, Turku University Hospital, Turku, Finland.'}, {'ForeName': 'Kaisa', 'Initials': 'K', 'LastName': 'Vepsäläinen', 'Affiliation': 'Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Sauli', 'Initials': 'S', 'LastName': 'Palmu', 'Affiliation': 'Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Helminen', 'Affiliation': 'Research, Development and Innovation Centre, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Timo', 'Initials': 'T', 'LastName': 'Peltomäki', 'Affiliation': 'Department of Ear and Oral Diseases, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Olli', 'Initials': 'O', 'LastName': 'Lohi', 'Affiliation': 'Tampere Center for Child Health Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}]",Pediatric blood & cancer,['10.1002/pbc.28520'] 2564,32726041,[Randomized double-blind parallel controlled multicenter trial of Reyanning Mixture in treatment of acute tonsillitis].,"This study is a randomized controlled trial of Reyanning Mixture in the treatment of acute tonsillitis. According to the ratio of 1∶1∶1, a total of 144 patients were randomly divided into Reyanning Mixture group(RYN), Reyanning Mixture+Amoxicillin Capsules group(RYN+Amoxil) and Amoxicillin Capsules group(Amoxil), with 48 cases in each group, in order to evaluate the efficacy and safety of RYN alone or combined with Amoxil in the treatment of acute tonsillitis, and provided high-quality evidences for treatment of infectious diseases with traditional Chinese medicine and reduced use of antibiotics. The dosage of RYN was 20 mL, 3 times a day, 100 mL/bottle, oral for 7 days, and Amoxil dosage was 0.5 g, 3 times a day, 0.5 g×12 tablets/plate, oral for 7 days. A total of 144 cases were included, 3 cases were excluded(1 case was mistakenly included, 2 cases did not take drugs after inclu-ded), and a total of 141 cases were included in the full analysis set(FAS). The results showed statistical differences in the recovery time of the disease, the disappearance rate of fever on the 3 rd day and the disappearance rate of tonsillar redness and swelling between RYN and Amoxil. There were statistical differences in the cure rate of disease, recovery time of disease, body temperature recovery time, fever disappearance rate on the 3 rd day, pharynx swelling and pain disappearance rate and tonsil swelling disappearance rate between the RYN+Amoxil and Amoxil, but with no significant difference in the above aspects compared with RYN. The DDD of antibiotic use in RYN+Amoxil was significantly lower than that in Amoxil(P<0.01). According to the findings, when RYN was used alone in the treatment of acute tonsillitis, it was superior to Amoxil in time of recovery, short-term improvement of fever and redness and swelling of tonsil. Compared with RYN+Amoxil, there was no difference in cure rate of disease, recovery time of disease, body temperature recovery time, short-term improvement of fever, swelling of pharynx and swelling of tonsil, with a better efficacy than Amoxil. The clinical effect of RYN was similar to that of combined Amoxil in the treatment of acute tonsillitis, and RYN was superior to Amoxil in the time of recovery, short-term improvement of fever and redness and swelling of tonsil, with no adverse event or adverse reaction. RYN+Amoxil can significantly reduce the DDD value of antibiotics in the treatment of acute tonsillitis, with significant clinical advantages over Amoxil.",2020,"RYN+Amoxil can significantly reduce the DDD value of antibiotics in the treatment of acute tonsillitis, with significant clinical advantages over Amoxil.","['A total of 144 cases were included, 3 cases were excluded(1 case was mistakenly included, 2 cases did not take drugs after inclu-ded), and a total of 141 cases were included in the full analysis set(FAS', 'acute tonsillitis', '144 patients']","['RYN alone or combined with Amoxil', 'RYN+Amoxil', 'Reyanning Mixture', 'Reyanning Mixture+Amoxicillin Capsules group(RYN+Amoxil) and Amoxicillin Capsules group(Amoxil']","['disappearance rate of tonsillar redness and swelling between RYN and Amoxil', 'fever and redness and swelling of tonsil', 'DDD value of antibiotics', 'efficacy and safety', 'recovery time of the disease, the disappearance rate of fever', 'cure rate of disease, recovery time of disease, body temperature recovery time, fever disappearance rate on the 3 rd day, pharynx swelling and pain disappearance rate and tonsil swelling disappearance rate', 'fever and redness and swelling of tonsil, with no adverse event or adverse reaction', 'DDD of antibiotic use in RYN+Amoxil', 'cure rate of disease, recovery time of disease, body temperature recovery time, short-term improvement of fever, swelling of pharynx and swelling of tonsil']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4760627', 'cui_str': '144'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C4517572', 'cui_str': '141'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0001361', 'cui_str': 'Acute tonsillitis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}]","[{'cui': 'C0040421', 'cui_str': 'Tonsillar structure (palatine)'}, {'cui': 'C0041834', 'cui_str': 'Erythema'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}, {'cui': 'C0439962', 'cui_str': 'Mixture'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002645', 'cui_str': 'Amoxicillin'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0011037', 'cui_str': 'DDD'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0031354', 'cui_str': 'Pharyngeal structure'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0549123', 'cui_str': 'Large tonsils'}, {'cui': 'C1963761', 'cui_str': 'No adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}]",144.0,0.0560318,"RYN+Amoxil can significantly reduce the DDD value of antibiotics in the treatment of acute tonsillitis, with significant clinical advantages over Amoxil.","[{'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Lyu', 'Affiliation': 'Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.'}, {'ForeName': 'Cui', 'Initials': 'C', 'LastName': 'Yang', 'Affiliation': 'Beijing First Integrated Traditional Chinese and Western Medicine Hospital Beijing 100021, China.'}, {'ForeName': 'Lian-Xin', 'Initials': 'LX', 'LastName': 'Wang', 'Affiliation': 'Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.'}, {'ForeName': 'Yan-Ming', 'Initials': 'YM', 'LastName': 'Xie', 'Affiliation': 'Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.'}, {'ForeName': 'Xue-Qing', 'Initials': 'XQ', 'LastName': 'Yu', 'Affiliation': 'the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou 450004, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Gu', 'Affiliation': 'Beijing Chaoyang Hospital, Capital Medical University Beijing 100043, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gao', 'Affiliation': 'Wangjing Hospital, China Academy of Chinese Medical Sciences Beijing 100102, China.'}, {'ForeName': 'Jing-Xiao', 'Initials': 'JX', 'LastName': 'Zhang', 'Affiliation': 'School of Statistics, Renmin University of China Beijing 100872, China.'}, {'ForeName': 'Xiao-Kang', 'Initials': 'XK', 'LastName': 'Yu', 'Affiliation': 'School of Statistics, Renmin University of China Beijing 100872, China.'}]",Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,['10.19540/j.cnki.cjcmm.20200420.501'] 2565,32726075,Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option.,"Inhalation therapy is integral in the management of patients with chronic obstructive pulmonary disease (COPD). Specifically, intravenous augmentation therapy is available to patients with alpha-1 antitrypsin deficiency (AATD), although there is insufficient alpha-1 antitrypsin (AAT) delivery to the lungs to modify airways inflammation. In contrast, the inhaled route allows replacement therapy to reach the target site of action and with higher AAT levels. Patients certainly support the inhalation route as an alternative to intravenous injections, obviating repetitive needle insertion and allowing treatment empowerment rather than dependency on traveling to specialized units. The difficulty with inhalation has been the ability to target the formulation to the pathophysiological site of disease: the emphysematous lung parenchyma of the small alveolated airways. Recent advances have suggested nebulizers as being able to deliver an adequate dose, consistently and reproducibly, and, coupled with developments in formulation science, allowed replacement therapy to reach the epithelial lining fluid of the small airways. The bench science has been translated to the first randomized, placebo-controlled clinical trial to study the effects of nebulized AAT, which, although not meeting the primary endpoint of prolonging time to first exacerbation, showed this treatment modality was safe and achievable in a large patient cohort. Indeed, learning from this trial suggests the importance of choosing the right clinical endpoints, and recent key advances in lung physiology indices allow better assessment of the ""silent zone"" of small airways disease. Knowledge from other respiratory diseases will complement treating patients with AATD, where there is considerable innovation in aerosol science and inhalation medicine directed at utilizing the inhaled route. Indeed, it could be postulated that the inhaled route may not only achieve local pulmonary therapeutic benefit, but through systemic absorption and controlled pharmacokinetic profiling, the formulation may reach and treat liver disease.",2020,"The bench science has been translated to the first randomized, placebo-controlled clinical trial to study the effects of nebulized AAT, which, although not meeting the primary endpoint of prolonging time to first exacerbation, showed this treatment modality was safe and achievable in a large patient cohort.","['patients with chronic obstructive pulmonary disease (COPD', 'patients with alpha-1 antitrypsin deficiency (AATD']","['Inhalation therapy', 'intravenous augmentation therapy', 'Aerosolized Alpha-1 Antitrypsin', 'nebulized AAT', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0221757', 'cui_str': 'Alpha-1-antitrypsin deficiency'}]","[{'cui': 'C0021459', 'cui_str': 'Inhalation therapy procedure'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332509', 'cui_str': 'Increased size'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002191', 'cui_str': 'alpha 1-Antitrypsin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.0240576,"The bench science has been translated to the first randomized, placebo-controlled clinical trial to study the effects of nebulized AAT, which, although not meeting the primary endpoint of prolonging time to first exacerbation, showed this treatment modality was safe and achievable in a large patient cohort.","[{'ForeName': 'Omar S', 'Initials': 'OS', 'LastName': 'Usmani', 'Affiliation': 'National Heart and Lung Institute, Imperial College London, United Kingdom.'}]","Chronic obstructive pulmonary diseases (Miami, Fla.)",['10.15326/jcopdf.7.3.2019.0179'] 2566,32452181,[Application of pain pressure threshold test in lumbar intervertebral disc herniation study].,"OBJECTIVE To quantify pain pressure threshold(PPT) in the patients with lumbar intervertebral disc herniation before and after treatment, and to study the clinical effects of the PPT test in lumbar intervertebral disc herniation. METHODS From January to December 2017, 59 patients with lumbar intervertebral disc hernation were treated, and another 59 normal persons were recruited as the normal control group. Visual analogue scale (VAS) was used to measure the patient's subjective pain intensity at admission, and the pain threshold of lumbar posterior joints was measured by the tenderness gauge. The pain threshold was measured three times with an interval of 1 min at the most painful posterior joints and the contralateral posterior joints, and the average value was recorded as the T-value.All patients were treated with one course of conservative treatment ( Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation). VAS score and pain threshold of posterior lumbar joints were measured after the treatment. One lumbar posterior joint was randomly selected in the normal control group to measure the pain threshold. RESULTS (1)The patient group and the normal control group were comparable. There was no significant difference in age, body height, body weight and BMI between the two groups( P >0.05). (2) The pressure pain threshold test was consistent:variance analysis on the T-value before treatment [(4.72±2.14) kg / cm 2 , (4.96±2.10) kg / cm 2 , (5.11±2.09) kg / cm 2 ] of the affected posterior joint, the T-value after treatment [(7.38±2.36) kg / cm 2 , (7.62±2.51) kg / cm 2 , (7.58±2.47) kg / cm 2 ], the T-value of before treatment [(7.18±2.80) kg / cm 2 , (7.19±2.68) kg / cm 2 , (7.20±2.69) kg / cm 2 ] of the contralateral posterior joint, T value after treatment [(9.54±2.89) kg / cm 2 , (9.76±3.01) kg / cm 2 , (9.77±3.09) kg / cm 2 ]; and normal joint T-value [(12.23±1.56) kg / cm 2 , (12.51±1.48) kg / cm 2 , (12.6±1.63) kg / cm 2 ] showed that there were no significant differences in the three successive measurements of pain threshold ( P >0.05). (3) After conservative treatment, the pain threshold of the affected side[(7.58±2.38) kg / cm 2 ] and the contralateral lumbar posterior joints [(9.70±2.92) kg / cm 2 ] increased significantly, but T-value of the affected side was still lower than that of the contralateral side, and T value of the both sides were lower than that of the normal group [(12.48±1.44) kg / cm 2 ]. The T-value of the affected side and the contralateral side had significant difference between before and after treatment ( P <0.05). After treatment, there was significant difference in T-value between the affected side and the contralateral side ( P <0.05);there were significant differences in T-value among the affected side, contralateral side and the normal group( P <0.05). (4)Greater the subjective pain intensity of the patient was lower the posterior joint pain threshold of the affected side would be. As the subjective pain intensity decreased, the posterior joint pain threshold of the lumbar spine also increased. There was a significant difference in the VAS score before and after treatment ( P <0.05). Multiple regression analysis showed that the correlation coefficient r between the VAS score before and after treatment and the corresponding T-value of the affected side were significantly different( P <0.05), and the corresponding T-value of the contralateral side were not significantly different( P >0.05). CONCLUSION The pressure pain threshold test can accurately evaluate the pain intensity and its changing patterns in the lumbar posterior joint. The pain pressure threshold test is clinically significantin the lumbar disc herniation.",2020,"There was no significant difference in age, body height, body weight and BMI between the two groups( P >0.05).","['patients with lumbar intervertebral disc herniation before and after treatment', 'One lumbar posterior joint', 'From January to December 2017, 59 patients with lumbar intervertebral disc hernation were treated, and another 59 normal persons were recruited as the normal control group', 'lumbar intervertebral disc herniation study']","['conservative treatment ( Fengshi spine fixed-point rotation reduction plus routine dehydration and anti-inflammation', 'pain pressure threshold test']","['VAS score and pain threshold of posterior lumbar joints', 'posterior joint pain threshold of the lumbar spine', 'VAS score', 'contralateral posterior joint, T value', 'T-value', 'Visual analogue scale (VAS', 'corresponding T-value of the contralateral side', 'pain intensity', 'pain threshold', 'contralateral lumbar posterior joints', 'subjective pain intensity at admission, and the pain threshold of lumbar posterior joints', 'normal joint T-value', 'subjective pain intensity', 'age, body height, body weight and BMI']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0242362', 'cui_str': 'Intervertebral disc prolapse'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0021815', 'cui_str': 'Structure of intervertebral disc'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0459914', 'cui_str': 'Conservative therapy'}, {'cui': 'C0037949', 'cui_str': 'Structure of vertebral column'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0011175', 'cui_str': 'Dehydration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]","[{'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C0162703', 'cui_str': 'Pain threshold'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0224590', 'cui_str': 'Lumbar spine joint structure'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0024091', 'cui_str': 'Bone structure of lumbar vertebra'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]",59.0,0.0260142,"There was no significant difference in age, body height, body weight and BMI between the two groups( P >0.05).","[{'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Zhao', 'Affiliation': ""Air Force General Hospital of People's Liberation Army of China, Beijing 100000, China.""}, {'ForeName': 'Chun-Zheng', 'Initials': 'CZ', 'LastName': 'Zhu', 'Affiliation': ""Air Force General Hospital of People's Liberation Army of China, Beijing 100000, China.""}, {'ForeName': 'Huan', 'Initials': 'H', 'LastName': 'Yang', 'Affiliation': ""Air Force General Hospital of People's Liberation Army of China, Beijing 100000, China.""}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Guo', 'Affiliation': ""Air Force General Hospital of People's Liberation Army of China, Beijing 100000, China.""}]",Zhongguo gu shang = China journal of orthopaedics and traumatology,['10.12200/j.issn.1003-0034.2020.05.009'] 2567,31609422,High-fat Overfeeding Does Not Exacerbate Rapid Changes in Forearm Glucose and Fatty Acid Balance During Immobilization.,"CONTEXT Physical inactivity and high-fat overfeeding have been shown to independently induce insulin resistance. OBJECTIVE Establish the contribution of muscle disuse and lipid availability to the development of inactivity-induced insulin resistance. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS 20 healthy males underwent 7 days of forearm cast immobilization combined with a fully controlled eucaloric diet (n = 10, age 23 ± 2 yr, body mass index [BMI] 23.8 ± 1.0 kg·m-2) or a high-fat diet (HFD) providing 50% excess energy from fat (high-fat diet, n = 10, age 23 ± 2 yr, BMI 22.4 ± 0.8 kg·m-2). MAIN OUTCOME MEASURES Prior to casting and following 2 and 7 days of immobilization, forearm glucose uptake (FGU) and nonesterified fatty acid (NEFA) balance were assessed using the arterialized venous-deep venous (AV-V) forearm balance method following ingestion of a mixed macronutrient drink. RESULTS 7 days of HFD increased body weight by 0.9 ± 0.2 kg (P = 0.002), but did not alter fasting, arterialized whole-blood glucose and serum insulin concentrations or the associated homeostatic model assessment of insulin resistance or Matsuda indices. Two and 7 days of forearm immobilization led to a 40 ± 7% and 52 ± 7% decrease in FGU, respectively (P < 0.001), with no difference between day 2 and 7 and no effect of HFD. Forearm NEFA balance tended to increase following 2 and 7 days of immobilization (P = 0.095). CONCLUSIONS Forearm immobilization leads to a rapid and substantial decrease in FGU, which is accompanied by an increase in forearm NEFA balance but is not exacerbated by excess dietary fat intake. Altogether, our data suggest that disuse-induced insulin resistance of glucose metabolism occurs as a physiological adaptation in response to the removal of muscle contraction.",2020,"Two and 7 days of forearm immobilization led to a 40 ± 7% and 52 ± 7% decrease in FGU, respectively (P < 0.001), with no difference between day 2 and 7 and no effect of HFD.","['20 healthy males underwent 7 days of', 'n = 10, age 23 ± 2 yr, body mass index']","['forearm cast immobilization combined with a fully controlled eucaloric diet', 'High-fat Overfeeding']","['FGU', 'body weight', 'fasting, arterialized whole-blood glucose and serum insulin concentrations', 'Forearm NEFA balance', 'forearm glucose uptake (FGU) and nonesterified fatty acid (NEFA) balance', 'Forearm Glucose and Fatty Acid Balance', 'forearm NEFA balance']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0179686', 'cui_str': 'Cast'}, {'cui': 'C0020944', 'cui_str': 'Immobilization - action'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0015677', 'cui_str': 'Fat'}]","[{'cui': 'C0016536', 'cui_str': 'Forearm structure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood'}, {'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}]",20.0,0.0278584,"Two and 7 days of forearm immobilization led to a 40 ± 7% and 52 ± 7% decrease in FGU, respectively (P < 0.001), with no difference between day 2 and 7 and no effect of HFD.","[{'ForeName': 'Marlou L', 'Initials': 'ML', 'LastName': 'Dirks', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Benjamin T', 'Initials': 'BT', 'LastName': 'Wall', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Britt', 'Initials': 'B', 'LastName': 'Otten', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'Cruz', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Mandy V', 'Initials': 'MV', 'LastName': 'Dunlop', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Barker', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}, {'ForeName': 'Francis B', 'Initials': 'FB', 'LastName': 'Stephens', 'Affiliation': 'Department of Sport and Health Sciences, College of Life and Environmental Sciences, University of Exeter, UK.'}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgz049'] 2568,31808717,Tailored texts: An application of regulatory fit to text messages designed to reduce high-risk drinking.,"This study used the regulatory focus/fit framework to compare the impact of text message wording on college students' drinking behaviors. In this 2 × 3 × 2 pre-test/post-test experiment, participants ( N  = 279) were randomly assigned to one of the three groups: messages matching regulatory focus (congruent group), messages mismatching regulatory focus (incongruent group), and general health messages (control group). Messages were tailored by regulatory fit (prevention-oriented or promotion-oriented). Mixed factorial analyses of covariance revealed that prevention-oriented individuals who received text messages incongruent with their regulatory focus reported drinking alcohol for more hours and were more likely to consume a higher quantity of drinks than participants in the congruent or control group. These findings suggest that health messages mismatched to a receiver's regulatory focus might exacerbate unhealthy behavior.",2020,Mixed factorial analyses of covariance revealed that prevention-oriented individuals who received text messages incongruent with their regulatory focus reported drinking alcohol for more hours and were more likely to consume a higher quantity of drinks than participants in the congruent or control group.,"[""college students' drinking behaviors""]","['messages matching regulatory focus (congruent group), messages mismatching regulatory focus (incongruent group), and general health messages (control group']",[],"[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0013124', 'cui_str': 'Drinking Behavior'}]","[{'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0000936', 'cui_str': 'Ocular accommodation'}, {'cui': 'C0439853', 'cui_str': 'Congruent'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1321310', 'cui_str': 'Incongruous'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],279.0,0.0177878,Mixed factorial analyses of covariance revealed that prevention-oriented individuals who received text messages incongruent with their regulatory focus reported drinking alcohol for more hours and were more likely to consume a higher quantity of drinks than participants in the congruent or control group.,"[{'ForeName': 'Elizabeth M', 'Initials': 'EM', 'LastName': 'Glowacki', 'Affiliation': 'Northeastern University, USA.'}, {'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Bernhardt', 'Affiliation': ''}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'McGlone', 'Affiliation': 'University of Texas at Austin, USA.'}]",Health informatics journal,['10.1177/1460458219889279'] 2569,32721163,Effects of Weight Loss on Obstructive Sleep Apnea Severity: 10-year Results of the Sleep AHEAD Study.,"RATIONALE Weight loss is recommended to treat obstructive sleep apnea (OSA). OBJECTIVE Determine whether initial benefit of intensive lifestyle intervention (ILI) for weight loss on OSA severity is maintained at 10 years. METHODS 10-year follow-up polysomnograms of 134 of 264 adults in Sleep AHEAD with overweight/obesity, type 2 diabetes mellitus and OSA randomized to ILI for weight loss or diabetes support and education (DSE). MEASUREMENT Change in apnea-hypopnea index (AHI). MAIN RESULTS Mean weight losses of ILI participants of 10.7±0.7 (SE), 7.4±0.7, 5.1±0.7, and 7.1±0.8 kg at 1, 2, 4, and 10 years, respectively, were significantly greater than the 1-kg weight loss at 1, 2, and 4 years and 3.5±0.8 kg weight loss at 10 years for the DSE group (P values≤0.0001). AHI was lower with ILI than DSE by 9.7, 8.0, 7.9 events/hr at 1, 2, and 4 years, respectively (P values≤0.0004) and 4.0 events/hr at 10 years (P=0.109). Change in AHI over time was related to amount of weight loss, baseline AHI, visit year (P values<0.0001) and intervention independent of weight change (P=0.01). OSA remission at 10 years was more common with ILI (34.4%) than DSE (22.2%). CONCLUSIONS Participants with OSA and type 2 diabetes mellitus receiving ILI for weight loss had reduced OSA severity at 10 years. No difference in OSA severity was present between ILI and DSE groups at 10 years. Improvement in OSA severity over the 10-year period with ILI was related to change in body weight, baseline AHI and intervention independent of weight change.",2020,"OSA remission at 10 years was more common with ILI (34.4%) than DSE (22.2%). ","['obstructive sleep apnea (OSA', 'Obstructive Sleep Apnea Severity', '10-year follow-up polysomnograms of 134 of 264 adults in Sleep AHEAD with overweight/obesity, type 2 diabetes mellitus and OSA randomized to ILI for weight loss or diabetes support and education (DSE', 'Participants with OSA and type 2 diabetes mellitus']","['intensive lifestyle intervention (ILI', 'Weight Loss']","['OSA severity', 'weight change', 'OSA remission', 'Mean weight losses', 'kg weight loss', '1-kg weight loss', 'weight loss, baseline AHI, visit year', 'apnea-hypopnea index (AHI']","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}]","[{'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0005911', 'cui_str': 'Weight change'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2111846', 'cui_str': 'Apnea Hypopnea Index'}, {'cui': 'C0439234', 'cui_str': 'year'}]",,0.0137996,"OSA remission at 10 years was more common with ILI (34.4%) than DSE (22.2%). ","[{'ForeName': 'Samuel T', 'Initials': 'ST', 'LastName': 'Kuna', 'Affiliation': 'Philadelphia VAMC, Philadlephia, Pennsylvania, United States; Samuel.Kuna@va.gov.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Reboussin', 'Affiliation': 'Wake Forest University, 8676, Winston-Salem, North Carolina, United States.'}, {'ForeName': 'Elsa S', 'Initials': 'ES', 'LastName': 'Strotmeyer', 'Affiliation': 'University of Pittsburgh, 6614, Pittsburgh, Pennsylvania, United States.'}, {'ForeName': 'Richard P', 'Initials': 'RP', 'LastName': 'Millman', 'Affiliation': 'Brown University, Providence, Rhode Island, United States.'}, {'ForeName': 'Gary', 'Initials': 'G', 'LastName': 'Zammit', 'Affiliation': 'Clinilabs, New York, New York, United States.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Walkup', 'Affiliation': 'Wake Forest University, 8676, Winston-Salem, North Carolina, United States.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Wadden', 'Affiliation': 'Temple University, 6558, Philadelphia, Pennsylvania, United States.'}, {'ForeName': 'Rena R', 'Initials': 'RR', 'LastName': 'Wing', 'Affiliation': 'Brown University, 6752, Providence, Rhode Island, United States.'}, {'ForeName': 'F Xavier', 'Initials': 'FX', 'LastName': 'Pi-Sunyer', 'Affiliation': 'Columbia University, 5798, New York, New York, United States.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Spira', 'Affiliation': 'Johns Hopkins University Bloomberg School of Public Health, 25802, Baltimore, Maryland, United States.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Foster', 'Affiliation': 'Weight Watchers International, 43385, New York, New York, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201912-2511OC'] 2570,32721189,Preferred Music Genre Benefits During Strength Tests: Increased Maximal Strength and Strength-Endurance and Reduced Perceived Exertion.,"The ability to increase muscle strength seems to be influenced by extrinsic factors such as the characteristics of an exercise environment. Given that many people train while listening to music, the music environment is an important research topic. However, no studies have investigated whether a preferred music genre differentially affects strength production when compared to a non-preferred music genre. This study evaluated the influence of listening to varied conditions of musical genre preference on maximal strength and strength-endurance testing, and on ratings of perceived exertion (RPE). We submitted 20 young men to three different listening conditions during strength testing: (a) preferred music genre (PMG), (b) non-preferred music genre (NPMG), and (c) no music (NM), with the order of these conditions randomized. We measured maximal strength with a handgrip dynamometer, strength-endurance through the participant's maximal repetition execution in the lat-pulldown exercise, and RPE by participant-completed Borg's scales at the end of the strength tests. Using three-way analyses of variances (ANOVAs) and a significance level of p  < 0.05, we found that participants produced higher maximal strength, performed more repetitions of the lat-pulldown exercise, and reported decreased RPE in the PMG condition, compared to the NPMG (maximal strength p  < 0.01, strength-endurance p  < 0.01, RPE p  = 0.016) and NM (maximal strength p  < 0.01, strength-endurance p  < 0.01, RPE p  = 0.023) conditions. Individually determined PMG appears to improve maximal strength and strength-endurance performance during exercise, and to decrease RPE in the PMG condition.",2020,"Individually determined PMG appears to improve maximal strength and strength-endurance performance during exercise, and to decrease RPE in the PMG condition.",['20 young men to three different'],"['listening conditions during strength testing: (a) preferred music genre (PMG), (b) non-preferred music genre (NPMG), and (c) no music (NM']","['ratings of perceived exertion (RPE', 'maximal strength and strength-endurance performance', 'strength production', 'Maximal Strength and Strength-Endurance and Reduced Perceived Exertion', 'maximal strength', 'maximal strength with a handgrip dynamometer, strength-endurance']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C1444752', 'cui_str': 'Status during'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0026867', 'cui_str': 'Music'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}]",20.0,0.0210131,"Individually determined PMG appears to improve maximal strength and strength-endurance performance during exercise, and to decrease RPE in the PMG condition.","[{'ForeName': 'Nilson Ribeiro Dos Santos', 'Initials': 'NRDS', 'LastName': 'Silva', 'Affiliation': 'School of Physical Education and Sport of Ribeirão Preto, University of São Paulo.'}, {'ForeName': 'Felipe Gabriel', 'Initials': 'FG', 'LastName': 'Rizardi', 'Affiliation': 'School of Physical Education and Sport of Ribeirão Preto, University of São Paulo.'}, {'ForeName': 'Rafael Akira', 'Initials': 'RA', 'LastName': 'Fujita', 'Affiliation': 'College of Nursing of Ribeirão Preto, University of São Paulo.'}, {'ForeName': 'Marina Mello', 'Initials': 'MM', 'LastName': 'Villalba', 'Affiliation': 'College of Nursing of Ribeirão Preto, University of São Paulo.'}, {'ForeName': 'Matheus Machado', 'Initials': 'MM', 'LastName': 'Gomes', 'Affiliation': 'School of Physical Education and Sport of Ribeirão Preto, University of São Paulo.'}]",Perceptual and motor skills,['10.1177/0031512520945084'] 2571,32721210,Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma: The TASMA Randomized Trial.,"RATIONALE Bronchial Thermoplasty (BT) is a bronchoscopic treatment for severe asthma targeting airway smooth muscle (ASM). Observational studies have shown ASM mass reduction after BT but appropriate control groups are lacking. Furthermore, as treatment response is variable, identifying optimal candidates for BT treatment is important. AIMS First, to assess the effect of BT on ASM mass and second, to identify patient characteristics that correlate with BT-response. METHODS Severe asthma patients (n=40) were randomized to immediate (n=20) or delayed (n=20) BT-treatment. Prior to randomization, clinical, functional, blood and airway biopsy data were collected. In the delayed control group, re-assessment, including biopsies, was performed after 6 months of standard clinical care, followed by BT. In both groups, post-BT data including biopsies were obtained after 6 months. ASM mass (% positive desmin or α-smooth muscle actin area in the total biopsy) was calculated with automated digital analyses software. Associations between baseline characteristics and Asthma Control and Asthma Quality of Life Questionnaire (ACQ/AQLQ) improvement were explored. RESULTS Median ASM mass decreased by >50% in the immediate BT group (n=17) versus no change in the delayed control group (n=19) (p=0.0004). In the immediate group ACQ scores improved with -0.79 (-1.61;0.02 IQR) compared to 0.09 (-0.25;1.17 IQR) in the delayed group (p=0.006). AQLQ scores improved with 0.83 (-0.15;1.69 IQR) versus -0.02 (-0.77;0.75 IQR) (p=0.04). Treatment response in the total group (n=35) was positively associated with serum IgE and eosinophils, but not with baseline ASM mass. CONCLUSION ASM mass significantly decreases after BT when compared to a randomized non-BT treated control group. Treatment response was associated with serum IgE and eosinophil levels but not with ASM mass. Clinical trial registration available at www.clinicaltrials.gov, ID:NCT0222539.",2020,In the immediate group ACQ scores improved with -0.79 (-1.61;0.02 IQR) compared to 0.09 (-0.25;1.17 IQR) in the delayed group (p=0.006).,"['Severe asthma patients (n=40', 'severe asthma targeting airway smooth muscle (ASM', 'Severe Asthma']","['Bronchial Thermoplasty (BT', 'Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction']","['Median ASM mass', 'serum IgE and eosinophil levels', 'Asthma Control and Asthma Quality of Life Questionnaire (ACQ/AQLQ', 'ACQ scores', 'serum IgE and eosinophils', 'AQLQ scores']","[{'cui': 'C0581126', 'cui_str': 'Severe asthma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C1267092', 'cui_str': 'Smooth muscle (tissue)'}]","[{'cui': 'C3854686', 'cui_str': 'Thermoplasty of bronchus'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C1267092', 'cui_str': 'Smooth muscle (tissue)'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0178987', 'cui_str': 'Airway device'}, {'cui': 'C1267092', 'cui_str': 'Smooth muscle (tissue)'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0020846', 'cui_str': 'Immunoglobulin E'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.133815,In the immediate group ACQ scores improved with -0.79 (-1.61;0.02 IQR) compared to 0.09 (-0.25;1.17 IQR) in the delayed group (p=0.006).,"[{'ForeName': 'Annika W M', 'Initials': 'AWM', 'LastName': 'Goorsenberg', 'Affiliation': 'Amsterdam UMC, 522567, University of Amsterdam, Department of Respiratory Medicine, Amsterdam, The Netherlands., Amsterdam, Netherlands.'}, {'ForeName': 'Julia N S', 'Initials': 'JNS', 'LastName': ""d'Hooghe"", 'Affiliation': 'University of Amsterdam, 1234, Department of Respiratory Medicine, Amsterdam, The Netherlands., Amsterdam, Netherlands.'}, {'ForeName': 'Karthikan', 'Initials': 'K', 'LastName': 'Srikanthan', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, 4964, Respiratory Medicine, London, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Nick H T', 'Initials': 'NHT', 'LastName': 'Ten Hacken', 'Affiliation': 'University Medical Center Groningen, Groningen, Netherlands.'}, {'ForeName': 'Els J M', 'Initials': 'EJM', 'LastName': 'Weersink', 'Affiliation': 'Amsterdam University Medical Centres, 522567, Respiratory Medicine, Amsterdam, Netherlands.'}, {'ForeName': 'Joris J T H', 'Initials': 'JJTH', 'LastName': 'Roelofs', 'Affiliation': 'Amsterdam University Medical Centres, 522567, Pathology, Amsterdam, Netherlands.'}, {'ForeName': 'Samuel V', 'Initials': 'SV', 'LastName': 'Kemp', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, 4964, London, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Elisabeth H', 'Initials': 'EH', 'LastName': 'Bel', 'Affiliation': 'Amsterdam University Medical Centres, 522567, Respiratory Medicine, Amsterdam, Netherlands.'}, {'ForeName': 'Pallav L', 'Initials': 'PL', 'LastName': 'Shah', 'Affiliation': 'Royal Brompton and Harefield NHS Foundation Trust, 4964, London, United Kingdom of Great Britain and Northern Ireland.'}, {'ForeName': 'Jouke T', 'Initials': 'JT', 'LastName': 'Annema', 'Affiliation': 'Amsterdam UMC, 522567, University of Amsterdam, Department of Respiratory Medicine, Amsterdam, The Netherlands., Amsterdam, Netherlands.'}, {'ForeName': 'Peter I', 'Initials': 'PI', 'LastName': 'Bonta', 'Affiliation': 'Amsterdam UMC, 522567, University of Amsterdam, Department of Respiratory Medicine, Amsterdam, The Netherlands., Amsterdam, Netherlands; p.i.bonta@amsterdamumc.nl.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201911-2298OC'] 2572,32729244,"Effects of short-term xylitol chewing gum on pro-inflammatory cytokines and Streptococcus mutans: a randomized, placebo-controlled trial.","INTRODUCTION Dental caries is an infectious disease with predominantly of cariogenic bacteria such as Streptococcus mutans (S. mutans). Xylitol is considered as one of the effective agents that can limit this dental infection. In this randomized, placebo-controlled trial, we aimed to evaluate the potential reflection of short-term xylitol consumption on pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) and S. mutans counts by ELISA and qPCR (Quantitative real-time PCR), respectively. METHODS In this study, 154 participants were assigned to two groups, control and xylitol. Dental examination, saliva and swab samples were done at baseline and at 3-week for clinical and microbiological assessment. RESULTS In xylitol group at the end of 3-week, gingival and plaque index scores were significantly decreased with respect to baseline values (p<0.001 and p<0.05, respectively). The salivary concentration of TNF-α, IL-6 and IL-8 were statistically declined at 3-week, more so than those at baseline in xylitol group (p<0.001). S. mutans expression was reduced about 5-fold at 3-week use of xylitol and it was a statistically significant difference compared to baseline (p<0.001). CONCLUSION Intriguingly, even short-term consumption of xylitol might play a favorable role in maintaining the oral health status, possibly as a result of decreasing the release of pro-inflammatory cytokines and the counts of S. mutans. Nonetheless, this investigation warrants further endorsement.",2020,"The salivary concentration of TNF-α, IL-6 and IL-8 were statistically declined at 3-week, more so than those at baseline in xylitol group (p<0.001).",['154 participants'],"['xylitol', 'short-term xylitol chewing gum', 'Xylitol', 'control and xylitol', 'placebo']","['pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) and S. mutans counts by ELISA and qPCR (Quantitative real-time PCR', 'gingival and plaque index scores', 'pro-inflammatory cytokines and Streptococcus mutans', 'S. mutans expression', 'salivary concentration of TNF-α, IL-6 and IL-8']","[{'cui': 'C5191279', 'cui_str': '154'}]","[{'cui': 'C0043369', 'cui_str': 'Xylitol'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0008037', 'cui_str': 'Chewing Gum'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0038402', 'cui_str': 'Streptococcus'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0014441', 'cui_str': 'Enzyme-linked immunosorbent assay'}, {'cui': 'C1709846', 'cui_str': 'Real-Time PCR'}, {'cui': 'C0017562', 'cui_str': 'Gingival structure'}, {'cui': 'C0011390', 'cui_str': 'Dental Plaque Indices'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}]",154.0,0.136313,"The salivary concentration of TNF-α, IL-6 and IL-8 were statistically declined at 3-week, more so than those at baseline in xylitol group (p<0.001).","[{'ForeName': 'Özer', 'Initials': 'Ö', 'LastName': 'Akgül', 'Affiliation': 'Istanbul Aydin University, Faculty of Medicine, Department of Medical Microbiology, Istanbul, Turkey.'}, {'ForeName': 'Aslıopaloğlu', 'Initials': 'A', 'LastName': 'Ak', 'Affiliation': 'Istanbul Aydin University, School of Dentistry, Department of Pedodontics, Istanbul, Turkey.'}, {'ForeName': 'Sevgi', 'Initials': 'S', 'LastName': 'Zorlu', 'Affiliation': 'Istanbul Aydin University, School of Dentistry, Department of Pedodontics, Istanbul, Turkey.'}, {'ForeName': 'Didemner', 'Initials': 'D', 'LastName': 'Özdaş', 'Affiliation': 'Istanbul Aydin University, School of Dentistry, Department of Pedodontics, Istanbul, Turkey.'}, {'ForeName': 'Melisa', 'Initials': 'M', 'LastName': 'Uslu', 'Affiliation': 'Istanbul Aydin University, School of Dentistry, Department of Pedodontics, Istanbul, Turkey.'}, {'ForeName': 'Dilara', 'Initials': 'D', 'LastName': 'Çayirgan', 'Affiliation': 'Istanbul Aydin University, School of Dentistry, Department of Pedodontics, Istanbul, Turkey.'}]",International journal of clinical practice,['10.1111/ijcp.13623'] 2573,32725960,Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling for Improving Lower Limb Motor Function After Stroke: An Exploratory Study.,"BACKGROUND/OBJECTIVES Repetitive transcranial magnetic stimulation (rTMS) has been recognized as a promising intervention for the treatment of post-stroke motor deficits. Here, we explore safety, feasibility, and potential effectiveness of high-frequency rTMS (HF-rTMS) delivered with the Hesed coil (H-coil) during active cycling on paretic lower extremity (LE) motor function in chronic stroke. MATERIALS AND METHODS Twelve subjects with a first-ever stroke were recruited in this double-blind, placebo controlled, crossover study. Eleven sessions of HF-rTMS (40 2s-trains of 20 Hz at 90% resting leg motor threshold) were delivered over the LE motor areas using the H-coil during active cycling for three weeks. Each subject underwent both real and sham rTMS treatments separated by a four-week washout period, in a random sequence. Vital signs were recorded before and after each rTMS session. Any discomfort related to stimulation and side effects were recorded. LE function was also evaluated with Fugl-Meyer assessment (FMA-LE), spasticity was assessed with modified-Ashworth scale and measures of gait speed and endurance (10-meter and 6-min walk tests, respectively) were recorded. RESULTS No participant reported serious adverse effects. During real rTMS, 4 of 12 subjects reported mild side effects including transitory dizziness and muscle twitches on shoulder, so that intensity of stimulation initially set at 90% of RMT was reduced to 80% of RMT on average in these four subjects. Only real treatment was associated with a significant and sustained improvement in FMA-LL (67% responders vs. 9% of the sham). Spasticity significantly ameliorated only after the real rTMS. Real treatment did not offer advantages on walking timed measures when compared with sham. CONCLUSIONS This exploratory study suggests that bilateral HF-rTMS combined with cycling is safe and potentially effective in ameliorating paretic LE motor function and spasticity, rather than gait speed or endurance, in chronic stroke.",2020,"During real rTMS, 4 of 12 subjects reported mild side effects including transitory dizziness and muscle twitches on shoulder, so that intensity of stimulation initially set at 90% of RMT was reduced to 80% of RMT on average in these four subjects.",['Twelve subjects with a first-ever stroke'],"['Repetitive transcranial magnetic stimulation (rTMS', 'HF-rTMS', 'Repetitive Transcranial Magnetic Stimulation With H-Coil Coupled With Cycling', 'high-frequency rTMS (HF-rTMS', 'placebo']","['Lower Limb Motor Function', 'LE function', 'walking timed measures', 'Spasticity', 'gait speed and endurance', 'mild side effects including transitory dizziness and muscle twitches on shoulder', 'FMA-LL', 'Fugl-Meyer assessment (FMA-LE), spasticity', 'serious adverse effects']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0419518', 'cui_str': 'Contraceptive coil'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0205212', 'cui_str': 'High frequency'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0015644', 'cui_str': 'Muscle fasciculation'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",12.0,0.170696,"During real rTMS, 4 of 12 subjects reported mild side effects including transitory dizziness and muscle twitches on shoulder, so that intensity of stimulation initially set at 90% of RMT was reduced to 80% of RMT on average in these four subjects.","[{'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Chieffo', 'Affiliation': 'Neurorehabilitation Department, Hospital San Raffaele, Milan, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Giatsidis', 'Affiliation': 'University Vita-Salute San Raffaele, Milan, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Santangelo', 'Affiliation': 'Experimental Neurophysiology Unit, INSPE - Institute of Experimental Neurology, Hospital San Raffaele, Milan, Italy.'}, {'ForeName': 'Uri', 'Initials': 'U', 'LastName': 'Alyagon', 'Affiliation': 'Department of Life Sciences, Ben-Gurion University, Beer-Sheva, Israel.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Comola', 'Affiliation': 'Neurorehabilitation Department, Hospital San Raffaele, Milan, Italy.'}, {'ForeName': 'Abraham', 'Initials': 'A', 'LastName': 'Zangen', 'Affiliation': 'Department of Life Sciences, Ben-Gurion University, Beer-Sheva, Israel.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Comi', 'Affiliation': 'Neurorehabilitation Department, Hospital San Raffaele, Milan, Italy.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Leocani', 'Affiliation': 'Neurorehabilitation Department, Hospital San Raffaele, Milan, Italy.'}]",Neuromodulation : journal of the International Neuromodulation Society,['10.1111/ner.13228'] 2574,32725998,Impact of Angiotensin II Receptor Blockers on Clinical Outcomes after Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014).,"BACKGROUND AND OBJECTIVES The effectiveness of angiotensin II receptor blockers (ARBs) compared with angiotensin converting enzyme inhibitors (ACEIs) in patients with acute myocardial infarction (AMI) has not been established. We investigated the effects of ARBs on clinical outcomes after percutaneous coronary intervention (PCI) in AMI patients. METHODS Patients receiving ACEIs or ARBs after AMI treated with PCI between January 2005 and December 2014 were selected from the Korean National Health Insurance Service database. The primary endpoint was major cardiovascular adverse event (MACE; all-cause death, myocardial infarct [MI], or stroke). RESULTS We included patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) (medication possession ratio ≥80%). Compared with the ACEI group, the ARB group contained more females (31% vs. 18%), were older (mean, 63 vs. 60 years), and had more comorbidities, including hypertension (62.8% vs. 44.8%), diabetes (33.9% vs. 26.4%), congestive heart failure (7.9% vs. 4.3%), chronic obstructive pulmonary disease (25.5% vs. 18.9%), and end-stage renal disease (1.3% vs. 0.4%) (p<0.001 for all). After propensity score-matching, ARBs were associated with a 23% lower risk of MACE (hazard ratio [HR], 0.774; 95% confidence interval [CI], 0.715-0.838; p<0.001) than ACEIs. ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659-0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638-0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773-0.861; p<0.001). CONCLUSIONS ARB use was associated with a lower risk of MACE, MI, and revascularization than ACEIs in our retrospective analysis of AMI patients who underwent PCI.",2020,"ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659-0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638-0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773-0.861; p<0.001). ","['Patients receiving ACEIs or ARBs after AMI treated with PCI between January 2005 and December 2014 were selected from the Korean National Health Insurance Service database', 'patients regularly taking ACEIs (n=22,331) or ARBs (n=28,533) (medication possession ratio ≥80', 'AMI patients', 'patients with acute myocardial infarction (AMI', 'Patients with Acute Myocardial Infarction Based on Data from the Korean National Health Insurance Database (2005-2014']","['percutaneous coronary intervention (PCI', 'Percutaneous Coronary Intervention', 'ACEI', 'ARB', 'Angiotensin II Receptor Blockers', 'ARBs', 'angiotensin converting enzyme inhibitors (ACEIs', 'angiotensin II receptor blockers (ARBs']","['chronic obstructive pulmonary disease', 'diabetes', 'risk of death', 'major cardiovascular adverse event (MACE; all-cause death, myocardial infarct [MI], or stroke', 'congestive heart failure', 'stage renal disease', 'hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0155626', 'cui_str': 'Acute myocardial infarction'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C0027452', 'cui_str': 'National Health Insurance'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0993637', 'cui_str': 'Data Base'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0521942', 'cui_str': 'Angiotensin II receptor antagonist'}, {'cui': 'C0003015', 'cui_str': 'Angiotensin-converting enzyme inhibitor'}]","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",,0.17824,"ARB use was also associated with a significantly reduced risk of death (HR, 0.741; 95% CI, 0.659-0.834; p<0.001), MI (HR, 0.731; 95% CI, 0.638-0.837; p<0.001), and revascularization (HR, 0.816; 95% CI, 0.773-0.861; p<0.001). ","[{'ForeName': 'Gwang Sil', 'Initials': 'GS', 'LastName': 'Kim', 'Affiliation': 'Department of Cardiology, Sanggye-Paik Hospital, Inje University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Young Guk', 'Initials': 'YG', 'LastName': 'Ko', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea. ygko@yuhs.ac.'}, {'ForeName': 'Yongsung', 'Initials': 'Y', 'LastName': 'Suh', 'Affiliation': 'Department of Cardiology, Myeongji Hospital, Goyang, Korea.'}, {'ForeName': 'Hoyoun', 'Initials': 'H', 'LastName': 'Won', 'Affiliation': 'Cardiovascular & Arrhythmia Center, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sung Jin', 'Initials': 'SJ', 'LastName': 'Hong', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Chul Min', 'Initials': 'CM', 'LastName': 'Ahn', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Jung Sun', 'Initials': 'JS', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Byeong Keuk', 'Initials': 'BK', 'LastName': 'Kim', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Donghoon', 'Initials': 'D', 'LastName': 'Choi', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Myeong Ki', 'Initials': 'MK', 'LastName': 'Hong', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}, {'ForeName': 'Yangsoo', 'Initials': 'Y', 'LastName': 'Jang', 'Affiliation': 'Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea.'}]",Korean circulation journal,['10.4070/kcj.2020.0057'] 2575,32726003,[Large- scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules].,"To scientifically evaluate the intervention effect of Chinese medicine preventive administration(combined use of Huo-xiang Zhengqi Oral Liquid and Jinhao Jiere Granules) on community population in the case of coronavirus disease 2019(COVID-19), a large cohort, prospective, randomized, and parallel-controlled clinical study was conducted. Total 22 065 subjects were included and randomly divided into 2 groups. The non-intervention group was given health guidance only, while the traditional Chinese medicine(TCM) intervention group was given two coordinated TCM in addition to health guidance. The medical instructions were as follows. Huoxiang Zhengqi Oral Liquid: oral before meals, 10 mL/time, 2 times/day, a course of 5 days. Jinhao Jiere Granules: dissolve in boiling water and take after meals, 8 g/time, 2 times/day, a course of 5 days, followed up for 14 days, respectively. The study found that with the intake of medication, the incidence rate of TCM intervention group was basically maintained at a low and continuous stable level(0.01%-0.02%), while the non-intervention group showed an overall trend of continuous growth(0.02%-0.18%) from 3 to 14 days. No suspected or confirmed COVID-19 case occurred in either group. There were 2 cases of colds in the TCM intervention group and 26 cases in the non-intervention group. The incidence of colds in the TCM intervention group was significantly lower(P<0.05) than that in the non-intervention group. In the population of 16-60 years old, the incidence rate of non-intervention and intervention groups were 0.01% and 0.25%, respectively. The difference of colds incidence between the two groups was statistically significant(P<0.05). In the population older than 60 years old, they were 0.04% and 0.21%, respectively. The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference. The protection rate of TCM for the whole population was 91.8%, especially for the population of age 16-60(95.0%). It was suggested that TCM intervention(combined use of Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules) could effectively protect community residents against respiratory diseases, such as colds, which was worthy of promotion in the community. In addition, in terms of safety, the incidence of adverse events and adverse reactions in the TCM intervention group was relatively low, which was basically consistent with the drug instructions.",2020,"The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference.","['community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules', 'community population in the case of coronavirus disease 2019(COVID-19', 'Total 22 065 subjects']","['TCM intervention', 'health guidance only, while the traditional Chinese medicine(TCM) intervention group was given two coordinated TCM in addition to health guidance', 'Chinese medicine preventive administration(combined use of Huo-xiang Zhengqi Oral Liquid and Jinhao Jiere Granules']","['protection rate of TCM', 'incidence rate', 'colds incidence', 'adverse events and adverse reactions', 'incidence of colds']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C1871293', 'cui_str': 'Huoxiang-zhengqi'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0042934', 'cui_str': 'Vocational counseling'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0427184', 'cui_str': 'No incoordination'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0204169', 'cui_str': 'Preventive dental procedure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0010837', 'cui_str': 'Cytoplasmic Granules'}]","[{'cui': 'C0025124', 'cui_str': 'Traditional Chinese Medicine'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009443', 'cui_str': 'Common cold'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}]",22065.0,0.020795,"The incidence of colds in the non-intervention group was higher than that in the intervention group, but not reaching statistical difference.","[{'ForeName': 'Bo-Hua', 'Initials': 'BH', 'LastName': 'Yan', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Zhi-Wei', 'Initials': 'ZW', 'LastName': 'Jiang', 'Affiliation': 'Beijing Key Tech Statistical Consulting Co., Ltd. Beijing 100015, China.'}, {'ForeName': 'Jie-Ping', 'Initials': 'JP', 'LastName': 'Zeng', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jian-Yuan', 'Initials': 'JY', 'LastName': 'Tang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Ding', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jie-Lai', 'Initials': 'JL', 'LastName': 'Xia', 'Affiliation': ""Air Force Military Medical University of People's Liberation Army Xi'an 710032, China.""}, {'ForeName': 'Shao-Rong', 'Initials': 'SR', 'LastName': 'Qin', 'Affiliation': 'Taiji Group Co., Ltd. Chongqing 408000, China.'}, {'ForeName': 'Si-Cen', 'Initials': 'SC', 'LastName': 'Jin', 'Affiliation': 'Taiji Group Co., Ltd. Chongqing 408000, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Na', 'Initials': 'N', 'LastName': 'Zhang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Zhi-Hong', 'Initials': 'ZH', 'LastName': 'Wang', 'Affiliation': 'Chengdu Zhongxiang Pharmaceutical Technology Co., Ltd. Chengdu 610000, China.'}, {'ForeName': 'Hai-Yan', 'Initials': 'HY', 'LastName': 'Li', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Xiao-Ya', 'Initials': 'XY', 'LastName': 'Sang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Li-Na', 'Initials': 'LN', 'LastName': 'Wu', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Shi-Yun', 'Initials': 'SY', 'LastName': 'Tang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Meng-Yao', 'Initials': 'MY', 'LastName': 'Tao', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Qiao-Ling', 'Initials': 'QL', 'LastName': 'Wang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Jun-Dong', 'Initials': 'JD', 'LastName': 'Wang', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Hong-Yan', 'Initials': 'HY', 'LastName': 'Xie', 'Affiliation': 'Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075,China.'}, {'ForeName': 'Qi-Yuan', 'Initials': 'QY', 'LastName': 'Chen', 'Affiliation': 'Yingmenkou Community Service Center Chengdu 610036, China.'}, {'ForeName': 'Sheng-Wen', 'Initials': 'SW', 'LastName': 'Yang', 'Affiliation': ""Xi'anlu Community Service Center Chengdu 610072, China.""}, {'ForeName': 'Nian-Shuang', 'Initials': 'NS', 'LastName': 'Hu', 'Affiliation': 'Jiangxijie Community Service Center Chengdu 610041, China.'}, {'ForeName': 'Jian-Qiong', 'Initials': 'JQ', 'LastName': 'Yang', 'Affiliation': 'Supo Community Service Center Chengdu 610091, China.'}, {'ForeName': 'Xiao-Xia', 'Initials': 'XX', 'LastName': 'Bao', 'Affiliation': 'Caoshi Yuhe Community Service Center Chengdu 610014, China.'}, {'ForeName': 'Qiong', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'Shuangnan Community Service Center Chengdu 610047, China.'}, {'ForeName': 'Xiao-Li', 'Initials': 'XL', 'LastName': 'Yang', 'Affiliation': 'Yulin Community Service Center Chengdu 610044, China.'}, {'ForeName': 'Chang-Yong', 'Initials': 'CY', 'LastName': 'Jiang', 'Affiliation': 'Jinyang Community Service Center Chengdu 610045, China.'}, {'ForeName': 'Hong-Yan', 'Initials': 'HY', 'LastName': 'Luo', 'Affiliation': 'Caotang Community Service Center Chengdu 610072, China.'}, {'ForeName': 'Zheng-Hua', 'Initials': 'ZH', 'LastName': 'Cai', 'Affiliation': 'Xinhua Shaocheng Community Service Center Chengdu 610014, China.'}, {'ForeName': 'Shu-Guang', 'Initials': 'SG', 'LastName': 'Yu', 'Affiliation': 'Chengdu University of Traditional Chinese Medicine Chengdu 611137, China.'}]",Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,['10.19540/j.cnki.cjcmm.20200430.501'] 2576,30632837,Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.,"The GALLIUM trial compared obinutuzumab (GA101, G)-based chemotherapy followed by G monotherapy (G + chemo) for up to two years to rituximab (R)-based chemotherapy followed by R monotherapy (R + chemo) for up to two years in previously untreated follicular lymphoma (FL) patients. We estimated the cost-effectiveness of G + chemo versus R + chemo utilizing GALLIUM trial data and published literature. G + chemo had increased drug costs (undiscounted: $135,200 versus $127,700 for R + chemo), representing a relative increase of 5.9%. However, this was offset by a $6,400 lower cost for disease progression. G + chemo led to increased quality-adjusted life years (QALYs) relative to R + chemo of 0.81 (95% credible range, [CR]: 0.22-1.37), and the overall discounted incremental cost was $1,900 (95% CR: -$7,400 to $8,900). The incremental cost-effectiveness ratio was ∼$2,300 per QALY gained, and the results were highly robust to sensitivity analyses. Treatment with G + chemo compared to R + chemo is cost-effective in previously untreated FL patients in the US.",2019,"G + chemo led to increased quality-adjusted life years (QALYs) relative to R + chemo of 0.81 (95% credible range, [CR]: 0.22-1.37), and the overall discounted incremental cost was $1,900 (95% CR: -$7,400 to $8,900).",[],"['rituximab plus chemotherapy', 'rituximab (R)-based chemotherapy followed by R monotherapy (R\u2009+\u2009chemo', 'G\u2009+\u2009chemo versus R\u2009+\u2009chemo', 'obinutuzumab (GA101, G)-based chemotherapy followed by G monotherapy (G\u2009+\u2009chemo', 'Obinutuzumab plus chemotherapy']","['quality-adjusted life years (QALYs) relative to R\u2009+\u2009chemo', 'incremental cost-effectiveness ratio', 'drug costs', 'cost-effectiveness', 'overall discounted incremental cost']",[],"[{'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C2742503', 'cui_str': 'obinutuzumab'}]","[{'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0392920', 'cui_str': 'Antineoplastic chemotherapy regimen'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0085123', 'cui_str': 'Drug Costs'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0010186', 'cui_str': 'Cost'}]",,0.0465087,"G + chemo led to increased quality-adjusted life years (QALYs) relative to R + chemo of 0.81 (95% credible range, [CR]: 0.22-1.37), and the overall discounted incremental cost was $1,900 (95% CR: -$7,400 to $8,900).","[{'ForeName': 'Gregory F', 'Initials': 'GF', 'LastName': 'Guzauskas', 'Affiliation': 'a Department of Pharmacy , University of Washington , Seattle , WA , USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Masaquel', 'Affiliation': 'b Genentech, Inc. , South San Francisco , CA , USA.'}, {'ForeName': 'Per-Olof', 'Initials': 'PO', 'LastName': 'Thuresson', 'Affiliation': 'c F. Hoffmann-La Roche Ltd. , Basel , Switzerland.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Dawson', 'Affiliation': 'b Genentech, Inc. , South San Francisco , CA , USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Veenstra', 'Affiliation': 'a Department of Pharmacy , University of Washington , Seattle , WA , USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2018.1551532'] 2577,30705097,Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.,"Asparagine levels in cerebrospinal fluid and serum asparaginase activity were monitored in children with acute lymphoblastic leukemia treated with pegylated-asparaginase. The drug was given intravenously at a dose of 2,500 IU/m 2 on days 12 and 26. Serum and cerebrospinal fluid samples obtained on days 33 and 45 were analyzed centrally. Since physiological levels of asparagine in the cerebrospinal fluid of children and adolescents are 4-10 μmol/L, in this study asparagine depletion was considered complete when the concentration of asparagine was ≤0.2 μmol/L, i.e. below the lower limit of quantification of the assay used. Over 24 months 736 patients (AIEOP n=245, BFM n=491) and 903 cerebrospinal fluid samples (n=686 on day 33 and n=217 on day 45) were available for analysis. Data were analyzed separately for the AIEOP and BFM cohorts and yielded superimposable results. Independently of serum asparaginase activity levels, cerebrospinal fluid asparagine levels were significantly reduced during the investigated study phase but only 28% of analyzed samples showed complete asparagine depletion while relevant levels, ≥1 μmol/L, were still detectable in around 23% of them. Complete cerebrospinal fluid asparagine depletion was found in around 5-6% and 33-37% of samples at serum asparaginase activity levels <100 and ≥ 1,500 IU/L, respectively. In this study cerebrospinal fluid asparagine levels were reduced during pegylated-asparaginase treatment, but complete depletion was only observed in a minority of patients. No clear threshold of serum pegylated-asparaginase activity level resulting in complete cerebrospinal fluid asparagine depletion was identified. The consistency of the results found in the two independent data sets strengthen the observations of this study. Details of the treatment are available in the European Clinical Trials Database at https://www.clin-icaltrialsregister.eu/ctr-search/trial/2007-004270-43/IT .",2019,"Independently of serum asparaginase activity levels, cerebrospinal fluid asparagine levels were significantly reduced during the investigated study phase but only 28% of analyzed samples showed complete asparagine depletion while relevant levels, ≥1 μmol/L, were still detectable in around 23% of them.","['Over 24 months 736 patients (AIEOP n=245, BFM n=491) and 903 cerebrospinal fluid samples (n=686 on day 33 and n=217 on day 45', 'children with acute lymphoblastic leukemia treated with', 'children with acute lymphoblastic leukemia treated with pegylated-asparaginase']",['pegylated-asparaginase'],"['cerebrospinal fluid asparagine levels', 'Complete cerebrospinal fluid asparagine depletion', 'Asparagine levels', 'serum pegylated-asparaginase activity level', 'Asparagine levels in cerebrospinal fluid and serum asparaginase activity', 'serum asparaginase activity levels, cerebrospinal fluid asparagine levels']","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292530', 'cui_str': 'Cerebrospinal fluid sample'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}]","[{'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}]","[{'cui': 'C0007806', 'cui_str': 'Cerebrospinal fluid'}, {'cui': 'C0003995', 'cui_str': 'Asparagine'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0333668', 'cui_str': 'Depletion'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0003993', 'cui_str': 'ASPARAGINASE'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",,0.0401236,"Independently of serum asparaginase activity levels, cerebrospinal fluid asparagine levels were significantly reduced during the investigated study phase but only 28% of analyzed samples showed complete asparagine depletion while relevant levels, ≥1 μmol/L, were still detectable in around 23% of them.","[{'ForeName': 'Carmelo', 'Initials': 'C', 'LastName': 'Rizzari', 'Affiliation': 'Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy c.rizzari@asst-monza.it.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Lanvers-Kaminsky', 'Affiliation': ""Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.""}, {'ForeName': 'Maria Grazia', 'Initials': 'MG', 'LastName': 'Valsecchi', 'Affiliation': 'Medical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Ballerini', 'Affiliation': 'Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Matteo', 'Affiliation': 'Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Gerss', 'Affiliation': 'Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Wuerthwein', 'Affiliation': ""Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.""}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Silvestri', 'Affiliation': 'Medical Statistics Unit, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Milan, Italy.'}, {'ForeName': 'Antonella', 'Initials': 'A', 'LastName': 'Colombini', 'Affiliation': 'Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.'}, {'ForeName': 'Valentino', 'Initials': 'V', 'LastName': 'Conter', 'Affiliation': 'Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Biondi', 'Affiliation': 'Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, Monza, Italy.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schrappe', 'Affiliation': 'Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Moericke', 'Affiliation': 'Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Zimmermann', 'Affiliation': 'Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Arend', 'Initials': 'A', 'LastName': 'von Stackelberg', 'Affiliation': 'Pediatric Hematology and Oncology, Charité, Berlin, Germany.'}, {'ForeName': 'Christin', 'Initials': 'C', 'LastName': 'Linderkamp', 'Affiliation': 'Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Frühwald', 'Affiliation': ""Children's Hospital, Augsburg, Germany.""}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Legien', 'Affiliation': 'Pediatrics 5 (Oncology, Hematology, Immunology); Stuttgart Cancer Center; Klinikum Stuttgart - Olgahospital, Stuttgart, Germany.'}, {'ForeName': 'Andishe', 'Initials': 'A', 'LastName': 'Attarbaschi', 'Affiliation': ""Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.""}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Reismüller', 'Affiliation': ""Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Vienna, Austria.""}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Kasper', 'Affiliation': 'Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Smisek', 'Affiliation': 'Czech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Stary', 'Affiliation': 'Czech Paediatric Haematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic.'}, {'ForeName': 'Luciana', 'Initials': 'L', 'LastName': 'Vinti', 'Affiliation': 'Department of Pediatric Hemato-Oncology, Ospedale Bambino Gesù, Rome, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Barisone', 'Affiliation': ""Department of Pediatric Hemato-Oncology, Regina Margherita Children's Hospital, Turin, Italy.""}, {'ForeName': 'Rosanna', 'Initials': 'R', 'LastName': 'Parasole', 'Affiliation': 'Department of Pediatric Hematology-Oncology, Ospedale Pausillipon, Naples, Italy.'}, {'ForeName': 'Concetta', 'Initials': 'C', 'LastName': 'Micalizzi', 'Affiliation': 'Department of Pediatric Hematology-Oncology, IRCCS I.G. Gaslini, Genova, Italy.'}, {'ForeName': 'Massimo', 'Initials': 'M', 'LastName': 'Zucchetti', 'Affiliation': 'Department of Oncology, Laboratory of Cancer Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Boos', 'Affiliation': ""Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Münster, Germany.""}]",Haematologica,['10.3324/haematol.2018.206433'] 2578,30773105,The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors.,,2019,,[],['telemedicine platform'],[],[],"[{'cui': 'C0162648', 'cui_str': 'Telemedicine'}]",[],,0.0412173,,"[{'ForeName': 'Anureet C', 'Initials': 'AC', 'LastName': 'Copeland', 'Affiliation': 'a Department of Hematology/Oncology , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Foster', 'Affiliation': 'a Department of Hematology/Oncology , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Benyam', 'Initials': 'B', 'LastName': 'Muluneh', 'Affiliation': 'b Department of Pharmacy , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Xenakis', 'Affiliation': 'c Department of Biostatistics , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Anastasia', 'Initials': 'A', 'LastName': 'Ivanova', 'Affiliation': 'c Department of Biostatistics , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Frankfurt', 'Affiliation': 'd Department of Hematology/Oncology , Northwestern University , Chicago , IL , USA.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Clayton', 'Affiliation': 'a Department of Hematology/Oncology , University of North Carolina , Chapel Hill , NC , USA.'}, {'ForeName': 'Anderson', 'Initials': 'A', 'LastName': 'Black', 'Affiliation': 'e UNC Rex Healthcare , Raleigh , NC , USA.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Rapchak', 'Affiliation': 'f Leap of Faith Technologies , Crystal Lake , IL , USA.'}, {'ForeName': 'Robert S', 'Initials': 'RS', 'LastName': 'Wehbie', 'Affiliation': 'e UNC Rex Healthcare , Raleigh , NC , USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2018.1551540'] 2579,31013455,Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity.,"BACKGROUND Two major constituents of cannabis are Δ 9 -tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. AIMS We examined the effects of two strains of cannabis and placebo on the human brain's resting-state networks using fMRI. METHODS Seventeen healthy volunteers (experienced with cannabis, but not regular users) underwent three drug treatments and scanning sessions. Treatments were cannabis containing THC (Cann-CBD; 8 mg THC), cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD), and matched placebo cannabis. Seed-based resting-state functional connectivity analyses were performed on three brain networks: the default mode (DMN; defined by positive connectivity with the posterior cingulate cortex: PCC+), executive control (ECN; defined by negative connectivity with the posterior cingulate cortex: PCC-) and salience (SAL; defined by positive connectivity with the anterior insula: AI+) network. RESULTS Reductions in functional connectivity (relative to placebo) were seen in the DMN (PCC+) and SAL (AI+) networks for both strains of cannabis, with spatially dissociable effects. Across the entire salience network (AI+), Cann-CBD reduced connectivity relative to Cann+CBD. The PCC in the DMN was specifically disrupted by Cann-CBD, and this effect correlated with subjective drug effects, including feeling 'stoned' and 'high'. CONCLUSIONS THC disrupts the DMN, and the PCC is a key brain region involved in the subjective experience of THC intoxication. CBD restores disruption of the salience network by THC, which may explain its potential to treat disorders of salience such as psychosis and addiction.",2019,"The PCC in the DMN was specifically disrupted by Cann-CBD, and this effect correlated with subjective drug effects, including feeling 'stoned' and 'high'. ","['Seventeen healthy volunteers (experienced with cannabis, but not regular users']","['THC', 'cannabis with and without cannabidiol', 'cannabis and placebo', 'tetrahydrocannabinol ', 'placebo cannabis', 'CBD', 'cannabis containing THC (Cann-CBD; 8 mg THC), cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD']","['THC) and cannabidiol (CBD', 'functional connectivity']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0205272', 'cui_str': 'Regular'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0024808', 'cui_str': 'Marihuana'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0332256', 'cui_str': 'Containing'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",17.0,0.0928762,"The PCC in the DMN was specifically disrupted by Cann-CBD, and this effect correlated with subjective drug effects, including feeling 'stoned' and 'high'. ","[{'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Wall', 'Affiliation': '1 Invicro London, Hammersmith Hospital, London, UK.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Pope', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Freeman', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Oliwia S', 'Initials': 'OS', 'LastName': 'Kowalczyk', 'Affiliation': '6 Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK.'}, {'ForeName': 'Lysia', 'Initials': 'L', 'LastName': 'Demetriou', 'Affiliation': '1 Invicro London, Hammersmith Hospital, London, UK.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Mokrysz', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Hindocha', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Will', 'Initials': 'W', 'LastName': 'Lawn', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Michael Ap', 'Initials': 'MA', 'LastName': 'Bloomfield', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Abigail M', 'Initials': 'AM', 'LastName': 'Freeman', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Feilding', 'Affiliation': '9 The Beckley Foundation, Oxford, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Nutt', 'Affiliation': '3 Division of Brain Sciences, Imperial College London, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': '2 Clinical Psychopharmacology Unit, University College London, London, UK.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881119841568'] 2580,31491556,Bright light exposure advances consolidation of motor skill accuracy in humans.,"Light has attracted increasing attention as a critical determinant of memory processing. While sleep selectively consolidates newly encoded memories according to their future relevance, the role of light in human memory consolidation is largely unknown. Here, we report how bright light (BL), provided during encoding, influences online and offline consolidation of motor skill learning. We sought to determine whether relatively slower and faster key-press transitions within individuals were differentially consolidated by BL. Healthy human subjects were briefly exposed to either BL (>8000 lx) or control light (CL; <500 lx) during memory encoding at 13:00 h, when light minimally affects circadian phase-shifting, and were retested 24 h later. The effects of BL on online and offline performance gains were determined by accuracy and speed. BL-exposed subjects showed better overall performance accuracy during training and lower overnight accuracy gains after a subsequent night of sleep than did CL-exposed subjects. BL preferentially improved the initially most difficult individual key-press transitions during practice; these were only improved overnight under CL. By contrast, accuracy during what had been the easiest key-press transitions at the beginning of the experiment was unaffected by light conditions or online/offline learning processes. BL effects were not observed for performance speed, mood, or sleep-wake patterns. Brief BL exposure during training may advance motor memory selection and consolidation that optimally meet individual requirements for potential gains, which would otherwise depend on post-training sleep. This suggests a new way of enhancing brain plasticity to compensate for impaired sleep-dependent memory consolidation in neuropsychiatric conditions.",2019,BL-exposed subjects showed better overall performance accuracy during training and lower overnight accuracy gains after a subsequent night of sleep than did CL-exposed subjects.,"['Healthy human subjects', 'humans']","['bright light (BL', 'BL', 'BL (>8000\u202flx) or control light (CL; <500\u202flx) during memory encoding at 13:00\u202fh, when light minimally affects circadian phase-shifting']","['BL effects', 'performance speed, mood, or sleep-wake patterns', 'overall performance accuracy', 'BL']","[{'cui': 'C0080105', 'cui_str': 'Human Subjects'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}]","[{'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C3840857', 'cui_str': '8000'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3816747', 'cui_str': '500'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0423899', 'cui_str': 'Above average intellect'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.017968,BL-exposed subjects showed better overall performance accuracy during training and lower overnight accuracy gains after a subsequent night of sleep than did CL-exposed subjects.,"[{'ForeName': 'Takuya', 'Initials': 'T', 'LastName': 'Yoshiike', 'Affiliation': 'Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Department of Psychiatry, Shiga University of Medical Science, Seta Tsukinowacho, Otsu, Shiga 520-2192, Japan. Electronic address: yoshiike@ncnp.go.jp.'}, {'ForeName': 'Motoyasu', 'Initials': 'M', 'LastName': 'Honma', 'Affiliation': 'Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Department of Physiology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa, Tokyo 142-8555, Japan.'}, {'ForeName': 'Hiroki', 'Initials': 'H', 'LastName': 'Ikeda', 'Affiliation': 'Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Research Center for Overwork-Related Disorders, National Institute of Occupational Safety and Health, 6-21-1 Nagao, Tama-Ku, Kawasaki, Kanagawa 214-8585, Japan.'}, {'ForeName': 'Kenichi', 'Initials': 'K', 'LastName': 'Kuriyama', 'Affiliation': 'Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Department of Sleep-Wake Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8553, Japan; Department of Psychiatry, Shiga University of Medical Science, Seta Tsukinowacho, Otsu, Shiga 520-2192, Japan.'}]",Neurobiology of learning and memory,['10.1016/j.nlm.2019.107084'] 2581,32721437,"Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.","BACKGROUND & AIMS Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it is not clear if these drugs are effective for long-term maintenance of remission. METHODS We performed a double-blind trial to compare the efficacy and safety of 2 doses of a budesonide orodispersible tablet (BOT) vs placebo in maintaining remission of EoE. Maintenance of remission was defined as absence of clinical and histological relapse and no premature withdrawal for any reason. Two hundred and four adults with EoE in clinical and histologic remission, from 29 European study sites, were randomly assigned to groups given BOT 0.5 mg twice daily (n=68), BOT 1.0 mg twice daily (n=68), or placebo twice daily (n=68) for up to 48 weeks. RESULTS At end of treatment, 73.5% of patients receiving BOT 0.5 mg twice daily and 75% receiving BOT 1.0 mg twice daily were in persistent remission, compared with 4.4% of patients in the placebo group (P<.001 for both comparisons of BOT with placebo). Median time to relapse in the placebo group was 87 days. The frequency of adverse events was similar in the BOT and placebo groups. Morning serum levels of cortisol were in the normal range at baseline and did not significantly change during treatment. Four patients receiving BOT developed asymptomatic, low serum levels of cortisol. Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. CONCLUSIONS In a phase 3 trial, up to 48 weeks of treatment with BOT (.5 mg or 1.0 mg, twice daily) was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well tolerated. (Funded by Dr. Falk Pharma GmbH; EudraCT number; 2014-001485-99; ClinicalTrials.gov number, NCT02434029.).",2020,"Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. ","['Patients With Eosinophilic Esophagitis', 'Two hundred and four adults with EoE in clinical and histologic remission, from 29 European study sites']","['budesonide orodispersible tablet (BOT) vs placebo', 'Placebo', 'Budesonide Orodispersible Tablets', 'Swallowed topical-acting corticosteroids', 'BOT 0.5 mg twice daily (n=68), BOT 1.0 mg twice daily (n=68), or placebo', 'BOT', 'placebo']","['Median time to relapse', 'Morning serum levels of cortisol', 'asymptomatic, low serum levels of cortisol', 'frequency of adverse events', 'efficacy and safety', 'effective and well tolerated', 'Clinically manifested candidiasis']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0341106', 'cui_str': 'Eosinophilic esophagitis'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}]","[{'cui': 'C0054201', 'cui_str': 'Budesonide'}, {'cui': 'C2960508', 'cui_str': 'Orodispersible tablet'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0011167', 'cui_str': 'Deglutition'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0006840', 'cui_str': 'Candidiasis'}]",204.0,0.627341,"Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. ","[{'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Straumann', 'Affiliation': 'Swiss EoE Research Group, Olten, Switzerland; Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: alex.straumann@hin.ch.'}, {'ForeName': 'Alfredo J', 'Initials': 'AJ', 'LastName': 'Lucendo', 'Affiliation': 'Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain, and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Spain, Instituto de Investigación Sanitaria Princesa, Madrid, Spain.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Miehlke', 'Affiliation': 'Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany, and Center for Esophageal Disorders, University Hospital Hamburg-Eppendorf, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Vieth', 'Affiliation': 'Institute for Pathology, Klinikum Bayreuth, Bayreuth, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Schlag', 'Affiliation': 'II. Medizinische Klinik, Klinikum rechts der Isar, TU München, Munich, Germany.'}, {'ForeName': 'Luc', 'Initials': 'L', 'LastName': 'Biedermann', 'Affiliation': 'Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Cecilio Santander', 'Initials': 'CS', 'LastName': 'Vaquero', 'Affiliation': 'Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Madrid, Spain, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Spain, Instituto de Investigación Sanitaria Princesa, Madrid, Spain.'}, {'ForeName': 'Constanza', 'Initials': 'C', 'LastName': 'Ciriza de Los Rios', 'Affiliation': 'Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Schmoecker', 'Affiliation': 'Department of Gastroenterology, Sana Klinikum Lichtenberg, Berlin, Germany.'}, {'ForeName': 'Ahmed', 'Initials': 'A', 'LastName': 'Madisch', 'Affiliation': 'Department of Gastroenterology, CRH Clinic Siloah, Hannover, Germany.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Hruz', 'Affiliation': 'Department of Gastroenterology, University Hospital Basel, Basel, Switzerland.'}, {'ForeName': 'Jamal', 'Initials': 'J', 'LastName': 'Hayat', 'Affiliation': ""Department of Gastroenterology, Saint George's University Hospitals NHS Trust, London, United Kingdom.""}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'von Arnim', 'Affiliation': 'Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg, Magdeburg, Germany.'}, {'ForeName': 'Albert Jan', 'Initials': 'AJ', 'LastName': 'Bredenoord', 'Affiliation': 'Department of Gastroenterology and Hepatology, AMC Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schubert', 'Affiliation': 'Gastroenterologist in private practice, Berlin, Germany.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Mueller', 'Affiliation': 'Department of Clinical Research & Development, Dr. Falk Pharma GmbH, Freiburg, Germany.'}, {'ForeName': 'Roland', 'Initials': 'R', 'LastName': 'Greinwald', 'Affiliation': 'Department of Clinical Research & Development, Dr. Falk Pharma GmbH, Freiburg, Germany.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Schoepfer', 'Affiliation': 'Department of Gastroenterology & Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Attwood', 'Affiliation': 'Department of Health Services Research, Durham University, Durham, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Gastroenterology,['10.1053/j.gastro.2020.07.039'] 2582,32721482,Resin composite Core and Fiber Post improved the Fracture parameters of Endodontically-treated Maxillary Premolars with Wedge-shaped Cervical lesions.,"INTRODUCTION The aim of this study was to evaluate the fracture resistance and fracture patterns of endodontically-treated maxillary premolars with wedge-shaped cervical lesions restored with resin composite core with/without a fiber post under non-axial loading. METHODS Sixty extracted human maxillary premolars with two root canals were randomly allocated into 4 groups (n=15). Forty five teeth were prepared a wedge-shaped lesion at the buccal cervical area and root canal treatment. There were three restoration groups: no restoration (EB), restoration with resin composite core (EBC), and restoration with resin composite core and a fiber post (EBP). Intact teeth served as the control group. All teeth were subjected to thermocycling and cyclic loading. A 45 o compressive load was applied to the palatal plane of buccal cusp until tooth fracture. The fracture resistance and facture patterns were analyzed using one-way ANOVA and Chi-square test (α=0.05), respectively. RESULTS The EB group demonstrated the lowest fracture resistance and was significantly different from other groups (P<0.001). The intact teeth presented the highest fracture resistance, which was not significantly different from the EBP group (P>0.05). The failure patterns were significantly different between groups (P<0.001). Most intact teeth fractured coronal to the CEJ level, while most teeth in other groups fractured at the gingival margin of cervical lesion. CONCLUSIONS Endodontically-treated maxillary premolars, with wedge-shaped cervical lesions, restored with fiber posts and resin composite cores had a fracture resistance equivalent to intact teeth. However, their fracture patterns were not improved by the fiber post and resin composite core.",2020,The EB group demonstrated the lowest fracture resistance and was significantly different from other groups (P<0.001).,"['Endodontically-treated Maxillary Premolars with Wedge-shaped Cervical lesions', 'Sixty extracted human maxillary premolars with two root canals', 'Forty five teeth were prepared a wedge-shaped lesion at the buccal cervical area and root canal treatment', 'endodontically-treated maxillary premolars with wedge-shaped cervical lesions restored with resin composite core with/without a fiber post under non-axial loading']",[],"['lowest fracture resistance', 'no restoration (EB), restoration with resin composite core (EBC), and restoration with resin composite core and a fiber post (EBP', 'highest fracture resistance', 'fracture resistance and fracture patterns', 'fracture resistance and facture patterns', 'Fracture parameters', 'failure patterns']","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0024947', 'cui_str': 'Bone structure of maxilla'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0332503', 'cui_str': 'Wedge shape'}, {'cui': 'C0235656', 'cui_str': 'Lesion of cervix'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0035849', 'cui_str': 'Therapy, Root Canal'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0442010', 'cui_str': 'Buccal'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0000696', 'cui_str': 'A Fibers'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C4279935', 'cui_str': 'Axial Loading'}]",[],"[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0009570', 'cui_str': 'Composite Resins'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0000696', 'cui_str': 'A Fibers'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",60.0,0.0211447,The EB group demonstrated the lowest fracture resistance and was significantly different from other groups (P<0.001).,"[{'ForeName': 'Pavita', 'Initials': 'P', 'LastName': 'Tangsripongkul', 'Affiliation': 'Department of Operative Dentistry, Faculty of Dentistry, Chulalongkorn University, 34 Henri Dunant Road, Pathumwan, Bangkok, 10330, Thailand.'}, {'ForeName': 'Thanomsuk', 'Initials': 'T', 'LastName': 'Jearanaiphaisarn', 'Affiliation': 'Department of Operative Dentistry, Faculty of Dentistry, Chulalongkorn University, 34 Henri Dunant Road, Pathumwan, Bangkok, 10330, Thailand. Electronic address: thanomsuk@hotmail.com.'}]",Journal of endodontics,['10.1016/j.joen.2020.07.018'] 2583,32721549,High intensity interval training combined with L-citrulline supplementation: Effects on physical performance in healthy older adults.,"INTRODUCTION The aim of this study was to evaluate the effect of citrulline (CIT) supplementation combined to high intensity interval training (HIIT) on physical performance in healthy older adults. METHODS This study is a secondary analysis from a double-blind, randomized trial. Among the participants (sedentary & inactive older adults aged over 65 yrs), 44 were non obese (BMI <30 kg/m 2 ) and completed the intervention: Placebo + HIIT (PLA; n = 21) or CIT + HIIT (n = 23). All participants ingested either 10 g of CIT supplementation/day or placebo and followed HIIT sessions (30 min/session; cycle: 30 s > 85% of maximal heart rate (HR) and Borg scale >17/20 + 1:50 min at 65% HR and Borg scale between 13 and 16) on an elliptical device 3 times per week over a 12-week period. Body composition, muscle strength, muscle power, functional capacities (unipodal balance; self-paced and fast Timed Up and Go (nTUG; fTUG); chair test; step tests; 4-meter walking test; 6-minute walking test); dietary intake, energy expenditure and biological markers were measured pre and post-intervention. A repeated-measure analysis of variance was used to estimate time (HIIT intervention), group (PLA vs. CIT) and time*group effects. RESULTS The decrease in BMI (p = 0.02) and android fat mass (p = 0.05) were significantly greater in the HIIT+CIT group than in the HIIT+PLA group. Finally, a greater increase in self-paced gait speed (nTUG) (p = 0.02) and fast-paced gait speed (fTUG) (p = 0.03) were also observed in the HIIT+CIT group than in the HIIT+PLA group. CONCLUSION CIT supplementation combined to HIIT is more effective in improving functional capacities and body composition in healthy older adults than HIIT alone.",2020,"Finally, a greater increase in self-paced gait speed (nTUG) (p = 0.02) and fast-paced gait speed (fTUG) (p = 0.03) were also observed in the HIIT+CIT group than in the HIIT+PLA group. ","['participants (sedentary & inactive older adults aged over 65\u202fyrs), 44 were non obese (BMI <30\u202fkg/m 2 ) and completed the intervention', 'healthy older adults']","['HIIT+CIT', 'citrulline (CIT) supplementation combined to high intensity interval training (HIIT', 'HIIT+PLA', 'CIT supplementation/day or placebo and followed HIIT sessions', 'CIT supplementation combined to HIIT', 'Placebo + HIIT (PLA; n\u202f=\u202f21) or CIT\u202f+\u202fHIIT', 'High intensity interval training combined with L-citrulline supplementation']","['Body composition, muscle strength, muscle power, functional capacities (unipodal balance; self-paced and fast Timed Up and Go (nTUG; fTUG); chair test; step tests; 4-meter walking test; 6-minute walking test); dietary intake, energy expenditure and biological markers', 'BMI', 'physical performance', 'self-paced gait speed (nTUG', 'fast-paced gait speed (fTUG', 'android fat mass', 'functional capacities and body composition']","[{'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0008864', 'cui_str': 'Citrulline'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0427052', 'cui_str': 'Finding of power of skeletal muscle'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0087028', 'cui_str': 'Step Test'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C1286104', 'cui_str': 'Dietary intake'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0336541', 'cui_str': 'Android'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]",,0.15454,"Finally, a greater increase in self-paced gait speed (nTUG) (p = 0.02) and fast-paced gait speed (fTUG) (p = 0.03) were also observed in the HIIT+CIT group than in the HIIT+PLA group. ","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Buckinx', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Liège, Belgium.""}, {'ForeName': 'L P', 'Initials': 'LP', 'LastName': 'Carvalho', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.""}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Marcangeli', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dulac', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Hajj Boutros', 'Affiliation': ""Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.""}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Gouspillou', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Gaudreau', 'Affiliation': ""Département de Médecine, Université de Montréal, Montréal, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada.""}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Noirez', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Inserm UMR S-1124 & IRMES EA7329, Université de Paris, Paris, France.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Aubertin-Leheudre', 'Affiliation': ""Département des Sciences de l'Activité Physique, GRAPA, Université du Québec À Montréal, Montréal, Canada; Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, Montréal, Canada. Electronic address: aubertin-leheudre.mylene@uqam.ca.""}]",Experimental gerontology,['10.1016/j.exger.2020.111036'] 2584,32721986,Effect of a Multicomponent Intervention Program on Community-Dwelling People With Intellectual Disabilities.,"Objective To investigate the effectiveness of a novel and complex intervention in community-dwelling people with intellectual disabilities. Methods Forty-three participants completed the experiment. The subjects were randomly assigned the experimental (n=33) or control (n=10) groups. The multicomponent intervention program comprised exercise and nutrition management and behavior modification. The intervention was performed for 60 minutes once weekly for 10 weeks. The assessment included anthropometric data, body composition and blood pressure analysis, and blood tests. In addition, pulmonary function, physical function, and health-related quality of life were measured before and after the intervention. Results No adverse events occurred during the intervention. After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). Conclusion This innovative intervention was effective in improving cardiovascular health. Even greater effects could be achieved through improvements in implementation strategies to increase compliance.",2020,"After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). ","['Methods\n\n\nForty-three participants completed the experiment', 'community-dwelling people with intellectual disabilities', 'Community-Dwelling People With Intellectual Disabilities']","['novel and complex intervention', 'multicomponent intervention program comprised exercise and nutrition management and behavior modification', 'Multicomponent Intervention Program']","['cardiovascular health', 'anthropometric data, body composition and blood pressure analysis, and blood tests', 'adverse events', 'pulmonary function, physical function, and health-related quality of life', 'high-density lipoprotein cholesterol level']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3714756', 'cui_str': 'Intellectual disability'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1258068', 'cui_str': 'Nutrition management'}, {'cui': 'C0004933', 'cui_str': 'Behavioral therapy'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement'}]",43.0,0.0433813,"After the intervention, the experimental group showed a significantly higher increase in high-density lipoprotein cholesterol level than did the control group (effect size=0.152, p=0.019). ","[{'ForeName': 'Ye-Soon', 'Initials': 'YS', 'LastName': 'Kim', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}, {'ForeName': 'Jong-Hoon', 'Initials': 'JH', 'LastName': 'Moon', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}, {'ForeName': 'Bo Kyoon', 'Initials': 'BK', 'LastName': 'Hong', 'Affiliation': 'Department of Occupational Therapy, Graduate School, Yonsei University, Wonju, Korea.'}, {'ForeName': 'Seung Hee', 'Initials': 'SH', 'LastName': 'Ho', 'Affiliation': 'Department of Healthcare and Public Health Research, National Rehabilitation Research Institute, National Rehabilitation Center, Seoul, Korea.'}]",Annals of rehabilitation medicine,['10.5535/arm.19124'] 2585,32721988,A Fully Immersive Virtual Reality Method for Upper Limb Rehabilitation in Spinal Cord Injury.,"Objective To determine whether a fully immersive virtual reality (VR) intervention combined with conventional rehabilitation (CR) can improve upper limb function more than CR alone in patients with spinal cord injury (SCI), we conducted a prospective, randomized, controlled clinical trial. Methods Participants were randomly assigned to either the control group (CG; n=10) or experimental group (EG; n=10). The participants in the CG received 60 minutes of conventional therapy per day, 4 days per week for 4 weeks, whereas those in the EG received 30 minutes of VR training and 30 minutes of conventional therapy per day, 4 days per week for 4 weeks. The clinical outcome measures included Medical Research Council grade, the American Spinal Injury Association upper extremity motor score (ASIA-UEMS), and scores in the Hand Strength Test, Box and Block Test, Nine-Hole Peg Test, Action Research Arm Test, and Korean version of the Spinal Cord Independence Measure (K-SCIM). The assessments were performed at the beginning (T0) and end of the intervention (T1). Results Grip power and K-SCIM score significantly improved in the EG after the intervention. When comparing differences between the groups, elbow extensor, wrist extensor, ASIA-UEMS, grip power, lateral pinch power, and palmar pinch power were all significantly improved. Conclusion VR training of upper limb function after SCI can provide an acceptable adjunctive rehabilitation method without significant adverse effects.",2020,"When comparing differences between the groups, elbow extensor, wrist extensor, ASIA-UEMS, grip power, lateral pinch power, and palmar pinch power were all significantly improved. ","['Spinal Cord Injury', 'patients with spinal cord injury (SCI']","['CR alone', 'fully immersive virtual reality (VR) intervention combined with conventional rehabilitation (CR', 'conventional therapy', 'VR training and 30 minutes of conventional therapy']","['Grip power and K-SCIM score', 'Medical Research Council grade, the American Spinal Injury Association upper extremity motor score (ASIA-UEMS), and scores in the Hand Strength Test, Box and Block Test, Nine-Hole Peg Test, Action Research Arm Test, and Korean version of the Spinal Cord Independence Measure (K-SCIM', 'elbow extensor, wrist extensor, ASIA-UEMS, grip power, lateral pinch power, and palmar pinch power']","[{'cui': 'C0037929', 'cui_str': 'Spinal cord injury'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0456693', 'cui_str': '/30 min'}]","[{'cui': 'C0220843', 'cui_str': 'Grasp'}, {'cui': 'C0022774', 'cui_str': 'Korean language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0037925', 'cui_str': 'Spinal cord structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0079816', 'cui_str': 'Research, Medical'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0037937', 'cui_str': 'Spinal injury'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0242959', 'cui_str': 'Hand Strength'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0006080', 'cui_str': 'Boxing'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0451335', 'cui_str': 'Nine hole peg test'}, {'cui': 'C4720875', 'cui_str': 'Action research arm test'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0418416', 'cui_str': 'Pinched'}, {'cui': 'C1184147', 'cui_str': 'Palmar'}]",,0.035922,"When comparing differences between the groups, elbow extensor, wrist extensor, ASIA-UEMS, grip power, lateral pinch power, and palmar pinch power were all significantly improved. ","[{'ForeName': 'Da Young', 'Initials': 'DY', 'LastName': 'Lim', 'Affiliation': 'Department of Rehabilitation Medicine, Chungnam National University College of Medicine, Daejeon, Korea.'}, {'ForeName': 'Dong Min', 'Initials': 'DM', 'LastName': 'Hwang', 'Affiliation': 'Department of Rehabilitation Medicine, Chungnam National University College of Medicine, Daejeon, Korea.'}, {'ForeName': 'Kang Hee', 'Initials': 'KH', 'LastName': 'Cho', 'Affiliation': 'Department of Rehabilitation Medicine, Chungnam National University College of Medicine, Daejeon, Korea.'}, {'ForeName': 'Chang Won', 'Initials': 'CW', 'LastName': 'Moon', 'Affiliation': 'Department of Rehabilitation Medicine, Chungnam National University College of Medicine, Daejeon, Korea.'}, {'ForeName': 'So Young', 'Initials': 'SY', 'LastName': 'Ahn', 'Affiliation': 'Department of Rehabilitation Medicine, Chungnam National University College of Medicine, Daejeon, Korea.'}]",Annals of rehabilitation medicine,['10.5535/arm.19181'] 2586,32722015,A Dairy Product to Reconstitute Enriched with Bioactive Nutrients Stops Bone Loss in High-Risk Menopausal Women without Pharmacological Treatment.,"Osteoporosis is a multifactorial disease characterized by the loss of bone mass and deterioration of the internal structure of the bone, increasing the risk of fractures, and is becoming an economic and social problem. The main treatment is pharmacological, however, the population demands other therapies, such as foods with nutrients beneficial to bone health. Seventy-eight healthy menopausal women at risk of osteoporosis or untreated osteopenia were recruited for a randomized, parallel, double-blind clinical trial with two intervention groups: one group consumed a serving a day of the experimental enriched product (experimental group (EG)) and the other group (control group (CG)) consumed the same product without enrichment. The main objective was to compare the effect of consuming a dairy preparation to reconstitute, similar to yogurt when prepared, enriched in calcium, vitamin D, vitamin K, vitamin C, zinc, magnesium, L-leucine and probiotic ( Lactobacillus plantarum 3547 ) on bone metabolism markers for 24 weeks. The EG showed a significantly increased bone mass compared to the CG (0.01 ± 0.03 vs. -0.01 ± 0.03 kg; p < 0.05). In addition, the EG maintained their bone mineral density (BMD) compared to the CG, whose BMD significantly decreased at the end of the study. For biochemical markers, the EG significantly increased the serum levels of the N-terminal propeptide of type I collagen (P1NP) bone formation marker (13.19 ± 25.17 vs. -4.21 ± 15.62 ng/mL; p < 0.05), and decreased the carbo-terminal telopeptide of type I collagen (CTx) bone resorption marker compared to the CG (-0.05 ± 0.19 vs. 0.04 ± 0.14 ng/mL; p < 0.05). On the other hand, the EG exhibited a significantly decreased systolic and diastolic blood pressure compared to the start of the study. Finally, the EG significantly increased their dietary calcium and vitamin D intake compared to the CG. In conclusion, the regular consumption of a dairy product to reconstitute enriched with bioactive nutrients improves bone health markers in menopausal women at risk of osteoporosis without pharmacological treatment.",2020,The EG showed a significantly increased bone mass compared to the CG (0.01 ± 0.03 vs. -0.01 ± 0.03 kg; p < 0.05).,"['High-Risk Menopausal Women without Pharmacological Treatment', 'Seventy-eight healthy menopausal women at risk of osteoporosis or untreated osteopenia', 'menopausal women at risk of osteoporosis without pharmacological treatment']","['bioactive nutrients', 'Bioactive Nutrients', 'calcium, vitamin D, vitamin K, vitamin C, zinc, magnesium, L-leucine and probiotic', 'serving a day of the experimental enriched product (experimental group (EG)) and the other group (control group (CG)) consumed the same product without enrichment']","['bone health markers', 'bone mass', 'carbo-terminal telopeptide of type I collagen (CTx) bone resorption marker', 'systolic and diastolic blood pressure', 'BMD', 'bone mineral density (BMD', 'dietary calcium and vitamin D intake', 'serum levels of the N-terminal propeptide of type I collagen (P1NP) bone formation marker', 'bone metabolism markers']","[{'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C1277579', 'cui_str': 'At risk of osteoporosis'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}]","[{'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0042878', 'cui_str': 'Vitamin K'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0024467', 'cui_str': 'Magnesium'}, {'cui': 'C0023401', 'cui_str': 'Leucine'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0006726', 'cui_str': 'Dietary Calcium'}, {'cui': 'C0564439', 'cui_str': 'Vitamin D intake'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0029433', 'cui_str': 'Bone formation'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}]",,0.0367566,The EG showed a significantly increased bone mass compared to the CG (0.01 ± 0.03 vs. -0.01 ± 0.03 kg; p < 0.05).,"[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Morato-Martínez', 'Affiliation': 'Nutrition Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain.'}, {'ForeName': 'Bricia', 'Initials': 'B', 'LastName': 'López-Plaza', 'Affiliation': 'Nutrition Research Group, La Paz University Hospital Institute for Health Research (IdiPAZ), 28046 Madrid, Spain.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Santurino', 'Affiliation': 'Nutrition Research Group, La Paz University Hospital Institute for Health Research (IdiPAZ), 28046 Madrid, Spain.'}, {'ForeName': 'Samara', 'Initials': 'S', 'LastName': 'Palma-Milla', 'Affiliation': 'Nutrition Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Gómez-Candela', 'Affiliation': 'Nutrition Department, La Paz University Hospital Institute for Health Research (IdiPAZ), Autonomous University of Madrid, 28046 Madrid, Spain.'}]",Nutrients,['10.3390/nu12082203'] 2587,32722084,Effects of Supplementary Strength-Power Training on Neuromuscular Performance in Young Female Athletes.,"This study examined the effects of a short-duration supplementary strength-power training program on neuromuscular performance and sport-specific skills in adolescent athletes. Twenty-three female ""Gymnastics for All"" athletes, aged 13 ± 2 years, were divided into a training group (TG, n = 12) and a control group (CG, n = 11). Both groups underwent a test battery before and after 10 weeks of intervention. TG completed, in addition to gymnastics training, a supplementary 7-9 min program that included two rounds of strength and power exercises for arms, torso, and legs, executed in a circuit fashion with 1 min rest between rounds, three times per week. Initially, six exercises were performed (15 s work-15 s rest), while the number of exercises was decreased to four and the duration of each exercise was increased to 30 s (30 s rest) after the fifth week. TG improved countermovement jump performance with one leg (11.5% ± 10.4%, p = 0.002) and two legs (8.2% ± 8.8%, p = 0.004), drop jump performance (14.4% ± 12.6%, p = 0.038), single-leg jumping agility (13.6% ± 5.2%, p = 0.001), and sport-specific performance (8.8% ± 7.4%, p = 0.004), but not 10 m sprint performance (2.4% ± 6.6%, p = 0.709). No change was observed in the CG ( p = 0.41 to 0.97). The results of this study indicated that this supplementary strength-power program performed for 7-9 min improves neuromuscular and sport-specific performance after 10 weeks of training.",2020,"TG improved countermovement jump performance with one leg (11.5% ± 10.4%, p = 0.002) and two legs (8.2% ± 8.8%, p = 0.004), drop jump performance (14.4% ± 12.6%, p = 0.038), single-leg jumping agility (13.6% ± 5.2%, p = 0.001), and sport-specific performance (8.8% ± 7.4%, p = 0.004), but not 10 m sprint performance (2.4% ± 6.6%, p = 0.709).","['Twenty-three female ""Gymnastics for All"" athletes, aged 13 ± 2 years', 'adolescent athletes', 'Young Female Athletes']","['short-duration supplementary strength-power training program', 'Supplementary Strength-Power Training']","['single-leg jumping agility', 'neuromuscular performance and sport-specific skills', 'Neuromuscular Performance', 'neuromuscular and sport-specific performance', 'drop jump performance', 'number of exercises', 'sport-specific performance', 'countermovement jump performance']","[{'cui': 'C0450348', 'cui_str': '23'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0018409', 'cui_str': 'Gymnastics'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C0439593', 'cui_str': 'Short duration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",6.0,0.012243,"TG improved countermovement jump performance with one leg (11.5% ± 10.4%, p = 0.002) and two legs (8.2% ± 8.8%, p = 0.004), drop jump performance (14.4% ± 12.6%, p = 0.038), single-leg jumping agility (13.6% ± 5.2%, p = 0.001), and sport-specific performance (8.8% ± 7.4%, p = 0.004), but not 10 m sprint performance (2.4% ± 6.6%, p = 0.709).","[{'ForeName': 'Konstantina', 'Initials': 'K', 'LastName': 'Karagianni', 'Affiliation': 'School of Physical Education and Sports Science, National and Kapodistrian University of Athens, 17237 Athens, Greece.'}, {'ForeName': 'Olyvia', 'Initials': 'O', 'LastName': 'Donti', 'Affiliation': 'School of Physical Education and Sports Science, National and Kapodistrian University of Athens, 17237 Athens, Greece.'}, {'ForeName': 'Christos', 'Initials': 'C', 'LastName': 'Katsikas', 'Affiliation': 'School of Physical Education and Sports Science, National and Kapodistrian University of Athens, 17237 Athens, Greece.'}, {'ForeName': 'Gregory C', 'Initials': 'GC', 'LastName': 'Bogdanis', 'Affiliation': 'School of Physical Education and Sports Science, National and Kapodistrian University of Athens, 17237 Athens, Greece.'}]","Sports (Basel, Switzerland)",['10.3390/sports8080104'] 2588,32723507,Effectiveness of early versus delayed exercise and nutritional intervention on segmental body composition of sarcopenic elders - A randomized controlled trial.,"BACKGROUND & AIMS Although resistance training with nutritional support is considered the best treatment option for sarcopenia, the importance of home-based exercise should not be overlooked. For managing sarcopenia, a fundamental issue is whether home-based exercise or a supervised training program should be administered first. Therefore, the present trial aimed to compare the effect of early versus delayed exercise intervention with nutritional support on the physical performance and body composition of sarcopenic elders. METHODS The study was a randomized controlled trial using a parallel-group design. Each group received two therapeutic periods lasted 12 weeks with an interval of 2 weeks in between. Physical performance and body composition were assessed at baseline and immediately following the end of the first and second phases. One phase included hospital-based resistance training and nutritional support (amino acid, calcium, and vitamin D3), whereas the other phase included home-based exercise. In the early intervention group, supervised exercise and nutrition supplementation were administered first followed by home-based exercise, whereas the sequence was reversed in the delayed intervention group. The influence of intervention sequence on the outcome variables was examined using a 3∗2 repeated-measures analysis of variance. The primary endpoints were defined as changes in lean mass and related physical function (grip strength and gait speed) over 12 and 26 weeks of interventions. RESULTS A total of 57 sarcopenic elders were randomly assigned to the early (n = 29) and delayed (n = 28) intervention groups. Among the primary endpoints, the only significant group-time interaction was recognized on the changes of lower extremity lean mass (p = 0.039). The early intervention was associated with an earlier increase in lower extremity lean mass (770.8 g, 95% confidence interval (CI), 564.8 g-976.9 g) than delayed intervention (294.2 g, 95% CI, -42.13 to 630.5 g) which was evident from the between-group comparison between baseline and the 1st follow-up (p = 0.016). No significant effect of group-time interaction was observed on the physical performance and other components of body composition. CONCLUSIONS Early exercise and nutritional intervention may be helpful in an earlier restoration of lower extremity muscle mass but not physical function in sarcopenic elders. When designing a rehabilitation program for patients with sarcopenia, resistance training with nutrition support can be prescribed first for the rapid enlargement of the muscle volume, and structuralized home-based exercise can be administered subsequently to preserve the prior intervention effect. TRIAL REGISTRATION ClinicalTrials.gov (NCT02779088).",2020,The early intervention was associated with an earlier increase in lower extremity lean mass (770.8 ,"['sarcopenic elders', '57 sarcopenic elders']","['hospital-based resistance training and nutritional support (amino acid, calcium, and vitamin D3', 'delayed exercise and nutritional intervention', 'delayed exercise intervention with nutritional support', 'supervised exercise and nutrition supplementation', 'Early exercise and nutritional intervention']","['physical performance and other components of body composition', 'changes of lower extremity lean mass', 'Physical performance and body composition', 'lower extremity lean mass', 'changes in lean mass and related physical function (grip strength and gait speed']","[{'cui': 'C0331055', 'cui_str': 'Genus Sambucus'}]","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0242739', 'cui_str': 'Nutritional support'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0086153', 'cui_str': 'Diet Modification'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}]",57.0,0.0653281,The early intervention was associated with an earlier increase in lower extremity lean mass (770.8 ,"[{'ForeName': 'Ke-Vin', 'Initials': 'KV', 'LastName': 'Chang', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Community and Geriatric Medicine Research Center, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Wei-Ting', 'Initials': 'WT', 'LastName': 'Wu', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Kuo-Chin', 'Initials': 'KC', 'LastName': 'Huang', 'Affiliation': 'Community and Geriatric Medicine Research Center, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Department of Family Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.'}, {'ForeName': 'Der-Sheng', 'Initials': 'DS', 'LastName': 'Han', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Community and Geriatric Medicine Research Center, National Taiwan University Hospital, Bei-Hu Branch, Taiwan; Department of Physical Medicine and Rehabilitation, National Taiwan University College of Medicine, Taipei, Taiwan; Health Science and Wellness Center, National Taiwan University, Taipei, Taiwan. Electronic address: dshan1121@yahoo.com.tw.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2020.06.037'] 2589,32723512,The effectiveness of electronic pulsed soft tissue vibration compared with topical anaesthesia in reducing the pain of injection of local anaesthetics in adults: a randomized controlled split-mouth clinical trial.,"The purpose of this study was to evaluate the effectiveness of an electronic hand-held pulsed vibration device on the pain of local analgesia (LA) injection and physiologic changes. A prospective randomized controlled clinical trial using split-mouth (crossover) design was implemented. The control-side injection was performed after using topical anaesthesia. The experimental side injection was carried out without topical anaesthesia, but with the aid of a switched-on vibration device. Overall, 332 dental LA injections were given to 166 patients for routine exodontia. The pain at penetration and pain during injection were significantly lower in the experimental sides (vibrations sides) compared with those of the controls (P<0.001). Similarly, the heart rate changes at penetration and during injections were significantly lower in the experimental sides (P<0.001). The vibration device was clinically and statistically more effective than topical anaesthesia in the reduction of dental injection pain in adults, measured subjectively and objectively, regardless of the gender, injection technique (infiltration or block) or anxiety level.",2020,"The vibration device was clinically and statistically more effective than topical anaesthesia in the reduction of dental injection pain in adults, measured subjectively and objectively, regardless of the gender, injection technique (infiltration or block) or anxiety level.",['adults'],"['electronic hand-held pulsed vibration device', 'electronic pulsed soft tissue vibration', 'topical anaesthesia']","['heart rate changes at penetration', 'subjectively and objectively, regardless of the gender, injection technique (infiltration or block) or anxiety level', 'pain of local analgesia (LA) injection and physiologic changes', 'pain at penetration and pain during injection', 'pain of injection of local anaesthetics', 'dental injection pain']","[{'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0013850', 'cui_str': 'Electronic'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0675390', 'cui_str': 'ARID1A protein, human'}, {'cui': 'C0455941', 'cui_str': 'Vibration - treatment'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0225317', 'cui_str': 'Soft tissue'}, {'cui': 'C0472473', 'cui_str': 'Topical local anesthetic'}]","[{'cui': 'C0232189', 'cui_str': 'Alteration in heart rate'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C2960425', 'cui_str': 'Injection technique'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0002766', 'cui_str': 'Pain management'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1096717', 'cui_str': 'Pain during injection'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}]",332.0,0.043904,"The vibration device was clinically and statistically more effective than topical anaesthesia in the reduction of dental injection pain in adults, measured subjectively and objectively, regardless of the gender, injection technique (infiltration or block) or anxiety level.","[{'ForeName': 'R G', 'Initials': 'RG', 'LastName': 'Salma', 'Affiliation': 'Department of Oral and Maxillofacial Surgery, Riyadh Elm University, Saudi Arabia. Electronic address: rsalma@yahoo.com.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Alsayeh', 'Affiliation': 'General Dental Practice, Riyadh Elm University, Saudi Arabia.'}, {'ForeName': 'A B', 'Initials': 'AB', 'LastName': 'Maneea', 'Affiliation': 'General Dental Practice, Riyadh Elm University, Saudi Arabia.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Alrassan', 'Affiliation': 'General Dental Practice, Riyadh Elm University, Saudi Arabia.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Almarshad', 'Affiliation': 'General Dental Practice, Riyadh Elm University, Saudi Arabia.'}]",International journal of oral and maxillofacial surgery,['10.1016/j.ijom.2020.07.010'] 2590,32723669,The Effect of Shoulder Mobilization on Scapular and Shoulder Muscle Activity During Resisted Shoulder Abduction: A Crossover Study of Asymptomatic Individuals.,"OBJECTIVE The primary aim was to investigate the effect of inferior shoulder mobilization on scapular and shoulder muscle activity during resisted shoulder abduction in asymptomatic individuals. METHODS This was a lab-based, repeated-measures, crossover, randomized controlled study. Twenty-two participants were recruited. The order of experimental conditions was randomized. Each participant performed 5 repetitions of resisted shoulder abduction before and after the control and mobilization (grade +IV inferior shoulder mobilization, 3 sets, 60 seconds) conditions. Surface electromyography recorded the muscle activity of anterior, middle, and posterior deltoid; supraspinatus; infraspinatus; upper and lower trapezius; serratus anterior; and latissimus dorsi muscles. RESULTS Muscle activity levels reduced for infraspinatus (11.3% MVIC, 95% CI: 1.7-20.8), middle (22.4% MVIC, 95% CI: 15.9-28.8) and posterior deltoid (8.7 % MVIC, 95% CI: 4.6-12.9), and serratus anterior (-28.1% MVIC, 95% CI: 15.6-40.8) muscles after the mobilization condition during the eccentric phase of shoulder abduction. No carryover effects were observed, and within-session reliability was excellent (intraclass correlation coefficient scores ranging from 0.94 to 0.99). CONCLUSION Our findings suggest that inferior glenohumeral mobilization reduces activity levels of some scapular and shoulder muscles. Given the exploratory nature of our study, changes in muscle activity levels may have been found by chance. Confirmatory studies are required.",2020,"RESULTS Muscle activity levels reduced for infraspinatus (11.3% MVIC, 95% CI: 1.7-20.8), middle (22.4% MVIC, 95% CI: 15.9-28.8) and posterior deltoid (8.7 % MVIC, 95% CI: 4.6-12.9), and serratus anterior (-28.1% MVIC, 95% CI: 15.6-40.8) muscles after the mobilization condition during the eccentric phase of shoulder abduction.","['Asymptomatic Individuals', 'During Resisted Shoulder Abduction', 'Twenty-two participants were recruited', 'asymptomatic individuals']","['inferior shoulder mobilization', 'Shoulder Mobilization']","['Scapular and Shoulder Muscle Activity', 'Muscle activity levels', 'carryover effects', 'activity levels', 'posterior deltoid']","[{'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0086505', 'cui_str': 'Kidnapping'}, {'cui': 'C4284772', 'cui_str': '22'}]","[{'cui': 'C0542339', 'cui_str': 'Inferior'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0185112', 'cui_str': 'Mobilization'}]","[{'cui': 'C0687023', 'cui_str': 'Structure of skeletal muscle of shoulder'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0224234', 'cui_str': 'Structure of deltoid muscle'}]",22.0,0.126965,"RESULTS Muscle activity levels reduced for infraspinatus (11.3% MVIC, 95% CI: 1.7-20.8), middle (22.4% MVIC, 95% CI: 15.9-28.8) and posterior deltoid (8.7 % MVIC, 95% CI: 4.6-12.9), and serratus anterior (-28.1% MVIC, 95% CI: 15.6-40.8) muscles after the mobilization condition during the eccentric phase of shoulder abduction.","[{'ForeName': 'Abbey', 'Initials': 'A', 'LastName': 'Patterson', 'Affiliation': 'Centre for Health, Activity and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, Otago, New Zealand.'}, {'ForeName': 'Clark R', 'Initials': 'CR', 'LastName': 'Dickerson', 'Affiliation': 'Department of Kinesiology, Faculty of Applied Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.'}, {'ForeName': 'Daniel C', 'Initials': 'DC', 'LastName': 'Ribeiro', 'Affiliation': 'Centre for Health, Activity and Rehabilitation Research, School of Physiotherapy, University of Otago, Dunedin, Otago, New Zealand. Electronic address: Daniel.ribeiro@otago.ac.nz.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2019.11.006'] 2591,32723670,"A Phase III, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Once-Daily SPN-812 (Viloxazine Extended-Release) in the Treatment of Attention-Deficit/Hyperactivity Disorder in School-age Children.","PURPOSE The limitations of current US Food and Drug Administration (FDA)-approved medications for the treatment of attention-deficit/hyperactivity disorder (ADHD) set the need for the development of novel, effective, and tolerable medications to treat this disorder. The purpose of this study was to evaluate whether treatment with SPN-812 (viloxazine extended-release) significantly reduces symptoms of ADHD in children. METHODS This study was a randomized, double-blind, placebo-controlled 6-week trial to assess the efficacy and safety of once-daily 100- and 200-mg SPN-812 in the treatment of ADHD in male and female children 6-11 years of age. Inclusion criteria required subjects to have a confirmed Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, ADHD diagnosis, an ADHD-Rating Scale-5 (ADHD-RS-5) score ≥28, a Clinical Global Impression-Severity score ≥4, and for subjects to be free of ADHD medication ≥1 week before randomization. The primary efficacy endpoint was the change from baseline (CFB) at end of study (EOS) in ADHD-RS-5 Total score. Key secondary endpoints included Clinical Global Impression-Improvement (CGI-I) scores at EOS and CFB at EOS in the Conners 3-Parent Short Form (Conners 3-PS) Composite T-score and the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Total average score. Safety assessments included adverse events (AEs), laboratory tests, vital signs, physical examinations, ECGs, and the Columbia-Suicide Severity Rating Scale. The primary efficacy endpoint was analyzed by using a mixed model for repeated measures; all secondary measures were analyzed by using an ANCOVA model. RESULTS A total of 477 subjects were randomized to treatment (intent-to-treat population, n = 460). The majority of subjects were male (63%) and either White (51.3%) or African American (43.7%). The demographic and baseline characteristics between the groups were similar. Statistically significant improvements in ADHD-RS-5 Total score were observed in both the 100- and 200-mg/day SPN-812 treatment groups compared to placebo at week 1 of treatment (P = 0.0004 and P = 0.0244, respectively), which was maintained through EOS (P = 0.0004 and P < 0.0001). Significant improvements were also observed at EOS in the CGI-I scale (P = 0.0020 and P < 0.0001), Conners 3-PS Composite T-score (P = 0.0003 and P = 0.0002), and WFIRS-P Total average score (P = 0.0019 and P = 0.0002) versus placebo. Treatment-related AEs reported in ≥5% of subjects included somnolence, decreased appetite, and headache. The discontinuation rate due to AEs was <5%. IMPLICATIONS SPN-812 significantly reduced ADHD symptoms in children and was well tolerated. SPN-812 may prove to be an effective treatment for children with ADHD. ClinicalTrials.gov identifier: NCT03247530.",2020,"Significant improvements were also observed at EOS in the CGI-I scale (P = 0.0020 and P < 0.0001), Conners 3-PS Composite T-score (P = 0.0003 and P = 0.0002), and WFIRS-P Total average score (P = 0.0019 and P = 0.0002) versus placebo.","['male and female children 6-11 years of age', 'children', 'children with ADHD', 'Attention-Deficit/Hyperactivity Disorder in School-age Children', '477 subjects', 'subjects were male (63%) and either White (51.3%) or African American (43.7']","['once-daily 100- and 200-mg SPN-812', 'Placebo', 'SPN-812 (viloxazine extended-release', 'current US Food and Drug Administration (FDA)-approved medications', 'SPN-812', 'Once-Daily SPN-812 (Viloxazine Extended-Release', 'placebo']","['Efficacy and Safety', 'Composite T-score and the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P) Total average score', 'discontinuation rate', 'tolerated', 'adverse events (AEs), laboratory tests, vital signs, physical examinations, ECGs, and the Columbia-Suicide Severity Rating Scale', 'ADHD-RS-5 Total score', 'WFIRS-P Total average score', 'somnolence, decreased appetite, and headache', 'efficacy and safety', 'Conners 3-PS Composite T-score', 'ADHD symptoms', 'CGI-I scale', 'Clinical Global Impression-Improvement (CGI-I) scores at EOS and CFB at EOS in the Conners 3-Parent Short Form (Conners 3-PS', 'change from baseline (CFB) at end of study (EOS) in ADHD-RS-5 Total score']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0870604', 'cui_str': 'Female child'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085756', 'cui_str': 'African American'}]","[{'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C2350019', 'cui_str': 'Solitary nodule of lung'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042665', 'cui_str': 'Viloxazine'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0041714', 'cui_str': 'United States Food, Drug Administration'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0022885', 'cui_str': 'Laboratory procedure'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013798', 'cui_str': 'Electrocardiogram'}, {'cui': 'C3888485', 'cui_str': 'Columbia suicide severity rating scale'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0200638', 'cui_str': 'Eosinophil count'}, {'cui': 'C0009002', 'cui_str': 'Clofibrate'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",477.0,0.172322,"Significant improvements were also observed at EOS in the CGI-I scale (P = 0.0020 and P < 0.0001), Conners 3-PS Composite T-score (P = 0.0003 and P = 0.0002), and WFIRS-P Total average score (P = 0.0019 and P = 0.0002) versus placebo.","[{'ForeName': 'Azmi', 'Initials': 'A', 'LastName': 'Nasser', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA. Electronic address: anasser@supernus.com.'}, {'ForeName': 'Tesfaye', 'Initials': 'T', 'LastName': 'Liranso', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Toyin', 'Initials': 'T', 'LastName': 'Adewole', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Fry', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Joseph T', 'Initials': 'JT', 'LastName': 'Hull', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Fatima', 'Initials': 'F', 'LastName': 'Chowdhry', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Busse', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Cutler', 'Affiliation': 'SUNY Upstate Medical University, and Neuroscience Education Institute, Lakewood Ranch, FL, USA.'}, {'ForeName': 'Nandita Joshi', 'Initials': 'NJ', 'LastName': 'Jones', 'Affiliation': 'CNS Healthcare, Jacksonville, FL, USA.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Findling', 'Affiliation': 'Virginia Commonwealth University School of Medicine, Richmond, VA, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Schwabe', 'Affiliation': 'Supernus Pharmaceuticals, Inc, Rockville, MD, USA.'}]",Clinical therapeutics,['10.1016/j.clinthera.2020.05.021'] 2592,32723679,Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study.,"OBJECTIVE To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. METHODS An exploratory, post-hoc analysis of the randomized phase II trial, Gynecologic Oncology Group-0186I, was performed. One hundred and seven patients with recurrent ovarian carcinoma, treated with up to 3 prior regimens, were randomized to bevacizumab 15 mg/kg body weight with or without intravenous fosbretabulin 60 mg/m 2 body surface area every 21 days until progression or unacceptable toxicity. The primary analysis favored the combination (HR 0.69; 95% CI, 0.47-1.00; p = .049) [Monk BJ, et al. J Clin Oncol 2016;34:2279-86]. The Cox proportional hazards model was used to estimate the treatment effect in various subpopulations. RESULTS With extended follow-up, the median PFS for bevacizumab plus fosbretabulin was 7.6  months as compared to 4.8  months with bevacizumab alone (HR 0.74; 90% CI, 0.54-1.02). Overall survival was similar in the experimental and control arms (25.2 vs 24.4 mos, respectively, HR 0.85; 90% CI, 0.59-1.22; p = .461). Eighty-one patients had measurable disease and median tumor size was 5.7  cm. In the ≤5.7  cm subgroup, the HR for progression or death was 0.77 (90% CI 0.45-1.31). Patients with tumors >5.7  cm (n = 40) had a HR for progression or death of 0.55; 90% CI, 0.32-0.96; p = .075). CONCLUSIONS Although no significant survival benefit was observed, the trend showing a reduced HR for progression or death with increasing tumor size when fosbretabulin is added to bevacizumab compared to bevacizumab alone warrants further study.",2020,"RESULTS With extended follow-up","['recurrent ovarian cancer', 'One hundred and seven patients with recurrent ovarian carcinoma']","['bevacizumab 15\u202fmg/kg body weight with or without intravenous fosbretabulin 60\u202fmg/m 2 body surface area', 'combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab', 'bevacizumab', 'Bevacizumab plus fosbretabulin']","['survival benefit', 'Overall survival', 'measurable disease and median tumor size', 'HR for progression or death', 'median PFS for bevacizumab plus fosbretabulin']","[{'cui': 'C0278689', 'cui_str': 'Recurrent ovarian cancer'}, {'cui': 'C4517529', 'cui_str': '107'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0560741', 'cui_str': 'mg/kg body weight'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0056154', 'cui_str': 'fosbretabulin'}, {'cui': 'C0005902', 'cui_str': 'Body surface area'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0596087', 'cui_str': 'Angiogenesis inhibitor'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0056154', 'cui_str': 'fosbretabulin'}]",107.0,0.0982756,"RESULTS With extended follow-up","[{'ForeName': 'Krishnansu S', 'Initials': 'KS', 'LastName': 'Tewari', 'Affiliation': 'University of California, Irvine, Division of Gynecologic Oncology, Orange, CA, United States. Electronic address: ktewari@uci.edu.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Sill', 'Affiliation': 'NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park, Buffalo, NY 14263, United States. Electronic address: sillm@nrgoncology.org.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Coleman', 'Affiliation': 'MD Anderson Cancer Center, Houston, TX, United States.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Aghajanian', 'Affiliation': 'Memorial Sloan-Kettering Cancer Center, New York, NY, United States. Electronic address: aghajanc@MSKCC.org.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Mannel', 'Affiliation': 'The Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, 800 NE 10(th) St., SOCC 6043, Oklahoma City, OK 73104, United States. Electronic address: robert-mannel@ouhsc.edu.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'DiSilvestro', 'Affiliation': 'Women and Infants Hospital of Rhode Island, 101 Dudley St., Providence, RI 02905, United States. Electronic address: PDiSilvestro@WIHRI.org.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Powell', 'Affiliation': 'Washington University School of Medicine, 4911 Barnes Jewish Hospital Plaza, St. Louis, MO 63110, United States. Electronic address: mpowell@wustl.edu.'}, {'ForeName': 'Leslie M', 'Initials': 'LM', 'LastName': 'Randall', 'Affiliation': 'University of California, Irvine, Division of Gynecologic Oncology, Orange, CA, United States. Electronic address: Leslie.Randall@vcuhealth.org.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Farley', 'Affiliation': ""Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Pheonix, AZ 85013, United States. Electronic address: John.farley@chw.edu.""}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Rubin', 'Affiliation': 'Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA 19111, United States. Electronic address: stephen.rubin@fccc.edu.'}, {'ForeName': 'Bradley J', 'Initials': 'BJ', 'LastName': 'Monk', 'Affiliation': ""Arizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine, St. Joseph's Hospital, Phoenix, AZ, United States. Electronic address: Bradley.Monk@usoncology.com.""}]",Gynecologic oncology,['10.1016/j.ygyno.2020.07.015'] 2593,32723680,Same-day discharge after elective percutaneous coronary intervention: A single center experience.,"INTRODUCTION AND OBJECTIVES Elective percutaneous coronary intervention (PCI) has become an increasingly safe procedure. However, same day discharge (SDD) has yet to become standard practice. Our aim is to characterize the patients who underwent elective PCI and compare outcomes between the overnight stay (ONS) patient group and the group that was discharged on the same day at 24 hours and at 30 days. METHODS One-year registry of patients who underwent an elective PCI. The possibility of SDD was established by the operator. Appropriate candidates were discharged at least four hours after the end of the intervention. The primary endpoints were defined as: Major adverse cardiac and cerebrovascular events (MACCE) - death, myocardial infarction (MI) stroke or transient ischemic attack (TIA), non-planned re-intervention - and vascular complications. Secondary endpoints were any unplanned hospital visit, readmission and re-catheterization. RESULTS We performed 155 elective PCIs. One patient was admitted to the coronary care unit; 111 patients stayed overnight (ONS Group); 43 patients were discharged the same day (SDD Group). Three patients had early (<4 hours) post procedure complications: two TIAs and one vascular access site complication. There were no MACCE between four and 24 hours, nor at 30 days. At 24 hours, two patients from the SDD group had unplanned visits. Between one and 30 days, more patients from the SDD group had unplanned visits (9.3% vs. 0.9%. p=0.02). One patient from the ONS group had a recatherization. There were no readmissions or reinterventions. CONCLUSION Same day discharge of selected patients who undergo elective PCIs is feasible and safe.",2020,"There were no readmissions or reinterventions. ","['One-year registry of patients who underwent an elective PCI', 'One patient was admitted to the coronary care unit; 111 patients stayed overnight (ONS Group); 43 patients were discharged the same day (SDD Group']",['Elective percutaneous coronary intervention (PCI'],"['unplanned hospital visit, readmission and', 'Major adverse cardiac and cerebrovascular events (MACCE) - death, myocardial infarction (MI) stroke or transient ischemic attack (TIA), non-planned re-intervention - and vascular complications', 'unplanned visits', 'readmissions or reinterventions']","[{'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0010066', 'cui_str': 'Coronary Care Units'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",155.0,0.0488091,"There were no readmissions or reinterventions. ","[{'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Rodrigues', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal. Electronic address: rodrigues.jal@gmail.com.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Silva', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Almeida', 'Affiliation': 'Hospital do Divino Espírito Santo de Ponta Delgada, Ponta Delgada, Açores, Portugal.'}, {'ForeName': 'Francisco Castro', 'Initials': 'FC', 'LastName': 'Ferreira', 'Affiliation': 'Hospital da Senhora da Oliveira, Guimarães, Portugal.'}, {'ForeName': 'Gustavo Pires de', 'Initials': 'GP', 'LastName': 'Morais', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.'}, {'ForeName': 'Lino', 'Initials': 'L', 'LastName': 'Santos', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Melica', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Braga', 'Affiliation': 'Centro Hospitalar de Gaia/Espinho, Vila Nova de Gaia, Portugal.'}]",Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,['10.1016/j.repc.2019.10.008'] 2594,32723696,"A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF.","RESEARCH QUESTION Does clinical performance of personalized embryo transfer (PET) guided by endometrial receptivity analysis (ERA) differ from frozen embryo transfer (FET) or fresh embryo transfer in infertile patients undergoing IVF? DESIGN Multicentre, open-label randomized controlled trial; 458 patients aged 37 years or younger undergoing IVF with blastocyst transfer at first appointment were randomized to PET guided by ERA, FET or fresh embryo transfer in 16 reproductive clinics. RESULTS Clinical outcomes by intention-to-treat analysis were comparable, but cumulative pregnancy rate was significantly higher in the PET (93.6%) compared with FET (79.7%) (P = 0.0005) and fresh embryo transfer groups (80.7%) (P = 0.0013). Analysis per protocol demonstrates that live birth rates at first embryo transfer were 56.2% in PET versus 42.4% in FET (P = 0.09), and 45.7% in fresh embryo transfer groups (P = 0.17). Cumulative live birth rates after 12 months were 71.2% in PET versus 55.4% in FET (P = 0.04), and 48.9% in fresh embryo transfer (P = 0.003). Pregnancy rates at the first embryo transfer in PET, FET and fresh embryo transfer arms were 72.5% versus 54.3% (P = 0.01) and 58.5% (P = 0.05), respectively. Implantation rates at first embryo transfer were 57.3% versus 43.2% (P = 0.03), and 38.6% (P = 0.004), respectively. Obstetrical outcomes, type of delivery and neonatal outcomes were similar in all groups. CONCLUSIONS Despite 50% of patients dropping out compared with 30% initially planned, per protocol analysis demonstrates statistically significant improvement in pregnancy, implantation and cumulative live birth rates in PET compared with FET and fresh embryo transfer arms, indicating the potential utility of PET guided by the ERA test at the first appointment.",2020,"Implantation rates at first embryo transfer were 57.3% versus 43.2% (P = 0.03), and 38.6% (P = 0.004), respectively.","['458 patients aged 37 years or younger undergoing IVF with blastocyst transfer at first appointment', 'in 16 reproductive clinics', 'infertile patients undergoing IVF']","['FET', 'PET guided by ERA, FET or fresh embryo transfer', 'personalized embryo transfer (PET) guided by endometrial receptivity analysis (ERA) differ from frozen embryo transfer (FET) or fresh embryo transfer', 'personalized, frozen and fresh blastocyst transfer']","['pregnancy, implantation and cumulative live birth rates', 'Implantation rates', 'live birth rates at first embryo transfer', 'Obstetrical outcomes, type of delivery and neonatal outcomes', 'Pregnancy rates', 'cumulative pregnancy rate', 'Cumulative live birth rates']","[{'cui': 'C5191377', 'cui_str': '458'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0015915', 'cui_str': 'In vitro fertilization'}, {'cui': 'C0936221', 'cui_str': 'Blastocyst Transfer'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0035150', 'cui_str': 'Reproduction'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0021359', 'cui_str': 'Sterility'}]","[{'cui': 'C0404110', 'cui_str': 'Frozen embryo transfer'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0440732', 'cui_str': 'Fresh embryo'}, {'cui': 'C0040671', 'cui_str': 'Transfer (Psychology)'}, {'cui': 'C0016701', 'cui_str': 'Freezing'}, {'cui': 'C0443224', 'cui_str': 'Fresh'}, {'cui': 'C0936221', 'cui_str': 'Blastocyst Transfer'}]","[{'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0013938', 'cui_str': 'Embryo transfer'}, {'cui': 'C0028773', 'cui_str': 'Obstetrics'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011209', 'cui_str': 'Delivery procedure'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rates'}]",458.0,0.196615,"Implantation rates at first embryo transfer were 57.3% versus 43.2% (P = 0.03), and 38.6% (P = 0.004), respectively.","[{'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Simón', 'Affiliation': 'Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia 46010, Spain; Igenomix Foundation-INCLIVA, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain; IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain. Electronic address: carlos.simon@uv.es.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gómez', 'Affiliation': 'Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Cabanillas', 'Affiliation': 'IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.'}, {'ForeName': 'Iavor', 'Initials': 'I', 'LastName': 'Vladimirov', 'Affiliation': 'SBALAGRM-Sofia, 5 Baku St, Sofia 1756, Bulgaria.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Castillón', 'Affiliation': 'IVI-RMA Barcelona, Ronda General Mitre 14 Barcelona 08017, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Giles', 'Affiliation': 'IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.'}, {'ForeName': 'Kubra', 'Initials': 'K', 'LastName': 'Boynukalin', 'Affiliation': 'Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.'}, {'ForeName': 'Necati', 'Initials': 'N', 'LastName': 'Findikli', 'Affiliation': 'Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.'}, {'ForeName': 'Mustafa', 'Initials': 'M', 'LastName': 'Bahçeci', 'Affiliation': 'Bahçeci Health Group-Fulya IVF Centre, Hakki Yeten Cad, 11 Kat 3, Terrace Fulya Istanbul 34365, Turkey.'}, {'ForeName': 'Israel', 'Initials': 'I', 'LastName': 'Ortega', 'Affiliation': 'IVI-RMA Madrid, Av Del Talgo 68, Aravaca Madrid 28023, Spain.'}, {'ForeName': 'Carmina', 'Initials': 'C', 'LastName': 'Vidal', 'Affiliation': 'IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.'}, {'ForeName': 'Miyako', 'Initials': 'M', 'LastName': 'Funabiki', 'Affiliation': 'Oak Clinic Japan, 2-7-9 Tamade-Nishi, Nishinari-ku Osaka 557-0045, Japan.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Izquierdo', 'Affiliation': 'ProcreaTec, Calle Manuel de Falla 6-8, Madrid 28036, Spain.'}, {'ForeName': 'Lourdes', 'Initials': 'L', 'LastName': 'López', 'Affiliation': 'ProcreaTec, Calle Manuel de Falla 6-8, Madrid 28036, Spain.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Portela', 'Affiliation': 'IVI-RMA Vigo, Plaza Francisco Fernández del Riego 7, Vigo 36203, Spain.'}, {'ForeName': 'Nilo', 'Initials': 'N', 'LastName': 'Frantz', 'Affiliation': 'Nilo Frantz Reproductive Medicine, Av Dr Nilo Peçanha 1221 - 10° andar, Boa Vista Porto Alegre, Brazil.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Kulmann', 'Affiliation': 'Nilo Frantz Reproductive Medicine, Av Dr Nilo Peçanha 1221 - 10° andar, Boa Vista Porto Alegre, Brazil.'}, {'ForeName': 'Sagiri', 'Initials': 'S', 'LastName': 'Taguchi', 'Affiliation': 'Oak Clinic Japan, 2-7-9 Tamade-Nishi, Nishinari-ku Osaka 557-0045, Japan.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Labarta', 'Affiliation': 'IVI-RMA Valencia, Plaza de la Policía Local 3, Valencia 46015, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Colucci', 'Affiliation': 'Centro de Infertilidade e Medicina Fetal do Norte Fluminense, R Barão da Lagoa Dourada 409 - Centro, Campos dos Goytacazes Rio de Janeiro 28035-210, Brazil.'}, {'ForeName': 'Shari', 'Initials': 'S', 'LastName': 'Mackens', 'Affiliation': 'Department of Reproductive Medicine, Universitair Ziekenhuis Brussel, 101 Laarbeeklaan, Jette Brussels 1090, Belgium.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Santamaría', 'Affiliation': 'IVI-RMA Barcelona, Ronda General Mitre 14 Barcelona 08017, Spain.'}, {'ForeName': 'Elkin', 'Initials': 'E', 'LastName': 'Muñoz', 'Affiliation': 'IVI-RMA Vigo, Plaza Francisco Fernández del Riego 7, Vigo 36203, Spain.'}, {'ForeName': 'Saúl', 'Initials': 'S', 'LastName': 'Barrera', 'Affiliation': 'IVI-RMA Panama, Calle 50 & Calle 57 Este, Panama City Panamá 07185.'}, {'ForeName': 'Juan Antonio', 'Initials': 'JA', 'LastName': 'García-Velasco', 'Affiliation': 'IVI-RMA Madrid, Av Del Talgo 68, Aravaca Madrid 28023, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Fernández', 'Affiliation': 'IVI-RMA Sevilla, Av República Argentina 58 Sevilla 41011, Spain; Departamento de Cirugía, Universidad de Sevilla, Avda. Sánchez Pizjuan S/N Sevilla 41009, Spain; Departamento de Biología Molecular e Ingeniería Bioquímica, Universidad Pablo de Olavide Sevilla 41013, Spain.'}, {'ForeName': 'Marcos', 'Initials': 'M', 'LastName': 'Ferrando', 'Affiliation': 'IVI-RMA Bilbao, Leioa Paseo Landabarri 1Vizcaya 48940, Spain.'}, {'ForeName': 'María', 'Initials': 'M', 'LastName': 'Ruiz', 'Affiliation': 'Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.'}, {'ForeName': 'Ben W', 'Initials': 'BW', 'LastName': 'Mol', 'Affiliation': 'Department of Obstetrics and Gynaecology, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton Victoria 3168, Australia.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'Valbuena', 'Affiliation': 'Igenomix Foundation-INCLIVA, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain; Igenomix SL, Parque Tecnológico de Paterna, Ronda Narciso Monturiol Estarriol 11B, Paterna Valencia 46980, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Reproductive biomedicine online,['10.1016/j.rbmo.2020.06.002'] 2595,32723718,Haptic Nudges Increase Affected Upper Limb Movement During Inpatient Stroke Rehabilitation: Multiple-Period Randomized Crossover Study.,"BACKGROUND As many as 80% of stroke survivors experience upper limb (UL) disability. The strong relationships between disability, lost productivity, and ongoing health care costs mean reducing disability after stroke is critical at both individual and society levels. Unfortunately, the amount of UL-focused rehabilitation received by people with stroke is extremely low. Activity monitoring and promotion using wearable devices offer a potential technology-based solution to address this gap. Commonly, wearable devices are used to deliver a haptic nudge to the wearer with the aim of promoting a particular behavior. However, little is known about the effectiveness of haptic nudging in promoting behaviors in patient populations. OBJECTIVE This study aimed to estimate the effect of haptic nudging delivered via a wrist-worn wearable device on UL movement in people with UL disability following stroke undertaking inpatient rehabilitation. METHODS A multiple-period randomized crossover design was used to measure the association of UL movement with the occurrence of haptic nudge reminders to move the affected UL in 20 people with stroke undertaking inpatient rehabilitation. UL movement was observed and classified using movement taxonomy across 72 one-minute observation periods from 7:00 AM to 7:00 PM on a single weekday. On 36 occasions, a haptic nudge to move the affected UL was provided just before the observation period. On the other 36 occasions, no haptic nudge was given. The timing of the haptic nudge was randomized across the observation period for each participant. Statistical analysis was performed using mixed logistic regression. The effect of a haptic nudge was evaluated from the intention-to-treat dataset as the ratio of the odds of affected UL movement during the observation period following a ""Planned Nudge"" to the odds of affected limb movement during the observation period following ""No Nudge."" RESULTS The primary intention-to-treat analysis showed the odds ratio (OR) of affected UL movement following a haptic nudge was 1.44 (95% CI 1.28-1.63, P<.001). The secondary analysis revealed an increased odds of affected UL movement following a Planned Nudge was predominantly due to increased odds of spontaneous affected UL movement (OR 2.03, 95% CI 1.65-2.51, P<.001) rather than affected UL movement in conjunction with unaffected UL movement (OR 1.13, 95% CI 0.99-1.29, P=.07). CONCLUSIONS Haptic nudging delivered via a wrist-worn wearable device increases affected UL movement in people with UL disability following stroke undertaking inpatient rehabilitation. The promoted movement appears to be specific to the instructions given. TRIAL REGISTRATION Australia New Zealand Clinical Trials Registry 12616000654459; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370687&isReview=true.",2020,"The secondary analysis revealed an increased odds of affected UL movement following a Planned Nudge was predominantly due to increased odds of spontaneous affected UL movement (OR 2.03, 95% CI 1.65-2.51, P<.001) rather than affected UL movement in conjunction with unaffected UL movement (OR 1.13, 95% CI 0.99-1.29, P=.07). ","['20 people with stroke undertaking inpatient rehabilitation', 'people with UL disability following stroke undertaking inpatient rehabilitation']","['haptic nudging delivered via a wrist-worn wearable device', 'Haptic nudging delivered via a wrist-worn wearable device', 'haptic nudge']","['Upper Limb Movement', 'odds ratio (OR) of affected UL movement']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist region structure'}, {'cui': 'C4505348', 'cui_str': 'Wearable Technology'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0392760', 'cui_str': 'Affecting'}]",20.0,0.185218,"The secondary analysis revealed an increased odds of affected UL movement following a Planned Nudge was predominantly due to increased odds of spontaneous affected UL movement (OR 2.03, 95% CI 1.65-2.51, P<.001) rather than affected UL movement in conjunction with unaffected UL movement (OR 1.13, 95% CI 0.99-1.29, P=.07). ","[{'ForeName': 'Nada Elizabeth June', 'Initials': 'NEJ', 'LastName': 'Signal', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'McLaren', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Usman', 'Initials': 'U', 'LastName': 'Rashid', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Vandal', 'Affiliation': 'Department of Statistics, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'King', 'Affiliation': 'Callaghan Innovation, Christchurch, New Zealand.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Almesfer', 'Affiliation': 'Exsurgo Rehabilitation, Auckland, New Zealand.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Henderson', 'Affiliation': 'Assessment, Treatment and Rehabilitation Department, Waitakere Hospital, Waitemata District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Taylor', 'Affiliation': 'Health and Rehabilitation Research Institute, Auckland University of Technology, Auckland, New Zealand.'}]",JMIR mHealth and uHealth,['10.2196/17036'] 2596,32723722,Virtual Reality Smartphone-Based Intervention for Smoking Cessation: Pilot Randomized Controlled Trial on Initial Clinical Efficacy and Adherence.,"BACKGROUND Obstacles to current tobacco cessation programs include limited access and adherence to effective interventions. Digital interventions offer a great opportunity to overcome these difficulties, yet virtual reality has not been used as a remote and self-administered tool to help increase adherence and effectiveness of digital interventions for tobacco cessation. OBJECTIVE This study aimed to evaluate participant adherence and smoking cessation outcomes in a pilot randomized controlled trial of the digital intervention Mindcotine (MindCotine Inc) using a self-administered treatment of virtual reality combined with mindfulness. METHODS A sample of 120 participants was recruited in the city of Buenos Aires, Argentina (mean age 43.20 years, SD 9.50; 57/120, 47.5% female). Participants were randomly assigned to a treatment group (TG), which received a self-assisted 21-day program based on virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists, or a control group (CG), which received the online version of the smoking cessation manual from the Argentine Ministry of Health. Follow-up assessments were conducted by online surveys at postintervention and 90-day follow-up. The primary outcome was self-reported abstinence at postintervention, with missing data assumed as still smoking. Secondary outcomes included sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit. RESULTS Follow-up rates at day 1 were 93% (56/60) for the TG and 100% (60/60) for the CG. At postintervention, the TG reported 23% (14/60) abstinence on that day compared with 5% (3/60) in the CG. This difference was statistically significant (χ 2 1 =8.3; P=.004). The TG reported sustained abstinence of 33% (20/60) at 90 days. Since only 20% (12/60) of participants in the CG completed the 90-day follow-up, we did not conduct a statistical comparison between groups at this follow-up time point. Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005). A total of 41% (23/56) of participants completed the treatment in the time frame recommended by the program. CONCLUSIONS Results provide initial support for participant adherence to and efficacy of Mindcotine and warrant testing the intervention in a fully powered randomized trial. However, feasibility of trial follow-up assessment procedures for control group participants needs to be improved. Further research is needed on the impact of VR-MET on long-term outcomes. TRIAL REGISTRATION ISRCTN Registry ISRCTN50586181; http://www.isrctn.com/ISRCTN50586181.",2020,"Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005).","['A sample of 120 participants was recruited in the city of Buenos Aires, Argentina (mean age 43.20 years, SD 9.50; 57/120, 47.5% female', 'Smoking Cessation']","['digital intervention Mindcotine (MindCotine Inc', 'Virtual Reality Smartphone-Based Intervention', 'virtual reality combined with mindfulness', 'self-assisted 21-day program based on virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support moderated by psychologists, or a control group (CG), which received the online version of the smoking cessation manual from the Argentine Ministry of Health', 'Mindcotine']","['self-reported abstinence at postintervention, with missing data assumed as still smoking', 'ready to quit', 'sustained abstinence at 90-day follow-up, adherence to the program, and readiness to quit']","[{'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C1741275', 'cui_str': 'AIRE protein, human'}, {'cui': 'C0003761', 'cui_str': 'Argentina'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}]","[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0033908', 'cui_str': 'Psychologist'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C0024763', 'cui_str': 'Manuals as Topic'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}]",120.0,0.0805419,"Among participants still smoking at postintervention, the TG was significantly more ready to quit compared to the CG (TG: mean 7.71, SD 0.13; CG: mean 7.16, SD 0.13; P=.005).","[{'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Goldenhersch', 'Affiliation': 'Laboratorio de Investigación en Neurociencia y Ciencias Sociales, Universidad de Flores, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Thrul', 'Affiliation': 'Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.'}, {'ForeName': 'Joaquín', 'Initials': 'J', 'LastName': 'Ungaretti', 'Affiliation': 'Facultad de Psicología, Universidad de Buenos Aires, Buenos Aires, Argentina.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rosencovich', 'Affiliation': 'Escuela de Ingeniería Biomédica, Universidad Nacional de Córdoba, Córdoba, Argentina.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Waitman', 'Affiliation': 'Universidad Siglo XXI, Córdoba, Argentina.'}, {'ForeName': 'Marcelo Rodriguez', 'Initials': 'MR', 'LastName': 'Ceberio', 'Affiliation': 'Laboratorio de Investigación en Neurociencia y Ciencias Sociales, Universidad de Flores, Ciudad Autónoma de Buenos Aires, Argentina.'}]",Journal of medical Internet research,['10.2196/17571'] 2597,32723723,Acceptance and Commitment Therapy Delivered via a Mobile Phone Messaging Robot to Decrease Postoperative Opioid Use in Patients With Orthopedic Trauma: Randomized Controlled Trial.,"BACKGROUND Acceptance and commitment therapy (ACT) is a pragmatic approach to help individuals decrease avoidable pain. OBJECTIVE This study aims to evaluate the effects of ACT delivered via an automated mobile messaging robot on postoperative opioid use and patient-reported outcomes (PROs) in patients with orthopedic trauma who underwent operative intervention for their injuries. METHODS Adult patients presenting to a level 1 trauma center who underwent operative fixation of a traumatic upper or lower extremity fracture and who used mobile phone text messaging were eligible for the study. Patients were randomized in a 1:1 ratio to either the intervention group, who received twice-daily mobile phone messages communicating an ACT-based intervention for the first 2 weeks after surgery, or the control group, who received no messages. Baseline PROs were completed. Two weeks after the operative intervention, follow-up was performed in the form of an opioid medication pill count and postoperative administration of PROs. The mean number of opioid tablets used by patients was calculated and compared between groups. The mean PRO scores were also compared between the groups. RESULTS A total of 82 subjects were enrolled in the study. Of the 82 participants, 76 (38 ACT and 38 controls) completed the study. No differences between groups in demographic factors were identified. The intervention group used an average of 26.1 (SD 21.4) opioid tablets, whereas the control group used 41.1 (SD 22.0) tablets, resulting in 36.5% ([41.1-26.1]/41.1) less tablets used by subjects receiving the mobile phone-based ACT intervention (P=.004). The intervention group subjects reported a lower postoperative Patient-Reported Outcome Measure Information System Pain Intensity score (mean 45.9, SD 7.2) than control group subjects (mean 49.7, SD 8.8; P=.04). CONCLUSIONS In this study, the delivery of an ACT-based intervention via an automated mobile messaging robot in the acute postoperative period decreased opioid use in selected patients with orthopedic trauma. Participants receiving the ACT-based intervention also reported lower pain intensity after 2 weeks, although this may not represent a clinically important difference. TRIAL REGISTRATION ClinicalTrials.gov NCT03991546; https://clinicaltrials.gov/ct2/show/NCT03991546.",2020,"The intervention group subjects reported a lower postoperative Patient-Reported Outcome Measure Information System Pain Intensity score (mean 45.9, SD 7.2) than control group subjects (mean 49.7, SD 8.8; P=.04). ","['patients with orthopedic trauma who underwent operative intervention for their injuries', 'Patients', '82 participants, 76 (38 ACT and 38 controls) completed the study', 'Adult patients presenting to a level 1 trauma center who underwent operative fixation of a traumatic upper or lower extremity fracture and who used mobile phone text messaging were eligible for the study', 'selected patients with orthopedic trauma', 'A total of 82 subjects were enrolled in the study']","['commitment therapy (ACT', 'mobile phone-based ACT intervention', 'ACT-based intervention', 'ACT delivered via an automated mobile messaging robot', 'ACT-based intervention via an automated mobile messaging robot', 'twice-daily mobile phone messages communicating an ACT-based intervention']","['lower postoperative Patient-Reported Outcome Measure Information System Pain Intensity score', 'pain intensity', 'mean number of opioid tablets', 'Postoperative Opioid Use', 'mean PRO scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1274117', 'cui_str': 'Trauma & orthopedics'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0040786', 'cui_str': 'Trauma center'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0332663', 'cui_str': 'Traumatic'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C1542178', 'cui_str': 'Fracture of lower leg'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0029917', 'cui_str': 'Outpatient Commitment'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0205196', 'cui_str': 'Communicating'}]","[{'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0021428', 'cui_str': 'Information system'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0033382', 'cui_str': 'Proline'}]",82.0,0.223987,"The intervention group subjects reported a lower postoperative Patient-Reported Outcome Measure Information System Pain Intensity score (mean 45.9, SD 7.2) than control group subjects (mean 49.7, SD 8.8; P=.04). ","[{'ForeName': 'Chris A', 'Initials': 'CA', 'LastName': 'Anthony', 'Affiliation': 'Department of Orthopaedics, University of Pennsylvania, Philadelphia, PA, United States.'}, {'ForeName': 'Edward Octavio', 'Initials': 'EO', 'LastName': 'Rojas', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Keffala', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Natalie Ann', 'Initials': 'NA', 'LastName': 'Glass', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Apurva S', 'Initials': 'AS', 'LastName': 'Shah', 'Affiliation': ""Children's Hospital of Philadelphia Main Campus Division of Orthopaedics, Philadelphia, PA, United States.""}, {'ForeName': 'Benjamin J', 'Initials': 'BJ', 'LastName': 'Miller', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Hogue', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Michael C', 'Initials': 'MC', 'LastName': 'Willey', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Karam', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}, {'ForeName': 'John Lawrence', 'Initials': 'JL', 'LastName': 'Marsh', 'Affiliation': 'Department of Orthopaedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.'}]",Journal of medical Internet research,['10.2196/17750'] 2598,32723754,Motivational Interview to improve vascular health in Adolescents with poorly controlled type 1 Diabetes (MIAD): a randomized controlled trial.,"INTRODUCTION We studied if motivational interviewing (MI) added to standard educational care (SEC) improves vascular health in adolescents with poorly controlled type 1 diabetes. RESEARCH DESIGN AND METHODS 47 adolescents with type 1 diabetes of at least 2 years duration and hemoglobin A1c >75 mmol/mol (>9.0%) on two visits were randomized to MI+SEC or SEC. We also compared vascular health parameters of patients with type 1 diabetes at trial baseline with a group of healthy historical controls matched for age and body size. RESULTS 39 adolescents (20 MI+SEC) completed the vascular health study. At 12 months, parameter changes were not statistically significantly different between MI+SEC and SEC (carotid-femoral pulse wave velocity (cfPWV): mean difference 0.052 m/s (95% CI -0.395 to 0.500, p=0.81); carotid-radial PWV (crPWV): 0.118 m/s (95% to 0.478 to 0.713, p=0.69), carotid intima-media thickness (IMT): 0.002 mm (95% CI -0.37 to 0.40, p=0.93), systolic blood pressure (BP) z-score: 0.495 (95% CI -0.099 to 1.09, p=0.10). At baseline, duration of type 1 diabetes was associated with radial IMT (r=0.430, p=0.007) and cfPWV (r=0.373, p=0.018), and carotid, femoral and brachial IMT were correlated with continuous glucose monitoring (CGM) SD (r=0.440, p=0.017; r=0.377, p=0.048; r=0.387, p=0.038). There was an inverse association between CGM time-in-range (3.9-10.0 mmol/L) and crPWV (r=-0.476, p=0.022) changes. Systolic BP change was associated with body mass index change (r=0.374, p=0.019) and IMT change (r=0.461, p=0.016 for carotid IMT; r=0.498, p=0.010 for femoral IMT). PWVs were higher and common carotid compliance lower among patients with type 1 diabetes at baseline compared with healthy controls, but no other differences were found. CONCLUSION There was no effect of MI added to SEC on vascular health parameters. Although disease duration and glycemic control were associated with vascular health at baseline, there were only limited associations between glycemic control and vascular health parameter changes. Vascular health parameter changes were interrelated suggesting clustering of cardiovascular risk. TRIAL REGISTRATION NUMBER NCT02637154.",2020,"At 12 months, parameter changes were not statistically significantly different between MI+SEC and SEC (carotid-femoral pulse wave velocity (cfPWV): mean difference 0.052 m/s (95% CI -0.395 to 0.500, p=0.81); carotid-radial PWV (crPWV): 0.118 m/s (95% to 0.478 to 0.713, p=0.69), carotid intima-media thickness (IMT): 0.002 mm (95% CI -0.37 to 0.40, p=0.93), systolic blood pressure (BP) z-score: 0.495 (95% CI -0.099 to 1.09, p=0.10).","['patients with type 1 diabetes at trial baseline with a group of healthy historical controls matched for age and body size', '39 adolescents (20 MI+SEC) completed the vascular health study', '47 adolescents with type 1 diabetes of at least 2 years duration and hemoglobin A1c', 'Adolescents with poorly controlled type 1 Diabetes (MIAD', 'adolescents with poorly controlled type 1 diabetes']","['MI+SEC\u2009or SEC', 'Motivational Interview', 'motivational interviewing (MI) added to standard educational care (SEC']","['vascular health parameters', 'body mass index change', 'cfPWV', 'continuous glucose monitoring (CGM) SD', 'IMT change', 'carotid, femoral and brachial IMT', 'radial IMT', 'PWVs', 'vascular health', 'CGM time-in-range', 'systolic blood pressure', 'carotid intima-media thickness', 'Systolic BP change']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005901', 'cui_str': 'Body Size'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0441729', 'cui_str': 'Type 1'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}]","[{'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0334121', 'cui_str': 'Inflammatory myofibroblastic tumor'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0445456', 'cui_str': 'Brachial'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}]",47.0,0.269754,"At 12 months, parameter changes were not statistically significantly different between MI+SEC and SEC (carotid-femoral pulse wave velocity (cfPWV): mean difference 0.052 m/s (95% CI -0.395 to 0.500, p=0.81); carotid-radial PWV (crPWV): 0.118 m/s (95% to 0.478 to 0.713, p=0.69), carotid intima-media thickness (IMT): 0.002 mm (95% CI -0.37 to 0.40, p=0.93), systolic blood pressure (BP) z-score: 0.495 (95% CI -0.099 to 1.09, p=0.10).","[{'ForeName': 'Mari-Anne', 'Initials': 'MA', 'LastName': 'Pulkkinen', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Anna-Kaisa', 'Initials': 'AK', 'LastName': 'Tuomaala', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Hero', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.""}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Gordin', 'Affiliation': 'Folkhälsan Research Center, Folkhälsan Institute of Genetics, Helsinki, Finland.'}, {'ForeName': 'Taisto', 'Initials': 'T', 'LastName': 'Sarkola', 'Affiliation': ""Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland taisto.sarkola@helsinki.fi.""}]",BMJ open diabetes research & care,['10.1136/bmjdrc-2020-001216'] 2599,32723804,"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.","BACKGROUND AND OBJECTIVES Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates genes related to iron metabolism. The efficacy (noninferiority) and safety of daprodustat compared with standard therapy (darbepoetin alfa) was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS This was a randomized, phase 3, double-blind, active-control study in Japanese patients receiving hemodialysis with anemia of CKD. Participants' treatment was switched from current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin alfa 10-60 μ g once weekly (on the basis of the prestudy ESA dose). Dose was adjusted every 4 weeks for daprodustat or every 2 weeks for darbepoetin alfa, according to a protocol-specified algorithm. The primary end point was mean hemoglobin during weeks 40-52 in the intent-to-treat population. RESULTS Of 332 participants screened, 271 participants were randomized (safety evaluation: 271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin during weeks 40-52 were maintained within the target range in both groups (10.9 g/dl [95% confidence interval (95% CI), 10.8 to 11.0] for daprodustat, and 10.8 g/dl [95% CI, 10.7 to 11.0] for darbepoetin alfa). Daprodustat was noninferior to darbepoetin alfa, as the lower bound of the confidence interval for the treatment difference (0.1 g/dl; 95% CI, -0.1 to 0.2 g/dl) was greater than the noninferiority criterion of -1.0 g/dl. For most participants, hemoglobin was maintained within the target range (10.0-12.0 g/dl) during weeks 40-52 (88% daprodustat; 90% darbepoetin alfa). Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group. Frequency of adverse events were generally similar between daprodustat and darbepoetin alfa. CONCLUSIONS Oral daprodustat was noninferior to darbepoetin alfa as measured by mean hemoglobin over weeks 40-52 in Japanese patients receiving hemodialysis switched from ESAs. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER 201754, Clinicaltrials.gov, NCT02969655.",2020,"Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group.","['Japanese Hemodialysis Patients with Anemia', 'Japanese patients receiving hemodialysis switched from ESAs', 'Japanese patients receiving hemodialysis with anemia of CKD', '332 participants screened, 271 participants were randomized', '271 participants; efficacy evaluation: 267 intent-to-treat population']","['current erythropoiesis-stimulating agents (ESAs) to daprodustat 4 mg once daily or darbepoetin alfa', 'standard therapy (darbepoetin alfa', 'Daprodustat Compared with Darbepoetin Alfa']","['Efficacy and Safety', 'Geometric mean hepcidin levels', 'mean hemoglobin', 'hemoglobin', 'total iron-binding capacity', 'Frequency of adverse events']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0032659', 'cui_str': 'Population'}]","[{'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0014819', 'cui_str': 'Erythrocyte production'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0556983', 'cui_str': 'Once daily'}, {'cui': 'C0937950', 'cui_str': 'darbepoetin alfa'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0966897', 'cui_str': 'Hepcidin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0700379', 'cui_str': 'Total iron binding capacity'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",271.0,0.415077,"Geometric mean hepcidin levels decreased more at week 52 with daprodustat (-37%; 95% CI, -49 to -23) than with darbepoetin alfa (-20%; 95% CI, -36 to -1), and an increase in total iron-binding capacity was observed in the daprodustat group.","[{'ForeName': 'Tadao', 'Initials': 'T', 'LastName': 'Akizawa', 'Affiliation': 'Division of Nephrology, Showa University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Masaomi', 'Initials': 'M', 'LastName': 'Nangaku', 'Affiliation': 'Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Taeko', 'Initials': 'T', 'LastName': 'Yonekawa', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan taeko.yonekawa@gsk.com.'}, {'ForeName': 'Nobuhiko', 'Initials': 'N', 'LastName': 'Okuda', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Kawamatsu', 'Affiliation': 'Clinical Operations, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Onoue', 'Affiliation': 'Biomedical Data Sciences, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Yukihiro', 'Initials': 'Y', 'LastName': 'Endo', 'Affiliation': 'Medicines Development, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Katsutoshi', 'Initials': 'K', 'LastName': 'Hara', 'Affiliation': 'Clinical Pharmacology, Japan Development, GlaxoSmithKline, Tokyo, Japan.'}, {'ForeName': 'Alexander R', 'Initials': 'AR', 'LastName': 'Cobitz', 'Affiliation': 'Medicine Delivery, GlaxoSmithKline, Collegeville, Pennsylvania.'}]",Clinical journal of the American Society of Nephrology : CJASN,['10.2215/CJN.16011219'] 2600,32723843,Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA 1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIAL Study.,"OBJECTIVE International type 1 diabetes registries have shown that HbA 1c levels are highest in young people with type 1 diabetes; however, improving their glycemic control remains a challenge. We propose that use of the factory-calibrated Dexcom G6 CGM system would improve glycemic control in this cohort. RESEARCH DESIGN AND METHODS We conducted a randomized crossover trial in young people with type 1 diabetes (16-24 years old) comparing the Dexcom G6 CGM system and self-monitoring of blood glucose (SMBG). Participants were assigned to the interventions in random order during two 8-week study periods. During SMBG, blinded continuous glucose monitoring (CGM) was worn by each participant for 10 days at the start, week 4, and week 7 of the control period. HbA 1c measurements were drawn after enrollment and before and after each treatment period. The primary outcome was time in range 70-180 mg/dL. RESULTS Time in range was significantly higher during CGM compared with control (35.7 ± 13.5% vs. 24.6 ± 9.3%; mean difference 11.1% [95% CI 7.0-15.2]; P < 0.001). CGM use reduced mean sensor glucose (219.7 ± 37.6 mg/dL vs. 251.9 ± 36.3 mg/dL; mean difference -32.2 mg/dL [95% CI -44.5 to -20.0]; P < 0.001) and time above range (61.7 ± 15.1% vs. 73.6 ± 10.4%; mean difference 11.9% [95% CI -16.4 to -7.4]; P < 0.001). HbA 1c level was reduced by 0.76% (95% CI -1.1 to -0.4) (-8.5 mmol/mol [95% CI -12.4 to -4.6]; P < 0.001). Times spent below range (<70 mg/dL and <54 mg/dL) were low and comparable during both study periods. Sensor wear was 84% during the CGM period. CONCLUSIONS CGM use in young people with type 1 diabetes improves time in target and HbA 1c levels compared with SMBG.",2020,mean difference 11.1% [95% CI 7.0-15.2]; P < 0.001).,"['young people with type 1 diabetes (16-24 years old', 'Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes', 'young people with type 1 diabetes']","['Factory-Calibrated Real-time Continuous Glucose Monitoring', 'CGM', 'Dexcom G6 CGM system and self-monitoring of blood glucose (SMBG', 'factory-calibrated Dexcom G6 CGM system', 'dL']","['mean sensor glucose', 'glycemic control', 'time in range 70-180 mg/dL.\nRESULTS\n\n\nTime in range', 'HbA 1c level']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0442614', 'cui_str': 'Factory'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0005803', 'cui_str': 'Self-monitoring of blood glucose'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0183210', 'cui_str': 'Sensor device'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0460094', 'cui_str': 'Within reference range'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",,0.046691,mean difference 11.1% [95% CI 7.0-15.2]; P < 0.001).,"[{'ForeName': 'Hood', 'Initials': 'H', 'LastName': 'Thabit', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K. hood.thabit@mft.nhs.uk.'}, {'ForeName': 'Joshi Navis', 'Initials': 'JN', 'LastName': 'Prabhu', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K.'}, {'ForeName': 'Womba', 'Initials': 'W', 'LastName': 'Mubita', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Fullwood', 'Affiliation': 'Research and Innovation, Manchester Royal Infirmary, Manchester, U.K.'}, {'ForeName': 'Shazli', 'Initials': 'S', 'LastName': 'Azmi', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Urwin', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Doughty', 'Affiliation': ""Royal Manchester Children's Hospital, Manchester Royal Infirmary, Manchester, U.K.""}, {'ForeName': 'Lalantha', 'Initials': 'L', 'LastName': 'Leelarathna', 'Affiliation': 'Manchester Diabetes Centre, Manchester Royal Infirmary, Manchester, U.K.'}]",Diabetes care,['10.2337/dc20-0736'] 2601,32723859,Subject Preferences and Psychological Implications of Portable Oxygen Concentrator versus Compressed Oxygen Cylinder in Chronic Lung Disease.,"BACKGROUND Oxygen therapy represents the elective therapy to improve the quality of life for patients with chronic respiratory diseases like COPD and interstitial lung disease. Lightweight portable oxygen concentrators (POCs) are a valid alternative to traditional systems such as portable compressed oxygen cylinders. However, patient preference and the possible psychological implications related to the use of both devices have been poorly assessed. We sought to evaluate patient preference between the ambulatory oxygen systems (ie, a POC or a small cylinder) for patients with COPD and interstitial lung disease experiencing exertional desaturation in a rehabilitation setting. Furthermore, the use of one device in comparison with the other was related to specific mechanical characteristics and related to perceived quality of life, anxiety, and depressive symptoms. METHODS 30 subjects with COPD and interstitial lung disease, who demonstrated exertional desaturation on room air during 6-min walk test (6MWT), were recruited. Each subject performed 2 6MWTs, in random order: one breathing oxygen via a POC and one with a portable compressed oxygen cylinder. Both devices were set up to ensure oxyhemoglobin saturation between 92% and 95% during the 6MWTs. All subjects completed a questionnaire assessing anxiety, depression, and quality of life. Each device was randomly assigned to each subject for 1 week, and then replaced with the other in the following week. At the end of the trial period, all subjects completed a questionnaire evaluating several aspects of the oxygen therapy devices. RESULTS There were no significant differences in oxygen saturation or the mean distances achieved during the 6MWTs between the 2 portable oxygen devices. The subjects expressed greater preference for the POC (73.3%), basing their choice mainly on ease of transport and lower weight. Subjects' age also correlated with preferences: younger subjects were more negatively focused on the weight of the portable compressed oxygen cylinder, whereas older subjects considered the POC easier to manage. No significant differences in preferences were present between COPD and interstitial lung disease. CONCLUSIONS The POC and the portable compressed oxygen cylinder performed in a comparable manner during 6MWT for subjects with COPD and interstitial lung disease and exertional desaturation. Subjects preferred the POC because it was associated with better mobility.",2020,There were no significant differences in oxygen saturation or the mean distances achieved during the 6MWTs between the 2 portable oxygen devices.,"['patients with chronic respiratory diseases like COPD and interstitial lung disease', ""Subjects' age also correlated with preferences: younger subjects"", 'patients with COPD and interstitial lung disease experiencing exertional desaturation in a rehabilitation setting', 'subjects with COPD and interstitial lung disease and exertional desaturation', '30 subjects with COPD and interstitial lung disease, who demonstrated exertional desaturation on room air during 6-min walk test (6MWT), were recruited', 'Chronic Lung Disease']","['breathing oxygen via a POC and one with a portable compressed oxygen cylinder', 'Portable Oxygen Concentrator versus Compressed Oxygen Cylinder', 'Lightweight portable oxygen concentrators (POCs', 'ambulatory oxygen systems (ie, a POC or a small cylinder']","['quality of life', 'questionnaire assessing anxiety, depression, and quality of life', 'oxygen saturation', 'quality of life, anxiety, and depressive symptoms', 'oxyhemoglobin saturation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0264220', 'cui_str': 'Chronic disease of respiratory system'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0206062', 'cui_str': 'Interstitial lung disease'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0746961', 'cui_str': 'Oxygen saturation below reference range'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0746102', 'cui_str': 'Chronic lung disease'}]","[{'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0182124', 'cui_str': 'Oxygen cylinder'}, {'cui': 'C1618343', 'cui_str': 'Portable oxygen concentrator'}, {'cui': 'C0332260', 'cui_str': 'Compressing'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0181797', 'cui_str': 'Medical gas cylinder'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0030069', 'cui_str': 'Oxyhemoglobin'}, {'cui': 'C0522534', 'cui_str': 'Saturated'}]",30.0,0.0181871,There were no significant differences in oxygen saturation or the mean distances achieved during the 6MWTs between the 2 portable oxygen devices.,"[{'ForeName': 'Pasquale', 'Initials': 'P', 'LastName': 'Moretta', 'Affiliation': 'Neurology Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Molino', 'Affiliation': 'Respiratory Division, Department of Respiratory Medicine, Federico II University, Naples, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Martucci', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.'}, {'ForeName': 'Salvatore', 'Initials': 'S', 'LastName': 'Fuschillo', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'De Felice', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.'}, {'ForeName': 'Pietro', 'Initials': 'P', 'LastName': 'Guida', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Motta', 'Affiliation': 'Institute of Biomolecular Chemistry, National Research Council, Naples, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Vitacca', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Lumezzane, Brescia, Italy.'}, {'ForeName': 'Mauro', 'Initials': 'M', 'LastName': 'Maniscalco', 'Affiliation': 'Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy. mauro.maniscalco@icsmaugeri.it.'}]",Respiratory care,['10.4187/respcare.07829'] 2602,32729838,Effects of the e-Motivate4Change Program on Metabolic Syndrome in Young Adults Using Health Apps and Wearable Devices: Quasi-Experimental Study.,"BACKGROUND The health behaviors of young adults lag behind those of other age groups, and active health management is needed to improve health behaviors and prevent chronic diseases. In addition, developing good lifestyle habits earlier in life could reduce the risk of metabolic syndrome (MetS) later on. OBJECTIVE The aim of this study is to investigate the effects of the e-Motivate4Change program, for which health apps and wearable devices were selected based on user needs. The program was developed for the prevention and management of MetS in young adults. METHODS This experimental study used a nonequivalent control group. In total, 59 students from 2 universities in Daegu, Korea participated in the study (experimental group n=30; control group n=29). Data were collected over 4 months, from June 1 to September 30, 2018. The experimental group received a 12-week e-Motivate4Change program intervention, and the control group received MetS education and booklets without the e-Motivate4Change program intervention. RESULTS After the program, the experimental group had significantly higher scores for health-related lifestyle (t=3.86; P<.001) and self-efficacy (t=6.00; P<.001) than did the control group. Concerning BMI, there were significant effects by group (F=1.01; P<.001) and for the group × time interaction (F=4.71; P=.034). Concerning cholesterol, there were significant main effects for group (F=4.32; P=.042) and time (F=9.73; P<.001). CONCLUSIONS The e-Motivate4Change program effectively improved participants' health-related lifestyle scores and self-efficacy, and significantly reduced their BMI and cholesterol levels. The program can be used to identify and prevent MetS among young adults.",2020,"Concerning cholesterol, there were significant main effects for group (F=4.32; P=.042) and time (F=9.73; P<.001). ","['59 students from 2 universities in Daegu, Korea participated in the study (experimental group n=30; control group n=29', 'young adults', 'Young Adults Using Health Apps and Wearable Devices']","['e-Motivate4Change program', '12-week e-Motivate4Change program intervention, and the control group received MetS education and booklets without the e-Motivate4Change program intervention', 'e-Motivate4Change Program']","[""participants' health-related lifestyle scores and self-efficacy"", 'higher scores for health-related lifestyle', 'Metabolic Syndrome', 'self-efficacy', 'BMI and cholesterol levels']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0022771', 'cui_str': 'Korea'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C4505348', 'cui_str': 'Wearable Technology'}]","[{'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}]",59.0,0.0179104,"Concerning cholesterol, there were significant main effects for group (F=4.32; P=.042) and time (F=9.73; P<.001). ","[{'ForeName': 'Ji-Soo', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Keimyung University, Daegu, Republic of Korea.'}, {'ForeName': 'Min-Ah', 'Initials': 'MA', 'LastName': 'Kang', 'Affiliation': 'Keimyung University, Daegu, Republic of Korea.'}, {'ForeName': 'Soo-Kyoung', 'Initials': 'SK', 'LastName': 'Lee', 'Affiliation': 'Keimyung University, Daegu, Republic of Korea.'}]",Journal of medical Internet research,['10.2196/17031'] 2603,32729843,Technology-Enabled Self-Management of Chronic Obstructive Pulmonary Disease With or Without Asynchronous Remote Monitoring: Randomized Controlled Trial.,"BACKGROUND Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality and leads to frequent hospital admissions and emergency department (ED) visits. COPD exacerbations are an important patient outcome, and reducing their frequency would result in significant cost savings. Remote monitoring and self-monitoring could both help patients manage their symptoms and reduce the frequency of exacerbations, but they have different resource implications and have not been directly compared. OBJECTIVE This study aims to compare the effectiveness of implementing a technology-enabled self-monitoring program versus a technology-enabled remote monitoring program in patients with COPD compared with a standard care group. METHODS We conducted a 3-arm randomized controlled trial evaluating the effectiveness of a remote monitoring and a self-monitoring program relative to standard care. Patients with COPD were recruited from outpatient clinics and a pulmonary rehabilitation program. Patients in both interventions used a Bluetooth-enabled device kit to monitor oxygen saturation, blood pressure, temperature, weight, and symptoms, but only patients in the remote monitoring group were monitored by a respiratory therapist. All patients were assessed at baseline and at 3 and 6 months after program initiation. Outcomes included self-management skills, as measured by the Partners in Health (PIH) Scale; patient symptoms measured with the St George's Respiratory Questionnaire (SGRQ); and the Bristol COPD Knowledge Questionnaire (BCKQ). Patients were also asked to self-report on health system use, and data on health use were collected from the hospital. RESULTS A total of 122 patients participated in the study: 40 in the standard care, 41 in the self-monitoring, and 41 in the remote monitoring groups. Although all 3 groups improved in PIH scores, BCKQ scores, and SGRQ impact scores, there were no significant differences among any of the groups. No effects were observed on the SGRQ activity or symptom scores or on hospitalizations, ED visits, or clinic visits. CONCLUSIONS Despite regular use of the technology, patients with COPD assigned to remote monitoring or self-monitoring did not have any improvement in patient outcomes such as self-management skills, knowledge, or symptoms, or in health care use compared with each other or with a standard care group. This may be owing to low health care use at baseline, the lack of structured educational components in the intervention groups, and the lack of integration of the action plan with the technology. TRIAL REGISTRATION ClinicalTrials.gov NCT03741855; https://clinicaltrials.gov/ct2/show/ NCT03741855.",2020,"No effects were observed on the SGRQ activity or symptom scores or on hospitalizations, ED visits, or clinic visits. ","['Chronic obstructive pulmonary disease (COPD', 'patients with COPD compared with a standard care group', 'Patients with COPD were recruited from outpatient clinics and a pulmonary rehabilitation program', '122 patients participated in the study: 40 in the standard care, 41 in the self-monitoring, and 41 in the remote monitoring groups', 'Chronic Obstructive Pulmonary Disease']","['technology-enabled self-monitoring program versus a technology-enabled remote monitoring program', 'remote monitoring and a self-monitoring program relative to standard care']","['PIH scores, BCKQ scores, and SGRQ impact scores', 'SGRQ activity or symptom scores or on hospitalizations, ED visits, or clinic visits', ""self-management skills, as measured by the Partners in Health (PIH) Scale; patient symptoms measured with the St George's Respiratory Questionnaire (SGRQ); and the Bristol COPD Knowledge Questionnaire (BCKQ"", 'Bluetooth-enabled device kit to monitor oxygen saturation, blood pressure, temperature, weight, and symptoms', 'COPD exacerbations']","[{'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0199529', 'cui_str': 'Pulmonary rehabilitation'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C3875154', 'cui_str': 'Relative to'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0008952', 'cui_str': 'Clinic Visits'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C3508933', 'cui_str': 'Chronic obstructive pulmonary disease exacerbation'}]",122.0,0.0434727,"No effects were observed on the SGRQ activity or symptom scores or on hospitalizations, ED visits, or clinic visits. ","[{'ForeName': 'Vess', 'Initials': 'V', 'LastName': 'Stamenova', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Liang', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Yang', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Katrina', 'Initials': 'K', 'LastName': 'Engel', 'Affiliation': 'Respiratory Therapy Department, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'van Lieshout', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Lalingo', 'Affiliation': 'Medicine, Care Transitions, Access & Flow, Respiratory Therapy, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Angelica', 'Initials': 'A', 'LastName': 'Cheung', 'Affiliation': 'Respiratory Therapy Department, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Erwood', 'Affiliation': 'Support Services & Transformation, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Radina', 'Affiliation': 'Center for Respiratory Health, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Greenwald', 'Affiliation': 'Center for Respiratory Health, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Payal', 'Initials': 'P', 'LastName': 'Agarwal', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Aman', 'Initials': 'A', 'LastName': 'Sidhu', 'Affiliation': 'University Health Network, Toronto, ON, Canada.'}, {'ForeName': 'R Sacha', 'Initials': 'RS', 'LastName': 'Bhatia', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Shaw', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'Shafai', 'Affiliation': 'Hospital to Home and Community Medicine Clinic, Markham Stouffville Hospital, Markham, ON, Canada.'}, {'ForeName': 'Onil', 'Initials': 'O', 'LastName': 'Bhattacharyya', 'Affiliation': ""Institute for Health System Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}]",Journal of medical Internet research,['10.2196/18598'] 2604,32729887,Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.,"Importance For women with a 20% or more familial risk of breast cancer without a known BRCA1/2 (BRCA1, OMIM 113705; and BRCA2, OMIM 114480) or TP53 (OMIM 151623) variant, screening guidelines vary substantially, and cost-effectiveness analyses are scarce. Objective To assess the cost-effectiveness of magnetic resonance imaging (MRI) screening strategies for women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant. Design, Setting, and Participants In this economic evaluation, conducted from February 1, 2019, to May 25, 2020, microsimulation modeling was used to estimate costs and effectiveness on a lifetime horizon from age 25 years until death of MRI screening among a cohort of 10 million Dutch women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant. A Dutch screening setting was modeled. Most data were obtained from the randomized Familial MRI Screening (FaMRIsc) trial, which included Dutch women aged 30 to 55 years. A health care payer perspective was applied. Interventions Several screening protocols with varying ages and intervals including those of the randomized FaMRIsc trial, consisting of the mammography (Mx) protocol (annual mammography and clinical breast examination) and the MRI protocol (annual MRI and clinical breast examination plus biennial mammography). Main Outcomes and Measures Costs, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated and discounted by 3%. A threshold of €22 000 (US $24 795.87) per QALY was applied. Results This economic evaluation modeling study estimated that, on a lifetime horizon per 1000 women with the Mx protocol of the FaMRIsc trial, 346 breast cancers would be detected, and 49 women were estimated to die from breast cancer, resulting in 22 885 QALYs and total costs of €7 084 767 (US $7 985 134.61). The MRI protocol resulted in 79 additional QALYs and additional €2 657 266 (US $2 994 964.65). Magnetic resonance imaging performed only every 18 months between the ages of 35 and 60 years followed by the national screening program was considered optimal, with an ICER of €21 380 (US $24 097.08) compared with the previous nondominated strategy in the ranking, when applying the National Institute for Health and Care Excellence threshold. Annual screening alternating MRI and mammography between the ages of 35 and 60 years, followed by the national screening program, gave similar outcomes. Higher thresholds would favor annual MRI screening. The ICER was most sensitive to the unit cost of MRI and the utility value for ductal carcinoma in situ and localized breast cancer. Conclusions and Relevance This study suggests that MRI screening every 18 months between the ages of 35 and 60 years for women with a family history of breast cancer is cost-effective within the National Institute for Health and Care Excellence threshold for all densities. Higher thresholds would favor annual MRI screening. These outcomes support a change of current screening guidelines for this specific risk group and support MRI screening.",2020,The MRI protocol resulted in 79 additional QALYs and additional €2 657 266 (US $2 994 964.65).,"['age 25 years until death of MRI screening among a cohort of 10 million Dutch women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant', 'Dutch women aged 30 to 55 years', 'Women at Familial Risk', '1000 women with the Mx protocol of the FaMRIsc trial, 346 breast cancers would be detected, and 49 women were estimated to die from breast cancer, resulting in 22\u202f885 QALYs and total costs of €7\u202f084\u202f767 (US $7\u202f985\u202f134.61', 'women with a 20% or more familial risk for breast cancer without a known BRCA1/2 or TP53 variant', 'MRI screening every 18 months between the ages of 35 and 60 years for women with a family history of breast cancer']","['Magnetic resonance imaging', 'mammography (Mx) protocol (annual mammography and clinical breast examination) and the MRI protocol (annual MRI and clinical breast examination plus biennial mammography', 'Breast Cancer Screening With Magnetic Resonance Imaging', 'magnetic resonance imaging (MRI) screening strategies']","['Measures\n\n\nCosts, life-years, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs']","[{'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0079419', 'cui_str': 'Genes, TP53'}, {'cui': 'C0205419', 'cui_str': 'Variant'}, {'cui': 'C1883310', 'cui_str': '1000'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1261325', 'cui_str': 'Family history of breast cancer'}]","[{'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0199850', 'cui_str': 'Examination of breast'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0281182', 'cui_str': 'Screening for malignant neoplasm of breast'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",0.0,0.0459929,The MRI protocol resulted in 79 additional QALYs and additional €2 657 266 (US $2 994 964.65).,"[{'ForeName': 'H Amarens', 'Initials': 'HA', 'LastName': 'Geuzinge', 'Affiliation': 'Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Inge-Marie', 'Initials': 'IM', 'LastName': 'Obdeijn', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Emiel J T', 'Initials': 'EJT', 'LastName': 'Rutgers', 'Affiliation': 'Department of Surgery, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.'}, {'ForeName': 'Sepideh', 'Initials': 'S', 'LastName': 'Saadatmand', 'Affiliation': 'Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Ritse M', 'Initials': 'RM', 'LastName': 'Mann', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Radboud University Hospital, Nijmegen, the Netherlands.'}, {'ForeName': 'Jan C', 'Initials': 'JC', 'LastName': 'Oosterwijk', 'Affiliation': 'Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.'}, {'ForeName': 'Rob A E M', 'Initials': 'RAEM', 'LastName': 'Tollenaar', 'Affiliation': 'Department of Surgery, Leiden University Medical Centre, Leiden, the Netherlands.'}, {'ForeName': 'Diderick B W', 'Initials': 'DBW', 'LastName': 'de Roy van Zuidewijn', 'Affiliation': 'Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.'}, {'ForeName': 'Marc B I', 'Initials': 'MBI', 'LastName': 'Lobbes', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.'}, {'ForeName': 'Martijne', 'Initials': 'M', 'LastName': ""van 't Riet"", 'Affiliation': 'Department of Surgery, Reinier de Graaf Gasthuis, Delft, the Netherlands.'}, {'ForeName': 'Maartje J', 'Initials': 'MJ', 'LastName': 'Hooning', 'Affiliation': 'Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Margreet G E M', 'Initials': 'MGEM', 'LastName': 'Ausems', 'Affiliation': 'Department of Genetics, University Medical Centre Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Claudette E', 'Initials': 'CE', 'LastName': 'Loo', 'Affiliation': 'Department of Radiology and Nuclear Medicine, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.'}, {'ForeName': 'Jelle', 'Initials': 'J', 'LastName': 'Wesseling', 'Affiliation': 'Department of Pathology, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.'}, {'ForeName': 'Ernest J T', 'Initials': 'EJT', 'LastName': 'Luiten', 'Affiliation': 'Department of Surgery, Amphia Ziekenhuis, Breda, the Netherlands.'}, {'ForeName': 'Harmien M', 'Initials': 'HM', 'LastName': 'Zonderland', 'Affiliation': 'Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Cees', 'Initials': 'C', 'LastName': 'Verhoef', 'Affiliation': 'Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Eveline A M', 'Initials': 'EAM', 'LastName': 'Heijnsdijk', 'Affiliation': 'Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Madeleine M A', 'Initials': 'MMA', 'LastName': 'Tilanus-Linthorst', 'Affiliation': 'Department of Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Harry J', 'Initials': 'HJ', 'LastName': 'de Koning', 'Affiliation': 'Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA oncology,['10.1001/jamaoncol.2020.2922'] 2605,32729888,Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.,"Importance Faricimab, the first bispecific antibody designed for intraocular use, simultaneously and independently binds and neutralizes angiopoietin 2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). Objective To assess the efficacy and safety of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Design, Setting, and Participants AVENUE was a 36-week, multiple-dose-regimen, active comparator-controlled, double-masked, phase 2 randomized clinical study performed at 58 sites in the United States. Eligible participants were anti-VEGF treatment naive with choroidal neovascularization secondary to nAMD and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 (Snellen equivalent, 20/40) to 24 (Snellen equivalent, 20/320). Data were collected from August 11, 2015, to January 12, 2017, with the final patient visit completed September 26, 2017. Data were analyzed from August 11, 2015, to October 4, 2019. Interventions Patients were randomized 3:2:2:2:3 to receive ranibizumab, 0.5 mg every 4 weeks (arm A [n = 68]); faricimab, 1.5 mg every 4 weeks (arm B [n = 47]); faricimab, 6.0 mg every 4 weeks (arm C [n = 42]); faricimab, 6.0 mg every 4 weeks until week 12, then faricimab, 6.0 mg every 8 weeks (arm D [n = 47]); and ranibizumab, 0.5 mg every 4 weeks until week 8, then faricimab, 6.0 mg every 4 weeks (arm E [n = 69]). Main Outcomes and Measures Mean change in BCVA from baseline to week 36, proportion of participants gaining at least 15 letters, BCVA of 20/40 or better or 20/200 or worse, and ocular coherence tomographic outcomes in anti-VEGF treatment-naive participants (arms A, B, C, D) and from weeks 12 to 36 in those with incomplete response (participants in arms A and E with week 12 BCVA ETDRS letter score of ≤68 [Snellen equivalent, 20/50 or worse]). Results A total of 263 participants were included in the analysis (172 [65.4%] female; 258 [98.1%] white; mean [SD] age, 78.3 [8.7] years). At week 36, adjusted mean change in BCVA vs ranibizumab was 1.6 (80% CI, -1.6 to 4.7) letters for arm B (P = .52), -1.6 (80% CI, -4.9 to 1.7) letters for arm C (P = .53), and -1.5 (80% CI, -4.6 to 1.6) letters for arm D (P = .53). For arm E, adjusted mean change from week 12 was -1.7 (80% CI, -3.8 to 0.4) letters (P = .30). Conclusions and Relevance AVENUE did not meet its primary end point of superiority of faricimab over ranibizumab in BCVA at week 36. Although not superior to monthly ranibizumab as given in this trial, overall visual and anatomical gains noted with faricimab support pursuing phase 3 trials for a potential alternative to monthly anti-VEGF therapy. Faricimab showed no new or unexpected safety signals. Trial Registration ClinicalTrials.gov Identifier: NCT02484690.",2020,"For arm E, adjusted mean change from week 12 was -1.7","['Data were collected from August 11, 2015, to January 12, 2017, with the final patient visit completed September 26, 2017', 'A total of 263 participants were included in the analysis (172 [65.4%] female; 258 [98.1%] white; mean [SD] age, 78.3 [8.7] years', 'Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 (Snellen equivalent, 20/40) to 24 (Snellen equivalent, 20/320', 'Neovascular Age-Related Macular Degeneration', 'patients with neovascular age-related macular degeneration (nAMD', 'Eligible participants were anti-VEGF treatment naive with choroidal neovascularization secondary to nAMD and best-corrected visual acuity (BCVA']","['faricimab vs ranibizumab', 'Faricimab vs Ranibizumab', 'BCVA', 'ranibizumab']","['efficacy and safety', 'BCVA of 20/40 or better or 20/200 or worse, and ocular coherence tomographic outcomes', 'Safety and Efficacy']","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517880', 'cui_str': '8.7'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0282413', 'cui_str': 'Letters as Topic'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0183370', 'cui_str': 'Snellen chart'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0442752', 'cui_str': 'Distance vision 6/12'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0600518', 'cui_str': 'Choroidal neovascularisation'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0442752', 'cui_str': 'Distance vision 6/12'}, {'cui': 'C0442756', 'cui_str': 'Distance vision 6/60'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",263.0,0.321469,"For arm E, adjusted mean change from week 12 was -1.7","[{'ForeName': 'Jayashree', 'Initials': 'J', 'LastName': 'Sahni', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix.'}, {'ForeName': 'Sunil S', 'Initials': 'SS', 'LastName': 'Patel', 'Affiliation': 'West Texas Retina Consultants, Abilene.'}, {'ForeName': 'Mark E', 'Initials': 'ME', 'LastName': 'Chittum', 'Affiliation': 'Retina Consultants of Southern Colorado, Colorado Springs.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Berger', 'Affiliation': 'Retina Research Center, Austin, Texas.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Del Valle Rubido', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Shamil', 'Initials': 'S', 'LastName': 'Sadikhov', 'Affiliation': 'Roche Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Szczesny', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Schwab', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Everson', 'Initials': 'E', 'LastName': 'Nogoceke', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Weikert', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}, {'ForeName': 'Sascha', 'Initials': 'S', 'LastName': 'Fauser', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffman-La Roche Ltd, Basel, Switzerland.'}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2020.2685'] 2606,32020863,The effects of add-on self-care education on quality of life and fatigue in gastrointestinal cancer patients undergoing chemotherapy.,"BACKGROUND Gastrointestinal cancer is one of the most common malignancies and imposes heavy burdens on both individual health and social economy. We sought to survey the effect of a self-care education program on quality of life and fatigue in gastrointestinal cancer patients who received chemotherapy. METHODS Ninety-one eligible gastrointestinal cancer patients were enrolled in this study and 86 valid samples were analyzed. Data were acquired with a demographics questionnaire, endpoint multidimensional questionnaire and the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30. The collected data were analyzed using SPSS software. RESULTS The self-care education intervention significantly improved the quality of life with respect to emotional function (p = 0.018), role function (p = 0.041), cognitive function (p = 0.038) and alleviated side effects such as nausea/vomiting (p = 0.028) and fatigue (p = 0.029). Further analysis demonstrated that the self-care education benefited total fatigue, affective fatigue and cognitive fatigue in gastrointestinal cancer patients regardless of baseline depression. CONCLUSION Our results suggested the beneficial effects of the self-care education in both quality of life and anti-fatigue in gastrointestinal cancer patients under chemotherapy. The self-care education could be considered as a complementary approach during combination chemotherapy in gastrointestinal cancer patients.",2020,"Further analysis demonstrated that the self-care education benefited total fatigue, affective fatigue and cognitive fatigue in gastrointestinal cancer patients regardless of baseline depression. ","['gastrointestinal cancer patients undergoing chemotherapy', 'gastrointestinal cancer patients', 'gastrointestinal cancer patients regardless of baseline depression', 'Ninety-one eligible gastrointestinal cancer patients were enrolled in this study and 86 valid samples were analyzed', 'gastrointestinal cancer patients who received chemotherapy', 'gastrointestinal cancer patients under chemotherapy']",['self-care education program'],"['quality of life with respect to emotional function', 'fatigue', 'quality of life and fatigue', 'total fatigue, affective fatigue and cognitive fatigue', 'cognitive function', 'nausea/vomiting', 'role function', 'demographics questionnaire, endpoint multidimensional questionnaire and the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire QLQ-C30']","[{'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}]","[{'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0029237', 'cui_str': 'Organization'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}]",91.0,0.0255977,"Further analysis demonstrated that the self-care education benefited total fatigue, affective fatigue and cognitive fatigue in gastrointestinal cancer patients regardless of baseline depression. ","[{'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Xie', 'Affiliation': ""Department of Oncology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.""}, {'ForeName': 'Tingli', 'Initials': 'T', 'LastName': 'Zhu', 'Affiliation': ""Nursing Department, Wuxi Children's Hospital, Wuxi, 214023, China. zhutingli_wuxi@163.com.""}, {'ForeName': 'Qun', 'Initials': 'Q', 'LastName': 'Lu', 'Affiliation': ""Internal Medicine Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China. 1662935168@qq.com.""}, {'ForeName': 'Xiaomin', 'Initials': 'X', 'LastName': 'Xu', 'Affiliation': ""Internal Medicine Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.""}, {'ForeName': 'Yinghua', 'Initials': 'Y', 'LastName': 'Cai', 'Affiliation': ""Internal Medicine Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.""}, {'ForeName': 'Zhenghong', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': ""Internal Medicine Department, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.""}]",BMC complementary medicine and therapies,['10.1186/s12906-019-2800-5'] 2607,32253202,Are routine antibiotics after operative vaginal birth beneficial?,"Review of: Knight M, Chiocchia V, Partlett C, et al Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet 2019;393:2395-403.",2020,"Review of: Knight M, Chiocchia V, Partlett C, et al Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. ",[],"['Knight M, Chiocchia V, Partlett C, et al Prophylactic antibiotics']",[],[],"[{'cui': 'C0362063', 'cui_str': 'Other prophylactic chemotherapy'}]",[],,0.162774,"Review of: Knight M, Chiocchia V, Partlett C, et al Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. ",[],Drug and therapeutics bulletin,['10.1136/dtb.2020.000023'] 2608,32354725,Dexamethasone or prednisolone for croup.,"Review of: Parker CM, Cooper MN. Prednisolone versus dexamethasone for croup: a randomized controlled trial. Pediatrics 2019;144:e20183772.",2020,Pediatrics 2019;144:e20183772.,['croup'],"['dexamethasone', 'Prednisolone', 'Dexamethasone or prednisolone']",[],"[{'cui': 'C0010380', 'cui_str': 'Croup'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0032950', 'cui_str': 'prednisolone'}]",[],,0.232919,Pediatrics 2019;144:e20183772.,[],Drug and therapeutics bulletin,['10.1136/dtb.2020.000028'] 2609,32447279,Patiromer plus spironolactone in resistant hypertension and CKD.,"Review of: Agarwal R, Rossignal P, Romero A, et al Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540-1550.",2020,Lancet 2019;394:1540-1550.,['patients with resistant hypertension and chronic kidney disease'],"['Patiromer plus spironolactone', 'spironolactone', 'placebo']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0745130', 'cui_str': 'Resistant hypertensive disorder'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}]","[{'cui': 'C4045522', 'cui_str': 'patiromer'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]",[],,0.294141,Lancet 2019;394:1540-1550.,[],Drug and therapeutics bulletin,['10.1136/dtb.2020.000033'] 2610,31353274,Factors influencing credentialing of interventionists in the CREST-2 trial.,"BACKGROUND The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a pair of randomized trials assessing the relative efficacy of carotid revascularization in the setting of intensive medical management (IMM) in patients with asymptomatic high-grade atherosclerotic stenosis. One of the trials assesses IMM with or without carotid artery stenting (CAS). Given the low risk of stroke in nonrevascularized patients receiving IMM, it is essential that there be low periprocedural risk of stroke for CAS if it is to show incremental benefit. Thus, credentialing of interventionists to ensure excellence is vital. This analysis describes the protocol-driven approach to credentialing of CAS interventionists for CREST-2 and its outcomes. METHODS To be eligible to perform stenting in CREST-2, interventionists needed to be credentialed on the basis of a detailed Interventional Management Committee (IMC) review of data from their last 25 consecutive cases during the past 24 months along with self-reported lifetime experience case numbers. When necessary, additional prospective cases performed in a companion registry were requested after webinar training. Here we review the IMC experience from the first formal meeting on March 21, 2014 through October 14, 2017. RESULTS The IMC had 102 meetings, and 8311 cases submitted by 334 interventionists were evaluated. Most were either cardiologists or vascular surgeons, although no single specialty made up the majority of applicants. The median total experience was 130 cases (interquartile range [IQR], 75-266; range, 25-2500). Only 9% (30/334) of interventionists were approved at initial review; approval increased to 46% (153/334) after submission of new cases with added training and re-review. The median self-reported lifetime case experience for those approved was 211.5 (IQR, 100-350), and the median number of cases submitted for review was 30 (IQR, 27-35). The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001). CONCLUSIONS Identification of interventionists who were deemed sufficiently skilled for CREST-2 has required substantial oversight and a controlled system to judge current skill level that controls for specialty-based practice variability, procedural experience, and periprocedural outcomes. High-volume interventionists, particularly those with more recent experience, were more likely to be approved to participate in CREST-2. Primary approval was not affected by operator specialty.",2020,"The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001). ",['patients with asymptomatic high-grade atherosclerotic stenosis'],"['carotid revascularization', 'IMM with or without carotid artery stenting (CAS', 'intensive medical management (IMM']","['median self-reported lifetime case experience', 'median total experience']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0678234', 'cui_str': 'Form of stenosis'}]","[{'cui': 'C3495793', 'cui_str': 'Carotid revascularisation'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}]","[{'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",,0.0661835,"The number of CAS procedures performed per month (case rate) was the only factor associated with approval during the initial cycle of review (P < .00001). ","[{'ForeName': 'Brajesh K', 'Initials': 'BK', 'LastName': 'Lal', 'Affiliation': 'Department of Surgery, University of Maryland, Baltimore, Md. Electronic address: blal@som.umaryland.edu.'}, {'ForeName': 'James F', 'Initials': 'JF', 'LastName': 'Meschia', 'Affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Fla.'}, {'ForeName': 'Gary S', 'Initials': 'GS', 'LastName': 'Roubin', 'Affiliation': 'Department of Cardiology, Cardiovascular Associates of the Southeast/Brookwood, Baptist Medical Center, Birmingham, Ala.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Jankowitz', 'Affiliation': 'Department of Neurosurgery, UPMC Presbyterian University Hospital, Pittsburgh, Pa.'}, {'ForeName': 'Donald', 'Initials': 'D', 'LastName': 'Heck', 'Affiliation': 'Department of Radiology, Novant Health Clinical Research, Winston-Salem, NC.'}, {'ForeName': 'Tudor', 'Initials': 'T', 'LastName': 'Jovin', 'Affiliation': 'Department of Neurology, UPMC Presbyterian University Hospital, Pittsburgh, Pa.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'White', 'Affiliation': 'Department of Cardiology, Ochsner Health System, New Orleans, La.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Rosenfield', 'Affiliation': 'Department of Cardiology, Massachusetts General Hospital, Boston, Mass.'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Katzen', 'Affiliation': 'Department of Interventional Radiology, Miami Cardiac and Vascular Institute at Baptist Hospital of Miami, Miami, Fla.'}, {'ForeName': 'Guilherme', 'Initials': 'G', 'LastName': 'Dabus', 'Affiliation': 'Department of Interventional Neuroradiology, Miami Cardiac and Vascular Institute at Baptist Hospital of Miami, Miami, Fla.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Gray', 'Affiliation': 'Department of Cardiology, Lankenau Medical Center, Wynnewood, Pa.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Matsumura', 'Affiliation': 'Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisc.'}, {'ForeName': 'L Nelson', 'Initials': 'LN', 'LastName': 'Hopkins', 'Affiliation': 'Department of Neurosurgery, SUNY Buffalo, Buffalo, NY.'}, {'ForeName': 'Sothear', 'Initials': 'S', 'LastName': 'Luke', 'Affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Fla.'}, {'ForeName': 'Jashank', 'Initials': 'J', 'LastName': 'Sharma', 'Affiliation': 'Department of Surgery, University of Maryland, Baltimore, Md.'}, {'ForeName': 'Jenifer H', 'Initials': 'JH', 'LastName': 'Voeks', 'Affiliation': 'Department of Neurology, Medical University of South Carolina, Charleston, SC.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Howard', 'Affiliation': 'Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Ala.'}, {'ForeName': 'Thomas G', 'Initials': 'TG', 'LastName': 'Brott', 'Affiliation': 'Department of Neurology, Mayo Clinic, Jacksonville, Fla.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular surgery,['10.1016/j.jvs.2019.05.035'] 2611,31818531,Effect of α-linolenic acid on vascular function and metabolic risk markers during the fasting and postprandial phase: A randomized placebo-controlled trial in untreated (pre-)hypertensive individuals.,"BACKGROUND Only a limited number of studies have examined the vascular and postprandial effects of α-linolenic acid (ALA, C18:3n-3). Therefore, we performed a well-controlled trial focusing specifically on the effects of ALA on vascular function and metabolic risk markers during the fasting and postprandial phase in untreated (pre-)hypertensive individuals. METHODS In a double-blind randomized, placebo-controlled parallel study, 59 overweight and obese adults (40 men and 19 women, aged 60 ± 8 years) with a high-normal blood pressure or mild (stage I) hypertension consumed daily either 10 g of refined cold-pressed flaxseed oil, providing 4.7 g ALA (n = 29), or 10 g of high-oleic sunflower (control) oil (n = 30) for 12 weeks. RESULTS As compared with the high-oleic oil control, intake of flaxseed oil did not change brachial artery flow-mediated vasodilation, carotid-to-femoral pulse wave velocity, retinal microvascular calibers and plasma markers of microvascular endothelial function during the fasting and postprandial phase. Fasting plasma concentrations of free fatty acid (FFA) and TNF-α decreased by 58 μmol/L (P = 0.02) and 0.14 pg/mL (P = 0.03), respectively. No differences were found in other fasting markers of lipid and glucose metabolism, and low-grade systemic inflammation. In addition, dietary ALA did not affect postprandial changes in glucose, insulin, triacylglycerol, FFA and plasma inflammatory markers after meal intake. CONCLUSION A high intake of ALA, about 3-5 times the recommended daily intake, for 12 weeks decreased fasting FFA and TNF-α plasma concentrations. No effects were found on other metabolic risk markers and vascular function during the fasting and postprandial phase in untreated high-normal and stage I hypertensive individuals.",2020,Fasting plasma concentrations of free fatty acid (FFA) and TNF-α decreased by 58 μmol/L (P = 0.02) and 0.14 pg/mL,"['untreated (pre-)hypertensive individuals', '59 overweight and obese adults (40 men and 19 women, aged 60\xa0±\xa08 years) with a high-normal blood pressure or mild (stage I) hypertension consumed daily either 10\xa0g of']","['refined cold-pressed flaxseed oil, providing 4.7\xa0g ALA (n\xa0=\xa029), or 10\xa0g of high-oleic sunflower (control) oil', 'α-linolenic acid', 'ALA', 'dietary ALA', 'placebo']","['fasting FFA and TNF-α plasma concentrations', 'vascular function and metabolic risk markers', 'brachial artery flow-mediated vasodilation, carotid-to-femoral pulse wave velocity, retinal microvascular calibers and plasma markers of microvascular endothelial function', 'metabolic risk markers and vascular function', 'postprandial changes in glucose, insulin, triacylglycerol, FFA and plasma inflammatory markers', 'Fasting plasma concentrations of free fatty acid (FFA) and TNF-α', 'fasting markers of lipid and glucose metabolism, and low-grade systemic inflammation']","[{'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C1318182', 'cui_str': '10G'}]","[{'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0023754', 'cui_str': 'Linseed Oil'}, {'cui': 'C0001898', 'cui_str': 'Alanine'}, {'cui': 'C1318182', 'cui_str': '10G'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0947381', 'cui_str': 'Helianthus annuus'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0051405', 'cui_str': 'alpha-Linolenic Acid'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0232337', 'cui_str': 'Vascular function'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0042401', 'cui_str': 'Vasodilatation'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0443258', 'cui_str': 'Microvascular'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",59.0,0.304726,Fasting plasma concentrations of free fatty acid (FFA) and TNF-α decreased by 58 μmol/L (P = 0.02) and 0.14 pg/mL,"[{'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Joris', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, PO Box 616, 6200 MD Maastricht, the Netherlands. Electronic address: p.joris@maastrichtuniversity.nl.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Draijer', 'Affiliation': 'Unilever R&D Vlaardingen, Department of Future Health and Wellness, PO Box 114, 3130 AC Vlaardingen, the Netherlands.'}, {'ForeName': 'Dagmar', 'Initials': 'D', 'LastName': 'Fuchs', 'Affiliation': 'Unilever R&D Vlaardingen, Department of Future Health and Wellness, PO Box 114, 3130 AC Vlaardingen, the Netherlands.'}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, PO Box 616, 6200 MD Maastricht, the Netherlands.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.11.032'] 2612,32726499,A Comparative Study for the Effects of Nifedipine GITS and Amlodipine Besylate Administrated in Daytime or at Nighttime on Recovery of Blood Pressure Rhythm and Arterial Stiffness in the Young and Middle-aged Subjects with Non-dipper Hypertension (NARRAS): Design and Rationale.,"INTRODUCTION Hypertensive patients with a blunted or absent nocturnal blood pressure (BP) drop (non-dipper) are associated with arterial stiffening and additional cardiovascular risk. Non-dipper hypertension is prevalent in young and middle-aged adults; but the optimal antihypertensive strategy remains unclear. There is a need to explore the effects of different antihypertensive agents and time of administration on recovery of dipper rhythm and arterial stiffness in this population. METHODS AND ANALYSIS NARRAS is a randomized controlled trial (RCT), designed to evaluate the effects of long-acting antihypertensive agents administrated in daytime or at nighttime on BP rhythm restoration and arterial stiffness in young and middle-aged non-dipper hypertensive patients. Participants will be randomly assigned to nifedipine GITS (gastrointestinal therapeutic system) 30mg or amlodipine besylate 5mg once daily, either taken in the morning or at night. Subjects will be divided into the following groups: group A. nifedipine administrated in the morning (N-M); B. nifedipine at night (N-N); C. amlodipine in the morning (A-M); D. amlodipine at night (A-N). If BP is not at goal during 4week's visit, dosage of antihypertensive agents will be doubled. BP is measured via 24-hour ambulatory BP monitoring (ABPM) and arterial stiffness is examined before and after 8 weeks of pharmaceutical intervention. The primary endpoint is the difference of average nighttime systolic BP reduction between nifedipine GITS and amlodipine. The second endpoint is the percentage of restoration of a dipper rhythm at 8week. The potential of nighttime dosing on arterial stiffness is also investigated. A sample size of 120 will have 80% power to detect a 3mmHg nighttime systolic BP difference between two drugs determined with ABPM. CONCLUSIONS NARRAS study is the first RCT to evaluate the effects of nifedipine GITS and amlodipine besylate on restoration of dipping rhythm and arterial elasticity, either administrated in the morning or evening, in younger non-dipper hypertensive subjects. The findings of NARRAS are likely to be potential to facilitate new therapeutic strategies for this condition.",2020,The primary endpoint is the difference of average nighttime systolic BP reduction between nifedipine GITS and amlodipine.,"['Young and Middle-aged Subjects with Non-dipper Hypertension (NARRAS', 'young and middle-aged non-dipper hypertensive patients', 'Hypertensive patients with a blunted or absent nocturnal blood pressure (BP) drop (non-dipper', 'young and middle-aged adults', 'younger non-dipper hypertensive subjects']","['nifedipine GITS and amlodipine', 'nifedipine GITS and amlodipine besylate', 'nifedipine', 'amlodipine', 'Nifedipine GITS and Amlodipine Besylate', 'nifedipine GITS (gastrointestinal therapeutic system', 'amlodipine besylate', 'nifedipine at night (N-N); C. amlodipine']","['BP is measured via 24-hour ambulatory BP monitoring (ABPM) and arterial stiffness', 'Blood Pressure Rhythm and Arterial Stiffness', 'percentage of restoration of a dipper rhythm at 8week', 'BP rhythm restoration and arterial stiffness', 'average nighttime systolic BP reduction', 'nighttime systolic BP difference']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0326560', 'cui_str': 'Cinclidae'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0857121', 'cui_str': 'Hypertensive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332197', 'cui_str': 'Absent'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0028066', 'cui_str': 'Nifedipine'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0354468', 'cui_str': 'Amlodipine besylate'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0026426', 'cui_str': 'Blood pressure monitoring'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0326560', 'cui_str': 'Cinclidae'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",,0.0299538,The primary endpoint is the difference of average nighttime systolic BP reduction between nifedipine GITS and amlodipine.,"[{'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""Department of Cardiology, Peking University People's Hospital, Beijing, China.""}]",International journal of clinical practice,['10.1111/ijcp.13628'] 2613,32726513,Scalene and sternocleidomastoid activation during normoxic and hypoxic incremental inspiratory loading.,"The purpose of this study was to examine scalene (SA) and sternocleidomastoid (SM) activation during normoxic (norm-ITL; FIO 2  = 21%) and hypoxic (hyp-ITL; FIO 2  = 15%) incremental inspiratory threshold loading (ITL). Thirteen healthy participants (33 ± 4 years, 9 female) performed two ITL tests breathing randomly assigned gas mixtures through an inspiratory loading device where the load was increased every two minutes until task failure. SA and SM root mean square (RMS) electromyography (EMG) were calculated and expressed as a percentage of maximum (RMS %max ) to reflect muscle activation intensity. Myoelectric manifestations of fatigue were characterized as decreased SA or SM EMG median frequency during maximum inspiratory pressure maneuvers before and after ITL. Dyspnea was recorded at baseline and task failure. Ventilatory parameters and mouth pressure (Pm) were recorded throughout the ITL. SA,RMS %max and SM,RMS %max increased in association with ITL load (p ≤ .01 for both). SA,RMS %max was similar between norm-ITL and hyp-ITL (p = .17), whereas SM,RMS %max was greater during the latter (p = .001). Neither SA nor SM had a decrease in EMG median frequency after ITL (p = .75 and 0.69 respectively). Pm increased in association with ITL load (p < .001) and tended to be higher during hyp-ITL compared to norm-ITL (p = .05). Dyspnea was similar during both conditions (p > .05). There was a trend for higher tidal volumes during hyp-ITL compared to norm-ITL (p = .10). Minute ventilation was similar between both conditions (p = .23). RMS, %max of the SA and SM increased linearly with increasing ITL. The presence of hypoxia only increased SM activation. Neither SA nor SM presented myoelectric manifestations of fatigue during both conditions.",2020,"SA,RMS %max and SM,RMS %max increased in association with ITL load (p ≤ .01 for both).","['Thirteen healthy participants (33\xa0±\xa04 years, 9 female']",['ITL tests breathing randomly assigned gas mixtures through an inspiratory loading device'],"['Dyspnea', 'scalene (SA) and sternocleidomastoid (SM) activation', 'EMG median frequency', 'RMS, %max of the SA and SM increased linearly with increasing ITL', 'SA,RMS %max', 'Ventilatory parameters and mouth pressure (Pm', 'SM activation', 'Minute ventilation', 'SA and SM root mean square (RMS) electromyography (EMG', 'higher tidal volumes', 'ITL load']","[{'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0581444', 'cui_str': 'Gas mixture'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}]","[{'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0224153', 'cui_str': 'Structure of sternocleidomastoid muscle'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C1301655', 'cui_str': 'Minute ventilation'}, {'cui': 'C0040452', 'cui_str': 'Tooth root structure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0040210', 'cui_str': 'Tidal volume'}]",13.0,0.023465,"SA,RMS %max and SM,RMS %max increased in association with ITL load (p ≤ .01 for both).","[{'ForeName': 'Nada', 'Initials': 'N', 'LastName': 'Basoudan', 'Affiliation': 'Department of Physical Therapy, University of British Columbia (UBC), Vancouver, BC, Canada.'}, {'ForeName': 'Antenor', 'Initials': 'A', 'LastName': 'Rodrigues', 'Affiliation': 'Physical Therapy, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Alessio', 'Initials': 'A', 'LastName': 'Gallina', 'Affiliation': 'Centre of Precision Rehabilitation for Spinal Pain (CPR Spine), School of Sport, Exercise and Rehabilitation Sciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Jayne', 'Initials': 'J', 'LastName': 'Garland', 'Affiliation': 'Faculty of Health Sciences, Western University, London, ON, Canada.'}, {'ForeName': 'Jordan A', 'Initials': 'JA', 'LastName': 'Guenette', 'Affiliation': 'Department of Physical Therapy, University of British Columbia (UBC), Vancouver, BC, Canada.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Shadgan', 'Affiliation': 'International Collaboration on Repair Discoveries, Vancouver, BC, Canada.'}, {'ForeName': 'Jeremy', 'Initials': 'J', 'LastName': 'Road', 'Affiliation': 'Division of Respiratory Medicine, Department of Medicine, University of British Columbia (UBC), Vancouver, BC, Canada.'}, {'ForeName': 'W Darlene', 'Initials': 'WD', 'LastName': 'Reid', 'Affiliation': 'Physical Therapy, University of Toronto, Toronto, ON, Canada.'}]",Physiological reports,['10.14814/phy2.14522'] 2614,32726514,Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.,"We assessed pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of interleukin-6 (IL-6), soluble IL-6 receptor, and C-reactive protein (CRP) in serum, and absolute neutrophil count (ANC) in blood following single doses of subcutaneous sarilumab versus intravenous tocilizumab (NCT02097524) from patients with rheumatoid arthritis (RA) who are inadequate responders to methotrexate (MTX) and on a stable dose of MTX. Patients with RA randomized (1:1:1:1) to single-dose sarilumab (150 or 200 mg subcutaneously) or tocilizumab (4 or 8 mg/kg intravenously) were included (n = 101), and PK, PD, and PK/PD relationships and safety were assessed over 6 weeks postdose. PK profiles for both drugs are described by parallel linear and nonlinear target-mediated clearance pathways. PD markers showed similar onset of effect during the first week postdose, regardless of dose or route of administration. CRP and ANC decreased, with median postdose nadirs at 7-15 days for CRP and 3-5 days for ANC. Both drugs at low and high doses achieved the same nadir for ANC and a similar return toward baseline within 2 weeks postdose, suggesting a saturation of effect. Safety profiles of sarilumab and tocilizumab were generally similar. In conclusion, despite differences in PK, the onset of the decrease in CRP (efficacy) and ANC (safety) after a single dose were similar for subcutaneous sarilumab and intravenous tocilizumab. PD effects and safety were consistent with previous studies.",2020,"CRP and ANC decreased, with median postdose nadirs at 7-15 days for CRP and 3-5 days for ANC.","['patients with rheumatoid arthritis (RA) who are inadequate responders to', 'Patients With Active Rheumatoid Arthritis on Stable Methotrexate']","['sarilumab and tocilizumab', 'methotrexate (MTX', 'tocilizumab', 'MTX', 'Subcutaneous Sarilumab and Intravenous Tocilizumab']","['CRP and ANC', 'PD effects and safety', 'median postdose nadirs', 'CRP (efficacy) and ANC (safety', 'pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of interleukin-6 (IL-6), soluble IL-6 receptor, and C-reactive protein (CRP) in serum, and absolute neutrophil count (ANC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0205412', 'cui_str': 'Inadequate'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C3885145', 'cui_str': 'sarilumab'}, {'cui': 'C1609165', 'cui_str': 'tocilizumab'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}]","[{'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0948762', 'cui_str': 'Absolute neutrophil count'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0063717', 'cui_str': 'Lymphocyte antigen CD126'}, {'cui': 'C0229671', 'cui_str': 'Serum'}]",,0.0891761,"CRP and ANC decreased, with median postdose nadirs at 7-15 days for CRP and 3-5 days for ANC.","[{'ForeName': 'Anne J', 'Initials': 'AJ', 'LastName': 'Paccaly', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Kovalenko', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Janie', 'Initials': 'J', 'LastName': 'Parrino', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Boyapati', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Xu', 'Affiliation': 'Sanofi Genzyme, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Hubert', 'Initials': 'H', 'LastName': 'van Hoogstraten', 'Affiliation': 'Sanofi Genzyme, Bridgewater, New Jersey, USA.'}, {'ForeName': 'Tomonori', 'Initials': 'T', 'LastName': 'Ishii', 'Affiliation': 'Tohoku University Hospital, Sendai, Japan.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Davis', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}, {'ForeName': 'A Thomas', 'Initials': 'AT', 'LastName': 'DiCioccio', 'Affiliation': 'Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.'}]",Journal of clinical pharmacology,['10.1002/jcph.1703'] 2615,32726528,Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.,"BACKGROUND Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose. METHODS In this trial conducted in both northern and southern hemispheres, we evaluated nirsevimab for the prevention of RSV-associated lower respiratory tract infection in healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation). We randomly assigned the infants in a 2:1 ratio to receive nirsevimab, at a dose of 50 mg in a single intramuscular injection, or placebo at the start of an RSV season. The primary end point was medically attended RSV-associated lower respiratory tract infection through 150 days after administration of the dose. The secondary efficacy end point was hospitalization for RSV-associated lower respiratory tract infection through 150 days after administration of the dose. RESULTS From November 2016 through November 2017, a total of 1453 infants were randomly assigned to receive nirsevimab (969 infants) or placebo (484 infants) at the start of the RSV season. The incidence of medically attended RSV-associated lower respiratory tract infection was 70.1% lower (95% confidence interval [CI], 52.3 to 81.2) with nirsevimab prophylaxis than with placebo (2.6% [25 infants] vs. 9.5% [46 infants]; P<0.001) and the incidence of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower (95% CI, 51.9 to 90.3) with nirsevimab than with placebo (0.8% [8 infants] vs. 4.1% [20 infants]; P<0.001). These differences were consistent throughout the 150-day period after the dose was administered and across geographic locations and RSV subtypes. Adverse events were similar in the two trial groups, with no notable hypersensitivity reactions. CONCLUSIONS A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants. (Funded by AstraZeneca and Sanofi Pasteur; ClinicalTrials.gov number, NCT02878330.).",2020,A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.,"['healthy infants who had been born preterm (29 weeks 0 days to 34 weeks 6 days of gestation', 'Preterm Infants', 'northern and southern hemispheres', '969 infants) or', 'healthy preterm infants', 'From November 2016 through November 2017, a total of 1453 infants', 'healthy infants']","['placebo', 'nirsevimab']","['Adverse events', 'incidence of medically attended RSV-associated lower respiratory tract infection', 'medically attended RSV-associated lower respiratory tract infection', 'incidence of hospitalization for RSV-associated lower respiratory tract infection', 'hospitalization for RSV-associated lower respiratory tract infection']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0021294', 'cui_str': 'Premature infant'}, {'cui': 'C0439810', 'cui_str': 'Total'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",1453.0,0.503207,A single injection of nirsevimab resulted in fewer medically attended RSV-associated lower respiratory tract infections and hospitalizations than placebo throughout the RSV season in healthy preterm infants.,"[{'ForeName': 'M Pamela', 'Initials': 'MP', 'LastName': 'Griffin', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Therese', 'Initials': 'T', 'LastName': 'Takas', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Joseph B', 'Initials': 'JB', 'LastName': 'Domachowske', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Shabir A', 'Initials': 'SA', 'LastName': 'Madhi', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Manzoni', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Eric A F', 'Initials': 'EAF', 'LastName': 'Simões', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Esser', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Anis A', 'Initials': 'AA', 'LastName': 'Khan', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Filip', 'Initials': 'F', 'LastName': 'Dubovsky', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'Tonya', 'Initials': 'T', 'LastName': 'Villafana', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'DeVincenzo', 'Affiliation': ""From AstraZeneca, Gaithersburg, MD (M.P.G., Y.Y., T.T., M.T.E., A.A.K., F.D., T.V.); SUNY Upstate Medical University, Syracuse, NY (J.B.D.); Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, and Department of Science and Technology/National Research Foundation South African Research Chair, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg (S.A.M.); the Division of Pediatrics and Neonatology, Department of Maternal, Neonatal, and Infant Medicine, Nuovo Ospedale Degli Infermi, Biella, and Neonatology and NICU, Sant'Anna Hospital, AOU Città della Salute e della Scienza, Turin - both in Italy (P.M.); the University of Colorado School of Medicine, Aurora (E.A.F.S.); and the Children's Foundation Research Institute at Le Bonheur Children's Hospital, Memphis, TN (J.P.D.V.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1913556'] 2616,32726531,Phase 1 Trial of a Therapeutic Anti-Yellow Fever Virus Human Antibody.,"BACKGROUND Insufficient vaccine doses and the lack of therapeutic agents for yellow fever put global health at risk, should this virus emerge from sub-Saharan Africa and South America. METHODS In phase 1a of this clinical trial, we assessed the safety, side-effect profile, and pharmacokinetics of TY014, a fully human IgG1 anti-yellow fever virus monoclonal antibody. In a double-blind, phase 1b clinical trial, we assessed the efficacy of TY014, as compared with placebo, in abrogating viremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril). The primary safety outcomes were adverse events reported 1 hour after the infusion and throughout the trial. The primary efficacy outcome was the dose of TY014 at which 100% of the participants tested negative for viremia within 48 hours after infusion. RESULTS A total of 27 healthy participants were enrolled in phase 1a, and 10 participants in phase 1b. During phase 1a, TY014 dose escalation to a maximum of 20 mg per kilogram of body weight occurred in 22 participants. During phases 1a and 1b, adverse events within 1 hour after infusion occurred in 1 of 27 participants who received TY014 and in none of the 10 participants who received placebo. At least one adverse event occurred during the trial in 22 participants who received TY014 and in 8 who received placebo. The mean half-life of TY014 was approximately 12.8 days. At 48 hours after the infusion, none of the 5 participants who received the starting dose of TY014 of 2 mg per kilogram had detectable YF17D-204 viremia; these participants remained aviremic throughout the trial. Viremia was observed at 48 hours after the infusion in 2 of 5 participants who received placebo and at 72 hours in 2 more placebo recipients. Symptoms associated with yellow fever vaccine were less frequent in the TY014 group than in the placebo group. CONCLUSIONS This phase 1 trial of TY014 did not identify worrisome safety signals and suggested potential clinical benefit, which requires further assessment in a phase 2 trial. (Funded by Tysana; ClinicalTrials.gov number, NCT03776786.).",2020,At least one adverse event occurred during the trial in 22 participants who received TY014 and in 8 who received placebo.,"['27 healthy participants were enrolled in phase 1a, and 10 participants in phase 1b']","['Therapeutic Anti-Yellow Fever Virus Human Antibody', 'placebo']","['Viremia', 'negative for viremia', 'adverse event', 'adverse events', 'detectable YF17D-204 viremia']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0043396', 'cui_str': 'Yellow fever virus'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",22.0,0.484793,At least one adverse event occurred during the trial in 22 participants who received TY014 and in 8 who received placebo.,"[{'ForeName': 'Jenny G', 'Initials': 'JG', 'LastName': 'Low', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Justin H J', 'Initials': 'JHJ', 'LastName': 'Ng', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Eugenia Z', 'Initials': 'EZ', 'LastName': 'Ong', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Kalimuddin', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Limin', 'Initials': 'L', 'LastName': 'Wijaya', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Yvonne F Z', 'Initials': 'YFZ', 'LastName': 'Chan', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Dorothy H L', 'Initials': 'DHL', 'LastName': 'Ng', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Hwee-Cheng', 'Initials': 'HC', 'LastName': 'Tan', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Anjali', 'Initials': 'A', 'LastName': 'Baglody', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Yok-Hian', 'Initials': 'YH', 'LastName': 'Chionh', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Debbie C P', 'Initials': 'DCP', 'LastName': 'Lee', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Yadunanda', 'Initials': 'Y', 'LastName': 'Budigi', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Sasisekharan', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}, {'ForeName': 'Eng-Eong', 'Initials': 'EE', 'LastName': 'Ooi', 'Affiliation': 'From the Duke-National University of Singapore Medical School (J.G.L., E.Z.O., H.-C.T., E.-E.O.), Singapore General Hospital (J.G.L., S.K., L.W., Y.F.Z.C., D.H.L.N.), Tysana (J.H.J.N., A.B., Y.-H.C., D.C.P.L., Y.B.), and the Singapore-MIT (Massachusetts Institute of Technology) Alliance for Research and Technology (R.S., E.-E.O.) - all in Singapore; and the Massachusetts Institute of Technology, Cambridge (R.S.).'}]",The New England journal of medicine,['10.1056/NEJMoa2000226'] 2617,32724326,An Investigation into the Rehabilitative Mechanism of Tuina in the Treatment of Sciatic Nerve Injury.,"Objective To explore the effect of tuina on the gene expression at the point of nerve injury in rats with sciatic nerve injury (SNI) and to elucidate the repair mechanism of tuina promoting the functional recovery of peripheral nerve injury. Methods In the Sham group, the right sciatic nerve was exposed without clamping. The SNI model was established using the sciatic nerve clamp method on the right leg and then randomly divided into the SNI group and the Tuina group. Seven days after modeling, the Tuina group was treated daily with a ""massage and tuina manipulation simulator"" (Patent No. ZL 2007 0187403.1), which was used daily to stimulate Yinmen (BL37), Yanglingquan (GB34), and Chengshan (BL57) with point-pressing method, plucking method, and kneading method. The stimulating force was 4N, and the stimulating frequency was 60 times per minute; each method and each point were used for 1 minute, totaling 9 minutes (1 min/acupoint/method × 3 methods × 3 acupoints). Treatment was administered for 21 days, followed by a 1-day rest after the 10th treatment, for a total of 20 times of intervention. The sciatic function index (SFI) was used to evaluate the fine movements of the hind limbs of rats in each group. The ultrastructural changes at the point of nerve injury were observed by transmission electron microscopy, and the gene changes at the point of nerve injury were detected using RNA-sequencing (RNA-seq) technology. Results Compared with the baseline, the SFI of the SNI group and the Tuina group decreased significantly at the 0th intervention (7 days after molding); compared with the SNI group, the SFI of the Tuina group increased at the 10th intervention ( P < 0.05) and increased significantly at the 15th and 20th intervention ( P < 0.01). Compared with the Sham group, the myelin sheath integrity of the sciatic nerve in the SNI group was destroyed and the myelin sheath collapsed seriously, even forming myelin sheath ball, accompanied with severe axonal atrophy and mitochondrial degeneration. The tuina intervention could significantly improve the ultrastructure of the nerve injury point, and the nerve fiber myelin sheath in the Tuina group remained intact, without obvious axonal swelling or atrophy. Atrophic thread granules could be seen in the axon, but there were no vacuolated mitochondria. RNA-seq results showed that there were differences at 221 genes at the point of nerve injury between the Tuina group and the SNI group and the differentially expressed genes (DEGs) are enriched in the biological processes related to the regulation of myocyte. Regulations include the regulation of striated muscle cell differentiation, myoblast differentiation, and myotube differentiation. Conclusion Tuina can improve the fine motor recovery and protect the myelin integrity in rats with peripheral nerve injury, and this is achieved by changing the gene sequence at the injured point.",2020,"The tuina intervention could significantly improve the ultrastructure of the nerve injury point, and the nerve fiber myelin sheath in the Tuina group remained intact, without obvious axonal swelling or atrophy.","['rats with peripheral nerve injury', 'rats with sciatic nerve injury (SNI']","['massage and tuina manipulation simulator"" (Patent No. ZL 2007 0187403.1), which was used daily to stimulate Yinmen (BL37), Yanglingquan (GB34), and Chengshan (BL57) with point-pressing method, plucking method, and kneading method']","['right sciatic nerve', 'sciatic function index (SFI', 'myelin sheath integrity of the sciatic nerve', 'ultrastructure of the nerve injury point, and the nerve fiber myelin sheath']","[{'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0262593', 'cui_str': 'Injury of peripheral nerve'}, {'cui': 'C0161467', 'cui_str': 'Injury of sciatic nerve'}]","[{'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0030650', 'cui_str': 'Patents'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0040953', 'cui_str': 'Trichotillomania'}]","[{'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0036394', 'cui_str': 'Structure of sciatic nerve'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026973', 'cui_str': 'Myelin sheath structure'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0041623', 'cui_str': 'ultrastructure'}, {'cui': 'C0161479', 'cui_str': 'Nerve injury'}, {'cui': 'C0027749', 'cui_str': 'Nerve fiber'}]",,0.0293094,"The tuina intervention could significantly improve the ultrastructure of the nerve injury point, and the nerve fiber myelin sheath in the Tuina group remained intact, without obvious axonal swelling or atrophy.","[{'ForeName': 'Taotao', 'Initials': 'T', 'LastName': 'Lv', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yanjun', 'Initials': 'Y', 'LastName': 'Mo', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Tianyuan', 'Initials': 'T', 'LastName': 'Yu', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yumo', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Shuai', 'Initials': 'S', 'LastName': 'Shao', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yuting', 'Initials': 'Y', 'LastName': 'Luo', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Mengqian', 'Initials': 'M', 'LastName': 'Lu', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Steven Gregory', 'Initials': 'SG', 'LastName': 'Wong', 'Affiliation': 'School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/5859298'] 2618,32724346,Effect of dexmedetomidine on brain function and hemodynamics in patients undergoing lung cancer resection.,"Effect of dexmedetomidine on the brain function and hemodynamics in patients undergoing lung cancer resection were explored. Eighty-seven patients with lung cancer undergoing lung cancer resection in Weifang People's Hospital from January 2014 to June 2018 were enrolled in this study. Patients conventionally anesthetized by propofol, midazolam, sufentanil, or cisatracurium besilate (41 cases) were assigned to the control group and those anesthetized by conventional anesthetic and dexmedetomidine (46 cases) were assigned to the research group. The hemodynamic parameters, neuron-specific enolase (NSE), and astrocyte S-100p protein (S-100β) were compared between the two groups before induction (T0), 5 min after induction (T1), at the end of surgery (T2), time of extubation (T3), and 5 min after extubation (T4). The cognitive function of patients was graded by the mini-mental state examination (MMSE) after patients recovered from anesthesia. In both the control group and the research group, the levels of mean arterial pressure (MAP), heart rate (HR), and central venous pressure (CVP). were statistically higher at T2 and T3 than those at T0 (all P<0.05). The levels of MAP, HR, and CVP were statistically lower in the research group than those in the control group at T2 and T3 (P<0.05). The levels of serum NSE and S100β protein in the research group and the control group increased at T2, T3, and T4, the control group was higher than the research group at each time point, and the difference was statistically significant (P<0.05). Comparison of the MMSE score and the total case number of adverse reactions between the two groups showed no statistical difference (both P>0.05). The MMSE score was positively correlated with the serum levels of NSE and S100β in the two groups (r-values were 0.661 and 0.585, P<0.05). Dexmedetomidine can effectively protect patients' perioperative brain function with small impacts on perioperative hemodynamics, so it is worthy of clinical application.",2020,"The levels of MAP, HR, and CVP were statistically lower in the research group than those in the control group at T2 and T3 (P<0.05).","['41 cases', ""Eighty-seven patients with lung cancer undergoing lung cancer resection in Weifang People's Hospital from January 2014 to June 2018 were enrolled in this study"", 'patients undergoing lung cancer resection']","['propofol, midazolam, sufentanil, or cisatracurium besilate', 'Dexmedetomidine', 'control group and those anesthetized by conventional anesthetic and dexmedetomidine', 'dexmedetomidine']","['serum levels of NSE and S100β', 'levels of MAP, HR, and CVP', 'brain function and hemodynamics', 'MMSE score', 'levels of mean arterial pressure (MAP), heart rate (HR), and central venous pressure (CVP', 'hemodynamic parameters, neuron-specific enolase (NSE), and astrocyte S-100p protein (S-100β', 'levels of serum NSE and S100β protein', 'MMSE score and the total case number of adverse reactions']","[{'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C4517895', 'cui_str': '87'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0530105', 'cui_str': 'Cisatracurium besylate'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1720436', 'cui_str': 'Under anesthesia'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0202144', 'cui_str': 'Neuron-specific enolase measurement'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0199666', 'cui_str': 'Measurement of central venous pressure'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0004112', 'cui_str': 'Astrocyte'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",87.0,0.0290143,"The levels of MAP, HR, and CVP were statistically lower in the research group than those in the control group at T2 and T3 (P<0.05).","[{'ForeName': 'Yunfeng', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Pharmacy, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.""}, {'ForeName': 'Chunyu', 'Initials': 'C', 'LastName': 'Wang', 'Affiliation': ""Department of Anesthesiology, Qingdao Eighth People's Hospital, Qingdao, Shandong 266100, P.R. China.""}, {'ForeName': 'Mingzhuang', 'Initials': 'M', 'LastName': 'Bi', 'Affiliation': ""Department of Anesthesiology, Qingdao Women and Children's Hospital, Qingdao, Shandong 266034, P.R. China.""}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Gao', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.'}, {'ForeName': 'Xue', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China.'}, {'ForeName': 'Haitao', 'Initials': 'H', 'LastName': 'Tian', 'Affiliation': ""Department of Anesthesiology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China.""}]",Oncology letters,['10.3892/ol.2020.11675'] 2619,32724370,Application of dexmedetomidine combined with sufentanil in colon cancer resection and its effect on immune and coagulation function of patients.,"Application of dexmedetomidine combined with sufentanil in colon cancer resection and its effect on immune and coagulation function of patients was studied. Colon cancer cases (n=176) admitted to Xiangya Hospital Central South University were selected into the study. They were divided into group A (n=92) and group B (n=84). In group A, patients underwent surgery anesthesia with dexmedetomidine combined with sufentanil. In group B, patients underwent surgery anesthesia only with sufentanil. The anesthesia induced intubation, operation time and incidence of postoperative adverse reaction of patients were compared between the two groups. Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were observed and recorded before induction, before intubation and after intubation. Blood coagulation analyzer was used to detect four items of coagulation before and after operation. FACSCalibur flow cytometry was used to detect T lymphocyte subsets in peripheral blood of patients in the two groups. The pain scores (VAS) of patients in the two groups were measured and recorded after surgery at 4, 24 and 48 h. There was a difference in anesthesia induced intubation and operation time of patients in both groups (P<0.05). There were differences in HR, SBP and DBP of patients in both groups after intubation (P<0.05), in postoperative coagulation function (P<0.05), and in postoperative immune function of patients in both groups (P<0.05). The VAS scores of patients in both groups were different at different time-points after operation (P<0.05). There were differences in postoperative adverse reactions of patients in both groups (P<0.05). Dexmedetomidine combined with sufentanil is a viable anesthetic regimen for colon cancer resection. The coagulation function and immune function have certain improvement effect for patients.",2020,There was a difference in anesthesia induced intubation and operation time of patients in both groups (P<0.05).,"['Colon cancer cases (n=176) admitted to Xiangya Hospital Central South University', 'patients', 'colon cancer resection']","['surgery anesthesia only with sufentanil', 'sufentanil', 'Dexmedetomidine', 'dexmedetomidine combined with sufentanil', 'dexmedetomidine']","['postoperative adverse reactions', 'anesthesia induced intubation, operation time and incidence of postoperative adverse reaction', 'pain scores (VAS', 'Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP', 'postoperative immune function', 'immune and coagulation function', 'Blood coagulation analyzer', 'anesthesia induced intubation and operation time', 'postoperative coagulation function', 'HR, SBP and DBP', 'VAS scores']","[{'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0143993', 'cui_str': 'Sufentanil'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C1817756', 'cui_str': 'Immunologic function'}, {'cui': 'C0439662', 'cui_str': 'Immune'}, {'cui': 'C0005778', 'cui_str': 'Coagulation, Blood'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0336657', 'cui_str': 'Blood coagulation analyzer'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0204775,There was a difference in anesthesia induced intubation and operation time of patients in both groups (P<0.05).,"[{'ForeName': 'Liqun', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'Xiangya Nursing School, Central South University, Changsha, Hunan 410013, P.R. China.'}, {'ForeName': 'Yinglan', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Xiangya Nursing School, Central South University, Changsha, Hunan 410013, P.R. China.'}]",Oncology letters,['10.3892/ol.2020.11643'] 2620,32270176,Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.,"BACKGROUND Esketamine nasal spray was recently approved for treatment-resistant depression. The current analysis evaluated the impact of symptom-based treatment frequency changes during esketamine treatment on clinical outcomes. METHODS This is a post-hoc analysis of an open-label, long-term (up to 1 year) study of esketamine in patients with treatment-resistant depression (SUSTAIN 2). During a 4-week induction phase, 778 patients self-administered esketamine twice weekly plus a new oral antidepressant daily. In responders (≥50% reduction in Montgomery-Åsberg Depression Rating Scale total score from baseline), esketamine treatment frequency was thereafter decreased during an optimization/maintenance phase to weekly for 4 weeks and then adjusted to the lowest frequency (weekly or every other week) that maintained remission (Montgomery-Åsberg Depression Rating Scale ≤ 12) based on a study-defined algorithm. The relationship between treatment frequency and symptom response, based on clinically meaningful change in Clinical Global Impression-Severity score, was subsequently evaluated 4 weeks after treatment frequency adjustments in the optimization/maintenance phase. RESULTS Among 580 responders treated with weekly esketamine for the first 4 weeks in the optimization/maintenance phase (per protocol), 26% continued to improve, 50% maintained clinical benefit, and 24% worsened. Thereafter, when treatment frequency could be reduced from weekly to every other week, 19% further improved, 49% maintained benefit, and 32% worsened. For patients no longer in remission after treatment frequency reduction, an increase (every other week to weekly) resulted in 47% improved, 43% remained unchanged, and 10% worsened. CONCLUSIONS These findings support individualization of esketamine nasal spray treatment frequency to optimize treatment response in real-world clinical practice. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02497287.",2020,"In responders (≥50% reduction in Montgomery-Åsberg Depression Rating Scale total score from baseline), esketamine treatment frequency was thereafter decreased during an optimization/maintenance phase to weekly for 4 weeks and then adjusted to the lowest frequency (weekly or every other week) that maintained remission (Montgomery-Åsberg Depression Rating Scale ≤ 12) based on a study-defined algorithm.","['580 responders treated with weekly esketamine for the first 4 weeks in the optimization/maintenance phase (per protocol', '778 patients self-administered', 'patients with treatment-resistant depression (SUSTAIN 2']",['esketamine twice weekly plus a new oral antidepressant daily'],"['Clinical Global Impression-Severity score', 'Montgomery-Åsberg Depression Rating Scale total score from baseline), esketamine treatment frequency']","[{'cui': 'C4517818', 'cui_str': '580'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C2825616', 'cui_str': 'esketamine'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}]","[{'cui': 'C2825616', 'cui_str': 'esketamine'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C0332173', 'cui_str': 'Daily'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C2960593', 'cui_str': 'Montgomery-Åsberg depression rating scale'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C2825616', 'cui_str': 'esketamine'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",778.0,0.0275424,"In responders (≥50% reduction in Montgomery-Åsberg Depression Rating Scale total score from baseline), esketamine treatment frequency was thereafter decreased during an optimization/maintenance phase to weekly for 4 weeks and then adjusted to the lowest frequency (weekly or every other week) that maintained remission (Montgomery-Åsberg Depression Rating Scale ≤ 12) based on a study-defined algorithm.","[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Nijs', 'Affiliation': 'Janssen Research and Development, LLC, Department of Global Analytics - Neuroscience, Titusville.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Wajs', 'Affiliation': 'Janssen Research and Development, Belgium, Department of Neuroscience, Beerse, Belgium.'}, {'ForeName': 'Leah', 'Initials': 'L', 'LastName': 'Aluisio', 'Affiliation': 'Janssen Research and Development, LLC, Department of Neuroscience, San Diego, CA.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Turkoz', 'Affiliation': 'Janssen Research and Development, LLC, Department of Statistics & Decision Sciences, Titusville, NJ.'}, {'ForeName': 'Ella', 'Initials': 'E', 'LastName': 'Daly', 'Affiliation': 'Janssen Research and Development, LLC, Department of Clinical Medical Affairs, Titusville, NJ.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Janik', 'Affiliation': 'Janssen Research and Development, LLC, Department of Neuroscience, San Diego, CA.'}, {'ForeName': 'Stephane', 'Initials': 'S', 'LastName': 'Borentain', 'Affiliation': 'Janssen Research and Development, LLC, Department of Clinical Medical Affairs, Titusville, NJ.'}, {'ForeName': 'Jaskaran B', 'Initials': 'JB', 'LastName': 'Singh', 'Affiliation': 'Janssen Research and Development, LLC, Department of Neuroscience, San Diego, CA.'}, {'ForeName': 'Allitia', 'Initials': 'A', 'LastName': 'DiBernardo', 'Affiliation': 'Janssen Research and Development, France, Department of Clinical Medical Affairs, Issy-les-Moulineaux, France.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Wiegand', 'Affiliation': 'Janssen Research and Development, LLC, Department of Clinical Medical Affairs, Titusville, NJ.'}]",The international journal of neuropsychopharmacology,['10.1093/ijnp/pyaa027'] 2621,30052325,A Study to Assess the Proarrhythmic Potential of Mirtazapine Using Concentration-QTc (C-QTc) Analysis.,"Most new chemical entities with systemic availability are required to be tested in a study specifically designed to exclude drug-induced corrected QT interval (QTc) effects, the so-called thorough QT/QTc study. Mirtazapine (Remeron™) is an antidepressant indicated for the treatment of episodes of major depression, which was originally approved in 1994 without a thorough QT study. To evaluate the proarrhythmic potential of mirtazapine, we performed a QT/QTc study with a novel design including implementation of an analysis of the relationship between drug concentration and the QTc interval as the primary assessment of proarrhythmic potential of mirtazapine. The least squares mean differences of the corrected QT interval between mirtazapine and placebo at the geometric mean maximum concentration of drug in blood plasma (90% confidence interval) were 2.39 milliseconds (0.70, 4.07) at the 45-mg dose and 4.00 milliseconds (1.18, 6.83) at the 75-mg dose level of mirtazapine. Modeling of the concentration/QTc relationship for moxifloxacin confirmed that the assay method was adequately sensitive. This trial showed a positive relationship between mirtazapine concentrations and prolongation of the QTc interval. However, the degree of QT prolongation observed with both 45-mg and 75-mg doses of mirtazapine was not at a level generally considered to be clinically meaningful. This study further demonstrates that analysis of the relationship between drug concentration and the QTc interval may be a reasonable alternative to traditional TQT studies to assess risk of QT prolongation.",2019,"The least squares mean differences of the corrected QT interval between mirtazapine and placebo at the geometric mean maximum concentration of drug in blood plasma (90% confidence interval) were 2.39 milliseconds (0.70, 4.07) at the 45-mg dose and 4.00 milliseconds (1.18, 6.83) at the 75-mg dose level of mirtazapine.",[],"['Mirtazapine (Remeron™', 'mirtazapine', 'Mirtazapine', 'moxifloxacin', 'placebo']","['QT prolongation', 'mirtazapine concentrations and prolongation of the QTc interval', 'corrected QT interval (QTc) effects', 'corrected QT interval', 'blood plasma']",[],"[{'cui': 'C0049506', 'cui_str': 'Mirtazapine'}, {'cui': 'C0525726', 'cui_str': 'Zispin'}, {'cui': 'C0536495', 'cui_str': 'moxifloxacin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0151878', 'cui_str': 'Prolonged QT interval'}, {'cui': 'C0049506', 'cui_str': 'Mirtazapine'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429028', 'cui_str': 'QT interval feature'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",,0.0547099,"The least squares mean differences of the corrected QT interval between mirtazapine and placebo at the geometric mean maximum concentration of drug in blood plasma (90% confidence interval) were 2.39 milliseconds (0.70, 4.07) at the 45-mg dose and 4.00 milliseconds (1.18, 6.83) at the 75-mg dose level of mirtazapine.","[{'ForeName': 'Sevgi', 'Initials': 'S', 'LastName': 'Gurkan', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Fang', 'Initials': 'F', 'LastName': 'Liu', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Chain', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Gutstein', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.605'] 2622,32728421,Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).,"Many patients with pulmonary arterial hypertension do not achieve treatment goals with monotherapy, and therefore combination therapy is becoming the standard of care. The soluble guanylate cyclase stimulator riociguat is licensed for the treatment of pulmonary arterial hypertension; here we present findings from patients who were receiving combined riociguat plus endothelin receptor antagonists or non-intravenous prostanoids in the randomized, placebo-controlled PATENT-1 study and its open-label extension (PATENT-2). Moreover, we include new data from patients receiving early sequential combination therapy (three to six months of endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy (>6 months). Patients were randomized to riociguat 2.5 mg-maximum ( N  = 131 pretreated patients) and placebo ( N  = 60 pretreated patients). Riociguat improved 6-min walking distance (PATENT-1 primary endpoint), functional capacity, and hemodynamics after 12 weeks in pretreated patients. The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients. In the early sequential combination and long-term background endothelin receptor antagonist groups, the placebo-corrected changes in 6-min walking distance were +65 m (95% CI: 17 to 113 m) and +13 m (95% CI: -8 to 33 m), respectively. In conclusion, these data suggest that early sequential combination of an endothelin receptor antagonist plus riociguat is a feasible treatment option. Both early sequential therapy and long-term background endothelin receptor antagonist plus riociguat were well tolerated in the PATENT studies.",2020,The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients.,"['pulmonary arterial hypertension', 'patients with pulmonary arterial hypertension', 'patients with pulmonary arterial hypertension (PATENT studies']","['endothelin receptor antagonist treatment) or long-term background endothelin receptor antagonist therapy', 'combined riociguat plus endothelin receptor antagonists', 'riociguat', 'riociguat 2.5\u2009mg-maximum ( N \u2009=\u2009131 pretreated patients) and placebo', 'placebo']","['functional capacity, and hemodynamics', '6-min walking distance', 'Efficacy and safety']","[{'cui': 'C2973725', 'cui_str': 'Pulmonary arterial hypertension'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030650', 'cui_str': 'Patents'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1134681', 'cui_str': 'Endothelin receptor antagonist'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C2717561', 'cui_str': 'riociguat'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3667605', 'cui_str': 'riociguat 2.5 MG'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",131.0,0.0999791,The placebo-corrected changes in 6-min walking distance were +24 m in endothelin receptor antagonist-pretreated patients and +106 m in the small group of prostanoid-pretreated patients.,"[{'ForeName': 'Hossein-Ardeschir', 'Initials': 'HA', 'LastName': 'Ghofrani', 'Affiliation': 'University of Giessen and Marburg Lung Center, Member of German Center for Lung Research, Giessen, Germany.'}, {'ForeName': 'Ekkehard', 'Initials': 'E', 'LastName': 'Grünig', 'Affiliation': 'Center for Pulmonary Hypertension, Thoraxklinic, University Hospital Heidelberg, Member of the German Center for Lung Research (DZL), Heidelberg, Germany.'}, {'ForeName': 'Pavel', 'Initials': 'P', 'LastName': 'Jansa', 'Affiliation': 'First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Langleben', 'Affiliation': 'Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Rosenkranz', 'Affiliation': 'Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Köln, Germany.'}, {'ForeName': 'Ioana R', 'Initials': 'IR', 'LastName': 'Preston', 'Affiliation': 'Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Franck', 'Initials': 'F', 'LastName': 'Rahaghi', 'Affiliation': 'Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Florida, Weston, FL, USA.'}, {'ForeName': 'Namita', 'Initials': 'N', 'LastName': 'Sood', 'Affiliation': 'The Lung Center, The Ohio State University, Columbus, OH, USA.'}, {'ForeName': 'Dennis', 'Initials': 'D', 'LastName': 'Busse', 'Affiliation': 'Chrestos Concept GmbH & Co. KG, Essen, Germany.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Meier', 'Affiliation': 'Bayer AG, Berlin, Germany.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Humbert', 'Affiliation': ""Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, and Institut National de la Santé et de la Recherche Médicale Unité 999, Le Kremlin-Bicêtre, France.""}]",Pulmonary circulation,['10.1177/2045894020942121'] 2623,32728436,Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: A randomized controlled trial.,"Background COPD patients often require multiple therapies to enhance their lung function and reduce their symptoms in exacerbations. This study aimed to investigate the relative effects of combination adjunctive nebulized furosemide and salbutamol therapy versus single agent treatment in COPD patients. Methods Sixty-nine COPD patients were randomly divided into two groups. The first group (G1, 34 cases) received salbutamol in their first episode. The second group (G2, 35 cases) received furosemide in their first episode. Spirometry indices (FEV1, FVC, and FEV1/FVC), mMRC and BORG (COPD assessment) were assessed and recorded for all patients.To study the efficacy of combination adjunctive therapy, in 2nd episodes, the nebulized furosemide was added to nebulized salbutamol in the G1, and nebulized salbutamol was added to nebulized furosemide in G2. The aforementioned indices were then re-assessed. Results The mean age was (64.92 ± 11.71 years, 55% males. The use of nebulized furosemide and salbutamol as single agents slightly improved the spirometeric parameters, but it was not noteworthy compared to the significant improvement of the FEV1, FVC, FEV1/FVC, mMRC, and Borg parameters with combination therapy ( p -value< 0.001). In the first episode, there was no difference in spirometeric indices, between groups ( p -value > 0.1), so furosemide is considered as effective as nebulized salbutamol. Also, the results of sequential drugs administration, in the two groups was similar. Conclusion Conjunction of nebulized furosemide and salbutamol is more effective than single therapy and can be considered as preferred drug regimen without any reported side effect in the treatment of COPD.",2020,"In the first episode, there was no difference in spirometeric indices, between groups ( p -value > 0.1), so furosemide is considered as effective as nebulized salbutamol.","['The mean age was (64.92\xa0±\xa011.71 years, 55% males', 'Methods\n\n\nSixty-nine COPD patients', 'COPD patients']","['nebulized furosemide', 'nebulized salbutamol', 'Combination adjunctive nebulized furosemide and salbutamol', 'furosemide', 'salbutamol', 'nebulized furosemide and salbutamol', 'combination adjunctive nebulized furosemide and salbutamol therapy']","['Spirometry indices (FEV1, FVC, and FEV1/FVC), mMRC and BORG (COPD assessment', 'FEV1, FVC, FEV1/FVC, mMRC', 'spirometeric parameters', 'spirometeric indices']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0450388', 'cui_str': '69'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0016860', 'cui_str': 'Furosemide'}, {'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0037981', 'cui_str': 'Spirometry'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C3714541', 'cui_str': 'Forced vital capacity'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",69.0,0.0185217,"In the first episode, there was no difference in spirometeric indices, between groups ( p -value > 0.1), so furosemide is considered as effective as nebulized salbutamol.","[{'ForeName': 'Mohammadali', 'Initials': 'M', 'LastName': 'Saba', 'Affiliation': 'Department Pulmonary, Shahid Beheshti Hospital, Kashan, Iran.'}, {'ForeName': 'Abdoulhossein', 'Initials': 'A', 'LastName': 'Davoodabadi', 'Affiliation': 'Departments of Surgery, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Azin', 'Initials': 'A', 'LastName': 'Ghaffari', 'Affiliation': 'Internal Medicine, Shahid Beheshti Hospital, Kashan, Iran.'}, {'ForeName': 'Hamidreza', 'Initials': 'H', 'LastName': 'Gilasi', 'Affiliation': 'Departments of Epidemiology & Biostatistics, Kashan University of Medical Sciences, Kashan, Iran.'}, {'ForeName': 'Babak', 'Initials': 'B', 'LastName': 'Haghpanah', 'Affiliation': 'Orthopedic Surgery, Kashan University of Medical Sciences, Kashan, Iran.'}]",Annals of medicine and surgery (2012),['10.1016/j.amsu.2020.07.005'] 2624,32728474,One year later: Highlighting the challenges and opportunities in disseminating a breathing-retraining digital behaviour change intervention.,"Digital behaviour change interventions can provide effective and cost-effective treatments for a range of health conditions. However, after rigorous evaluation, there still remain challenges to disseminating and implementing evidence-based interventions that can hinder their effectiveness 'in the real world'. We conducted a large-scale randomised controlled trial of self-guided breathing retraining, which we then disseminated freely as a digital intervention. Here we share our experience of this process after one year, highlighting the opportunities that digital health interventions can offer alongside the challenges that must be addressed in order to harness their effectiveness. Whilst such treatments can support many individuals at extremely low cost, careful dissemination strategies should be proactively planned in order to ensure such opportunities are maximised and interventions remain up to date in a fast-moving digital landscape.",2020,Digital behaviour change interventions can provide effective and cost-effective treatments for a range of health conditions.,[],"['Digital behaviour change interventions', 'self-guided breathing retraining']",[],[],"[{'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]",[],,0.0241376,Digital behaviour change interventions can provide effective and cost-effective treatments for a range of health conditions.,"[{'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Ainsworth', 'Affiliation': 'Department of Psychology, University of Bath, UK.'}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Bruton', 'Affiliation': 'School of Health Sciences, University of Southampton, UK.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'Thomas', 'Affiliation': 'Primary Care and Population Sciences, University of Southampton, UK.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Yardley', 'Affiliation': 'School of Psychological Science, University of Bristol, UK.'}]",Digital health,['10.1177/2055207620936441'] 2625,32728484,Perceived Changes in General Well-being: Findings from the 'MOVEdiabetes' Physical Activity Randomized Control Trial.,"Objectives Studies have consistently reported the health benefits of physical activity (PA) in diabetes care. Our study aimed to explore perceptions of general well-being in participants of the 'MOVEdiabetes' intervention aimed at increasing PA in adults with type 2 diabetes in Oman. Methods 'MOVEdiabetes' is a cluster-randomized study where participants in the intervention group (IG) received PA consultations, pedometers, and WhatsApp messages versus the usual care in the control group (CG). At baseline and 12 months, perceptions on well-being were assessed using an English translated to Arabic 13-item questionnaire. Between groups differences in responses were compared using chi-squared tests. Spearman correlation analysis was utilized to explore associations between changes in responses and self-reported PA levels (metabolic equivalent of task.min/week). Results Of the 232 participants in the 'MOVEdiabetes' study, 75.0% completed the study. Overall, findings indicate a positive effect of the intervention on perceived general health, sleep, mental health, pain, and responses to quality of life. For the IG and CG, significant associations were shown between changes in self-reported PA and general health (r = 0.70 and 0.36, p < 0.001), feeling calm/peaceful (r = 0.86 and 0.93, p < 0.001), energetic (r = 0.86 and 0.82, p < 0.001), and depressed (r = -0.35 and -0.30, p < 0.001). However, the Cronbach's alpha value was 0.50, indicating insufficient internal consistency of the assessment tool. Conclusions The intervention has a positive effect on many parameters of well-being. Further studies are needed to identify robust tools to measure associations between well-being and PA in culturally bounded Arabic speaking countries.",2020,"For the IG and CG, significant associations were shown between changes in self-reported PA and general health (r = 0.70 and 0.36, p < 0.001), feeling calm/peaceful (r = 0.86 and 0.93, p < 0.001), energetic (r = 0.86 and 0.82, p < 0.001), and depressed (r = -0.35 and -0.30, p < 0.001).","['adults with type 2 diabetes in Oman', ""232 participants in the 'MOVEdiabetes' study, 75.0% completed the study""]","['PA consultations, pedometers, and WhatsApp messages versus the usual care in the control group (CG']","['perceived general health, sleep, mental health, pain, and responses to quality of life', 'energetic', 'self-reported PA and general health', 'feeling calm/peaceful']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0028971', 'cui_str': 'Oman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0522165', 'cui_str': 'Feeling calm'}]",232.0,0.0566516,"For the IG and CG, significant associations were shown between changes in self-reported PA and general health (r = 0.70 and 0.36, p < 0.001), feeling calm/peaceful (r = 0.86 and 0.93, p < 0.001), energetic (r = 0.86 and 0.82, p < 0.001), and depressed (r = -0.35 and -0.30, p < 0.001).","[{'ForeName': 'Thamra S', 'Initials': 'TS', 'LastName': 'Al-Ghafri', 'Affiliation': 'Directorate General of Health Services, Ministry of Health, Muscat, Oman.'}, {'ForeName': 'Saud M', 'Initials': 'SM', 'LastName': 'Al-Harthi', 'Affiliation': 'Directorate General of Health Services, Ministry of Health, Muscat, Oman.'}, {'ForeName': 'Yahya', 'Initials': 'Y', 'LastName': 'Al-Farsi', 'Affiliation': 'Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.'}, {'ForeName': 'Angela M', 'Initials': 'AM', 'LastName': 'Craigie', 'Affiliation': 'Centre for Public Health Nutrition Research, University of Dundee, Scotland, UK.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Bannerman', 'Affiliation': 'Global Academy of Agriculture and Food Security, The Royal (Dick) School of Veterinary Studies, University of Edinburgh, Scotland, UK.'}, {'ForeName': 'Annie S', 'Initials': 'AS', 'LastName': 'Anderson', 'Affiliation': 'Centre for Public Health Nutrition Research, University of Dundee, Scotland, UK.'}]",Oman medical journal,['10.5001/omj.2020.68'] 2626,32728536,To Study the Effect of Calorie Deficit Diet and Strength Training in Patients with Mild to Moderate Obstructive Sleep Apnoea.,"OSA is a disease of modernisation. Though many modalities are available for its treatment from invasive to non-invasive; the role of lifestyle modification can never be underrated. Lifestyle modification normally includes walk; diet with less fat; abstinence from alcohol and smoking along with regularising of sleep schedule. However the role of calorie deficit diet along with strength training in OSA has not been extensively researched till date. The present study aimed to evaluate the effect of the calorie deficit diet and strength training in patients with mild to moderate obstructive sleep apnea. It is a prospective randomised control trial of 40 patients. The patients were divided into 2 groups. Group A was given lifestyle modification while Group B was given Lifestyle Modification with calorie deficit diet and strength training. The outcomes were measured by comparing pre-intervention and post-intervention polysomnography and Epworth sleepiness score after 3 months. The most common symptom found in our group was excessive daytime sleepiness and Loud snoring; both present in 39/40 patients. Other common symptoms were Awakening with a dry mouth or sore throat; morning headache; difficulty concentrating during the day; experiencing mood changes, such as depression or irritability and high blood pressure. The post intervention BMI in Group A was - 1.75 ± 0.698 than pre-intervention BMI while in Group B the difference between pre-intervention and post intervention was - 3.05 ± 1.32. The difference in AHI events pre-intervention versus post-intervention in Group A and Group B was - 3.5 ± 1.11 and - 5.55 ± 1.90 respectively. The ESS decreased by - 2.2 ± 0.871 and - 3.31 ± 0.05 respectively in Group A and Group B post-intervention. Calorie deficit diet along with strength training markedly improves the AHI index; BMI and ESS score in Mild to moderate OSA patients and is highly recommended in motivated patients in addition to lifestyle modification.",2020,The ESS decreased by - 2.2 ± 0.871 and - 3.31 ± 0.05 respectively in Group A and Group B post-intervention.,"['Patients with Mild to Moderate Obstructive Sleep Apnoea', 'patients with mild to moderate obstructive sleep apnea', '40 patients', 'Mild to moderate OSA patients']","['Calorie deficit diet along with strength training', 'lifestyle modification while Group B was given Lifestyle Modification with calorie deficit diet and strength training', 'Calorie Deficit Diet and Strength Training', 'Lifestyle modification normally includes walk; diet with less fat; abstinence from alcohol and smoking along with regularising of sleep schedule', 'calorie deficit diet and strength training', 'OSA']","['pre-intervention and post-intervention polysomnography and Epworth sleepiness score', 'depression or irritability and high blood pressure', 'AHI index; BMI and ESS score', 'ESS', 'excessive daytime sleepiness and Loud snoring']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}]","[{'cui': 'C0439259', 'cui_str': 'kcal'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0037369', 'cui_str': 'Smoking'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}]","[{'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0013144', 'cui_str': 'Drowsiness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0022107', 'cui_str': 'Feeling irritable'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0206630', 'cui_str': 'Endometrial stromal sarcoma'}, {'cui': 'C4551761', 'cui_str': 'Excessive daytime sleepiness'}, {'cui': 'C0178733', 'cui_str': 'Loudness'}, {'cui': 'C0037384', 'cui_str': 'Snoring'}]",40.0,0.0128056,The ESS decreased by - 2.2 ± 0.871 and - 3.31 ± 0.05 respectively in Group A and Group B post-intervention.,"[{'ForeName': 'Jaskaran', 'Initials': 'J', 'LastName': 'Singh', 'Affiliation': 'Sri Guru Ram Das Institute of Health Sciences and Research Amritsar, HIG 202 Sector 71, Mohali, 160071 India.'}, {'ForeName': 'Bhanu', 'Initials': 'B', 'LastName': 'Bhardwaj', 'Affiliation': 'Sri Guru Ram Das Institute of Health Sciences and Research Amritsar, 27-C; Sant Avenue; The Mall, Amritsar, 143001 India.'}]",Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India,['10.1007/s12070-019-01739-2'] 2627,32728649,"Protocol for a multicenter randomized, double blind, controlled pilot trial of higher neural function in overactive bladder patients after anticholinergic, beta-3 adrenergic agonist, or placebo.","Introduction Overactive bladder (OAB) syndrome has a negative impact on quality of life and prevalence increases with advanced age. Anticholinergics (AC) and beta-3 adrenergic agonists (β3a) are commonly prescribed medications for treatment of OAB. AC medication has been associated with dementia in population studies and with cortical atrophy in imaging studies. Higher neural effects of both classes of OAB medications have not been evaluated with functional neuroimaging. Longitudinal clinical assessments of cognition after OAB therapy with AC has produced conflicting results. β3a medication is has not been associated with dementia in clinical studies; however, higher neural effects are unknown.Our multicenter, double blind, randomized, placebo-controlled trial uses functional magnetic resonance imaging (fMRI) and cognitive testing to evaluate the effects of AC and β3a on brain functional connectivity in females with non-neurogenic OAB. Methods and Analysis and analysis: Female patients with OAB symptoms ages 50-90 years old without baseline cognitive impairment, moderate to severe depression or anxiety, neurologic disorders, or significant incomplete bladder emptying are invited to participate. Subjects are randomized to one of three interventions for 29 ± 1 day: AC (Solifenacin succinate, Teva), β3a (Mirabegron, Myrbetriq, Astellas), or placebo. Functional neuroimaging data at baseline and post-intervention will be analyzed accordingly. Clinical cognitive assessments will be compared from baseline to post-intervention. Ethics All qualifying patients are properly consented before enrolling in this study that has been approved by the Institutional Review Board of participating institutions.",2020,Anticholinergics (AC) and beta-3 adrenergic agonists (β3a) are commonly prescribed medications for treatment of OAB.,"[' Female patients with OAB symptoms ages 50-90 years old without baseline cognitive impairment, moderate to severe depression or anxiety, neurologic disorders, or significant incomplete bladder emptying are invited to participate', 'overactive bladder patients after', 'females with non-neurogenic OAB']","['Anticholinergics (AC) and beta-3 adrenergic agonists (β3a', 'anticholinergic, beta-3 adrenergic agonist, or placebo', 'AC and β3a', 'AC medication', 'AC (Solifenacin succinate, Teva), β3a (Mirabegron, Myrbetriq, Astellas), or placebo', 'functional magnetic resonance imaging (fMRI) and cognitive testing', 'placebo']",['brain functional connectivity'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0878773', 'cui_str': 'Overactive bladder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0027765', 'cui_str': 'Disorder of nervous system'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0344365', 'cui_str': 'Incomplete emptying of bladder'}]","[{'cui': 'C0242896', 'cui_str': 'Acetylcholine receptor antagonist'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0001648', 'cui_str': 'Adrenergic receptor agonist'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C1509436', 'cui_str': 'Solifenacin succinate'}, {'cui': 'C2983812', 'cui_str': 'mirabegron'}, {'cui': 'C3485428', 'cui_str': 'Myrbetriq'}, {'cui': 'C0376335', 'cui_str': 'Magnetic Resonance Imaging, Functional'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0205245', 'cui_str': 'Functional'}]",,0.617808,Anticholinergics (AC) and beta-3 adrenergic agonists (β3a) are commonly prescribed medications for treatment of OAB.,"[{'ForeName': 'Rachel A', 'Initials': 'RA', 'LastName': 'High', 'Affiliation': 'Department of Obstetrics and Gynecology, Baylor Scott and White Health, 2401 South 31st Street, Temple, TX, 76508, USA.'}, {'ForeName': 'Jill M', 'Initials': 'JM', 'LastName': 'Danford', 'Affiliation': 'Department of Urology, Baylor Scott and White Health, 2401 South 31st Street, Temple, TX, 76508, USA.'}, {'ForeName': 'Zhaoyue', 'Initials': 'Z', 'LastName': 'Shi', 'Affiliation': 'Department of MRI Core, Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA.'}, {'ForeName': 'Christof', 'Initials': 'C', 'LastName': 'Karmonik', 'Affiliation': 'Department of MRI Core, Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Kuehl', 'Affiliation': 'Department of Obstetrics and Gynecology, Baylor Scott and White Health, 2401 South 31st Street, Temple, TX, 76508, USA.'}, {'ForeName': 'Erin T', 'Initials': 'ET', 'LastName': 'Bird', 'Affiliation': 'Department of Urology, Baylor Scott and White Health, 2401 South 31st Street, Temple, TX, 76508, USA.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Khavari', 'Affiliation': 'Department of Urology, Methodist Hospital, 6560 Fannin St. Ste 2100, Houston, TX, 77030, USA.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100621'] 2628,32728650,Investigating the efficacy of a self-directed parenting intervention to reduce risky behaviors among college students: Study protocol for a multi-arm hybrid type 2 randomized control trial.,"Background Early adulthood is a critical developmental period when many youth transition from living at home to the relative autonomy of college. This transition results in increased opportunity for positive growth and identity development - and for risky substance use and sexual behaviors. Parents continue to influence young adult behavior even from a distance; however, few studies have rigorously tested parent-college student interventions. Methods This multi-arm hybrid type 2 trial tests the short- and long-term efficacy of a self-directed handbook for parents of first-year college students. In the summer before college, parent-student dyads are randomly assigned to one of three conditions: control, Parent Handbook, or Parent Handbook Plus. Handbook parents receive encouragement via phone calls to read the handbook and complete activities with their student before leaving for college. Handbook Plus parents also receive booster messages targeted at risky or stressful times. Participants complete surveys of intervention-targeted knowledge, attitudes, and behaviors at baseline and four months after baseline. Students complete three additional surveys at nine, 16, and 21 months after baseline. Dyads in the intervention conditions also reported on handbook utilization, perceived usefulness, and engagement with intervention materials. Discussion Self-directed family interventions may be a feasible strategy for involving parents of college students. This trial aimed to determine: 1) the efficacy of a self-directed handbook intervention for parents of first-year college students, including whether the addition of periodic booster messages enhanced efficacy; and 2) how variations in handbook utilization, perceived usefulness, and engagement were linked to student outcomes.",2020,trial tests the short- and long-term efficacy of a self-directed handbook for parents of first-year college students.,"['parents of college students', 'college students', 'parents of first-year college students']","['self-directed handbook intervention', 'self-directed parenting intervention', 'self-directed handbook', 'control, Parent Handbook, or Parent Handbook']","['handbook utilization, perceived usefulness, and engagement with intervention materials', 'risky behaviors']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0596654', 'cui_str': 'Handbooks'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C0596654', 'cui_str': 'Handbooks'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0770529,trial tests the short- and long-term efficacy of a self-directed handbook for parents of first-year college students.,"[{'ForeName': 'Brittany Rhoades', 'Initials': 'BR', 'LastName': 'Cooper', 'Affiliation': 'Washington State University, Department of Human Development, United States.'}, {'ForeName': 'Laura G', 'Initials': 'LG', 'LastName': 'Hill', 'Affiliation': 'Washington State University, Department of Human Development, United States.'}, {'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Haggerty', 'Affiliation': 'University of Washington, School of Social Work, Social Development Research Group, United States.'}, {'ForeName': 'Martie', 'Initials': 'M', 'LastName': 'Skinner', 'Affiliation': 'University of Washington, School of Social Work, Social Development Research Group, United States.'}, {'ForeName': 'Matthew F', 'Initials': 'MF', 'LastName': 'Bumpus', 'Affiliation': 'Washington State University, Department of Human Development, United States.'}, {'ForeName': 'Porismita', 'Initials': 'P', 'LastName': 'Borah', 'Affiliation': 'Washington State University, College of Communication, United States.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Casey-Goldstein', 'Affiliation': 'University of Washington, School of Social Work, Social Development Research Group, United States.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Catalano', 'Affiliation': 'University of Washington, School of Social Work, Social Development Research Group, United States.'}]",Contemporary clinical trials communications,['10.1016/j.conctc.2020.100627'] 2629,32728652,"Oral cancer screening using mobile phone-based(mHealth) approach versus conventional oral examination approach, protocol of a cluster randomized study with cost-effectiveness analysis.","Introduction Oral cancer is a significant health problem in India. Diagnosis is often delayed. The effectiveness of conventional oral screening has been shown in the Trivandrum oral cancer screening study. The present study will be a step forward to test a mobile phone-based (the mHealth approach) comparing it with the conventional approach. The purpose of this paper is to report the protocol for this study. The primary objective will be to compare both methods in diagnosing oral potentially malignant disorders and cancers. The secondary objective would be to study the cost-effectiveness. Methods and analysis This will be a cluster-randomized clinical trial of the population in Ernakulam district of Kerala state in India. They will undergo oral cancer screening by community health workers, who will be pre-assigned to the randomly allotted intervention (mHealth) or control (conventional method) clusters. We will enrol a minimum of 9696 subjects from all 6 clusters over 18 months. The cost-effectiveness of the two strategies for oral screening will be determined using data from this randomized controlled trial. The incremental cost per oral cancer/high-risk dysplasia detected, and the incremental cost per life saved will be reported. We will conduct sensitivity and scenario analysis to evaluate the robustness of the findings. Ethics and dissemination When completed, this will be the first cluster randomized population-based study to test the technology-based approach in India. The knowledge from this study will indicate whether specialists can make a remote diagnosis of oral lesions accurately based on the information gathered using a mobile phone health application and whether the mHealth strategy will be cost-effective in Oral cancer screening. The study will follow the ethical guidelines and will be published in an indexed journal.",2020,The knowledge from this study will indicate whether specialists can make a remote diagnosis of oral lesions accurately based on the information gathered using a mobile phone health application and whether the mHealth strategy will be cost-effective in Oral cancer screening.,"['population in Ernakulam district of Kerala state in India', '9696 subjects from all 6 clusters over 18\xa0months']","['conventional oral screening', 'Oral cancer screening using mobile phone-based(mHealth) approach versus conventional oral examination approach']","['incremental cost per oral cancer/high-risk dysplasia', 'cost-effectiveness']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0443018', 'cui_str': 'Kerala'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021201', 'cui_str': 'India'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0153381', 'cui_str': 'Malignant tumor of oral cavity'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0376306', 'cui_str': 'Oral examination'}]","[{'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1527415', 'cui_str': 'Oral route'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0334044', 'cui_str': 'Dysplasia'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0977221,The knowledge from this study will indicate whether specialists can make a remote diagnosis of oral lesions accurately based on the information gathered using a mobile phone health application and whether the mHealth strategy will be cost-effective in Oral cancer screening.,"[{'ForeName': 'Krishnakumar', 'Initials': 'K', 'LastName': 'Thankappan', 'Affiliation': 'Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.'}, {'ForeName': 'Praveen', 'Initials': 'P', 'LastName': 'Birur', 'Affiliation': ""Department in Oral Medicine and Radiology, KLE Society's Institute of Dental Sciences, Bangalore, India.""}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Raj', 'Affiliation': 'Division of Paediatrics and Public Health Research, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.'}, {'ForeName': 'Sandjar', 'Initials': 'S', 'LastName': 'Djalalov', 'Affiliation': 'Westminster International University in Tashkent, Tashkent, Uzbekistan.'}, {'ForeName': 'Sujha', 'Initials': 'S', 'LastName': 'Subramanian', 'Affiliation': 'RTI International Waltham, MA, USA.'}, {'ForeName': 'Subramania', 'Initials': 'S', 'LastName': 'Iyer', 'Affiliation': 'Department of Head and Neck Surgery and Oncology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.'}, {'ForeName': 'Moni', 'Initials': 'M', 'LastName': 'Abraham Kuriakose', 'Affiliation': 'Cochin Cancer Research Centre, Kochi, India.'}]",International journal of surgery protocols,['10.1016/j.isjp.2020.07.001'] 2630,32728702,Effects of Acute Alcohol Consumption on Food Intake and Pictorial Stroop Response to High-Calorie Food Cues.,"AIMS We examined (a) the effect of an acute dose of alcohol on the consumption of energy-dense food and (b) on cognitive bias towards high-energy-dense food cues and (3) whether the effect of an acute dose of alcohol on the consumption of energy-dense food would be mediated by cognitive bias towards high-energy-dense food cues. METHODS Heavy social drinkers (n = 40) abstained from drinking for 12 hours before testing. On the test day, participants completed pre-challenge measures of alcohol and food craving, and cognitive bias towards alcohol in a placebo-controlled, double-blind design. Participants performed post-challenge measures of alcohol and food craving, ad lib energy-dense food consumption and cognitive bias. RESULTS We did not observe any of the hypothesized interactions between challenge condition, consumption of energy-dense food and cognitive bias towards high-energy-dense food cues. CONCLUSIONS Our data suggest that acute alcohol consumption does not influence the consumption of energy-dense food or cognitive bias towards high-energy-dense food cues. These findings may reflect that alcohol does not increase the appetitive value of food and food-related cues or that the measures used in this study were not sensitive to detect an effect. Further research is required to determine whether alcohol at higher doses and/or food cues that are frequently paired with alcohol intake stimulates changes in food intake and the reward value of food cues.",2020,"We did not observe any of the hypothesized interactions between challenge condition, consumption of energy-dense food and cognitive bias towards high-energy-dense food cues. ",['Heavy social drinkers (n\xa0=\xa040) abstained from drinking for 12 hours before testing'],"['Acute Alcohol Consumption', 'alcohol']","['alcohol and food craving, and cognitive bias towards alcohol', 'Food Intake and Pictorial Stroop Response']","[{'cui': 'C0439539', 'cui_str': 'Heavy (weight)'}, {'cui': 'C0337676', 'cui_str': 'Social drinker'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C1292430', 'cui_str': '12 hours'}, {'cui': 'C0392366', 'cui_str': 'Tests'}]","[{'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0872380', 'cui_str': 'Food craving'}, {'cui': 'C0005346', 'cui_str': 'Biases'}, {'cui': 'C0013470', 'cui_str': 'Eating'}]",,0.0530057,"We did not observe any of the hypothesized interactions between challenge condition, consumption of energy-dense food and cognitive bias towards high-energy-dense food cues. ","[{'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Adams', 'Affiliation': 'Addiction and Mental Health Group, Department of Psychology, University of Bath, 10 West, Bath BA2 7AY, UK.'}, {'ForeName': 'Elise', 'Initials': 'E', 'LastName': 'Wijk', 'Affiliation': 'Addiction and Mental Health Group, Department of Psychology, University of Bath, 10 West, Bath BA2 7AY, UK.'}]","Alcohol and alcoholism (Oxford, Oxfordshire)",['10.1093/alcalc/agaa063'] 2631,32728881,Dietary macronutrients do not differently affect postprandial vascular endothelial function in apparently healthy overweight and slightly obese men.,"PURPOSE Well-designed trials comparing side-by-side effects of macronutrients on postprandial endothelial function are missing. Therefore, we investigated under well-controlled and isocaloric condition effects of fat, carbohydrates, and protein on postprandial endothelial function as assessed by brachial artery flow-mediated vasodilation (FMD), an important non-invasive technique to assess endothelial function. METHODS Eighteen apparently healthy overweight and slightly obese men (BMI 26.0-35.0 kg/m 2 ) completed this randomized, double-blinded, cross-over trial. The study consisted of three test days each separated by a wash-out period of at least 1 week. After an overnight fast, men received an isocaloric meal providing 3987 kJ (953 kcal) that was either high in dietary fat (En% fat [F]/carbohydrates [C]/protein [P]: 52.3, 39.2, 8.0), carbohydrates (En% F/C/P: 9.6, 81.5, 8.6), or protein (En% F/C/P: 10.6, 51.5, 36.9). Fasting and 2-h postprandial FMD responses were measured. RESULTS A postprandial decrease of 1.2% point in FMD was observed after the high-protein meal (P = 0.015). However, postprandial changes did not differ between meals (P = 0.45). An increase in baseline brachial artery diameters was observed after the high-protein meal (P < 0.001) and changes differed between meals (P = 0.020). A meal*time interaction was found for plasma glucose concentrations, with the most pronounced increases after the high-carbohydrate meal at T15, T30, T60, and T90 (P < 0.05). A significant time and meal (P < 0.001), but no time*meal effect (P = 0.06) was found for serum insulin concentrations. Increases in serum triacylglycerol concentrations did not differ between meals (P = 0.014). CONCLUSION Macronutrients did not differently affect postprandial endothelial function in apparently healthy overweight and slightly obese men. TRIAL REGISTRATION Trial registration number (ClinicalTrials.gov) NCT03139890 in May 2017.",2020,An increase in baseline brachial artery diameters was observed after the high-protein meal (P < 0.001) and changes differed between meals (P = 0.020).,"['apparently healthy overweight and slightly obese men', 'Eighteen apparently healthy overweight and slightly obese men (BMI 26.0-35.0\xa0kg/m 2 ']","['fat, carbohydrates, and protein', 'isocaloric meal']","['serum insulin concentrations', 'brachial artery flow-mediated vasodilation (FMD', 'serum triacylglycerol concentrations', 'baseline brachial artery diameters', 'FMD', 'plasma glucose concentrations', 'postprandial vascular endothelial function', 'postprandial changes', 'Fasting and 2-h postprandial FMD responses', 'postprandial endothelial function']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0750482', 'cui_str': 'Slightly'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1998602', 'cui_str': 'Meals'}]","[{'cui': 'C0428357', 'cui_str': 'Serum insulin measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006087', 'cui_str': 'Structure of brachial artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0042401', 'cui_str': 'Vasodilatation'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C2584434', 'cui_str': 'Plasma glucose concentration'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0011744', 'cui_str': 'Deuterium'}]",18.0,0.166585,An increase in baseline brachial artery diameters was observed after the high-protein meal (P < 0.001) and changes differed between meals (P = 0.020).,"[{'ForeName': 'Ellen T H C', 'Initials': 'ETHC', 'LastName': 'Smeets', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, PO Box 616, 6200 MD, Maastricht, The Netherlands.'}, {'ForeName': 'Ronald P', 'Initials': 'RP', 'LastName': 'Mensink', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, PO Box 616, 6200 MD, Maastricht, The Netherlands.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Joris', 'Affiliation': 'Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, PO Box 616, 6200 MD, Maastricht, The Netherlands. p.joris@maastrichtuniversity.nl.'}]",European journal of nutrition,['10.1007/s00394-020-02340-y'] 2632,32728920,"Effect of Contact-Based Education on Medical Student Barriers to Treating Severe Mental Illness: a Non-randomized, Controlled Trial.","OBJECTIVE Emerging evidence suggests that contact-based education-learning via structured social interactions designed around intergroup contact theory-could be an important educational adjunct in improving attitudes, beliefs, and behaviors of medical students toward patients with severe mental illness (SMI). However, existing literature in the area lacks structured curriculum, control group designs, or longitudinal analyses. The authors conducted a longitudinal, non-randomized, controlled trial of the National Alliance on Mental Illness (NAMI) Provider Education Program-a 15-h contact-based adjunctive curriculum-on the attitudes, beliefs, and behavior of third-year medical students (MS3) at a single institution. METHODS Two-hundred and thirty-one students were invited to participate. Forty-one students elected to complete the curriculum and eighty served as the control group (response rate = 52%). Participants in both conditions completed questionnaires assessing aspects of caring for patients with SMI at pre-test, 1-week post-curriculum, and at 3-month follow-up. RESULTS Results indicated that participants in the curriculum reported improved attitudes, beliefs, and behavior in working with SMI as compared with their cohort-matched peers. The majority of these outcomes were maintained at 3-months post-intervention, with effect sizes in the medium to large range. The largest improvement was in behavioral responses to a vignette describing an acute psychiatric emergency. CONCLUSIONS The present study provides evidence that a contact-based curriculum leads to improvements in the attitudes, beliefs, and behaviors of MS3 students when offered as an adjunctive program following their first year of clinical rotations.",2020,"Participants in both conditions completed questionnaires assessing aspects of caring for patients with SMI at pre-test, 1-week post-curriculum, and at 3-month follow-up. ","['Two-hundred and thirty-one students were invited to participate', 'Medical Student Barriers to Treating Severe Mental Illness', 'medical students toward patients with severe mental illness (SMI']","['Contact-Based Education', 'Provider Education Program-a 15-h contact-based adjunctive curriculum']","['Mental Illness (NAMI', 'attitudes, beliefs, and behavior in working with SMI', 'behavioral responses']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0038495', 'cui_str': 'Medical student'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0557351', 'cui_str': 'Employed'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]",231.0,0.0658887,"Participants in both conditions completed questionnaires assessing aspects of caring for patients with SMI at pre-test, 1-week post-curriculum, and at 3-month follow-up. ","[{'ForeName': 'Jeritt R', 'Initials': 'JR', 'LastName': 'Tucker', 'Affiliation': 'Des Moines University, Des Moines, IA, USA. drtucker@drtuckerphd.com.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Seidman', 'Affiliation': 'Des Moines University, Des Moines, IA, USA.'}, {'ForeName': 'Julia R', 'Initials': 'JR', 'LastName': 'Van Liew', 'Affiliation': 'Des Moines University, Des Moines, IA, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Streyffeler', 'Affiliation': 'Des Moines University, Des Moines, IA, USA.'}, {'ForeName': 'Teri', 'Initials': 'T', 'LastName': 'Brister', 'Affiliation': 'National Alliance on Mental Illness, Arlington, VA, USA.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Hanson', 'Affiliation': 'Des Moines University, Des Moines, IA, USA.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Des Moines University, Des Moines, IA, USA.'}]",Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry,['10.1007/s40596-020-01290-1'] 2633,32728976,Effects of a 12-week home exercise therapy program on pain and neuromuscular activity in patients with patellofemoral pain syndrome.,"INTRODUCTION The aim of this study is to evaluate the effects of a 12-week home exercise therapy program on pain, function and neuromuscular activity of the vastus medialis and vastus lateralis. MATERIALS AND METHODS Fifty patients with patellofemoral pain syndrome were treated with a 12-week online home exercise program. The primary outcomes of pain and function were assessed at the 12-week follow-up using the Visual Analog Scale and Kujala Score, respectively. Secondary outcomes were the muscle onset time and the ratio of vastus medialis and vastus lateralis during different daily activities. RESULTS After 12 weeks, patients showed significant (p < 0.05) improvements of 27 points on the Visual Analog Scale and 10 points on Kujala Score. Differences in pre-post comparison regarding both temporal and amplitude-related neurophysiological differences between the vastus medialis and lateralis were only found when the subjects were divided into groups of different electromyographic patterns. Then changes in the pre-post comparison were particularly evident in the patient group with a delayed vastus medialis onset and a lower activity of the vastus medialis compared to the VL. CONCLUSION Pain and function improved significantly after a home exercise therapy program in patients with patellofemoral pain syndrome. In addition, patients with a delayed onset or reduced activity of the vastus medialis compared to the vastus lateralis experienced a reduction in this imbalance.",2020,"After 12 weeks, patients showed significant (p < 0.05) improvements of 27 points on the Visual Analog Scale and 10 points on Kujala Score.","['Fifty patients with patellofemoral pain syndrome', 'patients with patellofemoral pain syndrome']","['home exercise therapy program', 'online home exercise program']","['Visual Analog Scale and Kujala Score', 'muscle onset time and the ratio of vastus medialis and vastus lateralis during different daily activities', 'pain and function', 'pain, function and neuromuscular activity', 'pain and neuromuscular activity', 'Visual Analog Scale and 10 points on Kujala Score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0877149', 'cui_str': 'Patellofemoral pain syndrome'}]","[{'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0452240', 'cui_str': 'Exercises'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0475647', 'cui_str': 'Home exercise program'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0449244', 'cui_str': 'Time of onset'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",50.0,0.019378,"After 12 weeks, patients showed significant (p < 0.05) improvements of 27 points on the Visual Analog Scale and 10 points on Kujala Score.","[{'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Kölle', 'Affiliation': 'Institut für Rehabilitationsmedizinische Forschung, Universität Ulm, Am Kurpark 1, 88422, Bad Buchau, Germany. theresa.koelle@ifr-ulm.de.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Alt', 'Affiliation': 'Institut für Sport- Und Bewegungswissenschaft, Universität Stuttgart, Allmandring 28, 70569, Stuttgart, Germany.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wagner', 'Affiliation': 'Hessingpark Clinic, Hessingstrasse 17, 86199, Augsburg, Germany.'}]",Archives of orthopaedic and trauma surgery,['10.1007/s00402-020-03543-y'] 2634,32729014,Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation.,"INTRODUCTION Current guidelines recommend starting antiviral prophylaxis to prevent hepatitis B virus (HBV) reactivation in patients receiving immunosuppressive treatments (IST). The aim of this study was to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) for prophylaxis. METHODS Patients, who were HBsAg and/or anti-HBc IgG positive and scheduled to receive IST for oncologic and hematologic diseases, were enrolled into the study. Those who were already receiving an antiviral treatment for HBV or had an associated HIV, hepatitis C, D were excluded. The remaining patients with a prophylaxis indication according to the AGA guideline were randomized to receive either ETV (0.5 mg/day) or TDF (245 mg/day). Prophylaxis was continued for 6-12 months after completion of IST. Patients were followed up for 1 year after completion of prophylaxis. The HBV reactivation rates and side effects of the drugs were compared. RESULTS The study group included 120 patients. There was no significant difference between the demographic data, viral serologic parameters and reactivation risk profiles of the ETV (n = 60) and TDF (n = 60) groups. Forty-one patients in the ETV and 36 in the TDF group completed the antiviral prophylaxis, and no HBV reactivation was observed. HBV reactivation was observed in 4 of 37 patients (10.8%) in the ETV group and 5 of 35 (14.3%) patients in the TDF group (including one with flare) during the follow-up after completion of prophylaxis. Ten patients in the ETV group (16.7%) and 14 patients (23.3%) in the TDF group experienced side effects (p = 0.77). One patient in the TDF group had to switch to ETV due to severe itchy, maculopapular rash-like lesions. CONCLUSIONS ETV and TDF had a similar efficacy in the prophylaxis of HBV reactivation in patients undergoing IST, with none of the patients experiencing reactivation.",2020,HBV reactivation was observed in 4 of 37 patients (10.8%) in the ETV group and 5 of 35 (14.3%) patients in the TDF group (including one with flare) during the follow-up after completion of prophylaxis.,"['patients receiving immunosuppressive treatments (IST', 'remaining patients with a prophylaxis indication according to the AGA guideline', '120 patients', 'Patients, who were HBsAg', 'Those who were already receiving an antiviral treatment for HBV or had an associated HIV, hepatitis C, D were excluded']","['IST', 'TDF', 'ETV', 'entecavir (ETV) and tenofovir disoproxil fumarate (TDF', 'Tenofovir Disoproxil Fumarate and Entecavir']","['HBV reactivation', 'severe itchy, maculopapular rash-like lesions', 'HBV reactivation rates and side effects', 'antiviral prophylaxis, and no HBV reactivation', 'demographic data, viral serologic parameters and reactivation risk profiles', 'side effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0071561', 'cui_str': 'polyethylene glycol-glutaminase-asparaginase'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0019168', 'cui_str': 'Hepatitis B surface antigen'}, {'cui': 'C2363964', 'cui_str': 'Antiviral treatment'}, {'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0019196', 'cui_str': 'Viral hepatitis C'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}]","[{'cui': 'C0021081', 'cui_str': 'Immunosuppressant agent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1099776', 'cui_str': 'Tenofovir disoproxil fumarate'}, {'cui': 'C0971023', 'cui_str': 'entecavir'}]","[{'cui': 'C0019169', 'cui_str': 'Hepatitis B Virus'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0423791', 'cui_str': 'Maculopapular rash'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0877137', 'cui_str': 'Antiviral prophylaxis'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0205473', 'cui_str': 'Serologic'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.023059,HBV reactivation was observed in 4 of 37 patients (10.8%) in the ETV group and 5 of 35 (14.3%) patients in the TDF group (including one with flare) during the follow-up after completion of prophylaxis.,"[{'ForeName': 'Bilal', 'Initials': 'B', 'LastName': 'Toka', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Sakarya University, Korucuk Campus, Sakarya, Turkey. bilaltoka@hotmail.com.'}, {'ForeName': 'Aydin Seref', 'Initials': 'AS', 'LastName': 'Koksal', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Sakarya University, Korucuk Campus, Sakarya, Turkey.'}, {'ForeName': 'Ahmet Tarik', 'Initials': 'AT', 'LastName': 'Eminler', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Sakarya University, Korucuk Campus, Sakarya, Turkey.'}, {'ForeName': 'Mukaddes', 'Initials': 'M', 'LastName': 'Tozlu', 'Affiliation': 'Department of Gastroenterology, Sakarya Eğitim ve Araştırma Hastanesi, Sakarya, Turkey.'}, {'ForeName': 'Mustafa Ihsan', 'Initials': 'MI', 'LastName': 'Uslan', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Sakarya University, Korucuk Campus, Sakarya, Turkey.'}, {'ForeName': 'Erkan', 'Initials': 'E', 'LastName': 'Parlak', 'Affiliation': 'Department of Gastroenterology, Faculty of Medicine, Sakarya University, Korucuk Campus, Sakarya, Turkey.'}]",Digestive diseases and sciences,['10.1007/s10620-020-06506-w'] 2635,32726775,Safety of Upper Pole Puncture in Percutaneous Nephrolithotomy with the Guidance of Ultrasonography versus Fluoroscopy: A Comparative Study.,"INTRODUCTION The aim of this study was to compare the safety of ultrasonography-guided (UG) puncture and fluoroscopy-guided (FG) upper pole access (UPA) in percutaneous nephrolithotomy (PCNL). METHODS Consecutive patients with a solitary UPA were enrolled into the study from 2012 to 2020 and analyzed in a retrospective manner. In total, 177 patients were divided into 2 groups according to the method during the puncture phase of the access: FG (n = 105) and UG (n = 72). The UG and FG groups were compared in terms of complications (i.e., pleural injury and blood transfusion rate) and surgical outcomes. RESULTS Gender, side, grade of hydronephrosis, type of access (i.e., supracostal vs. subcostal), Guy's stone score, age, stone diameter, skin-to-stone distance, and stone density were similar in the 2 groups (p > 0.05). Only in 25.9% of cases, UPA was done using a subcostal approach. The overall complication rates were similar between the groups (p > 0.178). For the UG and FG groups, the rate of pleural injury (8.5 vs. 4.1%) and the blood transfusion rate (8.5 vs. 2.8%) were also similar (p > 0.05). The fluoroscopy time and mean hemoglobin drop were significantly lower in the UG group than in the FG group (134.2 vs. 82.2 s, respectively, p = 0.001; 20.8 ± 9.8 vs. 16.8 ± 7.9 g/L, respectively, p = 0.001). Stone-free rate (SFR) was also similar in the FG and UG groups (77.1 vs. 75.0%, respectively, p = 0.742). CONCLUSION While it is commonly expected that the complication rates are lower in UG puncture for UPA in PCNL than they are in FG puncture, the present study failed to show this difference. However, the radiation exposure time seemed to be lower in UG puncture than FG puncture and had a similar stone-free rate (SFR) for UPA in PCNL.",2020,"For the UG and FG groups, the rate of pleural injury (8.5 vs. 4.1%) and the blood transfusion rate (8.5 vs. 2.8%) were also similar (p > 0.05).","['177 patients', 'Consecutive patients with a solitary UPA were enrolled into the study from 2012 to 2020 and analyzed in a retrospective manner', 'percutaneous nephrolithotomy (PCNL']","['FG puncture', 'ultrasonography-guided (UG) puncture and fluoroscopy-guided (FG) upper pole access (UPA', 'Ultrasonography versus Fluoroscopy']","['complication rates', 'rate of pleural injury', 'Stone-free rate (SFR', 'complications (i.e., pleural injury and blood transfusion rate) and surgical outcomes', 'blood transfusion rate', ""Gender, side, grade of hydronephrosis, type of access (i.e., supracostal vs. subcostal), Guy's stone score, age, stone diameter, skin-to-stone distance, and stone density"", 'overall complication rates', 'stone-free rate (SFR', 'fluoroscopy time and mean hemoglobin drop']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205171', 'cui_str': 'Singular'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0035363', 'cui_str': 'Retrospective Study'}, {'cui': 'C0162428', 'cui_str': 'Removal of calculus of renal pelvis through percutaneous nephrostomy'}]","[{'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0337815', 'cui_str': 'Poles'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1522720', 'cui_str': 'Pleural'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0020295', 'cui_str': 'Hydronephrosis'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0442184', 'cui_str': 'Subcostal'}, {'cui': 'C0018408', 'cui_str': 'Guyana'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0178587', 'cui_str': 'Density'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0162119', 'cui_str': 'Hemoglobin low'}]",177.0,0.0290418,"For the UG and FG groups, the rate of pleural injury (8.5 vs. 4.1%) and the blood transfusion rate (8.5 vs. 2.8%) were also similar (p > 0.05).","[{'ForeName': 'Ahmet', 'Initials': 'A', 'LastName': 'Sahan', 'Affiliation': 'Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey, dr.ahmetsahan@gmail.com.'}, {'ForeName': 'Alkan', 'Initials': 'A', 'LastName': 'Cubuk', 'Affiliation': 'Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Orkunt', 'Initials': 'O', 'LastName': 'Ozkaptan', 'Affiliation': 'Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Kasım', 'Initials': 'K', 'LastName': 'Ertaş', 'Affiliation': 'Department of Urology, Van Yuzuncu Yil University, School of Medicine, Van, Turkey.'}, {'ForeName': 'Cengiz', 'Initials': 'C', 'LastName': 'Canakci', 'Affiliation': 'Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Bilal', 'Initials': 'B', 'LastName': 'Eryildirim', 'Affiliation': 'Department of Urology, Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Tuncay', 'Initials': 'T', 'LastName': 'Toprak', 'Affiliation': 'Department of Urology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey.'}, {'ForeName': 'Yiloren', 'Initials': 'Y', 'LastName': 'Tanidir', 'Affiliation': 'Department of Urology, Marmara University, School of Medicine, Istanbul, Turkey.'}]",Urologia internationalis,['10.1159/000509448'] 2636,32726873,"Impact of WeChat-Based ""Three Good Things"" on Turnover Intention and Coping Style in Burnout Nurses.","BACKGROUND Few studies have considered functions of nurses' positive personality and behaviours on addressing their turnover intention. AIMS To explore the effects of WeChat-based ""three good things"" (3GT) on burnout nurses' turnover intention and coping styles. METHODS A randomised controlled trial. 73 nurses were included in the intervention group (n = 33) and the control group (n = 40). The intervention group received WeChat-based 3GT. Turnover intention and coping style were measured before and after the intervention. RESULTS WeChat-based 3GT effectively reduced turnover intention and negative coping style (each p < 0.05). Positive coping style was promoted after the intervention ( p < 0.05). Time effects as well as intervention and time interactions were significant in turnover intention and negative coping style (each p < 0.05). CONCLUSION Benefits of WeChat-based 3GT on turnover intention and coping style in burnout nurses were found. Nurses experienced lower levels of turnover intention and negative coping style and increased the usage of positive coping style after the intervention. IMPLICATIONS FOR NURSING MANAGEMENT Nurse Managers should incorporate 3GT intervention with popular social communication programs to improve nurses' coping strategies toward clinical issues and maintain the stability of nursing teams.",2020,"RESULTS WeChat-based 3GT effectively reduced turnover intention and negative coping style (each p < 0.05).",['73 nurses were included in the intervention group (n = 33) and the control group (n = 40'],"['WeChat-based ""three good things"" (3GT', 'WeChat-based 3GT', 'WeChat-Based ""Three Good Things']","['usage of positive coping style', 'Turnover Intention and Coping Style', 'Turnover intention and coping style', 'Positive coping style', 'turnover intention and coping style', 'turnover intention and negative coping style']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]","[{'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0031227', 'cui_str': 'Employee Turnover'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]",73.0,0.0277152,"RESULTS WeChat-based 3GT effectively reduced turnover intention and negative coping style (each p < 0.05).","[{'ForeName': 'Yu-Fang', 'Initials': 'YF', 'LastName': 'Guo', 'Affiliation': 'School of Nursing, ShanDong University, Jinan, Shandong, China.'}, {'ForeName': 'Virginia', 'Initials': 'V', 'LastName': 'Plummer', 'Affiliation': 'School of Nursing and Midwifery, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Cross', 'Affiliation': 'School of Health, Federation University Australia, Berwick, Victoria, Australia.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Lam', 'Affiliation': 'School of Health, Federation University Australia, Berwick, Victoria, Australia.'}, {'ForeName': 'Jing-Ping', 'Initials': 'JP', 'LastName': 'Zhang', 'Affiliation': 'Nursing Psychology Research Center of Xiangya Nursing School, Central South University, Changsha, Hunan, China.'}]",Journal of nursing management,['10.1111/jonm.13111'] 2637,32726887,Concentration response to the coenzyme Q 10 supplement Q-Gel in human volunteers.,"Coenzyme Q 10 (CoQ 10 ) is essential for every cell in the body, and deficiency has been implicated in many diseases. Studies to confirm the benefit of supplementation require efficacious supplementation. Previously we found Q-Gel to be highly bioavailable. The objective of the present study was to identify the most efficacious dose of Q-Gel for use in supplementation studies. In a randomized crossover design, 8 young healthy male volunteers received single doses of 60, 150, and 300 mg CoQ 10 via Q-Gel 30-mg capsules, and of 300 mg via 100-mg Q-Gel capsules. Doses were given after a 10-hour overnight fast, a week apart. Plasma was analyzed for CoQ 10 , total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triacylglycerols at baseline and at 2, 4, 6, 8, and 10 hours after supplement ingestion. Areas under the curve (AUCs) were calculated for each participant at each dose and compared by 1-way analysis of variance. AUC increased significantly between 60- and 150-mg doses (P < .001), but not between 150- and 300-mg doses (P = .198). A plateau in absorption occurs near 200 mg. AUC for the 300-mg dose via 100-mg capsules was significantly lower than that for 300 mg via 30-mg capsules (P < .001), which may be due to the lower ratio of CoQ 10 to oil in the 30-mg capsules or to the higher vitamin E content in the 100-mg capsules. We conclude that the most efficacious single dose of Q-Gel is 200 mg, and higher absorption is obtained using multiple smaller capsules.",2007,"AUC increased significantly between 60- and 150-mg doses (P < .001), but not between 150- and 300-mg doses (P = .198).","['human volunteers', '8 young healthy male volunteers']","['Coenzyme Q 10 (CoQ 10 ', 'CoQ 10 via Q-Gel 30-mg capsules, and of 300 mg via 100-mg Q-Gel capsules', 'Q-Gel', 'coenzyme']","['CoQ 10 , total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triacylglycerols', 'AUC', 'Concentration response']","[{'cui': 'C0020155', 'cui_str': 'Human Volunteers'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C2962579', 'cui_str': 'Q-Gel'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0009235', 'cui_str': 'Cofactors, Enzyme'}]","[{'cui': 'C0056077', 'cui_str': 'Ubiquinone'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0023822', 'cui_str': 'HDL cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",8.0,0.16819,"AUC increased significantly between 60- and 150-mg doses (P < .001), but not between 150- and 300-mg doses (P = .198).","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Molyneux', 'Affiliation': 'Canterbury Health Laboratories, Christchurch 8140, New Zealand; University of Canterbury, Christchurch 8140, New Zealand. Electronic address: sarah.molyneux@cdhb.govt.nz.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Florkowski', 'Affiliation': 'Canterbury Health Laboratories, Christchurch 8140, New Zealand.'}, {'ForeName': 'Yasmin', 'Initials': 'Y', 'LastName': 'McGrane', 'Affiliation': 'Canterbury Health Laboratories, Christchurch 8140, New Zealand.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lever', 'Affiliation': 'Canterbury Health Laboratories, Christchurch 8140, New Zealand; University of Canterbury, Christchurch 8140, New Zealand.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'George', 'Affiliation': 'Canterbury Health Laboratories, Christchurch 8140, New Zealand.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2007.04.011'] 2638,32726888,Restricted-energy diets rich in vegetables or cereals improve cardiovascular risk factors in overweight/obese women.,"This study was conducted to determine how the follow-up of 2 different energy-restricted (hypocaloric) diets, based on approximating the diet to its theoretical ideal, influences cardiovascular risk factors such as obesity, blood pressure, serum cholesterol, serum low-density lipoprotein and very low density lipoprotein, serum triacylglycerol and homocysteine, and serum high-density lipoprotein. Fifty-seven young overweight or obese women were randomly assigned to one of 2 different weight-control programs designed to approximate the diet to the theoretical ideal. Twenty-eight women were assigned to the vegetable (V) group; this group was characterized by a relatively increased consumption of vegetables. Twenty-nine women were assigned to the cereal (C) group, which was characterized by a relatively increased consumption of cereals. Dietetic, anthropometric, and biochemical data were collected at the outset of the study and again 2 and 6 weeks into the program in both groups. Both interventions resulted in a significant improvement in warning parameters of obesity (weight, body mass index, and waist/hip ratio), total serum cholesterol, and homocysteine at the end of the study. Plasma homocysteine levels fell by 14.9 ± 13.6% in the group C subjects and by 8.8 ± 14.0% in the group V subjects after 6 weeks. This may have been due to an increase in the intake and serum levels of vitamin B 6 and folate in both groups. At the end of the intervention, the V group exhibited a significant reduction in low-density lipoprotein cholesterol and in non-high-density lipoprotein cholesterol. Group C subjects showed a reduction in diastolic blood pressure at this time. The results suggest that both hypocaloric diets with a relative increase in the consumption of vegetables or cereals were effective in improving cardiovascular risk factors in overweight and obese women.",2007,Plasma homocysteine levels fell by 14.9 ± 13.6% in the group C subjects and by 8.8 ± 14.0% in the group V subjects after 6 weeks.,"['overweight/obese women', 'Fifty-seven young overweight or obese women', 'Twenty-nine women', 'overweight and obese women', 'Twenty-eight women']",['energy-restricted (hypocaloric) diets'],"['cardiovascular risk factors such as obesity, blood pressure, serum cholesterol, serum low-density lipoprotein and very low density lipoprotein, serum triacylglycerol and homocysteine, and serum high-density lipoprotein', 'low-density lipoprotein cholesterol', 'cardiovascular risk factors', 'warning parameters of obesity (weight, body mass index, and waist/hip ratio), total serum cholesterol, and homocysteine', 'Plasma homocysteine levels', 'diastolic blood pressure']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517815', 'cui_str': '57'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C4283787', 'cui_str': '28'}]","[{'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0587184', 'cui_str': 'Serum cholesterol measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0023825', 'cui_str': 'Very low density lipoprotein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0019878', 'cui_str': 'Homocysteine'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0023824', 'cui_str': 'LDL cholesterol'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C1445957', 'cui_str': 'Serum total cholesterol measurement'}, {'cui': 'C1278165', 'cui_str': 'Plasma homocysteine measurement'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}]",28.0,0.0233611,Plasma homocysteine levels fell by 14.9 ± 13.6% in the group C subjects and by 8.8 ± 14.0% in the group V subjects after 6 weeks.,"[{'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Rodríguez-Rodríguez', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain. Electronic address: elerodri@farm.ucm.es.'}, {'ForeName': 'Rosa M', 'Initials': 'RM', 'LastName': 'Ortega', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Ana M', 'Initials': 'AM', 'LastName': 'López-Sobaler', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Andrés', 'Affiliation': 'Laboratorio de Técnicas Instrumentales, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Aránzazu', 'Initials': 'A', 'LastName': 'Aparicio', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Bermejo', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}, {'ForeName': 'Luisa', 'Initials': 'L', 'LastName': 'García-González', 'Affiliation': 'Departamento de Nutrición, Facultad de Farmacia, Universidad Complutense, Madrid, Spain.'}]","Nutrition research (New York, N.Y.)",['10.1016/j.nutres.2007.04.014'] 2639,32726899,Effects of a Gluteal Muscles Specific Exercise Program on the Vertical Jump.,"The vertical jump is a complex movement where many factors are involved in the final result. Currently, how a specific exercise program for gluteal muscles can affect the vertical jump is unknown. So, the aim of this study was to examine the effect of a specific exercise program for the gluteal muscles on a vertical jump. Forty-nine amateur athletes completed an 8-week program. The experimental group received a specific gluteal muscle training program in addition to their regular training routine, whereas the control group received their regular training routine. Jump height, flight time, speed and power were assessed (baseline, postintervention, and 4-week follow-up). Repeated-measures analyses of variance were conducted with ∝ ≤ 0.05. We calculated Eta squared effect sizes with 95% confidence intervals. Measurements at 8 weeks revealed significant increases in the experimental group compared to the control group for the values: jump height ( p < 0.05) (experimental group = 17.15%; control group = 3.09%), flight time ( p < 0.001) (experimental group = 7.98%; control group = 3.52%), speed ( p < 0.01) (experimental group = 1.96%; control group = 1.83%) and power ( p < 0.05) (experimental group = 4.43%; control group = 0.32%). However, at follow-up, these changes were not maintained. These data suggest that this specific training protocol for the gluteal muscles is effective in order to improve vertical jump performance in amateur athletes who use the vertical jump in their routine training habits.",2020,"Measurements at 8 weeks revealed significant increases in the experimental group compared to the control group for the values: jump height ( p < 0.05) (experimental group = 17.15%; control group = 3.09%), flight time ( p < 0.001) (experimental group = 7.98%; control group = 3.52%), speed ( p < 0.01) (experimental group = 1.96%; control group = 1.83%) and power ( p < 0.05) (experimental group = 4.43%; control group = 0.32%).","['Forty-nine amateur athletes completed an 8-week program', 'amateur athletes who use the vertical jump in their routine training habits']","['specific exercise program', 'Gluteal Muscles Specific Exercise Program', 'specific gluteal muscle training program in addition to their regular training routine, whereas the control group received their regular training routine']","['Jump height, flight time, speed and power', 'vertical jump performance', 'flight time']","[{'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0018464', 'cui_str': 'Habits'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205272', 'cui_str': 'Regular'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}]",49.0,0.0148403,"Measurements at 8 weeks revealed significant increases in the experimental group compared to the control group for the values: jump height ( p < 0.05) (experimental group = 17.15%; control group = 3.09%), flight time ( p < 0.001) (experimental group = 7.98%; control group = 3.52%), speed ( p < 0.01) (experimental group = 1.96%; control group = 1.83%) and power ( p < 0.05) (experimental group = 4.43%; control group = 0.32%).","[{'ForeName': 'Tomás', 'Initials': 'T', 'LastName': 'Gallego-Izquierdo', 'Affiliation': 'Physiotherapy and Pain Group, Department of Physical Therapy, University of Alcala, 28801 Madrid, Spain.'}, {'ForeName': 'Gerardo', 'Initials': 'G', 'LastName': 'Vidal-Aragón', 'Affiliation': 'Physical Therapist, Department of Physical Therapy, University of Alcala, 28801 Madrid, Spain.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Calderón-Corrales', 'Affiliation': 'Physical Therapist, Department of Physical Therapy, University of Alcala, 28801 Madrid, Spain.'}, {'ForeName': 'Álvaro', 'Initials': 'Á', 'LastName': 'Acuña', 'Affiliation': 'Physical Therapist, Department of Physical Therapy, University of Alcala, 28801 Madrid, Spain.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Achalandabaso-Ochoa', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain..'}, {'ForeName': 'Agustín', 'Initials': 'A', 'LastName': 'Aibar-Almazán', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain..'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Martínez-Amat', 'Affiliation': 'Department of Health Sciences, Faculty of Health Sciences, University of Jaén, 23071 Jaén, Spain..'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Pecos-Martín', 'Affiliation': 'Physiotherapy and Pain Group, Department of Physical Therapy, University of Alcala, 28801 Madrid, Spain.'}]",International journal of environmental research and public health,['10.3390/ijerph17155383'] 2640,32727086,"Evaluating the Implementation and Effectiveness of the SWITCH-MS: An Ecological, Multi-Component Adolescent Obesity Prevention Intervention.","Background : The purpose of this study was to evaluate the implementation and effectiveness of an ecological, multi-component adolescent obesity prevention intervention called School Wellness Integration Targeting Child Health-Middle School (SWITCH-MS). Methods : Following the effectiveness-implementation hybrid type 3 quasi-experimental design, seven middle schools (377 students) in Iowa, United States, were stratified into ""experienced"" ( n = 3; 110 students) or ""inexperienced"" ( n = 4; 267 students) groups to receive the 12-week SWITCH-MS intervention. To evaluate implementation, school informants ( n = 10) responded to a survey and students completed behavioral tracking in the classroom on a website. For effectiveness evaluation, students in 6th, 7th, and 8th grades completed a validated questionnaire before and after intervention, to measure behaviors of physical activity (PA; ""Do""), screen-based activity (""View""), and fruits and vegetable consumption (""Chew""). Results : The two groups of schools showed similar levels of implementation for best practices, awareness, and engagement. Behavioral tracking rate favored the experienced schools early on (47.5% vs. 11.7%), but differences leveled off in weeks 3-12 (sustained at 30.1-44.3%). Linear mixed models demonstrated significant time effects for ""Do"" (at school and out of school; p < 0.01) and ""View"" behaviors ( p = 0.02), after controlling for student- and school-level covariates. Conclusions : This study demonstrates that prior experience with SWITCH-MS may not be a prominent factor for implementation and effectiveness, although greater experience is associated with favorable behavioral tracking when the intervention is first launched.",2020,"Linear mixed models demonstrated significant time effects for ""Do"" (at school and out of school; p < 0.01) and ""View"" behaviors ( p = 0.02), after controlling for student- and school-level covariates. ","['seven middle schools (377 students) in Iowa, United States, were stratified into ""experienced"" ( n = 3; 110 students) or ""inexperienced"" ( n = 4; 267 students) groups to']",['receive the 12-week SWITCH-MS intervention'],"['Behavioral tracking rate', 'similar levels of implementation for best practices, awareness, and engagement', 'View"" behaviors', 'behaviors of physical activity (PA; ""Do""), screen-based activity (""View""), and fruits and vegetable consumption (""Chew']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0022037', 'cui_str': 'Iowa'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205363', 'cui_str': 'Stratified'}, {'cui': 'C4517536', 'cui_str': '110'}, {'cui': 'C4517672', 'cui_str': '267'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008078', 'cui_str': 'Child health care'}, {'cui': 'C0557797', 'cui_str': 'Middle school'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetable'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0024888', 'cui_str': 'Mastication'}]",377.0,0.0127318,"Linear mixed models demonstrated significant time effects for ""Do"" (at school and out of school; p < 0.01) and ""View"" behaviors ( p = 0.02), after controlling for student- and school-level covariates. ","[{'ForeName': 'Senlin', 'Initials': 'S', 'LastName': 'Chen', 'Affiliation': 'School of Kinesiology, Louisiana State University, Baton Rouge, LA 70803, USA.'}, {'ForeName': 'Richard R', 'Initials': 'RR', 'LastName': 'Rosenkranz', 'Affiliation': 'Department of Food, Nutrition, Dietetics, & Health, Kansas State University, Manhattan, KS 66506, USA.'}, {'ForeName': 'Gabriella M', 'Initials': 'GM', 'LastName': 'McLoughlin', 'Affiliation': 'College of Human Sciences and Education, Iowa State University, Ames, IA 50011, USA.'}, {'ForeName': 'Spyridoula', 'Initials': 'S', 'LastName': 'Vazou', 'Affiliation': 'College of Human Sciences and Education, Iowa State University, Ames, IA 50011, USA.'}, {'ForeName': 'Lorraine', 'Initials': 'L', 'LastName': 'Lanningham-Foster', 'Affiliation': 'College of Human Sciences and Education, Iowa State University, Ames, IA 50011, USA.'}, {'ForeName': 'Douglas A', 'Initials': 'DA', 'LastName': 'Gentile', 'Affiliation': 'College of Human Sciences and Education, Iowa State University, Ames, IA 50011, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Dzewaltowski', 'Affiliation': 'University of Nebraska Medical Center, Omaha, NE 69198, USA.'}]",International journal of environmental research and public health,['10.3390/ijerph17155401'] 2641,32727108,High Intensity Training to Treat Chronic Nonspecific Low Back Pain: Effectiveness of Various Exercise Modes.,"High-intensity training (HIT) improves rehabilitation outcomes such as functional disability and physical performance in several chronic disorders. Promising results were also found in chronic nonspecific low back pain (CNSLBP). However, the impact of different exercise modes on HIT effectiveness in CNSLBP remains unclear. Therefore, this study evaluated the effectiveness of various HIT exercise modes and compared differences between these modes, on pain intensity, disability, and physical performance, as a therapeutic intervention for persons with CNSLBP. In a randomized comparative trial, consisting of a 12-week program, persons with CNSLBP were divided into four HIT groups, i.e., cardiorespiratory interval training coupled with either general resistance training, core strength training, combined general resistance and core strength training, or mobility exercises. Before and after the program, the Numeric Pain Rating Scale (NPRS), Modified Oswestry Disability Index (MODI), and Patient Specific Functioning Scale (PSFS) were recorded, and a cardiopulmonary exercise test (VO 2 max, cycling time) and isometric trunk strength test (maximum muscle torque) were performed. Eighty participants (mean age: 44.0 y, 34 males) were included. Improvements were found within all groups after the HIT programs and ranged from -39 to -57% on the NPRS, +27 to +64% on the MODI, +38 to +89% on the PSFS, +7 to +14% on VO 2 max, and +11 to +18% on cycling time. No differences between groups were found. High-intensity cardiorespiratory interval training improves CNSLBP rehabilitation outcomes when performed with other HIT exercise modes or mobility exercises. Hence, when setting up an exercise therapy program in CNSLBP rehabilitation, various HIT modes can be considered as therapy modalities.",2020,"Improvements were found within all groups after the HIT programs and ranged from -39 to -57% on the NPRS, +27 to +64% on the MODI, +38 to +89% on the PSFS, +7 to +14% on VO 2 max, and +11 to +18% on cycling time.","['several chronic disorders', 'Chronic Nonspecific Low Back Pain', '44.0 y, 34 males) were included', 'persons with CNSLBP', 'Eighty participants (mean age']","['Various Exercise Modes', 'cardiorespiratory interval training coupled with either general resistance training, core strength training, combined general resistance and core strength training, or mobility exercises', 'High-intensity cardiorespiratory interval training', 'High Intensity Training', 'High-intensity training (HIT']","['pain intensity, disability, and physical performance', 'cardiopulmonary exercise test (VO 2 max, cycling time) and isometric trunk strength test (maximum muscle torque', 'Numeric Pain Rating Scale (NPRS), Modified Oswestry Disability Index (MODI), and Patient Specific Functioning Scale (PSFS', 'functional disability and physical performance', 'chronic nonspecific low back pain (CNSLBP', 'HIT effectiveness']","[{'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0444669', 'cui_str': 'Core'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}]","[{'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0460005', 'cui_str': 'Trunk structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0024031', 'cui_str': 'Low back pain'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",80.0,0.0116419,"Improvements were found within all groups after the HIT programs and ranged from -39 to -57% on the NPRS, +27 to +64% on the MODI, +38 to +89% on the PSFS, +7 to +14% on VO 2 max, and +11 to +18% on cycling time.","[{'ForeName': 'Jonas', 'Initials': 'J', 'LastName': 'Verbrugghe', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Anouk', 'Initials': 'A', 'LastName': 'Agten', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Sjoerd', 'Initials': 'S', 'LastName': 'Stevens', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Hansen', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Demoulin', 'Affiliation': 'Department of Sport and Rehabilitation Sciences, University of Liege, 4000 Liege, Belgium.'}, {'ForeName': 'Bert O', 'Initials': 'BO', 'LastName': 'Eijnde', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Vandenabeele', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}, {'ForeName': 'Annick', 'Initials': 'A', 'LastName': 'Timmermans', 'Affiliation': 'Hasselt University, REVAL-Rehabilitation Research Center, BIOMED, Faculty of Rehabilitation Sciences, 3500 Hasselt, Belgium.'}]",Journal of clinical medicine,['10.3390/jcm9082401'] 2642,32727162,Impact of Varying Dosages of Fish Oil on Recovery and Soreness Following Eccentric Exercise.,"Fish oils (FOs) are rich in omega-3 long-chain polyunsaturated fatty acids, which have been purported to enhance recovery of muscular performance and reduce soreness post-exercise. However, the most effective FO dose for optimizing recovery remains unclear. The purpose of this investigation was to examine the effect of FO supplementation dosing on the recovery of measures of muscular performance, perceived soreness, and markers of muscle damage following a rigorous bout of eccentric exercise. Thirty-two college-aged resistance-trained males (~23.6 years, 71.6 kg, 172.1 cm) were supplemented with 2, 4, 6 g/day (G) FO or placebo (PL) for ~7.5 weeks. Following 7 weeks of supplementation, pre-exercise (PRE) performance assessments of vertical jump (VJ), knee extensor strength, 40-yard sprint, T-test agility, and perceived soreness were completed prior to a bout of muscle-damaging exercise and were repeated immediately post (IP), 1-, 2-, 4-, 24-, 48-, and 72-h (H) post-exercise. Repeated measures analysis of variance indicated a treatment × time interaction ( p < 0.001) for VJ and perceived soreness, but no group differences were observed at any time point. VJ returned to PRE (54.8 ± 7.9 cm) by 1H (51.8 ± 6.5 cm, p = 0.112) for 6G, while no other groups returned to baseline until 48H. Lower soreness scores were observed in 6G compared to PL at 2H (mean difference [MD] = 2.74, p = 0.046), at 24H (MD: 3.45, p < 0.001), at 48H (MD = 4.45, p < 0.001), and at 72H (MD = 3.00, p = 0.003). Supplementation with 6G of FO optimized the recovery of jump performance and muscle soreness following a damaging bout of exercise.",2020,"Repeated measures analysis of variance indicated a treatment × time interaction ( p < 0.001) for VJ and perceived soreness, but no group differences were observed at any time point.","['Thirty-two college-aged resistance-trained males (~23.6 years, 71.6 kg, 172.1 cm']","['Fish oils (FOs', 'FO supplementation', 'Fish Oil', 'FO or placebo (PL']","['jump performance and muscle soreness', 'VJ and perceived soreness', 'soreness scores', 'pre-exercise (PRE) performance assessments of vertical jump (VJ), knee extensor strength, 40-yard sprint, T-test agility, and perceived soreness', 'muscular performance, perceived soreness, and markers of muscle damage']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0016157', 'cui_str': 'Fish Oils'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0205128', 'cui_str': 'Vertical'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0439205', 'cui_str': 'yd'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}]",,0.39067,"Repeated measures analysis of variance indicated a treatment × time interaction ( p < 0.001) for VJ and perceived soreness, but no group differences were observed at any time point.","[{'ForeName': 'Trisha A', 'Initials': 'TA', 'LastName': 'VanDusseldorp', 'Affiliation': 'Department of Exercise Science and Sport Management, Kennesaw State University, Kennesaw, GA 30144, USA.'}, {'ForeName': 'Kurt A', 'Initials': 'KA', 'LastName': 'Escobar', 'Affiliation': 'Department of Kinesiology, California State University Long Beach, Long Beach, CA 90840, USA.'}, {'ForeName': 'Kelly E', 'Initials': 'KE', 'LastName': 'Johnson', 'Affiliation': 'Department of Exercise and Sport Science, Coastal Carolina University, Conway, SC 29528, USA.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Stratton', 'Affiliation': 'Kinesiology and Sport Management, Texas Tech University, Lubbock, TX 79409, USA.'}, {'ForeName': 'Terence', 'Initials': 'T', 'LastName': 'Moriarty', 'Affiliation': 'Department of Kinesiology, University of Northern Iowa, Cedar Falls, IA, 50614, USA.'}, {'ForeName': 'Chad M', 'Initials': 'CM', 'LastName': 'Kerksick', 'Affiliation': 'School of Health Sciences, Lindenwood University, St. Charles, MO 63301, USA.'}, {'ForeName': 'Gerald T', 'Initials': 'GT', 'LastName': 'Mangine', 'Affiliation': 'Department of Exercise Science and Sport Management, Kennesaw State University, Kennesaw, GA 30144, USA.'}, {'ForeName': 'Alyssa J', 'Initials': 'AJ', 'LastName': 'Holmes', 'Affiliation': 'Department of Exercise Science and Sport Management, Kennesaw State University, Kennesaw, GA 30144, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Lee', 'Affiliation': 'Department of Exercise Science and Sport Management, Kennesaw State University, Kennesaw, GA 30144, USA.'}, {'ForeName': 'Marvin R', 'Initials': 'MR', 'LastName': 'Endito', 'Affiliation': 'Department of Health, Exercise and Sports Sciences, University of New Mexico, Albuquerque, NM 87131, USA.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Mermier', 'Affiliation': 'Department of Health, Exercise and Sports Sciences, University of New Mexico, Albuquerque, NM 87131, USA.'}]",Nutrients,['10.3390/nu12082246'] 2643,32727192,[Gunsight closure versus purse-string closure techniques in loop stoma reversal: a multicenter prospective randomized controlled trial].,"Objective: To compare the wound healing time, Surgical site infection (SSI) rate and other postoperative outcomes between the gunsight closure and purse-string closure technique in loop stoma closure. Methods: Between November 2013 and December 2017, a total of 143 patients who underwent gunsight stoma reversal were included in this multicenter prospective randomized controlled trial. The patients were randomized to undergo gunsight (gunsight group, n= 72) or purse-string closure technique (purse-string group, n= 71). The primary endpoint was wound healing time. The second endpoints were the incidence of SSI, morbidity, and patient satisfaction. Statistical analysis between groups was performed using the t -test, repeated measures analysis of variance, Mann-Whitney U test, χ(2) test or Fisher's exact test. Results: There were 45 males and 27 females with age of 67 (11) (M( Q(R) )) years in gunsight group, 42 males and 29 females with age of 65 (20) years in purse-string group. The body mass index, American Society of Anesthesiologist classification, comorbidities, primary diagnosis, the type of ostomy, intraoperative blood loss, perioperative complications, postoperative hospital stay, hospitalization cost, SSI rate and incisional hernia (stoma site) between the 2 groups were not significantly different ( P> 0.05). Although had a statistically longer operating time (80(10) minutes vs . 70(10) minutes, Z= -2.381, P= 0.017), patients who underwent gunsight procedure and a significantly shorter wound healing time (17(2) days vs . 25(4) days, Z= -10.199, P< 0.01), higher patient satisfaction score with regards to wound healing time (3(1) vs . 3(1), Z= -4.526, P< 0.01), and higher total patient satisfaction score (25(3) vs . 25(3), Z= -2.529, P= 0.011) compared with those who underwent purse-string procedure. Conclusions: The gunsight and purse-string techniques are effective procedures for stoma reversal and both have low SSI rate. The gunsight technique is associated with shorter wound healing time, higher levels of patient satisfaction compared with purse-string technique, and is recommended as the closure technique of choice.",2020,"The gunsight technique is associated with shorter wound healing time, higher levels of patient satisfaction compared with purse-string technique, and is recommended as the closure technique of choice.","['45 males and 27 females with age of 67 (11) (M( Q(R) ', 'years in gunsight group, 42 males and 29 females with age of 65 (20) years in purse-string group', 'Methods: Between November 2013 and December 2017, a total of 143 patients who underwent gunsight stoma reversal']","['Gunsight closure versus purse-string closure techniques', 'gunsight closure and purse-string closure technique', 'undergo gunsight (gunsight group, n= 72) or purse-string closure technique']","['wound healing time, Surgical site infection (SSI) rate and other postoperative outcomes', 'incidence of SSI, morbidity, and patient satisfaction', 'higher patient satisfaction score', 'intraoperative blood loss, perioperative complications, postoperative hospital stay, hospitalization cost, SSI rate and incisional hernia (stoma site', 'wound healing time', 'total patient satisfaction score']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443313', 'cui_str': 'Stringing'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517573', 'cui_str': '143'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1955856', 'cui_str': 'Stoma site'}]","[{'cui': 'C0030972', 'cui_str': 'Perceptual Completion Phenomena'}, {'cui': 'C0443313', 'cui_str': 'Stringing'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0451370', 'cui_str': 'Patient satisfaction score'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C4545429', 'cui_str': 'Perioperative complication'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0267716', 'cui_str': 'Incisional hernia'}, {'cui': 'C1955856', 'cui_str': 'Stoma site'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",143.0,0.0853584,"The gunsight technique is associated with shorter wound healing time, higher levels of patient satisfaction compared with purse-string technique, and is recommended as the closure technique of choice.","[{'ForeName': 'J G', 'Initials': 'JG', 'LastName': 'Han', 'Affiliation': 'Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Zhou', 'Affiliation': 'Department of General Surgery, the First Hospital of China Medical University, Shenyang 110001, China.'}, {'ForeName': 'G Y', 'Initials': 'GY', 'LastName': 'Wang', 'Affiliation': 'Department of General Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050051, China.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China.'}, {'ForeName': 'Y C', 'Initials': 'YC', 'LastName': 'Yang', 'Affiliation': 'Department of General Surgery, Beijing Friendship Hospital, Capital Medical University,Beijing 100050, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'Department of General Surgery, the Affiliated Hospital of Qingdao University, Qingdao 266000, China.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.'}, {'ForeName': 'A W', 'Initials': 'AW', 'LastName': 'Wu', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing 100142, China.'}, {'ForeName': 'H W', 'Initials': 'HW', 'LastName': 'Yao', 'Affiliation': 'Department of General Surgery, Beijing Friendship Hospital, Capital Medical University,Beijing 100050, China.'}, {'ForeName': 'Z J', 'Initials': 'ZJ', 'LastName': 'Wang', 'Affiliation': 'Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Zhonghua wai ke za zhi [Chinese journal of surgery],['10.3760/cma.j.cn112139-20200421-00315'] 2644,32727193,[Accuracy comparision of abdominal enhanced CT and endoscopic ultrasound in the staging of gastric cancer after neoadjuvant chemotherapy: a post hoc analysis of a randomized clinical trial].,"Objective: To compare the accuracy of abdominal enhanced CT and endoscopic ultrasound in the staging of gastric cancer after neoadjuvant chemotherapy (yc stage). Methods: Clinic data of 86 locally advanced gastric cancer patients admitted in Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute from April 2015 to November 2017 were analyzed retrospectively. Totally 86 patients completed both abdominal enhanced CT and endoscopic ultrasound after neoadjuvant chemotherapy. There were 60 males and 26 females, aged (57.8±9.7) years (range: 32 to 76 years). The diagnostic accuracy of abdominal enhanced CT and endoscopic ultrasound for yc stage were calculated by the area under the multiclass receiver operation characteristic curve (M-AUC), retrospectively. McNemar test was used to compared the diagnostic sensitivity. Results: The M-AUC of ycT stage evaluated by abdominal enhanced CT (CT-ycT stage) and by endoscopic ultrasound (EUS-ycT stage) was 0.614 and 0.704, respectively. For middle and lower gastric cancer, the M-AUC of CT-ycT stage was 0.599 and 0.613, respectively, while EUS-ycT stage was 0.558 and 0.709, respectively. For tumor in the lesser and non-lesser curvature, the M-AUC of CT-ycT stage was 0.630 and 0.607, respectively, while EUS-ycT stage was 0.616 and 0.749, respectively. For patients in CT-ycT1-CT-ycT4, there was no statistically significant difference in the sensitivity between CT-ycT stage and EUS-ycT stage (2/18, 2/15, 52.8%(19/36), 8/13 vs . 0, 4/15, 55.6%(20/36), 7/13; χ(2)=2.00, P= 0.157; χ(2)=2.00, P= 0.157; χ(2)=0.08, P= 0.782; χ(2)=0.33, P= 0.564). The M-AUC of ycN stage evaluated by abdominal enhanced CT (CT-ycN stage) was 0.654, while ycN stage evaluated by endoscopic ultrasound (EUS-ycN stage) was 0.533. For patients in CT-ycN0, there was statistically significant difference in the sensitivity between CT-ycN stage and EUS-ycN stage (12.7%(7/55) vs . 5.5%(3/55); χ(2)=4.00, P= 0.046). For patients in CT-ycN1, N2, and N3, there was no statistically significant difference in the sensitivity between CT-ycN stage and EUS-ycN stage (2/19, 1/10, 0 vs . 1/19, 1/10, 0; χ(2)=1.00, P= 0.317; the other P cannot be estimated). Conclusions: There was no significant difference between the diagnostic efficacy of abdominal enhanced CT and endoscopic ultrasound for yc stage of gastric cancer. Considering the invasiveness of ultrasound gastroscopy, it should not be recommend for patients after neoadjuvant chemotherapy routinely.",2020,There was no significant difference between the diagnostic efficacy of abdominal enhanced CT and endoscopic ultrasound for yc stage of gastric cancer.,"['60 males and 26 females, aged (57.8±9.7) years (range: 32 to 76 years', 'Totally 86 patients completed both abdominal enhanced CT and endoscopic ultrasound after neoadjuvant chemotherapy', 'patients after neoadjuvant chemotherapy routinely', '86 locally advanced gastric cancer patients admitted in Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute from April 2015 to November 2017 were analyzed retrospectively', 'gastric cancer after neoadjuvant chemotherapy (yc stage']","['abdominal enhanced CT and endoscopic ultrasound', 'neoadjuvant chemotherapy']","['sensitivity between CT-ycT stage and EUS-ycT stage', 'sensitivity between CT-ycN stage and EUS-ycN stage', 'diagnostic efficacy of abdominal enhanced CT', 'M-AUC of ycT stage evaluated by abdominal enhanced CT (CT-ycT stage) and by endoscopic ultrasound (EUS-ycT stage']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0685938', 'cui_str': 'Malignant neoplasm of gastrointestinal tract'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0019999', 'cui_str': 'Cancer hospital'}, {'cui': 'C0021622', 'cui_str': 'Institutes'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]","[{'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0376443', 'cui_str': 'Endoscopic ultrasonography'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}]",86.0,0.0472549,There was no significant difference between the diagnostic efficacy of abdominal enhanced CT and endoscopic ultrasound for yc stage of gastric cancer.,"[{'ForeName': 'Y K', 'Initials': 'YK', 'LastName': 'Wang', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Shan', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'X J', 'Initials': 'XJ', 'LastName': 'Ying', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'Q Y', 'Initials': 'QY', 'LastName': 'Xiao', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Tang', 'Affiliation': 'Department of Radiology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Wu', 'Affiliation': 'Department of Endoscopy Center, Peking University Cancer Hospital & Institute, Key Laboratory ofCarcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'Z Y', 'Initials': 'ZY', 'LastName': 'Li', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}, {'ForeName': 'J F', 'Initials': 'JF', 'LastName': 'Ji', 'Affiliation': 'Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Beijing 100142, China.'}]",Zhonghua wai ke za zhi [Chinese journal of surgery],['10.3760/cma.j.cn112139-20200114-00027'] 2645,32727231,Skin preparation type and post-cesarean infection with use of adjunctive azithromycin prophylaxis.,"OBJECTIVE To compare the frequency of postoperative surgical site infection (SSI) by type of skin preparation used for unscheduled cesarean in the setting of adjunctive azithromycin prophylaxis. METHODS Secondary analysis of a multi-center randomized controlled trial of adjunctive azithromycin (500 mg intravenous) versus placebo in women who were ≥24 weeks gestation and undergoing unscheduled cesarean (i.e. during labor or ≥4 h after membrane rupture). Type of skin preparation used was identified based on the protocol at the hospital at the time of delivery: iodine-alcohol, chlorhexidine, chlorhexidine-alcohol, or the combination of chlorhexidine-alcohol and iodine. The primary outcome of this analysis was incidence of post-operative SSI, as defined by CDC criteria. Multivariable logistic regression was applied for adjustments. RESULTS All 2013 women in the primary trial were included in this analysis. Women were grouped according to type of skin preparation received: iodine-alcohol ( n  = 193), chlorhexidine ( n  = 733), chlorhexidine-alcohol ( n  = 656), and chlorhexidine-alcohol and iodine combined sequentially ( n  = 431). The unadjusted rates of wound infection ranged from 2.9% to 5.7%. Using iodine-alcohol as the referent, the adjusted odds ratios for wound SSI were 0.71 (95% CI 0.30-1.66) for chlorhexidine, 0.97 (95% CI 0.41-2.28) for chlorhexidine-alcohol, and 0.88 (95% CI 0.36-2.20) for chlorhexidine-alcohol with iodine combination. CONCLUSION In women undergoing unscheduled cesarean delivery in a trial of adjunctive azithromycin, the type of skin preparation used did not appear to be associated with the frequency of wound SSI.",2020,"Using iodine-alcohol as the referent, the adjusted odds ratios for wound SSI were 0.71 (95% CI 0.30-1.66) for chlorhexidine, 0.97 (95% CI 0.41-2.28) for chlorhexidine-alcohol, and 0.88 (95% CI 0.36-2.20) for chlorhexidine-alcohol with iodine combination. ","['women undergoing unscheduled cesarean delivery in a trial of', 'All 2013 women in the primary trial', 'women who were ≥24\u2009weeks gestation and undergoing unscheduled cesarean (i.e. during labor or ≥4\u2009h after membrane rupture']","['adjunctive azithromycin prophylaxis', 'adjunctive azithromycin', 'chlorhexidine-alcohol and iodine combined sequentially', 'chlorhexidine', 'iodine-alcohol', 'chlorhexidine-alcohol with iodine combination', 'iodine-alcohol, chlorhexidine, chlorhexidine-alcohol, or the combination of chlorhexidine-alcohol and iodine', 'chlorhexidine-alcohol', 'placebo']","['adjusted odds ratios for wound SSI', 'incidence of post-operative SSI, as defined by CDC criteria', 'unadjusted rates of wound infection', 'frequency of wound SSI']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3854240', 'cui_str': 'Unscheduled'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0022864', 'cui_str': 'Labor'}, {'cui': 'C0233308', 'cui_str': 'Spontaneous rupture of fetal membranes'}]","[{'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0033107', 'cui_str': 'prevention & control'}, {'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0456081', 'cui_str': 'Adjustment - action'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C0332803', 'cui_str': 'Surgical wound'}, {'cui': 'C0578491', 'cui_str': 'Infection by site'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0038941', 'cui_str': 'Postoperative wound infection'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0007670', 'cui_str': 'Centers for Disease Control and Prevention (U.S.)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0043241', 'cui_str': 'Local infection of wound'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}]",,0.0893631,"Using iodine-alcohol as the referent, the adjusted odds ratios for wound SSI were 0.71 (95% CI 0.30-1.66) for chlorhexidine, 0.97 (95% CI 0.41-2.28) for chlorhexidine-alcohol, and 0.88 (95% CI 0.36-2.20) for chlorhexidine-alcohol with iodine combination. ","[{'ForeName': 'Elizabeth B', 'Initials': 'EB', 'LastName': 'Ausbeck', 'Affiliation': ""Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'ForeName': 'Victoria C', 'Initials': 'VC', 'LastName': 'Jauk', 'Affiliation': ""Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'ForeName': 'Kim A', 'Initials': 'KA', 'LastName': 'Boggess', 'Affiliation': 'Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Saade', 'Affiliation': 'The University of Texas Medical Branch, Galveston, TX, USA.'}, {'ForeName': 'Sherri', 'Initials': 'S', 'LastName': 'Longo', 'Affiliation': 'Department of Obstetrics and Gynecology, Ochsner Health System, New Orleans, LA, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Esplin', 'Affiliation': 'The University of Utah, Salt Lake City, UT, USA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Cleary', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Wapner', 'Affiliation': 'Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA.'}, {'ForeName': 'Kellett', 'Initials': 'K', 'LastName': 'Letson', 'Affiliation': 'Mission Hospital, Asheville, NC, USA.'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Owens', 'Affiliation': 'Department of Obstetrics and Gynecology, University of Mississippi, Jackson, MS, USA.'}, {'ForeName': 'Sean', 'Initials': 'S', 'LastName': 'Blackwell', 'Affiliation': 'Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Sciences Center, Houston, TX, USA.'}, {'ForeName': 'Namasivayam', 'Initials': 'N', 'LastName': 'Ambalavanan', 'Affiliation': 'Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.'}, {'ForeName': 'Jeff M', 'Initials': 'JM', 'LastName': 'Szychowski', 'Affiliation': ""Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Andrews', 'Affiliation': ""Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'ForeName': 'Alan T N', 'Initials': 'ATN', 'LastName': 'Tita', 'Affiliation': ""Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2020.1797665'] 2646,32727247,Motor Behavior-Induced Prefrontal Cortex Activation and Episodic Memory Function.,"The objective of this paper was to evaluate the potential individual and combined effects of acute exercise coupled with bilateral interhemispheric activation on episodic memory function. Six experiments were conducted. Experiment 1 was a four-visit, within-subject, counterbalanced randomized controlled experiment. Participants completed four visits, including 1) exercise and saccadic eye movements, 2) exercise only, 3) saccadic eye movements only, and 4) no exercise and no saccadic eye movements (control). A word-list based episodic memory assessment was employed, including a long-term (20-min delay) memory evaluation. In Experiment 2, we evaluated the effects of saccadic eye movements on prefrontal cortex oxygenation, a proxy for neuronal activity. Similarly, in our third experiment, we evaluated the effects of acute exercise on prefrontal cortex oxygenation. Thus, experiments 2 and 3 were employed to provide mechanistic insights from the results shown in experiment 1. Experiment 4 replicated Experiment 1, but instead of inducing bilateral interhemispheric activation via saccadic eye movements, we used a fist clenching protocol. Experiment 5 evaluated the effects of fist clenching on prefrontal cortex oxygenation. Collectively, these 5 experimental studies showed that acute exercise (Experiment 1), saccadic eye movements (Experiment 1), and fist clenching (Experiment 4) enhanced memory function, and that acute exercise (Experiment 3), saccadic eye movements (Experiment 2) and fist clenching (Experiment 5) all increased PFC oxygenation. Experiment 6 demonstrated that PFC oxygenation was statistically significantly positively associated with episodic memory function. As such, these six experiments suggest that several behaviors, such as acute exercise, saccadic eye movements and fist clenching may improve memory function and may, potentially, do so via increases in PFC oxygenation.",2020,"In Experiment 2, we evaluated the effects of saccadic eye movements on prefrontal cortex oxygenation, a proxy for neuronal activity.",[],"['acute exercise coupled with bilateral interhemispheric activation', 'exercise and saccadic eye movements, 2) exercise only, 3) saccadic eye movements only, and 4) no exercise and no saccadic eye movements (control', 'acute exercise', 'saccadic eye movements', 'fist clenching']","['episodic memory function', 'acute exercise (Experiment 1), saccadic eye movements (Experiment 1), and fist clenching (Experiment 4) enhanced memory function, and that acute exercise (Experiment 3), saccadic eye movements (Experiment 2) and fist clenching (Experiment 5) all increased PFC oxygenation', 'PFC oxygenation', 'prefrontal cortex oxygenation', 'Motor Behavior-Induced Prefrontal Cortex Activation and Episodic Memory Function']",[],"[{'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0238767', 'cui_str': 'Right and left'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0036019', 'cui_str': 'Saccadic eye movement'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0336667', 'cui_str': 'Fist'}]","[{'cui': 'C0561843', 'cui_str': 'Episodic memory'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0036019', 'cui_str': 'Saccadic eye movement'}, {'cui': 'C0336667', 'cui_str': 'Fist'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]",6.0,0.0180645,"In Experiment 2, we evaluated the effects of saccadic eye movements on prefrontal cortex oxygenation, a proxy for neuronal activity.","[{'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Loprinzi', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Crawford', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Damien', 'Initials': 'D', 'LastName': 'Moore', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Jeremiah', 'Initials': 'J', 'LastName': 'Blough', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Burnett', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Chism', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}, {'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Robinson', 'Affiliation': 'Exercise & Memory Laboratory, Department of Health, Exercise Science and Recreation Management, The University of Mississippi, University, MS 38677.'}]",The International journal of neuroscience,['10.1080/00207454.2020.1803307'] 2647,32727255,Addressing Electroconvulsive Therapy Knowledge Gaps and Stigmatized Views Among Nursing Students Through a Psychiatrist-APRN Didactic Partnership.,"BACKGROUND: Knowledge gaps and stigmatized perceptions regarding electroconvulsive therapy (ECT) among patients and health providers contribute to the underutilization of an important therapeutic modality. The proactive education of future advanced practice registered nurses (APRNs) provides an opportunity to optimize the use of this evidence-based clinical practice. AIMS: As part of a general course in psychiatry during the first year of nursing school, we dedicated 1 hour to treatment-refractory depression, including ECT, and a second hour to a summary discussion of mood disorders. We evaluated the efficacy of this didactic offering, which was co-taught by a psychiatrist and a psychiatric APRN. METHOD: At baseline, consenting students ( n = 94) provided three words they associated with ECT and then completed three validated instruments: (a) Questionnaire on Attitudes and Knowledge of ECT, (b) Opening Minds Stigma Scale for Health Care Providers, and (c) Self-Stigma of Seeking Help. Among the 67 students who repeated the assessment at endpoint, 39 attended the ECT didactic (Intervention group, 58%) and 28 did not (Control, 42%). RESULTS: After completion of the 3-month course, students showed improvement across all measures ( p < .001). The only outcomes that improved differentially between the Intervention and Control groups were the Questionnaire on Attitudes and Knowledge of ECT Attitudes and Knowledge scales ( p = .01). Word choice valence associated with ECT shifted favorably by endpoint ( p < .001). CONCLUSIONS: An educational intervention co-led by a psychiatric-mental health APRN had a significant impact on nursing students' knowledge and perceptions of ECT. This approach can be readily implemented at other institutions. Future refinements will include the videotaped depiction of a simulated patient undergoing the consent, treatment, and recovery phases of ECT.",2020,An educational intervention co-led by a psychiatric-mental health APRN had a significant impact on nursing students' knowledge and perceptions of ECT.,"['patients and health providers', '67 students who repeated the assessment at endpoint, 39 attended the ECT didactic (Intervention group, 58%) and 28 did not (Control, 42']","['Questionnaire on Attitudes and Knowledge of ECT, (b) Opening Minds Stigma Scale for Health Care Providers, and (c) Self-Stigma of Seeking Help', 'electroconvulsive therapy (ECT']",['Questionnaire on Attitudes and Knowledge of ECT Attitudes and Knowledge scales'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0277787', 'cui_str': 'Stigma'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",,0.0219078,An educational intervention co-led by a psychiatric-mental health APRN had a significant impact on nursing students' knowledge and perceptions of ECT.,"[{'ForeName': 'Brandon M', 'Initials': 'BM', 'LastName': 'Kitay', 'Affiliation': 'Brandon M. Kitay, MD, PhD, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Walde', 'Affiliation': 'Tina Walde, DNP, APRN, PMHNP, Yale University, Orange, CT, USA.'}, {'ForeName': 'Dilice', 'Initials': 'D', 'LastName': 'Robertson', 'Affiliation': 'Dilice Robertson, DNP, APRN, PMHNP, Yale University, Orange, CT, USA.'}, {'ForeName': 'Tammy', 'Initials': 'T', 'LastName': 'Cohen', 'Affiliation': 'Tammy Cohen, APRN, Yale Psychiatric Hospital, New Haven, CT, USA.'}, {'ForeName': 'Robbert', 'Initials': 'R', 'LastName': 'Duvivier', 'Affiliation': 'Robbert Duvivier, MD, PhD, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Andrés Martin, MD, MPH, Yale University, New Haven, CT, USA.'}]",Journal of the American Psychiatric Nurses Association,['10.1177/1078390320945778'] 2648,32727302,Lifestyle counselling by persuasive information and communications technology reduces prevalence of metabolic syndrome in a dose-response manner: a randomized clinical trial (PrevMetSyn).,"OBJECTIVES The aim was to investigate whether lifestyle changes produced by persuasive Information and Communication Technology (ICT) counselling can lower the prevalence of metabolic syndrome (MetS). METHODS A total of 532 participants (20-60 years, body mass index 27-35 kg/m 2 ) were randomly assigned to six arms according to counselling type (no, short-term, or intensive) with or without ICT intervention. In this report the prevalence of MetS and its components were compared between no-ICT group and ICT group. Moreover, the frequency of the web information system usage was analysed for the number of logins, responses to weekly messages, and other record variables. RESULTS The ICT group had significantly lower proportion of MetS (33.7% vs. 45.3%, p  = .022) than the no-ICT group at 2-year follow-up. In mixed model, the ICT group had lower prevalence of MetS than no-ICT group (OR 0.50, 95%CI 0.27-0.90) after intervention. The tertile with the highest utilization had 71% lower prevalence of MetS compared with the lowest utilization tertile or the no-ICT group. CONCLUSIONS Web-based ICT is able to reduce the prevalence of MetS. In addition, higher utilization of the web information system is associated with a greater decrease in the prevalence of MetS. Key messages Our internet health behaviour change support system based on persuasive design and cognitive behaviour therapy markedly reduces metabolic syndrome in overweight/obese subjects. As a stand-alone tool it may save healthcare personnel resources as it is suitable at a low cost for both obese/overweight patients and the public at large.",2020,"The ICT group had significantly lower proportion of MetS (33.7% vs. 45.3%, p  = .022) than the no-ICT group at 2-year follow-up.","['overweight/obese subjects', '532 participants (20-60 years, body mass index 27-35\u2009kg/m 2 ']","['counselling type (no, short-term, or intensive) with or without ICT intervention', 'persuasive Information and Communication Technology (ICT) counselling', 'ICT', 'Lifestyle counselling by persuasive information and communications technology']","['prevalence of MetS', 'proportion of MetS', 'metabolic syndrome']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0341618', 'cui_str': 'Counsel'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0683867', 'cui_str': 'Information Technology'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0730543', 'cui_str': 'Lifestyle education'}]","[{'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0524620', 'cui_str': 'Metabolic syndrome X'}]",532.0,0.0498603,"The ICT group had significantly lower proportion of MetS (33.7% vs. 45.3%, p  = .022) than the no-ICT group at 2-year follow-up.","[{'ForeName': 'Young-Gyun', 'Initials': 'YG', 'LastName': 'Seo', 'Affiliation': 'Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Tuire', 'Initials': 'T', 'LastName': 'Salonurmi', 'Affiliation': 'Biocenter Oulu, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Terhi', 'Initials': 'T', 'LastName': 'Jokelainen', 'Affiliation': 'Unit of Medicine, Oulu University Hospital, Oulu, Finland.'}, {'ForeName': 'Pasi', 'Initials': 'P', 'LastName': 'Karppinen', 'Affiliation': 'Oulu Advanced Research on Service and Information Systems, Faculty of Information Technology and Electrical Engineering, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Teeriniemi', 'Affiliation': 'Biocenter Oulu, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Junhee', 'Initials': 'J', 'LastName': 'Han', 'Affiliation': 'Department of Statistics, Hallym University, Chuncheon, Gangwon-do, Republic of Korea.'}, {'ForeName': 'Kyung Hee', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Department of Family Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, Republic of Korea.'}, {'ForeName': 'Harri', 'Initials': 'H', 'LastName': 'Oinas-Kukkonen', 'Affiliation': 'Oulu Advanced Research on Service and Information Systems, Faculty of Information Technology and Electrical Engineering, University of Oulu, Oulu, Finland.'}, {'ForeName': 'Markku J', 'Initials': 'MJ', 'LastName': 'Savolainen', 'Affiliation': 'Biocenter Oulu, Research Unit of Internal Medicine, University of Oulu, Oulu, Finland.'}]",Annals of medicine,['10.1080/07853890.2020.1783455'] 2649,32727335,"Anti-Neuroinflammatory Properties of n-3 Fatty Acids and Nano-Curcumin on Migraine Patients, from Cellular to Clinical Insight: A Randomized, Double Blind, and Placebo-Controlled Trial.","BACKGROUND AND OBJECTIVES Migraine is an exhausting neuro-inflammatory disorder recognized as recurrent headache attacks. Evidence has shown that Interleukin (IL)-1β plays a substantial role in the neuro-immunity pathogenicity of migraine. n-3 fatty acids and curcumin revealed neuro-modulatory and anti-inflammatory effects through several pathways, of which the suppression of IL-1β gene expression is an important inflammatory pathway. The aim of this study was the investigation of synergistic relation of n -3 fatty acids and nano-curcumin on IL-1β gene expression and serum levels in migraine patients. METHODS This study was performed as a randomized double-blind, placebo-controlled trial in the period of two months. A total of 80 episodic migraines were assigned in 4 groups of 1) n-3 fatty acids and curcumin combination; 2) n -3 fatty acids; 3) nano-curcumin; and 4) n-3 fatty acids and curcumin placebo. The gene expression and serum level of IL1β were measured by real-time PCR and ELISA methods respectively, at the beginning and the end of the interventions. RESULTS Results showed the n-3 fatty acids and nano-curcumin combination significantly reduced the attack frequency in a synergistic status (P < 0.001). A significantly greater reduction in serum level of IL-1β was observed in the combination group, and the differences in the other groups were not statistically significant. The IL-1β gene expression in combination group showed a significant reduction with respect to other treatment groups (P < 0.05), but these significant differences were absent after multiple testing Bonferroni corrections. CONCLUSION Present findings revealed that n -3 fatty acids and curcumin co-supplementation can be suggested as a promising new approach in migraine headache management, but further studies are needed to confirm these findings.",2020,"The IL-1β gene expression in combination group showed a significant reduction with respect to other treatment groups (P < 0.05), but these significant differences were absent after multiple testing Bonferroni corrections. ","['migraine patients', '80 episodic migraines']","['Placebo', 'n-3 fatty acids', 'n-3 Fatty Acids and Nano-Curcumin', 'n-3 fatty acids and curcumin combination; 2) n -3 fatty acids; 3) nano-curcumin; and 4) n-3 fatty acids and curcumin placebo', 'placebo']","['IL-1β gene expression', 'attack frequency', 'gene expression and serum level of IL1β', 'n-3 fatty acids', 'serum level of IL-1β']","[{'cui': 'C0149931', 'cui_str': 'Migraine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4760993', 'cui_str': 'Episodic migraine'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}]","[{'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}]",80.0,0.181622,"The IL-1β gene expression in combination group showed a significant reduction with respect to other treatment groups (P < 0.05), but these significant differences were absent after multiple testing Bonferroni corrections. ","[{'ForeName': 'Niyaz Mohammadzadeh', 'Initials': 'NM', 'LastName': 'Honarvar', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Soveid', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Mina', 'Initials': 'M', 'LastName': 'Abdolahi', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Mahmoud', 'Initials': 'M', 'LastName': 'Djalali', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Hatami', 'Affiliation': 'Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran. Iran.'}, {'ForeName': 'Nazanin Hazhir', 'Initials': 'NH', 'LastName': 'Karzar', 'Affiliation': 'Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA. United States.'}]","Endocrine, metabolic & immune disorders drug targets",['10.2174/1871530320666200729144430'] 2650,32727392,Who should be responsible for the care of advanced chronic kidney disease? Do the guidelines point to the end of nephrology follow-up of advanced CKD or are they the starting point for a new approach?,"The editorial comments on a recently published study in which 242 patients, with ""stable"" chronic kidney disease, recruited during a hospital stay, were randomised either to receiving support from nephrologists (co-management by primary care physicians and nephrologists), or to be managed by primary care physicians with written instructions and nephrology consultations on demand. After a mean follow-up of 4 years, the results in terms of dialysis start, hospitalisation and death were similar for both groups.This study gave the possibility to discuss about the options of follow-up of CKD patients, including on one side the advantage of a greater involvement of primary care physicians, who could oversee care by applying a common set of simplified guidelines, and on the other one the importance of a direct and deep involvement of the specialists that seems necessary in particular if personalised approaches have to be pursuit. The data of the present study are somehow in disagreement with the literature, usually suggesting better outcomes in intensive treatment, in which specialists are directly involved. The literature is heterogeneous, the goals vary and the populations are differently selected. The compliance issue is probably one of the missing pieces of the puzzle, and specific interventions should also be tailored to ""reluctant"" patients. Guidelines should probably be staring points for improvement, and not the standard of care; the study herein discussed may suggest that primary care physicians may be of great help in granting a good standard of care, hopefully as a baseline for further improvement, and personalised care.",2020,"After a mean follow-up of 4 years, the results in terms of dialysis start, hospitalisation and death were similar for both groups.","['242 patients, with ""stable"" chronic kidney disease, recruited during a hospital stay']","['receiving support from nephrologists (co-management by primary care physicians and nephrologists), or to be managed by primary care physicians with written instructions and nephrology consultations on demand']","['dialysis start, hospitalisation and death']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]","[{'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0260039', 'cui_str': 'Nephrologist'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0033131', 'cui_str': 'Primary care physician'}, {'cui': 'C1273870', 'cui_str': 'Management procedure'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0027712', 'cui_str': 'Nephrology'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",242.0,0.0179744,"After a mean follow-up of 4 years, the results in terms of dialysis start, hospitalisation and death were similar for both groups.","[{'ForeName': 'Giorgina Barbara', 'Initials': 'GB', 'LastName': 'Piccoli', 'Affiliation': 'Department of Clinical and Biological Sciences, University of Torino, 10124, Torino, Italy. gbpiccoli@yahoo.it.'}]",BMC nephrology,['10.1186/s12882-020-01908-4'] 2651,32727393,"A stepped-wedge randomised-controlled trial assessing the implementation, impact and costs of a prospective feedback loop to promote appropriate care and treatment for older patients in acute hospitals at the end of life: study protocol.","BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience. There is evidence that some of these patients received non-beneficial treatment during their final hospitalisation with a third of the non-beneficial treatment duration spent in intensive care units. This study aims to increase appropriate care and treatment decisions and pathways for older patients at the end of life in Australia. This study will implement and evaluate a prospective feedback loop and tailored clinical response intervention at three hospitals in Queensland, Australia. METHODS A stepped-wedge cluster randomised trial will be conducted with up to 21 clinical teams in three acute hospitals over 70 weeks. The study involves clinical teams providing care to patients aged 75 years or older, who are prospectively identified to be at risk of non-beneficial treatment using two validated tools for detecting death and deterioration risks. The intervention's feedback loop will provide the teams with a summary of these patients' risk profiles as a stimulus for a tailored clinical response in the intervention phase. The Consolidated Framework for Implementation Research will be used to inform the intervention's implementation and process evaluation. The study will determine the impact of the intervention on patient outcomes related to appropriate care and treatment at the end of life in hospitals, as well as the associated healthcare resource use and costs. The primary outcome is the proportion of patients who are admitted to intensive care units. A process evaluation will be carried out to assess the implementation, mechanisms of impact, and contextual barriers and enablers of the intervention. DISCUSSION This intervention is expected to have a positive impact on the care of older patients near the end of life, specifically to improve clinical decision-making about treatment pathways and what constitutes appropriate care for these patients. These will reduce the incidence of non-beneficial treatment, and improve the efficiency of hospital resources and quality of care. The process evaluation results will be useful to inform subsequent intervention implementation at other hospitals. TRIAL REGISTRATION Australia New Zealand Clinical Trial Registry (ANZCTR), ACTRN12619000675123p (approved 6 May 2019).",2020,"BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience.","['21 clinical teams in three acute hospitals over 70\u2009weeks', 'older patients in acute hospitals at the end of life', 'three hospitals in Queensland, Australia', 'older patients at the end of life in Australia', 'patients aged 75\u2009years or older, who are prospectively identified to be at risk of non-beneficial treatment using two validated tools for detecting death and deterioration risks']",[],['proportion of patients who are admitted to intensive care units'],"[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0034391', 'cui_str': 'Queensland'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0442726', 'cui_str': 'Detected'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0583239', 'cui_str': 'Admission to intensive care unit'}]",,0.131548,"BACKGROUND Hospitalisation rates for the older population have been increasing with end-of-life care becoming a more medicalised and costly experience.","[{'ForeName': 'Xing J', 'Initials': 'XJ', 'LastName': 'Lee', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia. xj.lee@qut.edu.au.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Farrington', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Carter', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Shield', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Graves', 'Affiliation': 'Duke-NUS Postgraduate Medical School, National University of Singapore, Singapore, Singapore.'}, {'ForeName': 'Steven M', 'Initials': 'SM', 'LastName': 'McPhail', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Gillian', 'Initials': 'G', 'LastName': 'Harvey', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Ben P', 'Initials': 'BP', 'LastName': 'White', 'Affiliation': 'Australia Centre for Heath Law Research, Faculty of Law, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Lindy', 'Initials': 'L', 'LastName': 'Willmott', 'Affiliation': 'Australia Centre for Heath Law Research, Faculty of Law, Queensland University of Technology, Brisbane, Queensland, Australia.'}, {'ForeName': 'Magnolia', 'Initials': 'M', 'LastName': 'Cardona', 'Affiliation': 'Gold Coast University Hospital, Southport, Queensland, Australia.'}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Hillman', 'Affiliation': 'Simpson Centre for Health Services Research, South West Sydney Clinical School, University of New South Wales, Liverpool, New South Wales, Australia.'}, {'ForeName': 'Leonie', 'Initials': 'L', 'LastName': 'Callaway', 'Affiliation': 'Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland, Australia.'}, {'ForeName': 'Adrian G', 'Initials': 'AG', 'LastName': 'Barnett', 'Affiliation': 'Faculty of Health, School of Public Health and Social Work, Queensland University of Technology (QUT), Kelvin Grove, Queensland, Australia.'}]",BMC geriatrics,['10.1186/s12877-020-01660-2'] 2652,32727416,Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).,"BACKGROUND For loco-regionally advanced, but transorally resectable oropharyngeal cancer (OPSCC), the current standard of care includes surgical resection and risk-adapted adjuvant (chemo) radiotherapy, or definite chemoradiation with or without salvage surgery. While transoral surgery for OPSCC has increased over the last decade for example in the United States due to transoral robotic surgery, this treatment approach has a long history in Germany. In contrast to Anglo-Saxon countries, transoral surgical approaches have been used frequently in Germany to treat patients with oro-, hypopharyngeal and laryngeal cancer. Transoral laser microsurgery (TLM) has had a long tradition since its introduction in the early 70s. To date, the different therapeutic approaches to transorally resectable OPSCC have not been directly compared to each other in a randomized trial concerning disease control and survival. The goal of this study is to compare initial transoral surgery to definitive chemoradiation for resectable OPSCC, especially with regards to local and regional control. METHODS TopROC is a prospective, two-arm, open label, multicenter, randomized, and controlled comparative effectiveness study. Eligible patients are ≥18 years old with treatment-naïve, histologically proven OPSCC (T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c, M0 UICC vers. 7) which are amenable to transoral resection. Two hundred eighty patients will be randomly assigned (1:1) to surgical treatment (arm A) or chemoradiation (arm B). Standard of care treatment will be performed according to daily routine practice. Arm A consists of transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy. Patients treated in arm B receive standard chemoradiation, residual tumor may be subject to salvage surgery. Follow-up visits for 3 years are planned. Primary endpoint is time to local or locoregional failure (LRF). Secondary endpoints include overall and disease free survival, toxicity, and patient reported outcomes. Approximately 20 centers will be involved in Germany. This trial is supported by the German Cancer Aid and accompanied by a scientific support program. DISCUSSION This study will shed light on an urgently-needed randomized comparison of the strategy of primary chemoradiation vs. primary surgical approach. As a comparative effectiveness trial, it is designed to provide data based on two established regimens in daily clinical routine. TRIAL REGISTRATION NCT03691441 Registered 1 October 2018 - Retrospectively registered.",2020,"While transoral surgery for OPSCC has increased over the last decade for example in the United States due to transoral robotic surgery, this treatment approach has a long history in Germany.","['oropharyngeal cancer (TopROC', '1 October 2018', 'Eligible patients are ≥18\u2009years old with treatment-naïve, histologically proven OPSCC (T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c, M0 UICC vers', 'Two hundred eighty patients', 'patients with oro-, hypopharyngeal and laryngeal cancer']","['adjuvant (chemo) radiotherapy, or definite chemoradiation with or without salvage surgery', 'transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy', 'Transoral laser microsurgery (TLM', 'primary chemoradiation vs. primary surgical approach', 'standard chemoradiation', 'transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy', 'surgical treatment (arm A) or chemoradiation']","['time to local or locoregional failure (LRF', 'overall and disease free survival, toxicity, and patient reported outcomes']","[{'cui': 'C0153382', 'cui_str': 'Malignant tumor of oropharynx'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205462', 'cui_str': 'Histologic'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0445079', 'cui_str': 'Node stage N2a'}, {'cui': 'C0441914', 'cui_str': 'UICC'}, {'cui': 'C0042553', 'cui_str': 'Versed'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C1522409', 'cui_str': 'Oropharyngeal'}, {'cui': 'C0020629', 'cui_str': 'Hypopharyngeal structure'}, {'cui': 'C0007107', 'cui_str': 'Malignant tumor of larynx'}]","[{'cui': 'C0242939', 'cui_str': 'Adjuvant Radiotherapy'}, {'cui': 'C0439544', 'cui_str': 'Definite'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0085405', 'cui_str': 'Salvage therapy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0442366', 'cui_str': 'Transoral approach'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0398395', 'cui_str': 'Block dissection of cervical lymph nodes'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0677850', 'cui_str': 'Adjuvant therapy'}, {'cui': 'C0023089', 'cui_str': 'Laser device'}, {'cui': 'C0026035', 'cui_str': 'Microsurgery'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0449446', 'cui_str': 'Surgical approach'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0460004', 'cui_str': 'Structure of head and/or neck'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}]",280.0,0.0657933,"While transoral surgery for OPSCC has increased over the last decade for example in the United States due to transoral robotic surgery, this treatment approach has a long history in Germany.","[{'ForeName': 'Lara', 'Initials': 'L', 'LastName': 'Bußmann', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Laban', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Ulm, Ulm, Germany.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Wittekindt', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Gießen, Gießen, Germany.'}, {'ForeName': 'Carmen', 'Initials': 'C', 'LastName': 'Stromberger', 'Affiliation': 'Department of Radiation Oncology, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Tribius', 'Affiliation': 'Hermann-Holthusen-Institut for Radiation Oncology, Asklepios Klinik St. Georg, Hamburg, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Möckelmann', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Arne', 'Initials': 'A', 'LastName': 'Böttcher', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Christian Stephan', 'Initials': 'CS', 'LastName': 'Betz', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Jens Peter', 'Initials': 'JP', 'LastName': 'Klussmann', 'Affiliation': 'Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Volker', 'Initials': 'V', 'LastName': 'Budach', 'Affiliation': 'Department of Radiation Oncology, Charité University Medicine Berlin, Berlin, Germany.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Muenscher', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Chia-Jung', 'Initials': 'CJ', 'LastName': 'Busch', 'Affiliation': 'Department of Otorhinolaryngology and Head and Neck Surgery, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. cjbusch@uke.de.'}]",BMC cancer,['10.1186/s12885-020-07127-2'] 2653,32727420,An integrated community mental healthcare program to reduce suicidal ideation and improve maternal mental health during the postnatal period: the findings from the Nagano trial.,"BACKGROUND During the perinatal period, suicides are more likely to occur in those with depression and who are not receiving active treatment at the time of death. Suicide is a common outcome in people with suicide ideation. We developed an intervention program taking care of comprehensive perinatal maternal mental healthcare to prevent suicide ideation. We hypothesized that our intervention program could reduce postnatal suicide ideation and improve maternal mental health. METHODS We performed a controlled trial to examine the usual postnatal care plus a maternal suicide prevention program (the intervention group) compared with usual postnatal care alone, which comprised home visits by public health nurses without mental health screening (the control group) in Nagano city, Japan. In total, 464 women were included; 230 were allocated to the control group and 234 to the intervention group. The intervention had three components: 1) all the women received postnatal mental health screening by public health nurses who completed home visits during the neonatal period, 2) the intervention was administered by a multidisciplinary clinical network, and 3) systematic follow-up sheets were used to better understand bio-psycho-social characteristics of both the mothers and their infants and develop responsive care plans. We measured the participants' mental health at 3-4 months postpartum (T1) and 7-8 months postpartum (T2) using the Japanese version of the Edinburgh Postnatal Depression Scale (EPDS). RESULTS Suicidal ideation was significantly lower in the intervention group compared with the control group at T1 (p = 0.014); however, this significant between-group difference did not continue to T2 (p = 0.111). We measured the intervention effects on maternal mental health using the total score of the EPDS, which was significantly improved in the intervention group compared with the control group at T1. Here, the significant difference continued to T2 (p = 0.049). CONCLUSIONS Our results indicate that our program may reduce maternal suicidal ideation at 3-4 months postnatally and improve women's mental health during the postnatal periods of 3-4 to 7-8 months. Postnatal maternal mental healthcare, including services to reduce suicide ideation, should be included as an important component of general postnatal care. TRIAL REGISTRATION Name of registry: A multidisciplinary intervention program for maternal mental health in perinatal periods. UMIN Clinical Trials Registry number: UMIN000033396 . Registration URL: https://upload.umin.ac.jp/cgibin/ctr/ctr_view_reg.cgi?recptno=R000038076 Registration date: July 15, 2018. Registration timing: retrospective.",2020,"RESULTS Suicidal ideation was significantly lower in the intervention group compared with the control group at T1 (p = 0.014); however, this significant between-group difference did not continue to T2 (p = 0.111).","[""participants' mental health at 3-4\u2009months postpartum (T1) and 7-8\u2009months postpartum (T2) using the Japanese version of the Edinburgh Postnatal Depression Scale (EPDS"", 'maternal mental health in perinatal periods', 'people with suicide ideation', '464 women were included; 230 were allocated to the control group and 234 to the intervention group']","['multidisciplinary intervention program', 'postnatal mental health screening by public health nurses who completed home visits during the neonatal period, 2) the intervention was administered by a multidisciplinary clinical network, and 3) systematic follow-up sheets were used to better understand bio-psycho-social characteristics of both the mothers and their infants and develop responsive care plans', 'usual postnatal care plus a maternal suicide prevention program', 'usual postnatal care alone, which comprised home visits by public health nurses without mental health screening (the control group) in Nagano city, Japan']","['Suicidal ideation', ""women's mental health"", 'suicidal ideation', 'maternal mental health', 'postnatal suicide ideation and improve maternal mental health', 'maternal suicidal ideation']","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0178795', 'cui_str': 'Perinatal period'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C0392348', 'cui_str': 'Ideation'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0242479', 'cui_str': 'Interdisciplinary Studies'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0184646', 'cui_str': 'Mental health screening'}, {'cui': 'C0034022', 'cui_str': 'Public health nurse'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0021289', 'cui_str': 'Newborn'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0439643', 'cui_str': 'Sheets'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205342', 'cui_str': 'Responsive'}, {'cui': 'C0178916', 'cui_str': 'Care plan'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0204732', 'cui_str': 'Suicide prevention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0022341', 'cui_str': 'Japan'}]","[{'cui': 'C0424000', 'cui_str': 'Suicidal thoughts'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0443281', 'cui_str': 'Postnatal'}, {'cui': 'C0038661', 'cui_str': 'Suicide'}, {'cui': 'C0392348', 'cui_str': 'Ideation'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",464.0,0.137203,"RESULTS Suicidal ideation was significantly lower in the intervention group compared with the control group at T1 (p = 0.014); however, this significant between-group difference did not continue to T2 (p = 0.111).","[{'ForeName': 'Yoshiyuki', 'Initials': 'Y', 'LastName': 'Tachibana', 'Affiliation': 'Division of Infant and Toddler Mental Health, Department of Psychosocial Medicine, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. tachibana-y@ncchd.go.jp.'}, {'ForeName': 'Noriaki', 'Initials': 'N', 'LastName': 'Koizumi', 'Affiliation': 'Nagano Prefectural Center for Mental Health and Welfare, Nagano, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Mikami', 'Affiliation': 'Department of Biostatistics, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan.'}, {'ForeName': 'Kana', 'Initials': 'K', 'LastName': 'Shikada', 'Affiliation': 'Nagano City Public Health Center, Nagano, Japan.'}, {'ForeName': 'Sayaka', 'Initials': 'S', 'LastName': 'Yamashita', 'Affiliation': 'Nagano City Public Health Center, Nagano, Japan.'}, {'ForeName': 'Mieko', 'Initials': 'M', 'LastName': 'Shimizu', 'Affiliation': 'Nagano City Public Health Center, Nagano, Japan.'}, {'ForeName': 'Kazuyo', 'Initials': 'K', 'LastName': 'Machida', 'Affiliation': 'Nagano City Public Health Center, Nagano, Japan.'}, {'ForeName': 'Hiroto', 'Initials': 'H', 'LastName': 'Ito', 'Affiliation': 'Japan Organization of Occupational Health and Safety, Kanagawa, Japan.'}]",BMC psychiatry,['10.1186/s12888-020-02765-z'] 2654,32727422,Binary Tönnis classification: simplified modification demonstrates better inter- and intra-observer reliability as well as agreement in surgical management of hip pathology.,"BACKGROUND The traditional Tönnis Classification System has inherent drawbacks as it is vulnerable to the subjectivity of a four-grade system. A two-grade classification could potentially be more reliable. The purpose of this study is to (1) compare the inter-observer and intra-observer reliability of the traditional Tönnis Classification System and a simplified Binary Tönnis Classification System for hip osteoarthritis and to (2) evaluate the clinical applicability of both systems. Our hypothesis is that the proposed Binary Tönnis Classification System will have better reliability and agreement for surgical decision-making. METHODS Forty consecutive patients were selected to participate in this study. Patients were included in this study if they were between 35 and 60 years old. Patients were excluded if they had prior hip surgeries or conditions. All radiographs were randomized and blinded by a non-observer. Five fellowship-trained hip surgeons from a single center, in a fully crossed design, analyzed and graded all the radiographs utilizing the traditional Tönnis Classification System and the proposed Binary Tönnis Classification System. Intra- and inter-observer reliability values for both the systems were calculated using the Cohen's κ coefficient. A multi-rater κ was calculated using the weighted Fleiss method. RESULTS The study sample contained 40 anterosuperior hip radiographs. For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866). For the proposed Binary Tönnis Classification System, both inter-observer and intra-observer reliability demonstrated excellent values, (κ = 0.858 and 0.928, respectively). On average, the Binary Tönnis Classification System correctly captured 87% of cases. When the traditional Tönnis Classification System was dichotomized, the capture rate was 84%. CONCLUSION A simplified binary Tönnis Classification System demonstrates better reliability and clinical implementation than the traditional Tönnis Classification System.",2020,"For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866).","['Forty consecutive patients were selected to participate in this study', 'Patients were included in this study if they were between 35 and 60\u2009years old', 'Patients were excluded if they had prior hip surgeries or conditions']",['traditional Tönnis Classification System and a simplified Binary Tönnis Classification System'],"['excellent intra-observer reliability', 'Intra- and inter-observer reliability values']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0596706', 'cui_str': 'Hip surgery'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0008902', 'cui_str': 'Classification'}]","[{'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0035035', 'cui_str': 'Reliability (Epidemiology)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",40.0,0.0162168,"For the traditional Tönnis Classification System, the weighted κ showed a fair inter-observer reliability (κ = 0.474) and excellent intra-observer reliability (κ mean = 0.866).","[{'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Shapira', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Jeffrey W', 'Initials': 'JW', 'LastName': 'Chen', 'Affiliation': 'Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.'}, {'ForeName': 'Rishika', 'Initials': 'R', 'LastName': 'Bheem', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Rosinsky', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Maldonado', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Ajay C', 'Initials': 'AC', 'LastName': 'Lall', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA.'}, {'ForeName': 'Benjamin G', 'Initials': 'BG', 'LastName': 'Domb', 'Affiliation': 'American Hip Institute Research Foundation, Des Plaines, IL, 60018, USA. drdomb@americanhipinstitute.org.'}]",BMC musculoskeletal disorders,['10.1186/s12891-020-03520-x'] 2655,32727451,Assessing and reporting patient participation by means of patient preferences and experiences.,"BACKGROUND Although patient participation is strongly associated with high quality of healthcare, valid means to measure and report a comprehensive notion of patient participation are scarce. The Patient Preferences for Patient Participation (4Ps) is a new healthcare practice and research tool, comprising patients' preferences as well as experiences. The 4Ps employs 12 items for the patient to conceptualise patient participation. The aim of this paper is to describe how the two perspectives of patient participation, namely preferences and experiences, can be combined to visualise and report preference-based patient participation. METHODS With four response alternatives in each section, the 4Ps offers sixteen possible combinations of degree of match per item. Theoretical and clinical principles fostered a tentative order of six ranks and three levels of preference-based patient participation. To test the standard, statistical analyses for ordinal data were performed, using data from a randomised controlled trial evaluating an intervention aiming to improve patient participation. Further, structures for visualising the preference-based patient participation of individuals and groups were suggested. RESULTS Data from the 4Ps demonstrated the individuals' preference-based patient participation, indicating either a match or a mismatch for each item. Mismatches represented either the experience of participation surpassing the patient's preferences, or the patient's preferences for patient participation not being established. At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group. These results had not been identified earlier, when using the preferences and experiences of patient participation as separate measures. CONCLUSIONS Ways to easily acquaint stakeholders with patients' preferences for patient participation are needed, in order for healthcare staff to better use resources to match the basic requirements of individuals and groups. While the 4Ps can guide professionals to patient participation as framed in legislations, concept analyses and by patients, a visualisation of the results is needed to capture preference-based patient participation. The proposed route to representing degree of match in preferences and experiences may also be relevant to other dimensions of quality of healthcare.",2020,"At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group.",['With four response alternatives in each section'],[],['proportion of sufficient preference-based patient participation for certain items'],[],[],"[{'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0030699', 'cui_str': 'Client participation'}, {'cui': 'C0205423', 'cui_str': 'Certain'}]",,0.0188797,"At group level, the suggested approach for visualising and reporting the 4Ps demonstrated that the intervention group had a significantly higher proportion of sufficient preference-based patient participation for certain items than the control group.","[{'ForeName': 'Ann Catrine', 'Initials': 'AC', 'LastName': 'Eldh', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, SE-581 83, Linköping, Sweden. ann.catrine.eldh@liu.se.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Holmefur', 'Affiliation': 'School of Health Sciences, Faculty of Medicine and Health, Örebro University, S701 82, Örebro, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Luhr', 'Affiliation': 'School of Health Sciences, Faculty of Medicine and Health, Örebro University, S701 82, Örebro, Sweden.'}, {'ForeName': 'Marika', 'Initials': 'M', 'LastName': 'Wenemark', 'Affiliation': 'Department of Health, Medicine and Caring Sciences, Linköping University, SE-581 83, Linköping, Sweden.'}]",BMC health services research,['10.1186/s12913-020-05574-y'] 2656,32727493,Implementation of family psychosocial risk assessment in pediatric cancer with the Psychosocial Assessment Tool (PAT): study protocol for a cluster-randomized comparative effectiveness trial.,"BACKGROUND Childhood cancer affects and is affected by multiple levels of the social ecology, including social and relational determinants of health (e.g., economic stability, housing, childcare, healthcare access, child and family problems). The 2015 Standards of Psychosocial Care in Pediatric Cancer outline optimal psychosocial care sensitive to these ecological factors, starting with assessment of psychosocial healthcare needs to promote medical and psychosocial outcomes across all children with cancer. To address the first standard of family psychosocial assessment, the Psychosocial Assessment Tool (PAT) is a validated screener ready for broad implementation. METHOD The PAT will be implemented across a national sample of 18 pediatric cancer programs ranging in size (annual new patients) in a mixed methods, comparative effectiveness study, guided by the Interactive Systems Framework for Dissemination and Implementation, comparing two implementation strategies. It is hypothesized that implementation will be more successful at the patient/family, provider, and institutional level when training (strategy I) is combined with implementation expanded resources (strategy II). There are three aims: (1) Refine the two implementation strategies using semi-structured qualitative interviews with 19 stakeholders including parent advocates, providers, pediatric oncology organization representatives, healthcare industry leaders; (2) Compare the two theoretically based and empirically informed strategies to implement the PAT in English and Spanish using a cluster-randomized controlled trial across 18 sites. Stratified by size, sites will be randomized to cohort (3) and strategy (2). Outcomes include adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution); (3) Based on the results of the trial and feedback from the first and second aim, we will develop and disseminate a web-based PAT Implementation Toolkit. DISCUSSION Use of the PAT across children's cancer programs nationally can achieve the assessment standard and inform equitable delivery of psychosocial care matched to family need for all patients. TRIAL REGISTRATION ClinicalTrials.gov , NCT04446728 , registered 23 June 2020.",2020,It is hypothesized that implementation will be more successful at,"['18 pediatric cancer programs ranging in size (annual new patients', 'children with cancer', 'pediatric cancer with the Psychosocial Assessment Tool (PAT']","['PAT', 'Psychosocial Assessment Tool (PAT']","['adoption and penetration of screening (patient/family), staff job satisfaction/burnout (provider), and cost-effective use of resources consistent with family risk (institution']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0332181', 'cui_str': 'Annual'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1455743', 'cui_str': 'Psychosocial assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C1455743', 'cui_str': 'Psychosocial assessment'}, {'cui': 'C0336791', 'cui_str': 'Tool'}]","[{'cui': 'C0001593', 'cui_str': 'Adoption'}, {'cui': 'C0205321', 'cui_str': 'Penetrating'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0022397', 'cui_str': 'Work Satisfaction'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0018704', 'cui_str': 'Healthcare facility'}]",18.0,0.0715876,It is hypothesized that implementation will be more successful at,"[{'ForeName': 'Anne E', 'Initials': 'AE', 'LastName': 'Kazak', 'Affiliation': ""Nemours Children's Health System, Wilmington, DE, USA. anne.kazak@nemours.org.""}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Deatrick', 'Affiliation': 'University of Pennsylvania School of Nursing, Philadelphia, PA, USA.'}, {'ForeName': 'Michele A', 'Initials': 'MA', 'LastName': 'Scialla', 'Affiliation': 'A.I. du Pont Hospital for Children, Wilmington, DE, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Sandler', 'Affiliation': ""Nemours Children's Clinic, Jacksonville, FL, USA.""}, {'ForeName': 'Rebecca E', 'Initials': 'RE', 'LastName': 'Madden', 'Affiliation': ""The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Lamia P', 'Initials': 'LP', 'LastName': 'Barakat', 'Affiliation': ""The Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}]",Implementation science : IS,['10.1186/s13012-020-01023-w'] 2657,32727496,"Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial.","BACKGROUND To evaluate if a combination therapy with micropulse diode laser (MPL) shows non-inferiority on visual acuity (BCVA) within 12 months in comparison to standard therapy, i.e. intravitreal injection of ranibizumab alone. SETTING Institutional. Prospective randomized single-center trial. METHODS Patients with diabetic macular edema (DME) received three intravitreal injections of 0.5 mg ranibizumab during the upload phase and were then randomised 1:1 to receive either the same dosage of ranibizumab (0.5 mg) injections pro re nata alone (IVOM-Group; n = 9), or with two additional treatments with micropulse diode laser (IVOM+Laser-Group; n = 10). The primary endpoint was change in BCVA after 12 months. Secondary endpoints were change in central macular thickness and overall number of ranibizumab injections. RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01). Patients with additional laser treatment had better visual improvement (group comparison p = 0.075) and needed fewer ranibizumab injections (cumulative proportion of injections 9.68 versus 7.46 in IVOM-Group and IVOM+Laser-Group, respectively). CONCLUSION Non-inferiority of combination therapy in comparison to standard therapy alone could be demonstrated. Patients with additional laser therapy needed fewer ranibizumab injections. TRIAL REGISTRATION Registered 10 February 2014 on ClinicalTrials.gov; NCT02059772 .",2020,"RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01).","['Patients with additional laser therapy needed fewer ranibizumab injections', 'diabetic macular edema (ReCaLL', 'Patients with diabetic macular edema (DME']","['ranibizumab alone', 'intravitreal injections of 0.5\u2009mg ranibizumab', 'micropulse diode laser (MPL', 'ranibizumab with micropulse diode laser', 'ranibizumab (0.5\u2009mg) injections pro re nata alone (IVOM-Group; n\u2009=\u20099), or with two additional treatments with micropulse diode laser (IVOM+Laser-Group; n\u2009=\u200910']","['change in central macular thickness and overall number of ranibizumab injections', 'visual acuity (BCVA', 'change in BCVA', 'visual improvement', 'central macular thickness', 'BCVA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0279027', 'cui_str': 'Low power laser therapy'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0205388', 'cui_str': 'Few'}, {'cui': 'C4050112', 'cui_str': 'ranibizumab Injection'}, {'cui': 'C0730285', 'cui_str': 'Macular edema due to diabetes mellitus'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1554888', 'cui_str': 'Intravitreal Injections'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0392254', 'cui_str': 'Semiconductor laser device'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0067792', 'cui_str': 'N-acetyltryptophanamide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C4050112', 'cui_str': 'ranibizumab Injection'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]",,0.230585,"RESULTS BCVA increased significantly in both groups (IVOM: + 5.86, p < 0.001; IVOM+Laser: + 9.30; p < 0.001) with corresponding decrease in central macular thickness (IVOM: - 105 μm, p < 0.01; IVOM+Laser: - 125 μm; p < 0.01).","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Furashova', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany. o.furashova@skc.de.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Strassburger', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany.'}, {'ForeName': 'Klio Ai', 'Initials': 'KA', 'LastName': 'Becker', 'Affiliation': 'Hessemer MVZ, Augenmedizin Darmstadt, Martinspfad 72, 64285, Darmstadt, Germany.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Engelmann', 'Affiliation': 'Department of Ophthalmology, Klinikum Chemnitz gGmbH, Flemmingstrasse 2, 09116, Chemnitz, Germany.'}]",BMC ophthalmology,['10.1186/s12886-020-01576-w'] 2658,32728586,Instrumental music therapy reduced depression levels in stroke patients.,"Background: Stroke is the fifth cause of death and disability, leading also to depression. However, depression in stroke patients is hardly handled optimally. The purpose of this study therefore is to determine the effectiveness of instrumental music therapy in reducing depressive symptoms in stroke patients. Design and methods: It used a quasi-experiment pre-post design with a simple random sampling with 59 respondents. The respondents were divided into 3 groups as follows; group A (standard treatment), group B (instrumental music therapy), and group C (combined treatment). Results: The results show that the combined treatment provided the most significant influence on reducing the level of depression (P=0.001) with a contribution of 68.6% compared to the group A which was given standard treatment (P=0.001) with a contribution of 61.7%. Instrumental music therapy had no effect (P=0.986), though it contributed most among the three interventions, specifically 82.6%. Conclusions: The study recommended further improvement to include music as treatment options for reducing depression among stroke patients.",2020,"Instrumental music therapy had no effect (P=0.986), though it contributed most among the three interventions, specifically 82.6%. ",['stroke patients'],"['Instrumental music therapy', 'instrumental music therapy']","['depression levels', 'level of depression', 'depressive symptoms']","[{'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0026868', 'cui_str': 'Music therapy'}]","[{'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",,0.0278796,"Instrumental music therapy had no effect (P=0.986), though it contributed most among the three interventions, specifically 82.6%. ","[{'ForeName': 'Vione Deisi Oktavina', 'Initials': 'VDO', 'LastName': 'Sumakul', 'Affiliation': 'Doctoral Program of Public Health.'}, {'ForeName': 'Hari Basuki', 'Initials': 'HB', 'LastName': 'Notobroto', 'Affiliation': 'Department of Biostatistics and Population, Faculty of Public Health, Universitas Airlangga, Mulyorejo, Surabaya.'}, {'ForeName': 'Ni Luh', 'Initials': 'NL', 'LastName': 'Widani', 'Affiliation': 'Master of Medical Surgical Nursing, Sint Carolus School of Health Sciences, Jakarta, Indonesia.'}, {'ForeName': 'M Havidz', 'Initials': 'MH', 'LastName': 'Aima', 'Affiliation': 'Master of Medical Surgical Nursing, Sint Carolus School of Health Sciences, Jakarta, Indonesia.'}]",Journal of public health research,['10.4081/jphr.2020.1847'] 2659,32728595,Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial.,"Therapeutic angiogenesis may improve outcomes in patients with coronary artery disease undergoing surgical revascularization. Angiogenic factors may promote blood vessel growth and regenerate regions of ischemic but viable myocardium. Previous clinical trials of vascular endothelial growth factor A (VEGF-A) gene therapy with DNA or viral vectors demonstrated safety but not efficacy. AZD8601 is VEGF-A 165 mRNA formulated in biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression with minimal innate immune response. EPICCURE is an ongoing randomized, double-blind, placebo-controlled study of the safety of AZD8601 in patients with moderately decreased left ventricular function (ejection fraction 30%-50%) undergoing elective coronary artery bypass surgery. AZD8601 3 mg, 30 mg, or placebo is administered as 30 epicardial injections in a 10-min extension of cardioplegia. Injections are targeted to ischemic but viable myocardial regions in each patient using quantitative 15 O-water positron emission tomography (PET) imaging (stress myocardial blood flow < 2.3 mL/g/min; resting myocardial blood flow > 0.6 mL/g/min). Improvement in regional and global myocardial blood flow quantified with 15 O-water PET is an exploratory efficacy outcome, together with echocardiographic, clinical, functional, and biomarker measures. EPICCURE combines high-efficiency delivery with quantitative targeting and follow-up for robust assessment of the safety and exploratory efficacy of VEGF-A mRNA angiogenesis (ClinicalTrials.gov: NCT03370887).",2020,Previous clinical trials of vascular endothelial growth factor A (VEGF-A) gene therapy with DNA or viral vectors demonstrated safety but not efficacy.,"['patients with coronary artery disease undergoing surgical revascularization', 'Patients', 'Undergoing Coronary Artery Bypass Grafting', 'patients with moderately decreased left ventricular function (ejection fraction 30%-50%) undergoing elective coronary artery bypass surgery']","['AZD8601', 'placebo']",['regional and global myocardial blood flow'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0242698', 'cui_str': 'Impaired left ventricular function'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}]",,0.245831,Previous clinical trials of vascular endothelial growth factor A (VEGF-A) gene therapy with DNA or viral vectors demonstrated safety but not efficacy.,"[{'ForeName': 'Vesa', 'Initials': 'V', 'LastName': 'Anttila', 'Affiliation': 'Heart Center, Turku University Hospital and University of Turku, Turku, Finland.'}, {'ForeName': 'Antti', 'Initials': 'A', 'LastName': 'Saraste', 'Affiliation': 'Heart Center, Turku University Hospital and University of Turku, Turku, Finland.'}, {'ForeName': 'Juhani', 'Initials': 'J', 'LastName': 'Knuuti', 'Affiliation': 'Turku PET Center, Turku University Hospital and University of Turku, Turku, Finland.'}, {'ForeName': 'Pekka', 'Initials': 'P', 'LastName': 'Jaakkola', 'Affiliation': 'Heart Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Marja', 'Initials': 'M', 'LastName': 'Hedman', 'Affiliation': 'Heart Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Svedlund', 'Affiliation': 'Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Lagerström-Fermér', 'Affiliation': 'Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Kjaer', 'Affiliation': 'Early Biometrics and Statistical Innovation, Data Science & AI, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Jeppsson', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Li-Ming', 'Initials': 'LM', 'LastName': 'Gan', 'Affiliation': 'Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.'}]",Molecular therapy. Methods & clinical development,['10.1016/j.omtm.2020.05.030'] 2660,32728626,"Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study.","Aim of the study Chronic hepatitis C (CHC) affects more than 71 million people worldwide. Many therapies containing different direct-acting antivirals (DAAs) are now used. However, lipid profile is considered an important outcome with DAAs. So, this study aimed to assess clinical effects of statins in CHC patients. Material and methods One hundred patients were recruited from Kobri El koba Armed Forces Hospital and randomly assigned to: the drug group (D; n = 50) receiving simvastatin 10 mg plus sofosbuvir 400 mg/daclatasvir 60 mg (SOF/DAC) daily for 12 weeks; and the placebo group (P; n = 50), receiving placebo plus the same (SOF/DAC) regimen. Sustained virological response at 12 weeks after treatment (SVR12), lipid profile, C-reactive protein (CRP) and fibrosis stage were assessed. Results One hundred treatment-naïve CHC patients completed 12 weeks of the protocol with no clinically significant side effects. There was an increase in SVR failure rate in P (10%) compared to D (only 2%) but not reaching statistical significant difference; SVR12 ( p > 0.05). Logistic regression analysis showed that high baseline CRP, low baseline hemoglobin level and non-statin usage had an independent effect on increasing the probability of SVR failure in both groups; p = 0.03, p = 0.0028, p = 0.02, respectively. Conclusions Statins could have an irreplaceable role in successful treatment of CHC patients receiving sofosbuvir/daclatasvir.",2020,There was an increase in SVR failure rate in P (10%) compared to D (only 2%) but not reaching statistical significant difference; SVR12 ( p > 0.05).,"['Material and methods\n\n\nOne hundred patients were recruited from Kobri El koba Armed Forces Hospital and randomly assigned to: the drug group (D; n = 50) receiving', 'chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination', 'CHC patients', 'CHC patients receiving sofosbuvir/daclatasvir', '71 million people worldwide']","['simvastatin', 'simvastatin 10 mg plus sofosbuvir 400 mg/daclatasvir 60 mg (SOF/DAC', 'placebo plus the same (SOF/DAC) regimen', 'placebo']","['probability of SVR failure', 'Sustained virological response', 'lipid profile, C-reactive protein (CRP) and fibrosis stage', 'SVR failure rate']","[{'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026126', 'cui_str': 'Military personnel'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0524910', 'cui_str': 'Chronic hepatitis C'}, {'cui': 'C2976303', 'cui_str': 'sofosbuvir'}, {'cui': 'C3252090', 'cui_str': 'daclatasvir'}, {'cui': 'C1881839', 'cui_str': '1000000'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0074554', 'cui_str': 'Simvastatin'}, {'cui': 'C0989914', 'cui_str': 'Simvastatin 10 MG'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C3696663', 'cui_str': 'sofosbuvir 400 MG'}, {'cui': 'C4046943', 'cui_str': 'daclatasvir 60 MG [Daklinza]'}, {'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}]","[{'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1258192', 'cui_str': 'Systemic vascular resistance'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205466', 'cui_str': 'Virologic'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0016059', 'cui_str': 'Fibrosis'}, {'cui': 'C0205390', 'cui_str': 'Phase'}]",100.0,0.46228,There was an increase in SVR failure rate in P (10%) compared to D (only 2%) but not reaching statistical significant difference; SVR12 ( p > 0.05).,"[{'ForeName': 'Hossam Z', 'Initials': 'HZ', 'LastName': 'Mohamed', 'Affiliation': 'Hepatology Department, Kobri El koba Armed Forces Hospital, Cairo, Egypt.'}, {'ForeName': 'Nagwa A', 'Initials': 'NA', 'LastName': 'Sabri', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Hossam M', 'Initials': 'HM', 'LastName': 'Zaki', 'Affiliation': 'Hepatology Department, Kobri El koba Armed Forces Hospital, Cairo, Egypt.'}, {'ForeName': 'Sara M', 'Initials': 'SM', 'LastName': 'Shaheen', 'Affiliation': 'Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.'}]",Clinical and experimental hepatology,['10.5114/ceh.2020.95566'] 2661,32728734,Using an Adjunctive Treatment to Address Psychological Distress in a National Weight Management Program: Results of an Integrated Pilot Study.,"INTRODUCTION Obesity is highly comorbid with psychological symptoms in veterans, particularly post-traumatic stress disorder (PTSD), depression, and anxiety. Obese veterans with comorbid psychological symptoms often display suboptimal weight loss and poor physical functioning when participating in weight management programs. The MOVE! program aims to increase healthy eating and physical activity to promote weight loss in obese veterans. Adequately addressing psychological barriers is necessary to maximize outcomes in MOVE! for veterans with PTSD, depression, and anxiety. We examined the preliminary outcomes of administering the Healthy Emotions and Improving Health BehavioR Outcomes (HERO) intervention. HERO is adjunctive cognitive-behavioral therapy to MOVE! that addresses PTSD, depression, and anxiety symptom barriers to engagement in physical activity. MATERIALS AND METHODS All recruitment and study procedures were approved by the institutional review board and research and development committees of the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine in Houston, Texas. Participants gave written informed consent before enrollment. Thirty-four obese veterans with a diagnosis of PTSD, depression, and/or anxiety who were attending MOVE! were assigned to the 8-session HERO group or the usual care (UC) group. Veterans completed assessments of PTSD, depression and anxiety symptoms, physical activity, physical functioning, and weight at baseline, 8 and 16 weeks post treatment. Changes from baseline to 8- and 16-week follow-up on the self-report and clinician-rated measures were assessed, using independent samples t-tests and analyses of covariance. RESULTS At 8 weeks post treatment, participants in the HERO group had significantly higher step counts per day than participants in the UC group. Similarly, at 16 weeks post-treatment, participants in the HERO group continued to experience a significant increase in daily steps taken per day, as well as statistically and clinically significantly lower scores on the depression symptom and PTSD symptom severity. Participants in the HERO group also demonstrated significantly higher scores on the physical functioning inventory than participants in the UC group (44.1 ± 12.1 vs. 35.7 ± 10.7, P = 0.04) at 16 weeks post treatment. CONCLUSIONS Findings of this small trial have important implications pending replication in a more rigorously designed large-scale study. Providing an adjunctive treatment to MOVE! that addresses psychological distress has potential benefits for psychological symptom reduction, engagement in healthy dietary habits, and greater physical activity for individuals who traditionally experience barriers to making positive weight management changes.",2020,"At 8 weeks post treatment, participants in the HERO group had significantly higher step counts per day than participants in the UC group.","['Thirty-four obese veterans with a diagnosis of PTSD, depression, and/or anxiety who were attending MOVE', 'Psychological Distress in a National Weight Management Program', 'All recruitment and study procedures were approved by the institutional review board and research and development committees of the Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine in Houston, Texas', 'Obese veterans with comorbid psychological symptoms often display suboptimal weight loss and poor physical functioning when participating in weight management programs', 'obese veterans', 'veterans with PTSD, depression, and anxiety']","['HERO', '8-session HERO group or the usual care (UC']","['Health BehavioR', 'PTSD, depression and anxiety symptoms, physical activity, physical functioning, and weight', 'physical functioning inventory', 'healthy eating and physical activity', 'daily steps', 'depression symptom and PTSD symptom severity']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0815107', 'cui_str': 'Emotional Distress'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C4273558', 'cui_str': 'Weight management program'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205540', 'cui_str': 'Approved'}, {'cui': 'C0086911', 'cui_str': 'Ethics Committee, Research'}, {'cui': 'C0035170', 'cui_str': 'Research and Development'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039711', 'cui_str': 'Texas'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0452415', 'cui_str': 'Healthy diet'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity'}]",,0.0176149,"At 8 weeks post treatment, participants in the HERO group had significantly higher step counts per day than participants in the UC group.","[{'ForeName': 'Gina', 'Initials': 'G', 'LastName': 'Evans-Hudnall', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, (MEDVAMC 152), 2002 Holcombe Blvd., Houston, TX 77030.'}, {'ForeName': 'Mary O', 'Initials': 'MO', 'LastName': 'Odafe', 'Affiliation': 'Department of Clinical Psychology, University of Houston, Heyne building # 126, Houston, TX 77204.'}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'Johnson', 'Affiliation': 'William S. Middleton Veterans Affairs Hospital, 2500 Overlook Terrace, Madison, WI 53705.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Armenti', 'Affiliation': 'Department of Clinical Psychology, University of Houston, Heyne building # 126, Houston, TX 77204.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': ""O'Neil"", 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, One Baylor Plaza, Baylor College of Medicine, Houston, TX 77030.'}, {'ForeName': 'Evan', 'Initials': 'E', 'LastName': 'Lawson', 'Affiliation': 'Department of Counseling Psychology, University of North Texas, 1155 Union Circle #311280, Denton, Texas 76203-5017.'}, {'ForeName': 'Lisa H', 'Initials': 'LH', 'LastName': 'Trahan', 'Affiliation': 'Trahan Counseling, 631 Mill Street, Suite 101 San Marcos, Texas 78666.'}, {'ForeName': 'Fenan S', 'Initials': 'FS', 'LastName': 'Rassu', 'Affiliation': 'Department of Psychiatry and Behavioral Medicine, One Baylor Plaza, Baylor College of Medicine, Houston, TX 77030.'}]",Military medicine,['10.1093/milmed/usaa145'] 2662,32728763,Anthropometric Aspects in the Breast Augmentation.,"BACKGROUND Studies have demonstrated the importance of anthropometric measurements of the breasts, based on linear measurements for the selection of the volume of breast implants, their positioning, and surgical planning. OBJECTIVES The objective of this study is to evaluate the main changes in anthropometric measurements in breast augmentation. METHODS A prospective, randomized clinical study with 74 female candidates for breast augmentation. All the individuals were split into five groups, according to the implant volume. The implants used were of different textures, from three different brands (LifeSil, Politech, and Silimed). The following measures were taken: distance from the nipple to the inframammary fold (N-IMF), inter-nipple-areolar complex distance (N-N), distance from the Sternal notch to the Nipple (SN-N), areola diameter, and breast projection. RESULTS The most significant breast anthropometric alteration after mammoplasty was the N-IMF distance; that is, an expansion of the lower pole of the breast, followed by an increase in the areolar diameter. Mostly of measurements showed stability between 3rd and 6th months after the surgery. The projection was the most interesting measure due to presenting two patterns of behavior according to the analysis criteria performed. When comparing the implant projection and the final breast projection, it was observed that the implant profile represented a 27% increase in the final breast projection. CONCLUSIONS This study provides an essential comparative analysis between anthropometric changes in breast augmentations and serves as a predictive tool in the preoperative evaluation of the patient during surgical planning. LEVEL OF EVIDENCE IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .",2020,"When comparing the implant projection and the final breast projection, it was observed that the implant profile represented a 27% increase in the final breast projection. ",['74 female candidates for breast augmentation'],['IV'],"['nipple to the inframammary fold (N-IMF), inter-nipple-areolar complex distance (N-N), distance from the Sternal notch to the Nipple (SN-N), areola diameter, and breast projection']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0191925', 'cui_str': 'Augmentation mammoplasty'}]",[],"[{'cui': 'C0028109', 'cui_str': 'Nipple structure'}, {'cui': 'C0442099', 'cui_str': 'Inframammary'}, {'cui': 'C0185026', 'cui_str': 'Plication'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205316', 'cui_str': 'Notched'}, {'cui': 'C0222608', 'cui_str': 'Areola structure'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0016538', 'cui_str': 'Projections and Predictions'}]",74.0,0.034736,"When comparing the implant projection and the final breast projection, it was observed that the implant profile represented a 27% increase in the final breast projection. ","[{'ForeName': 'Luiz', 'Initials': 'L', 'LastName': 'Charles-de-Sá', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, Training and Research, State University of Rio de Janeiro- UERJ-RJ, Av. Joana Angélica, 124/602, Ipanema, Rio de Janeiro-Rj-Cep, 22420-030, Brazil. clinicaperforma@uol.com.br.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'de Aguiar Valladão', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, Training and Research, State University of Rio de Janeiro- UERJ-RJ, Av. Joana Angélica, 124/602, Ipanema, Rio de Janeiro-Rj-Cep, 22420-030, Brazil.'}, {'ForeName': 'Diogo Maciel Lobão', 'Initials': 'DML', 'LastName': 'Vieira', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, Training and Research, State University of Rio de Janeiro- UERJ-RJ, Av. Joana Angélica, 124/602, Ipanema, Rio de Janeiro-Rj-Cep, 22420-030, Brazil.'}, {'ForeName': 'José Horácio', 'Initials': 'JH', 'LastName': 'Aboudib', 'Affiliation': 'Department of Plastic, Reconstructive and Aesthetic Surgery, Training and Research, State University of Rio de Janeiro- UERJ-RJ, Av. Joana Angélica, 124/602, Ipanema, Rio de Janeiro-Rj-Cep, 22420-030, Brazil.'}]",Aesthetic plastic surgery,['10.1007/s00266-020-01853-5'] 2663,32728814,"Isotretinoin plus 420 nm intense pulsed light versus isotretinoin alone for the treatment of acne vulgaris: a randomized, controlled study of efficacy, safety, and patient satisfaction in Chinese subjects.","Either isotretinoin or intense pulsed light (IPL) proved to be effective to alleviate acne lesions, but the combined treatment has rarely been reported. The study aimed to evaluate the efficacy, safety, and patient satisfaction of isotretinoin and 420 nm IPL combined treatment. Forty-seven patients with facial acne with Global Evaluation Acne (GEA) graded 2-4 were randomized into study group and control group. The patients in the control group received oral isotretinoin for 8 weeks. The patients in the study group were treated with oral isotretinoin for 8 weeks, together with a biweekly 420 nm IPL treatment for 4 weeks. Topical agents included adapalene and fusidic acid. Efficacy was evaluated using digital photographies taken at baseline and week 12 by an independent dermatologist, including GEA grade, lesion count, lesion reduction percentage, and effective rate. All patients completed a questionnaire about dermatology life quality index (DLQI) and satisfaction visual analog scale (VAS) on week 12, and were followed up for another 2 months. Adverse events were recorded. The patients in the study group experienced significant reduction in GEA grade, total lesions, and inflammatory lesions on week 12, compared with the control group (p < 0.05). The patients in the study group reported lower DLQI and higher VAS satisfaction (p < 0.05) and experienced lower incidence of relapse (p < 0.05). No severe adverse event was identified in both groups. Compared with isotretinoin alone, isotretinoin and 420 nm IPL combined treatment proved to be more effective within limited treatment duration. It was well-tolerated and the patients' satisfaction was high.",2020,The patients in the study group reported lower DLQI and higher VAS satisfaction (p < 0.05) and experienced lower incidence of relapse (p < 0.05).,"['Forty-seven patients with facial acne with Global Evaluation Acne (GEA) graded 2-4', 'Chinese subjects', 'acne vulgaris']","['Isotretinoin plus 420\xa0nm intense pulsed light versus isotretinoin alone', 'isotretinoin or intense pulsed light (IPL', 'isotretinoin alone, isotretinoin', 'adapalene and fusidic acid', 'oral isotretinoin']","['Adverse events', 'severe adverse event', 'GEA grade, lesion count, lesion reduction percentage, and effective rate', 'GEA grade, total lesions, and inflammatory lesions', 'incidence of relapse', 'Efficacy', 'questionnaire about dermatology life quality index (DLQI) and satisfaction visual analog scale (VAS', 'efficacy, safety, and patient satisfaction', 'lower DLQI and higher VAS satisfaction']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0022265', 'cui_str': 'Isotretinoin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C4517774', 'cui_str': '420'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C0165631', 'cui_str': 'adapalene'}, {'cui': 'C0016875', 'cui_str': 'fusidic acid'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1519275', 'cui_str': 'Common terminology criteria for adverse events grade 3'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3872830', 'cui_str': 'Inflammatory lesion'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451112', 'cui_str': 'Dermatology life quality index'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205250', 'cui_str': 'High'}]",47.0,0.0237701,The patients in the study group reported lower DLQI and higher VAS satisfaction (p < 0.05) and experienced lower incidence of relapse (p < 0.05).,"[{'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': ""Department of Dermatology and Venerology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.""}, {'ForeName': 'Jiangting', 'Initials': 'J', 'LastName': 'Zhu', 'Affiliation': ""Department of Dermatology and Venerology, The First Affiliated Hospital of Chengdu Medical College, 278 Baoguang Ave, Chengdu, 610041, Sichuan, People's Republic of China.""}, {'ForeName': 'Yunjie', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': ""Department of Dermatology and Venerology, The First Affiliated Hospital of Chengdu Medical College, 278 Baoguang Ave, Chengdu, 610041, Sichuan, People's Republic of China.""}, {'ForeName': 'Xiarong', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': ""Department of Dermatology and Venerology, The First Affiliated Hospital of Chengdu Medical College, 278 Baoguang Ave, Chengdu, 610041, Sichuan, People's Republic of China.""}, {'ForeName': 'Junru', 'Initials': 'J', 'LastName': 'Ye', 'Affiliation': ""Department of Dermatology and Venerology, The First Affiliated Hospital of Chengdu Medical College, 278 Baoguang Ave, Chengdu, 610041, Sichuan, People's Republic of China. dryejunru@163.com.""}]",Lasers in medical science,['10.1007/s10103-020-03113-z'] 2664,32728819,Immediate effects of neurodynamic nerve gliding versus static stretching on hamstring neuromechanical properties.,"PURPOSE We investigated the immediate effects of neurodynamic nerve gliding (ND) on hamstring flexibility, viscoelasticity, and mechanosensitivity, compared with traditional static stretching (ST). METHODS Twenty-two physically active men aged 21.9 ± 1.9 years were divided randomly into two equal intervention groups using ST or ND. An isokinetic dynamometer was used to measure the active knee joint position sense, perform passive knee extension, record the passive extension range of motion (ROM) and the passive-resistive torque of hamstrings. Stiffness was determined from the slope of the passive torque-angle relationship. A stress relaxation test (SRT) was performed to analyze the viscoelastic behavior of the hamstrings. The passive straight leg raise (SLR) test was used to evaluate hamstring flexibility. RESULTS A significant interaction was observed for ROM and passive ultimate stiffness, reflected by an increase in these indicators after ND but not after SD. SLR increased significantly in both groups. After ST, a significantly faster initial stress relaxation was observed over the first 4 s. than after ND. There was no significant change in the active knee joint position sense. CONCLUSIONS ND provided a slightly greater increase in hamstring extensibility and passive stiffness, possibly by decreasing nerve tension and increasing strain in connective tissues than ST. The ST mostly affected the viscoelastic behavior of the hamstrings, but neither intervention had a significant impact on proprioception.",2020,"A significant interaction was observed for ROM and passive ultimate stiffness, reflected by an increase in these indicators after ND but not after SD.",['Twenty-two physically active men aged 21.9\u2009±\u20091.9\xa0years'],"['stress relaxation test (SRT', 'ST or ND', 'neurodynamic nerve gliding versus static stretching', 'traditional static stretching (ST', 'neurodynamic nerve gliding (ND']","['hamstring neuromechanical properties', 'ROM and passive ultimate stiffness', 'SLR', 'hamstring flexibility, viscoelasticity, and mechanosensitivity', 'hamstring extensibility and passive stiffness', 'initial stress relaxation', 'viscoelastic behavior', 'proprioception', 'active knee joint position sense']","[{'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0556453', 'cui_str': 'Physically active'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0270814', 'cui_str': 'Spastic syndrome'}, {'cui': 'C0000741', 'cui_str': 'Abducens nerve structure'}, {'cui': 'C0336966', 'cui_str': 'Gliding'}, {'cui': 'C1720875', 'cui_str': 'Static Stretching'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0871161', 'cui_str': 'Property'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0427008', 'cui_str': 'Stiffness'}, {'cui': 'C0422926', 'cui_str': 'Straight leg raise test response'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0033499', 'cui_str': 'Proprioception'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0022745', 'cui_str': 'Knee joint structure'}, {'cui': 'C0234219', 'cui_str': 'Postural sense'}]",22.0,0.0127856,"A significant interaction was observed for ROM and passive ultimate stiffness, reflected by an increase in these indicators after ND but not after SD.","[{'ForeName': 'Danguole', 'Initials': 'D', 'LastName': 'Satkunskiene', 'Affiliation': 'Institute of Sports Science and Innovation, Lithuanian Sports University, Sporto g. 6, 44221, Kaunas, Lithuania.'}, {'ForeName': ""Ra'ad M"", 'Initials': 'RM', 'LastName': 'Khair', 'Affiliation': 'Institute of Sports Science and Innovation, Lithuanian Sports University, Sporto g. 6, 44221, Kaunas, Lithuania.'}, {'ForeName': 'Pornpimol', 'Initials': 'P', 'LastName': 'Muanjai', 'Affiliation': 'Faculty of Allied Health Sciences, Burapha University, Chonburi, Thailand.'}, {'ForeName': 'Mantas', 'Initials': 'M', 'LastName': 'Mickevicius', 'Affiliation': 'Institute of Sports Science and Innovation, Lithuanian Sports University, Sporto g. 6, 44221, Kaunas, Lithuania. mantas.mickevicius@lsu.lt.'}, {'ForeName': 'Sigitas', 'Initials': 'S', 'LastName': 'Kamandulis', 'Affiliation': 'Institute of Sports Science and Innovation, Lithuanian Sports University, Sporto g. 6, 44221, Kaunas, Lithuania.'}]",European journal of applied physiology,['10.1007/s00421-020-04422-5'] 2665,32729065,Postoperative respiratory state assessment using the Integrated Pulmonary Index (IPI) and resultant nurse interventions in the post-anesthesia care unit: a randomized controlled trial.,"Although postoperative adverse respiratory events, defined by a decrease in respiratory rate (RR) and/or a drop in oxygen saturation (SpO 2 ), occur frequently, many of such events are missed. The purpose of the current study was to assess whether continuous monitoring of the integrated pulmonary index (IPI), a composite index of SpO 2 , RR, end-tidal PCO 2 and heart rate, alters our ability to identify and prevent adverse respiratory events in postoperative patients. Eighty postoperative patients were subjected to continuous respiratory monitoring during the first postoperative night using RR and pulse oximetry and the IPI monitor. Patients were randomized to receive intervention based on standard care (observational) or based on the IPI monitor (interventional). Nurses were asked to respond to adverse respiratory events with an intervention to improve the patient's respiratory condition. There was no difference in the number of patients that experienced at least one adverse respiratory event: 21 and 16 in observational and interventional group, respectively (p = 0.218). Compared to the observational group, the use of the IPI monitor led to an increase in the number of interventions performed by nurses to improve the respiratory status of the patient (average 13 versus 39 interventions, p < 0.001). This difference was associated with a significant reduction of the median number of events per patient (2.5 versus 6, p < 0.05) and a shorter median duration of events (62 s versus 75 s, p < 0.001). The use of the IPI monitor in postoperative patients did not result in a reduction of the number of patients experiencing adverse respiratory events, compared to standard clinical care. However, it did lead to an increased number of nurse interventions and a decreased number and duration of respiratory events in patients that experienced postoperative adverse respiratory events.",2020,"Compared to the observational group, the use of the IPI monitor led to an increase in the number of interventions performed by nurses to improve the respiratory status of the patient (average 13 versus 39 interventions, p < 0.001).","['Eighty postoperative patients', 'postoperative patients']","['intervention based on standard care (observational) or based on the IPI monitor (interventional', 'Postoperative respiratory state assessment using the Integrated Pulmonary Index (IPI) and resultant nurse interventions']","['respiratory rate (RR) and/or a drop in oxygen saturation', 'shorter median duration of events', 'number of nurse interventions', 'median number of events per patient', 'number and duration of respiratory events']","[{'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030695', 'cui_str': 'Monitoring of patient'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}]","[{'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C1321095', 'cui_str': 'Drop - unit of product usage'}, {'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1320717', 'cui_str': 'Respiratory event'}]",80.0,0.0433942,"Compared to the observational group, the use of the IPI monitor led to an increase in the number of interventions performed by nurses to improve the respiratory status of the patient (average 13 versus 39 interventions, p < 0.001).","[{'ForeName': 'Suzanne J L', 'Initials': 'SJL', 'LastName': 'Broens', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Prins', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Dorinne', 'Initials': 'D', 'LastName': 'de Kleer', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'Niesters', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Albert', 'Initials': 'A', 'LastName': 'Dahan', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'van Velzen', 'Affiliation': 'Anesthesia and Pain Research Unit, Department of Anesthesiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands. m.van_velzen@lumc.nl.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-020-00564-1'] 2666,32729099,Renal protective effect of N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy-induced renal injury: a prospective randomized trial.,"PURPOSE To evaluate the role of combination of N-acetylcysteine with stepwise ramping voltage in renal protection against the ischemic, vascular and oxidative effects of extracorporeal shock wave lithotripsy. PATIENTS AND METHODS A prospective randomized trial on 164 adult patients scheduled for ESWL for single renal stones. Patients with radio-lucent stones, diabetes, hypertension, febrile UTI, and preoperative albuminuria were excluded from the study. Patients were randomized into one of four groups. Group A patients received maximal fixed voltage of ESWL. Group B patients received stepwise ramping voltage of ESWL. Group C patients received fixed maximal voltage with N-acetylcysteine (NAC) 600 mg/bid from 48 h before to 24 h after the procedure. Group D patients received gradual ramping voltage with NAC. Urinary β 2 -microglobulin, 24 h albumin and N-acetyl-β-D-glucosaminidase/creatinine ratio at 1 day and 5 days post-ESWL and the stone free rate at 2 weeks were measured. RESULTS Group D was the only group that showed no significant difference pre and post ESWL in urinary albumin, β 2 -microglobulin and N-acetyl-β-D-glucosaminidase/creatinine ratio. Post hoc analysis revealed no significant difference between group B and group C in albumin, β 2 -microglobulin N-acetyl-β-D-glucosaminidase/creatinine ratio, but both of them had significantly lower levels than group A and significantly higher levels than group D. There was no statistically significant difference between all groups in the stone free rate at 2 weeks. CONCLUSION N-acetylcysteine protects the kidney against ESWL-induced renal injuries especially if combined with stepwise ramping voltage.",2020,"Post hoc analysis revealed no significant difference between group B and group C in albumin, β 2 -microglobulin N-acetyl-β-D-glucosaminidase/creatinine ratio, but both of them had significantly lower levels than group A and significantly higher levels than group D.","['Patients with radio-lucent stones, diabetes, hypertension, febrile UTI, and preoperative albuminuria were excluded from the study', 'induced renal injury', '164 adult patients scheduled for ESWL for single renal stones']","['N-acetylcysteine with stepwise ramping voltage', 'fixed maximal voltage with N-acetylcysteine (NAC', 'maximal fixed voltage of ESWL', 'stepwise ramping voltage of ESWL', 'N-acetylcysteine with stepwise ramping voltage against extracorporeal shock wave lithotripsy', 'extracorporeal shock wave lithotripsy', 'gradual ramping voltage with NAC']","['albumin, β 2 -microglobulin N-acetyl-β-D-glucosaminidase/creatinine ratio', 'post ESWL in urinary albumin, β 2 -microglobulin and N-acetyl-β-D-glucosaminidase/creatinine ratio', 'stone free rate', 'Urinary β 2 -microglobulin, 24\xa0h albumin and N-acetyl-β-D-glucosaminidase/creatinine ratio']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034546', 'cui_str': 'Radio'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0015967', 'cui_str': 'Fever'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal shockwave lithotripsy'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0022650', 'cui_str': 'Kidney stone'}]","[{'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}, {'cui': 'C0034646', 'cui_str': 'Ramp'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal shockwave lithotripsy'}, {'cui': 'C0439833', 'cui_str': 'Gradual'}]","[{'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0017724', 'cui_str': 'Glucosaminidase'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0015359', 'cui_str': 'Extracorporeal shockwave lithotripsy'}, {'cui': 'C0006736', 'cui_str': 'Calculus'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",164.0,0.0558888,"Post hoc analysis revealed no significant difference between group B and group C in albumin, β 2 -microglobulin N-acetyl-β-D-glucosaminidase/creatinine ratio, but both of them had significantly lower levels than group A and significantly higher levels than group D.","[{'ForeName': 'Esam A E', 'Initials': 'EAE', 'LastName': 'Desoky', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Sakr', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Alhefnawy', 'Affiliation': 'Urology Department, Faculty of Medicine, Benha University, Benha, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Omran', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Mohamed M H', 'Initials': 'MMH', 'LastName': 'Abdalla', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Ashraf S', 'Initials': 'AS', 'LastName': 'Shahin', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.'}, {'ForeName': 'Maged M', 'Initials': 'MM', 'LastName': 'Ali', 'Affiliation': 'Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt. dr_magood@hotmail.com.'}]",International urology and nephrology,['10.1007/s11255-020-02580-1'] 2667,32729105,Expectations and Preferences for Psychotherapy Among African American and White Young Adults.,"OBJECTIVES This study examined beliefs, expectations, and preferences related to mental health problems and treatment in a sample of young adults who are in a developmental period when many types of psychopathology emerge. Prior studies on this topic have primarily included samples that are older and predominately White. It is not clear whether results from that research generalize to diverse samples of young adults. METHODS Participants were 370 undergraduate students (41.3% African American; 76.5% female) who completed questionnaires about expectations and preferences for psychotherapy and therapists. RESULTS Findings regarding racial differences include African Americans having less experience with mental health services and different goals for psychotherapy than did Whites. Additionally, African Americans, relative to Whites, demonstrated stronger preferences for couple, family, and group psychotherapy, a male therapist their same race, and a therapist who is assertive and structured in session. CONCLUSIONS The results of this study provide information about young adults' perceptions, expectations, and preferences related to mental health problems and psychotherapy. Findings suggest some barriers to treatment that might be addressed to improve treatment engagement and utilization of psychological services among young adults in general and among African American young adults specifically.",2020,"Additionally, African Americans, relative to Whites, demonstrated stronger preferences for couple, family, and group psychotherapy, a male therapist their same race, and a therapist who is assertive and structured in session. ","['Participants were 370 undergraduate students (41.3% African American; 76.5% female) who completed questionnaires about expectations and preferences for psychotherapy and therapists', 'African American and White Young Adults', 'young adults', 'young adults who are in a developmental period when many types of psychopathology emerge']",[],[],"[{'cui': 'C4517743', 'cui_str': '370'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C4517770', 'cui_str': '41.3'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0033968', 'cui_str': 'Psychotherapy'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0458003', 'cui_str': 'Developmental'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}]",[],[],370.0,0.0241878,"Additionally, African Americans, relative to Whites, demonstrated stronger preferences for couple, family, and group psychotherapy, a male therapist their same race, and a therapist who is assertive and structured in session. ","[{'ForeName': 'Nora E', 'Initials': 'NE', 'LastName': 'Charles', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA. nora.charles@usm.edu.'}, {'ForeName': 'Taylor R', 'Initials': 'TR', 'LastName': 'Rodriguez', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA.'}, {'ForeName': 'Margaret R', 'Initials': 'MR', 'LastName': 'Bullerjahn', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA.'}, {'ForeName': 'LaQuitta', 'Initials': 'L', 'LastName': 'Simpson', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA.'}, {'ForeName': 'Latisha M', 'Initials': 'LM', 'LastName': 'Swygert', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA.'}, {'ForeName': 'Jacob A', 'Initials': 'JA', 'LastName': 'Finn', 'Affiliation': 'Extended Care & Rehabilitation Service Line, Minneapolis VA Health Care System, Minneapolis, MN, USA.'}, {'ForeName': 'Joye C', 'Initials': 'JC', 'LastName': 'Anestis', 'Affiliation': 'School of Psychology, The University of Southern Mississippi, 118 College Dr., #5025, Hattiesburg, MS, 39406, USA.'}]",Journal of racial and ethnic health disparities,['10.1007/s40615-020-00827-2'] 2668,32729120,"The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol.","OBJECTIVE Interest in the use of cannabidiol (CBD) is increasing worldwide as its therapeutic effects are established and legal restrictions moderated. Unlike Δ 9 -tetrahydrocannabinol (Δ 9 -THC), CBD does not appear to cause cognitive or psychomotor impairment. However, further assessment of its effects on cognitively demanding day-to-day activities, such as driving, is warranted. Here, we describe a study investigating the effects of CBD on simulated driving and cognitive performance. METHODS Thirty healthy individuals will be recruited to participate in this randomised, double-blind, placebo-controlled crossover trial. Participants will complete four research sessions each involving two 30-min simulated driving performance tests completed 45 and 210 min following oral ingestion of placebo or 15, 300, or 1,500 mg CBD. Cognitive function and subjective drug effects will be measured, and blood and oral fluid sampled, at regular intervals. Oral fluid drug testing will be performed using the Securetec DrugWipe® 5S and Dräger DrugTest® 5000 devices to determine whether CBD increases the risk of ""false-positive"" roadside tests to Δ 9 -THC. Noninferiority analyses will test the hypothesis that CBD is no more impairing than placebo. CONCLUSION This study will clarify the risks involved in driving following CBD use and assist in ensuring the safe use of CBD by drivers.",2020,"Participants will complete four research sessions each involving two 30-min simulated driving performance tests completed 45 and 210 min following oral ingestion of placebo or 15, 300, or 1,500 mg CBD.",['Thirty healthy individuals'],"['cannabidiol (CBD', 'cannabidiol', 'CBD', 'placebo']","['simulated car driving performance', 'Cognitive function and subjective drug effects']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0004381', 'cui_str': 'Automobile'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0728866', 'cui_str': 'drug effects'}]",30.0,0.520948,"Participants will complete four research sessions each involving two 30-min simulated driving performance tests completed 45 and 210 min following oral ingestion of placebo or 15, 300, or 1,500 mg CBD.","[{'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'McCartney', 'Affiliation': 'Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Benson', 'Affiliation': 'Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Anastasia S', 'Initials': 'AS', 'LastName': 'Suraev', 'Affiliation': 'Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Irwin', 'Affiliation': 'School of Allied Health Sciences, Griffith University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Thomas R', 'Initials': 'TR', 'LastName': 'Arkell', 'Affiliation': 'Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ronald R', 'Initials': 'RR', 'LastName': 'Grunstein', 'Affiliation': 'Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Camilla M', 'Initials': 'CM', 'LastName': 'Hoyos', 'Affiliation': 'Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Iain S', 'Initials': 'IS', 'LastName': 'McGregor', 'Affiliation': 'Lambert Initiative for Cannabinoid Therapeutics, The University of Sydney, Sydney, New South Wales, Australia.'}]",Human psychopharmacology,['10.1002/hup.2749'] 2669,32729141,Comparison of surgical outcomes using Gyrus PKS™ vs LigaSure™ in total laparoscopic hysterectomy: A randomised controlled trial.,"BACKGROUND Advanced vessel sealing devices are widely used in laparoscopic surgery. However, there remains a lack of adequately powered trials comparing laparoscopic advanced vessel sealing devices in the clinical setting, especially in gynaecology. AIMS This single-blinded randomised controlled trial aims to compare the surgical outcomes of total laparoscopic hysterectomy (TLH) using either the Gyrus PKS™ LYONS dissecting forceps or the LigaSure™ Maryland jaw vessel sealer/divider. MATERIALS AND METHODS Women who required TLHs for benign indications were randomised to having their surgeries performed using either Gyrus PKS™ or LigaSure™. Time to haemostasis (from initial skin incision to detachment of the uterus with secured haemostasis) was the primary outcome; a 20% difference in time was considered clinically significant. Secondary outcomes measured were intra-operative blood loss, complications, conversions, post-operative analgesia use, and length of stay. This study was registered with the Australia New Zealand Clinical Trials Registry ACTRN12615000639516. RESULTS Sixty-four women were included in the study - 33 and 31 in the Gyrus PKS™ and LigaSure™ arms, respectively. TLHs performed by LigaSure™ had statistically significantly shorter time to haemostasis compared to Gyrus PKS™ by 10.6 min (95% CI 1.3-2.0, P = 0.03). There were no differences in any of the other secondary outcomes measured. CONCLUSIONS This trial suggests there is no difference between using either device. TLHs performed using LigaSure™ have statistically significantly shorter time to haemostasis than those using Gyrus PKS™; however, the difference is not considered clinically significant as it was only 14.2%. No other differences in surgical outcomes were detected.",2020,"TLHs performed by LigaSure™ had statistically significantly shorter time to haemostasis compared to Gyrus PKS™ by 10.6 min (95% CI 1.3-2.0, P = 0.03).","['total laparoscopic hysterectomy', 'Women who required TLHs for benign indications', 'Sixty-four women were included in the study - 33 and 31 in the Gyrus PKS™ and LigaSure™ arms, respectively']","['Gyrus PKS™ vs LigaSure', 'Gyrus PKS™ or LigaSure™', 'total laparoscopic hysterectomy (TLH']","['Time to haemostasis', 'intra-operative blood loss, complications, conversions, post-operative analgesia use, and length of stay', 'shorter time to haemostasis', 'surgical outcomes']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205183', 'cui_str': 'Benign'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C4517839', 'cui_str': '64'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0265449', 'cui_str': 'Tetrasomy 12p'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0265449', 'cui_str': 'Tetrasomy 12p'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0404089', 'cui_str': 'Laparoscopic hysterectomy'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0456904', 'cui_str': 'Intraoperative'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0439836', 'cui_str': 'Conversions'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C1274040', 'cui_str': 'Result'}]",64.0,0.336996,"TLHs performed by LigaSure™ had statistically significantly shorter time to haemostasis compared to Gyrus PKS™ by 10.6 min (95% CI 1.3-2.0, P = 0.03).","[{'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Wong', 'Affiliation': 'Sydney West Advanced Pelvic Surgery Unit, Sydney, New South Wales, Australia.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Goh', 'Affiliation': 'Sydney West Advanced Pelvic Surgery Unit, Sydney, New South Wales, Australia.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Merkur', 'Affiliation': 'Sydney West Advanced Pelvic Surgery Unit, Sydney, New South Wales, Australia.'}]",The Australian & New Zealand journal of obstetrics & gynaecology,['10.1111/ajo.13217'] 2670,32729405,Acute Stress Improves Concentration Performance.,"Acute stress can have both detrimental and beneficial effects on cognitive processing, but effects on concentration performance remain unclear. Here, we investigate the effects of acute psychosocial stress on concentration performance and possible underlying physiological and psychological mechanisms. The study sample comprised 47 healthy male participants who were randomly assigned either to a psychosocial stress situation (Trier Social Stress Test) or a neutral control task. Concentration performance was assessed using the d2 Test of Attention before and 30 min after the stress or control task. Salivary cortisol and alpha-amylase were repeatedly measured before and up to 1 hr after stress. We repeatedly assessed state anxiety using the State-Trait Anxiety Inventory and anticipatory cognitive stress appraisal using the Primary Appraisal Secondary Appraisal questionnaire. The stress group showed a significantly stronger improvement of concentration performance compared to the control group ( p = .042). Concentration performance improvement was predicted by increased state anxiety ( p = .020) and lower cortisol (stress) changes ( p = .043). Neither changes in alpha-amylase nor cognitive stress appraisal did relate to concentration performance. Our results show improved concentration performance after acute psychosocial stress induction that was predicted by higher state anxiety increases and lower cortisol increases. This points to a potential modulating role of specific psycho-emotional and physiological factors with opposite effects.",2020,The stress group showed a significantly stronger improvement of concentration performance compared to the control group ( p = .042).,['47 healthy male participants'],['psychosocial stress situation (Trier Social Stress Test) or a neutral control task'],"['Salivary cortisol and alpha-amylase', 'state anxiety increases and lower cortisol increases', 'Concentration performance improvement', 'state anxiety using the State-Trait Anxiety Inventory and anticipatory cognitive stress appraisal', 'state anxiety', 'Concentration Performance', 'lower cortisol (stress) changes', 'concentration performance', 'Concentration performance']","[{'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0065404', 'cui_str': 'lysyl-5-fluorotryptophyl-lysine'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0020268', 'cui_str': 'Hydrocortisone'}, {'cui': 'C0002245', 'cui_str': 'alpha-Amylase'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0740379', 'cui_str': 'Cortisol decreased'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",47.0,0.0253662,The stress group showed a significantly stronger improvement of concentration performance compared to the control group ( p = .042).,"[{'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Degroote', 'Affiliation': 'Biological Work and Health Psychology, Department of Psychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Schwaninger', 'Affiliation': 'School of Applied Psychology, University of Applied Sciences and Arts Northwestern Switzerland (FHNW), Olten, Switzerland.'}, {'ForeName': 'Nadja', 'Initials': 'N', 'LastName': 'Heimgartner', 'Affiliation': 'Division of Clinical Psychology and Psychotherapy, University of Basel, Basel, Switzerland.'}, {'ForeName': 'Patrik', 'Initials': 'P', 'LastName': 'Hedinger', 'Affiliation': 'Clienia Littenheid AG, Private Hospital for Psychiatric and Psychotherapy, Littenheid, Switzerland.'}, {'ForeName': 'Ulrike', 'Initials': 'U', 'LastName': 'Ehlert', 'Affiliation': 'Department of Clinical Psychology and Psychotherapy, University of Zurich, Zurich, Switzerland.'}, {'ForeName': 'Petra H', 'Initials': 'PH', 'LastName': 'Wirtz', 'Affiliation': 'Biological Work and Health Psychology, Department of Psychology, University of Konstanz, Konstanz, Germany.'}]",Experimental psychology,['10.1027/1618-3169/a000481'] 2671,32729407,The Opposite of Stress.,"Cognition is affected by psychophysiological states. While the influence of stress on cognition has been investigated intensively, less studies have addressed how the opposite of stress, a state of relaxation, affects cognition. We investigated whether the extent of parasympathetic activation is positively related to divergent thinking. Sixty healthy female participants were randomly allocated to a standardized vagus nerve massage ( n = 19), a standardized soft shoulder massage ( n = 22), or a resting control group ( n = 19). Subsequently, participants completed the Alternative Uses Test (AUT), a measure of divergent thinking. Respiratory sinus arrhythmia (RSA), a vagally mediated heart rate variability component, was monitored throughout the experiment. The area under the curve with respect to the increase was calculated for RSA trajectories as an indicator of vagal tone during the relaxing intervention. Regressions tested the effect of vagal tone on AUT outcomes. We found an association between vagal tone and subsequent AUT outcomes. Yet, this association was no longer significant when controlling for the effect of the creative potential of an individual, which was strongly related to AUT outcomes. Being exploratory, we found a positive association between creative potential and vagal tone. These results imply that creative potential might be related to the capacity to relax.",2020,"Yet, this association was no longer significant when controlling for the effect of the creative potential of an individual, which was strongly related to AUT outcomes.",['Sixty healthy female participants'],"['standardized soft shoulder massage', 'standardized vagus nerve massage']",['Respiratory sinus arrhythmia (RSA'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0205358', 'cui_str': 'Soft'}, {'cui': 'C0037004', 'cui_str': 'Shoulder region structure'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0042276', 'cui_str': 'Vagus nerve structure'}]","[{'cui': 'C0003813', 'cui_str': 'Sinus arrhythmia'}]",60.0,0.0189613,"Yet, this association was no longer significant when controlling for the effect of the creative potential of an individual, which was strongly related to AUT outcomes.","[{'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Meier', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Unternaehrer', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Sabine M', 'Initials': 'SM', 'LastName': 'Schorpp', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Wenzel', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Annika', 'Initials': 'A', 'LastName': 'Benz', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Ulrike U', 'Initials': 'UU', 'LastName': 'Bentele', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Dimitroff', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Denk', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}, {'ForeName': 'Jens C', 'Initials': 'JC', 'LastName': 'Prüssner', 'Affiliation': 'Department of Psychology, Division of Clinical Neuropsychology, University of Konstanz, Konstanz, Germany.'}]",Experimental psychology,['10.1027/1618-3169/a000483'] 2672,32729416,Development and Validation of a Five-immune gene pair Signature in Endometrial carcinoma.,"BACKGROUND Endometrial cancer (EC) is a common gynecological malignancy worldwide. Immunity is closely related to occurrence and prognosis of EC. At the same time, immune-related genes have great potential as prognostic mark-ers in many types of cancer. OBJECTIVE Therefore, we attempts to develop immune-related gene markers to enhance prognosis prediction of EC. METHODS 542 samples of EC gene expression data and clinical follow-up information from were downloaded from The Cancer Genome Atlas (TCGA). The samples were randomly divided into two groups, one group as a training set (N=271), and one set as a validation set. (N=271). In the training set, the gene pairs were established based on the relative expression levels of 271 immune genes, and the prognosis-related gene pairs were screened. The lasso was used to select the features, and finally the robust biomarkers were screened. Finally, the prognostic model of the immune gene pair was established and verified by validation data set. RESULTS 10030 immune gene pair (IRGPs) were obtained, and univariate survival analysis was used to identify 1809 prog-nostic-related IRGPs (p<0.05). 5-IRGPs were obtained by lasso regression feature selection, and multivariate regression was used to establish 5-IRGPs signature, 5-IRGPs signature is an independent prognostic factor for EC patients, and could be risk stratified in patients with TCGA datasets, age, ethnicity, stage, and histological classification (p<0.05). The mean AUC of survival in both the training set and the validation set was greater than 0.7, indicating that 5-IRGPs signature has superior classification performance in patients with EC. In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. CONCLUSION This study constructed a 5-IRGPs signature as a novel prognostic marker for predicting survival in patients with EC.",2020,"In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. ","['Endometrial carcinoma', '542 samples of EC gene expression data and clinical follow-up information from were downloaded from The Cancer Genome Atlas (TCGA', 'patients with EC']",[],"['highest average C index', 'mean AUC of survival']","[{'cui': 'C0476089', 'cui_str': 'Endometrial carcinoma'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0007103', 'cui_str': 'Endometrial neoplasms malignant'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]",[],"[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0038952', 'cui_str': 'Survival'}]",10030.0,0.038112,"In addition, 5-IRGPs have the highest average C index (0.795) compared to the prognostic characteristics of the three endometrial cancers reported in the past and Stage and Age. ","[{'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Li', 'Affiliation': 'Reproductive Medicine Center, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, Guangxi Autonomous Region, 545001. China.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Yu', 'Affiliation': 'College of Life Science and Technology, Guangxi University, Nanning, 530004. China.'}, {'ForeName': 'Zhong', 'Initials': 'Z', 'LastName': 'Lin', 'Affiliation': 'Reproductive Medicine Center, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, Guangxi Autonomous Region, 545001. China.'}, {'ForeName': 'Dingyuan', 'Initials': 'D', 'LastName': 'Zeng', 'Affiliation': 'Department of Obstetrics and Gynecology，Liuzhou Maternity and Child Health Care Hospital, Liuzhou, Guangxi Autonomous Region, 545001. China.'}]",Combinatorial chemistry & high throughput screening,['10.2174/1386207323999200729113641'] 2673,32729423,High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients.,"BACKGROUND Vitamin D (VD) deficiency has been related to several endocrine metabolic and cardiovascular diseases. Effect of VD supplementation on blood pressure (BP) in patients with diabetes is controversial. OBJECTIVE The aim of this study was to evaluate high-dose vitamin D supplementation effects on blood pressure of normotensive type 1 diabetes mellitus (T1DM) patients by 24-hour ambulatory blood pressure monitoring (ABPM). METHODS We performed a clinical trial including 35 T1DM normotensive patients, who received doses of 4,000 or 10,000 IU/day of cholecalciferol for 12 weeks according to previous VD levels. They underwent 24-hour ABPM, along with glycated hemoglobin, creatine, lipids profile and PCRus dosage before and after VD supplementation. RESULTS AND DISCUSSION We found an expressive reduction of systolic and diastolic morning blood pressures (117±14 vs 112±14, p<0,05; 74±9 vs 70±10 mmHg, p<0,05, respectively) with no changes in other pressoric markers. Besides, we noticed a relation between levels of VD after supplementation and diastolic morning blood pressure (r= -0,4; p<0.05). CONCLUSION Our study suggests an association between supplementation of high doses of vitamin D and the reduction of morning blood pressure in normotensive T1DM patients.",2020,"We found an expressive reduction of systolic and diastolic morning blood pressures (117±14 vs 112±14, p<0,05; 74±9 vs 70±10 mmHg, p<0,05, respectively) with no changes in other pressoric markers.","['35 T1DM normotensive patients, who received doses of 4,000 or 10,000 IU/day of', 'normotensive type 1 diabetes mellitus (T1DM) patients by 24-hour ambulatory blood pressure monitoring (ABPM', 'patients with diabetes is controversial', 'Normotensive DM1 Patients', 'normotensive T1DM patients']","['cholecalciferol', 'VD supplementation', 'Cholecalciferol Supplementation', 'vitamin D', 'vitamin D supplementation']","['blood pressure', 'glycated hemoglobin, creatine, lipids profile and PCRus dosage', 'levels of VD after supplementation and diastolic morning blood pressure', 'morning blood pressure', 'blood pressure (BP', 'Morning Blood Pressure', 'expressive reduction of systolic and diastolic morning blood pressures']","[{'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439465', 'cui_str': 'IU/day'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0242876', 'cui_str': 'Ambulatory Blood Pressure Monitoring'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0010286', 'cui_str': 'Creatine'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0039155', 'cui_str': 'Systole'}]",35.0,0.0884431,"We found an expressive reduction of systolic and diastolic morning blood pressures (117±14 vs 112±14, p<0,05; 74±9 vs 70±10 mmHg, p<0,05, respectively) with no changes in other pressoric markers.","[{'ForeName': 'Natércia Neves Marques', 'Initials': 'NNM', 'LastName': 'de Queiroz', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Franciane Trindade Cunha', 'Initials': 'FTC', 'LastName': 'de Melo', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Fabrício de Souza', 'Initials': 'FS', 'LastName': 'Resende', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Luísa Corrêa', 'Initials': 'LC', 'LastName': 'Janaú', 'Affiliation': 'State University of Pará, Platter Perebebuí, 2623, Marco, Belém, Pará. Brazil.'}, {'ForeName': 'Norberto Jorge Kzan', 'Initials': 'NJK', 'LastName': 'de Souza Neto', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Manuela Nascimento', 'Initials': 'MN', 'LastName': 'de Lemos', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Maria Clara Neres Iunes', 'Initials': 'MCNI', 'LastName': 'de Oliveira', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Angélica Leite', 'Initials': 'AL', 'LastName': 'de Alcântara', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Lorena Vilhena', 'Initials': 'LV', 'LastName': 'de Moraes', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Apolone da', 'Initials': 'AD', 'LastName': 'Mota Queiroz', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Ícaro José Araújo', 'Initials': 'ÍJA', 'LastName': 'de Souza', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Nivin Mazen', 'Initials': 'NM', 'LastName': 'Said', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Márcia Costa', 'Initials': 'MC', 'LastName': 'Dos Santos', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Lilian de Souza', 'Initials': 'LS', 'LastName': ""D'Albuquerque Silva"", 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Ana Regina Bastos', 'Initials': 'ARB', 'LastName': 'Motta', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Melissa de Sá Oliveira', 'Initials': 'MSO', 'LastName': 'Dos Reis', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Isabel Jane Campos', 'Initials': 'IJC', 'LastName': 'Lobato', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Priscila Boaventura Barbosa', 'Initials': 'PBB', 'LastName': 'de Figueiredo', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Ana Carolina Contente Braga', 'Initials': 'ACCB', 'LastName': 'de Souza', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Pedro Paulo', 'Initials': 'PP', 'LastName': 'Freire Piani', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'Karem Miléo', 'Initials': 'KM', 'LastName': 'Felício', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'João Felício', 'Initials': 'JF', 'LastName': 'Abrahão Neto', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}, {'ForeName': 'João Soares', 'Initials': 'JS', 'LastName': 'Felício', 'Affiliation': 'University Hospital João de Barros Barreto, Federal University of Pará, Endocrinology Division, Mundurucus Street, 4487, Guamá, Belém, Pará. Brazil.'}]",Current diabetes reviews,['10.2174/1573399816999200729131508'] 2674,32729586,Effects of intragastric tryptophan on acute changes in the plasma tryptophan/large neutral amino acids ratio and relationship with subsequent energy intake in lean and obese men.,"Circulating tryptophan/large neutral amino acids (tryptophan/LNAA) ratio, an indicator of brain serotonin levels, may be important in appetite regulation, together with gastrointestinal (gastric emptying, plasma cholecystokinin) mechanisms. We have compared effects of intragastric tryptophan ('Trp') on the plasma tryptophan/LNAA ratio in lean and obese men, and the associations of the tryptophan/LNAA ratio, gastric emptying and CCK concentrations with energy intake. Lean and obese male participants (n = 16 each) received 3 g Trp or volume-matched control intragastrically, 15 min before a mixed-nutrient drink (300 mL, 400 kcal) (t = 0 min) in randomised, double-blind fashion. Plasma amino acid (for calculation of the plasma tryptophan/LNAA ratio) and CCK concentrations were measured from t = -20-60 min. Gastric emptying was assessed from t = 0-60 min, and ad-libitum energy intake from a standardised buffet-style meal from t = 60-90 min. The increase in the plasma tryptophan/LNAA ratio was less in obese, than lean, participants (P < 0.05), and greater in lean participants who reduced their energy intake (by >0 kcal) after Trp compared with those who did not (by ≤0 kcal) (P < 0.05). Moreover, in participants who reduced their energy intake, the ratio was lower in obese, than in lean (P < 0.05). There was a trend for an inverse correlation between energy intake with the plasma tryptophan/LNAA ratio in lean (r = -0.4, P = 0.08), but not in obese, participants. There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not. In conclusion, the plasma tryptophan/LNAA ratio appears to be a determinant of the suppression of energy intake in response to tryptophan in normal-weight people, but not in those with obesity. The role of the plasma tryptophan/LNAA ratio to regulate energy intake, and potential changes in obesity, warrant evaluation in prospective studies.",2020,There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not.,"['Lean and obese male participants (n = 16 each) received', 'lean and obese men']","['intragastric tryptophan', ""intragastric tryptophan ('Trp"", '3 g Trp or volume-matched control intragastrically, 15 min before a mixed-nutrient drink']","['plasma tryptophan/LNAA ratio in lean', 'plasma tryptophan/LNAA ratio', 'Gastric emptying', 'tryptophan/LNAA ratio, gastric emptying and CCK concentrations with energy intake', 'gastric emptying or CCK', 'Plasma amino acid (for calculation of the plasma tryptophan/LNAA ratio) and CCK concentrations', 'energy intake']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0442113', 'cui_str': 'Intragastric'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0678695', 'cui_str': 'Nutrients'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0017127', 'cui_str': 'Gastric emptying'}, {'cui': 'C0008328', 'cui_str': 'Cholecystokinin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0002520', 'cui_str': 'amino acids'}, {'cui': 'C1441506', 'cui_str': 'Calculation technique'}]",,0.103926,There was no significant difference in gastric emptying or CCK between participants who reduced their energy intake and those who did not.,"[{'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Hajishafiee', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}, {'ForeName': 'Sina S', 'Initials': 'SS', 'LastName': 'Ullrich', 'Affiliation': 'Institute for Prevention and Cancer Epidemiology, Faculty of Medicine and Medical Centre, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Steinert', 'Affiliation': 'Department of Surgery, Division of Visceral and Transplantation Surgery, University Hospital Zürich, Zürich, Switzerland.'}, {'ForeName': 'Sally D', 'Initials': 'SD', 'LastName': 'Poppitt', 'Affiliation': 'Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand.'}, {'ForeName': 'Natalie D', 'Initials': 'ND', 'LastName': 'Luscombe-Marsh', 'Affiliation': 'Commonwealth Scientific and Industrial Research Organisation - Health and Biosecurity, Adelaide, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Horowitz', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Feinle-Bisset', 'Affiliation': 'Adelaide Medical School and Centre of Research Excellence in Translating Nutritional Science to Good Health, University of Adelaide, Adelaide, Australia. christine.feinle@adelaide.edu.au.'}]",Food & function,['10.1039/d0fo00773k'] 2675,32727577,Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects.,"BACKGROUND To investigate the effects of coadministration of esaxerenone with amlodipine on the pharmacokinetics (PK) of each drug, and of esaxerenone on the PK of digoxin. METHODS In three open-label, single-sequence, crossover studies, healthy Japanese males received single oral doses of esaxerenone 2.5 mg (Days 1, 15), with amlodipine 10 mg/day (Days 8-18) (Study 1, N = 24); single doses of amlodipine 2.5 mg (Days 1, 21), with esaxerenone 5 mg/day (Days 8-25) (Study 2; N = 20); or digoxin 0.25 mg/day (Days 1-15) with esaxerenone 5 mg/day (Days 11-15) (Study 3; N = 20). PK parameters and safety were assessed. RESULTS Study 1: esaxerenone peak plasma concentration (C max ) and time to C max were unaltered by amlodipine coadministration, but mean half-life was slightly prolonged from 18.5 to 20.9 h. Geometric least-squares mean (GLSM) ratios for C max , area under the plasma concentration-time curve (AUC) from zero to last measurable concentration and from zero to infinity for esaxerenone + amlodipine versus esaxerenone were 0.958, 1.154, and 1.173, respectively. Study 2: corresponding GLSM ratios for amlodipine + esaxerenone versus amlodipine were 1.099, 1.185, and 1.214. Study 3: esaxerenone did not markedly alter digoxin PK. GLSM ratios for C max , trough plasma concentration, and AUC during a dosing interval for digoxin versus esaxerenone + digoxin were 1.130, 1.088, and 1.072, respectively. CONCLUSIONS No drug-drug interactions are expected during combination therapy with esaxerenone and either amlodipine or digoxin, based on a lack of any clinically relevant PK changes. TRIAL REGISTRATION Studies 1 and 2: JapicCTI-163379 (registered on 20 September 2016); Study 3: JapicCTI-163443 (registered on 24 November 2016).",2020,"No drug-drug interactions are expected during combination therapy with esaxerenone and either amlodipine or digoxin, based on a lack of any clinically relevant PK changes. ","['JapicCTI-163379 (registered on 20 September 2016); Study 3: JapicCTI-163443 (registered on 24 November 2016', 'healthy Japanese subjects', 'healthy Japanese males']","['esaxerenone with amlodipine and digoxin', 'esaxerenone + amlodipine', 'amlodipine or digoxin', 'digoxin versus esaxerenone + digoxin', 'esaxerenone with amlodipine', 'amlodipine', 'esaxerenone', 'esaxerenone 2.5\u2009mg', 'amlodipine + esaxerenone versus amlodipine', 'digoxin']","['esaxerenone peak plasma concentration (C max ) and time to C max', 'digoxin PK', 'GLSM ratios', 'PK parameters and safety', 'GLSM) ratios for C max , area under the plasma concentration-time curve (AUC', 'GLSM ratios for C max , trough plasma concentration, and AUC']","[{'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C5139864', 'cui_str': 'esaxerenone'}, {'cui': 'C0051696', 'cui_str': 'Amlodipine'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}, {'cui': 'C3844011', 'cui_str': '2.5'}]","[{'cui': 'C5139864', 'cui_str': 'esaxerenone'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0012265', 'cui_str': 'Digoxin'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0444506', 'cui_str': 'Trough'}]",,0.106603,"No drug-drug interactions are expected during combination therapy with esaxerenone and either amlodipine or digoxin, based on a lack of any clinically relevant PK changes. ","[{'ForeName': 'Yoshiaki', 'Initials': 'Y', 'LastName': 'Kirigaya', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan. kirigaya.yoshiaki.c8@daiichisankyo.co.jp.'}, {'ForeName': 'Masanari', 'Initials': 'M', 'LastName': 'Shiramoto', 'Affiliation': 'SOUSEIKAI Hakata Clinic, 6-18, Tenyamachi, Hakata-ku, Fukuoka, 812-0025, Japan.'}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Ishizuka', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}, {'ForeName': 'Hinako', 'Initials': 'H', 'LastName': 'Uchimaru', 'Affiliation': 'SOUSEIKAI Hakata Clinic, 6-18, Tenyamachi, Hakata-ku, Fukuoka, 812-0025, Japan.'}, {'ForeName': 'Shin', 'Initials': 'S', 'LastName': 'Irie', 'Affiliation': 'SOUSEIKAI Hakata Clinic, 6-18, Tenyamachi, Hakata-ku, Fukuoka, 812-0025, Japan.'}, {'ForeName': 'Manabu', 'Initials': 'M', 'LastName': 'Kato', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}, {'ForeName': 'Takako', 'Initials': 'T', 'LastName': 'Shimizu', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Nakatsu', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Nishikawa', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Ishizuka', 'Affiliation': 'Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan.'}]",BMC pharmacology & toxicology,['10.1186/s40360-020-00423-4'] 2676,32727601,Effect of self-care counselling on depression and anxiety in women with endometriosis: a randomized controlled trial.,"BACKGROUND Considering the prevalence of endometriosis and consequent depression and anxiety as well as the resultant effects on the body, mind, and quality of life of patients, this study aimed to determine the effects of self-care counselling on depression and anxiety (primary outcome) and on quality of life (secondary outcome) among women with endometriosis. METHOD This randomized controlled clinical trial was conducted on 76 women with endometriosis who were treated at Al-Zahra Teaching and Treatment Center of Tabriz within the 2015-2019 period. The random blocking method was employed to divide the patients into intervention (counselling) and control groups. In the intervention group, seven self-care group counselling sessions were held on a weekly basis. The control group received routine care. A sociodemographic questionnaire, Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory (STAI) and the SF-36 Quality of Life Questionnaire were completed by the researcher through an interview before and 4 weeks after the intervention. RESULTS There was no significant difference between the intervention and control groups in terms of sociodemographic characteristics (p > 0.05). After the intervention, the mean scores of state anxiety (mean difference: - 0.12, 95% confidence interval: - 9.6 to - 14.4, p < 0.001) and trait anxiety (mean difference: - 10.9: 95% confidence interval: - 9.1 to - 12.7, p = 0.001) were significantly lower in the counselling group than those of the control group. The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565). The mean score of quality of life for physical health (mean difference = 17.2, 95% confidence interval: 13.8 to 20.5, p < 0.001) and for mental health (mean difference = 12.0, 95% confidence interval: 9.0 to 14.9, p < 0.001) were significantly higher in the counselling group than in the control group. CONCLUSION Self-care counselling affects the anxiety and quality of life of women with endometriosis. Therefore, in addition to other therapies, this method is proposed to improve quality of life and mental health of patients with endometriosis. TRIAL REGISTRATION IRCT Registration Number: IRCT 20111219008459 N13, registered on February 10, 2019 ( https://irct.ir/user/trial/35915 ).",2020,"The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565).","['women with endometriosis', 'patients with endometriosis', '76 women with endometriosis who were treated at Al-Zahra Teaching and Treatment Center of Tabriz within the 2015-2019 period']","['routine care', 'Self-care counselling', 'self-care counselling']","['quality of life', 'A sociodemographic questionnaire, Beck Depression Inventory, Spielberger State-Trait Anxiety Inventory (STAI) and the SF-36 Quality of Life Questionnaire', 'quality of life and mental health', 'mean score of depression', 'mental health', 'anxiety and quality of life', 'sociodemographic characteristics', 'trait anxiety', 'mean scores of state anxiety', 'depression and anxiety', 'mean score of quality of life for physical health']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205099', 'cui_str': 'Central'}]","[{'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0036592', 'cui_str': 'Self-care interventions'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0451497', 'cui_str': 'Spielberger state-trait anxiety inventory'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0700613', 'cui_str': 'Anxiety state'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",76.0,0.140972,"The mean score of depression was lower in the counselling group than in the control group; however, it was not significant (p = 0/565).","[{'ForeName': 'Nooshin', 'Initials': 'N', 'LastName': 'Farshi', 'Affiliation': 'Student Research Committee, Midwifery Department, Nursing and Midwifery Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Shirin', 'Initials': 'S', 'LastName': 'Hasanpour', 'Affiliation': ""Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. shirinhasanpoor@yahoo.com.""}, {'ForeName': 'Mojgan', 'Initials': 'M', 'LastName': 'Mirghafourvand', 'Affiliation': 'Midwifery Department, Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Khalil', 'Initials': 'K', 'LastName': 'Esmaeilpour', 'Affiliation': 'Faculty of Education and Psychology, University of Tabriz, Tabriz, Iran.'}]",BMC psychiatry,['10.1186/s12888-020-02795-7'] 2677,32727603,"Research on allergic rhinitis improvement in asthmatic children after dust mite exposure reduction: a randomized, double-blind, cross-placebo study protocol.","BACKGROUND Allergic rhinitis (AR) in children is a major respiratory inflammatory disease with a high incidence that is increasing yearly. In China, 54.93% of children with asthma have AR, which often requires synchronous treatment. House dust mites (HDMs) are common allergens that often cause attacks of AR and asthma. Reducing allergen exposure is one of the most important measures to control and treat AR and asthma attacks. Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms. This single-centre, randomized, double-blind, cross-placebo trial will explore the improvement in AR in asthmatic children after dust mite exposure reduction. METHODS We will recruit 60 children (aged 3-12 years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test. Participants will randomly receive the Hestelia Mite Bait intervention for 8 weeks and the placebo intervention for 8 weeks. There will be a 4-week washout period between the two interventions. The primary outcome is the visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations. DISCUSSION This study aims to scientifically and objectively evaluate the effects of mite bait on rhinitis and asthma improvement after dust mite exposure reduction and provides a convenient means for future prevention and treatment of allergic diseases involving the airways in children. TRIAL REGISTRATION www.chictr.org.cn ChiCTR1900024688. Registered on July 21, 2019.",2020,"Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms.","['children', 'asthmatic children after dust mite exposure reduction', '60 children (aged 3-12\u2009years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test']","['placebo intervention', 'mite bait', 'Hestelia Mite Bait, containing 0.1% emamectin', 'Hestelia Mite Bait intervention', 'placebo']","['visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0998367', 'cui_str': 'House dust mite'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0449891', 'cui_str': 'Test allergen used'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0026231', 'cui_str': 'Mite'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C4517420', 'cui_str': '0.1'}, {'cui': 'C1100440', 'cui_str': 'emamectin'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008711', 'cui_str': 'Chronic rhinitis'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0861155', 'cui_str': 'Rhinoconjunctivitis'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0998367', 'cui_str': 'House dust mite'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C2919686', 'cui_str': 'Asthma control questionnaire'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0582415', 'cui_str': 'Acute asthma'}, {'cui': 'C0004063', 'cui_str': 'Assault'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}]",60.0,0.158494,"Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms.","[{'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Chen', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'YuFen', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Shuhua', 'Initials': 'S', 'LastName': 'Yuan', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jiande', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Luanluan', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jinhong', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China. zhangjing_yq@163.com.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Yin', 'Affiliation': ""Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China. yinyong9999@163.com.""}]",Trials,['10.1186/s13063-020-04614-6'] 2678,32728833,Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis.,"INTRODUCTION The aim of this study was to evaluate the efficacy and safety of ultra-rapid lispro (URLi) versus lispro in a subgroup analysis of Japanese adults with type 2 diabetes mellitus (T2DM) from the phase 3 PRONTO-T2D trial. METHODS After an 8-week lead-in period during which patients transitioned to insulin lispro 3 times a day before main meals in association with basal insulin (glargine or degludec), the patients were randomized to 26 weeks of double-blind URLi or lispro injected immediately prior to meals. The primary endpoint was change in hemoglobin A1c (HbA1c) from baseline to week 26 between URLi and lispro. The multiplicity-adjusted objectives were 1- and 2-h postprandial glucose (PPG) excursions after a test meal and change in HbA1c from baseline to week 26 in the URLi and lispro groups. RESULTS Results were obtained from prespecified exploratory analyses of 26-week data in Japanese patients randomized to receive URLi (n = 47) or lispro (n = 46). Mean baseline HbA1c levels significantly improved during the lead-in period to a baseline value of 7.50% and 7.60% in patients subsequently randomized to the URLi and lispro treatment groups, respectively. At week 26, the least squares mean (LSM) difference in HbAc1 between the URLi and lispro groups was 0.13% (95% confidence interval [CI] - 0.12 to 0.39) (1.4 mmol/mol, 95% CI - 1.3 to 4.2). Although there were no significant differences in PPG excursions at any time-point, numerically smaller PPG excursions were consistently observed from 30 min to 3 h during the mixed-meal tolerance test in patients on URLi compared to those on lispro. LSM differences in PPG excursions at week 26 were - 10.5 mg/dL (95% CI - 32.7 to 11.7) (- 0.58 mmol/L, 95% CI - 1.82 to 0.65) at 1 h and - 14.9 mg/dL (95% CI - 40.3 to 10.5) (- 0.83 mmol/L, 95% CI - 2.24 to 0.58) at 2 h. There were no significant differences between treatments in rates of severe/overall hypoglycemia or incidence of treatment-emergent adverse events. CONCLUSIONS URLi administered as prandial insulin in combination with basal insulin provides effective glycemic control when administered immediately before a meal in Japanese patients with T2DM. URLi was well tolerated in this population. TRIAL REGISTRATION ClinicalTrials.gov, NCT03214380.",2020,"Although there were no significant differences in PPG excursions at any time-point, numerically smaller PPG excursions were consistently observed from 30 min to 3 h during the mixed-meal tolerance test in patients on URLi compared to those on lispro.","['Japanese adults with type 2 diabetes mellitus (T2DM', 'Japanese Patients With Type 2 Diabetes', 'Japanese patients with T2DM']","['double-blind URLi or lispro injected immediately prior to meals', 'Humalog®', 'ultra-rapid lispro (URLi) versus lispro', 'lispro', 'URLi', 'insulin lispro 3 times a day before main meals in association with basal insulin (glargine or degludec']","['change in hemoglobin A1c (HbA1c', 'rates of severe/overall hypoglycemia or incidence of treatment-emergent adverse events', 'LSM differences in PPG excursions', 'PPG excursions', 'Mean baseline HbA1c levels', 'efficacy and safety', 'postprandial glucose (PPG) excursions', 'Ultra-Rapid Lispro Efficacy and Safety']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0528249', 'cui_str': 'Humalog'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C3491971', 'cui_str': 'insulin degludec'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0023189', 'cui_str': 'Analysis, Least-Squares'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0049716', 'cui_str': ""6-thioguanosine 5'-diphosphate""}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0474680', 'cui_str': 'Hemoglobin A1c measurement'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}]",,0.143219,"Although there were no significant differences in PPG excursions at any time-point, numerically smaller PPG excursions were consistently observed from 30 min to 3 h during the mixed-meal tolerance test in patients on URLi compared to those on lispro.","[{'ForeName': 'Hideaki', 'Initials': 'H', 'LastName': 'Jinnouchi', 'Affiliation': 'Jinnouchi Hospital, 6 Chome-2-3 Kuhonji, Chuo Ward, Kumamoto, 862-0976, Japan.'}, {'ForeName': 'Makoto', 'Initials': 'M', 'LastName': 'Imori', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K, 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan. imori_makoto@lilly.com.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Nishiyama', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K, 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Imaoka', 'Affiliation': 'Medicines Development Unit Japan and Medical Affairs, Eli Lilly Japan K.K, 5-1-28, Isogami-dori, Chuo-ku, Kobe, Hyogo, 651-0086, Japan.'}]","Diabetes therapy : research, treatment and education of diabetes and related disorders",['10.1007/s13300-020-00890-2'] 2679,32728879,Effect of coffee and cocoa-based confectionery containing coffee on markers of cardiometabolic health: results from the pocket-4-life project.,"PURPOSE Coffee is an important source of bioactive compounds, including caffeine, trigonelline, and phenolic compounds. Several studies have highlighted the preventive effects of coffee consumption on major cardiometabolic (CM) diseases, but the impact of different coffee dosages on markers of CM risk in a real-life setting has not been fully understood. This study aimed to investigate the effect of coffee and cocoa-based confectionery containing coffee consumption on several CM risk factors in healthy subjects. METHODS In a three-arm, crossover, randomized trial, 21 volunteers were assigned to consume in a random order for 1 month: 1 cup of espresso coffee/day, 3 cups of espresso coffee/day, and 1 cup of espresso coffee plus 2 cocoa-based products containing coffee, twice per day. At the last day of each treatment, blood samples were collected and used for the analysis of inflammatory markers, trimethylamine N-oxide, nitric oxide, blood lipids, and markers of glucose/insulin metabolism. Moreover, anthropometric parameters and blood pressure were measured. Finally, food consumption during the interventions was monitored. RESULTS After 1 month, energy intake did not change among treatments, while significant differences were observed in the intake of saturated fatty acids, sugars, and total carbohydrates. No significant effect on CM markers was observed following neither the consumption of different coffee dosages nor after cocoa-based products containing coffee. CONCLUSIONS The daily consumption of common dosages of coffee and its substitution with cocoa-based products containing coffee showed no effect on CM risk factors in healthy subjects. TRIAL REGISTRATION NUMBER Registered at clinicaltrials.gov as NCT03166540, May 21, 2017.",2020,"No significant effect on CM markers was observed following neither the consumption of different coffee dosages nor after cocoa-based products containing coffee. ","['21 volunteers', 'healthy subjects']","['coffee and cocoa-based confectionery containing coffee', 'cup of espresso coffee/day, 3 cups of espresso coffee/day, and 1 cup of espresso coffee plus 2 cocoa-based products containing coffee', 'coffee and its substitution with cocoa-based products containing coffee', 'coffee and cocoa-based confectionery containing coffee consumption']","['anthropometric parameters and blood pressure', 'several CM risk factors', 'cardiometabolic health', 'intake of saturated fatty acids, sugars, and total carbohydrates', 'CM markers', 'CM risk factors', 'inflammatory markers, trimethylamine N-oxide, nitric oxide, blood lipids, and markers of glucose/insulin metabolism', 'energy intake']","[{'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0006622', 'cui_str': 'Theobroma cacao'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0006855', 'cui_str': 'Candy'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0220647', 'cui_str': 'Carcinoma of unknown primary'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0360301', 'cui_str': 'Product base'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}]","[{'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0077194', 'cui_str': 'trimethyloxamine'}, {'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",21.0,0.109093,"No significant effect on CM markers was observed following neither the consumption of different coffee dosages nor after cocoa-based products containing coffee. ","[{'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Martini', 'Affiliation': 'Human Nutrition Unit, Department of Veterinary Sciences, University of Parma, University Hospital Building 27, Via Gramsci 14, 43126, Parma, Italy.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Rosi', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Tassotti', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Antonini', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.'}, {'ForeName': 'Margherita', 'Initials': 'M', 'LastName': ""Dall'Asta"", 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Bresciani', 'Affiliation': 'Human Nutrition Unit, Department of Veterinary Sciences, University of Parma, University Hospital Building 27, Via Gramsci 14, 43126, Parma, Italy.'}, {'ForeName': 'Federica', 'Initials': 'F', 'LastName': 'Fantuzzi', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Spigoni', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.'}, {'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Domínguez-Perles', 'Affiliation': 'Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, University Campus of Espinardo, Edif. 25, 30100, Murcia, Spain.'}, {'ForeName': 'Donato', 'Initials': 'D', 'LastName': 'Angelino', 'Affiliation': 'Human Nutrition Unit, Department of Veterinary Sciences, University of Parma, University Hospital Building 27, Via Gramsci 14, 43126, Parma, Italy.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Ricci', 'Affiliation': 'Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany.'}, {'ForeName': 'Soledad', 'Initials': 'S', 'LastName': 'Del Pozo-Luengo', 'Affiliation': 'Clinical Analysis Service, University Hospital Virgen de la Arrixaca, 30120, El Palmar, Murcia, Spain.'}, {'ForeName': 'Pedro Luis', 'Initials': 'PL', 'LastName': 'Tornel', 'Affiliation': 'Clinical Analysis Service, University Hospital Virgen de la Arrixaca, 30120, El Palmar, Murcia, Spain.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Scazzina', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}, {'ForeName': 'Angel', 'Initials': 'A', 'LastName': 'Gil-Izquierdo', 'Affiliation': 'Research Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, CEBAS-CSIC, University Campus of Espinardo, Edif. 25, 30100, Murcia, Spain.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Dei Cas', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.'}, {'ForeName': 'Furio', 'Initials': 'F', 'LastName': 'Brighenti', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Bonadonna', 'Affiliation': 'Department of Medicine and Surgery, University of Parma, 43126, Parma, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Del Rio', 'Affiliation': 'Human Nutrition Unit, Department of Veterinary Sciences, University of Parma, University Hospital Building 27, Via Gramsci 14, 43126, Parma, Italy. daniele.delrio@unipr.it.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Mena', 'Affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125, Parma, Italy.'}]",European journal of nutrition,['10.1007/s00394-020-02347-5'] 2680,32729181,Sentinel lymph node biopsy vs no axillary surgery in early breast cancer clinically and ultrasonographically node negative: A prospective randomized controlled trial-VENUS trial.,,2020,,['early breast cancer clinically and ultrasonographically node negative'],['Sentinel lymph node biopsy vs no axillary surgery'],[],"[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0205160', 'cui_str': 'Negative'}]","[{'cui': 'C0796693', 'cui_str': 'Sentinel lymph node biopsy'}, {'cui': 'C0004454', 'cui_str': 'Axillary'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]",[],,0.0920033,,"[{'ForeName': 'Danielle Cristina Miyamoto', 'Initials': 'DCM', 'LastName': 'Araújo', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}, {'ForeName': 'Giuliano Mendes', 'Initials': 'GM', 'LastName': 'Duarte', 'Affiliation': 'Breast and gynecologic oncology department, Hospital da Mulher Prof. Dr. J. A. Pinotti-CAISM-Unicamp, Campinas, Brazil.'}, {'ForeName': 'Rodrigo Menezes', 'Initials': 'RM', 'LastName': 'Jales', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}, {'ForeName': 'Julia Yoriko', 'Initials': 'JY', 'LastName': 'Shinzato', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}, {'ForeName': 'Cassio', 'Initials': 'C', 'LastName': 'Cardoso Filho', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}, {'ForeName': 'Renato Zocchio', 'Initials': 'RZ', 'LastName': 'Torresan', 'Affiliation': 'Breast and gynecologic oncology department, Hospital da Mulher Prof. Dr. J. A. Pinotti-CAISM-Unicamp, Campinas, Brazil.'}, {'ForeName': 'Fabrício Palermo', 'Initials': 'FP', 'LastName': 'Brenelli', 'Affiliation': 'Breast and gynecologic oncology department, Hospital da Mulher Prof. Dr. J. A. Pinotti-CAISM-Unicamp, Campinas, Brazil.'}, {'ForeName': 'Sergio Carlos Barros', 'Initials': 'SCB', 'LastName': 'Esteves', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}, {'ForeName': 'Luis Otavio', 'Initials': 'LO', 'LastName': 'Sarian', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas-Unicamp, Brazil.'}]",The breast journal,['10.1111/tbj.13994'] 2681,32729211,Humanism and professionalism training for pediatric hematology-oncology fellows: Results of a multicenter randomized trial.,"PURPOSE Although humanism and professionalism are central tenets to the practice of medicine, few formal curricula exist for medical trainees. Following a national needs assessment among pediatric hematology-oncology (PHO) fellows, we created a novel curriculum entitled ""Humanism and Professionalism for Pediatric Hematology-Oncology"" (HP-PHO). In this study, we measure outcomes of this curricular intervention. METHOD We cluster-randomized 20 PHO fellowship programs to deliver usual training in humanism and professionalism (UT) or the novel curriculum (intervention) during the 2016-2017 academic year. The primary outcome measure was the Pediatric Hematology-Oncology Self-Assessment in Humanism (PHOSAH). Secondary measures included the Maslach Burnout Inventory, Patient-Provider Orientation Scale, Empowerment at Work Scale, and a 5-point satisfaction scale. Participating fellows completed pre- and posttests at the beginning and end of the academic year, respectively, and we calculated change scores for each study instrument. RESULTS Cluster randomization yielded 59 intervention and 41 UT fellows. The nine intervention sites administered 33 of 36 modules. Change scores on the PHOSAH were not significantly different between the UT and intervention arms. However, fellows on the intervention arm gave significantly higher ratings on several items within the satisfaction scale related to physician burnout, physician depression, balancing professional duties and personal life, and humanism overall. CONCLUSIONS Exposure to the HP-PHO curriculum did not alter fellows' self-assessed humanism and professionalism skills. However, intervention fellows expressed significantly higher levels of satisfaction in their humanism training, indicating the curriculum's potential for positive impact on the fellows' perceived learning environment.",2020,"However, fellows on the intervention arm gave significantly higher ratings on several items within the satisfaction scale related to physician burnout, physician depression, balancing professional duties and personal life, and humanism overall. ","['pediatric hematology-oncology fellows', 'pediatric hematology-oncology (PHO) fellows']","['Humanism and professionalism training', 'usual training in humanism and professionalism (UT) or the novel curriculum (intervention']","['Pediatric Hematology-Oncology Self-Assessment in Humanism (PHOSAH', ""fellows' self-assessed humanism and professionalism skills"", 'physician burnout, physician depression, balancing professional duties and personal life, and humanism overall', 'Maslach Burnout Inventory, Patient-Provider Orientation Scale, Empowerment at Work Scale, and a 5-point satisfaction scale', 'Change scores on the PHOSAH']","[{'cui': 'C1518927', 'cui_str': 'Pediatric hematology oncology'}]","[{'cui': 'C0020156', 'cui_str': 'Humanism'}, {'cui': 'C0815219', 'cui_str': 'Professionalism'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C1518927', 'cui_str': 'Pediatric hematology oncology'}, {'cui': 'C0036591', 'cui_str': 'Self Assessment'}, {'cui': 'C0020156', 'cui_str': 'Humanism'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0815219', 'cui_str': 'Professionalism'}, {'cui': 'C0031831', 'cui_str': 'Physician'}, {'cui': 'C0476644', 'cui_str': 'Physical AND emotional exhaustion state'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",20.0,0.0296202,"However, fellows on the intervention arm gave significantly higher ratings on several items within the satisfaction scale related to physician burnout, physician depression, balancing professional duties and personal life, and humanism overall. ","[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Kesselheim', 'Affiliation': ""Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.""}, {'ForeName': 'Justin N', 'Initials': 'JN', 'LastName': 'Baker', 'Affiliation': ""Department of Oncology, Division of Quality of Life and Palliative Care, St Jude Children's Research Hospital, Memphis, Tennessee.""}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Kersun', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.""}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Lee-Miller', 'Affiliation': ""Department of Oncology, Phoenix Children's Hospital, Phoenix, Arizona.""}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Moerdler', 'Affiliation': ""Department of Pediatrics, The Children's Hospital at Montefiore, New York City, New York.""}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Snaman', 'Affiliation': ""Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.""}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Warwick', 'Affiliation': 'Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.'}, {'ForeName': 'Shicheng', 'Initials': 'S', 'LastName': 'Weng', 'Affiliation': 'Department of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': 'Zilu', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Department of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Pediatric blood & cancer,['10.1002/pbc.28308'] 2682,32729217,A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control.,"AIMS To compare the safety and efficacy of insulin glargine 300 U/mL (Gla-300) versus first-generation standard-of-care basal insulin analogues (SOC-BI; insulin glargine 100 U/mL or insulin detemir) at 6 months. METHODS In the 12-month, open-label, multicentre, randomized, pragmatic ACHIEVE Control trial, insulin-naïve adults with type 2 diabetes (T2D) and glycated haemoglobin A1c (HbA1c) 64-97 mmol/mol (8.0%-11.0%) after ≥1 year of treatment with ≥2 diabetes medications were randomized to Gla-300 or SOC-BI. The composite primary endpoint, evaluated at 6 months, was the proportion of participants achieving individualized HbA1c targets per HEDIS criteria without documented symptomatic (blood glucose ≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia at any time of the day at 6 months. RESULTS Of 1651 and 1653 participants randomized to Gla-300 and SOC-BI, respectively, 31.3% and 27.9% achieved the composite primary endpoint at 6 months (odds ratio [OR] 1.19; 95% CI 1.01-1.39; P = 0.03 for superiority); 78.4% and 75.3% had no documented symptomatic or severe hypoglycaemia (OR 1.19; 95% CI 1.01-1.41). Changes from baseline to month 6 in HbA1c, fasting plasma glucose, weight, and BI analogue dose were similar between groups. CONCLUSIONS Among insulin-naïve adults with poorly controlled T2D, Gla-300 was associated with a statistically significant higher proportion of participants achieving individualized HEDIS HbA1c targets without documented symptomatic or severe hypoglycaemia (versus SOC-BI) in a real-life population managed in a usual-care setting. The ACHIEVE Control study results add value to treatment decisions and options for patients, healthcare providers, payers, and decision makers. ClinicalTrials.gov identifier: NCT02451137 This article is protected by copyright. All rights reserved.",2020,"Changes from baseline to month 6 in HbA1c, fasting plasma glucose, weight, and BI analogue dose were similar between groups. ","['naïve adults with type 2 diabetes (T2D) and glycated haemoglobin A1c (HbA1c) 64-97\u2009mmol/mol (8.0%-11.0%) after ≥1 year of treatment with ≥2 diabetes medications', 'naïve adults with poorly controlled T2D', 'insulin-naïve adults with type 2 diabetes']","['insulin', 'insulin glargine 300 U/mL versus first-generation basal insulin analogues', 'Gla-300 or SOC-BI', 'insulin glargine 300 U/mL (Gla-300) versus first-generation standard-of-care basal insulin analogues (SOC-BI; insulin glargine 100 U/mL or insulin detemir']","['proportion of participants achieving individualized HbA1c targets per HEDIS criteria without documented symptomatic (blood glucose', 'safety and efficacy', 'severe hypoglycaemia', 'symptomatic or severe hypoglycaemia', 'HbA1c, fasting plasma glucose, weight, and BI analogue dose']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mol'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0907402', 'cui_str': 'Insulin Glargine'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439340', 'cui_str': 'kU/L'}, {'cui': 'C0079411', 'cui_str': 'Generations'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0537270', 'cui_str': 'insulin detemir'}]","[{'cui': 'C1318607', 'cui_str': 'HBA1c target'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C4728082', 'cui_str': 'Severe hypoglycaemia'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",1653.0,0.18777,"Changes from baseline to month 6 in HbA1c, fasting plasma glucose, weight, and BI analogue dose were similar between groups. ","[{'ForeName': 'Luigi F', 'Initials': 'LF', 'LastName': 'Meneghini', 'Affiliation': 'University of Texas Southwestern Medical Center and Parkland Health & Hospital System, Dallas, Texas.'}, {'ForeName': 'Sean D', 'Initials': 'SD', 'LastName': 'Sullivan', 'Affiliation': 'CHOICE Institute, School of Pharmacy, University of Washington, Seattle, Washington.'}, {'ForeName': 'Gerry', 'Initials': 'G', 'LastName': 'Oster', 'Affiliation': 'Policy Analysis Inc., Brookline, Massachusetts.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Busch', 'Affiliation': 'Albany Medical College Faculty Practice: Community Endocrine Group, Albany, New York.'}, {'ForeName': 'Anna M G', 'Initials': 'AMG', 'LastName': 'Cali', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Dauchy', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Jasvinder', 'Initials': 'J', 'LastName': 'Gill', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Bailey', 'Affiliation': 'AMCR Institute, Escondido, California.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14152'] 2683,32729222,Combination Therapy with Pioglitazone/Exenatide Improves Beta Cell Function and Produces Superior Glycemic Control Compared to Basal/Bolus Insulin in Poorly Controlled T2DM: 3-Year Follow-up of the Qatar Study.,"AIM To examine the long term efficacy of combination therapy with agents known to improve beta cell failure in T2DM, i.e. thiazolidinedione plus GLP-1 RA, versus basal-bolus insulin on glycemic control and beta cell function in poorly controlled T2DM patients on metformin plus sulfonylurea. MATERIALS AND METHODS 331 poorly controlled T2DM patients were recruited over 3 years and followed for an additional one year. Subjects received 75-gram OGTT at baseline and at study end. After completing the baseline OGTT, subjects were randomized to receive: (i) pioglitazone plus weekly exenatide (Combination Therapy), or (ii) basal/bolus insulin (Insulin Therapy) to maintain HbA1c <7.0%. The primary outcome of the study was the difference in HbA1c at study end between the two treatment groups. RESULTS Both therapies caused a robust decrease in HbA1c. However, Combination Therapy caused a greater decrement (-1.1%, p<0.0001) than Insulin Therapy, and more subjects in the Combination Therapy group (86%) achieved the ADA goal of glycemic control, HbA1c<7.0% than in Insulin Therapy group (44%) (p<0.0001). Both therapies improved insulin secretion. However, the improvement in insulin secretion with Combination Therapy was (2.5-fold) greater (p<0.001) than with Insulin Therapy (50%). Insulin Therapy caused more weight gain and hypoglycemia. CONCLUSION Both Combination Therapy and Insulin Therapy effectively reduced the HbA1c in poorly controlled T2DM on multiple oral agents. However, Combination Therapy produced greater improvement in insulin secretion and decrease in HbA1c with lower risk of hypoglycemia. This article is protected by copyright. All rights reserved.",2020,"However, Combination Therapy caused a greater decrement (-1.1%, p<0.0001) than Insulin Therapy, and more subjects in the Combination Therapy group (86%) achieved the ADA goal of glycemic control, HbA1c<7.0% than in Insulin Therapy group (44%)","['331 poorly controlled T2DM patients were recruited over 3 years and followed for an additional one year', 'poorly controlled T2DM patients on metformin plus sulfonylurea']","['Insulin Therapy', 'Pioglitazone/Exenatide', 'thiazolidinedione plus GLP-1 RA', 'pioglitazone plus weekly exenatide (Combination Therapy), or (ii) basal/bolus insulin (Insulin Therapy) to maintain HbA1c <7.0']","['Beta Cell Function', 'ADA goal of glycemic control', 'glycemic control and beta cell function', 'insulin secretion', 'weight gain and hypoglycemia']","[{'cui': 'C3853134', 'cui_str': 'Poorly controlled'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0038766', 'cui_str': 'Sulfonylurea'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0071097', 'cui_str': 'pioglitazone'}, {'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C0289779', 'cui_str': '2,4-thiazolidinedione'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-like peptide 1'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}]","[{'cui': 'C0030281', 'cui_str': 'Structure of beta Cell of islet'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0001457', 'cui_str': 'Adenosine deaminase'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}]",,0.0567023,"However, Combination Therapy caused a greater decrement (-1.1%, p<0.0001) than Insulin Therapy, and more subjects in the Combination Therapy group (86%) achieved the ADA goal of glycemic control, HbA1c<7.0% than in Insulin Therapy group (44%)","[{'ForeName': 'Muhammad', 'Initials': 'M', 'LastName': 'Abdul-Ghani', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, TX.'}, {'ForeName': 'Osama', 'Initials': 'O', 'LastName': 'Migahid', 'Affiliation': 'Academic Health System, Hamad General Hospital, Doha, Qatar.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Megahed', 'Affiliation': 'Academic Health System, Hamad General Hospital, Doha, Qatar.'}, {'ForeName': 'Ralph A', 'Initials': 'RA', 'LastName': 'DeFronzo', 'Affiliation': 'Division of Diabetes, University of Texas Health Science Center at San Antonio, TX.'}, {'ForeName': 'Ebaa', 'Initials': 'E', 'LastName': 'Al-Ozairi', 'Affiliation': 'Dasman Diabetes Institute, Kuwait City, Kuwait.'}, {'ForeName': 'Amin', 'Initials': 'A', 'LastName': 'Jayyousi', 'Affiliation': 'Academic Health System, Hamad General Hospital, Doha, Qatar.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14153'] 2684,32729231,A collaborative approach in patient education for diabetes foot and wound care: A pragmatic randomised controlled trial.,"Foot care education is an important strategy in reducing lower limb complications. There is evidence that contemporary communication approaches can improve patient education outcomes. To inform the potential of such methods in diabetic foot education, we trialled a collaborative approach in patient education counselling in a podiatry clinic. We conducted a single-blind pragmatic randomised controlled trial on 52 diabetes patients who had an active foot ulcer. Participants were randomised to either collaborative education or traditional didactic education. Outcomes on knowledge and self-care behaviours were collected via a pre and post study questionnaire (max score: 75). The study ended at 12 weeks or when the wound healed prior. 42 (80.7%) participants completed the study. The collaborative patient education group had a significant increase in score post-study (38.8 ± 8.5) compared to pre-study (32.8 ± 6.9; P < .001). The control group had no significant increase in score post study. The difference in scores between groups had a moderate effect size (d = 0.54). The use of a collaborative approach in patient education was able to produce significantly greater increase in knowledge retention and self-care behaviours, without the need for additional consultation time in a podiatry clinic.",2020,"The use of a collaborative approach in patient education was able to produce significantly greater increase in knowledge retention and self-care behaviours, without the need for additional consultation time in a podiatry clinic.","['52 diabetes patients who had an active foot ulcer', 'patient education for diabetes foot and wound care', 'patient education counselling in a podiatry clinic']",['collaborative education or traditional didactic education'],"['knowledge retention and self-care behaviours', 'knowledge and self-care behaviours']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0085119', 'cui_str': 'Ulcer of foot'}, {'cui': 'C0030688', 'cui_str': 'Patient education'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0886052', 'cui_str': 'Wound care'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C3244278', 'cui_str': 'Podiatry clinic'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0474417', 'cui_str': 'Self-care behavior'}]",52.0,0.178581,"The use of a collaborative approach in patient education was able to produce significantly greater increase in knowledge retention and self-care behaviours, without the need for additional consultation time in a podiatry clinic.","[{'ForeName': 'Marabelle Liwen', 'Initials': 'ML', 'LastName': 'Heng', 'Affiliation': 'Podiatry Department, Singapore General Hospital, Singapore.'}, {'ForeName': 'Yu Heng', 'Initials': 'YH', 'LastName': 'Kwan', 'Affiliation': 'Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore.'}, {'ForeName': 'Nik', 'Initials': 'N', 'LastName': 'Ilya', 'Affiliation': 'Podiatry Department, Singapore General Hospital, Singapore.'}, {'ForeName': 'Izza Atiqa', 'Initials': 'IA', 'LastName': 'Ishak', 'Affiliation': 'Podiatry Department, Singapore General Hospital, Singapore.'}, {'ForeName': 'Patricia Huixia', 'Initials': 'PH', 'LastName': 'Jin', 'Affiliation': 'Medical Social Services, Singapore General Hospital, Singapore.'}, {'ForeName': 'Debbie', 'Initials': 'D', 'LastName': 'Hogan', 'Affiliation': 'Academy of Solutions Focused Training, Singapore.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Carmody', 'Affiliation': 'Department of Endocrinology, Singapore General Hospital, Singapore.'}]",International wound journal,['10.1111/iwj.13450'] 2685,32729280,Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study.,"INTRODUCTION Linkage to care among people with substance misuse remains a barrier to the elimination of the hepatitis C virus (HCV). We aimed to determine if point-of-care (PoC) education, screening and staging for liver disease with direct access to hospitals would improve linkage to care among this group. METHODS All participants were offered PoC education and HCV screening. HCV-positive participants were randomised to standard care (controls) or direct access, which provided a direct pathway to hospitals. Linkage to care was determined by reviewing electronic medical records. Linkage of care cascade was defined as attendance at the specialist clinic, confirmation of viraemia by HCV RNA testing, discussion about HCV treatment and initiation of treatment. RESULTS 351 halfway house residents were screened. The overall HCV prevalence was 30.5% (n = 107), with 69 residents in the control group and 38 in the direct access group. The direct access group had a significantly higher percentage of cases linked to specialist review for confirmatory RNA testing (63.2% vs. 40.6%, p = 0.025), HCV treatment discussion (p = 0.009) and treatment initiation (p = 0.01) compared to the controls. Overall, only 12.6% (n = 13) had treatment initiation during follow-up. PoC HCV screening with direct access referral had significantly higher linkage to HCV treatment initiation (adjusted odds ratio 9.13, p = 0.005) in multivariate analysis. CONCLUSION PoC HCV screening with direct access improves linkage to care and simplifies the HCV care cascade, leading to improved treatment uptake. PoC education, screening, diagnosis and treatment may be an effective strategy to achieving HCV micro-elimination in this population.",2020,"PoC HCV screening with direct access referral had significantly higher linkage to HCV treatment initiation (adjusted odds ratio 9.13, p = 0.005) in multivariate analysis. ","['people with substance misuse', '351 halfway house residents were screened', 'HCV-positive participants']","['PoC', 'standard care (controls) or direct access']",['overall HCV prevalence'],"[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0439861', 'cui_str': 'Substance'}, {'cui': 'C0018518', 'cui_str': 'Halfway house'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]","[{'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0079500', 'cui_str': 'Hepacivirus'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}]",351.0,0.0376455,"PoC HCV screening with direct access referral had significantly higher linkage to HCV treatment initiation (adjusted odds ratio 9.13, p = 0.005) in multivariate analysis. ","[{'ForeName': 'John Chen', 'Initials': 'JC', 'LastName': 'Hsiang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.'}, {'ForeName': 'Pream', 'Initials': 'P', 'LastName': 'Sinnaswami', 'Affiliation': 'Saw Swee Hock School of Public Health, National University of Singapore, Singapore.'}, {'ForeName': 'Mui Yok', 'Initials': 'MY', 'LastName': 'Lee', 'Affiliation': 'Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.'}, {'ForeName': 'Meng Meng', 'Initials': 'MM', 'LastName': 'Zhang', 'Affiliation': 'Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.'}, {'ForeName': 'Kwang Ee', 'Initials': 'KE', 'LastName': 'Quek', 'Affiliation': 'Clinical Trials and Research Unit, Changi General Hospital, Singapore.'}, {'ForeName': 'Keng Hwee', 'Initials': 'KH', 'LastName': 'Tan', 'Affiliation': 'Clinical Trials and Research Unit, Changi General Hospital, Singapore.'}, {'ForeName': 'Yew Meng', 'Initials': 'YM', 'LastName': 'Wong', 'Affiliation': 'Clinical Trials and Research Unit, Changi General Hospital, Singapore.'}, {'ForeName': 'Prem Harichander', 'Initials': 'PH', 'LastName': 'Thurairajah', 'Affiliation': 'Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.'}]",Singapore medical journal,['10.11622/smedj.2020116'] 2686,32729342,Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: A trial-based health economics study.,"AIMS The aim of this health economics study was to estimate the cost-utility of an aseptically processed, dehydrated human amnion and chorion allograft (dHACA) plus standard of care (SOC) (group 1) versus SOC alone (group 2) based on a published randomized controlled trial in which patients who had an eligible Wagner 1 diabetic foot ulcer wound were randomized to either of these treatments. MATERIALS AND METHODS A Markov microsimulation was used to project trial results out to a 1-year horizon time with a third-party payer perspective. The starting health state was an unhealed non-infected ulcer with other health states of healed ulcer, infected non-healed ulcer, cellulitis, osteomyelitis, and absorbing states of dead or amputation. All patients started with unhealed non-infected ulcers at cycle 0. Costs were incurred by patients for procedures at hospital outpatient wound care provider-based departments (PBDs) and hospitals (if complications occurred) and were calculated using time-based activity costing methods. Effectiveness units were quality-adjusted life years (QALYs) computed from literature utility values. One-way and probabilistic sensitivity analysis (PSA) were also conducted. RESULTS After 1 year, the calculated incremental cost-effectiveness ratio (ICER) for group 1 versus group 2 was -$4,373 with group 1 (dHACA) being dominant over group 2 (SOC). PSA demonstrated that group 1 had 69.2% lower cost values with increased positive incremental effectiveness for 94.9% of values. A willingness to pay (WTP) curve showed that about 92% of interventions were cost effective for group 1 when $50,000 was paid. CONCLUSIONS The results of this study demonstrated that dHACA added to SOC compared to SOC alone was extremely cost-effective in the defined trial population.",2020,PSA demonstrated that group 1 had 69.2% lower cost values with increased positive incremental effectiveness for 94.9% of values.,"['Wagner 1 diabetic foot ulcers', 'patients who had an eligible Wagner 1 diabetic foot ulcer wound']","['Dehydrated human amnion and chorion allograft versus standard of care alone', 'aseptically processed, dehydrated human amnion and chorion allograft (dHACA) plus standard of care (SOC', 'SOC', 'dHACA', 'SOC alone']","['calculated incremental cost-effectiveness ratio (ICER', 'cost effective']","[{'cui': 'C1456868', 'cui_str': 'Diabetic foot ulcer'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0021501', 'cui_str': 'wounds'}]","[{'cui': 'C0011175', 'cui_str': 'Dehydration'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0002630', 'cui_str': 'Structure of amnion'}, {'cui': 'C0008503', 'cui_str': 'Chorionic structure'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0444686', 'cui_str': 'Calculated'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0820619,PSA demonstrated that group 1 had 69.2% lower cost values with increased positive incremental effectiveness for 94.9% of values.,"[{'ForeName': 'Marissa J', 'Initials': 'MJ', 'LastName': 'Carter', 'Affiliation': 'Strategic Solutions, Inc., Bozeman, MT, USA.'}]",Journal of medical economics,['10.1080/13696998.2020.1803888'] 2687,32729334,Platycodon grandiflorum Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients.,"Background: Anthracycline-based chemotherapy is an effective treatment used for early-stage breast cancer patients. However, anthracycline use is limited due to its cardiotoxic effects. Recent studies have shown that Platycodon grandiflorum (PG) protects the heart from anthracycline-induced cardiotoxicity. However, no randomized, placebo-controlled clinical trial has been performed to investigate the clinical use of PG to prevent anthracycline-induced cardiotoxicity. This study aimed to evaluate the cardioprotective effects and safety of PG in early breast cancer patients receiving anthracycline-based chemotherapy. Methods: A total of 125 early breast cancer patients receiving anthracycline-based chemotherapy were enrolled and randomized into a PG group or placebo group in a 1:1 ratio. Results: Only 2 (3.1%) participants in the placebo group and 1 (1.6%) participant in the PG group experienced NYHA (New York Heart Association) class III or IV heart failure. There were no significant differences observed between the 2 groups. However, compared with the placebo group, patients in the PG group showed a lower incidence of subclinical heart failure (21.9% vs 8.2%, respectively, P = .033), as well as lower cardiac troponin T levels (48.4% vs 31.1%, respectively, P = .002). Importantly, there were no differences observed in the antitumor effects of anthracycline between the 2 groups (disease-free survival: hazards ratio = 1.09, 95% confidence interval = 0.45-2.62, P = .84; overall survival: hazards ratio = 1.46, 95% confidence interval = 0.33-6.43, P = .62). Conclusion: PG prevents anthracycline-induced acute and chronic cardiac injury in early-stage breast cancer patients without compromising the antitumor effects of chemotherapy.",2020,PG prevents anthracycline-induced acute and chronic cardiac injury in early-stage breast cancer patients without compromising the antitumor effects of chemotherapy.,"['early-stage breast cancer patients', 'early breast cancer patients receiving anthracycline-based chemotherapy', '125 early breast cancer patients receiving', 'Early Breast Cancer Patients']","['chemotherapy', 'anthracycline-based chemotherapy', 'Platycodon grandiflorum Protects Against Anthracycline-Induced Cardiotoxicity', 'Anthracycline-based chemotherapy', 'anthracycline', 'placebo']","['cardiac troponin T levels', 'antitumor effects of anthracycline', 'subclinical heart failure']","[{'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C4319551', 'cui_str': '125'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1135815', 'cui_str': 'Balloon Flower'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0876994', 'cui_str': 'Cardiotoxicity'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0523953', 'cui_str': 'Troponin T cardiac measurement'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0003234', 'cui_str': 'Anthracycline'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}]",125.0,0.285257,PG prevents anthracycline-induced acute and chronic cardiac injury in early-stage breast cancer patients without compromising the antitumor effects of chemotherapy.,"[{'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hao', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Youyang', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Yuenong', 'Initials': 'Y', 'LastName': 'Qin', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Chenping', 'Initials': 'C', 'LastName': 'Sun', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Liying', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Chunyu', 'Initials': 'C', 'LastName': 'Wu', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Yijia', 'Initials': 'Y', 'LastName': 'Bao', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}, {'ForeName': 'Sheng', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Long Hua Hospital, Shanghai, China.'}]",Integrative cancer therapies,['10.1177/1534735420945017'] 2688,32729350,Comparison of the benefits and hemodynamic side effects of oxytocin between intravenous infusion with and without bolus injection during caesarean section.,"The aim of this study was to compare the benefits and hemodynamic side effects of oxytocin between intravenous infusion with and without a bolus injection during a caesarean section. Women with singleton pregnancies who underwent caesarean sections under spinal anaesthesia were included. Oxytocin was administered by an iv bolus injection (5 U) followed by an intravenous infusion (10 U of oxytocin in 500 mL normal saline); this was switched to just an intravenous infusion. The amount of blood loss did not differ between the groups. In a multivariate analysis, the adjusted odds ratios for the risk of hypotension (≥20% reduction of systolic BP) and tachycardia (heart rate ≥100 bpm) were 4.5 (95% confidence interval [CI], 1.6-12.5) and 3.7 (95%CI 1.9-7.2) in the iv bolus group, respectively, compared with the just the infusion group. The oxytocin administration by iv bolus injection did not decrease blood loss and increased the rate of hemodynamic side effects. Impact statement What is already known on this subject? Oxytocin is used as the first-line uterotonic treatment to prevent a postpartum haemorrhage in women undergoing Caesarean Sections. Oxytocin is known to relax vascular smooth muscle, which can cause hypotension and tachycardia. The protocols for administering oxytocin during CS vary by institution. What do the results of this study add? Combined treatment with oxytocin by iv bolus injection (5 U) followed by iv infusion (10 U of oxytocin in 500 mL normal saline) during CS increased the risk of developing adverse hemodynamic side effects, including hypotension, tachycardia, and the need for vasopressors, without any benefit in the control of intraoperative blood loss in comparison to iv infusion alone. What are the implications of these findings for clinical practice and/or further research? We should abandon the iv bolus injection of oxytocin during CS, especially for women undergoing an elective CS who are not in labour.",2020,The amount of blood loss did not differ between the groups.,"['Women with singleton pregnancies who underwent caesarean sections under spinal anaesthesia were included', 'women undergoing Caesarean Sections', 'women undergoing an elective CS who are not in labour', 'caesarean section']","['oxytocin', 'Oxytocin']","['risk of hypotension', 'rate of hemodynamic side effects', 'risk of developing adverse hemodynamic side effects, including hypotension, tachycardia, and the need for vasopressors', 'systolic BP) and tachycardia', 'blood loss']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0007876', 'cui_str': 'Cesarean section'}, {'cui': 'C0002928', 'cui_str': 'Spinal anesthesia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0022864', 'cui_str': 'Labor'}]","[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0020649', 'cui_str': 'Low blood pressure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0039231', 'cui_str': 'Tachycardia'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C0042397', 'cui_str': 'Vasoconstrictor agent'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}]",,0.302,The amount of blood loss did not differ between the groups.,"[{'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Miyoshi', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Shohei', 'Initials': 'S', 'LastName': 'Kaneko', 'Affiliation': 'Department of Anesthesiology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Sachie', 'Initials': 'S', 'LastName': 'Suga', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Megumi', 'Initials': 'M', 'LastName': 'Koga', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'So', 'Initials': 'S', 'LastName': 'Sugimi', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Yamashita', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Michiko', 'Initials': 'M', 'LastName': 'Yamaguchi', 'Affiliation': 'Department of Anesthesiology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}, {'ForeName': 'Ichiro', 'Initials': 'I', 'LastName': 'Yasuhi', 'Affiliation': 'Department of Obstetrics and Gynecology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.'}]",Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,['10.1080/01443615.2020.1780421'] 2689,32729404,Central Sympathetic Nervous System Effects on Cognitive-Motor Performance.,"The intriguing interplay between acute stress physiology and cognitive processes has long been noted. However, while stress-induced release of glucocorticoids has repeatedly been shown to impact brain mechanisms underlying cognition and memory, less experimental research addressed the effects of stress-induced central sympathetic nervous system (SNS) activation on cognitive performance. Moreover, despite the long-standing notion that the way performance is modulated by arousal may crucially depend on task complexity, mechanistic research demonstrating a direct, causal influence of altered SNS activity is scarce. Twelve healthy men participated in a placebo-controlled, pharmacologic dose-response study involving three within-subject assessments (1-week intervals). Subjective and objective indices of SNS activity as well as reaction time (RT) in three different tasks varying in cognitive demand (simple RT, choice RT, and verbal RT in complex mental arithmetic) were assessed during modulation of central SNS tone by intravenous infusions of dexmedetomidine (alpha2-agonist), yohimbine (alpha2-antagonist), and placebo. Cognitive performance was negatively affected by alpha2-agonism in all task conditions. By contrast, administration of yohimbine improved simple RT, while diminishing complex RT, supporting the assumption of a nonlinear way of action depending on task characteristics. Our results highlight the consequences of central (noradrenergic) SNS activation for cognitive-motor performance in RT tasks of varying complexity.",2020,"Subjective and objective indices of SNS activity as well as reaction time (RT) in three different tasks varying in cognitive demand (simple RT, choice RT, and verbal RT in complex mental arithmetic) were assessed during modulation of central SNS tone by intravenous infusions of dexmedetomidine (alpha2-agonist), yohimbine (alpha2-antagonist), and placebo.",['Twelve healthy men participated in a'],"['dexmedetomidine (alpha2-agonist), yohimbine (alpha2-antagonist), and placebo', 'yohimbine', 'placebo']","['Cognitive performance', 'cognitive demand (simple RT, choice RT, and verbal RT in complex mental arithmetic', 'Cognitive-Motor Performance', 'reaction time (RT']","[{'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0724441', 'cui_str': 'yohimbine'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0034746', 'cui_str': 'Response Time'}, {'cui': 'C0008300', 'cui_str': 'Choice Behavior'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}]",12.0,0.040691,"Subjective and objective indices of SNS activity as well as reaction time (RT) in three different tasks varying in cognitive demand (simple RT, choice RT, and verbal RT in complex mental arithmetic) were assessed during modulation of central SNS tone by intravenous infusions of dexmedetomidine (alpha2-agonist), yohimbine (alpha2-antagonist), and placebo.","[{'ForeName': 'Johannes B', 'Initials': 'JB', 'LastName': 'Finke', 'Affiliation': 'Institute of Psychobiology, Department of Clinical Psychophysiology, University of Trier, Trier, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Schächinger', 'Affiliation': 'Institute of Psychobiology, Department of Clinical Psychophysiology, University of Trier, Trier, Germany.'}]",Experimental psychology,['10.1027/1618-3169/a000475'] 2690,32729749,Cost-utility analysis of normothermic liver perfusion with OrganOx compared to static cold storage in the United Kingdom.,"Background: Rising numbers of patients on the active transplant list of liver transplantation has led to the utilisation of organs from higher-risk donors that are more likely to be discarded and are prone to post-transplant complications. Storage and transportation of the livers in low temperatures can cause damage. OrganOx metra is a portable device intended to preserve and maintain the donated liver in normothermic conditions for up to 24 hours between the point of retrieval and transplantation. Objective: To evaluate the cost-utility of normothermic machine perfusion with OrganOx metra in liver transplantation compared to the current practice of static cold storage (SCS). Methods: A de novo decision analytic model (a decision tree along with a Markov model), based on current treatment pathways, was developed to estimate the costs and outcomes. Results from a randomised clinical trial and national standard sources were used to inform the model. Costs were estimated from the National Health Service and Personal Social Services perspective. Deterministic and probabilistic sensitivity analyses (PSA) were conducted to explore uncertainty surrounding input parameters. Results: Over a lifetime time horizon, liver transplantation with OrganOx metra was more costly and more effective than the current practice of static cold storage. The total costs per patient were £37,370 versus £46,711 and the total effectiveness per patient was 9.09 QALYs versus 10.27 QALYs for SCS and OrganOx metra groups, respectively. The estimated ICER was £7,876 per each QALY gained. Results from the PSA showed that use of OrganOx metra has 99% probability of being cost-effective at a £20,000 willingness-to-pay threshold. OrganOx metra led to the utilisation of 54 additional livers with patients experiencing lower rates of early allograft dysfunction and adverse events. Conclusions: Use of OrganOx metra for the perfusion and transportation of livers prior to transplantation is a cost-effective strategy. Key Points for Decision MakersIntroduction of OrganOx metra into NHS could increase the utilisation of donated livers with patients experiencing lower rates of early allograft dysfunction and adverse events, compared with current practice.Results of the economic analysis indicate that the OrganOx metra is highly likely to be cost-effective and result in improved patient outcomes.",2020,OrganOx metra led to the utilisation of 54 additional livers with patients experiencing lower rates of early allograft dysfunction and adverse events.,[],"['OrganOx metra', 'normothermic machine perfusion with OrganOx metra', 'OrganOx']","['total costs per patient', 'early allograft dysfunction and adverse events']",[],"[{'cui': 'C0445103', 'cui_str': 'Normothermia'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.035054,OrganOx metra led to the utilisation of 54 additional livers with patients experiencing lower rates of early allograft dysfunction and adverse events.,"[{'ForeName': 'Mehdi', 'Initials': 'M', 'LastName': 'Javanbakht', 'Affiliation': 'Optimax Access UK Ltd, University of Southampton Science Park, Chilworth, Hampshire, UK.'}, {'ForeName': 'Atefeh', 'Initials': 'A', 'LastName': 'Mashayekhi', 'Affiliation': 'Optimax Access UK Ltd, University of Southampton Science Park, Chilworth, Hampshire, UK.'}, {'ForeName': 'Miranda', 'Initials': 'M', 'LastName': 'Trevor', 'Affiliation': 'Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Branagan-Harris', 'Affiliation': 'Device Access UK Ltd, Market Access Consultancy, University of Southampton Science Park, Chilworth, Hampshire, UK.'}, {'ForeName': 'Jowan', 'Initials': 'J', 'LastName': 'Atkinson', 'Affiliation': 'Device Access UK Ltd, Market Access Consultancy, University of Southampton Science Park, Chilworth, Hampshire, UK.'}]",Journal of medical economics,['10.1080/13696998.2020.1804391'] 2691,32729761,Effects of using standardized patients on nursing students' moral skills.,"BACKGROUND Nurses and nursing students increasingly confront ethical problems in clinical practice. Moral sensitivity, moral reasoning, and ethical decision-making are therefore important skills throughout the nursing profession. Innovative teaching methods as part of the ethics training of nursing students help them acquire these fundamental skills. AIM This study investigated the effects and potential benefits of using standardized patients in ethics education on nursing baccalaureate students' moral sensitivity, moral reasoning, and ethical decision-making by comparing this method with in-class case analyses. RESEARCH DESIGN This is a quasi-experimental study. PARTICIPANTS AND RESEARCH CONTEXT The sample comprised 89 students in Hacettepe University's Faculty of Nursing. Following lectures describing the theoretical components of ethics, students were randomly assigned to two working groups, one using standardized patients and the other using in-class case analyses. Data were collected using the Moral Sensitivity Questionnaire, Rest's Defining Issues Test, and the Nursing Dilemma Test. All data were analysed using IBM SPSS Statistics Version 23. ETHICAL CONSIDERATIONS Ethical approval and official permission were obtained. All participating students completed informed consent forms. FINDINGS According to the results, the moral sensitivity of students in the standardized patient group significantly improved over time compared to those in the case analysis group, while the mean scores of students in both groups for moral reasoning and ethical decision-making were not statistically significant. CONCLUSION Based on our results, we recommend the use of both standardized patients and case analysis as appropriate teaching methods in ethics education.",2020,"According to the results, the moral sensitivity of students in the standardized patient group significantly improved over time compared to those in the case analysis group, while the mean scores of students in both groups for moral reasoning and ethical decision-making were not statistically significant. ","['Nurses and nursing students', ""89 students in Hacettepe University's Faculty of Nursing""]",[],['moral reasoning and ethical decision-making'],"[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0015535', 'cui_str': 'Faculty'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}]",[],"[{'cui': 'C0026531', 'cui_str': 'Morality'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}, {'cui': 'C0011109', 'cui_str': 'Decision making'}]",89.0,0.0297933,"According to the results, the moral sensitivity of students in the standardized patient group significantly improved over time compared to those in the case analysis group, while the mean scores of students in both groups for moral reasoning and ethical decision-making were not statistically significant. ","[{'ForeName': 'Gulhan Erkus', 'Initials': 'GE', 'LastName': 'Kucukkelepce', 'Affiliation': 'Adiyaman University, Turkey.'}, {'ForeName': 'Leyla', 'Initials': 'L', 'LastName': 'Dinc', 'Affiliation': ''}, {'ForeName': 'Melih', 'Initials': 'M', 'LastName': 'Elcin', 'Affiliation': 'Hacettepe University, Turkey.'}]",Nursing ethics,['10.1177/0969733020935954'] 2692,32729763,The effects of moderate alterations in adrenergic activity on acute appetite regulation in obese women: A randomised crossover trial.,"BACKGROUND Previous evidence has demonstrated that serum leptin is correlated with appetite in combination with, but not without, modest exercise. AIM The present experiments investigated the effects of exogenous adrenaline and α/β adrenoceptor blockade in combination with moderate exercise on serum leptin concentrations, appetite/satiety sensations and subsequent food intake in obese women. METHODS A total of 10 obese women ((mean ± SEM), age: 50 (1.9) years, body mass index 36 (4.1) kg/m 2 , waist 104.8 (4.1) cm) participated in two separate, double-blind randomised experimental trials. Experiment 1: moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally) versus moderate exercise plus placebo; experiment 2: adrenaline infusion for 20 minutes versus saline infusion. Appetite/satiety and biochemistry were measured at baseline, pre- and immediately post-intervention, then 1 hour post-intervention (i.e., before dinner). Food intake was assessed via ad libitum buffet-style dinner. RESULTS No differences were found in appetite/satiety, subsequent food intake or serum leptin in any of the studies (experiment 1 or experiment 2). In experiment 1, blood glucose was higher ( p < 0.01) and plasma free fatty acids lower ( p = 0.04) versus placebo. In experiment 2, plasma free fatty acids ( p < 0.05) increased after adrenaline versus saline infusion. CONCLUSIONS Neither inhibition of exercise-induced adrenergic activity by combined α/β adrenergic blockade nor moderate increases in adrenergic activity induced by intravenous adrenaline infusion affected acute appetite regulation.",2020,"No differences were found in appetite/satiety, subsequent food intake or serum leptin in any of the studies (experiment 1 or experiment 2).","['10 obese women ((mean ± SEM), age: 50 (1.9) years, body mass index 36 (4.1) kg/m 2 , waist 104.8 (4.1) cm', 'obese women']","['adrenaline infusion', 'moderate exercise after α/β adrenergic blocker (labetalol, 100 mg orally) versus moderate exercise plus placebo', 'exogenous adrenaline and α/β adrenoceptor blockade', 'adrenaline', 'placebo']","['Appetite/satiety and biochemistry', 'blood glucose', 'plasma free fatty acids lower', 'plasma free fatty acids', 'Food intake', 'appetite/satiety, subsequent food intake or serum leptin', 'serum leptin concentrations, appetite/satiety sensations and subsequent food intake', 'adrenergic activity']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0262878', 'cui_str': 'Scanning electron microscope'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517756', 'cui_str': '4.1'}, {'cui': 'C0230097', 'cui_str': 'Structure of waist (surface region)'}]","[{'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0242889', 'cui_str': 'Substance with adrenergic receptor antagonist mechanism of action'}, {'cui': 'C0022860', 'cui_str': 'Labetalol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0005477', 'cui_str': 'Biochemistry'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0015688', 'cui_str': 'Unesterified fatty acid'}, {'cui': 'C0441994', 'cui_str': 'Lower'}, {'cui': 'C0013470', 'cui_str': 'Eating'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}]",10.0,0.382086,"No differences were found in appetite/satiety, subsequent food intake or serum leptin in any of the studies (experiment 1 or experiment 2).","[{'ForeName': 'Fotini', 'Initials': 'F', 'LastName': 'Tsofliou', 'Affiliation': 'Human Nutrition, School of Medicine, University of Glasgow, United Kingdom.'}, {'ForeName': 'Yannis P', 'Initials': 'YP', 'LastName': 'Pitsiladis', 'Affiliation': 'College of Medical Veterinary and Life Science, Institute of Cardiovascular & Medical Sciences, University of Glasgow, United Kingdom.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Lara', 'Affiliation': 'Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, United Kingdom.'}, {'ForeName': 'Marios', 'Initials': 'M', 'LastName': 'Hadjicharalambous', 'Affiliation': 'College of Medical Veterinary and Life Science, Institute of Cardiovascular & Medical Sciences, University of Glasgow, United Kingdom.'}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Macdonald', 'Affiliation': ""School of Life Sciences, University of Nottingham Medical School, Queen's Medical Centre, United Kingdom.""}, {'ForeName': 'Mike A', 'Initials': 'MA', 'LastName': 'Wallace', 'Affiliation': 'University Department of Pathological Biochemistry, Glasgow Royal Infirmary, United Kingdom.'}, {'ForeName': 'Mike E J', 'Initials': 'MEJ', 'LastName': 'Lean', 'Affiliation': 'Human Nutrition, School of Medicine, University of Glasgow, United Kingdom.'}]",Nutrition and health,['10.1177/0260106020942117'] 2693,32729784,Postprandial glycemia and insulin secretion following glutamine administration: A randomized controlled trial.,"Objective : The objective of the present study is to investigate the effects of glutamine administration on postprandial glycemia, insulin, and C-peptide concentration in patients with type 2 diabetes. Methods : A randomized, double-blind, placebo-controlled trial was conducted on patients with type 2 diabetes so that 33 subjects were recruited in each group. The patients were randomly allocated to receive either 30 g/d glutamine or placebo (with instructions to take in half glass of ice-cold water 5 to 10 min before each main meal) for 6 weeks. Postprandial C-peptide, insulin, and glucose were measured at the baseline and at the end of the study at 30 and 90 min after consuming a meal comprising wheat-cake and reduced fat milk. Results : The repeated measures ANOVA revealed no significant difference between the groups for glucose and insulin after 6 weeks of intervention ( p  > 0.05). However, C-peptide was reduced in both intervention groups at all measurement points. Between-group differences remained significant by the end of the study ( p  = 0.02). Conclusions : Glutamine supplementation before each main meal does not represent an effective nutritional strategy to improve postprandial glycemic control or postprandial insulin secretion in type 2 diabetes patients.",2020,The repeated measures ANOVA revealed no significant difference between the groups for glucose and insulin after 6 weeks of intervention ( p  > 0.05).,"['type 2 diabetes patients', 'patients with type 2 diabetes so that 33 subjects were recruited in each group', 'patients with type 2 diabetes']","['glutamine', 'glutamine administration', '30\xa0g/d glutamine or placebo', 'placebo']","['Postprandial glycemia and insulin secretion', 'postprandial glycemia, insulin, and C-peptide concentration', 'postprandial glycemic control or postprandial insulin secretion', 'Postprandial C-peptide, insulin, and glucose', 'glucose and insulin', 'C-peptide']","[{'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0017797', 'cui_str': 'Glutamine'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0439417', 'cui_str': 'g/24h'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C1256369', 'cui_str': 'Insulin Secretion'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}]",,0.235122,The repeated measures ANOVA revealed no significant difference between the groups for glucose and insulin after 6 weeks of intervention ( p  > 0.05).,"[{'ForeName': 'Asieh', 'Initials': 'A', 'LastName': 'Mansour', 'Affiliation': 'Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Mohajeri-Tehrani', 'Affiliation': 'Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Qorbani', 'Affiliation': 'Department of Biostatistics and Epidemiology, Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.'}, {'ForeName': 'Mahsa', 'Initials': 'M', 'LastName': 'Ghamari', 'Affiliation': 'Student Research Committee Faculty of Medical Urima, University of Medical Sciences, Uremia, Iran.'}, {'ForeName': 'Bagher', 'Initials': 'B', 'LastName': 'Larijani', 'Affiliation': 'Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Saeed', 'Initials': 'S', 'LastName': 'Hosseini', 'Affiliation': 'Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.'}]",International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition,['10.1024/0300-9831/a000463'] 2694,32729789,"A Randomized, Double-Blind, Crossover Study to Determine the Available Energy from Soluble Fiber.","OBJECTIVE Determining the available energy (caloric value) of dietary non-digestible fibers that are fermented to varying degrees by intestinal microbes and metabolized to short chain fatty acids is important for provision of accurate information to food and beverage manufacturers for reformulation and labeling purposes. The objective of this human study was to determine the available energy of soluble fiber products by measuring post consumption breath hydrogen, with inulin as a control. METHODS PROMITOR ® Soluble Corn Fiber 70 (SCF70) and PROMITOR ® Soluble Corn Fiber 85B (SCF85B) are Tate & Lyle dietary fiber products with 70% and 85% fiber, respectively. The fiber portion of these products is structurally representative of the fiber portion of all PROMITOR ® SCF products. The study conducted was a randomized, double-blind, crossover design. Breath hydrogen was quantified following consumption of beverages consisting of 8 oz. of water and: inulin (control), SCF70, or SCF85B at 5, 10, or 15 g (total ingredient weight, ""as is""). Subjects were generally healthy men and women (N = 19), age 18 to 34 years, with body mass index (BMI) 19.3 to 24.8 kg/m 2 . The primary outcome was incremental area under the curve over 10 h (iAUC0-10 h) for inulin, SCF70, and SCF85B at each dose. The available energy (kcal/g ingredient and kcal/g fiber) from SCF70 and SCF85B at each dose was then calculated using inulin as the reference. RESULTS Results demonstrated that breath hydrogen production was significantly lower following consumption of SCF70 and SCF85B compared to inulin at all consumption amounts. There were no significant differences in breath hydrogen production following consumption of SCF70 compared to SCF85B. CONCLUSION The available energy per gram of fiber was not significantly different between the SCF70 and SCF85B PROMITOR ® products. The available energy of the fiber portion of PROMITOR ® SCF products was determined to be 0.2 kcal/gram.",2020,"There were no significant differences in breath hydrogen production following consumption of SCF70 compared to SCF85B. CONCLUSION The available energy per gram of fiber was not significantly different between the SCF70 and SCF85B PROMITOR ® products.","['Subjects were generally healthy men and women (N\u2009=\u200919), age 18 to 34\u2009years, with body mass index (BMI) 19.3 to 24.8\u2009kg/m 2 ']","['® Soluble Corn Fiber 70 (SCF70) and PROMITOR ® Soluble Corn Fiber 85B (SCF85B', 'water and: inulin (control), SCF70, or SCF85B at 5, 10, or 15']","['Breath hydrogen', 'breath hydrogen production', 'incremental area under the curve over 10\u2009h (iAUC0-10\u2009h) for inulin, SCF70, and SCF85B']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0010028', 'cui_str': 'Zea mays'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}]","[{'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0020275', 'cui_str': 'Hydrogen'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0021936', 'cui_str': 'Inulin'}]",,0.166909,"There were no significant differences in breath hydrogen production following consumption of SCF70 compared to SCF85B. CONCLUSION The available energy per gram of fiber was not significantly different between the SCF70 and SCF85B PROMITOR ® products.","[{'ForeName': 'Kirstie', 'Initials': 'K', 'LastName': 'Canene-Adams', 'Affiliation': 'Innovation and Commercial Development, Tate & Lyle, Hoffman Estates, Illinois, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Spence', 'Affiliation': 'Innovation and Commercial Development, Tate & Lyle, Hoffman Estates, Illinois, USA.'}, {'ForeName': 'Lore W', 'Initials': 'LW', 'LastName': 'Kolberg', 'Affiliation': 'Innovation and Commercial Development, Tate & Lyle, Hoffman Estates, Illinois, USA.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Karnik', 'Affiliation': 'Innovation and Commercial Development, Tate & Lyle, Hoffman Estates, Illinois, USA.'}, {'ForeName': 'DeAnn', 'Initials': 'D', 'LastName': 'Liska', 'Affiliation': 'Biofortis, Merieux NutriSciences, Addison, Illinois, USA.'}, {'ForeName': 'Eunice', 'Initials': 'E', 'LastName': 'Mah', 'Affiliation': 'Biofortis, Merieux NutriSciences, Addison, Illinois, USA.'}]",Journal of the American College of Nutrition,['10.1080/07315724.2020.1790440'] 2695,30690509,Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants.,"BACKGROUND A major challenge to HIV cure strategies is the quantification of persistent reactivation-prone virus in people living with HIV. OBJECTIVES To determine whether anti-gp41 antibody levels correlate with viral suppression and HIV-1 DNA levels in patients on ART. METHODS Participants with plasma HIV-1 RNA below 50 copies/mL for >12 months were included from three ANRS cohorts (COPANA, MONOI and APROCO). Antibody levels to gp41 were measured by a low-sensitivity enzyme-linked immunoassay. Correlations with patient and virus characteristics, plasma HIV-1 RNA load (standard and ultrasensitive tests) and cell-associated HIV-1 DNA were assessed. RESULTS Median age was 41 years and 77.5% of the 683 participants were men. Median CD4+ T cell count was 582 cells/mm3 and median viral suppression duration was 6.6 years (IQR 2.0-9.5). The overall median anti-gp41 antibody titre was 1.3 (IQR 0.6-1.9); median HIV-1 DNA level was 2.6 (IQR 2.1-3.0) log10 copies/106 leucocytes; and HIV-1 RNA was undetectable in 56% of samples. A lower titre of anti-gp41 antibodies correlated with male gender, longer viral suppression and lower HIV-1 DNA burden. Sustained undetectable HIV-1 RNA was associated with lower anti-gp41 levels [median 1.1 (IQR 0.5-1.6) versus 1.4 (IQR 0.7-1.9), P = 0.009]. CONCLUSIONS Anti-gp41 levels decreased with the duration of antiviral suppression on ART. Lower titres were associated with lower HIV-1 DNA levels and longer duration of viral suppression, reflecting minimal antigen stimulation. Anti-gp41 antibody titration may be a useful biomarker reflecting long-term HIV-1 suppression on ART.",2019,"A lower titre of anti-gp41 antibodies correlated with male gender, longer viral suppression and lower HIV-1 DNA burden.","['long-term antiretroviral-treated trial participants', 'Participants with plasma HIV-1 RNA below 50\u2009copies/mL for >12\u2009months were included from three ANRS cohorts (COPANA, MONOI and APROCO', 'patients on ART', 'people living with HIV', 'Median age was 41\u2009years and 77.5% of the 683 participants were men']",[],"['HIV-1 RNA', 'viral suppression and HIV-1 DNA levels', 'Median CD4+ T cell count', 'HIV-1 DNA levels and longer duration of viral suppression', 'plasma HIV-1 RNA load (standard and ultrasensitive tests) and cell-associated HIV-1 DNA', 'median viral suppression duration', 'overall median anti-gp41 antibody titre', 'titre of anti-gp41 antibodies', 'median HIV-1 DNA level']","[{'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0003826', 'cui_str': 'Arts'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0025266', 'cui_str': 'Man'}]",[],"[{'cui': 'C0369499', 'cui_str': 'Human immunodeficiency virus 1 RNA'}, {'cui': 'C0521026', 'cui_str': 'viruses'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0486948', 'cui_str': 'Human immunodeficiency virus 1 DNA'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0439591', 'cui_str': 'Long duration'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0019692', 'cui_str': 'Envelope Protein gp41, HIV'}, {'cui': 'C0474643', 'cui_str': 'Antibody titer measurement'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",683.0,0.11183,"A lower titre of anti-gp41 antibodies correlated with male gender, longer viral suppression and lower HIV-1 DNA burden.","[{'ForeName': 'Héloïse M', 'Initials': 'HM', 'LastName': 'Delagreverie', 'Affiliation': 'Laboratoire de Virologie, EA 2211, Hôpital Saint-Louis, AP-HP, Paris, France.'}, {'ForeName': 'Maxime', 'Initials': 'M', 'LastName': 'Grude', 'Affiliation': ""Université Pierre et Marie Curie, Sorbonne Universités, INSERM U1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris, France.""}, {'ForeName': 'Sidonie', 'Initials': 'S', 'LastName': 'Lambert-Niclot', 'Affiliation': ""Université Pierre et Marie Curie, Sorbonne Universités, INSERM U1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris, France.""}, {'ForeName': 'Marie-Laure', 'Initials': 'ML', 'LastName': 'Nere', 'Affiliation': 'Laboratoire de Virologie, EA 2211, Hôpital Saint-Louis, AP-HP, Paris, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Jadand', 'Affiliation': 'INSERM UMR1137, Université Paris Diderot, Paris, France.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Leport', 'Affiliation': 'INSERM UMR1137, Université Paris Diderot, Paris, France.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Raffi', 'Affiliation': 'Service des Maladies Infectieuses and INSERM CIC 1413, CHU de Nantes, Nantes, France.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Ghislain', 'Affiliation': 'INSERM U1018, Centre de recherche en Épidémiologie et Santé des Population, Université Paris Sud, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Cécile', 'Initials': 'C', 'LastName': 'Goujard', 'Affiliation': 'INSERM U1018, Centre de recherche en Épidémiologie et Santé des Population, Université Paris Sud, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Laurence', 'Initials': 'L', 'LastName': 'Meyer', 'Affiliation': 'INSERM U1018, Centre de recherche en Épidémiologie et Santé des Population, Université Paris Sud, Le Kremlin-Bicêtre, France.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Calvez', 'Affiliation': ""Université Pierre et Marie Curie, Sorbonne Universités, INSERM U1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris, France.""}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Katlama', 'Affiliation': 'Maladies Infectieuses et Tropicales, Hôpital La Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris, France.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Flandre', 'Affiliation': ""Université Pierre et Marie Curie, Sorbonne Universités, INSERM U1136, Institut Pierre Louis d'épidémiologie et de Santé Publique, Paris, France.""}, {'ForeName': 'Francis', 'Initials': 'F', 'LastName': 'Barin', 'Affiliation': 'Laboratoire de Virologie and Centre National de Référence du VIH, CHU de Tours, INSERM U1259, Université de Tours, Tours, France.'}, {'ForeName': 'Constance', 'Initials': 'C', 'LastName': 'Delaugerre', 'Affiliation': 'Laboratoire de Virologie, EA 2211, Hôpital Saint-Louis, AP-HP, Paris, France.'}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkz004'] 2696,32729269,Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode.,"OBJECTIVE This study aimed to prospectively compare the efficacy, safety, and mid-term outcomes of dual-switching monopolar (DSM) radiofrequency ablation (RFA) to those of conventional single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND METHODS This single-center, two-arm, parallel-group, randomized controlled study was approved by the Institutional Review Board. Written informed consent was obtained from all patients upon enrollment. A total of 80 patients with 94 HCC nodules were randomized into either the DSM-RFA group or SSM-RFA group in a 1:1 ratio, using a blocked randomization method (block size 2). The primary endpoint was the minimum diameter of the ablation zone per unit time. The secondary endpoints included other technical parameters, complication rate, technique efficacy, and 2-year clinical outcomes. RESULTS Significantly higher ablation energy per unit time was delivered to the DSM-RFA group than to the SSM-RFA group (1.7 ± 0.2 kcal/min vs. 1.2 ± 0.3 kcal/min; p < 0.001). However, no significant differences were observed between the two groups for the analyzed variables, including primary endpoint, regarding size of the ablation zone and ablation time. Major complication rates were 4.9% in the DSM-RFA group and 2.6% in the SSM-RFA group ( p = 1.000). The 2-year local tumor progression (LTP) rates of the HCC nodules treated using DSM-RFA and SSM-RFA were 8.5% and 4.7%, respectively ( p = 0.316). The 2-year LTP-free survival rates of patients in the DSM-RFA and SSM-RFA groups were 90.0% and 94.4%, respectively ( p = 0.331), and the 2-year recurrence-free survival rates were 54.9% and 75.7%, respectively ( p = 0.265). CONCLUSION Although DSM-RFA using a separable clustered electrode delivers higher ablation energy than SSM-RFA, its effectiveness failed to show superiority over SSM-RFA in the treatment of HCC.",2020,Significantly higher ablation energy per unit time was delivered to the DSM-RFA group than to the SSM-RFA group (1.7 ± 0.2 kcal/min vs. 1.2 ± 0.3 kcal/min; p < 0.001).,"['hepatocellular carcinoma (HCC', '80 patients with 94 HCC nodules', 'Hepatocellular Carcinomas']","['Dual-Switching Monopolar Mode', 'DSM-RFA group or SSM-RFA', 'conventional single-switching monopolar (SSM) RFA', 'SSM-RFA', 'DSM-RFA', 'dual-switching monopolar (DSM) radiofrequency ablation (RFA', 'Radiofrequency Ablation Using a Separable Clustered Electrode']","['size of the ablation zone and ablation time', '2-year recurrence-free survival rates', '2-year LTP-free survival rates', 'minimum diameter of the ablation zone per unit time', 'technical parameters, complication rate, technique efficacy, and 2-year clinical outcomes', 'Major complication rates', '2-year local tumor progression (LTP) rates', 'ablation energy per unit time']","[{'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028259', 'cui_str': 'Nodule'}]","[{'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}]","[{'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0206249', 'cui_str': 'Long-Term Potentiation'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0178874', 'cui_str': 'Tumor progression'}]",80.0,0.0389754,Significantly higher ablation energy per unit time was delivered to the DSM-RFA group than to the SSM-RFA group (1.7 ± 0.2 kcal/min vs. 1.2 ± 0.3 kcal/min; p < 0.001).,"[{'ForeName': 'Jae Won', 'Initials': 'JW', 'LastName': 'Choi', 'Affiliation': 'Department of Radiology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Jeong Min', 'Initials': 'JM', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Dong Ho', 'Initials': 'DH', 'LastName': 'Lee', 'Affiliation': 'Department of Radiology, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Jung Hwan', 'Initials': 'JH', 'LastName': 'Yoon', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Yoon Jun', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Jeong Hoon', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Su Jong', 'Initials': 'SJ', 'LastName': 'Yu', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Eun Ju', 'Initials': 'EJ', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}]",Korean journal of radiology,['10.3348/kjr.2020.0134'] 2697,32729273,Effects of Remote Ischemic Pre-Conditioning to Prevent Contrast-Induced Nephropathy after Intravenous Contrast Medium Injection: A Randomized Controlled Trial.,"OBJECTIVE We aimed to assess the effects of remote ischemic pre-conditioning (RIPC) on the incidence of contrast-induced nephropathy (CIN) after an intravenous (IV) or intra-arterial injection of contrast medium (CM) in patient and control groups. MATERIALS AND METHODS This prospective, randomized, single-blinded, controlled trial included 26 patients who were hospitalized for the evaluation of the feasibility of transcatheter aortic valve implantation and underwent investigations including contrast-enhanced computed tomography (CT), with Mehran risk scores greater than or equal to six. All the patients underwent four cycles of five minute-blood pressure cuff inflation followed by five minutes of total deflation. In the RIPC group (n = 13), the cuff was inflated to 50 mm Hg above the patient's systolic blood pressure (SBP); in the control group (n = 13), it was inflated to 10 mm Hg below the patient's SBP. The primary endpoint was the occurrence of CIN. Additionally, variation in the serum levels of cystatin C was assessed. RESULTS One case of CIN was observed in the control group, whereas no cases were detected in the RIPC group ( p = 0.48, analysis of 25 patients). Mean creatinine values at the baseline, 24 hours after injection of CM, and 48 hours after injection of CM were 88 ± 32 μmol/L, 91 ± 28 μmol/L and 82 ± 29 μmol/L, respectively ( p = 0.73) in the RIPC group, whereas in the control group, they were 100 ± 36 μmol/L, 110 ± 36 μmol/L, and 105 ± 34 μmol/L, respectively ( p = 0.78). Cystatin C values (median [Q1, Q3]) at the baseline, 24 hours after injection of CM, and 48 hours after injection of CM were 1.10 [1.08, 1.18] mg/L, 1.17 [0.97, 1.35] mg/L, and 1.12 [0.99, 1.24] mg/L, respectively ( p = 0.88) in the RIPC group, whereas they were 1.11 [0.97, 1.28] mg/L, 1.13 [1.08, 1.25] mg/L, and 1.16 [1.03, 1.31] mg/L, respectively ( p = 0.93), in the control group. CONCLUSION The risk of CIN after an IV injection of CM is very low in patients with Mehran risk score greater than or equal to six and even in the patients who are unable to receive preventive hyperhydration. Hence, the Mehran risk score may not be an appropriate method for the estimation of the risk of CIN after IV CM injection.",2020,"One case of CIN was observed in the control group, whereas no cases were detected in the RIPC group ( p = 0.48, analysis of 25 patients).","['patient and control groups', '26 patients who were hospitalized for the evaluation of the feasibility of transcatheter aortic valve implantation and underwent investigations including contrast-enhanced computed tomography (CT), with Mehran risk scores greater than or equal to six']","['Intravenous Contrast Medium Injection', 'remote ischemic pre-conditioning (RIPC', 'intravenous (IV) or intra-arterial injection of contrast medium (CM', 'Remote Ischemic Pre-Conditioning']","['incidence of contrast-induced nephropathy (CIN', 'Mean creatinine values', 'Cystatin C values (median [Q1, Q3', 'serum levels of cystatin C', 'CIN', 'occurrence of CIN', 'systolic blood pressure (SBP']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C1261322', 'cui_str': 'Evaluation procedure'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439091', 'cui_str': '>='}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0205157', 'cui_str': 'Remote'}, {'cui': 'C0376466', 'cui_str': 'Ischemic Pre-Conditioning'}, {'cui': 'C0021487', 'cui_str': 'Intra-arterial injection'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0071744', 'cui_str': 'Cystatin C'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",26.0,0.0690735,"One case of CIN was observed in the control group, whereas no cases were detected in the RIPC group ( p = 0.48, analysis of 25 patients).","[{'ForeName': 'Dihia', 'Initials': 'D', 'LastName': 'Belabbas', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Koch', 'Affiliation': 'Department of Radiodology, Toulouse University Hospital, Toulouse, France.'}, {'ForeName': 'Ségolène', 'Initials': 'S', 'LastName': 'Chaudru', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Mathieu', 'Initials': 'M', 'LastName': 'Lederlin', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Laviolle', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Estelle', 'Initials': 'E', 'LastName': 'Le Pabic', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Dominique', 'Initials': 'D', 'LastName': 'Boulmier', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Jean François', 'Initials': 'JF', 'LastName': 'Heautot', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France.'}, {'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Mahe', 'Affiliation': 'Vascular Medicine Unit, Department of Radiology, University Hospital Pontchaillou, Rennes, France. maheguillaume@yahoo.fr.'}]",Korean journal of radiology,['10.3348/kjr.2019.0916'] 2698,32729275,Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial.,"OBJECTIVE To report the mid-term results of a single-center randomized controlled trial comparing drug-coated balloon angioplasty (DBA) and plain balloon angioplasty (PBA) for the treatment of dysfunctional radiocephalic arteriovenous fistulas (RCAVFs). MATERIALS AND METHODS In this prospective study, 39 patients (mean age, 62.2 years; 21 males, 18 females) with RCAVFs failing due to juxta-anastomotic stenosis were randomly assigned to undergo either both DBA and PBA (n = 20, DBA group) or PBA alone (n = 19, PBA group) between June 2016 and June 2018. Primary endpoints were technical and clinical success and target lesion primary patency (TLPP); secondary outcomes were target lesion secondary patency (TLSP) and complication rates. Statistical analysis was performed using the Kaplan-Meier product limit estimator. RESULTS Demographic data and baseline clinical characteristics were comparable between the groups. Technical and clinical success rates were 100% in both groups. There was no significant difference between the groups in the mean duration of TLPP (DBA group: 26.7 ± 3.6 months; PBA group: 27.0 ± 3.8 months; p = 0.902) and TLSP (DBA group: 37.3 ± 2.6 months; PBA group: 40.4 ± 1.5 months; p = 0.585). No procedural or post-procedural complications were identified. CONCLUSION Paclitaxel-coated balloon use did not significantly improve TLPP or TLSP in the treatment of juxta-anastomotic stenosis of dysfunctional RCAVFs.",2020,There was no significant difference between the groups in the mean duration of TLPP (DBA group: 26.7 ± 3.6 months; PBA group: 27.0 ± 3.8 months; p = 0.902) and TLSP (DBA group: 37.3 ± 2.6 months; PBA group: 40.4 ± 1.5 months; p = 0.585).,"['39 patients (mean age, 62.2 years; 21 males, 18 females) with RCAVFs failing due to juxta-anastomotic stenosis', 'Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas', 'n = 19, PBA group) between June 2016 and June 2018', 'dysfunctional radiocephalic arteriovenous fistulas (RCAVFs']","['Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty', 'drug-coated balloon angioplasty (DBA) and plain balloon angioplasty (PBA', 'DBA and PBA', 'Paclitaxel-coated balloon', 'PBA alone']","['Technical and clinical success rates', 'mean duration of TLPP', 'No procedural or post-procedural complications', 'TLPP or TLSP', 'technical and clinical success and target lesion primary patency (TLPP); secondary outcomes were target lesion secondary patency (TLSP) and complication rates']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0003855', 'cui_str': 'Arteriovenous fistula'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205117', 'cui_str': 'Juxta-posed'}, {'cui': 'C0919938', 'cui_str': 'Anastomotic stenosis'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0002996', 'cui_str': 'Balloon Angioplasty'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0453946', 'cui_str': 'Coat'}]","[{'cui': 'C0449851', 'cui_str': 'Technique'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1141930', 'cui_str': 'Post procedural complication'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0009566', 'cui_str': 'Complication'}]",39.0,0.0701242,There was no significant difference between the groups in the mean duration of TLPP (DBA group: 26.7 ± 3.6 months; PBA group: 27.0 ± 3.8 months; p = 0.902) and TLSP (DBA group: 37.3 ± 2.6 months; PBA group: 40.4 ± 1.5 months; p = 0.585).,"[{'ForeName': 'Jong Woo', 'Initials': 'JW', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jeong Ho', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. ho7ok7@gilhospital.com.'}, {'ForeName': 'Sung Su', 'Initials': 'SS', 'LastName': 'Byun', 'Affiliation': 'Health Promotion Center, Inha University Hospital, Incheon, Korea.'}, {'ForeName': 'Jin Mo', 'Initials': 'JM', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.'}, {'ForeName': 'Ji Hoon', 'Initials': 'JH', 'LastName': 'Shin', 'Affiliation': 'Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}]",Korean journal of radiology,['10.3348/kjr.2020.0067'] 2699,32729615,Two weeks of early time-restricted feeding (eTRF) improves skeletal muscle insulin and anabolic sensitivity in healthy men.,"BACKGROUND Altering the temporal distribution of energy intake (EI) and introducing periods of intermittent fasting (IF) exert important metabolic effects. Restricting EI to earlier in the day [early time-restricted feeding (eTRF)] is a novel type of IF. OBJECTIVES We assessed the chronic effects of eTRF compared with an energy-matched control on whole-body and skeletal muscle insulin and anabolic sensitivity. METHODS Sixteen healthy males (aged 23 ± 1 y; BMI 24.0 ± 0.6 kg·m-2) were assigned to 2 groups that underwent either 2 wk of eTRF (n = 8) or control/caloric restriction (CON:CR; n = 8) diet. The eTRF diet was consumed ad libitum and the intervention was conducted before the CON:CR, in which the diet was provided to match the reduction in EI and body weight observed in eTRF. During eTRF, daily EI was restricted to between 08:00 and 16:00, which prolonged the overnight fast by ∼5 h. The metabolic responses to a carbohydrate/protein drink were assessed pre- and post-interventions following a 12-h overnight fast. RESULTS When compared with CON:CR, eTRF improved whole-body insulin sensitivity [between-group difference (95% CI): 1.89 (0.18, 3.60); P = 0.03; η2p = 0.29] and skeletal muscle uptake of glucose [between-group difference (95% CI): 4266 (261, 8270) μmol·min-1·kg-1·180 min; P = 0.04; η2p = 0.31] and branched-chain amino acids (BCAAs) [between-group difference (95% CI): 266 (77, 455) nmol·min-1·kg-1·180 min; P = 0.01; η2p = 0.44]. eTRF caused a reduction in EI (∼400 kcal·d-1) and weight loss (-1.04 ± 0.25 kg; P = 0.01) that was matched in CON:CR (-1.24 ± 0.35 kg; P = 0.01). CONCLUSIONS Under free-living conditions, eTRF improves whole-body insulin sensitivity and increases skeletal muscle glucose and BCAA uptake. The metabolic benefits of eTRF are independent of its effects on weight loss and represent chronic adaptations rather than the effect of the last bout of overnight fast. This trial was registered at clinicaltrials.gov as NCT03969745.",2020,"Under free-living conditions, eTRF improves whole-body insulin sensitivity and increases skeletal muscle glucose and BCAA uptake.","['Sixteen healthy males (aged 23\xa0±\xa01 y', 'healthy men']","['early time-restricted feeding (eTRF', 'CON:CR, eTRF', 'eTRF (n\xa0=\xa08) or control/caloric restriction (CON:CR; n\xa0=\xa08) diet', 'eTRF']","['skeletal muscle glucose and BCAA uptake', 'whole-body insulin sensitivity', 'weight loss', 'branched-chain amino acids (BCAAs', 'skeletal muscle insulin and anabolic sensitivity', 'reduction in EI (∼400 kcal·d-1) and weight loss', 'skeletal muscle uptake of glucose']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C4704883', 'cui_str': 'Time Restricted Feeding'}, {'cui': 'C1135809', 'cui_str': 'Decreased energy diet'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}]","[{'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0002521', 'cui_str': 'Branched-chain amino acid'}, {'cui': 'C0229960', 'cui_str': 'Entire body as a whole'}, {'cui': 'C0920563', 'cui_str': 'Insulin Sensitivity'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0002845', 'cui_str': 'Anabolic steroid'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}]",16.0,0.0887892,"Under free-living conditions, eTRF improves whole-body insulin sensitivity and increases skeletal muscle glucose and BCAA uptake.","[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Pardeep', 'Initials': 'P', 'LastName': 'Pabla', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Mallinson', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Aline', 'Initials': 'A', 'LastName': 'Nixon', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Tariq', 'Initials': 'T', 'LastName': 'Taylor', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Bennett', 'Affiliation': 'School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}, {'ForeName': 'Kostas', 'Initials': 'K', 'LastName': 'Tsintzas', 'Affiliation': 'MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, School of Life Sciences, University of Nottingham Medical School, Nottingham, United Kingdom.'}]",The American journal of clinical nutrition,['10.1093/ajcn/nqaa192'] 2700,32729619,Comparing two measures of sleep depth/intensity.,"STUDY OBJECTIVES To compare delta spectral power (delta) and odds ratio product (ORP) as measures of sleep depth during sleep restriction with placebo or a drug that increases delta. METHODS This is a secondary analysis of data from a study of 41 healthy participants randomized to receive placebo or gaboxadol 15 mg during sleep restriction. Participants underwent in-laboratory sleep studies on two baseline, four sleep restriction (5-h), and two recovery nights. Relation between delta or ORP and sleep depth was operationally defined as the degree of association of each metric to the probability of arousal or awakening occurring during the next 30 s (arousability). RESULTS ORP values in wake, N1, N2, N3, and REM were significantly different. Delta differed between both N2 and N3 and other sleep stages but not between wake and N1 or N1 and REM. Epoch-by-epoch and individual correlations between ORP and delta power were modest or insignificant. The relation between ORP and arousability was linear across the entire ORP range. Delta also changed with arousability but only when delta values were less than 300 μV2. Receiver-operating-characteristic analysis found the ability to predict imminent arousal to be significantly greater with ORP than with log delta power for all experimental conditions. Changes in ORP, but not log delta, across the night correlated with next-day physiologic sleep tendency. CONCLUSIONS Compared to delta power, ORP is more discriminating among sleep stages, more sensitive to sleep restriction, and more closely associated with arousability. This evidence supports ORP as a measure of sleep depth/intensity.",2020,Delta differed between both N2 and N3 and other sleep stages but not between wake and N1 or N1 and REM.,"['Participants underwent in-laboratory sleep studies on two baseline, four sleep restriction (5-h), and two recovery nights', '41 healthy participants']","['placebo or gaboxadol', 'placebo']","['delta spectral power (delta) and odds ratio product (ORP', 'ORP values in wake, N1, N2, N3, and REM', 'delta or ORP and sleep depth', 'sleep depth/intensity', 'Changes in ORP']","[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0240526', 'cui_str': 'Night time'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0047845', 'cui_str': 'gaboxadol'}]","[{'cui': 'C0439097', 'cui_str': 'Delta'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0560134', 'cui_str': 'rem'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0392747', 'cui_str': 'Changing'}]",41.0,0.0283715,Delta differed between both N2 and N3 and other sleep stages but not between wake and N1 or N1 and REM.,"[{'ForeName': 'Magdy', 'Initials': 'M', 'LastName': 'Younes', 'Affiliation': 'Sleep Disorders Centre, Misericordia Health Centre, University of Manitoba, Winnipeg, Canada.'}, {'ForeName': 'Paula K', 'Initials': 'PK', 'LastName': 'Schweitzer', 'Affiliation': ""Sleep Medicine & Research Center, St. Luke's Hospital, Chesterfield, MO.""}, {'ForeName': 'Kara S', 'Initials': 'KS', 'LastName': 'Griffin', 'Affiliation': ""Sleep Medicine & Research Center, St. Luke's Hospital, Chesterfield, MO.""}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Balshaw', 'Affiliation': 'Centre for Healthcare Innovation, Rady Faculty of Health Science, University of Manitoba, Winnipeg, Canada.'}, {'ForeName': 'James K', 'Initials': 'JK', 'LastName': 'Walsh', 'Affiliation': ""Sleep Medicine & Research Center, St. Luke's Hospital, Chesterfield, MO.""}]",Sleep,['10.1093/sleep/zsaa127'] 2701,32729631,Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis.,"OBJECTIVES Patients with Alzheimer's disease psychosis (ADP) commonly experience concomitant agitation and aggression. We investigated whether a reduction in ADP following pimavanserin treatment conferred a reduction in associated agitation and aggression METHODS: ACP-103-019 was a 12-week, randomized, double-blind, placebo-controlled study that evaluated the efficacy of pimavanserin (34 mg) in reducing psychotic symptoms in patients with ADP. The primary endpoint was change from baseline in Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score (NPI-NH-PS) at week six. A post hoc analysis examined whether there was a greater reduction in agitation and aggression (NPI-NH domain C [agitation/aggression] and Cohen-Mansfield Agitation Inventory-Short Form [CMAI-SF]) in pimavanserin-treated patients who experienced a reduction of hallucinations and delusions (psychosis responders defined as ≥50% reduction from baseline in NPI-NH-PS, week six) when compared with those who did not (nonresponders). RESULTS Pimavanserin-treated patients with ≥50% response in psychotic symptoms (n = 44) showed a greater improvement in agitation and aggression symptoms on the NPI-NH domain C (week six, least squares mean [LSM] difference = -3.64, t = -4.69, P < 0.0001) and the CMAI-SF (week six, LSM difference = -3.71, t = -2.01, P = 0.0483) than nonresponders (n = 32). Differences between psychosis responders and nonresponders were also observed in patients with more severe agitation and aggression at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13; week six, LSM difference = -3.03, t = -2.44, P = 0.019). CONCLUSIONS Patients with ADP who show improvement in psychotic symptoms following pimavanserin treatment also experience an improvement in concomitant agitation and aggression. This article is protected by copyright. All rights reserved.",2020,"Differences between psychosis responders and nonresponders were also observed in patients with more severe agitation and aggression at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13; week six, LSM difference = ","[""patients with Alzheimer's disease psychosis"", 'patients with ADP', ""Patients with Alzheimer's disease psychosis (ADP) commonly experience concomitant agitation and aggression""]","['pimavanserin', 'placebo']","['agitation and aggression', 'severe agitation and aggression', 'concomitant agitation and aggression', 'psychotic symptoms', 'CMAI-SF', 'agitation and aggression (NPI-NH domain C [agitation/aggression] and Cohen-Mansfield Agitation Inventory-Short Form [CMAI-SF', 'agitation and aggression symptoms', 'Neuropsychiatric Inventory-Nursing Home Version-Psychosis Score (NPI-NH-PS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}]","[{'cui': 'C1722267', 'cui_str': 'pimavanserin'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0085631', 'cui_str': 'Feeling agitated'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C0871189', 'cui_str': 'Psychotic symptom'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0028688', 'cui_str': 'Long term care facility'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.405078,"Differences between psychosis responders and nonresponders were also observed in patients with more severe agitation and aggression at baseline on the NPI-NH domain C (responders, n = 26; nonresponders, n = 13; week six, LSM difference = ","[{'ForeName': 'Clive G', 'Initials': 'CG', 'LastName': 'Ballard', 'Affiliation': 'University of Exeter Medical School, Exeter, UK.'}, {'ForeName': 'Bruce', 'Initials': 'B', 'LastName': 'Coate', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, California, USA.'}, {'ForeName': 'Vic', 'Initials': 'V', 'LastName': 'Abler', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, California, USA.'}, {'ForeName': 'Serge', 'Initials': 'S', 'LastName': 'Stankovic', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, California, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Foff', 'Affiliation': 'ACADIA Pharmaceuticals Inc., San Diego, California, USA.'}]",International journal of geriatric psychiatry,['10.1002/gps.5381'] 2702,32729696,[Impact of psychoeducation on compliance of inpatients with first episode psychosis].,"OBJECTIVE To assess the impact of brief group inpatient psychoeducation interventions on compliance of patients with first episode psychosis (FEP) and emergency hospitalization. MATERIAL AND METHODS One hundred and fifty-eight patients of treatment group and 79 patients of the control group were enrolled into the study. All patients were hospitalized emergently due to psychotic condition. Patients in treatment group had group psychoeducation sessions (5 sessions), patients in the control group received basic treatment only. Before discharge from the hospital, patients were accessed with PANSS, CGI-S, CGI-I and «Medication compliance scale». RESULTS Patient in treatment group showed significantly better results than the control group in medication compliance scale assessment ( p <0.001). The rate of readmissions was significantly higher in the control group than in the psychoeducation group ( p =0.02). CONCLUSION Brief psychoeducation for inpatients with FEP and emergency hospitalizations has beneficial effect on patients' compliance.",2020,"The rate of readmissions was significantly higher in the control group than in the psychoeducation group ( p =0.02). ","['All patients were hospitalized emergently due to psychotic condition', 'patients with first episode psychosis (FEP) and emergency hospitalization', 'One hundred and fifty-eight patients of treatment group and 79 patients of the control group were enrolled into the study', 'inpatients with first episode psychosis', 'inpatients with FEP and emergency hospitalizations']","['brief group inpatient psychoeducation interventions', 'psychoeducation']","['medication compliance scale assessment', 'I and «Medication compliance scale', 'rate of readmissions']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]","[{'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0871175', 'cui_str': 'Psychoeducation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}]",158.0,0.0147329,"The rate of readmissions was significantly higher in the control group than in the psychoeducation group ( p =0.02). ","[{'ForeName': 'O A', 'Initials': 'OA', 'LastName': 'Karpenko', 'Affiliation': 'Alekseev Psychiatric Clinical Hospital No. 1, Moscow, Russia.'}]",Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,['10.17116/jnevro202012006292'] 2703,32729721,Three Alternatives for Graphing Behavioral Data: A Comparison of Usability and Acceptability.,"Making treatment decisions based upon graphed data is important in helping professions. A small amount of research has compared usability between equal-interval and semi-log graphs, but no prior studies have compared different types of semi-log graphs. Using a randomized, cross-over, experimental design with 72 participants, this study examined the relative usability and acceptability of three types of graphs: Regular (equal-interval), Standard Celeration Chart (SCC; semi-log), and Standard Behavior Graph (SBG; semi-log). All participants used each graph across three usability tasks (Plotting Data, Writing Values, and Interpreting Trends). For the Plotting and Writing tasks, the equal-interval graph produced the greatest rate of correct responses. However, for the Interpreting task the SBG produced the greatest rate of corrects, while the equal-interval graph produced the smallest rate. User acceptability mainly favored the equal-interval and SBG graphs. Study findings and implications are discussed with respect to graph usability and acceptability during day-to-day practice.",2020,"However, for the Interpreting task the SBG produced the greatest rate of corrects, while the equal-interval graph produced the smallest rate.",[],[],[],[],[],[],72.0,0.0227561,"However, for the Interpreting task the SBG produced the greatest rate of corrects, while the equal-interval graph produced the smallest rate.","[{'ForeName': 'Chad E L', 'Initials': 'CEL', 'LastName': 'Kinney', 'Affiliation': 'Florida Institute of Technology, Melbourne, FL, USA.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Begeny', 'Affiliation': 'North Carolina State University, Raleigh, NC, USA.'}, {'ForeName': 'Scott A', 'Initials': 'SA', 'LastName': 'Stage', 'Affiliation': 'North Carolina State University, Raleigh, NC, USA.'}, {'ForeName': 'Sierra', 'Initials': 'S', 'LastName': 'Patterson', 'Affiliation': 'North Carolina State University, Raleigh, NC, USA.'}, {'ForeName': 'Amirra', 'Initials': 'A', 'LastName': 'Johnson', 'Affiliation': 'North Carolina State University, Raleigh, NC, USA.'}]",Behavior modification,['10.1177/0145445520946321'] 2704,32729896,Randomized study defining the optimum target interlesion distance in ablation index-guided atrial fibrillation ablation.,"AIMS While the CLOSE protocol proposes a maximally tolerable interlesion distance (ILD) of 6 mm for ablation index ablation index-guided atrial fibrillation (AF) ablation, a target ILD has never been defined. This randomized study sought to establish a target ILD for ablation index-guided AF ablation. METHODS AND RESULTS Consecutive patients scheduled for first-time pulmonary vein (PV) isolation (PVI) were randomly assigned to ablation protocols with a target ILD of 5.0-6.0 mm or 3.0-4.0 mm, with the primary endpoint of first-pass PVI. In compliance with the CLOSE protocol, the maximum tolerated ILD was 6.0 mm in both study protocols. A target ablation index of ≥550 (anterior) or ≥400 (posterior) was defined for the '5-6 mm' protocol and ≥500 (anterior) or ≥350 (posterior) for the '3-4 mm' protocol. The study was terminated early for superiority of the '3-4 mm' protocol. Forty-two consecutive patients were randomized and 84 ipsilateral PV pairs encircled according to the study protocol. First-pass PVI was accomplished in 35.0% of the '5-6 mm' group and 90.9% of the '3-4 mm' group (P < 0.0001). Median ILD was 5.2 mm in the '5-6 mm' group and 3.6 mm in the '3-4 mm' group (P < 0.0001). In line with the distinct ablation index targets, median ablation index was lower in the '3-4 mm' group (416 vs. 452, P < 0.0001). While mean procedure time was shorter in the '3-4 mm' group (149 ± 27 vs. 167 ± 33min, P = 0.004), fluoroscopy times did not differ significantly (4.7 ± 2.2 vs. 5.1 ± 1.8 min, P = 0.565). CONCLUSION In ablation index-guided AF ablation, an ILD of 3.0-4.0 mm should be targeted rather than 5.0-6.0 mm. Moreover, the lower target ILD may allow for less extensive ablation at each given point.",2020,"In line with the distinct ablation index targets, median ablation index was lower in the '3-4 mm' group (416 vs. 452, P < 0.0001).","['Forty-two consecutive patients were randomized and 84 ipsilateral PV pairs encircled according to the study protocol', 'Consecutive patients scheduled for first-time pulmonary vein (PV) isolation (PVI']",['ablation index-guided atrial fibrillation ablation'],"['mean procedure time', 'fluoroscopy times', 'median ablation index', 'Median ILD', 'maximum tolerated ILD']","[{'cui': 'C4319566', 'cui_str': '42'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0034090', 'cui_str': 'Structure of vein of pulmonary circulation'}, {'cui': 'C0205113', 'cui_str': 'Circumferential'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C0030703', 'cui_str': 'Patient Schedules'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}]","[{'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0547070', 'cui_str': 'Ablation - action'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",,0.0509827,"In line with the distinct ablation index targets, median ablation index was lower in the '3-4 mm' group (416 vs. 452, P < 0.0001).","[{'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Hoffmann', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}, {'ForeName': 'Ivan', 'Initials': 'I', 'LastName': 'Diaz Ramirez', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}, {'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Baldenhofer', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Stangl', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}, {'ForeName': 'Lluís', 'Initials': 'L', 'LastName': 'Mont', 'Affiliation': 'Hospital Clínic Atrial Fibrillation Unit (UFA), Arrhythmia Section, Cardiovascular Institute, Hospital Clínic, Universitat de Barcelona, C/Villarroel N° 170, 08036 Barcelona, Catalonia, Spain.'}, {'ForeName': 'Till F', 'Initials': 'TF', 'LastName': 'Althoff', 'Affiliation': 'Department of Cardiology and Angiology, Charité-University Medicine Berlin, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany.'}]","Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology",['10.1093/europace/euaa147'] 2705,32729897,Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.,"Importance Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. Objective To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular degeneration. Design, Setting, and Participants This phase 2 randomized clinical trial was a 52-week multicenter, active comparator-controlled, parallel-group study. Study participants were enrolled in 25 sites in the US from January and March 2017 with treatment-naive choroidal neovascularization secondary to neovascular age-related macular degeneration and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter score of 73 (approximate Snellen equivalent, 20/40) to 24 (approximate Snellen equivalent, 20/320). Analysis began January 2017 and ended March 2018. Interventions Participants were randomized 1:2:2 to receive intravitreal ranibizumab, 0.5 mg, every 4 weeks or faricimab, 6.0 mg, every 12 or 16 weeks. Participants in the faricimab arms initially received 4 monthly injections of faricimab. No rescue injections were allowed. Participants randomized to dosing every 16 weeks were assessed for disease activity at week 24 using prespecified criteria. Those with no active disease continued dosing every 16 weeks through trial end; participants with disease activity continued received dosing every 12 weeks. Main Outcomes and Measures Mean change in BCVA from baseline at week 40. Results Of 76 participants enrolled (mean [SD] age, 78.5 [8.5] years; age range, 56-94 years; 41 women [58%]; 69 white [97%]), 16 (21.0%) were randomized to ranibizumab every 4 weeks, 29 (38.2%) to faricimab every 12 weeks, and 31 (40.8%) to faricimab every 16 weeks. At week 24, 12 weeks after their last initiation injection, 65% (36 of 55) of all faricimab-treated participants had no disease activity. At week 40, adjusted mean BCVA gains from baseline (Early Treatment Diabetic Retinopathy Study letters) were +11.4 (80% CI, 7.8-15.0), +9.3 (80% CI, 6.4-12.3), and +12.5 (80% CI, 9.9-15.1) for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively. Participants received a mean (SD) total of 12.9 (0.25), 6.7 (0.91), and 6.2 (093) injections, for the ranibizumab every 4 weeks, faricimab every 12 weeks, and faricimab every 16 weeks arms, respectively, through week 52. The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks. No new or unexpected safety signals were identified. Conclusions and Relevance At week 52, faricimab dosing every 16 weeks and every 12 weeks resulted in maintenance of initial vision and anatomic improvements comparable with monthly ranibizumab. These results suggest a role for simultaneous neutralization of angiopoietin-2 and vascular endothelial growth factor A in providing sustained efficacy through extended durability, warranting further investigation. Trial Registration ClinicalTrials.gov Identifier: NCT03038880.",2020,The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks.,"['76 participants enrolled (mean [SD] age, 78.5 [8.5] years; age range, 56-94 years', 'Neovascular Age-Related Macular Degeneration', 'patients with neovascular age-related macular degeneration', ' 41 women [58%]; 69 white [97%]), 16 (21.0', 'Study participants were enrolled in 25 sites in the US from January and March 2017 with treatment-naive choroidal neovascularization secondary to neovascular age-related macular degeneration and best-corrected visual acuity (BCVA']","['faricimab', 'Faricimab vs Ranibizumab', 'intravitreal ranibizumab', 'ranibizumab']","['disease activity', 'mean BCVA gains']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0600518', 'cui_str': 'Choroidal neovascularisation'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1517572', 'cui_str': 'Intravitreal route'}]","[{'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}]",76.0,0.243984,The secondary BCVA and anatomical imaging end points supported the primary end point and were comparable with ranibizumab every 4 weeks.,"[{'ForeName': 'Arshad M', 'Initials': 'AM', 'LastName': 'Khanani', 'Affiliation': 'Sierra Eye Associates, Reno, Nevada.'}, {'ForeName': 'Sunil S', 'Initials': 'SS', 'LastName': 'Patel', 'Affiliation': 'West Texas Retina Consultants, Abilene.'}, {'ForeName': 'Philip J', 'Initials': 'PJ', 'LastName': 'Ferrone', 'Affiliation': 'Long Island and Queens Vitreoretinal Consultants, PC, Great Neck, New York.'}, {'ForeName': 'Aaron', 'Initials': 'A', 'LastName': 'Osborne', 'Affiliation': 'Genentech Inc, South San Francisco, California.'}, {'ForeName': 'Jayashree', 'Initials': 'J', 'LastName': 'Sahni', 'Affiliation': 'Roche Innovation Center Basel, Roche Pharma Research and Early Development, F. Hoffmann-La Roche, Basel, Switzerland.'}, {'ForeName': 'Susanna', 'Initials': 'S', 'LastName': 'Grzeschik', 'Affiliation': 'Genentech Inc, South San Francisco, California.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Basu', 'Affiliation': 'Genentech Inc, South San Francisco, California.'}, {'ForeName': 'Jason S', 'Initials': 'JS', 'LastName': 'Ehrlich', 'Affiliation': 'Genentech Inc, South San Francisco, California.'}, {'ForeName': 'Zdenka', 'Initials': 'Z', 'LastName': 'Haskova', 'Affiliation': 'Genentech Inc, South San Francisco, California.'}, {'ForeName': 'Pravin U', 'Initials': 'PU', 'LastName': 'Dugel', 'Affiliation': 'Retinal Consultants of Arizona, Phoenix.'}]",JAMA ophthalmology,['10.1001/jamaophthalmol.2020.2699'] 2706,32729923,Nitrate-Rich Beetroot Juice Reduces Blood Pressure in Tanzanian Adults with Elevated Blood Pressure: A Double-Blind Randomized Controlled Feasibility Trial.,"BACKGROUND In Sub-Saharan Africa, current strategies are struggling to control the burgeoning hypertension epidemic. Dietary interventions such as inorganic nitrate or folic acid supplementation could represent promising strategies for reducing blood pressure (BP) in this setting. OBJECTIVES This feasibility study explores the effects of dietary inorganic nitrate supplementation, alone or in combination with folic acid, on BP in Tanzanian adults with elevated BP in Tanzania. METHODS A placebo-controlled, double-blind, randomized controlled feasibility trial was conducted. Forty-seven middle-aged and older participants (age: 50-70 y, BMI: 26.3-29.1 kg/m2) were randomly assigned to 3 conditions for a period of 60 d: 1) high-nitrate beetroot juice (∼400 mg nitrate) and folic acid (∼5 mg folic acid) (N + F), 2) high-nitrate beetroot juice and placebo (N + P), or 3) nitrate-depleted beetroot juice and placebo (P + P). Clinic and 24-h ambulatory BP and measurements of compliance in plasma (nitrate and folate concentrations) and saliva (nitrate and nitrite) were obtained at baseline, 30 d, and 60 d. RESULTS Baseline resting systolic and diastolic BP (mean ± SD) was 151.0 ± 19.4 mm Hg and 91.8 ± 11.7 mm Hg, respectively. Compliance to the interventions was high (>90%) in all groups which was confirmed by the significant increase in nitrate and folic acid concentrations in plasma and saliva samples in the treatment arms. After 60 d, 24-h systolic BP dropped by -10.8 ± 9.8 mm Hg (P < 0.001), -6.1 ± 13.2 mm Hg (P = 0.03), and -0.3 ± 9.7 mm Hg (P = 0.83) in the N + P, N + F, and P + P groups, respectively. There was a significant decrease in 24-h diastolic BP in the N + P group (-5.4 ± 5.0 mm Hg, P = 0.004), whereas changes were not significant in the N + F (-1.8 ± 8.1 mm Hg, P = 0.32) and P + P (1.6 ± 8.3 mm Hg, P = 0.43) groups. CONCLUSIONS Dietary inorganic nitrate represents a potential nutritional strategy to lessen the hypertension epidemic in Sub-Saharan Africa. These findings support the rationale for future long-term investigations exploring the efficacy of dietary nitrate for lowering BP and attenuating cardiovascular disease risk in this setting.This trial was registered at isrctn.com as ISRCTN67978523.",2020,Compliance to the interventions was high (>90%) in all groups which was confirmed by the significant increase in nitrate and folic acid concentrations in plasma and saliva samples in the treatment arms.,"['Forty-seven middle-aged and older participants (age: 50-70 y, BMI: 26.3-29.1\xa0kg/m2', 'Tanzanian adults with elevated BP in Tanzania', 'Tanzanian Adults with Elevated Blood Pressure']","['inorganic nitrate or folic acid supplementation', 'high-nitrate beetroot juice (∼400\xa0mg nitrate) and folic acid (∼5\xa0mg folic acid', 'Nitrate-Rich Beetroot Juice', 'Dietary inorganic nitrate', 'nitrate-depleted beetroot juice and placebo', 'dietary inorganic nitrate supplementation, alone or in combination with folic acid', 'placebo']","['Baseline resting systolic and diastolic BP (mean ± SD', '24-h diastolic BP', 'nitrate and folic acid concentrations in plasma and saliva samples', 'blood pressure (BP', '24-h systolic BP', 'Clinic and 24-h ambulatory BP and measurements of compliance in plasma (nitrate and folate concentrations) and saliva (nitrate and nitrite', 'Blood Pressure']","[{'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517668', 'cui_str': '26.3'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C0039298', 'cui_str': 'Tanzania'}]","[{'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0556110', 'cui_str': 'Folic acid supplement agent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1095905', 'cui_str': 'Beets preparation'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0428883', 'cui_str': 'Diastolic blood pressure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0016410', 'cui_str': 'Folic Acid'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0028137', 'cui_str': 'Nitrite salt'}]",,0.369246,Compliance to the interventions was high (>90%) in all groups which was confirmed by the significant increase in nitrate and folic acid concentrations in plasma and saliva samples in the treatment arms.,"[{'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Siervo', 'Affiliation': 'School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Shannon', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'Navneet', 'Initials': 'N', 'LastName': 'Kandhari', 'Affiliation': 'Faculty of Medical Sciences, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'Meghna', 'Initials': 'M', 'LastName': 'Prabhakar', 'Affiliation': 'Faculty of Medical Sciences, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Fostier', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Köchl', 'Affiliation': 'Human Nutrition Research Centre, Population Health Sciences Institute, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Rogathi', 'Affiliation': 'Kilimanjaro Christian Medical University College, Moshi, Tanzania.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Temu', 'Affiliation': 'Kilimanjaro Christian Medical University College, Moshi, Tanzania.'}, {'ForeName': 'Blossom C M', 'Initials': 'BCM', 'LastName': 'Stephan', 'Affiliation': 'Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'William K', 'Initials': 'WK', 'LastName': 'Gray', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Haule', 'Affiliation': 'District Medical Officer, Hai District Hospital, Bomangombe, Tanzania.'}, {'ForeName': 'Stella-Maria', 'Initials': 'SM', 'LastName': 'Paddick', 'Affiliation': 'Clinical and Translational Medicine, Newcastle University, Newcastle on Tyne, United Kingdom.'}, {'ForeName': 'Blandina T', 'Initials': 'BT', 'LastName': 'Mmbaga', 'Affiliation': 'Kilimanjaro Christian Medical University College, Moshi, Tanzania.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Walker', 'Affiliation': 'Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom.'}]",The Journal of nutrition,['10.1093/jn/nxaa170'] 2707,32729970,A technology-based information and coaching/support program and self-efficacy of Asian American breast cancer survivors.,"Women's self-efficacy for coping with breast cancer is one of the key factors that lead to successful breast cancer survivorship. Due to the cultural stigma linked to breast cancer (e.g., breast cancer is a genetic disease), Asian Americans are known as a high-risk group within breast cancer survivors. However, healthcare providers are challenged to promote women's self-efficacy while considering their cultural beliefs and attitudes. In this study, the efficacy of a technology-based information and coaching/support program was examined in improving self-efficacy for coping with breast cancer among Asian American survivors. A randomized repeated measures control group study was conducted with 67 Asian American breast cancer survivors. The questions on background characteristics, the Personal Resource Questionnaire, the Perceived Isolation Scale, the Supportive Care Needs Survey Short Form 34, and the Cancer Behavior Inventory were used. The data were analyzed using repeated measurement analyses, χ 2 tests, and decision tree analyses. There were significant increases in the self-efficacy scores of both control and intervention groups over time (p = .017). However, the increase in the control group's self-efficacy scores was only up to post 1 month, and there was a decrease in the scores by post 3 months. When the participants were divided into high and low-change groups based on the changes in their self-efficacy scores for 3 months, the intervention group had more participants who belonged to the high-change group (p = .036). The technology-based intervention was effective in improving self-efficacy for coping with breast cancer among Asian American breast cancer survivors.",2020,The technology-based intervention was effective in improving self-efficacy for coping with breast cancer among Asian American breast cancer survivors.,"['Asian American breast cancer survivors', 'Asian American survivors', '67 Asian American breast cancer survivors']",['technology-based information and coaching/support program'],['self-efficacy scores'],"[{'cui': 'C0003988', 'cui_str': 'Asian Americans'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",67.0,0.0110013,The technology-based intervention was effective in improving self-efficacy for coping with breast cancer among Asian American breast cancer survivors.,"[{'ForeName': 'Eun-Ok', 'Initials': 'EO', 'LastName': 'Im', 'Affiliation': 'Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.'}, {'ForeName': 'Jee-Seon', 'Initials': 'JS', 'LastName': 'Yi', 'Affiliation': 'Duke University, Durham, North Carolina.'}, {'ForeName': 'Hyeoneui', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Duke University, Durham, North Carolina.'}, {'ForeName': 'Wonshik', 'Initials': 'W', 'LastName': 'Chee', 'Affiliation': 'Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.'}]",Research in nursing & health,['10.1002/nur.22059'] 2708,32726105,Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.,"Background: Acne vulgaris and inflammation-associated sequelae are highly prevalent in black and Hispanic populations. In a phase 2 study, a novel polymeric emulsion formulation of tazarotene 0.045% lotion had relatively fewer adverse events than tazarotene 0.1% cream, but with comparable efficacy. The objective was to evaluate tazarotene 0.045% lotion by race and ethnicity in the pivotal trials. Methods: In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), participants with moderate-to-severe acne were randomized 1:1 to tazarotene 0.045% lotion or vehicle lotion (N=1,614). This pooled, post hoc analysis included subsets of participants that self-identified as white (n=1191) or black (n=262) and Hispanic (n=352) or non-Hispanic (n=1262). Coprimary endpoints were inflammatory/noninflammatory lesion counts and treatment success (defined as at least a 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 'clear' or 'almost clear'). Treatment-emergent adverse events (TEAEs) and cutaneous safety and tolerability were evaluated. Results: At week 12, tazarotene 0.045% lotion led to significantly greater percent reductions in inflammatory and noninflammatory lesions compared with vehicle in white, Hispanic, and non-Hispanic participants (P<0.05, all). Black participants had significantly greater reductions in noninflammatory lesions following treatment with tazarotene 0.045% versus vehicle (P<0.05). Treatment success rates in all subpopulations were higher with tazarotene 0.045% lotion (29.4-34.1%) versus vehicle (16.4-23.1%). TEAE rates were similar across tazarotene-treated groups and most were mild-to-moderate in severity. The incidence of hyperpigmentation decreased in black tazarotene-treated participants from baseline to week 12. Conclusions: Tazarotene 0.045% lotion demonstrated efficacy and was well tolerated across racial and ethnic subpopulations in this pooled analysis. J Drugs Dermatol. 2020;19(7) doi:10.36849/JDD.2020.5125.",2020,"At week 12, tazarotene 0.045% lotion led to significantly greater percent reductions in inflammatory and noninflammatory lesions compared with vehicle in white, Hispanic, and non-Hispanic participants (P<0.05, all).","['Moderate-to-Severe Acne', 'participants with moderate-to-severe acne', 'participants that self-identified as white (n=1191) or black (n=262) and Hispanic (n=352) or non-Hispanic (n=1262']","['Tazarotene', 'tazarotene 0.045% lotion', 'tazarotene 0.045% lotion or vehicle lotion', 'Novel Polymeric Tazarotene 0.045% Lotion', 'tazarotene']","['noninflammatory lesions', 'incidence of hyperpigmentation', 'Treatment-emergent adverse events (TEAEs) and cutaneous safety and tolerability', 'inflammatory and noninflammatory lesions', 'adverse events', 'TEAE rates', ""inflammatory/noninflammatory lesion counts and treatment success (defined as at least a 2-grade reduction from baseline in Evaluator's Global Severity Score and a score of 'clear' or 'almost clear""]","[{'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0001144', 'cui_str': 'Acne vulgaris'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0005680', 'cui_str': 'Black - ethnic group'}, {'cui': 'C0086409', 'cui_str': 'Hispanic'}]","[{'cui': 'C0288792', 'cui_str': 'tazarotene'}, {'cui': 'C4517410', 'cui_str': '0.045'}, {'cui': 'C0544341', 'cui_str': 'Lotion'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0032521', 'cui_str': 'Polymer'}]","[{'cui': 'C0442743', 'cui_str': 'Noninflammatory'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0162834', 'cui_str': 'Hyperpigmentation'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1522447', 'cui_str': 'Cutaneous route'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}]",,0.195816,"At week 12, tazarotene 0.045% lotion led to significantly greater percent reductions in inflammatory and noninflammatory lesions compared with vehicle in white, Hispanic, and non-Hispanic participants (P<0.05, all).","[{'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Bhatia', 'Affiliation': ''}, {'ForeName': 'Jonathan S', 'Initials': 'JS', 'LastName': 'Weiss', 'Affiliation': ''}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Sadick', 'Affiliation': ''}, {'ForeName': 'Fran E', 'Initials': 'FE', 'LastName': 'Cook-Bolden', 'Affiliation': ''}, {'ForeName': 'Stephen K', 'Initials': 'SK', 'LastName': 'Tyring', 'Affiliation': ''}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Guenin', 'Affiliation': ''}, {'ForeName': 'Anya', 'Initials': 'A', 'LastName': 'Loncaric', 'Affiliation': ''}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': ''}]",Journal of drugs in dermatology : JDD,['10.36849/JDD.2020.5125'] 2709,32726201,Effectiveness of Brain Protection With Histidine-Tryptophan-Ketoglutarate Solutions.,"BACKGROUND Tissue-protective solutions increase resistance of cells to ischemic conditions. Especially in carotid and aortic arch surgeries where the brain perfusion is at risk, these solutions may be beneficial to prevent ischemic brain damage. This study was designed to demonstrate the effectiveness of histidine-tryptophan-ketoglutarate (HTK) solution in increasing resistance of brain tissue to ischemic conditions. METHODS Three separate randomized groups were created, each consisting of eight rabbits. The groups were called the ischemia, HTK and sham groups, respectively. In the ischemia group, temporary brain ischemia was created for 15 minutes by placing clamps on the bilateral subclavian and common carotid arteries. Then the clamps were removed, and the brain was reperfused for 30 minutes. In the HTK group, HTK solution was sent to the brain through the internal carotid artery before the same ischemia-reperfusion protocol was applied. Histopathological analyses using a visual scoring system to assess the degree of ischemic changes and the apoptotic cell index by TUNEL test were performed in all brain tissue samples. RESULTS Apoptotic cell indices of the HTK (20.6%) and sham (17.8%) groups were lower than the ischemia group (56.8%) (P < .05). Statistically significant differences were detected between all groups in categorical scores (P < .05). CONCLUSIONS It was shown that less ischemic damage occurs in the brain tissue with the use of HTK solution, and it may be a candidate approach to prevent the brain from ischemic insults during cerebrovascular surgery. Further studies are required to demonstrate its exact effectiveness, in terms of dose, duration, and temperature.",2020,"Statistically significant differences were detected between all groups in categorical scores (P < .05). ",[],"['histidine-tryptophan-ketoglutarate (HTK) solution', 'Histidine-Tryptophan-Ketoglutarate Solutions']","['Apoptotic cell indices of the HTK', 'categorical scores', 'temporary brain ischemia']",[],"[{'cui': 'C0019602', 'cui_str': 'Histidine'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0054039', 'cui_str': 'Bretschneider cardioplegic solution'}]","[{'cui': 'C0007584', 'cui_str': 'Cell count'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0019602', 'cui_str': 'Histidine'}, {'cui': 'C0041249', 'cui_str': 'Tryptophan'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0205374', 'cui_str': 'Transitory'}, {'cui': 'C0007786', 'cui_str': 'Ischemic encephalopathy'}]",,0.0284558,"Statistically significant differences were detected between all groups in categorical scores (P < .05). ","[{'ForeName': 'Sonay', 'Initials': 'S', 'LastName': 'Oğuz', 'Affiliation': 'Department of Cardiovascular Surgery, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey. soguz@comu.edu.tr.'}, {'ForeName': 'Halil F', 'Initials': 'HF', 'LastName': 'Aşgün', 'Affiliation': 'Department of Cardiovascular Surgery, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey. soguz@comu.edu.tr.'}, {'ForeName': 'Başak', 'Initials': 'B', 'LastName': 'Büyük', 'Affiliation': 'Department of Histology and Embryology, Faculty of Medicine, İzmir Democracy University, İzmir, Turkey. soguz@comu.edu.tr.'}]",The heart surgery forum,['10.1532/hsf.3103'] 2710,32726208,Comparison of Distal Transradial Access in Anatomic Snuffbox Versus Transradial Access for Coronary Angiography.,"BACKGROUND To compare distal transradial access (dTRA) in the anatomic snuffbox and conventional transradial access (cTRA) for coronary angiography. METHODS Eighty cases that underwent coronary angiography were selected at The 903 Hospital of PLA in China from April 2017 to March 2018. Patients in the dTRA group underwent distal transradial access, and patients in the cTRA group received conventional transradial access. Puncture success rate, fluoroscopy time, and hemostasis time were determined. RESULTS The puncture success ratio was 85% in the dTRA group and 100% in the cTRA group (P < .05). The fluoroscopy time was 36 minutes and 19 min minutes in the dTRA group and cTRA group (P < .05), respectively. The compression hemostasis time after operation was 120 minutes and 240 minutes in the dTRA group and cTRA group (P < .05), respectively. The complication rate in the cTRA group was 7.5%, while there was no complication in the dTRA group. In addition, there also was no significant difference between the two groups in the rate of complications (cTRA = 7.5%, dTRA = 0.0%, P > .05). CONCLUSION Distal transradial access in the anatomical snuffbox for coronary angiogram is a potential alternative to conventional radial arterial access.",2020,"The fluoroscopy time was 36 minutes and 19 min minutes in the dTRA group and cTRA group (P < .05), respectively.","['Coronary Angiography', 'Eighty cases that underwent coronary angiography were selected at The 903 Hospital of PLA in China from April 2017 to March 2018']","['dTRA', 'distal transradial access (dTRA', 'conventional transradial access']","['compression hemostasis time', 'fluoroscopy time', 'Puncture success rate, fluoroscopy time, and hemostasis time', 'complication rate', 'rate of complications', 'puncture success ratio']","[{'cui': 'C0085532', 'cui_str': 'Coronary angiography'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0456170', 'cui_str': 'Left atrial pressure'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}]","[{'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0019116', 'cui_str': 'Hemostatic function'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0352078,"The fluoroscopy time was 36 minutes and 19 min minutes in the dTRA group and cTRA group (P < .05), respectively.","[{'ForeName': 'Hongjiang', 'Initials': 'H', 'LastName': 'Lu', 'Affiliation': 'Department of Cardiology, The 903 Hospital of PLA, Hangzhou 310013, China. JhOKL45@163.com.'}, {'ForeName': 'Danning', 'Initials': 'D', 'LastName': 'Wu', 'Affiliation': 'Department of Cardiology, The 903 Hospital of PLA, Hangzhou 310013, China. HUIK87oik@163.com.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Department of Cardiology, The 903 Hospital of PLA, Hangzhou 310013, China. ChenXiangsry@163.com.'}]",The heart surgery forum,['10.1532/hsf.3041'] 2711,32726268,Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection.,"INTRODUCTION A small percentage of patients with skin infections later develop necrotizing fasciitis (NF). Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department (ED) after antibiotic initiation. Elevated lactate has been associated with NF; existing estimates of the frequency of NF are based on retrospective reviews, and cases often lack testing for lactate. We present the incidence of patients with skin infections who developed NF and their baseline lactates. METHODS In four phase-3 trials, 2883 adults with complicated or acute bacterial skin and skin structure infections were randomized to dalbavancin or comparator, with early and late follow-up visits through Day 28. We prospectively collected baseline plasma lactates in one trial to assess an association with NF. RESULTS NF was diagnosed in 3/2883 patients (0.1%); all three survived. In the study with prospectively collected baseline lactates (n = 622), 15/622 (2.4%) had a lactate ≥4 millimoles per liter (mmol/L), including 3/622 (0.5%) with a lactate ≥7 mmol/L. NF was not seen in patients with a lactate <4 mmol/L; NF was seen in 1/15 (6.7%) with a lactate ≥4 mmol/L, including 1/3 (33.3%) with lactate ≥7 mmol/L. CONCLUSIONS NF incidence within 72 hours of antibiotic initiation in patients with complicated or acute bacterial skin and skin structure infections was extremely low (0.1%) and occurred in 6.7% with a lactate ≥4 mmol/L. Lactate <4 mmol/L can be used to identify patients at low risk of NF who could be safely discharged from the ED after antibiotic initiation.",2020,Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department (ED) after antibiotic initiation.,"['patients with skin infections who developed NF and their baseline lactates', '2883 adults with complicated or acute bacterial skin and skin structure infections', 'patients with skin infections later develop necrotizing fasciitis (NF', 'patients with skin infections at low risk of NF who could be discharged from the emergency department (ED) after antibiotic initiation']",['dalbavancin'],"['Necrotizing Fasciitis', 'acute bacterial skin and skin structure infections']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007642', 'cui_str': 'Cellulitis'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0231242', 'cui_str': 'Complicated'}, {'cui': 'C4552481', 'cui_str': 'Acute bacterial skin and skin structure infection'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation'}]","[{'cui': 'C1172636', 'cui_str': 'dalbavancin'}]","[{'cui': 'C4552481', 'cui_str': 'Acute bacterial skin and skin structure infection'}]",2883.0,0.0229485,Diagnostic testing is needed to identify patients with skin infections at low risk of NF who could be discharged from the emergency department (ED) after antibiotic initiation.,"[{'ForeName': 'Urania', 'Initials': 'U', 'LastName': 'Rappo', 'Affiliation': 'Allergan PLC, Madison, New Jersey.'}, {'ForeName': 'H Bryant', 'Initials': 'HB', 'LastName': 'Nguyen', 'Affiliation': 'Loma Linda University, Division of Pulmonary, Critical Care, Hyperbaric, Allergy and Sleep Medicine Loma Linda, California.'}, {'ForeName': 'Sailaja', 'Initials': 'S', 'LastName': 'Puttagunta', 'Affiliation': 'Allergan PLC, Madison, New Jersey.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Ojaimi', 'Affiliation': 'Allergan PLC, Madison, New Jersey.'}, {'ForeName': 'Karthik', 'Initials': 'K', 'LastName': 'Akinapelli', 'Affiliation': 'Independent consultant, Hamden, Connecticut.'}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Dunne', 'Affiliation': 'Allergan PLC, Madison, New Jersey.'}]",The western journal of emergency medicine,['10.5811/westjem.2020.5.46046'] 2712,32726308,Improved patient satisfaction and diagnostic accuracy in skin diseases with a Visual Clinical Decision Support System-A feasibility study with general practitioners.,"Patient satisfaction is an important indicator of health care quality, and it remains an important goal for optimal treatment outcomes to reduce the level of misdiagnoses and inappropriate or absent therapeutic actions. Digital support tools for differential diagnosis to assist clinicians in reaching the correct diagnosis may be helpful, but how the use of these affect patients is not clear. The primary objective of this feasibility study was to investigate patient experience and satisfaction in a primary care setting where general practitioners (GPs) used a visual clinical decision support system (CDSS) compared with standard consultations. Secondary objectives were diagnostic accuracy and length of consultation. Thirty-one patients with a dermatologist-confirmed skin diagnosis were allocated to consult GPs that had been randomized to conduct either standard consultations (SDR, n = 21) or CDSS (n = 16) on two separate study days one week apart. All patients were diagnosed independently by multiple GPs (n = 3-8) in both the SDR and CDSS study arms. Using the CDSS, more patients felt involved in the decision making (P = 0.05). In addition, more patients were exposed to images during the consultations (P = 6.8e-27), and 83% of those that were shown images replied they felt better supported in the consultation. The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms). This study shows for the first time that compared with standard GP consultations, CDSS assist the GP on skin related diagnoses and improve patient satisfaction and diagnostic accuracy without impacting the duration of the consultations. This is likely to increase correct treatment choices, patient adherence, and overall result in better healthcare outcomes.",2020,"The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms).","['Thirty-one patients with a dermatologist-confirmed skin diagnosis', 'general practitioners']","['CDSS', 'visual clinical decision support system (CDSS']","['patient satisfaction and diagnostic accuracy', 'diagnostic accuracy', 'duration of the consultation', 'diagnostic accuracy and length of consultation']","[{'cui': 'C0450355', 'cui_str': '31'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0259831', 'cui_str': 'Dermatologist'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0017319', 'cui_str': 'General physician'}]","[{'cui': 'C0525070', 'cui_str': 'Clinical Decision Support Systems'}, {'cui': 'C0234621', 'cui_str': 'Visual'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",31.0,0.0505547,"The use of CDSS significantly improved the diagnostic accuracy (34%, P = 0.007), and did not increase the duration of the consultation (median 10 minutes in both arms).","[{'ForeName': 'Eckhard W', 'Initials': 'EW', 'LastName': 'Breitbart', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Kohelia', 'Initials': 'K', 'LastName': 'Choudhury', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Anders Daniel', 'Initials': 'AD', 'LastName': 'Andersen', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}, {'ForeName': 'Henriette', 'Initials': 'H', 'LastName': 'Bunde', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Breitbart', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'Antonia Maria', 'Initials': 'AM', 'LastName': 'Sideri', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Fengler', 'Affiliation': 'Association of Dermatological Prevention (ADP), Hamburg, Germany.'}, {'ForeName': 'John Robert', 'Initials': 'JR', 'LastName': 'Zibert', 'Affiliation': 'LEO Innovation Lab, Copenhagen, Denmark.'}]",PloS one,['10.1371/journal.pone.0235410'] 2713,32732777,Performing Soccer-Specific Training With Blood Flow Restriction Enhances Physical Capacities in Youth Soccer Players.,"Hosseini Kakhak, SA, Kianigul, M, Haghighi, AH, Nooghabi, MJ, and Scott, BR. Performing soccer-specific training with blood flow restriction enhances physical capacities in youth soccer players. J Strength Cond Res XX(X): 000-000, 2020-This study investigated the effect of soccer training with blood flow restriction (BFR) on physical performance in youth athletes. Nineteen semiprofessional soccer players were randomly assigned to either normal soccer training (ST; n = 9) or soccer training with BFR (STBFR; n = 10). Both groups performed identical activities during a 6-week preseason training phase, either with or without lower limb BFR. Training included soccer-specific drills, small-sided games, plyometrics, and continuous running. Before and after the intervention, players were assessed for leg extension strength and endurance, countermovement jump performance, 40-yd sprint time, change-of-direction (COD) ability, aerobic endurance, and soccer-specific endurance (while dribbling a ball). Significantly larger improvements were observed in the STBFR compared with the ST group for tests of muscular endurance (74.8 ± 34.1% vs. 4.0 ± 14.6%), COD (8.1 ± 3.7% vs. 2.8 ± 4.7%), and aerobic (54.1 ± 19.6% vs. 24.7 ± 27.2%) and soccer-specific endurance (58.4 ± 19.6% vs. 22.7 ± 10.2%). Main effects for time were observed for maximal strength, jumping, and sprinting performance (p < 0.001) but with no group and time interaction. These findings demonstrate that team sport training with BFR can enhance physical qualities that are related to performance in youth soccer players. This application of BFR may improve the adaptive responses of muscles, without having to dedicate additional training time to muscular qualities.",2020,"Main effects for time were observed for maximal strength, jumping, and sprinting performance (p < 0.001) but with no group and time interaction.","['youth soccer players', ' 000-000', 'Nineteen semiprofessional soccer players', 'youth athletes', 'Youth Soccer Players']","['J Strength Cond Res XX(X', 'Performing Soccer-Specific Training With Blood Flow Restriction', 'normal soccer training (ST; n = 9) or soccer training with BFR', 'soccer training with blood flow restriction (BFR', 'ST', 'blood flow restriction']","['soccer-specific endurance', 'maximal strength, jumping, and sprinting performance', 'leg extension strength and endurance, countermovement jump performance, 40-yd sprint time, change-of-direction (COD) ability, aerobic endurance, and soccer-specific endurance (while dribbling a ball', 'Hosseini Kakhak, SA, Kianigul, M, Haghighi, AH, Nooghabi, MJ, and Scott, BR']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0205307', 'cui_str': 'Normal'}]","[{'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0013132', 'cui_str': 'Dribbling from mouth'}, {'cui': 'C0039597', 'cui_str': 'Testis structure'}]",,0.0148377,"Main effects for time were observed for maximal strength, jumping, and sprinting performance (p < 0.001) but with no group and time interaction.","[{'ForeName': 'Seyed A', 'Initials': 'SA', 'LastName': 'Hosseini Kakhak', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.'}, {'ForeName': 'Mojtaba', 'Initials': 'M', 'LastName': 'Kianigul', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.'}, {'ForeName': 'Amir-Hossein', 'Initials': 'AH', 'LastName': 'Haghighi', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Hakim Sabzevari University, Sabzevar, Iran.'}, {'ForeName': 'Mehdi Jabbari', 'Initials': 'MJ', 'LastName': 'Nooghabi', 'Affiliation': 'Department of Statistics, Ferdowsi University of Mashhad, Mashhad, Iran.'}, {'ForeName': 'Brendan R', 'Initials': 'BR', 'LastName': 'Scott', 'Affiliation': 'Department of Exercise Science, College of Science, Health, Engineering and Education, Murdoch University, Perth, Australia.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003737'] 2714,32729819,Bioequivalence study of two formulations of memantine hydrochloride tablets in healthy male Chinese subjects under fasting and fed conditions
.,"PURPOSE Memantine is currently the only drug that acts on the glutamate energy system to treat Alzheimer's disease. A generic memantine tablet was developed to offer an alternative to the marketed tablet formulation. The purpose of this study was to assess the bioequivalence of two different memantine formulations among healthy male Chinese subjects under fasting and fed conditions. MATERIALS AND METHODS We carried out single-center, randomized, single-dose, open-label, two-period, cross-over studies which including 20 healthy male Chinese subjects under fasting and fed conditions, respectively. Plasma samples were collected prior to and up to 240 hours after dosing. Key pharmacokinetic parameters including area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t ), area from time zero to infinite (AUC 0-∞ ), and C max were used for bioequivalence assessment. RESULTS Under fasting condition, the 90% CIs of the geometric mean ratios of the test/reference drug for memantine were 106.5 - 114.0% for C max , 99.4 - 107.9% for AUC 0-t , and 100.0 - 109.6% for AUC 0-∞ . Under fed condition, the 90% CIs of the geometric mean ratios of the test/reference drug for memantine were 94.8 - 104.3% for C max , 98.2 - 110.5% for AUC 0-t , and 99.2 - 113.0% for AUC 0-∞ . CONCLUSION The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state. That is to say, the test formulation of memantine 10-mg tablet is bioequivalent to the reference formulation (Ebixa 10-mg tablet).",2020,The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state.,"['20 healthy male Chinese subjects under fasting and fed conditions, respectively', 'healthy male Chinese subjects under fasting and fed conditions', 'healthy male Chinese subjects under fasting and fed conditions\u2029']","['memantine hydrochloride tablets', 'memantine', 'memantine formulations', 'Memantine']","['plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t ), area from time zero to infinite (AUC 0-∞ ), and C max', 'geometric mean ratios of the test/reference drug for memantine']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0342895', 'cui_str': 'Fish-eye disease'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0771988', 'cui_str': 'Memantine hydrochloride'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}]","[{'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0919414', 'cui_str': '0'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0025242', 'cui_str': 'Memantine'}]",20.0,0.0343325,The observed pharmacokinetic parameters of memantine of the test drug were similar to those of the reference formulation both in the fasting and fed state.,"[{'ForeName': 'Juntao', 'Initials': 'J', 'LastName': 'Zheng', 'Affiliation': ''}, {'ForeName': 'Jiangying', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ''}, {'ForeName': 'Jingjing', 'Initials': 'J', 'LastName': 'Wu', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Liping', 'Initials': 'L', 'LastName': 'Mai', 'Affiliation': ''}, {'ForeName': 'Xiyong', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ''}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Huang', 'Affiliation': ''}, {'ForeName': 'Guoping', 'Initials': 'G', 'LastName': 'Zhong', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203683'] 2715,32729820,"Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study
.","OBJECTIVES To evaluate the pharmacokinetics, pharmacodynamics, and tolerability of JY09, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, in healthy subjects. MATERIALS AND METHODS Healthy subjects were enrolled into 5 cohorts (0.3, 0.7, 1.5, 3.0, and 6.0 mg JY09) and received subcutaneous JY09 or placebo according to a randomized, double-blind, placebo-controlled, single-center, dose-escalating phase I trial design. Blood samples were collected over a 42-day period, and JY09 in plasma was determined by an electrochemical luminescence method. For the pharmacodynamic evaluation, oral glucose tolerance tests (OGTTs) were conducted predose and on day 5 after the target dose, during which plasma glucose, insulin, C-peptide, and glucagon concentrations were analyzed. Tolerability was assessed using physical examination and queries, vital sign measurements, laboratory analysis, and detection of immunogenicity. RESULTS In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09. The half-life of JY09 was ~ 9.3 days, and the peak concentration was reached at ~ 60 - 72 hours. Following the OGTT, an increase in C-peptide concentration was observed after exposure to JY09 at the dose of 6.0 mg compared to the placebo group. JY09 was well tolerated in healthy Chinese subjects following a single dose of up to 6.0 mg. No symptomatic hypoglycemia was reported, and the most commonly observed adverse event was suppressed appetite, and its incidence was dose-dependent. Four subjects (13%) developed anti-JY09 antibodies. CONCLUSION JY09 has a long half-life of ~ 9.3 days, with an acceptable safety profile.",2020,"In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09.","['Healthy subjects were enrolled into 5 cohorts (0.3, 0.7, 1.5, 3.0, and 6.0 mg JY09) and received', 'healthy Chinese subjects', 'healthy subjects']","['subcutaneous JY09 or placebo', 'placebo']","['symptomatic hypoglycemia', 'tolerated', 'plasma glucose, insulin, C-peptide, and glucagon concentrations', 'Blood samples', 'AUC 0-inf and C max', 'peak concentration', 'C-peptide concentration', 'pharmacokinetics, pharmacodynamics, and tolerability', 'physical examination and queries, vital sign measurements, laboratory analysis, and detection of immunogenicity', 'Tolerability', 'Pharmacokinetics, pharmacodynamics, and\xa0tolerability']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4068885', 'cui_str': '0.3'}, {'cui': 'C4517474', 'cui_str': '0.7'}, {'cui': 'C3844012', 'cui_str': '1.5'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}]","[{'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0006558', 'cui_str': 'C-peptide'}, {'cui': 'C0017687', 'cui_str': 'Glucagon'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",,0.236705,"In healthy Chinese subjects, JY09 exhibited a dose-dependent increase in AUC 0-inf and C max from 0.7 to 6.0 mg JY09.","[{'ForeName': 'Guangyu', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Cao', 'Affiliation': ''}, {'ForeName': 'Yuanxun', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': ''}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Geng', 'Affiliation': ''}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': ''}, {'ForeName': 'Junyi', 'Initials': 'J', 'LastName': 'Jiang', 'Affiliation': ''}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ''}, {'ForeName': 'Zuyi', 'Initials': 'Z', 'LastName': 'Weng', 'Affiliation': ''}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Zhang', 'Affiliation': ''}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': ''}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203730'] 2716,32729824,Multiple-dose pharmacokinetics and safety of amoxicillin/clavulanate in healthy elderly subjects
.,"BACKGROUND Amoxicillin/clavulanate is a widely used oral formulation of penicillin combined with a β-lactamase inhibitor. When using amoxicillin/clavulanate in the elderly, the risk of adverse drug reaction may be greater. This study aimed to evaluate the pharmacokinetics (PKs) and safety of multiple-dose amoxicillin/clavulanate administration in healthy elderly subjects and to compare the observed PK profiles with those in healthy younger adults. An open-label, one-sequence, multiple administration study was conducted in 16 healthy elderly subjects. MATERIALS AND METHODS Subjects orally received amoxicillin and clavulanate 750/187.5 twice daily for 9 days. For PK analysis, serial blood samples were collected up to 12 hours after the last administration of amoxicillin/clavulanate. The demographic and PK data of this study were compared to those of healthy young adults from a separate study with a similar design. Safety assessments including clinical laboratory tests, physical examination, vital signs, and adverse event (AE) monitoring were performed throughout the study. RESULTS All AEs were mild, and no serious AEs were reported in this study. The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects. However, the time required to reach maximum concentration at steady state and the elimination half-life were similar in the two age groups. CONCLUSION Although multiple administration of amoxicillin/clavulanate 750/187.5 mg was safe and well-tolerated, the systemic exposure of amoxicillin and clavulanate was higher in elderly subjects than in younger subjects.",2020,"The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects.","['healthy young adults', 'healthy younger adults', 'healthy elderly subjects', '16 healthy elderly subjects', 'healthy elderly subjects\u2029', 'elderly subjects than in younger subjects', 'Subjects orally received']","['Amoxicillin/clavulanate', 'amoxicillin/clavulanate', 'amoxicillin and clavulanate']","['systemic exposure of amoxicillin and clavulanate', 'clinical laboratory tests, physical examination, vital signs, and adverse event (AE) monitoring', 'safe and well-tolerated, the systemic exposure of amoxicillin and clavulanate']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0054066', 'cui_str': 'Amoxicillin and clavulanate'}]","[{'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0054066', 'cui_str': 'Amoxicillin and clavulanate'}, {'cui': 'C4505474', 'cui_str': 'Clinical Laboratory Tests'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}]",16.0,0.0121701,"The systemic exposure of amoxicillin and clavulanate was ~ 90% and 60% higher, respectively, in the elderly subjects than in the younger subjects.","[{'ForeName': 'Sang Won', 'Initials': 'SW', 'LastName': 'Lee', 'Affiliation': ''}, {'ForeName': 'Yewon', 'Initials': 'Y', 'LastName': 'Choi', 'Affiliation': ''}, {'ForeName': 'Kyungho', 'Initials': 'K', 'LastName': 'Jang', 'Affiliation': ''}, {'ForeName': 'Seo Hyun', 'Initials': 'SH', 'LastName': 'Yoon', 'Affiliation': ''}, {'ForeName': 'Jae-Yong', 'Initials': 'JY', 'LastName': 'Chung', 'Affiliation': ''}]",International journal of clinical pharmacology and therapeutics,['10.5414/CP203773'] 2717,32729835,Effects of Incentives on Adherence to a Web-Based Intervention Promoting Physical Activity: Naturalistic Study.,"BACKGROUND Despite many advantages of web-based health behavior interventions such as wide accessibility or low costs, these interventions are often accompanied by high attrition rates, particularly in usage under real-life conditions. It would therefore be helpful to implement strategies such as the use of financial incentives to motivate program participation and increase adherence. OBJECTIVE This naturalistic study examined real-life usage data of a 12-week web-based physical activity (PA) intervention (Fitness Coach) among insurants who participated in an additional incentive program (incentive group) and those who did not (nonincentive group). Users in the incentive group had the perspective of receiving €30 (about US $33) cash back at the end of the intervention. METHODS Registration and real-life usage data as part of routine data management and evaluation of the Fitness Coach were analyzed between September 2016 and June 2018. Depending on the duration of use and the weekly recording of tasks, 4 adherence groups (low, occasional, strong, and complete adherence) were defined. Demographic characteristics were collected by a self-reported questionnaire at registration. We analyzed baseline predictors and moderators of complete adherence such as participation in the program, age, gender, and BMI using binary logistic regressions. RESULTS A total of 18,613 eligible persons registered for the intervention. Of these, 15,482 users chose to participate in the incentive program (incentive group): mean age 42.4 (SD 14.4) years, mean BMI 24.5 (SD 4.0) kg/m 2 , median (IQR) BMI 23.8 (21.7-26.4) kg/m 2 ; 65.12% (10,082/15,482) female; and 3131 users decided not to use the incentive program (nonincentive group): mean age 40.7 (SD 13.4) years, mean BMI 26.2 (SD 5.0) kg/m 2 , median BMI 25.3 (IQR 22.6-28.7) kg/m 2 ; 72.18% (2260/3131) female. At the end of the intervention, participants in the incentive program group showed 4.8 times higher complete adherence rates than those in the nonincentive program group (39.2% vs 8.1%), also yielding significantly higher odds to complete the intervention (odds ratio [OR] 12.638) for the incentive program group. Gender significantly moderated the effect with men in the incentive group showing higher odds to be completely adherent than women overall and men in the nonincentive group (OR 1.761). Furthermore, older age and male gender were significant predictors of complete adherence for all participants, whereas BMI did not predict intervention completion. CONCLUSIONS This is the first naturalistic study in the field of web-based PA interventions that shows the potential of even small financial incentives to increase program adherence. Male users, in particular, seem to be strongly motivated by incentives to complete the intervention. Based on these findings, health care providers can use differentiated incentive systems to increase regular participation in web-based PA interventions.",2020,"At the end of the intervention, participants in the incentive program group showed 4.8 times higher complete adherence rates than those in the nonincentive program group (39.2% vs 8.1%), also yielding significantly higher odds to complete the intervention (odds ratio [OR] 12.638) for the incentive program group.","['Male users', '18,613 eligible persons registered for the intervention', 'age 42.4 (SD 14.4) years, mean BMI 24.5 (SD 4.0) kg/m 2 , median (IQR) BMI 23.8 (21.7-26.4) kg/m 2 ; 65.12% (10,082/15,482) female; and 3131 users decided not to use the incentive program (nonincentive group', '15,482 users chose to participate in the incentive program (incentive group): mean', 'insurants who participated in an additional incentive program (incentive group) and those who did not (nonincentive group', 'mean age 40.7 (SD 13.4) years, mean BMI 26.2']",['12-week web-based physical activity (PA) intervention (Fitness Coach'],['complete adherence rates'],"[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C5191366', 'cui_str': '21.7'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C4517558', 'cui_str': '13.4'}]","[{'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0557773', 'cui_str': 'Coach'}]","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}]",18613.0,0.0359261,"At the end of the intervention, participants in the incentive program group showed 4.8 times higher complete adherence rates than those in the nonincentive program group (39.2% vs 8.1%), also yielding significantly higher odds to complete the intervention (odds ratio [OR] 12.638) for the incentive program group.","[{'ForeName': 'Ramona', 'Initials': 'R', 'LastName': 'Wurst', 'Affiliation': 'Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Maliezefski', 'Affiliation': 'IGEL-M GbR, Bad Oldesloe, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Ramsenthaler', 'Affiliation': 'Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Brame', 'Affiliation': 'Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Fuchs', 'Affiliation': 'Department of Sport and Sport Science, University of Freiburg, Freiburg, Germany.'}]",Journal of medical Internet research,['10.2196/18338'] 2718,32728322,Effect of Goal-directed Hemodynamic Therapy in Postcardiac Surgery Patients.,"Background and aims Early goal-directed therapy (EGDT) provides preset goals to be achieved by intravenous fluid therapy and inotropic therapy with earliest detection of change in the hemodynamic profile. Improved outcome in cardiac surgery patients has been shown by perioperative volume optimization, while postoperative intensive care unit (ICU) stay can be decreased by improving oxygen delivery. Our aim of this study was to study the outcome of EGDT in patients undergoing elective cardiac surgery. Materials and methods This is a prospective single institute study involving a total of 478 patients. Patients were divided into group I, who received standard hospital care, and group II, who received EGDT. Postoperatively, patients were observed in ICU for 72 hours. Hemodynamics, laboratory data, fluid bolus, inotrope score, complication, ventilatory time, and mortality data were collected. Results Postoperative ventilatory period (11.12 ± 10.11 vs 9.45 ± 8.87, p = 0.0719) and frequency of change in inotropes (1.900 ± 0.9 vs 1.19 ± 0.61, p = 0.0717) were lower in group II. Frequency of crystalloid boluses (1.33 ± 0.65 vs 1.75 ± 1.09, p = 0.0126), and quantity of packed cell volume (PCV) used (1.63 ± 1.03 vs 2.04 ± 1.42, p = 0.0364) were highly significant in group II. Use of colloids was higher in group II and was statistically significant (1.98 ± 1.99 vs 3.05 ± 2.17, p = 0.0012). The acute kidney injury (AKI) rate was (58 (23.10%) vs 30 (13.21%), p = 0.007) lower and statistically significant ( p = 0.007) in group II. Conclusion Early goal-directed therapy reduces the postoperative ventilatory period, frequency of changes in inotropes, and incidence of AKI, and decreases ventilation hours, number of times inotropes changed, and AKI. How to cite this article Patel H, Parikh N, Shah R, Patel R, Thosani R, Shah P, et al. Effect of Goal-directed Hemodynamic Therapy in Postcardiac Surgery Patients. Indian J Crit Care Med 2020;24(5):321-326.",2020,"Use of colloids was higher in group II and was statistically significant (1.98 ± 1.99 vs 3.05 ± 2.17, p = 0.0012).","['patients undergoing elective cardiac surgery', 'cardiac surgery patients', 'Postcardiac Surgery Patients', '478 patients']","['Goal-directed Hemodynamic Therapy', ' and aims\n\n\nEarly goal-directed therapy (EGDT', 'standard hospital care, and group II, who received EGDT', 'EGDT']","['postoperative ventilatory period, frequency of changes in inotropes, and incidence of AKI, and decreases ventilation hours, number of times inotropes changed, and AKI', 'frequency of change in inotropes', 'acute kidney injury (AKI) rate', 'quantity of packed cell volume (PCV', 'postoperative intensive care unit (ICU) stay', 'Hemodynamics, laboratory data, fluid bolus, inotrope score, complication, ventilatory time, and mortality data', 'Use of colloids']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0439851', 'cui_str': 'Direct'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C2744535', 'cui_str': 'CD69 protein, human'}, {'cui': 'C4505227', 'cui_str': 'Early Goal-Directed Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0449809', 'cui_str': 'Number of times'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C1265611', 'cui_str': 'Quantity'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0456238', 'cui_str': 'Ventilation cycle time'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}]",478.0,0.0308804,"Use of colloids was higher in group II and was statistically significant (1.98 ± 1.99 vs 3.05 ± 2.17, p = 0.0012).","[{'ForeName': 'Hasmukh', 'Initials': 'H', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiac Anesthesia, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Nirav', 'Initials': 'N', 'LastName': 'Parikh', 'Affiliation': 'Department of Cardiac Anesthesia, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Ritesh', 'Initials': 'R', 'LastName': 'Shah', 'Affiliation': 'Department of Cardiac Anesthesia, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Ramesh', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Department of Cardiac Anesthesia, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Thosani', 'Affiliation': 'Department of Cardiac Anesthesia, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Pratik', 'Initials': 'P', 'LastName': 'Shah', 'Affiliation': 'Department of Research, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Lokesh', 'Initials': 'L', 'LastName': 'Prajapat', 'Affiliation': 'Department of Research, UN Mehta Institute of Cardiology and Research Centre, Ahmedabad, Gujarat, India.'}]","Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine",['10.5005/jp-journals-10071-23427'] 2719,32728325,Comparative Efficacy of Hand Disinfection Potential of Hand Sanitizer and Liquid Soap among Dental Students: A Randomized Controlled Trial.,"Background Hands are the most common medium for initiation and spread of infection in clinics. Hand hygiene is the simplest and most economic method for reducing the healthcare-associated infections (HCAIs). Aim The aim of the present study was to compare the efficacy of hand sanitizer, liquid soap, and their combination for reducing the microbial colonies on hands. Materials and methods The study was a single-blinded randomized controlled trial executed in a dental college on 90 participants, which were randomly assigned into three intervention groups of 30 each. The participants were instructed to contaminate their hands followed by a hand hygiene protocol for the liquid hand-wash group, the alcohol-based hand sanitizer (ABHS) group, and the combination group according to WHO guidelines. The swabs were collected pre- and post-intervention and mean colony-forming units were determined for each group. Results Median percentage reduction was highest for the combination group (100%), followed by the ABHS group (94.29%) and lowest for the liquid soap (92.31%). This difference in the amount of colony-forming units (CFU) among all the groups was nonsignificant ( p = 0.114). Conclusion The results of the study show that there was no significant difference in hand disinfection potential among hand sanitizer, liquid soap, or their combination. All the three interventions were equally effective with the reduction of total bacterial contamination from participants' hands. How to cite this article Khairnar MR, Anitha G, Dalvi TM, Kalghatgi S, Datar UV, Wadgave U, et al. Comparative Efficacy of Hand Disinfection Potential of Hand Sanitizer and Liquid Soap among Dental Students: A Randomized Controlled Trial. Indian J Crit Care Med 2020;24(5):336-339.",2020,"The results of the study show that there was no significant difference in hand disinfection potential among hand sanitizer, liquid soap, or their combination.","['Dental Students', 'dental college on 90 participants']","['hand sanitizer, liquid soap', 'Hand Disinfection Potential of Hand Sanitizer and Liquid Soap', 'contaminate their hands followed by a hand hygiene protocol for the liquid hand-wash group, the alcohol-based hand sanitizer (ABHS']","['total bacterial contamination', 'Median percentage reduction']","[{'cui': 'C0038493', 'cui_str': 'Dental Student'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0557806', 'cui_str': 'College'}]","[{'cui': 'C1330330', 'cui_str': 'Hand Antiseptics'}, {'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0037392', 'cui_str': 'Soap'}, {'cui': 'C0018570', 'cui_str': 'Disinfection, Hand'}, {'cui': 'C0205279', 'cui_str': 'Contaminated'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C3494474', 'cui_str': 'Hand Hygiene'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0700382', 'cui_str': 'Washing hands'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",90.0,0.0460543,"The results of the study show that there was no significant difference in hand disinfection potential among hand sanitizer, liquid soap, or their combination.","[{'ForeName': 'Mahesh R', 'Initials': 'MR', 'LastName': 'Khairnar', 'Affiliation': 'Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}, {'ForeName': 'Anitha', 'Initials': 'A', 'LastName': 'G', 'Affiliation': 'Department of Periodontology, ESIC Dental College, Gulbarga, Karnataka, India.'}, {'ForeName': 'Tanushri M', 'Initials': 'TM', 'LastName': 'Dalvi', 'Affiliation': 'Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}, {'ForeName': 'Shrivardhan', 'Initials': 'S', 'LastName': 'Kalghatgi', 'Affiliation': 'Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}, {'ForeName': 'Uma V', 'Initials': 'UV', 'LastName': 'Datar', 'Affiliation': 'Department of Oral Pathology and Microbiology, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}, {'ForeName': 'Umesh', 'Initials': 'U', 'LastName': 'Wadgave', 'Affiliation': 'Department of Public Health Dentistry, ESIC Dental College, Gulbarga, Karnataka, India.'}, {'ForeName': 'Shrushti', 'Initials': 'S', 'LastName': 'Shah', 'Affiliation': 'Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}, {'ForeName': 'Lucky', 'Initials': 'L', 'LastName': 'Preet', 'Affiliation': 'Department of Public Health Dentistry, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Sangli, Maharashtra, India.'}]","Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine",['10.5005/jp-journals-10071-23420'] 2720,32728362,Influence of low-opioid anesthesia in cardiac surgery on dynamics of pro-inflammatory interleukin-6.,"Introduction With coronary artery bypass grafting, patients are subjected to additional risk caused by both surgical treatment itself and pathophysiological changes in homeostasis, provoked by the action of anesthetics and cardiopulmonary bypass. Material and methods The study involved 60 patients, who had been subjected to coronary artery bypass grafting with cardiopulmonary bypass. All patients were divided into two groups: group I (30 patients) - low-opioid scheme of anesthesia and group II (30 patients) - standard scheme of anesthetic management. Blood interleukin-6 (IL-6) was identified before and after cardiopulmonary bypass using an ELISA test. Results Having compared IL-6 values between study groups after completion of cardiopulmonary bypass, it was established that IL-6 levels were 27.51% ( p = 0.001) lower in patients of group I compared with the results of patients in group II. Patients in the first group had a significantly shorter time of mechanical ventilation compared to group II (2.1 ±0.7 hours vs. 3.9 ±0.9 hours, p = 0.021). Low cardiac output syndrome was significantly less frequently reported in patients of group I (10.0% vs. 33.3%, p = 0.028). In addition, patients in group I had a significantly shorter time of intensive care unit (ICU) stay (2.5 ±0.7 days vs. 3.5 ±1.0 days, p = 0.044). Conclusions Application of multimodal low-opioid anesthesia was associated with significantly lower IL-6 at the end of surgery, shorter mechanical ventilation duration, less frequent low cardiac output syndrome and need for catecholamines, and shorter ICU stays.",2020,"Low cardiac output syndrome was significantly less frequently reported in patients of group I (10.0% vs. 33.3%, ","['60 patients, who had been subjected to coronary artery bypass grafting with cardiopulmonary bypass']","['low-opioid anesthesia', 'coronary artery bypass grafting', ' low-opioid scheme of anesthesia and group II (30 patients) - standard scheme of anesthetic management']","['Blood interleukin-6 (IL-6', 'IL-6 values', 'IL-6 levels', 'mechanical ventilation duration', 'Low cardiac output syndrome', 'dynamics of pro-inflammatory interleukin-6', 'shorter time of intensive care unit (ICU) stay', 'shorter time of mechanical ventilation']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0002930', 'cui_str': 'Anesthetics'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]","[{'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0600177', 'cui_str': 'Low cardiac output syndrome'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}]",60.0,0.0164503,"Low cardiac output syndrome was significantly less frequently reported in patients of group I (10.0% vs. 33.3%, ","[{'ForeName': 'Oleh', 'Initials': 'O', 'LastName': 'Loskutov', 'Affiliation': 'Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.'}, {'ForeName': 'Stepan', 'Initials': 'S', 'LastName': 'Maruniak', 'Affiliation': 'Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.'}, {'ForeName': 'Olexandr', 'Initials': 'O', 'LastName': 'Dryzhyna', 'Affiliation': 'State Institution ""Heart Institute Ministry of Health of Ukraine"", Kyiv, Ukraine.'}, {'ForeName': 'Ihor', 'Initials': 'I', 'LastName': 'Malysh', 'Affiliation': 'Clinical Municipal Communal Emergency Hospital, Kyiv, Ukraine.'}, {'ForeName': 'Volodymyr', 'Initials': 'V', 'LastName': 'Kolesnykov', 'Affiliation': 'Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine.'}, {'ForeName': 'Natalia', 'Initials': 'N', 'LastName': 'Korotchuk', 'Affiliation': 'State Institution ""Heart Institute Ministry of Health of Ukraine"", Kyiv, Ukraine.'}]",Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery,['10.5114/kitp.2020.94190'] 2721,32728371,Two early rehabilitation training models in male patients after coronary artery bypass surgery: application of continuous walking training as an alternative to interval cycle ergometer training.,"Introduction Walking training is a good alternative to the commonly used cycle ergometer training. It is still necessary to develop rehabilitation programs based on walking characterized by a high degree of safety and effectiveness. Aim Application of continuous walking training as an alternative to interval cycle ergometer training in men after coronary artery bypass graft (CABG) surgery, using the 6-minute walk test (6-MWT) to determine the initial training load. Material and methods Forty-four men aged 45 to 76 years, up to 3 months after CABG surgery, were randomly assigned to continuous training on a treadmill (study group) or interval training on a cycle ergometer (control group), performed 6 times per week (12-15 sessions). Participants underwent the treadmill exercise stress test (TEST) and 6-MWT at the begining and after completion of the rehabilitation program. Before and 3 minutes after the 6 th and 12 th training session blood lactate concentration was determined. Results Energy expenditure in TEST increased from 4.4 to 6.3 MET in the study group and from 5.0 to 6.5 MET in the control group. Distance walked in 6-MWT increased from 420 to 519 m and from 438 to 510 m, respectively. Resting heart rate (HR) and double product (DP) decreased only in the study group as well as systolic blood pressure (SBP), HR and DP at peak exercise load in baseline TEST. Mean energy expenditure during training sessions was 2.6 MET in the study group and 2.8 MET in the control group (NS). Exercise blood lactate concentration did not exceed 2.0 mmol/l in both groups. Conclusions Both rehabilitation programs were of similar effectiveness and their intensity did not exceed the anaerobic threshold.",2020,Mean energy expenditure during training sessions was 2.6 MET in the study group and 2.8 MET in the control group (NS).,"['men after coronary artery bypass graft (CABG) surgery', 'male patients after coronary artery bypass surgery', 'Material and methods\n\n\nForty-four men aged 45 to 76 years, up to 3 months after CABG surgery']","['treadmill exercise stress test (TEST) and 6-MWT', 'interval cycle ergometer training', 'Introduction\n\n\nWalking training', 'continuous walking training', 'continuous training on a treadmill (study group) or interval training on a cycle ergometer (control group']","['Exercise blood lactate concentration', 'Resting heart rate (HR) and double product (DP', 'systolic blood pressure (SBP), HR and DP at peak exercise load', 'Energy expenditure in TEST', 'Distance walked in 6-MWT', 'Mean energy expenditure']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0010055', 'cui_str': 'Coronary artery bypass graft'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1821417', 'cui_str': 'Resting heart rate'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0014272', 'cui_str': 'Energy expenditure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0430515', 'cui_str': '6-minute walk test'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",44.0,0.0139793,Mean energy expenditure during training sessions was 2.6 MET in the study group and 2.8 MET in the control group (NS).,"[{'ForeName': 'Dorota', 'Initials': 'D', 'LastName': 'Dolecińska', 'Affiliation': 'Department of Cardiological and Rheumatological Rehabilitation, Poznan University of Physical Education, Poznan, Poland.'}, {'ForeName': 'Izabela', 'Initials': 'I', 'LastName': 'Przywarska', 'Affiliation': 'Department of Cardiological and Rheumatological Rehabilitation, Poznan University of Physical Education, Poznan, Poland.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Podgórski', 'Affiliation': 'Department of Physiology and Biochemistry, Poznan University of Physical Education, Poznan, Poland.'}, {'ForeName': 'Piotr', 'Initials': 'P', 'LastName': 'Dylewicz', 'Affiliation': 'Department of Cardiological and Rheumatological Rehabilitation, Poznan University of Physical Education, Poznan, Poland.'}]",Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery,['10.5114/kitp.2020.97265'] 2722,32726364,Four weeks of augmented eccentric loading using a novel leg press device improved leg strength in well-trained athletes and professional sprint track cyclists.,"This study assessed the efficacy of strength training using augmented eccentric loading to provoke increases in leg strength in well-trained athletes, and sprint track cyclists, using a novel leg press device. Twelve well-trained athletes were randomly allocated traditional resistance training (TRAD, n = 6), or resistance training using augmented eccentric loading (AEL, n = 6). A further 5 full-time, professional sprint track cyclists from a senior national squad programme also trained with augmented eccentric loading (AEL-ATH) alongside their usual sport-specific training. Participants completed four weeks of twice-weekly resistance training using the leg press exercise. In TRAD the lowering phase of the lift was set relative to concentric strength. In AEL and AEL-ATH the lowering phase was individualised to eccentric strength. Concentric, eccentric, isometric and coupled eccentric-concentric leg press strength, and back squat 1 repetition maximum (1RM), were assessed pre- and post-training. The AEL and AEL-ATH groups performed the eccentric phase with an average 26 ± 4% greater load across the programme. All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01). The TRAD and AEL groups also increased isometric strength (p < 0.05). A four-week period of augmented eccentric loading increased leg strength in well-trained athletes and track cyclists. The eccentric leg press stimulus was well-tolerated, supporting the inclusion of such training in the preparation programmes of athletes.",2020,"All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01).","['Twelve well-trained athletes', 'well-trained athletes and track cyclists', 'well-trained athletes and professional sprint track cyclists']","['strength training', 'augmented eccentric loading', 'resistance training using the leg press exercise', 'traditional resistance training (TRAD, n = 6), or resistance training using augmented eccentric loading (AEL, n = 6']","['concentric', 'Concentric, eccentric, isometric and coupled eccentric-concentric leg press strength, and back squat 1 repetition maximum (1RM', 'leg strength', 'squat 1RM', 'isometric strength']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0040594', 'cui_str': 'Track'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0023440', 'cui_str': 'Acute myeloid leukemia, M6 type'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0806909', 'cui_str': 'Max'}]",,0.0141622,"All groups experienced increases in concentric (5%, 7% and 3% for TRAD, AEL & AEL-ATH respectively), eccentric (7%, 11% and 6% for TRAD, AEL & AEL-ATH respectively), and squat 1RM (all p < 0.05), where the AEL-ATH group experienced relatively greater increases (13% vs. 5% in TRAD and AEL, p < 0.01).","[{'ForeName': 'Mellissa', 'Initials': 'M', 'LastName': 'Harden', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Wolf', 'Affiliation': 'English Institute of Sport, Manchester, United Kingdom.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'The Football Association, Burton on Trent, United Kingdom.'}, {'ForeName': 'Kirsty Marie', 'Initials': 'KM', 'LastName': 'Hicks', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Thomas', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}, {'ForeName': 'Glyn', 'Initials': 'G', 'LastName': 'Howatson', 'Affiliation': 'Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle, United Kingdom.'}]",PloS one,['10.1371/journal.pone.0236663'] 2723,32726408,Functional dysconnectivity of frontal cortex to striatum predicts ketamine infusion response in treatment-resistant depression.,"BACKGROUND Frontostriatal dysconnectivity plays a crucial role in the pathophysiology of major depressive disorder. However, whether the baseline functional connectivity (FC) of the frontostriatal network could predict the treatment outcome of low-dose ketamine infusion remained unknown. METHODS In total, 48 patients with treatment-resistant depression (TRD) were randomly divided into three treatment groups (a single-dose 40-min intravenous infusion) as follows: 0.5 mg/kg ketamine, 0.2 mg/kg ketamine, and saline placebo infusion. Patients were subsequently followed up for 2 weeks. Resting-state functional magnetic resonance imaging was performed for each patient before infusion administration. In addition, the baseline frontostriatal FC of patients with TRD was also compared with that of healthy controls. RESULTS Compared with the healthy controls, patients with TRD had a decreased FC in the frontostriatal circuits, especially between the right superior frontal cortex and executive region of the striatum and between the right paracingulate cortex and rostral-motor region of the striatum. The baseline hypoconnectivity of the bilateral superior frontal cortex to the executive region of the striatum was associated with a greater reduction of depression symptoms after a single 0.2 mg/kg ketamine infusion. CONCLUSION Reduced connectivity of the superior frontal cortex to the striatum predicted the response to ketamine infusion among patients with TRD.",2020,"Compared with the healthy controls, patients with TRD had a decreased FC in the frontostriatal circuits, especially between the right superior frontal cortex and executive region of the striatum and between the right paracingulate cortex and rostral-motor region of the striatum.","['patients with TRD', '48 patients with treatment-resistant depression (TRD']","['ketamine, 0.2 mg/kg ketamine, and saline placebo infusion']",['depression symptoms'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2063866', 'cui_str': 'Therapy-Resistant Depression'}]","[{'cui': 'C0022614', 'cui_str': 'Ketamine'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0439272', 'cui_str': 'ug/g'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}]","[{'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}]",48.0,0.0373466,"Compared with the healthy controls, patients with TRD had a decreased FC in the frontostriatal circuits, especially between the right superior frontal cortex and executive region of the striatum and between the right paracingulate cortex and rostral-motor region of the striatum.","[{'ForeName': 'Mu-Hong', 'Initials': 'MH', 'LastName': 'Chen', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Wan-Chen', 'Initials': 'WC', 'LastName': 'Chang', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Wei-Chen', 'Initials': 'WC', 'LastName': 'Lin', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Pei-Chi', 'Initials': 'PC', 'LastName': 'Tu', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Cheng-Ta', 'Initials': 'CT', 'LastName': 'Li', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Ya-Mei', 'Initials': 'YM', 'LastName': 'Bai', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Shih-Jen', 'Initials': 'SJ', 'LastName': 'Tsai', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}, {'ForeName': 'Wen-Sheng', 'Initials': 'WS', 'LastName': 'Huang', 'Affiliation': 'Department of Nuclear Medicine, and Division of Radiology Oncology, Department of Oncology,\xa0Taipei\xa0Veterans\xa0General Hospital,\xa0Taipei, Taiwan.'}, {'ForeName': 'Tung-Ping', 'Initials': 'TP', 'LastName': 'Su', 'Affiliation': 'Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.'}]",The international journal of neuropsychopharmacology,['10.1093/ijnp/pyaa056'] 2724,32726431,Risk factors for viremia in CMV- recipient seronegative donor seropositive liver transplant recipients who receive preemptive antiviral therapy.,"BACKGROUND The risk factors for development of viremia in high-risk donor CMV-seropositive and recipient CMV-seronegative (D+R-) transplant recipients are incompletely defined. METHODS The study population was comprised of patients in the preemptive therapy (PET) arm of a randomized, controlled trial of PET versus prophylaxis using valganciclovir in D+R- liver transplant recipients. Weekly surveillance monitoring for viremia for 100 days was performed using a sensitive CMV-DNA PCR assays. RESULTS Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (OR 2.20 for each quartile increase in donor age, 95% CI 1.07-4.52, p=0.031). Recipients who developed early-onset viremia (within 4 weeks) also had significantly older donors than those with later-onset viremia (difference in age 10.1 years, 95% CI 2-19, p=0.03). CONCLUSIONS Older donor age was an independent predictor of viremia and earlier-onset of viremia in D+R- liver transplant recipients. Future studies should assess the mechanistic links underlying this novel association.",2020,"RESULTS Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (OR 2.20 for each quartile increase in donor age, 95% CI 1.07-4.52, p=0.031).","['CMV- recipient seronegative donor seropositive liver transplant recipients who receive', 'D+R- liver transplant recipients']","['PET', 'preemptive therapy (PET', 'preemptive antiviral therapy']","['Viremia', 'early-onset viremia', 'viremia']","[{'cui': 'C0010823', 'cui_str': 'Cytomegalovirus infection'}, {'cui': 'C0521144', 'cui_str': 'Seronegative'}, {'cui': 'C0013018', 'cui_str': 'Donors'}, {'cui': 'C0521143', 'cui_str': 'Seropositive'}, {'cui': 'C0455647', 'cui_str': 'H/O: liver recipient'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0280274', 'cui_str': 'Antiviral therapy'}]","[{'cui': 'C0042749', 'cui_str': 'Viremia'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}]",,0.0310473,"RESULTS Viremia developed in 84% (79/94) of recipients and older donor age was the only independent factor associated with viremia (OR 2.20 for each quartile increase in donor age, 95% CI 1.07-4.52, p=0.031).","[{'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Singh', 'Affiliation': 'University of Pittsburgh, and VA Pittsburgh Healthcare System, Pittsburgh, PA.'}, {'ForeName': 'Drew J', 'Initials': 'DJ', 'LastName': 'Winston', 'Affiliation': 'University of California Los Angeles Medical Center, Los Angeles, CA.'}, {'ForeName': 'Raymund R', 'Initials': 'RR', 'LastName': 'Razonable', 'Affiliation': 'Mayo Clinic, Rochester, MN.'}, {'ForeName': 'G Marshall', 'Initials': 'GM', 'LastName': 'Lyon', 'Affiliation': 'Emory University, Atlanta, GA.'}, {'ForeName': 'Fernanda P', 'Initials': 'FP', 'LastName': 'Silveira', 'Affiliation': 'University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh PA.'}, {'ForeName': 'Marilyn M', 'Initials': 'MM', 'LastName': 'Wagener', 'Affiliation': 'University of Pittsburgh, and VA Pittsburgh Healthcare System, Pittsburgh, PA.'}, {'ForeName': 'Ajit P', 'Initials': 'AP', 'LastName': 'Limaye', 'Affiliation': 'University of Washington, Seattle, WA.'}]",The Journal of infectious diseases,['10.1093/infdis/jiaa470'] 2725,32726473,Disentangling the process of epistemic change: The role of epistemic volition.,"BACKGROUND Many interventions on epistemic beliefs (i.e., individual beliefs about knowledge and knowing) are based on Bendixen and Rule's Integrative Model for Personal Epistemology Development. Empirically, however, the model is still insufficiently validated. This is especially true for its epistemic volition component - a will or desire to actively change one's beliefs. AIMS To experimentally scrutinize the role of epistemic volition, we investigated (incremental) effects on epistemic change of an epistemic volition intervention. SAMPLE 412 psychology students enrolled at German universities completed the study. METHODS We employed a randomized pre-post design with three experimental groups that differed in the administered epistemic volition and resolvable controversies interventions. The purpose of the latter was to initiate an epistemic change process, thereby laying the foundation for the epistemic volition intervention. Both data collection and interventions were conducted online. In addition to self-report measures, we applied a complementary source evaluation task to analyse epistemic change. RESULTS Even though we found small- to medium-sized changes in epistemic beliefs, these changes did not differ between experimental conditions. Exploratory analyses suggested, however, that source evaluation task performance might have been promoted by the epistemic volition intervention and that - across experimental groups - manipulation check measures on both interventions interacted positively. CONCLUSION Ultimately, we failed to separate the effects that our epistemic volition intervention had on epistemic change from these of the resolvable controversies intervention. Nonetheless, our study makes some strong contributions to - and interconnects - the growing bodies of research on epistemic change and multiple source use.",2020,"Even though we found small- to medium-sized changes in epistemic beliefs, these changes did not differ between experimental conditions.",['412 psychology students enrolled at German universities completed the study'],['epistemic volition intervention'],[],"[{'cui': 'C0033909', 'cui_str': 'Psychology'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0017477', 'cui_str': 'German language'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0042950', 'cui_str': 'Volition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",[],412.0,0.0146377,"Even though we found small- to medium-sized changes in epistemic beliefs, these changes did not differ between experimental conditions.","[{'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Kerwer', 'Affiliation': 'Leibniz Institute for Psychology Information, Trier, Germany.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Rosman', 'Affiliation': 'Leibniz Institute for Psychology Information, Trier, Germany.'}, {'ForeName': 'Oliver', 'Initials': 'O', 'LastName': 'Wedderhoff', 'Affiliation': 'Leibniz Institute for Psychology Information, Trier, Germany.'}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Chasiotis', 'Affiliation': 'Leibniz Institute for Psychology Information, Trier, Germany.'}]",The British journal of educational psychology,['10.1111/bjep.12372'] 2726,32726475,Effectiveness of Advance Care Planning Group Visits Among Older Adults in Primary Care.,"BACKGROUND Group visits can support health behavior change and self-efficacy. In primary care, an advance care planning (ACP) group visit may leverage group dynamics and peer mentorship to facilitate education and personal goal setting that result in ACP engagement. OBJECTIVE To determine whether the ENgaging in Advance Care Planning Talks (ENACT) group visits intervention improves ACP documentation and readiness in older adults. METHODS This randomized clinical trial was conducted among geriatric primary care patients from the University of Colorado Hospital Seniors Clinic, Aurora, CO, from August 2017 to November 2019. Participants randomized to ENACT group visits (n = 55) participated in two 2-hour sessions with discussions of ACP topics and use of ACP tools (i.e., Conversation Starter Kit, Medical Durable Power of Attorney form, and PREPARE videos). Participants randomized to the control arm (n = 55) received the Conversation Starter Kit and a Medical Durable Power of Attorney form by mail. The primary outcomes included presence of ACP documents or medical decision-maker documentation in the electronic health record (EHR) at 6 months, and a secondary outcome was ACP readiness (validated four-item ACP Engagement Survey) at 6 months. RESULTS Participants were a mean of 77 years old, 60% female, and 79% white. At 6 months, 71% of ENACT participants had an advance directive in the EHR (26% higher) compared with 45% of control arm participants (P < .001). Similarly, 93% of ENACT participants had decision-maker documentation in the EHR (29% higher) compared with 73% in the control arm (P < .001). ENACT participants trended toward higher readiness to engage in ACP compared with control (4.56 vs 4.13; P = .16) at 6 months. CONCLUSION An ACP group visit increased ACP documentation and readiness to engage in ACP behavior change. Primary care teams can explore implementation and adaptation of ACP group visits into routine care, as well as longer-term impact on patient health outcomes.",2020,"ENACT participants trended toward higher readiness to engage in ACP compared with control (4.56 vs 4.13; P = .16) at 6 months. ","['geriatric primary care patients from the University of Colorado Hospital Seniors Clinic, Aurora, CO, from August 2017 to November 2019', 'Participants were a mean of 77\u2009years old, 60% female, and 79% white', 'older adults', 'Older Adults in Primary Care']","['discussions of ACP topics and use of ACP tools (i.e., Conversation Starter Kit, Medical Durable Power of Attorney form, and PREPARE videos', 'Conversation Starter Kit and a Medical Durable Power of Attorney form by mail', 'ENgaging in Advance Care Planning Talks (ENACT) group visits intervention', 'ACP', 'Advance Care Planning Group Visits', 'advance care planning (ACP) group visit may leverage group dynamics and peer mentorship to facilitate education and personal goal setting that result in ACP engagement', 'ENACT']","['readiness to engage in ACP', 'presence of ACP documents or medical decision-maker documentation in the electronic health record (EHR', 'decision-maker documentation', 'ACP documentation and readiness', 'ACP documentation and readiness to engage in ACP behavior change', 'advance directive in the EHR']","[{'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0009399', 'cui_str': 'Colorado'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C1278569', 'cui_str': 'WAS A'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0557061', 'cui_str': 'Discussion'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C1522168', 'cui_str': 'Topical route'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0812225', 'cui_str': 'Device kit'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0586806', 'cui_str': 'Power of attorney observable'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0025370', 'cui_str': 'Mentorships'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}]","[{'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0600371', 'cui_str': 'Advance care planning'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0554244', 'cui_str': 'Maker'}, {'cui': 'C0175636', 'cui_str': 'Documentation procedure'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0001683', 'cui_str': 'Advance Directives'}]",,0.0679267,"ENACT participants trended toward higher readiness to engage in ACP compared with control (4.56 vs 4.13; P = .16) at 6 months. ","[{'ForeName': 'Hillary D', 'Initials': 'HD', 'LastName': 'Lum', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Dukes', 'Affiliation': 'University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Andrea E', 'Initials': 'AE', 'LastName': 'Daddato', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Juarez-Colunga', 'Affiliation': 'Division of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.'}, {'ForeName': 'Prajakta', 'Initials': 'P', 'LastName': 'Shanbhag', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Jean S', 'Initials': 'JS', 'LastName': 'Kutner', 'Affiliation': 'Division of General Internal Medicine , Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.'}, {'ForeName': 'Cari R', 'Initials': 'CR', 'LastName': 'Levy', 'Affiliation': 'Denver-Seattle Center of Innovation for Veteran-Centered and Value Driven Care, Eastern Colorado Health Care System, Aurora, Colorado, USA.'}, {'ForeName': 'Rebecca L', 'Initials': 'RL', 'LastName': 'Sudore', 'Affiliation': 'Division of Geriatric Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.'}]",Journal of the American Geriatrics Society,['10.1111/jgs.16694'] 2727,32726556,Randomized Controlled Trial Comparing the Efficacy and Safety of Two Injection Techniques of IncobotulinumtoxinA for Axillary Hyperhidrosis.,"Background: Botulinum toxin A (BoNT-A) is an effective treatment for axillary hyperhidrosis (AH) typically applied by multiple injection punctures. Objective: To compare the efficacy and safety of two BoNT-A injection techniques for AH. Methods: Randomized, evaluator-blinded trial, in which each axilla of the same patient received 50 U of incobotulinumtoxin A (IncoA; Xeomin), one injected intradermally using multiple punctures, the other subcutaneously by radial approach. Follow-up visits occurred after 30, 120, 180, and 270 days. Outcomes included procedure duration and pain, gravimetry and starch-iodine tests and safety. Results: Twenty-four patients with severe hyperhidrosis were included; 67% were female and mean age was 34.7 years. Radial injection was faster applied than multiple punctures (P<0.001) but showed higher pain scores (P=0.001). Pre- and post-treatment gravimetric measures showed that IncoA led to a significant sweat reduction, by both techniques, with 95% of responders (≥50% reduction from baseline) after 30 days of treatment. Similarly, Minor's test showed an excellent response (90-100% reduction) by most patients regardless of the technique used, after 30 days and sustained for at least 270 days. At most time points, there were no significant differences between the two techniques; however, multiple punctures showed a higher reduction of gravimetric measures at days 30 and 180, and of Minor's test at day 270. Treatment was well tolerated. Conclusions: IncoA is an effective and safe treatment for AH irrespective to the technique used for injection. Our study suggests that multiple punctures injection may confer better outcomes at some time points. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.4989.",2020,Radial injection was faster applied than multiple punctures (P<0.001) but showed higher pain scores (P=0.001).,['Twenty-four patients with severe hyperhidrosis were included; 67% were female and mean age was 34.7 years'],"['IncobotulinumtoxinA', 'Botulinum toxin A (BoNT-A', '50 U of incobotulinumtoxin A (IncoA; Xeomin']","['pain scores', 'gravimetric measures', 'Radial injection', 'tolerated', 'efficacy and safety', 'excellent response', 'procedure duration and pain, gravimetry and starch-iodine tests and safety']","[{'cui': 'C3715070', 'cui_str': '24'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0020458', 'cui_str': 'Hyperhidrosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C2930113', 'cui_str': 'IncobotulinumtoxinA'}, {'cui': 'C0006050', 'cui_str': 'Botulinum Toxin Type A'}, {'cui': 'C2744602', 'cui_str': 'Xeomin'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0442038', 'cui_str': 'Radial'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1961136', 'cui_str': 'Excellent'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0038179', 'cui_str': 'Starch'}, {'cui': 'C0021966', 'cui_str': 'Iodide salt'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}]",24.0,0.0922736,Radial injection was faster applied than multiple punctures (P<0.001) but showed higher pain scores (P=0.001).,"[{'ForeName': 'Ada Regina', 'Initials': 'AR', 'LastName': 'Trindade de Almeida', 'Affiliation': ''}, {'ForeName': 'Leandro Fonseca', 'Initials': 'LF', 'LastName': 'Noriega', 'Affiliation': ''}, {'ForeName': 'Liliana', 'Initials': 'L', 'LastName': 'Bechelli', 'Affiliation': ''}, {'ForeName': 'Maria Victoria', 'Initials': 'MV', 'LastName': 'Suárez', 'Affiliation': ''}]",Journal of drugs in dermatology : JDD,['10.36849/JDD.2020.4989'] 2728,32726566,Carbohydrate mouth rinse improves resistance exercise capacity in the glycogen-lowered state.,"The effect of carbohydrate mouth rinse (CHO MR) on resistance exercise performance is equivocal, and may be moderated by carbohydrate availability. This study determined the effect of CHO MR on low-load resistance exercise capacity completed in a fed but glycogen-lowered state. Twelve resistance-trained men (age: 22±4 years; height: 1.79±0.05m; weight: 78.7±7.8kg; bench press 1-RM: 87±21kg; squat 1-RM: 123±19kg) completed two fed-state resistance exercise bouts consisting of 6 sets of bench press and 6 sets of squat to failure at 40% 1-RM. Each bout was preceded by glycogen-depleting cycling the evening before, with feeding controlled to create acute energy deficit and maintain low muscle glycogen. During resistance exercise, participants rinsed with either a 6% CHO MR solution or a taste-matched placebo (PLA) between sets. Total volume workload was greater with CHO MR (9354±2051kg vs. 8525±1911kg, p=0.010). Total number of repetitions of squat were greater with CHO MR (107±26 vs. 92±16, p=0.017); the number of repetitions of bench press were not significantly different (CHO MR: 120±24 vs. PLA: 115±22, p=0.146). This was independent of differences in feeling or arousal. CHO MR may be an effective ergogenic aid for athletes completing resistance exercise when in energy deficit and with low carbohydrate availability. Novelty • CHO MR can increase low-load resistance exercise capacity undertaken in a glycogen-lowered but fed state. • This effect was driven by a greater number of repetitions-to-failure in the squat - using muscles lowered in glycogen content with exhaustive cycling on the evening prior to resistance exercise - but not bench press.",2020,"Total volume workload was greater with CHO MR (9354±2051kg vs. 8525±1911kg, p=0.010).",['Twelve resistance-trained men (age: 22±4 years; height: 1.79±0.05m; weight: 78.7±7.8kg; bench press 1-RM: 87±21kg; squat 1-RM: 123±19kg) completed two'],"['Carbohydrate mouth rinse', 'carbohydrate mouth rinse (CHO MR', 'CHO MR', 'fed-state resistance exercise bouts consisting of 6 sets of bench press and 6 sets of squat to failure at 40% 1-RM', '6% CHO MR solution or a taste-matched placebo (PLA']","['resistance exercise performance', 'Total volume workload', 'resistance exercise capacity', 'Total number of repetitions of squat', 'number of repetitions of bench press', 'Novelty •', 'low-load resistance exercise capacity', 'feeling or arousal']","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]","[{'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0204695', 'cui_str': 'Feeding patient'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0039336', 'cui_str': 'Finding of sense of taste'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0085122', 'cui_str': 'Work Load'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0454326', 'cui_str': 'Bench press'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}]",,0.119801,"Total volume workload was greater with CHO MR (9354±2051kg vs. 8525±1911kg, p=0.010).","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Durkin', 'Affiliation': 'Leeds Beckett University - Headingley Campus, 150707, Institute for Sport, Physical Activity & Leisure, Leeds, Leeds, United Kingdom of Great Britain and Northern Ireland ; mattdurkin95@gmail.com.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Akeroyd', 'Affiliation': 'Leeds Beckett University - Headingley Campus, 150707, Institute for Sport, Physical Activity & Leisure, Leeds, Leeds, United Kingdom of Great Britain and Northern Ireland ; harriet.akeroyd@gmail.com.'}, {'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Holliday', 'Affiliation': 'Leeds Beckett University - Headingley Campus, 150707, Institute for Sport, Physical Activity & Leisure, Leeds, Leeds, United Kingdom of Great Britain and Northern Ireland ; a.j.holliday@leedsbeckett.ac.uk.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2020-0298'] 2729,32726666,Intermittent theta burst stimulation over the dorsomedial prefrontal cortex modulates resting-state connectivity in depressive patients: A sham-controlled study.,"The mechanisms underlying repetitive transcranial magnetic stimulation (rTMS) treatment are largely unknown. Although there is a general lack of sham controlled studies, findings show altered functional connectivity to the stimulated region following treatment. When targeting the dorsolateral prefrontal cortex (dlPFC), connectivity with the subgenual anterior cingulate cortex (sgACC) is predictive of response, but less is known about the effects on functional connectivity of targeting the dorsomedial PFC (dmPFC). Here, 30 patients with an ongoing depressive episode were recruited and randomized to 20 sessions at target intensity of either active or sham intermittent theta burst stimulation (iTBS) over dmPFC. Those receiving sham was offered active treatment in a subsequent open phase. A seven minute resting-state scan and depressive symptom assessment was performed before and after treatment. After exclusions due to attrition and excessive head movements 23 patients remained for analysis. Seed-based resting-state connectivity was calculated using two seeds for the dmPFC target as well as the sgACC. A symptom related increase in dmPFC connectivity after active treatment, compared to sham treatment, was found. The effect was observed in a region overlapping the precuneus and the posterior cingulate cortex (PCC), suggesting an increase in the connectivity between the targeted salience network and the default mode network mediating improvement in depressive symptoms. Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment. The findings have implications for understanding the mechanisms behind iTBS and may inform future efforts to individualize the treatment.",2020,Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment.,"['30 patients with an ongoing depressive episode', 'depressive patients']","['repetitive transcranial magnetic stimulation (rTMS', 'Intermittent theta burst stimulation', 'active or sham intermittent theta burst stimulation (iTBS) over dmPFC']",['dmPFC connectivity'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0349217', 'cui_str': 'Depressive episode, unspecified'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}]","[{'cui': 'C4521595', 'cui_str': 'US Military enlisted E3'}]",30.0,0.0349908,Connectivity between the precuneus and both the sgACC and the treatment target was predictive of symptom improvement following active treatment.,"[{'ForeName': 'J', 'Initials': 'J', 'LastName': 'Persson', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden. Electronic address: jonas.persson@neuro.uu.se.'}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Struckmann', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Gingnell', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Fällmar', 'Affiliation': 'Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Bodén', 'Affiliation': 'Department of Neuroscience, Psychiatry, Uppsala University, Uppsala, Sweden.'}]",Behavioural brain research,['10.1016/j.bbr.2020.112834'] 2730,32726727,Effects of a health education program targeted to Chinese women adhering to their cultural practice of doing the month: A randomized controlled trial.,"BACKGROUND ""Doing the month"" is a prevalent Chinese postpartum custom which is believed to restore health after delivery. However, some traditional practices are potentially harmful for women's health. OBJECTIVES To examine the effect of an evidence-based health education program on Chinese postpartum women's adherence to traditional practices of doing the month and the effect of adherence to doing the month on maternal physiological and psychological health. METHODS A randomized controlled trial was conducted. During December 2016-July 2017, we recruited postpartum women at a tertiary hospital. Women randomized to the intervention group received evidence-based health education within 1 week after returning home and received a second visit 1 month later. The control group received routine postpartum home visits. Adherence to doing the month was measured by the Adherence to Doing-the-Month Practices questionnaire (ADP). Maternal physical health was measured by the Chair Stand Test and Postpartum Symptom Checklist. Maternal psychological health was measured by the Edinburgh Postnatal Depression Scale (EPDS). Descriptive statistics, t-test, and chi-squared test were used to analyze the differences in scores and symptoms of the two groups. RESULTS We recruited 124 eligible postpartum women and 108 of them (54 intervention group, 54 control group) completed this study. The ADP score of the intervention group was significantly lower than that of the control group (p < 0.001). The number of participants in the experimental group with poor appetite and indigestion was significantly lower than that of control group. No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). CONCLUSIONS Evidence-based health education can reduce postpartum women's adherence to some traditional practices of doing the month and improve women's physical health.",2020,"No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). ","['During December 2016-July 2017, we recruited postpartum women at a tertiary hospital', '124 eligible postpartum women and 108 of them (54 intervention group, 54 control group) completed this study', ""Chinese postpartum women's"", 'Chinese women adhering to their cultural practice of doing the month']","['health education program', 'routine postpartum home visits', 'evidence-based health education program', 'evidence-based health education']","['Edinburgh Postnatal Depression Scale (EPDS', 'poor appetite and indigestion', 'Maternal physical health', 'ADP score', 'Maternal psychological health', 'numbers of symptoms and average EPDS scores', 'Chair Stand Test and Postpartum Symptom Checklist']","[{'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0451144', 'cui_str': 'Edinburgh postnatal depression scale'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite'}, {'cui': 'C0013395', 'cui_str': 'Indigestion'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C3472185', 'cui_str': 'Edinburgh postnatal depression scale score'}, {'cui': 'C0179847', 'cui_str': 'Chair'}, {'cui': 'C0231472', 'cui_str': 'Orthostatic body position'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0451524', 'cui_str': 'Symptom checklist'}]",124.0,0.0672713,"No significant differences were found in numbers of symptoms and average EPDS scores between the 2 study groups (p > 0.05). ","[{'ForeName': 'YanQun', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}, {'ForeName': 'JuYing', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Obstetrics Department of Hubei Maternal and Child Health Hospital, China.'}, {'ForeName': 'XiaoLi', 'Initials': 'X', 'LastName': 'Chen', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Yu', 'Affiliation': 'Emory University Nell Hodgson Woodruff School of Nursing, China. Electronic address: yuyun7169@163.com.'}, {'ForeName': 'JinBing', 'Initials': 'J', 'LastName': 'Bai', 'Affiliation': 'Wuhan University School of Health Sciences, China.'}]",Midwifery,['10.1016/j.midw.2020.102796'] 2731,32733586,STW1 and Its Versatile Pharmacological and Clinical Effects in Rheumatic Disorders: A Comprehensive Report.,"Aim To review the published and unpublished experimental and clinical studies about the efficacy and tolerability of STW1 and to compare the results to the efficacy and tolerability of investigated NSAIDs in parallel. Content. STW1 (Phytodolor®) contains a fixed combination of extracts from aspen leaves and bark ( Populus tremula ), common ash bark ( Fraxinus excelsior ), and goldenrod herb ( Solidago virgaurea ). It belongs to the group of anti-inflammatory and antirheumatic drugs, and it is authorized for the treatment of painful disorders of degenerative and inflammatory rheumatic diseases. The individual components have complementary effects. Its multifocal mode of action includes antiphlogistic, analgesic, antiexudative, antioxidative, antipyretic, and antiproliferative properties. The effects of both STW1 and its components have been verified in comprehensive pharmacological investigations. Open and randomized, placebo- and verum-controlled, and single-blind (sb) or double-blind (db) clinical trials, performed in different subtypes of rheumatic diseases confirm the pharmacological evidence. Its efficacy is comparable to a range of standard nonsteroidal anti-inflammatory drugs (NSAIDs) studied in parallel, but it has a superior safety profile. Conclusion STW1 is a reasonable alternative to NSAIDs with comparable efficacy and a superior safety profile. It is also suitable to reduce the intake of NSAIDs.",2020,"Its efficacy is comparable to a range of standard nonsteroidal anti-inflammatory drugs (NSAIDs) studied in parallel, but it has a superior safety profile. ",['Rheumatic Disorders'],"['STW1', 'placebo- and verum-controlled, and single-blind (sb) or double-blind', 'STW1 (Phytodolor®']",['efficacy and tolerability'],"[{'cui': 'C3495832', 'cui_str': 'Rheumatic disorder'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0242570', 'cui_str': 'Single-Masked Study'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}]",,0.0217308,"Its efficacy is comparable to a range of standard nonsteroidal anti-inflammatory drugs (NSAIDs) studied in parallel, but it has a superior safety profile. ","[{'ForeName': 'Karl-Josef', 'Initials': 'KJ', 'LastName': 'Gundermann', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin 70-111, Poland.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Müller', 'Affiliation': 'I&D Phytomedicines, Steigerwald Arzneimittelwerk GmbH, Darmstadt 64295, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Kraft', 'Affiliation': 'Chair of Naturopathic Medicine, University Medicine Rostock, Rostock 18057, Germany.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/7841748'] 2732,32733592,"Effects of Kamishoyosan, a Traditional Japanese Medicine, on Menopausal Symptoms: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.","Objective Kampo medicine, a traditional Japanese medicine, is widely used in Japan, especially in the field of menopause medicine. However, few studies have shown evidence-based effects. This study aimed to confirm the effects of kamishoyosan on menopausal symptoms with a randomized, placebo-controlled, double-blind clinical trial. Methods Subjects were randomly allocated to groups that received either kamishoyosan ( n  = 101) or a placebo resembling kamishoyosan ( n  = 104). The primary outcomes were the change in the number of hot flashes, depression scores, improvements of anxiety, quality of life (QOL), and menopausal symptoms before and 4 and 8 weeks after initiation of treatment with the study drug. The secondary outcome was drug safety. Results After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups. The changes in SDS scores showed the same results. Moreover, no significant differences were observed between the two groups in assessments with the STAI, SF-36, and JSOG menopausal index. No serious adverse effect was reported. Conclusions This first placebo-controlled double-blind randomized trial with kamishoyosan demonstrated that it was safe and had some effects on climacteric symptoms, but not significant compared with placebo. Some problems, such as placebo effects, in the study of Kampo therapy for menopausal symptoms, were revealed. This trial is registered with the trial registration number. UMIN 000006042.",2020,"After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups.",[],"['Placebo', 'kamishoyosan', 'placebo resembling kamishoyosan', 'Kamishoyosan, a Traditional Japanese Medicine', 'placebo']","['serious adverse effect', 'menopausal symptoms', 'climacteric symptoms', 'STAI, SF-36, and JSOG menopausal index', 'drug safety', 'SDS scores', 'number of hot flashes', 'change in the number of hot flashes, depression scores, improvements of anxiety, quality of life (QOL), and menopausal symptoms']",[],"[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}, {'cui': 'C1306878', 'cui_str': 'Climacteric discomfort'}, {'cui': 'C0683457', 'cui_str': 'State-trait anger expression inventory'}, {'cui': 'C0025320', 'cui_str': 'Menopause'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037506', 'cui_str': 'Sodium lauryl sulfate'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0600142', 'cui_str': 'Menopausal flushing'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.699113,"After 8 weeks, the number of hot flashes decreased after treatment in both groups, but there was no significant difference between the two groups.","[{'ForeName': 'Kiyoshi', 'Initials': 'K', 'LastName': 'Takamatsu', 'Affiliation': 'Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Sugano 5-11-13, Ichikawa-City, Chiba 272-8513, Japan.'}, {'ForeName': 'Mariko', 'Initials': 'M', 'LastName': 'Ogawa', 'Affiliation': 'Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Sugano 5-11-13, Ichikawa-City, Chiba 272-8513, Japan.'}, {'ForeName': 'Tsuyoshi', 'Initials': 'T', 'LastName': 'Higuchi', 'Affiliation': 'Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Zaifu-cho 5, Hirosaki-City, Aomori 036-8562, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Takeda', 'Affiliation': ""Division of Women's Health, Research Institute of Traditional Asian Medicine, Kindai University, Oonohigashi 377-2, Osaka-sayama-City, Osaka 589-8511, Japan.""}, {'ForeName': 'Kunihiko', 'Initials': 'K', 'LastName': 'Hayashi', 'Affiliation': 'Department of International/Community Health Laboratory Sciences, Graduate School of Health Sciences, Gunma University, Showa-Machi 3-39-22, Maebashi-city, Gunma 371-8514, Japan.'}, {'ForeName': 'Hideki', 'Initials': 'H', 'LastName': 'Mizunuma', 'Affiliation': 'Fukushima Medical Center for Children and Women, Fukushima Medical University, Hikariga-oka 1, Fukushima-City, Fukushima 960-1295, Japan.'}]",Evidence-based complementary and alternative medicine : eCAM,['10.1155/2020/9285317'] 2733,32733600,Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.,"Background and Aims Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevated high-sensitivity C-reactive protein (⩾3 mg/l) who were naïve to anti-tumor necrosis factor therapy. Patients were randomized to double-blind adalimumab 160/80 mg at weeks 0/2 and 40 mg at weeks 4/6 or placebo at weeks 0/2 followed by blinded adalimumab 160/80 mg at weeks 4/6. At week 8, all patients received open-label 40 mg adalimumab every other week through week 26. The primary endpoint was clinical remission [CD activity index (CDAI) <150] at week 4. Clinical remission at week 26 was assessed in week-8 responders (decrease in CDAI ⩾70 points at week 8 from baseline) and compared with a clinically meaningful threshold of 30%. Adverse events (AEs) were recorded throughout the study. Results At baseline, 205 patients were enrolled, with mean [standard deviation (SD)] age of 32.9 (9.9) years and CD duration of 2.7 (3.0) years. At week 4, 38/102 patients (37%) receiving adalimumab and 7/103 (7%) receiving placebo ( p  < 0.001) achieved clinical remission. Among week-8 responders, 93/144 (65%) achieved clinical remission at week 26 ( p  < 0.001). No unexpected AEs and no malignancies, active tuberculosis, or deaths were reported. Conclusions Adalimumab induced and maintained remission in Chinese patients with CD. Safety results were consistent with the known safety profile of adalimumab. ClinicalTrialsgov identifier NCT02499783.",2020,"Among week-8 responders, 93/144 (65%) achieved clinical remission at week 26 ( p  < 0.001).","[""Chinese patients with moderately to severely active Crohn's disease"", '205 patients were enrolled, with mean [standard deviation (SD)] age of 32.9 (9.9) years and CD duration of 2.7 (3.0) years', ""Crohn's disease (CD"", 'Chinese patients with CD', 'patients with moderately to severely active CD and elevated high-sensitivity C-reactive protein (⩾3\u2009mg/l) who were naïve to anti-tumor necrosis factor therapy']","['open-label 40\u2009mg adalimumab', 'adalimumab', 'Adalimumab', 'placebo']","['clinical remission [CD activity index (CDAI', 'Clinical remission', 'Efficacy and safety', 'efficacy and safety', 'Adverse events (AEs', 'unexpected AEs and no malignancies, active tuberculosis, or deaths', 'clinical remission']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0010346', 'cui_str': ""Crohn's disease""}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0439268', 'cui_str': 'mg/L'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C1122087', 'cui_str': 'adalimumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0451071', 'cui_str': ""Crohn's disease activity index""}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0041296', 'cui_str': 'Tuberculosis'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",205.0,0.351745,"Among week-8 responders, 93/144 (65%) achieved clinical remission at week 26 ( p  < 0.001).","[{'ForeName': 'Baili', 'Initials': 'B', 'LastName': 'Chen', 'Affiliation': 'The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Gao', 'Affiliation': 'The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Zhong', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.'}, {'ForeName': 'Jianlin', 'Initials': 'J', 'LastName': 'Ren', 'Affiliation': 'Zhongshan Hospital Xiamen University, Xiamen, China.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': 'The First Affiliated Hospital of Nanchang University, Nanchang, China.'}, {'ForeName': 'Zhanju', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Shanghai Tenth People's Hospital, Shanghai, China.""}, {'ForeName': 'Kaichun', 'Initials': 'K', 'LastName': 'Wu', 'Affiliation': ""The First Affiliated Hospital of Fourth Military Medical University, Xi'an, China.""}, {'ForeName': 'Jasmina', 'Initials': 'J', 'LastName': 'Kalabic', 'Affiliation': 'AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.'}, {'ForeName': 'Zhuqing', 'Initials': 'Z', 'LastName': 'Yu', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Bidan', 'Initials': 'B', 'LastName': 'Huang', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Nisha', 'Initials': 'N', 'LastName': 'Kwatra', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Thao', 'Initials': 'T', 'LastName': 'Doan', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Robinson', 'Affiliation': 'AbbVie Inc., North Chicago, IL, USA.'}, {'ForeName': 'Min-Hu', 'Initials': 'MH', 'LastName': 'Chen', 'Affiliation': 'Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road II, Guangzhou, China.'}]",Therapeutic advances in gastroenterology,['10.1177/1756284820938960'] 2734,32733757,Does Upper Extremity Proprioceptive Training Have an Impact on Functional Outcomes in Chronic Stroke Patients?,"Objective We aimed to investigate the effect of upper extremity proprioceptive training on spasticity and functional motor skills in patients with chronic hemiplegia occurring after stroke. Method Thirty chronic hemiplegic patients (17 females, mean age: 66.47±12.55 years) admitted to the Research Center with a diagnosis of chronic hemiplegia developed after stroke were included in the study. Patients were divided into two groups. The first group received a conventional physiotherapy program (PTR) for 5 days a week and the second group additionally received a proprioceptive training program (PTR-PT) for 5 days a week. Before and 6 weeks after the treatment modified Ashworth scale (MAS), Fugl-Meyer upper extremity motor evaluation scale (FMA) and action-research-arm-test (ARAT) and motor activity log-28 scale (MAL-28) were applied. SSPS-22.0 program was used for statistical evaluation and p <0.05 was considered as the level of statistical significance. Results There was no difference in MAS scores before and after treatment in the groups (p>0.05). There was a statistically significant improvement in both PTR (p<0.05) and PTR-PT groups (p<0.001) for the FMA, ARAT and MAL-28. scale scores. Although the results obtained in the PTR, and PT groups were more improved, there was a significant result in favor of PTR-PT only regarding the MAL-28 scale scores (p<0.05). It was determined that adding proprioception-based exercises had the greatest effect on FMA, ARAT and MAL-28 in the evaluation of the effect size (>0.3). Conclusion It was observed that upper extremity proprioceptive training yielded better results in patients with chronic hemiplegia developed after stroke than conventional therapy in increasing the frequency and quality of movement in upper extremity. This result shows that proprioceptive training programs should be added to stroke rehabilitation methods.",2020,It was observed that upper extremity proprioceptive training yielded better results in patients with chronic hemiplegia developed after stroke than conventional therapy in increasing the frequency and quality of movement in upper extremity.,"['Chronic Stroke Patients', 'patients with chronic hemiplegia occurring after stroke', 'Thirty chronic hemiplegic patients (17 females, mean age: 66.47±12.55 years) admitted to the Research Center with a diagnosis of chronic hemiplegia developed after stroke were included in the study', 'patients with chronic hemiplegia']","['Upper Extremity Proprioceptive Training', 'proprioceptive training programs', 'conventional physiotherapy program (PTR', 'upper extremity proprioceptive training', 'proprioceptive training program (PTR-PT']","['Ashworth scale (MAS), Fugl-Meyer upper extremity motor evaluation scale (FMA) and action-research-arm-test (ARAT) and motor activity log-28 scale (MAL-28', 'scale scores', 'MAS scores', 'frequency and quality of movement in upper extremity', 'FMA, ARAT and MAL-28', 'spasticity and functional motor skills', 'MAL-28 scale scores']","[{'cui': 'C3536593', 'cui_str': 'Chronic cerebrovascular accident'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0018991', 'cui_str': 'Hemiplegia'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0242481', 'cui_str': 'Research Activities'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0206711', 'cui_str': 'Pilomatrixoma'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C4720875', 'cui_str': 'Action research arm test'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0026838', 'cui_str': 'Spasticity'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}]",30.0,0.00988572,It was observed that upper extremity proprioceptive training yielded better results in patients with chronic hemiplegia developed after stroke than conventional therapy in increasing the frequency and quality of movement in upper extremity.,"[{'ForeName': 'Numan Melik', 'Initials': 'NM', 'LastName': 'Ocal', 'Affiliation': 'Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physiotherapy and Rehabilitation, Istanbul, Turkey.'}, {'ForeName': 'Nuray', 'Initials': 'N', 'LastName': 'Alaca', 'Affiliation': 'Acibadem Mehmet Ali Aydinlar University, Faculty of Health Sciences Department of Physiotherapy and Rehabilitation, Istanbul, Turkey.'}, {'ForeName': 'Mehmet Kerem', 'Initials': 'MK', 'LastName': 'Canbora', 'Affiliation': 'Uskudar University, Faculty of Medicine, Department of Orthopedics and Traumatology, Istanbul, Turkey.'}]",Medeniyet medical journal,['10.5222/MMJ.2020.48752'] 2735,32727497,Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.,"PURPOSE To test the efficacy and feasibility of pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT) in reducing grade 2 or higher hematological toxicity (HT2+) for patients with cervical cancer treated with concurrent chemoradiotherapy. METHODS AND MATERIALS A total of 164 patients with Stage Ib2-IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center and were randomly allocated into the PBMS group or the control group. The control group received weekly cisplatin concurrently with IMRT, followed by intracavitary brachytherapy. The PBMS group additionally received PBM dose constraint. The dosimetric parameters of the pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS) and the corresponding bone marrow were recorded. The endpoint of the trial was acute hematologic or gastrointestinal toxicity. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints. RESULTS Eighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis. The incidence of HT2+ in the PBMS group was 50.0%, significantly lower than the 69.5% incidence in the control group (P = 0.02). Patients with PB V40 ≥ 28% were more likely to experience HT2+ (OR = 2.85, P = 0.006), while the incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events did not differ significantly between the two groups (P > 0.05). Dosimetric parameters of LSS showed stronger associations with HT2+ than other subsites. The patients with LSS V10 ≥ 87% and LSS mean ≥ 39 Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). CONCLUSION PBMS-IMRT reduced HT compared with IMRT alone. Efforts to maintain LSS V10 < 87%, LSS mean < 39 Gy and PB V40 < 28% simultaneously may reduce the risk of HT2 +. TRIAL REGISTRATION The trial was registered with Chinese clinical trial registry ( ChiCTR1800015069 ).",2020,"Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). ","['164 patients with Stage Ib2-IIIb cervical cancer were prospectively enrolled from March 2018 to March 2019 at a single center', 'patients with cervical cancer treated with concurrent chemoradiotherapy', 'patients with cervical cancer receiving concurrent', 'patients with LSS V10\u2009≥\u200987% and LSS mean\u2009≥\u200939', 'Eighty-two patients in the PBMS group and 82 in the control group were enrolled for statistical analysis']","['cisplatin concurrently with IMRT, followed by intracavitary brachytherapy', 'chemoradiotherapy', 'IMRT', 'Pelvic bone marrow sparing intensity modulated radiotherapy', 'PBMS', 'pelvic bone marrow sparing intensity modulated radiotherapy (PBMS-IMRT']","['hematological toxicity (HT2', 'hematologic toxicity', 'pelvic bone (PB) and the subsites including hip bone (HIP) and lumbosacral spine (LSS', 'acute hematologic or gastrointestinal toxicity', 'incidence of grade 2 or higher gastrointestinal toxicity (GT2+) events', 'incidence of HT2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0007847', 'cui_str': 'Malignant tumor of cervix'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C3178775', 'cui_str': 'Concomitant Radiochemotherapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent'}, {'cui': 'C0223603', 'cui_str': 'Structure of lumbosacral vertebrae'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}]","[{'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C1512814', 'cui_str': 'Intensity modulated radiation therapy'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0021864', 'cui_str': 'Intracavitary brachytherapy'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0065764', 'cui_str': 'MBD protocol'}]","[{'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0450566', 'cui_str': 'HT2'}, {'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0030786', 'cui_str': 'Hip Bone'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0223603', 'cui_str': 'Structure of lumbosacral vertebrae'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C1142499', 'cui_str': 'Gastrointestinal toxicity'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",164.0,0.0383442,"Gy were more likely to experience HT2+ (OR = 3.13, P = 0.001;OR = 3.03, P = 0.002, respectively). ","[{'ForeName': 'Jin', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.'}, {'ForeName': 'Fei', 'Initials': 'F', 'LastName': 'Gu', 'Affiliation': 'Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.'}, {'ForeName': 'Tianlong', 'Initials': 'T', 'LastName': 'Ji', 'Affiliation': 'Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Zhao', 'Affiliation': 'Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.'}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Li', 'Affiliation': 'Department of radiotherapy, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang, 110001, Liaoning, China. dr_liguang@163.com.'}]","Radiation oncology (London, England)",['10.1186/s13014-020-01606-3'] 2736,32727509,The effects of a prolonged exposure workshop with and without consultation on provider and patient outcomes: a randomized implementation trial.,"BACKGROUND Prolonged exposure therapy (PE) is an evidence-based treatment for posttraumatic stress disorder (PTSD) that is underutilized in the military health system. Standard workshop training in PE may not be sufficient to alter provider behavior, but post-workshop consultation requires significant resources. Therefore, it is important to determine the incremental utility of post-workshop consultation. METHODS This study used a hybrid type III randomized implementation trial at 3 US Army installations. Providers were randomized to receive a 4-day prolonged exposure workshop (Standard training condition, n = 60), or the prolonged exposure workshop followed by 6-8 months of post-workshop expert case consultation (Extended training condition, n = 43). The effects training condition were examined on provider attitudes (self-efficacy in delivering PE, expectations for patient improvement, and beliefs about PE), use of PE and PE components, and clinical outcomes of patients with PTSD (using the Clinician-Administered PTSD Scale (CAPS-5)). RESULTS Extended condition providers reported greater improvements in self-efficacy, b = .83, 95% CI [.38, 1.27], t(79) = 3.71, p = .001, and d = .63. A greater proportion of patients in the Extended condition (44%) than in the Standard condition (27%) received at least 1 PE session, b = .76, t(233) = 2.53, p = .012, and OR = 2.13. Extended condition providers used more PE components (M = .9/session) than did Standard condition providers (M = .5/session), b = .54, 95% CI [.15, .93], t(68) = 2.70, p = .007, and d = .68. Finally, decrease in patients' PTSD symptoms was faster for patients of Extended condition providers than for patients of Standard condition providers, b = - 1.81, 95% CI [- 3.57, - .04], t(263) = - 2.02, p = .045, and d = .66, and their symptoms were lower at the second assessment, b = - 5.47, 95% CI [- 9.30, - 1.63], t(210) = - 2.81, p = .005, and d = .66. CONCLUSIONS Post-workshop consultation improved self-efficacy for delivering PE, greater use of PE, faster PTSD reduction, and lower PTSD severity at the second assessment. To our knowledge, this is the first demonstration that post-workshop case consultation for PE improves patient outcomes. TRIAL REGISTRATION Clinicaltrials.gov , NCT02982538 . Registered December 5, 2016; retrospectively registered.",2020,"RESULTS Extended condition providers reported greater improvements in self-efficacy,",[],"['Prolonged exposure therapy (PE', '4-day prolonged exposure workshop (Standard training condition, n = 60), or the prolonged exposure workshop followed by 6-8\u2009months of post-workshop expert case consultation', 'prolonged exposure workshop with and without consultation']","[""patients' PTSD symptoms"", 'provider attitudes (self-efficacy in delivering PE, expectations for patient improvement, and beliefs about PE), use of PE and PE components, and clinical outcomes of patients with PTSD (using the Clinician-Administered PTSD Scale (CAPS-5', 'PTSD severity', 'self-efficacy']",[],"[{'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0870527', 'cui_str': 'Exposure Therapy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0439793', 'cui_str': 'Severities'}]",,0.106804,"RESULTS Extended condition providers reported greater improvements in self-efficacy,","[{'ForeName': 'Edna B', 'Initials': 'EB', 'LastName': 'Foa', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. foa@pennmedicine.upenn.edu.'}, {'ForeName': 'Carmen P', 'Initials': 'CP', 'LastName': 'McLean', 'Affiliation': 'National Center for PTSD, Dissemination and Training Division, VA Palo Alto Health Care System, Menlo Park, CA, USA.'}, {'ForeName': 'Lily A', 'Initials': 'LA', 'LastName': 'Brown', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Yinyin', 'Initials': 'Y', 'LastName': 'Zang', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rosenfield', 'Affiliation': 'Department of Psychology, Southern Methodist University, Dallas, TX, USA.'}, {'ForeName': 'Laurie J', 'Initials': 'LJ', 'LastName': 'Zandberg', 'Affiliation': 'Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Ealey', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Brenda S', 'Initials': 'BS', 'LastName': 'Hanson', 'Affiliation': 'William Beaumont Army Medical Center, Fort Bliss, TX, USA.'}, {'ForeName': 'Lora Rose', 'Initials': 'LR', 'LastName': 'Hunter', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Ivett J', 'Initials': 'IJ', 'LastName': 'Lillard', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Patterson', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Julio', 'Initials': 'J', 'LastName': 'Rosado', 'Affiliation': 'William Beaumont Army Medical Center, Fort Bliss, TX, USA.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Scott', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Weber', 'Affiliation': 'Evans Army Community Hospital, Fort Carson, CO, USA.'}, {'ForeName': 'Joseph E', 'Initials': 'JE', 'LastName': 'Wise', 'Affiliation': 'Blanchfield Army Community Hospital, Fort Campbell, KY, USA.'}, {'ForeName': 'Charles D', 'Initials': 'CD', 'LastName': 'Zamora', 'Affiliation': 'William Beaumont Army Medical Center, Fort Bliss, TX, USA.'}, {'ForeName': 'Jim', 'Initials': 'J', 'LastName': 'Mintz', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Young-McCaughan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.'}, {'ForeName': 'Alan L', 'Initials': 'AL', 'LastName': 'Peterson', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Implementation science : IS,['10.1186/s13012-020-01014-x'] 2737,32727539,Intermittent theta burst stimulation (iTBS) combined with working memory training to improve cognitive function in schizophrenia: study protocol for a randomized controlled trial.,"BACKGROUND Working memory deficit is one of the most critical complex cognitive impairments in schizophrenia. Repetitive transcranial magnetic stimulation (rTMS) is an effective adjuvant therapy, but not still unsatisfactory. Intermittent theta burst stimulation (iTBS), which has recently been used in clinical practice, may have faster and stronger effects comparing the traditional model (10-Hz high-frequency rTMS). A large number of studies have showed that rTMS, especially iTBS, can enhance the neural plasticity of the brain, and cognitive training can improve the cognitive function of schizophrenia. Is there any facilitation effect of iTBS add on cognitive training (such as working memory training, WMT) on cognitive function enhancement in schizophrenia is still unknown. METHODS/DESIGN The proposed study is designed of a double-center, double-blinded, randomized controlled trial that will include 200 schizophrenia patients between 18 and 45 years of age. The patients will be randomized to four groups, i.e., the study group (iTBS+WMT), WMS control group (iTBS+ Simple Response Training (SRT)), iTBS control group (sham iTBS+WMT), and placebo control (sham iTBS+SRT). The patients will receive 3 min 20 s of real or sham stimulation, followed by a short 1-2-min rest and 40 min of WMT training or SRT immediately. Neuropsychological and clinical symptom assessments, with functional and structural MRI, will be performed on baseline, post-treatment, and 3- and 6-month follow-up periods. The primary outcome is cognitive function measured by the MATRICS Consensus Cognitive Battery (MCCB). The secondary outcomes are changes in neuroplasticity, as measured by MRI and other behavioral assessments. DISCUSSION The aim of our study is to explore the facilitation effects of iTBS added on WMT in improving cognitive function of schizophrenia. That means, patients with schizophrenia will benefit more in cognitive function improvement from the combination training mode of ""preheating (iTBS stimulation changes the neural activity of working memory-related brain regions) and ironning (working memory training)."" And the long-term effects of this combined training model will be assessed at a 6-month follow-up period. In case of a significant improvement of working memory with a prolonged effect, the iTBS combined with WMT protocol could be considered as a first-line clinical protocol in schizophrenia treatment. More broadly, the potential for increased universality and efficiency of rTMS with the iTBS model to enhance the neural plasticity of the brain should have a more positive effect on cognitive function in schizophrenia. TRIAL REGISTRATION chictr.org.cn ChiCTR1900023405 . Registered on 25 May 2019.",2020,"Is there any facilitation effect of iTBS add on cognitive training (such as working memory training, WMT) on cognitive function enhancement in schizophrenia is still unknown. ","['patients with schizophrenia', 'schizophrenia', '200 schizophrenia patients between 18 and 45\u2009years of age']","['Repetitive transcranial magnetic stimulation (rTMS', 'Intermittent theta burst stimulation (iTBS) combined with working memory training', '3\xa0min 20\xa0s of real or sham stimulation, followed by a short 1-2-min rest and 40\u2009min of WMT training or SRT immediately', 'Intermittent theta burst stimulation (iTBS', 'WMT', 'iTBS', 'WMS control group (iTBS+ Simple Response Training (SRT)), iTBS control group (sham iTBS+WMT), and placebo control (sham iTBS+SRT']","['changes in neuroplasticity, as measured by MRI and other behavioral assessments', 'working memory', 'cognitive function measured by the MATRICS Consensus Cognitive Battery (MCCB', 'cognitive function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0439101', 'cui_str': 'Theta'}, {'cui': 'C0439818', 'cui_str': 'Bursting sensation quality'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0234742', 'cui_str': 'Speech reception threshold'}, {'cui': 'C0205548', 'cui_str': 'Stat'}, {'cui': 'C0175702', 'cui_str': 'Williams syndrome'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205352', 'cui_str': 'Simple'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0027880', 'cui_str': 'Plasticity, Neuronal'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C1160858', 'cui_str': 'Behavior assessment'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}]",200.0,0.0980112,"Is there any facilitation effect of iTBS add on cognitive training (such as working memory training, WMT) on cognitive function enhancement in schizophrenia is still unknown. ","[{'ForeName': 'Jiaqi', 'Initials': 'J', 'LastName': 'Song', 'Affiliation': 'Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Liu', 'Affiliation': 'Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China.'}, {'ForeName': 'Meng', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China.'}, {'ForeName': 'Huiqiu', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Psychiatry Rehabilitation, Anning Hospital, Shenyang, 110164, Liaoning, China.'}, {'ForeName': 'Shuping', 'Initials': 'S', 'LastName': 'Tan', 'Affiliation': 'Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, 100096, China. shupingtan@126.com.'}]",Trials,['10.1186/s13063-020-04563-0'] 2738,32727558,Efficacy of high-dose versus low-dose vitamin D supplementation on serum levels of inflammatory factors and mortality rate in severe traumatic brain injury patients: study protocol for a randomized placebo-controlled trial.,"BACKGROUND Traumatic brain injury (TBI) is the most common trauma worldwide and is a leading cause of injury-related death and disability. Inflammation is initiated as a result of the TBI, which is in association with severity of illness and mortality in brain trauma patients, especially in subdural hemorrhage and epidural hemorrhage cases. A high percentage of adults admitted to the intensive care unit with TBI are diagnosed with vitamin D deficiency; this deficiency may induce impaired immune responses and increase the risk of infections. Vitamin D intervention has been shown to modulate pro- and anti-inflammatory cytokines in non-critically ill patients, but to date, there is no substantial data on the effectiveness of vitamin D for the improvement of immune function in traumatic brain injury patients. METHODS/DESIGN A randomized clinical trial (RCT) will be performed on 74 Iranian adults 18-65 years old with brain trauma and will be treated daily with vitamin D supplements (100,000 IU oral drop) or a similar placebo (1000 IU) for 5 days. DISCUSSION If this randomized clinical trial demonstrates reductions in inflammatory cytokines, it would provide evidence for a multicenter clinical trial to evaluate the efficacy of vitamin D supplementation in neurocritically ill patients. Since vitamin D supplements are inexpensive and safe, this clinical trial could have the potential to improve clinical outcomes in traumatic brain injury patients through reduction of inflammation and infection-associated morbidity and mortality rates. TRIAL REGISTRATION Iranian Registry of Clinical Trials, IRCT20180619040151N3 . Registered on 10 August 2019.",2020,"Since vitamin D supplements are inexpensive and safe, this clinical trial could have the potential to improve clinical outcomes in traumatic brain injury patients through reduction of inflammation and infection-associated morbidity and mortality rates. ","['74 Iranian adults 18-65\u2009years old with brain trauma and will be treated daily with', 'adults admitted to the intensive care unit with TBI are diagnosed with vitamin D deficiency', 'Traumatic brain injury (TBI', 'traumatic brain injury patients', 'neurocritically ill patients', 'severe traumatic brain injury patients']","['vitamin D supplements', 'high-dose versus low-dose vitamin D supplementation', 'vitamin D supplements (100,000\u2009IU oral drop) or a similar placebo', 'Vitamin D intervention', 'vitamin D', 'vitamin D supplementation', 'placebo']",['serum levels of inflammatory factors and mortality rate'],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0876926', 'cui_str': 'Traumatic brain injury'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0042870', 'cui_str': 'Vitamin D deficiency'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231218', 'cui_str': 'Malaise'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0420176', 'cui_str': 'Vitamin D supplement therapy'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0991577', 'cui_str': 'Oral drops'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",74.0,0.688393,"Since vitamin D supplements are inexpensive and safe, this clinical trial could have the potential to improve clinical outcomes in traumatic brain injury patients through reduction of inflammation and infection-associated morbidity and mortality rates. ","[{'ForeName': 'Seyed Mostafa', 'Initials': 'SM', 'LastName': 'Arabi', 'Affiliation': 'Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Sedaghat', 'Affiliation': 'Cardiac Anesthesia Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Reza', 'Initials': 'MR', 'LastName': 'Ehsaei', 'Affiliation': 'Department of Neurosurgery, Shahid Kamiab Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Safarian', 'Affiliation': 'Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Golnaz', 'Initials': 'G', 'LastName': 'Ranjbar', 'Affiliation': 'Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Rezaee', 'Affiliation': 'Department of Neurosurgery, Shahid Kamiab Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Rezvani', 'Affiliation': 'Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hamed', 'Initials': 'H', 'LastName': 'Tabesh', 'Affiliation': 'Department of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Abdolreza', 'Initials': 'A', 'LastName': 'Norouzy', 'Affiliation': 'Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Norouzya97@gmail.com.'}]",Trials,['10.1186/s13063-020-04622-6'] 2739,32727618,Integrated stepped alcohol treatment for patients with HIV and at-risk alcohol use: a randomized trial.,"BACKGROUND At-risk levels of alcohol use threaten the health of patients with HIV (PWH), yet evidence-based strategies to decrease alcohol use and improve HIV-related outcomes in this population are lacking. We examined the effectiveness of integrated stepped alcohol treatment (ISAT) on alcohol use and HIV outcomes among PWH and at-risk alcohol use. METHODS In this multi-site, randomized trial conducted between January 28, 2013 through July 14, 2017, we enrolled PWH and at-risk alcohol use [defined as alcohol consumption of ≥ 14 drinks per week or ≥ 4 drinks per occasion in men ≤ 65 years old or ≥ 7 drinks per week or ≥ 3 drinks per occasion in women or men > 65 years old]. ISAT (n = 46) involved: Step 1- Brief Negotiated Interview with telephone booster, Step 2- Motivational Enhancement Therapy, and Step 3- Addiction Physician Management. Treatment as usual (TAU) (n = 47) involved receipt of a health handout plus routine care. Analyses were conducted based on intention to treat principles. RESULTS Despite a multi-pronged approach, we only recruited 37% of the target population (n = 93/254). Among ISAT participants, 50% advanced to Step 2, among whom 57% advanced to Step 3. Participants randomized to ISAT and TAU had no observed difference in drinks per week over the past 30 days at week 24 (primary outcome) [least square means (Ls mean) (95% CI) = 8.8 vs. 10.6; adjusted mean difference (AMD) (95% CI) =  - 0.4 (- 3.9, 3.0)]. CONCLUSION An insufficient number of patients were interested in participating in the trial. Efforts to enhance motivation of PWH with at-risk alcohol use to engage in alcohol-related research and build upon ISAT are needed. Trial registration Clinicaltrials.gov: NCT01410123, First posted August 4, 2011.",2020,Participants randomized to ISAT and TAU had no observed difference in drinks per week over the past 30 days at week 24 (primary outcome) [least square means (Ls mean) (95% CI) = 8.8 vs. 10.6; adjusted mean difference (AMD) (95% CI) =  ,"['patients with HIV (PWH', '65\xa0years old', 'January 28, 2013 through July 14, 2017, we enrolled PWH and at-risk alcohol use [defined as alcohol consumption of\u2009≥\u200914 drinks per week or', 'patients with HIV and at-risk alcohol use']","['ISAT', 'Integrated stepped alcohol treatment', '≥\u20094 drinks per occasion in men\u2009≤\u200965\xa0years old or\u2009≥\u20097 drinks per week or\u2009≥\u20093 drinks per occasion in women or men\u2009', 'health handout plus routine care', 'ISAT and TAU', 'integrated stepped alcohol treatment (ISAT']",[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}]","[{'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0452428', 'cui_str': 'Drink'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0205547', 'cui_str': 'Routine'}, {'cui': 'C0281351', 'cui_str': 'uridine triacetate'}]",[],,0.0953817,Participants randomized to ISAT and TAU had no observed difference in drinks per week over the past 30 days at week 24 (primary outcome) [least square means (Ls mean) (95% CI) = 8.8 vs. 10.6; adjusted mean difference (AMD) (95% CI) =  ,"[{'ForeName': 'E Jennifer', 'Initials': 'EJ', 'LastName': 'Edelman', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA. ejennifer.edelman@yale.edu.'}, {'ForeName': 'Stephen A', 'Initials': 'SA', 'LastName': 'Maisto', 'Affiliation': 'Syracuse University, Syracuse, NY, 13244, USA.'}, {'ForeName': 'Nathan B', 'Initials': 'NB', 'LastName': 'Hansen', 'Affiliation': 'Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, 06510, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Cutter', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Dziura', 'Affiliation': 'Yale Center for Analytic Sciences, Yale University School of Public Health, New Haven, CT, 06511, USA.'}, {'ForeName': 'Yanhong', 'Initials': 'Y', 'LastName': 'Deng', 'Affiliation': 'Yale Center for Analytic Sciences, Yale University School of Public Health, New Haven, CT, 06511, USA.'}, {'ForeName': 'Lynn E', 'Initials': 'LE', 'LastName': 'Fiellin', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}, {'ForeName': 'Patrick G', 'Initials': 'PG', 'LastName': ""O'Connor"", 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}, {'ForeName': 'Roger', 'Initials': 'R', 'LastName': 'Bedimo', 'Affiliation': 'Veterans Affairs North Texas Health Care System and UT Southwestern, Dallas, TX, 75216, USA.'}, {'ForeName': 'Cynthia L', 'Initials': 'CL', 'LastName': 'Gibert', 'Affiliation': 'D.C. VAMC and George, Washington University School of Medicine and Health Sciences, Washington, D.C, 20422, USA.'}, {'ForeName': 'Vincent C', 'Initials': 'VC', 'LastName': 'Marconi', 'Affiliation': 'Atlanta VAMC and Emory University School of Medicine, Atlanta, GA, 30033, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rimland', 'Affiliation': 'Atlanta VAMC and Emory University School of Medicine, Atlanta, GA, 30033, USA.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Rodriguez-Barradas', 'Affiliation': 'Michael E. DeBakey VAMC and Baylor College of Medicine, Texas Houston, Houston, TX, 77030, USA.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Simberkoff', 'Affiliation': 'VA NY Harbor Healthcare System and New York University School of Medicine, New York, NY, 10010, USA.'}, {'ForeName': 'Janet P', 'Initials': 'JP', 'LastName': 'Tate', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}, {'ForeName': 'Amy C', 'Initials': 'AC', 'LastName': 'Justice', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}, {'ForeName': 'Kendall J', 'Initials': 'KJ', 'LastName': 'Bryant', 'Affiliation': 'National Institute On Alcohol Abuse and Alcoholism HIV/AIDS Program, Bethesda, MD, 20892-7003, USA.'}, {'ForeName': 'David A', 'Initials': 'DA', 'LastName': 'Fiellin', 'Affiliation': 'Yale School of Medicine, 367 Cedar Street, ESH A, New Haven, CT, 06510, USA.'}]",Addiction science & clinical practice,['10.1186/s13722-020-00200-y'] 2740,32727619,Sanfu herbal patch applied at acupoints in patients with bronchial asthma: study protocol for a randomized controlled trial.,"BACKGROUND Bronchial asthma is one of the most common inflammatory airway disorders. As one of the main non-drug therapies, the Sanfu herbal patch (SHP) has been widely used to treat bronchial asthma, although the evidence for its efficacy and associated mechanism are inconclusive. The objective of this trial is to clarify the clinical efficacy and safety of the SHP in the treatment of bronchial asthma in the chronic persistent or clinical remission stage and to provide high-quality data for further research. METHODS We propose a multicentre, double-blinded, parallel, randomized, placebo-controlled clinical trial involving 4 study hospitals in China. A total of 72 eligible participants will be randomized into an SHP group and a placebo group. They will receive an SHP for 3 treatment sessions. The primary outcome will be changes in forced expiratory volume in 1 s after 3 treatment sessions. Secondary outcomes will include the following: (1) the Asthma Quality of Life Questionnaire, Asthma Control Test, and Asthma Long-term Follow-up Scale; (2) levels of Metallothionein-2 and Transgelin-2 in blood and urine; and (3) levels of IL-5, IL-13, IL-23, IL-25, and thymic stromal lymphopoietin in blood. Analysis of the data will be performed at baseline, at the end of the 2nd and 3rd treatment sessions, and at the 24-week follow-up. The safety of the SHP will be evaluated at each treatment session. DISCUSSION The aims of this trial are to determine whether the SHP is more effective than placebo in the treatment of patients with bronchial asthma, as well as whether the SHP works by reducing airway inflammation and reversing bronchoconstriction. TRIAL REGISTRATION Chinese Clinical Trial Registry ( http://www.chictr.org.cn ), ChiCTR1900024616. Registered on 19 July 2019.",2020,"The aims of this trial are to determine whether the SHP is more effective than placebo in the treatment of patients with bronchial asthma, as well as whether the SHP works by reducing airway inflammation and reversing bronchoconstriction. ","['patients with bronchial asthma', '4 study hospitals in China', '72 eligible participants']","['Sanfu herbal patch (SHP', 'SHP', 'placebo']","['Asthma Quality of Life Questionnaire, Asthma Control Test, and Asthma Long-term Follow-up Scale; (2) levels of Metallothionein-2 and Transgelin-2 in blood and urine; and (3) levels of IL-5, IL-13, IL-23, IL-25, and thymic stromal lymphopoietin in blood', 'changes in forced expiratory volume in 1\xa0s']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0008115', 'cui_str': 'China'}]","[{'cui': 'C0376667', 'cui_str': 'Herbals'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C4048375', 'cui_str': 'Asthma control test'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0025545', 'cui_str': 'Metallothionein'}, {'cui': 'C0074673', 'cui_str': 'SM 22 muscle protein'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0021759', 'cui_str': 'Interleukin-5'}, {'cui': 'C0214743', 'cui_str': 'Interleukin 13'}, {'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C1100024', 'cui_str': 'IL-17E'}, {'cui': 'C0762640', 'cui_str': 'thymic stromal lymphopoietin'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0016529', 'cui_str': 'Forced expired volume'}]",72.0,0.378926,"The aims of this trial are to determine whether the SHP is more effective than placebo in the treatment of patients with bronchial asthma, as well as whether the SHP works by reducing airway inflammation and reversing bronchoconstriction. ","[{'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Xie', 'Affiliation': 'Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.'}, {'ForeName': 'Danghan', 'Initials': 'D', 'LastName': 'Xu', 'Affiliation': 'Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Lixing', 'Initials': 'L', 'LastName': 'Zhuang', 'Affiliation': 'Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Hui', 'Initials': 'H', 'LastName': 'Liu', 'Affiliation': 'Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.'}, {'ForeName': 'Sui', 'Initials': 'S', 'LastName': 'Tan', 'Affiliation': 'Guangzhou University of Chinese Medicine, Guangzhou, 510006, China.'}, {'ForeName': 'Yanqing', 'Initials': 'Y', 'LastName': 'Lu', 'Affiliation': 'The Fifth Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510095, China.'}, {'ForeName': 'Meiyi', 'Initials': 'M', 'LastName': 'Su', 'Affiliation': 'The Fifth Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510095, China.'}, {'ForeName': 'Jie', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Guangdong Second Provincial General Hospital, Guangzhou, 510317, China.'}, {'ForeName': 'Haihua', 'Initials': 'H', 'LastName': 'Pan', 'Affiliation': ""Pingshan District Peoples' Hospital of Shenzhen, Shenzhen, 518118, China.""}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Lu', 'Affiliation': 'Lingnan Medical Research Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Yiming', 'Initials': 'Y', 'LastName': 'Xu', 'Affiliation': 'Guangzhou Medical University, Guangzhou, 515000, China.'}, {'ForeName': 'Muxi', 'Initials': 'M', 'LastName': 'Liao', 'Affiliation': 'Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Zhanqiong', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'He', 'Affiliation': 'Department of Rehabilitation Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510405, China. hejuntcm@hotmail.com.'}]",Trials,['10.1186/s13063-020-04604-8'] 2741,32727624,"RECOVERY- Respiratory Support: Respiratory Strategies for patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care: A structured summary of a study protocol for a randomised controlled trial.","OBJECTIVE The trial objective is to determine if Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO) is clinically effective compared to standard oxygen therapy in patients with confirmed or suspected COVID-19. TRIAL DESIGN Adaptive (group-sequential), parallel group, pragmatic, superiority randomised controlled, open-label, multi-centre, effectiveness trial. PARTICIPANTS The trial is being conducted across approximately 60 hospitals across England, Wales, Scotland, and Northern Ireland. Inpatients at participating hospitals are eligible to participate if they have respiratory failure with suspected or proven COVID-19, and meet all of the inclusion criteria and none of the exclusion criteria. INCLUSION CRITERIA 1) Adults ≥ 18 years; 2) Admitted to hospital with suspected or proven COVID-19; 3) Receiving oxygen with fraction of inspired oxygen (FiO 2 ) ≥0.4 and peripheral oxygen saturation (SpO 2 ) ≤94%; and 4) Plan for escalation to tracheal intubation if needed. EXCLUSION CRITERIA 1) Planned tracheal intubation and mechanical ventilation imminent within 1 hour; 2) Known or clinically apparent pregnancy; 3) Any absolute contraindication to CPAP or HFNO; 4) Decision not to intubate due to ceiling of treatment or withdrawal of treatment anticipated; and 5) Equipment for both CPAP and HFNO not available. INTERVENTION AND COMPARATOR Intervention one: Continuous positive airway pressure delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Intervention two: High-flow nasal oxygen delivered by any device. Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Comparator group: Standard care- oxygen delivered by face mask or nasal cannula (excluding the use of continuous positive airway pressure or high-flow nasal oxygen). Set-up and therapy titration is not protocolised and is delivered in accordance with clinical discretion. Intervention delivery continues up to the point of death, tracheal intubation, or clinical determination that there is no ongoing need (palliation or improvement). MAIN OUTCOMES The primary outcome is a composite outcome comprising tracheal intubation or mortality within 30 days following randomisation. Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay. RANDOMISATION Participants are randomised in a 1:1:1 ratio to receive either continuous positive airway pressure, high-flow nasal oxygen or standard care. Due to the challenging environment of study delivery, a specific intervention may not always be available at the hospital site. The study uses two integrated randomisation systems to allow, where required, the site to randomise between all three interventions, between CPAP and standard care, and between HFNO and standard care. System integration ensures maintenance of balance between interventions. Randomisation is performed using a telephone-based interactive voice response system to maintain allocation concealment. The randomisation sequence was computer-generated using the minimisation method. Participant randomisation is stratified by site, gender (M/F), and age (<50, >=50 years). BLINDING (MASKING) The nature of the trial interventions precludes blinding of the researcher, patient and clinical team. Primary and secondary outcomes are all objective outcomes, thereby minimising the risk of detection bias. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) 4002 participants (1334 to be randomized to each of the three study arms) TRIAL STATUS: Current protocol: Version 4.0, 29 th May 2020. Recruitment began on April 6, 2020 and is anticipated to be complete by April 5, 2021. The trial has been awarded Urgent Public Health status by the National Institute of Health Research on 13 th April 2020. TRIAL REGISTRATION ISRCTN, ISRCTN16912075. Registered 6 th April 2020, http://www.isrctn.com/ISRCTN16912075 FULL PROTOCOL: The full protocol (version 4.0, 29 th May 2020) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).",2020,"Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay. ","['approximately 60 hospitals across England, Wales, Scotland, and Northern Ireland', 'Adults ≥ 18 years', 'Inpatients at participating hospitals are eligible to participate if they have respiratory failure with suspected or proven COVID-19, and meet all of the inclusion criteria and none of the exclusion criteria', 'patients with suspected or proven COVID-19 respiratory failure; Continuous Positive Airway Pressure, High-flow Nasal Oxygen, and standard care', 'patients with confirmed or suspected COVID-19', ' 2) Admitted to hospital with suspected or proven COVID-19; 3) Receiving oxygen with fraction of inspired oxygen (FiO 2 ) ≥0.4 and peripheral oxygen saturation (SpO 2 ) ≤94%; and 4) Plan for escalation to tracheal intubation if needed', '4002 participants (1334 to be randomized to each of the three study arms']","['care- oxygen delivered by face mask or nasal cannula (excluding the use of continuous positive airway pressure or high-flow nasal oxygen', 'continuous positive airway pressure, high-flow nasal oxygen or standard care', 'Continuous Positive Airway Pressure (CPAP) or High-Flow Nasal Oxygen (HFNO']","['tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay', 'composite outcome comprising tracheal intubation or mortality within 30 days following randomisation', 'objective outcomes, thereby minimising the risk of detection bias']","[{'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0028415', 'cui_str': 'Northern Ireland'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C1145670', 'cui_str': 'Respiratory failure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750491', 'cui_str': 'Suspected'}, {'cui': 'C0456369', 'cui_str': 'Proven'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0428167', 'cui_str': 'Fraction of inspired oxygen'}, {'cui': 'C2317096', 'cui_str': 'Peripheral oxygen saturation'}, {'cui': 'C0270724', 'cui_str': 'Infantile neuroaxonal dystrophy'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0199451', 'cui_str': 'Continuous positive airway pressure ventilation treatment'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0010337', 'cui_str': 'Care of intensive care unit patient'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0005346', 'cui_str': 'Biases'}]",4002.0,0.188009,"Secondary outcomes include tracheal intubation rate, time to tracheal intubation, duration of invasive ventilation, mortality rate, time to mortality, length of hospital stay, and length of critical care stay. ","[{'ForeName': 'Gavin D', 'Initials': 'GD', 'LastName': 'Perkins', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Couper', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Bronwen', 'Initials': 'B', 'LastName': 'Connolly', 'Affiliation': ""Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'J Kenneth', 'Initials': 'JK', 'LastName': 'Baillie', 'Affiliation': 'The Roslin Institute, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Judy M', 'Initials': 'JM', 'LastName': 'Bradley', 'Affiliation': ""Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dark', 'Affiliation': 'Division of Infection, Immunity and Respiratory Medicine, NIHR Manchester Biomedical Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'De Soyza', 'Affiliation': 'Institute of Cellular Medicine, NIHR Biomedical Research Centre for Ageing, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Ellen', 'Initials': 'E', 'LastName': 'Gorman', 'Affiliation': ""Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Alasdair', 'Initials': 'A', 'LastName': 'Gray', 'Affiliation': 'Emergency Medicine Research Group of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Hamilton', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Hart', 'Affiliation': ""Centre for Human and Applied Physiological Sciences, King's College London, London, UK.""}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Ji', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Ranjit', 'Initials': 'R', 'LastName': 'Lall', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'McGowan', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Regan', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Anita K', 'Initials': 'AK', 'LastName': 'Simonds', 'Affiliation': 'Sleep and Ventilation Unit, Royal Brompton and Harefield NHS Foundation Trust, London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Skilton', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Nigel', 'Initials': 'N', 'LastName': 'Stallard', 'Affiliation': 'Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Stimpson', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Yeung', 'Affiliation': 'Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""Wellcome Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science Queen's University Belfast, Belfast, UK. d.f.mcauley@qub.ac.uk.""}]",Trials,['10.1186/s13063-020-04617-3'] 2742,32727703,Effect of tongue-to-palate resistance training on tongue strength in healthy adults.,"OBJECTIVE Tongue strength is crucial for safe and efficient oropharyngeal swallowing. This study examined the effect of tongue-to-palate resistance training (TPRT) on anterior and posterior tongue strength by conducting a prospective, randomized, parallel allocation trial. METHODS Ninety-one healthy adults were recruited in this study and were randomly assigned to an experimental group (n = 44) or a control group (n = 47). The experimental group performed TPRT for 8 weeks (5 days per week), whereas the control group performed the usual daily activities. Tongue strength was measured using the Iowa Oral Performance Instrument (IOPI) before and after the practice program was conducted at weeks 2, 4, 6, and 8, to evaluate the feasibility of the developed training protocol. RESULTS This experimental group demonstrated more improvements in both anterior tongue strength (p < .05) and posterior tongue strength (p < .05). The positive effects of the intervention on tongue strength appeared at 8 weeks for the anterior region and 2 weeks for the posterior region. CONCLUSIONS These findings illustrate that TPRT can improve tongue strength. It is suggested that people integrate this exercise protocol into their daily life, positive change in tongue strength may prevent or halt presbyphagia.",2020,This experimental group demonstrated more improvements in both anterior tongue strength (p < .05) and posterior tongue strength (p < .05).,"['Ninety-one healthy adults', 'healthy adults']","['tongue-to-palate resistance training', 'tongue-to-palate resistance training (TPRT', 'TPRT']","['posterior tongue strength', 'Tongue strength', 'anterior tongue strength', 'tongue strength']","[{'cui': 'C3816959', 'cui_str': '90'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}]","[{'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0700374', 'cui_str': 'Palatal'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0226958', 'cui_str': 'Structure of root of tongue'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C0226945', 'cui_str': 'Structure of body of tongue'}]",91.0,0.028836,This experimental group demonstrated more improvements in both anterior tongue strength (p < .05) and posterior tongue strength (p < .05).,"[{'ForeName': 'Chun-Hao', 'Initials': 'CH', 'LastName': 'Lin', 'Affiliation': 'Department of Internal Medicine, Dali Jen-Ai Hospital, Taichung, Taiwan, ROC. Electronic address: chunhao.lin@gmail.com.'}, {'ForeName': 'Shu-Ying', 'Initials': 'SY', 'LastName': 'Chung', 'Affiliation': 'Department of Nursing, Central Taiwan University of Science and Technology, Taichung, Taiwan, ROC. Electronic address: sychung@ctust.edu.tw.'}, {'ForeName': 'Chi-Te', 'Initials': 'CT', 'LastName': 'Lin', 'Affiliation': 'Department of Nursing, Central Taiwan University of Science and Technology, Taichung, Taiwan, ROC. Electronic address: 107917@ctust.edu.tw.'}, {'ForeName': 'Yueh-Juen', 'Initials': 'YJ', 'LastName': 'Hwu', 'Affiliation': 'College of Nursing, Central Taiwan University of Science and Technology, NO.666, Buzih Rd., Beitun District, Taichung 40601, Taiwan, ROC. Electronic address: yjhwu@ctust.edu.tw.'}]","Auris, nasus, larynx",['10.1016/j.anl.2020.07.014'] 2743,32727707,Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901.,"BACKGROUND The role of maintenance therapy for malignant pleural mesothelioma (MPM) is unknown. We performed a randomized phase II trial to determine if continuation of pemetrexed after first-line pemetrexed and platinum would improve progression-free survival (PFS). PATIENTS AND METHODS Eligible patients with unresectable MPM, without disease progression following 4 to 6 cycles of pemetrexed and platinum were randomized 1:1 to observation or continuation of pemetrexed until progression, stratified by number of cycles (< 6 or 6), cis- or carboplatin containing regimen, and histology. Study size was calculated based on the assumption that observation would produce a median PFS of 3 months and pemetrexed would yield median PFS of 6 months. RESULTS A total of 72 patients were registered from December 2010 to June 2016. The study closed early after 53 patients were randomized; 49 eligible (22 on the observation arm and 27 on the pemetrexed arm) were included in the analysis. The median PFS was 3 months (95% confidence interval [CI], 2.6-11.9 months) on observation and 3.4 months (95% CI, 2.8-9.8 months) on pemetrexed (hazard ratio [HR], 0.99; 95% CI, 0.51-1.90; P = .9733). The median overall survival (OS) was 11.8 months (95% CI, 9.3-28.7 months) for observation, and 16.3 months (95% CI, 10.5-26.0 months) for pemetrexed (HR, 0.86; 95% CI, 0.44-1.71; P = .6737). Grade 3 or 4 toxicities on the pemetrexed arm included anemia (8%), lymphopenia (8%), neutropenia (4%), and fatigue (4%). A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). CONCLUSION Maintenance pemetrexed following initial pemetrexed and platinum chemotherapy does not improve PFS in patients with MPM.",2020,"A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). ","['patients with MPM', 'malignant pleural mesothelioma (MPM', '53 patients were randomized; 49 eligible (22 on the observation arm and 27 on the pemetrexed arm) were included in the analysis', '72 patients were registered from December 2010 to June 2016', 'Eligible patients with unresectable MPM, without disease progression following 4 to 6 cycles of']","['cis- or carboplatin containing regimen, and histology', 'pemetrexed and platinum chemotherapy', 'pemetrexed and platinum', 'pemetrexed after first-line pemetrexed and platinum', 'Maintenance Pemetrexed']","['PFS', 'neutropenia', 'median overall survival (OS', 'anemia', 'Grade 3 or 4 toxicities', 'lymphopenia', 'progression-free survival (PFS', 'median PFS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0812413', 'cui_str': 'Malignant mesothelioma of pleura'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0007099', 'cui_str': 'Carcinoma in situ'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0019638', 'cui_str': 'Histology'}, {'cui': 'C0032207', 'cui_str': 'Platinum'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0024312', 'cui_str': 'Lymphocytopenia'}]",72.0,0.170713,"A higher baseline level of soluble mesothelin-related peptide was associated with worse PFS (HR, 1.86; 95% CI, 1.00-3.46; P = .049). ","[{'ForeName': 'Arkadiusz Z', 'Initials': 'AZ', 'LastName': 'Dudek', 'Affiliation': 'Regions Cancer Care Center, HealthPartners Inc, Minneapolis, MN. Electronic address: arkadiusz.z.dudek@healthpartners.com.'}, {'ForeName': 'Xiaofei', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Lin', 'Initials': 'L', 'LastName': 'Gu', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Duong', 'Affiliation': 'Alliance Statistics and Data Center, Duke University, Durham, NC.'}, {'ForeName': 'Thomas E', 'Initials': 'TE', 'LastName': 'Stinchcombe', 'Affiliation': 'Duke Cancer Institute, Duke University, Durham, NC.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kratzke', 'Affiliation': 'Division of Hematology, Oncology and Transplantation, University of Minnesota/Masonic Cancer Center, Minneapolis, MN.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Borghaei', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, PA.'}, {'ForeName': 'Everett E', 'Initials': 'EE', 'LastName': 'Vokes', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}, {'ForeName': 'Hedy L', 'Initials': 'HL', 'LastName': 'Kindler', 'Affiliation': 'Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL.'}]",Clinical lung cancer,['10.1016/j.cllc.2020.06.025'] 2744,32727732,Impact of spectacles wear on uncorrected visual acuity among urban migrant primary school children in China: a cluster-randomised clinical trial.,"OBJECTIVE To estimate the effect of providing free spectacles on uncorrected visual acuity (VA) among urban migrant Chinese school children. DESIGN Exploratory analysis from a parallel cluster-randomised clinical trial. METHODS After baseline survey and VA screening, eligible children were randomised by school to receive one of the two interventions: free glasses and a teacher incentive (tablet computer if ≥80% of children given glasses were wearing them on un-announced examination) (treatment group) or glasses prescription and letter to parents (control group). The primary outcome was uncorrected logarithm of the minimal angle of resolution (LogMAR) VA at study closeout, adjusted for baseline uncorrected VA. RESULTS Among 4376 randomly selected children, 728 (16.6%, mean age 10.9 years, 51.0% boys) at 94 schools failed VA screening and met eligibility criteria. Of these, 358 children (49.2%) at 47 schools were randomised to treatment and 370 children (50.8%) at 47 schools to control. Among these, 679 children (93.3%) completed follow-up and underwent analysis. Spectacle wear in the treatment and control groups was 68.3% and 29.3% (p<0.001), respectively. Uncorrected final VA for eyes of treatment children was significantly better than control children, adjusting only for baseline VA (difference of 0.039 LogMAR units, 95% CI: 0.008, 0.070, equivalent to 0.39 lines, p=0.014) or baseline VA and other baseline factors (0.040 LogMAR units, 95% CI 0.007 to 0.074, equivalent to 0.40 lines, p=0.020). CONCLUSION We found no evidence that spectacles wear worsens children's uncorrected VA among urban migrant Chinese school children.",2020,We found no evidence that spectacles wear worsens children's uncorrected VA among urban migrant Chinese school children.,"['679 children (93.3%) completed follow-up and underwent analysis', 'urban migrant primary school children in China', '358 children (49.2%) at 47 schools were randomised to treatment and 370 children (50.8%) at 47 schools to control', 'urban migrant Chinese school children', '4376 randomly selected children, 728 (16.6%, mean age 10.9\xa0years, 51.0% boys) at 94 schools failed VA screening and met eligibility criteria']",['teacher incentive (tablet computer if ≥80% of children given glasses were wearing them on un-announced examination) (treatment group) or glasses prescription and letter to parents (control group'],"['uncorrected logarithm of the minimal angle of resolution (LogMAR) VA', 'uncorrected visual acuity (VA', 'uncorrected visual acuity']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0026093', 'cui_str': 'Migrant'}, {'cui': 'C0033145', 'cui_str': 'Primary school'}, {'cui': 'C0008115', 'cui_str': 'China'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C4517743', 'cui_str': '370'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C0260267', 'cui_str': 'School child'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C0221457', 'cui_str': 'Teacher'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C4045980', 'cui_str': 'Tablet Computers'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0015421', 'cui_str': 'Eyeglasses'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0547040', 'cui_str': 'Minimal'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C1637380', 'cui_str': 'Uncorrected visual acuity'}]",4376.0,0.654494,We found no evidence that spectacles wear worsens children's uncorrected VA among urban migrant Chinese school children.,"[{'ForeName': 'Xinwu', 'Initials': 'X', 'LastName': 'Zhang', 'Affiliation': ""School of Public Administration, Northwest University, Xi'an, China.""}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Zhou', 'Affiliation': ""School of Public Administration, Northwest University, Xi'an, China.""}, {'ForeName': 'Xiaochen', 'Initials': 'X', 'LastName': 'Ma', 'Affiliation': 'China Center for Health Development Studies, Peking University, Beijing, China.'}, {'ForeName': 'Hongmei', 'Initials': 'H', 'LastName': 'Yi', 'Affiliation': 'Center for Chinese Agricultural Policy, Peking University, Beijing, China.'}, {'ForeName': 'Haiqing', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'College of Economics and Management, Shanghai Ocean University, Shanghai, China.'}, {'ForeName': 'Xiuqin', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.'}, {'ForeName': 'Ling', 'Initials': 'L', 'LastName': 'Jin', 'Affiliation': 'Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Kovin', 'Initials': 'K', 'LastName': 'Naidoo', 'Affiliation': 'African Vision Research Institute, University of Kwazulu-Natal, Durban, South Africa.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Minto', 'Affiliation': 'Brien Holden Vision Institute, Sydney, Australia.'}, {'ForeName': 'Haidong', 'Initials': 'H', 'LastName': 'Zou', 'Affiliation': 'Shanghai Eye Disease Prevention and Treatment Center, Shanghai, China.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Rozelle', 'Affiliation': 'Rural Education Action Program, Freeman Spogli Institute for International Studies, Stanford University, CA, USA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Congdon', 'Affiliation': 'Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yue', 'Initials': 'Y', 'LastName': 'Ma', 'Affiliation': 'Rural Education Action Program, Freeman Spogli Institute for International Studies, Stanford University, CA, USA yma3@stanford.edu.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2020-316213'] 2745,32727733,Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy.,"AIMS To investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC). METHODS Fifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT. RESULTS The rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups. CONCLUSIONS A 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT. TRIAL REGISTRATION NUMBER NCT01630863.",2020,"The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively).","['chronic central serous chorioretinopathy (CSC', 'chronic central serous chorioretinopathy', 'Fifty-one eyes of 51 patients with chronic CSC']","['photodynamic therapy', 'photodynamic therapy (PDT']","['success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications', 'mean BCVA', 'Mean CFT and SFCT', 'rate of complications', 'recurrence rate', 'rate of complete subretinal fluid (SRF) resolution']","[{'cui': 'C0730314', 'cui_str': 'Chronic central serous chorioretinopathy'}, {'cui': 'C0730328', 'cui_str': 'Central serous chorioretinopathy'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}]","[{'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0442185', 'cui_str': 'Subfoveal'}, {'cui': 'C0205266', 'cui_str': 'Intact'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}]",51.0,0.0775136,"The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively).","[{'ForeName': 'Dong-Geun', 'Initials': 'DG', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, South Korea.'}, {'ForeName': 'Seongyong', 'Initials': 'S', 'LastName': 'Jeong', 'Affiliation': 'Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, South Korea.'}, {'ForeName': 'Donghyoun', 'Initials': 'D', 'LastName': 'Noh', 'Affiliation': 'Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, South Korea.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Sagong', 'Affiliation': 'Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, South Korea msagong@ynu.ac.kr.'}]",The British journal of ophthalmology,['10.1136/bjophthalmol-2020-316837'] 2746,32728111,Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial.,"Eighty Japanese children, aged 8-12 years, with a spherical equivalent refraction (SER) of - 1.00 to - 6.00 dioptres (D) were randomly allocated into two groups to receive either a combination of orthokeratology (OK) and 0.01% atropine solution (combination group) or monotherapy with OK (monotherapy group). Seventy-three subjects completed the 2-year study. Over the 2 years, axial length increased by 0.29 ± 0.20 mm (n = 38) and 0.40 ± 0.23 mm (n = 35) in the combination and monotherapy groups, respectively (P = 0.03). Interactions between combination treatment and age or SER did not reach significance level (age, P = 0.18; SER, P = 0.06). In the subgroup of subjects with an initial SER of - 1.00 to - 3.00 D, axial length increased by 0.30 ± 0.22 mm (n = 27) and 0.48 ± 0.22 mm (n = 23) in the combination and monotherapy groups, respectively (P = 0.005). In the - 3.01 to - 6.00 D subgroup, axial length increased by 0.27 ± 0.15 mm (n = 11) and 0.25 ± 0.17 mm (n = 12) in the combination and monotherapy groups, respectively (P = 0.74). The combination therapy may be effective for slowing axial elongation, especially in children with low initial myopia.",2020,"Interactions between combination treatment and age or SER did not reach significance level (age, P = 0.18; SER, P = 0.06).","['Seventy-three subjects completed the 2-year study', 'children with myopia', 'Eighty Japanese children, aged 8-12\xa0years, with a spherical equivalent refraction (SER) of -\u20091.00 to -\u20096.00 dioptres (D', 'children with low initial myopia']","['combination of orthokeratology (OK) and 0.01% atropine solution (combination group) or monotherapy with OK (monotherapy', 'combined orthokeratology and 0.01% atropine solution']",['axial length'],"[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027092', 'cui_str': 'Myopia'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0332501', 'cui_str': 'Spherical shape'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}, {'cui': 'C0439484', 'cui_str': 'Diopters'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0205265', 'cui_str': 'Initial'}]","[{'cui': 'C1533088', 'cui_str': 'Orthokeratology'}, {'cui': 'C4517393', 'cui_str': '0.01'}, {'cui': 'C0004259', 'cui_str': 'Atropine'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0205131', 'cui_str': 'Axial'}, {'cui': 'C1444754', 'cui_str': 'Length'}]",80.0,0.0902463,"Interactions between combination treatment and age or SER did not reach significance level (age, P = 0.18; SER, P = 0.06).","[{'ForeName': 'Nozomi', 'Initials': 'N', 'LastName': 'Kinoshita', 'Affiliation': 'Department of Ophthalmology, Saitama Medical Centre, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan. nozomik@omiya.jichi.ac.jp.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Konno', 'Affiliation': 'Konno Eye Clinic, Saitama, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Hamada', 'Affiliation': 'Omiya Hamada Eye Clinic, Saitama, Japan.'}, {'ForeName': 'Yoshinobu', 'Initials': 'Y', 'LastName': 'Kanda', 'Affiliation': 'Department of Hematology, Saitama Medical Centre, Jichi Medical University, Saitama, Japan.'}, {'ForeName': 'Machiko', 'Initials': 'M', 'LastName': 'Shimmura-Tomita', 'Affiliation': 'Department of Ophthalmology, Saitama Medical Centre, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan.'}, {'ForeName': 'Toshikatsu', 'Initials': 'T', 'LastName': 'Kaburaki', 'Affiliation': 'Department of Ophthalmology, Saitama Medical Centre, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan.'}, {'ForeName': 'Akihiro', 'Initials': 'A', 'LastName': 'Kakehashi', 'Affiliation': 'Department of Ophthalmology, Saitama Medical Centre, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama-shi, Saitama, 330-8503, Japan.'}]",Scientific reports,['10.1038/s41598-020-69710-8'] 2747,32728226,"A randomised, prospective study of 'off-the-shelf' use of toric intraocular lenses for cataract patients with pre-existing corneal astigmatism in the NHS.","BACKGROUND/OBJECTIVES To compare visual and refractive outcomes of monofocal intraocular lenses (IOLs) with limbal relaxing incisions (LRI) with 'off-the-shelf' use of toric IOLs (TIOLs), with a fixed 2-dioptre cylinder (DC) correction, for cataract patients with pre-existing corneal astigmatism in a public-sector setting. SUBJECTS/METHODS Seventy-seven patients (77 eyes, first treated eye) with visually significant cataract and pre-operative corneal astigmatism ≥2.00 DC were randomised to receive either 'off-the-shelf' TIOLs, with a fixed 2.00 DC cylinder correction (39 eyes), or monofocal IOLs (38 eyes) with LRIs. The concept of fixing the cylindrical correction was to minimise costs, allow a full TIOL bank to be available and eliminate the need for individual TIOL ordering. Outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA) and refraction. Astigmatic changes were evaluated using the Alpins vector method. RESULTS Mean UDVA improved from logMAR 0.88 (SD 0.56)[~20/150] pre-operatively to 0.18 (SD 0.19)[~20/30] post-operatively in TIOL group, versus 0.82 (SD 0.55)[~20/130] to 0.27 (SD 0.15)[~20/40] in monofocal/LRI group (P = 0.02; 95% CI: -0.17, -0.01). Mean CDVA improved from logMAR 0.40 (SD 0.26)[~20/50] to 0.01 (SD 0.12)[~20/20] in TIOL group, and 0.41 (SD 0.38)[~20/40] to 0.06 (SD 0.12)[~20/25] in LRI group (P = 0.07; 95% CI: -0.11, 0.01). Average post-operative refractive cylinder in TIOL group was 1.35 DC (SD 0.84 DC) and in LRI group 1.91 DC (SD 1.07 DC) (P = 0.01; 95% CI: -1, -0.12). Mean difference vector magnitude was 1.92 DC (SD 1.08 DC) in LRI group and 1.37 DC (SD 0.84 DC) in TIOL group (P = 0.02; 95% CI: 0.11, 0.99). CONCLUSIONS TIOLs with a fixed 2.00 DC correction during cataract surgery may improve UDVA, reduce post-operative cylinder and result in a more reliable astigmatic correction compared with monofocal IOLs with LRIs.",2020,"RESULTS Mean UDVA improved from logMAR 0.88 (SD 0.56)[~20/150] pre-operatively to 0.18","['Seventy-seven patients (77 eyes, first treated eye) with visually significant cataract and pre-operative corneal astigmatism', 'cataract patients with pre-existing corneal astigmatism in the NHS', 'cataract patients with pre-existing corneal astigmatism in a public-sector setting']","['fixed 2.00 DC cylinder correction (39 eyes), or monofocal IOLs (38 eyes) with LRIs', 'monofocal intraocular lenses (IOLs) with limbal relaxing incisions (LRI', 'toric IOLs (TIOLs), with a fixed 2-dioptre cylinder (DC) correction', 'toric intraocular lenses']","['Mean difference vector magnitude', 'uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA) and refraction', 'Mean CDVA', 'Mean UDVA']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0086543', 'cui_str': 'Cataract'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0339682', 'cui_str': 'Regular astigmatism - corneal'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0034035', 'cui_str': 'Public Sector'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0439484', 'cui_str': 'Diopters'}, {'cui': 'C0181797', 'cui_str': 'Medical gas cylinder'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0023311', 'cui_str': 'Insertion of intraocular lens'}, {'cui': 'C0443251', 'cui_str': 'Limbal'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C0281658', 'cui_str': 'Intraocular Lymphoma'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012656', 'cui_str': 'Infectious Disease Vectors'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0429537', 'cui_str': 'Distance visual acuity'}, {'cui': 'C0205202', 'cui_str': 'Corrected'}, {'cui': 'C0429585', 'cui_str': 'Refraction measurement - finding'}]",,0.196616,"RESULTS Mean UDVA improved from logMAR 0.88 (SD 0.56)[~20/150] pre-operatively to 0.18","[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Stanojcic', 'Affiliation': ""Department of Ophthalmology, King's College London Frost Eye Research Unit, Guy's and St Thomas' NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK. nstanojcic@doctors.org.uk.""}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Roberts', 'Affiliation': ""Department of Ophthalmology, King's College London Frost Eye Research Unit, Guy's and St Thomas' NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK.""}, {'ForeName': 'Vijay', 'Initials': 'V', 'LastName': 'Wagh', 'Affiliation': ""Department of Ophthalmology, King's College London Frost Eye Research Unit, Guy's and St Thomas' NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK.""}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Zuberbuhler', 'Affiliation': 'Zubimed Augenzentrum, Niederhasli, Switzerland.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': ""O'Brart"", 'Affiliation': ""Department of Ophthalmology, King's College London Frost Eye Research Unit, Guy's and St Thomas' NHS Foundation Trust, Lambeth Palace Road, London, SE1 7EH, UK.""}]","Eye (London, England)",['10.1038/s41433-020-0919-8'] 2748,29808395,Parental Depressive Symptoms as a Predictor of Outcome in the Treatment of Child Internalizing and Externalizing Problems.,"Child internalizing and externalizing problems have been identified as high priority intervention targets by the World Health Organization. Parental depression is a risk factor for development of these childhood problems and may negatively influence intervention outcomes; however, studies have rarely assessed its influence on these outcomes. The present study assessed whether baseline parental depressive symptoms predicted psychotherapy outcomes among children treated for clinically significant internalizing and externalizing problems. The sample included 142 children (79 with primary internalizing problems, 63 with primary externalizing problems). Children were aged 7-13, 67.6% boys, and race included Caucasian (46.5%), African-American (9.9%), Latino (5.6%), Asian (1.4%), and multi-racial (32.4%). Analyses focused on child- and parent-reported weekly trajectories of change and post-treatment symptoms among children treated for internalizing and externalizing problems whose parents did (N = 28 and 25) and did not (N = 51 and 38) have elevated depressive symptoms. For children with internalizing problems, growth curve analyses showed markedly different trajectories, by child- and parent-report: children with less depressed parents showed significantly steeper symptom declines than did children with more depressed parents, who showed an increase in symptoms. ANCOVAs showed marginally lower post-treatment symptoms for children of less depressed versus more depressed parents (p = 0.064 by child-report). For children with externalizing problems, growth curve analyses showed trajectories in the opposite direction, by child- and parent-report; however, ANCOVAs showed no group differences at post-treatment. These findings suggest that it may be important to consider the impact of parental depressive symptoms when treating child internalizing and externalizing problems.",2019,ANCOVAs showed marginally lower post-treatment symptoms for children of less depressed versus more depressed parents (p = 0.064 by child-report).,"['children treated for clinically significant internalizing and externalizing problems', 'Children were aged 7-13, 67.6% boys, and race included Caucasian (46.5%), African-American (9.9%), Latino (5.6%), Asian (1.4%), and multi-racial (32.4', '142 children (79 with primary internalizing problems, 63 with primary externalizing problems']",[],"['Child Internalizing and Externalizing Problems', 'steeper symptom declines', 'symptoms', 'elevated depressive symptoms', 'Parental Depressive Symptoms']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332154', 'cui_str': 'Received therapy or drug for'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C4517794', 'cui_str': '5.6'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C4517709', 'cui_str': '32.4'}, {'cui': 'C0205225', 'cui_str': 'Principal'}]",[],"[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]",142.0,0.0426167,ANCOVAs showed marginally lower post-treatment symptoms for children of less depressed versus more depressed parents (p = 0.064 by child-report).,"[{'ForeName': 'Dikla', 'Initials': 'D', 'LastName': 'Eckshtain', 'Affiliation': 'Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, 185 Cambridge Street, Boston, MA, 02114, USA. deckshtain@mgh.harvard.edu.'}, {'ForeName': 'Lauren Krumholz', 'Initials': 'LK', 'LastName': 'Marchette', 'Affiliation': 'Department of Psychiatry, Cambridge Health Alliance, Harvard Medical School, 1493 Cambridge St, Cambridge, MA, 02139, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Schleider', 'Affiliation': 'Department of Psychology, Harvard University, 1032 William James Hall, 33 Kirkland Street, Cambridge, MA, 02138, USA.'}, {'ForeName': 'Spencer', 'Initials': 'S', 'LastName': 'Evans', 'Affiliation': 'Department of Psychology, Harvard University, 1032 William James Hall, 33 Kirkland Street, Cambridge, MA, 02138, USA.'}, {'ForeName': 'John R', 'Initials': 'JR', 'LastName': 'Weisz', 'Affiliation': 'Department of Psychology, Harvard University, 1032 William James Hall, 33 Kirkland Street, Cambridge, MA, 02138, USA.'}]",Journal of abnormal child psychology,['10.1007/s10802-018-0446-2'] 2749,30636072,"1-(2-Hydroxyethyl)-2-imidazolidinone, a heparanase and matrix metalloproteinase inhibitor, improves epidermal basement membrane structure and epidermal barrier function.","Daily exposure to sunlight is known to affect the structure and function of the epidermal basement membrane (BM), as well as epidermal differentiation and epidermal barrier function. The aim of this study is to clarify whether the inhibition of BM-degrading enzymes such as heparanase and matrix metalloproteinase 9 (MMP-9) can improve the epidermal barrier function of facial skin, which is exposed to the sun on a daily basis. 1-(2-hydroxyethyl)-2-imidazolidinone (HEI) was synthesized as an inhibitor of both heparanase and MMP-9. HEI inhibited not only the BM damage at the DEJ but also epidermal proliferation, differentiation, water contents and transepidermal water loss abnormalities resulting from ultraviolet B (UVB). This was determined in this study by the use of UVB-induced human cultured skins as compared with the control without HEI. Moreover, topical application of HEI improved epidermal barrier function by increasing water content and decreasing transepidermal water loss in daily sun-exposed facial skin as compared with non-treated skins. These results suggest that the inhibition of both heparanase and MMP-9 is an effective way to care for regularly sun-exposed facial skin by protecting the BM from damage.",2019,"HEI inhibited not only the BM damage at the DEJ but also epidermal proliferation, differentiation, water contents and transepidermal water loss abnormalities resulting from ultraviolet B (UVB).",[],"['1-(2-hydroxyethyl)-2-imidazolidinone', 'UVB-induced human cultured skins', '1-(2-Hydroxyethyl)-2-imidazolidinone']","['epidermal proliferation, differentiation, water contents and transepidermal water loss abnormalities', 'epidermal barrier function', 'BM damage', 'transepidermal water loss']",[],"[{'cui': 'C0059814', 'cui_str': 'Imidazolidinone'}, {'cui': 'C1532472', 'cui_str': 'Ultra-violet'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0450138', 'cui_str': 'Cultured graft of skin'}]","[{'cui': 'C0014520', 'cui_str': 'Epidermis structure'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0007589', 'cui_str': 'Differentiation, Cell'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0000768', 'cui_str': 'Congenital malformation'}, {'cui': 'C0173022', 'cui_str': 'Barrier (varnish)'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0004799', 'cui_str': 'Basement membrane'}, {'cui': 'C0010957', 'cui_str': 'Damage'}]",,0.0195746,"HEI inhibited not only the BM damage at the DEJ but also epidermal proliferation, differentiation, water contents and transepidermal water loss abnormalities resulting from ultraviolet B (UVB).","[{'ForeName': 'Shunsuke', 'Initials': 'S', 'LastName': 'Iriyama', 'Affiliation': 'Shiseido Global Innovation Center, Yokohama, Japan.'}, {'ForeName': 'Haruyo', 'Initials': 'H', 'LastName': 'Yamanishi', 'Affiliation': 'Shiseido Global Innovation Center, Yokohama, Japan.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Kunizawa', 'Affiliation': 'Shiseido Global Innovation Center, Yokohama, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Hirao', 'Affiliation': 'Shiseido Global Innovation Center, Yokohama, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Amano', 'Affiliation': 'Shiseido Global Innovation Center, Yokohama, Japan.'}]",Experimental dermatology,['10.1111/exd.13876'] 2750,32734564,Intermittent pneumatic compression combined with rehabilitation training improves motor function deficits in patients with acute cerebral infarction.,"To investigate the effect of intermittent pneumatic compression (IPC) combined with rehabilitation training on patients with acute cerebral infarction and motor impairment, seventy-four patients with acute cerebral infarction and hemiplegia were randomly and equally divided into two groups, the control group and the IPC treatment group. The patients in the control group received conventional drug therapy and rehabilitation training, and the patients in the treatment group received the IPC treatment in addition to the treatment given in the control group. Motor function, the primary outcome, of the two groups was evaluated by Fugl-Meyer motor function scores. The Barthel index assessment scale was used to evaluate the ability to perform activities of daily living of the two groups, as a secondary outcome. All these indicators were collected and compared before treatment and at 7 days, 14 days, and 30 days after treatment. The incidence of adverse reactions associated with treatment was also recorded. At 7, 14, and 30 days after treatment, the Fugl-Meyer scores (27.16 ± 7.37, 33.41 ± 7.16 and 38.72 ± 7.65) and Barthel scores (47.16 ± 7.37, 52.41 ± 7.16, and 56.09 ± 8.32) of the treatment group were also significantly higher than those (23.65 ± 3.11, 26.13 ± 3.25, and 28.75 ± 5.92; 44.15 ± 3.11, 46.63 ± 3.25 and 47.75 ± 4.22) of the control group (all P < 0.05). With the extension of follow-up time, both scores were higher. There were no treatment-related adverse events in either of the two groups of patients during or after treatment. In conclusion, the IPC combined with rehabilitation training can effectively improve motor function deficits, the ability to perform activities of daily living, and quality of life for patients.",2020,There were no treatment-related adverse events in either of the two groups of patients during or after treatment.,"['patients with acute cerebral infarction', 'patients with acute cerebral infarction and motor impairment,\xa0seventy-four patients with acute cerebral infarction and hemiplegia']","['Intermittent pneumatic compression combined with rehabilitation training', 'intermittent pneumatic compression (IPC) combined with rehabilitation training', 'IPC treatment', 'conventional drug therapy and rehabilitation training', 'IPC combined with rehabilitation training']","['Barthel scores', 'Fugl-Meyer scores', 'adverse reactions', 'adverse events', 'motor function deficits', 'Fugl-Meyer motor function scores', 'activities of daily living, and quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0007785', 'cui_str': 'Cerebral infarction'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C4517867', 'cui_str': '74'}, {'cui': 'C0018991', 'cui_str': 'Hemiplegia'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0234130', 'cui_str': 'Motor function'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",74.0,0.020727,There were no treatment-related adverse events in either of the two groups of patients during or after treatment.,"[{'ForeName': 'Jiangshan', 'Initials': 'J', 'LastName': 'Wei', 'Affiliation': ""Department of Neurology, Hongze Huai'an District People's Hospital, No.1 Huanghe West Road, Huai'an, 223300, Jiangsu, People's Republic of China.""}, {'ForeName': 'Xiangyu', 'Initials': 'X', 'LastName': 'Zhu', 'Affiliation': ""ICU, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, No.62 Huaihai South Road, Huai'an, 223002, Jiangsu, People's Republic of China.""}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Xia', 'Affiliation': ""Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': ""Department of Neurology, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, 223002, Jiangsu, China.""}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Yang', 'Affiliation': ""Department of Neurology, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, 223002, Jiangsu, China.""}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': ""Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, 223300, Jiangsu, China. dahuihui19830809@163.com.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Shen', 'Affiliation': ""Department of Neurology, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, 223002, Jiangsu, China. dr_shenjun79@126.com.""}]",Acta neurologica Belgica,['10.1007/s13760-020-01414-2'] 2751,32734606,A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations.,"Smoking increases the risk of cancer and other diseases, causing an estimated 7 million deaths per year. Nicotine replacement therapy (NRT) reduces craving for smoking, therefore increasing an individual's probability to remain abstinent. In this work, we for the first time quantitatively described the relationship between craving and smoking abstinence, using retrospectively collected data from 19 studies, including three NRT formulations (inhaler, mouth spray, patch) and a combination of inhaler and patch. Smokers motivated to quit were included in NRT or placebo arms. Integrated craving (i.e. craving over a period of time) was assessed with 4-category, 5-category or 100-mm visual analogue scales (VAS). The bounded integer model was used to assess latent craving from all scales. A time-to-event model linked predicted integrated craving to the hazard of smoking relapse. Available data included 9,323 adult subjects, observed for 3 weeks up to 2 years. At the study end, 9% (11% for NRT and 5% for placebo) on average remained abstinent according to the protocol definition. A Gompertz-Makeham hazard best described the data, with a hazard of smoking relapse decreasing over time. Latent integrated craving was positively related to the hazard of smoking relapse, through a sigmoidal E max function. For the same craving, being on NRT was found to reduce the hazard of relapse by an additional 30% compared to placebo. This work confirmed that low craving is associated with a high probability of remaining smoking abstinent and that NRT, in addition to reducing craving, increases the probability of remaining smoking abstinent.",2020,"For the same craving, being on NRT was found to reduce the hazard of relapse by an additional 30% compared to placebo.","['9,323 adult subjects, observed for 3 weeks up to 2 years']","['nicotine replacement therapy formulations', 'placebo', 'Nicotine replacement therapy (NRT']","['Integrated craving (i.e. craving', '4-category, 5-category or 100-mm visual analogue scales (VAS', 'Latent integrated craving', 'hazard of relapse', 'risk of cancer and other diseases']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C0524527', 'cui_str': 'Pharmaceutical Formulation'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0205275', 'cui_str': 'Latent'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",9323.0,0.0388632,"For the same craving, being on NRT was found to reduce the hazard of relapse by an additional 30% compared to placebo.","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Germovsek', 'Affiliation': 'Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Hansson', 'Affiliation': 'McNeil AB, Helsingborg, Sweden.'}, {'ForeName': 'Mats O', 'Initials': 'MO', 'LastName': 'Karlsson', 'Affiliation': 'Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'Åke', 'Initials': 'Å', 'LastName': 'Westin', 'Affiliation': 'McNeil AB, Helsingborg, Sweden.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Soons', 'Affiliation': 'Janssen R&D, a division of Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'An', 'Initials': 'A', 'LastName': 'Vermeulen', 'Affiliation': 'Janssen R&D, a division of Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'Kjellsson', 'Affiliation': 'Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.2000'] 2752,32734638,Surgiflo ® may have a potential impact on the healing process in cricotracheal resection anastomosis.,"OBJECTIVES To evaluate the role of thrombin based hemostatic agent Surgiflo® (Ethicon, Somerville, USA) in improving the outcome of cricotracheal resection anastomosis. DESIGN Randomized controlled clinical trial. SETTING Otorhinolaryngology Department, Mansoura University Hospitals, Egypt. PARTICIPANTS This study included 55 patients with grade III and IV subglottic and/or cervical tracheal stenosis, who underwent cricotracheal resection anastomosis. Patients were randomly assigned into two groups: Surgiflo group (n=20) and control group (n=35). In Surgiflo patients, Surgiflo® was applied at the end of surgery over the whole operative field including the line of airway anastomosis with the purpose of adequate hemostasis and enhancing healing of the anastomosis. MAIN OUTCOME MEASURES The success rate and the incidence of complications in both groups were compared. RESULTS At the end of treatment, decannulation rate was 95% (19/20) in the Surgiflo groups and 82.8% (29/35) in the control group. The overall incidence of complications was significantly lower in the Surgiflo group (p=0.021). Need for further surgical airway interventions in the form of repeated dilatation, granulation tissue removal or performing a tracheotomy was reported in 22.9% (8/35) of control group patients, in comparison to 5% (1/20) in Surgiflo group. CONCLUSION Direct Surgiflo® application in the operative field enhances the anastomotic healing, decreases the incidence of anastomotic complications and subsequently improves the outcome. It can be recommended as an adjuvant to surgery in patients undergoing cricotracheal resection anastomosis.",2020,The overall incidence of complications was significantly lower in the Surgiflo group (p=0.021).,"['patients undergoing cricotracheal resection anastomosis', '55 patients with grade III and IV subglottic and/or cervical tracheal stenosis, who underwent', 'Otorhinolaryngology Department, Mansoura University Hospitals, Egypt', 'cricotracheal resection anastomosis']","['thrombin based hemostatic agent Surgiflo® (Ethicon, Somerville, USA', 'cricotracheal resection anastomosis']","['success rate and the incidence of complications', 'incidence of anastomotic complications', 'overall incidence of complications', 'anastomotic healing', 'decannulation rate']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0040583', 'cui_str': 'Stenosis of trachea'}, {'cui': 'C0587514', 'cui_str': 'Ear, nose and throat department'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0013715', 'cui_str': 'Egypt'}]","[{'cui': 'C0040018', 'cui_str': 'Thrombin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0019120', 'cui_str': 'Hemostatic agent'}, {'cui': 'C4058557', 'cui_str': 'Surgiflo'}, {'cui': 'C0041703', 'cui_str': 'United States of America'}, {'cui': 'C0015252', 'cui_str': 'Removal'}, {'cui': 'C0332853', 'cui_str': 'Anastomosis'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C1141928', 'cui_str': 'Anastomotic complication'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0677554', 'cui_str': 'Anastomosis - action'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0178148', 'cui_str': 'Removal of tracheostomy tube'}]",55.0,0.0231968,The overall incidence of complications was significantly lower in the Surgiflo group (p=0.021).,"[{'ForeName': 'Ahmed Musaad', 'Initials': 'AM', 'LastName': 'Abd El-Fattah', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'HishamAtef', 'Initials': 'H', 'LastName': 'Ebada', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Tawfik', 'Affiliation': 'Department of Otorhinolaryngology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}]",Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery,['10.1111/coa.13614'] 2753,32734691,"Genetic variation of lean body mass, changes of appetite, and weight loss in response to diet interventions: the POUNDS Lost trial.","AIMS Emerging evidence has implicated lean body mass (LBM) in regulating appetite and adiposity. We investigated whether the genetic risk score (GRS) for LBM modified the effects of weight-loss diets on changes in appetite and adiposity among overweight and obese individuals. MATERIALS AND METHODS In the 2-year Preventing Overweight Using Novel Dietary Strategies (POUNDS Lost) trial, we included 692 adults who were randomly assigned to 1 of 4 diets varying in macronutrient intake. A GRS was calculated using 5 single nucleotide polymorphisms (SNPs) associated with LBM. RESULTS The LBM-GRS was not associated with the baseline LBM measured by dual-energy x-ray absorptiometry in a subgroup (50%) of the study population. We found that LBM-GRS had significantly different associations with changes in appetite from baseline to 6 months according to the low-/high-fat group (p-interaction<0.001, 0.021, 0.005, and 0.024 for total appetite score, hunger, fullness, and prospective consumption, respectively). Individuals with lower LBM-GRS (indicating a greater genetic predisposition to LBM) was associated with greater decreases in the total appetite score (p < 0.001), hunger (p = 0.01), fullness (p = 0.001), and prospective consumption (p = 0.019) in the low-fat diet group, whereas no significant associations with these appetite measures were observed in the high-fat diet group. In addition, lower LBM-GRS was associated with a greater reduction in body weight (p = 0.003) and waist circumference (p = 0.011) among participants in a low-fat diet group, while no associations were observed in the high-fat diet group. The interactions attenuated along with weight regain from 6 months to 2 years. CONCLUSIONS Our findings suggest that genetic variation of LBM may differentially associate with appetite changes, and subsequently related to changes in body weight and waist circumference, according to dietary fat intake. This article is protected by copyright. All rights reserved.",2020,The LBM-GRS was not associated with the baseline LBM measured by dual-energy x-ray absorptiometry in a subgroup (50%) of the study population.,"['overweight and obese individuals', '692 adults who were randomly assigned to 1 of 4']","['weight-loss diets', 'LBM-GRS', 'diets varying in macronutrient intake']","['appetite and adiposity', 'hunger', 'appetite measures', 'waist circumference', 'fullness', 'body weight', 'total appetite score', 'appetite', 'total appetite score, hunger, fullness, and prospective consumption, respectively', 'genetic risk score (GRS']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}]","[{'cui': 'C0012167', 'cui_str': 'Weight reduction diet'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C2346926', 'cui_str': 'Macronutrient'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}]","[{'cui': 'C0003618', 'cui_str': 'Food appetite'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0020175', 'cui_str': 'Hungry'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0439650', 'cui_str': 'Fullness'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",692.0,0.0282244,The LBM-GRS was not associated with the baseline LBM measured by dual-energy x-ray absorptiometry in a subgroup (50%) of the study population.,"[{'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, United States.'}, {'ForeName': 'Tao', 'Initials': 'T', 'LastName': 'Zhou', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, United States.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Ma', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, United States.'}, {'ForeName': 'Yoriko', 'Initials': 'Y', 'LastName': 'Heianza', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, United States.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Champagne', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, United States.'}, {'ForeName': 'Donald A', 'Initials': 'DA', 'LastName': 'Williamson', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, United States.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Bray', 'Affiliation': 'Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana, United States.'}, {'ForeName': 'Frank M', 'Initials': 'FM', 'LastName': 'Sacks', 'Affiliation': 'Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States.'}, {'ForeName': 'Lu', 'Initials': 'L', 'LastName': 'Qi', 'Affiliation': 'Department of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, United States.'}]","Diabetes, obesity & metabolism",['10.1111/dom.14155'] 2754,32734722,"Efficacy of additional tunica vaginalis flap coverage for protecting against urethrocutaneous fistulas in tubularized incised plate urethroplasty: A prospective, randomized controlled trial.","PURPOSE We compared the protective effect of additional tunica vaginalis flap coverage combined with a dartos flap against urethrocutaneous fistulas in tubularized incised plate (TIP) urethroplasty in a randomized controlled trial. MATERIALS AND METHODS This prospective, randomized controlled trial in a single tertiary center enrolled 50 patients in whom it was feasible to perform single TIP urethroplasty between 2016 and 2017. Consecutive children were randomly allocated to study group A (additional tunica vaginalis flap coverage, n=25) or control group B (dartos-only coverage, n=25). All patients were examined in the outpatient clinic at 1, 3, 12, and 24 months. Postoperative cosmetic outcomes were evaluated by surgeons and parents using the Pediatric Penile Perception Scale questionnaire. RESULTS In group B, 1 of 25 patients (4.0%) developed an urethrocutaneous fistula within 12 months. An additional two cases of fistula were found in all proximal-type hypospadias patients at 24 months in the same group without statistical significance (p=0.07). The penile cosmetic satisfaction rate was not significantly different between the groups according to scores on the Pediatric Penile Perception Scale. CONCLUSIONS Our randomized controlled trial did not show a significant decrease in the incidence of or a significant slowing of the progression of postoperative fistulas after TIP urethroplasty by the use of additional tunica vaginalis coverage. A tunica vaginalis flap is not routinely recommended but could have a selective role in proximal-type TIP urethroplasty with deficient dartos and subcutaneous tissue to cover the neourethra.",2020,"The penile cosmetic satisfaction rate was not significantly different between the groups according to scores on the Pediatric Penile Perception Scale. ","['tubularized incised plate urethroplasty', 'Consecutive children', 'single tertiary center enrolled 50 patients in whom it was feasible to perform single TIP urethroplasty between 2016 and 2017']","['additional tunica vaginalis flap coverage combined with a dartos flap against urethrocutaneous fistulas', 'additional tunica vaginalis flap coverage']","['Pediatric Penile Perception Scale', 'Postoperative cosmetic outcomes', 'penile cosmetic satisfaction rate', 'urethrocutaneous fistula', 'Pediatric Penile Perception Scale questionnaire']","[{'cui': 'C0005971', 'cui_str': 'Bone plate'}, {'cui': 'C0161922', 'cui_str': 'Repair of urethra'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0228014', 'cui_str': 'Tunica vaginalis structure'}, {'cui': 'C0038925', 'cui_str': 'Flap'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}]","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0030851', 'cui_str': 'Penile structure'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0010164', 'cui_str': 'Cosmetic'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0016169', 'cui_str': 'Fistula'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",,0.0689132,"The penile cosmetic satisfaction rate was not significantly different between the groups according to scores on the Pediatric Penile Perception Scale. ","[{'ForeName': 'Jae Hyeon', 'Initials': 'JH', 'LastName': 'Han', 'Affiliation': 'Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sang Hoon', 'Initials': 'SH', 'LastName': 'Song', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.'}, {'ForeName': 'Je Seong', 'Initials': 'JS', 'LastName': 'Lee', 'Affiliation': 'Eastern Virginia Medical School, Norfolk, VA, USA.'}, {'ForeName': 'Sungchan', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.'}, {'ForeName': 'Sung Jin', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.'}, {'ForeName': 'Kun Suk', 'Initials': 'KS', 'LastName': 'Kim', 'Affiliation': 'Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. kskim2@amc.seoul.kr.'}]",Investigative and clinical urology,['10.4111/icu.20200024'] 2755,32727613,"Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.","OBJECTIVES The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during an epidemic period. As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2 (defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2 infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection. TRIAL DESIGN Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial. PARTICIPANTS Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited. Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and confirmed cases of COVID-19. For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment. INTERVENTION AND COMPARATOR Eligible participants will be allocated to one of the two study groups: Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine (2 tablets of 200 mg per Dolquine® tablet) daily the first four consecutive days, followed by 400 mg weekly for a period of 6 months. CONTROL GROUP participants will receive placebo tablets with identical physical appearance to hydroxychloroquine 200 mg (Dolquine®) tablets following the same treatment schedule of the intervention group. Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines. MAIN OUTCOMES The primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and serology at day 0. As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood markers to predict SARS-CoV-2 infection. RANDOMISATION Participants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated random numbers. BLINDING (MASKING) Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will be blinded to group assignment. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) Each intervention group will have 220 participants, giving a total of 440 participants. TRIAL STATUS The current protocol version is 1.5, 2 nd of June 2020. Two hundred and seventy-fiveparticipants were recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been suspended (26 th of June) until new epidemic curve occurs. TRIAL REGISTRATION This trial was registered on April 2 nd 2020 at clinicaltrials.gov with the number NCT04331834. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,"Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines. ","['healthcare workers with high risk of SARS-CoV-2 infection', '220 participants, giving a total of 440 participants', 'For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are invited to participate', 'Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any contraindication to hydroxychloroquine treatment', 'Two hundred and seventy-fiveparticipants', 'high-risk healthcare workers during the COVID-19 pandemic', 'Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la', 'healthcare workers with high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2']","['pre-exposure prophylaxis (PrEP', 'Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine', 'hydroxychloroquine against placebo', 'hydroxychloroquine 200 mg (Dolquine®) tablets', 'Santa Creu', 'hydroxychloroquine', 'personal protection equipment (PPE', 'hydroxychloroquine or non-PrEP control group', 'placebo']","['number of confirmed cases of a COVID-19 (defined by a positive PCR for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion', 'SARS-CoV-2 seroconversion']","[{'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C4517650', 'cui_str': '220'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517777', 'cui_str': '440'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0005507', 'cui_str': 'Bioassay'}, {'cui': 'C0205473', 'cui_str': 'Serologic'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0456962', 'cui_str': 'Rapid'}, {'cui': 'C0430022', 'cui_str': 'Diagnostic procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0003451', 'cui_str': 'Antiviral'}, {'cui': 'C0599685', 'cui_str': 'Antiretroviral-containing product'}, {'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008269', 'cui_str': 'Chloroquine'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0522473', 'cui_str': 'Contraindication to'}, {'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C1615608', 'cui_str': 'Pandemics'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}]","[{'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0039225', 'cui_str': 'Tablet'}, {'cui': 'C0014672', 'cui_str': 'Equipment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0332290', 'cui_str': 'Consistent with'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}]",440.0,0.362036,"Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to current hospital guidelines. ","[{'ForeName': 'Berta', 'Initials': 'B', 'LastName': 'Grau-Pujol', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain. berta.grau@isglobal.org.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Camprubí', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Helena', 'Initials': 'H', 'LastName': 'Marti-Soler', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Fernández-Pardos', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Guinovart', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Muñoz', 'Affiliation': 'Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.'}]",Trials,['10.1186/s13063-020-04621-7'] 2756,32727748,Is Low Inferior Mesenteric Artery Ligation Worthwhile to Prevent Urinary and Sexual Dysfunction After Total Mesorectal Excision for Rectal Cancer?,"BACKGROUND/AIM We studied the role of high or low inferior mesenteric artery (IMA) tie on defecatory, sexual and urinary dysfunctions in patients who underwent laparoscopic TME for early rectal cancer. PATIENTS AND METHODS Forty-six consecutive patients undergoing curative laparoscopic resection for pT2N0M0, rectal adenocarcinoma from February 2013 to March 2019 were enrolled into this prospective randomized open label parallel trial to have a laparoscopic TME with a high (Group 1) or low IMA ligation (Group 2). Demographic data and information on symptoms and comorbidity, intra- and post-operative outcomes and defecatory, sexual and urinary functions before and after surgery according to the validated International quality of life questionnaires. RESULTS A significant difference in postoperative total score of FIQL scale, Jorge-Wexner incontinence score and Agachan-Wexner constipation score were observed between the high and low tie groups at 1, 6, and 12 months after surgery. ICIQ-UI short form, FSFI, and IIEF demonstrated at 1, 6 and 12 months, the scores were significantly higher for patients of Group 1 as compared to those of Group 2. CONCLUSION A low IMA ligation permits a better fecal continence, less abdominal pain, and less genito-urinary and sexual dysfunctions in patients submitted to TME for rectal cancer.",2020,"A significant difference in postoperative total score of FIQL scale, Jorge-Wexner incontinence score and Agachan-Wexner constipation score were observed between the high and low tie groups at 1, 6, and 12 months after surgery.","['for pT2N0M0, rectal adenocarcinoma from February 2013 to March 2019', 'patients who underwent', 'Forty-six consecutive patients undergoing', 'for early rectal cancer', 'patients submitted to TME for rectal cancer']","['laparoscopic TME with a high (Group 1) or low IMA ligation', 'laparoscopic TME', 'Total Mesorectal Excision', 'high or low inferior mesenteric artery (IMA) tie', 'curative laparoscopic resection']","['fecal continence, less abdominal pain', 'Urinary and Sexual Dysfunction', 'genito-urinary and sexual dysfunctions', 'postoperative total score of FIQL scale, Jorge-Wexner incontinence score and Agachan-Wexner constipation score', 'ICIQ-UI short form, FSFI, and IIEF', 'Demographic data and information on symptoms and comorbidity, intra- and post-operative outcomes and defecatory, sexual and urinary functions']","[{'cui': 'C0149978', 'cui_str': 'Adenocarcinoma of rectum'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}]","[{'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C1273428', 'cui_str': 'Total mesorectal excision'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0162860', 'cui_str': 'Structure of inferior mesenteric artery'}, {'cui': 'C0023690', 'cui_str': 'Ligation'}, {'cui': 'C0453920', 'cui_str': 'Tie'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0015252', 'cui_str': 'Removal'}]","[{'cui': 'C0429956', 'cui_str': 'Bowels: fully continent'}, {'cui': 'C0000737', 'cui_str': 'Abdominal pain'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0042034', 'cui_str': 'Micturition'}]",46.0,0.0291762,"A significant difference in postoperative total score of FIQL scale, Jorge-Wexner incontinence score and Agachan-Wexner constipation score were observed between the high and low tie groups at 1, 6, and 12 months after surgery.","[{'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Fiori', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Crocetti', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy danielecrocetti@hotmail.it.'}, {'ForeName': 'Antonietta', 'Initials': 'A', 'LastName': 'Lamazza', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'DE Felice', 'Affiliation': 'Department of Radiology, Radiotherapy, Oncology and Pathology, ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Antonio V', 'Initials': 'AV', 'LastName': 'Sterpetti', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Irace', 'Affiliation': 'Department of Surgery ""Paride Stefanini"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Mingoli', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Sapienza', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'DE Toma', 'Affiliation': 'Department of Surgery ""Pietro Valdoni"", ""Sapienza"" University of Rome, Rome, Italy.'}]",Anticancer research,['10.21873/anticanres.14423'] 2757,32727752,Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study.,"BACKGROUND/AIM A prospective non-randomized study was performed on 68 women who had recently undergone curative treatment (surgery +/- adjuvant radio/chemotherapy) for breast cancer. PATIENTS AND METHODS Patients were distributed into 2 subgroups, control (C) group (n=21) and experimental (E) group (n=47). The last group participated in a 12-week rehabilitation program associating physical activity and psychoeducational workshops, including management of stress, diet, and sleep disorders. RESULTS Despite the initial imbalance between the groups (patients from C group were older and had received less chemotherapy than those from the E group), at the end of the rehabilitation program, we observed a significant improvement in global health feeling and in objective physical tests (distance covered in 6 min and objective measures of ergospirometry), and a decrease in pathological fatigue, while these different items remained quite stable over time in the control group. CONCLUSION It is suggested to recommend structured rehabilitation to any patient who does not have a contraindication to it. In addition, the scientific literature encourages us to extend the spectrum of oncological rehabilitation to pathologies other than breast cancer.",2020,"Despite the initial imbalance between the groups (patients from C group were older and had received less chemotherapy than those from the E group), at the end of the rehabilitation program, we observed a significant improvement in global health feeling and in objective physical tests (distance covered in 6 min and objective measures of ergospirometry), and a decrease in pathological fatigue, while these different items remained quite stable over time in the control group. ","['Early Breast Cancer', 'breast cancer', 'Patients were distributed into 2 subgroups, control (C) group (n=21) and experimental (E) group (n=47', '68 women who had recently undergone curative treatment (surgery ', 'Women']","['Physical Exercise and Lifestyle Accompaniment', 'adjuvant radio/chemotherapy', 'rehabilitation program associating physical activity and psychoeducational workshops']","['pathological fatigue', 'global health feeling and in objective physical tests (distance covered in 6 min and objective measures of ergospirometry']","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0034546', 'cui_str': 'Radio'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation therapy'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}]","[{'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0439844', 'cui_str': 'Covered'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C3805144', 'cui_str': 'Ergospirometry'}]",68.0,0.012646,"Despite the initial imbalance between the groups (patients from C group were older and had received less chemotherapy than those from the E group), at the end of the rehabilitation program, we observed a significant improvement in global health feeling and in objective physical tests (distance covered in 6 min and objective measures of ergospirometry), and a decrease in pathological fatigue, while these different items remained quite stable over time in the control group. ","[{'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Marechal', 'Affiliation': 'Oncology Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Marie-Pascale', 'Initials': 'MP', 'LastName': 'Graas', 'Affiliation': 'Oncology Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Ludivine', 'Initials': 'L', 'LastName': 'Collard', 'Affiliation': 'Oncology Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Morgan', 'Initials': 'M', 'LastName': 'Collin', 'Affiliation': 'Oncology Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Raskin', 'Affiliation': 'Physiotherapy Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Geoffrey', 'Initials': 'G', 'LastName': 'Brands', 'Affiliation': 'Physiotherapy Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Evrard', 'Affiliation': 'Cardiology Department, Groupe Santé CHC, Liège, Belgium.'}, {'ForeName': 'Jean-Pierre', 'Initials': 'JP', 'LastName': 'Lobelle', 'Affiliation': 'Statistics Office, Beernem, Belgium.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Focan', 'Affiliation': 'Oncology Department, Groupe Santé CHC, Liège, Belgium christian.focan@chc.be.'}]",Anticancer research,['10.21873/anticanres.14427'] 2758,32727835,Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.,"OBJECTIVE The phase IIIb VELOCE study (NCT02545868) assessed responses to selected vaccines in ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis. METHODS Patients were randomized 2:1 into Group OCR (n=68; OCR 600mg); or Control (n=34; interferon-β or no disease-modifying therapy). All received tetanus toxoid (TT)-containing vaccine, Pneumovax® (23-PPV) and keyhole limpet hemocyanin (KLH). Group OCR was subdivided into OCR1 (n=33) and OCR2 (n=35) at randomization. OCR1 received Prevnar® (13-PCV) 4 weeks after 23-PPV; OCR2 and Control received influenza vaccine. Vaccinations started 12 weeks after OCR initiation (Group OCR) or on Day 1 (Control). RESULTS Positive response rate to TT vaccine at 8 weeks was 23.9% in OCR vs 54.5% in Control. Positive response rate to ≥5 serotypes in 23-PPV at 4 weeks was 71.6% in OCR and 100% in Control. Prevnar® did not enhance response to pneumococcal serotypes in common with Pneumovax®. Humoral response to KLH was decreased in OCR vs Control. Seroprotection rates at 4 weeks against five influenza strains ranged from 55.6-80.0% in OCR2 and 75.0-97.0% in Control. CONCLUSION Peripherally B-cell depleted OCR recipients mounted attenuated humoral responses to clinically relevant vaccines and the neoantigen, KLH, suggesting use of standard non-live vaccines while on OCR treatment remains a consideration. For seasonal influenza vaccines, it is recommended to vaccinate patients on OCR, as a potentially protective humoral response, even if attenuated, can be expected. CLASSIFICATION OF EVIDENCE This study provides Class II evidence confirming that the humoral response to non-live vaccines in patients with RMS following ocrelizumab treatment is attenuated compared with untreated or interferon-β-treated patients, though can still be expected to be protective. CLINICALTRIALSGOV REGISTRY NUMBER NCT02545868.",2020,"RESULTS Positive response rate to TT vaccine at 8 weeks was 23.9% in OCR vs 54.5% in Control.","['patients with multiple sclerosis', 'Patients were randomized 2:1 into Group OCR (n=68', 'ocrelizumab (OCR)-treated patients with relapsing multiple sclerosis']","['interferon-β or no disease-modifying therapy', 'tetanus toxoid (TT)-containing vaccine, Pneumovax® (23-PPV) and keyhole limpet hemocyanin (KLH', 'TT vaccine', 'influenza vaccine', 'OCR2', 'ocrelizumab', 'interferon-β-treated', 'OCR1 received Prevnar® (13-PCV']","['Humoral response to KLH', 'Seroprotection rates', 'Positive response rate', 'vaccine responses']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}]","[{'cui': 'C0021747', 'cui_str': 'Interferon'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039620', 'cui_str': 'Tetanus vaccine'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0071315', 'cui_str': 'Pneumovax'}, {'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C0305062', 'cui_str': 'tetanus toxoid vaccine, inactivated'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}, {'cui': 'C1882138', 'cui_str': 'ocrelizumab'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0876134', 'cui_str': 'Prevnar'}, {'cui': 'C0018935', 'cui_str': 'Hematocrit determination'}]","[{'cui': 'C0064332', 'cui_str': 'Keyhole-limpet hemocyanin'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}]",,0.0381286,"RESULTS Positive response rate to TT vaccine at 8 weeks was 23.9% in OCR vs 54.5% in Control.","[{'ForeName': 'Amit', 'Initials': 'A', 'LastName': 'Bar-Or', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA amitbar@pennmedicine.upenn.edu.'}, {'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Calkwood', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Cathy', 'Initials': 'C', 'LastName': 'Chognot', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'Evershed', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Edward J', 'Initials': 'EJ', 'LastName': 'Fox', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Ann', 'Initials': 'A', 'LastName': 'Herman', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Manfrini', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'McNamara', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Derrick S', 'Initials': 'DS', 'LastName': 'Robertson', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Stokmaier', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Jeanette K', 'Initials': 'JK', 'LastName': 'Wendt', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Kevin L', 'Initials': 'KL', 'LastName': 'Winthrop', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Traboulsee', 'Affiliation': 'Amit Bar-Or, Perelman School of Medicine, University of Pennsylvania, Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics, Philadelphia, PA, USA.'}]",Neurology,['10.1212/WNL.0000000000010380'] 2759,32727938,"Immunogenicity and Safety of Typhoid Conjugate Vaccine in Healthy Indian Subjects: A Randomized, Active-controlled, Comparative Clinical Trial.","OBJECTIVE To compare the immunogenicity and safety of an investigational typhoid Vi conjugate vaccine (Test TCV) with a marketed typhoid Vi conjugate vaccine (Comparator TCV). DESIGN Randomized, controlled trial. SETTING Tertiary care and multispecialty hospitals. PARTICIPANTS 240 healthy subjects of 6 months to 45 years. Pediatric (<18 years) subjects were enrolled after day 21 safety assessment of adult subjects. INTERVENTION Participants received a single-dose of test TCV or comparator TCV at baseline and were followed up for 6 weeks post-vaccination. MAIN OUTCOME MEASURE Primary variable was to demonstrate non-inferiority of the test TCV with the comparator TCV for seroconversion post-vaccination (³4-fold rise in antibody titre). Secondary variables were seroconversion in the adult and pediatric cohorts, and geometric mean titre of antibodies while the safety was based on reported adverse events. RESULTS A total of 117 subjects (Adult-58, Pediatric-59) and 119 subjects (Adult-60, Pediatric-59) in test and comparator group, respectively completed the study. The seroconversion rate with test TCV (overall-94.8%, adult-96.6% and pediatric-93.1%) was non-inferior to comparator TCV (overall-91.6%, adult-91.7% and pediatric-91.5%). The geometric mean titres of antibodies (EU/mL) at baseline (test TCV: overall-7.6, adult-10.0, and pediatric-5.7; and comparator TCV: overall-8.0, adult-12.0, and pediatric-5.3) and at end of study (test TCV: overall-1121.0, adult-1411.0 and pediatric-891.1; and comparator TCV: overall-1104.0, adult-1199.0 and pediatric-1014.0) were also comparable between the groups (P>0.05 for all). The most common adverse event was injection-site pain followed by fever in both the groups. CONCLUSIONS The immunogenicity and safety of test TCV is comparable to already marketed comparator TCV.",2020,"The seroconversion rate with test TCV (overall-94.8%, adult-96.6% and pediatric-93.1%) was non-inferior to comparator TCV (overall-91.6%, adult-91.7% and pediatric-91.5%).","['240 healthy subjects of 6 months to 45 years', 'Pediatric (<18 years) subjects were enrolled after day 21 safety assessment of adult subjects', 'Tertiary care and multispecialty hospitals', '117 subjects (Adult-58, Pediatric-59) and 119 subjects (Adult-60, Pediatric-59) in test and comparator group, respectively completed the study', 'Healthy Indian Subjects']","['investigational typhoid Vi conjugate vaccine (Test TCV', 'typhoid Vi conjugate vaccine (Comparator TCV', 'Typhoid Conjugate Vaccine', 'TCV or comparator TCV', 'TCV']","['immunogenicity and safety', 'Immunogenicity and Safety', 'seroconversion rate with test TCV', 'geometric mean titres of antibodies (EU/mL']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3494403', 'cui_str': 'Tertiary Care'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002460', 'cui_str': 'American Indian race'}]","[{'cui': 'C0041466', 'cui_str': 'Typhoid fever'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C1532292', 'cui_str': 'Ehrlich units/milliliter'}]",240.0,0.362144,"The seroconversion rate with test TCV (overall-94.8%, adult-96.6% and pediatric-93.1%) was non-inferior to comparator TCV (overall-91.6%, adult-91.7% and pediatric-91.5%).","[{'ForeName': 'Ritabrata', 'Initials': 'R', 'LastName': 'Kundu', 'Affiliation': 'Department of Pediatrics, Institute of Child Health, Kolkata, West Bengal, India.'}, {'ForeName': 'Ambrose Kumar', 'Initials': 'AK', 'LastName': 'Kandulna', 'Affiliation': 'GCS Medical College, Hospital and Research Centre, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Uma', 'Initials': 'U', 'LastName': 'Nayak', 'Affiliation': 'GMERS Medical College and General Hospital, Vadodara, Gujarat, India.'}, {'ForeName': 'Sanjay Kumar', 'Initials': 'SK', 'LastName': 'Jangid', 'Affiliation': 'Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India.'}, {'ForeName': 'T Ramesh', 'Initials': 'TR', 'LastName': 'Babu', 'Affiliation': 'Gandhi Medical College and Hospital, Secunderabad, Telangana, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Vukkala', 'Affiliation': 'Indo-US Superspeciality Hospital, Hyderabad, Telangana, India.'}, {'ForeName': 'Shrikant', 'Initials': 'S', 'LastName': 'Sharma', 'Affiliation': 'SMS Medical College and Hospital, Jaipur, Rajasthan, India.'}, {'ForeName': 'Vimal Kant', 'Initials': 'VK', 'LastName': 'Goyal', 'Affiliation': 'Panchsheel Hospital Pvt Ltd, New Delhi, India.'}, {'ForeName': 'Pavankumar', 'Initials': 'P', 'LastName': 'Daultani', 'Affiliation': 'Department of New Product Development, Cadila Healthcare Ltd, Ahmedabad, Gujarat, India. Correspondence to: Dr Pavankumar Daultani, Senior Manager, Department of New Product Development, Cadila Healthcare Ltd., Sigma CommerZone, Opp. ISCON Temple BRTS Stand, Near Satellite Cross Roads, Ambli-Bopal Road, Ahmedabad 380 015, Gujarat, India. drpavandaultani@gmail.com.'}, {'ForeName': 'Ravindra', 'Initials': 'R', 'LastName': 'Mittal', 'Affiliation': 'Department of New Product Development, Cadila Healthcare Ltd, Ahmedabad, Gujarat, India.'}, {'ForeName': 'Pradip', 'Initials': 'P', 'LastName': 'Patel', 'Affiliation': 'Vaccine Manufacturing, Cadila Healthcare Ltd, Ahmedabad, Gujarat, India.'}]",Indian pediatrics,[] 2760,32727947,Response to Journal Club: Cluster Randomized Trial Evaluating Impact of a Community-based Microfinance Scheme on Childhood Nutritional Status: Evidence-based Medicine Viewpoint.,,2020,,[],['Community-based Microfinance Scheme'],[],[],"[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",[],,0.0397567,,"[{'ForeName': 'Shalini', 'Initials': 'S', 'LastName': 'Ojha', 'Affiliation': 'Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Alan R', 'Initials': 'AR', 'LastName': 'Smyth', 'Affiliation': 'Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK. smyth@nottingham.ac.uk.'}]",Indian pediatrics,[] 2761,32727948,Response to Journal Club: Cluster Randomized Trial Evaluating Impact of a Community-based Microfinance Scheme on Childhood Nutritional Status: Evidence-based Medicine Viewpoint: Author's Reply.,,2020,,['Childhood Nutritional Status'],['Community-based Microfinance Scheme'],[],"[{'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0392209', 'cui_str': 'Nutritional status'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]",[],,0.0345605,,"[{'ForeName': 'Joseph L', 'Initials': 'JL', 'LastName': 'Mathew', 'Affiliation': 'Advanced Pediatrics Centre, PGIMER, Chandigarh, India. dr.joseph.l.mathew@gmail.com.'}]",Indian pediatrics,[] 2762,32732587,Fixation using Alternative Implants for the Treatment of Hip Fractures (FAITH-2): The Clinical Outcomes of a Multi-Centre 2x2 Factorial Randomized Controlled Pilot Trial in Young Femoral Neck Fracture Patients.,"OBJECTIVE To assess whether fixation method and vitamin D supplementation impact the risk of patient important outcomes within 12 months of injury in non-geriatric femoral neck fracture patients. DESIGN Pilot factorial randomized controlled trial. SETTING 15 North American clinical sites. PARTICIPANTS 91 adults aged 18-60 years with a femoral neck fracture requiring surgical fixation. INTERVENTION Participants were randomized to a surgical intervention (sliding hip screw or cancellous screws) and a vitamin D intervention (vitamin D3 4,000 IU daily versus placebo for 6 months). MAIN OUTCOME MEASUREMENTS The primary clinical outcome was a composite of patient important complications (re-operation, femoral head osteonecrosis, severe femoral neck malunion, nonunion). Secondary outcomes included fracture healing complications and radiographic fracture healing. RESULTS 86 participants with a mean age of 41 years were included. We found no statistically significant difference in the risk of patient important outcomes between the surgical treatment arms (hazard ratio (HR) 0.90, 95% CI 0.40-2.02, p=0.80) and vitamin D supplementation treatment arms (HR 0.96, 95% CI 0.42- 2.18, p=0.92). CONCLUSIONS These pilot trial results continue to describe the results of current fixation implants, inform the challenges of improving outcomes in this fracture population, and may guide future vitamin D trials to improve healing outcomes in young fracture populations. Although the pilot trial was not adequately powered to detect treatment effects, publishing these results may facilitate future meta-analyses on this topic. LEVEL OF EVIDENCE Therapeutic Level II.",2020,"We found no statistically significant difference in the risk of patient important outcomes between the surgical treatment arms (hazard ratio (HR) 0.90, 95% CI 0.40-2.02, p=0.80) and vitamin D supplementation treatment arms (HR 0.96, 95% CI 0.42- 2.18, p=0.92). ","['15 North American clinical sites', '91 adults aged 18-60 years with a femoral neck fracture requiring surgical fixation', 'Young Femoral Neck Fracture Patients', '86 participants with a mean age of 41 years were included', 'young fracture populations', '12 months of injury in non-geriatric femoral neck fracture patients', 'Hip Fractures (FAITH-2']","['surgical intervention (sliding hip screw or cancellous screws) and a vitamin D intervention (vitamin D3 4,000 IU daily versus placebo', 'fixation method and vitamin D supplementation', 'Fixation using Alternative Implants']","['composite of patient important complications (re-operation, femoral head osteonecrosis, severe femoral neck malunion, nonunion', 'healing outcomes', 'risk of patient important outcomes', 'fracture healing complications and radiographic fracture healing']","[{'cui': 'C0425358', 'cui_str': 'North American origin'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0015806', 'cui_str': 'Fracture of neck of femur'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0016658', 'cui_str': 'Fracture'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0019557', 'cui_str': 'Hip fracture'}]","[{'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0332246', 'cui_str': 'Sliding'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0005975', 'cui_str': 'Bone screw'}, {'cui': 'C0310589', 'cui_str': 'Vitamin A- and vitamin D-containing product'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008318', 'cui_str': 'Cholecalciferol'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4524013', 'cui_str': 'Vitamin D supplementation'}, {'cui': 'C0021102', 'cui_str': 'Implant'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0015813', 'cui_str': 'Structure of head of femur'}, {'cui': 'C0029445', 'cui_str': 'Bone necrosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0015815', 'cui_str': 'Structure of neck of femur'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0152231', 'cui_str': 'Fracture, healed'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}]",91.0,0.184045,"We found no statistically significant difference in the risk of patient important outcomes between the surgical treatment arms (hazard ratio (HR) 0.90, 95% CI 0.40-2.02, p=0.80) and vitamin D supplementation treatment arms (HR 0.96, 95% CI 0.42- 2.18, p=0.92). ","[{'ForeName': 'Writing Committee', 'Initials': 'WC', 'LastName': 'Gerard P Slobogean', 'Affiliation': 'R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland, 21201, USA.'}, {'ForeName': 'Sheila', 'Initials': 'S', 'LastName': 'Sprague', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.'}, {'ForeName': 'Sofia', 'Initials': 'S', 'LastName': 'Bzovsky', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.'}, {'ForeName': 'Taryn', 'Initials': 'T', 'LastName': 'Scott', 'Affiliation': 'Division of Orthopaedic Surgery, Department of Surgery, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.'}, {'ForeName': 'Lehana', 'Initials': 'L', 'LastName': 'Thabane', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Heels-Ansdell', 'Affiliation': 'Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.'}, {'ForeName': 'Robert V', 'Initials': 'RV', 'LastName': ""O'Toole"", 'Affiliation': 'R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland, 21201, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Howe', 'Affiliation': 'R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland, 21201, USA.'}, {'ForeName': 'Greg E', 'Initials': 'GE', 'LastName': 'Gaski', 'Affiliation': 'Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA.'}, {'ForeName': 'Lauren C', 'Initials': 'LC', 'LastName': 'Hill', 'Affiliation': 'Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA.'}, {'ForeName': 'Krista M', 'Initials': 'KM', 'LastName': 'Brown', 'Affiliation': 'Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, Indiana, 46202, USA.'}, {'ForeName': 'Darius', 'Initials': 'D', 'LastName': 'Viskontas', 'Affiliation': 'Department of Orthopaedics, University of British Columbia, New Westminster, British Columbia, V6T 1Z4, Canada.'}, {'ForeName': 'Mauri', 'Initials': 'M', 'LastName': 'Zomar', 'Affiliation': 'Division of Orthopaedics, Fraser Health Authority, New Westminster, British Columbia, V3L 3W2.'}, {'ForeName': 'Gregory J', 'Initials': 'GJ', 'LastName': 'Della Rocca', 'Affiliation': 'Department of Orthopaedic Surgery, University of Missouri, Columbia, Missouri, 65212, USA.'}, {'ForeName': 'Nathan N', 'Initials': 'NN', 'LastName': ""O'Hara"", 'Affiliation': 'R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland, 21201, USA.'}, {'ForeName': 'Mohit', 'Initials': 'M', 'LastName': 'Bhandari', 'Affiliation': 'R Adams Cowley Shock Trauma Center, Department of Orthopaedics, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, Maryland, 21201, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of orthopaedic trauma,['10.1097/BOT.0000000000001773'] 2763,32732620,Impaired Vagal Efficiency Predicts Auricular Neurostimulation Response in Adolescent Functional Abdominal Pain Disorders.,"INTRODUCTION To determine whether pretreatment vagal efficiency (VE), respiratory sinus arrhythmia, and heart period can predict pain improvement with auricular neurostimulation in pediatric functional abdominal pain disorders. METHODS A total of 92 adolescents with functional abdominal pain disorders underwent a 4-week randomized, double-blinded, sham-controlled auricular neurostimulation trial. Electrocardiogram-derived variables at baseline were used to predict pain using mixed effects modeling. RESULTS A 3-way interaction (95% confidence intervals: 0.004-0.494) showed that the treatment group subjects with low baseline VE had lower pain scores at week 3. There was no substantial change in the placebo or high VE treatment group subjects. This effect was supported by a significant correlation between baseline VE and degree of pain reduction only in the treatment group. DISCUSSION Impaired cardiac vagal regulation measured by VE predicts pain improvement with auricular neurostimulation.",2020,A 3-way interaction (95% confidence intervals: 0.004-0.494) showed that the treatment group subjects with low baseline VE had lower pain scores at week 3.,"['pediatric functional abdominal pain disorders', '92 adolescents with functional abdominal pain disorders', 'Adolescent Functional Abdominal Pain Disorders']",['placebo'],"['pain scores', 'Impaired cardiac vagal regulation', 'pain reduction']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C1609533', 'cui_str': 'Functional abdominal pain'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]",92.0,0.420766,A 3-way interaction (95% confidence intervals: 0.004-0.494) showed that the treatment group subjects with low baseline VE had lower pain scores at week 3.,"[{'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Kovacic', 'Affiliation': 'Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Kolacz', 'Affiliation': 'Socioneural Physiology Laboratory, Kinsey Institute, Indiana University, Bloomington, Indiana, USA.'}, {'ForeName': 'Gregory F', 'Initials': 'GF', 'LastName': 'Lewis', 'Affiliation': ''}, {'ForeName': 'Stephen W', 'Initials': 'SW', 'LastName': 'Porges', 'Affiliation': 'Traumatic Stress Research Consortium, Kinsey Institute, Indiana University, Bloomington, Indiana, USA.'}]",The American journal of gastroenterology,['10.14309/ajg.0000000000000753'] 2764,32732643,A Pilot Randomized Controlled Trial of a Text Message Intervention to Promote Help Seeking for Psychiatric Outpatients.,"Mental illness often affects and is affected by other diseases, such as cardiovascular disease, cancer, and AIDS/HIV infection, and people living with mental illness require additional common services and resource mobilization efforts. Therefore, we developed a mobile phone intervention and conducted a randomized controlled trial with 45 psychiatric outpatients with mental illnesses. Data from 39 individuals (intervention group: 20, control group: 19; mean [SD] age, 44.64 [14.12] years) were included in the analyses. The intervention involved the promotion of help-seeking behaviors by sending text messages, including information about social welfare services, for 3 months. After the intervention period, no significant differences were found in the proportion of help-seeking behaviors between the intervention and control groups. However, concerning the reason for not using social services, the proportion of participants who answered ""I do not know how to use it"" in the intervention group was significantly lower compared to the control group. More than 80% of participants in the intervention group reported that the text messaging service was helpful and useful, and they wanted more messages and information. This was the first randomized controlled trial to promote psychiatric patients' help-seeking behavior using text messaging. Moreover, the text messaging intervention was found to be cost-effective.",2020,"After the intervention period, no significant differences were found in the proportion of help-seeking behaviors between the intervention and control groups.","['Psychiatric Outpatients', '39 individuals (intervention group: 20, control group: 19; mean [SD] age, 44.64', '45 psychiatric outpatients with mental illnesses']","['mobile phone intervention', 'Text Message Intervention']","['proportion of help-seeking behaviors', 'text messaging service']","[{'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]","[{'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}]","[{'cui': 'C0683301', 'cui_str': 'Help-Seeking Behavior'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C0557854', 'cui_str': 'Services'}]",45.0,0.106481,"After the intervention period, no significant differences were found in the proportion of help-seeking behaviors between the intervention and control groups.","[{'ForeName': 'Toyohiko', 'Initials': 'T', 'LastName': 'Kodama', 'Affiliation': 'Author Affiliations: School of Health Sciences, University of Occupational and Environmental Health (Dr Kodama); Mie University Graduate School of Medicine (Drs Tamura, Komori, Kataoka); School of Nursing, Gifu Kyoritsu University (Dr Igura); and Kobe University Graduate School of Health Sciences, (Dr Hashimoto), Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Tamura', 'Affiliation': ''}, {'ForeName': 'Teruhisa', 'Initials': 'T', 'LastName': 'Komori', 'Affiliation': ''}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Kataoka', 'Affiliation': ''}, {'ForeName': 'Kazumasa', 'Initials': 'K', 'LastName': 'Igura', 'Affiliation': ''}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Hashimoto', 'Affiliation': ''}]","Computers, informatics, nursing : CIN",['10.1097/CIN.0000000000000636'] 2765,32732684,Feasibility and Acceptability of Mobile Phone Self-monitoring and Automated Feedback to Enhance Telephone Coaching for People with Risky Substance Use: The QUIT-Mobile Pilot Study.,"OBJECTIVES This study evaluates the feasibility, acceptability, and perceived benefits of mobile-phone delivered self-monitoring queries and feedback integrated into the evidence-based Quit Using Drugs Intervention Trial (QUIT) screening and brief telephone health coaching intervention to prevent progression from risky drug use to addiction as the QUIT-Mobile intervention. METHODS Participants (n = 20) were primarily Black/African American and Latino men in Los Angeles with risky substance use. Self-monitoring surveys were sent by text-message twice-weekly for 6 weeks and once-weekly from 6 to 12-weeks. Surveys consisted of 10 questions regarding drug and alcohol use (ie, # days of use) and cravings, quality of life, and medication adherence. Feedback messages praised or encouraged drug use reductions. Coaches monitored patient responses and discussed them in QUIT's telephone coaching sessions. Participants' experiences were assessed qualitatively at 3-month follow-up. RESULTS Nineteen out of 20 participants that completed the qualitative evaluation from the 12-week follow-up reported: (1) self-monitoring surveys helped them adhere to drug use reduction goals and reflect on associations between self-monitoring domains; (2) preference for higher frequency (twice-weekly) self-monitoring during the 6-week coaching period, and then weekly surveys thereafter but not monthly; and (3) self-monitoring and coaching were mutually reinforcing for their drug use reduction goals. CONCLUSIONS Results are consistent with prior similar research suggesting that mobile phone self-monitoring of drug use and related factors is feasible and acceptable among diverse adults with risky drug use. Findings also suggest the potential benefits of integrating electronic self-monitoring and feedback into substance use reduction interventions such as QUIT to enhance patient self-management and coaching or counseling intervention components.",2020,"CONCLUSIONS Results are consistent with prior similar research suggesting that mobile phone self-monitoring of drug use and related factors is feasible and acceptable among diverse adults with risky drug use.","['Nineteen out of 20 participants', 'Participants (n\u200a=\u200a20) were primarily Black/African American and Latino men in Los Angeles with risky substance use', 'People with Risky Substance Use']","['self-monitoring and coaching were mutually reinforcing for their drug use reduction goals', 'mobile-phone delivered self-monitoring queries and feedback integrated into the evidence-based Quit Using Drugs Intervention Trial (QUIT) screening and brief telephone health coaching intervention', 'Mobile Phone Self-monitoring and Automated Feedback to Enhance Telephone Coaching']","['cravings, quality of life, and medication adherence']","[{'cui': 'C0450337', 'cui_str': '19'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0588436', 'cui_str': 'Self monitoring'}, {'cui': 'C0449889', 'cui_str': 'Drug used'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C1136360', 'cui_str': 'Car Phone'}, {'cui': 'C3543841', 'cui_str': 'Query'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205554', 'cui_str': 'Automated'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}]",20.0,0.0221036,"CONCLUSIONS Results are consistent with prior similar research suggesting that mobile phone self-monitoring of drug use and related factors is feasible and acceptable among diverse adults with risky drug use.","[{'ForeName': 'Dallas', 'Initials': 'D', 'LastName': 'Swendeman', 'Affiliation': 'Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA (DS, SS, WSC); Department of Family Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA (EG, LG); Department of Epidemiology, School of Public Health, University of California, Los Angeles, California (PMG, DS).'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Sumstine', 'Affiliation': ''}, {'ForeName': 'Efren', 'Initials': 'E', 'LastName': 'Aguilar', 'Affiliation': ''}, {'ForeName': 'Pamina M', 'Initials': 'PM', 'LastName': 'Gorbach', 'Affiliation': ''}, {'ForeName': 'W Scott', 'Initials': 'WS', 'LastName': 'Comulada', 'Affiliation': ''}, {'ForeName': 'Lillian', 'Initials': 'L', 'LastName': 'Gelberg', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000707'] 2766,32733255,"Tolerability, Safety, Pharmacokinetics and Drug Interaction of Cefotaxime Sodium-Tazobactam Sodium Injection (6:1) Following Single and Multiple Intravenous Doses in Chinese Healthy Subjects.","Purpose To evaluate the tolerability, safety, pharmacokinetics and drug interaction of cefotaxime sodium-tazobactam sodium injection (6:1) in Chinese healthy subjects. The results of the safety and pharmacokinetic studies supported further clinical trials. Method A randomized, single-blind, ascending dose, placebo-controlled, single-center study was conducted. Sixty healthy subjects (38 males, 22 females) participated in this study. For the single-dose part, 0.47, 1.17, 2.34, 3.51, and 4.68 g of cefotaxime sodium-tazobactam sodium injection (6:1) was administered. For the multiple-dose part, the subjects were administered 2.34 and 3.51 g cefotaxime sodium-tazobactam sodium injection (6:1) three times a day for 7 consecutive days. For the drug interaction part, the subjects received 2.0 g cefotaxime sodium and 0.34 g tazobactam sodium alone and in combination. Results Most adverse events and adverse drug reactions were mild. Moderate rash was considered a serious adverse event because of prolongation of hospitalization. The main pharmacokinetic parameters of cefotaxime and tazobactam had no significance difference between the 1.17, 2.34, and 3.51 g dose cohorts and between genders. There was no difference in trough concentrations on days 6, 7, and 8. The R C max and R AUC were (0.921 ± 0.070) and (0.877 ± 0.057) for cefotaxime, and (0.913 ± 0.046) and (0.853 ± 0.060) for tazobactam, respectively. Following the administration of cefotaxime and tazobactam alone and in combination, the 90% confidence intervals of the geometric mean ratios for C max and AUC were within the predetermined range of 80-125%. In the single-dose part, the renal cumulative excretion ratios were (51.7 ± 6.2)% for cefotaxime, and (84.3 ± 8.1)% for tazobactam. There was no significant difference in the maximum excretion rates and cumulative excretion ratios for cefotaxime and tazobactam, alone or in combination. Conclusions Cefotaxime sodium-tazobactam sodium injection (6:1) was well-tolerated at doses of 0.47 to 4.68 g. The pharmacokinetics of cefotaxime and tazobactam were reported as linear over a dose range of 1.17-3.51 g. Cefotaxime was partially excreted via urine, whereas tazobactam was mainly excreted via urine. There was no significant accumulation after administration over 7 consecutive days. The pharmacokinetics and excretion of cefotaxime and tazobactam were not affected by the co-administration of cefotaxime-tazobactam.",2020,The pharmacokinetics and excretion of cefotaxime and tazobactam were not affected by the co-administration of cefotaxime-tazobactam.,"['Chinese Healthy Subjects', 'Chinese healthy subjects', 'Sixty healthy subjects (38 males, 22 females) participated in this study']","['cefotaxime and tazobactam', 'cefotaxime-tazobactam', 'Cefotaxime Sodium-Tazobactam Sodium Injection (6:1', 'Cefotaxime sodium-tazobactam sodium injection', 'cefotaxime sodium and 0.34 g tazobactam sodium alone and in\xa0combination', 'tazobactam', 'cefotaxime sodium-tazobactam sodium injection', 'placebo']","['R C max and R AUC', 'maximum excretion rates and cumulative excretion ratios', 'geometric mean ratios for C max and AUC', 'Tolerability, Safety, Pharmacokinetics and Drug Interaction', 'Moderate rash', 'trough concentrations', 'pharmacokinetics and excretion of cefotaxime and tazobactam', 'tolerability, safety, pharmacokinetics and drug interaction', 'renal cumulative excretion ratios']","[{'cui': 'C0008120', 'cui_str': 'Chinese language'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0007554', 'cui_str': 'Cefotaxime'}, {'cui': 'C0075870', 'cui_str': 'tazobactam'}, {'cui': 'C0700445', 'cui_str': 'Cefotaxime sodium'}, {'cui': 'C0724700', 'cui_str': 'Tazobactam sodium'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0376690', 'cui_str': 'Area under the curve'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0678798', 'cui_str': 'Adverse drug interaction'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}, {'cui': 'C0444506', 'cui_str': 'Trough'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0007554', 'cui_str': 'Cefotaxime'}, {'cui': 'C0075870', 'cui_str': 'tazobactam'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}]",60.0,0.0268078,The pharmacokinetics and excretion of cefotaxime and tazobactam were not affected by the co-administration of cefotaxime-tazobactam.,"[{'ForeName': 'Ning', 'Initials': 'N', 'LastName': 'Chen', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Lu-Ning', 'Initials': 'LN', 'LastName': 'Sun', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Wen-Hui', 'Initials': 'WH', 'LastName': 'Hu', 'Affiliation': 'Department of Bioanalysis, Nanjing Clinical Tech. Laboratories Inc., Nanjing, China.'}, {'ForeName': 'Yi-Ya', 'Initials': 'YY', 'LastName': 'Wang', 'Affiliation': 'Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.'}, {'ForeName': 'Li-Jun', 'Initials': 'LJ', 'LastName': 'Xie', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Hong-Wen', 'Initials': 'HW', 'LastName': 'Zhang', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Yong-Qing', 'Initials': 'YQ', 'LastName': 'Wang', 'Affiliation': 'Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Ding', 'Affiliation': 'Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China.'}]",Frontiers in pharmacology,['10.3389/fphar.2020.01033'] 2767,32733285,Effects of Acute Exercise and Training on the Sarcoplasmic Reticulum Ca 2+ Release and Uptake Rates in Highly Trained Endurance Athletes.,"Little is presently known about the effects of acute high-intensity exercise or training on release and uptake of Ca 2+ by the sarcoplasmic reticulum (SR). The aims here were to characterize this regulation in highly trained athletes following (1) repeated bouts of high-intensity exercise and (2) a period of endurance training including high-intensity sessions. Eleven cross-country skiers (25 ± 4 years, 65 ± 4 mL O 2 ⋅kg -1 ⋅min -1 ) performed four self-paced sprint time-trials (STT 1-4) lasting ≈ 4 min each (STT 1-4) and separated by 45 min of recovery; while 19 triathletes and road cyclists (25 ± 4 years, 65 ± 5 mL O 2 ⋅kg -1 ⋅min -1 ) completed 4 weeks of endurance training in combination with three sessions of high-intensity interval cycling per week. Release (μmol⋅g -1 prot⋅min -1 ) and uptake [tau (s)] of Ca 2+ by SR vesicles isolated from m. triceps brachii and m. vastus lateralis were determined before and after STT 1 and 4 in the skiers and in m. vastus lateralis before and after the 4 weeks of training in the endurance athletes. The Ca 2+ release rate was reduced by 17-18% in both limbs already after STT 1 (arms: 2.52 ± 0.74 to 2.08 ± 0.60; legs: 2.41 ± 0.45 to 1.98 ± 0.51, P < 0.0001) and attenuated further following STT 4 (arms: 2.24 ± 0.67 to 1.95 ± 0.45; legs: 2.13 ± 0.51 to 1.83 ± 0.36, P < 0.0001). Also, there was a tendency toward an impairment in the SR Ca 2+ uptake from pre STT1 to post STT4 in both arms and legs (arms: from 22.0 ± 3.7 s to 25.3 ± 6.0 s; legs: from 22.5 ± 4.7 s to 25.5 ± 7.7 s, P = 0.05). Endurance training combined with high-intensity exercise increased the Ca 2+ release rate by 9% (1.76 ± 0.38 to 1.91 ± 0.44, P = 0.009), without altering the Ca 2+ uptake (29.6 ± 7.0 to 29.1 ± 8.7 s; P = 0.98). In conclusion, the Ca 2+ release and uptake rates by SR in exercising limbs of highly trained athletes declines gradually by repetitive bouts of high-intensity exercise. We also demonstrate, for the first time, that the SR Ca 2+ release rate can be enhanced by a specific program of training in highly trained athletes, which may have important implications for performance parameters.",2020,"Endurance training combined with high-intensity exercise increased the Ca 2+ release rate by 9% (1.76 ± 0.38 to 1.91 ± 0.44, P = 0.009), without altering the Ca 2+ uptake (29.6 ± 7.0 to 29.1 ± 8.7 s; P = 0.98).","['Highly Trained Endurance Athletes', 'highly trained athletes following (1']","['repeated bouts of high-intensity exercise and (2) a period of endurance training including high-intensity sessions', 'endurance training in combination with three sessions of high-intensity interval cycling per week', 'Acute Exercise and Training', 'Endurance training combined with high-intensity exercise']","['triceps brachii and m. vastus lateralis', 'Ca 2+ release and uptake rates', 'Ca 2+ release rate']","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C0231290', 'cui_str': 'Status post'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4704697', 'cui_str': 'Endurance Training'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C4279937', 'cui_str': 'Acute Exercise'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}]","[{'cui': 'C0596235', 'cui_str': 'Calcium ion'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}]",,0.047925,"Endurance training combined with high-intensity exercise increased the Ca 2+ release rate by 9% (1.76 ± 0.38 to 1.91 ± 0.44, P = 0.009), without altering the Ca 2+ uptake (29.6 ± 7.0 to 29.1 ± 8.7 s; P = 0.98).","[{'ForeName': 'Kasper Degn', 'Initials': 'KD', 'LastName': 'Gejl', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Erik P', 'Initials': 'EP', 'LastName': 'Andersson', 'Affiliation': 'Swedish Winter Sports Research Centre, Department of Health Sciences, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Nielsen', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}, {'ForeName': 'Hans-Christer', 'Initials': 'HC', 'LastName': 'Holmberg', 'Affiliation': 'Swedish Winter Sports Research Centre, Department of Health Sciences, Mid Sweden University, Östersund, Sweden.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Ørtenblad', 'Affiliation': 'Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, Odense, Denmark.'}]",Frontiers in physiology,['10.3389/fphys.2020.00810'] 2768,32733292,Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: A Pilot Randomized Clinical Trial.,"Introduction Cognitive deficits are a cause of functional disability in psychotic disorders. Cognitive remediation therapy (CRT) might be applied to improve these deficits. We conducted a pilot study to explore whether thyroid hormones might predict the response to CRT in patients with recent-onset psychosis (ROP). Methods Twenty-eight stable ROP outpatients (9 women) were randomized to receive computerized CRT (N=14) or treatment as usual (TAU) (N=14), over three months. Both cognitive and thyroid functions were assessed at the baseline and after those three months to all patients. A full cognitive battery (CANTAB) was administered before and after the treatment. Serum levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT4) were measured. FT4 concentrations were recoded into a dichotomic variable (FT4 group) based on the median of the sample (1.2 ng/dL). Data were analyzed on an intention-to-treat basis with linear mixed models. Afterwards, we offered CRT to all participants from the TAU group and seven enrolled CRT, reassessing them when finished. Secondary analyses were repeated in a sample of 14 participants who completed the CRT (either from the beginning or after the TAU period) and attended at least one third of the sessions. Results The linear mixed models showed a significant time x CRT x FT4 group effect in two cognitive tasks dealing with executive functions and sustained attention (participants with higher FT4 concentrations worsened executive functions but improved sustained attention after CRT). In the secondary analysis including all patients assigned to CRT, higher FT4 concentrations were associated with a poorer response in verbal memory but a better response in spatial working memory. Conclusions Free thyroxine concentrations moderate the response to a CRT in patients with early psychosis.",2020,The linear mixed models showed a significant time x CRT x FT4 group effect in two cognitive tasks dealing with executive functions and sustained attention (participants with higher FT4 concentrations worsened executive functions but improved sustained attention after CRT).,"['Methods\n\n\nTwenty-eight stable ROP outpatients (9 women', 'People With Early Psychosis', 'patients with recent-onset psychosis (ROP', 'patients with early psychosis']","['Cognitive Remediation Therapy', 'computerized CRT (N=14) or treatment as usual (TAU', 'Cognitive remediation therapy (CRT']","['verbal memory', 'Serum levels of thyroid-stimulating hormone (TSH) and free thyroxine (FT4', 'FT4 concentrations']","[{'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0332185', 'cui_str': 'Recent'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0033975', 'cui_str': 'Psychotic disorder'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040160', 'cui_str': 'Thyrotropin'}, {'cui': 'C0202225', 'cui_str': 'T4 free measurement'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",28.0,0.0890239,The linear mixed models showed a significant time x CRT x FT4 group effect in two cognitive tasks dealing with executive functions and sustained attention (participants with higher FT4 concentrations worsened executive functions but improved sustained attention after CRT).,"[{'ForeName': 'Francesc', 'Initials': 'F', 'LastName': 'Estrada', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Josep Maria', 'Initials': 'JM', 'LastName': 'Crosas', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Maribel', 'Initials': 'M', 'LastName': 'Ahuir', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Pérez-Muñoz', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Wanda', 'Initials': 'W', 'LastName': 'Zabala', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Aguayo', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Juan David', 'Initials': 'JD', 'LastName': 'Barbero', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Itziar', 'Initials': 'I', 'LastName': 'Montalvo', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Meritxell', 'Initials': 'M', 'LastName': 'Tost', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Llauradó', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Armand', 'Initials': 'A', 'LastName': 'Guardia', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Diego', 'Initials': 'D', 'LastName': 'Palao', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'José Antonio', 'Initials': 'JA', 'LastName': 'Monreal', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Labad', 'Affiliation': ""Department of Mental Health, Institut d'Investigació i Innovació Parc Taulí (I3PT), Parc Taulí Hospital Universitari, Sabadell, Spain.""}]",Frontiers in psychiatry,['10.3389/fpsyt.2020.00636'] 2769,32733303,Social Facebook With Big Six Approaches for Improved Students' Learning Performance and Behavior: A Case Study of a Project Innovation and Implementation Course.,"In Taiwan, classroom lectures are gradually shifting from traditional to diverse digital learning environments through social network websites. Facebook is being used to provide a space for sharing and discussing learning materials and knowledge for teachers and students. In this paper, we focus on the effects of applying Big Six approaches to Facebook on students' learning performance and behavior in a project innovation and implementation course. The participants were 72 first-year students in a college located in north Taiwan. The experimental participants who took the course were divided into two classes: the experimental group and the control group. While the experimental group used Facebook combined with Big Six approaches, the control group used traditional classroom tools combined with Big Six approaches. The experimental results show that the learning performance and creativity development of students from the experimental group are enhanced after using Facebook with Big Six approaches indicating a great social interaction and discussion cycle. On the other hand, students from the control group were only guided by the teacher. Owing to the lack of interactions between the Internet and the social learning community, there is no obvious enhancement in students' learning performance and creativity. In addition, we found that the teacher practiced the tips for guiding experimental students to solve the encountered problem, and then the students replied to the classmate's questions.",2020,The experimental results show that the learning performance and creativity development of students from the experimental group are enhanced after using Facebook with Big Six approaches indicating a great social interaction and discussion cycle.,"['participants were 72 first-year students in a college located in north Taiwan', ""Students' Learning Performance and Behavior""]","['Social Facebook With Big Six Approaches', 'Facebook']",[],"[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C0039260', 'cui_str': 'Taiwan'}, {'cui': 'C0582590', 'cui_str': 'Learning performance'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]","[{'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}]",[],72.0,0.0162935,The experimental results show that the learning performance and creativity development of students from the experimental group are enhanced after using Facebook with Big Six approaches indicating a great social interaction and discussion cycle.,"[{'ForeName': 'Yu-Sheng', 'Initials': 'YS', 'LastName': 'Su', 'Affiliation': 'Department of Computer Science and Engineering, National Taiwan Ocean University, Keelung City, Taiwan.'}, {'ForeName': 'Hong-Ren', 'Initials': 'HR', 'LastName': 'Chen', 'Affiliation': 'Department of Digital Content and Technology, National Taichung University of Education, Taichung City, Taiwan.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01166'] 2770,32734356,Evaluation of the Integrated Pulmonary Index® during non-anesthesiologist sedation for percutaneous endoscopic gastrostomy.,"Standard monitoring of heart rate, blood pressure and arterial oxygen saturation during endoscopy is recommended by current guidelines on procedural sedation. A number of studies indicated a reduction of hypoxic (art. oxygenation < 90% for > 15 s) and severe hypoxic events (art. oxygenation < 85%) by additional use of capnography. Therefore, U.S. and the European guidelines comment that additional capnography monitoring can be considered in long or deep sedation. Integrated Pulmonary Index® (IPI) is an algorithm-based monitoring parameter that combines oxygenation measured by pulse oximetry (art. oxygenation, heart rate) and ventilation measured by capnography (respiratory rate, apnea > 10 s, partial pressure of end-tidal carbon dioxide [PetCO 2 ]). The aim of this paper was to analyze the value of IPI as parameter to monitor the respiratory status in patients receiving propofol sedation during PEG-procedure. Patients reporting for PEG-placement under sedation were randomized 1:1 in either standard monitoring group (SM) or capnography monitoring group including IPI (IM). Heart rate, blood pressure and arterial oxygen saturation were monitored in SM. In IM additional monitoring was performed measuring PetCO 2 , respiratory rate and IPI. Capnography and IPI values were recorded for all patients but were only visible to the endoscopic team for the IM-group. IPI values range between 1 and 10 (10 = normal; 8-9 = within normal range; 7 = close to normal range, requires attention; 5-6 = requires attention and may require intervention; 3-4 = requires intervention; 1-2 requires immediate intervention). Results on capnography versus standard monitoring of the same study population was published previously. A total of 147 patients (74 in SM and 73 in IM) were included in the present study. Hypoxic events occurred in 62 patients (42%) and severe hypoxic events in 44 patients (29%), respectively. Baseline characteristics were equally distributed in both groups. IPI = 1, IPI < 7 as well as the parameters PetCO 2  = 0 mmHg and apnea > 10 s had a high sensitivity for hypoxic and severe hypoxic events, respectively (IPI = 1: 81%/81% [hypoxic/severe hypoxic event], IPI < 7: 82%/88%, PetCO 2 : 69%/68%, apnea > 10 s: 84%/84%). All four parameters had a low specificity for both hypoxic and severe hypoxic events (IPI = 1: 13%/12%, IPI < 7: 7%/7%, PetCO 2 : 29%/27%, apnea > 10 s: 7%/7%). In multivariate analysis, only SM and PetCO 2  = 0 mmHg were independent risk factors for hypoxia. IPI (IPI = 1 and IPI < 7) as well as the individual parameters PetCO 2  = 0 mmHg and apnea > 10 s allow a fast and convenient conclusion on patients' respiratory status in a morbid patient population. Sensitivity is good for most parameters, but specificity is poor. In conclusion, IPI can be a useful metric to assess respiratory status during propofol-sedation in PEG-placement. However, IPI was not superior to PetCO 2 and apnea > 10 s.",2020,"All four parameters had a low specificity for both hypoxic and severe hypoxic events (IPI = 1: 13%/12%, IPI < 7: 7%/7%, PetCO 2 : 29%/27%, apnea > ","['147 patients (74 in SM and 73 in IM', 'patients receiving propofol sedation during PEG-procedure', ""patients' respiratory status in a morbid patient population"", 'Patients reporting for PEG-placement under sedation', 'percutaneous endoscopic gastrostomy']","['PetCO', 'standard monitoring group (SM) or capnography monitoring group including IPI (IM', 'Integrated Pulmonary Index®', 'Integrated Pulmonary Index® (IPI', 'capnography']","['low specificity for both hypoxic and severe hypoxic events', 'mmHg and apnea\u2009', 'IPI (IPI\u2009=\u20091 and IPI', 'Hypoxic events', 'severe hypoxic events', 'Capnography and IPI values', 'Heart rate, blood pressure and arterial oxygen saturation', 'heart rate, blood pressure and arterial oxygen saturation', 'IPI values range', 'PetCO 2 , respiratory rate and IPI', 'high sensitivity for hypoxic and severe hypoxic events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0033487', 'cui_str': 'Propofol'}, {'cui': 'C0235195', 'cui_str': 'Sedated'}, {'cui': 'C0176751', 'cui_str': 'Percutaneous endoscopic gastrostomy'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0032478', 'cui_str': 'Polyethylene Glycol 400'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0542276', 'cui_str': 'Respired carbon dioxide monitoring'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0376529', 'cui_str': 'Capnography'}]","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C0242184', 'cui_str': 'Hypoxia'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0439475', 'cui_str': 'mmHg'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0376529', 'cui_str': 'Capnography'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0428175', 'cui_str': 'Oxygen saturation measurement, arterial'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}]",147.0,0.0176867,"All four parameters had a low specificity for both hypoxic and severe hypoxic events (IPI = 1: 13%/12%, IPI < 7: 7%/7%, PetCO 2 : 29%/27%, apnea > ","[{'ForeName': 'Florian Alexander', 'Initials': 'FA', 'LastName': 'Michael', 'Affiliation': 'Department of Internal Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. Florian-Alexander.Michael@kgu.de.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Peveling-Oberhag', 'Affiliation': 'Department of Internal Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Herrmann', 'Affiliation': 'Institute of Biostatistic and Mathematical Modelling, Goethe-University, Frankfurt, Germany.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Zeuzem', 'Affiliation': 'Department of Internal Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.'}, {'ForeName': 'Jörg', 'Initials': 'J', 'LastName': 'Bojunga', 'Affiliation': 'Department of Internal Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.'}, {'ForeName': 'Mireen', 'Initials': 'M', 'LastName': 'Friedrich-Rust', 'Affiliation': 'Department of Internal Medicine 1, University Hospital Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.'}]",Journal of clinical monitoring and computing,['10.1007/s10877-020-00563-2'] 2771,32734366,"A Multicentre, Randomised Clinical Trial to Compare a Topical Nitrizinc ® Complex Solution Versus Cryotherapy for the Treatment of Anogenital Warts.","INTRODUCTION Anogenital warts (AGW) are a relevant clinical issue in the field of sexually transmitted disease, and to date no treatment provides a satisfactory clearance rate. Treatment can be both medical and surgical, and be provided by a healthcare provider or by the patient. Cryotherapy (CRYO) is among the most common treatments for AGW. Nitrizinc® Complex solution (NZCS) is a solution containing organic acids, nitric acid and zinc and copper salts that is applied topically to warts, producing mummification of the damaged tissue. It is considered to be an effective and well-tolerated treatment for genital and common warts. The aim of our study was to compare NZCS to CRYO in the treatment of AGW. METHODS We performed a prospective, multicentre, single-blind, randomised, superiority clinical study involving 120 patients, aged 18-55 years, diagnosed with a first episode of AGW, with each patient having from three to ten AGW. The patients were treated either with NZCS or CRYO for a maximum of four treatments. Primary endpoints were: (1) comparison of the clinical efficacy of CRYO and NZCS, based on response to treatment (clearance of AGW) within four treatment sessions; and (2) tolerability, assessed via a short questionnaire at the end of each treatment session. Secondary endpoints were: (1) number of treatments needed for clearance; and (2) recurrence at 1 and 3e months after confirmed clearance. The results were analysed on an intention-to-treat basis. RESULTS A complete response was achieved in 89.7% of the NZCS group and in 75.4% of the CRYO group (p = 0.0443). NZCS was found to be better tolerated. There was no difference between the NZCS and CRYO treatment arms in the number of sessions needed to clear the lesions. Recurrence occurred after 1 month in 18.4% of the NZCS group and 38.1% of the CRYO group (p = 0.0356), and after 3 months in 25 and 40.6% of these groups, respectively (p = 0.1479). CONCLUSIONS Nitrizinc® Complex solution can be considered to be as effective as CRYO for the treatment of small (< 5 mm) external AGW, with a better tolerability profile and lower rate of recurrence. TRIAL REGISTRATION ISRCTN identifier, ISRCTN36102369.",2020,"Recurrence occurred after 1 month in 18.4% of the NZCS group and 38.1% of the CRYO group (p = 0.0356), and after 3 months in 25 and 40.6% of these groups, respectively (p = 0.1479). ","['120 patients, aged 18-55\xa0years, diagnosed with a first episode of AGW, with each patient having from three to ten AGW', 'Anogenital Warts']","['Nitrizinc® Complex solution (NZCS', 'Topical Nitrizinc ® Complex Solution Versus Cryotherapy', 'Cryotherapy (CRYO', 'NZCS or CRYO', 'NZCS']","['number of sessions needed to clear the lesions', 'tolerated', 'Recurrence', 'clinical efficacy of CRYO and NZCS, based on response to treatment (clearance of AGW) within four treatment sessions; and (2) tolerability, assessed via a short questionnaire', '1) number of treatments needed for clearance; and (2) recurrence']","[{'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0439615', 'cui_str': 'First episode'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}]","[{'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0027552', 'cui_str': 'Needed'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0087113', 'cui_str': 'Clinical Efficacy'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0009663', 'cui_str': 'Genital warts'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}]",120.0,0.0861442,"Recurrence occurred after 1 month in 18.4% of the NZCS group and 38.1% of the CRYO group (p = 0.0356), and after 3 months in 25 and 40.6% of these groups, respectively (p = 0.1479). ","[{'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Pontini', 'Affiliation': ""Unit of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122, Milan, Italy. pontini.p@gmail.com.""}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Mastorino', 'Affiliation': 'Dermatology Clinic, Department of Medical Sciences, Azienda Ospedaliera Universitaria Città della Salute e della Scienza-University of Turin, Turin, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Gaspari', 'Affiliation': ""Unit of Dermatology, Head and Neck Department, Sant'Orsola Malpighi University Hospital, Bologna, Italy.""}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Granger', 'Affiliation': 'Innovation and Development, ISDIN, Barcelona, Spain.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Ramoni', 'Affiliation': ""Unit of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122, Milan, Italy.""}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Delmonte', 'Affiliation': 'Dermatology Clinic, Department of Medical Sciences, Azienda Ospedaliera Universitaria Città della Salute e della Scienza-University of Turin, Turin, Italy.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Evangelista', 'Affiliation': ""Unit of Dermatology, Head and Neck Department, Sant'Orsola Malpighi University Hospital, Bologna, Italy.""}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Cusini', 'Affiliation': ""Unit of Dermatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Pace 9, 20122, Milan, Italy.""}]",Dermatology and therapy,['10.1007/s13555-020-00430-7'] 2772,32734378,Cathodal Cerebellar tDCS Combined with Visual Feedback Improves Balance Control.,"Balance control is essential to maintain a stable body position and to prevent falls. The aim of this study was to determine whether balance control could be improved by using cerebellar transcranial direct current stimulation (tDCS) and visual feedback in a combined approach. A total of 90 healthy volunteers were randomly assigned to six groups defined by the delivery of tDCS (cathodal or anodal or sham) and the provision or not of visual feedback on balance during the acquisition phase. tDCS was delivered over the cerebellar hemisphere ipsilateral to the dominant leg for 20 min at 2 mA during a unipedal stance task. Body sway (i.e., ankle angle and hip position) was measured as an overall maximal unit in anteroposterior and mediolateral direction, together with participant rating of perception of stability, before (baseline), during (acquisition), and after (final) the intervention. We found a reduction in body sway during the acquisition session when visual feedback alone was provided. When the visual feedback was removed (final session), however, body sway increased above baseline. Differently, the reduction in overall maximal body sway was maintained during the final session when the delivery of cathodal tDCS and visual feedback was combined. These findings suggest that cathodal tDCS may support the short-term maintenance of the positive effects of visual feedback on balance and provide the basis for a new approach to optimize balance control, with potential translational implications for the elderly and patients with impaired posture control.",2020,The aim of this study was to determine whether balance control could be improved by using cerebellar transcranial direct current stimulation (tDCS) and visual feedback in a combined approach.,"['elderly and patients with impaired posture control', '90 healthy volunteers']","['cerebellar transcranial direct current stimulation (tDCS) and visual feedback', 'Cathodal Cerebellar tDCS Combined with Visual Feedback', 'tDCS', 'cathodal tDCS', 'tDCS (cathodal or anodal or sham) and the provision or not of visual feedback']","['overall maximal body sway', 'body sway', 'Body sway (i.e., ankle angle and hip position']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C0561949', 'cui_str': 'Does control posture'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007765', 'cui_str': 'Cerebellar structure'}, {'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0003086', 'cui_str': 'Tarsus'}, {'cui': 'C0205143', 'cui_str': 'Angular'}, {'cui': 'C0019552', 'cui_str': 'Bone structure of hip'}, {'cui': 'C0733755', 'cui_str': 'Position'}]",90.0,0.0253658,The aim of this study was to determine whether balance control could be improved by using cerebellar transcranial direct current stimulation (tDCS) and visual feedback in a combined approach.,"[{'ForeName': 'Mehran', 'Initials': 'M', 'LastName': 'Emadi Andani', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy.'}, {'ForeName': 'Bernardo', 'Initials': 'B', 'LastName': 'Villa-Sánchez', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy.'}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Raneri', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Dametto', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Tinazzi', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy.'}, {'ForeName': 'Mirta', 'Initials': 'M', 'LastName': 'Fiorio', 'Affiliation': 'Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Via Casorati, 43, 37131, Verona, Italy. mirta.fiorio@univr.it.'}]","Cerebellum (London, England)",['10.1007/s12311-020-01172-0'] 2773,32734413,The effect of an educational video on long-acting reversible contraception (LARC) utilization at 6-8 weeks postpartum period: a randomized controlled trial.,"PURPOSE Long-acting reversible contraception is highly effective in preventing unintended pregnancy and unsafe abortion. An educational video administered during early postpartum period might be an effective tool to improve postpartum LARC use. The objectives were to evaluate whether a postpartum educational video about LARC could increase postpartum LARC utilization at 6-8 weeks postpartum and to assess why postpartum women did not receive LARC. METHODS This randomized-controlled trial was conducted at the postpartum unit of a university Hospital between August 2016 and February 2017. Postpartum women who were aged > 20 years and willing to participate were recruited. Participants allocated to the study group watched the 7-min educational video on LARC methods while the control group did not. To assess LARC utilization, data were collected at 6-8 weeks postpartum using telephone calls and/or medical record review to determine postpartum contraception use and reasons for not using LARC. RESULTS Two-hundred and seventy participants were enrolled, and the video (135) and non-video (135) groups had similar baseline characteristics. In the video group, 57.8% (95% CI 49.0-66.2) reported using a LARC method, compared to 25.9% (95% CI 18.8-34.2) in the non-video group (p < 0.05). The reasons for not using LARC in both groups were inconvenience of access (42.0-43.8%) and uncertainty about methods (17.0-24.6%). CONCLUSION The educational video introduced at immediate postpartum period was efficacious in increasing the utilization of LARC at 6-8 weeks postpartum. Inconvenience of access was the most common reason cited for not using LARC. CLINICAL TRIAL REGISTRATION NUMBER Clinicaltrials.in.th TCTR20171225001 ""retrospectively registered"".",2020,The educational video introduced at immediate postpartum period was efficacious in increasing the utilization of LARC at 6-8 weeks postpartum.,"['Two-hundred and seventy participants were enrolled, and the video (135) and non-video (135) groups had similar baseline characteristics', 'Postpartum women who were aged\u2009', 'postpartum unit of a university Hospital between August 2016 and February 2017', '20\xa0years and willing to participate were recruited']","['educational video on long-acting reversible contraception (LARC) utilization', 'postpartum educational video about LARC']",['postpartum LARC utilization'],"[{'cui': 'C4319603', 'cui_str': '270'}, {'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0032804', 'cui_str': 'Postpartum Women'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0600109', 'cui_str': 'Willing'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C4505307', 'cui_str': 'Long-Acting Reversible Contraception'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0086839', 'cui_str': 'Postpartum'}]","[{'cui': 'C0086839', 'cui_str': 'Postpartum'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",270.0,0.264079,The educational video introduced at immediate postpartum period was efficacious in increasing the utilization of LARC at 6-8 weeks postpartum.,"[{'ForeName': 'Chada', 'Initials': 'C', 'LastName': 'Burapasikarin', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama VI Rd., Bangkok, 10400, Thailand.'}, {'ForeName': 'Jittima', 'Initials': 'J', 'LastName': 'Manonai', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama VI Rd., Bangkok, 10400, Thailand. jittima.man@mahidol.ac.th.'}, {'ForeName': 'Rujira', 'Initials': 'R', 'LastName': 'Wattanayingcharoenchai', 'Affiliation': 'Department of Obstetrics and Gynaecology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Rama VI Rd., Bangkok, 10400, Thailand.'}]",Archives of gynecology and obstetrics,['10.1007/s00404-020-05710-3'] 2774,32730089,Short-term effects of spinal thrust joint manipulation on postural sway in patients with chronic mechanical neck pain: a randomized controlled trial.,"PURPOSE Our aim was to compare the efficacy of spinal manipulation of the upper cervical spine (C1-C2) on postural sway in patients with chronic mechanical neck pain with the application of a combination of cervical (C3-C4), cervicothoracic (C7-T1) and thoracic spine (T5-T6) thrust joint manipulation. METHODS One hundred eighty-six ( n  = 186) individuals with chronic mechanical neck pain were randomised to receive an upper cervical spine manipulation ( n  = 93) or three different spinal manipulation techniques applied to the cervical spine, cervicothoracic joint and thoracic spine ( n  = 93). Measures included the assessment of stabilometric parameters using the Medicapteurs S-Plate platform. Secondarily, neck pain was analysed using the Numeric Pain Rating Scale. RESULTS We observe a decrease in the length of the centre of pressure path, average speed, medio-lateral and antero-posterior displacement with statistically significant results ( p  < 0.05) in the upper cervical manipulation group. Both interventions are equally effective in reducing neck pain after fifteen days ( p  < 0.001). CONCLUSION The application of upper cervical thrust joint manipulation is more effective in improving stabilometric parameters in patients with chronic mechanical neck pain. Trial registration: The study was registered in the Australian and New Zealand Clinical Trial Registry (no. ACTRN12619000546156). Implications for rehabilitation Patients who suffer from neck pain exhibit increased postural sway than asymptomatic subjects. Both spinal manipulation treatments applied in this study are equally effective in reducing neck pain. Spinal manipulation treatment on the upper cervical spine improves postural stability parameters.",2020,The application of upper cervical thrust joint manipulation is more effective in improving stabilometric parameters in patients with chronic mechanical neck pain. ,"['One hundred eighty-six ( n \u2009=\u2009186) individuals with chronic mechanical neck pain', 'patients with chronic mechanical neck pain', 'rehabilitation Patients who suffer from neck pain exhibit increased postural sway than asymptomatic subjects', 'patients with chronic mechanical neck pain with the application of a combination of cervical (C3-C4), cervicothoracic (C7-T1) and thoracic spine (T5-T6) thrust joint manipulation']","['upper cervical spine manipulation ( n \u2009=\u200993) or three different spinal manipulation techniques applied to the cervical spine, cervicothoracic joint and thoracic spine', 'spinal thrust joint manipulation', 'spinal manipulation of the upper cervical spine (C1-C2', 'Spinal manipulation treatment', 'upper cervical thrust joint manipulation']","['Secondarily, neck pain', 'length of the centre of pressure path, average speed, medio-lateral and antero-posterior displacement', 'postural stability parameters', 'postural sway', 'Numeric Pain Rating Scale', 'neck pain']","[{'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C3816958', 'cui_str': '80'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0015272', 'cui_str': 'Exhibits as Topic'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0450195', 'cui_str': 'Cervicothoracic'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure'}, {'cui': 'C0556783', 'cui_str': 'Manipulation of joint - non-surgical'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0203928', 'cui_str': 'Manipulation of the cervical spine'}, {'cui': 'C0086586', 'cui_str': 'Manipulation of spine'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0728985', 'cui_str': 'Structure of cervical vertebral column'}, {'cui': 'C0450195', 'cui_str': 'Cervicothoracic'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0581269', 'cui_str': 'Thoracic spine structure'}, {'cui': 'C0556783', 'cui_str': 'Manipulation of joint - non-surgical'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}]","[{'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0205093', 'cui_str': 'Lateral'}, {'cui': 'C0333044', 'cui_str': 'Posterior displacement'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0175659', 'cui_str': 'Scale'}]",186.0,0.0479385,The application of upper cervical thrust joint manipulation is more effective in improving stabilometric parameters in patients with chronic mechanical neck pain. ,"[{'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Romero Del Rey', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almería, Almería, Spain.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'Saavedra Hernández', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almería, Almería, Spain.'}, {'ForeName': 'Cleofás', 'Initials': 'C', 'LastName': 'Rodríguez Blanco', 'Affiliation': 'Department of Physical Therapy, Faculty of Nursing, Physiotherapy and Podiatry, University of Sevilla, Sevilla, Spain.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Palomeque Del Cerro', 'Affiliation': 'Escuela de Osteopatía de Madrid, Madrid, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Alarcón Rodríguez', 'Affiliation': 'Department of Nursing, Physiotherapy and Medicine, University of Almería, Almería, Spain.'}]",Disability and rehabilitation,['10.1080/09638288.2020.1798517'] 2775,32730122,Salivary fluoride concentration and retention after rinsing with 0.05 and 0.2% sodium fluoride (NaF) compared with a new high F rinse containing 0.32% NaF.,"OBJECTIVE To compare salivary fluoride (F) concentration and F retention after rinsing with a new 0.32% sodium fluoride (NaF) rinse and conventional 0.05 and 0.2% NaF rinses. METHODS Seventeen subjects (aged 22-26 years), with normal salivary secretion rates, participated in a double blind, cross-over study. In three separate sessions with a minimum washout period of 48 h, they rinsed for 1 min with 10 ml of 0.05, 0.2 or 0.32% NaF mouthrinse. Unstimulated whole saliva was collected before (baseline: 0 min) and after 1, 3, 5, 10, 20, 30, 45 and 60 min. The F concentration was plotted against time, and the area under the curve (AUC) calculated. Salivary F concentration and F retention for the three mouthrinses were compared by a randomized block test, followed by Tukey's test and a paired 2-tailed test. RESULTS There was a clear dose-response for AUC 3-60 min; 0.32% > 0.2% > 0.05% ( p  < .05). The mean F retention was 0.25 mg for 0.05% NaF, 0.86 mg F for 0.2% Na and 1.31 mg F for 0.32% NaF, ( p  < .05). CONCLUSIONS The higher salivary F concentration over time and the higher F retention after rinsing with an 0.32% NaF solution suggests a potential application in prevention of caries and dental erosion.",2020,The higher salivary F concentration over time and the higher F retention after rinsing with an 0.32% NaF solution suggests a potential application in prevention of caries and dental erosion.,"['Seventeen subjects (aged 22-26\u2009years), with normal salivary secretion rates, participated in a double blind, cross-over study']","['NaF mouthrinse', 'sodium fluoride (NaF) rinse and conventional 0.05 and 0.2% NaF rinses', 'sodium fluoride (NaF']","['salivary fluoride (F) concentration and F retention', 'Salivary F concentration and F retention', 'F concentration', 'mean F retention', 'Salivary fluoride concentration and retention']","[{'cui': 'C0450331', 'cui_str': '17'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0036104', 'cui_str': 'Salivary secretion'}, {'cui': 'C0013072', 'cui_str': 'Double-Blind Study'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}]","[{'cui': 'C0037508', 'cui_str': 'Sodium Fluoride'}, {'cui': 'C1701810', 'cui_str': 'Rinse'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C4517436', 'cui_str': '0.2'}]","[{'cui': 'C0442040', 'cui_str': 'Salivary'}, {'cui': 'C0016327', 'cui_str': 'Fluoride'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",,0.0331689,The higher salivary F concentration over time and the higher F retention after rinsing with an 0.32% NaF solution suggests a potential application in prevention of caries and dental erosion.,"[{'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Larsson', 'Affiliation': 'Department of Cariology, Faculty of Odontology, Malmö University, Malmö, Sweden.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Stime', 'Affiliation': 'Kungstandläkarna AB, Stockholm, Sweden.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Hansen', 'Affiliation': 'Lycko Pers väg, Trelleborg, Sweden.'}, {'ForeName': 'Dowen', 'Initials': 'D', 'LastName': 'Birkhed', 'Affiliation': 'Fersens väg, Malmö, Sweden.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Ericson', 'Affiliation': 'Department of Cariology, Faculty of Odontology, Malmö University, Malmö, Sweden.'}]",Acta odontologica Scandinavica,['10.1080/00016357.2020.1800085'] 2776,32730170,Comparison of Graphic Organizers Versus Online Flash Cards as Study Aids in an Elective Veterinary Cardiology Course.,"The ideal study aid format for veterinary students remains unknown. Both graphic organizers (GOs) and flash cards (FCs) have shown utility for enhancing learning in specific contexts. A mixed-methods prospective randomized crossover trial was undertaken with veterinary students ( n = 59) in an elective cardiology course. All students received identical content presented via weekly in-class lectures and were given study aids in either GO or FC format. One week later, students completed quizzes of content knowledge for each lesson and indicated amount of time spent studying. Crossover occurred such that groups of students alternated between receiving GOs and FCs. Quantitative and qualitative data were collected in the form of in-depth pre- and post-course surveys. Overall, there was no significant difference in quiz scores ( p = .26) or time spent studying ( p = .33) based on study aid type. Time spent studying for each quiz, as well as other measures of study habits, decreased significantly throughout the semester. Post-survey responses showed overall higher student satisfaction for GOs compared to FCs ( p = .022), as well as a shift in preference away from FCs throughout the semester ( p = .03). Free-text survey responses revealed that individual students had strong preferences either for or against FCs in the context of their particular study habits. In an elective veterinary cardiology course, use of GO format compared to FC format study aids resulted in equivalent short-term learning outcomes and time spent studying, with each study aid format appealing to specific learning preferences of individual students.",2020,"Post-survey responses showed overall higher student satisfaction for GOs compared to FCs ( p = .022), as well as a shift in preference away from FCs throughout the semester ( p = .03).",['veterinary students ( n = 59) in an elective cardiology course'],"['graphic organizers (GOs) and flash cards (FCs', 'Graphic Organizers']","['quiz scores', 'student satisfaction']","[{'cui': 'C0042614', 'cui_str': 'veterinary'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0750729', 'cui_str': 'Courses'}]","[{'cui': 'C0085635', 'cui_str': 'Photopsia'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0147144,"Post-survey responses showed overall higher student satisfaction for GOs compared to FCs ( p = .022), as well as a shift in preference away from FCs throughout the semester ( p = .03).","[{'ForeName': 'Jessica L', 'Initials': 'JL', 'LastName': 'Ward', 'Affiliation': ''}, {'ForeName': 'Courtney A', 'Initials': 'CA', 'LastName': 'Vengrin', 'Affiliation': ''}]",Journal of veterinary medical education,['10.3138/jvme.2019-0136'] 2777,32730174,Inspiratory muscle strength training lowers blood pressure and sympathetic activity in older adults with OSA: A randomized controlled pilot trial.,"Previous work has shown lowered casual blood pressure after just six weeks of inspiratory muscle strength training (IMST), suggesting IMST as a potential therapeutic in the prevention/treatment of hypertension. In this study, we assessed the effects of IMST on cardiovascular parameters in older, overweight adults diagnosed with moderate and severe obstructive sleep apnea (OSA). Subjects were randomly assigned to one of two interventions i) high intensity IMST (n=15, 75% maximal inspiratory pressure) or ii) a control intervention (n=10, 15% maximum inspiratory pressure). Subjects in both groups trained at home completing 30 training breaths/day, 5 days/week for 6 weeks. Pre- and post- training measures included maximal inspiratory pressure, casual and ambulatory blood pressures, spontaneous cardiac baroreflex sensitivity, and muscle sympathetic nerve activity. Men and women in the high intensity IMST group exhibited reductions in casual systolic, diastolic and mean arterial blood pressures (SBP: -8.82 ± 4.98 mmHg; DBP: -4.69 ± 2.81 mmHg; MAP: -6.06 ± 1.03 mmHg; p<0.002), and nighttime SBP (pre: -12.00 ± 8.20 mmHg; (p<0.01). Muscle sympathetic nerve activities also were lower (-6.97 ± 2.29 bursts/min -1 ; p=0.01 and -9.55 ± 2.42 bursts per 100 heartbeats; p=0.002) by Week 6. Conversely, subjects allocated to the control group showed no change in casual blood pressure or muscle sympathetic nerve activity and a trend toward higher overnight blood pressures. A short course of high intensity IMST may offer significant respiratory and cardiovascular benefits for older, overweight adults with OSA. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Identifier: NCT02709941.",2020,Muscle sympathetic nerve activities also were lower (-6.97 ± 2.29 bursts/min -1 ; p=0.01 and -9.55 ± 2.42 bursts per 100 heartbeats; p=0.002) by Week 6.,"['older adults with OSA', 'older, overweight adults with OSA', 'older, overweight adults diagnosed with moderate and severe obstructive sleep apnea (OSA']","['intensity IMST (n=15, 75% maximal inspiratory pressure) or ii) a control intervention', 'Pre- and post', 'Inspiratory muscle strength training', 'IMST', 'high intensity IMST', 'inspiratory muscle strength training (IMST), suggesting IMST']","['maximal inspiratory pressure, casual and ambulatory blood pressures, spontaneous cardiac baroreflex sensitivity, and muscle sympathetic nerve activity', 'casual systolic, diastolic and mean arterial blood pressures', 'cardiovascular parameters', 'casual blood pressure', 'casual blood pressure or muscle sympathetic nerve activity', 'overnight blood pressures', 'Muscle sympathetic nerve activities', 'blood pressure and sympathetic activity', 'nighttime SBP']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0520679', 'cui_str': 'Obstructive sleep apnea syndrome'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}]","[{'cui': 'C4083126', 'cui_str': 'Maximum Inspiratory Pressure'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0206162', 'cui_str': 'Baroreceptor reflex'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C0012000', 'cui_str': 'Diastole'}, {'cui': 'C0428886', 'cui_str': 'Mean blood pressure'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C0085805', 'cui_str': 'Androgen Binding Protein'}]",,0.0309803,Muscle sympathetic nerve activities also were lower (-6.97 ± 2.29 bursts/min -1 ; p=0.01 and -9.55 ± 2.42 bursts per 100 heartbeats; p=0.002) by Week 6.,"[{'ForeName': 'Guadalupe Elizabeth', 'Initials': 'GE', 'LastName': 'Ramos-Barrera', 'Affiliation': 'Department of Physiology, University of Arizona, United States.'}, {'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'DeLucia', 'Affiliation': 'Department of Physiology, University of Arizona, United States.'}, {'ForeName': 'E Fiona', 'Initials': 'EF', 'LastName': 'Bailey', 'Affiliation': 'Department of Physiology, College of Medicine, University of Arizona, United States.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00024.2020'] 2778,30724760,Severity of Analgesic Dependence and Medication-overuse Headache.,"BACKGROUND AND AIMS Medication-overuse headache (MOH) is a common chronic headache caused by overuse of headache analgesics. It has similarities with substance dependence disorders. The treatment of choice for MOH is withdrawal of the offending analgesics. Behavioral brief intervention treatment using methods adapted from substance misuse settings is effective. Here we investigate the severity of analgesics dependence in MOH using the Severity of Dependence Scale (SDS), validate the SDS score against formal substance dependence diagnosis based on the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) and examine whether the SDS predicts successful withdrawal. METHODS Representative recruitment from the general population; 60 MOH patients, 15 chronic headache patients without medication overuse and 25 population controls. Headaches were diagnosed using the International Classification of Headache Disorders, medication use was assessed and substance dependence classified according to the DSM-IV. The SDS was scored by interviewers blinded to patient group. Descriptive statistics were used and validity of the SDS score assessed against a substance dependence diagnosis using ROC analysis. RESULTS Sixty-two percent of MOH patients overused simple analgesics, 38% centrally acting analgesics (codeine, opiates, triptans). Fifty percent of MOH patients were classified as DSM-IV substance dependent. Centrally active medication and high SDS scores were associated with higher proportions of dependence. ROC analysis showed SDS scores accurately identified dependence (area under curve 88%). Lower SDS scores were associated with successful withdrawal (P = 0.004). CONCLUSIONS MOH has characteristics of substance dependence which should be taken into account when choosing treatment strategy. TRIAL REGISTRATION Based on data collected in previously reported randomized BIMOH trial (; in the present manuscript, Clinical trials registration number: NCT01314768). The present part, however, represents observational data and is not a treatment trial.",2019,"Lower SDS scores were associated with successful withdrawal (P = 0.004). ","['Representative recruitment from the general population; 60 MOH patients, 15 chronic headache patients without medication overuse and 25 population controls']",[],"['Severity of Analgesic Dependence and Medication-overuse Headache', 'Lower SDS scores']","[{'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0522254', 'cui_str': 'Analgesic overuse headache'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0151293', 'cui_str': 'Chronic Headache'}, {'cui': 'C3266697', 'cui_str': 'Medication overuse'}, {'cui': 'C0032662', 'cui_str': 'Population Control'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0011546', 'cui_str': 'Dependency, Psychology'}, {'cui': 'C0522254', 'cui_str': 'Analgesic overuse headache'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",,0.0351921,"Lower SDS scores were associated with successful withdrawal (P = 0.004). ","[{'ForeName': 'Christofer', 'Initials': 'C', 'LastName': 'Lundqvist', 'Affiliation': ""Research Centre, Akershus University Hospital, Lørenskog (CL, ESK); Department of Neurology, Akershus University Hospital, Nordbyhagen (CL, ESK); Institute of Clinical Medicine, Campus Akershus University Hospital, University of Oslo, Nordbyhagen, Norway (CL, MBR); National Addiction Centre, King's College, London, UK (MG); Head and Neck Research Group, Research Centre, Akershus University Hospital, Lørenskog (MBR); Department of General Practice, Institute of Health and Society, University of Oslo, Oslo, Norway (JS, ESK).""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gossop', 'Affiliation': ''}, {'ForeName': 'Michael Bjørn', 'Initials': 'MB', 'LastName': 'Russell', 'Affiliation': ''}, {'ForeName': 'Jørund', 'Initials': 'J', 'LastName': 'Straand', 'Affiliation': ''}, {'ForeName': 'Espen Saxhaug', 'Initials': 'ES', 'LastName': 'Kristoffersen', 'Affiliation': ''}]",Journal of addiction medicine,['10.1097/ADM.0000000000000504'] 2779,31136926,Comparison of the novel CompEx asthma exacerbation endpoint to the ATS/ERS adapted moderate/severe asthma exacerbation definition used in the MITRA trial.,,2019,,[],['ATS/ERS'],[],[],[],[],,0.020844,,"[{'ForeName': 'Göran', 'Initials': 'G', 'LastName': 'Eriksson', 'Affiliation': 'Department of Respiratory Medicine and Allergology, Lund University Hospital, Lund, Sweden.'}, {'ForeName': 'Hendrik', 'Initials': 'H', 'LastName': 'Nolte', 'Affiliation': 'ALK, USA.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ljørring', 'Affiliation': 'ALK, Hørsholm, Denmark.'}, {'ForeName': 'Bente', 'Initials': 'B', 'LastName': 'Riis', 'Affiliation': 'ALK, Hørsholm, Denmark. Electronic address: clinicaltrials@alk.net.'}, {'ForeName': 'Johann Christian', 'Initials': 'JC', 'LastName': 'Virchow', 'Affiliation': 'Department of Pneumology/Intensive Care Medicine, University of Rostock, Germany.'}]",Respiratory medicine,['10.1016/j.rmed.2019.04.014'] 2780,31176057,"The effect of agency on women's mental distress: A prospective cohort study from rural Rajasthan, India.","Agency, the ability to identify goals and then act upon them, is a core component of women's empowerment and has important implications for the rights and well-being of women and girls. However, inadequate measurement of agency impedes empirical investigation, and few studies have investigated the relation between agency and health. Using a theory-based measure of women's agency, we investigated the longitudinal association between agency and mental distress among women living in rural Rajasthan, India. Women completed baseline interviews between June and October 2016 and follow-up interviews between June and November 2017 (n = 2859). We measured mental distress with the Hindi version of the 12 item General Health Questionnaire, which asked women 12 questions about symptoms of mental distress (score range: 0-12). We measured agency using a measurement model which was composed of 23 indicators tapping into four domains of agency and validated in a prior research study. We modeled the relation between women's agency and mental distress using Poisson regression and an individual-level fixed effects approach to account for time-fixed characteristics of individuals. In models that controlled for time-varying confounding (e.g., household wealth, number of sons), a one standard deviation increase in agency was associated with a reduction of 0.21 distress symptoms (95% CI: -0.32, -0.09), which corresponds to a 7% reduction (95% CI: 3%, 11%) relative to the mean. We found that specific domains of agency varied in their association with mental distress; namely, an increase in women's agency regarding her attitudes about gender norms corresponded to a reduction in mental distress, whereas an increase in women's agency regarding speaking up in public corresponded to an increase in mental distress. Our research demonstrates that agency may be a determinant of mental health and that comprehensive measurement can reveal nuanced relationships.",2019,"We found that specific domains of agency varied in their association with mental distress; namely, an increase in women's agency regarding her attitudes about gender norms corresponded to a reduction in mental distress, whereas an increase in women's agency regarding speaking up in public corresponded to an increase in mental distress.","[""women's mental distress"", 'women living in rural Rajasthan, India']",[],['mental distress'],"[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0235109', 'cui_str': 'Mental distress'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0021201', 'cui_str': 'India'}]",[],"[{'cui': 'C0235109', 'cui_str': 'Mental distress'}]",,0.0477734,"We found that specific domains of agency varied in their association with mental distress; namely, an increase in women's agency regarding her attitudes about gender norms corresponded to a reduction in mental distress, whereas an increase in women's agency regarding speaking up in public corresponded to an increase in mental distress.","[{'ForeName': 'Robin A', 'Initials': 'RA', 'LastName': 'Richardson', 'Affiliation': 'Department of Epidemiology, Columbia University, New York, USA. Electronic address: rr3239@cumc.columbia.edu.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Harper', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Institute for Health and Social Policy, McGill University, Montreal, Canada.'}, {'ForeName': 'Lisa M', 'Initials': 'LM', 'LastName': 'Bates', 'Affiliation': 'Department of Epidemiology, Columbia University, New York, USA.'}, {'ForeName': 'Arijit', 'Initials': 'A', 'LastName': 'Nandi', 'Affiliation': 'Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada; Institute for Health and Social Policy, McGill University, Montreal, Canada.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2019.05.052'] 2781,32732745,Comparison of Ultrasound-Guided Local Ozone (O2-O3) Injection Vs Corticosteroid Injection in Patients with Mild to Moderate Carpal Tunnel Syndrome.,"OBJECTIVE Recently, ozone injection has been used to treat various musculoskeletal diseases. This study was performed to compare ultrasound-guided corticosteroid vs ozone injections in the treatment of Carpal tunnel syndrome (CTS). DESIGN Forty patients with mild to moderate CTS were enrolled and randomly placed in one of the two groups of receiving a corticosteroid or ozone injection under ultrasound guidance. In order to determine the effectiveness of both injection techniques and compare their outcomes, Visual Analogue Scale and scores of Boston Carpal Tunnel Questionnaire, as well as ultrasound and electrodiagnostic criteria, were followed at 0, 6, and 12 weeks after the injection. RESULTS Both groups showed improvement in Visual Analogue Scale and Boston Carpal Tunnel Questionnaire at week 6, and this improvement continued until the 12th week after the injections. However, electrodiagnostic values of Sensory nerve action potentials and Compound motor action potentials latency, and ultrasound CTS criteria showed significant improvement only among the subjects in the corticosteroid group at 6 and 12 weeks after the injection (P<0.05). CONCLUSION Ozone might be as effective as corticosteroid injection in reducing pain and improving the function. Objective improvements in electrodiagnostic and ultrasound criteria of CTS were shown only among patients after corticosteroid injection.",2020,"Both groups showed improvement in Visual Analogue Scale and Boston Carpal Tunnel Questionnaire at week 6, and this improvement continued until the 12th week after the injections.","['Forty patients with mild to moderate CTS', 'Carpal tunnel syndrome (CTS', 'Patients with Mild to Moderate Carpal Tunnel Syndrome']","['corticosteroid or ozone injection under ultrasound guidance', 'ozone injection', 'Ultrasound-Guided Local Ozone (O2-O3) Injection Vs Corticosteroid Injection', 'ultrasound-guided corticosteroid vs ozone injections']","['Visual Analogue Scale and Boston Carpal Tunnel Questionnaire', 'Visual Analogue Scale and scores of Boston Carpal Tunnel Questionnaire', 'pain and improving the function', 'electrodiagnostic values of Sensory nerve action potentials and Compound motor action potentials latency, and ultrasound CTS criteria', 'electrodiagnostic and ultrasound criteria of CTS']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}]","[{'cui': 'C0001617', 'cui_str': 'Adrenal cortex hormone'}, {'cui': 'C0030106', 'cui_str': 'Ozone'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0205276', 'cui_str': 'Local'}]","[{'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0007286', 'cui_str': 'Carpal tunnel syndrome'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0522219', 'cui_str': 'Sensory potential'}, {'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0001272', 'cui_str': 'Action Potentials'}, {'cui': 'C0242465', 'cui_str': 'Response Latency'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]",40.0,0.011792,"Both groups showed improvement in Visual Analogue Scale and Boston Carpal Tunnel Questionnaire at week 6, and this improvement continued until the 12th week after the injections.","[{'ForeName': 'Bijan', 'Initials': 'B', 'LastName': 'Forough', 'Affiliation': 'Professor, Neuromusculoskeletal Research Center, Department of physical medicine and rehabilitation, Iran university of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Mohamadi', 'Affiliation': 'Department of physical medicine and rehabilitation, Iran university of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Hamid Reza', 'Initials': 'HR', 'LastName': 'Fadavi', 'Affiliation': 'Physical Medicine and Rehabilitation specialist with subspecialty in Interventional Pain Management, Clinical director, Mission Pain and Spine, Mission Viejo, CA, USA.'}, {'ForeName': 'Pejman', 'Initials': 'P', 'LastName': 'Madani', 'Affiliation': 'Associate Professor, Neuromusculoskeletal Research Center, Department of physical medicine and rehabilitation, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Negar', 'Initials': 'N', 'LastName': 'Aflakian', 'Affiliation': 'Resident of Physical Medicine and Rehabilitation, Neuromusculoskeletal Research Center, Department of Physical Medicine and Rehabilitation, Iran university of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Fateme', 'Initials': 'F', 'LastName': 'Ghazaie', 'Affiliation': 'Department of physical medicine and rehabilitation, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Arash', 'Initials': 'A', 'LastName': 'Babaei-Ghazani', 'Affiliation': 'Associate Professor, Neuromusculoskeletal Research Center, Department of physical medicine and rehabilitation, Iran University of Medical Sciences, Tehran, Iran.'}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001546'] 2782,32732771,Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome: Erratum.,,2020,,['Infants with Neonatal Abstinence Syndrome'],[],[],"[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0027609', 'cui_str': 'Neonatal Abstinence Syndrome'}]",[],[],,0.028922,,[],Journal of developmental and behavioral pediatrics : JDBP,['10.1097/DBP.0000000000000823'] 2783,32732772,Effectiveness of a 2-Week Strength Training Learning Intervention on Self-selected Weight-Training Intensity.,"Glass, SC, Ahmad, S, and Gabler, T. Effectiveness of a 2-week strength training learning intervention on self-selected weight-training intensity. J Strength Cond Res XX(X): 000-000, 2020-The purpose of this study was to determine the effectiveness of an imposed (IM) vs. self-selected (SS) 2-week strength training intervention on SS resistance training intensity. Subjects 18-40 years (SS n = 10 and IM n = 10) were provided resistance training orientation (chest press, leg press, triceps extension, bicep curl, and shoulder press). On 6 different training days, subjects completed 2 sets on each machine while blinded to the load. The SS group SS loads without any intensity or effort feedback. Load, repetitions, and ratings of perceived exertion (RPE) were recorded. The IM group was encouraged to lift to fatigue, and if they exceeded 12 repetitions, subsequent load was increased (goal-attain 70% one repetition maximum [1RM]). After training, SS and IM SS loads and repetitions for all lifts, plus 3 novel lifts (pec fly, leg extension, and shoulder raise). One repetition maximum was assessed last. Comparisons between groups were made using 2-way analysis of variance. There were significant main effects for % 1RM for the condition and day (day 1 IM = 57.2 ± 12.0%, SS = 47.2 ± 13.7% and day 6 IM = 74.7 ± 10.8%, SS = 66.2 ± 13.4%). There were significant effects across days for reps (day 1 IM = 10.8 ± 4.8, SS = 12.3 ± 4.0 and day 6 IM = 9.3 ± 3.6, SS = 10.0 ± 3.0) and RPE (day 1 = 15.4 ± 2.0 and day 6 = 16.5 ± 1.9). For both SS and IM post-training SS loads exceeded 60% 1RM. However, among the novel lifts, only the pec fly was greater than 60% 1RM (pec fly 63.0 ± 11.0%, leg extension 39.8 ± 12.5%, and shoulder raise 53.1 ± 12.8%). Two weeks of supervised resistance training resulted in both IM and SS self-selecting loads greater than 60% 1RM. There were no differences after 2-weeks of training between IM load and SS load groups.",2020,"There were significant effects across days for reps (day 1 IM = 10.8 ± 4.8, SS = 12.3 ± 4.0 and day 6 IM = 9.3 ± 3.6, SS = 10.0 ± 3.0) and RPE (day 1 = 15.4 ± 2.0 and day 6 = 16.5 ± 1.9).",['Subjects 18-40 years (SS n = 10 and IM n = 10'],"['J Strength Cond Res XX(X', 'strength training learning intervention', 'resistance training orientation (chest press, leg press, triceps extension, bicep curl, and shoulder press', 'imposed (IM) vs. self-selected (SS', 'supervised resistance training', '2-Week Strength Training Learning Intervention', '2-week strength training intervention']","['Load, repetitions, and ratings of perceived exertion (RPE', 'SS resistance training intensity']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0036588', 'cui_str': 'Self'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}, {'cui': 'C0817096', 'cui_str': 'Thoracic'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0559499', 'cui_str': 'Biceps brachii muscle structure'}, {'cui': 'C0010474', 'cui_str': ""Curling's ulcers""}, {'cui': 'C0454325', 'cui_str': 'Shoulder press'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439230', 'cui_str': 'week'}]","[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}]",10.0,0.012273,"There were significant effects across days for reps (day 1 IM = 10.8 ± 4.8, SS = 12.3 ± 4.0 and day 6 IM = 9.3 ± 3.6, SS = 10.0 ± 3.0) and RPE (day 1 = 15.4 ± 2.0 and day 6 = 16.5 ± 1.9).","[{'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'Glass', 'Affiliation': 'Department of Movement Science, Human Performance Laboratory, Grand Valley State University, Allendale, Michigan.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Ahmad', 'Affiliation': ''}, {'ForeName': 'Taylor', 'Initials': 'T', 'LastName': 'Gabler', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003729'] 2784,32732773,The Effect of Blood Flow Restriction Therapy on Recovery After Experimentally Induced Muscle Weakness and Pain.,"Wong, V, Dankel, SJ, Spitz, RW, Bell, ZW, Viana, RB, Chatakondi, RN, Abe, T, and Loenneke, JP. The effect of blood flow restriction therapy on recovery after experimentally induced muscle weakness and pain. J Strength Cond Res XX(X): 000-000, 2020-The purpose was to determine if blood flow restriction with no external load could be used as a means of active therapy after experimentally induced fatigue and soreness. Twelve women and 7 men (aged 18-35 years) participated in a randomized controlled trial using a within-subject design. The study intervention was 3 consecutive visits. Visit 1 included the fatiguing/soreness-inducing protocol for the elbow flexors, which was performed only once during the study. Torque was measured before/after to confirm individuals began in a weakened state. Subjects then completed blood flow restriction therapy on one arm and the sham therapy on the other. Subjects performed elbow flexion/contraction with no external load on both arms. Torque was measured once more 10 minutes after the fatiguing/soreness-inducing protocol. Twenty-four hours later, soreness and torque were assessed in each arm, followed by another bout of therapy. Forty-eight hours after the initial visit, soreness and torque were measured again. There were no differences (median difference [95% credible interval]) in the recovery of torque between the blood flow restriction and sham therapy conditions at 10 minutes (0.5 [-2.7, 3.8] N·m), 24 hours (-2.34 [-6, 1.14] N·m), or 48 hours (-1.94 [-5.45, 1.33] N·m). There were also no differences in ratings of soreness at 24 hours (-2.48 [-10.05, 5.05]) or 48 hours (2.58 [-4.96, 10.09]). Our results indicate that this specific model of blood flow restriction therapy did not enhance the recovery of the muscle compared with a sham condition without the application of pressure.",2020,"There were no differences (median difference [95% credible interval]) in the recovery of torque between the blood flow restriction and sham therapy conditions at 10 minutes (0.5 [-2.7, 3.8] N·m), 24 hours (-2.34 [-6, 1.14] N·m), or 48 hours (-1.94 [-5.45, 1.33] N·m).",['Twelve women and 7 men (aged 18-35 years'],"['blood flow restriction therapy', 'J Strength Cond Res XX(X', 'Blood Flow Restriction Therapy']","['ratings of soreness', 'V, Dankel, SJ, Spitz, RW, Bell, ZW, Viana, RB, Chatakondi, RN, Abe, T, and Loenneke, JP', 'Recovery', 'soreness and torque', 'muscle weakness and pain', 'recovery of torque between the blood flow restriction', 'Muscle Weakness and Pain', 'Torque']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}]","[{'cui': 'C0234233', 'cui_str': 'Soreness'}, {'cui': 'C0155685', 'cui_str': 'Acute bacterial endocarditis'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}, {'cui': 'C0030552', 'cui_str': 'Paresis'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}]",12.0,0.0660368,"There were no differences (median difference [95% credible interval]) in the recovery of torque between the blood flow restriction and sham therapy conditions at 10 minutes (0.5 [-2.7, 3.8] N·m), 24 hours (-2.34 [-6, 1.14] N·m), or 48 hours (-1.94 [-5.45, 1.33] N·m).","[{'ForeName': 'Vickie', 'Initials': 'V', 'LastName': 'Wong', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Scott J', 'Initials': 'SJ', 'LastName': 'Dankel', 'Affiliation': 'Department of Health and Exercise Science, Exercise Physiology Laboratory, Rowan University, Glassboro, New Jersey.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Spitz', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Zachary W', 'Initials': 'ZW', 'LastName': 'Bell', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Ricardo B', 'Initials': 'RB', 'LastName': 'Viana', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Raksha N', 'Initials': 'RN', 'LastName': 'Chatakondi', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Abe', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}, {'ForeName': 'Jeremy P', 'Initials': 'JP', 'LastName': 'Loenneke', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, Kevser Ermin Applied Physiology Laboratory, University of Mississippi, University, Mississippi.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003692'] 2785,32732774,Can Simulated Partners Boost Workout Effort in Long-Term Exercise?,"Feltz, DL, Hill, CR, Samendinger, S, Myers, ND, Pivarnik, JM, Winn, B, Ede, A, and Ploutz-Snyder, L. Can simulated partners boost workout effort in long-term exercise? J Strength Cond Res XX(X): 000-000, 2020-We tested whether exercising with a stronger simulated (i.e., software-generated) partner leads to greater work effort compared to exercising alone, to help those seeking to maintain or improve fitness levels with long-term high-intensity training, but who find it necessary or practical to exercise in social isolation. Forty-one middle-aged adults, who participated in at least 30 minutes of vigorous exercise 3x·wk, trained on a cycle ergometer 6 days per week for 24 weeks in an alternating regimen of moderate-intensity 30-minute continuous and 3 types of high-intensity interval sessions (8 × 30-second sprints, 6 × 2-minute ladders, and 4 × 4-minute intervals). They were assigned either no partner (control), an always superior partner, or a not always superior partner. Participants varied cycle power output to increase or decrease session intensity during the repeated moderate-intensity sessions (30-minute continuous) and 1 of the 3 high-intensity sessions (4 × 4-minute intervals). Changes in intensity were used as a measure of effort motivation over time. Nested multilevel models of effort trajectory were developed and alpha was set to 0.05. For continuous and interval sessions, effort trajectory was positive and significant for those with an always superior partner, but not significantly different from control. Within interval sessions, those with an always superior partner significantly increased effort in the fourth interval compared to control (p = 0.02). Exercising with an always superior partner leads to greater work efforts during the hardest interval training compared to exercising alone.",2020,Exercising with an always superior partner leads to greater work efforts during the hardest interval training compared to exercising alone.,"['Forty-one middle-aged adults, who participated in at least 30 minutes of']","['J Strength Cond Res XX(X', 'exercising with a stronger simulated (i.e., software-generated) partner leads to greater work effort compared to exercising alone, to help those seeking to maintain or improve fitness levels with long-term high-intensity training, but who find it necessary or practical to exercise in social isolation', 'vigorous exercise 3x·wk, trained on a cycle ergometer 6 days per week for 24 weeks in an alternating regimen of moderate-intensity 30-minute continuous and 3 types of high-intensity interval sessions']","['session intensity', 'Feltz, DL, Hill, CR, Samendinger, S, Myers, ND, Pivarnik, JM, Winn, B, Ede, A, and Ploutz-Snyder']","[{'cui': 'C0205847', 'cui_str': 'Middle aged'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0456693', 'cui_str': '/30 min'}]","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442821', 'cui_str': 'Strong'}, {'cui': 'C0037585', 'cui_str': 'Software'}, {'cui': 'C0682323', 'cui_str': 'Partner in relationship'}, {'cui': 'C0023175', 'cui_str': 'Lead'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0024501', 'cui_str': 'Maintenance'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0037421', 'cui_str': 'Social isolation'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0677547', 'cui_str': 'days/week'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332270', 'cui_str': 'Alternating'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0456693', 'cui_str': '/30 min'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]","[{'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0442532', 'cui_str': 'Hill'}]",41.0,0.015072,Exercising with an always superior partner leads to greater work efforts during the hardest interval training compared to exercising alone.,"[{'ForeName': 'Deborah L', 'Initials': 'DL', 'LastName': 'Feltz', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Hill', 'Affiliation': 'Department of Kinesiology, California State University, San Bernardino, California.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Samendinger', 'Affiliation': 'Department of Health Promotion and Wellness, Farmingdale State College, Farmingdale, New York.'}, {'ForeName': 'Nicholas D', 'Initials': 'ND', 'LastName': 'Myers', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Pivarnik', 'Affiliation': 'Department of Kinesiology, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Winn', 'Affiliation': 'Department of Media and Information, Michigan State University, East Lansing, Michigan.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Ede', 'Affiliation': 'Department of Kinesiology, California State University, Long Beach, California.'}, {'ForeName': 'Lori', 'Initials': 'L', 'LastName': 'Ploutz-Snyder', 'Affiliation': 'School of Kinesiology, University of Michigan, Ann Arbor, Michigan.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003732'] 2786,32733306,Transcutaneous Vagus Nerve Stimulation (tVNS) Improves High-Confidence Recognition Memory but Not Emotional Word Processing.,"Previous clinical research found that invasive vagus nerve stimulation (VNS) enhanced word recognition memory in epileptic patients, an effect assumed to be related to the activation of brainstem arousal systems. In this study, we applied non-invasive transcutaneous auricular VNS (tVNS) to replicate and extend the previous work. Using a single-blind, randomized, between-subject design, 60 healthy volunteers received active or sham stimulation during a lexical decision task, in which emotional and neutral stimuli were classified as words or non-words. In a subsequent recognition memory task (1 day after stimulation), participants' memory performance on these words and their subjective memory confidence were tested. Salivary alpha-amylase (sAA) levels, a putative indirect measure of central noradrenergic activation, were also measured before and after stimulation. During encoding, pleasant words were more accurately detected than neutral and unpleasant words. However, no tVNS effects were observed on task performance or on overall sAA level changes. tVNS also did not modulate overall recognition memory, which was particularly enhanced for pleasant emotional words. However, when hit rates were split based on confidence ratings reflecting familiarity- and recollection-based memory, higher recollection-based memory performance (irrespective of emotional category) was observed during active stimulation than during sham stimulation. To summarize, we replicated prior findings of enhanced processing and memory for emotional (pleasant) words. Whereas tVNS showed no effects on word processing, subtle effects on recollection-based memory performance emerged, which may indicate that tVNS facilitates hippocampus-mediated consolidation processes.",2020,"Whereas tVNS showed no effects on word processing, subtle effects on recollection-based memory performance emerged, which may indicate that tVNS facilitates hippocampus-mediated consolidation processes.","['60 healthy volunteers received', 'epileptic patients']","['invasive vagus nerve stimulation (VNS', 'active or sham stimulation during a lexical decision task, in which emotional and neutral stimuli were classified as words or non-words', 'Transcutaneous Vagus Nerve Stimulation (tVNS', 'invasive transcutaneous auricular VNS (tVNS']","['Salivary alpha-amylase (sAA) levels, a putative indirect measure of central noradrenergic activation', 'task performance or on overall sAA level changes', 'confidence ratings reflecting familiarity- and recollection-based memory, higher recollection-based memory performance (irrespective of emotional category', 'overall recognition memory']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0014544', 'cui_str': 'Epilepsy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C2350432', 'cui_str': 'Vagal Nerve Stimulation'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C1292856', 'cui_str': 'Stimulation'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0234402', 'cui_str': 'Stimulus'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0042926', 'cui_str': 'Vocabulary'}, {'cui': 'C1522191', 'cui_str': 'Otic route'}]","[{'cui': 'C2350322', 'cui_str': 'Salivary alpha-Amylases'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439852', 'cui_str': 'Indirect'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0237529', 'cui_str': 'Self-confidence'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0600269', 'cui_str': 'Familiarity'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1285654', 'cui_str': 'Memory performance'}, {'cui': 'C0013987', 'cui_str': 'Emotion'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}]",60.0,0.0721418,"Whereas tVNS showed no effects on word processing, subtle effects on recollection-based memory performance emerged, which may indicate that tVNS facilitates hippocampus-mediated consolidation processes.","[{'ForeName': 'Manon', 'Initials': 'M', 'LastName': 'Giraudier', 'Affiliation': 'Department of Biological Psychology and Affective Science, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Ventura-Bort', 'Affiliation': 'Department of Biological Psychology and Affective Science, University of Potsdam, Potsdam, Germany.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Weymar', 'Affiliation': 'Department of Biological Psychology and Affective Science, University of Potsdam, Potsdam, Germany.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01276'] 2787,32733313,Adoption of Human Personality Development Theory Combined With Deep Neural Network in Entrepreneurship Education of College Students.,"In this research, the probability matrix factorization (PMF) algorithm was introduced to optimize the deep neural network algorithm model with the purpose of studying the application value of personality development theory and deep learning neural network in college students' entrepreneurship psychological education courses. Based on the personality development theory, a recommendation algorithm system for entrepreneurial projects under optimized deep neural network was established. A total of 518 college students from several universities were divided into an experimental group and a control group, with 259 students in each group. In addition to the normal courses of entrepreneurship psychology education, students in the experimental group were taught the entrepreneurship project recommendation system based on the optimized deep neural network designed in this research, while students in the control group were taught entrepreneurship psychology education normally. The intervention effect before and after entrepreneurship education was evaluated by the questionnaire of college students' entrepreneurial intention and college students' entrepreneurial mental resilience scale. The results demonstrate that the system recall rate and accuracy based on the algorithm in this research have been significantly higher than that of PMF algorithm and deep belief network (DBN) algorithm, and the difference is statistically significant ( p < 0.05); the mean square error (MSE) of the proposed algorithm is significantly smaller than that of PMF algorithm and DBN algorithm, and the difference is statistically significant ( p < 0.05); the improvement of entrepreneurial toughness, entrepreneurial strength, optimism, entrepreneurial possibility, and behavioral tendency of the experimental group after the test was significantly higher than that of the control group ( p < 0.05). Therefore, compared with traditional algorithms, the proposed method for entrepreneurial projects based on the theory of personality development and the optimized deep neural network shows better performance, and it can effectively improve the entrepreneurial intention and psychological resilience of college students.",2020,The intervention effect before and after entrepreneurship education was evaluated by the questionnaire of college students' entrepreneurial intention and college students' entrepreneurial mental resilience scale.,"['College Students', ""college students' entrepreneurship psychological education courses"", ""college students' entrepreneurial intention and college students' entrepreneurial mental resilience scale"", 'college students', '518 college students from several universities were divided into an experimental group and a control group, with 259 students in each group']",['Human Personality Development Theory Combined With Deep Neural Network'],"['system recall rate and accuracy', 'mean square error (MSE', 'entrepreneurial toughness, entrepreneurial strength, optimism, entrepreneurial possibility, and behavioral tendency']","[{'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0085116', 'cui_str': 'Entrepreneurship'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0031210', 'cui_str': 'Personality Development'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0242406', 'cui_str': 'Neural Networks (Anatomic)'}]","[{'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0205120', 'cui_str': 'Square'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",518.0,0.0199519,The intervention effect before and after entrepreneurship education was evaluated by the questionnaire of college students' entrepreneurial intention and college students' entrepreneurial mental resilience scale.,"[{'ForeName': 'Zhen', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'School of Humanities and Law, Northeastern University, Shenyang, China.'}, {'ForeName': 'Xiaoxuan', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': 'School of Humanities and Law, Northeastern University, Shenyang, China.'}]",Frontiers in psychology,['10.3389/fpsyg.2020.01346'] 2788,32733445,Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women.,"The RV144 HIV-vaccine trial highlighted the importance of envelope-specific non-neutralizing antibody (nNAb) Fc-mediated functions as immune correlates of reduced risk of infection. Since pre-exposure prophylaxis (PrEP) and HIV-vaccines are being used as a combination prevention strategy in at risk populations, the effects of PrEP on nNAb functions both mucosally and systemically remain undefined. Previous animal and human studies demonstrated reduced HIV-specific antibody binding avidity post-HIV seroconversion with PrEP, which in turn may affect antibody functionality. In seroconverters from the CAPRISA 004 tenofovir gel trial, we previously reported significantly higher detection and titres of HIV-specific binding antibodies in the plasma and genital tract (GT) that distinguished the tenofovir from the placebo arm. We hypothesized that higher HIV-specific antibody titres and detection reflected corresponding increased antibody-dependent neutrophil-mediated phagocytosis (ADNP) and NK-cell-activated antibody-dependent cellular cytotoxic (ADCC) activities. HIV-specific V1V2-gp70, gp120, gp41, p66, and p24 antibodies in GT and plasma samples of 48 seroconverters from the CAPRISA 004 tenofovir gel trial were tested for ADCP and ADCC at 3, 6- and 12-months post-HIV-infection. GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively ( p < 0.05). Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC increased significantly over time ( p < 0.05) in the tenofovir arm. In the tenofovir arm only, significant inverse correlations were observed between gp120-specific ADCC and gp120-antibody titres ( r = -0.54; p = 0.009), and gp41-specific ADNP and gp41-specific antibody titres at 6 months post-infection ( r = -0.50; p = 0.015). In addition, in the tenofovir arm, gp41-specific ADCC showed significant direct correlations between the compartments ( r = 0.53; p = 0.045). Certain HIV-specific nNAb activities not only dominate specific immunological compartments but can also exhibit diverse functions within the same compartment. Our previous findings of increased HIV specific antibody detection and titres in women who used tenofovir gel, and the limited differences in nNAb activities between the arms, suggest that prior PrEP did not modulate these nNAb functions post-HIV seroconversion. Together these data provide insight into envelope-specific-nNAb Fc-mediated functions at the site of exposure which may inform on ensuing immunity during combination HIV prevention strategies including PrEP and HIV vaccines.",2020,GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively ( p < 0.05).,['Women'],"['Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific', 'tenofovir', 'placebo']","['higher HIV-specific antibody titres and detection reflected corresponding increased antibody-dependent neutrophil-mediated phagocytosis (ADNP) and NK-cell-activated antibody-dependent cellular cytotoxic (ADCC) activities', 'gp41-specific ADNP and gp41-specific antibody titres', 'Plasma gp120-, gp41-, and p66-specific ADNP, and GT gp41-specific ADCC', 'Fc-Mediated Antibody Activities', 'detection and titres of HIV-specific binding antibodies in the plasma and genital tract (GT', 'gp120-specific ADCC and gp120-antibody titres', 'GT gp41- and p24-specific ADNP']","[{'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0384228', 'cui_str': 'Tenofovir'}, {'cui': 'C3850098', 'cui_str': 'Pre-Exposure Prophylaxis (PrEP)'}, {'cui': 'C0026724', 'cui_str': 'Mucosal'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}, {'cui': 'C0558058', 'cui_str': 'Reflecting'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0027950', 'cui_str': 'Polymorphonuclear leukocyte'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}, {'cui': 'C0031308', 'cui_str': 'Phagocytosis'}, {'cui': 'C0022688', 'cui_str': 'NK-cell'}, {'cui': 'C0007634', 'cui_str': 'Cell structure'}, {'cui': 'C0304497', 'cui_str': 'Cytotoxic agent'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0019692', 'cui_str': 'Envelope Protein gp41, HIV'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0019691', 'cui_str': 'env Protein gp120, HIV'}, {'cui': 'C0017420', 'cui_str': 'Reproductive System'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0332297', 'cui_str': 'Bounded by'}, {'cui': 'C0085219', 'cui_str': 'HIV p24 antigen'}]",,0.0497038,GT gp41- and p24-specific ADNP were significantly higher in the tenofovir than the placebo arm at 6 and 12 months respectively ( p < 0.05).,"[{'ForeName': 'Kimone Leigh', 'Initials': 'KL', 'LastName': 'Fisher', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Jennifer M', 'Initials': 'JM', 'LastName': 'Mabuka', 'Affiliation': 'Africa Health Research Institute, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Sivro', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Sinaye', 'Initials': 'S', 'LastName': 'Ngcapu', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Jo-Ann Shelley', 'Initials': 'JS', 'LastName': 'Passmore', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Farzana', 'Initials': 'F', 'LastName': 'Osman', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Bongiwe', 'Initials': 'B', 'LastName': 'Ndlovu', 'Affiliation': 'HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Quarraisha', 'Initials': 'Q', 'LastName': 'Abdool Karim', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Salim S', 'Initials': 'SS', 'LastName': 'Abdool Karim', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Amy W', 'Initials': 'AW', 'LastName': 'Chung', 'Affiliation': 'Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'Cheryl', 'Initials': 'C', 'LastName': 'Baxter', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}, {'ForeName': 'Derseree', 'Initials': 'D', 'LastName': 'Archary', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.'}]",Frontiers in immunology,['10.3389/fimmu.2020.01274'] 2789,32733565,Time-Dependent Effect of Chitosan Nanoparticles as Final Irrigation on the Apical Sealing Ability and Push-Out Bond Strength of Root Canal Obturation.,"Materials and Methods Fifty-six premolars were used in this study and divided by two evaluations: 28 teeth for apical sealing ability and 28 others for bond strength. Each study was assigned randomly into two groups of fourteen teeth: Group-1, final irrigation with 17% EDTA; Group-2, with 0.5% chitosan nanoparticles. Each group was further divided into two groups of 7 each: Group-A, final irrigation was applied for 1 minute; Group-B, for 3 minutes. All teeth were obturated with epoxy resin-based sealer and gutta-percha. In the apical sealing ability study, the obturated teeth were immersed in 2% methylene blue and observed under a stereomicroscope (8x magnification). In the bond strength study, the teeth were tested using the push-out technique and observed under a stereomicroscope (40x magnification) to determine the failure type. Data from each evaluation were analysed with two-way ANOVA followed by the LSD test. Results Final irrigation using 0.5% chitosan nanoparticles produced the same apical sealing ability and bond strength as 17% EDTA ( p > 0.05). A significant difference occurred between application times ( p < 0.05). The failure type was observed predominantly as cohesive, and the least was adhesive. Conclusion Regardless of the final irrigation solution used, 3-minute application time produced greater apical sealing ability and push-out bond strength than 1-minute application time.",2020,"Regardless of the final irrigation solution used, 3-minute application time produced greater apical sealing ability and push-out bond strength than 1-minute application time.",['Materials and Methods\n\n\nFifty-six premolars were used in this study and divided by two evaluations: 28 teeth for apical sealing ability and 28 others for bond strength'],"['Chitosan Nanoparticles', 'epoxy resin-based sealer and gutta-percha', 'final irrigation with 17% EDTA; Group-2, with 0.5% chitosan nanoparticles']","['apical sealing ability and push-out bond strength', 'Apical Sealing Ability and Push-Out Bond Strength of Root Canal Obturation', 'apical sealing ability and bond strength']","[{'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C1704302', 'cui_str': 'Structure of premolar tooth'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}]","[{'cui': 'C0162969', 'cui_str': 'Chitosan'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C0014631', 'cui_str': 'Epoxy resin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0449942', 'cui_str': 'Sealer'}, {'cui': 'C0018407', 'cui_str': 'Gutta percha'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0022100', 'cui_str': 'Irrigation'}, {'cui': 'C0013618', 'cui_str': 'Edetic Acid'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0444500', 'cui_str': '0.5'}]","[{'cui': 'C0205111', 'cui_str': 'Apical'}, {'cui': 'C0036492', 'cui_str': 'Seal'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0580841', 'cui_str': 'Does push'}, {'cui': 'C0028758', 'cui_str': 'Bonding (Psychology)'}, {'cui': 'C0035848', 'cui_str': 'Root canal obturation'}]",56.0,0.0145571,"Regardless of the final irrigation solution used, 3-minute application time produced greater apical sealing ability and push-out bond strength than 1-minute application time.","[{'ForeName': 'Diatri Nari', 'Initials': 'DN', 'LastName': 'Ratih', 'Affiliation': 'Department of Conservative Dentistry, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.'}, {'ForeName': 'Nikita Ika', 'Initials': 'NI', 'LastName': 'Sari', 'Affiliation': 'Specialist Study Program of Conservative Dentistry, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.'}, {'ForeName': 'Pribadi', 'Initials': 'P', 'LastName': 'Santosa', 'Affiliation': 'Department of Conservative Dentistry, Faculty of Dentistry, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.'}, {'ForeName': 'Nofa Mardia Ningsih', 'Initials': 'NMN', 'LastName': 'Kaswati', 'Affiliation': 'Nanotech Indonesia, Serpong, Tangerang Selatan, Banten 15314, Indonesia.'}]",International journal of dentistry,['10.1155/2020/8887593'] 2790,32734204,Interventions to Improve Blood Pressure Control Among Socioeconomically Disadvantaged Patients With CKD: Kidney Awareness Registry and Education Pilot Randomized Controlled Trial.,"Rationale & Objective Sustainable interventions that enhance chronic kidney disease (CKD) management are not often studied in safety-net primary care, in which populations bear a disproportionate burden of disease and experience translational gaps between research and practice. We tested the feasibility of implementing and the impact of 2 technology-enhanced interventions designed to enhance CKD care delivery. Study Design A 2×2 randomized controlled pilot trial. Setting & Participants Primary care provider teams (n = 6) and 137 patients with CKD aged 18 to 75 years from 2 safety-net primary care clinics, 2013 to 2015. Interventions Primary care provider teams were randomly assigned to access a CKD registry with point-of-care notifications and quarterly feedback or a usual-care registry for 12 months. Patients within provider teams were randomly assigned to participate in a CKD self-management support program or usual care for 12 months. Outcomes We examined recruitment, randomization, and participation in each intervention. We also examined the impact of each intervention and their combination on change in systolic blood pressure (SBP), albuminuria, and patient self-reported behavioral measures after 12 months. Results Among potentially eligible patients identified using the electronic health record, 24% were eligible for study participation, of whom 35% (n = 137) were enrolled. Mean age was 55 years, 41% were non-English speaking, and 93% were of racial/ethnic minority. Mean baseline estimated glomerular filtration rate was 70.5 (SD = 30.3) mL/min/1.73 m 2 ; mean baseline SBP was 131 (SD = 21.8) mm Hg. Nearly 90% of clinicians reported that the CKD registry influenced their CKD management. More than 95% of patients randomly assigned to CKD self-management support engaged regularly with the intervention. Estimated changes in SBP over 1 year were nonstatistically different in each of the 3 intervention groups compared with usual care: (usual care: 0.5 [95% CI, -5.2 to 6.3] mm Hg; CKD registry only: -5.4 [95% CI, -12.2 to 1.4] mm Hg; CKD self-management support only: -6.4 [95% CI, -13.7 to 1.0] mm Hg; and CKD registry plus CKD self-management support: -0.5 [-5.5 to 4.5] mm Hg), though differences were larger among those with baseline SBPs > 140/90 mm Hg. Decreases in albuminuria were similarly nonstatistically different in each of the intervention groups compared with usual care. No differences were observed in patient self-reported behaviors. Limitations Single health system. Conclusions Patient and provider interventions to improve CKD care are feasible to implement in low-income settings with promising results among those with uncontrolled blood pressure. Funding National Institute of Diabetes and Digestive and Kidney Diseases. Trial Registration ClinicalTrials.gov, number: NCT01530958.",2019,"Estimated changes in SBP over 1 year were nonstatistically different in each of the 3 intervention groups compared with usual care: (usual care: 0.5 [95% CI, -5.2 to 6.3] mm Hg; CKD registry only: -5.4","['Socioeconomically Disadvantaged Patients With CKD', 'Mean age was 55 years, 41% were non-English speaking, and 93% were of racial/ethnic minority', 'aged 18 to 75 years from 2 safety-net primary care clinics, 2013 to\xa02015', 'potentially eligible patients identified using the electronic health record, 24% were eligible for study participation, of whom 35% (n\xa0= 137) were enrolled', 'Patients within provider teams', 'Interventions\n\n\nPrimary care provider teams', 'Setting & Participants\n\n\nPrimary care provider teams (n\xa0= 6) and 137 patients with CKD']","['CKD registry with point-of-care notifications and quarterly feedback or a usual-care registry for 12 months', 'CKD self-management support program or usual care for 12 months']","['patient self-reported behaviors', 'Decreases in albuminuria', 'systolic blood pressure (SBP), albuminuria, and patient self-reported behavioral measures', 'Blood Pressure Control', 'glomerular filtration rate', 'SBP']","[{'cui': 'C0012613', 'cui_str': 'Disadvantaged'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0015031', 'cui_str': 'Ethnic group'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1456447', 'cui_str': 'SLC6A2 protein, human'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2735026', 'cui_str': 'Primary care provider'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}]","[{'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0282664', 'cui_str': 'Point-of-Care'}, {'cui': 'C0422202', 'cui_str': 'Notifications'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0086969', 'cui_str': 'Self Management'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}]",137.0,0.0457037,"Estimated changes in SBP over 1 year were nonstatistically different in each of the 3 intervention groups compared with usual care: (usual care: 0.5 [95% CI, -5.2 to 6.3] mm Hg; CKD registry only: -5.4","[{'ForeName': 'Delphine S', 'Initials': 'DS', 'LastName': 'Tuot', 'Affiliation': 'Division of Nephrology, University of California, San Francisco, CA.'}, {'ForeName': 'Anna D', 'Initials': 'AD', 'LastName': 'Rubinsky', 'Affiliation': 'Kidney Health Research Collaborative, University of California, San Francisco, CA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Velasquez', 'Affiliation': 'Division of Nephrology, University of California, San Francisco, CA.'}, {'ForeName': 'Charles E', 'Initials': 'CE', 'LastName': 'McCulloch', 'Affiliation': 'Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Schillinger', 'Affiliation': 'Center for Vulnerable Populations at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA.'}, {'ForeName': 'Margaret A', 'Initials': 'MA', 'LastName': 'Handley', 'Affiliation': 'Center for Vulnerable Populations at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA.'}, {'ForeName': 'Chi-Yuan', 'Initials': 'CY', 'LastName': 'Hsu', 'Affiliation': 'Division of Nephrology, University of California, San Francisco, CA.'}, {'ForeName': 'Neil R', 'Initials': 'NR', 'LastName': 'Powe', 'Affiliation': 'Center for Vulnerable Populations at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, University of California, San Francisco, CA.'}]",Kidney medicine,['10.1016/j.xkme.2019.07.004'] 2791,32734207,Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies.,"Rationale & Objective Epoetin alfa-epbx is a biosimilar to the reference product, epoetin alfa. We compare the safety of epoetin alfa-epbx versus epoetin alfa based on a pooled analysis of findings from 2 randomized, double-blind, comparative clinical studies, and report new data for the long-term safety of epoetin alfa-epbx. Study Design Pooled analyses of previously conducted studies. Setting & Participants Hemodialysis patients with anemia. Interventions Data from patients who received 1 or more subcutaneous or intravenous doses of study drug were integrated across route of administration in combined randomized groups (epoetin alfa-epbx, n = 423; epoetin alfa, n = 426). Data from patients who received 1 or more doses of epoetin alfa-epbx in either open-label extension trial were integrated across route of administration in a combined long-term safety studies group (n = 576). Outcomes Adverse events (AEs), immunogenicity, and other outcomes were assessed. Results Incidences of treatment-emergent AEs, serious AEs, and discontinuation of study drug treatment because of treatment-emergent AEs were similar between combined randomized epoetin alfa-epbx and epoetin alfa, which had mean treatment durations of 18.1 and 17.7 weeks, respectively. Incidences of treatment-emergent AEs, serious AEs, and discontinuation of study drug treatment because of treatment-emergent AEs were 86.5%, 39.4%, and 6.6%, respectively, for the combined long-term safety studies group, which had a mean treatment duration of 40.0 weeks. In total, 12 patients across the combined randomized groups (epoetin alfa-epbx, n = 5; epoetin alfa, n = 7) and 9 patients in the combined long-term safety studies group tested anti-recombinant human erythropoietin antibody positive in 1 or more visits during study conduct. No patient in any group developed neutralizing antibodies or pure red blood cell aplasia. Limitations Epoetin alfa comparator not included in the long-term safety studies, greater cumulative exposure to study drug for epoetin alfa-epbx, shorter follow-up in the randomized studies, and potential for selection bias among patients in the open-label long-term safety studies. Conclusions This analysis reinforces previous conclusions of similar safety profiles between epoetin alfa-epbx and epoetin alfa. Furthermore, epoetin alfa-epbx had no unexpected safety signals during long-term treatment. Funding This study was funded by Hospira Inc, which was acquired by Pfizer Inc in September 2015. Trial Registration ClinicalTrials.gov EPOE-10-13 (NCT01473420); EPOE-10-01 (NCT01473407); EPOE-11-04 (NCT01628120); EPOE-11-03 (NCT01628107).",2019,"No patient in any group developed neutralizing antibodies or pure red blood cell aplasia. ","['Participants\n\n\nHemodialysis patients with anemia', 'Anemia in ESKD']","['epoetin alfa-epbx', 'Epoetin alfa-epbx', 'Epoetin Alfa-epbx', 'epoetin alfa-epbx versus epoetin alfa', 'epoetin alfa-epbx and epoetin alfa', 'epoetin alfa-epbx, n\xa0= 5; epoetin alfa, n\xa0= 7) and 9 patients in the combined long-term safety studies group tested anti-recombinant human erythropoietin antibody positive', 'epoetin alfa-epbx, n\xa0= 423; epoetin alfa']","['neutralizing antibodies or pure red blood cell aplasia', 'Outcomes\n\n\nAdverse events (AEs), immunogenicity, and other outcomes', 'safety signals']","[{'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}]","[{'cui': 'C4694938', 'cui_str': 'epoetin alfa-epbx'}, {'cui': 'C0357126', 'cui_str': 'Epoetin Alfa'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0014822', 'cui_str': 'erythropoietin'}, {'cui': 'C0741132', 'cui_str': 'Antibody test positive'}]","[{'cui': 'C0282682', 'cui_str': 'Blocking antibody'}, {'cui': 'C0014772', 'cui_str': 'Red blood cell count'}, {'cui': 'C0000846', 'cui_str': 'Agenesis'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0037083', 'cui_str': 'Signal transduction'}]",,0.249311,"No patient in any group developed neutralizing antibodies or pure red blood cell aplasia. ","[{'ForeName': 'Jay B', 'Initials': 'JB', 'LastName': 'Wish', 'Affiliation': 'Indiana University, Indianapolis, IN.'}, {'ForeName': 'Marcelo G', 'Initials': 'MG', 'LastName': 'Rocha', 'Affiliation': 'Pfizer Inc, Lake Forest, IL.'}, {'ForeName': 'Nancy E', 'Initials': 'NE', 'LastName': 'Martin', 'Affiliation': 'Pfizer Inc, Lake Forest, IL.'}, {'ForeName': 'Christian Russel D', 'Initials': 'CRD', 'LastName': 'Reyes', 'Affiliation': 'Pfizer Inc, Manila, Philippines.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Fishbane', 'Affiliation': 'Hofstra Northwell School of Medicine, Hempstead, NY.'}, {'ForeName': 'Mark T', 'Initials': 'MT', 'LastName': 'Smith', 'Affiliation': 'Nephrology Associates, Augusta, GA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Nassar', 'Affiliation': 'Houston Methodist Hospital, Houston, TX.'}]",Kidney medicine,['10.1016/j.xkme.2019.06.009'] 2792,32734226,Nonsurgical Periodontal Therapy in CKD: Findings of the Kidney and Periodontal Disease (KAPD) Pilot Randomized Controlled Trial.,"Rationale & Objective Observational studies have suggested that periodontal disease may be a modifiable risk factor for chronic kidney disease (CKD). The Kidney and Periodontal Disease (KAPD) Study was designed to determine the feasibility of conducting a periodontal disease treatment trial among a high-risk (mostly poor and racial/ethnic minority) population and estimate the magnitude and variability of kidney and inflammatory biomarker levels in response to intensive periodontal treatment. Study Design Single-center, unmasked, intention-to-treat, randomized, controlled, pilot trial with 2:1 allocation to the treatment and comparison groups. Setting & Participants English- and Spanish-speaking individuals aged 20 to 75 years receiving primary care within the San Francisco Community Health Network with evidence of both moderate to severe periodontal disease and CKD. Intervention Immediate intensive nonsurgical periodontal treatment versus rescue treatment for progressive disease at baseline and 4, 8, and 12 months. Outcomes Feasibility and process outcomes. Levels of biomarkers of kidney function, kidney injury, and systemic inflammation obtained at baseline and 4 and 12 months. Results KAPD randomly assigned 51 participants to the immediate (34 participants) or rescue (17 participants) groups. 14% dropped out of the study (4 immediate, 3 rescue) and 80% completed all 4 visits of the 12-month protocol (28 immediate, 13 rescue). Fewer than half the teeth recommended for extraction were extracted and 40% of immediate group visits were outside the protocol window. Bleeding on probing and probing depth improved more in the immediate group than in the rescue group; there was no significant separation in periodontal status. Levels of markers of vascular endothelial and systemic injury declined in both groups. Limitations No true control group. Conclusions This 12-month, pilot, randomized, controlled trial successfully recruited and retained a high-risk population but was less successful observing treatment adherence, treatment effect, and variability of biomarker levels. Although KAPD did not meet all of its goals, important lessons learned can be applied to future studies. Funding National Institute of Diabetes and Digestive and Kidney Disease (Bethesda, MD; grant number 1K23DK093710-01A1) and Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation, Princeton, NJ. Funders had no role in study design; collection, analysis, or interpretation of data; writing the report; or the decision to submit the report for publication. Trial Registration NCT01802216.",2020,Bleeding on probing and probing depth improved more in the immediate group than in the rescue group; there was no significant separation in periodontal status.,"['aged 20 to 75 years receiving primary care within the San Francisco Community Health Network with evidence of both moderate to severe periodontal disease and CKD', 'Kidney and Periodontal Disease (KAPD', '51 participants to the immediate (34 participants) or rescue (17 participants) groups', 'Setting & Participants\n\n\nEnglish- and Spanish-speaking individuals']",['KAPD'],"['periodontal status', 'Levels of biomarkers of kidney function, kidney injury, and systemic inflammation', 'Bleeding on probing and probing depth', 'Levels of markers of vascular endothelial and systemic injury']","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0036152', 'cui_str': 'San Francisco'}, {'cui': 'C0282622', 'cui_str': 'Community Health Networks'}, {'cui': 'C0332120', 'cui_str': 'Evidence of'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0037750', 'cui_str': 'Spanish language'}, {'cui': 'C0027361', 'cui_str': 'Person'}]","[{'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0031090', 'cui_str': 'Periodontal disease'}]","[{'cui': 'C2960678', 'cui_str': 'Periodontal route'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0232804', 'cui_str': 'Renal function'}, {'cui': 'C0160420', 'cui_str': 'Injury of kidney'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0014257', 'cui_str': 'Structure of endothelium tissue'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}]",51.0,0.0584869,Bleeding on probing and probing depth improved more in the immediate group than in the rescue group; there was no significant separation in periodontal status.,"[{'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Grubbs', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA.'}, {'ForeName': 'Faviola', 'Initials': 'F', 'LastName': 'Garcia', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vittinghoff', 'Affiliation': 'Division of Epidemiology & Biostatistics, University of California, San Francisco, CA.'}, {'ForeName': 'Bonnie L', 'Initials': 'BL', 'LastName': 'Jue', 'Affiliation': 'Oral Epidemiology & Dental Public Health, Department of Preventive & Restorative Dental Sciences, University of California, San Francisco, CA.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Ryder', 'Affiliation': 'Division of Periodontology, University of California, San Francisco, CA.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Lovett', 'Affiliation': 'Division of Nephrology, San Francisco Veterans Affairs Medical Center, San Francisco, CA.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Offenbacher', 'Affiliation': 'Department of Periodontology, Center for Oral and Systemic Diseases, UNC School of Dentistry, San Francisco, CA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Taylor', 'Affiliation': 'Oral Epidemiology & Dental Public Health, Department of Preventive & Restorative Dental Sciences, University of California, San Francisco, CA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Ganz', 'Affiliation': 'Division of Cardiology, University of California, San Francisco, San Francisco, CA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Bibbins-Domingo', 'Affiliation': 'Division of Epidemiology & Biostatistics, University of California, San Francisco, CA.'}, {'ForeName': 'Neil R', 'Initials': 'NR', 'LastName': 'Powe', 'Affiliation': 'Department of Medicine, University of California, San Francisco, CA.'}]",Kidney medicine,['10.1016/j.xkme.2019.09.005'] 2793,32734238,Efficacy and Safety of a Balanced Salt Solution Versus a 0.9% Saline Infusion for the Prevention of Contrast-Induced Acute Kidney Injury After Contrast-Enhanced Computed Tomography.,"Rationale & Objective We aimed to elucidate whether a balanced salt solution decreases the occurrence of contrast-induced acute kidney injury (CI-AKI) after contrast-enhanced computed tomography (CE-CT) as compared to 0.9% saline solution. Study Design A randomized clinical trial. Setting & Participants The study was performed in 14 tertiary hospitals in South Korea. Patients with estimated glomerular filtration rates (eGFRs) < 45 or <60 mL/min/1.73 m 2 and additional risk factors (age ≥ 60 years or diabetes) who were undergoing scheduled CE-CT were included from December 2016 to December 2018. Intervention An open-label intervention was performed. The study group received a balanced salt solution and the control group received 0.9% saline solution as prophylactic fluids for CE-CT. Outcomes The primary outcome was CI-AKI, defined by creatinine level elevation ≥ 0.5 mg/dL or 25% from baseline within 48 to 72 hours after CE-CT. Secondary outcomes included AKI defined based on the KDIGO (Kidney Disease: Improving Global Outcomes) guideline, eGFR changes, death, or requiring dialysis within 6 months after CE-CT. Results 493 patients received the study fluids. The control and study groups included 251 and 242 patients, respectively. The occurrence of CI-AKI in the study (10 [4.2%]) and control (17 [6.8%]) groups was not significantly different ( P  = 0.27). No significant difference was present for the secondary outcomes; AKI by the KDIGO definition (study: 19 [7.9%], control: 27 [10.8%]; P  = 0.33), death/dialysis (study: 11 [4.7%], control: 9 [3.7%]; P  = 0.74), and eGFR changes (study: 0.1 ± 0.2 mg/dL, control: 0.3 ± 2.8 mg/dL; P  = 0.69). Limitations This study failed to meet target enrollment. Conclusions The risk for CI-AKI was similar after administration of a balanced salt solution and after use of 0.9% saline solution during CE-CT in higher-risk patients. Funding This study was funded by CJ Healthcare (CS2015_0046). Trial Registration Registered at ClinicalTrials.gov with study number NCT02799368.",2020,groups was not significantly different ( P  = 0.27).,"['Setting & Participants', 'Patients with estimated glomerular filtration rates (eGFRs', 'm 2 and additional risk factors (age\xa0≥\xa060 years or diabetes) who were undergoing scheduled CE-CT were included from December 2016 to December\xa02018', '493 patients received the study fluids', '14 tertiary hospitals in South Korea']","['balanced salt solution', 'Intervention\n\n\nAn open-label intervention', 'contrast-enhanced computed tomography (CE-CT', 'Balanced Salt Solution', 'balanced salt solution and the control group received 0.9% saline solution', 'mg/dL, control: 0.3\xa0±']","['Efficacy and Safety', 'occurrence of contrast-induced acute kidney injury (CI-AKI', 'Acute Kidney Injury', 'AKI defined based on the KDIGO (Kidney Disease: Improving Global Outcomes) guideline, eGFR changes, death, or requiring dialysis within 6 months after CE-CT', 'death/dialysis', 'occurrence of CI-AKI', 'CI-AKI, defined by creatinine level elevation\xa0≥', 'risk for CI-AKI']","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0017654', 'cui_str': 'Glomerular filtration rate'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0005889', 'cui_str': 'Body fluid'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}, {'cui': 'C0022773', 'cui_str': 'Republic of Korea'}]","[{'cui': 'C0205415', 'cui_str': 'Balanced'}, {'cui': 'C3653289', 'cui_str': 'Salt solutions'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0445115', 'cui_str': 'Normal Saline'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C4068885', 'cui_str': '0.3'}]","[{'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0009924', 'cui_str': 'Contrast media'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0022660', 'cui_str': 'Acute renal failure syndrome'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0162791', 'cui_str': 'Guidelines as Topic'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0201975', 'cui_str': 'Creatinine measurement'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}]",,0.405472,groups was not significantly different ( P  = 0.27).,"[{'ForeName': 'Sehoon', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Armed Forces Capital Hospital, Gyeonggi-do, Korea.'}, {'ForeName': 'Dong Ki', 'Initials': 'DK', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}, {'ForeName': 'Hee-Yeon', 'Initials': 'HY', 'LastName': 'Jung', 'Affiliation': 'Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Chan-Duck', 'Initials': 'CD', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Jang-Hee', 'Initials': 'JH', 'LastName': 'Cho', 'Affiliation': 'Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.'}, {'ForeName': 'Ran-Hui', 'Initials': 'RH', 'LastName': 'Cha', 'Affiliation': 'Department of Internal Medicine, National Medical Center, Seoul, Korea.'}, {'ForeName': 'Jong Cheol', 'Initials': 'JC', 'LastName': 'Jeong', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea.'}, {'ForeName': 'Sejoong', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea.'}, {'ForeName': 'Hyung-Jong', 'Initials': 'HJ', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Bundang CHA Medical Center, CHA University, Gyeonggi-do, Korea.'}, {'ForeName': 'Tae Hyun', 'Initials': 'TH', 'LastName': 'Ban', 'Affiliation': ""Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Byung Ha', 'Initials': 'BH', 'LastName': 'Chung', 'Affiliation': ""Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.""}, {'ForeName': 'Jung Pyo', 'Initials': 'JP', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.'}, {'ForeName': 'Jung Tak', 'Initials': 'JT', 'LastName': 'Park', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Seung Hyeok', 'Initials': 'SH', 'LastName': 'Han', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Tae-Hyun', 'Initials': 'TH', 'LastName': 'Yoo', 'Affiliation': 'Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Dong-Ryeol', 'Initials': 'DR', 'LastName': 'Ryu', 'Affiliation': 'Department of Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, Korea.'}, {'ForeName': 'Sung Jin', 'Initials': 'SJ', 'LastName': 'Moon', 'Affiliation': ""Department of Internal Medicine, Catholic Kwandong University International St. Mary's Hospital, Incheon, Korea.""}, {'ForeName': 'Jung Eun', 'Initials': 'JE', 'LastName': 'Lee', 'Affiliation': 'Department of Internal Medicine, Samsung Medical Center, Seoul, Korea.'}, {'ForeName': 'Wooseong', 'Initials': 'W', 'LastName': 'Huh', 'Affiliation': 'Department of Internal Medicine, Samsung Medical Center, Seoul, Korea.'}, {'ForeName': 'Ea Wha', 'Initials': 'EW', 'LastName': 'Kang', 'Affiliation': 'Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea.'}, {'ForeName': 'Tae Ik', 'Initials': 'TI', 'LastName': 'Chang', 'Affiliation': 'Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Gyeonggi-do, Korea.'}, {'ForeName': 'Kwon Wook', 'Initials': 'KW', 'LastName': 'Joo', 'Affiliation': 'Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.'}]",Kidney medicine,['10.1016/j.xkme.2019.12.003'] 2794,32730797,Balance training monitoring and individual response during unstable vs. stable balance Exergaming in elderly adults: Findings from a randomized controlled trial.,"OBJECTIVE Exercise-based fall prevention programs mainly refer to multimodal and challenging balance exercises. Individual load monitoring and interpretations are crucial to enable adequate adaptation responses on the individual level. Thus, assessing internal responses to external stimuli throughout an intervention period need to be adequately addressed. The aim of this secondary analysis of a 3-armed randomized controlled trial was to analyze internal and external loads of unstable vs. stable balance Exergame training in healthy seniors. We intended to elucidate whether differences of external and internal load criteria occur over the intervention period. METHODS A total of 51 healthy seniors (females: n = 34; males: n = 17; age: 69 ± 6 years; BMI: 27 ± 5) were allocated to either volitional stepping (VOL), volitional stepping under unstable conditions (VOL + US) or an inactive control group (CON). VOL and VOL + US completed 8 weeks of Exergame based step training (three weekly sessions, 45 min each) using the Dividat Senso device. Twelve different balance Exergames were used, consisting of virtual reality like video games. The original nonswinging, stable platform was employed for VOL, whereas VOL + US used an adapted Senso mounted on a swinging Posturomed Rack. The instability level was increased for VOL + US only every second week. External (game scores) and internal (perceived efforts, using the rated perceived exertion scale (RPE)) load measures were individually recorded for every session. Statistical analysis was carried out using linear mixed-effects modelling. RESULTS Although VOL + US completed similar games at identical training volumes under unstable conditions, the achieved game scores did not significantly differ between both training groups (p = 0.71). Both intervention groups notably improved their game scores over the 8 training weeks (p < 0.01). A significant time x group interaction effect was observed for perceived effort (p < 0.01), serving as an internal load measure. Subsequent post-hoc testing revealed significant greater perceived exertion values in each of the first 7 weeks (p < 0.05) in VOL + US compared to VOL. No between-group differences were found for RPE in week 8. Whereas RPE values in VOL + US decreased over time (week 1: 4.6 ± 1.9; week 8: 3.1 ± 1.6), VOL indicated similar RPE values for all weeks (week 1: 3.1 ± 1.3; week 8: 2.9 ± 1.4). A detailed analysis of all twelve games revealed that differences in perceived exertion depend on the game content: in 75% of the involved games the RPE level was significantly higher in VOL + US compared to VOL (p < 0.05). CONCLUSION Monitoring internal and external loads on individual level are paramount for gaining adequate training adaptations. Our results indicate that between-group differences in perceived efforts a) can funnel over time, b) depend on game content and c) do not necessarily affect overall scoring. Future studies should individually employ and monitor measures of perceived efforts to guarantee an adequate challenge to the balance system within exercise-based fall prevention programs.",2020,Both intervention groups notably improved their game scores over the 8 training weeks (p < 0.01).,"['51 healthy seniors (females: n\u202f=\u202f34; males: n\u202f=\u202f17; age: 69\u202f±\u202f6\u202fyears; BMI: 27\u202f±\u202f5', 'healthy seniors', 'elderly adults']","['unstable vs. stable balance Exergame training', 'volitional stepping (VOL), volitional stepping under unstable conditions (VOL\u202f+\u202fUS) or an inactive control group (CON', 'Balance training monitoring', 'Exercise-based fall prevention programs']","['instability level', 'game scores', 'perceived exertion', 'RPE values', 'exertion values', 'RPE level', 'External (game scores) and internal (perceived efforts, using the rated perceived exertion scale (RPE)) load measures']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0443343', 'cui_str': 'Unstable status'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0150369', 'cui_str': 'Preventive monitoring'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0150223', 'cui_str': 'Fall prevention'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0085633', 'cui_str': 'Mood swings'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0034693', 'cui_str': 'Rattus norvegicus'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0079809', 'cui_str': 'Measure'}]",51.0,0.0158194,Both intervention groups notably improved their game scores over the 8 training weeks (p < 0.01).,"[{'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Bakker', 'Affiliation': 'Institute of Exercise Training and Sport Informatics, German Sport University, Cologne, Germany.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Donath', 'Affiliation': 'Institute of Exercise Training and Sport Informatics, German Sport University, Cologne, Germany.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Rein', 'Affiliation': 'Institute of Exercise Training and Sport Informatics, German Sport University, Cologne, Germany. Electronic address: r.rein@dshs-koeln.de.'}]",Experimental gerontology,['10.1016/j.exger.2020.111037'] 2795,32730798,"Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase.","BACKGROUND Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction with severe complications. Therapies for cortisol reduction are often necessary. Here we report the outcomes from the pivotal phase III study of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, mitochondrial [11β-hydroxylase]; Novartis Pharma AG, Basel, Switzerland) in patients with Cushing's disease. METHODS LINC 3 was a prospective, multicentre, open-label, phase III study with a double-blind randomised withdrawal period, that comprised four periods. Patients aged 18-75 years, with confirmed persistent or recurrent Cushing's disease (defined as mean 24-h urinary free cortisol [UFC] concentration >1·5 times the upper limit of normal [ULN] and morning plasma adrenocorticotropic hormone above the lower limit of normal) who had previously had pituitary surgery or irradiation, or were newly diagnosed and who refused surgery or were not surgical candidates, were recruited from 66 hospital sites and private clinical practices in 19 countries. In period 1, open-label osilodrostat was initiated in all participants and adjusted every 2 weeks (1-30 mg twice daily; film-coated tablets for oral administration) on the basis of mean 24-h UFC concentration and safety until week 12. In period 2, weeks 13-24, osilodrostat was continued at the therapeutic dose determined during period 1. In period 3, beginning at week 26, participants who had a mean 24-h UFC concentration of less than or equal to the ULN at week 24, without up-titration after week 12, were randomly assigned (1:1), via an interactive-response technology, stratified by osilodrostat dose at week 24 and history of pituitary irradiation, to continue osilodrostat or switch to placebo for 8 weeks. Participants and investigators were masked to treatment assignment. Ineligible participants continued open-label osilodrostat. In period 4, weeks 35-48, all participants were given open-label osilodrostat until core-study end. The primary objective was to compare the efficacy of osilodrostat versus placebo at the end of period 3. The primary endpoint was the proportion of participants who had been randomly assigned to treatment or placebo with a complete response (ie, mean 24-h UFC concentration of ≤ULN) at the end of the randomised withdrawal period (week 34), without up-titration during this period. The key secondary endpoint was the proportion of participants with a complete response at the end of the single-arm, open-label period (ie, period 2, week 24) without up-titration during weeks 13-24. Analysis was by intention-to-treat for all patients who received at least one dose of osilodrostat (full analysis set; key secondary endpoint) or randomised treatment (randomised analysis set; primary endpoint) and safety was assessed in all enrolled patients who received at least one dose of osilodrostat and had at least one post-baseline safety assessment. LINC 3 is registered with ClinicalTrials.gov, NCT02180217, and is now complete. FINDINGS Between Nov 12, 2014, and March 22, 2017, 202 patients were screened and 137 were enrolled. The median age was 40·0 years (31·0-49·0) and 106 (77%) participants were female. 72 (53%) participants were eligible for randomisation during the withdrawal phase, of whom 36 were assigned to continue osilodrostat and 35 were assigned to placebo; one patient was not randomly assigned due to investigator decision and continued open-label osilodrostat. More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001). At week 24, 72 (53%; 95% CI 43·9-61·1) of 137 patients maintained a complete response without up-titration after week 12. Most common adverse events (ie, occurred in >25% of participants) were nausea (57 [42%]), headache (46 [34%]), fatigue (39 [28%]), and adrenal insufficiency (38 [28%]). Hypocortisolism occurred in 70 (51%) patients and adverse events related to adrenal hormone precursors occurred in 58 (42%) patients. One patient died, unrelated to study drug, after the core study phase. INTERPRETATION Twice-daily osilodrostat rapidly reduced mean 24-h UFC and sustained this reduction alongside improvements in clinical signs of hypercortisolism; it was also generally well tolerated. Osilodrostat is an effective new treatment option that is approved in Europe for the treatment of endogenous Cushing's syndrome and in the USA for Cushing's disease. FUNDING Novartis Pharma AG.",2020,More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001).,"[""patients with Cushing's disease"", '72 (53%) participants were eligible for randomisation during the withdrawal phase, of whom 36 were assigned to continue osilodrostat and 35 were assigned to', 'participants who had a mean 24-h UFC concentration of less than or equal to the ULN at week 24, without up-titration after week 12', 'Between Nov 12, 2014, and March 22, 2017, 202 patients were screened and 137 were enrolled', '137 patients', 'The median age was 40·0 years (31·0-49·0) and 106 (77%) participants were female', ""Patients aged 18-75 years, with confirmed persistent or recurrent Cushing's disease (defined as mean 24-h urinary free cortisol [UFC] concentration >1·5 times the upper limit of normal [ULN] and morning plasma adrenocorticotropic hormone above the lower limit of normal) who had previously had pituitary surgery or irradiation, or were newly diagnosed and who refused surgery or were not surgical candidates, were recruited from 66 hospital sites and private clinical practices in 19 countries"", ""patients with Cushing's disease (LINC 3""]","['osilodrostat versus placebo', 'investigator decision and continued open-label osilodrostat', 'osilodrostat', 'placebo']","['headache', 'adrenal hormone precursors', 'proportion of participants with a complete response', 'fatigue', 'complete response (ie, mean 24-h UFC concentration of ≤ULN', 'Efficacy and safety', 'adrenal insufficiency', 'nausea', 'Hypocortisolism']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0221406', 'cui_str': 'Pituitary dependent hypercortisolism'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0439090', 'cui_str': '<='}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0162621', 'cui_str': 'Titration method'}, {'cui': 'C0949920', 'cui_str': 'Norovirus'}, {'cui': 'C1856053', 'cui_str': 'Hydranencephaly with Renal Aplasia-Dysplasia'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0332996', 'cui_str': 'Persistent embryonic structure'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0474662', 'cui_str': 'Cortisol measurement, free, urine'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C1271647', 'cui_str': 'Plasma ACTH level'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032002', 'cui_str': 'Disorder of pituitary gland'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0017095', 'cui_str': 'Trash'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0033175', 'cui_str': 'Private Room'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0035173', 'cui_str': 'Researcher'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0175566', 'cui_str': 'Open'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C1445654', 'cui_str': 'Adrenal hormone'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0001623', 'cui_str': 'Hypoadrenalism'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0001403', 'cui_str': ""Addison's disease""}]",202.0,0.359008,More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001).,"[{'ForeName': 'Rosario', 'Initials': 'R', 'LastName': 'Pivonello', 'Affiliation': 'Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy. Electronic address: rosario.pivonello@unina.it.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fleseriu', 'Affiliation': 'Northwest Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health and Science University, Portland, OR, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Newell-Price', 'Affiliation': 'Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Bertagna', 'Affiliation': 'Department of Endocrinology, Centre de Référence des Maladies Rares de la Surrénale, Hôpital Cochin, Faculté de Médecine Paris Descartes, Université Paris 5, Paris, France.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Findling', 'Affiliation': 'Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Akira', 'Initials': 'A', 'LastName': 'Shimatsu', 'Affiliation': 'Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan; Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu, Japan.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Gu', 'Affiliation': 'Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Auchus', 'Affiliation': 'Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Rattana', 'Initials': 'R', 'LastName': 'Leelawattana', 'Affiliation': 'Prince of Songkla University, Songkhla, Thailand.'}, {'ForeName': 'Eun Jig', 'Initials': 'EJ', 'LastName': 'Lee', 'Affiliation': 'Pituitary Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Jung Hee', 'Initials': 'JH', 'LastName': 'Kim', 'Affiliation': 'Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'André', 'Initials': 'A', 'LastName': 'Lacroix', 'Affiliation': ""Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.""}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Laplanche', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': ""O'Connell"", 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Libuse', 'Initials': 'L', 'LastName': 'Tauchmanova', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Alberto M', 'Initials': 'AM', 'LastName': 'Pedroncelli', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Beverly M K', 'Initials': 'BMK', 'LastName': 'Biller', 'Affiliation': 'Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, MA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. Diabetes & endocrinology,['10.1016/S2213-8587(20)30240-0'] 2796,32730842,The association between REM sleep and decision-making: supporting evidences.,"Studies suggest that REM sleep is important for the maintenance of prefrontal cortex functioning. Therefore, reducing REM sleep may have an impact on cognitive functions such as impulse control and decision-making processes. This study examined the association between impulsiveness and sensation seeking personality traits, REM sleep and performance on a decision-making computer task following a habitual night of sleep and a partial sleep deprivation (PSD) condition with advanced wake-up time. Eighteen young adults participated in two experimental conditions: a control (habitual bedtime and wake time) and a 50% PSD with an advanced wake time. Impulsiveness and sensation seeking personality traits were measured with a personality inventory (NEO-PI-3), sleep was assessed using standard polysomnography and the Iowa Gambling Task (IGT) was completed at noon following each sleep condition. Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT. Results also showed that REM sleep duration and REM sleep deprivation were associated with riskier decisions on the IGT. Moreover, impulsiveness was associated with riskier decisions after a normal night of sleep. These findings suggest that REM sleep duration and impulsiveness are important factors to consider while investigating decision-making processes under conditions of uncertainty and risk.",2020,"Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT.",['Eighteen young adults'],['control (habitual bedtime and wake time) and a 50% PSD with an advanced wake time'],"['personality inventory (NEO-PI-3), sleep was assessed using standard polysomnography and the Iowa Gambling Task (IGT', 'REM sleep duration and REM sleep deprivation', 'Impulsiveness and sensation seeking personality traits']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0521112', 'cui_str': 'Bedtime'}, {'cui': 'C0442696', 'cui_str': 'Waking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0037316', 'cui_str': 'Sleep deprivation'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}]","[{'cui': 'C0003944', 'cui_str': 'As If Personality'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0142580', 'cui_str': 'PI3 protein, human'}, {'cui': 'C0037313', 'cui_str': 'Sleep'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0162701', 'cui_str': 'Polysomnography'}, {'cui': 'C0022037', 'cui_str': 'Iowa'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0037322', 'cui_str': 'Rapid eye movement sleep'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0751506', 'cui_str': 'REM Sleep Deprivation'}, {'cui': 'C0564567', 'cui_str': 'Impulsive character'}, {'cui': 'C0871336', 'cui_str': 'Sensation seeking'}, {'cui': 'C0233849', 'cui_str': 'Character trait finding'}]",18.0,0.0117207,"Results showed that when sleep deprived, participants choose more often to play riskier decks of cards during the last half of the IGT.","[{'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Brunet', 'Affiliation': 'Laboratoire du Sommeil, Département de Psychoéducation et de Psychologie, Université du Québec en Outaouais, Gatineau, Canada, J8X 3X7.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'McNeil', 'Affiliation': 'Behavioral and Metabolic Research Unit, School of Human Kinetics, University of Ottawa, Ottawa, Canada, K1N 6N5.'}, {'ForeName': 'Éric', 'Initials': 'É', 'LastName': 'Doucet', 'Affiliation': 'Behavioral and Metabolic Research Unit, School of Human Kinetics, University of Ottawa, Ottawa, Canada, K1N 6N5.'}, {'ForeName': 'Geneviève', 'Initials': 'G', 'LastName': 'Forest', 'Affiliation': 'Laboratoire du Sommeil, Département de Psychoéducation et de Psychologie, Université du Québec en Outaouais, Gatineau, Canada, J8X 3X7. Electronic address: genevieve.forest@uqo.ca.'}]",Physiology & behavior,['10.1016/j.physbeh.2020.113109'] 2797,32732787,Impact of a Follow-up Telephone Call Program on 30-Day Readmissions (FUTR-30): A Pragmatic Randomized Controlled Real-world Effectiveness Trial.,"BACKGROUND Telephone call programs are a common intervention used to improve patients' transition to outpatient care after hospital discharge. OBJECTIVE To examine the impact of a follow-up telephone call program as a readmission reduction initiative. RESEARCH DESIGN Pragmatic randomized controlled real-world effectiveness trial. SUBJECTS We enrolled and randomized all patients discharged home from a hospital general medicine service to a follow-up telephone call program or usual care discharge. Patients discharged against medical advice were excluded. The intervention was a hospital program, delivering a semistructured follow-up telephone call from a nurse within 3-7 days of discharge, designed to assess understanding and provide education, and assistance to support discharge plan implementation. MEASURES Our primary endpoint was hospital inpatient readmission within 30 days identified by the electronic health record. Secondary endpoints included observation readmission, emergency department revisit, and mortality within 30 days, and patient experience ratings. RESULTS All 3054 patients discharged home were enrolled and randomized to the telephone call program (n=1534) or usual care discharge (n=1520). Using a prespecified intention-to-treat analysis, we found no evidence supporting differences in 30-day inpatient readmissions [14.9% vs. 15.3%; difference -0.4 (95% confidence interval, 95% CI), -2.9 to 2.1; P=0.76], observation readmissions [3.8% vs. 3.6%; difference 0.2 (95% CI, -1.1 to 1.6); P=0.74], emergency department revisits [6.1% vs. 5.4%; difference 0.7 (95% CI, -1.0 to 2.3); P=0.43], or mortality [4.4% vs. 4.9%; difference -0.5 (95% CI, -2.0 to 1.0); P=0.51] between telephone call and usual care groups. CONCLUSIONS We found no evidence of an impact on 30-day readmissions or mortality due to the postdischarge telephone call program.",2020,We found no evidence of an impact on 30-day readmissions or mortality due to the postdischarge telephone call program.,"['Patients discharged against medical advice were excluded', ""patients' transition to outpatient care after hospital discharge"", 'All 3054 patients discharged home were enrolled and randomized to the', 'We enrolled and randomized all patients discharged home from a hospital general medicine service to a follow-up telephone call program or usual care discharge']","['telephone call program (n=1534) or usual care discharge', 'Follow-up Telephone Call Program']","['30-day readmissions or mortality', 'observation readmission, emergency department revisit, and mortality within 30 days, and patient experience ratings', 'emergency department revisits', 'hospital inpatient readmission', 'mortality', '30-day inpatient readmissions', 'observation readmissions', '30-Day Readmissions (FUTR-30']","[{'cui': 'C1304701', 'cui_str': 'Patient self-discharge against medical advice'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002423', 'cui_str': 'Outpatient Care'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}, {'cui': 'C0030685', 'cui_str': 'Patient discharge'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0023449', 'cui_str': 'Acute lymphoid leukemia'}, {'cui': 'C0086343', 'cui_str': 'General medicine'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0030700', 'cui_str': 'Thirty Day Readmission'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}, {'cui': 'C0562508', 'cui_str': 'Accident and Emergency department'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0239966', 'cui_str': 'Hospital patient'}, {'cui': 'C0021562', 'cui_str': 'Inpatient'}]",3054.0,0.401488,We found no evidence of an impact on 30-day readmissions or mortality due to the postdischarge telephone call program.,"[{'ForeName': 'Maame Yaa', 'Initials': 'MY', 'LastName': 'A B Yiadom', 'Affiliation': 'Departments of Emergency Medicine.'}, {'ForeName': 'Henry J', 'Initials': 'HJ', 'LastName': 'Domenico', 'Affiliation': 'Biostatistics.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'Byrne', 'Affiliation': 'Biostatistics.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Hasselblad', 'Affiliation': 'Medicine, Vanderbilt University.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Kripalani', 'Affiliation': 'Medicine, Vanderbilt University.'}, {'ForeName': 'Neesha', 'Initials': 'N', 'LastName': 'Choma', 'Affiliation': 'Medicine, Vanderbilt University.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Tucker-Marlow', 'Affiliation': 'Medicine, Vanderbilt University.'}, {'ForeName': 'Cheryl L', 'Initials': 'CL', 'LastName': 'Gatto', 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research.'}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Wang', 'Affiliation': 'Biostatistics.'}, {'ForeName': 'Monisha C', 'Initials': 'MC', 'LastName': 'Bhatia', 'Affiliation': 'School of Medicine, Vanderbilt University Medical Center, Nashville, TN.'}, {'ForeName': 'Johnston', 'Initials': 'J', 'LastName': 'Morrison', 'Affiliation': 'Medicine, Vanderbilt University.'}, {'ForeName': 'Frank E', 'Initials': 'FE', 'LastName': 'Harrell', 'Affiliation': 'Biostatistics.'}, {'ForeName': 'Tina V', 'Initials': 'TV', 'LastName': 'Hartert', 'Affiliation': 'Vanderbilt Institute for Clinical and Translational Research.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Lindsell', 'Affiliation': 'Departments of Emergency Medicine.'}, {'ForeName': 'Gordon R', 'Initials': 'GR', 'LastName': 'Bernard', 'Affiliation': 'Medicine, Vanderbilt University.'}]",Medical care,['10.1097/MLR.0000000000001353'] 2798,32733232,Corticomotor Plasticity Predicts Clinical Efficacy of Combined Neuromodulation and Cognitive Training in Alzheimer's Disease.,"Objective To investigate the efficacy of repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training for treatment of cognitive symptoms in patients with Alzheimer's disease (AD). A secondary objective was to analyze associations between brain plasticity and cognitive effects of treatment. Methods In this randomized, sham-controlled, multicenter clinical trial, 34 patients with AD were assigned to three experimental groups receiving 30 daily sessions of combinatory intervention. Participants in the real/real group ( n = 16) received 10 Hz repetitive transcranial magnetic stimulation (rTMS) delivered separately to each of six cortical regions, interleaved with computerized cognitive training. Participants in the sham rTMS group ( n = 18) received sham rTMS combined with either real (sham/real group, n = 10) or sham (sham/sham group, n = 8) cognitive training. Effects of treatment on neuropsychological (primary outcome) and neurophysiological function were compared between the 3 treatment groups. These, as well as imaging measures of brain atrophy, were compared at baseline to 14 healthy controls (HC). Results At baseline, patients with AD had worse cognition, cerebral atrophy, and TMS measures of cortico-motor reactivity, excitability, and plasticity than HC. The real/real group showed significant cognitive improvement compared to the sham/sham, but not the real/sham group. TMS-induced plasticity at baseline was predictive of post-intervention changes in cognition, and was modified across treatment, in association with changes of cognition. Interpretation Combined rTMS and cognitive training may improve the cognitive status of AD patients, with TMS-induced cortical plasticity at baseline serving as predictor of therapeutic outcome for this intervention, and potential mechanism of action. Clinical Trial Registration www.ClinicalTrials.gov, identifier NCT01504958.",2020,"The real/real group showed significant cognitive improvement compared to the sham/sham, but not the real/sham group.","[""patients with Alzheimer's disease (AD"", '34 patients with AD', ""Alzheimer's Disease""]","['rTMS and cognitive training', 'sham rTMS', 'combinatory intervention', 'repetitive transcranial magnetic stimulation (rTMS) combined with cognitive training', '10 Hz repetitive transcranial magnetic stimulation (rTMS) delivered separately to each of six cortical regions, interleaved with computerized cognitive training', 'Combined Neuromodulation and Cognitive Training', 'sham rTMS combined with either real (sham/real group, n = 10) or sham (sham/sham group, n = 8) cognitive training']","['brain plasticity and cognitive effects', 'cognitive symptoms', 'cognitive improvement', 'TMS-induced plasticity', 'worse cognition, cerebral atrophy, and TMS measures of cortico-motor reactivity, excitability, and plasticity than HC', 'neurophysiological function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0002395', 'cui_str': ""Alzheimer's disease""}]","[{'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0394674', 'cui_str': 'Neurostimulation/modulation'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C5200806', 'cui_str': 'Brain Plasticity'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0525041', 'cui_str': 'Cognitive Symptoms'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0678558', 'cui_str': 'Plasticity'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0235946', 'cui_str': 'Cerebral atrophy'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0031843', 'cui_str': 'PH'}]",34.0,0.219647,"The real/real group showed significant cognitive improvement compared to the sham/sham, but not the real/sham group.","[{'ForeName': 'Anna-Katharine', 'Initials': 'AK', 'LastName': 'Brem', 'Affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Di Iorio', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopaedics, Polyclinic A. Gemelli Foundation-IRCCS, Rome, Italy.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Fried', 'Affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Albino J', 'Initials': 'AJ', 'LastName': 'Oliveira-Maia', 'Affiliation': 'Champalimaud Research and Clinical Centre, Champalimaud Centre for the Unknown, Lisbon, Portugal.'}, {'ForeName': 'Camillo', 'Initials': 'C', 'LastName': 'Marra', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopaedics, Polyclinic A. Gemelli Foundation-IRCCS, Rome, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Profice', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopaedics, Polyclinic A. Gemelli Foundation-IRCCS, Rome, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Quaranta', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopaedics, Polyclinic A. Gemelli Foundation-IRCCS, Rome, Italy.'}, {'ForeName': 'Lukas', 'Initials': 'L', 'LastName': 'Schilberg', 'Affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Natasha J', 'Initials': 'NJ', 'LastName': 'Atkinson', 'Affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Erica E', 'Initials': 'EE', 'LastName': 'Seligson', 'Affiliation': 'Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Paolo Maria', 'Initials': 'PM', 'LastName': 'Rossini', 'Affiliation': 'Department of Neuroscience and Neurorehabilitation, IRCCS San Raffaele, Rome, Italy.'}, {'ForeName': 'Alvaro', 'Initials': 'A', 'LastName': 'Pascual-Leone', 'Affiliation': 'Hinda and Arthur Marcus Institute for Aging Research and Center for Memory Health, Hebrew SeniorLife, Boston, MA, United States.'}]",Frontiers in aging neuroscience,['10.3389/fnagi.2020.00200'] 2799,32733236,Phytotherapy for Cachexia: Where Do We Stand?,"Background In contrast to Western medicine which currently offers no approved pharmacotherapy options for cachexia, in Japan multi-component extracts of medicinal plants are used with coverage by the national health insurance. This so called ""Kampo"" medicine is an example of the modern concept of multi-component/multi-target therapy. For the three traditional preparations Hochuekkito (), Juzentaihoto (), and Rikkunshito (), a multitude of clinical research data relating to cachexia has been published. These preparations are also referred to as ""Hozai"" (). A similar concept is found in Russian herbal medicine, where the term ""Adaptogen"" was coined for pharmacologically active substances which enhance adaptive stress repose. Methods Scientific literature-including original Japanese articles-was reviewed regarding the effects of these herbal preparations on cachexia. Cachexia is a complex set of symptoms including muscle atrophy with loss of weight, fatigue, and weakness. Results In a 1985 study by Kuroda et al., Hochuekkito showed efficacy in involuntary weight loss and fatigue in 63% of 162 patients with genitourinary cancer. For cancer-related fatigue, a significant improvement was reported within 2 weeks by Jeong et al. in 2010. In patients with chronic fatigue syndrome, Hochuekkito showed an overall improvement with 8-12 weeks of therapy in a 1997 study by Kuratsune et al. In a 2005 randomized placebo-controlled trial by Satoh et al. on 13 geriatric Q1 patients in a 16-week treatment protocol, Hochuekkito showed significant improvement of general health, physical functioning and the Profile of Mood States (POMS). In 71 geriatric COPD patients in a 2009 placebo-controlled randomized study, Tatsumi et al. found a significant body weight increase and a CRP, TNF-α, IL-6 decrease over 6 months of therapy. For Juzentaihoto in 48 hepatocellular carcinoma patients, Tsuchiya et al. 2008 documented a significantly longer recurrence-free survival (49 vs. 24 months) as compared to the control group (p=0.023). For the much simpler Rikkunshito prescription, a 2011 retrospective study by Fujitsuka et al. on 39 Stage III/IV pancreatic cancer patients treated with Gemcitabine (n=33) or Gemcitabine/Rikkunshito (n=6) showed a significantly prolonged median survival with 224 vs. 378.5 days (p < 0.05). In a 2011 open-label clinical study by Utumi et al. on geriatric cachexia in 6 dementia patients, treatment with Rikkunshito for 4 weeks resulted in a significant body weight increase. In all the above studies, the standardized dosage of 3x2.5 g/d extract granules for most Japanese health insurance-covered Kampo extract-preparations was applied. Conclusion As there is currently no accepted pharmacotherapy option for cachexia available in the West, a transfer of these East Asian gold standard prescriptions into the European market would be desirable. We were further able to demonstrate that the mTOR, interleucin, and melatonin pathways are modified by herbal compounds which thus counteract cachexia. More research in this field is urgently needed in order to provide new, effective treatments for cachexia patients.",2020,2008 documented a significantly longer recurrence-free survival (49 vs. 24 months) as compared to the control group (p=0.023).,"['48 hepatocellular carcinoma patients', '13 geriatric Q1 patients', '71 geriatric COPD patients in a 2009', 'Phytotherapy for Cachexia', 'cachexia patients', 'patients with chronic fatigue syndrome', '162 patients with genitourinary cancer', '6 dementia patients', 'on 39 Stage III/IV pancreatic cancer patients treated with']","['Gemcitabine', 'Gemcitabine/Rikkunshito', 'traditional preparations Hochuekkito (), Juzentaihoto (), and Rikkunshito ', 'placebo']","['body weight increase and a CRP, TNF-α, IL-6 decrease', 'geriatric cachexia', 'median survival', 'involuntary weight loss and fatigue', 'general health, physical functioning and the Profile of Mood States (POMS', 'longer recurrence-free survival']","[{'cui': 'C2239176', 'cui_str': 'Hepatocellular carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0242388', 'cui_str': 'Herbal therapy'}, {'cui': 'C0006625', 'cui_str': 'Cachexia'}, {'cui': 'C0015674', 'cui_str': 'Chronic fatigue syndrome'}, {'cui': 'C5191360', 'cui_str': '162'}, {'cui': 'C0751569', 'cui_str': 'Urogenital Cancer'}, {'cui': 'C0011265', 'cui_str': 'Presenile dementia'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0235974', 'cui_str': 'Carcinoma of pancreas'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}]","[{'cui': 'C0045093', 'cui_str': 'gemcitabine'}, {'cui': 'C0248645', 'cui_str': 'rikkunshi-to'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0911380', 'cui_str': 'hochu-ekki-to'}, {'cui': 'C0083104', 'cui_str': 'juzentaihoto'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0017469', 'cui_str': 'Geriatric medicine'}, {'cui': 'C0006625', 'cui_str': 'Cachexia'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C2363736', 'cui_str': 'Unintentional weight loss'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0424575', 'cui_str': 'General body state finding'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0451394', 'cui_str': 'Profile of mood states'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}]",6.0,0.0195635,2008 documented a significantly longer recurrence-free survival (49 vs. 24 months) as compared to the control group (p=0.023).,"[{'ForeName': 'Kenny', 'Initials': 'K', 'LastName': 'Kuchta', 'Affiliation': 'Clinic for Gastroenterology and Gastrointestinal Oncology, University of Göttingen Medical School, Göttingen, Germany.'}, {'ForeName': 'Silke', 'Initials': 'S', 'LastName': 'Cameron', 'Affiliation': 'Clinic for Gastroenterology and Gastrointestinal Oncology, University of Göttingen Medical School, Göttingen, Germany.'}]",Frontiers in pharmacology,['10.3389/fphar.2020.00917'] 2800,32733860,Brain-Machine Neurofeedback: Robotics or Electrical Stimulation?,"Neurotechnology such as brain-machine interfaces (BMI) are currently being investigated as training devices for neurorehabilitation, when active movements are no longer possible. When the hand is paralyzed following a stroke for example, a robotic orthosis, functional electrical stimulation (FES) or their combination may provide movement assistance; i.e., the corresponding sensory and proprioceptive neurofeedback is given contingent to the movement intention or imagination, thereby closing the sensorimotor loop. Controlling these devices may be challenging or even frustrating. Direct comparisons between these two feedback modalities (robotics vs. FES) with regard to the workload they pose for the user are, however, missing. Twenty healthy subjects controlled a BMI by kinesthetic motor imagery of finger extension. Motor imagery-related sensorimotor desynchronization in the EEG beta frequency-band (17-21 Hz) was turned into passive opening of the contralateral hand by a robotic orthosis or FES in a randomized, cross-over block design. Mental demand, physical demand, temporal demand, performance, effort, and frustration level were captured with the NASA Task Load Index (NASA-TLX) questionnaire by comparing these workload components to each other (weights), evaluating them individually (ratings), and estimating the respective combinations (adjusted workload ratings). The findings were compared to the task-related aspects of active hand movement with EMG feedback. Furthermore, both feedback modalities were compared with regard to their BMI performance. Robotic and FES feedback had similar workloads when weighting and rating the different components. For both robotics and FES, mental demand was the most relevant component, and higher than during active movement with EMG feedback. The FES task led to significantly more physical ( p = 0.0368) and less temporal demand ( p = 0.0403) than the robotic task in the adjusted workload ratings. Notably, the FES task showed a physical demand 2.67 times closer to the EMG task, but a mental demand 6.79 times closer to the robotic task. On average, significantly more onsets were reached during the robotic as compared to the FES task (17.22 onsets, SD = 3.02 vs. 16.46, SD = 2.94 out of 20 opportunities; p = 0.016), even though there were no significant differences between the BMI classification accuracies of the conditions ( p = 0.806; CI = -0.027 to -0.034). These findings may inform the design of neurorehabilitation interfaces toward human-centered hardware for a more natural bidirectional interaction and acceptance by the user.",2020,The FES task led to significantly more physical ( p = 0.0368) and less temporal demand ( p = 0.0403) than the robotic task in the adjusted workload ratings.,"['Twenty healthy subjects controlled a BMI by kinesthetic motor imagery of finger extension', 'Brain-Machine Neurofeedback']","['Motor imagery-related sensorimotor desynchronization', 'Robotic and FES feedback', 'feedback modalities (robotics vs. FES']","['BMI classification accuracies', 'NASA Task Load Index (NASA-TLX) questionnaire', 'Mental demand, physical demand, temporal demand, performance, effort, and frustration level']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C3494289', 'cui_str': 'Brain-Machine Interfaces'}, {'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0016129', 'cui_str': 'Digit of hand structure'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}]","[{'cui': 'C0150627', 'cui_str': 'Simple guided imagery'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}, {'cui': 'C0242776', 'cui_str': 'National Aeronautics and Space Administration'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0016770', 'cui_str': 'Feeling frustrated'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",20.0,0.0182645,The FES task led to significantly more physical ( p = 0.0368) and less temporal demand ( p = 0.0403) than the robotic task in the adjusted workload ratings.,"[{'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Guggenberger', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Monika', 'Initials': 'M', 'LastName': 'Heringhaus', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Gharabaghi', 'Affiliation': 'Institute for Neuromodulation and Neurotechnology, Department of Neurosurgery and Neurotechnology, University of Tübingen, Tübingen, Germany.'}]",Frontiers in bioengineering and biotechnology,['10.3389/fbioe.2020.00639'] 2801,32734245,Physicians' Recognition and Management of Kidney Disease: A Randomized Vignette Study Evaluating the Impact of the KDIGO 2012 CKD Classification System.,"Rationale & Objective The Kidney Disease Outcome Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) chronic kidney disease (CKD) classification systems published in 2002 and 2012, respectively, are recommended worldwide and based on strong epidemiologic data. However, their impact on CKD recognition and management is not well evaluated in clinical practice, and we therefore investigated whether they help physicians recognize and appropriately care for patients with CKD. Study Design Randomized vignette experiment with fractional factorial design based on 6 kidney-related scenarios and 3 laboratory presentation methods reflecting the CKD guidelines. Participants evaluated 1 of 3 subsets of the 18 vignettes (ie, 6 vignettes each with 4 answer alternatives). Setting & Participants 249 interns, general practitioners, and residents/fellows attending postgraduate meetings and courses in Norway and the United States. Intervention Kidney-related results (serum creatinine level and urinary albumin excretion) were presented as the ""minimal data"" (high/low levels), KDOQI-2002 (estimated glomerular filtration rate [eGFR] reported automatically), or KDIGO-2012 (eGFR + albuminuria categorization + risk for complications) laboratory report. Outcome CKD management choice by physicians. Results When kidney laboratory data were presented as the KDOQI-2002 report (automatic eGFR calculation), there was a significantly higher odds for correct patient management decisions compared with the minimal data report (OR, 1.57; P  < 0.001). Additional significant improvement was obtained with the KDIGO-2012 report (OR, 2.28 for correct answer vs minimal data report [ P  < 0.001]; OR, 1.45 compared to KDOQI-2002 report [ P  = 0.005]). The KDIGO classification system improved physician management in 4 of the 6 clinical scenarios covering a wide range of kidney-related topics. Interaction analysis showed that general practitioners and those with 1 to 3 years of internal medicine experience had the greatest improvements with the new presentation techniques. Limitations Physicians' management was evaluated by theoretical scenarios rather than direct patient care. Conclusions Automatic GFR estimation, albuminuria categorization, and notification of the associated risk for complications improve most physicians` recognition and management of a wide range of CKD clinical scenarios.",2020,The KDIGO classification system improved physician management in 4 of the 6 clinical scenarios covering a wide range of kidney-related topics.,"['patients with CKD', 'Setting & Participants\n\n\n249 interns, general practitioners, and residents/fellows attending postgraduate meetings and courses in Norway and the United States', 'Participants evaluated 1 of 3 subsets of the 18 vignettes (ie, 6 vignettes each with 4 answer alternatives', 'Kidney Disease']",[],"['KDIGO-2012 (eGFR\xa0+ albuminuria categorization\xa0+ risk for complications) laboratory report', 'Intervention\n\n\nKidney-related results (serum creatinine level and urinary albumin excretion', 'Kidney Disease Outcome Quality Initiative (KDOQI) and Kidney Disease', 'Improving Global Outcomes (KDIGO) chronic kidney disease (CKD) classification systems']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C1320928', 'cui_str': 'Resident physician'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0556656', 'cui_str': 'Meetings'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}]",[],"[{'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0200370', 'cui_str': 'Laboratory reporting'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0201976', 'cui_str': 'Creatinine measurement, serum'}, {'cui': 'C0001924', 'cui_str': 'albumin'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0424093', 'cui_str': 'Initiative'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}]",,0.0491676,The KDIGO classification system improved physician management in 4 of the 6 clinical scenarios covering a wide range of kidney-related topics.,"[{'ForeName': 'Stein I', 'Initials': 'SI', 'LastName': 'Hallan', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Dena E', 'Initials': 'DE', 'LastName': 'Rifkin', 'Affiliation': 'Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA.'}, {'ForeName': 'O Alison', 'Initials': 'OA', 'LastName': 'Potok', 'Affiliation': 'Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA.'}, {'ForeName': 'Knut A', 'Initials': 'KA', 'LastName': 'Langlo', 'Affiliation': 'Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.'}, {'ForeName': 'Friedo W', 'Initials': 'FW', 'LastName': 'Dekker', 'Affiliation': 'Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Joachim H', 'Initials': 'JH', 'LastName': 'Ix', 'Affiliation': 'Division of Nephrology-Hypertension, University of California San Diego, San Diego, CA.'}]",Kidney medicine,['10.1016/j.xkme.2019.12.008'] 2802,32734246,An Exercise Program for Peritoneal Dialysis Patients in the United States: A Feasibility Study.,"Background People with end-stage kidney disease receiving peritoneal dialysis (PD) are generally physically inactive and frail. Exercise studies in PD are scarce and currently there are no PD exercise programs in the United States. The primary objective of this study was to test the feasibility of a combined resistance and cardiovascular exercise program for PD patients under the care of a dedicated home dialysis center in the United States. Study Design Parallel randomized controlled feasibility study. Setting & Participants PD patients were recruited from a single center and randomly assigned to the intervention (exercise; n = 18) or control (nonexercise; n = 18) group. Intervention The intervention group received monthly exercise physiologist consultation, exercise prescription (resistance and aerobic exercise program using exercise bands), and 4 exercise support telephone calls over 12 weeks. The control group received standard care. Outcomes The primary outcome was study feasibility as measured by eligibility rates, recruitment rates, retention rates, adherence rates, adverse events, and sustained exercise rates. Secondary outcome measures were changes in physical function (sit-to-stand test, timed-up-and-go test, and pinch-strength tests) and patient-reported outcome measures. Results From a single center with 75 PD patients, 57 (76%) were deemed eligible, resulting in a recruitment rate of 36 (63%) patients. Participants were randomly assigned into 2 groups of 18 (1:1). 10 patients discontinued the study (5 in each arm), resulting in 26 (72%) patients, 13 in each arm, completing the study. 10 of 13 (77%) intervention patients were adherent to the exercise program. A t test analysis of covariance found a difference between the treatment groups for the timed-up-and-go test ( P  = 0.04) and appetite ( P  = 0.04). No serious adverse events caused by the exercise program were reported. Limitations Single center, no blinded assessors. Conclusions A resistance and cardiovascular exercise program appears feasible and safe for PD patients. We recommend that providers of PD therapy consider including exercise programs coordinated by exercise professionals to reduce the physical deterioration of PD patients. Funding None. Trial Registration NCT03980795.",2020,A t test analysis of covariance found a difference between the treatment groups for the timed-up-and-go test ( P  = 0.04) and appetite ( P  = 0.04).,"['Setting & Participants', '\n\n\nPeople with end-stage kidney disease receiving', '10 patients discontinued the study (5 in each arm), resulting in 26 (72%) patients, 13 in each arm, completing the study', 'PD patients', 'PD patients under the care of a dedicated home dialysis center in the United States', 'Peritoneal Dialysis Patients in']","['standard care', 'peritoneal dialysis (PD', 'intervention (exercise; n\xa0= 18) or control (nonexercise; n\xa0= 18) group', 'cardiovascular exercise program', 'combined resistance and cardiovascular exercise program', 'monthly exercise physiologist consultation, exercise prescription (resistance and aerobic exercise program using exercise bands), and 4 exercise support telephone calls']","['serious adverse events', 'changes in physical function (sit-to-stand test, timed-up-and-go test, and pinch-strength tests) and patient-reported outcome measures', 'eligibility rates, recruitment rates, retention rates, adherence rates, adverse events, and sustained exercise rates', 'appetite']","[{'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0332294', 'cui_str': 'Resulting in'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C1301808', 'cui_str': 'State'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0031139', 'cui_str': 'Peritoneal dialysis'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0260141', 'cui_str': 'Physiologist'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0588464', 'cui_str': 'Exercise on prescription'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0175723', 'cui_str': 'Band'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0560801', 'cui_str': 'Does stand from sitting'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C1720876', 'cui_str': 'Pinch Strength'}, {'cui': 'C4277735', 'cui_str': 'Patient Reported Outcome Measures'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0003618', 'cui_str': 'Food appetite'}]",,0.107247,A t test analysis of covariance found a difference between the treatment groups for the timed-up-and-go test ( P  = 0.04) and appetite ( P  = 0.04).,"[{'ForeName': 'Paul N', 'Initials': 'PN', 'LastName': 'Bennett', 'Affiliation': 'Satellite Healthcare, San Jose, CA.'}, {'ForeName': 'Wael F', 'Initials': 'WF', 'LastName': 'Hussein', 'Affiliation': 'Satellite Healthcare, San Jose, CA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Matthews', 'Affiliation': 'Satellite Wellbound, Sacramento, CA.'}, {'ForeName': 'Mike', 'Initials': 'M', 'LastName': 'West', 'Affiliation': 'Satellite Wellbound, Sacramento, CA.'}, {'ForeName': 'Erick', 'Initials': 'E', 'LastName': 'Smith', 'Affiliation': 'Satellite Healthcare, San Jose, CA.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Reiterman', 'Affiliation': 'Satellite Healthcare, San Jose, CA.'}, {'ForeName': 'Grace', 'Initials': 'G', 'LastName': 'Alagadan', 'Affiliation': 'Satellite Wellbound, Sacramento, CA.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Shragge', 'Affiliation': 'Satellite Wellbound, Sacramento, CA.'}, {'ForeName': 'Jignesh', 'Initials': 'J', 'LastName': 'Patel', 'Affiliation': 'Satellite Wellbound, Sacramento, CA.'}, {'ForeName': 'Brigitte M', 'Initials': 'BM', 'LastName': 'Schiller', 'Affiliation': 'Satellite Healthcare, San Jose, CA.'}]",Kidney medicine,['10.1016/j.xkme.2020.01.005'] 2803,32734251,Group-Based Care in Adults and Adolescents With Hypertension and CKD: A Feasibility Study.,"Rationale & Objective Group-based care provides an opportunity to increase patient access to providers without increasing physician time and is effective in the management of chronic diseases in the general population. This model of care has not been investigated in chronic kidney disease (CKD). Study Design Randomized controlled trial in adults (n = 50); observational study in adolescents (n = 10). Setting & Participants Adults and adolescents with CKD and hypertension in the Bronx, NY. Intervention Group-based care (monthly sessions over 6 months) versus usual care in adults. All adolescents received group-based care and were analyzed separately. Outcomes Participant attendance and satisfaction with group-based care were used to evaluate intervention feasibility. The primary clinical outcome was change in mean 24-hour ambulatory blood pressure. Secondary outcomes included physical activity, medication adherence, quality of life, and sodium intake as assessed by 24-hour urinary sodium excretion and food frequency questionnaires. Results Among adults randomly assigned to group-based care, attendance was high (77% of participants attended ≥3 sessions) and most reported higher satisfaction. Mean 24-hour ambulatory systolic blood pressure decreased by -4.2 (95% CI, -13.3 to 5.8) mm Hg in group-based care patients compared with usual care at 6 months but this was not statistically significant. Similarly, we did not detect significant differences in health-related behaviors (such as medication adherence, sodium intake, and physical activity) or quality-of-life measures between the 2 groups. Among the adolescents, attendance was very poor; self-reported satisfaction, although high, did not change from baseline compared with the 6-month follow-up. Limitations Small study size, missing data. Conclusions Group-based care is feasible and acceptable among adults with hypertension and CKD. However, a larger trial is needed to determine the effect on blood pressure and health-related behaviors. Patient participation may limit the effectiveness of group-based care models in adolescents. Funding National Institutes of Health R34 DK102174. Trial registration https://clinicaltrials.gov/show/NCT02467894.",2020,"Among adults randomly assigned to group-based care, attendance was high (77% of participants attended ≥3 sessions) and most reported higher satisfaction.","['Adults and Adolescents With Hypertension and CKD', 'Participants\n\n\nAdults and adolescents with CKD and hypertension in the Bronx, NY', 'adults (n\xa0=\xa050); observational study in adolescents (n\xa0=\xa010', 'adolescents', 'adults with hypertension and CKD']",['Intervention\n\n\nGroup-based care (monthly sessions over 6 months) versus usual care in adults'],"['health-related behaviors (such as medication adherence, sodium intake, and physical activity) or quality-of-life measures', 'blood pressure and health-related behaviors', 'physical activity, medication adherence, quality of life, and sodium intake as assessed by 24-hour urinary sodium excretion and food frequency questionnaires', 'mean 24-hour ambulatory blood pressure', 'Mean 24-hour ambulatory systolic blood pressure']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0237121', 'cui_str': 'Health-related behavior'}, {'cui': 'C2364172', 'cui_str': 'Drug compliance good'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}]",,0.0718176,"Among adults randomly assigned to group-based care, attendance was high (77% of participants attended ≥3 sessions) and most reported higher satisfaction.","[{'ForeName': 'Tanya S', 'Initials': 'TS', 'LastName': 'Johns', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Denver D', 'Initials': 'DD', 'LastName': 'Brown', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Alain H', 'Initials': 'AH', 'LastName': 'Litwin', 'Affiliation': 'University of South Carolina School of Medicine-Greenville, Greenville, SC.'}, {'ForeName': 'Georgette', 'Initials': 'G', 'LastName': 'Goldson', 'Affiliation': 'Montefiore Care Management Organization, Yonkers, NY.'}, {'ForeName': 'Rupinder S', 'Initials': 'RS', 'LastName': 'Buttar', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Kreimerman', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Yungtai', 'Initials': 'Y', 'LastName': 'Lo', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Kimberly J', 'Initials': 'KJ', 'LastName': 'Reidy', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Laurie', 'Initials': 'L', 'LastName': 'Bauman', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Frederick', 'Initials': 'F', 'LastName': 'Kaskel', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}, {'ForeName': 'Michal L', 'Initials': 'ML', 'LastName': 'Melamed', 'Affiliation': 'Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.'}]",Kidney medicine,['10.1016/j.xkme.2020.01.013'] 2804,32734288,A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis: a cost-effectiveness analysis.,"OBJECTIVE To determine whether a patient-initiated DMARD self-monitoring service for people on MTX is a cost-effective model of care for patients with RA or PsA. METHODS An economic evaluation was undertaken alongside a randomized controlled trial involving 100 patients. Outcome measures were quality of life and ESR assessed at baseline and post-intervention. Costs were calculated for healthcare usage using a United Kingdom National Health Service economic perspective. Sensitivity analysis was performed to explore the impact of nurse-led telephone helplines. Uncertainty around the cost-effectiveness ratios was estimated by bootstrapping and analysing the cost-effectiveness planes. RESULTS Fifty-two patients received the intervention and 48 usual care. The difference in mean cost per case indicated that the intervention was £263 more expensive (P < 0.001; 95% CI: £149.14, £375.86) when the helpline costs were accounted for and £94 cheaper (P = 0.08; 95% CI: -£199.26, £10.41) when these costs were absorbed by the usual service. There were, however, statistically significant savings for the patient (P = 0.02; 95% CI: -£28.98, £3.00). When costs and effectiveness measures of ESR and quality of life measured, using the Short Form-12v1, were combined this did not show the patient-initiated service to be cost-effective at a statistically significant level. CONCLUSION This patient-initiated service led to reductions in primary and secondary healthcare services that translated into reduced costs, in comparison with usual care, but were not cost-effective. Further work is needed to establish how nurse-led telephone triage services are integrated into rheumatology services and the associated costs of setting up and delivering them. TRIAL REGISTRATION ClinicalTrials.gov, http://clinicaltrials.gov, ISRCTN21613721.",2020,"The difference in mean cost per case indicated that the intervention was £263 more expensive (P < 0.001; 95% CI: £149.14, £375.86) when the helpline costs were accounted for and £94 cheaper (P = 0.08; 95% CI: -£199.26, £10.41) when these costs were absorbed by the usual service.","['people with rheumatoid or psoriatic arthritis', '100 patients', 'patients with RA or PsA.\nMETHODS']",['MTX'],"['ESR and quality of life', 'cost-effectiveness ratios', 'helpline costs', 'quality of life and ESR', 'mean cost per case']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0003872', 'cui_str': 'Psoriatic arthritis'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0025663', 'cui_str': 'Method'}]","[{'cui': 'C0025677', 'cui_str': 'Methotrexate'}]","[{'cui': 'C0013845', 'cui_str': 'Electron spin resonance measurement'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0868928', 'cui_str': 'Case'}]",100.0,0.206487,"The difference in mean cost per case indicated that the intervention was £263 more expensive (P < 0.001; 95% CI: £149.14, £375.86) when the helpline costs were accounted for and £94 cheaper (P = 0.08; 95% CI: -£199.26, £10.41) when these costs were absorbed by the usual service.","[{'ForeName': 'Hayley', 'Initials': 'H', 'LastName': 'McBain', 'Affiliation': 'School of Health Sciences, City, University of London.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Flood', 'Affiliation': 'School of Health and Social Care, London South Bank University.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Shipley', 'Affiliation': 'Department of Rheumatology, University College London Hospital, London, UK.'}, {'ForeName': 'Abigail', 'Initials': 'A', 'LastName': 'Olaleye', 'Affiliation': 'Department of Rheumatology, University College London Hospital, London, UK.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Moore', 'Affiliation': 'Department of Rheumatology, University College London Hospital, London, UK.'}, {'ForeName': 'Stanton', 'Initials': 'S', 'LastName': 'Newman', 'Affiliation': 'School of Health and Social Care, London South Bank University.'}]","Rheumatology (Oxford, England)",['10.1093/rheumatology/keaa309'] 2805,32734789,Application of Compound Polymyxin B Ointment in the Treatment of Chronic Refractory Wounds.,"The purpose of this study was to investigate the clinical efficacy of compound polymyxin B ointment for treating chronic refractory wounds. A retrospective analysis was performed on 111 patients who underwent chronic refractory wound treatment. Patients were divided into 2 groups, with 45 patients included in the experimental group (compound polymyxin B group) and 66 patients included in the control group (silver sulfadiazine group). After thorough debridement in both groups, either compound polymyxin B ointment or silver sulfadiazine cream was evenly applied to the patient's wound and covered with sterile gauze. In both groups, dressing changes were dependent on the wound's condition and secretions. Using the Bates-Jensen Wound Assessment Tool (BWAT), patients in both groups were scored, after which wound healing, infection, and healing time were compared. There was no significant difference in BWAT scores between the 2 groups on the 7th or 14th day; however, on the 21st day, the BWAT score in the experimental group was significantly lower than that of the control group. The difference was statistically significant ( P < .05). There was no significant difference in the BWAT-I scores between the 2 groups on the seventh day. The healing time in the experimental group was significantly shorter than that of the control group, and the difference was statistically significant ( P < .05). For the treatment of chronic refractory wounds, thorough debridement followed by compound polymyxin B ointment topical application can reduce and control wound infection effectively and accelerate the process of wound repair.",2020,"The healing time in the experimental group was significantly shorter than that of the control group, and the difference was statistically significant ( P < .05).","['111 patients who underwent chronic refractory wound treatment', 'Chronic Refractory Wounds']","['compound polymyxin B ointment or silver sulfadiazine cream', 'Compound Polymyxin B Ointment', 'polymyxin B ointment topical application', 'polymyxin', 'polymyxin B ointment', 'control group (silver sulfadiazine']","['healing time', 'BWAT scores', 'wound healing, infection, and healing time', 'BWAT-I scores', 'BWAT score']","[{'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205191', 'cui_str': 'Chronic'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C1272654', 'cui_str': 'Wound care management'}, {'cui': 'C0021501', 'cui_str': 'wounds'}]","[{'cui': 'C0205198', 'cui_str': 'Compound'}, {'cui': 'C0032535', 'cui_str': 'Polymyxin B'}, {'cui': 'C0028912', 'cui_str': 'Ointment'}, {'cui': 'C1252047', 'cui_str': 'silver sulfadiazine Topical Cream'}, {'cui': 'C0991554', 'cui_str': 'Cutaneous ointment'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0032539', 'cui_str': 'Polymyxin'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037134', 'cui_str': 'silver sulfadiazine'}]","[{'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C3665438', 'cui_str': 'Juxtapapillary focal retinitis AND retinochoroiditis'}, {'cui': 'C0016204', 'cui_str': 'Flatus'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0336791', 'cui_str': 'Tool'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}]",111.0,0.0142228,"The healing time in the experimental group was significantly shorter than that of the control group, and the difference was statistically significant ( P < .05).","[{'ForeName': 'Jiajun', 'Initials': 'J', 'LastName': 'Tang', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Haonan', 'Initials': 'H', 'LastName': 'Guan', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Dong', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Yingkai', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Jiaoyun', 'Initials': 'J', 'LastName': 'Dong', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Lifang', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Jingqi', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}, {'ForeName': 'Shuliang', 'Initials': 'S', 'LastName': 'Lu', 'Affiliation': 'Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.'}]",The international journal of lower extremity wounds,['10.1177/1534734620944512'] 2806,32734815,Salt Intake Impacts Sympathetic Neural Control But Not Morning Blood Pressure Surge in Premenopausal Women with A History of Normal Pregnancy.,"Salt intake may alter blood pressure (BP) regulation, but no study has investigated the impact of salt reduction versus salt loading on morning blood pressure surge (MBPS) and sympathetic neural control in premenopausal women with a history of normal pregnancy. Nine healthy women [42±3 (SD) yr] were given a low-salt (LS; 50 mEq sodium/day) and high-salt diet (HS; 250 mEq sodium/day) for 1 week each (~2-month apart with the order randomized), while water intake was ad libitum. Twenty-four-hour ambulatory BP was measured and the percent change in blood volume (BV) was calculated following LS and HS. MBPS was defined as the morning systolic BP (averaged for 2-hour after wake-up) minus the lowest nocturnal systolic BP. Beat-by-beat BP, heart rate, and muscle sympathetic nerve activity (MSNA) were measured during supine rest. Signal-averaging was used to characterize changes in beat-by-beat mean arterial pressure and total vascular conductance following spontaneous MSNA bursts to assess sympathetic vascular transduction. Ambulatory BP and MBPS (32±7 vs. 26±12 mmHg, p=0.208) did not differ between LS and HS. From LS to HS, BV increased by 4.3±3.7% (p=0.008). MSNA (30±20 vs. 18±13 bursts·100 heart beats -1 , p=0.005) was higher whereas sympathetic vascular transduction was lower in LS than HS (both, p<0.01). Changes in MSNA from LS to HS were correlated to %changes in BV (r=-0.673, p=0.047). Thus, salt intake affects sympathetic neural control but not MBPS in premenopausal women with a history of normal pregnancy. The underlying mechanisms remain unknown, however, alterations in sympathetic vascular transduction may, in part, contribute.",2020,"From LS to HS, BV increased by 4.3±3.7% (p=0.008).","['Nine healthy women [42±3 (SD) yr', 'premenopausal women with a history of normal pregnancy', 'Premenopausal Women with A History of Normal Pregnancy']","['Salt Intake Impacts Sympathetic Neural Control', 'low-salt (LS; 50 mEq sodium/day) and high-salt diet (HS; 250 mEq sodium/day) for 1 week each', 'salt reduction versus salt loading']","['blood pressure (BP) regulation', 'MBPS', 'morning systolic BP', 'Beat-by-beat BP, heart rate, and muscle sympathetic nerve activity (MSNA', 'blood volume (BV', 'sympathetic vascular transduction', 'Ambulatory BP and MBPS', 'nocturnal systolic BP']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0232989', 'cui_str': 'Normal pregnancy'}]","[{'cui': 'C0036140', 'cui_str': 'Salts'}, {'cui': 'C3251814', 'cui_str': 'Measurement of fluid intake'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0439152', 'cui_str': 'mEq'}, {'cui': 'C0037473', 'cui_str': 'Sodium'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C1442452', 'cui_str': 'One week'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0871470', 'cui_str': 'Systolic blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0459521', 'cui_str': 'Sympathetic nerve structure'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0005850', 'cui_str': 'Blood volume'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0855316', 'cui_str': 'Blood pressure ambulatory'}, {'cui': 'C0240526', 'cui_str': 'Night time'}]",9.0,0.0561719,"From LS to HS, BV increased by 4.3±3.7% (p=0.008).","[{'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Takeda', 'Affiliation': 'Texas Health Presbyterian Hospital.'}, {'ForeName': 'Abigail S L', 'Initials': 'ASL', 'LastName': 'Stickford', 'Affiliation': 'Texas Health Presbyterian Hospital.'}, {'ForeName': 'Stuart Alexander', 'Initials': 'SA', 'LastName': 'Best', 'Affiliation': 'Texas Health Presbyterian Hospital.'}, {'ForeName': 'Jeung-Ki', 'Initials': 'JK', 'LastName': 'Yoo', 'Affiliation': 'Texas Health Presbyterian Hospital.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': 'Texas Health Presbyterian Hospital.'}]",American journal of physiology. Heart and circulatory physiology,['10.1152/ajpheart.00197.2020'] 2807,32734919,Goal management training as a cognitive remediation intervention in depression: A randomized controlled trial.,"BACKGROUND Major depressive disorder (MDD) is associated with deficits in executive functioning (EF) that may have a detrimental effect on everyday functioning. Despite this, there are no established cognitive remediation interventions available targeting EF in MDD. Hence, the primary aim of the present pre-registered randomized controlled trial was to evaluate the effectiveness of Goal Management Training (GMT), a metacognitive and strategy-based cognitive remediation intervention to improve EF in MDD. METHODS Sixty-three participants with current or previous mild or moderate MDD and self-reported executive deficits were included and randomized to nine sessions of either GMT (two hours, once weekly; n = 35) or computerized cognitive training (one hour, twice weekly; n = 28). Assessments were conducted at baseline (T1), immediately following training (T2), and at six-month follow-up (T3). The primary outcome measure was The Behavior Rating Inventory of Executive Function - Adult version, pertained to daily life EF. Secondary outcome measures included additional EF assessments (performance-based measures and questionnaires), and depressive symptom severity. RESULTS Forty-three participants completed treatment. Both groups improved following training, and linear mixed model analyses revealed no statistically significant differences between the groups for any outcome measure. Additional exploratory within-group analyses revealed a statistically significant reduction of everyday executive dysfunction and reduced depressive symptoms at the six-month follow-up in GMT only. LIMITATIONS The study was single-blind, and the sample size was modest. CONCLUSIONS Our findings indicate comparable improvements in everyday and performance-based measures of EF, in addition to reductions in depressive symptoms following both GMT and CCT.",2020,"Both groups improved following training, and linear mixed model analyses revealed no statistically significant differences between the groups for any outcome measure.","['Forty-three participants completed treatment', 'Major depressive disorder (MDD', 'depression', 'Sixty-three participants with current or previous mild or moderate MDD and self-reported executive deficits']","['cognitive remediation intervention', 'computerized cognitive training', 'Goal management training', 'GMT', 'Goal Management Training (GMT), a metacognitive and strategy-based cognitive remediation intervention']","['everyday executive dysfunction and reduced depressive symptoms', 'everyday and performance-based measures of EF', 'additional EF assessments (performance-based measures and questionnaires), and depressive symptom severity', 'Behavior Rating Inventory of Executive Function - Adult version, pertained to daily life EF', 'depressive symptoms']","[{'cui': 'C0450368', 'cui_str': '43'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0041696', 'cui_str': 'Depression, Unipolar'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C4319614', 'cui_str': '63'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0205156', 'cui_str': 'Previous'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}]","[{'cui': 'C4277695', 'cui_str': 'Cognitive Remediation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C2748208', 'cui_str': 'Executive dysfunction'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0376558', 'cui_str': 'Life'}]",63.0,0.270869,"Both groups improved following training, and linear mixed model analyses revealed no statistically significant differences between the groups for any outcome measure.","[{'ForeName': 'Bjørn Ingulfsvann', 'Initials': 'BI', 'LastName': 'Hagen', 'Affiliation': 'Department of Research, Lovisenberg Diaconal Hospital, Norway. Electronic address: boha@lds.no.'}, {'ForeName': 'Bjørn', 'Initials': 'B', 'LastName': 'Lau', 'Affiliation': 'Department of Psychology, University of Oslo, Norway.'}, {'ForeName': 'Jutta', 'Initials': 'J', 'LastName': 'Joormann', 'Affiliation': 'Department of Psychology, Yale University, United States.'}, {'ForeName': 'Milada Cvancarova', 'Initials': 'MC', 'LastName': 'Småstuen', 'Affiliation': 'Department of Research, Lovisenberg Diaconal Hospital, Norway; Faculty of Health Science, Oslo Metropolitan University, Norway.'}, {'ForeName': 'Nils Inge', 'Initials': 'NI', 'LastName': 'Landrø', 'Affiliation': 'Department of Psychology, University of Oslo, Norway.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Stubberud', 'Affiliation': 'Department of Research, Lovisenberg Diaconal Hospital, Norway; Department of Psychology, University of Oslo, Norway.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.015'] 2808,32734929,Self-Myofascial Release Intervention and Mobile App in Patients With Hemophilic Ankle Arthropathy: Protocol for a Randomized Controlled Trial.,"BACKGROUND Hemophilic ankle arthropathy is manifested by degenerative functional alterations and chronic pain. Myofascial release techniques are used to treat soft tissue adhesions, relieve pain, and reduce tissue sensitivity. OBJECTIVE This study aims to evaluate the safety and efficacy of a protocol using self-myofascial release with a foam roller to be applied in patients with hemophilic ankle arthropathy. METHODS Patients with ankle arthropathy (N=70) will be recruited, enrolled, and assigned to one of two groups-experimental or control-in a 1:1 allocation ratio. Patients will be recruited from 5 centers in different regions of Spain. Patient data will be collected at baseline, posttreatment, and follow-up. The primary outcome will be frequency of ankle joint bleeding (self-reported). The secondary outcomes will be ankle range of motion (measured with a digital goniometer); joint pain (measured with a visual analog scale and an algometer); joint status (measured using the Hemophilia Joint Health Score); muscle strength (measured with a dynamometer); functionality of lower limbs (measured using the 6-minute walking test); activity (self-reported); and muscle flexibility (measured using the fingertip-to-floor test). The treatment program includes 11 exercises that must be administered bilaterally. A mobile app will be developed where each patient will be able to observe the exercises to be carried out. Each session will last 15 minutes with 5 physiotherapy sessions per week for a period of 3 months. It is expected that patients with hemophilia who receive the foam roller intervention will show improvement in mobility, pain, and status of the ankle joint; muscle strength; and function in the lower extremities. RESULTS The study has been approved by the institutional review board of the University of Murcia. Patient recruitment will begin in September 2020, and the intervention period will last until June 2021. Data collection will take place between September 2020 and October 2021. CONCLUSIONS This protocol describes a randomized clinical trial to examine the safety and efficacy of a self-myofascial release intervention using a foam roller in patients with hemophilic ankle arthropathy. TRIAL REGISTRATION ClinicalTrials.gov NCT03914287; http://clinicaltrials.gov/ct2/show/NCT03914287. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/15612.",2020,"It is expected that patients with hemophilia who receive the foam roller intervention will show improvement in mobility, pain, and status of the ankle joint; muscle strength; and function in the lower extremities. ","['Patients', 'Patients with ankle arthropathy (N=70', 'patients with hemophilia', 'Patients will be recruited from 5 centers in different regions of Spain', 'patients with hemophilic ankle arthropathy']","['Self-Myofascial Release Intervention and Mobile App', 'self-myofascial release intervention']","['frequency of ankle joint bleeding (self-reported', 'safety and efficacy', 'mobility, pain, and status of the ankle joint; muscle strength; and function', 'ankle range of motion (measured with a digital goniometer); joint pain (measured with a visual analog scale and an algometer); joint status (measured using the Hemophilia Joint Health Score); muscle strength (measured with a dynamometer); functionality of lower limbs (measured using the 6-minute walking test); activity (self-reported); and muscle flexibility (measured using the fingertip-to-floor test']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0741040', 'cui_str': 'Ankle arthropathy'}, {'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0037747', 'cui_str': 'Spain'}]","[{'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0695600', 'cui_str': 'Myofascial release'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0003087', 'cui_str': 'Ankle joint structure'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0576183', 'cui_str': 'Ankle joint - range of movement'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0003862', 'cui_str': 'Joint pain'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0022417', 'cui_str': 'Joint structure'}, {'cui': 'C0019069', 'cui_str': 'Hereditary factor VIII deficiency disease'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0180572', 'cui_str': 'Dynamometer'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0729895', 'cui_str': 'Tip of finger'}, {'cui': 'C0016249', 'cui_str': 'Walking surface of room'}]",,0.163128,"It is expected that patients with hemophilia who receive the foam roller intervention will show improvement in mobility, pain, and status of the ankle joint; muscle strength; and function in the lower extremities. ","[{'ForeName': 'Antonio Javier', 'Initials': 'AJ', 'LastName': 'Meroño-Gallut', 'Affiliation': 'Tú. Bienestar 360º, Physiotherapy and Medical Center, San Javier-Murcia, Spain.'}, {'ForeName': 'Rubén', 'Initials': 'R', 'LastName': 'Cuesta-Barriuso', 'Affiliation': 'Department of Physiotherapy, European University of Madrid, Madrid, Spain.'}, {'ForeName': 'Raúl', 'Initials': 'R', 'LastName': 'Pérez-Llanes', 'Affiliation': 'Department of Physiotherapy, Catholic University San Antonio-UCAM, Murcia, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Donoso-Úbeda', 'Affiliation': 'Optimus Osteopathy and Physiotherapy Clinic, Murcia, Spain.'}, {'ForeName': 'José-Antonio', 'Initials': 'JA', 'LastName': 'López-Pina', 'Affiliation': 'Department of Basic Phycology and Methodology, University of Murcia, Murcia, Spain.'}]",JMIR research protocols,['10.2196/15612'] 2809,32735216,Perceived Effectiveness and Motivations for the Use of Web-Based Mental Health Programs: Qualitative Study.,"BACKGROUND The prevalence of depression is high and has been stable despite increased treatment, research, and dissemination. People encounter barriers to seeking traditional mental health services, which could be mitigated by using web-based prevention methods. OBJECTIVE This study aims to understand what people at high risk for depression perceive as effective aspects of web-based mental health programs and what motivates people at high risk for depression to use web-based mental health programs. METHODS We conducted an inductive content analysis using telephone interview data from 77 participants at high risk for depression who were recruited from 2 randomized controlled trials (RCTs). Participants from the first RCT were working men who had been randomly assigned to 1 of the following 3 groups: control group, who had access to general depression information from a website called BroMatters; intervention group 1, who had access to the BroMatters website along with the associated BroHealth web-based mental health program; and intervention group 2, who had access to the BroMatters website, the BroHealth web-based mental health program, and telephone sessions with a life coach. Participants from the second RCT were men and women who had been assigned to the intervention group, who received access to the HardHat web-based mental health program, or the control group, who only received access to the HardHat web-based mental health program following completion of the RCT. Participants for this inductive content analysis study were recruited from the intervention groups in both RCTs. Two groups of participants (n=41 and n=20) were recruited from the BroHealth RCT, and a third group comprised 16 participants that were recruited from the HardHat RCT. RESULTS We generated four categories regarding the perceived effectiveness of web-based programs and five categories related to what motivates the use of web-based programs. Participants identified awareness, program medium and functionality, program content, and coaches as categories related to the effectiveness of the programs. Categories of motivators to use web-based programs included providing reminders or incentives, promotion of the programs, providing appropriate medium and functionality, appropriate content, and perceived need. The final category related to motivators reflects perceptions of participants who were either unsure about what motivates them or believed that there is no way to motivate use. CONCLUSIONS Conflicting evidence was obtained regarding the perceived effectiveness of aspects of the content and functionality of web-based programs. In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach. However, the results also revealed that it is difficult to motivate people to begin using web-based mental health programs. Strategies that may motivate the use of such programs include perceived personal need, effective promotion, providing incentives and reminders, and improving functionality.",2020,"In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach.","['Participants from the first RCT were working men who had been randomly assigned to 1 of the following 3 groups', 'Two groups of participants (n=41 and n=20) were recruited from the BroHealth RCT, and a third group comprised 16 participants that were recruited from the HardHat RCT', '77 participants at high risk for depression who were recruited from 2 randomized controlled trials (RCTs', 'Participants from the second RCT were men and women who had been assigned to the intervention group, who received']","['control group, who had access to general depression information from a website called BroMatters; intervention group 1, who had access to the BroMatters website along with the associated BroHealth web-based mental health program; and intervention group 2, who had access to the BroMatters website, the BroHealth web-based mental health program, and telephone sessions with a life coach', 'access to the HardHat web-based mental health program, or the control group, who only received access to the HardHat web-based mental health program following completion of the RCT']",[],"[{'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0205436', 'cui_str': 'Second'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0557773', 'cui_str': 'Coach'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0205197', 'cui_str': 'Complete'}]",[],77.0,0.075457,"In general, web-based mental health programs were perceived to help increase mental health awareness, especially when it includes live access to a coach.","[{'ForeName': 'Heidi', 'Initials': 'H', 'LastName': 'Eccles', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Molly', 'Initials': 'M', 'LastName': 'Nannarone', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Lashewicz', 'Affiliation': 'Department of Community Health Sciences,, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Attridge', 'Affiliation': 'Attridge Consulting, Inc, Minneapolis, MN, United States.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Marchand', 'Affiliation': 'School of Industrial Relations, University of Montreal, Montreal, QC, Canada.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Aiken', 'Affiliation': 'Office of Research and Innovation, Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Kendall', 'Initials': 'K', 'LastName': 'Ho', 'Affiliation': 'Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada.'}, {'ForeName': 'Jianli', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Work & Mental Health Research Unit, The Institute of Mental Health Research, University of Ottawa, Ottawa, ON, Canada.'}]",Journal of medical Internet research,['10.2196/16961'] 2810,32735218,Effects of an mHealth Brisk Walking Intervention on Increasing Physical Activity in Older People With Cognitive Frailty: Pilot Randomized Controlled Trial.,"BACKGROUND Cognitive frailty is the coexistence of physical frailty and cognitive impairment and is an at-risk state for many adverse health outcomes. Moderate-to-vigorous physical activity (MVPA) is protective against the progression of cognitive frailty. Physical inactivity is common in older people, and brisk walking is a feasible form of physical activity that can enhance their MVPA. Mobile health (mHealth) employing persuasive technology has been successful in increasing the levels of physical activity in older people. However, its feasibility and effects on older people with cognitive frailty are unclear. OBJECTIVE We aimed to identify the issues related to the feasibility of an mHealth intervention and the trial (ie, recruitment, retention, participation, and compliance) and to examine the effects of the intervention on cognitive function, physical frailty, walking time, and MVPA. METHODS An open-label, parallel design, randomized controlled trial (RCT) was employed. The eligibility criteria for the participants were age ≥60 years, having cognitive frailty, and having physical inactivity. In the intervention group, participants received both conventional behavior change intervention and mHealth (ie, smartphone-assisted program using Samsung Health and WhatsApp) interventions. In the control group, participants received conventional behavior change intervention only. The outcomes included cognitive function, frailty, walking time, and MVPA. Permuted block randomization in 1:1 ratio was used. The feasibility issue was described in terms of participant recruitment, retention, participation, and compliance. Wilcoxon signed-rank test was used to test the within-group effects in both groups separately. RESULTS We recruited 99 participants; 33 eligible participants were randomized into either the intervention group (n=16) or the control (n=17) group. The median age was 71.0 years (IQR 9.0) and the majority of them were females (28/33, 85%). The recruitment rate was 33% (33/99), the participant retention rate was 91% (30/33), and the attendance rate of all the face-to-face sessions was 100% (33/33). The majority of the smartphone messages were read by the participants within 30 minutes (91/216, 42.1%). ActiGraph (58/66 days, 88%) and smartphone (54/56 days, 97%) wearing compliances were good. After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups. The increase in frailty reduction (P=.005), walking time (P=.03), step count (P=.02), brisk walking time (P=.009), peak cadence (P=.003), and MVPA time (P=.02) were significant only in the intervention group. CONCLUSIONS Our mHealth intervention is feasible for implementation in older people with cognitive impairment and is effective at enhancing compliance with the brisk walking training program delivered by the conventional behavior change interventions. We provide preliminary evidence that this mHealth intervention can increase MVPA time to an extent sufficient to yield clinical benefits (ie, reduction in cognitive frailty). A full-powered and assessor-blinded RCT should be employed in the future to warrant these effects. TRIAL REGISTRATION HKU Clinical Trials Registry HKUCTR-2283; http://www.hkuctr.com/Study/Show/31df4708944944bd99e730d839db4756.",2020,"After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups.","['older people with cognitive impairment', 'participants were age ≥60 years, having cognitive frailty, and having physical inactivity', 'older people with cognitive frailty', 'older people', '99 participants; 33 eligible participants', 'Older People']","['conventional behavior change intervention and mHealth (ie, smartphone-assisted program using Samsung Health and WhatsApp) interventions', 'conventional behavior change intervention', 'ActiGraph', 'mHealth intervention', 'Mobile health (mHealth) employing persuasive technology', 'mHealth Brisk Walking Intervention', 'Moderate-to-vigorous physical activity (MVPA']","['cognitive function, physical frailty, walking time, and MVPA', 'attendance rate', 'cognitive function improvement', 'frailty reduction', 'recruitment rate', 'participant retention rate', 'Physical Activity', 'walking time', 'brisk walking time', 'MVPA time', 'cognitive function, frailty, walking time, and MVPA', 'peak cadence']","[{'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C3890554', 'cui_str': 'Physical Inactivity'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0542299', 'cui_str': 'Change in behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0424594', 'cui_str': 'Frailty'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0237484', 'cui_str': 'School attendance'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0443162', 'cui_str': 'Brisk'}, {'cui': 'C0444505', 'cui_str': 'Peak'}]",33.0,0.0726845,"After the interventions, cognitive function improvement was significant in both the intervention (P=.003) and the control (P=.009) groups.","[{'ForeName': 'Rick Yc', 'Initials': 'RY', 'LastName': 'Kwan', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Lee', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Paul H', 'Initials': 'PH', 'LastName': 'Lee', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong (China).'}, {'ForeName': 'Mimi', 'Initials': 'M', 'LastName': 'Tse', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Daphne Sk', 'Initials': 'DS', 'LastName': 'Cheung', 'Affiliation': 'Centre for Gerontological Nursing, School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong (China).'}, {'ForeName': 'Ladda', 'Initials': 'L', 'LastName': 'Thiamwong', 'Affiliation': 'College of Nursing, University of Central Florida, Orlando, FL, United States.'}, {'ForeName': 'Kup-Sze', 'Initials': 'KS', 'LastName': 'Choi', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong (China).'}]",JMIR mHealth and uHealth,['10.2196/16596'] 2811,32735221,Effectiveness of a Mobile App Intervention for Anxiety and Depression Symptoms in University Students: Randomized Controlled Trial.,"BACKGROUND Depression and anxiety symptoms are common among university students, but many do not receive treatment. This is often because of lack of availability, reluctance to seek help, and not meeting the diagnostic criteria required to access services. Internet-based interventions, including smartphone apps, can overcome these issues. However, a large number of apps are available, each with little evidence of their effectiveness. OBJECTIVE This study aims to evaluate for the first time the effectiveness of a self-guided mobile app, Feel Stress Free, for the treatment of depression and anxiety symptoms in students. METHODS A web-based randomized controlled trial compared a cognitive behavioral therapy (CBT)-based mobile app Feel Stress Free with a wait-list control. University students self-identified as experiencing symptoms of anxiety or depression and were randomized to 6 weeks of intervention (n=84) or control (n=84), unblinded. The app is self-guided and incorporates behavioral relaxation activities, mood tracking and thought challenging, and minigames. Participants completed the Hospital Anxiety and Depression Scale online at baseline and every fortnight. RESULTS At week 6, the primary end point, there was evidence that the Feel Stress Free app reduced depression symptoms (mean difference -1.56; 95% CI -2.67 to -0.44; P=.006) but only very weak evidence that it reduced anxiety symptoms (mean difference -1.36; 95% CI -2.93 to 0.21; P=.09). At week 4, there was evidence to support the effectiveness of the intervention for anxiety symptoms (mean difference -1.94; 95% CI -3.11 to -0.77; P=.001) and, though weaker, depression symptoms (mean difference -1.08; 95% CI -2.12 to -0.04; P=.04). At week 6, 83% (34/41) of participants indicated that they were using the app weekly or more frequently. CONCLUSIONS The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT. Further research is needed to establish its effectiveness at and beyond 6 weeks. TRIAL REGISTRATION ClinicalTrials.gov NCT03032952; https://clinicaltrials.gov/ct2/show/NCT03032952.",2020,The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT.,"['depression and anxiety symptoms in students', 'University students self-identified as experiencing symptoms of anxiety or depression', 'University Students', 'university students']","['Mobile App Intervention', 'cognitive behavioral therapy (CBT)-based mobile app Feel Stress Free with a wait-list control']","['anxiety symptoms', 'Hospital Anxiety and Depression Scale online', 'Feel Stress Free app reduced depression symptoms', 'Anxiety and Depression Symptoms', 'depression symptoms']","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]","[{'cui': 'C3658310', 'cui_str': 'Mobile Apps'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0086132', 'cui_str': 'Symptoms of depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.247771,The Feel Stress Free app is a promising mobile intervention for treating symptoms of anxiety and depression in students and overcomes many of the barriers to traditional CBT.,"[{'ForeName': 'Tayla', 'Initials': 'T', 'LastName': 'McCloud', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Jones', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Lewis', 'Affiliation': 'Division of Psychiatry, University College London, London, United Kingdom.'}, {'ForeName': 'Vaughan', 'Initials': 'V', 'LastName': 'Bell', 'Affiliation': 'Division of Psychology & Language Sciences, University College London, London, United Kingdom.'}, {'ForeName': 'Elias', 'Initials': 'E', 'LastName': 'Tsakanikos', 'Affiliation': ""Health Service and Population Research Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.""}]",JMIR mHealth and uHealth,['10.2196/15418'] 2812,32735225,Use of a Smartphone App for Weight Loss Versus a Paper-Based Dietary Diary in Overweight Adults: Randomized Controlled Trial.,"BACKGROUND Mobile health (mHealth) tools may be useful platforms for dietary monitoring and assessment. OBJECTIVE This study aims to evaluate the effectiveness of a mobile dietary self-monitoring app for weight loss versus a paper-based diary among adults with a BMI of 23 kg/m 2 or above. METHODS A total of 33 men and 17 women aged 18-39 years participated in a 6-week randomized controlled trial. We randomly assigned participants to one of two groups: (1) a smartphone app group (n=25) or (2) a paper-based diary group (n=25). The smartphone app group recorded foods and dietary supplements that they consumed and received immediate dietary feedback using Well-D, a dietary self-monitoring app developed by our team. The paper-based diary group was instructed to record foods or supplements that they consumed using a self-recorded diary. The primary outcomes were weight, BMI, waist circumference, body fat mass, and skeletal muscle mass. We also examined changes in nutrient intake, including energy, carbohydrate, protein, fat, dietary fiber, vitamins, and minerals, using 3-day 24-hour recalls. Differences in changes between the two groups were analyzed using independent t tests or Wilcoxon Mann-Whitney tests. All of the data were analyzed using intent-to-treat analysis. RESULTS The mean number of days recorded was 18.5 (SD 14.1) for the app group and 15.5 (SD 10.1) for the paper-based diary group. The differences in changes in weight, BMI, and waist circumference were not significantly different between the app group and paper-based diary group (P=.33, .34, and .70, respectively). Similarly, changes in body fat mass or skeletal muscle mass did not differ between the two groups (P=.71 and .054, respectively). Although energy intake was reduced in both groups, there was no significant difference in changes in energy intake between the two groups (P=.98). CONCLUSIONS There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group. Both mobile dietary self-monitoring app and paper-based diary may be useful for improving anthropometric measures. TRIAL REGISTRATION Clinical Research Information Service KCT0003170; https://cris.nih.go.kr/cris/search/search_result_st01_en.jsp?seq=11642<ype=&rtype=.",2020,There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group.,"['Overweight Adults', '33 men and 17 women aged 18-39 years', 'adults with a BMI of 23 kg/m 2 or above']","['smartphone app group (n=25) or (2) a paper-based diary group', 'Smartphone App', 'smartphone app group recorded foods and dietary supplements that they consumed and received immediate dietary feedback using Well-D, a dietary self-monitoring app developed by our team', 'mobile dietary self-monitoring app']","['weight, BMI, waist circumference, body fat mass, and skeletal muscle mass', 'weight, BMI, and waist circumference', 'Weight Loss', 'nutrient intake, including energy, carbohydrate, protein, fat, dietary fiber, vitamins, and minerals, using 3-day 24-hour recalls', 'anthropometric measures and nutrient intake', 'body fat mass or skeletal muscle mass', 'weight loss', 'mean number of days recorded', 'energy intake']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0030351', 'cui_str': 'Paper'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0376660', 'cui_str': 'Diaries'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0016452', 'cui_str': 'Foods'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0588436', 'cui_str': 'Self monitoring'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0006777', 'cui_str': 'Energy intake'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0007004', 'cui_str': 'carbohydrates'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0012173', 'cui_str': 'Dietary fiber'}, {'cui': 'C0042890', 'cui_str': 'Vitamin'}, {'cui': 'C0006660', 'cui_str': 'Physiologic Calcification'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0439584', 'cui_str': '24 hours'}, {'cui': 'C0034770', 'cui_str': 'Mental Recall'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}]",33.0,0.148849,There were no differences in changes in anthropometric measures and nutrient intake between the app group and the paper-based diary group.,"[{'ForeName': 'Jeong Sun', 'Initials': 'JS', 'LastName': 'Ahn', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Heejin', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}, {'ForeName': 'Jiae', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Platform Development Team, Bluecore, Seoul, Republic of Korea.'}, {'ForeName': 'Haemin', 'Initials': 'H', 'LastName': 'Park', 'Affiliation': 'Platform Development Team, Bluecore, Seoul, Republic of Korea.'}, {'ForeName': 'Dong Woo', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Department of Home Economics, Korea National Open University, Seoul, Republic of Korea.'}, {'ForeName': 'Jung Eun', 'Initials': 'JE', 'LastName': 'Lee', 'Affiliation': 'Department of Food and Nutrition, College of Human Ecology, Seoul National University, Seoul, Republic of Korea.'}]",JMIR mHealth and uHealth,['10.2196/14013'] 2813,32731443,Evolution of Inflammatory and Oxidative Stress Markers in Romanian Obese Male Patients with Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy: One Year Follow-Up.,"Geography is one of the key drivers of the significant variation in the etiopathogenic profile and prevalence of type 2 diabetes mellitus (T2DM) and obesity, therefore geographically based data are fundamental for implementing the appropriate interventions. Presently, the selection criteria of T2DM and obesity patients for laparoscopic sleeve gastrectomy (LSG) have not reached a worldwide consensus-highlighting the need for sharing experts' guidance in the preoperative evaluation, choice of the interventional procedure, perioperative management and patient long-term care. The aim of the current study was to evaluate the impact of LSG on T2DM (T2DM) remission in Romanian obese male patients, based on a multiparametric, prospective investigation. We have conducted a randomized controlled study on 41 obese male participants with the body mass index (BMI) ≥ 30 kg/m 2 , aged 30-65 years, which were randomly divided in two study groups: one receiving conventional treatment and the second undergoing LSG. The clinical and anthropometrical parameters, resting metabolic rate, general biochemical status, adipocytes profile, gastrointestinal hormones levels, proinflammatory, oxidant and antioxidant profiles were determined at three time points: V1 (baseline), V2 (after six months) and V3 (after 12 months). Glycated hemoglobin (HbA1c), blood glucose levels, BMI, weight, visceral fat level, HDL-cholesterol, incretin hormones, proinflammatory and the oxidative stress status were significantly improved in the LSG versus conventional treatment group. This is the first study reporting on the evaluation of metabolic surgery impact on Romanian obese male patients with T2DM. Our results confirm that LSG could contribute to T2DM remission in patients with diabesity, but this beneficial effect seems to be critically influenced by the duration of T2DM rather than by the obesity status. Our results show that, in addition to the parameters included in the prediction algorithm, the proinsulin levels, proinsulin/insulin ratio and the visceral fat percentage could bring added value to the assessment of metabolic status.",2020,"Geography is one of the key drivers of the significant variation in the etiopathogenic profile and prevalence of type 2 diabetes mellitus (T2DM) and obesity, therefore geographically based data are fundamental for implementing the appropriate interventions.","['Romanian obese male patients with T2DM', 'Romanian Obese Male Patients with Type 2 Diabetes Mellitus after Laparoscopic Sleeve Gastrectomy', '41 obese male participants with the body mass index (BMI) ≥ 30 kg/m 2 , aged 30-65 years', 'Romanian obese male patients']","['laparoscopic sleeve gastrectomy (LSG', 'LSG', 'conventional treatment and the second undergoing LSG']","['proinsulin levels, proinsulin/insulin ratio and the visceral fat percentage', 'Glycated hemoglobin (HbA1c), blood glucose levels, BMI, weight, visceral fat level, HDL-cholesterol, incretin hormones, proinflammatory and the oxidative stress status', 'T2DM (T2DM) remission', 'resting metabolic rate, general biochemical status, adipocytes profile, gastrointestinal hormones levels, proinflammatory, oxidant and antioxidant profiles']","[{'cui': 'C0035827', 'cui_str': 'Rumanian language'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1960816', 'cui_str': 'Laparoscopic sleeve gastrectomy'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0205436', 'cui_str': 'Second'}]","[{'cui': 'C0033362', 'cui_str': 'Proinsulin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1563740', 'cui_str': 'Abdominal Visceral Fat'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0392201', 'cui_str': 'Glucose measurement, blood'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0018667', 'cui_str': 'Cholesterol in high density lipoprotein subfraction 2'}, {'cui': 'C1562292', 'cui_str': 'Incretin'}, {'cui': 'C0242606', 'cui_str': 'Oxidative stress'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C4082350', 'cui_str': 'Resting Metabolic Rate'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0205474', 'cui_str': 'Biochemical'}, {'cui': 'C0206131', 'cui_str': 'Adipocyte'}, {'cui': 'C1287358', 'cui_str': 'Gastrointestinal hormone level - finding'}, {'cui': 'C0085403', 'cui_str': 'Oxidizing Agents'}, {'cui': 'C0003402', 'cui_str': 'Anti-Oxidants'}]",41.0,0.0161901,"Geography is one of the key drivers of the significant variation in the etiopathogenic profile and prevalence of type 2 diabetes mellitus (T2DM) and obesity, therefore geographically based data are fundamental for implementing the appropriate interventions.","[{'ForeName': 'Ariana', 'Initials': 'A', 'LastName': 'Picu', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Petcu', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Diana Simona', 'Initials': 'DS', 'LastName': 'Ştefan', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Grațiela', 'Initials': 'G', 'LastName': 'Grădișteanu Pîrcălăbioru', 'Affiliation': 'Faculty of Biology, University of Bucharest, 5th district, 050095 Bucharest, Romania.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Mitu', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Daiana', 'Initials': 'D', 'LastName': 'Bajko', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Lixandru', 'Affiliation': 'Department of Biochemistry, ""Carol Davila"" University of Medicine and Pharmacy, 5th district, 050474 Bucharest, Romania.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Guja', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Octavian', 'Initials': 'O', 'LastName': 'Savu', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}, {'ForeName': 'Anca Pantea', 'Initials': 'AP', 'LastName': 'Stoian', 'Affiliation': 'Department of Diabetes, Nutrition and Metabolic Diseases, ""Carol Davila"" University of Medicine and Pharmacy, 5th district, 050474 Bucharest, Romania.'}, {'ForeName': 'Alina', 'Initials': 'A', 'LastName': 'Constantin', 'Affiliation': '""Nicolae Simionescu"" Institute of Cellular Biology and Pathology, 5th district, 050107 Bucharest, Romania.'}, {'ForeName': 'Bogdan', 'Initials': 'B', 'LastName': 'Smeu', 'Affiliation': 'Metabolic and Bariatric Surgery Center of Excellence, Ponderas Academic Hospital, 1st district, 014142 Bucharest, Romania.'}, {'ForeName': 'Cătălin', 'Initials': 'C', 'LastName': 'Copăescu', 'Affiliation': 'Metabolic and Bariatric Surgery Center of Excellence, Ponderas Academic Hospital, 1st district, 014142 Bucharest, Romania.'}, {'ForeName': 'Mariana Carmen', 'Initials': 'MC', 'LastName': 'Chifiriuc', 'Affiliation': 'Faculty of Biology, University of Bucharest, 5th district, 050095 Bucharest, Romania.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Ionica', 'Affiliation': 'Faculty of Biology, University of Bucharest, 5th district, 050095 Bucharest, Romania.'}, {'ForeName': 'Constantin', 'Initials': 'C', 'LastName': 'Ionescu-Tîrgovişte', 'Affiliation': 'NIDNMD ""Prof. N.C. Paulescu"", 2nd district, 020042 Bucharest, Romania.'}]",Metabolites,['10.3390/metabo10080308'] 2814,32731453,Effect of Manual Therapy and Splint Therapy in People with Temporomandibular Disorders: A Preliminary Study.,"BACKGROUND Isolated manual therapy techniques (MT) have shown beneficial effects in patients with temporomandibular disorders (TMD) but the effect of the combination of such techniques, together with the well-stablished splint therapy (ST) remains to be elucidated. OBJECTIVE This study was conducted to ascertain whether a combined program of MT techniques, including intraoral treatment, plus traditional ST improves pain and clinical dysfunction in subjects with TMD. METHODS A preliminary trial was conducted. 16 participants were assigned to either the MT plus ST-Experimental Group (EG, n = 8) or the ST alone-Control Group (CG, n = 8). Forty-five minute sessions of combined MT techniques were performed, once a week for four weeks. Three evaluations were conducted: baseline, post-treatment, and one-month follow-up. Outcome measures were pain perception, pain pressure threshold (PPT), TMD dysfunction, and perception of change after treatment. RESULTS EG showed significant reduction on pain, higher PPT, significant improvement of dysfunction and significantly positive perception of change after treatment ( p < 0.05 all). Additionally, such positive effects were maintained at follow-up with a high treatment effect (R 2 explaining 26.6-33.2% of all variables). CONCLUSION MT plus ST showed reduction on perceived pain (3 points decrease), higher PPT (of at least 1.0 kg/cm 2 ), improvement of disability caused by pain (4.4 points decrease), and positive perception of change (EG: 50% felt ""much improvement""), compared to ST alone.",2020,"MT plus ST showed reduction on perceived pain (3 points decrease), higher PPT (of at least 1.0 kg/cm 2 ), improvement of disability caused by pain (4.4 points decrease), and positive perception of change (EG: 50% felt ""much improvement""), compared to ST alone.","['People with Temporomandibular Disorders', 'patients with temporomandibular disorders (TMD', 'subjects with TMD', '16 participants']","['manual therapy techniques (MT', 'Manual Therapy and Splint Therapy', 'MT plus ST-Experimental Group (EG, n = 8) or the ST alone-Control Group (CG']","['perceived pain', 'pain perception, pain pressure threshold (PPT), TMD dysfunction, and perception of change after treatment', 'pain and clinical dysfunction', 'pain']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0454525', 'cui_str': 'Manual therapy'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0038009', 'cui_str': 'Splint'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0039494', 'cui_str': 'Temporomandibular joint disorder'}, {'cui': 'C0031847', 'cui_str': 'physiopathology'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",16.0,0.0281987,"MT plus ST showed reduction on perceived pain (3 points decrease), higher PPT (of at least 1.0 kg/cm 2 ), improvement of disability caused by pain (4.4 points decrease), and positive perception of change (EG: 50% felt ""much improvement""), compared to ST alone.","[{'ForeName': 'Gemma Victoria', 'Initials': 'GV', 'LastName': 'Espí-López', 'Affiliation': 'Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Gascó Oliag Street nº 5, 46010 Valencia, Spain.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Arnal-Gómez', 'Affiliation': 'Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Gascó Oliag Street nº 5, 46010 Valencia, Spain.'}, {'ForeName': 'Alba', 'Initials': 'A', 'LastName': 'Cuerda Del Pino', 'Affiliation': 'Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Gascó Oliag Street nº 5, 46010 Valencia, Spain.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Benavent-Corai', 'Affiliation': 'Cavanilles Institute for Biodiversity and Evolutionary Biology, University of Valencia, 46980 Paterna, Spain.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Serra-Añó', 'Affiliation': 'Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Gascó Oliag Street nº 5, 46010 Valencia, Spain.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Inglés', 'Affiliation': 'Department of Physiotherapy, Faculty of Physiotherapy, University of Valencia, Gascó Oliag Street nº 5, 46010 Valencia, Spain.'}]",Journal of clinical medicine,['10.3390/jcm9082411'] 2815,32731478,"A Randomized, Crossover Study of the Acute Cognitive and Cerebral Blood Flow Effects of Phenolic, Nitrate and Botanical Beverages in Young, Healthy Humans.","BACKGROUND In whole foods, polyphenols exist alongside a wide array of other potentially bioactive phytochemicals. Yet, investigations of the effects of combinations of polyphenols with other phytochemicals are limited. OBJECTIVE The current study investigated the effects of combining extracts of beetroot, ginseng and sage with phenolic-rich apple, blueberry and coffee berry extracts. DESIGN This randomized, double-blind, placebo-controlled crossover design investigated three active beverages in 32 healthy adults aged 18-49 years. Each investigational beverage comprised extracts of beetroot, ginseng and sage. Each also contained a phenolic-rich extract derived from apple (containing 234 mg flavanols), blueberry (300 mg anthocyanins) or coffee berry (440 mg chlorogenic acid). Cognition, mood and CBF parameters were assessed at baseline and then again at 60, 180 and 360 min post-drink. RESULTS Robust effects on mood and CBF were seen for the apple and coffee berry beverages, with increased subjective energetic arousal and hemodynamic responses being observed. Fewer effects were seen with the blueberry extract beverage. CONCLUSIONS Either the combination of beetroot, ginseng and sage was enhanced by the synergistic addition of the apple and coffee berry extract (and to a lesser extent the blueberry extract) or the former two phenolic-rich extracts were capable of evincing the robust mood and CBF effects alone.",2020,"RESULTS Robust effects on mood and CBF were seen for the apple and coffee berry beverages, with increased subjective energetic arousal and hemodynamic responses being observed.","['Young, Healthy Humans', '32 healthy adults aged 18-49 years']","['Phenolic, Nitrate and Botanical Beverages', 'phenolic-rich extract derived from apple (containing 234 mg flavanols), blueberry (300 mg anthocyanins) or coffee berry (440 mg chlorogenic acid', 'beetroot, ginseng and sage with phenolic-rich apple, blueberry and coffee berry extracts', 'beetroot, ginseng and sage', 'placebo']","['subjective energetic arousal and hemodynamic responses', 'Cognition, mood and CBF parameters', 'mood and CBF']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0359916', 'cui_str': 'Substance with phenol structure'}, {'cui': 'C0028125', 'cui_str': 'Nitrate salt'}, {'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0699759', 'cui_str': 'Wealthy'}, {'cui': 'C0185115', 'cui_str': 'Extraction'}, {'cui': 'C0003625', 'cui_str': 'Malus'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0950037', 'cui_str': 'Blueberries'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0003161', 'cui_str': 'Anthocyanin'}, {'cui': 'C0009237', 'cui_str': 'Coffee'}, {'cui': 'C0005135', 'cui_str': 'Berry'}, {'cui': 'C4517777', 'cui_str': '440'}, {'cui': 'C0008240', 'cui_str': 'Chlorogenic acid'}, {'cui': 'C0453112', 'cui_str': 'Beetroot'}, {'cui': 'C0086767', 'cui_str': 'Ginseng'}, {'cui': 'C1122976', 'cui_str': 'Sage'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0003808', 'cui_str': 'Arousal'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0007818', 'cui_str': 'Circulation, Cerebrovascular'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",32.0,0.110089,"RESULTS Robust effects on mood and CBF were seen for the apple and coffee berry beverages, with increased subjective energetic arousal and hemodynamic responses being observed.","[{'ForeName': 'Philippa A', 'Initials': 'PA', 'LastName': 'Jackson', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Wightman', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Veasey', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Forster', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Khan', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Saunders', 'Affiliation': 'PepsiCo, Nutrition Sciences Global R&D, 700 Anderson Hill Rd, Purchase, NY 10577, USA.'}, {'ForeName': 'Siobhan', 'Initials': 'S', 'LastName': 'Mitchell', 'Affiliation': 'PepsiCo, Nutrition Sciences Global R&D, 700 Anderson Hill Rd, Purchase, NY 10577, USA.'}, {'ForeName': 'Crystal F', 'Initials': 'CF', 'LastName': 'Haskell-Ramsay', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}, {'ForeName': 'David O', 'Initials': 'DO', 'LastName': 'Kennedy', 'Affiliation': 'Brain Performance and Nutrition Research Centre, Northumbria University, Newcastle Upon Tyne NE1 8ST, UK.'}]",Nutrients,['10.3390/nu12082254'] 2816,32731521,"Evaluation of a Cervical Stabilization Exercise Program for Pain, Disability, and Physical Impairments in University Violinists with Nonspecific Neck Pain.","Cervical stabilization exercises are frequently used to reduce pain, maximize function, and improve physical impairments for people with nonspecific neck pain. We conducted a single arm study to evaluate the effects of a home-based cervical stabilization exercise program for university violin players with nonspecific neck pain who frequently assume an asymmetrical neck posture and activate their superficial cervical flexors to stabilize the violin. Twenty violin players with nonspecific neck pain from university symphony orchestras participated in this study. All participants received assessments twice before the intervention and once immediately after a 6-week cervical stabilization exercise program. No significant differences were found between the two pretests before the intervention. After the intervention, the Numeric Rating Scale, the Neck Disability Index, the craniocervical flexion test, muscle endurance tests, cervical range of motion (all directions except flexion) tests, and cervicocephalic relocation tests (flexion and left rotation) showed improvements. The forward head posture indicated by the craniovertebral angle also slightly improved. The results of this single arm study suggest that cervical stabilization exercise is feasible and has the potential to improve physical health for collegiate violin players with nonspecific neck pain.",2020,"After the intervention, the Numeric Rating Scale, the Neck Disability Index, the craniocervical flexion test, muscle endurance tests, cervical range of motion (all directions except flexion) tests, and cervicocephalic relocation tests (flexion and left rotation) showed improvements.","['people with nonspecific neck pain', 'collegiate violin players with nonspecific neck pain', 'Twenty violin players with nonspecific neck pain from university symphony orchestras participated in this study', 'university violin players with nonspecific neck pain who frequently assume an asymmetrical neck posture and activate their superficial cervical flexors to stabilize the violin', 'University Violinists with Nonspecific Neck Pain']","['cervical stabilization exercise', 'Cervical Stabilization Exercise Program', 'home-based cervical stabilization exercise program', 'cervical stabilization exercise program', 'Cervical stabilization exercises']","['Numeric Rating Scale, the Neck Disability Index, the craniocervical flexion test, muscle endurance tests, cervical range of motion (all directions except flexion) tests, and cervicocephalic relocation tests (flexion and left rotation', 'Pain, Disability, and Physical Impairments']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C0332514', 'cui_str': 'Asymmetry'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0872410', 'cui_str': 'Posturing'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1627359', 'cui_str': 'Flexion test'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0439755', 'cui_str': 'Directions'}, {'cui': 'C0231452', 'cui_str': 'Flexion'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231171', 'cui_str': 'Physical impairment'}]",,0.0369142,"After the intervention, the Numeric Rating Scale, the Neck Disability Index, the craniocervical flexion test, muscle endurance tests, cervical range of motion (all directions except flexion) tests, and cervicocephalic relocation tests (flexion and left rotation) showed improvements.","[{'ForeName': 'Yi-Liang', 'Initials': 'YL', 'LastName': 'Kuo', 'Affiliation': 'Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 70152, Taiwan.'}, {'ForeName': 'Tsung-Han', 'Initials': 'TH', 'LastName': 'Lee', 'Affiliation': 'Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 70152, Taiwan.'}, {'ForeName': 'Yi-Ju', 'Initials': 'YJ', 'LastName': 'Tsai', 'Affiliation': 'Department of Physical Therapy, College of Medicine, National Cheng Kung University, Tainan 70152, Taiwan.'}]",International journal of environmental research and public health,['10.3390/ijerph17155430'] 2817,32731764,The Effect of Reducing Insomnia Severity on Work- and Activity-Related Impairment.,"OBJECTIVE/BACKGROUND The effectiveness of Cognitive Behavioral Therapy for Insomnia (CBT-I) for alleviating sleep problems is well established. However, few studies have explored its impact on work productivity and activity. PARTICIPANTS Seventy-seven currently employed adults with insomnia disorder (59 females) recruited to a randomized trial of digital versus face-to-face CBT-I. METHODS AND MATERIALS The general health version of the Work Productivity and Activity Impairment questionnaire was used to measure absenteeism, presenteeism, total work impairment, and activity impairment. We assessed changes in work productivity and activity pre-to-post-therapy for the total sample and then for subgroups categorized according to response or remission of insomnia disorder (evaluated using the Insomnia Severity Index). RESULTS Study participants showed significant improvements in presenteeism ( p = .001; Cohen's d = 0.46), total work impairment ( p < .001; d = 0.48), and activity ( p < .001; d = 0.66), but not absenteeism ( p = .51; d = 0.084) between baseline and follow-up assessment. Individuals meeting criteria for remission showed significantly greater improvement in presenteeism ( p = .002), total work impairment ( p < .001), and activity ( p = .006), but not absenteeism ( p = .064). CONCLUSION This study suggests that the benefits of CBT-I extend beyond improvement in sleep to encompass moderate-to-large improvements in work productivity and activity levels particularly for individuals who achieve remission from insomnia. Given the importance of these behaviors, there is a need for future large-scale randomized trials and cohort studies which should strive to include objective measurement of daytime activity and work performance more frequently.",2020,"Individuals meeting criteria for remission showed significantly greater improvement in presenteeism ( p = .002), total work impairment ( p < .001), and activity ( p = .006), but not absenteeism ( p = .064). ",['Seventy-seven currently employed adults with insomnia disorder (59 females'],['Cognitive Behavioral Therapy'],"['response or remission of insomnia disorder', 'activity', 'Insomnia Severity on Work- and Activity-Related Impairment', 'presenteeism', 'absenteeism, presenteeism, total work impairment, and activity impairment', 'total work impairment']","[{'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0521116', 'cui_str': 'Current'}, {'cui': 'C0014003', 'cui_str': 'Employment'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}]","[{'cui': 'C0544452', 'cui_str': 'Remission phase'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0221099', 'cui_str': 'Impaired'}, {'cui': 'C4042785', 'cui_str': 'Sickness Presence'}, {'cui': 'C0000849', 'cui_str': 'Absenteeism'}, {'cui': 'C0439810', 'cui_str': 'Total'}]",77.0,0.0402372,"Individuals meeting criteria for remission showed significantly greater improvement in presenteeism ( p = .002), total work impairment ( p < .001), and activity ( p = .006), but not absenteeism ( p = .064). ","[{'ForeName': 'Kaia', 'Initials': 'K', 'LastName': 'Kjørstad', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Børge', 'Initials': 'B', 'LastName': 'Sivertsen', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Øystein', 'Initials': 'Ø', 'LastName': 'Vedaa', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Langsrud', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Faaland', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Vethe', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Cecilie L', 'Initials': 'CL', 'LastName': 'Vestergaard', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}, {'ForeName': 'Håvard', 'Initials': 'H', 'LastName': 'Kallestad', 'Affiliation': 'Department of Mental Health, Norwegian University of Science and Technology , Trondheim, Norway.'}]",Behavioral sleep medicine,['10.1080/15402002.2020.1799792'] 2818,32731776,Effects of early aspirin therapy on utero-placental hemodynamics in patients at risk of preeclampsia.,"OBJECTIVES To evaluate the effects of early aspirin therapy on the mean pulsatility index of both uterine arteries (utA PI) at 1st and 2nd trimester in women at risk of preeclampsia (PE). METHODS Uterine artery (utA) blood flow characteristics were obtained in 315 women, 73 women at risk for PE and early aspirin treatment (group 1), 124 without specific risk factors and no aspirin treatment (group 2) and 118 women with manifest PE (group 3). Mean utA PI of group 1 and group 2 were compared within and between the groups at the 1st and 2nd trimester time points. Furthermore, values at 2nd trimester were compared with those of group 3. Observed to expected mean utA PI ratio (O/E ratio) were calculated for comparison between the groups. RESULTS Mean utA PI of group 1 was significantly higher in the 1st trimester compared to group 2 (1.74 vs. 1.47, p  = .0117). In the 2nd trimester mean PI decreased significantly in both groups from 1.74 to 1.16 in group 1 and from 1.47 to 0.90 in group 2 ( p  < .0001). Nevertheless, the difference between the groups was significantly higher in the 2nd trimester than in the 1st trimester (0.29 vs. 0.27, p  < .001). Correction for gestational age by analyzing mean utA O/E ratios showed a comparable pattern with a significantly decrease in both groups (1.40 to 1.10 in group 1 and 1.18 to 0.78 in group 2, p  < .0001), but a significant higher decrease in the 2nd trimester in group 2 (0.31 vs.0.22, p  < 0001). The prevalence of PE was 15.1% (11/73) in group 1 (4 early/7 late onset PE) and 4.7% (6/124) in group 2 (1 early/5 late onset). Mean utA PI and O/E ratio obtained in the 2nd trimester were higher in all PE cases with no significant difference between early and late onset PE (1.49/1.57 and 1.25/1.36 in group 1 and 0.80/0.97 and 0.77/0.99 in group 2). However, mean utA PI and O/E ratio decreased in all cases without PE in both groups, whereas mean utA PI was 1,37 and O/E-ratio was 1,29 in patients with manifest PE at admission, with significantly higher values in early onset than in late onset PE (1.45/1.31 vs. 1.07/1.02, p  < .0001). CONCLUSIONS Our results show that early aspirin treatment leads to a decrease of elevated mean utA PI between 1st and 2nd trimester in patients at elevated risk for PE which is inferior to the decrease observed in women at standard risk for PE. While aspirin improves trophoblast invasion during early second trimester, vascular resistance remains well above average levels. Limited vascular remodeling capacity in the utero-placental perfusion area seems to be the explanation why aspirin does not abrogate PE in all women and has little effect on birth weight. Another explanation might be that a dose of 100 mg aspirin was used as compared to the 150 mg which is recommended today. Our findings underscore the need to study the effects of intervention already during the early stages of trophoblast invasion in the first trimester.",2020,In the 2nd trimester mean PI decreased significantly in both groups from 1.74 to 1.16 in group 1 and from 1.47 to 0.90 in group 2 ( p  < .0001).,"['patients at risk of preeclampsia', 'Uterine artery (utA) blood flow characteristics were obtained in 315 women, 73 women at risk for PE and early aspirin treatment (group 1), 124 without specific risk factors and no aspirin treatment (group 2) and 118 women with manifest PE (group 3', 'women at risk of preeclampsia (PE']","['aspirin therapy', 'aspirin']","['late onset PE', 'mean utA PI ratio (O/E ratio', 'utero-placental hemodynamics', 'prevalence of PE', 'mean pulsatility index of both uterine arteries (utA PI', 'Mean utA PI and O/E ratio', 'Mean utA PI', 'mean utA PI and O/E ratio', 'mean PI', 'mean utA PI', 'mean utA O/E ratios', 'trophoblast invasion']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0226378', 'cui_str': 'Structure of uterine artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C1301820', 'cui_str': 'Obtained'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C4517553', 'cui_str': '124'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C1454756', 'cui_str': 'N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C4517542', 'cui_str': '118'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0441869', 'cui_str': 'Group 3'}]","[{'cui': 'C4303556', 'cui_str': 'Aspirin therapy'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}]","[{'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0206132', 'cui_str': 'Age-at-Onset'}, {'cui': 'C0032914', 'cui_str': 'Pre-eclampsia'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0226378', 'cui_str': 'Structure of uterine artery'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1318003', 'cui_str': 'Uta'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C0032043', 'cui_str': 'Placental structure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0429863', 'cui_str': 'Pulsatility index, arterial velocity waveform'}, {'cui': 'C0041178', 'cui_str': 'Trophoblast structure'}, {'cui': 'C1269955', 'cui_str': 'Tumour invasion'}]",315.0,0.0435164,In the 2nd trimester mean PI decreased significantly in both groups from 1.74 to 1.16 in group 1 and from 1.47 to 0.90 in group 2 ( p  < .0001).,"[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Malah', 'Affiliation': 'Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Hofstaetter', 'Affiliation': 'Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Raio', 'Affiliation': 'Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Surbek', 'Affiliation': 'Department of Obstetrics and Gynecology, Inselspital, University of Bern, Bern, Switzerland.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2020.1786048'] 2819,32731786,Improving cognitive and physical function through 12-weeks of resistance training in older adults: Randomized controlled trial.,"We performed a randomized, controlled trial to analyse the effects of resistance training (RT) on cognitive and physical function among older adults. Fifty participants (mean age 67 years, ~60% woman) were randomly assigned to an RT program or a control group. Participants allocated to RT performed three sets of 10-15RM in nine exercises, three times per week, for 12-weeks. Control group did not perform any exercise. Variables included cognitive (global and executive function) and physical function (gait, mobility and strength) outcomes. At completion of the intervention, RT was shown to have significantly mitigated the drop in selective attention and conflict resolution performance (Stroop test: -494.6; 95%CI: -883.1; -106.1) and promoted a significant improvement in working memory (digit span forward: -0.6; 95%CI: -1.0; -0.1 and forward minus backward: -0.9; 95% CI: -1.6; -0.2) and verbal fluency (animal naming: +1.4, 95%CI 0.3, 2.5). No significant between-group differences were observed for other cognitive outcomes. Regarding physical function, at completion of the intervention, the RT group demonstrated improved fast-pace gait performance (-0.3; 95% CI: -0.6; -0.0) and 1-RM (+21.4 kg; 95%CI: 16.6; 26.2). No significant between-group differences were observed for other mobility-related outcomes. In conclusion, RT improves cognitive and physical function of older adults.",2020,"At completion of the intervention, RT was shown to have significantly mitigated the drop in selective attention and conflict resolution performance (Stroop test:","['Fifty participants (mean age 67 years, ~60% woman', 'older adults']","['RT program or a control group', 'RT', 'resistance training (RT', 'resistance training', '95%CI']","['verbal fluency', 'working memory (digit span forward', 'cognitive and physical function', 'selective attention and conflict resolution performance (Stroop test', 'cognitive outcomes', 'fast-pace gait performance', 'cognitive (global and executive function) and physical function (gait, mobility and strength) outcomes']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0582802', 'cui_str': 'Digit structure'}, {'cui': 'C0439780', 'cui_str': 'Forward'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0150526', 'cui_str': 'Conflict Resolution'}, {'cui': 'C2718024', 'cui_str': 'Stroop Task'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0287990', 'cui_str': 'Furin'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0037426', 'cui_str': 'Social Mobility'}]",50.0,0.0643416,"At completion of the intervention, RT was shown to have significantly mitigated the drop in selective attention and conflict resolution performance (Stroop test:","[{'ForeName': 'Paulo Ricardo Pereira Dos', 'Initials': 'PRPD', 'LastName': 'Santos', 'Affiliation': 'Clinical Exercise Lab (LABEC), Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF) , Petrolina, Brazil.'}, {'ForeName': 'Bruno Remígio', 'Initials': 'BR', 'LastName': 'Cavalcante', 'Affiliation': 'Clinical Exercise Lab (LABEC), Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF) , Petrolina, Brazil.'}, {'ForeName': 'Andreya Karolyne Dos Santos', 'Initials': 'AKDS', 'LastName': 'Vieira', 'Affiliation': 'Clinical Exercise Lab (LABEC), Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF) , Petrolina, Brazil.'}, {'ForeName': 'Marcos Duarte', 'Initials': 'MD', 'LastName': 'Guimarães', 'Affiliation': 'Department of Medicine, Federal University of Vale Do São Francisco (UNIVASF), Petrolina , Pernambuco, Brazil.'}, {'ForeName': 'Antônio Marconi', 'Initials': 'AM', 'LastName': 'Leandro Da Silva', 'Affiliation': 'Department of Medicine, Federal University of Vale Do São Francisco (UNIVASF), Petrolina , Pernambuco, Brazil.'}, {'ForeName': 'Anderson Da Costa', 'Initials': 'ADC', 'LastName': 'Armstrong', 'Affiliation': 'Department of Medicine, Federal University of Vale Do São Francisco (UNIVASF), Petrolina , Pernambuco, Brazil.'}, {'ForeName': 'Rodrigo Gustavo Da Silva', 'Initials': 'RGDS', 'LastName': 'Carvalho', 'Affiliation': 'Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF), Petrolina , Pernambuco, Brazil.'}, {'ForeName': 'Ferdinando Oliveira De', 'Initials': 'FO', 'LastName': 'Carvalho', 'Affiliation': 'Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF), Petrolina , Pernambuco, Brazil.'}, {'ForeName': 'Mariana Ferreira De', 'Initials': 'MF', 'LastName': 'Souza', 'Affiliation': 'Clinical Exercise Lab (LABEC), Physical Education Department, Federal University of Vale Do São Francisco (UNIVASF) , Petrolina, Brazil.'}]",Journal of sports sciences,['10.1080/02640414.2020.1763740'] 2820,32731812,Early Parenting Intervention Effects on Brain Responses to Maternal Cues Among High-Risk Children.,"OBJECTIVE Early adversity is correlated with increased risk for negative outcomes, including psychopathology and atypical neurodevelopment. The authors aimed to test the causal impact of an early parenting intervention (the Attachment and Biobehavioral Catch-Up; ABC) on children's neural processing of parent cues and on psychosocial functioning in a longitudinal randomized clinical trial. METHODS Participants (N=68, mean age, 10.0 years [SD=0.8 years]) were 46 high-risk children whose parents were randomly assigned to receive either the ABC intervention (N=22) or a control intervention (N=24) while the children were infants, in addition to a comparison sample of low-risk children (N=22). During functional MRI scanning, children viewed pictures of their own mothers and of a stranger. RESULTS Children in the ABC condition showed greater maternal cue-related activation than children in the control condition in clusters of brain regions, including the precuneus, the cingulate gyrus, and the hippocampus, regions commonly associated with social cognition. Additionally, greater activity in these regions was associated with fewer total behavior problems. There was an indirect effect of early intervention on middle childhood psychosocial functioning mediated through increased activity in brain regions in response to maternal cues. CONCLUSIONS These results suggest that early parenting intervention (in this case the ABC intervention) can enhance brain regions supporting children's social cognitive development. In addition, the findings highlight these brain effects as a possible neural pathway through which ABC may prevent future behavior problems among high-risk children, yielding psychosocial benefits that endure through at least middle childhood without the need to intervene with the child directly.",2020,"RESULTS Children in the ABC condition showed greater maternal cue-related activation than children in the control condition in clusters of brain regions, including the precuneus, the cingulate gyrus, and the hippocampus, regions commonly associated with social cognition.","['Participants (N=68, mean age, 10.0 years [SD=0.8 years]) were 46 high-risk children whose parents', 'High-Risk Children']","['early parenting intervention', 'ABC intervention', 'control intervention', 'early parenting intervention (the Attachment and Biobehavioral Catch-Up; ABC']","[""children's neural processing of parent cues"", 'maternal cue-related activation', 'Brain Responses to Maternal Cues', 'total behavior problems']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0085092', 'cui_str': 'Parenting behavior'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0152244', 'cui_str': 'Aneurysmal bone cyst'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}, {'cui': 'C0231617', 'cui_str': 'Catch'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0233514', 'cui_str': 'Abnormal behavior'}]",,0.0293274,"RESULTS Children in the ABC condition showed greater maternal cue-related activation than children in the control condition in clusters of brain regions, including the precuneus, the cingulate gyrus, and the hippocampus, regions commonly associated with social cognition.","[{'ForeName': 'Emilio A', 'Initials': 'EA', 'LastName': 'Valadez', 'Affiliation': 'Department of Human Development and Quantitative Methodology, University of Maryland, College Park (Valadez); Department of Psychology, Columbia University, New York (Tottenham); Department of Psychological and Brain Sciences, University of Delaware, Newark (Tabachnick, Dozier).'}, {'ForeName': 'Nim', 'Initials': 'N', 'LastName': 'Tottenham', 'Affiliation': 'Department of Human Development and Quantitative Methodology, University of Maryland, College Park (Valadez); Department of Psychology, Columbia University, New York (Tottenham); Department of Psychological and Brain Sciences, University of Delaware, Newark (Tabachnick, Dozier).'}, {'ForeName': 'Alexandra R', 'Initials': 'AR', 'LastName': 'Tabachnick', 'Affiliation': 'Department of Human Development and Quantitative Methodology, University of Maryland, College Park (Valadez); Department of Psychology, Columbia University, New York (Tottenham); Department of Psychological and Brain Sciences, University of Delaware, Newark (Tabachnick, Dozier).'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Dozier', 'Affiliation': 'Department of Human Development and Quantitative Methodology, University of Maryland, College Park (Valadez); Department of Psychology, Columbia University, New York (Tottenham); Department of Psychological and Brain Sciences, University of Delaware, Newark (Tabachnick, Dozier).'}]",The American journal of psychiatry,['10.1176/appi.ajp.2020.20010011'] 2821,32731825,Migration of a novel 3D-printed cementless versus a cemented total knee arthroplasty: two-year results of a randomized controlled trial using radiostereometric analysis.,"AIMS Although bone cement is the primary mode of fixation in total knee arthroplasty (TKA), cementless fixation is gaining interest as it has the potential of achieving lasting biological fixation. By 3D printing an implant, highly porous structures can be manufactured, promoting osseointegration into the implant to prevent aseptic loosening. This study compares the migration of cementless, 3D-printed TKA to cemented TKA of a similar design up to two years of follow-up using radiostereometric analysis (RSA) known for its ability to predict aseptic loosening. METHODS A total of 72 patients were randomized to either cementless 3D-printed or a cemented cruciate retaining TKA. RSA and clinical scores were evaluated at baseline and postoperatively at three, 12, and 24 months. A mixed model was used to analyze the repeated measurements. RESULTS The mean maximum total point motion (MTPM) at three, 12, and 24 months was 0.33 mm (95% confidence interval (CI) 0.25 to 0.42), 0.42 mm (95% CI 0.33 to 0.51), and 0.47 mm (95% CI 0.38 to 0.57) respectively in the cemented group, versus 0.52 mm (95% CI 0.43 to 0.63), 0.62 mm (95% CI 0.52 to 0.73), and 0.64 mm (95% CI 0.53 to 0.75) in the cementless group (p = 0.003). However, using three months as baseline, no difference in mean migration between groups was found (p = 0.497). Three implants in the cemented group showed a > 0.2 mm increase in MTPM between one and two years of follow-up. In the cementless group, one implant was revised due to pain and progressive migration, and one patient had a liner-exchange due to a deep infection. CONCLUSION The cementless TKA migrated more than the cemented TKA in the first two-year period. This difference was mainly due to a higher initial migration of the cementless TKA in the first three postoperative months after which stabilization was observed in all but one malaligned and early revised TKA. Whether the biological fixation of the cementless implants will result in an increased long-term survivorship requires a longer follow-up. Cite this article: Bone Joint J 2020;102-B(8):1016-1024.",2020,Three implants in the cemented group showed a > 0.2 mm increase in MTPM between one and two years of follow-up.,['72 patients'],"['cementless 3D-printed or a cemented cruciate retaining TKA', 'novel 3D-printed cementless versus a cemented total knee arthroplasty', 'cemented TKA']","['mean maximum total point motion (MTPM', 'RSA and clinical scores', 'MTPM', 'mean migration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0033161', 'cui_str': 'Printing'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}, {'cui': 'C0333118', 'cui_str': 'Retained'}, {'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0205314', 'cui_str': 'New'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0026597', 'cui_str': 'Motion'}, {'cui': 'C3178874', 'cui_str': 'Roentgen Stereophotogrammetry'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237731', 'cui_str': 'Human Migration'}]",72.0,0.134871,Three implants in the cemented group showed a > 0.2 mm increase in MTPM between one and two years of follow-up.,"[{'ForeName': 'Shaho', 'Initials': 'S', 'LastName': 'Hasan', 'Affiliation': 'Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Koen T', 'Initials': 'KT', 'LastName': 'van Hamersveld', 'Affiliation': 'Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Perla J', 'Initials': 'PJ', 'LastName': 'Marang-van de Mheen', 'Affiliation': 'Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Bart L', 'Initials': 'BL', 'LastName': 'Kaptein', 'Affiliation': 'Department of Orthopaedic Surgery, Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Rob G H H', 'Initials': 'RGHH', 'LastName': 'Nelissen', 'Affiliation': 'Leiden University Medical Centre, Leiden, Netherlands.'}, {'ForeName': 'Sören', 'Initials': 'S', 'LastName': 'Toksvig-Larsen', 'Affiliation': 'Department of Orthopaedic Surgery, Hässleholm Hospital, Hässleholm, Sweden.'}]",The bone & joint journal,['10.1302/0301-620X.102B8.BJJ-2020-0054.R1'] 2822,32734179,Pilot Intervention Addressing Social Support and Functioning of Low Socioeconomic Status Older Adults With ESRD: The Seniors Optimizing Community Integration to Advance Better Living with ESRD (SOCIABLE) Study.,"Rationale & Objective Older adults with end-stage kidney disease have increased morbidity, fatigue, and decreased physical function, which can inhibit self-care and social engagement. We pilot tested a home-based program to improve physical and social functioning of low socioeconomic status older adults treated with hemodialysis (HD). Study Design Qualitative study and randomized waitlist control intervention. Setting & Participants Older adult HD patients in Baltimore, MD. Interventions We identified functional needs and home environmental barriers to social engagement through focus groups; mapped findings onto aspects of an established program, which includes home visits with an occupational therapist, nurse, and handyman to provide ≤$1,300 worth of repairs, modifications, and devices; and piloted the program (Seniors Optimizing Community Integration to Advance Better Living with ESRD [SOCIABLE]) among 12 older adult HD patients. We delivered the services over 5 months in a staggered fashion. Outcomes Feasibility and acceptability of the intervention and change in disability scores. Results Focus group themes included fatigue, lack of social support, and desire to live independently. SOCIABLE pilot participants were recruited from 2 dialysis units and all were African American (50% men); mean age was 69 years. At baseline, the mean disability score for activities of daily living (ADLs) was 4.4 and for instrumental ADLs (IADLs) was 6.3 (both out of a possible 16). Among the 9 participants alive at follow-up, there was 100% intervention completion and outcomes assessment. All treated participants improved a mean score of 2.3 for ADL and 2.6 for IADL disability, and social support and social network scores improved by 4.8 and 4.6, respectively. Limitations Small sample size; all participants were African American. Conclusions A home-based intervention addressing physical and social functioning of low socioeconomic status older adults on HD therapy was feasible and acceptable.",2019,"We pilot tested a home-based program to improve physical and social functioning of low socioeconomic status older adults treated with hemodialysis (HD). ","['low socioeconomic status older adults treated with hemodialysis (HD', 'pilot participants were recruited from 2 dialysis units and all were African American (50% men); mean age was 69 years', '12 older adult HD patients', 'of Low Socioeconomic Status Older Adults', 'Participants\n\n\nOlder adult HD patients in Baltimore, MD', 'Older adults with end-stage kidney disease', 'low socioeconomic status older adults']","['ESRD', 'home-based program', 'home visits with an occupational therapist, nurse, and handyman to provide\xa0≤$1,300 worth of repairs, modifications, and devices; and piloted the program (Seniors Optimizing Community Integration to Advance Better Living with ESRD [SOCIABLE', 'Pilot Intervention Addressing Social Support and Functioning', 'HD therapy']","['mean disability score for activities of daily living (ADLs', 'fatigue, lack of social support, and desire to live independently', 'IADL disability, and social support and social network scores', 'disability scores']","[{'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0086996', 'cui_str': 'Socioeconomic Status'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C1629858', 'cui_str': 'Dialysis unit'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0004716', 'cui_str': 'Baltimore'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}]","[{'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0028807', 'cui_str': 'Occupational therapist'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C3494302', 'cui_str': 'Community Integration'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0376649', 'cui_str': 'Addresses'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0001288', 'cui_str': 'Activity of daily living'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C2364105', 'cui_str': 'Inadequate social support'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0150641', 'cui_str': 'Instrumental activities of daily living'}, {'cui': 'C0037438', 'cui_str': 'Social support'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}]",12.0,0.0246509,"We pilot tested a home-based program to improve physical and social functioning of low socioeconomic status older adults treated with hemodialysis (HD). ","[{'ForeName': 'Deidra C', 'Initials': 'DC', 'LastName': 'Crews', 'Affiliation': 'Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Alice M', 'Initials': 'AM', 'LastName': 'Delaney', 'Affiliation': 'Clinical Center, National Institutes of Health, Bethesda.'}, {'ForeName': 'Janiece L', 'Initials': 'JL', 'LastName': 'Walker Taylor', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Thomas K M', 'Initials': 'TKM', 'LastName': 'Cudjoe', 'Affiliation': 'Division of Geriatrics, Department of Medicine, Baltimore, MD.'}, {'ForeName': 'Manka', 'Initials': 'M', 'LastName': 'Nkimbeng', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Laken', 'Initials': 'L', 'LastName': 'Roberts', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Savage', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Allyson', 'Initials': 'A', 'LastName': 'Evelyn-Gustave', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Jill', 'Initials': 'J', 'LastName': 'Roth', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Dingfen', 'Initials': 'D', 'LastName': 'Han', 'Affiliation': 'Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'LaPricia Lewis', 'Initials': 'LL', 'LastName': 'Boyér', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD.'}, {'ForeName': 'Roland J', 'Initials': 'RJ', 'LastName': 'Thorpe', 'Affiliation': 'Center on Aging and Health, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Roth', 'Affiliation': 'Center on Aging and Health, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Laura N', 'Initials': 'LN', 'LastName': 'Gitlin', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}, {'ForeName': 'Sarah L', 'Initials': 'SL', 'LastName': 'Szanton', 'Affiliation': 'Johns Hopkins University School of Nursing, Johns Hopkins Medical Institutions, Baltimore.'}]",Kidney medicine,['10.1016/j.xkme.2018.12.001'] 2823,32734199,"Efficacy of a Moisturizer for Pruritus Accompanied With Asteatosis in Dialysis Patients: An Open-Label, Randomized, Exploratory Study.","Background In dialysis patients, skin disorders (dryness and itching) are frequently observed and treated with a moisturizer, in the absence of clear evidence of efficacy. Study Design An open-label, randomized, before/after, parallel-group, comparative/exploratory study. Setting & Participants 12 Japanese patients with chronic kidney failure undergoing maintenance hemodialysis who presented with dry skin and itching. Intervention Patients received a topical heparinoid moisturizer as the study drug for 2 weeks from the first day of the study treatment, followed by either a 2-week washout (group A: 6 participants) or further 2-week treatment (group B: 6 participants). Outcomes The primary end point was change in water content in the stratum corneum in the hypochondrium. Secondary end points included change in visual analogue scale itching score and subjective evaluations of symptoms. To evaluate safety, adverse events were also investigated. Measurements Water content of the stratum corneum, dryness/itching improvement rating, itching visual analogue scale/duration of itching, photographic evaluation of skin symptoms, principal investigator's overall assessment of study drug, and adverse events. Results Mean water content of the stratum corneum in the combined groups significantly increased at week 2 (51.2 arbitrary units [AU] vs treatment start day, 31.6 AU; P <0.001), but significantly decreased at week 4 in group A, in which patients discontinued treatment with the study drug (39.4 AU; P  = 0.005). Other efficacy end points, including the visual analogue scale itching score, were also improved by treatment with the study drug, but such improvement was not sustained after discontinuation of treatment. There were no adverse events related to the study treatment. Limitations Only Japanese patients were included in the study, with a small sample size. Conclusions Continuous application of the topical heparinoid moisturizer increased water content in the stratum corneum and lessened itching in dialysis patients. Funding Maruho Co, Ltd. Trial Registration Registered at the University Hospital Medical Information Network Clinical Trials Registry with study number UMIN000017016.",2019,"Mean water content of the stratum corneum in the combined groups significantly increased at week 2 (51.2 arbitrary units [AU] vs treatment start day, 31.6 AU; P <0.001), but significantly decreased at week 4 in group A, in which patients discontinued treatment with the study drug (39.4 AU; P  = 0.005).","['Only Japanese patients were included in the study, with a small sample size', 'dialysis patients', '12 Japanese patients with chronic kidney failure undergoing maintenance hemodialysis who presented with dry skin and itching', 'Dialysis Patients']","['topical heparinoid moisturizer', 'Moisturizer']","['change in water content', 'change in visual analogue scale itching score and subjective evaluations of symptoms', ""Measurements\n\n\nWater content of the stratum corneum, dryness/itching improvement rating, itching visual analogue scale/duration of itching, photographic evaluation of skin symptoms, principal investigator's overall assessment of study drug, and adverse events"", 'visual analogue scale itching score', 'safety, adverse events', 'adverse events', 'Mean water content of the stratum corneum', 'skin disorders (dryness and itching']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0547044', 'cui_str': 'Lesser'}, {'cui': 'C0242618', 'cui_str': 'Sample Size'}, {'cui': 'C0011945', 'cui_str': 'Dialysis'}, {'cui': 'C0022661', 'cui_str': 'Chronic renal failure'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0151908', 'cui_str': 'Dry skin'}]","[{'cui': 'C0332237', 'cui_str': 'Topical'}, {'cui': 'C0019142', 'cui_str': 'Heparinoids'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C0423896', 'cui_str': 'Feeling content'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0846574', 'cui_str': 'Psychiatric evaluation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0221921', 'cui_str': 'Stratum corneum structure'}, {'cui': 'C0033774', 'cui_str': 'Itching'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0586407', 'cui_str': 'Skin symptom'}, {'cui': 'C1521895', 'cui_str': 'Principal investigator'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0037274', 'cui_str': 'Disorder of skin'}]",12.0,0.0269715,"Mean water content of the stratum corneum in the combined groups significantly increased at week 2 (51.2 arbitrary units [AU] vs treatment start day, 31.6 AU; P <0.001), but significantly decreased at week 4 in group A, in which patients discontinued treatment with the study drug (39.4 AU; P  = 0.005).","[{'ForeName': 'Yukie', 'Initials': 'Y', 'LastName': 'Yoshida', 'Affiliation': 'Department of Nephrology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Kazumasa', 'Initials': 'K', 'LastName': 'Hashimoto', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Hidehisa', 'Initials': 'H', 'LastName': 'Saeki', 'Affiliation': 'Department of Dermatology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Fumiaki', 'Initials': 'F', 'LastName': 'Itagaki', 'Affiliation': 'Department of Nephrology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Akio', 'Initials': 'A', 'LastName': 'Hirama', 'Affiliation': 'Department of Nephrology, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Atsuko', 'Initials': 'A', 'LastName': 'Suzuki', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Kayo', 'Initials': 'K', 'LastName': 'Iiyama', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Yumi', 'Initials': 'Y', 'LastName': 'Fukunaga', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Enomoto', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Eiji', 'Initials': 'E', 'LastName': 'Kushima', 'Affiliation': 'Kidney Disease Clinic of Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Momoyo', 'Initials': 'M', 'LastName': 'Kishida', 'Affiliation': 'Maruho Co, Ltd., Osaka, Japan.'}, {'ForeName': 'Seiki', 'Initials': 'S', 'LastName': 'Fujimoto', 'Affiliation': 'Maruho Co, Ltd., Osaka, Japan.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Tsuruoka', 'Affiliation': 'Department of Nephrology, Nippon Medical School, Tokyo, Japan.'}]",Kidney medicine,['10.1016/j.xkme.2019.04.008'] 2824,32734423,Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.,"INTRODUCTION Nintedanib, a tyrosine kinase receptor inhibitor, may be associated with increased bleeding risk. Thus, patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatelet therapy, have been excluded from clinical trials of nintedanib in idiopathic pulmonary fibrosis (IPF). OBJECTIVE Our objective was to examine real-world bleeding events in patients with IPF treated with antifibrotics, including those receiving anticoagulants and/or antiplatelet therapy. METHODS The European MultiPartner IPF Registry (EMPIRE) enrolled 2794 patients with IPF: group A (1828: no anticoagulant or antiplatelet treatment), group B (227: anticoagulant treatment), group C (659: antiplatelet treatment), and group D (80: anticoagulant and antiplatelet treatment). Overall, 673 (24.1%) received nintedanib and 933 (33.4%) received pirfenidone. Bleeding events and their relationship to antifibrotic and anticoagulation treatment were characterized. RESULTS Group A patients, versus those in groups B, C, and D, were typically younger and generally had the lowest comorbidity rates. A higher proportion of patients in groups A and C, versus group B, received nintedanib. Pirfenidone, most common in group D, was more evenly balanced across groups. In patients with reported bleeding events, seven of eight received nintedanib (groups A, C, and D). Bleeding incidence was 3.0, 0, 1.3, and 18.1 per 10,000 patient-years (groups A, B, C, and D, respectively). CONCLUSION Real-world data from EMPIRE showed that patients on anticoagulant medications received nintedanib less frequently, perhaps based on its mechanism of action. Overall, bleeding incidence was low (0.29%: nintedanib 0.25%; pirfenidone 0.04%) and irrespective of anticoagulant or antiplatelet therapy received (P = 0.072).",2020,"Overall, bleeding incidence was low (0.29%: nintedanib 0.25%; pirfenidone 0.04%) and irrespective of anticoagulant or antiplatelet therapy received (P = 0.072).","['2794 patients with IPF: group A', 'patients with an inherited predisposition to bleeding, or those receiving therapeutic doses of anticoagulants or high-dose antiplatelet therapy, have been excluded from clinical trials of nintedanib in idiopathic pulmonary fibrosis (IPF', 'Central European Patients with Idiopathic Pulmonary Fibrosis (IPF', 'patients with IPF treated with antifibrotics, including those receiving anticoagulants and/or antiplatelet therapy']","['Pirfenidone', 'pirfenidone']","['Bleeding incidence', 'Bleeding events', 'Anticoagulant Use and Bleeding Risk', 'Overall, bleeding incidence', 'bleeding events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1800706', 'cui_str': 'Idiopathic pulmonary fibrosis'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0314657', 'cui_str': 'Genetic predisposition'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0444956', 'cui_str': 'High dose'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C2930789', 'cui_str': 'nintedanib'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0239307', 'cui_str': 'European'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0298067', 'cui_str': 'pirfenidone'}]","[{'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0003280', 'cui_str': 'Anticoagulant'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",2794.0,0.0171192,"Overall, bleeding incidence was low (0.29%: nintedanib 0.25%; pirfenidone 0.04%) and irrespective of anticoagulant or antiplatelet therapy received (P = 0.072).","[{'ForeName': 'Abigél M', 'Initials': 'AM', 'LastName': 'Kolonics-Farkas', 'Affiliation': 'Department of Pulmonology, Semmelweis University, Tömő utca 25-29, Budapest, 1083, Hungary. kolonics-farkas.abigel@med.semmelweis-univ.hu.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Šterclová', 'Affiliation': 'Department of Respiratory Diseases of the First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.'}, {'ForeName': 'Nesrin', 'Initials': 'N', 'LastName': 'Mogulkoc', 'Affiliation': 'Department of Pulmonary Medicine, Ege University Medical School, Izmir, Turkey.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Kus', 'Affiliation': 'Department of Pulmonary Diseases, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Hájková', 'Affiliation': 'Clinic of Pneumology and Phthisiology, University Hospital Bratislava, Bratislava, Slovakia.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Müller', 'Affiliation': 'Department of Pulmonology, Semmelweis University, Tömő utca 25-29, Budapest, 1083, Hungary.'}, {'ForeName': 'Dragana', 'Initials': 'D', 'LastName': 'Jovanovic', 'Affiliation': 'University Hospital of Pulmonology, Clinical Center of Serbia, Belgrade, Serbia.'}, {'ForeName': 'Jasna', 'Initials': 'J', 'LastName': 'Tekavec-Trkanjec', 'Affiliation': 'Pulmonary Department, University Hospital Dubrava, Zagreb, Croatia.'}, {'ForeName': 'Simona', 'Initials': 'S', 'LastName': 'Littnerová', 'Affiliation': 'Institute of Biostatistics and Analyses, Masaryk University, Faculty of Medicine, Brno, Czech Republic.'}, {'ForeName': 'Karel', 'Initials': 'K', 'LastName': 'Hejduk', 'Affiliation': 'Institute of Biostatistics and Analyses, Masaryk University, Faculty of Medicine, Brno, Czech Republic.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Vašáková', 'Affiliation': 'Department of Respiratory Diseases of the First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, Czech Republic.'}]",Drug safety,['10.1007/s40264-020-00978-5'] 2825,32734457,68 Ga-PSMA PET/CT targeted biopsy for the diagnosis of clinically significant prostate cancer compared with transrectal ultrasound guided biopsy: a prospective randomized single-centre study.,"PURPOSE 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is valuable for detecting primary and recurrent prostatic lesions. This study aimed to evaluate the efficacy of 68 Ga-PSMA-11 PET/CT as a triage tool for prostate biopsy (PSMA-TB) and compare with transrectal ultrasound-guided biopsy (TRUS-GB) for the diagnosis of clinically significant prostate cancer (csPCa). METHODS This single-centre study randomly allocated 120 patients with elevated serum prostate-specific antigen (PSA) levels (> 4 ng/ml) to PSMA-PET or TRUS group. Patients with PSMA-avid lesions (SUVmax ≥ 8.0) underwent PSMA-TB via a single-puncture percutaneous transgluteal approach (n = 25), whilst patients with negative PSMA-PET underwent systematic TRUS-GB (n = 35). All patients in the TRUS group underwent TRUS-GB directly (n = 60). RESULTS PCa and csPCa were detected in 26/60 (43.3%) and 24/60 (40.0%) patients in the PSMA-PET group and 19/60 (31.6%) and 15/60 (25.0%) in the TRUS group, respectively. In the PSMA-PET group, the detection rate of PCa and csPCa were significantly higher in PSMA-PET-positive than negative patients (PCa, 23/25 (92.0%) vs 3/35 (8.6%), P < 0.01; csPCa, 22/25 (88.0%) vs 2/35 (5.7%), P < 0.01). PSMA-TB detected significantly more PCa and csPCa than TRUS-GB in the TRUS controls (PCa, 21/25 (84.0%) vs 19/60 (31.6%), P < 0.01; csPCa, 20/25 (80.0%) vs 15/60 (25.0%), P < 0.01). PSMA-PET detected significantly more cases of csPCa amongst patients with PSA 4.0-20.0 ng/ml than TRUS (27.02% vs 8.82%, P < 0.05). No haematuria, urinary retention or pelvic infection was observed after PSMA-TB compare with TRUS-GB. CONCLUSIONS 68 Ga-PSMA-11 PET/CT is a feasible imaging technique that may serve as a triage tool for prostate biopsy, and may improve the detection rate of csPCa compared with TRUS-GB, especially in patients with serum PSA 4.0-20.0 ng/ml.",2020,"No haematuria, urinary retention or pelvic infection was observed after PSMA-TB compare with TRUS-GB. ","['Patients with PSMA-avid lesions (SUVmax ≥\u20098.0) underwent', '68 Ga-prostate-specific membrane antigen (PSMA', '120 patients with elevated serum prostate-specific antigen (PSA) levels (>\u20094\xa0ng/ml) to PSMA-PET or TRUS group']","['68 Ga-PSMA PET/CT targeted biopsy', 'negative PSMA-PET underwent systematic TRUS-GB', 'transrectal ultrasound-guided biopsy (TRUS-GB', '68 Ga-PSMA-11 PET/CT', 'PSMA-TB via a single-puncture percutaneous transgluteal approach', 'positron emission tomography/computed tomography (PET/CT', 'transrectal ultrasound guided biopsy', 'PSMA']","['No haematuria, urinary retention or pelvic infection', 'csPCa', 'PCa and csPCa', 'detection rate of PCa and csPCa']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0067685', 'cui_str': 'Glutamate carboxypeptidase II'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0303226', 'cui_str': 'Gallium-68'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0138741', 'cui_str': 'Prostate specific antigen'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439275', 'cui_str': 'ug/L'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0303226', 'cui_str': 'Gallium-68'}, {'cui': 'C0067685', 'cui_str': 'Glutamate carboxypeptidase II'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0031268', 'cui_str': 'Companion Animals'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0373345', 'cui_str': 'Transrectal ultrasound'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C3656970', 'cui_str': 'Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach'}, {'cui': 'C0444462', 'cui_str': 'Transgluteal approach'}]","[{'cui': 'C0018965', 'cui_str': 'Blood in urine'}, {'cui': 'C0080274', 'cui_str': 'Bladder retention of urine'}, {'cui': 'C0030790', 'cui_str': 'Infection of pelvis'}, {'cui': 'C0030131', 'cui_str': 'p-Chloramphetamine'}, {'cui': 'C0206100', 'cui_str': 'Signal Detection (Psychology)'}]",120.0,0.100778,"No haematuria, urinary retention or pelvic infection was observed after PSMA-TB compare with TRUS-GB. ","[{'ForeName': 'Le-Le', 'Initials': 'LL', 'LastName': 'Zhang', 'Affiliation': 'Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Wen-Cheng', 'Initials': 'WC', 'LastName': 'Li', 'Affiliation': 'Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Zheng', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Jiang', 'Affiliation': 'Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Shi-Ming', 'Initials': 'SM', 'LastName': 'Zang', 'Affiliation': 'Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Lu-Wei', 'Initials': 'LW', 'LastName': 'Xu', 'Affiliation': 'Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Wen-Bing', 'Initials': 'WB', 'LastName': 'Huang', 'Affiliation': 'Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China.'}, {'ForeName': 'Feng', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. fengwangcn@hotmail.com.'}, {'ForeName': 'Hong-Bin', 'Initials': 'HB', 'LastName': 'Sun', 'Affiliation': 'Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, 210006, China. docshb@126.com.'}]",European journal of nuclear medicine and molecular imaging,['10.1007/s00259-020-04863-2'] 2826,32734461,An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions.,"PURPOSE The primary purpose of this study was to evaluate the effect of the fatty acid amide hydrolase (FAAH) inhibitor ASP3652 on efficacy and safety in patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The secondary purpose was to evaluate phenotyping based on Hunner's lesions (HL). METHODS In this randomized trial, adult female patients with moderate/severe IC/BPS received 12 weeks of treatment with an oral dose of ASP3652 (50, 150, or 300 mg twice daily) or placebo. A Bayesian model was employed using accumulating data to adjust the randomization probability and to analyze the primary efficacy variable (change from baseline to end of treatment in Mean Daily Pain [MDP; range 0-10]). Study outcomes and patient characteristics of patients with and without HL (HL+ and HL-) were compared. RESULTS In total, 287 patients were randomized. The 300 mg dose group (n = 97) showed the largest effect, i.e., a mean change from baseline to end of treatment of -1.73 in MDP. However, the mean difference from placebo was 0.02. The probability that this dose was better than placebo was 13.5%. Adverse event incidence was low and similar between study groups. HL+ patients were older and had more severe symptoms than HL-. An association was suggested in HL+ patients between changes in micturition frequency and MDP (R = 0.41 [95% CI 0.18, 0.63]), which was not observed in HL- (R = 0.04 [95% CI -0.16, 0.29]). CONCLUSION ASP3652 was safe and well tolerated, but did not show efficacy in IC/BPS. The observed differences between HL+ and HL- suggest that IC/BPS diagnosis and treatment may be approached differently in these two phenotypes. TRIAL REGISTRATION EudraCT number 2011-004555-39, date of registration: 2012-05-07.",2020,Adverse event incidence was low and similar between study groups.,"['287 patients were randomized', 'EudraCT number 2011-004555-39, date of registration', 'patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS', 'interstitial cystitis/bladder pain syndrome', 'adult female patients with moderate/severe IC/BPS']","['HL', 'ASP3652', 'fatty acid amide hydrolase (FAAH) inhibitor ASP3652', 'placebo']","['patient characteristics of patients with and without HL (HL+ and HL', 'severe symptoms', 'Adverse event incidence', 'efficacy and safety', 'HL', 'safe and well tolerated']","[{'cui': 'C4517682', 'cui_str': '287'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0011008', 'cui_str': 'Date'}, {'cui': 'C0282488', 'cui_str': 'Ulcerative cystitis'}, {'cui': 'C1720830', 'cui_str': 'Bladder Pain Syndrome'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205082', 'cui_str': 'Severe'}]","[{'cui': 'C0268824', 'cui_str': 'Chronic ulcerating interstitial cystitis'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0531004', 'cui_str': 'fatty acid amide hydrolase'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0268824', 'cui_str': 'Chronic ulcerating interstitial cystitis'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0436345', 'cui_str': 'Symptom severe'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",287.0,0.365953,Adverse event incidence was low and similar between study groups.,"[{'ForeName': 'Jos G A', 'Initials': 'JGA', 'LastName': 'Houbiers', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'J W Olivier', 'Initials': 'JWO', 'LastName': 'van Till', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands. olivier.vantill@astellas.com.'}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Kaper', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'Yalcin', 'Initials': 'Y', 'LastName': 'Yavuz', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'Reynaldo V', 'Initials': 'RV', 'LastName': 'Martina', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'Dirk', 'Initials': 'D', 'LastName': 'Cerneus', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Melis', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'Otto', 'Initials': 'O', 'LastName': 'Stroosma', 'Affiliation': 'Astellas Pharma Europe B.V, Leiden, The Netherlands.'}, {'ForeName': 'J Curtis', 'Initials': 'JC', 'LastName': 'Nickel', 'Affiliation': 'Department of Urology, Queens University, Kingston, Canada.'}, {'ForeName': 'Phil M', 'Initials': 'PM', 'LastName': 'Hanno', 'Affiliation': 'Department of Urology, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Jørgen', 'Initials': 'J', 'LastName': 'Nordling', 'Affiliation': 'Department of Urology, University of Copenhagen, Copenhagen, Denmark.'}]",World journal of urology,['10.1007/s00345-020-03372-z'] 2827,32734480,"Correction to: Health economic evaluation of an internet intervention for depression (deprexis), a randomized controlled trial.",An amendment to this paper has been published and can be accessed via the original article.,2020,An amendment to this paper has been published and can be accessed via the original article.,[],['internet intervention'],[],[],"[{'cui': 'C3898714', 'cui_str': 'Internet Intervention'}]",[],,0.08344,An amendment to this paper has been published and can be accessed via the original article.,"[{'ForeName': 'Viola', 'Initials': 'V', 'LastName': 'Gräfe', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany. viola.graefe@uni-bielefeld.de.'}, {'ForeName': 'Steffen', 'Initials': 'S', 'LastName': 'Moritz', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.'}, {'ForeName': 'Wolfgang', 'Initials': 'W', 'LastName': 'Greiner', 'Affiliation': 'Department of Health Economics and Health Care Management, School of Public Health, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany.'}]",Health economics review,['10.1186/s13561-020-00280-1'] 2828,32734504,New technologies for intensive prevention programs after myocardial infarction: rationale and design of the NET-IPP trial.,"INTRODUCTION Current health care data reveal suboptimal prevention in patients with coronary artery disease and an unmet need to develop effective preventive strategies. The New Technologies for Intensive Prevention Programs (NET-IPP) Trial will investigate if a long-term web-based prevention program after myocardial infarction (MI) will reduce clinical events and risk factors. In a genetic sub study the impact of disclosure of genetic risk using polygenic risk scores (PRS) will be assessed. STUDY DESIGN Patients hospitalized for MI will be prospectively enrolled and assigned to either a 12-months web-based intensive prevention program or standard care. The web-based program will include telemetric transmission of risk factor data, e-learning and electronic contacts between a prevention assistant and the patients. The combined primary study endpoint will comprise severe adverse cardiovascular events after 2 years. Secondary endpoints will be risk factor control, adherence to medication and quality of life. In a genetic sub study genetic risk will be assessed in all patients of the web-based intensive prevention program group by PRS and patients will be randomly assigned to genetic risk disclosure vs. no disclosure. The study question will be if disclosure of genetic risk has an impact on patient motivation and cardiovascular risk factor control. CONCLUSIONS The randomized multicenter NET-IPP study will evaluate for the first time the effects of a long-term web-based prevention program after MI on clinical events and risk factor control. In a genetic sub study the impact of disclosure of genetic risk using PRS will be investigated.",2020,The New Technologies for Intensive Prevention Programs (NET-IPP),"['Patients hospitalized for MI', 'patients with coronary artery disease']","['12-months web-based intensive prevention program or standard care', 'long-term web-based prevention program', 'Intensive Prevention Programs (NET-IPP']","['risk factor control, adherence to medication and quality of life', 'severe adverse cardiovascular events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0701159', 'cui_str': 'Patient in hospital'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0199176', 'cui_str': 'Preventive procedure'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0039421', 'cui_str': 'Technology'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}]",,0.0672279,The New Technologies for Intensive Prevention Programs (NET-IPP),"[{'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'Wienbergen', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277, Bremen, Germany. harm.wienbergen@klinikum-bremen-ldw.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Fach', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277, Bremen, Germany.'}, {'ForeName': 'Jeanette', 'Initials': 'J', 'LastName': 'Erdmann', 'Affiliation': 'Institute for Cardiogenetics, Lübeck University Heart Center, Lübeck, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Katalinic', 'Affiliation': 'Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Nora', 'Initials': 'N', 'LastName': 'Eisemann', 'Affiliation': 'Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Krawitz', 'Affiliation': 'Institute for Genomic Statistics and Bioinformatics, University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Carlo', 'Initials': 'C', 'LastName': 'Maj', 'Affiliation': 'Institute for Genomic Statistics and Bioinformatics, University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Oleg', 'Initials': 'O', 'LastName': 'Borisov', 'Affiliation': 'Institute for Genomic Statistics and Bioinformatics, University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Munz', 'Affiliation': 'Institute for Cardiogenetics, Lübeck University Heart Center, Lübeck, Germany.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Noethen', 'Affiliation': 'Institute of Human Genetics, University Hospital of Bonn, Bonn, Germany.'}, {'ForeName': 'Roza', 'Initials': 'R', 'LastName': 'Meyer-Saraei', 'Affiliation': 'Medical Clinic II, Lübeck University Heart Center, Ratzeburger Allee 160, 23538, Lübeck, Germany.'}, {'ForeName': 'Rico', 'Initials': 'R', 'LastName': 'Osteresch', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277, Bremen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Schmucker', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277, Bremen, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Linke', 'Affiliation': 'Heart Center, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.'}, {'ForeName': 'Ingo', 'Initials': 'I', 'LastName': 'Eitel', 'Affiliation': 'Medical Clinic II, Lübeck University Heart Center, Ratzeburger Allee 160, 23538, Lübeck, Germany.'}, {'ForeName': 'Rainer', 'Initials': 'R', 'LastName': 'Hambrecht', 'Affiliation': 'Bremen Institute for Heart and Circulation Research at the Klinikum Links der Weser, Senator-Wessling-Str. 1, 28277, Bremen, Germany.'}, {'ForeName': 'Harald', 'Initials': 'H', 'LastName': 'Langer', 'Affiliation': 'Medical Clinic II, Lübeck University Heart Center, Ratzeburger Allee 160, 23538, Lübeck, Germany.'}]",Clinical research in cardiology : official journal of the German Cardiac Society,['10.1007/s00392-020-01695-w'] 2829,32734932,Effectiveness of a Theory- and Web-Based Adaptive Implementation Intervention on Nurses' and Nursing Students' Intentions to Provide Brief Counseling: Protocol for a Randomized Controlled Trial.,"BACKGROUND Brief counseling can motivate patients to initiate health behavior change. However, increasing the provision of brief counseling by nurses is difficult due to contextual and practitioner-level factors impeding nurses' motivation and intentions to provide brief counseling (eg, unfavorable attitude toward brief counseling, lack of perceived control linked to barriers). Theory-based implementation interventions could address these practitioner-level factors and support evidence-based practice in the context of brief counseling. Web-based, adaptive e-learning (electronic learning) programs are a novel type of implementation intervention that could address the limitations of current brief counseling training programs, such as accessibility and personalization. OBJECTIVE This paper presents a study protocol for evaluating the effectiveness of the E_MOTIV A implementation intervention-a theory- and web-based adaptive e-learning program-to increase nurses' and nursing students' intentions to provide brief counseling for smoking, an unbalanced diet, and medication nonadherence. METHODS A two-group, single-blind, randomized controlled trial will be conducted with nurses and nursing students enrolled in a Bachelor of Science in Nursing program in Quebec, Canada. Participants in the experimental group will be allocated to the E_MOTIV A intervention-a theory- and web-based adaptive e-learning program-while participants in the active control group will be allocated to the E_MOTIV B intervention, a knowledge- and web-based standardized e-learning program. The E_MOTIV A intervention was designed to influence the constructs of the Theory of Planned Behavior (eg, attitude, subjective norms, and perceived behavioral control) in the context of brief counseling. The Cognitive Load Index and User Engagement Scale will be used to assess participants' cognitive load and engagement related to e-learning. Participants will complete the Brief Counseling Nursing Practices Questionnaire-Abridged Version at baseline and follow-up. All study measures will be completed online. RESULTS The study is ongoing. The results of the study will provide answers to the primary hypothesis (H1) that experimental group participants will demonstrate a greater change in the score of intentions to provide brief counseling between baseline (-T1) and follow-up (T4). Secondary hypotheses include greater improvements in scores of attitude (H2), subjective norms (H3), perceived control (H4), behavioral beliefs (H5), normative beliefs (H6), and control beliefs (H7) regarding brief counseling in the experimental group between baseline and follow-up. We also anticipate lower intrinsic and extrinsic cognitive loads (H8, H9), higher germane cognitive load (H10), and higher engagement (H11, H12) in the experimental group. CONCLUSIONS This study will be among the first in evaluating a novel type of implementation intervention, a theory- and web-based adaptive e-learning program, in nurses and nursing students. This type of intervention has the potential to support evidence-based practice through accessible, personalized training in wide-ranging domains in nursing. TRIAL REGISTRATION ISRCTN Registry ISRCTN32603572; http://www.isrctn.com/ISRCTN32603572. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) PRR1-10.2196/18894.",2020,"Secondary hypotheses include greater improvements in scores of attitude (H2), subjective norms (H3), perceived control (H4), behavioral beliefs (H5), normative beliefs (H6), and control beliefs (H7) regarding brief counseling in the experimental group between baseline and follow-up.","['nurses and nursing students enrolled in a Bachelor of Science in Nursing program in Quebec, Canada', 'nurses and nursing students', ""Nurses' and Nursing Students' Intentions to Provide Brief Counseling""]","['intervention-a theory- and web-based adaptive e-learning program-while participants in the active control group will be allocated to the E_MOTIV B intervention, a knowledge- and web-based standardized e-learning program', 'Theory- and Web-Based Adaptive Implementation Intervention', 'implementation intervention-a theory- and web-based adaptive e-learning program']","['scores of attitude (H2), subjective norms (H3), perceived control (H4), behavioral beliefs (H5), normative beliefs (H6), and control beliefs (H7) regarding brief counseling', 'intrinsic and extrinsic cognitive loads (H8, H9), higher germane cognitive load (H10), and higher engagement (H11, H12']","[{'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0038496', 'cui_str': 'Student nurse'}, {'cui': 'C0337600', 'cui_str': 'Bachelor'}, {'cui': 'C0036397', 'cui_str': 'Science'}, {'cui': 'C0006147', 'cui_str': 'Breast fed'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0034390', 'cui_str': 'Quebec'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]","[{'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0237750', 'cui_str': 'Societal Norms'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0205102', 'cui_str': 'Internal'}, {'cui': 'C0205101', 'cui_str': 'External'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married'}, {'cui': 'C0643681', 'cui_str': 'RHOA protein, human'}]",,0.0339233,"Secondary hypotheses include greater improvements in scores of attitude (H2), subjective norms (H3), perceived control (H4), behavioral beliefs (H5), normative beliefs (H6), and control beliefs (H7) regarding brief counseling in the experimental group between baseline and follow-up.","[{'ForeName': 'Guillaume', 'Initials': 'G', 'LastName': 'Fontaine', 'Affiliation': 'Research Center, Montreal Heart Institute, Montréal, QC, Canada.'}, {'ForeName': 'Sylvie', 'Initials': 'S', 'LastName': 'Cossette', 'Affiliation': 'Research Center, Montreal Heart Institute, Montréal, QC, Canada.'}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Gagnon', 'Affiliation': 'Faculty of Nursing, Université Laval, Québec, QC, Canada.'}, {'ForeName': 'Véronique', 'Initials': 'V', 'LastName': 'Dubé', 'Affiliation': 'Faculty of Nursing, Université de Montréal, Montréal, QC, Canada.'}, {'ForeName': 'José', 'Initials': 'J', 'LastName': 'Côté', 'Affiliation': 'Faculty of Nursing, Université de Montréal, Montréal, QC, Canada.'}]",JMIR research protocols,['10.2196/18894'] 2830,32735021,Platelet-rich Plasma for Androgenetic Alopecia Treatment: A Randomized Placebo-controlled Pilot Study.,"Platelet-rich plasma injections have been presented as an effective treatment for androgenetic alopecia; however, reliable study data concerning this therapy are lacking. The current randomized, placebo-controlled pilot study explored this novel therapy in 30 healthy male subjects with androgenetic alopecia. Five platelet-rich plasma treatments, at intervals of 4-6 weeks, and 2 follow-up examinations were performed. Twenty subjects were injected intracutaneously with platelet-rich plasma and 10 with physiological saline. Treatment efficacy was assessed by changes in hair number and diameter, measured with the TrichoScan system. A secondary objective was to assess clinical improvement, which was evaluated by an independent reviewer using patient photographs and a 5-point Likert scale. In addition, subject satisfaction was assessed by survey. No improvements were seen over the course of the trial, using TrichoScan measurements or visual assessment. In conclusion, treatment with platelet-rich plasma as a monotherapy does not improve hair growth in men with androgenetic alopecia.",2020,"No improvements were seen over the course of the trial, using TrichoScan measurements or visual assessment.","['30 healthy male subjects with androgenetic alopecia', 'Twenty subjects were', 'Androgenetic Alopecia Treatment', 'men with androgenetic alopecia']","['Platelet-rich plasma injections', 'injected intracutaneously with platelet-rich plasma and 10 with physiological saline', 'Placebo', 'placebo']","['TrichoScan measurements or visual assessment', 'hair growth']","[{'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0162311', 'cui_str': 'Alopecia hereditaria'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C1720154', 'cui_str': 'Inject'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0234621', 'cui_str': 'Visual'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0232407', 'cui_str': 'Hair growth'}]",30.0,0.0799981,"No improvements were seen over the course of the trial, using TrichoScan measurements or visual assessment.","[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Gressenberger', 'Affiliation': 'Department of Dermatology, Medical University of Graz, AT-8036 Graz, Austria. paul.gressenberger@medunigraz.at.'}, {'ForeName': 'Gudrun', 'Initials': 'G', 'LastName': 'Pregartner', 'Affiliation': ''}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Gary', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Wolf', 'Affiliation': ''}, {'ForeName': 'Daisy', 'Initials': 'D', 'LastName': 'Kopera', 'Affiliation': ''}]",Acta dermato-venereologica,['10.2340/00015555-3609'] 2831,32735029,"Metoclopramide, Dexamethasone or Palonosetron for Prevention of Delayed Chemotherapy-induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy (MEDEA): a Randomized, Phase III, Noninferiority Trial.","BACKGROUND For the prevention of chemotherapy-induced nausea and vomiting (CINV) during the delayed phase (24-120 hr) after moderately emetogenic chemotherapy (MEC), the use of 3-day dexamethasone (DEX) is often recommended. This study compared the efficacy and safety of two DEX-sparing regimens with 3-day DEX, focusing on delayed nausea. PATIENTS AND METHODS This open-label, randomized, phase III study was designed to demonstrate noninferiority of two DEX-sparing regimens: ondansetron + DEX on day 1, metoclopramide on days 2-3 (MCP arm), and palonosetron + DEX on day 1 (PAL arm) to ondansetron on day 1 + DEX on days 1-3 (DEX arm) in chemotherapy-naïve patients receiving MEC. Primary efficacy endpoint was total control (TC; no emetic episodes, no use of rescue medication, no nausea) in the delayed phase. Noninferiority was defined as a lower 95% CI greater than the noninferiority margin set at -20%. Secondary endpoints included no vomiting, no rescue medication, no (significant) nausea, impact of CINV on quality of life, antiemetics-associated side-effects. RESULTS Treatment arms were comparable for 189 patients analyzed: predominantly male (55.7%); median age 65.0 years; colorectal cancer (85.7%); oxaliplatin-based chemotherapy (81.5%). MCP demonstrated noninferiority to DEX for delayed TC [MCP 56.1% versus DEX 50.0%, 95% CI (-11.3%, 23.5%)]. PAL also demonstrated noninferiority to DEX [PAL 55.6% versus DEX 50.0%, 95% CI (-12.0%, 23.2%)]. There were no statistically significant differences for all secondary endpoints between treatment arms. CONCLUSION This study showed that DEX-sparing regimens are noninferior to multiple-day DEX in terms of delayed TC rate in patients undergoing MEC. TRIAL REGISTRATION This study was registered in ClinicalTrials.gov (number: NCT02135510). IMPLICATIONS FOR PRACTICE Chemotherapy-induced nausea and vomiting (CINV) in the delayed phase (24-120 hr post-chemotherapy) remains one of the most troublesome adverse effects associated with cancer treatment. In particular, delayed nausea is often poorly controlled. The role of dexamethasone (DEX) in the prevention of delayed nausea after moderately emetogenic chemotherapy (MEC) is controversial. Our study is the first to include nausea assessment as a part of the primary study outcome to better gauge the effectiveness of CINV control and patients' experience. We show that a DEX-sparing strategy does not result in any significant loss of overall antiemetic control: DEX-sparing strategies incorporating palonosetron or multiple-day metoclopramide are safe and at least as effective as standard treatment with a 3-day DEX regimen with ondansetron in controlling delayed CINV - and nausea in particular - following MEC.",2020,"MCP demonstrated noninferiority to DEX for delayed TC [MCP 56.1% versus DEX 50.0%, 95% CI (-11.3%, 23.5%)].","['189 patients analyzed: predominantly male (55.7%); median age 65.0\u2009years; colorectal cancer (85.7', 'patients undergoing MEC']","['DEX-sparing regimens: ondansetron + DEX', 'Emetogenic Chemotherapy (MEDEA', 'DEX', 'DEX-sparing regimens with 3-day DEX', 'chemotherapy-naïve patients receiving MEC', 'metoclopramide', 'palonosetron + DEX', 'emetogenic chemotherapy (MEC', 'oxaliplatin-based chemotherapy', 'dexamethasone (DEX', 'Metoclopramide, Dexamethasone or Palonosetron', 'ondansetron']","['delayed CINV - and nausea', 'delayed nausea', 'nausea and vomiting (CINV', 'Nausea and Vomiting', 'efficacy and safety', 'delayed TC rate', 'total control (TC; no emetic episodes, no use of rescue medication, no nausea', 'no vomiting, no rescue medication, no (significant) nausea, impact of CINV on quality of life, antiemetics-associated side-effects']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0009402', 'cui_str': 'Colorectal cancer'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C1843661', 'cui_str': 'Spastic Paraplegia, Ataxia, And Mental Retardation'}, {'cui': 'C0040808', 'cui_str': 'Protocols, Treatment'}, {'cui': 'C0061851', 'cui_str': 'Ondansetron'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0025853', 'cui_str': 'Metoclopramide'}, {'cui': 'C0220578', 'cui_str': 'palonosetron'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}]","[{'cui': 'C0401160', 'cui_str': 'Chemotherapy-induced nausea and vomiting'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0027498', 'cui_str': 'Nausea and vomiting'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0013973', 'cui_str': 'Emetic'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0423584', 'cui_str': 'No nausea'}, {'cui': 'C0375548', 'cui_str': 'No vomiting'}, {'cui': 'C0040456', 'cui_str': 'Impacted tooth'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0042963', 'cui_str': 'Vomiting'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0003297', 'cui_str': 'Antiemetic agent'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}]",,0.0745552,"MCP demonstrated noninferiority to DEX for delayed TC [MCP 56.1% versus DEX 50.0%, 95% CI (-11.3%, 23.5%)].","[{'ForeName': 'Maurice J D L', 'Initials': 'MJDL', 'LastName': 'van der Vorst', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Elisa C', 'Initials': 'EC', 'LastName': 'Toffoli', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Marlien', 'Initials': 'M', 'LastName': 'Beusink', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Myra E', 'Initials': 'ME', 'LastName': 'van Linde', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Theo', 'Initials': 'T', 'LastName': 'van Voorthuizen', 'Affiliation': 'Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Brouwer', 'Affiliation': 'Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.'}, {'ForeName': 'Annette A', 'Initials': 'AA', 'LastName': 'van Zweeden', 'Affiliation': 'Department of Internal Medicine, Amstelland Hospital, Amstelveen, The Netherlands.'}, {'ForeName': 'Suzan', 'Initials': 'S', 'LastName': 'Vrijaldenhoven', 'Affiliation': 'Department of Internal Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.'}, {'ForeName': 'Johan C', 'Initials': 'JC', 'LastName': 'Berends', 'Affiliation': 'Department of Internal Medicine, Noordwest Ziekenhuisgroep, Den Helder, The Netherlands.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Berkhof', 'Affiliation': 'Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}, {'ForeName': 'Henk M W', 'Initials': 'HMW', 'LastName': 'Verheul', 'Affiliation': 'Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.'}]",The oncologist,['10.1634/theoncologist.2020-0305'] 2832,32735053,Therapist-guided smartphone-based aftercare for inpatients with severe anorexia nervosa (SMART-AN): Study protocol of a randomized controlled trial.,"OBJECTIVE Inpatient treatment for patients with anorexia nervosa (AN) is recommended in extreme or severe cases after failure of outpatient treatment and is highly effective. However, a number of patients show symptom increase and relapse after discharge. The aim of this study is to evaluate the efficacy of a therapist-guided smartphone-based aftercare intervention for inpatients with AN to support symptom stabilization. METHOD A total of 186 female patients with a DSM-5 diagnosis of AN (307.1) will be randomized either to receive a 16-week smartphone-based aftercare intervention with therapist feedback as add-on to treatment as usual (TAU) or TAU alone. Data will be assessed at discharge (= baseline, T0), after 16 weeks (= end of the aftercare intervention, T1) and after 10 months (= 6-month follow-up, T2). Primary outcome will be overall eating disorder symptomatology (Eating Disorder Examination Global score). Secondary outcome measures will include body mass index, depression, motivation to change, self-efficacy, patient satisfaction with and adherence to the smartphone-based aftercare intervention as well as rehospitalization rate. DISCUSSION This study will be the first randomized controlled trial to examine a therapist-guided smartphone-based aftercare intervention for inpatients with AN. Results may reveal whether and to which extent this novel intervention can support symptom stabilization after inpatient treatment.",2020,"The aim of this study is to evaluate the efficacy of a therapist-guided smartphone-based aftercare intervention for inpatients with AN to support symptom stabilization. ","['inpatients with AN to support symptom stabilization', '186 female patients with a DSM-5 diagnosis of AN (307.1', 'inpatients with AN', 'patients with anorexia nervosa (AN', 'inpatients with severe anorexia nervosa (SMART-AN']","['therapist-guided smartphone-based aftercare intervention', 'Therapist-guided smartphone-based aftercare', 'smartphone-based aftercare intervention with therapist feedback as add-on to treatment as usual (TAU) or TAU alone']","['overall eating disorder symptomatology (Eating Disorder Examination Global score', 'body mass index, depression, motivation to change, self-efficacy, patient satisfaction with and adherence to the smartphone-based aftercare intervention as well as rehospitalization rate']","[{'cui': 'C0021562', 'cui_str': 'Inpatient'}, {'cui': 'C0003125', 'cui_str': 'Anorexia nervosa'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C1293130', 'cui_str': 'Stabilization'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0235048', 'cui_str': 'Smarting pain'}]","[{'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0013473', 'cui_str': 'Eating disorder'}, {'cui': 'C2959762', 'cui_str': 'Eating disorder examination questionnaire global score'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0026605', 'cui_str': 'Motivation'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0001758', 'cui_str': 'Aftercare'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]",186.0,0.146869,"The aim of this study is to evaluate the efficacy of a therapist-guided smartphone-based aftercare intervention for inpatients with AN to support symptom stabilization. ","[{'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Schlegl', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital of Munich (LMU), Munich, Germany.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Neumayr', 'Affiliation': 'Schoen Clinic Roseneck, Prien am Chiemsee, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Voderholzer', 'Affiliation': 'Department of Psychiatry and Psychotherapy, University Hospital of Munich (LMU), Munich, Germany.'}]",The International journal of eating disorders,['10.1002/eat.23357'] 2833,32735335,Effect of a Videoconference-Based Online Group Intervention for Traumatic Stress in Parents of Children With Life-threatening Illness: A Randomized Clinical Trial.,"Importance A substantial proportion of parents whose child is diagnosed with a life-threatening illness experience high levels of distress that can lead to long-term mental health difficulties. This can affect the child's recovery. Objective To evaluate the efficacy of an acceptance and commitment therapy-based group intervention, delivered using videoconferencing, in reducing posttraumatic stress symptoms (PTSS) in these parents. Design, Setting, and Participants This study was a randomized clinical trial of an intervention for parents with elevated acute stress symptoms. It was a single-site study conducted in a tertiary pediatric hospital in Australia. Parents of children aged 0 to 18 years admitted for a life-threatening illness or injury to the oncology, cardiology, or pediatric intensive care departments were eligible. Participants were screened for eligibility within the first month after diagnosis or admission and then were randomized to the intervention group or the waiting list control group 4 to 10 months after diagnosis or admission. Recruitment commenced January 2014, and final postintervention follow-up was completed in February 2018. Data analysis was performed from July to September 2018. Interventions Treatment was a psychological acceptance and commitment therapy-based group therapy program called Take a Breath, which consisted of a 6-session parent-mediated psychological intervention delivered via online videoconferences over the course of 8 weeks. Waiting list control participants received treatment as usual and were offered the intervention 3 months after randomization. Main Outcomes and Measures The primary outcome was PTSS, as measured by the Posttraumatic Stress Disorder Checklist-Version 5 (total score range, 0-80, with higher scores indicating greater symptom severity). The PTSS was measured both before and immediately after the intervention. Changes in psychological skills taught within the intervention were also evaluated, including acceptance, mindfulness, values-based living, and psychological flexibility. Results Of 1232 parents who were assessed for eligibility, 313 were randomized; 161 were allocated to the waiting list control group, and 152 were allocated to the intervention group. Of those allocated, 44 parents in the waiting list group and 37 in the intervention group completed the postintervention questionnaire and were analyzed (81 participants total; mean [SD] age, 37.17 [6.43] years). Sixty-five participants (80.2%) were women, 48 participants (59.3%) were married, and 40 participants (49.4%) lived in rural or regional areas, or in a different state. In addition, 24 parents (29.6%) were in the cardiology illness group, 32 parents (39.5%) were in the oncology group, and 25 parents (30.9%) were in the pediatric intensive care unit group. The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03). The mean Posttraumatic Stress Disorder Checklist-Version 5 scores decreased from 31.7 (95% CI, 27.0-36.4) to 26.2 (95% CI, 21.8-30.7) in the waiting list control group and from 23.3 (95% CI, 18.6-28.1) to 17.8 (95% CI, 13.8-21.8) in the intervention group. Conclusions and Relevance The findings of this study support the use of acceptance and commitment therapy to reduce PTSS in parents of very ill children, regardless of diagnosis. These findings also suggest that a brief, group format using a videoconferencing platform can be used effectively to access hard-to-reach populations, particularly fathers and caregivers living in nonmetropolitan areas. Trial Registration Australian New Zealand Clinical Trials Registry Identifier: ACTRN12611000090910.",2020,"The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03).","['parents with elevated acute stress symptoms', '44 parents in the waiting list group and 37 in the intervention group completed the postintervention questionnaire and were analyzed (81 participants total; mean [SD] age, 37.17 [6.43] years', 'Parents of Children', 'Participants were screened for eligibility within the first month after diagnosis or admission', 'Sixty-five participants (80.2%) were women, 48 participants (59.3%) were married, and 40 participants (49.4%) lived in rural or regional areas, or in a different state', 'tertiary pediatric hospital in Australia', 'With Life-threatening Illness', '24 parents (29.6%) were in the cardiology illness group, 32 parents (39.5%) were in the oncology group, and 25 parents (30.9%) were in the pediatric intensive care unit group', '1232 parents who were assessed for eligibility', 'Parents of children aged 0 to 18 years admitted for a life-threatening illness or injury to the oncology, cardiology, or pediatric intensive care departments were eligible']","['waiting list control', 'Videoconference-Based Online Group Intervention', 'acceptance and commitment therapy-based group intervention, delivered using videoconferencing', 'videoconferencing platform', 'psychological acceptance and commitment therapy-based group therapy program called Take a Breath, which consisted of a 6-session parent-mediated psychological intervention delivered via online videoconferences']","['mean Posttraumatic Stress Disorder Checklist-Version 5 scores', 'acceptance, mindfulness, values-based living, and psychological flexibility', 'PTSS, as measured by the Posttraumatic Stress Disorder Checklist-Version 5 (total score range', 'posttraumatic stress symptoms (PTSS', 'PTSS']","[{'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0450385', 'cui_str': '65'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0555047', 'cui_str': 'Married'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0205147', 'cui_str': 'Regional'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0021710', 'cui_str': 'Pediatric intensive care unit'}, {'cui': 'C0005604', 'cui_str': 'Birth trauma'}, {'cui': 'C1627360', 'cui_str': 'Pediatric intensive care'}]","[{'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and commitment therapy'}, {'cui': 'C1450048', 'cui_str': 'Videoconferencing'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0033971', 'cui_str': 'Group psychotherapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C1720420', 'cui_str': 'Call'}, {'cui': 'C0225386', 'cui_str': 'Breath'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0086597', 'cui_str': 'Mediate'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0038436', 'cui_str': 'Posttraumatic stress disorder'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0237445', 'cui_str': 'Social Acceptance'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}, {'cui': 'C0521991', 'cui_str': 'Symptoms of stress'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",313.0,0.132341,"The intervention group demonstrated significantly greater improvements in PTSS compared with the waiting list group (Cohen d = 1.10; 95% CI, 0.61-1.59; P = .03).","[{'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Muscara', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Maria C', 'Initials': 'MC', 'LastName': 'McCarthy', 'Affiliation': ""Children's Cancer Centre, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Meredith', 'Initials': 'M', 'LastName': 'Rayner', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Jan M', 'Initials': 'JM', 'LastName': 'Nicholson', 'Affiliation': 'Judith Lumley Centre, La Trobe University, Bundoora, Victoria, Australia.'}, {'ForeName': 'Anica', 'Initials': 'A', 'LastName': 'Dimovski', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'McMillan', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Stephen J C', 'Initials': 'SJC', 'LastName': 'Hearps', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Yamada', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}, {'ForeName': 'Kylie', 'Initials': 'K', 'LastName': 'Burke', 'Affiliation': 'Parenting and Family Support Centre, School of Psychology, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Robyn', 'Initials': 'R', 'LastName': 'Walser', 'Affiliation': 'Department of Psychology, University of California, Berkeley.'}, {'ForeName': 'Vicki A', 'Initials': 'VA', 'LastName': 'Anderson', 'Affiliation': ""Clinical Sciences, Murdoch Children's Research Institute, The Royal Children's Hospital, Parkville, Victoria, Australia.""}]",JAMA network open,['10.1001/jamanetworkopen.2020.8507'] 2834,32730026,Protecting the Mental Health of Small-to-Medium Enterprise Owners: A Randomized Control Trial Evaluating a Self-Administered Versus Telephone Supported Intervention.,"OBJECTIVE Small-medium enterprises (SMEs) are under-represented in occupational health research. Owner/managers face mental ill-health risks/exacerbating factors including financial stress and long working hours. This study assessed the effectiveness of a workplace mental health and wellbeing intervention specifically for SME owner/managers. METHODS Two hundred ninety seven owner/managers of SMEs were recruited and invited to complete a baseline survey assessing their mental health and wellbeing and were then randomly allocated to one of three intervention groups: (1) self-administered, (2) self-administered plus telephone, or (3) an active control condition. After a four-month intervention period they were followed up with a second survey. RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. CONCLUSION The provision of telephone support for self-administered interventions in this context appears warranted.",2020,"RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. ",['Two hundred ninety seven owner/managers of SMEs were recruited and invited to complete a baseline survey assessing their mental health and wellbeing'],"['workplace mental health and wellbeing intervention', 'self-administered, (2) self-administered plus telephone, or (3) an active control condition']",['psychological distress'],"[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0439073', 'cui_str': '97'}, {'cui': 'C0335141', 'cui_str': 'Manager'}, {'cui': 'C2919920', 'cui_str': 'Northern Sami language'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0282121', 'cui_str': 'Baseline Survey'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0162579', 'cui_str': 'Work environment'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]","[{'cui': 'C0815107', 'cui_str': 'Emotional Distress'}]",,0.0826076,"RESULTS Intention to treat analyses showed a significant decrease in psychological distress for both the active control and the telephone facilitated intervention groups, with the telephone group demonstrating a greater ratio of change. ","[{'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Martin', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania (Dr Martin, Dr Kiilpatrick, Dr Cocker), Tasmanian School of Business and Economics, University of Tasmania (Dr Dawkins), School of Health Sciences, University of East Anglia (Dr Sanderson), School of Psychology, Griffith University (Dr Brough).'}, {'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Kilpatrick', 'Affiliation': ''}, {'ForeName': 'Jenn', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': ''}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Cocker', 'Affiliation': ''}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Dawkins', 'Affiliation': ''}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Brough', 'Affiliation': ''}, {'ForeName': 'Kristy', 'Initials': 'K', 'LastName': 'Sanderson', 'Affiliation': ''}]",Journal of occupational and environmental medicine,['10.1097/JOM.0000000000001882'] 2835,32730049,Expectancy effects of placebo neurofeedback in ADHD treatment seekers: A neuropsychological investigation.,"OBJECTIVE Though there is evidence to suggest that expectancies can impact outcomes of various medical and psychological treatments, little is known about the role of expectancy effects in neurocognitive interventions, such as neurofeedback for attention-deficit/hyperactivity disorder (ADHD). The present study investigated the effects of treatment expectancies on ADHD symptom report and neuropsychological performance by using an expectancy manipulation in the context of placebo neurofeedback. METHOD Eighty-five young adults seeking treatment for ADHD were administered 1 session of placebo neurofeedback and randomly assigned to positive or negative expectancy groups. Primary outcome measures include ADHD symptom self-report questionnaires and neuropsychological tests. RESULTS Consistent with hypotheses, participants in the positive expectancy group who received positive false feedback reported fewer ADHD symptoms at postfeedback ( p < .001, η p ² = .41), whereas participants in the negative expectancy group who received negative false feedback reported more symptoms at postfeedback ( p = .01, η p ² = .15). As expected, individuals who received positive expectancies also significantly improved their performance on a working memory test ( p = .002, η p ² = .22); no other neuropsychological test performance was impacted by expectancies. Beliefs about neurofeedback effectiveness did not moderate or mediate expectancy effects. CONCLUSION Results indicate that treatment expectancies impact ADHD symptom report and some neuropsychological test performance. Therefore, expectancy effects should be considered in the evaluation of outcomes for neurocognitive interventions, such as neurofeedback for ADHD. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"As expected, individuals who received positive expectancies also significantly improved their performance on a working memory test ( p = .002, η p ² = .22); no other neuropsychological test performance was impacted by expectancies.","['Eighty-five young adults seeking treatment for ADHD', 'ADHD treatment seekers']","['placebo neurofeedback and randomly assigned to positive or negative expectancy groups', 'placebo neurofeedback']","['ADHD symptom report and neuropsychological performance', 'performance on a working memory test', 'ADHD symptoms', 'neuropsychological test performance', 'ADHD symptom self-report questionnaires and neuropsychological tests']","[{'cui': 'C4517892', 'cui_str': '85'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2713543', 'cui_str': 'Electroencephalographic biofeedback'}, {'cui': 'C1516050', 'cui_str': 'Assigned'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",85.0,0.1328,"As expected, individuals who received positive expectancies also significantly improved their performance on a working memory test ( p = .002, η p ² = .22); no other neuropsychological test performance was impacted by expectancies.","[{'ForeName': 'Grace J', 'Initials': 'GJ', 'LastName': 'Lee', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Suhr', 'Affiliation': 'Department of Psychology.'}]",Neuropsychology,['10.1037/neu0000689'] 2836,32730052,Implementation intentions and prospective memory function in late adulthood.,"Prospective memory (PM) is a critically important component of memory that often declines in late adulthood. Implementation intentions, an encoding strategy, consisting of an explicit if-then ""I will . . ."" statement, has been effectively used to enhance older adults' prospective memory function. However, it remains to be established whether forming a mental representation of carrying out the task when forming the intention enhances these age effects, as well as whether the type of cue (event or time based) moderates age-related benefits. To test these questions, we randomly allocated 125 younger and 125 older adults to 1 of 5 conditions, in which they were directed to use different strategies when forming their PM intentions (Statement Only, Imagine in Game, Statement and Imagine Combined, Imagine in Daily Life, Control). The results indicated that use of the implementation intentions statement alone and in combination with forming a mental representation of carrying out the task substantially enhanced older adults' event- but not time-based PM. In addition, while the Statement Only condition reduced age-related difficulties for event-based tasks, the condition that combined this statement with visualization led to the greatest reduction in age effects. These data suggest that both rehearsing the implementations intention in the specific statement format combined with visualizing may be optimally effective for enhancing PM function in late adulthood but that the type of PM cue is an important moderator of these age effects. In addition to theoretical implications, these results may inform the refinement of interventions focused on enhancing PM function in late adulthood. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,The results indicated that use of the implementation intentions statement alone and in combination with forming a mental representation of carrying out the task substantially enhanced older adults' event- but not time-based PM.,"['125 younger and 125 older adults to 1 of 5 conditions', 'late adulthood']","['PM intentions (Statement Only, Imagine in Game, Statement and Imagine Combined, Imagine in Daily Life, Control']","[""older adults' event- but not time-based PM""]","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0700597', 'cui_str': 'Adulthood'}]","[{'cui': 'C0589154', 'cui_str': 'Prospective memory'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0589154', 'cui_str': 'Prospective memory'}]",,0.0229072,The results indicated that use of the implementation intentions statement alone and in combination with forming a mental representation of carrying out the task substantially enhanced older adults' event- but not time-based PM.,"[{'ForeName': 'Julie D', 'Initials': 'JD', 'LastName': 'Henry', 'Affiliation': 'School of Psychology, The University of Queensland.'}, {'ForeName': 'Gill', 'Initials': 'G', 'LastName': 'Terrett', 'Affiliation': 'Department of Psychology, Australian Catholic University.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Grainger', 'Affiliation': 'School of Psychology, The University of Queensland.'}, {'ForeName': 'Nathan S', 'Initials': 'NS', 'LastName': 'Rose', 'Affiliation': 'Department of Psychology, University of Notre Dame.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Kliegel', 'Affiliation': 'School of Psychology, University of Geneva.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Bugge', 'Affiliation': ''}, {'ForeName': 'Clare', 'Initials': 'C', 'LastName': 'Ryrie', 'Affiliation': 'Department of Psychology, Australian Catholic University.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Rendell', 'Affiliation': 'Department of Psychology, Australian Catholic University.'}]",Psychology and aging,['10.1037/pag0000563'] 2837,32732334,Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.,"The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. Here we report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any subsequent CT scanning to identify those at high risk of lung cancer reduces the incidence of patients with stage III/IV/Unspecified lung cancer at diagnosis, compared with the standard clinical practice at the time the study began.ECLS was a randomised controlled trial of 12 208 participants at risk of developing lung cancer in Scotland. The intervention arm received the EarlyCDT-Lung test and, if test positive, low-dose CT scanning six-monthly for up to 2 years. EarlyCDT-Lung test negative and control arm participants received standard clinical care. Outcomes were assessed at 2 years post-randomisation using validated data on cancer occurrence, cancer staging, mortality and comorbidities.At 2 years, 127 lung cancers were detected in the study population (1.0%).In the intervention arm, 33/56 (58.9%) lung cancers were diagnosed at stage III/IV compared to 52/71 (73.2%) in the control arm. The hazard ratio for stage III/IV presentation was 0.64 (95% confidence interval 0.41, 0.99). There were non-significant differences in lung cancer and all-cause mortality after 2 years.ECLS compared EarlyCDT-Lung plus CT screening to standard clinical care (symptomatic presentation), and was not designed to assess the incremental contribution of the EarlyCDT-Lung test. The observation of a stage-shift towards earlier-stage lung cancer diagnosis merits further investigations to evaluate whether the EarlyCDT-Lung test adds anything to the emerging standard of LDCT.",2020,The hazard ratio for stage III/IV presentation was 0.64,"['12\u200a208 participants at risk of developing lung cancer in Scotland', 'patients with stage III/IV/Unspecified lung cancer at diagnosis']","['standard clinical care', 'EarlyCDT-Lung test and any subsequent CT scanning', 'EarlyCDT-Lung test and, if test positive, low-dose CT scanning six-monthly for up to 2\u2005years', 'ECLS compared EarlyCDT-Lung plus CT screening', 'ECLS']","['lung cancer and all-cause mortality', 'cancer occurrence, cancer staging, mortality and comorbidities', 'hazard ratio for stage III/IV presentation']","[{'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0205370', 'cui_str': 'Non-specific'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C0585339', 'cui_str': 'Every six months'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}]","[{'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0027646', 'cui_str': 'Cancer staging'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}]",12208.0,0.0525652,The hazard ratio for stage III/IV presentation was 0.64,"[{'ForeName': 'Frank M', 'Initials': 'FM', 'LastName': 'Sullivan', 'Affiliation': 'School of Medicine, University of St Andrews, St Andrews, United Kingdom fms20@st-andrews.ac.uk.'}, {'ForeName': 'Frances S', 'Initials': 'FS', 'LastName': 'Mair', 'Affiliation': 'Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Anderson', 'Affiliation': 'Respiratory Medicine, NHS Tayside, Dundee, United Kingdom.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Armory', 'Affiliation': 'Tayside Clinical Trials Unit, University of Dundee, Dundee, United Kingdom.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Briggs', 'Affiliation': 'Department of Health Services Research & Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Chew', 'Affiliation': 'Radiology, NHS Lanarkshire, Bothwell, United Kingdom.'}, {'ForeName': 'Alistair', 'Initials': 'A', 'LastName': 'Dorward', 'Affiliation': 'Respiratory Medicine, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Haughney', 'Affiliation': 'General Practice, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Hogarth', 'Affiliation': 'Tayside Clinical Trials Unit, University of Dundee, Dundee, United Kingdom.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Kendrick', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Roberta', 'Initials': 'R', 'LastName': 'Littleford', 'Affiliation': 'Centre for Clinical Research, University of Queensland, Saint Lucia, Australia.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'McConnachie', 'Affiliation': 'Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'McCowan', 'Affiliation': 'School of Medicine, University of St Andrews, St Andrews, United Kingdom.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Mcmeekin', 'Affiliation': 'Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Manish', 'Initials': 'M', 'LastName': 'Patel', 'Affiliation': 'Respiratory Medicine, NHS Lanarkshire, Bothwell, United Kingdom.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Rauchhaus', 'Affiliation': 'Tayside Clinical Trials Unit, University of Dundee, Dundee, United Kingdom.'}, {'ForeName': 'Lewis', 'Initials': 'L', 'LastName': 'Ritchie', 'Affiliation': 'The Institute of Applied Health Sciences, University of Aberdeen, Glasgow, United Kingdom.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Robertson', 'Affiliation': 'Department of Mathematics and Statistics, University of Strathclyde, Glasgow, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Robertson', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Robles-Zurita', 'Affiliation': 'Institute of Health & Wellbeing, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Sarvesvaran', 'Affiliation': 'Respiratory Medicine, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Sewell', 'Affiliation': 'School of Life Sciences, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Sproule', 'Affiliation': 'Radiology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Taylor', 'Affiliation': 'Radiology, NHS Tayside, Dundee, United Kingdom.'}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Tello', 'Affiliation': 'School of Medicine, University of St Andrews, St Andrews, United Kingdom.'}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Treweek', 'Affiliation': 'Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom.'}, {'ForeName': 'Kavita', 'Initials': 'K', 'LastName': 'Vedhara', 'Affiliation': 'School of Medicine, University of Nottingham, Nottingham, United Kingdom.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Schembri', 'Affiliation': 'Respiratory Medicine, NHS Tayside, Dundee, United Kingdom.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The European respiratory journal,['10.1183/13993003.00670-2020'] 2838,32732336,Spontaneous clearance of genital and extragenital Neisseria gonorrhoeae : data from GToG.,"OBJECTIVES Neisseria gonorrhoeae (NG) infection can resolve without antibiotic treatment, however the literature describing the frequency of clearance at individual sites, how rapidly it occurs and potential predictive factors is limited. In this analysis of a subpopulation identified from a large multicentre UK cohort, we describe the overall rate of spontaneous clearance of infection and explore factors associated with this. METHODS Data from the Gentamicin compared with Ceftriaxone for the Treatment of Gonorrhoea randomised controlled trial consisting of 720 patients with NG were analysed. A subgroup of individuals had both a pretrial test sample and a trial enrolment sample taken. Those who had cleared NG between initial presentation and subsequent entry into the trial without antibiotic treatment were deemed to have spontaneously cleared. Sociodemographic characteristics, sexual history and sites of infection for those who spontaneously cleared infection were compared with that of those who did not. We also estimated the time interval to clearance. RESULTS Overall, the proportion who had spontaneous clearance was 20.5% (83/405). Clearance of infection occurred over a median of 10 days (IQR 7-15 days). The cohort who spontaneously cleared were similar to those who did not in terms of age, gender, sexual orientation, HIV status and previous NG infection. Chlamydia coinfection was more frequent in the 'no spontaneous clearance group' (11.1% (9/83) cf 22.0% (69/322)) (p=0.029). Dysuria was reported more often in the 'no spontaneous clearance group' (4.8% (4/83) cf 13.0% (42/322)) (p=0.035). CONCLUSION We present data from a large cohort of NG-infected individuals, of whom a significant proportion had spontaneous clearance of infection. This is consistent with previous smaller studies. If this is indicative of cure, point-of-care testing prior to treatment has the potential to reduce unnecessary exposure to antimicrobials. Further work to assess the importance of bacterial load, genotype and host immune response on spontaneous clearance of infection is required. TRIAL REGISTRATION NUMBER ISRCTN51783227.",2020,"The cohort who spontaneously cleared were similar to those who did not in terms of age, gender, sexual orientation, HIV status and previous NG infection.",['720 patients with NG were analysed'],"['Ceftriaxone', 'Gentamicin']","['Sociodemographic characteristics, sexual history and sites of infection', 'spontaneous clearance of infection', 'Clearance of infection', 'spontaneous clearance', 'Dysuria', 'Chlamydia coinfection', 'time interval to clearance']","[{'cui': 'C4517865', 'cui_str': '720'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0007561', 'cui_str': 'Ceftriaxone'}, {'cui': 'C0017436', 'cui_str': 'Gentamycins'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0019664', 'cui_str': 'History'}, {'cui': 'C2945843', 'cui_str': 'Site of'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous'}, {'cui': 'C0449297', 'cui_str': 'Clearance'}, {'cui': 'C0013428', 'cui_str': 'Dysuria'}, {'cui': 'C0008148', 'cui_str': 'Chlamydia'}, {'cui': 'C0275524', 'cui_str': 'Mixed infectious disease'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272706', 'cui_str': 'Interval'}]",720.0,0.139926,"The cohort who spontaneously cleared were similar to those who did not in terms of age, gender, sexual orientation, HIV status and previous NG infection.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Mensforth', 'Affiliation': 'Department of Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK sarahmensforth@nhs.net.'}, {'ForeName': 'Oluseyi Cyril', 'Initials': 'OC', 'LastName': 'Ayinde', 'Affiliation': 'Department of Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Ross', 'Affiliation': 'Department of Sexual Health and HIV, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}]",Sexually transmitted infections,['10.1136/sextrans-2020-054500'] 2839,32732353,Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.,"OBJECTIVES To clarify which rheumatoid arthritis (RA) patients benefit most from the anti-receptor activator of nuclear factor-κB ligand antibody denosumab to reduce the progression of joint destruction. METHODS We pooled patient data from the 12-month, double-blind, placebo-controlled DRIVE (phase II) and DESIRABLE (phase III) studies. In DRIVE, concomitant treatment was limited to methotrexate, salazosulfapyridine and bucillamine. In DESIRABLE, patients could receive any disease-modifying antirheumatic drug. RA patients were randomised to denosumab 60 mg every 6 months (Q6M), every 3 months (Q3M) or placebo. Efficacy was assessed by van der Heijde-modified total Sharp score (mTSS), bone erosion score (ES) and joint space narrowing score (JSNS). Change in mTSS was assessed in subgroups stratified by risk factors for radiographic damage if the interaction factor was significant. RESULTS The pooled analysis included 909 patients. Denosumab reduced worsening of mTSS (mean (SD)) at 12 months in the Q6M (0.88 (3.30), p=0.0024) and Q3M (0.66 (2.16), p=0.0002) groups versus placebo (1.50 (3.73)). This reduction in mTSS progression was due to the change in ES (Q6M, 0.44 (1.89), p=0.0006; Q3M, 0.20 (0.86), p<0.0001) versus placebo (0.98 (2.54)); no effect was observed on JSNS. Anti-cyclic citrullinated peptide (CCP) antibodies, glucocorticoid use and baseline ES showed a significant interaction. Denosumab was particularly effective in patients who were anti-CCP antibody positive (p<0.05). Changes in mTSS versus placebo were observed in all denosumab dose groups, regardless of glucocorticoid use and baseline ES. CONCLUSIONS Denosumab broadly reduced the progression of joint destruction in RA patients with risk factors for radiographic damage such as especially anti-CCP antibody positivity.",2020,Denosumab was particularly effective in patients who were anti-CCP antibody positive (p<0.05).,"['RA patients', 'patients could receive any disease-modifying antirheumatic drug', '909 patients']","['denosumab', 'methotrexate, salazosulfapyridine and bucillamine', 'Denosumab', 'placebo']","['worsening of mTSS (mean (SD', 'Change in mTSS', 'van der Heijde-modified total Sharp score (mTSS), bone erosion score (ES) and joint space narrowing score (JSNS', 'Efficacy', 'mTSS progression', 'Q3M', 'progression of joint destruction']","[{'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242708', 'cui_str': 'Disease-Modifying Antirheumatic Drugs'}]","[{'cui': 'C1690432', 'cui_str': 'denosumab'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0036078', 'cui_str': 'Sulfasalazine'}, {'cui': 'C0073917', 'cui_str': 'bucillamine'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0332271', 'cui_str': 'Worsening'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C1444775', 'cui_str': 'Sharp sensation quality'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0557775', 'cui_str': 'Van'}, {'cui': 'C0587240', 'cui_str': 'Bone erosion'}, {'cui': 'C0333307', 'cui_str': 'Superficial ulcer'}, {'cui': 'C0224497', 'cui_str': 'Articular space'}, {'cui': 'C0332463', 'cui_str': 'Narrowed structure'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332179', 'cui_str': 'Trimonthly'}, {'cui': 'C0541875', 'cui_str': 'Joint destruction'}]",909.0,0.178567,Denosumab was particularly effective in patients who were anti-CCP antibody positive (p<0.05).,"[{'ForeName': 'Yoshiya', 'Initials': 'Y', 'LastName': 'Tanaka', 'Affiliation': 'First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan tanaka@med.uoeh-u.ac.jp.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Soen', 'Affiliation': 'Department of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, Ikoma, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Ishiguro', 'Affiliation': 'Department of Orthopaedics, Nagoya University Graduate School of Medicine, Aichi, Japan.'}, {'ForeName': 'Hisashi', 'Initials': 'H', 'LastName': 'Yamanaka', 'Affiliation': 'Director of Rheumatology, Sanno Medical Center, Tokyo, Japan.'}, {'ForeName': 'Toshiyuki', 'Initials': 'T', 'LastName': 'Yoneda', 'Affiliation': 'Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan.'}, {'ForeName': 'Sakae', 'Initials': 'S', 'LastName': 'Tanaka', 'Affiliation': 'Department of Orthopaedic Surgery, The University of Tokyo, Tokyo, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Ohira', 'Affiliation': 'Clinical Development Department, Daiichi Sankyo Co Ltd, Tokyo, Japan.'}, {'ForeName': 'Takaya', 'Initials': 'T', 'LastName': 'Nitta', 'Affiliation': 'Clinical Development Department, Daiichi Sankyo Co Ltd, Tokyo, Japan.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Okubo', 'Affiliation': 'Data Intelligence Department, Daiichi Sankyo Co Ltd, Tokyo, Japan.'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Genant', 'Affiliation': 'Departments of Radiology, University of California San Francisco, California, USA.'}, {'ForeName': 'Desirée', 'Initials': 'D', 'LastName': 'van der Heijde', 'Affiliation': 'Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Takeuchi', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.'}]",RMD open,['10.1136/rmdopen-2020-001249'] 2840,32732374,The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial.,"OBJECTIVE The aim of this study was to examine the effect of a novel low-volume high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or placebo (PLA) intervention on liver fat, glycemia, and cardiorespiratory fitness using a randomized placebo-controlled design. RESEARCH DESIGN AND METHODS Thirty-five inactive adults (age 54.6 ± 1.4 years, 54% male; BMI 35.9 ± 0.9 kg/m 2 ) with obesity and type 2 diabetes were randomized to 12 weeks of supervised MICT ( n = 12) at 60% VO 2peak for 45 min, 3 days/week; HIIT ( n = 12) at 90% VO 2peak for 4 min, 3 days/week; or PLA ( n = 11). Liver fat percent was quantified through proton MRS. RESULTS Liver fat reduced in MICT (-0.9 ± 0.7%) and HIIT (-1.7 ± 1.1%) but increased in PLA (1.2 ± 0.5%) ( P = 0.046). HbA 1c improved in MICT (-0.3 ± 0.3%) and HIIT (-0.3 ± 0.3%) but not in PLA (0.5 ± 0.2%) ( P = 0.014). Cardiorespiratory fitness improved in MICT (2.3 ± 1.2 mL/kg/min) and HIIT (1.1 ± 0.5 mL/kg/min) but not in PLA (-1.5 ± 0.9 mL/kg/min) ( P = 0.006). CONCLUSIONS MICT or a low-volume HIIT approach involving 12 min of weekly high-intensity aerobic exercise may improve liver fat, glycemia, and cardiorespiratory fitness in type 2 diabetes in the absence of weight loss. Further studies are required to elucidate the relationship between exercise-induced reductions in liver fat and improvements in glycemia.",2020,Cardiorespiratory fitness improved in MICT (2.3 ± 1.2 mL/kg/min) and HIIT (1.1 ± 0.5 mL/kg/min) but not in PLA (-1.5 ± 0.9 mL/kg/min),"['Liver Fat in Type 2 Diabetes', 'Thirty-five inactive adults (age 54.6 ± 1.4 years, 54% male; BMI 35.9 ± 0.9 kg/m 2 ) with obesity and type 2 diabetes']","['supervised MICT', 'Novel Low-Volume Aerobic Exercise Intervention', 'novel low-volume high-intensity interval training (HIIT), moderate-intensity continuous training (MICT), or placebo (PLA) intervention', 'PLA', 'placebo']","['liver fat, glycemia, and cardiorespiratory fitness', 'HbA 1c improved in MICT', 'Cardiorespiratory fitness', 'Liver fat reduced in MICT']","[{'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0441730', 'cui_str': 'Type 2'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0205254', 'cui_str': 'Inactive'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517503', 'cui_str': '1.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4068881', 'cui_str': '0.9'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0023884', 'cui_str': 'Liver structure'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0005802', 'cui_str': 'Glucose, Blood'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}]",35.0,0.0767634,Cardiorespiratory fitness improved in MICT (2.3 ± 1.2 mL/kg/min) and HIIT (1.1 ± 0.5 mL/kg/min) but not in PLA (-1.5 ± 0.9 mL/kg/min),"[{'ForeName': 'Angelo', 'Initials': 'A', 'LastName': 'Sabag', 'Affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia angelo.sabag@sydney.edu.au.'}, {'ForeName': 'Kimberley L', 'Initials': 'KL', 'LastName': 'Way', 'Affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Rachelle N', 'Initials': 'RN', 'LastName': 'Sultana', 'Affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Shelley E', 'Initials': 'SE', 'LastName': 'Keating', 'Affiliation': 'Centre for Research on Exercise, Physical Activity and Health, School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Gerofi', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Vivienne H', 'Initials': 'VH', 'LastName': 'Chuter', 'Affiliation': 'School of Health Sciences, University of Newcastle, Callaghan, New South Wales, Australia.'}, {'ForeName': 'Nuala M', 'Initials': 'NM', 'LastName': 'Byrne', 'Affiliation': 'School of Health Sciences, College of Health and Medicine, University of Tasmania, Tasmania, Australia.'}, {'ForeName': 'Michael K', 'Initials': 'MK', 'LastName': 'Baker', 'Affiliation': 'School of Behavioural and Health Sciences, Australian Catholic University, Fitzroy, New South Wales, Australia.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'George', 'Affiliation': 'Storr Liver Centre, Westmead Institute for Medical Research and Westmead Hospital, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ian D', 'Initials': 'ID', 'LastName': 'Caterson', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Stephen M', 'Initials': 'SM', 'LastName': 'Twigg', 'Affiliation': 'The Boden Collaboration for Obesity, Nutrition, Exercise and Eating Disorders, The University of Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Nathan A', 'Initials': 'NA', 'LastName': 'Johnson', 'Affiliation': 'Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.'}]",Diabetes care,['10.2337/dc19-2523'] 2841,31100296,A single bout of hard RPE-based cycling exercise increases salivary alpha-amylase.,"Exercise exerts beneficial effects on cognition, in part by stimulating an arousal response that includes the release of catecholamines. Sympathetic nervous system arousal and activation of the noradrenergic system in particular may enhance cognitive performance. Measurement of salivary alpha-amylase, a non-invasive biomarker of central noradrenergic activity, is a promising avenue for characterizing the arousal-mediated effects of exercise on cognition. However, the effectiveness of high-intensity acute exercise, and the time course of sAA concentrations following exercise, has not been clearly described. The purpose of this study was to determine the effects of 20 min of perceived exertion-based high-intensity cycling exercise on salivary alpha-amylase levels in healthy young adults. We utilized a repeated-measures design to examine the sAA response to cycling exercise, rest, and an emotional picture viewing task. Thirty-two participants between the ages of 18-30 viewed pleasant, neutral, and unpleasant pictures from the International Affective Picture System. Before and after the task, participants completed either 20 min of seated rest or cycling exercise at an intensity corresponding to 15 (""hard"") on Borg's Ratings of Perceived Exertion scale. Salivary alpha-amylase was assessed at time points immediately before and after rest, exercise, and the picture viewing task. Exercise elicited a robust increase in salivary alpha-amylase approximately six times higher than that induced by emotional picture viewing. Importantly, the observed exercise-induced increase in salivary alpha-amylase returned to a level comparable to baseline after ten minutes. These findings have meaningful implications for future work characterizing the relationship between exercise and arousal-mediated effects on cognitive performance.",2019,Exercise elicited a robust increase in salivary alpha-amylase approximately six times higher than that induced by emotional picture viewing.,"['Thirty-two participants between the ages of 18-30 viewed pleasant, neutral, and unpleasant pictures from the International Affective Picture System', 'healthy young adults']","['20\u202fmin of perceived exertion-based high-intensity cycling exercise', '20\u202fmin of seated rest or cycling exercise', 'hard RPE-based cycling exercise']","['Salivary alpha-amylase', 'salivary alpha-amylase levels', 'salivary alpha-amylase']","[{'cui': 'C0450357', 'cui_str': '32'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0449911', 'cui_str': 'View'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0277814', 'cui_str': 'Sitting position'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0018599', 'cui_str': 'Hard'}, {'cui': 'C0035322', 'cui_str': 'Structure of retinal pigment epithelium'}]","[{'cui': 'C2350322', 'cui_str': 'Salivary alpha-Amylases'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",32.0,0.0582111,Exercise elicited a robust increase in salivary alpha-amylase approximately six times higher than that induced by emotional picture viewing.,"[{'ForeName': 'Lauren R', 'Initials': 'LR', 'LastName': 'Weiss', 'Affiliation': 'Program in Neuroscience and Cognitive Science, University of Maryland, College Park, MD, USA; Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA. Electronic address: lrweiss@terpmail.umd.edu.'}, {'ForeName': 'Andrew C', 'Initials': 'AC', 'LastName': 'Venezia', 'Affiliation': 'Department of Exercise Science and Sport, The University of Scranton, Scranton, PA, USA.'}, {'ForeName': 'J Carson', 'Initials': 'JC', 'LastName': 'Smith', 'Affiliation': 'Program in Neuroscience and Cognitive Science, University of Maryland, College Park, MD, USA; Department of Kinesiology, School of Public Health, University of Maryland, College Park, MD, USA.'}]",Physiology & behavior,['10.1016/j.physbeh.2019.05.016'] 2842,32734732,"Effects of Air Purifiers on Patients with Allergic Rhinitis: a Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study.","PURPOSE Exposure to particulate matter (PM) is a well-known risk factor in the triggering and exacerbation of allergic airway disease. Indoor environments, where people spend most of their time, are of utmost importance. To assess the effects of air purifiers [equipped with high-efficiency particulate air (HEPA) filters] on allergic rhinitis (AR) in adult patients, we performed a multicenter, randomized, double-blind, and placebo-controlled study. MATERIALS AND METHODS Patients with house dust mite (HDM)-induced AR were randomly assigned to either active or mockup (placebo) air-purification groups. Two air purifiers (placed in living room and bedroom) were operated for 6 weeks in each home environment. The primary study endpoint was to achieve improvement in AR symptoms and medication scores. Secondary endpoints were to achieve improvement in the quality of life (QoL) and visual analog scale (VAS) scores, as well as in the indoor (bedroom and living room) concentrations of PM 2.5 and PM 10 . RESULTS After 6 weeks of air purifier use, medication scores improved significantly in the active (vs. placebo) group, although subjective measures (symptoms, VAS, and QoL scores) did not differ. Bedroom PM 2.5 concentrations initially exceeded living room or outdoor levels, but declined (by up to 51.8%) following active purifier operation. Concentrations of PM 2.5 in living room and PM 10 in bedroom and living room were also significantly reduced through active purification. CONCLUSION The use of air purifiers with HEPA filters significantly reduced medication requirements for patients with HDM-induced AR and significantly lowered indoor PM 2.5 concentrations, regardless of room placement. Active intervention to reduce household air pollutants may help improve allergic airway disease (clinicaltrials.gov NCT03313453).",2020,"After 6 weeks of air purifier use, medication scores improved significantly in the active (vs. placebo) group, although subjective measures (symptoms, VAS, and QoL scores) did not differ.","['allergic rhinitis (AR) in adult patients', 'Patients with house dust mite (HDM)-induced AR', 'Patients with Allergic Rhinitis']","['Placebo', 'air purifiers with HEPA filters', 'Two air purifiers (placed in living room and bedroom', 'active or mockup (placebo) air-purification groups', 'Air Purifiers', 'air purifiers [equipped with high-efficiency particulate air (HEPA) filters', 'placebo']","['AR symptoms and medication scores', 'Bedroom PM 2.5 concentrations initially exceeded living room or outdoor levels', 'medication scores', 'medication requirements', 'subjective measures (symptoms, VAS, and QoL scores', 'quality of life (QoL) and visual analog scale (VAS) scores, as well as in the indoor (bedroom and living room']","[{'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0998367', 'cui_str': 'House dust mite'}, {'cui': 'C0205263', 'cui_str': 'Induced'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0262774', 'cui_str': 'Air Purifier'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0457784', 'cui_str': 'Particulate'}, {'cui': 'C0180861', 'cui_str': 'Air filter'}, {'cui': 'C0442504', 'cui_str': 'Place'}, {'cui': 'C0557652', 'cui_str': 'Bedroom'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0243114', 'cui_str': 'purification'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0180860', 'cui_str': 'Filter'}]","[{'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0557652', 'cui_str': 'Bedroom'}, {'cui': 'C1720884', 'cui_str': 'Particulate Matter'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}]",,0.306739,"After 6 weeks of air purifier use, medication scores improved significantly in the active (vs. placebo) group, although subjective measures (symptoms, VAS, and QoL scores) did not differ.","[{'ForeName': 'Kyung Hee', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Da Woon', 'Initials': 'DW', 'LastName': 'Sim', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sang Chul', 'Initials': 'SC', 'LastName': 'Lee', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sunyoung', 'Initials': 'S', 'LastName': 'Moon', 'Affiliation': 'Air Care Advanced R&D, Home Appliance & Air Solution Company, LG Electronics, Seoul, Korea.'}, {'ForeName': 'Eunju', 'Initials': 'E', 'LastName': 'Choe', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyejung', 'Initials': 'H', 'LastName': 'Shin', 'Affiliation': 'Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Sung Ryeol', 'Initials': 'SR', 'LastName': 'Kim', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Jae Hyun', 'Initials': 'JH', 'LastName': 'Lee', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}, {'ForeName': 'Hyung Ho', 'Initials': 'HH', 'LastName': 'Park', 'Affiliation': 'Air Care Advanced R&D, Home Appliance & Air Solution Company, LG Electronics, Seoul, Korea.'}, {'ForeName': 'Deok', 'Initials': 'D', 'LastName': 'Huh', 'Affiliation': 'Air Care Advanced R&D, Home Appliance & Air Solution Company, LG Electronics, Seoul, Korea.'}, {'ForeName': 'Jung Won', 'Initials': 'JW', 'LastName': 'Park', 'Affiliation': 'Division of Allergy and Immunology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.'}]",Yonsei medical journal,['10.3349/ymj.2020.61.8.689'] 2843,32734750,The effect of Pilates exercise on the happiness and depression of elderly women: a clinical trial study.,"OBJECTIVES The available approaches for reducing mental problems, particularly for elderlies, include physical activities and exercise. Pilates is a sport that has received much attention during the past few years. The present study was conducted to explore the influence of Pilates on depression and happiness levels of elderly women. MATERIALS AND METHODS This randomized trial work was conducted on 60 elderly women referred to the health center of Rafsanjan city, Southern Iran. The participants were randomly assigned into two intervention (Pilates) and control groups, each with 30 members. In the intervention group, participants did Pilates three sessions each week for 8 weeks. The control group did not receive any intervention similar to the intervention group.The happiness level of the participants was measured using the Oxford Happiness Inventory (OHI) and their depression was measured using the Beck Depression Inventory (BDI) before, one month after, and two months after the intervention. A mixed ANOVA was applied for data analysis. RESULTS The majority of the participants were married housewives with primary education and age range of above 62 years. Based on the findings of this study, the mean happiness and depression scores of the participants at the end of months one and two in the intervention groups increased significantly compared to those of the control group. CONCLUSIONS Doing Pilates for 8 weeks may positively affect the depression and happiness levels of the elderly. Thus, it is recommended as a healthy exercise for elderlies.",2020,The control group did not receive any intervention similar to the intervention group.,"['60 elderly women referred to the health center of Rafsanjan city, Southern Iran', 'participants were married housewives with primary education and age range of above 62 years', 'elderly women']",['Pilates exercise'],"['depression and happiness levels', 'mean happiness and depression scores', 'Beck Depression Inventory (BDI', 'Oxford Happiness Inventory (OHI) and their depression']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman'}, {'cui': 'C1691010', 'cui_str': 'Referral placed'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0022065', 'cui_str': 'Iran'}, {'cui': 'C0024841', 'cui_str': 'Marriage'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C1321049', 'cui_str': 'Pilates exercise'}]","[{'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0018592', 'cui_str': 'Cheerful mood'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",60.0,0.0273639,The control group did not receive any intervention similar to the intervention group.,"[{'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Ravari', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Tayebeh', 'Initials': 'T', 'LastName': 'Mirzaei', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran - t.mirzaei@rums.ac.ir.'}, {'ForeName': 'Ruhollah', 'Initials': 'R', 'LastName': 'Bahremand', 'Affiliation': 'Geriatric Care Nursing Master of Science Student, School of Nursing and Midwifery, Rafsanjan university of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Mohadeseh', 'Initials': 'M', 'LastName': 'Raeisi', 'Affiliation': 'Department of Medical Surgical Nursing, School of Nursing and Midwifery, Geriatric Care Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'ForeName': 'Zahra', 'Initials': 'Z', 'LastName': 'Kamiab', 'Affiliation': 'Department of Family Medicine, School of Medicine, Clinical Research Development Unit, Ali-Ibn Abi-Talib Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.10730-8'] 2844,32734751,"A comparison of the effects of plyometric and virtual training on physical and functional performance: a randomized, controlled, clinical trial.","BACKGROUND This study compared the effects of plyometric training (PT) and virtual training (VT) on physical and functional performance. METHODS Fifty-five moderately-trained women participated in this randomized, controlled, prospective study. The subjects were randomly assigned to VT (n=20), PT (n=18), and control (CG, n=17) groups. The VT was performed using the Your Body Shape Fitness Evolved 2012TM exergame in an Xbox360/KineticTM environment. The PT was based on the methods used in previous studies. Both interventions were performed 3 times per week for 8 weeks. Participants in the CG were not submitted to any type of intervention. Physical performance (fitness and athleticism levels) was assessed using the Nike+ Kinetic TrainingTM exergame in an Xbox360/KineticTM environment. Functional performance was assessed using the shuttle run (SR), triple hop test (THT), and six-meter timed hop test (STHT). RESULTS Post-intervention fitness and athleticism levels were significantly greater in VT (P < 0.001 and P = 0.009) and in PT (P < 0.001 and P = 0.003) than baselines values. Only VT post-intervention fitness level was significantly greater compared to CG (P = 0.03). Postintervention SR values were significantly lower than baselines values in all groups (P <0.001). VT (P = 0.08) and PT (P = 0.006) post-intervention values were significantly lower compared to CG. Post-intervention THT values were significantly greater than baselines values in VT and PT (P < 0.001). VT (P = 0.04 - dominant limb) and PT (P = 0.003 -dominant limb and P = 0.03 - non-dominant limb) post-intervention values were significantly greater compared to CG. Post-intervention STHT values were significantly lower than baselines values in VT (P < 0.001), PT (P < 0.001) and CG (P = 0.01-0.02). PT post-intervention dominant (P = 0.01) and non-dominant (P = 0.03) limb values were significantly lower compared to CG. CONCLUSIONS Both VT and PT are beneficial for improving physical and functional performance. Therefore, VT might be a new tool that can be used for physical exercise practice and conditioning training in moderately-trained women.",2020,"Post-intervention STHT values were significantly lower than baselines values in VT (P < 0.001), PT (P < 0.001) and CG (P = 0.01-0.02).","['moderately-trained women', 'Fifty-five moderately-trained women participated']","['plyometric training (PT) and virtual training (VT', 'VT', 'VT and PT', 'shuttle run (SR), triple hop test (THT), and six-meter timed hop test (STHT', 'plyometric and virtual training']","['athleticism levels', 'physical and functional performance', 'Functional performance', 'Physical performance (fitness and athleticism levels', 'Postintervention SR values', 'limb values']","[{'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0450382', 'cui_str': '55'}]","[{'cui': 'C3178799', 'cui_str': 'Plyometric Drill'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205174', 'cui_str': 'Triple'}, {'cui': 'C0078040', 'cui_str': 'VAP protocol'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0441074', 'cui_str': 'Meters'}, {'cui': 'C0040223', 'cui_str': 'Time'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0015385', 'cui_str': 'Limb structure'}]",55.0,0.0195447,"Post-intervention STHT values were significantly lower than baselines values in VT (P < 0.001), PT (P < 0.001) and CG (P = 0.01-0.02).","[{'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'Lobato', 'Affiliation': 'Human Movement Analysis Laboratory, Applied Physical Therapy Department, Federal University of Triangulo Mineiro, Uberaba, Brazil - daniel.lobato@uftm.edu.br.'}, {'ForeName': 'Vitória A', 'Initials': 'VA', 'LastName': 'Teixeira', 'Affiliation': 'Human Movement Analysis Laboratory, Applied Physical Therapy Department, Federal University of Triangulo Mineiro, Uberaba, Brazil.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Froes', 'Affiliation': 'Human Movement Analysis Laboratory, Applied Physical Therapy Department, Federal University of Triangulo Mineiro, Uberaba, Brazil.'}, {'ForeName': 'Marina A', 'Initials': 'MA', 'LastName': 'Donzeli', 'Affiliation': 'Human Movement Analysis Laboratory, Applied Physical Therapy Department, Federal University of Triangulo Mineiro, Uberaba, Brazil.'}, {'ForeName': 'Dernival', 'Initials': 'D', 'LastName': 'Bertoncello', 'Affiliation': 'Human Movement Analysis Laboratory, Applied Physical Therapy Department, Federal University of Triangulo Mineiro, Uberaba, Brazil.'}]",The Journal of sports medicine and physical fitness,['10.23736/S0022-4707.20.10882-X'] 2845,32735112,Bicarbonate Unlocks the Ergogenic Action of Ketone Monoester Intake in Endurance Exercise.,"PURPOSE We recently reported that oral ketone ester (KE) intake before and during the initial 30 min of a ~3h 15 min simulated cycling race (RACE) transiently decreased blood pH and bicarbonate without affecting maximal performance in the final quarter of the event. We hypothesized that acid-base disturbances due to KE overrules the ergogenic potential of exogenous ketosis in endurance exercise. METHODS Nine well-trained male cyclists participated in a similar RACE consisting of 3h submaximal intermittent cycling (IMT180') followed by a 15-min time-trial (TT15') preceding an all-out sprint at 175% of lactate threshold (SPRINT). In a randomized cross-over design participants received either i) 65g ketone ester (KE), ii) 300 mg/kg body weight NaHCO3 (BIC), iii) KE+BIC or iv) a control drink (CON), together with consistent 60g per h carbohydrate intake. RESULTS KE ingestion transiently elevated blood D-ß-hydroxybutyrate to ~2-3 mM during the initial 2 hours of RACE (p< 0.001 vs. CON). In KE, blood pH concomitantly dropped from 7.43 to 7.36 whilst bicarbonate decreased from 25.5 to 20.5 mM (both p<0.001 vs. CON). Additional BIC resulted in 0.5 to 0.8 mM higher blood D-ß-hydroxybutyrate during the first half of IMT180' (p < 0.05 vs. KE) and increased blood bicarbonate to 31.1±1.8 mM and blood pH to 7.51±0.03 by the end of IMT180' (p<0.001 vs. KE). Mean power output during TT15' was similar between KE, BIC and CON at ~255 W, but was 5% higher in KE+BIC (p=0.02 vs. CON). Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88). Gastrointestinal symptoms were similar between groups. DISCUSSION Co-ingestion of oral bicarbonate and KE enhances high-intensity performance at the end of an endurance exercise event without causing gastrointestinal distress.",2020,Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88).,['Nine well-trained male cyclists participated in a similar RACE consisting of 3h'],"['bicarbonate and KE', 'i', ""submaximal intermittent cycling (IMT180') followed by a 15-min time-trial (TT15') preceding an all-out sprint at 175% of lactate threshold (SPRINT"", 'Bicarbonate', 'oral ketone ester (KE', '65g ketone ester (KE), ii) 300 mg/kg body weight NaHCO3 (BIC), iii', 'control drink (CON']","['blood pH', 'blood pH and bicarbonate', 'Time-to-exhaustion', 'blood D-ß-hydroxybutyrate', 'blood bicarbonate', 'KE ingestion transiently elevated blood D-ß-hydroxybutyrate', 'Mean power output during TT15', 'Gastrointestinal symptoms']","[{'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0034510', 'cui_str': 'Racial group'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}]","[{'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0014898', 'cui_str': 'Ester'}, {'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0022924', 'cui_str': 'Lactates'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0560741', 'cui_str': 'mg/kg body weight'}, {'cui': 'C0074722', 'cui_str': 'Sodium Bicarbonate'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0452428', 'cui_str': 'Drink'}]","[{'cui': 'C0853363', 'cui_str': 'Blood pH'}, {'cui': 'C0005367', 'cui_str': 'Bicarbonate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0392674', 'cui_str': 'Exhaustion'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0020332', 'cui_str': 'Hydroxybutyrates'}, {'cui': 'C0853263', 'cui_str': 'Blood bicarbonate'}, {'cui': 'C0022634', 'cui_str': 'Ketone'}, {'cui': 'C0014898', 'cui_str': 'Ester'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}]",,0.0531584,Time-to-exhaustion in the sprint was similar between all conditions at ~60s (p=0.88).,"[{'ForeName': 'Chiel', 'Initials': 'C', 'LastName': 'Poffé', 'Affiliation': '1Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, Leuven, Belgium 2Department of Physical and Rehabilitation Medicine; University Hospitals Leuven, Leuven, Belgium 3Locomotor and neurological disorders, Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium 4Bakala Academy-Athletic Performance Center, KU Leuven, Leuven, Belgium.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Ramaekers', 'Affiliation': ''}, {'ForeName': 'Stijn', 'Initials': 'S', 'LastName': 'Bogaerts', 'Affiliation': ''}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hespel', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002467'] 2846,32735113,The Effect of Preexercise Expiratory Muscle Loading on Exercise Tolerance in Healthy Men.,"PURPOSE Acute non-fatiguing inspiratory muscle loading transiently increases diaphragm excitability and global inspiratory muscle strength, and may improve subsequent exercise performance. We investigated the effect of acute expiratory muscle loading on expiratory muscle function and exercise tolerance in healthy men. METHODS Ten males cycled at 90% of peak power output to the limit of tolerance (TLIM) after: 1) 2 × 30 expiratory efforts against a pressure-threshold load of 40% maximal expiratory gastric pressure (PgaMAX) (EML-EX); and 2) 2 × 30 expiratory efforts against a pressure-threshold load of 10% PgaMAX (SHAM-EX). Changes in expiratory muscle function were assessed by measuring the mouth pressure (PEMAX) and PgaMAX responses to maximal expulsive efforts, and magnetically evoked (1-Hz) gastric twitch pressure (Pgatw). RESULTS Expiratory loading at 40% of PgaMAX increased PEMAX (10 ± 5%, P = 0.001) and PgaMAX (9 ± 5%, P = 0.004). Conversely, there was no change in PEMAX (166 ± 40 vs. 165 ± 35 cmH2O, P = 1.000) or PgaMAX (196 ± 38 vs. 192 ± 39 cmH2O, P = 0.215) from before to after expiratory loading at 10% of PgaMAX. Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651). Similarly, exercise-induced expiratory muscle fatigue was not different in EML-EX vs. SHAM-EX (-28 ± 12 vs. -26 ± 7% reduction in Pgatw amplitude, P = 0.280). Perceptual ratings of dyspnea and leg discomfort were not different during EML-EX vs. SHAM-EX. CONCLUSION Acute expiratory muscle loading enhances expiratory muscle function but does not improve subsequent severe-intensity exercise tolerance in healthy men.",2020,"Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651).","['Healthy Men', 'healthy men', 'Ten males cycled at 90% of peak power output to the limit of tolerance (TLIM) after: 1) 2 × 30']","['Preexercise Expiratory Muscle Loading', 'acute expiratory muscle loading', 'expiratory efforts against a pressure-threshold load of 40% maximal expiratory gastric pressure (PgaMAX) (EML-EX); and 2) 2 × 30 expiratory efforts against a pressure-threshold load of 10% PgaMAX (SHAM-EX']","['mouth pressure (PEMAX) and PgaMAX responses to maximal expulsive efforts, and magnetically evoked (1-Hz) gastric twitch pressure (Pgatw', 'Exercise time', 'expiratory muscle fatigue', 'diaphragm excitability and global inspiratory muscle strength', 'expiratory muscle function and exercise tolerance', 'Perceptual ratings of dyspnea and leg discomfort', 'expiratory muscle function', 'Expiratory loading']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0013220', 'cui_str': 'Drug tolerance'}]","[{'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0429216', 'cui_str': 'Gastric pressure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C1444748', 'cui_str': 'Evoked'}, {'cui': 'C0038351', 'cui_str': 'Stomach'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0439587', 'cui_str': 'Exercise time'}, {'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0242979', 'cui_str': 'Muscle fatigue'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0013404', 'cui_str': 'Dyspnea'}, {'cui': 'C0859235', 'cui_str': 'Leg discomfort'}]",,0.116673,"Exercise time was not different in EML-EX vs. SHAM-EX (7.91 ± 1.96 vs. 8.09 ± 1.77 min, 95% CI = -1.02 to 0.67, P = 0.651).","[{'ForeName': 'Tim A', 'Initials': 'TA', 'LastName': 'Hardy', 'Affiliation': '1School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom 2School of Sport & Exercise, University of Gloucestershire, Gloucester, United Kingdom 3School of Sport & Health Sciences, College of Life & Environmental Sciences, University of Exeter, Exeter, United Kingdom 4Department of Cardiovascular Diseases, Mayo Clinic in Florida, Jacksonville, FL.'}, {'ForeName': 'Stephen C', 'Initials': 'SC', 'LastName': 'How', 'Affiliation': ''}, {'ForeName': 'Bryan J', 'Initials': 'BJ', 'LastName': 'Taylor', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002468'] 2847,32735114,Multidirectional Walking in Hematopoietic Stem Cell Transplant Patients.,"BACKGROUND The effect of a peri-transplant multidirectional walking intervention to target losses in physical function and quality of life has not been investigated. PURPOSE This study examined the effects of a novel multidirectional walking program on physical function and quality of life in adults receiving a hematopoietic stem cell transplant (HSCT). METHODS Thirty-five adults receiving an autologous or allogeneic HSCT were randomized to a multidirectional walking (WALK) or usual care (CONT) group. The WALK group received supervised training during hospitalization; the CONT group received usual care. Patients were assessed at admission (t0), three to five days post-HSCT (t1), and 30-days post-HSCT (t2). Physical function measures included the six-minute walk test (6MWT), the Physical Performance Test, and the Timed-Up-and-Go. Health-related quality of life (QOL) was collected using the FACT-BMT questionnaire. RESULTS There were no significant between-group changes for physical function or QOL. However, after the intervention (t1 to t2), the WALK group showed significant improvement in aerobic capacity (6MWT, p=.01), physical (p<.01) and functional well-being (p=.04), and overall QOL scores (p<.01). The CONT group saw no significant changes in physical function or QOL. Effect sizes showed the WALK group had a larger positive effect on physical function and QOL. Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. CONCLUSION A multi-directional walking program during the transplant period may be effective at increasing aerobic capacity and QOL for patients receiving HSCT compared to no structured exercise.",2020,"Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. ","['Thirty-five adults receiving an autologous or allogeneic HSCT', 'adults receiving a hematopoietic stem cell transplant (HSCT', 'Hematopoietic Stem Cell Transplant Patients']","['HSCT', 'peri-transplant multidirectional walking intervention', 'Multidirectional Walking', 'novel multidirectional walking program', 'supervised training during hospitalization; the CONT group received usual care', 'multidirectional walking (WALK) or usual care (CONT']","['6MWT and FACT-BMT', 'physical function and QOL', 'Health-related quality of life (QOL', 'six-minute walk test (6MWT), the Physical Performance Test, and the Timed-Up-and-Go', 'aerobic capacity (6MWT, p=.01), physical (p<.01) and functional well-being (p=.04), and overall QOL scores', 'physical function and quality of life', 'physical function or QOL', 'aerobic capacity and QOL']","[{'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0472699', 'cui_str': 'Hemopoietic stem cell transplant'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0040732', 'cui_str': 'Transplantation'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0005961', 'cui_str': 'Transplantation of bone marrow'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",35.0,0.0340436,"Minimal clinically important differences in the 6MWT and FACT-BMT were exceeded in the WALK group. ","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Potiaumpai', 'Affiliation': '1Penn State Cancer Institute, Hershey, PA 2Sylvester Comprehensive Cancer Center, Miami, FL 3Dana-Farber Cancer Institute, Boston, MA 4University of Miami, Coral Gables, FL 5Ultimate Software, Weston, FL.'}, {'ForeName': 'Stacy', 'Initials': 'S', 'LastName': 'Cutrono', 'Affiliation': ''}, {'ForeName': 'Tamia', 'Initials': 'T', 'LastName': 'Medina', 'Affiliation': ''}, {'ForeName': 'Maximillian', 'Initials': 'M', 'LastName': 'Koeppel', 'Affiliation': ''}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Pereira', 'Affiliation': ''}, {'ForeName': 'William F', 'Initials': 'WF', 'LastName': 'Pirl', 'Affiliation': ''}, {'ForeName': 'Kevin A', 'Initials': 'KA', 'LastName': 'Jacobs', 'Affiliation': ''}, {'ForeName': 'Moataz', 'Initials': 'M', 'LastName': 'Eltoukhy', 'Affiliation': ''}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Signorile', 'Affiliation': ''}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002474'] 2848,32735145,Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis.,"Objectives : To compare the radiographic and clinical effects of 25 versus 10 mg twice-weekly (BIW) etanercept over 52 weeks in Japanese patients with active rheumatoid arthritis (RA). Methods : This was a post-hoc analysis of a Phase 3 study where Japanese patients with active RA were randomized to receive BIW etanercept 25 mg (n = 182), etanercept 10 mg (n = 192), or methotrexate (n = 176) for 52 weeks (NCT00445770). This analysis included assessments of week-24 and week-52 disease activity, week-52 radiographic progression, and the relationship between baseline characteristics and week 52 clinical outcomes with clinically relevant radiographic progression (CRRP) at week 52. Results : At week 52, there were no significant differences between 25 and 10 mg etanercept in terms of achieving low disease activity or remission. CRRP was observed in 36% and 32% patients in the 10 and 25 mg groups, respectively. Predictor analysis suggested that worse background disease status, treatment with methotrexate rather than etanercept, and poorer clinical outcomes at week 52 were associated with CRRP. Conclusions : The 25 mg BIW etanercept dosage does not appear to be significantly more efficacious than 10 mg in Japanese patients with RA. Further studies evaluating the optimal etanercept dosing regimen in this patient population may be merited.NCT: NCT00445770.",2020,"At week 52, there were no significant differences between 25 and 10 mg etanercept in terms of achieving low disease activity or remission.","['Japanese patients with active rheumatoid arthritis', 'Japanese patients with RA', 'Japanese patients with active RA', 'Japanese patients with active rheumatoid arthritis (RA']","['NCT', 'etanercept 10\u2009mg (n\u2009=\u2009192), or methotrexate', 'etanercept', 'methotrexate', '10\u2009mg and 25\u2009mg twice-weekly etanercept', 'BIW etanercept', '25 versus 10\u2009mg twice-weekly (BIW) etanercept']","['CRRP', 'low disease activity or remission']","[{'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0003873', 'cui_str': 'Rheumatoid arthritis'}]","[{'cui': 'C0717758', 'cui_str': 'Etanercept'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0025677', 'cui_str': 'Methotrexate'}, {'cui': 'C0556985', 'cui_str': 'Twice weekly'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0544452', 'cui_str': 'Remission phase'}]",,0.0483493,"At week 52, there were no significant differences between 25 and 10 mg etanercept in terms of achieving low disease activity or remission.","[{'ForeName': 'Tsutomu', 'Initials': 'T', 'LastName': 'Takeuchi', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.'}, {'ForeName': 'Nobuyuki', 'Initials': 'N', 'LastName': 'Miyasaka', 'Affiliation': 'Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.'}, {'ForeName': 'Ron D', 'Initials': 'RD', 'LastName': 'Pedersen', 'Affiliation': 'Pfizer, Collegeville, PA, USA.'}, {'ForeName': 'Noriko', 'Initials': 'N', 'LastName': 'Sugiyama', 'Affiliation': 'Clinical Statistics, Biometrics, and Data Management, Pfizer R&D Japan, Tokyo, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Hirose', 'Affiliation': 'Immunology & Inflammation Medical Affairs, Innovative Medicines Business, Pfizer Japan Inc, Tokyo, Japan.'}]",Modern rheumatology,['10.1080/14397595.2020.1805142'] 2849,32730181,"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.","PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used in combination with alkylating agents and dexamethasone. We prospectively compared the efficacy and safety of MDex and MDex with the addition of bortezomib (BMDex). METHODS This was a phase III, multicenter, randomized, open-label trial. Patients were stratified according to cardiac stage. Patients with advanced cardiac stage (stage IIIb) amyloidosis were not eligible. The primary end point was hematologic response rate at 3 months. This trial is registered with ClinicalTrials.gov identifier NCT01277016. RESULTS A total of 109 patients, 53 in the BMDex and 56 in the MDex group, received ≥ 1 dose of therapy (from January 2011 to February 2016). Hematologic response rate at 3 months was higher in the BMDex arm (79% v 52%; P = .002). Higher rates of very good partial or complete response rates (64% v 39%; hazard ratio [HR], 2.47; 95% CI, 1.30 to 4.71) and improved overall survival, with a 2-fold decrease in mortality rate (HR, 0.50; 95% CI, 0.27 to 0.90), were observed in the BMDex arm. Grade 3 and 4 adverse events (the most common being cytopenia, peripheral neuropathy, and heart failure) were more common in the BMDex arm, occurring in 20% versus 10% of cycles performed. CONCLUSION BMDex improved hematologic response rate and overall survival. To our knowledge, this is the first time a controlled study has demonstrated a survival advantage in AL amyloidosis. BMDex should be considered a new standard of care for AL amyloidosis.",2020,"Grade 3 and 4 adverse events (the most common being cytopenia, peripheral neuropathy, and heart failure) were more common in the BMDex arm, occurring in 20% versus 10% of cycles performed. ","['Patients with advanced cardiac stage (stage IIIb) amyloidosis', 'A total of 109 patients, 53 in the BMDex and 56 in the MDex group, received ≥ 1 dose of therapy (from January 2011 to February 2016']","['Bortezomib, Melphalan, and Dexamethasone', 'bortezomib (BMDex', 'dexamethasone', 'BMDex', 'melphalan and dexamethasone (MDex', 'bortezomib']","['hematologic response rate', 'overall survival', 'Hematologic response rate', 'Higher rates of very good partial or complete response rates', 'mortality rate', 'peripheral neuropathy, and heart failure', 'hematologic response rate and overall survival', 'Grade 3 and 4 adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}, {'cui': 'C0002726', 'cui_str': 'Amyloidosis'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C1176309', 'cui_str': 'bortezomib'}, {'cui': 'C0025241', 'cui_str': 'Melphalan'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}]","[{'cui': 'C0018943', 'cui_str': 'Hematology'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C3641222', 'cui_str': 'Very good'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1869037', 'cui_str': 'Peripheral neuropathy (SMQ)'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",109.0,0.254965,"Grade 3 and 4 adverse events (the most common being cytopenia, peripheral neuropathy, and heart failure) were more common in the BMDex arm, occurring in 20% versus 10% of cycles performed. ","[{'ForeName': 'Efstathios', 'Initials': 'E', 'LastName': 'Kastritis', 'Affiliation': 'Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Leleu', 'Affiliation': 'Hopital Huriez Centre Hospitalier Régional Universitaire, Lille, France.'}, {'ForeName': 'Bertrand', 'Initials': 'B', 'LastName': 'Arnulf', 'Affiliation': 'Immunohematology Unit, Hospital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Zamagni', 'Affiliation': 'Bologna University School of Medicine, Bologna, Italy.'}, {'ForeName': 'María Teresa', 'Initials': 'MT', 'LastName': 'Cibeira', 'Affiliation': 'Amyloidosis and Myeloma Unit, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Kwok', 'Affiliation': 'Westmead Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Mollee', 'Affiliation': 'Princess Alexandra Hospital and University of Queensland, Brisbane, Queensland, Australia.'}, {'ForeName': 'Roman', 'Initials': 'R', 'LastName': 'Hájek', 'Affiliation': 'Department of Hemato-oncology, University Hospital, Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'Centre Hospitalier Universitaire Hotel Dieu, Nantes, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Jaccard', 'Affiliation': 'Centre Hospitalier Universitaire, Limoges, France.'}, {'ForeName': 'Stefan O', 'Initials': 'SO', 'LastName': 'Schönland', 'Affiliation': 'Medical Department V, Amyloidosis Centre, University Hospital, Heidelberg, Germany.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Filshie', 'Affiliation': ""St Vincent's Hospital, Melbourne, Victoria, Australia.""}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Nicolas-Virelizier', 'Affiliation': 'Centre Leon Berard, Lyon, France.'}, {'ForeName': 'Bradley', 'Initials': 'B', 'LastName': 'Augustson', 'Affiliation': 'Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.'}, {'ForeName': 'María-Victoria', 'Initials': 'MV', 'LastName': 'Mateos', 'Affiliation': 'University Hospital of Salamanca, Instituto de Investigación Biosanitaria de Salamanc, Institute of Cancer Molecular and Cellular Biology, Salamanca, Spain.'}, {'ForeName': 'Ashutosh', 'Initials': 'A', 'LastName': 'Wechalekar', 'Affiliation': 'University College London Medical School, Royal Free Hospital Campus, London, United Kingdom.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hachulla', 'Affiliation': 'Hopital Huriez Centre Hospitalier Régional Universitaire, Lille, France.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Milani', 'Affiliation': 'Amyloidosis Research and Treatment Center ""Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo,"" Pavia, Italy.'}, {'ForeName': 'Meletios A', 'Initials': 'MA', 'LastName': 'Dimopoulos', 'Affiliation': 'Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.'}, {'ForeName': 'Jean-Paul', 'Initials': 'JP', 'LastName': 'Fermand', 'Affiliation': 'Immunohematology Unit, Hospital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Foli', 'Affiliation': 'Amyloidosis Research and Treatment Center ""Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo,"" Pavia, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Gavriatopoulou', 'Affiliation': 'Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Klersy', 'Affiliation': 'Clinical Epidemiology and Biometry Service, ""Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo,"" Pavia, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Palumbo', 'Affiliation': 'University of Torino, Torino, Italy.'}, {'ForeName': 'Pieter', 'Initials': 'P', 'LastName': 'Sonneveld', 'Affiliation': 'Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Hans Erik', 'Initials': 'HE', 'LastName': 'Johnsen', 'Affiliation': 'Aalborg University Hospital, Aalborg, Denmark.'}, {'ForeName': 'Giampaolo', 'Initials': 'G', 'LastName': 'Merlini', 'Affiliation': 'Amyloidosis Research and Treatment Center ""Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo,"" Pavia, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Palladini', 'Affiliation': 'Amyloidosis Research and Treatment Center ""Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo,"" Pavia, Italy.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.20.01285'] 2850,32730183,Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).,"PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab intensification during the first 4 cycles of R-CHOP could improve the outcome of these patients compared with standard R-CHOP. PATIENTS AND METHODS A total of 574 patients with DLBCL age 18 to 80 years were randomly assigned to induction therapy with 6 or 8 cycles of R-CHOP-14 with (RR-CHOP-14) or without (R-CHOP-14) intensification of rituximab in the first 4 cycles. The primary end point was complete remission (CR) on induction. Analyses were performed by intention to treat. RESULTS CR was achieved in 254 (89%) of 286 patients in the R-CHOP-14 arm and 249 (86%) of 288 patients in the RR-CHOP-14 arm (hazard ratio [HR], 0.82; 95% CI, 0.50 to 1.36; P = .44). After a median follow-up of 92 months (range, 1-131 months), 3-year failure-free survival was 74% (95% CI, 68% to 78%) in the R-CHOP-14 arm versus 69% (95% CI, 63% to 74%) in the RR-CHOP-14 arm (HR, 1.26; 95% CI, 0.98 to 1.61; P = .07). Progression-free survival at 3 years was 74% (95% CI, 69% to 79%) in the R-CHOP-14 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15). Overall survival at 3 years was 81% (95% CI, 76% to 85%) in the R-CHOP-14 arm versus 76% (95% CI, 70% to 80%) in the RR-CHOP-14 arm (HR, 1.27; 95% CI, 0.97 to 1.67; P = .09). Patients between ages 66 and 80 years experienced significantly more toxicity during the first 4 cycles in the RR-CHOP-14 arm, especially neutropenia and infections. CONCLUSION Early rituximab intensification during R-CHOP-14 does not improve outcome in patients with untreated DLBCL.",2020,"Progression-free survival at 3 years was 74% (95% CI, 69% to 79%) in the R-CHOP-14 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15).","['574 patients with DLBCL age 18 to 80 years', 'patients with untreated DLBCL', 'patients with diffuse large B-cell lymphoma (DLBCL', 'Large B-Cell Lymphoma']","['Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP', 'Rituximab-CHOP With Early Rituximab']","['neutropenia and infections', 'Progression-free survival', 'Overall survival', 'toxicity', 'complete remission (CR) on induction', '3-year failure-free survival']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0079731', 'cui_str': 'B-cell lymphoma (clinical)'}]","[{'cui': 'C4087148', 'cui_str': 'Immunochemotherapy'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0055598', 'cui_str': 'CHOP protocol'}, {'cui': 'C1279919', 'cui_str': 'Early'}]","[{'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",574.0,0.114829,"Progression-free survival at 3 years was 74% (95% CI, 69% to 79%) in the R-CHOP-14 arm versus 71% (95% CI, 66% to 76%) in the RR-CHOP-14 arm (HR, 1.20; 95% CI, 0.94 to 1.55; P = .15).","[{'ForeName': 'Pieternella Johanna', 'Initials': 'PJ', 'LastName': 'Lugtenburg', 'Affiliation': 'Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'de Nully Brown', 'Affiliation': 'Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Bronno', 'Initials': 'B', 'LastName': 'van der Holt', 'Affiliation': 'Haemato Oncology Foundation for Adults in the Netherlands (HOVON) Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Francesco A', 'Initials': 'FA', 'LastName': ""D'Amore"", 'Affiliation': 'Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Harry R', 'Initials': 'HR', 'LastName': 'Koene', 'Affiliation': 'St Antonius Hospital, Nieuwegein, the Netherlands.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'de Jongh', 'Affiliation': 'Albert Schweitzer Hospital, Dordrecht, the Netherlands.'}, {'ForeName': 'Rob', 'Initials': 'R', 'LastName': 'Fijnheer', 'Affiliation': 'Meander MC, Amersfoort, the Netherlands.'}, {'ForeName': 'Joost W', 'Initials': 'JW', 'LastName': 'van Esser', 'Affiliation': 'Amphia Hospital, Breda, the Netherlands.'}, {'ForeName': 'Lara H', 'Initials': 'LH', 'LastName': 'Böhmer', 'Affiliation': 'Haga Teaching Hospital, The Hague, the Netherlands.'}, {'ForeName': 'Johannes F', 'Initials': 'JF', 'LastName': 'Pruijt', 'Affiliation': ""Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.""}, {'ForeName': 'Gregor E', 'Initials': 'GE', 'LastName': 'Verhoef', 'Affiliation': 'University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'Mels', 'Initials': 'M', 'LastName': 'Hoogendoorn', 'Affiliation': 'Medical Center Leeuwarden, Leeuwarden, the Netherlands.'}, {'ForeName': 'Memis Y', 'Initials': 'MY', 'LastName': 'Bilgin', 'Affiliation': 'Admiraal de Ruijter Hospital, Goes, the Netherlands.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Nijland', 'Affiliation': 'University Medical Center Groningen, Groningen, the Netherlands.'}, {'ForeName': 'Nicole C', 'Initials': 'NC', 'LastName': 'van der Burg-de Graauw', 'Affiliation': 'Bravis Hospital, Roosendaal, the Netherlands.'}, {'ForeName': 'Margreet', 'Initials': 'M', 'LastName': 'Oosterveld', 'Affiliation': 'Canisius Wilhelmina Hospital, Nijmegen, the Netherlands.'}, {'ForeName': 'Kon-Siong G', 'Initials': 'KG', 'LastName': 'Jie', 'Affiliation': 'Zuyderland Medical Center, Heerlen, the Netherlands.'}, {'ForeName': 'Thomas Stauffer', 'Initials': 'TS', 'LastName': 'Larsen', 'Affiliation': 'Odense University Hospital, Odense, Denmark.'}, {'ForeName': 'Marjolein W', 'Initials': 'MW', 'LastName': 'van der Poel', 'Affiliation': 'Maastricht University MC, Maastricht, the Netherlands.'}, {'ForeName': 'Maria B', 'Initials': 'MB', 'LastName': 'Leijs', 'Affiliation': 'Maasstad Hospital, Rotterdam, the Netherlands.'}, {'ForeName': 'Matthijs H', 'Initials': 'MH', 'LastName': 'Silbermann', 'Affiliation': 'Tergooi Hospitals, Hilversum, the Netherlands.'}, {'ForeName': 'Marinus', 'Initials': 'M', 'LastName': 'van Marwijk Kooy', 'Affiliation': 'Isala Hospital, Zwolle, the Netherlands.'}, {'ForeName': 'Aart', 'Initials': 'A', 'LastName': 'Beker', 'Affiliation': 'Spaarne Gasthuis, Hoofddorp, the Netherlands.'}, {'ForeName': 'Marie J', 'Initials': 'MJ', 'LastName': 'Kersten', 'Affiliation': 'Amsterdam UMC, AMC, Amsterdam, the Netherlands.'}, {'ForeName': 'Jeanette K', 'Initials': 'JK', 'LastName': 'Doorduijn', 'Affiliation': 'Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Lidwine W', 'Initials': 'LW', 'LastName': 'Tick', 'Affiliation': 'Maxima Medical Center, Eindhoven, the Netherlands.'}, {'ForeName': 'Rolf E', 'Initials': 'RE', 'LastName': 'Brouwer', 'Affiliation': 'Reinier de Graaf Hospital, Delft, the Netherlands.'}, {'ForeName': 'King H', 'Initials': 'KH', 'LastName': 'Lam', 'Affiliation': 'Erasmus MC Cancer Institute, Rotterdam, the Netherlands.'}, {'ForeName': 'Coreline N', 'Initials': 'CN', 'LastName': 'Burggraaff', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Bart', 'Initials': 'B', 'LastName': 'de Keizer', 'Affiliation': 'UMC Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'Anne I', 'Initials': 'AI', 'LastName': 'Arens', 'Affiliation': 'Radboud UMC, Nijmegen, the Netherlands.'}, {'ForeName': 'Daphne', 'Initials': 'D', 'LastName': 'de Jong', 'Affiliation': 'HOVON Pathology Facility and Biobank, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Otto S', 'Initials': 'OS', 'LastName': 'Hoekstra', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}, {'ForeName': 'Josée M', 'Initials': 'JM', 'LastName': 'Zijlstra-Baalbergen', 'Affiliation': 'Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.'}]",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,['10.1200/JCO.19.03418'] 2851,32730283,"Comparison of Glidescope® Go™, King Vision™, Dahlhausen VL, I‑View™ and Macintosh laryngoscope use during difficult airway management simulation by experienced and inexperienced emergency medical staff: A randomized crossover manikin study.","BACKGROUND In pre-hospital emergency care, video laryngoscopes (VLs) with disposable blades are preferably used due to hygienic reasons. However, there is limited existing data on the use of VLs with disposable blades by emergency medical staff. Therefore, the aim of this study was to compare the efficacy of four different VLs with disposable blades and the conventional standard Macintosh laryngoscope, when used by anesthetists with extensive previous experience and paramedics with little previous experience in endotracheal intubation (ETI) in a simulated difficult airway. METHODS Fifty-eight anesthetists and fifty-four paramedics participated in our randomized crossover manikin trial. Each performed ETI with the new Glidescope® Go™, the Dahlhausen VL, the King Vision™, the I-View™ and the Macintosh laryngoscope. ""Time to intubate"" was the primary endpoint. Secondary endpoints were ""time to vocal cords"", ""time to ventilate"", overall success rate, number of intubation attempts and optimization maneuvers, Cormack-Lehane score, severity of dental compression and subjective impressions. RESULTS The Glidescope® Go™, the Dahlhausen VL and the King Vision™ provided superior intubation conditions in both groups without affecting the number of intubation attempts or the time required for successful intubation. When used by anesthetists with extensive experience in ETI, the use of VLs did not affect the overall success rate. In the hands of paramedics with little previous experience in ETI, the failure rate with the Macintosh laryngoscope (14.8%) decreased to 3.7% using the Glidescope® Go™ and the Dahlhausen VL. Despite the advantages of hyperangulated video laryngoscopes, the I-View™ performed worst. CONCLUSIONS VLs with hyperangulated blades facilitated ETI in both groups and decreased the failure rate by an absolute 11.1% when used by paramedics with little previous experience in ETI. Our results therefore suggest that hyperangulated VLs could be beneficial and might be the method of choice in comparable settings, especially for emergency medical staff with less experience in ETI.",2020,"CONCLUSIONS VLs with hyperangulated blades facilitated ETI in both groups and decreased the failure rate by an absolute 11.1% when used by paramedics with little previous experience in ETI.",['Fifty-eight anesthetists and fifty-four paramedics participated'],"['conventional standard Macintosh laryngoscope', 'endotracheal intubation (ETI']","['number of intubation attempts or the time required for successful intubation', 'overall success rate', 'failure rate', 'Dahlhausen VL and the King Vision™', 'time to vocal cords"", ""time to ventilate"", overall success rate, number of intubation attempts and optimization maneuvers, Cormack-Lehane score, severity of dental compression and subjective impressions']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0013963', 'cui_str': 'Paramedic'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0180453', 'cui_str': 'Laryngoscope'}, {'cui': 'C0021932', 'cui_str': 'Insertion of endotracheal tube'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}, {'cui': 'C0042930', 'cui_str': 'Vocal cord structure'}, {'cui': 'C0042491', 'cui_str': 'Ventilation'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C0332459', 'cui_str': 'Compression'}, {'cui': 'C0439655', 'cui_str': 'Subjective'}]",58.0,0.028898,"CONCLUSIONS VLs with hyperangulated blades facilitated ETI in both groups and decreased the failure rate by an absolute 11.1% when used by paramedics with little previous experience in ETI.","[{'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Moritz', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Veronika', 'Initials': 'V', 'LastName': 'Leonhardt', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Prottengeier', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Torsten', 'Initials': 'T', 'LastName': 'Birkholz', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Schmidt', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Irouschek', 'Affiliation': 'Department of Anesthesiology, University Hospital Erlangen, Faculty of Medicine, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.'}]",PloS one,['10.1371/journal.pone.0236474'] 2852,32730289,Acute effects of kinesiology tape tension on soleus muscle h-reflex modulations during lying and standing postures.,"Kinesiology tape (KT) has been widely used in the areas of sports and rehabilitation. However, there is no gold standard for the tape tension used during a KT application. The purpose of this study was to examine the effects of KT application with different tension intensities on soleus muscle Hoffmann-reflex (H-reflex) modulation during lying and standing postures. Fifteen healthy university students were tested with 3 tape tension intensities during separate visits with a randomized sequence: tape-on no tension (0KT), moderate (about 50% of the maximal tape tension: (ModKT), and maximal tape tension (MaxKT). During each experimental visit, the H-reflex measurements on the soleus muscle were taken before, during, and after the KT application for both lying and standing postures. The H-wave and M-wave recruitment curves were generated using surface electromyography (EMG). There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture. Even though the tension factor had a large effect (ηp2 = 0.165), different tape tensions showed no significant differential effects for the Hmax/Mmax ratio. The spinal motoneuron excitability was not altered, even during the maximal tension KT application on the soleus muscle. Thus, the tension used during a KT application should not be a concern in terms of modulating the sensorimotor activity ascribed to elastic taping during lying and standing postures.",2020,"There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture.",['Fifteen healthy university students'],"['kinesiology tape tension', '3 tape tension intensities during separate visits with a randomized sequence: tape-on no tension (0KT), moderate (about 50% of the maximal tape tension: (ModKT), and maximal tape tension (MaxKT', 'KT', 'Kinesiology tape (KT']","['spinal motoneuron excitability', 'soleus muscle Hoffmann-reflex (H-reflex) modulation', 'soleus muscle h-reflex modulations', 'maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}]","[{'cui': 'C0343138', 'cui_str': 'Strapping procedure'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0443299', 'cui_str': 'Separate'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0004793', 'cui_str': 'Base sequence'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}]","[{'cui': 'C0026609', 'cui_str': 'Motor neuron'}, {'cui': 'C0235169', 'cui_str': 'Excitability'}, {'cui': 'C0242694', 'cui_str': 'Soleus muscle structure'}, {'cui': 'C0034929', 'cui_str': 'Reflex'}, {'cui': 'C0018447', 'cui_str': 'H-reflex'}, {'cui': 'C0443264', 'cui_str': 'Modulated'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0034519', 'cui_str': 'Electromagnetic radiation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",,0.0133263,"There was a main effect for posture (p = 0.001) for the maximal peak-to-peak amplitude of the H-wave and M-wave (Hmax/Mmax) ratio, showing the depressed Hmax/Mmax ratio during standing, when compared to the lying posture.","[{'ForeName': 'Yung-Sheng', 'Initials': 'YS', 'LastName': 'Chen', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan.'}, {'ForeName': 'Wei-Chin', 'Initials': 'WC', 'LastName': 'Tseng', 'Affiliation': 'Department of Exercise and Health Sciences, University of Taipei, Taipei, Taiwan.'}, {'ForeName': 'Che-Hsiu', 'Initials': 'CH', 'LastName': 'Chen', 'Affiliation': 'Department of Sport Performance, National Taiwan University of Sports, Taichung, Taiwan.'}, {'ForeName': 'Pedro', 'Initials': 'P', 'LastName': 'Bezerra', 'Affiliation': 'Escola Superior de Desporto e Lazer, Instituto Politécnico de Viana do Castelo, Melgaço, Portugal.'}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, The University of Mississippi, Oxford, Mississippi, United States of America.'}]",PloS one,['10.1371/journal.pone.0236587'] 2853,32730561,Association of Nonoperative Management Using Antibiotic Therapy vs Laparoscopic Appendectomy With Treatment Success and Disability Days in Children With Uncomplicated Appendicitis.,"Importance Nonoperative management with antibiotics alone has the potential to treat uncomplicated pediatric appendicitis with fewer disability days than surgery. Objective To determine the success rate of nonoperative management and compare differences in treatment-related disability, satisfaction, health-related quality of life, and complications between nonoperative management and surgery in children with uncomplicated appendicitis. Design, Setting, and Participants Multi-institutional nonrandomized controlled intervention study of 1068 children aged 7 through 17 years with uncomplicated appendicitis treated at 10 tertiary children's hospitals across 7 US states between May 2015 and October 2018 with 1-year follow-up through October 2019. Of the 1209 eligible patients approached, 1068 enrolled in the study. Interventions Patient and family selection of nonoperative management with antibiotics alone (nonoperative group, n = 370) or urgent (≤12 hours of admission) laparoscopic appendectomy (surgery group, n = 698). Main Outcomes and Measures The 2 primary outcomes assessed at 1 year were disability days, defined as the total number of days the child was not able to participate in all of his/her normal activities secondary to appendicitis-related care (expected difference, 5 days), and success rate of nonoperative management, defined as the proportion of patients initially managed nonoperatively who did not undergo appendectomy by 1 year (lowest acceptable success rate, ≥70%). Inverse probability of treatment weighting (IPTW) was used to adjust for differences between treatment groups for all outcome assessments. Results Among 1068 patients who were enrolled (median age, 12.4 years; 38% girls), 370 (35%) chose nonoperative management and 698 (65%) chose surgery. A total of 806 (75%) had complete follow-up: 284 (77%) in the nonoperative group; 522 (75%) in the surgery group. Patients in the nonoperative group were more often younger (median age, 12.3 years vs 12.5 years), Black (9.6% vs 4.9%) or other race (14.6% vs 8.7%), had caregivers with a bachelor's degree (29.8% vs 23.5%), and underwent diagnostic ultrasound (79.7% vs 74.5%). After IPTW, the success rate of nonoperative management at 1 year was 67.1% (96% CI, 61.5%-72.31%; P = .86). Nonoperative management was associated with significantly fewer patient disability days at 1 year than did surgery (adjusted mean, 6.6 vs 10.9 days; mean difference, -4.3 days (99% CI, -6.17 to -2.43; P < .001). Of 16 other prespecified secondary end points, 10 showed no significant difference. Conclusion and Relevance Among children with uncomplicated appendicitis, an initial nonoperative management strategy with antibiotics alone had a success rate of 67.1% and, compared with urgent surgery, was associated with statistically significantly fewer disability days at 1 year. However, there was substantial loss to follow-up, the comparison with the prespecified threshold for an acceptable success rate of nonoperative management was not statistically significant, and the hypothesized difference in disability days was not met. Trial Registration ClinicalTrials.gov Identifier: NCT02271932.",2020,"Patients in the nonoperative group were more often younger (median age, 12.3 years vs 12.5 years), Black (9.6% vs 4.9%) or other race (14.6% vs 8.7%), had caregivers with a bachelor's degree (29.8% vs 23.5%), and underwent diagnostic ultrasound (79.7% vs 74.5%).","['1209 eligible patients approached, 1068 enrolled in the study', ""1068 children aged 7 through 17 years with uncomplicated appendicitis treated at 10 tertiary children's hospitals across 7 US states between May 2015 and October 2018 with 1-year follow-up through October 2019"", 'Children With Uncomplicated Appendicitis', 'children with uncomplicated appendicitis', '1068 patients who were enrolled (median age, 12.4 years; 38% girls), 370 (35%) chose nonoperative management and 698 (65%) chose surgery']","['Antibiotic Therapy vs Laparoscopic Appendectomy', 'antibiotics alone', 'antibiotics alone (nonoperative group, n\u2009=\u2009370) or urgent (≤12 hours of admission) laparoscopic appendectomy (surgery group, n\u2009=\u2009698']","['total number of days the child was not able to participate in all of his/her normal activities secondary to appendicitis-related care', 'disability, satisfaction, health-related quality of life, and complications', 'patient disability days', 'Inverse probability of treatment weighting (IPTW', 'success rate', 'success rate of nonoperative management']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0443334', 'cui_str': 'Uncomplicated'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0591126', 'cui_str': 'AT-10'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0020017', 'cui_str': ""Children's hospital""}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C4517543', 'cui_str': '12.4'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C4517743', 'cui_str': '370'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0372525', 'cui_str': 'Laparoscopic appendectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4517743', 'cui_str': '370'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0439227', 'cui_str': 'hour'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0003615', 'cui_str': 'Appendicitis'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439850', 'cui_str': 'Inverse'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0001554', 'cui_str': 'Administration'}]",1068.0,0.123447,"Patients in the nonoperative group were more often younger (median age, 12.3 years vs 12.5 years), Black (9.6% vs 4.9%) or other race (14.6% vs 8.7%), had caregivers with a bachelor's degree (29.8% vs 23.5%), and underwent diagnostic ultrasound (79.7% vs 74.5%).","[{'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Minneci', 'Affiliation': ""Center for Surgical Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.""}, {'ForeName': 'Erinn M', 'Initials': 'EM', 'LastName': 'Hade', 'Affiliation': 'Departments of Biomedical Informatics and Obstetrics & Gynecology, The Ohio State University College of Medicine, Columbus, Ohio.'}, {'ForeName': 'Amy E', 'Initials': 'AE', 'LastName': 'Lawrence', 'Affiliation': ""Center for Surgical Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.""}, {'ForeName': 'Yuri V', 'Initials': 'YV', 'LastName': 'Sebastião', 'Affiliation': ""Center for Surgical Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.""}, {'ForeName': 'Jacqueline M', 'Initials': 'JM', 'LastName': 'Saito', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri.'}, {'ForeName': 'Grace Z', 'Initials': 'GZ', 'LastName': 'Mak', 'Affiliation': 'Section of Pediatric Surgery, Department of Surgery, University of Chicago Medicine and Biologic Sciences, Chicago, Illinois.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Fox', 'Affiliation': 'Section of Pediatric Surgery, Department of Surgery, University of Chicago Medicine and Biologic Sciences, Chicago, Illinois.'}, {'ForeName': 'Ronald B', 'Initials': 'RB', 'LastName': 'Hirschl', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Michigan School of Medicine, Ann Arbor.'}, {'ForeName': 'Samir', 'Initials': 'S', 'LastName': 'Gadepalli', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Michigan School of Medicine, Ann Arbor.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Helmrath', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.'}, {'ForeName': 'Jonathan E', 'Initials': 'JE', 'LastName': 'Kohler', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.'}, {'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'Leys', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.'}, {'ForeName': 'Thomas T', 'Initials': 'TT', 'LastName': 'Sato', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee.'}, {'ForeName': 'Dave R', 'Initials': 'DR', 'LastName': 'Lal', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee.'}, {'ForeName': 'Matthew P', 'Initials': 'MP', 'LastName': 'Landman', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis.'}, {'ForeName': 'Rashmi', 'Initials': 'R', 'LastName': 'Kabre', 'Affiliation': ""Division of Pediatric Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'ForeName': 'Mary E', 'Initials': 'ME', 'LastName': 'Fallat', 'Affiliation': 'Division of Pediatric Surgery, Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky.'}, {'ForeName': 'Jennifer N', 'Initials': 'JN', 'LastName': 'Cooper', 'Affiliation': ""Center for Surgical Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.""}, {'ForeName': 'Katherine J', 'Initials': 'KJ', 'LastName': 'Deans', 'Affiliation': ""Center for Surgical Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JAMA,['10.1001/jama.2020.10888'] 2854,32730613,Effect of an Early Palliative Care Telehealth Intervention vs Usual Care on Patients With Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial.,"Importance National guidelines recommend early palliative care for patients with advanced heart failure, which disproportionately affects rural and minority populations. Objective To determine the effect of an early palliative care telehealth intervention over 16 weeks on the quality of life, mood, global health, pain, and resource use of patients with advanced heart failure. Design, Setting, and Participants A single-blind, intervention vs usual care randomized clinical trial was conducted from October 1, 2015, to May 31, 2019, among 415 patients 50 years or older with New York Heart Association class III or IV heart failure or American College of Cardiology stage C or D heart failure at a large Southeastern US academic tertiary medical center and a Veterans Affairs medical center serving high proportions of rural dwellers and African American individuals. Interventions The ENABLE CHF-PC (Educate, Nurture, Advise, Before Life Ends Comprehensive Heartcare for Patients and Caregivers) intervention comprises an in-person palliative care consultation and 6 weekly nurse-coach telephonic sessions (20-40 minutes) and monthly follow-up for 48 weeks. Main Outcomes and Measures Primary outcomes were quality of life (as measured by the Kansas City Cardiomyopathy Questionnaire [KCCQ]: score range, 0-100; higher scores indicate better perceived health status and clinical summary scores ≥50 are considered ""fairly good"" quality of life; and the Functional Assessment of Chronic Illness Therapy-Palliative-14 [FACIT-Pal-14]: score range, 0-56; higher scores indicate better quality of life) and mood (as measured by the Hospital Anxiety and Depression Scale [HADS]) over 16 weeks. Secondary outcomes were global health (Patient Reported Outcome Measurement System Global Health), pain (Patient Reported Outcome Measurement System Pain Intensity and Interference), and resource use (hospital days and emergency department visits). Results Of 415 participants (221 men; baseline mean [SD] age, 63.8 [8.5] years) randomized to ENABLE CHF-PC (n = 208) or usual care (n = 207), 226 (54.5%) were African American, 108 (26.0%) lived in a rural area, and 190 (45.8%) had a high-school education or less, and a mean (SD) baseline KCCQ score of 52.6 (21.0). At week 16, the mean (SE) KCCQ score improved 3.9 (1.3) points in the intervention group vs 2.3 (1.2) in the usual care group (difference, 1.6; SE, 1.7; d = 0.07 [95% CI, -0.09 to 0.24]) and the mean (SE) FACIT-Pal-14 score improved 1.4 (0.6) points in the intervention group vs 0.2 (0.5) points in the usual care group (difference, 1.2; SE, 0.8; d = 0.12 [95% CI, -0.03 to 0.28]). There were no relevant between-group differences in mood (HADS-anxiety, d = -0.02 [95% CI, -0.20 to 0.16]; HADS-depression, d = -0.09 [95% CI, -0.24 to 0.06]). Conclusions and Relevance This randomized clinical trial with a majority African American sample and baseline good quality of life did not demonstrate improved quality of life or mood with a 16-week early palliative care telehealth intervention. However, pain intensity and interference (secondary outcomes) demonstrated a clinically important improvement. Trial Registration ClinicalTrials.gov Identifier: NCT02505425.",2020,"At week 16, the mean (SE) KCCQ score improved 3.9 (1.3) points in the intervention group vs 2.3 (1.2) in the usual care group (difference, 1.6; SE, 1.7; d = 0.07 [95% CI, -0.09 to 0.24]) and the mean (SE) FACIT-Pal-14 score improved 1.4 (0.6) points in the intervention group vs 0.2 (0.5) points in the usual care group (difference, 1.2; SE, 0.8; d = 0.12 [95% CI, -0.03 to 0.28]).","['patients with advanced heart failure, which disproportionately affects rural and minority populations', '415 patients 50 years or older with New York Heart Association class III or IV heart failure or American College of Cardiology stage C or D heart failure at a large Southeastern US academic tertiary medical center and a Veterans Affairs medical center serving high proportions of rural dwellers and African American individuals', 'Patients and Caregivers', '415 participants (221 men', ' baseline mean [SD] age, 63.8 [8.5] years) randomized to ENABLE CHF-PC (n\u2009=\u2009208) or usual care (n\u2009=\u2009207), 226 (54.5%) were African American, 108 (26.0%) lived in a rural area, and 190 (45.8%) had a high-school education or less, and a mean (SD) baseline KCCQ score of 52.6 (21.0', 'patients with advanced heart failure', 'Patients With Heart Failure']","['early palliative care telehealth intervention', 'Early Palliative Care Telehealth Intervention vs Usual Care', 'person palliative care consultation and 6 weekly nurse-coach telephonic sessions']","['mean (SE) KCCQ score', 'pain intensity and interference', 'quality of life (as measured by the Kansas City Cardiomyopathy Questionnaire [KCCQ]: score range, 0-100; higher scores indicate better perceived health status and clinical summary scores ≥50 are considered ""fairly good"" quality of life; and the Functional Assessment of Chronic Illness Therapy-Palliative-14 [FACIT-Pal-14]: score range, 0-56; higher scores indicate better quality of life) and mood (as measured by the Hospital Anxiety and Depression Scale [HADS', 'global health (Patient Reported Outcome Measurement System Global Health), pain (Patient Reported Outcome Measurement System Pain Intensity and Interference), and resource use (hospital days and emergency department visits', 'quality of life, mood, global health, pain, and resource use', 'mood (HADS-anxiety, d\u2009', 'quality of life or mood', 'mean (SE) FACIT-Pal-14 score']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0018801', 'cui_str': 'Heart failure'}, {'cui': 'C0001721', 'cui_str': 'Affect'}, {'cui': 'C0026192', 'cui_str': 'Minority Groups'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4517772', 'cui_str': '415'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0441887', 'cui_str': 'Class 3'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0007189', 'cui_str': 'Cardiology'}, {'cui': 'C0441785', 'cui_str': 'Stage C'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0205372', 'cui_str': 'Tertiary'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0085756', 'cui_str': 'African American'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0085537', 'cui_str': 'Caregiver'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517877', 'cui_str': '8.5'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C4517622', 'cui_str': '190'}, {'cui': 'C0455002', 'cui_str': 'Education and schooling detail'}, {'cui': 'C0449820', 'cui_str': 'Score'}]","[{'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0162648', 'cui_str': 'Telemedicine'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0009818', 'cui_str': 'Consultation'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0028661', 'cui_str': 'Nursing personnel'}, {'cui': 'C0557773', 'cui_str': 'Coach'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathy'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018759', 'cui_str': 'Health status'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0278372', 'cui_str': 'Functional assessment'}, {'cui': 'C0008679', 'cui_str': 'Chronic disease'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0030360', 'cui_str': 'Papillon-Lefèvre syndrome'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C3539657', 'cui_str': 'Hospital anxiety and depression scale'}, {'cui': 'C1456573', 'cui_str': 'Global Health'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0085104', 'cui_str': 'Drug Targeting'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0587438', 'cui_str': 'Day hospital'}, {'cui': 'C0586082', 'cui_str': 'Emergency department patient visit'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}]",,0.155537,"At week 16, the mean (SE) KCCQ score improved 3.9 (1.3) points in the intervention group vs 2.3 (1.2) in the usual care group (difference, 1.6; SE, 1.7; d = 0.07 [95% CI, -0.09 to 0.24]) and the mean (SE) FACIT-Pal-14 score improved 1.4 (0.6) points in the intervention group vs 0.2 (0.5) points in the usual care group (difference, 1.2; SE, 0.8; d = 0.12 [95% CI, -0.03 to 0.28]).","[{'ForeName': 'Marie A', 'Initials': 'MA', 'LastName': 'Bakitas', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'J Nicholas', 'Initials': 'JN', 'LastName': 'Dionne-Odom', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Deborah B', 'Initials': 'DB', 'LastName': 'Ejem', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Wells', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Azuero', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Macy L', 'Initials': 'ML', 'LastName': 'Stockdill', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Konda', 'Initials': 'K', 'LastName': 'Keebler', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Sockwell', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Sheri', 'Initials': 'S', 'LastName': 'Tims', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Engler', 'Affiliation': 'School of Nursing, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Steinhauser', 'Affiliation': 'Center for Innovation, Veterans Affairs Medical Center, Durham, North Carolina.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kvale', 'Affiliation': 'Department of Medicine, Dell Medical School, University of Texas at Austin, Austin.'}, {'ForeName': 'Raegan W', 'Initials': 'RW', 'LastName': 'Durant', 'Affiliation': 'Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Rodney O', 'Initials': 'RO', 'LastName': 'Tucker', 'Affiliation': 'Division of Gerontology, Geriatrics and Palliative Care, UAB Center for Palliative and Supportive Care, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Burgio', 'Affiliation': 'Division of Gerontology, Geriatrics and Palliative Care, UAB Center for Palliative and Supportive Care, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Tallaj', 'Affiliation': 'Division of Cardiovascular Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Keith M', 'Initials': 'KM', 'LastName': 'Swetz', 'Affiliation': 'Division of Gerontology, Geriatrics and Palliative Care, UAB Center for Palliative and Supportive Care, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}, {'ForeName': 'Salpy V', 'Initials': 'SV', 'LastName': 'Pamboukian', 'Affiliation': 'Division of Cardiovascular Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham.'}]",JAMA internal medicine,['10.1001/jamainternmed.2020.2861'] 2855,32730628,Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.,"AIM Platelet inhibition induced by P2Y12 receptor antagonists in patients with ST-elevation myocardial infarction (STEMI) can be affected by concomitant use of opioids. The aim of this trial was to examine the effect of intravenous (iv) acetaminophen compared with iv fentanyl on P2Y12 receptor inhibition in patients with STEMI. METHODS AND RESULTS The ON-TIME 3 trial randomised 195 STEMI patients who were scheduled to undergo primary percutaneous coronary intervention (PCI) and were pre-treated with crushed ticagrelor to iv acetaminophen (N = 98) or iv fentanyl (N = 97) in the ambulance.The primary endpoint, consisting of the level of platelet reactivity units (PRU) measured immediately after primary PCI, was not significantly different between the study arms (median PRU 104 [IQR 37-215] vs. 175 [63-228], P = 0.18). However, systemic levels of ticagrelor were significantly higher in the acetaminophen arm at the start of primary PCI (151 ng/mL [32-509] vs. 60 ng/mL [13-206], P = 0.007), immediately after primary PCI (326 ng/mL [94-791] vs. 115 ng/mL [38-326], P = 0.002) and at one-hour after primary PCI (488 ng/mL [281-974]) vs. 372 ng/mL [95-635], P = 0.002). Acetaminophen resulted in the same extent of pain relief as compared to fentanyl (reduction of 3 points on 10-step-pain scale before primary PCI [IQR 1-5] in both study arms (P = 0.67) and immediately after PCI (reduction of 5 points [3-7]; P = 0.96). CONCLUSION Iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients, but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.",2020,"Iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients, but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.","['patients with ST-elevation myocardial infarction (STEMI', '195 STEMI patients who were scheduled to undergo primary percutaneous coronary intervention (PCI) and were pre-treated with', 'patients with STEMI', '94-791] vs. 115', 'patients with ST-elevation myocardial infarction who are pre-treated with']","['Acetaminophen', 'opioids', 'crushed ticagrelor: Opioids aNd crushed Ticagrelor', 'P2Y12 receptor antagonists', 'intravenous (iv) acetaminophen', 'crushed ticagrelor to iv acetaminophen (N\u2009=\u200998) or iv fentanyl', 'acetaminophen']","['platelet reactivity', 'pain relief', 'ticagrelor plasma levels', 'P2Y12-receptor inhibition', 'level of platelet reactivity units (PRU', 'systemic levels of ticagrelor']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1303258', 'cui_str': 'Acute ST segment elevation myocardial infarction'}, {'cui': 'C4517624', 'cui_str': '195'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C4517540', 'cui_str': '115'}]","[{'cui': 'C0000970', 'cui_str': 'Acetaminophen'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0185060', 'cui_str': 'Crushing'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C2936585', 'cui_str': 'P2Y12 Purinoceptor Antagonists'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0015846', 'cui_str': 'Fentanyl'}]","[{'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0443286', 'cui_str': 'Reaction'}, {'cui': 'C0451615', 'cui_str': 'Pain relief'}, {'cui': 'C1999375', 'cui_str': 'Ticagrelor'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0034783', 'cui_str': 'Adrenergic receptor'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0439148', 'cui_str': 'Unit'}, {'cui': 'C0205373', 'cui_str': 'Systemic'}]",195.0,0.14291,"Iv acetaminophen in comparison with iv fentanyl was not associated with significantly lower platelet reactivity in STEMI patients, but resulted in significantly higher ticagrelor plasma levels and was effective in pain relief.","[{'ForeName': 'A H', 'Initials': 'AH', 'LastName': 'Tavenier', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'R S', 'Initials': 'RS', 'LastName': 'Hermanides', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'J P', 'Initials': 'JP', 'LastName': 'Ottervanger', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Tolsma', 'Affiliation': 'RAV IJsselland, Zwolle, The Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'van Beurden', 'Affiliation': 'GGD Zuid-Limburg, Heerlen, The Netherlands.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Slingerland', 'Affiliation': 'Department of Clinical Chemistry, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'P G J', 'Initials': 'PGJ', 'LastName': 'Ter Horst', 'Affiliation': 'Department of Clinical Pharmacy, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'A T M', 'Initials': 'ATM', 'LastName': 'Gosselink', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'J H E', 'Initials': 'JHE', 'LastName': 'Dambrink', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'M A H', 'Initials': 'MAH', 'LastName': 'van Leeuwen', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Roolvink', 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Kedhi', 'Affiliation': 'Department of Cardiology, AZ Sint-Jan, Brugge, Belgium.'}, {'ForeName': 'O H', 'Initials': 'OH', 'LastName': 'Klungel', 'Affiliation': 'Department of Pharmacoepidemiology, University of Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'Belitser', 'Affiliation': 'Department of Pharmacoepidemiology, University of Utrecht, Utrecht, the Netherlands.'}, {'ForeName': 'D J', 'Initials': 'DJ', 'LastName': 'Angiolillo', 'Affiliation': 'Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States of America.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pustjens', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, The Netherlands.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Rasoul', 'Affiliation': 'Department of Cardiology, Maastricht University Medical Centre, The Netherlands.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Gho', 'Affiliation': 'Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Stein', 'Affiliation': 'Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Ruiters', 'Affiliation': 'Department of Cardiology, Zuyderland Medical Centre, Heerlen, The Netherlands.'}, {'ForeName': 'A W J', 'Initials': 'AWJ', 'LastName': ""van 't Hof"", 'Affiliation': 'Department of Cardiology, Isala, Zwolle, The Netherlands.'}]",European heart journal. Cardiovascular pharmacotherapy,['10.1093/ehjcvp/pvaa095'] 2856,32730719,Robotic approach to the reduction of dental anxiety in children.,"OBJECTIVE We introduced a humanoid robot for the use of techno-psychological distraction techniques in children aged 4-10 to reduce their anxiety and improve their behaviour during dental treatment. MATERIALS AND METHODS Two hundred children (98 boys, 102 girls; mean age: 6.5 ± 1.66 years) appointed for first time for dental caries were included and randomly divided into two groups [ N  = 100 for each group; RG: Robot Group (accompanied by the robot), CG: Control Group (without robot accompaniment)]. Half of the children were treated under local anaesthesia (infiltration anaesthesia) ( n  = 50 within each group) and half of the children were treated without any local anaesthesia ( n  = 50 within each group) within each group. The success rate of the new robotic distraction technique was evaluated by using Parental Corah Dental Anxiety Scale, Facial Image Scale (FIS), physiological pulse rate and Frankl Behaviour Rating Scale (FBRS). RESULT Pulse rates, which measured during treatment and after treatment, were statistically higher in CG than in RG ( p  < .05). After dental treatment, the FIS score was significantly higher in CG than RG ( p  < .05). 88.3% of the children in RG stated that they wanted the robot to be with them at the next treatment session. CONCLUSIONS Robotic technology can successfully help in coping with dental anxiety and stress, and helps children to behave better in dental office.",2020,"After dental treatment, the FIS score was significantly higher in CG than RG ( p  < .05).","['Two hundred children (98 boys, 102 girls; mean age: 6.5\u2009±\u20091.66\u2009years) appointed for first time for dental caries', 'children aged 4-10', 'children']","['Robotic approach', 'local anaesthesia', 'humanoid robot', 'Robotic technology', 'RG: Robot Group (accompanied by the robot), CG: Control Group (without robot accompaniment', 'local anaesthesia (infiltration anaesthesia']","['success rate of the new robotic distraction technique', 'Parental Corah Dental Anxiety Scale, Facial Image Scale (FIS), physiological pulse rate and Frankl Behaviour Rating Scale (FBRS', 'dental anxiety', 'FIS score']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3844007', 'cui_str': '6.5'}, {'cui': 'C4517510', 'cui_str': '1.66'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0011334', 'cui_str': 'Dental caries'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C1292724', 'cui_str': 'Procedural approach'}, {'cui': 'C0002921', 'cui_str': 'Local anesthesia'}, {'cui': 'C0336537', 'cui_str': 'Robot'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0234945', 'cui_str': 'Infiltration anaesthesia'}]","[{'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0150189', 'cui_str': 'Distraction training'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0475483', 'cui_str': 'Behavior rating scale'}, {'cui': 'C3489630', 'cui_str': 'Isolated Familial Somatotropinoma'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",200.0,0.0252787,"After dental treatment, the FIS score was significantly higher in CG than RG ( p  < .05).","[{'ForeName': 'Yelda', 'Initials': 'Y', 'LastName': 'Kasimoglu', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Simin', 'Initials': 'S', 'LastName': 'Kocaaydin', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Karsli', 'Affiliation': 'Department of Orthodontics, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Merve', 'Initials': 'M', 'LastName': 'Esen', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.'}, {'ForeName': 'Irmak', 'Initials': 'I', 'LastName': 'Bektas', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Marmara University, Istanbul, Turkey.'}, {'ForeName': 'Gökhan', 'Initials': 'G', 'LastName': 'Ince', 'Affiliation': 'Department of Computer Engineering, Istanbul Technical University, Istanbul, Turkey.'}, {'ForeName': 'Elif Bahar', 'Initials': 'EB', 'LastName': 'Tuna', 'Affiliation': 'Department of Pediatric Dentistry, Faculty of Dentistry, Istanbul University, Istanbul, Turkey.'}]",Acta odontologica Scandinavica,['10.1080/00016357.2020.1800084'] 2857,32736540,Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.,"BACKGROUND The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of accuracy in identifying HR patients with conventional risk factors (large, deep, FNCLCC grade 3, extremity STS) is an issue that cannot be neglected. For example, while the FNCLCC grading system is a powerful tool, it has several limitations. CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade. Regardless of FNCLCC grade, CINSARC stratifies patients into two separate prognostic groups: one with an excellent prognosis (low-risk (LR) CINSARC) and the other with a worse outcome (HR-CINSARC) in terms of metastatic relapse. Here we evaluate the role of chemotherapy in grade 1-2 STS patients with HR-CINSARC and assess the prognostic value of CINSARC in patients treated with standard of care. METHODS CHIC is a parallel, randomized, open-label, multicenter study evaluating the effect on metastasis-free survival of adding perioperative chemotherapy to standard of care in patients with grade ½ STS sarcoma defined as HR by CINSARC. In this target selection design, 600 patients will be screened with CINSARC to randomize 250 HR-CINSARC patients between standard of care and standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype). LR-CINSARC patients will be treated by standard of care according to the investigator. The primary endpoint is metastasis-free survival. Secondary endpoints include overall survival, disease-free survival and safety. Furthermore, the prognostic value of CINSARC will be evaluated by comparing LR-CINSARC patients to HR-CINSARC patients randomized in standard of care. DISCUSSION CHIC is a prospective randomized phase III trial designed to comprehensively evaluate the benefit of chemotherapy in HR-CINSARC patients and to prospectively validate the prognostic value of CINSARC in grade ½ STS sarcoma patients. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT04307277 Date of registration: 13 March 2020.",2020,"CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade.","['soft tissue sarcoma (STS', '600 patients will be screened with CINSARC to randomize 250 HR-CINSARC patients between standard of care and standard of', 'patients with grade ½ STS sarcoma defined as HR by CINSARC', 'grade ½ STS sarcoma patients', 'grade 1-2 STS patients with HR-CINSARC and assess the prognostic value of CINSARC in patients treated with standard of care', 'patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma']","['care plus chemotherapy', 'perioperative chemotherapy', 'intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide', 'peri-operative chemotherapy']","['overall survival, disease-free survival and safety', 'metastasis-free survival']","[{'cui': 'C1261473', 'cui_str': 'Sarcoma'}, {'cui': 'C3816748', 'cui_str': '600'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C2348831', 'cui_str': '250'}, {'cui': 'C0332167', 'cui_str': 'High risk of'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0392752', 'cui_str': 'Localized'}]","[{'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0413365', 'cui_str': 'Intravenous chemotherapy'}, {'cui': 'C0013089', 'cui_str': 'Doxorubicin'}, {'cui': 'C0010927', 'cui_str': 'Dacarbazine'}, {'cui': 'C0020823', 'cui_str': 'Ifosfamide'}, {'cui': 'C0347985', 'cui_str': 'During values'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242793', 'cui_str': 'Survival, Disease-Free'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332296', 'cui_str': 'Free of'}]",600.0,0.117648,"CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade.","[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Filleron', 'Affiliation': 'Biostatistics Unit, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse Cedex, France. Filleron.thomas@iuct-oncopole.fr.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Le Guellec', 'Affiliation': 'Department of Pathology, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Chevreau', 'Affiliation': 'Department of Medical Oncology, Institut Claudius Regaud IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Bastien', 'Initials': 'B', 'LastName': 'Cabarrou', 'Affiliation': 'Biostatistics Unit, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse Cedex, France.'}, {'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Lesluyes', 'Affiliation': 'INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.'}, {'ForeName': 'Sabrina', 'Initials': 'S', 'LastName': 'Lodin', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Angélique', 'Initials': 'A', 'LastName': 'Massoubre', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Mounier', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Muriel', 'Initials': 'M', 'LastName': 'Poublanc', 'Affiliation': 'Clinical Trials Office, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Chibon', 'Affiliation': 'Department of Pathology, Institut Claudius Regaud, IUCT-O, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.'}, {'ForeName': 'Thibaud', 'Initials': 'T', 'LastName': 'Valentin', 'Affiliation': 'INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.'}]",BMC cancer,['10.1186/s12885-020-07207-3'] 2858,32736542,"Study protocol of the Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE) trial: a two-arm, two-centre randomized controlled trial.","BACKGROUND Up to 75% of women diagnosed with breast cancer report chemotherapy-related cognitive changes (CRCC) during treatment, including decreased memory, attention, and processing speed. Though CRCC negatively impacts everyday functioning and reduces overall quality of life in women diagnosed with breast cancer, effective interventions to prevent and/or manage CRCC are elusive. Consequently, women seldom receive advice on how to prevent or manage CRCC. Aerobic exercise is associated with improved cognitive functioning in healthy older adults and adults with cognitive impairments. Accordingly, it holds promise as an intervention to prevent and/or manage CRCC. However, evidence from randomized controlled trials (RCTs) supporting a beneficial effect of aerobic exercise on CRCC is limited. The primary aim of the ACTIVATE trial is to evaluate the impact of supervised aerobic exercise on CRCC in women receiving chemotherapy for breast cancer. METHODS The ACTIVATE trial is a two-arm, two-centre RCT. Women diagnosed with stage I-III breast cancer and awaiting neo-adjuvant or adjuvant chemotherapy are recruited from hospitals in Ottawa (Ontario) and Vancouver (British Columbia), Canada. Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy). The primary outcome is cognitive functioning as measured by a composite cognitive summary score (COGSUM) of several neuropsychological tests. Secondary outcomes are self-reported cognitive functioning, quality of life, and brain structure and functioning (measured by magnetic resonance imaging (MRI)/functional MRI and electroencephalography). Assessments take place pre-chemotherapy (pre-intervention), mid-way through chemotherapy (mid-intervention/mid-wait period), end of chemotherapy (post-intervention/post-wait period; primary endpoint), 16-weeks post-chemotherapy, and at 1-year post-baseline. DISCUSSION Aerobic exercise is a promising intervention for preventing and/or managing CRCC and enhancing quality of life among women diagnosed with breast cancer. The ACTIVATE trial tests several novel hypotheses, including that aerobic exercise can prevent and/or mitigate CRCC and that this effect is mediated by the timing of intervention delivery (i.e., during versus post-chemotherapy). Findings may support prescribing exercise during (or post-) chemotherapy for breast cancer and elucidate the potential role of aerobic exercise as a management strategy for CRCC in women with early-stage breast cancer. TRIAL REGISTRATION The trial was registered with the ClinicalTrials.gov database ( NCT03277898 ) on September 11, 2017.",2020,Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy).,"['women diagnosed with breast cancer report chemotherapy-related cognitive changes (CRCC', 'women receiving chemotherapy for breast cancer', 'women with breAsT cancEr', 'Women diagnosed with stage I-III breast cancer and awaiting neo-adjuvant or adjuvant chemotherapy are recruited from hospitals in Ottawa (Ontario) and Vancouver (British Columbia), Canada', 'women diagnosed with breast cancer', 'women with early-stage breast cancer', 'healthy older adults and adults with cognitive impairments']","['CRCC', 'supervised aerobic exercise', 'Aerobic exercise', 'Aerobic exercise and CogniTIVe functioning', 'intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy', 'prescribing exercise during (or post-) chemotherapy', 'aerobic exercise']","['self-reported cognitive functioning, quality of life, and brain structure and functioning (measured by magnetic resonance imaging (MRI)/functional MRI and electroencephalography', 'cognitive functioning as measured by a composite cognitive summary score (COGSUM) of several neuropsychological tests', 'overall quality of life', 'cognitive functioning']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0006142', 'cui_str': 'Malignant tumor of breast'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006193', 'cui_str': 'British Columbia'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C2363430', 'cui_str': 'Early stage'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}]","[{'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439577', 'cui_str': 'Post-chemotherapy'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0687676', 'cui_str': 'After values'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0392334', 'cui_str': 'Ability to perform cognitive activity'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0006104', 'cui_str': 'Brain structure'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0013819', 'cui_str': 'Electroencephalogram'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",,0.341436,Recruits are randomized to the intervention group (aerobic exercise during chemotherapy) or the wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy).,"[{'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Brunet', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, 125 University Private, Montpetit Hall, Ottawa, ON, K1N 6N5, Canada. jennifer.brunet@uottawa.ca.'}, {'ForeName': 'Meagan', 'Initials': 'M', 'LastName': 'Barrett-Bernstein', 'Affiliation': 'School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, 125 University Private, Montpetit Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Kendra', 'Initials': 'K', 'LastName': 'Zadravec', 'Affiliation': 'Rehabiliation Sciences Graduate Program, Faculty of Medicine, University of British Columbia, T114-2211 Wesbrook Mall, Vancouver, BC, V6T 1Z7, Canada.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Taljaard', 'Affiliation': 'The Ottawa Hospital Research Institute, Clinical Epidemiology Program, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'LeVasseur', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.'}, {'ForeName': 'Amirrtha', 'Initials': 'A', 'LastName': 'Srikanthan', 'Affiliation': 'Department of Medicine, The Ottawa Hospital, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.'}, {'ForeName': 'Kelcey A', 'Initials': 'KA', 'LastName': 'Bland', 'Affiliation': 'Mary MacKillop Institute for Health Research, Australian Catholic University, Level 5, 215 Spring Street, Melbourne, VIC, 3000, Australia.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Collins', 'Affiliation': 'School of Psychology, Faculty of Social Sciences, University of Ottawa, 136 Jean-Jacques Lussier, Vanier Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Julia W Y', 'Initials': 'JWY', 'LastName': 'Kam', 'Affiliation': 'Department of Psychology & Hotchkiss Brain Institute, University of Calgary, 2500 Campus Drive, Calgary, AB, T2N 1N4, Canada.'}, {'ForeName': 'Todd C', 'Initials': 'TC', 'LastName': 'Handy', 'Affiliation': 'Department of Psychology, University of British Columbia, 3406-2136 West Mall, Vancouver, BC, V6T 1Z4, Canada.'}, {'ForeName': 'Sherri', 'Initials': 'S', 'LastName': 'Hayden', 'Affiliation': 'Division of Neurology/Faculty of Medicine, University of British Columbia, P213-2211 Westbrook Mall, Vancouver, BC, V6T 2B5, Canada.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Simmons', 'Affiliation': 'British Columbia Cancer Agency, Vancouver, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.'}, {'ForeName': 'Andra M', 'Initials': 'AM', 'LastName': 'Smith', 'Affiliation': 'School of Psychology, Faculty of Social Sciences, University of Ottawa, 136 Jean-Jacques Lussier, Vanier Hall, Ottawa, ON, K1N 6N5, Canada.'}, {'ForeName': 'Naznin', 'Initials': 'N', 'LastName': 'Virji-Babul', 'Affiliation': 'Department of Physical Therapy, Faculty of Medicine, University of British Columbia, 2215 Westbrook Mall, Vancouver, BC, V6T 1Z3, Canada.'}, {'ForeName': 'Kristin L', 'Initials': 'KL', 'LastName': 'Campbell', 'Affiliation': 'Department of Physical Therapy, Faculty of Medicine, University of British Columbia, 2215 Westbrook Mall, Vancouver, BC, V6T 1Z3, Canada.'}]",BMC cancer,['10.1186/s12885-020-07196-3'] 2859,32736555,Experiential learning for children's dental anxiety: a cluster randomized trial.,"BACKGROUND Dental anxiety (DA) has an impact on the quality of dental treatment and may have long-lasting implications for children. A recent study introducing experiential learning (EL) into children's oral health promotion resulted in better oral hygiene. The purpose of the study is to evaluate whether EL can reduce children's DA. METHODS In September 2018, we recruited 988 children aged 7-8 years from 24 classes to participate in a cluster-randomized trial. Classes were randomly assigned to EL (in which children received a lively presentation on oral health and participated in a role play in a simulated dental clinic in the classroom) or the Tell-Show-Do (TSD) group (in which children received a conventional TSD behavior management). The primary outcome was the prevalence of high DA after the procedure of pit and fissure sealant (PFS), assessed by a modified Children's Fear Survey Schedule-Dental Subscale. Secondary outcomes were changes in blood pressures (BP) and pulse rates (PR) before and after the PFS procedure. The intervention effects were estimated by means of mixed effect models, which included covariates of gender and school (and baseline value for BP and PR only), and a random cluster effect. RESULTS In 396 children of the EL group who received the PFS treatment, the prevalence of high DA (score ≥ 38) was 18.5%, compared with 24.3% in 391 children of the TSD group (OR = 0.65; 95% confidence interval, 0.46-0.93; P = 0.019). The increases in BP and PR after the PFS were also significantly less in the EL group. CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. TRIAL REGISTRATION The trial was registered in Chinese Clinical Trial Registry on 5 January 2020 (No.: ChiCTR2000028878 , retrospectively registered).",2020,"CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. ","['In September 2018, we recruited 988 children aged 7-8\u2009years from 24 classes to participate in a cluster-randomized trial', ""children's dental anxiety"", '396 children of the EL group who received the', 'children']","['Experiential learning', 'PFS', 'lively presentation on oral health and participated in a role play in a simulated dental clinic in the classroom) or the Tell-Show-Do (TSD', 'experiential learning (EL', 'EL', 'School-based experiential learning intervention', 'conventional TSD behavior management']","['changes in blood pressures (BP) and pulse rates (PR', 'BP and PR', 'prevalence of high DA', ""prevalence of high DA after the procedure of pit and fissure sealant (PFS), assessed by a modified Children's Fear Survey Schedule-Dental Subscale""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0456387', 'cui_str': 'Class'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C5191354', 'cui_str': '396'}, {'cui': 'C0680063', 'cui_str': 'Child of'}, {'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0243012', 'cui_str': 'Active Learning'}, {'cui': 'C0031992', 'cui_str': 'Pit Fissure Sealants'}, {'cui': 'C0449450', 'cui_str': 'Presentation'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0284447', 'cui_str': 'Simulate composite resin'}, {'cui': 'C0011344', 'cui_str': 'Dental clinic'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0150143', 'cui_str': 'Behavior management'}]","[{'cui': 'C1268766', 'cui_str': 'Blood pressure alteration'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0232117', 'cui_str': 'Pulse rate'}, {'cui': 'C0033105', 'cui_str': 'Prevalence'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0085380', 'cui_str': 'Dental phobia'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0031992', 'cui_str': 'Pit Fissure Sealants'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0451158', 'cui_str': 'Fear survey schedule'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}]",988.0,0.160375,"CONCLUSION School-based experiential learning intervention before a dental visit is feasible and effective in reducing children's dental anxiety during PFS. ","[{'ForeName': 'Minmin', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China. zhuminmin1982@163.com.'}, {'ForeName': 'Hongbing', 'Initials': 'H', 'LastName': 'Yu', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Xie', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Hongwen', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Maternal and Child Health Care Hospital, Shenzhen, 518054, China.'}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'He', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Huimin', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Su', 'Affiliation': 'Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, 518054, China.'}, {'ForeName': 'Xueqi', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Shenzhen Nanshan Maternal and Child Health Care Hospital, Shenzhen, 518054, China. 756296691@qq.com.'}]",BMC oral health,['10.1186/s12903-020-01204-5'] 2860,32736576,The role of vaginal palpation in motor learning of the pelvic floor muscles for women with stress urinary incontinence: study protocol for a randomized controlled trial.,"BACKGROUND Approximately 30 to 50% of women are unable to correctly perform pelvic floor muscle (PFM) contractions. For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted. The purpose of this study is to evaluate whether vaginal palpation together with verbal instructions about PFMs and body awareness techniques helps women with SUI learn how to correctly contract the PFMs and improve their functions. METHODS This single-centre, double-blind randomized controlled trial with two intervention groups was designed following the standard protocol items for randomized interventional trials (SPIRIT). The results will be reported in a manner consistent with the Consolidated Standards of Reporting Trials (CONSORT) guidelines. Patients with SUI (n = 172) will be recruited. The experimental group will receive verbal instructions about PFM function and body awareness techniques together with vaginal palpation; the control group will receive similar protocol without vaginal palpation. The primary outcome includes the number of fast-twitch muscle fibres assessed by vaginal palpation and visual observation. Secondary outcomes include power and muscular endurance that will be assessed by visual observation and vaginal palpation (Oxford scale), the use of accessory muscles during the voluntary contraction of PFMs, and the self-efficacy and the expectations for the results using the self-efficacy scale of pelvic floor exercises. DISCUSSION This study will determine whether vaginal palpation can help women with SUI to correctly perform PFM contractions and improve their functions. TRIAL REGISTRATION ClinicalTrials.gov NCT03325543 . Registered on 30 November 2017. Study protocol version 1; 30 November 2020. Prospectively registered.",2020,"For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted.","['women with SUI', 'Patients with SUI (n\u2009=\u2009172', 'women with stress urinary incontinence', 'women with SUI learn', 'Study protocol version 1; 30 November 2020']","['pelvic floor muscle training (PFMT) programme', 'vaginal palpation in motor learning of the pelvic floor muscles', 'verbal instructions about PFM function and body awareness techniques together with vaginal palpation; the control group will receive similar protocol without vaginal palpation']","['power and muscular endurance that will be assessed by visual observation and vaginal palpation (Oxford scale), the use of accessory muscles during the voluntary contraction of PFMs, and the self-efficacy and the expectations for the results using the self-efficacy scale of pelvic floor exercises', 'number of fast-twitch muscle fibres assessed by vaginal palpation and visual observation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4517601', 'cui_str': '172'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C2599718', 'cui_str': 'Clinical Trial Protocols'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C4087139', 'cui_str': 'Pelvic floor muscle training'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0206248', 'cui_str': 'Pelvic floor structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0033344', 'cui_str': 'Programmed Instruction'}, {'cui': 'C0231484', 'cui_str': 'Muscle function'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0004448', 'cui_str': 'Cognitive function: awareness'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C0442025', 'cui_str': 'Muscular'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0199219', 'cui_str': 'Inspection'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0030247', 'cui_str': 'Palpation'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0158784', 'cui_str': 'Accessory skeletal muscle'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0679138', 'cui_str': 'Expectations'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0262718', 'cui_str': 'Pelvic floor exercises'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0225326', 'cui_str': 'Fiber'}]",,0.120631,"For women to benefit from a pelvic floor muscle training (PFMT) programme for stress urinary incontinence (SUI), the awareness phase of PFMT cannot be omitted.","[{'ForeName': 'Letícia', 'Initials': 'L', 'LastName': 'de Azevedo Ferreira', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil. leticia_azfe@hotmail.com.'}, {'ForeName': 'Fátima Faní', 'Initials': 'FF', 'LastName': 'Fitz', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Márcia Maria', 'Initials': 'MM', 'LastName': 'Gimenez', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Mayanni Magda Pereira', 'Initials': 'MMP', 'LastName': 'Matias', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Maria Augusta Tezelli', 'Initials': 'MAT', 'LastName': 'Bortolini', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}, {'ForeName': 'Rodrigo Aquino', 'Initials': 'RA', 'LastName': 'Castro', 'Affiliation': 'Department of Gynaecology, Federal University of Sao Paulo (UNIFESP), Rua Napoleão de Barros, 608 - Vila Clementino, São Paulo, SP, CEP 04024-002, Brazil.'}]",Trials,['10.1186/s13063-020-04624-4'] 2861,32736622,"Uncovering spatial variation in maternal healthcare service use at subnational level in Jimma Zone, Ethiopia.","BACKGROUND Analysis of disaggregated national data suggest uneven access to essential maternal healthcare services within countries. This is of concern as it hinders equitable progress in health outcomes. Mounting an effective response requires identification of subnational areas that may be lagging behind. This paper aims to explore spatial variation in maternal healthcare service use at health centre catchment, village and household levels. Spatial correlations of service use with household wealth and women's education levels were also assessed. METHODS Using survey data from 3758 households enrolled in a cluster randomized trial geographical variation in the use of maternity waiting homes (MWH), antenatal care (ANC), delivery care and postnatal care (PNC) was investigated in three districts in Jimma Zone. Correlations of service use with education and wealth levels were also explored among 24 health centre catchment areas using choropleth maps. Global spatial autocorrelation was assessed using Moran's I. Cluster analyses were performed at village and household levels using Getis Ord Gi* and Kulldorf spatial scan statistics to identify cluster locations. RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use. Hot spots were detected in health centre catchments in Gomma district while Kersa district had cold spots. High poverty or low education catchments generally had low levels of service use, but there were exceptions. At village level, hot and cold spots were detected for ANC, delivery care and PNC use. Household-level analyses revealed a primary cluster of elevated MWH-use not detected previously. Further investigation of spatial heterogeneity is warranted. CONCLUSIONS Sub-national variation in maternal healthcare services exists in Jimma Zone. There was relatively higher poverty and lower education in areas where service use cold spots were identified. Re-directing resources to vulnerable sub-groups and locations lagging behind will be necessary to ensure equitable progress in maternal health.",2020,"RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use.","['maternal healthcare service use at health centre catchment, village and household levels', '3758 households enrolled in a cluster randomized trial geographical variation in the use of maternity waiting homes (MWH), antenatal care (ANC), delivery care and postnatal care (PNC) was investigated in three districts in Jimma Zone', 'maternal healthcare service use at subnational level in Jimma Zone, Ethiopia']",[],"['delivery care', 'Global spatial autocorrelation']","[{'cui': 'C0026591', 'cui_str': 'Mother'}, {'cui': 'C0557829', 'cui_str': 'Healthcare services'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0475309', 'cui_str': 'Health center'}, {'cui': 'C0562518', 'cui_str': 'Village environment'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0009085', 'cui_str': 'Clustering'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0033052', 'cui_str': 'Antenatal care'}, {'cui': 'C1171257', 'cui_str': 'Delivery care'}, {'cui': 'C0032782', 'cui_str': 'Postpartum care'}, {'cui': 'C1292732', 'cui_str': 'Investigates'}, {'cui': 'C0015024', 'cui_str': 'Ethiopia'}]",[],"[{'cui': 'C1171257', 'cui_str': 'Delivery care'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0814927', 'cui_str': 'Spatial Autocorrelation'}]",3758.0,0.0712674,"RESULTS Significant global spatial autocorrelation was present in ANC use (Moran's I = 0.15, p value = 0.025), delivery care (Moran's I = 0.17, p value = 0.01) and PNC use (Moran's I = 0.31, p value < 0.01), but not MWH use (Moran's I = -0.005, p value = 0.94) suggesting clustering of villages with similarly high (hot spots) and/or low (cold spots) service use.","[{'ForeName': 'Jaameeta', 'Initials': 'J', 'LastName': 'Kurji', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada. jkurj022@uottawa.ca.'}, {'ForeName': 'Benoit', 'Initials': 'B', 'LastName': 'Talbot', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}, {'ForeName': 'Gebeyehu', 'Initials': 'G', 'LastName': 'Bulcha', 'Affiliation': 'Jimma Zone Health Office, Jimma Zone, Oromia Region, Jimma, Ethiopia.'}, {'ForeName': 'Kunuz Haji', 'Initials': 'KH', 'LastName': 'Bedru', 'Affiliation': 'Jimma Zone Health Office, Jimma Zone, Oromia Region, Jimma, Ethiopia.'}, {'ForeName': 'Sudhakar', 'Initials': 'S', 'LastName': 'Morankar', 'Affiliation': 'Department of Health, Behaviour & Society, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Lakew Abebe', 'Initials': 'LA', 'LastName': 'Gebretsadik', 'Affiliation': 'Department of Health, Behaviour & Society, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Muluemebet Abera', 'Initials': 'MA', 'LastName': 'Wordofa', 'Affiliation': 'Department of Population & Family Health, Jimma University, Jimma, Ethiopia.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Welch', 'Affiliation': 'Centre for Global Health, Bruyere Research Institute, Ottawa, Canada.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Labonte', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}, {'ForeName': 'Manisha A', 'Initials': 'MA', 'LastName': 'Kulkarni', 'Affiliation': 'School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, Ontario, K1G 5Z3, Canada.'}]",BMC health services research,['10.1186/s12913-020-05572-0'] 2862,32736639,Enhancing healthcare efficiency to achieve the Quadruple Aim: an exploratory study.,"OBJECTIVE Healthcare is battling a conflict between the Quadruple Aims-reducing costs; improving population health, patient experience, and team well-being-and productivity. This quasi-experimental pilot study tested a 2 week intervention aimed to address the Quadruple Aims while improving productivity. Participants were 25 employees and their patients in a primary care clinic. One provider and their team implemented an efficiency-focused intervention that modified work roles and processes focused on utilizing all team members' skills as allowable by applicable licensure restrictions. The five remaining providers and their teams comprised the reference group, who continued patient care as usual. Study outcomes were measured via provider/staff and patient surveys and administrative data. RESULTS In total, 46 team surveys and 156 patient surveys were collected. Clinic output data were retrieved for 467 visits. Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures. The intervention group offered 48% more patient slots than the average reference team. These preliminary results support the feasibility of introducing substantial process changes that show promising improvement in both the Quadruple Aims and productivity. A larger-scale study over a longer time period is needed to confirm findings and examine feasibility and cost-effectiveness.",2020,"Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures.","['In total, 46 team surveys and 156 patient surveys were collected', 'Participants were 25 employees and their patients in a primary care clinic']",[],['provider/staff and patient surveys and administrative data'],"[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0599987', 'cui_str': 'Employee'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}]",[],"[{'cui': 'C2700616', 'cui_str': 'Manpower'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C1292785', 'cui_str': 'Administrative action'}]",25.0,0.0256599,"Compared to the reference team, the intervention team performed better in all Quadruple Aims and productivity measures.","[{'ForeName': 'Bengt B', 'Initials': 'BB', 'LastName': 'Arnetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA. arnetzbe@msu.edu.'}, {'ForeName': 'Courtney M', 'Initials': 'CM', 'LastName': 'Goetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Judith E', 'Initials': 'JE', 'LastName': 'Arnetz', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Sukhesh', 'Initials': 'S', 'LastName': 'Sudan', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'vanSchagen', 'Affiliation': 'Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.'}, {'ForeName': 'Kyle', 'Initials': 'K', 'LastName': 'Piersma', 'Affiliation': 'Trinity Health, Livonia, MI, USA.'}, {'ForeName': 'Fredric', 'Initials': 'F', 'LastName': 'Reyelts', 'Affiliation': 'Mercy Health, Grand Rapids, MI, USA.'}]",BMC research notes,['10.1186/s13104-020-05199-8'] 2863,32730310,Monetary incentives for improving smartphone-measured oral hygiene behaviors in young children: A randomized pilot trial.,"AIMS To assess feasibility, acceptability, and early efficacy of monetary incentive-based interventions on fostering oral hygiene in young children measured with a Bluetooth-enabled toothbrush and smartphone application. DESIGN A stratified, parallel-group, three-arm individually randomized controlled pilot trial. SETTING Two Los Angeles area Early Head Start (EHS) sites. PARTICIPANTS 36 parent-child dyads enrolled in an EHS home visit program for 0-3 year olds. INTERVENTIONS Eligible dyads, within strata and permuted blocks, were randomized in equal allocation to one of three groups: waitlist (delayed monetary incentive) control group, fixed monetary incentive package, or lottery monetary incentive package. The intervention lasted 8 weeks. OUTCOMES Primary outcomes were a) toothbrushing performance: mean number of Bluetooth-recorded half-day episodes per week when the child's teeth were brushed, and b) dental visit by the 2-month follow-up among children with no prior dental visit. The a priori milestone of 20% more frequent toothbrushing identified the intervention for a subsequent trial. Feasibility and acceptability measures were also assessed, including frequency of parents syncing the Bluetooth-enabled toothbrush to the smartphone application and plaque measurement from digital photographs. FINDINGS Digital monitoring of toothbrushing was feasible. Mean number of weekly toothbrushing episodes over 8 weeks was 3.9 in the control group, 4.1 in the fixed incentive group, and 6.0 in the lottery incentive group. The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group. Exploratory analyses showed effects concentrated among children ≤24 months. Follow-up dental visit attendance was similar across groups. iPhone 7 more reliably captured evaluable images than Photomed Cannon G16. CONCLUSIONS Trial protocol and outcome measures were deemed feasible and acceptable. Results informed the study protocol for a fully powered trial of lottery incentives versus a delayed control using the smart toothbrush and remote digital incentive program administration. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03862443.",2020,The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group.,"['young children', 'young children measured with a Bluetooth-enabled toothbrush and smartphone application', 'Two Los Angeles area', '36 parent-child dyads enrolled in an EHS home visit program for 0-3 year olds']","['monetary incentive-based interventions', 'waitlist (delayed monetary incentive) control group, fixed monetary incentive package, or lottery monetary incentive package']","['Mean number of weekly toothbrushing episodes', ""toothbrushing performance: mean number of Bluetooth-recorded half-day episodes per week when the child's teeth were brushed, and b) dental visit"", 'Feasibility and acceptability measures', 'frequent toothbrushing', 'feasibility, acceptability, and early efficacy', 'smartphone-measured oral hygiene behaviors']","[{'cui': 'C0337547', 'cui_str': 'Younger child'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0562342', 'cui_str': 'Empowered'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0018670', 'cui_str': 'Head structure'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0020043', 'cui_str': 'Home visit'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0043010', 'cui_str': 'Waiting Lists'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0013194', 'cui_str': 'Packaging, Drug'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0183975', 'cui_str': 'Toothbrush'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0040461', 'cui_str': 'Brushing of teeth'}, {'cui': 'C0011365', 'cui_str': 'Health Services, Dental'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0332183', 'cui_str': 'Frequent'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0029164', 'cui_str': 'Dental Hygiene'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}]",,0.0928108,The lottery group had 53% more frequent toothbrushing than the control group and 47% more frequent toothbrushing than the fixed group.,"[{'ForeName': 'Justin S', 'Initials': 'JS', 'LastName': 'White', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Ramos-Gomez', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jenny X', 'Initials': 'JX', 'LastName': 'Liu', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Bonnie', 'Initials': 'B', 'LastName': 'Jue', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Finlayson', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jeremiah R', 'Initials': 'JR', 'LastName': 'Garza', 'Affiliation': 'Section of Pediatric Dentistry, School of Dentistry, University of California Los Angeles, Los Angeles, California, United States of America.'}, {'ForeName': 'Alexandra H', 'Initials': 'AH', 'LastName': 'Crawford', 'Affiliation': 'California Protons Cancer Therapy Center, University of California San Diego Health, San Diego, California, United States of America.'}, {'ForeName': 'Sarit', 'Initials': 'S', 'LastName': 'Helman', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Santo', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'Jing', 'Initials': 'J', 'LastName': 'Cheng', 'Affiliation': ""Center to Address Disparities in Children's Oral Health, University of California San Francisco, San Francisco, California, United States of America.""}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Kahn', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}, {'ForeName': 'Stuart A', 'Initials': 'SA', 'LastName': 'Gansky', 'Affiliation': 'Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, San Francisco, California, United States of America.'}]",PloS one,['10.1371/journal.pone.0236692'] 2864,32730325,The safety and feasibility of a Halliwick style of aquatic physiotherapy for falls and balance dysfunction in people with Parkinson's Disease: A single blind pilot trial.,"BACKGROUND There is growing evidence that aquatic physiotherapy may be effective for people with Parkinson's Disease (PD) but most studies have investigated land based type exercises in the aquatic environment. Few studies have examined customised aquatic therapies such as the Halliwick concept which focuses on trunk rotation and core stabilisation. OBJECTIVE The primary aim was to determine the feasibility of a Halliwick style aquatic physiotherapy intervention for people with PD. The secondary aim was to compare the Halliwick intervention with traditional aquatic and land based physiotherapy in terms of disease severity, balance and fear of falling. METHODS Halliwick style aquatic, traditional aquatic and land based physiotherapy were trialled in a single blind pilot study. All interventions ran for 60 minutes per week over 12 weeks. Feasibility outcomes were safety, adherence and attrition. Secondary outcomes included the Unified Parkinson's Disease Rating Scale motor subsection (UPDRS-III), Berg Balance Scale (BBS), Mini BESTest and modified Falls Efficacy Scale (mFES). RESULTS 30 participants with moderate PD were recruited. Participant mean age was 72 years (SD 8.4; range 51-86) with moderate disease severity (median Hoehn & Yahr score 3; IQR 1).No falls occurred during intervention sessions, however ten participants reported falls during the study period. No other adverse consequences were reported. All groups had adherence over 85%. No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). CONCLUSIONS Despite people with PD being a vulnerable population, aquatic physiotherapy, including the Halliwick style is a safe treatment option. Promising results for balance in the Halliwick aquatic group were observed, but further studies with larger sample sizes is required to increase confidence in the results.",2020,"No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). ","['Participant mean age was 72 years (SD 8.4; range 51-86) with moderate disease severity (median Hoehn & Yahr score 3; IQR 1).No falls occurred during intervention sessions, however ten participants reported falls during the study period', ""people with Parkinson's Disease"", '30 participants with moderate PD', ""people with Parkinson's Disease (PD"", 'people with PD']","['Halliwick style aquatic, traditional aquatic and land based physiotherapy', 'aquatic physiotherapy', 'Halliwick style aquatic physiotherapy intervention', 'Halliwick intervention with traditional aquatic and land based physiotherapy', 'Halliwick style of aquatic physiotherapy']","['safety, adherence and attrition', 'UPDRS-III, BBS or mFES scores', 'adverse consequences', 'disease severity, balance and fear of falling', ""Unified Parkinson's Disease Rating Scale motor subsection (UPDRS-III), Berg Balance Scale (BBS"", 'Mini BESTest and modified Falls Efficacy Scale (mFES']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517876', 'cui_str': '8.4'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C2745955', 'cui_str': 'Occurrence'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0557668', 'cui_str': 'Landing'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2364055', 'cui_str': 'Compliant behavior'}, {'cui': 'C0004277', 'cui_str': 'Dental Attrition'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0686907', 'cui_str': 'Consequence of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0877040', 'cui_str': 'Fear of falling'}, {'cui': 'C0445542', 'cui_str': 'Mini'}]",30.0,0.0617848,"No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31, t (10) = -2.98). ","[{'ForeName': 'Aan Fleur', 'Initials': 'AF', 'LastName': 'Terrens', 'Affiliation': 'Movement Disorder Program, Peninsula Health, VIC, Australia.'}, {'ForeName': 'Sze-Ee', 'Initials': 'SE', 'LastName': 'Soh', 'Affiliation': 'Department of Physiotherapy, Monash University, VIC, Australia.'}, {'ForeName': 'Prue', 'Initials': 'P', 'LastName': 'Morgan', 'Affiliation': 'Department of Physiotherapy, Monash University, VIC, Australia.'}]",PloS one,['10.1371/journal.pone.0236391'] 2865,32730437,[Effect of the presence of student-assistants on the quality of care perception by ambulatory patients].,"BACKGROUND The time dedicated to patients and how they are treated are crucial in the evaluation of health care quality. Medical students acting as medical assistants could improve the perception of a good quality of care among ambulatory patients. AIM To evaluate if the presence of Student-Assistants improves the patients' perception of health care quality in ambulatory primary care. PATIENTS AND METHODS Quasi-experimental exploratory study. In two health care centers, patients answered a questionnaire about their perception of how they were treated at baseline and after an intervention period. In one center, prior to the appointment of the patient with the doctor, the student interviewed patients focusing on chief complaints and registered their vital signs, orally presenting this information to the clinician. In the other center, there was no student intervention. Patients answered the questionnaire at the end of appointments. RESULTS At baseline 103 patients answered the questionnaire (58 in the experimental and 45 in the control center). After the intervention, 121 patients answered it (56 in the experimental and 65 in the control center). Basal scores were 6,25 and 6,06 in experimental and control center, respectively (p = NS). After the intervention, the scores were 6,49 and 6,15, respectively (p = 0,01). CONCLUSIONS These data support the hypothesis that the presence of a Student-Assistant could improve the perception of patients about how they are treated at primary health care centers.",2020,"After the intervention, the scores were 6,49 and 6,15, respectively (p = 0,01). ","['At baseline 103 patients answered the questionnaire (58 in the experimental and 45 in the control center', 'ambulatory patients', '121 patients answered it (56 in the experimental and 65 in the control center']",['student-assistants'],"['quality of care perception', 'Basal scores']","[{'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C4517526', 'cui_str': '103'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}]","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0011327', 'cui_str': 'Dental assistant'}]","[{'cui': 'C0034379', 'cui_str': 'Quality of Care'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0205112', 'cui_str': 'Basal'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",121.0,0.0179607,"After the intervention, the scores were 6,49 and 6,15, respectively (p = 0,01). ","[{'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Concha I', 'Affiliation': 'Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Hirschberg G', 'Affiliation': 'Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Arraño R', 'Affiliation': 'Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Marcela', 'Initials': 'M', 'LastName': 'Cárcamo I', 'Affiliation': 'Departamento de Salud Pública y Epidemiología, Facultad de Medicina, Universidad de los Andes, Santiago, Chile.'}, {'ForeName': 'Jaime', 'Initials': 'J', 'LastName': 'Mañalich M', 'Affiliation': 'Departamento de Salud Pública y Epidemiología, Facultad de Medicina, Universidad de los Andes, Santiago, Chile.'}]",Revista medica de Chile,['10.4067/S0034-98872020000100060'] 2866,32730920,The role of endogenous GIP and GLP-1 in postprandial bone homeostasis.,"The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are well known for their insulinotropic effects and they are thought to affect bone homeostasis as mediators in the so-called entero-osseous axis. We examined the contributions of endogenous GIP and GLP-1, respectively, to postprandial bone homeostasis, in healthy subjects in two randomized and double-blind crossover studies. We included healthy men who received either four oral glucose tolerance tests (OGTTs) (n = 18, median age 27 (range 20-70), BMI 27.2 (22.4-37.0) kg/m 2 ) or liquid mixed meal tests (MMTs) (n = 12, .age 23 (19-65), BMI 23.7 (20.3-25.5) kg/m 2 ) with infusions of 1) the GIP receptor antagonist GIP(3-30)NH 2 , 2) the GLP-1 receptor antagonist exendin(9-39)NH 2 , 3) both GIP(3-30)NH 2 and exendin(9-39)NH 2 , or 4) placebo infusions (saline) on four separate visits. Bone resorption was evaluated from levels of circulating carboxy-terminal collagen crosslinks (CTX) and bone formation from levels of procollagen type 1 amino-terminal propeptide (P1NP). During placebo infusions, baseline-subtracted area under the curve values for CTX were -39±5.0 (OGTT) and -57±4.3 ng/ml × min (MMT). When GIP(3-30)NH 2 was administered, CTX suppression was significantly diminished compared to placebo (-30±4.8 (OGTT) and -45±4.6 ng/ml × min (MMT), P=0.0104 and P=0.0288, respectively, compared to placebo. During exendin(9-39)NH 2 infusion, CTX suppression after OGTT/MMT was similar to placebo (P=0.28 (OGTT) and P=0.93 (MMT)). The relative contribution of endogenous GIP to postprandial suppression of bone resorption during both OGTT and MMT was similar and reached 22-25%. There were no differences in P1NP concentrations between interventions. In conclusion, endogenous GIP contributes by up to 25% to postprandial suppression of bone resorption in humans whereas an effect of endogenous GLP-1 could not be demonstrated.",2020,There were no differences in P1NP concentrations between interventions.,"['healthy subjects', 'healthy men who received either four oral glucose tolerance tests (OGTTs) (n = 18, median age 27 (range 20-70), BMI 27.2 (22.4-37.0) kg/m 2 ) or']","['liquid mixed meal tests (MMTs', 'placebo infusions (saline', 'placebo']","['bone resorption', 'CTX suppression', 'P1NP concentrations', 'Bone resorption']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C5191357', 'cui_str': '27.2'}]","[{'cui': 'C0301571', 'cui_str': 'Liquid diet'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C1998602', 'cui_str': 'Meals'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0046370', 'cui_str': '2-methylcyclopentadienyl manganese tricarbonyl'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0574032', 'cui_str': 'Infusion'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]","[{'cui': 'C0005974', 'cui_str': 'Bone resorption'}, {'cui': 'C0010377', 'cui_str': 'Crotoxin'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0072053', 'cui_str': 'Procollagen peptide, type 1 N-terminal'}, {'cui': 'C0004268', 'cui_str': 'Attention'}]",,0.20213,There were no differences in P1NP concentrations between interventions.,"[{'ForeName': 'Mads M', 'Initials': 'MM', 'LastName': 'Helsted', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Lærke S', 'Initials': 'LS', 'LastName': 'Gasbjerg', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Amalie R', 'Initials': 'AR', 'LastName': 'Lanng', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Natasha C', 'Initials': 'NC', 'LastName': 'Bergmann', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Signe', 'Initials': 'S', 'LastName': 'Stensen', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.'}, {'ForeName': 'Bolette', 'Initials': 'B', 'LastName': 'Hartmann', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mikkel B', 'Initials': 'MB', 'LastName': 'Christensen', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Pharmacology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jens J', 'Initials': 'JJ', 'LastName': 'Holst', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Vilsbøll', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark.'}, {'ForeName': 'Mette M', 'Initials': 'MM', 'LastName': 'Rosenkilde', 'Affiliation': 'Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Filip K', 'Initials': 'FK', 'LastName': 'Knop', 'Affiliation': 'Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center Copenhagen, Gentofte, Denmark. Electronic address: filipknop@dadlnet.dk.'}]",Bone,['10.1016/j.bone.2020.115553'] 2867,32730930,A novel autologous bone graft substitute comprised of rhBMP6 blood coagulum as carrier tested in a randomized and controlled Phase I trial in patients with distal radial fractures.,"Bone morphogenetic proteins (BMPs) are known to induce new bone formation in vivo but treating trabecular bone defects with a BMP based therapeutic remains controversial. Here, we evaluated the safety and efficacy of a novel Autologous Bone Graft Substitute (ABGS) comprised of recombinant human BMP6 (rhBMP6) dispersed within an autologous blood coagulum (ABC) as a physiological natural carrier in patients with a closed distal radial fracture (DRF). We enrolled 32 patients in a randomized, standard of care (SoC) and placebo (PBO) controlled, double-blinded Phase I First in Human (FiH) clinical trial. ABGS was prepared from peripheral blood as 250 μg rhBMP6/mL ABC or PBO (1 mL ABC containing excipients only) and was administered dorsally via a syringe injection into the fracture site following closed fracture fixation with 3 Kirschner wires. Patients carried an immobilization for 5 weeks and were followed-up for 0 to 26 weeks by clinical examination, safety, serial radiographic analyses and CT. During the 13 weeks follow-up and at 26 weeks post study there were no serious adverse reactions recorded. The results showed that there were no detectable anti-rhBMP6 antibodies in the blood of any of the 32 patients at 13- and 26-weeks following treatment. Pharmacokinetic analyses of plasma from patients treated with ABGS showed no detectable rhBMP6 at any time point within the first 24 hours following administration. The CT image and radiographic analyses score from patients treated with AGBS showed significantly accelerated bone healing as compared to PBO and SoC at 5 and 9 weeks (with high effect sizes and P=0.027), while at week 13 all patients had similar healing outcomes. In conclusion, we show that intraosseous administration of ABGS (250 μg rhBMP6/mL ABC) into the distal radial fracture site demonstrated a good tolerability with no serious adverse reactions as well as early accelerated trabecular bone healing as compared to control PBO and SoC patients.",2020,"The CT image and radiographic analyses score from patients treated with AGBS showed significantly accelerated bone healing as compared to PBO and SoC at 5 and 9 weeks (with high effect sizes and P=0.027), while at week 13 all patients had similar healing outcomes.","['patients with distal radial fractures', 'patients with a closed distal radial fracture (DRF']","['ABGS', 'novel Autologous Bone Graft Substitute (ABGS', 'standard of care (SoC) and placebo (PBO) controlled, double-blinded Phase', 'novel autologous bone graft substitute', 'Bone morphogenetic proteins (BMPs', 'recombinant human BMP6 (rhBMP6']","['accelerated bone healing', 'safety and efficacy', 'CT image and radiographic analyses score', 'detectable anti-rhBMP6 antibodies']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205108', 'cui_str': 'Distal'}, {'cui': 'C0034628', 'cui_str': 'Fracture of radius'}, {'cui': 'C0587267', 'cui_str': 'Closed'}]","[{'cui': 'C1699650', 'cui_str': 'Autologous bone graft'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0053932', 'cui_str': 'Bone morphogenetic proteins'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1612225', 'cui_str': 'BMP6 protein, human'}]","[{'cui': 'C0521110', 'cui_str': 'Accelerated'}, {'cui': 'C1321023', 'cui_str': 'Bone healing status'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C1612225', 'cui_str': 'BMP6 protein, human'}, {'cui': 'C0003241', 'cui_str': 'Antibody'}]",32.0,0.0547507,"The CT image and radiographic analyses score from patients treated with AGBS showed significantly accelerated bone healing as compared to PBO and SoC at 5 and 9 weeks (with high effect sizes and P=0.027), while at week 13 all patients had similar healing outcomes.","[{'ForeName': 'Dragan', 'Initials': 'D', 'LastName': 'Durdevic', 'Affiliation': 'Clinical Hospital Center ""Sisters of Mercy"", Clinic of Traumatology, Draskoviceva 19, 10000, Zagreb, Croatia.'}, {'ForeName': 'Tomislav', 'Initials': 'T', 'LastName': 'Vlahovic', 'Affiliation': 'Clinical Hospital Center ""Sisters of Mercy"", Clinic of Traumatology, Draskoviceva 19, 10000, Zagreb, Croatia.'}, {'ForeName': 'Sanja', 'Initials': 'S', 'LastName': 'Pehar', 'Affiliation': 'Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia.'}, {'ForeName': 'Dina', 'Initials': 'D', 'LastName': 'Miklic', 'Affiliation': 'Clinical Hospital Center ""Sisters of Mercy"", Clinic of Traumatology, Draskoviceva 19, 10000, Zagreb, Croatia.'}, {'ForeName': 'Hermann', 'Initials': 'H', 'LastName': 'Oppermann', 'Affiliation': 'Genera Research, Svetonedeljska 2, Kalinovica, 10436 Rakov Potok, Croatia.'}, {'ForeName': 'Tatjana', 'Initials': 'T', 'LastName': 'Bordukalo-Niksic', 'Affiliation': 'Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia.'}, {'ForeName': 'Ismet', 'Initials': 'I', 'LastName': 'Gavrankapetanovic', 'Affiliation': 'University Clinical Center Sarajevo, Clinic of Orthopedics and Traumatology, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Mehmed', 'Initials': 'M', 'LastName': 'Jamakosmanovic', 'Affiliation': 'University Clinical Center Sarajevo, Clinic of Orthopedics and Traumatology, Bolnicka 25, 71000 Sarajevo, Bosnia and Herzegovina.'}, {'ForeName': 'Milan', 'Initials': 'M', 'LastName': 'Milosevic', 'Affiliation': 'School of Public Health ""Andrija Stampar"", University of Zagreb School of Medicine, Rockefellerova 4, 10000 Zagreb, Croatia.'}, {'ForeName': 'Snjezana', 'Initials': 'S', 'LastName': 'Martinovic', 'Affiliation': 'SmartMedico, Zupanova 5, 10000, Zagreb, Croatia.'}, {'ForeName': 'T Kuber', 'Initials': 'TK', 'LastName': 'Sampath', 'Affiliation': 'perFormBiologics Inc., Holliston, MA 01746, USA.'}, {'ForeName': 'Mihaela', 'Initials': 'M', 'LastName': 'Peric', 'Affiliation': 'Department for intracellular communication, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 2, 10000 Zagreb, Croatia.'}, {'ForeName': 'Lovorka', 'Initials': 'L', 'LastName': 'Grgurevic', 'Affiliation': 'Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia.'}, {'ForeName': 'Slobodan', 'Initials': 'S', 'LastName': 'Vukicevic', 'Affiliation': 'Laboratory for Mineralized Tissues, Centre for Translational and Clinical Research, University of Zagreb School of Medicine, Salata 11, 10000 Zagreb, Croatia. Electronic address: slobodan.vukicevic@mef.hr.'}]",Bone,['10.1016/j.bone.2020.115551'] 2868,32730946,"Domain-specific involvement of the posterior parietal cortex in attention network and attentional control of ADHD: A randomized, cross-over, sham-controlled tDCS study.","Transcranial direct current stimulation (tDCS) has been increasingly used in attention-deficit hyperactivity disorder (ADHD) with mixed results. Previous studies merely targeted the dorsolateral prefrontal cortex and right inferior frontal gyrus with partial or no improving effects on cognitive deficits respectively. Posterior parietal cortex is another region involved in attentional functioning of ADHD, however, its contribution to attention functions has not been explored via tDCS studies in this disease. Moreover, attention networks are not investigated in the previous tDCS studies in ADHD. Here, we explored the effects of anodal tDCS over the right posterior parietal cortex (r-PPC) on attentional functioning (attention networks, selective attention, shifting attention) and response inhibition in ADHD children. 19 children with ADHD were recruited and underwent anodal/sham tDCS (1 mA, 20 min) during task performance in a randomized cross-over design. Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations. Furthermore, activation of the r-PPC had a deteriorating effect on the top-down attentional control required for selective attention measured by the Stroop test. Modeling of the current flow showed a stronger electrical field induced in the inferior PPC (BA 39,40) which mediates bottom-up attentional control. No significant effect on shifting attention and response inhibition was found. Our results show a domain-specific involvement of the r-PPC in attention orienting network of ADHD children. Activation of the r-PPC improves bottom-up but hinders top-down attentional control suggesting a critical role of the r-PPC in bottom-up attentional control in ADHD.",2020,"Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations.","['ADHD', 'ADHD children', '19 children with ADHD']","['Transcranial direct current stimulation (tDCS', 'anodal tDCS', 'anodal r-PPC tDCS', 'anodal/sham tDCS']","['attentional functioning (attention networks, selective attention, shifting attention', 'shifting attention and response inhibition']","[{'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0008059', 'cui_str': 'Child'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0456855', 'cui_str': 'Right posterior'}, {'cui': 'C0030560', 'cui_str': 'Parietal lobe structure'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0233421', 'cui_str': 'Selective inattention'}, {'cui': 'C0333051', 'cui_str': 'Shift'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}]",19.0,0.0442588,"Our results show an improving effect of anodal r-PPC tDCS specifically on the orienting but alerting or executive networks, in line with findings of healthy populations.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ali Salehinejad', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany; Ruhr-University Bochum, International Graduate School of Neuroscience, Bochum, Germany.'}, {'ForeName': 'Elnaz', 'Initials': 'E', 'LastName': 'Ghayerin', 'Affiliation': 'Department of Psychology, Shahid Beheshti University, Tehran, Iran.'}, {'ForeName': 'Vahid', 'Initials': 'V', 'LastName': 'Nejati', 'Affiliation': 'Department of Psychology, Shahid Beheshti University, Tehran, Iran. Electronic address: nejati@sbu.ac.ir.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Yavari', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Nitsche', 'Affiliation': 'Leibniz Research Centre for Working Environment and Human Factors, Department of Psychology and Neurosciences, Dortmund, Germany; University Medical Hospital Bergmannsheil, Department of Neurology, Bochum, Germany.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.037'] 2869,32730948,An integrative clustering approach to tDCS individual response variability in cognitive performance: beyond a null effect on working memory.,"Despite the growing interest in the use of transcranial direct current stimulation (tDCS) for the modulation of human cognitive function, there are contradictory findings regarding the cognitive benefits of this technique. Inter-individual response variability to tDCS may play a significant role. We explored the effects of anodal versus sham tDCS over the left prefrontal cortex (LPFC) on working memory performance, taking into account the inter-individual variability. Twenty-nine healthy volunteers received an 'offline' anodal tDCS (1.5mA, 15min) to the left prefrontal cortex (F3 electrode site) in an intra-individual, cross-over, sham-controlled experimental design. n-back and Sternberg task performance was assessed before (baseline), immediately after tDCS administration (T1) and 5 minutes post-T1 (T2). We applied an integrative clustering approach to characterize both the group and individual responses to tDCS, as well as identifying naturally occurring subgroups that may be present within the total sample. Anodal tDCS failed to improve working memory performance in the total sample. Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition. The proportion of 'responders' ranged from 15% to 59% across task conditions and behavioral outputs. Our findings show a high inter-individual variability of the tDCS response, suggesting that the use of tCDS may not be an effective tool to improve working memory performance in healthy subjects. We propose that the use of clustering methods is more suitable in identifying 'responders' and for evaluating the efficacy of this technique.",2020,"Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition.","['Twenty-nine healthy volunteers', 'healthy subjects']","['Anodal tDCS', 'transcranial direct current stimulation (tDCS', 'anodal versus sham tDCS', ""offline' anodal tDCS (1.5mA, 15min) to the left prefrontal cortex (F3 electrode site) in an intra-individual, cross-over, sham-controlled experimental design""]","['n-back and Sternberg task performance', 'working memory performance']","[{'cui': 'C0450351', 'cui_str': '29'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C3850024', 'cui_str': 'tDCS'}, {'cui': 'C0073980', 'cui_str': 'salicylhydroxamic acid'}, {'cui': 'C0450424', 'cui_str': 'To the left'}, {'cui': 'C0162783', 'cui_str': 'Prefrontal Cortex'}, {'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010366', 'cui_str': 'Genetic crossing over'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0015320', 'cui_str': 'Designs, Experimental'}]","[{'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}]",29.0,0.0384338,"Cluster analysis identified a subgroup of 'responders' who significantly improved their performance after anodal (vs. sham) stimulation, although not to a greater extent than the best baseline or sham condition.","[{'ForeName': 'Luque-Casado', 'Initials': 'LC', 'LastName': 'Antonio', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education. Center for Sport Studies, King Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Rodríguez-Freiría', 'Initials': 'RF', 'LastName': 'Rocío', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, Performance and Health Group, A Coruña, Spain.'}, {'ForeName': 'Fogelson', 'Initials': 'F', 'LastName': 'Noa', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education. Center for Sport Studies, King Juan Carlos University, Madrid, Spain.'}, {'ForeName': 'Iglesias-Soler', 'Initials': 'IS', 'LastName': 'Eliseo', 'Affiliation': 'Department of Physical Education and Sport, Faculty of Sports Sciences and Physical Education, University of A Coruna, Performance and Health Group, A Coruña, Spain.'}, {'ForeName': 'Fernández-Del-Olmo', 'Initials': 'FD', 'LastName': 'Miguel', 'Affiliation': 'Area of Sport Sciences, Faculty of Sports Sciences and Physical Education. Center for Sport Studies, King Juan Carlos University, Madrid, Spain. Electronic address: miguel.delolmo@urjc.es.'}]",Neuroscience,['10.1016/j.neuroscience.2020.07.036'] 2870,32730977,"Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial.","OBJECTIVE Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD). We tested efficacy of bumetanide on core symptom domains using a mono-center, parallel-group, participant-randomized, double-blind, placebo-controlled phase-2 superiority trial in a tertiary Netherlands hospital. METHOD Unmedicated children aged 7-15 with ASD and IQ>55 were block-randomized 1:1 to oral-solution bumetanide vs. placebo, titrated to a maximum of 1.0mg twice-daily for 91 days (D91) followed by a 28-day wash-out period. The primary outcome was difference in Social Responsiveness Scale-2 (SRS-2) total score at D91 analyzed by modified intention-to-treat with linear mixed models. RESULTS 92 participants (mean age 10.5 years [SD 2.4]) enrolled between June 2016 and December 2018. 47 children were allocated to bumetanide and 45 to placebo. Two participants dropped out per treatment arm. After 91 days, bumetanide was not superior to placebo on the primary outcome, the SRS-2 (Mean difference -3.16, 95% CI: -9.6823 to 3.3659, p=0.3375). A superior effect was found on one of the secondary outcomes, the Repetitive Behavior Scale-Revised (Mean difference -4.16, 95%CI: -8.0649 to -0.2473, p=0.0375), not on the Sensory Profile (Mean difference 5.64, 95%CI: -11.30 to 22.57, p=0.508) nor the Aberrant Behavior Checklist Irritability Subscale (Mean difference -0.65, 95%CI: -2.83 to 1.52, p=0.552). No significant wash-out effect was observed. Significant adverse effects were predominantly diuretic effects (orthostatic hypotension (17[36%] vs 5[11%], p=.007); hypokalemia (24[51%] vs 0[0%], p<0.0001), whose occurrence did not statistically influence treatment outcome. CONCLUSION The trial was negative as no superior effect was found on the primary outcome. The secondary outcomes might suggest efficacy on repetitive behavior symptoms for a subset of patients.",2020,"After 91 days, bumetanide was not superior to placebo on the primary outcome, the SRS-2","['92 participants (mean age 10.5 years [SD 2.4]) enrolled between June 2016 and December 2018', 'Autism Spectrum Disorder (BAMBI', 'autism spectrum disorder (ASD', '47 children', 'Unmedicated children aged 7-15 with ASD and IQ>55 were block-randomized 1:1 to']","['bumetanide', 'oral-solution bumetanide vs. placebo', 'Placebo', 'Bumetanide', 'placebo']","['SRS-2', 'diuretic effects (orthostatic hypotension', 'Repetitive Behavior Scale-Revised', 'Sensory Profile', 'repetitive behavior symptoms', 'Social Responsiveness Scale-2 (SRS-2) total score at D91 analyzed by modified intention-to-treat with linear mixed models', 'hypokalemia', 'Aberrant Behavior Checklist Irritability Subscale']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517521', 'cui_str': '10.5'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517631', 'cui_str': '2.4'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C1436698', 'cui_str': 'BAMBI protein, human'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}]","[{'cui': 'C0006376', 'cui_str': 'Bumetanide'}, {'cui': 'C0991536', 'cui_str': 'Oral solution'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0948429', 'cui_str': 'Diuretic Effects'}, {'cui': 'C0020651', 'cui_str': 'Orthostatic hypotension'}, {'cui': 'C1827547', 'cui_str': 'Repetitious behavior'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C2732625', 'cui_str': 'Sensory profile'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1292734', 'cui_str': 'Treatment intent'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0026339', 'cui_str': 'Biological Models'}, {'cui': 'C0020621', 'cui_str': 'Hypokalemia'}, {'cui': 'C0443127', 'cui_str': 'Aberrant'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}, {'cui': 'C0022107', 'cui_str': 'Feeling irritable'}]",47.0,0.766947,"After 91 days, bumetanide was not superior to placebo on the primary outcome, the SRS-2","[{'ForeName': 'Jan J', 'Initials': 'JJ', 'LastName': 'Sprengers', 'Affiliation': 'UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Dorinde M', 'Initials': 'DM', 'LastName': 'van Andel', 'Affiliation': 'UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Nicolaas Pa', 'Initials': 'NP', 'LastName': 'Zuithoff', 'Affiliation': 'Amsterdam UMC, University of Amsterdam, The Netherlands.'}, {'ForeName': 'Mandy G', 'Initials': 'MG', 'LastName': 'Keijzer-Veen', 'Affiliation': 'Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Annelien Ja', 'Initials': 'AJ', 'LastName': 'Schulp', 'Affiliation': 'Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Floortje E', 'Initials': 'FE', 'LastName': 'Scheepers', 'Affiliation': 'UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Marc R', 'Initials': 'MR', 'LastName': 'Lilien', 'Affiliation': 'Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Bob', 'Initials': 'B', 'LastName': 'Oranje', 'Affiliation': 'UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands.'}, {'ForeName': 'Hilgo', 'Initials': 'H', 'LastName': 'Bruining', 'Affiliation': ""UMC Utrecht Brain Centre, University Medical Centre Utrecht, The Netherlands; Wilhelmina Children's Hospital, University Medical Centre Utrecht, The Netherlands. Electronic address: h.bruining@amsterdamumc.nl.""}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2020.07.888'] 2871,32730985,"Randomized clinical trial: Expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery.","BACKGROUND CONTEXT While autogenous iliac crest bone graft (AICBG) is considered the gold-standard graft material for spinal fusion, new bone substitutes are being developed to avoid associated complications and disadvantages. By combining autologous bone marrow mesenchymal stromal cells (MSCs) expanded ex vivo and allogenic cancellous bone graft, we obtain a tissue-engineered product that is osteoconductive and potentially more osteogenic and osteoinductive than AICBG, owing to the higher concentration of MSCs. PURPOSE This study aimed to evaluate the feasibility and safety of implanting a tissue-engineered product consisting of expanded bone marrow MSCs loaded onto allograft bone (MSC+allograft) for spinal fusion in degenerative spine disease, as well as to assess its clinical and radiological efficacy. STUDY DESIGN/SETTING A prospective, multicenter, open-label, blinded-reader, randomized, parallel, single-dose phase I-II clinical trial. PATIENT SAMPLE A total of 73 adult patients from 5 hospitals, with Meyerding grade I-II L4-L5 degenerative spondylolisthesis and/or with L4-L5 degenerative disc disease who underwent spinal fusion through transforaminal lumbar interbody fusion (TLIF). OUTCOME MEASURES Spinal fusion was assessed by plain X-ray at 3, 6, and 12 months and by computed tomography (CT) at 6 and 12 months posttreatment. An independent radiologist performed blinded assessments of all images. Clinical outcomes were measured as change from baseline value: visual analog scale (VAS) for lumbar and sciatic pain at 12 days, 3, 6, and 12 months posttreatment, and Oswestry Disability Index (ODI) and Short Form-36 (SF-36) at 3, 6, and 12 months posttreatment. METHODS Patients who underwent L4-L5 TLIF were randomized for posterior graft type only, and received either MSC+allograft (the tissue-engineered product, group A) or AICBG (standard graft material, group B). Standard graft material was used for anterior fusion in all patients. Feasibility was measured primarily as the percentage of randomized patients who underwent surgery in each treatment group. Safety was assessed by analyzing treatment-emergent adverse events (AEs) for the full experimental phase and appraising their relationship to the experimental treatment. Outcome measures, both radiological and clinical, were compared between the groups. RESULTS Seventy-three patients were randomized in this study, 36 from the MSC+allograft group and 37 from the AICBG group, and 65 were surgically treated (31 group A, 34 group B). Demographic and comorbidity data showed no difference between groups. Most patients were diagnosed with grade I or II degenerative spondylolisthesis. MSC+allograft was successfully implanted in 86.1% of randomized group A patients. Most patients suffered treatment-emergent AEs during the study (88.2% in group A and 97.1% in group B), none related to the experimental treatment. X-ray-based rates of posterior spinal fusion were significantly higher for the experimental group at 6 months (p=.012) and 12 months (p=.0003). CT-based posterior fusion rates were significantly higher for MSC+allograft at 6 months (92.3% vs 45.7%; p=.0001) and higher, but not significantly, at 12 months (76.5% vs 65.7%; p=.073). CT-based complete response (defined as the presence of both posterior intertransverse fusion and anterior interbody fusion) was significantly higher at 6 months for MSC+allograft than for AICBG (70.6% vs 40%; p=.0038), and remained so at 12 months (70.6% vs 51.4%; p=.023). Clinical results including patient-reported outcomes improved postsurgery, although there were no differences between groups. CONCLUSIONS Compared to the current gold standard, our experimental treatment achieved a higher rate of posterior spinal fusion and radiographic complete response to treatment at 6 and 12 months after surgery. The treatment clearly improved patient quality of life and decreased pain and disability at rates similar to those for the control arm. The safety profile of the tissue-engineered product was also similar to that for the standard material, and no AEs were linked to the product. Procedural AEs did not increase as a result of BM aspiration. The use of expanded bone marrow MSCs combined with cancellous allograft is a feasible and effective technique for spinal fusion, with no product-related AEs found in our study.",2020,"CT-based posterior fusion rates were significantly higher for MSC+allograft at 6 months (92.3% vs 45.7%; p=.0001) and higher, but not significantly, at 12 months (76.5% vs 65.7%; p=.073).","['73 adult patients from 5 hospitals, with Meyerding grade I-II L4-L5 degenerative spondylolisthesis and/or with L4-L5 degenerative disc disease who underwent spinal fusion through transforaminal lumbar interbody fusion (TLIF', 'Patients who underwent', 'Most patients were diagnosed with grade I or II degenerative spondylolisthesis', 'Seventy-three patients were randomized in this study, 36 from the MSC+allograft group and 37 from the AICBG group, and 65 were surgically treated (31 group A, 34 group B', 'lumbar fusion surgery']","['autologous bone marrow mesenchymal cells combined with allogeneic bone tissue', 'autogenous iliac crest bone graft (AICBG', 'autologous iliac crest graft', 'implanting a tissue-engineered product consisting of expanded bone marrow MSCs loaded onto allograft bone (MSC+allograft', 'autologous bone marrow mesenchymal stromal cells (MSCs', 'MSC+allograft', 'L4-L5', 'expanded bone marrow MSCs combined with cancellous allograft', 'MSC+allograft (the tissue-engineered product, group A) or AICBG']","['Safety', 'CT-based complete response', 'rate of posterior spinal fusion and radiographic complete response', 'patient quality of life and decreased pain and disability', 'Oswestry Disability Index (ODI) and Short Form-36 (SF-36', 'X-ray-based rates of posterior spinal fusion', 'CT-based posterior fusion rates', 'change from baseline value: visual analog scale (VAS) for lumbar and sciatic pain', 'feasibility and safety', 'BM aspiration', 'Feasibility']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0264184', 'cui_str': 'Degenerative spondylolisthesis'}, {'cui': 'C0158266', 'cui_str': 'Degeneration of intervertebral disc'}, {'cui': 'C0037935', 'cui_str': 'Spinal arthrodesis'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0223651', 'cui_str': 'Iliac crest structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005953', 'cui_str': 'Bone marrow structure'}, {'cui': 'C1257975', 'cui_str': 'Mesenchymal stem cell'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0391978', 'cui_str': 'Bone (tissue) structure'}, {'cui': 'C0443145', 'cui_str': 'Autogenous'}, {'cui': 'C0223651', 'cui_str': 'Iliac crest structure'}, {'cui': 'C0181074', 'cui_str': 'Graft material'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0596171', 'cui_str': 'Tissue Engineering'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0205229', 'cui_str': 'Expanding'}, {'cui': 'C3178844', 'cui_str': 'Mesenchymal Stromal Cells'}, {'cui': 'C0407564', 'cui_str': 'Allogeneic bone graft'}, {'cui': 'C0040739', 'cui_str': 'Allogeneic transplantation'}, {'cui': 'C0441835', 'cui_str': 'Group A'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0040405', 'cui_str': 'Computerized axial tomography'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0677874', 'cui_str': 'In full remission'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0037935', 'cui_str': 'Spinal arthrodesis'}, {'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205216', 'cui_str': 'Decreased'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0004056', 'cui_str': 'Aspiration, Psychology'}]",73.0,0.125911,"CT-based posterior fusion rates were significantly higher for MSC+allograft at 6 months (92.3% vs 45.7%; p=.0001) and higher, but not significantly, at 12 months (76.5% vs 65.7%; p=.073).","[{'ForeName': 'Ana García', 'Initials': 'AG', 'LastName': 'de Frutos', 'Affiliation': 'Department of Orthopedic Surgery, Hospital Vall d´Hebron, Barcelona, Spain; Department of Orthopedic Surgery ICATME. Hospital Universitari Quiron Dexeus, Barcelona, Spain; Univ Autonoma de Barcelona, Spain. Electronic address: agf.agfrutos@gmail.com.'}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'González-Tartière', 'Affiliation': ""Spine research unit, Vall d'Hebron Research Institute, Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: pilartartiere@gmail.com.""}, {'ForeName': 'Ruth Coll', 'Initials': 'RC', 'LastName': 'Bonet', 'Affiliation': 'Banc de Sang i Teixits de Catalunya, Barcelona, Spain. Electronic address: rucoll@bst.cat.'}, {'ForeName': 'Maria Teresa Ubierna', 'Initials': 'MTU', 'LastName': 'Garcés', 'Affiliation': 'Department of Orthopedic Surgery ICATME. Hospital Universitari Quiron Dexeus, Barcelona, Spain; Department of Orthopedic Surgery, Hospital Germas Trias i Pujol, Badalona, Spain. Electronic address: maiteubi8587@gmail.com.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Del Arco Churruca', 'Affiliation': 'Department of Orthopedic Surgery, Hospital de Sant Pau, Barcelona, Spain; Unitat Funcional de Cirurgia de la Columna Vertebral. Parc de Salut Mar. Barcelona, Spain. Electronic address: alexdelarco2502@gmail.com.'}, {'ForeName': 'Antoni Rivas', 'Initials': 'AR', 'LastName': 'García', 'Affiliation': ""Department of Radiodiagnosis, Hospital Vall d'Hebron, Barcelona, Spain. Electronic address: 10804arg@comb.cat.""}, {'ForeName': 'Antonia Matamalas', 'Initials': 'AM', 'LastName': 'Adrover', 'Affiliation': 'Department of Orthopedic Surgery, Hospital Vall d´Hebron, Barcelona, Spain. Electronic address: amatamalasadrover@gmail.com.'}, {'ForeName': 'Guillem Saló', 'Initials': 'GS', 'LastName': 'Bru', 'Affiliation': 'Univ Autonoma de Barcelona, Spain; Unitat Funcional de Cirurgia de la Columna Vertebral. Parc de Salut Mar. Barcelona, Spain. Electronic address: gsalobru@gmail.com.'}, {'ForeName': 'Juan Jose', 'Initials': 'JJ', 'LastName': 'Velazquez', 'Affiliation': 'Department of Orthopedic Surgery, Hospital de Sant Pau, Barcelona, Spain. Electronic address: JVelazquez@santpau.cat.'}, {'ForeName': 'Gemma', 'Initials': 'G', 'LastName': 'Vila-Canet', 'Affiliation': 'Department of Orthopedic Surgery ICATME. Hospital Universitari Quiron Dexeus, Barcelona, Spain; Department of Orthopedic Surgery, Hospital de Sant Pau, Barcelona, Spain. Electronic address: gvilacanet@gmail.com.'}, {'ForeName': 'Joan', 'Initials': 'J', 'LastName': 'García-Lopez', 'Affiliation': 'Banc de Sang i Teixits de Catalunya, Barcelona, Spain. Electronic address: joangarcia@bst.cat.'}, {'ForeName': 'Joaquim', 'Initials': 'J', 'LastName': 'Vives', 'Affiliation': ""Univ Autonoma de Barcelona, Spain; Banc de Sang i Teixits de Catalunya, Barcelona, Spain; Musculoskeletal Tissue Engineering Group, Vall d'Hebron Research Institute, Barcelona, Spain. Electronic address: jvives@bst.cat.""}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Codinach', 'Affiliation': 'Banc de Sang i Teixits de Catalunya, Barcelona, Spain. Electronic address: mcodinach@bst.cat.'}, {'ForeName': 'Luciano', 'Initials': 'L', 'LastName': 'Rodriguez', 'Affiliation': 'Banc de Sang i Teixits de Catalunya, Barcelona, Spain. Electronic address: lrodriguez@bst.cat.'}, {'ForeName': 'Joan Bagó', 'Initials': 'JB', 'LastName': 'Granell', 'Affiliation': 'Department of Orthopedic Surgery, Hospital Vall d´Hebron, Barcelona, Spain. Electronic address: jbago.gr@gmail.com.'}, {'ForeName': 'Enric Càceres', 'Initials': 'EC', 'LastName': 'Palou', 'Affiliation': 'Department of Orthopedic Surgery, Hospital Vall d´Hebron, Barcelona, Spain; Department of Orthopedic Surgery ICATME. Hospital Universitari Quiron Dexeus, Barcelona, Spain; Univ Autonoma de Barcelona, Spain. Electronic address: cacerespalou@gmail.com.'}]",The spine journal : official journal of the North American Spine Society,['10.1016/j.spinee.2020.07.014'] 2872,32731011,The effect of Hatha yoga intervention on students' creative ability.,"There is increasing demand for individual creativity as organizations seek innovative ways to remain relevant. Higher education institutions, particularly business schools, are sensitive to this demand and are constantly in search for innovative ways to enhance the creative ability of their students. Prior studies have shown encouraging results for physical activity-oriented interventions. Building on this research, this study uses Randomized Controlled Trial (RCT) to understand if an acute combinatory intervention, involving both physical and mental exercises embodied in Hatha yoga can improve individual creativity. This study uses 92 MBA student participants to investigate the impact of a 20-minute Hatha yoga session intervention against a short 20-minute case study session for the control group. Creative ability of the participants is operationalized through divergent and convergent thinking, which are then assessed through counter-balanced forms of Guilford Alternate Uses tasks and Remote Associate Test, respectively. The results show that while Hatha yoga significantly improves divergent thinking, the control group shows deterioration in divergent thinking. There is no effect on convergent thinking. These findings lend some support to the executive function hypothesis. The study also finds that prodding a person to be more creative on a routine academic task may not enhance their creative ability.",2020,There is no effect on convergent thinking.,"['92 MBA student participants', ""students' creative ability""]",['Hatha yoga intervention'],"['divergent thinking', 'individual creativity']","[{'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0010297', 'cui_str': 'Creative thought'}]",92.0,0.0286741,There is no effect on convergent thinking.,"[{'ForeName': 'Ashish', 'Initials': 'A', 'LastName': 'Bollimbala', 'Affiliation': 'Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India; T A Pai Management Institute, Manipal, Karnataka, 576104, India. Electronic address: ashish@tapmi.edu.in.'}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'James', 'Affiliation': 'IFIM Business School, Bangalore, Karnataka, India.'}, {'ForeName': 'Shirshendu', 'Initials': 'S', 'LastName': 'Ganguli', 'Affiliation': 'T A Pai Management Institute, Manipal, Karnataka, 576104, India. Electronic address: shirshenduganguli@tapmi.edu.in.'}]",Acta psychologica,['10.1016/j.actpsy.2020.103121'] 2873,32731118,"Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.","BACKGROUND This long-term follow-up (LTFU) trial was conducted to evaluate the long-term safety and tolerability of brivaracetam (BRV) at individualized doses (maximum of 200 mg/day) in patients with focal seizures. The secondary objective was to evaluate the efficacy of BRV over time. METHODS Two Phase III, randomized, double-blind, historical-controlled conversion-to-monotherapy trials (N01276: NCT00698581; N01306: NCT00699283) were conducted in patients aged ≥16 years with uncontrolled focal seizures. Patients who completed either of these core trials or who met a protocol-defined exit criterion could enter this LTFU trial (N01315; NCT00761774). Patients entered LTFU at a recommended BRV dose of 100 mg/day, with flexible dosing of 50-200 mg/day, as monotherapy or adjunctive therapy; additional AEDs could be prescribed and adapted in dose if clinically indicated. Safety variables included treatment-emergent adverse events (TEAEs). Efficacy variables included duration of continuous monotherapy, reduction in focal seizure frequency and seizure freedom. Safety and efficacy variables were assessed for all patients in the safety set or efficacy set, respectively, regardless of BRV treatment regimen. In addition, a post hoc subgroup analysis was conducted for patients who completed the BRV monotherapy period in either core trial, and entered the LTFU on BRV monotherapy. For this subgroup, TEAEs were summarized by 3-month time intervals over the first 12 months of LTFU. RESULTS 108 patients were enrolled in the LTFU trial between November 2008 and February 2010. 79 (73.1 %) patients discontinued the LTFU trial, most commonly due to lack of efficacy [37 (34.3 %)] and adverse events [16 (14.8 %)]. At core trial baseline, patients had a median of 6.3 focal seizures/28 days and 53 (49.1 %) had failed ≥5 previous lifetime AEDs. During LTFU, 70 (64.8 %) patients had ≥12 months and 56 (51.9 %) patients had ≥24 months of BRV treatment. TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %). Median percent reduction from baseline in focal seizure frequency/28 days was 56.8 %. Among 86 patients who completed at least 6 months of treatment, 29 (33.7 %) patients were seizure-free for ≥6 months and 22 (25.6 %) were seizure-free for ≥12 months. 50/108 patients were included in the BRV monotherapy subgroup; 33/50 (66.0 %) patients reported a TEAE in the core trials, while 26/50 (52.0 %), 15/37 (40.5 %), 14/33 (42.4 %) and 9/27 (33.3 %) patients reported any TEAE during LTFU months 1-3, 4-6, 7-9 and 10-12, respectively. In the BRV monotherapy subgroup, the most common TEAEs (≥5% of patients) during LTFU months 1-3 were fatigue [3/50 (6.0 %)] and dizziness [3/50 (6.0 %)]. INTERPRETATION Results from the LTFU trial support the long-term safety of BRV at individualized doses of up to 200 mg/day as a well-tolerated, and effective treatment for patients with focal seizures. Efficacy analyses indicate that seizure reductions with brivaracetam were generally maintained over time.",2020,"TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %).","['patients with focal seizures', '86 patients who completed at least 6 months of treatment, 29 (33.7 %) patients were seizure-free for ≥6 months and 22 (25.6 %) were seizure-free for ≥12 months', 'patients aged ≥16 years with uncontrolled focal seizures', 'adults with focal seizures', '108 patients were enrolled in the LTFU trial between November 2008 and February 2010']","['brivaracetam', 'brivaracetam (BRV', 'LTFU']","['dizziness', 'treatment-emergent adverse events (TEAEs', 'fatigue', 'Safety and efficacy variables', 'focal seizure frequency and seizure freedom', 'adverse events', 'nasopharyngitis', 'depression', 'seizure reductions with brivaracetam']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1299590', 'cui_str': 'Seizure free'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0205318', 'cui_str': 'Uncontrolled'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517530', 'cui_str': '108'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C1699861', 'cui_str': 'Brivaracetam'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0589120', 'cui_str': 'Follow-up status'}]","[{'cui': 'C0012833', 'cui_str': 'Dizziness'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0751495', 'cui_str': 'Partial seizure'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C0027441', 'cui_str': 'Nasopharyngitis'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C1699861', 'cui_str': 'Brivaracetam'}]",108.0,0.524516,"TEAEs were reported by 98 (90.7 %) patients; most commonly (≥15 % of patients) convulsion (17.6 %), nasopharyngitis (17.6 %), depression (16.7 %) and fatigue (15.7 %).","[{'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Arnold', 'Affiliation': 'Department of Neurology, Schön Klinik Vogtareuth, Krankenhausstraße 20, 83569, Vogtareuth, Germany. Electronic address: SArnold@Schoen-Kliniken.de.'}, {'ForeName': 'Cédric', 'Initials': 'C', 'LastName': 'Laloyaux', 'Affiliation': 'UCB Pharma, Allée de la Recherche, 60, B - 1070 Brussels, Belgium. Electronic address: Cedric.Laloyaux@ucb.com.'}, {'ForeName': 'Anne-Liv', 'Initials': 'AL', 'LastName': 'Schulz', 'Affiliation': 'UCB Pharma, Alfred-Nobel-Strasse 10, 40789 Monheim am Rhein, Germany. Electronic address: Anne-Liv.Schulz@ucb.com.'}, {'ForeName': 'Sami', 'Initials': 'S', 'LastName': 'Elmoufti', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: Sami.Elmoufti@ucb.com.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Yates', 'Affiliation': 'UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA. Electronic address: Stephen.Yates@ucb.com.'}, {'ForeName': 'Toufic', 'Initials': 'T', 'LastName': 'Fakhoury', 'Affiliation': 'St. Joseph Health System, 1401 Harrodsburg Road, Suite B-280, Lexington, KY 40504, USA. Electronic address: TouficFakhoury@catholichealth.net.'}]",Epilepsy research,['10.1016/j.eplepsyres.2020.106404'] 2874,32731214,Efficacy and feasibility of magnifying blue laser imaging without biopsy confirmation for the diagnosis of the demarcation of gastric tumors: A randomized controlled study.,"BACKGROUND Accurate diagnosis of the demarcation line (DL) of gastric tumors is essential for curative complete resection by endoscopic submucosal dissection (ESD). It is controversial to perform only magnifying endoscopy for diagnosing the DL of gastric tumors prior to ESD. This study aimed to evaluate the diagnostic accuracy for the DL of gastric adenomas and well- differentiated adenocarcinomas using only magnifying blue laser imaging (M-BLI) compared to that using both M-BLI and biopsy confirmation. METHODS In this prospective, single-center study, 96 well-differentiated adenocarcinomas and 32 gastric adenomas were enrolled between July 2015 and December 2016. A total of 122 lesions with a clear DL on M-BLI were randomly allocated to undergo M-BLI only (the M-BLI group) or M-BLI with biopsy confirmation (the M-BLI-BC group), performed as biopsies in four directions from non-cancerous tissues approximately 5 mm outside the lesion before ESD. The primary endpoint was to clarify the non-inferiority of M-BLI without biopsy confirmation compared to that with biopsy confirmation, in terms of the diagnostic accuracy and complete resection. RESULTS There were no significant differences in sex, median age, color, circumference, macroscopic type, biopsy-based diagnosis, and Helicobacter pylori infection between the two groups. The diagnostic accuracy for the DL was 100% and 95.0%, and the complete resection was 100% and 100%, in the M-BLI and M-BLI-BC groups, respectively. CONCLUSION The diagnostic ability of M-BLI is excellent in diagnosing the demarcation of gastric adenoma and well-differentiated adenocarcinoma. biopsy confirmation is not needed for these lesions with a clear DL by M-BLI.",2020,"There were no significant differences in sex, median age, color, circumference, macroscopic type, biopsy-based diagnosis, and Helicobacter pylori infection between the two groups.","['gastric tumors', 'A total of 122 lesions with a clear DL on M-BLI', 'curative complete resection by endoscopic submucosal dissection (ESD', '96 well-differentiated adenocarcinomas and 32 gastric adenomas were enrolled between July 2015 and December 2016']","['magnifying blue laser imaging without biopsy confirmation', 'magnifying blue laser imaging (M-BLI']","['sex, median age, color, circumference, macroscopic type, biopsy-based diagnosis, and Helicobacter pylori infection', 'complete resection', 'Efficacy and feasibility', 'non-inferiority of M-BLI without biopsy confirmation', 'diagnostic accuracy and complete resection', 'diagnostic accuracy']","[{'cui': 'C0038356', 'cui_str': 'Neoplasm of stomach'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0521097', 'cui_str': 'Cleared by'}, {'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C1276305', 'cui_str': 'Curative - procedure intent'}, {'cui': 'C0015250', 'cui_str': 'Complete excision'}, {'cui': 'C1700929', 'cui_str': 'Endoscopic Submucosal Dissection'}, {'cui': 'C0205615', 'cui_str': 'Well differentiated'}, {'cui': 'C0001418', 'cui_str': 'Adenocarcinoma'}, {'cui': 'C0149826', 'cui_str': 'Gastric adenoma'}]","[{'cui': 'C1289895', 'cui_str': 'Laser light, blue'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}]","[{'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009393', 'cui_str': 'Color'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0439806', 'cui_str': 'Gross'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}, {'cui': 'C0850666', 'cui_str': 'Infection caused by Helicobacter pylori'}, {'cui': 'C0015250', 'cui_str': 'Complete excision'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0521091', 'cui_str': 'Confirmation of'}, {'cui': 'C0443131', 'cui_str': 'Accurate'}]",,0.0372465,"There were no significant differences in sex, median age, color, circumference, macroscopic type, biopsy-based diagnosis, and Helicobacter pylori infection between the two groups.","[{'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Nakano', 'Affiliation': ''}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Dohi', 'Affiliation': ''}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Naito', 'Affiliation': ''}, {'ForeName': 'Kei', 'Initials': 'K', 'LastName': 'Terasaki', 'Affiliation': ''}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Iwai', 'Affiliation': ''}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Ueda', 'Affiliation': ''}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Majima', 'Affiliation': ''}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Horii', 'Affiliation': ''}, {'ForeName': 'Yuriko', 'Initials': 'Y', 'LastName': 'Yasuda-Onozawa', 'Affiliation': ''}, {'ForeName': 'Tomoko', 'Initials': 'T', 'LastName': 'Kitaichi', 'Affiliation': ''}, {'ForeName': 'Ryohei', 'Initials': 'R', 'LastName': 'Hirose', 'Affiliation': ''}, {'ForeName': 'Ken', 'Initials': 'K', 'LastName': 'Inoue', 'Affiliation': ''}, {'ForeName': 'Naohisa', 'Initials': 'N', 'LastName': 'Yoshida', 'Affiliation': ''}, {'ForeName': 'Kazuhiro', 'Initials': 'K', 'LastName': 'Kamada', 'Affiliation': ''}, {'ForeName': 'Kazuhiko', 'Initials': 'K', 'LastName': 'Uchiyama', 'Affiliation': ''}, {'ForeName': 'Osamu', 'Initials': 'O', 'LastName': 'Handa', 'Affiliation': ''}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Ishikawa', 'Affiliation': ''}, {'ForeName': 'Tomohisa', 'Initials': 'T', 'LastName': 'Takagi', 'Affiliation': ''}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Konishi', 'Affiliation': ''}, {'ForeName': 'Mitsuo', 'Initials': 'M', 'LastName': 'Kishimoto', 'Affiliation': ''}, {'ForeName': 'Yoshito', 'Initials': 'Y', 'LastName': 'Itoh', 'Affiliation': ''}]","Digestive diseases (Basel, Switzerland)",['10.1159/000510559'] 2875,32731249,Early Anticoagulation or Antiplatelet Therapy Is Critical in Craniocervical Artery Dissection: Results from the COMPASS Registry.,"INTRODUCTION Craniocervical artery dissection (CeAD) is a leading cause of stroke in the young patient population. Recent studies reported a low rate of major adverse cardiac events (MACEs) in patients with CeAD, with no significant difference between patients randomized to anticoagulation or antiplatelet therapy. OBJECTIVE To compare the effectiveness of anticoagulation and antiplatelet therapy in patients with CeAD. METHODS All CeAD patients from 2015 to 2017 were consecutively identified by an electronic medical record-based application and enrolled in this prospective longitudinal registry. CeAD was confirmed by imaging and graded using the Denver scale for blunt cerebrovascular injury. Patients were followed for 12 months for MACE defined as stroke, transient ischemic attack (TIA), or death. RESULTS The cohort included 111 CeAD patients (age 53 ± 15.9 years, 56% Caucasian, 50% female). CeAD was detected by magnetic resonance (5%), computed tomography (88%), or catheter angiography (7%). CeAD was noted in the carotid (59%), vertebral (39%), and basilar (2%) arteries, 82% of which were extracranial dissections. CeAD was classified as grade I, II, III, and IV in 16, 33, 19, and 32%, respectively. A total of 40% of dissections were due to known trauma. A predisposing factor was noted in the majority (78%) of patients, including violent sneezing (21%), carrying a heavy load (19%), sports/recreational activity (11%), chiropractic manipulation (9%), abrupt/prolonged rotation of head (9%), and prolonged phone use (9%). At presentation, 41% had a stroke, 5% had TIA, 39% had headache, and 36% were asymptomatic. Favorable outcome defined as a modified Rankin Scale score of 0-2 was noted in 68% at 3 months and 71% at 12 months. The rate of MACEs at 3 and 12 months was 11 and 14%, respectively, with more events observed in patients who were not receiving anticoagulation/antiplatelet therapy due to contraindications (p = 0.008). CONCLUSIONS We report diagnostic characteristics, as well as short- and long-term outcomes of CeAD. A high MACE rate was observed within the first 2 weeks of CeAD diagnosis, notably in patients not initiated on anticoagulation or antiplatelet therapy.",2020,Favorable outcome defined as a modified Rankin Scale score of 0-2 was noted in 68% at 3 months and 71% at 12 months.,"['young patient population', 'Craniocervical Artery Dissection', 'patients with CeAD', 'patients with CeAD.\nMETHODS\n\n\nAll CeAD patients from 2015 to 2017 were consecutively identified by an electronic medical record-based application and enrolled in this prospective longitudinal registry', '111 CeAD patients (age 53 ± 15.9 years, 56% Caucasian, 50% female']",['Craniocervical artery dissection (CeAD'],"['headache', 'sports/recreational activity', 'stroke, transient ischemic attack (TIA), or death', 'modified Rankin Scale score of 0-2', 'chiropractic manipulation', 'MACE rate', 'CeAD', 'violent sneezing', 'rate of MACEs']","[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0002949', 'cui_str': 'Dissection of artery'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C2362543', 'cui_str': 'Computer record of patient'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0023981', 'cui_str': 'Longitudinal Studies'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C4517538', 'cui_str': '111'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0007457', 'cui_str': 'Caucasian'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0002949', 'cui_str': 'Dissection of artery'}]","[{'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0038039', 'cui_str': 'Sport'}, {'cui': 'C0034872', 'cui_str': 'Recreation'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007787', 'cui_str': 'Transient cerebral ischemia'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0600577', 'cui_str': 'Chiropractic manipulation'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0002949', 'cui_str': 'Dissection of artery'}, {'cui': 'C0242151', 'cui_str': 'Violent'}, {'cui': 'C0037383', 'cui_str': 'Sneezing'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",111.0,0.0650806,Favorable outcome defined as a modified Rankin Scale score of 0-2 was noted in 68% at 3 months and 71% at 12 months.,"[{'ForeName': 'Lauren M', 'Initials': 'LM', 'LastName': 'Rosati', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Vezzetti', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Kolby T', 'Initials': 'KT', 'LastName': 'Redd', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Brittiny', 'Initials': 'B', 'LastName': 'McMillian', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Giamberardino', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Nishanth', 'Initials': 'N', 'LastName': 'Kodumuri', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Ravish', 'Initials': 'R', 'LastName': 'Kothari', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Anil V', 'Initials': 'AV', 'LastName': 'Yallapragada', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA.'}, {'ForeName': 'Souvik', 'Initials': 'S', 'LastName': 'Sen', 'Affiliation': 'Department of Neurology, Prisma Health Richland, University of South Carolina School of Medicine, Columbia, South Carolina, USA, souvik.sen@uscmed.sc.edu.'}]","Cerebrovascular diseases (Basel, Switzerland)",['10.1159/000509415'] 2876,32731259,A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.,"Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel, highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease were randomly assigned 1:1 to treatment with either ibrutinib or zanubrutinib. The primary endpoint was the proportion of patients achieving a complete or very good partial response (CR or VGPR) by independent review. Key secondary endpoints included major response rate (MRR), progression-free survival (PFS), duration of response (DOR), disease burden, and safety. A total of 201 patients were randomized, and 199 received ≥1 dose of study treatment. No patient achieved a CR. Twenty-nine (28%) zanubrutinib and 19 (19%) ibrutinib patients achieved a VGPR, a non-statistically significant difference (P = .09). MRRs were 77% and 78% , respectively. Median DOR and PFS were not reached; 84% and 85% of ibrutinib and zanubrutinib patients were progression-free at 18 months. Incidence of atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia, as well as adverse events leading to treatment discontinuation, were all lower among zanubrutinib recipients. Incidence of neutropenia was higher with zanubrutinib, although grade ≥3 infection rates were similar in both arms (1.2 and 1.1 events/100 person-months). These results demonstrate that zanubrutinib and ibrutinib are highly effective in the treatment of WM, but zanubrutinib treatment was associated with a trend toward better response quality and less toxicity, particularly cardiovascular toxicity.",2020,"Incidence of neutropenia was higher with zanubrutinib, although grade ≥3 infection rates were similar in both arms (1.2 and 1.1 events/100 person-months).","['201 patients', 'Patients with MYD88L265P disease', 'patients with Waldenström macroglobulinemia (WM', 'patients with WM']","['Bruton tyrosine kinase (BTK) inhibition', 'ibrutinib or zanubrutinib']","['major response rate (MRR), progression-free survival (PFS), duration of response (DOR), disease burden, and safety', 'Incidence of atrial fibrillation, contusion, diarrhea, peripheral edema, hemorrhage, muscle spasms, and pneumonia', 'proportion of patients achieving a complete or very good partial response (CR or VGPR', 'grade ≥3 infection rates', 'MRRs', 'response quality and less toxicity, particularly cardiovascular toxicity', 'Median DOR and PFS', 'efficacy and safety', 'Incidence of neutropenia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0024419', 'cui_str': ""Waldenstrom's macroglobulinemia""}]","[{'cui': 'C0218158', 'cui_str': ""Bruton's Tyrosine Kinase""}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C3501358', 'cui_str': 'Ibrutinib'}, {'cui': 'C4683810', 'cui_str': 'zanubrutinib'}]","[{'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0004238', 'cui_str': 'Atrial fibrillation'}, {'cui': 'C0009938', 'cui_str': 'Contusion'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0085649', 'cui_str': 'Peripheral edema'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0037763', 'cui_str': 'Spasm'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C3641222', 'cui_str': 'Very good'}, {'cui': 'C1521726', 'cui_str': 'In partial remission'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0332306', 'cui_str': 'Quality'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}]",201.0,0.0497721,"Incidence of neutropenia was higher with zanubrutinib, although grade ≥3 infection rates were similar in both arms (1.2 and 1.1 events/100 person-months).","[{'ForeName': 'Constantine S', 'Initials': 'CS', 'LastName': 'Tam', 'Affiliation': 'Peter MacCallum Cancer Centre, East Melbourne, Australia.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Opat', 'Affiliation': 'Monash Medical Centre, Clayton, Australia.'}, {'ForeName': 'Shirley', 'Initials': 'S', 'LastName': ""D'Sa"", 'Affiliation': 'UCLH Centre for Waldenströms Macroglobulinaemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Jurczak', 'Affiliation': 'Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.'}, {'ForeName': 'Hui-Peng', 'Initials': 'HP', 'LastName': 'Lee', 'Affiliation': 'Flinders Medical Centre, Adelaide, Australia.'}, {'ForeName': 'Gavin', 'Initials': 'G', 'LastName': 'Cull', 'Affiliation': 'Sir Charles Gairdiner Hospital, Nedlands, Australia.'}, {'ForeName': 'Roger G', 'Initials': 'RG', 'LastName': 'Owen', 'Affiliation': 'The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.'}, {'ForeName': 'Paula', 'Initials': 'P', 'LastName': 'Marlton', 'Affiliation': 'Princess Alexandra Hospital, Brisbane, Australia.'}, {'ForeName': 'Björn Engelbrekt', 'Initials': 'BE', 'LastName': 'Wahlin', 'Affiliation': 'Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Ramon', 'Initials': 'R', 'LastName': 'Garcia-Sanz', 'Affiliation': 'University Hospital of Salamanca, Salamanca, Spain.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'McCarthy', 'Affiliation': 'Royal Bournemouth Hospital, Bournemouth, United Kingdom.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Mulligan', 'Affiliation': 'Royal North Shore Hospital, Sydney, Australia.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Tedeschi', 'Affiliation': 'ASST Grande Ospedale Metropolitano Niguarda Hospital, Milano, Italy.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Castillo', 'Affiliation': 'Harvard Medical School, United States.'}, {'ForeName': 'Jaroslaw', 'Initials': 'J', 'LastName': 'Czyz', 'Affiliation': '23Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Fernández de Larrea', 'Affiliation': 'Hospital Clínic de Barcelona, Barcelona, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Belada', 'Affiliation': 'University Hospital and Medical School, Hradec Kralove, Hradec Kralove 5, Czech Republic.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Libby', 'Affiliation': 'University of Washington, Seattle, Washington, United States.'}, {'ForeName': 'Jeffrey V', 'Initials': 'JV', 'LastName': 'Matous', 'Affiliation': 'Colorado Blood Cancer Institute, Denver, Colorado, United States.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Motta', 'Affiliation': 'ASST Spedali Civili di Brescia, Lombardia, Italy.'}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Siddiqi', 'Affiliation': 'City of Hope National Medical Center, Duarte, California, United States.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Tani', 'Affiliation': 'Ospedale Civile S.Maria delle Croci, Ravenna, Italy.'}, {'ForeName': 'Marek', 'Initials': 'M', 'LastName': 'Trneny', 'Affiliation': '1st Faculty of Medicine, Charles University, Praha, Czech Republic.'}, {'ForeName': 'Monique C', 'Initials': 'MC', 'LastName': 'Minnema', 'Affiliation': 'UMC Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Buske', 'Affiliation': 'Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm, Germany.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Leblond', 'Affiliation': 'Hopital Pitie-Salpetriere, Paris, France.'}, {'ForeName': 'Wai Y', 'Initials': 'WY', 'LastName': 'Chan', 'Affiliation': 'BeiGene USA, Inc., San Mateo, California, United States.'}, {'ForeName': 'Jingjing Yan', 'Initials': 'JY', 'LastName': 'Schneider', 'Affiliation': 'BeiGene USA, Inc., San Mateo, California, United States.'}, {'ForeName': 'Sunhee', 'Initials': 'S', 'LastName': 'Ro', 'Affiliation': 'BeiGene USA, Inc., San Mateo, California, United States.'}, {'ForeName': 'Aileen', 'Initials': 'A', 'LastName': 'Cohen', 'Affiliation': 'BeiGene USA, Inc., San Mateo, California, United States.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'BeiGene USA, Inc, San Mateo, California, United States.'}, {'ForeName': 'Meletios A', 'Initials': 'MA', 'LastName': 'Dimopoulos', 'Affiliation': 'National and Kapodistrian University of Athens, Athens, Greece.'}]",Blood,['10.1182/blood.2020006844'] 2877,32736891,The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: A prospective randomized controlled study.,"BACKGROUND Linagliptin does not require dose adjustment in diabetes mellitus patients with chronic kidney disease (CKD). But, renal effects of linagliptin are not clear. Our aim was to examine the effect of linagliptin on renal disease progression in only insulin dependent type 2 diabetes mellitus (DM) patients with CKD. METHODS Stage 3-4 CKD patients were randomized into 2 groups in this prospective randomized controlled study. In the first group, linagliptin 5mg was added in addition to the background insulin therapy. In the second group, patients continued their insulin therapy. Patients were followed up at 3-month intervals for one year. RESULTS The study population consisted of 164 patients (90 patients in linagliptin group, 74 patients in other group) with a mean age of 67.5±8.8 years. eGFR significantly increased in linagliptin group (p=0.033), but decreased in other group (p=0.003). No significant change was observed in total insulin dose in linagliptin group (p=0.111), but in other group, total insulin dose significantly increased (p<0.001). Proteinuria levels decreased in both groups, but there was no significant change. In the multiple logistic regression analysis, male gender and proteinuria emerged as variables that showed significant association with increased risk and the use of linagliptin emerged as variable that showed significant association with decreased risk for CKD progression. CONCLUSION Linagliptin in DM patients with CKD was able to improve renal progression without significant effect on proteinuria and glucose control. With regard to treating diabetic nephropathy, linagliptin may offer a new therapeutic approach.",2020,Linagliptin in DM patients with CKD was able to improve renal progression without significant effect on proteinuria and glucose control.,"['diabetes mellitus patients with chronic kidney disease (CKD', 'only insulin dependent type 2 diabetes mellitus (DM) patients with CKD.\nMETHODS\n\n\nStage 3-4 CKD patients', 'group, 74 patients in other group) with a mean age of 67.5±8.8 years', 'DM patients with CKD', '164 patients (90 patients in', 'type-2 diabetes mellitus patients with chronic kidney disease']","['Linagliptin', 'linagliptin']","['Proteinuria levels', 'renal progression', 'renal disease progression', 'eGFR', 'proteinuria and glucose control', 'total insulin dose']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0011860', 'cui_str': 'Type 2 diabetes mellitus'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C0441771', 'cui_str': 'Stage level 3'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C2746078', 'cui_str': 'Linagliptin'}]","[{'cui': 'C0033687', 'cui_str': 'Proteinuria'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0022658', 'cui_str': 'Kidney disease'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}]",164.0,0.0171951,Linagliptin in DM patients with CKD was able to improve renal progression without significant effect on proteinuria and glucose control.,"[{'ForeName': 'Ali Ihsan', 'Initials': 'AI', 'LastName': 'Yagoglu', 'Affiliation': 'Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey. Electronic address: ali.ihsan.yagoglu@gmail.com.'}, {'ForeName': 'Oguzhan Sıtkı', 'Initials': 'OS', 'LastName': 'Dizdar', 'Affiliation': 'Department of Internal Medicine and Clinical Nutrition, Kayseri City Training and Research Hospital, Kayseri, Turkey.'}, {'ForeName': 'Selahattin', 'Initials': 'S', 'LastName': 'Erdem', 'Affiliation': 'Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey.'}, {'ForeName': 'Berkan', 'Initials': 'B', 'LastName': 'Akcakaya', 'Affiliation': 'Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey.'}, {'ForeName': 'Ali Ihsan', 'Initials': 'AI', 'LastName': 'Gunal', 'Affiliation': 'Department of Internal Medicine Division of Nephrology, Kayseri City Training and Research Hospital, Kayseri, Turkey.'}]",Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia,['10.1016/j.nefro.2020.04.023'] 2878,32736893,Effect of clopidogrel vs. aspirin on pro-atherosclerotic NLRP1 inflammasome expression in endothelial cells. ECLOAS study.,"INTRODUCTION AND OBJECTIVES NRP1 inflammasome is crucial in endothelial dysfunction. Platelets are mandatory for the inflammation that precedes it. Aspirin could inhibit NLRP1 inflammasome in endothelial cells, and clopidogrel could also provoke a reduction in vascular inflammation. A study was carried out on the influence of platelet inflammatory inhibition by P2Y receptor inhibition versus COX enzyme inhibition on the transcription of NLRP1 inflammasome in endothelial cells. METHODS An open-label, prospective, randomised crossover study with two periods of platelet inhibition enrolled 20 healthy volunteers. They received clopidogrel 75mg/day/7days and aspirin 100mg/day/7days. A venous blood sample was collected from all participants before and after this period. Human aortic endothelial cells (HAECs) were exposed for 2h in cultures. NLRP1 gene expression was then analysed in these cultures. RESULTS HAEC cultures that were exposed to baseline plasma showed higher expression of NLRP1 than HAECs exposed to plasma after one week of aspirin or clopidogrel intake [relative quantification (RQ), 1.077±0.05 vs. 1.002±0.06; OR, 1.8; 95% CI, 1.1-2.9; P<.01 and 1.077±0.05 vs. 1.04±0.03; OR, 1.7; 95% CI, 1.2-2.6; P<.001, respectively]. NLRP1 expression in HAEC cultures exposed to plasma after one week of aspirin or clopidogrel was similar to that observed in control HAECs that was no exposed to human plasma (PBS) [RQ; 1.002±0.06 vs. 1.009±0.03; OR, 0.9; 95% CI, 0.5-1.4; P=.7, and 1.04±0.03 vs. 1.009±0.03; OR, 0.8; 95% CI, 0.3-1.2; P=.5, respectively]. No difference was observed in NLRP1 percentage reduction in HAEC after aspirin or clopidogrel exposure (3.8% vs. 2.8%, P=.3, respectively). CONCLUSIONS Platelet inhibition by P2Y pathway is similar to COX pathway in NLRP1 expression inhibition in HAECs.",2020,"Aspirin could inhibit NLRP1 inflammasome in endothelial cells, and clopidogrel could also provoke a reduction in vascular inflammation.","['20 healthy volunteers', 'endothelial cells']","['aspirin or clopidogrel', 'clopidogrel vs. aspirin', 'clopidogrel 75mg/day/7days and aspirin 100mg/day/7days', 'Aspirin', 'P2Y receptor inhibition versus COX enzyme inhibition']","['NLRP1 percentage reduction in HAEC', 'Human aortic endothelial cells (HAECs', 'NLRP1 gene expression', 'NLRP1 expression', 'human plasma (PBS) [RQ']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}]","[{'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C0390418', 'cui_str': 'purinoceptor P2Y6'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0033551', 'cui_str': 'Prostaglandin synthase'}, {'cui': 'C0877008', 'cui_str': 'Enzyme inhibition'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0086418', 'cui_str': 'Homo sapiens'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0225336', 'cui_str': 'Endothelial cell'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}]",20.0,0.0498052,"Aspirin could inhibit NLRP1 inflammasome in endothelial cells, and clopidogrel could also provoke a reduction in vascular inflammation.","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Bleda', 'Affiliation': 'Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Getafe, Madrid, España. Electronic address: silbleik@yahoo.es.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'de Haro', 'Affiliation': 'Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Getafe, Madrid, España.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Sánchez', 'Affiliation': 'Departamento de Investigación, Fundación para la investigación biomédica del Hospital Universitario de Getafe, Madrid, España.'}, {'ForeName': 'Ilsem', 'Initials': 'I', 'LastName': 'Laime', 'Affiliation': 'Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Getafe, Madrid, España.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Acin', 'Affiliation': 'Servicio de Angiología y Cirugía Vascular, Hospital Universitario de Getafe, Madrid, España.'}]",Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis,['10.1016/j.arteri.2020.03.002'] 2879,32736909,Singing Improves Oxygen Saturation in Simulated High-Altitude Environment.,"At high altitude, low oxygen partial pressure predisposes human body to hypobaric hypoxia that may lead to high-altitude illness. Currently, singing had been used for rehabilitation of patients with lung diseases but its role in high-altitude low oxygen environment is still scarce. This study aims to examine the effect of singing in improving oxygen saturation at different levels of high altitudes in a hypobaric chamber. Eight healthy volunteers were assigned to three interventions at three simulated altitudes (sea level, 3000 m and 5000 m). The oxygen saturation (SpO 2 ) was measured via pulse oximetry under three conditions: no singing (NS), singing aloud (SA), and singing silently (SS). The ""birthday song"" was used as the standard song for 4 minutes. At sea level, mean NS SpO 2 was 97.75% ± 1.04%. With SS, the level increased to 98.25% ± 1.04%. Mean SA SpO 2 increased to 98.38% ± 0.92% (P < 0.05). At 3000 m, mean NS SpO 2 was 92.75% ± 3.73% and rose to 94.50% ± 2.51% and 94.63% ± 2.00% respectively with SA and SS (P < 0.05). At 5000 m, NS level of 79.88P ± 3.60% increased to 82.13 ± 5.87 and 82.88% ± 7.12% with SA and SS respectively (P < 0.05). The repeated measure ANOVA showed significant difference for altitude (P < 0.001) and intervention (P = 0.05). In conclusion, singing both either ""aloud"" or ""silently"" significantly increased the level of SpO 2 in simulated high altitude at 3000 m and above. The study suggests that singing as a potential intervention to improve oxygen saturation at high altitudes. Study with larger sample in hypobaric chamber as well as in real environment is recommended.",2020,The repeated measure ANOVA showed significant difference for altitude (P < 0.001) and intervention (P = 0.05).,['Eight healthy volunteers'],[],"['oxygen saturation', 'oxygen saturation (SpO 2 ', 'Oxygen Saturation', 'Mean SA SpO 2', 'singing (NS), singing aloud (SA), and singing silently (SS']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]",[],"[{'cui': 'C0523807', 'cui_str': 'Oxygen saturation measurement'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0234857', 'cui_str': 'Singing'}]",8.0,0.017979,The repeated measure ANOVA showed significant difference for altitude (P < 0.001) and intervention (P = 0.05).,"[{'ForeName': 'Alzamani Mohammad', 'Initials': 'AM', 'LastName': 'Idrose', 'Affiliation': 'Emergency Department, Hospital Kuala Lumpur, Malaysia; Faculty of Sports Science & Recreation, Universiti Teknologi MARA, Shah Alam, Malaysia.'}, {'ForeName': 'Norsham', 'Initials': 'N', 'LastName': 'Juliana', 'Affiliation': 'Faculty of Medicine and Health Science, Universiti Sains Islam Malaysia, Malaysia. Electronic address: njuliana@usim.edu.my.'}, {'ForeName': 'Sahar', 'Initials': 'S', 'LastName': 'Azmani', 'Affiliation': 'Faculty of Medicine and Health Science, Universiti Sains Islam Malaysia, Malaysia.'}, {'ForeName': 'Noor Anisah Abu', 'Initials': 'NAA', 'LastName': 'Yazit', 'Affiliation': 'Faculty of Medicine and Health Science, Universiti Sains Islam Malaysia, Malaysia.'}, {'ForeName': 'Munawarah Silam Abu', 'Initials': 'MSA', 'LastName': 'Muslim', 'Affiliation': 'Aviation Institute, Royal Malaysian Air Force, Malaysia.'}, {'ForeName': 'Mazdy', 'Initials': 'M', 'LastName': 'Ismail', 'Affiliation': 'Aviation Institute, Royal Malaysian Air Force, Malaysia.'}, {'ForeName': 'Syazwan Nazri', 'Initials': 'SN', 'LastName': 'Amir', 'Affiliation': 'Faculty of Medicine and Health Science, Universiti Sains Islam Malaysia, Malaysia.'}]",Journal of voice : official journal of the Voice Foundation,['10.1016/j.jvoice.2020.06.031'] 2880,32736928,"The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.","BACKGROUND Instillation therapy for non-muscle-invasive bladder cancer (NMIBC) reduces recurrences but is associated with side effects. Preoperative instillation of chemotherapy could potentially be associated with fewer side effects compared with adjuvant instillations and in some patients make tumour resection (transurethral resection of the bladder tumour [TURBT]) superfluous. OBJECTIVE To investigate tumour response and adverse events related to short-term, intensive chemoresection with mitomycin C compared with adjuvant instillations in patients with recurrent NMIBC. DESIGN, SETTING, AND PARTICIPANTS A randomised, controlled trial was conducted in two urological departments in Denmark from January 2018 to June 2019. In total, 120 participants with a history of Ta bladder tumours, low grade or high grade, were included upon recurrence. INTERVENTION Intravesical mitomycin C (40 mg/40 ml) three times a week for 2 wk in the intervention group (59 patients) was compared with TURBT and six weekly adjuvant instillations in the control group (61 patients). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS Tumour response was evaluated in the intervention group by flexible cystoscopy after 4 wk. Side effects were prospectively registered in both groups using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Groups were compared using χ 2 or Fisher's exact test. RESULTS AND LIMITATIONS Complete tumour response was seen in 33 participants (57%) in the intervention group. Fewer adverse events were reported in the intervention group than in the control group. Two patients in each group ceased instillation treatment due to adverse events. The main limitation is the current lack of long-term follow-up. CONCLUSIONS Short-term, intensive chemoresection yields a tumour response of 57%. Hence, only half of those treated with chemoresection needed TURBT. The treatment was furthermore associated with fewer clinically significant side effects. Owing to small numbers, further investigations on Ta high-grade tumours are needed. PATIENT SUMMARY We compared a nonsurgical treatment with standard treatment in patients with superficial bladder tumours. We found it to be safe and able to avoid surgery in more than half of the patients.",2020,Fewer adverse events were reported in the intervention group than in the control group.,"['two urological departments in Denmark from January 2018 to June 2019', '120 participants with a history of Ta bladder tumours, low grade or high grade, were included upon recurrence', 'Non-muscle-invasive Bladder Cancer', 'patients with superficial bladder tumours', 'patients with recurrent NMIBC']","['Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations', 'TURBT', 'mitomycin C', 'Intravesical mitomycin C', 'chemotherapy']","['Side effects', 'adverse events', 'Tumour response', 'side effects']","[{'cui': 'C3653764', 'cui_str': 'UROLOGICALS'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0005682', 'cui_str': 'Urinary bladder structure'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C1962916', 'cui_str': 'Low grade (lymphoma)'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1827293', 'cui_str': 'Carcinoma of urinary bladder, invasive'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205124', 'cui_str': 'Superficial'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}, {'cui': 'C0021917', 'cui_str': 'Instillation of bladder'}, {'cui': 'C0401496', 'cui_str': 'Transurethral resection of bladder neoplasm'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0442124', 'cui_str': 'Intravesical approach'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]",120.0,0.0896226,Fewer adverse events were reported in the intervention group than in the control group.,"[{'ForeName': 'Maria S', 'Initials': 'MS', 'LastName': 'Lindgren', 'Affiliation': 'Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Regional Hospital West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark. Electronic address: maalin@rm.dk.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Bue', 'Affiliation': 'Department of Urology, Regional Hospital West Jutland, Holstebro, Denmark.'}, {'ForeName': 'Nessn', 'Initials': 'N', 'LastName': 'Azawi', 'Affiliation': 'Department of Urology, Zealand University Hospital, Roskilde, Denmark.'}, {'ForeName': 'Linea', 'Initials': 'L', 'LastName': 'Blichert-Refsgaard', 'Affiliation': 'Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Maria O', 'Initials': 'MO', 'LastName': 'Sundelin', 'Affiliation': 'Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Regional Hospital West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Dyrskjøt', 'Affiliation': 'Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark; Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.'}, {'ForeName': 'Jørgen B', 'Initials': 'JB', 'LastName': 'Jensen', 'Affiliation': 'Department of Urology, Aarhus University Hospital, Aarhus, Denmark; Department of Urology, Regional Hospital West Jutland, Holstebro, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.'}]",European urology,['10.1016/j.eururo.2020.07.009'] 2881,32736963,Inspiratory Muscle Training Improves Inspiratory Muscle Strength and Functional Exercise Capacity in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Randomised Controlled Study.,"BACKGROUND Exercise intolerance is present even in the early stages of pulmonary arterial hypertension (PAH) and is associated with poorer prognosis. Respiratory muscle dysfunction is common and may contribute to exercise limitation. We sought to investigate the effects of inspiratory muscle training (IMT) to improve exercise capacity in PAH. METHODS Adults with PAH were prospectively recruited and randomly assigned to either IMT or a control group. At baseline and after 8 weeks, assessment of respiratory muscle function, pulmonary function, neurohormonal activation, 6-minute walk distance and cardiopulmonary exercise testing variables were conducted. Inspiratory muscle strength was assessed by maximal static inspiratory pressure (PImax). The IMT group performed two cycles of 30 breaths at 30-40% of their PImax 5 days a week for 8 weeks. RESULTS Twelve (12) PAH patients (60±14 years, 10 females) were recruited and randomised (six in the IMT group and six in the control group). After 8 weeks, the IMT group improved PImax by 31 cmH 2 O compared with 10 cmH 2 O in controls, p=0.02. Following IMT, 6-minute walk distance improved by 24.5 m in the IMT group and declined by 12 m in the controls (mean difference 36.5 m, 95% CI 3.5-69.5, p=0.03). There was no difference in peak oxygen uptake between-groups (mean difference 0.4 mL/kg/min, 95% CI -2.6 to 3.4, p=0.77). There was no difference in the mean change between-groups in neurohormonal activation or pulmonary function. CONCLUSION In this pilot randomised controlled study, IMT improved PImax and 6-minute walk distance in PAH patients.",2020,"Following IMT, 6-minute walk distance improved by 24.5 m in the IMT group and declined by 12 m in the controls (mean difference 36.5 m, 95% CI 3.5-69.5, p=0.03).","['Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension', 'PAH patients', 'Adults with PAH', 'Twelve (12) PAH patients (60±14 years, 10 females']","['IMT', 'inspiratory muscle training (IMT', 'Inspiratory Muscle Training Improves Inspiratory Muscle Strength and Functional Exercise Capacity']","['PImax and 6-minute walk distance', 'maximal static inspiratory pressure (PImax', 'respiratory muscle function, pulmonary function, neurohormonal activation, 6-minute walk distance and cardiopulmonary exercise testing variables', 'peak oxygen uptake', '6-minute walk distance', 'Inspiratory muscle strength', 'neurohormonal activation or pulmonary function']","[{'cui': 'C2973725', 'cui_str': 'Pulmonary arterial hypertension'}, {'cui': 'C2363973', 'cui_str': 'Chronic thromboembolic pulmonary hypertension'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0454284', 'cui_str': 'Functional exercises'}]","[{'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0429886', 'cui_str': 'Walking distance'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0021724', 'cui_str': 'Structure of intercostal muscle'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0231921', 'cui_str': 'Pulmonary function'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary exercise test'}, {'cui': 'C0439828', 'cui_str': 'Variable'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0429627', 'cui_str': 'Oxygen uptake'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}]",,0.106105,"Following IMT, 6-minute walk distance improved by 24.5 m in the IMT group and declined by 12 m in the controls (mean difference 36.5 m, 95% CI 3.5-69.5, p=0.03).","[{'ForeName': 'Derek', 'Initials': 'D', 'LastName': 'Tran', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Phillip', 'Initials': 'P', 'LastName': 'Munoz', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Edmund M T', 'Initials': 'EMT', 'LastName': 'Lau', 'Affiliation': 'Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Jennifer A', 'Initials': 'JA', 'LastName': 'Alison', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia; Department of Physiotherapy, Royal Prince Alfred Hospital, Sydney, Australia.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Brown', 'Affiliation': 'Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.'}, {'ForeName': 'Yizhong', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Department of Respiratory and Sleep Medicine, St George Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Corkery', 'Affiliation': 'Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Wong', 'Affiliation': 'Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Lindstrom', 'Affiliation': 'Department of Respiratory and Sleep Medicine, St George Hospital, Sydney, NSW, Australia.'}, {'ForeName': 'David S', 'Initials': 'DS', 'LastName': 'Celermajer', 'Affiliation': 'Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Glen M', 'Initials': 'GM', 'LastName': 'Davis', 'Affiliation': 'Sydney School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Rachael', 'Initials': 'R', 'LastName': 'Cordina', 'Affiliation': 'Department of Cardiology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia. Electronic address: rachael.cordina@sydney.edu.au.'}]","Heart, lung & circulation",['10.1016/j.hlc.2020.06.006'] 2882,32737091,Choice of ANaesthesia for EndoVAScular treatment of acute ischaemic stroke at posterior circulation (CANVAS II): protocol for an exploratory randomised controlled study.,"INTRODUCTION Observational and interventional studies indicate that the type of anaesthesia may be associated with the postprocedural neurological function in patients with anterior circulation acute ischaemic stroke undergoing endovascular treatment. Patients with acute posterior circulation ischaemic stroke may experience different physiological changes and result in severe neurological outcome. However, the effect of the type of anaesthesia on postprocedure neurological function remained unclear in this population. METHODS AND ANALYSIS This is an exploratory randomised controlled trial that will be carried out at Beijing Tiantan Hospital, Capital Medical University. Patients with acute posterior circulation ischaemic stroke and deemed suitable for emergency endovascular recanalisation will be recruited in this trial. Eighty-four patients will be randomised to receive either general anaesthesia or conscious sedation with 1:1 allocation ratio. The primary endpoint is the 90-day modified Rankin Scale. ETHICS AND DISSEMINATION The study has been reviewed by and approved by Ethics Committee of Beijing Tiantan Hospital of Capital Medical University (KY2017-074-02). If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke. The findings of the study will be published in peer-reviewed journals and presented at national or international conferences. TRIAL REGISTRATION NUMBER NCT03317535.",2020,"If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke.","['Patients with acute posterior circulation ischaemic stroke', 'Beijing Tiantan Hospital of Capital Medical University (KY2017-074-02', 'patients with anterior circulation acute ischaemic stroke undergoing endovascular treatment', 'acute ischaemic stroke at posterior circulation (CANVAS II', 'Beijing Tiantan Hospital, Capital Medical University']","['ANaesthesia', 'general anaesthesia or conscious sedation with 1:1 allocation ratio', 'emergency endovascular recanalisation']","['90-day modified Rankin Scale', 'postprocedure neurological function']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0205095', 'cui_str': 'Dorsal'}, {'cui': 'C0005775', 'cui_str': 'Circulation, Blood'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke'}, {'cui': 'C4042832', 'cui_str': 'Peking'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0006909', 'cui_str': 'Capital'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0205094', 'cui_str': 'Anterior'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0002903', 'cui_str': 'Administration of anesthesia'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0079159', 'cui_str': 'Conscious sedation'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0175673', 'cui_str': 'Emergency'}, {'cui': 'C0034771', 'cui_str': 'Recanalization'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0027767', 'cui_str': 'Nervous system function'}]",84.0,0.174259,"If the results are positive, the study will indicate whether the type of anaesthesia affects neurological outcome after endovascular treatment of posterior stroke.","[{'ForeName': 'Fa', 'Initials': 'F', 'LastName': 'Liang', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Zhao', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Yan', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Youxuan', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Xiuheng', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Minyu', 'Initials': 'M', 'LastName': 'Jian', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Shu', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Zhongrong', 'Initials': 'Z', 'LastName': 'Miao', 'Affiliation': 'Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Ruquan', 'Initials': 'R', 'LastName': 'Han', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Yuming', 'Initials': 'Y', 'LastName': 'Peng', 'Affiliation': 'Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China florapym766@163.com.'}]",BMJ open,['10.1136/bmjopen-2019-036358'] 2883,32737097,Ensemble programme for early intervention in informal caregivers of psychiatric adult patients: a protocol for a randomised controlled trial.,"INTRODUCTION Informal caregivers play a major role in the support and maintenance of community patients with severe psychiatric disorders. A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. METHODS AND ANALYSIS This randomised controlled trial aims to compare the efficacy of using Ensemble in improving informal caregivers' psychological health states and the ability to play an active role in their situations with that of support as usual. Improvements on the psychological health global index will be measured three times (T0-pre, T1-post and T3 2 months follow) with standardised questionnaires (the Global Severity Index of Brief Inventory Symptoms, the Life Orientation Test-Revised, the 36-item Medical Outcome Study Short-Form Health Survey and the French Zarit Burden Interview). Differences between groups in post-test and pretest values will be examined using an analysis of covariance for each outcome variable. The severity of illness measured by the Social and Occupational Functioning Assessment Scale will also be collected at T0 and T2 to compare eventual patient improvements. At the end of the programme, the experiences of the 20 patients participating in the Ensemble programme will be evaluated qualitatively. ETHICS AND DISSEMINATION The research protocol received full authorisation from the Human Research Ethics Committee of the Vaud state, Switzerland. The principal paper will concern the results of the experimental design used to test the Ensemble programme. The research team will prioritise open access publications. TRIAL REGISTRATION NUMBER NCT04020497.",2020,"A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. ","['informal caregivers of psychiatric adult patients', 'community patients with severe psychiatric disorders', '20 patients participating in the Ensemble programme will be evaluated qualitatively']",[],"['severity of illness measured by the Social and Occupational Functioning Assessment Scale', 'Global Severity Index of Brief Inventory Symptoms, the Life Orientation Test-Revised, the 36-item Medical Outcome Study Short-Form Health Survey and the French Zarit Burden Interview', 'psychological health state and optimism', 'psychological health global index']","[{'cui': 'C1319882', 'cui_str': 'Informal caregiver'}, {'cui': 'C0033873', 'cui_str': 'Psychiatry'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}]",[],"[{'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0221423', 'cui_str': 'Illness'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0521127', 'cui_str': 'Occupational'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0582640', 'cui_str': 'Life orientation test'}, {'cui': 'C1527075', 'cui_str': 'Revision procedure'}, {'cui': 'C0199168', 'cui_str': 'Medical service'}, {'cui': 'C0543472', 'cui_str': 'Outcome Studies'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0376246', 'cui_str': 'French language'}, {'cui': 'C0021822', 'cui_str': 'Interviews as Topic'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0237428', 'cui_str': 'Positive attitude'}]",20.0,0.0922263,"A pilot study showed that an individualised brief intervention such as the Ensemble programme leads to significant improvements in psychological health state and optimism. ","[{'ForeName': 'Shyhrete', 'Initials': 'S', 'LastName': 'Rexhaj', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland s.rexhaj@ecolelasource.ch.'}, {'ForeName': 'Shadya', 'Initials': 'S', 'LastName': 'Monteiro', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Golay', 'Affiliation': 'Community Psychiatry Service, Department of Psychiatry, Lausanne, CHUV, Lausanne, VD, Switzerland.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Coloni-Terrapon', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Wenger', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}, {'ForeName': 'Jérôme', 'Initials': 'J', 'LastName': 'Favrod', 'Affiliation': 'La Source, School of Nursing, University of Applied Sciences and Arts Western Switzerland, HES-SO, Lausanne, Vaud, Switzerland.'}]",BMJ open,['10.1136/bmjopen-2020-038781'] 2884,32737183,Effects of Inactivation of the Periaqueductal Gray on Song Production in Testosterone-Treated Male Canaries ( Serinus canaria ).,"Male canaries ( Serinus canaria ) display seasonal changes in the motivation to sing which have been found to be dependent on the action of testosterone (T). During the breeding season when T is high, males sing at a higher rate compared to males with low T. The effect of T on song rate is known to be mediated by the medial preoptic nucleus (POM); however, it is unclear how T-signaling in POM impacts song production. One potential mechanism is via modulation of dopaminergic input into song control nuclei by the periaqueductal gray (PAG). In order to test the role of PAG in T-mediated song production, we treated male canaries with peripheral T implants and implanted a guide cannula targeting the PAG. Through this guide cannula, we transiently inactivated PAG with injections of the GABA A agonist, muscimol. Each bird received multiple infusions of both muscimol and saline with a 48-hour washout period between treatments. The order of injection type was randomized and counterbalanced between individuals. Muscimol infusion into the PAG, but not nearby regions, increased the latency to sing post-injection. These results support the hypothesis that PAG is involved in the production of song, potentially mediating the motivation to sing or alternatively interfering with the pre-motor activity of nucleus RA. Other song features were however not affected. SIGNIFICANCE STATEMENT Communication is essential for social species relying on coordinated behavior for survival and reproduction. However, the neural mechanisms underlying the motivation to engage in vocal communication are currently unknown. Here, we show that inhibition of the periaqueductal gray (PAG) increases the latency for male canaries to sing, but does not influence features of song quality once they resume singing. These results indicate that the PAG is involved in regulating the motor initiation or the underlying motivation of the complex, learned behavior of singing but not of innate vocalizations, such as calls. Our findings suggest that the PAG is likely involved in transmitting preoptic signals to the song control system, probably via dopaminergic projections from this region to song control nuclei.",2020,"Muscimol infusion into the PAG, but not nearby regions, increased the latency to sing post-injection.",['Testosterone-Treated Male Canaries ( Serinus canaria '],['muscimol and saline'],[],"[{'cui': 'C0039601', 'cui_str': 'Testosterone'}, {'cui': 'C0087111', 'cui_str': 'Therapeutic procedure'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0006824', 'cui_str': 'Genus Serinus'}, {'cui': 'C1095844', 'cui_str': 'Serinus canaria'}]","[{'cui': 'C0026818', 'cui_str': 'Muscimol'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}]",[],,0.0304729,"Muscimol infusion into the PAG, but not nearby regions, increased the latency to sing post-injection.","[{'ForeName': 'Chelsea M', 'Initials': 'CM', 'LastName': 'Haakenson', 'Affiliation': 'Program in Neuroscience and Cognitive Science, Department of Psychology, University of Maryland, College Park, MD, USA chaakens@umd.edu.'}, {'ForeName': 'Jacques', 'Initials': 'J', 'LastName': 'Balthazart', 'Affiliation': 'Laboratory of Behavioral Neuroendocrinology, GIGA Neurosciences, University of Liege, Belgium.'}, {'ForeName': 'Gregory F', 'Initials': 'GF', 'LastName': 'Ball', 'Affiliation': 'Program in Neuroscience and Cognitive Science, Department of Psychology, University of Maryland, College Park, MD, USA.'}]",eNeuro,['10.1523/ENEURO.0048-20.2020'] 2885,32737210,Enhancing help-seeking behaviour among men who have sex with men at risk for sexually transmitted infections: the syn.bas.in randomised controlled trial.,"OBJECTIVES Men who have sex with men (MSM) are at increased risk for STIs and mental disorders. Syndemic theory holds that psychosocial issues co-occur and interact, and thus increase sexual risk behaviour. Psychosocial issue identification, referral and management might reduce risk behaviour. METHODS In the syndemic-based intervention study, an open-label randomised controlled trial, MSM were enrolled at the STI outpatient clinic of the Public Health Service of Amsterdam. We screened participants using validated questionnaires on the following problem domains: alcohol and substance use, sexual compulsivity, anxiety, depression, attention deficit hyperactivity disorder, alexithymia, intimate partner violence and childhood sexual abuse. Individuals were randomly assigned (1:1) to receive either tailored, face-to-face feedback and help-seeking advice on mental health screening, or no feedback and no help-seeking advice. Participants were followed trimonthly for a year. The primary outcomes were self-reported and confirmed help-seeking behaviour. RESULTS We included 155 MSM: 76 in the intervention group and 79 in the control group. At inclusion, 128 participants (83.1%) scored positive in at least one problem domain. We found no significant differences in self-reported or confirmed help-seeking behaviour between the intervention and the control group: 41% vs 29% (p=0.14) and 28% vs 22% (p=0.44), respectively. There were also no differences in STI incidence and condomless anal sex acts between the two groups. CONCLUSION Screening showed high prevalence of problems related to mental health and substance use, while tailored feedback, advice and referral did not significantly increase help-seeking behaviour. Other interventions are needed to tackle the high burden of mental disorders among MSM. TRIAL REGISTRATION NUMBER NCT02859935.",2020,"We found no significant differences in self-reported or confirmed help-seeking behaviour between the intervention and the control group: 41% vs 29% (p=0.14) and 28% vs 22% (p=0.44), respectively.","['Men who have sex with men (MSM', 'men who have sex with men at risk for sexually transmitted infections', 'screened participants using validated questionnaires on the following problem domains: alcohol and substance use, sexual compulsivity, anxiety, depression, attention deficit hyperactivity disorder, alexithymia, intimate partner violence and childhood sexual abuse', 'MSM were enrolled at the STI outpatient clinic of the Public Health Service of Amsterdam', '155 MSM: 76 in the intervention group and 79 in the control group']","['tailored, face-to-face feedback and help-seeking advice on mental health screening, or no feedback and no help-seeking advice']","['sexual risk behaviour', 'STI incidence and condomless anal sex acts', 'seeking behaviour', 'help-seeking behaviour', 'self-reported and confirmed help-seeking behaviour']","[{'cui': 'C0242657', 'cui_str': 'Men Who Have Sex With Men'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0001962', 'cui_str': 'Ethanol'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C1263846', 'cui_str': 'Attention deficit hyperactivity disorder'}, {'cui': 'C0002020', 'cui_str': 'Alexithymia'}, {'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0231335', 'cui_str': 'Childhood'}, {'cui': 'C0282350', 'cui_str': 'Sexual abuse'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0041734', 'cui_str': 'United States. Public Health Service'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C0150600', 'cui_str': 'Recommendation to'}, {'cui': 'C0184646', 'cui_str': 'Mental health screening'}]","[{'cui': 'C0036864', 'cui_str': 'Sexual behavior'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0036916', 'cui_str': 'Sexually transmitted infectious disease'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0282347', 'cui_str': 'Anal sex'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C1269765', 'cui_str': 'Assisted'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}]",155.0,0.0923846,"We found no significant differences in self-reported or confirmed help-seeking behaviour between the intervention and the control group: 41% vs 29% (p=0.14) and 28% vs 22% (p=0.44), respectively.","[{'ForeName': 'Roeland Christiaan Alfons', 'Initials': 'RCA', 'LastName': 'Achterbergh', 'Affiliation': 'STI Outpatient Clinic, Infectious Diseases Department, Public Health Sevice of Amsterdam, Amsterdam, North Holland, The Netherlands.'}, {'ForeName': 'Martijn S', 'Initials': 'MS', 'LastName': 'van Rooijen', 'Affiliation': 'STI Outpatient Clinic, Infectious Diseases Department, Public Health Sevice of Amsterdam, Amsterdam, North Holland, The Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van den Brink', 'Affiliation': 'Department of Psychiatry, Amsterdam UMC Location AMC, Amsterdam, North Holland, The Netherlands.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Boyd', 'Affiliation': 'Department of Infectious Diseases Research and Prevention, Public Health Service of Amsterdam, Amsterdam, Noord-Holland, The Netherlands.'}, {'ForeName': 'Henry John Christiaan', 'Initials': 'HJC', 'LastName': 'de Vries', 'Affiliation': 'STI Outpatient Clinic, Infectious Diseases Department, Public Health Sevice of Amsterdam, Amsterdam, North Holland, The Netherlands h.j.devries@amc.nl.'}]",Sexually transmitted infections,['10.1136/sextrans-2020-054438'] 2886,32737249,Correction: Cost-utility analysis of learning and coping versus standard education in cardiac rehabilitation: a randomised controlled trial with 3 years of follow-up.,,2020,,['cardiac rehabilitation'],['learning and coping versus standard education'],[],"[{'cui': 'C0150497', 'cui_str': 'Cardiac rehabilitation'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0009967', 'cui_str': 'Coping behavior'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}]",[],,0.11373,,[],Open heart,['10.1136/openhrt-2019-001184corr1'] 2887,32737482,Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.,"BACKGROUND Switching from boosted PIs to dolutegravir in virologically suppressed HIV-infected patients with high cardiovascular risk significantly decreased total cholesterol and other proatherogenic lipid fractions at 48 weeks. The impact of this strategy on subclinical cardiovascular disease is unknown. METHODS NEAT022 is a European, multicentre, open-label, randomized, non-inferiority trial. HIV-infected adults aged >50 years or with a Framingham score >10% were eligible if plasma HIV RNA was <50 copies/mL for >24 weeks on a boosted PI-based regimen. Patients were randomized 1:1 to switch from boosted PIs to dolutegravir or to continue on boosted PIs. Common carotid arteries intima-media thickness (CIMT) and pulse wave velocity (PWV) were measured following a standardized protocol in a subgroup of NEAT022 study participants at baseline and at Week 48. RESULTS One hundred and fifty-six patients participated in the ultrasonography and arterial stiffness substudies, respectively. In each substudy, population characteristics did not differ between arms and matched those of the main study. At 48 weeks, patients who switched to dolutegravir had lower mean progression of both right (+4 versus +14.6 μm) and left (-6.1 versus +1.6 μm) CIMT and also a smaller increase in mean PWV (+0.18 versus +0.39 m/s) than patients continuing on boosted PIs, although differences were not statistically significant. CIMT trends were consistent across Framingham score, age and country. Inconsistent effects were seen in arterial stiffness. CONCLUSIONS Relative to continuing on boosted PIs, switching to dolutegravir in virologically suppressed patients with high cardiovascular risk showed consistent favourable although non-significant trends on CIMT progression at 48 weeks.",2020,"Common carotid arteries intima-media thickness (CIMT) and pulse wave velocity (PWV) were measured following a standardized protocol in a subgroup of NEAT022 study participants at baseline and at Week 48. ","['HIV-infected patients with high cardiovascular risk', 'HIV-infected adults aged >50\u2009years or with a Framingham score', 'One hundred and fifty-six patients participated in the ultrasonography and arterial stiffness substudies, respectively']",[],"['Common carotid arteries intima-media thickness (CIMT) and pulse wave velocity (PWV', 'arterial stiffness', 'mean PWV', 'mean progression of both right', 'total cholesterol and other proatherogenic lipid fractions', 'CIMT progression']","[{'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}]",[],"[{'cui': 'C0007272', 'cui_str': 'Carotid artery structure'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0599949', 'cui_str': 'Arterial stiffness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C1264633', 'cui_str': 'Fraction of'}]",156.0,0.107148,"Common carotid arteries intima-media thickness (CIMT) and pulse wave velocity (PWV) were measured following a standardized protocol in a subgroup of NEAT022 study participants at baseline and at Week 48. ","[{'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Gonzalez-Cordon', 'Affiliation': 'Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Lambert', 'Initials': 'L', 'LastName': 'Assoumou', 'Affiliation': ""Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013 Paris, France.""}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Camafort', 'Affiliation': 'Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Domenech', 'Affiliation': 'Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Guaraldi', 'Affiliation': 'University of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'Pere', 'Initials': 'P', 'LastName': 'Domingo', 'Affiliation': 'Hospital de Sant Pau, Barcelona, Spain.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Rusconi', 'Affiliation': 'DIBIC Luigi Sacco, University of Milan, Milan, Italy.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Raffi', 'Affiliation': 'Hotel-Dieu University Hospital, Nantes, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Katlama', 'Affiliation': 'Hôpital Pitié-Salpêtrière, Paris, France.'}, {'ForeName': 'Mar', 'Initials': 'M', 'LastName': 'Masia', 'Affiliation': 'Hospital General Universitario de Elche, Elche, Spain.'}, {'ForeName': 'Jose I', 'Initials': 'JI', 'LastName': 'Bernardino', 'Affiliation': 'Hospital Universitario La Paz, Madrid, Spain.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Saumoy', 'Affiliation': 'Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Pozniak', 'Affiliation': 'Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.'}, {'ForeName': 'Jose M', 'Initials': 'JM', 'LastName': 'Gatell', 'Affiliation': 'Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Esteban', 'Initials': 'E', 'LastName': 'Martinez', 'Affiliation': 'Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona, Spain.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Journal of antimicrobial chemotherapy,['10.1093/jac/dkaa292'] 2888,32737577,"Oral mycophenolate mofetil as a stabilizing treatment for progressive non-segmental vitiligo: results from a prospective, randomized, investigator-blinded pilot study.","Dexamethasone oral mini-pulse (OMP) is commonly used to halt progression of non-segmental vitiligo (NSV). There is an unmet need for non-phototherapy, non-corticosteroid therapeutic options for stabilizing actively spreading NSV. To assess the efficacy of oral mycophenolate mofetil in stabilizing active NSV in comparison to OMP. In this prospective, randomized, investigator-blinded study, 50 patients of active vitiligo [baseline vitiligo disease activity (VIDA) score 4] were randomized into two groups in 1:1 ratio. Group A received oral dexamethasone (2.5 mg on two successive days a week) and group B received mycophenolate mofetil (up to 2 g) for 180 days with a treatment-free follow-up period of 90 days. Assessment was done using VIDA, number of new lesions in past 30 days, and Vitiligo Area Scoring Index (VASI). Arrest of disease progression was defined as the absence of any new lesions in past 30 days. Twenty-five patients received OMP (group A, 11 males, 14 females), and 25 received mycophenolate (group B, 12 males, 13 females). In both groups, Kruskal-Wallis revealed a significant trend for reduction in VIDA and the number of new lesions in last 30 days, over the treatment and follow-up duration when compared to baseline (p < 0.001). The first significant reduction in VIDA was noticed on 90th day in groups A and B (p < 0.001). In both groups, VIDA reduced significantly at the 180th day compared to baseline (p < 0.001, WMP), only to increase significantly at the 270th day (p < 0.001, WMP). VIDA in group B was marginally higher at 270 days than group A (p 0.03; Mann-Whitney). Eighteen and 17 patients achieved VIDA 2 + on the 180th day in groups A and B, respectively. The mean number of new lesions in last 30 days reduced significantly in both groups at the 180th day (p < 0.001) and 270th day [p < 0.001; Wilcoxon matched pairs (WMP)] when compared to baseline; but increased significantly at the 270th day compared to the 180th day (p 0.006 WMP). Twenty patients in group A and 18 patients in group B had arrest of the disease activity with treatment. Mean duration to arrest disease progression was 47.2 ± 12.1 days in group A, and 52.5 ± 9.3 days in group B; p 0.21. The difference between VASI at baseline and VASI at the 180 and 270th days was non-significant in both groups (p 0.18 WMP). Five patients in each group failed the respective treatments. Acne (n = 3), weight gain (n = 3), headache, insomnia and menstrual irregularity (n = 1 each) were the important adverse effects noted with dexamethasone pulse; whereas nausea (n = 6) and diarrhea (n = 4) were the commonest adverse effects noted with mycophenolate. Two patients in group B discontinued treatment because of leucopenia (n = 1) and transaminitis (n = 1) that resolved after the discontinuation of mycophenolate. Both OMP and mycophenolate mofetil halt actively spreading vitiligo, and have distinct adverse effect profiles. These should be offered in progressive vitiligo, especially in circumstances precluding the use of phototherapy. Relapse occurred significantly earlier with mycophenolate, and relapse rate was higher (though non-significant) than dexamethasone OMP. The repigmentation potential is minimal for both therapies. This study was approved by Institute Ethics Committee, and retrospectively registered with clinical trial registry of India (CTRI/2018/02/011,664).",2020,"In both groups, Kruskal-Wallis revealed a significant trend for reduction in VIDA and the number of new lesions in last 30 days, over the treatment and follow-up duration when compared to baseline (p < 0.001).","['progressive non-segmental vitiligo', 'group A, 11 males, 14 females), and 25 received', '50 patients of active vitiligo [baseline vitiligo disease activity (VIDA) score 4', 'group B, 12 males, 13 females']","['mycophenolate', 'mycophenolate mofetil', 'Dexamethasone oral mini-pulse (OMP', 'oral dexamethasone', 'OMP', 'Oral mycophenolate mofetil']","['Arrest of disease progression', 'diarrhea', 'arrest of the disease activity', 'Relapse', 'Mean duration to arrest disease progression', 'weight gain', 'leucopenia', 'VASI at baseline and VASI', 'Vitiligo Area Scoring Index (VASI', 'mean number of new lesions', 'reduction in VIDA and the number of new lesions', 'relapse rate', 'nausea', 'VIDA', 'headache, insomnia and menstrual irregularity']","[{'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C1274648', 'cui_str': 'Segmental vitiligo'}, {'cui': 'C0441835', 'cui_str': 'Group A'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0348801', 'cui_str': 'Group B streptococcal pneumonia'}]","[{'cui': 'C0883242', 'cui_str': 'MYCOPHENOLATE'}, {'cui': 'C0209368', 'cui_str': 'mycophenolate mofetil'}, {'cui': 'C0360528', 'cui_str': 'Dexamethasone-containing product in oral dose form'}, {'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0018790', 'cui_str': 'Cardiac arrest'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0043094', 'cui_str': 'Weight gain'}, {'cui': 'C0023530', 'cui_str': 'Leukopenia'}, {'cui': 'C0042900', 'cui_str': 'Vitiligo'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0221198', 'cui_str': 'Lesion'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0018681', 'cui_str': 'Headache'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0156404', 'cui_str': 'Irregular periods'}]",,0.0590256,"In both groups, Kruskal-Wallis revealed a significant trend for reduction in VIDA and the number of new lesions in last 30 days, over the treatment and follow-up duration when compared to baseline (p < 0.001).","[{'ForeName': 'Anuradha', 'Initials': 'A', 'LastName': 'Bishnoi', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.'}, {'ForeName': 'Keshavamurthy', 'Initials': 'K', 'LastName': 'Vinay', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.'}, {'ForeName': 'Muthu Sendhil', 'Initials': 'MS', 'LastName': 'Kumaran', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India.'}, {'ForeName': 'Davinder', 'Initials': 'D', 'LastName': 'Parsad', 'Affiliation': 'Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India. parsad@me.com.'}]",Archives of dermatological research,['10.1007/s00403-020-02108-8'] 2889,32737585,Effects of state anxiety on gait: a 7.5% carbon dioxide challenge study.,"We used the 7.5% carbon dioxide (CO 2 ) model of anxiety induction to investigate the effects of state anxiety on normal gait and gait when navigating an obstacle. Healthy volunteers (n = 22) completed a walking task during inhalations of 7.5% CO 2 and medical air (placebo) in a within-subjects design. The order of inhalation was counterbalanced across participants and the gas was administered double-blind. Over a series of trials, participants walked the length of the laboratory, with each trial requiring participants to navigate through an aperture (width adjusted to participant size), with gait parameters measured via a motion capture system. The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air. These findings indicate changes in locomotor behaviour during heightened state anxiety that may reflect greater caution when moving in an agitated state. Advances in sensing technology offer the opportunity to monitor locomotor behaviour, and these findings suggest that in doing so, we may be able to infer emotional states from movement in naturalistic settings.",2020,"The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air.",['Healthy volunteers (n\u2009=\u200922'],"['carbon dioxide', 'walking task during inhalations of 7.5% CO 2 and medical air (placebo']","['gait', 'walking speed', 'body orientation']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0004048', 'cui_str': 'Inhaling'}, {'cui': 'C4517859', 'cui_str': '7.5'}, {'cui': 'C3536832', 'cui_str': 'Air'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C2009910', 'cui_str': 'Gait speed'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0029266', 'cui_str': 'Orientation'}]",,0.0840547,"The main findings were that walking speed was slower, but the adjustment in body orientation was greater, during 7.5% CO 2 inhalation compared to air.","[{'ForeName': 'Angela S', 'Initials': 'AS', 'LastName': 'Attwood', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK. angela.attwood@bristol.ac.uk.'}, {'ForeName': 'Casimir J H', 'Initials': 'CJH', 'LastName': 'Ludwig', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Ian S', 'Initials': 'IS', 'LastName': 'Penton-Voak', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Poh', 'Affiliation': 'School of Experimental Psychology, University of Bristol, 12a Priory Road, Bristol, BS8 1TU, UK.'}, {'ForeName': 'Alex S F', 'Initials': 'ASF', 'LastName': 'Kwong', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.'}, {'ForeName': 'Marcus R', 'Initials': 'MR', 'LastName': 'Munafò', 'Affiliation': 'MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.'}]",Psychological research,['10.1007/s00426-020-01393-2'] 2890,32730905,Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patients undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.,"BACKGROUND New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective is to evaluate the potential benefit of apixaban plus aspirin compared with standard of care dual antiplatelet therapy (DAPT) in reducing thrombotic restenosis and artery re-occlusion in patients undergoing endovascular infrapopliteal revascularization. STUDY DESIGN This multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, proof-of-concept, exploratory trial aims to randomize 200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI). Patients will be randomly assigned in a 1:1 ratio to receive oral apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months or clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding or clinically relevant non-major bleeding at 12 months. SUMMARY This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared with DAPT (clopidogrel plus aspirin) in patients with CLI undergoing endovascular infrapopliteal revascularization and might prove the concept of an alternative antithrombotic regimen for these patients to be tested in a future large randomized clinical trial.",2020,"The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months.","['200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI', 'patients with peripheral artery disease (PAD) undergoing arterial angioplasty', 'patients undergoing InfraPoPliteal angioplasty for critical limb ischemia', 'patients with CLI undergoing endovascular infrapopliteal revascularization', 'patients undergoing endovascular infrapopliteal revascularization']","['apixaban plus aspirin', 'apixaban 2.5 mg twice daily plus aspirin', 'Apixaban versus ClopidoGRel', 'standard of care dual antiplatelet therapy (DAPT', 'DAPT (clopidogrel plus aspirin', 'aspirin', 'clopidogrel', 'oral apixaban']","['composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death', 'thrombotic restenosis and artery re-occlusion', 'composite of major bleeding or clinically relevant non-major bleeding at 12 months', 'efficacy and safety']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1292423', 'cui_str': '72 hours'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C1704436', 'cui_str': 'Peripheral Arterial Diseases'}, {'cui': 'C0397654', 'cui_str': 'Angioplasty of artery'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}]","[{'cui': 'C1831808', 'cui_str': 'apixaban'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0004057', 'cui_str': 'Aspirin'}, {'cui': 'C3530461', 'cui_str': 'apixaban 2.5 MG'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C0070166', 'cui_str': 'clopidogrel'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0205173', 'cui_str': 'Double'}, {'cui': 'C1096021', 'cui_str': 'Antiplatelet therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0014742', 'cui_str': 'Erythema multiforme'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C0001168', 'cui_str': 'Complete obstruction'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0286421', 'cui_str': 'ACE protocol 2'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0038454', 'cui_str': 'Cerebrovascular accident'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0003842', 'cui_str': 'Arterial structure'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.221901,"The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events - MACE (myocardial infarction, stroke or cardiovascular death) at 12 months.","[{'ForeName': 'Rodrigo Bruno', 'Initials': 'RB', 'LastName': 'Biagioni', 'Affiliation': 'São Paulo State Public Servant Hospital, São Paulo, Brazil. Electronic address: rbbiagioni@gmail.com.'}, {'ForeName': 'Renato Delascio', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.'}, {'ForeName': 'Leandro Barile', 'Initials': 'LB', 'LastName': 'Agati', 'Affiliation': 'Science Valley Research Institute, Santo André, São Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Sacilotto', 'Affiliation': 'São Paulo State Public Servant Hospital, São Paulo, Brazil.'}, {'ForeName': 'Nelson', 'Initials': 'N', 'LastName': 'Wolosker', 'Affiliation': 'Albert Einstein Hospital, São Paulo, Brazil; Hospital das Clínicas de São Paulo, São Paulo University, São Paulo, Brazil.'}, {'ForeName': 'Marcone Lima', 'Initials': 'ML', 'LastName': 'Sobreira', 'Affiliation': 'Universidade Estadual Paulista (UNESP), Botucatu, Brazil.'}, {'ForeName': 'Bruno Leonardo', 'Initials': 'BL', 'LastName': 'de Freitas Soares', 'Affiliation': 'Santa Casa de Maceio, Maceio, Alagoas, Brazil.'}, {'ForeName': 'Edwaldo Edner', 'Initials': 'EE', 'LastName': 'Joviliano', 'Affiliation': 'Hospital das Clínicas de Ribeirão Preto, São Paulo University Medical School (USP), Ribeirão Preto, São Paulo, Brazil.'}, {'ForeName': 'Walkiria Hueb', 'Initials': 'WH', 'LastName': 'Bernardi', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Valter Castelli', 'Initials': 'VC', 'LastName': 'Junior', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Roberto Augusto', 'Initials': 'RA', 'LastName': 'Caffaro', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Fioranelli', 'Affiliation': 'Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}, {'ForeName': 'Bonno', 'Initials': 'B', 'LastName': 'Van Bellen', 'Affiliation': 'Beneficência Portuguesa de São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ivan Benaduce', 'Initials': 'IB', 'LastName': 'Casella', 'Affiliation': 'Hospital das Clínicas de São Paulo, São Paulo University, São Paulo, Brazil.'}, {'ForeName': 'Ronald José Ribeiro', 'Initials': 'RJR', 'LastName': 'Fidelis', 'Affiliation': 'Vascular and Endovascular Surgery-Federal University of Bahia.'}, {'ForeName': 'Ronald Luiz Gomes', 'Initials': 'RLG', 'LastName': 'Flumignan', 'Affiliation': 'Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Anthony James', 'Initials': 'AJ', 'LastName': 'Comerota', 'Affiliation': 'Inova Heart and Vascular Institute, Falls Church, VA, USA.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Ramacciotti', 'Affiliation': 'Hemostasis & Thrombosis Research Laboratories at Loyola University Medical Center, Maywood, IL, USA; Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.'}]",American heart journal,['10.1016/j.ahj.2020.06.010'] 2891,32731365,Effectiveness of Resistance Training with the Use of a Suspension System in Patients after Myocardial Infarction.,"The aim of the study was to assess the effects of resistance training with the use of a suspension system on exercise tolerance, evaluated through an exercise test, and the changes in selected echocardiographic parameters of patients after myocardial infarction. The study involved 44 males. The subjects were divided into two groups: Standard (20) and Suspension system (24). All the subjects had undergone an angioplasty with stent implantation. The standard and suspension system groups carried out a 24-day improvement program comprising 22 training units. Each session consisted of endurance, general stamina and resistance training. Instead of resistance training, the experimental group made multijoint exercises with a suspension system. Statistically significant changes in both groups were observed in the parameters of the echocardiographic exercise test, such as test duration ( p = 0.000), distance covered ( p = 0.000), MET ( p = 0.000), VO2max ( p = 0.000) and SBPrest ( p = 0.013). Additionally, SBPmax in the suspension system group improved ( p = 0.035). The echocardiographic test revealed significant improvement of Left Ventricular Ejection Fraction in both groups (SP group p = 0.001, standard group p = 0.005). The lipid profile test in the SP group revealed statistically significant improvement of TC ( p = 0.003), HDL ( p = 0.000) and LDL ( p = 0.005). Training with the suspension system had a positive effect on the change of exercise tolerance level, left ventricular function and blood lipid profile.",2020,"The echocardiographic test revealed significant improvement of Left Ventricular Ejection Fraction in both groups (SP group p = 0.001, standard group p = 0.005).","['patients after myocardial infarction', 'Patients after Myocardial Infarction', '44 males']","['angioplasty with stent implantation', 'endurance, general stamina and resistance training', 'Resistance Training', 'resistance training']","['exercise tolerance level, left ventricular function and blood lipid profile', 'echocardiographic exercise test, such as test duration', 'Left Ventricular Ejection Fraction', 'LDL', 'VO2max', 'HDL', 'TC']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0086582', 'cui_str': 'Male'}]","[{'cui': 'C0162577', 'cui_str': 'Angioplasty of blood vessel'}, {'cui': 'C0038257', 'cui_str': 'Stent'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0518031', 'cui_str': 'Endurance'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0162521', 'cui_str': 'Exercise tolerance'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0080310', 'cui_str': 'Left ventricular function'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0023779', 'cui_str': 'Lipid'}, {'cui': 'C0015260', 'cui_str': 'Exercise tolerance test'}, {'cui': 'C0429930', 'cui_str': 'Test duration'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0023169', 'cui_str': 'LDL(1)'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}]",44.0,0.0138713,"The echocardiographic test revealed significant improvement of Left Ventricular Ejection Fraction in both groups (SP group p = 0.001, standard group p = 0.005).","[{'ForeName': 'Agata', 'Initials': 'A', 'LastName': 'Nowak', 'Affiliation': ""Department of Physiotherapy, Jerzy Kukuczka's Academy of Physical Education, 40-065 Katowice, Poland.""}, {'ForeName': 'Michał', 'Initials': 'M', 'LastName': 'Morawiec', 'Affiliation': 'Uppersilesian Center of Medicine and Rehabilitation AMED, 40-514 Katowice, Poland.'}, {'ForeName': 'Tomasz', 'Initials': 'T', 'LastName': 'Gabrys', 'Affiliation': 'Department of Physical Education and Sport Science, Faculty of Pedagogy, University of West Bohemia, 301 00 Pilsen, Czech Republic.'}, {'ForeName': 'Zbigniew', 'Initials': 'Z', 'LastName': 'Nowak', 'Affiliation': ""Department of Physiotherapy, Jerzy Kukuczka's Academy of Physical Education, 40-065 Katowice, Poland.""}, {'ForeName': 'Urszula', 'Initials': 'U', 'LastName': 'Szmatlan-Gabryś', 'Affiliation': 'Department Anathomy Faculty of Rehabilitation University of Physical Education, 31-571 Krakow, Poland.'}, {'ForeName': 'Vaclav', 'Initials': 'V', 'LastName': 'Salcman', 'Affiliation': 'Department of Physical Education and Sport Science, Faculty of Pedagogy, University of West Bohemia, 301 00 Pilsen, Czech Republic.'}]",International journal of environmental research and public health,['10.3390/ijerph17155419'] 2892,32731401,Sodium Hypochlorite Reduces Postoperative Discomfort and Painful Early Failure after Carious Exposure and Direct Pulp Capping-Initial Findings of a Randomized Controlled Trial.,"In this randomized controlled single-center clinical trial on 96 adult patients with parallel experimental groups ( n = 48), the effects of washing a dentin/pulp wound in non-symptomatic teeth with extremely deep caries and pulpal exposure were compared between a 2.5% sodium hypochlorite (NaOCl) solution and a chemically-inert physiological saline control solution. After the allocated wound lavage, the pulps were capped with a mineral trioxide aggregate, covered by a glass-ionomer/resin liner, and the teeth were immediately restored with a resin-bonded-composite. In this first report, the early events were analyzed: postoperative discomfort (on an NRS-11 scale) at day-3 and -7 after intervention, and the occurrence of unbearable pain causing patients to contact the principal investigator to perform a root canal treatment (pulpectomy) during the first three months. The NaOCl solution caused a highly significant reduction in post-operative discomfort ( p = 0.0010 day 3; p = 0.0007 day 7) and early painful failures ( p = 0.0008) compared with the control. These novel findings highlight the importance of infection control in teeth with extremely deep carious lesions. Based on these observations, the use of an NaOCl solution to wash the exposed dentin/pulp wound in the vital pulp treatment is highly recommended in order to reduce pain and early failure.",2020,The NaOCl solution caused a highly significant reduction in post-operative discomfort ( p = 0.0010 day 3; p = 0.0007 day 7) and early painful failures ( p = 0.0008) compared with the control.,['96 adult patients with parallel experimental groups ( n = 48'],"['Sodium Hypochlorite', 'washing a dentin/pulp wound in non-symptomatic teeth with extremely deep caries and pulpal exposure were compared between a 2.5% sodium hypochlorite (NaOCl) solution and a chemically-inert physiological saline control solution']","['Postoperative Discomfort and Painful Early Failure', 'early painful failures', 'post-operative discomfort', 'unbearable pain', 'postoperative discomfort']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0037518', 'cui_str': 'sodium hypochlorite'}, {'cui': 'C1547959', 'cui_str': 'Wash'}, {'cui': 'C0011429', 'cui_str': 'Dentin structure'}, {'cui': 'C0011399', 'cui_str': 'Structure of pulp of tooth'}, {'cui': 'C0021501', 'cui_str': 'wounds'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0205403', 'cui_str': 'Extreme'}, {'cui': 'C0333523', 'cui_str': 'Deep caries'}, {'cui': 'C0274281', 'cui_str': 'Effect of exposure to external cause'}, {'cui': 'C3844011', 'cui_str': '2.5'}, {'cui': 'C0220806', 'cui_str': 'Chemical'}, {'cui': 'C0205463', 'cui_str': 'Physiologic'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037633', 'cui_str': 'Solution'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C2364135', 'cui_str': 'Discomfort'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0231174', 'cui_str': 'Failure'}]",96.0,0.0563414,The NaOCl solution caused a highly significant reduction in post-operative discomfort ( p = 0.0010 day 3; p = 0.0007 day 7) and early painful failures ( p = 0.0008) compared with the control.,"[{'ForeName': 'Nidambur Vasudev', 'Initials': 'NV', 'LastName': 'Ballal', 'Affiliation': 'Department of Conservative Dentistry & Endodontics, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.'}, {'ForeName': 'Henry F', 'Initials': 'HF', 'LastName': 'Duncan', 'Affiliation': 'Dublin Dental University Hospital, Trinity College Dublin, University of Dublin, D02 F859 Dublin, Ireland.'}, {'ForeName': 'Namith', 'Initials': 'N', 'LastName': 'Rai', 'Affiliation': 'Department of Conservative Dentistry & Endodontics, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.'}, {'ForeName': 'Prateek', 'Initials': 'P', 'LastName': 'Jalan', 'Affiliation': 'Department of Conservative Dentistry & Endodontics, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, Manipal 576104, Karnataka, India.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Zehnder', 'Affiliation': 'Division of Endodontology, Clinic of Conservative and Preventive Dentistry, University of Zürich, 8032 Zürich, Switzerland.'}]",Journal of clinical medicine,['10.3390/jcm9082408'] 2893,32731424,Healthy Promotion for Fighting Metabolic Syndrome: Insights from Multi-Center HeRO-FiT Cohort.,"We know that metabolic syndrome (MS) is a modern cardiovascular (CV) ""epidemic"", especially in western populations. MS is indeed strictly related to the risk of developing CV diseases (CVD) and/or diabetes. Therefore, the aim of our multi-center study was to promote a ""healthy style"" for fighting MS. Each participating center analyzed its own database of outpatients and globally we have pulled out 100 volunteers to participate in the study. Before starting, we collected their written consent. Enrolled subjects have not any history of overt CVD and/or diabetes, but they matched National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP) criteria for MS. After enrolment (t0), subjects were randomly divided into two homogeneous groups: a) only diet suggestions; b) both diet and exercise prescription. Later, we measured for each subject: blood pressure (BP), heart rate (HR), height, weight, body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), six-minute walking test (WT6M), distance and common blood tests such as fasting plasma glucose, high-density lipoproteins (HDL) and triglycerides (T1 assessments). At six months (T2), the same parameters were measured and then statistical comparisons were performed. Attention to diet caused significant changes only in WC and WHR, whilst a coupling of exercise and diet revealed a statistically significant improvement in HR, BP, BMI, blood samplings and WT6M too. In conclusion, a healthy lifestyle should be more encouraged by physicians and/or collaborators (such as dieticians) operating in preventive settings. Diet and physical activity may be early useful strategies in the ""battle"" against MS even before any medication choices. Further studies will be necessary in order to better address the topic.",2020,"Attention to diet caused significant changes only in WC and WHR, whilst a coupling of exercise and diet revealed a statistically significant improvement in HR, BP, BMI, blood samplings and WT6M too.","['Enrolled subjects have not any history of overt CVD and/or diabetes, but they matched National Cholesterol Education Program/Adult Treatment Panel (NCEP/ATP) criteria for MS', 'Each participating center analyzed its own database of outpatients and globally we have pulled out 100 volunteers to participate in the study']",['diet and exercise prescription'],"['WC and WHR', 'HR, BP, BMI, blood samplings and WT6M too', 'blood pressure (BP), heart rate (HR), height, weight, body mass index (BMI), waist circumference (WC), waist hip ratio (WHR), six-minute walking test (WT6M), distance and common blood tests such as fasting plasma glucose, high-density lipoproteins (HDL) and triglycerides (T1 assessments']","[{'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0729314', 'cui_str': 'Education provision'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441833', 'cui_str': 'Groups'}, {'cui': 'C0001480', 'cui_str': 'Adenosine Triphosphate'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0012155', 'cui_str': 'Dietary finding'}, {'cui': 'C0588464', 'cui_str': 'Exercise on prescription'}]","[{'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0005834', 'cui_str': 'Collection of blood specimen for laboratory'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0205682', 'cui_str': 'Waist/hip ratio'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0012751', 'cui_str': 'Distance'}, {'cui': 'C0205214', 'cui_str': 'Common'}, {'cui': 'C0018941', 'cui_str': 'Blood test'}, {'cui': 'C0583513', 'cui_str': 'Plasma fasting glucose measurement'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}]",100.0,0.0113874,"Attention to diet caused significant changes only in WC and WHR, whilst a coupling of exercise and diet revealed a statistically significant improvement in HR, BP, BMI, blood samplings and WT6M too.","[{'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Gianturco', 'Affiliation': 'Hospital for the Elderly ""Madonna del Divino Amore"", Via Casilina, 1839, 00132 Borghesiana, Rome, Italy.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Gianturco', 'Affiliation': 'ASST Rhodense, Cardiac-Rehab Unit, Passirana-Rho Hospital, Via Luigi Settembrini, 1, 20017 Rho Milan, Italy.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Regnoli', 'Affiliation': 'IRCCS Galeazzi Orthopedic Institute, Dietician Service, Via Riccardo Galeazzi, 4, 20161 Milan, Italy.'}, {'ForeName': 'Bruno Dino', 'Initials': 'BD', 'LastName': 'Bodini', 'Affiliation': 'ASST Rhodense, Pulmonology Rehab Unit, Passirana-Rho Hospital, Via Luigi Settembrini, 1, 20017 Rho Milan, Italy.'}, {'ForeName': 'Maurizio', 'Initials': 'M', 'LastName': 'Turiel', 'Affiliation': 'IRCCS Galeazzi Orthopedic Institute, Cardiology Unit, Via Riccardo Galeazzi, 4, 20161 Milan, Italy.'}, {'ForeName': 'Martino', 'Initials': 'M', 'LastName': 'Trapani', 'Affiliation': 'ASST Rhodense, Public Health Division, Garbagnate Hospital, Via Carlo Forlanini, 20024 Garbagnate Milanese Milan, Italy.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Bini', 'Affiliation': 'ASST Rhodense, Chief of Pulmonology, Garbagnate Hospital, Via Carlo Forlanini, 20024 Garbagnate Milanese Milan, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'De Angelis', 'Affiliation': 'ASST Rhodense, Cardiac-Rehab Unit, Passirana-Rho Hospital, Via Luigi Settembrini, 1, 20017 Rho Milan, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph17155424'] 2894,32731571,Dynamics of Platelet Counts in Major Trauma: The Impact of Haemostatic Resuscitation and Effects of Platelet Transfusion-A Sub-Study of the Randomized Controlled RETIC Trial.,"Although platelets play a central role in haemostasis, the dynamics of platelet counts during haemostatic resuscitation, the response to platelet transfusion, and effects on clinical outcome are poorly described for trauma patients. As a sub-study of the already published randomized controlled RETIC Study ""Reversal of Trauma-induced Coagulopathy using First-line Coagulation Factor Concentrates or Fresh-Frozen Plasma"" trial, we here analysed whether the type of first-line haemostatic resuscitation influences the frequency of platelet transfusion and determined the effects of platelet transfusion in coagulopathic patients with major trauma. Patients randomly received first-line plasma (FFP) or coagulation factor concentrates (CFC), mainly fibrinogen concentrate. In both groups, platelets were transfused to maintain platelet counts between 50 and 100 × 10 9 /L. Transfusion rates were significantly higher in the FFP (n = 44) vs. CFC (n = 50) group (FFP 47.7% vs. CFC 26%); p = 0.0335. Logistic regression analysis adjusted for the stratification variables injury severity score (ISS) and brain injury confirmed that first-line FFP therapy increases the odds for platelet transfusion (odds ratio (OR) 5.79 (1.89 to 20.62), p = 0.0036) and this effect was larger than a 16-point increase in ISS (OR 4.33 (2.17 to 9.74), p = 0.0001). In conclusion, early fibrinogen supplementation exerted a platelet-saving effect while platelet transfusions did not substantially improve platelet count and might contribute to poor clinical outcome.",2020,Transfusion rates were significantly higher in the FFP (n = 44) vs. CFC,"['coagulopathic patients with major trauma', 'Major Trauma']","['first-line plasma (FFP) or coagulation factor concentrates (CFC), mainly fibrinogen concentrate', 'CFC', 'FFP']","['ISS', 'Transfusion rates', 'platelet count', 'platelet transfusion (odds ratio (OR']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332677', 'cui_str': 'Major injury'}]","[{'cui': 'C0205132', 'cui_str': 'Linear'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0005789', 'cui_str': 'Blood clotting factor'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C2587184', 'cui_str': 'fibrinogen concentrate (human)'}, {'cui': 'C0016709', 'cui_str': 'Fresh frozen plasma'}]","[{'cui': 'C1740819', 'cui_str': 'Idiopathic short stature'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0086818', 'cui_str': 'Platelet transfusion'}, {'cui': 'C0028873', 'cui_str': 'Cross-Product Ratio'}]",,0.0356908,Transfusion rates were significantly higher in the FFP (n = 44) vs. CFC,"[{'ForeName': 'Helmuth', 'Initials': 'H', 'LastName': 'Tauber', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Innerhofer', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'von Langen', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Mathias', 'Initials': 'M', 'LastName': 'Ströhle', 'Affiliation': 'Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Fries', 'Affiliation': 'Department of General and Surgical Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Markus', 'Initials': 'M', 'LastName': 'Mittermayr', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Hell', 'Affiliation': 'Department of Mathematics, Faculty of Mathematics, Computer Science and Physics, University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Elgar', 'Initials': 'E', 'LastName': 'Oswald', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Innerhofer', 'Affiliation': 'Department of Anesthesiology and Intensive Care Medicine, Medical University of Innsbruck, 6020 Innsbruck, Austria.'}]",Journal of clinical medicine,['10.3390/jcm9082420'] 2895,32731714,Optimization of pathogenetic therapy in patients with chronic obstructive lung disease.,"OBJECTIVE The aim of the study is to increase the effectiveness of the treatment of exacerbation of COPD group B GOLD II with the use of combined therapy of the combined drug PulmoBRIZ containing two components - ambroxol and acetylcysteine and the course of halotherapy. PATIENTS AND METHODS Materials and methods: We observed 60 patients with COPD B, GOLD II. They were divided into two groups: the first - the main (n=30) - patients receiving basic therapy, mucolytic therapy - a combination of Ambroxol and acetylcysteine - 200/30 to 1 tabl. 2 times a day, number 7 days and, from the 3rd day - sessions of halotherapy 1 time per day № 10. The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. RESULTS Results: Patients receiving therapy with the combination of ambroxol and acetylcysteine and halotherapy sessions experienced a significant increase in FEV1 by 8.3% (p <0.05); the Tiffon index was 7.2% (p<0.05), reactive anxiety levels (RA) and manifestations of autonomic dysfunction decreased, whereas in patients in the control group these indicators did not improve significantly. CONCLUSION Conclusions: The proposed complex therapy of COPD patients with the inclusion of the combined drug ambroxol and acetylcysteine and halotherapy sessions contributes to the improvement of the quality of life of patients.",2020,"The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. ","['60 patients with COPD B, GOLD II', 'COPD patients', 'patients with chronic obstructive lung disease']","['followed only basic therapy, did not take mucolytics and halotherapy sessions', 'ambroxol and acetylcysteine and halotherapy sessions', 'acetylcysteine and halotherapy sessions', 'basic therapy, mucolytic therapy - a combination of Ambroxol and acetylcysteine - 200/30 to 1 tabl', 'pathogenetic therapy']","['reactive anxiety levels (RA) and manifestations of autonomic dysfunction', 'Tiffon index', 'FEV1']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0024117', 'cui_str': 'Chronic obstructive lung disease'}, {'cui': 'C0018026', 'cui_str': 'Gold'}]","[{'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C0026698', 'cui_str': 'Mucolytic agent'}, {'cui': 'C0002421', 'cui_str': 'Ambroxol'}, {'cui': 'C0001047', 'cui_str': 'Acetylcysteine'}]","[{'cui': 'C0205332', 'cui_str': 'Reactive'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety'}, {'cui': 'C0205319', 'cui_str': 'Manifest'}, {'cui': 'C0013363', 'cui_str': 'Dysautonomia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}]",60.0,0.0175743,"The second group, the control group (n=30), followed only basic therapy, did not take mucolytics and halotherapy sessions. ","[{'ForeName': 'Mаksym M', 'Initials': 'MM', 'LastName': 'Potyazhenko', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Kostiantyn Ye', 'Initials': 'KY', 'LastName': 'Ishcheikin', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Tetiana V', 'Initials': 'TV', 'LastName': 'Nastroga', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Nina L', 'Initials': 'NL', 'LastName': 'Sokolyuk', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Oksana Ye', 'Initials': 'OY', 'LastName': 'Kitura', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}, {'ForeName': 'Inesa M', 'Initials': 'IM', 'LastName': 'Gorodnytska', 'Affiliation': 'Ukrainian Medical Stomatological Academy, Poltava, Ukraine.'}]","Wiadomosci lekarskie (Warsaw, Poland : 1960)",[] 2896,32731750,Long term efficacy of mobilisation with movement on pain and functional status in patients with knee osteoarthritis: a randomised clinical trial.,"OBJECTIVES To evaluate the long term effect of mobilisation with movement on disability, pain and function in subjects with symptomatic knee osteoarthritis. DESIGN A randomised controlled trial. SETTING A general hospital. SUBJECTS Forty adults with knee osteoarthritis (grade 1-3 Kellgren-Lawrence scale). INTERVENTIONS The experimental group received mobilisation with movement and usual care (exercise and moist heat) while the control group received usual care alone in six sessions over two weeks. MAIN MEASURES The primary outcome was the Western Ontario McMaster University Osteoarthritis index, higher scores indicating greater disability. Pain intensity over 24 hours and during sit to stand were measured on a 10 centimetre visual analogue scale. Functional outcomes were the timed up and go test, the 12 step stair test, and knee range of motion. Patient satisfaction was measured on an 11 point numerical rating scale. Variables were evaluated blind pre- and post intervention, and at three and six months follow-up. RESULTS Thirty five participants completed the study. At each follow-up including six-months, significant differences were found between groups favouring those receiving mobilisation with movement for all variables except knee mobility. The primary outcome disability showed a mean difference of 7.4 points (95% confidence interval, 4.5 to 10.3) at six-months and a mean difference of 13.6 points (95% confidence interval, 9.3 to 17.9) at three-months follow-up. CONCLUSION In patients with symptomatic knee osteoarthritis, the addition of mobilisation with movement provided clinically significant improvements in disability, pain, functional activities and patient satisfaction six months later.",2020,"At each follow-up including six-months, significant differences were found between groups favouring those receiving mobilisation with movement for all variables except knee mobility.","['Forty adults with knee osteoarthritis (grade 1-3 Kellgren-Lawrence scale', 'patients with symptomatic knee osteoarthritis', 'subjects with symptomatic knee osteoarthritis', 'Thirty five participants completed the study', 'A general hospital', 'patients with knee osteoarthritis']",['mobilisation with movement and usual care (exercise and moist heat) while the control group received usual care alone'],"['Patient satisfaction', 'pain and functional status', 'Western Ontario McMaster University Osteoarthritis index, higher scores indicating greater disability', 'Pain intensity', 'disability, pain and function', '12 step stair test, and knee range of motion', 'disability, pain, functional activities and patient satisfaction six months later']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0475269', 'cui_str': 'G1 grade'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C4319605', 'cui_str': '35'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0020008', 'cui_str': 'Hospitals, General'}]","[{'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205381', 'cui_str': 'Wet'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0030702', 'cui_str': 'Client satisfaction'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0029040', 'cui_str': 'Ontario'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0029408', 'cui_str': 'Degenerative polyarthritis'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0205393', 'cui_str': 'Most'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0576094', 'cui_str': 'Knee joint - range of movement'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0205087', 'cui_str': 'Late'}]",40.0,0.137725,"At each follow-up including six-months, significant differences were found between groups favouring those receiving mobilisation with movement for all variables except knee mobility.","[{'ForeName': 'Aishwarya', 'Initials': 'A', 'LastName': 'Nigam', 'Affiliation': 'Department of Musculoskeletal Physiotherapy, Smt. Kashibai Navale College of Physiotherapy, Pune, Maharashatra, India.'}, {'ForeName': 'Kiran H', 'Initials': 'KH', 'LastName': 'Satpute', 'Affiliation': 'Department of Musculoskeletal Physiotherapy, Smt. Kashibai Navale College of Physiotherapy, Pune, Maharashatra, India.'}, {'ForeName': 'Toby M', 'Initials': 'TM', 'LastName': 'Hall', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, WA, Australia.'}]",Clinical rehabilitation,['10.1177/0269215520946932'] 2897,32731757,Effectiveness of extracorporeal shock wave therapy versus standard care in the treatment of neck and upper back myofascial pain: a single blinded randomised clinical trial.,"OBJECTIVES To compare the efficacy of extracorporeal shock wave therapy versus standard care (ultrasound + hot pack + self-stretch-exercises) in treatment of neck and upper back myofascial pain syndrome. DESIGN Single-blind randomised clinical trial. SETTING Outpatients setting. SUBJECTS Patients with neck and upper back myofascial pain. INTERVENTION Participants were randomly allocated into shock wave group ( n  = 24), standard care (ultrasound + hot pack + self-stretch-exercises) group ( n  = 24) and control (self-stretch-exercises) group ( n  = 24) for four weeks. MAIN MEASURES The primary outcomes were pain intensity (visual analogue scale), pain pressure threshold (algometer) and disability (neck disability index). Measures were performed at baseline (week 0), week 1 and post-intervention (week 4). RESULTS Shock wave and ultrasound improved visual analogue scale (7.50 ± 1.71 to 5.72 ± 2.20 and 6.22 ± 2.54 to 4.95 ± 2.86, respectively, P  = 0.083) and disability index (54.24 ± 15.53 to 39.04 ± 19.58 50.23 ± 19.57 to 32.10 ± 18.34, respectively, P  = 0.495) similarly at first week examinations that were significantly higher than control ( P  < 0.05). In week 4 measurements, additional improvements were achieved concerning visual analogue scale and disability index in the shock wave (-4.00 ± 2.22 and -20.24 ± 16.56, respectively) and ultrasound (-2.18 ± 2.71 and -21.79 ± 10.56, respectively) groups. However, visual analogue scale improved more significantly in shock wave group than ultrasound group in fourth week measurements ( P  = 0.012). CONCLUSION Extracorporeal shock wave therapy was more effective in controlling of the pain intensity compared to ultrasound one month after treatment. However it had no superiority over ultrasound in improving neck disability index at this time point.Trial registrationwww.irct.ir, IRCT201608154104N5, registered 2016-09-25.",2020,"In week 4 measurements, additional improvements were achieved concerning visual analogue scale and disability index in the shock wave (-4.00 ± 2.22 and -20.24 ± 16.56, respectively) and ultrasound (-2.18 ± 2.71 and -21.79 ± 10.56, respectively) groups.","['neck and upper back myofascial pain', 'Outpatients setting', 'neck and upper back myofascial pain syndrome', 'Patients with neck and upper back myofascial pain']","['extracorporeal shock wave therapy versus standard care (ultrasound + hot pack + self-stretch-exercises', 'Extracorporeal shock wave therapy', 'standard care (ultrasound + hot pack + self-stretch-exercises) group ( n \u2009=\u200924) and control (self-stretch-exercises', 'extracorporeal shock wave therapy versus standard care']","['neck disability index', 'visual analogue scale', 'pain intensity', 'visual analogue scale and disability index', 'disability index', 'pain intensity (visual analogue scale), pain pressure threshold (algometer) and disability (neck disability index']","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0230101', 'cui_str': 'Upper back structure'}, {'cui': 'C0553642', 'cui_str': 'Myofascial pain'}, {'cui': 'C0029921', 'cui_str': 'Outpatient'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0016053', 'cui_str': 'Fibromyalgia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C1737238', 'cui_str': 'Extracorporeal shock wave therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0444519', 'cui_str': 'Hot'}, {'cui': 'C0184967', 'cui_str': 'Insertion of pack'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0033095', 'cui_str': 'Pressure - physical agent'}, {'cui': 'C0234200', 'cui_str': 'Threshold perception'}]",,0.0750904,"In week 4 measurements, additional improvements were achieved concerning visual analogue scale and disability index in the shock wave (-4.00 ± 2.22 and -20.24 ± 16.56, respectively) and ultrasound (-2.18 ± 2.71 and -21.79 ± 10.56, respectively) groups.","[{'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Rahbar', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Maryam', 'Initials': 'M', 'LastName': 'Samandarian', 'Affiliation': 'Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Yaghoub', 'Initials': 'Y', 'LastName': 'Salekzamani', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Zhila', 'Initials': 'Z', 'LastName': 'Khamnian', 'Affiliation': 'Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Neda', 'Initials': 'N', 'LastName': 'Dolatkhah', 'Affiliation': 'Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran.'}]",Clinical rehabilitation,['10.1177/0269215520947074'] 2898,32731960,Cryotherapy With Mobilization Versus Cryotherapy With Mobilization Reinforced With Home Stretching Exercises in Treatment of Chronic Neck Pain: A Randomized Trial.,"OBJECTIVES The purpose of this study was to compare the effectiveness of cryotherapy with mobilization (CM) vs cryotherapy with mobilization reinforced with home stretching exercises (CMS) on pain and disability. METHOD A randomized clinical trial with 2-arm parallel design, concealed allocation, assessor blinding, and intention to-treat analysis. Sixty participants were in 2 groups. Group 1 included cryotherapy with mobilization twice per week for 5 weeks. Group 2 included cryotherapy with mobilization plus home stretching exercises 5 times per week for 5 weeks. The evaluations were at baseline and 2 days posttreatment for the numeric pain rating scale, neck disability index, patient-specific functional scale, and global rating of change. RESULTS The CM and CMS decreased neck pain and disability (P = .000). The statistical significance between the groups' differences favored the CM in the numeric pain rating scale, patient-specific functional scale, global rating of change (P = .000), and neck disability index (P = .004). CONCLUSION Cryotherapy with mobilization for subjects in this study was more effective in decreasing disability and neck pain than CMS.",2020,"The statistical significance between the groups' differences favored the CM in the numeric pain rating scale, patient-specific functional scale, global rating of change (P = .000), and neck disability index (P = .004). ","['Chronic Neck Pain', 'Sixty participants were in 2 groups']","['Mobilization Reinforced With Home Stretching Exercises', 'Cryotherapy With Mobilization Versus Cryotherapy', 'Cryotherapy with mobilization', 'cryotherapy with mobilization (CM) vs cryotherapy with mobilization reinforced with home stretching exercises (CMS', 'cryotherapy with mobilization plus home stretching exercises', 'cryotherapy with mobilization']","['neck disability index', 'pain and disability', 'disability and neck pain', 'numeric pain rating scale, neck disability index, patient-specific functional scale, and global rating of change', 'numeric pain rating scale, patient-specific functional scale, global rating of change', 'neck pain and disability']","[{'cui': 'C0746815', 'cui_str': 'Chronic neck pain'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0185112', 'cui_str': 'Mobilization'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C4551716', 'cui_str': 'Cryotherapy'}, {'cui': 'C0600080', 'cui_str': 'Stretching exercises'}, {'cui': 'C0041718', 'cui_str': 'Centers for Medicare and Medicaid Services'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0027530', 'cui_str': 'Neck structure'}, {'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0007859', 'cui_str': 'Neck pain'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4304943', 'cui_str': 'Patient-Specific Functional Scale'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}]",60.0,0.0535214,"The statistical significance between the groups' differences favored the CM in the numeric pain rating scale, patient-specific functional scale, global rating of change (P = .000), and neck disability index (P = .004). ","[{'ForeName': 'Pawel', 'Initials': 'P', 'LastName': 'Lizis', 'Affiliation': 'Department of Physiotherapy, Cracow College of Health Protection, Cracow, Poland. Electronic address: pawel_lizis@poczta.onet.pl.'}, {'ForeName': 'Wojciech', 'Initials': 'W', 'LastName': 'Kobza', 'Affiliation': 'Physiotherapy Laboratory, Żywiec, Poland.'}, {'ForeName': 'Grzegorz', 'Initials': 'G', 'LastName': 'Manko', 'Affiliation': 'Department of Ergonomics and Physiology of Physical Effort, Jagiellonian University, Cracow, Poland.'}, {'ForeName': 'Jaroslaw', 'Initials': 'J', 'LastName': 'Jaszczur-Nowicki', 'Affiliation': 'Department of Tourism, Recreation and Ecology, University of Warmia and Mazury, Olsztyn, Poland.'}, {'ForeName': 'Jacek', 'Initials': 'J', 'LastName': 'Perlinski', 'Affiliation': 'Faculty of Health Sciences, University of Humanities and Economy, Elblag, Poland.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Para', 'Affiliation': 'Health Protection, Med-On Company, Liszki, Poland.'}]",Journal of manipulative and physiological therapeutics,['10.1016/j.jmpt.2018.11.030'] 2899,32732022,"Effects of a leaflet on breast cancer screening knowledge, explicit attitudes, and implicit associations.","OBJECTIVE To assess the effect of an information leaflet on knowledge, explicit attitudes, implicit associations, and attendance for breast cancer screening. METHODS Dutch women (aged 49-75 years) were approached three months before their breast cancer screening invitation. After providing informed consent, participants were randomised to receiving the information leaflet (intervention condition) or not (control condition). Screening knowledge, explicit attitudes, and implicit associations were assessed through web-based questionnaires, at baseline and two weeks later. Actual screening attendance data were collected. RESULTS In total, 988 women completed both questionnaires. Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition. This contrast was bigger among first-time invitees. Implicit associations were not correlated with explicit attitudes or attendance. Explicit attitudes were moderately correlated with attendance (r=.30, p < 0.001). CONCLUSION The information leaflet led to more knowledge and more positive explicit attitudes. Implicit associations towards breast cancer screening were not correlated with attendance. PRACTICE IMPLICATIONS Encouragement to learn about the screening programme can increase levels of knowledge of invitees and therefore support their decision-making about participation. This might be especially relevant for first-time invitees.",2020,"Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition.","['988 women completed both questionnaires', 'Dutch women (aged 49-75 years']",['information leaflet (intervention condition) or not (control condition'],"['Explicit attitudes', 'positive explicit attitudes', 'Implicit associations towards breast cancer screening', 'breast cancer screening knowledge, explicit attitudes, and implicit associations', 'knowledge']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0013331', 'cui_str': 'Dutch'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0281182', 'cui_str': 'Screening for malignant neoplasm of breast'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",988.0,0.0280732,"Participants in the leaflet condition scored higher on knowledge (9.9 versus 9.6, p < 0.001, scale 0-11), and more often had positive explicit attitudes (97 % versus 95 %, p = 0.03), than those in the control condition.","[{'ForeName': 'Lindy M', 'Initials': 'LM', 'LastName': 'Kregting', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands. Electronic address: l.kregting@erasmusmc.nl.'}, {'ForeName': 'Nicolien T', 'Initials': 'NT', 'LastName': 'van Ravesteyn', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Wolfert', 'Initials': 'W', 'LastName': 'Spijker', 'Affiliation': 'Bevolkingsonderzoek Zuid-West, Rotterdam, the Netherlands.'}, {'ForeName': 'Tessa', 'Initials': 'T', 'LastName': 'Dierks', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Clare A', 'Initials': 'CA', 'LastName': 'Aitken', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'H Amarens', 'Initials': 'HA', 'LastName': 'Geuzinge', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}, {'ForeName': 'Ida J', 'Initials': 'IJ', 'LastName': 'Korfage', 'Affiliation': 'Department of Public Health, Erasmus MC, University Medical Center Rotterdam, the Netherlands.'}]",Patient education and counseling,['10.1016/j.pec.2020.06.032'] 2900,32732104,A Randomized Controlled Trial of High-Intensity Exercise and Executive Functioning in Cognitively Normal Older Adults.,"BACKGROUND There is a paucity of interventional research that systematically assesses the role of exercise intensity and cardiorespiratory fitness, and their relationship with executive function in older adults. To address this limitation, we have examined the effect of a systematically manipulated exercise intervention on executive function. METHODS Ninety-nine cognitively normal participants (age = 69.10 ± 5.2 years; n = 54 female) were randomized into either a high-intensity cycle-based exercise, moderate-intensity cycle-based exercise, or no-intervention control group. All participants underwent neuropsychological testing and fitness assessment at baseline (preintervention), 6-month follow-up (postintervention), and 12-month postintervention. Executive function was measured comprehensively, including measures of each subdomain: Shifting, Updating/ Working Memory, Inhibition, Verbal Generativity, and Nonverbal Reasoning. Cardiorespiratory fitness was measured by analysis of peak aerobic capacity; VO 2 peak. RESULTS First, the exercise intervention was found to increase cardiorespiratory fitness (VO 2 peak) in the intervention groups, in comparison to the control group (F =10.40, p≤0.01). However, the authors failed to find mean differences in executive function scores between the high-intensity, moderate intensity, or inactive control group. On the basis of change scores, cardiorespiratory fitness was found to associate positively with the executive function (EF) subdomains of Updating/Working Memory (β = 0.37, p = 0.01, r = 0.34) and Verbal Generativity (β = 0.30, p = 0.03, r = 0.28) for intervention, but not control participants. CONCLUSION At the aggregate level, the authors failed to find evidence that 6-months of high-intensity aerobic exercise improves EF in older adults. However, it remains possible that individual differences in experimentally induced changes in cardiorespiratory fitness may be associated with changes in Updating/ Working Memory and Verbal Generativity.",2020,"First, the exercise intervention was found to increase cardiorespiratory fitness (VO 2 peak) in the intervention groups, in comparison to the control group (F =10.40, p≤0.01).","['Ninety-nine cognitively normal participants (age\u202f=\u202f69.10 ± 5.2 years; n\u202f=\u202f54 female', 'Cognitively Normal Older Adults', 'older adults']","['manipulated exercise intervention', 'intensity aerobic exercise', 'High-Intensity Exercise and Executive Functioning', 'high-intensity cycle-based exercise, moderate-intensity cycle-based exercise, or no-intervention control group']","['Executive function', 'executive function scores', 'Verbal Generativity', 'Cardiorespiratory fitness', 'executive function (EF) subdomains of Updating/Working Memory', 'Updating/ Working Memory, Inhibition, Verbal Generativity, and Nonverbal Reasoning', 'cardiorespiratory fitness']","[{'cui': 'C3828813', 'cui_str': '99'}, {'cui': 'C0205307', 'cui_str': 'Normal'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517790', 'cui_str': '5.2'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0947647', 'cui_str': 'Manipulation'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0001701', 'cui_str': 'Aerobic exercises'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0935584', 'cui_str': 'Executive Control'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0025265', 'cui_str': 'Immediate memory'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}]",99.0,0.0225818,"First, the exercise intervention was found to increase cardiorespiratory fitness (VO 2 peak) in the intervention groups, in comparison to the control group (F =10.40, p≤0.01).","[{'ForeName': 'Natalie J', 'Initials': 'NJ', 'LastName': 'Frost', 'Affiliation': ""School of Psychological Science (NF, MW, GG), University of Western Australia, Crawley, Western Australia, Australia; Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia. Electronic address: natalie.frost@research.uwa.edu.au.""}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Weinborn', 'Affiliation': ""School of Psychological Science (NF, MW, GG), University of Western Australia, Crawley, Western Australia, Australia; Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; School of Medical and Health Sciences (MW, SRRS, HRS, SML, RNM), Edith Cowan University, Joondalup, Western Australia, Australia.""}, {'ForeName': 'Gilles E', 'Initials': 'GE', 'LastName': 'Gignac', 'Affiliation': 'School of Psychological Science (NF, MW, GG), University of Western Australia, Crawley, Western Australia, Australia.'}, {'ForeName': 'Stephanie R', 'Initials': 'SR', 'LastName': 'Rainey-Smith', 'Affiliation': ""Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia; School of Medical and Health Sciences (MW, SRRS, HRS, SML, RNM), Edith Cowan University, Joondalup, Western Australia, Australia.""}, {'ForeName': 'Shaun', 'Initials': 'S', 'LastName': 'Markovic', 'Affiliation': ""Exercise Science, College of Science, Health, Engineering and Education (SM, NG, JJP, BMB), Murdoch University, Murdoch, Western Australia, Australia; Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Gordon', 'Affiliation': 'Exercise Science, College of Science, Health, Engineering and Education (SM, NG, JJP, BMB), Murdoch University, Murdoch, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia.'}, {'ForeName': 'Hamid R', 'Initials': 'HR', 'LastName': 'Sohrabi', 'Affiliation': ""Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; School of Medical and Health Sciences (MW, SRRS, HRS, SML, RNM), Edith Cowan University, Joondalup, Western Australia, Australia; School of Biomedical Sciences, Faculty of Medicine and Health Sciences (HRS, RNM), Macquarie University, New South Wales, Australia; Centre for Healthy Ageing, School of Psychology and Exercise Science (HRS), Murdoch University, Murdoch, WA, Australia.""}, {'ForeName': 'Simon M', 'Initials': 'SM', 'LastName': 'Laws', 'Affiliation': 'School of Medical and Health Sciences (MW, SRRS, HRS, SML, RNM), Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences (SML), Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences (SML), Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.'}, {'ForeName': 'Ralph N', 'Initials': 'RN', 'LastName': 'Martins', 'Affiliation': ""Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; School of Medical and Health Sciences (MW, SRRS, HRS, SML, RNM), Edith Cowan University, Joondalup, Western Australia, Australia; School of Biomedical Sciences, Faculty of Medicine and Health Sciences (HRS, RNM), Macquarie University, New South Wales, Australia.""}, {'ForeName': 'Jeremiah J', 'Initials': 'JJ', 'LastName': 'Peiffer', 'Affiliation': 'Exercise Science, College of Science, Health, Engineering and Education (SM, NG, JJP, BMB), Murdoch University, Murdoch, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia.'}, {'ForeName': 'Belinda M', 'Initials': 'BM', 'LastName': 'Brown', 'Affiliation': ""Exercise Science, College of Science, Health, Engineering and Education (SM, NG, JJP, BMB), Murdoch University, Murdoch, Western Australia, Australia; Australian Alzheimer's Research Foundation (NF, MW, SRRS, SM, HRS, RNM, BMB), Sarich Neurosciences Research Institute, Nedlands, Western Australia, Australia; Ageing, Cognition and Exercise Research Group (NF, SRRS, SM, NG, HRS, JJP, BMB), School of Psychology and Exercise Science, Murdoch University, Murdoch, Western Australia, Australia.""}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2020.06.015'] 2901,32732105,Effect of self-administered vaginal dinoprostone on pain perception during copper intrauterine device insertion in parous women: a randomized controlled trial.,"OBJECTIVE(S) To assess efficacy and safety of self-administered 3 mg dinoprostone vaginally in reducing pain during copper intrauterine device (IUD) insertion in parous women. DESIGN Randomized, double-blinded, placebo-controlled trial. SETTING Family planning clinic in a tertiary referral hospital. PATIENT(S) Multiparous women who were attending a family planning clinic and requesting copper IUD insertion. INTERVENTIONS(S) We randomly assigned 160 participants into two groups: The dinoprostone group (n = 80) received 3 mg dinoprostone vaginally, and the placebo group (n = 80) received placebo vaginally. MAIN OUTCOME MEASURE(S) Our primary outcome was mean pain scores during IUD insertion. Our secondary outcomes were mean pain scores during tenaculum application, during uterine sounding, and 15 minutes after insertion, ease of insertion, satisfaction score, need for additional analgesics, and side-effects. RESULT(S) Both groups showed no significant difference in anticipated pain score (P=.41), pain during tenaculum placement (P=.22), and pain during sound insertion (P=.07). The dinoprostone group had significantly lower pain scores during IUD insertion (34.8 ± 10.1 vs. 57.8 ± 11.8) and 15 minutes after insertion (20.6 ± 6.4 vs. 29.6 ± 6.2), easier IUD insertion (43.6 ± 21.9 vs. 64.7 ± 18.1), and higher satisfaction (83.9 ± 11.6 vs. 63.0 ± 9.1) compared with the placebo group. Fewer patients required additional analgesics in the dinoprostone group compared with the placebo group (P=.01). Side-effects were similar between the groups. CONCLUSION(S) Self-administered 3 mg dinoprostone vaginally before copper IUD insertion in parous women reduces pain scores during IUD insertion, making insertion easier and increasing women's satisfaction, with tolerable side-effects. CLINICAL TRIAL REGISTRATION NUMBER NCT04046302.",2020,"Both groups showed no significant difference in anticipated pain score (P=.41), pain during tenaculum placement (P=.22), and pain during sound insertion (P=.07).","['parous women', 'Multiparous women who were attending a family planning clinic and requesting copper IUD insertion', 'Family planning clinic in a tertiary referral hospital']","['dinoprostone', 'self-administered vaginal dinoprostone', 'placebo vaginally', 'placebo']","['pain during tenaculum placement (P=.22), and pain', 'pain scores', 'Side-effects', 'additional analgesics', 'pain during copper intrauterine device (IUD) insertion', 'easier IUD insertion', 'mean pain scores', 'anticipated pain score', 'mean pain scores during tenaculum application, during uterine sounding, and 15 minutes after insertion, ease of insertion, satisfaction score, need for additional analgesics, and side-effects', 'pain perception']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0026751', 'cui_str': 'Multiparous'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C3840184', 'cui_str': 'Family planning clinic'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0021901', 'cui_str': 'Copper Intrauterine Devices'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0587437', 'cui_str': 'Tertiary referral hospital'}]","[{'cui': 'C0012472', 'cui_str': 'Dinoprostone'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0042232', 'cui_str': 'Vaginal structure'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0180964', 'cui_str': 'Tenaculum'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0002771', 'cui_str': 'Analgesic'}, {'cui': 'C0021901', 'cui_str': 'Copper Intrauterine Devices'}, {'cui': 'C0021900', 'cui_str': 'Intrauterine contraceptive device'}, {'cui': 'C0332219', 'cui_str': 'Easy'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0042149', 'cui_str': 'Uterine structure'}, {'cui': 'C1442447', 'cui_str': 'Fifteen minutes'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C3714605', 'cui_str': 'Pain sensation, function'}]",160.0,0.854206,"Both groups showed no significant difference in anticipated pain score (P=.41), pain during tenaculum placement (P=.22), and pain during sound insertion (P=.07).","[{'ForeName': 'Ahmed Sa', 'Initials': 'AS', 'LastName': 'Ashour', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hala', 'Initials': 'H', 'LastName': 'Nabil', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed F', 'Initials': 'MF', 'LastName': 'Yosif', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Hussein', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed A', 'Initials': 'AA', 'LastName': 'Mageed A Allah', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mostafa', 'Initials': 'M', 'LastName': 'Mahmoud', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Hossam', 'Initials': 'H', 'LastName': 'Abdou', 'Affiliation': 'Obstetrics and Gynecology, Helwan University, Cairo, Egypt.'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Kholaif', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed Mahmoud', 'Initials': 'MM', 'LastName': 'Mohamed Kotb', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El Sharkawy', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ahmed Mohamed', 'Initials': 'AM', 'LastName': 'Abdelhakim', 'Affiliation': 'Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: ahmed.m.rohei@students.kasralainy.edu.eg.'}, {'ForeName': 'Ahmed Said', 'Initials': 'AS', 'LastName': 'Ali', 'Affiliation': 'Faculty of Medicine, Al-Azhar University, Cairo, Egypt.'}, {'ForeName': 'Salma Ashraf', 'Initials': 'SA', 'LastName': 'Nassar', 'Affiliation': 'Obstetrics and Gynecology, Ain Shams University, Cairo, Egypt.'}, {'ForeName': 'Amr Hazim', 'Initials': 'AH', 'LastName': 'Abbassy', 'Affiliation': 'Obstetrics and Gynecology, National Research Center, Cairo, Egypt.'}, {'ForeName': 'Nevein Kamal', 'Initials': 'NK', 'LastName': 'Ghamry', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ali Abdelhafeez', 'Initials': 'AA', 'LastName': 'Abdel-Latif', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Taher', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'El Mahy', 'Affiliation': 'Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Cairo, Egypt.'}]",Fertility and sterility,['10.1016/j.fertnstert.2020.05.004'] 2902,32732142,"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.","Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata) may offer broader protection against seasonal influenza. This study examined the immunogenicity and safety of a candidate IIV4. A randomized, double-blind, controlled phase III clinical trial was conducted in healthy subjects aged ≥3 years. Subjects were randomly assigned into three groups in a 2:1:1 ratio, receiving single dose of IIV4 or inactivated trivalent influenza vaccine (IIV3) which contains either B/Victoria strain (BV) or B/Yamagata strain (BY). Blood samples were collected before and 28 days after vaccination to test hemagglutination inhibition (HI) antibodies of the four influenza strains. Safety information was collected for 28 days after vaccination. A total of 2320 subjects (IIV4: 1160, IIV3-BV: 580, IIV3-BY: 580) were enrolled in this study. After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively. Geometric mean titers (GMTs) against the four influenza strains were 523.91, 274.13, 115.35 and 257.81, respectively. The investigational IIV4 was non-inferiority to IIV3 for the four strains, meanwhile superior to IIV3 for additional B strains (B/BV, B/BY). For safety, there had no significant difference in the incidence of the adverse reactions among the three groups (P = 0.5986). No serious adverse events related to vaccination occurred. The IIV4 had good immunogenicity and safety, which added an influenza B protection with no increased safety concerns. (ClinicalTrials.gov number: NCT03853993).",2020,"After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively.","['A total of 2320 subjects (IIV4: 1160, IIV3-BV: 580, IIV3-BY: 580', 'healthy population aged ≥3\xa0years', 'healthy subjects aged ≥3\xa0years']","['Inactivated quadrivalent influenza vaccine (IIV4) containing two influenza A strains (H1N1 and H3N2) and one strain from each B lineage (Victoria and Yamagata', 'single dose of IIV4 or inactivated trivalent influenza vaccine (IIV3) which contains either B/Victoria strain (BV) or B/Yamagata strain (BY', 'inactivated quadrivalent influenza vaccine']","['immunogenicity and safety', 'Safety information', 'Geometric mean titers (GMTs', 'Blood samples', 'seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains', 'safety concerns', 'adverse reactions', 'Immunogenicity and safety']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C4517818', 'cui_str': '580'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C4318638', 'cui_str': 'Quadrivalent Influenza Vaccine'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C1615607', 'cui_str': 'Influenza A virus subtype H1N1'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0021403', 'cui_str': 'Influenza virus vaccine'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C4042908', 'cui_str': 'Seroconversion'}, {'cui': 'C0580264', 'cui_str': 'H1N1'}, {'cui': 'C0580267', 'cui_str': 'H3N2'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",2320.0,0.194904,"After vaccination, the seroconversion rates of IIV4 against H1N1, H3N2, BV and BY strains were 77.15%, 81.93%, 60.14% and 64.57%, respectively.","[{'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Kangwei', 'Initials': 'K', 'LastName': 'Xu', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China.'}, {'ForeName': 'Rong', 'Initials': 'R', 'LastName': 'Tang', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Xiaohui', 'Initials': 'X', 'LastName': 'Tian', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China.'}, {'ForeName': 'Jialei', 'Initials': 'J', 'LastName': 'Hu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.'}, {'ForeName': 'Tuantuan', 'Initials': 'T', 'LastName': 'Yang', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing 102629, China. Electronic address: changguili@aliyun.com.'}, {'ForeName': 'Yuemei', 'Initials': 'Y', 'LastName': 'Hu', 'Affiliation': 'Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Electronic address: 993832717@qq.com.'}, {'ForeName': 'Gang', 'Initials': 'G', 'LastName': 'Zeng', 'Affiliation': 'Clinical Research Department, Sinovac Biotech Co., LTD., Beijing 100085, China. Electronic address: zengg@sinovac.com.'}]",Vaccine,['10.1016/j.vaccine.2020.06.071'] 2903,32732154,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of an Omega-3 Fatty Acid Supplement in Patients With Predialysis Chronic Kidney Disease.","OBJECTIVE Omega-3 fatty acids may reduce albuminuria and cardiovascular risk factors in patients with chronic kidney disease (CKD). We aimed to assess the effects of omega-3 fatty acid supplementation on albuminuria, blood pressure, pulse wave velocity, and inflammatory markers in patients with CKD. METHODS Patients with CKD and a urine albumin excretion of at least 30 mg/g creatinine were supplemented for 3 months with 3,666 mg/day of docosahexaenoic and eicosapentaenoic acids or a corn oil supplement. The study was double blind. At baseline, 6 weeks, and 12 weeks, fasting blood and morning spot urine samples were obtained. Blood pressure, carotid intima media thickness, and pulse wave velocity were measured. The main outcome measure was a reduction of ≥20% in urine albumin. RESULTS One hundred patients were randomized (50 received omega-3 fatty acids and 50 received corn oil). Four patients who received omega-3 fatty acids and 5 who received vegetable oil were lost to follow-up. In patients receiving omega-3 fatty acids, the omega-3 index increased from 3.08 (2.32-3.81) to 5.48 (3.045-7.04) percent. A 20% reduction in urine albumin excretion was observed in 13 participants of the control group and 19 participants of omega-3 group (Fisher's exact P = .274). However, the supplement had a significant and positive effect on pulse wave velocity and triglyceride level. CONCLUSION An omega-3 fatty acid supplement of 3,666 mg/day did not modify urine albumin excretion in patients with CKD but did improve pulse wave velocity and serum triglyceride levels.",2020,"An omega-3 fatty acid supplement of 3,666 mg/day did not modify urine albumin excretion in patients with CKD but did improve pulse wave velocity and serum triglyceride levels.","['patients with chronic kidney disease (CKD', 'Patients With Predialysis Chronic Kidney Disease', 'patients with CKD', 'Patients with CKD and a urine albumin excretion of at least 30\xa0mg/g creatinine', 'One hundred patients']","['omega-3 fatty acids', 'Placebo', 'omega-3 fatty acid supplement', 'Omega-3 fatty acids', 'Omega-3 Fatty Acid Supplement', 'omega-3 fatty acids and 5 who received vegetable oil', 'omega-3 fatty acids and 50 received corn oil', 'docosahexaenoic and eicosapentaenoic acids or a corn oil supplement', 'omega-3 fatty acid supplementation']","['urine albumin excretion', 'albuminuria and cardiovascular risk factors', 'reduction of ≥20% in urine albumin', 'albuminuria, blood pressure, pulse wave velocity, and inflammatory markers', 'Blood pressure, carotid intima media thickness, and pulse wave velocity', 'fasting blood and morning spot urine samples', 'pulse wave velocity and serum triglyceride levels', 'pulse wave velocity and triglyceride level', 'omega-3 index']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0042038', 'cui_str': 'Albumin urine'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0439324', 'cui_str': 'Milligram per gram of creatinine'}, {'cui': 'C1704407', 'cui_str': '100'}]","[{'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0042438', 'cui_str': 'Vegetable oil'}, {'cui': 'C0010029', 'cui_str': 'Corn Oil'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C0561929', 'cui_str': 'N-3 fatty acid supplementation'}]","[{'cui': 'C0042038', 'cui_str': 'Albumin urine'}, {'cui': 'C0221102', 'cui_str': 'Excretory function'}, {'cui': 'C0001925', 'cui_str': 'Albuminuria'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0162864', 'cui_str': 'Tunica intima'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0332170', 'cui_str': 'Morning'}, {'cui': 'C0457208', 'cui_str': 'Spot urine sample'}, {'cui': 'C0542495', 'cui_str': 'Measurement of serum triglyceride level'}, {'cui': 'C0202236', 'cui_str': 'Triglycerides measurement'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",100.0,0.232525,"An omega-3 fatty acid supplement of 3,666 mg/day did not modify urine albumin excretion in patients with CKD but did improve pulse wave velocity and serum triglyceride levels.","[{'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bunout', 'Affiliation': 'Aging Department, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile. Electronic address: dbunout@inta.uchile.cl.'}, {'ForeName': 'Gladys', 'Initials': 'G', 'LastName': 'Barrera', 'Affiliation': 'Aging Department, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Hirsch', 'Affiliation': 'Aging Department, Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile.'}, {'ForeName': 'Eduardo', 'Initials': 'E', 'LastName': 'Lorca', 'Affiliation': 'East Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile; Aging Department, Nephrology Service, Hospital del Salvador, Providencia, Chile.'}]",Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation,['10.1053/j.jrn.2020.04.004'] 2904,32732305,Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial.,"Compared with standard glycemic control, intensive glycemic control caused increased mortality in the ACCORD trial. Preliminary data from several studies suggests that intensive glycemic control is associated with QT prolongation, which may lead to ventricular arrhythmias as a possible explanation of this increased mortality. We sought to assess the effects of intensive glycemic control and intensive blood pressure control on the risk of incident QT prolongation. Cox proportional hazards models were used to compare the risk of incident QT prolongation (>460 ms in women or >450 ms in men) in the intensive versus standard glycemic control arms. Over a combined 48,634 person-years of follow-up (mean 4.9), 634 participants (6.4%) developed a prolonged QTc. Participants in the intensive glycemic control arm did not have an increased risk of QT prolongation. Similarly, a strategy of intensive blood pressure control did not result in a significant change in risk of prolonged QTc. Sensitivity analyses using alternative QT correction formulas (Hodges, Bazett) yielded overall similar findings. In conclusion, the increased mortality observed in the intensive glycemic control arm in the ACCORD trial is not likely to be explained by QT prolongation leading to lethal ventricular arrhythmias.",2020,Participants in the intensive glycemic control arm did not have an increased risk of QT prolongation.,['Diabetes'],"['Intensive Glycemic and Blood Pressure Control', 'intensive glycemic control and intensive blood pressure control']","['risk of QT prolongation', 'risk of prolonged QTc', 'mortality']","[{'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0151878', 'cui_str': 'Prolonged QT interval'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0860814', 'cui_str': 'QTc'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}]",,0.0626446,Participants in the intensive glycemic control arm did not have an increased risk of QT prolongation.,"[{'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Singleton', 'Affiliation': 'Section of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina mjsingle@wakehealth.edu.'}, {'ForeName': 'Elsayed Z', 'Initials': 'EZ', 'LastName': 'Soliman', 'Affiliation': 'Section of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Alain G', 'Initials': 'AG', 'LastName': 'Bertoni', 'Affiliation': 'Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'S Patrick', 'Initials': 'SP', 'LastName': 'Whalen', 'Affiliation': ''}, {'ForeName': 'Prashant', 'Initials': 'P', 'LastName': 'D Bhave', 'Affiliation': 'Section of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Yeboah', 'Affiliation': 'Section of Cardiology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}]",Diabetes,['10.2337/db20-0401'] 2905,32738069,Long-Term Influence of Electrode Array Length on Speech Recognition in Cochlear Implant Users.,"OBJECTIVES/HYPOTHESIS Results from a prospective trial demonstrated better speech recognition for cochlear implant (CI) recipients implanted with a long lateral wall electrode array compared to subjects with a short array after 1 year of listening experience. As short array recipients may require an extended adaptation period, this study investigated whether differences in speech recognition continued through 4 years of CI use. STUDY DESIGN Long-term follow-up of a prospective randomized trial. METHODS Subjects were randomized to receive a MED-EL medium (24 mm) or standard (31.5 mm) array. Linear mixed models compared speech recognition between cohorts with word recognition in quiet and sentence recognition in noise at 1, 3, 6, 12, 24, and 48 months postactivation. Postoperative imaging and electric frequency filters were reviewed to assess the influence of frequency-to-place mismatch and angular separation between neighboring contacts, a metric associated with peripheral spectral selectivity. RESULTS Long (31.5 mm) array recipients demonstrated superior speech recognition out to 4 years postactivation. There was a significant effect of angular separation between contacts, with more closely spaced contacts associated with poorer speech recognition. There was no significant effect of mismatch, yet this may have been obscured by changes in frequency filters over time. CONCLUSIONS Conventional MED-EL CI recipients implanted with 31.5-mm arrays experience better speech recognition than 24-mm array recipients, initially and with long-term listening experience. The benefit conferred by longer arrays in the present cohort can be partially attributed to more widely spaced electrode contacts, presumably a result of reduced channel interaction. LEVEL OF EVIDENCE 2 Laryngoscope, 2020.",2020,"There was a significant effect of angular separation between contacts, with more closely spaced contacts associated with poorer speech recognition.","['Subjects', 'Cochlear Implant Users']","['Electrode Array Length', 'MED-EL medium', 'Conventional MED-EL CI']","['superior speech recognition', 'poorer speech recognition', 'speech recognition', 'Speech Recognition']","[{'cui': 'C0009199', 'cui_str': 'Cochlear prosthesis'}]","[{'cui': 'C0013812', 'cui_str': 'Electrode'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C0009458', 'cui_str': 'Communications Media'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0009199', 'cui_str': 'Cochlear prosthesis'}]","[{'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0524637', 'cui_str': 'Recognition'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]",,0.0299567,"There was a significant effect of angular separation between contacts, with more closely spaced contacts associated with poorer speech recognition.","[{'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Canfarotta', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Margaret T', 'Initials': 'MT', 'LastName': 'Dillon', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Craig A', 'Initials': 'CA', 'LastName': 'Buchman', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, U.S.A.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Buss', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Brendan P', 'Initials': 'BP', 'LastName': ""O'Connell"", 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Meredith A', 'Initials': 'MA', 'LastName': 'Rooth', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'English R', 'Initials': 'ER', 'LastName': 'King', 'Affiliation': 'Department of Audiology, University of North Carolina Health Care, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Harold C', 'Initials': 'HC', 'LastName': 'Pillsbury', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}, {'ForeName': 'Oliver F', 'Initials': 'OF', 'LastName': 'Adunka', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, The Ohio State University, Columbus, Ohio, U.S.A.'}, {'ForeName': 'Kevin D', 'Initials': 'KD', 'LastName': 'Brown', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, U.S.A.'}]",The Laryngoscope,['10.1002/lary.28949'] 2906,31566063,Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis.,,2020,,['patients with erosive hand osteoarthritis'],['Etanercept therapy'],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439679', 'cui_str': 'Erosive'}, {'cui': 'C0263746', 'cui_str': 'Degenerative joint disease of hand'}]","[{'cui': 'C4075969', 'cui_str': 'Etanercept therapy'}]",[],,0.011433,,"[{'ForeName': 'Fpb', 'Initials': 'F', 'LastName': 'Kroon', 'Affiliation': 'Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'A C', 'Initials': 'AC', 'LastName': 'Bay-Jensen', 'Affiliation': 'Biomarker and Research, Nordic Bioscience, Herlev, Denmark.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Wittoek', 'Affiliation': 'Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Verbruggen', 'Affiliation': 'Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Smolen', 'Affiliation': 'Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kloppenburg', 'Affiliation': 'Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Ramonda', 'Affiliation': 'Rheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.'}]",Scandinavian journal of rheumatology,['10.1080/03009742.2019.1657493'] 2907,32731829,Cost-utility analysis of standard dressing compared with incisional negative-pressure wound therapy among patients with closed surgical wounds following major trauma to the lower limb.,"AIMS To compare the cost-utility of standard dressing with incisional negative-pressure wound therapy (iNPWT) in adults with closed surgical wounds associated with major trauma to the lower limbs. METHODS A within-trial economic evaluation was conducted from the UK NHS and personal social services (PSS) perspective based on data collected from the Wound Healing in Surgery for Trauma (WHiST) multicentre randomized clinical trial. Health resource utilization was collected over a six-month post-randomization period using trial case report forms and participant-completed questionnaires. Cost-utility was reported in terms of incremental cost per quality-adjusted life year (QALY) gained. Sensitivity analysis was conducted to test the robustness of cost-effectiveness estimates while uncertainty was handled using confidence ellipses and cost-effectiveness acceptability curves. RESULTS The incremental cost of standard dressing versus iNPWT over six months was £2,037 (95% confidence interval (CI) £349 to £3,724). There was an insignificant increment in QALYs gained in the iNPWT group (0.005, 95% CI -0.018 to 0.028). The probability of iNPWT being cost-effective at £20,000 per QALY was 1.9%. The results remained robust in the sensitivity analysis. CONCLUSION The within-trial economic evaluation suggests that iNPWT is unlikely to be a cost-effective alternative to standard dressing in adults with closed surgical wounds to their lower limbs. Cite this article: Bone Joint J 2020;102-B(8):1072-1081.",2020,The within-trial economic evaluation suggests that iNPWT is unlikely to be a cost-effective alternative to standard dressing in adults with closed surgical wounds to their lower limbs.,"['adults with closed surgical wounds to their lower limbs', 'A within-trial economic evaluation was conducted from the UK NHS and personal social services (PSS) perspective based on data collected from the Wound Healing in Surgery for Trauma (WHiST) multicentre', 'patients with closed surgical wounds following major trauma to the lower limb', 'adults with closed surgical wounds associated with major trauma to the lower limbs']","['standard dressing', 'incisional negative-pressure wound therapy', 'standard dressing with incisional negative-pressure wound therapy (iNPWT']","['QALYs gained', 'Cost-utility', 'probability of iNPWT being cost-effective', 'Health resource utilization']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0587267', 'cui_str': 'Closed'}, {'cui': 'C0332803', 'cui_str': 'Surgical wound'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0150099', 'cui_str': 'Economic Evaluation'}, {'cui': 'C0004927', 'cui_str': 'Behavior finding'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0037441', 'cui_str': 'Social Service'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0043240', 'cui_str': 'Tissue repair'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0332677', 'cui_str': 'Major injury'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013119', 'cui_str': 'Medical dressing'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}]","[{'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0184898', 'cui_str': 'Incision'}, {'cui': 'C1956078', 'cui_str': 'Topical Negative-Pressure Therapy'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0018741', 'cui_str': 'Health Resources'}, {'cui': 'C0042153', 'cui_str': 'utilization'}]",,0.129161,The within-trial economic evaluation suggests that iNPWT is unlikely to be a cost-effective alternative to standard dressing in adults with closed surgical wounds to their lower limbs.,"[{'ForeName': 'May E', 'Initials': 'ME', 'LastName': 'Png', 'Affiliation': 'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jason J', 'Initials': 'JJ', 'LastName': 'Madan', 'Affiliation': 'Statistics and Epidemiology, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Melina', 'Initials': 'M', 'LastName': 'Dritsaki', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.'}, {'ForeName': 'Juul', 'Initials': 'J', 'LastName': 'Achten', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Parsons', 'Affiliation': 'Statistics and Epidemiology, Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Miguel', 'Initials': 'M', 'LastName': 'Fernandez', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Grant', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK.'}, {'ForeName': 'Jagdeep', 'Initials': 'J', 'LastName': 'Nanchahal', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.'}, {'ForeName': 'Matthew L', 'Initials': 'ML', 'LastName': 'Costa', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The bone & joint journal,['10.1302/0301-620X.102B8.BJJ-2020-0126.R1'] 2908,32731836,Uncemented tantalum metal components versus cemented tibial components in total knee arthroplasty: 11- to 15-year outcomes of a single-blinded randomized controlled trial.,"AIMS Total knee arthroplasty is an established treatment for knee osteoarthritis with excellent long-term results, but there remains controversy about the role of uncemented prostheses. We present the long-term results of a randomized trial comparing an uncemented tantalum metal tibial component with a conventional cemented component of the same implant design. METHODS Patients under the age of 70 years with symptomatic osteoarthritis of the knee were randomized to receive either an uncemented tantalum metal tibial monoblock component or a standard cemented modular component. The mean age at time of recruitment to the study was 63 years (50 to 70), 46 (51.1%) knees were in male patients, and the mean body mass index was 30.4 kg/m 2 (21 to 36). The same cruciate retaining total knee system was used in both groups. All patients received an uncemented femoral component and no patients had their patella resurfaced. Patient outcomes were assessed preoperatively and postoperatively using the modified Oxford Knee Score, Knee Society Score, and 12-Item Short-Form Health Survey questionnaire (SF-12) score. Radiographs were analyzed using the American Knee Society Radiograph Evaluation score. Operative complications, reoperations, or revision surgery were recorded. A total of 90 knees were randomized and at last review 77 knees were assessed. In all, 11 patients had died and two were lost to follow-up. RESULTS At final review all patients were between 11 and 15 years following surgery. In total, 41 of the knees were cemented and 36 uncemented. There were no revisions in the cemented group and one revision in the uncemented group for fracture. The uncemented group reported better outcomes with both statistically and clinically significant (p = 0.001) improvements in knee-specific Oxford and Knee Society scores compared with the cemented group. The global SF-12 scores demonstrated no statistical difference (p = 0.812). Uncemented knees had better radiological analysis compared with the cemented group (p < 0.001). CONCLUSION Use of an uncemented trabecular metal tibial implant can afford better long-term clinical outcomes when compared to cemented tibial components of a matched design. However, both have excellent survivorship up to 15 years after implantation. Cite this article: Bone Joint J 2020;102-B(8):1025-1032.",2020,"Uncemented knees had better radiological analysis compared with the cemented group (p < 0.001). ","['total knee arthroplasty', 'Patients under the age of 70 years with symptomatic osteoarthritis of the knee', 'A total of 90 knees', 'mean age at time of recruitment to the study was 63 years (50 to 70), 46 (51.1%) knees were in male patients, and the mean body mass index was 30.4 kg/m 2 (21 to 36']","['uncemented femoral component', 'uncemented trabecular metal tibial implant', 'uncemented tantalum metal tibial monoblock component or a standard cemented modular component', 'Uncemented tantalum metal components versus cemented tibial components', 'uncemented tantalum metal tibial component']","['knee-specific Oxford and Knee Society scores', 'modified Oxford Knee Score, Knee Society Score, and 12-Item Short-Form Health Survey questionnaire (SF-12) score', 'Operative complications, reoperations, or revision surgery', 'global SF-12 scores']","[{'cui': 'C0086511', 'cui_str': 'Total knee replacement'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0031221', 'cui_str': 'Personnel Recruitment'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}]","[{'cui': 'C0449434', 'cui_str': 'Femoral component'}, {'cui': 'C0025552', 'cui_str': 'Metal'}, {'cui': 'C0040184', 'cui_str': 'Bone structure of tibia'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0039297', 'cui_str': 'Tantalum'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0011343', 'cui_str': 'Cementum structure'}]","[{'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C1997265', 'cui_str': 'Oxford knee score'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0018762', 'cui_str': 'Health Surveys'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0035110', 'cui_str': 'Reoperation'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}]",90.0,0.099678,"Uncemented knees had better radiological analysis compared with the cemented group (p < 0.001). ","[{'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Hampton', 'Affiliation': 'Department of Trauma and Orthopaedics, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.'}, {'ForeName': 'Junaid', 'Initials': 'J', 'LastName': 'Mansoor', 'Affiliation': 'Department of Trauma and Orthopaedics, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Getty', 'Affiliation': 'Department of Trauma and Orthopaedics, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Sutton', 'Affiliation': 'Department of Trauma and Orthopaedics, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.'}]",The bone & joint journal,['10.1302/0301-620X.102B8.BJJ-2019-1448.R1'] 2909,32731927,Repeat Aortic Valve Surgery or Transcatheter Valve-in-Valve Therapy: We Need a Randomized Trial.,,2020,,[],['Repeat Aortic Valve Surgery or Transcatheter Valve-in-Valve Therapy'],[],[],"[{'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0442343', 'cui_str': 'Transcatheter approach'}, {'cui': 'C0018826', 'cui_str': 'Cardiac valve structure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]",[],,0.0210824,,"[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Borger', 'Affiliation': 'University Clinic for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. Electronic address: michael.borger@helios-kliniken.de.'}, {'ForeName': 'Matthias', 'Initials': 'M', 'LastName': 'Raschpichler', 'Affiliation': 'University Clinic for Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany; Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}, {'ForeName': 'Raj', 'Initials': 'R', 'LastName': 'Makkar', 'Affiliation': 'Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.06.049'] 2910,32731928,Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.,"BACKGROUND Myocardial fibrosis may contribute to the pathophysiology of heart failure with preserved ejection fraction. Given the biochemical targets of sacubitril/valsartan, this study hypothesized that circulating biomarkers reflecting the mechanisms that determine extracellular matrix homeostasis are altered by sacubitril/valsartan compared with valsartan alone. OBJECTIVES This study investigated the effects of sacubitril/valsartan on biomarkers of extracellular matrix homeostasis and the association between biomarkers and the primary endpoint (total heart failure hospitalizations and cardiovascular death). METHODS N-terminal propeptide of collagen I and III, tissue inhibitor of matrix metalloproteinase 1, carboxyl-terminal telopeptide of collagen type I, and soluble ST2 were measured at baseline (n = 1,135) and 16 (n = 1,113) and 48 weeks (n = 1,016) after randomization. The effects of sacubitril/valsartan on these biomarkers were compared with those of valsartan alone. Baseline biomarker values and changes from baseline to 16 weeks were related to primary endpoint. RESULTS At baseline, all 5 biomarkers were higher than published referent control values. Sixteen weeks after randomization, sacubitril/valsartan decreased tissue inhibitor of matrix metalloproteinase 1 by 8% (95% confidence interval [CI]: 6% to 10%; p < 0.001), soluble ST2 by 4% (95% CI: 1% to 7%; p = 0.002), and N-terminal propeptide of collagen III by 3% (95% CI: 0% to 6%; p = 0.04) and increased carboxyl-terminal telopeptide of collagen type I by 4% (95% CI: 1% to 8%; p = 0.02) compared with valsartan alone, consistently in men and women and patients with left ventricular ejection fraction above or below the median of 57%. Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2 at baseline and increases in these markers at 16 weeks were associated with higher primary endpoint event rates. CONCLUSIONS Biomarkers reflecting extracellular matrix homeostasis are elevated in heart failure with preserved ejection fraction, favorably altered by sacubitril/valsartan, and have important prognostic value. (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).",2020,"Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2 at baseline and increases in these markers at 16 weeks were associated with higher primary endpoint event rates. ",['Patients With HFpEF'],"['matrix metalloproteinase 1, carboxyl-terminal telopeptide of collagen type', 'valsartan', 'sacubitril/valsartan', 'Sacubitril/Valsartan', 'HF']","['soluble ST2', 'Extracellular Matrix Regulation', 'tissue inhibitor of matrix metalloproteinase', 'carboxyl-terminal telopeptide of collagen type I', 'Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2']","[{'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0127082', 'cui_str': 'Interstitial Collagenase'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0009325', 'cui_str': 'Collagen'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0216784', 'cui_str': 'valsartan'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}]","[{'cui': 'C0450499', 'cui_str': 'ST2'}, {'cui': 'C0015350', 'cui_str': 'Matrix, Extracellular'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0623362', 'cui_str': 'MMPs'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0041455', 'cui_str': 'Collagen Type I'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0127082', 'cui_str': 'Interstitial Collagenase'}]",1135.0,0.0719257,"Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2 at baseline and increases in these markers at 16 weeks were associated with higher primary endpoint event rates. ","[{'ForeName': 'Jonathan W', 'Initials': 'JW', 'LastName': 'Cunningham', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Claggett', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Eileen', 'Initials': 'E', 'LastName': ""O'Meara"", 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'Margaret F', 'Initials': 'MF', 'LastName': 'Prescott', 'Affiliation': 'Novartis, East Hanover, New Jersey.'}, {'ForeName': 'Marc A', 'Initials': 'MA', 'LastName': 'Pfeffer', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Sanjiv J', 'Initials': 'SJ', 'LastName': 'Shah', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}, {'ForeName': 'Margaret M', 'Initials': 'MM', 'LastName': 'Redfield', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Faiez', 'Initials': 'F', 'LastName': 'Zannad', 'Affiliation': ""Centre d'Investigations Cliniques-Plurithématique 1433, and Institut National de la Santé et de la Recherche Médicale U1116, Centre Hospitalier Regional Universitaire, French Clinical Research Infrastructure Network, Investigation Network Initiative Cardiovascular and Renal Clinical Trialists, Nancy, France.""}, {'ForeName': 'Lu-May', 'Initials': 'LM', 'LastName': 'Chiang', 'Affiliation': 'Novartis, East Hanover, New Jersey.'}, {'ForeName': 'Adel R', 'Initials': 'AR', 'LastName': 'Rizkala', 'Affiliation': 'Novartis, East Hanover, New Jersey.'}, {'ForeName': 'Victor C', 'Initials': 'VC', 'LastName': 'Shi', 'Affiliation': 'Novartis, East Hanover, New Jersey.'}, {'ForeName': 'Martin P', 'Initials': 'MP', 'LastName': 'Lefkowitz', 'Affiliation': 'Novartis, East Hanover, New Jersey.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Rouleau', 'Affiliation': 'Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.'}, {'ForeName': 'John J V', 'Initials': 'JJV', 'LastName': 'McMurray', 'Affiliation': 'British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Scott D', 'Initials': 'SD', 'LastName': 'Solomon', 'Affiliation': ""Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: ssolomon@bwh.harvard.edu.""}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Zile', 'Affiliation': 'Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina; Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina. Electronic address: zilem@musc.edu.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2020.05.072'] 2911,32732442,Clinical Outcome of Fixed Versus Adjustable Loop Cortical Suspension Devices in Arthroscopic Anterior Cruciate Ligament Reconstruction.,"BACKGROUND Anterior cruciate ligament (ACL) reconstruction has remained the gold standard for ACL injuries, especially for young individuals and athletes exposed to high level sporting activities aiming to return to their preinjury level of activity. Cortical suspensory femoral fixation is commonly performed for graft fixation to the femur in anterior cruciate ligament reconstruction using hamstring tendons. The aim of this study was to compare the clinical results of using fixed and adjustable loop cortical suspension devices in arthroscopic ACL reconstruction using the Lysholm Knee Scoring Scale after 12 months postoperatively. MATERIAL AND METHODS This study included a total of sixty patients who underwent transportal arthroscopic ACL reconstruction using a hamstring tendon autograft from November 2016 to December 2017. For femoral graft fixation, a fixed-length loop device was used in 30 patients (fixed-loop group) and an adjustable-length loop device was used in 30 patients (adjustable-loop group) randomly.For tibial graft fixation, interference screw was used for all patients. RESULTS The present study shows that there was no statistically significant difference between the two groups regarding the Lysholm score with highly statistically significant difference between preoperative and postoperative Lysholm score in each group separately. CONCLUSION Both fixed loop and adjustable loop devices in ACL reconstruction provided good clinical outcomes but without significant statistical difference between both groups from the clinical point of view postoperatively using the Lysholm score.",2020,Both fixed loop and adjustable loop devices in ACL reconstruction provided good clinical outcomes but without significant statistical difference between both groups from the clinical point of view postoperatively using the Lysholm score.,"['sixty patients who underwent', 'from November 2016 to December 2017', 'Arthroscopic Anterior Cruciate Ligament Reconstruction', 'anterior cruciate ligament reconstruction using hamstring tendons', '30 patients (fixed-loop group) and an', 'young individuals and athletes']","['fixed and adjustable loop cortical suspension devices', 'Fixed Versus Adjustable Loop Cortical Suspension Devices', 'Anterior cruciate ligament (ACL) reconstruction', 'adjustable-length loop device', 'transportal arthroscopic ACL reconstruction using a hamstring tendon autograft', 'Cortical suspensory femoral fixation']",['preoperative and postoperative Lysholm score'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C1267157', 'cui_str': 'Hamstring Tendons'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}]","[{'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0445022', 'cui_str': 'Loop'}, {'cui': 'C0001613', 'cui_str': 'Adrenal cortex structure'}, {'cui': 'C0007985', 'cui_str': 'Chemical suspension'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0078960', 'cui_str': 'Structure of anterior cruciate ligament of knee joint'}, {'cui': 'C0020912', 'cui_str': 'Image Reconstruction'}, {'cui': 'C1444754', 'cui_str': 'Length'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}, {'cui': 'C0039508', 'cui_str': 'Tendon structure'}, {'cui': 'C0040736', 'cui_str': 'Autogenous transplantation'}, {'cui': 'C0015811', 'cui_str': 'Bone structure of femur'}, {'cui': 'C0185023', 'cui_str': 'Fixation - action'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",60.0,0.0249142,Both fixed loop and adjustable loop devices in ACL reconstruction provided good clinical outcomes but without significant statistical difference between both groups from the clinical point of view postoperatively using the Lysholm score.,"[{'ForeName': 'Ramy Said Assaad Ahmed', 'Initials': 'RSAA', 'LastName': 'Mohamed', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, University of Alexandria, Egypt.'}, {'ForeName': 'Mohamed Hossam', 'Initials': 'MH', 'LastName': 'El-Din El-Shafie', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, University of Alexandria, Egypt.'}, {'ForeName': 'Mohamed Ahmed', 'Initials': 'MA', 'LastName': 'El-Sheikh', 'Affiliation': 'Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, University of Alexandria, Egypt.'}]","Ortopedia, traumatologia, rehabilitacja",['10.5604/01.3001.0014.3234'] 2912,32732500,Tranexamic acid is associated with reduced complement activation in trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography.,": Trauma with hemorrhagic shock causes massive tissue plasminogen activator release, plasmin generation, and hyperfibrinolysis. Tranexamic acid (TXA) has recently been used to treat bleeding in trauma by preventing plasmin generation to limit fibrinolysis. Trauma patients also have increased complement activation that correlates with mortality and organ failure, but the source of activation is not clear, and plasmin has recently been shown to efficiently cleave C3 and C5 to their activated fragments. We hypothesized that trauma patients in hemorrhagic shock with hyperfibrinolysis on thromboelastography (TEG) LY30 would have increased complement activation at early time points, as measured by soluble C5b-9 complex, and TXA would prevent this. Plasma samples were obtained from an unrelated, previously performed IRB-approved prospective randomized study of trauma patients. Three groups were studied with n = 5 patients in each group: patients without hyperfibrinolysis (TEG LY30 < 3%) (who therefore did not get TXA), patients with hyperfibrinolysis (TEG LY30 > 3%) who did not get TXA, and patients with hyperfibrinolysis who were then treated with TXA. We found that patients who did not receive TXA, regardless of fibrinolytic phenotype, had elevated soluble C5b-9 levels at 6 h relative to emergency department levels. In contrast, all five patients with initial TEG LY30 more than 3% and were then treated with TXA had reduced soluble C5b-9 levels at 6 h relative to emergency department levels. There were no differences in PF1 + 2, Bb, or C4d levels between groups, suggesting that coagulation and complement activation pathways may not be primarily responsible for the observed differences.",2020,"There were no differences in PF1 + 2, Bb, or C4d levels between groups, suggesting that coagulation and complement activation pathways may not be primarily responsible for the observed differences.","['trauma patients with hemorrhagic shock and hyperfibrinolysis on thromboelastography', 'trauma patients', 'trauma patients in hemorrhagic shock with hyperfibrinolysis on thromboelastography (TEG) LY30', 'Trauma patients', 'patients with hyperfibrinolysis']","['TXA', 'TEG LY30', 'Tranexamic acid (TXA', 'hyperfibrinolysis (TEG LY30', 'Tranexamic acid']","['soluble C5b-9 levels', 'PF1\u200a+\u200a2, Bb, or C4d levels']","[{'cui': 'C0043251', 'cui_str': 'Injuries, Wounds'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0036982', 'cui_str': 'Hemorrhagic shock'}, {'cui': 'C3805089', 'cui_str': 'Hyperfibrinolysis'}, {'cui': 'C0040017', 'cui_str': 'Thromboelastography'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0040017', 'cui_str': 'Thromboelastography'}, {'cui': 'C3805089', 'cui_str': 'Hyperfibrinolysis'}]","[{'cui': 'C0009545', 'cui_str': 'Active C5b6789'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0056195', 'cui_str': 'Complement component C4d'}]",5.0,0.0310447,"There were no differences in PF1 + 2, Bb, or C4d levels between groups, suggesting that coagulation and complement activation pathways may not be primarily responsible for the observed differences.","[{'ForeName': 'Christopher D', 'Initials': 'CD', 'LastName': 'Barrett', 'Affiliation': 'Departments of Biological Engineering and Biology, Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge.'}, {'ForeName': 'Navin', 'Initials': 'N', 'LastName': 'Vigneshwar', 'Affiliation': 'Department of Surgery, University of Colorado Denver.'}, {'ForeName': 'Hunter B', 'Initials': 'HB', 'LastName': 'Moore', 'Affiliation': 'Department of Surgery, University of Colorado Denver.'}, {'ForeName': 'Arsen', 'Initials': 'A', 'LastName': 'Ghasabyan', 'Affiliation': 'Department of Surgery, Ernest E Moore Shock Trauma Center at Denver Health, Denver, Colorado, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Chandler', 'Affiliation': 'Department of Surgery, Ernest E Moore Shock Trauma Center at Denver Health, Denver, Colorado, USA.'}, {'ForeName': 'Ernest E', 'Initials': 'EE', 'LastName': 'Moore', 'Affiliation': 'Department of Surgery, University of Colorado Denver.'}, {'ForeName': 'Michael B', 'Initials': 'MB', 'LastName': 'Yaffe', 'Affiliation': 'Departments of Biological Engineering and Biology, Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge.'}]",Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,['10.1097/MBC.0000000000000938'] 2913,32732515,Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction.,"OBJECTIVE The aim of this study was to investigate the effect of sacubitril/valsartan (Sal/Val) on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute anterior wall myocardial infarction (AAMI). METHODS AAMI patients with LV systolic dysfunction were enrolled in this study. All patients underwent percutaneous coronary intervention. After hemodynamic stabilization, patients were randomly assigned either to group T (Sal/Val treatment) or group C (enalapril treatment). Changes in echocardiographic parameters and plasma biochemical markers were used to evaluate the effects of Sal/Val on LV remodeling and cardiac function. The incidence of major cardiac adverse events (MACEs) and adverse reactions during follow-ups was also recorded. RESULTS In total, 137 eligible patients were prospectively included. Compared to group C, LV ejection fraction significantly improved (P < 0.05), while the LV end-systolic volume index and wall motion score index showed a tendency to decrease in group T. There was no difference in the LV end-diastolic volume index between groups. During follow-ups, the plasma N-terminal pro-B-type natriuretic peptide and soluble suppression of tumorigenesis-2 levels in both groups decreased (all P < 0.05), and the change was more prominent in group T. Additionally, drug-related adverse effects were similar between the two groups (P > 0.05); however, the incidence of MACEs was lower in group T than in group C (39.71% vs. 53.62%, P = 0.103), although the difference was insignificant. CONCLUSION Sac/Val attenuated LV remodeling and dysfunction and was safe and effective in LV systolic dysfunction patients post AAMI.",2020,"Compared to group C, LV ejection fraction significantly improved (P < 0.05), while the LV end-systolic volume index and wall motion score index showed a tendency to decrease in group T.","['patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction', 'patients with LV systolic dysfunction following acute anterior wall myocardial infarction (AAMI', 'AAMI patients with LV systolic dysfunction', '137 eligible patients were prospectively included']","['group T (Sal/Val treatment) or group C (enalapril treatment', 'sacubitril/valsartan', 'percutaneous coronary intervention', 'sacubitril/valsartan (Sal/Val']","['incidence of MACEs', 'LV ejection fraction', 'LV end-systolic volume index and wall motion score index', 'incidence of major cardiac adverse events (MACEs) and adverse reactions', 'LV end-diastolic volume index', 'ventricular remodeling', 'LV remodeling and cardiac function', 'adverse effects', 'plasma N-terminal pro-B-type natriuretic peptide and soluble suppression of tumorigenesis-2 levels']","[{'cui': 'C0030650', 'cui_str': 'Patents'}, {'cui': 'C0018827', 'cui_str': 'Cardiac ventricular structure'}, {'cui': 'C0749225', 'cui_str': 'Systolic dysfunction'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C2349195', 'cui_str': 'Acute myocardial infarction of anterior wall'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0340293', 'cui_str': 'Myocardial Infarction, Anterior Wall'}, {'cui': 'C4517569', 'cui_str': '137'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0036669', 'cui_str': 'Group T'}, {'cui': 'C4033631', 'cui_str': 'valsartan and sacubitril'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0441837', 'cui_str': 'Group C'}, {'cui': 'C0014025', 'cui_str': 'Enalapril'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0080308', 'cui_str': 'Ventricular End-Systolic Volume'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C4324428', 'cui_str': 'Wall motion score index'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}, {'cui': 'C0042509', 'cui_str': 'Ventricular End-Diastolic Volume'}, {'cui': 'C0600519', 'cui_str': 'Ventricular remodelling'}, {'cui': 'C0600520', 'cui_str': 'Left Ventricular Remodeling'}, {'cui': 'C0232164', 'cui_str': 'Cardiac function'}, {'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression'}, {'cui': 'C0007621', 'cui_str': 'Neoplastic Cell Transformation'}, {'cui': 'C0456948', 'cui_str': 'Level 2'}]",137.0,0.0303235,"Compared to group C, LV ejection fraction significantly improved (P < 0.05), while the LV end-systolic volume index and wall motion score index showed a tendency to decrease in group T.","[{'ForeName': 'Haiyan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.'}, {'ForeName': 'Xianghua', 'Initials': 'X', 'LastName': 'Fu', 'Affiliation': ''}]",Coronary artery disease,['10.1097/MCA.0000000000000932'] 2914,32732573,Platelet-rich Plasma or Autologous Blood Do Not Reduce Pain or Improve Function in Patients with Lateral Epicondylitis: A Randomized Controlled Trial.,"BACKGROUND Platelet-rich plasma (PRP) and autologous blood are commonly used therapies for lateral epicondylitis, but the evidence from randomized, placebo-controlled trials is conflicting. Thus, it is still unclear if patients benefit from these treatments. QUESTIONS/PURPOSES In the setting of a randomized, placebo-controlled trial, we compared PRP, autologous blood, and saline injections in the treatment of lateral epicondylitis with respect to: (1) VAS pain scores, and (2) functional outcomes (DASH score and grip strength) 1 year after treatment. METHODS We performed a parallel-group, randomized, controlled participant- and assessor-blinded study including adults with clinically diagnosed lateral epicondylitis. We defined lateral epicondylitis as pain in the lateral humeral epicondyle area exacerbated during resisted wrist extension and epicondyle compression. The participants were recruited from a secondary referral center, after not responding to initial nonoperative treatment. Patients with other concomitant upper-limb symptoms and surgical treatment of the elbow were excluded. Randomization sequence was generated with computer software and concealed from the investigators. We randomized 119 participants to receive an injection of PRP, autologous blood, or saline (1:1:1) in the proximal insertion of the extensor carpi radialis brevis muscle; 40 participants received PRP, 40 received autologous blood, and 39 received a saline injection. To prepare the PRP, we collected venous blood with a syringe kit followed by centrifugation, whereas autologous blood group received unprepared blood injection. Two unblinded investigators gave injections while the participant was unable to see the injection. There was no formal postinjection rehabilitation protocol and the use of NSAIDs was similar between different treatment arms. Follow-up visits were at 4, 8, 12, 26, and 52 weeks after the injection. The primary outcome measure was improvement in pain, measured with VAS scale (without specification as to whether the pain was activity related or at rest; range 0-10; a higher score indicates worse pain; the minimum clinically important difference [MCID] on the 10-cm scale was 1.5 cm), from baseline to 52 weeks. The secondary outcomes were the DASH score (range 0-100; a higher indicates a poorer outcome, and the MCID was 10.2 points) and grip strength. All patients were included in the analyses, and analyses were performed using the intention-to-treat principle. There was no crossover between treatment groups. At 52 weeks, nearly all (95% [38 of 40]) participants in autologous blood group were available for analysis whereas 78% (31 of 40) and 82% (32 of 39) were available in PRP and saline groups. This study was registered at ClinicalTrials.gov and funded by the local hospital district. With 40 patients in each group, we had 80% power to detect a clinically important improvement in pain (1.5 cm on the 10-cm VAS pain scale). RESULTS There were no clinically important differences in the mean VAS pain or DASH scores among the groups at any timepoint. At 52 weeks, the mean difference in the VAS score for pain was -0.2 (95% CI -1.5 to 1.1; p = 0.75) for PRP versus saline and 0.5 (95% CI -0.7 to 1.7; p = 0.40) for autologous blood versus saline. The corresponding mean differences in the DASH score were 0.0 (95% CI -9.2 to 9.2; p > 0.99) and 7.7 (95% CI -1.3 to 16.7; p = 0.09) and those for grip strength were 1.4 kg (95% CI -3.3 to 6.1; p = 0.56) and -0.2 kg (95% CI -5.0 to 4.5; p = 0.92). No complications occurred because of the injections. CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection. However, because the 95% CIs did not exclude the MCID in VAS scores for autologous blood versus saline at 52 weeks, it is possible that a larger study could identify a between-group difference that we missed, but the effect size of that difference (based on our findings), even if present, is likely still to be small. Until or unless future randomized trials convincingly show a benefit either to PRP or autologous blood injections, we recommend against their use in patients with lateral epicondylitis. LEVEL OF EVIDENCE Level II, therapeutic study.",2020,"CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection.","['Patients with other concomitant upper-limb symptoms and surgical treatment of the elbow were excluded', 'participants were recruited from a secondary referral center, after not responding to initial nonoperative treatment', '119 participants to receive an', 'Patients with Lateral Epicondylitis', 'patients with lateral epicondylitis', 'adults with clinically diagnosed lateral epicondylitis']","['PRP or autologous blood injections', 'injection of PRP, autologous blood, or saline (1:1:1) in the proximal insertion of the extensor carpi radialis brevis muscle; 40 participants received PRP, 40 received autologous blood, and 39 received a saline injection', 'PRP versus saline', 'PRP, autologous blood, and saline injections', 'Platelet-rich Plasma or Autologous Blood', 'placebo']","['improvement in pain, measured with VAS scale', 'VAS score for pain', 'pain or function', '10-cm VAS pain scale', 'lateral epicondylitis with respect to: (1) VAS pain scores, and (2) functional outcomes (DASH score and grip strength', 'grip strength', 'pain', 'DASH score', 'mean VAS pain or DASH scores', 'VAS scores']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0521115', 'cui_str': 'Simultaneous'}, {'cui': 'C1140618', 'cui_str': 'Upper limb structure'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0543467', 'cui_str': 'Surgery'}, {'cui': 'C0013769', 'cui_str': 'Elbow region structure'}, {'cui': 'C0332196', 'cui_str': 'Exclude'}, {'cui': 'C3658282', 'cui_str': 'Secondary Referral Center'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0370220', 'cui_str': 'Platelet rich plasma'}, {'cui': 'C0439859', 'cui_str': 'Autologous'}, {'cui': 'C0005767', 'cui_str': 'Blood'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C2957363', 'cui_str': 'Injection of platelet-rich plasma'}, {'cui': 'C0036082', 'cui_str': 'Sodium chloride solution'}, {'cui': 'C0205107', 'cui_str': 'Proximal'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}, {'cui': 'C0679133', 'cui_str': 'Respect'}, {'cui': 'C0582148', 'cui_str': 'Pain score'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0429271', 'cui_str': 'Grip strength'}, {'cui': 'C0444504', 'cui_str': 'Mean'}]",119.0,0.492009,"CONCLUSIONS PRP or autologous blood injections did not improve pain or function at 1 year of follow-up in people with lateral epicondylitis compared with those who were given a saline injection.","[{'ForeName': 'Lasse', 'Initials': 'L', 'LastName': 'Linnanmäki', 'Affiliation': 'L. Linnanmäki, K. Kanto, J. Lehtinen, Tays Hatanpää Hospital, Tampere University Hospital, Tampere, Finland T. Karjalainen, Central Finland Central Hospital, Jyväskylä, Finland O. V. Leppänen, Department of Hand and Microsurgery, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Kanto', 'Affiliation': ''}, {'ForeName': 'Teemu', 'Initials': 'T', 'LastName': 'Karjalainen', 'Affiliation': ''}, {'ForeName': 'Olli V', 'Initials': 'OV', 'LastName': 'Leppänen', 'Affiliation': ''}, {'ForeName': 'Janne', 'Initials': 'J', 'LastName': 'Lehtinen', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001185'] 2915,32732574,CORR Insights®: Platelet-rich Plasma or Autologous Blood Do Not Reduce Pain or Improve Function in Patients with Lateral Epicondylitis: A Randomized Controlled Trial.,,2020,,['Patients with Lateral Epicondylitis'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039516', 'cui_str': 'Lateral epicondylitis'}]",[],[],,0.233205,,"[{'ForeName': 'Nash H', 'Initials': 'NH', 'LastName': 'Naam', 'Affiliation': 'N. H. Naam, Professor of Clinical Hand Surgery, Southern Illinois University, Southern Illinois Hand Center, Effingham, IL, USA.'}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001249'] 2916,32732583,Letter to the Editor: Does an Antimicrobial Incision Drape Prevent Intraoperative Contamination? A Randomized Controlled Trial of 1187 Patients.,,2020,,['1187 Patients'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}]",[],[],,0.137678,,"[{'ForeName': 'Zhen Chang', 'Initials': 'ZC', 'LastName': 'Liang', 'Affiliation': 'Z. C. Liang, M. S. Y. Chong, S. S. Tan, B. Z. Chin, D. Murphy, J. H. P. Hui, National University of Singapore, Department of Orthopaedic Surgery, National University Health System, Singapore.'}, {'ForeName': 'Mark Seng Ye', 'Initials': 'MSY', 'LastName': 'Chong', 'Affiliation': ''}, {'ForeName': 'Sara Shuhui', 'Initials': 'SS', 'LastName': 'Tan', 'Affiliation': ''}, {'ForeName': 'Brian Zhaojie', 'Initials': 'BZ', 'LastName': 'Chin', 'Affiliation': ''}, {'ForeName': 'Diarmuid', 'Initials': 'D', 'LastName': 'Murphy', 'Affiliation': ''}, {'ForeName': 'James Hoi Po', 'Initials': 'JHP', 'LastName': 'Hui', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000001331'] 2917,31710995,Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.,"BACKGROUND Valid prognostic tools are needed to guide risk-adjusted treatment approaches in patients with diffuse large B-cell lymphoma (DLBCL). METHODS We assessed total metabolic tumor volume (TMTV) and standardized uptake value (SUV)-based interim positron emission tomography (iPET) response in 510 patients with DLBCL participating in the positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL) trial (NCT00554164). TMTV was analyzed with a relative (SUV 41max ) and a fixed thresholding method (SUV 4 ), and iPET was evaluated using the ΔSUV max procedure. We determined associations between TMTV and international prognostic index (IPI) factors using Welch's t-test, investigated effects of TMTV, iPET response, and the IPI factors on time to progression (TTP), progression-free survival (PFS), and overall survival (OS) by Cox regression, and estimated the outcome using Kaplan-Meier curves. FINDINGS TMTV was associated with all IPI factors except age. Irrespective of the thresholding method used, TMTV and iPET response were correlated with TTP, PFS, and OS, and remained the only independent outcome predictors in Cox regression analysis. By dichotomizing TMTV (cut-off: 328 cm³ by SUV 41max ) and iPET response (cut-off: 66% SUV max reduction), we defined three groups at different risk of treatment failure (low [57.1% of patients]: low TMTV/good iPET response; intermediate [37.8%]: high TMTV/good iPET response or low TMTV/poor iPET response; and high [5.1%]: high TMTV/poor iPET response), with corresponding 2-year probabilities of 93.8% vs. 67.3% vs. 38.5% for TTP, 90.9% vs. 62.5% vs. 29.9% for PFS, and 95.5% vs. 77.4% vs. 37.1% for OS. INTERPRETATION The PET-based risk model proposed may help identify patients who may benefit from treatment modifications or novel approaches.",2020,"Irrespective of the thresholding method used, TMTV and iPET response were correlated with TTP, PFS, and OS, and remained the only independent outcome predictors in Cox regression analysis.","['510 patients with DLBCL participating in the positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL) trial (NCT00554164', 'diffuse large B-cell lymphoma', 'patients with diffuse large B-cell lymphoma (DLBCL']","['Dynamic risk assessment based on positron emission tomography scanning', 'TMTV']","['TMTV, iPET response, and the IPI factors on time to progression (TTP), progression-free survival (PFS), and overall survival (OS', 'TMTV and international prognostic index (IPI) factors', 'total metabolic tumor volume (TMTV) and standardized uptake value (SUV)-based interim positron emission tomography (iPET) response', 'TMTV/good iPET response or low TMTV/poor iPET response', 'iPET response', 'TMTV and iPET response']","[{'cui': 'C4517800', 'cui_str': '510'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0079744', 'cui_str': 'Malignant lymphoma, large B-cell, diffuse'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0001807', 'cui_str': 'Aggressive behavior'}, {'cui': 'C0024305', 'cui_str': 'Malignant lymphoma, non-Hodgkin'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0729333', 'cui_str': 'Dynamic'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0475276', 'cui_str': 'Tumor volume'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0668760', 'cui_str': 'diinosine pentaphosphate'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C1512894', 'cui_str': 'International Prognostic Index'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}]",510.0,0.0501823,"Irrespective of the thresholding method used, TMTV and iPET response were correlated with TTP, PFS, and OS, and remained the only independent outcome predictors in Cox regression analysis.","[{'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Schmitz', 'Affiliation': 'Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: christine.schmitz@uk-essen.de.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Hüttmann', 'Affiliation': 'Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Stefan P', 'Initials': 'SP', 'LastName': 'Müller', 'Affiliation': 'Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Maher', 'Initials': 'M', 'LastName': 'Hanoun', 'Affiliation': 'Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Boellaard', 'Affiliation': 'Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands.'}, {'ForeName': 'Marcus', 'Initials': 'M', 'LastName': 'Brinkmann', 'Affiliation': 'Center for Clinical Trials, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Karl-Heinz', 'Initials': 'KH', 'LastName': 'Jöckel', 'Affiliation': 'Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Ulrich', 'Initials': 'U', 'LastName': 'Dührsen', 'Affiliation': 'Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Rekowski', 'Affiliation': 'Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.09.027'] 2918,30712813,Oxytocin does not improve working memory in schizophrenia.,,2019,,[],['Oxytocin'],[],[],"[{'cui': 'C0030095', 'cui_str': 'Oxytocin'}]",[],,0.0430129,,"[{'ForeName': 'Ellen R', 'Initials': 'ER', 'LastName': 'Bradley', 'Affiliation': ""University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America. Electronic address: ellen.bradley@ucsf.edu.""}, {'ForeName': 'Adrienne', 'Initials': 'A', 'LastName': 'van Nieuwenhuizen', 'Affiliation': ""University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America.""}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Abram', 'Affiliation': ""University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America.""}, {'ForeName': 'Andrea N', 'Initials': 'AN', 'LastName': 'Niles', 'Affiliation': ""University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America.""}, {'ForeName': 'Joshua D', 'Initials': 'JD', 'LastName': 'Woolley', 'Affiliation': ""University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America.""}]",Schizophrenia research,['10.1016/j.schres.2019.01.020'] 2919,30742718,Parental asthma and risk of autism spectrum disorder in offspring: A population and family-based case-control study.,"BACKGROUND Associations between parental asthma and prenatal exposure to asthma medications with offspring autism spectrum disorder (ASD) have been reported. However, the associations might be confounded by unmeasured (genetic and shared environmental) familial factors. OBJECTIVE We investigated the association between (a) maternal/paternal asthma and offspring ASD, and (b) prenatal exposures to β2-agonists, other asthma medications and offspring ASD using cases and controls selected from the population as well as biological relatives with different degrees of relatedness. METHODS We included all children (N = 1 579 263) born in Sweden 1992-2007. A nested case-control design was used to compare 22 894 ASD cases identified from the National Patient Register to (a) 228 940 age-, county- and sex-matched controls randomly selected from the population, (b) their eligible full-siblings (n = 1267), (c) half-siblings (n = 1323), (d) full-cousins (n = 11 477) and (e) half-cousins (n = 3337). Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) for ASD in children differentially exposed to parental asthma or prenatal asthma medications. RESULTS Maternal asthma was associated with increased risk of offspring ASD (OR 1.43, 95% CI 1.38-1.49); there was a weaker association for paternal asthma (OR 1.17, 95% CI 1.11-1.23). The risk of offspring ASD in mothers with asthma showed similar estimates when adjusting for shared familial factors among paternal half-siblings (OR 1.20, 95% CI 0.80-1.81), full-cousins (OR 1.28, 95% CI 1.16-1.41) and half-cousins (OR 1.30, 95% CI 1.10-1.54), albeit with wider confidence intervals. Prenatal exposure to asthma medications among subjects whose mothers had asthma was not associated with subsequent ASD. CONCLUSIONS AND CLINICAL RELEVANCE In this large observational study, parental asthma was associated with slightly elevated risk of ASD in offspring. More specifically, the increased risk by maternal asthma did not seem to be confounded by familial factors. There was no evidence of an association between asthma medications during pregnancy and offspring ASD.",2019,"The risk of offspring ASD in mothers with asthma showed similar estimates when adjusting for shared familial factors among paternal half-siblings (OR 1.20, 95% CI 0.80-1.81), full-cousins (OR 1.28, 95% CI 1.16-1.41) and half-cousins (OR 1.30, 95% CI 1.10-1.54), albeit with wider confidence intervals.","['1\xa0579\xa0263) born in Sweden 1992-2007', '22\xa0894 ASD cases identified from the National Patient Register to (a) 228\xa0940 age-, county- and sex-matched controls randomly selected from the population, (b) their eligible full-siblings (n\xa0=\xa01267), (c) half-siblings (n\xa0=\xa01323), (d) full-cousins (n\xa0=\xa011\xa0477) and (e) half-cousins (n\xa0=\xa03337', 'all children (N\xa0', 'offspring autism spectrum disorder (ASD']",[],"['risk of offspring ASD', 'Parental asthma and risk of autism spectrum disorder', 'paternal asthma']","[{'cui': 'C4517671', 'cui_str': '263'}, {'cui': 'C1277386', 'cui_str': 'Born in Sweden'}, {'cui': 'C0456592', 'cui_str': '1992'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0868928', 'cui_str': 'Case'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0015737', 'cui_str': 'National Government'}, {'cui': 'C0585825', 'cui_str': 'Patient registered'}, {'cui': 'C4517905', 'cui_str': '940'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0443225', 'cui_str': 'Full'}, {'cui': 'C0337505', 'cui_str': 'Half-sibling'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0337580', 'cui_str': 'Cousin'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",[],"[{'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0524528', 'cui_str': 'Autism spectrum disorder'}, {'cui': 'C0030551', 'cui_str': 'Parent'}, {'cui': 'C0004096', 'cui_str': 'Asthma'}, {'cui': 'C0337493', 'cui_str': 'Paternal'}]",,0.0304828,"The risk of offspring ASD in mothers with asthma showed similar estimates when adjusting for shared familial factors among paternal half-siblings (OR 1.20, 95% CI 0.80-1.81), full-cousins (OR 1.28, 95% CI 1.16-1.41) and half-cousins (OR 1.30, 95% CI 1.10-1.54), albeit with wider confidence intervals.","[{'ForeName': 'Tong', 'Initials': 'T', 'LastName': 'Gong', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Lundholm', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Gustaf', 'Initials': 'G', 'LastName': 'Rejnö', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Sven', 'Initials': 'S', 'LastName': 'Bölte', 'Affiliation': ""Center of Neurodevelopmental Disorders at Karolinska Institutet (KIND), Center for Psychiatric Research, Department of Women's & Children's Health, Karolinska Institutet & Child and Adolescent Psychiatry, Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.""}, {'ForeName': 'Henrik', 'Initials': 'H', 'LastName': 'Larsson', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Brian M', 'Initials': 'BM', 'LastName': ""D'Onofrio"", 'Affiliation': 'Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Lichtenstein', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Catarina', 'Initials': 'C', 'LastName': 'Almqvist', 'Affiliation': 'Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.'}]",Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,['10.1111/cea.13353'] 2920,30982223,Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.,"Understanding transporter-mediated drug-drug interactions is an integral part of risk assessment in drug development. Recent studies support the use of hexadecanedioate (HDA), tetradecanedioate (TDA), coproporphyrin (CP)-I, and CP-III as clinical biomarkers for evaluating organic anion-transporting polypeptide (OATP)1B1 (SLCO1B1) inhibition. The current study investigated the effect of OATP1B1 genotype c.521T>C (OATP1B1-Val174Ala) on the extent of interaction between cyclosporin A (CsA) and pravastatin, and associated endogenous biomarkers of the transporter (HDA, TDA, CP-I, and CP-III), in 20 healthy volunteers. The results show that the levels of each clinical biomarker and pravastatin were significantly increased in plasma samples of the volunteers following administration of pravastatin plus CsA compared with pravastatin plus placebo. The overall fold change in the area under the concentration-time curve (AUC) and maximum plasma concentration (C max ) was similar among the four biomarkers (1.8-2.5-fold, paired t-test P value < 0.05) in individuals who were homozygotes or heterozygotes of the major allele, c.521T. However, the fold change in AUC and C max for HDA and TDA was significantly abolished in the subjects who were c.521-CC, whereas the respective fold change in AUC and C max for pravastatin and CP-I and CP-III were slightly weaker in individuals who were c.521-CC compared with c.521-TT/TC genotypes. In addition, this study provides the first evidence that SLCO1B1 c.521T>C genotype is significantly associated with CP-I but not CP-III levels. Overall, these results suggest that OATP1B1 genotype can modulate the effects of CsA on biomarker levels; the extent of modulation differs among the biomarkers.",2019,"< 0.05) in individuals who were homozygotes or heterozygotes of the major allele, c.521T.","['Healthy Volunteers', '20 healthy volunteers', 'individuals who were homozygotes or heterozygotes of the major allele, c.521T']","['pravastatin plus placebo', 'hexadecanedioate (HDA), tetradecanedioate (TDA), coproporphyrin (CP)-I', 'OATP1B1 genotype c.521T>C (OATP1B1-Val174Ala', 'cyclosporin A (CsA) and pravastatin', 'pravastatin plus CsA']","['concentration-time curve (AUC) and maximum plasma concentration (C max ', 'levels of each clinical biomarker and pravastatin', 'plasma samples', 'AUC and C max for pravastatin and CP-I and CP-III', 'CP', 'Organic Anion Transporter Polypeptide 1B1', 'AUC and C max for HDA and TDA']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0019904', 'cui_str': 'Homozygote'}, {'cui': 'C0019425', 'cui_str': 'Heterozygote'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0002085', 'cui_str': 'Genetic alleles'}]","[{'cui': 'C0085542', 'cui_str': 'Pravastatin'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C1955290', 'cui_str': 'Hexadecanedioate'}, {'cui': 'C1979811', 'cui_str': 'Tetradecanedioate'}, {'cui': 'C0056315', 'cui_str': 'Coproporphyrin 1 isomer'}, {'cui': 'C0017431', 'cui_str': 'Genotype'}, {'cui': 'C0010592', 'cui_str': 'Cyclosporine'}]","[{'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205134', 'cui_str': 'Curved'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0032105', 'cui_str': 'blood plasma'}, {'cui': 'C0127092', 'cui_str': 'Max protein'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0085542', 'cui_str': 'Pravastatin'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0056315', 'cui_str': 'Coproporphyrin 1 isomer'}, {'cui': 'C0056317', 'cui_str': 'Coproporphyrin 3 isomer'}, {'cui': 'C0009988', 'cui_str': 'Coproporphyrin'}, {'cui': 'C0949791', 'cui_str': 'OATP Proteins'}, {'cui': 'C1305923', 'cui_str': 'Polypeptide'}, {'cui': 'C1955290', 'cui_str': 'Hexadecanedioate'}, {'cui': 'C1979811', 'cui_str': 'Tetradecanedioate'}]",20.0,0.0238977,"< 0.05) in individuals who were homozygotes or heterozygotes of the major allele, c.521T.","[{'ForeName': 'Sook Wah', 'Initials': 'SW', 'LastName': 'Yee', 'Affiliation': 'Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.'}, {'ForeName': 'Marilyn M', 'Initials': 'MM', 'LastName': 'Giacomini', 'Affiliation': 'Drug Metabolism Department, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Shen', 'Affiliation': 'Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA.'}, {'ForeName': 'W Griffith', 'Initials': 'WG', 'LastName': 'Humphreys', 'Affiliation': 'Department of Metabolism and Pharmacokinetics, Bristol-Myers Squibb Research and Development, Princeton, New Jersey, USA.'}, {'ForeName': 'Howard', 'Initials': 'H', 'LastName': 'Horng', 'Affiliation': 'Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.'}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'Brian', 'Affiliation': 'Disposition Safety and Animal Research, Sanofi-Aventis, Great Valley, Pennsylvania, USA.'}, {'ForeName': 'Yurong', 'Initials': 'Y', 'LastName': 'Lai', 'Affiliation': 'Drug Metabolism Department, Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Deanna L', 'Initials': 'DL', 'LastName': 'Kroetz', 'Affiliation': 'Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.'}, {'ForeName': 'Kathleen M', 'Initials': 'KM', 'LastName': 'Giacomini', 'Affiliation': 'Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.'}]",Clinical and translational science,['10.1111/cts.12625'] 2921,31353272,Patient information sources when facing repair of abdominal aortic aneurysm.,"OBJECTIVE Shared medical decision making is most important when there are competing options for repair such as in treatment of abdominal aortic aneurysm (AAA). We sought to understand the sources of patients' pre-existing knowledge about AAA to better inform treating physicians about patients' needs for preoperative counseling. METHODS We performed a multicenter survey of patients facing AAA repair at 20 Veterans Affairs hospitals across the United States as part of the Preferences for Open Versus Endovascular Repair of AAA study. A validated survey instrument was administered to examine the sources of information available and commonly used by patients to learn about their repair options. The survey was administered by study personnel before the patient had any interaction with the vascular surgeon because survey data were collected before the vascular clinic visit. RESULTS Preliminary analysis of data from 99 patients showed that our cohort was primarily male (99%) and elderly (mean age 73 years). Patients commonly had a history of hypertension (86%), prior myocardial infarction (32%), diabetes (32%), and were overweight (58%). Patients arrived at their surgeon's office appointment with limited information. A majority of patients (52%) reported that they had not talked to their primary care physician at all about their options for AAA repair, and one-half (50%) reported that their view of the different surgical options had not been influenced by anyone. Slightly less than one-half of patients reported that they did not receive any information about open surgical aneurysm repair and endovascular aortic aneurysm repair (41% and 37%, respectively). Few patients indicated using the internet as their main source of information about open surgical aneurysm repair and endovascular aortic aneurysm repair (10% and 11%, respectively). CONCLUSIONS Patients are commonly referred for AAA repair having little to no information regarding AAA pathology or repair options. Fewer than one in five patients searched the internet or had accessed other sources of information on their own. Most vascular surgeons should assume that patients will present to their first vascular surgery appointment with minimal understanding of the treatment options available to them.",2020,"Few patients indicated using the internet as their main source of information about open surgical aneurysm repair and endovascular aortic aneurysm repair (10% and 11%, respectively). ","['99 patients showed that our cohort was primarily male (99%) and elderly (mean age 73\xa0years', 'Patients commonly had a history of hypertension (86%), prior myocardial infarction (32%), diabetes (32%), and were overweight (58', ""Patients arrived at their surgeon's office appointment with limited information"", 'patients facing AAA repair at 20 Veterans Affairs hospitals across the United States as part of the Preferences for Open Versus Endovascular Repair of AAA study']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0455527', 'cui_str': 'H/O: hypertension'}, {'cui': 'C0155668', 'cui_str': 'Old myocardial infarction'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0015450', 'cui_str': 'Face structure'}, {'cui': 'C0741152', 'cui_str': 'Repair of aneurysm of abdominal aorta'}, {'cui': 'C0042610', 'cui_str': 'Veterans'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0558295', 'cui_str': 'Preferences'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0918249', 'cui_str': 'Endovascular repair of abdominal aortic aneurysm'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]",[],[],,0.0778165,"Few patients indicated using the internet as their main source of information about open surgical aneurysm repair and endovascular aortic aneurysm repair (10% and 11%, respectively). ","[{'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Anderson', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt; Geisel School of Medicine at Dartmouth, Hanover, NH.'}, {'ForeName': 'Zachary J', 'Initials': 'ZJ', 'LastName': 'Wanken', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Perri', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Jesse A', 'Initials': 'JA', 'LastName': 'Columbo', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Ravinder', 'Initials': 'R', 'LastName': 'Kang', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Emily L', 'Initials': 'EL', 'LastName': 'Spangler', 'Affiliation': 'Birmingham VA, Birmingham, Ala.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Newhall', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Benjamin S', 'Initials': 'BS', 'LastName': 'Brooke', 'Affiliation': 'Salt Lake City VA, Salt Lake City, Utah.'}, {'ForeName': 'Hasan', 'Initials': 'H', 'LastName': 'Dosluoglu', 'Affiliation': 'Buffalo VAMC, Buffalo, NY.'}, {'ForeName': 'Eugene S', 'Initials': 'ES', 'LastName': 'Lee', 'Affiliation': 'Sacramento VAMC, Mather, Calif.'}, {'ForeName': 'Joseph D', 'Initials': 'JD', 'LastName': 'Raffetto', 'Affiliation': 'West Roxbury VA, Boston, Mass.'}, {'ForeName': 'Peter K', 'Initials': 'PK', 'LastName': 'Henke', 'Affiliation': 'Ann Arbor VAMC, Ann Arbor, Mich.'}, {'ForeName': 'Gale L', 'Initials': 'GL', 'LastName': 'Tang', 'Affiliation': 'Seattle VAMC, Seattle, Wash.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Mureebe', 'Affiliation': 'Durham VAMC, Durham, NC.'}, {'ForeName': 'Panagiotis', 'Initials': 'P', 'LastName': 'Kougias', 'Affiliation': 'Houston VAMC, Houston, Tex.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Johanning', 'Affiliation': 'Omaha VAMC, Omaha, Neb.'}, {'ForeName': 'Shipra', 'Initials': 'S', 'LastName': 'Arya', 'Affiliation': 'Atlanta VAMC, Atlanta, Ga.'}, {'ForeName': 'Salvatore T', 'Initials': 'ST', 'LastName': 'Scali', 'Affiliation': 'Gainesville VAMC, Gainesville, Fla.'}, {'ForeName': 'David H', 'Initials': 'DH', 'LastName': 'Stone', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Bjoern D', 'Initials': 'BD', 'LastName': 'Suckow', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Orion', 'Affiliation': 'West Haven VAMC, West Haven, Conn.'}, {'ForeName': 'Vivienne', 'Initials': 'V', 'LastName': 'Halpern', 'Affiliation': 'Phoenix VAMC, Phoenix, Ariz.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': ""O'Connell"", 'Affiliation': 'Los Angeles VAMC, Los Angeles, Calif.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Inhat', 'Affiliation': 'Minneapolis VAMC, Minneapolis, Minn.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Nelson', 'Affiliation': 'Muskogee VAMC, Muskogee, Okla.'}, {'ForeName': 'Edith', 'Initials': 'E', 'LastName': 'Tzeng', 'Affiliation': 'Pittsburgh VAMC, Pittsburgh, Pa.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Zhou', 'Affiliation': 'Tucson VAMC, Tucson, Ariz.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Barry', 'Affiliation': 'Massachusetts General Hospital Center for Shared Decision Making, Boston, Mass.'}, {'ForeName': 'Brenda', 'Initials': 'B', 'LastName': 'Sirovich', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt.'}, {'ForeName': 'Philip P', 'Initials': 'PP', 'LastName': 'Goodney', 'Affiliation': 'Department of Surgery and VA Outcomes Group, White River Junction VA Medical Center, White River Junction, Vt. Electronic address: philip.goodney@hitchcock.org.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of vascular surgery,['10.1016/j.jvs.2019.04.460'] 2922,31518627,The mediating role of perceived crime in gender and built environment associations with park use and park-based physical activity among park users in high poverty neighborhoods.,"Women use parks less for physical activity than men, and explanations include gendered concerns regarding personal safety and access to walking paths. This study conducted mediation analyses to examine the effects of gender and presence of park walking path on park use, participation in park programs, and park-based physical activity through the hypothesized mediator (perception of crime). The sample included 3213 park users from 48 parks in high poverty neighborhoods in Los Angeles surveyed between 2013 and 2015; park-level factors were assessed through systematic observations of study parks. Women reported fewer park visits than men in the last 7 days (β = -0.17, p = 0.02) and had significantly higher perceived crime (β = 0.12, p < 0.0001) and perceived crime partially mediated the gender association with park visits (β gender, direct  = -0.09, p = 0.19; β gender, indirect  = -0.07, p < 0.0001). Similarly, the existence of a walking path in the park was significantly related to increased park use (β = 0.27, p = 0.006) and a lower level of perceived crime (β = -0.25, p = 0.0034) and perceived crime partially mediated the association of walking path with park visits (β walking path, direct  = 0.18, p = 0.10; β walking path, indirect  = 0.15, p = 0.005). The associations between gender, walking path, and park-based exercise and program participation were not meaningfully mediated by perceived crime. Among park users in majority Latino, high poverty neighborhoods, addressing crime concerns are likely necessary to increase park use among women and adults whose parks do not have a walking path. For park-based exercise and participation in park programs, gendered preferences regarding park-based physical activity should be explored.",2019,"Women reported fewer park visits than men in the last 7 days (β = -0.17, p = 0.02) and had significantly higher perceived crime (β = 0.12, p < 0.0001) and perceived crime partially mediated the gender association with park visits (β gender, direct  = -0.09, p = 0.19; β gender, indirect  = -0.07, p < 0.0001).","['3213 park users from 48 parks in high poverty neighborhoods in Los Angeles surveyed between 2013 and 2015; park-level factors were assessed through systematic observations of study parks', 'park users in majority Latino, high poverty neighborhoods', 'park users in high poverty neighborhoods']",['park walking path'],"['park visits', 'walking path with park visits (β walking path']","[{'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C0027569', 'cui_str': 'Neighborhood'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0008902', 'cui_str': 'Classification'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}]","[{'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]","[{'cui': 'C0237771', 'cui_str': 'Parks, Recreational'}, {'cui': 'C0080331', 'cui_str': 'Walking'}]",3213.0,0.0261094,"Women reported fewer park visits than men in the last 7 days (β = -0.17, p = 0.02) and had significantly higher perceived crime (β = 0.12, p < 0.0001) and perceived crime partially mediated the gender association with park visits (β gender, direct  = -0.09, p = 0.19; β gender, indirect  = -0.07, p < 0.0001).","[{'ForeName': 'Kathryn P', 'Initials': 'KP', 'LastName': 'Derose', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, United States of America. Electronic address: derose@rand.org.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Han', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, United States of America. Electronic address: bhan@rand.org.'}, {'ForeName': 'Sujeong', 'Initials': 'S', 'LastName': 'Park', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, United States of America. Electronic address: sujeongp@rand.org.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Williamson', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, United States of America. Electronic address: swilliam@rand.org.'}, {'ForeName': 'Deborah A', 'Initials': 'DA', 'LastName': 'Cohen', 'Affiliation': 'RAND Corporation, 1776 Main Street, Santa Monica, CA 90401, United States of America. Electronic address: dcohen@rand.org.'}]",Preventive medicine,['10.1016/j.ypmed.2019.105846'] 2923,32736216,Combined exercise training improves cognitive functions in multiple sclerosis patients with cognitive impairment: A single-blinded randomized controlled trial.,"BACKGROUND Cognitive impairment is common in patients with multiple sclerosis (MS). The effects of different exercise trainings on cognitive functions in patients with MS are promising. However, the effects are not yet clear in MS patients with cognitive impairment. This study aimed to investigate the effect of combined exercise training on different cognitive functions in MS patients with cognitive impairment. METHODS Relapsing-remitting and mild disabled MS patients with cognitive impairment were randomly assigned to two groups: Exercise Group (EG, n:17) and the Control Group (CG, n:17). The EG received a combined exercise training consisting of aerobic and Pilates training in three sessions per week for 8 weeks while the CG performed the relaxation exercises at home. Cognitive functions, walking capacity, fatigue, mood, and quality of life were assessed at baseline and after eight weeks using the Brief Repeatable Battery of Neuropsychological Tests (BRB-N), Six-Minute Walk Test (6-MWT), Fatigue Impact Scale (FIS), Beck's Depression Inventory (BDI) and MS Quality of Life-54 (MSQoL-54), respectively. RESULTS This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003). Moreover, verbal memory, visuospatial memory, verbal fluency, information processing speed, walking capacity, fatigue, and quality of life improved in the EG (p<0.05) while only verbal memory increased in the CG (p<0.05). Furthermore, the change in visuospatial memory was associated with the change in mental quality of life (r:0.352, p: 0.041) while the change in verbal fluency (r: -0.362, p:0.035) and processing speed (r: -0.356, p:0.039) were associated with the change in mood. CONCLUSION Combined exercise training has beneficial effects on different cognitive functions in mild disabled RRMS patients with cognitive impairment. In addition, there is a mutual relationship in improvements in cognitive functions, mood, and quality of life after exercise.",2020,"This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003).","['mild disabled RRMS patients with cognitive impairment', 'multiple sclerosis patients with cognitive impairment', 'patients with MS', 'Relapsing-remitting and mild disabled MS patients with cognitive impairment', 'patients with multiple sclerosis (MS', 'MS patients with cognitive impairment']","['Combined exercise training', 'combined exercise training consisting of aerobic and Pilates training', 'exercise trainings', 'Exercise Group (EG, n:17) and the Control Group (CG, n:17', 'combined exercise training']","['change in visuospatial memory', 'verbal fluency', 'long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life', 'processing speed', 'Cognitive functions, walking capacity, fatigue, mood, and quality of life', 'cognitive functions', ""Brief Repeatable Battery of Neuropsychological Tests (BRB-N), Six-Minute Walk Test (6-MWT), Fatigue Impact Scale (FIS), Beck's Depression Inventory (BDI) and MS Quality of Life-54 (MSQoL-54), respectively"", 'verbal memory, visuospatial memory, verbal fluency, information processing speed, walking capacity, fatigue, and quality of life improved in the EG (p<0.05) while only verbal memory', 'mental quality of life', 'cognitive functions, mood, and quality of life']","[{'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0018576', 'cui_str': 'Handicapped'}, {'cui': 'C1522002', 'cui_str': 'RRM Motif'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0338656', 'cui_str': 'Impaired cognition'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0439824', 'cui_str': 'Verbal'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0233324', 'cui_str': 'Term birth of newborn'}, {'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C2733557', 'cui_str': 'Fatigue impact scale'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory'}, {'cui': 'C0026769', 'cui_str': 'Multiple sclerosis'}, {'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0184511', 'cui_str': 'Improved'}]",,0.0502248,"This study showed significant group-by-time interactions on long-term verbal memory, walking capacity, cognitive fatigue, and physical quality of life in favor of the EG (p<0.003).","[{'ForeName': 'Cagla', 'Initials': 'C', 'LastName': 'Ozkul', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey. Electronic address: caglaozkul@hotmail.com.'}, {'ForeName': 'Arzu', 'Initials': 'A', 'LastName': 'Guclu-Gunduz', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Kader', 'Initials': 'K', 'LastName': 'Eldemir', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Apaydin', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Gokhan', 'Initials': 'G', 'LastName': 'Yazici', 'Affiliation': 'Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey.'}, {'ForeName': 'Ceyla', 'Initials': 'C', 'LastName': 'Irkec', 'Affiliation': 'Gazi University, Faculty of Medicine, Department of Neurology, Ankara, Turkey.'}]",Multiple sclerosis and related disorders,['10.1016/j.msard.2020.102419'] 2924,32736299,"A beverage containing ora-pro-nobis flour improves intestinal health, weight, and body composition: A double-blind randomized prospective study.","OBJECTIVE The aim of this study was to verify the effect of a beverage containing ora-pro-nobis (OPN) flour on intestinal microbiota, gastrointestinal symptoms, and anthropometric parameters in women. METHODS This prospective, double-blinded, randomized clinical trial included 24 women volunteers. For 6 wk, the test group received a beverage supplemented with OPN, and the control group received the same beverage without OPN. Fecal microbiota were evaluated by the fluorescence in situ hybridization method. Each participant responded to a questionnaire based on the Gastrointestinal Symptom Rating Scale. The data were analyzed by Student's t test to compare the effects between treatments (P < 0.05). RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000). Additionally, the treatment increased satiety (P = 0.039), reduced eructation (P = 0.038) and constipation (P = 0.017), and improved feces consistency (P = 0.017). CONCLUSION The OPN flour beverage has an effect on weight reduction, body fat composition, and improvement in gastrointestinal symptoms. These results highlight the beneficial effects of ora-pro-nobis flour beverage against the development of obesity.",2020,"RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000).","['24 women volunteers', 'women']","['beverage containing ora-pro-nobis (OPN) flour', 'beverage supplemented with OPN, and the control group received the same beverage without OPN']","['weight', 'waist circumference', 'feces consistency', 'satiety', 'Gastrointestinal Symptom Rating Scale', 'intestinal health, weight, and body composition', 'weight reduction, body fat composition, and improvement in gastrointestinal symptoms', 'reduced eructation', 'Fecal microbiota', 'intestinal microbiota, gastrointestinal symptoms, and anthropometric parameters', 'body fat', 'constipation']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}]","[{'cui': 'C0001967', 'cui_str': 'Alcoholic beverage'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0033382', 'cui_str': 'Proline'}, {'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0242295', 'cui_str': 'Nutrient supplementation'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0036239', 'cui_str': 'Satiety'}, {'cui': 'C0426576', 'cui_str': 'Gastrointestinal symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0005885', 'cui_str': 'Body composition'}, {'cui': 'C1262477', 'cui_str': 'Weight decreased'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0014724', 'cui_str': 'Eructation'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}]",24.0,0.165472,"RESULTS Supplementation with the OPN beverage reduced weight (P = 0.008), waist circumference (P = 0.010), and body fat (P = 0.000).","[{'ForeName': 'Camilla Ribeiro', 'Initials': 'CR', 'LastName': 'Vieira', 'Affiliation': 'Department of Nutrition, Universidade Federal de Alfenas, Alfenas, Brazil.'}, {'ForeName': 'Mariana', 'Initials': 'M', 'LastName': 'Grancieri', 'Affiliation': 'Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Hércia Stampini Duarte', 'Initials': 'HSD', 'LastName': 'Martino', 'Affiliation': 'Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.'}, {'ForeName': 'Dionéia Evangelista', 'Initials': 'DE', 'LastName': 'César', 'Affiliation': 'Department of Biology, Universidade Federal de Juiz de Fora, Juiz de Fora, Brazil.'}, {'ForeName': 'Roberta Ribeiro Silva', 'Initials': 'RRS', 'LastName': 'Barra', 'Affiliation': 'Department of Nutrition, Universidade Federal de Alfenas, Alfenas, Brazil. Electronic address: betaribeiro@hotmail.com.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110869'] 2925,32736338,Acute Neuromuscular Electrical Stimulation (NMES) With Blood Flow Restriction: The Effect of Restriction Pressures.,"CONTEXT Neuromuscular electrical stimulation (NMES) combined with blood flow restriction (BFR) has been shown to improve muscular strength and size better than NMES alone. However, previous studies used varied methodologies not recommended by previous NMES or BFR research. OBJECTIVE The present study investigated the acute effects of NMES combined with varying degrees of BFR using research-recommended procedures to enhance understanding and the clinical applicability of this combination. DESIGN Randomized crossover. SETTING Physiology laboratory. PARTICIPANTS A total of 20 healthy adults (age 27 [4] y; height 177 [8] cm; body mass 77 [13] kg). INTERVENTIONS Six sessions separated by at least 7 days. The first 2 visits served as familiarization, with the experimental conditions performed in the final 4 sessions: NMES alone, NMES 40% BFR, NMES 60% BFR, and NMES 80% BFR. MAIN OUTCOME MEASURES Maximal voluntary isometric contraction, muscle thickness, blood pressure, heart rate, rating of perceived exertion, and pain were all recorded before and after each condition. RESULTS The NMES 80% BFR caused greater maximal voluntary isometric contraction decline than any other condition (-38.9 [22.3] N·m, P < .01). Vastus medialis and vastus lateralis muscle thickness acutely increased after all experimental conditions (P < .05). Pain and ratings of perceived exertion were higher after NMES 80% BFR compared with all other experimental conditions (P < .05). No cardiovascular effects were observed between conditions. CONCLUSION The NMES combined with 80% BFR caused greater acute force decrement than the other conditions. However, greater perceptual ratings of pain and ratings of perceived exertion were observed with NMES 80% BFR. These acute observations must be investigated during chronic interventions to corroborate any relationship to changes in muscle strength and size in clinical populations.",2020,Vastus medialis and vastus lateralis muscle thickness acutely increased after all experimental conditions (P < .05).,['A total of 20 healthy adults (age 27 [4]\xa0y; height 177 [8]\xa0cm; body mass 77 [13]\xa0kg'],"['BFR', 'NMES alone, NMES 40% BFR, NMES 60% BFR, and NMES 80% BFR', 'NMES', 'Neuromuscular electrical stimulation (NMES) combined with blood flow restriction (BFR', 'Blood Flow Restriction', 'Acute Neuromuscular Electrical Stimulation (NMES']","['cardiovascular effects', 'perceptual ratings of pain and ratings of perceived exertion', 'Vastus medialis and vastus lateralis muscle thickness acutely', 'Maximal voluntary isometric contraction, muscle thickness, blood pressure, heart rate, rating of perceived exertion, and pain', 'maximal voluntary isometric contraction decline', 'acute force decrement', 'Pain and ratings of perceived exertion']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0686750', 'cui_str': 'Well adult'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}]","[{'cui': 'C0232338', 'cui_str': 'Vascular flow'}, {'cui': 'C0443288', 'cui_str': 'Restricted'}, {'cui': 'C0013786', 'cui_str': 'Stimulation, Electric'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}]","[{'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0015264', 'cui_str': 'Exertion'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0022205', 'cui_str': 'Muscle isometric contraction'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0205178', 'cui_str': 'Acuteness'}, {'cui': 'C0443221', 'cui_str': 'Forced'}]",20.0,0.0851296,Vastus medialis and vastus lateralis muscle thickness acutely increased after all experimental conditions (P < .05).,"[{'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Head', 'Affiliation': ''}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Waldron', 'Affiliation': ''}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Theis', 'Affiliation': ''}, {'ForeName': 'Stephen David', 'Initials': 'SD', 'LastName': 'Patterson', 'Affiliation': ''}]",Journal of sport rehabilitation,['10.1123/jsr.2019-0505'] 2926,32736344,Effects of 2 Methods of Combined Training on Cardiometabolic Risk Factors in Adolescents: A Randomized Controlled Trial.,"PURPOSE To analyze the effects of 2 combined training methods on the cardiometabolic risk factors in adolescents. METHODS A total of 76 adolescents (16.1 [1.1] y, n = 44 female) were randomized into groups of moderate-intensity continuous training combined with resistance training (MICT + RT), high-intensity interval training combined with resistance training (HIIT + RT), or control. The training sessions were performed twice weekly for 12 weeks. The outcomes evaluated included body fat percentage, waist circumference, fasting blood glucose, fasting insulin, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, glycated hemoglobin, insulin resistance index, blood pressure, peak oxygen consumption (VO2peak), and cardiometabolic risk Z score. RESULTS The intervention groups presented a significant reduction in the cardiometabolic risk Z score after 12 weeks of the combined exercise program. In relation to the cardiometabolic risk Z score between groups, the HIIT + RT group presented a significant intervention effect when compared with the control group (Cohen d = 0.23; P < .05). Significant intervention effects were found when comparing the MICT + RT and control groups for body fat percentage, high-density lipoprotein, and VO2peak. Between the HIIT + RT and control groups, significant intervention effects were found for body fat percentage, blood pressure, and VO2peak. There were not significant differences between the HIIT + RT and MICT + RT groups. CONCLUSION Twelve weeks of HIIT + RT and MICT + RT were effective in significantly reducing the cardiometabolic risk in these adolescents.",2020,The intervention groups presented a significant reduction in the cardiometabolic risk Z score after 12 weeks of the combined exercise program.,"['76 adolescents (16.1 [1.1]\xa0y, n = 44 female', 'Adolescents', 'adolescents']","['MICT + RT', 'HIIT + RT', 'HIIT + RT and MICT + RT', 'Combined Training', 'moderate-intensity continuous training combined with resistance training (MICT + RT), high-intensity interval training combined with resistance training (HIIT + RT), or control']","['Cardiometabolic Risk Factors', 'body fat percentage, high-density lipoprotein, and VO2peak', 'cardiometabolic risk Z score', 'cardiometabolic risk', 'body fat percentage, waist circumference, fasting blood glucose, fasting insulin, total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein, glycated hemoglobin, insulin resistance index, blood pressure, peak oxygen consumption (VO2peak), and cardiometabolic risk Z score', 'body fat percentage, blood pressure, and VO2peak', 'cardiometabolic risk factors']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C4319689', 'cui_str': '16.1'}, {'cui': 'C4517491', 'cui_str': '1.1'}, {'cui': 'C0043210', 'cui_str': 'Woman'}]","[{'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C4277545', 'cui_str': 'High-intensity interval training'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C0001527', 'cui_str': 'Adipose tissue'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0023821', 'cui_str': 'High density lipoprotein'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0455829', 'cui_str': 'Waist circumference'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0201950', 'cui_str': 'Cholesterol measurement'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023823', 'cui_str': 'Low density lipoprotein'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0021655', 'cui_str': 'Insulin resistance'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0005823', 'cui_str': 'Blood pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0030055', 'cui_str': 'Body oxygen consumption'}]",76.0,0.020327,The intervention groups presented a significant reduction in the cardiometabolic risk Z score after 12 weeks of the combined exercise program.,"[{'ForeName': 'Waynne F', 'Initials': 'WF', 'LastName': 'Faria', 'Affiliation': 'State University of Northern Paraná.'}, {'ForeName': 'Filipe R', 'Initials': 'FR', 'LastName': 'Mendonça', 'Affiliation': 'State University of Northern Paraná.'}, {'ForeName': 'Géssika C', 'Initials': 'GC', 'LastName': 'Santos', 'Affiliation': 'State University of Londrina.'}, {'ForeName': 'Sarah G', 'Initials': 'SG', 'LastName': 'Kennedy', 'Affiliation': 'University of Newcastle.'}, {'ForeName': 'Rui G M', 'Initials': 'RGM', 'LastName': 'Elias', 'Affiliation': 'State University of Northern Paraná.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Stabelini Neto', 'Affiliation': 'State University of Northern Paraná.'}]",Pediatric exercise science,['10.1123/pes.2020-0016'] 2927,32735653,Efficacy of bezlotoxumab in trial participants infected with Clostridioides difficile strain BI associated with poor outcomes.,"BACKGROUND Bezlotoxumab reduced rates of recurrent Clostridioides difficile infection (rCDI) versus placebo in MODIFY I/II trial participants receiving antibacterial drug treatment for CDI. A secondary objective of MODIFY I/II was to assess bezlotoxumab's efficacy against C. difficile strains associated with increased rates of morbidity and mortality. METHODS In this post-hoc analysis of pooled MODIFY I/II data, efficacy endpoints were assessed in participants infected with restriction endonuclease analysis (REA) BI and non-BI strains of C. difficile at study entry. Treatment outcomes were compared between participants receiving bezlotoxumab (alone or with actoxumab: B, B+A) and those receiving no bezlotoxumab (placebo or actoxumab: P, A). RESULTS From 2559 randomized participants, C. difficile was isolated from 1588 (67.2%) baseline stool samples. Participants with BI strains (n=328) were older and had more risk factors for rCDI than non-BI strain participants (n=1260). There were no differences in initial clinical cure rate between BI and non-BI strains in either group. The rCDI rates for BI strains treated with bezlotoxumab was lower than for the no bezlotoxumab group (B, B+A vs P, A: 23.6% vs 43.9%) and was also lower for the non-BI strains (B, B+A vs P, A: 21.4% vs 36.1%). Rates of 30-day CDI-associated re-hospitalization were greater with BI versus non-BI strains in both groups. CONCLUSIONS Infection with BI strains of C. difficile predicted poor outcomes in the MODIFY I/II trials. Bezlotoxumab (B, B+A) treatment was effective both in BI and non-BI subpopulations.",2020,"From 2559 randomized participants, C. difficile was isolated from 1588 (67.2%) baseline stool samples.","['trial participants infected with Clostridioides difficile strain BI associated with poor outcomes', 'From 2559 randomized participants, C. difficile was isolated from 1588 (67.2%) baseline stool samples', 'Participants with BI strains (n=328) were older and had more risk factors for rCDI than non-BI strain participants (n=1260', 'participants receiving antibacterial drug treatment for CDI']","['MODIFY', 'bezlotoxumab (placebo or actoxumab', 'Bezlotoxumab (B, B+A', 'bezlotoxumab', 'bezlotoxumab (alone or with actoxumab: B, B+A', 'placebo']","['rates of morbidity and mortality', 'rCDI rates', 'Rates of 30-day CDI-associated re-hospitalization', 'initial clinical cure rate']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0079134', 'cui_str': 'Clostridium difficile (bacteria)'}, {'cui': 'C0080194', 'cui_str': 'Muscle strain'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0032854', 'cui_str': 'Financially poor'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205409', 'cui_str': 'Isolated'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1550661', 'cui_str': 'Stool specimen'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0035648', 'cui_str': 'Risk factor'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0343386', 'cui_str': 'Clostridioides difficile infection'}, {'cui': 'C0279516', 'cui_str': 'Antibacterial'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0282601', 'cui_str': 'Compact Disk Interactive'}]","[{'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C4291320', 'cui_str': 'bezlotoxumab'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C4308583', 'cui_str': 'actoxumab'}]","[{'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026565', 'cui_str': 'Mortality rate'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0343386', 'cui_str': 'Clostridioides difficile infection'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0282601', 'cui_str': 'Compact Disk Interactive'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}]",2559.0,0.136694,"From 2559 randomized participants, C. difficile was isolated from 1588 (67.2%) baseline stool samples.","[{'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Johnson', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Diane M', 'Initials': 'DM', 'LastName': 'Citron', 'Affiliation': 'R.M. Alden Research Laboratory, Culver City, CA, USA.'}, {'ForeName': 'Dale N', 'Initials': 'DN', 'LastName': 'Gerding', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Mark H', 'Initials': 'MH', 'LastName': 'Wilcox', 'Affiliation': 'Leeds Teaching Hospital, Leeds, UK.'}, {'ForeName': 'Ellie J C', 'Initials': 'EJC', 'LastName': 'Goldstein', 'Affiliation': 'R.M. Alden Research Laboratory, Culver City, CA, USA.'}, {'ForeName': 'Susan P', 'Initials': 'SP', 'LastName': 'Sambol', 'Affiliation': 'Edward Hines, Jr. VA Hospital, Hines, IL, USA.'}, {'ForeName': 'Emma L', 'Initials': 'EL', 'LastName': 'Best', 'Affiliation': 'Leeds Teaching Hospital, Leeds, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Eves', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Jansen', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Dorr', 'Affiliation': 'Merck & Co., Inc., Kenilworth, NJ, USA.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciaa1035'] 2928,32735704,Double-Blind Placebo-Controlled Trial of Bepotastine Salicylate in Patients With Allergic Rhinitis.,"OBJECTIVES/HYPOTHESIS To evaluate the efficacy and safety of a slow-release form of bepotastine salicylate (HL151, Belion CR) in patients with perennial allergic rhinitis (PAR). STUDY DESIGN Double-blind, placebo-controlled multicenter comparative study. METHODS Two hundred seventy-two PAR patients (aged 19-65 years) were studied to determine the efficacy and safety of HL151 (20 mg once daily administration) relative to those of a placebo in terms of improvements in total and nasal symptom scores. The subjects were randomized to the placebo (n = 138) or HL151 group (n = 134, 20 mg orally once daily for 4 weeks), and reflective and instantaneous total nasal symptom scores (TNSS) were measured daily in comparison with baseline. Among 272 subjects, 229 subjects (119 in the placebo group, 110 in the HL151 group) who completed the study were included for efficacy analysis. RESULTS Instantaneous and reflective TNSS and nasal symptoms such as rhinorrhea, nasal itching, and sneezing at 2 and 4 weeks showed that HL151 was superior to the placebo (all P < .05). There were no significant differences in terms of adverse events and adverse drug reactions between the two groups. Regarding serious adverse events, there was only one case of acute hepatitis B, which was reported not to be associated with HL151. CONCLUSIONS This multicenter trial showed that once-daily use of HL151 is efficacious and safe in adult patients with PAR and could improve compliance due to its convenience. LEVEL OF EVIDENCE 1b Laryngoscope, 2020.",2020,There were no significant differences in terms of adverse events and adverse drug reactions between the two groups.,"['Two hundred seventy-two PAR patients (aged 19-65\u2009years', 'adult patients with PAR', 'patients with perennial allergic rhinitis (PAR', '272 subjects, 229 subjects (119 in the placebo group, 110 in the HL151 group) who completed the study were included for efficacy analysis', 'group (n = 134, 20', 'Patients With Allergic Rhinitis']","['Placebo', 'Bepotastine Salicylate', 'placebo', 'bepotastine salicylate (HL151, Belion CR', 'HL151']","['total and nasal symptom scores', 'reflective and instantaneous total nasal symptom scores (TNSS', 'efficacy and safety', 'adverse events and adverse drug reactions', 'Instantaneous and reflective TNSS and nasal symptoms such as rhinorrhea, nasal itching, and sneezing', 'efficacy and safety of HL151']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C4319632', 'cui_str': '72'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035457', 'cui_str': 'Perennial allergic rhinitis'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0303401', 'cui_str': 'Indium-110'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C4517565', 'cui_str': '134'}, {'cui': 'C2607914', 'cui_str': 'Allergic rhinitis'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C2698371', 'cui_str': 'bepotastine'}, {'cui': 'C0036075', 'cui_str': 'Salicylate'}]","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0231918', 'cui_str': 'Nose symptoms'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0041755', 'cui_str': 'Adverse reaction to drug'}, {'cui': 'C1260880', 'cui_str': 'Nasal discharge'}, {'cui': 'C0850060', 'cui_str': 'Nasal pruritus'}, {'cui': 'C0037383', 'cui_str': 'Sneezing'}]",272.0,0.337457,There were no significant differences in terms of adverse events and adverse drug reactions between the two groups.,"[{'ForeName': 'Ji-Hun', 'Initials': 'JH', 'LastName': 'Mo', 'Affiliation': 'Department of Otorhinolaryngology, Dankook University College of Medicine, Cheonan, South Korea.'}, {'ForeName': 'Jin Hyeok', 'Initials': 'JH', 'LastName': 'Jeong', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Hanyang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Tae Hoon', 'Initials': 'TH', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Korea University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seon-Tae', 'Initials': 'ST', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Gachon University College of Medicine, Incheon, South Korea.'}, {'ForeName': 'Soo Whan', 'Initials': 'SW', 'LastName': 'Kim', 'Affiliation': ""Department of Otorhinolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.""}, {'ForeName': 'Kun Hee', 'Initials': 'KH', 'LastName': 'Lee', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Kyung Hee University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seung-No', 'Initials': 'SN', 'LastName': 'Hong', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Hyo Yeol', 'Initials': 'HY', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.'}, {'ForeName': 'Dae Woo', 'Initials': 'DW', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Dong-Young', 'Initials': 'DY', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chang-Hoon', 'Initials': 'CH', 'LastName': 'Kim', 'Affiliation': 'Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Seok Hyun', 'Initials': 'SH', 'LastName': 'Cho', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Hanyang University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Chae-Seo', 'Initials': 'CS', 'LastName': 'Rhee', 'Affiliation': 'Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, South Korea.'}]",The Laryngoscope,['10.1002/lary.28906'] 2929,32735782,"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.","Background A substantial and unmet clinical need exists for pharmacological treatment of cannabis use disorders. Cannabidiol could offer a novel treatment, but it is unclear which doses might be efficacious or safe. Therefore, we aimed to identify efficacious doses and eliminate inefficacious doses in a phase 2a trial using an adaptive Bayesian design. METHODS We did a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial at the Clinical Psychopharmacology Unit (University College London, London, UK). We used an adaptive Bayesian dose-finding design to identify efficacious or inefficacious doses at a-priori interim and final analysis stages. Participants meeting cannabis use disorder criteria from DSM-5 were randomly assigned (1:1:1:1) in the first stage of the trial to 4-week treatment with three different doses of oral cannabidiol (200 mg, 400 mg, or 800 mg) or with matched placebo during a cessation attempt by use of a double-blinded block randomisation sequence. All participants received a brief psychological intervention of motivational interviewing. For the second stage of the trial, new participants were randomly assigned to placebo or doses deemed efficacious in the interim analysis. The primary objective was to identify the most efficacious dose of cannabidiol for reducing cannabis use. The primary endpoints were lower urinary 11-nor-9-carboxy-δ-9-tetrahydrocannabinol (THC-COOH):creatinine ratio, increased days per week with abstinence from cannabis during treatment, or both, evidenced by posterior probabilities that cannabidiol is better than placebo exceeding 0·9. All analyses were done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov (NCT02044809) and the EU Clinical Trials Register (2013-000361-36). FINDINGS Between May 28, 2014, and Aug 12, 2015 (first stage), 48 participants were randomly assigned to placebo (n=12) and to cannabidiol 200 mg (n=12), 400 mg (n=12), and 800 mg (n=12). At interim analysis, cannabidiol 200 mg was eliminated from the trial as an inefficacious dose. Between May 24, 2016, and Jan 12, 2017 (second stage), randomisation continued and an additional 34 participants were allocated (1:1:1) to cannabidiol 400 mg (n=12), cannabidiol 800 mg (n=11), and placebo (n=11). At final analysis, cannabidiol 400 mg and 800 mg exceeded primary endpoint criteria (0·9) for both primary outcomes. For urinary THC-COOH:creatinine ratio, the probability of being the most efficacious dose compared with placebo given the observed data was 0·9995 for cannabidiol 400 mg and 0·9965 for cannabidiol 800 mg. For days with abstinence from cannabis, the probability of being the most efficacious dose compared with placebo given the observed data was 0·9966 for cannabidiol 400 mg and 0·9247 for cannabidiol 800 mg. Compared with placebo, cannabidiol 400 mg decreased THC-COOH:creatinine ratio by -94·21 ng/mL (95% interval estimate -161·83 to -35·56) and increased abstinence from cannabis by 0·48 days per week (0·15 to 0·82). Compared with placebo, cannabidiol 800 mg decreased THC-COOH:creatinine ratio by -72·02 ng/mL (-135·47 to -19·52) and increased abstinence from cannabis by 0·27 days per week (-0·09 to 0·64). Cannabidiol was well tolerated, with no severe adverse events recorded, and 77 (94%) of 82 participants completed treatment. INTERPRETATION In the first randomised clinical trial of cannabidiol for cannabis use disorder, cannabidiol 400 mg and 800 mg were safe and more efficacious than placebo at reducing cannabis use. FUNDING Medical Research Council.",2020,"Cannabidiol was well tolerated, with no severe adverse events recorded, and 77 (94%) of 82 participants completed treatment. ","['48 participants', 'Participants meeting cannabis use disorder criteria from DSM-5', 'Between May 28, 2014, and Aug 12, 2015 (first stage']","['placebo', 'oral cannabidiol', 'placebo, cannabidiol', 'brief psychological intervention of motivational interviewing', 'cannabidiol 400 mg (n=12), cannabidiol 800 mg (n=11), and placebo']","['THC-COOH:creatinine ratio', 'lower urinary 11-nor-9-carboxy-δ-9-tetrahydrocannabinol (THC-COOH):creatinine ratio']","[{'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C3160814', 'cui_str': 'Cannabis use'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0006863', 'cui_str': 'Cannabidiol'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0205486', 'cui_str': 'Psychologic'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C3844106', 'cui_str': '800'}]","[{'cui': 'C0039663', 'cui_str': 'dronabinol'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0205251', 'cui_str': 'Low'}]",48.0,0.767603,"Cannabidiol was well tolerated, with no severe adverse events recorded, and 77 (94%) of 82 participants completed treatment. ","[{'ForeName': 'Tom P', 'Initials': 'TP', 'LastName': 'Freeman', 'Affiliation': ""Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK; Clinical Psychopharmacology Unit, University College London, London, UK; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, London, UK; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: t.p.freeman@bath.ac.uk.""}, {'ForeName': 'Chandni', 'Initials': 'C', 'LastName': 'Hindocha', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Baio', 'Affiliation': 'Department of Statistical Science, University College London, London, UK.'}, {'ForeName': 'Natacha D C', 'Initials': 'NDC', 'LastName': 'Shaban', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Emily M', 'Initials': 'EM', 'LastName': 'Thomas', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Danica', 'Initials': 'D', 'LastName': 'Astbury', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Abigail M', 'Initials': 'AM', 'LastName': 'Freeman', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Lees', 'Affiliation': 'Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Craft', 'Affiliation': ""Addiction and Mental Health Group, Department of Psychology, University of Bath, Bath, UK; National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Paul D', 'Initials': 'PD', 'LastName': 'Morrison', 'Affiliation': ""Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Michael A P', 'Initials': 'MAP', 'LastName': 'Bloomfield', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK; Translational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK; The Traumatic Stress Clinic, St Pancras Hospital, Camden and Islington National Health Service Foundation Trust, London, UK; Pain Management Centre, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, UK.'}, {'ForeName': 'Dominic', 'Initials': 'D', 'LastName': ""O'Ryan"", 'Affiliation': 'Substance Misuse Services, Camden and Islington National Health Service Foundation Trust, London, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Kinghorn', 'Affiliation': 'Translational Research Office, School of Life and Medical Sciences, University College London, London, UK.'}, {'ForeName': 'Celia J A', 'Initials': 'CJA', 'LastName': 'Morgan', 'Affiliation': 'Psychopharmacology and Addiction Research Centre, University of Exeter, Exeter, UK.'}, {'ForeName': 'Ali', 'Initials': 'A', 'LastName': 'Mofeez', 'Affiliation': 'Pain Management Centre, National Hospital for Neurology and Neurosurgery, University College London Hospitals, London, UK.'}, {'ForeName': 'H Valerie', 'Initials': 'HV', 'LastName': 'Curran', 'Affiliation': 'Clinical Psychopharmacology Unit, University College London, London, UK; National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK.'}]",The lancet. Psychiatry,['10.1016/S2215-0366(20)30290-X'] 2930,32735809,Needleless connector decontamination for prevention of central venous access device infection: a pilot randomized controlled trial.,"Pilot randomized controlled trial (180 patients) of needleless connector decontamination. Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients. Larger definitive trials are feasible and needed.",2020,"Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients.",['180 patients) of needleless connector decontamination'],"['chlorhexidine gluconate', 'Needleless connector decontamination']",['Central line-associated bloodstream infection'],"[{'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011121', 'cui_str': 'Decontamination'}]","[{'cui': 'C0055361', 'cui_str': 'Chlorhexidine gluconate'}, {'cui': 'C0011121', 'cui_str': 'Decontamination'}]","[{'cui': 'C3161235', 'cui_str': 'CLABSI - central line associated bloodstream infection'}]",180.0,0.205212,"Central line-associated bloodstream infection occurred in 2% (1/61) of 70% isopropyl alcohol (IPA) wipe, 2% (1/59) of 70% IPA cap, and zero (0/58) infections in 2% chlorhexidine gluconate in 70% IPA wipe patients.","[{'ForeName': 'Claire M', 'Initials': 'CM', 'LastName': 'Rickard', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. Electronic address: c.rickard@griffith.edu.au.""}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Flynn', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland, Australia.""}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Larsen', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.""}, {'ForeName': 'Gabor', 'Initials': 'G', 'LastName': 'Mihala', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Medicine, Griffith University, Nathan, Queensland, Australia.'}, {'ForeName': 'E Geoffrey', 'Initials': 'EG', 'LastName': 'Playford', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Infection Management Services, Princess Alexandra Hospital, Buranda, Queensland, Australia.'}, {'ForeName': 'Joanie', 'Initials': 'J', 'LastName': 'Shaw', 'Affiliation': 'Cancer, Immunology and Palliative Care, Gold Coast Health, Southport, Queensland, Australia.'}, {'ForeName': 'Samantha', 'Initials': 'S', 'LastName': 'Keogh', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland, Australia.""}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Ullman', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; Queensland Children's Hospital, South Brisbane, Queensland, Australia.""}, {'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Zhang', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Dental Health Science, Griffith University, Gold Coast, Queensland, Australia.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Gavin', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; School of Nursing, Queensland University of Technology, Kelvin Grove, Queensland, Australia.""}, {'ForeName': 'Tricia', 'Initials': 'T', 'LastName': 'Kleidon', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Queensland Children's Hospital, South Brisbane, Queensland, Australia.""}, {'ForeName': 'Vineet', 'Initials': 'V', 'LastName': 'Chopra', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.'}, {'ForeName': 'Sandie', 'Initials': 'S', 'LastName': 'McCarthy', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing, University of Queensland, St Lucia, Queensland, Australia.'}, {'ForeName': 'Patricia Kuerten', 'Initials': 'PK', 'LastName': 'Rocha', 'Affiliation': 'Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Federal University of Santa Catarina, Florianopolis, SC, Brazil.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Marsh', 'Affiliation': ""Alliance for Vascular Access Teaching and Research, Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; School of Nursing and Midwifery, Griffith University, Brisbane, Queensland, Australia; Centre for Clinical Nursing, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.""}]",American journal of infection control,['10.1016/j.ajic.2020.07.026'] 2931,32736046,"Evaluation of sedative effects of an intranasal dosage form containing saffron, lettuce seeds and sweet violet in primary chronic insomnia: A randomized, double-dummy, double-blind placebo controlled clinical trial.","ETHNOPHARMACOLOGICAL RELEVANCE Traditional Persian Medicine (TPM) has been established as a valuable source of medicinal plants for the treatment of insomnia for thousands of years. Accordingly, oil extracts from plants' parts have been widely used to alleviate central nervous system (CNS) ailments including sleep disorders. A number of preparations have been recommended by TPM for the treatment of insomnia. Among them, an intranasal formulation containing oily macerates of Viola odorata L., Crocus sativus L. and Lactuca sativa L. stands out. AIM OF THE STUDY In the present double-dummy, double-blind placebo controlled clinical trial, we aim to evaluate the effectiveness of a combination of violet oil, saffron oil, and lettuce seeds oil nasal drop compared with the placebo (sesame oil). MATERIALS AND METHODS Fifty patients with primary chronic insomnia were randomly assigned in TPM-treatment or placebo groups, received either two drops of the herbal oil or placebo into each nostril every noon and evening for 8 weeks. Before the study commencement and after 1, 4 and 8 weeks of treatment, Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) questionnaires were completed by all patients. The primary outcome measure was considered as any changes in ISI scores between the first visit and after 8 weeks. Changes in PSQI scores during the study and possible side effects were also assessed. The multicompound herbal oil was standardized using HPLC analysis and contained 0.02 mg/mL crocin and 4 μg/mL isoquercitrin. RESULTS Our study revealed a significant reduction in the ISI and PSQI scores from baseline by the study endpoint (P≤0.01). The mean ISI scores in week 8 decreased significantly for the intervention group (P=0.001) and also the placebo group (P<0.01) when compared with baseline. Moreover, the use of hypnotic drugs in the intervention group was significantly reduced (P<0.001), while in the control group was maintained at baseline level. CONCLUSIONS It seems that intranasal use of the multi-herbal preparation can be used to improve chronic insomnia and to reduce the dose of conventional hypnotic medications in insomniac patients.",2020,The mean ISI scores in week 8 decreased significantly for the intervention group (P=0.001) and also the placebo group (P<0.01) when compared with baseline.,"['primary chronic insomnia', 'Fifty patients with primary chronic insomnia']","['violet oil, saffron oil, and lettuce seeds oil nasal drop', 'placebo (sesame oil', 'TPM-treatment or placebo', 'TPM', 'intranasal dosage form containing saffron, lettuce seeds and sweet violet', 'herbal oil or placebo', 'placebo']","['ISI scores', 'mean ISI scores', 'chronic insomnia', 'PSQI scores', 'ISI and PSQI scores', 'Insomnia Severity Index (ISI) and Pittsburgh Sleep Quality Index (PSQI) questionnaires']","[{'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0330463', 'cui_str': 'Viola'}, {'cui': 'C0028908', 'cui_str': 'Oil'}, {'cui': 'C0162753', 'cui_str': 'Saffron Stain'}, {'cui': 'C0242765', 'cui_str': 'Lettuce'}, {'cui': 'C0036563', 'cui_str': 'Plant seeds'}, {'cui': 'C0991524', 'cui_str': 'Nasal drops'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0036845', 'cui_str': 'Sesame Oil'}, {'cui': 'C0443324', 'cui_str': 'Traditional'}, {'cui': 'C0031188', 'cui_str': 'Persian language'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach'}, {'cui': 'C0013058', 'cui_str': 'Pharmaceutical dose form'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0330464', 'cui_str': 'Viola odorata'}, {'cui': 'C0376667', 'cui_str': 'Herbals'}]","[{'cui': 'C4706228', 'cui_str': 'ISI (Insomnia Severity Index) score'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0751249', 'cui_str': 'Chronic insomnia'}, {'cui': 'C4545801', 'cui_str': 'Pittsburgh Sleep Quality Index score'}, {'cui': 'C4520529', 'cui_str': 'Insomnia severity index'}, {'cui': 'C3697468', 'cui_str': 'Pittsburgh sleep quality index'}]",50.0,0.415055,The mean ISI scores in week 8 decreased significantly for the intervention group (P=0.001) and also the placebo group (P<0.01) when compared with baseline.,"[{'ForeName': 'Zhila', 'Initials': 'Z', 'LastName': 'Taherzadeh', 'Affiliation': 'Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Hosein', 'Initials': 'H', 'LastName': 'Khaluyan', 'Affiliation': 'Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Milad', 'Initials': 'M', 'LastName': 'Iranshahy', 'Affiliation': 'Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Fariborz', 'Initials': 'F', 'LastName': 'Rezaeitalab', 'Affiliation': 'Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Hosein', 'Initials': 'MH', 'LastName': 'Eshaghi Ghalibaf', 'Affiliation': 'B.Sc. of Anesthesiology, Mashhad University of Medical Sciences, Mashhad, Iran.'}, {'ForeName': 'Behjat', 'Initials': 'B', 'LastName': 'Javadi', 'Affiliation': 'Department of Traditional Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: javadib@mums.ac.ir.'}]",Journal of ethnopharmacology,['10.1016/j.jep.2020.113116'] 2932,31168046,Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan.,"BACKGROUND The cost-effectiveness of percutaneous coronary intervention (PCI) for ischemic heart disease is undetermined in Japan. The aim of this study was to analyze the cost-effectiveness of PCI compared with medical therapy for ST-elevation myocardial infarction (STEMI) and angina pectoris (AP) in Japan.Methods and Results:We used Markov models for STEMI and AP to assess the costs and benefits associated with PCI or medical therapy from a health system perspective. We estimated the incremental cost-effectiveness ratio (ICER), expressed as quality-adjusted life-years (QALY), and ICER <¥5 m per QALY gained was judged to be cost-effective. The impact of PCI on cardiovascular events was based on previous publications. In STEMI patients, the ICER of PCI over medical treatment was ¥0.97 m per QALY gained. The cost-effectiveness probability of PCI was 99.9%. In AP patients, the ICER of fractional flow reserve (FFR)-guided PCI over medical treatment was ¥4.63 m per QALY gained. The cost-effectiveness probability of PCI was 50.4%. The ICER of FFR-guided PCI for asymptomatic patients was ¥23 m per QALY gained. CONCLUSIONS In STEMI patients, PCI was cost-effective compared with medical therapy. In AP patients, FFR-guided PCI for symptomatic patients could be cost-effective compared with medical therapy. FFR-guided PCI for asymptomatic patients with myocardial ischemia was not cost-effective.",2019,"In AP patients, the ICER of fractional flow reserve (FFR)-guided PCI over medical treatment was ¥","['Japan', 'asymptomatic patients with myocardial ischemia', 'Ischemic Heart Disease in Japan']","['percutaneous coronary intervention (PCI', 'Percutaneous Coronary Intervention', 'Medical Therapy', 'FFR-guided PCI', 'medical therapy', 'PCI']","['cost-effectiveness probability of PCI', 'ICER of PCI', 'ICER of fractional flow reserve', 'Cost-Effectiveness', 'cost-effectiveness', 'cardiovascular events', 'incremental cost-effectiveness ratio (ICER), expressed as quality-adjusted life-years (QALY), and ICER']","[{'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0010054', 'cui_str': 'Coronary arteriosclerosis'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}]","[{'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0418981', 'cui_str': 'Medical therapy'}, {'cui': 'C1299469', 'cui_str': 'Fractional flow reserve'}, {'cui': 'C0181090', 'cui_str': 'Guide'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous coronary intervention'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C1299469', 'cui_str': 'Fractional flow reserve'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0017262', 'cui_str': 'Gene expression'}, {'cui': 'C0080071', 'cui_str': 'Quality adjusted life years'}]",,0.0189888,"In AP patients, the ICER of fractional flow reserve (FFR)-guided PCI over medical treatment was ¥","[{'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Kodera', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Morita', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.'}, {'ForeName': 'Arihiro', 'Initials': 'A', 'LastName': 'Kiyosue', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.'}, {'ForeName': 'Jiro', 'Initials': 'J', 'LastName': 'Ando', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.'}, {'ForeName': 'Issei', 'Initials': 'I', 'LastName': 'Komuro', 'Affiliation': 'Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.'}]",Circulation journal : official journal of the Japanese Circulation Society,['10.1253/circj.CJ-19-0148'] 2933,31254849,Increasing support by nasal high flow acutely modifies the ROX index in hypoxemic patients: A physiologic study.,"The ROX (Respiratory rate-OXygenation) index is an early predictor of failure of nasal high flow (NHF), with lower values indicating higher risk of intubation. We measured the ROX index at set flow rate of 30 and 60 l/min in 57 hypoxemic patients on NHF. Patients with increased ROX index values at higher flow (n = 40) showed worse baseline oxygenation, higher respiratory rate and lower ROX index in comparison to patients with unchanged or decreased ROX index values (n = 17). The ROX index variation between flows was correlated with the change in end expiratory lung volume. Set flow rate during NHF might impact the ROX index value.",2019,"Patients with increased ROX index values at higher flow (n = 40) showed worse baseline oxygenation, higher respiratory rate and lower ROX index in comparison to patients with unchanged or decreased ROX index values (n = 17).","['57 hypoxemic patients on NHF', 'hypoxemic patients']",[],"['ROX index', 'ROX (Respiratory rate-OXygenation) index', 'ROX index variation', 'baseline oxygenation, higher respiratory rate and lower ROX index', 'ROX index values']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0028429', 'cui_str': 'Nasal'}, {'cui': 'C0205250', 'cui_str': 'High'}]",[],"[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",57.0,0.0238577,"Patients with increased ROX index values at higher flow (n = 40) showed worse baseline oxygenation, higher respiratory rate and lower ROX index in comparison to patients with unchanged or decreased ROX index values (n = 17).","[{'ForeName': 'Tommaso', 'Initials': 'T', 'LastName': 'Mauri', 'Affiliation': ""Department of Pathophysiology and Transplantation, University of Milan, Italy; Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Electronic address: tommaso.mauri@unimi.it.""}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Carlesso', 'Affiliation': 'Department of Pathophysiology and Transplantation, University of Milan, Italy.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Spinelli', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Turrini', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine, Section of Anesthesia and Intensive Care, University of Ferrara, Italy.'}, {'ForeName': 'Francesca Dalla', 'Initials': 'FD', 'LastName': 'Corte', 'Affiliation': 'Department of Morphology, Surgery and Experimental Medicine, Section of Anesthesia and Intensive Care, University of Ferrara, Italy.'}, {'ForeName': 'Riccarda', 'Initials': 'R', 'LastName': 'Russo', 'Affiliation': ""Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Jean-Damien', 'Initials': 'JD', 'LastName': 'Ricard', 'Affiliation': 'AP-HP, Hôpital Louis Mourier, Service de Réanimation Médico-Chirurgicale, F-92700 Colombes, France; INSERM, IAME, UMR 1137, F-75018 Paris, France; Universite Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Pesenti', 'Affiliation': ""Department of Pathophysiology and Transplantation, University of Milan, Italy; Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'ForeName': 'Oriol', 'Initials': 'O', 'LastName': 'Roca', 'Affiliation': ""Critical Care Department, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain; Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.""}, {'ForeName': 'Giacomo', 'Initials': 'G', 'LastName': 'Grasselli', 'Affiliation': ""Department of Pathophysiology and Transplantation, University of Milan, Italy; Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}]",Journal of critical care,['10.1016/j.jcrc.2019.06.020'] 2934,31254850,Aeration changes induced by high flow nasal cannula are more homogeneous than those generated by non-invasive ventilation in healthy subjects.,"BACKGROUND Non-invasive mechanical ventilation (NIV) is a standard respiratory support technique used in intensive care units. High-Flow Nasal Cannula (HFNC) has emerged as an alternative, but further evidence is needed. The lung aeration and diaphragm changes achieved with these two strategies in healthy subjects have not been compared to date. METHODS Twenty healthy subjects were recruited. Ten were ventilated with NIV and ten underwent HFNC. Lung impedance and diaphragmatic ultrasound measurements were performed before and after 30 min of respiratory support. The Mar-index was defined as the ratio of the diaphragm excursion-time index to the respiratory rate. RESULTS Both groups showed significant decreases in respiratory rate (NIV: 14.4 (4.1) vs 10.4 (1.6), p = 0.009; HFNC: 13.6 (4.3) vs 7.9 (1.5) bpm, p = 0.002) and significant increases in the end-expiratory lung impedance (EELI) (NIV: 66,348(10,761) vs. 73,697 (6858), p = 0.005; HFNC: 66,252 (9793) vs 69,869 (9135), p = 0.012). NIV subjects showed a significant increase in non-dependent silent spaces (4.13 (2.25) vs 5.81 (1.49)%, p = 0.037) while the increase was more homogeneous with HFNC. The variation in EELI tended to be higher in NIV than in HFNC (8137.08 (6152.04) vs 3616.94 (3623.03), p = 0.077). The Mar-index was higher in HFNC group (13.15 vs 5.27 cm-sec 2 /bpm, p = 0.02). CONCLUSIONS NIV and HFNC increased EELI in healthy subjects, suggesting an increase in the functional residual capacity. The EELI increase may be higher in NIV, but HFNC produced a more homogeneous change in lung ventilation. HFNC group has a higher MAR-index that could reflect a different ventilatory system adaptation.",2019,The Mar-index was higher in HFNC group (13.15 vs 5.27 cm-sec,"['Twenty healthy subjects were recruited', 'healthy subjects']","['High-Flow Nasal Cannula (HFNC', 'Non-invasive mechanical ventilation (NIV', 'HFNC']","['functional residual capacity', 'end-expiratory lung impedance (EELI', 'Mar-index', 'Lung impedance and diaphragmatic ultrasound measurements', 'lung aeration and diaphragm changes', 'NIV and HFNC increased EELI', 'respiratory rate', 'non-dependent silent spaces']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}]","[{'cui': 'C0016815', 'cui_str': 'Functional residual capacity'}, {'cui': 'C0442700', 'cui_str': 'End-expiration'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0162537', 'cui_str': 'Impedance'}, {'cui': 'C0024782', 'cui_str': 'Marathi language'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0011980', 'cui_str': 'Diaphragm structure'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0242485', 'cui_str': 'Measurement'}, {'cui': 'C0037400', 'cui_str': 'Social Change'}, {'cui': 'C0205303', 'cui_str': 'Non-invasive'}, {'cui': 'C0199470', 'cui_str': 'Mechanical ventilation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0179574', 'cui_str': 'Nasal Cannulae'}, {'cui': 'C0205217', 'cui_str': 'Increased'}, {'cui': 'C0231832', 'cui_str': 'Respiratory rate'}, {'cui': 'C0429964', 'cui_str': 'Dependent for dressing'}, {'cui': 'C0443304', 'cui_str': 'Silent'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}]",20.0,0.0237504,The Mar-index was higher in HFNC group (13.15 vs 5.27 cm-sec,"[{'ForeName': 'Purificación', 'Initials': 'P', 'LastName': 'Pérez-Terán', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain; UAB/UPF School of Medicine, Barcelona, Spain. Electronic address: pperez@psmar.cat.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Marin-Corral', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain; UAB/UPF School of Medicine, Barcelona, Spain.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Dot', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Sans', 'Affiliation': 'UAB/UPF School of Medicine, Barcelona, Spain.'}, {'ForeName': 'Rosana', 'Initials': 'R', 'LastName': 'Muñoz-Bermúdez', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Bosch', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain.'}, {'ForeName': 'Clara', 'Initials': 'C', 'LastName': 'Vila', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain.'}, {'ForeName': 'Joan Ramon', 'Initials': 'JR', 'LastName': 'Masclans', 'Affiliation': 'Critical Care Department, Hospital del Mar. GREPAC - IMIM, Barcelona, Spain; UAB/UPF School of Medicine, Barcelona, Spain; HISpaFlow (Grupo Español Multidiscipinar de Terapia de Soporte con Alto Flujo en Adultos), Spain.'}]",Journal of critical care,['10.1016/j.jcrc.2019.06.009'] 2935,32736460,"[Aortic valve replacement via J-shaped partial upper sternotomy: randomized trial, mid-term results].","OBJECTIVE To evaluate the effectiveness and safety of aortic valve replacement through upper partial J-shaped sternotomy compared to conventional sternotomy. MATERIAL AND METHODS There were 240 procedures of isolated aortic valve replacement for the period 2012-2017. According to inclusion criteria, 112 patients were randomized into 2 groups: group I - median sternotomy, group II - upper partial J-shaped sternotomy. Mean age of patients was 56.1±14.3 and 53.1±14.9 years, respectively ( p =0.284). Females prevailed in both groups (55.4% vs. 57.1%, p =0.848). Peak pressure gradient on the aortic valve was 106.2±23.9 and 102.8±25.3 mm Hg, respectively ( p =0.484). RESULTS In-hospital mortality was 1.8% ( n =1) in group I ( p =0.315). Incidence of postoperative complications (complete atrioventricular blockade, ventricular septal defect) was similar ( p =1.0). Mean time cross clamping in I and II groups was 65.5±12.5 and 64.7±13.1 min ( p =0.729). Mean follow-up period was 31.6 and 33.5 months, respectively. Kaplan-Meier survival rate was 92.6 and 93.0%, respectively (log-rank test=0,767). Freedom from thromboembolic events was 91.7 and 90% (log-rank test=0.213). CONCLUSION. U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.",2020,"U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.",['There were 240 procedures of isolated aortic valve replacement for the period 2012-2017'],"['conventional sternotomy', 'aortic valve replacement through upper partial J-shaped sternotomy', 'group I - median sternotomy, group II - upper partial J-shaped sternotomy', 'Aortic valve replacement via J-shaped partial upper sternotomy', 'U\n\n\nPper partial J-shaped sternotomy']","['Incidence of postoperative complications (complete atrioventricular blockade, ventricular septal defect', 'Kaplan-Meier survival rate', 'Peak pressure gradient on the aortic valve', 'hospital mortality', 'Mean time cross clamping', 'thromboembolic events']","[{'cui': 'C4319600', 'cui_str': '240'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}]","[{'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0185792', 'cui_str': 'Sternotomy'}, {'cui': 'C0003506', 'cui_str': 'Replacement of aortic valve'}, {'cui': 'C1282910', 'cui_str': 'Upper'}, {'cui': 'C0728938', 'cui_str': 'Partial'}, {'cui': 'C0441843', 'cui_str': 'Group I'}, {'cui': 'C1282959', 'cui_str': 'Median sternotomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0332206', 'cui_str': 'Blocking'}, {'cui': 'C0018818', 'cui_str': 'Ventricular septal defect'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0445174', 'cui_str': 'Peak pressure'}, {'cui': 'C0003501', 'cui_str': 'Aortic valve structure'}, {'cui': 'C0085556', 'cui_str': 'Hospital Mortalities'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0205203', 'cui_str': 'Crossed'}, {'cui': 'C0521213', 'cui_str': 'Clamping'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}]",112.0,0.0217576,"U Pper partial J-shaped sternotomy is safe and effective for aortic valve surgery and characterized by similar outcomes compared to conventional sternotomy.","[{'ForeName': 'Yu A', 'Initials': 'YA', 'LastName': 'Shneider', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'M D', 'Initials': 'MD', 'LastName': 'Tsoi', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'M S', 'Initials': 'MS', 'LastName': 'Fomenko', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Pavlov', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Shilenko', 'Affiliation': 'Federal Center for High Medical Technologies of the Ministry of Health, Kaliningrad, Russia.'}]",Khirurgiia,['10.17116/hirurgia202007125'] 2936,32736462,[Effectiveness of light strengthened endoprosthesis in the treatment of middle and large ventral hernia].,"OBJECTIVE To evaluate an effectiveness of light strengthened polypropylene endoprosthesis in the treatment of patients with middle and large ventral hernias. MATERIAL AND METHODS Early and long-term outcomes of surgical treatment were analyzed in 60 patients with middle and large ventral hernias. Onlay hernia repair was performed. Patients were divided into two groups by 30 patients. Abdominal wall repair with conventional polypropylene endoprosthesis was performed in the first group, light strengthened endoprosthesis was used in the second group. RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period. Moreover, we observed better functional state of abdominal rectus muscles in long-term postoperative period in the same group. Improved physical component of health by 4.5% was found in the 2 nd group. As a result, incidence of excellent outcomes increased by 13.3%, good results by 6.7%, incidence of satisfactory results decreased by 20%. Recurrent hernia was absent. CONCLUSION Light strengthened endoprosthesis is effective and advisable in patients with middle and large ventral hernia.",2020,"RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period.","['patients with middle and large ventral hernias', 'patients with middle and large ventral hernia', '60 patients with middle and large ventral hernias', 'middle and large ventral hernia']","['light strengthened endoprosthesis', 'Light strengthened endoprosthesis', 'light strengthened polypropylene endoprosthesis', 'Abdominal wall repair with conventional polypropylene endoprosthesis']","['inflammatory response and higher intensity of reparative processes', 'Recurrent hernia', 'physical component of health', 'incidence of satisfactory results', 'functional state of abdominal rectus muscles']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0227972', 'cui_str': 'Structure of median lobe of prostate'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0019326', 'cui_str': 'Hernia of anterior abdominal wall'}]","[{'cui': 'C0023693', 'cui_str': 'Light'}, {'cui': 'C4704931', 'cui_str': 'Endoprostheses'}, {'cui': 'C0032582', 'cui_str': 'Polypropylene'}, {'cui': 'C0198542', 'cui_str': 'Repair of abdominal wall'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C1455761', 'cui_str': 'Episodic'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0205245', 'cui_str': 'Functional'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0448311', 'cui_str': 'Rectus eye muscle structure'}]",60.0,0.016704,"RESULTS Application of light strengthened polypropylene endoprosthesis was accompanied by reduced inflammatory response and higher intensity of reparative processes in the area of implantation in early postoperative period.","[{'ForeName': 'B S', 'Initials': 'BS', 'LastName': 'Sukovatikh', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'Yu Yu', 'Initials': 'YY', 'LastName': 'Blinkov', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'A A', 'Initials': 'AA', 'LastName': 'Netyaga', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Zatolokina', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'Yu Yu', 'Initials': 'YY', 'LastName': 'Polevoy', 'Affiliation': 'Kursk state medical university, Kursk, Russia.'}, {'ForeName': 'V A', 'Initials': 'VA', 'LastName': 'Zhukovskiy', 'Affiliation': 'Saint-Petersburg State University of Industrial Technologies and Design, Saint-Petersburg, Russia.'}]",Khirurgiia,['10.17116/hirurgia202007139'] 2937,32736464,[Early and long-term outcomes of minimally invasive interventions in urgent colon surgery].,"OBJECTIVE To analyze the results of minimally invasive surgical treatment of patients with urgent colon diseases. MATERIAL AND METHODS There were 89 patients with urgent colon diseases. All patients were divided into 2 groups: the main group - 31 patients who underwent laparoscopic surgeries, the control group - 58 patients operated via open access. Both groups were comparable by age and underlying disease. However, significant differences in gender, severity of comorbidities and complications of the underlying disease were observed. RESULTS Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups. Quality of life was significantly better in the main group compared with the control group if colostomy was absent. In case of stoma, there were no between-group differences. CONCLUSION Laparoscopic surgery is associated with reduced need for analgesics, similar duration of intervention and postoperative morbidity. Complete restoration of quality of life in these patients is observed in 6 months after surgery. Colostomy results similar quality of life after laparoscopic and open surgery.",2020,"Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups.","['patients with urgent colon diseases', 'urgent colon surgery', 'There were 89 patients with urgent colon diseases']","['minimally invasive interventions', 'Laparoscopic surgery', 'laparoscopic and open surgery', 'laparoscopic surgeries, the control group - 58 patients operated via open access']","['quality of life', 'Complete restoration of quality of life', 'Quality of life', 'postoperative hospital-stay', 'Surgery time, postoperative morbidity', 'gender, severity of comorbidities and complications of the underlying disease']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0439609', 'cui_str': 'Urgent'}, {'cui': 'C0009373', 'cui_str': 'Disorder of colon'}, {'cui': 'C0192817', 'cui_str': 'Operation on colon'}]","[{'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0751429', 'cui_str': 'Laparoscopic surgery'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0348025', 'cui_str': 'Open approach'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0444454', 'cui_str': 'Access'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",89.0,0.0477338,"Surgery time, postoperative morbidity (9.7% vs. 6.9%) and postoperative hospital-stay were similar in both groups.","[{'ForeName': 'B M', 'Initials': 'BM', 'LastName': 'Niyozbekov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'T Z', 'Initials': 'TZ', 'LastName': 'Rzaev', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'Z B', 'Initials': 'ZB', 'LastName': 'Khalilov', 'Affiliation': 'Central Hospital of Baku, Baku, Republic of Azerbaijan.'}, {'ForeName': 'F S', 'Initials': 'FS', 'LastName': 'Kurbanov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'R Kh', 'Initials': 'RK', 'LastName': 'Azimov', 'Affiliation': 'Central Clinical Hospital of the Russian Academy of Sciences, Moscow, Russia.'}, {'ForeName': 'M A', 'Initials': 'MA', 'LastName': 'Chinikov', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}, {'ForeName': 'I S', 'Initials': 'IS', 'LastName': 'Panteleeva', 'Affiliation': ""Russian People's Friendship University, Moscow, Russia.""}]",Khirurgiia,['10.17116/hirurgia202007154'] 2938,32736535,Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.,"BACKGROUND Treatment with tumor-Infiltrating Lymphocytes (TIL) is an innovative therapy for advanced melanoma with promising clinical phase I/II study results and likely beneficial cost-effectiveness. As a randomized controlled trial on the effectiveness of TIL therapy in advanced melanoma compared to ipilimumab is still ongoing, adoption of TIL therapy by the field is confronted with uncertainty. To deal with this, scenario drafting can be used to identify potential barriers and enables the subsequent anticipation on these barriers. This study aims to inform adoption decisions of TIL by evaluating various scenarios and evaluate their effect on the cost-effectiveness. METHODS First, 14 adoption scenarios for TIL-therapy were drafted using a Delphi approach with a group of involved experts. Second, the likelihood of the scenarios taking place within 5 years was surveyed among international experts using a web-based questionnaire. Third, based on the questionnaire results and recent literature, scenarios were labeled as being either ""likely"" or ""-unlikely"". Finally, the cost-effectiveness of TIL treatment involving the ""likely"" scored scenarios was calculated. RESULTS Twenty-nine experts from 12 countries completed the questionnaire. The scenarios showed an average likelihood ranging from 29 to 58%, indicating that future developments of TIL-therapy were surrounded with quite some uncertainty. Eight of the 14 scenarios were labeled as ""likely"". The net monetary benefit per patient is presented as a measure of cost-effectiveness, where a positive value means that a scenario is cost-effective. For six of these scenarios the cost-effectiveness was calculated: ""Commercialization of TIL production"" (the price was assumed to be 3 times the manufacturing costs in the academic setting) (-€51,550), ""Pharmaceutical companies lowering the prices of ipilimumab"" (€11,420), ""Using TIL-therapy combined with ipilimumab"" (-€10,840), ""Automatic TIL production"" (€22,670), ""TIL more effective"" (€23,270), ""Less Interleukin-2"" (€20,370). CONCLUSIONS Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios. These scenarios could function as facilitators for adoption. Contrary, TIL therapy was expected to not be cost-effective when sold at commercial prices, or when combined with ipilimumab. These scenarios should be considered in the adoption decision as these may act as crucial barriers.",2020,"Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios.",['advanced melanoma'],"['ipilimumab', 'TIL therapy']",[],"[{'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0025202', 'cui_str': 'Malignant melanoma'}]","[{'cui': 'C1367202', 'cui_str': 'ipilimumab'}, {'cui': 'C0280661', 'cui_str': 'TIL therapy'}]",[],14.0,0.0242862,"Incorporating possible future developments, TIL-therapy was calculated to be cost-effective compared to ipilimumab in the majority of ""likely"" scenarios.","[{'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Lindenberg', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Valesca', 'Initials': 'V', 'LastName': 'Retèl', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Maartje', 'Initials': 'M', 'LastName': 'Rohaan', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'van den Berg', 'Affiliation': 'Biotherapeutics Unit (BTU), The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Haanen', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands.'}, {'ForeName': 'Wim', 'Initials': 'W', 'LastName': 'van Harten', 'Affiliation': 'Division of Psychosocial Research and Epidemiology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands. w.v.harten@nki.nl.'}]",BMC cancer,['10.1186/s12885-020-07166-9'] 2939,32736578,Brief motivational therapy versus enhanced usual care for alcohol use disorders in primary care in Chile: study protocol for an exploratory randomized trial.,"BACKGROUND Harmful alcohol use is a leading cause of global disability and death. However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services. Incorporating treatment for such disorders into primary care is of paramount importance for improving access and health outcomes. This study aims to estimate the effectiveness of a Brief Motivational Treatment (BMT) applied in primary care for treatment of these disorders. METHODS A parallel-group, single-blinded, severity-stratified, randomized clinical trial will test the superiority of BMT over enhanced usual care. Eligible participants will be those seeking treatment and who fulfill DSM-V criteria for alcohol use disorder and criteria for harmful alcohol use. With an estimated a loss to follow-up of 20%, a total of 182 participants will be recruited and equally randomized to each treatment group. The intervention group will receive an adaptation of the motivational enhancement therapy, as manualized in Project MATCH. This treatment consists of four 45-min sessions provided by a general psychologist with at least 3 years of primary care experience. The primary outcome is the change from baseline in the drinks per drinking day during the last 90 days, which will be captured using the Timeline Follow Back method. Secondary outcomes will describe the changes in alcohol use pattern, motivational status, and severity of the disorder. All participants will be analyzed according to the group they were allocated, regardless of the treatment actually received. Mean differences (MD) will be computed for continuous outcomes and relative risks (RR) and RR reductions (RRR) for dichotomous results. Linear models will deliver the subgroup analyses. Missingness is assumed to be associated with the baseline alcohol use pattern and severity, so a multiple imputation method will be used to handle missing data. DISCUSSION This trial aims to test the superiority of BMT over enhanced usual care with a reasonable superiority margin, over which the BMT could be further considered for incorporation into PC in Chile. Its pragmatic approach ultimately aims to inform policymakers about the benefit of including a brief psychosocial treatment into PC. TRIAL REGISTRATION ClinicalTrials.gov NCT04345302 . Registered on 28 April 2020.",2020,"However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services.","['Eligible participants will be those seeking treatment and who fulfill DSM-V criteria for alcohol use disorder and criteria for harmful alcohol use', 'alcohol use disorders in primary care in Chile', '182 participants']","['motivational enhancement therapy', 'Brief Motivational Treatment (BMT', 'BMT', 'Brief motivational therapy']","['relative risks (RR) and RR reductions (RRR', 'changes in alcohol use pattern, motivational status, and severity of the disorder']","[{'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0001956', 'cui_str': 'Alcohol use disorder'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0008107', 'cui_str': 'Chile'}]","[{'cui': 'C0683474', 'cui_str': 'Motivational interviewing'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0242492', 'cui_str': 'Relative Risk'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0001948', 'cui_str': 'Alcohol intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",182.0,0.0501927,"However, increased detection and brief intervention capacity of more severe alcohol use disorders has not been accompanied by increased availability of treatment services.","[{'ForeName': 'Nicolas A', 'Initials': 'NA', 'LastName': 'Barticevic', 'Affiliation': 'Department of Family Medicine, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Poblete', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile. fcpoblete@uc.cl.'}, {'ForeName': 'Soledad M', 'Initials': 'SM', 'LastName': 'Zuzulich', 'Affiliation': 'Nursing School, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Rodriguez', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Bradshaw', 'Affiliation': 'Department of Public Health, School of Medicine, Pontificia Universidad Católica de Chile, Alameda 340, PO 8331150, Santiago, Chile.'}]",Trials,['10.1186/s13063-020-04589-4'] 2940,32736583,Online patient simulation training to improve clinical reasoning: a feasibility randomised controlled trial.,"BACKGROUND Online patient simulations (OPS) are a novel method for teaching clinical reasoning skills to students and could contribute to reducing diagnostic errors. However, little is known about how best to implement and evaluate OPS in medical curricula. The aim of this study was to assess the feasibility, acceptability and potential effects of eCREST - the electronic Clinical Reasoning Educational Simulation Tool. METHODS A feasibility randomised controlled trial was conducted with final year undergraduate students from three UK medical schools in academic year 2016/2017 (cohort one) and 2017/2018 (cohort two). Student volunteers were recruited in cohort one via email and on teaching days, and in cohort two eCREST was also integrated into a relevant module in the curriculum. The intervention group received three patient cases and the control group received teaching as usual; allocation ratio was 1:1. Researchers were blind to allocation. Clinical reasoning skills were measured using a survey after 1 week and a patient case after 1 month. RESULTS Across schools, 264 students participated (18.2% of all eligible). Cohort two had greater uptake (183/833, 22%) than cohort one (81/621, 13%). After 1 week, 99/137 (72%) of the intervention and 86/127 (68%) of the control group remained in the study. eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148). Of the intervention group, most (80/98, 82%) agreed eCREST helped them to learn clinical reasoning skills. CONCLUSIONS eCREST was highly acceptable and improved data gathering skills that could reduce diagnostic errors. Uptake was low but improved when integrated into course delivery. A summative trial is needed to estimate effectiveness.",2020,"eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148).","['final year undergraduate students from three UK medical schools in academic year 2016/2017 (cohort one) and 2017/2018 (cohort two', '264 students participated (18.2% of all eligible', 'Student volunteers were recruited in cohort one via email and on teaching days, and in cohort two eCREST was also integrated into a relevant module in the curriculum']","['control group received teaching as usual; allocation ratio', 'Online patient simulation training']","['Clinical reasoning skills', 'clinical reasoning', 'Uptake']","[{'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0036378', 'cui_str': 'Medical School'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C4517610', 'cui_str': '18.2'}, {'cui': 'C0042960', 'cui_str': 'Voluntary worker'}, {'cui': 'C0013849', 'cui_str': 'Email'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C3542953', 'cui_str': 'Module'}, {'cui': 'C0010478', 'cui_str': 'Curricula'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039401', 'cui_str': 'Education'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0085137', 'cui_str': 'Patient Simulation'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0684328', 'cui_str': 'Reasoning'}]",264.0,0.147911,"eCREST improved students' ability to gather essential information from patients over controls (OR = 1.4; 95% CI 1.1-1.7, n = 148).","[{'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Plackett', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK. ruth.plackett.15@ucl.ac.uk.'}, {'ForeName': 'Angelos P', 'Initials': 'AP', 'LastName': 'Kassianos', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Kambouri', 'Affiliation': 'Institute of Education, UCL, London, UK.'}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Kay', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Sophie', 'Initials': 'S', 'LastName': 'Mylan', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Jenny', 'Initials': 'J', 'LastName': 'Hopwood', 'Affiliation': 'UCL Medical School, UCL, London, UK.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Schartau', 'Affiliation': 'Primary Care and Population Health Department, UCL, London, UK.'}, {'ForeName': 'Shani', 'Initials': 'S', 'LastName': 'Gray', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Timmis', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Bennett', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Valerio', 'Affiliation': 'Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.'}, {'ForeName': 'Veena', 'Initials': 'V', 'LastName': 'Rodrigues', 'Affiliation': 'Norwich Medical School, UEA, Norwich, UK.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Player', 'Affiliation': 'Norwich Medical School, UEA, Norwich, UK.'}, {'ForeName': 'Willie', 'Initials': 'W', 'LastName': 'Hamilton', 'Affiliation': 'Institute of Health Service Research, University of Exeter, Exeter, UK.'}, {'ForeName': 'Rosalind', 'Initials': 'R', 'LastName': 'Raine', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Duffy', 'Affiliation': 'Wolfson Institute of Preventive Medicine, QMUL, London, UK.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Sheringham', 'Affiliation': 'Department of Applied Health Research, University College London, 1-19 Torrington Place, London, WC1E 7HB, UK.'}]",BMC medical education,['10.1186/s12909-020-02168-4'] 2941,32736592,muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial.,"OBJECTIVES To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). TRIAL DESIGN Randomised, parallel arm, open-label, adaptive platform Phase 2/3 trial of potential disease modifying therapies in patients with late stage 1/stage 2 COVID-19-related disease, with a diagnosis based either on a positive assay or high suspicion of COVID-19 infection by clinical, laboratory and radiological assessment. PARTICIPANTS Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) >3 OR ≥3 if risk count includes ""Radiographic severity score >3"". A risk count is calculated by the following features on admission (1 point for each): radiographic severity score >3, male gender, non-white ethnicity, diabetes, hypertension, neutrophils >8.0 x10 9 /L, age >40 years and CRP >40 mg/L. Patients should be considered an appropriate subject for intervention with immunomodulatory or other disease modifying agents in the opinion of the investigator and are able to swallow capsules or tablets. The complete inclusion and exclusion criteria as detailed in the Additional file 1 should be fulfilled. Drug specific inclusion and exclusion criteria will also be applied to the active arms. Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support. Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust. Other centres will be approached internationally in view of the evolving pandemic. INTERVENTION AND COMPARATOR There is increasing evidence of the role of immunomodulation in altering the course of COVID-19. Additionally, various groups have demonstrated the presence of pulmonary shunting in patients with COVID-19 as well as other cardiovascular complications. TACTIC-E will assess the efficacy of the novel immunomodulatory agent EDP1815 versus the approved cardio-pulmonary drugs, Dapagliflozin in combination with Ambrisentan versus the prevailing standard of care. EDP1815 will be given as 2 capsules twice daily (1.6 x 10 11 cells) for up to 7 days with the option to extend up to 14 days at the discretion of the principal investigator or their delegate, if the patient is felt to be clinically responding to treatment, is tolerating treatment, and is judged to be likely to benefit from a longer treatment course. Ambrisentan 5mg and Dapagliflozin 10mg will be given in combination once daily orally for up to maximum of 14 days. Patients will be randomised in a 1:1:1 ratio across treatments. Each active arm will be compared with standard of care alone. Additional arms may be added as the trial progresses. No comparisons will be made between active arms in this platform trial. MAIN OUTCOMES The primary outcome is the incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). RANDOMISATION Eligible patients will be randomised using a central web-based randomisation service (Sealed Envelope) in a 1:1:1 ratio, stratified by site to one of the treatment arms or standard of care. BLINDING (MASKING) This is an open-label trial. Data analysis will not be blinded. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) There is no fixed sample size for this study. There will be an early biomarker-based futility analysis performed at a point during the study. If this biomarker futility analysis is not conclusive, then a second futility analysis based on clinical endpoints will be performed after approximately 125 patients have been recruited per arm. Provisionally, further analyses of clinical endpoints will be performed after 229 patients per active arm and later 469 patients per arm have been recruited. Further additional analyses may be triggered by the independent data monitoring committee. TRIAL STATUS TACTIC-E Protocol version number 1.0 date May 27 th , 2020. Recruitment starts on the 3 rd of July 2020. The end trial date will be 18 months after the last patient's last visit and cannot be accurately predicted at this time. TRIAL REGISTRATION Registered on EU Clinical Trials Register EudraCT Number: 2020-002229-27 registered: 9 June 2020. The trial was also registered on ClinicalTrials.gov (NCT04393246) on 19 May 2020. FULL PROTOCOL The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,"To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). ","['125 patients have been recruited per arm', 'patients with late stage', ""Participants will be recruited across multiple centres in the UK including initially at Cambridge University Hospitals NHS Foundation Trust and St George's University NHS Foundation Trust"", 'pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E', 'Patients aged 18 and over, with a clinical picture strongly suggestive of COVID-19-related disease (with/without a positive COVID-19 test) AND a risk count (as defined below) ', '229 patients per active arm and later 469 patients per arm have been recruited', 'Patients will be enrolled prior to the need for invasive mechanical ventilation, cardiac or renal support', 'patients with COVID-19-related disease to organ failure or death']","['specific intervention', 'EDP1815', 'Ambrisentan 5mg and Dapagliflozin']","['Radiographic severity score', 'presence of pulmonary shunting', 'death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure', 'incidence (from baseline up to Day 14) to the occurrence of the any one of the following events: death, invasive mechanical ventilation, extra corporeal membrane oxygenation, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min']","[{'cui': 'C4319551', 'cui_str': '125'}, {'cui': 'C0332310', 'cui_str': 'Has patient'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1279941', 'cui_str': 'Late stage'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0205265', 'cui_str': 'Initial'}, {'cui': 'C0020028', 'cui_str': 'University Hospitals'}, {'cui': 'C0796085', 'cui_str': 'Nance-Horan syndrome'}, {'cui': 'C0016617', 'cui_str': 'Foundations'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0013230', 'cui_str': 'Investigational New Drugs'}, {'cui': 'C0441712', 'cui_str': 'Mechanisms'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441468', 'cui_str': 'Photograph'}, {'cui': 'C0332299', 'cui_str': 'Suggestive of'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C3539106', 'cui_str': 'Defined'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0332152', 'cui_str': 'Before'}, {'cui': 'C0686904', 'cui_str': 'Patient need for'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0022646', 'cui_str': 'Kidney structure'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction'}, {'cui': 'C0011065', 'cui_str': 'Death'}]","[{'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1949327', 'cui_str': 'ambrisentan 5 MG'}, {'cui': 'C2353951', 'cui_str': 'dapagliflozin'}]","[{'cui': 'C0444708', 'cui_str': 'Radiographic'}, {'cui': 'C0457451', 'cui_str': 'Severity score'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0024109', 'cui_str': 'Lung structure'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1868981', 'cui_str': 'Invasive mechanical ventilation'}, {'cui': 'C0015357', 'cui_str': 'Extracorporeal membrane oxygenation'}, {'cui': 'C0007226', 'cui_str': 'Structure of cardiovascular system'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0009346', 'cui_str': 'Balloon pump'}, {'cui': 'C0035078', 'cui_str': 'Renal insufficiency'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0547043', 'cui_str': 'Up'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0025255', 'cui_str': 'Membrane Tissue'}, {'cui': 'C0231940', 'cui_str': 'Alveolar ventilation (V)'}, {'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0373595', 'cui_str': 'Measurement of renal clearance of creatinine'}, {'cui': 'C0439232', 'cui_str': 'min'}]",,0.40292,"To determine if a specific intervention reduces the composite of progression of patients with COVID-19-related disease to organ failure or death as measured by time to incidence of any one of the following: death, invasive mechanical ventilation, ECMO, cardiovascular organ support (inotropes or balloon pump), or renal failure (estimated Cockcroft Gault creatinine clearance <15ml/min). ","[{'ForeName': 'Ing Ni', 'Initials': 'IN', 'LastName': 'Lu', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. ing.lu@addenbrookes.nhs.uk.'}, {'ForeName': 'Spoorthy', 'Initials': 'S', 'LastName': 'Kulkarni', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Fisk', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Michalis', 'Initials': 'M', 'LastName': 'Kostapanos', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Banham-Hall', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Sonakshi', 'Initials': 'S', 'LastName': 'Kadyan', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Bond', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Norton', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Cope', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Galloway', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Frances', 'Initials': 'F', 'LastName': 'Hall', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Jayne', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Ian B', 'Initials': 'IB', 'LastName': 'Wilkinson', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Cheriyan', 'Affiliation': 'Clinical Pharmacology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.'}]",Trials,['10.1186/s13063-020-04618-2'] 2942,32736596,"ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial.","OBJECTIVES Stage 1: To evaluate the safety and efficacy of candidate agents as add-on therapies to standard of care (SoC) in patients hospitalised with COVID-19 in a screening stage. Stage 2: To confirm the efficacy of candidate agents selected on the basis of evidence from Stage 1 in patients hospitalised with COVID-19 in an expansion stage. TRIAL DESIGN ACCORD is a seamless, Phase 2, adaptive, randomised controlled platform study, designed to rapidly test candidate agents in the treatment of COVID-19. Designed as a master protocol with each candidate agent being included via its own sub-protocol, initially randomising equally between each candidate and a single contemporaneous SoC arm (which can adapt into 2:1). Candidate agents currently include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin. For each candidate a total of 60 patients will be recruited in Stage 1. If Stage 1 provides evidence of efficacy and acceptable safety the candidate will enter Stage 2 where a total of approximately 126 patients will be recruited into each study arm sub-protocol. Enrollees and outcomes will not be shared across the Stages; the endpoint, analysis and sample size for Stage 2 may be adjusted based on evidence from Stage 1. Additional arms may be added as new potential candidate agents are identified via candidate agent specific sub-protocols. PARTICIPANTS The study will include hospitalised adult patients (≥18 years) with confirmed SARS-CoV-2 infection, the virus that causes COVID-19, that clinically meet Grades 3 (hospitalised - mild disease, no oxygen therapy), Grades 4 (hospitalised, oxygen by mask or nasal prongs) and 5 (hospitalised, non-invasive ventilation or high flow oxygen) of the WHO Working Group on the Clinical Characteristics of COVID-19 9-point category ordinal scale. Participants will be recruited from England, Northern Ireland, Wales and Scotland. INTERVENTION AND COMPARATOR Comparator is current standard of care (SoC) for the treatment of COVID-19. Current candidate experimental arms include bemcentinib, MEDI3506, acalabrutinib, zilucoplan and nebulised heparin with others to be added over time. Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein. ACCORD is linked with the UK national COVID therapeutics task force to help prioritise candidate agents. MAIN OUTCOMES Time to sustained clinical improvement of at least 2 points (from randomisation) on the WHO 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale), whichever comes first, by Day 29 (this will also define the ""responder"" for the response rate analyses). RANDOMISATION An electronic randomization will be performed by Cenduit using Interactive Response Technology (IRT). Randomisation will be stratified by baseline severity grade. Randomisation will proceed with an equal allocation to each arm and a contemporaneous SoC arm (e.g. 1:1 if control and 1 experimental arm; 1:1:1 if two experimental candidate arms etc) but will be reviewed as the trial progresses and may be changed to 2:1 in favour of the candidate agents. BLINDING (MASKING) The trial is open label and no blinding is currently planned in the study. NUMBERS TO BE RANDOMISED (SAMPLE SIZE) This will be in the order of 60 patients per candidate agent for Stage 1, and 126 patients for Stage 2. However, sample size re-estimation may be considered after Stage 1. It is estimated that up to 1800 patients will participate in the overall study. TRIAL STATUS Master protocol version ACCORD-2-001 - Master Protocol (Amendment 1) 22 nd April 2020, the trial has full regulatory approval and recruitment is ongoing in the bemcentinib (first patient recruited 6/5/2020), MEDI3506 (first patient recruited 19/5/2020), acalabrutinib (first patient recruited 20/5/2020) and zilucoplan (first patient recruited 19/5/2020) candidates (and SoC). The recruitment dates of each arm will vary between candidate agents as they are added or dropped from the trial, but will have recruited and reported within a year. TRIAL REGISTRATION EudraCT 2020-001736-95 , registered 28 th April 2020. FULL PROTOCOL The full protocol (Master Protocol with each of the candidate sub-protocols) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.",2020,Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.,"['patients hospitalised with COVID-19 in a screening stage', 'patients hospitalised with COVID-19 in an expansion stage', 'Participants will be recruited from England, Northern Ireland, Wales and Scotland', 'hospitalised adult patients (≥18 years) with confirmed SARS-CoV-2 infection, the virus that causes COVID-19, that clinically meet Grades 3 (hospitalised - mild disease, no oxygen therapy), Grades 4 (hospitalised, oxygen by mask or nasal prongs) and 5 (hospitalised, non-invasive ventilation or high flow oxygen) of the WHO Working Group on the Clinical Characteristics of COVID-19 9-point category ordinal scale', 'bemcentinib (first patient recruited 6/5/2020), MEDI3506 (first patient recruited 19/5/2020), acalabrutinib (first patient recruited 20/5/2020) and zilucoplan (first patient recruited 19/5/2020) candidates (and SoC', '22 nd April 2020', '2020-001736-95', 'Hospitalised Patients', '1800 patients will participate in the overall study', '60 patients will be recruited in Stage 1', '60 patients per candidate agent for Stage 1, and 126 patients for Stage 2', 'Master protocol version ACCORD-2-001 - Master Protocol (Amendment 1', '126 patients will be recruited into each study arm sub-protocol']","['ACCORD', 'heparin', 'EudraCT']","['Time to sustained clinical improvement of at least 2 points (from randomisation) on the WHO 9-point category ordinal scale, live discharge from the hospital, or considered fit for discharge (a score of 0, 1, or 2 on the ordinal scale', 'Efficacy and Safety', 'safety and efficacy']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0028415', 'cui_str': 'Northern Ireland'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0009450', 'cui_str': 'Communicable disease'}, {'cui': 'C0042769', 'cui_str': 'Viral disease'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0025646', 'cui_str': 'Methionine'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0184633', 'cui_str': 'Oxygen therapy'}, {'cui': 'C3537125', 'cui_str': 'Common terminology criteria for adverse events grade 4'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0024861', 'cui_str': 'Mask'}, {'cui': 'C0445087', 'cui_str': 'Nasal prongs'}, {'cui': 'C1997883', 'cui_str': 'Noninvasive ventilation'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0043227', 'cui_str': 'Working'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C4078312', 'cui_str': 'acalabrutinib'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}, {'cui': 'C0757844', 'cui_str': 'TNFSF13 protein, human'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0450442', 'cui_str': 'Agent'}, {'cui': 'C0470256', 'cui_str': '126'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0444649', 'cui_str': 'Master'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C2607870', 'cui_str': 'Version'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C0542339', 'cui_str': 'Inferior'}]","[{'cui': 'C0019134', 'cui_str': 'heparin'}]","[{'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0443318', 'cui_str': 'Sustained'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0439080', 'cui_str': 'Ordinal number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0595998', 'cui_str': 'Household composition'}, {'cui': 'C0012621', 'cui_str': 'Discharge'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0036572', 'cui_str': 'Seizure'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",60.0,0.215769,Bemcentinib could potentially reduce viral infection and blocks SARS-CoV-2 spike protein; MEDI3506 is a clinic-ready anti-IL-33 monoclonal antibody with the potential to treat respiratory failure caused by COVID; acalabrutinib is a BTK inhibitor which is anti-viral and anti-inflammatory; zilucoplan is a complement C5 inhibitor which may block the severe inflammatory response in COVID-19 and; nebulised heparin has been shown to bind with the spike protein.,"[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Wilkinson', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK.'}, {'ForeName': 'Rupert', 'Initials': 'R', 'LastName': 'Dixon', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Clive', 'Initials': 'C', 'LastName': 'Page', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Miles', 'Initials': 'M', 'LastName': 'Carroll', 'Affiliation': 'Public Health England, London, UK.'}, {'ForeName': 'Gareth', 'Initials': 'G', 'LastName': 'Griffiths', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK. G.O.Griffiths@soton.ac.uk.'}, {'ForeName': 'Ling-Pei', 'Initials': 'LP', 'LastName': 'Ho', 'Affiliation': 'NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'De Soyza', 'Affiliation': 'Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Felton', 'Affiliation': 'Manchester NIHR Biomedical Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Keir E', 'Initials': 'KE', 'LastName': 'Lewis', 'Affiliation': 'Swansea University, Swansea, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Phekoo', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Chalmers', 'Affiliation': 'University of Dundee, Dundee, UK.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Gordon', 'Affiliation': 'Imperial College London, London, UK.'}, {'ForeName': 'Lorcan', 'Initials': 'L', 'LastName': 'McGarvey', 'Affiliation': ""Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Jillian', 'Initials': 'J', 'LastName': 'Doherty', 'Affiliation': 'University Hospital Southampton NHS Foundation Trust, Southampton, UK.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Read', 'Affiliation': 'University of Southampton, Southampton, Hampshire, UK.'}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Shankar-Hari', 'Affiliation': ""King's College London, London, UK.""}, {'ForeName': 'Nuria', 'Initials': 'N', 'LastName': 'Martinez-Alier', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': ""O'Kelly"", 'Affiliation': 'IQVIA, Dublin, Ireland.'}, {'ForeName': 'Graeme', 'Initials': 'G', 'LastName': 'Duncan', 'Affiliation': 'IQVIA, Edinburgh, UK.'}, {'ForeName': 'Roelize', 'Initials': 'R', 'LastName': 'Walles', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Sykes', 'Affiliation': 'IQVIA, Reading, UK.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Summers', 'Affiliation': 'University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'University of Manchester, Manchester, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Trials,['10.1186/s13063-020-04584-9'] 2943,32736597,PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.,"OBJECTIVES Hydroxychloroquine has shown to have antiviral activity in vitro against coronaviruses, specifically SARS-CoV-2. It is believed to block virus infection by increasing endosomal pH required for virus cell fusion and glycosylation of viral surface proteins. In addition to its antiviral activity, hydroxychloroquine has an immune-modulating activity that may synergistically enhance its antiviral effect in vivo, making it a potentially promising drug for the prevention and the cure of SARS-CoV-19. However, randomized controlled trials are needed to assess whether it can be used safely to treat COVID-19 patients or to prevent infection. The main objective of the present study is to evaluate the efficacy of hydroxychloroquine for (I) the prevention of COVID-19 or related symptoms in SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients. TRIAL DESIGN This is a controlled, open label, cluster-randomized, superiority trial with parallel group design. Subjects will be randomized either to receive hydroxychloroquine or to observation (2:1). PARTICIPANTS SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled. Paucisymptomatic patients are defined as patients with a low number of mild symptoms. All subjects must be aged ≥18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (intolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation). The study is monocentric and will be conducted at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS. Subjects will be enrolled from a large epidemic region (North-Central Italy). The Public Health Departments of several Italian regions will collaborate by identifying potentially eligible subjects. INTERVENTION AND COMPARATOR The participants will be randomized (2:1 randomization) to receive either hydroxychloroquine (Arm A) or to Observation (Arm B). Hydroxychloroquine will be administered with the following schedule: Group1: A loading dose hydroxychloroquine 400 mg twice daily on day 1, followed by a weekly dose of hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, for a total of one month of treatment. Group 2: A loading dose hydroxychloroquine 400 mg twice daily on day 1 followed by 200 mg twice daily for a total of 5-7 days. The comparator in this trial is observation given that currently neither treatment is administered to asymptomatic or paucisymptomatic subjects, nor prophylaxis is available for contacts. Hydroxychloroquine will be shipped to subjects within 24 hours of randomization. Given the extraordinary nature of the COVID-19 pandemic, only telephonic interviews will be carried out and electronic Patient Reported Outcomes (ePRO) completed. During treatment, each subject will be contacted every other day for the first week and weekly thereafter (Group 2) or weekly (Group 1) by a study physician to assess early onset of any COVID-19 symptom or any adverse reaction to hydroxychloroquine and to check subject compliance. Furthermore, all subjects will receive periodic ePROs which may be completed through smartphone or tablets to record drug self-administration and onset of any symptom or adverse event. All subjects will be followed up for a total of 6 months by periodic telephonic interviews and ePROs. MAIN OUTCOMES The primary endpoint/outcome measure for this trial is: for Group 1, the proportion of subjects who become symptomatic and/or swab-positive in each arm within one month of randomization; for Group 2, the proportion of subjects who become swab-negative in each arm within 14 days of randomization. RANDOMIZATION All household members and/or contacts of each COVID-19 index case, and the COVID-19 patient himself/herself, fulfilling all inclusion criteria will be grouped into a single cluster and this cluster will be randomized (2:1) to either arm A or arm B. Information on each subject will be recorded in specific data records. Randomization lists will be stratified according to the following factors regarding COVID-19 index cases: 1. COVID-19 risk level on the basis of province of residence (high vs. low/intermediate); 2. Index case is a healthcare professional (yes vs.no) 3. Index case with COVID-19 treatment (yes vs. no) An independent statistician not otherwise involved in the trial will generate the allocation sequence, and COVID-19 response teams will be unaware of the allocation of clusters. Randomization will be performed through an interactive web-based electronic data-capturing database. An Independent Data Monitoring Committee has been established. BLINDING (MASKING) This study is open label. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE) For Group 1, a sample size of about 2000 SARS-CoV-2-exposed subjects such as household members and/or contacts of COVID-19 patients will take part in the study. Assuming around 1.5-2.0 asymptomatic household members and/or contacts for each COVID-19 patient, we expect to identify approximately 1000-1300 COVID-19 index cases to be randomized. An interim analysis on efficacy is planned using standard alpha-spending function. For Group 2, sufficient power for primary objective (negative swab within 14 days of randomization) will be reached given a sample size of 300 asymptomatic or paucisymptomatic COVID-19 subjects in home situations not treated for COVID-19 (25%-30% of about 1000-1300 expected index cases). Since up to date reduced evidence about COVID-19 infection epidemiology, the continuous update of diagnostic and therapeutic approaches, the sample size estimation could be updated after a one third of population will be recruited and eventually modified according to a substantial protocol amendment. An interim analysis at 100 enrolled COVID-19 patients is planned. We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates. The above reported sample size analysis is therefore to be considered conservative. TRIAL STATUS The current version of the PROTECT trial protocol is 'Final version, 15 April 2020'. The study started on 9 th May 2020. The first patient was enrolled on 14 th May 2020. Recruitment is expected to last through September 2020. TRIAL REGISTRATION The PROTECT trial is registered in the EudraCT database (no. 2020-001501-24) and in ClinicalTrials.gov ( NCT04363827 ), date of registration 24 April 2020. FULL PROTOCOL The full PROTECT protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interests of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol (Protocol final version, 15 th April 2020). The study protocol has been reported in accordance with Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).",2020,"We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates.","['SARS-CoV-2-exposed subjects, such as as household members/contacts of COVID-19 patients and (II) the treatment of early-phase asymptomatic or paucisymptomatic COVID-19 patients', 'Subjects will be enrolled from a large epidemic region (North-Central Italy', 'in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness', 'SARS-CoV-2-exposed subjects, including household members and/or contacts of COVID-19 patients and healthcare professionals (Group 1) or patients with COVID-19 (positive PCR test on a rhinopharyngeal or oropharyngeal swab for SARS-CoV-2), asymptomatic or paucisymptomatic in home situations who are not undergoing treatment with any anti COVID-19 medication (Group 2), will be enrolled', '2000 SARS-CoV-2-exposed subjects such as household members', 'All subjects must be aged ≥18 years, male or female', 'Coronavirus disease (COVID-19']","['hydroxychloroquine (intolerance', 'hydroxychloroquine', 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS', 'Hydroxychloroquine', 'hydroxychloroquine/chloroquine, bradycardia or reduction']",['proportion of subjects who become symptomatic and/or swab-positive'],"[{'cui': 'C0332157', 'cui_str': 'Exposure to'}, {'cui': 'C0020052', 'cui_str': 'Households'}, {'cui': 'C0680022', 'cui_str': 'Member of'}, {'cui': 'C0332158', 'cui_str': 'Contact with'}, {'cui': 'TS-COV19', 'cui_str': 'COVID-19'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205390', 'cui_str': 'Phase'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic'}, {'cui': 'C0549177', 'cui_str': 'Large'}, {'cui': 'C0014499', 'cui_str': 'Epidemic'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0022277', 'cui_str': 'Italy'}, {'cui': 'C0232187', 'cui_str': 'Cardiac rhythm type'}, {'cui': 'C0003811', 'cui_str': 'Cardiac arrhythmia'}, {'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C0035309', 'cui_str': 'Retinal disorder'}, {'cui': 'C0018802', 'cui_str': 'Congestive heart failure'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C0012798', 'cui_str': 'Diuretic'}, {'cui': 'C0015702', 'cui_str': 'Favism'}, {'cui': 'C2939465', 'cui_str': 'Deficiency of glucose-6-phosphate dehydrogenase'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C1561643', 'cui_str': 'Chronic kidney disease'}, {'cui': 'C0011946', 'cui_str': 'Dialysis procedure'}, {'cui': 'C0205309', 'cui_str': 'Known'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0085612', 'cui_str': 'Ventricular arrhythmia'}, {'cui': 'C0205478', 'cui_str': 'Oncologic'}, {'cui': 'C0376545', 'cui_str': 'Hematologic neoplasm'}, {'cui': 'C0205494', 'cui_str': 'Neurologic'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0018724', 'cui_str': 'Health Care Providers'}, {'cui': 'C0441861', 'cui_str': 'Group 1'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0032520', 'cui_str': 'Polymerase chain reaction'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0027442', 'cui_str': 'Nasopharyngeal'}, {'cui': 'C0521367', 'cui_str': 'Oropharyngeal structure'}, {'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C0442519', 'cui_str': 'Domestic'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0441865', 'cui_str': 'Group 2'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0020336', 'cui_str': 'Hydroxychloroquine'}, {'cui': 'C0231199', 'cui_str': 'Intolerance'}, {'cui': 'C0008269', 'cui_str': 'Chloroquine'}, {'cui': 'C0428977', 'cui_str': 'Bradycardia'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}]","[{'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0183753', 'cui_str': 'Swab'}, {'cui': 'C1446409', 'cui_str': 'Positive'}]",,0.210316,"We have planned a Generalized Estimating Equation analysis, which is more efficient than a cluster level analysis, to take advantage of subject-specific covariates.","[{'ForeName': 'Oriana', 'Initials': 'O', 'LastName': 'Nanni', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. oriana.nanni@irst.emr.it.'}, {'ForeName': 'Pierluigi', 'Initials': 'P', 'LastName': 'Viale', 'Affiliation': 'Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.'}, {'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Vertogen', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Lilli', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Zingaretti', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Donati', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Masini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Monti', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Patrizia', 'Initials': 'P', 'LastName': 'Serra', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Vespignani', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Veruska', 'Initials': 'V', 'LastName': 'Grossi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Annibale', 'Initials': 'A', 'LastName': 'Biggeri', 'Affiliation': 'Dipartimento di Statistica, Informatica, Applicazioni ""G. Parenti"" (DISIA), Università degli studi Firenze, Florence, Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Scarpi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Galardi', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Bertoni', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Americo', 'Initials': 'A', 'LastName': 'Colamartini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Falcini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Mattia', 'Initials': 'M', 'LastName': 'Altini', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Ilaria', 'Initials': 'I', 'LastName': 'Massa', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Raffaella', 'Initials': 'R', 'LastName': 'Gaggeri', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Martinelli', 'Affiliation': 'Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.'}]",Trials,['10.1186/s13063-020-04527-4'] 2944,32737664,Efficacy of a 0.03% chlorhexidine and 0.05% cetylpyridinium chloride mouth rinse in reducing inflammation around the teeth and implants: a randomized clinical trial.,"OBJECTIVES To evaluate the efficacy of a 0.03% chlorhexidine (CHX) and 0.05% cetylpyridinium chloride (CPC) mouth rinse, as an adjunct to professional plaque removal (PPR) and mechanical hygiene, in the treatment of peri-implant mucositis (PiM) and gingivitis. MATERIAL AND METHODS Patients displaying PiM in, at least, one implant were included in this randomized, double-blinded, clinical trial. Subjects received PPR (at baseline and 6-month visits) and were instructed to rinse, twice daily, during 1 year with the tested mouth rinse or a placebo. Clinical and patient-reported outcomes were recorded at baseline and 6 and 12 months. RESULTS Fifty-four patients were included in the study and 46 attended the final visit. In the teeth and implants with inflammation, a higher reduction in BOP was observed in the test group. Statistically significant differences between groups were only observed in the lingual sites of the teeth with gingivitis (mean difference = 11.96%; 95% confidence interval [1.09; 22.83]; p = 0.03). Overall, compliance and satisfaction were good, even though staining were higher for the test group (p < 0.05). CONCLUSIONS The combined use of mechanical debridement with a 0.03% CHX and 0.05% CPC mouth rinse may have adjunctive benefits in the management of gingivitis, and it is associated with a higher degree of staining. CLINICAL RELEVANCE The control of gingivitis can be improved, after professional mechanical debridement, with toothbrushing and the supplementary use of a 0.03% CHX and 0.05% CPC mouth rinse at home. CLINICAL TRIAL REGISTRATION NUMBER NCT03533166.",2020,"Overall, compliance and satisfaction were good, even though staining were higher for the test group (p < 0.05). ","['reducing inflammation around the teeth and implants', 'peri-implant mucositis (PiM) and gingivitis', 'Fifty-four patients were included in the study and 46 attended the final visit', 'Patients displaying PiM in, at least, one implant']","['chlorhexidine (CHX) and 0.05% cetylpyridinium chloride (CPC) mouth rinse', 'chlorhexidine and 0.05% cetylpyridinium chloride mouth rinse', 'mechanical debridement with a 0.03% CHX and 0.05% CPC mouth rinse', 'placebo']","['Overall, compliance and satisfaction', 'lingual sites of the teeth with gingivitis', 'BOP']","[{'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0021102', 'cui_str': 'Implant'}, {'cui': 'C0347985', 'cui_str': 'During values'}, {'cui': 'C3698407', 'cui_str': 'Peri-implant mucositis'}, {'cui': 'C4517807', 'cui_str': '54'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}]","[{'cui': 'C0008196', 'cui_str': 'Chlorhexidine'}, {'cui': 'C4517411', 'cui_str': '0.05'}, {'cui': 'C0007907', 'cui_str': 'Cetylpyridinium chloride'}, {'cui': 'C0026647', 'cui_str': 'Oromucosal solution for gargle'}, {'cui': 'C0443254', 'cui_str': 'Mechanical'}, {'cui': 'C0011079', 'cui_str': 'Debridement'}, {'cui': 'C4517402', 'cui_str': '0.03'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0040408', 'cui_str': 'Tongue structure'}, {'cui': 'C2945843', 'cui_str': 'Site of'}, {'cui': 'C0040426', 'cui_str': 'Tooth structure'}, {'cui': 'C0796232', 'cui_str': 'Bohring Opitz syndrome'}]",54.0,0.375487,"Overall, compliance and satisfaction were good, even though staining were higher for the test group (p < 0.05). ","[{'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Bollain', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Pulcini', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Sanz-Sánchez', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Figuero', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain. elfiguer@ucm.es.'}, {'ForeName': 'Bettina', 'Initials': 'B', 'LastName': 'Alonso', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Sanz', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Herrera', 'Affiliation': 'ETEP (Etiology and Therapy of Periodontal and Peri-implant Diseases) Research Group, Faculty of Dentistry, University Complutense of Madrid, Madrid, Spain.'}]",Clinical oral investigations,['10.1007/s00784-020-03474-3'] 2945,32737760,A Comparison of Analgesia After a Thoracoscopic Lung Cancer Operation with a Sustained Epidural Block and a Sustained Paravertebral Block: A Randomized Controlled Study.,"INTRODUCTION This study aimed to compare the challenge of puncture and catheterization and the effect of postoperative analgesia of ultrasound-guided continuous thoracic paravertebral block and the continuous epidural analgesia in patients receiving thoracoscopic surgery for lung cancer. METHODS One-hundred and fifty patients received elective unilateral thoracoscopic surgery for lung cancer and were randomized into three groups; test group 1 (T group), test group 2 (P group), and the control group (E group). Both of the test groups received ultrasound-guided continuous thoracic paravertebral block (TPVB) while the control group received continuous epidural analgesia. After the operation, all the patients in the test groups received the same postoperative analgesia; loading dose 0.5 mg kg -1 , background dose 0.25 mg kg -1  h -1 , patient controlled analgesia (PCA) 0.25 mg kg -1 , and a locking time of 60 min, while the patients in the control group received a loading dose of 5 ml, a background dose of 5 ml h -1 , and a locking time of 20 min. The outcomes of this study were the success rate of the puncture and catheter placement, the blocked segments, numerical rating scale (NRS) scores at rest and during coughing, and the segments with reduced or lost cold and pinpricking sensation. RESULTS The success rates of the puncture and catheterization in group T were the highest. Compared with group P, the failure rate of the puncture in group E was lower (p < 0.05), but the success rate of catheterization was higher (p < 0.05). The puncture time in group T was the shortest; there was no difference between group E and group T. The time of catheterization in group P was the longest, this was followed by group T, and was the fastest in group E. The stable time of the block level in group E was shorter than that in groups P and T, but was similar between groups P and T. The block level of all three groups in the 4 h postoperative period was similar (p > 0.05), while the 4 h postoperative levels of groups P and T were reduced significantly (p < 0.05). CONCLUSION The continuous analgesia technique of paravertebral space catheterization cannot replace the continuous epidural analgesia in thoracoscopic lung cancer surgery as the latter technique is still considered to be the gold standard. TRIAL REGISTRATION China Clinical Trial Registration Center identifier ChiCTR1900020973.",2020,"Compared with group P, the failure rate of the puncture in group E was lower (p < 0.05), but the success rate of catheterization was higher (p < 0.05).","['One-hundred and fifty patients received', 'for lung cancer', 'patients receiving thoracoscopic surgery for lung cancer', 'thoracoscopic lung cancer surgery']","['postoperative analgesia of ultrasound-guided continuous thoracic paravertebral block', 'Thoracoscopic Lung Cancer Operation with a Sustained Epidural Block', 'loading dose of 5\xa0ml, a background dose of 5', 'elective unilateral thoracoscopic surgery', 'paravertebral space catheterization', 'puncture and catheterization', 'ultrasound-guided continuous thoracic paravertebral block (TPVB) while the control group received continuous epidural analgesia']","['failure rate of the puncture', 'puncture time', 'success rates of the puncture and catheterization', 'stable time of the block level', 'block level', 'time of catheterization', 'success rate of the puncture and catheter placement, the blocked segments, numerical rating scale (NRS) scores at rest and during coughing, and the segments with reduced or lost cold and pinpricking sensation', 'success rate of catheterization']","[{'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C0041618', 'cui_str': 'Ultrasonography'}, {'cui': 'C0181090', 'cui_str': 'Guide'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0729233', 'cui_str': 'Dissecting aortic aneurysm, thoracic'}, {'cui': 'C0442150', 'cui_str': 'Paravertebral'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0242379', 'cui_str': 'Malignant tumor of lung'}, {'cui': 'C0038895', 'cui_str': 'operative procedures'}, {'cui': 'C0002913', 'cui_str': 'Epidural anesthesia'}, {'cui': 'C3714444', 'cui_str': 'Loading dose'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0751551', 'cui_str': 'Thoracoscopic Surgical Procedures'}, {'cui': 'C0282173', 'cui_str': 'Space (Astronomy)'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0002769', 'cui_str': 'Epidural analgesia'}]","[{'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0033119', 'cui_str': 'Puncture'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0007430', 'cui_str': 'Catheterization'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0028778', 'cui_str': 'Obstruction'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0883301', 'cui_str': 'Catheter placement'}, {'cui': 'C0441635', 'cui_str': 'Segment'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0443144', 'cui_str': 'At rest'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C0009264', 'cui_str': 'Low temperature'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}]",150.0,0.0451201,"Compared with group P, the failure rate of the puncture in group E was lower (p < 0.05), but the success rate of catheterization was higher (p < 0.05).","[{'ForeName': 'Qiao-Wen', 'Initials': 'QW', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China.'}, {'ForeName': 'Jia-Bin', 'Initials': 'JB', 'LastName': 'Li', 'Affiliation': 'Department of Anesthesiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China.'}, {'ForeName': 'Ye', 'Initials': 'Y', 'LastName': 'Huang', 'Affiliation': 'Department of Anesthesiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China.'}, {'ForeName': 'Wen-Qing', 'Initials': 'WQ', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China.'}, {'ForeName': 'Zhi-Wei', 'Initials': 'ZW', 'LastName': 'Lu', 'Affiliation': 'Department of Anesthesiology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, 363000, China. luzhiwei9366@163.com.'}]",Advances in therapy,['10.1007/s12325-020-01446-3'] 2946,32737814,Examining Change in Self-Reported Gambling Measures Over Time as Related to Socially Desirable Responding Bias.,"Socially desirable responding is a response bias that can affect the accuracy of self-reports. It is especially likely when questions address sensitive topics, such as gambling attitudes, problems and behaviours. A sample of 321 participants were recruited from Amazon's mTurk crowdsourcing platform for a randomized controlled trial investigating an online gambling intervention. Data from this study was used to examine the influence of socially desirable responding on gambling self-report measures over time. At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year. Controlling for demographic variability, mixed effects models examining the relationship between socially desirable responding factors [SD and impression management (IM)] and time were conducted. Among males, there were significant interactions between IM with the NORC DSM-IV screen for gambling problems (NODS) and the gambling symptom assessment scale (G-SAS) scores respectively, over time. In other words, males with higher IM scores, demonstrated less change in NODS and G-SAS scores from baseline to 6-month follow-up compared to males with lower IM scores. There were no significant interactions in any models among females or among the full sample. Controlling the well-documented effect of socially desirable responding on self-reported measures in addictions research should be considered as a method to help reduce error and improve validity. Future research should continue to examine the effect of this bias on gambling measures over time and in each gender.Trial registration: https://ClinicalTrials.gov/NCT03124589 , registered 19 January 2017.",2020,"At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year.","[""321 participants were recruited from Amazon's mTurk crowdsourcing platform"", 'registered 19 January 2017']",['online gambling intervention'],"['NODS and G-SAS scores', 'Self-Reported Gambling Measures', 'self-deception (SD), a factor of socially desirable responding', 'gambling symptom assessment scale (G-SAS) scores']","[{'cui': 'C0325969', 'cui_str': 'Genus Amazona'}, {'cui': 'C3494386', 'cui_str': 'Crowd Sourcing'}, {'cui': 'C0600375', 'cui_str': 'Registers'}]","[{'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}]","[{'cui': 'C0220952', 'cui_str': 'DSM-IV'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0016995', 'cui_str': 'Gambling'}, {'cui': 'C0033213', 'cui_str': 'Problem'}, {'cui': 'C3494437', 'cui_str': 'Symptom Assessment'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0024195', 'cui_str': 'Deception'}, {'cui': 'C0050325', 'cui_str': 'A-factor (Streptomyces)'}]",321.0,0.0618734,"At baseline, self-deception (SD), a factor of socially desirable responding, was significantly higher among males than females and among those with household incomes greater than $20,000 per year.","[{'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Schell', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Godinho', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada.'}, {'ForeName': 'John A', 'Initials': 'JA', 'LastName': 'Cunningham', 'Affiliation': 'Institute of Mental Health and Policy Research, Centre for Addiction and Mental Health, 33 Russell St., Toronto, ON, M5S 2S1, Canada. john.cunningham@camh.ca.'}]",Journal of gambling studies,['10.1007/s10899-020-09970-1'] 2947,32737844,Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults.,"BACKGROUND In 2016, an expert working group was convened under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and formulated consensus recommendations for the conduct of clinical trials for drugs to prevent or treat sarcopenia. AIMS The objective of the current paper is to provide a 2020 update of the previous recommendations in accordance with the evidence that has become available since our original recommendations. METHODS This paper is based on literature reviews performed by members of the ESCEO working group and followed up with face to face meetings organized for the whole group to make amendments and discuss further recommendations. RESULTS The randomized placebo-controlled double-blind parallel-arm drug clinical trials should be the design of choice for both phase II and III trials. Treatment and follow-up should run at least 6 months for phase II and 12 months for phase III trials. Overall physical activity, nutrition, co-prescriptions and comorbidity should be recorded. Participants in these trials should be at least 70-years-old and present with a combination of low muscle strength and low physical performance. Severely malnourished individuals, as well as bedridden patients, patients with extremely limited mobility or individuals with physical limitations clearly attributable to the direct effect of a specific disease, should be excluded. Multiple outcomes are proposed for phase II trials, including, as example, physical performance, muscle strength and mass, muscle metabolism and muscle-bone interaction. For phase III trials, we recommend a co-primary endpoint of a measure of functional performance and a Patient Reported Outcome Measure. CONCLUSION The working group has formulated consensus recommendations on specific aspects of trial design, and in doing so hopes to contribute to an improvement of the methodological robustness and comparability of clinical trials. Standardization of designs and outcomes would advance the field by allowing better comparison across studies, including performing individual patient-data meta-analyses, and different pro-myogenic therapies.",2020,"Multiple outcomes are proposed for phase II trials, including, as example, physical performance, muscle strength and mass, muscle metabolism and muscle-bone interaction.","['Participants in these trials should be at least 70-years-old and present with a combination of low muscle strength and low physical performance', 'older adults']",['placebo'],"['Overall physical activity, nutrition, co-prescriptions and comorbidity', 'physical performance, muscle strength and mass, muscle metabolism and muscle-bone interaction']","[{'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0001792', 'cui_str': 'Elderly person'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0028707', 'cui_str': 'Nutrition Sciences'}, {'cui': 'C0033080', 'cui_str': 'Prescription'}, {'cui': 'C0009488', 'cui_str': 'Comorbidity'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0025519', 'cui_str': 'General metabolic function'}, {'cui': 'C0262950', 'cui_str': 'Bone structure'}, {'cui': 'C0021797', 'cui_str': 'Interpersonal Relations'}]",,0.0426337,"Multiple outcomes are proposed for phase II trials, including, as example, physical performance, muscle strength and mass, muscle metabolism and muscle-bone interaction.","[{'ForeName': 'Jean-Yves', 'Initials': 'JY', 'LastName': 'Reginster', 'Affiliation': 'WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium.'}, {'ForeName': 'Charlotte', 'Initials': 'C', 'LastName': 'Beaudart', 'Affiliation': 'WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium. c.beaudart@uliege.be.'}, {'ForeName': 'Nasser', 'Initials': 'N', 'LastName': 'Al-Daghri', 'Affiliation': 'Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Avouac', 'Affiliation': 'Department of Rheumatology, CHU Henri Mondor, Creteil, France.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Bauer', 'Affiliation': 'Center for Geriatric Medicine and Network Aging Research, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Bere', 'Affiliation': 'European Medicines Agency, Amsterdam, The Netherlands.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Bruyère', 'Affiliation': 'WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Cerreta', 'Affiliation': 'European Medicines Agency, Amsterdam, The Netherlands.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Cesari', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.'}, {'ForeName': 'Mario Miguel', 'Initials': 'MM', 'LastName': 'Rosa', 'Affiliation': 'Departamento de Neurociências/Laboratório de Farmacologia Clínica E Terapêutica, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.'}, {'ForeName': 'Cyrus', 'Initials': 'C', 'LastName': 'Cooper', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Alfonso J', 'Initials': 'AJ', 'LastName': 'Cruz Jentoft', 'Affiliation': 'Hospital Universitario Ramón Y Cajal (IRYCIS), Madrid, Spain.'}, {'ForeName': 'Elaine', 'Initials': 'E', 'LastName': 'Dennison', 'Affiliation': 'MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Geerinck', 'Affiliation': 'WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium.'}, {'ForeName': 'Evelien', 'Initials': 'E', 'LastName': 'Gielen', 'Affiliation': 'Division of Geriatrics, UZ Leuven, Leuven, Belgium.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Landi', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart Rome, Milan, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Laslop', 'Affiliation': 'Scientific Office, Federal Office for Safety in Health Care, Vienna, Austria.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Maggi', 'Affiliation': 'CNR Aging Branch-IN, Padua, Italy.'}, {'ForeName': 'María Concepción', 'Initials': 'MC', 'LastName': 'Prieto Yerro', 'Affiliation': 'Agencia Española de Medicamentos Y Productos Sanitarios, Madrid, Spain.'}, {'ForeName': 'René', 'Initials': 'R', 'LastName': 'Rizzoli', 'Affiliation': 'Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Hildrun', 'Initials': 'H', 'LastName': 'Sundseth', 'Affiliation': ""European Institute of Women's Health, Dublin, Ireland.""}, {'ForeName': 'Cornel', 'Initials': 'C', 'LastName': 'Sieber', 'Affiliation': 'Institute for Biomedicine of Aging Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Trombetti', 'Affiliation': 'Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Vellas', 'Affiliation': 'Department of Internal and Geriatrics Medicine, Gerontopole, CHU de Toulouse, UMR 1027 INSERM, University Toulouse III, Toulouse, France.'}, {'ForeName': 'Nicola', 'Initials': 'N', 'LastName': 'Veronese', 'Affiliation': 'Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy.'}, {'ForeName': 'Marjolein', 'Initials': 'M', 'LastName': 'Visser', 'Affiliation': 'Department of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Mila', 'Initials': 'M', 'LastName': 'Vlaskovska', 'Affiliation': 'Medical Faculty, Department of Pharmacology and Toxicology, Medical University Sofia, Sofia, Bulgaria.'}, {'ForeName': 'Roger A', 'Initials': 'RA', 'LastName': 'Fielding', 'Affiliation': 'Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center On Aging, Tufts University, Boston, USA.'}]",Aging clinical and experimental research,['10.1007/s40520-020-01663-4'] 2948,32738573,"Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: A double-blind, placebo-controlled randomized trial.","OBJECTIVE The aim of this study was to evaluate the effect of a multispecies probiotic on gut microbiota composition and constipation symptoms. METHODS A randomized, double-blind, placebo-controlled clinical trial was conducted with 35 individuals with constipation for 30 days. The individuals were randomized into two groups: the control capsule (CC) and the probiotic capsule (PC) groups. Constipation symptoms were evaluated by the ROME IV criteria and by evacuation diaries. Fecal microbiota was analyzed by 16 S rRNA gene sequencing. RESULTS The majority of participants were women (85.7%). There was a significant reduction in the percent of participants who had incomplete defecation (P = 0.034), blockage sensation (P = 0.025), and rarely present liquid stools without the aid of laxatives (P = 0.046) only within the PC group (but no significant difference between groups). There was a significant increase in the relative abundance percentage of Blautia faecis and Ruminococcus torques in the CC group (P = 0.003 and P = 0.011, respectively), although there was no significant change in the PC group (P = 0.794 and P = 0.958, respectively), with a significant difference between groups (P = 0.029 and P 0.013, respectively), suggesting that probiotic treatment prevented the increase of percent relative abundance of these two species. CONCLUSION These results suggest that multispecies probiotics in capsule form may modulate gut microbiota by reducing the bacteria that are commonly increased in patients with constipation, contributing to the balance of microbiota and, consequently, to the well-being of the individual. Future studies with larger numbers of patients are required.",2020,"There was a significant reduction in the percent of participants who had incomplete defecation (P = 0.034), blockage sensation (P = 0.025), and rarely present liquid stools without the aid of laxatives (P = 0.046) only within the PC group (but no significant difference between groups).","['individuals with intestinal constipation', '35 individuals with constipation for 30 days', 'patients with constipation']","['control capsule (CC) and the probiotic capsule (PC', 'multispecies probiotic', 'placebo']","['incomplete defecation', 'gut microbiota composition and constipation symptoms', 'Constipation symptoms', 'blockage sensation', 'Fecal microbiota', 'gut microbiota composition', 'relative abundance percentage of Blautia faecis and Ruminococcus torques']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0021853', 'cui_str': 'Intestinal'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0006935', 'cui_str': 'Capsule'}, {'cui': 'C0525033', 'cui_str': 'Probiotic'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0205257', 'cui_str': 'Incomplete'}, {'cui': 'C0011135', 'cui_str': 'Defecation'}, {'cui': 'C2985398', 'cui_str': 'Intestinal Microbiota'}, {'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C0009806', 'cui_str': 'Constipation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0036658', 'cui_str': 'Sensory perception'}, {'cui': 'C0015733', 'cui_str': 'Feces'}, {'cui': 'C3887843', 'cui_str': 'Microbial Community'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C2658870', 'cui_str': 'Blautia'}, {'cui': 'C0318074', 'cui_str': 'Ruminococcus'}, {'cui': 'C0318082', 'cui_str': 'Ruminococcus torques'}]",35.0,0.289849,"There was a significant reduction in the percent of participants who had incomplete defecation (P = 0.034), blockage sensation (P = 0.025), and rarely present liquid stools without the aid of laxatives (P = 0.046) only within the PC group (but no significant difference between groups).","[{'ForeName': 'Patrícia Borges', 'Initials': 'PB', 'LastName': 'Botelho', 'Affiliation': 'Department of Nutrition, Faculty of Health Sciences, University of Brasília, Brasília, Brazil. Electronic address: patriciabotelho@unb.br.'}, {'ForeName': 'Marcus Vinícius Rodrigues', 'Initials': 'MVR', 'LastName': 'Ferreira', 'Affiliation': 'Department of Nutrition, Faculty of Health Sciences, University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Ananda de Mesquita', 'Initials': 'AM', 'LastName': 'Araújo', 'Affiliation': 'Department of Nutrition, Faculty of Health Sciences, University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Marcela Moraes', 'Initials': 'MM', 'LastName': 'Mendes', 'Affiliation': 'Department of Nutrition, Faculty of Health Sciences, University of Brasília, Brasília, Brazil.'}, {'ForeName': 'Eduardo Yoshio', 'Initials': 'EY', 'LastName': 'Nakano', 'Affiliation': 'Statistics Department, University of Brasilia, Brasília, Brazil.'}]","Nutrition (Burbank, Los Angeles County, Calif.)",['10.1016/j.nut.2020.110890'] 2949,32738599,Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial.,"OBJECTIVES IRX-2 is a primary-cell-derived immune-restorative consisting of multiple human cytokines that act to overcome tumor-mediated immunosuppression and provide an in vivo tumor vaccination to increase tumor infiltrating lymphocytes (TILs). A randomized phase II trial was conducted of the IRX regimen 3 weeks prior to surgery consisting of an initial dose of cyclophosphamide followed by 10 days of regional perilymphatic IRX-2 cytokine injections and daily oral indomethacin, zinc and omeprazole (Regimen 1) compared to the identical regimen without IRX-2 cytokines (Regimen 2). METHODS A total of 96 patients with previously untreated, stage II-IV oral cavity SCC were randomized 2:1 to experimental (1) or control (2) regimens (64:32). Paired biopsy and resection specimens from 62 patients were available for creation of tissue microarray (n = 39), and multiplex immunohistology (n = 54). Increases in CD8+ TIL infiltrate scores of at least 10 cells/mm 2 were used to characterize immune responders (IR). RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2. In p16 negative cancers (n = 26), significant increases in CD8+ and overall TILs were evident in Regimen 1 (p = 0.004, and 0.04 respectively). IRs were more frequent in Regimen 1 (74% vs 31%, p = 0.01). Multiplex immunohistology for PD-L1 expression confirmed an increase in PD-L1 H score for Regimen 1 compared to Regimen 2 (p = 0.11). CONCLUSIONS The findings demonstrate significant increases in TILs after perilymphatic IRX-2 injections. Three quarters of patients showed significant immune responses to IRX-2. (NCT02609386).",2020,"RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2.","['96 patients with previously untreated, stage II-IV oral cavity SCC', 'oral squamous cell carcinoma']","['indomethacin, zinc and omeprazole', 'cyclophosphamide', 'neoadjuvant IRX-2 immunotherapy']","['PD-L1 H score', 'CD8+ TIL infiltrate scores', 'CD8+ infiltrates', 'CD8+ and overall TILs']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332155', 'cui_str': 'Did not receive therapy or drug for'}, {'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0585362', 'cui_str': 'Squamous cell carcinoma of mouth'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0007137', 'cui_str': 'Squamous cell carcinoma'}]","[{'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0028978', 'cui_str': 'Omeprazole'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0758290', 'cui_str': 'IRX 2'}, {'cui': 'C0005525', 'cui_str': 'Modifiers, Biological Response'}]","[{'cui': 'C0965245', 'cui_str': 'CD274 protein, human'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0079722', 'cui_str': 'Tumor-Infiltrating Lymphocytes'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",96.0,0.0184539,"RESULTS Regimen 1 was associated with significant increases in CD8+ infiltrates (p = 0.01) compared to Regimen 2.","[{'ForeName': 'Gregory T', 'Initials': 'GT', 'LastName': 'Wolf', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States. Electronic address: gregwolf@umich.edu.'}, {'ForeName': 'Siyu', 'Initials': 'S', 'LastName': 'Liu', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Emily', 'Initials': 'E', 'LastName': 'Bellile', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Maureen', 'Initials': 'M', 'LastName': 'Sartor', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Rozek', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Dafydd', 'Initials': 'D', 'LastName': 'Thomas', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Ariane', 'Initials': 'A', 'LastName': 'Nguyen', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Zarins', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': 'Jonathan B', 'Initials': 'JB', 'LastName': 'McHugh', 'Affiliation': 'Michigan Medicine, University of Michigan, Ann Arbor, MI 48109, United States.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Oral oncology,['10.1016/j.oraloncology.2020.104928'] 2950,32738662,"Reaching reliable change using short, daily, cognitive training exercises delivered on a mobile application: The case of Relationship Obsessive Compulsive Disorder (ROCD) symptoms and cognitions in a subclinical cohort.","BACKGROUND Relationship Obsessive Compulsive Disorder (ROCD) is a presentation of OCD centering on interpersonal relationships. The aim of this Randomized Control Trial (RCT) was to assess the efficacy of short, game like, daily cognitive interventions delivered via mobile application in reducing subclinical ROCD symptoms and associated phenomena. METHODS Fifty university students identified as having subclinical levels of ROCD symptoms (using the Structured Clinical Interview for DSM-5 Clinical Version) were randomized into: immediate-use group (iApp group; n = 25) and delayed-use group (dApp group; n = 25). The iApp group started using the evaluated cognitive-behavioral training application at baseline for 15 days (T0 to T1). The dApp group commenced using the application at T1 for 15 days (T1 to T2). All participants completed questionnaires at baseline (T0), 15 days from baseline (T1), and 30 days from baseline (T2). RESULTS Repeated measure MANOVAs showed significant Group (iApp vs. dApp) × Time (T0 vs. T1) interactions. These interactions indicated greater decrease in ROCD symptoms, OCD beliefs and social anxiety symptoms, as well as a greater increase in self-esteem in the iApp group compared to dApp group at T1. Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). LIMITATIONS Sample size and the use of self-report measures limits the generalizability of the results. CONCLUSIONS Short, daily cognitive training interventions delivered via mobile applications may be useful in reducing subclinical ROCD symptoms and associated features. Further testing is needed for clinical populations.",2020,"Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). ",['Fifty university students identified as having subclinical levels of ROCD symptoms (using the Structured Clinical Interview for DSM-5 Clinical Version'],"['immediate-use group (iApp group; n\xa0=\xa025) and delayed-use group (dApp group; n\xa0=\xa025', 'cognitive training exercises delivered on a mobile application']","['subclinical ROCD symptoms', 'Relationship Obsessive Compulsive Disorder (ROCD) symptoms and cognitions', 'ROCD symptoms, OCD beliefs and social anxiety symptoms', 'subclinical ROCD symptoms and associated phenomena', 'self-esteem', 'ROCD symptoms']","[{'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0199182', 'cui_str': 'History taking'}, {'cui': 'C1137105', 'cui_str': 'DSM-V'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C2607870', 'cui_str': 'Version'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate'}, {'cui': 'C0042153', 'cui_str': 'utilization'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0063684', 'cui_str': 'Amylin'}, {'cui': 'C0088932', 'cui_str': '1-(diethylaminopropyl)-4-phenylpiperazine'}, {'cui': 'C1868940', 'cui_str': 'Cognitive training'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C3658310', 'cui_str': 'Mobile Apps'}]","[{'cui': 'C0205211', 'cui_str': 'Subclinical'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0028768', 'cui_str': 'Obsessive-compulsive disorder'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0009595', 'cui_str': 'Obsessive compulsive personality disorder'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0424166', 'cui_str': 'Social fear'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0036597', 'cui_str': 'Self-esteem'}]",,0.0611703,"Moreover, the Reliable Change Index (RCI) indicated reliable change on ROCD symptoms for a significant portion of participants (42-52%). ","[{'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Cerea', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy. Electronic address: silvia.cerea@unipd.it.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Ghisi', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Gioia', 'Initials': 'G', 'LastName': 'Bottesi', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Carraro', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Broggio', 'Affiliation': 'Department of General Psychology, University of Padova, Via Venezia, 8, 35131 Padua, Italy.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Doron', 'Affiliation': 'Baruch Ivcher School of Psychology, Interdisciplinary Center Herzliya, PO Box 167, Herzliya 46150, Israel. Electronic address: gdoron@idc.ac.il.'}]",Journal of affective disorders,['10.1016/j.jad.2020.07.043'] 2951,32738817,Effect of Electroacupuncture in Pre- and Postmenopausal Women with Stress Urinary Incontinence.,"OBJECTIVE To evaluate the effect of electroacupuncture and assess the impact of menopausal status in women with stress urinary incontinence or stress predominant mixed urinary incontinence. METHODS This study was conducted as a subgroup analysis of the data collected from two multicenter, randomized controlled trials conducted on 1004 women; 384 of these subjects were pre- or postmenopausal women who received the same electroacupuncture treatment for stress urinary incontinence or stress-predominant mixed urinary incontinence. The primary outcome evaluated in this study was the proportion of subjects who had at least a 50% reduction in the mean 72-h incontinence episodes frequency from baseline and the difference between pre- and postmenopausal groups, as measured at the end of 6 weeks using the 72-h bladder dairy. RESULTS Among the 384 women, 132 were premenopausal and 252 were postmenopausal. Compared to baseline, measurement at the end of 6 weeks of treatment showed at least 50% reduction in the mean 72-h incontinence episodes frequency in 61.83% and 58.85% of the women in the premenopausal and postmenopausal groups, respectively (difference 1.06%, 95% confidence interval, -13.87 to 15.99; p=0.889). No statistically significant intergroup differences were noted in the changes from baseline in the International Consultation on Incontinence Questionnaire-Short Form score and the 1-h amount of urine leakage. Electroacupuncture-related adverse events occurred in 1.52% of the premenopausal and 1.59% of the postmenopausal women. CONCLUSION This subgroup analysis indicated that electroacupuncture can improve the symptoms of urinary incontinence in women with stress urinary incontinence or stress-predominant mixed urinary incontinence and that menopausal status may not affect the effects of electroacupuncture in subjects.",2020,No statistically significant intergroup differences were noted in the changes from baseline in the International Consultation on Incontinence Questionnaire-Short Form score and the 1-h amount of urine leakage.,"['women with stress urinary incontinence or stress predominant mixed urinary incontinence', '1004 women; 384 of these subjects were pre- or postmenopausal women who received the same', 'women with stress urinary incontinence or stress-predominant mixed urinary incontinence', 'Pre- and Postmenopausal Women with Stress Urinary Incontinence', '384 women, 132 were premenopausal and 252 were postmenopausal']","['electroacupuncture treatment', 'electroacupuncture', 'Electroacupuncture']","['symptoms of urinary incontinence', 'stress urinary incontinence or stress-predominant mixed urinary incontinence', 'International Consultation on Incontinence Questionnaire-Short Form score and the 1-h amount of urine leakage', 'mean 72-h incontinence episodes frequency', 'adverse events']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state'}, {'cui': 'C1096235', 'cui_str': 'Premenopausal symptoms'}]","[{'cui': 'C0013794', 'cui_str': 'Electroacupuncture'}, {'cui': 'C0039798', 'cui_str': 'therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0042024', 'cui_str': 'Urinary incontinence'}, {'cui': 'C0042025', 'cui_str': 'Genuine stress incontinence'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C0205430', 'cui_str': 'Mixed'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0700308', 'cui_str': 'Protium'}, {'cui': 'C0152245', 'cui_str': 'Extravasation of urine'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0015732', 'cui_str': 'Incontinence of feces'}, {'cui': 'C0332189', 'cui_str': 'Episode of'}, {'cui': 'C0237630', 'cui_str': 'Stimulus frequency'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",1004.0,0.15483,No statistically significant intergroup differences were noted in the changes from baseline in the International Consultation on Incontinence Questionnaire-Short Form score and the 1-h amount of urine leakage.,"[{'ForeName': 'Zhiyi', 'Initials': 'Z', 'LastName': 'Xiong', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Key Laboratory of Chinese Internal Medicine of Ministry of Education, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.'}, {'ForeName': 'Tongsheng', 'Initials': 'T', 'LastName': 'Su', 'Affiliation': ""Shanxi Province Hospital of Traditional Chinese Medicine, Xi 'an, Shanxi Province, China.""}, {'ForeName': 'Zhishun', 'Initials': 'Z', 'LastName': 'Liu', 'Affiliation': ""Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.""}]",International journal of clinical practice,['10.1111/ijcp.13631'] 2952,32736660,Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.,"BACKGROUND Office-based buprenorphine treatment of opioid use disorder (OUD) does not typically include in-person directly observed therapy (DOT), potentially leading to non-adherence. Video DOT technologies may safeguard against this issue and thus enhance likelihood of treatment success. We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. METHODS Participants will be recruited from office-based opioid addiction treatment programs in outpatient clinics at two urban medical centers and randomized to either video DOT (intervention) delivered via a HIPAA-compliant, asynchronous, mobile health (mHealth) technology platform, or treatment-as-usual (control). Eligibility criteria are: 18 years or older, prescribed sublingual buprenorphine for a cumulative total of 28 days or less from the office-based opioid treatment program, and able to read and understand English. Patients will be considered ineligible if they are unable or unwilling to use the intervention, provide consent, or complete weekly study visits. All participants will complete 13 in-person weekly visits and be followed via electronic health record data capture at 12- and 24-weeks post-randomization. Data gathered include the following: demographics; current and previous treatment for OUD; self-reported diversion of prescribed buprenorphine; status of their mental and physical health; and self-reported lifetime and past 30-day illicit substance use. Participants provide urine samples at each weekly visit to test for illicit drugs and buprenorphine. The primary outcome is percentage of weekly urines that are negative for opioids over the 12-weeks. The secondary outcome is engagement in treatment at week 12. DISCUSSION Video DOT delivered through mHealth technology platform offers possibility of improving patients' buprenorphine adherence by providing additional structure and accountability. The TAAB study will provide important preliminary estimates of the impact of this mHealth technology for patients initiating buprenorphine, as well as the feasibility of study procedures, thus paving the way for further research to assess feasibility and generate preliminary data for design of a future Phase III trial. Trial Registration ClinicalTrails.gov, NCT03779997, Registered on December 19, 2018.",2020,"We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. ","['patients initiating', 'Participants will be recruited from office-based opioid addiction treatment programs in outpatient clinics at two urban medical centers and randomized to either', 'for a cumulative total of 28\xa0days or less from the office-based opioid treatment program, and able to read and understand English', 'Eligibility criteria are: 18\xa0years or older, prescribed', 'opioid use disorder patients receiving office-based']","['Video directly observed therapy intervention', 'sublingual buprenorphine', 'video DOT (intervention) delivered via a HIPAA-compliant, asynchronous, mobile health (mHealth) technology platform, or treatment-as-usual (control', 'buprenorphine', 'Buprenorphine', 'video DOT delivered via a smartphone app']",['percentage of weekly urines that are negative for opioids'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0442603', 'cui_str': 'Office'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0524662', 'cui_str': 'Opioid dependence'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0442529', 'cui_str': 'Urban environment'}, {'cui': 'C0565990', 'cui_str': 'Medical center'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}, {'cui': 'C0586740', 'cui_str': 'Able to read'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C0376245', 'cui_str': 'English language'}, {'cui': 'C0013893', 'cui_str': 'Eligibility Determination'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C2239117', 'cui_str': 'Prescription of drug'}, {'cui': 'C4324621', 'cui_str': 'Opioid use disorder'}]","[{'cui': 'C0042655', 'cui_str': 'Video'}, {'cui': 'C0872145', 'cui_str': 'Directly Observed Therapy'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0600593', 'cui_str': 'Public Law 104-191'}, {'cui': 'C0566588', 'cui_str': 'Compliant'}, {'cui': 'C0439581', 'cui_str': 'Asynchronous'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}]","[{'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0042036', 'cui_str': 'Urine'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C0002772', 'cui_str': 'OPIOIDS'}]",,0.149029,"We describe the rationale and protocol for the Trial of Adherence Application for Buprenorphine treatment (TAAB) study, a pilot randomized controlled trial (RCT) to evaluate the effects of video DOT delivered via a smartphone app on office-based buprenorphine treatment outcomes, namely illicit opioid use and retention. ","[{'ForeName': 'Zachery A', 'Initials': 'ZA', 'LastName': 'Schramm', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Brian G', 'Initials': 'BG', 'LastName': 'Leroux', 'Affiliation': 'Department of Biostatistics, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Andrea C', 'Initials': 'AC', 'LastName': 'Radick', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Alicia S', 'Initials': 'AS', 'LastName': 'Ventura', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Jared W', 'Initials': 'JW', 'LastName': 'Klein', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA.'}, {'ForeName': 'Jeffrey H', 'Initials': 'JH', 'LastName': 'Samet', 'Affiliation': 'Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Saxon', 'Affiliation': 'Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System, Seattle, WA, USA.'}, {'ForeName': 'Theresa W', 'Initials': 'TW', 'LastName': 'Kim', 'Affiliation': 'Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Judith I', 'Initials': 'JI', 'LastName': 'Tsui', 'Affiliation': 'Division of General Internal Medicine, Department of Medicine, University of Washington, Mailbox 359780, 325 Ninth Avenue, Seattle, WA, 98104, USA. tsuij@uw.edu.'}]",Addiction science & clinical practice,['10.1186/s13722-020-00203-9'] 2953,32736776,Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study.,"BACKGROUND The mechanisms surrounding cancer-associated venous thromboembolism (VTE) are not well characterized. AVERT, a randomized placebo controlled thromboprophylaxis study in ambulatory cancer patients, provides a unique opportunity to gain insights into thrombotic mechanism(s). METHODS All available citrated platelet-free plasma samples collected at the point of randomization from individuals enrolled in the AVERT study were evaluated for the expression of D-dimer, soluble P-selectin (sP- selectin), active plasminogen activator inhibitor 1 (aPAI-1), clot lysis time (CLT) and activated factor XIa-C1 inhibitor complex (FXIa-C1). We compared the differential expression of sP-selectin, aPAI-1, CLT and FXIa-C1 among individual tumor types with normal controls. We evaluated the impact of disease type (hematologic versus solid organ malignancy) and stage (metastatic versus non-metastatic) on individual biomarker expression. RESULTS We included 449 AVERT participants in this analysis. Baseline expression of the selected thrombosis biomarkers differed significantly by individual tumor type compared with normal controls. Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05). Individuals with metastatic solid organ disease had elevated levels of D-dimer and sP-selectin compared to those with non-metastatic disease (p<0.05). CONCLUSION Among a cohort of ambulatory patients at intermediate to high risk of VTE, these exploratory findings suggest that baseline activation of coagulation and fibrinolysis pathways vary significantly by tumor type and disease stage.",2020,"Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05).","['449 AVERT participants in this analysis', 'All available citrated platelet-free plasma samples collected at the point of randomization from individuals enrolled in the AVERT study', 'ambulatory cancer patients', 'cancer patients at risk for venous thromboembolism', 'Individuals with metastatic solid organ disease']","['VTE', 'placebo']","['Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin', 'expression of D-dimer, soluble P-selectin (sP- selectin), active plasminogen activator inhibitor 1 (aPAI-1), clot lysis time (CLT) and activated factor XIa-C1 inhibitor complex (FXIa-C1', 'Baseline expression of the selected thrombosis biomarkers']","[{'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0470187', 'cui_str': 'Availability of'}, {'cui': 'C0008857', 'cui_str': 'Citrates'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0002424', 'cui_str': 'Ambulatory care site'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0036525', 'cui_str': 'Metastatic to'}, {'cui': 'C0440790', 'cui_str': 'Solid organ'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1861172', 'cui_str': 'Thromboembolism, Venous'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0066198', 'cui_str': 'methyl 4-azidophenylacetimidate'}, {'cui': 'C0282651', 'cui_str': 'Selectins'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0134835', 'cui_str': 'Lymphocyte antigen CD62'}, {'cui': 'C0205177', 'cui_str': 'Active'}, {'cui': 'C0030190', 'cui_str': 'Plasminogen activator inhibitor-1'}, {'cui': 'C0200464', 'cui_str': 'Fibrinolysin assay, screening'}, {'cui': 'C0015524', 'cui_str': 'Coagulation factor XIa'}, {'cui': 'C1446194', 'cui_str': 'Serum C1 esterase inhibitor antigen level'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}]",449.0,0.0336838,"Levels of aPAI-1, CLT, FXIa-C1 and sP-selectin were significantly elevated in individuals with lymphoma compared to individuals with non-metastatic solid organ malignancies (p<0.05).","[{'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Ilich', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; These authors contributed equally.'}, {'ForeName': 'Vaibhav', 'Initials': 'V', 'LastName': 'Kumar', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; These authors contributed equally.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Henderson', 'Affiliation': 'Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.'}, {'ForeName': 'Ranjeeta', 'Initials': 'R', 'LastName': 'Mallick', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Philip', 'Initials': 'P', 'LastName': 'Wells', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Carrier', 'Affiliation': 'Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Canada.'}, {'ForeName': 'Nigel S', 'Initials': 'NS', 'LastName': 'Key', 'Affiliation': 'Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA. Electronic address: nigel_key@med.unc.edu.'}]",Thrombosis research,['10.1016/S0049-3848(20)30394-7'] 2954,32736882,"Letter to the Editor: ""Comparison of virtual reality rehabilitation and conventional rehabilitation in Parkinson's disease: a randomised controlled trial"".",,2020,,"[""Parkinson's disease""]",['virtual reality rehabilitation and conventional rehabilitation'],[],"[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0007237', 'cui_str': 'Care involving use of rehabilitation procedure, unspecified'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}]",[],,0.0815069,,"[{'ForeName': 'Fatih', 'Initials': 'F', 'LastName': 'Özden', 'Affiliation': 'Muğla Sıtkı Koçman University, Köyceğiz Vocational School of Health Services, Elderly, Care Department, Turkey. Electronic address: fatihozden@mu.edu.tr.'}]",Physiotherapy,['10.1016/j.physio.2020.04.001'] 2955,32737003,Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.,"BACKGROUND The multicenter, single-arm, phase II study CEBIFOX evaluated the efficacy of a biweekly cetuximab administration in combination with FOLFOX6 as first-line therapy in KRAS (exon 2) wild-type (wt) metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients received FOLFOX6 with cetuximab (500 mg/m 2 ) every second week. Primary endpoint was objective response rate (ORR), among others secondary endpoints were safety, progression-free survival (PFS), overall survival (OS), and patient-reported outcome (PRO). The impact on the treatment efficacy was evaluated in explorative subgroup analyses, including extended molecular profiling and primary tumor location. RESULTS In total, 57 were included in the intention-to-treat (ITT) analyses. New RAS mutations were detected in 14.0% by post hoc next-generation sequencing analysis in 43 patients. The ORR in the all RASwt population was 70.3% with a median PFS and OS of 10.9 (95% confidence interval [CI], 9.0-12.9) and 33.8 (95% CI, 21.1-45.5) months. Grade 3-5 adverse events occurred in 66.7% of the ITT, without significant impact on the PRO. Patients with right-sided primary tumors had a reduced ORR (54.5%), and median PFS and OS (10.1 and 23.8 months). BRAF mutations were detected in 11.3%. These patients had a significantly lower ORR, and median PFS and OS. Patients with RASwt/BRAFwt tumors had a notably high median PFS and OS of 14.3 and 38.9 months. CONCLUSIONS This study supports the efficacy and safety of biweekly cetuximab given in combination with FOLFOX6 in patients with RASwt/BRAFwt mCRC with left-sided primary tumor. CEBIFOX is the first trial reporting the complete dataset, including extended molecular profiling and tumor location of a biweekly administered cetuximab/FOLFOX6 in mCRC. Clinical trial number: NCT01051167.",2020,"Grade 3-5 adverse events occurred in 66.7% of the ITT, without significant impact on the PRO.","['Patients with RASwt', 'With RAS Wild-Type Metastatic Colorectal Cancer', 'Patients', 'patients with RASwt/BRAFwt mCRC with left-sided primary tumor', 'exon 2) wild-type (wt) metastatic colorectal cancer (mCRC', '43 patients']","['Biweekly Cetuximab Plus FOLFOX6', 'FOLFOX6 with cetuximab', 'cetuximab', 'KRAS']","['objective response rate (ORR', 'ORR, and median PFS and OS', 'reduced ORR', 'efficacy and safety', 'PRO', 'safety, progression-free survival (PFS), overall survival (OS), and patient-reported outcome (PRO', 'median PFS and OS', 'BRAF mutations', 'Grade 3-5 adverse events']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0445392', 'cui_str': 'Wild'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0205091', 'cui_str': 'Left'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0015295', 'cui_str': 'Exons'}]","[{'cui': 'C0585332', 'cui_str': 'Biweekly'}, {'cui': 'C0995188', 'cui_str': 'cetuximab'}, {'cui': 'C0332287', 'cui_str': 'With'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0392756', 'cui_str': 'Reduced'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2987124', 'cui_str': 'Patient Reported Outcome'}, {'cui': 'C1259929', 'cui_str': 'BRAF protein, human'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.124934,"Grade 3-5 adverse events occurred in 66.7% of the ITT, without significant impact on the PRO.","[{'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Kasper', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany. Electronic address: stefan.kasper-virchow@uk-essen.de.'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Meiler', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Heike', 'Initials': 'H', 'LastName': 'Knipp', 'Affiliation': 'Department of Medicine I, Alfried Krupp von Bohlen and Halbach Hospital, Essen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Höhler', 'Affiliation': 'Department of Medicine I, Prosper Hospital, Recklinghausen, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Reimer', 'Affiliation': 'Department of Hematology and Medical Oncology, Protestant Hospital, Essen-Werden, Germany.'}, {'ForeName': 'Tilman', 'Initials': 'T', 'LastName': 'Steinmetz', 'Affiliation': 'Group Practice Hematology/Oncology, Köln, Germany.'}, {'ForeName': 'Winfried', 'Initials': 'W', 'LastName': 'Berger', 'Affiliation': 'Department of Hematology, and Medical Oncology, Catholic Hospital, Essen, Germany.'}, {'ForeName': 'Gabriele', 'Initials': 'G', 'LastName': 'Linden', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Henning', 'Initials': 'H', 'LastName': 'Reis', 'Affiliation': 'Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Markus', 'Affiliation': 'Department of General, Visceral and Trauma Surgery, Elisabeth Hospital, Essen, Germany.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Paul', 'Affiliation': 'German Cancer Consortium (DKTK), Heidelberg, Germany; West German Cancer Centre, Department of General, Visceral and Transplantation Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Dechêne', 'Affiliation': 'West German Cancer Centre, Department of Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Schumacher', 'Affiliation': 'Department of Gastroenterology, Elisabeth Hospital, Essen, Germany.'}, {'ForeName': 'Karina', 'Initials': 'K', 'LastName': 'Kostbade', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Virchow', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Saskia', 'Initials': 'S', 'LastName': 'Ting', 'Affiliation': 'Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Karl', 'Initials': 'K', 'LastName': 'Worm', 'Affiliation': 'Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Kurt W', 'Initials': 'KW', 'LastName': 'Schmid', 'Affiliation': 'German Cancer Consortium (DKTK), Heidelberg, Germany; Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Herold', 'Affiliation': 'Institute of Pathology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Wiesweg', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Schuler', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Trarbach', 'Affiliation': 'Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.'}]",Clinical colorectal cancer,['10.1016/j.clcc.2020.03.003'] 2956,32737004,"Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).","BACKGROUND No treatment option was available for patients with RAS-mutated (RASmt) metastatic colorectal cancer (mCRC) who progress after standard combined chemotherapies at the time of the study. After promising results in phase II, the aim of the present NEXIRI-2/PRODIGE 27 trial was to assess the 2-month non-progression rate for sorafenib (NEX) plus irinotecan (IRI), that is, NEXIRI, treatment. METHODS Patients with RASmt mCRC after failure of oxaliplatin, IRI, fluoropyrimidines, and bevacizumab were randomized between NEXIRI (IRI 120-180 mg/m 2 intravenous, D1 = D15 plus oral NEX 400 mg twice a day) versus IRI (180 mg/m 2 ) versus NEX. Primary endpoint was the 2-month non-progression rate. Secondary endpoints included progression-free and overall survival (PFS and OS), safety, and germline cyclin D1 (CCND1) rs9344 polymorphisms analyses. RESULTS A total of 173 patients were included, 59 in NEXIRI, 57 in IRI, and 57 in NEX arms. The 2-month non-progression rate was 52.6% (95% confidence interval [CI]: 39%-66%), 21.4% (10%-33%), and 19.3% (9%-30%) for NEXIRI, IRI, and NEX. Median PFS was 3.6 (95% CI: 2-4.2), 1.7 (1.7-1.8), and 2 (1.8-2.3) months and the median OS was 7.2 (5.8-9.4), 6.3 (4.8-8), and 5.6 (3.9-7.7) months for NEXIRI, IRI, and NEX, respectively. For NEXIRI rs9344CCND1 A/A genotype patients, OS was 19.6 months (95% CI: 4.8-not reached). Main grade 3 toxicities included neutropenia, febrile neutropenia, diarrhea, hand-foot syndrome, and hypertension. CONCLUSIONS In patients with RASmt mCRC who progressed after standard combined chemotherapies, the results of 2-month non-progression rate and median PFS in the NEXIRI arm were in favor of an increase of the time before progression.",2020,"For NEXIRI rs9344CCND1 A/A genotype patients, OS was 19.6 months (95% CI: 4.8-not reached).","['A total of 173 patients were included, 59 in NEXIRI, 57 in IRI, and 57 in NEX arms', 'Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies', 'patients with RAS-mutated (RASmt) metastatic colorectal cancer (mCRC', 'Patients with RASmt mCRC after failure of oxaliplatin, IRI, fluoropyrimidines, and']","['NEXIRI (IRI 120-180 mg/m 2 intravenous, D1\xa0= D15 plus oral NEX 400 mg twice a day) versus IRI', 'NEX', 'sorafenib (NEX) plus irinotecan (IRI', 'Sorafenib Plus Irinotecan Combination', 'bevacizumab']","['2-month non-progression rate', 'progression-free and overall survival (PFS and OS), safety, and germline cyclin D1 (CCND1) rs9344 polymorphisms analyses', 'Median PFS', 'median OS', 'Main grade 3 toxicities included neutropenia, febrile neutropenia, diarrhea, hand-foot syndrome, and hypertension', '2-month non-progression rate and median PFS']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C0003798', 'cui_str': 'Armenia'}, {'cui': 'C4721579', 'cui_str': 'Secondary malignant neoplasm of colon and/or rectum'}, {'cui': 'C0205269', 'cui_str': 'Intractable'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0231174', 'cui_str': 'Failure'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}]","[{'cui': 'C0123931', 'cui_str': 'irinotecan'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0348016', 'cui_str': 'Intravenous'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C3816746', 'cui_str': '400'}, {'cui': 'C0585361', 'cui_str': 'Twice a day'}, {'cui': 'C1516119', 'cui_str': 'sorafenib'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0174680', 'cui_str': 'bcl-1 Proto-Oncogene Proteins'}, {'cui': 'C0032529', 'cui_str': 'Genetic polymorphism'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0475271', 'cui_str': 'G3 grade'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0027947', 'cui_str': 'Neutropenic disorder'}, {'cui': 'C0746883', 'cui_str': 'Febrile neutropenia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0549410', 'cui_str': 'Palmar-plantar erythrodysaesthesia syndrome'}, {'cui': 'C0020538', 'cui_str': 'Hypertensive disorder'}]",173.0,0.152104,"For NEXIRI rs9344CCND1 A/A genotype patients, OS was 19.6 months (95% CI: 4.8-not reached).","[{'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Samalin', 'Affiliation': 'Medical Oncology Departement, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France; IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France. Electronic address: emmanuelle.samalin@icm.unicancer.fr.'}, {'ForeName': 'Christelle de la', 'Initials': 'C', 'LastName': 'Fouchardière', 'Affiliation': 'Medical Oncology Departement, Centre Léon Bérard, Lyon, France.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Thézenas', 'Affiliation': 'Biometrics Unit, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Boige', 'Affiliation': 'Medical Oncology Departement, Gustave Roussy, Villejuif, France.'}, {'ForeName': 'Hélène', 'Initials': 'H', 'LastName': 'Senellart', 'Affiliation': ""Medical Oncology Departement, Institut de Cancérologie de l'Ouest René Gauducheau, Saint Herblain, France.""}, {'ForeName': 'Rosine', 'Initials': 'R', 'LastName': 'Guimbaud', 'Affiliation': 'Medical Oncology Department, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.'}, {'ForeName': 'Julien', 'Initials': 'J', 'LastName': 'Taïeb', 'Affiliation': 'Medical Oncology Departement, Sorbonne Paris Cité, Siric Carpem, Université Paris Descartes, AP-HP, HEGP, Paris, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'François', 'Affiliation': 'Medical Oncology Departement, Centre Antoine Lacassagne, Nice, France.'}, {'ForeName': 'Marie-Pierre', 'Initials': 'MP', 'LastName': 'Galais', 'Affiliation': 'Medical Oncology Departement, Centre François Baclesse, Caen, France.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Lièvre', 'Affiliation': 'Medical Oncology Departement, Institut Curie, Saint Cloud, France.'}, {'ForeName': 'Jean-François', 'Initials': 'JF', 'LastName': 'Seitz', 'Affiliation': 'Medical Oncology Departement, Hôpital de La Timone, AP-HM, Marseille, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Metges', 'Affiliation': 'Medical Oncology Departement, Centre Hospitalier Universitaire de Brest, Brest, France.'}, {'ForeName': 'Olivier', 'Initials': 'O', 'LastName': 'Bouché', 'Affiliation': 'Medical Oncology Departement, Centre Hospitalier Universitaire de Reims, Reims, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Boissière-Michot', 'Affiliation': 'Translational Research Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.'}, {'ForeName': 'Evelyne', 'Initials': 'E', 'LastName': 'Lopez-Crapez', 'Affiliation': 'Translational Research Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France; Institut régional du Cancer de Montpellier (IRCM), INSERM, Univ. Montpellier, ICM, Montpellier.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Bibeau', 'Affiliation': 'Institut régional du Cancer de Montpellier (IRCM), INSERM, Univ. Montpellier, ICM, Montpellier; Pathology Department, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Ho-Pun-Cheung', 'Affiliation': 'Translational Research Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France; Institut régional du Cancer de Montpellier (IRCM), INSERM, Univ. Montpellier, ICM, Montpellier.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Ychou', 'Affiliation': 'Medical Oncology Departement, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France; Translational Research Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Adenis', 'Affiliation': 'Medical Oncology Departement, Centre Oscar Lambret, Lille, France.'}, {'ForeName': 'Frédéric', 'Initials': 'F', 'LastName': 'Di Fiore', 'Affiliation': 'Digestive Oncology Unit, Department of Hepatogastroenterology, Rouen University Hospital, Rouen, France.'}, {'ForeName': 'Thibault', 'Initials': 'T', 'LastName': 'Mazard', 'Affiliation': 'Medical Oncology Departement, Institut du Cancer de Montpellier (ICM), Univ. Montpellier, Montpellier, France; Institut régional du Cancer de Montpellier (IRCM), INSERM, Univ. Montpellier, ICM, Montpellier.'}]",Clinical colorectal cancer,['10.1016/j.clcc.2020.04.008'] 2957,32737072,Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.,"OBJECTIVE To better understand ozanimod's mechanism of action (MOA), we conducted exploratory analyses from a phase 1 study to characterize ozanimod's effect on circulating leukocyte subsets in patients with relapsing multiple sclerosis. METHODS An open-label pharmacodynamic study randomized patients to oral ozanimod hydrochloride (HCl) 0.5 (n = 13) or 1 mg/d (n = 11) for ∼12 weeks (including 7-day dose escalation). Circulating leukocyte subsets were quantified using flow cytometry (days 28, 56, and 85) and epigenetic cell counting (days 2, 5, 28, 56, and 85) and compared with baseline (day 1) using descriptive statistics. RESULTS Ozanimod caused dose-dependent reductions in absolute lymphocyte counts. Observed by both methodologies, circulating CD19 + B- and CD3 + T-cell counts were reduced by >50% with ozanimod HCl 0.5 mg and >75% with 1 mg at day 85. Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85. In the flow cytometry analysis, changes in monocytes, natural killer, and natural killer T cells were minimal. Using epigenetic cell counting, greater reductions for Th17 than T regulatory cells were determined. CONCLUSION Ozanimod induced dose-dependent reductions in circulating B- and T-cell counts and differential effects on naive and memory CD4 + and CD8 + T cells and CD19 + B cells. Data characterized with both a novel epigenetic cell-counting method and flow cytometry support ozanimod's MOA. CLINICAL TRIAL REGISTRATION clinicaltrials.gov NCT02797015.",2020,"Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85.","['patients with relapsing multiple sclerosis', 'relapsing MS']","['sphingosine-1-phosphate receptor modulator ozanimod', 'ozanimod HCl', 'oral ozanimod hydrochloride (HCl']","['circulating CD19 + B- and CD3 + T-cell counts', 'Circulating leukocyte subsets', 'absolute lymphocyte counts', 'circulating B- and T-cell counts and differential effects on naive and memory CD4 + and CD8 + T cells and CD19 + B cells', 'CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells', 'changes in monocytes, natural killer, and natural killer T cells']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0856120', 'cui_str': 'Multiple sclerosis relapse'}, {'cui': 'C0035020', 'cui_str': 'Relapse phase'}]","[{'cui': 'C4760638', 'cui_str': 'Sphingosine Receptor Modulators'}, {'cui': 'C4278675', 'cui_str': 'ozanimod'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}]","[{'cui': 'C0175630', 'cui_str': 'Circulating'}, {'cui': 'C0108748', 'cui_str': 'Lymphocyte antigen CD19'}, {'cui': 'C1277786', 'cui_str': 'CD3 T-cell count procedure'}, {'cui': 'C0023508', 'cui_str': 'White blood cell count'}, {'cui': 'C3544087', 'cui_str': 'Absolute lymphocyte count'}, {'cui': 'C0039194', 'cui_str': 'T lymphocyte'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0443199', 'cui_str': 'Differential'}, {'cui': 'C1280500', 'cui_str': 'Effect'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}, {'cui': 'C0003323', 'cui_str': 'Lymphocyte antigen CD4'}, {'cui': 'C0242629', 'cui_str': 'Lymphocyte positive for CD8 antigen'}, {'cui': 'C0004561', 'cui_str': 'B lymphocyte'}, {'cui': 'C0085358', 'cui_str': 'Lymphocyte antigen CD8'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C4543203', 'cui_str': 'Effector'}, {'cui': 'C0301630', 'cui_str': 'Reduction (chemical)'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0392747', 'cui_str': 'Changing'}, {'cui': 'C0026473', 'cui_str': 'Monocyte'}, {'cui': 'C0205296', 'cui_str': 'Natural'}, {'cui': 'C2350466', 'cui_str': 'Natural Killer T-Cell'}]",,0.0568721,"Based on flow cytometry, ozanimod HCl 1 mg showed greater decreases in CD4 + than CD8 + T cells, greater decreases in both CD4 + and CD8 + central memory vs effector memory T cells, and reductions in mean CD4 + and CD8 + naive T cells by ≥90% at day 85.","[{'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Harris', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF). sarah.harris@bms.com.'}, {'ForeName': 'Jonathan Q', 'Initials': 'JQ', 'LastName': 'Tran', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Harry', 'Initials': 'H', 'LastName': 'Southworth', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Collin M', 'Initials': 'CM', 'LastName': 'Spencer', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Bruce A C', 'Initials': 'BAC', 'LastName': 'Cree', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}, {'ForeName': 'Scott S', 'Initials': 'SS', 'LastName': 'Zamvil', 'Affiliation': 'From Bristol-Myers Squibb Company (S.H., J.Q.T.), Princeton, NJ; Data Clarity Consulting Ltd. (H.S.), Stockport, England, United Kingdom; and Department of Neurology, Weill Institute for Neurosciences (C.M.S., B.A.C.C., S.S.Z.), and Program in Immunology (C.M.S., S.S.Z.), University of California San Francisco (UCSF).'}]",Neurology(R) neuroimmunology & neuroinflammation,['10.1212/NXI.0000000000000839'] 2958,32737087,"Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.","INTRODUCTION Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. METHODS AND ANALYSIS The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32 mg of sublingual buprenorphine (±naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing substudies will examine implementation barriers and facilitators at the client and provider level. ETHICS AND DISSEMINATION The study has received ethics approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national and international scientific conferences, and in relevant community organisation publications and forums. TRIAL REGISTRATION NUMBER NCT03809143 PROTOCOL IDENTIFIER: CoLAB1801, V.4.0 dated 01 August 2019.",2020,"The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. ","['people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia', 'Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia', 'people with opioid dependence']","['depot buprenorphine', 'Buprenorphine (CoLAB', 'subcutaneous BUP-XR injections', 'BUP-XR injections', 'sublingual buprenorphine (±naloxone']","['participant retention', 'dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0524662', 'cui_str': 'Opioid dependence'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332128', 'cui_str': 'Examined for'}, {'cui': 'C0086034', 'cui_str': 'Community Healthcare'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0017319', 'cui_str': 'General physician'}, {'cui': 'C0087009', 'cui_str': 'Hospital specialist'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}, {'cui': 'C0557854', 'cui_str': 'Services'}, {'cui': 'C0332285', 'cui_str': 'In'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0043015', 'cui_str': 'Wales'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0037715', 'cui_str': 'South Australia'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0079613', 'cui_str': 'Adoptive Immunotherapy'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}, {'cui': 'C0001565', 'cui_str': 'Sublingual route'}]","[{'cui': 'C0035280', 'cui_str': 'Retention (Psychology)'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0035008', 'cui_str': 'Reinforcement Schedule'}, {'cui': 'C0042333', 'cui_str': 'Genetic variation'}, {'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0152128', 'cui_str': 'Drug withdrawal'}, {'cui': 'C0237123', 'cui_str': 'Substance use'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0023672', 'cui_str': 'Life Experiences'}]",,0.105725,"The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. ","[{'ForeName': 'Briony', 'Initials': 'B', 'LastName': 'Larance', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Byrne', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Lintzeris', 'Affiliation': 'Discipline of Addiction Medicine, University of Sydney, Surry Hills, New South Wales, Australia.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Nielsen', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jason', 'Initials': 'J', 'LastName': 'Grebely', 'Affiliation': 'The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Louisa', 'Initials': 'L', 'LastName': 'Degenhardt', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Jeyran', 'Initials': 'J', 'LastName': 'Shahbazi', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Shanahan', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Kari', 'Initials': 'K', 'LastName': 'Lancaster', 'Affiliation': 'Centre for Social Research in Health, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Dore', 'Affiliation': 'The Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Ali', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Farrell', 'Affiliation': 'National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, New South Wales, Australia michael.farrell@unsw.edu.au.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",BMJ open,['10.1136/bmjopen-2019-034389'] 2959,32737263,Transradial Crossover Balloon Occlusion Technique for Primary Access Hemostasis During Transcatheter Aortic Valve Replacement: Initial Experience With the Oceanus 140 cm and 200 cm Balloon Catheters.,"OBJECTIVES The crossover balloon occlusion technique (CBOT) facilitates primary access hemostasis in patients undergoing transfemoral transcatheter aortic valve replacement (TAVR). The CBOT is usually performed through the contralateral femoral artery. The aim of this study was to evaluate, in patients undergoing TAVR, the safety and feasibility of transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular). METHODS This multicenter study included 104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR. A modified CBOT through the radial artery was performed in all patients with the Oceanus balloon catheter. Data regarding transradial CBOT, balloon performance, vascular complications, and 30-day clinical events were recorded. RESULTS Up to 21% of patients had a height >170 cm and 17% presented with severe aortic/iliofemoral tortuosity. The transradial CBOT (left radial 74%, right radial 26%) was performed using either the 140 cm Oceanus (37.5%) or the 200 cm Oceanus (62.5%) balloon catheter. The balloon reached the femoral artery in all patients, and balloon inflation achieved an appropriate vessel closure in 98%. There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access. The 30-day rates of primary access major vascular complications and death were 3.8% and 1.9%, respectively. CONCLUSION In patients undergoing transfemoral TAVR, transradial CBOT with the Oceanus balloon dilatation catheter was feasible and safe. A balloon length up to 200 cm allowed the use of this technique (from right or left radial access) in all patients regardless of patient height or the presence of a challenging vascular anatomy.",2020,"There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access.","['104 patients (mean age, 81 ± 7 years; 43% women) undergoing transfemoral TAVR', 'patients undergoing', 'patients undergoing transfemoral transcatheter aortic valve replacement (TAVR', 'patients with the Oceanus balloon catheter']","['transradial CBOT using the new Oceanus balloon dilatation catheter (iVascular', 'Transcatheter Aortic Valve Replacement', 'Transradial Crossover Balloon Occlusion Technique', 'TAVR', 'crossover balloon occlusion technique (CBOT']","['30-day rates of primary access major vascular complications and death', 'transradial CBOT, balloon performance, vascular complications, and 30-day clinical events', 'transradial CBOT', 'severe aortic/iliofemoral tortuosity']","[{'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter'}]","[{'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C0441127', 'cui_str': 'Balloon dilatation catheter'}, {'cui': 'C2711836', 'cui_str': 'Percutaneous replacement of aortic valve using fluoroscopic guidance'}]","[{'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0444454', 'cui_str': 'Access'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0005847', 'cui_str': 'Blood vessel structure'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C0887842', 'cui_str': 'Balloon Occlusion'}, {'cui': 'C0025664', 'cui_str': 'methods'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0441471', 'cui_str': 'Event'}, {'cui': 'C0003483', 'cui_str': 'Aortic'}, {'cui': 'C0333076', 'cui_str': 'Tortuosity'}]",104.0,0.101355,"There were no complications related to the balloon catheter, and only 1 patient (1.0%) suffered a minor vascular complication related to the secondary radial access.","[{'ForeName': 'Lucía', 'Initials': 'L', 'LastName': 'Junquera', 'Affiliation': ''}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Vilalta', 'Affiliation': ''}, {'ForeName': 'Ramiro', 'Initials': 'R', 'LastName': 'Trillo', 'Affiliation': ''}, {'ForeName': 'Manel', 'Initials': 'M', 'LastName': 'Sabaté', 'Affiliation': ''}, {'ForeName': 'Azeem', 'Initials': 'A', 'LastName': 'Latib', 'Affiliation': ''}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Nombela-Franco', 'Affiliation': ''}, {'ForeName': 'César', 'Initials': 'C', 'LastName': 'Moris', 'Affiliation': ''}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Garcia Del Blanco', 'Affiliation': ''}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'Larman', 'Affiliation': ''}, {'ForeName': 'José Maria', 'Initials': 'JM', 'LastName': 'Hernandez', 'Affiliation': ''}, {'ForeName': 'Andres', 'Initials': 'A', 'LastName': 'Iñiguez', 'Affiliation': ''}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Amat-Santos', 'Affiliation': ''}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Fernandez-Nofrerias', 'Affiliation': ''}, {'ForeName': 'Ander', 'Initials': 'A', 'LastName': 'Regueiro', 'Affiliation': ''}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Colombo', 'Affiliation': ''}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Tzanis', 'Affiliation': ''}, {'ForeName': 'Pilar', 'Initials': 'P', 'LastName': 'Jiménez-Quevedo', 'Affiliation': ''}, {'ForeName': 'Isabel', 'Initials': 'I', 'LastName': 'Pérez-Serranos', 'Affiliation': ''}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Duran-Priu', 'Affiliation': ''}, {'ForeName': 'Lluis', 'Initials': 'L', 'LastName': 'Duocastella', 'Affiliation': ''}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Paradis', 'Affiliation': ''}, {'ForeName': 'Josep', 'Initials': 'J', 'LastName': 'Rodés Cabau', 'Affiliation': 'Quebec Heart & Lung Institute, Laval University 2725 Chemin Ste-Foy, G1V 4GS Quebec City, Quebec, Canada. josep.rodes@criucpq.ulaval.ca.'}]",The Journal of invasive cardiology,[] 2960,32737350,Effects of combining exercise with long-chain polyunsaturated fatty acid supplementation on cognitive function in the elderly: a randomised controlled trial.,"Multifactorial lifestyle intervention is known to be more effective for ameliorating cognitive decline than single factor intervention; however, the effects of combining exercise with long-chain polyunsaturated fatty acids (LCPUFA) on the elderlies' cognitive function remain unclear. We conducted a randomised, single-masked placebo-controlled trial in non-demented elderly Japanese individuals. Participants were randomly allocated to the exercise with LCPUFA, placebo, or no exercise with placebo (control) groups. Participants in the exercise groups performed 150 min of exercise per week, comprised resistance and aerobic training, for 24 weeks with supplements of either LCPUFA (docosahexaenoic acid, 300 mg/day; eicosapentaenoic acid, 100 mg/day; arachidonic acid, 120 mg/day) or placebo. Cognitive functions were evaluated by neuropsychological tests prior to and following the intervention. The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests. Subgroup analysis for participants with low skeletal muscle mass index (SMI) corresponding to sarcopenia cut-off value showed changes in selective attention, while working memory in the exercise with LCPUFA group was better than in the control group. These findings suggest that exercise with LCPUFA supplementation potentially improves attention and working memory in the elderly with low SMI.",2020,The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests.,"['elderly', 'non-demented elderly Japanese individuals', 'elderly with low SMI']","['exercise with LCPUFA, placebo, or no exercise with placebo (control', 'Multifactorial lifestyle intervention', '150\xa0min of exercise per week, comprised resistance and aerobic training', 'LCPUFA (docosahexaenoic acid, 300\xa0mg/day; eicosapentaenoic acid, 100\xa0mg/day; arachidonic acid, 120\xa0mg/day) or placebo', 'combining exercise with long-chain polyunsaturated fatty acids (LCPUFA', 'combining exercise with long-chain polyunsaturated fatty acid supplementation', 'LCPUFA supplementation', 'placebo']","['neuropsychological tests', 'Cognitive functions', 'cognitive function', 'attention and working memory']","[{'cui': 'C0001792', 'cui_str': 'Elderly person'}, {'cui': 'C0860630', 'cui_str': 'Demented'}, {'cui': 'C0376247', 'cui_str': 'Japanese language'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0242692', 'cui_str': 'Skeletal muscle structure'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205166', 'cui_str': 'Long'}, {'cui': 'C0337112', 'cui_str': 'Chain'}, {'cui': 'C0015684', 'cui_str': 'Fatty acid'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0023676', 'cui_str': 'Life style'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C4321486', 'cui_str': '150'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0012968', 'cui_str': 'Docosahexenoic Acids'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0439422', 'cui_str': 'mg/24h'}, {'cui': 'C0000545', 'cui_str': 'Eicosapentaenoic acid'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C0003695', 'cui_str': 'Arachidonic acid'}, {'cui': 'C4319550', 'cui_str': '120'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0242297', 'cui_str': 'Nutritional supplementation'}]","[{'cui': 'C0027902', 'cui_str': 'Neuropsychological testing'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025260', 'cui_str': 'Memory function'}]",,0.127031,The per-protocol set analysis (n = 76) revealed no significant differences between the exercise and the control groups in changes of neuropsychological tests.,"[{'ForeName': 'Hisanori', 'Initials': 'H', 'LastName': 'Tokuda', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan. Hisanori_Tokuda@suntory.co.jp.'}, {'ForeName': 'Mika', 'Initials': 'M', 'LastName': 'Ito', 'Affiliation': 'Safety Science Institute, Suntory MONOZUKURI Expert Ltd., Kyoto, Japan.'}, {'ForeName': 'Toshiaki', 'Initials': 'T', 'LastName': 'Sueyasu', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Hideyuki', 'Initials': 'H', 'LastName': 'Sasaki', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Satoshi', 'Initials': 'S', 'LastName': 'Morita', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Yoshihisa', 'Initials': 'Y', 'LastName': 'Kaneda', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Tomohiro', 'Initials': 'T', 'LastName': 'Rogi', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}, {'ForeName': 'Sumio', 'Initials': 'S', 'LastName': 'Kondo', 'Affiliation': 'Medical Corporation Kenshokai, Fukushima Healthcare Center, Osaka, Japan.'}, {'ForeName': 'Motoki', 'Initials': 'M', 'LastName': 'Kouzaki', 'Affiliation': 'Laboratory of Neurophysiology, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Tsukiura', 'Affiliation': 'Department of Cognitive and Behavioral Sciences, Graduate School of Human and Environmental Studies, Kyoto University, Kyoto, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Shibata', 'Affiliation': 'Institute for Health Care Science, Suntory Wellness Ltd., Kyoto, Japan.'}]",Scientific reports,['10.1038/s41598-020-69560-4'] 2961,32737420,Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.,"BACKGROUND Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexisting CVD treated with GnRH agonists. Here, we investigated the potential relationship between serum levels of the cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NTproBNP), D-dimer, C-reactive protein (CRP), and high-sensitivity troponin (hsTn) and the risk of new CV events in prostate cancer patients with a history of CVD receiving a GnRH agonist or antagonist. METHODS Post-hoc analyses were performed of a phase II randomized study that prospectively assessed CV events in patients with prostate cancer and preexisting CVD, receiving GnRH agonist or antagonist. Cox proportional hazards models were used to determine whether the selected biomarkers had any predictive effect on CV events at baseline and across a 12-month treatment period. RESULTS Baseline and disease characteristics of the 80 patients who took part in the study were well balanced between treatment arms. Ischemic heart disease (66%) and myocardial infarction (37%) were the most common prior CVD and the majority (92%) of patients received CV medication. We found that high levels of NTproBNP (p = 0.008), and hsTn (p = 0.004) at baseline were associated with the development of new CV events in the GnRH agonist group but not in the antagonist. In addition, a nonsignificant trend was observed between higher levels of NTproBNP over time and the development of new CV events in the GnRH agonist group. CONCLUSIONS The use of cardiac biomarkers may be worthy of further study as tools in the prediction of CV risk in prostate cancer patients receiving ADT. Analysis was limited by the small sample size; larger studies are required to validate biomarker use to predict CV events among patients receiving ADT.",2020,"We found that high levels of NTproBNP (p = 0.008), and hsTn (p = 0.004) at baseline were associated with the development of new CV events in the GnRH agonist group but not in the antagonist.","['patients with prostate cancer and preexisting CVD, receiving', 'advanced and metastatic prostate cancer', 'prostate cancer patients with a history of CVD receiving a GnRH agonist or antagonist', 'prostate cancer patients receiving ADT', 'patients with preexisting CVD treated with GnRH agonists', 'patients with prostate cancer and cardiovascular disease receiving', 'patients receiving ADT']","['GnRH agonist or antagonist', 'gonadotrophin releasing hormone agonist vs antagonist', 'Gonadotrophin releasing hormone (GnRH) agonists and antagonists', 'Androgen deprivation therapy (ADT']","['Ischemic heart disease', 'higher levels of NTproBNP over time and the development of new CV events', 'new CV events', 'myocardial infarction', 'testosterone levels', 'serum levels of the cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NTproBNP), D-dimer, C-reactive protein (CRP), and high-sensitivity troponin (hsTn', 'CV events', 'risk of cardiovascular (CV) events and CV disease (CVD']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0376358', 'cui_str': 'Malignant tumor of prostate'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0936223', 'cui_str': 'Prostate cancer metastatic'}, {'cui': 'C0262926', 'cui_str': 'History of'}, {'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}]","[{'cui': 'C0023610', 'cui_str': 'Gonadorelin'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0231491', 'cui_str': 'Antagonist muscle action'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy'}]","[{'cui': 'C0151744', 'cui_str': 'Myocardial ischemia'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0754710', 'cui_str': 'Pro-brain natriuretic peptide'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0018271', 'cui_str': 'Growth and Development'}, {'cui': 'C0205314', 'cui_str': 'New'}, {'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0027051', 'cui_str': 'Myocardial infarction'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0018787', 'cui_str': 'Heart structure'}, {'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0060323', 'cui_str': 'D-dimer'}, {'cui': 'C0006560', 'cui_str': 'C reactive protein'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0041199', 'cui_str': 'Troponin'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0007222', 'cui_str': 'Disorder of cardiovascular system'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",,0.0970567,"We found that high levels of NTproBNP (p = 0.008), and hsTn (p = 0.004) at baseline were associated with the development of new CV events in the GnRH agonist group but not in the antagonist.","[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Margel', 'Affiliation': 'Division of Urology, Rabin Medical Center, Petach Tikva, Israel. sdmargel@gmail.com.'}, {'ForeName': 'Yaara', 'Initials': 'Y', 'LastName': 'Ber', 'Affiliation': 'Division of Urology, Rabin Medical Center, Petach Tikva, Israel.'}, {'ForeName': 'Avivit', 'Initials': 'A', 'LastName': 'Peer', 'Affiliation': 'Department of Oncology, Rambam Health Care Campus, Haifa, Israel.'}, {'ForeName': 'Liat', 'Initials': 'L', 'LastName': 'Shavit-Grievink', 'Affiliation': 'Division of Urology, Rabin Medical Center, Petach Tikva, Israel.'}, {'ForeName': 'Jehonathan H', 'Initials': 'JH', 'LastName': 'Pinthus', 'Affiliation': 'Department of Surgery, Division of Urology, McMaster University, Hamilton, ON, Canada.'}, {'ForeName': 'Guy', 'Initials': 'G', 'LastName': 'Witberg', 'Affiliation': 'Department of Cardiology, Rabin Medical Center, Petach Tikva, Israel.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Baniel', 'Affiliation': 'Division of Urology, Rabin Medical Center, Petach Tikva, Israel.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Kedar', 'Affiliation': 'Division of Urology, Rabin Medical Center, Petach Tikva, Israel.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Rosenbaum', 'Affiliation': 'Davidoff Cancer Centre, Rabin Medical Center, Petach Tikva, Israel.'}]",Prostate cancer and prostatic diseases,['10.1038/s41391-020-0264-9'] 2962,32737450,Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.,"Mismatch repair (MMR) deficiency is an indicator of good prognosis in localized colon cancer but also associated with lack of expression of caudal-type homeobox transcription factor 2 (CDX2) and high tumor grade; markers that in isolation indicate a poor prognosis. Our study aims to identify clinically relevant prognostic subgroups by combining information about tumor grade, MMR phenotype, and CDX2 expression. Immunohistochemistry for MMR proteins and CDX2 was performed in 544 patients with colon cancer stage II-III, including a cohort from a randomized trial. In patients with proficient MMR (pMMR) and CDX2 negativity, hazard ratio (HR) for cancer death was 2.93 (95% CI 1.23-6.99, p = 0.015). Cancer-specific survival for pMMR/CDX2-negative cases was 35.8 months (95% CI 23.4-48.3) versus 52.1-53.5 months (95% CI 45.6-58.6, p = 0.001) for the remaining cases (CDX2-positive tumors or deficient MMR (dMMR)/CDX2-negative tumors). In our randomized cohort, high tumor grade was predictive of response to adjuvant fluorouracil-levamisole in pMMR patients, with a significant interaction between tumor grade and treatment (p = 0.036). For pMMR patients, high tumor grade was a significant marker of poor prognosis in the surgery-only group (HR 4.60 (95% CI 1.68-12.61), p = 0.003) but not in the group receiving chemotherapy (HR 0.66 (95% CI 0.15-3.00), p = 0.587). To conclude, patients with pMMR and CDX2 negativity have a very poor prognosis. Patients with pMMR and high-graded tumors have a poor prognosis but respond well to adjuvant chemotherapy. CDX2 expression and tumor grade did not impact prognosis in patients with dMMR.",2020,"Immunohistochemistry for MMR proteins and CDX2 was performed in 544 patients with colon cancer stage II-III, including a cohort from a randomized trial.","['stage II-III colon cancer', 'Patients with pMMR and high-graded tumors', 'patients with dMMR', '544 patients with colon cancer stage II-III']",['fluorouracil-levamisole'],"['CDX2 expression and tumor grade', 'Cancer-specific survival', 'CDX2 negativity, hazard ratio (HR) for cancer death']","[{'cui': 'C0441767', 'cui_str': 'Stage level 2'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0007102', 'cui_str': 'Malignant tumor of colon'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0006416', 'cui_str': 'Burma'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0278479', 'cui_str': 'Carcinoma of colon, stage II'}]","[{'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C0023556', 'cui_str': 'Levamisole'}]","[{'cui': 'C0255194', 'cui_str': 'Transcription Factor CDX2'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0006826', 'cui_str': 'Malignant neoplastic disease'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",544.0,0.052648,"Immunohistochemistry for MMR proteins and CDX2 was performed in 544 patients with colon cancer stage II-III, including a cohort from a randomized trial.","[{'ForeName': 'Kjersti Elvestad', 'Initials': 'KE', 'LastName': 'Hestetun', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway. Kjersti.Hestetun@uib.no.'}, {'ForeName': 'Kristine', 'Initials': 'K', 'LastName': 'Aasebø', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Nina Benedikte', 'Initials': 'NB', 'LastName': 'Rosenlund', 'Affiliation': 'Department of Oncology, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Yvonne', 'Initials': 'Y', 'LastName': 'Müller', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Olav', 'Initials': 'O', 'LastName': 'Dahl', 'Affiliation': 'Department of Clinical Science, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Mette Pernille', 'Initials': 'MP', 'LastName': 'Myklebust', 'Affiliation': 'Department of Oncology, Haukeland University Hospital, Bergen, Norway.'}]","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",['10.1038/s41379-020-0634-9'] 2963,32737862,"Effectiveness of virtual reality games for falls, postural oscillations, pain and quality of life of individual HAM/TSP: a randomized, controlled, clinical trial.","People with HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP) have sensorimotor losses and postural instability, resulting in frequent falls. These findings stimulate the use of exercise protocols associated with postural control. This study investigated the effectiveness of a balance training exercise protocol through a virtual game. This is a randomized crossover clinical trial performed in subjects with imbalance disorders (HAM/TSP). To evaluate postural oscillations by baropodometry (total area, anterior, posterior and lateral projection), the Footwork® system was used and by cinemetry (angle of the body, hip and ankle alignment in the lateral view), the CVMob system. In addition, the Brief Pain Inventory and the WHOQoL Bref were used to measure pain intensity and quality of life. Comparison tests of the averages (intra and inter groups) and correlations were applied considering an alpha of 5% and power of 80%. The study was approved by the Ethics Committee of the Catholic University of Salvador and registered in the Clinical Trials database (NCT02877030). The final sample consisted of 26, predominantly female subjects. An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed. Virtual game training did not improve the static balance, promoting an increase in postural oscillations. Immediately after the application of the protocol, there was a reduction in fall occurrence and improvement in the quality of life.",2020,"An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed.","['People with HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP', 'subjects with imbalance disorders (HAM/TSP']","['balance training exercise protocol', 'Virtual game training', 'virtual reality games']","['quality of life', 'static balance', 'falls, postural oscillations, pain and quality of life of individual HAM/TSP', 'postural oscillations', 'fall occurrence', 'pain intensity and quality of life', 'occurrence of falls']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020094', 'cui_str': 'Human T-lymphotropic virus 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0871582', 'cui_str': 'Virtual Reality'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0441463', 'cui_str': 'Static'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0000921', 'cui_str': 'Accidental fall'}, {'cui': 'C0205278', 'cui_str': 'Postural'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0020094', 'cui_str': 'Human T-lymphotropic virus 1'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0005956', 'cui_str': 'Bone marrow disorder'}, {'cui': 'C0030481', 'cui_str': 'Human T-cell lymphotropic virus 1-associated myelopathy'}, {'cui': 'C0243132', 'cui_str': 'occurrence'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}]",,0.0290692,"An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed.","[{'ForeName': 'Naiane Araújo', 'Initials': 'NA', 'LastName': 'Patrício', 'Affiliation': 'Doutoranda em Medicina e Saúde pela Universidade Federal da Bahia, Salvador, BA, Brazil. naianearaujopatricio@gmail.com.'}, {'ForeName': 'Diogo Guedes', 'Initials': 'DG', 'LastName': 'Vidal', 'Affiliation': 'Unidade de Pesquisa em Ecologia e Meio Ambiente e Saúde (Portugal), Colaboradora de Pesquisa da Faculdade de Medicina e Saúde Pública da Bahia, Universidade do Porto, Porto, Portugal.'}, {'ForeName': 'Elen Beatriz', 'Initials': 'EB', 'LastName': 'Pinto', 'Affiliation': 'Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.'}, {'ForeName': 'Katia Nunes', 'Initials': 'KN', 'LastName': 'Sá', 'Affiliation': 'Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.'}, {'ForeName': 'Abrahão Fontes', 'Initials': 'AF', 'LastName': 'Baptista', 'Affiliation': 'Universidade Federal do ABC, Sao Bernardo, Sao Paulo, Brazil.'}]",Journal of neurovirology,['10.1007/s13365-020-00880-x'] 2964,32737893,"Preoperative tranexamic acid does not reduce transfusion rates in major oncologic surgery: Results of a randomized, double-blind, and placebo-controlled trial.","BACKGROUND AND OBJECTIVES Allogeneic blood transfusions are associated with worse postoperative outcomes in oncologic surgery. The aim of this study was to introduce a preoperative intervention to reduce transfusion rates in this population. METHODS Adult patients undergoing major oncologic surgery in five categories with similar transfusion rates were recruited. Enrollees received a single preoperative intravenous dose of placebo or tranexamic acid (1000 mg). The primary outcome measure was perioperative transfusion rate. Secondary outcome measures included: estimated blood loss, thromboembolic events, morbidity, hospital length of stay, and readmission rate. RESULTS Seventy-six patients were enrolled, 39 in the tranexamic acid group and 37 in the placebo group, respectively. Demographics and surgery type were equivalent between groups. The transfusion rates were 8 out of 39 (20.5%) in the tranexamic acid group and 5 out of 37 (13.5%) in the placebo group, respectively (P = .418). Median estimated blood loss was 400 mL (interquartile range [IQR] = 150-600) in the tranexamic acid group compared with 300 mL (IQR = 150-800) in the placebo group (P = .983). There was one pulmonary embolism in each arm and no deep venous thrombosis (P > .999). CONCLUSION Preoperative administration of tranexamic acid at a 1000 mg intravenous dose does not decrease transfusion rates or estimated blood loss in patients undergoing major oncologic surgery.",2020,"CONCLUSION Preoperative administration of tranexamic acid at a 1000 mg intravenous dose does not decrease transfusion rates or estimated blood loss in patients undergoing major oncologic surgery.","['Adult patients undergoing major oncologic surgery in five categories with similar transfusion rates were recruited', 'major oncologic surgery', 'Seventy-six patients were enrolled, 39 in the', 'patients undergoing major oncologic surgery']","['placebo', 'placebo or tranexamic acid', 'tranexamic acid', 'Preoperative tranexamic acid']","['perioperative transfusion rate', 'pulmonary embolism', 'transfusion rates', 'Median estimated blood loss', 'deep venous thrombosis', 'estimated blood loss, thromboembolic events, morbidity, hospital length of stay, and readmission rate']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C1515090', 'cui_str': 'Surgical oncology'}, {'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C4319622', 'cui_str': '76'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}]","[{'cui': 'C0005841', 'cui_str': 'Transfusion of blood product'}, {'cui': 'C0034065', 'cui_str': 'Pulmonary embolism'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0149871', 'cui_str': 'Deep venous thrombosis'}, {'cui': 'C1443559', 'cui_str': 'Estimated blood loss'}, {'cui': 'C0040038', 'cui_str': 'Thromboembolus'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0600290', 'cui_str': 'Hospital re-admission'}]",76.0,0.755947,"CONCLUSION Preoperative administration of tranexamic acid at a 1000 mg intravenous dose does not decrease transfusion rates or estimated blood loss in patients undergoing major oncologic surgery.","[{'ForeName': 'Gerald Paul', 'Initials': 'GP', 'LastName': 'Wright', 'Affiliation': 'Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan.'}, {'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Wolf', 'Affiliation': 'Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan.'}, {'ForeName': 'Tracy L', 'Initials': 'TL', 'LastName': 'Waldherr', 'Affiliation': 'Department of Research Services, Spectrum Health Cancer Center, Grand Rapids, Michigan.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Ritz-Holland', 'Affiliation': 'Department of Research Services, Spectrum Health Cancer Center, Grand Rapids, Michigan.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Laney', 'Affiliation': 'Department of Research Services, Spectrum Health Cancer Center, Grand Rapids, Michigan.'}, {'ForeName': 'Heidi A', 'Initials': 'HA', 'LastName': 'Chapman', 'Affiliation': 'Department of Research Services, Spectrum Health Cancer Center, Grand Rapids, Michigan.'}, {'ForeName': 'Brian R', 'Initials': 'BR', 'LastName': 'Lane', 'Affiliation': 'Division of Urology, Spectrum Health Medical Group, Grand Rapids, Michigan.'}, {'ForeName': 'M Mura', 'Initials': 'MM', 'LastName': 'Assifi', 'Affiliation': 'Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan.'}, {'ForeName': 'Mathew H', 'Initials': 'MH', 'LastName': 'Chung', 'Affiliation': 'Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan.'}]",Journal of surgical oncology,['10.1002/jso.26142'] 2965,32737900,Nitric Oxide Added to the Sweep Gas of the Oxygenator during Cardiopulmonary Bypass in Infants: A Pilot Randomized Controlled Trial.,"Our objective was to assess the effect of nitric oxide added to the sweep gas of the oxygenator during cardiopulmonary bypass (CPB) in infants on platelet count, platelet function, clinical outcomes, and safety. A randomized, double blinded, placebo controlled clinical trial in infants less than a year of age undergoing cardiac surgery requiring CPB was undertaken. Nitric oxide at a dose of 20 ppm was added to the sweep gas in the treatment group. Blood was collected at baseline and prior to separation from CPB to measure platelet count and function as determined by responsiveness to specific agonists. Clinical outcomes were observed through hospital discharge. Methemoglobin levels were measured pre-operatively, at the conclusion of CPB, and upon admission to the ICU. Forty patients consented and were randomized in the trial. Eighteen patients were randomized to the treatment group and twenty-two were included in the placebo group. The groups were similar in terms of age, weight, gender, and surgical complexity. No significant differences were found in measures of platelet count, platelet response to agonist, or clinical outcomes. Patients in the treatment group had higher methemoglobin levels after receiving nitric oxide, but no levels approached toxicity (maximum 2.4%). Nitric oxide added to the sweep gas of the oxygenator during CPB in infants did not have an appreciable effect on preservation of platelet count, platelet responsiveness to agonist, or clinical outcomes. Methemoglobin levels were increased after receiving nitric oxide but were far below a toxic level of 15%.",2020,"No significant differences were found in measures of platelet count, platelet response to agonist, or clinical outcomes.","['infants less than a year of age undergoing cardiac surgery requiring CPB was undertaken', 'Infants', 'Forty patients consented and were randomized in the trial', 'Eighteen patients were randomized to the treatment group and twenty-two were included in the']","['Nitric Oxide Added to the Sweep Gas of the Oxygenator', 'nitric oxide', 'Nitric oxide', 'placebo']","['platelet count, platelet response to agonist, or clinical outcomes', 'Methemoglobin levels', 'toxicity', 'platelet count, platelet function, clinical outcomes, and safety', 'hospital discharge', 'methemoglobin levels']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0439092', 'cui_str': '<'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0018821', 'cui_str': 'Operation on heart'}, {'cui': 'C0007202', 'cui_str': 'Cardiopulmonary bypass operation'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0332257', 'cui_str': 'Including'}]","[{'cui': 'C0028128', 'cui_str': 'Nitric Oxide'}, {'cui': 'C0004269', 'cui_str': 'Child attention deficit disorder'}, {'cui': 'C0017110', 'cui_str': 'Gas'}, {'cui': 'C0030067', 'cui_str': 'Oxygenator'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0032181', 'cui_str': 'Platelet count'}, {'cui': 'C0005821', 'cui_str': 'thrombocytes'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0025635', 'cui_str': 'Methemoglobin'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0920267', 'cui_str': 'Platelet aggregation test'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0586003', 'cui_str': 'Discharge from hospital'}]",18.0,0.13949,"No significant differences were found in measures of platelet count, platelet response to agonist, or clinical outcomes.","[{'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Niebler', 'Affiliation': 'Medical College of Wisconsin, Departments of Pediatrics, Milwaukee, WI, USA.'}, {'ForeName': 'Huang', 'Initials': 'H', 'LastName': 'Chiang-Ching', 'Affiliation': 'University of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Daley', 'Affiliation': ""Herma Heart Institute, Children's Wisconsin, Milwaukee, WI, USA.""}, {'ForeName': 'Rae', 'Initials': 'R', 'LastName': 'Janecke', 'Affiliation': 'Versiti Blood Research Institute, Milwaukee, WI, USA.'}, {'ForeName': 'Shawn M', 'Initials': 'SM', 'LastName': 'Jobe', 'Affiliation': 'Medical College of Wisconsin, Departments of Pediatrics, Milwaukee, WI, USA.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Mitchell', 'Affiliation': 'Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Caleb', 'Initials': 'C', 'LastName': 'Varner', 'Affiliation': ""Herma Heart Institute, Children's Wisconsin, Milwaukee, WI, USA.""}, {'ForeName': 'Katherine', 'Initials': 'K', 'LastName': 'Woods', 'Affiliation': 'Medical College of Wisconsin, Departments of Pediatrics, Milwaukee, WI, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Scott', 'Affiliation': 'Medical College of Wisconsin, Departments of Pediatrics, Milwaukee, WI, USA.'}]",Artificial organs,['10.1111/aor.13788'] 2966,32737923,Understanding Inhaled Technosphere Insulin: Results of an Early Randomized Trial in Type 1 Diabetes Mellitus.,"BACKGROUND Technosphere® Insulin (TI) is an inhaled insulin. Studies comparing TI with short-acting insulin analogues provide important insights on efficacy, dosing, and time course of action. METHODS Planned enrollment of 230 subjects was limited to 138 due to premature study discontinuation. The primary efficacy endpoint was a non-inferiority of HbA1c of 0.4%. for TI compared with insulin lispro (LIS) in a 16-week phase 3 randomized clinical trial in type 1 diabetes mellitus. RESULTS Glycated hemoglobin values were similar in the TI and LIS groups at the beginning of the trial ( 7.8 and 7.6%, respectively) and at trial endpoint (7.7 and 7.6%, respectively). Least squares mean changes from baseline were similar between study groups. Glucose values after a standard meal were significantly lower with TI in the first 90 minutes post-meal compared with LIS. Mild or moderate hypoglycemia event rates were also significantly lower with TI compared with LIS (5.97 vs 8.01, respectively; P=0.0269). Cough was the most commonly reported adverse event with TI. Pulmonary function as measured by forced expiratory volume in 1 second was not different between groups at baseline, 16 weeks or 4 weeks off study drug. CONCLUSIONS HbA1c was unchanged and overall glucose control was comparable between groups. Treatment with TI resulted in improved post-meal glucose and a lower risk of hypoglycemia compared with LIS.",2020,"Pulmonary function as measured by forced expiratory volume in 1 second was not different between groups at baseline, 16 weeks or 4 weeks off study drug. ","['230 subjects was limited to 138 due to premature study discontinuation', 'type 1 diabetes mellitus', 'Type 1 Diabetes Mellitus']","['Technosphere Insulin', 'insulin lispro (LIS']","['forced expiratory volume', 'Cough', 'post-meal glucose and a lower risk of hypoglycemia', 'Glycated hemoglobin values', 'non-inferiority of HbA1c of 0.4', 'Glucose values', 'overall glucose control', 'Mild or moderate hypoglycemia event rates']","[{'cui': 'C0439801', 'cui_str': 'Limited'}, {'cui': 'C0678226', 'cui_str': 'Due to'}, {'cui': 'C0151526', 'cui_str': 'Premature pregnancy delivered'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1444662', 'cui_str': 'Discontinued'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}]","[{'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C0293359', 'cui_str': 'Insulin Lispro'}]","[{'cui': 'C0016529', 'cui_str': 'Forced expired volume'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}, {'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C3538919', 'cui_str': 'Low risk'}, {'cui': 'C0020615', 'cui_str': 'Hypoglycemia'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0237666', 'cui_str': 'Inferiority feeling'}, {'cui': 'C0019018', 'cui_str': 'Hemoglobin A, Glycosylated'}, {'cui': 'C4517457', 'cui_str': '0.4'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1513302', 'cui_str': 'Common terminology criteria for adverse events grade 1'}, {'cui': 'C0205081', 'cui_str': 'Moderate'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.122263,"Pulmonary function as measured by forced expiratory volume in 1 second was not different between groups at baseline, 16 weeks or 4 weeks off study drug. ","[{'ForeName': 'Janet B', 'Initials': 'JB', 'LastName': 'McGill', 'Affiliation': 'Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, Missouri, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Weiss', 'Affiliation': 'Your Diabetes Endocrine Nutrition Group, Inc, Mentor, Ohio, USA.'}, {'ForeName': 'Marshall', 'Initials': 'M', 'LastName': 'Grant', 'Affiliation': 'MannKind Corporation, 30930 Russell Ranch Rd, STE 301, Westlake Village, California, USA.'}, {'ForeName': 'Marisa C', 'Initials': 'MC', 'LastName': 'Jones', 'Affiliation': 'MannKind Corporation, 30930 Russell Ranch Rd, STE 301, Westlake Village, California, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Kendall', 'Affiliation': 'MannKind Corporation, 30930 Russell Ranch Rd, STE 301, Westlake Village, California, USA.'}, {'ForeName': 'Byron J', 'Initials': 'BJ', 'LastName': 'Hoogwerf', 'Affiliation': 'Endocrinology, Diabetes and Metabolism (Emeritus), Cleveland Clinic, Cleveland, Ohio, USA.'}]",Journal of diabetes,['10.1111/1753-0407.13099'] 2967,32737613,Varying roles of glucoregulatory function measures in postprandial cognition following milk consumption.,"PURPOSE Past work suggests milk consumption may facilitate cognition in children and college students with higher fasting glucose compared to other beverages (e.g., fruit juice). However, no studies have evaluated this phenomenon in adults, or considered other measures of glucoregulatory function. This open-label study assessed the role of glucoregulatory function in postprandial cognition after milk intake in adults. We hypothesized participants with lower fasting or post-consumption plasma glucose following a glucose excursion challenge (glucose response) would demonstrate better cognition following beverages of higher (juice) versus lower (milk) or no (water) glycemic content. METHODS Forty-four nondiabetic, overnight-fasted adults attended three laboratory visits, ingesting 237 mL of 2% fat milk, apple juice, or water at each visit in a randomized, counterbalanced, crossover design. Participants completed cognitive testing (CNS Vital Signs) at baseline and 30, 90, and 150 min post-ingestion; primary outcomes were CNS Vital Signs composite scores. Fasting and post-consumption plasma glucose levels were assessed, with glucose response indexed as the change in plasma glucose from baseline to 30 min after juice (ΔGlucose). RESULTS Mixed modeling revealed participants with higher fasting glucose demonstrated better complex attention after water versus juice at 30 min, but better performance after juice versus water at 150 min (p = 0.02). Participants with a larger ΔGlucose demonstrated better processing speed (p = 0.01) 30 min after milk versus water; this effect also reversed at 150 min. CONCLUSION Different methods of measuring glucoregulatory function reveal its differing roles in postprandial cognition. Time since ingestion may also determine which beverages best optimize cognition.",2020,Participants with a larger ΔGlucose demonstrated better processing speed (p = 0.01),"['postprandial cognition after milk intake in adults', 'children and college students with higher fasting glucose', 'Forty-four nondiabetic, overnight-fasted adults attended three', 'postprandial cognition following milk consumption', 'participants with lower fasting or post-consumption plasma glucose following a glucose excursion challenge (glucose response']","['laboratory visits, ingesting 237\xa0mL of 2% fat milk, apple juice, or water at each visit']","['processing speed', 'complex attention', 'plasma glucose', 'Fasting and post-consumption plasma glucose levels', 'cognitive testing (CNS Vital Signs', 'CNS Vital Signs composite scores']","[{'cui': 'C0376674', 'cui_str': 'Postprandial'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0556180', 'cui_str': 'Milk intake'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0557806', 'cui_str': 'College'}, {'cui': 'C0038492', 'cui_str': 'Student'}, {'cui': 'C0205250', 'cui_str': 'High'}, {'cui': 'C0017725', 'cui_str': 'Glucose'}, {'cui': 'C4319568', 'cui_str': '44'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0231290', 'cui_str': 'Status post'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}]","[{'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C0232478', 'cui_str': 'Ingestion'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0452454', 'cui_str': 'Apple juice'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}]","[{'cui': 'C1522240', 'cui_str': 'Process'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0056210', 'cui_str': 'complex V (mitochondrial oxidative phosphorylation system)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma'}, {'cui': 'C0015663', 'cui_str': 'Fasting'}, {'cui': 'C0687676', 'cui_str': 'After values'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C0392366', 'cui_str': 'Tests'}, {'cui': 'C0028654', 'cui_str': 'Clinical nurse specialist'}, {'cui': 'C0150404', 'cui_str': 'Taking patient vital signs'}, {'cui': 'C0205199', 'cui_str': 'Composite'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",44.0,0.0365146,Participants with a larger ΔGlucose demonstrated better processing speed (p = 0.01),"[{'ForeName': 'Jason R', 'Initials': 'JR', 'LastName': 'Anderson', 'Affiliation': 'Department of Psychological Sciences, Kent State University, 600 Hilltop Drive, Kent, OH, 44240, USA.'}, {'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Maki', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, 60640, USA.'}, {'ForeName': 'Orsolya M', 'Initials': 'OM', 'LastName': 'Palacios', 'Affiliation': 'Midwest Biomedical Research, Addison, IL, 60640, USA.'}, {'ForeName': 'Indika', 'Initials': 'I', 'LastName': 'Edirisinghe', 'Affiliation': 'Department of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, 60616, USA.'}, {'ForeName': 'Britt', 'Initials': 'B', 'LastName': 'Burton-Freeman', 'Affiliation': 'Department of Food Science and Nutrition, Illinois Institute of Technology, Chicago, IL, 60616, USA.'}, {'ForeName': 'Mary Beth', 'Initials': 'MB', 'LastName': 'Spitznagel', 'Affiliation': 'Department of Psychological Sciences, Kent State University, 600 Hilltop Drive, Kent, OH, 44240, USA. mspitzna@kent.edu.'}]",European journal of nutrition,['10.1007/s00394-020-02343-9'] 2968,32737637,Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial.,"BACKGROUND Surgical resection with adequate lymphadenectomy is regarded the only curative option for gastric cancer. Regarding minimally invasive techniques, mainly Asian studies showed comparable oncological and short-term postoperative outcomes. The incidence of gastric cancer is lower in the Western population and patients often present with more advanced stages of disease. Therefore, the reproducibility of these Asian results in the Western population remains to be investigated. METHODS A randomized trial was performed in thirteen hospitals in Europe. Patients with an indication for total gastrectomy who received neoadjuvant chemotherapy were eligible for inclusion and randomized between open total gastrectomy (OTG) or minimally invasive total gastrectomy (MITG). Primary outcome was oncological safety, measured as the number of resected lymph nodes and radicality. Secondary outcomes were postoperative complications, recovery and 1-year survival. RESULTS Between January 2015 and June 2018, 96 patients were included in this trial. Forty-nine patients were randomized to OTG and 47 to MITG. The mean number of resected lymph nodes was 43.4 ± 17.3 in OTG and 41.7 ± 16.1 in MITG (p = 0.612). Forty-eight patients in the OTG group had a R0 resection and 44 patients in the MITG group (p = 0.617). One-year survival was 90.4% in OTG and 85.5% in MITG (p = 0.701). No significant differences were found regarding postoperative complications and recovery. CONCLUSION These findings provide evidence that MITG after neoadjuvant therapy is not inferior regarding oncological quality of resection in comparison to OTG in Western patients with resectable gastric cancer. In addition, no differences in postoperative complications and recovery were seen.",2020,One-year survival was 90.4% in OTG and 85.5% in MITG (p = 0.701).,"['Between January 2015 and June 2018, 96 patients were included in this trial', 'thirteen hospitals in Europe', 'Patients with an indication for total gastrectomy who received', 'Western patients with resectable gastric cancer', 'Forty-nine patients']","['open total gastrectomy (OTG) or minimally invasive total gastrectomy (MITG', 'OTG', 'Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy', 'neoadjuvant chemotherapy']","['oncological safety, measured as the number of resected lymph nodes and radicality', 'mean number of resected lymph nodes', 'One-year survival', 'gastric cancer', 'postoperative complications, recovery and 1-year survival', 'postoperative complications and recovery']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0015176', 'cui_str': 'Europe'}, {'cui': 'C0392360', 'cui_str': 'Indication of'}, {'cui': 'C0161899', 'cui_str': 'Total gastrectomy'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}]","[{'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0161899', 'cui_str': 'Total gastrectomy'}, {'cui': 'C0205281', 'cui_str': 'Invasive'}, {'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0024204', 'cui_str': 'Structure of lymph node'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C4082117', 'cui_str': 'One year'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0024623', 'cui_str': 'Malignant tumor of stomach'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0439234', 'cui_str': 'year'}]",49.0,0.107117,One-year survival was 90.4% in OTG and 85.5% in MITG (p = 0.701).,"[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'van der Wielen', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands. ni.vanderwielen@amsterdamumc.nl.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Straatman', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Freek', 'Initials': 'F', 'LastName': 'Daams', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Rosati', 'Affiliation': 'Department of Surgery, San Raffaele Hospital, Milan, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Parise', 'Affiliation': 'Department of Surgery, San Raffaele Hospital, Milan, Italy.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Weitz', 'Affiliation': 'Department of Visceral-, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Reiβfelder', 'Affiliation': 'Department of Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.'}, {'ForeName': 'Ismael', 'Initials': 'I', 'LastName': 'Diez Del Val', 'Affiliation': 'Department of Surgery, Hospital Universitario de Basurto, Bilbao, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Loureiro', 'Affiliation': 'Department of Surgery, Hospital Universitario de Basurto, Bilbao, Spain.'}, {'ForeName': 'Purificación', 'Initials': 'P', 'LastName': 'Parada-González', 'Affiliation': 'Department of Surgery, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Pintos-Martínez', 'Affiliation': 'Department of Surgery, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain.'}, {'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Mateo Vallejo', 'Affiliation': 'Department of Surgery, Hospital de Jerez, Jerez de la Frontera, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Medina Achirica', 'Affiliation': 'Department of Surgery, Hospital de Jerez, Jerez de la Frontera, Spain.'}, {'ForeName': 'Andrés', 'Initials': 'A', 'LastName': 'Sánchez-Pernaute', 'Affiliation': 'Department of Surgery, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Ruano Campos', 'Affiliation': 'Department of Surgery, Hospital Clínico San Carlos, Madrid, Spain.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Bonavina', 'Affiliation': 'Department of Surgery, IRCCS Policlinico San Donato, Milan, Italy.'}, {'ForeName': 'Emanuele L G', 'Initials': 'ELG', 'LastName': 'Asti', 'Affiliation': 'Department of Surgery, IRCCS Policlinico San Donato, Milan, Italy.'}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Alonso Poza', 'Affiliation': 'Department of Surgery, Hospital del Sureste, Madrid, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Gilsanz', 'Affiliation': 'Department of Surgery, Hospital del Sureste, Madrid, Spain.'}, {'ForeName': 'Magnus', 'Initials': 'M', 'LastName': 'Nilsson', 'Affiliation': 'Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Mats', 'Initials': 'M', 'LastName': 'Lindblad', 'Affiliation': 'Department of Surgery, Karolinska University Hospital, Stockholm, Sweden.'}, {'ForeName': 'Suzanne S', 'Initials': 'SS', 'LastName': 'Gisbertz', 'Affiliation': 'Department of Gastro-intestinal Surgery, Amsterdam University Medical Center Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Mark I', 'Initials': 'MI', 'LastName': 'van Berge Henegouwen', 'Affiliation': 'Department of Gastro-intestinal Surgery, Amsterdam University Medical Center Location AMC, Amsterdam, The Netherlands.'}, {'ForeName': 'Uberto', 'Initials': 'U', 'LastName': 'Fumagalli Romario', 'Affiliation': 'Department of Surgery, ASST Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'De Pascale', 'Affiliation': 'Department of Surgery, ASST Spedali Civili, Brescia, Italy.'}, {'ForeName': 'Khurshid', 'Initials': 'K', 'LastName': 'Akhtar', 'Affiliation': 'Department of Surgery, Salford Royal NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Jaap Bonjer', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Miguel A', 'Initials': 'MA', 'LastName': 'Cuesta', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands.'}, {'ForeName': 'Donald L', 'Initials': 'DL', 'LastName': 'van der Peet', 'Affiliation': 'Department of Gastro-Intestinal Surgery, Amsterdam University Medical Center, Location VU University, De Boelelaan 1117, ZH 7F020, 1081 HV, Amsterdam, The Netherlands.'}]",Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,['10.1007/s10120-020-01109-w'] 2969,32737973,Multimodal Balance Training Supported by Rhythmic Auditory Stimuli in Parkinson Disease: Effects in Freezers and Nonfreezers.,"OBJECTIVE To fulfill the potential of nonpharmacological interventions in Parkinson disease (PD), individually tailored treatment is needed. Multimodal balance training supported by rhythmic auditory stimuli can improve balance and gait in PD. The purpose of this study is to determine whether both freezers and nonfreezers benefit. METHODS A secondary analysis was conducted on a large randomized controlled trial that included 154 patients with PD (Hoehn & Yahr Stages 1-3 while ON-medication) who were assigned randomly to 3 groups: (1) multimodal balance training with rhythmic auditory stimuli delivered by a metronome (RAS-supported multimodal balance training), (2) regular multimodal balance training without rhythmic auditory cues, and (3) a control intervention (involving an educational program). Training was performed for 5 weeks, twice per week. The primary outcome was the Mini-BESTest score directly after the training period. Assessments were performed by a single, masked assessor at baseline, directly postintervention, and after 1-month and 6-month follow-up. Outcomes were analyzed in 1 analysis, and the results were presented separately for freezers and nonfreezers with a linear mixed model, adjusted for baseline Mini-BESTest scores, Unified Parkinson's Disease Rating Scale scores, and levodopa equivalent dose. RESULTS In both freezers and nonfreezers, both RAS-supported multimodal training and regular training significantly improved the Mini-BESTest scores compared with baseline scores and with the control group scores. The improvement was larger for RAS-supported training compared with regular training, for both freezers and nonfreezers. Only the RAS-supported training group retained the improvements compared with baseline measurements at 6-month follow-up, and this was true for both freezers and nonfreezers. CONCLUSION RAS-supported multimodal training is effective in improving balance performance in both freezers and nonfreezers. IMPACT Until this study, it was unknown whether both freezers and nonfreezers could benefit from multimodal balance training. With this information, clinicians who work with people with PD will be better able to apply personalized gait rehabilitation.",2020,"Only the RAS-supported training group retained the improvements compared with baseline measurements at 6-month follow-up, and this was true for both freezers and nonfreezers. ","['154 patients with PD (Hoehn & Yahr Stages 1-3 while ON-medication', 'Parkinson Disease', 'Parkinson disease (PD']","['multimodal balance training with rhythmic auditory stimuli delivered by a metronome (RAS-supported multimodal balance training), (2) regular multimodal balance training without rhythmic auditory cues, and (3) a control intervention (involving an educational program', 'Multimodal balance training', 'Multimodal Balance Training', 'RAS-supported multimodal training']","['Mini-BESTest scores', 'balance performance', 'Mini-BESTest score directly', ""baseline Mini-BESTest scores, Unified Parkinson's Disease Rating Scale scores, and levodopa equivalent dose"", 'balance and gait in PD']","[{'cui': 'C5191279', 'cui_str': '154'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0441766', 'cui_str': 'Stage level 1'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceutical / biologic product'}]","[{'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0178490', 'cui_str': 'Auditory stimulus'}, {'cui': 'C0183683', 'cui_str': 'Support'}, {'cui': 'C0205272', 'cui_str': 'Regular'}, {'cui': 'C0439825', 'cui_str': 'Auditory'}, {'cui': 'C0010439', 'cui_str': 'Cues'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C1314939', 'cui_str': 'Involvement'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0445542', 'cui_str': 'Mini'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0014653', 'cui_str': 'Equilibrium'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0205163', 'cui_str': 'Equal'}, {'cui': 'C0178602', 'cui_str': 'Dosage'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}]",154.0,0.0633119,"Only the RAS-supported training group retained the improvements compared with baseline measurements at 6-month follow-up, and this was true for both freezers and nonfreezers. ","[{'ForeName': 'Tamine T C', 'Initials': 'TTC', 'LastName': 'Capato', 'Affiliation': 'Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, and Center of Expertise for Parkinson & Movement Disorders, Radboud University Medical Center; Nijmegen, the Netherlands; and Movement Disorders Clinic, Department of Neurology, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Nienke M', 'Initials': 'NM', 'LastName': 'de Vries', 'Affiliation': 'Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, and Center of Expertise for Parkinson & Movement Disorders, Radboud University Medical Center.'}, {'ForeName': 'Joanna', 'Initials': 'J', 'LastName': 'IntHout', 'Affiliation': 'Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.'}, {'ForeName': 'Jordache', 'Initials': 'J', 'LastName': 'Ramjith', 'Affiliation': 'Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center.'}, {'ForeName': 'Egberto R', 'Initials': 'ER', 'LastName': 'Barbosa', 'Affiliation': 'Movement Disorders Clinic, Department of Neurology, University of São Paulo.'}, {'ForeName': 'Jorik', 'Initials': 'J', 'LastName': 'Nonnekes', 'Affiliation': 'Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, and Center of Expertise for Parkinson & Movement Disorders, Radboud University Medical Center; Nijmegen, the Netherlands; and Department of Rehabilitation, Sint Maartenskliniek, Nijmegen, the Netherlands.'}, {'ForeName': 'Bastiaan R', 'Initials': 'BR', 'LastName': 'Bloem', 'Affiliation': 'Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, and Center of Expertise for Parkinson & Movement Disorders, Radboud University Medical Center; Nijmegen, the Netherlands.'}]",Physical therapy,['10.1093/ptj/pzaa146'] 2970,32737983,A decade of using a remifentanil target-controlled infusion technique for awake fibreoptic intubations.,,2020,,['awake fibreoptic intubations'],[],[],"[{'cui': 'C0234422', 'cui_str': 'Awake'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}]",[],[],,0.0165954,,"[{'ForeName': 'S V', 'Initials': 'SV', 'LastName': 'Shah', 'Affiliation': 'Imperial School of Anaesthesia, London, UK.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Lacey', 'Affiliation': 'Royal Marsden NHS Foundation Trust, London, UK.'}]",Anaesthesia,['10.1111/anae.15226'] 2971,32737993,Clinical Trial Readiness Study of Distal Myopathy and Dysphagia in Nephropathic Cystinosis.,"INTRODUCTION Nephropathic cystinosis is a lysosomal storage disorder with late-onset systemic complications, such as myopathy and dysphagia. Currently employed outcome measures lack sensitivity and responsiveness for dysphagia and myopathy, a limitation to clinical trial readiness. METHODS We evaluated 20 patients with nephropathic cystinosis in two visits over the course of a year to identify outcomes sensitive to detect changes over time. Patients also underwent an expiratory muscle strength training program to assess any effects on aspiration and dysphagia. RESULTS There were significant differences in the Timed Up and Go Test (TUG) and Timed 25-Foot Walk (25-FW) between baseline and one-year follow-up (p < 0.05). Maximum Expiratory Pressure (MEP) and Peak Cough Flow (PCF) significantly improved following respiratory training (p < 0.05). DISCUSSION Improved respiratory outcomes may enhance patients' ability to expel aspirated material from the airway, stave off pulmonary sequelae associated with chronic aspiration, and yield an overall improvement in physical health and well-being.",2020,"Maximum Expiratory Pressure (MEP) and Peak Cough Flow (PCF) significantly improved following respiratory training (p < 0.05). ","['Distal Myopathy and Dysphagia in Nephropathic Cystinosis', '20 patients with nephropathic cystinosis in two visits over the course of a year']",['expiratory muscle strength training program'],"['Timed Up and Go Test (TUG) and Timed 25-Foot Walk (25-FW', 'Maximum Expiratory Pressure (MEP) and Peak Cough Flow (PCF']","[{'cui': 'C0751336', 'cui_str': 'Distal muscular dystrophy'}, {'cui': 'C0011168', 'cui_str': 'Dysphagia'}, {'cui': 'C0015624', 'cui_str': 'Fanconi syndrome'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0750729', 'cui_str': 'Courses'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0231800', 'cui_str': 'Expiration'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}]","[{'cui': 'C1319201', 'cui_str': 'Timed up and go mobility test'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0232022', 'cui_str': 'Peak expiratory pressure'}, {'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0010200', 'cui_str': 'Coughing'}]",20.0,0.0494736,"Maximum Expiratory Pressure (MEP) and Peak Cough Flow (PCF) significantly improved following respiratory training (p < 0.05). ","[{'ForeName': 'Reza', 'Initials': 'R', 'LastName': 'Sadjadi', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Stacey', 'Initials': 'S', 'LastName': 'Sullivan', 'Affiliation': 'Department of Speech, Language and Swallowing Disorders, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Grant', 'Affiliation': 'Center for Rare Neurological Diseases, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Susan E', 'Initials': 'SE', 'LastName': 'Thomas', 'Affiliation': 'Division of Pediatric Nephrology, Department of Pediatrics and Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Doyle', 'Affiliation': 'Department of Social Work, School of Health Sciences, Quinnipiac University, Hamden, Connecticut.'}, {'ForeName': 'Colleen', 'Initials': 'C', 'LastName': 'Hammond', 'Affiliation': 'Cystinosis Adult Care Excellence Initiative, Reading, MA.'}, {'ForeName': 'Camille', 'Initials': 'C', 'LastName': 'Corre', 'Affiliation': 'Center for Rare Neurological Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Mello', 'Affiliation': 'Center for Rare Neurological Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'William S', 'Initials': 'WS', 'LastName': 'David', 'Affiliation': 'Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Eichler', 'Affiliation': 'Center for Rare Neurological Diseases, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.'}]",Muscle & nerve,['10.1002/mus.27039'] 2972,32738019,"Lipoatrophy in children, adolescents and adults with insulin pump treatment: is there a beneficial effect of insulin glulisine?","AIM To investigate whether zinc-free insulin is an effective treatment option for lipoatrophy. METHODS Controlled, randomized, open-label parallel study in young people with type 1 diabetes, pump treatment and lipoatrophy at injection sites. Participants underwent dermatological examination and evaluation of affected areas using ultrasound and MRI. After randomization, half of themswitched to insulin glulisine (intervention group) for 6 months. The control group continued their treatment with zinc-containing insulin and switched to insulin glulisine 6 months later. Both groups were followed-up until month 12. Primary endpoint was the increase of the relative thickness of the subcutaneous fat layer of the most atrophic site at 6 months as documented by MRI. RESULTS Fourteen participants were included into the study. While relative thickness of subcutaneous fat tissue was comparable between intervention [-60% (-98.8 to -17.6), n=7) and control group [-50% (-72.7 to -1.0), p=.511; median (range), n=7]at baseline, it improved in the intervention [-14.3% (-85.7 to 83.3) vs. -31.3% (-66.7 to 0), p=.031], but not in the control group (p=.125) after 6 months. At 12 months, relative fat thickness (p=.003), number (p=.015) and size of most atrophic sites (p=.001) were improved in the intervention group. Number (p=.018) and size of most atrophic sites (p=.008) were also reduced in the control group between 6 and 12 months. CONCLUSIONS Although the present pilot study is based on a small sample, the data give first hint that the use of the zinc-free insulin glulisine may be beneficial in people with diabetes, pump and lipoatrophy. This article is protected by copyright. All rights reserved.",2020,"At 12 months, relative fat thickness (p=.003), number (p=.015) and size of most atrophic sites (p=.001) were improved in the intervention group.","['children, adolescents and adults with insulin pump treatment', 'young people with type 1 diabetes, pump treatment and lipoatrophy at injection sites', 'Fourteen participants were included into the study']","['zinc-containing insulin and switched to insulin glulisine 6 months later', 'Lipoatrophy', 'zinc-free insulin']","['number (p=.015) and size of most atrophic sites', 'relative thickness of the subcutaneous fat layer of the most atrophic site at 6 months as documented by MRI', 'relative fat thickness', 'relative thickness of subcutaneous fat tissue', 'size of most atrophic sites']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1140609', 'cui_str': 'Insulin pump'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0023787', 'cui_str': 'Lipodystrophy'}, {'cui': 'C0221208', 'cui_str': 'Injection site'}, {'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0021641', 'cui_str': 'Insulin'}, {'cui': 'C1313386', 'cui_str': 'Insulin, Glulisine, Human'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0023787', 'cui_str': 'Lipodystrophy'}, {'cui': 'C0487017', 'cui_str': 'Free insulin'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0456389', 'cui_str': 'Size'}, {'cui': 'C0333641', 'cui_str': 'Atrophy'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0080103', 'cui_str': 'Relative'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous fatty tissue'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C1301725', 'cui_str': 'Documented'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}]",14.0,0.0696432,"At 12 months, relative fat thickness (p=.003), number (p=.015) and size of most atrophic sites (p=.001) were improved in the intervention group.","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Kordonouri', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Torben', 'Initials': 'T', 'LastName': 'Biester', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Jürgen', 'Initials': 'J', 'LastName': 'Weidemann', 'Affiliation': 'Pediatric Radiology, Hannover, Germany.'}, {'ForeName': 'Hagen', 'Initials': 'H', 'LastName': 'Ott', 'Affiliation': ""Pediatric Dermatology at the Children's Hospital AUF DER BULT, Hannover, Germany.""}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Remus', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Grothaus', 'Affiliation': ""Pediatric Dermatology at the Children's Hospital AUF DER BULT, Hannover, Germany.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Pisarek', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Reinhard', 'Initials': 'R', 'LastName': 'Hartmann', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Kerstin', 'Initials': 'K', 'LastName': 'Adolph', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Lange', 'Affiliation': 'Medical Psychology, Hannover Medical School, Hannover, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Danne', 'Affiliation': 'Diabetes Center for Children and Adolescents, Hannover, Germany.'}]",Pediatric diabetes,['10.1111/pedi.13094'] 2973,32738042,Phase 3 trial of a small volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty.,"CONTEXT Gonadotropin releasing hormone agonists (GnRHa) are standard of care for central precocious puberty (CPP). A 6-month subcutaneous injection has recently been approved by Food and Drug Administration. OBJECTIVE Determine efficacy, pharmacokinetics and safety of 6-month 45 mg subcutaneous leuprolide acetate for CPP. DESIGN Phase 3 multicenter, open-label, single-arm study. SETTING 25 sites in 6 countries. SUBJECTS 64 GnRHa naive children with CPP (age: 7.5±0.1 years) received study drug: 59 completed the study. INTERVENTION(S) 2 doses of 45 mg subcutaneous leuprolide acetate (0.375 mL) at 0 and 24 weeks, children followed for 48 weeks. MAIN OUTCOME MEASURE(S) Percentage of children with serum luteinizing hormone (LH) <4 IU/L 30 minutes following GnRHa stimulation at week 24. RESULTS 54/62 (87%) children achieved post-stimulation LH <4 IU/L at week 24. 49/56 (88%) girls and 1/2 boys maintained peak LH <4 IU/L at week 48. Mean growth velocity decreased from 8.9 cm/year at week 4 to 6.0 cm/year at week 48. Mean bone age was advanced 3.0 years beyond chronological age at screening and 2.7 years at week 48. Breast pubertal stage regressed or was stable in 97% of girls and external genitalia development regressed in both boys. Adverse events were mild and did not cause treatment discontinuation. CONCLUSIONS A small volume of 45 mg subcutaneous leuprolide acetate administered at a 6-month interval effectively suppressed pubertal hormones and stopped or caused regression of pubertal progression. This long-acting GnRHa preparation of leuprolide acetate is a new effective and well-tolerated therapy for children with CPP.",2020,Breast pubertal stage regressed or was stable in 97% of girls and external genitalia development regressed in both boys.,"['Mean bone age was advanced 3.0 years beyond chronological age at screening and 2.7 years at week 48', '64 GnRHa naive children with CPP (age: 7.5±0.1 years) received study drug: 59 completed the study', 'children with CPP', '25 sites in 6 countries', 'central precocious puberty']","['Gonadotropin releasing hormone agonists (GnRHa', 'leuprolide acetate treatment', 'leuprolide acetate', 'subcutaneous leuprolide acetate', 'luteinizing hormone (LH', '6-month 45 mg subcutaneous leuprolide acetate']","['pubertal hormones and stopped or caused regression of pubertal progression', 'Mean growth velocity', 'Adverse events']","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0429620', 'cui_str': 'Bone age'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C4517635', 'cui_str': '2.7'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0342543', 'cui_str': 'Central precocious puberty'}, {'cui': 'C0013175', 'cui_str': 'Clinical drug trial'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0454664', 'cui_str': 'Country'}]","[{'cui': 'C1518041', 'cui_str': 'Gonadotropin releasing hormone analogues'}, {'cui': 'C0700596', 'cui_str': 'Leuprolide acetate'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0443315', 'cui_str': 'Subcutaneous'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C1627769', 'cui_str': 'Pubertal'}, {'cui': 'C0019932', 'cui_str': 'Hormone'}, {'cui': 'C0450446', 'cui_str': 'Stops'}, {'cui': 'C0015127', 'cui_str': 'etiology'}, {'cui': 'C0684321', 'cui_str': 'Regression - mental defense mechanism'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",,0.0790454,Breast pubertal stage regressed or was stable in 97% of girls and external genitalia development regressed in both boys.,"[{'ForeName': 'Karen O', 'Initials': 'KO', 'LastName': 'Klein', 'Affiliation': ""Rady Children's Hospital and University of California, San Diego CA, USA.""}, {'ForeName': 'Analía', 'Initials': 'A', 'LastName': 'Freire', 'Affiliation': 'Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina.'}, {'ForeName': 'Mirta Graciela', 'Initials': 'MG', 'LastName': 'Gryngarten', 'Affiliation': 'Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina.'}, {'ForeName': 'Gad B', 'Initials': 'GB', 'LastName': 'Kletter', 'Affiliation': 'MultiCare Institute for Research and Innovation, Tacoma WA, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Benson', 'Affiliation': ""Nemours Children's Hospital, Orlando FL, USA.""}, {'ForeName': 'Bradley S', 'Initials': 'BS', 'LastName': 'Miller', 'Affiliation': ""University of Minnesota Masonic Children's Hospital, Minneapolis MN, USA.""}, {'ForeName': 'Tala S', 'Initials': 'TS', 'LastName': 'Dajani', 'Affiliation': 'School of Osteopathic Medicine in Arizona, A.T. Still University, Mesa AZ, USA.'}, {'ForeName': 'Erica A', 'Initials': 'EA', 'LastName': 'Eugster', 'Affiliation': 'Riley Hospital for Children at Indiana University Health, Indianapolis IN, USA.'}, {'ForeName': 'Nelly', 'Initials': 'N', 'LastName': 'Mauras', 'Affiliation': ""Nemours Children's Health System, Jacksonville FL, USA.""}]",The Journal of clinical endocrinology and metabolism,['10.1210/clinem/dgaa479'] 2974,30908587,Sevoflurane EC50 for intravenous cannulation attempt and movement in children.,"BACKGROUND Intravenous cannulation at lighter planes of anaesthesia can lead to adverse respiratory and haemodynamic events. So far, there is no consensus on optimum end tidal sevoflurane concentration required for intravenous cannulation in children. We aimed to evaluate the optimum end tidal concentration at which an intravenous cannulation can be successfully attempted without movements in paediatric patients after inhalational induction of general anaesthesia. MATERIAL AND METHODS In this clinical trial, paediatric subjects of either sex aged 1-3 years, weighing 7-15 kg having American Society of Anaesthesiologists physical status I/II of undergoing elective cataract surgery were included. After inhalational induction of general anaesthesia with 8% sevoflurane and 100% oxygen, end tidal sevoflurane concentration was maintained at 2% for 4 minutes for the first child. This was followed by intravenous cannulation attempted by an experienced anesthesiologist. The intravenous cannulation was considered to be unsuccessful if there was ""movement"" and successful if there was ""no movement"" in response to the stimuli of cannulation. End-tidal concentration was increased/decreased (step-size 0.2% for sevoflurane) using Dixon and Massey up and down method in the next patient depending upon previous patient's response. RESULTS The sevoflurane EC50 for successful intravenous cannulation is 1.32% ± 1.0%. Pearson correlation (r) between weight of the child and response to intravenous cannulation was found to be 0.40 with P value of 0.008. CONCLUSION Intravenous cannulation can be accomplished without movements at end tidal sevoflurane of 1.3% in children aged 1-3 years in 50% of children.",2019,"Pearson correlation (r) between weight of the child and response to intravenous cannulation was found to be 0.40 with P value of 0.008. ","['paediatric subjects of either sex aged 1-3\xa0years, weighing 7-15\xa0kg having American Society of Anaesthesiologists physical status I/II of undergoing elective cataract surgery were included', 'paediatric patients after inhalational induction of general anaesthesia', 'children aged 1-3\xa0years in 50% of children', 'children']","['Sevoflurane EC50', 'sevoflurane EC50', 'Intravenous cannulation', 'general anaesthesia with 8% sevoflurane']","['End-tidal concentration', 'tidal sevoflurane concentration']","[{'cui': 'C0030755', 'cui_str': 'Pediatric specialty'}, {'cui': 'C0009253', 'cui_str': 'Intercourse'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient'}, {'cui': 'C0062074', 'cui_str': 'HAC protocol'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0206058', 'cui_str': 'Optional surgery'}, {'cui': 'C0007389', 'cui_str': 'Extraction of cataract'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0412768', 'cui_str': 'Inhalational induction'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0680063', 'cui_str': 'Child of'}]","[{'cui': 'C0074414', 'cui_str': 'sevoflurane'}, {'cui': 'C0398266', 'cui_str': 'Catheterization of vein'}, {'cui': 'C0002915', 'cui_str': 'General anesthesia'}]","[{'cui': 'C0444930', 'cui_str': 'End'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0074414', 'cui_str': 'sevoflurane'}]",,0.101551,"Pearson correlation (r) between weight of the child and response to intravenous cannulation was found to be 0.40 with P value of 0.008. ","[{'ForeName': 'Nitika', 'Initials': 'N', 'LastName': 'Goel', 'Affiliation': 'Department of Anaesthesia and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Divya', 'Initials': 'D', 'LastName': 'Jain', 'Affiliation': 'Department of Anaesthesia and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}, {'ForeName': 'Babita', 'Initials': 'B', 'LastName': 'Ghai', 'Affiliation': 'Department of Anaesthesia and Critical Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13363'] 2975,30940010,Conflating Temporal Advancement and Epistemic Advancement: The Progression Bias in Judgment and Decision Making.,"When seeking out the truth about a certain aspect of the world, people frequently conduct several inquiries successively over a time span. Later inquiries usually improve upon earlier ones; thus, it is typically rational to expect the finding of a later inquiry to be closer to the truth than that of an earlier one. However, when no meaningful differences exist between earlier and later inquiries, later findings should not be considered epistemically superior. However, in these cases, people continue to regard findings from later inquiries as closer to the truth than earlier ones. In 10 experiments, when later inquiries conflicted with-but did not epistemically improve upon-earlier ones, participants' global judgments about the truth aligned more with later findings than earlier ones, an effect referred to as progression bias. The liability to progression bias may have severe ramifications for the well-being of the society and its members.",2019,"However, in these cases, people continue to regard findings from later inquiries as closer to the truth than earlier ones.",[],['Conflating Temporal Advancement and Epistemic Advancement'],[],[],"[{'cui': 'C0442043', 'cui_str': 'Temporal'}, {'cui': 'C0441478', 'cui_str': 'Surgical advancement - action'}]",[],,0.0129788,"However, in these cases, people continue to regard findings from later inquiries as closer to the truth than earlier ones.","[{'ForeName': 'Haotian', 'Initials': 'H', 'LastName': 'Zhou', 'Affiliation': 'ShanghaiTech University, China.'}, {'ForeName': 'Xilin', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'The University of Chicago, IL, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Sim', 'Affiliation': 'Elmhurst College, IL, USA.'}]",Personality & social psychology bulletin,['10.1177/0146167219838542'] 2976,30954378,Quantification of contact lens wettability after prolonged visual device use under low humidity conditions.,"PURPOSE Discomfort of silicone hydrogel (SiHy) contact lenses (CL) is associated with longer wearing time, demanding visual tasks, and dry environments. This study investigated the impact of challenging environmental conditions on thewettability of four daily disposable SiHy CL. METHODS Habitual wearers of delefilcon A (n=32) and somofilcon A (n=32) were tested with their habitual lenses and with stenfilcon A and narafilcon A lenses. Digital videos were captured using non-invasive Tearscope illumination after 3 hrs of conventional wear and 3 hrs of computer use at 20% relative humidity (RH). Masked investigators analysed non-invasive break up time (NIBUT), minimum protected area (MPA) ofthe lens surface by the tear film, and dehydration speed (DS) over the interblink period after exposure to 20% RH. RESULTS For habitual delefilcon A wearers, mean NIBUT was longer with delefilcon A (9.2 sec) than stenfilcon A (6.3 sec, p = 0.052) and narafilcon A (5.1 sec, p = 0.006); mean MPA was significantly higher with delefilcon A (95.4%)than stenfilcon A (84.4%, p = 0.002) and narafilcon A (82.9%, p = 0.006); mean DS was lower with delefilcon A (0.28 mm2/sec) than stenfilcon A (0.81 mm2/sec, p = 0.002) and narafilcon A (0.60 mm2/sec, p = 0.056). For habitual somofilcon A wearers, mean MPA was lower for narafilcon A (76.2%) than for somofilcon A (89.0%, p < 0.001) but not stenfilcon A (88.4%, p = 0.748) and mean DS was higher for narafilcon A (0.96 mm2/sec) than somofilcon A (0.60mm2/sec, p = 0.029) but not stenfilcon A (0.51 mm2/sec, p = 0.701). CONCLUSIONS Delefilcon A CL performed betterthan stenfilcon A and narafilcon A after 6 hrs of wear including 3 hrs intensive visual tasks under challenging environmental conditions. Delefilcon A CL may be preferable for CL wearers with intensive computers and/or digital devices usage.",2019,"A wearers, mean NIBUT was longer with delefilcon A (9.2 sec) than stenfilcon A (6.3 sec, p = 0.052) and narafilcon A (5.1 sec, p = 0.006); mean MPA was significantly higher with delefilcon A (95.4%)than stenfilcon A (84.4%, p = 0.002) and narafilcon A (82.9%, p = 0.006); mean DS was lower with delefilcon A (0.28 mm2/sec) than stenfilcon A (0.81 mm2/sec, p = 0.002) and narafilcon A (0.60 mm2/sec, p = 0.056).","['CL wearers with intensive computers and/or digital devices usage', 'Habitual wearers of delefilcon A (n=32) and somofilcon A (n=32']","['habitual lenses and with stenfilcon A and narafilcon A lenses', 'silicone hydrogel (SiHy) contact lenses (CL', 'habitual delefilcon']","['mean DS', 'mean MPA']","[{'cui': 'C0920138', 'cui_str': 'Contact lens wearer'}, {'cui': 'C0009622', 'cui_str': 'Computer'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray'}, {'cui': 'C0025080', 'cui_str': 'Biomedical equipment'}, {'cui': 'C0457083', 'cui_str': 'Usage'}, {'cui': 'C0205353', 'cui_str': 'Habitual'}]","[{'cui': 'C0205353', 'cui_str': 'Habitual'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel'}, {'cui': 'C0009836', 'cui_str': 'Contact lenses'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0011175', 'cui_str': 'Dehydration'}, {'cui': 'C0025611', 'cui_str': 'Methamphetamine'}, {'cui': 'C0017446', 'cui_str': 'Geographic Locations'}]",32.0,0.0310312,"A wearers, mean NIBUT was longer with delefilcon A (9.2 sec) than stenfilcon A (6.3 sec, p = 0.052) and narafilcon A (5.1 sec, p = 0.006); mean MPA was significantly higher with delefilcon A (95.4%)than stenfilcon A (84.4%, p = 0.002) and narafilcon A (82.9%, p = 0.006); mean DS was lower with delefilcon A (0.28 mm2/sec) than stenfilcon A (0.81 mm2/sec, p = 0.002) and narafilcon A (0.60 mm2/sec, p = 0.056).","[{'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Guillon', 'Affiliation': 'OCULAR TECHNOLOGY GROUP - International, 66 Buckingham Gate, London SW1E 6AU, UK; School of Life and Health Sciences, Aston University, Aston Express Way, Birmingham B4 7ET, UK. Electronic address: mguillon@otg.co.uk.'}, {'ForeName': 'Trisha', 'Initials': 'T', 'LastName': 'Patel', 'Affiliation': 'OCULAR TECHNOLOGY GROUP - International, 66 Buckingham Gate, London SW1E 6AU, UK.'}, {'ForeName': 'Kishan', 'Initials': 'K', 'LastName': 'Patel', 'Affiliation': 'OCULAR TECHNOLOGY GROUP - International, 66 Buckingham Gate, London SW1E 6AU, UK.'}, {'ForeName': 'Ruchi', 'Initials': 'R', 'LastName': 'Gupta', 'Affiliation': 'OCULAR TECHNOLOGY GROUP - International, 66 Buckingham Gate, London SW1E 6AU, UK.'}, {'ForeName': 'Cecile A', 'Initials': 'CA', 'LastName': 'Maissa', 'Affiliation': 'Alcon Research, Ltd., 11460 Johns Creek Parkway, Johns Creek, GA, USA.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.03.004'] 2977,30995970,Effects of scleral-lens oxygen transmissibility on corneal thickness: A pilot study.,"PURPOSE To investigate the effect of various oxygen transmissibilities (Dk/t) of scleral lenses and corneal thickness recovery time from overnight eye closure with patching on corneal edema during 5 h lens wear. METHODS Scleral lenses (hofocon A, 15.6 mm diameter) were worn bilaterally with three different Dks (100, 140, and 160 Barrer). Central and peripheral corneal thickness (CCT and PCT) were measured using optical coherence tomography. Four subjects were randomly selected for one additional visit and asked to patch one eye before night sleeping. The patch was not removed until lens insertion to avoid corneal deswelling. Then CCT of both eyes was measured. RESULTS Ten neophytes with healthy eyes participated in the study. Mean [95% CI] Dk/t of the study lenses was 32.0 [29.2, 34.7] hBarrer/cm. Mean [95% CI] CCT immediately upon lens insertion and after 5 h of lens wear were 532.4 [520.3, 544.5] μm and 538.7 [526.5, 551.0] μm, respectively. Mean [95% CI] percentage change (%Δ) in CCT was 1.2% [0.9%, 1.5%], 1.2% [0.9%, 1.4%], and 0.8% [0.6%, 1.1%] for CCT, nasal PCT, and temporal PCT, respectively. There was an inverse relationship between temporal Dk/t and %ΔPCT (p < 0.05) while Dk/t was not found significantly associated with either CCT or nasal PCT. The patched eyes maintained a relatively stable CCT and showed progressive deswelling, starting and ending with 2.8% and 0.6%, respectively. In contrast, the unpatched eyes swelled, starting with nearly 0% and ending with 0.7% with a maximum swelling of 1.8%. CONCLUSION There was limited amount of corneal edema induced by short-term scleral lens wear with lens Dk/t ranging from 21 to 47 hBarrer/cm and lenses with lower lens Dk/t did not induce significantly higher corneal swelling. Scleral lens insertion soon after overnight eye closure with patching did not introduce additional swelling for young and healthy eyes.",2019,Dk/t did not induce significantly higher corneal swelling.,"['Ten neophytes with healthy eyes participated in the study', 'Scleral lenses (hofocon A, 15.6\u2009mm diameter) were worn bilaterally with three different Dks (100, 140, and 160 Barrer', 'young and healthy eyes']","['CCT', 'scleral-lens oxygen transmissibility', 'various oxygen transmissibilities (Dk/t) of scleral lenses and corneal thickness recovery time from overnight eye closure with patching']","['Central and peripheral corneal thickness (CCT and PCT', 'Mean', 'corneal edema', 'corneal swelling', 'corneal thickness']","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C1301886', 'cui_str': 'Diameter'}, {'cui': 'C1704407', 'cui_str': '100'}, {'cui': 'C4319553', 'cui_str': '140'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0332239', 'cui_str': 'Young'}]","[{'cui': 'C4049005', 'cui_str': 'Cataract, total congenital with posterior sutural opacities in Heterozygotes'}, {'cui': 'C0023317', 'cui_str': 'Lens clear'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0429493', 'cui_str': 'Corneal thickness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439583', 'cui_str': 'Overnight'}, {'cui': 'C1269837', 'cui_str': 'Surgical closure of eye structure'}, {'cui': 'C0332461', 'cui_str': 'Plaque'}]","[{'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0205100', 'cui_str': 'Peripheral'}, {'cui': 'C0429493', 'cui_str': 'Corneal thickness'}, {'cui': 'C4049005', 'cui_str': 'Cataract, total congenital with posterior sutural opacities in Heterozygotes'}, {'cui': 'C0032452', 'cui_str': 'Polychlorotriphenyl Compounds'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0010037', 'cui_str': 'Corneal edema'}, {'cui': 'C0038999', 'cui_str': 'Swelling'}]",4.0,0.0459304,Dk/t did not induce significantly higher corneal swelling.,"[{'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Tan', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States.'}, {'ForeName': 'Vivien', 'Initials': 'V', 'LastName': 'Tse', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States.'}, {'ForeName': 'Young Hyun', 'Initials': 'YH', 'LastName': 'Kim', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States; Vision Science Graduate Program, University of California, Berkeley, United States; Chemical and Biomolecular Engineering Department, University of California, Berkeley, United States.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Lin', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States.'}, {'ForeName': 'Yixiu', 'Initials': 'Y', 'LastName': 'Zhou', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States.'}, {'ForeName': 'Meng C', 'Initials': 'MC', 'LastName': 'Lin', 'Affiliation': 'Clinical Research Center, School of Optometry, University of California, Berkeley, United States; Vision Science Graduate Program, University of California, Berkeley, United States. Electronic address: mlin@berkeley.edu.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2019.04.002'] 2978,32735422,The Effects of a Preconditioning Rolling Session on Subsequent Eccentric Exercise-Induced Muscle Damage.,"West, JT, Miller, WM, Jeon, S, and Ye, X. The effects of a preconditioning rolling session on subsequent eccentric exercise-induced muscle damage. J Strength Cond Res 34(8): 2112-2119, 2020-The aim of this study was to examine the effects of a preexercise unilateral quadriceps muscle rolling intervention on subsequent ipsilateral (IPSI) or contralateral (CTRA) knee extension eccentric exercise-induced muscle damage. Twenty-seven healthy volunteers (14 men) underwent an eccentric exercise protocol (6 sets of 10 repetitions with 75% of the maximal isometric strength) with a single-leg knee extension machine. Before the eccentric exercise, the subjects were randomly assigned to either (a) IPSI group: rolling the ipsilateral knee extensor muscles, (b) CTRA: rolling the contralateral muscles, or (c) Control: sitting for 6 minutes (same duration as the rolling intervention protocol) relaxed. The muscle soreness, passive knee extension range of motion, and knee extension isometric strength were measured before, immediately, 24 hours, and 48 hours after exercise. The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control. Isometric strength (p = 0.783) and muscle soreness (p = 0.586) responses were not significantly different among the 3 groups (time points and sexes merged). Additionally, women displayed an overall faster recovery than men in isometric strength (p = 0.001) and muscle soreness (p = 0.024), evidenced by the measurements at 48 hours after exercise. Our study suggests that unilateral quadriceps rolling intervention before high-intensity muscle-damaging exercise has a beneficial effect on maintaining range of motion in both the ipsilateral and contralateral muscles.",2020,"The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control.","['J Strength Cond Res 34(8', 'Twenty-seven healthy volunteers (14 men']","['eccentric exercise protocol (6 sets of 10 repetitions with 75% of the maximal isometric strength) with a single-leg knee extension machine', 'Preconditioning Rolling Session', 'preconditioning rolling session', 'preexercise unilateral quadriceps muscle rolling intervention', 'IPSI group: rolling the ipsilateral knee extensor muscles, (b) CTRA: rolling the contralateral muscles, or (c) Control: sitting for 6 minutes (same duration as the rolling intervention protocol) relaxed']","['Subsequent Eccentric Exercise-Induced Muscle Damage', 'muscle soreness, passive knee extension range of motion, and knee extension isometric strength', 'magnitudes of the range of motion decrement', 'subsequent eccentric exercise-induced muscle damage', 'muscle soreness ', 'muscle soreness', 'Isometric strength', 'subsequent ipsilateral (IPSI) or contralateral (CTRA) knee extension eccentric exercise-induced muscle damage']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0025266', 'cui_str': 'Man'}]","[{'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}, {'cui': 'C0036849', 'cui_str': 'Set (Psychology)'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0037179', 'cui_str': 'Single person'}, {'cui': 'C0023216', 'cui_str': 'Lower limb structure'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C1709632', 'cui_str': 'Precondition'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0037216', 'cui_str': 'SITS'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}]","[{'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C0439740', 'cui_str': 'Eccentric'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0410158', 'cui_str': 'Muscle damage NOS'}, {'cui': 'C0231528', 'cui_str': 'Muscle pain'}, {'cui': 'C0022742', 'cui_str': 'Bone structure of knee'}, {'cui': 'C0231448', 'cui_str': 'Extension'}, {'cui': 'C0080078', 'cui_str': 'Range of joint movement'}, {'cui': 'C0022206', 'cui_str': 'Isometric exercise'}, {'cui': 'C0449286', 'cui_str': 'Degree'}, {'cui': 'C0441989', 'cui_str': 'Ipsilateral'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}]",27.0,0.0249743,"The magnitudes of the range of motion decrement were attenuated in both the IPSI (p = 0.031) and CTRA (p = 0.014) groups 24 hours after the eccentric exercise, when compared with the control.","[{'ForeName': 'Jonathan T', 'Initials': 'JT', 'LastName': 'West', 'Affiliation': 'Department of Health, Exercise Science, and Recreation Management, The University of Mississippi, University, Mississippi.'}, {'ForeName': 'William M', 'Initials': 'WM', 'LastName': 'Miller', 'Affiliation': ''}, {'ForeName': 'Sunggun', 'Initials': 'S', 'LastName': 'Jeon', 'Affiliation': ''}, {'ForeName': 'Xin', 'Initials': 'X', 'LastName': 'Ye', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003678'] 2979,32735423,Effectiveness of a Generic vs. Specific Program Training to Prevent the Short-Term Detraining on Repeated-Sprint Ability of Youth Soccer Players.,"Rodríguez-Fernández, A, Villa, JG, Sánchez-Sánchez, J, and Rodríguez-Marroyo, JA. Effectiveness of a generic vs. specific program training to prevent the short-term detraining on repeated-sprint ability of youth soccer players. J Strength Cond Res 34(8): 2128-2135, 2020-The aim of this study was to analyze the effects of 2 short-term training programs to prevent the negative effect of detraining on repeated-sprint ability (RSA) performance. The study was performed during a 2-week midseason break without official matches. Forty-five youth soccer players (17.7 ± 0.8 years, 175.4 ± 5.5 cm, and 67.2 ± 5.1 kg) were split into 3 groups during the intervention period: inactivity group (IN; N = 16), generic high-intensity training group (GG; N = 15), and specific training group (SG; N = 14). IN was instructed to avoid performing physical activity during the 2-week training intervention. However, GG and SG performed 8 training sessions. GG performed a generic aerobic interval training consisting of 4 repetitions of 4 minutes of exercise at 90-95% of maximal heart rate. SG performed a specific conditioning through small-sided games (4 vs. 4, 4 × 4-minute) and repeated sprints (6 × 30-m). Testing sessions included an RSA test and a Yo-Yo intermittent recovery test level 1 (YYIR1). Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25). Both GG and IN declined their performance in post-test (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.19-0.22). No significant effect, group × time, was analyzed for YYIR1 performance. This study suggests that only specific training, based on small-sided games and repeated sprints, leads to short-term improvements on RSA performance in youth soccer players.",2020,"Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25).","['Youth Soccer Players', 'J Strength Cond Res 34(8', 'youth soccer players', 'Forty-five youth soccer players (17.7 ± 0.8 years, 175.4 ± 5.5 cm, and 67.2 ± 5.1 kg']","['generic vs. specific program training', 'Generic vs. Specific Program Training', 'generic high-intensity training group (GG; N = 15), and specific training']","['YYIR1 performance', 'repeated-sprint ability (RSA) performance', 'RSA performance', 'Repeated-sprint ability performance']","[{'cui': 'C0001578', 'cui_str': 'Adolescence'}, {'cui': 'C0037393', 'cui_str': 'Soccer'}, {'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C4319567', 'cui_str': '45'}, {'cui': 'C4517598', 'cui_str': '17.7'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C3844008', 'cui_str': '5.5'}]","[{'cui': 'C0085155', 'cui_str': 'Generic Drugs'}, {'cui': 'C0205369', 'cui_str': 'Specific'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}]","[{'cui': 'C0205267', 'cui_str': 'Intermittent'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0456947', 'cui_str': 'Level 1'}, {'cui': 'C0205341', 'cui_str': 'Repeat'}, {'cui': 'C0085732', 'cui_str': 'Ability'}]",,0.0153561,"Repeated-sprint ability performance only improved after the training intervention in SG (∼2%, p < 0.01, (Equation is included in full-text article.)= 0.23-0.25).","[{'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Rodríguez-Fernández', 'Affiliation': '1VALFIS Research Group, Institute of Biomedicine (IBIOMED), University of León, León, Spain; 2Faculty of Health Sciences, University Isabel I, Burgos, Spain; and 3Pontifical University of Salamanca, Salamanca, Spain.'}, {'ForeName': 'José G', 'Initials': 'JG', 'LastName': 'Villa', 'Affiliation': ''}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Sánchez-Sánchez', 'Affiliation': ''}, {'ForeName': 'Jose A', 'Initials': 'JA', 'LastName': 'Rodríguez-Marroyo', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003670'] 2980,32735426,Acute Effects of Different Rest Intervals Between Sets of Resistance Exercise on Neuromuscular Fatigue in Trained Older Women.,"Jambassi Filho, JC, Gurjão, ALD, Prado, AKG, Gallo, LH, and Gobbi, S. Acute effects of different rest intervals between sets of resistance exercise on neuromuscular fatigue in trained older women. J Strength Cond Res 34(8): 2235-2240, 2020-The aim of this study was to investigate the acute effect of different rest intervals (RIs) between sets on total volume, time under tension, maximal voluntary contraction (MVC), and integrated electromyography (iEMG) activity of the vastus lateralis (VL) and vastus medialis (VM) muscles. Twenty-one resistance-trained older women (66.4 ± 4.4 years; 69.1 ± 11.4 kg; 157.5 ± 5.0 cm) completed 3 different test sessions, performed 48-72 hours apart, in a randomized and counterbalanced within-subjects design. In 2 test sessions, the participants performed 3 sets to voluntary exhaustion with loads that corresponded to 15 maximum repetitions, with either 1-minute RI (RI-1) or 3-minute RI (RI-3). In another test session, the participants remained at rest for 15 minutes. The total volume of exercise and time under tension for the RI-3 session was statistically higher (p ≤ 0.05) than the RI-1 session. Postexercise MVC for the RI-3 session showed significantly greater reductions (-7.8%; p ≤ 0.05) compared with the RI-1 and control sessions. No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05). The findings of this study suggest that different RIs between sets lead to different acute neuromuscular responses. The longer RI seemed to induce higher neuromuscular fatigue, likely due to higher total volume and time under tension. Thus, longer RI may be a strategy that possibly would lead to greater long-term gains in muscle strength and hypertrophy of the lower limbs in trained older women.",2020,No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05).,"['J Strength Cond Res 34(8', 'trained older women', 'Twenty-one resistance-trained older women (66.4 ± 4.4 years; 69.1 ± 11.4 kg; 157.5 ± 5.0 cm', 'Trained Older Women']","['Resistance Exercise', 'resistance exercise']","['postexercise iEMG activity of the VL and VM', 'total volume, time under tension, maximal voluntary contraction (MVC), and integrated electromyography (iEMG) activity of the vastus lateralis (VL) and vastus medialis (VM) muscles', 'total volume and time under tension', 'Postexercise MVC', 'neuromuscular fatigue', 'Neuromuscular Fatigue', 'total volume of exercise and time under tension for the RI-3 session']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C3715213', 'cui_str': '21'}, {'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C4517761', 'cui_str': '4.4'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C4517533', 'cui_str': '11.4'}]","[{'cui': 'C0162535', 'cui_str': 'Electrical Resistance'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0224445', 'cui_str': 'Structure of vastus medialis muscle'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0233494', 'cui_str': 'Tension'}, {'cui': 'C0205289', 'cui_str': 'Maximal'}, {'cui': 'C0439656', 'cui_str': 'Voluntary'}, {'cui': 'C0567116', 'cui_str': 'Finding of uterine contractions'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C0234116', 'cui_str': 'Neuromuscular fatigue'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]",,0.0376553,No significant changes in postexercise iEMG activity of the VL and VM were shown for any of the sessions (all p > 0.05).,"[{'ForeName': 'José C', 'Initials': 'JC', 'LastName': 'Jambassi Filho', 'Affiliation': '1Department of Physical Education, Institute of Biosciences, São Paulo State University, Sao Paulo, Brazil; 2School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil; 3Department of Physical Education, Federal University of São Francisco Valley, Petrolina, Brazil; 4Department of Physical Education, Faculty of Physical Education, Federal University of Mato Grosso, Cuiabá, Brazil; and 5Federal University of Paraná, Curitiba, Paraná, Brazil.'}, {'ForeName': 'André L D', 'Initials': 'ALD', 'LastName': 'Gurjão', 'Affiliation': ''}, {'ForeName': 'Alexandre K G', 'Initials': 'AKG', 'LastName': 'Prado', 'Affiliation': ''}, {'ForeName': 'Luiza H', 'Initials': 'LH', 'LastName': 'Gallo', 'Affiliation': ''}, {'ForeName': 'Sebastião', 'Initials': 'S', 'LastName': 'Gobbi', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002409'] 2981,32735427,Use of Visual Feedback During Jump-Squat Training Aids Improvement in Sport-Specific Tests in Athletes.,"Vanderka, M, Bezák, A, Longová, K, Krčmár, M, and Walker, S. Use of visual feedback during jump-squat training aids improvement in sport-specific tests in athletes. J Strength Cond Res 34(8): 2250-2257, 2020-This study investigated the effects of instantaneous performance feedback during the jump-squat exercise over a 6-week training period. Twenty-five strength-trained athletes were randomly divided into an instant feedback (n = 13, half-squat 3-repetition maximum (3RM)/body mass = 2.38 ± 0.19) or a nonfeedback (n = 12, half-squat 3RM/body mass = 2.03 ± 0.44) group. Both groups performed the same training program (3 × week), consisting of 4 sets of 8 repetitions (weeks 1-3) and 8 sets of 4 repetitions (weeks 4-6) using a barbell with a load that maximized the average concentric power output (Pmax) of each athlete. Subjects in the instant feedback group were given real-time data after each repetition. Pre-, mid-, and post-training testing consisted of maximum 20-, 30-, and 50-m running speed, 3RM back half-squat load, Pmax and the load that maximized average concentric power output (Pmax load), countermovement jump (CMJ), and squat jump (SJ) height. Results revealed that the feedback group significantly improved all selected tests vs. nonfeedback (time × group interaction, p < 0.01). Significant improvements after training for 20, 30, 50 m, 3RM load, Pmax load, CMJ, and SJ were observed in the feedback group only (p < 0.01). Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05). The results of this study indicate that the use of instant feedback during jump-squat training in athletes was beneficial for improving multiple performance tasks over 6 weeks of training. Instant feedback is an important element of power training to maximize adaptations when training strength-trained athletes.",2020,Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05).,"['J Strength Cond Res 34(8', 'Athletes', 'Twenty-five strength-trained athletes']","['jump-squat exercise', 'Visual Feedback During Jump-Squat Training Aids']","['concentric power output (Pmax load), countermovement jump (CMJ), and squat jump (SJ) height', 'SJ and Pmax (W) and Pmax load', 'Vanderka, M, Bezák, A, Longová, K, Krčmár, M, and Walker, S. Use of visual feedback', 'multiple performance tasks', '3RM load, Pmax load, CMJ, and SJ']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0238703', 'cui_str': 'Athletes'}, {'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0021588', 'cui_str': 'Artificial insemination, heterologous'}]","[{'cui': 'C0439744', 'cui_str': 'Concentric'}, {'cui': 'C0445194', 'cui_str': 'Power output'}, {'cui': 'C0221189', 'cui_str': 'Jumping'}, {'cui': 'C0241236', 'cui_str': 'Does squat'}, {'cui': 'C0005890', 'cui_str': 'Body height measure'}, {'cui': 'C0043016', 'cui_str': 'Walker'}, {'cui': 'C1524063', 'cui_str': 'Use of'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0439064', 'cui_str': 'Numerous'}]",,0.0150862,Training without instant feedback did not lead to significant performance improvements; this group actually demonstrated significant decreases in SJ and Pmax (W) and Pmax load (p < 0.05).,"[{'ForeName': 'Marián', 'Initials': 'M', 'LastName': 'Vanderka', 'Affiliation': '1Department of Track and Field, Faculty of Physical Education and Sport, Comenius University, Bratislava, Slovakia; 2Hamar Institute for Human Performance, Faculty of Physical Education and Sport, Comenius University, Bratislava, Slovakia; and 3Neuromuscular Research Center, Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland.'}, {'ForeName': 'Anton', 'Initials': 'A', 'LastName': 'Bezák', 'Affiliation': ''}, {'ForeName': 'Katarína', 'Initials': 'K', 'LastName': 'Longová', 'Affiliation': ''}, {'ForeName': 'Matúš', 'Initials': 'M', 'LastName': 'Krčmár', 'Affiliation': ''}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Walker', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000002634'] 2982,32353052,A semi-automated machine-learning based workflow for ellipsoid zone analysis in eyes with macular edema: SCORE2 pilot study.,"BACKGROUND AND OBJECTIVE To develop a semi-automated, machine-learning based workflow to evaluate the ellipsoid zone (EZ) assessed by spectral domain optical coherence tomography (SD-OCT) in eyes with macular edema secondary to central retinal or hemi-retinal vein occlusion in SCORE2 treated with anti-vascular endothelial growth factor agents. METHODS SD-OCT macular volume scans of a randomly selected subset of 75 SCORE2 study eyes were converted to the Digital Imaging and Communications in Medicine (DICOM) format, and the EZ layer was segmented using nonproprietary software. Segmented layer coordinates were exported and used to generate en face EZ thickness maps. Within the central subfield, the area of EZ defect was measured using manual and semi-automated approaches via a customized workflow in the open-source data analytics platform, Konstanz Information Miner (KNIME). RESULTS A total of 184 volume scans from 74 study eyes were analyzed. The mean±SD area of EZ defect was similar between manual (0.19±0.22 mm2) and semi-automated measurements (0.19±0.21 mm2, p = 0.93; intra-class correlation coefficient = 0.90; average bias = 0.01, 95% confidence interval of limits of agreement -0.18-0.20). CONCLUSIONS A customized workflow generated via an open-source data analytics platform that applied machine-learning methods demonstrated reliable measurements of EZ area defect from en face thickness maps. The result of our semi-automated approach were comparable to manual measurements.",2020,"The mean±SD area of EZ defect was similar between manual (0.19±0.22 mm2) and semi-automated measurements (0.19±0.21 mm2, p = 0.93; intra-class correlation coefficient = 0.90; average bias = 0.01, 95% confidence interval of limits of agreement -0.18-0.20). ","['SD-OCT macular volume scans of a randomly selected subset of 75', 'A total of 184 volume scans from 74 study eyes were analyzed', 'eyes with macular edema secondary to central retinal or hemi-retinal vein occlusion in SCORE2 treated with anti-vascular endothelial growth factor agents', 'eyes with macular edema']","['semi-automated machine-learning based workflow', 'ellipsoid zone (EZ) assessed by spectral domain optical coherence tomography (SD-OCT']",['mean±SD area of EZ defect'],"[{'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}, {'cui': 'C0449468', 'cui_str': 'Volume'}, {'cui': 'C0034606', 'cui_str': 'Nuclear medicine imaging procedure'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C4517616', 'cui_str': '184'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0271051', 'cui_str': 'Macular retinal edema'}, {'cui': 'C0175668', 'cui_str': 'Secondary'}, {'cui': 'C0205099', 'cui_str': 'Central'}, {'cui': 'C0035298', 'cui_str': 'Retinal structure'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}, {'cui': 'C0035328', 'cui_str': 'Retinal vein occlusion'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0078058', 'cui_str': 'Vascular endothelial growth factor'}, {'cui': 'C0450442', 'cui_str': 'Agent'}]","[{'cui': 'C0205554', 'cui_str': 'Automated'}, {'cui': 'C0336779', 'cui_str': 'Machine'}, {'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C1710679', 'cui_str': 'Work Flow'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0920367', 'cui_str': 'Optical coherence tomography'}]","[{'cui': 'C0017446', 'cui_str': 'Geographic Locations'}, {'cui': 'C0243067', 'cui_str': 'defects'}]",,0.075151,"The mean±SD area of EZ defect was similar between manual (0.19±0.22 mm2) and semi-automated measurements (0.19±0.21 mm2, p = 0.93; intra-class correlation coefficient = 0.90; average bias = 0.01, 95% confidence interval of limits of agreement -0.18-0.20). ","[{'ForeName': 'Tyler', 'Initials': 'T', 'LastName': 'Etheridge', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.'}, {'ForeName': 'Ellen T A', 'Initials': 'ETA', 'LastName': 'Dobson', 'Affiliation': 'Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Marcel', 'Initials': 'M', 'LastName': 'Wiedenmann', 'Affiliation': 'KNIME GmbH, Konstanz, Germany.'}, {'ForeName': 'Chandana', 'Initials': 'C', 'LastName': 'Papudesu', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.'}, {'ForeName': 'Ingrid U', 'Initials': 'IU', 'LastName': 'Scott', 'Affiliation': 'Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, PA, United States of America.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Ip', 'Affiliation': 'Doheny Eye Institute, University of California Los Angeles Stein Eye Institute, Los Angeles, CA, United States of America.'}, {'ForeName': 'Kevin W', 'Initials': 'KW', 'LastName': 'Eliceiri', 'Affiliation': 'Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, Madison, WI, United States of America.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Blodi', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.'}, {'ForeName': 'Amitha', 'Initials': 'A', 'LastName': 'Domalpally', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.'}]",PloS one,['10.1371/journal.pone.0232494'] 2983,32353056,Physical activity of first graders in Norwegian after-school programs: A relevant contribution to the development of motor competencies and learning of movements? Investigated utilizing a mixed methods approach.,"BACKGROUND Development of motor competencies and learning of movements in children is dependent on varied physical activity (PA). After-school programs (ASP) might provide opportunities for young schoolchildren to participate in PA. The aim of the current study was to investigate the PA of first graders in ASP and to consider its contribution to the development of motor competencies and the learning of movements. METHODS The study was performed utilizing a mixed methods design. A total of 42 first graders were sampled from 14 ASPs in Norway. Direct observations of the children's activities were conducted for the duration of one entire ASP day. PA intensity was measured using ActiGraph accelerometers. Qualitative data were analyzed using qualitative content analysis, while the Mann-Whitney U test and the Wilcoxon signed-rank test were used to analyze the quantitative data. RESULTS The median PA time among the observed children was 61.5 minutes. The median stationary time was 75.9 minutes. There was considerable variation within the sample. Girls were significantly more engaged in stationary behavior than boys. Frequent changes in activity type and intensity were typical features of the children's ASP day. PA duration and intensity were significantly higher outdoors than indoors. Adult-managed time had longer periods of stationary behavior than child-managed time. The PA at all intensity levels contained barrier-breaking movements-especially at light intensity levels. CONCLUSION Most of the first graders studied were engaged in a variety of activity types of different duration and intensity levels, favorable for the development of motor competencies and for the learning of movements. Hence, it is reasonable to highlight that light PA, in combination with moderate and vigorous PA, is also of great importance for children during the time they spend in ASP. Ultimately, there is a need for staff members who can also stimulate varied PA among the most stationary children.",2020,PA duration and intensity were significantly higher outdoors than indoors.,"['A total of 42 first graders were sampled from 14 ASPs in Norway', 'first graders in Norwegian after-school programs', 'young schoolchildren to participate in PA']",['school programs (ASP'],"['PA duration and intensity', 'Physical activity', 'PA intensity', 'activity type and intensity', 'median PA time', 'median stationary time']","[{'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0004015', 'cui_str': 'Aspartic Acid'}, {'cui': 'C0028423', 'cui_str': 'Norway'}, {'cui': 'C0028424', 'cui_str': 'Norwegian language'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}]","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0522510', 'cui_str': 'With intensity'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0439835', 'cui_str': 'Stationary'}]",42.0,0.025042,PA duration and intensity were significantly higher outdoors than indoors.,"[{'ForeName': 'Knut', 'Initials': 'K', 'LastName': 'Løndal', 'Affiliation': 'Department of Primary and Secondary Teacher Education, Faculty of Education and International Studies, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Anders Lund Hage', 'Initials': 'ALH', 'LastName': 'Haugen', 'Affiliation': 'Department of Primary and Secondary Teacher Education, Faculty of Education and International Studies, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Siv', 'Initials': 'S', 'LastName': 'Lund', 'Affiliation': 'Department of Primary and Secondary Teacher Education, Faculty of Education and International Studies, Oslo Metropolitan University, Oslo, Norway.'}, {'ForeName': 'Kirsti', 'Initials': 'K', 'LastName': 'Riiser', 'Affiliation': 'Department of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.'}]",PloS one,['10.1371/journal.pone.0232486'] 2984,30652395,EVEREST study report 4: Fluorescein angiography features predictive of polypoidal choroidal vasculopathy.,"IMPORTANCE It is important to identify features of polypoidal choroidal vasculopathy (PCV) that differentiate it from typical neovascular age-related macular degeneration (nAMD) on various imaging modalities, including fluorescein angiography (FA). BACKGROUND PCV was thought to be indistinguishable from nAMD using FA alone. In real-world practice, indocyanine-green angiography may often be unavailable or contraindicated. DESIGN Analysis of FA images from a prospective, multicentre study. PARTICIPANTS Study images of both PCV and nAMD patients from the EVEREST study. METHODS FA features at baseline were independently graded by masked graders (fellowship-trained ophthalmologists) using standardized diagnostic algorithms. MAIN OUTCOME MEASURES Predictive indicators (sensitivity, specificity, positive and negative predictive values) for PCV. RESULTS Of the 95 patients screened, 61 had PCV. Of the 34 screening failures, 15 were diagnosed as nAMD. Hyperfluorescent nodules on FA were observed in 80% of patients with PCV vs 20% with nAMD (P < 0.001). Blocked fluorescence on FA, which corresponded to the presence of subretinal haemorrhage, occurred more frequently among patients with PCV vs nAMD (61.7% vs 13.3%, P = 0.001). Similarly, the leakage characteristic of occult choroidal neovascularization occurred more frequently among patients with PCV vs nAMD (95.0% vs 73.3%, P = 0.026). The positive predictive value for PCV was 94.1% for hyperfluorescent nodules, 94.9% for blocked fluorescence, 83.8% for occult choroidal neovascularization and 82.0% for pigment epithelial detachment. CONCLUSIONS AND RELEVANCE This study demonstrated that certain FA features can be predictive of PCV and may be considered as an indication for retina specialists to perform indocyanine green angiography as confirmatory test.",2019,"Blocked fluorescence on FA, which corresponded to the presence of subretinal haemorrhage, occurred more frequently among patients with PCV vs nAMD (61.7% vs 13.3%, P = 0.001).","['95 patients screened', 'Study images of both PCV and nAMD patients from the EVEREST study', 'polypoidal choroidal vasculopathy', 'FA features at baseline were independently graded by masked graders (fellowship-trained ophthalmologists) using standardized diagnostic algorithms']","['Fluorescein angiography', 'indocyanine green angiography', 'indocyanine-green angiography']","['Predictive indicators (sensitivity, specificity, positive and negative predictive values) for PCV', 'subretinal haemorrhage', 'leakage characteristic of occult choroidal neovascularization', 'Hyperfluorescent nodules on FA']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0199230', 'cui_str': 'Screening for cancer'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1846009', 'cui_str': 'Intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomaly syndrome'}, {'cui': 'C1504336', 'cui_str': 'Polypoidal choroidal vasculopathy'}, {'cui': 'C0271084', 'cui_str': 'Exudative age-related macular degeneration'}, {'cui': 'C0016313', 'cui_str': 'Fluorescein angiography of eye'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0015770', 'cui_str': 'Fellowships'}, {'cui': 'C0336809', 'cui_str': 'Railway train'}, {'cui': 'C1704292', 'cui_str': 'Ophthalmologist'}, {'cui': 'C0011900', 'cui_str': 'Diagnosis'}]","[{'cui': 'C0016313', 'cui_str': 'Fluorescein angiography of eye'}, {'cui': 'C0430879', 'cui_str': 'Indocyanine green angiography'}]","[{'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205160', 'cui_str': 'Negative'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C1504336', 'cui_str': 'Polypoidal choroidal vasculopathy'}, {'cui': 'C0271049', 'cui_str': 'Subretinal hemorrhage'}, {'cui': 'C0015376', 'cui_str': 'Extravasation'}, {'cui': 'C0028794', 'cui_str': 'Occultism'}, {'cui': 'C0600518', 'cui_str': 'Choroidal neovascularisation'}, {'cui': 'C0028259', 'cui_str': 'Nodule'}, {'cui': 'C0016313', 'cui_str': 'Fluorescein angiography of eye'}]",,0.115357,"Blocked fluorescence on FA, which corresponded to the presence of subretinal haemorrhage, occurred more frequently among patients with PCV vs nAMD (61.7% vs 13.3%, P = 0.001).","[{'ForeName': 'Colin S', 'Initials': 'CS', 'LastName': 'Tan', 'Affiliation': 'Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore.'}, {'ForeName': 'Wei K', 'Initials': 'WK', 'LastName': 'Ngo', 'Affiliation': 'National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.'}, {'ForeName': 'Louis W', 'Initials': 'LW', 'LastName': 'Lim', 'Affiliation': 'National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.'}, {'ForeName': 'Nikolle W', 'Initials': 'NW', 'LastName': 'Tan', 'Affiliation': 'National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore.'}, {'ForeName': 'Tock H', 'Initials': 'TH', 'LastName': 'Lim', 'Affiliation': 'Fundus Image Reading Centre, National Healthcare Group Eye Institute, Singapore, Singapore.'}]",Clinical & experimental ophthalmology,['10.1111/ceo.13464'] 2985,32735428,Different Foot Positioning During Calf Training to Induce Portion-Specific Gastrocnemius Muscle Hypertrophy.,"Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES. Different foot positioning during calf training to induce portion-specific gastrocnemius muscle hypertrophy. J Strength Cond Res 34(8): 2347-2351, 2020-The aim of this study was to compare the changes in gastrocnemius muscle thickness (MT) between conditions such as which foot was pointed outward (FPO), foot was pointed inward (FPI), or foot was pointed forward (FPF). Twenty-two young men (23 ± 4 years) were selected and performed a whole-body resistance training program 3 times per week for 9 weeks, with differences in the exercise specific for calves. The calf-raise exercise was performed unilaterally, in a pin-loaded seated horizontal leg-press machine, in 3 sets of 20-25 repetitions for training weeks 1-3 and 4 sets for weeks 4-9. Each subject's leg was randomly assigned for 1 of the 3 groups according to the foot position: FPO, FPI, and FPF. Measurements with a B-mode ultrasound were performed to assess changes in MT of medial and lateral gastrocnemius heads. After the training period, there were observed increases in MT of both medial (FPO = 8.4%, FPI = 3.8%, and FPF = 5.8%) and lateral (FPO = 5.5%, FPI = 9.1%, and FPF = 6.4%) gastrocnemius heads, and significant differences for magnitude of the gains were observed between FPO and FPI conditions (p < 0.05). Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head. Our results suggest that head-specific muscle hypertrophy may be obtained selectively for gastrocnemius after 9 weeks of calf training in young male adults.",2020,"Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head.","['J Strength Cond Res 34(8', 'young male adults', 'Twenty-two young men (23 ± 4 years']","['calf training', 'Different Foot Positioning', 'Calf Training']","['Nunes, JP, Costa, BDV, Kassiano, W, Kunevaliki, G, Castro-e-Souza, P, Rodacki, ALF, Fortes, LS, and Cyrino, ES', 'MT of both medial', 'gastrocnemius muscle thickness (MT']","[{'cui': 'C1856054', 'cui_str': 'Hutterite cerebroosteonephrodysplasia syndrome'}, {'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0086582', 'cui_str': 'Male'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4284772', 'cui_str': '22'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0439234', 'cui_str': 'year'}]","[{'cui': 'C0230445', 'cui_str': 'Structure of calf of leg'}, {'cui': 'C0040607', 'cui_str': 'Training Programs'}, {'cui': 'C0016504', 'cui_str': 'Foot structure'}, {'cui': 'C0150305', 'cui_str': 'Positioning - therapy'}]","[{'cui': 'C0035561', 'cui_str': 'Bone structure of rib'}, {'cui': 'C1431931', 'cui_str': 'ALF protein, human'}, {'cui': 'C0026845', 'cui_str': 'Muscle tissue'}, {'cui': 'C1280412', 'cui_str': 'Thick'}, {'cui': 'C0205098', 'cui_str': 'Medial'}, {'cui': 'C0242691', 'cui_str': 'Gastrocnemius muscle structure'}]",22.0,0.0207449,"Positioning FPO potentiated the increases in MT of the medial gastrocnemius head, whereas FPI provided greater gains for the lateral gastrocnemius head.","[{'ForeName': 'João Pedro', 'Initials': 'JP', 'LastName': 'Nunes', 'Affiliation': '1Metabolism, Nutrition, and Exercise Laboratory, Physical Education and Sport Center, Londrina State University, Londrina, Brazil; 2Department of Physical Education, Federal University of Paraná, Curitiba, Brazil; and 3Department of Physical Education, Federal University of Paraíba, João Pessoa, Brazil.'}, {'ForeName': 'Bruna D V', 'Initials': 'BDV', 'LastName': 'Costa', 'Affiliation': ''}, {'ForeName': 'Witalo', 'Initials': 'W', 'LastName': 'Kassiano', 'Affiliation': ''}, {'ForeName': 'Gabriel', 'Initials': 'G', 'LastName': 'Kunevaliki', 'Affiliation': ''}, {'ForeName': 'Pâmela', 'Initials': 'P', 'LastName': 'Castro-E-Souza', 'Affiliation': ''}, {'ForeName': 'André L F', 'Initials': 'ALF', 'LastName': 'Rodacki', 'Affiliation': ''}, {'ForeName': 'Leonardo S', 'Initials': 'LS', 'LastName': 'Fortes', 'Affiliation': ''}, {'ForeName': 'Edilson S', 'Initials': 'ES', 'LastName': 'Cyrino', 'Affiliation': ''}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003674'] 2986,32735501,Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF- α levels.,"PURPOSE To investigate the efficacy of combining the dopamine receptor agonist pramipexole with levodopa for Parkinson's disease (PD) treatment and to measure their effects on quality of life and tumor necrosis factor (TNF)-α levels in PD patients. BASIC PROCEDURE In total, 160 PD patients who were admitted to our hospital were equally randomized into a control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa). Both groups were treated for 12 weeks. FINDINGS After treatment, scores from the Unified Parkinson's Disease Rating Scales (1-3), the Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39) were significantly decreased in both groups, whereas Mini-Mental State Examination scores were significantly increased. After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group. The incidence of adverse reactions was significantly lower in the study group than in the control group. Furthermore, after treatment, serum TNF-α levels were significantly decreased in both groups compared with pre-treatment levels. CONCLUSION Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-α levels.",2020,"After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group.","['PD patients', '160 PD patients who were admitted to our hospital', ""Parkinson's disease (PD""]","['dopamine receptor agonist pramipexole with levodopa', 'pramipexole combined with levodopa', 'Pramipexole', 'control treatment group (levodopa alone) and the study group (pramipexole combined with levodopa', 'levodopa']","['quality of life', 'quality of life and tumor necrosis factor (TNF)-α levels', 'Mini-Mental State Examination scores', ""Unified Parkinson's Disease Rating Scales"", ""Hamilton Depression Scale, and the Parkinson's Disease Questionnaire (PDQ-39"", 'QOL and serum TNF- α levels', 'serum TNF-α levels', 'PD symptoms', 'incidence of adverse reactions']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C4319554', 'cui_str': '160'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission'}]","[{'cui': 'C0178601', 'cui_str': 'Dopamine receptor agonist'}, {'cui': 'C0074710', 'cui_str': 'Pramipexole'}, {'cui': 'C0023570', 'cui_str': 'Levodopa'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}]","[{'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0041368', 'cui_str': 'TNF Receptor Ligands'}, {'cui': 'C0441889', 'cui_str': 'Levels'}, {'cui': 'C2960235', 'cui_str': 'Mini-mental state examination score'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021149', 'cui_str': 'Incidence'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction'}]",160.0,0.0158009,"After treatment, the study group had significantly lower scores for all scales except the Mini-Mental State Examination, for which those who received combined treatment had significantly higher scores than the control group.","[{'ForeName': 'Jinzhong', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Hong', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Zhilong', 'Initials': 'Z', 'LastName': 'Yang', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Ding', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Ren', 'Affiliation': 'Department of Neurology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.'}]",The Journal of international medical research,['10.1177/0300060520922449'] 2987,32735514,Treatment Outcomes of a Multi-Component Mobile Health Smoking Cessation Pilot Intervention for People with Schizophrenia.,"OBJECTIVE The objective of this study was to investigate the feasibility and acceptability of a multi-component mobile contingency management (CM) pilot intervention for smoking cessation for people with schizophrenia. Methods: This intervention included mobile CM (i.e., monetary compensation for bioverification of abstinence through using a phone app), cognitive behavioral therapy (CBT), and pharmacotherapy for smoking cessation. This intervention was compared to an intensive treatment comparison (ITC), which contained all components except the CM. Participants were bioverified with carbon monoxide and saliva cotinine at a 6-month follow-up session. Results: In this pilot, the treatment group did not differ from the ITC at any time point. However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. Conclusions: Despite lack of long-term abstinence for participants, adherence to the mobile application intervention indicates the potential for future investigation of mobile smoking cessation treatments for people with schizophrenia.",2020,"However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. ","['People with Schizophrenia', 'people with schizophrenia', 'smokers with schizophrenia']","['multi-component mobile contingency management (CM) pilot intervention', 'mobile CM (i.e., monetary compensation for bioverification of abstinence through using a phone app), cognitive behavioral therapy (CBT), and pharmacotherapy for smoking cessation', 'Multi-Component Mobile Health Smoking Cessation Pilot Intervention']","['feasibility and acceptability', 'bioverified with carbon monoxide and saliva cotinine']","[{'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenia'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0439064', 'cui_str': 'Numerous'}, {'cui': 'C0449432', 'cui_str': 'Component'}, {'cui': 'C0001554', 'cui_str': 'Administration'}, {'cui': 'C0473169', 'cui_str': 'Pilot - aircraft'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0152057', 'cui_str': 'Compensation'}, {'cui': 'C0036899', 'cui_str': 'Celibacy'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0611285', 'cui_str': 'APP protein, human'}, {'cui': 'C0009244', 'cui_str': 'Cognitive therapy'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0085134', 'cui_str': 'Stopping Smoking'}, {'cui': 'C2718080', 'cui_str': 'mHealth'}]","[{'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0036087', 'cui_str': 'Saliva'}, {'cui': 'C0010194', 'cui_str': 'Cotinine'}]",,0.0259744,"However, measures of treatment feasibility and acceptability indicated that smokers with schizophrenia were able to navigate the CM phone application and adhere to the protocol, demonstrating the potential utility of mobile interventions in this population. ","[{'ForeName': 'Alyssa M', 'Initials': 'AM', 'LastName': 'Medenblik', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Adam M', 'Initials': 'AM', 'LastName': 'Mann', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Tiffany A', 'Initials': 'TA', 'LastName': 'Beaver', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Dedert', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Sarah M', 'Initials': 'SM', 'LastName': 'Wilson', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Patrick S', 'Initials': 'PS', 'LastName': 'Calhoun', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}, {'ForeName': 'Jean C', 'Initials': 'JC', 'LastName': 'Beckham', 'Affiliation': 'Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.'}]",Journal of dual diagnosis,['10.1080/15504263.2020.1797259'] 2988,32735552,Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.,"Background The impact of hormones on the development of breast cancer is despite extensive studies, incompletely understood. Combined estrogen-progestogen treatment augments the risk for breast cancer beyond that of estrogen alone, according to numerous studies. The role of breast cell proliferation as a promoter in the development and growth of breast cancer is well recognized. Materials and methods Seventy-nine patients from three randomised trials were subject to a re-analysis of breast cell proliferation: (1) 22 women received continuous combined treatment with oral estradiol (E2) 2 mg/norethisterone acetate (NETA) 1 mg once daily for 3 months. (2) Thirty-seven women received 2 months of sequential treatment with oral conjugated equine estrogens (CEE) 0.625 mg daily combined with medroxyprogesterone acetate (MPA) 5 mg for 14/28 days of each cycle. (3) Twenty women received oral estradiol-valerate (E2V) 2 mg daily combined with levonorgestrel (LNG) intrauterine system (IUS), 20 μg/24 h for 2 months. Fine needle aspiration (FNA) (studies 1 and 3) and core needle biopsy (CNB) (study 2) were used for the assessment of breast cell proliferation. Results There were no baseline proliferation differences, but at the end of treatment there was a highly significant between-group difference for E2V/LNG IUS versus the other two groups (p = 0.0025). E2/NETA and CEE treatments gave a 4-7-old increase in proliferation during treatment (p = 0.04) and (p = 0.007), respectively, which was absent in the E2V/LNG group, showing a significant correlation with insulin-like growth factor binding protein-3 (IGFBP-3) serum levels. Conclusion E2V in combination with very low serum concentrations of LNG in the IUS gives no increase in proliferation in the normal breast.",2020,"There were no baseline proliferation differences, but at the end of treatment there was a highly significant between-group difference for E2V/LNG IUS versus the other two groups (p = 0.0025).","['2) Thirty-seven women', 'Materials and methods Seventy-nine patients from three randomised trials were subject to a re-analysis of breast cell proliferation: (1) 22 women received']","['continuous combined treatment with oral estradiol (E2) 2 mg/norethisterone acetate (NETA', 'oral conjugated equine estrogens (CEE) 0.625 mg daily combined with medroxyprogesterone acetate (MPA', 'Combined estrogen-progestogen treatment', 'Progestogen addition with low-dose levonorgestrel intrauterine system', 'Fine needle aspiration (FNA) (studies 1 and 3) and core needle biopsy (CNB', 'norethisterone acetate or medroxyprogesterone acetate', 'E2V) 2 mg daily combined with levonorgestrel (LNG) intrauterine system (IUS', 'oral estradiol-valerate']","['normal breast tissue proliferation', 'insulin-like growth factor binding protein-3 (IGFBP-3) serum levels', 'proliferation']","[{'cui': 'C4319569', 'cui_str': '37'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0520510', 'cui_str': 'Material'}, {'cui': 'C0025663', 'cui_str': 'Method'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0006141', 'cui_str': 'Breast structure'}, {'cui': 'C0596290', 'cui_str': 'Cellular Proliferation'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0009429', 'cui_str': 'Combination therapy'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0985842', 'cui_str': 'Estradiol 2 MG'}, {'cui': 'C0068980', 'cui_str': 'Norethindrone acetate'}, {'cui': 'C0019944', 'cui_str': 'Equus caballus'}, {'cui': 'C0014939', 'cui_str': 'Estrogens'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C4517467', 'cui_str': '0.625'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0205195', 'cui_str': 'Combined'}, {'cui': 'C0065864', 'cui_str': 'Medroxyprogesterone acetate'}, {'cui': 'C0033306', 'cui_str': 'Progestational hormone'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0445550', 'cui_str': 'Low dose'}, {'cui': 'C4293465', 'cui_str': 'Levonorgestrel Intrauterine System [Kyleena]'}, {'cui': 'C1510483', 'cui_str': 'Fine needle aspiration biopsy - action'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C1318309', 'cui_str': 'Core needle biopsy'}, {'cui': 'C4293370', 'cui_str': 'Intrauterine System'}, {'cui': 'C0059623', 'cui_str': 'Estradiol valerate'}]","[{'cui': 'C0567498', 'cui_str': 'Breast normal'}, {'cui': 'C0040300', 'cui_str': 'Body tissue structure'}, {'cui': 'C0334094', 'cui_str': 'Proliferation'}, {'cui': 'C0123707', 'cui_str': 'Insulin-like growth factor binding protein 3'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441889', 'cui_str': 'Levels'}]",79.0,0.0672585,"There were no baseline proliferation differences, but at the end of treatment there was a highly significant between-group difference for E2V/LNG IUS versus the other two groups (p = 0.0025).","[{'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Lundström', 'Affiliation': ""Division for Obstetrics and Gynecology, Department of Children's and Women's Health, Karolinska Institutet, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.""}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Virijevic', 'Affiliation': 'Department of Obstetrics and Gynecology, Västerås Hospital, Västerås, Sweden.'}, {'ForeName': 'Gunnar', 'Initials': 'G', 'LastName': 'Söderqvist', 'Affiliation': ""Division for Obstetrics and Gynecology, Department of Children's and Women's Health, Karolinska Institutet, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.""}]",Hormone molecular biology and clinical investigation,['10.1515/hmbci-2019-0051'] 2989,32735903,Ultra-Response to Ranibizumab: Improvement by 4 or More Steps in Diabetic Retinopathy Severity in DRCR.net Protocol S.,"PURPOSE To quantify and evaluate patients with diabetic retinopathy (DR) who had at least 4-step improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in response to treatment with ranibizumab in the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol S study, and factors predictive of such improvements. DESIGN Post hoc retrospective analysis of 2-year outcomes in the phase 3 Protocol S study. PARTICIPANTS Patients randomized to treatment with ranibizumab 0.5 mg with sufficient baseline DRSS severity (≥47) to allow for an at least 4-step improvement (n = 181). METHODS Study eyes received a ranibizumab 0.5 mg injection at baseline and every 4 weeks for 12 weeks, with subsequent as-needed injections. Fundus photographs graded at baseline and years 1 and 2 using DRSS were used for this analysis. The data source is DRCR.net, but analyses, content, and conclusions of this report are solely the responsibility of the authors. MAIN OUTCOME MEASURES Proportion of eyes achieving an at least 4-step DRSS improvement (DR ultra-response) at years 1 and 2; treatment course for eyes achieving ultra-response; mean change in best-corrected visual acuity (BCVA) in eyes with and without ultra-response; factors associated with ultra-response (identified by univariate and multivariable analyses). RESULTS Nearly 30% of ranibizumab-treated eyes achieved DR ultra-response at year 1 (43/148; 29.1%) and year 2 (38/136; 27.9%); 74% of eyes with ultra-response at year 1 maintained their response at year 2. At year 2, patients with DR ultra-response had gained more than 5 additional ETDRS letters compared with those without DR ultra-response. Multivariable analyses identified presence of vitreous hemorrhage at baseline, increasing age, absence of epiretinal membrane, and glycated hemoglobin below 9 as predictive of DR ultra-response. Mean number of injections received was similar for eyes with versus without DR ultra-response to ranibizumab (mean, 7.4 vs. 7.6 in year 1; mean, 4.2 vs. 3.9 in year 2). CONCLUSIONS Approximately 30% of eyes with an DRSS score of at least 47 receiving ranibizumab 0.5 mg per study protocol experienced at least 4-step DR severity improvement on the DRSS, accompanied by meaningful improvements in BCVA.",2020,"Approximately 30% of eyes with an DRSS score of at least 47 receiving ranibizumab 0.5 mg per study protocol experienced at least 4-step DR severity improvement on the DRSS, accompanied by meaningful improvements in BCVA.","['patients with diabetic retinopathy (DR) who had at least 4-step improvement on the Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity Scale (DRSS) in response to treatment with', 'Diabetic Retinopathy Severity in DRCR.net Protocol S']","['ranibizumab 0.5 mg with sufficient baseline DRSS severity', 'ranibizumab 0.5 mg injection', 'Ranibizumab', 'ranibizumab']","['Proportion of eyes achieving an at least 4-step DRSS improvement (DR ultra-response', 'visual acuity (BCVA', 'vitreous hemorrhage', 'Mean number of injections', 'BCVA', 'ultra-response', 'DR ultra-response']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0521982', 'cui_str': 'Response to treatment'}, {'cui': 'C0150775', 'cui_str': 'Social Networks'}, {'cui': 'C0442711', 'cui_str': 'Protocols'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0444500', 'cui_str': '0.5'}, {'cui': 'C0205410', 'cui_str': 'Sufficient'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]","[{'cui': 'C0015392', 'cui_str': 'Eye structure'}, {'cui': 'C0427149', 'cui_str': 'Foot-drop gait'}, {'cui': 'C0011884', 'cui_str': 'Retinopathy due to diabetes mellitus'}, {'cui': 'C0439793', 'cui_str': 'Severities'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042812', 'cui_str': 'Visual acuity'}, {'cui': 'C0038848', 'cui_str': 'Supplies'}, {'cui': 'C1275680', 'cui_str': 'Corrected visual acuity'}, {'cui': 'C0042909', 'cui_str': 'Vitreous hemorrhage'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0021485', 'cui_str': 'Injection of therapeutic agent'}]",181.0,0.139807,"Approximately 30% of eyes with an DRSS score of at least 47 receiving ranibizumab 0.5 mg per study protocol experienced at least 4-step DR severity improvement on the DRSS, accompanied by meaningful improvements in BCVA.","[{'ForeName': 'Allen', 'Initials': 'A', 'LastName': 'Chiang', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania. Electronic address: achiang@midatlanticretina.com.'}, {'ForeName': 'Sunir J', 'Initials': 'SJ', 'LastName': 'Garg', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Klufas', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Allen C', 'Initials': 'AC', 'LastName': 'Ho', 'Affiliation': 'Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Hill', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Min', 'Initials': 'M', 'LastName': 'Tsuboi', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}, {'ForeName': 'Ivaylo', 'Initials': 'I', 'LastName': 'Stoilov', 'Affiliation': 'Genentech, Inc., South San Francisco, California.'}]",Ophthalmology. Retina,['10.1016/j.oret.2020.07.009'] 2990,32735952,Acute hyperglycaemia can impair driving skill in young type 1 diabetes mellitus patients.,"AIM Drivers with diabetes are at increased risk of being involved in road accidents. Therefore, this study aimed to evaluate the effects of acute hyperglycaemia (AH) compared with euglycaemia on driving ability in patients with type 1 diabetes mellitus (T1DM). METHODS Eighteen drivers with T1DM were asked to navigate twice through nine hazardous scenarios, using a driving simulator, during euglycaemia and then again during AH (mean blood glucose: 138 ± 34 mg/dL and 321 ± 29 mg/dL, respectively) in a counterbalanced crossover study. Driving performance was continually monitored for driving speed, steering wheel angle, acceleration, and location and velocity of other vehicles and obstacles, with drivers wearing a mobile head-mounted eye-tracking system. RESULTS The main findings were that, during AH, participants were less likely to identify a hazard [probability of identification (POI): 0.5725 ± 0.5], glanced fewer times at the hazard (3.24 ± 5.9), maintained shorter headway (between-vehicle) distance (mean: 40.87 ± 20.15 m) and had an increased number of braking events per km driven (6.69 ± 5.20) compared with driving during euglycaemia (POI: 0.733 ± 0.4; number of glances: 3.69 ± 6.99; headway distance: 50.46 ± 26.2 m; number of braking events per km driven: 4.31 ± 3.87; P <  0.05 for all parameters). CONCLUSION This study provides evidence that AH impairs driving performance in young T1DM patients by demonstrating the negative effects of AH on both hazard perception and speed management.",2020,"(mean blood glucose: 138 ± 34 mg/dL and 321 ± 29 mg/dL, respectively) in a counterbalanced crossover study.","['young T1DM patients', 'Eighteen drivers with T1DM', 'patients with type 1 diabetes mellitus (T1DM', 'young type 1 diabetes mellitus patients']","['navigate twice through nine hazardous scenarios, using a driving simulator, during euglycaemia and then again during AH', 'euglycaemia', 'acute hyperglycaemia (AH']",['number of braking events'],"[{'cui': 'C0332239', 'cui_str': 'Young'}, {'cui': 'C0011854', 'cui_str': 'Type 1 diabetes mellitus'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0684312', 'cui_str': 'Vehicle driver'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes mellitus'}]","[{'cui': 'C1720725', 'cui_str': 'Twice'}, {'cui': 'C0004379', 'cui_str': 'Driving'}, {'cui': 'C0183309', 'cui_str': 'Simulator'}, {'cui': 'C0342301', 'cui_str': 'Acute hyperglycemia'}]","[{'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0337108', 'cui_str': 'Brake'}, {'cui': 'C0441471', 'cui_str': 'Event'}]",,0.0707027,"(mean blood glucose: 138 ± 34 mg/dL and 321 ± 29 mg/dL, respectively) in a counterbalanced crossover study.","[{'ForeName': 'Alon', 'Initials': 'A', 'LastName': 'Haim', 'Affiliation': 'Pediatric Endocrinology & Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel. Electronic address: alonhaim@bgu.ac.il.'}, {'ForeName': 'Rotem Shalev', 'Initials': 'RS', 'LastName': 'Shamay', 'Affiliation': 'Pediatric Endocrinology & Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Dana', 'Initials': 'D', 'LastName': 'Ridel', 'Affiliation': 'Department of Industrial Engineering & Management, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Yisrael', 'Initials': 'Y', 'LastName': 'Parmet', 'Affiliation': 'Department of Industrial Engineering & Management, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Neta', 'Initials': 'N', 'LastName': 'Loewenthal', 'Affiliation': 'Pediatric Endocrinology & Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Idit', 'Initials': 'I', 'LastName': 'Liberty', 'Affiliation': 'Department of Internal Medicine, Adult Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel.'}, {'ForeName': 'Shai', 'Initials': 'S', 'LastName': 'Tejman-Yarden', 'Affiliation': 'Edmond J. Safra International Congenital Heart Center, Sheba Medical Center, Ramat Gan, Israel.'}, {'ForeName': 'Eli', 'Initials': 'E', 'LastName': 'Hershkovitz', 'Affiliation': 'Pediatric Endocrinology & Diabetes Unit, Soroka University Medical Center, Beer Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Avinoam', 'Initials': 'A', 'LastName': 'Borowsky', 'Affiliation': 'Department of Industrial Engineering & Management, Ben-Gurion University of the Negev, Beer Sheva, Israel.'}]",Diabetes & metabolism,['10.1016/j.diabet.2020.07.003'] 2991,32735987,"A Two-Site, Open-Label, Non-Randomized Trial Comparing Focal Electrically-Administered Seizure Therapy (FEAST) and Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy (RUL-UBP ECT).","BACKGROUND Focal Electrically-Administered Seizure Therapy (FEAST) is a form of electroconvulsive therapy (ECT) that spatially focuses the electrical stimulus to initiate seizure activity in right prefrontal cortex. Two open-label non-comparative studies suggested that FEAST has reduced cognitive side effects when compared to historical data from other forms of ECT. In two different ECT clinics, we compared the efficacy and cognitive side effects of FEAST and Right Unilateral Ultrabrief Pulse (RUL-UBP) ECT. METHODS Using a non-randomized, open-label design, 39 depressed adults were recruited after referral for ECT. Twenty patients received FEAST (14 women; age 45.2±12.7), and 19 received RUL-UBP ECT (16 women; age 43.2±16.4). Key cognitive outcome measures were the postictal time to reorientation and the Columbia University Autobiographical Memory Interview: Short-Form (CUAMI-SF). Antidepressant effects were assessed using the Hamilton Rating Scale for Depression (HRSD 24 ). RESULTS In the Intent-to-treat sample, a repeated measures mixed model suggested no between group difference in HRSD 24 score over time (F 1,35 = 0.82, p=0.37), while the response rate favored FEAST (FEAST: 65%; RUL-UBP ECT: 57.9%), and the remission rate favored RUL-UBP ECT (FEAST: 35%; RUL-UBP ECT: 47.4%). The FEAST group had numeric superiority in average time to reorientation (FEAST: 6.6±5.0 minutes; RUL-UBP ECT: 8.8±5.8 minutes; Cohens d = 0.41), and CUAMI-SF consistency score (FEAST: 69.2±14.2%; RUL-UBP ECT: 63.9±9.9%; Cohens d = 0.43); findings that failed to meet statistical significance. CONCLUSIONS FEAST exerts similar efficacy relative to an optimal form of conventional ECT and may have milder cognitive side effects. A blinded, randomized, non-inferiority trial is needed.",2020,"The FEAST group had numeric superiority in average time to reorientation (FEAST: 6.6±5.0 minutes; RUL-UBP ECT: 8.8±5.8 minutes; Cohens d = 0.41), and CUAMI-SF consistency score (FEAST: 69.2±14.2%; RUL-UBP ECT: 63.9±9.9%; Cohens d = 0.43); findings that failed to meet statistical significance. ","['Twenty patients received FEAST (14 women; age 45.2±12.7), and 19 received', '39 depressed adults were recruited after referral for ECT']","['electroconvulsive therapy (ECT', 'FEAST and Right Unilateral Ultrabrief Pulse (RUL-UBP) ECT', 'Focal Electrically-Administered Seizure Therapy (FEAST) and Right Unilateral Ultrabrief Pulse Electroconvulsive Therapy (RUL-UBP ECT', 'RUL-UBP ECT', 'FEAST', 'Focal Electrically-Administered Seizure Therapy (FEAST']","['cognitive side effects', 'CUAMI-SF consistency score', 'efficacy and cognitive side effects', 'postictal time to reorientation and the Columbia University Autobiographical Memory Interview: Short-Form (CUAMI-SF', 'Hamilton Rating Scale for Depression (HRSD 24 ', 'numeric superiority', 'Antidepressant effects', 'HRSD 24 score over time']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0344315', 'cui_str': 'Depressed mood'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C2585524', 'cui_str': 'Referral for'}, {'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}]","[{'cui': 'C0013806', 'cui_str': 'Electroconvulsive therapy'}, {'cui': 'C0205234', 'cui_str': 'Focal'}, {'cui': 'C0013790', 'cui_str': 'Electricity'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0022333', 'cui_str': 'Jacksonian Seizure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0205092', 'cui_str': 'Unilateral'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}]","[{'cui': 'C0001688', 'cui_str': 'adverse effects'}, {'cui': 'C0041740', 'cui_str': 'University'}, {'cui': 'C0451013', 'cui_str': 'Autobiographical memory interview'}, {'cui': 'C0453933', 'cui_str': 'Shorts'}, {'cui': 'C0205431', 'cui_str': 'Formed'}, {'cui': 'C0332529', 'cui_str': 'Consistency'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0451203', 'cui_str': 'Hamilton rating scale for depression'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant'}, {'cui': 'C1280500', 'cui_str': 'Effect'}]",39.0,0.0739028,"The FEAST group had numeric superiority in average time to reorientation (FEAST: 6.6±5.0 minutes; RUL-UBP ECT: 8.8±5.8 minutes; Cohens d = 0.41), and CUAMI-SF consistency score (FEAST: 69.2±14.2%; RUL-UBP ECT: 63.9±9.9%; Cohens d = 0.43); findings that failed to meet statistical significance. ","[{'ForeName': 'Gregory L', 'Initials': 'GL', 'LastName': 'Sahlem', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA. Electronic address: sahlem@musc.edu.'}, {'ForeName': 'William V', 'Initials': 'WV', 'LastName': 'McCall', 'Affiliation': 'Department of Psychiatry and Health Behavior, GA, USA; Medical College of Georgia, GA, USA; Augusta University, GA, USA.'}, {'ForeName': 'E Baron', 'Initials': 'EB', 'LastName': 'Short', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Rosenquist', 'Affiliation': 'Department of Psychiatry and Health Behavior, GA, USA; Medical College of Georgia, GA, USA; Augusta University, GA, USA.'}, {'ForeName': 'James B', 'Initials': 'JB', 'LastName': 'Fox', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA.'}, {'ForeName': 'Nagy A', 'Initials': 'NA', 'LastName': 'Youssef', 'Affiliation': 'Department of Psychiatry and Health Behavior, GA, USA; Medical College of Georgia, GA, USA; Augusta University, GA, USA.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Manett', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA.'}, {'ForeName': 'Suzanne E', 'Initials': 'SE', 'LastName': 'Kerns', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA.'}, {'ForeName': 'Morgan M', 'Initials': 'MM', 'LastName': 'Dancy', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA.'}, {'ForeName': 'Laryssa', 'Initials': 'L', 'LastName': 'McCloud', 'Affiliation': 'Department of Psychiatry and Health Behavior, GA, USA; Medical College of Georgia, GA, USA; Augusta University, GA, USA.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'George', 'Affiliation': 'Brain Stimulation Division, Department of Psychiatry, Medical University of South Carolina, SC, USA; Ralph H. Johnson VA Medical Center, SC, USA.'}, {'ForeName': 'Harold A', 'Initials': 'HA', 'LastName': 'Sackeim', 'Affiliation': 'Departments of Psychiatry and Radiology, Columbia University, NY, USA.'}]",Brain stimulation,['10.1016/j.brs.2020.07.015'] 2992,32736036,"Bouncing Back after Lumbar Spine Surgery: Early Postoperative Resilience is Associated with 12-Month Physical Function, Pain Interference, Social Participation, and Disability.","BACKGROUND CONTEXT Positive psychosocial factors early after surgery, such as resilience and self-efficacy, may be important characteristics for informing individualized postoperative care. PURPOSE To examine the association of early postoperative resilience and self-efficacy on 12-month physical function, pain interference, social participation, disability, pain intensity, and physical activity after lumbar spine surgery. STUDY DESIGN/SETTING Pooled secondary analysis of prospectively-collected trial data from two academic medical centers. PATIENT SAMPLE 248 patients who underwent laminectomy with or without fusion for a degenerative lumbar condition. OUTCOME MEASURES Physical function, pain inference, and social participation (ability to participate in social roles and activities) were measured using the Patient Reported Outcomes Measurement Information System. The Oswestry Disability Index, Numeric Rating Scale, and accelerometer activity counts were used to measure disability, pain intensity, and physical activity, respectively. METHODS Participants completed validated outcome questionnaires at 6 weeks (baseline) and 12 months after surgery. Baseline positive psychosocial factors included resilience (Brief Resilience Scale) and self-efficacy (Pain Self-Efficacy Questionnaire). Multivariable linear regression analyses were used to assess the associations between early postoperative psychosocial factors and 12-month outcomes adjusting for age, sex, study site, randomized group, fusion status, fear of movement (Tampa Scale of Kinesiophobia), and outcome score at baseline. This study was funded by Patient-Centered Outcomes Research Institute and Foundation for Physical Therapy Research. There are no conflicts of interest. RESULTS Resilience at 6 weeks after surgery was associated with 12-month physical function (unstandardized beta = 1.85 [95% CI: 0.29; 3.40]), pain interference (unstandardized beta = -1.80 [95% CI: -3.48; -0.12]), social participation (unstandardized beta = 2.69 [95% CI: 0.97; 4.41]), and disability (unstandardized beta = -3.03 [95% CI: -6.04; -0.02]). Self-efficacy was associated with 12-month disability (unstandardized beta = -0.21 [95% CI: -0.37; -0.04]. CONCLUSIONS Postoperative resilience and pain self-efficacy were associated with improved 12-month patient-reported outcomes after spine surgery. Future work should consider how early postoperative screening for positive psychosocial characteristics can enhance risk stratification and targeted rehabilitation management in patients undergoing spine surgery.",2020,Self-efficacy was associated with 12-month disability (unstandardized beta = -0.21 [95% CI: -0.37;,"['Participants completed validated outcome questionnaires at 6 weeks (baseline) and 12 months after surgery', 'Bouncing Back after Lumbar Spine Surgery', 'patients undergoing spine surgery', 'SAMPLE\n\n\n248 patients who underwent laminectomy with or without fusion for a degenerative lumbar condition']",[],"['disability (unstandardized beta', '12-month disability', '12-Month Physical Function, Pain Interference, Social Participation, and Disability', '12-month physical function, pain interference, social participation, disability, pain intensity, and physical activity', 'Oswestry Disability Index, Numeric Rating Scale, and accelerometer activity counts', 'social participation', '12-month physical function', 'disability, pain intensity, and physical activity, respectively', 'fusion status, fear of movement (Tampa Scale of Kinesiophobia), and outcome score', 'Postoperative resilience and pain self-efficacy', 'pain interference', 'Physical function, pain inference, and social participation (ability to participate in social roles and activities', 'Baseline positive psychosocial factors included resilience (Brief Resilience Scale) and self-efficacy (Pain Self-Efficacy Questionnaire', 'Self-efficacy']","[{'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0408578', 'cui_str': 'Operation on lumbar spine'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0920347', 'cui_str': 'Procedure on spinal cord'}, {'cui': 'C0370003', 'cui_str': 'Specimen'}, {'cui': 'C0022983', 'cui_str': 'Laminectomy'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0011164', 'cui_str': 'Degeneration'}, {'cui': 'C0024090', 'cui_str': 'Lumbar'}, {'cui': 'C0009647', 'cui_str': 'Conditioning'}]",[],"[{'cui': 'C0231170', 'cui_str': 'Disability'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0031843', 'cui_str': 'PH'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0521102', 'cui_str': 'Interferes with'}, {'cui': 'C0814554', 'cui_str': 'Social Participation'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index'}, {'cui': 'C0237753', 'cui_str': 'Number'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0026606', 'cui_str': 'Physical activity'}, {'cui': 'C0439157', 'cui_str': 'counts'}, {'cui': 'C0332466', 'cui_str': 'Fusion'}, {'cui': 'C0449438', 'cui_str': 'Status'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C4285782', 'cui_str': 'Kinesiophobia'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0032790', 'cui_str': 'Postoperative period'}, {'cui': 'C0683253', 'cui_str': 'Psychological resilience'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0035820', 'cui_str': 'Role'}, {'cui': 'C0168634', 'cui_str': 'BaseLine dental cement'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0033963', 'cui_str': 'Psychosocial Factors'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0453896', 'cui_str': 'Briefs'}, {'cui': 'C4075347', 'cui_str': 'Pain Self-efficacy Questionnaire'}]",248.0,0.07827,Self-efficacy was associated with 12-month disability (unstandardized beta = -0.21 [95% CI: -0.37;,"[{'ForeName': 'Rogelio A', 'Initials': 'RA', 'LastName': 'Coronado', 'Affiliation': 'Department of Orthopaedic Surgery, Center for Musculoskeletal Research, Department of Physical Medicine and Rehabilitation, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: rogelio.coronado@vumc.org.'}, {'ForeName': 'Payton E', 'Initials': 'PE', 'LastName': 'Robinette', 'Affiliation': 'Department of Orthopaedic Surgery, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: payton.e.robinette.1@vumc.org.'}, {'ForeName': 'Abigail L', 'Initials': 'AL', 'LastName': 'Henry', 'Affiliation': 'Department of Orthopaedic Surgery, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: abby.henry2845@gmail.com.'}, {'ForeName': 'Jacquelyn S', 'Initials': 'JS', 'LastName': 'Pennings', 'Affiliation': 'Department of Orthopaedic Surgery, Center for Musculoskeletal Research, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: jacquelyn.pennings@vumc.org.'}, {'ForeName': 'Christine M', 'Initials': 'CM', 'LastName': 'Haug', 'Affiliation': 'Department of Orthopaedic Surgery, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: chrissy.haug@cnsa.com.'}, {'ForeName': 'Richard L', 'Initials': 'RL', 'LastName': 'Skolasky', 'Affiliation': 'Department of Orthopaedic Surgery, Johns Hopkins University, 601 N. Caroline St, Baltimore, MD, 21287. Electronic address: rskolas1@jhmi.edu.'}, {'ForeName': 'Iii Lee H', 'Initials': 'ILH', 'LastName': 'Riley', 'Affiliation': 'Department of Orthopaedic Surgery, Johns Hopkins University, 601 N. Caroline St, Baltimore, MD, 21287, USA. Electronic address: lriley@jhmi.edu.'}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Neuman', 'Affiliation': 'Department of Orthopaedic Surgery, Johns Hopkins University, 601 N. Caroline St, Baltimore, MD, 21287, USA. Electronic address: bneuman7@jhmi.edu.'}, {'ForeName': 'Joseph S', 'Initials': 'JS', 'LastName': 'Cheng', 'Affiliation': 'Department of Neurological Surgery, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 2200, Cincinnati, OH, 45219, USA. Electronic address: chengj6@ucmail.uc.edu.'}, {'ForeName': 'Oran S', 'Initials': 'OS', 'LastName': 'Aaronson', 'Affiliation': 'Howell Allen Clinic, Saint Thomas Medical Partners, 2011 Murphy Avenue, Suite 301, Nashville, TN, USA, 37203. Electronic address: oaaronson@howellallen.com.'}, {'ForeName': 'Clinton J', 'Initials': 'CJ', 'LastName': 'Devin', 'Affiliation': 'Steamboat Orthopaedic and Spine Institute, 904 Central Park Drive, Suite 280, Steamboat Springs, CO, USA, 80487. Electronic address: clinton.j.devin@vumc.org.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Wegener', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Johns Hopkins University, 601 N. Caroline St, Baltimore, MD, 21287, USA. Electronic address: swegener@jhmi.edu.'}, {'ForeName': 'Kristin R', 'Initials': 'KR', 'LastName': 'Archer', 'Affiliation': 'Department of Orthopaedic Surgery, Center for Musculoskeletal Research, Department of Physical Medicine and Rehabilitation, Osher Center for Integrative Medicine, Vanderbilt University Medical Center, 1215 21st Avenue South, Medical Center East-South Tower, Suite 4200, Nashville, TN, USA, 37232. Electronic address: kristin.archer@vumc.org.'}]",The spine journal : official journal of the North American Spine Society,['10.1016/j.spinee.2020.07.013'] 2993,32738408,Positive health check evaluation: A type 1 hybrid design randomized trial to decrease HIV viral loads in patients seen in HIV primary care.,"For people with HIV, important transmission prevention strategies include early initiation and adherence to antiretroviral therapy and retention in clinical care with the goal of reducing viral loads as quickly as possible. Consequently, at this point in the HIV epidemic, innovative and effective strategies are urgently needed to engage and retain people in health care to support medication adherence. To address this gap, the Positive Health Check Evaluation Trial uses a type 1 hybrid randomized trial design to test whether the use of a highly tailored video doctor intervention will reduce HIV viral load and retain people with HIV in health care. Eligible and consenting patients from four HIV primary care clinical sites are randomly assigned to receive either the Positive Health Check intervention in addition to the standard of care or the standard of care only. The primary aim is to determine the effectiveness of the intervention. A second aim is to understand the implementation potential of the intervention in clinic workflows, and a third aim is to assess the costs of intervention implementation. The trial findings will have important real-world applicability for understanding how digital interventions that take the form of video doctors can be used to decrease viral load and to support retention in care among diverse patients attending HIV primary care clinics.",2020,Eligible and consenting patients from four HIV primary care clinical sites are randomly assigned to receive either the Positive Health Check intervention in addition to the standard of care or the standard of care only.,"['diverse patients attending HIV primary care clinics', 'Eligible and consenting patients from four HIV primary care clinical sites', 'people with HIV in health care', 'patients seen in HIV primary care']",['Positive Health Check intervention in addition to the standard of care or the standard of care only'],['HIV viral loads'],"[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0019682', 'cui_str': 'Human immunodeficiency virus'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic'}, {'cui': 'C2711213', 'cui_str': 'Consented'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0086388', 'cui_str': 'Healthcare'}, {'cui': 'C0042789', 'cui_str': 'Visual function'}]","[{'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C1283174', 'cui_str': 'Checking - action'}, {'cui': 'C0184661', 'cui_str': 'Procedure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C2936643', 'cui_str': 'Standards of Care'}]","[{'cui': 'C1168369', 'cui_str': 'HIV viral load'}]",4.0,0.0882936,Eligible and consenting patients from four HIV primary care clinical sites are randomly assigned to receive either the Positive Health Check intervention in addition to the standard of care or the standard of care only.,"[{'ForeName': 'Megan A', 'Initials': 'MA', 'LastName': 'Lewis', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Harshbarger', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Bann', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Burrus', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Susana', 'Initials': 'S', 'LastName': 'Peinado', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Garner', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Khavjou', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Ram', 'Initials': 'R', 'LastName': 'Shrestha', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Shawn', 'Initials': 'S', 'LastName': 'Karns', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Craig B', 'Initials': 'CB', 'LastName': 'Borkowf', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Brittany', 'Initials': 'B', 'LastName': 'Zulkiewicz', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America.'}, {'ForeName': 'Alexa', 'Initials': 'A', 'LastName': 'Ortiz', 'Affiliation': 'RTI International, Research Triangle Park, NC, United States of America. Electronic address: amortiz@rti.org.'}, {'ForeName': 'Carla', 'Initials': 'C', 'LastName': 'Galindo', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, GA, United States of America.'}, {'ForeName': 'Michelle Dalla', 'Initials': 'MD', 'LastName': 'Piazza', 'Affiliation': 'Rutgers New Jersey Medical School, Newark, NJ, United States of America.'}, {'ForeName': 'Pam', 'Initials': 'P', 'LastName': 'Holm', 'Affiliation': 'NO AIDS Task Force dba Crescent Care, New Orleans, LA, United States of America.'}, {'ForeName': 'Vincent C', 'Initials': 'VC', 'LastName': 'Marconi', 'Affiliation': 'Division of Infectious Diseases, Emory University School of Medicine, Emory Vaccine Center, and Rollins School of Public Health, Atlanta, GA, United States of America; Atlanta VA Medical Center, Decatur, GA, United States of America.'}, {'ForeName': 'Charurut', 'Initials': 'C', 'LastName': 'Somboonwit', 'Affiliation': 'University of South Florida, Morsani College of Medicine, Tampa, FL, United States of America.'}, {'ForeName': 'Shobha', 'Initials': 'S', 'LastName': 'Swaminathan', 'Affiliation': 'Rutgers New Jersey Medical School, Newark, NJ, United States of America.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2020.106097'] 2994,32738409,Acute effects of Adaptive Deep Brain Stimulation in Parkinson's disease.,"BACKGROUND Beta-based adaptive Deep Brain Stimulation (aDBS) is effective in Parkinson's disease (PD), when assessed in the immediate post-implantation phase. However, the potential benefits of aDBS in patients with electrodes chronically implanted, in whom changes due to the microlesion effect have disappeared, are yet to be assessed. METHODS To determine the acute effectiveness and side-effect profile of aDBS in PD compared to conventional continuous DBS (cDBS) and no stimulation (NoStim), years after DBS implantation, 13 PD patients undergoing battery replacement were pseudo-randomised in a crossover fashion, into three conditions (NoStim, aDBS or cDBS), with a two-minute interval between them. Patient videos were blindly evaluated using a short version of the Unified Parkinson's Disease Rating Scale (subUPDRS), and the Speech Intelligibility Test (SIT). RESULTS Mean disease duration was 16 years, and the mean time since DBS-implantation was 6.9 years. subUPDRS scores (11 patients tested) were significantly lower both in aDBS (p=<.001), and cDBS (p=.001), when compared to NoStim. Bradykinesia subscores were significantly lower in aDBS (p=.002), and did not achieve significance during cDBS (p=.08), when compared to NoStim. Two patients demonstrated re-emerging tremor during aDBS. SIT scores of patients who presented stimulation-induced dysarthria significantly worsened in cDBS (p=.009), but not in aDBS (p=.407), when compared to NoStim. Overall, stimulation was applied 48.8% of the time during aDBS. CONCLUSION Beta-based aDBS is effective in PD patients with bradykinetic phenotypes, delivers less stimulation than cDBS, and potentially has a more favourable speech side-effect profile. Patients with prominent tremor may require a modified adaptive strategy.",2020,"subUPDRS scores (11 patients tested) were significantly lower both in aDBS (p=<.001), and cDBS (p=.001), when compared to NoStim.","[""Parkinson's disease"", 'PD patients with bradykinetic phenotypes', '13 PD patients undergoing battery replacement', 'Patients with prominent tremor', ""Parkinson's disease (PD""]","['aDBS', 'Adaptive Deep Brain Stimulation', 'Beta-based aDBS', 'Beta-based adaptive Deep Brain Stimulation (aDBS', 'conventional continuous DBS (cDBS) and no stimulation (NoStim), years after DBS implantation']","['Mean disease duration', 'subUPDRS scores', 'SIT scores', ""Unified Parkinson's Disease Rating Scale (subUPDRS), and the Speech Intelligibility Test (SIT"", 'mean time since DBS-implantation', 'Bradykinesia subscores']","[{'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0031437', 'cui_str': 'Phenotype'}, {'cui': 'C0337088', 'cui_str': 'Electrical battery'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0205402', 'cui_str': 'Prominent'}, {'cui': 'C0040822', 'cui_str': 'Tremor'}]","[{'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0330390', 'cui_str': 'Beta'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0439858', 'cui_str': 'Conventional'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}, {'cui': 'C0445093', 'cui_str': 'No stimulation'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0037824', 'cui_str': 'Speech Intelligibility'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C0394162', 'cui_str': 'Deep brain stimulation'}, {'cui': 'C0021107', 'cui_str': 'Implantation procedure'}, {'cui': 'C0233565', 'cui_str': 'Bradykinesia'}]",,0.0348207,"subUPDRS scores (11 patients tested) were significantly lower both in aDBS (p=<.001), and cDBS (p=.001), when compared to NoStim.","[{'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Piña-Fuentes', 'Affiliation': 'Department of Neurosurgery, University Medical Centre Groningen, the Netherlands; Medical Research Council Brain Network Dynamics Unit at the University of Oxford, United Kingdom; Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.'}, {'ForeName': 'J Marc C', 'Initials': 'JMC', 'LastName': 'van Dijk', 'Affiliation': 'Department of Neurosurgery, University Medical Centre Groningen, the Netherlands.'}, {'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'van Zijl', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, the Netherlands.'}, {'ForeName': 'Harmen R', 'Initials': 'HR', 'LastName': 'Moes', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, the Netherlands.'}, {'ForeName': 'Teus', 'Initials': 'T', 'LastName': 'van Laar', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, the Netherlands.'}, {'ForeName': 'D L Marinus', 'Initials': 'DLM', 'LastName': 'Oterdoom', 'Affiliation': 'Department of Neurosurgery, University Medical Centre Groningen, the Netherlands.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Little', 'Affiliation': 'Department of Movement Disorders and Neuromodulation, University of California San Francisco, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Brown', 'Affiliation': 'Medical Research Council Brain Network Dynamics Unit at the University of Oxford, United Kingdom; Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.'}, {'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'Beudel', 'Affiliation': 'Department of Neurology, University Medical Centre Groningen, the Netherlands. Electronic address: m.beudel@umcg.nl.'}]",Brain stimulation,['10.1016/j.brs.2020.07.016'] 2995,32738416,"Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.","BACKGROUND Despite 1-4 % of NSCLC tumors harboring mutations in the HER2 gene, there are no approved HER2-pathway-targeted treatments available. We report an open-label, single-arm, multicenter phase II study investigating the efficacy and safety of afatinib in Asian patients with HER2-mutation positive (HER2m+) NSCLC. METHODS Eligible patients for Part A had confirmed stage IIIb/IV HER2m + NSCLC, had failed one or two prior lines of chemotherapy, and were EGFR/HER2-inhibitor naïve. Patients received oral afatinib 40 mg/day in continuous 28-day cycles, until disease progression or intolerable adverse events (AEs). Patients qualified for Part B if they had > 12 weeks' clinical benefit and Eastern Cooperative Oncology Group performance status ≤ 2. In Part B, patients were to receive afatinib at the last received dose, plus paclitaxel 80 mg/m 2 weekly, until disease progression or intolerable AEs. The primary endpoint in Part A was objective response (OR); secondary endpoints included disease control (DC), progression-free survival (PFS), and overall survival (OS). Further exploratory endpoints were OR, DC, and PFS in Part B. RESULTS Eighteen patients received afatinib in Part A. No patient achieved an OR; 11 patients (61.1 %) achieved stable disease, and six patients (33.3 %) had progressive disease. DC rate was therefore 61.1 % (95 % confidence interval [CI]: 35.7, 82.7). A decrease in tumor size from baseline of > 0 to < 30 % was observed in eight patients. At the time of analysis, 16 patients (88.9 %) had progressed or died. Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08). All patients experienced ≥ 1 AE, most commonly diarrhea (66.7 %) and rash (33.3 %). No patients met the inclusion criteria for Part B, and recruitment was slow; therefore, the study was terminated. CONCLUSIONS This study found no clinical benefit of afatinib for EGFR TKI-naïve patients with HER2m + NSCLC.",2020,"Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08).","['Eighteen patients received afatinib in Part A', ""Patients qualified for Part B if they had > 12 weeks' clinical benefit and Eastern Cooperative Oncology Group performance status ≤ 2"", 'EGFR TKI-naïve patients with HER2m\u202f+\u202fNSCLC', 'Asian patients with HER2-mutation positive (HER2m+) NSCLC', 'Eligible patients for Part A had confirmed stage IIIb/IV HER2m', 'patients with advanced non-small cell lung cancer harboring HER2 mutations']","['Afatinib', 'oral afatinib', 'plus paclitaxel 80\u202fmg/m 2 weekly, until disease progression or intolerable AEs', 'chemotherapy', 'afatinib']","['OR, DC, and PFS in Part B', 'diarrhea', 'DC rate', 'progressive disease', 'Median PFS', 'median OS', 'objective response (OR); secondary endpoints included disease control (DC), progression-free survival (PFS), and overall survival (OS', 'progressed or died', 'efficacy and safety', 'tumor size', 'stable disease', 'rash']","[{'cui': 'C3715206', 'cui_str': '18'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C2987648', 'cui_str': 'Afatinib'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0205210', 'cui_str': 'Clinical'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C1520224', 'cui_str': 'ECOG performance status'}, {'cui': 'C0034802', 'cui_str': 'Epidermal growth factor-urogastrone receptor'}, {'cui': 'C0069515', 'cui_str': 'Oncogene protein HER-2/neu'}, {'cui': 'C0007131', 'cui_str': 'Non-small cell lung cancer'}, {'cui': 'C0078988', 'cui_str': 'Oriental'}, {'cui': 'C0026882', 'cui_str': 'Genetic mutation'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by'}, {'cui': 'C0456599', 'cui_str': 'Stage 3B'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0475311', 'cui_str': 'Harbor'}]","[{'cui': 'C2987648', 'cui_str': 'Afatinib'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0332287', 'cui_str': 'With'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0332174', 'cui_str': 'Weekly'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}]","[{'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0205329', 'cui_str': 'Progressive'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0475440', 'cui_str': 'Tumor size'}, {'cui': 'C0205360', 'cui_str': 'Stable'}, {'cui': 'C0015230', 'cui_str': 'Eruption'}]",,0.160329,"Median PFS was 2.76 months (95 % CI: 1.87, 4.60) and median OS was 10.02 months (95 % CI: 8.47, 10.08).","[{'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Fan', 'Affiliation': 'Zhejiang Cancer Hospital, Hangzhou, China.'}, {'ForeName': 'Jianhua', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': 'Hunan Cancer Hospital, Changsha, China.'}, {'ForeName': 'Chengzhi', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'The First Affiliated Hospital of Guangzhou Medical University, Guangdong, China.'}, {'ForeName': 'Huijuan', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.'}, {'ForeName': 'Yongqian', 'Initials': 'Y', 'LastName': 'Shu', 'Affiliation': 'The First Affiliated Hospital with Nanjing Medical University, Jiangsu, China.'}, {'ForeName': 'Jacky', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.'}, {'ForeName': 'Hairui', 'Initials': 'H', 'LastName': 'Hua', 'Affiliation': 'Boehringer Ingelheim (China) Investment Co., Ltd, Shanghai, China.'}, {'ForeName': 'Dennis Chin-Lun', 'Initials': 'DC', 'LastName': 'Huang', 'Affiliation': 'Boehringer Ingelheim Taiwan Limited, Taipei, Taiwan.'}, {'ForeName': 'Caicun', 'Initials': 'C', 'LastName': 'Zhou', 'Affiliation': 'Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, China. Electronic address: caicunzhoudr@163.com.'}]","Lung cancer (Amsterdam, Netherlands)",['10.1016/j.lungcan.2020.07.017'] 2996,32738479,"Safety and immunogenicity of an alum-adjuvanted whole-virion H7N9 influenza vaccine: a randomized, blinded, clinical trial.","OBJECTIVES A case of H7N9 influenza virus infection was first identified in China in 2013. This virus is considered to have high pandemic potential. Here, we developed a H7N9 influenza vaccine containing an aluminium adjuvant and evaluated the safety and immunogenicity of the vaccine. METHODS From October 2017 through August 2018, we conducted a randomized, double-blind, single-centre phase I clinical trial in China among 360 participants aged 12 years or older. All participants received 2-doses of the vaccine (7.5, 15 or 30μg hemagglutinin antigen) or placebo at an interval of 21 days. Adverse event data were collected for 30 days after vaccination. Serum samples were collected on days 0, 21 and 42 for the hemagglutinin inhibition (HI) antibody assay. RESULTS A total of 347 participants (347/360, 96.4%) completed the study. The proportions of vaccine-related AEs after one injection were 56.7% (34/60) in the 7.5 μg group, 86.7% (52/60) in the 15μg group and 86.7% (52/60) in the 30μg group. The proportions of AEs after two injections were less than those reported after the first dose. None of the serious adverse events were related to the vaccine. After receiving 2-doses 7.5μg vaccine, the proportion of participants achieving an HI titer of 40 or higher was 98.2% (55/56, 95%CI, 72.3∼100.0%), with a geometric mean titers (GMTs) of 192.6 (95%CI, 162.9∼227.8). CONCLUSIONS The alum-adjuvanted H7N9 whole-virion inactivated vaccine was safe and strongly immunogenic in a population aged 12 years and older. THIS TRIAL IS REGISTERED AT CLINICALTRIALS.GOV: NCT03369808.",2020,The alum-adjuvanted H7N9 whole-virion inactivated vaccine was safe and strongly immunogenic in a population aged 12 years and older.,"['population aged 12\xa0years and older', 'A total of 347 participants (347/360, 96.4%) completed the study', 'From October 2017 through August 2018', '360 participants aged 12\xa0years or older']","['placebo', 'vaccine', 'alum-adjuvanted whole-virion H7N9 influenza vaccine', 'H7N9 influenza vaccine containing an aluminium adjuvant']","['proportion of participants achieving an HI titer', 'Safety and immunogenicity']","[{'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0580836', 'cui_str': 'Old'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0205197', 'cui_str': 'Complete'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C4319607', 'cui_str': '360'}]","[{'cui': 'C0032042', 'cui_str': 'Sham Treatment'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0002371', 'cui_str': 'Aluminum Hydroxide'}, {'cui': 'C0042760', 'cui_str': 'Virion'}, {'cui': 'C3665951', 'cui_str': 'Influenza due to Influenza A virus subtype H7N9'}, {'cui': 'C0332256', 'cui_str': 'Containing'}, {'cui': 'C0002367', 'cui_str': 'Aluminum'}, {'cui': 'C0001552', 'cui_str': 'Pharmaceutical Adjuvants'}]","[{'cui': 'C0018909', 'cui_str': 'Hemagglutinin'}, {'cui': 'C0021467', 'cui_str': 'Psychological Inhibition'}, {'cui': 'C0475208', 'cui_str': 'Titer'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",360.0,0.708817,The alum-adjuvanted H7N9 whole-virion inactivated vaccine was safe and strongly immunogenic in a population aged 12 years and older.,"[{'ForeName': 'Shilei', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China; Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.'}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Xie', 'Affiliation': 'Henan Center for Disease Control and Prevention, Vaccine Clinical Trail & Lab for Infectious.'}, {'ForeName': 'Lili', 'Initials': 'L', 'LastName': 'Huang', 'Affiliation': 'Henan Center for Disease Control and Prevention, Vaccine Clinical Trail & Lab for Infectious.'}, {'ForeName': 'Xu', 'Initials': 'X', 'LastName': 'Zhou', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Jian', 'Initials': 'J', 'LastName': 'Luo', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Yuelian', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Changgui', 'Initials': 'C', 'LastName': 'Li', 'Affiliation': 'National Institutes for Food and Drug Control and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Duan', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Wenting', 'Initials': 'W', 'LastName': 'Xu', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Dandan', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Bing', 'Initials': 'B', 'LastName': 'Wu', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Yongli', 'Initials': 'Y', 'LastName': 'Yang', 'Affiliation': 'Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.'}, {'ForeName': 'Xueying', 'Initials': 'X', 'LastName': 'Liu', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China.'}, {'ForeName': 'Yanxia', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Henan Center for Disease Control and Prevention, Vaccine Clinical Trail & Lab for Infectious.'}, {'ForeName': 'Zhenghong', 'Initials': 'Z', 'LastName': 'Yuan', 'Affiliation': 'Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.'}, {'ForeName': 'Di', 'Initials': 'D', 'LastName': 'Qu', 'Affiliation': 'Biosafety Level-3 Laboratory, Key Laboratory of Medical Molecular Virology MOE &MOH, School of Basic Medical Sciences, Fudan University, Shanghai, China.'}, {'ForeName': 'Ze', 'Initials': 'Z', 'LastName': 'Chen', 'Affiliation': 'Shanghai Institute of Biological Products, Shanghai, China. Electronic address: chenze2005@hotmail.com.'}, {'ForeName': 'Shengli', 'Initials': 'S', 'LastName': 'Xia', 'Affiliation': 'Henan Center for Disease Control and Prevention, Vaccine Clinical Trail & Lab for Infectious. Electronic address: 1792865518@qq.com.'}]",Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,['10.1016/j.cmi.2020.07.033'] 2997,32736164,The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms.,"INTRODUCTION Approximately 88% of men and 79% of women with Parkinson's disease (PD) identify an informal caregiver. Although caregivers can play a key role in supporting patients, little is known about how and whether PD patients with and without caregivers differ in terms of physical, cognitive, and mood outcomes. This study explored whether caregiver presence was associated with variations in patient presentation and outcomes in a palliative PD and atypical PD population. METHODS Secondary data on individuals with PD and their caregivers came from baseline data of a 3-site randomized controlled trial of outpatient palliative care for PD in the US and Canada. Measures included: MDS UPDRS III, Montreal Cognitive Assessment, quality of life (QOL) measures, depression, prolonged grief, spirituality (FACIT SP-12) and Palliative Performance Scale. RESULTS Of 210 participants, 175 (83%) had a caregiver. Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale. Despite poorer cognitive and motor function, those with caregivers had higher QOL as measured by the Quality of Life in Alzheimer Disease and less spiritual distress. There were no group differences on anxiety, depression, or grief. Caregiver presence moderated the association between lower MoCA score and worse motor symptoms. CONCLUSION Findings of the present study highlight the influence of caregiver engagement on PD patient outcomes. These findings have implications for clinical practice and suggest that presence of a caregiver may be an important modifying variable on patient outcomes to examine in future research.",2020,"Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale.","['Of 210 participants, 175 (83%) had a caregiver', ""patients with Parkinson's disease and atypical parkinsonisms"", 'Secondary data on individuals with PD and their caregivers came from baseline data of a 3-site randomized controlled trial of outpatient palliative care for PD in the US and Canada', ""Approximately 88% of men and 79% of women with Parkinson's disease (PD) identify an informal caregiver""]",[],"['Palliative Performance Scale', 'MDS UPDRS III, Montreal Cognitive Assessment, quality of life (QOL) measures, depression, prolonged grief, spirituality (FACIT SP-12) and Palliative Performance Scale', 'anxiety, depression, or grief', 'lower MoCA score and worse motor symptoms', 'motor difficulty, lower cognitive scores']","[{'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0585086', 'cui_str': 'Has a caregiver'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0030567', 'cui_str': ""Parkinson's disease""}, {'cui': 'C4302185', 'cui_str': 'Atypical Parkinsonism'}, {'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0960273', 'cui_str': 'CAME'}, {'cui': 'C0205145', 'cui_str': 'Site'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}, {'cui': 'C0030231', 'cui_str': 'Palliative care'}, {'cui': 'C0521125', 'cui_str': 'For'}, {'cui': 'C0006823', 'cui_str': 'Canada'}, {'cui': 'C0332232', 'cui_str': 'Approximate'}, {'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0205396', 'cui_str': 'Identified'}, {'cui': 'C1319882', 'cui_str': 'Informal caregiver'}]",[],"[{'cui': 'C4720846', 'cui_str': 'Palliative performance scale'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C4555213', 'cui_str': 'Assessment using Montreal cognitive assessment'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0079809', 'cui_str': 'Measure'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0439590', 'cui_str': 'Prolonged'}, {'cui': 'C0018235', 'cui_str': 'Normal grief reaction'}, {'cui': 'C0237104', 'cui_str': 'Spirituality'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0205251', 'cui_str': 'Low'}, {'cui': 'C4721272', 'cui_str': 'Montreal cognitive assessment score'}, {'cui': 'C0053267', 'cui_str': ""benzoylamido-4'-aminostilbene-2,2'-disulfonate""}, {'cui': 'C0426980', 'cui_str': 'Motor symptoms'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0449820', 'cui_str': 'Score'}]",210.0,0.115968,"Patients with caregivers had greater motor difficulty, lower cognitive scores, and greater palliative needs as measured by the Palliative Performance Scale.","[{'ForeName': 'Lindsay Penny', 'Initials': 'LP', 'LastName': 'Prizer', 'Affiliation': 'Division of General Medicine and Geriatrics, Emory University School of Medicine, 6 Executive Park, 1st Floor, Atlanta, GA, 30329, USA. Electronic address: lprizer@emory.edu.'}, {'ForeName': 'Benzi M', 'Initials': 'BM', 'LastName': 'Kluger', 'Affiliation': 'Departments of Neurology and Medicine, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Sillau', 'Affiliation': 'Department of Neurology, University of Colorado School of Medicine, USA.'}, {'ForeName': 'Maya', 'Initials': 'M', 'LastName': 'Katz', 'Affiliation': 'Weill Institute for Neurosciences, School of Medicine, University of California San Francisco, USA.'}, {'ForeName': 'Nicholas B', 'Initials': 'NB', 'LastName': 'Galifianakis', 'Affiliation': 'Weill Institute for Neurosciences, School of Medicine, University of California San Francisco, USA.'}, {'ForeName': 'Janis M', 'Initials': 'JM', 'LastName': 'Miyasaki', 'Affiliation': 'Parkinson and Movement Disorders Program, Neuropalliative Care, Department of Medicine, University of Alberta, Canada.'}]",Parkinsonism & related disorders,['10.1016/j.parkreldis.2020.07.003'] 2998,31813658,The efficacy of pentosan polysulfate monotherapy for preventing recurrent urinary tract infections in women: A multicenter open-label randomized controlled trial.,"BACKGROUND/PURPOSE Pentosan polysulfate sodium (PPS), a semi-synthetic polysaccharide that adheres to bladder mucosa, is effective in treating interstitial cystitis. We evaluated the clinical benefit of PPS for the prevention of recurrent urinary tract infection (UTI) in women. METHODS We conducted a multicenter, open-label, prospective, phase II, randomized controlled trial enrolling women with recurrent UTI ≥ 2 times in the past 6 months or ≥ 3 times in the past 12 months. Patients received oral PPS monotherapy for 16 weeks in treatment group. All patients were followed every 28 days until UTI recurrence or up to 112 days. The primary endpoint was the UTI recurrence-free survival. Adverse events were recorded as secondary endpoint. RESULTS A total of 26 women were eligible for analysis. In the PPS group, none (0%) of the 12 patients had UTI recurrence during the study period. However, 9 (64%) of 14 patients had UTI recurrence in the control group. The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004). One adverse event which led to discontinuation of the trial regimen was regarded as irrelevance of PPS treatment. The limitation was the small number of cases. CONCLUSION Among women with recurrent UTI, 16-week PPS monotherapy significantly reduced UTI recurrence when compared with the control group.",2020,The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004).,"['26 women were eligible for analysis', 'enrolling women with recurrent UTI\xa0≥\xa02 times in the past 6 months or\xa0≥\xa03 times in the past 12 months', 'women with recurrent UTI', 'women']","['oral PPS monotherapy', 'pentosan polysulfate monotherapy', 'PPS', 'Pentosan polysulfate sodium (PPS']","['UTI recurrence-free survival', 'recurrent urinary tract infections', 'Adverse events', 'UTI recurrence']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0002778', 'cui_str': 'Analysis'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection'}, {'cui': 'C0040223', 'cui_str': 'Time'}, {'cui': 'C1444637', 'cui_str': 'Past'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}]","[{'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C0524684', 'cui_str': 'pentosan polysulfate sodium'}, {'cui': 'C0600296', 'cui_str': 'Pentosan Polysulfate'}]","[{'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease'}, {'cui': 'C0262655', 'cui_str': 'Recurrent urinary tract infection'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0034897', 'cui_str': 'Recurrence'}]",26.0,0.0950051,The UTI recurrence-free survival was significantly higher in the PPS group than in the control group (log-rank test p = 0.0004).,"[{'ForeName': 'Chi-Shin', 'Initials': 'CS', 'LastName': 'Tseng', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Shang-Jen', 'Initials': 'SJ', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, Taipei Tzu Chi Hospital, New Taipei, Taiwan.'}, {'ForeName': 'En', 'Initials': 'E', 'LastName': 'Meng', 'Affiliation': 'Division of Urology, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.'}, {'ForeName': 'Hong-Chiang', 'Initials': 'HC', 'LastName': 'Chang', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan.'}, {'ForeName': 'Yuan-Ju', 'Initials': 'YJ', 'LastName': 'Lee', 'Affiliation': 'Department of Urology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan. Electronic address: leeyuanju@hotmail.com.'}]",Journal of the Formosan Medical Association = Taiwan yi zhi,['10.1016/j.jfma.2019.11.007'] 2999,31986451,A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.,"BACKGROUND The unmet need for predictive biomarkers emerged from the unpredictable pattern of response to androgen signalling inhibition in metastatic castration-resistant prostate cancer (mCRPC). Here, we report on the testing of a previously identified candidate androgen signalling signature associated with response to androgen signalling inhibition. PATIENTS AND METHODS We report on the outcome of the first module of a phase II trial on abiraterone acetate (AA) followed by combination with dasatinib or sunitinib. Bone marrow biopsies (BMBs) with matched bone marrow aspirate and blood samples were collected at baseline and upon progression. End-points included assessment of a prespecified molecular signature consisting of nuclear androgen receptor (AR) overexpression, cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17) expression, and AR-C-/N terminal expression ratio of ≥0.8 by immunohistochemistry (IHC) in patients with benefit versus primary resistance to AA (i.e. progression within 4 months). Tumour markers also included v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), androgen receptor splice variant (ARV7) by IHC and steroids by liquid chromatography-tandem mass spectrometry. RESULTS Of 170 patients accrued from 03/2011 to 02/2015, 44 (26%) were primary resistant to AA. Forty-eight patients had tumour infiltrated BMB at baseline. Pretreatment androgen signalling signature was linked to benefit from AA (p < 0.001). Presence of ERG was associated with benefit (p = 0.05), whereas nuclear ARV7 presence and 20 or more bone lesions at baseline with primary resistance (p = 0.04 and p = 0.0006, respectively). CONCLUSION Testing of a prespecified androgen signalling signature was highly supportive of its predictive value in maximal androgen deprivation strategies in mCRPC. Further validation is under way. TRIAL REGISTRATION ClinicalTrials.gov NCT01254864.",2020,"Tumour markers also included v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), androgen receptor splice variant (ARV7) by IHC and steroids by liquid chromatography-tandem mass spectrometry. ","['men with metastatic castration-resistant prostate cancer', 'metastatic castration-resistant prostate cancer (mCRPC', 'Of 170 patients accrued from 03/2011 to 02/2015, 44 (26%) were primary resistant to AA']","['abiraterone acetate (AA) followed by combination with dasatinib or sunitinib', 'abiraterone acetate']","['tumour infiltrated BMB', 'nuclear ARV7 presence and 20 or more bone lesions', 'nuclear androgen receptor (AR) overexpression, cytochrome P450, family 17, subfamily A, polypeptide 1 (CYP17) expression, and AR-C-/N terminal expression ratio of ≥0.8 by immunohistochemistry (IHC', 'Bone marrow biopsies (BMBs']","[{'cui': 'C0025266', 'cui_str': 'Man'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C4517599', 'cui_str': '170'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0205225', 'cui_str': 'Principal'}, {'cui': 'C0332325', 'cui_str': 'Resistant'}, {'cui': 'C0000975', 'cui_str': 'Acetate'}]","[{'cui': 'C2607886', 'cui_str': 'Abiraterone acetate'}, {'cui': 'C0332282', 'cui_str': 'Following'}, {'cui': 'C1455147', 'cui_str': 'dasatinib'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0027651', 'cui_str': 'Neoplasm'}, {'cui': 'C0332448', 'cui_str': 'Infiltration'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0238792', 'cui_str': 'Bone lesion'}, {'cui': 'C0034786', 'cui_str': 'Androgen receptor'}, {'cui': 'C0008381', 'cui_str': 'Cholesterol monooxygenase (side-chain cleaving)'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C1305923', 'cui_str': 'Polypeptide'}, {'cui': 'C0015457', 'cui_str': 'Facial expression'}, {'cui': 'C0205088', 'cui_str': 'End-stage'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}, {'cui': 'C0021044', 'cui_str': 'Immunohistochemistry'}, {'cui': 'C0005954', 'cui_str': 'Bone marrow sampling'}]",170.0,0.24658,"Tumour markers also included v-ets avian erythroblastosis virus E26 oncogene homologue (ERG), androgen receptor splice variant (ARV7) by IHC and steroids by liquid chromatography-tandem mass spectrometry. ","[{'ForeName': 'Myrto', 'Initials': 'M', 'LastName': 'Boukovala', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Nicholas', 'Initials': 'N', 'LastName': 'Spetsieris', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Justin A', 'Initials': 'JA', 'LastName': 'Weldon', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Alexandros', 'Initials': 'A', 'LastName': 'Tsikkinis', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Anh', 'Initials': 'A', 'LastName': 'Hoang', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Aparicio', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Shi-Ming', 'Initials': 'SM', 'LastName': 'Tu', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'John C', 'Initials': 'JC', 'LastName': 'Araujo', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Amado J', 'Initials': 'AJ', 'LastName': 'Zurita', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Paul G', 'Initials': 'PG', 'LastName': 'Corn', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Lance', 'Initials': 'L', 'LastName': 'Pagliaro', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Jeri', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Sumit K', 'Initials': 'SK', 'LastName': 'Subudhi', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Nizar M', 'Initials': 'NM', 'LastName': 'Tannir', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Christopher J', 'Initials': 'CJ', 'LastName': 'Logothetis', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Troncoso', 'Affiliation': 'Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'Sijin', 'Initials': 'S', 'LastName': 'Wen', 'Affiliation': 'Department of Biostatistics, West Virginia University School of Public Health, Morgantown, WV, USA.'}, {'ForeName': 'Eleni', 'Initials': 'E', 'LastName': 'Efstathiou', 'Affiliation': 'Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA. Electronic address: eefstathiou@mdanderson.org.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.027'] 3000,32030887,The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose ( 18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors.,"AIMS This multicenter phase II trial evaluates the efficacy of everolimus in poor prognosis grade 2 (G2) pancreatic neuroendocrine tumors (PNETs), defined by 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET) avidity. FDG-PET avidity in NETs is associated with a significantly higher risk of death, outperforming Ki-67 index or liver metastases as a poor prognostic factor. We hypothesized that everolimus has efficacy in patients with FDG-PET-avid G2 PNETs and prospectively evaluated progression-free survival (PFS) and response in the first-line setting. METHODS Patients with FDG-PET-avid G2 advanced PNET received everolimus 10 mg daily until disease progression. Patients were staged every 12 weeks with CT/MRI and FDG-PET and every 24 weeks with Gallium 68 (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate (DOTATATE, GaTate) PET. The primary endpoint was PFS at 6 months. Overall survival rate, PET/structural imaging response and toxicity were also measured. RESULTS Nine patients were accrued from December 2012 to February 2015. Median treatment duration was 13.8 months. The estimated PFS rate at 6 months was 78%. The best response on CT/MRI was stable disease in nine patients (100%) and partial response on FDG-PET in five patients (55.5%). Treatment-related adverse effects were consistent with previous studies of everolimus. CONCLUSION Everolimus is active with prolonged disease control in poor prognosis FDG-avid G2 PNETs. Treatment individualization based on functional imaging warrants further evaluation.",2020,"FDG-PET avidity in NETs is associated with a significantly higher risk of death, outperforming Ki-67 index or liver metastases as a poor prognostic factor.","['Patients with FDG-PET-avid G2 advanced PNET received', 'Nine patients were accrued from December 2012 to February 2015', 'patients with fluorodeoxyglucose ( 18 F) positron-emission tomography positive intermediate grade pancreatic neuroendocrine tumors']","['everolimus 10\xa0mg daily until disease progression', 'everolimus', '1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-octreotate', 'CT/MRI and FDG-PET and every 24\xa0weeks with Gallium 68 (68Ga', 'Everolimus']","['estimated PFS rate', 'risk of death, outperforming Ki-67 index or liver metastases', 'Overall survival rate, PET/structural imaging response and toxicity', 'Median treatment duration']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0475270', 'cui_str': 'G2 grade'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0206663', 'cui_str': 'Primitive neuroectodermal tumor'}, {'cui': 'C0046056', 'cui_str': 'Fluorodeoxyglucose F18'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0205103', 'cui_str': 'Intermediate'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0242363', 'cui_str': 'Pancreatic endocrine tumor'}]","[{'cui': 'C2682852', 'cui_str': 'everolimus 10 MG'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0242656', 'cui_str': 'Course of illness'}, {'cui': 'C0541315', 'cui_str': 'everolimus'}, {'cui': 'C0088359', 'cui_str': '1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid'}, {'cui': 'C0024485', 'cui_str': 'Magnetic resonance imaging'}, {'cui': 'C3641247', 'cui_str': 'FDG PET scan'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0303226', 'cui_str': 'Gallium-68'}]","[{'cui': 'C0750572', 'cui_str': 'Estimated'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk of'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0494165', 'cui_str': 'Secondary malignant neoplasm of liver'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}, {'cui': 'C0032743', 'cui_str': 'Positron emission tomography'}, {'cui': 'C0011923', 'cui_str': 'Imaging'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0549183', 'cui_str': 'Midline'}, {'cui': 'C0444921', 'cui_str': 'Duration of treatment'}]",9.0,0.0544879,"FDG-PET avidity in NETs is associated with a significantly higher risk of death, outperforming Ki-67 index or liver metastases as a poor prognostic factor.","[{'ForeName': 'Mei Sim', 'Initials': 'MS', 'LastName': 'Lung', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Rodney J', 'Initials': 'RJ', 'LastName': 'Hicks', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Pavlakis', 'Affiliation': 'Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, NSW, Australia.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Link', 'Affiliation': 'Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Jefford', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Thomson', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Wyld', 'Affiliation': ""Department of Medical Oncology, Royal Brisbane and Women's Hospital, QLD, Australia.""}, {'ForeName': 'Winston', 'Initials': 'W', 'LastName': 'Liauw', 'Affiliation': 'Department of Medical Oncology, Cancer Care Centre, Kogarah, NSW, Australia.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Akhurst', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}, {'ForeName': 'Narmatha', 'Initials': 'N', 'LastName': 'Kuru', 'Affiliation': 'Biostatistics and Clinical Trials Centre, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre Building, Melbourne, VIC, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Michael', 'Affiliation': 'Neuroendocrine Unit, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.'}]",Asia-Pacific journal of clinical oncology,['10.1111/ajco.13307'] 3001,32738130,"Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.","Background Few studies reported early results on efficacy, toxicity of combined modality treatment for locally advanced rectal cancer (LARC) by adding bevacizumab to preoperative chemoradiotherapy, but long-term data on survival, and late complications are lacking. Further, none of the studies reported on the assessment of quality of life (QOL). Patients and methods After more than 5 years of follow-up, we updated the results of our previous phase II trial in 61 patients with LARC treated with neoadjuvant capecitabine, radiotherapy and bevacizumab (CRAB study) before surgery and adjuvant chemotherapy. Secondary endpoints of updated analysis were local control (LC), disease free (DFS) and overall survival (OS), late toxicity and longitudinal health related QOL (before starting the treatment and one year after the treatment) with questionnaire EORTC QLQ-C30 and EORTC QLQ-CR38. Results Median follow-up was 67 months. During the follow-up period, 16 patients (26.7%) died. The 5-year OS, DFS and LC rate were 72.2%, 70% and 92.4%. Patients with pathological positive nodes or pathological T3-4 tumors had significantly worse survival than patients with pathological negative nodes or T0-2 tumors. Nine patients (14.8%) developed grade 33 late complications of combined modality treatment, first event 12 months and last 87 months after operation (median time 48 months). Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased. Based on QLQ-CR38 scores body image scores significantly increase, problems with weight loss significantly decrease, but sexual dysfunction in men and chemotherapy side effects significantly increase. Conclusions Patients with LARC and high risk factors, such as positive pathological lymph nodes and high pathological T stage, deserve more aggressive treatment in the light of improving long-term survival results. Patients after multimodality treatment should be given greater attention to the regulation of individual aspects of quality of life and the occurrence of late side effects.",2020,"Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased.","['61 patients with LARC treated with', 'locally advanced rectal cancer (LARC', 'locally advanced rectal cancer', 'Patients with pathological positive nodes or pathological T3-4 tumors']","['neoadjuvant capecitabine, radiotherapy and bevacizumab (CRAB study) before surgery and adjuvant chemotherapy', 'capecitabine based chemoradiotherapy with bevacizumab', 'bevacizumab']","['5-year OS, DFS and LC rate', 'grade 33 late complications', 'local control (LC), disease free (DFS) and overall survival (OS), late toxicity and longitudinal health related QOL', 'questionnaire EORTC QLQ-C30 and EORTC QLQ-CR38', 'survival', 'physical and social functioning', 'quality of life (QOL', 'efficacy, toxicity', 'QLQ-CR38 scores body image scores', 'sexual dysfunction', 'global QOL and three symptoms (pain, insomnia and diarrhea', 'survival rate, late toxicity and health-related quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0007113', 'cui_str': 'Rectal cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with'}, {'cui': 'C0205179', 'cui_str': 'Advanced'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C1446409', 'cui_str': 'Positive'}, {'cui': 'C0027651', 'cui_str': 'Neoplasm'}]","[{'cui': 'C0600558', 'cui_str': 'Neoadjuvant therapy'}, {'cui': 'C0671970', 'cui_str': 'capecitabine'}, {'cui': 'C0034619', 'cui_str': 'radiotherapy'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0010260', 'cui_str': 'Infraorder Brachyura'}, {'cui': 'C0008972', 'cui_str': 'Clinical Study'}, {'cui': 'C0445204', 'cui_str': 'Preoperative'}, {'cui': 'C0085533', 'cui_str': 'Drug Therapy, Adjuvant'}, {'cui': 'C0002055', 'cui_str': 'Alkali'}, {'cui': 'C0436307', 'cui_str': 'Radiochemotherapy'}]","[{'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0038952', 'cui_str': 'Survival'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0441800', 'cui_str': 'Grade'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0009566', 'cui_str': 'Complication'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0332296', 'cui_str': 'Free of'}, {'cui': 'C0040539', 'cui_str': 'TO'}, {'cui': 'C0205127', 'cui_str': 'Longitudinal'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0031809', 'cui_str': 'Physical examination'}, {'cui': 'C0037395', 'cui_str': 'Social adjustment'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0005891', 'cui_str': 'Body image'}, {'cui': 'C0549622', 'cui_str': 'Sexual disorder'}, {'cui': 'C0205246', 'cui_str': 'Generalized'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0917801', 'cui_str': 'Insomnia'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0038954', 'cui_str': 'Survival Rate'}]",61.0,0.0636662,"Based on EORTC QLQ-C30 scores one year after treatment there were no significant changes in global QOL and three symptoms (pain, insomnia and diarrhea), but physical and social functioning significantly decreased.","[{'ForeName': 'Vaneja', 'Initials': 'V', 'LastName': 'Velenik', 'Affiliation': 'Division of Radiotherapy, Institute of Oncology, Ljubljana, Slovenia.'}, {'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Zadnik', 'Affiliation': 'Division of Epidemiology, Institute of Oncology, Ljubljana, Slovenia.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Omejc', 'Affiliation': 'Division of Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Grosek', 'Affiliation': 'Division of Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Mojca', 'Initials': 'M', 'LastName': 'Tuta', 'Affiliation': 'Division of Radiology, Institute of Oncology, Ljubljana, Slovenia.'}]",Radiology and oncology,['10.2478/raon-2020-0043'] 3002,32738206,Determinants of Cardiorespiratory Fitness After Bariatric Surgery: Insights From a Randomised Controlled Trial of a Supervised Training Program.,"BACKGROUND Severely obese patients have decreased cardiorespiratory fitness (CRF) and poor functional capacity. Bariatric surgery-induced weight loss improves CRF, but the determinants of this improvement are not well known. We aimed to assess the determinants of CRF before and after bariatric surgery and the impact of an exercise training program on CRF after bariatric surgery. METHODS Fifty-eight severely obese patients (46.1 ± 6.1 kg/m 2 , 78% women) were randomly assigned to either an exercise group (n = 39) or usual care (n = 19). Exercise training was conducted from the 3rd to the 6th months after surgery. Anthropometric measurements, abdominal and mid-thigh computed tomographic scans, resting echocardiography, and maximal cardiopulmonary exercise testing was performed before bariatric surgery and 3 and 6 months after surgery. RESULTS Weight, fat mass, and fat-free mass were reduced significantly at 3 and 6 months, without any additive impact of exercise training in the exercise group. From 3 to 6 months, peak aerobic power (V̇O 2peak ) increased significantly (P < 0.0001) in both groups but more importantly in the exercise group (exercise group: from 18.6 ± 4.2 to 23.2 ± 5.7 mL/kg/min; control group: from 17.4 ± 2.3 to 19.7 ± 2.4 mL/kg/min; P value, group × time = 0.01). In the exercise group, determinants of absolute V̇O 2peak (L/min) were peak exercise ventilation, oxygen pulse, and heart rate reserve (r 2  = 0.92; P < 0.0001), whereas determinants of V̇O 2peak indexed to body mass (mL/kg/min) were peak exercise ventilation and early-to-late filling velocity ratio (r 2  = 0.70; P < 0.0001). CONCLUSIONS A 12-week supervised training program has an additive benefit on cardiorespiratory fitness for patients who undergo bariatric surgery.",2020,"From 3 to 6 months, peak aerobic power (V̇O 2peak ) increased significantly (P < 0.0001) in both groups but more importantly in the exercise group (exercise group: from 18.6 ± 4.2 to 23.2 ± 5.7 mL/kg/min; control group: from 17.4 ± 2.3 to 19.7 ± 2.4 mL/kg/min; P value, group ","['Fifty-eight severely obese patients (46.1 ± 6.1 kg/m 2 , 78% women', 'Severely obese patients', 'patients who undergo bariatric surgery']","['exercise group (n\xa0= 39) or usual care', 'exercise training program', 'Exercise training', 'exercise training']","['peak aerobic power (V̇O 2peak ', 'Weight, fat mass, and fat-free mass', 'absolute V̇O 2peak (L/min) were peak exercise ventilation, oxygen pulse, and heart rate reserve ', 'V̇O 2peak indexed to body mass', 'cardiorespiratory fitness (CRF', 'peak exercise ventilation and early-to-late filling velocity ratio', 'Cardiorespiratory Fitness', 'cardiorespiratory fitness']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C1456587', 'cui_str': 'Metabolic surgery'}]","[{'cui': 'C1276393', 'cui_str': 'Group exercise'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C0018106', 'cui_str': 'Government Programs'}]","[{'cui': 'C0444505', 'cui_str': 'Peak'}, {'cui': 'C0005910', 'cui_str': 'Body weight'}, {'cui': 'C0015677', 'cui_str': 'Fat'}, {'cui': 'C0577559', 'cui_str': 'Mass of body structure'}, {'cui': 'C0424679', 'cui_str': 'Fat-free mass'}, {'cui': 'C0205344', 'cui_str': 'Absolute'}, {'cui': 'C0439393', 'cui_str': 'L/min'}, {'cui': 'C0015259', 'cui_str': 'Exercise'}, {'cui': 'C0035203', 'cui_str': 'Respiratory function'}, {'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0034107', 'cui_str': 'Pulse taking'}, {'cui': 'C0018810', 'cui_str': 'Heart rate'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0152338', 'cui_str': 'Structure of body of caudate nucleus'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C1279919', 'cui_str': 'Early'}, {'cui': 'C0205087', 'cui_str': 'Late'}, {'cui': 'C0439830', 'cui_str': 'Velocity'}, {'cui': 'C0456603', 'cui_str': 'Ratio'}]",58.0,0.0370399,"From 3 to 6 months, peak aerobic power (V̇O 2peak ) increased significantly (P < 0.0001) in both groups but more importantly in the exercise group (exercise group: from 18.6 ± 4.2 to 23.2 ± 5.7 mL/kg/min; control group: from 17.4 ± 2.3 to 19.7 ± 2.4 mL/kg/min; P value, group ","[{'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Auclair', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Jany', 'Initials': 'J', 'LastName': 'Harvey', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Jacinthe', 'Initials': 'J', 'LastName': 'Leclerc', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Québec, Canada; Nursing Department, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada.'}, {'ForeName': 'Marie-Eve', 'Initials': 'ME', 'LastName': 'Piché', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Kim', 'Initials': 'K', 'LastName': ""O'Connor"", 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Éric', 'Initials': 'É', 'LastName': 'Nadreau', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Pettigrew', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Haykowsky', 'Affiliation': 'Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Marceau', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Biertho', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Frédéric-Simon', 'Initials': 'FS', 'LastName': 'Hould', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Stéfane', 'Initials': 'S', 'LastName': 'Lebel', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Biron', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Julien', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Léonie', 'Initials': 'L', 'LastName': 'Bouvet', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Odette', 'Initials': 'O', 'LastName': 'Lescelleur', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Medicine, Laval University, Québec, Québec, Canada.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Poirier', 'Affiliation': 'Québec Heart and Lung Institute, Laval University, Québec, Québec, Canada; Faculty of Pharmacy, Laval University, Québec, Québec, Canada. Electronic address: paul.poirier@criucpq.ulaval.ca.'}]",The Canadian journal of cardiology,['10.1016/j.cjca.2020.03.032'] 3003,32738349,"Clinical periodontal, bacterial, and immunological outcomes of antimicrobial photodynamic therapy in orthodontic treatment-induced gingival enlargement.","AIM The aim of the present clinical trial is to evaluate the clinical, bacterial, and immunological outcomes of photodynamic therapy (PDT) in adolescent patients with orthodontic treatment-induced gingival enlargement (OTGE). MATERIALS AND METHODS A total of 26 adolescent patients, 16 girls and 10 boys, of mean age 16.8 years, undergoing fixed orthodontic treatment for at least 6 months (mean duration in months, 8.3 ± 1.9) and presenting with GE were included in the clinical trial. All patients undergoing fixed orthodontic treatment with clinical diagnosis of OTGE were divided into two groups: Patients receiving full-mouth periodontal debridement (FMPD) 'Group-FMPD' and 'Group-PDT' included participants receiving methylene blue-assisted PDT in the selected area along with FMPD. Clinical periodontal assessments included the evaluation of plaque scores (PS), bleeding on probing (BOP), probing depth (PD) and hyperplastic index (HI). The total bacterial counts of Porphyromonas gingivalis (P. gingivalis), Treponema denticola (T. denticola), and Tannerella forsythia (T. forsythia) were estimated and expressed as log CFU/mL of each bacteria. Cytokines including interleukin (IL)-1β and IL-6 were analyzed using enzyme-linked immunosorbent assay (ELISA) kit. RESULTS The mean percentage of PS and BOP statistically significantly reduced with both FMPD and PDT from baseline to 4 weeks (p < 0.05). Although mean PD significantly reduced in both the groups at all time points, there was significantly higher reduction with PDT as compared to FMPD at 2 weeks post treatment (p < 0.05). Inter-group comparison showed PDT demonstrated significantly higher HI at 2- and 4-weeks post treatment (p < 0.05). The mean log CFU/mL of P. gingivalis and T. forsythia showed statistically significantly higher reduction with PDT than FMPD (p < 0.05) at both 2-and 4-weeks follow-up. T. denticola reported significantly reduced levels at 2 weeks follow-up period only with PDT (p < 0.05). No statistically significant difference appeared when both treatment modalities were compared with one another (p > 0.05). Four weeks after periodontal treatment, IL-6 significantly reduced with PDT compared to FMPD (p < 0.05). CONCLUSION PDT assisted in reducing bacterial counts and improving hyperplastic index in OTGE.",2020,The mean log CFU/mL of P. gingivalis and T. forsythia showed statistically significantly higher reduction with PDT than FMPD (p < 0.05) at both 2-and 4-weeks follow-up.,"['All patients undergoing fixed orthodontic treatment with clinical diagnosis of OTGE', '26 adolescent patients, 16 girls and 10 boys, of mean age 16.8 years, undergoing fixed orthodontic treatment for at least 6 months (mean duration in months, 8.3\u2009±\u20091.9) and presenting with GE were included in the clinical trial', 'orthodontic treatment-induced gingival enlargement', 'adolescent patients with orthodontic treatment-induced gingival enlargement (OTGE']","['antimicrobial photodynamic therapy', 'photodynamic therapy (PDT', ""Patients receiving full-mouth periodontal debridement (FMPD) 'Group-FMPD' and 'Group-PDT' included participants receiving methylene blue-assisted PDT""]","['mean percentage of PS and BOP', 'total bacterial counts of Porphyromonas gingivalis (P. gingivalis), Treponema denticola (T. denticola), and Tannerella forsythia (T. forsythia', 'plaque scores (PS), bleeding on probing (BOP), probing depth (PD) and hyperplastic index (HI', 'Cytokines including interleukin (IL)-1β and IL-6', 'mean PD', 'bacterial counts and improving hyperplastic index', 'mean log CFU/mL of P. gingivalis and T. forsythia']","[{'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0443218', 'cui_str': 'Fixed'}, {'cui': 'C0204193', 'cui_str': 'Orthodontic procedure'}, {'cui': 'C0332140', 'cui_str': 'Clinical diagnosis'}, {'cui': 'C0205263', 'cui_str': 'Induced'}, {'cui': 'C0017566', 'cui_str': 'Hyperplasia of gingiva'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0870221', 'cui_str': 'Male child'}, {'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0001779', 'cui_str': 'Age'}, {'cui': 'C4517591', 'cui_str': '16.8'}, {'cui': 'C0439234', 'cui_str': 'year'}, {'cui': 'C0332177', 'cui_str': 'Monthly'}, {'cui': 'C0449238', 'cui_str': 'Duration'}, {'cui': 'C4517517', 'cui_str': '1.9'}, {'cui': 'C0150312', 'cui_str': 'Present'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0008976', 'cui_str': 'Clinical trial'}]","[{'cui': 'C0003232', 'cui_str': 'Antibiotic'}, {'cui': 'C0031740', 'cui_str': 'Photochemotherapy'}, {'cui': 'C0030705', 'cui_str': 'Patient'}, {'cui': 'C0226896', 'cui_str': 'Oral cavity structure'}, {'cui': 'C2936227', 'cui_str': 'Nonsurgical Periodontal Debridement'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0025746', 'cui_str': 'Methylene blue'}, {'cui': 'C0018896', 'cui_str': 'Helping Behavior'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0011389', 'cui_str': 'Dental plaque'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0019080', 'cui_str': 'Hemorrhage'}, {'cui': 'C0182400', 'cui_str': 'Probe'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0004618', 'cui_str': 'Bacterial count'}, {'cui': 'C0206347', 'cui_str': 'Porphyromonas'}, {'cui': 'C0318222', 'cui_str': 'Treponema denticola'}, {'cui': 'C0314961', 'cui_str': 'Tannerella forsythia'}, {'cui': 'C1018538', 'cui_str': 'Lian qiao'}, {'cui': 'C0205125', 'cui_str': 'Deep'}, {'cui': 'C0020507', 'cui_str': 'Hyperplasia'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0079189', 'cui_str': 'Cytokine'}, {'cui': 'C0332257', 'cui_str': 'Including'}, {'cui': 'C0021764', 'cui_str': 'Interleukin'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0184511', 'cui_str': 'Improved'}, {'cui': 'C0439361', 'cui_str': 'cfu/mL'}]",26.0,0.0301008,The mean log CFU/mL of P. gingivalis and T. forsythia showed statistically significantly higher reduction with PDT than FMPD (p < 0.05) at both 2-and 4-weeks follow-up.,"[{'ForeName': 'Abdul Aziz', 'Initials': 'AA', 'LastName': 'Alshahrani', 'Affiliation': 'Department of Orthodontics and Pedodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Rafi A', 'Initials': 'RA', 'LastName': 'Togoo', 'Affiliation': 'Department of Orthodontics and Pedodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}, {'ForeName': 'Muhammad Abdullah', 'Initials': 'MA', 'LastName': 'Kamran', 'Affiliation': 'Department of Orthodontics and Pedodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia. Electronic address: muhammadabdkam@gmail.com.'}, {'ForeName': 'Ibrahim', 'Initials': 'I', 'LastName': 'Alshahrani', 'Affiliation': 'Department of Orthodontics and Pedodontics, College of Dentistry, King Khalid University, Abha, Saudi Arabia.'}]",Photodiagnosis and photodynamic therapy,['10.1016/j.pdpdt.2020.101934'] 3004,32738365,"Adjunctive effect of acupressure to pharmacological treatment on depression, anxiety and stress in knee osteoarthritis patients.","OBJECTIVES of the study were to check the effectiveness of acupressure therapy with pharmacological treatment on pain, depression, anxiety and stress in knee osteoarthritis patients. To assess the effect of pain improvement on psychological health. Eligible 212 knee osteoarthritis patients were recruited and divided into two groups (intervention and control group). The intervention group (n=106) received acupressure therapy in combination with pharmacological treatment, while control group (n=106) continued pharmacological treatment only. Pain and psychological symptoms were measured using Visual analogue scale and Depression Anxiety Stress Scale-21. Data of patients were collected and compared at different duration of the study. Pearson's correlation was used to check the effect of pain improvement on psychological health. Patients of both groups reported severe pain initially. On analyzing the results after completion of the study it was found that patients in intervention group scored better on pain scale (p ˂0.001) and DASS-21 scale (p=˂0.0001). However it may be noted that reduction in DASS-21 score was not found to be significant for control group (p=0.08). It was also found that patients of ≥50 subgroup of pain experienced better improvement in psychological symptoms. Pearson's correlation coefficients value ranged from 0.231 to 0.412 for DASS-21 scale (P˂ 0.05). On analysis it can be concluded that acupressure can be used as add on therapy in combination with conventional treatment (pharmacological treatment) which may assist in pain reduction. The reduction in pain directly contributes in improving the physiological wellness among knee osteoarthritis patients.",2020,However it may be noted that reduction in DASS-21 score was not found to be significant for control group (p=0.08).,"['knee osteoarthritis patients', 'Eligible 212 knee osteoarthritis patients']","['acupressure therapy in combination with pharmacological treatment, while control group (n=106) continued pharmacological treatment only', 'acupressure', 'acupressure therapy with pharmacological treatment']","['psychological health', 'pain, depression, anxiety and stress', 'pain improvement on psychological health', 'DASS-21 score', 'Pain and psychological symptoms', 'DASS-21 scale', 'psychological symptoms', 'Visual analogue scale and Depression Anxiety Stress Scale-21', 'depression, anxiety and stress', 'severe pain', 'pain scale']","[{'cui': 'C0409959', 'cui_str': 'Osteoarthritis of knee'}, {'cui': 'C0030705', 'cui_str': 'Patient'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0013216', 'cui_str': 'Drug therapy'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0549178', 'cui_str': 'Continuous'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011570', 'cui_str': 'Depression'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress'}, {'cui': 'C1832594', 'cui_str': 'Verloes Bourguignon syndrome'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0175659', 'cui_str': 'Scale'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}, {'cui': 'C0338908', 'cui_str': 'Mixed anxiety and depressive disorder'}, {'cui': 'C0278140', 'cui_str': 'Severe pain'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}]",212.0,0.0150036,However it may be noted that reduction in DASS-21 score was not found to be significant for control group (p=0.08).,"[{'ForeName': 'Meenu', 'Initials': 'M', 'LastName': 'Rani', 'Affiliation': 'Sawai Man Singh Medical College, Department of Pharmacology, Jaipur, Rajasthan, 302004, India. Electronic address: meenusaharan23@gmail.com.'}, {'ForeName': 'Lokendra', 'Initials': 'L', 'LastName': 'Sharma', 'Affiliation': 'Sawai Man Singh Medical College, Department of Pharmacology, Jaipur, Rajasthan, 302004, India. Electronic address: drlokendra29@gmail.com.'}, {'ForeName': 'Uma', 'Initials': 'U', 'LastName': 'Advani', 'Affiliation': 'Sawai Man Singh Medical College, Department of Pharmacology, Jaipur, Rajasthan, 302004, India. Electronic address: drupadvani@gmail.com.'}, {'ForeName': 'Susheel', 'Initials': 'S', 'LastName': 'Kumar', 'Affiliation': 'Sawai Man Singh Medical College, Department of Pharmacology, Jaipur, Rajasthan, 302004, India. Electronic address: susheelpn72@gmail.com.'}]",Journal of acupuncture and meridian studies,['10.1016/j.jams.2020.07.001'] 3005,32726529,Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.,"BACKGROUND Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants. METHODS Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season, were randomly assigned in an overall ratio of approximately 2:1 to receive a single intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo. Infants were followed for 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess safety. The primary end point was RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and the primary analysis of vaccine efficacy against the primary end point was performed in the per-protocol population of infants (prespecified criterion for success, lower bound of the 97.52% confidence interval [CI] of ≥30%). RESULTS A total of 4636 women underwent randomization, and there were 4579 live births. During the first 90 days of life, the percentage of infants with RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine group and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, -1.0 to 63.7; 95% CI, 5.3 to 61.2). The corresponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 95% CI, -8.2 to 75.3), and the percentages for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5). Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups. CONCLUSIONS RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life. The suggestion of a possible benefit with respect to other end-point events involving RSV-associated respiratory disease in infants warrants further study. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov NCT02624947.).",2020,"Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups. ","['Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season', 'A total of 4636 women underwent randomization, and there were 4579 live births', 'Infants', 'pregnant women']","['RSV F protein nanoparticle vaccination', 'RSV fusion (F) protein nanoparticle vaccine or placebo', 'placebo']","['vaccine efficacy', 'RSV-associated, medically significant lower respiratory tract infection', 'percentages for hospitalization for RSV-associated lower respiratory tract infection', 'respiratory tract infection with severe hypoxemia', 'respiratory tract infection', 'adverse events', 'Local injection-site reactions']","[{'cui': 'C0033011', 'cui_str': 'Pregnant woman'}, {'cui': 'C0439230', 'cui_str': 'week'}, {'cui': 'C0332173', 'cui_str': 'Daily'}, {'cui': 'C0032961', 'cui_str': 'Pregnancy'}, {'cui': 'C2825543', 'cui_str': 'Estimated date of delivery'}, {'cui': 'C0475806', 'cui_str': '1/3 meter'}, {'cui': 'C0439659', 'cui_str': 'Origins'}, {'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0036497', 'cui_str': 'Seasons'}, {'cui': 'C0439810', 'cui_str': 'Total'}, {'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0481667', 'cui_str': 'Live birth'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0033684', 'cui_str': 'Proteins'}, {'cui': 'C1450054', 'cui_str': 'Nanoparticles'}, {'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C0162768', 'cui_str': 'Fusion protein'}, {'cui': 'C0032042', 'cui_str': 'Sham Treatment'}]","[{'cui': 'C0042196', 'cui_str': 'Vaccination'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness'}, {'cui': 'C0035236', 'cui_str': 'Syncytial Virus, Respiratory'}, {'cui': 'C0332281', 'cui_str': 'Associated with'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0149725', 'cui_str': 'Lower respiratory tract infection'}, {'cui': 'C0439165', 'cui_str': 'Percent'}, {'cui': 'C0019993', 'cui_str': 'Inpatient care'}, {'cui': 'C0035243', 'cui_str': 'Respiratory tract infection'}, {'cui': 'C0205082', 'cui_str': 'Severe'}, {'cui': 'C0700292', 'cui_str': 'Hypoxemia'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205276', 'cui_str': 'Local'}, {'cui': 'C0151735', 'cui_str': 'Injection site reaction'}]",4636.0,0.368944,"Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups. ","[{'ForeName': 'Shabir A', 'Initials': 'SA', 'LastName': 'Madhi', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Fernando P', 'Initials': 'FP', 'LastName': 'Polack', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Pedro A', 'Initials': 'PA', 'LastName': 'Piedra', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Flor M', 'Initials': 'FM', 'LastName': 'Munoz', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Adrian A', 'Initials': 'AA', 'LastName': 'Trenholme', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Eric A F', 'Initials': 'EAF', 'LastName': 'Simões', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Geeta K', 'Initials': 'GK', 'LastName': 'Swamy', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Sapeckshita', 'Initials': 'S', 'LastName': 'Agrawal', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Khatija', 'Initials': 'K', 'LastName': 'Ahmed', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Allison', 'Initials': 'A', 'LastName': 'August', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Abdullah H', 'Initials': 'AH', 'LastName': 'Baqui', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Calvert', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Janice', 'Initials': 'J', 'LastName': 'Chen', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Iksung', 'Initials': 'I', 'LastName': 'Cho', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Mark F', 'Initials': 'MF', 'LastName': 'Cotton', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Clare L', 'Initials': 'CL', 'LastName': 'Cutland', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Janet A', 'Initials': 'JA', 'LastName': 'Englund', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Fix', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Gonik', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Hammitt', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Paul T', 'Initials': 'PT', 'LastName': 'Heath', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Joanne N', 'Initials': 'JN', 'LastName': 'de Jesus', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Christine E', 'Initials': 'CE', 'LastName': 'Jones', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Asma', 'Initials': 'A', 'LastName': 'Khalil', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Kimberlin', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Romina', 'Initials': 'R', 'LastName': 'Libster', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Conrado J', 'Initials': 'CJ', 'LastName': 'Llapur', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Marilla', 'Initials': 'M', 'LastName': 'Lucero', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Gonzalo', 'Initials': 'G', 'LastName': 'Pérez Marc', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Helen S', 'Initials': 'HS', 'LastName': 'Marshall', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Masebole S', 'Initials': 'MS', 'LastName': 'Masenya', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Federico', 'Initials': 'F', 'LastName': 'Martinón-Torres', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Jennifer K', 'Initials': 'JK', 'LastName': 'Meece', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Terry M', 'Initials': 'TM', 'LastName': 'Nolan', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Ayman', 'Initials': 'A', 'LastName': 'Osman', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Kirsten P', 'Initials': 'KP', 'LastName': 'Perrett', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Joyce S', 'Initials': 'JS', 'LastName': 'Plested', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Peter C', 'Initials': 'PC', 'LastName': 'Richmond', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Matthew D', 'Initials': 'MD', 'LastName': 'Snape', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Julie H', 'Initials': 'JH', 'LastName': 'Shakib', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Vivek', 'Initials': 'V', 'LastName': 'Shinde', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Tanya', 'Initials': 'T', 'LastName': 'Stoney', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'D Nigel', 'Initials': 'DN', 'LastName': 'Thomas', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Alan T', 'Initials': 'AT', 'LastName': 'Tita', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Michael W', 'Initials': 'MW', 'LastName': 'Varner', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Vatish', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Vrbicky', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Judy', 'Initials': 'J', 'LastName': 'Wen', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Khalequ', 'Initials': 'K', 'LastName': 'Zaman', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Heather J', 'Initials': 'HJ', 'LastName': 'Zar', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Gregory M', 'Initials': 'GM', 'LastName': 'Glenn', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': 'Louis F', 'Initials': 'LF', 'LastName': 'Fries', 'Affiliation': ""From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and Technology-National Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town - all in South Africa; Fundación INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del Niño Jesús, Tucumán (C.J.L.) - both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Children's Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore - all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. George's, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Women's and Reproductive Health, University of Oxford (M.V.), Oxford - all in the United Kingdom; the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology and Center for Women's Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Women's and Children's Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Children's Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Children's Hospital, Perth (P.C.R., T.S.) - all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); Pediatría Clínica, Infectología y Traslacional Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1908380'] 3006,32726530,Uterine-Artery Embolization or Myomectomy for Uterine Fibroids.,"BACKGROUND Uterine fibroids, the most common type of tumor among women of reproductive age, are associated with heavy menstrual bleeding, abdominal discomfort, subfertility, and a reduced quality of life. For women who wish to preserve their uterus and who have not had a response to medical treatment, myomectomy and uterine-artery embolization are therapeutic options. METHODS We conducted a multicenter, randomized, open-label trial to evaluate myomectomy, as compared with uterine-artery embolization, in women who had symptomatic uterine fibroids and did not want to undergo hysterectomy. Procedural options included open abdominal, laparoscopic, or hysteroscopic myomectomy. The primary outcome was fibroid-related quality of life, as assessed by the score on the health-related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (scores range from 0 to 100, with higher scores indicating a better quality of life) at 2 years; adjustment was made for the baseline score. RESULTS A total of 254 women, recruited at 29 hospitals in the United Kingdom, were randomly assigned: 127 to the myomectomy group (of whom 105 underwent myomectomy) and 127 to the uterine-artery embolization group (of whom 98 underwent embolization). Data on the primary outcome were available for 206 women (81%). In the intention-to-treat analysis, the mean (±SD) score on the health-related quality-of-life domain of the UFS-QOL questionnaire at 2 years was 84.6±21.5 in the myomectomy group and 80.0±22.0 in the uterine-artery embolization group (mean adjusted difference with complete case analysis, 8.0 points; 95% confidence interval [CI], 1.8 to 14.1; P = 0.01; mean adjusted difference with missing responses imputed, 6.5 points; 95% CI, 1.1 to 11.9). Perioperative and postoperative complications from all initial procedures, irrespective of adherence to the assigned procedure, occurred in 29% of the women in the myomectomy group and in 24% of the women in the uterine-artery embolization group. CONCLUSIONS Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those who underwent uterine-artery embolization. (Funded by the National Institute for Health Research Health Technology Assessment program; FEMME Current Controlled Trials number, ISRCTN70772394.).",2020,"Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those who underwent uterine-artery embolization.","['women who had symptomatic uterine fibroids and did not want to undergo hysterectomy', 'women who wish to preserve their uterus and who have not had a response to medical treatment, myomectomy and uterine-artery embolization', 'Uterine Fibroids', 'women with symptomatic uterine fibroids', '254 women, recruited at 29 hospitals in the United Kingdom']","['myomectomy', 'Uterine-Artery Embolization or Myomectomy', 'uterine-artery embolization', 'open abdominal, laparoscopic, or hysteroscopic myomectomy', 'myomectomy group (of whom 105 underwent myomectomy', 'uterine-artery embolization group (of whom 98 underwent embolization']","['mean (±SD) score on the health-related quality-of-life domain of the UFS-QOL questionnaire', 'Perioperative and postoperative complications', 'fibroid-related quality of life, as assessed by the score on the health-related quality-of-life domain of the Uterine Fibroid Symptom and Quality of Life (UFS-QOL) questionnaire (scores range', 'fibroid-related quality of life']","[{'cui': 'C0043210', 'cui_str': 'Woman'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C1299585', 'cui_str': 'Does not'}, {'cui': 'C1444647', 'cui_str': 'Wanted'}, {'cui': 'C0020699', 'cui_str': 'Hysterectomy'}, {'cui': 'C0033085', 'cui_str': 'Preservation, Biologic'}, {'cui': 'C0002838', 'cui_str': 'Andorra'}, {'cui': 'C0039798', 'cui_str': 'therapy'}, {'cui': 'C0195309', 'cui_str': 'Uterine myomectomy'}, {'cui': 'C0729536', 'cui_str': 'Embolization of uterine artery'}, {'cui': 'C0019994', 'cui_str': 'Hospitals'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom of Great Britain and Northern Ireland'}]","[{'cui': 'C0195309', 'cui_str': 'Uterine myomectomy'}, {'cui': 'C0729536', 'cui_str': 'Embolization of uterine artery'}, {'cui': 'C0175566', 'cui_str': 'Open'}, {'cui': 'C0000726', 'cui_str': 'Abdominal'}, {'cui': 'C0031150', 'cui_str': 'Laparoscopy'}, {'cui': 'C0439745', 'cui_str': 'Grouped'}, {'cui': 'C4319547', 'cui_str': '105'}, {'cui': 'C0013931', 'cui_str': 'Embolization - action'}]","[{'cui': 'C0444504', 'cui_str': 'Mean'}, {'cui': 'C0449820', 'cui_str': 'Score'}, {'cui': 'C4279947', 'cui_str': 'HRQOL'}, {'cui': 'C1514562', 'cui_str': 'Protein Domain'}, {'cui': 'C0042133', 'cui_str': 'Leiomyoma'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0518214', 'cui_str': 'Quality of life satisfaction'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0032787', 'cui_str': 'Postoperative complication'}, {'cui': 'C0023267', 'cui_str': 'Leiomyofibroma'}, {'cui': 'C0439849', 'cui_str': 'Relationships'}, {'cui': 'C3542016', 'cui_str': 'Concept model range'}]",254.0,0.316936,"Among women with symptomatic uterine fibroids, those who underwent myomectomy had a better fibroid-related quality of life at 2 years than those who underwent uterine-artery embolization.","[{'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'Manyonda', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Belli', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Mary-Ann', 'Initials': 'MA', 'LastName': 'Lumsden', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Moss', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'William', 'Initials': 'W', 'LastName': 'McKinnon', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Lee J', 'Initials': 'LJ', 'LastName': 'Middleton', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Versha', 'Initials': 'V', 'LastName': 'Cheed', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Wu', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Fusun', 'Initials': 'F', 'LastName': 'Sirkeci', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Jane P', 'Initials': 'JP', 'LastName': 'Daniels', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': 'Klim', 'Initials': 'K', 'LastName': 'McPherson', 'Affiliation': ""From St. George's Hospital and Medical School (I.M., A.-M.B.) and Whipps Cross Hospital (F.S.), London, the University of Glasgow, Glasgow (M.-A.L., J.M., O.W.), the University of Birmingham, Birmingham (W.M., L.J.M., V.C.), the University of Nottingham, Nottingham (J.P.D.), and the University of Oxford, Oxford (K.M.) - all in the United Kingdom.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The New England journal of medicine,['10.1056/NEJMoa1914735'] 3007,32726552,Objective Evaluation of Skin Sensitivity Across Fitzpatrick Skin Types.,"Context: Skin sensitivity may be best defined as self-reported intolerance to application of skincare products. It is commonly believed that individuals with darker skin are generally less sensitive, while those lighter skin are more sensitive. However, there is little objective data correlating sensitivity with skin type or with objective measures of sensitivity. Objective: This study assessed Fitzpatrick skin type and self-reported perception of skin sensitivity. Design: A single-blinded, lactic acid sting test was performed on the medial cheeks, where patients were randomized to receive room temperature 10% lactic acid on the left or right cheek with water applied to the contralateral cheek as a control. Outcome Measures: Stinging was assessed 1 minute after application of test solution to one cheek using a visual analogue scale (VAS). Results: There was a statistically significant difference in self-reported skin sensitivity in patients with Fitzpatrick skin types 1-3 vs 4-6 (73.6% vs 46.5%; P= 0.006). Patients who had higher perceived sensitivity were more likely to have objectively measured sensitivity as well, across all skin types (P<0.01). When stratified by skin type, a numerically higher percentage of subjects with Fitzpatrick skin types 1-3 experienced objective sensitivity compared to subjects with skin types 4-6 (45.6% vs 27.9; P=0.058). Conclusions: Patients with self-perceived skin sensitivity were more likely to develop objective stinging compared to those who did not report sensitivity. Skin sensitivity can occur across all skin types, and patients should be asked about self-perceptions of sensitivity as it is likely an indicator of true sensitivity. J Drugs Dermatol. 2020;19(7): doi:10.36849/JDD.2020.5880.",2020,"Patients who had higher perceived sensitivity were more likely to have objectively measured sensitivity as well, across all skin types (P<0.01).","['Skin Sensitivity Across Fitzpatrick Skin Types', 'individuals with darker skin']",['room temperature 10% lactic acid on the left or right cheek with water applied to the contralateral cheek as a control'],"['objective sensitivity', 'self-reported skin sensitivity', 'Fitzpatrick skin type and self-reported perception of skin sensitivity', '1 minute after application of test solution to one cheek using a visual analogue scale (VAS', 'Skin sensitivity', 'skin sensitivity']","[{'cui': 'C0520898', 'cui_str': 'Skin sensitivity'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0027361', 'cui_str': 'Person'}, {'cui': 'C0332582', 'cui_str': 'Dark color'}]","[{'cui': 'C0005903', 'cui_str': 'Body temperature'}, {'cui': 'C0064582', 'cui_str': 'lactic acid'}, {'cui': 'C0205090', 'cui_str': 'Right'}, {'cui': 'C0007966', 'cui_str': 'Cheek structure'}, {'cui': 'C0020311', 'cui_str': 'Hydrotherapy'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0441988', 'cui_str': 'Contralateral'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018017', 'cui_str': 'Goal'}, {'cui': 'C0020517', 'cui_str': 'Hypersensitivity reaction'}, {'cui': 'C2700446', 'cui_str': 'Self-reported'}, {'cui': 'C0520898', 'cui_str': 'Skin sensitivity'}, {'cui': 'C0444099', 'cui_str': 'Specimen from skin'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0439232', 'cui_str': 'min'}, {'cui': 'C0185125', 'cui_str': 'Application'}, {'cui': 'C0003647', 'cui_str': 'Aptitude Tests'}, {'cui': 'C0037633', 'cui_str': 'Solution'}, {'cui': 'C0007966', 'cui_str': 'Cheek structure'}, {'cui': 'C0042815', 'cui_str': 'Visual analog pain scale'}]",,0.0331919,"Patients who had higher perceived sensitivity were more likely to have objectively measured sensitivity as well, across all skin types (P<0.01).","[{'ForeName': 'Celina E', 'Initials': 'CE', 'LastName': 'Dubin', 'Affiliation': ''}, {'ForeName': 'Grace W', 'Initials': 'GW', 'LastName': 'Kimmel', 'Affiliation': ''}, {'ForeName': 'Peter W', 'Initials': 'PW', 'LastName': 'Hashim', 'Affiliation': ''}, {'ForeName': 'John K', 'Initials': 'JK', 'LastName': 'Nia', 'Affiliation': ''}, {'ForeName': 'Joshua A', 'Initials': 'JA', 'LastName': 'Zeichner', 'Affiliation': ''}]",Journal of drugs in dermatology : JDD,['10.36849/JDD.2020.5880'] 3008,31254633,Learning from the EPOCH trial (Editorial). What we have learnt from a trial of an intervention to improve survival following emergency laparotomy.,,2019,,[],[],[],[],[],[],,0.0830057,,"[{'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Stephens', 'Affiliation': 'Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK. Electronic address: t.t.stephens@qmul.ac.uk.'}, {'ForeName': 'Rupert M', 'Initials': 'RM', 'LastName': 'Pearse', 'Affiliation': 'Barts & The London School of Medicine and Dentistry, Queen Mary University of London, UK.'}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2019.06.006'] 3009,31219000,In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline.,"Mucosal leishmaniasis (ML) is characterized by high production of inflammatory cytokines. Administration of pentoxifylline (PTX), an inhibitor of TNF-alpha, with pentavalent antimony (Sb v ), has been successfully used as alternative treatment for refractory ML. Our study aims to investigate the in situ cellular response underlying the effectiveness of this therapy, by evaluating the intensity of the inflammatory infiltrate, cellular composition, and expression of cytokines and granzyme A in lesions from ML before and after treatment with Sb v alone or in combination with PTX. Our data showed no differences in the intensity of inflammatory infiltrate comparing before and after treatment, and comparing between different treatments. However, although the number and frequency of CD4 + and CD8 + cells were not different before and after treatments or comparing different treatments, frequency of CD68 + cells decreased after treatment with Sb v + PTX, but not with Sb v . This was due to a reduction in CD68 + TNF-alpha + and not in CD68 + IL-10 + cells. The frequency of TNF-alpha + cells was correlated with the intensity of the inflammatory infiltrate before treatment, but this correlation was lost after treatment with Sb v + PTX. Although the total expression of granzyme A did not significantly change after treatments, a clear trend of decrease was observed after treatment with Sb v + PTX. Interestingly, patients who took longer to heal, regardless of the treatment, displayed a higher frequency of granzyme A + cells. Our data suggest that treatment with Sb v + PTX acts in CD68 + cells reducing the expression of TNF-alpha but not IL-10, resulting in more efficient modulation of the inflammatory response, accelerating the healing process.",2019,This was due to a reduction in CD68 + TNF-alpha + and not in CD68 + IL-10 + cells.,[],"['pentoxifylline (PTX', 'Pentavalent Antimonial and Pentoxifylline', 'TNF-alpha, with pentavalent antimony (Sb v ', 'Sb v alone or in combination with PTX', 'Sb v + PTX']","['frequency of TNF-alpha + cells', 'number and frequency of CD4 + and CD8 + cells', 'intensity of inflammatory infiltrate', 'total expression of granzyme A', 'frequency of CD68 + cells']",[],"[{'cui': 'C0030899', 'cui_str': 'Pentoxifylline'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0202321', 'cui_str': 'Antimony measurement (procedure)'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C4316924', 'cui_str': 'Cell positive for CD8 antigen'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0061877', 'cui_str': 'Hanukah Factor'}]",,0.0559333,This was due to a reduction in CD68 + TNF-alpha + and not in CD68 + IL-10 + cells.,"[{'ForeName': 'Daniela Rodrigues de', 'Initials': 'DR', 'LastName': 'Faria', 'Affiliation': 'Centro Universitário de Formiga - UNIFOR-MG, Formiga, Brazil.'}, {'ForeName': 'Luiza Cenizio', 'Initials': 'LC', 'LastName': 'Barbieri', 'Affiliation': 'Laboratory of Cell-Cell Interactions, Department of Morphology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Carolina Cattoni', 'Initials': 'CC', 'LastName': 'Koh', 'Affiliation': 'Laboratory of Cell-Cell Interactions, Department of Morphology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'ForeName': 'Paulo Roberto Lima', 'Initials': 'PRL', 'LastName': 'Machado', 'Affiliation': 'Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais - INCT-DT, Salvador, Brazil.'}, {'ForeName': 'Carolina Cincurá', 'Initials': 'CC', 'LastName': 'Barreto', 'Affiliation': 'Immunology Service, Hospital Universitário Professor Edgar Santos, Universidade Federal da Bahia, Salvador, Brazil.'}, {'ForeName': 'Clara Monica Figueiredo de', 'Initials': 'CMF', 'LastName': 'Lima', 'Affiliation': 'Immunology Service, Hospital Universitário Professor Edgar Santos, Universidade Federal da Bahia, Salvador, Brazil.'}, {'ForeName': 'Marcus Miranda', 'Initials': 'MM', 'LastName': 'Lessa', 'Affiliation': 'Immunology Service, Hospital Universitário Professor Edgar Santos, Universidade Federal da Bahia, Salvador, Brazil.'}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Carvalho', 'Affiliation': 'Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais - INCT-DT, Salvador, Brazil.'}, {'ForeName': 'Kenneth J', 'Initials': 'KJ', 'LastName': 'Gollob', 'Affiliation': 'International Research Center, ACCamargo Cancer Center, São Paulo, Brazil.'}, {'ForeName': 'Walderez Ornelas', 'Initials': 'WO', 'LastName': 'Dutra', 'Affiliation': 'Laboratory of Cell-Cell Interactions, Department of Morphology, Biological Sciences Institute, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}]",The American journal of tropical medicine and hygiene,['10.4269/ajtmh.19-0139'] 3010,31335603,CORR Insights®: Perineal Pressure During Hip Arthroscopy Is Reduced by Use of Trendelenburg: A Prospective Study With Randomized Order of Positioning.,,2019,,[],"['Trendelenburg', 'CORR Insights®: Perineal Pressure', 'Hip Arthroscopy']",[],[],"[{'cui': 'C0031066', 'cui_str': 'Perineum'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0186190', 'cui_str': 'Arthroscopy of hip (procedure)'}]",[],,0.0267359,,"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Leunig', 'Affiliation': 'M. Leunig, Schulthess Clinic, Department of Orthopaedic Surgery, Zürich, Switzerland.'}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000000879'] 3011,31743617,Effects of aerobic and inspiratory training on skeletal muscle microRNA-1 and downstream-associated pathways in patients with heart failure.,"BACKGROUND The exercise intolerance in chronic heart failure with reduced ejection fraction (HFrEF) is mostly attributed to alterations in skeletal muscle. However, the mechanisms underlying the skeletal myopathy in patients with HFrEF are not completely understood. We hypothesized that (i) aerobic exercise training (AET) and inspiratory muscle training (IMT) would change skeletal muscle microRNA-1 expression and downstream-associated pathways in patients with HFrEF and (ii) AET and IMT would increase leg blood flow (LBF), functional capacity, and quality of life in these patients. METHODS Patients age 35 to 70 years, left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association functional classes II-III, were randomized into control, IMT, and AET groups. Skeletal muscle changes were examined by vastus lateralis biopsy. LBF was measured by venous occlusion plethysmography, functional capacity by cardiopulmonary exercise test, and quality of life by Minnesota Living with Heart Failure Questionnaire. All patients were evaluated at baseline and after 4 months. RESULTS Thirty-three patients finished the study protocol: control (n = 10; LVEF = 25 ± 1%; six males), IMT (n = 11; LVEF = 31 ± 2%; three males), and AET (n = 12; LVEF = 26 ± 2%; seven males). AET, but not IMT, increased the expression of microRNA-1 (P = 0.02; percent changes = 53 ± 17%), decreased the expression of PTEN (P = 0.003; percent changes = -15 ± 0.03%), and tended to increase the p-AKT ser473 /AKT ratio (P = 0.06). In addition, AET decreased HDAC4 expression (P = 0.03; percent changes = -40 ± 19%) and upregulated follistatin (P = 0.01; percent changes = 174 ± 58%), MEF2C (P = 0.05; percent changes = 34 ± 15%), and MyoD expression (P = 0.05; percent changes = 47 ± 18%). AET also increased muscle cross-sectional area (P = 0.01). AET and IMT increased LBF, functional capacity, and quality of life. Further analyses showed a significant correlation between percent changes in microRNA-1 and percent changes in follistatin mRNA (P = 0.001, rho = 0.58) and between percent changes in follistatin mRNA and percent changes in peak VO 2 (P = 0.004, rho = 0.51). CONCLUSIONS AET upregulates microRNA-1 levels and decreases the protein expression of PTEN, which reduces the inhibitory action on the PI3K-AKT pathway that regulates the skeletal muscle tropism. The increased levels of microRNA-1 also decreased HDAC4 and increased MEF2c, MyoD, and follistatin expression, improving skeletal muscle regeneration. These changes associated with the increase in muscle cross-sectional area and LBF contribute to the attenuation in skeletal myopathy, and the improvement in functional capacity and quality of life in patients with HFrEF. IMT caused no changes in microRNA-1 and in the downstream-associated pathway. The increased functional capacity provoked by IMT seems to be associated with amelioration in the respiratory function instead of changes in skeletal muscle. ClinicalTrials.gov (Identifier: NCT01747395).",2020,"AET, but not IMT, increased the expression of microRNA-1","['Patients age 35 to 70 years, left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association functional classes II-III', 'patients with heart failure', 'patients with HFrEF', 'chronic heart failure with reduced ejection fraction (HFrEF']","['i) aerobic exercise training (AET) and inspiratory muscle training (IMT', 'aerobic and inspiratory training', 'IMT']","['Skeletal muscle changes', 'upregulated follistatin', 'functional capacity and quality of life', 'leg blood flow (LBF), functional capacity, and quality of life', 'HDAC4 expression', 'skeletal muscle microRNA-1 and downstream-associated pathways', 'LBF, functional capacity, and quality of life', 'LBF', 'levels of microRNA-1 also decreased HDAC4 and increased MEF2c, MyoD, and follistatin expression, improving skeletal muscle regeneration', 'expression of PTEN', 'expression of microRNA-1', 'follistatin mRNA', 'MyoD expression', 'MEF2C', 'venous occlusion plethysmography, functional capacity by cardiopulmonary exercise test, and quality of life by Minnesota Living with Heart Failure Questionnaire']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0428772', 'cui_str': 'Left ventricular ejection fraction (observable entity)'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0018787', 'cui_str': 'Heart'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training (regime/therapy)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}]","[{'cui': 'C0242692', 'cui_str': 'Muscle, Voluntary'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0060623', 'cui_str': 'Activin-Binding Protein'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0034380'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}, {'cui': 'C0522506', 'cui_str': 'Downstream (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0349676', 'cui_str': 'Regeneration - action (qualifier value)'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0430494', 'cui_str': 'Venous occlusion plethysmography (procedure)'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}, {'cui': 'C0026183', 'cui_str': 'Minnesota'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",33.0,0.0230079,"AET, but not IMT, increased the expression of microRNA-1","[{'ForeName': 'Ligia M', 'Initials': 'LM', 'LastName': 'Antunes-Correa', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Patricia F', 'Initials': 'PF', 'LastName': 'Trevizan', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Aline V N', 'Initials': 'AVN', 'LastName': 'Bacurau', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Larissa', 'Initials': 'L', 'LastName': 'Ferreira-Santos', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'João L P', 'Initials': 'JLP', 'LastName': 'Gomes', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Urias', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Oliveira', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Maria Janieire N N', 'Initials': 'MJNN', 'LastName': 'Alves', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Dirceu R', 'Initials': 'DR', 'LastName': 'de Almeida', 'Affiliation': 'Division of Cardiology, Department of Medicine, Federal University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Patricia C', 'Initials': 'PC', 'LastName': 'Brum', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Edilamar M', 'Initials': 'EM', 'LastName': 'Oliveira', 'Affiliation': 'School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil.'}, {'ForeName': 'Ludhmila', 'Initials': 'L', 'LastName': 'Hajjar', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Roberto', 'Initials': 'R', 'LastName': 'Kalil Filho', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}, {'ForeName': 'Carlos Eduardo', 'Initials': 'CE', 'LastName': 'Negrão', 'Affiliation': 'Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.'}]","Journal of cachexia, sarcopenia and muscle",['10.1002/jcsm.12495'] 3012,31925600,Effectiveness of Housing First for Homeless Adults with Mental Illness Who Frequently Use Emergency Departments in a Multisite Randomized Controlled Trial.,"Frequent emergency department (ED) users experiencing homelessness are associated with high costs for healthcare systems yet interventions for this group have been minimally investigated. This study used 24-month data from a multisite randomized controlled trial of Housing First (HF) to examine how effective the intervention is in helping frequent ED users with a mental illness to achieve housing stability, improve behavioural health and functioning, and reduce their ED use. Findings showed that HF is effective in stably housing frequent ED users despite their complex health needs. Reductions in ED use and substance use problems, and improvements in mental health symptoms and community functioning were found for frequent ED users in both the HF and treatment as usual conditions.",2020,"Reductions in ED use and substance use problems, and improvements in mental health symptoms and community functioning were found for frequent ED users in both the HF and treatment as usual conditions.",['Homeless Adults with Mental Illness'],"['Housing First (HF', 'HF']",['mental health symptoms and community functioning'],"[{'cui': 'C0237154', 'cui_str': 'Homelessness'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}]","[{'cui': 'C0020056', 'cui_str': 'Housing'}]","[{'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0009462', 'cui_str': 'Community'}]",,0.152094,"Reductions in ED use and substance use problems, and improvements in mental health symptoms and community functioning were found for frequent ED users in both the HF and treatment as usual conditions.","[{'ForeName': 'Nick', 'Initials': 'N', 'LastName': 'Kerman', 'Affiliation': 'School of Psychology, University of Ottawa, Ottawa, Canada.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Aubry', 'Affiliation': 'School of Psychology, University of Ottawa, Ottawa, Canada. tim.aubry@uottawa.ca.'}, {'ForeName': 'Carol E', 'Initials': 'CE', 'LastName': 'Adair', 'Affiliation': 'Departments of Psychiatry and Community Health Sciences, University of Calgary, Calgary, Canada.'}, {'ForeName': 'Jino', 'Initials': 'J', 'LastName': 'Distasio', 'Affiliation': 'Department of Geography, University of Winnipeg, Winnipeg, Canada.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Latimer', 'Affiliation': 'Department of Psychiatry, McGill University, Montreal, Canada.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Somers', 'Affiliation': 'Department of Psychiatry, Simon Fraser University, Burnaby, Canada.'}, {'ForeName': 'Vicky', 'Initials': 'V', 'LastName': 'Stergiopoulos', 'Affiliation': 'Centre for Addiction and Mental Health, Toronto, Canada.'}]",Administration and policy in mental health,['10.1007/s10488-020-01008-3'] 3013,30417764,Postoperative stress and pain response applying fast-track protocol in patients undergoing hepatectomy.,,2019,"CONCLUSION Fast-track recovery protocols seem to be associated with improvement in several clinical parameters, without compromising, biologic or emotional stress in patients undergoing major liver resection.","['Eighty-eight patients suffering from malignant liver tumours', 'patients undergoing hepatectomy', 'patients undergoing major liver resection']",['fast-track recovery protocol and conventional treatment'],"['Postoperative stress and pain response', 'Zung self-rating depression scale and three Numeric Analog Scale self-reported questions', 'adrenocorticotropic hormone and cortisol', 'stress and pain response', 'Peripheral blood samples', 'pain scale (behavioural observation scale and visual analog scale), while depression levels', 'biologic or emotional stress']","[{'cui': 'C4517898', 'cui_str': '88 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0345904', 'cui_str': 'Cancer of Liver'}, {'cui': 'C0019144', 'cui_str': 'Hepatectomy'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C0040594', 'cui_str': 'Track'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0201835', 'cui_str': 'Adrenocorticotropic hormone measurement (procedure)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1319226', 'cui_str': 'Level of depression'}, {'cui': 'C4553887', 'cui_str': 'Biologic Drugs'}, {'cui': 'C0086209', 'cui_str': 'Emotional Stress'}]",88.0,,"CONCLUSION Fast-track recovery protocols seem to be associated with improvement in several clinical parameters, without compromising, biologic or emotional stress in patients undergoing major liver resection.","[{'ForeName': 'Kapritsou', 'Initials': 'K', 'LastName': 'Maria', 'Affiliation': 'Chief Nurse of PACU, Hellenic Anticancer Hospital ""Saint Savvas"", Day Care Surgery ""N. KOURKOULOS"" Hellenic Anticancer Institute, ""Saint Savvas"" Hospital, Athens, Greece.'}, {'ForeName': 'Konstantinou A', 'Initials': 'KA', 'LastName': 'Evangelos', 'Affiliation': 'Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Korkolis P', 'Initials': 'KP', 'LastName': 'Dimitris', 'Affiliation': 'Hellenic Anticancer Institute, ""Saint Savvas"" Hospital, Athens, Greece.'}, {'ForeName': 'Kalafati', 'Initials': 'K', 'LastName': 'Maria', 'Affiliation': 'Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Kaklamanos', 'Initials': 'K', 'LastName': 'Ioannis', 'Affiliation': 'Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Giannakopoulou', 'Initials': 'G', 'LastName': 'Margarita', 'Affiliation': 'Department of Nursing, National and Kapodistrian University of Athens, Athens, Greece.'}]",Journal of perioperative practice,['10.1177/1750458918812293'] 3014,31428143,Posttraining Alpha Transcranial Alternating Current Stimulation Impairs Motor Consolidation in Elderly People.,"The retention of a new sequential motor skill relies on repeated practice and subsequent consolidation in the absence of active skill practice. While the early phase of skill acquisition remains relatively unaffected in older adults, posttraining consolidation appears to be selectively impaired by advancing age. Motor learning is associated with posttraining changes of oscillatory alpha and beta neuronal activities in the motor cortex. However, whether or not these oscillatory dynamics relate to posttraining consolidation and how they relate to the age-specific impairment of motor consolidation in older adults remains elusive. Transcranial alternating current stimulation (tACS) is a noninvasive brain stimulation technique capable of modulating such neuronal oscillations. Here, we examined whether tACS targeting M1 immediately following explicit motor sequence training is capable of modulating motor skill consolidation in older adults. In two sets of double-blind, sham-controlled experiments, tACS targeting left M1 was applied at either 10 Hz (alpha-tACS) or 20 Hz (beta-tACS) immediately after termination of a motor sequence training with the right (dominant) hand. Task performance was retested after an interval of 6 hours to assess consolidation of the training-acquired skill. EEG was recorded over left M1 to be able to detect local after-effects on oscillatory activity induced by tACS. Relative to the sham intervention, consolidation was selectively disrupted by posttraining alpha-tACS of M1, while posttraining beta-tACS of M1 had no effect on delayed retest performance compared to the sham intervention. No significant postinterventional changes of oscillatory activity in M1 were detected following alpha-tACS or beta-tACS. Our findings point to a frequency-specific interaction of tACS with posttraining motor memory processing and may suggest an inhibitory role of immediate posttraining alpha oscillations in M1 with respect to motor consolidation in healthy older adults.",2019,No significant postinterventional changes of oscillatory activity in M1 were detected following alpha-tACS or beta-tACS.,"['older adults', 'healthy older adults', 'Elderly People']","['Transcranial alternating current stimulation (tACS', 'Posttraining Alpha Transcranial Alternating Current Stimulation']","['Task performance', 'oscillatory activity', 'delayed retest performance']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C3852966', 'cui_str': 'Transcranial Alternating Current Stimulation'}, {'cui': 'C0439095', 'cui_str': 'Alpha'}]","[{'cui': 'C0039333', 'cui_str': 'Task Performance'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0543431', 'cui_str': 'ret (qualifier value)'}]",,0.0516684,No significant postinterventional changes of oscillatory activity in M1 were detected following alpha-tACS or beta-tACS.,"[{'ForeName': 'Jost-Julian', 'Initials': 'JJ', 'LastName': 'Rumpf', 'Affiliation': 'Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Alexandru', 'Initials': 'A', 'LastName': 'Barbu', 'Affiliation': 'Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Fricke', 'Affiliation': 'Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Mirko', 'Initials': 'M', 'LastName': 'Wegscheider', 'Affiliation': 'Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Classen', 'Affiliation': 'Department of Neurology, University of Leipzig, 04103 Leipzig, Germany.'}]",Neural plasticity,['10.1155/2019/2689790'] 3015,31865235,Generalization of exposure in vivo in Complex Regional Pain Syndrome type I.,"Exposure in vivo has been found successful in reducing pain-related fear, disability, and experienced pain in chronic pain patients. Despite the success of exposure treatment, experimental studies show that extinction learning is fragile, raising doubts whether extinction of pain-related fear generalizes to new threatening activities after treatment. This study examined whether a particular exposure treatment, in which patients are exposed to a variety of activities (Multiple Exposure condition), promotes generalization of extinction to new threatening situations, compared to an exposure treatment in which subjects are repeatedly exposed to the same set of activities (Repeated Exposure condition). Generalization tests were combined with randomized replicated single case experimental designs (N = 8). Included were patients with Complex Regional Pain Syndrome type I reporting elevated levels of pain-related fear. The Multiple Exposure treatment condition consisted of at least 15 activities to which patients were exposed once. The Repeated Exposure treatment condition exposed patients to only three activities during five sessions each. Generalization was tested by exposing patients to new fearful activities post-treatment and 6-months follow-up. Patients from both conditions performed equally well at both generalization tests. Daily measures showed that the Multiple Exposure condition is preferred to reduce fear of movement/(re)injury, pain catastrophizing and pain experience.",2020,"Exposure in vivo has been found successful in reducing pain-related fear, disability, and experienced pain in chronic pain patients.","['patients with Complex Regional Pain Syndrome type I reporting elevated levels of pain-related fear', 'chronic pain patients']",[],"['fear of movement/(re)injury, pain catastrophizing and pain experience']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0034931', 'cui_str': 'CRPS Type I'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}]",[],"[{'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0026649', 'cui_str': 'Movement'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C3178745', 'cui_str': 'Pain Catastrophizing'}, {'cui': 'C0030193', 'cui_str': 'Pain'}]",,0.0138351,"Exposure in vivo has been found successful in reducing pain-related fear, disability, and experienced pain in chronic pain patients.","[{'ForeName': 'Marlies den', 'Initials': 'MD', 'LastName': 'Hollander', 'Affiliation': 'Experimental Health Psychology, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, the Netherlands; Department of Rehabilitation, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands; Adelante Centre of Expertise in Rehabilitation, Zandbergsweg 111, 6432 CC, Hoensbroek, the Netherlands. Electronic address: marlies.denhollander@maastrichtuniversity.nl.'}, {'ForeName': 'Jeroen', 'Initials': 'J', 'LastName': 'de Jong', 'Affiliation': 'Department of Rehabilitation, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands; CAPHRI - School for Public Health and Primary Care, Department of Rehabilitation Medicine, Maastricht University, Universiteitssingel 60, 6229 ER., Maastricht, the Netherlands.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Onghena', 'Affiliation': 'Research Group on Methods, Individual and Cultural Differences, Affect and Social Behaviour, KU Leuven - University of Leuven, Tiensestraat 102, 3000, Leuven, Belgium.'}, {'ForeName': 'Johan W S', 'Initials': 'JWS', 'LastName': 'Vlaeyen', 'Affiliation': 'Experimental Health Psychology, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, the Netherlands; Research Group Health Psychology, KU Leuven - University of Leuven, Tiensestraat 102, 3000, Leuven, Belgium.'}]",Behaviour research and therapy,['10.1016/j.brat.2019.103511'] 3016,31970581,"Stigma Related to HIV and Drug Use: Layers, Types, and Relations to Mental Health.","Stigma poses considerable challenges to the mental health of people living with HIV who use drugs (PLHWUD). In this study, we explored factors related to different types of stigma (perceived and internalized) attached to layered stigmatizing characters (HIV and drug use) and their mental health influences on PLHWUD. The study used baseline data of an ongoing randomized controlled trial among 241 PLHWUD recruited between March and December 2018 in Vietnam. A structural equation model was used to assess the relationships among different types and layers of stigma and mental health status. Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma. HIV-related stigma was negatively associated with mental health status; however, we did not find a significant relationship between drug-related stigma and mental health. Tailored intervention strategies in consideration of types and layers of stigma are needed to address stigma-related challenges faced by PLHWUD.",2020,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,['241 PLHWUD recruited between March and December 2018 in Vietnam'],[],[],"[{'cui': 'C0042658', 'cui_str': 'Viet Nam'}]",[],[],241.0,0.0331404,Both perceived and internalized drug-related stigma measures were significantly higher than their corresponding HIV-related stigma.,"[{'ForeName': 'Li', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA. lililili@ucla.edu.'}, {'ForeName': 'Chunqing', 'Initials': 'C', 'LastName': 'Lin', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Nan', 'Initials': 'N', 'LastName': 'Feng', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Diep Bich', 'Initials': 'DB', 'LastName': 'Nguyen', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Cao', 'Affiliation': 'Semel Institute for Neuroscience and Human Behavior - Center for Community Health, University of California, Los Angeles, CA, USA.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Le', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}, {'ForeName': 'Anh Tuan', 'Initials': 'AT', 'LastName': 'Nguyen', 'Affiliation': 'National Institute of Hygiene and Epidemiology, Hanoi, Vietnam.'}]",AIDS and behavior,['10.1007/s10461-020-02794-5'] 3017,32098714,"Correspondence in response to the letter ""Study validity depends on the study design and bias. Comment on ""Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia"".",,2020,,[],['scalp cooling'],['alopecia'],[],"[{'cui': 'C0036270', 'cui_str': 'Scalp'}]","[{'cui': 'C0002170', 'cui_str': 'Hair Loss'}]",,0.0453019,,"[{'ForeName': 'Jyoti', 'Initials': 'J', 'LastName': 'Bajpai', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India. Electronic address: dr_jyotibajpai@yahoo.co.in.'}, {'ForeName': 'Sadhna', 'Initials': 'S', 'LastName': 'Kannan', 'Affiliation': 'Statistician Department, Tata Memorial Hospital, Mumbai, India.'}, {'ForeName': 'Sudeep', 'Initials': 'S', 'LastName': 'Gupta', 'Affiliation': 'Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.'}]","Breast (Edinburgh, Scotland)",['10.1016/j.breast.2020.02.008'] 3018,31513849,Working memory updating training modulates a cascade of event-related potentials depending on task load.,"The brain mechanisms of working memory (WM) training in humans remain unclear. Here we examined how WM updating training modulates a cascade of event-related potentials (ERPs) elicited at different processing stages. We hypothesized that WM updating training results to decreases in the early responses reflecting stimulus selection and response preparation, and increases the late slow responses reflecting maintenance of to-be-remembered materials. Healthy adults were randomized to a WM updating group that trained an adaptive dual n-back task (n = 20), and an active control group that played a computer game (n = 20). Both groups performed three 25-min training sessions per week for five weeks. Pretest-posttest comparisons showed that the training group significantly improved their performance as compared to the active controls, but this was limited to the trained task. In line with our hypothesis, P2-N2-P3 complex showed changes from pre- to posttest. In the training group this was observed as decreased load-effect while in the control group there was an opposite pattern at some latencies. Slow waves elicited during the maintenance were decreased in the easy task and increased in the difficult task. Taken together, our findings suggest that the early and late ERPs are differentially affected by training. When task demands are high, training may lead to an improved ability to actively maintain several stimuli in memory, and when they are low, training results in more efficient processing and automatization.",2019,"Pretest-posttest comparisons showed that the training group significantly improved their performance as compared to the active controls, but this was limited to the trained task.",['Healthy adults'],"['working memory (WM) training', 'WM updating group that trained an adaptive dual n-back task (n\u202f=\u202f20), and an active control group that played a computer game']",['load-effect'],"[{'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0870328', 'cui_str': 'Computer Games'}]","[{'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.0282255,"Pretest-posttest comparisons showed that the training group significantly improved their performance as compared to the active controls, but this was limited to the trained task.","[{'ForeName': 'Juha', 'Initials': 'J', 'LastName': 'Salmi', 'Affiliation': 'Department of Neuroscience and Biomedical Engineering, Aalto University, Rakentajanaukio 3, Espoo, Finland; Department of Psychology, Åbo Akademi University, Turku, Finland; Department of Psychology, University of Turku, Turku, Finland; Institute for Advanced Studies, University of Turku, Turku, Finland. Electronic address: juha.salmitaival@utu.fi.'}, {'ForeName': 'Adrià', 'Initials': 'A', 'LastName': 'Vilà-Balló', 'Affiliation': ""Department of Psychology, Åbo Akademi University, Turku, Finland; Headache and Neurological Pain Group, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Department of Psychology, Faculty of Education and Psychology, University of Girona, Girona, Spain; Cognition and Brain Plasticity Group [Bellvitge Biomedical Research Institute - IDIBELL], L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Soveri', 'Affiliation': 'Department of Clinical Medicine, University of Turku, Turku, Finland.'}, {'ForeName': 'Carles', 'Initials': 'C', 'LastName': 'Rostan', 'Affiliation': 'Department of Psychology, Faculty of Education and Psychology, University of Girona, Girona, Spain.'}, {'ForeName': 'Antoni', 'Initials': 'A', 'LastName': 'Rodríguez-Fornells', 'Affiliation': ""Cognition and Brain Plasticity Group [Bellvitge Biomedical Research Institute - IDIBELL], L'Hospitalet de Llobregat, Barcelona, Spain; Department of Cognition, Development and Educational Psychology, Faculty of Psychology, University of Barcelona, Barcelona, Spain; Catalan Institution for Research and Advanced Studies, ICREA, Barcelona, Spain.""}, {'ForeName': 'Minna', 'Initials': 'M', 'LastName': 'Lehtonen', 'Affiliation': 'MultiLing Center for Multilingualism in Society across the Lifespan, Department of Linguistics and Scandinavian Studies, University of Oslo, Oslo, Norway.'}, {'ForeName': 'Matti', 'Initials': 'M', 'LastName': 'Laine', 'Affiliation': 'Department of Psychology, Åbo Akademi University, Turku, Finland; Brain and Mind Center, University of Turku, Turku, Finland.'}]",Neurobiology of learning and memory,['10.1016/j.nlm.2019.107085'] 3019,31573612,Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.,"BACKGROUND The phase III TRIBE and TRIBE2 studies randomized metastatic colorectal cancer patients to first-line FOLFOXIRI/bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab. The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs). In both trials, males and females aged between 18 and 70 years with ECOG PS ≤2 and between 71 and 75 years with ECOG PS = 0 were eligible. We investigated the effect of FOLFOXIRI/bevacizumab versus doublets/bevacizumab according to age and gender. PATIENTS AND METHODS Subgroup analyses according to age (<70 versus 70-75 years) and gender were carried out for overall response rate (ORR), progression-free survival (PFS), and AE rates. RESULTS Of 1187 patients, 1005 (85%) were aged <70 years and 182 (15%) 70-75 years; 693 (58%) were males and 494 (42%) females. There was no evidence of interaction between age or gender and the benefit provided by the intensification of the upfront chemotherapy in terms of ORR and PFS, or the increased risk of experiencing G3/4 AEs. Elderly patients and females experienced higher rates of overall G3/4 AEs (73% versus 60%, P < 0.01 and 69% versus 57%, P < 0.01, respectively). Notably, in the FOLFOXIRI/bevacizumab subgroup, G3/4 diarrhea and febrile neutropenia occurred in 27% and 16% of elderly patients, respectively, while females reported high incidences of any grade nausea (67%) and vomiting (50%). CONCLUSIONS The improvements in terms of ORR and PFS of FOLFOXIRI/bevacizumab versus doublets/bevacizumab are independent of gender and age, with a similar relative increase in AEs among elderly patients and females. Initial dose reductions and possibly primary G-CSF prophylaxis should be recommended for patients between 70 and 75 years old treated with FOLFOXIRI/bevacizumab, and a careful management of antiemetic prophylaxis should be considered among females.",2019,"There was no evidence of interaction between age or gender and the benefit provided by the intensification of the upfront chemotherapy in terms of ORR and PFS, or the increased risk of experiencing G3/4 AEs.","['Subgroup analyses according to age (<70 versus 70-75 years) and gender', 'metastatic colorectal cancer patients', 'metastatic colorectal cancer', 'elderly patients and females', 'patients between 70 and 75 years old treated with', 'males and females aged between 18 and 70 with ECOG PS\u2009≤\u20092 and between 71 and 75 with ECOG PS\u2009=\u20090 were eligible', 'Of 1187 patients, 1005 (85%) were aged <70 years and 182 (15%) 70-75 years; 693 (58%) were males and 494 (42%) females']","['chemotherapy plus bevacizumab', 'bevacizumab', 'FOLFOXIRI/bevacizumab', 'bevacizumab or a doublet (FOLFIRI or FOLFOX)/bevacizumab']","['overall response rate (ORR), progression-free survival (PFS) and AE rates', 'vomiting', 'grade nausea', 'ORR and PFS', 'rates of overall G3/4 AEs', 'diarrhea and febrile neutropenia']","[{'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0346973', 'cui_str': 'Secondary malignant neoplasm of large intestine'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0430797', 'cui_str': 'Intracranial EEG'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0042963', 'cui_str': 'Emesis'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0027497', 'cui_str': 'Nausea'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0746883', 'cui_str': 'Febrile Neutropenia'}]",1187.0,,"There was no evidence of interaction between age or gender and the benefit provided by the intensification of the upfront chemotherapy in terms of ORR and PFS, or the increased risk of experiencing G3/4 AEs.","[{'ForeName': 'F', 'Initials': 'F', 'LastName': 'Marmorino', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Rossini', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Lonardi', 'Affiliation': 'Department of Clinical and Experimental Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padova.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Moretto', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Zucchelli', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Aprile', 'Affiliation': 'Department of Oncology, General and University Hospital, Udine; Department of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': ""Dell'Aquila"", 'Affiliation': 'Department of Medical Oncology, Campus Biomedico University, Roma.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ratti', 'Affiliation': 'Oncology Department, Oncology Unit, ASST of Cremona, Cremona.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Bergamo', 'Affiliation': 'Department of Clinical and Experimental Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology - IRCCS, Padova.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Masi', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Urbano', 'Affiliation': 'Department of Radiological Science, Oncology and Pathology, Policlinico Umberto I, ""Sapienza"" University of Rome, Roma.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Ronzoni', 'Affiliation': 'Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milano.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Libertini', 'Affiliation': 'Medical Oncology Unit, Poliambulanza Foundation, Brescia.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Borelli', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Randon', 'Affiliation': 'Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Buonadonna', 'Affiliation': 'Department of Medical Oncology, IRCCS CRO National Cancer Institute, Aviano.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Allegrini', 'Affiliation': 'Department of Medical Oncology, Unit of Medical Oncology, Livorno Hospital, Azienda Toscana Nord Ovest, Livorno.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Pella', 'Affiliation': 'Department of Oncology, General and University Hospital, Udine.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Ricci', 'Affiliation': 'Department of Oncology, S. Croce and Carle Teaching Hospital, Cuneo.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Boccaccino', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'T P', 'Initials': 'TP', 'LastName': 'Latiano', 'Affiliation': 'Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cordio', 'Affiliation': 'Medical Oncology Unit, ARNAS Garibaldi Catania, Catania.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Passardi', 'Affiliation': 'Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Tamburini', 'Affiliation': 'Department of Medical Oncology, Card. G. Panico Hospital of Tricase, Tricase.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Boni', 'Affiliation': 'Clinical Trials Coordinating Center, Toscano Cancer Institute, University Hospital Careggi, Firenze, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Falcone', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Cremolini', 'Affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa. Electronic address: chiaracremolini@gmail.com.'}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz403'] 3020,32075993,Patient Semi-specific Computational Modeling of Electromagnetic Stimulation Applied to Neuroprotective Treatments in Acute Ischemic Stroke.,"Neuroprotective effects of pulsed electromagnetic fields (PEMFs) have been demonstrated both in vivo and in vitro. Moreover, preliminary clinical studies have been conducted and suggested PEMFs as a possible alternative therapy to treat acute ischemic stroke. In this work, we show that it's possible to build-up a patient semi-specific head model, where the 3D reconstruction of the ischemic lesion of the patient under treatment is inserted in the head of the human body model ""Duke"" (v.1.0, Zurich MedTech AG). The semi-specific model will be used in the randomized, placebo-controlled, double-blind study currently ongoing. Three patients were modelled and simulated, and results showed that each ischemic lesion experiences a magnetic flux density field comparable to the one for which biological effects have been attested. Such a kind of dosimetric analysis reveals a reliable tool to assess the correlation between levels of exposure and the beneficial effect. Thus, once the on-going double blind study is complete it will prove if PEMFs treatment triggers a clinical effect, and we will then be able to characterize a dose-response curve with the methodology arranged in this study.",2020,"Three patients were modelled and simulated, and results showed that each ischemic lesion experiences a magnetic flux density field comparable to the one for which biological effects have been attested.",['Acute Ischemic Stroke'],"['placebo', 'pulsed electromagnetic fields (PEMFs', 'Electromagnetic Stimulation']",[],"[{'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0013835', 'cui_str': 'Electromagnetic Fields'}, {'cui': 'C0013838', 'cui_str': 'Electromagnetics'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]",[],3.0,0.140432,"Three patients were modelled and simulated, and results showed that each ischemic lesion experiences a magnetic flux density field comparable to the one for which biological effects have been attested.","[{'ForeName': 'Micol', 'Initials': 'M', 'LastName': 'Colella', 'Affiliation': 'Department of Information Engineering, Electronics and Telecommunications (DIET), University of Rome ""La Sapienza"", Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Camera', 'Affiliation': 'Department of Information Engineering, Electronics and Telecommunications (DIET), University of Rome ""La Sapienza"", Rome, Italy.'}, {'ForeName': 'Fioravante', 'Initials': 'F', 'LastName': 'Capone', 'Affiliation': 'Unit of Neurology, Neurophysiology, Neurobiology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Setti', 'Affiliation': 'IGEA Biophysics Laboratory, Carpi, Italy.'}, {'ForeName': 'Ruggero', 'Initials': 'R', 'LastName': 'Cadossi', 'Affiliation': 'IGEA Biophysics Laboratory, Carpi, Italy.'}, {'ForeName': 'Vincenzo', 'Initials': 'V', 'LastName': 'Di Lazzaro', 'Affiliation': 'Unit of Neurology, Neurophysiology, Neurobiology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, Italy.'}, {'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Apollonio', 'Affiliation': 'Department of Information Engineering, Electronics and Telecommunications (DIET), University of Rome ""La Sapienza"", Rome, Italy.'}, {'ForeName': 'Micaela', 'Initials': 'M', 'LastName': 'Liberti', 'Affiliation': 'Department of Information Engineering, Electronics and Telecommunications (DIET), University of Rome ""La Sapienza"", Rome, Italy. micaela.liberti@uniroma1.it.'}]",Scientific reports,['10.1038/s41598-020-59471-9'] 3021,32197915,Post-antibiotic Ocular Surface Microbiome in Children: A Cluster-Randomized Trial.,,2020,,['Children'],[],[],"[{'cui': 'C0008059', 'cui_str': 'Child'}]",[],[],,0.0653268,,"[{'ForeName': 'Thuy', 'Initials': 'T', 'LastName': 'Doan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California. Electronic address: Thuy.Doan@ucsf.edu.'}, {'ForeName': 'Armin', 'Initials': 'A', 'LastName': 'Hinterwirth', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'Worden', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'Arzika', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Ramatou', 'Initials': 'R', 'LastName': 'Maliki', 'Affiliation': 'The Carter Center, Niamey, Niger.'}, {'ForeName': 'Cindi', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zhong', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Zhaoxia', 'Initials': 'Z', 'LastName': 'Zhou', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Nisha R', 'Initials': 'NR', 'LastName': 'Acharya', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Travis C', 'Initials': 'TC', 'LastName': 'Porco', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Keenan', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Lietman', 'Affiliation': 'Francis I Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California; Institute for Global Health Sciences, University of California San Francisco, San Francisco, California.'}]",Ophthalmology,['10.1016/j.ophtha.2020.02.014'] 3022,32112536,Commentary on: Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis: A randomized controlled trial.,,2020,,['patients with cirrhosis'],['transfusion protocols prior to central venous catheterization'],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}]","[{'cui': 'C0199960', 'cui_str': 'Transfusion - action (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0007435', 'cui_str': 'Central Catheterization'}]",[],,0.0684651,,"[{'ForeName': 'Nicolas M', 'Initials': 'NM', 'LastName': 'Intagliata', 'Affiliation': 'Division of Gastroenterology and Hepatology, University of Virginia Medical Center, Charlottesville, VA.'}, {'ForeName': 'Erica', 'Initials': 'E', 'LastName': 'Villa', 'Affiliation': 'Division of Gastroenterology, Department of Medical Specialties, University of Modena and Reggio Emilia, Modena, Italy.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14712'] 3023,32070184,Developing Capabilities From the Scope of Emotional Intelligence as Part of the Soft Skills Needed in the Long-Term Care Sector: Presentation of Pilot Study and Training Methodology.,"The article presents the results of the preliminary survey and pilot application of the methodological toolkit for the improvement of certain competencies, which are part of the soft skills of professionals in the long-term care sector in Bulgaria. Based on the survey the authors define 2 target competencies, namely conflict management and empathic interaction. These skills are considered a part of the scope of emotional intelligence and its constituent dimensions and authors use Daniel Goleman's ability-based model as a base for their conceptual frame and theoretical explanations. In order to present their thesis, the authors perform a soft skill analysis of the long-term care sector; define the construct emotional intelligence and justify their choice of a theoretical model for the subsequent survey. On this basis, they develop a training design for the development of these skills and present the results achieved through its pilot application. The study includes 62 participants randomly divided into a test and control groups. The level of targeted skills is measured (before and after) and the authors report a significant increase in those skills (empathic interaction, net effect 1.87; conflict management, net effect 1.75). In conclusion, the authors open a discussion on the importance of emotional management as an essential part of any profession related to health care and underline its importance for the quality of caregiving services.",2020,"The article presents the results of the preliminary survey and pilot application of the methodological toolkit for the improvement of certain competencies, which are part of the soft skills of professionals in the long-term care sector in Bulgaria.",['62 participants randomly divided into a test and control groups'],[],"['level of targeted skills', 'Emotional Intelligence']","[{'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1510539', 'cui_str': 'Emotional Intelligences'}]",62.0,0.0164275,"The article presents the results of the preliminary survey and pilot application of the methodological toolkit for the improvement of certain competencies, which are part of the soft skills of professionals in the long-term care sector in Bulgaria.","[{'ForeName': 'Yasen', 'Initials': 'Y', 'LastName': 'Dimitrov', 'Affiliation': 'VUZF Lab Research Centre Part of VUZF, Sofia, Bulgaria.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Vazova', 'Affiliation': 'Plovdiv University Paisii Hilendarski, Plovdiv, Bulgaria.'}]",Journal of primary care & community health,['10.1177/2150132720906275'] 3024,31404033,"A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION.","PURPOSE The LIGHTSITE I study investigated the efficacy and safety of photobiomodulation (PBM) treatment in subjects with dry age-related macular degeneration. METHODS Thirty subjects (46 eyes) were treated with the Valeda Light Delivery System, wherein subjects underwent two series of treatments (3× per week for 3-4 weeks) over 1 year. Outcome measures included best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments. RESULTS Photobiomodulation-treated subjects showed a best-corrected visual acuity mean letter score gain of 4 letters immediately after each treatment series at Month 1 (M1) and Month 7 (M7). Approximately 50% of PBM-treated subjects showed improvement of ≥5 letters versus 13.6% in sham-treated subjects at M1. High responding subjects (≥5-letter improvement) in the PBM-treated group showed a gain of 8 letters after initial treatment (P < 0.01) and exhibited earlier stages of age-related macular degeneration disease. Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05). No device-related adverse events were reported. CONCLUSION Photobiomodulation treatment statistically improved clinical and anatomical outcomes with more robust benefits observed in subjects with earlier stages of dry age-related macular degeneration. Repeated PBM treatments are necessary to maintain benefits. These pilot findings support previous reports and suggest the utility of PBM as a safe and effective therapy in subjects with dry age-related macular degeneration.",2020,"Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05).","['subjects with earlier stages of dry age-related macular degeneration', 'Thirty subjects (46 eyes', 'subjects with dry age-related macular degeneration']","['PBM', 'Valeda Light Delivery System', 'photobiomodulation (PBM']","['best-corrected visual acuity mean letter score gain', 'contrast sensitivity, central drusen volume, central drusen thickness, and quality of life', 'best-corrected visual acuity, contrast sensitivity, microperimetry, central drusen volume and drusen thickness, and quality of life assessments', 'improvement of ≥5 letters']","[{'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C3888461', 'cui_str': 'Dry age-related macular degeneration'}, {'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0071006', 'cui_str': 'phytobacteriomycin'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0449914', 'cui_str': 'Delivery system (attribute)'}]","[{'cui': 'C1690532', 'cui_str': 'Best corrected visual acuity'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0009928', 'cui_str': 'Visual Contrast Sensitivity'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C1260959', 'cui_str': 'Drusen'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]",30.0,0.0355068,"Statistically significant improvements in contrast sensitivity, central drusen volume, central drusen thickness, and quality of life were observed (P < 0.05).","[{'ForeName': 'Samuel N', 'Initials': 'SN', 'LastName': 'Markowitz', 'Affiliation': 'Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Robert G', 'Initials': 'RG', 'LastName': 'Devenyi', 'Affiliation': 'Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Marion R', 'Initials': 'MR', 'LastName': 'Munk', 'Affiliation': 'Department of Ophthalmology, Inselspital University Hospital Bern, Bern, Switzerland.'}, {'ForeName': 'Cindy L', 'Initials': 'CL', 'LastName': 'Croissant', 'Affiliation': 'LumiThera Inc, Poulsbo, Washington.'}, {'ForeName': 'Stephanie E', 'Initials': 'SE', 'LastName': 'Tedford', 'Affiliation': 'LumiThera Inc, Poulsbo, Washington.'}, {'ForeName': 'Rene', 'Initials': 'R', 'LastName': 'Rückert', 'Affiliation': 'Eyegnos Consulting, Bern, Switzerland.'}, {'ForeName': 'Michael G', 'Initials': 'MG', 'LastName': 'Walker', 'Affiliation': 'Walker Bioscience, Carlsbad, California.'}, {'ForeName': 'Beatriz E', 'Initials': 'BE', 'LastName': 'Patino', 'Affiliation': 'Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Nido', 'Affiliation': 'Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada.'}, {'ForeName': 'Clark E', 'Initials': 'CE', 'LastName': 'Tedford', 'Affiliation': 'LumiThera Inc, Poulsbo, Washington.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002632'] 3025,30635367,"Pictorial health warning labels on the waterpipe device are effective in reducing smoking satisfaction, puffing behaviour and exposure to CO: first evidence from a crossover clinical laboratory study.","OBJECTIVES This study examined the effect of pictorial health warning labels (HWLs) on the waterpipe (WP) device on smokers' experience, puffing behaviour, harm perception and exposure to respiratory toxicants. METHODS Thirty WP smokers completed two 45 min ad libitum smoking sessions (WP without HWL vs WP with HWL) in a crossover design study. Exhaled carbon monoxide (eCO) was measured before and after each smoking session. Puff topography was recorded throughout the smoking session, and participants completed survey questionnaires assessing subjective smoking experiences and harm perception. RESULTS Significant differences were observed in eCO levels between the two study conditions, with lower levels of eCO boost recorded following smoking the WP fitted with HWL (16 ppm) compared with WP without HWL (22.7 ppm). Participants had more puffs, shorter interpuff intervals and a higher total puff volume during smoking the WP without HWL relative to WP with HWL (p values <0.05). We documented enhanced reports of satisfaction, taste and puff liking following smoking the WP without HWL compared with the WP with HWL. WP harm perception was significantly higher among participants after smoking the WP with HWL compared with WP without HWL. CONCLUSION This pilot study shows that placing HWL on the WP device is effective in reducing WP smoker's positive experiences, puffing parameters and exposure to carbon monoxide. HWLs lead also to more appreciation of WP harmful effects, making them a promising regulatory approach for addressing the spread of WP smoking among young adults in the USA.",2019,"Participants had more puffs, shorter interpuff intervals and a higher total puff volume during smoking the WP without HWL relative to WP with HWL (p values <0.05).",['Thirty WP smokers'],"['libitum smoking sessions (WP without HWL vs WP with HWL', 'pictorial health warning labels (HWLs']","['satisfaction, taste and puff liking', 'total puff volume', 'eCO levels', 'smoking satisfaction', 'Puff topography', 'Exhaled carbon monoxide (eCO', 'WP harm perception']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0018684', 'cui_str': 'Health'}]","[{'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0039336', 'cui_str': 'Gustation'}, {'cui': 'C1533107', 'cui_str': 'Puffs'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0030971', 'cui_str': 'Perception'}]",,0.0197333,"Participants had more puffs, shorter interpuff intervals and a higher total puff volume during smoking the WP without HWL relative to WP with HWL (p values <0.05).","[{'ForeName': 'Wasim', 'Initials': 'W', 'LastName': 'Maziak', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Ziyad', 'Initials': 'Z', 'LastName': 'Ben Taleb', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Ebrahimi Kalan', 'Affiliation': 'Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Eissenberg', 'Affiliation': 'Department of Psychology, Center for the Study of Tobacco Products, Virginia Commonwealth University, Miami, Florida, USA.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Thrasher', 'Affiliation': 'Health Promotion, Education, and Behavior, Arnold School of Public Health, Columbia, South Carolina, USA.'}, {'ForeName': 'Alan', 'Initials': 'A', 'LastName': 'Shihadeh', 'Affiliation': 'College of Engeenering, American University of Beirut, Beirut, Lebanon.'}, {'ForeName': 'Taghrid', 'Initials': 'T', 'LastName': 'Asfar', 'Affiliation': 'Syrian Center for Tobacco Studies, Aleppo, Syrian Arab Republic.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054682'] 3026,31980993,The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.,"Women are disproportionately at risk of acquiring HIV in East and Southern Africa, despite global declines in incidence. Female-initiated HIV prevention methods, like the dapivirine vaginal ring, are needed to end the HIV epidemic. In-depth interviews and focus groups retrospectively explored peer influence on acceptability of and adherence to the ring during the ASPIRE trial, a phase III placebo-controlled trial. Results were analyzed using an inductive analytic approach. Study participants (peers) of all ages and adherence groups developed important interpersonal connections and reported being more open and honest with each other than with external peers or study staff. Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study. External peers provided primarily negative input about the ring and study, which sometimes led to ring removals. Peers' influence on each other's behavior in both prosocial and detrimental manners could have repercussions on adherence to a biomedical intervention, and consequently, individual disease risk and clinical trial outcomes. Future ring demonstration and implementation studies could use peer networks to intentionally influence uptake and adherence to the ring.",2020,Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study.,['Study participants (peers) of all ages and adherence groups developed important interpersonal connections and reported being more open and honest with each other than with external peers or study staff'],[],[],"[{'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0449379', 'cui_str': 'Connection (attribute)'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}]",[],[],,0.0378847,Study peers who knew each other prior to joining appeared to have a stronger influence on each other's adherence than peers who met in the study.,"[{'ForeName': 'Ariana W K', 'Initials': 'AWK', 'LastName': 'Katz', 'Affiliation': ""Women's Global Health Imperative, RTI International, 351 California St, Suite 500, San Francisco, CA, 94104, USA. awkatz@rti.org.""}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Naidoo', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Reddy', 'Affiliation': 'Wits Reproductive Health and HIV Institute (Wits RHI), Johannesburg, South Africa.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Chitukuta', 'Affiliation': 'University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Harare, Zimbabwe.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Nabukeera', 'Affiliation': 'Makerere University-Johns Hopkins University Research Unit, Kampala, Uganda.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Siva', 'Affiliation': 'HIV Prevention Research Unit, South African Medical Research Council, Durban, South Africa.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Zimba', 'Affiliation': 'University of North Carolina (UNC) Project-Lilongwe, Tidziwe Center, P/Bag A104, Lilongwe, Malawi.'}, {'ForeName': 'E T', 'Initials': 'ET', 'LastName': 'Montgomery', 'Affiliation': ""Women's Global Health Imperative, RTI International, 351 California St, Suite 500, San Francisco, CA, 94104, USA.""}]",AIDS and behavior,['10.1007/s10461-020-02799-0'] 3027,30526233,The effect of dose expectancies on caffeine withdrawal symptoms during tapered dose reduction.,"BACKGROUND Negative expectancies can exacerbate withdrawal symptoms via the nocebo effect. As such, information provided about dose reductions during attempts to taper a drug could contribute to withdrawal symptoms and increase the likelihood of relapse. The current study tested whether blinding participants to dose reductions during a supervised caffeine dose taper reduced these nocebo-induced withdrawal symptoms. METHODS Three groups of moderate to heavy coffee drinkers had their dose of caffeine reduced (tapered) from 300 mg per day to 0 mg over the course of five days and reported withdrawal symptoms twice daily. Groups were given differing information about how much caffeine they were receiving. An Open Reduction group was given accurate information about dose reductions. A Blind Reduction group was given no dose information whatsoever. A Deceptive Reduction group was misinformed about dose, with instructions suggesting that the dose remained on 300 mg for three days then dropped to 0 mg. RESULTS The Open Reduction group reported more pronounced caffeine withdrawal symptoms than the Deceptive Reduction group on the days with the greatest discrepancy between actual dose and informed dose, indicating a nocebo effect of open versus deceptive reductions. In addition, the rate of increase in reported withdrawal symptoms in the Blind Reduction and Deceptive Reduction groups was less than that of the Open Reduction group. CONCLUSION These results suggest that awareness of dose reductions during a dose taper can result in a nocebo withdrawal effect, and that removing this awareness can reduce withdrawal. This has important implications for standard supervised dose-tapering practice, where patients are aware of the timing and magnitude of dose reductions.",2019,"The Open Reduction group reported more pronounced caffeine withdrawal symptoms than the Deceptive Reduction group on the days with the greatest discrepancy between actual dose and informed dose, indicating a nocebo effect of open versus deceptive reductions.",[],['caffeine'],"['caffeine withdrawal symptoms', 'withdrawal symptoms']",[],"[{'cui': 'C0006644', 'cui_str': 'Caffeine'}]","[{'cui': 'C0521652', 'cui_str': 'Caffeine withdrawal (disorder)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0087169', 'cui_str': 'Withdrawal Symptoms'}]",,0.0241876,"The Open Reduction group reported more pronounced caffeine withdrawal symptoms than the Deceptive Reduction group on the days with the greatest discrepancy between actual dose and informed dose, indicating a nocebo effect of open versus deceptive reductions.","[{'ForeName': 'Llewellyn', 'Initials': 'L', 'LastName': 'Mills', 'Affiliation': '1 School of Psychology, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Boakes', 'Affiliation': '1 School of Psychology, University of Sydney, Sydney, NSW, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Colagiuri', 'Affiliation': '1 School of Psychology, University of Sydney, Sydney, NSW, Australia.'}]","Journal of psychopharmacology (Oxford, England)",['10.1177/0269881118817158'] 3028,32122797,The Effect of Using PARO for People Living With Dementia and Chronic Pain: A Pilot Randomized Controlled Trial.,"OBJECTIVES To evaluate the effect of interaction with a robotic seal (PARO) on pain and behavioral and psychological symptoms of people with dementia and chronic pain. DESIGN A parallel pilot randomized controlled trial conducted between January 2018 and January 2019. SETTING Three long-term care facilities in Australia. PARTICIPANTS Forty-three participants aged ≥65 years living with dementia and chronic pain. INTERVENTION Participants were randomized to the PARO group (individual, nonfacilitated, 30-minute sessions, 5 days per week for 6 weeks) or a usual care group using a computer-generated random number. MEASUREMENTS The primary outcome was researcher-rated observational pain behaviors before and after each session. Secondary outcomes were staff-rated pain level, agitation, depression, and anxiety measured at baseline and the end of week 6. Medications regularly prescribed and as needed were recorded weekly. Analyses followed intention-to-treat, using the generalized estimating equation model. Australian New Zealand Clinical Trials Registry (ACTRN12618000082202). RESULTS Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175, 95% CI -2.205 to -0.145, P = .025) than those in usual care after controlling for age, sex, cognitive function and medications. There were no significant differences in staff-rated pain, agitation, anxiety, and depression, nor regularly scheduled medications between intervention and control group. CONCLUSIONS AND IMPLICATIONS PARO shows promise in reducing pain and medications for individuals with dementia and chronic pain in long-term care facilities. This intervention might be incorporated into daily practice as an alternative to manage pain in people with dementia. Larger randomized controlled trials with longer time frames are needed to identify further and test the use of PARO in long-term care settings.",2020,"Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175","['January 2018 and January\xa02019', 'Forty-three participants aged ≥65\xa0years living with dementia and chronic pain', 'Three long-term care facilities in Australia', 'individuals with dementia and chronic pain in long-term care facilities', 'people with dementia and chronic pain', 'people with dementia', 'People Living With Dementia and Chronic Pain']","['robotic seal (PARO', 'usual care group using a computer-generated random number', 'PARO']","['researcher-rated observational pain behaviors', 'staff-rated pain level, agitation, depression, and anxiety', 'pain and medications', 'level of observed pain', 'pain and behavioral and psychological symptoms', 'staff-rated pain, agitation, anxiety, and depression, nor regularly scheduled medications']","[{'cui': 'C0450368', 'cui_str': '43 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0497327', 'cui_str': 'Amentia'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0035785', 'cui_str': 'Robotics'}, {'cui': 'C0036492', 'cui_str': 'Seal (organism)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}]","[{'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0085631', 'cui_str': 'Feeling agitated (finding)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0233397', 'cui_str': 'Psychological symptom'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]",43.0,0.236466,"Participants in the PARO group had a significantly lowered level of observed pain [-0.514, 95% confidence interval (CI) -0.774 to -0.254, P < .001] and used fewer pro re nata medications (-1.175","[{'ForeName': 'Lihui', 'Initials': 'L', 'LastName': 'Pu', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia. Electronic address: lihui.pu@griffithuni.edu.au.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Moyle', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Jones', 'Affiliation': 'Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia; Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Todorovic', 'Affiliation': 'School of Nursing and Midwifery, Nathan Campus, Griffith University, Brisbane, Queensland, Australia; Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2020.01.014'] 3029,31583708,Smartphone-based exposure treatment for dental phobia: a pilot randomized clinical trial.,"OBJECTIVES High levels of dental care-related fear/anxiety, as well as phobia, result in delay or avoidance of dental care, which are associated with poorer oral and overall health. Both pharmacotherapeutic and psychosocial methods are available to treat those with high levels of dental fear/anxiety or phobia, but they are infrequently used and not easily accessed. Smartphones are a potential vehicle for delivering exposure therapy (e.g., a treatment involving systematic encounter with fear-evoking stimuli), but there is a need to test the acceptability of this approach in regard to treatment of high levels of dental anxiety/fear and phobia. METHODS There were 36 patients with high dental anxiety/fear/phobia randomly assigned to either a treatment or a waitlist condition. Participants completed a pre- and two-week post-multimodal assessment, including a dental behavioral avoidance task. The treatment condition included 2 weeks of self-directed exposure delivered via a personal smartphone in the patients' natural environment. RESULTS Participants in the treatment condition utilized the smartphone exposure an average of 1.6 times daily (SD = 0.85), and found the self-directed exposure highly acceptable. Moreover, they had lower self-reported anxiety and decreased cardiac reactivity at the postassessment compared with the preassessment; no change in anxiety was found for the control condition from pre- to postassessment. CONCLUSIONS Highly anxious, fearful, and dental phobic participants utilized smartphone-delivered exposure therapy, and found it to be an acceptable treatment method. Results support the utility and promise for further testing of the personal smartphone in delivering self-directed exposure therapy for high dental fear/anxiety and phobia.",2020,There were 36 patients with high dental anxiety/fear/phobia randomly assigned to either a treatment or a waitlist condition.,"['dental phobia', '36 patients with high dental anxiety/fear/phobia']","['Smartphone-based exposure treatment', 'self-directed exposure delivered via a personal smartphone']","['anxiety', 'cardiac reactivity']","[{'cui': 'C0085380', 'cui_str': 'Fear, Dental'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0349231', 'cui_str': 'Phobias'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}]",36.0,0.0201543,There were 36 patients with high dental anxiety/fear/phobia randomly assigned to either a treatment or a waitlist condition.,"[{'ForeName': 'Matthew C', 'Initials': 'MC', 'LastName': 'Arias', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, USA.'}, {'ForeName': 'Daniel W', 'Initials': 'DW', 'LastName': 'McNeil', 'Affiliation': 'Department of Psychology, West Virginia University, Morgantown, WV, USA.'}]",Journal of public health dentistry,['10.1111/jphd.12340'] 3030,31653603,Lessons from the Established Status Epilepticus Treatment Trial.,"Convulsive status epilepticus (SE) is a relatively common emergency condition affecting individuals of all ages. The primary goal of treatment is prompt termination of seizures. Where first-line treatment with benzodiazepine has failed to achieve this, a condition known as established SE (ESE), there is uncertainty about which agent to use next. The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above with established convulsive SE. Enrollment was completed in January 2019, and the results are expected later this year. We discuss lessons learnt during the conduct of the study in relation to the following: ethical considerations; trial design and practical implementation in emergency settings, including pediatric and adult populations; quality assurance; and outcome determination where treating emergency clinicians may lack specialist expertise. We consider that the ESETT is already informing both clinical practice and future trial design. This article is part of the Special Issue ""Proceedings of the 7th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures"".",2019,"The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above with established convulsive SE.",['patients aged 2\u202fyears and above with established convulsive SE'],"['benzodiazepine', 'valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0443211', 'cui_str': 'Established (qualifier value)'}]","[{'cui': 'C0005064', 'cui_str': 'Benzodiazepine Compounds'}, {'cui': 'C0080356', 'cui_str': 'Valproate'}, {'cui': 'C0244656', 'cui_str': 'fosphenytoin'}, {'cui': 'C0377265', 'cui_str': 'Levetiracetam'}]",[],,0.0900024,"The Established Status Epilepticus Treatment Trial (ESETT) is a 3-arm (valproate (VPA), fosphenytoin (FOS), levetiracetam (LEV)), phase III, double-blind randomized comparative effectiveness study in patients aged 2 years and above with established convulsive SE.","[{'ForeName': 'Hannah R', 'Initials': 'HR', 'LastName': 'Cock', 'Affiliation': ""St George's University of London and Atkinson Morley Regional Epilepsy Network, St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: hannahrc@sgul.ac.uk.""}, {'ForeName': 'Lisa D', 'Initials': 'LD', 'LastName': 'Coles', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Jordan', 'Initials': 'J', 'LastName': 'Elm', 'Affiliation': 'Department of Public Health Science, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Silbergleit', 'Affiliation': 'Department of Emergency Medicine, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Chamberlain', 'Affiliation': ""Division of Emergency Medicine, Children's National Health System and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University Washington, DC, USA.""}, {'ForeName': 'James C', 'Initials': 'JC', 'LastName': 'Cloyd', 'Affiliation': 'Department of Experimental and Clinical Pharmacology, College of Pharmacy and Center for Orphan Drug Research, University of Minnesota, Minneapolis, MN, USA.'}, {'ForeName': 'Nathan', 'Initials': 'N', 'LastName': 'Fountain', 'Affiliation': 'Department of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Shlomo', 'Initials': 'S', 'LastName': 'Shinnar', 'Affiliation': 'Departments of Neurology, Pediatrics and Epidemiology and Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Lowenstein', 'Affiliation': 'Department of Neurology, University of California, San Francisco, CA, USA.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Conwit', 'Affiliation': 'National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Bleck', 'Affiliation': 'Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Jaideep', 'Initials': 'J', 'LastName': 'Kapur', 'Affiliation': 'Department of Neurology (Fountain, Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA; Department of Neuroscience (Kapur), Brain Institute, University of Virginia, Charlottesville, VA, USA.'}]",Epilepsy & behavior : E&B,['10.1016/j.yebeh.2019.04.049'] 3031,31715580,Self-Efficacy for Physical Activity-A Question of Item Framing and Age?,"Older adults process and remember positive information relatively better than negative information, compared with younger adults; this is known as the positivity effect. This study examined whether older adults compared with younger adults also respond differently to positively and negatively framed questionnaire items. Participants (N = 275; age = 18-81 years) were randomly assigned to a positively or negatively framed version of a self-efficacy for physical activity questionnaire. Self-efficacy, physical activity intentions, and planned physical activity in the following week were regressed on experimental group and age, controlling for baseline physical activity and covariates. A significant Age × Frame interaction showed that item framing made a difference in planned physical activity for the oldest age group (+350 min compared with the youngest group). This study provides initial support for the positivity effect in item framing on physical activity plans, but not on intentions or self-efficacy. Item framing should be taken into consideration for accurate measurement, but could also be a simple intervention approach.",2020,"This study provides initial support for the positivity effect in item framing on physical activity plans, but not on intentions or self-efficacy.","['Older adults', 'Participants (N = 275; age = 18-81 years', 'older adults compared with younger adults']",[],"['Self-efficacy, physical activity intentions, and planned physical activity', 'planned physical activity']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C4517676', 'cui_str': '275'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]",[],"[{'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1301732', 'cui_str': 'Planned'}]",,0.0225915,"This study provides initial support for the positivity effect in item framing on physical activity plans, but not on intentions or self-efficacy.","[{'ForeName': 'Johanna', 'Initials': 'J', 'LastName': 'Popp', 'Affiliation': ''}, {'ForeName': 'Nanna', 'Initials': 'N', 'LastName': 'Notthoff', 'Affiliation': ''}, {'ForeName': 'Lisa Marie', 'Initials': 'LM', 'LastName': 'Warner', 'Affiliation': ''}]",Journal of aging and physical activity,['10.1123/japa.2019-0059'] 3032,31917621,"Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial.","Rationale: Acute exacerbation during the course of idiopathic pulmonary fibrosis causes a poor prognosis. Coagulation abnormalities and endothelial damage are involved in its pathogenesis. Thrombomodulin alfa, a recombinant human soluble thrombomodulin, has anticoagulant and antiinflammatory effects. Several clinical studies have shown that thrombomodulin alfa may improve survival of acute exacerbation. Objectives: To determine the efficacy and safety of thrombomodulin alfa compared with placebo in acute exacerbation of idiopathic pulmonary fibrosis. Methods: This randomized, double-blind placebo-controlled phase 3 study conducted at 27 sites in Japan involved patients with an acute exacerbation of idiopathic pulmonary fibrosis. Subjects were randomized 1:1 to receive placebo or thrombomodulin alfa (380 U/kg/d for 14 d by intravenous drip infusion). All subjects were treated with high-dose corticosteroid therapy. The primary endpoint was the survival proportion on Day 90. Measurements and Main Results: Of the 82 randomized subjects, 77 completed the study and were included in the full analysis set (thrombomodulin alfa, n  = 40; placebo, n  = 37). The survival proportions on Day 90 were 72.5% (29 of 40) in the thrombomodulin alfa group and 89.2% (33 of 37) in the placebo group, a difference of -16.7 percentage points (95% confidence interval, -33.8 to 0.4%; P  = 0.0863). In the safety population ( n  = 80), bleeding adverse events occurred in the thrombomodulin alfa group (10 of 42; 23.8%) and the placebo group (4 of 38; 10.5%). Conclusions: Thrombomodulin alfa did not improve the 90-day survival proportion. The present results suggest that the use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis not be recommended.Clinical trial registered with www.clinicaltrials.gov (NCT02739165).",2020,"The survival proportion on Day 90 was 72.5% (29/40) in the thrombomodulin alfa group and 89.2% (33/37) in the placebo group, a difference of -16.7 percentage points (95% CI, -33.8% to 0.4%, p=0.0863).","['Acute Exacerbation of Idiopathic Pulmonary Fibrosis', 'acute exacerbation of idiopathic pulmonary fibrosis', '27 sites in Japan involved patients with an acute exacerbation of idiopathic pulmonary fibrosis']","['Placebo', 'Thrombomodulin alfa', 'corticosteroid therapy', 'placebo', 'Thrombomodulin alfa, a recombinant human soluble thrombomodulin', 'thrombomodulin alfa', 'placebo or thrombomodulin alfa']","['survival proportion', '90-day survival proportion', 'survival proportion on Day 90', 'bleeding adverse events']","[{'cui': 'C2242482', 'cui_str': 'Exacerbation of idiopathic pulmonary fibrosis'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0145779', 'cui_str': 'Thrombomodulin'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",77.0,0.706193,"The survival proportion on Day 90 was 72.5% (29/40) in the thrombomodulin alfa group and 89.2% (33/37) in the placebo group, a difference of -16.7 percentage points (95% CI, -33.8% to 0.4%, p=0.0863).","[{'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Kondoh', 'Affiliation': 'Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.'}, {'ForeName': 'Arata', 'Initials': 'A', 'LastName': 'Azuma', 'Affiliation': 'Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.'}, {'ForeName': 'Yoshikazu', 'Initials': 'Y', 'LastName': 'Inoue', 'Affiliation': 'Clincal Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Ogura', 'Affiliation': 'Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.'}, {'ForeName': 'Susumu', 'Initials': 'S', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.'}, {'ForeName': 'Kenji', 'Initials': 'K', 'LastName': 'Tsushima', 'Affiliation': 'Department of Pulmonary Medicine, School of Medicine, International University of Health and Welfare, Chiba, Japan.'}, {'ForeName': 'Takeshi', 'Initials': 'T', 'LastName': 'Johkoh', 'Affiliation': 'Department of Radiology, Kansai Rosai Hospital, Hyogo, Japan.'}, {'ForeName': 'Kiminori', 'Initials': 'K', 'LastName': 'Fujimoto', 'Affiliation': 'Department of Radiology and.'}, {'ForeName': 'Kazuya', 'Initials': 'K', 'LastName': 'Ichikado', 'Affiliation': 'Division of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.'}, {'ForeName': 'Yasuo', 'Initials': 'Y', 'LastName': 'Matsuzawa', 'Affiliation': 'Department of Respiratory Medicine, Toho University Medical Center-Sakura Hospital, Chiba, Japan.'}, {'ForeName': 'Takefumi', 'Initials': 'T', 'LastName': 'Saito', 'Affiliation': 'Department of Respiratory Medicine, National Hospital Organization, Ibarakihigashi National Hospital, Ibaraki, Japan.'}, {'ForeName': 'Kazuma', 'Initials': 'K', 'LastName': 'Kishi', 'Affiliation': 'Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan.'}, {'ForeName': 'Keisuke', 'Initials': 'K', 'LastName': 'Tomii', 'Affiliation': 'Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan.'}, {'ForeName': 'Noriho', 'Initials': 'N', 'LastName': 'Sakamoto', 'Affiliation': 'Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.'}, {'ForeName': 'Masahiro', 'Initials': 'M', 'LastName': 'Aoshima', 'Affiliation': 'Department of Pulmonology, Kameda Medical Center, Chiba, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Araya', 'Affiliation': 'Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Shinyu', 'Initials': 'S', 'LastName': 'Izumi', 'Affiliation': 'Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.'}, {'ForeName': 'Machiko', 'Initials': 'M', 'LastName': 'Arita', 'Affiliation': 'Department of Respiratory Medicine, Kurashiki Central Hospital, Okayama, Japan.'}, {'ForeName': 'Mitsuhiro', 'Initials': 'M', 'LastName': 'Abe', 'Affiliation': 'Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan.'}, {'ForeName': 'Hiroyoshi', 'Initials': 'H', 'LastName': 'Yamauchi', 'Affiliation': 'Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.'}, {'ForeName': 'Joe', 'Initials': 'J', 'LastName': 'Shindoh', 'Affiliation': 'Department of Respiratory Medicine, Ogaki Municipal Hospital, Gifu, Japan.'}, {'ForeName': 'Takafumi', 'Initials': 'T', 'LastName': 'Suda', 'Affiliation': 'Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Okamoto', 'Affiliation': 'Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.'}, {'ForeName': 'Masahito', 'Initials': 'M', 'LastName': 'Ebina', 'Affiliation': 'Department of Respiratory Medicine, Tohoku Medical and Pharmaceutical University, Miyagi, Japan.'}, {'ForeName': 'Yoshihito', 'Initials': 'Y', 'LastName': 'Yamada', 'Affiliation': 'Department of Respiratory Medicine, Japan Railway Tokyo General Hospital, Tokyo, Japan.'}, {'ForeName': 'Yuji', 'Initials': 'Y', 'LastName': 'Tohda', 'Affiliation': 'Department of Respiratory Medicine and Allergology, Faculty of Medicine, Kindai University, Osaka, Japan.'}, {'ForeName': 'Tetsuji', 'Initials': 'T', 'LastName': 'Kawamura', 'Affiliation': 'Department of Respiratory Medicine, National Hospital Organization Himeji Medical Center, Hyogo, Japan.'}, {'ForeName': 'Yoshio', 'Initials': 'Y', 'LastName': 'Taguchi', 'Affiliation': 'Department of Respiratory Medicine, Tenri Hospital, Nara, Japan.'}, {'ForeName': 'Hiroshi', 'Initials': 'H', 'LastName': 'Ishii', 'Affiliation': 'Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan.'}, {'ForeName': 'Naozumi', 'Initials': 'N', 'LastName': 'Hashimoto', 'Affiliation': 'Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Aichi, Japan.'}, {'ForeName': 'Shinji', 'Initials': 'S', 'LastName': 'Abe', 'Affiliation': 'Department of Respiratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.'}, {'ForeName': 'Hiroyuki', 'Initials': 'H', 'LastName': 'Taniguchi', 'Affiliation': 'Department of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Tagawa', 'Affiliation': 'Asahi-Kasei Pharma Corporation, Tokyo, Japan; and.'}, {'ForeName': 'Koji', 'Initials': 'K', 'LastName': 'Bessho', 'Affiliation': 'Asahi-Kasei Pharma Corporation, Tokyo, Japan; and.'}, {'ForeName': 'Natsuki', 'Initials': 'N', 'LastName': 'Yamamori', 'Affiliation': 'Asahi-Kasei Pharma Corporation, Tokyo, Japan; and.'}, {'ForeName': 'Sakae', 'Initials': 'S', 'LastName': 'Homma', 'Affiliation': 'Department of Advanced and Integrated Interstitial Lung Diseases Research, School of Medicine, Toho University, Tokyo, Japan.'}]",American journal of respiratory and critical care medicine,['10.1164/rccm.201909-1818OC'] 3033,32112528,"Reply to ""Comment on 'Comparison of three transfusion protocols prior to central venous catheterization in patients with cirrhosis; a randomized controlled trial'"".",,2020,,['patients with cirrhosis'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}]",[],[],,0.0503606,,"[{'ForeName': 'Leonardo L', 'Initials': 'LL', 'LastName': 'Rocha', 'Affiliation': 'Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.'}, {'ForeName': 'Thiago D', 'Initials': 'TD', 'LastName': 'Corrêa', 'Affiliation': 'Hospital Israelita Albert Einstein, São Paulo, Brazil.'}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14737'] 3034,32112529,Comment on Comparison of three transfusion protocols prior to central venous catheterisation in patients with cirrhosis; a randomised controlled trial.,,2020,,['patients with cirrhosis'],[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}]",[],[],,0.0812461,,"[{'ForeName': 'Lara N', 'Initials': 'LN', 'LastName': 'Roberts', 'Affiliation': ""King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Roopen', 'Initials': 'R', 'LastName': 'Arya', 'Affiliation': ""King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.""}, {'ForeName': 'Brian J', 'Initials': 'BJ', 'LastName': 'Hogan', 'Affiliation': ""Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, UK.""}]",Journal of thrombosis and haemostasis : JTH,['10.1111/jth.14732'] 3035,31628428,Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.,"RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098-0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]: 0.450 [0.266-0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk (TP53 mutation, 11q deletion, and/or unmutated IGHV) (PFS: HR [95% CI]: 0.083 [0.047-0.145]; OS: HR [95% CI]: 0.366 [0.181-0.736]). Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis). Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time.",2020,Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time.,"['patients with CLL/SLL', 'chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL', 'Patients aged ≥65 years (n\u2009=\u2009269']","['daily ibrutinib 420\u2009mg continuously or chlorambucil 0.5-0.8\u2009mg/kg for ≤12 cycles', 'first-line ibrutinib treatment', 'chlorambucil']","['hyponatremia', 'Investigator-assessed overall response rate', 'progression-free survival (PFS) and overall survival (OS) benefits', 'anemia', 'pneumonia', 'neutropenia', 'hypertension']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C0024303', 'cui_str': 'Lymphocytic lymphoma'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C4555385', 'cui_str': 'Ibrutinib 420 MG'}, {'cui': 'C0008163', 'cui_str': 'Chlorambucil'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C3501358', 'cui_str': 'Ibrutinib'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0020625', 'cui_str': 'Hyponatremia'}, {'cui': 'C0035173', 'cui_str': 'Investigators'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]",,0.152562,Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time.,"[{'ForeName': 'Jan A', 'Initials': 'JA', 'LastName': 'Burger', 'Affiliation': 'Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jaburger@mdanderson.org.'}, {'ForeName': 'Paul M', 'Initials': 'PM', 'LastName': 'Barr', 'Affiliation': 'Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.'}, {'ForeName': 'Tadeusz', 'Initials': 'T', 'LastName': 'Robak', 'Affiliation': 'Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Owen', 'Affiliation': 'Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Ghia', 'Affiliation': 'Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.'}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Tedeschi', 'Affiliation': 'ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.'}, {'ForeName': 'Osnat', 'Initials': 'O', 'LastName': 'Bairey', 'Affiliation': 'Rabin Medical Center, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Hillmen', 'Affiliation': 'The Leeds Teaching Hospitals, St. James Institute of Oncology, University of Leeds, Leeds, UK.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Coutre', 'Affiliation': 'Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA, USA.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Devereux', 'Affiliation': 'Kings College Hospital, NHS Foundation Trust, London, UK.'}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Grosicki', 'Affiliation': 'Department of Hematology and Cancer Prevention, Silesiam Medical University, Katowice, Poland.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'McCarthy', 'Affiliation': 'Royal Bournemouth General Hospital, Bournemouth, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Simpson', 'Affiliation': 'North Shore Hospital, Auckland, New Zealand.'}, {'ForeName': 'Fritz', 'Initials': 'F', 'LastName': 'Offner', 'Affiliation': 'Universitair Ziekenhuis Gent, Gent, Belgium.'}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Moreno', 'Affiliation': 'Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Dai', 'Affiliation': 'Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.'}, {'ForeName': 'Indu', 'Initials': 'I', 'LastName': 'Lal', 'Affiliation': 'Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Dean', 'Affiliation': 'Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.'}, {'ForeName': 'Thomas J', 'Initials': 'TJ', 'LastName': 'Kipps', 'Affiliation': 'UCSD Moores Cancer Center, San Diego, CA, USA.'}]",Leukemia,['10.1038/s41375-019-0602-x'] 3036,31402637,"Comparison of intubation condition and the quality of muscle relaxation between rocuronium and vecuronium using ""timing principle"".","Aim To compare the quality of the conditions for endotracheal intubation and muscle relaxation between rocuronium bromide and vecuronium bromide using the ''timing principle'' method for induction in anaesthesia. The ""timing principle"" includes the administration of muscle relaxants before the hypnotic agent during induction in anaesthesia. Method Sixty patients who had undergone elective surgery were randomly allocated into two equal groups using muscle relaxants: rocuronium (group R) and vecuronium (group V). The intubation conditions were assessed using Cooper's scoring system, based on jaw relaxation, vocal cords position and response to intubation. The quality of muscle relaxation was evaluated by recording the time of clinical weakness, a count of ''train of four'' (TOF) twitches at intubation, the time of loss TOF response and duration of direct laryngoscopy. Results The intubation conditions were excellent in 100% of patients in the group R versus excellent in 80% and good in 20% of patients in the group V (p<0.05). The time of clinical weakness was statistically significantly shorter in the group R than in the group V (p<0.000). The time of loss of TOF response was statistically significantly shorter in the group R (p<0.000). The absence of TOF twitches (the level of muscle relaxation of 100%) at intubation recorded in 25 (83.3%) patients in the group R versus five (16.7%) patients in the group V (p<0.000). Duration of direct laryngoscopy did not significantly differ between the groups. Conclusion Rocuronium bromide provides better intubation conditions and greater quality of muscle relaxation than vecuronium bromide using ''timing principle'' technique.",2020,The intubation conditions were excellent in 100% of patients in the group R versus excellent in 80% and good in 20% of patients in the group V (p<0.05).,['Method Sixty patients who had undergone elective surgery'],"['rocuronium bromide and vecuronium bromide', 'vecuronium bromide', 'vecuronium', 'rocuronium and vecuronium', 'muscle relaxants: rocuronium', 'Rocuronium bromide']","['time of clinical weakness', 'time of loss of TOF response', 'Duration of direct laryngoscopy', ""time of clinical weakness, a count of ''train of four'' (TOF) twitches at intubation, the time of loss TOF response and duration of direct laryngoscopy"", 'absence of TOF twitches', 'quality of muscle relaxation', 'jaw relaxation, vocal cords position and response to intubation', 'intubation conditions']","[{'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206058', 'cui_str': 'Elective Surgical Procedures'}]","[{'cui': 'C0069632', 'cui_str': 'rocuronium bromide'}, {'cui': 'C0042435', 'cui_str': 'Vecuronium Bromide'}, {'cui': 'C0242531', 'cui_str': 'Vecuronium'}, {'cui': 'C0209337', 'cui_str': 'Rocuronium'}, {'cui': 'C0026827', 'cui_str': 'Hypomyotonia'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C3714552', 'cui_str': 'Weakness - general'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0392823', 'cui_str': 'Direct laryngoscopy (procedure)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0231530', 'cui_str': 'Muscle twitch (finding)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0700323', 'cui_str': 'Neuromuscular block, function (observable entity)'}, {'cui': 'C0022359', 'cui_str': 'Jaw'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C0042930', 'cui_str': 'Vocal Fold'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]",,0.0322467,The intubation conditions were excellent in 100% of patients in the group R versus excellent in 80% and good in 20% of patients in the group V (p<0.05).,"[{'ForeName': 'Senada', 'Initials': 'S', 'LastName': 'Čaušević', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Unit, Cantonal Hospital Zenica, Bosnia and Herzegovina.'}, {'ForeName': 'Nermina', 'Initials': 'N', 'LastName': 'Rizvanović', 'Affiliation': 'Department of Anaesthesiology and Intensive Care Unit, Cantonal Hospital Zenica, Bosnia and Herzegovina.'}, {'ForeName': 'Belma', 'Initials': 'B', 'LastName': 'Pojskić', 'Affiliation': 'Department of Internal Diseases, Cantonal Hospital Zenica, Bosnia and Herzegovina.'}]","Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina",['10.17392/1045-20'] 3037,32080310,Effects of a High-Intensity Exercise Program on Weight Regain and Cardio-metabolic Profile after 3 Years of Bariatric Surgery: A Randomized Trial.,"Weight regain is one of the most common problems in the long-term after bariatric surgery. It is unknown if high-intensity exercise programs applied in late phases of post-surgical follow-up could counteract this trend. After a 3-year follow-up, 21 patients underwent sleeve gastrectomy were randomized into an exercise group (EG, n = 11), that performed a 5-month supervised exercise program, and a control group (CG, n = 10), that followed the usual care. Body composition, cardiorespiratory fitness, glycaemia and blood cholesterol were evaluated before and after the intervention. Finally, the EG repeated the evaluations 2 months after the end of the exercise program. Both groups reached their maximum weight loss at the first year after surgery and showed significant weight regain by the end of the follow-up. After the exercise program, the EG showed reductions in fat mass (-2.5 ± 2.6  kg, P < 0.05), glycaemia (-13.4 ± 8.7  mg·dL -1, P < 0.01) and blood cholesterol (-24.6 ± 29.1  mg·dL -1 , P < 0.05), whereas the CG during the same period showed increases in weight (1.5 ± 1.3  kg, P < 0.05) and fat mass (1.8 ± 0.9, P < 0.01). Two months after the end of the program, EG had increases in weight (1.1 ± 1.2  kg, P < 0.05), fat mass (2.6 ± 2.2  kg, P < 0.01), glycaemia (8.2 ± 11.6  mg·dL -1 , P < 0.05) and blood cholesterol (20.0 ± 22.1  mg·dL -1 , P < 0.05), when compared with the values after the exercise program. Therefore, in the medium-term after sleeve gastrectomy exercise may contribute to prevent weight regain and to reduce fat mass, glycaemia, and blood cholesterol.",2020,"After the exercise program, the EG showed reductions in fat mass (-2.5 ± 2.6  kg, P < 0.05), glycaemia (-13.4 ± 8.7  mg·dL -1, P < 0.01) and blood cholesterol (-24.6 ± 29.1  mg·dL -1 , P < 0.05), whereas the CG during the same period showed increases in weight (1.5 ± 1.3  kg, P < 0.05) and fat mass (1.8 ± 0.9, P < 0.01).","['21 patients underwent', 'after 3 Years of Bariatric Surgery']","['High-Intensity Exercise Program', 'sleeve gastrectomy', 'exercise group (EG, n\u2009=\u200911), that performed a 5-month supervised exercise program']","['weight regain', 'weight', 'fat mass', 'glycaemia', 'fat mass, glycaemia, and blood cholesterol', 'Weight regain', 'Weight Regain and Cardio-metabolic Profile', 'maximum weight loss', 'Body composition, cardiorespiratory fitness, glycaemia and blood cholesterol', 'blood cholesterol']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456587', 'cui_str': 'Bariatric Surgery'}]","[{'cui': 'C4081854', 'cui_str': 'High intensity'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3160799', 'cui_str': 'Sleeve gastrectomy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0518017', 'cui_str': 'Blood cholesterol'}, {'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}]",21.0,0.0191781,"After the exercise program, the EG showed reductions in fat mass (-2.5 ± 2.6  kg, P < 0.05), glycaemia (-13.4 ± 8.7  mg·dL -1, P < 0.01) and blood cholesterol (-24.6 ± 29.1  mg·dL -1 , P < 0.05), whereas the CG during the same period showed increases in weight (1.5 ± 1.3  kg, P < 0.05) and fat mass (1.8 ± 0.9, P < 0.01).","[{'ForeName': 'A', 'Initials': 'A', 'LastName': 'Marc-Hernández', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, 03202, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ruiz-Tovar', 'Affiliation': 'Centre of Excellence for the Diagnosis and Treatment of Obesity and Diabetes, Valladolid, 47004, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Aracil', 'Affiliation': 'Department of Sport Sciences, Miguel Hernandez University, Elche, 03202, Spain. fito@umh.es.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Guillén', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, 03202, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Moya-Ramón', 'Affiliation': 'Laboratory of Training Analysis and Optimization, Sport Research Center, Miguel Hernandez University, Elche, 03202, Spain. mmoya@umh.es.'}]",Scientific reports,['10.1038/s41598-020-60044-z'] 3038,31358875,Access to consciousness of briefly presented visual events is modulated by transcranial direct current stimulation of left dorsolateral prefrontal cortex.,"Adaptive behaviour requires the ability to process goal-relevant events at the expense of irrelevant ones. However, perception of a relevant visual event can transiently preclude access to consciousness of subsequent events - a phenomenon called attentional blink (AB). Here we investigated involvement of the left dorsolateral prefrontal cortex (DLPFC) in conscious access, by using transcranial direct current stimulation (tDCS) to potentiate or reduce neural excitability in the context of an AB task. In a sham-controlled experimental design, we applied between groups anodal or cathodal tDCS over the left DLPFC, and examined whether this stimulation modulated the proportion of stimuli that were consciously reported during the AB period. We found that tDCS over the left DLPFC affected the proportion of consciously perceived target stimuli. Moreover, anodal and cathodal tDCS had opposing effects, and exhibited different temporal patterns. Anodal stimulation attenuated the AB, enhancing conscious report earlier in the AB period. Cathodal stimulation accentuated the AB, reducing conscious report later in the AB period. These findings support the notion that the DLPFC plays a role in facilitating information transition from the unconscious to the conscious stage of processing.",2019,We found that tDCS over the left DLPFC affected the proportion of consciously perceived target stimuli.,[],"['tDCS', 'transcranial direct current stimulation (tDCS']",[],[],"[{'cui': 'C3850024', 'cui_str': 'tDCS'}]",[],,0.017081,We found that tDCS over the left DLPFC affected the proportion of consciously perceived target stimuli.,"[{'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Sdoia', 'Affiliation': 'Department of Psychology, Sapienza University, Rome, Italy. stefano.sdoia@uniroma1.it.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Conversi', 'Affiliation': 'Department of Psychology, Sapienza University, Rome, Italy.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Pecchinenda', 'Affiliation': 'Department of Psychology, Sapienza University, Rome, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Ferlazzo', 'Affiliation': 'Department of Psychology, Sapienza University, Rome, Italy.'}]",Scientific reports,['10.1038/s41598-019-47527-4'] 3039,29907999,Memory-Based Deception Detection: Extending the Cognitive Signature of Lying From Instructed to Self-Initiated Cheating.,"From a cognitive perspective, lying can be regarded as a complex cognitive process requiring the interplay of several executive functions. Meta-analytic research on 114 studies encompassing 3,307 participants (Suchotzki, Verschuere, Van Bockstaele, Ben-Shakhar, & Crombez, 2017) suggests that computerized paradigms can reliably assess the cognitive burden of lying, with large reaction time differences between lying and truth telling. These studies, however, lack a key ingredient of real-life deception, namely self-initiated behavior. Research participants have typically been instructed to commit a mock crime and conceal critical information, whereas in real life, people freely choose whether or not to engage in antisocial behavior. In this study, participants (n = 433) engaged in a trivia quiz and were provided with a monetary incentive for high accuracy performance. Participants were randomly allocated to either a condition where they were instructed to cheat on the quiz (mimicking the typical laboratory set-up) or to a condition in which they were provided with the opportunity to cheat, yet without explicit instructions to do so. Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information. The data indicate that the cognitive signature of lying is not restricted to explicitly instructed cheating, but it can also be observed for self-initiated cheating. These findings are highly encouraging from an ecological validity perspective.",2020,Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information.,"['3,307 participants (Suchotzki, Verschuere, Van Bockstaele, Ben-Shakhar, & Crombez, ', 'participants (n\xa0=\xa0433) engaged in a trivia quiz and were provided with a monetary incentive for high accuracy performance']",['Memory-Based Deception Detection'],[],"[{'cui': 'C0557775', 'cui_str': 'Van (physical object)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]","[{'cui': 'C0025260', 'cui_str': 'Memory'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0024195', 'cui_str': 'Deception'}]",[],3307.0,0.0265244,Assessments of their response times in a subsequent Concealed Information Test (CIT) revealed that both instructed cheaters (n = 107) and self-initiated cheaters (n = 142) showed the expected RT-slowing for concealed information.,"[{'ForeName': 'Linda M', 'Initials': 'LM', 'LastName': 'Geven', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}, {'ForeName': 'Gershon', 'Initials': 'G', 'LastName': 'Ben-Shakhar', 'Affiliation': 'Department of Psychology, Hebrew University of Jerusalem.'}, {'ForeName': 'Merel', 'Initials': 'M', 'LastName': 'Kindt', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Verschuere', 'Affiliation': 'Department of Clinical Psychology, University of Amsterdam.'}]",Topics in cognitive science,['10.1111/tops.12353'] 3040,32019343,Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.,"BACKGROUND Direct stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization. METHODS We performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double-blind, randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. Primary end point was 12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up. RESULTS Of the 575 patients included in this substudy, 185 (32%) patients underwent stent-only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19). During long-term follow-up (median of 2.7 years), the incidence of definite stent thrombosis (1% versus 5%; hazard ratio, 9.20 [95% CI, 1.23-68.92]; P =0.0085), the composite of definite or probable stent thrombosis (5% versus 11%; hazard ratio, 2.52 [95% CI, 1.23-5.18]; P =0.009), and target vessel myocardial infarction (8% versus 14%; hazard ratio, 1.92 [95% CI, 1.08-3.40]; P =0.023) was lower in the stent-only group. Multivariable analysis showed that a higher number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions were associated with increased target vessel failure during entire follow-up, while preintervention Thrombolysis in Myocardial Infarction-3 flow was protective. CONCLUSIONS In patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01121224.",2020,"Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19).","['patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions', 'Saphenous Vein Graft Percutaneous Coronary Intervention', 'patients enrolled in the', '575 patients included in this substudy']","['Direct stenting without pre-dilation or post-dilation', 'DIVA (Drug-Eluting Stents Versus Bare Metal Stents', 'stent-only percutaneous coronary intervention', 'Stent-Only Versus Adjunctive Balloon Angioplasty Approach']","['number of years since coronary artery bypass grafting and >1 target saphenous vein graft lesions', 'composite of definite or probable stent thrombosis', 'target vessel failure', 'vessel myocardial infarction', 'incidence of target vessel failure', '12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization', 'cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up', 'incidence of stent thrombosis', 'incidence of definite stent thrombosis', 'target vessel myocardial infarction']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0729538', 'cui_str': 'Saphenous vein graft (substance)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C3844102', 'cui_str': '575'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent (physical object)'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0002996', 'cui_str': 'Dilation, Transluminal Arterial'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C0729538', 'cui_str': 'Saphenous vein graft (substance)'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0439544', 'cui_str': 'Definite (qualifier value)'}, {'cui': 'C0332148', 'cui_str': 'Probable diagnosis (contextual qualifier) (qualifier value)'}, {'cui': 'C3897493', 'cui_str': 'Stent thrombosis'}, {'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0148346', 'cui_str': 'Vessel'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0376297', 'cui_str': 'Cardiac Death'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}]",575.0,0.419308,"Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08]; P =0.19).","[{'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Latif', 'Affiliation': 'VA Medical Center, Oklahoma City (F.L.).'}, {'ForeName': 'Lauren', 'Initials': 'L', 'LastName': 'Uyeda', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Edson', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': 'VA Boston Healthcare System, MA (D.L., S.K., R.S.V).'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Goldman', 'Affiliation': 'University of Arizona Sarver Heart Center, Tucson (S.G.).'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Holmes', 'Affiliation': 'Mayo Clinic, Rochester, MN (D.R.H.).'}, {'ForeName': 'Sunil V', 'Initials': 'SV', 'LastName': 'Rao', 'Affiliation': 'Durham VA Medical Center, NC (S.V.R.).'}, {'ForeName': 'Kendrick', 'Initials': 'K', 'LastName': 'Shunk', 'Affiliation': 'San Francisco VA Medical Center, CA (K.S.).'}, {'ForeName': 'Kul', 'Initials': 'K', 'LastName': 'Aggarwal', 'Affiliation': 'Harry S Truman VA Hospital, Columbia, MO (K.A.).'}, {'ForeName': 'Barry', 'Initials': 'B', 'LastName': 'Uretsky', 'Affiliation': 'Central Arkansas Veterans Health System, Little Rock (B.U.).'}, {'ForeName': 'Islam', 'Initials': 'I', 'LastName': 'Bolad', 'Affiliation': 'Indiana University School of Medicine, Indianapolis (I.B.).'}, {'ForeName': 'Khaled', 'Initials': 'K', 'LastName': 'Ziada', 'Affiliation': 'University of Kentucky, Lexington (K.Z.).'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'McFalls', 'Affiliation': 'VA Medical Center, Minneapolis, MN (E.M.).'}, {'ForeName': 'Anand', 'Initials': 'A', 'LastName': 'Irimpen', 'Affiliation': 'Southeast Louisiana Veterans Health Care System, New Orleans (A.I.).'}, {'ForeName': 'Huu Tam', 'Initials': 'HT', 'LastName': 'Truong', 'Affiliation': 'VA Loma Linda Medical Center, CA (H.T.T.).'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Kinlay', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Vasilios', 'Initials': 'V', 'LastName': 'Papademetriou', 'Affiliation': 'VA Medical center Washington DC (V.P.).'}, {'ForeName': 'Raghava S', 'Initials': 'RS', 'LastName': 'Velagaleti', 'Affiliation': 'VA Boston Healthcare System, MA (D.L., S.K., R.S.V).'}, {'ForeName': 'Bavana V', 'Initials': 'BV', 'LastName': 'Rangan', 'Affiliation': 'Minneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).'}, {'ForeName': 'Kreton', 'Initials': 'K', 'LastName': 'Mavromatis', 'Affiliation': 'Atlanta VA Healthcare System, GA (K.M.).'}, {'ForeName': 'Mei-Chiung', 'Initials': 'MC', 'LastName': 'Shih', 'Affiliation': 'VA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).'}, {'ForeName': 'Subhash', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Dallas VA Medical Center, TX (S.B.).'}, {'ForeName': 'Emmanouil S', 'Initials': 'ES', 'LastName': 'Brilakis', 'Affiliation': 'Minneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).'}]",Circulation. Cardiovascular interventions,['10.1161/CIRCINTERVENTIONS.119.008494'] 3041,31129719,"Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).","Although open-label observations report a positive effect of cannabinoids on non-motor symptoms (NMS) in Parkinson's disease (PD) patients, these effects remain to be investigated in a controlled trial for a broader use in NMS in PD patients. Therefore, we decided to design a proof-of-concept study to assess the synthetic cannabinoid nabilone for the treatment of NMS. We hypothesize that nabilone will improve NMS in patients with PD and have a favorable safety profile. The NMS-Nab Study is as a mono-centric phase II, randomized, placebo-controlled, double-blind, parallel-group, enriched enrollment withdrawal study. The primary efficacy criterion will be the change in Movement Disorders Society-Unified Parkinson's Disease-Rating Scale Part I score between baseline (i.e. randomization) and week 4. A total of 38 patients will have 80% power to detect a probability of 0.231 that an observation in the treatment group is less than an observation in the placebo group using a Wilcoxon rank-sum test with a 0.050 two-sided significance level assuming a true difference of 2.5 points between nabilone and placebo in the primary outcome measure and a standard deviation of the change of 2.4 points. The reduction of harm through an ineffective treatment, the possibility of individualized dosing, the reduction of sample size, and the possible evaluation of the influence of the placebo effect on efficacy outcomes justify this design for a single-centered placebo-controlled investigator-initiated trial of nabilone. This study should be the basis for further evaluations of long-term efficacy and safety of the use of cannabinoids in PD patients.",2019,A total of 38 patients will have 80% power to detect a probability of 0.231 that an observation in the treatment group is less than an observation in the placebo group using a Wilcoxon rank-sum test with a 0.050 two-sided significance level assuming a true difference of 2.5 points between nabilone and placebo in the primary outcome measure and a standard deviation of the change of 2.4 points.,"[""Parkinson's disease"", 'patients with PD', 'PD patients', ""Parkinson's disease (PD) patients""]","['Nabilone', 'placebo']","[""change in Movement Disorders Society-Unified Parkinson's Disease-Rating Scale Part""]","[{'cui': 'C0030567', 'cui_str': 'Idiopathic Parkinson Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0068333', 'cui_str': 'nabilone'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0026650', 'cui_str': 'Movement Disorder Syndromes'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C3639721', 'cui_str': 'UPDRS Panel'}]",38.0,0.510229,A total of 38 patients will have 80% power to detect a probability of 0.231 that an observation in the treatment group is less than an observation in the placebo group using a Wilcoxon rank-sum test with a 0.050 two-sided significance level assuming a true difference of 2.5 points between nabilone and placebo in the primary outcome measure and a standard deviation of the change of 2.4 points.,"[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Peball', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria. Marina.peball@i-med.ac.at.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Werkmann', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Ellmerer', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Raphaela', 'Initials': 'R', 'LastName': 'Stolz', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Dora', 'Initials': 'D', 'LastName': 'Valent', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Hans-Günther', 'Initials': 'HG', 'LastName': 'Knaus', 'Affiliation': 'Department for Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Peter-Mayr Straße 1, 6020, Innsbruck, Austria.'}, {'ForeName': 'Hanno', 'Initials': 'H', 'LastName': 'Ulmer', 'Affiliation': 'Department of Medical Statistics, Informatics and Health Economics, Innsbruck Medical University, Schöpfstraße 41/1, 6020, Innsbruck, Austria.'}, {'ForeName': 'Atbin', 'Initials': 'A', 'LastName': 'Djamshidian', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Poewe', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria.'}, {'ForeName': 'Klaus', 'Initials': 'K', 'LastName': 'Seppi', 'Affiliation': 'Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020, Innsbruck, Austria. Klaus.Seppi@tirol-kliniken.at.'}]","Journal of neural transmission (Vienna, Austria : 1996)",['10.1007/s00702-019-02021-z'] 3042,30959415,Greater perceived importance of earning abstinence-contingent incentives is associated with smoking cessation among socioeconomically disadvantaged adults.,"BACKGROUND Individuals' perceptions of the importance of earning financial incentives for smoking cessation may influence the effectiveness of contingency management interventions. This study prospectively explored the perceived importance of earning financial incentives for smoking cessation and its association with smoking cessation within a contingency management intervention among socioeconomically disadvantaged adults. METHODS This study is a secondary analysis of data from a randomized clinical trial that recruited socioeconomically disadvantaged adults from a safety-net hospital in Dallas County, Texas, from 2011 to 2013. Participants, who were randomly assigned to receive small financial incentives for smoking abstinence (N = 75), rated the importance of earning abstinence-contingent financial incentives one day after their scheduled quit day and one-week post-quit day. Self-reported smoking abstinence was biochemically confirmed weekly through the fourth week post-quit day and at the twelfth week post-quit day. Participants were considered continuously abstinent if self-reported abstinence since the quit date was biochemically confirmed. RESULTS Greater perceived importance of earning abstinence contingent incentives for smoking cessation was associated with a higher likelihood of achieving continuous abstinence during the four-week intervention period (OR = 3.95 [95% CI = 1.64, 9.53]) and through 12 weeks post-quit day (OR = 4.71 [95% CI = 1.56, 14.26]). CONCLUSIONS Findings suggest that the perceived importance of earning abstinence-contingent incentives early in a quit attempt predicts smoking cessation among socioeconomically disadvantaged adults and may indicate whether an individual will be responsive to the magnitude of incentives offered.",2019,"RESULTS Greater perceived importance of earning abstinence contingent incentives for smoking cessation was associated with a higher likelihood of achieving continuous abstinence during the four-week intervention period (OR = 3.95 [95% CI = 1.64, 9.53]) and through 12 weeks post-quit day (OR = 4.71 [95% CI = 1.56, 14.26]). ","['socioeconomically disadvantaged adults', 'recruited socioeconomically disadvantaged adults from a safety-net hospital in Dallas County, Texas, from 2011 to 2013']",['small financial incentives for smoking abstinence'],"['continuous abstinence', 'Self-reported smoking abstinence']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3661443', 'cui_str': 'Safety-net Hospitals'}, {'cui': 'C0039711', 'cui_str': 'Texas'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]","[{'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}]",,0.101134,"RESULTS Greater perceived importance of earning abstinence contingent incentives for smoking cessation was associated with a higher likelihood of achieving continuous abstinence during the four-week intervention period (OR = 3.95 [95% CI = 1.64, 9.53]) and through 12 weeks post-quit day (OR = 4.71 [95% CI = 1.56, 14.26]). ","[{'ForeName': 'Adam C', 'Initials': 'AC', 'LastName': 'Alexander', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States. Electronic address: Adam-Alexander@ouhsc.edu.'}, {'ForeName': 'Emily T', 'Initials': 'ET', 'LastName': 'Hébert', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Businelle', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}, {'ForeName': 'Darla E', 'Initials': 'DE', 'LastName': 'Kendzor', 'Affiliation': 'Oklahoma Tobacco Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.'}]",Addictive behaviors,['10.1016/j.addbeh.2019.04.001'] 3043,32032809,Hysteroscopic Assessment of Tubal Patency: A Randomized Comparison between the Flow and Parryscope Techniques.,"STUDY OBJECTIVE To evaluate the accuracy of the ""Parryscope"" and ""flow"" techniques for hysteroscopic assessment of tubal patency. DESIGN Prospective randomized clinical trial. SETTING From May to October 2019, women with subfertility undergoing laparoscopic and hysteroscopic surgery at the Medical University of Vienna were invited to participate in the study. The primary outcome was accuracy of Fallopian tube patency relative to the gold standard of laparoscopic chromopertubation. PATIENTS Sixty women with subfertility. INTERVENTIONS Hysteroscopy with either the ""Parryscope"" or the ""flow"" techniques for tubal assessment, directly followed by laparoscopy with chromopertubation. MEASUREMENTS AND MAIN RESULTS Hysteroscopic prediction of fallopian tube patency was possible in a statistically significant manner in both study groups (p <0.05). The Parryscope technique achieved higher sensitivity (90.6%, 95% CI: 61.7-98.4) and specificity (100%, 95% CI: 90.0-100.0) than the flow technique (sensitivity: 73.7%, 95% CI: 48.8-90.9 and specificity: 70.7%, 95% CI: 54.5-83.9). CONCLUSION Using the Parryscope technique to determine if air bubbles traverse the ostia can provide valuable additional information during hysteroscopy and is more accurate in predicting fallopian tubal occlusion than the flow method.",2020,Hysteroscopic prediction of Fallopian tube patency was possible in a statistically significant manner in both study groups (p< 0.05).,"['60 subfertile women', 'From May to October, 2019, subfertile women undergoing laparoscopic and hysteroscopic surgery at the Medical University of Vienna were invited to participate in the study']","['Hysteroscopy with either the ""Parryscope®"" or the ""flow"" techniques', 'Parryscope®"" and ""flow"" techniques']","['Fallopian tubal occlusion', 'Hysteroscopic Assessment of tubal patency', 'higher sensitivity', 'Hysteroscopic prediction of Fallopian tube patency', 'accuracy of Fallopian tube patency relative to the gold standard of laparoscopic chromopertubation', 'specificity']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0751614', 'cui_str': 'Hysteroscopic Surgical Procedures'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0020710', 'cui_str': 'Uterine Endoscopy'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0041275', 'cui_str': 'Tubal Occlusion'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0015560', 'cui_str': 'Oviducts, Mammalian'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C0018026', 'cui_str': 'Gold'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C3160762', 'cui_str': 'Chromopertubation'}, {'cui': 'C0037791', 'cui_str': 'Specificity'}]",,0.0788059,Hysteroscopic prediction of Fallopian tube patency was possible in a statistically significant manner in both study groups (p< 0.05).,"[{'ForeName': 'Marlene', 'Initials': 'M', 'LastName': 'Hager', 'Affiliation': 'Clinical Division of Gynecological Endocrinology and Reproductive Medicine (Drs. Hager, Ott, Holzer, and Kurz).'}, {'ForeName': 'Johannes', 'Initials': 'J', 'LastName': 'Ott', 'Affiliation': 'Clinical Division of Gynecological Endocrinology and Reproductive Medicine (Drs. Hager, Ott, Holzer, and Kurz). Electronic address: johannes.ott@meduniwien.ac.at.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Holzer', 'Affiliation': 'Clinical Division of Gynecological Endocrinology and Reproductive Medicine (Drs. Hager, Ott, Holzer, and Kurz).'}, {'ForeName': 'Rudolf', 'Initials': 'R', 'LastName': 'Seemann', 'Affiliation': 'Department of Oral and Maxillofacial Surgery (Dr. Seemann), Medical University of Vienna, Vienna, Austria.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Kurz', 'Affiliation': 'Clinical Division of Gynecological Endocrinology and Reproductive Medicine (Drs. Hager, Ott, Holzer, and Kurz).'}, {'ForeName': 'John Preston', 'Initials': 'JP', 'LastName': 'Parry', 'Affiliation': 'Parryscope and Positive Steps Fertility, Madison; Department of Obstetrics and Gynecology, University of Mississippi Medical Center (Dr. Parry), Jackson, Mississippi.'}]",Journal of minimally invasive gynecology,['10.1016/j.jmig.2020.01.014'] 3044,32114699,The effect of interprofessional education on healthcare providers' intentions to engage in interprofessional shared decision-making: Perspectives from the theory of planned behaviour.,"AIMS AND OBJECTIVES The present study aimed to investigate the effects of interprofessional education on healthcare providers' intentions to engage in an interprofessional shared decision-making (IP-SDM) process at emergency department and exploring the affecting factors on their intentions. METHODS We conducted the study through a sequential explanatory mixed method (quantitative-qualitative) design. All ED residents and nurses from two university hospitals were invited and assigned to the intervention and control groups. The intervention group was exposed to case-based learning sessions conducted by applying interprofessional strategies. The intentions of the participants engaged in IP-SDM were assessed before and 2 weeks after the intervention by a questionnaire designed based on the theory of planned behaviour. The questionnaire scores were compared between the intervention and control groups using analysis of covariance (ANCOVA). Partial eta-squared (η 2 ) was used for effect size calculations in ANCOVA. Subsequently, to explore the affecting factors in engagement in IP-SDM, qualitative data were collected through semi-structured individual interviews. The inductive content analysis approach by Elo and Kyngas was employed to analyze the qualitative data. RESULTS Out of 117 potentially eligible healthcare professionals, 113 completed the study in the intervention (n = 55) and control (n = 58) groups. The results showed that the difference between the mean scores of the learners in the intervention (1.41 ± 0.27) and control (0.80 ± 0.52) groups was statistically significant (P-value = .00001). The main effect of the intervention and a large educational effect size for the intervention were found to be statistically significant F (1, 11) = 180.54, P-value = .00001, η 2 = 0.62. The qualitative data analysis showed two main categories of ""team-based facilitators"" and ""contextual challenges"" as the main affecting factors in the engagement of participant in IP-SDM. CONCLUSION Our findings suggested that applying interprofessional education strategies could improve the learners' intention to engage in IP-SDM. Moreover, the results showed that the interprofessional collaboration among team members, adherence to the team-based care principles, and administrative support at different levels could be the influential factors the intentions of the participants to engage in IP-SDM.",2020,The intentions of the participants engaged in IP-SDM were assessed before and 2 weeks after the intervention by a questionnaire designed based on the theory of planned behaviour.,"['117 potentially eligible healthcare professionals, 113 completed the study in the intervention (n = 55) and control (n = 58) groups', 'All ED residents and nurses from two university hospitals']",['interprofessional education'],['questionnaire scores'],"[{'cui': 'C1704312', 'cui_str': 'Healthcare professional (occupation)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",117.0,0.0285659,The intentions of the participants engaged in IP-SDM were assessed before and 2 weeks after the intervention by a questionnaire designed based on the theory of planned behaviour.,"[{'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Keshmiri', 'Affiliation': 'Medical Education Department, Educational Development Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.'}, {'ForeName': 'Mahdi', 'Initials': 'M', 'LastName': 'Rezai', 'Affiliation': 'Emergency Medicine Management Research Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'ForeName': 'Nader', 'Initials': 'N', 'LastName': 'Tavakoli', 'Affiliation': 'Emergency Medicine Department, Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.'}]",Journal of evaluation in clinical practice,['10.1111/jep.13379'] 3045,32081989,A randomised controlled trial to assess the feasibility of utilising virtual reality to facilitate analgesia during external cephalic version.,"External cephalic version (ECV) is associated with a moderate degree of pain. Virtual reality (VR) is a technology that has shown promise in offering procedural analgesia. We undertook a clinical pilot to assess the viability of VR to reduce pain during ECV. In an open randomised controlled trial (RCT), we randomised 50 women to either VR or standard care each (25 per group). Women receiving VR were administered VR content (Skylights) via a headset. Pre- and post-procedural measures of pain, anxiety, device experience and vital signs were measured. There were no significant differences between groups (VR/no VR) in pain scores (60.68 vs 49.76; p = 0.2), ECV success rates (80% vs 76%; p = 0.7) or anxiety levels. The women receiving VR had a significantly higher anticipation of pain pre-procedurally (70.0 vs 50.0; p = 0.03). 20 (80%) of the VR women indicated that they would use VR again and 22 (88%) indicated they would recommend it to a friend having ECV. There were no significant differences between groups for side effects encountered or changes in vital signs. We have shown that using VR during ECV is feasible and appears safe. Our results inform the design of future RCTs.",2020,There were no significant differences between groups (VR/no VR) in pain scores (,['50 women to either VR or standard care each (25 per group'],"['Virtual reality (VR', 'External cephalic version (ECV', 'utilising virtual reality to facilitate analgesia during external cephalic version']","['vital signs', 'pain scores', 'ECV success rates', 'pain, anxiety, device experience and vital signs', 'anticipation of pain pre-procedurally', 'anxiety levels']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0871582', 'cui_str': 'Virtual Reality'}, {'cui': 'C0410877', 'cui_str': 'Version, External Cephalic'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}]","[{'cui': 'C0518766'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}]",50.0,0.0525311,There were no significant differences between groups (VR/no VR) in pain scores (,"[{'ForeName': 'Vinayak', 'Initials': 'V', 'LastName': 'Smith', 'Affiliation': 'The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, 252 Clayton Road, Clayton, 3168, Victoria, Australia. vinayak.smith@monash.edu.'}, {'ForeName': 'Ritesh Rikain', 'Initials': 'RR', 'LastName': 'Warty', 'Affiliation': 'The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, 252 Clayton Road, Clayton, 3168, Victoria, Australia.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Kashyap', 'Affiliation': ""Monash Women's, Monash Health, Monash Medical Centre, Clayton, Monash Health, 252 Clayton Road, Clayton, 3168, Victoria, Australia.""}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Neil', 'Affiliation': ""Monash Women's, Monash Health, Monash Medical Centre, Clayton, Monash Health, 252 Clayton Road, Clayton, 3168, Victoria, Australia.""}, {'ForeName': 'Carol', 'Initials': 'C', 'LastName': 'Adriaans', 'Affiliation': ""Monash Women's, Monash Health, Monash Medical Centre, Clayton, Monash Health, 252 Clayton Road, Clayton, 3168, Victoria, Australia.""}, {'ForeName': 'Amrish', 'Initials': 'A', 'LastName': 'Nair', 'Affiliation': 'Biorithm Pte. Ltd., Block 81, Ayer Rajah Crescent, Unit #03-53, 139967, Singapore, Singapore.'}, {'ForeName': 'Sathya', 'Initials': 'S', 'LastName': 'Krishnan', 'Affiliation': 'West Gippsland Health Service, Warragul, 3820, Victoria, Australia.'}, {'ForeName': 'Fabricio', 'Initials': 'F', 'LastName': 'Da Silva Costa', 'Affiliation': 'The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, 252 Clayton Road, Clayton, 3168, Victoria, Australia.'}, {'ForeName': 'Beverley', 'Initials': 'B', 'LastName': 'Vollenhoven', 'Affiliation': 'The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, 252 Clayton Road, Clayton, 3168, Victoria, Australia.'}, {'ForeName': 'Euan M', 'Initials': 'EM', 'LastName': 'Wallace', 'Affiliation': 'The Ritchie Centre, Department of Obstetrics and Gynaecology, Monash University, 252 Clayton Road, Clayton, 3168, Victoria, Australia.'}]",Scientific reports,['10.1038/s41598-020-60040-3'] 3046,30573298,"Evaluation of an enhanced viscosity artificial tear for moderate to severe dry eye disease: A multicenter, double-masked, randomized 30-day study.","PURPOSE In a randomized, controlled clinical trial, two lubricant artificial tear formulations with enhanced viscosity were compared: an investigational product at the time, containing carboxymethylcellulose 1.0% and glycerin 0.9% (CMC-GLY) with osmoprotectants, and a standard formula containing carboxymethylcellulose 1.0% alone (CMC). METHODS This double-masked study recruited patients with moderate to severe dry eye at 10 US centers. After a 7-day run-in with CMC 0.5% (Refresh Tears) patients were randomized to use either CMC-GLY or CMC as needed, but at least 2 times daily for 30 days. Patients were stratified by Ocular Surface Disease Index © (OSDI) score into moderate (23-32) and severe (> 32-65) subgroups. Assessments included OSDI (primary efficacy variable), corneal and conjunctival staining, tear break-up time (TBUT), symptom surveys, and safety variables. Study visits were days 1 (baseline/randomization), 7, and 30. RESULTS A total of 188 patients (94 CMC-GLY, 94 CMC) were enrolled. The severe subgroup had 67 CMC-GLY and 65 CMC patients. OSDI scores progressively improved and were similar at day 30 between treatment groups. At day 7, only the CMC-GLY group demonstrated significant improvements from baseline in OSDI score (all patients p < 0.001, severe p < 0.001), corneal staining (p = 0.004), and TBUT (p < 0.001). Between-group dose frequency for CMC-GLY was lower at day 7 (p = 0.031). Other efficacy results were similar between groups. The most commonly reported adverse event in both groups was blurred vision. CONCLUSIONS Overall, the CMC-GLY artificial tear formulation was as effective as the CMC formulation. CMC-GLY demonstrated improvements at an earlier stage (day 7). Both artificial tear formulations were safe and well tolerated, with no treatment-related serious adverse events. These results support the use of the CMC-GLY artificial tear formulation as an effective treatment to reduce the symptoms and signs of dry eye disease.",2019,Between-group dose frequency for CMC-GLY was lower at day 7 (p = 0.031).,"['Patients were stratified by Ocular Surface Disease Index © (OSDI) score into moderate (23-32) and severe (> 32-65) subgroups', 'moderate to severe dry eye disease', '188 patients (94 CMC-GLY, 94 CMC) were enrolled', 'patients with moderate to severe dry eye at 10 US centers']","['enhanced viscosity artificial tear', 'glycerin 0.9% (CMC-GLY) with osmoprotectants, and a standard formula containing carboxymethylcellulose 1.0% alone (CMC', 'CMC-GLY or CMC']","['safe and well tolerated', 'corneal staining', 'OSDI score', 'OSDI scores', 'CMC-GLY', 'OSDI (primary efficacy variable), corneal and conjunctival staining, tear break-up time (TBUT), symptom surveys, and safety variables']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0314719', 'cui_str': 'Dry eyes (finding)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0591126', 'cui_str': 'AT 10'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C4301986', 'cui_str': 'Viscosity (property) (qualifier value)'}, {'cui': 'C2608262', 'cui_str': 'Lubricating Eye Drops'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C4068881', 'cui_str': 'Zero point nine'}, {'cui': 'C3853255', 'cui_str': 'Standard formula'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0007068', 'cui_str': 'thylose'}]","[{'cui': 'C0423232', 'cui_str': 'Corneal epithelial staining pattern (observable entity)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C3203718', 'cui_str': 'Conjunctival staining'}, {'cui': 'C0039409', 'cui_str': 'Tears'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",2.0,0.0551136,Between-group dose frequency for CMC-GLY was lower at day 7 (p = 0.031).,"[{'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Lievens', 'Affiliation': 'Southern College of Optometry, Memphis, TN, USA. Electronic address: clievens@sco.edu.'}, {'ForeName': 'Gregg', 'Initials': 'G', 'LastName': 'Berdy', 'Affiliation': 'Washington University School of Medicine, and Ophthalmology Associates, Saint Louis, MO, USA. Electronic address: gregg.berdy@youreyedoc.com.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Douglass', 'Affiliation': 'Eye Center Northeast, Bangor, ME, USA. Electronic address: drd@eyecenternortheast.com.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Montaquila', 'Affiliation': 'West Bay Eye Associates, Warwick, RI, USA. Electronic address: drmontaquila@westbayeye.com.'}, {'ForeName': 'Hugh', 'Initials': 'H', 'LastName': 'Lin', 'Affiliation': 'Allergan Clinical Research, Irvine, CA, USA. Electronic address: hughlin@gmail.com.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Simmons', 'Affiliation': 'Allergan Clinical Research, Irvine, CA, USA. Electronic address: pasimmons17@gmail.com.'}, {'ForeName': 'Cindy', 'Initials': 'C', 'LastName': 'Carlisle-Wilcox', 'Affiliation': 'Allergan Clinical Research, Irvine, CA, USA. Electronic address: Carlisle_Cindy@allergan.com.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Vehige', 'Affiliation': 'Allergan Clinical Research, Irvine, CA, USA. Electronic address: j.vehige@sbcglobal.net.'}, {'ForeName': 'Sameena', 'Initials': 'S', 'LastName': 'Haque', 'Affiliation': 'Allergan International Medical Affairs, Marlow, Buckinghamshire, UK. Electronic address: Haque_Sameena@allergan.com.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2018.12.003'] 3047,30578003,Impact of soft contact lenses on lid- parallel conjunctival folds.,"PURPOSE Lid-parallel conjunctival folds (LIPCOF) are related to dry eye symptoms and appear to be related to mechanical forces in blinks. The primary aim of this longitudinal, parallel group study was to investigate impact of contact lens wear (CLW) on LIPCOF and secondly the impact of contact lens wear on lid-wiper epitheliopathy (LWE) and dry eye symptoms. METHODS After a 2-week wash-out phase with a hydrogen peroxide care regimen, 30 experienced contact lens wearers (female: 25, male: 5; median age: 34.5 years) with at least LIPCOF Sum grade 1 (nasal + temporal LIPCOF, either eye) were randomised into three groups: one which discontinued CLW (SPEC), one which were refitted with senofilcon A two-weekly replacement daily wear silicone hydrogel (OAS) and one which continued to wear their habitual lenses (HCL). LIPCOF Sum and LWE were evaluated at the enrolment visit and over a period of 12 weeks. LIPCOF were classified by fold number using a four-grade scale. LWE was classified using a five-point scale after staining with lissamine green and fluorescein. Symptoms were evaluated with the Ocular Surface Disease Index (OSDI). RESULTS On enrolment, there were no differences between groups for LIPCOF Sum (median 2.0), LWE (1.0) and OSDI scores (12.5) (Kruskal-Wallis, p > 0.718). Median changes at 12-weeks follow-up compared to the enrolment visit were (HCL-group: 0.5, 0.0, 0.0; OAS-group: -1.0, -0.5, -10.42; SPEC-group: -0.5, -0.5, -5.21; LIPCOF, LWE and OSDI, respectively). LIPCOF (Friedman-Test, p = 0.178), LWE (p = 0.791) and OSDI (p = 0.874) were unaltered over the period of observation in the HCL group. LWE (p = 0.120) was unaltered in OAS group but LIPCOF (p = 0.001) and OSDI (p = 0.003) significantly improved. In the SPEC group LIPCOF (p = 0.031), LWE (p = 0.002) and OSDI (ANOVA repeated measurements, p = 0.034) changed significantly. CONCLUSIONS Refitting experienced CLW with senofilcon A daily wear, 2-week reusable contact lenses, or ceasing lens wear, improved LIPCOF, LWE and dryness symptoms.",2019,"LIPCOF (Friedman-Test, p = 0.178), LWE (p = 0.791) and OSDI (p = 0.874) were unaltered over the period of observation in the HCL group.","['30 experienced contact lens wearers (female: 25, male: 5; median age: 34.5 years) with at least LIPCOF Sum grade 1 (nasal\u2009+\u2009temporal LIPCOF, either eye']","['discontinued CLW (SPEC), one which were refitted with senofilcon A two-weekly replacement daily wear silicone hydrogel (OAS) and one which continued to wear their habitual lenses (HCL', 'contact lens wear (CLW', 'hydrogen peroxide care regimen', 'lissamine green and fluorescein', 'soft contact lenses', 'LWE', 'Lid-parallel conjunctival folds (LIPCOF']","['OSDI', 'Ocular Surface Disease Index (OSDI', 'LIPCOF Sum (median 2.0), LWE (1.0) and OSDI scores', 'LIPCOF Sum and LWE', 'LIPCOF', 'LWE', 'lid- parallel conjunctival folds', 'Median changes', 'LIPCOF, LWE and dryness symptoms']","[{'cui': 'C0920138', 'cui_str': 'Contact lens wearer'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C4520890', 'cui_str': 'Nasal'}, {'cui': 'C0442043', 'cui_str': 'Temporal (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C1706472', 'cui_str': 'Discontinue - dosing instruction imperative'}, {'cui': 'C2002497', 'cui_str': 'senofilcon A'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0037114', 'cui_str': 'Silicones'}, {'cui': 'C0063083', 'cui_str': 'Hydrogel, Polyethylene Glycol Dimethacrylate'}, {'cui': 'C0023318', 'cui_str': 'Lenses'}, {'cui': 'C0443985', 'cui_str': 'Flinders medical center-7 marker (substance)'}, {'cui': 'C0009836', 'cui_str': 'Contact Lenses'}, {'cui': 'C0020281', 'cui_str': 'Hydrogen Peroxide'}, {'cui': 'C0332583', 'cui_str': 'Green color (qualifier value)'}, {'cui': 'C0060520', 'cui_str': 'Fluorescein'}, {'cui': 'C0009838', 'cui_str': 'Soft Contact Lenses'}, {'cui': 'C0459665', 'cui_str': 'Structure of conjunctival fold'}]","[{'cui': 'C1557335', 'cui_str': 'Ocular surface disease'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0459665', 'cui_str': 'Structure of conjunctival fold'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",1.0,0.031495,"LIPCOF (Friedman-Test, p = 0.178), LWE (p = 0.791) and OSDI (p = 0.874) were unaltered over the period of observation in the HCL group.","[{'ForeName': 'Heiko', 'Initials': 'H', 'LastName': 'Pult', 'Affiliation': 'Dr. Heiko Pult - Optometry and Vision Research, Weinheim, Germany; Cardiff University, School of Optometry and Vision Sciences, Cardiff, UK; Ophthalmic Research Group, Life and Health Sciences, Aston University, Birmingham, UK. Electronic address: ovr@heiko-pult.de.'}, {'ForeName': 'Britta H', 'Initials': 'BH', 'LastName': 'Riede-Pult', 'Affiliation': 'Dr. Heiko Pult - Optometry and Vision Research, Weinheim, Germany.'}]",Contact lens & anterior eye : the journal of the British Contact Lens Association,['10.1016/j.clae.2018.12.005'] 3048,31350681,The use of mobile technology and peer navigation to promote adolescent and young adult (AYA) cancer survivorship care: results of a randomized controlled trial.,"PURPOSE Adolescent and young adult (AYA) cancer survivors experience unique barriers that compromise receipt of survivorship care; therefore, development of innovative educational interventions to improve rates of AYA survivorship care is needed. The efficacy of text-messaging and peer navigation interventions was compared to standard-of-care survivorship educational materials to increase AYAs' (1) late effects knowledge and (2) knowledge, attitudes, and self-efficacy towards seeking survivor-focused care. METHODS This was a three-armed, prospective, randomized controlled trial with one control group and two intervention groups. The control group received current standard-of-care educational materials. One intervention group participated in a text-messaging program, and the second participated in a peer navigator program. Participants completed pre- and post-intervention questionnaires. Study outcome variables were quantified using Fisher exact tests, two-sample t tests, exact McNemar tests, conditional logistic regression models, and analysis of covariance. RESULTS Seventy-one survivors completed the study (control n = 24; text-messaging n = 23; peer navigation n = 24). Late effects knowledge was high at baseline for all groups. The text-messaging group had increased survivorship care knowledge compared to the control group (p < 0.05); the peer navigation group had increased survivorship care self-efficacy compared to the control group; p < 0.05. Both intervention groups showed increased attitudes towards seeking survivor-focused care compared to the control group (text-messaging p < 0.05; peer navigation p < 0.05). CONCLUSIONS Each intervention demonstrated significant benefits compared to the control group. IMPLICATIONS FOR CANCER SURVIVORS Given the preliminary effectiveness of both interventions, each can potentially be used in the future by AYA cancer survivors to educate and empower them to obtain needed survivorship care.",2019,The text-messaging group had increased survivorship care knowledge compared to the control group (p < 0.05); the peer navigation group had increased survivorship care self-efficacy compared to the control group; p < 0.05.,"['FOR CANCER SURVIVORS', 'Adolescent and young adult (AYA) cancer survivors', 'adolescent and young adult (AYA) cancer survivorship care']","['mobile technology and peer navigation', 'current standard-of-care educational materials', 'text-messaging and peer navigation interventions', 'text-messaging program, and the second participated in a peer navigator program']","['survivorship care knowledge', 'attitudes towards seeking survivor-focused care', ' (1) late effects knowledge and (2) knowledge, attitudes, and self-efficacy', 'survivorship care self-efficacy']","[{'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0038955'}]","[{'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C2936643', 'cui_str': 'Standard of Care'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}]","[{'cui': 'C0038955'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C1368999', 'cui_str': 'Late effect of'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}]",71.0,0.0304395,The text-messaging group had increased survivorship care knowledge compared to the control group (p < 0.05); the peer navigation group had increased survivorship care self-efficacy compared to the control group; p < 0.05.,"[{'ForeName': 'Jacqueline N', 'Initials': 'JN', 'LastName': 'Casillas', 'Affiliation': 'Department of Pediatrics, Division of Hematology/Oncology, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, A2-410 MDCC, Los Angeles, CA, 90095-1752, USA. jcasillas@mednet.ucla.edu.'}, {'ForeName': 'Lindsay F', 'Initials': 'LF', 'LastName': 'Schwartz', 'Affiliation': 'Department of Pediatrics, Division of Hematology/Oncology, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, A2-410 MDCC, Los Angeles, CA, 90095-1752, USA.'}, {'ForeName': 'Catherine M', 'Initials': 'CM', 'LastName': 'Crespi', 'Affiliation': 'Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.'}, {'ForeName': 'Patricia A', 'Initials': 'PA', 'LastName': 'Ganz', 'Affiliation': 'Center for Cancer Prevention and Control Research, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.'}, {'ForeName': 'Katherine L', 'Initials': 'KL', 'LastName': 'Kahn', 'Affiliation': 'Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.'}, {'ForeName': 'Margaret L', 'Initials': 'ML', 'LastName': 'Stuber', 'Affiliation': 'Department of Psychiatry, Resnick Neuropsychiatric Hospital, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.'}, {'ForeName': 'Roshan', 'Initials': 'R', 'LastName': 'Bastani', 'Affiliation': 'Center for Cancer Prevention and Control Research, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.'}, {'ForeName': 'Faisal', 'Initials': 'F', 'LastName': 'Alquaddomi', 'Affiliation': 'Department of Computer Science, Cornell University, New York, NY, USA.'}, {'ForeName': 'Deborah L', 'Initials': 'DL', 'LastName': 'Estrin', 'Affiliation': 'Department of Computer Science, Cornell University, New York, NY, USA.'}]",Journal of cancer survivorship : research and practice,['10.1007/s11764-019-00777-7'] 3049,32071329,A cluster-randomized trial of the effectiveness of a triple-faceted intervention promoting adherence to primary care physician visits by diabetes patients.,"We aimed to assess whether a triple-faceted intervention program administered in the primary care setting could decrease the risk of insufficient adherence to primary care physician (PCP) appointments among this patient population. We conducted a cluster-randomized controlled study to assess the effects of a 1-year intervention. The primary outcome was insufficient adherence to regular PCP attendance for diabetes treatment, defined as failure to visit a PCP within 2 months of an original appointment date. The intervention consisted of mailing patient reminders of their PCP appointments, providing patients with health education aimed at lifestyle modification and benchmarking PCP procedures. Eleven municipal level district medical associations employing 192 PCPs were divided into two subregions for assignment to intervention and control clusters, with 971 and 1,265 patients assigned to the intervention and control groups, respectively. Primary outcome data were available for 2,200 patients. The intervention reduced insufficient adherence to regular PCP appointments by 63% (hazard ratio, 0.37; 95% confidence interval [CI], 0.23-0.58). In conclusion, a triple-faceted intervention program consisting of health education, appointment reminders, and physician benchmarking may decrease the risk of incomplete adherence to regular PCP appointments by diabetes patients.",2020,"The intervention reduced insufficient adherence to regular PCP appointments by 63% (hazard ratio, 0.37; 95% confidence interval [CI], 0.23-0.58).","['primary care physician (PCP) appointments among this patient population', 'primary care physician visits by diabetes patients', 'Eleven municipal level district medical associations employing 192 PCPs']","['mailing patient reminders of their PCP appointments, providing patients with health education aimed at lifestyle modification and benchmarking PCP procedures', 'triple-faceted intervention', 'triple-faceted intervention program']","['insufficient adherence to regular PCP attendance for diabetes treatment, defined as failure to visit a PCP within 2 months of an original appointment date']","[{'cui': 'C0033131', 'cui_str': 'Primary Care Physicians'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0557351', 'cui_str': 'Employed (finding)'}, {'cui': 'C4517623', 'cui_str': '192'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}]","[{'cui': 'C0024492', 'cui_str': 'Mail'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0018701'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0332225', 'cui_str': 'Faceted (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0231180', 'cui_str': 'Insufficient'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205313', 'cui_str': 'Original (qualifier value)'}, {'cui': 'C0585085', 'cui_str': 'Appointment date (finding)'}]",192.0,0.0817496,"The intervention reduced insufficient adherence to regular PCP appointments by 63% (hazard ratio, 0.37; 95% confidence interval [CI], 0.23-0.58).","[{'ForeName': 'Mitsuhiko', 'Initials': 'M', 'LastName': 'Noda', 'Affiliation': 'Department of Diabetes, Metabolism and Endocrinology, Ichikawa Hospital, International University of Health and Welfare, 6-1-14 Kounodai, Ichikawa, Chiba, Japan. noda-m@iuhw.ac.jp.'}, {'ForeName': 'Yasuaki', 'Initials': 'Y', 'LastName': 'Hayashino', 'Affiliation': 'Department of Endocrinology, Tenri Hospital, 200 Mishimacho, Tenri, Nara, Japan.'}, {'ForeName': 'Katsuya', 'Initials': 'K', 'LastName': 'Yamazaki', 'Affiliation': 'First Department of Internal Medicine, Faculty of Medicine, Toyama University, 2630 Sugitani, Toyama, Toyama, Japan.'}, {'ForeName': 'Hikari', 'Initials': 'H', 'LastName': 'Suzuki', 'Affiliation': 'First Department of Internal Medicine, Faculty of Medicine, Toyama University, 2630 Sugitani, Toyama, Toyama, Japan.'}, {'ForeName': 'Atsushi', 'Initials': 'A', 'LastName': 'Goto', 'Affiliation': 'Diabetes Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Masayuki', 'Initials': 'M', 'LastName': 'Kato', 'Affiliation': 'Toranomon Hospital Health Management Center and Diagnostic Imaging Center, 2-2-2 Toranomon, Minato-ku, Tokyo, Japan.'}, {'ForeName': 'Kazuo', 'Initials': 'K', 'LastName': 'Izumi', 'Affiliation': 'Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan.'}, {'ForeName': 'Masashi', 'Initials': 'M', 'LastName': 'Kobayashi', 'Affiliation': 'First Department of Internal Medicine, Faculty of Medicine, Toyama University, 2630 Sugitani, Toyama, Toyama, Japan.'}]",Scientific reports,['10.1038/s41598-020-59588-x'] 3050,31396891,Influence of Postoperative Posture on Macular Slippage after Macula-Off Retinal Detachment: A Randomized Controlled Trial.,"INTRODUCTION To evaluate the effect of postoperative posture on the retinal shift after retinal detachment repair. METHODS Patients who underwent pars plana vitrectomy (PPV) for macula-off rhegmatogenous retinal detachment (RRD) were included prospectively in the current study. Patients were randomized into two groups: group A included patients who did a log roll postoperatively, and group B included patients who had to lie flat on their backs for 6 h postoperatively before moving into the end position. Patients in group A and patients in group B were reviewed after 3 weeks and after 6 weeks, respectively, and fundus autofluorescence images (FAF) were obtained to visualize the retinal rotation. RESULTS The sample included 50 eyes from 49 patients. Retinal shift occurred after RRD repair in 17 patients (34%). There was no statistically significant difference between the two groups (p = 0.94). Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure. Metamorphopsia was reported postoperatively by 10 of 17 patients with retinal shift (p < 0.001). CONCLUSION In our study, postoperative posture did not significantly influence postoperative macular slippage after RRD repair. The use of intraoperative heavy liquid appears to be associated with a lower occurrence of retinal shift.",2019,Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure.,"['for macula-off rhegmatogenous retinal detachment (RRD', 'Patients who underwent', 'Macular Slippage after Macula-Off Retinal Detachment', 'The sample included 50 eyes from 49 patients']","['Postoperative Posture', 'postoperative posture', 'pars plana vitrectomy (PPV']","['Metamorphopsia', 'Retinal shift', 'Postoperative macular shift']","[{'cui': 'C0332573', 'cui_str': 'Macule (morphologic abnormality)'}, {'cui': 'C0271055', 'cui_str': 'Rhegmatogenous retinal detachment (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035305', 'cui_str': 'Retinal Detachment'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C1262869', 'cui_str': 'Posture'}, {'cui': 'C0042903', 'cui_str': 'Vitrectomy'}]","[{'cui': 'C0271185', 'cui_str': 'Metamorphopsia'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",50.0,0.053386,Postoperative macular shift occurred significantly less often (p  = 0.049) in participants in whom heavy fluid was used in the procedure.,"[{'ForeName': 'Megir', 'Initials': 'M', 'LastName': 'Schawkat', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Valmaggia', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Corina', 'Initials': 'C', 'LastName': 'Lang', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland.'}, {'ForeName': 'Hendrik P N', 'Initials': 'HPN', 'LastName': 'Scholl', 'Affiliation': 'Institute of Molecular and Clinical Ophthalmology Basel (IOB), Basel, Switzerland.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Harsum', 'Affiliation': 'Epsom and St Helier University Hospitals, NHS Trust, London, UK.'}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Guber', 'Affiliation': 'Department of Ophthalmology, University of Geneva, Geneva, Switzerland.'}, {'ForeName': 'Josef', 'Initials': 'J', 'LastName': 'Guber', 'Affiliation': 'Eye Clinic, Cantonal Hospital Sankt Gallen, St. Gallen, Switzerland. josef.guber@kssg.ch.'}]",Ophthalmology and therapy,['10.1007/s40123-019-0204-8'] 3051,31219771,Sex differences in blood pressure regulation during ischemic isometric exercise: the role of the β-adrenergic receptors.,"We sought to investigate whether the β-adrenergic receptors play a pivotal role in sex-related differences in arterial blood pressure (BP) regulation during isometric exercise. Sixteen volunteers (8 women) performed 2 min of ischemic isometric handgrip exercise (IHE) and 2 min of postexercise circulatory occlusion (PECO). Heart rate (HR) and beat-to-beat arterial BP were continuously measured. Beat-to-beat estimates of stroke volume (ModelFlow) were obtained and matched with HR to calculate cardiac output (Q̇) and total peripheral resistance (TPR). Two trials were randomly conducted between placebo and nonselective β-adrenergic blockade (40 mg propranolol). Under the placebo condition, the magnitude of the BP response in IHE was lower in women compared with men. During PECO, the BP remained elevated and the sex differences persisted. The β-blockade attenuated the BP response during IHE in men (∆57 ± 4 vs. ∆45 ± 7 mmHg, P = 0.025) due to a reduction in Q̇ (∆3.7 ± 0.5 vs. ∆1.8 ± 0.2 L/min, P = 0.012) while TPR was not affected. In women, however, the BP response during IHE was unchanged (∆27 ± 3 vs. ∆28 ± 3 mmHg, P = 0.889), despite attenuated Q̇ (∆2.7 ± 0.4 vs. ∆1.3 ± 0.2 L/min, P = 0.012). These responses were mediated by a robust increase in TPR under β-blockade (∆-0.2 ± 0.4 vs. ∆2.2 ± 0.7 mmHg·L -1 ·min, P = 0.012). These findings demonstrate that the sex differences in arterial BP regulation during ischemic IHE are mediated by β-adrenergic receptors. NEW & NOTEWORTHY We found that the blood pressure response during isometric exercise in women is mediated by increases in cardiac output, whereas in men it is mediated by increases in both cardiac output and total peripheral resistance. In addition, women showed a robust increase in total peripheral resistance under β-blockade during isometric exercise and muscle metaboreflex activation. These findings demonstrate that sex differences in blood pressure regulation during isometric exercise are mediated by β-adrenergic receptors.",2019,These responses were mediated by a robust increase in TPR under β-blockade,['Sixteen volunteers (8 women'],"['placebo and non-selective β-adrenergic blockade (40mg propranolol', 'ischemic isometric handgrip exercise (IHE) and 2 min of post exercise circulatory occlusion (PECO', 'l/min vs ∆', 'L-1.min']","['Blood Pressure Regulation', 'arterial blood pressure (BP) regulation', 'arterial BP regulation', 'cardiac output (Q̇) and total peripheral resistance (TPR', 'Heart rate (HR) and beat-to-beat arterial BP', 'BP response in IHE', 'BP response', 'BP response during IHE', 'TPR under β-blockade']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0001637', 'cui_str': 'Adrenergic Drugs'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0033497', 'cui_str': 'Propranolol'}, {'cui': 'C0475224', 'cui_str': 'Ischemic (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1979962', 'cui_str': 'After exercise (qualifier value)'}, {'cui': 'C0441597', 'cui_str': 'Occlusion - action (qualifier value)'}, {'cui': 'C0439393', 'cui_str': 'liter/minute'}]","[{'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C1272641', 'cui_str': 'Arterial Tension'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C1258192', 'cui_str': 'Total Peripheral Resistance'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}]",16.0,0.122915,These responses were mediated by a robust increase in TPR under β-blockade,"[{'ForeName': 'Milena', 'Initials': 'M', 'LastName': 'Samora', 'Affiliation': 'NeuroV̇ASQ̇-Integrative Physiology Laboratory, Faculty of Physical Education, University of Brasília, Brasilia, Distrito Federal, Brazil.'}, {'ForeName': 'Anthony V', 'Initials': 'AV', 'LastName': 'Incognito', 'Affiliation': 'NeuroV̇ASQ̇-Integrative Physiology Laboratory, Faculty of Physical Education, University of Brasília, Brasilia, Distrito Federal, Brazil.'}, {'ForeName': 'Lauro C', 'Initials': 'LC', 'LastName': 'Vianna', 'Affiliation': 'NeuroV̇ASQ̇-Integrative Physiology Laboratory, Faculty of Physical Education, University of Brasília, Brasilia, Distrito Federal, Brazil.'}]","Journal of applied physiology (Bethesda, Md. : 1985)",['10.1152/japplphysiol.00270.2019'] 3052,30945515,Postoperative analgesia and early functional recovery after day-case anterior cruciate ligament reconstruction: a randomized trial on local anesthetic delivery methods for continuous infusion adductor canal block.,"BACKGROUND This study assessed the effects of different local anesthetic delivery techniques for continuous adductor canal block, after arthroscopic day-case anterior cruciate ligament reconstruction (ACLR). METHODS We enrolled 80 patients to randomly receive a ropivacaine 0.2% infusion 6 mL per hour through an adductor canal catheter by an electronic pump as follow: intermittent automatic bolus (intermittent group, N.=40) versus continuous infusion (continuous group, N.=40). Patient controlled bolus was 4 mL, lock out 20 minutes. Primary endpoint was postoperative pain by a numerical rating scale (NRS), secondary endpoints were rescue local anesthetic dose, opioid consumption, and physical performance at 72 h. A P<0.05 was considered significant. RESULTS No difference was found between the groups in NRS, opioid consumption, and physical performance at 72 h. The intermittent group required significantly less local anesthetic than continuous group throughout the postoperative period; the median [IQR (range)] at 24 h was 149 [140-164 (140-227)] mL in the intermittent group versus 165 [147-210 (140-280)] mL in the continuous group (P=0.004). At 48 h it was 295 [284-310 (280-367)] mL in the intermittent group versus 308 [296-367 (284-500)] mL in the continuous group (P=0.002), while at 72 h it was 432 [426-450 (320-528)] mL in the intermittent group and 452 [436-487 (412-671)] mL in the continuous group respectively (P<0.001). CONCLUSIONS Intermittent boluses did not provide superior analgesia over continuous infusion for adductor canal block after outpatient ACLR, but significantly decreased the local anesthetic consumption. Both techniques are suitable for the early functional recovery.",2019,"No difference was found between the groups in NRS, opioid consumption, and physical performance at 72h.","['after day-case anterior cruciate ligament reconstruction', 'At 48h it was 295 [284-310 (280-367']","['ropivacaine 0.2% infusion 6 ml per hour through an adductor canal catheter by an electronic pump as follow: intermittent automatic bolus (intermittent group', 'arthroscopic day-case anterior cruciate ligament reconstruction (ACLR']","['Postoperative analgesia and early functional recovery', 'postoperative pain by a numerical rating scale (NRS), secondary endpoints were rescue local anaesthetic dose, opioid consumption, and physical performance at 72h', 'NRS, opioid consumption, and physical performance', 'local anaesthetic', 'local anaesthetic consumption']","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C4517436', 'cui_str': '0.2'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0564385', 'cui_str': 'per hour'}, {'cui': 'C0225273', 'cui_str': 'Structure of adductor canal'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0205267', 'cui_str': 'Intermittent (qualifier value)'}, {'cui': 'C0205554', 'cui_str': 'Automated (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C3178820', 'cui_str': 'Anterior Cruciate Ligament Reconstruction'}]","[{'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0030201', 'cui_str': 'Pain, Postoperative'}, {'cui': 'C0222045'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0002934', 'cui_str': 'Conduction-Blocking Anesthetics'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C2607857'}]",80.0,0.0701864,"No difference was found between the groups in NRS, opioid consumption, and physical performance at 72h.","[{'ForeName': 'Andrea L', 'Initials': 'AL', 'LastName': 'Ambrosoli', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Palliative Care, ASST Sette laghi, Varese, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Guzzetti', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Palliative Care, ASST Sette laghi, Varese, Italy.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Severgnini', 'Affiliation': 'Unit of Anesthesia and Intensive Care, University of Insubria, Varese, Italy.'}, {'ForeName': 'Luisa L', 'Initials': 'LL', 'LastName': 'Fedele', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Palliative Care, ASST Sette laghi, Varese, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Musella', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Palliative Care, ASST Sette laghi, Varese, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Crespi', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Palliative Care, ASST Sette laghi, Varese, Italy.'}, {'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Novario', 'Affiliation': 'Department of Clinical Sciences, University of Insubria, Varese, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Cappelleri', 'Affiliation': 'Unit of Anesthesia, Intensive Care and Pain Therapy, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy - kappe@hotmail.com.'}]",Minerva anestesiologica,['10.23736/S0375-9393.19.13474-8'] 3053,32081901,The effects of NMDA receptor blockade on TMS-evoked EEG potentials from prefrontal and parietal cortex.,"Measuring the brain's response to transcranial magnetic stimulation (TMS) with electroencephalography (EEG) offers unique insights into the cortical circuits activated following stimulation, particularly in non-motor regions where less is known about TMS physiology. However, the mechanisms underlying TMS-evoked EEG potentials (TEPs) remain largely unknown. We assessed TEP sensitivity to changes in excitatory neurotransmission mediated by n-methyl-d-aspartate (NMDA) receptors following stimulation of non-motor regions. In fourteen male volunteers, resting EEG and TEPs from prefrontal (PFC) and parietal (PAR) cortex were measured before and after administration of either dextromethorphan (NMDA receptor antagonist) or placebo across two sessions in a double-blinded pseudo-randomised crossover design. At baseline, there were amplitude differences between PFC and PAR TEPs across a wide time range (15-250 ms), however the signals were correlated after ~80 ms, suggesting early peaks reflect site-specific activity, whereas late peaks reflect activity patterns less dependent on the stimulated sites. Early TEP peaks were not reliably altered following dextromethorphan compared to placebo, although findings were less clear for later peaks, and low frequency resting oscillations were reduced in power. Our findings suggest that early TEP peaks (<80 ms) from PFC and PAR reflect stimulation site specific activity that is largely insensitive to changes in NMDA receptor-mediated neurotransmission.",2020,"Early TEP peaks were not reliably altered following dextromethorphan compared to placebo, although findings were less clear for later peaks, and low frequency resting oscillations were reduced in power.",['fourteen male volunteers'],"['NMDA receptor blockade', 'transcranial magnetic stimulation (TMS) with electroencephalography (EEG', 'placebo', 'dextromethorphan (NMDA receptor antagonist) or placebo', 'dextromethorphan']","['resting EEG and TEPs from prefrontal (PFC) and parietal (PAR) cortex', 'Early TEP peaks']","[{'cui': 'C3715152', 'cui_str': '14'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0080093', 'cui_str': 'N-Methyl-D-Aspartate Receptors'}, {'cui': 'C3540676', 'cui_str': 'Blockade'}, {'cui': 'C0436548', 'cui_str': 'Transcranial magnetic stimulation (procedure)'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0011816', 'cui_str': 'Dextromethorphan'}, {'cui': 'C0598695', 'cui_str': 'NMDA receptor antagonist'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0013819', 'cui_str': 'EEG'}, {'cui': 'C0145334', 'cui_str': 'Pyrazine, tetraethyl-'}, {'cui': 'C0030560', 'cui_str': 'Parietal Cortex'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",14.0,0.0877341,"Early TEP peaks were not reliably altered following dextromethorphan compared to placebo, although findings were less clear for later peaks, and low frequency resting oscillations were reduced in power.","[{'ForeName': 'Nigel C', 'Initials': 'NC', 'LastName': 'Rogasch', 'Affiliation': 'Brain, Mind and Society Research Hub, School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia. nigel.rogasch@monash.edu.'}, {'ForeName': 'Carl', 'Initials': 'C', 'LastName': 'Zipser', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Ghazaleh', 'Initials': 'G', 'LastName': 'Darmani', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Tuomas P', 'Initials': 'TP', 'LastName': 'Mutanen', 'Affiliation': 'Centre for Cognitive Neuroimaging, Institute of Neuroscience and Psychology, University of Glasgow, Glasgow, United Kingdom.'}, {'ForeName': 'Mana', 'Initials': 'M', 'LastName': 'Biabani', 'Affiliation': 'Brain, Mind and Society Research Hub, School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Zrenner', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Debora', 'Initials': 'D', 'LastName': 'Desideri', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Belardinelli', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Müller-Dahlhaus', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Ziemann', 'Affiliation': 'Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.'}]",Scientific reports,['10.1038/s41598-020-59911-6'] 3054,32081945,Effect of manual approaches with osteopathic modality on brain correlates of interoception: an fMRI study.,"The present randomised placebo controlled trial explored the extent to which osteopathic manipulative treatment (OMT) affects brain activity, particularly the insula, during both an ""interoceptive awareness"" and ""exteroceptive awareness"" task in a sample of 32 right-handed adults with chronic Low Back Pain (CLBP) randomly assigned to either the OMT or sham group. Patients received 4 weekly sessions and fMRI was performed at enrolment (T0), immediately after the first session (T1) and at 1 month (T2). The results revealed that the OMT produced a distinct and specific reduction in BOLD response in specific brain areas related to interoception, i.e., bilateral insula, ACC, left striatum and rMFG. The observed trend across the three time points appears uncharacteristic. At T1, a marginal increase of the BOLD response was observed in all the above-mentioned areas except the rMFG, which showed a decrease in BOLD response. At T2, the response was the opposite: areas related to interoception (bilateral insula and ACC) as well as the rMFG and left striatum demonstrated significant decreased in BOLD response. The findings of this study provide an insight into the effects of manual therapies on brain activity and have implications for future research in the field.",2020,"The results revealed that the OMT produced a distinct and specific reduction in BOLD response in specific brain areas related to interoception, i.e., bilateral insula, ACC, left striatum and rMFG.",['32 right-handed adults with chronic Low Back Pain (CLBP'],"['placebo', 'OMT', 'manual approaches with osteopathic modality', 'osteopathic manipulative treatment (OMT']","['brain correlates of interoception', 'BOLD response']","[{'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0175674', 'cui_str': 'Manual (qualifier value)'}, {'cui': 'C1292724', 'cui_str': 'Procedure approach'}, {'cui': 'C0949744', 'cui_str': 'Osteopathic Manipulative Treatment'}]","[{'cui': 'C0006104', 'cui_str': 'Encephalon'}, {'cui': 'C3850156', 'cui_str': 'Interoception'}]",32.0,0.024855,"The results revealed that the OMT produced a distinct and specific reduction in BOLD response in specific brain areas related to interoception, i.e., bilateral insula, ACC, left striatum and rMFG.","[{'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Cerritelli', 'Affiliation': 'Department of Neuroscience, Imaging and Clinical Sciences, ""G. D\'Annunzio"" University of Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Chiacchiaretta', 'Affiliation': 'Department of Neuroscience, Imaging and Clinical Sciences, ""G. D\'Annunzio"" University of Chieti-Pescara, Chieti, Italy. p.chiacchiaretta@unich.it.'}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Gambi', 'Affiliation': 'Department of Neuroscience, Imaging and Clinical Sciences, ""G. D\'Annunzio"" University of Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Mauro Gianni', 'Initials': 'MG', 'LastName': 'Perrucci', 'Affiliation': 'Department of Neuroscience, Imaging and Clinical Sciences, ""G. D\'Annunzio"" University of Chieti-Pescara, Chieti, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Barassi', 'Affiliation': 'Department of Medical Oral and Biotechnological Science, ""Gabriele d\'Annunzio"" University, Chieti-Pescara, Italy.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Visciano', 'Affiliation': 'Department of Medical Oral and Biotechnological Science, ""Gabriele d\'Annunzio"" University, Chieti-Pescara, Italy.'}, {'ForeName': 'Rosa Grazia', 'Initials': 'RG', 'LastName': 'Bellomo', 'Affiliation': ""Department of Biomolecular Sciences, 'Carlo Bo' University, Urbino, Italy.""}, {'ForeName': 'Raoul', 'Initials': 'R', 'LastName': 'Saggini', 'Affiliation': 'Department of Medical Oral and Biotechnological Science, ""Gabriele d\'Annunzio"" University, Chieti-Pescara, Italy.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Ferretti', 'Affiliation': 'Department of Neuroscience, Imaging and Clinical Sciences, ""G. D\'Annunzio"" University of Chieti-Pescara, Chieti, Italy.'}]",Scientific reports,['10.1038/s41598-020-60253-6'] 3055,31373615,Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China.,"BACKGROUND Previous mass screening studies have shown that IgA antibodies against Epstein-Barr Virus (EBV) can facilitate early detection of nasopharyngeal carcinoma (NPC), but the impact of EBV-antibody screening for NPC-specific mortality remains unknown. PATIENTS AND METHODS A prospective, cluster randomized, controlled trial for NPC screening (PRO-NPC-001) was conducted in 3 selected towns of Zhongshan City and 13 selected towns of Sihui City in southern China beginning in 2008. Serum samples of the screening group were tested for two previously selected anti-EBV antibodies. Subjects with serological medium risk were subsequently retested annually for 3 years, and those with serological high risk were referred to otorhinolaryngologists for diagnostic check-up. An interim analysis was carried out to evaluate the primary end points of the NPC-specific mortality and the early diagnostic rate, and the secondary end point of the NPC incidence, through linkage with the database of Zhongshan City. RESULTS Among 70 296 total subjects, 29 413 screened participants (41.8% of the total subjects) in the screening group and 50 636 in the control group, 153 (43.3 per 100 000 person-year), 62 (55.3 per 100 000 person-year) and 99 (33.1 per 100 000 person-year) NPC cases were identified. The early diagnostic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%). Although no differences were found between NPC-specific mortality of the screening group and the control group [relative risk (RR)= 0.82, 95% confidence interval (CI) 0.37-1.79], lower NPC-specific mortality was noticed among participants from the screening group versus the control group (RR = 0.22, 95% CI 0.09-0.49). CONCLUSION IgA antibodies against EBV can identify high-risk population and was effective in screening for early asymptomatic NPC. Although the mortality reduction was not significant in the primary end point, we noted encouraging evidence of a mortality reduction in screening participants in this interim analysis. CLINICAL TRIAL NUMBER NCT00941538.",2019,"The early diagnositic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%).","['southern China', '3 selected towns of Zhongshan City and 13 selected towns of Sihui City in southern China beginning in 2008', '70,296 total subjects, 29,413 screened participants (41.8% of the total subjects) in the screening group and 50,636 in the control group, 153 (43.3 per 100,000 person-year), 62 (55.3 per 100,000 person-year) and 99 (33.1 per 100,000 person-year) NPC cases were identified', 'Subjects with serological medium risk were subsequently retested annually for three years, and those with serological high risk were referred to otorhinolaryngologists for diagnostic check-up']",['NPC screening (PRO-NPC-001'],"['Incidence and mortality of nasopharyngeal carcinoma', 'NPC-specific mortality', 'lower NPC-specific mortality', 'NPC-specific mortality and the early disgnositic rate', 'early diagnositic rates of NPC', 'mortality reduction']","[{'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0557750', 'cui_str': 'Towns'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0205473', 'cui_str': 'Serologic (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0334893', 'cui_str': 'Otorhinolaryngologist (occupation)'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}]","[{'cui': 'C0220908', 'cui_str': 'Screening'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C2931822', 'cui_str': 'Nasopharyngeal carcinoma (disorder)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]",,0.198412,"The early diagnositic rates of NPC were significantly higher in the participants (79.0%, P < 0.0001) and the screening group (45.9%, P < 0.0001) compared with the control group (20.6%).","[{'ForeName': 'M F', 'Initials': 'MF', 'LastName': 'Ji', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Sheng', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China.""}, {'ForeName': 'W M', 'Initials': 'WM', 'LastName': 'Cheng', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Ng', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China.""}, {'ForeName': 'B H', 'Initials': 'BH', 'LastName': 'Wu', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'X', 'Initials': 'X', 'LastName': 'Yu', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'K R', 'Initials': 'KR', 'LastName': 'Wei', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'F G', 'Initials': 'FG', 'LastName': 'Li', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'S F', 'Initials': 'SF', 'LastName': 'Lian', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'P P', 'Initials': 'PP', 'LastName': 'Wang', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'W', 'Initials': 'W', 'LastName': 'Quan', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Deng', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'X H', 'Initials': 'XH', 'LastName': 'Li', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'X D', 'Initials': 'XD', 'LastName': 'Liu', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'Y L', 'Initials': 'YL', 'LastName': 'Xie', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'S J', 'Initials': 'SJ', 'LastName': 'Huang', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China.""}, {'ForeName': 'S X', 'Initials': 'SX', 'LastName': 'Ge', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China.""}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Huang', 'Affiliation': ""Xiaolan Public Health Service Center, Zhongshan, People's Republic of China.""}, {'ForeName': 'X J', 'Initials': 'XJ', 'LastName': 'Liang', 'Affiliation': ""Xiaolan Public Health Service Center, Zhongshan, People's Republic of China.""}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'He', 'Affiliation': ""Xiaolan People's Hospital of Zhongshan City, Zhongshan, People's Republic of China.""}, {'ForeName': 'H W', 'Initials': 'HW', 'LastName': 'Huang', 'Affiliation': ""Chen Xinhai Hospital of Xiaolan, Zhongshan, People's Republic of China.""}, {'ForeName': 'S L', 'Initials': 'SL', 'LastName': 'Xia', 'Affiliation': ""Zhongshan Center for Disease Control and Prevention, Zhongshan, People's Republic of China.""}, {'ForeName': 'P S', 'Initials': 'PS', 'LastName': 'Ng', 'Affiliation': 'State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong, SAR.'}, {'ForeName': 'H L', 'Initials': 'HL', 'LastName': 'Chen', 'Affiliation': 'State Key Laboratory for Emerging Infectious Diseases, Department of Microbiology and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong, SAR.'}, {'ForeName': 'S H', 'Initials': 'SH', 'LastName': 'Xie', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Department of Epidemiology, Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.""}, {'ForeName': 'Q', 'Initials': 'Q', 'LastName': 'Liu', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Department of Epidemiology, Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.""}, {'ForeName': 'M H', 'Initials': 'MH', 'LastName': 'Hong', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Department of Epidemiology, Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Department of Epidemiology, Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.""}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Yuan', 'Affiliation': ""Cancer Research Institute of Zhongshan City, Zhongshan Hospital of Sun Yat-sen University, Zhongshan, People's Republic of China.""}, {'ForeName': 'N S', 'Initials': 'NS', 'LastName': 'Xia', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China.""}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': ""State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biological Products, School of Public Health, Xiamen University, Xiamen, People's Republic of China. Electronic address: zhangj@xmu.edu.cn.""}, {'ForeName': 'S M', 'Initials': 'SM', 'LastName': 'Cao', 'Affiliation': ""State Key Laboratory of Oncology in Southern China, Department of Epidemiology, Cancer Prevention Center, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China. Electronic address: caosm@sysucc.org.cn.""}]",Annals of oncology : official journal of the European Society for Medical Oncology,['10.1093/annonc/mdz231'] 3056,32101630,Effects of a lifestyle development program designed to reduce the risk factors for cognitive decline on the mental health of elderly individuals.,"BACKGROUND The incidence of Alzheimer's disease (AD) along with depression is high in the elderly. In the present study, a program that allows the elderly individuals to voluntarily manage and develop lifestyles that may reduce the risk factors for cognitive decline was applied to the participants to evaluate its effect on the mental health of these individuals. METHODS The participants were randomly assigned to an intervention group and a control group. The program was conducted during 7 months in the intervention group, and it had seven times of group activities, performed once a month for about 1 h, and individual activities to reduce the risk factors for cognitive decline, performed every day. To evaluate the effects of the program on the mental health of the participants, the Geriatric Depression Scale (GDS) and Philadelphia Geriatric Center Morale Scale (PGC) were used. These two scales were applied twice to the intervention and control groups. RESULTS The GDS score revealed no change in the score in the intervention group before and after the 7-month program implementation; however, in the control group, the score was significantly higher after program implementation than that before. The PGC score revealed no change in the intervention group before and after 7-month program implementation; however, in the control group, the score was significantly lower after program implementation than that before. Additionally, it revealed no change in the GDS score in the depression-prone control group before and after 7-month program implementation; however, in the depression-prone intervention group, the GDS score was significantly lower after program implementation than that before. CONCLUSIONS The intervention program that allows the elderly individuals to voluntarily manage and develop lifestyles that may reduce the risk factors for cognitive decline is expected to maintain mental health in elderly individuals.",2020,"The GDS score revealed no change in the score in the intervention group before and after the 7-month program implementation; however, in the control group, the score was significantly higher after program implementation than that before.",['elderly individuals'],['lifestyle development program'],"['GDS score', 'PGC score', 'Geriatric Depression Scale (GDS) and Philadelphia Geriatric Center Morale Scale (PGC']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0451184', 'cui_str': 'Geriatric depression scale (assessment scale)'}, {'cui': 'C0451377', 'cui_str': 'Philadelphia geriatric center morale scale (assessment scale)'}]",,0.0147637,"The GDS score revealed no change in the score in the intervention group before and after the 7-month program implementation; however, in the control group, the score was significantly higher after program implementation than that before.","[{'ForeName': 'Shinya', 'Initials': 'S', 'LastName': 'Takeda', 'Affiliation': 'Department of Clinical Psychology, Tottori University Graduate School of Medical Sciences, Tottori, Japan.'}, {'ForeName': 'Haruhiko', 'Initials': 'H', 'LastName': 'Fukushima', 'Affiliation': 'Yonago Health Cooperative, Tottori, Japan.'}, {'ForeName': 'Chihiro', 'Initials': 'C', 'LastName': 'Okamoto', 'Affiliation': 'Tottori Health Cooperative, Tottori, Japan.'}, {'ForeName': 'Yasushi', 'Initials': 'Y', 'LastName': 'Kitawaki', 'Affiliation': 'Tottori Health Cooperative, Tottori, Japan.'}, {'ForeName': 'Shigeki', 'Initials': 'S', 'LastName': 'Nakayama', 'Affiliation': 'National Institute of Technology, Yonago College, Tottori, Japan.'}]",Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society,['10.1111/psyg.12538'] 3057,31391739,Evaluate the Feasibility of Surgical Transversus Abdominis Plane Block for Postoperative Analgesia After Cesarean Section.,"Background Transversus abdominis plane (TAP) block is a fascial plane block providing postoperative analgesia after lower abdominal surgeries including Cesarean section. Conventionally, it is administered under ultrasound guidance or by blind technique. We studied a novel transperitoneal surgical TAP block for providing safe and effective analgesia after Cesarean section through transverse incision. Methods A hundred patients who fulfilled the inclusion criteria were included in the study after obtaining informed written consent. They were randomized in two groups: Group A with surgical TAP block and Group B without TAP block as control. Surgical TAP block was administered by transperitoneal route before the closure of peritoneum with 0.25% bupivacaine (dose adjusted with weight of the patient), and visual analogue score was assessed by a blind assessor. Time for rescue analgesia was noted and analyzed with the 'two independent sample t  test.' Results The duration of postoperative analgesia in hours was significantly longer in the TAP block group compared with the control group (5.14 ± 1.63 vs 2.61 ± 0.89, p  < 0.001). There was no reported complication of the surgical technique or any adverse effect of the used drug. Conclusion Surgical TAP block via the transperitoneal route is a safe, easy and effective mode of providing postoperative analgesia after Cesarean section. This technique does not need any costly specialist equipment, overcomes the technical limitations of ultrasound-guided TAP block and can be used in obese patients also. It has almost no side effects, and the technique can be easily mastered.",2019,"The duration of postoperative analgesia in hours was significantly longer in the TAP block group compared with the control group (5.14 ± 1.63 vs 2.61 ± 0.89, p  < 0.001).",['hundred patients who fulfilled the inclusion criteria were included in the study after obtaining informed written consent'],"['surgical TAP block and Group B without TAP block as control', '\n\n\nTransversus abdominis plane (TAP) block', 'TAP block', 'Surgical Transversus Abdominis Plane Block', 'bupivacaine', 'Surgical TAP block', 'transperitoneal surgical TAP block']","['duration of postoperative analgesia', 'Time for rescue analgesia', 'Postoperative Analgesia', 'visual analogue score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1301820', 'cui_str': 'Obtained (attribute)'}, {'cui': 'C0043266', 'cui_str': 'Writing'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}]","[{'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0034115', 'cui_str': 'Puncture and Drainage'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0441836', 'cui_str': 'Group B (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}, {'cui': 'C0205501', 'cui_str': 'Transperitoneal approach (qualifier value)'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0638071,"The duration of postoperative analgesia in hours was significantly longer in the TAP block group compared with the control group (5.14 ± 1.63 vs 2.61 ± 0.89, p  < 0.001).","[{'ForeName': 'Aniket', 'Initials': 'A', 'LastName': 'Kakade', 'Affiliation': '1Department of Obstetrics and Gynecology, Bharati Vidyapeeth (Deemed to be University) Medical College, Pune, India.'}, {'ForeName': 'Girija', 'Initials': 'G', 'LastName': 'Wagh', 'Affiliation': '1Department of Obstetrics and Gynecology, Bharati Vidyapeeth (Deemed to be University) Medical College, Pune, India.'}]",Journal of obstetrics and gynaecology of India,['10.1007/s13224-019-01241-3'] 3058,31392719,Educating parents to improve parent-child interactions: Fostering the development of attentional control and executive functioning.,"BACKGROUND Parent-child interaction is essential in the development of attentional control (AC) and executive functioning (EF). Educating parents in AC and EF development may help them to respond more adaptively to their child's developmental needs. AIM This study aimed to investigate whether parents can be educated to improve interactions with their child through a compact psycho-educational programme that focuses on fostering the development of AC and EF. SAMPLE Parents and their children in a low-risk sample of four- to eight-year-olds were randomly assigned to either the educational programme condition (N = 34) or the control condition (N = 36). METHODS Parental supportive presence and intrusiveness were observed during home visits, and children's performance-based AC and EF were assessed before and after the four-session programme. RESULT Parents in the educational programme improved significantly in support ( η p 2  = .19) and intrusiveness ( η p 2  = .09) compared to controls. There was no short-term programme mediation effect on child AC and EF through parental support and intrusiveness. This study showed, however, that parents who improved after the educational programme had children who improved on AC and EF. CONCLUSION Parent-child interaction can be enhanced in a low-risk sample of four- to eight-year-olds using a compact educational group programme within the school community. Future studies should aim at examining variations in programme responsiveness and assessing associations between parent-child interaction and AC and EF over time.",2020,Parents in the educational programme improved significantly in support ( η p 2  = .19) and intrusiveness ( η p 2  = .09) compared to controls.,['SAMPLE\n\n\nParents and their children in a low-risk sample of four- to eight-year-olds'],['educational programme condition (N\xa0=\xa034) or the control condition (N\xa0=\xa036'],['AC and EF'],"[{'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]","[{'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]",[],,0.0341529,Parents in the educational programme improved significantly in support ( η p 2  = .19) and intrusiveness ( η p 2  = .09) compared to controls.,"[{'ForeName': 'Andrea M', 'Initials': 'AM', 'LastName': 'Spruijt', 'Affiliation': 'Department of Clinical Child and Adolescent Studies, Faculty of Social and Behavioral Sciences, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Marielle C', 'Initials': 'MC', 'LastName': 'Dekker', 'Affiliation': 'Department of Clinical Child and Adolescent Studies, Faculty of Social and Behavioral Sciences, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Tim B', 'Initials': 'TB', 'LastName': 'Ziermans', 'Affiliation': 'Department of Clinical Child and Adolescent Studies, Faculty of Social and Behavioral Sciences, Leiden University, Leiden, The Netherlands.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Swaab', 'Affiliation': 'Department of Clinical Child and Adolescent Studies, Faculty of Social and Behavioral Sciences, Leiden University, Leiden, The Netherlands.'}]",The British journal of educational psychology,['10.1111/bjep.12312'] 3059,32097058,Auditory Perception and Ultrasound Biofeedback Treatment Outcomes for Children With Residual /ɹ/ Distortions: A Randomized Controlled Trial.,"Purpose This study evaluated whether outcomes from treatment, which includes ultrasound visual feedback (UVF), would be more or less effective when combined with auditory perception training for children with residual /ɹ/ errors. Method Children ages 8-16 years with /ɹ/ distortions participated in speech therapy that included real-time UVF of the tongue. Thirty-eight participants were randomized to speech therapy conditions that included a primary focus on articulation using UVF or a condition that included auditory perceptual training plus UVF (incorporating category goodness judgments and self-monitoring). Generalization of /ɹ/ production accuracy to untrained words was assessed before and after 14 hr of therapy. Additionally, the role of auditory perceptual acuity was explored using a synthetic /ɹ/-/w/ continuum. Results There was no difference between the treatment groups in rate of improvement of /ɹ/ accuracy (increase of 34% for each group; p = .95, η p 2 = .00). However, pretreatment auditory acuity was associated with treatment progress in both groups, with finer perceptual acuity corresponding to greater progress ( p = .015, η p 2 = .182). Conclusion Similar gains in speech sound accuracy can be made with treatment that includes UVF with or without auditory perceptual training. Fine-grained perceptual acuity may be a prognostic indicator with treatment. Supplemental Material https://doi.org/10.23641/asha.11886219.",2020,"There was no difference between the treatment groups in rate of improvement of /ɹ/ accuracy (increase of 34% for each group; p = .95, η p 2 = .00).","['Thirty-eight participants', 'Method Children ages 8-16 years with /ɹ/ distortions participated in speech therapy that included real-time UVF of the tongue', 'Children With Residual /ɹ/ Distortions', 'children with residual /ɹ/ errors']","['Supplemental Material https://doi.org/10.23641/asha.11886219', 'ultrasound visual feedback (UVF', 'Auditory Perception and Ultrasound Biofeedback', 'auditory perception training', 'speech therapy conditions that included a primary focus on articulation using UVF or a condition that included auditory perceptual training plus UVF (incorporating category goodness judgments and self-monitoring']","['auditory perceptual acuity', 'rate of improvement of /ɹ/ accuracy', 'pretreatment auditory acuity']","[{'cui': 'C0450361', 'cui_str': '38 (qualifier value)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332482', 'cui_str': 'Abnormal shape'}, {'cui': 'C0037831', 'cui_str': 'Speech Therapy'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0040408', 'cui_str': 'Tongue'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1609982', 'cui_str': 'Residual (qualifier value)'}]","[{'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C2936181', 'cui_str': 'Visual Feedback'}, {'cui': 'C0004309', 'cui_str': 'Auditory Perception'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0037831', 'cui_str': 'Speech Therapy'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0556503', 'cui_str': 'Perceptual training (regime/therapy)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0022423', 'cui_str': 'Judgment'}, {'cui': 'C0588436', 'cui_str': 'Self-monitoring (regime/therapy)'}]","[{'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0679027', 'cui_str': 'Auditory acuity'}]",38.0,0.0281561,"There was no difference between the treatment groups in rate of improvement of /ɹ/ accuracy (increase of 34% for each group; p = .95, η p 2 = .00).","[{'ForeName': 'Jonathan L', 'Initials': 'JL', 'LastName': 'Preston', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, NY.'}, {'ForeName': 'Elaine R', 'Initials': 'ER', 'LastName': 'Hitchcock', 'Affiliation': 'Department of Communication Sciences and Disorders, Montclair State University, NJ.'}, {'ForeName': 'Megan C', 'Initials': 'MC', 'LastName': 'Leece', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, NY.'}]","Journal of speech, language, and hearing research : JSLHR",['10.1044/2019_JSLHR-19-00060'] 3060,31085305,Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.,"Assessments of overall improvement and worsening of chronic graft-versus-host disease (GVHD) manifestations by the algorithm recommended by National Institutes of Health (NIH) response criteria do not align closely with those reported by providers, particularly when patients have mixed responses with improvement in some manifestations but worsening in others. To elucidate the changes that influence provider assessment of response, we used logistic regression to generate an overall change index based on specific manifestations of chronic GVHD measured at baseline and 6 months later. We hypothesized that this overall change index would correlate strongly with overall improvement as determined by providers. The analysis included 488 patients from 2 prospective observational studies who were randomly assigned in a 3:2 ratio to discovery and replication cohorts. Changes in bilirubin and scores of the lower gastrointestinal tract, mouth, joint/fascia, lung, and skin were correlated with provider-assessed improvement, suggesting that the main NIH response measures capture relevant information. Conversely, changes in the eye, esophagus, and upper gastrointestinal tract did not correlate with provider-assessed response, suggesting that these scales could be modified or dropped from the NIH response assessment. The area under the receiver operator characteristic curve in the replication cohort was 0.72, indicating that the scoring algorithm for overall change based on NIH response measures is not well calibrated with provider-assessed response.",2019,"Changes in bilirubin and scores of the lower gastrointestinal tract, mouth, joint/fascia, lung, and skin were correlated with provider-assessed improvement, suggesting that the main NIH response measures capture relevant information.","['Patients with Chronic Graft-versus-Host Disease', '488 patients from 2 prospective observational studies who were randomly assigned in a 3:2 ratio to discovery and replication cohorts']",[],"['chronic GVHD', 'bilirubin and scores of the lower gastrointestinal tract, mouth, joint/fascia, lung, and skin', 'eye, esophagus, and upper gastrointestinal tract']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0867389', 'cui_str': 'Chronic graft-versus-host disease (disorder)'}, {'cui': 'C1518527', 'cui_str': 'Observational Study'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",[],"[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0018133', 'cui_str': 'Homologous Wasting Disease'}, {'cui': 'C0005437', 'cui_str': 'Bilirubin IX alpha'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1272755', 'cui_str': 'Lowered'}, {'cui': 'C0017189', 'cui_str': 'Gastrointestinal Tract'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0014876', 'cui_str': 'Esophagus'}, {'cui': 'C3203348', 'cui_str': 'Upper Gastrointestinal Tract'}]",488.0,0.0666027,"Changes in bilirubin and scores of the lower gastrointestinal tract, mouth, joint/fascia, lung, and skin were correlated with provider-assessed improvement, suggesting that the main NIH response measures capture relevant information.","[{'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Martin', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address: pmartin@fredhutch.org.'}, {'ForeName': 'Barry E', 'Initials': 'BE', 'LastName': 'Storer', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.'}, {'ForeName': 'Jeanne', 'Initials': 'J', 'LastName': 'Palmer', 'Affiliation': 'Mayo Clinic, Phoenix, Arizona.'}, {'ForeName': 'Madan H', 'Initials': 'MH', 'LastName': 'Jagasia', 'Affiliation': 'Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.'}, {'ForeName': 'George L', 'Initials': 'GL', 'LastName': 'Chen', 'Affiliation': 'Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.'}, {'ForeName': 'Raewyn', 'Initials': 'R', 'LastName': 'Broady', 'Affiliation': 'Leukemia/Bone Marrow Transplant Program of British Columbia, BC Cancer Agency, Vancouver, British Columbia, Canada.'}, {'ForeName': 'Mukta', 'Initials': 'M', 'LastName': 'Arora', 'Affiliation': 'Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.'}, {'ForeName': 'Joseph A', 'Initials': 'JA', 'LastName': 'Pidala', 'Affiliation': 'Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.'}, {'ForeName': 'Betty K', 'Initials': 'BK', 'LastName': 'Hamilton', 'Affiliation': 'Blood and Marrow Transplantation, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.'}, {'ForeName': 'Stephanie J', 'Initials': 'SJ', 'LastName': 'Lee', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington.'}]",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,['10.1016/j.bbmt.2019.05.008'] 3061,31385918,REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study.,"PURPOSE To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). METHODS Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. RESULTS At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity ≥73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity ≥73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). CONCLUSION LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.",2020,Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group.,"['treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV', 'treatment-naive patients with PCV', 'neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study']","['VASCULOPATHY', 'intravitreal ranibizumab', 'ranibizumab']","['baseline visual acuity ≥73 letters maintained this level of vision', 'effectiveness and safety', 'central retinal thickness', 'visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events', 'visual acuity ≥73 letters', 'baseline visual acuity', 'mean visual acuity gain', 'rate of serious ocular adverse events']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1504336', 'cui_str': 'Polypoidal choroidal vasculopathy'}, {'cui': 'C0018935', 'cui_str': 'Erythrocyte Volume, Packed'}, {'cui': 'C0271084', 'cui_str': 'Neovascular age-related macular degeneration'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C1096774', 'cui_str': 'Letter'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C4521296', 'cui_str': 'Ocular (intended site)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",,0.177222,Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group.,"[{'ForeName': 'Adrian', 'Initials': 'A', 'LastName': 'Koh', 'Affiliation': 'Eye and Retina Surgeons, Camden Medical Centre, Singapore, Singapore.'}, {'ForeName': 'Timothy Y Y', 'Initials': 'TYY', 'LastName': 'Lai', 'Affiliation': 'Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong.'}, {'ForeName': 'Wen Bin', 'Initials': 'WB', 'LastName': 'Wei', 'Affiliation': 'Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China.'}, {'ForeName': 'Ryusaburo', 'Initials': 'R', 'LastName': 'Mori', 'Affiliation': 'Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.'}, {'ForeName': 'Harumi', 'Initials': 'H', 'LastName': 'Wakiyama', 'Affiliation': 'The Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.'}, {'ForeName': 'Kyu Hyung', 'Initials': 'KH', 'LastName': 'Park', 'Affiliation': 'Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University, College of Medicine, Kyeonggi, Republic of Korea.'}, {'ForeName': 'Fariza', 'Initials': 'F', 'LastName': 'Ngah', 'Affiliation': 'Department of Ophthalmology, Hospital Selayang, Lebuhraya Selayang-Kepong, Batu Caves, Selangor, Malaysia.'}, {'ForeName': 'Wayne', 'Initials': 'W', 'LastName': 'Macfadden', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Cornelia', 'Initials': 'C', 'LastName': 'Dunger-Baldauf', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}, {'ForeName': 'Soumil', 'Initials': 'S', 'LastName': 'Parikh', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002624'] 3062,31894843,The effect of wuling capsule on depression in Type 2 diabetic patients.,"OBJECTIVE Depression is a common complication in Type 2 diabetes mellitus (T2DM); however, it has long been underrecognized and undertreated. In the present study, we aimed to evaluate the clinical effects of Wuling capsule, a compound traditional Chinese herbal medicine, on T2DM complicated with depression. METHOD 66 patients were enrolled and randomly divided into Wuling capsule treatment group and placebo group, and finally 64 cases finished the present study. The levels of FPG, 2hPG, HbAlc, TNF-α, IL-6, SOD, MDA, Cor, ACTH, HOMA-β, HOMA-IR and ISI of patients were evaluated and compared. The HAMD scale for patients were recorded. RESULT After 12-week treatment, the HAMD scale decreased in both groups, and was lower in Wuling capsule group. The level of FPG in Wuling capsule group was significantly lower than in placebo group; however, no obvious changes of 2hPG and HbA1c were found. The levels of IL-6 and TNF-α were significantly decreased in both groups, and more obviously in Wuling capsule group. The level of SOD was increased while the level of MDA was decreased significantly in both groups, and the changes were more obviously in Wuling capsule group. The levels of Cor and ACTH were significantly decreased in both groups; however, there was no statistically significance between the two groups. Besides, the comparisons of HOMA-β, HOMA-IR and ISI between the two groups were not statistically significant. CONCLUSION Our results suggested that Wuling capsule ameliorated the depression in patients with T2DM, and also improved the state of inflammation and oxidative stress state. These results also strongly indicated the ability of clinical transformation of Wuling capsule in patients with T2DM in the future.",2020,"The levels of Cor and ACTH were significantly decreased in both groups, however, there was no statistically significance between the two groups.","['Type 2 Diabetic Patients', '66\xa0patients']","['placebo', 'Wuling Capsule']","['levels of FPG, 2hPG, HbAlc, TNF-α, IL-6, SOD, MDA, Cor, ACTH,\xa0HOMA-b, HOMA-IR and ISI', 'HAMD scale', 'HOMA-b, HOMA-IR and ISI', 'level of SOD', 'level of FPG', 'IL-6 and TNF-α', 'levels of Cor and ACTH', 'level of MDA']","[{'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C0241863', 'cui_str': 'Diabetic'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C2606506', 'cui_str': 'wuling'}, {'cui': 'C4319574', 'cui_str': 'Capsule'}]","[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0000379', 'cui_str': '1,3-Benzodioxole-5-ethanamine, alpha-methyl-'}, {'cui': 'C0201835', 'cui_str': 'Adrenocorticotropic hormone measurement (procedure)'}, {'cui': 'C0222045'}]",,0.0213207,"The levels of Cor and ACTH were significantly decreased in both groups, however, there was no statistically significance between the two groups.","[{'ForeName': 'Huanping', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Huizhen', 'Initials': 'H', 'LastName': 'Chen', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Yang', 'Initials': 'Y', 'LastName': 'Gao', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Shengju', 'Initials': 'S', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Xian', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Xiaomei', 'Initials': 'X', 'LastName': 'Tang', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Fang', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Xiaoyan', 'Initials': 'X', 'LastName': 'Shi', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Jia', 'Initials': 'J', 'LastName': 'Yao', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}, {'ForeName': 'Qiu', 'Initials': 'Q', 'LastName': 'Chen', 'Affiliation': 'Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, China.'}]",Bioscience reports,['10.1042/BSR20191260'] 3063,32100388,"Relationships of exercise timing with sleep, fatigue and rest-activity rhythms of lung cancer patients in Taiwan: An exploratory study.","OBJECTIVE To explore the relationship of exercise timing (exercising close to bedtime, exercising in daylight and maintaining fixed exercise schedule) with sleep quality, fatigue and rest-activity rhythms among lung cancer patients in Taiwan. METHODS Results from 43 lung cancer patients who were assigned and adhered to the exercise intervention in a 12-week randomised controlled trial were analysed. The MD Anderson Symptom Inventory and Pittsburgh Sleep Quality Index (PSQI) were administered. Actigraphs were used to assess rest-activity rhythms (in-bed less than out-of-bed dichotomy index, I < O) and objective sleep parameters, including total sleep time (TST) and sleep onset latency (SOL). RESULTS Patients who exercised >4 hr before bedtime had significant improvement in fatigue (p < .0001), sleep quality (p = .012 for PSQI; p = .037 for TST; p = .017 for SOL) and rest-activity rhythms (p = .048 for I < O). Furthermore, patients who exercised with daylight exposure had a significant improvement in fatigue (p = .037) and sleep quality (p = .039 for PSQI). CONCLUSIONS Exercising >4 hr before bedtime with daylight exposure is associated with improvement in rest-activity rhythms, sleep quality and fatigue in lung cancer patients. The causal relationship requires further investigation with experimental design.",2020,"Furthermore, patients who exercised with daylight exposure had a significant improvement in fatigue (p = .037) and sleep quality (p = .039 for PSQI). ","['43 lung cancer patients who were assigned and adhered to the', 'lung cancer patients', 'lung cancer patients in Taiwan']","['exercise intervention', 'exercise timing (exercising close to bedtime, exercising in daylight and maintaining fixed exercise schedule']","['rest-activity rhythms, sleep quality and fatigue', 'Quality Index (PSQI', 'sleep quality, fatigue and rest-activity rhythms', 'rest-activity rhythms', 'MD Anderson Symptom Inventory and Pittsburgh Sleep', 'total sleep time (TST) and sleep onset latency (SOL', 'fatigue', 'sleep quality']","[{'cui': 'C1306460', 'cui_str': 'Primary malignant neoplasm of lung'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0039260', 'cui_str': 'Formosa'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0449243', 'cui_str': 'Timing (attribute)'}, {'cui': 'C0587267', 'cui_str': 'Closed (qualifier value)'}, {'cui': 'C0521112', 'cui_str': 'Bedtime (qualifier value)'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0443218', 'cui_str': 'Fixed (qualifier value)'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]","[{'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0701413', 'cui_str': 'Sol'}]",43.0,0.09235,"Furthermore, patients who exercised with daylight exposure had a significant improvement in fatigue (p = .037) and sleep quality (p = .039 for PSQI). ","[{'ForeName': 'Hui-Mei', 'Initials': 'HM', 'LastName': 'Chen', 'Affiliation': 'School of Nursing, College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'Denise Shuk Ting', 'Initials': 'DST', 'LastName': 'Cheung', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.'}, {'ForeName': 'Yi-Yun', 'Initials': 'YY', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, Shu Zen College of Medicine and Management, Kaohsiung, Taiwan.'}, {'ForeName': 'Yu-Chung', 'Initials': 'YC', 'LastName': 'Wu', 'Affiliation': 'Division of Thoracic Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei, Taiwan.'}, {'ForeName': 'Chieh-Yu', 'Initials': 'CY', 'LastName': 'Liu', 'Affiliation': 'Department of Speech Language Pathology and Audiology, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'Kuan-Chia', 'Initials': 'KC', 'LastName': 'Lin', 'Affiliation': 'Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan.'}, {'ForeName': 'Yu-Jung', 'Initials': 'YJ', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, College of Nursing, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.'}, {'ForeName': 'Chia-Chin', 'Initials': 'CC', 'LastName': 'Lin', 'Affiliation': 'School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.'}]",European journal of cancer care,['10.1111/ecc.13233'] 3064,30967321,Effectiveness of Shared Decision-Making for Elderly Depressed Minority Primary Care Patients.,"OBJECTIVE The authors assessed the impact of a shared decision-making (SDM) intervention among elderly depressed minority primary care patients not currently receiving treatment. METHODS A total of 202 English and Spanish-speaking primary care participants aged 65 and older who scored positive on the Patient Health Questionnaire-9 (≥10) were randomized at the physician level to receive a brief SDM intervention or usual care (UC). Primary analyses focused on patient adherence to either psychotherapy or antidepressant medication, and reduction in depression severity (Hamilton Depression Rating Scale) over 12 weeks. RESULTS Patients randomized to physicians in the SDM condition were significantly more likely than patients of physicians randomized to UC to receive a mental health evaluation or initiate some form of treatment (39% versus 21%), and to adhere to psychotherapy visits over 12 weeks. There were no differences between groups in adherence to antidepressant medication or in reduction of depressive symptoms. CONCLUSION Among untreated elderly depressed minority patients from an inner-city municipal hospital, a brief SDM intervention was associated with greater initiation and adherence to psychotherapy. However, low treatment adherence rates across both groups and the intervention's lack of impact on clinical outcomes highlight the need to provide focused and accessible mental health services to patients choosing active treatments.",2019,"There were no differences between groups in adherence to antidepressant medication or in reduction of depressive symptoms. ","['Elderly Depressed Minority Primary Care Patients', 'elderly depressed minority primary care patients not currently receiving treatment', 'untreated elderly depressed minority patients from an inner-city municipal hospital', '202 English and Spanish-speaking primary care participants aged 65 and older who scored positive on the Patient Health Questionnaire-9 (≥10']","['SDM intervention', 'brief SDM intervention or usual care (UC', 'shared decision-making (SDM) intervention']","['depressive symptoms', 'patient adherence to either psychotherapy or antidepressant medication, and reduction in depression severity (Hamilton Depression Rating Scale']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0557849', 'cui_str': 'Inner city environment (environment)'}, {'cui': 'C0020013', 'cui_str': 'Hospitals, City, Public-Owned'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C4083201', 'cui_str': 'PHQ-9'}]","[{'cui': 'C0643808', 'cui_str': 'SDM'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0011109', 'cui_str': 'Decision Making'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C1321605', 'cui_str': 'Patient Cooperation'}, {'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0003289', 'cui_str': 'Antidepressant Drugs'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0222045'}]",202.0,0.039987,"There were no differences between groups in adherence to antidepressant medication or in reduction of depressive symptoms. ","[{'ForeName': 'Patrick J', 'Initials': 'PJ', 'LastName': 'Raue', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences (PJR), University of Washington School of Medicine, Seattle. Electronic address: praue@uw.edu.'}, {'ForeName': 'Herbert C', 'Initials': 'HC', 'LastName': 'Schulberg', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry (HCS, SB), Weill Cornell Medical College, White Plains, NY.'}, {'ForeName': 'Martha L', 'Initials': 'ML', 'LastName': 'Bruce', 'Affiliation': 'Department of Psychiatry (MLB), Geisel School of Medicine at Dartmouth, Hanover, NH.'}, {'ForeName': 'Samprit', 'Initials': 'S', 'LastName': 'Banerjee', 'Affiliation': 'Weill Cornell Institute of Geriatric Psychiatry (HCS, SB), Weill Cornell Medical College, White Plains, NY.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Artis', 'Affiliation': 'Heart & Vascular Institute Cleveland Clinic, Cleveland (AA).'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Espejo', 'Affiliation': 'Lincoln Medical and Mental Health Center (ME), Bronx, NY.'}, {'ForeName': 'Idalia', 'Initials': 'I', 'LastName': 'Catalan', 'Affiliation': 'Equity Project Charter School (IC), New York.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Romero', 'Affiliation': 'Fordham University (SR), Bronx, NY.'}]",The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry,['10.1016/j.jagp.2019.02.016'] 3065,31385737,Integrated Psychological Therapy and Treatment-Resistant Schizophrenia: Initial Findings.,"Objective: The aim of this Randomized Controlled Trial (RCT) is to present the initial findings of a larger RCT study conducted internationally for the first time, regarding the hypothesis, when the Integrated Psychological Therapy (IPT) for individuals with schizophrenia is more and when it is less effective, regarding Treatment-Resistant Schizophrenia (TRS) and nontreatment resistant schizophrenia (NTRS). Methods: Forty-eight outpatients with schizophrenia of an adult psychiatric department participated in this RCT study. Eleven outpatients of IPT and 11 of the Treatment as Usual (TAU) belong to TRS. Thirteen patients of IPT and 13 of TAU belong to NTRS. A test battery was given at baseline after therapy (10 weeks) and at 3 months' follow-up. Neurocognition, social cognition, psychopathology, and functional outcome were assessed. The General Linear Model (GLM) for repeated measurements was used. Effect sizes, z-scores, and the sign test were calculated. Results: There was a statistical significance for verbal memory; positive, negative symptoms and general psychopathology; Global Assessment and Functioning scale (GAF) and quality of life favoring NTRS. Effect sizes showed superiority of NTRS in comparison to TRS. The sign test showed a significant improvement in Integrated Psychological Therapy treatment-resistant schizophrenia (IPTTRS) that was maintained in the follow-up, in Integrated Psychological Therapy nontreatment resistant schizophrenia (IPTNTRS) and in Treatment as Usual nontreatment resistant schizophrenia (TAUNTRS). Conclusion: The IPT is more effective in NTRS in comparison to TRS, although IPTTRS showed some improvements, maintained at follow-up. Further RCT studies with larger samples are needed.",2019,"The sign test showed a significant improvement in Integrated Psychological Therapy treatment-resistant schizophrenia (IPTTRS) that was maintained in the follow-up, in Integrated Psychological Therapy nontreatment resistant schizophrenia (IPTNTRS) and in Treatment as Usual nontreatment resistant schizophrenia (TAUNTRS). ","['Forty-eight outpatients with schizophrenia of an adult psychiatric department participated in this RCT study', 'Eleven outpatients of IPT and 11 of the Treatment as Usual (TAU) belong to TRS', 'individuals with schizophrenia', 'Thirteen patients of IPT and 13 of TAU belong to NTRS']","['Integrated Psychological Therapy (IPT', 'NTRS']","['verbal memory; positive, negative symptoms and general psychopathology; Global Assessment and Functioning scale (GAF) and quality of life favoring NTRS', 'Neurocognition, social cognition, psychopathology, and functional outcome', 'Integrated Psychological Therapy treatment-resistant schizophrenia (IPTTRS']","[{'cui': 'C4319608', 'cui_str': 'Forty-eight'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0036341', 'cui_str': 'Schizophrenic Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0380193', 'cui_str': 'iodine-123-IPT'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C3715149', 'cui_str': '13'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1720655', 'cui_str': 'Tau'}]","[{'cui': 'C0841584', 'cui_str': 'Psychological therapies (procedure)'}, {'cui': 'C0380193', 'cui_str': 'iodine-123-IPT'}]","[{'cui': 'C0561770', 'cui_str': 'Verbal memory observable'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0033927', 'cui_str': 'Psychopathology'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0222045'}, {'cui': 'C0034380'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0841584', 'cui_str': 'Psychological therapies (procedure)'}, {'cui': 'C3544321', 'cui_str': 'Treatment-resistant schizophrenia'}]",48.0,0.0223627,"The sign test showed a significant improvement in Integrated Psychological Therapy treatment-resistant schizophrenia (IPTTRS) that was maintained in the follow-up, in Integrated Psychological Therapy nontreatment resistant schizophrenia (IPTNTRS) and in Treatment as Usual nontreatment resistant schizophrenia (TAUNTRS). ","[{'ForeName': 'Stavroula', 'Initials': 'S', 'LastName': 'Rakitzi', 'Affiliation': ''}, {'ForeName': 'Polyxeni', 'Initials': 'P', 'LastName': 'Georgila', 'Affiliation': ''}]",Psychiatry,['10.1080/00332747.2019.1616658'] 3066,31389909,Effects of Exercise Training and Statin Use in People Living with HIV with Dyslipidemia.,"PURPOSE To evaluate the effects of the combination of ET and statins in people living with HIV. METHODS This was a randomized, double-blind, placebo-controlled clinical trial. Eighty-three people living with HIV were assigned to either placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET) groups. Volunteers assigned to STA and STAET groups were administered 10 mg of rosuvastatin, whereas the PL and PLET groups were administered a placebo. PLET and STAET groups performed ET three times a week. Before and after the 12-week follow-up, the volunteers underwent to anthropometric assessment and blood collection to evaluate lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests were performed. RESULTS There was a decrease in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT) in the STA, PLET, and STAET groups compared to PL group (p<0.001). Furthermore, there was a decrease in TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels in the STAET groups compared to the STA (p<0.001) and PLET groups (p<0.001). There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001). The PLET and STAET groups reduced body fat mass, body fat percentage and increased lean body mass, MS and CF compared to PL (p<0.001) and STA (p<0.001) groups. CONCLUSION The combination of ET and statins is useful to enhance lipid and inflammatory profiles, reduce CVD markers, and improve Doppler ultrasound findings, MS and CF in people living with HIV.",2019,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","['people living with HIV', 'People Living with HIV with Dyslipidemia', 'Eighty-three people living with HIV']","['STA', 'placebo (PL), statins (STA), placebo + ET (PLET) or statins + ET (STAET', 'rosuvastatin', 'Exercise Training and Statin Use', 'placebo', 'PLET', 'ET and statins']","['TC, TG, LDL, IL-1β, IL-6, and IL-8 levels and in left and right cIMT and an increase in HDL-c levels', 'lipid profile, cardiovascular markers, inflammatory profile; a Doppler ultrasound examination, muscle strength (MS) and cardiorespiratory fitness (CF) tests', 'IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate', 'body fat mass, body fat percentage and increased lean body mass, MS and CF', 'total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-c), C-reactive protein, fibrinogen, interleukin (IL)-1β and right carotid intima-media thickness (cIMT']","[{'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0242339', 'cui_str': 'Dyslipidemias'}, {'cui': 'C4517888', 'cui_str': '83'}]","[{'cui': 'C1529286', 'cui_str': 'stas'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0965129', 'cui_str': 'rosuvastatin'}, {'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C1947944', 'cui_str': 'Use'}]","[{'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0162481', 'cui_str': 'Doppler Ultrasound'}, {'cui': 'C1273867', 'cui_str': 'Examination (heading)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C2981722', 'cui_str': 'Cardiorespiratory Fitness'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C0205380', 'cui_str': 'Walled (qualifier value)'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0982156', 'cui_str': 'fibrinogen (125I)'}, {'cui': 'C0021764', 'cui_str': 'Interleukins'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}]",83.0,0.0940275,"There was an increase in IL-10 levels, peak-systolic velocity, end-diastolic velocity, wall shear rate in the PLET and STAET groups compared to the PL (p<0.001) and STA groups (p<0.001).","[{'ForeName': 'Hugo Ribeiro', 'Initials': 'HR', 'LastName': 'Zanetti', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Alexandre', 'Initials': 'A', 'LastName': 'Gonçalves', 'Affiliation': 'Master Institute of Education President Antônio Carlos, Araguari/MG, Brazil.'}, {'ForeName': 'Leandro Teixeira', 'Initials': 'LT', 'LastName': 'Paranhos Lopes', 'Affiliation': 'Brazil University, Fernandópolis/SP, Brazil.'}, {'ForeName': 'Edmar Lacerda', 'Initials': 'EL', 'LastName': 'Mendes', 'Affiliation': 'Institute of Health Sciences, Department of Sport Sciences, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Roever', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}, {'ForeName': 'Mário Leon', 'Initials': 'ML', 'LastName': 'Silva-Vergara', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Fernando Freitas', 'Initials': 'FF', 'LastName': 'Neves', 'Affiliation': 'Institute of Health Sciences, Department of Medical Clinics, Clinics Hospital, Federal University of Triângulo Mineiro, Uberaba/MG, Brazil.'}, {'ForeName': 'Elmiro Santos', 'Initials': 'ES', 'LastName': 'Resende', 'Affiliation': 'Postgraduate Program in Health Science, Faculty of Medicine, Federal University of Uberlândia, Uberlândia/MG, Brazil.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002120'] 3067,32084035,Brain Connectivity Modulation After Exoskeleton-Assisted Gait in Chronic Hemiplegic Stroke Survivors: A Pilot Study.,"OBJECTIVE The aim of this study was to investigate electroencephalographic (EEG) connectivity short-term changes, quantified by node strength and betweenness centrality, induced by a single trial of exoskeleton-assisted gait in chronic stroke survivors. DESIGN Study design was randomized crossover. Electroencephalographic data (64-channel system) were recorded before gait (baseline) and after unassisted overground walking and overground exoskeleton-assisted walking. Coherence was estimated for alpha1, alpha2, and beta frequency ranges. Graph analysis assessed network model properties: node strength and betweenness centrality. RESULTS Nine participants were included in the final analysis. In the group (four participants) with a left-hemisphere stroke lesion (dominant hemisphere), over the vertex, node strength increased in alpha1, alpha2, and beta bands, and betweenness centrality decreased in alpha2 both after unassisted overground walking and exoskeleton-assisted walking. In the group (five participants) with a right-hemisphere lesion (nondominant hemisphere), node strength increased in alpha1 and alpha2 over the contralesional sensorimotor area and ipsilesional prefrontal area after overground exoskeleton-assisted walking, compared with baseline and unassisted overground walking. CONCLUSION A single session of exoskeleton training provides short-term neuroplastic modulation in chronic stroke. In participants with a nondominant hemisphere lesion, exoskeleton training induces activations similar to those observed in able-bodied participants, suggesting a role of lesion lateralization in networks' reorganization.",2020,"In the group (5 participants) with a right-hemisphere lesion (non-dominant hemisphere), NS increased in alpha1 and alpha2 over the contralesional sensorimotor area and ipsilesional prefrontal area after EXO, compared to BL and UW","['chronic hemiplegic stroke survivors', 'chronic stroke survivors', 'Nine participants were included in final analysis', 'participants with a non-dominant hemisphere lesion', 'chronic stroke']","['exoskeleton assisted gait', 'exoskeleton training']","['node strength (NS) and betweenness centrality (BC', 'vertex NS increased in alpha1, alpha2 and beta bands, and BC']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}]","[{'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0016928', 'cui_str': 'Gait'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0230003', 'cui_str': 'Vertex structure'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0330390', 'cui_str': 'Beta (organism)'}, {'cui': 'C0185014', 'cui_str': 'Banding'}]",9.0,0.122839,"In the group (5 participants) with a right-hemisphere lesion (non-dominant hemisphere), NS increased in alpha1 and alpha2 over the contralesional sensorimotor area and ipsilesional prefrontal area after EXO, compared to BL and UW","[{'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Molteni', 'Affiliation': 'From the Valduce Hospital, Villa Beretta Rehabilitation Center, Costa Masnaga, Lecco (FM, EG); Department of Neuroscience, Section of Rehabilitation, University of Padova, Padova (EF, AB, SM, ADF); Fondazione Ospedale San Camillo IRCCS, Venice (FP); and Padova Neuroscience Center, University of Padova, Padova (SM, ADF), Italy.'}, {'ForeName': 'Emanuela', 'Initials': 'E', 'LastName': 'Formaggio', 'Affiliation': ''}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Bosco', 'Affiliation': ''}, {'ForeName': 'Eleonora', 'Initials': 'E', 'LastName': 'Guanziroli', 'Affiliation': ''}, {'ForeName': 'Francesco', 'Initials': 'F', 'LastName': 'Piccione', 'Affiliation': ''}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Masiero', 'Affiliation': ''}, {'ForeName': 'Alessandra', 'Initials': 'A', 'LastName': 'Del Felice', 'Affiliation': ''}]",American journal of physical medicine & rehabilitation,['10.1097/PHM.0000000000001395'] 3068,32080973,Effectiveness of vialon biomaterial versus teflon catheters for peripheral intravenous placement: A randomized clinical trial.,"AIM This study was to determine the effects of the two types of catheter material (vialon biomaterial and teflon) on pain intensity, dwell time, and phlebitis score for peripheral intravenous catheter (PIVC) placement. METHODS Participants (N = 208) were randomly assigned to the vialon biomaterial group (n = 104), the teflon group (n = 104). After the PIVC placement, the intensity of pain and phlebitis score were evaluated. Catheter dwell mean time was determined. RESULTS The pain intensity scores were similar immediately after inserting the PIVC. No difference was observed between the pain scores in both groups (p ≥ .050). Catheter dwell mean time for the vialon biomaterial catheter group (4.72 ± 1.20 days) was significantly longer compared to the teflon catheter group (4.10 ± 0.92 days) (p ≤ .001). It was determined that the catheter was removed due to phlebitis development in 16.3% of the vialon biomaterial catheter group and 53.8% of the teflon catheter group. An advanced level of statistically significant difference was found between the two groups in terms of phlebitis development scores (p ≤ .001). CONCLUSIONS This study concluded that vialon biomaterial catheter (BD Insyte™ Autoguard™ BC winged) demonstrates longer dwell time of PIVC, lower phlebitis rate and phlebitis score than teflon catheter (BD Venflon™).",2020,"An advanced level of statistically significant difference was found between the two groups in terms of phlebitis development scores (p ≤ .001). ","['peripheral intravenous placement', 'Participants (N = 208']","['peripheral intravenous catheter (PIVC) placement', 'catheter material (vialon biomaterial and teflon', 'vialon biomaterial group', 'vialon biomaterial catheter (BD Insyte™ Autoguard™ BC winged', 'vialon biomaterial versus teflon catheters']","['Catheter dwell mean time', 'pain intensity, dwell time, and phlebitis score', 'pain intensity scores', 'pain scores', 'intensity of pain and phlebitis score', 'dwell time of PIVC, lower phlebitis rate and phlebitis score', 'phlebitis development', 'phlebitis development scores']","[{'cui': 'C0205100', 'cui_str': 'Peripheral (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C0179768', 'cui_str': 'Peripheral intravenous catheter, device (physical object)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0078223', 'cui_str': 'Vialon resin'}, {'cui': 'C0005479', 'cui_str': 'Biomaterials'}, {'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0429659', 'cui_str': 'Dwell time (observable entity)'}, {'cui': 'C0031542', 'cui_str': 'Phlebitis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}]",208.0,0.065711,"An advanced level of statistically significant difference was found between the two groups in terms of phlebitis development scores (p ≤ .001). ","[{'ForeName': 'Betül', 'Initials': 'B', 'LastName': 'Kuş', 'Affiliation': 'Health Science Faculty, Yozgat Bozok University, Yozgat, Turkey.'}, {'ForeName': 'Funda', 'Initials': 'F', 'LastName': 'Büyükyılmaz', 'Affiliation': 'Florence Nightingale Faculty of Nursing, Istanbul University-Cerrahpasa, Istanbul, Turkey.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12328'] 3069,31383564,Long term effect of spa therapy combined with patient education program on subjects with overweight and obesity - A controlled study.,"The aim of this single center prospective controlled study in volunteers with obesity and overweight was to evaluate the effect of a patient therapeutic education program (PTE group) combined with spa therapy on weight, physical activity, eating habits and quality of life versus spa therapy alone (control group). The main endpoint was weight change at 5 months after the end of the program. The PTE group of 151 subjects with obesity or overweight followed a 3-week program combining patient education with spa therapy and 189 attended a course of spa therapy alone. At 5 months significant loss was observed in the PTE group compared to controls (-2.69kg vs -1.24kg, p=0.008), a relative weight loss of -2.8% vs -1.3%. At 11 months after spa therapy, only the PTE group maintained a weight loss in addition to the weight loss obtained during spa therapy. The control group returned to the weight they had at the end of spa therapy. In both groups, a significant increase in physical activity was observed at 5 (p<0.001) and 11 months (p<0.001) with a significant better improvement in the PTE group. In addition, while in both groups some quality of life parameters and dietary choices were improved, the improvement (more fruit, vegetables, fish and water) was significantly higher in the PTE group, at both 5 and 11 months after spa therapy. In conclusion, while spa therapy alone initiated positive changes in weight loss, physical activity and some quality of life parameters, the PTE program enhanced this effect.",2019,"In both groups, a significant increase in physical activity was observed at 5 (p<0.001) and 11 months (p<0.001) with a significant better improvement in the PTE group.","['subjects with overweight and obesity - A controlled study', '151 subjects with obesity or overweight followed a 3-week program combining patient education with spa therapy and 189 attended a course of spa therapy alone', 'volunteers with obesity and overweight']","['PTE', 'patient therapeutic education program (PTE group) combined with spa therapy', 'spa therapy combined with patient education program', 'spa therapy alone (control group']","['relative weight loss', 'weight loss', 'weight, physical activity, eating habits and quality of life', 'quality of life parameters and dietary choices', 'physical activity', 'weight change', 'weight loss, physical activity and some quality of life parameters']","[{'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0729314', 'cui_str': 'Education provision (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1266864', 'cui_str': 'Eating habit'}, {'cui': 'C0034380'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0005911', 'cui_str': 'Body Weight Changes'}]",151.0,0.0194296,"In both groups, a significant increase in physical activity was observed at 5 (p<0.001) and 11 months (p<0.001) with a significant better improvement in the PTE group.","[{'ForeName': 'Coralie', 'Initials': 'C', 'LastName': 'Schnebelen-Berthier', 'Affiliation': 'Institut Pasteur de Lille, Nutrition & Physical Activity Department, 59019 Lille Cedex, France. Electronic address: coralie.berthier@pasteur-lille.fr.'}, {'ForeName': 'Nathalie', 'Initials': 'N', 'LastName': 'Negro', 'Affiliation': 'Thermal Cares Facility, Nutrition Department, 73573 Brides-les-Bains Cedex, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Jaruga', 'Affiliation': 'Institut Pasteur de Lille, Nutrition & Physical Activity Department, 59019 Lille Cedex, France.'}, {'ForeName': 'Christian-François', 'Initials': 'CF', 'LastName': 'Roques', 'Affiliation': 'Physical and Rehabilitation Medicine Department, Toulouse III University, France.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Lecerf', 'Affiliation': 'Institut Pasteur de Lille, Nutrition & Physical Activity Department, 59019 Lille Cedex, France.'}]",Obesity research & clinical practice,['10.1016/j.orcp.2019.06.005'] 3070,32086657,Comparing Fidelity Outcomes of Paraprofessional and Professional Delivery of a Perinatal Depression Preventive Intervention.,"Mothers and Babies (MB), a perinatal depression preventive intervention, has proven effective in decreasing depressive symptoms and preventing onset of major depression. An ongoing cluster-randomized trial is comparing the effectiveness of the six-session MB group intervention led by paraprofessionals versus mental health professionals. Twenty percent of all audio-recorded intervention sessions were randomly selected for fidelity checks. Analyses assessed mean facilitator adherence and competency overall, by study arm, and by session; and, examined site, facilitator, and client-specific effects. There were no significant differences found between study arms. Findings show paraprofessionals can deliver MB with similar fidelity as mental health professionals.",2020,"Mothers and Babies (MB), a perinatal depression preventive intervention, has proven effective in decreasing depressive symptoms and preventing onset of major depression.",['Mothers and Babies (MB'],['Paraprofessional and Professional Delivery of a Perinatal Depression Preventive Intervention'],"['mean facilitator adherence and competency overall, by study arm, and by session; and, examined site, facilitator, and client-specific effects']","[{'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C4284586', 'cui_str': 'Perinatal depression'}, {'cui': 'C1456501', 'cui_str': 'Preventive'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}]",,0.0355021,"Mothers and Babies (MB), a perinatal depression preventive intervention, has proven effective in decreasing depressive symptoms and preventing onset of major depression.","[{'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Diebold', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, Suite 643, Chicago, IL, 60611, USA. alicia.diebold@northwestern.edu.'}, {'ForeName': 'Jody D', 'Initials': 'JD', 'LastName': 'Ciolino', 'Affiliation': 'Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, USA.'}, {'ForeName': 'Jessica K', 'Initials': 'JK', 'LastName': 'Johnson', 'Affiliation': 'Institute for Public Health and Medicine, Center for Community Health, Feinberg School of Medicine, Northwestern University, 750 N. Lake Shore Drive, Suite 643, Chicago, IL, 60611, USA.'}, {'ForeName': 'Chen', 'Initials': 'C', 'LastName': 'Yeh', 'Affiliation': 'Division of Biostatistics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, USA.'}, {'ForeName': 'Jackie K', 'Initials': 'JK', 'LastName': 'Gollan', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Feinberg School of Medicine, Northwestern University, Chicago, USA.'}, {'ForeName': 'S Darius', 'Initials': 'SD', 'LastName': 'Tandon', 'Affiliation': 'Department of Medical Social Sciences, Institute for Public Health and Medicine, Center for Community Health, Feinberg School of Medicine, Northwestern University, Chicago, USA.'}]",Administration and policy in mental health,['10.1007/s10488-020-01022-5'] 3071,30877850,Obsessive-compulsive tendencies predict seeking proxies for understanding.,"BACKGROUND AND OBJECTIVES The Seeking Proxies for Internal States (SPIS) model of obsessive-compulsive disorder (OCD) postulates that obsessive-compulsive (OC) individuals have reduced access to their internal states and must therefore seek and rely on external proxies for these states. The present study extended this hypothesis to the feeling of understanding, which had not been examined previously in relation to OCD. METHODS We presented 148 participants with a computerized task requiring them to read and understand a text on medieval architecture. Participants were randomly assigned to an ongoing feedback condition (comprehension quiz and answers provided after each text segment) or no-feedback condition (quiz and answers provided only at the end). Throughout, participants were offered proxies in the form of ""learning aids,"" which were unrelated to text comprehension. Participants were divided to high vs. low OC tendencies based on a median split on a measure of OCD symptoms. RESULTS As predicted, lacking feedback on understanding was associated with higher use of proxies and high OC participants used more proxies than low OC participants in the no-feedback condition. Actual understanding, as assessed by comprehension scores, was unrelated to OC tendencies. LIMITATIONS Among other limitations discussed in the article, our results were obtained on a non-selected sample of students varying on OC tendencies. It would be important to replicate these findings with diagnosed OCD participants as compared to both non-clinical and anxiety disorders control participants. CONCLUSIONS These findings extend the SPIS model to the domain of understanding and may have important clinical implications.",2019,"As predicted, lacking feedback on understanding was associated with higher use of proxies and high OC participants used more proxies than low OC participants in the no-feedback condition.",['148 participants with a computerized task requiring them to read and understand a text on medieval architecture'],['ongoing feedback condition (comprehension quiz and answers provided after each text segment) or no-feedback condition (quiz and answers provided only at the end'],[],"[{'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0003737', 'cui_str': 'Architecture'}]","[{'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C3541382', 'cui_str': 'Text'}, {'cui': 'C0441635', 'cui_str': 'Segment (qualifier value)'}, {'cui': 'C1272693', 'cui_str': 'Ended'}]",[],148.0,0.0158582,"As predicted, lacking feedback on understanding was associated with higher use of proxies and high OC participants used more proxies than low OC participants in the no-feedback condition.","[{'ForeName': 'Reuven', 'Initials': 'R', 'LastName': 'Dar', 'Affiliation': 'Tel Aviv University, School of Psychological Sciences, Tel Aviv, 69978, Israel. Electronic address: ruvidar@tauex.tau.ac.il.'}, {'ForeName': 'Tal', 'Initials': 'T', 'LastName': 'Eden', 'Affiliation': 'Tel Aviv University, School of Psychological Sciences, Tel Aviv, 69978, Israel. Electronic address: taliko@gmail.com.'}, {'ForeName': 'Michal', 'Initials': 'M', 'LastName': 'van Dongen', 'Affiliation': 'Tel Aviv University, School of Psychological Sciences, Tel Aviv, 69978, Israel. Electronic address: michalvd55@gmail.com.'}, {'ForeName': 'Marit', 'Initials': 'M', 'LastName': 'Hauschildt', 'Affiliation': 'Tel Aviv University, School of Psychological Sciences, Tel Aviv, 69978, Israel. Electronic address: marith@tau.mail.ac.il.'}, {'ForeName': 'Nira', 'Initials': 'N', 'LastName': 'Liberman', 'Affiliation': 'Tel Aviv University, School of Psychological Sciences, Tel Aviv, 69978, Israel. Electronic address: niralib@tauex.tau.ac.il.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.03.004'] 3072,30883057,Coronary Angiography after Cardiac Arrest without ST-Segment Elevation.,"BACKGROUND Ischemic heart disease is a major cause of out-of-hospital cardiac arrest. The role of immediate coronary angiography and percutaneous coronary intervention (PCI) in the treatment of patients who have been successfully resuscitated after cardiac arrest in the absence of ST-segment elevation myocardial infarction (STEMI) remains uncertain. METHODS In this multicenter trial, we randomly assigned 552 patients who had cardiac arrest without signs of STEMI to undergo immediate coronary angiography or coronary angiography that was delayed until after neurologic recovery. All patients underwent PCI if indicated. The primary end point was survival at 90 days. Secondary end points included survival at 90 days with good cerebral performance or mild or moderate disability, myocardial injury, duration of catecholamine support, markers of shock, recurrence of ventricular tachycardia, duration of mechanical ventilation, major bleeding, occurrence of acute kidney injury, need for renal-replacement therapy, time to target temperature, and neurologic status at discharge from the intensive care unit. RESULTS At 90 days, 176 of 273 patients (64.5%) in the immediate angiography group and 178 of 265 patients (67.2%) in the delayed angiography group were alive (odds ratio, 0.89; 95% confidence interval [CI], 0.62 to 1.27; P = 0.51). The median time to target temperature was 5.4 hours in the immediate angiography group and 4.7 hours in the delayed angiography group (ratio of geometric means, 1.19; 95% CI, 1.04 to 1.36). No significant differences between the groups were found in the remaining secondary end points. CONCLUSIONS Among patients who had been successfully resuscitated after out-of-hospital cardiac arrest and had no signs of STEMI, a strategy of immediate angiography was not found to be better than a strategy of delayed angiography with respect to overall survival at 90 days. (Funded by the Netherlands Heart Institute and others; COACT Netherlands Trial Register number, NTR4973.).",2019,"At 90 days, 176 of 273 patients (64.5%) in the immediate angiography group and 178 of 265 patients (67.2%) in the delayed angiography group were alive (odds ratio, 0.89; 95% confidence interval [CI], 0.62 to 1.27; P = 0.51).","['552 patients who had cardiac arrest without signs of STEMI to undergo immediate coronary angiography or coronary angiography that was delayed until after neurologic recovery', 'patients who have been successfully resuscitated after cardiac arrest in the absence of ST-segment elevation myocardial infarction (STEMI) remains uncertain']","['immediate coronary angiography and percutaneous coronary intervention (PCI', 'Coronary Angiography']","['survival at 90 days with good cerebral performance or mild or moderate disability, myocardial injury, duration of catecholamine support, markers of shock, recurrence of ventricular tachycardia, duration of mechanical ventilation, major bleeding, occurrence of acute kidney injury, need for renal-replacement therapy, time to target temperature, and neurologic status at discharge from the intensive care unit', 'survival', 'overall survival', 'median time to target temperature']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0018790', 'cui_str': 'Cardiac Arrest'}, {'cui': 'C0311392', 'cui_str': 'Sign'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C2587207', 'cui_str': 'Resuscitate'}, {'cui': 'C0332197', 'cui_str': 'Absent (qualifier value)'}, {'cui': 'C0087130', 'cui_str': 'Uncertainty'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0085532', 'cui_str': 'Angiography of coronary arteries'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0007412', 'cui_str': 'Sympathins'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C1869063', 'cui_str': 'Shock (SMQ)'}, {'cui': 'C2825055', 'cui_str': 'Recurrence'}, {'cui': 'C0042514', 'cui_str': 'Tachycardia, Ventricular'}, {'cui': 'C0199470', 'cui_str': 'Mechanically assisted ventilation'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0206074', 'cui_str': 'Kidney Replacement Therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0039476', 'cui_str': 'Temperature'}, {'cui': 'C0205494', 'cui_str': 'Neurologic (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C3871203', 'cui_str': 'At discharge (qualifier value)'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",552.0,0.128389,"At 90 days, 176 of 273 patients (64.5%) in the immediate angiography group and 178 of 265 patients (67.2%) in the delayed angiography group were alive (odds ratio, 0.89; 95% confidence interval [CI], 0.62 to 1.27; P = 0.51).","[{'ForeName': 'Jorrit S', 'Initials': 'JS', 'LastName': 'Lemkes', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Gladys N', 'Initials': 'GN', 'LastName': 'Janssens', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Nina W', 'Initials': 'NW', 'LastName': 'van der Hoeven', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Lucia S D', 'Initials': 'LSD', 'LastName': 'Jewbali', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Eric A', 'Initials': 'EA', 'LastName': 'Dubois', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Martijn', 'Initials': 'M', 'LastName': 'Meuwissen', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Tom A', 'Initials': 'TA', 'LastName': 'Rijpstra', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Hans A', 'Initials': 'HA', 'LastName': 'Bosker', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Michiel J', 'Initials': 'MJ', 'LastName': 'Blans', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Gabe B', 'Initials': 'GB', 'LastName': 'Bleeker', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Rémon', 'Initials': 'R', 'LastName': 'Baak', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Georgios J', 'Initials': 'GJ', 'LastName': 'Vlachojannis', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Bob J W', 'Initials': 'BJW', 'LastName': 'Eikemans', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Pim', 'Initials': 'P', 'LastName': 'van der Harst', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Iwan C C', 'Initials': 'ICC', 'LastName': 'van der Horst', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Michiel', 'Initials': 'M', 'LastName': 'Voskuil', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Joris J', 'Initials': 'JJ', 'LastName': 'van der Heijden', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Albertus', 'Initials': 'A', 'LastName': 'Beishuizen', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Stoel', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Cyril', 'Initials': 'C', 'LastName': 'Camaro', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'van der Hoeven', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'José P', 'Initials': 'JP', 'LastName': 'Henriques', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Alexander P J', 'Initials': 'APJ', 'LastName': 'Vlaar', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Maarten A', 'Initials': 'MA', 'LastName': 'Vink', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Bas', 'Initials': 'B', 'LastName': 'van den Bogaard', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Ton A C M', 'Initials': 'TACM', 'LastName': 'Heestermans', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Wouter', 'Initials': 'W', 'LastName': 'de Ruijter', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Thijs S R', 'Initials': 'TSR', 'LastName': 'Delnoij', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Harry J G M', 'Initials': 'HJGM', 'LastName': 'Crijns', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Gillian A J', 'Initials': 'GAJ', 'LastName': 'Jessurun', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Pranobe V', 'Initials': 'PV', 'LastName': 'Oemrawsingh', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Marcel T M', 'Initials': 'MTM', 'LastName': 'Gosselink', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Koos', 'Initials': 'K', 'LastName': 'Plomp', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Magro', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Paul W G', 'Initials': 'PWG', 'LastName': 'Elbers', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Peter M', 'Initials': 'PM', 'LastName': 'van de Ven', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Heleen M', 'Initials': 'HM', 'LastName': 'Oudemans-van Straaten', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}, {'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'van Royen', 'Affiliation': 'From the Departments of Cardiology (J.S.L., G.N.J., N.W.H., N.R.), Intensive Care Medicine (P.W.G.E., H.M.O.-S.), and Epidemiology and Biostatistics (P.M.V.), Amsterdam University Medical Center VUmc, the Departments of Cardiology (J.P.H.) and Intensive Care Medicine (A.P.J.V.), Amsterdam University Medical Center AMC, and the Departments of Cardiology (M.A.V.) and Intensive Care Medicine (B.B.), Onze Lieve Vrouwe Gasthuis, Amsterdam, the Thorax Center, Erasmus Medical Center (L.S.D.J., E.A.D.), and the Departments of Cardiology (G.J.V.) and Intensive Care Medicine (B.J.W.E.), Maasstad Hospital, Rotterdam, the Departments of Cardiology (M. Meuwissen) and Intensive Care Medicine (T.A.R.), Amphia Hospital, Breda, the Departments of Cardiology (H.A.B.) and Intensive Care Medicine (M.J.B.), Rijnstate Hospital, Arnhem, the Departments of Cardiology (G.B.B.) and Intensive Care Medicine (R.B.), Haga Hospital, and the Department of Cardiology, Haaglanden Medical Center (P.V.O.), The Hague, the Departments of Cardiology (P.H.) and Intensive Care Medicine (I.C.C.H.), University of Groningen, Groningen, the Departments of Cardiology (M.V.) and Intensive Care Medicine (J.J.H.), University Medical Center Utrecht, Utrecht, the Departments of Intensive Care Medicine (A.B.) and Cardiology (M.S.), Medisch Spectrum Twente, Enschede, the Departments of Cardiology (C.C., N.R.) and Intensive Care Medicine (H.H.), Radboud University Medical Center, Nijmegen, the Departments of Cardiology (T.A.C.M.H.) and Intensive Care Medicine (W.R.), Noordwest Ziekenhuisgroep, Alkmaar, the Departments of Intensive Care Medicine (T.S.R.D.) and Cardiology (H.J.G.M.C.), Maastricht University Medical Center, Maastricht, the Department of Cardiology, Scheper Hospital, Emmen (G.A.J.J.), the Department of Cardiology, Isala Hospital, Zwolle (M.T.M.G.), the Department of Cardiology, Tergooi Hospital, Blaricum (K.P.), and the Department of Cardiology, Elisabeth-Tweesteden Hospital, Tilburg (M. Magro) - all in the Netherlands.'}]",The New England journal of medicine,['10.1056/NEJMoa1816897'] 3073,31667747,"Yoga, Physical Therapy, and Back Pain Education for Sleep Quality in Low-Income Racially Diverse Adults with Chronic Low Back Pain: a Secondary Analysis of a Randomized Controlled Trial.","BACKGROUND Poor sleep is common among adults with chronic low back pain (cLBP), but the influence of cLBP treatments, such as yoga and physical therapy (PT), on sleep quality is under studied. OBJECTIVE Evaluate the effectiveness of yoga and PT for improving sleep quality in adults with cLBP. DESIGN Secondary analysis of a randomized controlled trial. SETTING Academic safety-net hospital and 7 affiliated community health centers. PARTICIPANTS A total of 320 adults with cLBP. INTERVENTION Twelve weekly yoga classes, 1-on-1 PT sessions, or an educational book. MAIN MEASURES Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI) global score (0-21) at baseline, 12 weeks, and 52 weeks. Additionally, we also evaluated how the proportion of participants who achieved a clinically meaningful improvement in sleep quality (> 3-point reduction in PSQI) at 12 weeks varied by changes in pain and physical function at 6 weeks. KEY RESULTS Among participants (mean age = 46.0, 64% female, 82% non-white), nearly all (92%) reported poor sleep quality (PSQI > 5) at baseline. At 12 weeks, modest improvements in sleep quality were observed among the yoga (PSQI mean difference [MD] = - 1.19, 95% confidence interval [CI] - 1.82, - 0.55) and PT (PSQI MD = - 0.91, 95% CI - 1.61, - 0.20) groups. Participants who reported a ≥ 30% improvement in pain or physical function at 6 weeks, compared with those who improved < 10%, were more likely to be a sleep quality responder at 12 weeks (odds ratio [OR] = 3.51, 95% CI 1.73, 7.11 and OR = 2.16, 95% CI 1.18, 3.95, respectively). Results were similar at 52 weeks. CONCLUSION In a sample of adults with cLBP, virtually all with poor sleep quality prior to intervention, modest but statistically significant improvements in sleep quality were observed with both yoga and PT. Irrespective of treatment, clinically important sleep improvements at the end of the intervention were associated with mid-intervention pain and physical function improvements. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01343927.",2020,"Irrespective of treatment, clinically important sleep improvements at the end of the intervention were associated with mid-intervention pain and physical function improvements. ","['participants (mean age\u2009=\u200946.0, 64% female, 82% non-white', 'A total of 320 adults with cLBP', 'adults with cLBP', 'Low-Income Racially Diverse Adults with Chronic Low Back Pain', 'Academic safety-net hospital and 7 affiliated community health centers', 'adults with chronic low back pain (cLBP']","['Yoga, Physical Therapy, and Back Pain Education', 'yoga and PT']","['Sleep quality', 'mid-intervention pain and physical function improvements', 'Pittsburgh Sleep Quality Index (PSQI) global score', 'sleep quality', 'sleep quality responder', 'poor sleep quality', 'pain and physical function', 'pain or physical function']","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C4517711', 'cui_str': '320 (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0457949', 'cui_str': 'Chronic low back pain (finding)'}, {'cui': 'C3661443', 'cui_str': 'Safety-net Hospitals'}, {'cui': 'C0009469', 'cui_str': 'Satellite Centers'}]","[{'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0004604', 'cui_str': 'Backache'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0444598', 'cui_str': 'Mid (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3697468', 'cui_str': 'PSQI - Pittsburgh sleep quality index'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0235162', 'cui_str': 'Difficulty sleeping (finding)'}]",320.0,0.158432,"Irrespective of treatment, clinically important sleep improvements at the end of the intervention were associated with mid-intervention pain and physical function improvements. ","[{'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Roseen', 'Affiliation': 'Department of Family Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA. Eric.Roseen@bmc.org.'}, {'ForeName': 'Hanna', 'Initials': 'H', 'LastName': 'Gerlovin', 'Affiliation': 'Slone Epidemiology Center, Boston University School of Medicine, Boston, MA, USA.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Femia', 'Affiliation': 'Department of Family Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Jae', 'Initials': 'J', 'LastName': 'Cho', 'Affiliation': 'Department of Family Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Bertisch', 'Affiliation': ""Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Redline', 'Affiliation': ""Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Karen J', 'Initials': 'KJ', 'LastName': 'Sherman', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Saper', 'Affiliation': 'Department of Family Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05329-4'] 3074,32087113,Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial.,"BACKGROUND The effectiveness of contact isolation for decreasing the spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) has been questioned. The aim of this study was to establish the benefits of contact isolation over standard precautions for reducing the incidence density of ESBL-E colonisation and infection in adult medical and surgical wards with an active surveillance culture programme. METHODS We did a cluster-randomised crossover trial in adult wards in four European university hospitals. Medical, surgical, or combined medical-surgical wards without critical care were randomised to continue standard precautions alone or implement contact isolation alongside standard precautions for 12 months, followed by a 1 month washout period and 12 months of the alternate strategy. Randomisation was done via a computer-generated sequence, with a block size of two consecutive wards. Only laboratory technicians and data analysts were masked to allocation. Patients were screened for ESBL-E carriage within 3 days of admission, once a week thereafter, and on discharge. The primary outcome was the incidence density of ESBL-E, defined as the acquisition rate per 1000 patient-days at risk at the ward level and assessed in the per-protocol population, which included all patients screened at least twice with a length of stay of more than 1 week for each intervention period. No specific safety measures were assessed given the minimal risk of adverse events. The trial is registered, ISRCTN57648070. FINDINGS We enrolled 20 wards from four hospitals in Germany (eight wards), the Netherlands (four wards), Spain (four wards), and Switzerland (four wards). Between Jan 6, 2014, and Aug 31, 2016, 38 357 patients were admitted to these wards. Among 15 184 patients with a length of stay of more than 1 week, 11 368 patients (75%) were screened at least twice. The incidence density of ward-acquired ESBL-E was 6·0 events per 1000 patient-days at risk (95% CI 5·4-6·7) during periods of contact isolation and 6·1 (5·5-6·7) during periods of standard precautions (p=0·9710). Multivariable analysis adjusted for length of stay, percentage of patients screened, and prevalence in first screening cultures yielded an incidence rate ratio of 0·99 (95% CI 0·80-1·22; p=0·9177) for care under contact isolation compared with standard precautions. INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. FUNDING European Commission.",2020,"INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. ","['adult wards in four European university hospitals', 'adult medical and surgical wards with an active surveillance culture programme', 'Between Jan 6, 2014, and Aug 31, 2016, 38 357 patients were admitted to these wards', 'Medical, surgical, or combined medical-surgical wards without critical care', 'enrolled 20 wards from four hospitals in Germany (eight wards), the Netherlands (four wards), Spain (four wards), and Switzerland (four wards', 'Among 15\u2008184 patients with a length of stay of more than 1 week, 11\u2008368 patients (75%) were screened at least twice']",['Contact isolation versus standard precautions'],"['incidence density of ESBL-E, defined as the acquisition rate per 1000 patient-days at risk at the ward level', 'minimal risk of adverse events', 'incidence density of ward-acquired ESBL-E', 'ESBL-E carriage']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C1827061', 'cui_str': 'Active surveillance'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0010337', 'cui_str': 'Critical Care'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0017480', 'cui_str': 'Germany'}, {'cui': 'C0037747', 'cui_str': 'Spain'}, {'cui': 'C0039021', 'cui_str': 'Switzerland'}, {'cui': 'C4517616', 'cui_str': 'One hundred and eighty-four'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1720725', 'cui_str': 'Twice'}]","[{'cui': 'C0034386', 'cui_str': 'Quarantine'}, {'cui': 'C1443867', 'cui_str': 'Standard precautions'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C1444096', 'cui_str': 'Extended spectrum beta-lactamase producing bacteria'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439661', 'cui_str': 'Acquired (qualifier value)'}]",38357.0,0.141702,"INTERPRETATION Contact isolation showed no benefit when added to standard precautions for controlling the spread of ESBL-E on non-critical care wards with extensive surveillance screening. ","[{'ForeName': 'Friederike', 'Initials': 'F', 'LastName': 'Maechler', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: friederike.maechler@charite.de.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'Schwab', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Hansen', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Carolina', 'Initials': 'C', 'LastName': 'Fankhauser', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Harbarth', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Benedikt D', 'Initials': 'BD', 'LastName': 'Huttner', 'Affiliation': 'Infection Control Program, Geneva University Hospitals and Medical School, Geneva, Switzerland.'}, {'ForeName': 'Cristina', 'Initials': 'C', 'LastName': 'Diaz-Agero', 'Affiliation': 'Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Nieves', 'Initials': 'N', 'LastName': 'Lopez', 'Affiliation': 'Servicio de Medicina Preventiva y Salud Pública, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Canton', 'Affiliation': 'Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Ruiz-Garbajosa', 'Affiliation': 'Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.'}, {'ForeName': 'Hetty', 'Initials': 'H', 'LastName': 'Blok', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Marc J', 'Initials': 'MJ', 'LastName': 'Bonten', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Fieke', 'Initials': 'F', 'LastName': 'Kloosterman', 'Affiliation': 'Department of Medical Microbiology and Infection Control, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Joost', 'Initials': 'J', 'LastName': 'Schotsman', 'Affiliation': 'Department of Biostatistics and Research Support, Julius Center, University Medical Center Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'Ben S', 'Initials': 'BS', 'LastName': 'Cooper', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Behnke', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Golembus', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Axel', 'Initials': 'A', 'LastName': 'Kola', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Gastmeier', 'Affiliation': 'Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30626-7'] 3075,30743217,Preventive efforts in the aftermath of analogue trauma: The effects of Tetris and exercise on intrusive images.,"BACKGROUND AND OBJECTIVES Efficacious interventions soon after trauma exposure to prevent posttraumatic stress disorder (PTSD) are scarce. Evidence suggests that post-trauma, reminder cues to reactivate trauma memory followed by a cognitive visuospatial task, such as Tetris, reduce later intrusive images. Furthermore, studies indicate that aerobic exercise may reduce PTSD symptoms. The present study aimed to test whether playing Tetris, without prior reminder cues, after an experimental trauma limits the development of analogue symptoms and to compare Tetris to aerobic exercise, which could plausibly alter cognitive-affective processing of the trauma as well. METHODS Participants (N = 71) watched a distressing film and were randomly assigned to either playing Tetris, cycling, or remaining sedentary for 25 min without prior reminder cues. Intrusive images and co-occurring distress were recorded in a diary during the following week. After one week, participants completed a recognition test to assess voluntary memories of the film. RESULTS Neither Tetris nor exercise, without prior memory reactivation, reduced intrusive images and associated distress nor impeded voluntary memory compared to the control condition. There were no effects of physical fitness level at baseline or voluntary exercise during the subsequent week on analogue symptoms. LIMITATIONS Although participants were instructed to record intrusions as they occurred in diaries, they did not receive additional reminders throughout the follow-up period. CONCLUSIONS Our findings suggest that neither a single bout of aerobic exercise, nor playing Tetris without prior memory reactivation, after an analogue trauma reduces stress symptoms. Potential explanations and clinical implications are discussed.",2019,"Neither Tetris nor exercise, without prior memory reactivation, reduced intrusive images and associated distress nor impeded voluntary memory compared to the control condition.",['Participants (N\u202f=\u202f71) watched a distressing film'],"['aerobic exercise', 'playing', 'Tetris and exercise']","['Intrusive images and co-occurring distress', 'PTSD symptoms', 'physical fitness level', 'intrusive images and associated distress nor impeded voluntary memory']","[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C4319646', 'cui_str': 'Film'}]","[{'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C3542466', 'cui_str': 'Image (foundation metadata concept)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0038436', 'cui_str': 'Neuroses, Posttraumatic'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0025260', 'cui_str': 'Memory'}]",,0.0916578,"Neither Tetris nor exercise, without prior memory reactivation, reduced intrusive images and associated distress nor impeded voluntary memory compared to the control condition.","[{'ForeName': 'Antonia', 'Initials': 'A', 'LastName': 'Brühl', 'Affiliation': 'University of Braunschweig, Department of Psychology, Institute of Clinical Psychology, Psychotherapy and Assessment, Humboldtstr. 33, 38106, Braunschweig, Germany. Electronic address: a.bruehl@tu-bs.de.'}, {'ForeName': 'Nina', 'Initials': 'N', 'LastName': 'Heinrichs', 'Affiliation': 'University of Braunschweig, Department of Psychology, Institute of Clinical Psychology, Psychotherapy and Assessment, Humboldtstr. 33, 38106, Braunschweig, Germany. Electronic address: nheinric@uni-bremen.de.'}, {'ForeName': 'Emily E', 'Initials': 'EE', 'LastName': 'Bernstein', 'Affiliation': 'Harvard University, Department of Psychology, 1230 William James Hall, 33 Kirkland Street, Cambridge, MA, 02138-2044, USA. Electronic address: ebernstein@g.harvard.edu.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': 'McNally', 'Affiliation': 'Harvard University, Department of Psychology, 1230 William James Hall, 33 Kirkland Street, Cambridge, MA, 02138-2044, USA. Electronic address: rjm@wjh.harvard.edu.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.01.004'] 3076,32081236,The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.,"OBJECTIVES The goal of this study was to evaluate the 5-year follow-up data of the IN.PACT DEEP (Randomized IN.PACT Amphirion Drug-Coated Balloon [DCB] vs. Standard Percutaneous Transluminal Angioplasty [PTA] for the Treatment of Below-the-Knee Critical Limb Ischemia [CLI]) trial. BACKGROUND Initial studies from randomized controlled trials have shown comparable short-term outcomes of DCB angioplasty versus PTA in patients with CLI with infrapopliteal disease. However, the long-term safety and effectiveness of DCB angioplasty remain unknown in this patient population. METHODS IN.PACT DEEP was an independently adjudicated prospective, multicenter, randomized controlled trial that enrolled 358 subjects with CLI. Subjects were randomized 2:1 to DCB angioplasty or PTA. Assessments through 5 years included freedom from clinically driven target lesion revascularization, amputation, and all-cause death. Additional assessments were conducted to identify risk factors for death and major amputation, including paclitaxel dose tercile. RESULTS Freedom from clinically driven target lesion revascularization through 5 years was 70.9% and 76.0% (log-rank p = 0.406), and the incidence of the safety composite endpoint was 59.8% and 57.5% (log-rank p = 0.309) in the DCB angioplasty and PTA groups, respectively. The rate of major amputation was 15.4% for DCB angioplasty compared with 10.6% for PTA (log-rank p = 0.108). Given the recent concern regarding a late mortality signal in patients treated with paclitaxel-coated devices, additional analyses from this study showed no increase in all-cause mortality with DCB angioplasty (39.4%) compared with PTA (44.9%) (log-rank p = 0.727). Predictors of mortality included age, Rutherford category >4, and previous revascularization but not paclitaxel by dose tercile. CONCLUSIONS Tibial artery revascularization in patients with CLI using DCB angioplasty resulted in comparable long-term safety and effectiveness as PTA. Paclitaxel exposure was not related to increased risk for amputation or all-cause mortality at 5-year follow-up. (Study of IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia [INPACT-DEEP]; NCT00941733).",2020,The rate of major amputation was 15.4% for DCB angioplasty compared with 10.6% for PTA,"['Below the Knee Critical Limb Ischemia', 'patients with CLI with infrapopliteal disease', 'enrolled 358 subjects with CLI', 'patients with CLI using']","['PTA', 'Tibial artery revascularization', 'IN.PACT Amphirion™ Drug Eluting Balloon vs. Standard PTA', 'IN.PACT DEEP (Randomized IN.PACT Amphirion Drug-Coated Balloon [DCB] vs. Standard Percutaneous Transluminal Angioplasty [PTA', 'DCB angioplasty or PTA', 'Paclitaxel', 'DCB angioplasty', 'DCB angioplasty versus PTA']","['rate of major amputation', 'late mortality signal', 'incidence of the safety composite endpoint']","[{'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C1142264', 'cui_str': 'Critical limb ischemia'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C0015522', 'cui_str': 'Factor Eleven'}, {'cui': 'C0085427', 'cui_str': 'Tibial Arteries'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0336867', 'cui_str': 'Balloon aircraft (physical object)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0453946', 'cui_str': 'Coat (physical object)'}, {'cui': 'C2936666', 'cui_str': 'Percutaneous Transluminal Angioplasty'}, {'cui': 'C0162577', 'cui_str': 'Angioplasty'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0002688', 'cui_str': 'Amputation'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}]",358.0,0.12449,The rate of major amputation was 15.4% for DCB angioplasty compared with 10.6% for PTA,"[{'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Zeller', 'Affiliation': 'Universitaets-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany. Electronic address: thomas.zeller@universitaets-herzzentrum.de.'}, {'ForeName': 'Antonio', 'Initials': 'A', 'LastName': 'Micari', 'Affiliation': 'Department of Cardiology, Humanitas Gavazzeni Hospital, Bergamo, Italy.'}, {'ForeName': 'Dierk', 'Initials': 'D', 'LastName': 'Scheinert', 'Affiliation': 'University of Leipzig Medical Center, Leipzig, Germany.'}, {'ForeName': 'Iris', 'Initials': 'I', 'LastName': 'Baumgartner', 'Affiliation': 'Swiss Cardiovascular Center, Division of Angiology, University Hospital, Inselspital, Bern, Switzerland.'}, {'ForeName': 'Marc', 'Initials': 'M', 'LastName': 'Bosiers', 'Affiliation': 'Department of Vascular Surgery, A.Z. Sint-Blasius, Dendermonde, Belgium.'}, {'ForeName': 'Frank E G', 'Initials': 'FEG', 'LastName': 'Vermassen', 'Affiliation': 'Department of Vascular Surgery, Ghent University Hospital, Gent, Belgium.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Banyai', 'Affiliation': 'Department of Angiology, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Mehdi H', 'Initials': 'MH', 'LastName': 'Shishehbor', 'Affiliation': 'Heart & Vascular Institute, University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio.'}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Wang', 'Affiliation': 'Medtronic, Santa Rosa, California.'}, {'ForeName': 'Marianne', 'Initials': 'M', 'LastName': 'Brodmann', 'Affiliation': 'Department of Internal Medicine, Division of Angiology, Medical University, Graz, Austria.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.10.059'] 3077,31305329,Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.,"OBJECTIVE To evaluate the efficacy and safety of switching from an abacavir/lamivudine (ABC/3TC)-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single-tablet regimen in virologically suppressed, HIV-1-infected adults. DESIGN Randomized, open-label, noninferiority study. METHODS Participants with HIV-1 RNA levels less than 50 copies/ml receiving ABC/3TC plus a third agent for at least 6 months were randomized 2 : 1 to switch immediately to E/C/F/TAF (immediate-switch group) for 48 weeks or to continue receiving ABC/3TC plus a third agent for 24 weeks followed by E/C/F/TAF for 24 weeks (delayed-switch group). The primary endpoint was HIV-1 RNA less than 50 copies/ml at Week 24 by Food and Drug Administration Snapshot algorithm (-12% noninferiority margin). RESULTS Baseline characteristics of 274 participants (183 in immediate-switch group and 91 in delayed-switch group) were similar. Virologic response was maintained at Week 24 by 93.4 and 97.8% of participants in the immediate-switch and delayed-switch groups, respectively, with a treatment difference of -4.4% (95% confidence interval: -9.4 to 1.9%), confirming noninferiority. Adverse events of any grade were similar between groups through Week 24 (66% E/C/F/TAF, 64% ABC/3TC); adverse event-related drug discontinuations occurred in 4% of participants switching to E/C/F/TAF (no discontinuations because of renal events) and no participants continuing ABC/3TC. Renal biomarkers of urine albumin:creatinine and beta-2-microglobulin:creatinine ratios significantly improved on E/C/F/TAF. Self-reported treatment satisfaction was significantly higher with E/C/F/TAF. CONCLUSION Switching to E/C/F/TAF was noninferior to continuing ABC/3TC plus a third agent for maintenance of HIV RNA suppression at Week 24. This study supports E/C/F/TAF as an efficacious and well tolerated option for participants switching from ABC/3TC-based regimens.",2019,"Adverse events of any grade were similar between groups through Week 24 (66% E/C/F/TAF, 64% ABC/3TC); adverse event-related drug discontinuations occurred in 4% of participants switching to E/C/F/TAF (no discontinuations because of renal events) and no participants continuing ABC/3TC.","['virologically suppressed, HIV-1-infected adults', 'Participants with HIV-1 RNA levels less than 50\u200acopies/ml receiving ABC/3TC plus a third agent for at least 6 months were', '274 participants (183 in immediate-switch group and 91 in delayed-switch group', 'participants switching from ABC/3TC-based regimens']","['abacavir/lamivudine (ABC/3TC)-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF', 'randomized 2\u200a:\u200a1 to switch immediately to E/C/F/TAF (immediate-switch group) for 48 weeks or to continue receiving ABC/3TC plus a third agent for 24 weeks followed by E/C/F/TAF', 'elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen', 'abacavir/lamivudine']","['Self-reported treatment satisfaction', 'Adverse events', 'Virologic response', 'HIV-1 RNA less', 'adverse event-related drug discontinuations', 'Renal biomarkers of urine albumin:creatinine and beta-2-microglobulin:creatinine ratios', 'efficacy and safety']","[{'cui': 'C1260953', 'cui_str': 'Suppressed (qualifier value)'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C4517615', 'cui_str': 'One hundred and eighty-three'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C1613391', 'cui_str': 'abacavir / Lamivudine'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2606637', 'cui_str': 'elvitegravir'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}, {'cui': 'C4059167', 'cui_str': 'emtricitabine / tenofovir alafenamide'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205466', 'cui_str': 'virology'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0035668', 'cui_str': 'RNA'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0042037'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0010294', 'cui_str': 'Creatinine'}, {'cui': 'C0201910', 'cui_str': 'Beta-2-microglobulin measurement (procedure)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",274.0,0.122403,"Adverse events of any grade were similar between groups through Week 24 (66% E/C/F/TAF, 64% ABC/3TC); adverse event-related drug discontinuations occurred in 4% of participants switching to E/C/F/TAF (no discontinuations because of renal events) and no participants continuing ABC/3TC.","[{'ForeName': 'Giuliano', 'Initials': 'G', 'LastName': 'Rizzardini', 'Affiliation': 'ASST Fatebenefratelli-Sacco, Milan, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Gori', 'Affiliation': 'Infectious Diseases Unit, San Gerardo Hospital, Monza, Italy.'}, {'ForeName': 'Celia', 'Initials': 'C', 'LastName': 'Miralles', 'Affiliation': 'Complejo Hospitalario Universitario de Vigo, Vigo.'}, {'ForeName': 'Julián', 'Initials': 'J', 'LastName': 'Olalla', 'Affiliation': 'Hospital Universitario Cruces, Bilbao, Spain.'}, {'ForeName': 'Jean-Michel', 'Initials': 'JM', 'LastName': 'Molina', 'Affiliation': 'Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris, University Paris Diderot.'}, {'ForeName': 'François', 'Initials': 'F', 'LastName': 'Raffi', 'Affiliation': 'Department of Infectious Diseases, University Hospital of Nantes and CIC 1413, INSERM, Nantes, France.'}, {'ForeName': 'Princy', 'Initials': 'P', 'LastName': 'Kumar', 'Affiliation': 'Division of Infectious Diseases, Georgetown University, Washington, DC, USA.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Antinori', 'Affiliation': 'HIV/AIDS Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.'}, {'ForeName': 'Moti', 'Initials': 'M', 'LastName': 'Ramgopal', 'Affiliation': 'Midway Immunology and Research Center, Fort Pierce, Florida, USA.'}, {'ForeName': 'Hans-Jürgen', 'Initials': 'HJ', 'LastName': 'Stellbrink', 'Affiliation': 'ICH Study Center, Hamburg, Germany.'}, {'ForeName': 'Moupali', 'Initials': 'M', 'LastName': 'Das', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Hoa', 'Initials': 'H', 'LastName': 'Chu', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Renee', 'Initials': 'R', 'LastName': 'Ram', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Will', 'Initials': 'W', 'LastName': 'Garner', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Yongwu', 'Initials': 'Y', 'LastName': 'Shao', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Susan K', 'Initials': 'SK', 'LastName': 'Chuck', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Piontkowsky', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}, {'ForeName': 'Richard H', 'Initials': 'RH', 'LastName': 'Haubrich', 'Affiliation': 'Gilead Sciences, Inc., Foster City, California, USA.'}]","AIDS (London, England)",['10.1097/QAD.0000000000002244'] 3078,31306167,Risk of HIV-1 acquisition among South African women using a variety of contraceptive methods in a prospective study.,"OBJECTIVE Observational studies have associated use of intramuscular injectable depot medroxyprogesterone acetate (DMPA-IM) with increased risk of HIV-1 acquisition, but limited data are available to assess HIV-1 risk for alternate contraceptive methods. METHODS Within a randomized trial of the dapivirine vaginal ring for HIV-1 prevention, we assessed HIV-1 incidence by contraceptive method. We limited analyses to participants from South African sites and to women who used DMPA-IM, the alternative injectable norethisterone enanthate, implants, or copper intrauterine devices (IUDs). Contraceptive method was assessed as a time-dependent exposure and multivariate models adjusted for trial randomization arm, age, sexual behaviour, and incident sexually transmitted infections. RESULTS A total of 95 incident HIV-1 infections were observed: incidence 5.8 (DMPA-IM, n = 52), 6.2 (norethisterone enanthate, n = 28), 1.9 (implant, n = 3), and 4.5 (IUD, n = 12) cases per 100 woman-years. In multivariable models, there were no statistically significant differences between contraceptive methods in the risk of HIV-1 acquisition. However, compared with the IUD, the three hormonal methods each had point estimates near 1 while the implant had risk that was approximately half that of the IUD. When the three hormonal methods were combined, their relative risk compared with IUD was 0.90 (95% confidence interval 0.45-1.76). CONCLUSION Among women at risk of HIV-1 infections in South Africa, we found no statistically significant differences in HIV-1 incidence by contraceptive method. Implants had the lowest point estimate for HIV-1 incidence, and IUDs had risk comparable with injectable methods in multivariate models. Large, prospective studies are needed to define better the relative HIV-1 risks across different contraceptive methods.",2019,"Implants had the lowest point estimate for HIV-1 incidence, and IUDs had risk comparable with injectable methods in multivariate models.","['women at risk of HIV-1 infections in South Africa', ' n\u200a=\u200a28), 1.9 (implant, n\u200a=\u200a3), and 4.5 (IUD, n\u200a=\u200a12) cases per 100 woman-years', 'participants from South African sites and to women who used DMPA-IM, the alternative injectable', 'South African women']","['intramuscular injectable depot medroxyprogesterone acetate (DMPA-IM', 'norethisterone enanthate', 'norethisterone enanthate, implants, or copper intrauterine devices (IUDs', 'dapivirine vaginal ring for HIV-1 prevention']",['HIV-1 incidence'],"[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C2363741', 'cui_str': 'HIV-1 infection'}, {'cui': 'C0037712', 'cui_str': 'Union of South Africa'}, {'cui': 'C4517517', 'cui_str': '1.9 (qualifier value)'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0067376', 'cui_str': 'N,N-dimethyl-para-anisidine'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0086466', 'cui_str': 'Injectable Product'}, {'cui': 'C0065864', 'cui_str': 'medroxyprogesterone acetate'}, {'cui': 'C0067376', 'cui_str': 'N,N-dimethyl-para-anisidine'}, {'cui': 'C0068981', 'cui_str': 'norethindrone enanthate'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0021901', 'cui_str': 'IUD, Copper Releasing'}, {'cui': 'C1434916', 'cui_str': '4-((4-((2,4,6-trimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile'}, {'cui': 'C0042260', 'cui_str': 'Vaginal Ring'}, {'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}]","[{'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.455723,"Implants had the lowest point estimate for HIV-1 incidence, and IUDs had risk comparable with injectable methods in multivariate models.","[{'ForeName': 'Thesla', 'Initials': 'T', 'LastName': 'Palanee-Phillips', 'Affiliation': 'Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.'}, {'ForeName': 'Elizabeth R', 'Initials': 'ER', 'LastName': 'Brown', 'Affiliation': 'Fred Hutchinson Cancer Research Center.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Szydlo', 'Affiliation': 'Fred Hutchinson Cancer Research Center.'}, {'ForeName': 'Flavia', 'Initials': 'F', 'LastName': 'Matovu Kiweewa', 'Affiliation': 'Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.'}, {'ForeName': 'Arendevi', 'Initials': 'A', 'LastName': 'Pather', 'Affiliation': 'South African Medical Research Council.'}, {'ForeName': 'Ishana', 'Initials': 'I', 'LastName': 'Harkoo', 'Affiliation': 'Centre for the AIDS Programme of Research in South Africa, Durban.'}, {'ForeName': 'Gonasagrie', 'Initials': 'G', 'LastName': 'Nair', 'Affiliation': 'University of Cape Town, Cape Town, South Africa.'}, {'ForeName': 'Lydia', 'Initials': 'L', 'LastName': 'Soto-Torres', 'Affiliation': 'National Institutes of Health, Bethesda, Maryland.'}, {'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Hillier', 'Affiliation': 'University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Jared M', 'Initials': 'JM', 'LastName': 'Baeten', 'Affiliation': 'University of Washington, Seattle, Washington, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","AIDS (London, England)",['10.1097/QAD.0000000000002260'] 3079,19497643,[Non-pharmacological intervention as a strategy to improve antihypertensive treatment compliance].,"OBJECTIVE To evaluate the efficacy of an intervention by means of an educational magazine on treatment compliance in uncontrolled arterial hypertension (AHT). DESIGN Controlled, randomised clinical trial. SETTING 87 primary care centres. Spain. PARTICIPANTS A total of 450 patients with uncontrolled hypertension were included. INTERVENTION Two groups of 225 patients were formed: 1) Control group (CG): standard health intervention; 2) Intervention Group (IG): received a twice monthly educational magazine at home. MAIN MEASUREMENTS Compliance was measured using the Medication Event Monitoring System (MEMS-Aardex). Compliance rate (CR) was recorded. Compliers were defined as individuals with a treatment compliance of 80-110%. The percentage of compliers, the mean percentage of doses taken and the percentage of patients taking the medication at the correct times were estimated. The mean blood pressures (BPs) and the percentage of controlled patientswere calculated. The number needed to treat (NNT) was calculated. RESULTS A total of 393 individuals were evaluable (Age: 62.4 years), 196 in the IG and 197 in the CG. There were 83.2% (95% CI 78-88.4) and 49.2% (95% CI 42.2-56.2) (P=0.0001) of overall compliers in the IG and CG, respectively and 74% (95% CI: 67.9-80.1) and 42.6% (95% CI=35.7-49.5) (P=0.0001) of correct times compliers. A total of 81.6% (95% CI=76.2-86.5%)) were controlled in the IG and 56.3% (95% CI=49.4-63.2) in the CG. The NNT was 3.3 patients. CONCLUSIONS Therapeutic non-compliance was very high. The educational magazine is an effective strategy to improve the compliance and degree of control of the AHT.",2009,A total of 81.6% (95% CI=76.2-86.5%)) were controlled in the IG and 56.3% (95% CI=49.4-63.2) in the CG.,"['393 individuals were evaluable (Age: 62.4 years), 196 in the IG and 197 in the CG', 'uncontrolled arterial hypertension (AHT', 'A total of 450 patients with uncontrolled hypertension were included', 'Two groups of 225 patients were formed: 1', '87 primary care centres']","['educational magazine', 'Control group (CG): standard health intervention; 2) Intervention Group (IG): received a twice monthly educational magazine at home']","['Medication Event Monitoring System (MEMS-Aardex', 'mean blood pressures (BPs', 'Compliance rate (CR', 'number needed to treat (NNT']","[{'cui': 'C4517754', 'cui_str': 'Three hundred and ninety-three'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517625', 'cui_str': '196'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3844104', 'cui_str': 'Four hundred and fifty'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1868885', 'cui_str': 'Uncontrolled hypertension'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4517652', 'cui_str': '225 (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0162443', 'cui_str': 'Magazines'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0585303', 'cui_str': 'Twice monthly (qualifier value)'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}]","[{'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0009563', 'cui_str': 'Compliance'}, {'cui': 'C3179138', 'cui_str': 'Numbers Needed To Treat'}]",450.0,0.0597967,A total of 81.6% (95% CI=76.2-86.5%)) were controlled in the IG and 56.3% (95% CI=49.4-63.2) in the CG.,"[{'ForeName': 'Emilio', 'Initials': 'E', 'LastName': 'Márquez Contreras', 'Affiliation': 'Centro de Salud la Orden, Huelva, España. Electronic address: emarquezc@papps.org.'}, {'ForeName': 'Nieves', 'Initials': 'N', 'LastName': 'Martel Claros', 'Affiliation': 'Unidad de Hipertensión, Hospital Clínico San Carlos, Madrid, España.'}, {'ForeName': 'Vicente', 'Initials': 'V', 'LastName': 'Gil Guillén', 'Affiliation': 'Centro de Salud Monovar, Alicante, España.'}, {'ForeName': 'José Luis', 'Initials': 'JL', 'LastName': 'Martín De Pablos', 'Affiliation': 'Centro de Salud la Orden, Huelva, España.'}, {'ForeName': 'Mariano', 'Initials': 'M', 'LastName': 'De la Figuera Von Wichman', 'Affiliation': 'ABS la Mina, Barcelona, España.'}, {'ForeName': 'José Joaquín', 'Initials': 'JJ', 'LastName': 'Casado Martínez', 'Affiliation': 'Centro de Salud la Orden, Huelva, España.'}, {'ForeName': 'Jacinto', 'Initials': 'J', 'LastName': 'Espinosa García', 'Affiliation': 'Centro de Salud Villanueva de la Serena, Villanueva de la Serena, Badajoz, España.'}, {'ForeName': 'José Carlos', 'Initials': 'JC', 'LastName': 'Pastoriza Vilas', 'Affiliation': 'Centro de Salud Adoratrices, Huelva, España.'}]",Atencion primaria,['10.1016/j.aprim.2009.02.004'] 3080,31705465,How Clinicians Discuss Medications During Primary Care Encounters Among Older Adults with Cognitive Impairment.,"BACKGROUND People with cognitive impairment experience high rates of polypharmacy and potentially inappropriate medication use. How clinicians communicate about medications may affect to what extent patients and family companions understand and participate in decisions about medication use. OBJECTIVE To characterize how primary care clinicians discuss medications during encounters with older adults with cognitive impairment and their companions. DESIGN Qualitative content analysis of audio-recorded clinical encounters from SAME Page, a randomized controlled trial to examine the effects of a patient-family agenda setting checklist on primary care visit communication among patients with cognitive impairment. Visits occurred between August 2016 and August 2017. PARTICIPANTS Patients were 65 or older, had > 1 incorrect answer on a cognitive screener, and attended visits with a relative or unpaid companion. Clinicians were physicians, nurse practitioners, or physician assistants at participating practices. APPROACH The encounters were transcribed verbatim. We used qualitative content analysis to identify major themes. KEY RESULTS Patients were on average 79.9 years of age. The average MMSE score was 21.6. About half of clinicians reported practicing for 15 or more years (n = 8). We identified three major themes. First, we found numerous instances in which primary care clinicians introduced patients and companions to key principles of optimal prescribing and deprescribing. Second, clinicians used a variety of approaches to foster shared decision-making about medication use. Third, several challenges prevented clinicians from working together with patients and companions to optimize prescribing and deprescribing. CONCLUSIONS This study offers insight into key language clinicians can use to initiate discussions about optimizing prescribing, as well as barriers they face in doing so. Examples identified in these transcripts should be tested with patients and caregivers to examine how such communications are received and interpreted. Future research should develop and test interventions that seek to overcome obstacles to optimizing prescribing for older adults with cognitive impairment.",2020,"How clinicians communicate about medications may affect to what extent patients and family companions understand and participate in decisions about medication use. ","['patients with cognitive impairment', 'Patients were on average 79.9\xa0years of age', 'encounters with older adults with cognitive impairment and their companions', 'older adults with cognitive impairment', 'Patients were 65 or older, had >\u20091 incorrect answer on a cognitive screener, and attended visits with a relative or unpaid companion', 'Clinicians were physicians, nurse practitioners, or physician assistants at participating practices', 'Older Adults with Cognitive Impairment']",['patient-family agenda setting checklist'],"['Visits', 'average MMSE score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0338656', 'cui_str': 'Cognitive Dysfunction'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0335343', 'cui_str': 'Companions'}, {'cui': 'C4280965', 'cui_str': '>1'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0028657', 'cui_str': 'Nurse practitioner (occupation)'}, {'cui': 'C0031833', 'cui_str': ""Physicians' Extenders""}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C1707357', 'cui_str': 'Checklist'}]","[{'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0251259,"How clinicians communicate about medications may affect to what extent patients and family companions understand and participate in decisions about medication use. ","[{'ForeName': 'Ariel R', 'Initials': 'AR', 'LastName': 'Green', 'Affiliation': 'Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ariel@jhmi.edu.'}, {'ForeName': 'Jennifer L', 'Initials': 'JL', 'LastName': 'Wolff', 'Affiliation': 'Roger C. Lipitz Center for Integrated Health Care, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Diane M', 'Initials': 'DM', 'LastName': 'Echavarria', 'Affiliation': 'Roger C. Lipitz Center for Integrated Health Care, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.'}, {'ForeName': 'Malcolm', 'Initials': 'M', 'LastName': 'Chapman', 'Affiliation': 'University of North Carolina School of Medicine, Chapel Hill, NC, USA.'}, {'ForeName': 'Annie', 'Initials': 'A', 'LastName': 'Phung', 'Affiliation': 'Philadelphia College of Osteopathic Medicine - Georgia, Suwanee, GA, USA.'}, {'ForeName': 'Devon', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Northeast Ohio Medical University, Rootstown, OH, USA.'}, {'ForeName': 'Cynthia M', 'Initials': 'CM', 'LastName': 'Boyd', 'Affiliation': 'Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05424-6'] 3081,32088664,The Effects Of Slow Breathing Exercise On Heart Rate Dynamics And Cardiorespiratory Coherence In Preschool Children: A Prospective Clinical Study.,"Background Slow breathing has been used to improve psychophysiological regulation due to positive action on the autonomic nervous system. Primary Study Objective We evaluated the effects of slow breathing on heart rate autonomic control in preschool-aged children. Methods/Design Prospective clinical study. Setting Campinas, Brazil. Participants We included 42 children in the experimental group (age 5.7 ± 0.3) and 33 children in the control group (age 6.2 ± 0.3). Intervention Children received a daily training of eight weeks duration for practicing a slow breathing technique. Primary Outcome Measures • We analyzed heart rate variability (HRV) and cardiorespiratory coherence at rest under spontaneous breathing and during respiratory sinus arrhythmia (RSA) at the end of the 1st, 4th, and 8th weeks of training. Results The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001; ShanEnt, P = .0106; Lmean, P = .0066) during RSA compared to spontaneous breathing after slow breathing training period. Conclusion Slow breathing training exercise induced increased cardiorespiratory coherence and increased nonlinear behavior of heart rate dynamics suggesting improvements in health status. Increased cardiorespiratory coherence reinforces the importance of including respiratory exercises in strategies that aim to promote physical health and self-regulation skills in educational settings.",2020,"The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001;","['Participants\n\n\nWe included 42 children in the experimental group (age 5.7 ± 0.3) and 33 children in the control group (age 6.2 ± 0.3', 'preschool-aged children', 'Preschool Children']","['Slow Breathing Exercise', 'daily training of eight weeks duration for practicing a slow breathing technique', 'Slow breathing training exercise', 'slow breathing']","['heart rate variability (HRV) and cardiorespiratory coherence at rest under spontaneous breathing and during respiratory sinus arrhythmia (RSA', 'heart rate autonomic control', 'HRV', 'Heart Rate Dynamics And Cardiorespiratory Coherence', 'percentage of high coherence ratio', 'cardiorespiratory coherence', 'complexity of HRV']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517795', 'cui_str': 'Five point seven'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C4517820', 'cui_str': '6.2'}, {'cui': 'C0008100', 'cui_str': 'Child, Preschool'}]","[{'cui': 'C0231837', 'cui_str': 'Slow respiration (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0025664', 'cui_str': 'techniques'}]","[{'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0443144', 'cui_str': 'At rest (qualifier value)'}, {'cui': 'C0205359', 'cui_str': 'Spontaneous (qualifier value)'}, {'cui': 'C0035203', 'cui_str': 'Breathing'}, {'cui': 'C3812870', 'cui_str': 'Respiratory Sinus Arrhythmia'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}]",42.0,0.0420492,"The percentage of high coherence ratio increased (P < .0001), HRV reduced (SDNN, P = .0066; RMSSD, P = .0015; pNN50, P < .0001; SD1, P = .0015; SD2, P = .0166) and the complexity of HRV increased (ApEn, P = .0004; MSE area, P < .0001; DFAαl, P = .0001;","[{'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Zuanazzi Cruz', 'Affiliation': ''}, {'ForeName': 'Moacir', 'Initials': 'M', 'LastName': 'Fernandes de Godoy', 'Affiliation': ''}, {'ForeName': 'Vitor E', 'Initials': 'VE', 'LastName': 'Valenti', 'Affiliation': ''}, {'ForeName': 'Alfredo', 'Initials': 'A', 'LastName': 'Pereira', 'Affiliation': ''}, {'ForeName': 'Roberto Antonio', 'Initials': 'RA', 'LastName': 'Dias Cardoso', 'Affiliation': ''}]",Alternative therapies in health and medicine,[] 3082,32076564,Cost-utility analysis of learning and coping versus standard education in cardiac rehabilitation: a randomised controlled trial with 3 years of follow-up.,"Objectives To enhance adherence to cardiac rehabilitation (CR), a patient education programme called 'learning and coping' (LC-programme) was implemented in three hospitals in Denmark. The aim of this study was to investigate the cost-utility of the LC-programme compared with the standard CR-programme. Methods 825 patients with ischaemic heart disease or heart failure were randomised to the LC-programme or the standard CR-programme and were followed for 3 years.A societal cost perspective was applied and quality-adjusted life years (QALY) were based on SF-6D measurements. Multiple imputation technique was used to handle missing data on the SF-6D. The statistical analyses were based on means and bootstrapped SEs. Regression framework was employed to estimate the net benefit and to illustrate cost-effectiveness acceptability curves. Results No statistically significant differences were found between the two programmes in total societal costs (4353 Euros; 95% CI -3828 to 12 533) or in QALY (-0.006; 95% CI -0.053 to 0.042). At a threshold of 40 000 Euros, the LC-programme was found to be cost-effective at 15% probability; however, for patients with heart failure, due to increased cost savings, the probability of cost-effectiveness increased to 91%. Conclusions While the LC-programme did not appear to be cost-effective in CR, important heterogeneity was noted for subgroups of patients. The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure. However, further research is needed to study the dynamic value of heterogeneity due to the small sample size in this subgroup.",2020,The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure.,"['825 patients with ischaemic heart disease or heart failure', 'patients with heart failure', 'cardiac rehabilitation']","['learning and coping versus standard education', 'LC-programme or the standard CR-programme', ""cardiac rehabilitation (CR), a patient education programme called 'learning and coping' (LC-programme"", 'LC-programme']","['total societal costs', 'cost savings, the probability of cost-effectiveness', 'cost-utility']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0151744', 'cui_str': 'Ischemic Heart Disease'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}]","[{'cui': 'C0023185', 'cui_str': 'Learning'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0030688', 'cui_str': 'Education of Patients'}, {'cui': 'C1720420', 'cui_str': 'Call'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0085550', 'cui_str': 'Saving, Cost'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",825.0,0.0314959,The LC-programme was demonstrated to increase adherence to the rehabilitation programme and to be cost-effective among patients with heart failure.,"[{'ForeName': 'Nasrin', 'Initials': 'N', 'LastName': 'Tayyari Dehbarez', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Camilla', 'Initials': 'C', 'LastName': 'Palmhøj Nielsen', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Bettine Wulff', 'Initials': 'BW', 'LastName': 'Risør', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Vinther Nielsen', 'Affiliation': 'DEFACTUM, Aarhus N, Denmark.'}, {'ForeName': 'Vibeke', 'Initials': 'V', 'LastName': 'Lynggaard', 'Affiliation': 'Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark.'}]",Open heart,['10.1136/openhrt-2019-001184'] 3083,32081238,A Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal Lesions: The BATTLE Trial.,"OBJECTIVES The primary objective of the BATTLE (Bare Metal Stent vs. Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate-Length Femoropopliteal Lesions) trial is to demonstrate the clinical superiority of the Zilver PTX stent over the Misago stent in the treatment of femoropopliteal lesions. BACKGROUND No randomized studies have compared self-expanding paclitaxel-eluting stents with bare-metal stents in the treatment of femoropopliteal lesions. METHODS BATTLE is a multicenter randomized controlled trial in patients with symptomatic (Rutherford category 2 to 5) de novo lesions of the superficial femoral or proximal popliteal artery. The primary endpoint is freedom from in-stent restenosis (ISR) at 1 year, with restenosis defined as a peak systolic velocity index >2.4 at the target lesion. The Kaplan-Meier method was used to evaluate time-to-event data for freedom from ISR over the 2-year follow-up period. RESULTS Between March 2014 and August 2016, 186 patients were enrolled; 91 were assigned to the Misago arm and 90 to the Zilver PTX arm. Kaplan-Meier 1-year estimates of freedom from ISR were 88.6% for Misago and 91% for Zilver PTX (hazard ratio [HR]: 1.2; 95% confidence interval [CI]: 0.6 to 2.4; p = 0.64). Comparing Misago with Zilver PTX, 2-year estimates were 6.4% and 1.2% (HR: 7.3; 95% CI: 0.9 to 59.3; p = 0.0632) for mortality, 74.6% and 78.8% (HR: 1.2; 95% CI: 0.6 to 2.1; p = 0.62) for patency, and 14.4% and 12.4% (HR: 1.2; 95% CI: 0.5 to 2.8; p = 0.69) for target lesion revascularization. CONCLUSIONS In the treatment of symptomatic femoropopliteal lesions, the Zilver PTX stent failed to show superiority over the Misago stent in freedom from ISR at 1 year.",2020,Kaplan-Meier 1-year estimates of freedom from ISR were 88.6% for Misago and 91% for Zilver PTX (hazard ratio [HR]: 1.2; 95% confidence interval [CI]: 0.6 to 2.4; p = 0.64).,"['Femoropopliteal Lesions', 'Between March 2014 and August 2016', 'Primary Stenting of Intermediate-Length Femoropopliteal Lesions', '186 patients were enrolled; 91 were assigned to the Misago arm and 90 to the Zilver PTX arm', 'patients with symptomatic (Rutherford category 2 to 5) de novo lesions of the superficial femoral or proximal popliteal artery']","['Polymer-Free Paclitaxel-Eluting Stent Versus a Bare-Metal Stent', 'Zilver PTX stent', 'Paclitaxel Eluting Stent', 'paclitaxel-eluting stents with bare-metal stents']","['freedom from in-stent restenosis (ISR) at 1 year, with restenosis defined as a peak systolic velocity index']","[{'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0205124', 'cui_str': 'Superficial (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0032649', 'cui_str': 'Popliteal Artery'}]","[{'cui': 'C0032521', 'cui_str': 'Polymers'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C2825200', 'cui_str': 'Bare metal stent (physical object)'}]","[{'cui': 'C0016694', 'cui_str': 'Liberty'}, {'cui': 'C3272317', 'cui_str': 'Stent restenosis'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0333186', 'cui_str': 'Restenosis'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",186.0,0.109721,Kaplan-Meier 1-year estimates of freedom from ISR were 88.6% for Misago and 91% for Zilver PTX (hazard ratio [HR]: 1.2; 95% confidence interval [CI]: 0.6 to 2.4; p = 0.64).,"[{'ForeName': 'Yann', 'Initials': 'Y', 'LastName': 'Gouëffic', 'Affiliation': 'Hôpital Paris St. Joseph, Department of Vascular and Endovascular Surgery, Paris, France; Laboratoire de Physiopathologie de la Résorption Osseuse, Inserm-UN UMR-957, Nantes, France. Electronic address: ygoueffic@hpsj.fr.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Sauguet', 'Affiliation': 'Clinique Pasteur, Toulouse, France.'}, {'ForeName': 'Pascal', 'Initials': 'P', 'LastName': 'Desgranges', 'Affiliation': 'AP-HP, Hôpital Henri Mondor, Service de Chirurgie Vasculaire, Créteil, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Feugier', 'Affiliation': 'Hôpital Edouard Herriot, Service de Chirurgie Vasculaire, Lyon, France.'}, {'ForeName': 'Eugenio', 'Initials': 'E', 'LastName': 'Rosset', 'Affiliation': 'CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Chirurgie Vasculaire, Clermont-Ferrand, France.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Ducasse', 'Affiliation': 'CHU Bordeaux, Hôpital Pellegrin, Service de Chirurgie Vasculaire, Bordeaux, France.'}, {'ForeName': 'Adrien', 'Initials': 'A', 'LastName': 'Kaladji', 'Affiliation': 'CHU Rennes, Service de Chirurgie Vasculaire, Rennes, France.'}, {'ForeName': 'Lucie', 'Initials': 'L', 'LastName': 'Salomon du Mont', 'Affiliation': 'CHU Besançon, Hôpital Jean Minjoz, Service de Chirurgie Vasculaire, Besançon, France.'}, {'ForeName': 'Jean Marc', 'Initials': 'JM', 'LastName': 'Pernès', 'Affiliation': ""Hôpital Privé d'Antony, Antony, France.""}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Commeau', 'Affiliation': 'Polycliniq ue Les Fleurs, Ollioules, France.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Lermusiaux', 'Affiliation': 'Bourgoin-Jallieu, Bourgoin-Jallieu, France.'}, {'ForeName': 'Brice', 'Initials': 'B', 'LastName': 'Leclere', 'Affiliation': 'CHU Nantes, Department of Epidemiology, Nantes, France.'}, {'ForeName': 'Béatrice', 'Initials': 'B', 'LastName': ""Guyomarc'h"", 'Affiliation': 'CHU Nantes, Institut du Thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.'}, {'ForeName': 'Clément T', 'Initials': 'CT', 'LastName': 'Hoffmann', 'Affiliation': 'CHU Brest, Service de Médecine Vasculaire, Brest, France.'}, {'ForeName': 'Blandine', 'Initials': 'B', 'LastName': 'Maurel', 'Affiliation': 'Laboratoire de Physiopathologie de la Résorption Osseuse, Inserm-UN UMR-957, Nantes, France; CHU de Nantes, Service de Chirurgie Vasculaire, Institut du Thorax, Nantes, France.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.12.028'] 3084,32081240,"The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.","OBJECTIVES The aim of this study was to investigate bipolar radiofrequency renal denervation in patients with hypertension not receiving medications at baseline. BACKGROUND A blood pressure-reducing effect of renal denervation has been difficult to isolate in clinical investigations. METHODS REDUCE HTN: REINFORCE (Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension) was a randomized, sham-controlled multicenter trial. Patients with office systolic blood pressure (SBP) of 150 to 180 mm Hg and average 24-h ambulatory SBP of 135 to 170 mm Hg after medication washout underwent bipolar radiofrequency renal denervation or a sham procedure. The planned outcome was 8-week change in 24-h ambulatory SBP. Enrollment was terminated for apparent futility before a sufficient sample for powered efficacy comparisons was enrolled. Safety assessments included all-cause death, renal failure, severe hypotension or syncope, hypertensive crisis, and renal artery stenosis. RESULTS Baseline 24-h blood pressure was 148.3 ± 10.9/85.7 ± 9.1 mm Hg for the denervation group (n = 34, mean age 58.5 ± 10.1 years, 47% women) and 149.1 ± 7.2/86.4 ± 9.8 mm Hg for the control group (n = 17, mean age 58.2 ± 9.8 years, 24% women). At 8 weeks, mean 24-h SBP reductions for the renal denervation and control groups were -5.3 mm Hg (95% confidence interval [CI]: -8.8 to -1.8 mm Hg) and -8.5 mm Hg (95% CI: -13.3 to -3.8 mm Hg), respectively (difference 3.3 mm Hg; 95% CI: -2.8 to 9.3 mm Hg; p = 0.30). Antihypertensive medications could then be added. By 6 months, decreases in SBP were greater for the denervation group, yielding between-group differences of -7.2 mm Hg (95% CI: -15.2 to 0.8 mm Hg; p = 0.08), -9.7 mm Hg (95% CI: -17.7 to -1.7 mm Hg; p = 0.02), and -11.4 mm Hg (95% CI: -19.2 to -3.7 mm Hg; p < 0.01) for 24-h, daytime ambulatory, and office measurements, respectively. Through 12 months, 1 patient (renal denervation group) had a hypertensive urgency requiring immediate management, and 1 experienced progression of renal artery stenosis. CONCLUSIONS Future studies of radiofrequency renal denervation must anticipate delayed treatment effects. (Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension [REDUCE HTN: REINFORCE]; NCT02392351).",2020,"At 8 weeks, mean 24-h SBP reductions for the renal denervation and control groups were -5.3 ","['Hg for the control group (n\xa0=\xa017, mean age 58.2 ± 9.8 years, 24% women', 'Patients with office systolic blood pressure (SBP) of 150 to 180\xa0mm\xa0Hg and average 24-h ambulatory SBP of 135 to 170\xa0mm\xa0Hg after', 'Hg for the denervation group (n\xa0=\xa034, mean age 58.5 ± 10.1 years, 47% women) and 149.1 ± 7.2/86.4 ± 9.8\xa0mm', 'Hg', 'patients with hypertension not receiving medications at baseline']","['HTN: REINFORCE (Renal Denervation Using the Vessix Renal Denervation System', 'Bipolar Radiofrequency Renal Denervation', 'medication washout underwent bipolar radiofrequency renal denervation or a sham procedure']","['24-h ambulatory SBP', 'hypertensive urgency requiring immediate management', 'mean 24-h SBP reductions', 'progression of renal artery stenosis', 'cause death, renal failure, severe hypotension or syncope, hypertensive crisis, and renal artery stenosis', 'SBP']","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442603', 'cui_str': 'Office (environment)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C4517566', 'cui_str': '135'}, {'cui': 'C4517599', 'cui_str': 'One hundred and seventy'}, {'cui': 'C1321798', 'cui_str': 'Muscle denervation'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]","[{'cui': 'C1321798', 'cui_str': 'Muscle denervation'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0443156', 'cui_str': 'Bipolar (qualifier value)'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}]","[{'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0745138', 'cui_str': 'Hypertensive urgency'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0035067', 'cui_str': 'Renal Artery Stenosis'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0035078', 'cui_str': 'Kidney Failure'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0039070', 'cui_str': 'Fainting'}, {'cui': 'C0020546', 'cui_str': 'Hypertensive crisis'}]",,0.149885,"At 8 weeks, mean 24-h SBP reductions for the renal denervation and control groups were -5.3 ","[{'ForeName': 'Michael A', 'Initials': 'MA', 'LastName': 'Weber', 'Affiliation': 'State University of New York, Downstate Medical Center, Brooklyn, New York. Electronic address: michaelwebermd@cs.com.'}, {'ForeName': 'Ajay J', 'Initials': 'AJ', 'LastName': 'Kirtane', 'Affiliation': 'Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Weir', 'Affiliation': 'University of Maryland School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Jai', 'Initials': 'J', 'LastName': 'Radhakrishnan', 'Affiliation': 'Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Das', 'Affiliation': 'Texas Health Presbyterian Hospital, Dallas, Texas.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Berk', 'Affiliation': 'Texas Health Presbyterian Hospital, Dallas, Texas.'}, {'ForeName': 'Farrell', 'Initials': 'F', 'LastName': 'Mendelsohn', 'Affiliation': 'Baptist Medical Center Princeton, Cardiology PC Research, Birmingham, Alabama.'}, {'ForeName': 'Alain', 'Initials': 'A', 'LastName': 'Bouchard', 'Affiliation': 'Baptist Medical Center Princeton, Cardiology PC Research, Birmingham, Alabama.'}, {'ForeName': 'German', 'Initials': 'G', 'LastName': 'Larrain', 'Affiliation': 'Aspirus Heart and Vascular Institute, Wausau, Wisconsin.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Haase', 'Affiliation': 'Aspirus Heart and Vascular Institute, Wausau, Wisconsin.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Diaz-Cartelle', 'Affiliation': 'Boston Scientific, Marlborough, Massachusetts.'}, {'ForeName': 'Martin B', 'Initials': 'MB', 'LastName': 'Leon', 'Affiliation': 'Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, New York; Cardiovascular Research Foundation, New York, New York.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.10.061'] 3085,30884170,Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights.,"This trial (20010168) studied how body weight (BW) and body mass index (BMI) influenced the pharmacokinetics (PK) of anakinra. Subjects (n = 32) were assigned to four groups (n = 8) according to BW and BMI. Randomization was according to a four-treatment, four-period, four-sequence crossover design. The four anakinra injections were 100, 150, and 300 mg s.c. and 100 mg i.v. Plasma samples were measured by enzyme-linked immunosorbent assay and noncompartmental PK parameters estimated. BW demonstrated the following effects: after i.v. administration, significant effects (P < 0.05) were observed for exposure (area under the concentration-time curve from zero to infinity (AUC 0-∞ )), peak plasma concentration (C max ), volume of distribution at steady state, and clearance; whereas after s.c. administration, significant effects (P < 0.05) were observed for C max , AUC 0-∞ , terminal half-life, and estimated apparent clearance. Mean AUC was reduced 24% and 33% for heavier (BW ≥ 100 kg) vs. lighter subjects (BW ≤ 90 kg) after i.v. and s.c. administration, respectively. BMI increased clearance for heavier subjects. For example, mean (SD) plasma clearance of i.v. anakinra increased from 1.17 ± 0.29 to 1.62 ± 0.24 mL/minute/kg (P < 0.05) for larger (> 100 kg) obese (BMI > 36) vs. larger (> 100 kg) less obese (BMI < 35) subjects, respectively. Similarly, results following s.c. supported those after i.v. administration. Derived half-lives increased with higher BW and higher BMI ranging from 3.63 hour for less obese, lighter-weight subjects to 7.62 hour for obese, heavier-weight subjects. Absolute bioavailability ranged from 80-92% and was unrelated to BW or BMI. Anakinra exposure is statistically significantly related to BW and to a lesser extent BMI.",2019,"administration, significant effects (P < 0.05) were observed for exposure (area under the concentration-time curve from zero to infinity (AUC 0-∞ )), peak plasma concentration (C max ), volume of distribution at steady state, and clearance; whereas after s.c.","['heavier subjects', 'Subjects of Heavier vs. Lighter Body Weights', 'Subjects (n\xa0=\xa032']",[],"['peak plasma concentration (C max ), volume of distribution at steady state, and clearance', 'mean (SD) plasma clearance of i.v', 'BMI increased clearance', 'C max , AUC 0-∞ , terminal half-life', 'Mean AUC', 'body weight (BW) and body mass index (BMI) influenced the pharmacokinetics (PK) of anakinra', 'Absolute bioavailability']","[{'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",[],"[{'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0205361', 'cui_str': 'Steady (qualifier value)'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0449297', 'cui_str': 'Clearance (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0018517', 'cui_str': 'Halflife'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0245109', 'cui_str': 'anakinra'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}]",,0.023605,"administration, significant effects (P < 0.05) were observed for exposure (area under the concentration-time curve from zero to infinity (AUC 0-∞ )), peak plasma concentration (C max ), volume of distribution at steady state, and clearance; whereas after s.c.","[{'ForeName': 'Bing-Bing', 'Initials': 'BB', 'LastName': 'Yang', 'Affiliation': 'Amgen Inc., Thousand Oaks, California, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Gozzi', 'Affiliation': 'Swedish Orphan Biovitrum AB (Sobi), Stockholm, Sweden.'}, {'ForeName': 'John T', 'Initials': 'JT', 'LastName': 'Sullivan', 'Affiliation': 'Amgen Inc., Thousand Oaks, California, USA.'}]",Clinical and translational science,['10.1111/cts.12622'] 3086,32012284,Detection of Inflicted Bruises by Alternate Light: Results of a Randomized Controlled Trial.,"Bruises are often difficult to detect on victims of violence, potentially impacting investigation and prosecution. The purpose of our randomized controlled trial was to measure the effectiveness of an alternate light source (ALS) within visible and long ultraviolet spectrums at improving bruise detection compared to white light over time. We also examined the effects of skin color, age, gender, localized fat, and injury mechanism on bruise detection. Participants included 157 healthy adults with balanced sampling across six skin color categories. Bruises were created under the controlled application of a paintball pellet and dropped weight to one upper and lower arm, respectively. Using a crossover design, both bruises were examined 21 times over 4 weeks. Ten different wavelength (350-535 nm) and filter (yellow, orange, red) combinations were used. Multilevel models were used to analyze 2903 examinations on both upper and lower arms. Results in multivariable models showed after controlling for other covariates 415 and 450 nm using a yellow filter had greater odds of detecting evidence of bruising than white light (Upper Arm: 415 nm: OR = 5.34, 95% CI: 4.35-6.56; 450 nm: OR = 4.08, 95% CI: 3.36-4.96). Under either light source, being female and having more localized fat had increased odds of detecting bruises created by the dropped weight (female: OR = 2.96, 95% CI: 2.37-3.70; fat: OR = 1.21, 95% CI: 1.09-1.34). Our results support ALS as an appropriate tool to enhance concurrent physical assessment of bruises in the presence of known history of injury. Future development and evaluation of clinical practice guidelines for ALS application are needed.",2020,"Under either light source, being female and having more localized fat had increased odds of detecting bruises created by the dropped weight (female: OR = 2.96, 95% CI: 2.37-3.70; fat: OR = ","['Participants included 157 healthy adults with balanced sampling across six skin color categories', '415\xa0nm: OR\xa0']",['alternate light source (ALS'],[],"[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0037290', 'cui_str': 'Skin Tone'}, {'cui': 'C4517772', 'cui_str': 'Four hundred and fifteen'}]","[{'cui': 'C0332270', 'cui_str': 'Alternating (qualifier value)'}, {'cui': 'C0181633', 'cui_str': 'Light source'}]",[],157.0,0.0409469,"Under either light source, being female and having more localized fat had increased odds of detecting bruises created by the dropped weight (female: OR = 2.96, 95% CI: 2.37-3.70; fat: OR = ","[{'ForeName': 'Katherine N', 'Initials': 'KN', 'LastName': 'Scafide', 'Affiliation': 'College of Health and Human Services, George Mason University, 4400 University Drive, Fairfax, VA, 22030.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Sheridan', 'Affiliation': 'College of Nursing, Texas A&M University Health Sciences Center, 8447 Riverside Parkway, Bryan, TX, 77807.'}, {'ForeName': 'Nancy R', 'Initials': 'NR', 'LastName': 'Downing', 'Affiliation': 'College of Nursing, Texas A&M University Health Sciences Center, 8447 Riverside Parkway, Bryan, TX, 77807.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Hayat', 'Affiliation': 'School of Public Health, Georgia State University, 140 Decatur Street, Atlanta, GA, 30303.'}]",Journal of forensic sciences,['10.1111/1556-4029.14294'] 3087,31720933,Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.,"BACKGROUND This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin. METHODS In this prospective multicenter study, 121 mucinous appendiceal cancer patients, with evidence of peritoneal dissemination who underwent CRS, were randomized to receive mitomycin (divided 40 mg) or oxaliplatin (200 mg/m 2 ) for HIPEC. The Functional Assessment of Cancer Therapy Neurotoxicity (FACT-G/NTX) questionnaire was utilized to assess HRQOL. The Trial Outcome Index (TOI) is a summary index responsive to changes in physical/functional outcomes. Repeated measures mixed models with an unstructured variance matrix were applied to assess changes in HRQOL longitudinally. RESULTS Baseline questionnaire compliance was 95.9%. Baseline physical well-being (PWB) was independently associated with overall survival (hazard ratio 0.79, 95% confidence interval 0.66-0.96; p = 0.017). The TOI was significantly lower in the mitomycin group compared with the oxaliplatin arm at 12 weeks (p = 0.044; score difference 6.35) and 24 weeks after surgery (p = 0.049; score difference 5.61). At 12 weeks after surgery, declines from baseline were significant in the TOI (p = 0.004; score decline 8.99), PWB (p < 0.001; score decline 2.83), and FWB (p < 0.001; score decline 3.42) in the mitomycin group but not the oxaliplatin group. CONCLUSIONS Compared with mitomycin, HIPEC perfusion with oxaliplatin results in significantly better physical and functional outcomes. With similar survival outcomes and complication rates, oxaliplatin should be considered as the chemoperfusion agent of choice in mucinous appendiceal cancer patients undergoing CRS/HIPEC.",2020,"Baseline physical well-being (PWB) was independently associated with overall survival (hazard ratio 0.79, 95% confidence interval 0.66-0.96; p = 0.017).","['mucinous appendiceal cancer patients undergoing CRS/HIPEC', 'Mucinous Appendiceal Cancer', '121 mucinous appendiceal cancer patients, with evidence of peritoneal dissemination who underwent CRS', 'subjects with mucinous appendiceal neoplasms who underwent']","['mitomycin, HIPEC perfusion with oxaliplatin', 'mitomycin with oxaliplatin', 'Oxaliplatin and Mitomycin', 'cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC', 'mitomycin', 'Cytoreductive Surgery/HIPEC', 'HIPEC', 'Cancer Therapy Neurotoxicity (FACT-G/NTX) questionnaire', 'oxaliplatin']","['FWB', 'Baseline physical well-being (PWB', 'PWB', 'overall survival', 'physical and functional outcomes', 'TOI', 'Health-Related Quality of Life']","[{'cui': 'C0496779', 'cui_str': 'Appendiceal Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332120', 'cui_str': 'Evidence of (contextual qualifier) (qualifier value)'}, {'cui': 'C4087504', 'cui_str': 'Peritoneal dissemination'}, {'cui': 'C0003614', 'cui_str': 'Appendiceal Neoplasms'}]","[{'cui': 'C0002475', 'cui_str': 'Mitomycin'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0069717', 'cui_str': 'oxaliplatin'}, {'cui': 'C3850079', 'cui_str': 'Cytoreductive Surgery'}, {'cui': 'C1868801', 'cui_str': 'Hyperthermic Intraperitoneal Chemotherapy'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0235032', 'cui_str': 'Neurotoxin Diseases'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}]",,0.159859,"Baseline physical well-being (PWB) was independently associated with overall survival (hazard ratio 0.79, 95% confidence interval 0.66-0.96; p = 0.017).","[{'ForeName': 'Omeed', 'Initials': 'O', 'LastName': 'Moaven', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA.'}, {'ForeName': 'Konstantinos I', 'Initials': 'KI', 'LastName': 'Votanopoulos', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA.'}, {'ForeName': 'Perry', 'Initials': 'P', 'LastName': 'Shen', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Mansfield', 'Affiliation': 'Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'David L', 'Initials': 'DL', 'LastName': 'Bartlett', 'Affiliation': 'Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.'}, {'ForeName': 'Greg', 'Initials': 'G', 'LastName': 'Russell', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'McQuellon', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA.'}, {'ForeName': 'John H', 'Initials': 'JH', 'LastName': 'Stewart', 'Affiliation': 'Department of Surgery, University of Illinois, Chicago, IL, USA.'}, {'ForeName': 'Edward A', 'Initials': 'EA', 'LastName': 'Levine', 'Affiliation': 'Department of Surgery, Wake Forest University, Winston Salem, NC, USA. elevine@wakehealth.edu.'}]",Annals of surgical oncology,['10.1245/s10434-019-08064-6'] 3088,31373975,Effects of Different Training Interventions on the Recovery of Physical and Neuromuscular Performance After a Soccer Match.,"Trecroci, A, Porcelli, S, Perri, E, Pedrali, M, Rasica, L, Alberti, G, Longo, S, and Iaia, FM. Effects of different training interventions on the recovery of physical and neuromuscular performance after a soccer match. J Strength Cond Res 34(8): 2189-2196, 2020-In competitive soccer, players are frequently required to play in periods with congested fixtures in which they have limited time to recover between matches (3-4 days). Thus, finding the most appropriate intervention strategy to limit players' neuromuscular (muscle function of lower limbs) and physical (running performance) impairments in this short period becomes crucial. The aim of the study was to examine how muscle function of knee extensors and flexors and sprint performance recovered +72 hours after match in relation to different field-based training sessions. Using a crossover design, 9 subelite players (age 17.6 ± 0.5 years, height 1.77 ± 0.02 m, body mass 66.4 ± 5.8 kg) underwent a soccer-specific training (SST) session or an active recovery regime (AR) on the second day after a match. Immediately after (0 hour) and +72 hours after match, 30-m sprint and repeated sprint ability (RSA) were assessed. Maximum isometric voluntary force (MVF) of knee extensors and flexors was determined at 120° and 90° (with 180° being full extension), respectively. SST and AR promoted similar effects on the recovery kinetics of sprint, RSA, and MVF of knee extensors (p > 0.05). However, compared with SST, AR promoted a significantly better restoration of MVF of knee flexors (p < 0.05) after +72 hours from the match. Because muscle fatigue has been related with increased hamstring injury risk, a training based on AR can be a valid intervention to promote the recovery of muscle force production of knee flexors and reduce hamstring injury risk in the postmatch period.",2020,"SST and AR promoted similar effects on the recovery kinetics of sprint, RSA, and MVF of knee extensors (p > 0.05).","['9 subelite players (age 17.6 ± 0.5 years, height 1.77 ± 0.02 m, body mass 66.4 ± 5.8 kg) underwent a', ' 000-000, 2019-In competitive soccer, players are frequently required to play in periods with congested fixtures in which they have limited time to recover between matches (3-4 days', 'After a Soccer Match']","['training interventions', 'Different Training Interventions', 'soccer-specific training (SST) session or an active recovery regime (AR', 'J Strength Cond Res XX(X']","['Trecroci, A, Porcelli, S, Perri, E, Pedrali, M, Rasica, L, Alberti, G, Longo, S, and Iaia, FM', 'recovery of physical and neuromuscular performance', 'Recovery of Physical and Neuromuscular Performance', 'Maximum isometric voluntary force (MVF) of knee extensors and flexors', 'knee extensors and flexors and sprint performance', 'restoration of MVF of knee flexors', 'recovery kinetics of sprint, RSA, and MVF of knee extensors']","[{'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4517398', 'cui_str': '0.02'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0332183', 'cui_str': 'Frequent (qualifier value)'}, {'cui': 'C0032214', 'cui_str': 'Play'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0037393', 'cui_str': 'Soccers'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}]","[{'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0439656', 'cui_str': 'Voluntary (qualifier value)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0449982', 'cui_str': 'Type of restoration (attribute)'}]",,0.0212317,"SST and AR promoted similar effects on the recovery kinetics of sprint, RSA, and MVF of knee extensors (p > 0.05).","[{'ForeName': 'Athos', 'Initials': 'A', 'LastName': 'Trecroci', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milano, Italy.'}, {'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Porcelli', 'Affiliation': 'Institute of Molecular Bioimaging and Physiology, National Research Council, Segrate, Italy.'}, {'ForeName': 'Enrico', 'Initials': 'E', 'LastName': 'Perri', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milano, Italy.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Pedrali', 'Affiliation': 'Institute of Molecular Bioimaging and Physiology, National Research Council, Segrate, Italy.'}, {'ForeName': 'Letizia', 'Initials': 'L', 'LastName': 'Rasica', 'Affiliation': 'Institute of Molecular Bioimaging and Physiology, National Research Council, Segrate, Italy.'}, {'ForeName': 'Giampietro', 'Initials': 'G', 'LastName': 'Alberti', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milano, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Longo', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milano, Italy.'}, {'ForeName': 'F Marcello', 'Initials': 'FM', 'LastName': 'Iaia', 'Affiliation': 'Department of Biomedical Sciences for Health, University of Milan, Milano, Italy.'}]",Journal of strength and conditioning research,['10.1519/JSC.0000000000003269'] 3089,31951270,Effect of a Mobile Monitoring System vs Usual Care on Depression Symptoms and Psychological Health: A Randomized Clinical Trial.,,2020,,[],['Mobile Monitoring System vs Usual Care'],['Depression Symptoms and Psychological Health'],[],"[{'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}]",,0.0952709,,"[{'ForeName': 'Skyler', 'Initials': 'S', 'LastName': 'Place', 'Affiliation': 'CompanionMX, Boston, Massachusetts.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Blanch-Hartigan', 'Affiliation': 'Department of Natural and Applied Sciences, Bentley University, Waltham, Massachusetts.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Smith', 'Affiliation': 'CompanionMX, Boston, Massachusetts.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Erb', 'Affiliation': ""Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts.""}, {'ForeName': 'Carl D', 'Initials': 'CD', 'LastName': 'Marci', 'Affiliation': 'CompanionMX, Boston, Massachusetts.'}, {'ForeName': 'David K', 'Initials': 'DK', 'LastName': 'Ahern', 'Affiliation': ""Program in Behavioral Informatics and eHealth, Brigham and Women's Hospital, Boston, Massachusetts.""}]",JAMA network open,['10.1001/jamanetworkopen.2019.19403'] 3090,31373563,The Effect of Postoperative Telephone Counseling on the Sexual Life of Patients With a Bowel Stoma: A Randomized Controlled Trial.,"Sexual problems following ileostomy or colostomy surgery are common. PURPOSE The purpose of this study was to determine the effect of telephone counseling on the sexual lives of individuals with a bowel stoma. METHOD Using a randomized, controlled, quasi-experimental study design, patients who were between 18 and 70 years old, had a sexual partner, and had undergone ileostomy or colostomy surgery were eligible to participate. Patients were randomized to telephone counseling as needed (intervention) or regular outpatient follow-up care only (control) for 12 weeks following surgery. Sociodemographic data were collected, and the Golombok-Rust Inventory of Sexual Satisfaction (GRISS) was completed on admission for surgery and 6 and 12 weeks postoperatively. Data were analyzed using descriptive statistics and the Mann-Whitney U , Kruskal-Wallis, Friedman, Wilcoxon signed ranks, and chi-squared tests and Yates's correction for continuity. RESULTS Of the 70 participants (35 in each group), the average age of intervention group participants was 53.00 ± 11.18 years, and the average age of the control group was 50.74 ± 13.72 years; 19 (54.3%) in the intervention group and 18 (51.4%) in the control group were male. Neither the demographic data nor the GRISS scale scores were significantly different between groups at baseline. After discharge, patients in the intervention group called to receive counseling for their concerns regarding sexual life and challenges they experienced with their stoma an average of 3.57 ± 0.86 (range 2-5) times during the first 6 weeks and 6.52 ±.77 (range 5-8) times between weeks 6 and 12. Mean total and subscale GRISS scores improved significantly from 5.89 ± 1.33 to 7.33 ± 1.24 ( P <.01). CONCLUSION In this study, telephone counseling was effective in improving the sexual lives of patients with a colon- or ileostoma 12 weeks after surgery.",2019,"In this study, telephone counseling was effective in improving the sexual lives of patients with a colon- or ileostoma 12 weeks after surgery.","['patients with a colon- or ileostoma 12 weeks after surgery', 'Patients With a Bowel Stoma', 'patients who were between 18 and 70 years old, had a sexual partner, and had undergone ileostomy or colostomy surgery were eligible to participate', 'average age of intervention group participants was 53.00 ± 11.18 years, and the average age of the control group was 50.74 ± 13.72 years; 19 (54.3%) in the intervention group and 18 (51.4%) in the control group were male', 'individuals with a bowel stoma', '70 participants (35 in each group']","['ileostomy or colostomy surgery', 'telephone counseling', 'telephone counseling as needed (intervention) or regular outpatient follow-up care only (control', 'Postoperative Telephone Counseling']","['Golombok-Rust Inventory of Sexual Satisfaction (GRISS', 'sexual lives', 'Mean total and subscale GRISS scores', 'GRISS scale scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009368', 'cui_str': 'Colon'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0021853', 'cui_str': 'Intestines'}, {'cui': 'C1955856', 'cui_str': 'Surgical Stoma'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0036911', 'cui_str': 'Sexual Partners'}, {'cui': 'C0020883', 'cui_str': 'Ileostomy'}, {'cui': 'C0009410', 'cui_str': 'Colostomy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0020883', 'cui_str': 'Ileostomy'}, {'cui': 'C0009410', 'cui_str': 'Colostomy'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0001758', 'cui_str': 'Follow-Up Care'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]","[{'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0871356', 'cui_str': 'Sexual Satisfaction'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}]",70.0,0.042944,"In this study, telephone counseling was effective in improving the sexual lives of patients with a colon- or ileostoma 12 weeks after surgery.","[{'ForeName': 'Seçil', 'Initials': 'S', 'LastName': 'Taylan', 'Affiliation': 'Akdeniz University, Kumluca-Antalya, Turkey.'}, {'ForeName': 'Yasemin', 'Initials': 'Y', 'LastName': 'Akıl', 'Affiliation': 'Çukurova University, Adana, Turkey.'}]",Wound management & prevention,[] 3091,31373564,"Effect of Using a Simulation Device for Ostomy Self-care Teaching in Iran: A Pilot, Randomized Clinical Trial.","The appearance of a stoma and the potential for contact with stool may negatively affect postoperative teaching effectiveness, especially for patients with cultural and religious backgrounds that consider stool untouchable. Instruction that involves the use of a physical stoma simulator for practice may help address this problem. PURPOSE The aim of this pilot study was to determine the effects of simulation in ostomy self-care training on self-efficacy and adjustment. METHODS A randomized clinical trial was conducted among patients at 2 public medical center surgical units in eastern Iran from April 2015 to December 2015 using consecutive sampling. Patients who spoke Persian, were 18 to 65 years of age, had a temporary or permanent intestinal stoma, and did not have comorbidities that might interfere with self-care teaching were invited to participate and randomly allocated to the simulation (SG) or the control group (CG). Both groups were provided 4 training sessions; the first and fourth session was the same for each group, but in sessions 2 and 3, the SG group used a wearable stoma simulator, whereas the CG group used the demonstration-return method. Demographic and stoma variables were collected, and the Stoma Self-Efficacy Scale (SSES) and Ostomy Adjustment Inventory-23 (OAI-23) were administered at baseline (following surgery), after 4 instructional sessions, and 45 days following the last education session. Descriptive statistics and chi-squared, Fisher's exact, Mann-Whitney U , repeated measure, and least significant difference tests were used to analyze the data. RESULTS Of the 53 patients enrolled, 46 (23 in each group) completed the study. Mean age for SG and CG patients was 45.91 ± 10.40 and 53.78 ± 9.15, respectively ( P = .009). The majority of patients were female (SG: 11 [47.8%]; CG: 14 [60.9%]), married (SG: 20 [87.0%]; CG: 19 [82.6%]), and had a diagnosis of cancer (SG: 20 [87.0%]; CG: 21 [91.3%]). The mean SSES score for stoma self-efficacy was 103.82 ± 15.81 in the SG and 89.91 ± 13.41 in the CG after the fourth session. Results indicated an improvement in self-efficacy in both groups from baseline to final follow-up visit ( P <.0001). SSES in the SG was significantly different from baseline to final follow-up visit during the study (F = 3.183, P = .008). Mean OAI-23 scores were 51.04 ± 13.37 in the SG and 50.82 ± 13.84 in the CG at baseline and after the intervention (fourth session) were 60.56 ± 16.41 in the SG and 53.95 ± 13.22 in the CG group. The repeated measure test results indicated significant increases in adjustment scores from baseline to final follow-up visit in both groups ( P = .000). CONCLUSION The results of this pilot study suggest that using simulation to teach ostomy self-care improves self-efficacy after 3 and 9 weeks. Further randomized controlled trials that expand the sample size and demographic should be conducted.",2019,Results indicated an improvement in self-efficacy in both groups from baseline to final follow-up visit ( P <.0001).,"['Ostomy Self-care Teaching in Iran', 'patients at 2 public medical center surgical units in eastern Iran from April 2015 to December 2015 using consecutive sampling', 'Patients who spoke Persian, were 18 to 65 years of age, had a temporary or permanent intestinal stoma, and did not have comorbidities that might interfere with self-care teaching', '53 patients enrolled, 46 (23 in each group) completed the study']","['Simulation Device', 'SG group used a wearable stoma simulator', 'simulation (SG) or the control group (CG', 'ostomy self-care training']","['Stoma Self-Efficacy Scale (SSES) and Ostomy Adjustment Inventory-23 (OAI-23', 'mean SSES score for stoma self-efficacy', 'self-efficacy', 'Mean OAI-23 scores']","[{'cui': 'C0029473', 'cui_str': 'Ostomy'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0205355', 'cui_str': 'Permanent (qualifier value)'}, {'cui': 'C0559494', 'cui_str': 'Intestinal stoma (morphologic abnormality)'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0521102', 'cui_str': 'Interferes with (contextual qualifier) (qualifier value)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1955856', 'cui_str': 'Surgical Stoma'}, {'cui': 'C0183309', 'cui_str': 'Simulator (physical object)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0029473', 'cui_str': 'Ostomy'}, {'cui': 'C0036592', 'cui_str': 'Self Care'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C1955856', 'cui_str': 'Surgical Stoma'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0222045'}, {'cui': 'C0029473', 'cui_str': 'Ostomy'}, {'cui': 'C0456081', 'cui_str': 'Adjustment (procedure)'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0282028,Results indicated an improvement in self-efficacy in both groups from baseline to final follow-up visit ( P <.0001).,"[{'ForeName': 'Zohre', 'Initials': 'Z', 'LastName': 'Pouresmail', 'Affiliation': 'Mashhad University of the Sciences, Mashhad, Iran.'}, {'ForeName': 'Fatemeh Heshmati', 'Initials': 'FH', 'LastName': 'Nabavi', 'Affiliation': 'Mashhad University of the Sciences, Mashhad, Iran.'}, {'ForeName': 'Abbas', 'Initials': 'A', 'LastName': 'Abdollahi', 'Affiliation': 'Mashhad University of the Sciences, Mashhad, Iran.'}, {'ForeName': 'Mohammad Taghi', 'Initials': 'MT', 'LastName': 'Shakeri', 'Affiliation': 'Mashhad University of the Sciences, Mashhad, Iran.'}, {'ForeName': 'Azadeh', 'Initials': 'A', 'LastName': 'Saki', 'Affiliation': 'Mashhad University of the Sciences, Mashhad, Iran.'}]",Wound management & prevention,[] 3092,32077361,"Randomized phase 1 study of sequential (""primed"") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.",,2020,,['adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm'],"['sequential (""primed"") vs. concurrent decitabine', 'cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M']",[],"[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C1962917', 'cui_str': 'High grade (lymphoma)'}, {'cui': 'C2939461', 'cui_str': 'Myeloid neoplasm'}]","[{'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C0049065', 'cui_str': 'decitabine'}, {'cui': 'C0092801', 'cui_str': 'Cladribine'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C0079459', 'cui_str': 'G-CSF'}, {'cui': 'C0026259', 'cui_str': 'Mitoxantrone'}]",[],,0.0417158,,"[{'ForeName': 'Raffaele', 'Initials': 'R', 'LastName': 'Palmieri', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Buckley', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Megan', 'Initials': 'M', 'LastName': 'Othus', 'Affiliation': 'Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.'}, {'ForeName': 'Anna B', 'Initials': 'AB', 'LastName': 'Halpern', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Mary-Elizabeth M', 'Initials': 'MM', 'LastName': 'Percival', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Bart L', 'Initials': 'BL', 'LastName': 'Scott', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Paul C', 'Initials': 'PC', 'LastName': 'Hendrie', 'Affiliation': 'Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Pamela S', 'Initials': 'PS', 'LastName': 'Becker', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Vivian G', 'Initials': 'VG', 'LastName': 'Oehler', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Elihu H', 'Initials': 'EH', 'LastName': 'Estey', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}, {'ForeName': 'Roland B', 'Initials': 'RB', 'LastName': 'Walter', 'Affiliation': 'Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington, Seattle, WA, USA.'}]",Leukemia & lymphoma,['10.1080/10428194.2020.1728754'] 3093,31818628,Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY.,"BACKGROUND The clinical benefit of extending prophylaxis for venous thromboembolism (VTE) beyond hospital discharge after laparoscopic surgery for cancer is undefined. Extended prophylaxis with rivaroxaban is effective in reducing post-operative VTE after major orthopedic surgery without safety concern. METHODS PROLAPS II is an investigator-initiated, randomized, double-blind study aimed at assessing the efficacy and safety of extended antithrombotic prophylaxis with rivaroxaban compared with placebo after laparoscopic surgery for colorectal cancer in patients who had received antithrombotic prophylaxis with low molecular-weight heparin for 7 ± 2 days (NCT03055026). Patients are randomized to receive rivaroxaban (10 mg once daily) or placebo for 3 weeks (up to day 28 ± 2 from surgery). The primary study outcome is a composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected DVT or VTE-related death at 28 ± 2 days from laparoscopic surgery. The primary safety outcome is major bleeding defined according to the International Society of Thrombosis and Haemostasis. Symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected DVT, major bleeding or death by day 28 ± 2 and by day 90 from surgery are secondary outcomes. Assuming an 8% event rate with placebo and 60% reduction in the primary study outcome with rivaroxaban, 323 patients per group are necessary to show a statistically significant difference between the study groups. DISCUSSION The PROLAPS II is the first study with an oral anti-Xa agent in cancer surgery. The study has the potential to improve clinical practice by answering the question on the clinical benefit of extending prophylaxis after laparoscopic surgery for colorectal cancer.",2020,The study has the potential to improve clinical practice by answering the question on the clinical benefit of extending prophylaxis after laparoscopic surgery for colorectal cancer.,"['colorectal cancer', 'colorectal cancer in patients who had received antithrombotic prophylaxis with low molecular-weight heparin for 7\xa0±\xa02 days (NCT03055026']","['placebo', 'Rivaroxaban', 'oral anti-Xa agent', 'rivaroxaban']","['composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected DVT or VTE-related death at 28\xa0±\xa02 days from laparoscopic surgery', 'Symptomatic objectively confirmed VTE, asymptomatic ultrasonography-detected DVT, major bleeding or death', 'major bleeding defined according to the International Society of Thrombosis and Haemostasis']","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033107', 'cui_str': 'prophylaxis'}, {'cui': 'C0019139', 'cui_str': 'LMWH'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1739768', 'cui_str': 'rivaroxaban'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}]","[{'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C1456348', 'cui_str': 'Confirm'}, {'cui': 'C0630906', 'cui_str': 'triethoxyvinylsilane'}, {'cui': 'C0231221', 'cui_str': 'Asymptomatic (finding)'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0442726', 'cui_str': 'Detected (qualifier value)'}, {'cui': 'C0149871', 'cui_str': 'Deep Vein Thrombosis'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0751429', 'cui_str': 'Surgical Procedures, Laparoscopic'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0740166', 'cui_str': 'Haemostasis'}]",,0.443846,The study has the potential to improve clinical practice by answering the question on the clinical benefit of extending prophylaxis after laparoscopic surgery for colorectal cancer.,"[{'ForeName': 'Cecilia', 'Initials': 'C', 'LastName': 'Becattini', 'Affiliation': 'Department of Internal and Cardiovascular Medicine and Stroke Unit, University of Perugia, Italy. Electronic address: Cecilia.becattini@unipg.it.'}, {'ForeName': 'Ugo', 'Initials': 'U', 'LastName': 'Pace', 'Affiliation': 'National Cancer Institute, ""G. Pascale"" Foundation, Napoli, Italy. Electronic address: ugo.pace@yahoo.it.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Rondelli', 'Affiliation': 'Department of General Surgery, S. Giovanni Battista Hospital, Foligno, Italy. Electronic address: rondellif@hotmail.com.'}, {'ForeName': 'Paolo', 'Initials': 'P', 'LastName': 'Delrio', 'Affiliation': 'National Cancer Institute, ""G. Pascale"" Foundation, Napoli, Italy. Electronic address: delrio.paolo@gmail.com.'}, {'ForeName': 'Graziano', 'Initials': 'G', 'LastName': 'Ceccarelli', 'Affiliation': 'Department of General Surgery, S. Donato Hospital, Arezzo, Italy. Electronic address: g.cecca2003@libero.it.'}, {'ForeName': 'Michela', 'Initials': 'M', 'LastName': 'Boncompagni', 'Affiliation': 'Department of General Surgery, S. Maria della Misericordia Hospital, Perugia, Italy. Electronic address: michela.bcp@gmail.com.'}, {'ForeName': 'Luigina', 'Initials': 'L', 'LastName': 'Graziosi', 'Affiliation': 'Department of Oncology Surgery, University of Perugia, Perugia, Italy. Electronic address: luiginagraziosi@yahoo.it.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Visonà', 'Affiliation': 'Department of Vascular Medicine, S.Giacomo Apostolo Hospital, Catelfranco Veneto, Treviso, Italy. Electronic address: adrianavisona@gmail.com.'}, {'ForeName': 'Damiano', 'Initials': 'D', 'LastName': 'Chiari', 'Affiliation': 'Department of General Surgery, Istituto Clinico Humanitas Mater Domini, Castellanza, Varese, Italy. Electronic address: damiano.chiari@materdomini.it.'}, {'ForeName': 'Giampiero', 'Initials': 'G', 'LastName': 'Avruscio', 'Affiliation': 'Department of Cardiac, Thoracic and Vascular Sciences, Unit of Angiology, University Hospital of Padua, Padua, Italy. Electronic address: giampiero.avruscio@gmail.com.'}, {'ForeName': 'Stefania', 'Initials': 'S', 'LastName': 'Frasson', 'Affiliation': 'Research Department, FADOI Foundation, Milan, Italy. Electronic address: stefania.frasson@fadoi.org.'}, {'ForeName': 'Gualberto', 'Initials': 'G', 'LastName': 'Gussoni', 'Affiliation': 'Research Department, FADOI Foundation, Milan, Italy. Electronic address: gualberto.gussoni@gmail.com.'}, {'ForeName': 'Alessia', 'Initials': 'A', 'LastName': 'Biancafarina', 'Affiliation': 'Department of General Surgery, S. Donato Hospital, Arezzo, Italy. Electronic address: alessia.biancafarina@gmail.com.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Camporese', 'Affiliation': 'Department of Cardiac, Thoracic and Vascular Sciences, Unit of Angiology, University Hospital of Padua, Padua, Italy. Electronic address: giuseppe.camporese@aopd.veneto.it.'}, {'ForeName': 'Annibale', 'Initials': 'A', 'LastName': 'Donini', 'Affiliation': 'Department of Oncology Surgery, University of Perugia, Perugia, Italy. Electronic address: annibale.donini@unipg.it.'}, {'ForeName': 'Andrea Fares', 'Initials': 'AF', 'LastName': 'Bucci', 'Affiliation': 'National Cancer Institute, ""G. Pascale"" Foundation, Napoli, Italy. Electronic address: andrea.faresbucci@gmail.com.'}, {'ForeName': 'Giancarlo', 'Initials': 'G', 'LastName': 'Agnelli', 'Affiliation': 'Department of Internal and Cardiovascular Medicine and Stroke Unit, University of Perugia, Italy. Electronic address: giancarlo.agnelli@unipg.it.'}]",European journal of internal medicine,['10.1016/j.ejim.2019.11.015'] 3094,29949494,"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.","BACKGROUND Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising PSA level. METHODS In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo once daily. The primary end point was metastasis-free survival (defined as the time from randomization to radiographic progression or as the time to death without radiographic progression). RESULTS A total of 1401 patients (median PSA doubling time, 3.7 months) underwent randomization. As of June 28, 2017, a total of 219 of 933 patients (23%) in the enzalutamide group had metastasis or had died, as compared with 228 of 468 (49%) in the placebo group. The median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group (hazard ratio for metastasis or death, 0.29; 95% confidence interval, 0.24 to 0.35; P<0.001). The time to the first use of a subsequent antineoplastic therapy was longer with enzalutamide treatment than with placebo (39.6 vs. 17.7 months; hazard ratio, 0.21; P<0.001; such therapy was used in 15% vs. 48% of patients) as was the time to PSA progression (37.2 vs. 3.9 months; hazard ratio, 0.07; P<0.001; progression occurred in 22% vs. 69% of patients). At the first interim analysis of overall survival, 103 patients (11%) receiving enzalutamide and 62 (13%) receiving placebo had died. Adverse events of grade 3 or higher occurred in 31% of the patients receiving enzalutamide, as compared with 23% of those receiving placebo. CONCLUSIONS Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or death than placebo. Adverse events were consistent with the established safety profile of enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, NCT02003924 .).",2018,"The median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group (hazard ratio for metastasis or death, 0.29; 95% confidence interval, 0.24 to 0.35; P<0.001).","['men with nonmetastatic, castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were continuing androgen-deprivation therapy to receive', 'Men with nonmetastatic, castration-resistant prostate cancer', 'men with nonmetastatic, castration-resistant prostate cancer', 'Men with Nonmetastatic, Castration-Resistant Prostate Cancer', '1401 patients (median PSA doubling time, 3.7 months) underwent randomization', 'patients with metastatic, castration-resistant prostate cancer']","['enzalutamide', 'placebo', 'Enzalutamide']","['metastasis or had died', 'time to PSA progression', 'metastasis-free survival', 'Adverse events', 'median metastasis-free survival', 'overall survival', 'radiographic progression or as the time to death without radiographic progression']","[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1328504', 'cui_str': 'Castration-resistant prostate cancer'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0279492', 'cui_str': 'Androgen deprivation therapy (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4517696', 'cui_str': '3.7 (qualifier value)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}]","[{'cui': 'C3496793', 'cui_str': 'enzalutamide'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0027627', 'cui_str': 'Metastasis'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0444708', 'cui_str': 'Radiographic (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}]",1401.0,0.562252,"The median metastasis-free survival was 36.6 months in the enzalutamide group versus 14.7 months in the placebo group (hazard ratio for metastasis or death, 0.29; 95% confidence interval, 0.24 to 0.35; P<0.001).","[{'ForeName': 'Maha', 'Initials': 'M', 'LastName': 'Hussain', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Karim', 'Initials': 'K', 'LastName': 'Fizazi', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Fred', 'Initials': 'F', 'LastName': 'Saad', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Per', 'Initials': 'P', 'LastName': 'Rathenborg', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Shore', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Ubirajara', 'Initials': 'U', 'LastName': 'Ferreira', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Petro', 'Initials': 'P', 'LastName': 'Ivashchenko', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Eren', 'Initials': 'E', 'LastName': 'Demirhan', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Katharina', 'Initials': 'K', 'LastName': 'Modelska', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'De', 'Initials': '', 'LastName': 'Phung', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Krivoshik', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}, {'ForeName': 'Cora N', 'Initials': 'CN', 'LastName': 'Sternberg', 'Affiliation': 'From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).'}]",The New England journal of medicine,['10.1056/NEJMoa1800536'] 3095,32073145,Endoscopic ossiculoplasty: Is there any edge over the microscopic technique?,"OBJECTIVES/HYPOTHESIS To compare endoscopic ossiculoplasty with conventional microscopic technique in terms of postoperative hearing outcomes and complications. STUDY DESIGN Randomized controlled trial. METHODS One hundred eighteen patients diagnosed with ossicular chain discontinuity were randomly assigned into two groups, one undergoing endoscopic ossiculoplasty and the other undergoing ossiculoplasty by the microscopic technique, with the operating surgeon being same for both groups. The two groups were compared in terms of operative time, postoperative air-bone gap, mean air-bone gap closure, and incidence of complications. Teflon prostheses (partial ossicular chain replacement prosthesis [PORP] and total ossicular chain replacement prosthesis [TORP]) were used for reconstruction in all cases. RESULTS Endoscopic ossiculoplasty with PORP rendered a statistically significant mean postoperative air-bone gap and air-bone gap closure at 1 month when compared to that of microscopic PORP ossiculoplasty. However, there was no significant difference between the two techniques in terms of mean postoperative air-bone gap and air-bone gap closure at 3 and 6 months. In the TORP ossiculoplasty cases, there was no significant difference in mean postoperative air-bone gap and air-bone gap closure at 1, 3, and 6 months. In terms of operative time and incidence of complications, no statistical significance was found between the two groups. CONCLUSIONS Endoscopic ossiculoplasty appears to provide superior visualization and better early audiological outcome (in PORP ossiculoplasty cases) when compared to microscopic technique. However, long-term audiological outcomes and incidence of complications remain comparable. LEVEL OF EVIDENCE 1 Laryngoscope, 130:797-802, 2020.",2020,"The two groups were compared in terms of operative time, postoperative air-bone gap, mean air-bone gap closure, and incidence of complications.",['One hundred eighteen patients diagnosed with ossicular chain discontinuity'],"['Teflon prostheses (partial ossicular chain replacement prosthesis', 'total ossicular chain replacement prosthesis [TORP', 'Endoscopic ossiculoplasty', 'endoscopic ossiculoplasty and the other undergoing ossiculoplasty by the microscopic technique', 'conventional microscopic technique']","['operative time, postoperative air-bone gap, mean air-bone gap closure, and incidence of complications', 'operative time and incidence of complications', 'mean postoperative air-bone gap and air-bone gap closure']","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}]","[{'cui': 'C0032611', 'cui_str': 'Polytetrafluoroethylene'}, {'cui': 'C0728938', 'cui_str': 'Partial (qualifier value)'}, {'cui': 'C0337112', 'cui_str': 'Chain, device (physical object)'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}, {'cui': 'C0175649', 'cui_str': 'Prosthesis'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0040477', 'cui_str': 'TORP'}, {'cui': 'C1261340', 'cui_str': 'Reconstruction of ossicular chain (procedure)'}, {'cui': 'C0205288', 'cui_str': 'Microscopic (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}]","[{'cui': 'C3494201', 'cui_str': 'Length of Operative Time'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0185003', 'cui_str': 'Reparative closure (procedure)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}]",118.0,0.0240088,"The two groups were compared in terms of operative time, postoperative air-bone gap, mean air-bone gap closure, and incidence of complications.","[{'ForeName': 'Arindam', 'Initials': 'A', 'LastName': 'Das', 'Affiliation': 'Department of Otorhinolaryngology and Head Neck Surgery, Institute of Post Graduate Medical Education and Research and SSKM Hospital, Kolkata, India.'}, {'ForeName': 'Sandipta', 'Initials': 'S', 'LastName': 'Mitra', 'Affiliation': 'Department of Otorhinolaryngology and Head Neck Surgery, Institute of Post Graduate Medical Education and Research and SSKM Hospital, Kolkata, India.'}, {'ForeName': 'Debasish', 'Initials': 'D', 'LastName': 'Ghosh', 'Affiliation': 'Department of Otorhinolaryngology and Head Neck Surgery, Institute of Post Graduate Medical Education and Research and SSKM Hospital, Kolkata, India.'}, {'ForeName': 'Arunabha', 'Initials': 'A', 'LastName': 'Sengupta', 'Affiliation': 'Department of Otorhinolaryngology and Head Neck Surgery, Institute of Post Graduate Medical Education and Research and SSKM Hospital, Kolkata, India.'}]",The Laryngoscope,['10.1002/lary.28074'] 3096,31372757,"Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study.","Postpartum depression (PPD) is a common complication following delivery, though evidence-based treatment options are limited. This study explores the feasibility and efficacy of outpatient PPD treatment with transdermal estradiol (TE). In a pilot, double-blind, placebo-controlled trial, women with PPD were randomized to receive transdermal 17β-estradiol (100 mcg/day) or placebo patch. Over 6 weeks, women completed weekly ratings on the Beck Depression Inventory (BDI), Edinburgh Postnatal Depression Scale (EPDS), and Hamilton Depression Scale (HAM-D). Primary outcome measures were treatment response (> 50% decrease from baseline BDI) and remission (BDI < 10) at 6 weeks, and secondary outcome measures included severity on all scales at weeks 3 and 6. Of 12 recruited women, 6 received TE and 6 received placebo. By week 6, 5 women receiving TE responded to treatment and 4 showed symptom remission, compared to 2 responders and 1 remitter in the placebo group. This difference was not significant (p = 0.24). In a mixed-model of BDI ratings, TE was associated with a 9.2 point decrease at 3 weeks (95%CI - 19.5 to + 1.0, p = 0.074) and a 10.5 point decrease at 6 weeks (95%CI - 21.0-0.0, p = 0.049) compared to placebo, though these differences did not survive multiple comparisons correction. Analogous effects were found for HAM-D but not EPDS scores. Interestingly, no significant difference in plasma estradiol levels existed between groups. We were unable to demonstrate a significant therapeutic benefit of TE compared with placebo in PPD. Although limited by under-recruitment and loss to follow-up, our results suggest TE is a feasible option for outpatient PPD management, with preliminary evidence (based on secondary outcomes) for efficacy. Therapeutic effects may be seen as early as 3 weeks and may not directly depend on peripheral measures of estradiol.",2020,"In a mixed-model of BDI ratings, TE was associated with a 9.2 point decrease at 3 weeks (95%CI - 19.5 to + 1.0, p = 0.074) and a 10.5 point decrease at 6 weeks (95%CI - 21.0-0.0, p = 0.049) compared to placebo, though these differences did not survive multiple comparisons correction.","['Of 12 recruited women, 6 received TE and 6 received', 'postpartum depression', 'women with PPD']","['Transdermal estradiol', 'placebo', 'placebo patch', 'transdermal 17β-estradiol', 'outpatient PPD treatment with transdermal estradiol (TE']","['plasma estradiol levels', 'Postpartum depression (PPD', 'symptom remission', 'treatment response (>\u200950% decrease from baseline BDI) and remission', 'Beck Depression Inventory (BDI), Edinburgh Postnatal Depression Scale (EPDS), and Hamilton Depression Scale (HAM-D']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0221074', 'cui_str': 'Postnatal Depression'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}]","[{'cui': 'C4521342', 'cui_str': 'Transdermal (intended site)'}, {'cui': 'C1700235', 'cui_str': '(11BAPOP2) estradiol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0445403', 'cui_str': 'Human patch'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C1277973', 'cui_str': 'Plasma estradiol measurement'}, {'cui': 'C0221074', 'cui_str': 'Postnatal Depression'}, {'cui': 'C0034131', 'cui_str': 'Purified Protein Derivative of Tuberculin'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0451022', 'cui_str': 'Beck depression inventory (assessment scale)'}, {'cui': 'C0451144', 'cui_str': 'Edinburgh Postnatal Depression Scale'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C3853311', 'cui_str': 'Ham'}]",12.0,0.768545,"In a mixed-model of BDI ratings, TE was associated with a 9.2 point decrease at 3 weeks (95%CI - 19.5 to + 1.0, p = 0.074) and a 10.5 point decrease at 6 weeks (95%CI - 21.0-0.0, p = 0.049) compared to placebo, though these differences did not survive multiple comparisons correction.","[{'ForeName': 'Howard J', 'Initials': 'HJ', 'LastName': 'Li', 'Affiliation': 'Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Pedro E', 'Initials': 'PE', 'LastName': 'Martinez', 'Affiliation': 'Section on Behavioral Endocrinology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Xiaobai', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Biostatistics and Epidemiology, National Institutes of Health Clinical Center, Bethesda, MD, USA.'}, {'ForeName': 'Linda A', 'Initials': 'LA', 'LastName': 'Schenkel', 'Affiliation': 'Section on Behavioral Endocrinology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'Lynnette K', 'Initials': 'LK', 'LastName': 'Nieman', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.'}, {'ForeName': 'David R', 'Initials': 'DR', 'LastName': 'Rubinow', 'Affiliation': 'Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Schmidt', 'Affiliation': 'Section on Behavioral Endocrinology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. PeterSchmidt@mail.nih.gov.'}]",Archives of women's mental health,['10.1007/s00737-019-00991-3'] 3097,32071431,Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.,"We report a randomized prospective phase 3 study (CLL7), designed to evaluate the efficacy of fludarabine, cyclophosphamide, and rituximab (FCR) in patients with an early-stage high-risk chronic lymphocytic leukemia (CLL). Eight hundred patients with untreated-stage Binet A disease were enrolled as intent-to-treat population and assessed for four prognostic markers: lymphocyte doubling time <12 months, serum thymidine kinase >10 U/L, unmutated IGHV genes, and unfavorable cytogenetics (del(11q)/del(17p)/trisomy 12). Two hundred and one patients with ≥2 risk features were classified as high-risk CLL and 1:1 randomized to receive either immediate therapy with 6xFCR (Hi-FCR, 100 patients), or to be observed according to standard of care (Hi-W&W, 101 patients). The overall response rate after early FCR was 92.7%. Common adverse events were hematological toxicities and infections (61.0%/41.5% of patients, respectively). After median observation time of 55.6 (0-99.2) months, event-free survival was significantly prolonged in Hi-FCR compared with Hi-W&W patients (median not reached vs. 18.5 months, p < 0.001). There was no significant overall survival benefit for high-risk patients receiving early FCR therapy (5-year OS 82.9% in Hi-FCR vs. 79.9% in Hi-W&W, p = 0.864). In conclusion, although FCR is efficient to induce remissions in the Binet A high-risk CLL, our data do not provide evidence that alters the current standard of care ""watch and wait"" for these patients.",2020,"There was no significant overall survival benefit for high-risk patients receiving early FCR therapy (5-year OS 82.9% in Hi-FCR vs. 79.9% in Hi-W&W, p = 0.864).","['Two hundred and one patients with ≥2 risk features were classified as high-risk CLL', 'patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL', 'Eight hundred patients with untreated-stage Binet A disease were enrolled as intent-to-treat population and assessed for four prognostic markers: lymphocyte doubling time <12 months, serum thymidine kinase >10\u2009U/L, unmutated IGHV genes, and unfavorable cytogenetics (del(11q)/del(17p)/trisomy 12', 'patients with an early-stage high-risk chronic lymphocytic leukemia (CLL']","['immediate therapy with 6xFCR', 'fludarabine, cyclophosphamide, and rituximab (FCR', 'FCR']","['hematological toxicities and infections', 'overall survival benefit', 'overall response rate', 'event-free survival']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0008902', 'cui_str': 'Systematics'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0032659', 'cui_str': 'Population'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0040078', 'cui_str': 'Deoxythymidine Kinase'}, {'cui': 'C0439339', 'cui_str': 'mU/mL'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0010802', 'cui_str': 'Cytogenetic'}, {'cui': 'C0432408', 'cui_str': 'Trisomy 12 (disorder)'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}]","[{'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0059985', 'cui_str': 'fludarabine'}, {'cui': 'C0010583', 'cui_str': 'Cyclophosphamide'}, {'cui': 'C0393022', 'cui_str': 'rituximab'}]","[{'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}]",800.0,0.142644,"There was no significant overall survival benefit for high-risk patients receiving early FCR therapy (5-year OS 82.9% in Hi-FCR vs. 79.9% in Hi-W&W, p = 0.864).","[{'ForeName': 'Carmen D', 'Initials': 'CD', 'LastName': 'Herling', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. carmen.herling@uk-koeln.de.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Cymbalista', 'Affiliation': ""Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP), Service d'Hematologie Biologique, Bobigny, France.""}, {'ForeName': 'Carolin', 'Initials': 'C', 'LastName': 'Groß-Ophoff-Müller', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Jasmin', 'Initials': 'J', 'LastName': 'Bahlo', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Robrecht', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Langerbeins', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Anna-Maria', 'Initials': 'AM', 'LastName': 'Fink', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Othman', 'Initials': 'O', 'LastName': 'Al-Sawaf', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Raymonde', 'Initials': 'R', 'LastName': 'Busch', 'Affiliation': 'Institute for Medical Statistics and Epidemiology, Technical University, Munich, Germany.'}, {'ForeName': 'Raphael', 'Initials': 'R', 'LastName': 'Porcher', 'Affiliation': 'Center of Clinical Epidemiology, Hopital Hotel-Dieu, Paris, France.'}, {'ForeName': 'Bruno', 'Initials': 'B', 'LastName': 'Cazin', 'Affiliation': 'Service de Maladies du Sang, CHU Claude Huriez, Lille Cedex, France.'}, {'ForeName': 'Brigitte', 'Initials': 'B', 'LastName': 'Dreyfus', 'Affiliation': ""Service d'Hematologie, CHU Poitiers, Poitiers, France.""}, {'ForeName': 'Stefan', 'Initials': 'S', 'LastName': 'Ibach', 'Affiliation': 'WiSP Wissenschaftlicher Service Pharma GmbH, Langenfeld, Germany.'}, {'ForeName': 'Stéphane', 'Initials': 'S', 'LastName': 'Leprêtre', 'Affiliation': 'Inserm Unit U1245 and Department of Hematology, Cancer Centre Henri Becquerel and Normandie University Rouen, Rouen, France.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Florian', 'Initials': 'F', 'LastName': 'Kaiser', 'Affiliation': 'Day Clinic Hematology Oncology Palliative Care, Landshut, Germany.'}, {'ForeName': 'Barbara', 'Initials': 'B', 'LastName': 'Eichhorst', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Clemens-Martin', 'Initials': 'CM', 'LastName': 'Wentner', 'Affiliation': 'Department of Hematology Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.'}, {'ForeName': 'Manuela A', 'Initials': 'MA', 'LastName': 'Hoechstetter', 'Affiliation': 'Department of Hematology Oncology, Immunology, Palliative Medicine, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Döhner', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Veronique', 'Initials': 'V', 'LastName': 'Leblond', 'Affiliation': 'Department of Haematology, Hopital de la Pitie-Salpetriere, Paris, France.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kneba', 'Affiliation': 'Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Remi', 'Initials': 'R', 'LastName': 'Letestu', 'Affiliation': ""Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP), Service d'Hematologie Biologique, Bobigny, France.""}, {'ForeName': 'Sebastian', 'Initials': 'S', 'LastName': 'Böttcher', 'Affiliation': 'Second Department of Medicine, University of Schleswig-Holstein, Kiel, Germany.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Stilgenbauer', 'Affiliation': 'Department of Internal Medicine III, University of Ulm, Ulm, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Hallek', 'Affiliation': 'Department I of Internal Medicine and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Levy', 'Affiliation': 'Unite de Recherche Clinique, Hopital Avicenne, Bobigny, France.'}]",Leukemia,['10.1038/s41375-020-0747-7'] 3098,32072772,A randomized controlled trial examining an exam room poster to prompt communication about weight.,"BACKGROUND Recognition of childhood weight status is important to the adoption of healthy lifestyle behaviours. OBJECTIVES We assessed whether an exam room educational poster addressing weight and healthy lifestyle behaviours was acceptable to parents, prompted parent-provider communication or improved parental weight perception accuracy. METHODS In this multi-site randomized controlled trial, exam rooms were randomized to display the posters (English and Spanish) or not. Children ages 3 to 8 years (N = 965) attending well visits were weighed and roomed per usual clinic protocol. After the visit, parents completed a questionnaire assessing demographics, child weight status perceptions and whether they discussed weight status with provider or were shown growth charts. We used separate logistic regression analyses to examine associations between intervention status and: asking provider about child weight, being shown growth charts, and accuracy of weight perception, adjusting for covariates and clustering by exam room. RESULTS Of the parents who saw the poster, 97% liked seeing it and reported greater understanding of weight status visualization (96%) and healthy lifestyle behaviours (94%). Parents who saw the poster were more likely to report being shown a growth chart (OR 1.87, 95% 1.06, 3.30) but were not more likely to ask about their child's weight status nor accurately report their child's weight status. CONCLUSIONS An educational exam room poster about healthy weight was well-received by parents and prompted providers to show the child's growth chart but did not prompt parent-initiated conversations about weight status nor improve parental weight perception accuracy.",2020,", 97% liked seeing it and reported greater understanding of weight status visualization (96%) and healthy lifestyle behaviours (94%).",['Children ages 3 to 8\u2009years (N = 965) attending well visits were weighed and roomed per usual clinic protocol'],[],"['healthy lifestyle behaviours', 'weight status visualization']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}]",[],"[{'cui': 'C4277664', 'cui_str': 'Healthy Life Styles'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",965.0,0.0279247,", 97% liked seeing it and reported greater understanding of weight status visualization (96%) and healthy lifestyle behaviours (94%).","[{'ForeName': 'Callie L', 'Initials': 'CL', 'LastName': 'Brown', 'Affiliation': 'Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina.'}, {'ForeName': 'Janna B', 'Initials': 'JB', 'LastName': 'Howard', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, North Carolina.'}, {'ForeName': 'Eliana M', 'Initials': 'EM', 'LastName': 'Perrin', 'Affiliation': 'Department of Pediatrics, Duke University, Durham, North Carolina.'}]",Pediatric obesity,['10.1111/ijpo.12625'] 3099,32012053,Efficacy of an Electronic Health Management Program for Patients With Cardiovascular Risk: Randomized Controlled Trial.,"BACKGROUND In addition to medication, health behavior management is crucial in patients with multiple risks of cardiovascular mortality. OBJECTIVE This study aimed to examine the efficacy of a 3-month Smart Management Strategy for Health-based electronic program (Smart Healthing). METHODS A 2-arm randomized controlled trial was conducted to assess the efficacy of Smart Healthing in 106 patients with at least one indicator of poor disease control and who had hypertension, diabetes, or hypercholesterolemia. The intervention group (n=53) took part in the electronic program, which was available in the form of a mobile app and a Web-based PC application. The program covered 4 areas: self-assessment, self-planning, self-learning, and self-monitoring by automatic feedback. The control group (n=53) received basic educational material concerning disease control. The primary outcome was the percentage of participants who achieved their clinical indicator goal after 12 weeks into the program: glycated hemoglobin (HbA 1c ) <7.0%, systolic blood pressure (SBP) <140 mmHg, or low-density lipoprotein cholesterol <130 mg/dL. RESULTS The intervention group showed a significantly higher success rate (in comparison with the control group) for achieving each of 3 clinical indicators at the targeted goal levels (P<.05). Only the patients with hypertension showed a significant improvement in SBP from the baseline as compared with the control group (72.7% vs 35.7%; P<.05). There was a significant reduction in HbA 1c in the intervention group compared with the control group (difference=0.54%; P≤.05). In the intervention group, 20% of patients with diabetes exhibited a ≥1% decrease in HbA 1c (vs 0% among controls; P≤.05). CONCLUSIONS A short-term self-management strategy-based electronic program intervention may improve clinical outcomes among patients with cardiovascular risks. TRIAL REGISTRATION ClinicalTrials.gov NCT03294044; https://clinicaltrials.gov/ct2/show/NCT03294044.",2020,The intervention group showed a significantly higher success rate (in comparison with the control group) for achieving each of 3 clinical indicators at the targeted goal levels (P<.05).,"['106 patients with at least one indicator of poor disease control and who had hypertension, diabetes, or hypercholesterolemia', 'patients with cardiovascular risks', 'patients with multiple risks of cardiovascular mortality', 'Patients With Cardiovascular Risk']","['Smart Healthing', 'Electronic Health Management Program', 'basic educational material concerning disease control', 'electronic program intervention']","['systolic blood pressure (SBP', 'success rate', 'glycated hemoglobin (HbA 1c ', 'percentage of participants who achieved their clinical indicator goal', 'HbA 1c', 'SBP']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}, {'cui': 'C0020443', 'cui_str': 'High Cholesterol Levels'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]","[{'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0911267', 'cui_str': 'SBP protein, Papaver rhoeas'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0018017', 'cui_str': 'Goals'}]",106.0,0.0616857,The intervention group showed a significantly higher success rate (in comparison with the control group) for achieving each of 3 clinical indicators at the targeted goal levels (P<.05).,"[{'ForeName': 'Young Ho', 'Initials': 'YH', 'LastName': 'Yun', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'EunKyo', 'Initials': 'E', 'LastName': 'Kang', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Young Min', 'Initials': 'YM', 'LastName': 'Cho', 'Affiliation': 'Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Sang Min', 'Initials': 'SM', 'LastName': 'Park', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Yong-Jin', 'Initials': 'YJ', 'LastName': 'Kim', 'Affiliation': 'Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Hae-Young', 'Initials': 'HY', 'LastName': 'Lee', 'Affiliation': 'Seoul National University College of Medicine, Department of Internal Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kyae Hyung', 'Initials': 'KH', 'LastName': 'Kim', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Kiheon', 'Initials': 'K', 'LastName': 'Lee', 'Affiliation': 'Bundang Seoul National University Hospital, Department of Family Medicine, Seongnam, Republic of Korea.'}, {'ForeName': 'Hye Yeon', 'Initials': 'HY', 'LastName': 'Koo', 'Affiliation': 'Bundang Seoul National University Hospital, Department of Family Medicine, Seongnam, Republic of Korea.'}, {'ForeName': 'Soojeong', 'Initials': 'S', 'LastName': 'Kim', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'YeEun', 'Initials': 'Y', 'LastName': 'Rhee', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jihye', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jeong Hee', 'Initials': 'JH', 'LastName': 'Min', 'Affiliation': 'Seoul National University College of Medicine, Department of Family Medicine, Seoul, Republic of Korea.'}, {'ForeName': 'Jin-Ah', 'Initials': 'JA', 'LastName': 'Sim', 'Affiliation': 'Seoul National University College of Medicine, Cancer Research Institute, Seoul, Republic of Korea.'}]",Journal of medical Internet research,['10.2196/15057'] 3100,32012434,Brief O 2 uploading during continuous hypothermic machine perfusion is simple yet effective oxygenation method to improve initial kidney function in a porcine autotransplant model.,"With oxygenation proposed as a resuscitative measure during hypothermic models of preservation, the aim of this study was to evaluate the optimal start time of oxygenation during continuous hypothermic machine perfusion (HMP). In this porcine ischemia-reperfusion autotransplant model, the left kidney of a ±40 kg pig was exposed to 30 minutes of warm ischemia prior to 22 hours of HMP and autotransplantation. Kidneys were randomized to receive 2 hours of oxygenation during HMP either at the start (n = 6), or end of the perfusion (n = 5) and outcomes were compared to standard, nonoxygenated HMP (n = 6) and continuous oxygenated HMP (n = 8). The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, nonoxygenated HMP or kidneys oxygenated at the end of HMP. This correlated with significant metabolic differences in perfusate (eg, lactate, succinate, flavin mononucleotide) and tissues (eg, succinate, adenosine triphosphate, hypoxia-inducible factor-1α, nuclear factor erythroid 2-related factor 2) suggesting superior mitochondrial preservation with initial oxygenation. Brief initial O 2 uploading during HMP at procurement site might be an easy and effective preservation strategy to maintain aerobic metabolism, protect mitochondria, and achieve an improved early renal graft function compared with standard HMP or oxygen supply shortly at the end of HMP preservation.",2020,"The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, non-oxygenated HMP or kidneys oxygenated at the end of HMP.",[],"['standard, non-oxygenated HMP (n=6) and continuous oxygenated HMP']","['metabolic differences in perfusate (e.g. lactate, succinate, flavin mononucleotide) and tissues (e.g. succinate, ATP, HIF-1α, Nrf2', 'initial kidney function', 'superior graft recovery']",[],"[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0038617', 'cui_str': 'Succinates'}, {'cui': 'C0016388', 'cui_str': 'riboflavin mononucleotide'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0001480', 'cui_str': 'ATP'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0022646', 'cui_str': 'Kidney'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C1282910', 'cui_str': 'Upper (qualifier value)'}, {'cui': 'C1527362', 'cui_str': 'grafts'}]",,0.0203622,"The brief initial and continuous oxygenated HMP groups were associated with superior graft recovery compared to either standard, non-oxygenated HMP or kidneys oxygenated at the end of HMP.","[{'ForeName': 'Tom', 'Initials': 'T', 'LastName': 'Darius', 'Affiliation': 'Surgery and Abdominal Transplant Unit, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Martial', 'Initials': 'M', 'LastName': 'Vergauwen', 'Affiliation': 'Pole de Chirurgie Expérimentale et Transplantation, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Smith', 'Affiliation': 'The Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Isabelle', 'Initials': 'I', 'LastName': 'Gerin', 'Affiliation': 'Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Laboratory of Physiological Chemistry, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Joris', 'Affiliation': 'Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Mueller', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Selda', 'Initials': 'S', 'LastName': 'Aydin', 'Affiliation': 'Department of Pathology, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Muller', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Schlegel', 'Affiliation': 'Liver Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, Birmingham, UK.'}, {'ForeName': 'Jay', 'Initials': 'J', 'LastName': 'Nath', 'Affiliation': 'Department of Renal Transplantation, Southmead Hospital Bristol, Bristol, UK.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ludwig', 'Affiliation': 'The Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Chantal', 'Initials': 'C', 'LastName': 'Dessy', 'Affiliation': 'Pole of Pharmacology and Therapeutics, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Marie-Christine', 'Initials': 'MC', 'LastName': 'Many', 'Affiliation': 'Department of Morphology, Experimental and Clinical Research Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Guido', 'Initials': 'G', 'LastName': 'Bommer', 'Affiliation': 'Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Laboratory of Physiological Chemistry, de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Philipp', 'Initials': 'P', 'LastName': 'Dutkowski', 'Affiliation': 'Department of Surgery and Transplantation, Swiss HPB Center, University Hospital Zurich, Zurich, Switzerland.'}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Gianello', 'Affiliation': 'Pole de Chirurgie Expérimentale et Transplantation, Université Catholique de Louvain, Brussels, Belgium.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Mourad', 'Affiliation': 'Surgery and Abdominal Transplant Unit, University Clinics Saint Luc, Université Catholique de Louvain, Brussels, Belgium.'}]",American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,['10.1111/ajt.15800'] 3101,32007460,Carotid Wallstent Versus Roadsaver Stent and Distal Versus Proximal Protection on Cerebral Microembolization During Carotid Artery Stenting.,"OBJECTIVES The aim of this study was to randomly compare the double-layer Roadsaver stent (RS) (Terumo, Tokyo, Japan) with the single-layer Carotid Wallstent (CW) (Boston Scientific, Santa Clara, California) in association with either distal embolic protection with the FilterWire (FW) device (Boston Scientific) or proximal protection with the Mo.Ma Ultra device (Medtronic, Santa Rosa, California) in patients with lipid-rich carotid plaques. BACKGROUND The role of both stent type and brain protection during carotid artery stenting (CAS) remains unsettled. METHODS A total of 104 consecutive patients with carotid artery stenosis were randomized to CAS with FW + RS (group 1, n = 27), FW + CW (group 2, n = 25), Mo.Ma + RS (group 3, n = 27), or Mo.Ma + CW (group 4, n = 25). The primary endpoint was the number of microembolic signals (MES) on transcranial Doppler among groups in the following CAS steps: 1 and 2) target vessel access; 3) lesion wiring; 4) pre-dilation; 5) stent crossing; 6) stent deployment; 7) stent dilation; and 8) device retrieval and deflation. RESULTS No significant differences in baseline characteristics were found among the 4 groups. Compared with the FW device, the Mo.Ma Ultra device significantly reduced mean MES count (p < 0.0001) during lesion crossing, stent crossing, stent deployment, and post-dilation. Compared with the CW, the RS significantly reduced MES count (p = 0.016) in steps 6 to 8, including spontaneous MES (29% of patients). The combination of Mo.Ma + RS performed significantly better than Mo.Ma + CW (p = 0.043). Clinical major adverse cardiac and cerebrovascular events occurred in 3 patients (p = 0.51). After CAS, peak systolic velocity significantly decreased in all patients. In-stent restenosis developed in 1 patient (0.98%) at 6-month follow-up. The RS was an independent predictor of external carotid artery patency over time. CONCLUSIONS In patients with high-risk, lipid-rich plaque undergoing CAS, Mo.Ma + RS led to the lowest microembolic signals count. (Role of the Type of Carotid Stent and Cerebral Protection on Cerebral Microembolization During Carotid Artery Stenting. A Randomized Study Comparing Carotid Wallstent vs Roadsaver® Stent and Distal vs Proximal Protection; NCT02915328).",2020,"Ma Ultra device significantly reduced mean MES count (p < 0.0001) during lesion crossing, stent crossing, stent deployment, and post-dilation.","['patients with high-risk, lipid-rich plaque undergoing CAS, Mo', '104 consecutive patients with carotid artery stenosis', 'patients with lipid-rich carotid plaques']","['carotid artery stenting (CAS', 'Ma\xa0+ CW', 'Ma\xa0+ RS', 'FilterWire (FW) device (Boston Scientific', 'FW\xa0+ CW', 'CAS with FW\xa0+ RS', 'double-layer Roadsaver stent (RS) (Terumo, Tokyo, Japan) with the single-layer Carotid Wallstent (CW', 'Carotid Wallstent Versus Roadsaver Stent and Distal Versus Proximal Protection', 'Carotid Wallstent vs Roadsaver® Stent and Distal vs Proximal Protection', 'Ma Ultra device (Medtronic, Santa Rosa, California']","['number of microembolic signals (MES) on transcranial Doppler', 'external carotid artery patency', 'Clinical major adverse cardiac and cerebrovascular events', 'mean MES count', 'MES count', 'Cerebral Microembolization', 'peak systolic velocity', 'stent dilation; and 8) device retrieval and deflation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C4280983', 'cui_str': 'Lipid-rich plaque'}, {'cui': 'C4517527', 'cui_str': '104'}, {'cui': 'C0007282', 'cui_str': 'Carotid Artery Narrowing'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0699759', 'cui_str': 'Wealthy (finding)'}, {'cui': 'C0332461', 'cui_str': 'Plaque (morphologic abnormality)'}]","[{'cui': 'C0007272', 'cui_str': 'Carotid Arteries'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0006037', 'cui_str': 'Boston'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C0040371', 'cui_str': 'Tokyo'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0205108', 'cui_str': 'Distal (qualifier value)'}, {'cui': 'C0205107', 'cui_str': 'Proximal (qualifier value)'}, {'cui': 'C0035853', 'cui_str': 'Rose'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0442348', 'cui_str': 'Transcranial approach (qualifier value)'}, {'cui': 'C0007275', 'cui_str': 'Carotid Artery, External'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0442710', 'cui_str': 'Peak systolic, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0038257', 'cui_str': 'Stents'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",104.0,0.108948,"Ma Ultra device significantly reduced mean MES count (p < 0.0001) during lesion crossing, stent crossing, stent deployment, and post-dilation.","[{'ForeName': 'Piero', 'Initials': 'P', 'LastName': 'Montorsi', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Centro Cardiologico Monzino, IRCCS, Milan, Italy. Electronic address: piero.montorsi@ccfm.it.'}, {'ForeName': 'Luigi', 'Initials': 'L', 'LastName': 'Caputi', 'Affiliation': 'Department of Cerebrovascular Disease, Fondazione IRCCS Istituto Neurologico ""C. Besta,"" Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'Galli', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Paolo M', 'Initials': 'PM', 'LastName': 'Ravagnani', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Giovanni', 'Initials': 'G', 'LastName': 'Teruzzi', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Annoni', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Calligaris', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Franco', 'Initials': 'F', 'LastName': 'Fabbiocchi', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Trabattoni', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Stefano', 'Initials': 'S', 'LastName': 'de Martini', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Grancini', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Gianluca', 'Initials': 'G', 'LastName': 'Pontone', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Daniele', 'Initials': 'D', 'LastName': 'Andreini', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Troiano', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Restelli', 'Affiliation': 'Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}, {'ForeName': 'Antonio L', 'Initials': 'AL', 'LastName': 'Bartorelli', 'Affiliation': 'Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Centro Cardiologico Monzino, IRCCS, Milan, Italy.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.09.007'] 3102,31956037,Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.,"BACKGROUND The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. PATIENTS AND METHODS Patients participated in a randomised controlled trial of adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy carried out between 1993 and 1999 in stage III BC. Stromal TILs were scored according to International guidelines in these human epidermal growth factor receptor 2 (HER2)-negative tumours. BRCA-profiles were determined using Comparative Genomic Hybridization. RESULTS TIL levels were evaluated in 248 BCs. High TILs were associated with Triple Negative BC (TNBC). BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01). TIL levels in BRCA1-like tumours were higher compared to BRCA2-like tumours (median TILs of 20% versus 10%, p < 0.001). These correlations remained significant within the oestrogen (ER)-positive subgroup, however not within the TNBC subgroup. In this stage III BC cohort, high TIL level was associated with favourable outcome (TILs per 10% increment, recurrence-free survival (RFS): multivariate hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.71-0.94, p = 0.01; overall survival (OS): multivariate HR 0.80, 95% CI 0.68-0.94, p = 0.01). There was no significant interaction between TILs and benefit of intensified platinum-based chemotherapy. CONCLUSION In this high-risk breast cancer cohort, high TILs were associated with TNBC and BRCA1-like status. Within the ER-positive subgroup, TIL levels were higher in BRCA1-like compared to BRCA2-like tumours. When adjusted for clinical characteristics, TILs were significantly associated with a more favourable outcome in stage III BC patients.",2020,"BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01).","['stage III breast cancer patients', 'stage III BC patients', 'Patients participated', 'carried out between 1993 and 1999 in stage III BC']","['adjuvant intensified platinum-based chemotherapy versus conventional anthracycline-based chemotherapy', 'intensified platinum-based chemotherapy', 'adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy']","['recurrence-free survival (RFS): multivariate hazard ratio', 'Tumour-infiltrating lymphocytes (TILs) and BRCA-like status', 'TIL levels', 'TIL levels in BRCA1-like tumours', 'Triple Negative BC (TNBC', 'overall survival']","[{'cui': 'C0441771', 'cui_str': 'Stage level 3 (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0206243', 'cui_str': 'Carrying'}]","[{'cui': 'C1098768', 'cui_str': '(diethylenetriamine)-platinum(II)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0282564', 'cui_str': 'Anthracyclines'}]","[{'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0027651', 'cui_str': 'Neoplasia'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.195327,"BRCA-like tumours harboured higher TILs compared to non-BRCA-like tumours (median TILs of 20% versus 10%, p < 0.01).","[{'ForeName': 'Leonora', 'Initials': 'L', 'LastName': 'de Boo', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Cimino-Mathews', 'Affiliation': 'Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.'}, {'ForeName': 'Yoni', 'Initials': 'Y', 'LastName': 'Lubeck', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Antonios', 'Initials': 'A', 'LastName': 'Daletzakis', 'Affiliation': 'Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Opdam', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Sanders', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Erik', 'Initials': 'E', 'LastName': 'Hooijberg', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Annelot', 'Initials': 'A', 'LastName': 'van Rossum', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Zuzana', 'Initials': 'Z', 'LastName': 'Loncova', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Rieder', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Zlatko', 'Initials': 'Z', 'LastName': 'Trajanoski', 'Affiliation': 'Division of Bioinformatics, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Marieke', 'Initials': 'M', 'LastName': 'Vollebergh', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marcelo', 'Initials': 'M', 'LastName': 'Sobral-Leite', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brazil.'}, {'ForeName': 'Koen', 'Initials': 'K', 'LastName': 'van de Vijver', 'Affiliation': 'Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, Ghent University Hospital, Ghent, Belgium.'}, {'ForeName': 'Annegien', 'Initials': 'A', 'LastName': 'Broeks', 'Affiliation': 'Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Rianne', 'Initials': 'R', 'LastName': 'van der Wiel', 'Affiliation': 'Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Harm', 'Initials': 'H', 'LastName': 'van Tinteren', 'Affiliation': 'Biometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Sabine', 'Initials': 'S', 'LastName': 'Linn', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, University Medical Centre, Utrecht, the Netherlands.'}, {'ForeName': 'Hugo Mark', 'Initials': 'HM', 'LastName': 'Horlings', 'Affiliation': 'Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.'}, {'ForeName': 'Marleen', 'Initials': 'M', 'LastName': 'Kok', 'Affiliation': 'Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: m.kok@nki.nl.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.003'] 3103,32062862,"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity.","BACKGROUND Pharmacological treatment options for adolescents with obesity are very limited. Glucagon-like-peptide-1 (GLP-1) receptor agonist could be a treatment option for adolescent obesity. OBJECTIVE To investigate the effect of exenatide extended release on body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics as secondary outcomes, and its safety and tolerability in adolescents with obesity. METHODS Six-month, randomized, double-blinded, parallel, placebo-controlled clinical trial in patients (n = 44, 10-18 years, females n = 22) with BMI-SDS > 2.0 or age-adapted-BMI > 30 kg/m 2 according to WHO were included. Patients received lifestyle intervention and were randomized to exenatide extended release 2 mg (n = 22) or placebo (n = 22) subcutaneous injections given once weekly. Oral glucose tolerance tests (OGTT) were conducted at the beginning and end of the intervention. RESULTS Exenatide reduced (P < .05) BMI-SDS (-0.09; -0.18, 0.00), % BMI 95th percentile (-2.9%; -5.4, -0.3), weight (-3 kg; -5.8, -0.1), waist circumference (-3.2 cm; -5.8, -0.7), subcutaneous adipose tissue (-552 cm 3 ; -989, -114), 2-hour-glucose during OGTT (-15.3 mg/dL; -27.5, -3.1), total cholesterol (11.6 mg/dL; -21.7, -1.5), and BMI (-0.83 kg/m 2 ; -1.68, 0.01) without significant change in liver fat content (-1.36; -3.12, 0.4; P = .06) in comparison to placebo. Safety and tolerability profiles were comparable to placebo with the exception of mild adverse events being more frequent in exenatide-treated patients. CONCLUSIONS Treatment of adolescents with severe obesity with extended-release exenatide is generally well tolerated and leads to a modest reduction in BMI metrics and improvement in glucose tolerance and cholesterol. The study indicates that the treatment provides additional beneficial effects beyond BMI reduction for the patient group.",2020,"RESULTS Exenatide reduced (P < .05)","['adolescents with severe obesity', '30\u2009kg/m 2 according to WHO were included', 'patients (n = 44, 10-18\u2009years, females n = 22) with BMI-SDS\u2009>\u20092.0 or age-adapted-BMI\u2009', 'adolescents with obesity']","['Glucagon-like-peptide-1 (GLP-1) receptor agonist', 'lifestyle intervention', 'placebo', 'exenatide', 'exenatide extended release 2 mg (n = 22) or placebo']","['Safety and tolerability profiles', 'liver fat content', 'waist circumference', '2-hour-glucose during OGTT ', 'body mass index (BMI)-SDS as primary outcome, and glucose metabolism, cardiometabolic risk factors, liver steatosis, and other BMI metrics', 'total cholesterol', 'BMI metrics', 'BMI', 'safety and tolerability', 'glucose tolerance and cholesterol', 'subcutaneous adipose tissue', 'Oral glucose tolerance tests (OGTT']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0028756', 'cui_str': 'Obesity, Severe'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C4543206', 'cui_str': 'Receptor agonist (disposition)'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0167117', 'cui_str': 'exenatide'}, {'cui': 'C1963578', 'cui_str': 'Release (procedure)'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0023884', 'cui_str': 'Liver'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0455829', 'cui_str': 'Waist Circumference'}, {'cui': 'C1292425', 'cui_str': '2 hours (qualifier value)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0029161', 'cui_str': 'Oral Glucose Tolerance'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C2711227', 'cui_str': 'Liver Steatosis'}, {'cui': 'C0699680', 'cui_str': 'Metric'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0231197', 'cui_str': 'Tolerance, function (observable entity)'}, {'cui': 'C0222331', 'cui_str': 'Subcutaneous Fat'}]",22.0,0.3828,"RESULTS Exenatide reduced (P < .05)","[{'ForeName': 'D', 'Initials': 'D', 'LastName': 'Weghuber', 'Affiliation': 'Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Forslund', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Ahlström', 'Affiliation': 'Department of Radiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Alderborn', 'Affiliation': 'Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Bergström', 'Affiliation': 'Scandinavian CRO, Uppsala, Sweden.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Brunner', 'Affiliation': 'Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cadamuro', 'Affiliation': 'Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'I', 'Initials': 'I', 'LastName': 'Ciba', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Dahlbom', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Heu', 'Affiliation': 'Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Hofmann', 'Affiliation': 'Department of Paediatrics, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kristinsson', 'Affiliation': 'Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Kullberg', 'Affiliation': 'Department of Radiology, Uppsala University, Uppsala, Sweden.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ladinger', 'Affiliation': 'Department of Radiology, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'F B', 'Initials': 'FB', 'LastName': 'Lagler', 'Affiliation': 'Clinical Research Center Salzburg GmbH, Salzburg, Austria.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Lidström', 'Affiliation': 'Children Obesity Clinic, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Manell', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Meirik', 'Affiliation': 'Children Obesity Clinic, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Mörwald', 'Affiliation': 'Obesity Research Unit, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Roomp', 'Affiliation': 'Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg.'}, {'ForeName': 'R', 'Initials': 'R', 'LastName': 'Schneider', 'Affiliation': 'Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-Belval, Luxembourg.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Vilén', 'Affiliation': 'Children Obesity Clinic, Uppsala University Hospital, Uppsala, Sweden.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Widhalm', 'Affiliation': 'Obesity Research Unit, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Zsoldos', 'Affiliation': 'Obesity Research Unit, Paracelsus Medical University, Salzburg, Austria.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Bergsten', 'Affiliation': ""Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.""}]",Pediatric obesity,['10.1111/ijpo.12624'] 3104,32014812,"Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.","BACKGROUND The RAINBOW trial showed that second-line ramucirumab with paclitaxel prolongs overall survival (OS) and progression-free survival (PFS) compared with placebo plus paclitaxel for treatment of advanced gastric/gastroesophageal junction cancer. Plasma samples were collected from patients during the trial and tested to identify predictive and prognostic biomarkers. PATIENTS AND METHODS Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were assayed using: Intertek assays (24 markers, 380 samples, 57% of patients) and Lilly-developed assay (LDA) platform (5 markers, 257 samples, 39% of patients). Time-trend plots were generated for each marker from the Intertek assays. Baseline patient data were dichotomized into low- and high-marker subgroups. Markers were analyzed for predictive effects using interaction models and for prognostic effects using main-effects models. RESULTS The Intertek and LDA populations were representative of the full trial population. Plasma levels of VEGF-D and PlGF increased from baseline levels during treatment, then declined after treatment discontinued. Angiopoietin-2 exhibited a decrease during treatment, then increased after treatment discontinuation. No clear time trend was evident with the other markers. Analyses of baseline biomarker expression and its relationship with efficacy variables found no biomarker was predictive for efficacy outcomes, including VEGF-D. However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. CONCLUSIONS Pharmacodynamic and prognostic relationships were found from the exploratory biomarker analyses in RAINBOW; however, no predictive markers for ramucirumab in gastric cancer were identified in this trial.",2020,"However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. ","['Circulating factors in plasma samples from mutually exclusive subsets of RAINBOW patients were assayed using: Intertek assays (24 markers, 380 samples, 57% of patients) and Lilly-developed assay (LDA) platform (5 markers, 257 samples, 39% of patients', 'advanced gastric/gastroesophageal junction cancer', 'patients with advanced gastric cancer']","['placebo plus paclitaxel', 'paclitaxel']","['Plasma samples', 'CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1', 'Plasma levels of VEGF-D and PlGF', 'overall survival (OS) and progression-free survival (PFS']","[{'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C4319693', 'cui_str': 'Three hundred and eighty'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C1704242', 'cui_str': 'Gastric (qualifier value)'}, {'cui': 'C0014871', 'cui_str': 'Gastroesophageal Junction'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0024623', 'cui_str': 'Cancer of Stomach'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0144576', 'cui_str': 'Paclitaxel'}]","[{'cui': 'C0444263', 'cui_str': 'Plasma specimen'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C4319664', 'cui_str': 'ICAM3'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0078056', 'cui_str': 'CD106 Antigens'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0664390', 'cui_str': 'Vascular Endothelial Growth Factor D'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}]",,0.236128,"However, CRP, HGF, ICAM-3, IL-8, SAA, and VCAM-1 were identified as potential prognostic markers with low baseline levels corresponding to longer OS and PFS. ","[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Van Cutsem', 'Affiliation': 'Digestive Oncology, University Hospitals Gasthuisberg, Leuven and KULeuven, Leuven, Belgium. Electronic address: Eric.VanCutsem@uzleuven.be.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Muro', 'Affiliation': 'Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cunningham', 'Affiliation': 'Royal Marsden Hospital, Sutton, UK.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Bodoky', 'Affiliation': 'Department of Oncology, St. László Hospital, Budapest, Hungary.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Sobrero', 'Affiliation': 'Medical Oncology, IRCCS Ospedale San Martino IST, Genova, Italy.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Cascinu', 'Affiliation': 'Department of Medical Oncology, Università Politecnica Delle Marche, Ancona, Italy.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Ajani', 'Affiliation': 'Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.'}, {'ForeName': 'S C', 'Initials': 'SC', 'LastName': 'Oh', 'Affiliation': 'Korea University Guro Hospital, Seoul, South Korea.'}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Al-Batran', 'Affiliation': 'Institute of Clinical Cancer Research (IKF), UCT- University Cancer Center, Frankfurt, Germany.'}, {'ForeName': 'Z A', 'Initials': 'ZA', 'LastName': 'Wainberg', 'Affiliation': 'Medical Hematology and Oncology, University of California Los Angeles, Los Angeles, CA, USA.'}, {'ForeName': 'S R', 'Initials': 'SR', 'LastName': 'Wijayawardana', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Melemed', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Ferry', 'Affiliation': 'Eli Lilly and Company, Bridgewater, NJ, USA.'}, {'ForeName': 'R R', 'Initials': 'RR', 'LastName': 'Hozak', 'Affiliation': 'Eli Lilly and Company, Indianapolis, IN, USA.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Ohtsu', 'Affiliation': 'Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.10.026'] 3105,31773209,Effect of e-cigarette flavors on nicotine delivery and puffing topography: results from a randomized clinical trial of daily smokers.,"RATIONALE There is limited understanding regarding how various e-cigarette flavorings may influence the behavior of non-regular e-cigarette users who are regular cigarette smokers. OBJECTIVES To assess differences in nicotine delivery, puffing topography, subjective effects, and user satisfaction from different flavored e-liquids. METHODS Eighteen daily smokers (average age, 44.1 ± 7.0; 9 males; average CPD, 13.0 ± 5.8) smoked their tobacco cigarettes during an initial visit and returned five times to try an e-cigarette (eGo type) refilled with a nicotine solution (24 mg/ml) of five different flavors: cherry, tobacco, espresso, menthol, and vanilla (randomized order). Assessments at each visit included puffing topography, blood samples for nicotine analysis, and subjective reports of nicotine effects and flavor satisfaction. RESULTS Vaping different flavors resulted in different levels of plasma nicotine. The flavor producing the highest plasma nicotine concentration (C max ) was cherry (median 21.2 ng/ml), which was not significantly different than nicotine delivery from a combustible cigarette (29.2 ng/ml, p > .05). Vanilla e-liquid produced the lowest C max (9.7 ng/ml), and participants tended to puff less frequently on vanilla compared to tobacco flavor (p = .013). Flavors did not differ significantly in the speed of nicotine delivery (T max ). During controlled use, puff duration for all flavors was significantly longer than a combustible cigarette (p < 0.05). After controlling for nicotine delivery, significant differences in flavor enjoyment were detected. Menthol flavored e-liquid was rated as more enjoyable than vanilla and tobacco flavored e-liquids (p < 0.05). CONCLUSIONS Flavors tested in this study yielded different patterns of nicotine delivery and led to differences in reduction in smoking urges. TRIAL REGISTRATION ClinicalTrials.gov Identifier: #NCT02575885.",2020,"Menthol flavored e-liquid was rated as more enjoyable than vanilla and tobacco flavored e-liquids (p < 0.05). ","['Eighteen daily smokers (average age, 44.1 ± 7.0; 9 males; average CPD, 13.0 ± 5.8) smoked their tobacco cigarettes during an initial visit and returned five times to try an e-cigarette (eGo type) refilled with a', '24 mg/ml) of five different flavors: cherry, tobacco, espresso, menthol, and vanilla (randomized order']","['nicotine solution', 'e-cigarette flavors']","['highest plasma nicotine concentration (C max ', 'flavor enjoyment', 'speed of nicotine delivery (T max ', 'levels of plasma nicotine']","[{'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2001794', 'cui_str': '(BMIM)(TFSI) cpd'}, {'cui': 'C4517796', 'cui_str': '5.8'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0347984', 'cui_str': 'During (attribute)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C1533153', 'cui_str': 'Fives'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0013712', 'cui_str': 'Ego'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0439294', 'cui_str': 'mcg/mcL'}, {'cui': 'C0330657', 'cui_str': 'Pie Cherry'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0025368', 'cui_str': 'Menthol'}, {'cui': 'C0678424', 'cui_str': 'Vanilla (substance)'}, {'cui': 'C4284072', 'cui_str': 'Order (record artifact)'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}]","[{'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0706778,"Menthol flavored e-liquid was rated as more enjoyable than vanilla and tobacco flavored e-liquids (p < 0.05). ","[{'ForeName': 'Natalie', 'Initials': 'N', 'LastName': 'Voos', 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA. nataliedvoos@gmail.com.'}, {'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Smith', 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Kaiser', 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA.'}, {'ForeName': 'Martin C', 'Initials': 'MC', 'LastName': 'Mahoney', 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA.'}, {'ForeName': 'Clara M', 'Initials': 'CM', 'LastName': 'Bradizza', 'Affiliation': 'Department of Psychiatry, Jacobs School of Medicine and Biomedical Sciences, Buffalo, USA.'}, {'ForeName': 'Lynn T', 'Initials': 'LT', 'LastName': 'Kozlowski', 'Affiliation': 'School of Public Health and Health Professions, University at Buffalo, Buffalo, USA.'}, {'ForeName': 'Neal L', 'Initials': 'NL', 'LastName': 'Benowitz', 'Affiliation': 'Division of Clinical Pharmacology, Department of Medicine and Bioengineering & Therapeutic Sciences, University of California San Francisco, San Francisco, USA.'}, {'ForeName': 'Richard J', 'Initials': 'RJ', 'LastName': ""O'Connor"", 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA.'}, {'ForeName': 'Maciej L', 'Initials': 'ML', 'LastName': 'Goniewicz', 'Affiliation': 'Department of Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, USA.'}]",Psychopharmacology,['10.1007/s00213-019-05386-x'] 3106,31147187,Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial.,"BACKGROUND Increased shear stress conferred upon the circulation by continuous-flow pumps is associated with hemocompatibility-related adverse events, principally bleeding within the gastrointestinal system, and linked to the degradation of high-molecular-weight multimers (HMWMs) of von Willebrand factor (vWF). We evaluated the structure and functional characteristics of vWF HMWMs in patients with the fully magnetically levitated centrifugal-flow HeartMate 3 (HM3) and the continuous axial-flow HeartMate II (HMII) pump. Findings were correlated with bleeding events. METHODS In a prospective, multicenter, comparative cohort study, 60 patients from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 Continued Access Protocol (NCT02892955) with an HM3 pump were compared with 30 randomly selected HMII patients from the PREVENtion of HeartMate II Pump Thrombosis study (NCT02158403) biobank. The primary end point was the difference in the normalized vWF HMWM ratio (ratio of the HMWMs to the intermediate- and low-molecular-weight multimers, normalized to pooled plasma from healthy volunteers) between the HM3 and the HMII pump at 90 days after implantation. Assay tests for vWF activity, vWF antigen, vWF activity to antigen ratio, coagulation factor VIII activity, and ADAMTS13 activity were measured by using standard protocols. Differences in these markers were compared in the context of clinical characteristics and correlated with adjudicated bleeding events within the HM3 group. RESULTS Of 51 and 29 evaluable patients in the HM3 and HMII arms, respectively, those implanted with the HM3 pump exhibited greater preservation of the vWF HMWM ratio than those with the HMII pump at 90 days after implantation (54.1% vs 42.4%, p < 0.0001). Laboratory values for all vWF assays (antigen, activity, and coagulation factor VIII activity) remained within the normal functional range with no significant differences observed between the pumps at 90 days after implantation. At baseline, there was a decrease in the structural integrity of vWF HMWMs that correlated with increasing heart failure severity as measured by the Interagency Registry for Mechanically Assisted Circulatory Support profile. Multivariable modeling identified the HM3 pump as the only independent variable that determined post-implantation preservation of the structural integrity of vWF HMWMs. CONCLUSIONS This prospective, multicenter comparative analysis study demonstrates that the fully magnetically levitated centrifugal-flow HM3 left ventricular assist device is associated with greater preservation of the structure of vWF HMWMs than the HMII mechanical bearing axial-flow pump.",2019,"At baseline, there was a decrease in the structural integrity of vWF HMWMs that correlated with increasing heart failure severity as measured by the Interagency Registry for Mechanically Assisted Circulatory Support profile.","['patients with the fully magnetically levitated centrifugal-flow HeartMate 3 (HM3) and the continuous axial-flow HeartMate II (HMII) pump', '60 patients from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 Continued Access Protocol (NCT02892955) with an HM3 pump were compared with 30 randomly selected HMII patients from the PREVENtion of HeartMate II Pump Thrombosis study (NCT02158403) biobank']",['fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device'],"['adjudicated bleeding events', 'Laboratory values for all vWF assays (antigen, activity, and coagulation factor VIII activity', 'bleeding events', 'normalized vWF HMWM ratio (ratio of the HMWMs', 'vWF activity, vWF antigen, vWF activity to antigen ratio, coagulation factor VIII activity, and ADAMTS13 activity', 'structural integrity of vWF HMWMs', 'vWF HMWM ratio', 'heart failure severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1301962', 'cui_str': 'Centrifugal'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C0182537', 'cui_str': 'Pump'}, {'cui': 'C1096776', 'cui_str': 'Multicenter Study'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0443254', 'cui_str': 'Mechanical (qualifier value)'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C0040053', 'cui_str': 'Thrombosis'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C1301962', 'cui_str': 'Centrifugal'}, {'cui': 'C0205131', 'cui_str': 'Axial (qualifier value)'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}]","[{'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0003320', 'cui_str': 'Antigens'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0015506', 'cui_str': 'coagulation factor VIII'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]",60.0,0.0319889,"At baseline, there was a decrease in the structural integrity of vWF HMWMs that correlated with increasing heart failure severity as measured by the Interagency Registry for Mechanically Assisted Circulatory Support profile.","[{'ForeName': 'Aditya', 'Initials': 'A', 'LastName': 'Bansal', 'Affiliation': 'Ochsner Medical Center, New Orleans, Louisiana.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Uriel', 'Affiliation': 'University of Chicago School of Medicine and Medical Center, Chicago, Illinois.'}, {'ForeName': 'Paolo C', 'Initials': 'PC', 'LastName': 'Colombo', 'Affiliation': 'Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Keerthy', 'Initials': 'K', 'LastName': 'Narisetty', 'Affiliation': 'Baptist Health Medical Center, Little Rock, Arkansas.'}, {'ForeName': 'James W', 'Initials': 'JW', 'LastName': 'Long', 'Affiliation': 'Integris Baptist Medical Center, Oklahoma City, Oklahoma.'}, {'ForeName': 'Arvind', 'Initials': 'A', 'LastName': 'Bhimaraj', 'Affiliation': 'Methodist Hospital, Houston, Texas.'}, {'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Cleveland', 'Affiliation': 'University of Colorado Hospital, Aurora, Colorado.'}, {'ForeName': 'Daniel J', 'Initials': 'DJ', 'LastName': 'Goldstein', 'Affiliation': 'Montefiore Einstein Center for Heart and Vascular Care, Bronx, New York.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Stulak', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Samer S', 'Initials': 'SS', 'LastName': 'Najjar', 'Affiliation': 'Medstar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Lanfear', 'Affiliation': 'Henry Ford Hospital, Detroit, Michigan.'}, {'ForeName': 'Eric D', 'Initials': 'ED', 'LastName': 'Adler', 'Affiliation': 'University of California San Diego, La Jolla, California.'}, {'ForeName': 'Walter P', 'Initials': 'WP', 'LastName': 'Dembitsky', 'Affiliation': 'Sharp Memorial Hospital, San Diego, California.'}, {'ForeName': 'Sami I', 'Initials': 'SI', 'LastName': 'Somo', 'Affiliation': 'Abbott, Chicago, Illinois.'}, {'ForeName': 'Daniel L', 'Initials': 'DL', 'LastName': 'Crandall', 'Affiliation': 'Abbott, Chicago, Illinois.'}, {'ForeName': 'Dong', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Jean Marie', 'Initials': 'JM', 'LastName': 'Connors', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Mandeep R', 'Initials': 'MR', 'LastName': 'Mehra', 'Affiliation': ""Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: mmehra@bwh.harvard.edu.""}]",The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,['10.1016/j.healun.2019.05.006'] 3107,31356508,Physical Activity Is Higher in Patients with LVADs Compared to Chronic Heart Failure.,"PURPOSE Left ventricular assist devices (LVADs) are associated with an increased aerobic capacity in patients with chronic heart failure (CHF). However, studies evaluating the impact of LVAD implantation on physical activity (PA) are lacking. The aim of this study was to compare daily PA levels in participants with LVADs with well-matched CHF participants. METHODS Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation. Participants underwent a cardiopulmonary exercise test to determine peak oxygen consumption (V[Combining Dot Above]O2 peak). PA was monitored continuously for seven consecutive days with an Actiheart monitor. RESULTS V[Combining Dot Above]O2 peak in the CHF group (12.3 ± 3.5 ml·kg·min) was not significantly different to the LVAD group prior to LVAD implantation (10.4 ± 2.1 ml·kg·min), but was lower than in the LVAD group following implantation (15.8 ± 4.3 ml·kg·min; p < 0.05). PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001). LVAD participants spent more time performing moderate intensity PA than their CHF counterparts, 26 (24-40) [median (IQR)] vs. 12 (9-16) min/day; p < 0.001. PA was correlated with V[Combining Dot Above]O2 peak (r = 0.582; p = 0.001) across participants in the CHF and LVAD groups. CONCLUSION Higher levels of PA were observed in participants with LVAD compared with patients with advanced CHF. This may be due to a higher V[Combining Dot Above]O2 peak, resulting in an improved capacity to perform activities of daily living with less symptoms.",2019,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"['Sixteen participants with an LVAD (age: 59.1 ± 10.8 years) were case-matched to 16 participants with advanced CHF (age: 58.3 ± 8.7 years), who were listed or being considered for cardiac transplantation', 'patients with chronic heart failure (CHF', 'participants with LVADs with well-matched CHF participants']","['LVAD implantation', 'Left ventricular assist devices (LVADs', 'cardiopulmonary exercise test', 'LVAD']","['Dot Above]O2 peak', 'time performing moderate intensity PA', 'V[Combining Dot Above]O2 peak', 'PA', 'peak oxygen consumption (V[Combining Dot Above]O2 peak', 'Physical Activity', 'aerobic capacity', 'daily PA levels', 'Higher levels of PA']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517523', 'cui_str': '10.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C4517880', 'cui_str': '8.7 (qualifier value)'}, {'cui': 'C0018823', 'cui_str': 'Transplantation, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0264716', 'cui_str': 'Chronic heart failure (disorder)'}]","[{'cui': 'C0021107', 'cui_str': 'Insertion procedure'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}, {'cui': 'C2959886', 'cui_str': 'Cardiopulmonary Exercise Test'}]","[{'cui': 'C1720485', 'cui_str': 'Corneal epithelial microcysts'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C1305742', 'cui_str': 'Oxygen consumption'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",16.0,0.0464878,PA was higher in the LVAD (19.7 ± 6.4 kJ·kg·day) compared with the CHF group (11.6 ± 6.9 kJ·kg·day; p = 0.001).,"[{'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Moreno-Suarez', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Sylvia', 'Initials': 'S', 'LastName': 'Liew', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}, {'ForeName': 'Lawrence G', 'Initials': 'LG', 'LastName': 'Dembo', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Larbalestier', 'Affiliation': 'Advanced Heart Failure and Cardiac Transplant Service, Fiona Stanley Hospital, Murdoch, Australia.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Maiorana', 'Affiliation': 'School of Physiotherapy and Exercise Science, Curtin University, Perth, Australia.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000002104'] 3108,30994376,"Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness During Behavioral Weight Loss Treatment in Antipsychotic-Treated Youth: A Randomized Pilot Study.","Objectives: The purpose of this pilot study was to evaluate changes in adiposity, carotid intima media thickness (CIMT), and hepatic fat content measured via magnetic resonance imaging-estimated hepatic proton density fat fraction (PDFF) in antipsychotic (AP)-treated youth versus nonpsychiatric (NP) participants during participation in a 16-week behavioral weight loss (BWL) intervention. Subjects/Methods: Overweight/obese AP-treated youth ( n  = 26) were randomized 2:1 to weekly treatment versus recommended care (RC) over 16 weeks. NP controls ( n  = 21) were assigned to weekly treatment. Dual-energy X-ray absorptiometry (DEXA)-measured adiposity, CIMT, and PDFF were measured at baseline and 16 weeks. Analyses assessed group differences in the effect of BWL on adiposity, CIMT, and PDFF. Results: BWL was well tolerated in both AP-treated and NP groups. DEXA-measured fat decreased significantly in the NP group ( F [1,16] = 11.81, p  = 0.003), with modest improvements in adiposity and hepatic fat in the AP-treated group, while an increase in adiposity was observed in the RC group. Significant differences in endpoint DEXA total fat ( F [2,34] = 4.81, p  = 0.01) and PDFF ( F [2,30] = 3.60, p  = 0.04) occurred across treatment groups, explained by larger improvements in NP versus RC youth in DEXA total fat ( p  = 0.03) and PDFF ( p  = 0.04). Conclusions: Intensive, family-based BWL treatment can improve whole-body adiposity and liver fat in obese youth, with decreases or attenuation of additional fat gain observed in AP-treated youth.",2019,"Significant differences in endpoint DEXA total fat ( F [2,34] = 4.81, p  = 0.01) and PDFF ( F [2,30] = 3.60, p  = 0.04) occurred across treatment groups, explained by larger improvements in NP versus RC youth in DEXA total fat ( p  = 0.03) and PDFF ( p  = 0.04). ","['Antipsychotic-Treated Youth', 'Overweight/obese AP-treated youth ( n \u2009=\u200926']",['antipsychotic (AP)-treated youth versus nonpsychiatric (NP) participants during participation in a 16-week behavioral weight loss (BWL) intervention'],"['DEXA-measured fat', 'tolerated', 'PDFF', 'Dual-energy X-ray absorptiometry (DEXA)-measured adiposity, CIMT, and PDFF', 'adiposity', 'effect of BWL on adiposity, CIMT, and PDFF', 'adiposity, carotid intima media thickness (CIMT), and hepatic fat content', 'endpoint DEXA total fat', 'adiposity and hepatic fat', 'Adiposity, Hepatic Triglyceride, and Carotid Intima Media Thickness']","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0040615', 'cui_str': 'Antipsychotic Drugs'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0087178', 'cui_str': 'Youth'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1510486', 'cui_str': 'Dual X-Ray Absorptiometry'}, {'cui': 'C1563743', 'cui_str': 'Adiposis'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0162864', 'cui_str': 'Vascular Intima'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}]",26.0,0.0372611,"Significant differences in endpoint DEXA total fat ( F [2,34] = 4.81, p  = 0.01) and PDFF ( F [2,30] = 3.60, p  = 0.04) occurred across treatment groups, explained by larger improvements in NP versus RC youth in DEXA total fat ( p  = 0.03) and PDFF ( p  = 0.04). ","[{'ForeName': 'Ginger E', 'Initials': 'GE', 'LastName': 'Nicol', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Kolko', 'Affiliation': '2Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Eric J', 'Initials': 'EJ', 'LastName': 'Lenze', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Michael D', 'Initials': 'MD', 'LastName': 'Yingling', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'J Philip', 'Initials': 'JP', 'LastName': 'Miller', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Amanda R', 'Initials': 'AR', 'LastName': 'Ricchio', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Julia A', 'Initials': 'JA', 'LastName': 'Schweiger', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Findling', 'Affiliation': '4Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Denise', 'Initials': 'D', 'LastName': 'Wilfley', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}, {'ForeName': 'John W', 'Initials': 'JW', 'LastName': 'Newcomer', 'Affiliation': '1Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri.'}]",Journal of child and adolescent psychopharmacology,['10.1089/cap.2018.0120'] 3109,32053538,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Knackstedt', 'Affiliation': ''}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Gatherwright', 'Affiliation': ''}, {'ForeName': 'Risal', 'Initials': 'R', 'LastName': 'Djohan', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006782'] 3110,32053534,"Reply to: ""The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial"".",,2020,,['Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction'],"['Bupivacaine Hydrochloride', 'Liposomal Bupivacaine']",[],"[{'cui': 'C0444660', 'cui_str': 'Plane (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439859', 'cui_str': 'Autologous (qualifier value)'}, {'cui': 'C0443258', 'cui_str': 'Microvascular (qualifier value)'}, {'cui': 'C0085076', 'cui_str': 'Breast Reconstruction'}]","[{'cui': 'C0887621', 'cui_str': 'Bupivacaine Hydrochloride'}, {'cui': 'C0006400', 'cui_str': 'Bupivacaine'}]",[],,0.155102,,"[{'ForeName': 'Austin Y', 'Initials': 'AY', 'LastName': 'Ha', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Guffey', 'Affiliation': 'Department of Anesthesiology, Washington University School of Medicine, Saint Louis, MO.'}, {'ForeName': 'Terence M', 'Initials': 'TM', 'LastName': 'Myckatyn', 'Affiliation': 'Division of Plastic and Reconstructive Surgery, Washington University School of Medicine, Saint Louis, MO.'}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000006783'] 3111,2520143,Beneficial effects of vitamin C on risk factors of cardiovascular diseases.,"The aim of this investigation is to study the hypothesis that vitamin C has beneficial effects on some risk factors of cardiovascular diseases. Sixty-seven volunteers participated in this study. Thirty and thirty-seven subjects were assigned randomly to two groups. The first was given a placebo and the second was given a vitamin C, respectively. Both regimens were followed for six months. The dose of vitamin C was 500 mg/day. Double blind technique was used throughout the study. These data supported part of the beneficial effects of vitamin C on atherosclerosis process, i.e. reduce significantly body fat, systolic blood pressure, and pulse, and increase significantly high density lipoprotein. On the other hand, these data did not show favourable effects on other lipid parameters, i.e. cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein.",1989,"On the other hand, these data did not show favourable effects on other lipid parameters, i.e. cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein.","['Thirty and thirty-seven subjects', 'Sixty-seven volunteers participated in this study']","['vitamin C', 'placebo']","['risk factors of cardiovascular diseases', 'body fat, systolic blood pressure, and pulse, and increase significantly high density lipoprotein', 'lipid parameters, i.e. cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein']","[{'cui': 'C3816446', 'cui_str': '30'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C4517852', 'cui_str': '67'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C0344335', 'cui_str': 'Body Fat'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0523560', 'cui_str': 'VLDL cholesterol measurement'}]",67.0,0.100775,"On the other hand, these data did not show favourable effects on other lipid parameters, i.e. cholesterol, triglyceride, low density lipoprotein, and very low density lipoprotein.","[{'ForeName': '', 'Initials': '', 'LastName': 'Mostafa S el-D', 'Affiliation': ''}, {'ForeName': 'D D', 'Initials': 'DD', 'LastName': 'Garner', 'Affiliation': ''}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Garrett', 'Affiliation': ''}, {'ForeName': 'R F', 'Initials': 'RF', 'LastName': 'Whaley', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'el-Sekate', 'Affiliation': ''}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Kiker', 'Affiliation': ''}]",The Journal of the Egyptian Public Health Association,[] 3112,32056148,"Impact of National Egyptian school feeding program on growth, development, and school achievement of school children.","BACKGROUND School feeding program (SFP) increases access to education and to better health. This study aims to evaluate the effects of SFP on physical growth, cognitive development, psychosocial behavior, and learning achievement of school children. METHODS A quasi-experimental study was conducted. The intervention group included 903 pupils in the fifth grade receiving the school meal, while the control group included 886 pupils, matched for age and sex, without meal. The meal consisted of a pie made of flour fortified with vitamins A, B6, B12, C, thiamin, riboflavin, niacin, folate, calcium, iron, zinc, and phosphorus. Socioeconomic position, nutritional status, and dietary behavior were evaluated. Neuropsychological tests were done. Psychosocial behavior was rated and educational achievement was recorded. Post hoc and independent sample t tests were used to detect the association of the studied parameters with the intake of school snack. RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group. No significant changes of children's nutritional status were detected between the two groups. School meal was the main predictor of visual memory and auditory vigilance (P < 0.001), and was the strongest predictor of academic achievements when combined with family size and meals' frequency (P < 0.001). CONCLUSION School meal improves academic achievements of school children.",2020,"RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group.","['school children', '903 pupils in the fifth grade receiving the school meal, while the control group included 886 pupils, matched for age and sex, without meal']","['flour fortified with vitamins A, B6, B12, C, thiamin, riboflavin, niacin, folate, calcium, iron, zinc, and phosphorus', 'School meal', 'National Egyptian school feeding program', 'SFP', 'School feeding program (SFP']","['visual memory, auditory vigilance tests', 'afternoon attention and working memory test', 'Psychosocial behavior was rated and educational achievement', 'Socioeconomic position, nutritional status, and dietary behavior', 'growth, development, and school achievement', ""children's nutritional status"", 'score of externalizing behavior', 'visual memory and auditory vigilance', 'physical growth, cognitive development, psychosocial behavior, and learning achievement']","[{'cui': 'C0260267', 'cui_str': 'School child (occupation)'}, {'cui': 'C0034121', 'cui_str': 'Pupil'}, {'cui': 'C0205439', 'cui_str': 'Fifth (qualifier value)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0336766', 'cui_str': 'Matches'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C1314687', 'cui_str': 'Sexual intercourse - finding'}]","[{'cui': 'C0016260', 'cui_str': 'Flour'}, {'cui': 'C0042839', 'cui_str': 'Vitamin A'}, {'cui': 'C0039840', 'cui_str': 'Thiamine'}, {'cui': 'C0373720', 'cui_str': 'Vitamin B2'}, {'cui': 'C0027996', 'cui_str': 'Niacin'}, {'cui': 'C0178638', 'cui_str': 'Folate'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}, {'cui': 'C0337439', 'cui_str': 'Iron measurement (procedure)'}, {'cui': 'C0043481', 'cui_str': 'Zinc'}, {'cui': 'C0031705', 'cui_str': 'Phosphorus'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C0337801', 'cui_str': 'Egyptians (ethnic group)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0075029', 'cui_str': 'spleen fibrinolytic proteinase (human)'}]","[{'cui': 'C0542316', 'cui_str': 'Visual memory (observable entity)'}, {'cui': 'C0439825', 'cui_str': 'Auditory (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0439550', 'cui_str': 'Afternoon (qualifier value)'}, {'cui': 'C0004268', 'cui_str': 'Attention'}, {'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0013658', 'cui_str': 'Educational Achievement'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0392209', 'cui_str': 'Nutrition Status'}, {'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001072', 'cui_str': 'Achievement'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",,0.0169019,"RESULTS Children who took the meal had better scores on visual memory, auditory vigilance tests (9.71 ± 2.80 vs. 7.45 ± 3.25; 25.02 ± 3.36 vs. 10.82 ± 8.92, respectively, P < 0.001), the afternoon attention and working memory test (8.20 ± 2.21vs. 7.75 ± 3.05) (P < 0.001), but less score of externalizing behavior (P < 0.001) than the control group.","[{'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Metwally', 'Affiliation': 'Medical Research Division, Community Medicine Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'Marwa M', 'Initials': 'MM', 'LastName': 'El-Sonbaty', 'Affiliation': 'Department of Pediatrics, College of Medicine, Taibah University, Madinah, Kingdom of Saudi Arabia. elsonbatymostafa@yahoo.com.'}, {'ForeName': 'L A', 'Initials': 'LA', 'LastName': 'El Etreby', 'Affiliation': 'Medical Research Division, Community Medicine Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'E M', 'Initials': 'EM', 'LastName': 'Salah El-Din', 'Affiliation': 'Medical Research Division, Child Health Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Abdel Hamid', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'H A', 'Initials': 'HA', 'LastName': 'Hussien', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'A M', 'Initials': 'AM', 'LastName': 'Hassanin', 'Affiliation': 'Agricultural Research Centre, Giza, Egypt.'}, {'ForeName': 'Z M', 'Initials': 'ZM', 'LastName': 'Monir', 'Affiliation': 'Medical Research Division, Child Health Department, National Research Centre, (Affiliation ID: 60014618), Dokki, Cairo, Egypt.'}]",World journal of pediatrics : WJP,['10.1007/s12519-020-00342-8'] 3113,31364992,Use of 2 Types of Air-cell Mattresses for Pressure Ulcer Prevention and Comfort Among Patients With Advanced-stage Cancer Receiving Palliative Care: An Interventional Study.,"Patients with advanced- or terminal-stage cancer and persons receiving palliative care are at high risk for pressure ulcers (PUs). PURPOSE The purpose of this study was to examine the rate of PU development and levels of comfort of a dual-fit, air-cell mattress compared with an alternating, 2-layer overlay air-cell mattress in patients with advanced- or terminal-stage cancer receiving palliative care. METHODS From January 2011 to December 2013, hospitalized patients with advanced- or terminal-stage cancer who were referred to a palliative care team, at least 20 years of age, able to communicate, experiencing pain, and did not have a PU were recruited to participate. Patients who consented were alternately placed on the intervention (dual-fit, air-cell) or control (2-layer air) mattress until hospital discharge or death. Demographic and clinical data, pain scores, performance status, Palliative Performance Scale scores, Braden Scale scores, tissue interface pressure, and comfort were assessed via interview using closed-end questions. If a PU developed, clinical characteristics were assessed using DESIGN-R. Descriptive statistics and the Mann-Whitney U, chi-squared, and Fisher's exact tests were used to analyze the data. RESULTS Of the 123 eligible patients, 73 were randomized and 52 completed the study (23 intervention patients, median age 63 [range 27-80] years; and 29 control group patients, median age 61.0 [range 27-82] years). Mattresses were used a median of 17 (range 4-113) days in the intervention group and a median of 32 (range 3-270) days in the control group. The incidence of PUs did not significantly differ between the 2 groups (13% in the intervention and 17.2% in the control group). Interface pressures were significantly higher in the intervention group (27.0 mm Hg vs. 24.3 mm Hg). Comfort scores at rest were significantly better in the intervention than in the control group (sinking into bed [3 vs. 14, respectively]; slipping on bed [o vs. 16, respectively]; and feel pressure of air cell [2 vs. 14, respectively]), as were scores with movement (instability during movement [4 vs. 18, respectively] and feeling of floating of the buttocks [6 vs. 21, respectively]) (P <.05). CONCLUSION Dual-fit, air-cell mattresses may help prevent PUs and improve comfort at rest and during activity among patients with end-stage cancer receiving palliative care. Further research regarding mattress selection protocols for this patient population is warranted.",2019,Interface pressures were significantly higher in the intervention group (27.0 mm Hg vs. 24.3 mm Hg).,"['From January 2011 to December 2013, hospitalized patients with advanced- or terminal-stage cancer who were referred to a palliative care team, at least 20 years of age, able to communicate, experiencing pain, and did not have a PU were recruited to participate', 'Patients with advanced- or terminal-stage cancer and persons receiving palliative care are at high risk for pressure ulcers (PUs', '123 eligible patients, 73 were randomized and 52 completed the study (23 intervention patients, median age 63 [range 27-80] years; and 29 control group patients, median age 61.0', 'patients with advanced- or terminal-stage cancer receiving palliative care', 'patients with end-stage cancer receiving palliative care', 'Patients With Advanced-stage Cancer Receiving Palliative Care']","['dual-fit, air-cell mattress compared with an alternating, 2-layer overlay air-cell mattress', 'intervention (dual-fit, air-cell) or control (2-layer air) mattress until hospital discharge or death', 'Air-cell Mattresses']","['Pressure Ulcer Prevention and Comfort', 'incidence of PUs', 'Comfort scores', 'rate of PU development and levels of comfort', 'Interface pressures', 'Demographic and clinical data, pain scores, performance status, Palliative Performance Scale scores, Braden Scale scores, tissue interface pressure, and comfort were assessed via interview using closed-end questions', 'feel pressure of air cell', 'feeling of floating of the buttocks']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0700049', 'cui_str': 'Palliative care'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C2364293', 'cui_str': 'Able to communicate (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0011127', 'cui_str': 'Pressure Ulcer'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0741884', 'cui_str': 'End stage cancer'}, {'cui': 'C1306673', 'cui_str': 'Stages (qualifier value)'}]","[{'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0024940', 'cui_str': 'Mattresses'}, {'cui': 'C0444456', 'cui_str': 'Overlay (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0011065', 'cui_str': 'Death'}]","[{'cui': 'C0150315', 'cui_str': 'Pressure sore protection'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0517225', 'cui_str': 'Comfort level'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C4720846', 'cui_str': 'Palliative performance scale'}, {'cui': 'C0222045'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C1272693', 'cui_str': 'Ended'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0006497', 'cui_str': 'Buttocks'}]",73.0,0.0697972,Interface pressures were significantly higher in the intervention group (27.0 mm Hg vs. 24.3 mm Hg).,"[{'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Marutani', 'Affiliation': 'Graduate School of Medical Sciences, Kanazawa University, and Kanazawa University Hospital, Ishikawa, Japan.'}, {'ForeName': 'Mayumi', 'Initials': 'M', 'LastName': 'Okuwa', 'Affiliation': 'Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Kanazawa University Hospital, Ishikawa, Japan.'}, {'ForeName': 'Junko', 'Initials': 'J', 'LastName': 'Sugama', 'Affiliation': 'Institute for Frontier Science Initiative, Kanazawa University, Ishikawa, Japan.'}]",Wound management & prevention,[] 3114,32043205,Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool.,"PURPOSE Childhood, adolescent, and young adult cancer survivors treated with radiation therapy (RT) may be unaware of their high cardiovascular disease (CVD) risk or how to mitigate it. Tools are needed to improve understanding. We developed and pilot-tested a risk communication tool for shared decision-making with survivors regarding CVD risk reduction with statin therapy. We included quantitative and qualitative arms to further tool development and testing. METHODS The statin risk communication tool was adapted from a previously validated tool. Patients were at increased risk for CVD due to history of chest RT and recruited to usual care and intervention arms. The post-visit survey included Likert-like scales to explore acceptability of the tool, knowledge questions, and a decisional conflict scale. This pilot study used descriptive statistics and was not powered for significance. Semi-structured interviews with intervention arm participants explored shared decision-making processes. RESULTS Median participant (n = 46) age was 45. Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected ""not applicable"" regarding information acceptability. Most participants were unaware of their personal CVD risk or potential statin side effects. In semi-structured interviews, participants found the tool is helpful to visualize risk and aid conversations. CONCLUSIONS The risk communication tool was acceptable. Qualitative data suggested the tool improved decisional clarity and comfort. IMPLICATIONS FOR CANCER SURVIVORS Poor knowledge of CVD and statins and poor recall of CVD risk conversation suggest a need to continue to optimize conversations regarding cardiovascular risk and statin therapy.",2020,"Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected ""not applicable"" regarding information acceptability.","['young adult cancer survivors treated with', 'high-risk cancer survivors', '46) age was 45']","['radiation therapy (RT', 'statin therapy']","['personal CVD risk or potential statin side effects', 'decisional clarity and comfort', 'Likert-like scales to explore acceptability of the tool, knowledge questions, and a decisional conflict scale']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1516231', 'cui_str': 'Cancer Survivors'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C1278454', 'cui_str': 'Statin prophylaxis'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0360714', 'cui_str': 'Statins'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0486588', 'cui_str': 'Clarity (property) (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0231394', 'cui_str': 'Decisional conflict (finding)'}]",,0.0297871,"Most intervention patients (22/24, 92%) and 50% (11/22) of controls found statin information acceptable while 31% (7/22) of the control arm selected ""not applicable"" regarding information acceptability.","[{'ForeName': 'Nirupa J', 'Initials': 'NJ', 'LastName': 'Raghunathan', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA. raghunan@mskcc.org.'}, {'ForeName': 'Emily C', 'Initials': 'EC', 'LastName': 'Zabor', 'Affiliation': 'Department of Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.'}, {'ForeName': 'Nassim', 'Initials': 'N', 'LastName': 'Anderson', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'Oeffinger', 'Affiliation': 'Duke Cancer Institute, Durham, NC, USA.'}, {'ForeName': 'Emily S', 'Initials': 'ES', 'LastName': 'Tonorezos', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Korenstein', 'Affiliation': 'Department of Medicine, Memorial Sloan Kettering Cancer Center, 485 Lexington Ave, 2nd Floor, New York City, NY, 10017, USA.'}]",Journal of cancer survivorship : research and practice,['10.1007/s11764-020-00860-4'] 3115,31022311,A randomized controlled trial of adjuvant mitomycin-c in endoscopic surgery for laryngotracheal stenosis.,"OBJECTIVES/HYPOTHESIS Topical mitomycin-C (MMC) application is a commonly accepted adjuvant therapy in the surgical treatment for laryngotracheal stenosis (LTS). However, the efficacy of MMC has not been examined in a prospective, randomized clinical trial in humans. We aimed to examine the efficacy of MMC in the treatment of LTS patients as compared to a placebo-controlled group. STUDY DESIGN Prospective, randomized, double-blind, placebo-controlled clinical trial. METHODS Fifteen patients with LTS were enrolled in a 24-month trial and randomized into one of two groups: 1) endoscopic surgical treatment with topical application of MMC or 2) endoscopic surgical treatment with topical application of saline. Postoperatively, patients were evaluated at standardized intervals with a symptom questionnaire and spirometry. Subsequent surgery was performed as needed based on relapse of stenosis on exam and patient-reported symptom severity. RESULTS The average interval between surgical treatments was 17.9 months in the placebo group and 17.4 months in the MMC group (P = .95). There was no difference in magnitude of peak inspiratory flow (PIF) improvement between groups. The average magnitude of PIF change was 1.3 L/sec and 1.1 L/sec for the placebo and MMC groups, respectively (P = .64). Similarly, there was no difference in magnitude of symptom improvement or duration of symptom improvement between the two groups. CONCLUSIONS This prospective, randomized. double-blind. placebo-controlled trial suggests that the use of MMC as a topical adjuvant therapy has no additional benefit in the endoscopic surgical management of LTS. Further study is needed. LEVEL OF EVIDENCE 1b Laryngoscope, 130:706-711, 2020.",2020,There was no difference in magnitude of peak inspiratory flow (PIF) improvement between groups.,"['Fifteen patients with LTS', 'endoscopic surgery for laryngotracheal stenosis', 'laryngotracheal stenosis (LTS']","['placebo', 'MMC', 'endoscopic surgical treatment with topical application of MMC or 2) endoscopic surgical treatment with topical application of saline', 'Topical mitomycin-C (MMC) application', 'adjuvant mitomycin-c']","['magnitude of peak inspiratory flow (PIF) improvement', 'average interval', 'PIF change', 'magnitude of symptom improvement or duration of symptom improvement']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0282493', 'cui_str': 'Surgical Procedures, Endoscopic'}, {'cui': 'C0450117', 'cui_str': 'Laryngotracheal (qualifier value)'}, {'cui': 'C1261287', 'cui_str': 'Stenosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0002475', 'cui_str': 'Mitomycin'}]","[{'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0436359', 'cui_str': 'Time symptom lasts (observable entity)'}]",15.0,0.365755,There was no difference in magnitude of peak inspiratory flow (PIF) improvement between groups.,"[{'ForeName': 'Katherine C', 'Initials': 'KC', 'LastName': 'Yung', 'Affiliation': 'San Francisco Voice and Swallowing, San Francisco, California, U.S.A.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, California, U.S.A.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Courey', 'Affiliation': 'Eugen Grabscheid Voice Center, Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Health System, New York, New York, U.S.A.'}]",The Laryngoscope,['10.1002/lary.28025'] 3116,30508308,Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.,"Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is an oral once-daily single-tablet regimen for the treatment of human immunodeficiency virus-1 infection. Different administration modalities for the D/C/F/TAF fixed-dose combination tablet were explored in this phase 1 randomized, open-label, 3-period, 3-treatment crossover study enrolling 30 healthy adults. The primary objective was to assess the relative bioavailability of each component after a single dose of D/C/F/TAF (800/150/200/10 mg) administered as a split or crushed tablet (tests) versus swallowed whole (reference). Pharmacokinetic parameters (noncompartmental analysis; logarithm-transformed) for each component were compared using linear mixed-effects modeling. For the split versus whole tablet, the bioavailabilities (maximum plasma concentration [C max ] and area under the plasma concentration-time curve [AUC last ]) of each D/C/F/TAF component were comparable. For the crushed versus whole tablet, the bioavailabilities of darunavir, cobicistat, and emtricitabine were comparable, except for a 17% decrease in emtricitabine C max ; the relative bioavailability of tenofovir alafenamide decreased by 29% and 19% for C max and AUC last , respectively. All intakes were safe and generally well tolerated. In summary, there was no clinically relevant impact on the bioavailability of D/C/F/TAF components when administered as a split tablet compared with a tablet swallowed whole. Administration of a crushed tablet resulted in a modest decrease in tenofovir alafenamide bioavailability; the clinical relevance of this change has not been assessed but is expected to be minimal based on the wide therapeutic window for this agent.",2019,"For the crushed versus whole tablet, the bioavailabilities of darunavir, cobicistat, and emtricitabine were comparable, except for a 17% decrease in emtricitabine C max ; the relative bioavailability of tenofovir alafenamide decreased by 29% and 19% for C max and AUC last , respectively.","['human immunodeficiency virus-1 infection', '30 healthy adults']","['Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen', 'Splitting or Crushing', 'Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF']","['relative bioavailability of tenofovir alafenamide', 'tolerated', 'relative bioavailability', 'bioavailability of D/C/F/TAF components', 'tenofovir alafenamide bioavailability', 'bioavailabilities (maximum plasma concentration [C max ] and area under the plasma concentration-time curve [AUC last ]) of each D/C/F/TAF component', 'bioavailabilities of darunavir, cobicistat, and emtricitabine']","[{'cui': 'C0019704', 'cui_str': 'HIV-I'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}]","[{'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}, {'cui': 'C4059167', 'cui_str': 'emtricitabine / tenofovir alafenamide'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C1444777', 'cui_str': 'Splitting sensation quality'}, {'cui': 'C0185060', 'cui_str': 'Crushing - action (qualifier value)'}]","[{'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0005508', 'cui_str': 'Bioavailability'}, {'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}]",30.0,0.0543844,"For the crushed versus whole tablet, the bioavailabilities of darunavir, cobicistat, and emtricitabine were comparable, except for a 17% decrease in emtricitabine C max ; the relative bioavailability of tenofovir alafenamide decreased by 29% and 19% for C max and AUC last , respectively.","[{'ForeName': 'Kimberley', 'Initials': 'K', 'LastName': 'Brown', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, NJ, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Thomas', 'Affiliation': 'Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'McKenney', 'Affiliation': 'Janssen Research & Development, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Reeder', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Richard Bruce', 'Initials': 'RB', 'LastName': 'Simonson', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Ceyhun', 'Initials': 'C', 'LastName': 'Bicer', 'Affiliation': 'BICER Consulting & Research, Antwerp, Belgium.'}, {'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Nettles', 'Affiliation': 'Janssen Scientific Affairs, LLC, Titusville, NJ, USA.'}, {'ForeName': 'Herta', 'Initials': 'H', 'LastName': 'Crauwels', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.632'] 3117,32049562,Effect of inspiratory resistive training on diaphragm shear modulus and accessory inspiratory muscle activation.,"This study aimed to elucidate changes in diaphragm and accessory inspiratory muscle (sternocleidomastoid (SCM) muscle and intercostal muscle (IC)) function after a 6-week training program. Nineteen male elite collegiate swimmers were assigned to either a control group ( n = 9) or training group ( n = 10). The subjects in the training group performed 30 maximum inspirations at a load resistance of 50% of maximum inspiratory mouth pressure (PImax) using an inspiratory muscle training device. These were conducted twice per day and 6 days per week. At baseline and after 6 weeks, PImax, shear modulus of the diaphragm, and electromyograms (EMG) of the SCM and IC during a maximal inspiratory maneuver were evaluated. Relative change in PImax was greater in the training group than in controls. The shear modulus during a PImax maneuver had increased significantly in both groups after 6 weeks. EMG amplitudes of the SCM increased in the training group after 6 weeks, but not in the control group. EMG amplitudes of the IC did not change after 6 weeks in either group. These results suggest that 6-week inspiratory resistive training significantly improves the activation of the SCM, which could be one of the major mechanisms behind increases in inspiratory muscle strength after resistive training. Novelty Six-week inspiratory resistive training increased diaphragm stiffness during maximal inspiration maneuver. Six-week inspiratory resistive training increased electromyogram amplitudes of the sternocleidomastoid during maximal inspiration maneuver.",2020,Six-week inspiratory resistive training increased electromyogram amplitudes of the sternocleidomastoid during maximal inspiration maneuver.,['Nineteen male elite collegiate swimmers'],"['Six-week inspiratory resistive training', 'diaphragm and accessory inspiratory muscle (sternocleidomastoid [SCM', 'control group (n=9) or training group', 'inspiratory resistive training', 'training group performed 30 maximum inspirations at a load resistance of 50% of maximum inspiratory mouth pressure (PImax) using an inspiratory muscle training device']","['electromyogram amplitudes', 'PImax, shear modulus of the diaphragm, and electromyograms (EMG) of the SCM and IC', 'Relative change in PImax', 'inspiratory muscle strength', 'diaphragm stiffness', 'EMG amplitudes', 'diaphragm shear modulus and accessory inspiratory muscle activation', 'EMG amplitudes of the SCM']","[{'cui': 'C0450337', 'cui_str': '19 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0450068', 'cui_str': 'Swimmer (person)'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0011980', 'cui_str': 'Respiratory Diaphragm'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0230028', 'cui_str': 'Structure of oral region of face'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0454511', 'cui_str': 'Inspiratory muscle training (regime/therapy)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]","[{'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0011980', 'cui_str': 'Respiratory Diaphragm'}, {'cui': 'C0205345', 'cui_str': 'Relative (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0427008', 'cui_str': 'Stiffness (finding)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0429340', 'cui_str': 'EMG amplitude'}]",19.0,0.0129567,Six-week inspiratory resistive training increased electromyogram amplitudes of the sternocleidomastoid during maximal inspiration maneuver.,"[{'ForeName': 'Ryosuke', 'Initials': 'R', 'LastName': 'Ando', 'Affiliation': 'Department of Sports Research, Japan Institute of Sports Sciences, 3-15-1, Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}, {'ForeName': 'Toshiyuki', 'Initials': 'T', 'LastName': 'Ohya', 'Affiliation': 'School of Health and Sport Sciences, Chukyo University, Aichi, Japan.'}, {'ForeName': 'Kenta', 'Initials': 'K', 'LastName': 'Kusanagi', 'Affiliation': 'School of Health and Sport Sciences, Chukyo University, Aichi, Japan.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Koizumi', 'Affiliation': 'School of Health and Sport Sciences, Chukyo University, Aichi, Japan.'}, {'ForeName': 'Hayato', 'Initials': 'H', 'LastName': 'Ohnuma', 'Affiliation': 'Department of Sports Research, Japan Institute of Sports Sciences, 3-15-1, Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}, {'ForeName': 'Keisho', 'Initials': 'K', 'LastName': 'Katayama', 'Affiliation': 'Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan.'}, {'ForeName': 'Yasuhiro', 'Initials': 'Y', 'LastName': 'Suzuki', 'Affiliation': 'Department of Sports Research, Japan Institute of Sports Sciences, 3-15-1, Nishigaoka, Kita-ku, Tokyo, 115-0056, Japan.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0906'] 3118,32042406,"Is reduction in appetite beneficial for body weight management in the context of overweight and obesity? Yes, according to the SATIN (Satiety Innovation) study.","New dietary-based concepts are needed for treatment and effective prevention of overweight and obesity. The primary objective was to investigate if reduction in appetite is associated with improved weight loss maintenance. This cohort study was nested within the European Commission project Satiety Innovation (SATIN). Participants achieving ≥8% weight loss during an initial 8-week low-energy formula diet were included in a 12-week randomised double-blind parallel weight loss maintenance intervention. The intervention included food products designed to reduce appetite or matching controls along with instructions to follow national dietary guidelines. Appetite was assessed by ad libitum energy intake and self-reported appetite evaluations using visual analogue scales during standardised appetite probe days. These were evaluated at the first day of the maintenance period compared with baseline (acute effects after a single exposure of intervention products) and post-maintenance compared with baseline (sustained effects after repeated exposures of intervention products) regardless of randomisation. A total of 181 participants (forty-seven men and 134 women) completed the study. Sustained reduction in 24-h energy intake was associated with improved weight loss maintenance ( R 0·37; P = 0·001), whereas the association was not found acutely ( P = 0·91). Suppression in self-reported appetite was associated with improved weight loss maintenance both acutely ( R -0·32; P = 0·033) and sustained ( R -0·33; P = 0·042). Reduction in appetite seems to be associated with improved body weight management, making appetite-reducing food products an interesting strategy for dietary-based concepts.",2019,Suppression in self-reported appetite was associated with improved weight loss maintenance both acutely ( R -0·32; P = 0·033) and sustained ( R -0·33; P = 0·042).,"['Participants achieving ≥8% weight loss during an initial 8-week low-energy formula diet', '181 participants (forty-seven men and 134 women) completed the study']","['double-blind parallel weight loss maintenance intervention', 'food products designed to reduce appetite or matching controls along with instructions to follow national dietary guidelines']","['24-h energy intake', 'Appetite', 'weight loss maintenance']","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0012164'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4517565', 'cui_str': 'One hundred and thirty-four'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0456909', 'cui_str': 'Blindness'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0232462', 'cui_str': 'Decrease in appetite (finding)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C3658297', 'cui_str': 'Nutrition Guidelines'}]","[{'cui': 'C0006777', 'cui_str': 'Caloric Intake'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0024501', 'cui_str': 'Maintenances'}]",181.0,0.0254127,Suppression in self-reported appetite was associated with improved weight loss maintenance both acutely ( R -0·32; P = 0·033) and sustained ( R -0·33; P = 0·042).,"[{'ForeName': 'Thea Toft', 'Initials': 'TT', 'LastName': 'Hansen', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Copenhagen, Denmark.'}, {'ForeName': 'Bethan R', 'Initials': 'BR', 'LastName': 'Mead', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool L69 7ZA, UK.'}, {'ForeName': 'Jesús Francisco', 'Initials': 'JF', 'LastName': 'García-Gavilán', 'Affiliation': ""Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain.""}, {'ForeName': 'Sanne Kellebjerg', 'Initials': 'SK', 'LastName': 'Korndal', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Copenhagen, Denmark.'}, {'ForeName': 'Joanne A', 'Initials': 'JA', 'LastName': 'Harrold', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool L69 7ZA, UK.'}, {'ForeName': 'Lucia', 'Initials': 'L', 'LastName': 'Camacho-Barcía', 'Affiliation': ""Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain.""}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Ritz', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Copenhagen, Denmark.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Christiansen', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool L69 7ZA, UK.'}, {'ForeName': 'Jordi', 'Initials': 'J', 'LastName': 'Salas-Salvadó', 'Affiliation': ""Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain.""}, {'ForeName': 'Mads Fiil', 'Initials': 'MF', 'LastName': 'Hjorth', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Copenhagen, Denmark.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Blundell', 'Affiliation': 'Institute of Psychological Sciences, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.'}, {'ForeName': 'Mònica', 'Initials': 'M', 'LastName': 'Bulló', 'Affiliation': ""Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain.""}, {'ForeName': 'Jason C G', 'Initials': 'JCG', 'LastName': 'Halford', 'Affiliation': 'Department of Psychological Sciences, University of Liverpool, Liverpool L69 7ZA, UK.'}, {'ForeName': 'Anders', 'Initials': 'A', 'LastName': 'Sjödin', 'Affiliation': 'Department of Nutrition, Exercise and Sports, Section for Obesity Research, Faculty of Science, University of Copenhagen, 1958 Copenhagen, Denmark.'}]",Journal of nutritional science,['10.1017/jns.2019.36'] 3119,32060547,"When, How, & Where Tobacco Initiation and Relapse Occur During U.S. Air Force Technical Training.","INTRODUCTION Military personnel are at high risk for tobacco use, particularly during the first year of military service. Technical Training follows an 8½ week tobacco ban during basic military training and is a vulnerable time for personnel to both reinitiate and initiate tobacco use. Thus, this can be a crucial time to promote tobacco policies and interventions. However, there is limited research examining when, how, and where personnel access tobacco during the first year of service, particularly among users of newer products (eg, electronic cigarettes[e-cigarettes]). Thus, the purpose of the current study is to explore the timing, source, and location of tobacco use during Technical Training across all types of products. Furthermore, this study will examine differences in demographic characteristics and prior tobacco history in relationship to these tobacco behaviors. MATERIALS AND METHODS Participants were U.S. Air Force recruits completing Technical Training (2017-2018). Protocol was approved by the Institutional Review Board at the 59th Medical Wing of the U.S. Air Force. During the first week of Technical Training, Airmen were consented to participate in the study and completed a questionnaire about demographics and tobacco use history. Next, Airmen were randomized to receive one of three tobacco prevention interventions as part of military training. At a 3-month follow-up, during the last week of Technical Training, consented participants completed a questionnaire about current tobacco use. Airmen reported when (ie, first month vs. after), how (ie, ""bummed"" from another airman, bought on or off base, received from the internet or event), and where (ie, designated smoking areas on base, off base, bar or club, friend's house, cigar lounge, hookah bar, or vape shop) they used tobacco during Technical Training. Descriptive statistics were used to examine these behaviors across all tobacco products. Additionally, Wilcoxon-Mann-Whitney and Kruskal-Wallis tests compared differences in demographic characteristics and baseline tobacco use in relationship to these tobacco behaviors. RESULTS No significant differences were found when comparing prior users and first-time users in relationship to tobacco behaviors during Technical Training; however, significant differences in educational background and age were found in regard to the source and location of tobacco use. Additionally, how and where Airmen first used tobacco during Technical Training differed across products. Cigarettes and smokeless tobacco were equally likely to be bought on or off base and most commonly first used at a designated smoking area on base. However, e-cigarettes, cigarillos/little cigars, and hookah were more likely to be bought off base, and first used at a specialty store (ie, vape shop, hookah bar, or cigar lounge). CONCLUSIONS Tobacco use behaviors during Technical Training differed depending on the type of product. Specifically, new and emerging products were more likely to be bought off base and first used at a specialty store. Thus, military polices regulating on base tobacco pricing might not reduce the growing prevalence of e-cigarettes. Future policies might consider addressing the density of off-base tobacco retailers to reduce the high rates of tobacco use in this population.",2020,"No significant differences were found when comparing prior users and first-time users in relationship to tobacco behaviors during Technical Training; however, significant differences in educational background and age were found in regard to the source and location of tobacco use.",['Participants were U.S. Air Force recruits completing Technical Training (2017-2018'],['tobacco prevention interventions as part of military training'],['Tobacco Initiation and Relapse Occur'],"[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0199176', 'cui_str': 'Prophylaxis - procedure intent (qualifier value)'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0026126', 'cui_str': 'Armed Forces Personnel'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0589507', 'cui_str': 'Cognitive function: initiation (observable entity)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]",,0.0301639,"No significant differences were found when comparing prior users and first-time users in relationship to tobacco behaviors during Technical Training; however, significant differences in educational background and age were found in regard to the source and location of tobacco use.","[{'ForeName': 'Margaret Celice', 'Initials': 'MC', 'LastName': 'Fahey', 'Affiliation': 'Department of Psychology; 400 Innovation Drive, Memphis, TN 38111, USA.'}, {'ForeName': 'G Wayne', 'Initials': 'GW', 'LastName': 'Talcott', 'Affiliation': 'University of Virginia School of Medicine; Center for Addiction and Prevention Research; 560 Ray C. Hunt Drive, Charlottesville, VA 22908, USA.'}, {'ForeName': 'Timothy L', 'Initials': 'TL', 'LastName': 'McMurry', 'Affiliation': 'University of Virginia School of Medicine; Center for Addiction and Prevention Research; 560 Ray C. Hunt Drive, Charlottesville, VA 22908, USA.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Klesges', 'Affiliation': 'University of Virginia School of Medicine; Center for Addiction and Prevention Research; 560 Ray C. Hunt Drive, Charlottesville, VA 22908, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Tubman', 'Affiliation': 'University of Virginia School of Medicine; Center for Addiction and Prevention Research; 560 Ray C. Hunt Drive, Charlottesville, VA 22908, USA.'}, {'ForeName': 'Rebecca A', 'Initials': 'RA', 'LastName': 'Krukowski', 'Affiliation': 'University of Tennessee Health Science Center, Department of Preventive Medicine; 66 N Pauline Street Memphis, TN 38163, USA.'}, {'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Little', 'Affiliation': 'University of Virginia School of Medicine; Center for Addiction and Prevention Research; 560 Ray C. Hunt Drive, Charlottesville, VA 22908, USA.'}]",Military medicine,['10.1093/milmed/usaa016'] 3120,31637639,Satisfaction with Primary Care Providers and Health Care Services Among Patients with Chronic Pain: a Mixed-Methods Study.,"BACKGROUND Chronic pain is a prevalent health concern in the United States (US) and a frequent reason for patients to seek primary care. The challenges associated with developing effective pain management strategies can be perceived as a burden on the patient-provider relationship. OBJECTIVE This study explored the relationship between patients' overall satisfaction with their primary care providers (PCPs) and their satisfaction with their chronic pain treatment, as well as the provider behaviors that contributed to chronic pain patients' satisfaction with their PCPs. DESIGN Concurrent nested mixed-methods design PARTICIPANTS: 97 patients with chronic pain who were assigned to the usual care arm of the Pain Program for Active Coping and Training (PPACT) study. APPROACH We analyzed phone interview and survey data (n = 97). Interviews assessed provider behaviors that led to patient satisfaction. Interview transcripts were analyzed based on a content analysis approach. Survey responses assessed patient satisfaction with primary care and pain services. We calculated a Pearson's correlation coefficient using five response categories. KEY RESULTS Interviews revealed that high satisfaction with primary care was driven by five concrete PCP behaviors: (1) listening, (2) maintaining communication with patients, (3) acting as an access point to comprehensive pain care, (4) providing an honest assessment of the possibilities of pain care, and (5) taking time during consultations with patients. In surveys, participants reported higher satisfaction with their primary care services than with the pain services they received; these variables were only moderately correlated (r = 0.586). CONCLUSIONS Results suggest that patients with chronic pain can view the relationship with their PCPs as positive, even in the face of low satisfaction with their pain treatment. The expectations that these patients held of PCPs could be met regardless of providers' ability to successfully relieve chronic pain.",2020,The expectations that these patients held of PCPs could be met regardless of providers' ability to successfully relieve chronic pain.,"['97 patients with chronic pain who were assigned to the usual care arm of the', 'patients with chronic pain', 'Patients with Chronic Pain', ""chronic pain patients' satisfaction with their PCPs""]","['Health Care Services', 'Pain Program for Active Coping and Training (PPACT) study']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]","[{'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]",[],97.0,0.0559789,The expectations that these patients held of PCPs could be met regardless of providers' ability to successfully relieve chronic pain.,"[{'ForeName': 'Inga', 'Initials': 'I', 'LastName': 'Gruß', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR, USA. inga.gruss@kpchr.org.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Firemark', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR, USA.'}, {'ForeName': 'Carmit K', 'Initials': 'CK', 'LastName': 'McMullen', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR, USA.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Mayhew', 'Affiliation': 'Kaiser Permanente Center for Health Research, Portland, OR, USA.'}, {'ForeName': 'Lynn L', 'Initials': 'LL', 'LastName': 'DeBar', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.'}]",Journal of general internal medicine,['10.1007/s11606-019-05339-2'] 3121,32039724,"Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT.","BACKGROUND Metformin is widely used in pregnancy to treat gestational diabetes mellitus and polycystic ovary syndrome (PCOS). Association between PCOS and developmental delay in offspring, and larger head circumference of metformin-exposed newborns has been reported. The objective of this study was to explore whether metformin exposure in utero had any effect on offspring cognitive function. METHOD The current study is a follow-up of two randomized, placebo-controlled studies which were conducted at 11 public hospitals in Norway In the baseline studies (conducted in 2000-2003, and 2005-2009), participants were randomized to metformin 1700 and 2000 mg/d or placebo from first trimester to delivery. There was no intervention in the current study. We invited parents of 292 children to give permission for their children to participate; 93 children were included (mean age 7.7 years). The follow-up study was conducted in 2014-2016. The Wechsler Preschool and Primary Scale of Intelligence version III and the Wechsler Intelligence Scale for Children version IV were applied for cognitive assessment. Androstenedione and testosterone were measured in maternal blood samples at four time-points in pregnancy. RESULTS We found no difference in mean, full scale IQ in metformin (100.0 (SD 13.2)) vs. placebo-exposed (100.9 (SD 10.1)) children. There was an association between metformin exposure in utero and borderline intellectual function of children (full scale IQ between 70 and 85). Free testosterone index in gestational week 19, and androstenedione in gestational week 36 correlated positively to full scale IQ. CONCLUSIONS We found no evidence of long-term effect of metformin on average child cognitive function. The increase of borderline intellectual functioning in metformin-exposed children must be interpreted with caution due to small sample size. TRIAL REGISTRATION The baseline study was registered on 12 September 2005 at the US National Institute of Health (ClinicalTrials.gov) # NCT00159536.",2020,"Free testosterone index in gestational week 19, and androstenedione in gestational week 36 correlated positively to full scale IQ. ","['gestational diabetes mellitus and polycystic ovary syndrome (PCOS', '12 September 2005 at the US National Institute of Health (ClinicalTrials.gov', '2014-2016', 'exposed children, born to mothers with PCOS - follow-up of an RCT', '11 public hospitals in Norway', '292 children to give permission for their children to participate; 93 children were included (mean age 7.7\u2009years']","['metformin', 'placebo', 'Metformin', 'metformin 1700 and 2000\u2009mg/d or placebo']","['mean, full scale IQ', 'Cognitive function', 'Androstenedione and testosterone', 'Free testosterone index', 'maternal blood samples', 'Wechsler Preschool and Primary Scale of Intelligence version III and the Wechsler Intelligence Scale', 'borderline intellectual functioning', 'average child cognitive function']","[{'cui': 'C0085207', 'cui_str': 'Diabetes, Pregnancy-Induced'}, {'cui': 'C0032460', 'cui_str': 'Sclerocystic Ovary Syndrome'}, {'cui': 'C0027468', 'cui_str': 'United States National Institutes of Health'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0020022', 'cui_str': 'Hospitals, Public'}, {'cui': 'C0028423', 'cui_str': 'Kingdom of Norway'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517860', 'cui_str': '7.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0470277', 'cui_str': '2000'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0002860', 'cui_str': 'androstanedione'}, {'cui': 'C0523912', 'cui_str': 'Testosterone measurement (procedure)'}, {'cui': 'C0443483', 'cui_str': 'Free testosterone (substance)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C2828074', 'cui_str': 'Wechsler Preschool and Primary Scale of Intelligence'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0043089', 'cui_str': 'Wechsler Intelligence Scales'}, {'cui': 'C0006009', 'cui_str': 'Borderline mental retardation'}, {'cui': 'C0008059', 'cui_str': 'Child'}]",93.0,0.062763,"Free testosterone index in gestational week 19, and androstenedione in gestational week 36 correlated positively to full scale IQ. ","[{'ForeName': 'Hanne Klæboe', 'Initials': 'HK', 'LastName': 'Greger', 'Affiliation': 'Departement of Mental Health, Faculty of Medicine and Health Sciences, NTNU -Norwegian University of Science and Technology, Trondheim, Norway. Hanne.k.greger@ntnu.no.'}, {'ForeName': 'Liv Guro Engen', 'Initials': 'LGE', 'LastName': 'Hanem', 'Affiliation': 'St.Olavs Hospital, Trondheim, Norway.'}, {'ForeName': 'Heidi Furre', 'Initials': 'HF', 'LastName': 'Østgård', 'Affiliation': 'St.Olavs Hospital, Trondheim, Norway.'}, {'ForeName': 'Eszter', 'Initials': 'E', 'LastName': 'Vanky', 'Affiliation': 'St.Olavs Hospital, Trondheim, Norway.'}]",BMC pediatrics,['10.1186/s12887-020-1960-2'] 3122,32046671,"Protocol for Correcting Residual Errors with Spectral, ULtrasound, Traditional Speech therapy Randomized Controlled Trial (C-RESULTS RCT).","BACKGROUND Speech sound disorder in childhood poses a barrier to academic and social participation, with potentially lifelong consequences for educational and occupational outcomes. While most speech errors resolve by the late school-age years, between 2 and 5% of speakers exhibit residual speech errors (RSE) that persist through adolescence or even adulthood. Previous findings from small-scale studies suggest that interventions incorporating visual biofeedback can outperform traditional motor-based treatment approaches for children with RSE, but this question has not been investigated in a well-powered randomized controlled trial. METHODS/DESIGN This project, Correcting Residual Errors with Spectral, ULtrasound, Traditional Speech therapy Randomized Controlled Trial (C-RESULTS RCT), aims to treat 110 children in a parallel randomized controlled clinical trial comparing biofeedback and non-biofeedback interventions for RSE affecting the North American English rhotic sound /ɹ/. Eligible children will be American English speakers, aged 9-15 years, who exhibit RSE affecting /ɹ/ but otherwise show typical cognitive-linguistic and hearing abilities. Participants will be randomized, with stratification by site (Syracuse University or Montclair State University) and pre-treatment speech production ability, to receive either a motor-based treatment consistent with current best practices in speech therapy (40% of participants) or treatment incorporating visual biofeedback (60% of participants). Within the biofeedback condition, participants will be assigned in equal numbers to receive biofeedback in the form of a real-time visual display of the acoustic signal of speech or ultrasound imaging of the tongue during speech. The primary outcome measure will assess changes in the acoustics of children's production of /ɹ/ during treatment, while a secondary outcome measure will use blinded listeners to evaluate changes in the perceived accuracy of /ɹ/ production after the completion of all treatment. These measures will allow the treatment conditions to be compared with respect to both efficacy and efficiency. DISCUSSION By conducting the first well-powered randomized controlled trial comparing treatment with and without biofeedback, this study aims to provide high-quality evidence to guide treatment decisions for children with RSE. TRIAL REGISTRATION ClinicalTrials.gov identifier NCT03737318, November 9, 2018.",2020,"The primary outcome measure will assess changes in the acoustics of children's production of /ɹ/ during treatment, while a secondary outcome measure will use blinded listeners to evaluate changes in the perceived accuracy of /ɹ/ production after the completion of all treatment.","['Eligible children will be American English speakers, aged 9-15\u2009years, who exhibit RSE affecting /ɹ/ but otherwise show typical cognitive-linguistic and hearing abilities', '110 children', 'children with RSE']","['pre-treatment speech production ability, to receive either a motor-based treatment consistent with current best practices in speech therapy (40% of participants) or treatment incorporating visual biofeedback', 'visual biofeedback', 'biofeedback and non-biofeedback interventions']","[""acoustics of children's production of /ɹ/ during treatment""]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0015272', 'cui_str': 'Exhibits'}, {'cui': 'C0023741', 'cui_str': 'Linguistics'}, {'cui': 'C0018767', 'cui_str': 'Audition'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C4517536', 'cui_str': '110 (qualifier value)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0037817', 'cui_str': 'Speech'}, {'cui': 'C0033268'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0332290', 'cui_str': 'Consistent with (qualifier value)'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C0037831', 'cui_str': 'Speech Therapy'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0678663', 'cui_str': 'Biofeedback, function (observable entity)'}]","[{'cui': 'C0001166', 'cui_str': 'Acoustics'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0033268'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]",,0.187763,"The primary outcome measure will assess changes in the acoustics of children's production of /ɹ/ during treatment, while a secondary outcome measure will use blinded listeners to evaluate changes in the perceived accuracy of /ɹ/ production after the completion of all treatment.","[{'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'McAllister', 'Affiliation': 'Department of Communicative Sciences and Disorders, New York University, New York, NY, USA.'}, {'ForeName': 'Jonathan L', 'Initials': 'JL', 'LastName': 'Preston', 'Affiliation': 'Department of Communication Sciences and Disorders, Syracuse University, 621 Skytop Rd, Suite 1200, Syracuse, NY, 13244, USA. jopresto@syr.edu.'}, {'ForeName': 'Elaine R', 'Initials': 'ER', 'LastName': 'Hitchcock', 'Affiliation': 'Department of Communication Sciences & Disorders, Montclair State University, Bloomfield, NJ, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Hill', 'Affiliation': 'Department of Applied Statistics, Social Science, and the Humanities, New York University, New York, NY, USA.'}]",BMC pediatrics,['10.1186/s12887-020-1941-5'] 3123,32042407,Supplementation with cod protein hydrolysate in older adults: a dose range cross-over study.,"A large proportion of older adults are affected by impaired glucose metabolism. Previous studies with fish protein have reported improved glucose regulation in healthy adults, but the evidence in older adults is limited. Therefore, we wanted to assess the effect of increasing doses of a cod protein hydrolysate (CPH) on postprandial glucose metabolism in older adults. The study was a double-blind cross-over trial. Participants received four different doses (10, 20, 30 or 40 mg/kg body weight (BW)) of CPH daily for 1 week with 1-week washout periods in between. The primary outcome was postprandial response in glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min. The secondary outcome was postprandial response in plasma glucagon-like peptide 1 (GLP-1). Thirty-one subjects aged 60-78 years were included in the study. In a mixed-model statistical analysis, no differences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the higher doses (20, 30 or 40 mg/kg BW). The estimated maximum value of glucose was on average 0·28 mmol/l lower when the participants were given 40 mg/kg BW CPH compared with 10 mg/kg BW ( P = 0·13). The estimated maximum value of insulin was on average 5·14 mIU/l lower with 40 mg/kg BW of CPH compared with 10 mg/kg BW ( P = 0·20). Our findings suggest that serum glucose and insulin levels tend to decrease with increasing amounts of CPH. Due to preliminary findings, the results require further investigation.",2019,"In a mixed-model statistical analysis, no differences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the higher doses (20, 30 or 40 mg/kg BW).","['older adults', 'healthy adults', 'Thirty-one subjects aged 60-78 years were included in the study']","['CPH', 'cod protein hydrolysate (CPH', 'cod protein hydrolysate']","['postprandial response in glucose metabolism, measured by samples of serum glucose and insulin in 20 min intervals for 120 min', 'postprandial glucose metabolism', 'glucose regulation', 'serum glucose and insulin levels', 'postprandial response in plasma glucagon-like peptide 1 (GLP-1', 'estimated maximum value of glucose, insulin or GLP-1']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0450355', 'cui_str': '31 (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0459207', 'cui_str': 'Cod'}, {'cui': 'C0033631', 'cui_str': 'Protein Hydrolysates'}]","[{'cui': 'C0376674', 'cui_str': 'Postcibal Period'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0202041', 'cui_str': 'Glucose measurement, serum (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0220905', 'cui_str': 'regulations'}, {'cui': 'C1278023', 'cui_str': 'Plasma glucagon measurement'}, {'cui': 'C0030956', 'cui_str': 'Peptides'}, {'cui': 'C0061355', 'cui_str': 'Glucagon-Like Peptide 1'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}]",31.0,0.116223,"In a mixed-model statistical analysis, no differences in estimated maximum value of glucose, insulin or GLP-1 were observed when comparing the lowest dose of CPH (10 mg/kg BW) with the higher doses (20, 30 or 40 mg/kg BW).","[{'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Jensen', 'Affiliation': 'Department of Clinical Medicine, Centre for Nutrition, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Hanna F', 'Initials': 'HF', 'LastName': 'Dale', 'Affiliation': 'Department of Clinical Medicine, Centre for Nutrition, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Trygve', 'Initials': 'T', 'LastName': 'Hausken', 'Affiliation': 'Department of Clinical Medicine, Centre for Nutrition, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Einar', 'Initials': 'E', 'LastName': 'Lied', 'Affiliation': 'Firmenich Bjørge Biomarin AS, Ellingsøy, Ålesund, Norway.'}, {'ForeName': 'Jan G', 'Initials': 'JG', 'LastName': 'Hatlebakk', 'Affiliation': 'Department of Clinical Medicine, Centre for Nutrition, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Ingeborg', 'Initials': 'I', 'LastName': 'Brønstad', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Haukeland University Hospital, Bergen, Norway.'}, {'ForeName': 'Gülen A', 'Initials': 'GA', 'LastName': 'Lied', 'Affiliation': 'Department of Clinical Medicine, Centre for Nutrition, University of Bergen, Bergen, Norway.'}, {'ForeName': 'Dag Arne L', 'Initials': 'DAL', 'LastName': 'Hoff', 'Affiliation': 'Division of Gastroenterology, Department of Medicine, Ålesund Hospital, Møre & Romsdal Hospital Trust, Ålesund, Norway.'}]",Journal of nutritional science,['10.1017/jns.2019.37'] 3124,31698336,Evaluation of Step-Counting Interventions Differing on Intensity Messages.,"BACKGROUND Step-counting interventions with discrepant intensity emphases may elicit different effects. METHODS A total of 120 sedentary/low-active, postmenopausal women were randomly assigned to one of the following 3 groups: (1) 10,000 steps per day (with no emphasis on walking intensity/speed/cadence; basic intervention, 49 completers), (2) 10,000 steps per day and at least 30 minutes in moderate intensity (ie, at a cadence of at least 100 steps per minute; enhanced intervention, 47 completers), or (3) a control group (19 completers). NL-1000-determined steps and active minutes (a device-specific indicator of time at moderate+ intensity) were collected as process variables during the 12-week intervention. Outcome variables included systolic and diastolic blood pressure, anthropometric measurements, fasting blood glucose and insulin, flow-mediated dilation, gait speed, and ActiGraph GT3X+-determined physical activity and sedentary behavior. RESULTS The ""basic group"" increased 5173 to 9602 steps per day and 9.2 to 30.2 active minutes per day. The ""enhanced group"" similarly increased 5061 to 10,508 steps per day and 8.7 to 38.8 active minutes per day. The only significant change over time for clinical variables was body mass index. CONCLUSIONS Interventions that use simple step-counters can achieve elevated volume and intensity of daily physical activity, regardless of emphasis on intensity. Despite this, few clinical outcomes were apparent in this sample of postmenopausal women with generally normal or controlled hypertension.",2020,"The ""enhanced group"" similarly increased 5061 to 10,508 steps per day and 8.7 to 38.8 active minutes per day.","['120 sedentary/low-active, postmenopausal women', 'postmenopausal women with generally normal or controlled hypertension']",[],"['systolic and diastolic blood pressure, anthropometric measurements, fasting blood glucose and insulin, flow-mediated dilation, gait speed, and ActiGraph GT3X+-determined physical activity and sedentary behavior', 'elevated volume and intensity of daily physical activity']","[{'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C2363982', 'cui_str': 'Hypertension (SMQ)'}]",[],"[{'cui': 'C0039155', 'cui_str': 'Systole'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C2009910', 'cui_str': 'Gait Speed'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1532253', 'cui_str': 'Sedentary Behavior'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]",120.0,0.0543753,"The ""enhanced group"" similarly increased 5061 to 10,508 steps per day and 8.7 to 38.8 active minutes per day.","[{'ForeName': 'Catrine', 'Initials': 'C', 'LastName': 'Tudor-Locke', 'Affiliation': ''}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Schuna', 'Affiliation': ''}, {'ForeName': 'Damon L', 'Initials': 'DL', 'LastName': 'Swift', 'Affiliation': ''}, {'ForeName': 'Amber T', 'Initials': 'AT', 'LastName': 'Dragg', 'Affiliation': ''}, {'ForeName': 'Allison B', 'Initials': 'AB', 'LastName': 'Davis', 'Affiliation': ''}, {'ForeName': 'Corby K', 'Initials': 'CK', 'LastName': 'Martin', 'Affiliation': ''}, {'ForeName': 'William D', 'Initials': 'WD', 'LastName': 'Johnson', 'Affiliation': ''}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Church', 'Affiliation': ''}]",Journal of physical activity & health,['10.1123/jpah.2018-0439'] 3125,31575508,Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.,"BACKGROUND Benralizumab did not significantly reduce exacerbations compared with placebo in the phase 3 GALATHEA and TERRANOVA trials of benralizumab for patients with chronic obstructive pulmonary disease (COPD). We aimed to identify clinical and physiological characteristics of patients with COPD that could help to identify people who are likely to have the greatest treatment effect with benralizumab. METHODS We analysed individual study and pooled results from GALATHEA and TERRANOVA. At study enrolment, patients from GALATHEA and TERRANOVA were aged 40-85 years, had moderate to very severe airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations or one severe exacerbation in the previous year despite dual inhaled therapy (inhaled corticosteroids plus long-acting β 2 -agonists or long-acting β 2 -agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhaled corticosteroids plus long-acting β 2 -agonists plus long-acting muscarinic antagonists). We analysed data for 3910 patients who received benralizumab (30 mg or 100 mg subcutaneously every 8 weeks; first three doses every 4 weeks) or placebo with dual or triple therapy to identify factors consistently associated with annual exacerbation rate reduction. We evaluated the annual exacerbation rate for benralizumab versus placebo as the primary endpoint. GALATHEA and TERRANOVA are registered with ClinicalTrials.gov, NCT02138916 and NCT02155660, respectively. FINDINGS For 2665 patients with elevated blood eosinophil counts, treatment effect with benralizumab every 8 weeks at 100 mg, but not at 30 mg, occurred for patients with a history of more frequent exacerbations, poorer baseline lung function, or greater baseline lung function improvement with short-acting bronchodilators. Patients with baseline blood eosinophil counts of 220 cells per μL or greater with: three or more exacerbations in the previous year receiving benralizumab every 8 weeks versus placebo, had rate ratios (RRs) of 0·69 (95% CI 0·56-0·83) for 100 mg and 0·86 (0·71-1·04) for 30 mg; postbronchodilator FEV 1 of less than 40% had RRs of 0·76 (0·64-0·91) for 100 mg and 0·90 (0·76-1·06) for 30 mg; and postbronchodilator response of at least 15% had RRs of 0·67 (0·54-0·83) for 100 mg and 0·87 (0·71-1·07) for 30 mg. When combined factors were examined, patients with elevated baseline blood eosinophil counts, with three or more exacerbations in the previous year, and who were receiving triple therapy were identified as likely to benefit from benralizumab 100 mg every 8 weeks versus placebo (RR 0·70 [95% CI 0·56-0·88]). Benralizumab 30 mg every 8 weeks did not benefit patients meeting these criteria compared with placebo (RR 0·99 [95% CI 0·79-1·23]). INTERPRETATION Elevated blood eosinophil counts combined with clinical characteristics identified a subpopulation of patients with COPD who had reductions in exacerbations with benralizumab treatment. These hypothesis-generating analyses identified the potential efficacy of benralizumab 100 mg for this subpopulation. These findings require prospective evaluation in clinical trials. FUNDING AstraZeneca.",2020,"Benralizumab 30 mg every 8 weeks did not benefit patients meeting these criteria compared with placebo (RR 0·99 [95% CI 0·79-1·23]). ","['3910 patients who received', 'patients with COPD', 'chronic obstructive pulmonary disease', 'Patients with baseline blood eosinophil counts of 220 cells per μL or greater with: three or more exacerbations in the previous year receiving', 'patients from GALATHEA and TERRANOVA were aged 40-85 years, had moderate to very severe airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations or one severe exacerbation in the previous year despite dual inhaled therapy (inhaled corticosteroids plus long-acting β 2 -agonists or long-acting β 2 -agonists plus long-acting muscarinic antagonists) or triple inhaled therapy (inhaled corticosteroids plus long-acting β 2 -agonists plus long-acting muscarinic antagonists', '2665 patients with', 'patients with chronic obstructive pulmonary disease (COPD']","['Benralizumab', 'benralizumab', 'placebo', 'benralizumab versus placebo', 'placebo with dual or triple therapy']","['annual exacerbation rate', 'rate ratios (RRs', 'elevated blood eosinophil counts', 'postbronchodilator response']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C4048185', 'cui_str': 'Genus Terranova'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C3641272', 'cui_str': 'Extreme'}, {'cui': 'C0231999', 'cui_str': 'Airflow, function (observable entity)'}, {'cui': 'C0449295', 'cui_str': 'Limitation (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0243192', 'cui_str': 'agonists'}, {'cui': 'C0003385', 'cui_str': 'Antimuscarinic Agents'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}]","[{'cui': 'C2982078', 'cui_str': 'benralizumab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0014467', 'cui_str': 'Eosinophil, segmented (cell)'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}]",2665.0,0.313604,"Benralizumab 30 mg every 8 weeks did not benefit patients meeting these criteria compared with placebo (RR 0·99 [95% CI 0·79-1·23]). ","[{'ForeName': 'Gerard J', 'Initials': 'GJ', 'LastName': 'Criner', 'Affiliation': 'Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: gerard.criner@tuhs.temple.edu.'}, {'ForeName': 'Bartolome R', 'Initials': 'BR', 'LastName': 'Celli', 'Affiliation': ""Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Dave', 'Initials': 'D', 'LastName': 'Singh', 'Affiliation': 'University of Manchester, Manchester University NHS Hospital Trust, Manchester, UK.'}, {'ForeName': 'Alvar', 'Initials': 'A', 'LastName': 'Agusti', 'Affiliation': ""Respiratory Institute, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, Barcelona, Spain.""}, {'ForeName': 'Alberto', 'Initials': 'A', 'LastName': 'Papi', 'Affiliation': 'Department of Medical Sciences, University of Ferrara, Ferrara, Italy.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Jison', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Natalya', 'Initials': 'N', 'LastName': 'Makulova', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Vivian H', 'Initials': 'VH', 'LastName': 'Shih', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Brooks', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Barker', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Ubaldo J', 'Initials': 'UJ', 'LastName': 'Martin', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Newbold', 'Affiliation': 'AstraZeneca, Gaithersburg, MD, USA.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30338-8'] 3126,32029248,Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial.,"OBJECTIVES The aim of this study was to report the 2-year results of the SURTAVI (Surgical Replacement and Transcatheter Aortic Valve Implantation) trial and confirm the interim Bayesian analysis. BACKGROUND Transcatheter aortic valve replacement (TAVR) with a self-expanding valve was noninferior to surgery in patients with severe aortic stenosis and intermediate operative risk using Bayesian statistical methods. Novel Bayesian designs have been used to shorten the time to primary endpoint analysis in randomized clinical trials, although the predictive value of Bayesian analysis compared with frequentist approaches remains debated. METHODS The SURTAVI trial randomized 1,660 patients. An interim analysis was performed 1 year after the 1,400th patient was treated to estimate the primary 2-year endpoint of all-cause mortality or disabling strokes for all patients. RESULTS The Kaplan-Meier rate for the complete 2-year primary endpoint was 12.7% in the TAVR group and 12.6% in the surgery group (0.0% difference; 95% confidence interval: -3.4% to 3.5%), compared with 12.6% with TAVR and 14.0% with surgery (-1.4% difference; Bayesian credible interval: -5.2% to 2.3%) in the interim Bayesian analysis. A comparison of individual clinical, hemodynamic, and quality-of-life endpoints using Bayesian and frequentist methods found no significant differences. CONCLUSIONS The complete analysis of all patients with aortic stenosis at intermediate risk for surgery in the SURTAVI trial confirmed the noninferiority, with respect to the frequency of all-cause mortality or disabling stroke, of TAVR to surgery, as determined in the interim Bayesian analysis. Follow-up will extend out to 10 years.",2020,"The Kaplan-Meier rate for the complete 2-year primary endpoint was 12.7% in the TAVR group and 12.6% in the surgery group (0.0% difference; 95% confidence interval: -3.4% to 3.5%), compared with 12.6% with TAVR and 14.0% with surgery (-1.4% difference;","['1,660 patients', 'patients with severe aortic stenosis']","['TAVR', 'SURTAVI ', 'Transcatheter aortic valve replacement (TAVR', 'Surgical Replacement and Transcatheter Aortic Valve Implantation']","['mortality or disabling strokes', 'Kaplan-Meier rate']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0003507', 'cui_str': 'Aortic Stenosis'}]","[{'cui': 'C2711836', 'cui_str': 'TAVR - Transcatheter aortic valve replacement'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0035139', 'cui_str': 'Reimplantation'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]",1660.0,0.117764,"The Kaplan-Meier rate for the complete 2-year primary endpoint was 12.7% in the TAVR group and 12.6% in the surgery group (0.0% difference; 95% confidence interval: -3.4% to 3.5%), compared with 12.6% with TAVR and 14.0% with surgery (-1.4% difference;","[{'ForeName': 'Nicolas M', 'Initials': 'NM', 'LastName': 'Van Mieghem', 'Affiliation': 'Department of Interventional Cardiology, Erasmus University Medical Centre, Rotterdam, the Netherlands. Electronic address: n.vanmieghem@erasmusmc.nl.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Popma', 'Affiliation': 'Department of Interventional Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.'}, {'ForeName': 'G Michael', 'Initials': 'GM', 'LastName': 'Deeb', 'Affiliation': 'Cardiac Surgery, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Steven J', 'Initials': 'SJ', 'LastName': 'Yakubov', 'Affiliation': 'Interventional Cardiology, OhioHealth Riverside Methodist Hospital, Columbus, Ohio.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Cardiovascular Science Division of the National Heart and Lung Institute, Imperial College London, London, United Kingdom.'}, {'ForeName': 'Stephan', 'Initials': 'S', 'LastName': 'Windecker', 'Affiliation': 'Department of Interventional Cardiology, University Hospital Bern, Bern, Switzerland.'}, {'ForeName': 'Lars', 'Initials': 'L', 'LastName': 'Søndergaard', 'Affiliation': 'The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mubashir', 'Initials': 'M', 'LastName': 'Mumtaz', 'Affiliation': 'Cardiac Surgery, University of Pittsburgh Medical Center Pinnacle Health, Harrisburg, Pennsylvania.'}, {'ForeName': 'Hemal', 'Initials': 'H', 'LastName': 'Gada', 'Affiliation': 'Interventional Cardiology, University of Pittsburgh Medical Center Pinnacle Health, Harrisburg, Pennsylvania.'}, {'ForeName': 'Stanley', 'Initials': 'S', 'LastName': 'Chetcuti', 'Affiliation': 'Interventional Cardiology, University of Michigan, Ann Arbor, Michigan.'}, {'ForeName': 'Neal S', 'Initials': 'NS', 'LastName': 'Kleiman', 'Affiliation': 'Cardiology, Methodist DeBakey Heart and Vascular Center, Houston, Texas.'}, {'ForeName': 'Susheel', 'Initials': 'S', 'LastName': 'Kodali', 'Affiliation': 'Structural Heart and Valve Center, Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Isaac', 'Initials': 'I', 'LastName': 'George', 'Affiliation': 'Structural Heart and Valve Center, Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Patrick', 'Initials': 'P', 'LastName': 'Teefy', 'Affiliation': 'Department of Medicine, Cardiology Division, London Health Sciences Centre, University Hospital, London, Ontario, Canada.'}, {'ForeName': 'Bob', 'Initials': 'B', 'LastName': 'Kiaii', 'Affiliation': 'Department of Cardiovascular and Thoracic Surgery, London Health Sciences Centre, University Hospital, London, Ontario, Canada.'}, {'ForeName': 'Jae K', 'Initials': 'JK', 'LastName': 'Oh', 'Affiliation': 'Echocardiography Core Laboratory, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Arie Pieter', 'Initials': 'AP', 'LastName': 'Kappetein', 'Affiliation': 'Baaken Research Center, Medical Affairs, Medtronic, Maastricht, the Netherlands.'}, {'ForeName': 'Yanping', 'Initials': 'Y', 'LastName': 'Chang', 'Affiliation': 'Clinical, Medtronic, Mounds View, Minnesota.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Mugglin', 'Affiliation': 'Paradigm Biostatistics, Anoka, Minnesota.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Reardon', 'Affiliation': 'Department of Cardiothoracic Surgery, Methodist DeBakey Heart and Vascular Center, Houston, Texas.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.10.043'] 3127,32044751,Effect of a WeChat-Based Intervention (Run4Love) on Depressive Symptoms Among People Living With HIV in China: A Randomized Controlled Trial.,"BACKGROUND People living with HIV (PLWH) have high rates of depressive symptoms. However, only a few effective mental health interventions exist for this vulnerable population. OBJECTIVE The aim of this study was to assess the efficacy of a WeChat-based intervention, Run4Love, with a randomized controlled trial among 300 people living with HIV and depression (PLWHD) in China. METHODS We recruited PLWH from the HIV outpatient clinic in South China. Participants were screened based on the Center for Epidemiologic Studies-Depression (CES-D) scale. Those who scored 16 or higher were eligible to participate. A total of 300 eligible patients were enrolled. After obtaining informed consent from the participants, completion of a baseline survey, and collection of participants' hair samples for measuring cortisol, the participants were randomly assigned to an intervention or a control group in a 1:1 ratio. The intervention group received the Run4Love program, delivered via the popular social media app WeChat. Cognitive behavioral stress management courses and weekly reminders of exercise were delivered in a multimedia format. Participants' progress was monitored with timely and tailored feedback. The control group received usual care and a brochure on nutrition for PLWH. Data were collected at 3, 6, and 9 months. The primary outcome was depression, which was measured by a validated instrument. RESULTS Participants in the intervention and control groups were comparable at baseline; about 91.3% (139/150), 88.3% (132/150), and 86.7% (130/150) participants completed the 3-, 6-, and 9-month follow-ups, respectively. At the 3-month follow-up, a significant reduction in CES-D score was observed in the intervention group (from 23.9 to 17.7 vs from 24.3 to 23.8; mean difference=-5.77, 95% CI -7.82 to -3.71; P<.001; standard effect size d=0.66). The mean changes in CES-D score from baseline to the 6- and 9-month follow-ups between the two groups remained statistically significant. No adverse events were reported. CONCLUSIONS The WeChat-based mobile health (mHealth) intervention Run4Love significantly reduced depressive symptoms among PLWHD, and the effect was sustained. An app-based mHealth intervention could provide a feasible therapeutic option for many PLWHD in resource-limited settings. Further research is needed to assess generalizability and cost-effectiveness of this intervention. TRIAL REGISTRATION Chinese Clinical Trial Registry ChiCTR-IPR-17012606; http://www.chictr.org.cn/showproj.aspx?proj=21019 (Archived by WebCite at https://www.webcitation.org/78Bw2vouF).",2020,"At the 3-month follow-up, a significant reduction in CES-D score was observed in the intervention group (from 23.9 to 17.7 vs from 24.3 to 23.8; mean difference=-5.77, 95% CI -7.82 to -3.71; P<.001; standard effect size d=0.66).","['Those who scored 16 or higher were eligible to participate', 'People living with HIV (PLWH', '300 people living with HIV and depression (PLWHD) in China', 'We recruited PLWH from the HIV outpatient clinic in South China', 'People Living With HIV in China', 'Participants were screened based on the Center for Epidemiologic Studies-Depression (CES-D) scale', '300 eligible patients were enrolled']","['WeChat-Based Intervention (Run4Love', 'usual care and a brochure on nutrition for PLWH', 'WeChat-based intervention, Run4Love', 'Run4Love program, delivered via the popular social media app WeChat']","['mean changes in CES-D score', 'CES-D score', 'Depressive Symptoms', 'depressive symptoms', 'adverse events']","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0595998', 'cui_str': 'Household composition (observable entity)'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0002424', 'cui_str': 'Outpatient Clinics'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030258', 'cui_str': 'Booklets'}, {'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C3179065', 'cui_str': 'Social Media'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}]",300.0,0.172717,"At the 3-month follow-up, a significant reduction in CES-D score was observed in the intervention group (from 23.9 to 17.7 vs from 24.3 to 23.8; mean difference=-5.77, 95% CI -7.82 to -3.71; P<.001; standard effect size d=0.66).","[{'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Guo', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Y Alicia', 'Initials': 'YA', 'LastName': 'Hong', 'Affiliation': 'Department of Health Administration and Policy, College of Health and Human Services, George Mason University, Fairfax, VA, United States.'}, {'ForeName': 'Weiping', 'Initials': 'W', 'LastName': 'Cai', 'Affiliation': ""Department of Infectious Diseases, Guangzhou Number Eight People's Hospital, Guangzhou, China.""}, {'ForeName': 'Linghua', 'Initials': 'L', 'LastName': 'Li', 'Affiliation': ""Department of Infectious Diseases, Guangzhou Number Eight People's Hospital, Guangzhou, China.""}, {'ForeName': 'Yuantao', 'Initials': 'Y', 'LastName': 'Hao', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Jiaying', 'Initials': 'J', 'LastName': 'Qiao', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Zhimeng', 'Initials': 'Z', 'LastName': 'Xu', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Hanxi', 'Initials': 'H', 'LastName': 'Zhang', 'Affiliation': 'National Center of AIDS/STD Control and Prevention, Beijing, China.'}, {'ForeName': 'Chengbo', 'Initials': 'C', 'LastName': 'Zeng', 'Affiliation': 'South Carolina SmartState Center of Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, United States.'}, {'ForeName': 'Cong', 'Initials': 'C', 'LastName': 'Liu', 'Affiliation': ""Department of Infectious Diseases, Guangzhou Number Eight People's Hospital, Guangzhou, China.""}, {'ForeName': 'Yiran', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Mengting', 'Initials': 'M', 'LastName': 'Zhu', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Yu', 'Initials': 'Y', 'LastName': 'Zeng', 'Affiliation': 'Department of Epidemiology and Biostatistics, School of Public Health, Sun Yat-sen University, Guangzhou, China.'}, {'ForeName': 'Frank J', 'Initials': 'FJ', 'LastName': 'Penedo', 'Affiliation': 'Department of Psychology, University of Miami, Coral Gables, FL, United States.'}]",Journal of medical Internet research,['10.2196/16715'] 3128,31954680,Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial.,"OBJECTIVES The aim of this study was to investigate the incidence and impact on mortality of repeat revascularization after index percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) for left main coronary artery disease (LMCAD). BACKGROUND The impact on mortality of the need of repeat revascularization following PCI or CABG in patients with unprotected LMCAD is unknown. METHODS All patients with LMCAD and site-assessed low or intermediate SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores randomized to PCI (n = 948) or CABG (n = 957) in the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial were included. Repeat revascularization events were adjudicated by an independent clinical events committee. The effect of repeat revascularization on mortality through 3-year follow-up was examined in time-varying Cox regression models. RESULTS During 3-year follow-up, there were 346 repeat revascularization procedures among 185 patients. PCI was associated with higher rates of any repeat revascularization (12.9% vs. 7.6%; hazard ratio: 1.73; 95% confidence interval: 1.28 to 2.33; p = 0.0003). Need for repeat revascularization was independently associated with increased risk for 3-year all-cause mortality (adjusted hazard ratio: 2.05; 95% confidence interval: 1.13 to 3.70; p = 0.02) and cardiovascular mortality (adjusted hazard ratio: 4.22; 95% confidence interval: 2.10 to 8.48; p < 0.0001) consistently after both PCI and CABG (p int  = 0.85 for both endpoints). Although target vessel revascularization and target lesion revascularization were both associated with an increased risk for mortality, target vessel non-target lesion revascularization and non-target vessel revascularization were not. CONCLUSIONS In the EXCEL trial, repeat revascularization during follow-up was performed less frequently after CABG than PCI and was associated with increased mortality after both procedures. Reducing the need for repeat revascularization may further improve long-term survival after percutaneous or surgical treatment of LMCAD. (EXCEL Clinical Trial; NCT01205776).",2020,Need for repeat revascularization was independently associated with increased risk for 3-year all-cause mortality (adjusted hazard ratio: 2.05; 95% confidence interval:,"['185 patients', 'All patients with LMCAD and site-assessed low or intermediate SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) scores randomized to PCI (n\xa0=\xa0948) or', 'patients with unprotected LMCAD']","['index percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG', 'PCI or Coronary Artery Bypass Grafting', 'EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery', 'CABG']","['mortality', 'Repeat revascularization events', 'Mortality', 'cardiovascular mortality', 'risk for mortality, target vessel non-target lesion revascularization and non-target vessel revascularization', 'higher rates of any repeat revascularization']","[{'cui': 'C4517617', 'cui_str': '185 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0330199', 'cui_str': 'Taxus'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]","[{'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1532338', 'cui_str': 'Percutaneous Coronary Revascularization'}, {'cui': 'C0010055', 'cui_str': 'Coronary Artery Bypass Grafting'}, {'cui': 'C2740529', 'cui_str': 'Excel'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0581603', 'cui_str': 'Revascularization - action (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0449618', 'cui_str': 'Target vessel (attribute)'}, {'cui': 'C0014742', 'cui_str': 'Erythema Multiforme'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",346.0,0.181929,Need for repeat revascularization was independently associated with increased risk for 3-year all-cause mortality (adjusted hazard ratio: 2.05; 95% confidence interval:,"[{'ForeName': 'Gennaro', 'Initials': 'G', 'LastName': 'Giustino', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Patrick W', 'Initials': 'PW', 'LastName': 'Serruys', 'Affiliation': 'Imperial College of Science, Technology and Medicine, London, United Kingdom.'}, {'ForeName': 'Joseph F', 'Initials': 'JF', 'LastName': 'Sabik', 'Affiliation': 'Department of Surgery, UH Cleveland Medical Center, Cleveland, Ohio.'}, {'ForeName': 'Roxana', 'Initials': 'R', 'LastName': 'Mehran', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Akiko', 'Initials': 'A', 'LastName': 'Maehara', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'John D', 'Initials': 'JD', 'LastName': 'Puskas', 'Affiliation': ""Mount Sinai Heart at Mount Sinai St Luke's, New York, New York.""}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Simonton', 'Affiliation': 'Abbott Vascular, Santa Clara, California.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'Lembo', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'David E', 'Initials': 'DE', 'LastName': 'Kandzari', 'Affiliation': 'Piedmont Heart Institute, Atlanta, Georgia.'}, {'ForeName': 'Marie-Claude', 'Initials': 'MC', 'LastName': 'Morice', 'Affiliation': 'Ramsay Générale de Santé, Hopital Privé Jacques Cartier, Massy, France.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': 'Taggart', 'Affiliation': 'Department Cardiac Surgery, John Radcliffe Hospital, Oxford, United Kingdom.'}, {'ForeName': 'Anthony H', 'Initials': 'AH', 'LastName': 'Gershlick', 'Affiliation': 'University Hospitals of Leicester, Leicester, United Kingdom.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Ragosta', 'Affiliation': 'Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia.'}, {'ForeName': 'Irving L', 'Initials': 'IL', 'LastName': 'Kron', 'Affiliation': 'Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, Virginia.'}, {'ForeName': 'Yangbo', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Zixuan', 'Initials': 'Z', 'LastName': 'Zhang', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'McAndrew', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Ovidiu', 'Initials': 'O', 'LastName': 'Dressler', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Généreux', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey; Hôpital du Sacré-Coeur de Montréal, Montréal, Québec, Canada.'}, {'ForeName': 'Ori', 'Initials': 'O', 'LastName': 'Ben-Yehuda', 'Affiliation': 'Clinical Trials Center, Cardiovascular Research Foundation, New York, New York; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Pocock', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Arie Pieter', 'Initials': 'AP', 'LastName': 'Kappetein', 'Affiliation': 'Erasmus University Medical Center, Rotterdam, the Netherlands.'}, {'ForeName': 'Gregg W', 'Initials': 'GW', 'LastName': 'Stone', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York. Electronic address: gregg.stone@mountsinai.org.'}]",JACC. Cardiovascular interventions,['10.1016/j.jcin.2019.09.019'] 3129,30885800,"Care partner problem solving training (CP-PST) for care partners of adults with traumatic brain injury during inpatient rehabilitation: Study protocol for a multisite, randomized, single-blind clinical feasibility trial.","Traumatic brain injury (TBI) often leads to immediate and chronic functional impairments that affect care partners, or those providing physical and/or emotional support to individuals with TBI. The many challenges associated with being a care partner often lead to caregiver burden and can compromise the well-being and quality of life of care partners and individuals with TBI under their care. Equipping care partners with problem-solving skills could facilitate and sustain their transition into this supportive role. Problem-solving training (PST) has demonstrated efficacy for providing such skills to care partners of individuals with TBI after discharge from inpatient rehabilitation. We propose that PST delivered to care partners during inpatient rehabilitation of individuals with TBI will provide care partners with the skills to manage their caregiving roles across the transition from hospital to home. Herein, we describe the methodology of a current randomized controlled trial that examines the feasibility and efficacy of PST plus TBI education compared to TBI education alone to improve care partner burden, emotional distress, and adaptive coping when delivered during the inpatient rehabilitation stay of individuals with moderate-severe TBI.",2019,Problem-solving training (PST) has demonstrated efficacy for providing such skills to care partners of individuals with TBI after discharge from inpatient rehabilitation.,"['care partners of adults with traumatic brain injury during inpatient rehabilitation', 'care partners of individuals with TBI after discharge from inpatient rehabilitation', 'individuals with moderate-severe TBI']","['TBI education alone', 'PST', 'Care partner problem solving training (CP-PST', 'Problem-solving training (PST', 'PST plus TBI education']","['care partner burden, emotional distress, and adaptive coping']","[{'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0876926', 'cui_str': 'TBI (Traumatic Brain Injury)'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0543432', 'cui_str': 'Problem solving training (procedure)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0682323', 'cui_str': 'Companion'}, {'cui': 'C0700361', 'cui_str': 'Emotional distress'}]",,0.0250104,Problem-solving training (PST) has demonstrated efficacy for providing such skills to care partners of individuals with TBI after discharge from inpatient rehabilitation.,"[{'ForeName': 'Shannon B', 'Initials': 'SB', 'LastName': 'Juengst', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, United States; Department of Rehabilitation Counseling, University of Texas Southwestern Medical Center, Dallas, TX, United States. Electronic address: Shannon.Juengst@UTSouthwestern.edu.'}, {'ForeName': 'Valeria', 'Initials': 'V', 'LastName': 'Silva', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Yelena', 'Initials': 'Y', 'LastName': 'Goldin', 'Affiliation': 'Cognitive Rehabilitation Department, JFK Johnson Rehabilitation Institute, Hackensack Meridian Health, Edison, NJ, United States.'}, {'ForeName': 'Keith', 'Initials': 'K', 'LastName': 'Cicerone', 'Affiliation': 'Cognitive Rehabilitation Department, JFK Johnson Rehabilitation Institute, Hackensack Meridian Health, Edison, NJ, United States; Department of Physical Medicine & Rehabilitation, JFK Johnson Rehabilitation Institute, Hackensack Meridian Health, Edison, NJ, United States.'}, {'ForeName': 'Jean', 'Initials': 'J', 'LastName': 'Lengenfelder', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, Rutgers-New Jersey Medical School, Newark, NJ, United States; Department of Neurology, Rutgers-New Jersey Medical School, Newark, NJ, United States; Kessler Foundation, East Hanover, NJ, United States.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Chiaravalloti', 'Affiliation': 'Department of Neurology, Rutgers-New Jersey Medical School, Newark, NJ, United States; Kessler Foundation, East Hanover, NJ, United States.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Driver', 'Affiliation': 'Baylor Scott and White Institute for Rehabilitation, Dallas, TX, United States.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Mellick', 'Affiliation': 'Craig Hospital, Englewood, CO, United States.'}, {'ForeName': 'Georgianna', 'Initials': 'G', 'LastName': 'Dart', 'Affiliation': 'Cognitive Rehabilitation Department, JFK Johnson Rehabilitation Institute, Hackensack Meridian Health, Edison, NJ, United States.'}, {'ForeName': 'Chung Lin', 'Initials': 'CL', 'LastName': 'Kew', 'Affiliation': 'Department of Rehabilitation Counseling, University of Texas Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Nabasny', 'Affiliation': 'Department of Rehabilitation Counseling, University of Texas Southwestern Medical Center, Dallas, TX, United States.'}, {'ForeName': 'Kathleen R', 'Initials': 'KR', 'LastName': 'Bell', 'Affiliation': 'Department of Physical Medicine & Rehabilitation, University of Texas Southwestern Medical Center, Dallas, TX, United States.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.004'] 3130,32024950,"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).","Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or died divided by total duration of progression-free survival [PFS] in patient-years; co-primary endpoint) for intense, intermediate, and short dosing were 0.055 (80% confidence interval [CI], 0.014-0.096), 0.102 (80% CI, 0.044-0.160), and 0.206 (80% CI, 0.118-0.295), respectively, translating to a median PFS ≥24 months in all arms (P < 0.0001, <0.0001, and =0.0213, respectively). With longer follow-up (median follow-up, 25.9 months), CR rates were 4.9%, 9.8%, and 0% for intense, intermediate, and short dosing, respectively. PD/death rates for intense, intermediate, and short dosing were 0.059 (80% CI, 0.025-0.092), 0.107 (80% CI, 0.058-0.155), and 0.150 (80% CI, 0.089-0.211), respectively, again translating to a median PFS ≥ 24 months in all arms (P < 0.0001 for all arms). Twenty-four-month PFS rates were 89.9% (90% CI, 78.5-95.4%), 82.0% (90% CI, 69.0-89.9%), and 75.3% (90% CI, 61.1-85.0%) for intense, intermediate, and short dosing, respectively. Pharmacokinetic analyses indicated that intense dosing maintained target-saturating trough concentrations in most patients throughout weekly, every-2-week, and every-4-week dosing periods. No new safety signals were observed. These data provide the basis for an ongoing phase 3 study of daratumumab in SMM.",2020,"PD/death rates for intense, intermediate, and short dosing were 0.059 (80% CI, 0.025-0.092), 0.107 (80% CI, 0.058-0.155), and 0.150 (80% CI, 0.089-0.211), respectively, again translating to a median PFS ≥ 24 months in all arms (P < 0.0001 for all arms).","['patients with intermediate-risk or high-risk smoldering multiple myeloma', '123 patients with intermediate-risk or high-risk SMM']","['Daratumumab monotherapy', 'daratumumab 16\u2009mg/kg intravenously on extended intense (intense), extended intermediate (intermediate']","['Progressive disease (PD)/death rates', 'CR rates', 'CR rate', 'PD/death rates', 'PFS rates', 'complete response (CR) rates']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C1531608', 'cui_str': 'Asymptomatic Multiple Myeloma'}]","[{'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0231449', 'cui_str': 'Extended (qualifier value)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205848', 'cui_str': 'Death Rate'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]",123.0,0.0578349,"PD/death rates for intense, intermediate, and short dosing were 0.059 (80% CI, 0.025-0.092), 0.107 (80% CI, 0.058-0.155), and 0.150 (80% CI, 0.089-0.211), respectively, again translating to a median PFS ≥ 24 months in all arms (P < 0.0001 for all arms).","[{'ForeName': 'C Ola', 'Initials': 'CO', 'LastName': 'Landgren', 'Affiliation': 'Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. landgrec@mskcc.org.'}, {'ForeName': 'Ajai', 'Initials': 'A', 'LastName': 'Chari', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, NY, USA.'}, {'ForeName': 'Yael C', 'Initials': 'YC', 'LastName': 'Cohen', 'Affiliation': 'Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Spencer', 'Affiliation': 'Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Voorhees', 'Affiliation': 'Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.'}, {'ForeName': 'Jane A', 'Initials': 'JA', 'LastName': 'Estell', 'Affiliation': 'Haematology Department, Concord Cancer Centre, Concord Hospital, University of Sydney, Concord, NSW, Australia.'}, {'ForeName': 'Irwindeep', 'Initials': 'I', 'LastName': 'Sandhu', 'Affiliation': 'Department of Medicine, University of Alberta, Edmonton, AB, Canada.'}, {'ForeName': 'Matthew W', 'Initials': 'MW', 'LastName': 'Jenner', 'Affiliation': 'Southampton General Hospital, Southampton, UK.'}, {'ForeName': 'Catherine', 'Initials': 'C', 'LastName': 'Williams', 'Affiliation': 'Department of Clinical Haematology, Nottingham University Hospitals, Nottinghamshire, UK.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Cavo', 'Affiliation': 'Department of Experimental, Diagnostic and Specialty Medicine, ""Seràgnoli"" Institute of Hematology, University of Bologna, Bologna, Italy.'}, {'ForeName': 'Niels W C J', 'Initials': 'NWCJ', 'LastName': 'van de Donk', 'Affiliation': 'Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.'}, {'ForeName': 'Meral', 'Initials': 'M', 'LastName': 'Beksac', 'Affiliation': 'Department of Hematology, Ankara University, Ankara, Turkey.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'University Hospital Hôtel-Dieu, Nantes, France.'}, {'ForeName': 'Hartmut', 'Initials': 'H', 'LastName': 'Goldschmidt', 'Affiliation': 'University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg, Germany.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Kuppens', 'Affiliation': 'Janssen Research & Development, Beerse, Belgium.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Bandekar', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Pamela L', 'Initials': 'PL', 'LastName': 'Clemens', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Tobias', 'Initials': 'T', 'LastName': 'Neff', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Heuck', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Qi', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Craig C', 'Initials': 'CC', 'LastName': 'Hofmeister', 'Affiliation': 'Department of Hematology & Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. Craig.Hofmeister@emory.edu.'}]",Leukemia,['10.1038/s41375-020-0718-z'] 3131,31939564,Transcutaneous tibial nerve stimulation versus parasacral stimulation in the treatment of overactive bladder in elderly people: a triple-blinded randomized controlled trial.,"OBJECTIVES To evaluate the effect of transcutaneous tibial nerve stimulation (TTNS) and transcutaneous parasacral stimulation on the treatment of overactive bladder (OAB) in elderly people and to compare the final results between groups. METHODS Fifty female volunteers, mean age 68.62 (±5.9) years, were randomly allocated into two groups: those receiving TTNS (G1, N=25) and those receiving transcutaneous parasacral stimulation (G2, N=25). The primary outcome was the International Consultation on Incontinence Questionnaire (ICIQ-OAB) score, and secondary outcomes were the International Consultation on Incontinence Questionnaire - short form (ICIQ-SF) score and 3-day bladder diary measurements. Volunteers were assessed before and after the treatment. Clinical Trials (ReBeC): RBR-9Q7J7Y. RESULTS Both groups' symptoms improved as measured by the ICIQ-OAB (G1 = <0.001; G2 = <0.001) and ICIQ-SF (G1 = <0.001; G2 = <0.001). In the 3-day bladder diary assessments after treatment, G1 showed a reduced number of nocturia (p<0.001), urgency (p<0.001) and urge urinary incontinence episodes (p<0.001), whereas G2 showed only a reduced number of nocturia episodes (p<0.001). No difference between groups was found. CONCLUSION Both of the proposed treatments were effective in the improvement of OAB symptoms, but TTNS showed a reduction in a greater number of symptoms as measured by the 3-day bladder diary. No differences were found between groups.",2020,"In the 3-day bladder diary assessments after treatment, G1 showed a reduced number of nocturia (p<0.001), urgency (p<0.001) and urge urinary incontinence episodes (p<0.001), whereas G2 showed only a reduced number of nocturia episodes (p<0.001).","['Fifty female volunteers, mean age 68.62', 'elderly people', 'overactive bladder in elderly people']","['TTNS (G1, N=25) and those receiving transcutaneous parasacral stimulation', 'Transcutaneous tibial nerve stimulation versus parasacral stimulation', 'transcutaneous tibial nerve stimulation (TTNS) and transcutaneous parasacral stimulation']","['OAB symptoms', 'overactive bladder (OAB', 'number of nocturia (p<0.001), urgency (p<0.001) and urge urinary incontinence episodes', 'International Consultation on Incontinence Questionnaire (ICIQ-OAB) score, and secondary outcomes were the International Consultation on Incontinence Questionnaire - short form (ICIQ-SF) score and 3-day bladder diary measurements', 'number of nocturia episodes']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}]","[{'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0040186', 'cui_str': 'Tibial Nerve'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0878773', 'cui_str': 'Overactive Bladder'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0028734', 'cui_str': 'Nycturia'}, {'cui': 'C0439609', 'cui_str': 'Urgency (qualifier value)'}, {'cui': 'C0150045', 'cui_str': 'Urinary Reflex Incontinence'}, {'cui': 'C2711460', 'cui_str': 'International consultation on incontinence questionnaire (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0376315', 'cui_str': 'Form'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0430970', 'cui_str': 'Urinary frequency volume chart (procedure)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0332189', 'cui_str': 'Episodes (qualifier value)'}]",50.0,0.123912,"In the 3-day bladder diary assessments after treatment, G1 showed a reduced number of nocturia (p<0.001), urgency (p<0.001) and urge urinary incontinence episodes (p<0.001), whereas G2 showed only a reduced number of nocturia episodes (p<0.001).","[{'ForeName': 'Raquel Henriques', 'Initials': 'RH', 'LastName': 'Jacomo', 'Affiliation': 'Programa de Ciencias Medicas, Faculdade de Medicina, Universidade de Brasilia, Brasilia, DF, BR.'}, {'ForeName': 'Aline Teixeira', 'Initials': 'AT', 'LastName': 'Alves', 'Affiliation': 'Programa de Pos-Graduacao em Ciencias da Reabilitacao, Departamento de Fisioterapia, Universidade de Brasilia, Brasilia, DF, BR.'}, {'ForeName': 'Adélia', 'Initials': 'A', 'LastName': 'Lucio', 'Affiliation': 'Unidade de Reabilitacao, Hospital Universitario, Universidade do Mato Grosso do Sul, Campo Grande, MS, BR.'}, {'ForeName': 'Patrícia Azevedo', 'Initials': 'PA', 'LastName': 'Garcia', 'Affiliation': 'Programa de Pos-Graduacao em Ciencias da Reabilitacao, Departamento de Fisioterapia, Universidade de Brasilia, Brasilia, DF, BR.'}, {'ForeName': 'Dayanne Cristina Ramos', 'Initials': 'DCR', 'LastName': 'Lorena', 'Affiliation': 'Programa de Pos-Graduacao em Ciencias da Reabilitacao, Departamento de Fisioterapia, Universidade de Brasilia, Brasilia, DF, BR.'}, {'ForeName': 'João Batista', 'Initials': 'JB', 'LastName': 'de Sousa', 'Affiliation': 'Programa de Ciencias Medicas, Faculdade de Medicina, Universidade de Brasilia, Brasilia, DF, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1477'] 3132,32028859,The impact of alliance-focused and facilitative interpersonal relationship training on therapist skills: An RCT of brief training.,"Research on standard methods of therapist training has found mixed evidence to as to whether standard training methods are effective. This study investigated the impact of a novel, research-informed training protocol that integrated elements of alliance-focused training (AFT) and facilitative interpersonal skills (FIS). Beyond traditional training techniques of didactics and lecture, the AFT/FIS intervention incorporated empirically supported video simulations of therapy, which were reinforced by role plays and deliberate practice on key therapeutic interpersonal skills. Fifty-eight graduate-level therapy trainees and professional therapists from various helping fields were randomized to one of two brief trainings in a multi-site RCT: (i) the AFT/FIS workshop or (ii) a more traditional demonstration training (DT) workshop. Participants were assessed on critical, relational therapeutic skills before and after the training. After controlling for relevant covariates, participants in the AFT/FIS training saw a marginally higher post-intervention level of overall therapeutic skills. Subsequent exploratory analyses revealed AFT/FIS participants also had significantly higher levels of specifically targeted post-training therapist skills (i.e., empathy, alliance bond capacity, and alliance rupture-repair responsiveness) compared to participants in DT. Implications for future empirical investigations and training initiatives are discussed.",2020,"Subsequent exploratory analyses revealed AFT/FIS participants also had significantly higher levels of specifically targeted post-training therapist skills (i.e., empathy, alliance bond capacity, and alliance rupture-repair responsiveness) compared to participants in DT.",['Fifty-eight graduate-level therapy trainees and professional therapists from various helping fields'],"['facilitative interpersonal relationship training', 'alliance-focused training (AFT) and facilitative interpersonal skills (FIS', 'therapist training', 'AFT/FIS workshop or (ii) a more traditional demonstration training (DT) workshop', 'RCT']","['post-intervention level of overall therapeutic skills', 'levels of specifically targeted post-training therapist skills (i.e., empathy, alliance bond capacity, and alliance rupture-repair responsiveness']","[{'cui': 'C4517817', 'cui_str': '58'}, {'cui': 'C0588053', 'cui_str': 'Graduate (person)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0440042', 'cui_str': ""Field's""}]","[{'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0679005', 'cui_str': 'Interpersonal Skills'}, {'cui': 'C0242262', 'cui_str': 'Workshops'}, {'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0013989', 'cui_str': 'Empathy'}, {'cui': 'C0028758', 'cui_str': 'Object Relationship'}, {'cui': 'C0443294', 'cui_str': 'Ruptured (qualifier value)'}, {'cui': 'C0374711', 'cui_str': 'Surgical repair (procedure)'}]",58.0,0.0337088,"Subsequent exploratory analyses revealed AFT/FIS participants also had significantly higher levels of specifically targeted post-training therapist skills (i.e., empathy, alliance bond capacity, and alliance rupture-repair responsiveness) compared to participants in DT.","[{'ForeName': 'Matthew R', 'Initials': 'MR', 'LastName': 'Perlman', 'Affiliation': 'Psychology, Ohio University, Athens, OH, USA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Anderson', 'Affiliation': 'Psychology, Ohio University, Athens, OH, USA.'}, {'ForeName': 'Victoria K', 'Initials': 'VK', 'LastName': 'Foley', 'Affiliation': 'Psychology, The New School for Social Research, New York, NY, USA.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Mimnaugh', 'Affiliation': 'Psychology, The New School for Social Research, New York, NY, USA.'}, {'ForeName': 'Jeremy D', 'Initials': 'JD', 'LastName': 'Safran', 'Affiliation': 'Psychology, The New School for Social Research, New York, NY, USA.'}]",Psychotherapy research : journal of the Society for Psychotherapy Research,['10.1080/10503307.2020.1722862'] 3133,31542451,Respiratory Duty Cycles in Individuals With and Without Airway Hyperresponsiveness.,"BACKGROUND The respiratory duty cycle (T i /T tot ) can influence bronchoprovocation test results and nebulized drug delivery. The T i /T tot has not yet been examined in individuals with airway hyperresponsiveness (AHR) in typical bronchoprovocation test conditions. This study investigated the mean T i /T tot in participants with and without AHR and whether the T i /T tot changes with increasing bronchoconstriction. METHODS Fifteen participants with AHR and fifteen participants without AHR completed this randomized crossover study. An ultrasonic spirometer was used for continuous measurement of the T i /T tot as participants inhaled room air or aerosolized solution. Each participant completed two methacholine challenges, one using a continuous-output vibrating mesh nebulizer/ultrasonic spirometer and one with the nebulizer only. Prior to each methacholine challenge, participants inhaled room air and aerosolized saline through the nebulizer/spirometer setup to record baseline T i /T tot data. RESULTS The mean T i /T tot findings [95% CIs] during room air inhalation were 0.392 [0.378-0.406] and 0.447 [0.426-0.468] in participants with and without AHR, respectively (P < .001). The mean T i /T tot during saline inhalation were 0.389 [0.373-0.405] and 0.424 [0.398-0.450] in participants with and without AHR (P = .040). The T i /T tot showed a nonsignificant downward trend with progressive methacholine-induced bronchoconstriction. CONCLUSIONS The mean T i /T tot in participants with AHR closely resembles the assumed T i /T tot of 0.40 recommended for standard use when calculating methacholine challenge results. Since the T i /T tot did not change significantly over the course of a methacholine challenge, the same T i /T tot can be used to calculate the dose of methacholine inhaled, regardless of the level of bronchoconstriction. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT03505489; URL: www.clinicaltrials.gov.",2020,"The mean T i /T tot during saline inhalation were 0.389 +/-0.037 and 0.424 +/-0.071 in participants with and without AHR, respectively (p = 0.040).","['participants with and without AHR and whether the T i /T', 'individuals with and without airway hyperresponsiveness', 'individuals with airway hyperresponsiveness (AHR) in typical bronchoprovocation test conditions', 'Fifteen participants with AHR and fifteen participants without AHR']","['inhaled room air or aerosolized solution', 'inhaled room air and aerosolized saline']","['standard deviation during room air inhalation', 'progressive methacholine-induced bronchoconstriction', 'mean T', 'mean T i /T tot during saline inhalation', 'mean T i /T tot ']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0449910', 'cui_str': 'Test conditions (attribute)'}]","[{'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]","[{'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C1705211', 'cui_str': 'Inhalation - unit of product usage'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0600370', 'cui_str': 'Methacholine'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}, {'cui': 'C0079043', 'cui_str': 'Bronchial Constriction'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}]",15.0,0.0750936,"The mean T i /T tot during saline inhalation were 0.389 +/-0.037 and 0.424 +/-0.071 in participants with and without AHR, respectively (p = 0.040).","[{'ForeName': 'Christianne M', 'Initials': 'CM', 'LastName': 'Blais', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Beth E', 'Initials': 'BE', 'LastName': 'Davis', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Brian L', 'Initials': 'BL', 'LastName': 'Graham', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.'}, {'ForeName': 'Donald W', 'Initials': 'DW', 'LastName': 'Cockcroft', 'Affiliation': 'Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. Electronic address: don.cockcroft@usask.ca.'}]",Chest,['10.1016/j.chest.2019.09.005'] 3134,31762412,"""Connecting patients and therapists remotely using technology is feasible and facilitates exercise adherence after stroke"".","Purpose : Repetitive task practice after stroke is important to improve function, yet adherence to exercise is low. The aim of this study was to determine whether using the internet, a tablet application, and a chair sensor that connected to a therapist was feasible in monitoring adherence and progressing a functional exercise at home. Methods : Ten participants with stroke completed a 4-week sit-to-stand exercise using the technology at home (ACTRN12616000051448). A therapist remotely monitored exercise adherence, progressed goals, and provided feedback via the app. Measures of feasibility (design, recruitment/withdrawals, adherence, safety, participant satisfaction and estimates of effect on function) were collected. Results : Participants' mean age was 73.6 years [SD 9.9 years]. The system was feasible to deliver and monitor exercise remotely. All participants completed the study performing a mean 125% of prescribed sessions and 104% of prescribed repetitions. Participants rated the system usability (78%), enjoyment (70%) and system benefit (80%) as high. No adverse events were reported. The mean pre- and post-intervention difference in the total short performance physical battery score was 1.4 (95% CI 0.79, 2.00). Conclusions : It was feasible and safe to prescribe and monitor exercises using an app and sensor-based system. A definitive trial will determine whether such technology could facilitate greater exercise participation after stroke.",2020,"Participants rated the system usability (78%), enjoyment (70%) and system benefit (80%) as high.","['Ten participants with stroke completed a', ""Participants' mean age was 73.6 years [SD 9.9 years""]",['4-week sit-to-stand exercise'],"['feasibility (design, recruitment/withdrawals, adherence, safety, participant satisfaction and estimates of effect on function', 'system usability', 'adverse events', 'total short performance physical battery score']","[{'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C3888057', 'cui_str': 'Stand'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",10.0,0.0900905,"Participants rated the system usability (78%), enjoyment (70%) and system benefit (80%) as high.","[{'ForeName': 'Dawn B', 'Initials': 'DB', 'LastName': 'Simpson', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Marie-Louise', 'Initials': 'ML', 'LastName': 'Bird', 'Affiliation': 'GF Strong Rehabilitation Research Laboratory, University of British Colombia, Vancouver, Canada.'}, {'ForeName': 'Coralie', 'Initials': 'C', 'LastName': 'English', 'Affiliation': 'School of Health Sciences, University of Newcastle, Newcastle, Australia.'}, {'ForeName': 'Seana L', 'Initials': 'SL', 'LastName': 'Gall', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Monique', 'Initials': 'M', 'LastName': 'Breslin', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Smith', 'Affiliation': 'Division of Research, Southern Cross University, Coffs Harbour, Australia.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Schmidt', 'Affiliation': 'School of Health Sciences, University of Tasmania, Hobart, Australia.'}, {'ForeName': 'Michele L', 'Initials': 'ML', 'LastName': 'Callisaya', 'Affiliation': 'Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.'}]",Topics in stroke rehabilitation,['10.1080/10749357.2019.1690779'] 3135,31994616,Randomized trial of physiotherapy and hypertonic saline techniques for sputum induction in asthmatic children and adolescents.,"OBJECTIVES This study aimed to analyze the efficiency of physiotherapy techniques in sputum induction and in the evaluation of pulmonary inflammation in asthmatic children and adolescents. Although hypertonic saline (HS) is widely used for sputum induction (SI), specific techniques and maneuvers of physiotherapy (P) may facilitate the collection of mucus in some asthmatic children and adolescents. METHODS A randomized crossover study was performed in patients with well-controlled asthma, and 90 sputum samples were collected. Children and adolescents were assessed using spirometry and randomized at entry into one of three sputum induction techniques: (i) 3% hypertonic saline - HS technique; (ii) physiotherapy (oscillatory positive expiratory pressure, forced expiration, and acceleration of expiratory flow) - P technique; and (iii) hypertonic saline + physiotherapy - HSP technique. ClinicalTrials.gov: NCT03136042. RESULTS The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques. The sputum weight (g) in the HSP technique was significantly higher than that in the HS technique. In all techniques, the percentage of viable cells was >50%, and there was no difference between the HS and P techniques. Moreover, sputum induction did not cause any alterations in the pulmonary function of patients. CONCLUSION The physiotherapy sputum collection technique was effective in obtaining viable cells from mucus samples and yielded the same amount of sputum as the gold standard technique (hypertonic saline). In addition, the physiotherapy maneuvers were both safe and useful for sputum induction in asthmatic children and adolescents with well-controlled asthma.",2020,The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques.,"['asthmatic children and adolescents with well-controlled asthma', 'asthmatic children and adolescents', 'Children and adolescents', 'patients with well-controlled asthma, and 90 sputum samples were collected']","['physiotherapy techniques', 'hypertonic saline (HS', 'physiotherapy and hypertonic saline techniques', 'sputum induction techniques: (i) 3% hypertonic saline - HS technique; (ii) physiotherapy (oscillatory positive expiratory pressure, forced expiration, and acceleration of expiratory flow) - P technique; and (iii) hypertonic saline + physiotherapy - HSP technique']","['total cells (mL) and the percentage (%) of differential inflammatory cells', 'sputum weight (g) in the HSP technique', 'percentage of viable cells']","[{'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C3853142', 'cui_str': 'Well controlled'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444159', 'cui_str': 'Sputum specimen'}]","[{'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0454505', 'cui_str': 'Sputum induction technique (regime/therapy)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0000894', 'cui_str': 'Acceleration'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0443199', 'cui_str': 'Differential (qualifier value)'}, {'cui': 'C0440752', 'cui_str': 'Inflammatory cell'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0025664', 'cui_str': 'techniques'}, {'cui': 'C0443348', 'cui_str': 'Viable (qualifier value)'}]",,0.0828024,The total cells (mL) and the percentage (%) of differential inflammatory cells were similar in all techniques.,"[{'ForeName': 'Egberto Luiz', 'Initials': 'EL', 'LastName': 'Felicio-Júnior', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Viviani', 'Initials': 'V', 'LastName': 'Barnabé', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Francine Maria', 'Initials': 'FM', 'LastName': 'de Almeida', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Monise Dematte', 'Initials': 'MD', 'LastName': 'Avona', 'Affiliation': 'Universidade Cidade de Sao Paulo (UNICID), Sao Paulo, SP, BR.'}, {'ForeName': 'Isabella Santos', 'Initials': 'IS', 'LastName': 'de Genaro', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}, {'ForeName': 'Adriana', 'Initials': 'A', 'LastName': 'Kurdejak', 'Affiliation': 'Universidade Cidade de Sao Paulo (UNICID), Sao Paulo, SP, BR.'}, {'ForeName': 'Miriam Cardoso Neves', 'Initials': 'MCN', 'LastName': 'Eller', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Karina Pierantozzi', 'Initials': 'KP', 'LastName': 'Verganid', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Joaquim Carlos', 'Initials': 'JC', 'LastName': 'Rodrigues', 'Affiliation': 'Departamento de Pediatria e Pneumologia, Instituto da Criança, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Iolanda de Fátima Lopes Calvo', 'Initials': 'IFLC', 'LastName': 'Tibério', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Milton de Arruda', 'Initials': 'MA', 'LastName': 'Martins', 'Affiliation': 'Laboratorio de Terapeutica Experimental (LIM-20), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, BR.'}, {'ForeName': 'Beatriz Mangueira', 'Initials': 'BM', 'LastName': 'Saraiva-Romanholo', 'Affiliation': 'Hospital do Servidor Publico do Estado de Sao Paulo (IAMSPE), Sao Paulo, SP, BR.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1512'] 3136,30020512,"Comparative efficacy of a 12 week yoga-based lifestyle intervention and dietary intervention on adipokines, inflammation, and oxidative stress in adults with metabolic syndrome: a randomized controlled trial.","The present randomized controlled trial (RCT) evaluated the comparative efficacy of 12 week yoga-based lifestyle intervention (YBLI) and dietary intervention (DI) alone on adipokines, inflammation, and oxidative stress in Indian adults with metabolic syndrome (Met S). A parallel, two arm, RCT was conducted in Integral Health Clinic (IHC), All India Institute of Medical Sciences, India from 2012 to 2014. IHC is an outpatient facility conducting YBLI programs for prevention and management of chronic diseases. Two hundred sixty men and women (20-45 years) visiting the outpatient department of a tertiary care hospital were diagnosed with Met S and randomized 1:1 to receive 12 week YBLI (n = 130) or DI (n = 130). Primary outcomes were change in plasma levels of adipokines (leptin, adiponectin, and leptin:adiponectin ratio), markers of inflammation (tumor necrosis factor [TNF]-α, interleukin [IL]-6), markers of oxidative stress (thiobarbituric acid reactive substances [TBARS], 8-hydroxy-2'-deoxyguanosine [8-OHdG], and superoxide dismutase [SOD]) measured at baseline, 2 weeks, and 12 weeks. YBLI group showed a significant decrease in leptin, leptin:adiponectin ratio, IL-6, 8-OHdG, and TBARS levels, whereas there was a significant increase in adiponectin and SOD levels. No significant changes were noticed in DI alone group. YBLI showed significantly greater reduction in TBARS levels than in DI group, suggestive of reduced oxidative stress in adults with Met S. A 12 week YBLI had a positive impact on oxidative stress versus DI alone in adults with Met S.",2019,"YBLI group showed a significant decrease in leptin, leptin:adiponectin ratio, IL-6, 8-OHdG, and TBARS levels, whereas there was a significant increase in adiponectin and SOD levels.","['Indian adults with metabolic syndrome (Met S', 'Two hundred sixty men and women (20-45 years) visiting the outpatient department of a tertiary care hospital were diagnosed with Met S and randomized 1:1 to receive 12 week YBLI (n = 130) or DI (n = 130', 'adults with Met S', 'adults with metabolic syndrome']","['IHC', '12 week yoga-based lifestyle intervention and dietary intervention', '12 week yoga-based lifestyle intervention (YBLI) and dietary intervention (DI) alone', 'YBLI']","['oxidative stress', 'leptin, leptin:adiponectin ratio, IL-6, 8-OHdG, and TBARS levels', ""change in plasma levels of adipokines (leptin, adiponectin, and leptin:adiponectin ratio), markers of inflammation (tumor necrosis factor [TNF]-α, interleukin [IL]-6), markers of oxidative stress (thiobarbituric acid reactive substances [TBARS], 8-hydroxy-2'-deoxyguanosine [8-OHdG], and superoxide dismutase [SOD"", 'adipokines, inflammation, and oxidative stress', 'adiponectin and SOD levels', 'TBARS levels']","[{'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0524620', 'cui_str': 'Metabolic Syndrome X'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0337954', 'cui_str': 'Tertiary care hospital (environment)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}]","[{'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1883583', 'cui_str': 'Yoga'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0162781', 'cui_str': 'TBARs'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C1955907', 'cui_str': 'Adipocytokines'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0041368', 'cui_str': 'Tumor Necrosis Factors'}, {'cui': 'C0050078', 'cui_str': ""2'-deoxy-8-oxo-7,8-dihydroguanosine""}, {'cui': 'C0069638', 'cui_str': 'orgotein'}]",260.0,0.0368795,"YBLI group showed a significant decrease in leptin, leptin:adiponectin ratio, IL-6, 8-OHdG, and TBARS levels, whereas there was a significant increase in adiponectin and SOD levels.","[{'ForeName': 'Rashmi', 'Initials': 'R', 'LastName': 'Yadav', 'Affiliation': 'Department of Physiology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Raj Kumar', 'Initials': 'RK', 'LastName': 'Yadav', 'Affiliation': 'Department of Physiology, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Khadgawat', 'Affiliation': 'Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India.'}, {'ForeName': 'Ravindra Mohan', 'Initials': 'RM', 'LastName': 'Pandey', 'Affiliation': 'Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.'}]",Translational behavioral medicine,['10.1093/tbm/iby060'] 3137,30085287,Implementing a small media intervention to increase colorectal cancer screening in primary care clinics.,"Colorectal cancer (CRC) is one of the most common cancers in the USA. In 2017, an estimated 135,420 people were diagnosed with CRC and 50,260 people died from CRC. Several screening modalities are recommended by the United States Preventive Services Task Force (USPSTF), including annual stool tests that are usually completed at home and under-used compared with colonoscopy despite stated patient preferences for an alternative to colonoscopy. The Community Preventive Services Task Force recommends use of small media interventions (SMIs) to increase CRC screening and calls for a greater understanding of its independent impact on screening participation. This study tested whether a SMI increased the likelihood of participant return of a USPSTF recommended Fecal Immunochemical Test (FIT). In total, 804 individuals participated in a two-group, prospective randomized controlled trial. Descriptive statistics with chi-square tests compared differences in participant characteristics and return rates. Multivariable log-binomial modeling estimated combined effects of patient characteristics with FIT return rates. No differences in return rates were observed overall or by participant characteristics other than the year of enrollment. A multivariable model controlling for all covariates, found gender, insurance type, and regular place for healthcare to be significantly associated with return rates. Receipt of the SMI did not independently increase overall return rates but it may have improved the ease of completing the FIT by some participants, particularly women, those with insurance, and those with a regular place for healthcare.",2019,"Receipt of the SMI did not independently increase overall return rates but it may have improved the ease of completing the FIT by some participants, particularly women, those with insurance, and those with a regular place for healthcare.","['Colorectal cancer (CRC', 'In 2017, an estimated 135,420 people were diagnosed with CRC and 50,260 people died from CRC', '804 individuals participated in a two-group', 'primary care clinics']","['small media intervention', 'small media interventions (SMIs']","['colorectal cancer screening', 'return rates', 'overall return rates']","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}]","[{'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C0439536', 'cui_str': 'Medium (qualifier value)'}]","[{'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",804.0,0.0483993,"Receipt of the SMI did not independently increase overall return rates but it may have improved the ease of completing the FIT by some participants, particularly women, those with insurance, and those with a regular place for healthcare.","[{'ForeName': 'Cathy L', 'Initials': 'CL', 'LastName': 'Melvin', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina.'}, {'ForeName': 'Anissa I', 'Initials': 'AI', 'LastName': 'Vines', 'Affiliation': 'Department of Epidemiology, University of North Carolina Chapel Hill (UNC).'}, {'ForeName': 'Allison M', 'Initials': 'AM', 'LastName': 'Deal', 'Affiliation': 'Biostatistics Shared Resource, UNC Lineberger Comprehensive Cancer Center.'}, {'ForeName': 'Holly O', 'Initials': 'HO', 'LastName': 'Pierce', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina.'}, {'ForeName': 'William R', 'Initials': 'WR', 'LastName': 'Carpenter', 'Affiliation': 'UNC Lineberger Comprehensive Cancer Center.'}, {'ForeName': 'Paul A', 'Initials': 'PA', 'LastName': 'Godley', 'Affiliation': 'Division of Hematology and Oncology, School of Medicine, UNC.'}]",Translational behavioral medicine,['10.1093/tbm/iby063'] 3138,31712768,Effect of milk fat on LDL cholesterol and other cardiovascular risk markers in healthy humans: the INNOVALAIT project.,"BACKGROUND Milk has a specific saturated fatty acid profile and its calcium content may change the kinetics of fat absorption. OBJECTIVE The goal of this study was to compare the effect on LDL Cholesterol and other risk markers of four isolipidic diets differing by their fat food source, vegetable fat, spring milk fat, winter milk fat or winter milk fat supplemented with calcium, in healthy moderately hypercholesterolemic humans. INDIVIDUALS AND METHODS This double-blind, randomized trial with four parallel arms included 172 healthy adults with plasma LDL cholesterol (LDL-C) from 130 to 220 mg/dL and triglycerides below 300 mg/dL. Individual meal plans ensured a stable energy intake. In the three diets containing milk fat, milk fat provided 38% of energy. Vegetable fat and spring milk fat diets provided the same amount of saturated fatty acids while the winter milk fat diets were slightly richer in saturated fatty acids. Vegetable fat diet and winter milk fat diets provided the same amount of palmitic acid (7.0% EI), while the spring milk fat diet was slightly poorer in this fatty acid (5.1% EI). Cardiovascular risk markers were analyzed after 8 weeks of dietary intervention. RESULTS There was no significant difference in LDL-C and other markers, except total cholesterol (TC), apo C3 and CRP. TC was significantly higher with spring milk fat than with vegetable fat. CONCLUSIONS In this trial, the chosen vegetable fat did not have a significant beneficial effect on LDL-C compared to dairy fat. However, sub-group analysis showed differences in TC, apo C3 and CRP. These results need confirmation and long-term studies aiming at cardiovascular endpoints are warranted.",2020,"There was no significant difference in LDL-C and other markers, except total cholesterol (TC), apo C3 and CRP.","['healthy moderately hypercholesterolemic humans', '172 healthy adults with plasma LDL cholesterol (LDL-C) from 130 to 220\u2009mg/dL and triglycerides below 300\u2009mg/dL. Individual meal plans ensured a stable energy intake', 'healthy humans']","['milk fat', 'Vegetable fat and spring milk fat diets', 'Vegetable fat diet and winter milk fat diets', 'fat food source, vegetable fat, spring milk fat, winter milk fat or winter milk fat supplemented with calcium']","['LDL cholesterol and other cardiovascular risk markers', 'TC', 'TC, apo C3 and CRP', 'Cardiovascular risk markers', 'palmitic acid', 'LDL-C and other markers, except total cholesterol (TC), apo C3 and CRP']","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C4517601', 'cui_str': '172 (qualifier value)'}, {'cui': 'C0686750', 'cui_str': 'Well adult (finding)'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C4517650', 'cui_str': '220 (qualifier value)'}, {'cui': 'C0439269', 'cui_str': 'mg/dL'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C4553624', 'cui_str': 'With meals (qualifier value)'}, {'cui': 'C1301732', 'cui_str': 'Planned'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0006777', 'cui_str': 'Caloric Intake'}]","[{'cui': 'C0026131', 'cui_str': 'Milk'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0301585', 'cui_str': 'Fat diet (finding)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C4521696', 'cui_str': 'Source (property)'}, {'cui': 'C0006675', 'cui_str': 'Calcium'}]","[{'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0030234', 'cui_str': 'Palmitic Acid'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}]",172.0,0.0371022,"There was no significant difference in LDL-C and other markers, except total cholesterol (TC), apo C3 and CRP.","[{'ForeName': 'Jean-Marie', 'Initials': 'JM', 'LastName': 'Bard', 'Affiliation': ""Institut de Cancérologie de l'Ouest, Biopathologie, Centre de Recherche en Nutrition Humaine Ouest, EA 2160 - IUML FR3473 CNRS, Université de Nantes, Nantes, France. Jean-Marie.Bard@univ-nantes.fr.""}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Drouet', 'Affiliation': 'LTA-IVS INSERM U689, Hôpital Lariboisière, Paris, France.'}, {'ForeName': 'Denis', 'Initials': 'D', 'LastName': 'Lairon', 'Affiliation': 'UMR 1062-INSERM/1260-INRA, Faculté de Médecine, Université Aix-Marseille, Marseille, France.'}, {'ForeName': 'Murielle', 'Initials': 'M', 'LastName': 'Cazaubiel', 'Affiliation': 'Biofortis, Saint-Herblain, France.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Marmonier', 'Affiliation': 'CNIEL, Paris, France.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Ninio', 'Affiliation': 'Genomics and Pathophysiology of Cardiovascular Diseases, Institute of Cardiometabolism and Nutrition, ICAN, Pitié-Salpêtrière, INSERM UMR_S 1166-ICAN, Sorbonne Université, Paris, France.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Bal Dit Sollier', 'Affiliation': 'LTA-IVS INSERM U689, Hôpital Lariboisière, Paris, France.'}, {'ForeName': 'Jean-Charles', 'Initials': 'JC', 'LastName': 'Martin', 'Affiliation': 'UMR 1062-INSERM/1260-INRA, Faculté de Médecine, Université Aix-Marseille, Marseille, France.'}, {'ForeName': 'Constance', 'Initials': 'C', 'LastName': 'Boyer', 'Affiliation': 'CNIEL, Paris, France.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Bobin-Dubigeon', 'Affiliation': ""Institut de Cancérologie de l'Ouest, Biopathologie, Centre de Recherche en Nutrition Humaine Ouest, EA 2160 - IUML FR3473 CNRS, Université de Nantes, Nantes, France.""}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of clinical nutrition,['10.1038/s41430-019-0528-4'] 3139,32026250,"Addressing Intimate Partner Violence and Power in Intimate Relationships in HIV Testing Services in Nairobi, Kenya.","Intimate partner violence (IPV) undermines women's uptake of HIV services and violates their human rights. In a two-arm randomized controlled trial we evaluated a short intervention that went a step beyond IPV screening to discuss violence and power with women receiving HIV testing services during antenatal care (ANC). The intervention included training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor. One third (35%) of women (N = 688) reported experiencing IPV in the past year; 6% were living with HIV. Among women experiencing IPV, program participants were more likely to disclose violence to their counselor than women receiving standard care (32% vs. 7%, p < 0.001). At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001). Exploratory analyses of intent to use ARVs to prevent mother-to-child transmission and actions to address violence were also encouraging.",2020,"At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001).","[""Intimate partner violence (IPV) undermines women's uptake of HIV services and violates their human rights"", 'HIV Testing Services in Nairobi, Kenya', 'violence and power with women receiving HIV testing services during antenatal care (ANC']","['training and support for HIV counselors, a take-home card for clients, and an on-site IPV counselor']",['experiencing IPV'],"[{'cui': 'C4042876', 'cui_str': 'Intimate Partner Abuse'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0020138', 'cui_str': 'Human Rights'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}, {'cui': 'C0042693', 'cui_str': 'Violence'}, {'cui': 'C0033052', 'cui_str': 'Antenatal Care'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C1571885', 'cui_str': 'Counselors'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0008942', 'cui_str': 'Clients'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}]","[{'cui': 'C0276240', 'cui_str': 'Infectious pustular vulvovaginitis (disorder)'}]",,0.0526836,"At second ANC visit, intervention group women were significantly more likely to report that talking with their counselor made a positive difference (aOR 2.9; 95% CI 1.8, 4.4; p < 0.001) and felt more confident in how they deserved to be treated (aOR 2.7; 95% CI 1.7, 4.4; p < 0.001).","[{'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Haberland', 'Affiliation': 'Population Council, One Dag Hammarskjold Plaza, New York, NY, 10017, USA. nhaberland@popcouncil.org.'}, {'ForeName': 'Charity', 'Initials': 'C', 'LastName': 'Ndwiga', 'Affiliation': 'Population Council, Nairobi, Kenya.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'McCarthy', 'Affiliation': 'Population Council, One Dag Hammarskjold Plaza, New York, NY, 10017, USA.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Pulerwitz', 'Affiliation': 'Population Council, Washington, DC, USA.'}, {'ForeName': 'Rose', 'Initials': 'R', 'LastName': 'Kosgei', 'Affiliation': 'Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Margaret', 'Initials': 'M', 'LastName': ""Mak'anyengo"", 'Affiliation': 'Kenyatta National Hospital, Nairobi, Kenya.'}, {'ForeName': 'Amelia', 'Initials': 'A', 'LastName': 'Peltz', 'Affiliation': 'Office of HIV/AIDS, United States Agency for International Development, Washington, DC, USA.'}, {'ForeName': 'Vincent J', 'Initials': 'VJ', 'LastName': 'Wong', 'Affiliation': 'Office of HIV/AIDS, United States Agency for International Development, Washington, DC, USA.'}, {'ForeName': 'Sam', 'Initials': 'S', 'LastName': 'Kalibala', 'Affiliation': 'Population Council, Washington, DC, USA.'}]",AIDS and behavior,['10.1007/s10461-020-02801-9'] 3140,32026829,"""WALK30X5"": a feasibility study of a physiotherapy walking programme for people with mild to moderate musculoskeletal conditions.","OBJECTIVES To explore the feasibility of delivering and evaluating a web-based walking intervention for people with long term musculoskeletal conditions (LTMCs), to determine its acceptability and the feasibility of conducting a definitive trial. DESIGN Prospective randomised feasibility study, with blind outcome assessment at baseline, 3 and 6 months. SETTING Hospital based physiotherapy service. PARTICIPANTS Forty one adults referred for assessment and advice for any mild/moderate LTMCs. doing <120minutes of moderate intensity activity per week. INTERVENTIONS Participants randomised to: 1. Usual care: one usual physiotherapy advice and assessment session, including setting a physical activity goal and one follow up session (8 weeks). 2. ""Walk30×5"": session one, usual care plus intervention of walking programme. Participants were shown the website and podcasts and practiced how to use them. One follow up session (8 weeks). OUTCOME MEASURES Primary: timed six minute walk test (T6MWT). Secondary: step count, self-reported pain, fatigue, mood, self-efficacy, happiness, objective blood pressure, peak expiratory flow rate, and self-report and accelerometer measured physical activity. RESULTS Recruitment target achieved. No adverse events occurred. Adherence was high and the intervention acceptable. Loss to follow up n=3 (7%) at 3 months, n=8 (20%) at 6 months. T6MWT and step count proved suitable outcomes, unlike accelerometry. Estimated sample size for a definitive trial is 216. CONCLUSIONS ""Walk30×5"" is ready for evaluation in a future, appropriately powered (n=216), phase III trial. If effective, the intervention will provide a cheap, highly accessible intervention to enable people with mild/moderate LTMCs to achieve UK physical activity guidelines. CLINICAL TRIAL REGISTRATION NUMBER ISRCTN78581097.",2020,No adverse events occurred.,"['people with long term musculoskeletal conditions (LTMCs', 'Forty one adults referred for assessment and advice for any mild/moderate LTMCs', 'people with mild to moderate musculoskeletal conditions', 'Hospital based physiotherapy service']","['delivering and evaluating a web-based walking intervention', 'usual physiotherapy advice and assessment session', 'physiotherapy walking programme']","['six minute walk test (T6MWT', 'Adherence', 'count, self-reported pain, fatigue, mood, self-efficacy, happiness, objective blood pressure, peak expiratory flow rate, and self-report and accelerometer measured physical activity']","[{'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1299392', 'cui_str': 'Mild to moderate'}, {'cui': 'C0587631', 'cui_str': 'Hospital-based physiotherapy service (qualifier value)'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}]","[{'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0018592', 'cui_str': 'Happinesses'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1542834', 'cui_str': 'Peak expiratory flow rate (observable entity)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",41.0,0.110074,No adverse events occurred.,"[{'ForeName': 'Catherine J', 'Initials': 'CJ', 'LastName': 'Minns Lowe', 'Affiliation': 'Physiotherapy Research Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Windmill Road, Headington, Oxford OX3 7HE, UK. Electronic address: catherine.minnslowe@ouh.nhs.uk.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Kelly', 'Affiliation': 'Institute for Sport, Physical Education and Health Sciences (ISPEHS), Moray House School of Education, University of Edinburgh, EH8 8AQ, UK. Electronic address: p.kelly@ed.ac.uk.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Milton', 'Affiliation': 'The British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health, UK. Electronic address: k.milton@uea.ac.uk.'}, {'ForeName': 'Charlie', 'Initials': 'C', 'LastName': 'Foster', 'Affiliation': 'The British Heart Foundation Centre on Population Approaches for Non-Communicable Disease Prevention, Nuffield Department of Population Health, UK. Electronic address: charlie.foster@bristol.ac.uk.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Barker', 'Affiliation': 'Physiotherapy Research Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Windmill Road, Headington, Oxford OX3 7HE, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK. Electronic address: karen.barker@ouh.nhs.uk.'}]",Physiotherapy,['10.1016/j.physio.2019.08.010'] 3141,32026826,Impact of hypertonic saline nebulisation combined with oscillatory positive expiratory pressure on sputum expectoration and related symptoms in cystic fibrosis: a randomised crossover trial.,"OBJECTIVE To evaluate the impact of combining nebulised hyaluronic acid plus hypertonic saline (HA+HS) with oscillatory positive expiratory pressure (oscillatory-PEP) on sputum expectoration and related symptoms in adults with cystic fibrosis (CF). DESIGN Randomised crossover trial. SETTING Seven centres. PARTICIPANTS Twenty-two outpatients with CF. INTERVENTIONS Usual care (HA+HS followed by autogenic drainage) and combined therapy (HA+HS with oscillatory-PEP followed by autogenic drainage]. Each treatment was performed for 5 days. MAIN OUTCOME MEASURES Sputum expectoration was measured during the nebulisation period (primary outcome), during autogenic drainage and for 24hours post intervention. The Cough and Sputum Assessment Questionnaire (CASA-Q) and its domains (cough symptoms, cough impact, sputum symptoms and sputum impact), the Leicester Cough Questionnaire (LCQ) and lung function tests were used. Tolerance and patient preference were registered. RESULTS Twenty-two participants [mean age 25 (standard deviation 8) years, percentage predicted forced expiratory volume in 1second 67 (22)] were recruited. Combined therapy promoted greater sputum expectoration than usual care during the nebulisation period {median difference 1.8ml [95% confidence interval (CI) 0.2-6.2]}. Both treatments led to similar expectoration during autogenic drainage and for 24hours post intervention. Combined therapy led to a greater improvement in the sputum symptoms domain [6.7 points (95% CI 3.3-13.3] and total CASA-Q score [2.4 points (95% CI 0.1-9.3)] compared with usual care. No differences in LCQ score or lung function were observed. Fewer adverse events were reported using combined therapy, which was selected as the preferred intervention. CONCLUSIONS Combined nebulisation increased immediate sputum expectoration, improved sputum symptoms and reduced adverse events compared with usual care in patients with CF. CLINICAL TRIAL NUMBER NCT02303808.",2020,Combined therapy promoted greater sputum expectoration than usual care during the nebulisation period {median difference 1.8ml [95% confidence interval (CI) 0.2-6.2]}.,"['Twenty-two participants [mean age 25 (standard deviation 8) years, percentage predicted forced expiratory volume in 1second 67 (22)] were recruited', 'Seven centres', 'cystic fibrosis', 'adults with cystic fibrosis (CF', 'Twenty-two outpatients with CF']","['Usual care (HA+HS followed by autogenic drainage) and combined therapy (HA+HS with oscillatory-PEP followed by autogenic drainage', 'hypertonic saline nebulisation combined with oscillatory positive expiratory pressure', 'nebulised hyaluronic acid plus hypertonic saline (HA+HS) with oscillatory positive expiratory pressure (oscillatory-PEP']","['Cough and Sputum Assessment Questionnaire (CASA-Q) and its domains (cough symptoms, cough impact, sputum symptoms and sputum impact), the Leicester Cough Questionnaire (LCQ) and lung function tests', 'sputum expectoration', 'total CASA-Q score', 'Sputum expectoration', 'LCQ score or lung function', 'sputum symptoms domain', 'adverse events', 'immediate sputum expectoration, improved sputum symptoms and reduced adverse events']","[{'cui': 'C4284772', 'cui_str': '22 (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0010674', 'cui_str': 'Mucoviscidosis'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}]","[{'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0454507', 'cui_str': 'Autogenic pulmonary drainage'}, {'cui': 'C0033972', 'cui_str': 'Psychotherapy, Multiple'}, {'cui': 'C0359587', 'cui_str': 'Peptamen'}, {'cui': 'C0036085', 'cui_str': 'Sodium Chloride Solution, Hypertonic'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C1141990', 'cui_str': 'Hyaluronic acid'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0425512', 'cui_str': 'Sputum - symptom (finding)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C3541951', 'cui_str': 'Domain'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205253', 'cui_str': 'Immediate (qualifier value)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",22.0,0.224361,Combined therapy promoted greater sputum expectoration than usual care during the nebulisation period {median difference 1.8ml [95% confidence interval (CI) 0.2-6.2]}.,"[{'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'San Miguel-Pagola', 'Affiliation': 'Universidad San Jorge, Autovía Mudéjar, km. 299, Villanueva de Gállego, 50830, Zaragoza, Spain; Institut de Recherche Expérimentale et Clinique (IREC), Pneumologie, ORL and Dermatologie, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, Woluwe-Saint-Lambert, 1200, Brussels, Belgium. Electronic address: msanmiguelpagola@gmail.com.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Reychler', 'Affiliation': 'Institut de Recherche Expérimentale et Clinique (IREC), Pneumologie, ORL and Dermatologie, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, Woluwe-Saint-Lambert, 1200, Brussels, Belgium; Service de Pneumologie, Cliniques Universitaires Saint-Luc, Avenue Hippocrate 10, Woluwe-Saint-Lambert, 1200, Brussels, Belgium. Electronic address: gregory.reychler@uclouvain.be.'}, {'ForeName': 'María A', 'Initials': 'MA', 'LastName': 'Cebrià I Iranzo', 'Affiliation': 'Department of Physiotherapy, Universitat de València, Av. de Blasco Ibáñez, 13, 46010, Valencia, Spain; Physiotherapy, Cardiorespiratory Rehabilitation Service, Hospital Universitari i Politècnic La Fe, Avinguda de Fernando Abril Martorell, 106, 46026, Valencia, Cáceres, Spain. Electronic address: Angeles.Cebria@uv.es.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Gómez-Romero', 'Affiliation': 'Physiotherapy, Cystic Fibrosis Association, Carrera 8, bajo, 10002, Cáceres, Extremadura, Spain. Electronic address: margomrom@hotmail.com.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Díaz-Gutiérrez', 'Affiliation': 'Physiotherapy, Virgen del Rocío Hospital, Avda. Manuel Siurot, s/n, 41013, Sevilla, Spain. Electronic address: ferdigu@hotmail.com.'}, {'ForeName': 'Beatriz', 'Initials': 'B', 'LastName': 'Herrero-Cortina', 'Affiliation': 'Universidad San Jorge, Autovía Mudéjar, km. 299, Villanueva de Gállego, 50830, Zaragoza, Spain. Electronic address: beafisiorespi@gmail.com.'}]",Physiotherapy,['10.1016/j.physio.2019.11.001'] 3142,31764336,"The ""Cough Trick"" Reduces Pain During Removal of Closed-suction Drains after Total Knee Arthroplasty: A Randomized Trial.","BACKGROUND Drain removal after TKA can be painful. Prior research suggests that the ""cough trick,"" in which a patient coughs at the same time she or he receives an injection, effectively decreases pain. To our knowledge, this intervention has not been evaluated as a way to reduce pain during other brief but painful interventions, such as removal of closed-suction drains after orthopaedic surgery. QUESTION/PURPOSE Does the cough trick reduce pain while a surgeon is removing a closed-suction drain after TKA? METHODS Fifty-six patients with primary osteoarthritis who underwent primary TKA were randomized into two groups: drain removal as the patient coughed (n = 28 patients; three men, 25 women) or drain removal using the usual process, without the cough trick (n = 28 patients; three men, 25 women). The study groups were not different in terms of gender, BMI, surgical time, or other baseline variables, and other than the addition of the cough trick, there were no differences in surgical treatment or other elements of aftercare. Likewise, at baseline, the verbal numeric rating scale (VNRS) score for pain before the drain was removed was not different between the groups (3.1 ± 1.7 versus 3.3 ± 1.3; p = 0.72). The level of pain before and during drain removal was recorded using a VNRS by an orthopaedic surgeon who was not involved in the care of the study patients. We considered the minimum clinically important difference on the 10-point scale to be 2 points, based on prior evidence. RESULTS The mean ± SD VNRS for the pain level during drain removal was lower in the cough trick group than that in the control group (1.6 ± 1.0 versus 3.7 ± 1.9, mean difference 2.1; 95% CI, 1.3-2.9; p < 0.001). CONCLUSIONS The cough trick during removal of a closed-suction drain tube in patients undergoing TKA reduced the level of pain in this small randomized trial. We suggest that surgeons consider this technique when removing drains after TKA because it is a noninvasive technique and it is easy to perform. Because the cough trick has been shown by others to be effective at reducing pain during venipuncture and parenteral injections, and we found it was effective for that purpose during drain removal after TKA, we believe this finding probably generalizes well to most minor procedures that cause transient, sharp pain. We suggest that it could be used to make such procedures more comfortable for patients, as well as for drain removal in other types of surgery where drains still are commonly used (including spine surgery and tumor surgery). LEVEL OF EVIDENCE Level I, therapeutic study.",2019,"The mean ± SD VNRS for the pain level during drain removal was lower in the cough trick group than that in the control group (1.6 ± 1.0 versus 3.7 ± 1.9, mean difference 2.1; 95% CI, 1.3-2.9; p < 0.001). ","['n = 28 patients; three men, 25 women', 'after Total Knee Arthroplasty', 'n = 28 patients; three men, 25 women) or', 'Fifty-six patients with primary osteoarthritis who underwent primary TKA']","['drain removal as the patient coughed', 'Cough Trick"" Reduces Pain During Removal of Closed-suction Drains', 'drain removal using the usual process, without the cough trick']","['verbal numeric rating scale (VNRS) score for pain before the drain', 'level of pain', 'mean ± SD VNRS for the pain level during drain removal']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C1384584', 'cui_str': 'Generalized osteoarthritis (disorder)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}]","[{'cui': 'C0411815', 'cui_str': 'Removal of drain (procedure)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}, {'cui': 'C0441139', 'cui_str': 'Suction drain (physical object)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}]","[{'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0180499', 'cui_str': 'Drain, device (physical object)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C0411815', 'cui_str': 'Removal of drain (procedure)'}]",25.0,0.143798,"The mean ± SD VNRS for the pain level during drain removal was lower in the cough trick group than that in the control group (1.6 ± 1.0 versus 3.7 ± 1.9, mean difference 2.1; 95% CI, 1.3-2.9; p < 0.001). ","[{'ForeName': 'Varah', 'Initials': 'V', 'LastName': 'Yuenyongviwat', 'Affiliation': 'V. Yuenyongviwat, K. Iamthanaporn, P. Tuntarattanapong, T. Hongnaparak, Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla Thailand.'}, {'ForeName': 'Khanin', 'Initials': 'K', 'LastName': 'Iamthanaporn', 'Affiliation': ''}, {'ForeName': 'Pakjai', 'Initials': 'P', 'LastName': 'Tuntarattanapong', 'Affiliation': ''}, {'ForeName': 'Theerawit', 'Initials': 'T', 'LastName': 'Hongnaparak', 'Affiliation': ''}]",Clinical orthopaedics and related research,['10.1097/CORR.0000000000000901'] 3143,32017253,Effect of curcumin supplementation on disease severity in patients with liver cirrhosis: A randomized controlled trial.,"Recent reports indicated that curcumin had beneficial effects in animal models of liver injury and cirrhosis. Current study aimed to investigate the effects of curcumin supplementation in patients with liver cirrhosis. In this randomized double-blind placebo-controlled trial, 70 patients with liver cirrhosis aged 20-70 years were randomly divided into two groups to receive 1,000 mg/day curcumin (n = 35) or placebo (n = 35) for 3 months. Model for end-stage liver disease (MELD) (i), MELD, MELD-Na, and Child-Pugh scores were used to assess the severity of cirrhosis. Sixty patients (29 in the curcumin group and 31 in the placebo group) completed the study. MELD(i) (15.55 ± 3.78 to 12.41 ± 3.07), MELD (15.31 ± 3.07 to 12.03 ± 2.79), MELD-Na (15.97 ± 4.02 to 13.55 ± 3.51), and Child-Pugh (7.17 ± 1.54 to 6.72 ± 1.31) scores decreased significantly in the curcumin group after 3-month intervention (p < .001, p < .001, p = .001, and p = .051, respectively), whereas they increased significantly in the placebo group (p < .001, p < .001, p < .001, p = .001, respectively). Significant differences were only observed between the two groups in MELD(i), MELD, MELD-Na, and Child-Pugh scores after 3-month intervention (p < .001 for all of them). In this pilot study, beneficial effects of curcumin supplementation were observed in decreasing disease activity scores and severity of cirrhosis in patients with cirrhosis.",2020,"Significant differences were only observed between the two groups in MELD(i), MELD, MELD-Na, and Child-","['patients with liver cirrhosis', 'end-stage liver disease (MELD', 'Sixty patients (29 in the curcumin group and 31 in the placebo group) completed the study', '70 patients with liver cirrhosis aged 20-70\u2009years', 'patients with cirrhosis']","['curcumin supplementation', 'placebo', 'MELD(i']","['MELD(i), MELD, MELD-Na, and Child', 'disease activity scores and severity of cirrhosis', 'i), MELD, MELD-Na, and Child', 'Pugh scores', 'disease severity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023890', 'cui_str': 'Hepatic Cirrhosis'}, {'cui': 'C0745744', 'cui_str': 'End Stage Liver Disease'}, {'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}]","[{'cui': 'C0010467', 'cui_str': 'Curcumin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C4706353', 'cui_str': 'Disease Activity Score'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C1623038', 'cui_str': 'Cirrhosis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]",70.0,0.210468,"Significant differences were only observed between the two groups in MELD(i), MELD, MELD-Na, and Child-","[{'ForeName': 'Masoud', 'Initials': 'M', 'LastName': 'Nouri-Vaskeh', 'Affiliation': 'Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Aida', 'Initials': 'A', 'LastName': 'Malek Mahdavi', 'Affiliation': 'Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Hossein', 'Initials': 'H', 'LastName': 'Afshan', 'Affiliation': 'Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Leila', 'Initials': 'L', 'LastName': 'Alizadeh', 'Affiliation': 'Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.'}, {'ForeName': 'Mohammad', 'Initials': 'M', 'LastName': 'Zarei', 'Affiliation': 'Department of Pathology and Laboratory Medicine, Perlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.'}]",Phytotherapy research : PTR,['10.1002/ptr.6620'] 3144,32022904,Protocol and statistical analysis plan for the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury-REVERSE-AKI randomized controlled pilot trial.,"BACKGROUND Fluid accumulation frequently coexists with acute kidney injury (AKI) and is associated with increased risk for AKI progression and mortality. Among septic shock patients, restricted use of resuscitation fluid has been reported to reduce the risk of worsening of AKI. Restrictive fluid therapy, however, has not been studied in the setting of established AKI. Here, we present the protocol and statistical analysis plan of the REstricted fluid therapy VERsus Standard trEatment in Acute Kidney Injury-the REVERSE-AKI trial that compares a restrictive fluid therapy regimen to standard therapy in critically ill patients with AKI. METHODS REVERSE-AKI is an investigator-initiated, multinational, open-label, randomized, controlled, feasibility pilot trial conducted in seven ICUs in five countries. We aim to randomize 100 critically ill patients with AKI to a restrictive fluid treatment regimen vs standard management. In the restrictive fluid therapy regimen, the daily fluid balance target is neutral or negative. The primary outcome is the cumulative fluid balance assessed after 72 hours from randomization. Secondary outcomes include safety, feasibility, duration, and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). CONCLUSIONS This is the first multinational trial investigating the feasibility and safety of a restrictive fluid therapy regimen in critically ill patients with AKI. TRIAL REGISTRATION clinical.trials.gov NCT03251131.",2020,"Secondary outcomes include safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). ","['Acute Kidney Injury', '100 critically ill patients with AKI to a restrictive fluid treatment regimen versus standard management', 'septic shock patients', '7 ICUs in 5 countries', 'critically ill patients with AKI']",['restrictive fluid therapy regimen'],"['safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence', 'cumulative fluid balance']","[{'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0036983', 'cui_str': 'Septic Shock'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}]","[{'cui': 'C0016286', 'cui_str': 'Fluid Therapy'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C4551529', 'cui_str': 'Renal Dialysis'}, {'cui': 'C0439857', 'cui_str': 'Patient dependence on (contextual qualifier) (qualifier value)'}, {'cui': 'C0016284', 'cui_str': 'Fluid Balance'}]",100.0,0.24103,"Secondary outcomes include safety, feasibility, duration and severity of AKI, and outcome at 90 days (mortality and dialysis dependence). ","[{'ForeName': 'Suvi T', 'Initials': 'ST', 'LastName': 'Vaara', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Marlies', 'Initials': 'M', 'LastName': 'Ostermann', 'Affiliation': ""Department of Critical Care, King's College London, Guy's and St Thomas' Hospital, London, UK.""}, {'ForeName': 'Tuomas', 'Initials': 'T', 'LastName': 'Selander', 'Affiliation': 'Science Service Center, Kuopio University Hospital, Kuopio, Finland.'}, {'ForeName': 'Laurent', 'Initials': 'L', 'LastName': 'Bitker', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}, {'ForeName': 'Antoine', 'Initials': 'A', 'LastName': 'Schneider', 'Affiliation': 'Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Elettra', 'Initials': 'E', 'LastName': 'Poli', 'Affiliation': 'Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Hoste', 'Affiliation': 'Intensive Care Unit, Ghent University Hospital, Ghent University, Ghent, Belgium.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Joannidis', 'Affiliation': 'Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Zarbock', 'Affiliation': 'Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.'}, {'ForeName': 'Frank', 'Initials': 'F', 'LastName': 'van Haren', 'Affiliation': 'Australian National University Medical School, Canberra, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Prowle', 'Affiliation': 'Critical Care and Preoperative Medicine Research Group, Centre for Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, UK.'}, {'ForeName': 'Ville', 'Initials': 'V', 'LastName': 'Pettilä', 'Affiliation': 'Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.'}, {'ForeName': 'Rinaldo', 'Initials': 'R', 'LastName': 'Bellomo', 'Affiliation': 'Department of Intensive Care, Austin Hospital, Melbourne, Australia.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13557'] 3145,32017598,Velocity-based resistance training: impact of velocity loss in the set on neuromuscular performance and hormonal response.,"This study aimed to compare the effects of 2 resistance training (RT) programs with different velocity losses (VLs) allowed in each set: 10% (VL10%) versus 30% (VL30%) on neuromuscular performance and hormonal response. Twenty-five young healthy males were randomly assigned into 2 groups: VL10% ( n = 12) or VL30% ( n = 13). Subjects followed a velocity-based RT program for 8 weeks (2 sessions per week) using only the full-squat (SQ) exercise at 70%-85% 1-repetition maximum (1RM). Repetition velocity was recorded in all training sessions. A 20-m running sprint, countermovement jump (CMJ), 1RM, muscle endurance, and electromyogram (EMG) during SQ exercise and resting hormonal concentrations were assessed before and after the RT program. Both groups showed similar improvements in muscle strength and endurance variables (VL10%: 7.0%-74.8%; VL30%: 4.2%-73.2%). The VL10% resulted in greater percentage increments in CMJ (9.2% vs. 5.4%) and sprint performance (-1.5% vs. 0.4%) than VL30%, despite VL10% performing less than half of the repetitions than VL30% during RT. In addition, only VL10% showed slight increments in EMG variables, whereas no significant changes in resting hormonal concentrations were observed. Therefore, our results suggest that velocity losses in the set as low as 10% are enough to achieve significant improvements in neuromuscular performance, which means greater efficiency during RT. Novelty The VL10% group showed similar or even greater percentage of changes in physical performance compared with VL30%. No significant changes in resting hormonal concentrations were observed for any training group. Curvilinear relationships between percentage VL in the set and changes in strength and CMJ performance were observed.",2020,Both groups showed similar improvements in muscle strength and endurance variables (VL10%: 7.0-74.8%; VL30%: 4.2-73.2%).,['Twenty-five young healthy males'],"['Velocity-based resistance training', 'resistance training (RT', 'full-squat (SQ) exercise']","['physical performance', 'EMG variables', 'muscle strength and endurance variables', 'neuromuscular performance and hormonal response', 'strength and CMJ performance', 'Repetition velocity', 'resting hormonal concentrations', 'Novelty bullets •', 'neuromuscular performance', 'velocity losses', '20-m running sprint, countermovement jump (CMJ), 1RM, muscle endurance and EMG during SQ exercise, and resting hormonal concentrations', 'sprint performance', 'CMJ']","[{'cui': 'C3715062', 'cui_str': '25'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}, {'cui': 'C0241236', 'cui_str': 'Does squat (finding)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C2607857'}, {'cui': 'C0013839', 'cui_str': 'Electromyography'}, {'cui': 'C0439828', 'cui_str': 'Variable (qualifier value)'}, {'cui': 'C0517349', 'cui_str': 'Muscle Strength'}, {'cui': 'C0518031', 'cui_str': 'Endurance capacity'}, {'cui': 'C0458083', 'cui_str': 'Hormonal (qualifier value)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0035253', 'cui_str': 'Rest'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0336699', 'cui_str': 'Bullet, device (physical object)'}, {'cui': 'C0600140', 'cui_str': 'Does run (finding)'}, {'cui': 'C0560453', 'cui_str': 'Does jump (finding)'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]",25.0,0.0196751,Both groups showed similar improvements in muscle strength and endurance variables (VL10%: 7.0-74.8%; VL30%: 4.2-73.2%).,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Rodríguez-Rosell', 'Affiliation': 'Physical Performance & Sports Research Center, Universidad Pablo de Olavide, Seville 41013, Spain.'}, {'ForeName': 'Juan Manuel', 'Initials': 'JM', 'LastName': 'Yáñez-García', 'Affiliation': 'Physical Performance & Sports Research Center, Universidad Pablo de Olavide, Seville 41013, Spain.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Mora-Custodio', 'Affiliation': 'Physical Performance & Sports Research Center, Universidad Pablo de Olavide, Seville 41013, Spain.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Pareja-Blanco', 'Affiliation': 'Physical Performance & Sports Research Center, Universidad Pablo de Olavide, Seville 41013, Spain.'}, {'ForeName': 'Antonio G', 'Initials': 'AG', 'LastName': 'Ravelo-García', 'Affiliation': 'Institute for Technological Development and Innovation in Communications, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria 35017, Spain.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Ribas-Serna', 'Affiliation': 'Department of Medical Physiology and Biophysics, University of Seville, Seville 41009, Spain.'}, {'ForeName': 'Juan José', 'Initials': 'JJ', 'LastName': 'González-Badillo', 'Affiliation': 'Physical Performance & Sports Research Center, Universidad Pablo de Olavide, Seville 41013, Spain.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0829'] 3146,31810741,Treating periodontal disease in patients with myocardial infarction: A randomized clinical trial.,"BACKGROUND Periodontitis has been associated with coronary artery disease, but the impact of a periodontal treatment on the endothelial function of patients with a recent ST-segment elevation myocardial infarction (STEMI) was not investigated. METHODS Randomized controlled trial (NCT02543502). Patients admitted between August 2012 and January 2015 were included. Patients were screened during the index hospitalization for STEMI, and those with severe periodontal disease were randomized 2 weeks later to periodontal treatment or to control. The primary endpoint of this trial was the between group difference in the variation of flow-mediated vasodilation (FMD) in the brachial artery assessed by ultrasound from baseline to the 6-month follow-up. Secondary outcomes were cardiovascular events, adverse effects of periodontal treatment and inflammatory markers. RESULTS Baseline characteristics were balanced between patients in the intervention (n = 24) and control groups (n = 24). There was a significant FMD improvement in the intervention group (3.05%; p = .01), but not in the control group (-0.29%; p = .79) (p = .03 for the intergroup comparison). Periodontal treatment was not associated with any adverse events and the inflammatory profile and cardiovascular events were not significantly different between both groups. CONCLUSIONS Treatment of periodontal disease improves the endothelial function of patients with a recent myocardial infarction, without adverse clinical events. Larger trials are needed to assess the benefit of periodontal treatment on clinical outcomes. CLINICAL TRIAL REGISTRATION NCT02543502 (https://clinicaltrials.gov/ct2/show/NCT02543502?term=NCT02543502&rank=1).",2020,"Periodontal treatment was not associated with any adverse events and the inflammatory profile and cardiovascular events were not significantly different between both groups. ","['Patients admitted between August 2012 and January 2015 were included', 'Patients were screened during the index hospitalization for STEMI, and those with severe periodontal disease', 'patients with a recent myocardial infarction', 'patients with myocardial infarction']",[],"['FMD improvement', 'cardiovascular events, adverse effects of periodontal treatment and inflammatory markers', 'endothelial function', 'adverse events and the inflammatory profile and cardiovascular events', 'variation of flow-mediated vasodilation (FMD']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0031090', 'cui_str': 'Parodontosis'}, {'cui': 'C1998297', 'cui_str': 'Recent myocardial infarction (situation)'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}]",[],"[{'cui': 'C1320716', 'cui_str': 'Cardiovascular event'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0042401', 'cui_str': 'Vasorelaxation'}]",,0.136165,"Periodontal treatment was not associated with any adverse events and the inflammatory profile and cardiovascular events were not significantly different between both groups. ","[{'ForeName': 'Marcelo G', 'Initials': 'MG', 'LastName': 'Lobo', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Marcia M', 'Initials': 'MM', 'LastName': 'Schmidt', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Renato D', 'Initials': 'RD', 'LastName': 'Lopes', 'Affiliation': 'Duke Clinical Research Institute, Durham, NC, USA; Federal University of São Paulo (USP), São Paulo, Brazil; Brazilian Clinical Research Institute, São Paulo, Brazil.'}, {'ForeName': 'Thiago', 'Initials': 'T', 'LastName': 'Dipp', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Ivan P', 'Initials': 'IP', 'LastName': 'Feijó', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Karine E S', 'Initials': 'KES', 'LastName': 'Schmidt', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Cristina A', 'Initials': 'CA', 'LastName': 'Gazeta', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Mariana L', 'Initials': 'ML', 'LastName': 'Azeredo', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Melissa', 'Initials': 'M', 'LastName': 'Markoski', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Lucia C', 'Initials': 'LC', 'LastName': 'Pellanda', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Carlos A M', 'Initials': 'CAM', 'LastName': 'Gottschall', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil.'}, {'ForeName': 'Alexandre S', 'Initials': 'AS', 'LastName': 'Quadros', 'Affiliation': 'Instituto de Cardiologia do Rio Grande do Sul/ Fundação Universitária de Cardiologia (IC/FUC), Porto Alegre, Brazil. Electronic address: consult.asq@gmail.com.'}]",European journal of internal medicine,['10.1016/j.ejim.2019.08.012'] 3147,31674202,"Cranberry, D-mannose and anti-inflammatory agents prevent lower urinary tract symptoms in women undergoing prolapse surgery.","Objective: We assessed the effect on lower urinary tract symptoms (LUTS) of a supplement containing cranberry, D-mannose and anti-inflammatory molecules in postmenopausal women undergoing surgery for cystocele. Study design: Forty postmenopausal women were randomized 1:1 to an active group receiving the nutritional supplement twice a day for 2 weeks starting from surgery, or to a control group receiving surgery only. Primary outcomes were the effectiveness in the postoperative LUTS and urinary tract infections (UTI). LUTS were investigated by a validated questionnaire (ICIQ-FLUTS) at baseline and at week 4. Secondary outcomes were the safety and tolerability of the supplement and other perioperative outcomes. Results: No significant differences were found in perioperative outcomes and in incidence of UTI. After surgery, women treated with the supplement experienced significantly better scores on the filling domain of the questionnaire. A non-significant decrease in voiding scores was also found. No adverse events were detected. Conclusion: The use of an oral supplement containing cranberry, D-mannose and anti-inflammatory molecules decreases the perception of LUTS in postmenopausal women after anterior colporraphy. Our data suggest that perioperative use of nutritional supplements may be useful in the management of postoperative LUTS.",2020,No significant differences were found in perioperative outcomes and in incidence of UTI.,"['women undergoing prolapse surgery', 'postmenopausal women after anterior colporraphy', 'postmenopausal women undergoing surgery for cystocele', 'Forty postmenopausal women']","['Cranberry, D-mannose and anti-inflammatory agents', 'oral supplement containing cranberry, D-mannose and anti-inflammatory molecules', 'active group receiving the nutritional supplement twice a day for 2 weeks starting from surgery, or to a control group receiving surgery only']","['perioperative outcomes and in incidence of UTI', 'adverse events', 'urinary tract symptoms', 'voiding scores', 'safety and tolerability of the supplement and other perioperative outcomes', 'effectiveness in the postoperative LUTS and urinary tract infections (UTI']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0033377', 'cui_str': 'Prolapse'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0205094', 'cui_str': 'Anterior (qualifier value)'}, {'cui': 'C1394494', 'cui_str': 'Bladder cystocele'}]","[{'cui': 'C0936050', 'cui_str': 'Cranberry'}, {'cui': 'C0024742', 'cui_str': 'Mannose'}, {'cui': 'C0003209', 'cui_str': 'Antiinflammatories'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C0567416', 'cui_str': 'Molecule (substance)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0242295', 'cui_str': 'Dietary Supplementations'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0042027'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1280519', 'cui_str': 'Effectiveness (qualifier value)'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}]",40.0,0.058457,No significant differences were found in perioperative outcomes and in incidence of UTI.,"[{'ForeName': 'E', 'Initials': 'E', 'LastName': 'Russo', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Montt Guevara', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Giannini', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Mannella', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Palla', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Caretto', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'F', 'Initials': 'F', 'LastName': 'Pancetti', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}, {'ForeName': 'A D', 'Initials': 'AD', 'LastName': 'Genazzani', 'Affiliation': 'Department of Obstetrics and Gynecology, Gynecological Endocrinology Center, University of Modena and Reggio Emilia, Modena, Italy.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Simoncini', 'Affiliation': 'Obstetrics and Gynecology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.'}]",Climacteric : the journal of the International Menopause Society,['10.1080/13697137.2019.1679110'] 3148,32017599,Interactions of sprint interval exercise and psychological need-support on subsequent food intake among physically inactive men and women.,"The aim of this study was to investigate the effect of sprint interval training (SIT) and psychological need-support in exercise on postexercise appetite and energy intake. Forty physically inactive men and women (body mass index, 24.6 ± 4.8 kg·m -2 ; peak oxygen consumption, 26.6 ± 4.9 mL·kg -1 ·min -1 ) were randomised to either a need-support or no-support condition, with each participant completing 2 experimental trials involving 30 min of moderate-intensity continuous training (MICT; 60% peak oxygen consumption) and SIT (alternating 15 s at 170% peak oxygen consumption and 60 s at 32% peak oxygen consumption) matched for total work. Perceptions of appetite and appetite-related blood variables were assessed, together with ad libitum energy intake for 3 h following exercise using a laboratory test meal and available snacks. Greater enjoyment, perceived exertion, heart rate, and blood lactate were observed in SIT compared with MICT (all p ≤ 0.006). Ratings of perceived appetite were similar across conditions and trials ( p > 0.05); however, active ghrelin was lower following SIT compared with MICT ( p < 0.001), and there was a significant condition-by-type interaction for energy intake ( p = 0.033), with participants in the support group consuming less energy from foods following SIT (1895 ± 1040 kJ) than MICT (2475 ± 1192 kJ). Findings from this work highlight the need to reconsider traditional exercise guidelines where dietary intake is a concern. Novelty Enjoyment was greater during SIT compared with MICT. Enjoyment and choice were higher among participants provided with psychological need-support. In a need-supportive environment, SIT reduced subsequent energy intake compared with MICT.",2020,- Enjoyment was greater during SIT compared with MICT - Enjoyment and choice were higher among participants provided with psychological need-support -,"['Forty physically inactive men and women (BMI 24.6 ± 4.8 kg·m-2, V̇O2peak 26.6 ± 4.9 mL·kg-1·min-1', 'physically inactive men and women']","['need-support or no-support condition, with each participant completing two experimental trials involving 30 min of moderate-intensity continuous cycling (MICT; 60% V̇O2peak) and SIT', 'sprint interval exercise and psychological need-support', 'sprint interval exercise (SIT) and psychological need-support in exercise']","[' Enjoyment', 'active ghrelin', 'Greater enjoyment, perceived exertion, heart rate, and blood lactate', 'Ratings of perceived appetite']","[{'cui': 'C0205254', 'cui_str': 'Inactive (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4517765', 'cui_str': '4.8 (qualifier value)'}]","[{'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4081855', 'cui_str': 'Moderate intensity'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C2584297', 'cui_str': 'Seated Position'}, {'cui': 'C1272706', 'cui_str': 'Interval'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}]","[{'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0911014', 'cui_str': 'Ghrelin (substance)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0015264', 'cui_str': 'Exertion, function (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005768'}, {'cui': 'C0202115', 'cui_str': 'Lactic acid measurement (procedure)'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}]",40.0,0.120476,- Enjoyment was greater during SIT compared with MICT - Enjoyment and choice were higher among participants provided with psychological need-support -,"[{'ForeName': 'Natalya J', 'Initials': 'NJ', 'LastName': 'Beer', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'James A', 'Initials': 'JA', 'LastName': 'Dimmock', 'Affiliation': 'Department of Psychology, College of Healthcare Sciences, James Cook University, Townsville, QLD 4811, Australia.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': 'Jackson', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}, {'ForeName': 'Kym J', 'Initials': 'KJ', 'LastName': 'Guelfi', 'Affiliation': 'School of Human Sciences (Exercise and Sport Science), The University of Western Australia, Perth, WA 6009, Australia.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0672'] 3149,32020044,Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.,"More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome. After establishing a safe lenalidomide, dose elderly patients with AML were randomly assigned in this randomized Phase 2 study (n = 222) to receive standard chemotherapy (""3 + 7"") with or without lenalidomide at a dose of 20 mg/day 1-21. In the second cycle, patients received cytarabine 1000 mg/m 2 twice daily on days 1-6 with or without lenalidomide (20 mg/day 1-21). The CR/CRi rates in the two arms were not different (69 vs. 66%). Event-free survival (EFS) at 36 months was 19% for the standard arm versus 21% for the lenalidomide arm and overall survival (OS) 35% vs. 30%, respectively. The frequencies and grade of adverse events were not significantly different between the treatment arms. Cardiovascular toxicities were rare and equally distributed between the arms. The results of the present study show that the addition of lenalidomide to standard remission induction chemotherapy does not improve the therapeutic outcome of older AML patients. This trial is registered as number NTR2294 in The NederlandsTrial Register (www.trialregister.nl).",2020,The frequencies and grade of adverse events were not significantly different between the treatment arms.,"['older AML patients', 'patients with acute myeloid leukemia (AML) of older age', 'elderly patients with AML', 'older patients with AML and high-risk MDS']","['Lenalidomide', 'cytarabine 1000\u2009mg/m 2 twice daily on days 1-6 with or without lenalidomide', 'standard chemotherapy (""3\u2009+\u20097"") with or without lenalidomide']","['frequencies and grade of adverse events', 'Event-free survival (EFS', 'CR/CRi rates', 'Cardiovascular toxicities', 'overall survival']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0023467', 'cui_str': 'Nonlymphoblastic Leukemia, Acute'}, {'cui': 'C1999167', 'cui_str': 'Old-age (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0265219', 'cui_str': 'Lissencephaly Syndrome, Miller-Dieker'}]","[{'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C0010711', 'cui_str': 'Cytarabine'}, {'cui': 'C1883310', 'cui_str': '1000 (qualifier value)'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C3179739', 'cui_str': '(LaCit2)3+'}]","[{'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C4551700', 'cui_str': 'Event-Free Survival'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}]",,0.103256,The frequencies and grade of adverse events were not significantly different between the treatment arms.,"[{'ForeName': 'G J', 'Initials': 'GJ', 'LastName': 'Ossenkoppele', 'Affiliation': 'Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands. g.ossenkoppele@amsterdamumc.nl.'}, {'ForeName': 'D A', 'Initials': 'DA', 'LastName': 'Breems', 'Affiliation': 'Netwerk Antwerpen, Antwerp, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Stuessi', 'Affiliation': 'Bellinzona-IOSI, Bellinzona, Switzerland.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'van Norden', 'Affiliation': 'HOVON Data Center, Erasmus MC- Department of Hematology, Rotterdam, The Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Bargetzi', 'Affiliation': 'Aarau- Kantonsspital, Aarau, Switzerland.'}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Biemond', 'Affiliation': 'Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'A von dem Borne', 'Affiliation': 'Leiden University Medical Center, Leiden, Netherlands.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Chalandon', 'Affiliation': 'University Hospital and University of Geneva, Genève, Switzerland.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Cloos', 'Affiliation': 'Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Deeren', 'Affiliation': 'Roeselare-AZ Delta, Roeselare, Belgium.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Fehr', 'Affiliation': 'St Gallen-Kantonnsspital, St. Gallen, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Gjertsen', 'Affiliation': 'Haukeland University Hospital, Bergen (N), Norway.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Graux', 'Affiliation': 'Yvoir-MontGodinne, Yvoir, Belgium.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Huls', 'Affiliation': 'University Medical Center, Groningen, Netherlands.'}, {'ForeName': 'J J J W', 'Initials': 'JJJW', 'LastName': 'Janssen', 'Affiliation': 'Amsterdam University Medical Cente, location VUMC, Amsterdam, Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Jaspers', 'Affiliation': 'Hôpital Citadelle, Liège (B), Belgium.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Jongen-Lavrencic', 'Affiliation': 'Erasmus University Medical Center, Rotterdam, Netherlands.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'de Jongh', 'Affiliation': 'Dordrecht ASZ, Dordrecht, Netherlands.'}, {'ForeName': 'S K', 'Initials': 'SK', 'LastName': 'Klein', 'Affiliation': 'Meander Medical Center, Amersfoort, Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'van der Klift', 'Affiliation': 'Amphia-Breda, Breda, Netherlands.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'van Marwijk Kooy', 'Affiliation': 'Isala Hospital, Zwolle, Netherlands.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Maertens', 'Affiliation': 'Hospital Gasthuisberg, Leuven (B), Belgium.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Michaux', 'Affiliation': 'Center for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.'}, {'ForeName': 'M W M', 'Initials': 'MWM', 'LastName': 'van der Poel', 'Affiliation': 'Maastricht University Medical Center, Maastricht, Netherlands.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'van Rhenen', 'Affiliation': 'UMC Utrecht, Utrecht, Netherlands.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Tick', 'Affiliation': 'MaximaMC Eindhoven, Eindhoven, Netherlands.'}, {'ForeName': 'P', 'Initials': 'P', 'LastName': 'Valk', 'Affiliation': 'Hôpital Citadelle, Liège (B), Belgium.'}, {'ForeName': 'M C', 'Initials': 'MC', 'LastName': 'Vekemans', 'Affiliation': 'Hôpital St Luc, Bruxelles, Belgium.'}, {'ForeName': 'W J F M', 'Initials': 'WJFM', 'LastName': 'van der Velden', 'Affiliation': 'Radboudumc Nijmegen, Nijmegen, Netherlands.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'de Weerdt', 'Affiliation': 'St Antonius Hospital, Nieuwegein, Netherlands.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Pabst', 'Affiliation': 'Department of Oncology, University Hospital, Inselspital and University of Bern, Bern, Switzerland.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Manz', 'Affiliation': 'University Hospital, Zurich, Switzerland.'}, {'ForeName': 'B', 'Initials': 'B', 'LastName': 'Löwenberg', 'Affiliation': 'Hôpital Citadelle, Liège (B), Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Leukemia,['10.1038/s41375-020-0725-0'] 3150,32015491,"Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.","Despite advances in chronic lymphocytic leukaemia (CLL) treatment, globally chemotherapy remains a central treatment modality, with chemotherapy trials representing an invaluable resource to explore disease-related/genetic features contributing to long-term outcomes. In 499 LRF CLL4 cases, a trial with >12 years follow-up, we employed targeted resequencing of 22 genes, identifying 623 mutations. After background mutation rate correction, 11/22 genes were recurrently mutated at frequencies between 3.6% (NFKBIE) and 24% (SF3B1). Mutations beyond Sanger resolution (<12% VAF) were observed in all genes, with KRAS mutations principally composed of these low VAF variants. Firstly, employing orthogonal approaches to confirm <12% VAF TP53 mutations, we assessed the clinical impact of TP53 clonal architecture. Whilst ≥ 12% VAF TP53mut cases were associated with reduced PFS and OS, we could not demonstrate a difference between <12% VAF TP53 mutations and either wild type or ≥12% VAF TP53mut cases. Secondly, we identified biallelic BIRC3 lesions (mutation and deletion) as an independent marker of inferior PFS and OS. Finally, we observed that mutated MAPK-ERK genes were independent markers of poor OS in multivariate survival analysis. In conclusion, our study supports using targeted resequencing of expanded gene panels to elucidate the prognostic impact of gene mutations.",2020,"After background mutation rate correction, 11/22 genes were recurrently mutated at frequencies between 3.6% (NFKBIE) and 24% (SF3B1).","['chronic lymphocytic leukaemia (CLL', 'chronic lymphocytic leukaemia', '499 LRF CLL4 cases, a trial with >12 years follow-up, we employed targeted resequencing of 22 genes, identifying 623 mutations']",[],"['PFS and OS', 'Mutations beyond Sanger resolution', 'biallelic BIRC3 lesions (mutation and deletion']","[{'cui': 'C0023434', 'cui_str': 'Lymphoma, Small Lymphocytic'}, {'cui': 'C0868928', 'cui_str': 'Case - situation (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0017337', 'cui_str': 'Genes'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}]",[],"[{'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C0221198', 'cui_str': 'Lesion (morphologic abnormality)'}, {'cui': 'C1442161', 'cui_str': 'Deletion (morphologic abnormality)'}]",,0.0594031,"After background mutation rate correction, 11/22 genes were recurrently mutated at frequencies between 3.6% (NFKBIE) and 24% (SF3B1).","[{'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Blakemore', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Ruth', 'Initials': 'R', 'LastName': 'Clifford', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Parker', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Pavlos', 'Initials': 'P', 'LastName': 'Antoniou', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ewa', 'Initials': 'E', 'LastName': 'Stec-Dziedzic', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Marta', 'Initials': 'M', 'LastName': 'Larrayoz', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Zadie', 'Initials': 'Z', 'LastName': 'Davis', 'Affiliation': 'Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.'}, {'ForeName': 'Latha', 'Initials': 'L', 'LastName': 'Kadalyayil', 'Affiliation': 'Genetic Epidemiology and Bioinformatics, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Colins', 'Affiliation': 'Genetic Epidemiology and Bioinformatics, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Pauline', 'Initials': 'P', 'LastName': 'Robbe', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Dimitris', 'Initials': 'D', 'LastName': 'Vavoulis', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jade', 'Initials': 'J', 'LastName': 'Forster', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Carr', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Ricardo', 'Initials': 'R', 'LastName': 'Morilla', 'Affiliation': 'Division of Molecular Pathology, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Monica', 'Initials': 'M', 'LastName': 'Else', 'Affiliation': 'Division of Molecular Pathology, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'Dean', 'Initials': 'D', 'LastName': 'Bryant', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'McCarthy', 'Affiliation': 'Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.'}, {'ForeName': 'Renata J', 'Initials': 'RJ', 'LastName': 'Walewska', 'Affiliation': 'Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Steele', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Chan', 'Affiliation': 'Oxford Gene Technology, Begbroke Science Park, Begbroke, Oxfordshire, UK.'}, {'ForeName': 'Graham', 'Initials': 'G', 'LastName': 'Speight', 'Affiliation': 'Oxford Gene Technology, Begbroke Science Park, Begbroke, Oxfordshire, UK.'}, {'ForeName': 'Tanja', 'Initials': 'T', 'LastName': 'Stankovic', 'Affiliation': 'Institute of Cancer and Genomic Sciences, College of Medical and Dental Services, IBR West, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Mark S', 'Initials': 'MS', 'LastName': 'Cragg', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Catovsky', 'Affiliation': 'Division of Molecular Pathology, The Institute of Cancer Research, London, UK.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'Oscier', 'Affiliation': 'Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.'}, {'ForeName': 'Matthew J J', 'Initials': 'MJJ', 'LastName': 'Rose-Zerilli', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Schuh', 'Affiliation': 'Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jonathan C', 'Initials': 'JC', 'LastName': 'Strefford', 'Affiliation': 'Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. jcs@soton.ac.uk.'}]",Leukemia,['10.1038/s41375-020-0723-2'] 3151,32016680,Changes in quality of life and sleep across the perinatal period in women with mood disorders.,"INTRODUCTION The perinatal period represents a time of significant life changes associated with increases in sleep difficulties, depression, and potentially impaired quality of life (QoL). Associations between QoL and sleep among women with perinatal depression are poorly understood, and changes in QoL across the perinatal period have received little attention. METHODS Participants were the treatment-as-usual group (n = 23) from a clinical trial testing an intervention for perinatal mood disorders. They completed the WHOQOL-Bref, had depression assessed with the HAM-D-17, and wore wrist actigraphs to estimate sleep for 1 week during third trimester and at 6 weeks postpartum. RESULTS Higher education level was associated with better environmental QoL during pregnancy (p = .044) and presence of older children was associated with worse social QoL postpartum (p = .045). Psychological health QoL worsened (p = .014) across the perinatal period. Total sleep time (p = .001) and sleep efficiency (p = .008) decreased from third trimester to postpartum week 6, but sleep measures were not associated with QoL at either time point. Depressive symptoms decreased from pregnancy to postpartum week 6 and were inversely associated with postpartum physical and social QoL (p = .031 and .048). DISCUSSION Factors contributing to self-rated QoL are variable across multiple domains during the perinatal period. QoL among our participants was lower than population norms. In our sample of women with depression and/or anxiety, QoL was related to postpartum depressive symptoms, but not to objectively measured sleep quality, quantity, or timing. Links between QoL and sleep may be inherently complex in perinatal women.",2020,Total sleep time (p = .001) and sleep efficiency,"['women with perinatal depression', 'women with mood disorders', 'Participants were the treatment-as-usual group (n\u2009=\u200923) from a clinical trial testing an intervention for perinatal mood disorders']",[],"['sleep efficiency', 'environmental QoL', 'worse social QoL postpartum', 'sleep difficulties, depression, and potentially impaired quality of life (QoL', 'quality of life and sleep', 'Total sleep time', 'Psychological health QoL', 'Depressive symptoms', 'postpartum physical and social QoL']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C4284586', 'cui_str': 'Perinatal depression'}, {'cui': 'C0525045', 'cui_str': 'Affective Disorders'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}]",[],"[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C1299586', 'cui_str': 'Difficulty'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",,0.0500581,Total sleep time (p = .001) and sleep efficiency,"[{'ForeName': 'A W', 'Initials': 'AW', 'LastName': 'Kang', 'Affiliation': 'Brown University, Providence, RI, USA.'}, {'ForeName': 'T B', 'Initials': 'TB', 'LastName': 'Pearlstein', 'Affiliation': 'Brown University, Providence, RI, USA.'}, {'ForeName': 'K M', 'Initials': 'KM', 'LastName': 'Sharkey', 'Affiliation': 'Brown University, Providence, RI, USA. Katherine_Sharkey@brown.edu.'}]","Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation",['10.1007/s11136-020-02437-1'] 3152,32017322,Effects of 12-month exercise intervention on physical and cognitive functions of nursing home residents requiring long-term care: a non-randomised pilot study.,"AIMS We performed a 12-month exercise intervention for 'nursing home for the elderly' residents requiring long-term care. We evaluated changes in their muscular strength, muscle mass, and cognitive function. METHODS Thirty-seven nursing home residents (Mini-Mental State Examination (MMSE): 14.7 ± 7.0, Barthel Index: 44.2 ± 18.9) were enrolled. We divided the participants into the exercise intervention group (n = 19) and non-intervention group (n = 18) ensuring no significant difference in the participants' characteristics at baseline. For the exercise intervention group, exercise was performed for about 40 min twice a week for 12 months. Skeletal Mass Index and grip force were determined to evaluate muscle mass and muscle strength, respectively. MMSE, Trail Making Test (TMT) part A, and Geriatric Depression Scale 15 (GDS15) were used for cognitive function evaluation, with their changes investigated. RESULTS After 12 months, the MMSE scores were significantly improved in the exercise intervention group compared with the non-intervention group (change from baseline to 12 months: Non-intervention: -1.0 ± 2.8, Intervention: 1.2 ± 3.0; P = 0.04). Moreover, the grip force of the dominant arm was significantly improved in the exercise intervention group compared with the non-intervention group (change from baseline to 12 months: Non-intervention: -1.3 ± 2.8 kg, Intervention: 1.4 ± 4.6 kg; P = 0.007). The prevalence of sarcopenia was significantly increased after 12 months compared with baseline in the non-intervention group (Non-intervention: 61.1% → 75.0%, Intervention: 77.8% → 71.4%; P < 0.02). There were no significant changes in GDS15, Barthel Index and TMT after 12 months in intervention and non-intervention groups. CONCLUSION Exercise intervention may be effectively used for improving the physical and cognitive functions of nursing home residents requiring long-term care.",2020,"There were no significant changes in GDS15, Barthel Index and TMT after 12 months in intervention and non-intervention groups. ","[""nursing home for the elderly' residents requiring long-term care"", 'nursing home residents requiring long-term care', 'Thirty-seven nursing home residents (Mini-Mental State Examination (MMSE): 14.7\u2009±\u20097.0, Barthel Index: 44.2\u2009±\u200918.9) were enrolled']","['exercise intervention', 'Exercise intervention']","['GDS15, Barthel Index and TMT', 'prevalence of sarcopenia', 'muscular strength, muscle mass, and cognitive function', 'MMSE scores', 'physical and cognitive functions', 'grip force', 'Skeletal Mass Index and grip force']","[{'cui': 'C0028688', 'cui_str': 'Nursing Homes'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0023977'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C4319569', 'cui_str': '37 (qualifier value)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0451019', 'cui_str': 'Barthel index (assessment scale)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C0451019', 'cui_str': 'Barthel index (assessment scale)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0872084', 'cui_str': 'Sarcopenias'}, {'cui': 'C0442025', 'cui_str': 'Muscular (qualifier value)'}, {'cui': 'C0240417', 'cui_str': 'Form of muscle (finding)'}, {'cui': 'C0392335', 'cui_str': 'Cognitive functions (observable entity)'}, {'cui': 'C0451306', 'cui_str': 'Folstein Mini-Mental State Examination'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0600117', 'cui_str': 'Does grip (finding)'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}]",,0.0211375,"There were no significant changes in GDS15, Barthel Index and TMT after 12 months in intervention and non-intervention groups. ","[{'ForeName': 'Akito', 'Initials': 'A', 'LastName': 'Tsugawa', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Soichiro', 'Initials': 'S', 'LastName': 'Shimizu', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Hirose', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Tomohiko', 'Initials': 'T', 'LastName': 'Sato', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Hirokuni', 'Initials': 'H', 'LastName': 'Hatanaka', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Naoto', 'Initials': 'N', 'LastName': 'Takenoshita', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Yoshitsugu', 'Initials': 'Y', 'LastName': 'Kaneko', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Yusuke', 'Initials': 'Y', 'LastName': 'Ogawa', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Hirofumi', 'Initials': 'H', 'LastName': 'Sakurai', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}, {'ForeName': 'Haruo', 'Initials': 'H', 'LastName': 'Hanyu', 'Affiliation': 'Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan.'}]",Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society,['10.1111/psyg.12517'] 3153,32017413,Effect of a hand massage with a warm hand bath on sleep and relaxation in elderly women with disturbance of sleep: A crossover trial.,"AIM The purpose of the present study was to clarify the effects of a hand massage with a warm hand bath on sleep, autonomic nervous activity, subjective sleep quality, and relaxation in elderly women with sleep disturbance. METHODS A crossover design was used. Participants were assigned to two groups: a structured control first and intervention second condition, or an intervention first and control second condition. The sleep index as assessed by actigraphy, autonomic nervous activity, subjective sleep quality, and relaxation was then recorded. RESULTS The mean age of the participants was 77.8 ± 6.8 years (n = 28). According to the actigraph, the intervention day showed significantly improved sleep efficiency (p = .048) and sleep onset latency (p = .015). Regarding autonomic nervous activity, heart rate decreased significantly after the intervention (p = .001), but no significant differences were seen in the other indexes. Subjective sleep quality, which was investigated using the middle-age and aged version of the Oguri-Shirakawa-Azumi sleep questionnaire, was significantly higher after the intervention for four out of five factors. Subjective comfort and relaxation were significantly higher after the intervention for all items. CONCLUSIONS A hand massage with a warm hand bath in the evening improved sleep efficiency and sleep onset latency in elderly women with sleep disturbance. These results suggest that a hand bath and massage may improve subjective sleep quality and relaxation.",2020,"According to the actigraph, the intervention day showed significantly improved sleep efficiency (p = .048) and sleep onset latency (p = .015).","['elderly women with disturbance of sleep', 'The mean age of the participants was 77.8\u2009±\u20096.8\u2009years (n = 28', 'elderly women with sleep disturbance']","['structured control first and intervention second condition, or an intervention first and control second condition', 'hand massage with a warm hand bath']","['sleep efficiency', 'autonomic nervous activity, heart rate', 'subjective sleep quality and relaxation', 'Subjective sleep quality', 'Subjective comfort and relaxation', 'sleep onset latency', 'sleep efficiency and sleep onset latency', 'sleep, autonomic nervous activity, subjective sleep quality, and relaxation', 'sleep index as assessed by actigraphy, autonomic nervous activity, subjective sleep quality, and relaxation']","[{'cui': 'C0524338', 'cui_str': 'Elderly woman (person)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0700201', 'cui_str': 'Dyssomnias'}]","[{'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0024875', 'cui_str': 'Massage'}, {'cui': 'C0424744', 'cui_str': 'Warm hands (finding)'}, {'cui': 'C0150141'}]","[{'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0013682', 'cui_str': 'Efficiency'}, {'cui': 'C0027769', 'cui_str': 'Nervousness'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0035028', 'cui_str': 'Relaxation'}, {'cui': 'C4505222', 'cui_str': 'REM Sleep Latency'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1171301', 'cui_str': 'Actigraphy'}]",28.0,0.0249553,"According to the actigraph, the intervention day showed significantly improved sleep efficiency (p = .048) and sleep onset latency (p = .015).","[{'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Kudo', 'Affiliation': 'Department of Basic Nursing, Akita University Graduate School of Health Sciences, Akita, Japan.'}, {'ForeName': 'Makiko', 'Initials': 'M', 'LastName': 'Sasaki', 'Affiliation': 'Department of Basic Nursing, Akita University Graduate School of Health Sciences, Akita, Japan.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12327'] 3154,31841482,"STATE OF COGNITIVE FUNCTIONS IN CHILDREN WITH PATHOLOGY OF DIGESTIVE ORGANS, WHO LIVE AT RADIOACTIVE CONTAMINATED TERRITORIES OF UKRAINE.","OBJECTIVE to study the state of cognitive functions in children who were born and permanently live at radioactive contaminated territories (RCT) with pathology of the upper digestive tract, using pathopsychological testing; to increase the effectiveness of treatment and prophylactic measures aimed at preserving and restoring the health of RCT residents. DESIGN, PATIENTS AND METHODS A randomized blind controlled clinical trial was conducted. There were examined, a total of 90 persons aged 6 to 17 years (35 boys and 55 girls) who were divided into two groups: the control group (I) included 30 persons of the conventional «clean» territories, and the main group (II) - 60 patients with patho- logy of the digestive organs who were born and live at the RCT. The study program included: the collection of anam- nesis, complaints; clinical and instrumental examinations. The following tests were applied by us: «What things are hidden in the drawings», Toulouse-Pieron, Raven, and Luria testing. For detecting the anxiety level, and the subjec- tive signs of autonomic dysfunctions were used the Spilberg-Hanin self-diagnosis and the Wein questionnaire, respectively. RESULTS It was shown that in children aged 6-11 years, according to the results of the Toulouse-Pieron test, speed of cognitive information-processing was significantly decreased by 7.17 conventional units, while on the back- ground of the etiopathogenetic treatment of the digestive tract - by 10.24 conventional units relative to the va- lues of the control group. The long-term memory was statistically significantly decreased in the examined children of senior school age (from 12 to 17 years). A significant increase in reactive anxiety and a reverse correlation between the personal anxiety (PA) and speed of cognitive information-processing (r = -0.331) were recorded in patients aged 6-11 years. In older patients, PA was increased.Сonclusions. The obtained results indicate that the state of cognitive functions was characterized by a decrease in speed of cognitive information-processing, long-term memory and a high level of anxiety in children aged from 6 to 17 years residents of RСT with pathology of digestive organs, according to the used testing.",2019,The long-term memory was statistically significantly decreased in the examined children of senior school age (from 12 to 17 years).,"['90 persons aged 6 to 17 years (35 boys and 55 girls) who were divided into two groups: the control group (I) included 30 persons of the conventional «clean» territories, and the main group (II) - 60 patients with patho- logy of the digestive organs who were born and live at the RCT', 'children aged 6-11 years', 'children who were born and permanently live at radioactive contaminated territories (RCT) with pathology of the upper digestive tract, using pathopsychological testing']",[],"['speed of cognitive information-processing', 'reactive anxiety', 'personal anxiety (PA) and speed of cognitive information-processing', 'speed of cognitive information-processing, long-term memory and a high level of anxiety']","[{'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0870221', 'cui_str': 'Boys'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0402683', 'cui_str': 'Cleaner'}, {'cui': 'C0205225', 'cui_str': 'Principal (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0227435', 'cui_str': 'Digestive organ structure'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0030664', 'cui_str': 'Pathology'}, {'cui': 'C0226874', 'cui_str': 'Upper digestive tract structure'}]",[],"[{'cui': 'C0021420', 'cui_str': 'Information Processing'}, {'cui': 'C0205332', 'cui_str': 'Reactive (qualifier value)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0423909', 'cui_str': 'Memory, Longterm'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0564474', 'cui_str': 'Level of anxiety (observable entity)'}]",90.0,0.0182724,The long-term memory was statistically significantly decreased in the examined children of senior school age (from 12 to 17 years).,"[{'ForeName': 'L M', 'Initials': 'LM', 'LastName': 'Lisukha', 'Affiliation': 'O. O. Bogomoletz Institute of Physiology of National Academy of Sciences of Ukraine, 4 Bogomoletz St., Kyiv, 01024, Ukraine.'}, {'ForeName': 'I Ye', 'Initials': 'IY', 'LastName': 'Kolpakov', 'Affiliation': 'State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka St., Kyiv, 04050, Ukraine.'}]",Problemy radiatsiinoi medytsyny ta radiobiolohii,['10.33145/2304-8336-2019-24-395-410'] 3155,32014432,Impact on mortality after implementation of a network for ST-segment elevation myocardial infarction care. The IPHENAMIC study.,"INTRODUCTION AND OBJECTIVES Little is known about the impact of networks for ST-segment elevation myocardial infarction (STEMI) care on the population. The objective of this study was to determine whether the PROGALIAM (Programa Gallego de Atención al Infarto Agudo de Miocardio) improved survival in northern Galicia. METHODS We collected all events coded as STEMI between 2001 and 2013. A total of 6783 patients were identified and divided into 2 groups: pre-PROGALIAM (2001-2005), with 2878 patients, and PROGALIAM (2006-2013), with 3905 patients. RESULTS In the pre-PROGALIAM period, 5-year adjusted mortality was higher both in the total population (HR, 1.22, 95%CI, 1.14-1.29; P <.001) and in each area (A Coruña: HR, 1.12; 95%CI, 1.02-1.23; P=.02; Lugo: HR, 1.34; 95%CI, 1.2-1.49; P <.001 and Ferrol: HR, 1.23; 95%CI, 1.1-1.4; P=.001). Before PROGALIAM, 5-year adjusted mortality was higher in the areas of Lugo (HR, 1.25; 95%CI, 1.05-1.49; P=.02) and Ferrol (HR, 1.32; 95%CI, 1.13-1.55; P=.001) than in A Coruña. These differences disappeared after the creation of the STEMI network (Lugo vs A Coruña: HR, 0.88; 95%CI, 0.72-1.06; P=.18, Ferrol vs A Coruña: HR, 1.04; 95%CI, 0.89-1.22; P=.58. CONCLUSIONS For patients with STEMI, the creation of PROGALIAM in northern Galicia decreased mortality and increased equity in terms of survival both overall and in each of the areas where it was implemented. This study was registered at ClinicalTrials.gov (Identifier: NCT02501070).",2020,"In the pre-PROGALIAM period, 5-year adjusted mortality was higher both in the total population (HR, 1.22, 95%CI, 1.14-1.29; P <.001) and in each area (A Coruña: HR, 1.12; 95%CI, 1.02-1.23; P=.02; Lugo: HR, 1.34; 95%CI, 1.2-1.49; P <.001 and Ferrol: HR, 1.23; 95%CI, 1.1-1.4; P=.001).","['6783 patients were identified and divided into 2 groups: pre-PROGALIAM (2001-2005), with 2878 patients, and PROGALIAM (2006-2013), with 3905 patients']",[],"['mortality', '5-year adjusted mortality']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}]",[],"[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",6783.0,0.313738,"In the pre-PROGALIAM period, 5-year adjusted mortality was higher both in the total population (HR, 1.22, 95%CI, 1.14-1.29; P <.001) and in each area (A Coruña: HR, 1.12; 95%CI, 1.02-1.23; P=.02; Lugo: HR, 1.34; 95%CI, 1.2-1.49; P <.001 and Ferrol: HR, 1.23; 95%CI, 1.1-1.4; P=.001).","[{'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Aldama', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. Electronic address: guillermo.aldama.lopez@sergas.es.'}, {'ForeName': 'Manuel', 'Initials': 'M', 'LastName': 'López', 'Affiliation': 'Servicio de Cardiología, Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain.'}, {'ForeName': 'Melisa', 'Initials': 'M', 'LastName': 'Santás', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Lucus Augusti, Lugo, Spain.'}, {'ForeName': 'Xacobe', 'Initials': 'X', 'LastName': 'Flores', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'Piñón', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Salgado', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}, {'ForeName': 'Ramón', 'Initials': 'R', 'LastName': 'Calviño', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}, {'ForeName': 'Nicolás', 'Initials': 'N', 'LastName': 'Vázquez', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Mesías', 'Affiliation': 'Servicio de Cardiología, Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'González-Juanatey', 'Affiliation': 'Servicio de Cardiología, Hospital Universitario Lucus Augusti, Lugo, Spain.'}, {'ForeName': 'Javier', 'Initials': 'J', 'LastName': 'Muñiz', 'Affiliation': 'Instituto Universitario de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain; Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.'}, {'ForeName': 'José Manuel', 'Initials': 'JM', 'LastName': 'Vázquez', 'Affiliation': 'Servicio de Cardiología, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain.'}]",Revista espanola de cardiologia (English ed.),['10.1016/j.rec.2019.09.031'] 3156,32017923,Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring.,"BACKGROUND Maternal obesity increases the risk for pregnancy complications and adverse neonatal outcome and has been associated with long-lasting adverse effects in the offspring, including increased body fat mass, insulin resistance, and increased risk for premature cardiovascular disease. Lifestyle interventions in pregnancy have produced no or modest effects in the reduction of adverse pregnancy outcomes in obese mothers. The Metformin in Obese Pregnant Women trial was associated with reduced adverse pregnancy outcomes and had no effect on birthweight. However, the long-term implications of metformin on the health of offspring remain unknown. OBJECTIVE The purpose of this study was to assess whether prenatal exposure to metformin can improve the cardiovascular profile and body composition in the offspring of obese mothers. STUDY DESIGN In 151 children from the Metformin in Obese Pregnant Women trial, body composition, peripheral blood pressure, and arterial pulse wave velocity were measured. Central hemodynamics (central blood pressure and augmentation index) were estimated with the use of an oscillometric device. Left ventricular cardiac function and structure were assessed by echocardiography. RESULTS Children were 3.9±1.0 years old, and 77 of them had been exposed to metformin prenatally. There was no significant difference in peripheral blood pressure, arterial stiffness, and body composition apart from gluteal and tricep circumferences, which were lower in the metformin group (P<.05). The metformin group, compared with the placebo group, had lower central hemodynamics (mean adjusted decrease, -0.707 mm Hg for aortic systolic blood pressure, -1.65 mm Hg for aortic pulse pressure, and -2.68% for augmentation index; P<.05 for all) and lower left ventricular diastolic function (adjusted difference in left atrial area, -0.525 cm 2 , in isovolumic relaxation time, -0.324 msec, and in pulmonary venous systolic wave, 2.97 cm/s; P<.05 for all). There were no significant differences in metabolic profile between the groups. CONCLUSION Children of obese mothers who were exposed prenatally to metformin, compared with those who were exposed to placebo, had lower central hemodynamic and cardiac diastolic indices. These results suggest that the administration of metformin in obese pregnant women potentially may have a beneficial cardiovascular effect for their offspring.",2020,"The metformin, compared to the placebo group, had lower central hemodynamics (mean adjusted decrease -0.707mmHg for aortic systolic blood pressure, -1.65mmHg for aortic pulse pressure and -2.68% for augmentation index, p<0.05 for all) and lower left ventricular diastolic function (adjusted difference in left atrial area -0.525cm 2 , in isovolumic relaxation time -0.324msec and in pulmonary venous systolic wave 2.97cm/s, p<0.05 for all).","['offspring of obese mothers', 'Children of obese mothers', 'Obese mothers', 'obese mothers', '151 children from the', 'Children were 3.9±1.0 years of age and 77 were exposed to metformin prenatally', 'obese pregnant women', 'Obese Pregnant women trial']","['metformin', 'placebo', 'Metformin']","['metabolic profile', 'cardiovascular profile and body composition', 'adverse pregnancy outcomes', 'Central hemodynamics (central blood pressure and augmentation index', 'lower central hemodynamics', 'body composition, peripheral blood pressure and arterial pulse wave velocity', 'peripheral blood pressure, arterial stiffness and body composition apart from gluteal and tricep circumferences', 'aortic systolic blood pressure, -1.65mmHg for aortic pulse pressure', 'central hemodynamic and cardiac diastolic indices', 'left ventricular diastolic function', 'birthweight']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0680063', 'cui_str': 'Child of (finding)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}]","[{'cui': 'C0025598', 'cui_str': 'Metformin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C3853758', 'cui_str': 'Metabolic Profile'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0032972', 'cui_str': 'Pregnancy Outcome'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1293122', 'cui_str': 'Augmentation procedure'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0229664', 'cui_str': 'Peripheral blood (substance)'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C3494431', 'cui_str': 'Pulse Wave Velocity'}, {'cui': 'C0599949', 'cui_str': 'Arterial Stiffness'}, {'cui': 'C0332520', 'cui_str': 'Circumference'}, {'cui': 'C0003483', 'cui_str': 'Aorta'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C3494282', 'cui_str': 'Aortic Pulse Pressure'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}]",151.0,0.0623254,"The metformin, compared to the placebo group, had lower central hemodynamics (mean adjusted decrease -0.707mmHg for aortic systolic blood pressure, -1.65mmHg for aortic pulse pressure and -2.68% for augmentation index, p<0.05 for all) and lower left ventricular diastolic function (adjusted difference in left atrial area -0.525cm 2 , in isovolumic relaxation time -0.324msec and in pulmonary venous systolic wave 2.97cm/s, p<0.05 for all).","[{'ForeName': 'Olga', 'Initials': 'O', 'LastName': 'Panagiotopoulou', 'Affiliation': ""School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.""}, {'ForeName': 'Argyro', 'Initials': 'A', 'LastName': 'Syngelaki', 'Affiliation': ""Harris Birthright Research Centre for Fetal Medicine, Fetal Medicine Research Institute, King's College Hospital, London, UK.""}, {'ForeName': 'Georgios', 'Initials': 'G', 'LastName': 'Georgiopoulos', 'Affiliation': ""School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.""}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Simpson', 'Affiliation': ""School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.""}, {'ForeName': 'Ranjit', 'Initials': 'R', 'LastName': 'Akolekar', 'Affiliation': 'Fetal Medicine Unit, Medway Maritime Hospital, Gillingham, UK.'}, {'ForeName': 'Hassan', 'Initials': 'H', 'LastName': 'Shehata', 'Affiliation': 'Department of Maternal Medicine, Epsom and St Helier University Hospitals NHS Trust, Surrey, UK.'}, {'ForeName': 'Kypros', 'Initials': 'K', 'LastName': 'Nicolaides', 'Affiliation': ""Harris Birthright Research Centre for Fetal Medicine, Fetal Medicine Research Institute, King's College Hospital, London, UK.""}, {'ForeName': 'Marietta', 'Initials': 'M', 'LastName': 'Charakida', 'Affiliation': ""Harris Birthright Research Centre for Fetal Medicine, Fetal Medicine Research Institute, King's College Hospital, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK. Electronic address: Marietta.charakida@kcl.ac.uk.""}]",American journal of obstetrics and gynecology,['10.1016/j.ajog.2020.01.054'] 3157,32019278,PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.,"PURPOSE PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CA mutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. Materials and Methods A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues. RESULTS Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056). CONCLUSION TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracycline-based neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.",2020,"Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio [OR], 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047).","['92 patients with TNBC', 'Triple-Negative Breast Cancer Patients Treated with']","['Anthracycline-Taxane-Based Neoadjuvant Chemotherapy', 'PIK3CA mutation and pCR', 'anthracycline-based neoadjuvant chemotherapy', 'neoadjuvant chemotherapy']",['pCR rate'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3539878', 'cui_str': 'Triple Negative Breast Cancer'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0282564', 'cui_str': 'Anthracyclines'}, {'cui': 'C0796419', 'cui_str': 'Taxanes'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C0026882', 'cui_str': 'Mutation'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}]","[{'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}]",92.0,0.0339473,"Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio [OR], 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047).","[{'ForeName': 'Sanxing', 'Initials': 'S', 'LastName': 'Guo', 'Affiliation': 'Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.'}, {'ForeName': 'Sibylle', 'Initials': 'S', 'LastName': 'Loibl', 'Affiliation': 'German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Gunter', 'Initials': 'G', 'LastName': 'von Minckwitz', 'Affiliation': 'German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Darb-Esfahani', 'Affiliation': 'Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Bianca', 'Initials': 'B', 'LastName': 'Lederer', 'Affiliation': 'German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Carsten', 'Initials': 'C', 'LastName': 'Denkert', 'Affiliation': 'Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",Cancer research and treatment : official journal of Korean Cancer Association,['10.4143/crt.2019.497'] 3158,31841496,THE USAGE OF RADIOFREQUENCY ABLATION FOR TREATMENT OF KELOIDS AND HYPERTROPHIC SCARS.,"OBJECTIVE To evaluate the effectiveness of radiofrequency ablation (RFA) for scars tissue volume reduction, and influence on the clinical manifestations of keloid and hypertrophic scars. MATERIALS AND METHODS Seventeen patients (9 males, 8 females), 19-62 years old, with some scars were enrolled into the prospective randomized controlled study: 10 with keloids, 7 with hypertrophic scars. Previous failed attempts to correct the scars were undertaken in 8 patients with keloids and in 3 patients with hypertrophic scars. The efficacy of four scar volume reduction methods was compared (12 scars in each group, 5 sessions at 10-day inter- vals): the first group - RFA, the second - intralesional 5-fluorouracil (5-FU) injections, the third - RFA followed by 5-FU injections and the fourth - RFA, injections of verapamil and then 5-FU. RESULTS The scars volume reduction was faster after RFA (by 65.3 %) than after chemotherapy. Local verapamil application after RFA followed by 5-FU injections reduced scar volume after the fifth session by 78.3 %. Relieving of the associated symptoms and scars hyperaemia was faster after RFA than after cytostatic drug administration. Their simultaneous application, especially in combination with verapamil, intensified the effect. There were no infectious complications and haemorrhages. Ulcers 3-5 mm in diameter in the place of puncture on one scar in the first group, on two scars in the third and fourth groups were registered as the side effects. Seventeen scars in seven patients, who received RFA as a monotherapy or in combination with chemotherapy, were assessed 6 months after treatment. The average scars volume decreased from (3260.5 ± 2057.36) mm3 at the moment after the fifth session to (2110.6 ± 1296.16) mm3, p = 0.0033. CONCLUSIONS Scars volume reduction was faster after five sessions of RFA than following local 5-FU injections. Combination of RFA with scars infiltration with verapamil and 5-FU strengthened the effect. In the same way, the above-mentioned methods influenced clinical symptomatology associated with the scars. Scars hyperaemia was also reduced by RFA. Radiofrequency ablation of excess scar tissue is advisable to use as an initial method for the treat- ment of keloids and hypertrophic scars, since it is easy to carry, is not expensive and effectively reduces the scar vol- ume, demonstrating the patient the opportunity to achieve a positive result.",2019,Relieving of the associated symptoms and scars hyperaemia was faster after RFA than after cytostatic drug administration.,"['Seventeen patients (9 males, 8 females), 19-62 years old, with some scars were enrolled into the prospective randomized controlled study: 10 with keloids, 7 with hypertrophic scars', '8 patients with keloids and in 3 patients with hypertrophic scars']","['verapamil and then 5-FU', '5-FU injections', 'Radiofrequency ablation', 'radiofrequency ablation (RFA', '5-fluorouracil (5-FU) injections, the third - RFA followed by 5-FU injections', 'verapamil and 5-FU', 'Local verapamil', 'RFA', 'verapamil']","['scars volume reduction', 'clinical symptomatology', 'average scars volume', 'scar volume', 'Scars hyperaemia', 'symptoms and scars hyperaemia']","[{'cui': 'C0450331', 'cui_str': '17 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0022548', 'cui_str': 'Keloid'}, {'cui': 'C0162810', 'cui_str': 'Scars, Hypertrophic'}]","[{'cui': 'C0042523', 'cui_str': 'Verapamil'}, {'cui': 'C0016360', 'cui_str': 'Fluorouracil'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0850292', 'cui_str': 'Radio Frequency Ablation'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}]","[{'cui': 'C0008767', 'cui_str': 'Cicatrization'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0020452', 'cui_str': 'Hyperemia'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",,0.0135524,Relieving of the associated symptoms and scars hyperaemia was faster after RFA than after cytostatic drug administration.,"[{'ForeName': 'V', 'Initials': 'V', 'LastName': 'Teplyi', 'Affiliation': 'Bogomolets National Medical University, 13 T. Shevchenko Blvd., Kyiv, 01601, Ukraine.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Grebchenko', 'Affiliation': 'Bogomolets National Medical University, 13 T. Shevchenko Blvd., Kyiv, 01601, Ukraine.'}]",Problemy radiatsiinoi medytsyny ta radiobiolohii,['10.33145/2304-8336-2019-24-561-573'] 3159,31235428,Early laparoscopic cholecystectomy reduces hospital stay in mild gallstone pancreatitis. A randomized controlled trial.,"BACKGROUND Two strategies for same-admission cholecystectomy in mild gallstone pancreatitis (MGP) exist: early surgery (within 48-72 h from admission) and delayed surgery until resolution of symptoms and normalization of pancreatic tests. METHODS This was a single-center, open-label RCT. Patients with MGP according to revised Atlanta classification-2012 and SIRS criteria were randomly assigned to early laparoscopic cholecystectomy (E-LC) within 72 h from admission or delayed laparoscopic cholecystectomy (D-LC). Laparoscopic-endoscopic rendezvous was performed when common bile duct stones were found at systematic intraoperative cholangiography. The primary outcome was length of stay (LOS), and the secondary outcomes were complications at 90 days, need for ERCP/choledocolithiasis, conversion, and re-admission. One year of follow-up was carried-on. RESULTS At interim analysis, 52 patients were randomized (26 E-LC, 26 D-LC). E-LC versus D-LC was associated with a significantly shorter LOS (median 58 versus 167 h; P = 0.001). There were no differences in ERCP necessity for choledocolithiasis between the two approaches (E-LC 26.9% versus D-LC 23.1%, P = 1.00). No differences in postoperative complications were found. CONCLUSIONS E-LC approach in patients with MGP significantly reduced LOS and was not associated with clinically relevant postoperative complications. TRIAL REGISTRATION clinicaltrials.gov (NCT02590978).",2020,"There were no differences in ERCP necessity for choledocolithiasis between the two approaches (E-LC 26.9% versus D-LC 23.1%, P = 1.00).","['mild gallstone pancreatitis', 'Patients with MGP according to revised Atlanta classification-2012 and SIRS criteria']","['early laparoscopic cholecystectomy (E-LC) within 72\xa0h from admission or delayed laparoscopic cholecystectomy (D-LC', 'laparoscopic cholecystectomy', 'Laparoscopic-endoscopic rendezvous']","['postoperative complications', 'length of stay (LOS), and the secondary outcomes were complications at 90 days, need for ERCP/choledocolithiasis, conversion, and re-admission', 'ERCP necessity for choledocolithiasis', 'LOS', 'hospital stay']","[{'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0521614', 'cui_str': 'Gallstone pancreatitis (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0008903', 'cui_str': 'taxonomy'}, {'cui': 'C0242966', 'cui_str': 'Sepsis Syndrome'}, {'cui': 'C0243161', 'cui_str': 'criteria'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0162522', 'cui_str': 'Cholecystectomy, Celioscopic'}]","[{'cui': 'C0032787', 'cui_str': 'Postoperative Complications'}, {'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0439836', 'cui_str': 'Conversions (qualifier value)'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}]",52.0,0.244939,"There were no differences in ERCP necessity for choledocolithiasis between the two approaches (E-LC 26.9% versus D-LC 23.1%, P = 1.00).","[{'ForeName': 'Francisco', 'Initials': 'F', 'LastName': 'Riquelme', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile; University of Chile, Santiago, Chile. Electronic address: riquelmefran@gmail.com.'}, {'ForeName': 'Boris', 'Initials': 'B', 'LastName': 'Marinkovic', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile; University of Chile, Santiago, Chile.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'Salazar', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Waldo', 'Initials': 'W', 'LastName': 'Martínez', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Catan', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Sebastián', 'Initials': 'S', 'LastName': 'Uribe-Echevarría', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile; University of Chile, Santiago, Chile.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Puelma', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Jorge', 'Initials': 'J', 'LastName': 'Muñoz', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Canals', 'Affiliation': 'University of Chile, Santiago, Chile.'}, {'ForeName': 'Cristian', 'Initials': 'C', 'LastName': 'Astudillo', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile.'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Uribe', 'Affiliation': 'Department of Surgery, Hospital del Salvador, Santiago, Chile; University of Chile, Santiago, Chile.'}]",HPB : the official journal of the International Hepato Pancreato Biliary Association,['10.1016/j.hpb.2019.05.013'] 3160,31662210,The effect of executive function on adherence with a cardiac secondary prevention program and its interaction with an incentive-based intervention.,"Participation in secondary prevention programs such as cardiac rehabilitation (CR) reduces morbidity, mortality, and hospitalizations while improving quality of life. Executive function (EF) is a complex set of cognitive abilities that control and regulate behavior. EF predicts many health-related behaviors, but how EF interacts with interventions to improve treatment adherence is not well understood. The objective of this study is to examine if EF predicts CR treatment adherence and how EF interacts with an intervention to improve adherence. Data were collected from 2013 to 2018 in Vermont, USA. 130 Medicaid-enrolled individuals who had experienced a qualifying cardiac event were enrolled in a controlled clinical trial and randomized 1:1 to receive financial incentives for completing secondary prevention sessions or to usual care. In this secondary analysis, effects of EF on CR adherence (defined as completing ≥30/36 sessions) were examined in 112 participants (57 usual care, 55 intervention) who completed an EF battery. Delay-discounting, a measure of impulsivity, predicted CR adherence (p = 0.01) and interacted with the incentive intervention, such that those who exhibited greater discounting of future rewards benefitted more from the intervention than those who discounted less (F(1, 104) = 5.23, p = 0.02). Better cognitive flexibility, measured with the trail-making-task, also predicted CR adherence (p = 0.02). While EF has been associated with adherence to a variety of treatment regimens, this interaction between an incentive-based intervention to promote treatment adherence and EF is novel. This work illustrates the value of considering individual differences in EF when designing and implementing interventions to promote health-related behavior change.",2019,"Better cognitive flexibility, measured with the trail-making-task, also predicted CR adherence (p = 0.02).","['130 Medicaid-enrolled individuals who had experienced a qualifying cardiac event', '112 participants (57 usual care, 55 intervention) who completed an EF battery']","['financial incentives for completing secondary prevention sessions or to usual care', 'executive function', 'EF']","['Delay-discounting, a measure of impulsivity, predicted CR adherence', 'cardiac rehabilitation (CR) reduces morbidity, mortality, and hospitalizations while improving quality of life', 'CR adherence', 'Better cognitive flexibility']","[{'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C4319548', 'cui_str': '112'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0542351', 'cui_str': 'Battery (event)'}]","[{'cui': 'C0021147', 'cui_str': 'Incentives'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0679699', 'cui_str': 'Disease Prevention, Secondary'}, {'cui': 'C0935584', 'cui_str': 'Executive Control'}]","[{'cui': 'C3850035', 'cui_str': 'Intertemporal Decision Making'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0021125', 'cui_str': 'Impulsivity'}, {'cui': 'C0700431', 'cui_str': 'Cardiovascular Rehabilitation'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0026538', 'cui_str': 'Morbidity'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0332272', 'cui_str': 'Better (qualifier value)'}, {'cui': 'C0242808', 'cui_str': 'Flexibility'}]",130.0,0.0366044,"Better cognitive flexibility, measured with the trail-making-task, also predicted CR adherence (p = 0.02).","[{'ForeName': 'Diann E', 'Initials': 'DE', 'LastName': 'Gaalema', 'Affiliation': 'University of Vermont, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America. Electronic address: dgaalema@uvm.edu.'}, {'ForeName': 'Sarahjane', 'Initials': 'S', 'LastName': 'Dube', 'Affiliation': 'University of Vermont, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America.'}, {'ForeName': 'Alexandra', 'Initials': 'A', 'LastName': 'Potter', 'Affiliation': 'University of Vermont, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America.'}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Elliott', 'Affiliation': 'University of Vermont, United States of America.'}, {'ForeName': 'Katharine', 'Initials': 'K', 'LastName': 'Mahoney', 'Affiliation': 'University of Vermont, United States of America.'}, {'ForeName': 'Stacey C', 'Initials': 'SC', 'LastName': 'Sigmon', 'Affiliation': 'University of Vermont, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America.'}, {'ForeName': 'Stephen T', 'Initials': 'ST', 'LastName': 'Higgins', 'Affiliation': 'University of Vermont, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America.'}, {'ForeName': 'Philip A', 'Initials': 'PA', 'LastName': 'Ades', 'Affiliation': 'University of Vermont, United States of America; University of Vermont Medical Center, United States of America; Vermont Center on Behavior and Health, Burlington, VT, United States of America.'}]",Preventive medicine,['10.1016/j.ypmed.2019.105865'] 3161,31201046,Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II.,"Spinal muscular atrophy (SMA) is an autosomal recessive disease caused by homozygous deletions or loss-of-function mutations in SMN1, which result in a degeneration of motor neurons in the spinal cord and brain stem. Even without a randomized placebo-controlled trial, salbutamol has been offered to patients with SMA in the neuromuscular clinics of most of hospitals for many years. We describe the response to salbutamol in 48 patients with SMA type II who were not taking any other medication. We investigate the changes over an eighteen-month period in motor functional scales and we analyze side effects and subjective response to treatment. Our results suggest that oral administration of salbutamol might be helpful in the maintenance of motor function in patients with SMA type II. An apparent beneficial effect was observed in functional scales of children under the age of 6, especially during the first 6 months of therapy. The majority of patients of all ages referred some kind of subjective positive effect associated with therapy intake. Salbutamol seemed safe and was well tolerated without serious side effects.",2019,"An apparent beneficial effect was observed in functional scales of children under the age of 6, especially during the first 6 months of therapy.","['patients with SMA in the neuromuscular clinics of most of hospitals for many years', 'patients with spinal muscular atrophy type II', 'patients with SMA type II', '48 patients with SMA type II who were not taking any other medication']","['salbutamol', 'placebo', 'Salbutamol']","['Salbutamol tolerability and efficacy', 'tolerated without serious side effects', 'functional scales']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3839056', 'cui_str': 'Neuromuscular clinic (environment)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0393538', 'cui_str': 'Spinal Muscular Atrophy Type 2'}, {'cui': 'C0441730', 'cui_str': 'Type 2 (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0001927', 'cui_str': 'Albuterol'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0222045'}]",48.0,0.0366672,"An apparent beneficial effect was observed in functional scales of children under the age of 6, especially during the first 6 months of therapy.","[{'ForeName': 'A L', 'Initials': 'AL', 'LastName': 'Frongia', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Natera-de Benito', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain. Electronic address: dnatera@sjdhospitalbarcelona.org.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Ortez', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Alarcón', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Borrás', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Medina', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Vigo', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Padrós', 'Affiliation': 'Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'O', 'Initials': 'O', 'LastName': 'Moya', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Armas', 'Affiliation': 'Department of Rehabilitation and Physical Medicine, Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Carrera-García', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Expósito-Escudero', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Cuadras', 'Affiliation': 'Statistics Department, Fundacio Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Bernal', 'Affiliation': 'Department of Genetics, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Martorell', 'Affiliation': 'Department of Genetics, Hospital Sant Joan de Deu, Barcelona, Spain.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Colomer', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Nascimento', 'Affiliation': 'Neuromuscular Unit, Neuropaediatrics Department, Institut de Recerca Hospital Universitari Sant Joan de Deu, Barcelona, Spain; Center for the Biomedical Research on Rare Diseases (CIBERER), ISCIII, Spain.'}]",Neuromuscular disorders : NMD,['10.1016/j.nmd.2019.04.003'] 3162,31865333,Effect of Intradialytic Exercise on Physical Performance and Cardiovascular Risk Factors in Patients Receiving Maintenance Hemodialysis: A Pilot and Feasibility Study.,"INTRODUCTION Although intradialytic exercise is considered a form of ""nonpharmacological medicine"" for patients receiving maintenance hemodialysis (MHD), this practice has not been widely implemented in most dialysis centers because of clinical limitations. We, therefore, aimed to design an intradialytic exercise training program to improve the implementation of this practice and determine its impact on physical performance and cardiovascular risk factors in patients receiving MHD. METHODS A total of 132 MHD patients at 4 outpatient dialysis units were enrolled and assigned randomly into exercise (n = 67) and control groups (n = 65). During a 2-year period, patients in the exercise group participated in 20-min exercise training sessions within dialysis sessions on 3 days per week. All patients underwent assessments of physical function (6-min walk test) and cardiovascular risk factors (blood pressure [BP], total cholesterol [TC], low-density lipoprotein [LDL], high-sensitivity C-reactive protein [hsCRP], albumin [Alb], hemoglobin [Hb], and erythropoietin [EPO] dose) at the baseline and annually thereafter. RESULTS Of the participants, 50.8% had completed the study after 2 years. No statistically significant intragroup or intergroup differences were observed in the measures of 6MD, BP, TC, hsCRP, Alb, Hb, and EPO dose. CONCLUSION The results suggest that although this low-intensity, nonprogressive intradialytic exercise program may be practical, it was not sufficient to improve physiological function and reduce cardiovascular disease risk factors in patients receiving MHD.",2020,"No statistically significant intragroup or intergroup differences were observed in the measures of 6MD, BP, TC, hsCRP, Alb, Hb, and EPO dose. ","['patients receiving maintenance hemodialysis (MHD', '132 MHD patients at 4 outpatient dialysis units', 'patients receiving MHD', 'Patients Receiving Maintenance Hemodialysis']","['intradialytic exercise training program', '20-min exercise training sessions', 'intradialytic exercise', 'Intradialytic Exercise']","['Physical Performance and Cardiovascular Risk Factors', 'physical performance and cardiovascular risk factors', 'physical function (6-min walk test) and cardiovascular risk factors (blood pressure [BP], total cholesterol [TC], low-density lipoprotein [LDL], high-sensitivity C-reactive protein [hsCRP], albumin [Alb], hemoglobin [Hb], and erythropoietin [EPO] dose', '6MD, BP, TC, hsCRP, Alb, Hb, and EPO dose']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4040576', 'cui_str': 'Maintenance hemodialysis'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C1629858', 'cui_str': 'Dialysis unit'}]","[{'cui': 'C4279936', 'cui_str': 'Exercise Training'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C2607857'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0312418', 'cui_str': 'Sensitivity (finding)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C3711292', 'cui_str': '68Ga-albumin'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}, {'cui': 'C0014822', 'cui_str': 'Erythropoietin'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0912730', 'cui_str': 'aluminum boride'}]",132.0,0.0230089,"No statistically significant intragroup or intergroup differences were observed in the measures of 6MD, BP, TC, hsCRP, Alb, Hb, and EPO dose. ","[{'ForeName': 'Yan-Jiao', 'Initials': 'YJ', 'LastName': 'Cheng', 'Affiliation': 'Department of Nephrology, China Rehabilitation Research Center, Beijing Boai Hospital, Capital Medical University Rehabilitation Medical College, Beijing, China.'}, {'ForeName': 'Xin-Ju', 'Initials': 'XJ', 'LastName': 'Zhao', 'Affiliation': ""Department of Nephrology, Peking University People's Hospital, Beijing, China.""}, {'ForeName': 'Wen', 'Initials': 'W', 'LastName': 'Zeng', 'Affiliation': 'Department of Nephrology, ChuiYangLiu Hospital Affiliated with Tsinghua University, Beijing, China.'}, {'ForeName': 'Ming-Cheng', 'Initials': 'MC', 'LastName': 'Xu', 'Affiliation': 'Department of Nephrology, Beijing Zhanlanlu Hospital, Beijing, China.'}, {'ForeName': 'Ying-Chun', 'Initials': 'YC', 'LastName': 'Ma', 'Affiliation': 'Department of Nephrology, China Rehabilitation Research Center, Beijing Boai Hospital, Capital Medical University Rehabilitation Medical College, Beijing, China, mych323@163.com.'}, {'ForeName': 'Mei', 'Initials': 'M', 'LastName': 'Wang', 'Affiliation': ""Department of Nephrology, Peking University People's Hospital, Beijing, China.""}]",Blood purification,['10.1159/000504955'] 3163,31883933,"Efficacy and Safety of Ultrasound-Guided Supraclavicular Brachial Plexus Block during Angioplasty of Dysfunctional Arteriovenous Access: A Prospective, Randomized Single-Center Clinical Trial.","PURPOSE To evaluate the efficacy and safety of the ultrasound-guided supraclavicular brachial plexus block (BPB) during angioplasty of dysfunctional arteriovenous access. MATERIALS AND METHODS Eighty study participants with dysfunctional arteriovenous access were enrolled in this prospective, randomized clinical trial between November 2016 and February 2018. Eighty patients were randomized to either the ultrasound-guided supraclavicular BPB group (mean age ± standard deviation [SD], 65.1 ± 12.4; male:female = 17:23) or the no regional anesthesia group (mean age ± SD, 64.0 ± 11.7; male:female = 25:15). Pain was assessed on the 10-point Visual Analogue Scale. Participant satisfaction was examined. Six-month clinical follow-up was done to evaluate arteriovenous access patency and long-term complications. RESULTS The BPB group showed a lower average pain score than the control group (mean ± SD, 0.9 ± 1.9 vs 6.4 ± 2.5; P < .001). Participant satisfaction (mean ± SD, 2.8 ± 0.5 vs 2.1±0.8; P < .001) was also higher in the BPB group. Six-month patency was 65% (26/40) in the BPB group and 59% (23/39) in the control group, with no significant difference between the 2 groups (P = .59). No major immediate or delayed complications were observed. CONCLUSIONS Ultrasound-guided BPB is highly effective in reducing pain during angioplasty of dysfunctional arteriovenous access with an acceptable safety profile.",2020,"No major immediate or delayed complications were observed. ","['Dysfunctional Arteriovenous Access', 'Eighty study participants with dysfunctional arteriovenous access', 'group (mean age ± standard deviation [SD], 65.1 ± 12.4; male:female\xa0= 17:23) or the no regional anesthesia group (mean age ± SD, 64.0 ± 11.7; male:female\xa0= 25:15', 'Eighty patients']","['ultrasound-guided supraclavicular brachial plexus block (BPB', 'ultrasound-guided supraclavicular BPB', 'Ultrasound-guided BPB', 'Ultrasound-Guided Supraclavicular Brachial Plexus Block']","['Six-month patency', 'delayed complications', 'average pain score', 'efficacy and safety', 'Pain', '10-point Visual Analogue Scale', 'pain', 'Efficacy and Safety']","[{'cui': 'C0450109', 'cui_str': 'Arteriovenous (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871420', 'cui_str': 'Standard deviation'}, {'cui': 'C4517543', 'cui_str': '12.4 (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0002911', 'cui_str': 'Anesthesia, Regional'}, {'cui': 'C4517535', 'cui_str': '11.7 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0394699', 'cui_str': 'Brachial plexus block by supraclavicular approach (procedure)'}, {'cui': 'C1608675', 'cui_str': '4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide'}, {'cui': 'C0589496', 'cui_str': 'Supraclavicular approach (qualifier value)'}]","[{'cui': 'C4082120', 'cui_str': 'Six months'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}]",80.0,0.0849338,"No major immediate or delayed complications were observed. ","[{'ForeName': 'Subin', 'Initials': 'S', 'LastName': 'Heo', 'Affiliation': 'Department of Radiology, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, 443-749, Suwon, Korea.'}, {'ForeName': 'Je Hwan', 'Initials': 'JH', 'LastName': 'Won', 'Affiliation': 'Department of Radiology, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, 443-749, Suwon, Korea. Electronic address: wonkwak@ajou.ac.kr.'}, {'ForeName': 'Jinoo', 'Initials': 'J', 'LastName': 'Kim', 'Affiliation': 'Department of Radiology, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, 443-749, Suwon, Korea.'}, {'ForeName': 'Jong Yeop', 'Initials': 'JY', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, 443-749, Suwon, Korea.'}, {'ForeName': 'Han Bum', 'Initials': 'HB', 'LastName': 'Joe', 'Affiliation': 'Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine, 206 Worldcup-ro, Yeongtong-gu, 443-749, Suwon, Korea.'}]",Journal of vascular and interventional radiology : JVIR,['10.1016/j.jvir.2019.11.002'] 3164,31348051,"Comparison of Macintosh Laryngoscopy in Bed-up-Head-Elevated Position With GlideScope Laryngoscopy: A Randomized, Controlled, Noninferiority Trial.","BACKGROUND Approximately half of all difficult tracheal intubations (DTIs) are unanticipated; hence, proper positioning during intubation is critical to increase the likelihood of success. The bed-up-head-elevated (BUHE) intubation position has been shown to improve laryngeal view, reduce airway complications, and prolong safe apneic time during intubation. In this study, we sought to determine whether the BUHE intubation position is noninferior to Glidescope (GLSC)-assisted intubation with regard to laryngeal exposure. METHODS A total of 138 American Society of Anesthesiologists (ASA) I to III patients were randomly assigned into 2 groups and underwent baseline laryngoscopy in the sniffing position. Group BUHE patients (n = 69) were then intubated in the BUHE position, while group GLSC patients (n = 69) were intubated using GLSC laryngoscopy. Laryngeal exposure was measured using Percentage of Glottic Opening (POGO) score and Cormack-Lehane (CL) grading, and noninferiority will be declared if the difference in mean POGO scores between both groups do not exceed -15% at the lower limit of a 98% confidence interval (CI). Secondary outcomes measured included time required for intubation (TRI), number of intubation attempts, use of airway adjuncts, effort during laryngoscopy, and complications during intubation. RESULTS Mean POGO score in group BUHE was 80.14% ± 22.03%, while in group GLSC it was 86.45% ± 18.83%, with a mean difference of -6.3% (98% CI, -13.2% to 0.6%). In both groups, there was a significant improvement in mean POGO scores when compared to baseline laryngoscopy in the sniffing position (group BUHE, 25.8% ± 4.7%; group GLSC, 30.7% ± 6.8%) (P < .0001). The mean TRI was 36.23 ± 14.41 seconds in group BUHE, while group GLSC had a mean TRI of 44.33 ± 11.53 seconds (P < .0001). In patients with baseline CL 3 grading, there was no significant difference between mean POGO scores in both groups (group BUHE, 49.2% ± 19.6% versus group GLSC, 70.5% ± 29.7%; P = .054). CONCLUSIONS In the general population, BUHE intubation position provides a noninferior laryngeal view to GLSC intubation. The laryngeal views obtained in both approaches were superior to the laryngeal view obtained in the sniffing position. In view of the many advantages of the BUHE position for intubation, the lack of proven adverse effects, the simplicity, and the cost-effectiveness, we propose that clinicians should consider the BUHE position as the standard intubation position for the general population.",2020,"In both groups, there was a significant improvement in mean POGO scores when compared to baseline laryngoscopy in the sniffing position (group BUHE, 25.8% ± 4.7%; group GLSC, 30.7% ± 6.8%) (P < .0001).",['138 American Society of Anesthesiologists (ASA'],"['GlideScope Laryngoscopy', 'Glidescope (GLSC)-assisted intubation', 'baseline laryngoscopy in the sniffing position', 'Macintosh Laryngoscopy in Bed-up-Head-Elevated Position', 'GLSC laryngoscopy']","['mean POGO scores', 'Mean POGO score', 'time required for intubation (TRI), number of intubation attempts, use of airway adjuncts, effort during laryngoscopy, and complications during intubation', 'mean TRI', 'Percentage of Glottic Opening (POGO) score and Cormack-Lehane (CL) grading', 'safe apneic time', 'Laryngeal exposure']","[{'cui': 'C0037455', 'cui_str': 'Societies'}, {'cui': 'C0334910', 'cui_str': 'Anesthesiologist'}]","[{'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C1561964', 'cui_str': 'Patient Positioning'}, {'cui': 'C0004916', 'cui_str': 'Beds'}, {'cui': 'C0018670', 'cui_str': 'Head'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0021925', 'cui_str': 'Intubation'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0458827', 'cui_str': 'Airway structure (body structure)'}, {'cui': 'C0023072', 'cui_str': 'Laryngoscopy'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0065404', 'cui_str': 'Tri (L)'}, {'cui': 'C0175566', 'cui_str': 'Patent (qualifier value)'}, {'cui': 'C0003578', 'cui_str': 'Apnea'}, {'cui': 'C0023078', 'cui_str': 'Larynx'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}]",138.0,0.151325,"In both groups, there was a significant improvement in mean POGO scores when compared to baseline laryngoscopy in the sniffing position (group BUHE, 25.8% ± 4.7%; group GLSC, 30.7% ± 6.8%) (P < .0001).","[{'ForeName': 'Samuel E H', 'Initials': 'SEH', 'LastName': 'Tsan', 'Affiliation': 'From the Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Siu M', 'Initials': 'SM', 'LastName': 'Lim', 'Affiliation': 'From the Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Mohd F Z', 'Initials': 'MFZ', 'LastName': 'Abidin', 'Affiliation': 'From the Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Shahmini', 'Initials': 'S', 'LastName': 'Ganesh', 'Affiliation': 'From the Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Chew Y', 'Initials': 'CY', 'LastName': 'Wang', 'Affiliation': 'From the Department of Anaesthesiology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.'}]",Anesthesia and analgesia,['10.1213/ANE.0000000000004349'] 3165,31973713,Point OutWords: protocol for a feasibility randomised controlled trial of a motor skills intervention to promote communicative development in non-verbal children with autism.,"BACKGROUND Point OutWords is a caregiver-delivered, iPad-assisted intervention for non-verbal or minimally verbal children with autism. It aims to develop prerequisite skills for communication such as manual and oral motor skills, sequencing, and symbolic representation. This feasibility trial aims to determine the viability of evaluating the clinical efficacy of Point OutWords. METHODOLOGY We aim to recruit 46 non-verbal or minimally verbal children with autism and their families, approximately 23 per arm. Children in the intervention group will use Point OutWords for half an hour, five times a week, for 8 weeks. Children in the control group will have equal caregiver-led contact time with the iPad using a selection of control apps (e.g. sensory apps, drawing apps). Communication, motor, and daily living skills are assessed at baseline and post-intervention. Parents will keep diaries during the intervention period and will take part in focus groups when the intervention is completed. DISCUSSION Point OutWords was developed in collaboration with children with autism and their caregivers, to provide an intervention for a subgroup of autism that has been historically underserved. As autism is a heterogeneous condition, it is unlikely that one style of intervention will address all aspects of its symptomatology; the motor skills approach of Point OutWords can complement other therapies that address core autistic symptoms of social cognition and communication more directly. The current feasibility trial can inform the selection of outcome measures and design for future full-scale randomised controlled trials of Point OutWords and of other early interventions in autism. TRIAL REGISTRATION ISRCTN, ISRCTN12808402. Prospectively registered on 12 March 2019.",2020,"Children in the control group will have equal caregiver-led contact time with the iPad using a selection of control apps (e.g. sensory apps, drawing apps).","['46 non-verbal or minimally verbal children with autism and their families, approximately 23 per arm', 'children with autism and their caregivers', 'non-verbal or minimally verbal children with autism', 'autism', 'non-verbal children with autism']","['iPad-assisted intervention', 'motor skills intervention']","['Communication, motor, and daily living skills']","[{'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0332232', 'cui_str': 'Approximate (qualifier value)'}, {'cui': 'C1704764', 'cui_str': 'Per'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]","[{'cui': 'C1269765', 'cui_str': 'Assists (attribute)'}, {'cui': 'C0026612', 'cui_str': 'Motor Skills'}]","[{'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}]",,0.0932069,"Children in the control group will have equal caregiver-led contact time with the iPad using a selection of control apps (e.g. sensory apps, drawing apps).","[{'ForeName': 'Ailbhe', 'Initials': 'A', 'LastName': 'McKinney', 'Affiliation': 'Division of Psychology, Nottingham Trent University, Nottingham, UK. ailbhe.mc-kinney@ucdconnect.ie.'}, {'ForeName': 'Kathryn L', 'Initials': 'KL', 'LastName': 'Hotson', 'Affiliation': 'Division of Psychology, Nottingham Trent University, Nottingham, UK.'}, {'ForeName': 'Alicia', 'Initials': 'A', 'LastName': 'Rybicki', 'Affiliation': 'School of Psychology, University of Birmingham, Birmingham, UK.'}, {'ForeName': 'Emma J L', 'Initials': 'EJL', 'LastName': 'Weisblatt', 'Affiliation': 'Department of Psychology, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Días', 'Affiliation': 'Peterborough Integrated Neurodevelopmental Service, Cambridgeshire and Peterborough NHS Foundation Trust, Peterborough, UK.'}, {'ForeName': 'Juliet', 'Initials': 'J', 'LastName': 'Foster', 'Affiliation': ""Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.""}, {'ForeName': 'Sofía S', 'Initials': 'SS', 'LastName': 'Villar', 'Affiliation': 'MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Suzanne', 'Initials': 'S', 'LastName': 'Murphy', 'Affiliation': 'Institute for Health Research, University of Bedfordshire, Bedford, UK.'}, {'ForeName': 'Matthew K', 'Initials': 'MK', 'LastName': 'Belmonte', 'Affiliation': 'Division of Psychology, Nottingham Trent University, Nottingham, UK.'}]",Trials,['10.1186/s13063-019-3931-1'] 3166,31997146,The Effects of Personalizing Colorectal Cancer Risk Communication on Risk Perceptions and Health Behavior Intentions: a Randomized Trial of Average-Risk Adults.,"Risk assessment tools may help individuals gauge cancer risk and motivate lifestyle and screening behavior changes. Despite the evermore common availability of such tools, little is known about their potential utility in average-risk population approaches to cancer prevention. We evaluated the effects of providing personalized (vs. generic) information concerning colorectal cancer (CRC) risk factors on average-risk individuals' risk perceptions and intentions to engage in three risk-reducing behaviors: CRC screening, diet, and physical activity. Further, we explored whether the receipt of CRC-specific risk assessment feedback influenced individuals' breast cancer risk perceptions and mammography intentions. Using an online survey, N = 419 survey respondents aged 50-75 with no personal or family history of CRC were randomized to receive an average estimate of CRC lifetime risk and risk factor information that was either personalized (treatment) or invariant/non-personalized (control). Respondent risk perceptions and behavioral intentions were ascertained before and after risk assessment administration. No differences were observed in risk perceptions or behavioral intentions by study arm. However, regardless of study arm, CRC screening intentions significantly increased after risk assessment feedback was provided. This occurred despite a significant reduction in risk perceptions. Results support the role simple cancer risk assessment information could play in promoting screening behaviors while improving the accuracy of cancer risk perceptions. Providing cancer risk assessment information may decrease individuals' perceptions of cancer risk to more realistic levels while simultaneously facilitating screening intentions among an average-risk population, regardless of whether provided risk information is personalized.",2020,No differences were observed in risk perceptions or behavioral intentions by study arm.,"[""individuals' breast cancer risk perceptions and mammography intentions"", 'Average-Risk Adults', '419 survey respondents aged 50-75 with no personal or family history of CRC']","['CRC lifetime risk and risk factor information that was either personalized (treatment) or invariant/non-personalized (control', 'Personalizing Colorectal Cancer Risk Communication', 'CRC-specific risk assessment feedback']","['Risk Perceptions and Health Behavior Intentions', 'Respondent risk perceptions and behavioral intentions', 'risk perceptions or behavioral intentions', 'CRC screening intentions', 'risk perceptions']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0024671', 'cui_str': 'Mammography'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0241889', 'cui_str': 'Family Medical History'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}]","[{'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0086930', 'cui_str': 'Risk assessment (procedure)'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0030971', 'cui_str': 'Perception'}, {'cui': 'C0018687'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0282122', 'cui_str': 'Respondents'}, {'cui': 'C0170127', 'cui_str': 'Calcibiotic Root Canal Sealer'}, {'cui': 'C0220908', 'cui_str': 'Screening'}]",,0.0133177,No differences were observed in risk perceptions or behavioral intentions by study arm.,"[{'ForeName': 'Carrie A', 'Initials': 'CA', 'LastName': 'Miller', 'Affiliation': 'Department of Health Behavior and Policy, School of Medicine, and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA. carrie.a.miller@vcuhealth.org.'}, {'ForeName': 'Jennifer Elston', 'Initials': 'JE', 'LastName': 'Lafata', 'Affiliation': 'Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.'}, {'ForeName': 'Maria D', 'Initials': 'MD', 'LastName': 'Thomson', 'Affiliation': 'Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-020-01694-5'] 3167,31608676,Work-directed rehabilitation or physical activity to support work ability and mental health in common mental disorders: a pilot randomized controlled trial.,"OBJECTIVE To evaluate feasibility and potential effectiveness of work-directed rehabilitation in people with common mental disorders. DESIGN Pilot randomized controlled trial. SETTING Primary healthcare, Sweden. SUBJECTS Working adults ( n  = 42) of mean age 46.2 ± 11.1 years with depression or anxiety disorder. INTERVENTIONS Eight weeks of work-directed rehabilitation ( n  = 21) or physical activity ( n  = 21). Work-directed rehabilitation included sessions with a physiotherapist and/or an occupational therapist, to develop strategies to cope better at work. Physical activity included a planning session and access to a local gym. MAIN MEASURES Feasibility: attendance, discontinuation and adverse events. Measurements were the Work Ability Index, the Global Assessment of Functioning, the Montgomery-Asberg Depression Rating Scale, the Beck Anxiety Inventory and the World Health Organization-Five Well-Being Index. RESULTS Attendance to rehabilitation sessions was 88% ( n  = 147/167) and discontinuation rate was 14% ( n  = 3/21). No serious adverse events were reported. Within both groups, there was a significant improvement in Work Ability Index score (mean change: 3.6 (95% confidence interval (CI): 0.45, 6.7) in work-directed rehabilitation and 3.9 (95% CI: 0.9, 7.0) in physical activity) with no significant difference between groups. For the other outcomes, significant improvements were found within but not between groups. Per-protocol analysis showed a trend toward the antidepressant effect of work-directed rehabilitation compared to physical activity (mean difference in depression score -3.1 (95% CI: -6.8, 0.4), P  = 0.075). CONCLUSION Work-directed rehabilitation was feasible to persons with common mental disorders and improved their work ability and mental health. Comparable improvements were seen in the physical activity group. Suggested modifications for a larger trial include adding a treatment-as-usual control.",2020,"Within both groups, there was a significant improvement in Work Ability Index score (mean change: 3.6 (95% confidence interval (CI): 0.45, 6.7) in work-directed rehabilitation and 3.9 (95% CI: 0.9, 7.0) in physical activity) with no significant difference between groups.","['Primary healthcare, Sweden', 'persons with common mental disorders', 'people with common mental disorders', 'common mental disorders', 'Working adults ( n \u2009=\u200942) of mean age 46.2\u2009±\u200911.1\u2009years with depression or anxiety disorder']","['Work-directed rehabilitation', 'work-directed rehabilitation ( n \u2009=\u200921) or physical activity', 'work-directed rehabilitation', 'Work-directed rehabilitation or physical activity to support work ability and mental health']","['Feasibility: attendance, discontinuation and adverse events', 'work ability and mental health', 'discontinuation rate', 'Work Ability Index, the Global Assessment of Functioning, the Montgomery-Asberg Depression Rating Scale, the Beck Anxiety Inventory and the World Health Organization-Five Well-Being Index', 'Work Ability Index score', 'serious adverse events']","[{'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0038995', 'cui_str': 'Sweden'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0205214', 'cui_str': 'Common (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}]","[{'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0222045'}, {'cui': 'C0582613', 'cui_str': 'Beck anxiety inventory (assessment scale)'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C2960301', 'cui_str': 'Work ability index score'}]",,0.0794199,"Within both groups, there was a significant improvement in Work Ability Index score (mean change: 3.6 (95% confidence interval (CI): 0.45, 6.7) in work-directed rehabilitation and 3.9 (95% CI: 0.9, 7.0) in physical activity) with no significant difference between groups.","[{'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Danielsson', 'Affiliation': 'Research Unit, Angered Hospital, Angered, Sweden.'}, {'ForeName': 'Margda', 'Initials': 'M', 'LastName': 'Waern', 'Affiliation': 'Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Gunnel', 'Initials': 'G', 'LastName': 'Hensing', 'Affiliation': 'School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Holmgren', 'Affiliation': 'Department of Health and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.'}]",Clinical rehabilitation,['10.1177/0269215519880230'] 3168,31608677,The effects of preoperative balance training on balance and functional outcome after total knee replacement: a randomized controlled trial.,"OBJECTIVE To assess the effects of preoperative balance training on the early postoperative balance and functional outcomes after total knee replacement surgery and to test whether an outpatient intervention may be as effective as a domiciliary intervention. DESIGN This is a three-arm randomized controlled trial. SETTING University hospital. SUBJECTS Eighty-six individuals were recruited. Seventy-seven were analysed, aged 72.1 (SD 7.6) years, of which 68% were women. OUTCOME MEASURES Overall state of balance, as measured with the Berg Balance Scale, and patient-perceived functionality, as measured with the Knee Injury and Osteoarthritis Outcome Score Function in Activities in Daily Living (KOOS-ADL) questionnaire, were the primary outcomes. Secondary assessments targeted knee function, balance and mobility, quality of life, and self-reported outcomes. The primary end-point was six weeks after surgery. INTERVENTION The hospital group implemented a four-week preoperative outpatient balance-oriented intervention. The home group implemented similar training, but this was domiciliary. The control group was instructed to keep performing their normal activities. RESULTS Home and hospital groups presented a moderate effect against the control group ( d hospital-control = 0.54; d home-control = 0.63), both being similarly effective in improving the overall state of balance at six weeks after surgery ( P = 0.013). KOOS-ADL scores showed no between-group differences and a small effect size ( d < 0.5; P = 0.937). Secondary assessments suggested non-significant between-group differences. CONCLUSION Preoperative balance training, conducted either as domiciliary or as an outpatient, is an effective approach to enhance early postoperative balance outcome but not the perceived functionality of individuals undergoing total knee replacement.",2020,KOOS-ADL scores showed no between-group differences and a small effect size ( d < 0.5; P = 0.937).,"['total knee replacement surgery', 'total knee replacement', 'University hospital', 'Seventy-seven were analysed, aged 72.1 (SD 7.6) years, of which 68% were women', 'Eighty-six individuals were recruited', 'individuals undergoing total knee replacement']",['preoperative balance training'],"['KOOS-ADL scores', 'Overall state of balance, as measured with the Berg Balance Scale, and patient-perceived functionality, as measured with the Knee Injury and Osteoarthritis Outcome Score Function in Activities in Daily Living (KOOS-ADL) questionnaire', 'overall state of balance', 'balance and functional outcome', 'knee function, balance and mobility, quality of life, and self-reported outcomes']","[{'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C3816957', 'cui_str': '70'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0445204', 'cui_str': 'Preoperative (qualifier value)'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}]","[{'cui': 'C0001288', 'cui_str': 'ADL'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0179199', 'cui_str': 'Balance (physical object)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1998325', 'cui_str': 'Berg balance scale'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0022744', 'cui_str': 'Knee Injuries'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C1963703', 'cui_str': 'Knee region structure (body structure)'}, {'cui': 'C0449580', 'cui_str': 'Mobility (attribute)'}, {'cui': 'C0034380'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}]",86.0,0.063077,KOOS-ADL scores showed no between-group differences and a small effect size ( d < 0.5; P = 0.937).,"[{'ForeName': 'José-María', 'Initials': 'JM', 'LastName': 'Blasco', 'Affiliation': 'Group of Physiotherapy in the Ageing Process, Departamento de Fisioterapia, Universitat de València (UV), Valencia, Spain.'}, {'ForeName': 'Yolanda', 'Initials': 'Y', 'LastName': 'Acosta-Ballester', 'Affiliation': 'Group of Physiotherapy in the Ageing Process, Departamento de Fisioterapia, Universitat de València (UV), Valencia, Spain.'}, {'ForeName': 'Ignacio', 'Initials': 'I', 'LastName': 'Martínez-Garrido', 'Affiliation': 'Hospital Universitario y Politécnico La Fe, Valencia, Spain.'}, {'ForeName': 'Pablo', 'Initials': 'P', 'LastName': 'García-Molina', 'Affiliation': 'Departamento de Enfermería, Universitat de València, Valencia, Spain.'}, {'ForeName': 'Celedonia', 'Initials': 'C', 'LastName': 'Igual-Camacho', 'Affiliation': 'Group of Physiotherapy in the Ageing Process, Departamento de Fisioterapia, Universitat de València (UV), Valencia, Spain.'}, {'ForeName': 'Sergio', 'Initials': 'S', 'LastName': 'Roig-Casasús', 'Affiliation': 'Group of Physiotherapy in the Ageing Process, Departamento de Fisioterapia, Universitat de València (UV), Valencia, Spain.'}]",Clinical rehabilitation,['10.1177/0269215519880936'] 3169,31820559,Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.,"AIMS Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA-REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin. METHODS AND RESULTS Analyses were conducted on patients distinguished by the presence (n = 389) or absence (n = 6631) of AF at baseline. Outcome events were more frequent in patients with AF than those without AF. Empagliflozin compared to placebo reduced CV death or HF hospitalisation consistently in patients with AF [hazard ratio (HR) 0.58, 95% confidence interval (CI) 0.36-0.92] and without AF (HR 0.67, 95% CI 0.55-0.82, P interaction  = 0.56). Similar results were observed for the components of this endpoint, all-cause mortality, new or worsening nephropathy, first introduction of loop diuretics, or occurrence of oedema. The absolute number of prevented events was higher in patients with AF, resulting in larger absolute treatment effects of empagliflozin. New loop diuretics or oedema were associated with increased rates of subsequent events, and rates appeared lower in those randomised to empagliflozin. CONCLUSIONS In patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF-related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.",2020,Empagliflozin compared to placebo reduced CV death or HF hospitalisation consistently in patients with AF [hazard ratio (HR),"['Patients with diabetes, CV disease and AF', 'Analyses were conducted on patients distinguished by the presence (n\xa0=\xa0389) or absence (n\xa0=\xa06631) of AF at baseline', 'patients with AF [hazard ratio (HR', 'patients with diabetes and heart failure (HF', 'patients with atrial fibrillation']","['Empagliflozin', 'placebo', 'empagliflozin']","['rates of subsequent events, and rates', 'heart failure and renal outcomes', 'adverse HF outcomes', 'absolute number of prevented events', 'CV death or HF hospitalisation', 'HF-related and renal events', 'cause mortality, new or worsening nephropathy, first introduction of loop diuretics, or occurrence of oedema']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C4517752', 'cui_str': '389 (qualifier value)'}, {'cui': 'C1689985', 'cui_str': 'Absence'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0004238', 'cui_str': 'Auricular Fibrillation'}]","[{'cui': 'C3490348', 'cui_str': 'empagliflozin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0205344', 'cui_str': 'Absolute (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1292733', 'cui_str': 'Prevents'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C1293116', 'cui_str': 'Introduction'}, {'cui': 'C0354100', 'cui_str': 'Loop Diuretics'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0013604', 'cui_str': 'Hydrops'}]",,0.0821771,Empagliflozin compared to placebo reduced CV death or HF hospitalisation consistently in patients with AF [hazard ratio (HR),"[{'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Böhm', 'Affiliation': 'Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Slawik', 'Affiliation': 'Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Brueckmann', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Michaela', 'Initials': 'M', 'LastName': 'Mattheus', 'Affiliation': 'Boehringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany.'}, {'ForeName': 'Jyothis T', 'Initials': 'JT', 'LastName': 'George', 'Affiliation': 'Boehringer Ingelheim International GmbH, Ingelheim, Germany.'}, {'ForeName': 'Anne Pernille', 'Initials': 'AP', 'LastName': 'Ofstad', 'Affiliation': 'Medical Department, Boehringer Ingelheim, Asker, Norway.'}, {'ForeName': 'Silvio E', 'Initials': 'SE', 'LastName': 'Inzucchi', 'Affiliation': 'Section of Endocrinology, Yale School of Medicine, Yale-New Haven Hospital, New Haven, CT, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Fitchett', 'Affiliation': ""St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, ON, Canada.""}, {'ForeName': 'Stefan D', 'Initials': 'SD', 'LastName': 'Anker', 'Affiliation': 'Department of Cardiology (CVK), Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Nikolaus', 'Initials': 'N', 'LastName': 'Marx', 'Affiliation': 'Department of Internal Medicine I, Cardiology, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.'}, {'ForeName': 'Christoph', 'Initials': 'C', 'LastName': 'Wanner', 'Affiliation': 'Department of Medicine, Würzburg University Clinic, Würzburg, Germany.'}, {'ForeName': 'Bernard', 'Initials': 'B', 'LastName': 'Zinman', 'Affiliation': 'Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Subodh', 'Initials': 'S', 'LastName': 'Verma', 'Affiliation': ""Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Canada.""}]",European journal of heart failure,['10.1002/ejhf.1663'] 3170,31994278,"Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes.","AIM to evaluate if a nutraceutical compound containing Ilex paraguariensis, White Mulberry and Chromium Picolinate can ameliorate glycemic status in patients with pre-diabetes. METHODS we enrolled patients with IFG or IGT, not taking other hypoglycemic compounds. Patients were randomized to take placebo or the nutraceutical compound for 3 months, in a randomized, double-blind, placebo-controlled design. Both treatments were self-administered once a day, 1 tablet during the breakfast. RESULTS a reduction of FPG was observed with the nutraceutical combination (-7.8%). Furthermore, there was a decrease of HOMA-IR with the nutraceutical combination (-7.9%). M value was higher (p < 0.05 vs baseline and p < 0.05 vs placebo) at the end of the treatment. We obtained a reduction of Tg with the nutraceutical combination (-8.3%). About 16.6% of patients treated with nutraceutical returned to have a normal glycemia (< 100 mg/dL), and all patients had an improvement of insulin-resistance, in particular 67% of patients returned to have a M value inside range of normal insulin sensitivity. CONCLUSIONS a nutraceutical containing Ilex paraguariensis, White Mulberry and Chromium Picolinate at 500 mg can be helpful in improving glycemia and Tg value, in patients with pre-diabetes.",2020,"Furthermore, there was a decrease of HOMA-IR with the nutraceutical combination (-7.9%).","['patients with pre-diabetes', 'enrolled patients with IFG or IGT, not taking other hypoglycemic compounds']","['Ilex paraguariensis, white mulberry and chromium picolinate', 'placebo', 'nutraceutical compound containing Ilex paraguariensis, White Mulberry and Chromium Picolinate', 'Chromium Picolinate']","['FPG', 'insulin-resistance', 'normal glycemia', 'M value', 'glycemic status', 'HOMA-IR']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic Drugs'}, {'cui': 'C0205198', 'cui_str': 'Compound (qualifier value)'}]","[{'cui': 'C0874159', 'cui_str': 'Ilex paraguariensis'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0330540', 'cui_str': 'Mulberry'}, {'cui': 'C0163657', 'cui_str': 'CHROMIUM PICOLINATE'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1518478', 'cui_str': 'Nutraceuticals'}, {'cui': 'C0205198', 'cui_str': 'Compound (qualifier value)'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}]","[{'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}]",,0.137981,"Furthermore, there was a decrease of HOMA-IR with the nutraceutical combination (-7.9%).","[{'ForeName': 'Giuseppe', 'Initials': 'G', 'LastName': 'Derosa', 'Affiliation': 'Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': ""D'Angelo"", 'Affiliation': 'Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy.'}, {'ForeName': 'Pamela', 'Initials': 'P', 'LastName': 'Maffioli', 'Affiliation': 'Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy.'}]",Phytotherapy research : PTR,['10.1002/ptr.6611'] 3171,31996940,"Differential effects of nicotine delivery rate on subjective drug effects, urges to smoke, heart rate and blood pressure in tobacco smokers.","RATIONALE The nicotine delivery rate is a key feature of tobacco product design, yet there have been limited human studies examining the effects of nicotine as a function of delivery rate. OBJECTIVE We developed an intravenous nicotine infusion protocol to evaluate differential effects of nicotine delivery rate on subjective drug effects, smoking urges, abstinence symptoms, heart rate, and blood pressure. METHODS Eighteen non-treatment seeking, overnight abstinent male and female smokers (18 to 30 years old), who smoked ≥ 5 cigarettes per day for the past year completed four sessions, in which they were randomly assigned to a saline infusion, or a 1 mg per 70-kg body weight dose of nicotine delivered over 1, 5, or 10 min at rates of 0.24, 0.048, or 0.024 μg/kg/s, respectively. RESULTS Smoking urges, as assessed by the Brief Questionnaire of Smoking Urges, were reduced relative to placebo for the 1- and 5-min infusion, but not the 10-min infusion. Although the 1- and 5-min infusions reduced smoking urges to a similar extent, the 1-min infusion induced a greater heart rate and blood pressure increase. Changes to subjective drug effects, heart rate, and blood pressure delineate the differential effects of nicotine delivery rate for these outcomes. CONCLUSIONS We have characterized the delivery rate-response curve for a nicotine dose that is roughly the amount of nicotine (~ 1 mg) delivered by smoking a standard tobacco cigarette. Our findings reinforce the importance of nicotine delivery rate when evaluating the potential effects of nicotine from tobacco products.",2020,"RESULTS Smoking urges, as assessed by the Brief Questionnaire of Smoking Urges, were reduced relative to placebo for the 1- and 5-min infusion, but not the 10-min infusion.","['tobacco smokers', 'Eighteen non-treatment seeking, overnight abstinent male and female smokers (18 to 30\xa0years old), who smoked ≥\u20095 cigarettes per day for the past year completed four sessions']","['nicotine', 'saline infusion']","['subjective drug effects, heart rate, and blood pressure', 'subjective drug effects, urges to smoke, heart rate and blood pressure', 'Brief Questionnaire of Smoking Urges', 'subjective drug effects, smoking urges, abstinence symptoms, heart rate, and blood pressure', 'heart rate and blood pressure increase']","[{'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439583', 'cui_str': 'Overnight (qualifier value)'}, {'cui': 'C0457801', 'cui_str': 'Current non-drinker of alcohol (finding)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}]","[{'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0728867', 'cui_str': 'Drug action (finding)'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0497247', 'cui_str': 'Finding of increased blood pressure (finding)'}]",,0.043994,"RESULTS Smoking urges, as assessed by the Brief Questionnaire of Smoking Urges, were reduced relative to placebo for the 1- and 5-min infusion, but not the 10-min infusion.","[{'ForeName': 'Kevin P', 'Initials': 'KP', 'LastName': 'Jensen', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. kevin.jensen@yale.edu.'}, {'ForeName': 'Gerald', 'Initials': 'G', 'LastName': 'Valentine', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}, {'ForeName': 'Ralitza', 'Initials': 'R', 'LastName': 'Gueorguieva', 'Affiliation': 'Department of Biostatistics, Yale University School of Public Health, New Haven, CT, USA.'}, {'ForeName': 'Mehmet', 'Initials': 'M', 'LastName': 'Sofuoglu', 'Affiliation': 'Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.'}]",Psychopharmacology,['10.1007/s00213-020-05463-6'] 3172,31283555,"A randomized trial to assess the immediate impact of acupuncture on quantitative sensory testing, pain, and functional status.","In this randomized clinical trial, we examined whether the effect of true acupuncture can be differentiated from sham acupuncture (pain and functionality) by analyzing quantitative sensory testing (QST) profiles in chronic pain participants. We recruited 254 healthy or chronic back and neck pain participants. Healthy subjects were included to control for a possible effect of acupuncture on baseline QST changes. Study participants received 6 sessions (twice weekly) of true acupuncture, sham acupuncture, or no acupuncture treatment (routine care). Quantitative sensory testing profiles, pain scores, and functionality profile were obtained at baseline (visit 1) and after 3 (visit 4) or 6 sessions (visit 7). A total of 204 participants were analyzed. We found no QST profile changes among 3 groups (P = 0.533 and P = 0.549, likelihood ratio tests) in either healthy or chronic pain participants. In chronic back and neck pain participants, true acupuncture reduced pain (visit 4: difference in mean [DIM] = -0.8, 95% confidence interval [CI]: -1.4 to -0.1, adjusted P = 0.168; visit 7: DIM = -1.0, 95% CI: -1.7 to -0.3, adjusted P = 0.021) and improved functional status including physical functioning (DIM = 14.21, 95% CI: 5.84-22.58, adjusted P = 0.003) and energy/fatigue (DIM = 12.28, 95% CI: 3.46-21.11, adjusted P = 0.021) as compared to routine care. Our results indicate that QST was not helpful to differentiate between true acupuncture and sham acupuncture (primary outcome) in this study, although true acupuncture reduced pain and improved functionality (secondary outcomes) when compared with routine care.",2019,"We found no QST profile changes among three groups (P = 0.533 and P = 0.549, Likelihood-ratio tests) in either healthy or chronic pain participants.","['254 healthy or chronic back and neck pain participants', 'chronic pain participants', 'chronic back and neck pain participants', 'A total of 204 participants were analyzed', 'Healthy subjects']","['true acupuncture', 'acupuncture', 'true acupuncture, sham acupuncture, or no acupuncture treatment (routine care', 'QST']","['pain', 'quantitative sensory testing, pain, and functional status', 'pain and improved functionality', 'energy/fatigue', 'QST profile changes', 'QST profiles, pain scores and functionality profile', 'functional status including physical functioning']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0007859', 'cui_str': 'Neck Ache'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0205238', 'cui_str': 'True (qualifier value)'}, {'cui': 'C0001299', 'cui_str': 'Acupuncture'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C0394664', 'cui_str': 'Acupuncture Treatment'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0392762', 'cui_str': 'Quantitative (qualifier value)'}, {'cui': 'C0200116', 'cui_str': 'Sensory testing'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}]",204.0,0.288725,"We found no QST profile changes among three groups (P = 0.533 and P = 0.549, Likelihood-ratio tests) in either healthy or chronic pain participants.","[{'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Chen', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Hao', 'Initials': 'H', 'LastName': 'Deng', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Houle', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Shihab', 'Initials': 'S', 'LastName': 'Ahmed', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Zhang', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Shelly', 'Initials': 'S', 'LastName': 'Sullivan', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Arissa', 'Initials': 'A', 'LastName': 'Opalaze', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Roth', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Jen', 'Initials': 'J', 'LastName': 'Falacova', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Kristan', 'Initials': 'K', 'LastName': 'St Clair', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Tran', 'Initials': 'T', 'LastName': 'Vo', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Charline', 'Initials': 'C', 'LastName': 'Malarick', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Hyangin', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Zerong', 'Initials': 'Z', 'LastName': 'You', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Shiqian', 'Initials': 'S', 'LastName': 'Shen', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}, {'ForeName': 'Jianren', 'Initials': 'J', 'LastName': 'Mao', 'Affiliation': 'Department of Anesthesia, Critical Care and Pain Medicine, MGH Center for Translational Pain Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.'}]",Pain,['10.1097/j.pain.0000000000001651'] 3173,31997237,Effectiveness and Safety Evaluation of Qixiong Zhongzi Decoction () in Idiopathic Asthenozoospermia Treatment: A Randomized Controlled Trial.,"OBJECTIVE To evaluate the clinical effectiveness and safety of the Chinese medicine (CM) Qixiong Zhongzi Decoction (, QZD) in the treatment of patients with idiopathic asthenozoospermia. METHODS A total number of 66 patients with idiopathic asthenozoospermia were included and randomly divided into treatment and control groups by SAS-generated code from January 2015 to August 2016, 33 patients in each group. Patients in the treatment group were administered with 150 mL of QZD twice a day, whereas those in the control group were given 1 g of levocarnitine oral liquid twice a day. The two groups received the indicated medication for 12 weeks and were then followed up for 4 weeks. The primary outcome was sperm motility, and the secondary therapeutic indices were sperm volume, density, pregnancy probability, and CM syndrome score. The comparison between groups was carried out at 4, 8 and 12 weeks, respectively. The safety was determined before and after treatment. RESULTS (1) Drop-off: 5 cases (7.58%) were lost after treatment (2 from the treatment group and 3 from the control group). (2) Primary outcomes: after 8- and 12-week treatment, the progressive sperms in the two groups were significantly higher than the baseline (all P<0.05); however, the treatment group showed greater improvement compared with the control group at 12-week treatment (22.7% ± 9.0% vs. 14.1% ±8.8%, P<0.05). The increasement of non-progressive grade sperms at both groups was observed at 8- and 12-week treatment with statistical difference (all P<0.05), however, the treatment group showed remarkable improvement compared with the control group at 12-week treatment (38.7% ±14.1% vs. 26.2% ±15.4%, P<0.05). (3) Secondary outcomes: no significant statistical differences were found in semen volume and density (4, 8, and 12-week treatment) and pregnancy probability of patients' wives (12-week treatment) between two groups (all P>0.05), however, the CM syndrome score of the treatment group significantly declined compared with baseline level at each time points (all P<0.05). (4) Safety: no obvious side reactions were found during the treatment in both groups. CONCLUSION QZD could improve the progressive and non-progressive grade sperm in the treatment of idiopathic asthenozoospermia. It is safe with no obvious side effects.",2020,"The increasement of non-progressive grade sperms at both groups was observed at 8- and 12-week treatment with statistical difference (all P<0.05), however, the treatment group showed remarkable improvement compared with the control group at 12-week treatment (38.7% ±14.1% vs. 26.2% ±15.4%, P<0.05).","['patients with idiopathic asthenozoospermia', 'Idiopathic Asthenozoospermia Treatment', '66 patients with idiopathic asthenozoospermia']","['QZD', 'Qixiong Zhongzi Decoction (, QZD', 'Chinese medicine (CM', 'levocarnitine oral liquid twice a day', 'Qixiong Zhongzi Decoction ']","['no obvious side reactions', 'increasement of non-progressive grade sperms', 'sperm motility, and the secondary therapeutic indices were sperm volume, density, pregnancy probability, and CM syndrome score', 'CM syndrome score', 'progressive sperms', ""semen volume and density (4, 8, and 12-week treatment) and pregnancy probability of patients' wives""]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1608429', 'cui_str': 'Idiopathic (IPAH)'}, {'cui': 'C4082176', 'cui_str': 'Asthenozoospermia'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0087163', 'cui_str': 'l-carnitine'}, {'cui': 'C1273619', 'cui_str': 'Oral Liquid Product'}, {'cui': 'C0585361', 'cui_str': 'Twice a day (qualifier value)'}]","[{'cui': 'C0443286', 'cui_str': 'Reaction (qualifier value)'}, {'cui': 'C3839460', 'cui_str': 'Non-progressive'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0037868', 'cui_str': 'Sperm'}, {'cui': 'C0037848', 'cui_str': 'Sperm Motility'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0678793', 'cui_str': 'Therapeutic Index'}, {'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0178587', 'cui_str': 'Mass to volume ratio'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0033204', 'cui_str': 'Probability'}, {'cui': 'C0039082', 'cui_str': 'Symptom Cluster'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0242665', 'cui_str': 'Wife (person)'}]",,0.0162862,"The increasement of non-progressive grade sperms at both groups was observed at 8- and 12-week treatment with statistical difference (all P<0.05), however, the treatment group showed remarkable improvement compared with the control group at 12-week treatment (38.7% ±14.1% vs. 26.2% ±15.4%, P<0.05).","[{'ForeName': 'Fu', 'Initials': 'F', 'LastName': 'Wang', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Qing-He', 'Initials': 'QH', 'LastName': 'Gao', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Geng', 'Affiliation': 'Department of Andrology, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, China.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': 'Department of Andrology, Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, Beijing, 100010, China.'}, {'ForeName': 'Jia-You', 'Initials': 'JY', 'LastName': 'Zhao', 'Affiliation': 'Graduate School, China Academy of Chinese Medical Sciences, Beijing, 100700, China.'}, {'ForeName': 'Guo-Jin', 'Initials': 'GJ', 'LastName': 'Yu', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Ji-Wei', 'Initials': 'JW', 'LastName': 'Zhang', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Bin', 'Initials': 'B', 'LastName': 'Yan', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Guo', 'Affiliation': 'Department of Andrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.'}, {'ForeName': 'Chun-Sheng', 'Initials': 'CS', 'LastName': 'Song', 'Affiliation': 'Graduate School, China Academy of Chinese Medical Sciences, Beijing, 100700, China. sonchun@vip.163.com.'}]",Chinese journal of integrative medicine,['10.1007/s11655-020-3211-7'] 3174,31997236,Chinese Medicine Sequential Therapy Improves Pregnancy Outcomes after Surgery for Endometriosis-Associated Infertility: A Multicenter Randomized Double-blind Placebo Parallel Controlled Clinical Trial.,"OBJECTIVE To evaluate the efficacy and safety of Chinese medicine (CM) improving pregnancy outcomes after surgery for endometriosis-associated infertility. METHODS A multicenter, randomized, double-blind placebo parallel controlled clinical trial was designed. A total of 202 patients who had laparoscopy for endometriosis-associated infertility with qi stagnation and blood stasis syndrome were included and randomly divided into the CM treatment group and placebo control group at a ratio of 1:1 using a central block randomization from May 2014 to September 2017, 101 patients in each group. The two groups received continuous intervention at 1-5 days after surgery, for 6 menstrual cycles. Before ovulation, the CM group was treated Huoxue Xiaoyi Granule (); after ovulation, Bushen Zhuyun Granule ( was involved. The control group was treated with placebo. Transvaginal ultrasonography was performed every menstrual cycle during the treatment, and female hormone levels in the follicular and luteal phases were measured during the 1st, 3rd and 6th menstrual cycles. The analysis was continued until pregnancy. The primary outcomes were clinical pregnancy rate and pregnancy outcome, and the secondary outcomes were follicular development and endometrial receptivity. Safety evaluations were performed before and after treatment. RESULTS (1) Clinical pregnancy and live birth rates: the clinical pregnancy and live birth rates of the CM group were significantly higher than those of the placebo group [44.6% (45/101) vs. 29.7% (30/101), 34.7% (35/101) vs. 20.8% (21/101), both P<0.05]. (2) Follicle development: the incidence of dominant follicles, rate of cumulative cycle ovulation, and rate of cumulative cycle mature follicle ovulation were significantly higher in the CM group than those in the placebo group [93.8% (350/373) vs. 89.5% (341/381), 80.4% (275/342) vs. 69.1% (253/366), 65.8% (181/275) vs 56.1% (142/253), P<0.05 or P<0.01]). The incidence of cumulative cycle luteinized unruptured follicle syndrome was significantly lower in the CM group than in the placebo group [11.7% (40/342) vs. 17.8% (65/366), P<0.05). (3) Endometrial receptivity: after treatment, both endometrial types and endometrial blood flow types in the CM group were mainly types A and B, while those in the placebo group were mainly types B and C, with a significant difference between the two groups (both P<0.05). (4) Adverse events: the incidence of adverse events between the two groups was not significantly different (P>0.05). CONCLUSION Strategies for activating blood circulation-regulating Gan (Liver)-tonifying Shen (Kidney) sequential therapy can effectively improve the clinical pregnancy rate and live birth rate of endometriosis-associated infertility with qi stagnation and blood stasis after laparoscopy, improve follicular development, promote ovulation, improve endometrial receptivity, while being a safe treatment option. (Trial registration No. NCT02676713).",2020,"The incidence of cumulative cycle luteinized unruptured follicle syndrome was significantly lower in the CM group than in the placebo group [11.7% (40/342) vs. 17.8% (65/366), P<0.05).","['202 patients who had laparoscopy for endometriosis-associated infertility with qi stagnation and blood stasis syndrome', 'after Surgery for Endometriosis-Associated Infertility']","['Placebo', 'Transvaginal ultrasonography', 'CM treatment group and placebo control', 'Chinese medicine (CM', 'Chinese Medicine Sequential Therapy', 'placebo', 'Strategies for activating blood circulation-regulating Gan (Liver)-tonifying Shen (Kidney) sequential therapy', 'continuous intervention']","['Pregnancy Outcomes', 'clinical pregnancy rate and pregnancy outcome', 'efficacy and safety', 'incidence of dominant follicles, rate of cumulative cycle ovulation, and rate of cumulative cycle mature follicle ovulation', 'Endometrial receptivity', 'incidence of adverse events', 'Clinical pregnancy and live birth rates', 'clinical pregnancy and live birth rates', 'clinical pregnancy rate and live birth rate', 'incidence of cumulative cycle luteinized unruptured follicle syndrome', 'follicular development and endometrial receptivity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0031150', 'cui_str': 'Celioscopy'}, {'cui': 'C0021359', 'cui_str': 'Infertility'}, {'cui': 'C0005768'}, {'cui': 'C0005750', 'cui_str': 'Stagnant Loop Syndrome'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0014175', 'cui_str': 'Endometriosis'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0175672', 'cui_str': 'Vaginal approach (qualifier value)'}, {'cui': 'C0041618', 'cui_str': 'Echotomography'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0005775', 'cui_str': 'Blood Circulation'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}]","[{'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0032975', 'cui_str': 'Pregnancy Rate'}, {'cui': 'C0032972', 'cui_str': 'Pregnancy Outcome'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0029965', 'cui_str': 'Ovulation'}, {'cui': 'C0205286', 'cui_str': 'Mature (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0481667', 'cui_str': 'Live Birth'}, {'cui': 'C0473318', 'cui_str': 'Luteinized unruptured follicle syndrome (disorder)'}, {'cui': 'C0439682', 'cui_str': 'Follicular (qualifier value)'}, {'cui': 'C0243107', 'cui_str': 'development'}]",202.0,0.586146,"The incidence of cumulative cycle luteinized unruptured follicle syndrome was significantly lower in the CM group than in the placebo group [11.7% (40/342) vs. 17.8% (65/366), P<0.05).","[{'ForeName': 'Rui-Hua', 'Initials': 'RH', 'LastName': 'Zhao', 'Affiliation': ""Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. rhzh801@126.com.""}, {'ForeName': 'Yong', 'Initials': 'Y', 'LastName': 'Liu', 'Affiliation': ""Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.""}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Lu', 'Affiliation': 'Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Wu', 'Affiliation': 'Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Xiao-Yun', 'Initials': 'XY', 'LastName': 'Wang', 'Affiliation': 'Department of Gynecology, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, China.'}, {'ForeName': 'Wei-Li', 'Initials': 'WL', 'LastName': 'Li', 'Affiliation': 'Department of Gynecology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, 230031, China.'}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Zeng', 'Affiliation': 'Department of Gynecology, First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510405, China.'}, {'ForeName': 'Qing-Wei', 'Initials': 'QW', 'LastName': 'Meng', 'Affiliation': 'Department of Gynecology, Beijing Hospital, Beijing, 100730, China.'}, {'ForeName': 'Feng-Mei', 'Initials': 'FM', 'LastName': 'Lian', 'Affiliation': ""Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Zhou', 'Affiliation': 'Department of Gynecology, First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, 230031, China.'}, {'ForeName': 'Yun', 'Initials': 'Y', 'LastName': 'Shi', 'Affiliation': 'Department of Gynecology, Dongzhimen Hospital Beijing University of Chinese Medicine, Beijing, 100700, China.'}, {'ForeName': 'Wei-Wei', 'Initials': 'WW', 'LastName': 'Sun', 'Affiliation': ""Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.""}, {'ForeName': 'Qian', 'Initials': 'Q', 'LastName': 'Han', 'Affiliation': 'Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, 100026, China.'}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Tang', 'Affiliation': 'Maternal and Child Health Service Center of Pidu District, Chengdu, 611730, China.'}, {'ForeName': 'Guang', 'Initials': 'G', 'LastName': 'Shi', 'Affiliation': ""Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.""}]",Chinese journal of integrative medicine,['10.1007/s11655-019-3208-2'] 3175,31686529,Effects of a 3D-printed orthosis compared to a low-temperature thermoplastic plate orthosis on wrist flexor spasticity in chronic hemiparetic stroke patients: a randomized controlled trial.,"OBJECTIVE The aim of this study was to compare the effects of two kinds of wrist-hand orthosis on wrist flexor spasticity in chronic stroke patients. DESIGN This is a randomized controlled trial. SETTING The study was conducted in a rehabilitation center. PARTICIPANTS A total of 40 chronic hemiparetic stroke patients with wrist flexor spasticity were involved in the study. INTERVENTIONS Patients were randomly assigned to either an experimental group (conventional rehabilitation therapy + 3D-printed orthosis, 20 patients) or a control group (conventional rehabilitation therapy + low-temperature thermoplastic plate orthosis, 20 patients). The time of wearing orthosis was about 4-8 hours per day for six weeks. MAIN MEASURES Primary outcome measure : Modified Ashworth Scale was assessed three times (at baseline, three weeks, and six weeks). Secondary outcome measures : passive range of motion, Fugl-Meyer Assessment score, visual analogue scale score, and the swelling score were assessed twice (at baseline and six weeks). The subjective feeling score was assessed at six weeks. RESULTS No significant difference was found between the two groups in the change of Modified Ashworth Scale scores at three weeks (15% versus 25%, P  = 0.496). At six weeks, the Modified Ashworth Scale scores (65% versus 30%, P  = 0.02), passive range of wrist extension ( P  < 0.001), ulnar deviation ( P  = 0.028), Fugl-Meyer Assessment scores ( P  < 0.001), and swelling scores ( P  < 0.001) showed significant changes between the experimental group and the control group. No significant difference was found between the two groups in the change of visual analogue scale scores ( P  = 0.637) and the subjective feeling scores ( P  = 0.243). CONCLUSION 3D-printed orthosis showed greater changes than low-temperature thermoplastic plate orthosis in reducing spasticity and swelling, improving motor function of the wrist and passive range of wrist extension for stroke patients.",2020,"3D-printed orthosis showed greater changes than low-temperature thermoplastic plate orthosis in reducing spasticity and swelling, improving motor function of the wrist and passive range of wrist extension for stroke patients.","['chronic hemiparetic stroke patients', 'chronic stroke patients', '40 chronic hemiparetic stroke patients with wrist flexor spasticity were involved in the study']","['wrist-hand orthosis', '3D-printed orthosis compared to a low-temperature thermoplastic plate orthosis', 'experimental group (conventional rehabilitation therapy\u2009+\u20093D-printed orthosis, 20 patients) or a control group (conventional rehabilitation therapy\u2009+\u2009low-temperature thermoplastic plate orthosis']","['wrist flexor spasticity', 'change of visual analogue scale scores', 'time of wearing orthosis', 'Modified Ashworth Scale', 'Modified Ashworth Scale scores', 'change of Modified Ashworth Scale scores', 'swelling scores', 'ulnar deviation', 'subjective feeling scores', 'passive range of motion, Fugl-Meyer Assessment score, visual analogue scale score, and the swelling score', 'subjective feeling score', 'Fugl-Meyer Assessment scores', 'spasticity and swelling, improving motor function of the wrist and passive range of wrist extension', 'passive range of wrist extension']","[{'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}, {'cui': 'C1314939', 'cui_str': 'Involvement (attribute)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0009264', 'cui_str': 'Cold'}, {'cui': 'C0407295', 'cui_str': 'Fixation of fracture using plate (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0034991', 'cui_str': 'Rehabilitation'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0043262', 'cui_str': 'Wrist'}, {'cui': 'C0026838', 'cui_str': 'Muscle Spasticity'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C2960751', 'cui_str': 'Visual analog scale score'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C4707572', 'cui_str': 'Modified Ashworth Scale (assessment scale)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0038999', 'cui_str': 'Bulging (morphologic abnormality)'}, {'cui': 'C0449752', 'cui_str': 'Ulnar deviation (qualifier value)'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C1527305', 'cui_str': 'Feelings'}, {'cui': 'C0079991', 'cui_str': 'Passive Range of Motion'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0575735', 'cui_str': 'Passive range of wrist extension (observable entity)'}]",40.0,0.169557,"3D-printed orthosis showed greater changes than low-temperature thermoplastic plate orthosis in reducing spasticity and swelling, improving motor function of the wrist and passive range of wrist extension for stroke patients.","[{'ForeName': 'Yanan', 'Initials': 'Y', 'LastName': 'Zheng', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Gongliang', 'Initials': 'G', 'LastName': 'Liu', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Long', 'Initials': 'L', 'LastName': 'Yu', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Yanmin', 'Initials': 'Y', 'LastName': 'Wang', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Fang', 'Affiliation': 'School of Mechatronic Engineering and Automation, Shanghai University, Shanghai, China.'}, {'ForeName': 'Yikang', 'Initials': 'Y', 'LastName': 'Shen', 'Affiliation': 'School of Mechatronic Engineering and Automation, Shanghai University, Shanghai, China.'}, {'ForeName': 'Xiuling', 'Initials': 'X', 'LastName': 'Huang', 'Affiliation': 'School of Mechatronic Engineering and Automation, Shanghai University, Shanghai, China.'}, {'ForeName': 'Lei', 'Initials': 'L', 'LastName': 'Qiao', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Jianzhong', 'Initials': 'J', 'LastName': 'Yang', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Zhang', 'Affiliation': 'Department of Rehabilitation, Shanghai Xuhui Central Hospital, Shanghai, China.'}, {'ForeName': 'Zikai', 'Initials': 'Z', 'LastName': 'Hua', 'Affiliation': 'School of Mechatronic Engineering and Automation, Shanghai University, Shanghai, China.'}]",Clinical rehabilitation,['10.1177/0269215519885174'] 3176,32001798,"Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.","In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate (ORR) versus Rd in relapsed/refractory multiple myeloma (RRMM). Updated efficacy and safety after >3 years of follow-up are presented. Patients (N = 569) with ≥1 prior line received Rd (lenalidomide, 25 mg, on Days 1-21 of each 28-day cycle; dexamethasone, 40 mg, weekly) ± daratumumab at the approved dosing schedule. Minimal residual disease (MRD) was assessed by next-generation sequencing. After 44.3 months median follow-up, D-Rd prolonged progression-free survival (PFS) in the intent-to-treat population (median 44.5 vs 17.5 months; HR, 0.44; 95% CI, 0.35-0.55; P < 0.0001) and in patient subgroups. D-Rd demonstrated higher ORR (92.9 vs 76.4%; P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity (10 -5 ; 30.4 vs 5.3%; P < 0.0001). Median time to next therapy was prolonged with D-Rd (50.6 vs 23.1 months; HR, 0.39; 95% CI, 0.31-0.50; P < 0.0001). Median PFS on subsequent line of therapy (PFS2) was not reached with D-Rd versus 31.7 months with Rd (HR, 0.53; 95% CI, 0.42-0.68; P < 0.0001). No new safety concerns were reported. These data support using D-Rd in patients with RRMM after first relapse.",2020,"D-Rd demonstrated higher ORR (92.9 vs 76.4%; P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity (10 -5 ; 30.4 vs 5.3%; P < 0.0001).","['Patients (N\u2009=\u2009569) with ≥1 prior line received', 'relapsed/refractory multiple myeloma']","['Rd (lenalidomide', 'POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd', 'Daratumumab plus lenalidomide and dexamethasone', 'dexamethasone, 40\u2009mg, weekly)\u2009±\u2009daratumumab']","['Median time to next therapy', 'D-Rd prolonged progression-free survival (PFS', 'risk of disease progression or death', 'MRD negativity', 'Minimal residual disease (MRD', 'overall response rate (ORR', 'ORR', 'Median PFS on subsequent line of therapy (PFS2']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0205269', 'cui_str': 'Intractable (qualifier value)'}, {'cui': 'C0026764', 'cui_str': 'Myelomatosis'}]","[{'cui': 'C1144149', 'cui_str': 'lenalidomide'}, {'cui': 'C2346801', 'cui_str': 'daratumumab'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0011777', 'cui_str': 'Dexamethasone'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0242656', 'cui_str': 'Disease Progression'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0242596', 'cui_str': 'Minimal Disease, Residual'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}]",569.0,0.152505,"D-Rd demonstrated higher ORR (92.9 vs 76.4%; P < 0.0001) and deeper responses, including complete response or better (56.6 vs 23.2%; P < 0.0001) and MRD negativity (10 -5 ; 30.4 vs 5.3%; P < 0.0001).","[{'ForeName': 'Nizar J', 'Initials': 'NJ', 'LastName': 'Bahlis', 'Affiliation': 'University of Calgary, Charbonneau Cancer Research Institute, Calgary, AB, Canada. nbahlis@ucalgary.ca.'}, {'ForeName': 'Meletios A', 'Initials': 'MA', 'LastName': 'Dimopoulos', 'Affiliation': 'The National and Kapodistrian University of Athens, Athens, Greece.'}, {'ForeName': 'Darrell J', 'Initials': 'DJ', 'LastName': 'White', 'Affiliation': 'QEII Health Sciences Center and Dalhousie University, Halifax, NS, Canada.'}, {'ForeName': 'Lotfi', 'Initials': 'L', 'LastName': 'Benboubker', 'Affiliation': ""Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France.""}, {'ForeName': 'Gordon', 'Initials': 'G', 'LastName': 'Cook', 'Affiliation': ""St James's Institute of Oncology, Leeds Teaching Hospitals National Health Service Trust and University of Leeds, Leeds, UK.""}, {'ForeName': 'Merav', 'Initials': 'M', 'LastName': 'Leiba', 'Affiliation': 'Assuta University Hospital, Faculty of Health Science, Ben-Gurion University of the Negev, Beersheba, Israel.'}, {'ForeName': 'P Joy', 'Initials': 'PJ', 'LastName': 'Ho', 'Affiliation': 'Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.'}, {'ForeName': 'Kihyun', 'Initials': 'K', 'LastName': 'Kim', 'Affiliation': 'Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.'}, {'ForeName': 'Naoki', 'Initials': 'N', 'LastName': 'Takezako', 'Affiliation': 'Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Moreau', 'Affiliation': 'Hematology, University Hospital Hôtel-Dieu, Nantes, France.'}, {'ForeName': 'Jonathan L', 'Initials': 'JL', 'LastName': 'Kaufman', 'Affiliation': 'Winship Cancer Institute, Emory University, Atlanta, GA, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Krevvata', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Chiu', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Xiang', 'Initials': 'X', 'LastName': 'Qin', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Okonkwo', 'Affiliation': 'Janssen Research & Development, LLC, Raritan, NJ, USA.'}, {'ForeName': 'Sonali', 'Initials': 'S', 'LastName': 'Trivedi', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Jon', 'Initials': 'J', 'LastName': 'Ukropec', 'Affiliation': 'Janssen Global Medical Affairs, Horsham, PA, USA.'}, {'ForeName': 'Ming', 'Initials': 'M', 'LastName': 'Qi', 'Affiliation': 'Janssen Research & Development, LLC, Spring House, PA, USA.'}, {'ForeName': 'Jesus', 'Initials': 'J', 'LastName': 'San-Miguel', 'Affiliation': 'Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain.'}]",Leukemia,['10.1038/s41375-020-0711-6'] 3177,31989291,The effect of acupressure applied to points LV4 and LI4 on perceived acute postpartum perineal pain after vaginal birth with episiotomy: a randomized controlled study.,"PURPOSE Acupressure can be used for alleviating perineal pain sustained after a vaginal birth with episiotomy. To evaluate if a 10-min acupressure application relieved perineal pain after vaginal birth with episiotomy and if the analgesic effect was maintained for up to 120 min. METHODS A randomized controlled trial was conducted from January to May 2019 with 120 women. The participants were over 18 years old, had an episiotomy and experienced perineal pain ≥ 4, had not received anti-inflammatory medication or analgesics after childbirth, and were randomized to receive acupressure or ice-pack application on the perineum for 10 min or standard care. RESULTS Immediately post-intervention, the women in the experimental groups had a significantly higher decrease in perineal pain. Within 120 min, there was a significant difference in the pain levels between the three groups. Each method (acupressure, ice package and control group) is evaluated for 30 min (VAS 3), 60 min (VAS 4) and 120 min (VAS 5). Comparing these 3 methods the acupressure has significantly reduced pain after the application (VAS 3 3.20 ± 1.28 vs. 3.77 ± 1.27 vs. 4.82 ± 0.93, respectively, VAS 4 2.65 ± 1.33 vs. 3.5 ± 1.37 vs. 4.62 ± 0.97, respectively, VAS 5 2.02 ± 1.44 vs. 3.5 ± 1.37 vs. 4.57 ± 0.93, respectively, p < 0.05) CONCLUSION: Effective pain relief is achieved by applying acupressure for 10 min to the perineum and is maintained between 30, 60, and 120 min.",2020,"Comparing these 3 methods the acupressure has significantly reduced pain after the application (VAS 3 3.20 ± 1.28 vs. 3.77 ± 1.27 vs. 4.82 ± 0.93, respectively, VAS 4 2.65 ± 1.33 vs. 3.5 ± 1.37 vs. 4.62 ± 0.97, respectively, VAS 5 2.02 ± 1.44 vs. 3.5 ± 1.37 vs. 4.57 ± 0.93, respectively, p < 0.05) CONCLUSION:","['perineal pain sustained after a vaginal birth with episiotomy', 'January to May 2019 with 120 women', 'acute postpartum perineal pain after vaginal birth with episiotomy', 'participants were over 18\xa0years old, had an episiotomy and experienced perineal pain\u2009≥\u20094, had not received anti-inflammatory medication or analgesics after childbirth']","['acupressure or ice-pack application on the perineum for 10\xa0min or standard care', '10-min acupressure application', 'acupressure']","['pain', 'pain levels', 'Effective pain relief', 'perineal pain']","[{'cui': 'C0240717', 'cui_str': 'Perineal pain (finding)'}, {'cui': 'C0443318', 'cui_str': 'Sustained (qualifier value)'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0005615', 'cui_str': 'Birth'}, {'cui': 'C0014586', 'cui_str': 'Episiotomy'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086839', 'cui_str': 'Postpartum Period'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C1148523', 'cui_str': 'Childbirth'}]","[{'cui': 'C0282614', 'cui_str': 'Acupressure'}, {'cui': 'C0181264', 'cui_str': 'Ice bag, device (physical object)'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0031066', 'cui_str': 'Perineum'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0518087', 'cui_str': 'Pain level'}, {'cui': 'C1704419', 'cui_str': 'Effective (qualifier value)'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0240717', 'cui_str': 'Perineal pain (finding)'}]",,0.105413,"Comparing these 3 methods the acupressure has significantly reduced pain after the application (VAS 3 3.20 ± 1.28 vs. 3.77 ± 1.27 vs. 4.82 ± 0.93, respectively, VAS 4 2.65 ± 1.33 vs. 3.5 ± 1.37 vs. 4.62 ± 0.97, respectively, VAS 5 2.02 ± 1.44 vs. 3.5 ± 1.37 vs. 4.57 ± 0.93, respectively, p < 0.05) CONCLUSION:","[{'ForeName': 'Ayça', 'Initials': 'A', 'LastName': 'Şolt Kirca', 'Affiliation': 'Department of Midwifery, Kirklareli University School of Health, Kirklareli, Turkey. aycasolt@hotmail.com.'}, {'ForeName': 'Derya', 'Initials': 'D', 'LastName': 'Kanza Gul', 'Affiliation': 'Department of Obstetrics and Gynaecology, University of Istanbul Medipol, Istanbul, Turkey.'}]",Archives of gynecology and obstetrics,['10.1007/s00404-020-05439-z'] 3178,31988253,Physical Exercise Combined With CPAP in Subjects Who Underwent Surgical Myocardial Revascularization: A Randomized Clinical Trial.,"BACKGROUND Aerobic exercise and CPAP benefit patients in the postoperative period of cardiac surgery. To our knowledge, the association of aerobic exercise on an exercise bicycle with CPAP has not yet been demonstrated. Therefore, we aimed to evaluate the effectiveness of physical exercise on a cycle ergometer combined with CPAP in the postoperative period after coronary artery bypass graft surgery. METHODS This was a randomized clinical trial, with recruitment from May 2017 to December 2017 (registered in the Brazilian Clinical Trials Registry: RBR-69CDYF). The step group ( n = 16 subjects) started rehabilitation in the immediate postoperative period with breathing exercises and passive mobilization in the sitting position, progressing to active exercises, ambulation, and stair training. For the intervention group ( n = 15 subjects), dynamic exercises on a cycle ergometer combined with CPAP were added to the step program from the second to the fourth postoperative day in a single daily session. RESULTS Functional capacity decreased in both groups, but this reduction was not significant in the intervention group ( P = .11). The length of stay in ICU was lower in the intervention group ( P = .050). In both groups there was a decrease in maximum inspiratory and expiratory pressure, as well as in the 1-min sit-to-stand test on the fourth postoperative day compared to the preoperative period. CONCLUSIONS Physical exercise combined with CPAP promoted the maintenance of functional capacity and reduced the length of stay in the ICU.",2020,"RESULTS Functional capacity decreased in both groups, but this reduction was not significant in the intervention group ( P = .11).","['Subjects', 'with recruitment from May 2017 to December 2017 (registered in the Brazilian Clinical Trials Registry: RBR-69CDYF', 'patients in the postoperative period of cardiac surgery']","['Physical exercise combined with CPAP', 'Surgical Myocardial Revascularization', 'breathing exercises and passive mobilization in the sitting position, progressing to active exercises, ambulation, and stair training', 'dynamic exercises on a cycle ergometer combined with CPAP', 'CPAP', 'Aerobic exercise and CPAP benefit', 'physical exercise', 'Physical Exercise Combined With CPAP']","['length of stay in ICU', 'maximum inspiratory and expiratory pressure', 'length of stay', 'Functional capacity']","[{'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0600375', 'cui_str': 'Registers'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0034975', 'cui_str': 'Registries'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0032790', 'cui_str': 'Postoperative Period'}, {'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0027056', 'cui_str': 'Myocardial Revascularization'}, {'cui': 'C0300926', 'cui_str': 'mobilization'}, {'cui': 'C0277814', 'cui_str': 'Sitting position (finding)'}, {'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0419117', 'cui_str': 'Active exercise (regime/therapy)'}, {'cui': 'C0945826', 'cui_str': 'Ambulation'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0001701', 'cui_str': 'Exercise, Aerobic'}]","[{'cui': 'C0023303', 'cui_str': 'Length of Stay'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0460139', 'cui_str': 'Pressure (finding)'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",,0.0352745,"RESULTS Functional capacity decreased in both groups, but this reduction was not significant in the intervention group ( P = .11).","[{'ForeName': 'Pollyana', 'Initials': 'P', 'LastName': 'Windmöller', 'Affiliation': 'Undergraduate Program in Physical Therapy at the Regional University of Northwestern Rio Grande do Sul (UNIJUÍ), Ijuí, Brazil.'}, {'ForeName': 'Emely Teixeira', 'Initials': 'ET', 'LastName': 'Bodnar', 'Affiliation': 'Undergraduate Program in Physical Therapy at the Regional University of Northwestern Rio Grande do Sul (UNIJUÍ), Ijuí, Brazil.'}, {'ForeName': 'Julia', 'Initials': 'J', 'LastName': 'Casagrande', 'Affiliation': 'Undergraduate Program in Physical Therapy at the Regional University of Northwestern Rio Grande do Sul (UNIJUÍ), Ijuí, Brazil.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Dallazen', 'Affiliation': 'Undergraduate Program in Physical Therapy at the Regional University of Northwestern Rio Grande do Sul (UNIJUÍ), Ijuí, Brazil.'}, {'ForeName': 'Juliana', 'Initials': 'J', 'LastName': 'Schneider', 'Affiliation': 'Cardiovascular Surgery Unit of the Heart Institute of Ijuí Charity Hospital, Ijuí, Brazil.'}, {'ForeName': 'Silvana Agnolleto', 'Initials': 'SA', 'LastName': 'Berwanger', 'Affiliation': 'Cardiovascular Surgery Unit of the Heart Institute of Ijuí Charity Hospital, Ijuí, Brazil.'}, {'ForeName': 'Audrey', 'Initials': 'A', 'LastName': 'Borghi-Silva', 'Affiliation': 'Graduate Program in Physical Therapy of the Federal University of São Carlos (UFSCar), São Paulo-SP, Brazil.'}, {'ForeName': 'Eliane Roseli', 'Initials': 'ER', 'LastName': 'Winkelmann', 'Affiliation': 'Undergraduate Program in Physical Therapy at the Regional University of Northwestern Rio Grande do Sul (UNIJUÍ), Ijuí, Brazil. elianew@unijui.edu.br.'}]",Respiratory care,['10.4187/respcare.06919'] 3179,31603013,Lighting as an aid for recovery in hospitalized psychiatric patients: a randomized controlled effectiveness trial.,"Purpose: Artificial indoor lighting can disturb sleep and increase depressive symptoms; both common complaints in psychiatric inpatients. In this trial we aimed to improve sleep in psychiatric inpatients using a circadian lighting environment. Patients and methods: Investigator-blinded parallel-group randomised controlled effectiveness trial in an inpatient psychiatric ward with adjustable lighting. Admitted patients received a pre-set circadian lighting environment (intervention group) or lighting as usual (control group). The primary outcome was the Pittsburg Sleep Quality Index (PSQI) and secondary outcomes included the Major Depression Inventory and WHO-5 Well-Being Index. Results: We assessed 74 patients and included 54 (27 treated and 27 controls). Treated patients reported a non-significant change in mean sleep quality by -1.02 points on the PSQI (95% CI: -3.17; 1.12) and controls by -0.59 points (95% CI: -2.52; 1.33), difference -0.43 (95% CI: -3.05; 2.2, p -value .74). Similarly, treated patients reported a non-significant change in depressive symptoms and well-being compared to controls. Qualitative data indicated no serious side-effects and no patients in the intervention group were submitted to involuntary measures. Collection of data was non-complete and missing data from self-reported questionnaires amounted to 52.5%. Conclusions: The intervention showed no effect on sleep quality, mood or well-being. The circadian lighting environment was safe in our small and diverse patient sample. The trial integrated well with routine clinical care and our sample reflected the heterogeneity of the target population.",2020,"Treated patients reported a non-significant change in mean sleep quality by -1.02 points on the PSQI (95% CI: -3.17; 1.12) and controls by -0.59 points (95% CI: -2.52; 1.33), difference -0.43","['psychiatric inpatients', '74 patients and included 54 (27 treated and 27 controls', 'psychiatric inpatients using a circadian lighting environment', 'inpatient psychiatric ward with adjustable lighting', 'hospitalized psychiatric patients']","['pre-set circadian lighting environment (intervention group) or lighting as usual (control group', 'Artificial indoor lighting']","['depressive symptoms', 'mean sleep quality', 'sleep quality, mood or well-being', 'Pittsburg Sleep Quality Index (PSQI) and secondary outcomes included the Major Depression Inventory and WHO-5 Well-Being Index']","[{'cui': 'C0748064', 'cui_str': 'Psychiatric inpatient'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0023700', 'cui_str': 'Illumination'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0021562', 'cui_str': 'Inpatient (person)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C1305702', 'cui_str': 'Ward (environment)'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0023700', 'cui_str': 'Illumination'}, {'cui': 'C0014406', 'cui_str': 'Environment'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332264', 'cui_str': 'Light (weight) (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C2004457', 'cui_str': 'Artificial (qualifier value)'}]","[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0026516', 'cui_str': 'Mood'}, {'cui': 'C0600653', 'cui_str': 'Indexes'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}]",74.0,0.234677,"Treated patients reported a non-significant change in mean sleep quality by -1.02 points on the PSQI (95% CI: -3.17; 1.12) and controls by -0.59 points (95% CI: -2.52; 1.33), difference -0.43","[{'ForeName': 'Niels', 'Initials': 'N', 'LastName': 'Okkels', 'Affiliation': 'Department of Affective Disorders, Aarhus University Hospital Risskov, Aarhus, Denmark.'}, {'ForeName': 'Louis Gammelgaard', 'Initials': 'LG', 'LastName': 'Jensen', 'Affiliation': 'Department of Mathematics, Aarhus University, Aarhus, Denmark.'}, {'ForeName': 'Lykke Carolina', 'Initials': 'LC', 'LastName': 'Skovshoved', 'Affiliation': 'Department of Nursing, VIA University College, Aarhus, Denmark.'}, {'ForeName': 'Runhild', 'Initials': 'R', 'LastName': 'Arendt', 'Affiliation': 'Department of Affective Disorders, Aarhus University Hospital Risskov, Aarhus, Denmark.'}, {'ForeName': 'Anne Bastholm', 'Initials': 'AB', 'LastName': 'Blicher', 'Affiliation': 'Department of Affective Disorders, Aarhus University Hospital Risskov, Aarhus, Denmark.'}, {'ForeName': 'Eduard', 'Initials': 'E', 'LastName': 'Vieta', 'Affiliation': 'Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.'}, {'ForeName': 'Sune', 'Initials': 'S', 'LastName': 'Straszek', 'Affiliation': 'Department of Affective Disorders, Aarhus University Hospital Risskov, Aarhus, Denmark.'}]",Nordic journal of psychiatry,['10.1080/08039488.2019.1676465'] 3180,31896168,Topical antibiotics for chronic suppurative otitis media.,"BACKGROUND Chronic suppurative otitis media (CSOM), sometimes referred to as chronic otitis media (COM), is a chronic inflammation and often polymicrobial infection (involving more than one micro-organism) of the middle ear and mastoid cavity, characterised by ear discharge (otorrhoea) through a perforated tympanic membrane. The predominant symptoms of CSOM are ear discharge and hearing loss. Topical antibiotics, the most common treatment for CSOM, act to kill or inhibit the growth of micro-organisms that may be responsible for the infection. Antibiotics can be used alone or in addition to other treatments for CSOM, such as antiseptics or ear cleaning (aural toileting). OBJECTIVES To assess the effects of topical antibiotics (without steroids) for people with CSOM. SEARCH METHODS The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL via the Cochrane Register of Studies); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 1 April 2019. SELECTION CRITERIA We included randomised controlled trials (RCTs) with at least a one-week follow-up involving participants (adults and children) who had chronic ear discharge of unknown cause or CSOM, where the ear discharge had continued for more than two weeks. The interventions were any single, or combination of, topical antibiotic agent(s) of any class, applied directly into the ear canal as ear drops, powders or irrigations, or as part of an aural toileting procedure. The two main comparisons were topical antibiotic compared to a) placebo or no intervention and b) another topical antibiotic (e.g. topical antibiotic A versus topical antibiotic B). Within each comparison we separated studies where both groups of participants had received topical antibiotic a) alone or with aural toileting and b) on top of background treatment (such as systemic antibiotics). DATA COLLECTION AND ANALYSIS We used the standard Cochrane methodological procedures. We used GRADE to assess the certainty of the evidence for each outcome. Our primary outcomes were: resolution of ear discharge or 'dry ear' (whether otoscopically confirmed or not), measured at between one week and up to two weeks, two weeks to up to four weeks and after four weeks; health-related quality of life using a validated instrument; ear pain (otalgia) or discomfort or local irritation. Secondary outcomes included hearing, serious complications and ototoxicity measured in several ways. MAIN RESULTS We included 17 studies with a total of 2198 participants. Twelve studies reported the sample size in terms of participants (not ears); these had a total of 1797 participants. The remaining five studies reported both the number of participants and ears, representing 401 participants, or 510 ears. A: Topical antibiotics versus placebo or no treatment (with aural toilet in both arms and no other background treatment) One small study compared a topical antibiotic (ciprofloxacin) with placebo (saline). All participants received aural toilet. Although ciprofloxacin was better than saline in terms of resolution of discharge at one to two weeks: 84% versus 12% (risk ratio (RR) 6.74, 95% confidence interval (CI) 1.82 to 24.99; 35 participants, very low-certainty evidence), the very low certainty of the evidence means that it is very uncertain whether or not one intervention is better or worse than the other. The study authors reported that ""no medical side-effects and worsening of audiological measurements related to this topical medication were detected"" (very low-certainty evidence). B: Topical antibiotics versus placebo or no treatment (with use of oral antibiotics in both arms) Four studies compared topical ciprofloxacin to no treatment (three studies; 190 participants) or topical ceftizoxime to no treatment (one study; 248 participants). In each study all participants received the same antibiotic systemically (oral ciprofloxacin, injected ceftizoxime). In at least one study all participants received aural toilet. Useable data were only available from the first three studies; ciprofloxacin was better than no treatment, resolution of discharge occurring in 88.2% versus 60% at one to two weeks (RR 1.47, 95% CI 1.20 to 1.80; 2 studies, 150 participants; low-certainty evidence). None of the studies reported ear pain or discomfort/local irritation. C: Comparisons of different topical antibiotics The certainty of evidence for all outcomes in these comparisons is very low. Quinolones versus aminoglycosides Seven studies compared an aminoglycoside (gentamicin, neomycin or tobramycin) with ciprofloxacin (734 participants) or ofloxacin (214 participants). Whilst resolution of discharge at one to two weeks was higher in the quinolones group the very low certainty of the evidence means that it is very uncertain whether or not one intervention is better or worse than the other (RR 1.95, 95% CI 0.88 to 4.29; 6 studies, 694 participants). One study measured ear pain and reported no difference between the groups. Quinolones versus aminoglycosides/polymyxin B combination ±gramicidin We identified three studies but data on our primary outcome were only available in one study. Comparing ciprofloxacin to a neomycin/polymyxin B/gramicidin combination, for an unknown treatment duration (likely four weeks), ciprofloxacin was better (RR 1.12, 95% CI 1.03 to 1.22, 186 participants). A ""few"" patients experienced local irritation upon the first instillation of topical treatment (numbers/groups not stated). Others Other studies examined topical gentamicin versus a trimethoprim/sulphacetamide/polymixin B combination (91 participants) and rifampicin versus chloramphenicol (160 participants). Limited data were available and the findings were very uncertain. AUTHORS' CONCLUSIONS We are uncertain about the effectiveness of topical antibiotics in improving resolution of ear discharge in patients with CSOM because of the limited amount of low-quality evidence available. However, amongst this uncertainty there is some evidence to suggest that the use of topical antibiotics may be effective when compared to placebo, or when used in addition to a systemic antibiotic. There is also uncertainty about the relative effectiveness of different types of antibiotics; it is not possible to determine with any certainty whether or not quinolones are better or worse than aminoglycosides. These two groups of compounds have different adverse effect profiles, but there is insufficient evidence from the included studies to make any comment about these. In general, adverse effects were poorly reported.",2020,"Although ciprofloxacin was better than saline in terms of resolution of discharge at one to two weeks: 84% versus 12% (risk ratio (RR) 6.74, 95% confidence interval (CI) 1.82 to 24.99; 35 participants, very low-certainty evidence), the very low certainty of the evidence means that it is very uncertain whether or not one intervention is better or worse than the other.","['participants (not ears); these had a total of 1797 participants', '214 participants', '734 participants) or', 'Chronic suppurative otitis media (CSOM', 'patients with CSOM', '190 participants) or topical ceftizoxime to no treatment (one study; 248 participants', 'participants (adults and children) who had chronic ear discharge of unknown cause or CSOM, where the ear discharge had continued for more than two weeks', 'B', 'people with CSOM', '17 studies with a total of 2198 participants', 'chronic suppurative otitis media']","['topical antibiotic (e.g. topical antibiotic A versus topical antibiotic B', 'ciprofloxacin', 'aural toilet', 'antibiotic systemically (oral ciprofloxacin, injected ceftizoxime', 'ofloxacin', 'C', 'topical antibiotic (ciprofloxacin', 'topical antibiotics', 'trimethoprim/sulphacetamide/polymixin B combination', 'Quinolones versus aminoglycosides', 'Topical antibiotics', 'Quinolones', 'topical antibiotic agent(s) of any class, applied directly into the ear canal as ear drops, powders or irrigations, or as part of an aural toileting procedure', 'topical ciprofloxacin', 'neomycin/polymyxin B/gramicidin combination', 'topical gentamicin', 'topical antibiotics (without steroids', 'polymyxin B combination', 'placebo (saline', 'placebo', 'Topical antibiotics versus placebo', 'topical antibiotic a) alone or with aural toileting and b) on top of background treatment (such as systemic antibiotics', 'aminoglycoside (gentamicin, neomycin or tobramycin', 'rifampicin versus chloramphenicol']","['local irritation', 'health-related quality of life using a validated instrument; ear pain (otalgia) or discomfort or local irritation', ""resolution of ear discharge or 'dry ear"", 'ear pain', 'hearing, serious complications and ototoxicity measured in several ways', 'resolution of discharge', 'resolution of discharge occurring', 'ear pain or discomfort/local irritation']","[{'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0271454', 'cui_str': 'Chronic purulent otitis media (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517622', 'cui_str': 'One hundred and ninety'}, {'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0007560', 'cui_str': 'Ceftizoxime'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0155540', 'cui_str': 'Otorrhea (disorder)'}, {'cui': 'C0439673', 'cui_str': 'Unknown (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C4082118', 'cui_str': 'Two weeks'}]","[{'cui': 'C0332237', 'cui_str': 'Topical (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0008809', 'cui_str': 'Ciprofloxacin'}, {'cui': 'C1140607', 'cui_str': 'Toilets'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4521936', 'cui_str': 'Inject (administration method)'}, {'cui': 'C0007560', 'cui_str': 'Ceftizoxime'}, {'cui': 'C0028902', 'cui_str': 'Ofloxacin'}, {'cui': 'C0041041', 'cui_str': 'Trimethoprim'}, {'cui': 'C0038670', 'cui_str': 'Sulfacetamide'}, {'cui': 'C0034428', 'cui_str': 'Oxoquinolines'}, {'cui': 'C0002556', 'cui_str': 'Aminoglycosides'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C1632850', 'cui_str': 'Apply'}, {'cui': 'C0013444', 'cui_str': 'External Ear Canal'}, {'cui': 'C1154187', 'cui_str': 'Ear Drops'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0022100', 'cui_str': 'Lavage'}, {'cui': 'C1292711', 'cui_str': 'Part of (attribute)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C1445775', 'cui_str': 'Neomycin / Polymyxin B'}, {'cui': 'C0018165', 'cui_str': 'Gramicidin'}, {'cui': 'C0017436', 'cui_str': 'Gentamicins'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0032535', 'cui_str': 'Polymyxin B'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0027603', 'cui_str': 'Neomycin'}, {'cui': 'C0040341', 'cui_str': 'Tobramycin'}, {'cui': 'C0035608', 'cui_str': 'rifampicin'}, {'cui': 'C0008168', 'cui_str': 'Chloramphenicol'}]","[{'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0441723', 'cui_str': 'Irritation (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0013456', 'cui_str': 'Otalgia'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0155540', 'cui_str': 'Otorrhea (disorder)'}, {'cui': 'C0205222', 'cui_str': 'Dry (qualifier value)'}, {'cui': 'C0013443', 'cui_str': 'Vestibulocochlear Apparatus'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0235280', 'cui_str': 'Ototoxicity (disorder)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]",401.0,0.385148,"Although ciprofloxacin was better than saline in terms of resolution of discharge at one to two weeks: 84% versus 12% (risk ratio (RR) 6.74, 95% confidence interval (CI) 1.82 to 24.99; 35 participants, very low-certainty evidence), the very low certainty of the evidence means that it is very uncertain whether or not one intervention is better or worse than the other.","[{'ForeName': 'Christopher G', 'Initials': 'CG', 'LastName': 'Brennan-Jones', 'Affiliation': 'Telethon Kids Institute, The University of Western Australia, 15 Hospital Avenue, Perth, Western Australia, Australia, 6009.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Head', 'Affiliation': 'Nuffield Department of Surgical Sciences, University of Oxford, Cochrane ENT, UK Cochrane Centre, Summertown Pavilion, 18 - 24 Middle Way, Oxford, UK.'}, {'ForeName': 'Lee-Yee', 'Initials': 'LY', 'LastName': 'Chong', 'Affiliation': 'Nuffield Department of Surgical Sciences, University of Oxford, Cochrane ENT, UK Cochrane Centre, Summertown Pavilion, 18 - 24 Middle Way, Oxford, UK.'}, {'ForeName': 'Martin J', 'Initials': 'MJ', 'LastName': 'Burton', 'Affiliation': 'Cochrane UK, Summertown Pavilion, 18 - 24 Middle Way, Oxford, UK, OX2 7LG.'}, {'ForeName': 'Anne Gm', 'Initials': 'AG', 'LastName': 'Schilder', 'Affiliation': 'Faculty of Brain Sciences, University College London, evidENT, Ear Institute, 330 Grays Inn Road, London, UK, WC1X 8DA.'}, {'ForeName': 'Mahmood F', 'Initials': 'MF', 'LastName': 'Bhutta', 'Affiliation': 'Brighton and Sussex University Hospitals NHS Trust, Department of Otolaryngology, Eastern Road, Brighton, UK, BN2 5BE.'}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD013051.pub2'] 3181,31444929,"Treadmill training in patients affected by Charcot-Marie-Tooth neuropathy: results of a multicenter, prospective, randomized, single-blind, controlled study.","BACKGROUND AND PURPOSE Muscle-strengthening, stretching or proprioceptive treatments may slow symptom progression in Charcot-Marie-Tooth (CMT) neuropathy. The aim of the study was to evaluate safety and efficacy of treadmill training in CMT1A. METHODS We planned a multicenter, prospective, randomized, single-blind, controlled study. We recruited 53 outpatients affected by CMT1A and randomized them into two treatment groups: one underwent stretching and proprioceptive exercise, whereas the other was additionally treated with treadmill training (TreSPE). Primary outcome measures (OMs) were the walking evaluations and secondary OM was the balance assessment. All participants were assessed at baseline and after 3 and 6 months of treatment. RESULTS Most patients showed an improvement in at least one OM after 3 months [42/47 (89.4%)] and 6 months [38/40 (95%)] of treatment. No adverse events were reported in either group. CONCLUSIONS The most important finding was that both stretching and proprioceptive exercise and treadmill training had an objective benefit on patients affected by CMT disease, without causing overwork weakness. We had a low rate of drop out and did not find deterioration in motor performance. Our results also confirm that applying evidence-based medicine methods to rehabilitative research is the correct way to test the efficacy of a treatment.",2020,Most people showed an improvement in at least one OM at T1 (42/47; 89.4%) and T2 (38/40; 95%).,"['53 outpatients affected by', 'people affected by Charcot-Marie-Tooth (CMT) neuropathy']","['treadmill training in CMT1A', 'Treadmill training', 'CMT1A', 'stretching and proprioceptive exercise (SPE), while the other was additionally treated with Treadmill training (TreSPE', 'SPE and treadmill training']","['adverse events', 'walking evaluations, and secondary OM the balance assessment', 'safety and efficacy']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0442874', 'cui_str': 'Neuropathy (disorder)'}]","[{'cui': 'C0184069', 'cui_str': 'Treadmill, device (physical object)'}, {'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0454280', 'cui_str': 'Proprioceptive exercises (regime/therapy)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0080331', 'cui_str': 'Walking'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C1960377', 'cui_str': 'Assessment of sense of balance (procedure)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",53.0,0.17701,Most people showed an improvement in at least one OM at T1 (42/47; 89.4%) and T2 (38/40; 95%).,"[{'ForeName': 'L', 'Initials': 'L', 'LastName': 'Mori', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Signori', 'Affiliation': 'Department of Health Science, Biostatistics Section, University of Genoa, Genoa, Italy.'}, {'ForeName': 'V', 'Initials': 'V', 'LastName': 'Prada', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.'}, {'ForeName': 'D', 'Initials': 'D', 'LastName': 'Pareyson', 'Affiliation': 'Fondazione IRCCS, Istituto Neurologico Carlo Besta, Milan, Italy.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Piscosquito', 'Affiliation': ""Functional Neuromotor Rehabilitation Unit, IRCCS 'ICS Maugeri Spa - SB' Scientific Institute of Telese Terme, Telese Terme, Italy.""}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Padua', 'Affiliation': 'Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of Sacred Heart, Rome, Italy.'}, {'ForeName': 'C', 'Initials': 'C', 'LastName': 'Pazzaglia', 'Affiliation': 'Fondazione Don Carlo Gnocchi Onlus, Milan, Italy.'}, {'ForeName': 'G M', 'Initials': 'GM', 'LastName': 'Fabrizi', 'Affiliation': 'Neurology Section, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Picelli', 'Affiliation': 'Neuromotor and Cognitive Rehabilitation Research Center, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Schenone', 'Affiliation': 'Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",European journal of neurology,['10.1111/ene.14074'] 3182,31898874,"History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial.","OBJECTIVE To examine the effects of an intensive lifestyle intervention (ILI) on cardiovascular disease (CVD), the Action for Health in Diabetes (Look AHEAD) trial randomized 5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education. Although the primary outcome did not differ between the groups, there was suggestive evidence of heterogeneity for prespecified baseline CVD history subgroups (interaction P = 0.063). Event rates were higher in the ILI group among those with a CVD history (hazard ratio 1.13 [95% CI: 0.90-1.41]) and lower among those without CVD (hazard ratio 0.86 [95% CI: 0.72-1.02]). METHODS This study conducted post hoc analyses of the rates of the primary composite outcome and components, adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes. RESULTS Interaction P values for the primary and two secondary composites were similar (0.060-0.064). Of components, the interaction was significant for nonfatal MI (P = 0.035). This interaction was not due to confounding by baseline variables, different intervention responses for weight loss and physical fitness, or hypoglycemic events. In those with a CVD history, statin use was high and similar by group. In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group. CONCLUSIONS Intervention response heterogeneity was significant for nonfatal MI. Response heterogeneity may need consideration in a CVD-outcome trial design.",2020,"In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group. ","['Diabetes', '5,145 participants with type 2 diabetes and overweight/obesity to a ILI or diabetes support and education']",['intensive lifestyle intervention (ILI'],"['adjudicated cardiovascular death, nonfatal myocardial infarction (MI), stroke, and hospitalization for angina, as well as three secondary composite cardiovascular outcomes', 'cardiovascular disease (CVD', 'weight loss and physical fitness, or hypoglycemic events', 'Event rates', 'nonfatal MI', 'low-density lipoprotein cholesterol levels']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0011849', 'cui_str': 'Diabetes Mellitus'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0013621', 'cui_str': 'Education'}]","[{'cui': 'C0023676', 'cui_str': 'Lifestyle'}]","[{'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0002962', 'cui_str': 'Stenocardia'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0007222', 'cui_str': 'Cardiovascular Diseases'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0031812', 'cui_str': 'Physical Fitness'}, {'cui': 'C0020616', 'cui_str': 'Hypoglycemic Drugs'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}]",5145.0,0.198386,"In those without a CVD history, low-density lipoprotein cholesterol levels were higher (P = 0.003) and statin use was lower (P ≤ 0.001) in the ILI group. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}, {'ForeName': 'Cora E', 'Initials': 'CE', 'LastName': 'Lewis', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Bantle', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Alain G', 'Initials': 'AG', 'LastName': 'Bertoni', 'Affiliation': 'Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'George', 'Initials': 'G', 'LastName': 'Blackburn', 'Affiliation': 'Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Frederick L', 'Initials': 'FL', 'LastName': 'Brancati', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'George A', 'Initials': 'GA', 'LastName': 'Bray', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Lawrence J', 'Initials': 'LJ', 'LastName': 'Cheskin', 'Affiliation': 'Johns Hopkins University, Baltimore, Maryland, USA.'}, {'ForeName': 'Jeffrey M', 'Initials': 'JM', 'LastName': 'Curtis', 'Affiliation': ""Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases and St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.""}, {'ForeName': 'Caitlin', 'Initials': 'C', 'LastName': 'Egan', 'Affiliation': 'The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.'}, {'ForeName': 'Mary', 'Initials': 'M', 'LastName': 'Evans', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'John P', 'Initials': 'JP', 'LastName': 'Foreyt', 'Affiliation': 'Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'Siran', 'Initials': 'S', 'LastName': 'Ghazarian', 'Affiliation': 'University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Bethany', 'Initials': 'B', 'LastName': 'Barone Gibbs', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Stephen P', 'Initials': 'SP', 'LastName': 'Glasser', 'Affiliation': 'University of Alabama at Birmingham, Birmingham, Alabama, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'W Gregg', 'Affiliation': 'Centers for Disease Control and Prevention, Atlanta, Georgia, USA.'}, {'ForeName': 'Helen P', 'Initials': 'HP', 'LastName': 'Hazuda', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'Louise', 'Initials': 'L', 'LastName': 'Hesson', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'James O', 'Initials': 'JO', 'LastName': 'Hill', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Edward S', 'Initials': 'ES', 'LastName': 'Horton', 'Affiliation': 'Joslin Diabetes Center, Boston, Massachusetts, USA.'}, {'ForeName': 'Van S', 'Initials': 'VS', 'LastName': 'Hubbard', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.'}, {'ForeName': 'John M', 'Initials': 'JM', 'LastName': 'Jakicic', 'Affiliation': 'University of Pittsburgh, Pittsburgh, Pennsylvania, USA.'}, {'ForeName': 'Robert W', 'Initials': 'RW', 'LastName': 'Jeffery', 'Affiliation': 'University of Minnesota, Minneapolis, Minnesota, USA.'}, {'ForeName': 'Karen C', 'Initials': 'KC', 'LastName': 'Johnson', 'Affiliation': 'The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Steven E', 'Initials': 'SE', 'LastName': 'Kahn', 'Affiliation': 'US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Abbas E', 'Initials': 'AE', 'LastName': 'Kitabchi', 'Affiliation': 'The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Dalane', 'Initials': 'D', 'LastName': 'Kitzman', 'Affiliation': 'Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'William C', 'Initials': 'WC', 'LastName': 'Knowler', 'Affiliation': 'Southwestern American Indian Center, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona, USA.'}, {'ForeName': 'Edward', 'Initials': 'E', 'LastName': 'Lipkin', 'Affiliation': 'US Department of Veterans Affairs Puget Sound Health Care System, University of Washington, Seattle, Washington, USA.'}, {'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Michaels', 'Affiliation': 'Southwestern American Indian Center, Shiprock, New Mexico, USA.'}, {'ForeName': 'Maria G', 'Initials': 'MG', 'LastName': 'Montez', 'Affiliation': 'University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Nathan', 'Affiliation': 'Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Ebenezer', 'Initials': 'E', 'LastName': 'Nyenwe', 'Affiliation': 'The University of Tennessee Health Science Center, Memphis, Tennessee, USA.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Patricio', 'Affiliation': ""St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.""}, {'ForeName': 'Anne', 'Initials': 'A', 'LastName': 'Peters', 'Affiliation': 'University of Southern California, Los Angeles, California, USA.'}, {'ForeName': 'Xavier', 'Initials': 'X', 'LastName': 'Pi-Sunyer', 'Affiliation': ""St. Luke's Roosevelt Hospital Center, Columbia University, New York, New York, USA.""}, {'ForeName': 'Henry', 'Initials': 'H', 'LastName': 'Pownall', 'Affiliation': 'Baylor College of Medicine, Houston, Texas, USA.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Reboussin', 'Affiliation': 'Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Donna H', 'Initials': 'DH', 'LastName': 'Ryan', 'Affiliation': 'Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.'}, {'ForeName': 'Thomas A', 'Initials': 'TA', 'LastName': 'Wadden', 'Affiliation': 'University of Pennsylvania, Philadelphia, Pennsylvania, USA.'}, {'ForeName': 'Lynne E', 'Initials': 'LE', 'LastName': 'Wagenknecht', 'Affiliation': 'Wake Forest University, Winston-Salem, North Carolina, USA.'}, {'ForeName': 'Holly', 'Initials': 'H', 'LastName': 'Wyatt', 'Affiliation': 'University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.'}, {'ForeName': 'Rena R', 'Initials': 'RR', 'LastName': 'Wing', 'Affiliation': 'The Miriam Hospital, Brown Medical School, Providence, Rhode Island, USA.'}, {'ForeName': 'Susan Z', 'Initials': 'SZ', 'LastName': 'Yanovski', 'Affiliation': 'National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.'}]","Obesity (Silver Spring, Md.)",['10.1002/oby.22676'] 3183,31062349,"Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.","BACKGROUND Consistency of response across multiple attacks is typically measured as the proportion of study participants who achieve a categorical endpoint over a specified number of attacks (ie, 2-hour pain-free response in 2 of 3 attacks). We applied a novel analytic approach for measuring consistency of response in the acute treatment of episodic migraine using data from the COMPASS study. METHODS The COMPASS study (NCT01667679) was a multiple attack crossover study which compared AVP-825, a Breath Powered ® intranasal delivery system for low-dose sumatriptan powder (22 mg), with 100-mg oral sumatriptan tablets in the acute treatment of migraine. Participants were 18-65 years old, met ICHD-2 criteria for migraine with or without aura, and had migraine for ≥1 year prior to screening. They were instructed to treat up to 5 migraine attacks with each treatment and recorded migraine pain intensity and disability data at pre-dose and 10, 15, 30, 45, 60, 90, and 120 minutes post-dose for each attack. We explored the mean level and within-person variability (WPV; a measure of consistency) in migraine pain intensity and migraine-related disability across multiple attacks after treatment with AVP-825 (22 mg) vs oral sumatriptan (100 mg) using location scale mixed-effects models (LSMEMs). LSMEMs controlled for pre-dose pain/disability, demographics, treatment sequence, and treatment period. RESULTS The mean age was 40 and the sample was 84.6% women. Participants (N = 259) treated an average of 6.8 attacks each during the course of the study. Attacks treated with AVP-825 showed significantly lower mean pain intensity and mean disability from 10 to 90 minutes post-dose (effect sizes ranged from -0.09 to -0.29 and P values ranged from P < .0001 to P = .01). WPV was significantly greater at 10-15 minutes (WPV ratios ranged from 1.20 to 1.58 and P values ranged from P < .0001 to P = .04) but significantly reduced from 45 to 120 minutes for attacks treated with AVP-825 compared to oral sumatriptan (WPV ratios ranged from 0.67 to 0.81 and P values ranged from P < .0001 to P = .03). CONCLUSIONS LSMEMs demonstrate that treatment with AVP-825 is associated with lower average migraine pain intensity and disability from 10 to 90 minutes and greater within-person consistency across multiple migraine attacks (reduced WPV) from 45 to 120 minutes post-dose compared to oral sumatriptan. These findings may reflect the more rapid and consistent absorption of sumatriptan using AVP-825. Increased WPV with AVP-825 in the first 15 minutes likely reflects the earlier onset of treatment effects with the device compared to oral sumatriptan. LSMEMs show promise as a novel approach for assessing and comparing consistency of treatment response in migraine trials.",2019,Attacks treated with AVP-825 showed significantly lower mean pain intensity and mean disability from 10 to 90 minutes post-dose (effect sizes ranged from -0.09 to -0.29 and P values ranged from P < .0001 to P = .01).,"['Participants (N\xa0=\xa0259) treated an average of 6.8 attacks each during the course of the study', 'Participants were 18-65 years old, met ICHD-2 criteria for migraine with or without aura, and had migraine for ≥1 year prior to screening', 'mean age was 40 and the sample was 84.6% women']","['AVP-825 (22 mg) vs oral sumatriptan', '100-mg oral sumatriptan tablets', 'AVP-825 vs Oral Sumatriptan', 'sumatriptan powder', 'AVP-825']","['WPV', 'mean pain intensity and mean disability', 'mean level and within-person variability (WPV', 'Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability', 'migraine pain intensity and disability data', 'average migraine pain intensity and disability']","[{'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1304680', 'cui_str': 'Attack (finding)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0243161', 'cui_str': 'criteria'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0236018', 'cui_str': 'Aura'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0075632', 'cui_str': 'Sumatriptan'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0332529', 'cui_str': 'Consistency finding'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}]",,0.0369191,Attacks treated with AVP-825 showed significantly lower mean pain intensity and mean disability from 10 to 90 minutes post-dose (effect sizes ranged from -0.09 to -0.29 and P values ranged from P < .0001 to P = .01).,"[{'ForeName': 'James S', 'Initials': 'JS', 'LastName': 'McGinley', 'Affiliation': 'Vector Psychometric Group, LLC, Chapel Hill, NC, USA.'}, {'ForeName': 'Dawn C', 'Initials': 'DC', 'LastName': 'Buse', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'ForeName': 'Kenneth J', 'Initials': 'KJ', 'LastName': 'Shulman', 'Affiliation': 'Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.'}, {'ForeName': 'R J', 'Initials': 'RJ', 'LastName': 'Wirth', 'Affiliation': 'Vector Psychometric Group, LLC, Chapel Hill, NC, USA.'}, {'ForeName': 'Emmanuelle', 'Initials': 'E', 'LastName': 'Hugentobler', 'Affiliation': 'Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.'}, {'ForeName': 'Richard B', 'Initials': 'RB', 'LastName': 'Lipton', 'Affiliation': 'Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.'}]",Headache,['10.1111/head.13530'] 3184,30339891,Sedation with dexmedetomidine prolongs the analgesic duration of brachial plexus block: a randomised controlled trial.,"PURPOSE Dexmedetomidine, an alpha 2 receptor agonist, prolongs nerve block duration when administered in conjunction with peripheral nerve blocks. We hypothesised that sedation with dexmedetomidine could also significantly prolong the analgesic duration of brachial plexus block (BPB) during orthopaedic surgery on the upper extremities. MATERIALS AND METHODS One hundred and two patients received upper extremity surgery under BPB. The patients were randomly sedated with dexmedetomidine (D group) or midazolam (M group) following BPB using 25 mL of local anaesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine). Adequate sedation was evaluated with the modified Ramsay Sedation Scale. Primary outcome was measured as the time the patient first requested analgesic via a patient-controlled analgesia device. Total opioid consumption during the first 24 post-operative hours was also measured as secondary outcomes. RESULTS Time to first request for analgesia (mean ± standard deviation) was significantly longer in the D group (616.9 ± 158.2 min) than in the M group (443.7 ± 127.2 min) (P < 0.001, Mean difference [95% CI] 173.2 [114.8-231.5] min). Total opioid consumption were significantly lower in the D group (fentanyl equivalent, 280.0 μg [171.3;374.0] vs. 363.9 μg [208.3;570.1], P = 0.01). Although patients in the D group showed deeper sedation over time (P < 0.001), PACU stay time was only slightly extended in D group (5.2 [1.2-9.2] min). Perioperative complications did not differ in the two groups. CONCLUSION Sedation with dexmedetomidine not only prolongs analgesic duration of BPB, but also reduces total opioid consumption during the first 24 post-operative hours.",2019,"Although patients in the D group showed deeper sedation over time (P < 0.001), PACU stay time was only slightly extended in D group (5.2 [1.2-9.2] min).",[],"['dexmedetomidine', 'upper extremity surgery under BPB', 'Dexmedetomidine', 'midazolam (M group) following BPB using 25\u2009mL of local anaesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine']","['deeper sedation over time', 'Total opioid consumption', 'total opioid consumption', 'time the patient first requested analgesic via a patient-controlled analgesia device', 'modified Ramsay Sedation Scale', 'PACU stay time', 'Perioperative complications', 'analgesic duration of brachial plexus block (BPB', 'analgesic duration of brachial plexus block', 'analgesic duration of BPB']",[],"[{'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C1608675', 'cui_str': '4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide'}, {'cui': 'C0026056', 'cui_str': 'Midazolam'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0002934', 'cui_str': 'Conduction-Blocking Anesthetics'}, {'cui': 'C0439962', 'cui_str': 'Mixture (qualifier value)'}, {'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C4068882', 'cui_str': '0.75'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}]","[{'cui': 'C1956064', 'cui_str': 'Deep Sedation'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1272683', 'cui_str': 'Requested'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0078944', 'cui_str': 'Patient-Controlled Analgesia'}, {'cui': 'C0220819', 'cui_str': 'devices'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0559295', 'cui_str': 'Ramsay sedation scale'}, {'cui': 'C0034871', 'cui_str': 'Hospital Recovery Rooms'}, {'cui': 'C4545429', 'cui_str': 'Perioperative complication'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0394697', 'cui_str': 'Brachial Plexus Anesthesia'}, {'cui': 'C1608675', 'cui_str': '4-iodo-N-(4-(4-(2-methoxyphenyl)-piperazin-1-yl)butyl)-benzamide'}]",102.0,0.133508,"Although patients in the D group showed deeper sedation over time (P < 0.001), PACU stay time was only slightly extended in D group (5.2 [1.2-9.2] min).","[{'ForeName': 'Boohwi', 'Initials': 'B', 'LastName': 'Hong', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University College of Medicine, South Korea; Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'Choonho', 'Initials': 'C', 'LastName': 'Jung', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'Yumin', 'Initials': 'Y', 'LastName': 'Jo', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'Hyemin', 'Initials': 'H', 'LastName': 'Kang', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'Woosuk', 'Initials': 'W', 'LastName': 'Chung', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University College of Medicine, South Korea; Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'Yoon-Hee', 'Initials': 'YH', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University College of Medicine, South Korea; Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'ChaeSeong', 'Initials': 'C', 'LastName': 'Lim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University College of Medicine, South Korea; Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea.'}, {'ForeName': 'YoungKwon', 'Initials': 'Y', 'LastName': 'Ko', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine Chungnam National University College of Medicine, South Korea; Department of Anaesthesiology and Pain Medicine Chungnam National University Hospital, South Korea. Electronic address: annn8432@gmail.com.'}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2018.08.006'] 3185,30394347,Haemodynamic changes and incisional bleeding after scalp infiltration of dexmedetomidine with lidocaine in neurosurgical patients.,"BACKGROUND The purpose of this randomised controlled study is to compare the haemodynamic changes and the degree of incisional bleeding after scalp infiltration of lidocaine and dexmedetomidine versus lidocaine and epinephrine for patients with hemi-facial spasm undergoing microvascular decompression. METHODS Fifty-two patients were injected with 5 mL of 1% lidocaine with either dexmedetomidine (2 μg/mL) or epinephrine (1:100,000 dilution) to reduce scalp bleeding. Mean blood pressure and heart rate were recorded every minute for 15 minutes after scalp infiltration. The primary outcome was the incidence of predefined hypotension, which was treated with administration of 4 mg ephedrine as often as needed. The number of administrations and total amount of ephedrine administered were also recorded as a measure of the severity of hypotension. The neurosurgeon scored incisional bleeding by numeric rating scale from 0 (worst) to 10 (best). RESULTS The incidence of hypotension (68% vs. 34.8%, P = 0.02) and the frequency (P = 0.02) and total dose (P = 0.03) of ephedrine administered were lower in the dexmedetomidine group than in the epinephrine group. In addition, there was no difference in mean blood pressure between the two groups but heart rates were lower in the dexmedetomidine group (P = 0.01). Incisional site bleeding was better with epinephrine (median [interquartile range] of the numeric rating Score: 6 [4] in the dexmedetomidine group and 8 [2] in the epinephrine group; P < 0.001). CONCLUSION The dexmedetomidine-lidocaine combination may be recommended as a substitute for epinephrine-lidocaine for scalp infiltration in neurosurgical patients, especially neurologically compromised patients.",2019,"The incidence of hypotension (68% vs. 34.8%, P = 0.02) and the frequency (P = 0.02) and total dose (P = 0.03) of ephedrine administered were lower in the dexmedetomidine group than in the epinephrine group.","['patients with hemi-facial spasm undergoing microvascular decompression', 'Fifty-two patients', 'neurosurgical patients']","['lidocaine and epinephrine', 'dexmedetomidine-lidocaine', 'lidocaine', 'lidocaine and dexmedetomidine', 'epinephrine', 'dexmedetomidine', 'epinephrine-lidocaine', 'ephedrine']","['severity of hypotension', 'heart rates', 'Incisional site bleeding', 'incidence of predefined hypotension', 'number of administrations and total amount of ephedrine', 'scalp bleeding', 'Mean blood pressure and heart rate', 'neurosurgeon scored incisional bleeding by numeric rating scale', 'Haemodynamic changes and incisional bleeding', 'incidence of hypotension', 'mean blood pressure']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1285521', 'cui_str': 'Hemi'}, {'cui': 'C0278151', 'cui_str': 'Facial spasm'}, {'cui': 'C1328580', 'cui_str': 'Microvascular Decompression'}, {'cui': 'C4319570', 'cui_str': 'Fifty-two'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0014563', 'cui_str': 'Epinephrine'}, {'cui': 'C0113293', 'cui_str': 'Dexmedetomidine'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}]","[{'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0020649', 'cui_str': 'Blood Pressure, Low'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C1533734', 'cui_str': 'Administration'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0014479', 'cui_str': 'Ephedrine'}, {'cui': 'C0036270', 'cui_str': 'Scalp'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}, {'cui': 'C0237427', 'cui_str': 'Neurological Surgeons'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",52.0,0.21216,"The incidence of hypotension (68% vs. 34.8%, P = 0.02) and the frequency (P = 0.02) and total dose (P = 0.03) of ephedrine administered were lower in the dexmedetomidine group than in the epinephrine group.","[{'ForeName': 'Hyunzu', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Inha University College of Medicine, Incheon, South Korea.'}, {'ForeName': 'Seung-Ho', 'Initials': 'SH', 'LastName': 'Choi', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, South Korea; Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Sang-Hee', 'Initials': 'SH', 'LastName': 'Ha', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Won-Seok', 'Initials': 'WS', 'LastName': 'Chang', 'Affiliation': 'Department of Neurosurgery, Yonsei University College of Medicine, Seoul, South Korea.'}, {'ForeName': 'Gyoung-A', 'Initials': 'GA', 'LastName': 'Heo', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Inha University College of Medicine, Incheon, South Korea.'}, {'ForeName': 'Jimyeong', 'Initials': 'J', 'LastName': 'Jeong', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Inha University College of Medicine, Incheon, South Korea.'}, {'ForeName': 'Kyeong Tae', 'Initials': 'KT', 'LastName': 'Min', 'Affiliation': 'Department of Anaesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, South Korea; Anaesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: ktmin501@yuhs.ac.'}]","Anaesthesia, critical care & pain medicine",['10.1016/j.accpm.2018.10.016'] 3186,32087032,"Orally applied bacterial lysate in infants at risk for atopy does not prevent atopic dermatitis, allergic rhinitis, asthma or allergic sensitization at school age: Follow-up of a randomized trial.","BACKGROUND The allergy preventive effects of gut immune modulation by bacterial compounds are still not fully understood. OBJECTIVE We sought to evaluate the effect of bacterial lysate applied orally from the second until seventh months of life on the prevalence of allergic diseases at school age. METHODS In a randomized, placebo-controlled trial, 606 newborns with at least one allergic parent received orally a bacterial lysate consisting of heat-killed Gram-negative Escherichia coli Symbio and Gram-positive Enterococcus faecalis Symbio or placebo from week 5 until the end of month 7. A total of 402 children were followed until school age (6-11 years) for the assessment of current atopic dermatitis (AD), allergic rhinitis (AR), asthma and sensitization against aeroallergens. RESULTS AD was diagnosed in 11.0% (22/200) of children in the active and in 10.4% (21/202) of children in the placebo group. AR was diagnosed in 35% (70/200) of children in the active and in 38.1% (77/202) children in the placebo group. Asthma was diagnosed in 9% (18/199) of children in the active and in 6.6% (13/197) of children in the placebo group. Sensitization occurred in 46.5% (66/142) of participants in the active and 51.7% (76/147) in the placebo group. CONCLUSION An oral bacterial lysate of heat-killed Gram-negative Escherichia coli and Gram-positive Enterococcus faecalis applied during the first 7 months of life did not influence the development of AD, asthma and AR at school age.",2020,"Sensitization occurred in 46.5% (66/142) of participants in the active and 51.7% (76/147) in the placebo group. ","['606 newborns with at least one allergic parent received', '402 children were followed until school age (6 to 11 years) for the assessment of current atopic dermatitis (AD), allergic rhinitis (AR), asthma, and sensitization against aero-allergens']","['placebo', 'orally a bacterial lysate consisting of heat-killed gram-negative Escherichia coli Symbio and gram-positive Enterococcus faecalis Symbio or placebo', 'oral bacterial lysate of heat-killed gram-negative Escherichia coli and gram-positive Enterococcus faecalis']","['AR', 'Sensitization', 'atopic dermatitis, allergic rhinitis, asthma or allergic sensitization']","[{'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C1325847', 'cui_str': 'Sensitization'}, {'cui': 'C0002092', 'cui_str': 'Allergens'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C1569170', 'cui_str': 'polyvalent mechanical bacterial lysate'}, {'cui': 'C0018837', 'cui_str': 'Heat'}, {'cui': 'C4521763', 'cui_str': 'Killed'}, {'cui': 'C0439208', 'cui_str': 'gram (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0014834', 'cui_str': 'Escherichia coli'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0085494', 'cui_str': 'Enterococcus'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038404', 'cui_str': 'Enterococcus faecalis'}]","[{'cui': 'C1325847', 'cui_str': 'Sensitization'}, {'cui': 'C0011615', 'cui_str': 'Neurodermatitis, Disseminated'}, {'cui': 'C2607914', 'cui_str': 'Rhinitis, Allergic'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C3662483', 'cui_str': 'Allergic sensitization'}]",606.0,0.40587,"Sensitization occurred in 46.5% (66/142) of participants in the active and 51.7% (76/147) in the placebo group. ","[{'ForeName': 'Siri', 'Initials': 'S', 'LastName': 'Roßberg', 'Affiliation': 'Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Theresa', 'Initials': 'T', 'LastName': 'Keller', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Katja', 'Initials': 'K', 'LastName': 'Icke', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Siedmann', 'Affiliation': 'Helios Kliniken Berlin-Buch. Kinderklinik, Berlin, Germany.'}, {'ForeName': 'Imke', 'Initials': 'I', 'LastName': 'Lau', 'Affiliation': 'Sektion Humanmedizin, Universität zu Lübeck, Lübeck, Germany.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Keil', 'Affiliation': 'Institute of Social Medicine, Epidemiology and Health Economics, Charité Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Lau', 'Affiliation': 'Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité Universitätsmedizin Berlin, Berlin, Germany.'}]",Allergy,['10.1111/all.14247'] 3187,32069071,"Probiotic supplementation increases carbohydrate metabolism in trained male cyclists: a randomized, double-blind, placebo-controlled crossover trial.","We hypothesized that probiotic supplementation (PRO) increases the absorption and oxidation of orally ingested maltodextrin during 2 h endurance cycling, thereby sparing muscle glycogen for a subsequent time trial (simulating a road race). Measurements were made of lipid and carbohydrate oxidation, plasma metabolites and insulin, gastrointestinal (GI) permeability, and subjective symptoms of discomfort. Seven male cyclists were randomized to PRO (bacterial composition given in methods) or placebo for 4 wk, separated by a 14-day washout period. After each period, cyclists consumed a 10% maltodextrin solution (initial 8 mL/kg bolus and 2 mL/kg every 15 min) while exercising for 2 h at 55% maximal aerobic power output, followed by a 100-kJ time trial. PRO resulted in small increases in peak oxidation rates of the ingested maltodextrin (0.84 ± 0.10 vs. 0.77 ± 0.09 g/min; P = 0.016) and mean total carbohydrate oxidation (2.20 ± 0.25 vs. 1.87 ± 0.39 g/min; P = 0.038), whereas fat oxidation was reduced (0.40 ± 0.11 vs. 0.55 ± 0.10 g/min; P = 0.021). During PRO, small but significant increases were seen in glucose absorption, plasma glucose, and insulin concentration and decreases in nonesterified fatty acid and glycerol. Differences between markers of GI damage and permeability and time-trial performance were not significant ( P > 0.05). In contrast to the hypothesis, PRO led to minimal increases in absorption and oxidation of the ingested maltodextrin and small reductions in fat oxidation, whereas having no effect on subsequent time-trial performance.",2020,"During PRO small but significant increases were seen in glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol.","['trained male cyclists', 'Seven male cyclists']","['PRO (bacterial composition given in methods) or placebo (PLC', 'maltodextrin solution', 'placebo', 'PRO', 'Probiotic supplementation', 'probiotic supplementation (PRO']","['carbohydrate metabolism', 'subsequent time trial performance', 'mean total carbohydrate oxidation', 'glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol', 'fat oxidation', 'absorption and oxidation', 'GI damage and permeability and time trial performance', 'lipid and carbohydrate oxidation, plasma metabolites and insulin, gastrointestinal permeability, and subjective symptoms of discomfort', 'peak oxidation rates']","[{'cui': 'C0336809', 'cui_str': 'Railway train, device (physical object)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0205453', 'cui_str': '7'}]","[{'cui': 'C0486616', 'cui_str': 'Composition (property)'}, {'cui': 'C1947971', 'cui_str': 'Give'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0065601', 'cui_str': 'maltodextrin'}, {'cui': 'C0037633', 'cui_str': 'Solutions'}, {'cui': 'C0525033', 'cui_str': 'Probiotics'}]","[{'cui': 'C0302820', 'cui_str': 'Carbohydrate Metabolism'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C3541972', 'cui_str': 'Carbohydrate nutrients'}, {'cui': 'C0030011', 'cui_str': 'Oxidation, function (observable entity)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C2347023', 'cui_str': 'Absorption'}, {'cui': 'C0202042', 'cui_str': 'Glucose measurement, plasma (procedure)'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0015688', 'cui_str': 'NEFA'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C0010957', 'cui_str': 'Damage (morphologic abnormality)'}, {'cui': 'C0031164', 'cui_str': 'Permeability'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}]",,0.515573,"During PRO small but significant increases were seen in glucose absorption, plasma glucose and insulin concentration and decreases in NEFA and glycerol.","[{'ForeName': 'Jamie N', 'Initials': 'JN', 'LastName': 'Pugh', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Anton J M', 'Initials': 'AJM', 'LastName': 'Wagenmakers', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Dominic A', 'Initials': 'DA', 'LastName': 'Doran', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Simon C', 'Initials': 'SC', 'LastName': 'Fleming', 'Affiliation': 'Royal Cornwall Hospital, Truro, United Kingdom.'}, {'ForeName': 'Barbara A', 'Initials': 'BA', 'LastName': 'Fielding', 'Affiliation': 'Department of Nutritional Sciences, University of Surrey, Guildford, Surrey, United Kingdom.'}, {'ForeName': 'James P', 'Initials': 'JP', 'LastName': 'Morton', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}, {'ForeName': 'Graeme L', 'Initials': 'GL', 'LastName': 'Close', 'Affiliation': 'Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, United Kingdom.'}]",American journal of physiology. Endocrinology and metabolism,['10.1152/ajpendo.00452.2019'] 3188,30902918,Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.,"BACKGROUND Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first-line treatment for patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS Patients with mRCC from 13 clinical centers were randomly assigned in a 2:1 ratio to receive anlotinib ( n = 90) or sunitinib ( n = 43). Anlotinib was given orally at a dose of 12 mg once daily (2 weeks on/1 week off), and sunitinib was given orally at 50 mg once daily (4 weeks on/2 weeks off). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. RESULTS The median PFS was similar with anlotinib and sunitinib (17.5 vs. 16.6 months, p > .05). The median OS (30.9 vs. 30.5 months, p > .05), ORR (30.3% vs. 27.9%), and 6-week DCR (97.8% vs. 93.0%) were similar in the two groups. Adverse events (AEs) of grade 3 or 4 were significantly less frequent with anlotinib than with sunitinib (28.9% vs. 55.8%, p < .01), especially in terms of thrombocytopenia and neutropenia. AEs occurring at a lower frequency with anlotinib were hand-foot syndrome, eyelid edema, hair depigmentation, skin yellowing, neutropenia, thrombocytopenia, and anemia. The incidence of serious AEs was lower with anlotinib than with sunitinib. CONCLUSION The clinical efficacy of anlotinib was similar to that of sunitinib as the first-line treatment for mRCC, but with a more favorable safety profile. IMPLICATIONS FOR PRACTICE This study evaluated the efficacy and safety of anlotinib for the first-line treatment of metastatic renal cell carcinoma. Anlotinib, which was developed independently in China, is a new tyrosine kinase inhibitor inhibiting multiple kinases involved in angiogenesis and tumor proliferation. Results indicated that the efficacy of anlotinib is comparable to and the safety is better than that of sunitinib.",2019,"The median OS (30.9 vs. 30.5 months, p > .05), ORR (30.3% vs. 27.9%), and 6-week DCR (97.8% vs. 93.0%) were similar in the two groups.","['Metastatic Renal Cell Carcinoma', 'Patients with mRCC from 13 clinical centers', 'patients with metastatic renal cell carcinoma (mRCC', 'metastatic renal cell carcinoma']","['Anlotinib Versus Sunitinib', 'anlotinib ( n =\u200990) or sunitinib']","['progression-free survival (PFS', 'Adverse events (AEs) of grade 3 or 4', 'median OS', 'overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety', 'eyelid edema, hair depigmentation, skin yellowing, neutropenia, thrombocytopenia, and anemia', 'efficacy and safety', 'ORR', 'median PFS', 'incidence of serious AEs', 'thrombocytopenia and neutropenia']","[{'cui': 'C0278678', 'cui_str': 'Metastatic renal cell carcinoma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C4519250', 'cui_str': 'anlotinib'}, {'cui': 'C1176020', 'cui_str': 'sunitinib'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C1571702', 'cui_str': 'Objective observation'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0162285', 'cui_str': 'Edema of eyelid (disorder)'}, {'cui': 'C0018494', 'cui_str': 'Hair'}, {'cui': 'C0162835', 'cui_str': 'Hypomelanosis'}, {'cui': 'C1123023', 'cui_str': 'Skin'}, {'cui': 'C0027947', 'cui_str': 'Neutropenia'}, {'cui': 'C0040034', 'cui_str': 'Thrombopenia'}, {'cui': 'C0002871', 'cui_str': 'Anemia'}, {'cui': 'C0220856', 'cui_str': 'incidence'}]",,0.100328,"The median OS (30.9 vs. 30.5 months, p > .05), ORR (30.3% vs. 27.9%), and 6-week DCR (97.8% vs. 93.0%) were similar in the two groups.","[{'ForeName': 'Ai-Ping', 'Initials': 'AP', 'LastName': 'Zhou', 'Affiliation': ""National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.""}, {'ForeName': 'Yuxian', 'Initials': 'Y', 'LastName': 'Bai', 'Affiliation': ""Harbin Medical University Affiliated Tumor Hospital, Harbin, Heilongjiang, People's Republic of China.""}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Song', 'Affiliation': ""National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.""}, {'ForeName': 'Hong', 'Initials': 'H', 'LastName': 'Luo', 'Affiliation': ""Chongqing Cancer Hospital, Chongqing, Chongqing, People's Republic of China.""}, {'ForeName': 'Xiu-Bao', 'Initials': 'XB', 'LastName': 'Ren', 'Affiliation': ""Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China.""}, {'ForeName': 'Xiuwen', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': ""Qilu Hospital of Shandong University, Jinan, People's Republic of China.""}, {'ForeName': 'Benkang', 'Initials': 'B', 'LastName': 'Shi', 'Affiliation': ""Qilu Hospital of Shandong University, Jinan, People's Republic of China.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Fu', 'Affiliation': ""Liaoning Province Tumor Hospital, Shenyang, Liaoning, People's Republic of China.""}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Cheng', 'Affiliation': ""Jilin Cancer Hospital, Changchun, People's Republic of China.""}, {'ForeName': 'Jiyan', 'Initials': 'J', 'LastName': 'Liu', 'Affiliation': ""West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.""}, {'ForeName': 'Shukui', 'Initials': 'S', 'LastName': 'Qin', 'Affiliation': ""The 81st Hospital of Chinese PLA, Nanjing, Jiangsu, People's Republic of China.""}, {'ForeName': 'Jun', 'Initials': 'J', 'LastName': 'Li', 'Affiliation': ""Gansu Province Cancer Hospital, Lanzhou, People's Republic of China.""}, {'ForeName': 'Hanzhong', 'Initials': 'H', 'LastName': 'Li', 'Affiliation': ""Peking Union Medical College Hospital, Beijing, People's Republic of China.""}, {'ForeName': 'Xianzhong', 'Initials': 'X', 'LastName': 'Bai', 'Affiliation': ""Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, People's Republic of China.""}, {'ForeName': 'Dingwei', 'Initials': 'D', 'LastName': 'Ye', 'Affiliation': ""Cancer Hospital of Fudan University, Shanghai Shanghai, People's Republic of China.""}, {'ForeName': 'Jinwan', 'Initials': 'J', 'LastName': 'Wang', 'Affiliation': ""National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.""}, {'ForeName': 'Jianhui', 'Initials': 'J', 'LastName': 'Ma', 'Affiliation': ""National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China majianhui@csco.org.cn.""}]",The oncologist,['10.1634/theoncologist.2018-0839'] 3189,32130122,Feasibility of an Electronic Health Tool to Promote Physical Activity in Primary Care: Pilot Cluster Randomized Controlled Trial.,"BACKGROUND Physical inactivity is associated with increased health risks. Primary care providers (PCPs) are well positioned to support increased physical activity (PA) levels through screening and provision of PA prescriptions. However, PCP counseling on PA is not common. OBJECTIVE This study aimed to assess the feasibility of implementing an electronic health (eHealth) tool to support PA counseling by PCPs and estimate intervention effectiveness on patients' PA levels. METHODS A pragmatic pilot study was conducted using a stepped wedge cluster randomized trial design. The study was conducted at a single primary care clinic, with 4 pre-existing PCP teams. Adult patients who had a periodic health review (PHR) scheduled during the study period were invited to participate. The eHealth tool involved an electronic survey sent to participants before their PHR via an email or a tablet; data were used to automatically produce tailored resources and a PA prescription in the electronic medical record of participants in the intervention arm. Participants assigned to the control arm received usual care from their PCP. Feasibility was assessed by the proportion of completed surveys and patient-reported acceptability and fidelity measures. The primary effectiveness outcome was patient-reported PA at 4 months post-PHR, measured as metabolic equivalent of task (MET) minutes per week. Secondary outcomes assessed determinants of PA, including self-efficacy and intention to change based on the Health Action Process Approach behavior change theory. RESULTS A total of 1028 patients receiving care from 34 PCPs were invited to participate and 530 (51.55%) consented (intervention [n=296] and control [n=234]). Of the participants who completed a process evaluation, almost half (88/178, 49.4%) stated they received a PA prescription, with only 42 receiving the full intervention including tailored resources from their PCP. A cluster-level linear regression analysis yielded a non-statistically significant positive difference in MET-minutes reported per week at follow-up between intervention and control conditions (mean difference 1027; 95% CI -155 to 2209; P=.09). No statistically significant differences were observed for secondary outcomes. CONCLUSIONS Our results suggest that it is feasible to build an eHealth tool that screens and provides tailored resources for PA in a primary care setting but suboptimal intervention fidelity suggests greater work must be done to address PCP barriers to resource distribution. Participant responses to the primary effectiveness outcome (MET-minutes) were highly variable, reflecting a need for more robust measures of PA in future trials to address limitations in patient-reported data. TRIAL REGISTRATION ClinicalTrials.gov NCT03181295; https://clinicaltrials.gov/ct2/show/NCT03181295.",2020,"No statistically significant differences were observed for secondary outcomes. ","['Adult patients who had a periodic health review (PHR) scheduled during the study period were invited to participate', 'participants who completed a process evaluation, almost half (88/178, 49.4%) stated they received a PA prescription, with only 42 receiving the', 'Primary Care', '1028 patients receiving care from 34 PCPs were invited to participate and 530 (51.55%) consented', 'single primary care clinic, with 4 pre-existing PCP teams', ""patients' PA levels""]","['full intervention including tailored resources from their PCP', 'PCP counseling', 'Electronic Health Tool', 'usual care from their PCP']","['patient-reported PA at 4 months post-PHR, measured as metabolic equivalent of task (MET) minutes per week', 'determinants of PA, including self-efficacy and intention to change based on the Health Action Process Approach behavior change theory', 'physical activity (PA) levels']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332182', 'cui_str': 'Periodic (qualifier value)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0282443', 'cui_str': 'Review'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C2711213', 'cui_str': 'Consented (qualifier value)'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C1552443', 'cui_str': 'Primary care clinic (environment)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0035201', 'cui_str': 'Resources'}, {'cui': 'C0031381', 'cui_str': '1-(1-Phenylcyclohexyl)piperidine'}, {'cui': 'C0010210', 'cui_str': 'Counseling'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0336791', 'cui_str': 'Tool, device (physical object)'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C2983100', 'cui_str': 'MET - metabolic equivalent of task'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0332174', 'cui_str': 'Weekly (qualifier value)'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0441472', 'cui_str': 'Action (qualifier value)'}, {'cui': 'C4521054', 'cui_str': 'Process (qualifier value)'}, {'cui': 'C4046027', 'cui_str': 'Approach Behavior'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",1028.0,0.119664,"No statistically significant differences were observed for secondary outcomes. ","[{'ForeName': 'Payal', 'Initials': 'P', 'LastName': 'Agarwal', 'Affiliation': ""Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Natasha', 'Initials': 'N', 'LastName': 'Kithulegoda', 'Affiliation': ""Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Bouck', 'Affiliation': ""Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Beth', 'Initials': 'B', 'LastName': 'Bosiak', 'Affiliation': ""Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Ilana', 'Initials': 'I', 'LastName': 'Birnbaum', 'Affiliation': 'Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Lindsay', 'Initials': 'L', 'LastName': 'Reddeman', 'Affiliation': 'Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Liane', 'Initials': 'L', 'LastName': 'Steiner', 'Affiliation': ""St Michael's Hospital, Toronto, ON, Canada.""}, {'ForeName': 'Liora', 'Initials': 'L', 'LastName': 'Altman', 'Affiliation': 'Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Mawson', 'Affiliation': 'Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Roni', 'Initials': 'R', 'LastName': 'Propp', 'Affiliation': 'Rehabilitation Sciences Institute, University of Toronto, Toronto, ON, Canada.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Thornton', 'Affiliation': 'Fowler Kennedy Sport Medicine Clinic, Western University, London, ON, Canada.'}, {'ForeName': 'Noah', 'Initials': 'N', 'LastName': 'Ivers', 'Affiliation': ""Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Women's College Hospital, Toronto, ON, Canada.""}]",Journal of medical Internet research,['10.2196/15424'] 3190,32050090,"Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.","BACKGROUND Observational studies have suggested that accelerated surgery is associated with improved outcomes in patients with a hip fracture. The HIP ATTACK trial assessed whether accelerated surgery could reduce mortality and major complications. METHODS HIP ATTACK was an international, randomised, controlled trial done at 69 hospitals in 17 countries. Patients with a hip fracture that required surgery and were aged 45 years or older were eligible. Research personnel randomly assigned patients (1:1) through a central computerised randomisation system using randomly varying block sizes to either accelerated surgery (goal of surgery within 6 h of diagnosis) or standard care. The coprimary outcomes were mortality and a composite of major complications (ie, mortality and non-fatal myocardial infarction, stroke, venous thromboembolism, sepsis, pneumonia, life-threatening bleeding, and major bleeding) at 90 days after randomisation. Patients, health-care providers, and study staff were aware of treatment assignment, but outcome adjudicators were masked to treatment allocation. Patients were analysed according to the intention-to-treat principle. This study is registered at ClinicalTrials.gov (NCT02027896). FINDINGS Between March 14, 2014, and May 24, 2019, 27 701 patients were screened, of whom 7780 were eligible. 2970 of these were enrolled and randomly assigned to receive accelerated surgery (n=1487) or standard care (n=1483). The median time from hip fracture diagnosis to surgery was 6 h (IQR 4-9) in the accelerated-surgery group and 24 h (10-42) in the standard-care group (p<0·0001). 140 (9%) patients assigned to accelerated surgery and 154 (10%) assigned to standard care died, with a hazard ratio (HR) of 0·91 (95% CI 0·72 to 1·14) and absolute risk reduction (ARR) of 1% (-1 to 3; p=0·40). Major complications occurred in 321 (22%) patients assigned to accelerated surgery and 331 (22%) assigned to standard care, with an HR of 0·97 (0·83 to 1·13) and an ARR of 1% (-2 to 4; p=0·71). INTERPRETATION Among patients with a hip fracture, accelerated surgery did not significantly lower the risk of mortality or a composite of major complications compared with standard care. FUNDING Canadian Institutes of Health Research.",2020,"Among patients with a hip fracture, accelerated surgery did not significantly lower the risk of mortality or a composite of major complications compared with standard care. ","['69 hospitals in 17 countries', 'Patients with a hip fracture that required surgery and were aged 45 years or older were eligible', 'patients with a hip fracture', 'Between March 14, 2014, and May 24, 2019, 27\u2008701 patients were screened, of whom 7780 were eligible']","['Accelerated surgery versus standard care', 'accelerated surgery (n=1487) or standard care', 'central computerised randomisation system using randomly varying block sizes to either accelerated surgery (goal of surgery within 6 h of diagnosis) or standard care']","['mortality and a composite of major complications (ie, mortality and non-fatal myocardial infarction, stroke, venous thromboembolism, sepsis, pneumonia, life-threatening bleeding, and major bleeding', 'mortality and major complications', 'median time from hip fracture diagnosis', 'Major complications', 'risk of mortality or a composite of major complications']","[{'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]","[{'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0456389', 'cui_str': 'Size (attribute)'}, {'cui': 'C0521110', 'cui_str': 'Accelerated (contextual qualifier) (qualifier value)'}, {'cui': 'C0018017', 'cui_str': 'Goals'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}]","[{'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C1861172', 'cui_str': 'Venous Thromboembolism'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0019557', 'cui_str': 'Hip Fractures'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]",27701.0,0.169736,"Among patients with a hip fracture, accelerated surgery did not significantly lower the risk of mortality or a composite of major complications compared with standard care. ","[{'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(20)30058-1'] 3191,31897528,Zoledronate Slows Weight Loss and Maintains Fat Mass in Osteopenic Older Women: Secondary Analysis of a Randomized Controlled Trial.,"Studies in mice have suggested that osteocalcin plays an important role in glucose and fat metabolism. Since anti-resorptive drugs reduce circulating levels of osteocalcin they might be associated with increased fat mass and an increased risk of diabetes. Positive changes in body weight have been found in trials of alendronate and denosumab, but no significant effect in a previous trial of zoledronate. Whether those weight differences were in fat or lean mass is unknown. There were no effects of anti-resorptive treatments on fasting glucose concentrations or incidence of diabetes in those three studies. We have used our recent trial comparing zoledronate and placebo over 6 years in 2000 older osteopenic women to re-examine these questions. Both treatment groups lost body weight during the study (placebo 1.65 kg, zoledronate 1.05 kg), and this was significantly greater in the placebo group (P = 0.01). Both groups lost lean mass, and this loss was marginally (0.17 kg) but significantly (P = 0.02) greater in those receiving zoledronate. The placebo group had a mean loss of fat mass of 0.63 kg but there was no change in fat mass in the zoledronate group (between-groups comparison, P = 0.007). In the placebo group, there were 20 new diagnoses of diabetes, and in the zoledronate group, 19 (P = 0.87). Zoledronate prevented age-related loss of fat mass in these late postmenopausal women. The present study is the first to document a significant effect of zoledronate treatment on body weight, confirming results previously found with alendronate and denosumab. It also demonstrates that this is principally an effect to maintain fat mass rather than influencing lean mass, raising an important physiological question as to how anti-resorptive drugs have this effect on intermediary metabolism. It is possible that this anti-catabolic action contributes to the beneficial effects of anti-resorptive drugs on bone and longevity.",2020,"Both groups lost lean mass, and this loss was marginally (0.17 kg) but significantly (P = 0.02) greater in those receiving zoledronate.","['Osteopenic Older Women', '2000 older osteopenic women', 'late postmenopausal women']","['zoledronate', 'placebo', 'zoledronate and placebo', 'alendronate and denosumab', 'alendronate']","['mean loss of fat mass', 'fat mass', 'fasting glucose concentrations or incidence of diabetes', 'Zoledronate Slows Weight Loss and Maintains Fat Mass', 'body weight']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0470277', 'cui_str': '2000'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}]","[{'cui': 'C0392938', 'cui_str': 'Zoledronate (substance)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0102118', 'cui_str': 'Alendronate'}, {'cui': 'C1690432', 'cui_str': 'denosumab'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}, {'cui': 'C1287281', 'cui_str': 'Finding of glucose concentration, dipstick (finding)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0392938', 'cui_str': 'Zoledronate (substance)'}, {'cui': 'C0439834', 'cui_str': 'Slowly'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C1314677', 'cui_str': 'Maintained'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}]",2000.0,0.244491,"Both groups lost lean mass, and this loss was marginally (0.17 kg) but significantly (P = 0.02) greater in those receiving zoledronate.","[{'ForeName': 'Ian R', 'Initials': 'IR', 'LastName': 'Reid', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. i.reid@auckland.ac.nz.'}, {'ForeName': 'Anne M', 'Initials': 'AM', 'LastName': 'Horne', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.'}, {'ForeName': 'Borislav', 'Initials': 'B', 'LastName': 'Mihov', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Stewart', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.'}, {'ForeName': 'Sonja', 'Initials': 'S', 'LastName': 'Bastin', 'Affiliation': 'Auckland District Health Board, Auckland, New Zealand.'}, {'ForeName': 'Gregory D', 'Initials': 'GD', 'LastName': 'Gamble', 'Affiliation': 'Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.'}]",Calcified tissue international,['10.1007/s00223-019-00653-7'] 3192,32189958,Fenfluramine: New Treatment for Seizures in Dravet Syndrome.,"Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o. with Dravet Syndrome in an international double-blind, placebo-controlled clinical trial. A total of 119 patients (mean age 9.0 y, 54% male) were enrolled in the study.",2020,Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o.,"['119 patients (mean age 9.0', 'patients less than 18 y.o', 'Seizures in Dravet Syndrome', 'y, 54% male) were enrolled in the study']","['Fenfluramine', 'placebo']",['efficacy and safety'],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0751122', 'cui_str': 'Myoclonic Epilepsy, Severe, Of Infancy'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0015827', 'cui_str': 'Fenfluramine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",119.0,0.18489,Investigators for the FAiRE DS Study Group assessed the efficacy and safety of Fenfluramine for treating seizures in patients less than 18 y.o.,"[{'ForeName': 'Joanna Garcia', 'Initials': 'JG', 'LastName': 'Pierce', 'Affiliation': ""Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.""}, {'ForeName': 'Divakar S', 'Initials': 'DS', 'LastName': 'Mithal', 'Affiliation': ""Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.""}]",Pediatric neurology briefs,['10.15844/pedneurbriefs-34-8'] 3193,32187281,Intracoronary Sarcoplasmic Reticulum Calcium-ATPase Gene Therapy in Advanced Heart Failure Patients with reduced Ejection Fraction: A Prospective Cohort Study.,"OBJECTIVE Heart failure is a progressive and debilitating disease. Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy may improve the function of cardiac muscle cells. This study aimed to test the hypothesis that intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy can improve outcomes and reduce the number of recurrent and terminal events in advanced heart failure patients with reduced ejection fraction. METHODS A total of 768 heart failure patients with reduced ejection fraction and New York Heart Association classification II to IV were included in this prospective cohort study. Patients either underwent intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy (CA group, n=384) or received oral placebo (PA group; n=384). Data regarding recurrent and terminal event(s), treatment-emergent adverse effects, and outcome measures were collected and analyzed. RESULTS After a follow-up period of 18 months, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduced the number of hospital admissions (p=0.001), ambulatory treatments (p=0.0004), and deaths (p=0.024). Additionally, intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy improved the left ventricular ejection fraction (p<0.0001) and Kansas City Cardiomyopathy Questionnaire score (p<0.0001). The number of recurrent and terminal events/patients were higher in the PA group than in the CA group after the follow-up period of 18 months (p=0.015). The effect of the intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy was independent of the confounding variables. No new arrhythmias were reported in the CA group. CONCLUSIONS Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy reduces the number of recurrent and terminal events and improves the clinical course of advanced heart failure patients with reduced ejection fraction.",2020,The number of recurrent and terminal events/patients were higher in the PA group than in the CA group after the follow-up period of 18 months (p=0.015).,"['Advanced Heart Failure Patients with reduced Ejection Fraction', '768 heart failure patients with reduced ejection fraction and New York Heart Association classification II to IV', 'advanced heart failure patients with reduced ejection fraction']","['Intracoronary Sarcoplasmic Reticulum Calcium-ATPase Gene Therapy', 'intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy (CA group, n=384) or received oral placebo', 'Intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy', 'intracoronary sarcoplasmic reticulum calcium-ATPase gene therapy']","['number of recurrent and terminal events', 'number of hospital admissions', 'left ventricular ejection fraction (p<0.0001) and Kansas City Cardiomyopathy Questionnaire score']","[{'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0489482', 'cui_str': 'Ejection fraction'}, {'cui': 'C1275491', 'cui_str': 'New York Heart Association Classification'}]","[{'cui': 'C0916181', 'cui_str': 'Sarcoplasmic Reticulum Calcium ATPase'}, {'cui': 'C0017296', 'cui_str': 'Gene therapy (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0205088', 'cui_str': 'End-stage (qualifier value)'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0184666', 'cui_str': 'Hospital admission (procedure)'}, {'cui': 'C0042508', 'cui_str': 'Ventricular Ejection Fraction'}, {'cui': 'C0008848', 'cui_str': 'Cities'}, {'cui': 'C0878544', 'cui_str': 'Cardiomyopathies'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",768.0,0.0194071,The number of recurrent and terminal events/patients were higher in the PA group than in the CA group after the follow-up period of 18 months (p=0.015).,"[{'ForeName': 'Jianfeng', 'Initials': 'J', 'LastName': 'Zhang', 'Affiliation': 'Cardio-Pulmonary Rehabilitation Inpatient Area, Second Rehabilitation Hospital of Shanghai, Shanghai 200431, China.'}, {'ForeName': 'Guojin', 'Initials': 'G', 'LastName': 'Hu', 'Affiliation': 'Cardio-Pulmonary Rehabilitation Inpatient Area, Second Rehabilitation Hospital of Shanghai, Shanghai 200431, China.'}, {'ForeName': 'Shengyong', 'Initials': 'S', 'LastName': 'Yang', 'Affiliation': 'Cardio-Pulmonary Rehabilitation Inpatient Area, Second Rehabilitation Hospital of Shanghai, Shanghai 200431, China.'}]","Clinics (Sao Paulo, Brazil)",['10.6061/clinics/2020/e1530'] 3194,30803706,Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.,"RATIONALE & OBJECTIVE Vascular dysfunction, characterized by impaired vascular endothelial function and increased large-elastic artery stiffness, is evident early in autosomal dominant polycystic kidney disease (ADPKD) and is an important predictor of cardiovascular events and mortality. Aldosterone excess has been implicated in the development of endothelial dysfunction and arterial stiffness, in part by causing increased oxidative stress and inflammation. We hypothesized that aldosterone antagonism would reduce vascular dysfunction in patients with early-stage ADPKD. STUDY DESIGN Prospective, randomized, controlled, double-blind, clinical trial. SETTING & PARTICIPANTS 61 adults aged 20 to 55 years with ADPKD, estimated glomerular filtration rate ≥ 60mL/min/1.73m 2 , and receiving a renin-angiotensin-aldosterone system inhibitor. INTERVENTION Spironolactone (maximum dose, 50mg/d) or placebo for 24 weeks. OUTCOMES Change in brachial artery flow-mediated dilation (FMD BA ) was the primary end point and change in carotid-femoral pulse-wave velocity (CFPWV) was the secondary end point. RESULTS 60 participants completed the trial. Participants had a mean age of 34±10 (SD) years, 54% were women, and 84% were non-Hispanic white. Spironolactone did not change FMD BA (8.0% ± 5.5% and 7.8% ± 4.3% at baseline and 24 weeks, respectively, vs corresponding values in the placebo group of 8.4% ± 6.2% and 8.0% ± 4.6%; P=0.9for comparison of change between groups) or CFPWV (640±127 and 603±101cm/s at baseline and 24 weeks, respectively, vs corresponding values in the placebo group of 659±138 and 658±131cm/s; P=0.1). Brachial systolic blood pressure was reduced with spironolactone (median change, -6 [IQR, -15, 1] vs -2 [IQR, -7, 10] mm Hg in the placebo group; P=0.04). Spironolactone did not change the majority of circulating and/or endothelial cell markers of oxidative stress/inflammation and did not change vascular oxidative stress. LIMITATIONS Low level of baseline vascular dysfunction; lack of aldosterone measurements. CONCLUSIONS 24 weeks of aldosterone antagonism reduced systolic blood pressure without changing vascular function in patients with early-stage ADPKD. FUNDING NIDDK, NIH National Center for Advancing Translational Sciences, and the Zell Family Foundation. TRIAL REGISTRATION Registered at ClinicalTrials.gov with study number NCT01853553.",2019,"Spironolactone did not change the majority of circulating and/or endothelial cell markers of oxidative stress/inflammation and did not change vascular oxidative stress. ","['patients with early-stage ADPKD', '60 participants completed the trial', 'Participants had a mean age of 34±10 (SD) years, 54% were women, and 84% were non-Hispanic white', 'Early Autosomal Dominant Polycystic Kidney Disease', '61 adults aged 20 to 55 years with ADPKD, estimated glomerular filtration rate\xa0≥']","['Spironolactone (maximum dose, 50mg/d) or placebo', 'renin-angiotensin-aldosterone system inhibitor', 'Aldosterone', 'Mineralocorticoid Antagonism', 'Spironolactone', 'aldosterone antagonism', 'spironolactone']","['vascular dysfunction', 'brachial artery flow-mediated dilation (FMD BA ', 'change FMD BA', 'Brachial systolic blood pressure', 'systolic blood pressure', 'carotid-femoral pulse-wave velocity (CFPWV', 'majority of circulating and/or endothelial cell markers of oxidative stress/inflammation']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2363430', 'cui_str': 'Early stage (qualifier value)'}, {'cui': 'C0085413', 'cui_str': 'ADPKD'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3811844'}]","[{'cui': 'C0037982', 'cui_str': 'Spironolactone'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0086907', 'cui_str': 'Renin-Angiotensin-Aldosterone System'}, {'cui': 'C0243077', 'cui_str': 'inhibitors'}, {'cui': 'C0373535', 'cui_str': 'Aldosterone measurement (procedure)'}, {'cui': 'C3541395', 'cui_str': 'Mineralocorticoids'}]","[{'cui': 'C0031847', 'cui_str': 'pathophysiology'}, {'cui': 'C0006087', 'cui_str': 'Brachial Artery'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0445456', 'cui_str': 'Brachial (qualifier value)'}, {'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0232148', 'cui_str': 'Femoral pulse, function (observable entity)'}, {'cui': 'C0439830', 'cui_str': 'Velocity (property) (qualifier value)'}, {'cui': 'C0175630', 'cui_str': 'Circulating (qualifier value)'}, {'cui': 'C0225336', 'cui_str': 'Endothelial Cells'}, {'cui': 'C0242606', 'cui_str': 'Oxidative Stress'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}]",61.0,0.726539,"Spironolactone did not change the majority of circulating and/or endothelial cell markers of oxidative stress/inflammation and did not change vascular oxidative stress. ","[{'ForeName': 'Kristen L', 'Initials': 'KL', 'LastName': 'Nowak', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Electronic address: kristen.nowak@ucdenver.edu.'}, {'ForeName': 'Berenice', 'Initials': 'B', 'LastName': 'Gitomer', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Farmer-Bailey', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Wei', 'Initials': 'W', 'LastName': 'Wang', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Mikaela', 'Initials': 'M', 'LastName': 'Malaczewski', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Jelena', 'Initials': 'J', 'LastName': 'Klawitter', 'Affiliation': 'Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Zhiying', 'Initials': 'Z', 'LastName': 'You', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Diana', 'Initials': 'D', 'LastName': 'George', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Nayana', 'Initials': 'N', 'LastName': 'Patel', 'Affiliation': 'Department of Radiology, University of Colorado Anschutz Medical Campus, Aurora, CO.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Jovanovich', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Renal Section, Medical Service, Veteran Affairs Eastern Colorado Health Care System, Denver, CO.'}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'Chonchol', 'Affiliation': 'Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.'}]",American journal of kidney diseases : the official journal of the National Kidney Foundation,['10.1053/j.ajkd.2018.12.037'] 3195,30819520,Randomized Trial of Intravenous Lidocaine Versus Hydromorphone for Acute Abdominal Pain in the Emergency Department.,"STUDY OBJECTIVE We compare the efficacy and safety of intravenous lidocaine with that of hydromorphone for the treatment of acute abdominal pain in the emergency department (ED). METHODS This was a randomized, double-blind, clinical trial conducted in 2 EDs in the Bronx, NY. Adults weighing 60 to 120 kg were randomized to receive 120 mg of intravenous lidocaine or 1 mg of intravenous hydromorphone. Thirty minutes after administration of the first dose of the study drug, participants were asked whether they needed a second dose of the investigational medication to which they were randomized. Patients were also stratified according to clinical suspicion of nephrolithiasis. The primary outcome was improvement in pain scores of 0 to 10 between baseline and 90 minutes. An important secondary outcome was need for ""off-protocol"" parenteral analgesics, including opioids and nonsteroidal anti-inflammatory drugs. RESULTS We enrolled 154 patients, of whom 77 received lidocaine and 77 received hydromorphone. By 90 minutes, patients randomized to lidocaine improved by a mean of 3.8 points on the 0-to-10 scale, whereas those randomized to hydromorphone improved by a mean of 5.0 points (mean difference 1.2; 95% confidence interval 0.3 to 2.2). Need for off-protocol ""rescue"" analgesics occurred for 39 of 77 lidocaine patients (51%) and 20 of 77 hydromorphone patients (26%) (difference 25%; 95% confidence interval 10% to 40%). Adverse events were comparable between groups. Among the subset of 22 patients with nephrolithiasis, lidocaine patients reported a mean improvement of 3.4 points on the pain scale, whereas hydromorphone patients reported a mean improvement of 6.4 points (mean difference 3.0; 95% confidence interval 0.5 to 5.5). CONCLUSION Intravenous hydromorphone was superior to intravenous lidocaine both for general abdominal pain and a subset of patients with nephrolithiasis. A majority of patients randomly allocated to lidocaine required additional analgesics.",2019,Intravenous hydromorphone was superior to intravenous lidocaine both for general abdominal pain and a subset of patients with nephrolithiasis.,"['We enrolled 154 patients, of whom 77 received', 'Adults weighing 60 to 120 kg', 'Acute Abdominal Pain in the Emergency Department', 'patients with nephrolithiasis', 'acute abdominal pain in the emergency department (ED']","['lidocaine', 'Intravenous hydromorphone', 'Lidocaine Versus Hydromorphone', 'intravenous lidocaine', 'hydromorphone']","['Adverse events', '0-to-10 scale', 'need for ""off-protocol"" parenteral analgesics, including opioids and nonsteroidal anti-inflammatory drugs', 'pain scores', 'pain scale', 'efficacy and safety']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C4319550', 'cui_str': '120 (qualifier value)'}, {'cui': 'C0740577', 'cui_str': 'Acute abdominal pain (finding)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0392525', 'cui_str': 'Nephrolithiasis'}]","[{'cui': 'C0023660', 'cui_str': 'Lidocaine'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0012306', 'cui_str': 'Hydromorphone'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0222045'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0442711', 'cui_str': 'Protocols (qualifier value)'}, {'cui': 'C4522267', 'cui_str': 'Parenteral (intended site)'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",154.0,0.592385,Intravenous hydromorphone was superior to intravenous lidocaine both for general abdominal pain and a subset of patients with nephrolithiasis.,"[{'ForeName': 'Elliott', 'Initials': 'E', 'LastName': 'Chinn', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY; Department of Emergency Medicine, Jacobi Medical Center, Bronx, NY.'}, {'ForeName': 'Benjamin W', 'Initials': 'BW', 'LastName': 'Friedman', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY. Electronic address: bwfriedmanmd@gmail.com.'}, {'ForeName': 'Farnia', 'Initials': 'F', 'LastName': 'Naeem', 'Affiliation': 'Medical College, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}, {'ForeName': 'Eddie', 'Initials': 'E', 'LastName': 'Irizarry', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}, {'ForeName': 'Freda', 'Initials': 'F', 'LastName': 'Afrifa', 'Affiliation': 'Pharmacy Department, Montefiore, Bronx, NY.'}, {'ForeName': 'Eleftheria', 'Initials': 'E', 'LastName': 'Zias', 'Affiliation': 'Pharmacy Department, Montefiore, Bronx, NY.'}, {'ForeName': 'Michael P', 'Initials': 'MP', 'LastName': 'Jones', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY; Department of Emergency Medicine, Jacobi Medical Center, Bronx, NY.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Pearlman', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Chertoff', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Wollowitz', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}, {'ForeName': 'E John', 'Initials': 'EJ', 'LastName': 'Gallagher', 'Affiliation': 'Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore, Bronx, NY.'}]",Annals of emergency medicine,['10.1016/j.annemergmed.2019.01.021'] 3196,31028957,Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia.,"Anastrozole has been shown to prevent breast cancer in postmenopausal women at high risk of the disease, but has been associated with substantial accelerated loss of bone mineral density (BMD) and increased fractures. Here, we investigate the effect of risedronate on BMD after 5 years of follow-up in the IBIS-II prevention trial. 1410 women were enrolled in the bone sub-study and stratified into three strata according to the lowest baseline T-score at spine or femoral neck. The objective was to compare the effect of oral risedronate (35 mg weekly) versus placebo in osteopenic women in stratum II who were randomised to anastrozole in the main study. 258 osteopenic, postmenopausal women at high risk of developing breast cancer for whom baseline and follow-up bone mineral density measurements were available. 5-year mean BMD change at the lumbar spine for osteopenic women randomised to anastrozole and risedronate was -0.4% compared to -4.2% for those not on risedronate (P < 0.0001) but not significantly different between risedronate users and non-users at the hip (P = 0.2). 5-year mean PINP change was -20% for those randomised to anastrozole and risedronate compared to 3% for those not on risedronate but on anastrozole (P < 0.0001). Our results confirm the bone loss associated with the use of anastrozole and show that anastrozole-induced BMD loss in the spine can be controlled with risedronate treatment. However, our results suggest that weekly oral risedronate is unable to completely prevent anastrozole induced bone loss at the hip.",2019,mean PINP change was -20% for those randomised to anastrozole and risedronate compared to 3% for those not on risedronate but on anastrozole (P < 0.0001).,"['postmenopausal women', '258 osteopenic, postmenopausal women at high risk of developing breast cancer for whom baseline and follow-up bone mineral density measurements', '1410 women were enrolled in the bone sub-study and stratified into three strata according to the lowest baseline T-score at spine or femoral neck', 'osteopenic women in stratum II who were randomised to', 'women at high risk of developing breast cancer with osteopenia']","['placebo', 'Anastrozole', 'anastrozole and risedronate', 'oral risedronate', 'anastrozole', 'risedronate']","['5-year mean BMD change', 'bone loss', 'BMD', 'mean PINP change', '5-year', 'BMD loss', 'bone mineral density (BMD']","[{'cui': 'C0232970', 'cui_str': 'Postmenopausal state (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0332167', 'cui_str': 'High risk of (contextual qualifier) (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0262950', 'cui_str': 'Bones'}, {'cui': 'C1264637', 'cui_str': 'Substance amount'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C3854607', 'cui_str': 'T score'}, {'cui': 'C0037949', 'cui_str': 'Spinal Column'}, {'cui': 'C0015815', 'cui_str': 'Femoral Neck'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0290883', 'cui_str': 'anastrozole'}, {'cui': 'C0246719', 'cui_str': 'Risedronate'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0029453', 'cui_str': 'Osteopenia'}, {'cui': 'C0005938', 'cui_str': 'Bone Mineral Density'}]",1410.0,0.122595,mean PINP change was -20% for those randomised to anastrozole and risedronate compared to 3% for those not on risedronate but on anastrozole (P < 0.0001).,"[{'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Sestak', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: i.sestak@qmul.ac.uk.'}, {'ForeName': 'Glen M', 'Initials': 'GM', 'LastName': 'Blake', 'Affiliation': ""School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London SE1 7EH, UK.""}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Patel', 'Affiliation': 'Imperial College London, London SW7 2AZ, UK.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Coleman', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Cuzick', 'Affiliation': 'Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University London, Charterhouse Square, London EC1M 6BQ, UK.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Eastell', 'Affiliation': 'Department of Oncology and Metabolism, University of Sheffield, Western Bank, Sheffield S10 2TN, UK.'}]",Bone,['10.1016/j.bone.2019.04.016'] 3197,31055663,New insights into the natural course and clinical relevance of Modic changes over 2 years following lumbar limited discectomy: analysis of prospective collected data.,"PURPOSE Few retrospective studies have addressed Modic changes (MC) following lumbar spine surgery, though it is usually assumed that MC increase in grade and incidence. To test this conventional wisdom, we investigated the natural course of MC following primary lumbar limited discectomy with two-year follow-up. In addition, a possible clinical relevance to those changes was assessed. METHODS The data of the control group (278 subjects) of a prospective randomized, controlled trial (RCT) were evaluated retrospectively. RESULTS We did not observe a simple increase in MC with regard to grade. There is variable activity observed in Type 2 (at 12 months) and in Type 1 (at 24 months). Conversion from one grade to another may occur and may be upward or downward. The incidence of MC increased slightly over time, as after surgery a decreasing percentage of the study group remained without MC over two years (1 year: 34% (85/250); 2 years: 30% (72/237)). Radiological parameters (rotation, translation, and spondylolisthesis) had no significant correlation to MC or MC subtypes. Lastly, we found that neither the different MC types nor their changes were correlated with clinical parameters (VAS back, VAS leg, ODI score) preoperatively or during follow-up. CONCLUSION The pattern of Modic changes following lumbar limited discectomy is complex, not simply increasing. There is variable activity in MC Types 1 and 2 at the different time points of follow-up, and conversion from a higher grader to a lower one or vice versa is possible. These slides can be retrieved under Electronic Supplementary Material.",2019,"Radiological parameters (rotation, translation, and spondylolisthesis) had no significant correlation to MC or MC subtypes.",[],[],"['incidence of MC', 'clinical parameters (VAS back, VAS leg, ODI score', 'Radiological parameters (rotation, translation, and spondylolisthesis']",[],[],"[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0040712', 'cui_str': 'Translations'}, {'cui': 'C0038016', 'cui_str': 'Spondylisthesis'}]",,0.0423849,"Radiological parameters (rotation, translation, and spondylolisthesis) had no significant correlation to MC or MC subtypes.","[{'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Bostelmann', 'Affiliation': 'Department of Neurosurgery, Medical Faculty, University Hospital Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany. richard.bostelmann@med.uni-duesseldorf.de.'}, {'ForeName': 'Athanasios', 'Initials': 'A', 'LastName': 'Petridis', 'Affiliation': 'Department of Neurosurgery, Medical Faculty, University Hospital Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany.'}, {'ForeName': 'Katinka', 'Initials': 'K', 'LastName': 'Fischer', 'Affiliation': 'Mathematical Institute, Heinrich Heine University, Duesseldorf, Germany.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Vajkoczy', 'Affiliation': 'Department of Neurosurgery, Charité Universitätsmedizin, Berlin, Germany.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Bostelmann', 'Affiliation': 'Department of Neurosurgery, Medical Faculty, University Hospital Duesseldorf, Moorenstrasse 5, 40225, Duesseldorf, Germany.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Barth', 'Affiliation': 'Department of Neurosurgery, Klinikum Frankfurt Höchst, Frankfurt, Germany.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-019-05988-1'] 3198,32141834,Using the Technology Acceptance Model to Explore Adolescents' Perspectives on Combining Technologies for Physical Activity Promotion Within an Intervention: Usability Study.,"BACKGROUND Wearable activity trackers and social media have been identified as having the potential to increase physical activity among adolescents, yet little is known about the perceived ease of use and perceived usefulness of the technology by adolescents. OBJECTIVE The aim of this study was to use the technology acceptance model to explore adolescents' acceptance of wearable activity trackers used in combination with social media within a physical activity intervention. METHODS The Raising Awareness of Physical Activity study was a 12-week physical activity intervention that combined a wearable activity tracker (Fitbit Flex) with supporting digital materials that were delivered using social media (Facebook). A total of 124 adolescents aged 13 to 14 years randomized to the intervention group (9 schools) participated in focus groups immediately post intervention. Focus groups explored adolescents' perspectives of the intervention and were analyzed using pen profiles using a coding framework based on the technology acceptance model. RESULTS Adolescents reported that Fitbit Flex was useful as it motivated them to be active and provided feedback about their physical activity levels. However, adolescents typically reported that Fitbit Flex required effort to use, which negatively impacted on their perceived ease of use. Similarly, Facebook was considered to be a useful platform for delivering intervention content. However, adolescents generally noted preferences for using alternative social media websites, which may have impacted on negative perceptions concerning Facebook's ease of use. Perceptions of technological risks included damage to or loss of the device, integrity of data, and challenges with both Fitbit and Facebook being compatible with daily life. CONCLUSIONS Wearable activity trackers and social media have the potential to impact adolescents' physical activity levels. The findings from this study suggest that although the adolescents recognized the potential usefulness of the wearable activity trackers and the social media platform, the effort required to use these technologies, as well as the issues concerning risks and compatibility, may have influenced overall engagement and technology acceptance. As wearable activity trackers and social media platforms can change rapidly, future research is needed to examine the factors that may influence the acceptance of specific forms of technology by using the technology acceptance model. TRIAL REGISTRATION Australian and New Zealand Clinical Trials Registry ACTRN12616000899448; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370716.",2020,"RESULTS Adolescents reported that Fitbit Flex was useful as it motivated them to be active and provided feedback about their physical activity levels.","['Australian and New Zealand', '124 adolescents aged 13 to 14 years', 'Adolescents']","['Facebook', 'physical activity intervention that combined a wearable activity tracker (Fitbit Flex) with supporting digital materials that were delivered using social media (Facebook']",[],"[{'cui': 'C0027978', 'cui_str': 'New Zealand'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C4264352', 'cui_str': 'Activity Trackers'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0442015', 'cui_str': 'Digital X-ray (qualifier value)'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C3179065', 'cui_str': 'Social Media'}]",[],124.0,0.0223965,"RESULTS Adolescents reported that Fitbit Flex was useful as it motivated them to be active and provided feedback about their physical activity levels.","[{'ForeName': 'Mark', 'Initials': 'M', 'LastName': 'Drehlich', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Naraine', 'Affiliation': 'Deakin Business School, Deakin University, Burwood, Australia.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Rowe', 'Affiliation': 'Deakin Business School, Deakin University, Burwood, Australia.'}, {'ForeName': 'Samuel K', 'Initials': 'SK', 'LastName': 'Lai', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Jo', 'Initials': 'J', 'LastName': 'Salmon', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Brown', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Harriet', 'Initials': 'H', 'LastName': 'Koorts', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}, {'ForeName': 'Susie', 'Initials': 'S', 'LastName': 'Macfarlane', 'Affiliation': 'Learning Futures, Deakin University, Burwood, Australia.'}, {'ForeName': 'Nicola D', 'Initials': 'ND', 'LastName': 'Ridgers', 'Affiliation': 'Institute for Physical Activity and Nutrition, Deakin University, Burwood, Australia.'}]",Journal of medical Internet research,['10.2196/15552'] 3199,30908592,Restrictive vs liberal oxygen for trauma patients-the TRAUMOX1 pilot randomised clinical trial.,"INTRODUCTION Hyperoxaemia is commonly observed in trauma patients but has been associated with pulmonary complications and mortality in some patient populations. The objectives of this study were to evaluate whether maintenance of normoxia is feasible using a restrictive oxygen strategy in the initial phase after trauma and to evaluate the incidence of 30-day mortality and/or major pulmonary complications. METHODS Forty-one adult trauma patients admitted to our trauma centre were randomised to 24 hours of restrictive oxygen therapy (no supplemental oxygen if the arterial oxyhaemoglobin saturation (SpO 2 ) was at least 94%, n = 21) or liberal oxygen therapy (intubated patients: FiO 2 1.0 in the trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15 L/min via a non-rebreather mask, n = 20). Two blinded anaesthesiologists evaluated major in-hospital pulmonary complications within 30 days. RESULTS Protocol compliance was high, as the median arterial oxygen tension was significantly lower in the restrictive group (10.8 kPa [9.7-12.0] vs 30.4 kPa [23.7-39.0], P < 0.0001). There were seven episodes of SpO 2 below 90% in the restrictive group and one episode in the liberal group. Thirty-day mortality and/or major in-hospital pulmonary complications occurred in 4/20 (20%) in the restrictive group and in 6/18 (33%) in the liberal group: two patients in each group died within 30 days and the incidence of major in-hospital pulmonary complications was 2/20 (10%) in the restrictive group and 4/18 (22%) in the liberal group. CONCLUSION Maintenance of normoxia using a restrictive oxygen strategy following trauma is feasible. This pilot study serves as the basis for a larger clinical trial.",2019,"RESULTS Protocol compliance was high, as the median arterial oxygen tension was significantly lower in the restrictive group (10.8 kPa [9.7-12.0] vs 30.4 kPa [23.7-39.0], P < 0.0001).","['trauma patients', 'Forty-one adult trauma patients admitted to our trauma centre']","['Restrictive vs liberal oxygen', 'restrictive oxygen therapy (no supplemental oxygen if the arterial oxyhaemoglobin saturation (SpO 2 ', 'liberal oxygen therapy (intubated patients: FiO 2 1.0 in the trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15\xa0L/min via a non-rebreather mask']","['median arterial oxygen tension', '30-day mortality and/or major pulmonary complications', 'incidence of major in-hospital pulmonary complications', 'Thirty-day mortality and/or major in-hospital pulmonary complications']","[{'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0040786', 'cui_str': 'Trauma Centers'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0184633', 'cui_str': 'Oxygen Inhalation Therapy'}, {'cui': 'C0221464', 'cui_str': 'Arterial (qualifier value)'}, {'cui': 'C1168591', 'cui_str': 'Oxyhaemoglobin'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0043251', 'cui_str': 'Trauma'}, {'cui': 'C3203003', 'cui_str': 'Bays'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439393', 'cui_str': 'liter/minute'}, {'cui': 'C1960093', 'cui_str': 'Non-rebreather mask'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0202155', 'cui_str': 'Oxygen measurement, partial pressure, arterial (procedure)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C4522268', 'cui_str': 'Pulmonary'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C3816446', 'cui_str': '30'}]",,0.0817208,"RESULTS Protocol compliance was high, as the median arterial oxygen tension was significantly lower in the restrictive group (10.8 kPa [9.7-12.0] vs 30.4 kPa [23.7-39.0], P < 0.0001).","[{'ForeName': 'Josefine S', 'Initials': 'JS', 'LastName': 'Baekgaard', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Dan', 'Initials': 'D', 'LastName': 'Isbye', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Camilla Ikast', 'Initials': 'CI', 'LastName': 'Ottosen', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Mo Haslund', 'Initials': 'MH', 'LastName': 'Larsen', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jakob Hessel', 'Initials': 'JH', 'LastName': 'Andersen', 'Affiliation': 'Department of Anaesthesia, Zealand University Hospital, Køge, Denmark.'}, {'ForeName': 'Lars S', 'Initials': 'LS', 'LastName': 'Rasmussen', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Steinmetz', 'Affiliation': 'Department of Anaesthesia, Centre of Head and Orthopaedics, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.'}]",Acta anaesthesiologica Scandinavica,['10.1111/aas.13362'] 3200,32014843,Effectiveness of a Web-Based Menu-Planning Intervention to Improve Childcare Service Compliance With Dietary Guidelines: Randomized Controlled Trial.,"BACKGROUND Foods provided in childcare services are not consistent with dietary guideline recommendations. Web-based systems offer unique opportunities to support the implementation of such guidelines. OBJECTIVE This study aimed to assess the effectiveness of a Web-based menu planning intervention in increasing the mean number of food groups on childcare service menus that comply with dietary guidelines. Secondary aims were to assess the impact of the intervention on the proportion of service menus compliant with recommendations for (1) all food groups; (2) individual food groups; and (3) mean servings of individual food groups. Childcare service use and acceptability of the Web-based program were also assessed. METHODS A single-blind, parallel-group randomized controlled trial was undertaken with 54 childcare services in New South Wales, Australia. Services were randomized to a 12-month intervention or usual care control. Intervention services received access to a Web-based menu planning program linked to their usual childcare management software system. Childcare service compliance with dietary guidelines and servings of food groups were assessed at baseline, 3-month follow-up, and 12-month follow-up. RESULTS No significant differences in the mean number of food groups compliant with dietary guidelines and the proportion of service menus compliant with recommendations for all food groups, or for individual food groups, were found at 3- or 12-month follow-up between the intervention and control groups. Intervention service menus provided significantly more servings of fruit (P<.001), vegetables (P=.03), dairy (P=.03), and meat (P=.003), and reduced their servings of discretionary foods (P=.02) compared with control group at 3 months. This difference was maintained for fruit (P=.03) and discretionary foods (P=.003) at 12 months. Intervention childcare service staff logged into the Web-based program an average of 40.4 (SD 31.8) times and rated the program as highly acceptable. CONCLUSIONS Although improvements in childcare service overall menu and individual food group compliance with dietary guidelines were not statistically significant, findings indicate that a Web-based menu planning intervention can improve the servings for some healthy food groups and reduce the provision of discretionary foods. Future research exploring the effectiveness of differing strategies in improving the implementation of dietary guidelines in childcare services is warranted. TRIAL REGISTRATION Australian New Zealand Clinical Trial Registry (ANZCTR): 16000974404; http://www.anzctr.org.au/ACTRN12616000974404.aspx.",2020,This difference was maintained for fruit (P=.03) and discretionary foods (P=.003) at 12 months.,"['54 childcare services in New South Wales, Australia', 'mean number of food groups on childcare service menus that comply with dietary guidelines']","['Web-based menu planning intervention', 'intervention or usual care control', 'access to a Web-based menu planning program linked to their usual childcare management software system', 'Web-Based Menu-Planning Intervention']","['servings of discretionary foods', 'servings of fruit (P<.001), vegetables']","[{'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C3658297', 'cui_str': 'Nutrition Guidelines'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C0449913', 'cui_str': 'System (attribute)'}]","[{'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C0016767', 'cui_str': 'Fruit'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}]",,0.0686262,This difference was maintained for fruit (P=.03) and discretionary foods (P=.003) at 12 months.,"[{'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Grady', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Luke', 'Initials': 'L', 'LastName': 'Wolfenden', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Wiggers', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Rissel', 'Affiliation': 'School of Public Health, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.'}, {'ForeName': 'Meghan', 'Initials': 'M', 'LastName': 'Finch', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Victoria', 'Initials': 'V', 'LastName': 'Flood', 'Affiliation': 'Westmead Hospital, Western Sydney Local Health District, Westmead, Australia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Salajan', 'Affiliation': 'Healthy Australia Ltd, Melbourne, Australia.'}, {'ForeName': 'Ruby', 'Initials': 'R', 'LastName': ""O'Rourke"", 'Affiliation': 'Healthy Australia Ltd, Melbourne, Australia.'}, {'ForeName': 'Fiona', 'Initials': 'F', 'LastName': 'Stacey', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Wyse', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Christophe', 'Initials': 'C', 'LastName': 'Lecathelinais', 'Affiliation': 'Population Health, Hunter New England Local Health District, Wallsend, Australia.'}, {'ForeName': 'Courtney', 'Initials': 'C', 'LastName': 'Barnes', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}, {'ForeName': 'Sue', 'Initials': 'S', 'LastName': 'Green', 'Affiliation': 'Population Health, Hunter New England Local Health District, Wallsend, Australia.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Herrmann', 'Affiliation': 'Population Health, Hunter New England Local Health District, Wallsend, Australia.'}, {'ForeName': 'Sze Lin', 'Initials': 'SL', 'LastName': 'Yoong', 'Affiliation': 'School of Medicine and Public Health, University of Newcastle, Callaghan, Australia.'}]",Journal of medical Internet research,['10.2196/13401'] 3201,32012051,"""Asking Too Much?"": Randomized N-of-1 Trial Exploring Patient Preferences and Measurement Reactivity to Frequent Use of Remote Multidimensional Pain Assessments in Children and Young People With Juvenile Idiopathic Arthritis.","BACKGROUND Remote monitoring of pain using multidimensional mobile health (mHealth) assessment tools is increasingly being adopted in research and care. This assessment method is valuable because it is challenging to capture pain histories, particularly in children and young people in diseases where pain patterns can be complex, such as juvenile idiopathic arthritis (JIA). With the growth of mHealth measures and more frequent assessment, it is important to explore patient preferences for the timing and frequency of administration of such tools and consider whether certain administrative patterns can directly impact on children's pain experiences. OBJECTIVE This study aimed to explore the feasibility and influence (in terms of objective and subjective measurement reactivity) of several time sampling strategies in remote multidimensional pain reporting. METHODS An N-of-1 trial was conducted in a subset of children and young people with JIA and their parents recruited to a UK cohort study. Children were allocated to 1 of 4 groups. Each group followed a different schedule of completion of MPT for 8 consecutive weeks. Each schedule included 2 blocks, each comprising 4 different randomized time sampling strategies, with each strategy occurring once within each 4-week block. Children completed MPT according to time sampling strategies: once-a-day, twice-a-day, once-a-week, and as-and-when pain was experienced. Adherence to each strategy was calculated. Participants completed the Patient-Reported Outcomes Measurement Information System Pain Interference Scale at the end of each week to explore objective reactivity. Differences in pain interference scores between time sampling strategies were assessed graphically and using Friedman tests. Children and young people and their parents took part in a semistructured interview about their preferences for different time sampling strategies and to explore subjective reactivity. RESULTS A total of 14 children and young people (aged 7-16 years) and their parents participated. Adherence to pain reporting was higher in less intense time sampling strategies (once-a-week=63% [15/24]) compared with more intense time sampling strategies (twice-a-day=37.8% [127/336]). There were no statistically significant differences in pain interference scores between sampling strategies. Qualitative findings from interviews suggested that children preferred once-a-day (6/14, 43%) and as-and-when pain reporting (6/14, 43%). Creating routine was one of the most important factors for successful reporting, while still ensuring that comprehensive information about recent pain was captured. CONCLUSIONS Once-a-day pain reporting provides rich contextual information. Although patients were less adherent to this preferred sampling strategy, once-a-day reporting still provides more frequent assessment opportunities compared with other less intense or overburdensome schedules. Important issues for the design of studies and care incorporating momentary assessment techniques were identified. We demonstrate that patient reporting preferences are key to accommodate and are important where data capture quality is key. Our findings support frequent administration of such tools, using daily reporting methods where possible.",2020,There were no statistically significant differences in pain interference scores between sampling strategies.,"['remote multidimensional pain reporting', 'children and young people with JIA and their parents recruited to a UK cohort study', ""children's pain experiences"", '14 children and young people (aged 7-16 years) and their parents participated', 'Children and Young People With Juvenile Idiopathic Arthritis']",[],"['Outcomes Measurement Information System Pain Interference Scale', 'pain interference scores', 'Adherence to pain reporting']","[{'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3495559', 'cui_str': 'Arthritis, Juvenile Chronic'}]",[],"[{'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0021428', 'cui_str': 'Information Systems'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",14.0,0.100893,There were no statistically significant differences in pain interference scores between sampling strategies.,"[{'ForeName': 'Rebecca Rachael', 'Initials': 'RR', 'LastName': 'Lee', 'Affiliation': 'National Institute for Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Shoop-Worrall', 'Affiliation': 'Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Amir', 'Initials': 'A', 'LastName': 'Rashid', 'Affiliation': 'National Institute for Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom.'}, {'ForeName': 'Wendy', 'Initials': 'W', 'LastName': 'Thomson', 'Affiliation': 'Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.'}, {'ForeName': 'Lis', 'Initials': 'L', 'LastName': 'Cordingley', 'Affiliation': 'Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom.'}]",Journal of medical Internet research,['10.2196/14503'] 3202,31769551,Exploring parental perspectives after commencement of flash glucose monitoring for type 1 diabetes in adolescents and young adults not meeting glycaemic targets: a qualitative study.,"AIMS To explore parental perspectives after flash glucose monitoring commencement in adolescents and young adults with type 1 diabetes who were not meeting glycaemic targets. METHODS Twelve semi-structured interviews were conducted among parents of adolescents and young adults between the ages of 14 and 20 years (inclusive) with type 1 diabetes and not meeting glycaemic targets [HbA 1c 81-130 mmol/mol (9.6-14.0%)] participating in a randomized controlled trial. Interviews were transcribed, then thematic analysis was performed to identify themes regarding parental experiences. RESULTS Four key themes were found: flash glucose monitoring improved parental emotional well-being; flash glucose monitoring reduced diabetes-specific conflict within families; flash glucose monitoring facilitated the parental role in diabetes management; and sensor-related challenges, particularly sensors falling off, interfered with using flash glucose monitoring for diabetes management. The cost of self-funded sensors was the only barrier to continuing flash glucose monitoring that parents reported. CONCLUSIONS This study provides new insights into the potential benefits and challenges of flash glucose monitoring use, drawn from the perspective of parents of adolescents and young adults not meeting glycaemic targets. As parents are often key partners in obtaining or purchasing this technology, these findings can be used to further inform parental expectations of this technology.",2020,"RESULTS Four key themes were found: flash glucose monitoring improved parental emotional well-being; flash glucose monitoring reduced diabetes-specific conflict within families; flash glucose monitoring facilitated the parental role in diabetes management; and sensor-related challenges, particularly sensors falling off, interfered with using flash glucose monitoring for diabetes management.","['type 1 diabetes in adolescents and young adults not meeting glycaemic targets', 'Twelve semi-structured interviews were conducted among parents of adolescents and young adults between the ages of 14 and 20 years (inclusive) with type 1 diabetes and not meeting glycaemic targets [HbA 1c 81-130 mmol/mol (9.6-14.0%)] participating in a randomized controlled trial', 'parents of adolescents and young adults not meeting glycaemic targets', 'adolescents and young adults with type 1 diabetes who were not meeting glycaemic targets']","['flash glucose monitoring commencement', 'flash glucose monitoring']",['flash glucose monitoring improved parental emotional well-being; flash glucose monitoring reduced diabetes-specific conflict'],"[{'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0030551', 'cui_str': 'Parent of (observable entity)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0019016', 'cui_str': 'Hemoglobin A'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}, {'cui': 'C0439190', 'cui_str': 'mmol'}, {'cui': 'C0439189', 'cui_str': 'mole - unit'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0344323', 'cui_str': 'Flashing (disorder)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}]","[{'cui': 'C0344323', 'cui_str': 'Flashing (disorder)'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0849912', 'cui_str': 'Emotional (qualifier value)'}, {'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0009671', 'cui_str': 'Conflict'}]",130.0,0.0297884,"RESULTS Four key themes were found: flash glucose monitoring improved parental emotional well-being; flash glucose monitoring reduced diabetes-specific conflict within families; flash glucose monitoring facilitated the parental role in diabetes management; and sensor-related challenges, particularly sensors falling off, interfered with using flash glucose monitoring for diabetes management.","[{'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Boucher', 'Affiliation': ""Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.""}, {'ForeName': 'S Hye', 'Initials': 'SH', 'LastName': 'Aum', 'Affiliation': ""Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.""}, {'ForeName': 'H R', 'Initials': 'HR', 'LastName': 'Crocket', 'Affiliation': 'Faculty of Health, Sport and Human Performance, University of Waikato, Hamilton, New Zealand.'}, {'ForeName': 'E J', 'Initials': 'EJ', 'LastName': 'Wiltshire', 'Affiliation': 'Department of Paediatrics and Child Health, University of Otago, Wellington, New Zealand.'}, {'ForeName': 'P A', 'Initials': 'PA', 'LastName': 'Tomlinson', 'Affiliation': ""Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.""}, {'ForeName': 'M I', 'Initials': 'MI', 'LastName': 'de Bock', 'Affiliation': 'Department of Paediatrics, University of Otago, Christchurch, New Zealand.'}, {'ForeName': 'B J', 'Initials': 'BJ', 'LastName': 'Wheeler', 'Affiliation': ""Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.""}]",Diabetic medicine : a journal of the British Diabetic Association,['10.1111/dme.14188'] 3203,31810865,Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation.,"BACKGROUND Ventilator-associated pneumonia is the most common intensive care unit (ICU)-acquired infection, yet accurate diagnosis remains difficult, leading to overuse of antibiotics. Low concentrations of IL-1β and IL-8 in bronchoalveolar lavage fluid have been validated as effective markers for exclusion of ventilator-associated pneumonia. The VAPrapid2 trial aimed to determine whether measurement of bronchoalveolar lavage fluid IL-1β and IL-8 could effectively and safely improve antibiotic stewardship in patients with clinically suspected ventilator-associated pneumonia. METHODS VAPrapid2 was a multicentre, randomised controlled trial in patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland. Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia. Patients were randomly assigned (1:1) to biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit. Patients were randomised using randomly permuted blocks of size four and six and stratified by site, with allocation concealment. Clinicians were masked to patient assignment for an initial period until biomarker results were reported. Bronchoalveolar lavage was done in all patients, with concentrations of IL-1β and IL-8 rapidly determined in bronchoalveolar lavage fluid from patients randomised to the biomarker-based antibiotic recommendation group. If concentrations were below a previously validated cutoff, clinicians were advised that ventilator-associated pneumonia was unlikely and to consider discontinuing antibiotics. Patients in the routine use of antibiotics group received antibiotics according to usual practice at sites. Microbiology was done on bronchoalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at least 10 4 colony forming units per mL of bronchoalveolar lavage fluid. The primary outcome was the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage. Data were analysed on an intention-to-treat basis, with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group who defaulted to routine use of antibiotics because of failure to return an adequate biomarker result. An embedded process evaluation assessed factors influencing trial adoption, recruitment, and decision making. This study is registered with ISRCTN, ISRCTN65937227, and ClinicalTrials.gov, NCT01972425. FINDINGS Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study. 146 patients were ineligible, leaving 214 who were recruited to the study. Four patients were excluded before randomisation, meaning that 210 patients were randomly assigned to biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics (n=106). One patient in the biomarker-guided recommendation group was withdrawn by the clinical team before bronchoscopy and so was excluded from the intention-to-treat analysis. We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58). Bronchoalveolar lavage was associated with a small and transient increase in oxygen requirements. Established prescribing practices, reluctance for bronchoalveolar lavage, and dependence on a chain of trial-related procedures emerged as factors that impaired trial processes. INTERPRETATION Antibiotic use remains high in patients with suspected ventilator-associated pneumonia. Antibiotic stewardship was not improved by a rapid, highly sensitive rule-out test. Prescribing culture, rather than poor test performance, might explain this absence of effect. FUNDING UK Department of Health and the Wellcome Trust.",2020,We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58).,"['patients admitted to 24 ICUs from 17 National Health Service hospital trusts across England, Scotland, and Northern Ireland', 'patients with suspected ventilator-associated pneumonia', 'Patients were screened for eligibility and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected ventilator-associated pneumonia', 'Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study', 'suspected ventilator-associated pneumonia (VAPrapid2', 'Four patients were excluded before randomisation, meaning that 210 patients', '146 patients were ineligible, leaving 214 who were recruited to the study', 'patients with clinically suspected ventilator-associated pneumonia']","['biomarker-guided recommendation on antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service hosted by Newcastle Clinical Trials Unit', 'biomarker-guided recommendation on antibiotics (n=104) or routine use of antibiotics', 'Biomarker-guided antibiotic stewardship']","['oxygen requirements', 'distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage', 'Antibiotic stewardship']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0027462', 'cui_str': 'Health Services, National'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0237935', 'cui_str': 'Trust'}, {'cui': 'C0014282', 'cui_str': 'England'}, {'cui': 'C0036453', 'cui_str': 'Scotland'}, {'cui': 'C0028415', 'cui_str': 'Northern Ireland'}, {'cui': 'C0750491', 'cui_str': 'Suspected (qualifier value)'}, {'cui': 'C0087153', 'cui_str': 'Ventilators'}, {'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0521125', 'cui_str': 'For (qualifier value)'}, {'cui': 'C4319607', 'cui_str': '360 (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}]","[{'cui': 'C0005516', 'cui_str': 'Biological Markers'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]","[{'cui': 'C0030054', 'cui_str': 'Oxygen'}, {'cui': 'C0037775', 'cui_str': 'Distributions (qualifier value)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0332282', 'cui_str': 'Following (attribute)'}, {'cui': 'C1535502', 'cui_str': 'Lung Lavage'}, {'cui': 'C4505100', 'cui_str': 'Antibiotic Stewardship'}]",146.0,0.342377,We found no significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following bronchoalveolar lavage in the intention-to-treat analysis (p=0·58).,"[{'ForeName': 'Thomas P', 'Initials': 'TP', 'LastName': 'Hellyer', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Daniel F', 'Initials': 'DF', 'LastName': 'McAuley', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK; Regional Intensive Care Unit, The Royal Hospitals, Belfast, UK.""}, {'ForeName': 'Timothy S', 'Initials': 'TS', 'LastName': 'Walsh', 'Affiliation': ""Anaesthesia, Critical Care and Pain Medicine, University of Edinburgh, Queen's Medical Research Institute, Edinburgh, UK; Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.""}, {'ForeName': 'Niall', 'Initials': 'N', 'LastName': 'Anderson', 'Affiliation': 'Usher Institute, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Conway Morris', 'Affiliation': ""Division of Anaesthesia, Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.""}, {'ForeName': 'Suveer', 'Initials': 'S', 'LastName': 'Singh', 'Affiliation': 'Department of Cancer and Surgery, Imperial College London, London, UK.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Dark', 'Affiliation': 'Division of Infection Immunity and Respiratory Medicine, Manchester National Institute for Health Research Biomedical Research Centre, University of Manchester, Manchester, UK.'}, {'ForeName': 'Alistair I', 'Initials': 'AI', 'LastName': 'Roy', 'Affiliation': 'Integrated Critical Care Unit, Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.'}, {'ForeName': 'Gavin D', 'Initials': 'GD', 'LastName': 'Perkins', 'Affiliation': 'Warwick Medical School, University of Warwick, Coventry, UK; Intensive Care Unit, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.'}, {'ForeName': 'Ronan', 'Initials': 'R', 'LastName': 'McMullan', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Lydia M', 'Initials': 'LM', 'LastName': 'Emerson', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Bronagh', 'Initials': 'B', 'LastName': 'Blackwood', 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Stephen E', 'Initials': 'SE', 'LastName': 'Wright', 'Affiliation': 'Integrated Critical Care Unit, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.'}, {'ForeName': 'Kallirroi', 'Initials': 'K', 'LastName': 'Kefala', 'Affiliation': 'Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Cecilia M', 'Initials': 'CM', 'LastName': ""O'Kane"", 'Affiliation': ""The Wellcome-Wolfson Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.""}, {'ForeName': 'Simon V', 'Initials': 'SV', 'LastName': 'Baudouin', 'Affiliation': 'Intensive Care Unit, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.'}, {'ForeName': 'Ross L', 'Initials': 'RL', 'LastName': 'Paterson', 'Affiliation': 'Intensive Care Unit, Western General Hospital, Edinburgh, UK.'}, {'ForeName': 'Anthony J', 'Initials': 'AJ', 'LastName': 'Rostron', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; Integrated Critical Care Unit, Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Agus', 'Affiliation': 'Northern Ireland Clinical Trials Unit, The Royal Hospitals, Belfast, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Bannard-Smith', 'Affiliation': 'Intensive Care Unit, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.'}, {'ForeName': 'Nicole M', 'Initials': 'NM', 'LastName': 'Robin', 'Affiliation': 'Intensive Care Unit, Countess of Chester NHS Foundation Trust, Chester, UK.'}, {'ForeName': 'Ingeborg D', 'Initials': 'ID', 'LastName': 'Welters', 'Affiliation': 'Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Bassford', 'Affiliation': 'Intensive Care Unit, University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Yates', 'Affiliation': 'Intensive Care Unit, Northumbria Specialist Emergency Care Hospital, Cramlington, UK.'}, {'ForeName': 'Craig', 'Initials': 'C', 'LastName': 'Spencer', 'Affiliation': 'Intensive Care Unit, Preston Royal Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Shondipon K', 'Initials': 'SK', 'LastName': 'Laha', 'Affiliation': 'Intensive Care Unit, Preston Royal Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Hulme', 'Affiliation': 'Intensive Care Unit, Sandwell General Hospital, Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK.'}, {'ForeName': 'Stephen', 'Initials': 'S', 'LastName': 'Bonner', 'Affiliation': 'Intensive Care Unit, James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.'}, {'ForeName': 'Vanessa', 'Initials': 'V', 'LastName': 'Linnett', 'Affiliation': 'Intensive Care Unit, Queen Elizabeth Hospital, Gateshead NHS Foundation Trust, Gateshead, UK.'}, {'ForeName': 'Julian', 'Initials': 'J', 'LastName': 'Sonksen', 'Affiliation': 'Intensive Care Unit, Russells Hall Hospital, Dudley Group NHS Foundation Trust, Dudley, UK.'}, {'ForeName': 'Tina', 'Initials': 'T', 'LastName': 'Van Den Broeck', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Gert', 'Initials': 'G', 'LastName': 'Boschman', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Dw James', 'Initials': 'DJ', 'LastName': 'Keenan', 'Affiliation': 'Becton Dickinson Biosciences Europe, Erembodegem, Belgium.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Scott', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.'}, {'ForeName': 'A Joy', 'Initials': 'AJ', 'LastName': 'Allen', 'Affiliation': 'National Institute for Health Research Newcastle In Vitro Diagnostics Cooperative, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Phair', 'Affiliation': 'Northern Ireland Clinical Trials Unit, The Royal Hospitals, Belfast, UK.'}, {'ForeName': 'Jennie', 'Initials': 'J', 'LastName': 'Parker', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Susan A', 'Initials': 'SA', 'LastName': 'Bowett', 'Affiliation': 'Newcastle Clinical Trials Unit, Newcastle University, Newcastle, UK.'}, {'ForeName': 'A John', 'Initials': 'AJ', 'LastName': 'Simpson', 'Affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle, UK; National Institute for Health Research Newcastle In Vitro Diagnostics Cooperative, Newcastle University, Newcastle, UK. Electronic address: j.simpson@ncl.ac.uk.'}]",The Lancet. Respiratory medicine,['10.1016/S2213-2600(19)30367-4'] 3204,32146440,"The effects of circuit resistance training on plasma progranulin level, insulin resistance and body composition in obese men.","Background Progranulin (PGRN) is implicated in obesity and insulin resistance (IR). The aim of this study was to evaluate the effects of 8 weeks of circuit resistance training (CRT) on plasma PGRN, IR and body composition in obese men. Materials and methods Twenty-eight healthy obese men [age: 36 ± 7.7 years, body weight (BW): 96.4 ± 15.6 kg, body mass index (BMI): 32.4 ± 4.5 kg/m2] completed the study. Subjects were randomly assigned to two groups of control and training. Subjects in the training group underwent training for 8 weeks, 3 times a week. Blood samples and anthropometric characteristics were taken before the commencement of the exercise protocol and 72 h after the last training session. The homeostatic model assessment of insulin resistance (HOMA-IR) was used to measure IR. Results BW, BF%, BMI, waist-hip ratio (WHR), HOMA-IR and plasma PGRN levels except lean body mass (LBM) were significantly reduced in the training group (p < 0.05). Additionally, except for LBM, subjects in the training group had significantly decreased BW, BF%, BMI, WHR, HOMA-IR and plasma PGRN levels compared to changes in those in the control group (p < 0.05). Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05). Conclusions The findings showed that 8 weeks of CRT improved body composition and IR which were accompanied by reduced plasma PGRN levels. This study suggests that CRT has the potential for obese individuals to counteract obesity-associated health impairments.",2020,"Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05).","['obese men', 'obese individuals', 'Materials and methods Twenty-eight healthy obese men [age: 36 ± 7.7 years, body weight (BW): 96.4 ± 15.6 kg, body mass index (BMI): 32.4 ± 4.5 kg/m2] completed the study']","[' Progranulin (PGRN', 'circuit resistance training (CRT', 'circuit resistance training', 'CRT']","['plasma PGRN levels', 'plasma PGRN and the changes in insulin, HOMA-IR and BMI', 'Results BW, BF%, BMI, waist-hip ratio (WHR), HOMA-IR and plasma PGRN levels except lean body mass (LBM', 'body composition and IR', 'Blood samples and anthropometric characteristics', 'plasma PGRN, IR and body composition', 'homeostatic model assessment of insulin resistance (HOMA-IR', 'BW, BF%, BMI, WHR, HOMA-IR and plasma PGRN levels', 'plasma progranulin level, insulin resistance and body composition']","[{'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0520510', 'cui_str': 'Material (attribute)'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C4283787', 'cui_str': '28'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517860', 'cui_str': '7.7 (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C4517709', 'cui_str': '32.4 (qualifier value)'}, {'cui': 'C3844009', 'cui_str': 'Four point five'}, {'cui': 'C0456689', 'cui_str': 'kg/sq. m'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0168913', 'cui_str': 'Granulin Precursor Protein'}, {'cui': 'C0872279', 'cui_str': 'Strength Training'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0025320', 'cui_str': 'Change of Life, Female'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C1274040', 'cui_str': 'Result'}, {'cui': 'C0205682', 'cui_str': 'Waist-Hip Ratio'}, {'cui': 'C0424678', 'cui_str': 'Lean body mass (observable entity)'}, {'cui': 'C0005885', 'cui_str': 'Body Composition'}, {'cui': 'C0178913', 'cui_str': 'Blood specimen'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C0168913', 'cui_str': 'Granulin Precursor Protein'}]",28.0,0.0121934,"Significant correlations were found between the changes in plasma PGRN and the changes in insulin, HOMA-IR and BMI (p < 0.05).","[{'ForeName': 'Alireza', 'Initials': 'A', 'LastName': 'Safarzade', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Mazandaran, Babolsar, Iran.'}, {'ForeName': 'Hamid', 'Initials': 'H', 'LastName': 'Alizadeh', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, University of Mazandaran, Babolsar, Iran.'}, {'ForeName': 'Zainab', 'Initials': 'Z', 'LastName': 'Bastani', 'Affiliation': 'Department of Exercise Physiology, Faculty of Sport Sciences, Islamic Azad University of Sari Branch, Sari, Iran.'}]",Hormone molecular biology and clinical investigation,['10.1515/hmbci-2019-0050'] 3205,32007714,"Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).","BACKGROUND Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II trial (74% complete response or partial response marker negative, 90% confidence interval (CI) 61%-85%). AIM To assess long-term outcomes and late toxicity associated with CBOP/BEP. METHODS Patients with poor prognosis extracranial GCT were randomised to 4xBEP or CBOP/BEP (2xCBOP, 2xBO, 3xBEP with 15,000iu of bleomycin). Low-dose, stabilising chemotherapy before entry was permitted. Response rates (primary outcome) were reported previously. Here, we report secondary outcomes: progression-free survival (PFS), overall survival (OS) and late toxicity. Prognostic factors and the impact of marker decline are assessed in exploratory analysis. RESULTS Eighty-nine patients (43 CBOP/BEP) were randomised. After median 63 months follow-up, 3-year PFS is 55.7% (95% CI: 39.7%, 69.0%) for CBOP/BEP and 38.7% (95% CI: 24.7%, 52.4%) for BEP (hazard ratio [HR]: 0.59 (0.33, 1.06), p = 0.079). Three-year OS is 65.0% (48.8%, 77.2%) and 58.5% (43.0%, 71.2%), respectively (HR: 0.79 (0.41, 1.52), p = 0.49). Twelve-month toxicity was affected by subsequent treatments, with no clear differences between arms. Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. CONCLUSION Although not powered for PFS, results for CBOP/BEP are promising. Impact on OS was less clear (and will be affected by subsequent therapy). Further study in an international phase III trial is warranted. TRIAL REGISTRATION ISRCTN 53643604.",2020,"Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. ","['poor prognosis germ cell tumours', 'men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with', 'Patients with poor prognosis extracranial GCT', 'Eighty-nine patients (43 CBOP/BEP']","['Stabilising chemotherapy', 'intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin', 'CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP', 'standard BEP (bleomycin, etoposide and cisplatin) chemotherapy', 'CBOP/BEP', '4xBEP or CBOP/BEP (2xCBOP, 2xBO, 3xBEP with 15,000iu of bleomycin']","['progression-free survival (PFS), overall survival (OS) and late toxicity', 'Response rates', 'toxicity', '3-year PFS']","[{'cui': 'C0278252', 'cui_str': 'Prognosis bad (finding)'}, {'cui': 'C0205851', 'cui_str': 'Neoplasms, Germ Cell'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0036631', 'cui_str': 'Seminoma'}, {'cui': 'C1546956', 'cui_str': 'Dead (finding)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0580586', 'cui_str': 'Extracranial (qualifier value)'}, {'cui': 'C3816958', 'cui_str': 'Eighty'}]","[{'cui': 'C0013217', 'cui_str': 'pharmacotherapy'}, {'cui': 'C3179010', 'cui_str': 'Induction Chemotherapy'}, {'cui': 'C0079083', 'cui_str': 'Carboplatin'}, {'cui': 'C0005740', 'cui_str': 'Bleomycin'}, {'cui': 'C0042679', 'cui_str': 'Vincristine'}, {'cui': 'C0008838', 'cui_str': 'Cisplatin'}, {'cui': 'C0015133', 'cui_str': 'Etoposide'}, {'cui': 'C0038137', 'cui_str': 'standards'}]","[{'cui': 'C0242792', 'cui_str': 'Progression-Free Survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0205087', 'cui_str': 'Late (qualifier value)'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]",,0.300647,"Stabilising chemotherapy was associated with poorer PFS (HR: 2.09 (1.14, 3.81), p = 0.017), whereas unfavourable marker decline, in 60 (70%) patients, was not. ","[{'ForeName': 'Fay H', 'Initials': 'FH', 'LastName': 'Cafferty', 'Affiliation': 'MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK. Electronic address: f.cafferty@ucl.ac.uk.'}, {'ForeName': 'Jeff D', 'Initials': 'JD', 'LastName': 'White', 'Affiliation': 'Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Shamash', 'Affiliation': ""St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK.""}, {'ForeName': 'Ivo', 'Initials': 'I', 'LastName': 'Hennig', 'Affiliation': 'Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, NG5 1PB, UK.'}, {'ForeName': 'Sally P', 'Initials': 'SP', 'LastName': 'Stenning', 'Affiliation': 'MRC Clinical Trials Unit at UCL, 90 High Holborn, London, WC1V 6LJ, UK.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Huddart', 'Affiliation': 'The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.12.028'] 3206,31668721,"A randomized, controlled, double-blind crossover study on the effects of isoeffective and isovolumetric intravenous crystalloid and gelatin on blood volume, and renal and cardiac hemodynamics.","BACKGROUND & AIMS Blood volume expanding properties of colloids are superior to crystalloids. In addition to oncotic/osmotic properties, the electrolyte composition of infusions may have important effects on visceral perfusion, with infusions containing supraphysiological chloride causing hyperchloremic acidosis and decreased renal blood flow. In this non-inferiority study, a validated healthy human subject model was used to compare effects of colloid (4% succinylated gelatin) and crystalloid fluid regimens on blood volume, renal function, and cardiac output. METHODS Healthy male participants were given infusions over 60 min > 7 days apart in a randomized, crossover manner. Reference arm (A): 1.5 L of Sterofundin ISO, isoeffective arm (B): 0.5 L of 4% Gelaspan®, isovolumetric arm (C): 0.5 L of 4% Gelaspan® and 1 L of Sterofundin ISO (all B. Braun, Melsungen, Germany). Participants were studied over 240 min. Changes in blood volume were calculated from changes in weight and hematocrit. Renal volume, renal artery blood flow (RABF), renal cortex perfusion and diffusion, and cardiac index were measured with magnetic resonance imaging. RESULTS Ten of 12 males [mean (SE) age 23.9 (0.8) years] recruited, completed the study. Increase in body weight and extracellular fluid volume were significantly less after infusion B than infusions A and C, but changes in blood volume did not significantly differ between infusions. All infusions increased renal volume, with no significant differences between infusions. There was no significant difference in RABF across the infusion time course or between infusion types. Renal cortex perfusion decreased during the infusion (mean 18% decrease from baseline), with no significant difference between infusions. There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion. All infusions led to significant increases in cardiac index. CONCLUSIONS A smaller volume of colloid (4% succinylated gelatin) was as effective as a larger volume of crystalloid at expanding blood volume, increasing cardiac output and changing renal function. Significantly less interstitial space expansion occurred with the colloid. TRIAL REGISTRATION The protocol was registered with the European Union Drug Regulating Authorities Clinical Trials Database (https://eudract.ema.europa.eu) (EudraCT No. 2013-003260-32).",2020,There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion.,"['Ten of 12 males [mean (SE) age 23.9 (0.8) years] recruited, completed the study', 'Healthy male participants']","['infusions over 60\xa0min', 'isoeffective and isovolumetric intravenous crystalloid and gelatin', 'Sterofundin ISO, isoeffective arm (B): 0.5\xa0L of 4% Gelaspan®, isovolumetric arm (C): 0.5\xa0L of 4% Gelaspan® and 1\xa0L of Sterofundin ISO', 'colloid (4% succinylated gelatin) and crystalloid fluid regimens']","['renal volume', 'renal cortex diffusion', 'RABF', 'blood volume, renal function, and cardiac output', 'Renal volume, renal artery blood flow (RABF), renal cortex perfusion and diffusion, and cardiac index', 'cardiac index', 'Renal cortex perfusion', 'renal blood flow', 'body weight and extracellular fluid volume', 'interstitial space expansion', 'blood volume', 'blood volume, and renal and cardiac hemodynamics', 'cardiac output and changing renal function']","[{'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C4517481', 'cui_str': '0.8'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}]","[{'cui': 'C0574032', 'cui_str': 'Infusion - action (qualifier value)'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0056562', 'cui_str': 'Crystalloid'}, {'cui': 'C0017237', 'cui_str': 'Gelatin'}, {'cui': 'C0630627', 'cui_str': 'sterofundin'}, {'cui': 'C0911936', 'cui_str': 'iso(VL)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0009361', 'cui_str': 'Colloids'}, {'cui': 'C0143961', 'cui_str': 'succinylated gelatin'}, {'cui': 'C0444611', 'cui_str': 'Fluid - descriptor'}]","[{'cui': 'C0449468', 'cui_str': 'Volume (property) (qualifier value)'}, {'cui': 'C0022655', 'cui_str': 'Kidney Cortex'}, {'cui': 'C0012222', 'cui_str': 'Diffusion'}, {'cui': 'C0005850', 'cui_str': 'Blood Volume'}, {'cui': 'C0232804', 'cui_str': 'Renal function (observable entity)'}, {'cui': 'C0007165', 'cui_str': 'Cardiac Output'}, {'cui': 'C0035065', 'cui_str': 'Renal Artery'}, {'cui': 'C0232338', 'cui_str': 'Vascular flow, function (observable entity)'}, {'cui': 'C0031001', 'cui_str': 'Perfusion'}, {'cui': 'C0428776', 'cui_str': 'Cardiac index (observable entity)'}, {'cui': 'C1527409', 'cui_str': 'Renal blood flow, function (observable entity)'}, {'cui': 'C0005910', 'cui_str': 'Body Weight'}, {'cui': 'C0015349', 'cui_str': 'Extracellular Fluid'}, {'cui': 'C0225319', 'cui_str': 'Interstitial space (body structure)'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}]",,0.0853947,There was a trend for increased renal cortex diffusion (4.2% increase from baseline) for the crystalloid infusion.,"[{'ForeName': 'Christopher R', 'Initials': 'CR', 'LastName': 'Bradley', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Damian D', 'Initials': 'DD', 'LastName': 'Bragg', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Eleanor F', 'Initials': 'EF', 'LastName': 'Cox', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Ahmed M', 'Initials': 'AM', 'LastName': 'El-Sharkawy', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Charlotte E', 'Initials': 'CE', 'LastName': 'Buchanan', 'Affiliation': 'Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.'}, {'ForeName': 'Abeed H', 'Initials': 'AH', 'LastName': 'Chowdhury', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Ian A', 'Initials': 'IA', 'LastName': 'Macdonald', 'Affiliation': ""School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.""}, {'ForeName': 'Susan T', 'Initials': 'ST', 'LastName': 'Francis', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; Sir Peter Mansfield Imaging Centre, University Park, University of Nottingham, NG7 2RD, UK.""}, {'ForeName': 'Dileep N', 'Initials': 'DN', 'LastName': 'Lobo', 'Affiliation': ""Gastrointestinal Surgery, Nottingham Digestive Diseases Centre and National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK; MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK. Electronic address: dileep.lobo@nottingham.ac.uk.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.09.011'] 3207,31119765,Closer: A videoconference intervention for distance caregivers of cancer patients.,"Distance caregivers (DCGs) represent a growing demographic. The emotional burden of caregiving for a family member with cancer is amplified by the logistical challenges of providing support from afar. DCGs feel higher levels of distress, anxiety, and depression compared with local caregivers. Videoconference technology may alleviate both the emotional and practical burdens faced by DCGs. This is an ongoing randomized controlled trial in 32 outpatient ambulatory clinics at a large, urban, comprehensive cancer center. To date, 332 patient-DCG dyads have been enrolled. DCGs must have internet access and have been identified by the patient as a source of support. The intervention period is 4 months. DCGs are randomized to one of three arms: DCGs in Arm 1 receive four coaching sessions with an advanced practice nurse or social worker and four videoconference appointments during the oncologist-patient office visit. DCGs in Arm 2 participate in four videoconference appointments with the oncologist and patient, and Arm 3 is the control group, which receives access to information through a website. Primary outcome variables are DCG distress, anxiety, depression, burden, self-efficacy, and emotional support. These data are collected electronically at baseline, 4 months, and 6 months. Patient distress, anxiety, and depression are also assessed at these same intervals using brief in-person interviews. The change in each of the DCG outcomes over time will be examined by a repeated measures analysis of covariance.",2019,"DCGs feel higher levels of distress, anxiety, and depression compared with local caregivers.","['32 outpatient ambulatory clinics at a large, urban, comprehensive cancer center', '332 patient-DCG dyads have been enrolled', 'distance caregivers of cancer patients']","['videoconference intervention', 'Videoconference technology', 'coaching sessions with an advanced practice nurse or social worker and four videoconference appointments']","['DCG distress, anxiety, depression, burden, self-efficacy, and emotional support', 'distress, anxiety, and depression', 'Patient distress, anxiety, and depression']","[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0439841', 'cui_str': 'Ambulatory'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C1704243', 'cui_str': 'Greater (qualifier value)'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012751', 'cui_str': 'Distance (qualifier value)'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}]","[{'cui': 'C1450049', 'cui_str': 'Videoconference'}, {'cui': 'C0039421', 'cui_str': 'Technology'}, {'cui': 'C0557773', 'cui_str': 'Coach (physical object)'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0401999', 'cui_str': 'Practice nurse (occupation)'}, {'cui': 'C0037444', 'cui_str': 'Social worker (occupation)'}, {'cui': 'C0003629', 'cui_str': 'Appointments'}]","[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C0600015', 'cui_str': 'Emotional support (regime/therapy)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]",32.0,0.0606319,"DCGs feel higher levels of distress, anxiety, and depression compared with local caregivers.","[{'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Blackstone', 'Affiliation': 'Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Amy R', 'Initials': 'AR', 'LastName': 'Lipson', 'Affiliation': 'Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.'}, {'ForeName': 'Sara L', 'Initials': 'SL', 'LastName': 'Douglas', 'Affiliation': 'Case Comprehensive Cancer Center, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.'}]",Research in nursing & health,['10.1002/nur.21952'] 3208,30959123,Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.,"PURPOSE To validate whether prostate-specific antigen (PSA) level after neoadjuvant androgen suppression (neoAS) is associated with long-term outcome after neoAS and external beam radiation therapy (RT) with concurrent short-term androgen suppression (AS) in patients with prostate cancer. METHODS AND MATERIALS This study included 2404 patients. The patients were treated with neoAS before RT and concurrent AS (without post-RT AS) and were pooled from NRG Oncology/RTOG trials 9202, 9408, 9413, and 9910. Multivariable models were used to test associations between the prespecified dichotomized post-neoAS, pre-RT PSA level (≤0.1 vs >0.1 ng/mL) groupings, and clinical outcomes. RESULTS The median follow-up for surviving patients was 9.4 years. The median post-neoAS, pre-RT PSA level was 0.3 ng/mL, with 32% of patients having levels ≤0.1 ng/mL. Race, Gleason score, tumor stage, node stage, pretreatment PSA level, and duration of neoAS were associated with the groups of patients with PSA levels ≤0.1 and >0.1 ng/mL. In univariate analyses, post-neoAS, pre-RT PSA level >0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005). In multivariable models that also included baseline and treatment variables, post-neoAS, pre-RT PSA level >0.1 ng/mL was independently associated with increased risk of biochemical failure (HR, 2.00; P < .0001); local failure (HR, 2.33; P < .0001); and cause-specific mortality (HR, 1.75; P = .03). CONCLUSIONS Patients with a PSA level >0.1 ng/mL after neoAS and before the start of RT had less favorable clinical outcomes than patients whose PSA level was ≤0.1 ng/mL. The role of post-neoAS, pre-RT PSA level relative to PSA levels obtained along the continuum of medical care is not presently defined but could be tested in future clinical trials.",2019,">0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005).","['2404 patients', 'Patients with a PSA level', 'patients with prostate cancer', 'Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy']","['neoadjuvant androgen suppression (neoAS', 'neoAS and external beam radiation therapy (RT) with concurrent short-term androgen suppression (AS']","['median post-neoAS, pre-RT PSA level', 'local failure', 'RT PSA level', 'risk of biochemical failure', 'cause-specific mortality', 'risks of biochemical failure', 'Prostate-Specific Antigen']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0376358', 'cui_str': 'Prostate Cancer'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}, {'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}]","[{'cui': 'C0002844', 'cui_str': 'Androgenic Compounds'}, {'cui': 'C0221103', 'cui_str': 'Binocular vision suppression (disorder)'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0034619', 'cui_str': 'radiation therapy'}, {'cui': 'C0205420', 'cui_str': 'Concurrent (qualifier value)'}, {'cui': 'C1806781', 'cui_str': 'Short (qualifier value)'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0201544', 'cui_str': 'Prostate specific antigen measurement (procedure)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0231174', 'cui_str': 'Failure (finding)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0205474', 'cui_str': 'Biochemical (qualifier value)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0138741', 'cui_str': 'gamma-Seminoprotein'}]",2404.0,0.130269,">0.1 ng/mL was associated with increased risks of biochemical failure (hazard ratio [HR], 2.04; P < .0001); local failure (HR, 2.51; P < .0001); distant metastases (HR, 1.73; P = .0006); cause-specific mortality (HR, 2.36; P < .0001); and all-cause mortality (HR, 1.24; P = .005).","[{'ForeName': 'Christopher L', 'Initials': 'CL', 'LastName': 'Hallemeier', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota. Electronic address: hallemeier.christopher@mayo.edu.'}, {'ForeName': 'Peixin', 'Initials': 'P', 'LastName': 'Zhang', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Thomas M', 'Initials': 'TM', 'LastName': 'Pisansky', 'Affiliation': 'Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Gerald E', 'Initials': 'GE', 'LastName': 'Hanks', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'David G', 'Initials': 'DG', 'LastName': 'McGowan', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Mack', 'Initials': 'M', 'LastName': 'Roach', 'Affiliation': 'University of California, San Francisco, San Francisco, California.'}, {'ForeName': 'Kenneth L', 'Initials': 'KL', 'LastName': 'Zeitzer', 'Affiliation': 'Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.'}, {'ForeName': 'Selim Y', 'Initials': 'SY', 'LastName': 'Firat', 'Affiliation': 'Medical College of Wisconsin-Zablocki VA Medical Center, Milwaukee, Wisconsin.'}, {'ForeName': 'Siraj M', 'Initials': 'SM', 'LastName': 'Husain', 'Affiliation': 'Tom Baker Cancer Centre, Calgary, Alberta, Canada.'}, {'ForeName': 'David P', 'Initials': 'DP', 'LastName': ""D'Souza"", 'Affiliation': 'London Regional Cancer Program, London, Ontario, Canada.'}, {'ForeName': 'Luis', 'Initials': 'L', 'LastName': 'Souhami', 'Affiliation': 'McGill University Health Centre, Montreal, Quebec, Canada.'}, {'ForeName': 'Matthew B', 'Initials': 'MB', 'LastName': 'Parliament', 'Affiliation': 'Cross Cancer Institute, Edmonton, Alberta, Canada.'}, {'ForeName': 'Seth A', 'Initials': 'SA', 'LastName': 'Rosenthal', 'Affiliation': 'Radiological Associates of Sacramento, Sacramento, California.'}, {'ForeName': 'Himanshu R', 'Initials': 'HR', 'LastName': 'Lukka', 'Affiliation': 'McMaster University, Juravinski Cancer Center, Hamilton Health Sciences, Hamilton, Ontario, Canada.'}, {'ForeName': 'Marvin', 'Initials': 'M', 'LastName': 'Rotman', 'Affiliation': 'Brooklyn MB-CCOP/SUNY Downstate, Brooklyn, New York.'}, {'ForeName': 'Eric M', 'Initials': 'EM', 'LastName': 'Horwitz', 'Affiliation': 'Fox Chase Cancer Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Edward F', 'Initials': 'EF', 'LastName': 'Miles', 'Affiliation': 'Naval Medical Center Accruals Dartmouth Hitchcock Medical Center, Portsmouth, Virginia.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Paulus', 'Affiliation': 'NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania.'}, {'ForeName': 'Howard M', 'Initials': 'HM', 'LastName': 'Sandler', 'Affiliation': 'Cedars-Sinai Medical Center, Los Angeles, California.'}]","International journal of radiation oncology, biology, physics",['10.1016/j.ijrobp.2019.03.049'] 3209,30817709,Physical Activity and Cerebral Small Vein Integrity in Older Adults.,"Identifying promoters of cerebral small vein integrity is important to counter vascular contributions to cognitive impairment and dementia. PURPOSE In this preliminary investigation, the effects of a randomized 24-month physical activity (PA) intervention on changes in cerebral small vein integrity were compared to those of a health education (HE) control. METHODS Cerebral small vein integrity was measured in 24 older adults (n = 8, PA; n = 16, HE) using ultra-high field MRI before and at the end of the 24-month intervention. Deep medullary veins were defined as straight or tortuous; percent change in straight length, tortuous length, and tortuosity ratio were computed. Microbleed count and white matter hyperintensities were also rated. RESULTS Accelerometry-based values of PA increased by 17.2% in the PA group but declined by 28.0% in the HE group. The PA group, but not the HE group, had a significant increase in straight vein length from baseline to 24-month follow-up (P = 0.02 and P = 0.21, respectively); the between-group difference in percent change in straight length was significant (increase: median, 93.6%; interquartile range, 112.9 for PA; median, 28.4%; interquartile range, 90.6 for HE; P = 0.07). Between group differences in other markers were nonsignificant. CONCLUSIONS Increasing PA in late-life may promote cerebral small vein integrity. This should be confirmed in larger studies.",2019,"the between group difference in percent change in straight length was significant (median (IQR) increase: 93.6%(112.9) for PA, 28.4%(90.6) for HE; p=.07).","['24 older adults (n=8, PA; n=16, HE) using ultra-high field MRI before and at the end of the 24-month intervention', 'Older Adults']",['physical activity (PA) intervention'],"['straight vein length', 'straight length, tortuous length, and tortuosity ratio', 'Accelerometry-based values of PA', 'straight length', 'cerebral small vein integrity', 'Physical Activity and Cerebral Small Vein Integrity', 'Microbleed count and white matter hyperintensities']","[{'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0440042', 'cui_str': ""Field's""}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}]","[{'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0042449', 'cui_str': 'Veins'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0333076', 'cui_str': 'Tortuosity (morphologic abnormality)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0441677', 'cui_str': 'Accelerometry'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1273875', 'cui_str': 'Values (community)'}, {'cui': 'C0547044', 'cui_str': 'Lesser (qualifier value)'}, {'cui': 'C1947912', 'cui_str': 'Integrity (attribute)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C2938912'}]",24.0,0.0421069,"the between group difference in percent change in straight length was significant (median (IQR) increase: 93.6%(112.9) for PA, 28.4%(90.6) for HE; p=.07).","[{'ForeName': 'C Elizabeth', 'Initials': 'CE', 'LastName': 'Shaaban', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Howard Jay', 'Initials': 'HJ', 'LastName': 'Aizenstein', 'Affiliation': 'Center for the Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Dana R', 'Initials': 'DR', 'LastName': 'Jorgensen', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Rebecca L M', 'Initials': 'RLM', 'LastName': 'Mahbubani', 'Affiliation': 'Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Nicole A', 'Initials': 'NA', 'LastName': 'Meckes', 'Affiliation': 'Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Kirk I', 'Initials': 'KI', 'LastName': 'Erickson', 'Affiliation': 'Center for the Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Nancy W', 'Initials': 'NW', 'LastName': 'Glynn', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Mettenburg', 'Affiliation': 'Department of Radiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Jack', 'Initials': 'J', 'LastName': 'Guralnik', 'Affiliation': 'Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD.'}, {'ForeName': 'Anne B', 'Initials': 'AB', 'LastName': 'Newman', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Tamer S', 'Initials': 'TS', 'LastName': 'Ibrahim', 'Affiliation': 'Department of Radiology, University of Pittsburgh, Pittsburgh, PA.'}, {'ForeName': 'Paul J', 'Initials': 'PJ', 'LastName': 'Laurienti', 'Affiliation': 'Laboratory for Complex Brain Networks, Wake Forest University School of Medicine, Winston-Salem, NC.'}, {'ForeName': 'Abbe N', 'Initials': 'AN', 'LastName': 'Vallejo', 'Affiliation': ""Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA.""}, {'ForeName': 'Caterina', 'Initials': 'C', 'LastName': 'Rosano', 'Affiliation': 'Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA.'}]",Medicine and science in sports and exercise,['10.1249/MSS.0000000000001952'] 3210,30923022,Proactive text messaging (GetReady2Quit) and nicotine replacement therapy to promote smoking cessation among smokers in primary care: A pilot randomized trial protocol.,"INTRODUCTION Most smokers see a physician each year, but few use any assistance when they try to quit. Text messaging programs improve smoking cessation in community and school settings; however, their efficacy in a primary care setting is unclear. The current trial assesses the feasibility and preliminary clinical outcomes of text messaging and mailed nicotine replacement therapy (NRT) among smokers in primary care. METHODS In this single-center pilot randomized trial, eligible smokers in primary care are offered brief advice by phone and randomly assigned to one of four interventions: (1) Brief advice only, (2) text messages targeted to primary care patients and tailored to quit readiness, (3) a 2-week supply of nicotine patches and/or lozenges (NRT), and (4) both text messaging and NRT. Randomization is stratified by practice and intention to quit. The text messages (up to 5/day) encourage those not ready to quit to practice a quit attempt, assist those with a quit date through a quit attempt, and promote NRT use. The 2-week supply of NRT is mailed to patients' homes. RESULTS Feasibility outcomes include recruitment rates, study retention, and treatment adherence. Clinical outcomes are assessed at 1, 2, 6, and 12-weeks post-enrollment. The primary outcome is ≥1self-reported quit attempt(s). Secondary clinical outcomes include self-reported past 7- and 30-day abstinence, days not smoked, NRT adherence, and exhaled carbon monoxide. CONCLUSIONS This pilot assesses text messaging plus NRT, as a proactively offered intervention for smoking cessation support in smokers receiving primary care and will inform full-scale randomized trial planning. TRIAL REGISTRATION ClinicalTrials.govNCT03174158.",2019,"This pilot assesses text messaging plus NRT, as a proactively offered intervention for smoking cessation support in smokers receiving primary care and will inform full-scale randomized trial planning. ","[""patients' homes"", 'smokers in primary care', 'smokers receiving primary care']","['Text messaging programs', 'Proactive text messaging (GetReady2Quit) and nicotine replacement therapy', 'Brief advice only, (2) text messages targeted to primary care patients and tailored to quit readiness, (3) a 2-week supply of nicotine patches and/or lozenges (NRT), and (4) both text messaging and NRT', 'text messaging and mailed nicotine replacement therapy (NRT', 'NRT']","['self-reported past 7- and 30-day abstinence, days not smoked, NRT adherence, and exhaled carbon monoxide', 'recruitment rates, study retention, and treatment adherence', '≥1self-reported quit attempt(s']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}]","[{'cui': 'C3178908', 'cui_str': 'Texting'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C1278444', 'cui_str': 'Nicotine replacement therapy'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C3178910', 'cui_str': 'Text Messages'}, {'cui': 'C0033137', 'cui_str': 'Primary Care'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1318963', 'cui_str': 'Readiness'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C1875802', 'cui_str': 'Healthcare supplies'}, {'cui': 'C0358855', 'cui_str': 'Nicotine Transdermal Patch'}, {'cui': 'C4319836', 'cui_str': 'Lozenge'}, {'cui': 'C0024492', 'cui_str': 'Mail'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0231800', 'cui_str': 'Exhalation'}, {'cui': 'C0007018', 'cui_str': 'Carbon Monoxide'}, {'cui': 'C0271510', 'cui_str': 'Recruitment (disorder)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C4505265', 'cui_str': 'Treatment Adherence'}, {'cui': 'C0684224', 'cui_str': 'Report'}]",,0.100054,"This pilot assesses text messaging plus NRT, as a proactively offered intervention for smoking cessation support in smokers receiving primary care and will inform full-scale randomized trial planning. ","[{'ForeName': 'G R', 'Initials': 'GR', 'LastName': 'Kruse', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: gkruse@mgh.harvard.edu.'}, {'ForeName': 'E', 'Initials': 'E', 'LastName': 'Park', 'Affiliation': 'Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'J E', 'Initials': 'JE', 'LastName': 'Haberer', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'L', 'Initials': 'L', 'LastName': 'Abroms', 'Affiliation': 'Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, Washington, DC, USA.'}, {'ForeName': 'N N', 'Initials': 'NN', 'LastName': 'Shahid', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'S E', 'Initials': 'SE', 'LastName': 'Howard', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Chang', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.'}, {'ForeName': 'J S', 'Initials': 'JS', 'LastName': 'Haas', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.'}, {'ForeName': 'N A', 'Initials': 'NA', 'LastName': 'Rigotti', 'Affiliation': 'Division of General Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA; Tobacco Research and Treatment Center, Massachusetts General Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.006'] 3211,30904596,Specialized tobacco quitline and basic needs navigation interventions to increase cessation among low income smokers: Study protocol for a randomized controlled trial.,"Smoking in the United States follows a clear socioeconomic gradient: low-income Americans smoke more and quit less than those with more education and income. Evidence-based interventions like tobacco quitlines are designed to make effective cessation services available on a population basis to all smokers. However, these interventions do not address many of the unique challenges faced by low-income smokers, including unmet basic needs like food, housing, personal safety and money for necessities that often supersede health needs. Research is needed to maximize the use and effectiveness of tobacco quitlines in low-income populations. This paper details the rationale, design and methods for a 2 × 2 randomized controlled trial currently underway comparing the effects of Standard and Specialized Tobacco Quitlines with and without Basic Needs Navigation on intervention engagement and smoking cessation among low-income smokers. Smokers are recruited from United Way 2-1-1 in Missouri and all participants receive tobacco quitline services from Optum. Quitline and navigation services are provided for 3 months. Participants complete telephone surveys at baseline, 3- and 6-month follow up. The primary study outcome is self-reported 7-day point prevalence abstinence at 6-month follow up. Embedding the study in practice agencies will accelerate dissemination and scalability should our findings demonstrate intervention effectiveness.",2019,Evidence-based interventions like tobacco quitlines are designed to make effective cessation services available on a population basis to all smokers.,"['low income smokers', 'low-income smokers']","['Standard and Specialized Tobacco Quitlines with and without Basic Needs Navigation', 'Specialized tobacco quitline and basic needs navigation interventions', 'tobacco quitlines', 'tobacco quitline services from Optum']",['self-reported 7-day point prevalence abstinence'],"[{'cui': 'C0302604', 'cui_str': 'Low income'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}]","[{'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0557854', 'cui_str': 'Services (qualifier value)'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}]",,0.0609326,Evidence-based interventions like tobacco quitlines are designed to make effective cessation services available on a population basis to all smokers.,"[{'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'McQueen', 'Affiliation': 'Washington University, School of Medicine, Department of Medicine, United States of America; Washington University, Brown School, Health Communication Research Laboratory, United States of America. Electronic address: amcqueen@wustl.edu.'}, {'ForeName': 'Christina', 'Initials': 'C', 'LastName': 'Roberts', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Garg', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}, {'ForeName': 'Charlene', 'Initials': 'C', 'LastName': 'Caburnay', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}, {'ForeName': 'Qiang', 'Initials': 'Q', 'LastName': 'Fu', 'Affiliation': 'Saint Louis University College for Public Health and Social Justice, Department of Epidemiology and Biostatistics, United States of America.'}, {'ForeName': 'Jacob', 'Initials': 'J', 'LastName': 'Gordon', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}, {'ForeName': 'Terry', 'Initials': 'T', 'LastName': 'Bush', 'Affiliation': 'Optum Center for Wellbeing Research, United States of America.'}, {'ForeName': 'Robin', 'Initials': 'R', 'LastName': 'Pokojski', 'Affiliation': 'United Way of Greater St. Louis, United States of America.'}, {'ForeName': 'Tess', 'Initials': 'T', 'LastName': 'Thompson', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Kreuter', 'Affiliation': 'Washington University, Brown School, Health Communication Research Laboratory, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.009'] 3212,32199078,Correction to Lancet Infect Dis 2020; published online March 12. https://doi.org/10.1016/S1473-3099(20)30174-2.,,2020,,[],['https://doi.org/10.1016/S1473-3099(20)30174-2'],[],[],[],[],,0.0188256,,[],The Lancet. Infectious diseases,['10.1016/S1473-3099(20)30224-3'] 3213,31899723,Electromyographic Comparison of the Efficacy of Ultrasound-guided Suprainguinal and Infrainguinal Fascia Iliaca Compartment Block for Blockade of the Obturator Nerve in Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.,"BACKGROUND AND OBJECTIVES The knee is innervated by the femoral, obturator, and sciatic nerves. An infrainguinal fascia iliaca compartment block (FICB) is often used as a technique for pain management after hip and knee arthroplasty. This approach blocks the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. Previous studies show suprainguinal FICB achieves improved postoperative analgesia compared with infrainguinal FICB after hip fracture. However, the analgesic effects of suprainguinal or infrainguinal FICB on the obturator nerve after total knee arthroplasty (TKA) remain to be established. This study compared the efficacy of suprainguinal versus infrainguinal FICB for the blockade of the obturator nerve using electromyography and quantification of total opioid consumption during the 24 hours after TKA. METHODS This prospective, randomized controlled clinical study enrolled 74 patients scheduled to undergo TKA. Patients were randomized 1:1 to receive suprainguinal FICB (group S) or infrainguinal FICB (group I) with 30 mL of 0.375% ropivacaine. The primary endpoint was the mean amplitude of the adductor longus compound muscle action potential (CMAP) at 0 (before the block), 10, 20, and 30 minutes after FICB. The secondary endpoint was total opioid consumption during the 24 hours after TKA. RESULTS Data from 62 patients were included in the analysis. The mean amplitude of the adductor longus CMAP was significantly lower in group S compared with group I (repeated-measures analysis of variance; F=4.73, P=0.034). At 24 hours after TKA, mean (SD) total opioid consumption was significantly lower in group S, compared with group I (131.5±76.8 vs. 201.5±85.1 μg) (P=0.001). CONCLUSIONS Suprainguinal FICB significantly increased the incidence of successful obturator nerve block and significantly decreased fentanyl consumption 24 hours after TKA compared with infrainguinal FICB.",2020,"Mean amplitude of the adductor longus CMAP was significantly lower in Group S compared to Group I (repeated-measures analysis of variance; F=4.73, P=0.034).","['pain management after hip and knee arthroplasty', '74 patients scheduled to undergo TKA', 'Total Knee Arthroplasty', '62 patients were included in the analysis']","['infrainguinal FICB (Group I) with 30▒mL of 0.375% ropivacaine', 'suprainguinal FICB', 'Ultrasound-guided Suprainguinal and Infrainguinal Fascia Iliaca Compartment Block', 'infrainguinal fascia iliaca compartment block (FICB']","['total opioid consumption', 'mean amplitude of the adductor longus compound muscle action potential (CMAP', 'incidence of successful obturator nerve block', 'Mean amplitude of the adductor longus CMAP', 'mean (SD) total opioid consumption', 'postoperative analgesia']","[{'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0019552', 'cui_str': 'Coxa'}, {'cui': 'C0086511', 'cui_str': 'Knee Arthroplasty'}, {'cui': 'C0030703', 'cui_str': 'Schedules, Patient'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C1524024', 'cui_str': 'analysis'}]","[{'cui': 'C0441843', 'cui_str': 'Group I (qualifier value)'}, {'cui': 'C4517455', 'cui_str': '0.375 (qualifier value)'}, {'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0015641', 'cui_str': 'Fascia'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}]","[{'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0009830', 'cui_str': 'Consumption'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0522028', 'cui_str': 'Muscle action potential, function (observable entity)'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C1272703', 'cui_str': 'Successful'}, {'cui': 'C0394741', 'cui_str': 'Local anesthetic obturator nerve block (procedure)'}, {'cui': 'C0853389', 'cui_str': 'Postoperative analgesia'}]",74.0,0.108967,"Mean amplitude of the adductor longus CMAP was significantly lower in Group S compared to Group I (repeated-measures analysis of variance; F=4.73, P=0.034).","[{'ForeName': 'Yuying', 'Initials': 'Y', 'LastName': 'Qian', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Zhiyuan', 'Initials': 'Z', 'LastName': 'Guo', 'Affiliation': 'Wannan Medical College, Wuhu City, Anhui, China.'}, {'ForeName': 'Juanjuan', 'Initials': 'J', 'LastName': 'Huang', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Qunying', 'Initials': 'Q', 'LastName': 'Zhang', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Xiaofeng', 'Initials': 'X', 'LastName': 'An', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Huansheng', 'Initials': 'H', 'LastName': 'Hu', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Fengqin', 'Initials': 'F', 'LastName': 'Zhu', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}, {'ForeName': 'Xianghe', 'Initials': 'X', 'LastName': 'Wang', 'Affiliation': 'The 98th Clinical College of PLA, Anhui Medical University, Huzhou City, Zhejiang.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000795'] 3214,30281066,"A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.","BACKGROUND Group B Streptococcus (GBS) frequently colonizes pregnant women and can cause sepsis and meningitis in young infants. If colonization was prevented through maternal immunization, a reduction in perinatal GBS disease might be possible. A GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (III-TT) vaccine was evaluated for safety and efficacy in preventing acquisition of GBS colonization. METHODS Healthy, nonpregnant women aged 18-40 years and screened to be GBS III vaginal and rectal culture negative were randomized to receive III-TT conjugate or tetanus diphtheria toxoid vaccine in a multicenter, observer-blinded trial. GBS vaginal and rectal cultures and blood were obtained bimonthly over 18 months. Serum concentrations of GBS III CPS-specific antibodies were determined using enzyme-linked immunosorbent assay. RESULTS Among 1525 women screened, 650 were eligible for the intent-to-treat analysis. For time to first acquisition of vaginal GBS III, vaccine efficacy was 36% (95% confidence interval [CI], 1%-58%; P = .044), and for first rectal acquisition efficacy was 43% (95% CI, 11% to 63%; P = .014). Two months post-immunization, geometric mean concentrations of serum GBS type III CPS-specific immunoglobulin G were 12.6 µg/mL (95% CI, 9.95 to 15.81) in GBS III-TT recipients, representing a 4-fold increase from baseline in 95% of women, which persisted. Both vaccines were well tolerated. CONCLUSIONS GBS CPS III-TT conjugate vaccine significantly delayed acquisition of vaginal and rectal GBS III colonization. In addition to its use for maternal immunization to passively protect infants with maternally derived antibodies, a multivalent vaccine might also serve to reduce fetal and neonatal exposure to GBS. CLINICAL TRIALS REGISTRATION NCT00128219.",2019,"Two months post-immunization, geometric mean concentrations of serum GBS type III CPS-specific immunoglobulin G were 12.6 µg/mL (95% CI, 9.95 to 15.81) in GBS III-TT recipients, representing a 4-fold increase from baseline in 95% of women, which persisted.","['Healthy, nonpregnant women aged 18-40 years and screened to be GBS III vaginal and rectal culture negative', '1525 women screened, 650 were eligible for the intent-to-treat analysis', 'young infants']","['Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine', 'III-TT conjugate or tetanus diphtheria toxoid vaccine', 'GBS type III capsular polysaccharide (CPS)-tetanus toxoid conjugate (III-TT) vaccine', 'GBS CPS III-TT conjugate vaccine', 'Group B Streptococcus (GBS']","['first rectal acquisition efficacy', 'geometric mean concentrations of serum GBS type III CPS-specific immunoglobulin G', 'safety and efficacy', 'tolerated', 'delayed acquisition of vaginal and rectal GBS III colonization', 'vaginal GBS III, vaccine efficacy', 'GBS vaginal and rectal cultures and blood', 'Vaginal Colonization', 'Serum concentrations of GBS III CPS-specific antibodies']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0855652', 'cui_str': 'Culture negative'}, {'cui': 'C3844101', 'cui_str': '650'}, {'cui': 'C1283828', 'cui_str': 'Intentional'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C1524024', 'cui_str': 'analysis'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}]","[{'cui': 'C0441731', 'cui_str': 'Type 3 (qualifier value)'}, {'cui': 'C0205151', 'cui_str': 'Capsular (qualifier value)'}, {'cui': 'C0032594', 'cui_str': 'Glycans'}, {'cui': 'C0305062', 'cui_str': 'Clostridium tetani toxoid antigen, inactivated'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0301869', 'cui_str': 'Conjugate'}, {'cui': 'C0012551', 'cui_str': 'diphtheria toxoid vaccine, inactivated'}, {'cui': 'C0206515', 'cui_str': 'Vaccines, Conjugate'}, {'cui': 'C0579233', 'cui_str': 'Streptococcus agalactiae'}]","[{'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0441731', 'cui_str': 'Type 3 (qualifier value)'}, {'cui': 'C0358334', 'cui_str': 'Specific immunoglobulins'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C4521343', 'cui_str': 'Vaginal (intended site)'}, {'cui': 'C0439070', 'cui_str': 'III'}, {'cui': 'C0042210', 'cui_str': 'Vaccines'}, {'cui': 'C0220814', 'cui_str': 'culture'}, {'cui': 'C0005768'}, {'cui': 'C0443640', 'cui_str': 'Specific antibody (substance)'}]",650.0,0.0632893,"Two months post-immunization, geometric mean concentrations of serum GBS type III CPS-specific immunoglobulin G were 12.6 µg/mL (95% CI, 9.95 to 15.81) in GBS III-TT recipients, representing a 4-fold increase from baseline in 95% of women, which persisted.","[{'ForeName': 'Sharon L', 'Initials': 'SL', 'LastName': 'Hillier', 'Affiliation': 'University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pennsylvania.'}, {'ForeName': 'Patricia', 'Initials': 'P', 'LastName': 'Ferrieri', 'Affiliation': 'Department of Laboratory Medicine and Pathology and Pediatrics, University of Minnesota Medical School, Minneapolis.'}, {'ForeName': 'Morven S', 'Initials': 'MS', 'LastName': 'Edwards', 'Affiliation': 'Baylor College of Medicine, Department of Pediatrics, Feigin Center, Houston, Texas.'}, {'ForeName': 'Marian', 'Initials': 'M', 'LastName': 'Ewell', 'Affiliation': 'The EMMES Corporation, Rockville, Maryland.'}, {'ForeName': 'Daron', 'Initials': 'D', 'LastName': 'Ferris', 'Affiliation': 'Medical College of Georgia, Augusta.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Fine', 'Affiliation': 'Planned Parenthood Gulf Coast, Houston, Texas.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Carey', 'Affiliation': ""Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Leslie', 'Initials': 'L', 'LastName': 'Meyn', 'Affiliation': 'University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pennsylvania.'}, {'ForeName': 'Dakota', 'Initials': 'D', 'LastName': 'Hoagland', 'Affiliation': 'COTA Enterprises, McLouth, Kansas.'}, {'ForeName': 'Dennis L', 'Initials': 'DL', 'LastName': 'Kasper', 'Affiliation': 'Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Lawrence C', 'Initials': 'LC', 'LastName': 'Paoletti', 'Affiliation': 'Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts.'}, {'ForeName': 'Heather', 'Initials': 'H', 'LastName': 'Hill', 'Affiliation': 'The EMMES Corporation, Rockville, Maryland.'}, {'ForeName': 'Carol J', 'Initials': 'CJ', 'LastName': 'Baker', 'Affiliation': 'Divsion of Infectious Disease, Department of Pediatrics, University of Texas Health Science Center McGovern Medical School, Houston.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciy838'] 3215,31084292,Change in Patient Activation and Mental Illness Symptoms After Communication Training: A Multisite Study With a Diverse Patient Sample.,"OBJECTIVE Patient activation involves patients' ability and motivation to communicate about their health and health care. Research has demonstrated that clinician or patient interventions may improve patient activation. This study explored the degree to which clinician and patient interventions affected both patient activation and symptoms of depression and anxiety in a racially and ethnically diverse clinical sample. METHODS Data were from a randomized clinical trial that included 312 patients and 74 clinicians from 13 Massachusetts community- and hospital-based outpatient behavioral health clinics. Patients completed measures of patient activation and depression and anxiety symptoms. Secondary data analyses were conducted to examine the effect of patient and clinician interventions (DECIDE-PA and DECIDE-PC, respectively) on depression and anxiety symptoms and patient activation. A multilevel, mixed-effects simultaneous-equation model was estimated to assess the relationship between the interventions, changes in patients' symptoms, and patient activation. RESULTS Clinicians' greater intervention dosage (i.e., more completed DECIDE-PC training sessions) was associated with patients' decreased anxiety symptoms, but associations with patient activation or depression symptoms were not significant. The effect of clinician training dosage on anxiety symptoms was stronger when patients and clinicians were not of the same race-ethnicity. The reduction in patients' anxiety symptoms appeared to increase patient activation. CONCLUSIONS Clinician interventions designed to boost patient-clinician communication and the therapeutic alliance may serve to lessen patients' anxiety and may ultimately improve patient activation.",2019,The effect of clinician training dosage on anxiety symptoms was stronger when patients and clinicians were not of the same race-ethnicity.,['312 patients and 74 clinicians from 13 Massachusetts community- and hospital-based outpatient behavioral health clinics'],"['clinician training dosage', 'Communication Training']","[""patients' anxiety symptoms"", 'patient activation or depression symptoms', 'depression and anxiety symptoms and patient activation', 'patient activation and depression and anxiety symptoms', 'anxiety symptoms', 'Patient Activation and Mental Illness Symptoms']","[{'cui': 'C4517706', 'cui_str': '312 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C0870196', 'cui_str': 'Behavioral health (qualifier value)'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}]","[{'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0178602', 'cui_str': 'Dosages (qualifier value)'}, {'cui': 'C0009452', 'cui_str': 'Communication'}]","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C3853034', 'cui_str': 'Patient Activation'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}]",312.0,0.0227055,The effect of clinician training dosage on anxiety symptoms was stronger when patients and clinicians were not of the same race-ethnicity.,"[{'ForeName': 'Mengchun', 'Initials': 'M', 'LastName': 'Chiang', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}, {'ForeName': 'Janet', 'Initials': 'J', 'LastName': 'Chang', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}, {'ForeName': 'Ora', 'Initials': 'O', 'LastName': 'Nakash', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}, {'ForeName': 'Mario', 'Initials': 'M', 'LastName': 'Cruz-Gonzalez', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}, {'ForeName': 'Mirko K', 'Initials': 'MK', 'LastName': 'Fillbrunn', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}, {'ForeName': 'Margarita', 'Initials': 'M', 'LastName': 'Alegría', 'Affiliation': 'Counseling and Psychological Services, Carnegie Mellon University, Pittsburgh (Chiang); Department of Psychology, West Chester University, West Chester, Pennsylvania (Chang); School for Social Work, Smith College, Northampton, Massachusetts (Nakash); Disparities Research Unit, Department of Medicine, Massachusetts General Hospital, Boston (Cruz-Gonzalez, Fillbrunn, Alegría); Department of Medicine and Psychiatry, Harvard Medical School, Boston (Alegría).'}]","Psychiatric services (Washington, D.C.)",['10.1176/appi.ps.201800216'] 3216,31504336,The Effect of Helminth Infections and Their Treatment on Metabolic Outcomes: Results of a Cluster-Randomized Trial.,"BACKGROUND Helminths may protect against cardiometabolic risk through effects on inflammation and metabolism; their treatment may be detrimental to metabolic outcomes. METHODS In a cluster-randomized trial in 26 Ugandan fishing communities we investigated effects of community-wide intensive (quarterly single-dose praziquantel, triple-dose albendazole) vs standard (annual single-dose praziquantel, biannual single-dose albendazole) anthelminthic treatment on metabolic outcomes, and observational associations between helminths and metabolic outcomes. The primary outcome, homeostatic model assessment of insulin resistance (HOMA-IR), and secondary outcomes (including blood pressure, fasting blood glucose, lipids) were assessed after 4 years' intervention among individuals aged ≥10 years. RESULTS We analyzed 1898 participants. Intensive treatment had no effect on HOMA-IR (adjusted geometric mean ratio, 0.96 [95% confidence interval {CI}, .86-1.07]; P = .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.60 mmol/L; adjusted mean difference, 0.26 [95% CI, -.03 to .56]; P = .08). Lower LDL-c levels were associated with Schistosoma mansoni (2.37 vs 2.80 mmol/L; -0.25 [95% CI, -.49 to -.02]; P = .04) or Strongyloides (2.34 vs 2.69 mmol/L; -0.32 [95% CI, -.53 to -.12]; P = .003) infection. Schistosoma mansoni was associated with lower total cholesterol (4.24 vs 4.64 mmol/L; -0.25 [95% CI, -.44 to -.07]; P = .01) and moderate to heavy S. mansoni infection with lower triglycerides, LDL-c, and diastolic blood pressure. CONCLUSIONS Helminth infections improve lipid profiles and may lower blood pressure. Studies to confirm causality and investigate mechanisms may contribute to understanding the epidemiological transition and suggest new approaches to prevent cardiometabolic disease. CLINICAL TRIALS REGISTRATION ISRCTN47196031.",2020,"S. mansoni infection was associated with lower total cholesterol levels (4.24 vs 4.64 mmol/L, -0.25","['26 fishing communities, Lake Victoria, Uganda', 'Participants with moderate to heavy S. mansoni infection', '1898 participants']","['community-wide intensive (quarterly single-dose praziquantel, triple dose albendazole']","['metabolic outcomes', 'Lower LDL-cholesterol levels', 'blood pressure', 'lower triglycerides, LDL-cholesterol and diastolic blood pressure levels', 'mean LDL-cholesterol', 'HOMA-IR', 'total cholesterol levels', 'homeostatic model assessment of insulin resistance (HOMA-IR) and secondary outcomes (including blood pressure, fasting blood glucose and lipids']","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0337049', 'cui_str': 'Lakes'}, {'cui': 'C0042645', 'cui_str': 'Victoria'}, {'cui': 'C0041573', 'cui_str': 'Republic of Uganda'}, {'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C0439539', 'cui_str': 'Heavy sensation quality'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]","[{'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0332179', 'cui_str': 'q3mo'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0032911', 'cui_str': 'Praziquantel'}, {'cui': 'C0205174', 'cui_str': 'Triple (qualifier value)'}, {'cui': 'C0001911', 'cui_str': 'Albendazole'}]","[{'cui': 'C0853085', 'cui_str': 'Decreased LDL'}, {'cui': 'C0428466', 'cui_str': 'Finding of cholesterol level (finding)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C1305849', 'cui_str': 'Blood pressure diastolic'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0026350', 'cui_str': 'Models, Theoretic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0021655', 'cui_str': 'Insulin Resistance'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0428568', 'cui_str': 'Fasting blood glucose measurement'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}]",1898.0,0.334987,"S. mansoni infection was associated with lower total cholesterol levels (4.24 vs 4.64 mmol/L, -0.25","[{'ForeName': 'Richard E', 'Initials': 'RE', 'LastName': 'Sanya', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Emily L', 'Initials': 'EL', 'LastName': 'Webb', 'Affiliation': 'MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Zziwa', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Kizindo', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Moses', 'Initials': 'M', 'LastName': 'Sewankambo', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Josephine', 'Initials': 'J', 'LastName': 'Tumusiime', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Esther', 'Initials': 'E', 'LastName': 'Nakazibwe', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Gloria', 'Initials': 'G', 'LastName': 'Oduru', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Emmanuel', 'Initials': 'E', 'LastName': 'Niwagaba', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Prossy Kabuubi', 'Initials': 'PK', 'LastName': 'Nakawungu', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Joyce', 'Initials': 'J', 'LastName': 'Kabagenyi', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Jacent', 'Initials': 'J', 'LastName': 'Nassuuna', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Bridgious', 'Initials': 'B', 'LastName': 'Walusimbi', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Irene', 'Initials': 'I', 'LastName': 'Andia-Biraro', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}, {'ForeName': 'Alison M', 'Initials': 'AM', 'LastName': 'Elliott', 'Affiliation': 'Immunomodulation and Vaccines Programme, Medical Research Council (MRC)/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda.'}]",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,['10.1093/cid/ciz859'] 3217,31286828,Combining Fluoxetine and rTMS in Poststroke Motor Recovery: A Placebo-Controlled Double-Blind Randomized Phase 2 Clinical Trial.,"Background . Although recent evidence has shown a new role of fluoxetine in motor rehabilitation, results are mixed. We conducted a randomized clinical trial to evaluate whether combining repetitive transcranial magnetic stimulation (rTMS) with fluoxetine increases upper limb motor function in stroke. Methods . Twenty-seven hemiparetic patients within 2 years of ischemic stroke were randomized into 3 groups: Combined (active rTMS + fluoxetine), Fluoxetine (sham rTMS + fluoxetine), or Placebo (sham rTMS + placebo fluoxetine). Participants received 18 sessions of 1-Hz rTMS in the unaffected primary motor cortex and 90 days of fluoxetine (20 mg/d). Motor function was assessed using Jebsen-Taylor Hand Function (JTHF) and Fugl-Meyer Assessment (FMA) scales. Corticospinal excitability was assessed with TMS. Results . After adjusting for time since stroke, there was significantly greater improvement in JTHF in the combined rTMS + fluoxetine group (mean improvement: -214.33 seconds) than in the placebo (-177.98 seconds, P = 0.005) and fluoxetine (-50.16 seconds, P < 0.001) groups. The fluoxetine group had less improvement than placebo on both scales (respectively, JTHF: -50.16 vs -117.98 seconds, P = 0.038; and FMA: 6.72 vs 15.55 points, P = 0.039), suggesting that fluoxetine possibly had detrimental effects. The unaffected hemisphere showed decreased intracortical inhibition in the combined and fluoxetine groups, and increased intracortical facilitation in the fluoxetine group. This facilitation was negatively correlated with motor function improvement (FMA, r 2 = -0.398, P = 0.0395). Conclusion . Combined fluoxetine and rTMS treatment leads to better motor function in stroke than fluoxetine alone and placebo. Moreover, fluoxetine leads to smaller improvements than placebo, and fluoxetine's effects on intracortical facilitation suggest a potential diffuse mechanism that may hinder beneficial plasticity on motor recovery.",2019,"The unaffected hemisphere showed decreased intracortical inhibition in the combined and fluoxetine groups, and increased intracortical facilitation in the fluoxetine group.","['Twenty-seven hemiparetic patients within 2 years of ischemic stroke', 'stroke', 'Poststroke Motor Recovery']","['Combined (active rTMS + fluoxetine), Fluoxetine (sham rTMS + fluoxetine), or Placebo (sham rTMS + placebo fluoxetine', 'JTHF', 'placebo', 'Fluoxetine and rTMS', 'Placebo', 'fluoxetine', 'fluoxetine and rTMS', 'repetitive transcranial magnetic stimulation (rTMS', '1-Hz rTMS', 'rTMS + fluoxetine']","['JTHF', 'intracortical facilitation', 'Motor function', 'motor function improvement', 'Corticospinal excitability', 'Jebsen-Taylor Hand Function (JTHF) and Fugl-Meyer Assessment (FMA) scales', 'intracortical inhibition']","[{'cui': 'C4319602', 'cui_str': '27'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}]","[{'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0016365', 'cui_str': 'Fluoxetine'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0872259', 'cui_str': 'Transcranial Magnetic Stimulation, Repetitive'}]","[{'cui': 'C0234112', 'cui_str': 'Facilitation, function (observable entity)'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C0235169', 'cui_str': 'Excitability (finding)'}, {'cui': 'C0562230', 'cui_str': 'Hand functions (observable entity)'}, {'cui': 'C0450973', 'cui_str': 'Assessment scales (assessment scale)'}, {'cui': 'C0021469', 'cui_str': 'Inhibition, function (observable entity)'}]",27.0,0.0447246,"The unaffected hemisphere showed decreased intracortical inhibition in the combined and fluoxetine groups, and increased intracortical facilitation in the fluoxetine group.","[{'ForeName': 'Camila', 'Initials': 'C', 'LastName': 'Bonin Pinto', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Leon', 'Initials': 'L', 'LastName': 'Morales-Quezada', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Polyana Vulcano', 'Initials': 'PV', 'LastName': 'de Toledo Piza', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Dian', 'Initials': 'D', 'LastName': 'Zeng', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Faddi Ghassan', 'Initials': 'FG', 'LastName': 'Saleh Vélez', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Isadora Santos', 'Initials': 'IS', 'LastName': 'Ferreira', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Pedro Henrique', 'Initials': 'PH', 'LastName': 'Lucena', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Dante', 'Initials': 'D', 'LastName': 'Duarte', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Fernanda', 'Initials': 'F', 'LastName': 'Lopes', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Mirret M', 'Initials': 'MM', 'LastName': 'El-Hagrassy', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Luiz Vicente', 'Initials': 'LV', 'LastName': 'Rizzo', 'Affiliation': '3 Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Erica C', 'Initials': 'EC', 'LastName': 'Camargo', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Lin', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Mazwi', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Qing Mei', 'Initials': 'QM', 'LastName': 'Wang', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Randie', 'Initials': 'R', 'LastName': 'Black-Schaffer', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Felipe', 'Initials': 'F', 'LastName': 'Fregni', 'Affiliation': '1 Harvard Medical School, Boston, MA, USA.'}]",Neurorehabilitation and neural repair,['10.1177/1545968319860483'] 3218,31292176,Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: a qualitative study.,"OBJECTIVE Three types of central venous access devices (CVADs) are routinely used in the delivery of intravenous systemic anticancer therapy (SACT): peripherally inserted central catheters (PICCs), subcutaneously tunnelled central catheters (Hickman-type devices) and totally implantable chest wall ports (Ports). This qualitative study, nested within a multicentre, randomised controlled trial, sought to explore patient acceptability and experiences of the three devices. DESIGN Eight focus groups were audio-recorded, transcribed and thematically analysed. SETTING Six outpatient cancer treatment centres in the UK. PARTICIPANTS Forty-two patients (20 female, mean age 61.7 years) who had taken part or were taking part in the broader trial. INTERVENTION As part of the larger, randomised controlled trial, participants had been randomly assigned one of three CVADs for the administration of SACT. RESULTS Attitudes towards all three devices were positive, with patients viewing their CVAD as part of their treatment and recovery. Participants with PICCs and Hickmans tended to compare their device favourably with peripheral cannulation. By comparison, participants with Ports consistently compared their device with PICCs and Hickmans, emphasising the perceived superiority of Ports. Ports were perceived to offer unique psychological benefits, including a greater sense of freedom and less intrusion in the context of personal relationships. CONCLUSIONS Patient experiences and preferences have not been systematically used to inform policy and practice regarding CVAD availability and selection. Our research identified patterns of patient device preferences that favoured Ports, although this was not universal. Results of this study could improve support for patients and offer greater scope for incorporating patient perspectives into decision-making processes. TRIAL REGISTRATION NUMBER ISRCTN44504648.",2019,"By comparison, participants with Ports consistently compared their device with PICCs and Hickmans, emphasising the perceived superiority of Ports.","['Six outpatient cancer treatment centres in the UK', 'Forty-two patients (20 female, mean age 61.7 years) who had taken part or were taking part in the broader trial']","['intravenous systemic anticancer therapy (SACT): peripherally inserted central catheters (PICCs), subcutaneously tunnelled central catheters (Hickman-type devices) and totally implantable chest wall ports (Ports', 'central venous access devices (CVADs']",[],"[{'cui': 'C0029921', 'cui_str': 'Out-patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C4319566', 'cui_str': 'Forty-two'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C1515187', 'cui_str': 'Take'}]","[{'cui': 'C0348016', 'cui_str': 'Intravenous (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0179740', 'cui_str': 'Long line'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0085590', 'cui_str': 'Catheters'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0205076', 'cui_str': 'Chest Wall'}, {'cui': 'C0452253', 'cui_str': 'Port (substance)'}, {'cui': 'C0444466', 'cui_str': 'Central venous (qualifier value)'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}, {'cui': 'C0220819', 'cui_str': 'devices'}]",[],42.0,0.156818,"By comparison, participants with Ports consistently compared their device with PICCs and Hickmans, emphasising the perceived superiority of Ports.","[{'ForeName': 'Caoimhe', 'Initials': 'C', 'LastName': 'Ryan', 'Affiliation': 'School of Social Sciences, University of Dundee, Dundee, UK.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Hesselgreaves', 'Affiliation': 'School of Medical Education, Newcastle University, Newcastle, UK.'}, {'ForeName': 'Olivia', 'Initials': 'O', 'LastName': 'Wu', 'Affiliation': 'Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Jonathan', 'Initials': 'J', 'LastName': 'Moss', 'Affiliation': 'Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'James', 'Initials': 'J', 'LastName': 'Paul', 'Affiliation': 'Cancer Research UK Clinical Trials Unit, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Dixon-Hughes', 'Affiliation': 'Institute of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.'}, {'ForeName': 'Evi', 'Initials': 'E', 'LastName': 'Germeni', 'Affiliation': 'Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.'}]",BMJ open,['10.1136/bmjopen-2018-026077'] 3219,31556911,Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial.,"Importance Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to implement in trials the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which was developed to allow patients to self-report symptomatic AEs and improve the quality of symptomatic AE detection. Objectives To evaluate the feasibility of implementing PRO-CTCAE in a prespecified correlative analysis of the phase 3 COMET-2 trial and enumerate statistically significant between-group differences in symptomatic AEs using PRO-CTCAE and the CTCAE. Design, Setting, and Participants This correlative study of 119 men in the randomized, double-blind, placebo-controlled phase 3 COMET-2 trial with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment was conducted from March 2012 to July 2014. Participants completed PRO-CTCAE items using an automated telephone system from home prior to treatment and every 3 weeks during treatment. Statistical analysis was performed from May 2018 to June 2019. Main Outcomes and Measures The proportion of patients who completed expected PRO-CTCAE self-reports was computed as a measure of feasibility. Results Among the 119 men in the study (median age, 65 years [range, 44-80 years]), 534 of 587 (91.0%) expected PRO-CTCAE self-reports were completed, with consistently high rates of completion throughout participation. Rates of self-report adherence were similar between groups (cabozantinib s-maleate, 286 of 317 [90.2%]; and mitoxantrone hydrochloride-prednisone, 248 of 270 [91.9%]). Of 12 measured, patient-reported PRO-CTCAE symptomatic AEs, 4 reached statistical significance when comparing the proportion of patients with at least 1 postbaseline score greater than 0 between groups (differences ranged from 20.1% to 34.1% with higher proportions in the cabozantinib group; all P < .05), and use of a method for accounting for preexisting symptoms at baseline yielded 7 AEs with statistically significant differences between groups (differences ranged from 20.5% to 41.2% with higher proportions in the cabozantinib group; all P < .05). In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs. Conclusions and Relevance PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic AE detection in a phase 3 cancer trial. This analysis adds to mounting evidence of the feasibility and value of patient-reported AEs in oncology, which should be considered for inclusion in cancer trials that incorporate AE evaluation. Trial Registration ClinicalTrials.gov identifier: NCT01522443.",2019,"In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs. ","['119 men in the study (median age, 65 years [range, 44-80 years]), 534 of 587 (91.0%) expected PRO-CTCAE self-reports', '119 men', 'controlled phase 3 COMET-2 trial with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment was conducted from March 2012 to July 2014']","['placebo', 'mitoxantrone hydrochloride-prednisone']",['Rates of self-report adherence'],"[{'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0439561', 'cui_str': 'Phase 3 (qualifier value)'}, {'cui': 'C0282670', 'cui_str': 'Comets (Astronomy)'}, {'cui': 'C4721208', 'cui_str': 'Metastatic castration-resistant prostate cancer'}, {'cui': 'C0205132', 'cui_str': 'Linear (qualifier value)'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0700458', 'cui_str': 'Mitoxantrone Hydrochloride'}, {'cui': 'C0032952', 'cui_str': 'Prednisone'}]","[{'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}]",119.0,0.207639,"In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs. ","[{'ForeName': 'Amylou C', 'Initials': 'AC', 'LastName': 'Dueck', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona.'}, {'ForeName': 'Howard I', 'Initials': 'HI', 'LastName': 'Scher', 'Affiliation': 'Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Antonia V', 'Initials': 'AV', 'LastName': 'Bennett', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.'}, {'ForeName': 'Gina L', 'Initials': 'GL', 'LastName': 'Mazza', 'Affiliation': 'Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona.'}, {'ForeName': 'Gita', 'Initials': 'G', 'LastName': 'Thanarajasingam', 'Affiliation': 'Division of Hematology, Mayo Clinic, Rochester, Minnesota.'}, {'ForeName': 'Gisela', 'Initials': 'G', 'LastName': 'Schwab', 'Affiliation': 'Exelixis Inc, South San Francisco, California.'}, {'ForeName': 'Aaron L', 'Initials': 'AL', 'LastName': 'Weitzman', 'Affiliation': 'Independent Consultant, San Francisco, California.'}, {'ForeName': 'Lauren J', 'Initials': 'LJ', 'LastName': 'Rogak', 'Affiliation': 'Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.'}, {'ForeName': 'Ethan', 'Initials': 'E', 'LastName': 'Basch', 'Affiliation': 'Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill.'}]",JAMA oncology,['10.1001/jamaoncol.2019.3332'] 3220,30649836,Sunshine is an Important Determinant of Vitamin D Status Even Among High-dose Supplement Users: Secondary Analysis of a Randomized Controlled Trial in Crohn's Disease Patients.,"Sunshine is considered to be the most important source of vitamin D. Due to an increased risk of skin cancer, sun avoidance is advised, but this directly contributes to the high prevalence of vitamin D deficiency. The simple solution is to advise vitamin D supplementation. The aim of this study was to examine the absolute and relative contribution of sunshine and supplementation to vitamin status. This study was a secondary analysis of an RCT of 92 Crohn's disease patients in remission (49% female, median age = 44). Participants were randomized to 2000 IU day -1 of vitamin D3 or placebo for 1 year, with 25-hydroxyvitamin D (25(OH)D) being measured at baseline and every 4 months. Based on participant's place of residence, daily ambient UVB dose at wavelengths that can induce vitamin D synthesis (D-UVB) was obtained. Cumulative and weighted ambient D-UVB (cw-D-UVB) exposure prior to each blood draw was calculated for each participant. Linear regression analysis and multilevel modeling were used to examine the association between UVB exposure, supplementation and 25(OH)D concentration. There was considerable annual variation in D-UVB, cw-D-UVB and 25(OH)D. Both supplementation and cw-D-UVB were found to be strongly associated with 25(OH)D: in multilevel model, an increase of approximately 6 nmol L -1 for every 100 kJ m -2 in cw-D-UVB was found, among those receiving placebo and supplementation (P < 0.0001). Treatment was associated with increase of 23 nmol L -1 (P < 0.0001). Sunshine is an important determinant of 25(OH)D concentration, even in those who are taking high-dose vitamin D supplements and reside at a higher mid-latitude location.",2019,"There was considerable annual variation in D-UVB, cw-D-UVB and 25(OH)D.","[""Crohn's Disease Patients"", 'High-dose Supplement Users', ""92 Crohn's disease patients in remission (49% female, median age\xa0=\xa044""]","['vitamin D3 or placebo', 'placebo']","['Vitamin D Status', 'annual variation in D-UVB, cw-D-UVB and 25(OH)D', 'Cumulative and weighted ambient D-UVB (cw-D-UVB) exposure prior to each blood draw']","[{'cui': 'C0156147', 'cui_str': 'Colitis, Granulomatous'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C3265062', 'cui_str': 'vitamin D3'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0042866', 'cui_str': 'Vitamin D'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0332181', 'cui_str': 'Annual (qualifier value)'}, {'cui': 'C0205419', 'cui_str': 'Variant (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0332152', 'cui_str': 'Before (attribute)'}, {'cui': 'C0190979', 'cui_str': 'Venesection'}]",,0.131074,"There was considerable annual variation in D-UVB, cw-D-UVB and 25(OH)D.","[{'ForeName': 'Fiona', 'Initials': 'F', 'LastName': ""O'Sullivan"", 'Affiliation': 'Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Raftery', 'Affiliation': 'Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Michiel', 'Initials': 'M', 'LastName': 'van Weele', 'Affiliation': 'Royal Netherlands Meteorological Institute (KNMI), De Bilt, The Netherlands.'}, {'ForeName': 'Jos', 'Initials': 'J', 'LastName': 'van Geffen', 'Affiliation': 'Royal Netherlands Meteorological Institute (KNMI), De Bilt, The Netherlands.'}, {'ForeName': 'Deirdre', 'Initials': 'D', 'LastName': 'McNamara', 'Affiliation': 'Department of Gastroenterology, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Colm', 'Initials': 'C', 'LastName': ""O'Morain"", 'Affiliation': 'Department of Gastroenterology, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Nasir', 'Initials': 'N', 'LastName': 'Mahmud', 'Affiliation': 'Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Dervla', 'Initials': 'D', 'LastName': 'Kelly', 'Affiliation': 'Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Healy', 'Affiliation': ""Department of Biochemistry, St James's Hospital, Trinity College Dublin, Dublin, Republic of Ireland.""}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': ""O'Sullivan"", 'Affiliation': 'Department of Clinical Medicine, Trinity Centre for Health Sciences, Trinity College Dublin, Dublin, Republic of Ireland.'}, {'ForeName': 'Lina', 'Initials': 'L', 'LastName': 'Zgaga', 'Affiliation': 'Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin, Dublin, Republic of Ireland.'}]",Photochemistry and photobiology,['10.1111/php.13086'] 3221,30639763,Food for Thought: A Randomized Trial of Food Insecurity Screening in the Emergency Department.,"BACKGROUND Despite the growing interest in screening for food insecurity in the clinical setting, little evidence exists regarding screening formats that maximize disclosure and caregiver comfort. METHODS In this randomized trial, we asked English-speaking adult caregivers of pediatric patients in the emergency department at an urban, freestanding children's hospital to complete a validated, 2-question screen for food insecurity. Respondents were assigned via block randomization to complete the survey by either verbal interview or electronic tablet. Caregivers reported the perceived importance of the screening questions, comfort level with screening in the emergency department or in their child's primary care site, and their preferred screening modality. RESULTS Of the 1818 participants, 20.6% screened positive for food insecurity. There was a significantly higher rate of reported food insecurity for those screened by tablet (23.6%) compared to those screened verbally (17.7%) (P = .002). Of those who had a preference of screening modality, 83.2% of all participants and 84.5% of patients reporting food insecurity preferred the tablet-based screen over verbal interview. Overall, more participants reported comfort completing the screen in the emergency department compared to their child's doctor's office; however, comfort in both of these setting was rated highly (86.1% vs 80.2%; P < .001). CONCLUSIONS Although both verbal interview and tablet-based screening modalities were effective in identifying food insecurity, tablet-based screening had a higher disclosure rate and was the participants' preferred screening method. There is a high level of comfort with screening regardless of clinical setting; it is possible that an added level of anonymity in the emergency department enhanced participants' comfort levels.",2019,There was a significantly higher rate of reported food insecurity for those screened by tablet (23.6%) compared to those screened verbally (17.7%) (P = .002).,"['Of the 1818 participants, 20.6% screened positive for food insecurity', ""English-speaking adult caregivers of pediatric patients in the emergency department at an urban, freestanding children's hospital to complete a validated, 2-question screen for food insecurity"", 'Food for Thought']","['Food Insecurity Screening', 'verbal interview or electronic tablet']",['rate of reported food insecurity'],"[{'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C3494174', 'cui_str': 'Food Insecurity'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0020017', 'cui_str': 'Hospitals, Pediatric'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C4319827', 'cui_str': 'Thought'}]","[{'cui': 'C3494174', 'cui_str': 'Food Insecurity'}, {'cui': 'C0220908', 'cui_str': 'Screening'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C4281784', 'cui_str': 'Electronics'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}]","[{'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C3494174', 'cui_str': 'Food Insecurity'}]",1818.0,0.17576,There was a significantly higher rate of reported food insecurity for those screened by tablet (23.6%) compared to those screened verbally (17.7%) (P = .002).,"[{'ForeName': 'Danielle', 'Initials': 'D', 'LastName': 'Cullen', 'Affiliation': ""Division of Emergency Medicine (D Cullen and J Fein), The Children's Hospital of Philadelphia. Electronic address: CullenDL@email.chop.edu.""}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Woodford', 'Affiliation': 'Department of Neurosurgery (A Woodford), Thomas Jefferson University, Philadelphia PA.'}, {'ForeName': 'Joel', 'Initials': 'J', 'LastName': 'Fein', 'Affiliation': ""Division of Emergency Medicine (D Cullen and J Fein), The Children's Hospital of Philadelphia.""}]",Academic pediatrics,['10.1016/j.acap.2018.11.014'] 3222,31862249,"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.","BACKGROUND Dravet syndrome is a rare, treatment-resistant developmental epileptic encephalopathy characterised by multiple types of frequent, disabling seizures. Fenfluramine has been reported to have antiseizure activity in observational studies of photosensitive epilepsy and Dravet syndrome. The aim of the present study was to assess the efficacy and safety of fenfluramine in patients with Dravet syndrome. METHODS In this randomised, double-blind, placebo-controlled clinical trial, we enrolled children and young adults with Dravet syndrome. After a 6-week observation period to establish baseline monthly convulsive seizure frequency (MCSF; convulsive seizures were defined as hemiclonic, tonic, clonic, tonic-atonic, generalised tonic-clonic, and focal with clearly observable motor signs), patients were randomly assigned through an interactive web response system in a 1:1:1 ratio to placebo, fenfluramine 0·2 mg/kg per day, or fenfluramine 0·7 mg/kg per day, added to existing antiepileptic agents for 14 weeks. The primary outcome was the change in mean monthly frequency of convulsive seizures during the treatment period compared with baseline in the 0·7 mg/kg per day group versus placebo; 0·2 mg/kg per day versus placebo was assessed as a key secondary outcome. Analysis was by modified intention to treat. Safety analyses included all participants who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov with two identical protocols NCT02682927 and NCT02826863. FINDINGS Between Jan 15, 2016, and Aug 14, 2017, we assessed 173 patients, of whom 119 patients (mean age 9·0 years, 64 [54%] male) were randomly assigned to receive either fenfluramine 0·2 mg/kg per day (39), fenfluramine 0·7 mg/kg per day (40) or placebo (40). During treatment, the median reduction in seizure frequency was 74·9% in the fenfluramine 0·7 mg/kg group (from median 20·7 seizures per 28 days to 4·7 seizures per 28 days), 42·3% in the fenfluramine 0·2 mg/kg group (from median 17·5 seizures per 28 days to 12·6 per 28 days), and 19·2% in the placebo group (from median 27·3 per 28 days to 22·0 per 28 days). The study met its primary efficacy endpoint, with fenfluramine 0·7 mg/kg per day showing a 62·3% greater reduction in mean MCSF compared with placebo (95% CI 47·7-72·8, p<0·0001); fenfluramine 0·2 mg/kg per day showed a 32·4% reduction in mean MCSF compared with placebo (95% CI 6·2-52·3, p=0·0209). The most common adverse events (occurring in at least 10% of patients and more frequently in the fenfluramine groups) were decreased appetite, diarrhoea, fatigue, lethargy, somnolence, and decreased weight. Echocardiographic examinations revealed valve function within the normal physiological range in all patients during the trial and no signs of pulmonary arterial hypertension. INTERPRETATION In Dravet syndrome, fenfluramine provided significantly greater reduction in convulsive seizure frequency compared with placebo and was generally well tolerated, with no observed valvular heart disease or pulmonary arterial hypertension. Fenfluramine could be an important new treatment option for patients with Dravet syndrome. FUNDING Zogenix.",2019,"In Dravet syndrome, fenfluramine provided significantly greater reduction in convulsive seizure frequency compared with placebo and was generally well tolerated, with no observed valvular heart disease or pulmonary arterial hypertension.","['173 patients, of whom 119 patients (mean age 9·0 years, 64', 'seizures in Dravet syndrome', 'Between Jan 15, 2016, and Aug 14, 2017', 'participants who received at least one dose of study medication', 'enrolled children and young adults with Dravet syndrome', '54%] male', 'patients with Dravet syndrome']","['fenfluramine', 'placebo, fenfluramine 0·2 mg/kg per day, or fenfluramine 0·7', 'Fenfluramine hydrochloride', 'fenfluramine 0·7', 'placebo', 'Fenfluramine']","['median reduction in seizure frequency', 'efficacy and safety', 'convulsive seizure frequency', 'appetite, diarrhoea, fatigue, lethargy, somnolence, and decreased weight', 'valvular heart disease or pulmonary arterial hypertension', 'valve function', 'mean MCSF', 'change in mean monthly frequency of convulsive seizures']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0751122', 'cui_str': 'Myoclonic Epilepsy, Severe, Of Infancy'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0086582', 'cui_str': 'Males'}]","[{'cui': 'C0015827', 'cui_str': 'Fenfluramine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0439272', 'cui_str': 'microgram/g'}, {'cui': 'C0439505', 'cui_str': 'per day'}, {'cui': 'C0282179', 'cui_str': 'Fenfluramine Hydrochloride'}]","[{'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0036572', 'cui_str': 'Seizures'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0751494', 'cui_str': 'Convulsive Seizures'}, {'cui': 'C0003618', 'cui_str': 'Appetite'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0023380', 'cui_str': 'Lethargy'}, {'cui': 'C2830004', 'cui_str': 'Somnolence'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0018824', 'cui_str': 'Valvular Heart Diseases'}, {'cui': 'C2973725', 'cui_str': 'Pulmonary hypertensive arterial disease (disorder)'}, {'cui': 'C3888056', 'cui_str': 'Valve (physical object)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0332177', 'cui_str': 'Monthly (qualifier value)'}]",173.0,0.765917,"In Dravet syndrome, fenfluramine provided significantly greater reduction in convulsive seizure frequency compared with placebo and was generally well tolerated, with no observed valvular heart disease or pulmonary arterial hypertension.","[{'ForeName': 'Lieven', 'Initials': 'L', 'LastName': 'Lagae', 'Affiliation': 'Department of Paediatric Neurology, University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Joseph', 'Initials': 'J', 'LastName': 'Sullivan', 'Affiliation': ""University of California, San Francisco Benioff Children's Hospital, San Francisco, CA, USA.""}, {'ForeName': 'Kelly', 'Initials': 'K', 'LastName': 'Knupp', 'Affiliation': ""University of Colorado, Children's Hospital Colorado, Aurora, CO, USA.""}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Laux', 'Affiliation': 'Northwestern University Feinberg School of Medicine, Chicago, IL, USA.'}, {'ForeName': 'Tilman', 'Initials': 'T', 'LastName': 'Polster', 'Affiliation': 'Mara Hospital, Bielefeld, Germany.'}, {'ForeName': 'Marina', 'Initials': 'M', 'LastName': 'Nikanorova', 'Affiliation': 'Danish Epilepsy Centre, Dianalund, Denmark.'}, {'ForeName': 'Orrin', 'Initials': 'O', 'LastName': 'Devinsky', 'Affiliation': 'NYU Langone Medical Center, New York, NY, USA.'}, {'ForeName': 'J Helen', 'Initials': 'JH', 'LastName': 'Cross', 'Affiliation': 'UCL Great Ormond Street NIHR BRC Institute of Child Health, London, UK.'}, {'ForeName': 'Renzo', 'Initials': 'R', 'LastName': 'Guerrini', 'Affiliation': 'University of Florence, Florence, Italy.'}, {'ForeName': 'Dinesh', 'Initials': 'D', 'LastName': 'Talwar', 'Affiliation': 'University of Arizona Health Sciences Center, Tucson, AZ, USA.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Miller', 'Affiliation': ""Nicklaus Children's Hospital, Miami, FL, USA.""}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Farfel', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Bradley S', 'Initials': 'BS', 'LastName': 'Galer', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Arnold', 'Initials': 'A', 'LastName': 'Gammaitoni', 'Affiliation': 'Zogenix, Emeryville, CA, USA. Electronic address: agammaitoni@zogenix.com.'}, {'ForeName': 'Arun', 'Initials': 'A', 'LastName': 'Mistry', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Glenn', 'Initials': 'G', 'LastName': 'Morrison', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Lock', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Anupam', 'Initials': 'A', 'LastName': 'Agarwal', 'Affiliation': 'Zogenix, Emeryville, CA, USA.'}, {'ForeName': 'Wyman W', 'Initials': 'WW', 'LastName': 'Lai', 'Affiliation': ""CHOC Children's, Orange, CA, USA.""}, {'ForeName': 'Berten', 'Initials': 'B', 'LastName': 'Ceulemans', 'Affiliation': 'Department of Paediatric Neurology, University of Antwerp, Edegem, Belgium.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(19)32500-0'] 3223,32126977,"Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) - preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial.","BACKGROUND Neuroprotection and promotion of remyelination represent important therapeutic gaps in multiple sclerosis (MS). Acute optic neuritis (ON) is a frequent MS manifestation. Based on the presence and properties of sphingosine-1-phosphate receptors (S1PR) on astrocytes and oligodendrocytes, we hypothesized that remyelination can be enhanced by treatment with fingolimod, a S1PR modulator currently licensed for relapsing-remitting MS. METHODS MOVING was an investigator-driven, rater-blind, randomized clinical trial. Patients with acute unilateral ON, occurring as a clinically isolated syndrome or MS relapse, were randomized to 6 months of treatment with 0.5 mg oral fingolimod or subcutaneous IFN-β 1b 250 μg every other day. The change in multifocal visual evoked potential (mfVEP) latency of the qualifying eye was examined as the primary (month 6 vs. baseline) and secondary (months 3, 6 and 12 vs. baseline) outcome. In addition, full field visual evoked potentials, visual acuity, optical coherence tomography as well as clinical relapses and measures of disability, cerebral MRI, and self-reported visual quality of life were obtained for follow-up. The study was halted due to insufficient recruitment (n = 15), and available results are reported. RESULTS Per protocol analysis of the primary endpoint revealed a significantly larger reduction of mfVEP latency at 6 months compared to baseline with fingolimod treatment (n = 5; median decrease, 15.7 ms) than with IFN-β 1b treatment (n = 4; median increase, 8.15 ms) (p <  0.001 for interaction). Statistical significance was maintained in the secondary endpoint analysis. Descriptive results are reported for other endpoints. CONCLUSION Preliminary results of the MOVING trial argue in support of a beneficial effect of fingolimod on optic nerve remyelination when compared to IFN-β treatment. Interpretation is limited by the small number of complete observations, an unexpected deterioration of the control group and a difference in baseline mfVEP latencies. The findings need to be confirmed in larger studies. TRIAL REGISTRATION The trial was registered as EUDRA-CT 2011-004787-30 on October 26, 2012 and as NCT01647880 on July 24, 2012.",2020,"RESULTS Per protocol analysis of the primary endpoint revealed a significantly larger reduction of mfVEP latency at 6 months compared to baseline with fingolimod treatment (n = 5; median decrease, 15.7 ms) than with IFN-β 1b treatment (n = 4; median increase, 8.15 ms) (p <  0.001 for interaction).","['Patients with acute unilateral ON, occurring as a clinically isolated syndrome or MS relapse']","['sphingosine-1-phosphate receptors (S1PR', 'oral fingolimod or subcutaneous IFN-β']","['mfVEP latency', 'multifocal visual evoked potential (mfVEP) latency of the qualifying eye', 'full field visual evoked potentials, visual acuity, optical coherence tomography as well as clinical relapses and measures of disability, cerebral MRI, and self-reported visual quality of life']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205092', 'cui_str': 'Unilateral (qualifier value)'}, {'cui': 'C2921627', 'cui_str': 'Clinically isolated syndrome'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}]","[{'cui': 'C0390526', 'cui_str': 'Sphingosine-1-Phosphate Receptors'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C1699926', 'cui_str': 'fingolimod'}, {'cui': 'C1522438', 'cui_str': 'SC use'}]","[{'cui': 'C0205292', 'cui_str': 'Multifocal (qualifier value)'}, {'cui': 'C0546834', 'cui_str': 'Visual evoked potential study'}, {'cui': 'C0015392', 'cui_str': 'Eye'}, {'cui': 'C0439724', 'cui_str': 'Full field (qualifier value)'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0920367', 'cui_str': 'Tomography, Optical Coherence'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0035020', 'cui_str': 'Relapse'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0024485', 'cui_str': 'Steady-State Free Precession MRI'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0234621', 'cui_str': 'Visual (qualifier value)'}, {'cui': 'C0034380'}]",,0.185895,"RESULTS Per protocol analysis of the primary endpoint revealed a significantly larger reduction of mfVEP latency at 6 months compared to baseline with fingolimod treatment (n = 5; median decrease, 15.7 ms) than with IFN-β 1b treatment (n = 4; median increase, 8.15 ms) (p <  0.001 for interaction).","[{'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Albert', 'Affiliation': 'Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Allee nach Sanssouci 7, 14471, Potsdam, Germany.'}, {'ForeName': 'Janine', 'Initials': 'J', 'LastName': 'Mikolajczak', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Liekfeld', 'Affiliation': 'Department of Ophthalmology, Klinikum Ernst von Bergmann, Potsdam, Germany.'}, {'ForeName': 'Sophie K', 'Initials': 'SK', 'LastName': 'Piper', 'Affiliation': 'Institute of Biometry and Clinical Epidemiology, Charité-Universitätmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Scheel', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Hanna G', 'Initials': 'HG', 'LastName': 'Zimmermann', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Claus', 'Initials': 'C', 'LastName': 'Nowak', 'Affiliation': 'Berlin Institute of Health, Berlin, Germany.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Dörr', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Judith', 'Initials': 'J', 'LastName': 'Bellmann-Strobl', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Claudia', 'Initials': 'C', 'LastName': 'Chien', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Alexander U', 'Initials': 'AU', 'LastName': 'Brandt', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Friedemann', 'Initials': 'F', 'LastName': 'Paul', 'Affiliation': 'Neurocure Clinical Research Center, Charite-Universitätsmedizin Berlin, Berlin, Germany.'}, {'ForeName': 'Olaf', 'Initials': 'O', 'LastName': 'Hoffmann', 'Affiliation': 'Department of Neurology, Alexianer St. Josefs-Krankenhaus Potsdam, Allee nach Sanssouci 7, 14471, Potsdam, Germany. o.hoffmann@alexianer.de.'}]",BMC neurology,['10.1186/s12883-020-01645-z'] 3224,31762155,Coronally advanced flap with connective tissue graft or xenogeneic acellular dermal matrix in the treatment of multiple gingival recessions: A split-mouth randomized clinical trial.,"OBJECTIVE To evaluate the clinical efficacy of xenogeneic acellular dermal matrix (XADM) or connective tissue graft (CTG) combined with modified-coronally advanced flap (M-CAF) in the treatment of multiple gingival recessions. MATERIALS AND METHODS Twelve participants with bilateral MGRs (multiple gingival recession) (82 gingival recessions) randomly received XADM (test group, 41 teeth) on one side and subepithelial CTG (control group, 41 teeth) on the other side in conjunction with M-CAF in the same session and completed the 18-months study period. Recession depth (RD), recession width (RW), keratinized tissue width (KTW), probing depth (PD), and clinical attachment level (CAL) were recorded at baseline, and 6-, 18-months postoperatively. RESULTS PD was significantly higher in the test group at 18-months (P < .05). PD in the test group was also significantly higher at 6- and 18-months compared to baseline (P < .05). RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05). Percentage of teeth with complete root coverage in the test and control groups were similar at 6-months (78% and 70.7%, respectively) and at 18-months (both 87.8%) (P > .05). CONCLUSION Within the limits of the study, M-CAF combined with XADM or CTG seems to be similarly effective in RD reduction of class I and II MGRs at least in the short term. Soft tissue shrinkage and increase in PD may be observed with XADM, while; CTG seems to provide stable clinical outcomes for 18-months follow-up. CLINICAL SIGNIFICANCE Even though the CTG and XADM in conjunction with M-CAF may provide similar RD reduction in class I and II multiple gingival recessions in the short term. CTGs may be superior in terms of soft tissue shrinkage and PD values.",2020,RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05).,"['Twelve participants with bilateral MGRs (multiple gingival recession) (82 gingival recessions) randomly received', 'multiple gingival recessions']","['xenogeneic acellular dermal matrix (XADM) or connective tissue graft (CTG) combined with modified-coronally advanced flap (M-CAF', 'XADM or CTG', 'side and subepithelial CTG (control group, 41 teeth) on the other side in conjunction with M-CAF', 'Coronally advanced flap with connective tissue graft or xenogeneic acellular dermal matrix', 'XADM']","['RD reduction of class', 'RD and RW', 'Recession depth (RD), recession width (RW), keratinized tissue width (KTW), probing depth (PD), and clinical attachment level (CAL', 'PD', 'Percentage of teeth with complete root coverage', 'Soft tissue shrinkage and increase in PD']","[{'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0017572', 'cui_str': 'Gingival Recession'}]","[{'cui': 'C3494272', 'cui_str': 'Acellular Dermal Matrix'}, {'cui': 'C0009780', 'cui_str': 'Connective Tissue'}, {'cui': 'C1527362', 'cui_str': 'grafts'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0038925', 'cui_str': 'Surgical Flaps'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}]","[{'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0456387', 'cui_str': 'Classes (qualifier value)'}, {'cui': 'C0333047', 'cui_str': 'Recession (morphologic abnormality)'}, {'cui': 'C0205125', 'cui_str': 'Depth (qualifier value)'}, {'cui': 'C0487742', 'cui_str': 'Width (qualifier value)'}, {'cui': 'C0040300', 'cui_str': 'Tissues'}, {'cui': 'C3179165', 'cui_str': 'Probe (methazole)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0040426', 'cui_str': 'Tooth'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0563017', 'cui_str': 'Anal penetration using finger (finding)'}, {'cui': 'C0225317', 'cui_str': 'Soft tissues (body structure)'}, {'cui': 'C0332513', 'cui_str': 'Shrinkage (finding)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}]",12.0,0.0226828,RD and RW were significantly lower at 6- and 18-months compared to baseline in both groups (P < .05) and both parameters were significantly higher in the test group at 18-months (P < .05).,"[{'ForeName': 'Önder', 'Initials': 'Ö', 'LastName': 'Gürlek', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Pınar', 'Initials': 'P', 'LastName': 'Gümüş', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Nejat', 'Initials': 'N', 'LastName': 'Nizam', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}, {'ForeName': 'Nurcan', 'Initials': 'N', 'LastName': 'Buduneli', 'Affiliation': 'Department of Periodontology, School of Dentistry, Ege University, İzmir, Turkey.'}]",Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.],['10.1111/jerd.12547'] 3225,31087164,Ultrasound-guided transforaminal percutaneous endoscopic lumbar discectomy: a new guidance method that reduces radiation doses.,"PURPOSE The purpose of this study is to establish a new method to reduce the radiation dose during puncture and cannulation in percutaneous endoscopic lumbar discectomy (PELD). METHODS Sixty patients with lumbar disk herniation undergoing PELD were prospectively enrolled and randomly divided into an ultrasound (US) guidance group and an X-ray guidance group. The puncture, cannulation, and total operation times; number of fluoroscopy shots; and radiation dose were recorded in both groups. The factors influencing the operation were analyzed. The clinical effect of PELD was evaluated using the straight leg elevation test, visual analog scale (VAS) and Oswestry disability index (ODI). The researchers who collected and analyzed the data were blinded to the group assignments. RESULTS The puncture, cannulation and operation times in the US group were comparable to those in the X-ray group. The patients in the US group received 2.13 ± 0.35 fluoroscopy shots and a radiation dose of 5.34 ± 0.63 (mSV), which were significantly lower than the values in the X-ray group (7.57 shots ± 2.99 shots and 18.25 mSV ± 10.52 mSV) (P < 0.001). In the US group, the puncture time was significantly longer at the L5-S1 level, in patients with a BMI greater than 28 kg/m 2 and in patients with a high iliac crest. The US and X-ray groups had comparable VAS and ODI scores 1 h and 3 months after PELD, and the VAS scores were significantly lower after PELD (all P < 0.001). No complications were observed in either group. CONCLUSIONS US guidance is a new method that reduces the radiation dose required during puncture and cannulation in PELD. These slides can be retrieved under Electronic Supplementary Material.",2019,The US and X-ray groups had comparable VAS and ODI scores,['Sixty patients with lumbar disk herniation undergoing PELD'],"['ultrasound (US) guidance group and an X-ray guidance group', 'percutaneous endoscopic lumbar discectomy (PELD', 'Ultrasound-guided transforaminal percutaneous endoscopic lumbar discectomy']","['VAS and ODI scores', 'puncture, cannulation, and total operation times; number of fluoroscopy shots; and radiation dose', 'VAS scores', 'puncture time', 'puncture, cannulation and operation times', 'straight leg elevation test, visual analog scale (VAS) and Oswestry disability index (ODI']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0024090', 'cui_str': 'Lumbar Region'}, {'cui': 'C1705370', 'cui_str': 'Disc - unit of product usage'}, {'cui': 'C0019270', 'cui_str': 'Hernia'}]","[{'cui': 'C0442973', 'cui_str': 'Ultrasonic guidance procedure (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0034571', 'cui_str': 'radiography'}, {'cui': 'C0522523', 'cui_str': 'Percutaneous approach - access (qualifier value)'}, {'cui': 'C0408632', 'cui_str': 'Excision of lumbar intervertebral disc (procedure)'}, {'cui': 'C0220934', 'cui_str': 'ultrasound'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0033119', 'cui_str': 'Puncture wound - injury (disorder)'}, {'cui': 'C0917707', 'cui_str': 'Cannulation'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0038895', 'cui_str': 'operative therapy'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0016356', 'cui_str': 'Fluoroscopy'}, {'cui': 'C0851346', 'cui_str': 'Radiation'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1527360', 'cui_str': 'Heterosexuals'}, {'cui': 'C0023216', 'cui_str': 'Membrum inferius'}, {'cui': 'C0439775', 'cui_str': 'Elevation'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0451360', 'cui_str': 'Oswestry disability index (assessment scale)'}]",60.0,0.0167607,The US and X-ray groups had comparable VAS and ODI scores,"[{'ForeName': 'Mingbo', 'Initials': 'M', 'LastName': 'Zhang', 'Affiliation': 'Department of Ultrasound, General Hospital of Chinese PLA, Beijing, China.'}, {'ForeName': 'Longtao', 'Initials': 'L', 'LastName': 'Yan', 'Affiliation': 'Department of Pain, China-Japan Friendship Hospital, Beijing, China.'}, {'ForeName': 'Shoupeng', 'Initials': 'S', 'LastName': 'Li', 'Affiliation': 'Department of Ultrasound, General Hospital of Chinese PLA, Beijing, China.'}, {'ForeName': 'Yingying', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'Department of Ultrasound, General Hospital of Chinese PLA, Beijing, China.'}, {'ForeName': 'Peng', 'Initials': 'P', 'LastName': 'Huang', 'Affiliation': 'Department of Orthopedics, General Hospital of Chinese PLA, No. 28, Fuxing Road, Haidian District, Beijing, 100853, China. harryhp@vip.sina.com.'}]","European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society",['10.1007/s00586-019-05980-9'] 3226,31327563,"Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.","BACKGROUND Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. METHODS We did a randomised, double-blind, placebo-controlled, non-inferiority trial in eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam). Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled. Patients were given standard blood schizontocidal treatment and randomly assigned (2:2:1) to receive 7 days of supervised primaquine (1·0 mg/kg per day), 14 days of supervised primaquine (0·5 mg/kg per day), or placebo. The primary endpoint was the incidence rate of symptomatic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat population. A margin of 0·07 recurrences per person-year was used to establish non-inferiority of the 7-day regimen compared with the 14-day regimen. This trial is registered at ClinicalTrials.gov (NCT01814683). FINDINGS Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled. The incidence rate of symptomatic recurrent P vivax malaria was 0·18 (95% CI 0·15 to 0·21) recurrences per person-year for 935 patients in the 7-day primaquine group and 0·16 (0·13 to 0·18) for 937 patients in the 14-day primaquine group, a difference of 0·02 (-0·02 to 0·05, p=0·3405). The incidence rate for 464 patients in the placebo group was 0·96 (95% CI 0·83 to 1·08) recurrences per person-year. Potentially drug-related serious adverse events within 42 days of starting treatment were reported in nine (1·0%) of 935 patients in the 7-day group, one (0·1%) of 937 in the 14-day group and none of 464 in the control arm. Four of the serious adverse events were significant haemolysis (three in the 7-day group and one in the 14-day group). INTERPRETATION In patients with normal G6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine. The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. FUNDING UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).",2019,"The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. ","['eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam', 'Plasmodium vivax malaria', 'Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled', 'Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled', '464 patients in the']","['primaquine', 'Primaquine', 'supervised primaquine', 'placebo', 'standard blood schizontocidal treatment']","['incidence rate of symptomatic P vivax parasitaemia', 'incidence rate of symptomatic recurrent P vivax malaria', 'incidence rate']","[{'cui': 'C0086388', 'cui_str': 'Health Care'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0001732', 'cui_str': 'Afghanistan'}, {'cui': 'C0015024', 'cui_str': 'Federal Democratic Republic of Ethiopia'}, {'cui': 'C0021247', 'cui_str': 'East Indies'}, {'cui': 'C0042658', 'cui_str': 'Viet Nam'}, {'cui': 'C0024537', 'cui_str': 'Plasmodium vivax Malaria'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0205307', 'cui_str': 'Normal (qualifier value)'}, {'cui': 'C0017757', 'cui_str': 'Glucose-6-Phosphate Dehydrogenase'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}]","[{'cui': 'C0033126', 'cui_str': 'Primaquine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0005768'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C0024537', 'cui_str': 'Plasmodium vivax Malaria'}]",2336.0,0.525971,"The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. ","[{'ForeName': 'Walter R J', 'Initials': 'WRJ', 'LastName': 'Taylor', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Kamala', 'Initials': 'K', 'LastName': 'Thriemer', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.'}, {'ForeName': 'Lorenz', 'Initials': 'L', 'LastName': 'von Seidlein', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Prayoon', 'Initials': 'P', 'LastName': 'Yuentrakul', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Thanawat', 'Initials': 'T', 'LastName': 'Assawariyathipat', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Ashenafi', 'Initials': 'A', 'LastName': 'Assefa', 'Affiliation': 'Ethiopian Public Health Institute, Addis Ababa, Ethiopia.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Auburn', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.'}, {'ForeName': 'Krisin', 'Initials': 'K', 'LastName': 'Chand', 'Affiliation': 'Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Nguyen Hoang', 'Initials': 'NH', 'LastName': 'Chau', 'Affiliation': 'Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Phaik Yeong', 'Initials': 'PY', 'LastName': 'Cheah', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Le Thanh', 'Initials': 'LT', 'LastName': 'Dong', 'Affiliation': 'Institute of Malariology, Parasitology and Entomology, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Mehul', 'Initials': 'M', 'LastName': 'Dhorda', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Worldwide Antimalarial Resistance Network, Asia Regional Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Tamiru Shibru', 'Initials': 'TS', 'LastName': 'Degaga', 'Affiliation': 'College of Medicine & Health Sciences, Arbaminch University, Arbaminch, Ethiopia.'}, {'ForeName': 'Angela', 'Initials': 'A', 'LastName': 'Devine', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'Lenny L', 'Initials': 'LL', 'LastName': 'Ekawati', 'Affiliation': 'Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Fahmi', 'Initials': 'F', 'LastName': 'Fahmi', 'Affiliation': 'Universitas Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Asrat', 'Initials': 'A', 'LastName': 'Hailu', 'Affiliation': 'College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.'}, {'ForeName': 'Mohammad Anwar', 'Initials': 'MA', 'LastName': 'Hasanzai', 'Affiliation': 'Health Protection and Research Organisation, Kabul, Afghanistan.'}, {'ForeName': 'Tran Tinh', 'Initials': 'TT', 'LastName': 'Hien', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Htee', 'Initials': 'H', 'LastName': 'Khu', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Benedikt', 'Initials': 'B', 'LastName': 'Ley', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.'}, {'ForeName': 'Yoel', 'Initials': 'Y', 'LastName': 'Lubell', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Jutta', 'Initials': 'J', 'LastName': 'Marfurt', 'Affiliation': 'Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia.'}, {'ForeName': 'Hussein', 'Initials': 'H', 'LastName': 'Mohammad', 'Affiliation': 'Ethiopian Public Health Institute, Addis Ababa, Ethiopia.'}, {'ForeName': 'Kerryn A', 'Initials': 'KA', 'LastName': 'Moore', 'Affiliation': 'Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Maternal and Child Health Program, Life Sciences and Public Health, Burnet Institute, Melbourne, VIC, Australia.'}, {'ForeName': 'Mohammad Nader', 'Initials': 'MN', 'LastName': 'Naddim', 'Affiliation': 'Health Protection and Research Organisation, Kabul, Afghanistan.'}, {'ForeName': 'Ayodhia Pitaloka', 'Initials': 'AP', 'LastName': 'Pasaribu', 'Affiliation': 'Universitas Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Syahril', 'Initials': 'S', 'LastName': 'Pasaribu', 'Affiliation': 'Universitas Sumatera Utara, Medan, Indonesia.'}, {'ForeName': 'Cholrawee', 'Initials': 'C', 'LastName': 'Promnarate', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Worldwide Antimalarial Resistance Network, Asia Regional Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Awab Ghulam', 'Initials': 'AG', 'LastName': 'Rahim', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Nangarhar Medical Faculty, Nangarhar University, Ministry of Higher Education, Jalalabad, Afghanistan.'}, {'ForeName': 'Pasathron', 'Initials': 'P', 'LastName': 'Sirithiranont', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Hiwot', 'Initials': 'H', 'LastName': 'Solomon', 'Affiliation': 'Federal Ministry of Health, Addis Ababa, Ethiopia.'}, {'ForeName': 'Herawati', 'Initials': 'H', 'LastName': 'Sudoyo', 'Affiliation': 'Eijkman Institute for Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Inge', 'Initials': 'I', 'LastName': 'Sutanto', 'Affiliation': 'Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.'}, {'ForeName': 'Ngo Viet', 'Initials': 'NV', 'LastName': 'Thanh', 'Affiliation': 'Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam.'}, {'ForeName': 'Nguyen Thi', 'Initials': 'NT', 'LastName': 'Tuyet-Trinh', 'Affiliation': 'Krong-Pa Health Centre, Krong-Pa, Vietnam.'}, {'ForeName': 'Naomi', 'Initials': 'N', 'LastName': 'Waithira', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Adugna', 'Initials': 'A', 'LastName': 'Woyessa', 'Affiliation': 'Ethiopian Public Health Institute, Addis Ababa, Ethiopia.'}, {'ForeName': 'Fazal Yamin', 'Initials': 'FY', 'LastName': 'Yamin', 'Affiliation': 'Health and Social Development Organization, Kabul, Afghanistan.'}, {'ForeName': 'Arjen', 'Initials': 'A', 'LastName': 'Dondorp', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Simpson', 'Affiliation': 'Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.'}, {'ForeName': 'J Kevin', 'Initials': 'JK', 'LastName': 'Baird', 'Affiliation': 'Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Eijkman-Oxford Clinical Research Unit, Eijkman Institute of Molecular Biology, Jakarta, Indonesia.'}, {'ForeName': 'Nicholas J', 'Initials': 'NJ', 'LastName': 'White', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Nicholas P', 'Initials': 'NP', 'LastName': 'Day', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.'}, {'ForeName': 'Ric N', 'Initials': 'RN', 'LastName': 'Price', 'Affiliation': 'Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin University, Darwin, NT, Australia; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: rprice@menzies.edu.au.'}]","Lancet (London, England)",['10.1016/S0140-6736(19)31285-1'] 3227,31182528,"First-Time-in-Human Study and Prediction of Early Bactericidal Activity for GSK3036656, a Potent Leucyl-tRNA Synthetase Inhibitor for Tuberculosis Treatment.","This first-time-in-human (FTIH) study evaluated the safety, tolerability, pharmacokinetics, and food effect of single and repeat oral doses of GSK3036656, a leucyl-tRNA synthetase inhibitor. In part A, GSK3036656 single doses of 5 mg (fed and fasted), 15 mg, and 25 mg and placebo were administered. In part B, repeat doses of 5 and 15 mg and placebo were administered for 14 days once daily. GSK3036656 showed dose-proportional increase following single-dose administration and after dosing for 14 days. The maximum concentration of drug in serum ( C max ) and area under the concentration-time curve from 0 h to the end of the dosing period (AUC 0-τ ) showed accumulation with repeated administration of approximately 2- to 3-fold. Pharmacokinetic parameters were not altered in the presence of food. Unchanged GSK3036656 was the only drug-related component detected in plasma and accounted for approximately 90% of drug-related material in urine. Based on total drug-related material detected in urine, the minimum absorbed doses after single (25 mg) and repeat (15 mg) dosing were 50 and 78%, respectively. Unchanged GSK3036656 represented at least 44% and 71% of the 25- and 15-mg doses, respectively. Clinical trial simulations were performed to guide dose escalation during the FTIH study and to predict the GSK3036656 dose range that produces the highest possible early bactericidal activity (EBA 0-14 ) in the prospective phase II trial, with consideration of the predefined exposure limit. GSK3036656 was well tolerated after single and multiple doses, with no reports of serious adverse events. (This study has been registered at ClinicalTrials.gov under identifier NCT03075410.).",2019,GSK3036656 was well tolerated after single and multiple doses with no reports of serious adverse events.,[],['placebo'],"['safety, tolerability, pharmacokinetics and food effect', 'C max and AUC (0-τ', 'Pharmacokinetic parameters', 'tolerated']",[],"[{'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0016452', 'cui_str': 'Food'}, {'cui': 'C1280500', 'cui_str': 'Effect (qualifier value)'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0449381', 'cui_str': 'Observation parameter'}]",,0.0465602,GSK3036656 was well tolerated after single and multiple doses with no reports of serious adverse events.,"[{'ForeName': 'David', 'Initials': 'D', 'LastName': 'Tenero', 'Affiliation': 'GlaxoSmithKline Clinical Pharmacology Modeling and Simulation, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Geo', 'Initials': 'G', 'LastName': 'Derimanov', 'Affiliation': 'GlaxoSmithKline Clinical Pharmacology and Experimental Medicine, Collegeville, Pennsylvania, USA.'}, {'ForeName': 'Alex', 'Initials': 'A', 'LastName': 'Carlton', 'Affiliation': 'GlaxoSmithKline Biostatistics, Stockley Park, London, United Kingdom.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Tonkyn', 'Affiliation': 'GlaxoSmithKline Global Sciences and Delivery, Stevenage, Hertfordshire, United Kingdom.'}, {'ForeName': 'Matt', 'Initials': 'M', 'LastName': 'Davies', 'Affiliation': 'GlaxoSmithKline Safety and Medical Governance, Stockley Park, London, United Kingdom.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Cozens', 'Affiliation': 'GlaxoSmithKline, Translation Project Specialist Team, Ware, Hertfordshire, United Kingdom.'}, {'ForeName': 'Stephanie', 'Initials': 'S', 'LastName': 'Gresham', 'Affiliation': 'GlaxoSmithKline, Mechanistic Safety and Disposition, Ware, Hertfordshire, United Kingdom.'}, {'ForeName': 'Alison', 'Initials': 'A', 'LastName': 'Gaudion', 'Affiliation': 'Hammersmith Medicines Research, London, United Kingdom.'}, {'ForeName': 'Adeep', 'Initials': 'A', 'LastName': 'Puri', 'Affiliation': 'Hammersmith Medicines Research, London, United Kingdom.'}, {'ForeName': 'Morris', 'Initials': 'M', 'LastName': 'Muliaditan', 'Affiliation': 'GlaxoSmithKline DMPK Modelling, Stevenage, Hertfordshire, United Kingdom.'}, {'ForeName': 'Joaquin', 'Initials': 'J', 'LastName': 'Rullas-Trincado', 'Affiliation': 'GlaxoSmithKline Global Health, TBDPU, Tres Cantos, Madrid, Spain.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Mendoza-Losana', 'Affiliation': 'GlaxoSmithKline Global Health, TBDPU, Tres Cantos, Madrid, Spain.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Skingsley', 'Affiliation': 'GlaxoSmithKline Global Health Clinical Drug Development, Stockley Park, London, United Kingdom.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Barros-Aguirre', 'Affiliation': 'GlaxoSmithKline Global Health, TBDPU, Tres Cantos, Madrid, Spain david.a.barros@gsk.com.'}]",Antimicrobial agents and chemotherapy,['10.1128/AAC.00240-19'] 3228,31195195,Is women's empowerment a pathway to improving child nutrition outcomes in a nutrition-sensitive agriculture program?: Evidence from a randomized controlled trial in Burkina Faso.,"Nutrition-sensitive programs in low- and middle-income countries often aim to improve child nutrition outcomes in part by empowering women. Although previous studies have found cross-sectional associations linking women's empowerment and child nutritional status, there is limited empirical evidence supporting the hypothesis that empowering women as part of an intervention will, in turn, improve child nutritional outcomes. We tested this hypothesis using two waves of data from a cluster-randomized controlled trial of a nutrition-sensitive agricultural program in Burkina Faso. With structural equation models, we examined whether four domains of women's empowerment-purchasing decisions, healthcare decisions, family planning decisions, and spousal communication-mediated the program's impact on reducing wasting and increasing hemoglobin among children who were three to 12 months old at the start of the two-year program. We found that improvements in women's empowerment in the domains of spousal communication, purchasing decisions, healthcare decisions, and family planning decisions contributed to the program's impact on reducing wasting with the largest share being attributable to spousal communication. Improvements in women's empowerment did not contribute to the increase in hemoglobin. These findings provide the first evidence from a randomized controlled trial that women's empowerment is a pathway by which a nutrition-sensitive program can improve child wasting. Programs that aim to improve child nutritional status should incorporate interventions designed to empower women.",2019,"We found that improvements in women's empowerment in the domains of spousal communication, purchasing decisions, healthcare decisions, and family planning decisions contributed to the program's impact on reducing wasting with the largest share being attributable to spousal communication.","['part by empowering women', 'children who were three to 12 months old at the start of the two-year program']",['nutrition-sensitive agricultural program'],"['child nutrition outcomes', 'hemoglobin']","[{'cui': 'C0562342', 'cui_str': 'Empowered (finding)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1442959', 'cui_str': 'Nutrition, function (observable entity)'}, {'cui': 'C0332324', 'cui_str': 'Sensitive (qualifier value)'}, {'cui': 'C2728259', 'cui_str': 'Program'}]","[{'cui': 'C1720755', 'cui_str': 'Child Nutritional Physiology Phenomena'}, {'cui': 'C0019046', 'cui_str': 'Hemoglobin'}]",,0.0435775,"We found that improvements in women's empowerment in the domains of spousal communication, purchasing decisions, healthcare decisions, and family planning decisions contributed to the program's impact on reducing wasting with the largest share being attributable to spousal communication.","[{'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Heckert', 'Affiliation': 'Poverty, Health, and Nutrition Division, International Food Policy Research Institute, 1201 I Street, NW, Washington, DC, 20005, USA. Electronic address: J.Heckert@cgiar.org.'}, {'ForeName': 'Deanna K', 'Initials': 'DK', 'LastName': 'Olney', 'Affiliation': 'Poverty, Health, and Nutrition Division, International Food Policy Research Institute, 1201 I Street, NW, Washington, DC, 20005, USA. Electronic address: D.Olney@cgiar.org.'}, {'ForeName': 'Marie T', 'Initials': 'MT', 'LastName': 'Ruel', 'Affiliation': 'Poverty, Health, and Nutrition Division, International Food Policy Research Institute, 1201 I Street, NW, Washington, DC, 20005, USA. Electronic address: M.Ruel@cgiar.org.'}]",Social science & medicine (1982),['10.1016/j.socscimed.2019.05.016'] 3229,31078564,Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups.,"BACKGROUND In response to the opioid overdose epidemic, scalable interventions that instruct at-risk populations how to prevent and respond to overdose scenarios are needed. METHOD The following groups of at-risk individuals were recruited online: (1) Acute Pain patients with an opioid prescription, (2) Chronic Pain patients with an opioid prescription, and (3) persons without pain who use Illicit Opioids. Participants were tested on their opioid overdose knowledge using the Brief Opioid Overdose Knowledge (BOOK) questionnaire and randomized to one of two web-based interventions that contained 25 educational content slides. One intervention consisted of embedded questions with corrective feedback (Presentation + Mastery, n = 58), the other did not (Presentation, n = 61). Participants completed the BOOK again at the end of the intervention and 30 days later. Overdose risk behaviors were assessed at baseline and 30-days. RESULTS Relative to baseline, both Presentation and Presentation + Mastery interventions increased total BOOK scores immediately and 30 days later. There was a significant effect of Group on BOOK Knowledge, whereby those with Acute Pain had lower scores across time, regardless of intervention, relative to those with Chronic Pain and Illicit Opioid Use. Compared to baseline, all three groups reported fewer instances of using opioids alone or concurrently with alcohol at the 30-day follow-up. CONCLUSIONS A web-based intervention increased opioid overdose knowledge and decreased overdose risk behavior immediately and at a one-month follow-up, suggesting that this brief, practical, and scalable program could have utility in several populations who are at-risk of opioid overdose.",2019,"There was a significant effect of Group on BOOK Knowledge, whereby those with Acute Pain had lower scores across time, regardless of intervention, relative to those with Chronic Pain and Illicit Opioid Use.","['three unique risk groups', 'Participants were tested on their opioid overdose knowledge using the Brief Opioid Overdose Knowledge (BOOK) questionnaire and randomized to one of two web-based interventions that contained 25 educational content slides', 'groups of at-risk individuals were recruited online', '1) Acute Pain patients with an opioid prescription, (2) Chronic Pain patients with an opioid prescription, and (3) persons without pain who use Illicit Opioids']",[],"['opioid overdose knowledge and decreased overdose risk behavior', 'Presentation and Presentation + Mastery', 'total BOOK scores', 'Overdose risk behaviors']","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0029944', 'cui_str': 'Drug Overdose'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}, {'cui': 'C0332246', 'cui_str': 'Sliding (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0184567', 'cui_str': 'Acute Pain'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0033080', 'cui_str': 'Prescriptions'}, {'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332266', 'cui_str': 'Illicit (qualifier value)'}]",[],"[{'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0029944', 'cui_str': 'Drug Overdose'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0547047', 'cui_str': 'Decrease (qualifier value)'}, {'cui': 'C0086931', 'cui_str': 'Risk Behavior'}, {'cui': 'C0449450', 'cui_str': 'Presentation (attribute)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0006002', 'cui_str': 'Books'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",2.0,0.0267,"There was a significant effect of Group on BOOK Knowledge, whereby those with Acute Pain had lower scores across time, regardless of intervention, relative to those with Chronic Pain and Illicit Opioid Use.","[{'ForeName': 'Cecilia L', 'Initials': 'CL', 'LastName': 'Bergeria', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.'}, {'ForeName': 'Andrew S', 'Initials': 'AS', 'LastName': 'Huhn', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.'}, {'ForeName': 'Kelly E', 'Initials': 'KE', 'LastName': 'Dunn', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Electronic address: kdunn9@jhmi.edu.'}]",Preventive medicine,['10.1016/j.ypmed.2019.05.006'] 3230,30670877,CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.,"PURPOSE CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. METHODS Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS ® measures. RESULTS On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540). CONCLUSION These data support the potential benefits of CYP2D6-guided pain management.",2019,"This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. ",['Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n\u2009=\u2009235) or'],"['tramadol/codeine', 'tramadol or codeine', 'tramadol, with intermediate and poor metabolizers (IMs and PMs', 'usual care', 'CYP2D6-guided opioid prescribing', 'CYP2D6-guided opioid therapy']","['Pain', 'composite pain intensity', 'composite pain intensity (composite of current pain and worst and average pain', 'pain control in CYP2D6 intermediate and poor metabolizers']","[{'cui': 'C0150055', 'cui_str': 'Chronic pain (finding)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0205453', 'cui_str': '7'}, {'cui': 'C0442592', 'cui_str': 'Clinic (environment)'}, {'cui': 'C0057223', 'cui_str': 'CYP2D6'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}]","[{'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0009214', 'cui_str': 'Codeine'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0033046', 'cui_str': 'PMS - Premenstrual syndrome'}, {'cui': 'C0057223', 'cui_str': 'CYP2D6'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1457868', 'cui_str': 'Worsened'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C0057223', 'cui_str': 'CYP2D6'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}]",,0.0524809,"This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. ","[{'ForeName': 'D Max', 'Initials': 'DM', 'LastName': 'Smith', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Kristin W', 'Initials': 'KW', 'LastName': 'Weitzel', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Amanda R', 'Initials': 'AR', 'LastName': 'Elsey', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Taimour', 'Initials': 'T', 'LastName': 'Langaee', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Yan', 'Initials': 'Y', 'LastName': 'Gong', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Dyson T', 'Initials': 'DT', 'LastName': 'Wake', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Benjamin Q', 'Initials': 'BQ', 'LastName': 'Duong', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Melanie', 'Initials': 'M', 'LastName': 'Hagen', 'Affiliation': 'Division of General Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Harle', 'Affiliation': 'Department of Health Policy and Management, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Mercado', 'Affiliation': 'Department of Community Health and Family Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Ying', 'Initials': 'Y', 'LastName': 'Nagoshi', 'Affiliation': 'Division of General Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Kimberly', 'Initials': 'K', 'LastName': 'Newsom', 'Affiliation': 'University of Florida Health Pathology Laboratories, Gainesville, FL, USA.'}, {'ForeName': 'Ashleigh', 'Initials': 'A', 'LastName': 'Wright', 'Affiliation': 'Division of General Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Eric I', 'Initials': 'EI', 'LastName': 'Rosenberg', 'Affiliation': 'Division of General Internal Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Petr', 'Initials': 'P', 'LastName': 'Starostik', 'Affiliation': 'University of Florida Health Pathology Laboratories, Gainesville, FL, USA.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Clare-Salzler', 'Affiliation': 'University of Florida Health Pathology Laboratories, Gainesville, FL, USA.'}, {'ForeName': 'Siegfried O', 'Initials': 'SO', 'LastName': 'Schmidt', 'Affiliation': 'Department of Community Health and Family Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Roger B', 'Initials': 'RB', 'LastName': 'Fillingim', 'Affiliation': 'Clinical and Translational Science Institute, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Julie A', 'Initials': 'JA', 'LastName': 'Johnson', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.'}, {'ForeName': 'Larisa H', 'Initials': 'LH', 'LastName': 'Cavallari', 'Affiliation': 'Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA. lcavallari@cop.ufl.edu.'}]",Genetics in medicine : official journal of the American College of Medical Genetics,['10.1038/s41436-018-0431-8'] 3231,31601571,Rojiroti microfinance and child nutrition: a cluster randomised trial.,"OBJECTIVE To determine whether Rojiroti microfinance, for poor Indian women, improves child nutrition. DESIGN Cluster randomised trial. SETTING Tolas (village communities) in Bihar State. PARTICIPANTS Women and children under 5 years. INTERVENTIONS With Rojiroti microfinance, women form self-help groups and save their money to provide loans to group members. After 6 months, they receive larger external loans. Tolas were randomised to receive Rojiroti immediately or after 18 months. OUTCOME MEASURES The primary analysis compared the mean weight for height Z score (WHZ) of children under 5 years in the intervention versus control tolas who attended for weight and height measurement 18 months after randomisation. Secondary outcomes were weight for age Z score (WAZ), height for age Z score, mid-upper arm circumference (MUAC), wasting, underweight and stunting. RESULTS We randomised 28 tolas to each arm and collected data from 2469 children (1560 mothers) at baseline and 2064 children (1326 mothers) at follow-up. WHZ was calculated for 1718 children at baseline and 1377 (674 intervention and 703 control) at follow-up. At 18 months, mean WHZ was significantly higher for intervention (-1.02) versus controls (-1.37; regression coefficient adjusted for clustering β = 0.38, 95% CI 0.16 to 0.61, p=0.001). Significantly fewer children were wasted in the intervention group (122, 18%) versus control (200, 29%; OR=0.46, 95% CI 0.28 to 0.74, p=0.002). Mean WAZ was better in the intervention group (-2.13 vs -2.37; β = 0.27, 95% CI 0.11 to 0.43, p=0.001) as was MUAC (13.6 cm vs 13.4 cm; β = 0.22, 95% CI 0.03 to 0.40, p=0.02). In an analysis adjusting for baseline nutritional measures (259 intervention children and 300 control), only WAZ and % underweight showed significant differences in favour of the intervention. CONCLUSION In marginalised communities in rural India, child nutrition was better in those who received Rojiroti microfinance, compared with controls. TRIAL REGISTRATION NUMBER NCT01845545.",2020,"In marginalised communities in rural India, child nutrition was better in those who received Rojiroti microfinance, compared with controls. ","['Tolas', 'village communities) in Bihar State', 'Rojiroti microfinance and child nutrition', 'Women and children under 5 years', '1718 children at baseline and 1377 (674 intervention and 703 control) at follow-up', '2469 children (1560 mothers) at baseline and 2064 children (1326 mothers) at follow-up', 'poor Indian women, improves child nutrition']","['WHZ', 'Rojiroti microfinance']","['weight for age Z score (WAZ), height for age Z score, mid-upper arm circumference (MUAC), wasting, underweight and stunting', 'mean WHZ', 'mean weight for height Z score (WHZ', 'Mean WAZ']","[{'cui': 'C0562518', 'cui_str': 'Village environment (environment)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C1720755', 'cui_str': 'Child Nutritional Physiology Phenomena'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C1524069', 'cui_str': 'Indian (racial group)'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",[],"[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0562351', 'cui_str': 'Mid upper arm circumference (observable entity)'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C0018273', 'cui_str': 'Stunting'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0424670', 'cui_str': 'Weight for height (observable entity)'}]",1326.0,0.187303,"In marginalised communities in rural India, child nutrition was better in those who received Rojiroti microfinance, compared with controls. ","[{'ForeName': 'Shalini', 'Initials': 'S', 'LastName': 'Ojha', 'Affiliation': 'Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Lisa', 'Initials': 'L', 'LastName': 'Szatkowski', 'Affiliation': 'Division of Epidemiology & Public Health, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Ranjeet', 'Initials': 'R', 'LastName': 'Sinha', 'Affiliation': 'Department of Community Medicine, Patna Medical College, Patna, Bihar, India.'}, {'ForeName': 'Gil', 'Initials': 'G', 'LastName': 'Yaron', 'Affiliation': 'GY Associates Ltd and Trustee, Harpenden, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fogarty', 'Affiliation': 'Division of Epidemiology & Public Health, University of Nottingham, Nottingham, UK.'}, {'ForeName': 'Stephen John', 'Initials': 'SJ', 'LastName': 'Allen', 'Affiliation': 'Department of Child Health, The Liverpool School of Tropical Medicine, Liverpool, UK.'}, {'ForeName': 'Sunil', 'Initials': 'S', 'LastName': 'Choudhary', 'Affiliation': 'Centre for Promoting Sustainable Livelihood (CPSL), Patna, Bihar, India.'}, {'ForeName': 'Alan Robert', 'Initials': 'AR', 'LastName': 'Smyth', 'Affiliation': 'Division of Child Health, Obstetrics & Gynaecology, Nottingham University, Nottingham, UK alan.smyth@nottingham.ac.uk.'}]",Archives of disease in childhood,['10.1136/archdischild-2018-316471'] 3232,31623675,Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes.,"BACKGROUND Patients with haematological malignancies are often vitamin C deficient, and vitamin C is essential for the TET-induced conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), the first step in active DNA demethylation. Here, we investigate whether oral vitamin C supplementation can correct vitamin C deficiency and affect the 5hmC/5mC ratio in patients with myeloid cancers treated with DNA methyltransferase inhibitors (DNMTis). RESULTS We conducted a randomized, double-blinded, placebo-controlled pilot trial (NCT02877277) in Danish patients with myeloid cancers performed during 3 cycles of DNMTi-treatment (5-azacytidine, 100 mg/m 2 /d for 5 days in 28-day cycles) supplemented by oral dose of 500 mg vitamin C (n = 10) or placebo (n = 10) daily during the last 2 cycles. Fourteen patients (70%) were deficient in plasma vitamin C (< 23 μM) and four of the remaining six patients were taking vitamin supplements at inclusion. Global DNA methylation was significantly higher in patients with severe vitamin C deficiency (< 11.4 μM; 4.997 vs 4.656% 5mC relative to deoxyguanosine, 95% CI [0.126, 0.556], P = 0.004). Oral supplementation restored plasma vitamin C levels to the normal range in all patients in the vitamin C arm (mean increase 34.85 ± 7.94 μM, P = 0.0004). We show for the first time that global 5hmC/5mC levels were significantly increased in mononuclear myeloid cells from patients receiving oral vitamin C compared to placebo (0.037% vs - 0.029%, 95% CI [- 0.129, - 0.003], P = 0.041). CONCLUSIONS Normalization of plasma vitamin C by oral supplementation leads to an increase in the 5hmC/5mC ratio compared to placebo-treated patients and may enhance the biological effects of DNMTis. The clinical efficacy of oral vitamin C supplementation to DNMTis should be investigated in a large randomized, placebo-controlled clinical trial. TRIAL REGISTRATION ClinicalTrials.gov, NCT02877277 . Registered on 9 August 2016, retrospectively registered.",2019,"Global DNA methylation was significantly higher in patients with severe vitamin C deficiency (< 11.4 μM; 4.997 vs 4.656% 5mC relative to deoxyguanosine, 95% CI [0.126, 0.556], P = 0.004).","['Patients with\xa0haematological malignancies', 'patients with myeloid cancer on azacitidine treatment', 'patients with\xa0myeloid cancers treated with DNA methyltransferase inhibitors (DNMTis', 'Danish patients with\xa0myeloid cancers']","['Oral vitamin C supplementation', 'vitamin C', 'placebo', 'oral vitamin C supplementation', 'vitamin supplements', 'DNMTi-treatment (5-azacytidine, 100', 'oral vitamin C']","['5hmC/5mC ratio', 'Global DNA methylation', 'plasma vitamin C', 'plasma vitamin C levels', 'global 5hmC/5mC levels', 'mononuclear myeloid cells']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0376545', 'cui_str': 'Hematological Neoplasms'}, {'cui': 'C0439677', 'cui_str': 'Myeloid (qualifier value)'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0004475', 'cui_str': 'Azacitidine'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}, {'cui': 'C0012854', 'cui_str': 'Deoxyribonucleic Acid'}, {'cui': 'C4522039', 'cui_str': 'Methyltransferase inhibitor'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C4524018', 'cui_str': 'Vitamin C supplementation'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0681579', 'cui_str': 'Vitamin supplement'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0004475', 'cui_str': 'Azacitidine'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}]","[{'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0376452', 'cui_str': 'DNA Methylation'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0003968', 'cui_str': 'Ascorbic Acid'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0887899', 'cui_str': 'Myeloid Cells'}]",,0.621756,"Global DNA methylation was significantly higher in patients with severe vitamin C deficiency (< 11.4 μM; 4.997 vs 4.656% 5mC relative to deoxyguanosine, 95% CI [0.126, 0.556], P = 0.004).","[{'ForeName': 'Linn', 'Initials': 'L', 'LastName': 'Gillberg', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen Biocenter, Building 2, 3rd floor, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark.'}, {'ForeName': 'Andreas D', 'Initials': 'AD', 'LastName': 'Ørskov', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen Biocenter, Building 2, 3rd floor, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark.'}, {'ForeName': 'Ammar', 'Initials': 'A', 'LastName': 'Nasif', 'Affiliation': 'MRC London Institute of Medical Sciences (LMS), Imperial College, London, UK.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Ohtani', 'Affiliation': 'Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'ForeName': 'Zachary', 'Initials': 'Z', 'LastName': 'Madaj', 'Affiliation': 'Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'ForeName': 'Jakob W', 'Initials': 'JW', 'LastName': 'Hansen', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen Biocenter, Building 2, 3rd floor, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Rapin', 'Affiliation': 'Biotech Research and Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Johanne B', 'Initials': 'JB', 'LastName': 'Mogensen', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen Biocenter, Building 2, 3rd floor, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark.'}, {'ForeName': 'Minmin', 'Initials': 'M', 'LastName': 'Liu', 'Affiliation': 'Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'ForeName': 'Inge H', 'Initials': 'IH', 'LastName': 'Dufva', 'Affiliation': 'Department of Haematology, Herlev University Hospital, Copenhagen, Denmark.'}, {'ForeName': 'Jens', 'Initials': 'J', 'LastName': 'Lykkesfeldt', 'Affiliation': 'Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark.'}, {'ForeName': 'Petra', 'Initials': 'P', 'LastName': 'Hajkova', 'Affiliation': 'MRC London Institute of Medical Sciences (LMS), Imperial College, London, UK.'}, {'ForeName': 'Peter A', 'Initials': 'PA', 'LastName': 'Jones', 'Affiliation': 'Van Andel Research Institute, Grand Rapids, MI, USA.'}, {'ForeName': 'Kirsten', 'Initials': 'K', 'LastName': 'Grønbæk', 'Affiliation': 'Department of Haematology, Rigshospitalet, Copenhagen Biocenter, Building 2, 3rd floor, Ole Maaløes Vej 5, DK-2200, Copenhagen, Denmark. kirsten.groenbaek@regionh.dk.'}]",Clinical epigenetics,['10.1186/s13148-019-0739-5'] 3233,31164489,"Evolving IQOS packaging designs change perceptions of product appeal, uniqueness, quality and safety: a randomised experiment, 2018, USA.","BACKGROUND Globally, the tobacco industry is promoting heated tobacco products. These products may represent a strategy to promote dual use of tobacco products. One product, IQOS from Philip Morris International, is being proposed in the USA for marketing as a less harmful product. The visual design of tobacco products can influence consumers by implying product characteristics. Thus, we sought to test the impact of IQOS packaging designs on cognitive, affective and behavioural intention responses. METHODS From existing IQOS packages used globally, we developed three IQOS packages that decreasingly linked the product to the Marlboro brand. In September to October 2018, we assigned participants randomly to one package in an online experiment. All participants (n=954) were US adults reporting current smoking and no colour blindness. The experiment used quota sampling to ensure diversity by gender, sexual orientation, race, ethnicity and education. Measures were informed by the Context of Consumption Framework. To assess differences in ratings, we conducted non-parametric Kruskal-Wallis tests with post hoc comparisons using Dunn's test. RESULTS We found significant differences in cognitive indicators including appeal ( H =6.87, p=0.03), uniqueness ( H =15.68, p<0.01), brand equity-quality ( H =122.35, p<0.01) and perceived safety compared with other tobacco products ( H =14.27, p<0.01). Participants rated packages similarly on affective and behavioural intention measures. All were rated low for talking to others about the product and high for interest in trying with a coupon. CONCLUSION Linking or separating IQOS products with a well-established cigarette brand changes how adult smokers respond to the product. Regulators should consider the visual design of packaging.",2019,"We found significant differences in cognitive indicators including appeal ( H =6.87, p=0.03), uniqueness ( H =15.68, p<0.01), brand equity-quality ( H =122.35, p<0.01) and perceived safety compared with other tobacco products ( H =14.27, p<0.01).",['All participants (n=954) were US adults reporting current smoking and no colour blindness'],[],"['quality and safety', 'cognitive, affective and behavioural intention responses', 'brand equity-quality']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0242225', 'cui_str': 'Color blindness (disorder)'}]",[],"[{'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0162425', 'cui_str': 'Intention'}]",954.0,0.0580928,"We found significant differences in cognitive indicators including appeal ( H =6.87, p=0.03), uniqueness ( H =15.68, p<0.01), brand equity-quality ( H =122.35, p<0.01) and perceived safety compared with other tobacco products ( H =14.27, p<0.01).","[{'ForeName': 'Joseph G L', 'Initials': 'JGL', 'LastName': 'Lee', 'Affiliation': 'Department of Health Education and Promotion, College of Health and Human Performance, East Carolina University, Greenville, North Carolina, USA leejose14@ecu.edu.'}, {'ForeName': 'Tiffany M', 'Initials': 'TM', 'LastName': 'Blanchflower', 'Affiliation': 'Department of Interior Design and Merchandising, College of Health and Human Performance, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Kevin F', 'Initials': 'KF', 'LastName': ""O'Brien"", 'Affiliation': 'Department of Biostatistics, College of Allied Health Sciences, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Paige E', 'Initials': 'PE', 'LastName': 'Averett', 'Affiliation': 'School of Social Work, College of Health and Human Performance, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Leslie E', 'Initials': 'LE', 'LastName': 'Cofie', 'Affiliation': 'Department of Health Education and Promotion, College of Health and Human Performance, East Carolina University, Greenville, North Carolina, USA.'}, {'ForeName': 'Kyle R', 'Initials': 'KR', 'LastName': 'Gregory', 'Affiliation': 'Department of Health Education and Promotion, College of Health and Human Performance, East Carolina University, Greenville, North Carolina, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054910'] 3234,30885799,Design and recruitment of the randomized order safety trial evaluating resident-physician schedules (ROSTERS) study.,"INTRODUCTION While the Accreditation Council for Graduate Medical Education limited first year resident-physicians to 16 consecutive work hours from 2011 to 2017, resident-physicians in their second year or higher were permitted to work up to 28 h consecutively. This paper describes the Randomized Order Safety Trial Evaluating Resident-physician Schedules (ROSTERS) study, a clustered-randomized crossover clinical trial designed to evaluate the effectiveness of eliminating traditional shifts of 24 h or longer for second year or higher resident-physicians in pediatric intensive care units (PICUs). METHODS ROSTERS was a multi-center non-blinded trial in 6 PICUs at US academic medical centers. The primary aim was to compare patient safety between the extended duration work roster (EDWR), which included shifts ≥24 h, and a rapidly cycling work roster (RCWR), where shifts were limited to a maximum of 16 h. Information on potential medical errors was gathered and used for classification by centrally trained physician reviewers who were blinded to the study arm. Secondary aims were to assess the relationship of the study arm to resident-physician sleep duration, work hours and neurobehavioral performance. RESULTS The study involved 6577 patients with a total of 38,821 patient days (n = 18,749 EDWR, n = 20,072 RCWR). There were 413 resident-physician rotations included in the study (n = 203 EDWR, n = 210 RCWR). Resident-physician questionnaire data were over 95% complete. CONCLUSIONS Results from data collected in the ROSTERS study will be evaluated for the impact of resident-physician schedule roster on patient safety outcomes in PICUs, and will allow for examination of a number of secondary outcome measures. ClinicalTrials.gov Identifier: NCT02134847.",2019,"The primary aim was to compare patient safety between the extended duration work roster (EDWR), which included shifts ≥24 h, and a rapidly cycling work roster (RCWR), where shifts were limited to a maximum of 16 h. Information on potential medical errors was gathered and used for classification by centrally trained physician reviewers who were blinded to the study arm.","['pediatric intensive care units (PICUs', 'There were 413 resident-physician rotations included in the study (n\u202f=\u202f203 EDWR, n\u202f=\u202f210 RCWR', '6577 patients with a total of 38,821 patient days (n\u202f=\u202f18,749 EDWR, n\u202f=\u202f20,072 RCWR', 'ROSTERS was a multi-center non-blinded trial in 6 PICUs at US academic medical centers']","['traditional shifts of 24\u202fh or longer for second year or higher resident-physicians', 'extended duration work roster (EDWR), which included shifts ≥24\u202fh, and a rapidly cycling work roster (RCWR']","['patient safety', 'resident-physician sleep duration, work hours and neurobehavioral performance', 'Resident-physician questionnaire data']","[{'cui': 'C0021710', 'cui_str': 'PICU - Pediatric intensive care unit'}, {'cui': 'C1046445', 'cui_str': 'Picus'}, {'cui': 'C1320928', 'cui_str': 'Resident physician (occupation)'}, {'cui': 'C0035868', 'cui_str': 'Rotation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C4319559', 'cui_str': '210'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1292718', 'cui_str': 'Is a'}, {'cui': 'C3266262', 'cui_str': 'Multi'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0000872', 'cui_str': 'University Medical Centers'}]","[{'cui': 'C0443324', 'cui_str': 'Traditional (qualifier value)'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1320928', 'cui_str': 'Resident physician (occupation)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0456962', 'cui_str': 'Rapidly'}]","[{'cui': 'C1113679'}, {'cui': 'C1320928', 'cui_str': 'Resident physician (occupation)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}]",6577.0,0.144238,"The primary aim was to compare patient safety between the extended duration work roster (EDWR), which included shifts ≥24 h, and a rapidly cycling work roster (RCWR), where shifts were limited to a maximum of 16 h. Information on potential medical errors was gathered and used for classification by centrally trained physician reviewers who were blinded to the study arm.","[{'ForeName': 'Terri', 'Initials': 'T', 'LastName': 'Blackwell', 'Affiliation': 'California Pacific Medical Center Research Institute, San Francisco, CA, USA. Electronic address: tblackwell@sfcc-cpmc.net.'}, {'ForeName': 'Dana R', 'Initials': 'DR', 'LastName': 'Kriesel', 'Affiliation': 'California Pacific Medical Center Research Institute, San Francisco, CA, USA.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Vittinghoff', 'Affiliation': 'University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': 'Conor S', 'Initials': 'CS', 'LastName': ""O'Brien"", 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Sullivan', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Natalie C', 'Initials': 'NC', 'LastName': 'Viyaran', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA.""}, {'ForeName': 'Shadab A', 'Initials': 'SA', 'LastName': 'Rahman', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Steven W', 'Initials': 'SW', 'LastName': 'Lockley', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Laura K', 'Initials': 'LK', 'LastName': 'Barger', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Ann C', 'Initials': 'AC', 'LastName': 'Halbower', 'Affiliation': ""Children's Hospital Colorado Anschutz Medical Campus, Aurora, CO, USA.""}, {'ForeName': 'Sue E', 'Initials': 'SE', 'LastName': 'Poynter', 'Affiliation': ""Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.""}, {'ForeName': 'Kenneth P', 'Initials': 'KP', 'LastName': 'Wright', 'Affiliation': 'Sleep and Chronobiology Laboratory, Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA.'}, {'ForeName': 'Pearl L', 'Initials': 'PL', 'LastName': 'Yu', 'Affiliation': ""University of Virginia Children's Hospital, Charlottesville, VA, USA.""}, {'ForeName': 'Phyllis C', 'Initials': 'PC', 'LastName': 'Zee', 'Affiliation': 'Center for Circadian and Sleep Medicine, Department of Neurology, Northwestern University, Chicago, IL, USA.'}, {'ForeName': 'Christopher P', 'Initials': 'CP', 'LastName': 'Landrigan', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA; Division of General Pediatrics, Department of Medicine, Boston Children's Hospital, Boston, MA, USA.""}, {'ForeName': 'Charles A', 'Initials': 'CA', 'LastName': 'Czeisler', 'Affiliation': ""Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA; Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.""}, {'ForeName': 'Katie L', 'Initials': 'KL', 'LastName': 'Stone', 'Affiliation': 'California Pacific Medical Center Research Institute, San Francisco, CA, USA; University of California, San Francisco, San Francisco, CA, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.005'] 3235,30889096,Safety and feasibility of estrogen receptor-β targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial.,"OBJECTIVE PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-β (ERβ); and may enhance neuron function and estrogenic mechanisms in the brain without having peripheral estrogenic activity. METHODS We conducted an overarching, two-stage, dose-ranging, double-blinded, randomized, placebo-controlled trial of 12 weeks duration comparing 50 and 100 mg/d of phytoSERM with placebo for noncognitively impaired, perimenopausal women aged 45 to 60, with intact uteri and ovaries, with at least one cognitive complaint, and one vasomotor-related symptom. Primary objectives were to assess safety and tolerability of a 50 and 100 mg daily dose; and, secondly, to evaluate potential indicators of efficacy on cognition and vasomotor symptoms over 4 and 12 weeks, and using an embedded, 4-week, 2-period, placebo-controlled crossover trial for a subset of participants. RESULTS Seventy-one women were randomized to treatment; 70 were evaluated at 4 weeks; 12 were entered into the crossover study; 5 did not complete 12 weeks. Reasons for discontinuation were withdrawal of consent (n = 1) and lost to follow-up (n = 4). Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 mg/d treated participants; 85% were mild and none was severe. Vaginal bleeding occurred in 0, placebo; 1, 50 mg; and 3, 100 mg/d participants. CONCLUSIONS The phytoSERM formulation was well tolerated at 50 and 100 mg daily doses. Based on safety outcomes, vaginal bleeding at the 100 mg dose, and vasomotor symptoms and cognitive outcomes at 12 weeks, a daily dose of 50 mg was considered preferable for a phase 2 efficacy trial.",2019,"Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 ","['Seventy-one women were randomized to treatment; 70 were evaluated at 4 weeks; 12 were entered into the crossover study; 5 did not complete 12 weeks', 'menopausal symptoms', 'perimenopausal women aged 45 to 60, with intact uteri and ovaries, with at least one cognitive complaint, and one vasomotor-related symptom']","['estrogen receptor-β targeted phytoSERM formulation', 'phytoSERM with placebo', 'genistein, daidzein, and S-equol', 'placebo']","['Adverse events', 'safety and tolerability', 'Vaginal bleeding', 'safety outcomes, vaginal bleeding', 'cognition and vasomotor symptoms', 'vasomotor symptoms and cognitive outcomes']","[{'cui': 'C0450389', 'cui_str': '71 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0150097', 'cui_str': 'Crossover Trials'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0236075', 'cui_str': 'Menopausal symptom'}, {'cui': 'C3839366', 'cui_str': 'Perimenopausal state (finding)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205266', 'cui_str': 'Intact (qualifier value)'}, {'cui': 'C0042149', 'cui_str': 'Womb'}, {'cui': 'C0029939', 'cui_str': 'Ovary'}, {'cui': 'C0277786', 'cui_str': 'Presenting complaint'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]","[{'cui': 'C0034804', 'cui_str': 'Estrogen Receptors'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0061202', 'cui_str': 'Genistein'}, {'cui': 'C0057090', 'cui_str': 'diadzein'}, {'cui': 'C3892880', 'cui_str': '(R) - EQUOL'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C2979982', 'cui_str': 'Vaginal Bleeding'}, {'cui': 'C0009240', 'cui_str': 'Cognitive Function'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",71.0,0.611442,"Adverse events occurred in 16.7% (n = 4) placebo, 39.1% (n = 9) 50 mg/d, and 29.2% (n = 7) 100 ","[{'ForeName': 'Lon S', 'Initials': 'LS', 'LastName': 'Schneider', 'Affiliation': 'Keck School of Medicine of the University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Gerson', 'Initials': 'G', 'LastName': 'Hernandez', 'Affiliation': 'University of Arizona, Tucson, AZ.'}, {'ForeName': 'Liqin', 'Initials': 'L', 'LastName': 'Zhao', 'Affiliation': 'School of Pharmacy, University of Kansas, Lawrence, KS.'}, {'ForeName': 'Adrian A', 'Initials': 'AA', 'LastName': 'Franke', 'Affiliation': 'University of Hawaii Cancer Center, Honolulu, HI.'}, {'ForeName': 'Yu-Ling', 'Initials': 'YL', 'LastName': 'Chen', 'Affiliation': 'Keck School of Medicine of the University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Sonia', 'Initials': 'S', 'LastName': 'Pawluczyk', 'Affiliation': 'Keck School of Medicine of the University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Wendy J', 'Initials': 'WJ', 'LastName': 'Mack', 'Affiliation': 'Keck School of Medicine of the University of Southern California, Los Angeles, CA.'}, {'ForeName': 'Roberta D', 'Initials': 'RD', 'LastName': 'Brinton', 'Affiliation': 'University of Arizona, Tucson, AZ.'}]","Menopause (New York, N.Y.)",['10.1097/GME.0000000000001325'] 3236,30578922,Depressive Symptoms Among Urban Adolescents with Asthma: A Focus for Providers.,"OBJECTIVES Asthma is the most common chronic disease of childhood in the United States, disproportionately affecting urban, poor, and minority children. Adolescents are at high risk for poor asthma outcomes and for depressive symptoms. The purpose of this study is to investigate associations between depressive symptoms and asthma-related clinical and functional outcomes among urban teens. METHODS We used baseline data from a 3-arm randomized trial, School-Based Asthma Care for Teens, in Rochester, NY. We used the Center for Epidemiological Studies Depression Scale with a standard cutoff score of 16 to identify subjects at risk for clinical depression. We used structured in-home surveys and validated scales to assess clinical and functional outcomes and conducted bivariate and multivariate analyses to evaluate differences between groups. RESULTS We identified 277 eligible teens (ages 12 to 16, 80% participation, 54% black, 34% Hispanic, 45% female, 84% on Medicaid). Overall, 28% reported depressive symptoms. Teens with depressive symptoms experienced greater asthma symptom severity and more acute health care utilization for asthma (all P < .001); however, there was no difference in preventive care use between groups. Teens with depressive symptoms also reported lower asthma-related quality of life (P < .001), less sleep (P < .001), and more limitation in mild (adjusted odds ratio [aOR], 2.60; 95% confidence interval [CI], 1.34-5.02) and moderate (aOR, 2.56; 95% CI, 1.41-4.61) activity and in gym (aOR, 2.33; 95% CI, 1.30-4.17). CONCLUSIONS Depressive symptoms are prevalent among urban teens with asthma and are associated with worse asthma-related clinical outcomes, functional limitation, and quality of life. Providers should consider depression as a significant comorbidity that may impact multiple aspects of daily life for this population.",2019,"Teens with depressive symptoms experienced greater asthma symptom severity and more acute health care utilization for asthma (all P < .001); however, there was no difference in preventive care use between groups.","['School-Based Asthma Care for Teens, in Rochester, NY', 'urban teens with asthma', 'Urban Adolescents with Asthma', '277 eligible teens (ages 12 to 16, 80% participation, 54% black, 34% Hispanic, 45% female, 84% on Medicaid', 'urban teens']",[],"['Depressive symptoms', 'depressive symptoms', 'Depressive Symptoms', 'asthma-related quality of life', 'sleep', 'asthma symptom severity']","[{'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C1318955', 'cui_str': 'Asthma management'}, {'cui': 'C1521910', 'cui_str': 'Teens'}, {'cui': 'C0442529', 'cui_str': 'Urban environment (environment)'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439541', 'cui_str': 'Black color (qualifier value)'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0025071', 'cui_str': 'Medicaid'}]",[],"[{'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0004096', 'cui_str': 'Asthma, Bronchial'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C1319166', 'cui_str': 'Symptom severity (finding)'}]",,0.0805477,"Teens with depressive symptoms experienced greater asthma symptom severity and more acute health care utilization for asthma (all P < .001); however, there was no difference in preventive care use between groups.","[{'ForeName': 'Michelle', 'Initials': 'M', 'LastName': 'Shankar', 'Affiliation': 'Department of Pediatrics, Division of General Pediatrics (M Shankar, M Fagnano, SW Blaakman, and JS Halterman). Electronic address: michelle_shankar@urmc.rochester.edu.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Fagnano', 'Affiliation': 'Department of Pediatrics, Division of General Pediatrics (M Shankar, M Fagnano, SW Blaakman, and JS Halterman).'}, {'ForeName': 'Susan W', 'Initials': 'SW', 'LastName': 'Blaakman', 'Affiliation': 'Department of Pediatrics, Division of General Pediatrics (M Shankar, M Fagnano, SW Blaakman, and JS Halterman); School of Nursing (SW Blaakman and H Rhee), University of Rochester, Rochester, NY.'}, {'ForeName': 'Hyekyun', 'Initials': 'H', 'LastName': 'Rhee', 'Affiliation': 'School of Nursing (SW Blaakman and H Rhee), University of Rochester, Rochester, NY.'}, {'ForeName': 'Jill S', 'Initials': 'JS', 'LastName': 'Halterman', 'Affiliation': 'Department of Pediatrics, Division of General Pediatrics (M Shankar, M Fagnano, SW Blaakman, and JS Halterman).'}]",Academic pediatrics,['10.1016/j.acap.2018.12.004'] 3237,32012056,An Interactive Web-Based Lethal Means Safety Decision Aid for Suicidal Adults (Lock to Live): Pilot Randomized Controlled Trial.,"BACKGROUND Counseling to reduce access to lethal means such as firearms and medications is recommended for suicidal adults but does not routinely occur. We developed the Web-based Lock to Live (L2L) decision aid to help suicidal adults and their families choose options for safer home storage. OBJECTIVE This study aimed to test the feasibility and acceptability of L2L among suicidal adults in emergency departments (EDs). METHODS At 4 EDs, we enrolled participants (English-speaking, community-dwelling, suicidal adults) in a pilot randomized controlled trial. Participants were randomized in a 13:7 ratio to L2L or control (website with general suicide prevention information) groups and received a 1-week follow-up telephone call. RESULTS Baseline characteristics were similar between the intervention (n=33) and control (n=16) groups. At baseline, many participants reported having access to firearms (33/49, 67%), medications (46/49, 94%), or both (29/49, 59%). Participants viewed L2L for a median of 6 min (IQR 4-10 min). L2L also had very high acceptability; almost all participants reported that they would recommend it to someone in the same situation, that the options felt realistic, and that L2L was respectful of values about firearms. In an exploratory analysis of this pilot trial, more participants in the L2L group reported reduced firearm access at follow-up, although the differences were not statistically significant. CONCLUSIONS The L2L decision aid appears feasible and acceptable for use among adults with suicide risk and may be a useful adjunct to lethal means counseling and other suicide prevention interventions. Future large-scale studies are needed to determine the effect on home access to lethal means. TRIAL REGISTRATION ClinicalTrials.gov NCT03478501; https://clinicaltrials.gov/ct2/show/NCT03478501.",2020,The L2L decision aid appears feasible and acceptable for use among adults with suicide risk and may be a useful adjunct to lethal means counseling and other suicide prevention interventions.,"['Suicidal Adults (Lock to Live', 'enrolled participants (English-speaking, community-dwelling, suicidal adults', 'suicidal adults in emergency departments (EDs', 'adults with suicide risk']","['Web-based Lock to Live (L2L) decision', 'L2L or control (website with general suicide prevention information) groups and received a 1-week follow-up telephone call', 'L2L']",['reduced firearm access'],"[{'cui': 'C0438696', 'cui_str': 'Suicidal (finding)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C4045975', 'cui_str': 'Community Dwelling'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0563664', 'cui_str': 'Suicide risk'}]","[{'cui': 'C0332875', 'cui_str': 'Congenital webbing (morphologic abnormality)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0204732', 'cui_str': 'Suicide prevention (procedure)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0039457', 'cui_str': 'Telephone'}]","[{'cui': 'C0016139', 'cui_str': 'Firearms'}, {'cui': 'C0444454', 'cui_str': 'Access (attribute)'}]",,0.285755,The L2L decision aid appears feasible and acceptable for use among adults with suicide risk and may be a useful adjunct to lethal means counseling and other suicide prevention interventions.,"[{'ForeName': 'Marian E', 'Initials': 'ME', 'LastName': 'Betz', 'Affiliation': 'Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Christopher E', 'Initials': 'CE', 'LastName': 'Knoepke', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Scott', 'Initials': 'S', 'LastName': 'Simpson', 'Affiliation': 'Psychiatric Emergency Services, Denver Health Medical Center, Denver, CO, United States.'}, {'ForeName': 'Bonnie J', 'Initials': 'BJ', 'LastName': 'Siry', 'Affiliation': 'Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Ashley', 'Initials': 'A', 'LastName': 'Clement', 'Affiliation': 'Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Tamara', 'Initials': 'T', 'LastName': 'Saunders', 'Affiliation': 'School of Public Affairs, University of Colorado Colorado Springs, Colorado Springs, CO, United States.'}, {'ForeName': 'Rachel', 'Initials': 'R', 'LastName': 'Johnson', 'Affiliation': 'Department of Biostatistics & Informatics, Colorado School of Public Health, Aurora, CO, United States.'}, {'ForeName': 'Deborah', 'Initials': 'D', 'LastName': 'Azrael', 'Affiliation': 'Harvard Injury Control Research Center, Harvard School of Public Health, Boston, MA, United States.'}, {'ForeName': 'Edwin D', 'Initials': 'ED', 'LastName': 'Boudreaux', 'Affiliation': 'Departments of Emergency Medicine, Psychiatry, and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States.'}, {'ForeName': 'Faris', 'Initials': 'F', 'LastName': 'Omeragic', 'Affiliation': 'Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Leah M', 'Initials': 'LM', 'LastName': 'Adams', 'Affiliation': 'Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Sydney', 'Initials': 'S', 'LastName': 'Almond', 'Affiliation': 'University of Colorado Denver, Denver, CO, United States.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Juarez-Colunga', 'Affiliation': 'Adult & Child Consortium for Outcomes Research & Delivery Science, University of Colorado School of Medicine, Aurora, CO, United States.'}, {'ForeName': 'Daniel D', 'Initials': 'DD', 'LastName': 'Matlock', 'Affiliation': 'Eastern Colorado Geriatric Research Education and Clinical Center, Veterans Health Administration, Aurora, CO, United States.'}]",Journal of medical Internet research,['10.2196/16253'] 3238,31963274,An fMRI Study on Self-Perception of Patients after Aesthetic Implant-Prosthetic Rehabilitation.,"OBJECTIVES In this functional magnetic resonance (fMRI) study, we investigated the activation of cerebral pathways involved in the elaboration of self-retracting photos (SELF) and the same pictures of others (OTHER). Each of the photographs showed one of the participants during different stages of the rehabilitation: pre-treatment (PRE), virtual planning using ""Smile-Lynx"" smile design software (VIR), and post-rehabilitation (POST). METHODS We selected eighteen volunteers, both male and female, between 22 and 67 years of age, who previously underwent prosthetic rehabilitation. Each of them was subjected to an fMRI acquisition. Various stimuli were then shown to the subjects in the form of self-retracting photographs and photographs of other participants, all in pseudo-randomized order. We then carried out a two- stage mixed-effects group data analysis with statistical contrast targeting two main effects: one regarding the main effect of Identity (SELF vs. OTHER) and the other regarding the effect of the prosthetic rehabilitation phase (PRE vs. VIR vs. POS). All the effects mentioned above survived a peak-level of p < 0.05. RESULTS For the effect of identity, results reported the involvement of dorsolateral frontoparietal areas bilaterally. For the phase by identity effect, results reported activation in the supplementary motor area (SMA) in the right hemisphere. A stronger activation in observing self-retracting photos (SELF) post-treatment (POST) was reported compared to the other phases considered in the experiment. CONCLUSIONS All the collected data showed differences regarding the main effect of Identity (SELF vs. OTHER). Most importantly, the present study provides some trend-wise evidence that the pictures portraying the subject in their actual physiognomy (POST) have a somewhat special status in eliciting selectively greater brain activation in the SMA. This effect was interpreted as a plausible correlate of an empathic response for beautiful and neutral faces. The present research suggests a possible way to measure self-perception of the subject after an appearance-altering procedure such an implant-prosthetic rehabilitation. However, future clinical studies are needed to investigate this matter further.",2020,"A stronger activation in observing self-retracting photos (SELF) post-treatment (POST) was reported compared to the other phases considered in the experiment. ","['Patients after Aesthetic Implant-Prosthetic Rehabilitation', 'eighteen volunteers, both male and female, between 22 and 67 years of age, who previously underwent prosthetic rehabilitation']","['prosthetic rehabilitation phase (PRE vs. VIR vs. POS', 'rehabilitation: pre-treatment (PRE), virtual planning using ""Smile-Lynx"" smile design software (VIR), and post-rehabilitation (POST']",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0014901', 'cui_str': 'Esthetics'}, {'cui': 'C2828363', 'cui_str': 'Implant'}, {'cui': 'C0556028', 'cui_str': 'Prosthetic rehabilitation (regime/therapy)'}, {'cui': 'C3715206', 'cui_str': 'Eighteen'}, {'cui': 'C0042960', 'cui_str': 'Volunteer Workers'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}]","[{'cui': 'C0556028', 'cui_str': 'Prosthetic rehabilitation (regime/therapy)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C1306847', 'cui_str': 'Rehabilitation - specialty'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C0032074', 'cui_str': 'Cognitive function: planning (observable entity)'}, {'cui': 'C0037363', 'cui_str': 'Smilings'}, {'cui': 'C0325104', 'cui_str': 'Lynx'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}]",[],18.0,0.0247774,"A stronger activation in observing self-retracting photos (SELF) post-treatment (POST) was reported compared to the other phases considered in the experiment. ","[{'ForeName': 'Francesca', 'Initials': 'F', 'LastName': 'Cattoni', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, 20121 Milan, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Tetè', 'Affiliation': 'Department of Dentistry, IRCCS San Raffaele Hospital, 20121 Milan, Italy.'}, {'ForeName': 'Riccardo', 'Initials': 'R', 'LastName': 'Uccioli', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, 20121 Milan, Italy.'}, {'ForeName': 'Fabio', 'Initials': 'F', 'LastName': 'Manazza', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, 20121 Milan, Italy.'}, {'ForeName': 'Giorgio', 'Initials': 'G', 'LastName': 'Gastaldi', 'Affiliation': 'Dental School, Vita-Salute San Raffaele University, 20121 Milan, Italy.'}, {'ForeName': 'Daniela', 'Initials': 'D', 'LastName': 'Perani', 'Affiliation': 'Department of Nuclear Medicine and Division of Neuroscience, Vita Salute San Raffaele University, San Raffaele University, 20121 Milan, Italy.'}]",International journal of environmental research and public health,['10.3390/ijerph17020588'] 3239,32026827,Development and implementation of the physiotherapy-led exercise interventions for the treatment of rotator cuff disorders for the 'Getting it Right: Addressing Shoulder Pain' (GRASP) trial.,"OBJECTIVES The Getting it Right: Addressing Shoulder Pain (GRASP) trial is a large-scale, multicentre, 2×2 factorial randomised controlled trial investigating clinical and cost-effectiveness of a progressive exercise programme versus best-practice advice, with or without corticosteroid injection, for treating people with rotator cuff disorders. Here we describe the development, implementation and details of the physiotherapy-led interventions. METHODS Medical Research Council guidance for developing complex interventions were used, taking into account clinical guidelines, expert and patient opinion, research evidence, current practice variation, and deliverability. A stakeholder meeting of 26 experts, clinicians, researchers, and patient representatives was used to design key components of the interventions. Stakeholders prioritised strengthening posterior rotator cuff muscles and using practical, easy-to-do exercises. The interventions were designed to be deliverable across the UK National Health Service. RESULTS Progressive exercise consists of up to six sessions with a physiotherapist over 16 weeks. The best-practice advice consists of one face-to-face session with a physiotherapist with substantially greater reliance on self-management. Both interventions include self-management advice, home-exercise instruction, and behaviour-change strategies to target exercise adherence. All participants receive a Participant Information Booklet. The best-practice advice intervention is a self-guided system of progressively challenging exercises, with demonstration videos and written materials. The progressive exercise intervention has a wider range of exercise options, and greater flexibility for tailoring, progression, supervised practice and feedback. CONCLUSION GRASP has recruited 708 participants and will provide high quality evidence to inform management of people with shoulder pain due to a rotator cuff disorder. Results are anticipated in 2020. TRIAL REGISTRATION NUMBER ISRCTN16539266; EudraCT number:2016-002991-28.",2020,"The progressive exercise intervention has a wider range of exercise options, and greater flexibility for tailoring, progression, supervised practice and feedback. ","['people with rotator cuff disorders', 'Right']","['progressive exercise intervention', 'progressive exercise programme versus best-practice advice, with or without corticosteroid injection', 'physiotherapy-led exercise interventions']",[],"[{'cui': 'C0085515', 'cui_str': 'Rotator Cuff'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0205090', 'cui_str': 'Right (qualifier value)'}]","[{'cui': 'C0205329', 'cui_str': 'Progressive (qualifier value)'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C3179154', 'cui_str': 'Best Practices'}, {'cui': 'C3539185', 'cui_str': 'Corticosteroid nasal preparations for topical use'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0699718', 'cui_str': 'Physiotherapy (qualifier value)'}, {'cui': 'C0023175', 'cui_str': 'Lead'}]",[],,0.0901959,"The progressive exercise intervention has a wider range of exercise options, and greater flexibility for tailoring, progression, supervised practice and feedback. ","[{'ForeName': 'David J', 'Initials': 'DJ', 'LastName': 'Keene', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. Electronic address: david.keene@ndorms.ox.ac.uk.'}, {'ForeName': 'Hessam', 'Initials': 'H', 'LastName': 'Soutakbar', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sally', 'Initials': 'S', 'LastName': 'Hopewell', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Heine', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Anju', 'Initials': 'A', 'LastName': 'Jaggi', 'Affiliation': 'Royal National Orthopaedic Hospital NHS Trust, Stanmore, Middlesex, UK.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Littlewood', 'Affiliation': 'Primary Care and Health Sciences, Keele University, Keele, UK.'}, {'ForeName': 'Zara', 'Initials': 'Z', 'LastName': 'Hansen', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Barker', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.'}, {'ForeName': 'Willie', 'Initials': 'W', 'LastName': 'Hamilton', 'Affiliation': 'Institute of Health Research, University of Exeter, Exeter, UK.'}, {'ForeName': 'Andrew J', 'Initials': 'AJ', 'LastName': 'Carr', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sarah E', 'Initials': 'SE', 'LastName': 'Lamb', 'Affiliation': 'Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.'}]",Physiotherapy,['10.1016/j.physio.2019.07.002'] 3240,31348349,The Relationship between Hand Therapy and Long-Term Outcomes after Distal Radius Fracture in Older Adults: Evidence from the Randomized Wrist and Radius Injury Surgical Trial.,"BACKGROUND Older patients are frequently referred to hand therapy after distal radius fracture. Supervised therapy sessions place a transportation burden on patients and are costly on both the individual and systematic levels. Furthermore, there is little evidence that supervised therapy or home exercises improve long-term outcomes. METHODS Data were collected for the Wrist and Radius Injury Surgical Trial, a multicenter, international, pragmatic, randomized trial of distal radius fracture treatment in patients aged 60 years and older. Referral to therapy and therapy protocol were at the discretion of the treating surgeon and therapist. The authors examined outcomes between participants who underwent therapy and those who did not and assessed the duration of therapy. The authors also analyzed the effect of therapy on subgroups at risk for poor outcomes: older participants and those who had more comorbidities or lower baseline activity. RESULTS Eighty percent of participants underwent therapy; 70 percent participated in both supervised therapy and home exercises. Participants had a mean 9.2 supervised sessions over 14.2 weeks. There were no differences in patient-reported outcomes between participants who underwent therapy and those who did not. Participants who did not have therapy recovered more grip strength. Participants who engaged in therapy for a shorter time reported greater function, ability to work, and satisfaction. There were no relationships revealed in subgroup analyses. CONCLUSIONS Hand therapy after distal radius fracture may not be necessary for older patients. Encouraging participants to resume activities of daily living as soon as possible may be as effective as formal therapy. CLINICAL QUESTION/LEVEL OF EVIDENCE Therapeutic, II.",2019,There were no differences in patient-reported outcomes between participants who underwent therapy and those who did not.,"['participants who underwent therapy and those who did not and assessed the duration of therapy', 'patients aged 60 years and older', 'older patients', 'subgroups at risk for poor outcomes: older participants and those who had more comorbidities or lower baseline activity', 'Older Adults', 'Older patients']","['distal radius fracture treatment', 'Distal Radius Fracture']","['grip strength', 'function, ability to work, and satisfaction']","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0444917', 'cui_str': 'Duration of therapy (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C1444641', 'cui_str': 'At risk'}, {'cui': 'C0542537', 'cui_str': 'Poor - grade'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0441655', 'cui_str': 'Activity (observable entity)'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0588207', 'cui_str': 'Bone structure of distal radius (body structure)'}, {'cui': 'C0919720', 'cui_str': 'Fracture treatment'}, {'cui': 'C0016658', 'cui_str': 'Fractures, Bone'}]","[{'cui': 'C0429271', 'cui_str': 'Grip strength (observable entity)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}]",,0.0795896,There were no differences in patient-reported outcomes between participants who underwent therapy and those who did not.,"[{'ForeName': 'Kevin C', 'Initials': 'KC', 'LastName': 'Chung', 'Affiliation': 'Ann Arbor, Mich. From the Section of Plastic Surgery, Department of Surgery, University of Michigan Medical School.'}, {'ForeName': 'Sunitha', 'Initials': 'S', 'LastName': 'Malay', 'Affiliation': ''}, {'ForeName': 'Melissa J', 'Initials': 'MJ', 'LastName': 'Shauver', 'Affiliation': ''}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Plastic and reconstructive surgery,['10.1097/PRS.0000000000005829'] 3241,31255482,Hyperarousal in insomnia: pre-sleep and diurnal cortisol levels in response to chronic zolpidem treatment.,"OBJECTIVES To determine whether cortisol levels, both diurnal and pre-sleep, would vary as a function of MSLT and would be reduced by nightly placebo versus zolpidem 10 mg. METHODS DSM-IVR diagnosed subjects with insomnia (N = 95), aged 32-70 yrs, having no other sleep disorder, unstable medical or psychiatric diseases or drug dependency served. On a screening MSLT 27 had MSLTs <10 min (Lo) and 42 > 15 min (Hi). Participants took 10 mg zolpidem or placebo, double-blind, nightly for 12 months. In months one and 12 urine was collected over 24 h in 8 hr-aliquots and assayed for cortisol (Ward Laboratories, Ann Arbor, MI). Saliva samples were collected 35 min before bedtime and the 30 min drug administration in month one and eight, and analyzed for cortisol levels (Salimetrics, State College, PA). RESULTS Pre-sleep salivary cortisol was higher in insomniacs than controls, but did not differ as a function of MSLT. Nightly zolpidem reduced pre-sleep cortisol relative to placebo on month one and eight, with no month effects or interaction. Diurnal (0700-1500 h) urinary cortisol was higher overall in the Hi vs Lo MSLT subjects with insomnia, was stable across months, and was not reduced with zolpidem. CONCLUSIONS Hyperarousal among subjects with insomnia as operationalized by MSLT is associated with higher diurnal urinary cortisol than those without hyperarousal, but not differential pre-sleep salivary cortisol. Zolpidem relative to placebo reduced pre-sleep salivary cortisol in all subjects, but not diurnal urinary cortisol. CLINICAL TRIAL Safety and Efficacy of Chronic Hypnotic Use: http://www.clinicaltrials.gov NCT01006525.",2019,"Diurnal (0700-1500 h) urinary cortisol was higher overall in the Hi vs Lo MSLT subjects with insomnia, was stable across months, and was not reduced with zolpidem. ","['DSM-IVR diagnosed subjects with insomnia (N\xa0=\xa095), aged 32-70\xa0yrs, having no other sleep disorder, unstable medical or psychiatric diseases or drug dependency served']","['zolpidem or placebo', 'placebo', 'Nightly zolpidem', 'Zolpidem', 'placebo versus zolpidem']","['Pre-sleep salivary cortisol', 'Hyperarousal in insomnia: pre-sleep and diurnal cortisol levels', 'pre-sleep cortisol', 'pre-sleep salivary cortisol', 'cortisol levels, both diurnal and pre-sleep', 'diurnal urinary cortisol', 'urinary cortisol']","[{'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0236993', 'cui_str': 'Other sleep disorders'}, {'cui': 'C0443343', 'cui_str': 'Unstable status (qualifier value)'}, {'cui': 'C0205476', 'cui_str': 'Medical (qualifier value)'}, {'cui': 'C0205487', 'cui_str': 'Psychiatric (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C0011546', 'cui_str': 'Dependency'}]","[{'cui': 'C0078839', 'cui_str': 'zolpidem'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0740175', 'cui_str': 'Before values (qualifier value)'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0442040', 'cui_str': 'Salivary (qualifier value)'}, {'cui': 'C0201968', 'cui_str': 'Cortisol measurement (procedure)'}, {'cui': 'C4552570', 'cui_str': 'Hyperarousal'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0332169', 'cui_str': 'Daytime (qualifier value)'}]",,0.0422004,"Diurnal (0700-1500 h) urinary cortisol was higher overall in the Hi vs Lo MSLT subjects with insomnia, was stable across months, and was not reduced with zolpidem. ","[{'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'Roehrs', 'Affiliation': 'Henry Ford Health System, Sleep Disorders and Research Center, USA; Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, USA. Electronic address: troehrs1@hfhs.org.'}, {'ForeName': 'Thomas', 'Initials': 'T', 'LastName': 'Roth', 'Affiliation': 'Henry Ford Health System, Sleep Disorders and Research Center, USA; Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, Detroit, MI, USA.'}]",Sleep medicine,['10.1016/j.sleep.2019.04.010'] 3242,30690609,TheraBracelet Stimulation During Task-Practice Therapy to Improve Upper Extremity Function After Stroke: A Pilot Randomized Controlled Study.,"BACKGROUND Peripheral sensory stimulation has been used in conjunction with upper extremity movement therapy to increase therapy-induced motor gains in patients with stroke. The limitation is that existing sensory stimulation methods typically interfere with natural hand tasks and thus are administered prior to therapy, requiring patients' time commitment. To address this limitation, we developed TheraBracelet. This novel stimulation method provides subthreshold (ie, imperceptible) vibratory stimulation to the wrist and can be used during hand tasks/therapy without interfering with natural hand tasks. OBJECTIVE The objective was to determine the feasibility of using TheraBracelet during therapy to augment motor recovery after stroke. DESIGN The design was a triple-blinded pilot randomized controlled trial. METHODS Twelve chronic stroke survivors were assigned to the treatment or control group. All participants completed 2-hour task practice therapy sessions thrice weekly for 2 weeks. Both groups wore a small vibrator on the paretic wrist, which was turned on to provide TheraBracelet stimulation for the treatment group and turned off for the control group to provide sham stimulation. Outcome measures (Box and Block Test [BBT] and Wolf Motor Function Test [WMFT]) were obtained at baseline, 6 days after therapy, and at follow-up 19 days after therapy. RESULTS The intervention was feasible with no adverse events. The treatment group significantly improved their BBT scores after therapy and at follow-up compared with baseline, whereas the control group did not. For WMFT, the group × time interaction was short of achieving significance. Large effect sizes were obtained (BBT d = 1.43, WMFT d = 0.87). No indication of desensitization to TheraBracelet stimulation was observed. LIMITATIONS The limitation was a small sample size. CONCLUSIONS TheraBracelet could be a promising therapy adjuvant for upper extremity recovery after stroke.",2019,"The treatment group significantly improved their BBT scores after therapy and at follow-up compared with baseline, whereas the control group did not.","['patients with stroke', 'Twelve chronic stroke survivors']","['TheraBracelet Stimulation', 'WMFT']","['Outcome measures (Box and Block Test [BBT] and Wolf Motor Function Test [WMFT', 'Upper Extremity Function', 'BBT scores']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C3536593', 'cui_str': 'Chronic stroke'}, {'cui': 'C0206194', 'cui_str': 'Survivors'}]","[{'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}]","[{'cui': 'C1638312', 'cui_str': 'Boxes'}, {'cui': 'C0028778', 'cui_str': 'Obstruction (morphologic abnormality)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C0325001', 'cui_str': 'Wolves'}, {'cui': 'C0234130', 'cui_str': 'Motor function (observable entity)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0731137,"The treatment group significantly improved their BBT scores after therapy and at follow-up compared with baseline, whereas the control group did not.","[{'ForeName': 'Na J', 'Initials': 'NJ', 'LastName': 'Seo', 'Affiliation': 'Division of Occupation Therapy, Department of Health Professions, Department of Health Sciences and Research, Medical University of South Carolina, 151B Rutledge Ave, Charleston, SC 29425 (USA).'}, {'ForeName': 'Michelle L', 'Initials': 'ML', 'LastName': 'Woodbury', 'Affiliation': 'Department of Health Sciences and Research, Medical University of South Carolina.'}, {'ForeName': 'Leonardo', 'Initials': 'L', 'LastName': 'Bonilha', 'Affiliation': 'Department of Neurology, Medical University of South Carolina.'}, {'ForeName': 'Viswanathan', 'Initials': 'V', 'LastName': 'Ramakrishnan', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina.'}, {'ForeName': 'Steven A', 'Initials': 'SA', 'LastName': 'Kautz', 'Affiliation': 'Department of Health Sciences and Research, Medical University of South Carolina.'}, {'ForeName': 'Ryan J', 'Initials': 'RJ', 'LastName': 'Downey', 'Affiliation': 'Department of Health Professions, Medical University of South Carolina.'}, {'ForeName': 'Blair H S', 'Initials': 'BHS', 'LastName': 'Dellenbach', 'Affiliation': 'Department of Health Sciences and Research, Medical University of South Carolina.'}, {'ForeName': 'Abigail W', 'Initials': 'AW', 'LastName': 'Lauer', 'Affiliation': 'Department of Public Health Sciences, Medical University of South Carolina.'}, {'ForeName': 'Caroline M', 'Initials': 'CM', 'LastName': 'Roark', 'Affiliation': 'Division of Occupational Therapy, Medical University of South Carolina.'}, {'ForeName': 'Lauren E', 'Initials': 'LE', 'LastName': 'Landers', 'Affiliation': 'Division of Occupational Therapy, Medical University of South Carolina.'}, {'ForeName': 'Sarah K', 'Initials': 'SK', 'LastName': 'Phillips', 'Affiliation': 'Division of Occupational Therapy, Medical University of South Carolina.'}, {'ForeName': 'Amanda A', 'Initials': 'AA', 'LastName': 'Vatinno', 'Affiliation': 'College of Health Professions, Medical University of South Carolina.'}]",Physical therapy,['10.1093/ptj/pzy143'] 3243,30011020,Randomized factorial experiment of components of the SmokeFree Baby smartphone application to aid smoking cessation in pregnancy.,"Smartphone applications (apps) might be able to reach pregnant smokers who do not engage with face-to-face support. However, we do not know how far pregnant smokers will engage with smoking cessation apps or what components are likely to be effective. This study aimed to assess pregnant smokers' engagement with the SmokeFree Baby app (v1) and to assess the short-term efficacy of selected components (""modules"") for smoking abstinence. Positive outcomes would provide a basis for further development and evaluation. SmokeFree Baby was developed drawing on behavior change theories and relevant evidence. Pregnant smokers (18+) who were interested in quitting and set a quit date were recruited. Following multiphase optimization development principles, participants (N = 565) were randomly allocated to one of 32 (2 × 2 × 2 × 2 × 2) experimental groups in a full factorial design to evaluate five modules (each in minimal and full version: identity, health information, stress management, face-to-face support, and behavioral substitution). Measures of engagement included duration and frequency of engagement with the app. Smoking abstinence was measured by self-reported number of smoke-free days up to 4 weeks from the quit date. Participants engaged with the app for a mean of 4.5 days (SD = 8.5) and logged in a mean of 2.9 times (SD = 3.1). Main effects of the modules on the number of smoke-free days were not statistically significant (identity: p = .782, health information: p = .905, stress management: p = .103, face-to-face support: p = .397, behavioral substitution: p = .945). Despite systematic development and usability testing, engagement with SmokeFree Baby (v1) was low and the app did not appear to increase smoking abstinence during pregnancy.",2019,"Main effects of the modules on the number of smoke-free days were not statistically significant (identity: p = .782, health information: p = .905, stress management: p = .103, face-to-face support: p = .397, behavioral substitution: p = .945).","['participants (N = 565', 'Pregnant smokers (18+) who were interested in quitting and set a quit date were recruited', 'pregnant smokers', ""pregnant smokers' engagement with the SmokeFree Baby app (v1"", 'pregnant smokers who do not engage with face-to-face support']","['selected components (""modules', 'SmokeFree Baby smartphone application', 'five modules (each in minimal and full version: identity, health information, stress management, face-to-face support, and behavioral substitution']","['duration and frequency of engagement with the app', 'smoking abstinence', 'Smoking abstinence', 'number of smoke-free days']","[{'cui': 'C0549206', 'cui_str': 'Pregnancy not delivered'}, {'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0543488', 'cui_str': 'Interested (finding)'}, {'cui': 'C0036849', 'cui_str': 'Set'}, {'cui': 'C0011008', 'cui_str': 'Dates'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1299585', 'cui_str': 'Does not (qualifier value)'}, {'cui': 'C0425152', 'cui_str': 'Engaged to be married (finding)'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C3542953', 'cui_str': 'Module (core metadata concept)'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0547040', 'cui_str': 'Minimal (qualifier value)'}, {'cui': 'C2607870', 'cui_str': 'Version (morphologic abnormality)'}, {'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0538263', 'cui_str': 'fatty acid 2-chloroethyl ester synthase'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}]",565.0,0.03134,"Main effects of the modules on the number of smoke-free days were not statistically significant (identity: p = .782, health information: p = .905, stress management: p = .103, face-to-face support: p = .397, behavioral substitution: p = .945).","[{'ForeName': 'Ildiko', 'Initials': 'I', 'LastName': 'Tombor', 'Affiliation': 'Department of Behavioural Science and Health, University College London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Beard', 'Affiliation': 'Department of Behavioural Science and Health, University College London, UK.'}, {'ForeName': 'Jamie', 'Initials': 'J', 'LastName': 'Brown', 'Affiliation': 'Department of Behavioural Science and Health, University College London, UK.'}, {'ForeName': 'Lion', 'Initials': 'L', 'LastName': 'Shahab', 'Affiliation': 'Department of Behavioural Science and Health, University College London, UK.'}, {'ForeName': 'Susan', 'Initials': 'S', 'LastName': 'Michie', 'Affiliation': 'Department of Clinical, Educational and Health Psychology, University College London, UK.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'West', 'Affiliation': 'Department of Behavioural Science and Health, University College London, UK.'}]",Translational behavioral medicine,['10.1093/tbm/iby073'] 3244,31227472,Identifying Patient Readmissions: Are Our Data Sources Misleading?,"BACKGROUND The accuracy of data is vital to identifying hospitalization outcomes for clinical trials. Patient attrition and recall bias affects the validity of patient-reported outcomes, and the growing prevalence of Medicare Advantage (MA) could mean Fee-for-Service (FFS) claims are less reliable for ascertaining hospital utilization. Statewide health information exchanges (HIEs) may be a more complete data source but have not been frequently used for research. DESIGN Secondary analysis comparing identification of readmissions using 3 different acquisition approaches. SETTING Randomized controlled trial of heart failure (HF) disease management in 37 skilled nursing facilities (SNFs). PARTICIPANTS Patients with HF discharged from the hospital to SNF. MEASURES Readmissions up to 60 days post-SNF admission collected by patient self-report, recorded by nursing home (NH) staff during the SNF stay, or recorded in the state HIE. RESULTS Among 657 participants (mean age 79 ± 10 years, 49% with FFS), 295 unique readmissions within 60 days of SNF admission were identified. These readmissions occurred among 221 patients. Twenty percent of all readmissions were found using only patient self-report, 28% were only recorded by NH staff during the SNF stay, and 52% were identified only using the HIE. The readmission rate (first readmission only) based only on patient self-report and direct observation was 18% rather than 34% with the addition of the enhanced HIE method. CONCLUSIONS AND IMPLICATIONS More than one-quarter (34%) of HF patients were rehospitalized within 60 days post SNF admission. Use of a statewide HIE resulted in identifying an additional 153 admissions, 52% of all the readmissions seen in this study. Without use of an HIE, nearly half of readmissions would have been missed as a result of incomplete patient self-report or loss to follow-up. Thus, HIEs serve as an important resource for researchers to ensure accurate outcomes data.",2019,"The readmission rate (first readmission only) based only on patient self-report and direct observation was 18% rather than 34% with the addition of the enhanced HIE method. ","['37 skilled nursing facilities (SNFs', '657 participants (mean age 79 ± 10\xa0years, 49% with FFS), 295 unique readmissions within 60\xa0days of SNF admission were identified', 'Patients with HF discharged from the hospital to SNF']",[],"['readmission rate (first readmission only) based only on patient self-report and direct observation', 'nursing home (NH) staff during the SNF stay, or recorded in the state HIE']","[{'cui': 'C0037265', 'cui_str': 'Extended Care Facilities'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0205396', 'cui_str': 'Identified (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]",[],"[{'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0439851', 'cui_str': 'Direct (qualifier value)'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C0442519', 'cui_str': 'Domestic (environment)'}, {'cui': 'C2700616', 'cui_str': 'Manpowers'}, {'cui': 'C0034869', 'cui_str': 'Records as Topic'}, {'cui': 'C1301808', 'cui_str': 'State'}]",28.0,0.0432695,"The readmission rate (first readmission only) based only on patient self-report and direct observation was 18% rather than 34% with the addition of the enhanced HIE method. ","[{'ForeName': 'Andrea E', 'Initials': 'AE', 'LastName': 'Daddato', 'Affiliation': 'Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO. Electronic address: Andrea.Daddato@ucdenver.edu.'}, {'ForeName': 'Blythe', 'Initials': 'B', 'LastName': 'Dollar', 'Affiliation': 'Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO.'}, {'ForeName': 'Hillary D', 'Initials': 'HD', 'LastName': 'Lum', 'Affiliation': 'Division of Geriatric Medicine, University of Colorado School of Medicine, Aurora, CO; Veterans Affairs Eastern Colorado Geriatric Research Education and Clinical Center, Aurora, CO.'}, {'ForeName': 'Robert E', 'Initials': 'RE', 'LastName': 'Burke', 'Affiliation': 'Center for Health Equity Research and Promotion, Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.'}, {'ForeName': 'Rebecca S', 'Initials': 'RS', 'LastName': 'Boxer', 'Affiliation': 'Institute for Health Research, Kaiser Permanente, Aurora, CO.'}]",Journal of the American Medical Directors Association,['10.1016/j.jamda.2019.04.028'] 3245,32071129,Physiologic Effects of Nasal Aspiration and Nasopharyngeal Suctioning on Infants With Viral Bronchiolitis.,"BACKGROUND There is limited evidence supporting an optimum method for removing mucus from the airways of hospitalized infants with bronchiolitis. This study was designed to evaluate short-term physiologic effects between nasal aspiration and nasopharyngeal suctioning in infants. METHODS Sixteen infants requiring hospitalization for supportive management of bronchiolitis were instrumented with transcutaneously measured partial pressure of carbon dioxide ([Formula: see text]) and [Formula: see text] monitoring. Electrical impedance tomography (EIT) was used to estimate changes in inspiratory and end-expiratory lung volume loss and recovery. Subjects were suctioned with both nasal aspiration and nasopharyngeal suctioning methods in a randomized order (8 received nasal aspiration followed by nasopharyngeal suctioning, and 8 received nasophayrgeal suctioning followed by nasal aspiration). Noninvasive gas exchange and EIT measurements were obtained at baseline (pre-suction) and at 10, 20, and 30 min following each suctioning intervention. Sputum mass was obtained following suctioning, and clinical respiratory severity scores, before and after suctioning, were computed. RESULTS There were no differences in inspiratory EIT ( P = .93), change in end-expiratory lung impedance (ΔEELI; P = .53), [Formula: see text] ( P = .41), [Formula: see text] ( P = .88), heart rate ( P = .31), or breathing frequency ( P = .15) over the course of suctioning between nasal aspiration and nasopharyngeal suctioning. Sputum mass ( P = .14) and clinical respiratory score differences before and after suctioning ( P = .59) were not different between the 2 suctioning interventions. Sputum mass was not associated with ΔEELI at 30 min for nasal aspiration (ρ = 0.11, P = .69), but there was a moderate positive association for nasopharyngeal suctioning (ρ = 0.50, P = .048). CONCLUSIONS Infants with viral bronchiolitis appeared to tolerate both suctioning techniques without adverse short-term physiologic effects, as indicated by the unchanged gas exchange and estimated lung volumes (EIT). Nasopharyngeal suctioning recovered 36% more sputum than did nasal aspiration and there was moderate correlation between sputum mass and end-expiratory lung impedance change at 30 minutes post-suction with nasopharyngeal that was not present with nasal aspiration. It is possible that a subset of patients may benefit from one type of suctioning over another. Future research focusing on important outcomes for suctioning patients with bronchiolitis with varying degrees of lung disease severity is needed.",2020,"There were no differences in inspiratory EIT ( P = .93), change in end-expiratory lung impedance (ΔEELI; P = .53), P tcCO 2 ( P = .41), S","['Sixteen infants requiring hospitalization for supportive management of bronchiolitis were instrumented with', 'Infants with viral bronchiolitis', 'Infants With Viral Bronchiolitis', 'infants', 'suctioning patients with bronchiolitis with varying degrees of lung disease severity', 'hospitalized infants with bronchiolitis']","['nasal aspiration and nasopharyngeal suctioning methods', 'transcutaneously measured partial pressure of carbon dioxide (P tcCO 2 ) and S pO 2 monitoring', 'Electrical impedance tomography (EIT', 'Nasal Aspiration and Nasopharyngeal Suctioning', 'nasal aspiration followed by nasopharyngeal suctioning, and 8 received nasophayrgeal suctioning followed by nasal aspiration', 'nasal aspiration and nasopharyngeal suctioning']","['moderate positive association for nasopharyngeal suctioning', 'inspiratory EIT', 'sputum mass and end-expiratory lung impedance change', 'change in end-expiratory lung impedance', 'Nasopharyngeal suctioning', 'Sputum mass', 'breathing frequency', 'changes in inspiratory and end-expiratory lung volume loss and recovery', 'Noninvasive gas exchange and EIT measurements', 'heart rate']","[{'cui': 'C3715157', 'cui_str': '16'}, {'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0006271', 'cui_str': 'Bronchiolitis'}, {'cui': 'C4551823', 'cui_str': 'instruments'}, {'cui': 'C0006274', 'cui_str': 'Bronchiolitis, Viral'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0449286', 'cui_str': 'Degree (attribute)'}, {'cui': 'C0024115', 'cui_str': 'Pulmonary Diseases'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}]","[{'cui': 'C1142346', 'cui_str': 'Nasal aspiration'}, {'cui': 'C0027442', 'cui_str': 'Rhinopharynx'}, {'cui': 'C0025663', 'cui_str': 'Methods'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0030604', 'cui_str': 'Partial Pressure'}, {'cui': 'C0007012', 'cui_str': 'Carbon Dioxide'}, {'cui': 'C0297199', 'cui_str': 'PO-2'}, {'cui': 'C0162537', 'cui_str': 'Electrical Impedance'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}]","[{'cui': 'C0205081', 'cui_str': 'Moderate (severity modifier) (qualifier value)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0004083', 'cui_str': 'Association'}, {'cui': 'C0027442', 'cui_str': 'Rhinopharynx'}, {'cui': 'C0004048', 'cui_str': 'Inhalation'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C1306372', 'cui_str': 'Mass, a measure of quantity of matter (property) (qualifier value)'}, {'cui': 'C0442700', 'cui_str': 'End-expiration'}, {'cui': 'C0024109', 'cui_str': 'Lung'}, {'cui': 'C0162537', 'cui_str': 'Electrical Impedance'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0231953', 'cui_str': 'Lung volume, function (observable entity)'}, {'cui': 'C0596601', 'cui_str': 'Gas'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}]",16.0,0.0441428,"There were no differences in inspiratory EIT ( P = .93), change in end-expiratory lung impedance (ΔEELI; P = .53), P tcCO 2 ( P = .41), S","[{'ForeName': 'Coral N', 'Initials': 'CN', 'LastName': 'Ringer', 'Affiliation': ""Clinical Effectiveness, Quality and Safety Support, Seattle Children's Hospital, Seattle, Washington. coral.ringer@seattlechildrens.org.""}, {'ForeName': 'Rebecca J', 'Initials': 'RJ', 'LastName': 'Engberg', 'Affiliation': ""Pediatric Intensive Care Unit, Seattle Children's Hospital, Seattle, Washington.""}, {'ForeName': 'Kristen E', 'Initials': 'KE', 'LastName': 'Carlin', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Craig D', 'Initials': 'CD', 'LastName': 'Smallwood', 'Affiliation': ""Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts and Harvard Medical School, Boston, Massachusetts.""}, {'ForeName': 'Robert M', 'Initials': 'RM', 'LastName': 'DiBlasi', 'Affiliation': ""Respiratory Care Department, Seattle Children's Hospital, Seattle, Washington and Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington.""}]",Respiratory care,['10.4187/respcare.07269'] 3246,31734051,Improving growth of infants with congenital heart disease using a consensus-based nutritional pathway.,"OBJECTIVE Infants with congenital heart disease (CHD) often experience growth failure prior to surgery, which is associated with increased paediatric-intensive-care unit length of stay (PICU-LOS) and post-operative complications. This study assessed the impact of a pre-operative, consensus-based nutritional pathway (including support from a multi-disciplinary team) on growth and clinical outcome. DESIGN Single-centre prospective pilot study. SETTING Tertiary paediatric cardiology surgical centre. PATIENTS Infants with CHD. INTERVENTION Infants with CHD were followed for up to 4-months-of-age before cardiac surgery and then to 12-months-of-age following the implementation of the consensus-based nutritional-pathway (Intervention group: November 2017-August 2018), with outcomes compared to a historic control group. The nutrition pathway involved a dietitian contacting parents of infants with the highest risk of growth failure weekly; reviewing weight gain and providing feeding support. MAIN OUTCOME MEASURE Growth (weight-for-age, WAZ, and height-for-age-z-score, HAZ) at 4 and 12 months-of-age. RESULTS 44 infants in the intervention group were compared to 38 in the control group. Median (inter quartile range) change in WAZ from birth to 4 months-of-age (-0.9 (-1.5, 0.7)) and from birth to 12 months-of-age (-0.09 (-1.3, 1.1)) in the intervention group compared to the control group (-1.5 (-2.0, -0.4) (p = 0.04)) at 4 months-of age and at 12 months-of-age (-0.4 (1.9, 0.2) (p = 0.03)). HAZ at 4 months-of-age was -0.7 (-1.4, -0.1) vs. -1.0 (-1.9, -0.3) (p = 0.6) in the intervention and control groups respectively, and at 12 months-of-age HAZ was -0.7 (-1.9, -0.07) in the intervention group vs.-1.6 (-2.6, -0.4) in the control group (p = 0.04). Duration of PICU-LOS was 8.2 ± 11.6 days intervention vs. 18.3 ± 24.0 days control (p = 0.006). CONCLUSION Overall weight was well maintained and growth improved in infants who followed the pre-operative nutritional-pathway. The duration of PICU-LOS was significantly lower in the intervention group, which may be due to improved nutritional status, although this requires further investigation.",2020,"The duration of PICU-LOS was significantly lower in the intervention group, which may be due to improved nutritional status, although this requires further investigation.","['infants with congenital heart disease using a consensus-based nutritional pathway', 'Infants with congenital heart disease (CHD', 'Infants with CHD', 'Tertiary paediatric cardiology surgical centre']","['HAZ', 'historic control group']","['Growth (weight-for-age, WAZ, and height-for-age-z-score, HAZ', 'Overall weight', 'Duration of PICU-LOS', 'duration of PICU-LOS']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0152021', 'cui_str': 'Congenital heart disease (disorder)'}, {'cui': 'C0376298', 'cui_str': 'Consensus'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C1321166', 'cui_str': 'Pediatric cardiology'}, {'cui': 'C0543467', 'cui_str': 'Operative Procedures'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}]","[{'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C0018270', 'cui_str': 'Growth'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0871421', 'cui_str': 'Z-score'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C2926735', 'cui_str': 'Duration'}]",44.0,0.0569498,"The duration of PICU-LOS was significantly lower in the intervention group, which may be due to improved nutritional status, although this requires further investigation.","[{'ForeName': 'Luise V', 'Initials': 'LV', 'LastName': 'Marino', 'Affiliation': 'Department of Dietetics/ SLT, University Hospital Southampton NHS Foundation Trust, SO16 6YD, UK; NIHR Biomedical Research Centre Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK; School of Health Sciences, University of Southampton, UK. Electronic address: Luise.marino@uhs.nhs.uk.'}, {'ForeName': 'Mark J', 'Initials': 'MJ', 'LastName': 'Johnson', 'Affiliation': 'Department of Neonatal Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK; NIHR Biomedical Research Centre Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK.'}, {'ForeName': 'Natalie J', 'Initials': 'NJ', 'LastName': 'Davies', 'Affiliation': 'Department of Dietetics/ SLT, University Hospital Southampton NHS Foundation Trust, SO16 6YD, UK.'}, {'ForeName': 'Catherine S', 'Initials': 'CS', 'LastName': 'Kidd', 'Affiliation': 'Department of Dietetics/ SLT, University Hospital Southampton NHS Foundation Trust, SO16 6YD, UK.'}, {'ForeName': 'Julie', 'Initials': 'J', 'LastName': 'Fienberg', 'Affiliation': 'Department of Dietetics/ SLT, University Hospital Southampton NHS Foundation Trust, SO16 6YD, UK.'}, {'ForeName': 'Trevor', 'Initials': 'T', 'LastName': 'Richens', 'Affiliation': ""Paediatric Cardiology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK.""}, {'ForeName': 'Tara', 'Initials': 'T', 'LastName': 'Bharucha', 'Affiliation': ""Paediatric Cardiology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK.""}, {'ForeName': 'R Mark', 'Initials': 'RM', 'LastName': 'Beattie', 'Affiliation': ""Paediatric Gastroenterology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK; NIHR Biomedical Research Centre Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, S016 6YD, UK.""}, {'ForeName': 'Anne-Sophie E', 'Initials': 'AE', 'LastName': 'Darlington', 'Affiliation': 'School of Health Sciences, University of Southampton, UK.'}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.10.031'] 3247,31815658,A pragmatic pilot phase II randomised controlled trial of prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP) in adult patients who are undergoing heart surgery (PROPHESY).,"BACKGROUND Fresh frozen plasma (FFP) is the accepted standard treatment for clotting factor replacement in bleeding patients during or immediately after cardiac surgery. In the United Kingdom prothrombin complex concentrate (PCC) is not licensed in this setting, although it is being used in Europe because it has a higher concentration of clotting factor levels, and it can be administered rapidly and in small volume, resulting in less volume overload during cardiac surgery. METHODS PROPHESY is a pragmatic, single-centre, open-label, randomised, controlled pilot trial that will assess whether it is feasible to perform a large trial in the future that will compare PCC versus FFP in patients who are bleeding (not on warfarin) and who require blood transfusion. Over a 15-month period, 50 patients will be randomised to PCC versus FFP if they develop active bleeding within 24 h of cardiac surgery and for whom the clinician has decided to administer FFP for treatment of bleeding. Standard laboratory and point-of-care assessments will be performed as per routine practice, and additional research blood samples will be taken at three time points to assess haemostasis. Subjects will be assessed daily up to hospital discharge or 30 days or death (whichever occurs first) and will be seen in follow-up for 90 days after surgery to assess for thromboembolic complications and hospital re-admission since discharge. Quality-of-life assessment will be performed pre-surgery and at 90 days post-surgery. We will also perform qualitative research with clinical experts and patients to explore the understanding of and experience with the interventions, as well as adherence to study procedures and protocol. DISCUSSION There have been no randomised controlled trials that have compared the safety and efficacy of FFP versus PCC in cardiac surgery patients who are bleeding. This pilot study will assess if individual components of a large trial are deliverable to assess the safety and efficacy of the two blood products in the future. TRIAL REGISTRATION EudraCT, 2018-003041-41; ClinicalTrials.gov, NCT03715348. Registered on 29 July 2018.",2019,There have been no randomised controlled trials that have compared the safety and efficacy of FFP versus PCC in cardiac surgery patients who are bleeding.,"['cardiac surgery patients who are bleeding', 'bleeding patients during or immediately after cardiac surgery', 'patients who are bleeding (not on warfarin) and who require blood transfusion', 'adult patients who are undergoing heart surgery (PROPHESY']","['Fresh frozen plasma (FFP', 'PCC versus FFP', 'United Kingdom prothrombin complex concentrate (PCC', 'prothrombin complex concentrates (PCC) versus fresh frozen plasma (FFP', 'FFP']","['thromboembolic complications and hospital re-admission since discharge', 'Quality-of-life assessment', 'safety and efficacy']","[{'cui': 'C0524727', 'cui_str': 'Surgery, Cardiac'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0019080', 'cui_str': 'Bleeding'}, {'cui': 'C0043031', 'cui_str': 'Warfarin'}, {'cui': 'C1273858', 'cui_str': 'Transfusion Medicine'}, {'cui': 'C0001675', 'cui_str': 'Adult'}]","[{'cui': 'C0016709', 'cui_str': 'Fresh frozen plasma (product)'}, {'cui': 'C0044609', 'cui_str': '1-piperidinocyclohexanecarbonitrile'}, {'cui': 'C0041700', 'cui_str': 'United Kingdom'}, {'cui': 'C0072434', 'cui_str': 'cofact'}]","[{'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0600290', 'cui_str': 'Hospital Readmissions'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}, {'cui': 'C0034380'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",50.0,0.160577,There have been no randomised controlled trials that have compared the safety and efficacy of FFP versus PCC in cardiac surgery patients who are bleeding.,"[{'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Green', 'Affiliation': 'Blizard Institute, Queen Mary University of London, NHS Blood and Transplant and Barts Health NHS Trust, 4 Newark Street, Whitechapel, London, E1 2AT, UK. laura.green@qmul.ac.uk.'}, {'ForeName': 'Neil', 'Initials': 'N', 'LastName': 'Roberts', 'Affiliation': ""St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK.""}, {'ForeName': 'Jackie', 'Initials': 'J', 'LastName': 'Cooper', 'Affiliation': 'Barts Cardiovascular Clinical Trials Unit (CVCTU), William Harvey Research Institute, Heart Centre, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.'}, {'ForeName': 'Jane', 'Initials': 'J', 'LastName': 'Field', 'Affiliation': 'Barts Cardiovascular Clinical Trials Unit (CVCTU), William Harvey Research Institute, Heart Centre, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.'}, {'ForeName': 'Ravi', 'Initials': 'R', 'LastName': 'Gill', 'Affiliation': 'Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Klein', 'Affiliation': 'Papworth Hospitals NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK.'}, {'ForeName': 'Seema', 'Initials': 'S', 'LastName': 'Agarwal', 'Affiliation': 'Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Stanworth', 'Affiliation': 'Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford, OX3 9BQ, UK.'}, {'ForeName': 'Atholl', 'Initials': 'A', 'LastName': 'Johnston', 'Affiliation': 'William Harvey Research Institute, Heart Centre, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.'}, {'ForeName': 'Vivienne', 'Initials': 'V', 'LastName': 'Monk', 'Affiliation': 'Barts Cardiovascular Clinical Trials Unit (CVCTU), William Harvey Research Institute, Heart Centre, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.'}, {'ForeName': 'Ben', 'Initials': 'B', 'LastName': ""O'Brien"", 'Affiliation': ""St Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK.""}]",Trials,['10.1186/s13063-019-3759-8'] 3248,30964381,Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.,"Background: Little is known of the repeatability and reliability of mucociliary clearance (MCC) in former tobacco smokers who have both chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB). Less is known of the effect of roflumilast, a selective inhibitor of PDE4, on MCC in these patients. Methods: Former tobacco smokers with COPD and CB were treated for 4 weeks with either roflumilast, or placebo, in a randomized, crossover trial. The following were measured on two baseline and two posttreatment visits: MCC values through 90 minutes, following inhalation of 99m technetium sulfur colloid and gamma camera imaging; outer:inner (O:I) deposition ratio; forced expiratory volume in 1 second (FEV 1 ); and symptom scores. Comparisons included: MCC measures through 30 minutes (MCC30), 60 minutes (MCC60), and 90 minutes (MCC90) on the two baseline visits ( n  = 9) and mean change [(roflumilast - baseline)-(placebo - baseline)] for MCC30, MCC60, MCC90, and FEV 1 ( n  = 8). Associations between MCC measurements, FEV 1 and O:I ratio with symptom scores were also examined. Results: Pearson correlation tests indicated good repeatability for baseline measures of MCC30, MCC60, and MCC90 and intraclass correlation coefficients indicated good reliability. Only FEV 1 (percent predicted) improved significantly following roflumilast treatment. There were no statistically significant correlations between MCC measures and symptom scores. Lower FEV 1 values were significantly associated with increased shortness of breath (dyspnea), and lower O:I ratios (more inner region deposition) were significantly associated with increased cough and sputum. Conclusions: Measurements of MCC30, MCC60, and MCC90 are repeatable and reliable in former tobacco smokers with both COPD and CB. One month of treatment with roflumilast did not improve MCC in this limited study. Airway narrowing in the larger, central airways of these subjects could lead to decreased FEV 1 , increased inner region deposition of the radiolabeled particles, and the associated increase in symptoms of dyspnea, cough, and sputum.",2019,"Lower FEV 1 values were significantly associated with increased shortness of breath (dyspnea), and lower O:I ratios (more inner region deposition) were significantly associated with increased cough and sputum. ","['Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis', 'Former tobacco smokers with COPD and CB', 'former tobacco smokers who have both chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB']","['Roflumilast', 'roflumilast', 'roflumilast, or placebo', 'mucociliary clearance (MCC']","['cough and sputum', 'technetium sulfur colloid and gamma camera imaging; outer:inner (O:I) deposition ratio; forced expiratory volume in 1 second (FEV 1 ); and symptom scores', 'shortness of breath (dyspnea), and lower O:I ratios (more inner region deposition', 'Mucociliary Clearance', 'MCC measures through 30 minutes (MCC30), 60 minutes (MCC60), and 90 minutes (MCC90) on the two baseline visits (n\u2009=\u20099) and mean change [(roflumilast - baseline)-(placebo - baseline)] for MCC30, MCC60, MCC90, and FEV 1 (n\u2009=\u20098', 'symptoms of dyspnea, cough, and sputum', 'MCC measurements, FEV 1 and O:I ratio with symptom scores', 'MCC', 'MCC measures and symptom scores']","[{'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0008677', 'cui_str': 'Bronchitis, Chronic'}]","[{'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary Transport'}]","[{'cui': 'C0010200', 'cui_str': 'Complaining of cough (finding)'}, {'cui': 'C0038056', 'cui_str': 'Sputum'}, {'cui': 'C0039419', 'cui_str': 'technetium (99mTc) sulfur colloid'}, {'cui': 'C0034606', 'cui_str': 'Gamma Camera Imaging'}, {'cui': 'C0205101', 'cui_str': 'External (qualifier value)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0333562', 'cui_str': 'Deposition (morphologic abnormality)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0849974', 'cui_str': 'FEV 1'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0013404', 'cui_str': 'Breathlessness'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205147', 'cui_str': 'Region (attribute)'}, {'cui': 'C0026687', 'cui_str': 'Mucociliary Transport'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C1442458', 'cui_str': 'Thirty minutes (qualifier value)'}, {'cui': 'C3853333', 'cui_str': 'Sixty minutes'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0965618', 'cui_str': 'Roflumilast'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]",,0.114997,"Lower FEV 1 values were significantly associated with increased shortness of breath (dyspnea), and lower O:I ratios (more inner region deposition) were significantly associated with increased cough and sputum. ","[{'ForeName': 'Beth L', 'Initials': 'BL', 'LastName': 'Laube', 'Affiliation': '1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Kathryn A', 'Initials': 'KA', 'LastName': 'Carson', 'Affiliation': '2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.'}, {'ForeName': 'Gail', 'Initials': 'G', 'LastName': 'Sharpless', 'Affiliation': '1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Laura M', 'Initials': 'LM', 'LastName': 'Paulin', 'Affiliation': '3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Nadia N', 'Initials': 'NN', 'LastName': 'Hansel', 'Affiliation': '1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}]",Journal of aerosol medicine and pulmonary drug delivery,['10.1089/jamp.2018.1459'] 3249,30916463,Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder.,"AIMS To compare long-term criminal justice outcomes among opioid-dependent individuals randomized to receive buprenorphine or methadone. DESIGN, SETTING AND PARTICIPANTS A 5-year follow-up was conducted in 2011-14 of 303 opioid-dependent participants entering three opioid treatment programs in California, USA in 2006-09 and randomized to receive either buprenorphine/naloxone or methadone. INTERVENTION AND COMPARATOR Participants received buprenorphine/naloxone (BUP; n = 179) or methadone (MET; n = 124) for 24 weeks and then were tapered off their treatment over ≤ 8 weeks or referred for ongoing clinical treatment. Midway through the study, the randomization scheme was switched from 1 : 1 BUP : MET to 2 : 1 because of higher dropout in the BUP arm. MEASUREMENTS Study outcomes included arrests and self-reported incarceration. Predictors included randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection in the 30 days prior to baseline and study site. Treatment status (buprenorphine, methadone, none) during follow-up was included as a time-varying covariate. FINDINGS There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up. Among methadone-randomized individuals, arrest was less likely with methadone treatment (0.50, 0.35-0.72) during follow-up (relative to no treatment) and switching to buprenorphine had a lower likelihood of arrest than those receiving no treatment (0.39, 0.18-0.87). Among buprenorphine-randomized individuals, arrest was less likely with receipt of buprenorphine (0.49, 0.33-0.75) during follow-up and switching to methadone had a similar likelihood of arrest as methadone-randomized individuals receiving no treatment. Likelihood of arrest was also negatively associated with older age (0.98, 0.96-1.00); it was positively associated with Hispanic ethnicity (1.63, 1.04-2.56), cocaine use (2.00, 1.33-3.03), injection drug use (2.19, 1.26-3.83), and study site. CONCLUSIONS In a US sample of people treated for opioid use disorder, continued treatment with either buprenorphine or methadone was associated with a reduction in arrests relative to no treatment. Cocaine use, injection drug use, Hispanic ethnicity and younger age were associated with higher likelihood of arrest.",2019,"There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up.","['A 5-year follow-up was conducted in 2011-14 of 303 opioid-dependent participants entering three opioid treatment programs in California, USA in 2006-09 and randomized to receive either']","['buprenorphine or methadone', 'buprenorphine/naloxone or methadone', 'buprenorphine/naloxone (BUP; n\xa0=\xa0179) or methadone', 'Cocaine', 'buprenorphine', 'buprenorphine-naloxone', 'methadone', 'buprenorphine, methadone']","['arrests and self-reported incarceration', 'likelihood of arrest', 'randomization condition (buprenorphine versus methadone), age, gender, race/ethnicity, use of cocaine, drug injection', 'Hispanic ethnicity', 'Criminal justice outcomes']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0589120', 'cui_str': 'Follow-up'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0851827', 'cui_str': 'Dependent'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0006754', 'cui_str': 'California'}]","[{'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C1169989', 'cui_str': 'Buprenorphine / Naloxone'}, {'cui': 'C4517609', 'cui_str': '179 (qualifier value)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}]","[{'cui': 'C0237477', 'cui_str': 'Arrested (qualifier value)'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205255', 'cui_str': 'Imprisonment (finding)'}, {'cui': 'C0034656', 'cui_str': 'Randomization'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0006405', 'cui_str': 'Buprenorphine'}, {'cui': 'C0025605', 'cui_str': 'Methadone'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C3853635', 'cui_str': 'Race (observable entity)'}, {'cui': 'C0243103', 'cui_str': 'ethnicity'}, {'cui': 'C1524063', 'cui_str': 'Use of (attribute)'}, {'cui': 'C0009170', 'cui_str': 'Cocaine'}, {'cui': 'C0013227', 'cui_str': 'Pharmaceuticals'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0086072', 'cui_str': 'Criminal Justice'}]",3.0,0.0573535,"There was no significant difference by randomization condition in the proportion arrested (buprenorphine: 55.3%, methadone: 54.0%) or incarcerated (40.9%, 47.3%) during follow-up.","[{'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Evans', 'Affiliation': 'Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.'}, {'ForeName': 'Yuhui', 'Initials': 'Y', 'LastName': 'Zhu', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Yoo', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Huang', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}, {'ForeName': 'Yih-Ing', 'Initials': 'YI', 'LastName': 'Hser', 'Affiliation': 'UCLA Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA.'}]","Addiction (Abingdon, England)",['10.1111/add.14620'] 3250,30770436,Randomised controlled trial of real-time feedback and brief coaching to reduce indoor smoking.,"BACKGROUND Previous secondhand smoke (SHS) reduction interventions have provided only delayed feedback on reported smoking behaviour, such as coaching, or presenting results from child cotinine assays or air particle counters. DESIGN This SHS reduction trial assigned families at random to brief coaching and continuous real-time feedback (intervention) or measurement-only (control) groups. PARTICIPANTS We enrolled 298 families with a resident tobacco smoker and a child under age 14. INTERVENTION We installed air particle monitors in all homes. For the intervention homes, immediate light and sound feedback was contingent on elevated indoor particle levels, and up to four coaching sessions used prompts and praise contingent on smoking outdoors. Mean intervention duration was 64 days. MEASURES The primary outcome was 'particle events' (PEs) which were patterns of air particle concentrations indicative of the occurrence of particle-generating behaviours such as smoking cigarettes or burning candles. Other measures included indoor air nicotine concentrations and participant reports of particle-generating behaviour. RESULTS PEs were significantly correlated with air nicotine levels (r=0.60) and reported indoor cigarette smoking (r=0.51). Interrupted time-series analyses showed an immediate intervention effect, with reduced PEs the day following intervention initiation. The trajectory of daily PEs over the intervention period declined significantly faster in intervention homes than in control homes. Pretest to post-test, air nicotine levels, cigarette smoking and e-cigarette use decreased more in intervention homes than in control homes. CONCLUSIONS Results suggest that real-time particle feedback and coaching contingencies reduced PEs generated by cigarette smoking and other sources. TRIAL REGISTRATION NUMBER NCT01634334; Post-results.",2020,"Pretest to post-test, air nicotine levels, cigarette smoking and e-cigarette use decreased more in intervention homes than in control homes. ",['We enrolled 298 families with a resident tobacco smoker and a child under age 14'],"['real-time feedback and brief coaching', 'brief coaching and continuous real-time feedback (intervention) or measurement-only (control) groups', 'secondhand smoke (SHS) reduction interventions']","['indoor air nicotine concentrations and participant reports of particle-generating behaviour', ""particle events' (PEs) which were patterns of air particle concentrations indicative of the occurrence of particle-generating behaviours such as smoking cigarettes or burning candles"", 'air nicotine levels', 'indoor cigarette smoking', 'Mean intervention duration', 'indoor smoking', 'Pretest to post-test, air nicotine levels, cigarette smoking and e-cigarette use']","[{'cui': 'C0015576', 'cui_str': 'Family'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C4505217', 'cui_str': 'Smokers, Tobacco'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0542339', 'cui_str': 'Below (qualifier value)'}]","[{'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0015744', 'cui_str': 'Feedback'}, {'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0549178', 'cui_str': 'Continuous (qualifier value)'}, {'cui': 'C0242485', 'cui_str': 'Measurement procedure'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0037370', 'cui_str': 'Smoking, Passive'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}]","[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0441471', 'cui_str': 'Event (event)'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C2745955', 'cui_str': 'Occurrences (qualifier value)'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0006434', 'cui_str': 'Burns'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0700219', 'cui_str': 'Cigarette Smoking'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0392366', 'cui_str': 'Tests (qualifier value)'}, {'cui': 'C4280017', 'cui_str': 'E-Cig Use'}]",298.0,0.025272,"Pretest to post-test, air nicotine levels, cigarette smoking and e-cigarette use decreased more in intervention homes than in control homes. ","[{'ForeName': 'Melbourne F', 'Initials': 'MF', 'LastName': 'Hovell', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Bellettiere', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Sandy', 'Initials': 'S', 'LastName': 'Liles', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Benjamin', 'Initials': 'B', 'LastName': 'Nguyen', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Vincent', 'Initials': 'V', 'LastName': 'Berardi', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Johnson', 'Affiliation': 'Pediatrics, Naval Medical Center, San Diego, California, USA.'}, {'ForeName': 'Georg E', 'Initials': 'GE', 'LastName': 'Matt', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'John', 'Initials': 'J', 'LastName': 'Malone', 'Affiliation': 'Department of Medicine, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.'}, {'ForeName': 'Marie C', 'Initials': 'MC', 'LastName': 'Boman-Davis', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Penelope J E', 'Initials': 'PJE', 'LastName': 'Quintana', 'Affiliation': 'Environmental Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Saori', 'Initials': 'S', 'LastName': 'Obayashi', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Dale', 'Initials': 'D', 'LastName': 'Chatfield', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Robinson', 'Affiliation': 'Office on Smoking and Health, CDC, Atlanta, Georgia, USA.'}, {'ForeName': 'Elaine J', 'Initials': 'EJ', 'LastName': 'Blumberg', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Weg M', 'Initials': 'WM', 'LastName': 'Ongkeko', 'Affiliation': 'Surgery, University of California San Diego, La Jolla, California, USA.'}, {'ForeName': 'Neil E', 'Initials': 'NE', 'LastName': 'Klepeis', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': 'Suzanne C', 'Initials': 'SC', 'LastName': 'Hughes', 'Affiliation': 'Center for Behavioral Epidemiology and Community Health, Graduate School of Public Health, San Diego State University, San Diego, California, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Tobacco control,['10.1136/tobaccocontrol-2018-054717'] 3251,30413879,Local anesthetic spread into the paravertebral space with two types of quadratus lumborum blocks: a crossover volunteer study.,"PURPOSE Previous work showed that 20 mL of local anesthetic (LA) did not spread into the paravertebral space (PVS) via the intramuscular quadratus lumborum block (QLBi). If spread of LA into the PVS can be achieved by increasing the total LA volume, QLBi can be more effective. We hypothesized that a larger volume of LA for the QLBi would spread into the PVS. METHODS This crossover volunteer study included five healthy men. For comparison, both the ultrasound-guided QLB type 2 (QLB2) and QLBi were employed on opposite sides of each volunteer, and the spread of LA solution (0.7 mL/kg) mixed with contrast media in the PVS was assessed 1 h after the first injection using magnetic resonance imaging. Sensory loss was evaluated by pinprick 90 min post-injection. Each volunteer underwent both QLB types, and the same procedures were administered on opposite sides 7 days after the first experiment. RESULTS In total, 20 QLB blocks (10 QLB2 and 10 QLBi) were performed. LA did not spread into the PVS after the QLBi. The sensory block area included the lower abdomen after the QLB2, but not after the QLBi. The sensory block area did not extend to the upper abdominal region or the midline of the lower abdomen with either block method. CONCLUSION LA administered by the QLB2 spreads into the PVS of T10-T12, resulting in lower and lateral abdominal sensory loss. In contrast, LA administered by the QLBi does not spread into the PVS and results in only lateral abdominal sensory loss.",2019,"The sensory block area did not extend to the upper abdominal region or the midline of the lower abdomen with either block method. ",['five healthy men'],"['local anesthetic (LA', 'LA']","['lateral abdominal sensory loss', 'Sensory loss']","[{'cui': 'C0086418', 'cui_str': 'Humans'}]","[{'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}]","[{'cui': 'C0205093', 'cui_str': 'Lateral (qualifier value)'}, {'cui': 'C0000726', 'cui_str': 'Abdomen'}, {'cui': 'C0278134', 'cui_str': 'Absence of sensation (finding)'}]",5.0,0.0287345,"The sensory block area did not extend to the upper abdominal region or the midline of the lower abdomen with either block method. ","[{'ForeName': 'Takahiro', 'Initials': 'T', 'LastName': 'Tamura', 'Affiliation': 'Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ku, Nagoya, 466-8550, Japan. takahiro@med.nagoya-u.ac.jp.'}, {'ForeName': 'Shuichi', 'Initials': 'S', 'LastName': 'Yokota', 'Affiliation': 'Division of Anesthesia, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.'}, {'ForeName': 'Shigeki', 'Initials': 'S', 'LastName': 'Ito', 'Affiliation': 'Division of Diagnostic Radiology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.'}, {'ForeName': 'Yasuyuki', 'Initials': 'Y', 'LastName': 'Shibata', 'Affiliation': 'Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ku, Nagoya, 466-8550, Japan.'}, {'ForeName': 'Kimitoshi', 'Initials': 'K', 'LastName': 'Nishiwaki', 'Affiliation': 'Department of Anesthesiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-Ku, Nagoya, 466-8550, Japan.'}]",Journal of anesthesia,['10.1007/s00540-018-2578-5'] 3252,29778325,"Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial.","BACKGROUND Tranexamic acid can prevent death due to bleeding after trauma and post-partum haemorrhage. We aimed to assess whether tranexamic acid reduces haematoma expansion and improves outcome in adults with stroke due to intracerebral haemorrhage. METHODS We did an international, randomised placebo-controlled trial in adults with intracerebral haemorrhage from acute stroke units at 124 hospital sites in 12 countries. Participants were randomly assigned (1:1) to receive 1 g intravenous tranexamic acid bolus followed by an 8 h infusion of 1 g tranexamic acid or a matching placebo, within 8 h of symptom onset. Randomisation was done centrally in real time via a secure website, with stratification by country and minimisation on key prognostic factors. Treatment allocation was concealed from patients, outcome assessors, and all other health-care workers involved in the trial. The primary outcome was functional status at day 90, measured by shift in the modified Rankin Scale, using ordinal logistic regression with adjustment for stratification and minimisation criteria. All analyses were done on an intention-to-treat basis. This trial is registered with the ISRCTN registry, number ISRCTN93732214. FINDINGS We recruited 2325 participants between March 1, 2013, and Sept 30, 2017. 1161 patients received tranexamic acid and 1164 received placebo; the treatment groups were well balanced at baseline. The primary outcome was assessed for 2307 (99%) participants. The primary outcome, functional status at day 90, did not differ significantly between the groups (adjusted odds ratio [aOR] 0·88, 95% CI 0·76-1·03, p=0·11). Although there were fewer deaths by day 7 in the tranexamic acid group (101 [9%] deaths in the tranexamic acid group vs 123 [11%] deaths in the placebo group; aOR 0·73, 0·53-0·99, p=0·0406), there was no difference in case fatality at 90 days (250 [22%] vs 249 [21%]; adjusted hazard ratio 0·92, 95% CI 0·77-1·10, p=0·37). Fewer patients had serious adverse events after tranexamic acid than after placebo by days 2 (379 [33%] patients vs 417 [36%] patients), 7 (456 [39%] vs 497 [43%]), and 90 (521 [45%] vs 556 [48%]). INTERPRETATION Functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events. Larger randomised trials are needed to confirm or refute a clinically significant treatment effect. FUNDING National Institute of Health Research Health Technology Assessment Programme and Swiss Heart Foundation.",2018,"90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events.","['2325 participants between March 1, 2013, and Sept 30, 2017', 'adults with stroke due to intracerebral haemorrhage', 'adults with intracerebral haemorrhage from acute stroke units at 124 hospital sites in 12 countries', 'hyperacute primary IntraCerebral Haemorrhage (TICH-2', '1161 patients received']","['tranexamic acid or a matching placebo', 'tranexamic acid', 'Tranexamic acid', 'placebo']","['early deaths and serious adverse events', 'intracerebral haemorrhage', 'functional status at day 90, measured by shift in the modified Rankin Scale', 'functional status', 'serious adverse events', 'deaths']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0038454', 'cui_str': 'Apoplexy'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C0751956', 'cui_str': 'Stroke, Acute'}, {'cui': 'C0439148', 'cui_str': 'Units (attribute)'}, {'cui': 'C4517553', 'cui_str': '124 (qualifier value)'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0205145', 'cui_str': 'Site (attribute)'}, {'cui': 'C0454664', 'cui_str': 'Country (geographic location)'}, {'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C2937358', 'cui_str': 'Intracerebral Hemorrhage'}, {'cui': 'C0205245', 'cui_str': 'Functional (qualifier value)'}, {'cui': 'C0449438', 'cui_str': 'Status (attribute)'}, {'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0333051', 'cui_str': 'Shift (morphologic abnormality)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}]",2325.0,0.796746,"90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events.","[{'ForeName': 'Nikola', 'Initials': 'N', 'LastName': 'Sprigg', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK; Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK. Electronic address: nikola.sprigg@nottingham.ac.uk.'}, {'ForeName': 'Katie', 'Initials': 'K', 'LastName': 'Flaherty', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK.'}, {'ForeName': 'Jason P', 'Initials': 'JP', 'LastName': 'Appleton', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK.'}, {'ForeName': 'Rustam', 'Initials': 'R', 'LastName': 'Al-Shahi Salman', 'Affiliation': 'Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Bereczki', 'Affiliation': 'Department of Neurology, Semmelweis University, Budapest, Hungary.'}, {'ForeName': 'Maia', 'Initials': 'M', 'LastName': 'Beridze', 'Affiliation': 'The First University Clinic of Tbilisi State Medical University, Tbilisi, Georgia.'}, {'ForeName': 'Hanne', 'Initials': 'H', 'LastName': 'Christensen', 'Affiliation': 'Department of Neurology, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Ciccone', 'Affiliation': 'Neurology Unit, Azienda Socio Sanitaria Territoriale di Mantova, Mantua, Italy.'}, {'ForeName': 'Ronan', 'Initials': 'R', 'LastName': 'Collins', 'Affiliation': 'Stroke Service, Adelaide and Meath Hospital, Tallaght, Ireland.'}, {'ForeName': 'Anna', 'Initials': 'A', 'LastName': 'Czlonkowska', 'Affiliation': '2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Dineen', 'Affiliation': 'Radiological Sciences, Division of Clinical Neuroscience, University of Nottingham, Queens Medical Centre Campus, Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK.'}, {'ForeName': 'Lelia', 'Initials': 'L', 'LastName': 'Duley', 'Affiliation': ""Nottingham Clinical Trials Unit, University of Nottingham, Queen's Medical Centre, Nottingham, UK.""}, {'ForeName': 'Juan Jose', 'Initials': 'JJ', 'LastName': 'Egea-Guerrero', 'Affiliation': 'UGC de Medicina Intensiva, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain.'}, {'ForeName': 'Timothy J', 'Initials': 'TJ', 'LastName': 'England', 'Affiliation': 'Vascular Medicine, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital Centre, Derby, UK.'}, {'ForeName': 'Kailash', 'Initials': 'K', 'LastName': 'Krishnan', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK; Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK.'}, {'ForeName': 'Ann Charlotte', 'Initials': 'AC', 'LastName': 'Laska', 'Affiliation': 'Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.'}, {'ForeName': 'Zhe Kang', 'Initials': 'ZK', 'LastName': 'Law', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK; Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK; Department of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'Serefnur', 'Initials': 'S', 'LastName': 'Ozturk', 'Affiliation': 'Department of Neurology, Selcuk University Medical Faculty, Konya, Turkey.'}, {'ForeName': 'Stuart J', 'Initials': 'SJ', 'LastName': 'Pocock', 'Affiliation': 'Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Roberts', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Thompson G', 'Initials': 'TG', 'LastName': 'Robinson', 'Affiliation': 'Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.'}, {'ForeName': 'Christine', 'Initials': 'C', 'LastName': 'Roffe', 'Affiliation': 'Stroke Research, Faculty of Medicine and Health Sciences, Keele University, Staffordshire, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Seiffge', 'Affiliation': 'Stroke Center, Neurology and Department of Clinical Research, University Hospital, University Basel, Basel, Switzerland.'}, {'ForeName': 'Polly', 'Initials': 'P', 'LastName': 'Scutt', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK.'}, {'ForeName': 'Jegan', 'Initials': 'J', 'LastName': 'Thanabalan', 'Affiliation': 'Division of Neurosurgery, Department of Surgery, National University of Malaysia, Kuala Lumpur, Malaysia.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Werring', 'Affiliation': 'Stroke Research Centre, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, University College London, London, UK.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Whynes', 'Affiliation': 'School of Economics, University of Nottingham, University Park, Nottingham, UK.'}, {'ForeName': 'Philip M', 'Initials': 'PM', 'LastName': 'Bath', 'Affiliation': 'Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, City Hospital Campus, Nottingham, UK; Stroke, Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Lancet (London, England)",['10.1016/S0140-6736(18)31033-X'] 3253,32007604,"Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.","OBJECTIVE Stimulant medications are the most prevalent first-line pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD), but children with aggressive behavior often receive multi-agent treatment. There is sparse evidence for the benefits of adjunctive medications when stimulant monotherapy has proved inadequate, yet the adverse effects of common adjuncts are well-established. This study compared the efficacy in reducing aggressive behavior of risperidone (RISP), divalproex sodium (DVPX), and placebo (PBO) added to stimulant medication among children whose symptoms persisted after individually-optimized stimulant treatment. METHOD This trial enrolled 6-12-year-olds with ADHD, a disruptive disorder, significant aggressive behavior, and prior stimulant treatment. Open, systematically titrated stimulant treatment identified patients with inadequate reductions in aggressive behavior, who were then randomized to receive adjunctive RISP, DVPX, or PBO under double-blind conditions for 8 weeks. Family-based behavioral treatment was offered throughout the trial. The primary outcome was the parent-completed Retrospective-Modified Overt Aggression Scale. RESULTS 175 children participated, mean [sd] age 9.48 [2.04] years, 19% female. 151 participants completed the stimulant optimization phase, with aggression remitting among 96 (63%), and 45 were randomized to adjunctive treatment groups. The adjunctive RISP group showed greater reductions in aggression ratings than the PBO group; least squares means difference [ΔLSM], -2.33 (95% confidence interval [CI], -3.83 - -0.82; effect size [ES], -1.32), as did those receiving DVPX (ΔLSM, -1.60; 95% CI, -3.18 - -0.03; ES, -0.91). Mean standardized body mass index scores increased more among RISP-treated patients than those receiving -PBO (ΔLSM, 1.54; 95% CI, 0.68 - 2.40; ES = 0.58). CONCLUSION High response rate during the trial's open stimulant optimization phase suggests that rigorous titration of stimulant medication and concurrent behavioral therapy may avert the need for additional medications. Among nonremitters, RISP and DVPX were efficacious adjunctive treatments although RISP was associated with weight gain.",2020,"Among nonremitters, RISP and DVPX were efficacious adjunctive treatments although RISP was associated with weight gain.","['children whose symptoms persisted after individually-optimized stimulant treatment', 'Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior', 'patients with inadequate reductions in aggressive behavior', '175 children participated, mean [sd] age 9.48', '151 participants completed the stimulant optimization phase, with aggression remitting among 96 (63%), and 45', 'enrolled 6-12-year-olds with ADHD, a disruptive disorder, significant aggressive behavior, and prior stimulant treatment']","['risperidone (RISP), divalproex sodium (DVPX), and placebo (PBO', 'Adjunctive Risperidone, Divalproex Sodium, or Placebo', 'adjunctive RISP, DVPX, or PBO']","['weight gain', 'parent-completed Retrospective-Modified Overt Aggression Scale', 'aggression ratings', 'Mean standardized body mass index scores']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0242977', 'cui_str': 'Stimulants, Historical'}, {'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1263846', 'cui_str': 'ADDH'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205412', 'cui_str': 'Inadequate (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C4517605', 'cui_str': '175'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0439600', 'cui_str': 'Remitting (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0750502', 'cui_str': 'Significant'}]","[{'cui': 'C0073393', 'cui_str': 'Risperidone'}, {'cui': 'C0886883', 'cui_str': 'Divalproex Sodium'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0043094', 'cui_str': 'Weight Gain'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0001807', 'cui_str': 'Aggression'}, {'cui': 'C0222045'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",175.0,0.308042,"Among nonremitters, RISP and DVPX were efficacious adjunctive treatments although RISP was associated with weight gain.","[{'ForeName': 'Joseph C', 'Initials': 'JC', 'LastName': 'Blader', 'Affiliation': 'Matthews are with the University of Texas Health Science Center, San Antonio. Electronic address: blader@uthscsa.edu.'}, {'ForeName': 'Steven R', 'Initials': 'SR', 'LastName': 'Pliszka', 'Affiliation': 'Matthews are with the University of Texas Health Science Center, San Antonio.'}, {'ForeName': 'Vivian', 'Initials': 'V', 'LastName': 'Kafantaris', 'Affiliation': 'Zucker Hillside Hospital and the Feinstein Institute for Medical Research.'}, {'ForeName': 'Carmel A', 'Initials': 'CA', 'LastName': 'Foley', 'Affiliation': ""Cohen Children's Medical Center of New York, Divisions of Northwell Health, Manhasset, NY.""}, {'ForeName': 'Gabrielle A', 'Initials': 'GA', 'LastName': 'Carlson', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, NY.'}, {'ForeName': 'Judith A', 'Initials': 'JA', 'LastName': 'Crowell', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, NY.'}, {'ForeName': 'Brigitte Y', 'Initials': 'BY', 'LastName': 'Bailey', 'Affiliation': 'Matthews are with the University of Texas Health Science Center, San Antonio.'}, {'ForeName': 'Colin', 'Initials': 'C', 'LastName': 'Sauder', 'Affiliation': 'Adams Clinical, Watertown, MA.'}, {'ForeName': 'W Burleson', 'Initials': 'WB', 'LastName': 'Daviss', 'Affiliation': 'Geisel School of Medicine at Dartmouth, Lebanon, NH.'}, {'ForeName': 'Christa', 'Initials': 'C', 'LastName': 'Sinha', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, NY.'}, {'ForeName': 'Thomas L', 'Initials': 'TL', 'LastName': 'Matthews', 'Affiliation': 'Matthews are with the University of Texas Health Science Center, San Antonio.'}, {'ForeName': 'David M', 'Initials': 'DM', 'LastName': 'Margulies', 'Affiliation': 'Renaissance School of Medicine, Stony Brook University, NY.'}]",Journal of the American Academy of Child and Adolescent Psychiatry,['10.1016/j.jaac.2019.12.009'] 3254,32024323,Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6-10 weeks: a randomized double-blind active-controlled trial.,"BACKGROUND Pneumococcal diseases among children aged <5 years worldwide are associated with high annual mortality rates. PURPOSE This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 booster dose (2p+1) in healthy infants. METHODS This randomized active-controlled (Prevnar 13) double-blind phase 2 trial enrolled healthy subjects aged 6-10 weeks. Three serum concentrations of pneumococcal serotype-specific immunoglobulin G (IgG) were evaluated using the pneumococcal serotype-specific pneumonia polysaccharide enzyme-linked immunosorbent assay at 1 month after the primary doses and before and 1 month after the booster dose. The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. RESULTS After administration of the primary doses, the proportion of subjects who achieved pneumococcal serotype-specific IgG concentrations of >0.35 μg/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P<0.001). However, after administration of the booster dose, >97% of the subjects in each group achieved IgG concentrations of ≥0.35 μg/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003). CONCLUSION The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.",2020,"The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. ","['infants aged 6 to 10 weeks ', 'healthy infants', 'subjects were eligible if they were aged 6-10 weeks and healthy', 'children aged under 5 years worldwide']","['12-valent pneumococcal conjugate vaccine', 'GBP411']","['overall incidence of solicited systemic adverse events', 'overall incidence of solicited local adverse events', 'IgG concentrations', 'immunogenicity', 'proportion of subjects who achieved pneumococcal serotype-specific IgG concentrations', 'serum concentrations of pneumococcal serotype-specific immunoglobulin G (IgG', 'Immunogenicity and safety']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0047247', 'cui_str': 'ANDS'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C1579319', 'cui_str': 'Streptococcus pneumoniae conjugate vaccine'}]","[{'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C0220856', 'cui_str': 'incidence'}, {'cui': 'C0205373', 'cui_str': 'Systemic (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0020852', 'cui_str': 'Immunoglobulin G'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0449550', 'cui_str': 'Serotype (UK)'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0358334', 'cui_str': 'Specific immunoglobulins'}, {'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.534718,"The pneumococcal serotype-specific IgG titer was evaluated using a multiplex opsonophagocytic assay in a subset of 15 subjects per group. ","[{'ForeName': 'Jonghoon', 'Initials': 'J', 'LastName': 'Shin', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Jamaree', 'Initials': 'J', 'LastName': 'Teeratakulpisarn', 'Affiliation': 'Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand.'}, {'ForeName': 'Thanyawee', 'Initials': 'T', 'LastName': 'Puthanakit', 'Affiliation': 'Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Tuangtip', 'Initials': 'T', 'LastName': 'Theerawit', 'Affiliation': 'Department of Pediatrics and Center of Excellence in Pediatric Infectious Diseases and Vaccine Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.'}, {'ForeName': 'Ji Hwa', 'Initials': 'JH', 'LastName': 'Ryu', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Jinhwan', 'Initials': 'J', 'LastName': 'Shin', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Seulgi', 'Initials': 'S', 'LastName': 'Lee', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Hayoung', 'Initials': 'H', 'LastName': 'Lee', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Kyungjun', 'Initials': 'K', 'LastName': 'An', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}, {'ForeName': 'Hun', 'Initials': 'H', 'LastName': 'Kim', 'Affiliation': 'SK bioscience, Seonam-si, Republic of Korea.'}]",Clinical and experimental pediatrics,['10.3345/cep.2019.01067'] 3255,32032566,"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.","BACKGROUND PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant. METHODS This first-in-human, randomised, double-blind, placebo-controlled, dose escalation trial was done in two staggered phases, a phase 1A trial in 18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso. Volunteers were recruited into four sequential cohorts receiving PRIMVAC intramuscularly at day 0, 28, and 56: two cohorts in France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC. Volunteers were randomly assigned (1:1) to two groups (PRIMVAC adjuvanted with either Alhydrogel or GLA-SE) in France and randomly assigned (2:2:1) to three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo) in Burkina Faso. Randomisation was centralised, using stratification by cohort and blocks of variable size, and syringes were masked by opaque labels. The primary endpoint was the proportion of participants with any grade 3 or higher adverse reaction to vaccination up until day 35. Safety at later time points as well as humoral and cellular immunogenicity were assessed in secondary endpoints. This trial is registered with ClinicalTrials.gov, NCT02658253. FINDINGS Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included. No serious adverse event related to the vaccine occurred. PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57). PRIMVAC antibody titres reached a peak (geometric mean 11 843·0, optical density [OD] 1·0, 95% CI 7559·8-18 552·9 with 100 μg dose and GLA-SE) 1 week after the third vaccination (day 63). Compared with Alhydrogel, GLA-SE tended to improve the PRIMVAC antibody response (geometric mean 2163·5, OD 1·0, 95% CI 1315·7-3557·7 with 100 μg dose and Alhydrogel at day 63). 1 year after the last vaccination, 20 (71%) of 28 women who were vaccinated with PRIMVAC/Alhydrogel and 26 (93%) of 28 women who were vaccinated with PRIMVAC/GLA-SE still had anti-PRIMVAC antibodies, although antibody magnitude was markedly lower (452·4, OD 1·0, 95% CI 321·8-636·1 with 100 μg dose and GLA-SE). These antibodies reacted with native homologous VAR2CSA expressed by NF54-CSA infected erythrocytes (fold change from baseline at day 63 with 100 μg dose and GLA-SE: 10·74, 95% CI 8·36-13·79). Limited cross-recognition, restricted to sera collected from women that received the 100 μg PRIMVAC dose, was observed against heterologous VAR2CSA variants expressed by FCR3-CSA (fold change from baseline at day 63: 1·49, 95% CI 1·19-1·88) and 7G8-CSA infected erythrocytes (1·2, 1·08-1·34). INTERPRETATION PRIMVAC adjuvanted with Alhydrogel or GLA-SE had an acceptable safety profile, was immunogenic, and induced functional antibodies reacting with the homologous VAR2CSA variant expressed by NF54-CSA infected erythrocytes. Cross-reactivity against heterologous VAR2CSA variants was limited and only observed in the higher dose group. An alternate schedule of immunisation, antigen dose, and combinations with other VAR2CSA-based vaccines are envisaged to improve the cross-reactivity against heterologous VAR2CSA variants. FUNDING Bundesministerium für Bildung und Forschung, through Kreditanstalt für Wiederaufbau, Germany; Inserm, and Institut National de Transfusion Sanguine, France; Irish Aid, Department of Foreign Affairs and Trade, Ireland.",2020,PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57).,"['French and Burkinabe women who were not pregnant', '18-35-year-old women who were malaria naive in a hospital in France and a subsequent phase 1B trial in women who were naturally exposed to P falciparum and nulligravid in the clinical site of a research centre in Burkina Faso', 'Between April 19, 2016, and July 13, 2017, 68 women (18 in France, 50 in Burkina Faso) of 101 assessed for eligibility were included']","['Alhydrogel, GLA-SE', 'Alhydrogel or GLA-SE', 'placebo', 'France receiving 20 μg or 50 μg of PRIMVAC and then two in Burkina Faso receiving 50 μg or 100 μg of PRIMVAC', 'three groups (PRIMVAC adjuvanted with either Alhydrogel, GLA-SE, or placebo', 'GLA-SE', 'PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE', 'PRIMVAC adjuvanted with either Alhydrogel or GLA-SE']","['humoral and cellular immunogenicity', 'PRIMVAC antibody response', 'placental malaria', 'antibody magnitude', 'safety and immunogenicity', 'PRIMVAC antibody titres', 'proportion of participants with any grade 3 or higher adverse reaction']","[{'cui': 'C1556084', 'cui_str': 'French (ethnic group)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0232973', 'cui_str': 'Not pregnant (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0585064', 'cui_str': 'Numerical phases (qualifier value)'}, {'cui': 'C0332157', 'cui_str': 'Exposure to (contextual qualifier) (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C2945843', 'cui_str': 'Site of (attribute)'}, {'cui': 'C0035168'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}]","[{'cui': 'C0733770', 'cui_str': 'Alhydrogel'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0016674', 'cui_str': 'France'}, {'cui': 'C0006409', 'cui_str': 'Upper Volta'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0023779', 'cui_str': 'Lipids'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C0014020', 'cui_str': 'Emulsions'}]","[{'cui': 'C0003261', 'cui_str': 'Antibody Response'}, {'cui': 'C0024530', 'cui_str': 'Plasmodium Infections'}, {'cui': 'C0003241', 'cui_str': 'Antibodies'}, {'cui': 'C1704240', 'cui_str': 'Magnitudes (qualifier value)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C1287242', 'cui_str': 'Finding of antibody titer (finding)'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}]",,0.360643,PRIMVAC antibody titres increased with each dose and seroconversion was observed in all women vaccinated with PRIMVAC (n=57).,"[{'ForeName': 'Sodiomon B', 'Initials': 'SB', 'LastName': 'Sirima', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Richert', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France; Inria SISTM team, Talence, France.'}, {'ForeName': 'Arnaud', 'Initials': 'A', 'LastName': 'Chêne', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Amadou T', 'Initials': 'AT', 'LastName': 'Konate', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Cécilia', 'Initials': 'C', 'LastName': 'Campion', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Sébastien', 'Initials': 'S', 'LastName': 'Dechavanne', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Jean-Philippe', 'Initials': 'JP', 'LastName': 'Semblat', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France.'}, {'ForeName': 'Nadine', 'Initials': 'N', 'LastName': 'Benhamouda', 'Affiliation': ""INSERM U970, Paris Cardiovascular Research Centre, Université de Paris, Faculté de médecine, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.""}, {'ForeName': 'Mathilde', 'Initials': 'M', 'LastName': 'Bahuaud', 'Affiliation': ""Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Plateforme d'immuno-monitoring vaccinal, Laboratoire d'Immunologie, Paris, France.""}, {'ForeName': 'Pierre', 'Initials': 'P', 'LastName': 'Loulergue', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Alphonse', 'Initials': 'A', 'LastName': 'Ouédraogo', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issa', 'Initials': 'I', 'LastName': 'Nébié', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Moïse', 'Initials': 'M', 'LastName': 'Kabore', 'Affiliation': 'Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Désiré', 'Initials': 'D', 'LastName': 'Kargougou', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Aïssata', 'Initials': 'A', 'LastName': 'Barry', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'San Maurice', 'Initials': 'SM', 'LastName': 'Ouattara', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Valérie', 'Initials': 'V', 'LastName': 'Boilet', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Florence', 'Initials': 'F', 'LastName': 'Allais', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Gwenaelle', 'Initials': 'G', 'LastName': 'Roguet', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Nicolas', 'Initials': 'N', 'LastName': 'Havelange', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Elvira', 'Initials': 'E', 'LastName': 'Lopez-Perez', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Alexis', 'Initials': 'A', 'LastName': 'Kuppers', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Eleine', 'Initials': 'E', 'LastName': 'Konaté', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Caroline', 'Initials': 'C', 'LastName': 'Roussillon', 'Affiliation': ""Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; Direction de la Recherche Clinique et de l'Innovation, Unité de sécurité et vigilance des Essais Cliniques, CHU de Bordeaux, Bordeaux, France.""}, {'ForeName': 'Myriam', 'Initials': 'M', 'LastName': 'Kanté', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France.'}, {'ForeName': 'Linda', 'Initials': 'L', 'LastName': 'Belarbi', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Diarra', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso; Groupe de Recherche Action en Santé, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Noelie', 'Initials': 'N', 'LastName': 'Henry', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Issiaka', 'Initials': 'I', 'LastName': 'Soulama', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Amidou', 'Initials': 'A', 'LastName': 'Ouédraogo', 'Affiliation': 'Centre national de recherche et de formation sur le paludisme, Ouagadougou, Burkina Faso.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Esperou', 'Affiliation': 'INSERM, Institut de Santé Publique, Pôle de Recherche Clinique, Paris, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Leroy', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Frederic', 'Initials': 'F', 'LastName': 'Batteux', 'Affiliation': ""Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Plateforme d'immuno-monitoring vaccinal, Laboratoire d'Immunologie, Paris, France.""}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Tartour', 'Affiliation': ""INSERM U970, Paris Cardiovascular Research Centre, Université de Paris, Faculté de médecine, Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.""}, {'ForeName': 'Nicola K', 'Initials': 'NK', 'LastName': 'Viebig', 'Affiliation': 'European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.'}, {'ForeName': 'Rodolphe', 'Initials': 'R', 'LastName': 'Thiebaut', 'Affiliation': 'Universite Bordeaux, Inserm, Bordeaux Population Health Research Center, CHU Bordeaux, EUCLID/F-CRIN Clinical Trials Platform, Bordeaux, France; CHU Bordeaux, Pôle de Santé Publique, Bordeaux, France; Inria SISTM team, Talence, France.'}, {'ForeName': 'Odile', 'Initials': 'O', 'LastName': 'Launay', 'Affiliation': 'Université de Paris, Faculté de médecine, INSERM, CIC 1417, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, CIC Cochin Pasteur, Paris, France.'}, {'ForeName': 'Benoît', 'Initials': 'B', 'LastName': 'Gamain', 'Affiliation': 'Université de Paris, Biologie Intégrée du Globule Rouge, UMR_S1134, BIGR, INSERM, Paris, France; Institut National de la Transfusion Sanguine, Paris, France; Laboratory of excellence GR-Ex, Paris, France. Electronic address: benoit.gamain@inserm.fr.'}]",The Lancet. Infectious diseases,['10.1016/S1473-3099(19)30739-X'] 3256,31599637,"Reflective functioning, psychotherapeutic alliance, and outcome in two psychotherapies for bulimia nervosa.","Mentalization is a developmental achievement defined as the capacity to understand behavior in terms of mental states. This study investigated mentalization in psychoanalytic psychotherapy (PPT) and cognitive behavior therapy (CBT) through a secondary data analysis of findings from a randomized controlled trial for bulimia nervosa. It was hypothesized that mentalization would predict alliance and outcome in both treatments, whereas increase in mentalization was only expected after PPT. Furthermore, it was investigated whether change in mentalization predicted symptom change. A total of 70 participants with bulimia nervosa were randomized to PPT or CBT. Participants were assessed at 3 time points with the Eating Disorder Examination and the Adult Attachment Interview (rated for reflective functioning [RF]). Therapy sessions were rated with the Vanderbilt Therapeutic Alliance Scale. Higher intake RF significantly predicted better alliance, whereas no association was observed between RF and outcome. A significant interaction between time, therapy type, and RF found RF improving more in PPT than in CBT. There was a significant association between RF change and symptom change in the PPT group. The study suggests a relation between RF and psychotherapy process, whereas the relation between RF and outcome is more complex. Furthermore, PPT seems to enhance mentalization, which seems related to symptomatic improvement, suggesting that mentalization might serve as a specific mechanism of change in PPT. (PsycInfo Database Record (c) 2020 APA, all rights reserved).",2020,"A significant interaction between time, therapy type, and RF found RF improving more in PPT than in CBT.","['bulimia nervosa', '70 participants with bulimia nervosa']","['psychoanalytic psychotherapy (PPT) and cognitive behavior therapy (CBT', 'PPT or CBT']","['Vanderbilt Therapeutic Alliance Scale', 'mentalization', 'Eating Disorder Examination and the Adult Attachment Interview (rated for reflective functioning [RF', 'RF change and symptom change']","[{'cui': 'C2267227', 'cui_str': 'Bulimia Nervosa'}]","[{'cui': 'C1273567', 'cui_str': 'Psychotherapy (specialty)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0814487', 'cui_str': 'Therapeutic Alliance'}, {'cui': 'C0222045'}, {'cui': 'C4704687', 'cui_str': 'Mentalization'}, {'cui': 'C2732388', 'cui_str': 'Eating disorder examination'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0935630', 'cui_str': 'Interview'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}]",70.0,0.0460995,"A significant interaction between time, therapy type, and RF found RF improving more in PPT than in CBT.","[{'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Katznelson', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Fredrik', 'Initials': 'F', 'LastName': 'Falkenström', 'Affiliation': 'Department of Behavioral Sciences and Learning, Linköping University.'}, {'ForeName': 'Sarah I F', 'Initials': 'SIF', 'LastName': 'Daniel', 'Affiliation': 'Private practice.'}, {'ForeName': 'Susanne', 'Initials': 'S', 'LastName': 'Lunn', 'Affiliation': 'Department of Psychology.'}, {'ForeName': 'Sofie', 'Initials': 'S', 'LastName': 'Folke', 'Affiliation': 'Department for Military Psychology, Danish Veterans Centre.'}, {'ForeName': 'Signe Holm', 'Initials': 'SH', 'LastName': 'Pedersen', 'Affiliation': 'Department for Eating Disorders, Child and Adolescents Psychiatric Centre.'}, {'ForeName': 'Stig', 'Initials': 'S', 'LastName': 'Poulsen', 'Affiliation': 'Department of Psychology.'}]","Psychotherapy (Chicago, Ill.)",['10.1037/pst0000245'] 3257,30104408,Testing messages about comparative risk of electronic cigarettes and combusted cigarettes.,"INTRODUCTION Health agencies are grappling with communicating risks of electronic cigarettes (e-cigarettes) compared with combusted cigarettes. This study examined smokers' responses to two types of comparative risk messages with one type incorporating more negative antismoking elements in the design. METHODS In an online experiment, 1400 US adult (18+ years) current smokers and recent quitters were randomised to view one of three comparative risk messages about e-cigarettes (CR messages), one of three comparative risk messages that included more negative antismoking elements in the design (CR- messages) or a control message. Selection of outcomes was guided by the antismoking message impact framework. Multivariate analyses of covariance and logistic regression models analysed effects of messages on message evaluations, e-cigarette-related and cigarette-related beliefs and behavioural intentions. RESULTS Both CR and CR- messages decreased smokers' intentions to smoke cigarettes, increased intentions to switch to e-cigarettes completely and increased perceptions that e-cigarettes are less harmful than combusted cigarettes. Neither message type increased dual use intentions relative to exclusive e-cigarettes use or smoking cessation. CR messages decreased perceived absolute risks of e-cigarettes and self-exempting beliefs about smoking, whereas CR- versus CR messages produced higher self-efficacy to quit smoking. CONCLUSION Comparative risk communication might encourage smokers to switch to lower-harm tobacco products. Comparative risk messages with more negative antismoking elements in the design might be particularly effective, because they led to higher self-efficacy to quit smoking. Regulatory agencies may consider using comparative risk messages with more negative antismoking elements to educate the public about lower risk of e-cigarettes.",2019,Neither message type increased dual use intentions relative to exclusive e-cigarettes use or smoking cessation.,['1400 US adult (18+ years) current smokers and recent quitters'],"['comparative risk messages about e-cigarettes (CR messages), one of three comparative risk messages that included more negative antismoking elements in the design (CR- messages) or a control message']","['message evaluations, e-cigarette-related and cigarette-related beliefs and behavioural intentions', 'dual use intentions relative to exclusive e-cigarettes use or smoking cessation']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C3241966'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205160', 'cui_str': 'Negative (qualifier value)'}, {'cui': 'C0013879', 'cui_str': 'Elements'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0004951', 'cui_str': 'Beliefs'}, {'cui': 'C0162425', 'cui_str': 'Intention'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C3875154', 'cui_str': 'Relative to (attribute)'}, {'cui': 'C4280017', 'cui_str': 'E-Cig Use'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]",1400.0,0.0246293,Neither message type increased dual use intentions relative to exclusive e-cigarettes use or smoking cessation.,"[{'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Yang', 'Affiliation': 'Tobacco Center of Regulatory Science, School of Public Health, Georgia State University, Atlanta, Georgia, USA.'}, {'ForeName': 'Daniel', 'Initials': 'D', 'LastName': 'Owusu', 'Affiliation': 'Tobacco Center of Regulatory Science, School of Public Health, Georgia State University, Atlanta, Georgia, USA.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Popova', 'Affiliation': 'Tobacco Center of Regulatory Science, School of Public Health, Georgia State University, Atlanta, Georgia, USA.'}]",Tobacco control,['10.1136/tobaccocontrol-2018-054404'] 3258,30412360,"Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.","The effect of food on the bioavailability of the components of the once-daily, single-tablet human immunodeficiency virus (HIV) type 1 regimen containing darunavir (DRV 800 mg), cobicistat (COBI 150 mg), emtricitabine (FTC 200 mg), and tenofovir alafenamide (TAF 10 mg) (D/C/F/TAF) (NCT02475135) and the bioequivalence of D/C/F/TAF versus combined intake of the separate agents (NCT02578550) were evaluated. These were 2 phase 1, open-label, randomized, 2-period crossover studies (7-day washout between treatments) in HIV-negative healthy volunteers. Twenty-four participants each received a single dose of D/C/F/TAF in fasted conditions (test) or after a standardized high-fat breakfast (reference). Ninety-six participants each received a single dose of D/C/F/TAF (test) or combined intake of a single DRV 800-mg tablet, a COBI 150-mg tablet, and an FTC/TAF 200/10-mg tablet (reference), both after a standardized regular-calorie, regular-fat breakfast. Pharmacokinetic profiles for all D/C/F/TAF components, safety, and tolerability were assessed. Following D/C/F/TAF in fasted conditions, DRV peak concentration, area under the concentration-time curve from time of administration until the last time point with a measurable concentration (AUC) last , and extrapolated to infinity (AUC inf ) were lower by 45%, 34%, and 30%, respectively, compared with fed conditions, with no clinically relevant differences in COBI, FTC, or TAF exposures between fed and fasted conditions. In the bioequivalence study 90% confidence intervals of the geometric mean ratios of all main pharmacokinetic parameters were within the 80.00% to 125.00% bioequivalence limits for DRV, COBI, FTC, and TAF. No grade 3/4 adverse events (AEs), serious AEs, deaths, or discontinuations due to AEs occurred. D/C/F/TAF is bioequivalent to combined administration of the separate agents. Consistent with other (co)formulations of DRV, DRV exposure was lower in fasted than in fed conditions as evaluated when taken with food, so D/C/F/TAF should be taken with food.",2019,"No grade 3/4 adverse events (AEs), serious AEs, deaths, or discontinuations due to AEs occurred.",['HIV-negative healthy volunteers'],"['darunavir (DRV 800 mg), cobicistat (COBI 150 mg), emtricitabine (FTC 200 mg), and tenofovir alafenamide (TAF 10 mg', 'single dose of D/C/F/TAF (test) or combined intake of a single DRV 800-mg tablet, a COBI 150-mg tablet, and an FTC/TAF 200/10-mg tablet (reference), both after a standardized regular-calorie, regular-fat breakfast', 'Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide']","['COBI, FTC, or TAF exposures', 'F/TAF components, safety, and tolerability', 'grade 3/4 adverse events (AEs), serious AEs, deaths, or discontinuations due to AEs', 'DRV peak concentration, area under the concentration-time curve']","[{'cui': 'C0481430', 'cui_str': 'HTLV-3 antibody negative'}, {'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C1435444', 'cui_str': 'darunavir'}, {'cui': 'C3844106', 'cui_str': 'Eight hundred'}, {'cui': 'C3177235', 'cui_str': 'cobicistat'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0909839', 'cui_str': 'emtricitabine'}, {'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3713958', 'cui_str': 'tenofovir alafenamide'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C1705223', 'cui_str': 'Tablet'}, {'cui': 'C0205272', 'cui_str': 'Regular (qualifier value)'}, {'cui': 'C1879985', 'cui_str': 'calorie'}, {'cui': 'C0015677', 'cui_str': 'Fats'}, {'cui': 'C4553621', 'cui_str': 'With breakfast'}]","[{'cui': 'C0274281', 'cui_str': 'Injury due to exposure to external cause (disorder)'}, {'cui': 'C0449432', 'cui_str': 'Component (attribute)'}, {'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0441800', 'cui_str': 'Grading (attribute)'}, {'cui': 'C0442757', 'cui_str': '3/4'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}, {'cui': 'C0444505', 'cui_str': 'Peak (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0205146', 'cui_str': 'Area (qualifier value)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0205134', 'cui_str': 'Curved (qualifier value)'}]",96.0,0.0825928,"No grade 3/4 adverse events (AEs), serious AEs, deaths, or discontinuations due to AEs occurred.","[{'ForeName': 'Herta M', 'Initials': 'HM', 'LastName': 'Crauwels', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Bryan', 'Initials': 'B', 'LastName': 'Baugh', 'Affiliation': 'Janssen Research & Development LLC, Raritan, NJ, USA.'}, {'ForeName': 'Erika', 'Initials': 'E', 'LastName': 'Van Landuyt', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Simon', 'Initials': 'S', 'LastName': 'Vanveggel', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Hijzen', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}, {'ForeName': 'Magda', 'Initials': 'M', 'LastName': 'Opsomer', 'Affiliation': 'Janssen Pharmaceutica NV, Beerse, Belgium.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.628'] 3259,25923150,Randomized double blinded placebo controlled trial comparing diclofenac and piroxicam in management of acute renal colic and its clinical implications.,"PURPOSE To compare the efficacy of sublingual piroxicam 40 mg with intramuscular diclofenac 75 mg in treatment of acute renal colic. The secondary objective was to look for factors that can affect the severity of the pain and pain relief in acute renal colic. MATERIALS AND METHODS One hundred patients with acute renal colic were randomized into two groups. Group A (n = 50) received intramuscular diclofenac and sublingual methylcobalamin. Group B (n = 50) received sublingual piroxicam 40 mg and intramuscular distilled water. Pain severity was measured using Visual Analog Scale (VAS) and verbal and facial response scales. They were followed up for 3 h. Intramuscular injection of pentazocine 30 mg with promethazine 25 mg were used as rescue drugs. RESULTS Both groups were comparable for age, sex distribution, body mass index (BMI), and pain duration before presentation. Significant pain relief was noticed in both groups. Sixteen percent in group A and 18% in group B had complete pain relief within 30 min (P = .75). Fifteen patients in group A and 13 patients in group B needed rescue drugs, 84% of group A and 76% of group B had complete pain relief at the end of 3 hours (P = .25). Decrease in pain by each scoring method was also comparable (P = .75). In multiple regression analysis, increasing age, positively affects the severity of pain and pain relief while increasing BMI negatively affect the initial pain relief. Acute renal colic seems to affect men more commonly than women, 81% of the study population were men. Patients with low initial pain score did not require any additional pain relief. Average pain duration before presenting to hospital is 260 min. Sixty percent of renal colics are due to stones below pelvic brim. CONCLUSION The results show that sublingual piroxicam is as effective as intramuscular diclofenac. It can be easily self-administered and it overcomes the morbidity and time delay in getting intramuscular diclofenac.",2015,Sixteen percent in group A and 18% in group B had complete pain relief within 30 min (P = .75).,"['acute renal colic', 'One hundred patients with acute renal colic', 'Patients with low initial pain score']","['intramuscular diclofenac', 'pentazocine 30 mg with promethazine', 'placebo', 'sublingual piroxicam 40 mg and intramuscular distilled water', 'diclofenac and piroxicam', 'sublingual piroxicam', 'intramuscular diclofenac and sublingual methylcobalamin', 'diclofenac']","['pain', 'pain and pain relief', 'complete pain relief', 'Average pain duration', 'severity of pain and pain relief', 'Significant pain relief', 'additional pain relief', 'initial pain relief', 'Visual Analog Scale (VAS) and verbal and facial response scales', 'Pain severity']","[{'cui': 'C0152169', 'cui_str': 'Acute Renal Colic'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}]","[{'cui': 'C0442117', 'cui_str': 'Intramuscular (qualifier value)'}, {'cui': 'C0012091', 'cui_str': 'Diclofenac'}, {'cui': 'C0030873', 'cui_str': 'Pentazocine'}, {'cui': 'C0033405', 'cui_str': 'Promethazine'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4521982', 'cui_str': 'Sublingual'}, {'cui': 'C0031990', 'cui_str': 'Piroxicam'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0065844', 'cui_str': 'methylcobalamin'}]","[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C0205265', 'cui_str': 'Initial (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0222045'}]",100.0,0.0822738,Sixteen percent in group A and 18% in group B had complete pain relief within 30 min (P = .75).,"[{'ForeName': 'Gokul Vignesh', 'Initials': 'GV', 'LastName': 'KandaSwamy', 'Affiliation': 'Dudley Group Hospitals NHS Foundation Trust, Dudley-DY1 2HQ, West Midlands, UK. kgvignesh@yahoo.com.'}, {'ForeName': 'Ananda Kumar', 'Initials': 'AK', 'LastName': 'Dhanasekaran', 'Affiliation': 'Queen Elizabeth University Hospital, Birmingham, UK.'}, {'ForeName': 'Aravindhan', 'Initials': 'A', 'LastName': 'Elangovan', 'Affiliation': 'Dharan Hospital, Salem, India.'}, {'ForeName': 'Bobby', 'Initials': 'B', 'LastName': 'John', 'Affiliation': 'Department of Urology Malankara Orthodox Syrian Church Medical College, Kolenchery, India.'}, {'ForeName': 'Bobby', 'Initials': 'B', 'LastName': 'Viswaroop', 'Affiliation': 'Vedanayagam Hospital Private Limited, Coimbatore, India.'}, {'ForeName': 'Kandasami Sangam', 'Initials': 'KS', 'LastName': 'Vedanayagam', 'Affiliation': 'Department of Urology Vedanayagam Hospital, Private Limited, Coimbatore, India.'}]",Urology journal,[] 3260,31317627,"Oral sucrose for analgesia in children aged between 3 months and 3 years undergoing transurethral bladder catheterisation: A randomised, double-blinded, clinical trial.","AIM Many children admitted to hospital undergo invasive, painful and stressful procedures, including children who are not toilet trained undergoing transurethral bladder catheterisation (TUBC). Oral sucrose is commonly given to children to reduce procedural pain. In this study, we evaluated the effectiveness of oral sucrose in reducing procedural pain in children aged between 3 months and 3 years undergoing TUBC. METHODS This study was a randomised, double-blind, placebo-controlled study conducted at Nepean Hospital, Sydney, Australia from June 2005 to June 2010. A total of 40 participants requiring TUBC for diagnostic evaluation were included. The participants were randomly assigned to receive 4 mL of 75% oral sucrose (n = 20) or a placebo (sterilised water) (n = 20). The primary outcomes were changes in two paediatric pain scale scores (the FLACC pain scale and the OUCHER pain scale), assessed by the parent/guardian(s), the doctor performing the TUBC and the nurse assisting. The secondary outcomes were physiological (changes in heart rate) and behavioural pain (crying) indicators. RESULTS Of the outcome measures, 65% favoured the oral sucrose group, 31% favoured the placebo group, and 4% found no difference between the oral sucrose and placebo groups. CONCLUSION While the trends favouring the sucrose group in this study were encouraging, as the results were not statistically significant, there was insufficient evidence to demonstrate the effectiveness of oral sucrose in reducing procedural pain in children aged between 3 months and 3 years undergoing TUBC.",2020,"The primary outcomes were changes in two paediatric pain scale scores (the FLACC pain scale and the OUCHER pain scale), assessed by the parent/guardian(s), the doctor performing the TUBC and the nurse assisting.","['children aged between 3 months and 3 years undergoing TUBC', 'controlled study conducted at Nepean Hospital, Sydney, Australia from June 2005 to June 2010', '40 participants requiring TUBC for diagnostic evaluation were included', 'children admitted to hospital undergo invasive, painful and stressful procedures, including children who are not toilet trained undergoing', 'children aged between 3 months and 3 years undergoing transurethral bladder catheterisation']","['Oral sucrose', 'oral sucrose', 'placebo', '4 mL of 75% oral sucrose', 'placebo (sterilised water', 'transurethral bladder catheterisation (TUBC']","['physiological (changes in heart rate) and behavioural pain (crying) indicators', 'changes in two paediatric pain scale scores (the FLACC pain scale and the OUCHER pain scale), assessed by the parent/guardian(s), the doctor performing the TUBC and the nurse assisting', 'procedural pain']","[{'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}, {'cui': 'C0004340', 'cui_str': 'Australia'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0205281', 'cui_str': 'Invasive (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0700127', 'cui_str': 'Toilet trained (finding)'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach (qualifier value)'}, {'cui': 'C1970989', 'cui_str': 'Insertion of catheter into urinary bladder'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0038636', 'cui_str': 'Sucrose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0043047', 'cui_str': 'Water'}, {'cui': 'C0205497', 'cui_str': 'Transurethral approach (qualifier value)'}, {'cui': 'C1970989', 'cui_str': 'Insertion of catheter into urinary bladder'}]","[{'cui': 'C0205463', 'cui_str': 'Physiologic (qualifier value)'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0018810', 'cui_str': 'Cardiac rate'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C1504479', 'cui_str': 'Pain scale'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C1274041', 'cui_str': 'Guardian'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0028661', 'cui_str': 'Personnel, Nursing'}, {'cui': 'C1619712', 'cui_str': 'Pain, Procedural'}]",40.0,0.493548,"The primary outcomes were changes in two paediatric pain scale scores (the FLACC pain scale and the OUCHER pain scale), assessed by the parent/guardian(s), the doctor performing the TUBC and the nurse assisting.","[{'ForeName': 'Kevin', 'Initials': 'K', 'LastName': 'London', 'Affiliation': ""Department of Nuclear Medicine, Children's Hospital at Westmead, Sydney, New South Wales, Australia.""}, {'ForeName': 'Hamish', 'Initials': 'H', 'LastName': 'Watson', 'Affiliation': ""Department of Nuclear Medicine, Children's Hospital at Westmead, Sydney, New South Wales, Australia.""}, {'ForeName': 'Samson', 'Initials': 'S', 'LastName': 'Kwok', 'Affiliation': 'Department of Paediatrics, Nepean Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Ralph', 'Initials': 'R', 'LastName': 'Nanan', 'Affiliation': 'Department of Paediatrics, Nepean Hospital, Sydney, New South Wales, Australia.'}, {'ForeName': 'Anthony', 'Initials': 'A', 'LastName': 'Liu', 'Affiliation': 'Department of Paediatrics, Nepean Hospital, Sydney, New South Wales, Australia.'}]",Journal of paediatrics and child health,['10.1111/jpc.14559'] 3261,31415451,BASELINE CHARACTERISTICS OF VITREOMACULAR TRACTION PROGRESSING TO FULL-THICKNESS MACULAR OR LAMELLAR HOLES IN THE PHASE III TRIALS OF ENZYMATIC VITREOLYSIS.,"PURPOSE To identify characteristics associated with progression from vitreomacular traction (VMT) to a full-thickness macular hole (FTMH) or lamellar hole (LH). METHODS Post-hoc analysis of the Phase III clinical trial comparing ocriplasmin with placebo for treatment of vitreomacular adhesion (MIVI-TRUST). Exact logistic regression analyses were used to identify baseline characteristics significantly associated with progression from vitreomacular traction to FTMH or LH over the 6-month study period. RESULTS Twenty eyes (4.5%) developed an FTMH and 38 (9.7%) developed an LH during the study period. The rate of progression to FTMH or LH did not differ significantly between ocriplasmin- and saline-treated eyes (P = 0.090 for FTMH, P = 0.369 for LH). On univariate analysis, the presence of subretinal fluid (adjusted odds ratio 5.64, 95% confidence interval 2.02-17.17, P < 0.001) and mean subretinal fluid thickness (adjusted odds ratio 1.10, 95% confidence interval 1.04-1.16, P = 0.003) were associated with FTMH development. Both remained significantly associated with FTMH development on multivariate testing. On univariate analysis, the presence of macular schisis (adjusted odds ratio 2.26, 95% confidence interval 1.30-3.82, P = 0.004) and mean retinal thickness (adjusted odds ratio 1.06, 95% confidence interval 1.01-1.10, P = 0.010) were associated with LH development. Schisis remained a significant predictor of LH formation on multivariate testing. CONCLUSION Vitreomacular traction is more likely to progress to FTMH when associated with subretinal fluid, but when associated with intraretinal changes (such as schisis), vitreomacular traction appears more likely to progress to a LH after a single intravitreal injection of ocriplasmin or saline.",2020,"On univariate analysis, the presence of subretinal fluid (adjusted odds ratio 5.64, 95% confidence interval 2.02-17.17, P < 0.001) and mean subretinal fluid thickness (adjusted odds ratio 1.10, 95% confidence interval 1.04-1.16, P = 0.003) were associated with FTMH development.",[],"['ocriplasmin with placebo', 'ocriplasmin or saline', 'vitreomacular traction (VMT) to a full-thickness macular hole (FTMH) or lamellar hole (LH']","['LH formation', 'mean retinal thickness', 'mean subretinal fluid thickness', 'macular schisis', 'rate of progression to FTMH or LH']",[],"[{'cui': 'C0066522', 'cui_str': 'ocriplasmin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C0040597', 'cui_str': 'Traction'}, {'cui': 'C2733564', 'cui_str': 'Full thickness hole of macula lutea'}]","[{'cui': 'C0439634', 'cui_str': 'Formations (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0035331', 'cui_str': 'Retinal'}, {'cui': 'C1720732', 'cui_str': 'Subretinal fluid'}, {'cui': 'C0449258', 'cui_str': 'Progression (attribute)'}]",,0.324151,"On univariate analysis, the presence of subretinal fluid (adjusted odds ratio 5.64, 95% confidence interval 2.02-17.17, P < 0.001) and mean subretinal fluid thickness (adjusted odds ratio 1.10, 95% confidence interval 1.04-1.16, P = 0.003) were associated with FTMH development.","[{'ForeName': 'Eric W', 'Initials': 'EW', 'LastName': 'Schneider', 'Affiliation': 'Tennessee Retina, PC, Nashville, Tennessee.'}, {'ForeName': 'Glenn J', 'Initials': 'GJ', 'LastName': 'Jaffe', 'Affiliation': 'Department of Ophthalmology, Duke University Eye Center, Duke University, Durham, North Carolina.'}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002634'] 3262,29389542,Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.,"BACKGROUND Sub-Saharan Africa and southern Asia account for almost 85% of global maternal deaths from post-partum haemorrhage. Early administration of tranexamic acid, within 3 h of giving birth, was shown to reduce the risk of death due to bleeding in women with post-partum haemorrhage in the World Maternal Antifibrinolytic (WOMAN) trial. We aimed to assess the cost-effectiveness of early administration of tranexamic acid for treatment of post-partum haemorrhage. METHODS For this economic evaluation we developed a decision model to assess the cost-effectiveness of the addition of tranexamic acid to usual care for treatment of women with post-partum haemorrhage in Nigeria and Pakistan. We used data from the WOMAN trial to inform model parameters, supplemented by estimates from the literature. We estimated costs (calculated in 2016 US$), life-years, and quality-adjusted life-years (QALYs) with and without tranexamic acid, calculated incremental cost-effectiveness ratios (ICERs), and compared these to threshold values in each country. Costs were assessed from the health-care provider perspective and discounted at 3% per year in the base case analysis. We did a series of one-way sensitivity analyses and probabilistic sensitivity analysis to assess the robustness of the results to parameter uncertainty. FINDINGS Early treatment of post-partum haemorrhage with tranexamic acid generated an average gain of 0·18 QALYs at an additional cost of $37·12 per patient in Nigeria and an average gain of 0·08 QALYs at an additional cost of $6·55 per patient in Pakistan. The base case ICER results were $208 per QALY in Nigeria and $83 per QALY in Pakistan. These ICERs were below the lower bound of the cost-effectiveness threshold range in both countries. The ICERs were most sensitive to uncertainty in parameter inputs for the relative risk of death due to bleeding with tranexamic acid, the discount rate, the cost of the drug, and the baseline probability of death due to bleeding. INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. FUNDING London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation.",2018,"INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. ","['women with post-partum haemorrhage in the World Maternal Antifibrinolytic (WOMAN) trial', 'women with post-partum haemorrhage in Nigeria and Pakistan']","['Tranexamic acid', 'tranexamic acid']","['cost-effectiveness', 'average gain of 0·18 QALYs', 'estimated costs (calculated in 2016 US$), life-years, and quality-adjusted life-years (QALYs) with and without tranexamic acid, calculated incremental cost-effectiveness ratios (ICERs', 'risk of death due to bleeding']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C1869041', 'cui_str': 'Haemorrhages (SMQ)'}, {'cui': 'C0026591', 'cui_str': 'Mothers'}, {'cui': 'C0003304', 'cui_str': 'Antifibrinolysins'}, {'cui': 'C0028075', 'cui_str': 'Federal Republic of Nigeria'}, {'cui': 'C0030211', 'cui_str': 'Islamic Republic of Pakistan'}]","[{'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}]","[{'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}, {'cui': 'C0080071', 'cui_str': 'QALY'}, {'cui': 'C0750572', 'cui_str': 'Estimated (qualifier value)'}, {'cui': 'C0010186', 'cui_str': 'Cost'}, {'cui': 'C0444686', 'cui_str': 'Calculated (qualifier value)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0040613', 'cui_str': 'Tranexamic Acid'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0678226', 'cui_str': 'Due to (attribute)'}]",,0.319762,"INTERPRETATION Early treatment of post-partum haemorrhage with tranexamic acid is highly cost-effective in Nigeria and Pakistan, and is likely to be cost-effective in countries in sub-Saharan Africa and southern Asia with a similar baseline risk of death due to bleeding. ","[{'ForeName': 'Bernadette', 'Initials': 'B', 'LastName': 'Li', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: bernadette.li@lshtm.ac.uk.'}, {'ForeName': 'Alec', 'Initials': 'A', 'LastName': 'Miners', 'Affiliation': 'Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Haleema', 'Initials': 'H', 'LastName': 'Shakur', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': 'Ian', 'Initials': 'I', 'LastName': 'Roberts', 'Affiliation': 'Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The Lancet. Global health,['10.1016/S2214-109X(17)30467-9'] 3263,31120272,Psychological mechanisms driving stress resilience in mindfulness training: A randomized controlled trial.,"OBJECTIVE Mindfulness interventions have been shown to reduce stress; however, the mechanisms driving stress resilience effects are not known. Mindfulness interventions aim to teach individuals how to: (a) use attention to monitor present moment experiences; with (b) an attitude of acceptance and equanimity. A randomized controlled dismantling trial (RCT) was conducted to test the prediction that the removal of acceptance skills training would eliminate stress-reduction benefits of a mindfulness intervention. METHOD This preregistered RCT randomly assigned stressed community adults to 1 of 3 conditions: (a) Monitor and Accept (MA) mindfulness training, a standard 8-week Mindfulness-Based Stress Reduction (MBSR) intervention that provided explicit instruction in developing both monitoring and acceptance skills; (b) Monitor Only (MO) mindfulness training, a well-matched 8-week MBSR intervention that taught monitoring skills only; or (c) No Treatment (NT) control. Stress and nonjudgment were measured using ecological momentary assessment (EMA) for 3 days at baseline and 3 days at postintervention. RESULTS Consistent with predictions, MA participants increased in nonjudgment and decreased in both stress ratings and the proportion of assessments that they reported experiencing feelings of stress in daily life, relative to both MO and NT participants. CONCLUSIONS This RCT provides one of the first experimental tests of the mechanisms linking mindfulness interventions with stress resilience. These findings suggest that acceptance skills training may be a necessary active ingredient and support the value of integrating acceptance skills training into stress-reduction interventions. (PsycINFO Database Record (c) 2019 APA, all rights reserved).",2019,"Consistent with predictions, MA participants increased in nonjudgment and decreased in both stress ratings and the proportion of assessments that they reported experiencing feelings of stress in daily life, relative to both MO and NT participants. ",[],"['Monitor and Accept (MA) mindfulness training, a standard 8-week Mindfulness-Based Stress Reduction (MBSR) intervention that provided explicit instruction in developing both monitoring and acceptance skills; (b) Monitor Only', 'MO) mindfulness training, a well-matched 8-week MBSR intervention that taught monitoring skills only; or (c']","['ecological momentary assessment (EMA', 'stress ratings']",[],"[{'cui': 'C0181904', 'cui_str': 'Monitor, device (physical object)'}, {'cui': 'C1272684', 'cui_str': 'Accepted'}, {'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0039401', 'cui_str': 'Teaching'}, {'cui': 'C0336766', 'cui_str': 'Matches'}]","[{'cui': 'C4277684', 'cui_str': 'Ecological Momentary Assessment'}, {'cui': 'C0268596', 'cui_str': 'Glutaric Acidemia, Type 2'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}]",,0.0356366,"Consistent with predictions, MA participants increased in nonjudgment and decreased in both stress ratings and the proportion of assessments that they reported experiencing feelings of stress in daily life, relative to both MO and NT participants. ","[{'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Chin', 'Affiliation': 'Department of Psychology, Carnegie Mellon University.'}, {'ForeName': 'Emily K', 'Initials': 'EK', 'LastName': 'Lindsay', 'Affiliation': 'Department of Psychology, University of Pittsburgh.'}, {'ForeName': 'Carol M', 'Initials': 'CM', 'LastName': 'Greco', 'Affiliation': 'Department of Psychology, University of Pittsburgh.'}, {'ForeName': 'Kirk Warren', 'Initials': 'KW', 'LastName': 'Brown', 'Affiliation': 'Department of Psychology, Virginia Commonwealth University.'}, {'ForeName': 'Joshua M', 'Initials': 'JM', 'LastName': 'Smyth', 'Affiliation': 'Department of Biobehavioral Health, Pennsylvania State University.'}, {'ForeName': 'Aidan G C', 'Initials': 'AGC', 'LastName': 'Wright', 'Affiliation': 'Department of Psychology, University of Pittsburgh.'}, {'ForeName': 'J David', 'Initials': 'JD', 'LastName': 'Creswell', 'Affiliation': 'Department of Psychology, Carnegie Mellon University.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0000763'] 3264,31425628,Statins versus placebo for people with chronic obstructive pulmonary disease.,"BACKGROUND Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable respiratory disease. COPD exacerbations are associated with worse quality of life, increased hospitalisations, and increased mortality. Currently available pharmacological interventions have variable impact on exacerbation frequency. The anti-inflammatory effects of statins may lead to decreased pulmonary and systemic inflammation, resulting in fewer exacerbations of COPD. Several observational studies have shown potential benefits of statins for patients with COPD. OBJECTIVES This review aims to evaluate available evidence on benefits and harms associated with statin therapy compared with placebo as adjunct therapy for patients with COPD. Primary objectives include the following.• To determine whether statins reduce mortality rates in COPD.• To determine whether statins reduce exacerbation frequency, improve quality of life, or improve lung function in COPD.• To determine whether statins are associated with adverse effects. SEARCH METHODS We identified trials from the Cochrane Airways Trials Register, which contains studies identified through multiple electronic searches and handsearches of other sources. We also searched trial registries and reference lists of primary studies. We conducted the most recent search on 20 May 2019. SELECTION CRITERIA Parallel, randomised controlled trials recruiting adults with COPD. DATA COLLECTION AND ANALYSIS We used standard methods as expected by Cochrane. Prespecified primary outcomes were number of exacerbations, all-cause mortality, and COPD-specific mortality. MAIN RESULTS Eight studies including 1323 participants with COPD were included in the review. Participants had a mean age of 61.4 to 72 years, and most were male (median 73.4%). Mean baseline forced expiratory volume in one second (FEV₁) ranged from 41% to 90% predicted. All studies compared moderate- or high-intensity statin therapy versus placebo. The duration of treatment ranged from 12 weeks to 36 months.We found no statistically significant difference between statins and placebo in our primary outcome of number of exacerbations per person-year (mean difference (MD) -0.03, 95% confidence interval (CI) -0.25 to 0.19, 1 trial, 877 participants), including number of exacerbations requiring hospitalisation per person-year (MD 0.00, 95% CI -0.10 to 0.10, 1 trial, 877 exacerbations). This evidence was of moderate quality after downgrading for unclear risk of bias. Our primary outcomes of all-cause mortality (odds ratio (OR) 1.03, 95% CI 0.61 to 1.74, 2 trials, 952 participants) and COPD-specific mortality (OR 1.25, 95% CI 0.38 to 4.13, 1 trial, 877 participants) showed no significant difference between statins and placebo, with wide confidence intervals suggesting uncertainty about the precision of the results. This evidence was of low quality after downgrading for unclear risk of bias and imprecision.Results of the secondary outcomes analysis showed no clear differences between statins and placebo for FEV₁ (% predicted) (MD 1.18, 95% CI -2.6 to 4.97, 6 trials, 325 participants) but did show a statistically significant improvement in FEV₁/forced vital capacity (FVC) (MD 2.66, 95% CI 0.12 to 5.2; P = 0.04; 6 trials, 325 participants). A sensitivity analysis excluding two trials at high risk of bias showed no statistically significant difference in FEV₁/FVC (MD 2.05, 95% CI -0.87 to -4.97; P = 0.17; 4 trials, 255 participants). We also found no significant differences between the two groups in functional capacity measured by six-minute walk distance in metres (MD 1.79, 95% CI -52.51 to 56.09, 3 trials, 71 participants), with wide confidence intervals suggesting uncertainty about the precision of the results. Results show no clear difference in quality of life, which was reported in three trials, and a slight reduction in C-reactive protein (CRP) in the intervention group, which was statistically significant (MD -1.03, 95% CI -1.95 to -0.11; I² = 0%, P = 0.03; 3 trials, 142 participants). We noted a significant reduction in interleukin (IL)-6 in the intervention group (MD -2.11, 95% CI -2.65 to -1.56; I² = 0%, P ≤ 0.00001; 2 trials, 125 participants). All trials mentioned adverse events and indicated that statins were generally well tolerated. One study reported adverse events in detail and indicated that rates of all non-fatal adverse events (the number of serious adverse events per person-year) were similar in both groups (0.63 ± 1.56 events (intervention group) and 0.62 ± 1.48 events (control group); P > 0.20) for all comparisons, except for non-fatal serious adverse events involving the gastrointestinal tract, which were more frequent in the intervention group (in 30 patients (0.05 events per person-year) vs 17 patients (0.02 events per person-year); P = 0.02). Another trial lists the total numbers and percentages of adverse events in the intervention group (12 (26%)) and in the control group (21 (43%)) and of serious adverse events in the intervention group (4 (9%)) and in the control group (3 (6%)).The other trials stated that researchers found no significant adverse effects of statins but did not report adverse events in detail. AUTHORS' CONCLUSIONS A small number of trials providing low- or moderate-quality evidence were suitable for inclusion in this review. They showed that use of statins resulted in a reduction in CRP and IL-6, but that this did not translate into clear clinical benefit for people with COPD. Further randomised controlled trials are needed to explore this topic.",2019,"We also found no significant differences between the two groups in functional capacity measured by six-minute walk distance in metres (MD 1.79, 95% CI -52.51 to 56.09, 3 trials, 71 participants), with wide confidence intervals suggesting uncertainty about the precision of the results.","['people with COPD', '1323 participants with COPD', 'patients with COPD', 'people with chronic obstructive pulmonary disease', 'adults with COPD', 'Chronic obstructive pulmonary disease (COPD', 'Participants had a mean age of 61.4 to 72 years, and most were male (median 73.4']","['placebo', 'Statins versus placebo']","['quality of life, increased hospitalisations, and increased mortality', 'functional capacity', 'C-reactive protein (CRP', 'COPD exacerbations', 'number of exacerbations requiring hospitalisation', 'number of exacerbations, all-cause mortality, and COPD-specific mortality', 'quality of life', 'serious adverse events', 'quality of life, or improve lung function', 'interleukin (IL)-6', 'FEV₁/FVC', 'adverse effects', 'tolerated', 'number of exacerbations per person-year', 'total numbers and percentages of adverse events', 'rates of all non-fatal adverse events', 'Mean baseline forced expiratory volume', 'COPD-specific mortality', 'FEV₁/forced vital capacity (FVC', 'CRP and IL-6', 'cause mortality']","[{'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0360714', 'cui_str': 'Statins'}]","[{'cui': 'C0034380'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0740304', 'cui_str': 'COPD exacerbation'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0024117', 'cui_str': 'Chronic Obstructive Lung Disease'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0024119', 'cui_str': 'Lung Function Tests'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C1302234', 'cui_str': 'Fatal'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C1306036', 'cui_str': 'Forced expiratory volume'}, {'cui': 'C0430511', 'cui_str': 'Vital capacity test (procedure)'}]",877.0,0.738337,"We also found no significant differences between the two groups in functional capacity measured by six-minute walk distance in metres (MD 1.79, 95% CI -52.51 to 56.09, 3 trials, 71 participants), with wide confidence intervals suggesting uncertainty about the precision of the results.","[{'ForeName': 'Aisling', 'Initials': 'A', 'LastName': 'Walsh', 'Affiliation': 'Department of Paediatrics, Cork University Hospital, Cork, Ireland.'}, {'ForeName': 'Lucy', 'Initials': 'L', 'LastName': 'Perrem', 'Affiliation': ''}, {'ForeName': 'Ali S', 'Initials': 'AS', 'LastName': 'Khashan', 'Affiliation': ''}, {'ForeName': 'Michael T', 'Initials': 'MT', 'LastName': 'Henry', 'Affiliation': ''}, {'ForeName': 'Muireann', 'Initials': 'M', 'LastName': 'Ni Chroinin', 'Affiliation': ''}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD011959.pub2'] 3265,31519441,The Effect of Extended Continuous Positive Airway Pressure on Changes in Lung Volumes in Stable Premature Infants: A Randomized Controlled Trial.,"OBJECTIVE To compare changes in lung volumes, as measured by functional residual capacity (FRC), through to discharge in stable infants randomized to 2 weeks of extended continuous positive airway pressure CPAP (eCPAP) vs CPAP discontinuation (dCPAP). STUDY DESIGN Infants born at ≤32 weeks of gestation requiring ≥24 hours of CPAP were randomized to 2 weeks of eCPAP vs dCPAP when meeting CPAP stability criteria. FRC was measured with the nitrogen washout technique. Infants were stratified by gestational age (<28 and ≥ 28 weeks) and twin gestation. A linear mixed-effects model was used to evaluate the change in FRC between the 2 groups. Data were analyzed blinded to treatment group allocation. RESULTS Fifty infants were randomized with 6 excluded, for a total of 44 infants. Baseline characteristics were similar in the 2 groups. The infants randomized to eCPAP vs dCPAP had a greater increase in FRC from randomization through 2 weeks (12.6 mL vs 6.4 mL; adjusted 95% CI, 0.78-13.47; P = .03) and from randomization through discharge (27.2 mL vs 17.1 mL; adjusted 95% CI, 2.61-17.59; P = .01). CONCLUSIONS Premature infants randomized to eCPAP had a significantly greater increase in FRC through discharge compared with those randomized to dCPAP. An increased change in FRC may lead to improved respiratory health. TRIAL REGISTRATION ClinicalTrials.gov: NCT02249143.",2020,"CONCLUSIONS Premature infants randomized to eCPAP had a significantly greater increase in FRC through discharge compared with those randomized to dCPAP.","['Infants were stratified by gestational age (<28 and\xa0≥\xa028\xa0weeks) and twin gestation', 'Fifty infants were randomized with 6 excluded, for a total of 44 infants', 'Stable Premature Infants', 'Infants born at ≤32\xa0weeks of gestation requiring ≥24\xa0hours of CPAP']","['extended continuous positive airway pressure CPAP (eCPAP) vs CPAP discontinuation (dCPAP', 'eCPAP vs dCPAP', 'eCPAP', 'Extended Continuous Positive Airway Pressure']","['Lung Volumes', 'FRC', 'FRC through discharge']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C0205363', 'cui_str': 'Stratified (qualifier value)'}, {'cui': 'C0017504', 'cui_str': 'Fetal Maturity, Chronologic'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0205173', 'cui_str': 'Double (qualifier value)'}, {'cui': 'C0032961', 'cui_str': 'Gestation'}, {'cui': 'C0332196', 'cui_str': 'Exclude (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205360', 'cui_str': 'Stable (qualifier value)'}, {'cui': 'C4048294', 'cui_str': 'Preterm Infant'}, {'cui': 'C0004897', 'cui_str': 'Ursidae'}, {'cui': 'C0439227', 'cui_str': 'hour (qualifier value)'}, {'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}]","[{'cui': 'C0199451', 'cui_str': 'Continuous Positive Airway Pressure'}]","[{'cui': 'C0231953', 'cui_str': 'Lung volume, function (observable entity)'}, {'cui': 'C0016815', 'cui_str': 'Functional Residual Capacity'}, {'cui': 'C0012621', 'cui_str': 'Discharge - substance (substance)'}]",50.0,0.394834,"CONCLUSIONS Premature infants randomized to eCPAP had a significantly greater increase in FRC through discharge compared with those randomized to dCPAP.","[{'ForeName': 'Ryan', 'Initials': 'R', 'LastName': 'Lam', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Diane', 'Initials': 'D', 'LastName': 'Schilling', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Brian', 'Initials': 'B', 'LastName': 'Scottoline', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Astrid', 'Initials': 'A', 'LastName': 'Platteau', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Meike', 'Initials': 'M', 'LastName': 'Niederhausen', 'Affiliation': 'Biostatistics and Design Program, Oregon Health & Science University-Portland State University School of Public Health, Portland, OR.'}, {'ForeName': 'Kelli C', 'Initials': 'KC', 'LastName': 'Lund', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Robert L', 'Initials': 'RL', 'LastName': 'Schelonka', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Kelvin D', 'Initials': 'KD', 'LastName': 'MacDonald', 'Affiliation': 'Division of Pediatric Pulmonology, Oregon Health & Science University, Portland, OR.'}, {'ForeName': 'Cindy T', 'Initials': 'CT', 'LastName': 'McEvoy', 'Affiliation': 'Division of Neonatology, Department of Pediatrics, Oregon Health & Science University, Portland, OR. Electronic address: mcevoyc@ohsu.edu.'}]",The Journal of pediatrics,['10.1016/j.jpeds.2019.07.074'] 3266,29422189,A mindfulness-based intervention to increase resilience to stress in university students (the Mindful Student Study): a pragmatic randomised controlled trial.,"BACKGROUND The rising number of young people going to university has led to concerns about an increasing demand for student mental health services. We aimed to assess whether provision of mindfulness courses to university students would improve their resilience to stress. METHODS We did this pragmatic randomised controlled trial at the University of Cambridge, UK. Students aged 18 years or older with no severe mental illness or crisis (self-assessed) were randomly assigned (1:1), via remote survey software using computer-generated random numbers, to receive either an 8 week mindfulness course adapted for university students (Mindfulness Skills for Students [MSS]) plus mental health support as usual, or mental health support as usual alone. Participants and the study management team were aware of group allocation, but allocation was concealed from the researchers, outcome assessors, and study statistician. The primary outcome was self-reported psychological distress during the examination period, as measured with the Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM), with higher scores indicating more distress. The primary analysis was by intention to treat. This trial is registered with the Australia and New Zealand Clinical Trials Registry, number ACTRN12615001160527. FINDINGS Between Sept 28, 2015, and Jan 15, 2016, we randomly assigned 616 students to the MSS group (n=309) or the support as usual group (n=307). 453 (74%) participants completed the CORE-OM during the examination period and 182 (59%) MSS participants completed at least half of the course. MSS reduced distress scores during the examination period compared with support as usual, with mean CORE-OM scores of 0·87 (SD 0·50) in 237 MSS participants versus 1·11 (0·57) in 216 support as usual participants (adjusted mean difference -0·14, 95% CI -0·22 to -0·06; p=0·001), showing a moderate effect size (β -0·44, 95% CI -0·60 to -0·29; p<0·0001). 123 (57%) of 214 participants in the support as usual group had distress scores above an accepted clinical threshold compared with 88 (37%) of 235 participants in the MSS group. On average, six students (95% CI four to ten) needed to be offered the MSS course to prevent one from experiencing clinical levels of distress. No participants had adverse reactions related to self-harm, suicidality, or harm to others. INTERPRETATION Our findings show that provision of mindfulness training could be an effective component of a wider student mental health strategy. Further comparative effectiveness research with inclusion of controls for non-specific effects is needed to define a range of additional, effective interventions to increase resilience to stress in university students. FUNDING University of Cambridge and National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England.",2018,"BACKGROUND The rising number of young people going to university has led to concerns about an increasing demand for student mental health services.","['university students (the Mindful Student Study', 'university students', 'Students aged 18 years or older with no severe mental illness or crisis (self-assessed', 'Between Sept 28, 2015, and Jan 15, 2016, we randomly assigned 616 students to the MSS group (n=309) or the support as usual group (n=307']","['mindfulness training', 'via remote survey software using computer-generated random numbers, to receive either an 8 week mindfulness course adapted for university students (Mindfulness Skills for Students [MSS]) plus mental health support as usual, or mental health support as usual alone', 'mindfulness-based intervention']","['mean CORE-OM scores', 'MSS reduced distress scores', 'Clinical Outcomes in Routine Evaluation Outcome Measure (CORE-OM), with higher scores indicating more distress', 'distress scores', 'CORE-OM', 'adverse reactions related to self-harm, suicidality, or harm to others', 'self-reported psychological distress']","[{'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0231224', 'cui_str': 'Crisis (finding)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}]","[{'cui': 'C3542996', 'cui_str': 'Mindfulness'}, {'cui': 'C0220931', 'cui_str': 'Functional training'}, {'cui': 'C0205157', 'cui_str': 'Remote (qualifier value)'}, {'cui': 'C0038951', 'cui_str': 'Surveys'}, {'cui': 'C0037585', 'cui_str': 'Computer Programs'}, {'cui': 'C0009622', 'cui_str': 'Computers'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C0750729', 'cui_str': 'Courses (qualifier value)'}, {'cui': 'C0041740', 'cui_str': 'Universities'}, {'cui': 'C0038492', 'cui_str': 'Student (occupation)'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0025353', 'cui_str': 'Mental Hygiene'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0178499', 'cui_str': 'Base'}]","[{'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0444669', 'cui_str': 'Core (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0205547', 'cui_str': 'Routine (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C1444656', 'cui_str': 'Indicated'}, {'cui': 'C0559546', 'cui_str': 'Adverse reaction (disorder)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0085271', 'cui_str': 'Self-Injury'}, {'cui': 'C2700446', 'cui_str': 'Self-reported (qualifier value)'}, {'cui': 'C0205486', 'cui_str': 'Psychologic (qualifier value)'}]",616.0,0.258576,"BACKGROUND The rising number of young people going to university has led to concerns about an increasing demand for student mental health services.","[{'ForeName': 'Julieta', 'Initials': 'J', 'LastName': 'Galante', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK. Electronic address: mjg231@cam.ac.uk.'}, {'ForeName': 'Géraldine', 'Initials': 'G', 'LastName': 'Dufour', 'Affiliation': 'University Counselling Service, University of Cambridge, Cambridge, UK; British Association for Counselling and Psychotherapy: Universities and Colleges Division, Leicestershire, UK.'}, {'ForeName': 'Maris', 'Initials': 'M', 'LastName': 'Vainre', 'Affiliation': 'National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK.'}, {'ForeName': 'Adam P', 'Initials': 'AP', 'LastName': 'Wagner', 'Affiliation': 'National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK; Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.'}, {'ForeName': 'Jan', 'Initials': 'J', 'LastName': 'Stochl', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK.'}, {'ForeName': 'Alice', 'Initials': 'A', 'LastName': 'Benton', 'Affiliation': 'Educational and Student Policy, Academic Division, University of Cambridge, Cambridge, UK.'}, {'ForeName': 'Neal', 'Initials': 'N', 'LastName': 'Lathia', 'Affiliation': 'Department of Computer Science, University College London, London, UK.'}, {'ForeName': 'Emma', 'Initials': 'E', 'LastName': 'Howarth', 'Affiliation': 'National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK.'}, {'ForeName': 'Peter B', 'Initials': 'PB', 'LastName': 'Jones', 'Affiliation': 'Department of Psychiatry, University of Cambridge, Cambridge, UK; National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care East of England, Cambridge, UK.'}]",The Lancet. Public health,['10.1016/S2468-2667(17)30231-1'] 3267,30700178,Does timing of urinary catheter removal after elective cesarean section affects postoperative morbidity?: a prospective randomized trial.,"Objective: To assess whether immediate (0 h), intermediate (after 6 h), or delayed (after 24 h) removal of an urinary catheter after elective caesarian section (CS) regarding, the rate of urinary retention with recatheterization, rate of symptomatic urinary tract infections (UTI), time of ambulation, and the length of hospital stay. Methods: Prospective randomized controlled trial conducted at King Abd Al-Aziz Hospital, KSA. Two hundred twenty-one women underwent for term elective CS and were randomly allocated into three groups by simple randomization using computer-generated random numbers. Women in group A (73 patients) had their urinary catheter removed immediately after surgery. Group B (81 patients) had the catheter removed 6 h postoperatively while in group C (67 patients) the catheter was removed after 24 h. The following outcomes were assessed for each group: rate of recatheterization, symptomatic UTI, time of ambulation, and the length of hospital stay. Results: All groups were matched regarding maternal age, body mass index, gestational age at delivery, and duration of surgery there was a significantly higher incidence of urinary retention needing recatheterization in the immediate removal group compared to the intermediate and delayed removal groups (13.6 vs. 2.5 and 0%, respectively). Delayed urinary catheter removal was associated with a higher incidence of UTI (13.4%), delayed ambulation time (10.3 h), and longer hospital stay (3.9 days) compared to the early (1.4%, 4.1 h, and 1.9 days, respectively) and intermediate (3.7%, 6.8 h, and 2.4 days respectively) removal groups. Conclusion: Removal of the urinary catheter 6 h postoperatively appears to be more advantageous than early or late removal in cases of CS.",2020,"Delayed urinary catheter removal was associated with a higher incidence of UTI (13.4%), delayed ambulation time (10.3 h), and longer hospital stay (3.9 days) compared to the early (1.4%, 4.1 h, and 1.9 days, respectively) and intermediate (3.7%, 6.8 h, and 2.4 days respectively) removal groups. ",['Two hundred twenty-one women underwent for term elective CS'],[],"['rate of recatheterization, symptomatic UTI, time of ambulation, and the length of hospital stay', 'rate of urinary retention with recatheterization, rate of symptomatic urinary tract infections (UTI), time of ambulation, and the length of hospital stay', 'longer hospital stay', 'urinary retention needing recatheterization', 'Delayed urinary catheter removal', 'delayed ambulation time']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C3715213', 'cui_str': '21 (qualifier value)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0439608', 'cui_str': 'Elective (qualifier value)'}]",[],"[{'cui': 'C0231220', 'cui_str': 'Symptomatic (qualifier value)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0945826', 'cui_str': 'Ambulation'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C3489408', 'cui_str': 'Hospital Stay'}, {'cui': 'C0080274', 'cui_str': 'Urinary Retention'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0027552', 'cui_str': 'Needs'}, {'cui': 'C0179802', 'cui_str': 'Urinary catheter, device (physical object)'}, {'cui': 'C0015252', 'cui_str': 'Removal - action (qualifier value)'}]",221.0,0.0471994,"Delayed urinary catheter removal was associated with a higher incidence of UTI (13.4%), delayed ambulation time (10.3 h), and longer hospital stay (3.9 days) compared to the early (1.4%, 4.1 h, and 1.9 days, respectively) and intermediate (3.7%, 6.8 h, and 2.4 days respectively) removal groups. ","[{'ForeName': 'Nisreen Khaled', 'Initials': 'NK', 'LastName': 'Aref', 'Affiliation': 'Faculty of Medicine, Taif University, Taif, Saudi Arabia.'}]","The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians",['10.1080/14767058.2019.1569619'] 3268,31935118,Oral supplementation with omega-3 fatty acids and inflammation markers in patients with chronic kidney disease in hemodialysis.,"Chronic kidney disease (CKD) is an increasingly common public health problem that increases the risk of death because of cardiovascular complications by 2-3 times compared with the general population. This research concerns a prospective, randomized, double-blind study in patients with CKD undergoing hemodialysis. The participants were assigned to 1 of 2 groups: the study group (group A; 46 patients) received 4 capsules (2.4 g) of omega-3 fatty acids daily during the 12-week intervention, while patients in the control group (group B; 47 patients) received 4 capsules of paraffin oil. The patients' general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin (IL)-6, IL-10, and tumour necrosis factor alpha (TNF-α)) were evaluated. No differences were found between the general characteristics of the patients ( P < 0.05), and no differences were shown in the nutritional indicators and markers of kidney disease ( P < 0.05). Patients in group A showed significant decreases in levels of C-reactive protein, IL-6, TNF-α, and the IL-10/IL-6 ratio after 12 weeks of supplementation ( P < 0.05). Patients in group B did not show any significant changes in concentrations of inflammatory markers during the intervention ( P < 0.05). In conclusion, oral supplementation with omega-3 fatty acids produces a significant decrease in the concentrations of inflammation markers in patients with chronic kidney disease on hemodialysis. Novelty Oral supplementation with omega-3 fatty acids produced significant decreases in the concentrations of inflammation markers. This supplementation could be given to patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk.",2020,"Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05).","['patients with uremic syndrome and coronary heart disease to reduce cardiovascular risk', 'Chronic kidney disease (CKD', 'patients with CKD undergoing hemodialysis', 'patients with chronic kidney disease in hemodialysis', 'patients with chronic kidney disease on hemodialysis']","['Oral supplementation with omega-3 fatty acids', 'omega-3 fatty acids', 'paraffin oil']","['nutritional indicators and markers of kidney disease', 'levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio', 'concentrations of inflammation markers', 'concentrations of inflammatory markers', 'general characteristics, nutritional indicators, renal disease markers and inflammatory markers (C-reactive protein, interleukin-6, interleukin-10 and tumour necrosis factor alpha']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0302810', 'cui_str': 'Uraemic syndrome'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C1561643', 'cui_str': 'Chronic Kidney Diseases'}, {'cui': 'C0019004', 'cui_str': 'Hemodialysis'}]","[{'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0015689', 'cui_str': 'Omega-3 Fatty Acids'}, {'cui': 'C0070062', 'cui_str': 'paraffin oils'}]","[{'cui': 'C0021212', 'cui_str': 'Indicators'}, {'cui': 'C0022658', 'cui_str': 'Kidney Diseases'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0201657', 'cui_str': 'C-reactive protein measurement (procedure)'}, {'cui': 'C0021760', 'cui_str': 'Interleukin-6'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}, {'cui': 'C0085295', 'cui_str': 'Interleukin-10'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0021368', 'cui_str': 'Inflammation'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}]",47.0,0.0360031,"Patients in group A showed significant decreases in levels of C-reactive protein, interleukin-6, tumour necrosis factor alpha and the interleukin-10/interleukin-6 ratio after 12 weeks of supplementation (P <0.05).","[{'ForeName': 'José A', 'Initials': 'JA', 'LastName': 'Valle Flores', 'Affiliation': 'Nutrition and Food Science Program, University of Granada, Spain.'}, {'ForeName': 'Juan E', 'Initials': 'JE', 'LastName': 'Fariño Cortéz', 'Affiliation': 'Carrera de Enfermería, Facultad de Ciencias Sociales y de la Salud, Universidad Estatal de Santa Elena, Santa Elena, Ecuador, 241702.'}, {'ForeName': 'Gabriel A', 'Initials': 'GA', 'LastName': 'Mayner Tresol', 'Affiliation': 'Carrera de Medicina, Facultad de Ciencias Médicas, Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, 150950.'}, {'ForeName': 'Juan', 'Initials': 'J', 'LastName': 'Perozo Romero', 'Affiliation': 'Servicio de Nefrología, Hospital Central Dr. Urquinaona, Facultad de Medicina, Universidad de Zulia, Maracaibo, Venezuela, 4001.'}, {'ForeName': 'Miquel', 'Initials': 'M', 'LastName': 'Blasco Carlos', 'Affiliation': 'Instituto de Investigación e Innovación de Salud Integral, Universidad Católica de Santiago de Guayaquil, Avenue Carlos Julio Arosemena Tola, Guayaquil, Ecuador.'}, {'ForeName': 'Teresa', 'Initials': 'T', 'LastName': 'Nestares', 'Affiliation': 'Department of Physiology, Institute of Nutrition and Food Technology, University of Granada, Granada, Spain, 18010.'}]","Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme",['10.1139/apnm-2019-0729'] 3269,30953133,The role of proactive interference in working memory training and transfer.,"Recent work on working memory training has produced conflicting results regarding the degree and generality of transfer to other cognitive processes. However, few studies have investigated possible mechanisms underlying transfer. The current study was designed to test the role of proactive interference in working memory training and transfer. Eighty-six young adults participated in a pretest-posttest design, with ten training sessions in between. In the two working memory training conditions, subjects performed an operation span task, with one condition requiring recall of letters on every trial (operation-letters), whereas the other condition alternated between letters, digits, and words as the to-be-remembered items across trials (operation-mix). These groups were compared to an active-control group (visual-search). Working memory, verbal fluency, and reading comprehension measures were administered in pretest and posttest sessions. All groups significantly increased their performance over the ten training sessions. There was evidence of strategy-specific benefits on transfer, such that transfer to working memory measures was higher for the operation-letters group on tasks specifically involving letters, and no differential transfer to working memory tests without letters, to verbal fluency, or to reading comprehension. The results indicate that proactive interference does not appear to play a causal role in determining transfer from working memory training, and instead a strategy account based on stimulus content provides a more parsimonious explanation for the pattern of training and transfer.",2020,"There was evidence of strategy-specific benefits on transfer, such that transfer to working memory measures was higher for the operation-letters group on tasks specifically involving letters, and no differential transfer to working memory tests without letters, to verbal fluency, or to reading comprehension.",['Eighty-six young adults'],[],"['Working memory, verbal fluency, and reading comprehension measures']","[{'cui': 'C3816958', 'cui_str': 'Eighty'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}]",[],"[{'cui': 'C0025265', 'cui_str': 'Working Memory'}, {'cui': 'C0439824', 'cui_str': 'Verbal (qualifier value)'}, {'cui': 'C0034754', 'cui_str': 'Reading'}, {'cui': 'C0162340', 'cui_str': 'Understanding'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}]",86.0,0.0115994,"There was evidence of strategy-specific benefits on transfer, such that transfer to working memory measures was higher for the operation-letters group on tasks specifically involving letters, and no differential transfer to working memory tests without letters, to verbal fluency, or to reading comprehension.","[{'ForeName': 'Thomas S', 'Initials': 'TS', 'LastName': 'Redick', 'Affiliation': 'Department of Psychological Sciences, Purdue University, 703 Third Street, West Lafayette, IN, 47907, USA. tredick@purdue.edu.'}, {'ForeName': 'Elizabeth A', 'Initials': 'EA', 'LastName': 'Wiemers', 'Affiliation': 'Department of Psychological Sciences, Purdue University, 703 Third Street, West Lafayette, IN, 47907, USA.'}, {'ForeName': 'Randall W', 'Initials': 'RW', 'LastName': 'Engle', 'Affiliation': 'Georgia Institute of Technology, Atlanta, USA.'}]",Psychological research,['10.1007/s00426-019-01172-8'] 3270,31759771,"Simo decoction versus domperidone suspension for post-pyloric spiral nasoenteric tube placement: A multicenter, randomized, non-inferiority trial.","BACKGROUND & AIMS Leveraging prokinetics to facilitate trans-pyloric migration is a conventional strategy. However, due to restrictions on the use of domperidone suspension, oral prokinetics is relatively modest. The study aims to assess the effectiveness of simo decoction as an alternative to domperidone suspension in facilitating post-pyloric placement of spiral nasoenteric tubes. METHODS A prospective, open-label, parallel, and non-inferiority randomized controlled trial was performed involving critically ill adults in 6 university hospitals in China between September 2017 and May 2019. Patients were randomly assigned to receive either simo decoction 20 ml q8h, or domperidone suspension 20 mg/20 ml q6h for 24 h. The primary outcome was procedure success defined as post-pyloric placement (spiral nasoenteric tubes reached the first portion of the duodenum or beyond confirmed by abdominal X-ray 24 h after tube insertion). RESULTS Of 268 patients assessed for eligibility, 224 patients were enrolled and randomly assigned to the simo decoction group or the domperidone suspension group (n = 112 per group). The success rate of post-pyloric placement was 41.1% (46/112) in the simo decoction group, as compared with 47.3% (53/112) in the domperidone suspension group (a risk difference of -6.3%, 95% CI, -19.2% to 6.7%, adjusted risk difference -3.7%, 95% CI -16.3% to 9.0%), in the intention-to-treat analysis, crossing the prespecified margin of -10% for non-inferiority. There were no differences between groups in the success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond) and proximal jejunum placement, the incidences of any adverse events, length of ICU stay or mortality in ICU. CONCLUSIONS Non-inferiority of simo decoction to domperidone suspension was not confirmed in facilitating post-pyloric placement of spiral nasoenteric tubes. Registration: The trial was registered with the Chinese Clinical Trial Registry at http://www.chictr.org.cn (registration number ChiCTR-INR-17011311).",2020,"There were no differences between groups in the success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond) and proximal jejunum placement, the incidences of any adverse events, length of ICU stay or mortality in ICU. ","['268 patients assessed for eligibility, 224 patients', 'critically ill adults in 6 university hospitals in China between September 2017 and May 2019', 'Registration', 'group (n\xa0', 'post-pyloric spiral nasoenteric tube placement']","['domperidone suspension', 'simo decoction', 'simo decoction 20\xa0ml q8h, or domperidone suspension 20 mg/20', 'Simo decoction']","['success rates of post-D1', 'procedure success defined as post-pyloric placement (spiral nasoenteric tubes reached the first portion of the duodenum or beyond confirmed by abdominal X-ray 24\xa0h after tube insertion', 'success rate of post-pyloric placement', 'adverse events, length of ICU stay or mortality in ICU']","[{'cui': 'C4517673', 'cui_str': '268'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4319560', 'cui_str': '224'}, {'cui': 'C0010340', 'cui_str': 'Critically Ill'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0020028', 'cui_str': 'Hospitals, University'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0522554', 'cui_str': 'Spiral'}, {'cui': 'C1446323', 'cui_str': 'Nasoenteric tube'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}]","[{'cui': 'C0013015', 'cui_str': 'Domperidone'}, {'cui': 'C1382107', 'cui_str': 'Suspension'}, {'cui': 'C2718122', 'cui_str': 'simo'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C3539106', 'cui_str': 'Sufficiently defined concept definition status (core metadata concept)'}, {'cui': 'C0441587', 'cui_str': 'Insertion - action'}, {'cui': 'C0522554', 'cui_str': 'Spiral'}, {'cui': 'C1446323', 'cui_str': 'Nasoenteric tube'}, {'cui': 'C0596012', 'cui_str': 'Does reach (finding)'}, {'cui': 'C0013303', 'cui_str': 'Duodenum'}, {'cui': 'C0521093', 'cui_str': 'Confirmed by (contextual qualifier) (qualifier value)'}, {'cui': 'C0034573', 'cui_str': 'Radiography, Abdominal'}, {'cui': 'C4318415', 'cui_str': 'Tube (unit of presentation)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C1444754', 'cui_str': 'Length property'}, {'cui': 'C0021708', 'cui_str': 'Intensive care unit (environment)'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",224.0,0.212653,"There were no differences between groups in the success rates of post-D1 (reaching the second portion of the duodenum or beyond), post-D2 (reaching the third portion of the duodenum or beyond), post-D3 (reaching the fourth portion of the duodenum or beyond) and proximal jejunum placement, the incidences of any adverse events, length of ICU stay or mortality in ICU. ","[{'ForeName': 'Yingkai', 'Initials': 'Y', 'LastName': 'Xiao', 'Affiliation': ""Department of Intensive Care Unit of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 96 Dongchuan Road, Guangzhou, 510080, Guangdong, China. Electronic address: 13760735993@163.com.""}, {'ForeName': 'Zhimei', 'Initials': 'Z', 'LastName': 'He', 'Affiliation': ""Guangdong Provincial People's Hospital, School of Medicine, South China University of Technology, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: 1315178805@qq.com.""}, {'ForeName': 'Yi', 'Initials': 'Y', 'LastName': 'Long', 'Affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: longyi20100@163.com.""}, {'ForeName': 'Weisheng', 'Initials': 'W', 'LastName': 'Chen', 'Affiliation': ""Department of Emergency Intensive Care Unit, Huizhou Third People's Hospital, Guangzhou Medical University, 1 Xuebei Road, Huizhou, 516000, Guangdong, China. Electronic address: fanchugfw@hotmail.com.""}, {'ForeName': 'Dezhu', 'Initials': 'D', 'LastName': 'Chen', 'Affiliation': 'Department of Critical Care Medicine, Shunde Hospital of Guangzhou University of Chinese Medicine (Shunde District Hospital of Chinese Medicine of Foshan City), Shunde, Guangdong, China. Electronic address: 13751509401@163.com.'}, {'ForeName': 'Ruibin', 'Initials': 'R', 'LastName': 'Chi', 'Affiliation': ""Department of Critical Care Medicine, Xiaolan People's Hospital of Zhongshan, Zhongshan, Guangdong, China. Electronic address: crb77970922@163.com.""}, {'ForeName': 'Heng', 'Initials': 'H', 'LastName': 'Ye', 'Affiliation': ""Department of Critical Care Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China. Electronic address: yeheng@139.com.""}, {'ForeName': 'Xi', 'Initials': 'X', 'LastName': 'Deng', 'Affiliation': 'Department of Critical Care Medicine, Shenzhen Baoan Traditional Chinese Medicine Hospital Group, Shenzhen, Guangdong, China. Electronic address: 394614897@qq.com.'}, {'ForeName': 'Bo', 'Initials': 'B', 'LastName': 'Lv', 'Affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: gdlvbo@163.com.""}, {'ForeName': 'Cheng', 'Initials': 'C', 'LastName': 'Sun', 'Affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: suncheng2008@139.com.""}, {'ForeName': 'Bei', 'Initials': 'B', 'LastName': 'Hu', 'Affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: qhubei@hotmail.com.""}, {'ForeName': 'Zhiqiang', 'Initials': 'Z', 'LastName': 'Nie', 'Affiliation': ""Department of Epidemiology, Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: 304818029@qq.com.""}, {'ForeName': 'Shaodong', 'Initials': 'S', 'LastName': 'Gu', 'Affiliation': 'Department of Critical Care Medicine, Shenzhen Baoan Traditional Chinese Medicine Hospital Group, Shenzhen, Guangdong, China. Electronic address: 235197800@qq.com.'}, {'ForeName': 'Chunbo', 'Initials': 'C', 'LastName': 'Chen', 'Affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Guangzhou, 510080, Guangdong, China. Electronic address: gghccm@163.com.""}]","Clinical nutrition (Edinburgh, Scotland)",['10.1016/j.clnu.2019.11.009'] 3271,30249443,Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.,"The tumor necrosis factor (TNF) antagonist infliximab was previously found to reduce depressive symptoms in patients with treatment-resistant major depression (TRD) who exhibited high baseline inflammation, as reflected by plasma C-reactive protein (CRP) >5 mg/L. Further predictors of antidepressant response to infliximab included differential expression of peripheral blood gene transcripts that were related not only to inflammation but also to glucose and lipid metabolism. To determine whether plasma biomarkers of glucose and lipid metabolism were similarly associated with antidepressant response to infliximab and with relevant gene transcripts, we measured concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adiponectin), as well as cholesterols, triglycerides, and non-esterified fatty acids (NEFA), in medically-stable TRD outpatients at baseline and 2 weeks after the first infusion of infliximab (n = 26) or placebo (n = 26). Treatment response was defined as 50% reduction in depressive symptoms at any point during the 12-week trial. We found that baseline cholesterol (total, low-density lipoprotein [LDL], and non-high-density lipoprotein [non-HDL]), triglycerides and NEFA were elevated in patients who exhibited an antidepressant response to infliximab (all p < 0.05) but not placebo (all p > 0.299). HDL and non-HDL cholesterol concentrations also correlated with two lipid-related gene transcripts that were predictive of antidepressant response (r = 0.33 to 0.39, p < 0.05). Although not associated with response to infliximab, resistin correlated with numerous glucose-related transcripts (r = -0.32 to 0.37, p < 0.05) and was higher at 2 weeks post-infusion in patients treated with infliximab compared to placebo (p = 0.028). Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5 mg/L at baseline (all p < 0.05). These results are consistent with previous work showing that high inflammation in patients with depression is associated with metabolic alterations, which together predict response to both traditional and experimental antidepressant therapies. Additionally, our findings suggest a causal relationship between increased inflammation and high cholesterol in depression, as a single infusion of infliximab reduced cholesterol in TRD patients with high CRP compared to placebo.",2018,"Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5 mg/L at baseline (all p < 0.05).","['TRD patients with high CRP', 'patients with treatment-resistant depression']","['infliximab', 'placebo']","['plasma biomarkers of glucose and lipid metabolism', 'depressive symptoms', 'baseline cholesterol (total, low-density lipoprotein [LDL], and non-high-density lipoprotein [non-HDL]), triglycerides and NEFA', 'Concentrations of cholesterol (total, LDL, HDL, non-HDL', 'HDL and non-HDL cholesterol concentrations', 'concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adiponectin), as well as cholesterols, triglycerides, and non-esterified fatty acids (NEFA']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C2063866', 'cui_str': 'Refractory Depression'}]","[{'cui': 'C0666743', 'cui_str': 'infliximab'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0337438', 'cui_str': 'Glucose measurement (procedure)'}, {'cui': 'C0598783', 'cui_str': 'Lipid Metabolism'}, {'cui': 'C0086132', 'cui_str': 'Depressive Symptoms'}, {'cui': 'C0008377', 'cui_str': 'Cholesterol'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0392885', 'cui_str': 'High density lipoprotein measurement (procedure)'}, {'cui': 'C0041004', 'cui_str': 'Triacylglycerol'}, {'cui': 'C0015688', 'cui_str': 'NEFA'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0729627', 'cui_str': 'Non-HDL cholesterol'}, {'cui': 'C0202098', 'cui_str': 'Insulin measurement (procedure)'}, {'cui': 'C0682768', 'cui_str': 'Protein hormone'}, {'cui': 'C0019868', 'cui_str': 'Autoregulation'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0299583', 'cui_str': 'leptin'}, {'cui': 'C0963992', 'cui_str': 'Adipocyte Cysteine-Rich Secreted Protein FIZZ3'}, {'cui': 'C0389071', 'cui_str': 'Adiponectin'}, {'cui': 'C0369212', 'cui_str': 'Fatty Acids, Esterified'}]",,0.065705,"Concentrations of cholesterol (total, LDL, HDL, non-HDL) were also lower at 2 weeks in patients treated with infliximab compared to placebo, but only in those patients with CRP >5 mg/L at baseline (all p < 0.05).","[{'ForeName': 'Mandakh', 'Initials': 'M', 'LastName': 'Bekhbat', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States.'}, {'ForeName': 'Karen', 'Initials': 'K', 'LastName': 'Chu', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States.'}, {'ForeName': 'Ngoc-Anh', 'Initials': 'NA', 'LastName': 'Le', 'Affiliation': 'Biomarker Core Laboratory, Atlanta VAMC, Decatur, GA, 30033, United States.'}, {'ForeName': 'Bobbi J', 'Initials': 'BJ', 'LastName': 'Woolwine', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States.'}, {'ForeName': 'Ebrahim', 'Initials': 'E', 'LastName': 'Haroon', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA, 30322, United States.'}, {'ForeName': 'Andrew H', 'Initials': 'AH', 'LastName': 'Miller', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA, 30322, United States.'}, {'ForeName': 'Jennifer C', 'Initials': 'JC', 'LastName': 'Felger', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA, 30322, United States; The Winship Cancer Institute, Emory University, Atlanta, GA, 30322, United States. Electronic address: jfelger@emory.edu.'}]",Psychoneuroendocrinology,['10.1016/j.psyneuen.2018.09.004'] 3272,31615294,Health literacy is independently and inversely associated with carotid artery plaques and cardiovascular risk.,"AIMS Health literacy, the degree to which individuals understand and act upon health information, may have a pivotal role in the prevention of cardiovascular disease (CVD), with low health literacy potentially explaining poorer adherence to prevention guidelines. We investigated the associations between health literacy, ultrasound-detected carotid atherosclerosis and cardiovascular risk factors. METHODS Baseline data (cross-sectional analysis) from a randomized controlled trial, integrated within the Västerbotten Intervention Program, Northern Sweden, was used. We included 3459 individuals, aged 40 or 50 years with ≥1 conventional risk factor or aged 60 years old. The participants underwent clinical examination, blood sampling, carotid ultrasound assessment of intima-media wall thickness (CIMT) and plaque formation, and answered a questionnaire on health literacy - the Brief Health Literacy Screen. The European Systematic Coronary Risk Evaluation and Framingham Risk Score were calculated. RESULTS About 20% of the participants had low health literacy. Low health literacy was independently associated with the presence of ultrasound-detected carotid artery plaques after adjustment for age and education, odds ratio (95% confidence interval) 1.54 (1.28-1.85), demonstrating a similar level of risk as for smoking. Health literacy was associated with CIMT in men. Low health literacy was associated with higher CVD risk scores. Sensitivity analyses with low health literacy set to 9% or 30% of the study sample, respectively, yielded essentially the same results. CONCLUSIONS Low health literacy was independently associated with carotid artery plaques and a high level of CVD risk scores. Presenting health information in a fashion that is understood by all patients may improve preventive efforts.",2020,"Low health literacy was independently associated with the presence of ultrasound-detected carotid artery plaques after adjustment for age and education, odds ratio (95% confidence interval)","['3459 individuals, aged 40 or 50 years with ≥1 conventional risk factor or aged 60 years old']",[],"['carotid artery plaques and cardiovascular risk', 'Low health literacy', 'Health literacy', 'European Systematic Coronary Risk Evaluation and Framingham Risk Score', 'CVD risk scores', 'low health literacy']","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0439858', 'cui_str': 'Conventional (qualifier value)'}, {'cui': 'C0035648', 'cui_str': 'Risk factor (observable entity)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}]",[],"[{'cui': 'C0751633', 'cui_str': 'Carotid Artery Plaque'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0205251', 'cui_str': 'Low (qualifier value)'}, {'cui': 'C2362527', 'cui_str': 'Health Literacy'}, {'cui': 'C0239307', 'cui_str': 'European (ethnic group)'}, {'cui': 'C0220922', 'cui_str': 'systematics'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",,0.0740061,"Low health literacy was independently associated with the presence of ultrasound-detected carotid artery plaques after adjustment for age and education, odds ratio (95% confidence interval)","[{'ForeName': 'Bernt', 'Initials': 'B', 'LastName': 'Lindahl', 'Affiliation': 'Section of Sustainable Health, Department of Public Health and Clinical Medicine, Umeå University, Sweden.'}, {'ForeName': 'Margareta', 'Initials': 'M', 'LastName': 'Norberg', 'Affiliation': 'Section of Medicine, Department of Public Health and Clinical Medicine, Umeå University, Sweden.'}, {'ForeName': 'Helene', 'Initials': 'H', 'LastName': 'Johansson', 'Affiliation': 'Department of Epidemiology and Global Health, Umeå University, Sweden.'}, {'ForeName': 'Kristina', 'Initials': 'K', 'LastName': 'Lindvall', 'Affiliation': 'Department of Epidemiology and Global Health, Umeå University, Sweden.'}, {'ForeName': 'Nawi', 'Initials': 'N', 'LastName': 'Ng', 'Affiliation': 'Department of Epidemiology and Global Health, Umeå University, Sweden.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Nordin', 'Affiliation': 'Department of Psychology, Umeå University, Sweden.'}, {'ForeName': 'Steven', 'Initials': 'S', 'LastName': 'Nordin', 'Affiliation': 'Department of Psychology, Umeå University, Sweden.'}, {'ForeName': 'Ulf', 'Initials': 'U', 'LastName': 'Näslund', 'Affiliation': 'Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Sweden.'}, {'ForeName': 'Amanda', 'Initials': 'A', 'LastName': 'Persson', 'Affiliation': 'Section of Medicine, Department of Public Health and Clinical Medicine, Umeå University, Sweden.'}, {'ForeName': 'Davide', 'Initials': 'D', 'LastName': 'Vanoli', 'Affiliation': 'Heart Centre and Department of Public Health and Clinical Medicine, Umeå University, Sweden.'}, {'ForeName': 'Peter J', 'Initials': 'PJ', 'LastName': 'Schulz', 'Affiliation': 'Institute of Communication and Health, University of Lugano, Switzerland.'}]",European journal of preventive cardiology,['10.1177/2047487319882821'] 3273,31614214,Telephone interventions for co-morbid insomnia and osteoarthritis pain: The OsteoArthritis and Therapy for Sleep (OATS) randomized trial design.,"The OsteoArthritis and Therapy for Sleep (OATS) study is a population-based randomized controlled trial of cognitive behavioral therapy for insomnia (CBTI) with four innovative methodological aims. These are to: (1) Enroll representative participants across Washington state, including those from medically underserved communities; (2) Enroll persons with persistent insomnia and chronic osteoarthritis (OA) pain; (3) Test a scalable CBT-I intervention; and (4) Evaluate patient-reported outcomes (insomnia, pain severity, fatigue, depression) and cost-effectiveness over one year. This paper describes progress towards achieving these aims. The target population was persons age 60+ who had received OA care within the Kaiser Permanente Washington (KPW) health care system. We employed a two-phase screening via mail survey and telephone follow-up, with a 3-week interval between screens to exclude persons with spontaneous improvement in sleep or pain symptoms. Participants were randomized to a 6-session telephone-delivered CBT-I intervention or a 6-session telephone education only control condition (EOC). Blinded outcome assessments (completed online or on mailed paper forms) included primary and secondary sleep and pain outcome measures and quality of life measures. We obtained healthcare utilization from administrative claims data. Intent to treat analyses, including all participants randomized when they scheduled the first telephone session, will be conducted to compare CBT-I and EOC outcomes. The trial will be the largest experimental evaluation of telephone CBT-I to date, and the first to evaluate its cost-effectiveness. Trial registration: ClinicalTrials.gov identifier: NCT02946957.",2019,Participants were randomized to a 6-session telephone-delivered CBT-I intervention or a 6-session telephone education only control condition (EOC).,"['co-morbid insomnia and osteoarthritis pain', 'Enroll representative participants across Washington state, including those from medically underserved communities; (2) Enroll persons with persistent insomnia and chronic osteoarthritis (OA) pain; (3', 'target population was persons age 60+ who had received OA care within the Kaiser Permanente Washington (KPW) health care system']","['6-session telephone-delivered CBT-I intervention or a 6-session telephone education only control condition (EOC', 'Telephone interventions', 'cognitive behavioral therapy']","['primary and secondary sleep and pain outcome measures and quality of life measures', 'sleep or pain symptoms', 'outcomes (insomnia, pain severity, fatigue, depression) and cost-effectiveness']","[{'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0029408', 'cui_str': 'Arthritis, Degenerative'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0043038', 'cui_str': 'Washington'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0027361', 'cui_str': 'Persons'}, {'cui': 'C0393758', 'cui_str': 'Persistent insomnia (disorder)'}, {'cui': 'C0263778', 'cui_str': 'Chronic osteoarthritis (disorder)'}, {'cui': 'C0039309', 'cui_str': 'Target Population'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0018696', 'cui_str': 'Health Care Systems'}]","[{'cui': 'C0039457', 'cui_str': 'Telephone'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0439631', 'cui_str': 'Primary operation (qualifier value)'}, {'cui': 'C1522484', 'cui_str': 'metastatic'}, {'cui': 'C0424522', 'cui_str': 'Asleep (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0086749', 'cui_str': 'Outcome Measures'}, {'cui': 'C0034380'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0917801', 'cui_str': 'Sleeplessness'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0015672', 'cui_str': 'Fatigue'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0010181', 'cui_str': 'Cost Effectiveness'}]",,0.0977968,Participants were randomized to a 6-session telephone-delivered CBT-I intervention or a 6-session telephone education only control condition (EOC).,"[{'ForeName': 'Susan M', 'Initials': 'SM', 'LastName': 'McCurry', 'Affiliation': 'Department of Child, Family, and Population Health Nursing, University of Washington School of Nursing, Seattle, WA, United States of America. Electronic address: smccurry@uw.edu.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Von Korff', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America.'}, {'ForeName': 'Charles M', 'Initials': 'CM', 'LastName': 'Morin', 'Affiliation': 'Department of Psychology, Université Laval, Quebec City, Quebec, Canada.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Cunningham', 'Affiliation': 'Department of Child, Family, and Population Health Nursing, University of Washington School of Nursing, Seattle, WA, United States of America.'}, {'ForeName': 'Kenneth C', 'Initials': 'KC', 'LastName': 'Pike', 'Affiliation': 'Department of Child, Family, and Population Health Nursing, University of Washington School of Nursing, Seattle, WA, United States of America.'}, {'ForeName': 'Manu', 'Initials': 'M', 'LastName': 'Thakral', 'Affiliation': 'Department of Nursing, University of Massachusetts Boston, Boston, MA, United States of America.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Wellman', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America.'}, {'ForeName': 'Kai', 'Initials': 'K', 'LastName': 'Yeung', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America.'}, {'ForeName': 'Weiwei', 'Initials': 'W', 'LastName': 'Zhu', 'Affiliation': 'Kaiser Permanente Washington Health Research Institute, Seattle, WA, United States of America.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Vitiello', 'Affiliation': 'Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, United States of America.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.105851'] 3274,30857862,Randomized controlled trial comparing bilateral superficial cervical plexus block and local wound infiltration for pain control in thyroid surgery.,"BACKGROUD/OBJECTIVE Multiple approaches have been devised for pain control in patients undergoing thyroid surgery, with local wound infiltration (LWI) of analgesia and bilateral superficial cervical plexus block (BSCPB) among the popular choices cited. However, the results comparing these methods had either been contradictory or equivocal. This study was carried out to assess the efficacy of BSCPB in comparison to LWI in reducing post-operative pain, as well as any additional opioid requirement in the first 24 h after thyroid surgery. METHODS A prospective, double-blinded randomized controlled trial comparing the post-operative pain score between BSCPB and LWI was conducted among patients undergoing thyroid surgery. Ropivacaine 0.50% was used in the study. Pain score was measured at 4, 12, 16 and 24 h after surgery using the visual analog scale (VAS). Subcutaneous injection of Tramadol was given whenever the pain score was ≥4 or requested by patients. RESULTS A total of 70 patients were recruited, with 35 patients on each arm. There was no statistical difference in the post-operative pain score between the two groups at 4 h (p = 0.208), 12 h (p = 0.860), 16 h (p = 0.376) and 24 h (p = 0.375) after surgery. Time to the first rescue dose of Tramadol between the two arms was also insignificant (p = 0.949). One patient in the BSCPB arm developed transient left upper limb weakness, which resolved 12 h after surgery. CONCLUSION LWI remains the simplest, safest and most economical method of pain management. While BSCPB is comparable, it does however, come with potential regional block related complications.",2019,"There was no statistical difference in the post-operative pain score between the two groups at 4 h (p = 0.208), 12 h (p = 0.860), 16 h (p = 0.376) and 24 h (p = 0.375) after surgery.","['patients undergoing thyroid surgery, with local wound infiltration (LWI) of analgesia and bilateral superficial cervical plexus block (BSCPB', 'pain control in thyroid surgery', 'patients undergoing thyroid surgery', '70 patients were recruited, with 35 patients on each arm']","['Ropivacaine', 'Tramadol', 'bilateral superficial cervical plexus block and local wound infiltration', 'BSCPB', 'BSCPB and LWI']","['post-operative pain score', 'visual analog scale (VAS', 'pain score', 'Pain score', 'transient left upper limb weakness']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0040134', 'cui_str': 'thyroid (USP)'}, {'cui': 'C1274039', 'cui_str': 'Surgery'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0394871', 'cui_str': 'Wound infiltration (procedure)'}, {'cui': 'C3202977', 'cui_str': 'Analgesia'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0394691', 'cui_str': 'Superficial cervical plexus block (procedure)'}, {'cui': 'C1304888', 'cui_str': 'Pain control (procedure)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}]","[{'cui': 'C0073571', 'cui_str': 'ropivacaine'}, {'cui': 'C0040610', 'cui_str': 'Tramadol'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0394691', 'cui_str': 'Superficial cervical plexus block (procedure)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0394871', 'cui_str': 'Wound infiltration (procedure)'}]","[{'cui': 'C0687676', 'cui_str': 'After values (qualifier value)'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0205091', 'cui_str': 'Left (qualifier value)'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C3714552', 'cui_str': 'Weakness - general'}]",70.0,0.215204,"There was no statistical difference in the post-operative pain score between the two groups at 4 h (p = 0.208), 12 h (p = 0.860), 16 h (p = 0.376) and 24 h (p = 0.375) after surgery.","[{'ForeName': 'Siew-Yep', 'Initials': 'SY', 'LastName': 'Hoh', 'Affiliation': 'Department of Surgery, University of Malaya, Malaysia. Electronic address: siewyep@ummc.edu.my.'}, {'ForeName': 'Yoke-Kiet', 'Initials': 'YK', 'LastName': 'Doon', 'Affiliation': 'Department of Surgery, University of Malaya, Malaysia. Electronic address: dyokekiet@gmail.com.'}, {'ForeName': 'Shun-Siang', 'Initials': 'SS', 'LastName': 'Chong', 'Affiliation': 'Department of Surgery, University of Malaya, Malaysia. Electronic address: shawnchongshunsiang@gmail.com.'}, {'ForeName': 'Khoon-Leong', 'Initials': 'KL', 'LastName': 'Ng', 'Affiliation': 'Department of Surgery, University of Malaya, Malaysia. Electronic address: ngkl@um.edu.my.'}]",Asian journal of surgery,['10.1016/j.asjsur.2019.01.017'] 3275,30904595,Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.,"BACKGROUND Ranibizumab and aflibercept are anti-vascular endothelial growth factor therapies for diabetic macular edema (DME) but have only been directly compared in one study: the Protocol T study, a 24-month randomized controlled trial which compared the safety and efficacy of three anti-VEGF agents (ranibizumab 0.3 mg, aflibercept 2.0 mg and bevacizumab 1.25 mg). The ranibizumab dose used in Protocol T is not licensed for use outside of the US, where a higher ranibizumab dose of 0.5 mg is approved. Therefore, the relevance of the head-to-head Protocol T study findings to healthcare providers in Europe is limited. The purpose of this research was to predict the visual outcomes that may have been achieved in Protocol T with ranibizumab 0.5 mg. METHODS A simplified dose-response model was constructed to describe the relationship between average monthly dose and one-year best corrected visual acuity (BCVA) change from baseline. A linear mixed effects model was evaluated and Bayesian Monte-Carlo Markov chains method was used to estimate the model parameters. RESULTS If ranibizumab 0.5 mg PRN had been studied in Protocol T, it would have resulted in a BCVA gain of 14-15 early treatment diabetic retinopathy study (ETDRS) letters; 3-4 letters more than the actual BCVA gain reported with ranibizumab 0.3 mg PRN. In Protocol T patients with poor baseline BCVA (<69 letters), a similar additional letter gain would have been achieved. CONCLUSION The relevance of the Protocol T study findings are limited due to the use of ranibizumab 0.3 mg PRN which, based on the modelling approach reported herein, resulted in sub-optimal visual gains.",2019,"BACKGROUND Ranibizumab and aflibercept are anti-vascular endothelial growth factor therapies for diabetic macular edema (DME) but have only been directly compared in one study: the Protocol T study, a 24-month randomized controlled trial which compared the safety and efficacy of three anti-VEGF agents (ranibizumab 0.3 mg, aflibercept 2.0 mg and bevacizumab 1.25 mg).","['diabetic macular edema (DME', 'patients with diabetic macular edema']","['Ranibizumab and aflibercept', 'anti-VEGF agents (ranibizumab 0.3\u202fmg, aflibercept 2.0\u202fmg and bevacizumab', 'ranibizumab 0.5\u202fmg PRN', 'ranibizumab']","['safety and efficacy', 'BCVA gain']","[{'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0641456', 'cui_str': 'DMES'}, {'cui': 'C0030705', 'cui_str': 'Patients'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C1134659', 'cui_str': 'aflibercept'}, {'cui': 'C0078058', 'cui_str': 'Vascular Endothelial Growth Factor A'}, {'cui': 'C0450442', 'cui_str': 'Agent (attribute)'}, {'cui': 'C4068885', 'cui_str': 'Zero point three'}, {'cui': 'C0796392', 'cui_str': 'bevacizumab'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0558288', 'cui_str': 'prn'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}]",,0.161737,"BACKGROUND Ranibizumab and aflibercept are anti-vascular endothelial growth factor therapies for diabetic macular edema (DME) but have only been directly compared in one study: the Protocol T study, a 24-month randomized controlled trial which compared the safety and efficacy of three anti-VEGF agents (ranibizumab 0.3 mg, aflibercept 2.0 mg and bevacizumab 1.25 mg).","[{'ForeName': 'Yuan', 'Initials': 'Y', 'LastName': 'Xiong', 'Affiliation': 'Novartis Pharmaceuticals Inc, USA.'}, {'ForeName': 'Etienne', 'Initials': 'E', 'LastName': 'Pigeolet', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland. Electronic address: etienne.pigeolet@novartis.com.'}, {'ForeName': 'Zufar', 'Initials': 'Z', 'LastName': 'Mulyukov', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland. Electronic address: zufar.mulyukov@novartis.com.'}, {'ForeName': 'Philippe', 'Initials': 'P', 'LastName': 'Margaron', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland. Electronic address: philippe.margaron@novartis.com.'}, {'ForeName': 'Amy', 'Initials': 'A', 'LastName': 'Racine', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland. Electronic address: amy.racine@novartis.com.'}, {'ForeName': 'Andreas', 'Initials': 'A', 'LastName': 'Clemens', 'Affiliation': 'Novartis Pharma AG, Basel, Switzerland; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany. Electronic address: andreas.clemens@novartis.com.'}]",Contemporary clinical trials,['10.1016/j.cct.2019.03.008'] 3276,31140909,The Effect of Serum 25(OH)D3 Level on Breast Cancer-Related Lymphedema.,"Background: The aim of this study was to evaluate the effect of serum 25-hydroxyvitamin D3 [25(OH)D3] levels on the presence and severity of lymphedema, and on the levels of pain, disability, and function in patients with breast cancer-related lymphedema (BCRL). Methods and Results: This controlled study included 71 patients diagnosed with breast carcinoma. Participants were divided into two groups. The BCRL group included 37 breast cancer patients with lymphedema and the control group included 34 breast carcinoma patients without lymphedema. Demographic information, dominant extremity, affected breast, duration of malignancy, and serum 25(OH)D3 levels were recorded for all patients. The 25(OH)D3 levels were then compared between groups. The correlations between serum 25(OH)D3 levels and the visual analog scale (VAS) and Quick Disabilities of the Arm, Shoulder, and Hand Questionnaire (Q-DASH) scales and the volumetric and diametric differences between the upper extremities were analyzed in the BCRL group. Serum 25(OH)D3 levels did not show statistically significant differences between groups ( p  > 0.05). There was no correlation in the BCRL group between 25(OH)D3 levels and the VAS and Q-DASH scores or the diametric and volumetric differences of extremities ( r  ≤ 0.3; p  > 0.05). Conclusions: Serum 25(OH)D3 levels do not appear to affect the presence or severity of lymphedema, pain, disability, or physical function in BCRL patients. In routine clinical practice, evaluation of this vitamin level does not appear to be necessary for lymphedema in BCRL patients.",2020,Serum 25(OH)D3 levels did not show statistically significant differences between groups ( p  > 0.05).,"['patients with breast cancer-related lymphedema (BCRL', '37 breast cancer patients with lymphedema and the control group included 34 breast carcinoma patients without lymphedema', '71 patients diagnosed with breast carcinoma', 'Breast Cancer-Related Lymphedema']","['serum 25-hydroxyvitamin D3 [25(OH)D3', 'Serum 25(OH)D3 Level']","['presence or severity of lymphedema, pain, disability, or physical function', '25(OH)D3 levels and the VAS and Q-DASH scores or the diametric and volumetric differences of extremities ', 'Serum 25(OH)D3 levels', 'Demographic information, dominant extremity, affected breast, duration of malignancy, and serum 25(OH)D3 levels', '25(OH)D3 levels', 'pain, disability, and function', 'serum 25(OH)D3 levels and the visual analog scale (VAS) and Quick Disabilities of the Arm, Shoulder, and Hand Questionnaire (Q-DASH) scales and the volumetric and diametric differences between the upper extremities']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4277512', 'cui_str': 'Breast Cancer-Related Arm Lymphedema'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0678222', 'cui_str': 'Breast Carcinoma'}]","[{'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0006657', 'cui_str': 'Calcifediol'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]","[{'cui': 'C3854307', 'cui_str': 'Presence'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0024236', 'cui_str': 'Lymphedema'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0205485', 'cui_str': 'Physical (qualifier value)'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0445383', 'cui_str': 'Volumetric (qualifier value)'}, {'cui': 'C0015385', 'cui_str': 'Limbs'}, {'cui': 'C0229671', 'cui_str': 'Serum'}, {'cui': 'C0011298', 'cui_str': 'Demographics'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C1140618', 'cui_str': 'Membrum superius'}, {'cui': 'C0037004', 'cui_str': 'Shoulder'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0222045'}]",71.0,0.0242821,Serum 25(OH)D3 levels did not show statistically significant differences between groups ( p  > 0.05).,"[{'ForeName': 'Pınar', 'Initials': 'P', 'LastName': 'Doruk Analan', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Baskent University, Ankara, Turkey.'}, {'ForeName': 'Emine', 'Initials': 'E', 'LastName': 'Kaya', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Adana City Training and Research Hospital, Adana, Turkey.'}]",Lymphatic research and biology,['10.1089/lrb.2018.0071'] 3277,31138733,Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial.,"BACKGROUND Studies on the association of obesity with mortality in subjects with ARDS have yielded inconsistent results. METHODS In a sub-analysis of the Oscillation for ARDS Treated Early (OSCILLATE) randomized controlled trial, 451 subjects were divided into 5 strata based on their body mass index (BMI) using the World Health Organization definitions: underweight < 18.5 kg/m 2 ; normal weight 18.5-24.99 kg/m 2 ; overweight 25-29.99 kg/m 2 ; obese 30-39.99 kg/m 2 ; severely obese > 40 kg/m 2 . The primary outcome was all-cause hospital mortality across BMI strata for all subjects and for the 2 study arms (high-frequency oscillatory ventilation [HFOV] vs conventional ventilation) separately using multivariable logistic regression adjusting for potential confounding variables. RESULTS Hospital mortality was not different across the BMI strata for all subjects ( P = .86), for the HFOV arm ( P = .94) or for the conventional ventilation arm ( P = .59). After risk adjustment, BMI was not associated with increased risk for hospital mortality (odds ratio 1.01, 95% CI 0.97-1.04, P = .67), whereas HFOV was independently associated with increased mortality (odds ratio 1.74, 95% CI 1.11-2.72, P = .02) with no effect modification by BMI strata (for this interaction, P = .56). Although there was no difference in the use of rescue therapies or in the number of days on sedation or analgesia, higher daily doses of fentanyl and midazolam were administered as BMI increased. CONCLUSION There was no difference in adjusted hospital mortality across BMI strata in subjects with moderate to severe ARDS. Processes of care were not different across BMI strata except for higher daily doses of fentanyl as BMI increased. (ClinicalTrials.gov registration NCT0150640).",2019,"RESULTS Hospital mortality was not different across the BMI strata for all subjects ( P = .86), for the HFOV arm ( P = .94) or for the conventional ventilation arm ( P = .59).","['subjects with ARDS', 'subjects with moderate to severe ARDS', '451 subjects were divided into 5 strata based on their body mass index (BMI) using the World Health Organization definitions: underweight < 18.5 kg/m 2 ; normal weight 18.5-24.99 kg/m 2 ; overweight 25-29.99 kg/m 2 ; obese 30-39.99 kg/m 2 ; severely obese > 40 kg/m 2 ', 'Subjects With ARDS']",['midazolam'],"['cause hospital mortality across BMI strata', 'BMI increased', 'adjusted hospital mortality across BMI strata', 'HFOV', 'risk for hospital mortality', 'Body Mass Index and Mortality', 'mortality', 'Hospital mortality', 'BMI strata']","[{'cui': 'C0035222', 'cui_str': 'ARDS, Human'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0332849', 'cui_str': 'Divide'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0043237', 'cui_str': 'WHO'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0041667', 'cui_str': 'Underweight'}, {'cui': 'C4517611', 'cui_str': 'Eighteen point five'}, {'cui': 'C2712185', 'cui_str': 'Normal weight (finding)'}, {'cui': 'C0497406', 'cui_str': 'Overweight'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0026056', 'cui_str': 'Midazolam'}]","[{'cui': 'C0678227', 'cui_str': 'Causing (attribute)'}, {'cui': 'C0085556', 'cui_str': 'Mortalities, In-house'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0026566', 'cui_str': 'mortality'}]",451.0,0.291011,"RESULTS Hospital mortality was not different across the BMI strata for all subjects ( P = .86), for the HFOV arm ( P = .94) or for the conventional ventilation arm ( P = .59).","[{'ForeName': 'Haytham', 'Initials': 'H', 'LastName': 'Tlayjeh', 'Affiliation': 'Intensive Care Department, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.'}, {'ForeName': 'Yaseen M', 'Initials': 'YM', 'LastName': 'Arabi', 'Affiliation': 'Intensive Care Department, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. arabi@ngha.med.sa.'}, {'ForeName': 'Niall D', 'Initials': 'ND', 'LastName': 'Ferguson', 'Affiliation': 'Interdepartmental Division of Critical Care Medicine, Departments of Medicine and Physiology, Institute for Health Policy, Management and Evaluation, Division of Respirology, University of Toronto, Toronto, Canada.'}, {'ForeName': 'Qi', 'Initials': 'Q', 'LastName': 'Zhou', 'Affiliation': 'Department of Health Research Methods, Evaluation and Impact, McMaster University, Hamilton, Canada.'}, {'ForeName': 'Francois', 'Initials': 'F', 'LastName': 'Lamontagne', 'Affiliation': 'Université de Sherbrooke, Sherbrooke, Canada and Centre de recherche du CHU de Sherbrooke, Sherbrooke, Canada.'}, {'ForeName': 'Alejandro', 'Initials': 'A', 'LastName': 'Arroliga', 'Affiliation': 'Department of Medicine, Baylor Scott and White Health, Temple, Texas.'}, {'ForeName': 'Valerie', 'Initials': 'V', 'LastName': 'Danesh', 'Affiliation': 'School of Nursing, University of Texas at Austin, Texas.'}, {'ForeName': 'Guillermo', 'Initials': 'G', 'LastName': 'Dominguez-Cherit', 'Affiliation': 'Division of Pulmonary, Anesthesia and Critical Care Medicine, The National Institute of Medical Sciences and Nutrition, Salvador Zubirán, Tlalpan, Mexico.'}, {'ForeName': 'Edgar', 'Initials': 'E', 'LastName': 'Jimenez', 'Affiliation': 'Department of Medicine, Baylor Scott and White Health, Temple, Texas.'}, {'ForeName': 'Adam', 'Initials': 'A', 'LastName': 'Mullaly', 'Affiliation': 'Department of Medicine, Baylor Scott and White Health, Temple, Texas.'}, {'ForeName': 'Brandon', 'Initials': 'B', 'LastName': 'Staub', 'Affiliation': 'Department of Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.'}, {'ForeName': 'Maureen O', 'Initials': 'MO', 'LastName': 'Meade', 'Affiliation': 'Department of Health Research Methods, Evaluation and Impact, McMaster University, Hamilton, Canada.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Respiratory care,['10.4187/respcare.06675'] 3278,31619441,Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial.,"Electronic cigarette (e-cig) use is continuing to increase, particularly among youth never-smokers, and is used by some smokers to quit. The acute and chronic toxicity of e-cig use is unclear generally in the context of increasing reports of inflammatory-type pneumonia in some e-cig users. To assess lung effects of e-cigs without nicotine or flavors, we conducted a pilot study with serial bronchoscopies over 4 weeks in 30 never-smokers, randomized either to a 4-week intervention with the use of e-cigs containing only 50% propylene glycol (PG) and 50% vegetable glycerine or to a no-use control group. Compliance to the e-cig intervention was assessed by participants sending daily puff counts and by urinary PG. Inflammatory cell counts and cytokines were determined in bronchoalveolar lavage (BAL) fluids. Genome-wide expression, miRNA, and mRNA were determined from bronchial epithelial cells. There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups. However, in the intervention but not the control group, change in urinary PG as a marker of e-cig use and inhalation was significantly correlated with change in cell counts (cell concentrations, macrophages, and lymphocytes) and cytokines (IL8, IL13, and TNFα), although the absolute magnitude of changes was small. There were no significant changes in mRNA or miRNA gene expression. Although limited by study size and duration, this is the first experimental demonstration of an impact of e-cig use on inflammation in the human lung among never-smokers.",2020,"There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups.","['30 never-smokers', 'Human Lung', 'human lung among never-smokers']","['nicotine or flavors', 'e-cigs containing only 50% propylene glycol (PG) and 50% vegetable glycerine (VG) or to a no-use control group', 'Electronic Cigarette Constituents']","['Inflammatory cell counts and cytokines', 'changes of BAL inflammatory cell counts or cytokines', 'urinary PG', 'Genome-wide expression, microRNA, and mRNA', 'mRNA or microRNA gene expression', 'cell counts (cell concentrations, macrophages, and lymphocytes) and cytokines (IL-8, IL-13, and TNF-α']","[{'cui': 'C0337664', 'cui_str': 'Smoker'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0024109', 'cui_str': 'Lung'}]","[{'cui': 'C0028040', 'cui_str': 'Nicotine'}, {'cui': 'C3849993', 'cui_str': 'Electronic Cigarettes'}, {'cui': 'C0332256', 'cui_str': 'Containing (qualifier value)'}, {'cui': 'C4046690', 'cui_str': 'propylene glycol, (S)-'}, {'cui': 'C0042440', 'cui_str': 'Vegetables'}, {'cui': 'C0017861', 'cui_str': 'Glycerin'}, {'cui': 'C1947944', 'cui_str': 'Use'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C0729650', 'cui_str': 'Constituents (substance)'}]","[{'cui': 'C0440752', 'cui_str': 'Inflammatory cell'}, {'cui': 'C0439157', 'cui_str': 'counts (qualifier value)'}, {'cui': 'C0079189', 'cui_str': 'Cytokine (substance)'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0012383', 'cui_str': 'Dimercaprol'}, {'cui': 'C0017428', 'cui_str': 'Genome'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C1101610', 'cui_str': 'miRNA'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0007584', 'cui_str': 'Cell Number'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0086045', 'cui_str': 'Concentration'}, {'cui': 'C0024432', 'cui_str': 'Monocyte-Derived Macrophages'}, {'cui': 'C4018897', 'cui_str': 'Lymphocyte component of blood'}, {'cui': 'C0079633', 'cui_str': 'Interleukin-8'}, {'cui': 'C0214743', 'cui_str': 'IL13'}, {'cui': 'C1456820', 'cui_str': 'Tumor Necrosis Factor-alpha'}]",,0.0176126,"There were no significant differences in changes of BAL inflammatory cell counts or cytokines between baseline and follow-up, comparing the control and e-cig groups.","[{'ForeName': 'Min-Ae', 'Initials': 'MA', 'LastName': 'Song', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Sarah A', 'Initials': 'SA', 'LastName': 'Reisinger', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Jo L', 'Initials': 'JL', 'LastName': 'Freudenheim', 'Affiliation': 'Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.'}, {'ForeName': 'Theodore M', 'Initials': 'TM', 'LastName': 'Brasky', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Ewy A', 'Initials': 'EA', 'LastName': 'Mathé', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Joseph P', 'Initials': 'JP', 'LastName': 'McElroy', 'Affiliation': 'Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Quentin A', 'Initials': 'QA', 'LastName': 'Nickerson', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Daniel Y', 'Initials': 'DY', 'LastName': 'Weng', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio.'}, {'ForeName': 'Mark D', 'Initials': 'MD', 'LastName': 'Wewers', 'Affiliation': 'Department of Internal Medicine, Pulmonary and Critical Care Medicine, The Ohio State University, Columbus, Ohio.'}, {'ForeName': 'Peter G', 'Initials': 'PG', 'LastName': 'Shields', 'Affiliation': 'Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, Columbus, Ohio. Peter.Shields@osumc.edu.'}]","Cancer prevention research (Philadelphia, Pa.)",['10.1158/1940-6207.CAPR-19-0400'] 3279,31577546,Electrocatheter-mediated High-voltage Pulsed Radiofrequency of the Dorsal Root Ganglion in the Treatment of Chronic Lumbosacral Neuropathic Pain: A Randomized Controlled Study.,"OBJECTIVES Despite the interest in scientific community, there is still poor evidence about pulsed radiofrequency (PRF) efficacy in the treatment of neuropathic pain. In order to determine whether high-voltage PRF and epidural adhesiolysis (PRF-EA) showed better results than epidural adhesiolysis alone (EA), a randomized, double-blind, comparative-effectiveness study was conducted in patients with chronic lumbosacral radiating pain and neuropathic features. MATERIALS AND METHODS A total of 41 patients were randomly allocated to 2 groups. Twenty-one patients were randomized to receive 2 cycles of 240 seconds high-voltage PRF followed by the injection of local anesthetics, hyaluronidase, and betamethasone, whereas 20 patients underwent sham stimulation followed by adhesiolysis. The treatment was delivered at the affected lumbosacral roots and patients, treating physicians and assessors were blinded to intervention. RESULTS A significant reduction of radiating pain was observed in mean Numeric Rating Scale score at follow-up. A change of -3.43 versus -1.75 (P=0.031) after 1 month and -3.34 versus -0.80 (P=0.005) after 6 months was reported in patients undergoing PRF-EA in comparison with EA, respectively. After 1 month, 57% of patients in the PRF-EA group experienced a pain reduction of ≥50% versus only 25% of patients allocated to EA (P=0.037). Improvement decreased to 48% in the PRF-EA group whereas only 10% of EA reported significant pain relief after 6 months (P=0.008). DISCUSSION High-voltage PRF of dorsal root ganglion delivered through multifunctional electrode provided significant pain relief and may be considered a valuable treatment in chronic lumbosacral radicular pain with neuropathic features.",2020,A significant reduction of radiating pain was observed in mean numeric rating scale (NRS) score at follow-up.,"['41 patients', 'Twenty-one subjects', 'Chronic Lumbosacral Neuropathic Pain', 'patients with chronic lumbosacral radiating pain and neuropathic features']","['PRF-EA', 'sham stimulation followed by adhesiolysis', '240 seconds high-voltage pulsed radiofrequency followed by the injection of local anaesthetics, hyaluronidase and betamethasone', 'epidural adhesiolysis alone (EA', 'Electrocatheter-mediated High-voltage Pulsed Radiofrequency of the Dorsal Root Ganglion', 'high-voltage pulsed radiofrequency plus adhesiolysis (PRF-EA']","['pain relief', 'pain reduction', 'radiating pain', 'mean numeric rating scale (NRS) score']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C3715213', 'cui_str': '21 (qualifier value)'}, {'cui': 'C0205191', 'cui_str': 'Chronic (qualifier value)'}, {'cui': 'C0450206', 'cui_str': 'Lumbosacral (qualifier value)'}, {'cui': 'C0027796', 'cui_str': 'Neurodynia'}, {'cui': 'C0234254', 'cui_str': 'Radiating pain (finding)'}]","[{'cui': 'C0033374', 'cui_str': 'Prolactin-Releasing Peptide'}, {'cui': 'C0073980', 'cui_str': 'SHAM'}, {'cui': 'C1292856', 'cui_str': 'Stimulation procedure (procedure)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0012826', 'cui_str': 'Lysis of adhesions (procedure)'}, {'cui': 'C4319600', 'cui_str': '240 (qualifier value)'}, {'cui': 'C0457385', 'cui_str': 'Seconds (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0034107', 'cui_str': 'Pulse'}, {'cui': 'C1272883', 'cui_str': 'Injection'}, {'cui': 'C0002934', 'cui_str': 'Conduction-Blocking Anesthetics'}, {'cui': 'C0020197', 'cui_str': 'Hyaluronidase'}, {'cui': 'C0005308', 'cui_str': 'Betamethasone'}, {'cui': 'C0086597', 'cui_str': 'Mediate (qualifier value)'}, {'cui': 'C0017070', 'cui_str': 'Dorsal Root Ganglia'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C0451615', 'cui_str': 'Pain relief (procedure)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C0234254', 'cui_str': 'Radiating pain (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0222045'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",21.0,0.105959,A significant reduction of radiating pain was observed in mean numeric rating scale (NRS) score at follow-up.,"[{'ForeName': 'Simone', 'Initials': 'S', 'LastName': 'Vigneri', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Gianfranco', 'Initials': 'G', 'LastName': 'Sindaco', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Marco', 'Initials': 'M', 'LastName': 'La Grua', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Matteo', 'Initials': 'M', 'LastName': 'Zanella', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Giuliano', 'Initials': 'G', 'LastName': 'Lo Bianco', 'Affiliation': 'I.R.C.C.S. Centro Regionale Oncologico, Pain Medicine Unit, Rionero in Vulture, Italy.'}, {'ForeName': 'Valentina', 'Initials': 'V', 'LastName': 'Paci', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Francesca M', 'Initials': 'FM', 'LastName': 'Vinci', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Sciacca', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Ravaioli', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}, {'ForeName': 'Gilberto', 'Initials': 'G', 'LastName': 'Pari', 'Affiliation': 'Santa Maria Maddalena Hospital, Pain Medicine Unit, Occhiobello.'}]",The Clinical journal of pain,['10.1097/AJP.0000000000000766'] 3280,31314925,"Pharmacokinetic and Pharmacodynamic Effects of a γ-Secretase Modulator, PF-06648671, on CSF Amyloid-β Peptides in Randomized Phase I Studies.","γ-Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease by reducing pathogenic amyloid-β (Aβ) peptide production. Three phase I studies (NCT02316756, NCT02407353, and NCT02440100) investigated the safety/tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the oral GSM, PF-06648671. A PK/PD indirect-response model was developed (using biomarker data) to simultaneously characterize differential effects of PF-06648671 on multiple Aβ species in cerebrospinal fluid (CSF). Healthy subjects (n = 120) received single doses or multiple-ascending doses of PF-06648671/placebo for 14 days. No serious adverse events occurred; severe adverse eventswere deemed not drug related. PF-06648671 decreased Aβ42 and Aβ40 concentrations in CSF, with greater effects on Aβ42, and increased Aβ37 and Aβ38 levels, particularly Aβ37. No significant change in total Aβ was observed. The PK/PD model well described the tendency of observed CSF Aβ data and the steady-state effects of PF-06648671, supporting its use for predicting central Aβ effects and optimal dose selection for GSMs in future trials.",2020,"PF-06648671 decreased Aβ42 and Aβ40 concentrations in CSF, with greater effects on Aβ42, and increased Aβ37 and Aβ38 levels, particularly Aβ37.",['Healthy subjects (n=120) received'],"['γ-Secretase modulators (GSMs', 'single- or multiple-ascending doses of PF-06648671/placebo']","['safety/tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral GSM, PF-06648671', 'total Aβ', 'Aβ42, and increased Aβ37 and Aβ38 levels, particularly Aβ37']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}]","[{'cui': 'C0171484', 'cui_str': 'APP Secretase'}, {'cui': 'C0069228', 'cui_str': 'O-(glucuronic acid 2-sulfate)-(1--4)-O-(2,5)-anhydromannitol 6-sulfate'}, {'cui': 'C0205171', 'cui_str': 'Singular (qualifier value)'}, {'cui': 'C0439064', 'cui_str': 'Numerous (qualifier value)'}, {'cui': 'C0205385', 'cui_str': 'Ascending (qualifier value)'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0036043', 'cui_str': 'Safety'}, {'cui': 'C0031327', 'cui_str': 'Drug Kinetics'}, {'cui': 'C0243145', 'cui_str': 'pharmacodynamics'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0069228', 'cui_str': 'O-(glucuronic acid 2-sulfate)-(1--4)-O-(2,5)-anhydromannitol 6-sulfate'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}]",,0.0344376,"PF-06648671 decreased Aβ42 and Aβ40 concentrations in CSF, with greater effects on Aβ42, and increased Aβ37 and Aβ38 levels, particularly Aβ37.","[{'ForeName': 'Jae Eun', 'Initials': 'JE', 'LastName': 'Ahn', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Charles', 'Initials': 'C', 'LastName': 'Carrieri', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Fernando', 'Initials': 'F', 'LastName': 'Dela Cruz', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Terence', 'Initials': 'T', 'LastName': 'Fullerton', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Eva', 'Initials': 'E', 'LastName': 'Hajos-Korcsok', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Ping', 'Initials': 'P', 'LastName': 'He', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Constantino', 'Initials': 'C', 'LastName': 'Kantaridis', 'Affiliation': 'Brussels CRU, Pfizer Inc, Brussels, Belgium.'}, {'ForeName': 'Claire', 'Initials': 'C', 'LastName': 'Leurent', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Richann', 'Initials': 'R', 'LastName': 'Liu', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Jessica', 'Initials': 'J', 'LastName': 'Mancuso', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Laure', 'Initials': 'L', 'LastName': 'Mendes da Costa', 'Affiliation': 'Brussels CRU, Pfizer Inc, Brussels, Belgium.'}, {'ForeName': 'Ruolun', 'Initials': 'R', 'LastName': 'Qiu', 'Affiliation': 'Pfizer Inc, Cambridge, Massachusetts, USA.'}]",Clinical pharmacology and therapeutics,['10.1002/cpt.1570'] 3281,31851833,Taking a Short Break from Instagram: The Effects on Subjective Well-Being.,"This study investigated whether abstaining from Instagram (Ig) affects subjective well-being among young men and women. By comparing an intervention group (40 participants who take a break from Ig for a week) with a control group (40 participants who kept using Ig), we found that women who quitted Ig reported significantly higher levels of life satisfaction and positive affect than women who kept using it. Whereas positive affect increment depended on social appearance comparison, life satisfaction rose independent of the tendency to compare one's own appearance with others. It is possible that users who are no longer exposed to direct evaluative feedback about their images on Ig-be it related to their appearance, habits, or opinions-can witness an increase in their global satisfaction levels. No significant effects were found among men.",2020,"Whereas positive affect increment depended on social appearance comparison, life satisfaction rose independent of the tendency to compare one's own appearance with others.",['young men and women'],[],"['levels of life satisfaction and positive affect', 'social appearance comparison, life satisfaction']","[{'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C0043210', 'cui_str': 'Girls'}]",[],"[{'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0376558', 'cui_str': 'Life'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0392760', 'cui_str': 'Affecting (qualifier value)'}, {'cui': 'C0700364', 'cui_str': 'Appearances (qualifier value)'}]",40.0,0.0156459,"Whereas positive affect increment depended on social appearance comparison, life satisfaction rose independent of the tendency to compare one's own appearance with others.","[{'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Fioravanti', 'Affiliation': 'Psychology Unit, Department of Health Sciences, University of Florence, Florence, Italy.'}, {'ForeName': 'Alfonso', 'Initials': 'A', 'LastName': 'Prostamo', 'Affiliation': 'Psychology Unit, Department of Health Sciences, University of Florence, Florence, Italy.'}, {'ForeName': 'Silvia', 'Initials': 'S', 'LastName': 'Casale', 'Affiliation': 'Psychology Unit, Department of Health Sciences, University of Florence, Florence, Italy.'}]","Cyberpsychology, behavior and social networking",['10.1089/cyber.2019.0400'] 3282,31792646,"The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm.","RATIONALE Female cigarette smokers tend to show greater cessation failure compared with males. Variables that contribute to the maintenance of smoking, including stress and craving, may differentially impact male and female smokers. Novel pharmacotherapies, such as oxytocin, may attenuate stress reactivity and craving in smokers, but work in this area is limited. OBJECTIVES This study assessed the influence of gender and oxytocin on stress reactivity, craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. METHODS Male and female adult cigarette smokers (ages 18-45) were enrolled (women oversampled 2:1) and completed a laboratory session, in which intranasal oxytocin or placebo was administered followed by a laboratory social stress task. The role of gender and oxytocin were assessed on measures of stress reactivity, cigarette craving, latency to smoke in a resistance task, subjective responses to smoking, and ad-libitum smoking. RESULTS Participants (N = 144) had a mean age of 31 were 63% female and 56% White. Following stress induction, female smokers evidenced greater subjective stress than males, though males demonstrated greater neuroendocrine reactivity and smoking intensity than females. No gender differences were demonstrated for craving. Oxytocin did not attenuate any aspect of stress reactivity, craving, smoking, or subjective responses to smoking compared with placebo. CONCLUSIONS Gender differences in stress reactivity were shown in the hypothesized direction, but oxytocin appeared to exert little impact on subjective or behavioral metrics. Results highlight the complex relationship between gender, stress, and smoking, as well as the implications for oxytocin as a potential pharmacotherapy for smoking cessation.",2020,"Oxytocin did not attenuate any aspect of stress reactivity, craving, smoking, or subjective responses to smoking compared with placebo. ","['Female cigarette smokers', 'Participants (N = 144) had a mean age of 31 were 63% female and 56% White', 'Male and female adult cigarette smokers (ages 18-45) were enrolled (women oversampled 2:1) and completed a laboratory session, in which']","['placebo', 'intranasal oxytocin or placebo', 'oxytocin', 'Oxytocin']","['craving', 'stress reactivity, craving, and smoking', 'subjective stress', 'neuroendocrine reactivity and smoking intensity', 'stress reactivity, cigarette craving, latency to smoke in a resistance task, subjective responses to smoking, and ad-libitum smoking', 'stress reactivity, cigarette craving, and smoking', 'stress reactivity, craving, smoking, or subjective responses to smoking']","[{'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0337667', 'cui_str': 'Cigarette smoker (finding)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0043157', 'cui_str': 'Whites'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C0022877', 'cui_str': 'Laboratory'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0870371', 'cui_str': 'Craving'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0453996', 'cui_str': 'Tobacco Smoking'}, {'cui': 'C0439655', 'cui_str': 'Subjective observation'}, {'cui': 'C4049786', 'cui_str': 'Intensities'}, {'cui': 'C0677453', 'cui_str': 'Cigarette'}, {'cui': 'C0037366', 'cui_str': 'Smoke'}]",,0.0516614,"Oxytocin did not attenuate any aspect of stress reactivity, craving, smoking, or subjective responses to smoking compared with placebo. ","[{'ForeName': 'Erin A', 'Initials': 'EA', 'LastName': 'McClure', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA. mccluree@musc.edu.'}, {'ForeName': 'Nathaniel L', 'Initials': 'NL', 'LastName': 'Baker', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Kevin M', 'Initials': 'KM', 'LastName': 'Gray', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Caitlyn O', 'Initials': 'CO', 'LastName': 'Hood', 'Affiliation': 'Department of Psychology, College of Arts & Sciences, University of Kentucky, Lexington, KY, USA.'}, {'ForeName': 'Rachel L', 'Initials': 'RL', 'LastName': 'Tomko', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Matthew J', 'Initials': 'MJ', 'LastName': 'Carpenter', 'Affiliation': 'Department of Psychiatry and Behavioral Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Viswanathan R', 'Initials': 'VR', 'LastName': 'Ramakrishnan', 'Affiliation': 'Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Cole J', 'Initials': 'CJ', 'LastName': 'Buchanan', 'Affiliation': 'College of Medicine, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Michael E', 'Initials': 'ME', 'LastName': 'Saladin', 'Affiliation': 'Department of Health Sciences and Research, College of Health Professions, Medical University of South Carolina, Charleston, SC, USA.'}]",Psychopharmacology,['10.1007/s00213-019-05392-z'] 3283,31328876,Angiotensin II receptor blocker attenuates stress pressor response in young adult African Americans.,"African Americans (AAs) are susceptible to hypertension (HTN) and its associated organ damage leading to adverse cardiovascular (CV) outcomes. Psychological stress is proposed to contribute to the development of HTN; however, the potential role of the renin-angiotensin system (RAS) in stress-related HTN in AAs is largely unknown. In this study, we tested the hypothesis that activation of RAS is a potential contributing factor for altered CV responses to stress, and suppression of angiotensin II (Ang II) activity will improve hemodynamic responses to a prolonged mental stressor in healthy young AAs. Utilizing a double-blind, randomized, crossover study design, 132 normotensive AAs (25 ± 7 years) were treated with either a placebo (PLC) or 150 mg/d irbesartan (an Ang II type 1 receptor blocker; ARB) for 1 week. On the final day of each treatment, hemodynamic measures and urinary sodium excretion (UNaV) were collected before, during and after a 45 minute-mental stress. The magnitude of stress-induced increase in blood pressure with ARB was blunted and delayed compared to PLC. Systolic blood pressure at the end of recovery on ARB was significantly lower compared to either PLC (110 ± 13 vs 117 ± 12 mm Hg respectively; P < 0.001) or the prestress level on ARB (P = 0.02). ARB treatment reduced overall vasoconstriction and improved poststress UNaV. ARB attenuated blood pressure responses to mental stress and improved the poststress BP recovery process which were partly linked to reduced overall vasoconstriction and improved stress-induced UNaV in young adult AAs prior to the development of disease conditions. These results suggest that treatment approaches that inhibit RAS action could have significant relevance to potentially lower susceptibility to stress responses and eventually the premature development of HTN in AAs.",2019,ARB treatment reduced overall vasoconstriction and improved poststress UNaV. ARB attenuated blood pressure responses to mental stress and improved the poststress BP recovery process which were partly linked to reduced overall vasoconstriction and improved stress-induced UNaV in young adult AAs prior to the development of disease conditions.,"['African Americans (AAs', 'young adult African Americans', 'healthy young AAs', '132 normotensive AAs (25\xa0±\xa07\xa0years']","['PLC', 'Angiotensin II receptor blocker', 'placebo (PLC) or 150\xa0mg/d irbesartan (an Ang II type 1 receptor blocker; ARB', 'ARB']","['Systolic blood pressure', 'hemodynamic measures and urinary sodium excretion (UNaV', 'overall vasoconstriction', 'stress pressor response', 'blood pressure with ARB', 'overall vasoconstriction and improved stress-induced UNaV', 'ARB']","[{'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C2712122', 'cui_str': 'Normal blood pressure (finding)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}]","[{'cui': 'C0521942', 'cui_str': 'Angiotensin II Receptor Blockers'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C4321486', 'cui_str': '150 (qualifier value)'}, {'cui': 'C0288171', 'cui_str': 'irbesartan'}, {'cui': 'C0441729', 'cui_str': 'Type 1 (qualifier value)'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1264693', 'cui_str': 'Arbitrary'}]","[{'cui': 'C0871470', 'cui_str': 'Systolic Pressure'}, {'cui': 'C0019010', 'cui_str': 'Hemodynamics'}, {'cui': 'C1879489', 'cui_str': 'Measures (attribute)'}, {'cui': 'C3541959', 'cui_str': 'Sodium supplement (substance)'}, {'cui': 'C0221102', 'cui_str': 'Excretory function (observable entity)'}, {'cui': 'C0282416', 'cui_str': 'Overall'}, {'cui': 'C1456863', 'cui_str': 'Vasoconstriction'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C1264693', 'cui_str': 'Arbitrary'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}, {'cui': 'C0205263', 'cui_str': 'Induced (qualifier value)'}]",132.0,0.0239157,ARB treatment reduced overall vasoconstriction and improved poststress UNaV. ARB attenuated blood pressure responses to mental stress and improved the poststress BP recovery process which were partly linked to reduced overall vasoconstriction and improved stress-induced UNaV in young adult AAs prior to the development of disease conditions.,"[{'ForeName': 'Jin Hee', 'Initials': 'JH', 'LastName': 'Jeong', 'Affiliation': 'Department of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.'}, {'ForeName': 'Coral', 'Initials': 'C', 'LastName': 'Hanevold', 'Affiliation': 'Department of Pediatrics, Division of Nephrology, University of Washington, Seattle, Washington.'}, {'ForeName': 'Ryan A', 'Initials': 'RA', 'LastName': 'Harris', 'Affiliation': 'Department of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.'}, {'ForeName': 'Gaston', 'Initials': 'G', 'LastName': 'Kapuku', 'Affiliation': 'Department of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.'}, {'ForeName': 'Jennifer', 'Initials': 'J', 'LastName': 'Pollock', 'Affiliation': 'Department of Medicine, University of Alabama, Birmingham, Alabama.'}, {'ForeName': 'David', 'Initials': 'D', 'LastName': 'Pollock', 'Affiliation': 'Department of Medicine, University of Alabama, Birmingham, Alabama.'}, {'ForeName': 'Gregory', 'Initials': 'G', 'LastName': 'Harshfield', 'Affiliation': 'Department of Population Health Sciences, Georgia Prevention Institute, Augusta University, Augusta, Georgia.'}]","Journal of clinical hypertension (Greenwich, Conn.)",['10.1111/jch.13625'] 3284,30807516,PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment?,"PURPOSE Among eyes with proliferative diabetic retinopathy, identify whether baseline characteristics impact the benefit of ranibizumab over panretinal photocoagulation (PRP) in DRCR.net Protocol S. METHODS Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no previous PRP. Eyes were randomized to PRP or intravitreous 0.5-mg ranibizumab. RESULTS Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P < 0.001). Among 25 characteristics, there were none in which participants assigned to PRP had superior outcomes relative to ranibizumab-assigned participants. The relative benefit of ranibizumab over PRP for change in visual acuity seemed greater in participants with higher mean arterial pressure (P = 0.03), without previous focal/grid laser (P = 0.03), with neovascularization of the disk and elsewhere on clinical examination (P = 0.04), and with more advanced proliferative diabetic retinopathy on photographs (P = 0.02). For development of vision-impairing central-involved diabetic macular edema, the relative benefit of ranibizumab over PRP seemed greater among nonwhite participants (P = 0.01) and those with higher mean arterial pressure (P = 0.01). CONCLUSION There were no characteristics identified in which outcomes were superior with PRP compared with ranibizumab. These exploratory analyses provide additional support that ranibizumab may be a reasonable alternative to PRP for proliferative diabetic retinopathy over a 2-year period.",2019,"RESULTS Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P < 0.001).","['Participants had proliferative diabetic retinopathy, visual acuity of 20/320 or better, and no previous PRP', 'eyes with proliferative diabetic retinopathy']","['Ranibizumab', 'PRP', 'PRP or intravitreous 0.5-mg ranibizumab', 'ranibizumab over panretinal photocoagulation (PRP', 'ranibizumab']","['visual acuity and development of vision-impairing central-involved diabetic macular edema', 'mean arterial pressure', 'visual acuity']","[{'cui': 'C0154830', 'cui_str': 'PDR - proliferative diabetic retinopathy'}, {'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C0205156', 'cui_str': 'Previous (qualifier value)'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0015392', 'cui_str': 'Eye'}]","[{'cui': 'C1566537', 'cui_str': 'ranibizumab'}, {'cui': 'C0242848', 'cui_str': 'PrP (GSS)'}, {'cui': 'C0444500', 'cui_str': '0.5 (qualifier value)'}, {'cui': 'C0730064', 'cui_str': 'Scatter retinal laser photocoagulation'}]","[{'cui': 'C0042812', 'cui_str': 'Visual Acuity'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0042789', 'cui_str': 'Vision'}, {'cui': 'C0221099', 'cui_str': 'Impaired (qualifier value)'}, {'cui': 'C0205099', 'cui_str': 'Central (qualifier value)'}, {'cui': 'C0730285', 'cui_str': 'Diabetic macular edema'}, {'cui': 'C0428886', 'cui_str': 'Mean Arterial Pressure'}]",,0.511035,"RESULTS Ranibizumab was superior to PRP for change in visual acuity and development of vision-impairing central-involved diabetic macular edema over 2 years (P < 0.001).","[{'ForeName': 'Susan B', 'Initials': 'SB', 'LastName': 'Bressler', 'Affiliation': 'Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'ForeName': 'Wesley T', 'Initials': 'WT', 'LastName': 'Beaulieu', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Adam R', 'Initials': 'AR', 'LastName': 'Glassman', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Jeffrey G', 'Initials': 'JG', 'LastName': 'Gross', 'Affiliation': 'Carolina Retina Center PA, Columbia, South Carolina.'}, {'ForeName': 'Michele', 'Initials': 'M', 'LastName': 'Melia', 'Affiliation': 'Jaeb Center for Health Research, Tampa, Florida.'}, {'ForeName': 'Eric', 'Initials': 'E', 'LastName': 'Chen', 'Affiliation': 'Retina Consultants of Houston, Houston, Texas.'}, {'ForeName': 'Michael R', 'Initials': 'MR', 'LastName': 'Pavlica', 'Affiliation': 'Family Eye Group, Lancaster, Pennsylvania.'}, {'ForeName': 'Lee M', 'Initials': 'LM', 'LastName': 'Jampol', 'Affiliation': 'Feinberg School of Medicine, Northwestern University, Chicago, Illinois.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]","Retina (Philadelphia, Pa.)",['10.1097/IAE.0000000000002377'] 3285,31934865,An Online Pain Education Program for Working Adults: Pilot Randomized Controlled Trial.,"BACKGROUND Pain is a common public health concern, and the pain situation among the general population is serious in mainland China. Working adults commonly experience pain because of long sitting times, a lack of free time, and exercise. A lack of pain-related knowledge is also a significant factor. Educational and therapeutic programs delivered online were used more often in Western countries, and accessible programs in China are limited, especially for pain management. Therefore, we carried out an online pain education program for working adults to self-manage pain. The program was delivered through WeChat, a popular and secure social media with a large population base in China. OBJECTIVE This study aimed to (1) provide pain-related knowledge and self-relief strategies, (2) help participants reduce pain and improve pain-related emotional well-being, and (3) explore participants' learning performance and the acceptability of the online pain education program. METHODS This was a randomized controlled trial. Chinese adults aged between 16 and 60 years with full-time employment, with pain in the past 6 months, and without any mental illness were recruited using snowball sampling through the internet and were randomly allocated to an experimental group and a control group in 1:1 ratio after the baseline assessment. The 4-week educational program that included basic knowledge of pain, pharmacological and nonpharmacological treatments, and related resources was provided only to the experimental group. Outcomes of pain, depression, anxiety, stress, and pain self-efficacy were measured at baseline (T0), posttreatment (T1), and 1-month follow-up (T2). Participants' acceptability and satisfaction were explored after completing the educational program. RESULTS In total, 95 eligible participants joined in the program: 47 in the experimental group and 48 in the control group. Neck and shoulder, head, and back were most commonly reported pain sites with high pain scores. Pain intensity and interference of the experimental group were significantly reduced after the educational program. Depression, anxiety, and stress clinically improved and pain self-efficacy improved after the educational program. The difference in depression, anxiety, stress, and pain self-efficacy within a group or between groups was not statistically significant; however, clinical improvements were demonstrated. A significant correlation between dosage of the intervention and pain intensity and depression was demonstrated. After completing the educational program, more than half of the participants showed acceptance of and satisfaction with the program, and they were willing to recommend the program to others. CONCLUSIONS Our findings highlight the significant potential of this online education program in the treatment of pain. TRIAL REGISTRATION ClinicalTrials.gov NCT03952910; https://clinicaltrials.gov/ct2/show/NCT03952910.",2020,"The difference in depression, anxiety, stress, and pain self-efficacy within a group or between groups was not statistically significant; however, clinical improvements were demonstrated.","['working adults to self-manage pain', 'Chinese adults aged between 16 and 60 years with full-time employment, with pain in the past 6 months, and without any mental illness were recruited using snowball sampling through the internet', 'Working Adults', '95 eligible participants joined in the program: 47 in the experimental group and 48 in the control group']",[],"['pain, depression, anxiety, stress, and pain self-efficacy', 'pain intensity and depression', 'acceptability and satisfaction', 'depression, anxiety, stress, and pain self-efficacy', 'acceptance of and satisfaction', 'Pain intensity and interference', 'Depression, anxiety, and stress clinically improved and pain self-efficacy']","[{'cui': 'C0043227', 'cui_str': 'Work'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0002766', 'cui_str': 'Pain management (procedure)'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0682295', 'cui_str': 'Full-time employment (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C1444637', 'cui_str': 'In the past'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0004936', 'cui_str': 'Mental disorder (disorder)'}, {'cui': 'C0441621', 'cui_str': 'Sampling - action (qualifier value)'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]",[],"[{'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0600564', 'cui_str': 'Self Efficacy'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C3645535', 'cui_str': 'Acceptability'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0184511', 'cui_str': 'Improved (qualifier value)'}]",95.0,0.117673,"The difference in depression, anxiety, stress, and pain self-efficacy within a group or between groups was not statistically significant; however, clinical improvements were demonstrated.","[{'ForeName': 'Yajie', 'Initials': 'Y', 'LastName': 'Li', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.'}, {'ForeName': 'Mun Yee Mimi', 'Initials': 'MYM', 'LastName': 'Tse', 'Affiliation': 'School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.'}]",Journal of medical Internet research,['10.2196/15071'] 3286,29955161,Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial.,"Although small-scale studies have described the effects of oxytocin on social deficits in autism spectrum disorder (ASD), no large-scale study has been conducted. In this randomized, parallel-group, multicenter, placebo-controlled, double-blind trial in Japan, 106 ASD individuals (18-48 y.o.) were enrolled between Jan 2015 and March 2016. Participants were randomly assigned to a 6-week intranasal oxytocin (48IU/day, n = 53) or placebo (n = 53) group. One-hundred-three participants were analyzed. Since oxytocin reduced the primary endpoint, Autism Diagnostic Observation Schedule (ADOS) reciprocity, (from 8.5 to 7.7; P < .001) but placebo also reduced the score (8.3 to 7.2; P < .001), no between-group difference was found (effect size -0.08; 95% CI, -0.46 to 0.31; P = .69); however, plasma oxytocin was only elevated from baseline to endpoint in the oxytocin-group compared with the placebo-group (effect size -1.12; -1.53 to -0.70; P < .0001). Among the secondary endpoints, oxytocin reduced ADOS repetitive behavior (2.0 to 1.5; P < .0001) compared with placebo (2.0 to 1.8; P = .43) (effect size 0.44; 0.05 to 0.83; P = .026). In addition, the duration of gaze fixation on socially relevant regions, another secondary endpoint, was increased by oxytocin (41.2 to 52.3; P = .03) compared with placebo (45.7 to 40.4; P = .25) (effect size 0.55; 0.10 to 1.0; P = .018). No significant effects were observed for the other secondary endpoints. No significant difference in the prevalence of adverse events was observed between groups, although one participant experienced temporary gynecomastia during oxytocin administration. Based on the present findings, we cannot recommend continuous intranasal oxytocin treatment alone at the current dose and duration for treatment of the core social symptoms of high-functioning ASD in adult men, although this large-scale trial suggests oxytocin's possibility to treat ASD repetitive behavior.",2020,"Among the secondary endpoints, oxytocin reduced ADOS repetitive behavior (2.0 to 1.5; P < .0001) compared with placebo (2.0 to 1.8; P = .43) (effect size 0.44; 0.05 to 0.83; P = .026).","['autism spectrum disorder', 'adult men', 'autism spectrum disorder (ASD', 'One-hundred-three participants were analyzed', 'Japan, 106 ASD individuals (18-48 y.o.) were enrolled between Jan 2015 and March 2016']","['intranasal oxytocin', 'placebo', 'oxytocin']","['plasma oxytocin', 'prevalence of adverse events', 'temporary gynecomastia', 'duration of gaze fixation', 'oxytocin reduced ADOS repetitive behavior', 'Autism Diagnostic Observation Schedule (ADOS) reciprocity']","[{'cui': 'C1510586', 'cui_str': 'Autism Spectrum Disorders'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0086418', 'cui_str': 'Humans'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0022341', 'cui_str': 'Japan'}, {'cui': 'C0237401', 'cui_str': 'Individual (person)'}]","[{'cui': 'C0442118', 'cui_str': 'Intranasal approach (qualifier value)'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}, {'cui': 'C0220900', 'cui_str': 'prevalence'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205374', 'cui_str': 'Transitory (qualifier value)'}, {'cui': 'C0018418', 'cui_str': 'Male Breast Enlargement'}, {'cui': 'C2926735', 'cui_str': 'Duration'}, {'cui': 'C0553544', 'cui_str': 'Gaze (finding)'}, {'cui': 'C0185023', 'cui_str': 'pexy'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0004352', 'cui_str': 'Autism, Early Infantile'}, {'cui': 'C0348026', 'cui_str': 'Diagnostic'}, {'cui': 'C0302523', 'cui_str': 'Observation'}, {'cui': 'C0086960', 'cui_str': 'Schedules'}]",103.0,0.68114,"Among the secondary endpoints, oxytocin reduced ADOS repetitive behavior (2.0 to 1.5; P < .0001) compared with placebo (2.0 to 1.8; P = .43) (effect size 0.44; 0.05 to 0.83; P = .026).","[{'ForeName': 'Hidenori', 'Initials': 'H', 'LastName': 'Yamasue', 'Affiliation': 'Department of Psychiatry, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashiku, Hamamatsu City, 431-3192, Japan. yamasue@hama-med.ac.jp.'}, {'ForeName': 'Takashi', 'Initials': 'T', 'LastName': 'Okada', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Toshio', 'Initials': 'T', 'LastName': 'Munesue', 'Affiliation': 'Research Center for Child Mental Development, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Kuroda', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Toru', 'Initials': 'T', 'LastName': 'Fujioka', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Eiheiji, Fukui, 910-1193, Japan.'}, {'ForeName': 'Yota', 'Initials': 'Y', 'LastName': 'Uno', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Kaori', 'Initials': 'K', 'LastName': 'Matsumoto', 'Affiliation': 'Graduate School of Psychology, Kanazawa Institute of Technology, 7-1 Ohgigaoka, Nonoichi, 921-8054, Japan.'}, {'ForeName': 'Hitoshi', 'Initials': 'H', 'LastName': 'Kuwabara', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Daisuke', 'Initials': 'D', 'LastName': 'Mori', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Okamoto', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Eiheiji, Fukui, 910-1193, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Yoshimura', 'Affiliation': 'Research Center for Child Mental Development, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.'}, {'ForeName': 'Yuki', 'Initials': 'Y', 'LastName': 'Kawakubo', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Yuko', 'Initials': 'Y', 'LastName': 'Arioka', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Masaki', 'Initials': 'M', 'LastName': 'Kojima', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Teruko', 'Initials': 'T', 'LastName': 'Yuhi', 'Affiliation': 'Research Center for Child Mental Development, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.'}, {'ForeName': 'Keiho', 'Initials': 'K', 'LastName': 'Owada', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Walid', 'Initials': 'W', 'LastName': 'Yassin', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Itaru', 'Initials': 'I', 'LastName': 'Kushima', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Seico', 'Initials': 'S', 'LastName': 'Benner', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Nanayo', 'Initials': 'N', 'LastName': 'Ogawa', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Yosuke', 'Initials': 'Y', 'LastName': 'Eriguchi', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Naoko', 'Initials': 'N', 'LastName': 'Kawano', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Yukari', 'Initials': 'Y', 'LastName': 'Uemura', 'Affiliation': 'Biostatistics Division, Clinical Research Support Center, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Maeri', 'Initials': 'M', 'LastName': 'Yamamoto', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Yukiko', 'Initials': 'Y', 'LastName': 'Kano', 'Affiliation': 'Department of Child Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Kiyoto', 'Initials': 'K', 'LastName': 'Kasai', 'Affiliation': 'Department of Neuropsychiatry, School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.'}, {'ForeName': 'Haruhiro', 'Initials': 'H', 'LastName': 'Higashida', 'Affiliation': 'Research Center for Child Mental Development, Kanazawa University, 13-1 Takara-machi, Kanazawa, 920-8640, Japan.'}, {'ForeName': 'Norio', 'Initials': 'N', 'LastName': 'Ozaki', 'Affiliation': 'Department of Psychiatry, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan.'}, {'ForeName': 'Hirotaka', 'Initials': 'H', 'LastName': 'Kosaka', 'Affiliation': 'Research Center for Child Mental Development, University of Fukui, Eiheiji, Fukui, 910-1193, Japan.'}]",Molecular psychiatry,['10.1038/s41380-018-0097-2'] 3287,30500110,"Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study.","Saxagliptin is an orally administered, highly potent, and selective dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. This study was conducted to determine the effect of magnesium and aluminum hydroxides plus simethicone, famotidine, and omeprazole on the pharmacokinetics of saxagliptin and its active metabolite, 5-hydroxy saxagliptin. This was an open-label, randomized, 5-treatment, 5-period, 3-way crossover study in 15 healthy subjects. Mean C max of saxagliptin was 26% lower, but AUC was almost unchanged when saxagliptin was coadministered with Maalox Max. Mean C max was 14% higher, but AUC was almost unchanged when saxagliptin was coadministered with famotidine. Changes in pharmacokinetics of 5-hydroxy saxagliptin generally paralleled the changes in saxagliptin. These pharmacokinetic changes were unlikely to be clinically meaningful. Coadministration of omeprazole did not affect saxagliptin C max or AUC. Saxagliptin in combination with these medicines resulted in no unexpected safety or tolerability findings in these healthy subjects. No dose adjustment of saxagliptin or separation in the time of saxagliptin dosing is necessary with medicines that raise gastric pH when coadministered with saxagliptin.",2019,"Mean C max of saxagliptin was 26% lower, but AUC was almost unchanged when saxagliptin was coadministered with Maalox Max.","['Healthy Subjects', 'type 2 diabetes mellitus', 'healthy subjects', '15 healthy subjects']","['magnesium and aluminum hydroxides plus simethicone, famotidine, and omeprazole', 'Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone', 'omeprazole', 'saxagliptin', 'selective dipeptidyl peptidase-4 inhibitor', 'famotidine', 'Saxagliptin']","['saxagliptin C max or AUC', 'Mean C max of saxagliptin', 'Mean C max']","[{'cui': 'C1708335', 'cui_str': 'Healthy Participants'}, {'cui': 'C0011860', 'cui_str': 'Diabetes Mellitus, Type 2'}]","[{'cui': 'C3540792', 'cui_str': 'Magnesium supplements, alimentary tract and metabolism'}, {'cui': 'C0002371', 'cui_str': 'aluminium hydroxide'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0037138', 'cui_str': 'Simethicone'}, {'cui': 'C0015620', 'cui_str': 'Famotidine'}, {'cui': 'C0028978', 'cui_str': 'Omeprazole'}, {'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C1827106', 'cui_str': 'Dipeptidyl-Peptidase 4 Inhibitors'}]","[{'cui': 'C1611934', 'cui_str': 'saxagliptin'}, {'cui': 'C0806909', 'cui_str': 'Max'}, {'cui': 'C0376690', 'cui_str': 'AUC'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",15.0,0.0193412,"Mean C max of saxagliptin was 26% lower, but AUC was almost unchanged when saxagliptin was coadministered with Maalox Max.","[{'ForeName': 'Song', 'Initials': 'S', 'LastName': 'Ren', 'Affiliation': 'Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD, USA.'}, {'ForeName': 'David W', 'Initials': 'DW', 'LastName': 'Boulton', 'Affiliation': 'Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Gaithersburg, MD, USA.'}]",Clinical pharmacology in drug development,['10.1002/cpdd.634'] 3288,30981162,A randomised controlled trial of guided internet-based cognitive behavioural therapy for perfectionism: Effects on psychopathology and transdiagnostic processes.,"BACKGROUND AND OBJECTIVES Perfectionism is a transdiagnostic process that has been associated with a range of psychopathology and also with other transdiagnostic processes. We have previously shown that guided internet-based cognitive behavioural therapy (ICBT) can reduce symptoms of dysfunctional perfectionism, however, no impact was observed on symptoms of depression and anxiety. Here we explore the impact of guided ICBT for perfectionism on symptoms of other associated psychopathology, specifically obsessive-compulsive disorder (OCD) and eating disorders, and also on other associated transdiagnostic processes (self-esteem, intolerance of uncertainty, and self-compassion). METHODS Participants who presented with clinical levels of perfectionism were randomised to an experimental group that received the intervention (n = 62), or a wait list control group (n = 58). Questionnaires assessing symptoms of OCD, eating disorders, self-esteem, intolerance of uncertainty, and fear of self-compassion were completed pre-intervention, post-intervention (12 weeks), and at follow-up (24 weeks). Between group effect sizes are reported. RESULTS The intervention led to significant decreases in symptoms of OCD (d = -0.9; CI: -1.4, -0.4) and eating disorders (d = -0.6; CI: -1.0, -0.1), and had an impact on other transdiagnostic processes resulting in increased self-esteem (d = 0.7; CI: 0.2, 1.2), decreases in intolerance of uncertainty (d = -0.9; CI: -1.4, -0.4), and fear of self-compassion (d = -0.8; CI: -1.3, -0.3). At follow-up changes were maintained in symptoms of OCD (d = -1.3; CI: -1.8, -0.8), disordered eating (d = -0.7; CI: -1.2, -0.2), intolerance of uncertainty (d = -0.8; CI: -1.2, -0.3), and fear of self-compassion (d = -1.0; CI: -1.5, -0.5). CONCLUSIONS Guided ICBT for perfectionism improves associated psychopathology and transdiagnostic processes. ClinicalTrials.gov registration no. NCT02756871.",2019,"At follow-up changes were maintained in symptoms of OCD (d = -1.3; CI: -1.8, -0.8), disordered eating (d = -0.7; CI: -1.2, -0.2),",['Participants who presented with clinical levels of perfectionism'],"['guided ICBT', 'guided internet-based cognitive behavioural therapy (ICBT', 'guided internet-based cognitive behavioural therapy']","['symptoms of OCD', 'intolerance of uncertainty', 'eating disorders', 'self-esteem', 'intolerance of uncertainty (d', 'Questionnaires assessing symptoms of OCD, eating disorders, self-esteem, intolerance of uncertainty, and fear of self-compassion', 'fear of self-compassion', 'disordered eating']","[{'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0205210', 'cui_str': 'Clinical (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0815110', 'cui_str': 'Perfectionism'}]","[{'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0282111', 'cui_str': 'World Wide Web'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0009244', 'cui_str': 'Cognitive Therapy'}]","[{'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0231199', 'cui_str': 'Intolerance, function (observable entity)'}, {'cui': 'C0087130', 'cui_str': 'Uncertainty'}, {'cui': 'C0013473', 'cui_str': 'Eating Disorders'}, {'cui': 'C0036597', 'cui_str': 'Self Esteem'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C0015726', 'cui_str': 'Fear'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0242270', 'cui_str': 'Compassion'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}]",,0.083957,"At follow-up changes were maintained in symptoms of OCD (d = -1.3; CI: -1.8, -0.8), disordered eating (d = -0.7; CI: -1.2, -0.2),","[{'ForeName': 'Radha', 'Initials': 'R', 'LastName': 'Kothari', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, London, 1 - 19 Torrington Place, London, WC1E 7HB, United Kingdom; Institute of Child Health Population, Policy and Practice Programme, University College London, 30 Guilford Street, London, WC1N 1EH, United Kingdom. Electronic address: Radha.kothari.10@ucl.ac.uk.'}, {'ForeName': 'Chris', 'Initials': 'C', 'LastName': 'Barker', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, London, 1 - 19 Torrington Place, London, WC1E 7HB, United Kingdom. Electronic address: c.barker@ucl.ac.uk.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Pistrang', 'Affiliation': 'Division of Psychology and Language Sciences, University College London, London, 1 - 19 Torrington Place, London, WC1E 7HB, United Kingdom. Electronic address: n.pistrang@ucl.ac.uk.'}, {'ForeName': 'Alexander', 'Initials': 'A', 'LastName': 'Rozental', 'Affiliation': 'Institute of Child Health Population, Policy and Practice Programme, University College London, 30 Guilford Street, London, WC1N 1EH, United Kingdom; Department of Clinical Neuroscience, Karolinska Institutet, Norra Stationsgatan 69, 113 64, Stockholm, Sweden. Electronic address: alexander.rozental@ki.se.'}, {'ForeName': 'Sarah', 'Initials': 'S', 'LastName': 'Egan', 'Affiliation': 'School of Psychology, Faculty of Health Sciences, Curtin University, Kent St, Bentley, WA 6102, Perth, Australia. Electronic address: s.egan@curtin.edu.au.'}, {'ForeName': 'Tracey', 'Initials': 'T', 'LastName': 'Wade', 'Affiliation': 'School of Psychology, Flinders University, Adelaide, Sturt Rd, Bedford Park, SA, 5042, Australia. Electronic address: tracey.wade@flinders.edu.au.'}, {'ForeName': 'Hannah', 'Initials': 'H', 'LastName': 'Allcott-Watson', 'Affiliation': 'Institute of Child Health Population, Policy and Practice Programme, University College London, 30 Guilford Street, London, WC1N 1EH, United Kingdom. Electronic address: hannah.allcott-watson.14@ucl.ac.uk.'}, {'ForeName': 'Gerhard', 'Initials': 'G', 'LastName': 'Andersson', 'Affiliation': 'Department of Behavioural Sciences and Learning, Linkoping University, 581 83, Linköping, Sweden; Department of Clinical Neuroscience, Karolinska Institute, Solnavägen 1, 171 77 Solna, Stockholm, Sweden. Electronic address: gerhard.andersson@liu.se.'}, {'ForeName': 'Roz', 'Initials': 'R', 'LastName': 'Shafran', 'Affiliation': 'Institute of Child Health Population, Policy and Practice Programme, University College London, 30 Guilford Street, London, WC1N 1EH, United Kingdom. Electronic address: r.shafran@ucl.ac.uk.'}]",Journal of behavior therapy and experimental psychiatry,['10.1016/j.jbtep.2019.03.007'] 3289,31676252,Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study.,"AIMS To investigate levels and changes in diabetes distress over the course of the PRIORITY (Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In people with TYpe 2 diabetes and normoalbuminuria) randomised controlled trial of screening for diabetic kidney disease (DKD) risk among people with type 2 diabetes (T2D) at a specialist diabetes clinic in Denmark. METHODS Of 436 trial participants with T2D, 216 were invited to complete the 17-item diabetes distress scale at the time of screening (T1, n = 180), immediately after receiving the screening results at 6-8 weeks (T2, n = 169), and at 12 months follow up (T3, n = 107). Linear mixed models were used to explore changes in diabetes distress. RESULTS No significant changes in diabetes distress were observed between the time of screening, receiving results, and at 12 months. Changes in diabetes distress were not influenced by diabetes empowerment, sense of coherence, or perceived support for diabetes self-management. CONCLUSIONS In contrast to previous studies demonstrating that screening programmes can have negative psychological consequences, our findings indicate that participating in this screening programme for DKD does not influence emotional burden or physician-related distress among people with T2D.",2020,"Changes in diabetes distress were not influenced by diabetes empowerment, sense of coherence, or perceived support for diabetes self-management. ","['people with type 2 diabetes', 'T2D) at a specialist diabetes clinic in Denmark', 'Of 436 trial participants with T2D, 216 were invited to complete the 17-item diabetes distress scale at the time of screening (T1, n\u202f=\u202f180', 'early diabetic nephRopathy', 'diabetic kidney disease (DKD) risk among people with type 2 diabetes ', 'people with T2D']",['risk screening programme'],"['diabetes distress', 'diabetes empowerment, sense of coherence, or perceived support for diabetes self-management']","[{'cui': 'C0332307', 'cui_str': 'Type - attribute'}, {'cui': 'C0087009', 'cui_str': 'Specialists'}, {'cui': 'C3839636', 'cui_str': 'Diabetes clinic'}, {'cui': 'C0011318', 'cui_str': 'Denmark'}, {'cui': 'C4708905', 'cui_str': 'Two hundred and sixteen'}, {'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0222045'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}, {'cui': 'C4319557', 'cui_str': '180'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0011881', 'cui_str': 'Diabetic Nephropathy'}, {'cui': 'C0035647', 'cui_str': 'Risk'}]","[{'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C1305399', 'cui_str': 'Screening intent'}]","[{'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0679959', 'cui_str': 'Empowerment'}, {'cui': 'C3178983', 'cui_str': 'Salutogeneses'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}, {'cui': 'C0086969', 'cui_str': 'Self-Management'}]",216.0,0.0268754,"Changes in diabetes distress were not influenced by diabetes empowerment, sense of coherence, or perceived support for diabetes self-management. ","[{'ForeName': 'Lene Eide', 'Initials': 'LE', 'LastName': 'Joensen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: lene.eide.joensen@regionh.dk.'}, {'ForeName': 'Kristoffer Panduro', 'Initials': 'KP', 'LastName': 'Madsen', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: kristoffer.panduro.madsen@regionh.dk.'}, {'ForeName': 'Marie', 'Initials': 'M', 'LastName': 'Frimodt-Møller', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: marie.frimodt-moeller@regionh.dk.'}, {'ForeName': 'Nete', 'Initials': 'N', 'LastName': 'Tofte', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: nete.tofte@regionh.dk.'}, {'ForeName': 'Ingrid', 'Initials': 'I', 'LastName': 'Willaing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: ingrid.willaing.tapager@regionh.dk.'}, {'ForeName': 'Morten', 'Initials': 'M', 'LastName': 'Lindhardt', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Electronic address: morten.kofod.lindhardt@regionh.dk.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Rossing', 'Affiliation': 'Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark. Electronic address: peter.rossing@regionh.dk.'}]",Journal of diabetes and its complications,['10.1016/j.jdiacomp.2019.107467'] 3290,30270489,Hope and benefit finding: Results from the PRISM randomized controlled trial.,"BACKGROUND Adolescents and young adults (AYAs) with cancer are at risk for poor psychosocial outcomes, perhaps because they have not acquired skills to navigate the adversities of illness. In a recent phase II randomized controlled trial (RCT), the ""Promoting Resilience in Stress Management"" (PRISM) intervention was associated with improved patient-reported resilience, quality of life, and distress. In this planned analysis of secondary aims, we hypothesized PRISM would also improve targeted coping skills of hopeful thinking, benefit finding, and goal setting. METHODS We conducted this parallel RCT at Seattle Children's Hospital from January 2015 to October 2016. English-speaking AYAs (12-25 years old) with cancer were randomized one-to-one to PRISM or usual care (UC). PRISM teaches stress-management, goal-setting, cognitive-reframing, and meaning-making skills in four sessions delivered in-person every other week. Participants completed surveys at enrollment and 6 months later. Mixed effects linear regression models evaluated associations between PRISM and benefit finding (Benefit-Finding Scale for Children), hopeful thinking (Hope Scale), and an exploratory outcome of goal setting (queried with open-ended items about participant's goals, measured qualitatively by three blinded reviewers). RESULTS Of N = 92 AYAs (48 PRISM, 44 UC), 73% were 12-17 years old, 43% female, and 62% diagnosed with leukemia or lymphoma. PRISM was associated with improved benefit finding and hope with moderate-to-large effect sizes-benefit finding: +3.1 points, 95% CI 0.0, 6.2, d = 0.4, and P = 0.05; and hope: +3.6 points, 95% CI 0.7, 6.4, d = 0.6, and P = 0.01. We did not detect changes in goal setting (-0.5 points, 95% CI -1.2, 0.3, d = -0.3, P = 0.23). CONCLUSIONS PRISM was associated with improvements in benefit finding and hopeful thinking, two adaptive coping skills which may mitigate long-term psychosocial risk.",2019,"PRISM was associated with improved benefit finding and hope with moderate-to-large effect sizes-benefit finding: +3.1 points, 95% CI 0.0, 6.2, d = 0.4, and P = 0.05; and hope: +3.6 points, 95% CI 0.7, 6.4, d = 0.6, and P = 0.01.","['Adolescents and young adults (AYAs) with cancer', '73% were 12-17 years old, 43% female, and 62% diagnosed with leukemia or lymphoma', 'English-speaking AYAs (12-25 years old) with cancer', ""Seattle Children's Hospital from January 2015 to October 2016""]",['PRISM or usual care (UC'],"['patient-reported resilience, quality of life, and distress', 'PRISM teaches stress-management, goal-setting, cognitive-reframing, and meaning-making skills']","[{'cui': 'C0205653', 'cui_str': 'Adolescent'}, {'cui': 'C0238598', 'cui_str': 'Young Adult'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0023418', 'cui_str': 'Leucocythaemia'}, {'cui': 'C0024299', 'cui_str': 'Germinoblastoma'}, {'cui': 'C3540738', 'cui_str': 'English [International Organization for Standardization 639-1 code en] language reference set (foundation metadata concept)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C1510665', 'cui_str': 'Hospital environment (environment)'}]",[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0684224', 'cui_str': 'Report'}, {'cui': 'C0034380'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0150788', 'cui_str': 'Manage stress control'}, {'cui': 'C0150598', 'cui_str': 'Goal setting (qualifier value)'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}]",2.0,0.27976,"PRISM was associated with improved benefit finding and hope with moderate-to-large effect sizes-benefit finding: +3.1 points, 95% CI 0.0, 6.2, d = 0.4, and P = 0.05; and hope: +3.6 points, 95% CI 0.7, 6.4, d = 0.6, and P = 0.01.","[{'ForeName': 'Abby R', 'Initials': 'AR', 'LastName': 'Rosenberg', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Miranda C', 'Initials': 'MC', 'LastName': 'Bradford', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Krysta S', 'Initials': 'KS', 'LastName': 'Barton', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Nicole', 'Initials': 'N', 'LastName': 'Etsekson', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'McCauley', 'Affiliation': ""Center for Child Health, Behavior, and Development, Seattle Children's Research Institute, Seattle, Washington.""}, {'ForeName': 'J Randall', 'Initials': 'JR', 'LastName': 'Curtis', 'Affiliation': 'Division of Pulmonary, Critical Care, and Sleep Medicine, Harborview Medical Center, Seattle, Washington.'}, {'ForeName': 'Joanne', 'Initials': 'J', 'LastName': 'Wolfe', 'Affiliation': 'Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.'}, {'ForeName': 'K Scott', 'Initials': 'KS', 'LastName': 'Baker', 'Affiliation': ""Center for Cancer and Blood Disorders, Seattle Children's Hospital, Seattle, Washington.""}, {'ForeName': 'Joyce P', 'Initials': 'JP', 'LastName': 'Yi-Frazier', 'Affiliation': ""Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.""}]",Pediatric blood & cancer,['10.1002/pbc.27485'] 3291,31726193,Different Lifestyle Interventions in Adults From Underserved Communities: The FAMILIA Trial.,"BACKGROUND The current trends of unhealthy lifestyle behaviors in underserved communities are disturbing. Thus, effective health promotion strategies constitute an unmet need. OBJECTIVES The purpose of this study was to assess the impact of 2 different lifestyle interventions on parents/caregivers of children attending preschools in a socioeconomically disadvantaged community. METHODS The FAMILIA (Family-Based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health) study is a cluster-randomized trial involving 15 Head Start preschools in Harlem, New York. Schools, and their children's parents/caregivers, were randomized to receive either an ""individual-focused"" or ""peer-to-peer-based"" lifestyle intervention program for 12 months or control. The primary outcome was the change from baseline to 12 months in a composite health score related to blood pressure, exercise, weight, alimentation, and tobacco (Fuster-BEWAT Score [FBS]), ranging from 0 to 15 (ideal health = 15). To assess the sustainability of the intervention, this study evaluated the change of FBS at 24 months. Main pre-specified secondary outcomes included changes in FBS subcomponents and the effect of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound. Mixed-effects models were used to test for intervention effects. RESULTS A total of 635 parents/caregivers were enrolled: mean age 38 ± 11 years, 83% women, 57% Hispanic/Latino, 31% African American, and a baseline FBS of 9.3 ± 2.4 points. The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences. However, high-adherence participants to the intervention exhibited a greater change in FBS than their low-adherence counterparts: 0.30 points (95% confidence interval: 0.03 to 0.57; p = 0.027) versus 0.00 points (95% confidence interval: -0.43 to 0.43; p = 1.0), respectively. Furthermore, the knowledge by the participant of the presence of atherosclerosis significantly boosted the intervention effects. Similar results were sustained at 24 months. CONCLUSIONS Although overall significant differences were not observed between intervention and control groups, the FAMILIA trial highlights that high adherence rates to lifestyle interventions may improve health outcomes. It also suggests a potential contributory role of the presentation of atherosclerosis pictures, providing helpful information to improve future lifestyle interventions in adults.",2020,"The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences.","['adults', ""Schools, and their children's parents/caregivers"", 'parents/caregivers of children attending preschools in a socioeconomically disadvantaged community', 'Adults from Underserved Communities', '15 Head Start preschools in Harlem, New York', '635 parents/caregivers with a mean age of 38±11 years, 83% female, 57% Hispanic/Latino and 31% African American, and a baseline FBS of 9.3±2.4 points']","['individual-focused"" or ""peer-to-peer based"" lifestyle intervention program for 12 months or control', 'lifestyle interventions']","['health outcomes', 'composite health score related to Blood pressure, Exercise, Weight, Alimentation and Tobacco (Fuster-BEWAT Score, FBS), ranging from 0 to 15 (ideal health=15', 'FBS', 'changes in FBS subcomponents and the impact of the knowledge of presence of atherosclerosis as assessed by bilateral carotid/femoral vascular ultrasound']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0036375', 'cui_str': 'School'}, {'cui': 'C0085092', 'cui_str': 'Parenting'}, {'cui': 'C0085537', 'cui_str': 'Care Givers'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1456498', 'cui_str': 'Attended'}, {'cui': 'C0009462', 'cui_str': 'Community'}, {'cui': 'C0018670', 'cui_str': 'Head'}, {'cui': 'C1272689', 'cui_str': 'Started'}, {'cui': 'C0027976', 'cui_str': 'New York'}, {'cui': 'C0444504', 'cui_str': 'Mean (qualifier value)'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0086409', 'cui_str': 'Hispanics'}, {'cui': 'C0086528', 'cui_str': 'Latinos'}, {'cui': 'C0085756', 'cui_str': 'African American (ethnic group)'}]","[{'cui': 'C0237401', 'cui_str': 'Individual (person)'}, {'cui': 'C2981153', 'cui_str': 'Finding related to focusing'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0023676', 'cui_str': 'Lifestyle'}, {'cui': 'C2728259', 'cui_str': 'Program'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}]","[{'cui': 'C0018684', 'cui_str': 'Health'}, {'cui': 'C0205199', 'cui_str': 'Composite (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0005823', 'cui_str': 'Blood Pressure'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C0443172', 'cui_str': 'State changes'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0004153', 'cui_str': 'Atherosclerosis'}, {'cui': 'C0238767', 'cui_str': 'Right and left (qualifier value)'}, {'cui': 'C0015811', 'cui_str': 'Femur'}, {'cui': 'C0948543', 'cui_str': 'Vascular ultrasound'}]",635.0,0.0826365,"The mean within-group change in FBS from baseline to 12 months was ∼0.20 points in all groups, with no overall between-group differences.","[{'ForeName': 'Rodrigo', 'Initials': 'R', 'LastName': 'Fernandez-Jimenez', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; CIBER de Enfermedades Cardiovasculares, Madrid, Spain. Electronic address: https://twitter.com/rodrigo_fjez.'}, {'ForeName': 'Risa', 'Initials': 'R', 'LastName': 'Jaslow', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Sameer', 'Initials': 'S', 'LastName': 'Bansilal', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Raquel', 'Initials': 'R', 'LastName': 'Diaz-Munoz', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Monali', 'Initials': 'M', 'LastName': 'Fatterpekar', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Maribel', 'Initials': 'M', 'LastName': 'Santana', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Andrea', 'Initials': 'A', 'LastName': 'Clarke-Littman', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jacqueline', 'Initials': 'J', 'LastName': 'Latina', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Ana V', 'Initials': 'AV', 'LastName': 'Soto', 'Affiliation': 'Mount Sinai Medical Center, Miami Beach, Florida.'}, {'ForeName': 'Christopher A', 'Initials': 'CA', 'LastName': 'Hill', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Mohamed', 'Initials': 'M', 'LastName': 'Al-Kazaz', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rajeev', 'Initials': 'R', 'LastName': 'Samtani', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Rajesh', 'Initials': 'R', 'LastName': 'Vedanthan', 'Affiliation': 'Department of Population Health, NYU School of Medicine, New York, New York.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Giannarelli', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Jason C', 'Initials': 'JC', 'LastName': 'Kovacic', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Emilia', 'Initials': 'E', 'LastName': 'Bagiella', 'Affiliation': 'Center for Biostatistics, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Kasarskis', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Zahi A', 'Initials': 'ZA', 'LastName': 'Fayad', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.'}, {'ForeName': 'Valentin', 'Initials': 'V', 'LastName': 'Fuster', 'Affiliation': 'The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain. Electronic address: valentin.fuster@mountsinai.org.'}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.10.021'] 3292,31955429,Nutritional ketosis improves exercise metabolism in patients with very long-chain acyl-CoA dehydrogenase deficiency.,"A maladaptive shift from fat to carbohydrate (CHO) oxidation during exercise is thought to underlie myopathy and exercise-induced rhabdomyolysis in patients with fatty acid oxidation (FAO) disorders. We hypothesised that ingestion of a ketone ester (KE) drink prior to exercise could serve as an alternative oxidative substrate supply to boost muscular ATP homeostasis. To establish a rational basis for therapeutic use of KE supplementation in FAO, we tested this hypothesis in patients deficient in Very Long-Chain acyl-CoA Dehydrogenase (VLCAD). Five patients (range 17-45 y; 4 M/1F) patients were included in an investigator-initiated, randomised, blinded, placebo-controlled, 2-way cross-over study. Patients drank either a KE + CHO mix or an isocaloric CHO equivalent and performed 35 minutes upright cycling followed by 10 minutes supine cycling inside a Magnetic Resonance scanner at individual maximal FAO work rate (fatmax; approximately 40% VO 2 max). The protocol was repeated after a 1-week interval with the alternate drink. Primary outcome measures were quadriceps phosphocreatine (PCr), Pi and pH dynamics during exercise and recovery assayed by in vivo 31 P-MR spectroscopy. Secondary outcomes included plasma and muscle metabolites and respiratory gas exchange recordings. Ingestion of KE rapidly induced mild ketosis and increased muscle BHB content. During exercise at FATMAX, VLCADD-specific plasma acylcarnitine levels, quadriceps glycolytic intermediate levels and in vivo Pi/PCr ratio were all lower in KE + CHO than CHO. These results provide a rational basis for future clinical trials of synthetic ketone ester supplementation therapy in patients with FAO disorders. Trial registration: ClinicalTrials.gov. Protocol ID: NCT03531554; METC2014.492; ABR51222.042.14.",2020,"During exercise at FATMAX, VLCADD-specific plasma acylcarnitine levels, quadriceps glycolytic intermediate levels and in vivo Pi/PCr ratio were all lower in KE+CHO than CHO. ","['patients with fatty acid oxidation (FAO) disorders', 'patients deficient in Very Long-Chain acyl-CoA Dehydrogenase (VLCAD', 'Five patients (range 17-45 y; 4M/1F) patients', 'patients with very long-chain acyl-CoA dehydrogenase deficiency', 'patients with FAO disorders']","['placebo', 'ketone ester (KE) drink', 'synthetic ketone ester supplementation therapy', 'KE+CHO mix or an isocaloric CHO equivalent and performed 35 min upright cycling followed by 10 minutes supine cycling inside a Magnetic Resonance scanner', 'KE supplementation', 'Nutritional ketosis']","['exercise metabolism', 'plasma and muscle metabolites and respiratory gas exchange recordings', 'quadriceps phosphocreatine (PCr), Pi and pH dynamics during exercise and recovery assayed by in vivo 31 P-MR spectroscopy', 'VLCADD-specific plasma acylcarnitine levels, quadriceps glycolytic intermediate levels and in vivo Pi/PCr ratio', 'mild ketosis and increased muscle BHB content']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1456270', 'cui_str': 'Fatty acid oxidation disorder'}, {'cui': 'C0011155', 'cui_str': 'Deficient (qualifier value)'}, {'cui': 'C0065170', 'cui_str': 'Very-Long-Chain Acyl-CoA Dehydrogenase'}, {'cui': 'C3542016', 'cui_str': 'Range'}, {'cui': 'C3887523', 'cui_str': 'Acadvl'}, {'cui': 'C0012634', 'cui_str': 'Disease'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0022634', 'cui_str': 'Ketones'}, {'cui': 'C0014898', 'cui_str': 'Esters'}, {'cui': 'C0452428', 'cui_str': 'Drinks (substance)'}, {'cui': 'C1735596', 'cui_str': 'Supplementation therapy'}, {'cui': 'C1720722', 'cui_str': 'Mix'}, {'cui': 'C0205163', 'cui_str': 'Equal (qualifier value)'}, {'cui': 'C0884358', 'cui_str': 'Performed'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C0332283', 'cui_str': 'Followed by (attribute)'}, {'cui': 'C0205102', 'cui_str': 'Internal (qualifier value)'}, {'cui': 'C0917874', 'cui_str': 'Magnetic Resonance'}, {'cui': 'C0183115', 'cui_str': 'Scanner'}]","[{'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0025520', 'cui_str': 'metabolism'}, {'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0026845', 'cui_str': 'Muscle Tissue'}, {'cui': 'C0870883', 'cui_str': 'Metabolite'}, {'cui': 'C0596601', 'cui_str': 'Gas'}, {'cui': 'C0031634', 'cui_str': 'Phosphorylcreatine'}, {'cui': 'C0729333', 'cui_str': 'Dynamic (qualifier value)'}, {'cui': 'C0587107', 'cui_str': 'During exercise (qualifier value)'}, {'cui': 'C1510438', 'cui_str': 'Assay technique (qualifier value)'}, {'cui': 'C0024487', 'cui_str': 'MR Spectroscopy'}, {'cui': 'C0205369', 'cui_str': 'Specified'}, {'cui': 'C0368608', 'cui_str': 'acylcarnitine'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0205103', 'cui_str': 'Intermediate (qualifier value)'}, {'cui': 'C3853643', 'cui_str': 'Probe with target amplification technique (qualifier value)'}, {'cui': 'C0456603', 'cui_str': 'Ratio (property) (qualifier value)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0456205', 'cui_str': 'Contents (attribute)'}]",,0.165283,"During exercise at FATMAX, VLCADD-specific plasma acylcarnitine levels, quadriceps glycolytic intermediate levels and in vivo Pi/PCr ratio were all lower in KE+CHO than CHO. ","[{'ForeName': 'Jeannette C', 'Initials': 'JC', 'LastName': 'Bleeker', 'Affiliation': ""Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.""}, {'ForeName': 'Gepke', 'Initials': 'G', 'LastName': 'Visser', 'Affiliation': ""Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.""}, {'ForeName': 'Kieran', 'Initials': 'K', 'LastName': 'Clarke', 'Affiliation': 'Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Sacha', 'Initials': 'S', 'LastName': 'Ferdinandusse', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Ferdinand H', 'Initials': 'FH', 'LastName': 'de Haan', 'Affiliation': 'ACHIEVE, Center for Applied Research, Faculty of Health, University of Applied Sciences Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Riekelt H', 'Initials': 'RH', 'LastName': 'Houtkooper', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Lodewijk', 'Initials': 'L', 'LastName': 'IJlst', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Irene L', 'Initials': 'IL', 'LastName': 'Kok', 'Affiliation': ""Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.""}, {'ForeName': 'Mirjam', 'Initials': 'M', 'LastName': 'Langeveld', 'Affiliation': 'Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'W Ludo', 'Initials': 'WL', 'LastName': 'van der Pol', 'Affiliation': 'Department of Neurology and Neurosurgery, Rudolf Magnus Institute of Neuroscience, Spieren voor Spieren Kindercentrum, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Monique G M', 'Initials': 'MGM', 'LastName': 'de Sain-van der Velden', 'Affiliation': ""Department of Metabolic Diseases, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.""}, {'ForeName': 'Anita', 'Initials': 'A', 'LastName': 'Sibeijn-Kuiper', 'Affiliation': 'Neuroimaging Center, Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Tim', 'Initials': 'T', 'LastName': 'Takken', 'Affiliation': 'Center for Child Development & Exercise, Department of Medical Physiology, University Medical Center Utrecht, Utrecht, The Netherlands.'}, {'ForeName': 'Ronald J A', 'Initials': 'RJA', 'LastName': 'Wanders', 'Affiliation': ""Department of Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.""}, {'ForeName': 'Michel', 'Initials': 'M', 'LastName': 'van Weeghel', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Frits A', 'Initials': 'FA', 'LastName': 'Wijburg', 'Affiliation': ""Department of Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.""}, {'ForeName': 'Luc H', 'Initials': 'LH', 'LastName': 'van der Woude', 'Affiliation': 'Human Movement Sciences, University Medical Center Groningen, Groningen, The Netherlands.'}, {'ForeName': 'Rob C I', 'Initials': 'RCI', 'LastName': 'Wüst', 'Affiliation': 'Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.'}, {'ForeName': 'Pete J', 'Initials': 'PJ', 'LastName': 'Cox', 'Affiliation': 'Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.'}, {'ForeName': 'Jeroen A L', 'Initials': 'JAL', 'LastName': 'Jeneson', 'Affiliation': 'Neuroimaging Center, Department of Biomedical Sciences of Cells and Systems, University Medical Center Groningen, Groningen, The Netherlands.'}]",Journal of inherited metabolic disease,['10.1002/jimd.12217'] 3293,31985173,Sexism Interacts with Patient-Physician Gender Concordance in Influencing Patient Control Preferences: Findings from a Vignette Experimental Design.,"BACKGROUND Patient preferences regarding their involvement in shared treatments decisions is fundamental in clinical practice. Previous evidences demonstrated a large heterogeneity in these preferences. However, only few studies have analysed the influence of patients' individual differences, contextual and situational qualities, and their complex interaction in explaining this variability. METHODS We assessed the role of the interaction of patient's sociodemographic and psychological factors with a physician's gender. Specifically, we focused on patient gender and attitudes toward male or female physicians. One hundred fifty-three people participated in this randomised controlled study and were randomly assigned to one of two experimental conditions in which they were asked to imagine discussing their treatment with a male and a female doctor. RESULTS Analyses showed an interplay between attitude towards women and the gender of patients and doctors, explaining interindividual variability in patient preferences. CONCLUSIONS In conclusion, patients' attitudes toward the physicians' gender constitutes a relevant characteristic that may influence the degree of control patients want to have and the overall patient-physician relationship.",2020,"RESULTS Analyses showed an interplay between attitude towards women and the gender of patients and doctors, explaining interindividual variability in patient preferences. ","['patient gender and attitudes toward male or female physicians', 'One hundred fifty-three people participated', 'Patient Control Preferences']",[],[],"[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C0086582', 'cui_str': 'Males'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0031831', 'cui_str': 'Physicians'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0558295', 'cui_str': 'Preferences (qualifier value)'}]",[],[],153.0,0.0465349,"RESULTS Analyses showed an interplay between attitude towards women and the gender of patients and doctors, explaining interindividual variability in patient preferences. ","[{'ForeName': 'Dario', 'Initials': 'D', 'LastName': 'Monzani', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Laura', 'Initials': 'L', 'LastName': 'Vergani', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Silvia Francesca Maria', 'Initials': 'SFM', 'LastName': 'Pizzoli', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Giulia', 'Initials': 'G', 'LastName': 'Marton', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Ketti', 'Initials': 'K', 'LastName': 'Mazzocco', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Bailo', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}, {'ForeName': 'Chiara', 'Initials': 'C', 'LastName': 'Messori', 'Affiliation': 'Department of Oncology and Hemato-oncology, University of Milan, Italy.'}, {'ForeName': 'Luca', 'Initials': 'L', 'LastName': 'Pancani', 'Affiliation': 'Department of Psychology, University of Milan - Bicocca, Milan, Italy.'}, {'ForeName': 'Manuela', 'Initials': 'M', 'LastName': 'Cattelan', 'Affiliation': 'Department of Statistical Sciences, University of Padova, Padova, Italy.'}, {'ForeName': 'Gabriella', 'Initials': 'G', 'LastName': 'Pravettoni', 'Affiliation': 'Applied Research Division for Cognitive and Psychological Science, IEO, European Institute of Oncology IRCCS, Milan, Italy.'}]",Applied psychology. Health and well-being,['10.1111/aphw.12193'] 3294,31684696,Interventions for pityriasis rosea.,"BACKGROUND Pityriasis rosea is a scaly, itchy rash that mainly affects young adults and lasts for 2 to 12 weeks. The effects of many available treatments are uncertain. This is an update of a Cochrane Review first published in 2007. OBJECTIVES To assess the effects of interventions for the management of pityriasis rosea in any individual diagnosed by a medical practitioner. SEARCH METHODS We updated our searches of the following databases to October 2018: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We searched five trials registers. We also checked the reference lists of included and excluded studies, contacted trial authors, scanned the abstracts from major dermatology conference proceedings, and searched the CAB Abstracts database. We searched PubMed for adverse effects to November 2018. SELECTION CRITERIA Randomised controlled trials of interventions in pityriasis rosea. Treatment could be given in a single therapy or in combination. Eligible comparators were no treatment, placebo, vehicle only, another active compound, or placebo radiation treatment. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by the Cochrane. Our key outcomes were good or excellent rash improvement within two weeks, rated separately by the participant and medical practitioner; serious adverse events; resolution of itch within two weeks (participant-rated); reduction in itch score within two weeks (participant-rated); and minor participant-reported adverse events not requiring withdrawal of the treatment. MAIN RESULTS We included 14 trials (761 participants). In general, risk of selection bias was unclear or low, but risk of performance bias and reporting bias was high for 21% of the studies. Participant age ranged from 2 to 60 years, and sex ratio was similar. Disease severity was measured by various severity indices, which the included studies did not categorise. Six studies were conducted in India, three in Iran, two in the Philippines, and one each in Pakistan, the USA, and China. The included studies were conducted in dermatology departments and a paediatric clinic. Study duration ranged from 5 to 26 months. Three studies were funded by drug manufacturers; most studies did not report their funding source. The included studies assessed macrolide antibiotics, an antiviral agent, phototherapy, steroids and antihistamine, and Chinese medicine. None of the studies measured participant-rated good or excellent rash improvement. All reported outcomes were assessed within two weeks of treatment, except for adverse effects, which were measured throughout treatment. There is probably no difference between oral clarithromycin and placebo in itch resolution (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.47 to 1.52; 1 study, 28 participants) or rash improvement (medical practitioner-rated) (RR 1.13, 95% CI 0.89 to 1.44; 1 study, 60 participants). For this comparison, there were no serious adverse events (1 study, 60 participants); minor adverse events and reduction in itch score were not measured; and all evidence was of moderate quality. When compared with placebo, erythromycin may lead to increased rash improvement (medical practitioner-rated) (RR 4.02, 95% CI 0.28 to 56.61; 2 studies, 86 participants, low-quality evidence); however, the 95% CI indicates that the result may also be compatible with a benefit of placebo, and there may be little or no difference between treatments. Itch resolution was not measured, but one study measured reduction in itch score, which is probably larger with erythromycin (MD 3.95, 95% CI 3.37 to 4.53; 34 participants, moderate-quality evidence). In the same single, small trial, none of the participants had a serious adverse event, and there was no clear difference between groups in minor adverse events, which included gastrointestinal upset (RR 2.00, CI 0.20 to 20.04; moderate-quality evidence). Two trials compared oral azithromycin to placebo or vitamins. There is probably no difference between groups in itch resolution (RR 0.83, 95% CI 0.28 to 2.48) or reduction in itch score (MD 0.04, 95% CI -0.35 to 0.43) (both outcomes based on one study; 70 participants, moderate-quality evidence). Low-quality evidence from two studies indicates there may be no difference between groups in rash improvement (medical practitioner-rated) (RR 1.02, 95% CI 0.52 to 2.00; 119 participants). In these same two studies, no serious adverse events were reported, and there was no clear difference between groups in minor adverse events, specifically mild abdominal pain (RR 5.82, 95% CI 0.72 to 47.10; moderate-quality evidence). Acyclovir was compared to placebo, vitamins, or no treatment in three trials (all moderate-quality evidence). Based on one trial (21 participants), itch resolution is probably higher with placebo than with acyclovir (RR 0.34, 95% CI 0.12 to 0.94); reduction in itch score was not measured. However, there is probably a significant difference between groups in rash improvement (medical practitioner-rated) in favour of acyclovir versus all comparators (RR 2.45, 95% CI 1.33 to 4.53; 3 studies, 141 participants). Based on the same three studies, there were no serious adverse events in either group, and there was probably no difference between groups in minor adverse events (only one participant in the placebo group experienced abdominal pain and diarrhoea). One trial compared acyclovir added to standard care (calamine lotion and oral cetirizine) versus standard care alone (24 participants). The addition of acyclovir may lead to increased itch resolution (RR 4.50, 95% CI 1.22 to 16.62) and reduction in itch score (MD 1.26, 95% CI 0.74 to 1.78) compared to standard care alone. Rash improvement (medical practitioner-rated) was not measured. The trial reported no serious adverse events in either group, and there may be no difference between groups in minor adverse events, such as headache (RR 7.00, 95% CI 0.40 to 122.44) (all results based on low-quality evidence). AUTHORS' CONCLUSIONS When compared with placebo or no treatment, oral acyclovir probably leads to increased good or excellent, medical practitioner-rated rash improvement. However, evidence for the effect of acyclovir on itch was inconclusive. We found low- to moderate-quality evidence that erythromycin probably reduces itch more than placebo. Small study sizes, heterogeneity, and bias in blinding and selective reporting limited our conclusions. Further research is needed to investigate different dose regimens of acyclovir and the effect of antivirals on pityriasis rosea.",2019,"There is probably no difference between groups in itch resolution (RR 0.83, 95% CI 0.28 to 2.48) or reduction in itch score (MD 0.04, 95% CI -0.35 to 0.43) (both outcomes based on one study; 70 participants, moderate-quality evidence).","['pityriasis rosea', '24 participants', 'Six studies were conducted in India, three in Iran, two in the Philippines, and one each in Pakistan, the USA, and China', '14 trials (761 participants']","['acyclovir', 'placebo or vitamins', 'macrolide antibiotics, an antiviral agent, phototherapy, steroids and antihistamine, and Chinese medicine', 'placebo', 'placebo, erythromycin', 'azithromycin', 'erythromycin', 'placebo, vehicle only, another active compound, or placebo radiation treatment', 'placebo, vitamins', 'standard care (calamine lotion and oral cetirizine', 'Acyclovir', 'clarithromycin', 'standard care alone']","['serious adverse event', 'good or excellent, medical practitioner-rated rash improvement', 'itch score', 'serious adverse events', 'reduction in itch score', 'rash improvement', 'gastrointestinal upset', 'itch resolution', 'adverse events', 'Rash improvement (medical practitioner-rated', 'mild abdominal pain', 'headache', 'adverse events and reduction in itch score', 'Disease severity', 'excellent rash improvement', 'adverse effects', 'abdominal pain and diarrhoea', 'Itch resolution']","[{'cui': 'C0032026', 'cui_str': 'Pityriasis Rosea'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}, {'cui': 'C0021201', 'cui_str': 'Republic of India'}, {'cui': 'C0022065', 'cui_str': 'Islamic Republic of Iran'}, {'cui': 'C0030211', 'cui_str': 'Islamic Republic of Pakistan'}, {'cui': 'C0008115', 'cui_str': 'Mainland China'}]","[{'cui': 'C0001367', 'cui_str': 'Acyclovir'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0042890', 'cui_str': 'Vitamins'}, {'cui': 'C0003240', 'cui_str': 'Substance with macrolide structure and antibacterial mechanism of action (substance)'}, {'cui': 'C0003232', 'cui_str': 'Antibiotics'}, {'cui': 'C0003451', 'cui_str': 'Antiviral Drugs'}, {'cui': 'C0031765', 'cui_str': 'Photoradiation Therapy'}, {'cui': 'C0038317', 'cui_str': 'Steroids'}, {'cui': 'C0019590', 'cui_str': 'Antihistamines'}, {'cui': 'C0152035', 'cui_str': 'Chinese'}, {'cui': 'C0025118', 'cui_str': 'Medicine'}, {'cui': 'C0014806', 'cui_str': 'Erythromycin'}, {'cui': 'C0052796', 'cui_str': 'Azithromycin'}, {'cui': 'C0042444', 'cui_str': 'Drug vehicle (substance)'}, {'cui': 'C0205177', 'cui_str': 'Active (qualifier value)'}, {'cui': 'C0205198', 'cui_str': 'Compound (qualifier value)'}, {'cui': 'C1522449', 'cui_str': 'Radiation Treatment'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0357929', 'cui_str': 'Calamine'}, {'cui': 'C0544341', 'cui_str': 'Lotion (basic dose form)'}, {'cui': 'C4521986', 'cui_str': 'Oral (intended site)'}, {'cui': 'C0055147', 'cui_str': 'Cetirizine'}, {'cui': 'C0055856', 'cui_str': 'Clarithromycin'}]","[{'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0205170', 'cui_str': 'Good (qualifier value)'}, {'cui': 'C1961136', 'cui_str': 'Excellent (qualifier value)'}, {'cui': 'C1306754', 'cui_str': 'Medical practitioner (occupation)'}, {'cui': 'C0015230', 'cui_str': 'Skin Rash'}, {'cui': 'C0033774', 'cui_str': 'Pruritis'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C4551656', 'cui_str': 'Surgical reduction'}, {'cui': 'C2697368', 'cui_str': 'Gastrointestinal irritation (disorder)'}, {'cui': 'C2945599', 'cui_str': 'Mild (qualifier value)'}, {'cui': 'C0000737', 'cui_str': 'Abdominal Pain'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0012634', 'cui_str': 'Disease'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0001688', 'cui_str': 'side effects'}, {'cui': 'C0011991', 'cui_str': 'Diarrhea'}]",761.0,0.537574,"There is probably no difference between groups in itch resolution (RR 0.83, 95% CI 0.28 to 2.48) or reduction in itch score (MD 0.04, 95% CI -0.35 to 0.43) (both outcomes based on one study; 70 participants, moderate-quality evidence).","[{'ForeName': 'Jose', 'Initials': 'J', 'LastName': 'Contreras-Ruiz', 'Affiliation': 'Hospital General Dr. Manuel Gea González, Department of Dermatology, Puente de Piedra 150-T1-C111. Col. Toriello Guerra, Mexico City, Mexico, 14050.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Peternel', 'Affiliation': 'Clinical Hospital Center Rijeka, Department of Dermatovenereology, Kresimirova 42, Rijeka, Croatia, 51000.'}, {'ForeName': 'Carlos', 'Initials': 'C', 'LastName': 'Jiménez Gutiérrez', 'Affiliation': 'Universidad Tecnologica de México-Laureate International Universities, Adscrito Unidad de Investigación Traslacional, Kinchil 234-3, Col. Heroes de Padierna. Delegación Tlalpan, México.DF, DF, Mexico, 14200.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Culav-Koscak', 'Affiliation': 'General hospital ""Dr. Ivo Pedisic"", Department of Dermatology and Venereology, J.J. Strossmayera 59, Sisak, Croatia, 44000.'}, {'ForeName': 'Ludovic', 'Initials': 'L', 'LastName': 'Reveiz', 'Affiliation': 'Free time independent Cochrane reviewer, Potomac, MD, USA.'}, {'ForeName': 'Maria de Lourdes', 'Initials': 'ML', 'LastName': 'Silbermann-Reynoso', 'Affiliation': ""The University of Nottingham, c/o Cochrane Skin Group, A103, King's Meadow Campus, Lenton Lane, Nottingham, UK, NG7 2NR.""}]",The Cochrane database of systematic reviews,['10.1002/14651858.CD005068.pub3'] 3295,30768490,High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.,"BACKGROUND Monocyte activation may contribute to neuronal injury in aviremic HIV-infected adults; data are lacking in children. We examined the relation between monocyte activation markers and early and long-term neurodevelopmental outcomes in early-treated HIV-infected children. SETTING Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial (NCT00428116) and extended cohort study in Kenya. METHODS HIV-infected infants (N = 67) initiated antiretroviral therapy (ART) at age <5 months. Plasma soluble (s) CD163 (sCD163), sCD14, and neopterin were measured before ART (entry) and 6 months later. Milestone attainment was ascertained monthly during 24 months, and neuropsychological tests were performed at 5.8-8.2 years after initiation of ART (N = 27). The relationship between neurodevelopment and sCD163, sCD14, and neopterin at entry and 6 months after ART was assessed using Cox proportional hazards models and linear regression. RESULTS Infants with high entry sCD163 had unexpected earlier attainment of supported sitting (5 vs 6 months; P = 0.006) and supported walking (10 vs 12 months; P = 0.02) with trends in adjusted analysis. Infants with high 6-month post-ART sCD163 attained speech later (17 vs 15 months; P = 0.006; adjusted hazard ratio, 0.47; P = 0.02), threw toys later (18 vs 17 months; P = 0.01; adjusted hazard ratio, 0.53; P = 0.04), and at median 6.8 years after ART, had worse neuropsychological test scores (adj. mean Z-score differences, cognition, -0.42; P = 0.07; short-term memory, -0.52; P = 0.08; nonverbal test performance, -0.39, P = 0.05). CONCLUSIONS Before ART, monocyte activation may reflect transient neuroprotective mechanisms in infants. After ART and viral suppression, monocyte activation may predict worse short- and long-term neurodevelopment outcomes.",2019,"mean Z-score differences, cognition, -0.42; P = 0.07; short-term memory, -0.52; P = 0.08; nonverbal test performance, -0.39, P = 0.05). ","['infants', 'Early-Treated HIV-Infected Children', 'early-treated HIV-infected children', 'HIV-infected infants (N = 67) initiated antiretroviral therapy (ART) at age <5 months', 'Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial (NCT00428116) and extended cohort study in Kenya']",['ART'],"['Plasma soluble (s) CD163 (sCD163), sCD14, and neopterin', 'neuropsychological test scores', 'monocyte activation markers and early and long-term neurodevelopmental outcomes', 'High Plasma Soluble CD163', 'Milestone attainment']","[{'cui': 'C0021270', 'cui_str': 'Infant'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C1292734', 'cui_str': 'Treats'}, {'cui': 'C0019682', 'cui_str': 'HTLV-III'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C1963724', 'cui_str': 'Antiretroviral therapy'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0033522', 'cui_str': 'Prospective Studies'}, {'cui': 'C0008976', 'cui_str': 'Clinical Trials as Topic'}, {'cui': 'C0009247', 'cui_str': 'Concurrent Studies'}, {'cui': 'C0022558', 'cui_str': 'Republic of Kenya'}]","[{'cui': 'C0003826', 'cui_str': 'Arts'}]","[{'cui': 'C0032105', 'cui_str': 'Blood Plasma'}, {'cui': 'C0068527', 'cui_str': '2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone'}, {'cui': 'C0027902', 'cui_str': 'Neuropsychologic Tests'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0026473', 'cui_str': 'Monocytes'}, {'cui': 'C1279919', 'cui_str': 'Early (qualifier value)'}, {'cui': 'C0205166', 'cui_str': 'Long (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}]",67.0,0.0922526,"mean Z-score differences, cognition, -0.42; P = 0.07; short-term memory, -0.52; P = 0.08; nonverbal test performance, -0.39, P = 0.05). ","[{'ForeName': 'Sarah F', 'Initials': 'SF', 'LastName': 'Benki-Nugent', 'Affiliation': ''}, {'ForeName': 'Ira', 'Initials': 'I', 'LastName': 'Martopullo', 'Affiliation': 'Epidemiology, University of Washington, Seattle, WA.'}, {'ForeName': 'Tony', 'Initials': 'T', 'LastName': 'Laboso', 'Affiliation': 'Department of Pediatrics & Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Nancy', 'Initials': 'N', 'LastName': 'Tamasha', 'Affiliation': 'Department of Pediatrics & Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Dalton C', 'Initials': 'DC', 'LastName': 'Wamalwa', 'Affiliation': 'Department of Pediatrics & Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Kenneth', 'Initials': 'K', 'LastName': 'Tapia', 'Affiliation': ''}, {'ForeName': 'Agnes', 'Initials': 'A', 'LastName': 'Langat', 'Affiliation': 'Department of Pediatrics & Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Maleche-Obimbo', 'Affiliation': 'Department of Pediatrics & Child Health, University of Nairobi, Nairobi, Kenya.'}, {'ForeName': 'Christina M', 'Initials': 'CM', 'LastName': 'Marra', 'Affiliation': 'Department of Neurology, University of Washington, Seattle, WA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Bangirana', 'Affiliation': 'Department of Psychiatry, Makerere University, Kampala, Uganda.'}, {'ForeName': 'Michael J', 'Initials': 'MJ', 'LastName': 'Boivin', 'Affiliation': 'Department of Psychiatry, Michigan State University, East Lansing, MI.'}, {'ForeName': 'Grace C', 'Initials': 'GC', 'LastName': 'John-Stewart', 'Affiliation': 'Departments of Global Health, Medicine, Epidemiology and Pediatrics, University of Washington, Seattle, WA.'}]",Journal of acquired immune deficiency syndromes (1999),['10.1097/QAI.0000000000001979'] 3296,31705450,Effects of Boiled Dill Seed on Anxiety During Labor: A Randomized Clinical Trial.,"OBJECTIVE To evaluate the effect of boiled dill seed (Anethum graveolens) on anxiety during childbirth compared with oxytocin. METHODS This study was a randomized clinical trial with 100 pregnant women who were assigned to the oxytocin (50 cases) and the boiled dill seed (50 cases) group by a table of random number. In the boiled dill seed group, 10 g of dill seed was boiled in 100 mL for 10 min and was given to women after filtration once orally at the beginning of active phase. In the oxytocin group, 10 IU of oxytocin in 1000 mL of Ringer solution was prescribed according to the clinical routine. The State-Trait Anxiety Inventory (STAI) in both groups before (at the beginning of the active phase) and after (6 h after the delivery) was completed. Meanwhile, pain intensity and duration of labor, dilatation and effacement scores, Apgar score of newborns, and FHR were measured and evaluated. RESULTS No statistically significant differences were shown in obvious anxiety scores between the two groups at baseline (P0.05). After the delivery, in the boiled dill seed group, the number of women with severe [0 vs. 8.0% (4/50)] and almost severe [0 vs. 14.0% (7/50)] trait and almost severe [0 vs. 14.0% (7/50)] state anxiety was lower than those in the control group (P=0.050, P=0.041, respectively). Moreover, labor was shorter in the 1st (P 0.01), 2nd (P=0.78) and 3rd (P=0.10) stages in the boiled dill seed group compared to the control group CONCLUSIONS: Dill seed could be used as an effective treatment to reduce anxiety during labor. Dill seed can be effective in reducing the length of labor. Due to lack of maternal and fetal complications, the boiled dill seed could also be used to reduce cesarean section rates in women who are fearful and anxious of delivery. (RCT Code: IRCT201607177065N2).",2020,"state anxiety was lower than those in the control group (P=0.050, P=0.041, respectively).","['women who are fearful and anxious of delivery', '100 pregnant women who were assigned to the']","['Ringer solution', 'boiled dill seed (Anethum graveolens', 'Boiled Dill Seed', 'oxytocin']","['length of labor', 'labor', 'Anxiety', 'obvious anxiety scores', 'cesarean section rates', 'Meanwhile, pain intensity and duration of labor, dilatation and effacement scores, Apgar score of newborns, and FHR', 'State-Trait Anxiety Inventory (STAI', 'state anxiety', 'number of women with severe']","[{'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0458278', 'cui_str': 'Fearful (qualifier value)'}, {'cui': 'C0011209', 'cui_str': 'Obstetric Delivery'}, {'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C0033011', 'cui_str': 'Pregnant Women'}, {'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}]","[{'cui': 'C0073386', 'cui_str': ""Ringer's Solution""}, {'cui': 'C0242301', 'cui_str': 'Boils'}, {'cui': 'C1457892', 'cui_str': 'Dill Plant'}, {'cui': 'C0036563', 'cui_str': 'Zygotes, Plant'}, {'cui': 'C0030095', 'cui_str': 'Oxytocin'}]","[{'cui': 'C0566679', 'cui_str': 'Duration of labor (observable entity)'}, {'cui': 'C0022864', 'cui_str': 'Labor, Obstetric'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C0007876', 'cui_str': 'C-Section (OB)'}, {'cui': 'C1320357', 'cui_str': 'Pain intensity'}, {'cui': 'C1322279', 'cui_str': 'Dilation'}, {'cui': 'C0003533', 'cui_str': 'Apgar Score'}, {'cui': 'C0021289', 'cui_str': 'Newborns'}, {'cui': 'C1301808', 'cui_str': 'State'}, {'cui': 'C0021941', 'cui_str': 'Inventories'}, {'cui': 'C0237753', 'cui_str': 'Number (attribute)'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]",1000.0,0.0955291,"state anxiety was lower than those in the control group (P=0.050, P=0.041, respectively).","[{'ForeName': 'Seyedeh-Fatemeh', 'Initials': 'SF', 'LastName': 'Hekmatzadeh', 'Affiliation': 'Medicinal Plant Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.'}, {'ForeName': 'Fatemeh', 'Initials': 'F', 'LastName': 'Bazarganipour', 'Affiliation': 'Medicinal Plant Research Center, Yasuj University of Medical Sciences, Yasuj, Iran. f.bazarganipour@gmail.com.'}, {'ForeName': 'Helen', 'Initials': 'H', 'LastName': 'Allan', 'Affiliation': 'Centre for Critical Research in Nursing & Midwifery, School of Health & Education, Middlesex University, London, UK.'}, {'ForeName': 'Shahintaj', 'Initials': 'S', 'LastName': 'Aramesh', 'Affiliation': 'Department of Gynecology and Obstetrics, Yasuj University of Medical Sciences, Yasuj, Iran.'}, {'ForeName': 'Jamshid', 'Initials': 'J', 'LastName': 'Mohammadi', 'Affiliation': 'Medicinal Plant Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.'}]",Chinese journal of integrative medicine,['10.1007/s11655-019-3222-4'] 3297,30880405,Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report.,"OBJECTIVE Major depressive disorder commonly co-occurs with one or more anxiety disorders or with clinically significant levels of anxiety symptoms. Although evidence suggests that anxious forms of depression are prognostic of poorer antidepressant outcomes, there is no clear definition of anxious depression, and inferences about clinical outcomes are thus limited. Our objective was to compare and evaluate definitions of anxious depression and anxiety-related scales according to clinical and antidepressant outcome criteria. METHOD A total of 1008 adults with a current diagnosis of single-episode or recurrent, nonpsychotic, major depressive disorder were assessed at baseline on clinical features. Participants were then randomised to one of three antidepressants and reassessed at 8 weeks regarding remission and response of the 17-item Hamilton Rating Scale Depression (HRSD 17 ) and the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR 16 ). Anxious depression was defined as major depressive disorder with one or more anxiety disorders or major depressive disorder with a HRSD 17 anxiety/somatisation factor score ⩾7. Anxiety-related scales included the HRSD 17 anxiety/somatisation factor and the 42-item Depression Anxiety Stress Scales (DASS 42 ) anxiety and stress subscales. RESULTS Anxious depression definitions showed poor agreement (κ = 0.15) and the HRSD 17 anxiety/somatisation factor was weakly correlated with both DASS 42 anxiety ( r  = 0.24) and stress subscales ( r  = 0.20). Anxious depression definitions were also associated with few impairments on clinical features and did not predict poorer antidepressant treatment outcome. However, higher DASS 42 anxiety predicted poorer HRSD 17 and QIDS-SR 16 remission, and item-level analysis found higher scores on items 9 (situational anxiety) and 23 (somatic anxiety) of the DASS 42 predicted poorer treatment outcome, even after adjusting for covariates and multiple comparisons. CONCLUSION Common definitions of anxious depression show poor agreement and do not predict poorer treatment outcome. Anxiety symptoms may be better characterised dimensionally using DASS 42 when predicting treatment outcome.",2019,Anxious depression definitions showed poor agreement (κ = 0.15) and the HRSD 17 anxiety/somatisation factor was weakly correlated with both DASS 42 anxiety ( r = 0.24) and stress subscales ( r = 0.20).,"['1008 adults with a current diagnosis of single-episode or recurrent, nonpsychotic, major depressive disorder', 'major depressive disorder with one or more anxiety disorders or major depressive disorder with a HRSD 17 anxiety/somatisation factor score ⩾7']",[],"['Anxiety symptoms', 'DASS 42 anxiety', 'HRSD 17 anxiety/somatisation factor', 'Anxiety-related scales included the HRSD 17 anxiety/somatisation factor and the 42-item Depression Anxiety Stress Scales (DASS 42 ) anxiety and stress subscales', 'Anxious depression definitions', 'Anxious depression', 'stress subscales', 'remission and response of the 17-item Hamilton Rating Scale Depression (HRSD 17 ) and the 16-item Quick Inventory of Depressive Symptomatology']","[{'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0521116', 'cui_str': 'Current (qualifier value)'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0556986', 'cui_str': 'Single episode (qualifier value)'}, {'cui': 'C2945760', 'cui_str': 'Recurrent (qualifier value)'}, {'cui': 'C1269683', 'cui_str': 'Major Depressive Disorder'}, {'cui': 'C0003469', 'cui_str': 'Anxiety Disorders'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}]",[],"[{'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0222045'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C0038435', 'cui_str': 'Stress - value'}, {'cui': 'C0338908', 'cui_str': 'Mixed anxiety and depressive disorder (disorder)'}, {'cui': 'C3539107', 'cui_str': 'Definition (core metadata concept)'}, {'cui': 'C0544452', 'cui_str': 'Remission phase (qualifier value)'}, {'cui': 'C4720917', 'cui_str': 'Quick inventory of depressive symptomatology (assessment scale)'}]",1008.0,0.0367304,Anxious depression definitions showed poor agreement (κ = 0.15) and the HRSD 17 anxiety/somatisation factor was weakly correlated with both DASS 42 anxiety ( r = 0.24) and stress subscales ( r = 0.20).,"[{'ForeName': 'Taylor A', 'Initials': 'TA', 'LastName': 'Braund', 'Affiliation': '1 Brain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Donna M', 'Initials': 'DM', 'LastName': 'Palmer', 'Affiliation': '1 Brain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia.'}, {'ForeName': 'Leanne M', 'Initials': 'LM', 'LastName': 'Williams', 'Affiliation': '4 Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.'}, {'ForeName': 'Anthony Wf', 'Initials': 'AW', 'LastName': 'Harris', 'Affiliation': '1 Brain Dynamics Centre, The Westmead Institute for Medical Research, Sydney, NSW, Australia.'}]",The Australian and New Zealand journal of psychiatry,['10.1177/0004867419835933'] 3298,31704196,Outcomes of Severely Obese Patients Supported by a Centrifugal-Flow Left Ventricular Assist Device.,"BACKGROUND Ventricular assist devices provide improved outcomes for patients with advanced heart failure, but their benefit in the severely obese is not well documented. METHODS Patients enrolled in the HeartWare ADVANCE trial (n=382) were divided into 2 body mass index (BMI) groups. Patients with severe obesity (>35 kg/m 2 ) were compared with a control group with BMI ≤35 kg/m 2 . The association of BMI with survival was tested using Kaplan-Meier analysis and major adverse events were compared. RESULTS At implantation, 48 (13%) of patients were severely obese. There was no difference in survival through 2 years of support between severely obese patients and the control group. Severely obese patients were at higher risk of driveline infection (P = .01) and acute renal dysfunction (P = .002). Both groups experienced similar improvements in quality of life. Functional capacity improved in both severely obese and control patients, although severely obese patients had smaller improvements than controls in their 6-minute walk scores. CONCLUSIONS Despite an increased risk of adverse events, severe obesity was not associated with reduced survival or quality of life. A better understanding of the risks and benefits of left ventricular assist device therapy in obese patients will help in the shared decision-making of the patient selection process.",2020,"Functional capacity improved in both severely obese and control patients, although severely obese patients had smaller improvements than controls in their six-minute walk scores. ","['Patients with severe obesity (> 35 kg/m 2 ', 'advanced heart failure patients', 'Patients enrolled in the HeartWare ADVANCE trial (n=382', 'obese patients']","['LVAD therapy', 'Centrifugal-Flow Left Ventricular Assist Device']","['survival or quality of life', 'survival', 'quality of life', 'acute renal dysfunction', 'BMI with survival', 'driveline infection', 'risk of adverse events, severe obesity', 'Functional capacity']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0028756', 'cui_str': 'Obesity, Severe'}, {'cui': 'C0205179', 'cui_str': 'Advanced (qualifier value)'}, {'cui': 'C0018801', 'cui_str': 'Cardiac Failure'}, {'cui': 'C0028754', 'cui_str': 'Obesity'}]","[{'cui': 'C0087111', 'cui_str': 'Therapy'}, {'cui': 'C1301962', 'cui_str': 'Centrifugal'}, {'cui': 'C0181598', 'cui_str': 'Left ventricular assist device'}]","[{'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0034380'}, {'cui': 'C1565489', 'cui_str': 'Renal Insufficiency'}, {'cui': 'C3714514', 'cui_str': 'Infection'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0028756', 'cui_str': 'Obesity, Severe'}, {'cui': 'C1998319', 'cui_str': 'Functional capacity'}]",,0.175517,"Functional capacity improved in both severely obese and control patients, although severely obese patients had smaller improvements than controls in their six-minute walk scores. ","[{'ForeName': 'Michael S', 'Initials': 'MS', 'LastName': 'Kiernan', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts. Electronic address: mkiernan@tuftsmedicalcenter.org.'}, {'ForeName': 'Samer S', 'Initials': 'SS', 'LastName': 'Najjar', 'Affiliation': 'MedStar Washington Hospital Center, Washington, DC.'}, {'ForeName': 'Amanda R', 'Initials': 'AR', 'LastName': 'Vest', 'Affiliation': 'Tufts Medical Center, Boston, Massachusetts.'}, {'ForeName': 'Emma J', 'Initials': 'EJ', 'LastName': 'Birks', 'Affiliation': 'University of Louisville, Louisville, Kentucky.'}, {'ForeName': 'Nir', 'Initials': 'N', 'LastName': 'Uriel', 'Affiliation': 'University of Chicago, Chicago, Illinois.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Ewald', 'Affiliation': 'Washington University/Barnes-Jewish Hospital, St. Louis, Missouri.'}, {'ForeName': 'Katrin', 'Initials': 'K', 'LastName': 'Leadley', 'Affiliation': 'Endotronix Inc, Lisle, Illinois.'}, {'ForeName': 'Chetan B', 'Initials': 'CB', 'LastName': 'Patel', 'Affiliation': 'Duke University, Durham, North Carolina.'}]",Journal of cardiac failure,['10.1016/j.cardfail.2019.10.013'] 3299,30975019,Subjective Evaluation of Denture Adhesives: A Multicenter Randomized Controlled Trial.,"INTRODUCTION Many reports show that denture adhesives improve the retention and stability of dentures. However, few randomized controlled trials have examined the effects of denture adhesives. OBJECTIVE This 10-center randomized controlled trial with parallel groups involving 200 edentulous patients wearing complete dentures aimed to evaluate the effects of short-term use of cream and powder denture adhesives. METHODS Patients were allocated into 2 cream- and powder-type adhesive groups and 1 control group. Intervention groups were treated with the 2 adhesives (1 each), and the control group received saline solution. Adhesive or control was applied to the denture-mucosal surface for 4 d, and data at baseline and after day 4 of intervention (i.e., 8 meals) were obtained. Patient satisfaction was evaluated with a 100-mm visual analog scale. Oral health-related quality of life was measured with the Japanese version of the Oral Health Impact Profile for Edentulous Patients. Perceived chewing ability was evaluated by a questionnaire regarding ease of chewing and swallowing food. Between-group comparisons were performed with Kruskal-Wallis tests with the Mann-Whitney U test adjusted by Bonferroni correction. Within-group comparisons of pre- and postintervention measurements were performed with the Wilcoxon signed-rank test. Intention-to-treat analysis was also performed. RESULTS Between-group comparisons showed no significant differences for general satisfaction or Oral Health Impact Profile for Edentulous Patients. However, significant differences in satisfaction with various denture functions with cream- and powder-type adhesives were seen in pre- and postintervention comparisons ( P < 0.05). Significant differences were also observed for perceived chewing ability of hard foods ( P < 0.05). CONCLUSION These results suggest that although denture adhesives do not invariably improve denture function, they do affect subjective evaluations and possibly chewing of hard foods. Therefore, the effects of denture adhesive use are insufficient to resolve any fundamental dissatisfaction with dentures ( ClinicalTrials.gov NCT01712802 ). KNOWLEDGE TRANSFER STATEMENT The results of this study suggest that denture adhesives should be applied under certain conditions; however, an appropriate diagnosis is important before application. These practice-based data provide information to establish evidence-based guidelines for applying denture adhesives.",2020,"Significant differences were also observed for perceived chewing ability of hard foods ( P < 0.05). ","['200 edentulous patients wearing complete dentures', 'Edentulous Patients', 'Denture Adhesives', 'Patients were allocated into 2']","['saline solution', 'cream and powder denture adhesives', 'cream- and powder-type adhesive groups and 1 control group']","['100-mm visual analog scale', 'retention and stability of dentures', 'Patient satisfaction', 'Perceived chewing ability', 'denture function', 'perceived chewing ability of hard foods', 'Oral health-related quality of life', 'general satisfaction or Oral Health Impact Profile', 'satisfaction with various denture functions with cream- and powder-type adhesives']","[{'cui': 'C4319558', 'cui_str': '200'}, {'cui': 'C0026644', 'cui_str': 'Mouth, Toothless'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0011455', 'cui_str': 'Denture, Complete'}, {'cui': 'C0011394', 'cui_str': 'Dentures'}, {'cui': 'C0001516', 'cui_str': 'Adhesives'}]","[{'cui': 'C0036082', 'cui_str': 'Saline Solution'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0011394', 'cui_str': 'Dentures'}, {'cui': 'C0001516', 'cui_str': 'Adhesives'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}]","[{'cui': 'C1704407', 'cui_str': '100 (qualifier value)'}, {'cui': 'C3536884', 'cui_str': 'Visual Analog Scale'}, {'cui': 'C0035280', 'cui_str': 'Retention'}, {'cui': 'C0011394', 'cui_str': 'Dentures'}, {'cui': 'C0030702', 'cui_str': 'Patient Satisfaction'}, {'cui': 'C0699816', 'cui_str': 'Does chew (finding)'}, {'cui': 'C0085732', 'cui_str': 'Ability'}, {'cui': 'C0031843', 'cui_str': 'function'}, {'cui': 'C3714306', 'cui_str': 'Hard food (substance)'}, {'cui': 'C0029162'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0034380'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0242428', 'cui_str': 'Satisfaction'}, {'cui': 'C0333125', 'cui_str': 'Impacted (qualifier value)'}, {'cui': 'C1378128', 'cui_str': 'Cream'}, {'cui': 'C0032861', 'cui_str': 'Powdered drug preparation'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0001516', 'cui_str': 'Adhesives'}]",200.0,0.102174,"Significant differences were also observed for perceived chewing ability of hard foods ( P < 0.05). ","[{'ForeName': 'G', 'Initials': 'G', 'LastName': 'Ohwada', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Minakuchi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Kondo', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Nomura', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Tsuboi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'G', 'Initials': 'G', 'LastName': 'Hong', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Itoh', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Kawai', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'S', 'Initials': 'S', 'LastName': 'Kimoto', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Gunji', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'A', 'Initials': 'A', 'LastName': 'Suzuki', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Suzuki', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Kimoto', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'N', 'Initials': 'N', 'LastName': 'Hoshi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Saita', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Yoneyama', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Sato', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Morokuma', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'J', 'Initials': 'J', 'LastName': 'Okazaki', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Maeda', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nakai', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Ichikawa', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Nagao', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Fujimoto', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'H', 'Initials': 'H', 'LastName': 'Murata', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Kurogi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'K', 'Initials': 'K', 'LastName': 'Yoshida', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Nishimura', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'Y', 'Initials': 'Y', 'LastName': 'Nishi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'M', 'Initials': 'M', 'LastName': 'Murakami', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hosoi', 'Affiliation': 'The Japan Denture Care Society.'}, {'ForeName': 'T', 'Initials': 'T', 'LastName': 'Hamada', 'Affiliation': 'The Japan Denture Care Society.'}]",JDR clinical and translational research,['10.1177/2380084419837607'] 3300,31863406,One-Day Acceptance and Commitment Therapy Compared to Support for Depressed Migraine Patients: a Randomized Clinical Trial.,"In patients with migraine, depression is associated with poorer medical prognosis, decreased quality of life, and increased risk of suicidality and disability; yet, behavioral interventions have rarely been investigated. The current study compared the efficacy of two 1-day (5- to 6-h) interventions for co-occurring migraine and depression: (1) acceptance and commitment therapy plus migraine education (ACT-ED), and (2) support plus migraine education (S-ED). One hundred and thirty-six patients with comorbid depression and migraine were randomized to a treatment. One hundred and three (76%) completed the ACT-ED (N = 56) or S-ED (N = 47) workshop. Primary outcomes were depression diagnosis and symptoms. Secondary outcomes were anxiety symptoms, headache-related disability and general functioning, and quality of life. Assessments were completed at baseline and 3 and 6 months following the workshop. At the 6-month follow-up, on categorical outcomes, a significantly greater number of people in the ACT-ED condition no longer met criteria for a major depressive episode and exhibited a > 50% drop in symptoms on the Hamilton Rating Scale of Depression. Similarly, though, weaker results were found when examining depressive symptoms dimensionally. On secondary outcomes, people in the ACT-ED condition exhibited significantly greater improvements in anxiety, headache-related disability, and quality of social relationships, compared to S-ED, No differences between groups were observed in general functioning. A 1-day (5- to 6-h) ACT workshop can deliver substantial and lasting benefits to depressed migraineurs, over and above those provided by group support and education. This approach is an attractive alternative to weekly psychotherapy. Clinicaltrials.gov # NCT02108678.",2020,"On secondary outcomes, people in the ACT-ED condition exhibited significantly greater improvements in anxiety, headache-related disability, and quality of social relationships, compared to S-ED, No differences between groups were observed in general functioning.","['Depressed Migraine Patients', 'One hundred and thirty-six patients with comorbid depression and migraine']","['two 1-day (5- to 6-h) interventions for co-occurring migraine and depression: (1) acceptance and commitment therapy plus migraine education (ACT-ED), and (2) support plus migraine education']","['anxiety, headache-related disability, and quality of social relationships', 'quality of life, and increased risk of suicidality and disability', 'depression diagnosis and symptoms', 'anxiety symptoms, headache-related disability and general functioning, and quality of life', 'general functioning', 'Hamilton Rating Scale of Depression']","[{'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4517568', 'cui_str': 'One hundred and thirty-six'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}]","[{'cui': 'C0439228', 'cui_str': 'day (qualifier value)'}, {'cui': 'C0149931', 'cui_str': 'Migraine Disorders'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and Commitment Therapy'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0344211', 'cui_str': 'Supportive care'}]","[{'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C0018681', 'cui_str': 'Cephalodynia'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0231170', 'cui_str': 'Disability (finding)'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439849', 'cui_str': 'Relationships (qualifier value)'}, {'cui': 'C0034380'}, {'cui': 'C0205217', 'cui_str': 'Increased (qualifier value)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0011581', 'cui_str': 'Neurosis, Depressive'}, {'cui': 'C1704338', 'cui_str': 'diagnosis'}, {'cui': 'C0683368', 'cui_str': 'symptoms'}, {'cui': 'C0860603', 'cui_str': 'Anxiety symptoms'}, {'cui': 'C0205246', 'cui_str': 'Generalized (qualifier value)'}, {'cui': 'C0222045'}]",136.0,0.0886674,"On secondary outcomes, people in the ACT-ED condition exhibited significantly greater improvements in anxiety, headache-related disability, and quality of social relationships, compared to S-ED, No differences between groups were observed in general functioning.","[{'ForeName': 'Lilian N', 'Initials': 'LN', 'LastName': 'Dindo', 'Affiliation': 'Houston VA HSR&D Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Holcombe, Houston, TX, 77030, USA. lilian.dindo@bcm.edu.'}, {'ForeName': 'Ana', 'Initials': 'A', 'LastName': 'Recober', 'Affiliation': ""University of Pennsylvania & the Children's Hospital of Philadelphia, Philadelphia, PA, USA.""}, {'ForeName': 'Chadi A', 'Initials': 'CA', 'LastName': 'Calarge', 'Affiliation': 'Department of Internal Medicine, Section of Health Services Research, Baylor College of Medicine, Houston, TX, USA.'}, {'ForeName': 'Bridget M', 'Initials': 'BM', 'LastName': 'Zimmerman', 'Affiliation': 'Department of Biostatistics, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Aliza', 'Initials': 'A', 'LastName': 'Weinrib', 'Affiliation': 'Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.'}, {'ForeName': 'James N', 'Initials': 'JN', 'LastName': 'Marchman', 'Affiliation': 'Department of Psychology, University of Iowa, Iowa City, IA, USA.'}, {'ForeName': 'Carolyn', 'Initials': 'C', 'LastName': 'Turvey', 'Affiliation': 'Department of Psychiatry, University of Iowa, Iowa City, IA, USA.'}]",Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics,['10.1007/s13311-019-00818-0'] 3301,31404018,"Prevention of Infectious Complications in Acute Pancreatitis: Results of a Single-Center, Randomized, Controlled Trial.","OBJECTIVES This study aimed to investigate the efficiency of imipenem to prevent infectious complications in predicted severe acute pancreatitis (AP). METHODS Consecutive AP patients were randomized to imipenem 3 × 500 mg intravenously daily or an identical placebo. Exclusion criteria were prior AP, chronic pancreatitis, active malignancy, immune deficiency, active infection, concomitant antibiotic treatment, pregnancy, and patients younger than 18 years. Infectious complications including infected pancreatic necrosis, pneumonia, urinary tract infection, positive blood cultures, sepsis, and other infections were assessed as the primary outcome. Secondary outcomes included mortality, persistent organ failure, systemic inflammatory response syndrome, local complications, serious adverse events, and need for surgical intervention. RESULTS Forty-nine patients were randomized to each group. Infectious complications were present in 10 versus 12 of 49 patients (relative risk [RR], 0.833; 95% confidence interval [CI], 0.398-1.747). There were no significant differences in infected pancreatic necrosis (RR, 1.5; 95% CI, 0.262-8.588), pneumonia (RR, 1.5; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5; 95% CI, 0.047-5.336), sepsis (RR, 0.333; 95% CI, 0.036-3.095), and other (RR, 1.333; 95% CI, 0.315-5.648). We found no significant differences in secondary outcomes. CONCLUSIONS Concordantly to available evidence, there is currently no ground to support prophylactic use of antibiotics in predicted severe AP.",2019,"There were no significant differences in infected pancreatic necrosis (RR, 1.5; 95% CI, 0.262-8.588), pneumonia (RR, 1.5; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5; 95% CI, 0.047-5.336), sepsis (RR, 0.333; 95% CI, 0.036-3.095), and other (RR, 1.333; 95% CI, 0.315-5.648).","['Acute Pancreatitis', 'Forty-nine patients', 'Consecutive AP patients', 'patients younger than 18 years', 'predicted severe acute pancreatitis (AP']","['imipenem 3 × 500 mg intravenously daily or an identical placebo', 'imipenem']","['pneumonia', 'infected pancreatic necrosis', 'Infectious complications', 'urinary tract infection', 'positive blood cultures', 'mortality, persistent organ failure, systemic inflammatory response syndrome, local complications, serious adverse events, and need for surgical intervention', 'sepsis', 'infected pancreatic necrosis, pneumonia, urinary tract infection, positive blood cultures, sepsis, and other infections']","[{'cui': 'C0001339', 'cui_str': 'Acute pancreatitis (disorder)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0332239', 'cui_str': 'Young (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205082', 'cui_str': 'Severe (severity modifier) (qualifier value)'}]","[{'cui': 'C0020933', 'cui_str': 'Imipenem'}, {'cui': 'C3816747', 'cui_str': 'Five hundred'}, {'cui': 'C0332173', 'cui_str': 'Daily (qualifier value)'}, {'cui': 'C0205280', 'cui_str': 'Identical (qualifier value)'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0032285', 'cui_str': 'Pneumonia'}, {'cui': 'C0267953', 'cui_str': 'Necrosis of pancreas (disorder)'}, {'cui': 'C0009566', 'cui_str': 'Complication (disorder)'}, {'cui': 'C0042029', 'cui_str': 'Urinary tract infectious disease (disorder)'}, {'cui': 'C0740299', 'cui_str': 'Blood culture positive for microorganism'}, {'cui': 'C0026566', 'cui_str': 'mortality'}, {'cui': 'C0349410', 'cui_str': 'Single organ dysfunction (disorder)'}, {'cui': 'C0242966', 'cui_str': 'Sepsis Syndrome'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0686904', 'cui_str': 'Patient need for (contextual qualifier) (qualifier value)'}, {'cui': 'C0549433', 'cui_str': 'Surgical intervention'}, {'cui': 'C0243026', 'cui_str': 'Sepsis'}, {'cui': 'C3714514', 'cui_str': 'Infection'}]",49.0,0.498997,"There were no significant differences in infected pancreatic necrosis (RR, 1.5; 95% CI, 0.262-8.588), pneumonia (RR, 1.5; 95% CI, 0.262-8.588), urinary tract infection (RR, 0.6; 95% CI, 0.152-2.374), positive blood cultures (RR, 0.5; 95% CI, 0.047-5.336), sepsis (RR, 0.333; 95% CI, 0.036-3.095), and other (RR, 1.333; 95% CI, 0.315-5.648).","[{'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Poropat', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}, {'ForeName': 'Anja', 'Initials': 'A', 'LastName': 'Radovan', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}, {'ForeName': 'Marija', 'Initials': 'M', 'LastName': 'Peric', 'Affiliation': 'Faculty of Medicine, University of Medicine Rijeka, Rijeka, Croatia.'}, {'ForeName': 'Ivana', 'Initials': 'I', 'LastName': 'Mikolasevic', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}, {'ForeName': 'Vanja', 'Initials': 'V', 'LastName': 'Giljaca', 'Affiliation': 'Heart of England NHS Foundation Trust, University Hospitals Birmingham, Birmingham, United Kingdom.'}, {'ForeName': 'Goran', 'Initials': 'G', 'LastName': 'Hauser', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Milic', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}, {'ForeName': 'Davor', 'Initials': 'D', 'LastName': 'Stimac', 'Affiliation': 'From the Department of Gastroenterology, Clinical Hospital Center Rijeka, Faculty of Medicine, University of Rijeka.'}]",Pancreas,['10.1097/MPA.0000000000001368'] 3302,31780277,"Rectal indometacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients: a double-blind, randomised controlled trial.","BACKGROUND Although rectal indometacin 100 mg is effective in reducing the frequency and severity of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients, the optimal dose is unknown, and pancreatitis incidence remains high. The aim of this study was to compare the efficacy of two dose regimens of rectal indometacin on the frequency and severity of pancreatitis after ERCP in high-risk patients. METHODS In this randomised, double-blind, comparative effectiveness trial, we enrolled patients from six tertiary medical centres in the USA. Eligible patients were those at high risk for the development of pancreatitis after ERCP. We randomly assigned eligible patients (1:1) immediately after ERCP to receive either two 50 mg indometacin suppositories and a placebo suppository (standard-dose group) or three 50 mg indometacin suppositories (high-dose group). 4 h after the procedure, patients assigned to the high-dose group received an additional 50 mg indometacin suppository, whereas patients in the standard-dose group received an additional placebo suppository. The randomisation schedule, stratified according to study centre and with no other restrictions, was computer generated by an investigator who was uninvolved in the clinical care of any participants, distributed to the sites, and kept by personnel not directly involved with the study. These same personnel were responsible for packaging the drug and placebo in opaque envelopes. Patients, study personnel, and treating physicians were masked to study group assignment. The primary outcome of the study was the development of pancreatitis after ERCP. Analyses were done on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01912716, and enrolment is complete. FINDINGS Between July 9, 2013, and March 22, 2018, 1037 eligible patients were enrolled and randomly assigned to receive either standard-dose (n=515) or high-dose indometacin (n=522). Pancreatitis after ERCP occurred in 141 (14%) of 1037 patients-76 (15%) of 515 patients in the standard-dose indometacin group and 65 (12%) of 522 patients in the high-dose indometacin group (risk ratio [RR] 1·19, 95% CI 0·87-1·61; p=0·32). We observed 19 adverse events that were potentially attributable to study drug. Clinically significant bleeding occurred in 14 (1%) of 1037 patients-six (1%) of 515 patients in the standard-dose indometacin group and eight (2%) of 522 patients in the high-dose indometacin group (p=0·79). Three (1%) of 522 patients in the high-dose indometacin group developed acute kidney injury versus none in the standard-dose group (p=0·25). A non-ST elevation myocardial infarction occurred in the standard-dose indometacin group 2 days after ERCP. A transient ischaemic attack occurred in the high-dose indometacin group 5 days after ERCP. All 19 adverse events, in addition to the 141 patients who developed pancreatitis after ERCP, were considered serious as all required admission to hospital. We observed no allergic reactions or deaths at 30 day follow-up. INTERPRETATION Dose escalation to rectal indometacin 200 mg did not confer any advantage compared with the standard 100 mg regimen, with pancreatitis incidence remaining high in high-risk patients. Current practice should continue unchanged. Further research should consider the pharmacokinetics of non-steroidal anti-inflammatory drugs to determine the optimal timing of their administration to prevent pancreatitis after ERCP. FUNDING American College of Gastroenterology.",2020,"INTERPRETATION Dose escalation to rectal indometacin 200 mg did not confer any advantage compared with the standard 100 mg regimen, with pancreatitis incidence remaining high in high-risk patients.","['high-risk patients', '1037 eligible patients', 'enrolled patients from six tertiary medical centres in the USA', 'Eligible patients were those at high risk for the development of pancreatitis after ERCP', 'Between July 9, 2013, and March 22, 2018']","['rectal indometacin', 'placebo suppository', 'Rectal indometacin dose escalation', 'endoscopic retrograde cholangiopancreatography', 'endoscopic retrograde cholangiopancreatography (ERCP', 'placebo', 'indometacin', 'indometacin suppositories and a placebo suppository (standard-dose group) or three 50 mg indometacin suppositories', 'additional 50 mg indometacin suppository', 'standard-dose (n=515) or high-dose indometacin']","['acute kidney injury', 'frequency and severity of pancreatitis', 'transient ischaemic attack', 'development of pancreatitis after ERCP', 'Clinically significant bleeding', 'Pancreatitis after ERCP', 'allergic reactions or deaths', 'ST elevation myocardial infarction']","[{'cui': 'C4319571', 'cui_str': 'High risk (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0205372', 'cui_str': 'Tertiary (qualifier value)'}, {'cui': 'C0565990', 'cui_str': 'Medical center (environment)'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}]","[{'cui': 'C0205052', 'cui_str': 'Rectal (qualifier value)'}, {'cui': 'C0021246', 'cui_str': 'Indomethacin'}, {'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C0038854', 'cui_str': 'Suppository'}, {'cui': 'C0869039', 'cui_str': 'Unit dose'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0444956', 'cui_str': 'High dose (qualifier value)'}]","[{'cui': 'C2609414', 'cui_str': 'Acute Renal Injury'}, {'cui': 'C0376249', 'cui_str': 'Frequency (attribute)'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0030305', 'cui_str': 'Pancreatitis'}, {'cui': 'C0007787', 'cui_str': 'Brain TIA'}, {'cui': 'C0243107', 'cui_str': 'development'}, {'cui': 'C0008310', 'cui_str': 'ERCP'}, {'cui': 'C0750502', 'cui_str': 'Significant'}, {'cui': 'C1527304', 'cui_str': 'Allergic Reaction'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C1536220', 'cui_str': 'ST Elevated Myocardial Infarction'}]",1037.0,0.367675,"INTERPRETATION Dose escalation to rectal indometacin 200 mg did not confer any advantage compared with the standard 100 mg regimen, with pancreatitis incidence remaining high in high-risk patients.","[{'ForeName': 'Evan L', 'Initials': 'EL', 'LastName': 'Fogel', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA. Electronic address: efogel@iu.edu.'}, {'ForeName': 'Glen A', 'Initials': 'GA', 'LastName': 'Lehman', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Paul', 'Initials': 'P', 'LastName': 'Tarnasky', 'Affiliation': 'University of Texas Southwestern, Digestive Health Associates of Texas, Dallas, TX, USA.'}, {'ForeName': 'Gregory A', 'Initials': 'GA', 'LastName': 'Cote', 'Affiliation': 'Division of Gastroenterology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Suzette E', 'Initials': 'SE', 'LastName': 'Schmidt', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Akbar K', 'Initials': 'AK', 'LastName': 'Waljee', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Peter D R', 'Initials': 'PDR', 'LastName': 'Higgins', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'James L', 'Initials': 'JL', 'LastName': 'Watkins', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Stuart', 'Initials': 'S', 'LastName': 'Sherman', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Richard S Y', 'Initials': 'RSY', 'LastName': 'Kwon', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Grace H', 'Initials': 'GH', 'LastName': 'Elta', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Jeffrey J', 'Initials': 'JJ', 'LastName': 'Easler', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Douglas K', 'Initials': 'DK', 'LastName': 'Pleskow', 'Affiliation': 'Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'James M', 'Initials': 'JM', 'LastName': 'Scheiman', 'Affiliation': 'Division of Gastroenterology, University of Virginia, Charlottesville, VA, USA.'}, {'ForeName': 'Ihab I', 'Initials': 'II', 'LastName': 'El Hajj', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA; Division of Gastroenterology, University of Balamand, Beirut, Lebanon.'}, {'ForeName': 'Nalini M', 'Initials': 'NM', 'LastName': 'Guda', 'Affiliation': ""Division of Gastroenterology, University of Wisconsin, Milwaukee, WI, USA; Aurora St Luke's Medical Center, Milwaukee, WI, USA.""}, {'ForeName': 'Mark A', 'Initials': 'MA', 'LastName': 'Gromski', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Lee', 'Initials': 'L', 'LastName': 'McHenry', 'Affiliation': 'Division of Gastoenterology and Hepatology, Indiana University, Indianapolis, IN, USA.'}, {'ForeName': 'Seena', 'Initials': 'S', 'LastName': 'Arol', 'Affiliation': 'University of Texas Southwestern, Digestive Health Associates of Texas, Dallas, TX, USA.'}, {'ForeName': 'Sheryl', 'Initials': 'S', 'LastName': 'Korsnes', 'Affiliation': 'Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA.'}, {'ForeName': 'Alejandro L', 'Initials': 'AL', 'LastName': 'Suarez', 'Affiliation': 'Division of Gastroenterology, Medical University of South Carolina, Charleston, SC, USA; Division of Gastroenterology, Yale University, New Haven, CT, USA.'}, {'ForeName': 'Rebecca', 'Initials': 'R', 'LastName': 'Spitzer', 'Affiliation': 'Division of Gastroenterology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': 'Marilyn', 'Initials': 'M', 'LastName': 'Miller', 'Affiliation': 'Division of Gastroenterology, University of Wisconsin, Milwaukee, WI, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Hofbauer', 'Affiliation': 'Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA.'}, {'ForeName': 'B Joseph', 'Initials': 'BJ', 'LastName': 'Elmunzer', 'Affiliation': 'Division of Gastroenterology, Medical University of South Carolina, Charleston, SC, USA.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",The lancet. Gastroenterology & hepatology,['10.1016/S2468-1253(19)30337-1'] 3303,31020621,Using a Culturally Tailored Narrative to Increase Cervical Cancer Detection Among Spanish-Speaking Mexican-American Women.,"The objective of this study was to determine the feasibility and effectiveness of translating films, and whether the use of narrative is an effective vehicle for producing changes in knowledge, attitudes, and behaviors regarding cervical cancer compared with a nonnarrative film. A randomized controlled telephone trial surveyed the effectiveness of two films our team produced among a sample of 300 monolingual Spanish-speaking women, ages 25 to 45, who were of Mexican origin. Participants were recruited using random digit dialing (RDD) procedures from 2013 to 2014 in Los Angeles County and were randomly selected to view either a narrative or nonnarrative film. Data were collected by phone at baseline, 2 weeks, and 6 months after viewing. On average, participants arrived in the USA 25 years ago. The majority reported having less than high school education and limited English proficiency. Compared with their nonnarrative counterparts, women who received the cervical cancer-related information in the narrative film showed a significantly greater increase in new knowledge (p = 0.01) and in supportive attitudes about Pap tests expense (p = 0.05). Importantly, at 6 months, although not statistically significant, women who viewed the narrative film were also more likely to have had or scheduled a Pap test (62% vs 42%). Narratives are a useful and underutilized tool to communicate information about cancer prevention. These findings have important implications for the delivery of health education among Spanish-speaking, low-literacy immigrant women, and for the reduction of cancer-related disparities.",2020,"Importantly, at 6 months, although not statistically significant, women who viewed the narrative film were also more likely to have had or scheduled a Pap test (62% vs 42%).","['300 monolingual Spanish-speaking women, ages 25 to 45, who were of Mexican origin', 'Participants were recruited using random digit dialing (RDD) procedures from 2013 to 2014 in Los Angeles County', 'Spanish-Speaking Mexican-American Women']","['Culturally Tailored Narrative', 'narrative or nonnarrative film']","['supportive attitudes about Pap tests expense', 'new knowledge']","[{'cui': 'C4319604', 'cui_str': '300'}, {'cui': 'C3161473', 'cui_str': 'Spaniards (ethnic group)'}, {'cui': 'C0234856', 'cui_str': 'Using spoken communication'}, {'cui': 'C0043210', 'cui_str': 'Girls'}, {'cui': 'C0001792', 'cui_str': 'Elderly'}, {'cui': 'C0439659', 'cui_str': 'Origins (qualifier value)'}, {'cui': 'C0439605', 'cui_str': 'Random (qualifier value)'}, {'cui': 'C0582802', 'cui_str': 'Digit'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0025884', 'cui_str': 'Chicanas'}]","[{'cui': 'C4319646', 'cui_str': 'Film'}]","[{'cui': 'C0004271', 'cui_str': 'Attitude'}, {'cui': 'C3541459', 'cui_str': 'Papanicolaou Smear'}, {'cui': 'C0205314', 'cui_str': 'New (qualifier value)'}, {'cui': 'C0376554', 'cui_str': 'Knowledge'}]",,0.0282794,"Importantly, at 6 months, although not statistically significant, women who viewed the narrative film were also more likely to have had or scheduled a Pap test (62% vs 42%).","[{'ForeName': 'Carol Y', 'Initials': 'CY', 'LastName': 'Ochoa', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto Street, Los Angeles, CA, 90033, USA. caroloch@usc.edu.'}, {'ForeName': 'Sheila T', 'Initials': 'ST', 'LastName': 'Murphy', 'Affiliation': 'Annenberg School for Communication and Journalism, University of Southern California, Los Angeles, CA, USA.'}, {'ForeName': 'Lauren B', 'Initials': 'LB', 'LastName': 'Frank', 'Affiliation': 'Department of Communication, Portland State University, Portland, OR, USA.'}, {'ForeName': 'Lourdes A', 'Initials': 'LA', 'LastName': 'Baezconde-Garbanati', 'Affiliation': 'Department of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.'}]",Journal of cancer education : the official journal of the American Association for Cancer Education,['10.1007/s13187-019-01521-6'] 3304,31236874,Improvement in 6-min Walk Test Distance Following Treatment for Behavioral Weight Loss and Disinhibited Eating: an Exploratory Secondary Analysis.,"BACKGROUND Poor functional exercise capacity is common among those with obesity; however, objective measures of exercise capacity are rarely examined in behavioral treatments targeting obese individuals. We examined whether a 4-week acceptance and commitment therapy (ACT) intervention for disinhibited eating or a behavioral weight loss (BWL) intervention improved exercise capacity and explored demographic and disinhibited eating variables related to exercise capacity. METHODS Veterans (n = 61), randomized to receive ACT or BWL, completed an assessment of exercise capacity via the 6-min walk test (6MWT) at baseline and 6-month follow-up. Measures of disinhibited eating patterns and body mass index (BMI), at baseline and post-treatment, were also collected. Change in 6MWT distance and treatment group differences were examined using mixed ANOVAs. Characteristics related to baseline 6MWT and predictors of improvement in 6MWT at 6 months were examined with hierarchical multiple regression. RESULTS There were overall significant improvements on the 6MWT from baseline to 6-month follow-up (F(1,59) = 11.14, p = .001, η p 2  = .159) but no differences between the ACT and BWL groups. Baseline BMI (β = - .33, p = .005) was the only variable related to baseline 6MWT. Improvements on the 6MWT were related to younger age (β = - .41, p = 0.001), female gender (β = .36, p = .001), and treatment-related increases in dietary restraint behaviors (β = .42, p = .001). CONCLUSIONS Functional exercise capacity improved among participants completing behavioral interventions for weight and disinhibited eating. Improvements in dietary behavior regulatory skills may have generalized to improved regulation in other behavioral domains associated with exercise capacity.",2019,Improvements on the 6MWT were related to younger age (β ,"['Veterans (n\u2009=\u200961', 'participants completing behavioral interventions for weight and disinhibited eating']","['ACT or BWL, completed an assessment of exercise capacity via the 6-min walk test (6MWT', '4-week acceptance and commitment therapy (ACT) intervention for disinhibited eating or a behavioral weight loss (BWL) intervention']","['Baseline BMI', 'Behavioral Weight Loss and Disinhibited Eating', 'disinhibited eating patterns and body mass index (BMI', '6MWT', 'female gender (β', 'dietary restraint behaviors (β\u2009']","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}]","[{'cui': 'C0205197', 'cui_str': 'Complete (qualifier value)'}, {'cui': 'C1261322', 'cui_str': 'Clinical evaluation'}, {'cui': 'C0015259', 'cui_str': 'Physical Activity'}, {'cui': 'C0439232', 'cui_str': 'min (qualifier value)'}, {'cui': 'C4277740', 'cui_str': 'Walk Test'}, {'cui': 'C0439230', 'cui_str': 'week (qualifier value)'}, {'cui': 'C3658321', 'cui_str': 'Acceptance and Commitment Therapy'}, {'cui': 'C1262477', 'cui_str': 'Weight Reduction'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0013470', 'cui_str': 'Food Intake'}, {'cui': 'C0449774', 'cui_str': 'Patterns (qualifier value)'}, {'cui': 'C0005893', 'cui_str': 'Body mass index'}, {'cui': 'C0086287', 'cui_str': 'Females'}, {'cui': 'C0079399', 'cui_str': 'Gender'}, {'cui': 'C0004927', 'cui_str': 'Behavior'}]",,0.0492712,Improvements on the 6MWT were related to younger age (β ,"[{'ForeName': 'Jennalee S', 'Initials': 'JS', 'LastName': 'Wooldridge', 'Affiliation': 'VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Matthew S', 'Initials': 'MS', 'LastName': 'Herbert', 'Affiliation': 'VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Jeffrey', 'Initials': 'J', 'LastName': 'Hernandez', 'Affiliation': 'VA San Diego Healthcare System, San Diego, CA, USA.'}, {'ForeName': 'Cara', 'Initials': 'C', 'LastName': 'Dochat', 'Affiliation': 'San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA.'}, {'ForeName': 'Kathryn M', 'Initials': 'KM', 'LastName': 'Godfrey', 'Affiliation': 'Center for Weight, Eating and Lifestyle Science (WELL Center), Drexel University, Philadelphia, PA, USA.'}, {'ForeName': 'Marianna', 'Initials': 'M', 'LastName': 'Gasperi', 'Affiliation': 'Department of Psychiatry, University of California, San Diego, San Diego, CA, USA.'}, {'ForeName': 'Niloofar', 'Initials': 'N', 'LastName': 'Afari', 'Affiliation': 'VA San Diego Healthcare System, San Diego, CA, USA. nafari@ucsd.edu.'}]",International journal of behavioral medicine,['10.1007/s12529-019-09796-1'] 3305,31957268,Effects of smartphone application education combined with hands-on practice in breast self-examination on junior nursing students in South Korea.,"BACKGROUND Breast self-examination is a convenient and effective way to detect breast abnormalities. Based on Dale's Cone of Experience theory, we hypothesized that the combination of a smartphone application with hands-on practice would have a greater impact than using a smartphone application alone. The purpose of this study was to compare the effects of different educational methods on (a) knowledge, (b) attitudes, (c) skills, and (d) students' satisfaction with the learning methods. METHODS We conducted a pre- and post-test quasi-experimental design and developed a smartphone application using a video clip. One experimental group received smartphone-based education, another group received smartphone-based education combined with hands-on practice, and the control group received a one-time classroom lecture. We administered a pre-test, provided intervention, and conducted a post-test. RESULTS Among the three groups, the knowledge and attitude of the experimental groups were significantly higher than that of the control group. In addition, the group using the combination of the smartphone application and hands-on practice showed the highest score changes in skills and satisfaction with the learning methods. CONCLUSIONS Smartphone application use combined with hands-on practice could be an effective education method for breast self-examination.",2020,"Among the three groups, the knowledge and attitude of the experimental groups were significantly higher than that of the control group.",['junior nursing students in South Korea'],"['smartphone application education combined with hands', 'smartphone-based education, another group received smartphone-based education combined with hands-on practice, and the control group received a one-time classroom lecture']",['knowledge and attitude'],"[{'cui': 'C0038496', 'cui_str': 'Pupil Nurses'}, {'cui': 'C0022773', 'cui_str': 'South Korea'}]","[{'cui': 'C3204335', 'cui_str': 'Smart Phones'}, {'cui': 'C0185125', 'cui_str': 'Application (attribute)'}, {'cui': 'C0013621', 'cui_str': 'Education'}, {'cui': 'C0336789', 'cui_str': 'Combine'}, {'cui': 'C0018563', 'cui_str': 'Hand'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0009932', 'cui_str': 'Control Groups'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0376683', 'cui_str': 'Lecture'}]","[{'cui': 'C0376554', 'cui_str': 'Knowledge'}, {'cui': 'C0004271', 'cui_str': 'Attitude'}]",,0.0189596,"Among the three groups, the knowledge and attitude of the experimental groups were significantly higher than that of the control group.","[{'ForeName': 'So Ra', 'Initials': 'SR', 'LastName': 'Kang', 'Affiliation': 'Division of Nursing, Ewha Womans University, Seoul, South Korea.'}, {'ForeName': 'Hyewon', 'Initials': 'H', 'LastName': 'Shin', 'Affiliation': 'School of Nursing, Clemson University, Greenville, South Carolina, USA.'}, {'ForeName': 'JungMin', 'Initials': 'J', 'LastName': 'Lee', 'Affiliation': 'School of Nursing, University of North Carolina at Greensboro, Greensboro, North Carolina, USA.'}, {'ForeName': 'Shin-Jeong', 'Initials': 'SJ', 'LastName': 'Kim', 'Affiliation': 'School of Nursing, Hallym University, Chunchon, South Korea.'}]",Japan journal of nursing science : JJNS,['10.1111/jjns.12318'] 3306,29927273,How prescriptive support affects weight loss in weight-loss intervention participants and their untreated spouses.,"OBJECTIVE Controlling or prescriptive support styles (e.g., pressure) often hinder weight loss, but can sometimes be beneficial. This secondary analysis of data from a randomized controlled trial examined persuasion, pressure, and indirect social control among cohabiting couples and the effect of these supports on weight loss. METHODS Couples ( N Couples = 130) were randomized to either Weight Watchers (WW) or a self-guided control condition (SG). Only one member of each couple received the intervention; the other member of the couple was untreated. Couples were weighed and completed study measures at baseline, 3, and 6 months. RESULTS Dyadic multilevel models examined BMI change and differences across role (treated participant/untreated spouse) and condition (WW/SG). Prescriptive support predicted BMI change for treated participants in the WW condition only. For treated WW participants, there was no significant decrease in BMI when pressure was high (+1 SD ), B = -.25, p = .22, but a significant decrease when pressure was low (0), B = -.96, p < .001. Additionally, high levels of indirect social control (+1 SD ) predicted greater decreases in BMI compared to low (-1 SD ) indirect social control, B = -.91, p < .001, and, B = -.41, p < .01. CONCLUSIONS Considering both the type and context of support for weight management is worthwhile. Intervention participants had access to treatment resources that may have engendered more effective responses to spouses' concerns or a sense of obligation to their spouse (indirect social control), whereas pressures to lose weight-while engaged in treatment-may have undermined behavior-change efforts. (PsycINFO Database Record",2018,"For treated WW participants, there was no significant decrease in BMI when pressure was high (+1 SD ), B = -.25, ","['weight-loss intervention participants and their untreated spouses', 'Couples ( N Couples = 130']",['Weight Watchers (WW) or a self-guided control condition (SG'],"['BMI', 'weight loss', 'BMI change', 'high levels of indirect social control']","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0162409', 'cui_str': 'Married Persons'}, {'cui': 'C0010222', 'cui_str': 'Couples'}, {'cui': 'C4319552', 'cui_str': '130 (qualifier value)'}]","[{'cui': 'C1305866', 'cui_str': 'Weighing patient (procedure)'}, {'cui': 'C0036588', 'cui_str': 'Self'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C2587213', 'cui_str': 'Controlled (qualifier value)'}, {'cui': 'C0348080', 'cui_str': 'Condition (attribute)'}]","[{'cui': 'C1262477', 'cui_str': 'Weight Reduction'}, {'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0205250', 'cui_str': 'High (qualifier value)'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0439852', 'cui_str': 'Indirect (qualifier value)'}, {'cui': 'C0037405', 'cui_str': 'Social Control'}]",130.0,0.0382028,"For treated WW participants, there was no significant decrease in BMI when pressure was high (+1 SD ), B = -.25, ","[{'ForeName': 'Talea', 'Initials': 'T', 'LastName': 'Cornelius', 'Affiliation': 'Department of Medicine.'}, {'ForeName': 'Katelyn', 'Initials': 'K', 'LastName': 'Gettens', 'Affiliation': 'Department of Psychological Sciences.'}, {'ForeName': 'Erin', 'Initials': 'E', 'LastName': 'Lenz', 'Affiliation': 'Department of Psychological Sciences.'}, {'ForeName': 'Alexis C', 'Initials': 'AC', 'LastName': 'Wojtanowski', 'Affiliation': 'Weight Watchers International, Inc.'}, {'ForeName': 'Gary D', 'Initials': 'GD', 'LastName': 'Foster', 'Affiliation': 'Weight Watchers International, Inc.'}, {'ForeName': 'Amy A', 'Initials': 'AA', 'LastName': 'Gorin', 'Affiliation': 'Department of Psychological Sciences.'}]","Health psychology : official journal of the Division of Health Psychology, American Psychological Association",['10.1037/hea0000630'] 3307,31903494,Evaluating the Effects of a Brief Tobacco Intervention in the U.S. Air Force.,"INTRODUCTION Military personnel have among the highest rates of tobacco use in the US. Unfortunately, there are few interventions aimed at reducing tobacco use among this vulnerable population. The current study addresses this need by evaluating the short-term effectiveness of a Brief Tobacco Intervention (BTI), a 40-minute group-based intervention designed to reduce contemporary patterns of tobacco use among a sample of US military enlistees during an 11-week period of involuntary tobacco abstinence. METHODS Participants were 2,999 US Air Force Technical Trainees at Joint Base San Antonio-Lackland Air Force Base in San Antonio, Texas from April 2017 through January 2018. Participants were cluster randomized to three conditions: (1) BTI + Airman's Guide to Remaining Tobacco Free (AG), (2) AG intervention, or (3) standard smoking cessation intervention. The primary analysis was a comparison of the interventions' efficacies in preventing tobacco use during Technical Training, conducted using a generalized estimating equations logistic regression model controlling for covariates. Multiple imputation was used to account for loss to follow-up. RESULTS There was not a significant difference by condition in the use of tobacco products at follow-up (p=0.454). The BTI + AG condition did produce short-term changes in perceived harm, intentions to use tobacco, knowledge about tobacco products, and normative beliefs. CONCLUSIONS These findings suggest that while the intervention was effective in the short-term, it was not potent enough over a 12-week period to prevent Airmen from initiating tobacco use. Future studies should examine whether adding a booster session or media campaign enhances the effectiveness of the intervention.",2020,There was not a significant difference by condition in the use of tobacco products at follow-up (p=0.454).,"['Participants were 2,999 US Air Force Technical Trainees at Joint Base San Antonio-Lackland Air Force Base in San Antonio, Texas from April 2017 through January 2018']","['Brief Tobacco Intervention (BTI', 'Brief Tobacco Intervention', ""BTI + Airman's Guide to Remaining Tobacco Free (AG), (2) AG intervention, or (3) standard smoking cessation intervention""]",[],"[{'cui': 'C0001861', 'cui_str': 'Air'}, {'cui': 'C0443221', 'cui_str': 'Forced (qualifier value)'}, {'cui': 'C0022417', 'cui_str': 'Joints'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C0039711', 'cui_str': 'Texas'}]","[{'cui': 'C1879313', 'cui_str': 'Brief (qualifier value)'}, {'cui': 'C0040329', 'cui_str': 'Tobacco Products'}, {'cui': 'C4521691', 'cui_str': 'US Military enlisted E2'}, {'cui': 'C0302614', 'cui_str': 'Guide - clinical instrument'}, {'cui': 'C0038137', 'cui_str': 'standards'}, {'cui': 'C0085134', 'cui_str': 'Smokings, Giving Up'}]",[],,0.0315383,There was not a significant difference by condition in the use of tobacco products at follow-up (p=0.454).,"[{'ForeName': 'Melissa A', 'Initials': 'MA', 'LastName': 'Little', 'Affiliation': 'University of Virginia School of Medicine, Charlottesville, VA.'}, {'ForeName': 'Margaret C', 'Initials': 'MC', 'LastName': 'Fahey', 'Affiliation': 'University of Memphis, Memphis, TN.'}, {'ForeName': 'Robert C', 'Initials': 'RC', 'LastName': 'Klesges', 'Affiliation': 'University of Virginia School of Medicine, Charlottesville, VA.'}, {'ForeName': 'Timothy', 'Initials': 'T', 'LastName': 'McMurry', 'Affiliation': 'University of Virginia School of Medicine, Charlottesville, VA.'}, {'ForeName': 'Gerald W', 'Initials': 'GW', 'LastName': 'Talcott', 'Affiliation': 'University of Virginia School of Medicine, Charlottesville, VA.'}]",Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,['10.1093/ntr/ntaa001'] 3308,31366683,Local Anesthesia With General Anesthesia for Pediatric Bone Marrow Procedures.,"BACKGROUND Pediatric patients with cancer undergo repeated painful procedures, including bone marrow aspirations and biopsies (BMABs). Optimal management of procedure-related pain can reduce discomfort, anxiety, and distress. METHODS Children with neuroblastoma were randomly assigned to 1 of 2 arms on a prospective, single-blind, crossover trial conducted at Memorial Sloan Kettering Cancer Center from October 2016 to January 2018 (www.clinicaltrials.gov, identifier NCT02924324). Participants underwent 2 sequential BMABs: one with general anesthesia (GA) alone, the other with GA plus local anesthesia (LA) (GA + LA). The objective was to assess procedure-related pain and its interference with quality of life (QoL) with GA versus GA + LA. Primary outcome was percentage of participants requiring postprocedural opioids. Secondary outcomes were total opioid and nonopioid analgesics, pain scores, time to first analgesic, QoL, and toxicity. Management of postprocedural pain was standardized. RESULTS Of 56 participants randomly assigned (3-16.5 years old), 46 completed both procedures. There was no significant difference in percentage of participants requiring opioids with GA versus GA + LA (24% vs 20%, P = .5). Pain scores in the recovery room were significantly lower for GA + LA versus GA (median [IQR]: 0 [0-2] vs 2 [0-4], P = .002). There were no statistically significant differences in total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference. No adverse events occurred. CONCLUSIONS LA was associated with significant improvement in pain scores in the immediate recovery period. LA did not reduce postprocedural opioid use, nor did it improve QoL for patients undergoing BMAB with GA.",2019,"There were no statistically significant differences in total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference.","['56 participants randomly assigned (3-16.5 years old', 'Pediatric patients with cancer undergo repeated painful procedures, including bone marrow aspirations and biopsies (BMABs', 'Children with neuroblastoma']","['LA', 'GA versus GA + LA', 'Local Anesthesia With General Anesthesia', 'GA + LA', 'general anesthesia (GA) alone, the other with GA plus local anesthesia (LA) (GA + LA', 'sequential BMABs']","['discomfort, anxiety, and distress', 'adverse events', 'total opioid and nonopioid analgesics, pain scores, time to first analgesic, QoL, and toxicity', 'procedure-related pain and its interference with quality of life (QoL', 'percentage of participants requiring postprocedural opioids', 'Pain scores', 'total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference', 'pain scores']","[{'cui': 'C1516050', 'cui_str': 'Assigned (qualifier value)'}, {'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0030755', 'cui_str': 'Pediatrics'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1306459', 'cui_str': 'Primary malignant neoplasm'}, {'cui': 'C0205341', 'cui_str': 'Repeat (qualifier value)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0332257', 'cui_str': 'Including (qualifier value)'}, {'cui': 'C0398523', 'cui_str': 'Bone marrow aspiration procedure'}, {'cui': 'C0005558', 'cui_str': 'Biopsy'}, {'cui': 'C0008059', 'cui_str': 'Child'}, {'cui': 'C0027819', 'cui_str': 'Neuroblastoma'}]","[{'cui': 'C0002921', 'cui_str': 'Local anesthesia (procedure)'}, {'cui': 'C0002915', 'cui_str': 'General Anesthesia'}, {'cui': 'C0332287', 'cui_str': 'With (attribute)'}]","[{'cui': 'C2364135', 'cui_str': 'Discomfort (finding)'}, {'cui': 'C0003467', 'cui_str': 'Anxiety'}, {'cui': 'C3887804', 'cui_str': 'Feeling distress'}, {'cui': 'C0877248', 'cui_str': 'Adverse event'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0242402', 'cui_str': 'Opioids'}, {'cui': 'C0242937', 'cui_str': 'Non-Opioid Analgesics'}, {'cui': 'C0582148', 'cui_str': 'Pain score (observable entity)'}, {'cui': 'C1632851', 'cui_str': 'Times'}, {'cui': 'C0002771', 'cui_str': 'Analgesic Drugs'}, {'cui': 'C0600688', 'cui_str': 'Toxic effect'}, {'cui': 'C0184661', 'cui_str': 'Procedures'}, {'cui': 'C0445223', 'cui_str': 'Related (finding)'}, {'cui': 'C0030193', 'cui_str': 'Pain'}, {'cui': 'C0332306', 'cui_str': 'With quality (attribute)'}, {'cui': 'C0439584', 'cui_str': '24 hours (qualifier value)'}, {'cui': 'C2939193', 'cui_str': 'Median (qualifier value)'}]",56.0,0.229846,"There were no statistically significant differences in total opioid or nonopioid analgesic, 6- and 24-hour pain scores, median time to first analgesic, or pain interference.","[{'ForeName': 'Sara', 'Initials': 'S', 'LastName': 'Zarnegar-Lumley', 'Affiliation': 'Departments of Pediatrics, sara.zarnegar@vumc.org.'}, {'ForeName': 'Katharine R', 'Initials': 'KR', 'LastName': 'Lange', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Melissa D', 'Initials': 'MD', 'LastName': 'Mathias', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Miho', 'Initials': 'M', 'LastName': 'Nakajima-Hatano', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Katharine M', 'Initials': 'KM', 'LastName': 'Offer', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Ugochi O', 'Initials': 'UO', 'LastName': 'Ogu', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Michael V', 'Initials': 'MV', 'LastName': 'Ortiz', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Kay See', 'Initials': 'KS', 'LastName': 'Tan', 'Affiliation': 'Epidemiology and Biostatistics.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Kellick', 'Affiliation': 'Pharmacy, and.'}, {'ForeName': 'Shakeel', 'Initials': 'S', 'LastName': 'Modak', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Stephen S', 'Initials': 'SS', 'LastName': 'Roberts', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'Ellen M', 'Initials': 'EM', 'LastName': 'Basu', 'Affiliation': 'Departments of Pediatrics.'}, {'ForeName': 'R Scott', 'Initials': 'RS', 'LastName': 'Dingeman', 'Affiliation': 'Departments of Pediatrics.'}]",Pediatrics,['10.1542/peds.2018-3829'] 3309,31972249,Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.,"The IL-23/T helper type 17 cell axis is a target for psoriasis. The TYK2/Janus kinase 1 inhibitor PF-06700841 will directly suppress TYK2-dependent IL-12 and IL-23 signaling and Janus kinase 1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes. This clinical study sought to define the inflammatory gene and cellular pathways through which PF-06700841 improves the clinical manifestations of psoriasis. Patients (n = 30) with moderate-to-severe psoriasis were randomized to once-daily 30 mg (n = 14) or 100 mg (n = 7) PF-06700841 or placebo (n = 9) for 28 days. Biopsies were taken from nonlesional and lesional skin at baseline and weeks 2 and 4. Changes in the psoriasis transcriptome and genes induced by IL-17 in keratinocytes were evaluated with microarray profiling and reverse transcriptase-PCR. Reductions in IL-17A, IL-17F, and IL-12B mRNA were observed as early as 2 weeks and approximately 70% normalization of lesional gene expression after 4 weeks. Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3 + /CD8 + (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score. PF-06700841 improves clinical symptoms of chronic plaque psoriasis by inhibition of proinflammatory cytokines that require TYK2 and Janus kinase 1 for signal transduction.",2020,"Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score.",['Patients (n=30) with moderate-to-severe psoriasis'],"['interleukin (IL)-23/T-helper type 17 cell axis', 'placebo']","['markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells', 'lesional gene expression', 'histologic score', 'IL-17A, IL-17F, and IL-12B mRNA']","[{'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C1299393', 'cui_str': 'Moderate to severe'}, {'cui': 'C0033860', 'cui_str': 'Psoriasis'}]","[{'cui': 'C0963088', 'cui_str': 'IL-23'}, {'cui': 'C0441704', 'cui_str': 'Typings (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0004457', 'cui_str': 'C2 Vertebra'}, {'cui': 'C1696465', 'cui_str': 'placebo'}]","[{'cui': 'C0022567', 'cui_str': 'Keratinocyte (cell)'}, {'cui': 'C3854321', 'cui_str': 'Expression'}, {'cui': 'C0439662', 'cui_str': 'Immune (qualifier value)'}, {'cui': 'C0007634', 'cui_str': 'Cells'}, {'cui': 'C0332448', 'cui_str': 'Tissue infiltration'}, {'cui': 'C0039194', 'cui_str': 'Thymus-Dependent Lymphocytes'}, {'cui': 'C0011306', 'cui_str': 'Dendritic Cells'}, {'cui': 'C0017262', 'cui_str': 'Gene Expression'}, {'cui': 'C0205462', 'cui_str': 'Histologic (qualifier value)'}, {'cui': 'C0449820', 'cui_str': 'Scores (qualifier value)'}, {'cui': 'C1705947', 'cui_str': 'CTLA8'}, {'cui': 'C1705097', 'cui_str': 'Interleukin-17F'}, {'cui': 'C0035696', 'cui_str': 'mRNA'}]",,0.0954999,"Immunohistochemistry showed significant decreases in markers of keratinocyte activation, epidermal thickness, KRT16 and Ki-67 expression, and immune cell infiltrates CD3+/CD8+ (T cells) and CD11c (dendritic cells) after 2 weeks of treatment, corresponding with improvement in histologic score.","[{'ForeName': 'Karen M', 'Initials': 'KM', 'LastName': 'Page', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Mayte', 'Initials': 'M', 'LastName': 'Suarez-Farinas', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Maria', 'Initials': 'M', 'LastName': 'Suprun', 'Affiliation': 'Icahn School of Medicine at Mount Sinai, New York, New York, USA.'}, {'ForeName': 'Weidong', 'Initials': 'W', 'LastName': 'Zhang', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Sandra', 'Initials': 'S', 'LastName': 'Garcet', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Judilyn', 'Initials': 'J', 'LastName': 'Fuentes-Duculan', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Xuan', 'Initials': 'X', 'LastName': 'Li', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Matthew', 'Initials': 'M', 'LastName': 'Scaramozza', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Elizabeth', 'Initials': 'E', 'LastName': 'Kieras', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Christopher', 'Initials': 'C', 'LastName': 'Banfield', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'James D', 'Initials': 'JD', 'LastName': 'Clark', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'Andrew', 'Initials': 'A', 'LastName': 'Fensome', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA.'}, {'ForeName': 'James G', 'Initials': 'JG', 'LastName': 'Krueger', 'Affiliation': 'Rockefeller University, New York, New York, USA.'}, {'ForeName': 'Elena', 'Initials': 'E', 'LastName': 'Peeva', 'Affiliation': 'Pfizer, Cambridge, Massachusetts, USA. Electronic address: Elena.Peeva@pfizer.com.'}]",The Journal of investigative dermatology,['10.1016/j.jid.2019.11.027'] 3310,31550173,Complicated mild traumatic brain injury in older adults: Post-concussion symptoms and functional outcome at one week post injury.,"Primary Objective: Mild Traumatic Brain Injury (MTBI) is commonly categorized as complicated when injury severity criteria are mild, but an intracranial abnormality is present on acute neuroimaging. The current study examined whether functional outcomes differed at one week post injury among older adult patients based on injury severity and acute computed tomography (CT) findings. Research Design: Participants (≥55 years-old; n = 173) presenting sequentially to the emergency department with a head injury were divided into three groups: complicated MTBI (positive CT; n = 22), uncomplicated MTBI (negative CT; n = 68), and mild head injury (unperformed CT, no documented loss of consciousness or post-traumatic amnesia; n = 83). Methods and Procedures: At one week post injury, the Modified Rankin Scale (i.e., difference score between pre/post-injury ratings; ∆MRS), Glasgow Outcome Scale-Extended (GOS-E), and Rivermead Post-Concussion Symptoms Questionnaire (RPQ) were administered. Main Outcomes and Results: Participants differed on the ∆MRS and GOS-E, but not the RPQ. The complicated MTBI group had worse GOS-E ratings than the uncomplicated MTBI and mild head injury groups and worse ∆MRS than the mild head injury group, but the uncomplicated MTBI and mild head injury groups did not differ on either outcome. Conclusions: Macrostructural abnormality on CT was associated with worse functional outcome at one week post MTBI.",2020,"The complicated MTBI group had worse GOS-E ratings than the uncomplicated MTBI and mild head injury groups and worse ∆MRS than the mild head injury group, but the uncomplicated MTBI and mild head injury groups did not differ on either outcome. ","['Participants (≥55\xa0years-old; n =\xa0173) presenting sequentially to the emergency department with a head injury', 'older adults', 'older adult patients based on injury severity and acute computed tomography (CT) findings']",[],"['GOS-E ratings', '∆MRS', 'Modified Rankin Scale', '∆MRS and GOS-E', 'Glasgow Outcome Scale-Extended (GOS-E), and Rivermead Post-Concussion Symptoms Questionnaire (RPQ', 'Mild Traumatic Brain Injury (MTBI']","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0677546', 'cui_str': 'Old episode (qualifier value)'}, {'cui': 'C0150312', 'cui_str': 'Present (qualifier value)'}, {'cui': 'C0562508', 'cui_str': 'Emergency Room'}, {'cui': 'C0018674', 'cui_str': 'Head Trauma'}, {'cui': 'C0001675', 'cui_str': 'Adult'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0178499', 'cui_str': 'Base'}, {'cui': 'C3263722', 'cui_str': 'Traumatic AND/OR non-traumatic injury'}, {'cui': 'C0439793', 'cui_str': 'Severity (attribute)'}, {'cui': 'C0040395', 'cui_str': 'Tomographic imaging'}, {'cui': 'C2607943', 'cui_str': 'findings'}]",[],"[{'cui': 'C0392747', 'cui_str': 'Altered (qualifier value)'}, {'cui': 'C0451405', 'cui_str': 'Rankin scale'}, {'cui': 'C0701887', 'cui_str': 'Glasgow Outcome Scale'}, {'cui': 'C0231449', 'cui_str': 'Extended (qualifier value)'}, {'cui': 'C0546983', 'cui_str': 'Post-Concussion Symptoms'}, {'cui': 'C0034394', 'cui_str': 'Questionnaires'}, {'cui': 'C3508472', 'cui_str': 'Mild Traumatic Brain Injury'}]",,0.0440428,"The complicated MTBI group had worse GOS-E ratings than the uncomplicated MTBI and mild head injury groups and worse ∆MRS than the mild head injury group, but the uncomplicated MTBI and mild head injury groups did not differ on either outcome. ","[{'ForeName': 'Justin E', 'Initials': 'JE', 'LastName': 'Karr', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Grant L', 'Initials': 'GL', 'LastName': 'Iverson', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Ksenia', 'Initials': 'K', 'LastName': 'Berghem', 'Affiliation': 'Medical Imaging Centre, Department of Radiology, Tampere University Hospital, Tampere, Finland.'}, {'ForeName': 'Anna-Kerttu', 'Initials': 'AK', 'LastName': 'Kotilainen', 'Affiliation': 'Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.'}, {'ForeName': 'Douglas P', 'Initials': 'DP', 'LastName': 'Terry', 'Affiliation': 'Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA, USA.'}, {'ForeName': 'Teemu M', 'Initials': 'TM', 'LastName': 'Luoto', 'Affiliation': 'Department of Neurosurgery, Tampere University Hospital and Tampere University, Tampere, Finland.'}]",Brain injury,['10.1080/02699052.2019.1669825'] 3311,31948641,Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.,"BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE). METHODS One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina. RESULTS Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081). CONCLUSIONS Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402).",2020,"Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics.","['One to 12\xa0months after ACS, 18,924 patients on high-intensity statin therapy', 'patients with recent acute coronary syndrome (ACS']","['placebo', 'alirocumab', 'Alirocumab', 'alirocumab or placebo']","['Lipoprotein(a) and Cardiovascular Risk', 'coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina', 'corrected LDL-C', 'corrected LDL-C levels', 'lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C', 'risk of MACE', 'Alirocumab reduced lipoprotein(a', 'lipoprotein(a']","[{'cui': 'C0439231', 'cui_str': 'month (qualifier value)'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C4047691', 'cui_str': 'High-intensity statin therapy (procedure)'}, {'cui': 'C0332185', 'cui_str': 'Recent episode (qualifier value)'}, {'cui': 'C0948089', 'cui_str': 'Acute Coronary Syndrome'}]","[{'cui': 'C1696465', 'cui_str': 'placebo'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}]","[{'cui': 'C0023820', 'cui_str': 'Circulating Lipoproteins'}, {'cui': 'C4324389', 'cui_str': 'Cardiovascular risk'}, {'cui': 'C0010068', 'cui_str': 'Coronary Disease'}, {'cui': 'C0011065', 'cui_str': 'Death'}, {'cui': 'C0027051', 'cui_str': 'Heart Attack'}, {'cui': 'C0948008', 'cui_str': 'Ischemic stroke (disorder)'}, {'cui': 'C0019993', 'cui_str': 'Hospitalization'}, {'cui': 'C0002965', 'cui_str': 'Angina at Rest'}, {'cui': 'C0205202', 'cui_str': 'Remediated'}, {'cui': 'C0023823', 'cui_str': 'beta-Lipoproteins'}, {'cui': 'C0456079', 'cui_str': 'Level (attribute)'}, {'cui': 'C0202117', 'cui_str': 'Low density lipoprotein cholesterol measurement (procedure)'}, {'cui': 'C0035647', 'cui_str': 'Risk'}, {'cui': 'C0349381', 'cui_str': 'Mace (substance)'}, {'cui': 'C3491162', 'cui_str': 'alirocumab'}, {'cui': 'C0392756', 'cui_str': 'Reduced (qualifier value)'}]",,0.423186,"Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics.","[{'ForeName': 'Vera A', 'Initials': 'VA', 'LastName': 'Bittner', 'Affiliation': 'Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: vbittner@uab.edu.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Szarek', 'Affiliation': 'State University of New York, Downstate School of Public Health, Brooklyn, New York.'}, {'ForeName': 'Philip E', 'Initials': 'PE', 'LastName': 'Aylward', 'Affiliation': 'South Australian Health and Medical Research Institute, Flinders University and Medical Centre, Adelaide, South Australia, Australia.'}, {'ForeName': 'Deepak L', 'Initials': 'DL', 'LastName': 'Bhatt', 'Affiliation': ""Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. Electronic address: https://twitter.com/DLBHATTMD.""}, {'ForeName': 'Rafael', 'Initials': 'R', 'LastName': 'Diaz', 'Affiliation': 'Estudios Cardiológicos Latinoamérica, Instituto Cardiovascular de Rosario, Rosario, Argentina.'}, {'ForeName': 'Jay M', 'Initials': 'JM', 'LastName': 'Edelberg', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Zlatko', 'Initials': 'Z', 'LastName': 'Fras', 'Affiliation': 'Division of Medicine, Department of Vascular Medicine, Preventive Cardiology Unit, University Medical Centre Ljubljana, Ljubljana, Slovenia; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia.'}, {'ForeName': 'Shaun G', 'Initials': 'SG', 'LastName': 'Goodman', 'Affiliation': ""Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada; St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.""}, {'ForeName': 'Sigrun', 'Initials': 'S', 'LastName': 'Halvorsen', 'Affiliation': 'Department of Cardiology, Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway.'}, {'ForeName': 'Corinne', 'Initials': 'C', 'LastName': 'Hanotin', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Robert A', 'Initials': 'RA', 'LastName': 'Harrington', 'Affiliation': 'Stanford Center for Clinical Research, Department of Medicine, Stanford University, Stanford, California.'}, {'ForeName': 'J Wouter', 'Initials': 'JW', 'LastName': 'Jukema', 'Affiliation': 'Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.'}, {'ForeName': 'Virginie', 'Initials': 'V', 'LastName': 'Loizeau', 'Affiliation': 'Sanofi, Paris, France.'}, {'ForeName': 'Patrick M', 'Initials': 'PM', 'LastName': 'Moriarty', 'Affiliation': 'Division of Clinical Pharmacology, University of Kansas Medical Center, Kansas City, Kansas.'}, {'ForeName': 'Angèle', 'Initials': 'A', 'LastName': 'Moryusef', 'Affiliation': 'Sanofi, Bridgewater, New Jersey.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Pordy', 'Affiliation': 'Regeneron Pharmaceuticals Inc., Tarrytown, New York.'}, {'ForeName': 'Matthew T', 'Initials': 'MT', 'LastName': 'Roe', 'Affiliation': 'Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.'}, {'ForeName': 'Peter', 'Initials': 'P', 'LastName': 'Sinnaeve', 'Affiliation': 'Department of Cardiovascular Medicine, University Hospitals Leuven, Leuven, Belgium; University of Leuven, Leuven, Belgium.'}, {'ForeName': 'Sotirios', 'Initials': 'S', 'LastName': 'Tsimikas', 'Affiliation': 'Division of Cardiovascular Medicine, University of California San Diego, La Jolla, California.'}, {'ForeName': 'Robert', 'Initials': 'R', 'LastName': 'Vogel', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': 'Harvey D', 'Initials': 'HD', 'LastName': 'White', 'Affiliation': 'Green Lane Cardiovascular Services Auckland City Hospital, Auckland, New Zealand.'}, {'ForeName': 'Doron', 'Initials': 'D', 'LastName': 'Zahger', 'Affiliation': 'Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.'}, {'ForeName': 'Andreas M', 'Initials': 'AM', 'LastName': 'Zeiher', 'Affiliation': 'Department of Medicine III, Goethe University, Frankfurt am Main, Germany.'}, {'ForeName': 'Ph Gabriel', 'Initials': 'PG', 'LastName': 'Steg', 'Affiliation': 'Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université de Paris, FACT (French Alliance for Cardiovascular Trials), INSERM U1148, Paris, France; National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London, United Kingdom. Electronic address: https://twitter.com/gabrielsteg.'}, {'ForeName': 'Gregory G', 'Initials': 'GG', 'LastName': 'Schwartz', 'Affiliation': 'Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado.'}, {'ForeName': '', 'Initials': '', 'LastName': '', 'Affiliation': ''}]",Journal of the American College of Cardiology,['10.1016/j.jacc.2019.10.057'] 3312,31962198,Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.,"PURPOSE To investigate long-term results of patients with hormonal receptor-positive breast cancer treated with breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI). METHODS AND MATERIALS Within the 8 A trial of the Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS which was randomly followed by WBI (n = 439, group 1) or observation (n = 430, group 2). WBI was applied up to a mean total dosage of 50 Gy (+/- 10 Gy boost) in conventional fractionation. RESULTS After a median follow-up of 9.89 years, 10 in-breast recurrences (IBRs) were observed in group 1 and 31 in group 2, resulting in a 10-year local recurrence-free survival (LRFS) of 97.5% and 92.4%, respectively (p = 0.004). This translated into significantly higher rates for disease-free survival (DFS): 94.5% group 1 vs 88.4% group 2, p = 0.0156. For distant metastases-free survival (DMFS) and overall survival (OS), respective 10-year rates amounted 96.7% and 86.6% for group 1 versus 96.4% and 87.6%, for group 2 (ns). WBI (hazard ratio [HR]: 0.27, p < 0.01) and tumour grading (HR: 3.76, p = 0.03) were found as significant predictors for IBR in multiple cox regression analysis. CONCLUSIONS After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone. The omission of WBI and tumour grading, respectively, were the only negative predictors for LRFS.",2020,"After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone.","['low-risk breast cancer patients after breast-conserving surgery', 'Austrian Breast and Colorectal Cancer Study Group, a total of 869 patients received ET after BCS', '10', 'patients with hormonal receptor-positive breast cancer treated with']","['breast-conserving surgery (BCS) and consecutive endocrine therapy (ET) with or without whole breast irradiation (WBI', 'Endocrine therapy with or without whole breast irradiation']","['10-year local recurrence-free survival (LRFS', 'distant metastases-free survival (DMFS) and overall survival (OS), respective 10-year rates']","[{'cui': 'C3538919', 'cui_str': 'Low risk (qualifier value)'}, {'cui': 'C0006142', 'cui_str': 'Breast Cancer'}, {'cui': 'C0030705', 'cui_str': 'Patients'}, {'cui': 'C0917927', 'cui_str': 'Breast-Conserving Surgery'}, {'cui': 'C0337795', 'cui_str': 'Austrians (ethnic group)'}, {'cui': 'C0006141', 'cui_str': 'Breast'}, {'cui': 'C0346629', 'cui_str': 'Malignant tumor of large intestine (disorder)'}, {'cui': 'C0557651', 'cui_str': 'Study (environment)'}, {'cui': 'C0439745', 'cui_str': 'Grouped (qualifier value)'}, {'cui': 'C0439810', 'cui_str': 'Total (qualifier value)'}, {'cui': 'C0458083', 'cui_str': 'Hormonal (qualifier value)'}, {'cui': 'C0597357', 'cui_str': 'Receptor (substance)'}, {'cui': 'C1446409', 'cui_str': 'Positive (qualifier value)'}, {'cui': 'C0332293', 'cui_str': 'Treated with (attribute)'}]","[{'cui': 'C0917927', 'cui_str': 'Breast-Conserving Surgery'}, {'cui': 'C0279025', 'cui_str': 'Hormone therapy (procedure)'}, {'cui': 'C0457102', 'cui_str': 'Whole breast (qualifier value)'}, {'cui': 'C1282930', 'cui_str': 'Irradiation (physical force)'}]","[{'cui': 'C0439234', 'cui_str': 'year (qualifier value)'}, {'cui': 'C0205276', 'cui_str': 'Local (qualifier value)'}, {'cui': 'C2919733', 'cui_str': 'Surviving free of recurrence of neoplastic disease (finding)'}, {'cui': 'C0443203', 'cui_str': 'Distant (qualifier value)'}, {'cui': 'C0220921', 'cui_str': 'survival'}, {'cui': 'C0282416', 'cui_str': 'Overall'}]",869.0,0.0432399,"After a median follow-up of 10 years, WBI resulted in a better local control and DFS compared with ET alone.","[{'ForeName': 'Gerd', 'Initials': 'G', 'LastName': 'Fastner', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. Electronic address: g.fastner@salk.at.'}, {'ForeName': 'Felix', 'Initials': 'F', 'LastName': 'Sedlmayer', 'Affiliation': 'Department of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg, Landeskrankenhaus, Salzburg, Austria. Electronic address: f.sedlmayer@salk.at.'}, {'ForeName': 'Joachim', 'Initials': 'J', 'LastName': 'Widder', 'Affiliation': 'Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: joachim.widder@meduniwien.ac.at.'}, {'ForeName': 'Martina', 'Initials': 'M', 'LastName': 'Metz', 'Affiliation': 'Department of Radiooncology and Radiotherapy, Wiener Neustadt Hospital, Wiener Neustadt, Austria. Electronic address: martina.metz@wienerneustadt.lknoe.at.'}, {'ForeName': 'Hans', 'Initials': 'H', 'LastName': 'Geinitz', 'Affiliation': 'Department of Radiation Oncology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. Electronic address: hans.geinitz@ordensklinikum.at.'}, {'ForeName': 'Karin', 'Initials': 'K', 'LastName': 'Kapp', 'Affiliation': 'Department of Therapeutic Radiology and Oncology, Comprehensive Cancer Center (CCC), Medical University of Graz, Graz, Austria. Electronic address: karin.kapp@medunigraz.at.'}, {'ForeName': 'Christian', 'Initials': 'C', 'LastName': 'Fesl', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Electronic address: Christian.Fesl@abcsg.at.'}, {'ForeName': 'Lidija', 'Initials': 'L', 'LastName': 'Sölkner', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Electronic address: Lidija.Soelkner@abcsg.at.'}, {'ForeName': 'Richard', 'Initials': 'R', 'LastName': 'Greil', 'Affiliation': 'Department of Medical Oncology, Paracelsus Medical University, Salzburg, Austria. Electronic address: r.greil@salk.at.'}, {'ForeName': 'Raimund', 'Initials': 'R', 'LastName': 'Jakesz', 'Affiliation': 'Department of Medical Oncology, Paracelsus Medical University, Salzburg, Austria. Electronic address: raimund.jakesz@meduniwien.ac.at.'}, {'ForeName': 'Werner', 'Initials': 'W', 'LastName': 'Kwasny', 'Affiliation': 'Department of Surgery, Wiener Neustadt Hospital, Wiener Neustadt, Austria. Electronic address: werner.kwasny@wienerneustadt.lknoe.at.'}, {'ForeName': 'Dietmar', 'Initials': 'D', 'LastName': 'Heck', 'Affiliation': 'Department of Surgery, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria. Electronic address: dietmar.heck@ordensklinikum.at.'}, {'ForeName': 'Vesna', 'Initials': 'V', 'LastName': 'Bjelic-Radisic', 'Affiliation': 'Breast Unit, Universtiy Hospital Wuppertal, University Witten/Herdecke, Witten, Germany. Electronic address: vesna.bjelic-radisic@helios-gesundheit.de.'}, {'ForeName': 'Marija', 'Initials': 'M', 'LastName': 'Balic', 'Affiliation': 'Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria. Electronic address: marija.balic@medunigraz.at.'}, {'ForeName': 'Herbert', 'Initials': 'H', 'LastName': 'Stöger', 'Affiliation': 'Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria. Electronic address: herbert.stoeger@klinikum-graz.at.'}, {'ForeName': 'Ursula', 'Initials': 'U', 'LastName': 'Wieder', 'Affiliation': 'Department of Surgery, Hanusch Spital, Vienna, Austria. Electronic address: ursula.wieder@wgkk.at.'}, {'ForeName': 'Ronald', 'Initials': 'R', 'LastName': 'Zwrtek', 'Affiliation': 'Department of Surgery, Mistelbach Hospital, Mistelbach, Austria. Electronic address: ronald.zwrtek@mistelbach.lknoe.at.'}, {'ForeName': 'Dagmar', 'Initials': 'D', 'LastName': 'Semmler', 'Affiliation': 'Department of Surgery, Mistelbach Hospital, Mistelbach, Austria. Electronic address: dagmar.semmler@mistelbach.lknoe.at.'}, {'ForeName': 'Wilfried', 'Initials': 'W', 'LastName': 'Horvath', 'Affiliation': 'Department of Surgery, Guessing Hospital, Guessing, Austria. Electronic address: wilfried.horvath@krages.at.'}, {'ForeName': 'Elisabeth', 'Initials': 'E', 'LastName': 'Melbinger-Zeinitzer', 'Affiliation': 'Department of Gynecology, Wolfsberg Hospital, Wolfsberg, Austria. Electronic address: elisabeth.melbinger-zeinitzer@lkh-wo.at.'}, {'ForeName': 'Martin', 'Initials': 'M', 'LastName': 'Wiesholzer', 'Affiliation': 'Department of Internal Medicine I, Division of Nephrology and Hematology, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Pölten, Austria. Electronic address: martin.wiesholzer@stpoelten.lknoe.at.'}, {'ForeName': 'Viktor', 'Initials': 'V', 'LastName': 'Wette', 'Affiliation': 'Department of Surgery, Krankenhaus der Barmherzigen Brüder St Veit an der Glan, St. Veit an der Glan, Austria. Electronic address: wetteviktor@aon.at.'}, {'ForeName': 'Michael', 'Initials': 'M', 'LastName': 'Gnant', 'Affiliation': 'Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: michael.gnant@abcsg.at.'}]","European journal of cancer (Oxford, England : 1990)",['10.1016/j.ejca.2019.11.024']